From 8d7f50e5ba5f325c8e79b4d09f28720d0eacac9a Mon Sep 17 00:00:00 2001 From: =?UTF-8?q?Juli=C3=A1n?= <11237498+linuxpizzacats@users.noreply.github.com> Date: Tue, 12 Dec 2023 22:14:12 -0300 Subject: [PATCH 01/21] Branch renaming fixes in wf and docs (#52) prod branch renamed to main. Docs and workflows actions fixed --- .github/workflows/prod-env-wf.yml | 2 +- .github/workflows/prod-pr-wf.yml | 2 +- CONTRIBUTING.md | 8 ++++---- 3 files changed, 6 insertions(+), 6 deletions(-) diff --git a/.github/workflows/prod-env-wf.yml b/.github/workflows/prod-env-wf.yml index a165b0d..a2aa973 100644 --- a/.github/workflows/prod-env-wf.yml +++ b/.github/workflows/prod-env-wf.yml @@ -2,7 +2,7 @@ name: Prod enviroment workflow to build and push docker image on: push: branches: - - "prod" + - "main" jobs: docker-modulector: runs-on: ubuntu-latest diff --git a/.github/workflows/prod-pr-wf.yml b/.github/workflows/prod-pr-wf.yml index 803640d..1ca6058 100644 --- a/.github/workflows/prod-pr-wf.yml +++ b/.github/workflows/prod-pr-wf.yml @@ -2,7 +2,7 @@ name: Check if version exist on docker registry on: pull_request: branches: - - "prod" + - "main" jobs: version-check-repo: runs-on: ubuntu-latest diff --git a/CONTRIBUTING.md b/CONTRIBUTING.md index 77eaf34..0cbaadc 100644 --- a/CONTRIBUTING.md +++ b/CONTRIBUTING.md @@ -47,19 +47,19 @@ The entire contributing process consists in the following steps: ## Workflow -We use gitlab environment git workflow. The default branch is `dev` and the publishing branch is `prod`. The working branches are created from `dev` and must respect the following steps and actions: +We use gitlab environment git workflow. The default branch is `dev` and the publishing branch is `main`. The working branches are created from `dev` and must respect the following steps and actions: 1. A new branch is created from `dev`. 1. After finish working with it, a PR to `dev` must be created. 1. Automatic Action/Workflow for PR is executed. 1. The new branch is merged to `dev`. 1. Automatic Action/Workflow for _Push_ events into `dev` is executed. -1. When is ready to publish a new version of `dev`, a PR to `prod` is created. +1. When is ready to publish a new version of `dev`, a PR to `main` is created. 1. These Action/Workflow are executed: 1. PR. 1. Version checker (to avoid overwrite an existing image on Docker Hub repository). -1. `dev` is merged into `prod`. -1. Automatic Action/Workflow for _Push_ events into `prod` is executed to build a new Docker image for Modulector and publish it. +1. `dev` is merged into `main`. +1. Automatic Action/Workflow for _Push_ events into `main` is executed to build a new Docker image for Modulector and publish it. [**More information**](https://docs.google.com/presentation/d/1c1PXM89HLXJyF-zHAEpW_bcxb0iE_Fv2XEpEXYV2Tj4/edit?usp=sharing) From 3a58c1e9531895b906d19510b13a352e1126c695 Mon Sep 17 00:00:00 2001 From: Genaro Camele Date: Wed, 13 Dec 2023 12:58:21 -0300 Subject: [PATCH 02/21] Prevented tests to create and destroy the DB --- ModulectorBackend/settings.py | 3 ++ modulector/tests/data_init.py | 72 ---------------------------------- modulector/tests/runner.py | 13 ++++++ modulector/tests/test_views.py | 5 --- 4 files changed, 16 insertions(+), 77 deletions(-) delete mode 100644 modulector/tests/data_init.py create mode 100644 modulector/tests/runner.py diff --git a/ModulectorBackend/settings.py b/ModulectorBackend/settings.py index ab5d1f7..1cd60b3 100644 --- a/ModulectorBackend/settings.py +++ b/ModulectorBackend/settings.py @@ -163,6 +163,9 @@ MEDIA_ROOT = os.getenv('MEDIA_ROOT', os.path.join(BASE_DIR, '')) MEDIA_URL = os.getenv('MEDIA_URL', '/media/') +# Test runner +TEST_RUNNER = 'modulector.tests.runner.DjangoTestSuiteRunner' + # Email Server EMAIL_BACKEND = 'django.core.mail.backends.smtp.EmailBackend' # This email configuration is what postfix uses, for production, use your own diff --git a/modulector/tests/data_init.py b/modulector/tests/data_init.py deleted file mode 100644 index d4d11ac..0000000 --- a/modulector/tests/data_init.py +++ /dev/null @@ -1,72 +0,0 @@ -from datetime import datetime -from django.utils import timezone -from modulector.models import MirbaseIdMirna, UrlTemplate, Mirna, OldRefSeqMapping, GeneSymbolMapping, MirnaSource, \ - MirnaColumns, MirnaXGene, MirnaDisease, MirnaDrug - - -def load_test_data(cls): - MirbaseIdMirna.objects.create( - mirbase_accession_id='MIRBASETEST', - mature_mirna='hsa-test-1' - ) - UrlTemplate.objects.create( - name='mirdb', - url='test/url/com' - ) - mirna = Mirna.objects.create( - mirna_code='ASDAS_SDA@_SDASD' - ) - OldRefSeqMapping.objects.create( - old_value='NM_ASDAS', - new_value='NMAS@!DS' - ) - GeneSymbolMapping.objects.create( - refseq='REFSEQEXAMPLE', - symbol='SYMBOLTEST' - ) - source = MirnaSource.objects.create( - name='source', - site_url='this_site_url', - min_score=0, - max_score=70, - score_interpretation='this is a score interpretation', - description='this is a description', - synchronization_date=datetime.now(tz=timezone.utc), - file_separator='t' - ) - - MirnaColumns.objects.create( - mirna_source=source, - position=1, - column_name='column_name', - field_to_map='field_to_map' - - ) - - MirnaXGene.objects.create( - mirna=mirna, - gene='GEN_1', - score=80, - mirna_source=source - ) - - MirnaDisease.objects.create( - category='CAT', - mirna='MIRNA', - disease='DIS', - pubmed_id='12312312', - description='this is a description' - ) - - MirnaDrug.objects.create( - mature_mirna='ASSSDWA', - mirbase_accession_id='NMAEASDE', - small_molecule='SOME TEST', - fda_approved=True, - detection_method='detect method', - condition='condition this', - pubmed_id=2312, - reference='reference ', - support='suppport', - expression_pattern='pattern' - ) diff --git a/modulector/tests/runner.py b/modulector/tests/runner.py new file mode 100644 index 0000000..8e1aec6 --- /dev/null +++ b/modulector/tests/runner.py @@ -0,0 +1,13 @@ +from django.test.runner import DiscoverRunner + + +class DjangoTestSuiteRunner(DiscoverRunner): + """ + This runner prevents Django from creating and destroying the test database. This is useful as Modulector has + read-only preloaded data in the database. + """ + def setup_databases(self, **kwargs): + pass + + def teardown_databases(self, old_config, **kwargs): + pass diff --git a/modulector/tests/test_views.py b/modulector/tests/test_views.py index d604285..4c6865e 100644 --- a/modulector/tests/test_views.py +++ b/modulector/tests/test_views.py @@ -1,14 +1,9 @@ from django.test import Client, TestCase -from modulector.tests.data_init import load_test_data client = Client() class ViewTests(TestCase): - @classmethod - def setUpTestData(cls): - load_test_data(cls) - def __check_empty_pagination(self, response): """Checks if fields of response are valid for an empty pagination response""" self.assertEqual(response.data['count'], 0) From 46e8849e98bafe09e8c4d44a08ffc7a399fc90ed Mon Sep 17 00:00:00 2001 From: mauricio Date: Wed, 13 Dec 2023 17:03:33 -0300 Subject: [PATCH 03/21] gitignore updated --- .gitignore | 1 + 1 file changed, 1 insertion(+) diff --git a/.gitignore b/.gitignore index e6ba4b4..eede6b6 100644 --- a/.gitignore +++ b/.gitignore @@ -149,3 +149,4 @@ modulector/files/EPIC-8v2-0_A1.csv modulector/files/mirDIP_Unidirectional_search_v.5.txt *.sql.gz modulector/files/tmp_db.csv +docker-compose.mauri_dev.yml From 7a106f1bd34c84b3fb175f1e64233225d0301ccc Mon Sep 17 00:00:00 2001 From: mauricio Date: Wed, 13 Dec 2023 18:10:01 -0300 Subject: [PATCH 04/21] test of mirna endpoint added --- modulector/tests/test_mirna.py | 111 +++++++++++++++ modulector/tests/test_views.py | 239 +++++++++++++++++---------------- 2 files changed, 231 insertions(+), 119 deletions(-) create mode 100644 modulector/tests/test_mirna.py diff --git a/modulector/tests/test_mirna.py b/modulector/tests/test_mirna.py new file mode 100644 index 0000000..b4ae3e3 --- /dev/null +++ b/modulector/tests/test_mirna.py @@ -0,0 +1,111 @@ +from django.test import Client, TestCase + +client = Client() + + +class miRNATests(TestCase): + """ Testing of miRNA endpoints """ + + def __check_empty_pagination(self, response): + """Checks if fields of response are valid for an empty pagination response""" + self.assertEqual(response.data['count'], 0) + self.assertEqual(response.data['results'], []) + self.assertIsNone(response.data['next']) + self.assertIsNone(response.data['previous']) + + def __check_one_result_pagination(self, response): + """Checks if fields of response are valid for an one-result pagination response""" + self.assertEqual(response.data['count'], 1) + self.assertTrue(len(response.data['results']) == 1) + self.assertIsNone(response.data['next']) + self.assertIsNone(response.data['previous']) + + """ Testing /mirna/ endpoint """ + + def testMirnaList1(self): + """Tests mirna endpoint with a invalid mirna""" + response = client.get('/mirna/', {'mirna': 'goku_rules'}) + self.assertEqual(response.status_code, 404) + # Checks all fields + data = response.data + self.assertTrue('detail' in data) + + def testMirnaList2(self): + """Tests mirna endpoint with a valid mirna""" + response = client.get('/mirna/', {'mirna': 'hsa-miR-548ai'}) + self.assertEqual(response.status_code, 200) + # Checks all fields + data = response.data + self.assertTrue('aliases' in data) + self.assertIsInstance(data['aliases'], list) + self.assertTrue("MIMAT0018989" in data['aliases']) + + self.assertTrue('mirna_sequence' in data) + self.assertIsInstance(data['mirna_sequence'], str) + self.assertEqual(data['mirna_sequence'], "AAAGGUAAUUGCAGUUUUUCCC") + + self.assertTrue('mirbase_accession_id' in data) + self.assertIsInstance(data['mirbase_accession_id'], str) + self.assertEqual(data['mirbase_accession_id'], "MIMAT0018989") + + self.assertTrue('links' in data) + self.assertIsInstance(data['links'], list) + self.assertTrue(len(data['links']) == 1) + self.assertIsInstance(data['links'][0], dict) + self.assertTrue('source' in data['links'][0]) + self.assertTrue('url' in data['links'][0]) + self.assertIsInstance(data['links'][0]['source'], str) + self.assertIsInstance(data['links'][0]['url'], str) + + def testMirnaList3(self): + """Tests 404 error for mirna endpoint due to not specify the 'mirna' parameter""" + response = client.get('/mirna/') + self.assertEqual(response.status_code, 404) + + """ Testing /mirna-target-interactions/ endpoint """ + + def testMirnaTargetInteractions1(self): + """Tests with a invalid mirna""" + response = client.get( + '/mirna-target-interactions/', {'mirna': 'goku_capo'}) + self.assertEqual(response.status_code, 200) + self.__check_empty_pagination(response) + + def testMirnaTargetInteractions2(self): + """Tests with a valid mirna and gene""" + response = client.get( + '/mirna-target-interactions/', {'mirna': 'hsa-miR-891a-5p', 'gene': 'EGFR'}) + self.assertEqual(response.status_code, 200) + self.__check_one_result_pagination(response) + # Checks all fields + data = response.data['results'][0] + self.assertIsInstance(data, dict) + + self.assertTrue('id' in data) + self.assertIsInstance(data['id'], int) + + self.assertTrue('mirna' in data) + self.assertIsInstance(data['mirna'], str) + + self.assertTrue('gene' in data) + self.assertIsInstance(data['gene'], str) + + self.assertTrue('score' in data) + self.assertIsInstance(data['score'], str) + + self.assertTrue('source_name' in data) + self.assertIsInstance(data['source_name'], str) + + self.assertTrue('pubmeds' in data) + self.assertIsInstance(data['pubmeds'], set) + + self.assertTrue('sources' in data) + self.assertIsInstance(data['sources'], list) + + self.assertTrue('score_class' in data) + self.assertIsInstance(data['score_class'], str) + + def testMirnaTargetInteractions3(self): + """Tests 400 error for mirna endpoint due to not specify parameters""" + response = client.get('/mirna-target-interactions/') + self.assertEqual(response.status_code, 400) diff --git a/modulector/tests/test_views.py b/modulector/tests/test_views.py index 4c6865e..2054e53 100644 --- a/modulector/tests/test_views.py +++ b/modulector/tests/test_views.py @@ -4,122 +4,123 @@ class ViewTests(TestCase): - def __check_empty_pagination(self, response): - """Checks if fields of response are valid for an empty pagination response""" - self.assertEqual(response.data['count'], 0) - self.assertEqual(response.data['results'], []) - self.assertIsNone(response.data['next']) - self.assertIsNone(response.data['previous']) - - def testMirnaView(self): - """Tests mirna endpoint""" - response = client.get('/mirna/', {'mirna': 'ASDAS_SDA@_SDASD'}) - self.assertEqual(response.status_code, 200) - - # Checks all fields - data = response.data - self.assertTrue('aliases' in data) - self.assertTrue('mirna_sequence' in data) - self.assertTrue('links' in data) - - def testMirnaViewNotFound(self): - """Tests 404 error for mirna endpoint due to not specify the 'mirna' parameter""" - response = client.get('/mirna/') - self.assertEqual(response.status_code, 404) - - def testMirnaInteractionsView(self): - """Tests mirna-interactions endpoint""" - response = client.get('/mirna-interactions/', {'mirna': 'ASDAS_SDA@_SDASD'}) - self.assertEqual(response.status_code, 200) - self.assertEqual(response.data['count'], 1) - - # Checks all fields - first_result = response.data['results'][0] - self.assertTrue('id' in first_result) - self.assertTrue('mirna' in first_result) - self.assertTrue('gene' in first_result) - self.assertTrue('score' in first_result) - self.assertTrue('source_name' in first_result) - self.assertTrue('pubmeds' in first_result) - self.assertTrue('sources' in first_result) - self.assertTrue('score_class' in first_result) - - def testMirnaInteractionsViewNotFound(self): - """Test emtpy pagination for mirna-interactions endpoint""" - response = client.get('/mirna-interactions/', {'mirna': 'hsa-invalid'}) - self.assertEqual(response.status_code, 200) - self.__check_empty_pagination(response) - - def testMirnaXGenView(self): - """Tests mirna-target-interactions endpoint""" - response = client.get('/mirna-target-interactions/', {'mirna': 'ASDAS_SDA@_SDASD', 'gene': 'GEN_1'}) - self.assertEqual(response.status_code, 200) - - # Checks all fields - data = response.data - self.assertTrue('id' in data) - self.assertTrue('mirna' in data) - self.assertTrue('gene' in data) - self.assertTrue('score' in data) - self.assertTrue('source_name' in data) - self.assertTrue('pubmeds' in data) - self.assertTrue('sources' in data) - self.assertTrue('score_class' in data) - - def testMirnaXGenViewNotFound(self): - """Tests 404 error for mirna-target-interaction endpoint due to non-existent miRNA and gene""" - response = client.get('/mirna-target-interactions/', {'mirna': 'hsa-invalid', 'gene': 'gene-invalid'}) - self.assertEqual(response.status_code, 404) - - def testMirnaAliasesView(self): - """Tests mirna-aliases endpoint""" - response = client.get('/mirna-aliases/') - self.assertEqual(response.status_code, 200) - - def testDiseasesView(self): - """Tests diseases endpoint""" - response = client.get('/diseases/') - self.assertEqual(response.status_code, 200) - self.assertEqual(response.data['count'], 1) - - first_result = response.data['results'][0] - self.assertTrue('id' in first_result) - self.assertTrue('category' in first_result) - self.assertTrue('disease' in first_result) - self.assertTrue('pubmed' in first_result) - self.assertTrue('description' in first_result) - - def testDiseasesViewNotFound(self): - """Test emtpy pagination for diseases endpoint""" - response = client.get('/diseases/', {'mirna': 'hsa-invalid'}) - self.assertEqual(response.status_code, 200) - self.__check_empty_pagination(response) - - def testDrugsView(self): - """Test drugs endpoint""" - response = client.get('/drugs/') - self.assertEqual(response.status_code, 200) - self.assertEqual(response.data['count'], 1) - - # Checks all fields - first_result = response.data['results'][0] - self.assertTrue('id' in first_result) - self.assertTrue('small_molecule' in first_result) - self.assertTrue('fda_approved' in first_result) - self.assertTrue('detection_method' in first_result) - self.assertTrue('condition' in first_result) - self.assertTrue('pubmed' in first_result) - self.assertTrue('reference' in first_result) - self.assertTrue('expression_pattern' in first_result) - self.assertTrue('support' in first_result) - - def testDrugsViewNotFound(self): - """Test emtpy pagination for drugs endpoint""" - response = client.get('/drugs/', {'mirna': 'hsa-invalid'}) - self.assertEqual(response.status_code, 200) - self.__check_empty_pagination(response) - - def testRootView(self): - """Tests / endpoint""" - response = client.get('/') - self.assertEqual(response.status_code, 200) + pass + # def __check_empty_pagination(self, response): + # """Checks if fields of response are valid for an empty pagination response""" + # self.assertEqual(response.data['count'], 0) + # self.assertEqual(response.data['results'], []) + # self.assertIsNone(response.data['next']) + # self.assertIsNone(response.data['previous']) + + # def testMirnaView(self): + # """Tests mirna endpoint""" + # response = client.get('/mirna/', {'mirna': 'ASDAS_SDA@_SDASD'}) + # self.assertEqual(response.status_code, 200) + + # # Checks all fields + # data = response.data + # self.assertTrue('aliases' in data) + # self.assertTrue('mirna_sequence' in data) + # self.assertTrue('links' in data) + + # def testMirnaViewNotFound(self): + # """Tests 404 error for mirna endpoint due to not specify the 'mirna' parameter""" + # response = client.get('/mirna/') + # self.assertEqual(response.status_code, 404) + + # def testMirnaInteractionsView(self): + # """Tests mirna-interactions endpoint""" + # response = client.get('/mirna-interactions/', {'mirna': 'ASDAS_SDA@_SDASD'}) + # self.assertEqual(response.status_code, 200) + # self.assertEqual(response.data['count'], 1) + + # # Checks all fields + # first_result = response.data['results'][0] + # self.assertTrue('id' in first_result) + # self.assertTrue('mirna' in first_result) + # self.assertTrue('gene' in first_result) + # self.assertTrue('score' in first_result) + # self.assertTrue('source_name' in first_result) + # self.assertTrue('pubmeds' in first_result) + # self.assertTrue('sources' in first_result) + # self.assertTrue('score_class' in first_result) + + # def testMirnaInteractionsViewNotFound(self): + # """Test emtpy pagination for mirna-interactions endpoint""" + # response = client.get('/mirna-interactions/', {'mirna': 'hsa-invalid'}) + # self.assertEqual(response.status_code, 200) + # self.__check_empty_pagination(response) + + # def testMirnaXGenView(self): + # """Tests mirna-target-interactions endpoint""" + # response = client.get('/mirna-target-interactions/', {'mirna': 'ASDAS_SDA@_SDASD', 'gene': 'GEN_1'}) + # self.assertEqual(response.status_code, 200) + + # # Checks all fields + # data = response.data + # self.assertTrue('id' in data) + # self.assertTrue('mirna' in data) + # self.assertTrue('gene' in data) + # self.assertTrue('score' in data) + # self.assertTrue('source_name' in data) + # self.assertTrue('pubmeds' in data) + # self.assertTrue('sources' in data) + # self.assertTrue('score_class' in data) + + # def testMirnaXGenViewNotFound(self): + # """Tests 404 error for mirna-target-interaction endpoint due to non-existent miRNA and gene""" + # response = client.get('/mirna-target-interactions/', {'mirna': 'hsa-invalid', 'gene': 'gene-invalid'}) + # self.assertEqual(response.status_code, 404) + + # def testMirnaAliasesView(self): + # """Tests mirna-aliases endpoint""" + # response = client.get('/mirna-aliases/') + # self.assertEqual(response.status_code, 200) + + # def testDiseasesView(self): + # """Tests diseases endpoint""" + # response = client.get('/diseases/') + # self.assertEqual(response.status_code, 200) + # self.assertEqual(response.data['count'], 1) + + # first_result = response.data['results'][0] + # self.assertTrue('id' in first_result) + # self.assertTrue('category' in first_result) + # self.assertTrue('disease' in first_result) + # self.assertTrue('pubmed' in first_result) + # self.assertTrue('description' in first_result) + + # def testDiseasesViewNotFound(self): + # """Test emtpy pagination for diseases endpoint""" + # response = client.get('/diseases/', {'mirna': 'hsa-invalid'}) + # self.assertEqual(response.status_code, 200) + # self.__check_empty_pagination(response) + + # def testDrugsView(self): + # """Test drugs endpoint""" + # response = client.get('/drugs/') + # self.assertEqual(response.status_code, 200) + # self.assertEqual(response.data['count'], 1) + + # # Checks all fields + # first_result = response.data['results'][0] + # self.assertTrue('id' in first_result) + # self.assertTrue('small_molecule' in first_result) + # self.assertTrue('fda_approved' in first_result) + # self.assertTrue('detection_method' in first_result) + # self.assertTrue('condition' in first_result) + # self.assertTrue('pubmed' in first_result) + # self.assertTrue('reference' in first_result) + # self.assertTrue('expression_pattern' in first_result) + # self.assertTrue('support' in first_result) + + # def testDrugsViewNotFound(self): + # """Test emtpy pagination for drugs endpoint""" + # response = client.get('/drugs/', {'mirna': 'hsa-invalid'}) + # self.assertEqual(response.status_code, 200) + # self.__check_empty_pagination(response) + + # def testRootView(self): + # """Tests / endpoint""" + # response = client.get('/') + # self.assertEqual(response.status_code, 200) From 74c2f0c114b0e2667ccfba865dbe1ceb592eb1c3 Mon Sep 17 00:00:00 2001 From: mauricio Date: Mon, 18 Dec 2023 10:34:46 -0300 Subject: [PATCH 05/21] more tests of endpoints added --- modulector/tests/test_diseases.py | 38 +++++ modulector/tests/test_drugs.py | 43 +++++ modulector/tests/test_methylation.py | 245 +++++++++++++++++++++++++++ modulector/tests/test_mirna.py | 89 ++++++++++ modulector/tests/test_root.py | 10 ++ modulector/tests/test_views.py | 126 -------------- 6 files changed, 425 insertions(+), 126 deletions(-) create mode 100644 modulector/tests/test_diseases.py create mode 100644 modulector/tests/test_drugs.py create mode 100644 modulector/tests/test_methylation.py create mode 100644 modulector/tests/test_root.py delete mode 100644 modulector/tests/test_views.py diff --git a/modulector/tests/test_diseases.py b/modulector/tests/test_diseases.py new file mode 100644 index 0000000..30528cc --- /dev/null +++ b/modulector/tests/test_diseases.py @@ -0,0 +1,38 @@ +from django.test import Client, TestCase + +client = Client() + + +class diseaseTests(TestCase): + def __check_empty_pagination(self, response): + """Checks if fields of response are valid for an empty pagination response""" + self.assertEqual(response.data['count'], 0) + self.assertEqual(response.data['results'], []) + self.assertIsNone(response.data['next']) + self.assertIsNone(response.data['previous']) + + def __check_one_result_pagination(self, response): + """Checks if fields of response are valid for an one-result pagination response""" + self.assertEqual(response.data['count'], 1) + self.assertTrue(len(response.data['results']) == 1) + self.assertIsNone(response.data['next']) + self.assertIsNone(response.data['previous']) + + def testDiseasesView(self): + """ Test the disease endpoint for a valid mirna """ + response = client.get('/diseases/', {"mirna": "hsa-miR-9500"}) + self.assertEqual(response.status_code, 200) + self.__check_one_result_pagination(response) + self.assertEqual(response.data['count'], 1) + first_result = response.data['results'][0] + self.assertTrue('id' in first_result) + self.assertTrue('category' in first_result) + self.assertTrue('disease' in first_result) + self.assertTrue('pubmed' in first_result) + self.assertTrue('description' in first_result) + + def testDiseasesViewNotFound(self): + """Test emtpy pagination for diseases endpoint""" + response = client.get('/diseases/', {'mirna': 'hsa-invalid'}) + self.assertEqual(response.status_code, 200) + self.__check_empty_pagination(response) diff --git a/modulector/tests/test_drugs.py b/modulector/tests/test_drugs.py new file mode 100644 index 0000000..3afd378 --- /dev/null +++ b/modulector/tests/test_drugs.py @@ -0,0 +1,43 @@ +from django.test import Client, TestCase + +client = Client() + + +class drugsTests(TestCase): + def __check_empty_pagination(self, response): + """Checks if fields of response are valid for an empty pagination response""" + self.assertEqual(response.data['count'], 0) + self.assertEqual(response.data['results'], []) + self.assertIsNone(response.data['next']) + self.assertIsNone(response.data['previous']) + + def __check_one_result_pagination(self, response): + """Checks if fields of response are valid for an one-result pagination response""" + self.assertEqual(response.data['count'], 1) + self.assertTrue(len(response.data['results']) == 1) + self.assertIsNone(response.data['next']) + self.assertIsNone(response.data['previous']) + + def testDrugs(self): + """Test drugs endpoint""" + response = client.get('/drugs/', {'mirna': 'miR-378*'}) + self.assertEqual(response.status_code, 200) + self.__check_one_result_pagination(response) + + # Checks all fields + data = response.data['results'][0] + self.assertTrue('id' in data) + self.assertTrue('small_molecule' in data) + self.assertTrue('fda_approved' in data) + self.assertTrue('detection_method' in data) + self.assertTrue('condition' in data) + self.assertTrue('pubmed' in data) + self.assertTrue('reference' in data) + self.assertTrue('expression_pattern' in data) + self.assertTrue('support' in data) + + def testDrugsViewNotFound(self): + """Test emtpy pagination for drugs endpoint""" + response = client.get('/drugs/', {'mirna': 'hsa-invalid'}) + self.assertEqual(response.status_code, 200) + self.__check_empty_pagination(response) diff --git a/modulector/tests/test_methylation.py b/modulector/tests/test_methylation.py new file mode 100644 index 0000000..63845b8 --- /dev/null +++ b/modulector/tests/test_methylation.py @@ -0,0 +1,245 @@ +import json +from django.test import Client, TestCase + +client = Client() + + +class methylationTests(TestCase): + """ Testing of methylation endpoints """ + + def __check_pagination(self, response): + """check that the response is paginated""" + self.assertTrue('count' in response.data) + self.assertTrue('next' in response.data) + self.assertTrue('previous' in response.data) + self.assertTrue('results' in response.data) + self.assertIsInstance(response.data['results'], list) + self.assertIsInstance(response.data['count'], int) + + def __check_empty_pagination(self, response): + """Checks if fields of response are valid for an empty pagination response""" + self.assertEqual(response.data['count'], 0) + self.assertEqual(response.data['results'], []) + self.assertIsNone(response.data['next']) + self.assertIsNone(response.data['previous']) + + def __check_one_result_pagination(self, response): + """Checks if fields of response are valid for an one-result pagination response""" + self.assertEqual(response.data['count'], 1) + self.assertTrue(len(response.data['results']) == 1) + self.assertIsNone(response.data['next']) + self.assertIsNone(response.data['previous']) + + """ Testing /methylation/ endpoint """ + + def testMethylationDetails1(self): + """ Tests methylation endpoint with a valid methylation site """ + response = client.get( + '/methylation/', {'methylation_site': 'cg22461615'}) + self.assertEqual(response.status_code, 200) + # Checks all fields + data = response.data + self.assertTrue('name' in data) + self.assertTrue('chromosome_position' in data) + self.assertTrue('aliases' in data) + self.assertTrue('ucsc_cpg_islands' in data) + self.assertTrue('genes' in data) + self.assertIsInstance(data['name'], str) + self.assertIsInstance(data['chromosome_position'], str) + self.assertIsInstance(data['chromosome_position'], str) + self.assertIsInstance(data['aliases'], list) + self.assertIsInstance(data['ucsc_cpg_islands'], list) + self.assertIsInstance(data['genes'], dict) + self.assertEqual(data['name'], 'cg22461615') + self.assertEqual(data['chromosome_position'], 'chr4:82900764 [+]') + self.assertEqual(data['aliases'], ["cg22461615_TC11"]) + self.assertEqual(data['ucsc_cpg_islands'], [ + {"cpg_island": "chr4:82900535-82900912", "relation": "Island"}]) + self.assertEqual(data['genes']['THAP9'], ["5UTR", "exon_1"]) + self.assertEqual(data['genes']['THAP9-AS1'], ["exon_1"]) + self.assertEqual(data['genes']['SEC31A'], ["TSS200"]) + + def testMethylationDetails2(self): + """ Tests methylation endpoint with a invalid methylation site """ + response = client.get( + '/methylation/', {'methylation_site': 'thisIsNotAMethylationSite'}) + self.assertEqual(response.status_code, 400) + # Checks all fields + data = response.data + self.assertIsInstance(data, set) + self.assertTrue(len(data) == 1) + self.assertIsInstance(list(data)[0], str) + + def testMethylationDetails3(self): + """ Tests methylation endpoint without parameters """ + response = client.get('/methylation/') + self.assertEqual(response.status_code, 400) + # Checks all fields + data = response.data + self.assertIsInstance(data, set) + self.assertTrue(len(data) == 1) + self.assertIsInstance(list(data)[0], str) + + +""" Testing /methylation-sites-finder/ endpoint """ +""" Testing /methylation-sites/ endpoint """ +""" Testing /methylation-sites-genes/ endpoint """ + +# def testMirnaList2(self): +# """Tests mirna endpoint with a valid mirna""" +# response = client.get('/mirna/', {'mirna': 'hsa-miR-548ai'}) +# self.assertEqual(response.status_code, 200) +# # Checks all fields +# data = response.data +# self.assertTrue('aliases' in data) +# self.assertIsInstance(data['aliases'], list) +# self.assertTrue("MIMAT0018989" in data['aliases']) + +# self.assertTrue('mirna_sequence' in data) +# self.assertIsInstance(data['mirna_sequence'], str) +# self.assertEqual(data['mirna_sequence'], "AAAGGUAAUUGCAGUUUUUCCC") + +# self.assertTrue('mirbase_accession_id' in data) +# self.assertIsInstance(data['mirbase_accession_id'], str) +# self.assertEqual(data['mirbase_accession_id'], "MIMAT0018989") + +# self.assertTrue('links' in data) +# self.assertIsInstance(data['links'], list) +# self.assertTrue(len(data['links']) == 1) +# self.assertIsInstance(data['links'][0], dict) +# self.assertTrue('source' in data['links'][0]) +# self.assertTrue('url' in data['links'][0]) +# self.assertIsInstance(data['links'][0]['source'], str) +# self.assertIsInstance(data['links'][0]['url'], str) + +# def testMirnaList3(self): +# """Tests 404 error for mirna endpoint due to not specify the 'mirna' parameter""" +# response = client.get('/mirna/') +# self.assertEqual(response.status_code, 404) + +# """ Testing /mirna-target-interactions/ endpoint """ + +# def testMirnaTargetInteractions1(self): +# """Tests with a invalid mirna""" +# response = client.get( +# '/mirna-target-interactions/', {'mirna': 'goku_capo'}) +# self.assertEqual(response.status_code, 200) +# self.__check_pagination(response) +# self.__check_empty_pagination(response) + +# def testMirnaTargetInteractions2(self): +# """Tests with a valid mirna and gene""" +# response = client.get( +# '/mirna-target-interactions/', {'mirna': 'hsa-miR-891a-5p', 'gene': 'EGFR'}) +# self.assertEqual(response.status_code, 200) +# self.__check_pagination(response) +# self.__check_one_result_pagination(response) +# # Checks all fields +# data = response.data['results'][0] +# self.assertIsInstance(data, dict) + +# self.assertTrue('id' in data) +# self.assertIsInstance(data['id'], int) + +# self.assertTrue('mirna' in data) +# self.assertIsInstance(data['mirna'], str) + +# self.assertTrue('gene' in data) +# self.assertIsInstance(data['gene'], str) + +# self.assertTrue('score' in data) +# self.assertIsInstance(data['score'], str) + +# self.assertTrue('source_name' in data) +# self.assertIsInstance(data['source_name'], str) + +# self.assertTrue('pubmeds' in data) +# self.assertIsInstance(data['pubmeds'], set) + +# self.assertTrue('sources' in data) +# self.assertIsInstance(data['sources'], list) + +# self.assertTrue('score_class' in data) +# self.assertIsInstance(data['score_class'], str) + +# def testMirnaTargetInteractions3(self): +# """Tests 400 error for mirna endpoint due to not specify parameters""" +# response = client.get('/mirna-target-interactions/') +# self.assertEqual(response.status_code, 400) + +# """ Testing /mirna-aliases/ endpoint """ + +# def testMirnaAliases1(self): +# """ Test the entire mirna-aliases/ endpoint since it does not receive parameters """ +# response = client.get('/mirna-aliases/') +# self.assertEqual(response.status_code, 200) +# self.__check_pagination(response) + +# """ Testing /mirna-codes/ endpoint """ + +# def testMirnaCodes1(self): +# """ Tests with a valid body """ +# data = json.dumps({"mirna_codes": ["name_01", "Hsa-Mir-935-v2_5p*", +# "MIMAT0000066", +# "MI0026417", +# "hsa-let-7e-5p"] +# }) +# response = client.post('/mirna-codes/', data=data, +# content_type='application/json') +# self.assertEqual(response.status_code, 200) +# data = response.data +# self.assertTrue("name_01" in data) +# self.assertTrue("Hsa-Mir-935-v2_5p*" in data) +# self.assertTrue("MIMAT0000066" in data) +# self.assertTrue("MI0026417" in data) +# self.assertTrue("hsa-let-7e-5p" in data) +# self.assertIsNone(data["name_01"]) +# self.assertIsNone(data["Hsa-Mir-935-v2_5p*"]) +# self.assertEqual(data["MIMAT0000066"], "MIMAT0000066") +# self.assertEqual(data["MI0026417"], "MI0026417") +# self.assertEqual(data["hsa-let-7e-5p"], "MIMAT0000066") + +# def testMirnaCodes2(self): +# """ Tests with a invalid body type """ +# data = json.dumps({"mirna_codes": "Hsa-Mir-935-v2_5p*"}) +# response = client.post('/mirna-codes/', data=data, +# content_type='application/json') +# self.assertEqual(response.status_code, 400) +# data = response.data +# self.assertTrue("detail" in data) + +# def testMirnaCodes3(self): +# """ Tests with a invalid body key """ +# data = json.dumps({"mirna": ["Hsa-Mir-935-v2_5p*"]}) +# response = client.post('/mirna-codes/', data=data, +# content_type='application/json') +# self.assertEqual(response.status_code, 400) +# data = response.data +# self.assertTrue("detail" in data) + +# """ Testing /mirna-codes-finder/ endpoint """ + +# def testMirnaCodesFinder1(self): +# """ Tests with a valid response whit 7 results """ +# response = client.get( +# '/mirna-codes-finder/', {'query': 'hsa-', 'limit': 7}) +# self.assertEqual(response.status_code, 200) +# data = response.data +# self.assertIsInstance(data, list) +# self.assertTrue(len(data) == 7) + +# def testMirnaCodesFinder2(self): +# """ Tests default limit parameter value """ +# response = client.get('/mirna-codes-finder/', {'query': 'hsa-'}) +# self.assertEqual(response.status_code, 200) +# data = response.data +# self.assertIsInstance(data, list) +# self.assertTrue(len(data) == 50) + +# def testMirnaCodesFinder3(self): +# """ Tests endpoint without parameters """ +# response = client.get('/mirna-codes-finder/') +# self.assertEqual(response.status_code, 200) +# data = response.data +# self.assertIsInstance(data, list) +# self.assertTrue(len(data) == 0) diff --git a/modulector/tests/test_mirna.py b/modulector/tests/test_mirna.py index b4ae3e3..4f5fa7a 100644 --- a/modulector/tests/test_mirna.py +++ b/modulector/tests/test_mirna.py @@ -1,3 +1,4 @@ +import json from django.test import Client, TestCase client = Client() @@ -6,6 +7,15 @@ class miRNATests(TestCase): """ Testing of miRNA endpoints """ + def __check_pagination(self, response): + """check that the response is paginated""" + self.assertTrue('count' in response.data) + self.assertTrue('next' in response.data) + self.assertTrue('previous' in response.data) + self.assertTrue('results' in response.data) + self.assertIsInstance(response.data['results'], list) + self.assertIsInstance(response.data['count'], int) + def __check_empty_pagination(self, response): """Checks if fields of response are valid for an empty pagination response""" self.assertEqual(response.data['count'], 0) @@ -69,6 +79,7 @@ def testMirnaTargetInteractions1(self): response = client.get( '/mirna-target-interactions/', {'mirna': 'goku_capo'}) self.assertEqual(response.status_code, 200) + self.__check_pagination(response) self.__check_empty_pagination(response) def testMirnaTargetInteractions2(self): @@ -76,6 +87,7 @@ def testMirnaTargetInteractions2(self): response = client.get( '/mirna-target-interactions/', {'mirna': 'hsa-miR-891a-5p', 'gene': 'EGFR'}) self.assertEqual(response.status_code, 200) + self.__check_pagination(response) self.__check_one_result_pagination(response) # Checks all fields data = response.data['results'][0] @@ -109,3 +121,80 @@ def testMirnaTargetInteractions3(self): """Tests 400 error for mirna endpoint due to not specify parameters""" response = client.get('/mirna-target-interactions/') self.assertEqual(response.status_code, 400) + + """ Testing /mirna-aliases/ endpoint """ + + def testMirnaAliases1(self): + """ Test the entire mirna-aliases/ endpoint since it does not receive parameters """ + response = client.get('/mirna-aliases/') + self.assertEqual(response.status_code, 200) + self.__check_pagination(response) + + """ Testing /mirna-codes/ endpoint """ + + def testMirnaCodes1(self): + """ Tests with a valid body """ + data = json.dumps({"mirna_codes": ["name_01", "Hsa-Mir-935-v2_5p*", + "MIMAT0000066", + "MI0026417", + "hsa-let-7e-5p"] + }) + response = client.post('/mirna-codes/', data=data, + content_type='application/json') + self.assertEqual(response.status_code, 200) + data = response.data + self.assertTrue("name_01" in data) + self.assertTrue("Hsa-Mir-935-v2_5p*" in data) + self.assertTrue("MIMAT0000066" in data) + self.assertTrue("MI0026417" in data) + self.assertTrue("hsa-let-7e-5p" in data) + self.assertIsNone(data["name_01"]) + self.assertIsNone(data["Hsa-Mir-935-v2_5p*"]) + self.assertEqual(data["MIMAT0000066"], "MIMAT0000066") + self.assertEqual(data["MI0026417"], "MI0026417") + self.assertEqual(data["hsa-let-7e-5p"], "MIMAT0000066") + + def testMirnaCodes2(self): + """ Tests with a invalid body type """ + data = json.dumps({"mirna_codes": "Hsa-Mir-935-v2_5p*"}) + response = client.post('/mirna-codes/', data=data, + content_type='application/json') + self.assertEqual(response.status_code, 400) + data = response.data + self.assertTrue("detail" in data) + + def testMirnaCodes3(self): + """ Tests with a invalid body key """ + data = json.dumps({"mirna": ["Hsa-Mir-935-v2_5p*"]}) + response = client.post('/mirna-codes/', data=data, + content_type='application/json') + self.assertEqual(response.status_code, 400) + data = response.data + self.assertTrue("detail" in data) + + """ Testing /mirna-codes-finder/ endpoint """ + + def testMirnaCodesFinder1(self): + """ Tests with a valid response whit 7 results """ + response = client.get( + '/mirna-codes-finder/', {'query': 'hsa-', 'limit': 7}) + self.assertEqual(response.status_code, 200) + data = response.data + self.assertIsInstance(data, list) + self.assertTrue(len(data) == 7) + + def testMirnaCodesFinder2(self): + """ Tests default limit parameter value """ + response = client.get('/mirna-codes-finder/', {'query': 'hsa-'}) + self.assertEqual(response.status_code, 200) + data = response.data + self.assertIsInstance(data, list) + self.assertTrue(len(data) == 50) + + def testMirnaCodesFinder3(self): + """ Tests endpoint without parameters """ + response = client.get('/mirna-codes-finder/') + self.assertEqual(response.status_code, 200) + data = response.data + self.assertIsInstance(data, list) + self.assertTrue(len(data) == 0) diff --git a/modulector/tests/test_root.py b/modulector/tests/test_root.py new file mode 100644 index 0000000..2b04132 --- /dev/null +++ b/modulector/tests/test_root.py @@ -0,0 +1,10 @@ +from django.test import Client, TestCase + +client = Client() + + +class rootTests(TestCase): + def testRootView(self): + """Tests / endpoint""" + response = client.get('/') + self.assertEqual(response.status_code, 200) diff --git a/modulector/tests/test_views.py b/modulector/tests/test_views.py deleted file mode 100644 index 2054e53..0000000 --- a/modulector/tests/test_views.py +++ /dev/null @@ -1,126 +0,0 @@ -from django.test import Client, TestCase - -client = Client() - - -class ViewTests(TestCase): - pass - # def __check_empty_pagination(self, response): - # """Checks if fields of response are valid for an empty pagination response""" - # self.assertEqual(response.data['count'], 0) - # self.assertEqual(response.data['results'], []) - # self.assertIsNone(response.data['next']) - # self.assertIsNone(response.data['previous']) - - # def testMirnaView(self): - # """Tests mirna endpoint""" - # response = client.get('/mirna/', {'mirna': 'ASDAS_SDA@_SDASD'}) - # self.assertEqual(response.status_code, 200) - - # # Checks all fields - # data = response.data - # self.assertTrue('aliases' in data) - # self.assertTrue('mirna_sequence' in data) - # self.assertTrue('links' in data) - - # def testMirnaViewNotFound(self): - # """Tests 404 error for mirna endpoint due to not specify the 'mirna' parameter""" - # response = client.get('/mirna/') - # self.assertEqual(response.status_code, 404) - - # def testMirnaInteractionsView(self): - # """Tests mirna-interactions endpoint""" - # response = client.get('/mirna-interactions/', {'mirna': 'ASDAS_SDA@_SDASD'}) - # self.assertEqual(response.status_code, 200) - # self.assertEqual(response.data['count'], 1) - - # # Checks all fields - # first_result = response.data['results'][0] - # self.assertTrue('id' in first_result) - # self.assertTrue('mirna' in first_result) - # self.assertTrue('gene' in first_result) - # self.assertTrue('score' in first_result) - # self.assertTrue('source_name' in first_result) - # self.assertTrue('pubmeds' in first_result) - # self.assertTrue('sources' in first_result) - # self.assertTrue('score_class' in first_result) - - # def testMirnaInteractionsViewNotFound(self): - # """Test emtpy pagination for mirna-interactions endpoint""" - # response = client.get('/mirna-interactions/', {'mirna': 'hsa-invalid'}) - # self.assertEqual(response.status_code, 200) - # self.__check_empty_pagination(response) - - # def testMirnaXGenView(self): - # """Tests mirna-target-interactions endpoint""" - # response = client.get('/mirna-target-interactions/', {'mirna': 'ASDAS_SDA@_SDASD', 'gene': 'GEN_1'}) - # self.assertEqual(response.status_code, 200) - - # # Checks all fields - # data = response.data - # self.assertTrue('id' in data) - # self.assertTrue('mirna' in data) - # self.assertTrue('gene' in data) - # self.assertTrue('score' in data) - # self.assertTrue('source_name' in data) - # self.assertTrue('pubmeds' in data) - # self.assertTrue('sources' in data) - # self.assertTrue('score_class' in data) - - # def testMirnaXGenViewNotFound(self): - # """Tests 404 error for mirna-target-interaction endpoint due to non-existent miRNA and gene""" - # response = client.get('/mirna-target-interactions/', {'mirna': 'hsa-invalid', 'gene': 'gene-invalid'}) - # self.assertEqual(response.status_code, 404) - - # def testMirnaAliasesView(self): - # """Tests mirna-aliases endpoint""" - # response = client.get('/mirna-aliases/') - # self.assertEqual(response.status_code, 200) - - # def testDiseasesView(self): - # """Tests diseases endpoint""" - # response = client.get('/diseases/') - # self.assertEqual(response.status_code, 200) - # self.assertEqual(response.data['count'], 1) - - # first_result = response.data['results'][0] - # self.assertTrue('id' in first_result) - # self.assertTrue('category' in first_result) - # self.assertTrue('disease' in first_result) - # self.assertTrue('pubmed' in first_result) - # self.assertTrue('description' in first_result) - - # def testDiseasesViewNotFound(self): - # """Test emtpy pagination for diseases endpoint""" - # response = client.get('/diseases/', {'mirna': 'hsa-invalid'}) - # self.assertEqual(response.status_code, 200) - # self.__check_empty_pagination(response) - - # def testDrugsView(self): - # """Test drugs endpoint""" - # response = client.get('/drugs/') - # self.assertEqual(response.status_code, 200) - # self.assertEqual(response.data['count'], 1) - - # # Checks all fields - # first_result = response.data['results'][0] - # self.assertTrue('id' in first_result) - # self.assertTrue('small_molecule' in first_result) - # self.assertTrue('fda_approved' in first_result) - # self.assertTrue('detection_method' in first_result) - # self.assertTrue('condition' in first_result) - # self.assertTrue('pubmed' in first_result) - # self.assertTrue('reference' in first_result) - # self.assertTrue('expression_pattern' in first_result) - # self.assertTrue('support' in first_result) - - # def testDrugsViewNotFound(self): - # """Test emtpy pagination for drugs endpoint""" - # response = client.get('/drugs/', {'mirna': 'hsa-invalid'}) - # self.assertEqual(response.status_code, 200) - # self.__check_empty_pagination(response) - - # def testRootView(self): - # """Tests / endpoint""" - # response = client.get('/') - # self.assertEqual(response.status_code, 200) From e266643c1e99391b90bd3737b6c1e550a56cf527 Mon Sep 17 00:00:00 2001 From: mauricio Date: Mon, 18 Dec 2023 12:05:47 -0300 Subject: [PATCH 06/21] methylation tests added --- modulector/tests/test_methylation.py | 271 +++++++++++---------------- 1 file changed, 109 insertions(+), 162 deletions(-) diff --git a/modulector/tests/test_methylation.py b/modulector/tests/test_methylation.py index 63845b8..75f9a3d 100644 --- a/modulector/tests/test_methylation.py +++ b/modulector/tests/test_methylation.py @@ -1,4 +1,5 @@ import json +import sys from django.test import Client, TestCase client = Client() @@ -80,166 +81,112 @@ def testMethylationDetails3(self): self.assertTrue(len(data) == 1) self.assertIsInstance(list(data)[0], str) + """ Testing /methylation-sites-finder/ endpoint """ -""" Testing /methylation-sites-finder/ endpoint """ -""" Testing /methylation-sites/ endpoint """ -""" Testing /methylation-sites-genes/ endpoint """ - -# def testMirnaList2(self): -# """Tests mirna endpoint with a valid mirna""" -# response = client.get('/mirna/', {'mirna': 'hsa-miR-548ai'}) -# self.assertEqual(response.status_code, 200) -# # Checks all fields -# data = response.data -# self.assertTrue('aliases' in data) -# self.assertIsInstance(data['aliases'], list) -# self.assertTrue("MIMAT0018989" in data['aliases']) - -# self.assertTrue('mirna_sequence' in data) -# self.assertIsInstance(data['mirna_sequence'], str) -# self.assertEqual(data['mirna_sequence'], "AAAGGUAAUUGCAGUUUUUCCC") - -# self.assertTrue('mirbase_accession_id' in data) -# self.assertIsInstance(data['mirbase_accession_id'], str) -# self.assertEqual(data['mirbase_accession_id'], "MIMAT0018989") - -# self.assertTrue('links' in data) -# self.assertIsInstance(data['links'], list) -# self.assertTrue(len(data['links']) == 1) -# self.assertIsInstance(data['links'][0], dict) -# self.assertTrue('source' in data['links'][0]) -# self.assertTrue('url' in data['links'][0]) -# self.assertIsInstance(data['links'][0]['source'], str) -# self.assertIsInstance(data['links'][0]['url'], str) - -# def testMirnaList3(self): -# """Tests 404 error for mirna endpoint due to not specify the 'mirna' parameter""" -# response = client.get('/mirna/') -# self.assertEqual(response.status_code, 404) - -# """ Testing /mirna-target-interactions/ endpoint """ - -# def testMirnaTargetInteractions1(self): -# """Tests with a invalid mirna""" -# response = client.get( -# '/mirna-target-interactions/', {'mirna': 'goku_capo'}) -# self.assertEqual(response.status_code, 200) -# self.__check_pagination(response) -# self.__check_empty_pagination(response) - -# def testMirnaTargetInteractions2(self): -# """Tests with a valid mirna and gene""" -# response = client.get( -# '/mirna-target-interactions/', {'mirna': 'hsa-miR-891a-5p', 'gene': 'EGFR'}) -# self.assertEqual(response.status_code, 200) -# self.__check_pagination(response) -# self.__check_one_result_pagination(response) -# # Checks all fields -# data = response.data['results'][0] -# self.assertIsInstance(data, dict) - -# self.assertTrue('id' in data) -# self.assertIsInstance(data['id'], int) - -# self.assertTrue('mirna' in data) -# self.assertIsInstance(data['mirna'], str) - -# self.assertTrue('gene' in data) -# self.assertIsInstance(data['gene'], str) - -# self.assertTrue('score' in data) -# self.assertIsInstance(data['score'], str) - -# self.assertTrue('source_name' in data) -# self.assertIsInstance(data['source_name'], str) - -# self.assertTrue('pubmeds' in data) -# self.assertIsInstance(data['pubmeds'], set) - -# self.assertTrue('sources' in data) -# self.assertIsInstance(data['sources'], list) - -# self.assertTrue('score_class' in data) -# self.assertIsInstance(data['score_class'], str) - -# def testMirnaTargetInteractions3(self): -# """Tests 400 error for mirna endpoint due to not specify parameters""" -# response = client.get('/mirna-target-interactions/') -# self.assertEqual(response.status_code, 400) - -# """ Testing /mirna-aliases/ endpoint """ - -# def testMirnaAliases1(self): -# """ Test the entire mirna-aliases/ endpoint since it does not receive parameters """ -# response = client.get('/mirna-aliases/') -# self.assertEqual(response.status_code, 200) -# self.__check_pagination(response) - -# """ Testing /mirna-codes/ endpoint """ - -# def testMirnaCodes1(self): -# """ Tests with a valid body """ -# data = json.dumps({"mirna_codes": ["name_01", "Hsa-Mir-935-v2_5p*", -# "MIMAT0000066", -# "MI0026417", -# "hsa-let-7e-5p"] -# }) -# response = client.post('/mirna-codes/', data=data, -# content_type='application/json') -# self.assertEqual(response.status_code, 200) -# data = response.data -# self.assertTrue("name_01" in data) -# self.assertTrue("Hsa-Mir-935-v2_5p*" in data) -# self.assertTrue("MIMAT0000066" in data) -# self.assertTrue("MI0026417" in data) -# self.assertTrue("hsa-let-7e-5p" in data) -# self.assertIsNone(data["name_01"]) -# self.assertIsNone(data["Hsa-Mir-935-v2_5p*"]) -# self.assertEqual(data["MIMAT0000066"], "MIMAT0000066") -# self.assertEqual(data["MI0026417"], "MI0026417") -# self.assertEqual(data["hsa-let-7e-5p"], "MIMAT0000066") - -# def testMirnaCodes2(self): -# """ Tests with a invalid body type """ -# data = json.dumps({"mirna_codes": "Hsa-Mir-935-v2_5p*"}) -# response = client.post('/mirna-codes/', data=data, -# content_type='application/json') -# self.assertEqual(response.status_code, 400) -# data = response.data -# self.assertTrue("detail" in data) - -# def testMirnaCodes3(self): -# """ Tests with a invalid body key """ -# data = json.dumps({"mirna": ["Hsa-Mir-935-v2_5p*"]}) -# response = client.post('/mirna-codes/', data=data, -# content_type='application/json') -# self.assertEqual(response.status_code, 400) -# data = response.data -# self.assertTrue("detail" in data) - -# """ Testing /mirna-codes-finder/ endpoint """ - -# def testMirnaCodesFinder1(self): -# """ Tests with a valid response whit 7 results """ -# response = client.get( -# '/mirna-codes-finder/', {'query': 'hsa-', 'limit': 7}) -# self.assertEqual(response.status_code, 200) -# data = response.data -# self.assertIsInstance(data, list) -# self.assertTrue(len(data) == 7) - -# def testMirnaCodesFinder2(self): -# """ Tests default limit parameter value """ -# response = client.get('/mirna-codes-finder/', {'query': 'hsa-'}) -# self.assertEqual(response.status_code, 200) -# data = response.data -# self.assertIsInstance(data, list) -# self.assertTrue(len(data) == 50) - -# def testMirnaCodesFinder3(self): -# """ Tests endpoint without parameters """ -# response = client.get('/mirna-codes-finder/') -# self.assertEqual(response.status_code, 200) -# data = response.data -# self.assertIsInstance(data, list) -# self.assertTrue(len(data) == 0) + def testMethylationSitesFinder1(self): + """ Tests with a valid response whit 7 results """ + response = client.get( + '/methylation-sites-finder/', {'query': 'cg25', 'limit': 7}) + self.assertEqual(response.status_code, 200) + data = response.data + self.assertIsInstance(data, list) + self.assertTrue(len(data) == 7) + + def testMethylationSitesFinder2(self): + """ Tests default limit parameter value """ + response = client.get('/methylation-sites-finder/', {'query': 'cg25'}) + self.assertEqual(response.status_code, 200) + data = response.data + self.assertIsInstance(data, list) + self.assertTrue(len(data) == 50) + + def testMethylationSitesFinder3(self): + """ Tests endpoint without parameters """ + response = client.get('/methylation-sites-finder/') + self.assertEqual(response.status_code, 200) + data = response.data + self.assertIsInstance(data, list) + self.assertTrue(len(data) == 0) + + """ Testing /methylation-sites/ endpoint """ + + def testMethylationSites1(self): + """ Tests with a valid body """ + data_body = json.dumps( + { + "methylation_sites": [ + "cg22461615_TC11", + "cg01615704_TC11", + "cg25908985", + "invalid_data"] + } + ) + response = client.post('/methylation-sites/', data=data_body, + content_type='application/json') + self.assertEqual(response.status_code, 200) + data = response.data + # sys.exit(str(data)) + for k in data: + self.assertIsInstance(data[k], list) + self.assertTrue("cg22461615_TC11" in data) + self.assertTrue("cg01615704_TC11" in data) + self.assertTrue("cg25908985" in data) + self.assertTrue("invalid_data" in data) + # self.assertEqual(data["cg22461615_TC11"], ["cg22461615"]) + # self.assertEqual(data["cg01615704_TC11"], ["cg01615704"]) + # self.assertEqual(data["cg25908985"], ["cg25908985"]) + # self.assertEqual(data["invalid_data"], []) + + def testMethylationSites2(self): + """ Tests with a invalid body type """ + data = json.dumps({"methylation_sites": "cg01615704_TC11"}) + response = client.post('/methylation-sites/', data=data, + content_type='application/json') + self.assertEqual(response.status_code, 400) + data = response.data + self.assertTrue("detail" in data) + + def testMethylationSites3(self): + """ Tests with a invalid body key """ + data = json.dumps({"methylation": ["cg01615704_TC11"]}) + response = client.post('/methylation-sites/', data=data, + content_type='application/json') + self.assertEqual(response.status_code, 400) + data = response.data + self.assertTrue("detail" in data) + + """ Testing /methylation-sites-genes/ endpoint """ + + def testMethylationSitesToGenes1(self): + """ Tests with a valid body """ + data_body = json.dumps( + {"methylation_sites": ["cg17771854_BC11", "cg22461615", "name_007"]}) + response = client.post('/methylation-sites-genes/', data=data_body, + content_type='application/json') + self.assertEqual(response.status_code, 200) + data = response.data + # sys.exit(str(data)) + self.assertTrue("cg17771854_BC11" in data) + self.assertTrue("cg22461615" in data) + for k in data: + self.assertIsInstance(data[k], list) + self.assertEqual(data["cg17771854_BC11"], ["IPO13"]) + self.assertEqual(data["cg22461615"], ["THAP9", "THAP9-AS1", "SEC31A"]) + + def testMethylationSitesToGenes2(self): + """ Tests with a invalid body type """ + data = json.dumps({"methylation_sites": "cg17771854_BC11"}) + response = client.post('/methylation-sites-genes/', data=data, + content_type='application/json') + self.assertEqual(response.status_code, 400) + data = response.data + self.assertTrue("detail" in data) + + def testMethylationSitesToGenes3(self): + """ Tests with a invalid body key """ + data = json.dumps({"methylation": "cg17771854_BC11"}) + response = client.post('/methylation-sites-genes/', data=data, + content_type='application/json') + self.assertEqual(response.status_code, 400) + data = response.data + self.assertTrue("detail" in data) From f9e66fc59a4f570b2282505b755dc98154cd3368 Mon Sep 17 00:00:00 2001 From: mauricio Date: Thu, 21 Dec 2023 18:44:43 -0300 Subject: [PATCH 07/21] Test pending review: testMethylationSites1 --- modulector/tests/test_methylation.py | 12 ++++++------ 1 file changed, 6 insertions(+), 6 deletions(-) diff --git a/modulector/tests/test_methylation.py b/modulector/tests/test_methylation.py index 75f9a3d..40928c2 100644 --- a/modulector/tests/test_methylation.py +++ b/modulector/tests/test_methylation.py @@ -1,5 +1,4 @@ import json -import sys from django.test import Client, TestCase client = Client() @@ -125,17 +124,18 @@ def testMethylationSites1(self): content_type='application/json') self.assertEqual(response.status_code, 200) data = response.data - # sys.exit(str(data)) + print(data) for k in data: self.assertIsInstance(data[k], list) self.assertTrue("cg22461615_TC11" in data) self.assertTrue("cg01615704_TC11" in data) self.assertTrue("cg25908985" in data) self.assertTrue("invalid_data" in data) - # self.assertEqual(data["cg22461615_TC11"], ["cg22461615"]) - # self.assertEqual(data["cg01615704_TC11"], ["cg01615704"]) - # self.assertEqual(data["cg25908985"], ["cg25908985"]) - # self.assertEqual(data["invalid_data"], []) + # TODO arreglar + # self.assertEqual(data["cg22461615_TC11"][0], "cg22461615") + # self.assertEqual(data["cg01615704_TC11"][0], "cg01615704") + # self.assertEqual(data["cg25908985"][0], "cg25908985") + # self.assertTrue(len(data["invalid_data"][0]) == 0) def testMethylationSites2(self): """ Tests with a invalid body type """ From 3c4094c8e10853f6aea3ebadccec8baadb03cbb4 Mon Sep 17 00:00:00 2001 From: mauricio Date: Thu, 18 Jan 2024 19:18:23 -0300 Subject: [PATCH 08/21] Integrated databases added to the documentation --- DEPLOYING.md | 80 ++++------ README.md | 441 ++++++++++++++++++++++++++------------------------- 2 files changed, 263 insertions(+), 258 deletions(-) diff --git a/DEPLOYING.md b/DEPLOYING.md index 20cc290..cb742b9 100644 --- a/DEPLOYING.md +++ b/DEPLOYING.md @@ -2,27 +2,27 @@ Below are the steps to perform a production deploy. - ## Requirements 1. The entire deploy was configured to be simple from the tool Docker Compose. So you need to install: - [docker](https://docs.docker.com/desktop/#download-and-install) - [Docker Compose](https://docs.docker.com/compose/install/) - ## Instructions 1. Create MongoDB Docker volumes: + ```bash docker volume create --name=modulector_postgres_data ``` + 1. Make a copy of `docker-compose_dist.yml` with the name `docker-compose.yml`. 1. Set the environment variables that are empty with data. They are listed below by category: - Django: - `DJANGO_SETTINGS_MODULE`: indicates the `settings.py` file to read. In production, we set in `docker-compose_dist.yml` the value `ModulectorBackend.settings_prod` which contains several production properties. - `ALLOWED_HOSTS`: list of allowed host separated by commas. Default `['web', '.localhost', '127.0.0.1', '[::1]']`. - `ENABLE_SECURITY`: set the string `true` to enable Django's security mechanisms. In addition to this parameter, to have a secure site you must configure the HTTPS server, for more information on the latter see the section [Enable SSL/HTTPS](#enable-sslhttps). Default `false`. - - `CSRF_TRUSTED_ORIGINS`: in Django >= 4.x, it's mandatory to define this in production when you are using Daphne through NGINX. The value is a single host or list of hosts separated by commas. 'http://', 'https://' prefixes are mandatory. Examples of values: 'http://127.0.0.1', 'http://127.0.0.1,https://127.0.0.1:8000', etc. You can read more [here][csrf-trusted-issue]. + - `CSRF_TRUSTED_ORIGINS`: in Django >= 4.x, it's mandatory to define this in production when you are using Daphne through NGINX. The value is a single host or list of hosts separated by commas. 'http://', 'https://' prefixes are mandatory. Examples of values: '', '', etc. You can read more [here][csrf-trusted-issue]. - `SECRET_KEY`: Django's secret key. If not specified, one is generated with [generate-secret-key application](https://github.com/MickaelBergem/django-generate-secret-key) automatically. - `MEDIA_ROOT`: absolute path where will be stored the uploaded files. By default `/uploads`. - `MEDIA_URL`: URL of the `MEDIA_ROOT` folder. By default `/media/`. @@ -34,7 +34,7 @@ Below are the steps to perform a production deploy. - `POSTGRES_PORT` : Database server listen port. By default, the docker image uses `5432`. - `POSTGRES_DB` : Database name to be used. By default, the docker image uses `modulector`. - Health-checks and alerts: - - `HEALTH_URL` : indicates the url that will be requested on Docker health-checks. By default, it is http://localhost:8000/drugs/. The healthcheck makes a GET request on it. Any HTTP code value greater or equals than 400 is considered an error. + - `HEALTH_URL` : indicates the url that will be requested on Docker health-checks. By default, it is . The healthcheck makes a GET request on it. Any HTTP code value greater or equals than 400 is considered an error. - `HEALTH_ALERT_URL` : if you want to receive an alert when health-checks failed, you can set this variable to a webhook endpoint that will receive a POST request and a JSON body with the field **content** that contains the fail message. 1. Go back to the project's root folder and run the following commands: - Docker Compose: @@ -49,62 +49,57 @@ Below are the steps to perform a production deploy. 1. Run: `python3 manage.py createsuperuser` 1. Exit the container: `exit` - ### Start delays Due to the database restoration in the first start, the container `db_modulector` may take a while to be up a ready. We can follow the status of the startup process in the logs by doing: `docker compose logs --follow`. Sometimes this delay makes django server throws database connection errors. If it is still down and not automatically fixed when database is finally up, we can restart the services by doing: `docker compose up -d`. - ## Enable SSL/HTTPS To enable HTTPS, follow the steps below: 1. Set the `ENABLE_SECURITY` parameter to `true` as explained in the [Instructions](#instructions) section. -1. Copy the file `config/nginx/multiomics_intermediate_safe_dist.conf` and paste it into `config/nginx/conf.d/` with the name `multiomics_intermediate.conf`. -1. Get the `.crt` and `.pem` files for both the certificate and the private key and put them in the `config/nginx/certificates` folder. -1. Edit the `multiomics_intermediate.conf` file that we pasted in point 2. Uncomment the lines where both `.crt` and `.pem` files must be specified. -1. Edit the `docker-compose.yml` file so that the `nginx` service exposes both port 8000 and 443. Also, you need to add `certificates` folder to `volumes` section. It should look something like this: - -```yaml -... -nginx: - image: nginx:1.23.3 - ports: - - 80:8000 - - 443:443 - # ... - volumes: - ... - - ./config/nginx/certificates:/etc/nginx/certificates -... -``` +2. Copy the file `config/nginx/multiomics_intermediate_safe_dist.conf` and paste it into `config/nginx/conf.d/` with the name `multiomics_intermediate.conf`. +3. Get the `.crt` and `.pem` files for both the certificate and the private key and put them in the `config/nginx/certificates` folder. +4. Edit the `multiomics_intermediate.conf` file that we pasted in point 2. Uncomment the lines where both `.crt` and `.pem` files must be specified. +5. Edit the `docker-compose.yml` file so that the `nginx` service exposes both port 8000 and 443. Also, you need to add `certificates` folder to `volumes` section. It should look something like this: + + ```yaml + ... + nginx: + image: nginx:1.23.3 + ports: + - 80:8000 + - 443:443 + # ... + volumes: + ... + - ./config/nginx/certificates:/etc/nginx/certificates + ... + ``` 6. Redo the deployment with Docker. - ## Perform security checks Django provides in its official documentation a configuration checklist that must be present in the production file `settings_prod.py`. To verify that everything is fulfilled, you could execute the following command **once the server is up (this is because several environment variables are required that are set in the `docker-compose.yml`)**. -``` +```bash docker container exec modulector_backend python3 manage.py check --deploy --settings ModulectorBackend.settings_prod ``` Otherwise, you could set all the mandatory variables found in `settings_prod.py` and run directly without the need to pick up any service: -``` +```bash python3 manage.py check --deploy --settings ModulectorBackend.settings_prod ``` - ## Restart/stop the services If the configuration of the `docker-compose.yml` file has been changed, you can apply the changes without stopping the services, just running the `docker compose restart` command. If you want to stop all services, you can execute the command `docker compose down`. - ## See container status To check the different services' status you can run: @@ -113,7 +108,6 @@ To check the different services' status you can run: Where *\* could be `nginx_modulector`, `web_modulector` or `db_modulector`. - ## Creating Dumps and Restoring from Dumps ### Export @@ -124,15 +118,13 @@ In order to create a database dump you can execute the following command: That command will create a compressed file with the database dump inside. - ### Import You can use set Modulector DB in two ways. - ### Importing an existing database dump (recommended) -1. Start up a PostgreSQL service. You can use the same service listed in the `docker-compose.dev.yml` file. Run `docker compose -f docker-compose.dev.yml up -d db_modulector` to start the DB service. +1. Start up a PostgreSQL service. You can use the same service listed in the `docker-compose.dev.yml` file. Run `docker compose -f docker-compose.dev.yml up -d db_modulector` to start the DB service. 1. **Optional but recommended (you can omit these steps if it's the first time you are deploying Modulector)**: due to major changes, it's probably that an import thrown several errors when importing. To prevent that you could do the following steps before doing the importation: 1. Drop all the tables from the DB: `docker exec -i [name of the DB container] psql postgres -U postgres -c "DROP DATABASE modulector;"` 1. Create an empty database: `docker exec -i [name of the DB container] psql postgres -U postgres -c "CREATE DATABASE modulector;"` @@ -140,7 +132,6 @@ You can use set Modulector DB in two ways. 1. Restore the database: `zcat modulector.sql.gz | docker exec -i [name of the DB container] psql modulector -U modulector`. This command will restore the database using a compressed dump as source, **keep in mind that could take several minutes to finish the process**. - **NOTE**: in case you are working on Windows, the command must be executed from [Git Bash][git-bash] or WSL. - ### Regenerating the data manually 1. Download the files for the mirDIP database (version 5.2) and the Illumina 'Infinium MethylationEPIC 2.0' array. The files can be freely downloaded from their respective web pages. @@ -152,38 +143,35 @@ You can use set Modulector DB in two ways. **For the EPIC Methylation array**: - Go to the [Illumina product files web page](https://support.illumina.com/downloads/infinium-methylationepic-v2-0-product-files.html) and download the ZIP file called "*Infinium MethylationEPIC v2.0 Product Files (ZIP Format)*". - Unzip the file. - - Within the unzipped files you will find one called "*EPIC-8v2-0_A1.csv*". Move this file to the directory **"modulector/files/"**. + - Within the unzipped files you will find one called "*EPIC-8v2-0_A1.csv*". Move this file to the directory **"modulector/files/"**. - **NOTE:** the total weight of both files is about 5 GB. **For the mirBase database**: this database is embedded as it weighs only a few MBs. Its data is processed in Django migrations during the execution of the `python3 manage.py migrate` command. So, you don't have to do manual steps to incorporate mirBase data inside Modulector. -1. Start up a PostgreSQL service. You can use the same service listed in the _docker-compose.dev.yml_ file. +1. Start up a PostgreSQL service. You can use the same service listed in the *docker-compose.dev.yml* file. 1. Run `python3 manage.py migrate` to apply all the migrations (**NOTE:** this can take a long time to finish). - ## Update databases Modulector currently works with the mirDIP (version 5.2) and miRBase (version 22.1) databases for miRNA data, and with information from the Illumina 'Infinium MethylationEPIC 2.0' array for information about methylation sites. If new versions are released for these databases, and you want to update them, follow these steps: - - For **mirDIP** and **Illumina EPIC array** you must follow the same steps described in the [Regenerating the data manually](#regenerating-the-data-manually) section, replacing the named files with the most recent versions that have been published on their sites . - - For **miRBase**, follow the instructions below: - 1. Go to the [_Download_ section on the website][mirbase-download-page]. - 1. Download the files named _hairpin.fa_ and _mature.fa_ from the latest version of the database. - 1. Replace the files inside the _modulector/files/_ directory with the ones downloaded in the previous step. - 1. Start up a PostgreSQL service. You can use the same service listed in the _docker-compose.dev.yml_ file. +- For **mirDIP** and **Illumina EPIC array** you must follow the same steps described in the [Regenerating the data manually](#regenerating-the-data-manually) section, replacing the named files with the most recent versions that have been published on their sites . +- For **miRBase**, follow the instructions below: + 1. Go to the [*Download* section on the website][mirbase-download-page]. + 1. Download the files named *hairpin.fa* and *mature.fa* from the latest version of the database. + 1. Replace the files inside the *modulector/files/* directory with the ones downloaded in the previous step. + 1. Start up a PostgreSQL service. You can use the same service listed in the *docker-compose.dev.yml* file. 1. Run the command `python3 manage.py migrate` to apply all the migrations (**NOTE:** this can take a long time to finish). **Note:** These updates will work correctly as long as they maintain the format of the data in the source files. - ## Configure your API key When we notify user about updates of pubmeds they are subscribed to we interact with a ncbi api that uses an API_KEY, by default, we left a random API_KEY pre-configured in our settings file, you should replace it with your own. - ## Cron job configuration -For cron jobs we use the following [library](https://github.com/kraiz/django-crontab). In our settings file we configured our cron jobs inside the `CRONJOBS = []` +For cron jobs we use the following [library](https://github.com/kraiz/django-crontab). In our settings file we configured our cron jobs inside the `CRONJOBS = []` [mirbase-download-page]: https://www.mirbase.org/ftp.shtml [csrf-trusted-issue]: https://docs.djangoproject.com/en/4.2/ref/csrf/ diff --git a/README.md b/README.md index c679947..31837a3 100644 --- a/README.md +++ b/README.md @@ -1,8 +1,11 @@ # Modulector -Modulector is a performing open platform that provides information about miRNAs and genes based on a compilation of information from different databases. It offers data about: +Modulector is a performing open platform that provides information about miRNAs, genes and methylation sites based on a compilation of information from different resources. + +Document content: - [Modulector](#modulector) + - [Integrated databases](#integrated-databases) - [Usage](#usage) - [General](#general) - [Sorting](#sorting) @@ -29,6 +32,16 @@ Modulector is a performing open platform that provides information about miRNAs - [Sonarcloud](#sonarcloud) - [License](#license) +## Integrated databases + +Modulector obtains information from different bioinformatics databases or resources. These databases were installed locally to reduce data search time. The databases currently integrated to Modulector are: + +1. miRNA data: [mirDIP: microRNA Data Integration Portal](https://ophid.utoronto.ca/mirDIP/). + mirDIP is an integrative database of human microRNA target predictions. Modulector use mirDIP 5.2. +2. miRNA data: [miRBase: the microRNA database](https://mirbase.org/). + miRBase is a searchable database of published miRNA sequences and annotations. Each entry in the miRBase Sequence database represents a predicted hairpin portion of a miRNA transcript (termed hairpin in the database), with information on the location and sequence of the mature miRNA sequence (termed mature). Modulector use miRBase 22.1. +3. Methyaation data: Illumina [Infinium MethylationEPIC 2.0](https://www.illumina.com/products/by-type/microarray-kits/infinium-methylation-epic.html) array. + The Infinium MethylationEPIC v2.0 BeadChip Kit is a genome-wide methylation screening tool that targets over 935,000 CpG sites in the most biologically significant regions of the human methylome. At Modulector we use the information provided by Illumina on its [product files](https://support.illumina.com/downloads/infinium-methylationepic-v2-0-product-files.html) website. ## Usage @@ -36,12 +49,10 @@ Modulector can be used through the graphical interfaces provided in [Multiomix][ All services are available through a web API accessible from a browser or any other web client. All the responses are in JSON format. In addition to the information provided, sorting, filtering, searching and paging functions are also available. How to use these functions is explained below: - ### General All functions are used as a parameter in the URL. So if you want to access `https://modulector.multiomix.org/service/` by sending parameters to it, just add the following suffix to the end of the URL: `?parameter1=value¶meter2=value¶meter3=value`. The `?` indicates that the parameter section begins, these will be of the form `parameterName=parameterValue` and are separated, in case you need to send more than one, by a `&`. - ### Sorting In order to sort you must specify the parameter `ordering=fieldToSort`, if you want to sort descending you must add a `-` before the field name. You can specify several fields to sort separated by *commas*. @@ -50,21 +61,18 @@ For example, if you want to consume the [miRNA-target interactions](#mirna-targe `https://modulector.multiomix.org/mirna-target-interactions/?ordering=-score,gene` - ### Filters To filter it is enough to specify the field and the value by which you want to filter. For example, if you want to consume the [miRNA aliases](#mirna-aliases) service keeping only the aliases of `MIMAT0000062` you could access the following resource: `https://modulector.multiomix.org/mirna-aliases/?mirbase_accession_id=MIMAT0000062` - ### Search The search is done on the basis of a single parameter called `search` which must contain the value to be searched for. Unlike the filter, the search can be performed on multiple fields at once and is performed by *containing* the search term in the field and is case insensitive (while the filter is by exact value). The fields considered in the search are fixed and will be specified for each service later. For example, the [drugs](#drugs) service allows a search by the `condition`, `small_molecule` and `expression_pattern` fields, then the following query could be performed: `https://modulector.multiomix.org/drugs/?mirna=miR-126*search=breast` - ### Pagination Some services can return so many items that paginated responses were chosen, so that they are efficient queries of few items and can be traversed through parameterizable pages. There are two parameters that can be specified to handle pagination: @@ -79,7 +87,6 @@ All the paginated responses contain the following fields: - `previous`: link to the previous page. - `results`: array of elements (the structure of each element depends on the service and is explained in detail in the [services](#services) section). - ### Combining functions All of the above parameters can be used together! For example, if we wanted to consume the [diseases](#diseases) service by sorting ascending by disease, performing a disease search and keeping only the first 3 items, we could perform the following query (the order of the parameters **does not matter**): @@ -88,7 +95,6 @@ All of the above parameters can be used together! For example, if we wanted to c **It will be indicated for each service which fields are available for filtering, sorting and/or searching**. - ## Services ### MiRNA target interactions @@ -98,30 +104,31 @@ If no gene symbol is entered, all mirna interactions are returned. If a mirna is - URL: `/mirna-target-interactions` - Query params: - - `mirna`: miRNA (Accession ID or name in mirBase) to get its interactions with different genes targets. - - `gene`: gene symbol to get its interactions with different miRNAs targets. - - `score`: numerical score to filter the interactions (only interactions with a score greater than or equal to the parameter value are returned). The value of this score is provided by the mirDip database. - - `include_pubmeds`: if its value is 'true', the endpoint also returns a list of links to Pubmed where the mirnas are related to the genes (this may affect Modulector's response time). Default is 'false'. + - `mirna`: miRNA (Accession ID or name in mirBase) to get its interactions with different genes targets. + - `gene`: gene symbol to get its interactions with different miRNAs targets. + - `score`: numerical score to filter the interactions (only interactions with a score greater than or equal to the parameter value are returned). The value of this score is provided by the mirDip database. + - `include_pubmeds`: if its value is 'true', the endpoint also returns a list of links to Pubmed where the mirnas are related to the genes (this may affect Modulector's response time). Default is 'false'. *NOTE*: mirna or gene are required - Functions: - - Ordering fields: `gene` and `score` - - Filtering fields: filtering is not available for this service - - Searching fields: `gene` - - Pagination: yes + - Ordering fields: `gene` and `score` + - Filtering fields: filtering is not available for this service + - Searching fields: `gene` + - Pagination: yes - Success Response: - - Code: 200 - - Content: - - `id`: internal ID of the interaction. - - `mirna`: miRNA ID (mirbase MIMAT id or previous ID). The received one as query param. - - `gene`: target gene. - - `score`: interaction score (according mirDIP). - - `source_name`: database from which the interaction was extracted. - - `pubmeds`: array of pubmed for the miRNA-gene interaction (according to mirTaRBase). - - `sources`: miRNA-Gene interaction sources which publish this interaction. mirDIP score is based on the scores of those sources. This field is an array that contains the interaction score source names. - - `score_class`: `L` (Low), `M` (Medium), `H` (High) or `V` (Very high) - - Example: - - URL: http://localhost:8000/mirna-target-interactions/?mirna=hsa-miR-891a-5p&gene=EGFR&include_pubmeds=true - - Response: + - Code: 200 + - Content: + - `id`: internal ID of the interaction. + - `mirna`: miRNA ID (mirbase MIMAT id or previous ID). The received one as query param. + - `gene`: target gene. + - `score`: interaction score (according mirDIP). + - `source_name`: database from which the interaction was extracted. + - `pubmeds`: array of pubmed for the miRNA-gene interaction (according to mirTaRBase). + - `sources`: miRNA-Gene interaction sources which publish this interaction. mirDIP score is based on the scores of those sources. This field is an array that contains the interaction score source names. + - `score_class`: `L` (Low), `M` (Medium), `H` (High) or `V` (Very high) + - Example: + - URL: + - Response: + ```json { "count":1, @@ -152,10 +159,10 @@ If no gene symbol is entered, all mirna interactions are returned. If a mirna is ] } ``` -- Error Response: - - Code: 400 - - Content: `detail`: error description +- Error Response: + - Code: 400 + - Content: `detail`: error description ### MiRNA details @@ -163,22 +170,23 @@ Returns extra information of a miRNA. - URL: `/mirna` - Required query params: - - `mirna`: miRNA identifier (miRNA code or Accession ID) + - `mirna`: miRNA identifier (miRNA code or Accession ID) - Functions: - - Ordering fields: ordering is not available for this service - - Filtering fields: filtering is not available for this service - - Searching fields: searching is not available for this service - - Pagination: no + - Ordering fields: ordering is not available for this service + - Filtering fields: filtering is not available for this service + - Searching fields: searching is not available for this service + - Pagination: no - Success Response: - - Code: 200 - - Content: - - `aliases`: array of miRNA aliases (previous IDs according to mirBase). - - `mirna_sequence`: miRNA nucleotide sequence. - - `mirbase_accession_id`: miRNA accession ID (MIMAT). - - `links` array of URLs with extra information about this miRNA. - - Example: - - URL: http://localhost:8000/mirna/?mirna=hsa-miR-548ai - - Response: + - Code: 200 + - Content: + - `aliases`: array of miRNA aliases (previous IDs according to mirBase). + - `mirna_sequence`: miRNA nucleotide sequence. + - `mirbase_accession_id`: miRNA accession ID (MIMAT). + - `links` array of URLs with extra information about this miRNA. + - Example: + - URL: + - Response: + ```json { "aliases":[ @@ -196,10 +204,10 @@ Returns extra information of a miRNA. ] } ``` -- Error Response: - - Code: 404 - - Content: - +- Error Response: + - Code: 404 + - Content: - ### MiRNA aliases @@ -208,18 +216,19 @@ Returns a paginated response with aliases of a miRNA. - URL: `/mirna-aliases` - Required query params: - - Functions: - - Ordering fields: `mature_mirna` - - Filtering fields: `mature_mirna` and `mirbase_accession_id` - - Searching fields: searching is not available for this service - - Pagination: yes + - Ordering fields: `mature_mirna` + - Filtering fields: `mature_mirna` and `mirbase_accession_id` + - Searching fields: searching is not available for this service + - Pagination: yes - Success Response: - - Code: 200 - - Content: - - `mirbase_accession_id`: miRNA mirBase accession ID (MIMAT). - - `mature_mirna`: previous ID (according to mirBase). - - Example: - - URL: http://localhost:8000/mirna-aliases/?mirbase_accession_id=MIMAT0000062 - - Response: + - Code: 200 + - Content: + - `mirbase_accession_id`: miRNA mirBase accession ID (MIMAT). + - `mature_mirna`: previous ID (according to mirBase). + - Example: + - URL: + - Response: + ```json { "count":1, @@ -233,8 +242,8 @@ Returns a paginated response with aliases of a miRNA. ] } ``` -- Error Response: - +- Error Response: - ### MiRNA codes finder @@ -243,20 +252,21 @@ Service that takes a string of any length and returns a list of miRNAs that cont - URL: `/mirna-codes-finder` - Method: GET - Required query params: - - `query`: mirna search string. + - `query`: mirna search string. - Optional query params: - - `limit`: number of elements returned by the service. 50 by default and maximum 3000. + - `limit`: number of elements returned by the service. 50 by default and maximum 3000. - Functions: - - Ordering fields: ordering is not available for this service - - Filtering fields: filtering is not available for this service - - Searching fields: searching is not available for this service - - Pagination: no + - Ordering fields: ordering is not available for this service + - Filtering fields: filtering is not available for this service + - Searching fields: searching is not available for this service + - Pagination: no - Success Response: - - Code: 200 - - Content: a list of miRNAs (IDs or accession IDs from miRbase DB) matching the search criteria. - - Example: - - URL: http://localhost:8000/mirna-codes-finder/?query=hsa-let-7a - - Response: + - Code: 200 + - Content: a list of miRNAs (IDs or accession IDs from miRbase DB) matching the search criteria. + - Example: + - URL: + - Response: + ```json [ "hsa-let-7a-3", @@ -267,29 +277,30 @@ Service that takes a string of any length and returns a list of miRNAs that cont "hsa-let-7a-5p" ] ``` -- Error Response: - +- Error Response: - ### miRNA codes Searches for codes from a list of miRNA identifiers and returns the approved access identifier according to miRbase DB. -- URL: `/mirna-codes` +- URL: `/mirna-codes` - Method: POST - Required body params (in JSON format): - - `mirna_codes`: list of identifiers that you want to get your accession ID from miRbase DB. + - `mirna_codes`: list of identifiers that you want to get your accession ID from miRbase DB. - Functions: - - Ordering fields: ordering is not available for this service - - Filtering fields: filtering is not available for this service - - Searching fields: searching is not available for this service - - Pagination: no + - Ordering fields: ordering is not available for this service + - Filtering fields: filtering is not available for this service + - Searching fields: searching is not available for this service + - Pagination: no - Success Response: - - Code: 200 - - Content: - - `mirna_codes`: a JSON object with as many keys as miRNAs in the body of the request. For each miRNA, the value is a valid miRNA accession ID or `null`. - - Example: - - URL: http://localhost:8000/mirna-codes/ - - body: + - Code: 200 + - Content: + - `mirna_codes`: a JSON object with as many keys as miRNAs in the body of the request. For each miRNA, the value is a valid miRNA accession ID or `null`. + - Example: + - URL: + - body: + ```json { "mirna_codes":[ @@ -301,7 +312,9 @@ Searches for codes from a list of miRNA identifiers and returns the approved acc ] } ``` - - Response: + + - Response: + ```json { "name_01":null, @@ -311,33 +324,34 @@ Searches for codes from a list of miRNA identifiers and returns the approved acc "hsa-let-7e-5p":"MIMAT0000066" } ``` -- Error Response: - - Code: 400 - - Content: - - `detail`: a text with information about the error. +- Error Response: + - Code: 400 + - Content: + - `detail`: a text with information about the error. ### Methylation sites finder -Service that takes a text string of any length and returns a list of methylation sites names (loci) containing that search criteria within the Illumina _Infinium MethylationEPIC 2.0_ array. +Service that takes a text string of any length and returns a list of methylation sites names (loci) containing that search criteria within the Illumina *Infinium MethylationEPIC 2.0* array. - URL: `/methylation-sites-finder` - Method: GET - Required query params: - - `query`: Methylation search string. + - `query`: Methylation search string. - Optional query params: - - `limit`: number of elements returned by the service. 50 by default and maximum 3000. + - `limit`: number of elements returned by the service. 50 by default and maximum 3000. - Functions: - - Ordering fields: ordering is not available for this service - - Filtering fields: filtering is not available for this service - - Searching fields: searching is not available for this service - - Pagination: no + - Ordering fields: ordering is not available for this service + - Filtering fields: filtering is not available for this service + - Searching fields: searching is not available for this service + - Pagination: no - Success Response: - - Code: 200 - - Content: a list of methylation sites from the Illumina 'Infinium MethylationEPIC 2.0' array matching the search criteria. - - Example: - - URL: http://localhost:8000/methylation-sites-finder/?query=cg25&limit=5 - - Response: + - Code: 200 + - Content: a list of methylation sites from the Illumina 'Infinium MethylationEPIC 2.0' array matching the search criteria. + - Example: + - URL: + - Response: + ```json [ "cg25324105", @@ -347,29 +361,30 @@ Service that takes a text string of any length and returns a list of methylation "cg25487775" ] ``` -- Error Response: - +- Error Response: - ### Methylation sites -Searches a list of methylation site names or IDs from different Illumina array versions and returns the name for the _Infinium MethylationEPIC 2.0_ array. +Searches a list of methylation site names or IDs from different Illumina array versions and returns the name for the *Infinium MethylationEPIC 2.0* array. - URL: `/methylation-sites` - Method: POST - Required body params (in JSON format): - - `methylation_sites`: list of names or identifiers that you want to get your current name from Illumina 'Infinium MethylationEPIC 2.0' array. + - `methylation_sites`: list of names or identifiers that you want to get your current name from Illumina 'Infinium MethylationEPIC 2.0' array. - Functions: - - Ordering fields: ordering is not available for this service - - Filtering fields: filtering is not available for this service - - Searching fields: searching is not available for this service - - Pagination: no + - Ordering fields: ordering is not available for this service + - Filtering fields: filtering is not available for this service + - Searching fields: searching is not available for this service + - Pagination: no - Success Response: - - Code: 200 - - Content: - - `methylation_sites`: a JSON object with as many keys as methylation names in the body of the request. For each methylation name, the value is a list of valid methylation names to Illumina _Infinium MethylationEPIC 2.0_ array. - - Example: - - URL: http://localhost:8000/methylation-sites/ - - body: + - Code: 200 + - Content: + - `methylation_sites`: a JSON object with as many keys as methylation names in the body of the request. For each methylation name, the value is a list of valid methylation names to Illumina *Infinium MethylationEPIC 2.0* array. + - Example: + - URL: + - body: + ```json { "methylation_sites":[ @@ -378,7 +393,9 @@ Searches a list of methylation site names or IDs from different Illumina array v ] } ``` - - Response: + + - Response: + ```json { "cg17771854_BC11":[ @@ -389,11 +406,11 @@ Searches a list of methylation site names or IDs from different Illumina array v ] } ``` -- Error Response: - - Code: 400 - - Content: - - `detail`: a text with information about the error. +- Error Response: + - Code: 400 + - Content: + - `detail`: a text with information about the error. ### Genes of methylation sites @@ -402,19 +419,20 @@ A service that searches from a list of CpG methylation site identifiers from dif - URL: `/methylation-sites-genes` - Method: POST - Required body params (in JSON format): - - `methylation_sites`: list of Illumina array methylation site names or identifiers for which you want to know the gene(s). + - `methylation_sites`: list of Illumina array methylation site names or identifiers for which you want to know the gene(s). - Functions: - - Ordering fields: ordering is not available for this service - - Filtering fields: filtering is not available for this service - - Searching fields: searching is not available for this service - - Pagination: no + - Ordering fields: ordering is not available for this service + - Filtering fields: filtering is not available for this service + - Searching fields: searching is not available for this service + - Pagination: no - Success Response: - - Code: 200 - - Content: - - Returns a Json with as many keys as there are methylation names/ids in the body. For each methylation name/ID, the value is a list of genes that the name/id methylates. - - Example: - - URL: http://localhost:8000/methylation-sites-genes/ - - body: + - Code: 200 + - Content: + - Returns a Json with as many keys as there are methylation names/ids in the body. For each methylation name/ID, the value is a list of genes that the name/id methylates. + - Example: + - URL: + - body: + ```json { "methylation_sites":[ @@ -424,7 +442,9 @@ A service that searches from a list of CpG methylation site identifiers from dif ] } ``` - - Response: + + - Response: + ```json { "cg17771854_BC11":[ @@ -437,11 +457,11 @@ A service that searches from a list of CpG methylation site identifiers from dif ] } ``` -- Error Response: - - Code: 400 - - Content: - - `detail`: a text with information about the error. +- Error Response: + - Code: 400 + - Content: + - `detail`: a text with information about the error. ### Methylation site details @@ -449,25 +469,26 @@ Returns information of a methylation site. - URL: `/methylation` - Required query params: - - `methylation_site`: methylation_site name from Illumina _Infinium MethylationEPIC 2.0_ array + - `methylation_site`: methylation_site name from Illumina *Infinium MethylationEPIC 2.0* array - Functions: - - Ordering fields: ordering is not available for this service - - Filtering fields: filtering is not available for this service - - Searching fields: searching is not available for this service - - Pagination: no + - Ordering fields: ordering is not available for this service + - Filtering fields: filtering is not available for this service + - Searching fields: searching is not available for this service + - Pagination: no - Success Response: - - Code: 200 - - Content: - - `name`: name of methylation site. - - `aliases`: list of other names for the same methylation site on other illumina arrays (EPIC v2, EPIC v1, Methyl450 and Methyl27). - - `chromosome_position`: information about the chromosome, position and strand on which the site is located. - - `ucsc_cpg_islands`: List of islands related to the methylation site according to the UCSC database. Each element in the view is a json with the following content: - - `cpg_island`: chromosomal coordinates where the island is located. - - `relation`: Relation of the site to the CpG island. The values it can take are: *Island*=within boundaries of a CpG Island, *N_Shore*=0-2kb 5' of Island, *N_Shelf*=2kb-4kb 5' of Island, *S_Shore*=0-2kb 3' of Island, *S_Shelf*=2kb-4kb 3' of Island. - - `genes`: The value is a json where each key is a gene that is related to the methylation site. The values for each gene is a list that contains the region of the gene where the methylation site is located. These regions, according to the NCBI RefSeq database, can be: *5UTR*=5' untranslated region between the TSS and ATG start site, *3UTR*=3' untranslated region between stop codon and poly A signal, *exon_#*, *TSS200*=1-200 bp 5' the TSS, *TS1500*=200-1500 bp 5' of the TSS. - - Example: - - URL: http://localhost:8000/methylation/?methylation_site=cg22461615 - - Response: + - Code: 200 + - Content: + - `name`: name of methylation site. + - `aliases`: list of other names for the same methylation site on other illumina arrays (EPIC v2, EPIC v1, Methyl450 and Methyl27). + - `chromosome_position`: information about the chromosome, position and strand on which the site is located. + - `ucsc_cpg_islands`: List of islands related to the methylation site according to the UCSC database. Each element in the view is a json with the following content: + - `cpg_island`: chromosomal coordinates where the island is located. + - `relation`: Relation of the site to the CpG island. The values it can take are: *Island*=within boundaries of a CpG Island, *N_Shore*=0-2kb 5' of Island, *N_Shelf*=2kb-4kb 5' of Island, *S_Shore*=0-2kb 3' of Island, *S_Shelf*=2kb-4kb 3' of Island. + - `genes`: The value is a json where each key is a gene that is related to the methylation site. The values for each gene is a list that contains the region of the gene where the methylation site is located. These regions, according to the NCBI RefSeq database, can be: *5UTR*=5' untranslated region between the TSS and ATG start site, *3UTR*=3' untranslated region between stop codon and poly A signal, *exon_#*, *TSS200*=1-200 bp 5' the TSS, *TS1500*=200-1500 bp 5' of the TSS. + - Example: + - URL: + - Response: + ```json { "name":"cg22461615", @@ -495,11 +516,11 @@ Returns information of a methylation site. } } ``` + *NOTE*: Multiple values of the same gene name indicate splice variants. - Error Response: - - Code: 400 - - Content: error explanation text - + - Code: 400 + - Content: error explanation text ### Diseases @@ -508,23 +529,24 @@ Returns a paginated response of diseases related to a miRNA. - URL: `/diseases` - Method: GET - Required query params: - - `mirna`: miRNA (miRNA code or Accession ID) to get its interactions with different targets. If it is not specified, the service returns all the elements in a paginated response. + - `mirna`: miRNA (miRNA code or Accession ID) to get its interactions with different targets. If it is not specified, the service returns all the elements in a paginated response. - Functions: - - Ordering fields: `disease` - - Filtering fields: filtering is not available for this service - - Searching fields: `disease` - - Pagination: yes + - Ordering fields: `disease` + - Filtering fields: filtering is not available for this service + - Searching fields: `disease` + - Pagination: yes - Success Response: - - Code: 200 - - Content: - - `id`: internal ID of the record. - - `category`: disease category. - - `disease`: disease name. - - `pubmed`: Pubmed URL. - - `description`: description about why this miRNA is related to this disease. - - Example: - - URL: http://localhost:8000/diseases/?mirna=hsa-miR-9500 - - Response: + - Code: 200 + - Content: + - `id`: internal ID of the record. + - `category`: disease category. + - `disease`: disease name. + - `pubmed`: Pubmed URL. + - `description`: description about why this miRNA is related to this disease. + - Example: + - URL: + - Response: + ```json { "count":1, @@ -541,12 +563,12 @@ Returns a paginated response of diseases related to a miRNA. ] } ``` + - Error Response: - - Code: 200 - - Content: empty paginated response (number of elements = 0) + - Code: 200 + - Content: empty paginated response (number of elements = 0) - Additional details: **we capitalize the R present in the mirna for each record, because they are mature, however the file does not format it correctly and in the website they show up capitalized** - ### Drugs Returns a paginated response of experimentally validated small molecules (or drugs) effects on miRNA expression. @@ -554,28 +576,29 @@ Returns a paginated response of experimentally validated small molecules (or dru - URL: `/drugs` - Method: GET - Required query params: - - `mirna`: miRNA (miRNA code or Accession ID) to get its interactions with different targets. If it is not specified, the service returns all the elements in a paginated response. + - `mirna`: miRNA (miRNA code or Accession ID) to get its interactions with different targets. If it is not specified, the service returns all the elements in a paginated response. - Functions: - - Ordering fields: `condition`, `detection_method`, `small_molecule`, `expression_pattern`, `reference` + - Ordering fields: `condition`, `detection_method`, `small_molecule`, `expression_pattern`, `reference` and `support` - - Filtering fields: `fda_approved` (possible values: `true` or `false`) - - Searching fields: `condition`, `small_molecule` and `expression_pattern` - - Pagination: yes + - Filtering fields: `fda_approved` (possible values: `true` or `false`) + - Searching fields: `condition`, `small_molecule` and `expression_pattern` + - Pagination: yes - Success Response: - - Code: 200 - - Content: - - `id`: internal ID of the record. - - `small_molecule`: small molecule (or drug). - - `fda_approved`: approved by FDA or not. - - `detection_method`: experimental detection method. - - `condition`: tissues or conditions for detection. - - `pubmed`: Pubmed URL. - - `reference`: reference title. - - `expression_pattern`: expression pattern of miRNA. - - `support`: support information for this effect. - - Example: - - URL: http://localhost:8000/drugs/?mirna=miR-126* - - Response: + - Code: 200 + - Content: + - `id`: internal ID of the record. + - `small_molecule`: small molecule (or drug). + - `fda_approved`: approved by FDA or not. + - `detection_method`: experimental detection method. + - `condition`: tissues or conditions for detection. + - `pubmed`: Pubmed URL. + - `reference`: reference title. + - `expression_pattern`: expression pattern of miRNA. + - `support`: support information for this effect. + - Example: + - URL: * + - Response: + ```json { "count":1, @@ -596,12 +619,12 @@ Returns a paginated response of experimentally validated small molecules (or dru ] } ``` + - Error Response: - - Code: 200 - - Content: empty paginated response (number of elements = 0) + - Code: 200 + - Content: empty paginated response (number of elements = 0) - Additional details: **we are concatenating the 'hsa' prefix for all the drugs records because the file that we are using does not have it and to maintain consistency with the format for mature miRNAs** - ### Subscribe to PUBMEDS news Subscribes an email to our email service that sends news about new pubmeds associated to a mirna and/or gene @@ -609,17 +632,16 @@ Subscribes an email to our email service that sends news about new pubmeds assoc - URL: `/subscribe-pubmeds/` - Required query params: - - `mirna`: miRNA (miRNA code or Accession ID) - - `email`: valid email addres to send the information to + - `mirna`: miRNA (miRNA code or Accession ID) + - `email`: valid email addres to send the information to - Optional query params: - - `gene`: this param allows the user to filter with the mirna and the gene + - `gene`: this param allows the user to filter with the mirna and the gene - Success Response: - - Code: 200 - - Content: - - `token`: subscription token. + - Code: 200 + - Content: + - `token`: subscription token. - Error Response: - - Code: 400 - + - Code: 400 ### Unsubscribe from PUBMEDS news @@ -627,12 +649,11 @@ Subscribes an email to our email service that sends news about new pubmeds assoc - URL: `/unsubscribe-pubmeds/` - Required query params: - - `token`: token that references the subscription + - `token`: token that references the subscription - Success Response: - - Code: 200 + - Code: 200 - Error Response: - - Code: 400 - + - Code: 400 ## Considerations @@ -650,22 +671,18 @@ If you use any part of our code, or the tool itself is useful for your research, } ``` - ## Contributing All the contributions are welcome. Please read [CONTRIBUTING.md](CONTRIBUTING.md) for more information. - ## Sonarcloud We are using sonarcloud to analize repository code. We are not strictly following all the sonarCloud recomendations but we think that some recomendatios will help us to increase quality. [![Quality Gate Status](https://sonarcloud.io/api/project_badges/measure?project=omics-datascience_modulector&metric=alert_status)](https://sonarcloud.io/summary/new_code?id=omics-datascience_modulector) - ## License This repository is distributed under the terms of the MIT license. - [multiomix-site]: https://multiomix.org/ From 0c7d5538215d88c1a8bfc83eaa064cab860df16f Mon Sep 17 00:00:00 2001 From: Genaro Camele Date: Sun, 3 Mar 2024 19:09:04 -0300 Subject: [PATCH 09/21] Update README.md Fixed a lot of typos and grammatical errors --- README.md | 74 +++++++++++++++++++++++++++---------------------------- 1 file changed, 37 insertions(+), 37 deletions(-) diff --git a/README.md b/README.md index 31837a3..a17800e 100644 --- a/README.md +++ b/README.md @@ -40,14 +40,14 @@ Modulector obtains information from different bioinformatics databases or resour mirDIP is an integrative database of human microRNA target predictions. Modulector use mirDIP 5.2. 2. miRNA data: [miRBase: the microRNA database](https://mirbase.org/). miRBase is a searchable database of published miRNA sequences and annotations. Each entry in the miRBase Sequence database represents a predicted hairpin portion of a miRNA transcript (termed hairpin in the database), with information on the location and sequence of the mature miRNA sequence (termed mature). Modulector use miRBase 22.1. -3. Methyaation data: Illumina [Infinium MethylationEPIC 2.0](https://www.illumina.com/products/by-type/microarray-kits/infinium-methylation-epic.html) array. +3. Methylation data: Illumina [Infinium MethylationEPIC 2.0](https://www.illumina.com/products/by-type/microarray-kits/infinium-methylation-epic.html) array. The Infinium MethylationEPIC v2.0 BeadChip Kit is a genome-wide methylation screening tool that targets over 935,000 CpG sites in the most biologically significant regions of the human methylome. At Modulector we use the information provided by Illumina on its [product files](https://support.illumina.com/downloads/infinium-methylationepic-v2-0-product-files.html) website. ## Usage -Modulector can be used through the graphical interfaces provided in [Multiomix][multiomix-site], or it can be hosted on your own server (read [DEPLOYING.md](DEPLOYING.md) for more information). We strongly recommend use this software through Multiomix application. +Modulector can be used through the graphical interfaces provided in [Multiomix][multiomix-site], or it can be hosted on your server (read [DEPLOYING.md](DEPLOYING.md) for more information). We strongly recommend using this software through the Multiomix application. -All services are available through a web API accessible from a browser or any other web client. All the responses are in JSON format. In addition to the information provided, sorting, filtering, searching and paging functions are also available. How to use these functions is explained below: +All services are available through a web API accessible from a browser or any other web client. All the responses are in JSON format. In addition to the information provided, sorting, filtering, searching, and paging functions are also available. How to use these functions is explained below: ### General @@ -55,7 +55,7 @@ All functions are used as a parameter in the URL. So if you want to access `http ### Sorting -In order to sort you must specify the parameter `ordering=fieldToSort`, if you want to sort descending you must add a `-` before the field name. You can specify several fields to sort separated by *commas*. +To sort you must specify the parameter `ordering=fieldToSort`, if you want to sort descending you must add a `-` before the field name. You can specify several fields to sort separated by *commas*. For example, if you want to consume the [miRNA-target interactions](#mirna-target-interactions) service by sorting by `score` descending and by `gene` ascending you can access the URL: @@ -69,13 +69,13 @@ To filter it is enough to specify the field and the value by which you want to f ### Search -The search is done on the basis of a single parameter called `search` which must contain the value to be searched for. Unlike the filter, the search can be performed on multiple fields at once and is performed by *containing* the search term in the field and is case insensitive (while the filter is by exact value). The fields considered in the search are fixed and will be specified for each service later. For example, the [drugs](#drugs) service allows a search by the `condition`, `small_molecule` and `expression_pattern` fields, then the following query could be performed: +The search is done on the basis of a single parameter called `search` which must contain the value to be searched for. Unlike the filter, the search can be performed on multiple fields at once and is performed by *containing* the search term in the field and is case insensitive (while the filter is by exact value). The fields considered in the search are fixed and will be specified for each service later. For example, the [drugs](#drugs) service allows a search by the `condition`, `small_molecule`, and `expression_pattern` fields, then the following query could be performed: `https://modulector.multiomix.org/drugs/?mirna=miR-126*search=breast` ### Pagination -Some services can return so many items that paginated responses were chosen, so that they are efficient queries of few items and can be traversed through parameterizable pages. There are two parameters that can be specified to handle pagination: +Some services can return so many items that paginated responses were chosen so that they are efficient queries of few items and can be traversed through parameterizable pages. There are two parameters that can be specified to handle pagination: - `page`: allows you to specify the current page. If not specified, the default value `1` is used. - `page_size`: number of elements to return per page. If not specified, the default value `10` is used. The value cannot be greater than `1000`. @@ -93,22 +93,22 @@ All of the above parameters can be used together! For example, if we wanted to c `https://modulector.multiomix.org/diseases/?ordering=disease&search=leukemia&page_size=3` -**It will be indicated for each service which fields are available for filtering, sorting and/or searching**. +**It will be indicated for each service which fields are available for filtering, sorting, and/or searching**. ## Services ### MiRNA target interactions Receives a miRNA and/or a gene symbol and returns a paginated vector. Each vector entry represents a miRNA-Gene interaction. -If no gene symbol is entered, all mirna interactions are returned. If a mirna is not entered, all gene interactions are returned. If both are entered, the interaction of mirna with the gene is returned. +If no gene symbol is entered, all miRNA interactions are returned. If a miRNA is not entered, all gene interactions are returned. If both are entered, the interaction of mirna with the gene is returned. - URL: `/mirna-target-interactions` - Query params: - `mirna`: miRNA (Accession ID or name in mirBase) to get its interactions with different genes targets. - - `gene`: gene symbol to get its interactions with different miRNAs targets. + - `gene`: gene symbol to get its interactions with different miRNA targets. - `score`: numerical score to filter the interactions (only interactions with a score greater than or equal to the parameter value are returned). The value of this score is provided by the mirDip database. - - `include_pubmeds`: if its value is 'true', the endpoint also returns a list of links to Pubmed where the mirnas are related to the genes (this may affect Modulector's response time). Default is 'false'. -*NOTE*: mirna or gene are required + - `include_pubmeds`: if its value is 'true', the endpoint also returns a list of links to Pubmed where the miRNAs are related to the genes (this may affect Modulector's response time). The default is 'false'. +*NOTE*: `mirna` or `gene` are required - Functions: - Ordering fields: `gene` and `score` - Filtering fields: filtering is not available for this service @@ -118,11 +118,11 @@ If no gene symbol is entered, all mirna interactions are returned. If a mirna is - Code: 200 - Content: - `id`: internal ID of the interaction. - - `mirna`: miRNA ID (mirbase MIMAT id or previous ID). The received one as query param. + - `mirna`: miRNA ID (miRBase MIMAT id or previous ID). The received one as query param. - `gene`: target gene. - - `score`: interaction score (according mirDIP). + - `score`: interaction score (according to mirDIP). - `source_name`: database from which the interaction was extracted. - - `pubmeds`: array of pubmed for the miRNA-gene interaction (according to mirTaRBase). + - `pubmeds`: array of PubMed for the miRNA-gene interaction (according to mirTaRBase). - `sources`: miRNA-Gene interaction sources which publish this interaction. mirDIP score is based on the scores of those sources. This field is an array that contains the interaction score source names. - `score_class`: `L` (Low), `M` (Medium), `H` (High) or `V` (Very high) - Example: @@ -179,7 +179,7 @@ Returns extra information of a miRNA. - Success Response: - Code: 200 - Content: - - `aliases`: array of miRNA aliases (previous IDs according to mirBase). + - `aliases`: array of miRNA aliases (previous IDs according to miRBase). - `mirna_sequence`: miRNA nucleotide sequence. - `mirbase_accession_id`: miRNA accession ID (MIMAT). - `links` array of URLs with extra information about this miRNA. @@ -224,7 +224,7 @@ Returns a paginated response with aliases of a miRNA. - Code: 200 - Content: - `mirbase_accession_id`: miRNA mirBase accession ID (MIMAT). - - `mature_mirna`: previous ID (according to mirBase). + - `mature_mirna`: previous ID (according to miRBase). - Example: - URL: - Response: @@ -254,7 +254,7 @@ Service that takes a string of any length and returns a list of miRNAs that cont - Required query params: - `query`: mirna search string. - Optional query params: - - `limit`: number of elements returned by the service. 50 by default and maximum 3000. + - `limit`: number of elements returned by the service. `50` by default and a maximum of `3000`. - Functions: - Ordering fields: ordering is not available for this service - Filtering fields: filtering is not available for this service @@ -282,12 +282,12 @@ Service that takes a string of any length and returns a list of miRNAs that cont ### miRNA codes -Searches for codes from a list of miRNA identifiers and returns the approved access identifier according to miRbase DB. +Searches for codes from a list of miRNA identifiers and returns the approved access identifier according to miRBase DB. - URL: `/mirna-codes` - Method: POST - Required body params (in JSON format): - - `mirna_codes`: list of identifiers that you want to get your accession ID from miRbase DB. + - `mirna_codes`: list of identifiers that you want to get your accession ID from miRBase DB. - Functions: - Ordering fields: ordering is not available for this service - Filtering fields: filtering is not available for this service @@ -339,7 +339,7 @@ Service that takes a text string of any length and returns a list of methylation - Required query params: - `query`: Methylation search string. - Optional query params: - - `limit`: number of elements returned by the service. 50 by default and maximum 3000. + - `limit`: number of elements returned by the service. `50` by default and a maximum of `3000`. - Functions: - Ordering fields: ordering is not available for this service - Filtering fields: filtering is not available for this service @@ -428,7 +428,7 @@ A service that searches from a list of CpG methylation site identifiers from dif - Success Response: - Code: 200 - Content: - - Returns a Json with as many keys as there are methylation names/ids in the body. For each methylation name/ID, the value is a list of genes that the name/id methylates. + - Returns a Json with as many keys as there are methylation names/ids in the body. For each methylation name/ID, the value is a list of genes that the name/ID methylates. - Example: - URL: - body: @@ -465,7 +465,7 @@ A service that searches from a list of CpG methylation site identifiers from dif ### Methylation site details -Returns information of a methylation site. +Returns information on a methylation site. - URL: `/methylation` - Required query params: @@ -479,12 +479,12 @@ Returns information of a methylation site. - Code: 200 - Content: - `name`: name of methylation site. - - `aliases`: list of other names for the same methylation site on other illumina arrays (EPIC v2, EPIC v1, Methyl450 and Methyl27). - - `chromosome_position`: information about the chromosome, position and strand on which the site is located. - - `ucsc_cpg_islands`: List of islands related to the methylation site according to the UCSC database. Each element in the view is a json with the following content: + - `aliases`: list of other names for the same methylation site on other Illumina arrays (EPIC v2, EPIC v1, Methyl450, and Methyl27). + - `chromosome_position`: information about the chromosome, position, and strand on which the site is located. + - `ucsc_cpg_islands`: List of islands related to the methylation site according to the UCSC database. Each element in the view is a JSON with the following content: - `cpg_island`: chromosomal coordinates where the island is located. - - `relation`: Relation of the site to the CpG island. The values it can take are: *Island*=within boundaries of a CpG Island, *N_Shore*=0-2kb 5' of Island, *N_Shelf*=2kb-4kb 5' of Island, *S_Shore*=0-2kb 3' of Island, *S_Shelf*=2kb-4kb 3' of Island. - - `genes`: The value is a json where each key is a gene that is related to the methylation site. The values for each gene is a list that contains the region of the gene where the methylation site is located. These regions, according to the NCBI RefSeq database, can be: *5UTR*=5' untranslated region between the TSS and ATG start site, *3UTR*=3' untranslated region between stop codon and poly A signal, *exon_#*, *TSS200*=1-200 bp 5' the TSS, *TS1500*=200-1500 bp 5' of the TSS. + - `relation`: Relation of the site to the CpG island. The values it can take are *Island*=within boundaries of a CpG Island, *N_Shore*=0-2kb 5' of Island, *N_Shelf*=2kb-4kb 5' of Island, *S_Shore*=0-2kb 3' of Island, *S_Shelf*=2kb-4kb 3' of Island. + - `genes`: The value is a JSON where each key is a gene that is related to the methylation site. Values for each gene is a list that contains the region of the gene where the methylation site is located. These regions, according to the NCBI RefSeq database, can be: *5UTR*=5' untranslated region between the TSS and ATG start site, *3UTR*=3' untranslated region between stop codon and poly A signal, *exon_#*, *TSS200*=1-200 bp 5' the TSS, *TS1500*=200-1500 bp 5' of the TSS. - Example: - URL: - Response: @@ -567,11 +567,11 @@ Returns a paginated response of diseases related to a miRNA. - Error Response: - Code: 200 - Content: empty paginated response (number of elements = 0) -- Additional details: **we capitalize the R present in the mirna for each record, because they are mature, however the file does not format it correctly and in the website they show up capitalized** +- Additional details: **We capitalize the R present in the miRNA for each record because they are mature, however, the file does not format it correctly and on the website they show up capitalized** ### Drugs -Returns a paginated response of experimentally validated small molecules (or drugs) effects on miRNA expression. +Returns a paginated response of experimentally validated small molecules (or drugs) that affect miRNA expression. - URL: `/drugs` - Method: GET @@ -581,7 +581,7 @@ Returns a paginated response of experimentally validated small molecules (or dru - Ordering fields: `condition`, `detection_method`, `small_molecule`, `expression_pattern`, `reference` and `support` - Filtering fields: `fda_approved` (possible values: `true` or `false`) - - Searching fields: `condition`, `small_molecule` and `expression_pattern` + - Searching fields: `condition`, `small_molecule`, and `expression_pattern` - Pagination: yes - Success Response: - Code: 200 @@ -623,19 +623,19 @@ Returns a paginated response of experimentally validated small molecules (or dru - Error Response: - Code: 200 - Content: empty paginated response (number of elements = 0) -- Additional details: **we are concatenating the 'hsa' prefix for all the drugs records because the file that we are using does not have it and to maintain consistency with the format for mature miRNAs** +- Additional details: **We are concatenating the 'hsa' prefix for all the drugs records because the file that we are using does not have it and to maintain consistency with the format for mature miRNAs** ### Subscribe to PUBMEDS news -Subscribes an email to our email service that sends news about new pubmeds associated to a mirna and/or gene +Subscribes an email to our email service that sends news about new Pubmed associated with a miRNA and/or gene. - URL: `/subscribe-pubmeds/` - Required query params: - `mirna`: miRNA (miRNA code or Accession ID) - - `email`: valid email addres to send the information to + - `email`: valid email address to send the information to - Optional query params: - - `gene`: this param allows the user to filter with the mirna and the gene + - `gene`: this param allows the user to filter with the miRNA and the gene - Success Response: - Code: 200 - Content: @@ -645,11 +645,11 @@ Subscribes an email to our email service that sends news about new pubmeds assoc ### Unsubscribe from PUBMEDS news -Subscribes an email to our email service that sends news about new pubmeds associated to a mirna and/or gene +Subscribes an email to our email service that sends news about new Pubmed associated with a miRNA and/or gene - URL: `/unsubscribe-pubmeds/` - Required query params: - - `token`: token that references the subscription + - `token`: a token that references the subscription - Success Response: - Code: 200 - Error Response: @@ -677,7 +677,7 @@ All the contributions are welcome. Please read [CONTRIBUTING.md](CONTRIBUTING.md ## Sonarcloud -We are using sonarcloud to analize repository code. We are not strictly following all the sonarCloud recomendations but we think that some recomendatios will help us to increase quality. +We are using Sonarcloud to analyze repository code. We are not strictly following all the sonarCloud recommendations but we think that some recommendations will help us to increase quality. [![Quality Gate Status](https://sonarcloud.io/api/project_badges/measure?project=omics-datascience_modulector&metric=alert_status)](https://sonarcloud.io/summary/new_code?id=omics-datascience_modulector) From 0a92e0023d775389c37baa9ff95bd73b3f86ac99 Mon Sep 17 00:00:00 2001 From: mauricio Date: Wed, 6 Mar 2024 17:29:08 -0300 Subject: [PATCH 10/21] documentation improvements --- README.md | 30 +++++++++++++++--------------- 1 file changed, 15 insertions(+), 15 deletions(-) diff --git a/README.md b/README.md index a17800e..dc75f51 100644 --- a/README.md +++ b/README.md @@ -129,7 +129,7 @@ If no gene symbol is entered, all miRNA interactions are returned. If a miRNA is - URL: - Response: - ```json + ```JSON { "count":1, "next":null, @@ -187,7 +187,7 @@ Returns extra information of a miRNA. - URL: - Response: - ```json + ```JSON { "aliases":[ "hsa-miR-548ai", @@ -229,7 +229,7 @@ Returns a paginated response with aliases of a miRNA. - URL: - Response: - ```json + ```JSON { "count":1, "next":null, @@ -267,7 +267,7 @@ Service that takes a string of any length and returns a list of miRNAs that cont - URL: - Response: - ```json + ```JSON [ "hsa-let-7a-3", "hsa-let-7a-2", @@ -301,7 +301,7 @@ Searches for codes from a list of miRNA identifiers and returns the approved acc - URL: - body: - ```json + ```JSON { "mirna_codes":[ "name_01", @@ -315,7 +315,7 @@ Searches for codes from a list of miRNA identifiers and returns the approved acc - Response: - ```json + ```JSON { "name_01":null, "Hsa-Mir-935-v2_5p*":null, @@ -352,7 +352,7 @@ Service that takes a text string of any length and returns a list of methylation - URL: - Response: - ```json + ```JSON [ "cg25324105", "cg25383568", @@ -385,7 +385,7 @@ Searches a list of methylation site names or IDs from different Illumina array v - URL: - body: - ```json + ```JSON { "methylation_sites":[ "cg17771854_BC11", @@ -396,7 +396,7 @@ Searches a list of methylation site names or IDs from different Illumina array v - Response: - ```json + ```JSON { "cg17771854_BC11":[ "cg17771854" @@ -428,12 +428,12 @@ A service that searches from a list of CpG methylation site identifiers from dif - Success Response: - Code: 200 - Content: - - Returns a Json with as many keys as there are methylation names/ids in the body. For each methylation name/ID, the value is a list of genes that the name/ID methylates. + - Returns a JSON with as many keys as there are methylation names/ids in the body. For each methylation name/ID, the value is a list of genes that the name/ID methylates. - Example: - URL: - body: - ```json + ```JSON { "methylation_sites":[ "cg17771854_BC11", @@ -445,7 +445,7 @@ A service that searches from a list of CpG methylation site identifiers from dif - Response: - ```json + ```JSON { "cg17771854_BC11":[ "IPO13" @@ -489,7 +489,7 @@ Returns information on a methylation site. - URL: - Response: - ```json + ```JSON { "name":"cg22461615", "chromosome_position":"chr4:82900764 [+]", @@ -547,7 +547,7 @@ Returns a paginated response of diseases related to a miRNA. - URL: - Response: - ```json + ```JSON { "count":1, "next":null, @@ -599,7 +599,7 @@ Returns a paginated response of experimentally validated small molecules (or dru - URL: * - Response: - ```json + ```JSON { "count":1, "next":null, From 007139c80d9d4e53a12e77e5177029316fc570e5 Mon Sep 17 00:00:00 2001 From: mauricio Date: Wed, 6 Mar 2024 18:36:09 -0300 Subject: [PATCH 11/21] documentation improvements --- README.md | 398 +++++++++++++++++++++++++++--------------------------- 1 file changed, 199 insertions(+), 199 deletions(-) diff --git a/README.md b/README.md index dc75f51..be69d97 100644 --- a/README.md +++ b/README.md @@ -129,36 +129,36 @@ If no gene symbol is entered, all miRNA interactions are returned. If a miRNA is - URL: - Response: - ```JSON + ```JSON + { + "count":1, + "next":null, + "previous":null, + "results":[ { - "count":1, - "next":null, - "previous":null, - "results":[ - { - "id":629118277, - "mirna":"hsa-miR-891a-5p", - "gene":"EGFR", - "score":0.0684, - "source_name":"mirdip", - "pubmeds":[ - "https://pubmed.ncbi.nlm.nih.gov/5362487", - "https://pubmed.ncbi.nlm.nih.gov/10120249", - "https://pubmed.ncbi.nlm.nih.gov/8948606", - "https://pubmed.ncbi.nlm.nih.gov/5642539", - "https://pubmed.ncbi.nlm.nih.gov/9361765", - "https://pubmed.ncbi.nlm.nih.gov/4895700" - ], - "sources":[ - "MirAncesTar", - "mirmap_May_2021", - "MiRNATIP" - ], - "score_class":"M" - } - ] + "id":629118277, + "mirna":"hsa-miR-891a-5p", + "gene":"EGFR", + "score":0.0684, + "source_name":"mirdip", + "pubmeds":[ + "https://pubmed.ncbi.nlm.nih.gov/5362487", + "https://pubmed.ncbi.nlm.nih.gov/10120249", + "https://pubmed.ncbi.nlm.nih.gov/8948606", + "https://pubmed.ncbi.nlm.nih.gov/5642539", + "https://pubmed.ncbi.nlm.nih.gov/9361765", + "https://pubmed.ncbi.nlm.nih.gov/4895700" + ], + "sources":[ + "MirAncesTar", + "mirmap_May_2021", + "MiRNATIP" + ], + "score_class":"M" } - ``` + ] + } + ``` - Error Response: - Code: 400 @@ -187,23 +187,23 @@ Returns extra information of a miRNA. - URL: - Response: - ```JSON - { - "aliases":[ - "hsa-miR-548ai", - "MIMAT0018989", - "hsa-miR-548ai" - ], - "mirna_sequence":"AAAGGUAAUUGCAGUUUUUCCC", - "mirbase_accession_id":"MIMAT0018989", - "links":[ - { - "source":"mirbase", - "url":"http://www.mirbase.org/cgi-bin/mirna_entry.pl?acc=MIMAT0018989" - } - ] - } - ``` + ```JSON + { + "aliases":[ + "hsa-miR-548ai", + "MIMAT0018989", + "hsa-miR-548ai" + ], + "mirna_sequence":"AAAGGUAAUUGCAGUUUUUCCC", + "mirbase_accession_id":"MIMAT0018989", + "links":[ + { + "source":"mirbase", + "url":"http://www.mirbase.org/cgi-bin/mirna_entry.pl?acc=MIMAT0018989" + } + ] + } + ``` - Error Response: - Code: 404 @@ -229,19 +229,19 @@ Returns a paginated response with aliases of a miRNA. - URL: - Response: - ```JSON - { - "count":1, - "next":null, - "previous":null, - "results":[ - { - "mirbase_accession_id":"MIMAT0000062", - "mature_mirna":"hsa-let-7a-5p" - } - ] - } - ``` + ```JSON + { + "count":1, + "next":null, + "previous":null, + "results":[ + { + "mirbase_accession_id":"MIMAT0000062", + "mature_mirna":"hsa-let-7a-5p" + } + ] + } + ``` - Error Response: - @@ -267,16 +267,16 @@ Service that takes a string of any length and returns a list of miRNAs that cont - URL: - Response: - ```JSON - [ - "hsa-let-7a-3", - "hsa-let-7a-2", - "hsa-let-7a-3p", - "hsa-let-7a-2-3p", - "hsa-let-7a-1", - "hsa-let-7a-5p" - ] - ``` + ```JSON + [ + "hsa-let-7a-3", + "hsa-let-7a-2", + "hsa-let-7a-3p", + "hsa-let-7a-2-3p", + "hsa-let-7a-1", + "hsa-let-7a-5p" + ] + ``` - Error Response: - @@ -301,29 +301,29 @@ Searches for codes from a list of miRNA identifiers and returns the approved acc - URL: - body: - ```JSON - { - "mirna_codes":[ - "name_01", - "Hsa-Mir-935-v2_5p*", - "MIMAT0000066", - "MI0026417", - "hsa-let-7e-5p" - ] - } - ``` + ```JSON + { + "mirna_codes":[ + "name_01", + "Hsa-Mir-935-v2_5p*", + "MIMAT0000066", + "MI0026417", + "hsa-let-7e-5p" + ] + } + ``` - Response: - ```JSON - { - "name_01":null, - "Hsa-Mir-935-v2_5p*":null, - "MIMAT0000066":"MIMAT0000066", - "MI0026417":"MI0026417", - "hsa-let-7e-5p":"MIMAT0000066" - } - ``` + ```JSON + { + "name_01":null, + "Hsa-Mir-935-v2_5p*":null, + "MIMAT0000066":"MIMAT0000066", + "MI0026417":"MI0026417", + "hsa-let-7e-5p":"MIMAT0000066" + } + ``` - Error Response: - Code: 400 @@ -352,15 +352,15 @@ Service that takes a text string of any length and returns a list of methylation - URL: - Response: - ```JSON - [ - "cg25324105", - "cg25383568", - "cg25455143", - "cg25459778", - "cg25487775" - ] - ``` + ```JSON + [ + "cg25324105", + "cg25383568", + "cg25455143", + "cg25459778", + "cg25487775" + ] + ``` - Error Response: - @@ -385,27 +385,27 @@ Searches a list of methylation site names or IDs from different Illumina array v - URL: - body: - ```JSON - { - "methylation_sites":[ - "cg17771854_BC11", - "cg01615704_TC11" - ] - } - ``` + ```JSON + { + "methylation_sites":[ + "cg17771854_BC11", + "cg01615704_TC11" + ] + } + ``` - Response: - ```JSON - { - "cg17771854_BC11":[ - "cg17771854" - ], - "cg01615704_TC11":[ - "cg01615704" - ] - } - ``` + ```JSON + { + "cg17771854_BC11":[ + "cg17771854" + ], + "cg01615704_TC11":[ + "cg01615704" + ] + } + ``` - Error Response: - Code: 400 @@ -433,30 +433,30 @@ A service that searches from a list of CpG methylation site identifiers from dif - URL: - body: - ```JSON - { - "methylation_sites":[ - "cg17771854_BC11", - "cg22461615_TC11", - "name_007" - ] - } - ``` + ```JSON + { + "methylation_sites":[ + "cg17771854_BC11", + "cg22461615_TC11", + "name_007" + ] + } + ``` - Response: - ```JSON - { - "cg17771854_BC11":[ - "IPO13" - ], - "cg22461615_TC11":[ - "THAP9", - "THAP9-AS1", - "SEC31A" - ] - } - ``` + ```JSON + { + "cg17771854_BC11":[ + "IPO13" + ], + "cg22461615_TC11":[ + "THAP9", + "THAP9-AS1", + "SEC31A" + ] + } + ``` - Error Response: - Code: 400 @@ -489,33 +489,33 @@ Returns information on a methylation site. - URL: - Response: - ```JSON - { - "name":"cg22461615", - "chromosome_position":"chr4:82900764 [+]", - "aliases":[ - "cg22461615_TC11" - ], - "ucsc_cpg_islands":[ - { - "cpg_island":"chr4:82900535-82900912", - "relation":"Island" - } - ], - "genes":{ - "THAP9":[ - "5UTR", - "exon_1" - ], - "THAP9-AS1":[ - "exon_1" - ], - "SEC31A":[ - "TSS200" - ] - } - } - ``` + ```JSON + { + "name":"cg22461615", + "chromosome_position":"chr4:82900764 [+]", + "aliases":[ + "cg22461615_TC11" + ], + "ucsc_cpg_islands":[ + { + "cpg_island":"chr4:82900535-82900912", + "relation":"Island" + } + ], + "genes":{ + "THAP9":[ + "5UTR", + "exon_1" + ], + "THAP9-AS1":[ + "exon_1" + ], + "SEC31A":[ + "TSS200" + ] + } + } + ``` *NOTE*: Multiple values of the same gene name indicate splice variants. - Error Response: @@ -547,22 +547,22 @@ Returns a paginated response of diseases related to a miRNA. - URL: - Response: - ```JSON - { - "count":1, - "next":null, - "previous":null, - "results":[ - { - "id":3540992, - "category":"target gene", - "disease":"Liver Neoplasms", - "pubmed":"https://pubmed.ncbi.nlm.nih.gov/24658401", - "description":"The novel miR-9500 regulates the proliferation and migration of human lung cancer cells by targeting Akt1." - } - ] - } - ``` + ```JSON + { + "count":1, + "next":null, + "previous":null, + "results":[ + { + "id":3540992, + "category":"target gene", + "disease":"Liver Neoplasms", + "pubmed":"https://pubmed.ncbi.nlm.nih.gov/24658401", + "description":"The novel miR-9500 regulates the proliferation and migration of human lung cancer cells by targeting Akt1." + } + ] + } + ``` - Error Response: - Code: 200 @@ -599,26 +599,26 @@ Returns a paginated response of experimentally validated small molecules (or dru - URL: * - Response: - ```JSON - { - "count":1, - "next":null, - "previous":null, - "results":[ - { - "id":275028, - "small_molecule":"17beta-estradiol (E2)", - "fda_approved":true, - "detection_method":"Microarray", - "condition":"MCF-7AKT breast cancer cells", - "pubmed":"https://pubmed.ncbi.nlm.nih.gov/19528081", - "reference":"Estradiol-regulated microRNAs control estradiol response in breast cancer cells.", - "expression_pattern":"down-regulated", - "support":"To investigate this possibility, we determined microRNA-expression patterns in MCF-7p and MCF-7AKT cells with and without E2 treatment for 4 h. We observed 21 E2-inducible and 7 E2-repressible microRNAs in MCF-7p cells (statistical cutoff P-value <0.05 and fold change >1.5 or <0.7) (Table 1)." - } - ] - } - ``` + ```JSON + { + "count":1, + "next":null, + "previous":null, + "results":[ + { + "id":275028, + "small_molecule":"17beta-estradiol (E2)", + "fda_approved":true, + "detection_method":"Microarray", + "condition":"MCF-7AKT breast cancer cells", + "pubmed":"https://pubmed.ncbi.nlm.nih.gov/19528081", + "reference":"Estradiol-regulated microRNAs control estradiol response in breast cancer cells.", + "expression_pattern":"down-regulated", + "support":"To investigate this possibility, we determined microRNA-expression patterns in MCF-7p and MCF-7AKT cells with and without E2 treatment for 4 h. We observed 21 E2-inducible and 7 E2-repressible microRNAs in MCF-7p cells (statistical cutoff P-value <0.05 and fold change >1.5 or <0.7) (Table 1)." + } + ] + } + ``` - Error Response: - Code: 200 From e5d893c88900750006d3163fff0ffb6a43c2582a Mon Sep 17 00:00:00 2001 From: mauricio Date: Thu, 7 Mar 2024 18:26:45 -0300 Subject: [PATCH 12/21] tests methylation-sites --- modulector/tests/test_methylation.py | 9 ++++----- modulector/views.py | 20 +++++++++++++------- 2 files changed, 17 insertions(+), 12 deletions(-) diff --git a/modulector/tests/test_methylation.py b/modulector/tests/test_methylation.py index 40928c2..e94d58c 100644 --- a/modulector/tests/test_methylation.py +++ b/modulector/tests/test_methylation.py @@ -124,7 +124,6 @@ def testMethylationSites1(self): content_type='application/json') self.assertEqual(response.status_code, 200) data = response.data - print(data) for k in data: self.assertIsInstance(data[k], list) self.assertTrue("cg22461615_TC11" in data) @@ -132,10 +131,10 @@ def testMethylationSites1(self): self.assertTrue("cg25908985" in data) self.assertTrue("invalid_data" in data) # TODO arreglar - # self.assertEqual(data["cg22461615_TC11"][0], "cg22461615") - # self.assertEqual(data["cg01615704_TC11"][0], "cg01615704") - # self.assertEqual(data["cg25908985"][0], "cg25908985") - # self.assertTrue(len(data["invalid_data"][0]) == 0) + self.assertEqual(data["cg22461615_TC11"][0], "cg22461615") + self.assertEqual(data["cg01615704_TC11"][0], "cg01615704") + self.assertEqual(data["cg25908985"][0], "cg25908985") + self.assertTrue(len(data["invalid_data"][0]) == 0) def testMethylationSites2(self): """ Tests with a invalid body type """ diff --git a/modulector/views.py b/modulector/views.py index 53fe538..e5a7729 100644 --- a/modulector/views.py +++ b/modulector/views.py @@ -30,7 +30,7 @@ PROCESS_POOL_WORKERS: Final[int] = settings.PROCESS_POOL_WORKERS -def get_methylation_epic_sites_names(input_id: str) -> List[str]: +def get_methylation_epic_sites_names(input_id: str) -> tuple[str, List[str]]: """ Gets methylation sites from any type of Loci id. :param input_id: String to query in the DB. @@ -40,7 +40,7 @@ def get_methylation_epic_sites_names(input_id: str) -> List[str]: Q(methyl450_loci=input_id) | Q(methyl27_loci=input_id) | Q(epicv1_loci=input_id)).values_list('name', flat=True) - return list(res) + return (input_id, list(res)) def get_limit_parameter(value: Optional[str]) -> int: @@ -312,14 +312,20 @@ def post(request): # Generates a dict with the methylation sites as keys and the result of the query as values. # note: it uses ProcessPoolExecutor to parallelize the queries and not a ThreadPoolExecutor because # the latter has a bug closing Django connections (see https://stackoverflow.com/q/57211476/7058363) + # with ProcessPoolExecutor(max_workers=PROCESS_POOL_WORKERS) as executor: + # res = { + # methylation_name: result + # for methylation_name, result in zip(methylation_sites, executor.map( + # get_methylation_epic_sites_names, methylation_sites + # )) + # } + + # NEW: with ProcessPoolExecutor(max_workers=PROCESS_POOL_WORKERS) as executor: res = { - methylation_name: result - for methylation_name, result in zip(methylation_sites, executor.map( - get_methylation_epic_sites_names, methylation_sites - )) + result[0]: result[1] + for result in executor.map(get_methylation_epic_sites_names, methylation_sites) } - return Response(res) From 9d743d011cd68f4eb988755d5e20123bc6d9af4d Mon Sep 17 00:00:00 2001 From: Genaro Camele Date: Thu, 14 Mar 2024 18:16:31 -0300 Subject: [PATCH 13/21] Removed adminer service --- docker-compose.dev.yml | 9 --------- 1 file changed, 9 deletions(-) diff --git a/docker-compose.dev.yml b/docker-compose.dev.yml index a7ff1c3..26333f3 100644 --- a/docker-compose.dev.yml +++ b/docker-compose.dev.yml @@ -19,15 +19,6 @@ services: - modulector_postgres_data:/var/lib/postgresql/data/ - ./config/postgres/postgres.conf:/etc/postgresql/postgresql.conf - - # Web-based DB admin interface for DB management - adminer: - image: adminer - container_name: modulector_dev_adminer - restart: always - ports: - - '8080:8080' - # Uncomment if using empty Postgres service volumes: modulector_postgres_data: From 21386fc30ba762f82baf4bd4ab0424daeca47594 Mon Sep 17 00:00:00 2001 From: Genaro Camele Date: Fri, 15 Mar 2024 10:21:34 -0300 Subject: [PATCH 14/21] Made sequential again to fix tests + Fixed Index error in test --- modulector/tests/test_methylation.py | 5 ++-- modulector/views.py | 44 +++++++++++----------------- 2 files changed, 19 insertions(+), 30 deletions(-) diff --git a/modulector/tests/test_methylation.py b/modulector/tests/test_methylation.py index e94d58c..902d3ef 100644 --- a/modulector/tests/test_methylation.py +++ b/modulector/tests/test_methylation.py @@ -4,7 +4,7 @@ client = Client() -class methylationTests(TestCase): +class MethylationTests(TestCase): """ Testing of methylation endpoints """ def __check_pagination(self, response): @@ -130,11 +130,10 @@ def testMethylationSites1(self): self.assertTrue("cg01615704_TC11" in data) self.assertTrue("cg25908985" in data) self.assertTrue("invalid_data" in data) - # TODO arreglar self.assertEqual(data["cg22461615_TC11"][0], "cg22461615") self.assertEqual(data["cg01615704_TC11"][0], "cg01615704") self.assertEqual(data["cg25908985"][0], "cg25908985") - self.assertTrue(len(data["invalid_data"][0]) == 0) + self.assertTrue(len(data["invalid_data"]) == 0) def testMethylationSites2(self): """ Tests with a invalid body type """ diff --git a/modulector/views.py b/modulector/views.py index e5a7729..c7905cb 100644 --- a/modulector/views.py +++ b/modulector/views.py @@ -1,6 +1,6 @@ import re -from concurrent.futures import ProcessPoolExecutor -from typing import List, Optional, Final +from typing import Final + from django.conf import settings from django.db.models.query_utils import Q from django.http import Http404, HttpRequest @@ -10,6 +10,7 @@ from rest_framework.exceptions import ParseError from rest_framework.response import Response from rest_framework.views import APIView + from modulector.models import MethylationUCSC_CPGIsland, MethylationUCSCRefGene, MirnaXGene, Mirna, MirbaseIdMirna, \ MirnaDisease, MirnaDrug, GeneAliases, MethylationEPIC from modulector.pagination import StandardResultsSetPagination @@ -30,20 +31,20 @@ PROCESS_POOL_WORKERS: Final[int] = settings.PROCESS_POOL_WORKERS -def get_methylation_epic_sites_names(input_id: str) -> tuple[str, List[str]]: +def get_methylation_epic_sites_names(input_id: str) -> tuple[str, list[str]]: """ Gets methylation sites from any type of Loci id. :param input_id: String to query in the DB. - :return: List of Methylation sites. + :return: list of Methylation sites. """ res = MethylationEPIC.objects.filter(Q(ilmnid=input_id) | Q(name=input_id) | Q(methyl450_loci=input_id) | Q(methyl27_loci=input_id) | Q(epicv1_loci=input_id)).values_list('name', flat=True) - return (input_id, list(res)) + return input_id, list(res) -def get_limit_parameter(value: Optional[str]) -> int: +def get_limit_parameter(value: str | None) -> int: """ Gets a valid int value for the 'limit' parameter in requests :param value: Current value in GET request @@ -70,7 +71,7 @@ class MirnaTargetInteractions(generics.ListAPIView): handler400 = 'rest_framework.exceptions.bad_request' @staticmethod - def __get_gene_aliases(gene: str) -> List[str]: + def __get_gene_aliases(gene: str) -> list[str]: """Retrieves the aliases for a gene based on the gene provided""" match_gene = GeneAliases.objects.filter( Q(alias=gene) | Q(gene_symbol=gene)).first() @@ -142,7 +143,7 @@ class MirnaCodes(APIView): """Service that searches a list of miRNA codes and returns the code for the miRbase DB.""" @staticmethod - def __get_mirna_code(mirna_code: str) -> Optional[str]: + def __get_mirna_code(mirna_code: str) -> str | None: """ Receives a miRNA Previous ID or Accession ID, and returns the associated Accession ID. :param mirna_code: miRNA Previous ID or Accession ID. @@ -310,22 +311,11 @@ def post(request): return Response({"detail": "'methylation_sites' must be of list type"}, status=status.HTTP_400_BAD_REQUEST) # Generates a dict with the methylation sites as keys and the result of the query as values. - # note: it uses ProcessPoolExecutor to parallelize the queries and not a ThreadPoolExecutor because - # the latter has a bug closing Django connections (see https://stackoverflow.com/q/57211476/7058363) - # with ProcessPoolExecutor(max_workers=PROCESS_POOL_WORKERS) as executor: - # res = { - # methylation_name: result - # for methylation_name, result in zip(methylation_sites, executor.map( - # get_methylation_epic_sites_names, methylation_sites - # )) - # } - - # NEW: - with ProcessPoolExecutor(max_workers=PROCESS_POOL_WORKERS) as executor: - res = { - result[0]: result[1] - for result in executor.map(get_methylation_epic_sites_names, methylation_sites) - } + res = { + methylation_name: get_methylation_epic_sites_names(methylation_name)[1] + for methylation_name in methylation_sites + } + return Response(res) @@ -351,11 +341,11 @@ class MethylationSitesToGenes(APIView): versions of Illumina arrays and returns the gene(s) they belong to.""" @staticmethod - def __get_methylation_epic_sites_ids(input_name: str) -> List[str]: + def __get_methylation_epic_sites_ids(input_name: str) -> list[str]: """ Gets methylation sites from any type of Loci id :param input_name: String to query in the DB (site name) - :return: List of ID of Methylation sites from EPIC v2 database + :return: list of ID of Methylation sites from EPIC v2 database """ res = MethylationEPIC.objects.filter(Q(ilmnid=input_name) | Q(name=input_name) | Q(methyl450_loci=input_name) | Q(methyl27_loci=input_name) | @@ -363,7 +353,7 @@ def __get_methylation_epic_sites_ids(input_name: str) -> List[str]: return list(res) @staticmethod - def __get_genes_from_methylation_epic_site(input_id: str) -> List[str]: + def __get_genes_from_methylation_epic_site(input_id: str) -> list[str]: """ Gets genes from a specific methylation CpG site :param input_id: String to query in the DB (CpG ID) From bb947e1572104c5c369d36b093bf748f442ff92a Mon Sep 17 00:00:00 2001 From: Genaro Camele Date: Fri, 15 Mar 2024 10:21:43 -0300 Subject: [PATCH 15/21] Refactoring of duplicated condition --- modulector/views.py | 29 +++++++++++++++++------------ 1 file changed, 17 insertions(+), 12 deletions(-) diff --git a/modulector/views.py b/modulector/views.py index c7905cb..d56e2e4 100644 --- a/modulector/views.py +++ b/modulector/views.py @@ -31,15 +31,20 @@ PROCESS_POOL_WORKERS: Final[int] = settings.PROCESS_POOL_WORKERS +def get_methylation_match_condition(input_name: str) -> Q: + """Generates the condition to match a Methylation site.""" + return (Q(ilmnid=input_name) | Q(name=input_name) | Q(methyl450_loci=input_name) | Q(methyl27_loci=input_name) | + Q(epicv1_loci=input_name)) + + def get_methylation_epic_sites_names(input_id: str) -> tuple[str, list[str]]: """ Gets methylation sites from any type of Loci id. :param input_id: String to query in the DB. :return: list of Methylation sites. """ - res = MethylationEPIC.objects.filter(Q(ilmnid=input_id) | Q(name=input_id) | - Q(methyl450_loci=input_id) | Q(methyl27_loci=input_id) | - Q(epicv1_loci=input_id)).values_list('name', flat=True) + condition = get_methylation_match_condition(input_id) + res = MethylationEPIC.objects.filter(condition).values_list('name', flat=True) return input_id, list(res) @@ -185,20 +190,20 @@ def get(self, _request): limit = get_limit_parameter(limit) res_mirna = Mirna.objects.filter(mirna_code__istartswith=query)[ - :limit].values_list('mirna_code', flat=True) + :limit].values_list('mirna_code', flat=True) res.extend(res_mirna) res_mirna_count = len(res_mirna) if res_mirna_count < limit: num_of_reg = limit - res_mirna_count res_mirbaseidmirna_id = MirbaseIdMirna.objects.filter(mature_mirna__istartswith=query)[ - :num_of_reg].values_list('mature_mirna', flat=True) + :num_of_reg].values_list('mature_mirna', flat=True) res.extend(res_mirbaseidmirna_id) res = list(set(res)) # Removes duplicates res_mirna_count = len(res_mirbaseidmirna_id) if res_mirna_count < limit: num_of_reg = limit - res_mirna_count res_mirbaseidmirna_acc = MirbaseIdMirna.objects.filter(mirbase_accession_id__istartswith=query)[ - :num_of_reg].values_list('mirbase_accession_id', flat=True) + :num_of_reg].values_list('mirbase_accession_id', flat=True) res.extend(res_mirbaseidmirna_acc) res = list(set(res)) # remove duplicates @@ -300,6 +305,7 @@ def get(request): class MethylationSites(APIView): """Service that searches a list of methylation site identifiers from different Illumina array versions and returns the identifiers for the most recent version of the array.""" + @staticmethod def post(request): data = request.data @@ -332,7 +338,7 @@ def get(self, _request): limit = get_limit_parameter(limit) res = MethylationEPIC.objects.filter(name__istartswith=query)[ - :limit].values_list('name', flat=True) + :limit].values_list('name', flat=True) return Response(list(res)) @@ -347,9 +353,8 @@ def __get_methylation_epic_sites_ids(input_name: str) -> list[str]: :param input_name: String to query in the DB (site name) :return: list of ID of Methylation sites from EPIC v2 database """ - res = MethylationEPIC.objects.filter(Q(ilmnid=input_name) | Q(name=input_name) | - Q(methyl450_loci=input_name) | Q(methyl27_loci=input_name) | - Q(epicv1_loci=input_name)).values_list('id', flat=True) + condition = get_methylation_match_condition(input_name) + res = MethylationEPIC.objects.filter(condition).values_list('id', flat=True) return list(res) @staticmethod @@ -413,10 +418,10 @@ def get(self, _request): # Loads chromosome data if epic_data.strand_fr == "F": res["chromosome_position"] = epic_data.chr + \ - ":" + str(epic_data.mapinfo) + " [+]" + ":" + str(epic_data.mapinfo) + " [+]" elif epic_data.strand_fr == "R": res["chromosome_position"] = epic_data.chr + \ - ":" + str(epic_data.mapinfo) + " [-]" + ":" + str(epic_data.mapinfo) + " [-]" # load aliases to response res["aliases"] = [] From 5a8d59eff01c0bd061627ee3039fc3236322f485 Mon Sep 17 00:00:00 2001 From: Genaro Camele Date: Fri, 15 Mar 2024 10:36:23 -0300 Subject: [PATCH 16/21] Bumped Debian, Django, Django Stubs and Daphne versions --- Dockerfile | 2 +- config/requirements.txt | 8 ++++---- tools/run.sh | 5 ++++- 3 files changed, 9 insertions(+), 6 deletions(-) diff --git a/Dockerfile b/Dockerfile index ade05f0..ea3fe8c 100644 --- a/Dockerfile +++ b/Dockerfile @@ -1,4 +1,4 @@ -FROM python:3.12-slim-bullseye +FROM python:3.12-slim-bookworm # Default value for deploying with modulector DB image ENV POSTGRES_USERNAME "modulector" diff --git a/config/requirements.txt b/config/requirements.txt index b549112..f279328 100644 --- a/config/requirements.txt +++ b/config/requirements.txt @@ -1,11 +1,11 @@ -daphne==4.0.0 -Django==4.2.8 +daphne==4.1.0 +Django==4.2.11 django-crontab==0.7.1 django-filter==23.3 django-generate-secret-key==1.0.2 -django-stubs==4.2.6 +django-stubs==4.2.7 djangorestframework==3.14.0 -mypy==1.6.1 +mypy==1.9.0 pandas==2.1.2 psycopg2-binary==2.9.9 requests==2.31.0 diff --git a/tools/run.sh b/tools/run.sh index 8c8ec67..eda93bf 100644 --- a/tools/run.sh +++ b/tools/run.sh @@ -1,4 +1,5 @@ #!/bin/bash + logger "Starting app..." while ! python3 tools/test_db_connection.py @@ -8,4 +9,6 @@ do done -python3 manage.py generate_secret_key --settings='ModulectorBackend.settings' && python3 manage.py collectstatic --no-input && daphne -b 0.0.0.0 -p 8000 ModulectorBackend.asgi:application +python3 manage.py generate_secret_key --settings='ModulectorBackend.settings' && \ +python3 manage.py collectstatic --no-input && \ +daphne -b 0.0.0.0 -p 8000 ModulectorBackend.asgi:application From 1de0ad161006b982e9375afb248ae366583d615f Mon Sep 17 00:00:00 2001 From: Genaro Camele Date: Fri, 15 Mar 2024 10:36:34 -0300 Subject: [PATCH 17/21] Fixed a lot of typos --- modulector/tests/test_diseases.py | 4 ++-- modulector/tests/test_drugs.py | 4 ++-- modulector/tests/test_methylation.py | 12 ++++++------ modulector/tests/test_mirna.py | 12 ++++++------ modulector/tests/test_root.py | 2 +- 5 files changed, 17 insertions(+), 17 deletions(-) diff --git a/modulector/tests/test_diseases.py b/modulector/tests/test_diseases.py index 30528cc..91df0cf 100644 --- a/modulector/tests/test_diseases.py +++ b/modulector/tests/test_diseases.py @@ -3,7 +3,7 @@ client = Client() -class diseaseTests(TestCase): +class DiseaseTests(TestCase): def __check_empty_pagination(self, response): """Checks if fields of response are valid for an empty pagination response""" self.assertEqual(response.data['count'], 0) @@ -12,7 +12,7 @@ def __check_empty_pagination(self, response): self.assertIsNone(response.data['previous']) def __check_one_result_pagination(self, response): - """Checks if fields of response are valid for an one-result pagination response""" + """Checks if fields of response are valid for a one-result pagination response""" self.assertEqual(response.data['count'], 1) self.assertTrue(len(response.data['results']) == 1) self.assertIsNone(response.data['next']) diff --git a/modulector/tests/test_drugs.py b/modulector/tests/test_drugs.py index 3afd378..c956549 100644 --- a/modulector/tests/test_drugs.py +++ b/modulector/tests/test_drugs.py @@ -3,7 +3,7 @@ client = Client() -class drugsTests(TestCase): +class DrugsTests(TestCase): def __check_empty_pagination(self, response): """Checks if fields of response are valid for an empty pagination response""" self.assertEqual(response.data['count'], 0) @@ -12,7 +12,7 @@ def __check_empty_pagination(self, response): self.assertIsNone(response.data['previous']) def __check_one_result_pagination(self, response): - """Checks if fields of response are valid for an one-result pagination response""" + """Checks if fields of response are valid for a one-result pagination response""" self.assertEqual(response.data['count'], 1) self.assertTrue(len(response.data['results']) == 1) self.assertIsNone(response.data['next']) diff --git a/modulector/tests/test_methylation.py b/modulector/tests/test_methylation.py index 902d3ef..856b6aa 100644 --- a/modulector/tests/test_methylation.py +++ b/modulector/tests/test_methylation.py @@ -24,7 +24,7 @@ def __check_empty_pagination(self, response): self.assertIsNone(response.data['previous']) def __check_one_result_pagination(self, response): - """Checks if fields of response are valid for an one-result pagination response""" + """Checks if fields of response are valid for a one-result pagination response""" self.assertEqual(response.data['count'], 1) self.assertTrue(len(response.data['results']) == 1) self.assertIsNone(response.data['next']) @@ -60,7 +60,7 @@ def testMethylationDetails1(self): self.assertEqual(data['genes']['SEC31A'], ["TSS200"]) def testMethylationDetails2(self): - """ Tests methylation endpoint with a invalid methylation site """ + """ Tests methylation endpoint with an invalid methylation site """ response = client.get( '/methylation/', {'methylation_site': 'thisIsNotAMethylationSite'}) self.assertEqual(response.status_code, 400) @@ -136,7 +136,7 @@ def testMethylationSites1(self): self.assertTrue(len(data["invalid_data"]) == 0) def testMethylationSites2(self): - """ Tests with a invalid body type """ + """ Tests with an invalid body type """ data = json.dumps({"methylation_sites": "cg01615704_TC11"}) response = client.post('/methylation-sites/', data=data, content_type='application/json') @@ -145,7 +145,7 @@ def testMethylationSites2(self): self.assertTrue("detail" in data) def testMethylationSites3(self): - """ Tests with a invalid body key """ + """ Tests with an invalid body key """ data = json.dumps({"methylation": ["cg01615704_TC11"]}) response = client.post('/methylation-sites/', data=data, content_type='application/json') @@ -172,7 +172,7 @@ def testMethylationSitesToGenes1(self): self.assertEqual(data["cg22461615"], ["THAP9", "THAP9-AS1", "SEC31A"]) def testMethylationSitesToGenes2(self): - """ Tests with a invalid body type """ + """ Tests with an invalid body type """ data = json.dumps({"methylation_sites": "cg17771854_BC11"}) response = client.post('/methylation-sites-genes/', data=data, content_type='application/json') @@ -181,7 +181,7 @@ def testMethylationSitesToGenes2(self): self.assertTrue("detail" in data) def testMethylationSitesToGenes3(self): - """ Tests with a invalid body key """ + """ Tests with an invalid body key """ data = json.dumps({"methylation": "cg17771854_BC11"}) response = client.post('/methylation-sites-genes/', data=data, content_type='application/json') diff --git a/modulector/tests/test_mirna.py b/modulector/tests/test_mirna.py index 4f5fa7a..041bee1 100644 --- a/modulector/tests/test_mirna.py +++ b/modulector/tests/test_mirna.py @@ -4,7 +4,7 @@ client = Client() -class miRNATests(TestCase): +class MiRNATests(TestCase): """ Testing of miRNA endpoints """ def __check_pagination(self, response): @@ -24,7 +24,7 @@ def __check_empty_pagination(self, response): self.assertIsNone(response.data['previous']) def __check_one_result_pagination(self, response): - """Checks if fields of response are valid for an one-result pagination response""" + """Checks if fields of response are valid for a one-result pagination response""" self.assertEqual(response.data['count'], 1) self.assertTrue(len(response.data['results']) == 1) self.assertIsNone(response.data['next']) @@ -33,7 +33,7 @@ def __check_one_result_pagination(self, response): """ Testing /mirna/ endpoint """ def testMirnaList1(self): - """Tests mirna endpoint with a invalid mirna""" + """Tests mirna endpoint with an invalid mirna""" response = client.get('/mirna/', {'mirna': 'goku_rules'}) self.assertEqual(response.status_code, 404) # Checks all fields @@ -75,7 +75,7 @@ def testMirnaList3(self): """ Testing /mirna-target-interactions/ endpoint """ def testMirnaTargetInteractions1(self): - """Tests with a invalid mirna""" + """Tests with an invalid mirna""" response = client.get( '/mirna-target-interactions/', {'mirna': 'goku_capo'}) self.assertEqual(response.status_code, 200) @@ -155,7 +155,7 @@ def testMirnaCodes1(self): self.assertEqual(data["hsa-let-7e-5p"], "MIMAT0000066") def testMirnaCodes2(self): - """ Tests with a invalid body type """ + """ Tests with an invalid body type """ data = json.dumps({"mirna_codes": "Hsa-Mir-935-v2_5p*"}) response = client.post('/mirna-codes/', data=data, content_type='application/json') @@ -164,7 +164,7 @@ def testMirnaCodes2(self): self.assertTrue("detail" in data) def testMirnaCodes3(self): - """ Tests with a invalid body key """ + """ Tests with an invalid body key """ data = json.dumps({"mirna": ["Hsa-Mir-935-v2_5p*"]}) response = client.post('/mirna-codes/', data=data, content_type='application/json') diff --git a/modulector/tests/test_root.py b/modulector/tests/test_root.py index 2b04132..a4973b4 100644 --- a/modulector/tests/test_root.py +++ b/modulector/tests/test_root.py @@ -3,7 +3,7 @@ client = Client() -class rootTests(TestCase): +class RootTests(TestCase): def testRootView(self): """Tests / endpoint""" response = client.get('/') From 970a76b509c19cfa43bbf6cbe8af47bee6e99e47 Mon Sep 17 00:00:00 2001 From: mauricio Date: Tue, 19 Mar 2024 17:36:46 -0300 Subject: [PATCH 18/21] documentation --- README.md | 33 +- modulector/files/.Rhistory | 100 + modulector/files/aliases.txt | 88831 ++++++++++++++++ modulector/files/disease.txt | 35548 +++++++ modulector/files/drugs.xls | Bin 0 -> 1330176 bytes .../files/get_diseases_and_drugs_data.r | 70 + modulector/files/ref_seq_to_symbols.txt | 53233 +++++++++ modulector/files/ref_seq_translation.sql | 1 + 8 files changed, 177801 insertions(+), 15 deletions(-) create mode 100644 modulector/files/.Rhistory create mode 100644 modulector/files/aliases.txt create mode 100644 modulector/files/disease.txt create mode 100644 modulector/files/drugs.xls create mode 100644 modulector/files/get_diseases_and_drugs_data.r create mode 100644 modulector/files/ref_seq_to_symbols.txt create mode 100644 modulector/files/ref_seq_translation.sql diff --git a/README.md b/README.md index be69d97..99ae8e1 100644 --- a/README.md +++ b/README.md @@ -106,7 +106,7 @@ If no gene symbol is entered, all miRNA interactions are returned. If a miRNA is - Query params: - `mirna`: miRNA (Accession ID or name in mirBase) to get its interactions with different genes targets. - `gene`: gene symbol to get its interactions with different miRNA targets. - - `score`: numerical score to filter the interactions (only interactions with a score greater than or equal to the parameter value are returned). The value of this score is provided by the mirDip database. + - `score`: numerical score to filter the interactions (only interactions with a score greater than or equal to the parameter value are returned). The score corresponds to that obtained for the unidirectional analysis of the MirDip tool. MiRDIP groups information from [24 different predictors](https://ophid.utoronto.ca/mirDIP/statistics.jsp) to then calculate a score for each target gene. For more information about the calculation of the score, you can consult the [scientific publication](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9825511/) of the tool. - `include_pubmeds`: if its value is 'true', the endpoint also returns a list of links to Pubmed where the miRNAs are related to the genes (this may affect Modulector's response time). The default is 'false'. *NOTE*: `mirna` or `gene` are required - Functions: @@ -117,14 +117,14 @@ If no gene symbol is entered, all miRNA interactions are returned. If a miRNA is - Success Response: - Code: 200 - Content: - - `id`: internal ID of the interaction. + - `id`: Record identifier in MirDIP. - `mirna`: miRNA ID (miRBase MIMAT id or previous ID). The received one as query param. - `gene`: target gene. - - `score`: interaction score (according to mirDIP). - - `source_name`: database from which the interaction was extracted. - - `pubmeds`: array of PubMed for the miRNA-gene interaction (according to mirTaRBase). - - `sources`: miRNA-Gene interaction sources which publish this interaction. mirDIP score is based on the scores of those sources. This field is an array that contains the interaction score source names. - - `score_class`: `L` (Low), `M` (Medium), `H` (High) or `V` (Very high) + - `score`: interaction score (according to mirDIP). Value range between 0 and 1. + - `source_name`: database from which the interaction was extracted. For now you will always receive the `mirdip` value. + - `pubmeds`: array of PubMed URLs for the miRNA-gene interaction (according to mirTaRBase). + - `sources`: miRNA-Gene interaction sources. mirDIP score is based on the scores of those sources. This field is an array that contains the interaction score source names. The different source databases can be found on the [official miRDIP site](https://ophid.utoronto.ca/mirDIP/statistics.jsp). + - `score_class`: score class according to mirDIP. The possible values are: `V` (Very high: Top 1%), `H` (High: Top 5%), `M` (Medium: Top 1/3) or `L` (Low: Bottom 2/3). - Example: - URL: - Response: @@ -166,7 +166,7 @@ If no gene symbol is entered, all miRNA interactions are returned. If a miRNA is ### MiRNA details -Returns extra information of a miRNA. +This functionality allows obtaining different information about a miRNA, such as its sequence, its previous identifiers and databases where information about it can be found.. - URL: `/mirna` - Required query params: @@ -181,8 +181,10 @@ Returns extra information of a miRNA. - Content: - `aliases`: array of miRNA aliases (previous IDs according to miRBase). - `mirna_sequence`: miRNA nucleotide sequence. - - `mirbase_accession_id`: miRNA accession ID (MIMAT). - - `links` array of URLs with extra information about this miRNA. + - `mirbase_accession_id`: miRNA accession ID (MIMAT) according to miRBase DB. + - `links`: List of JSON containing the following information: + - `source`: Name of the database where you can find information related to miRNA. + - `url`: URL to access the `source` database for the miRNA of interest. - Example: - URL: - Response: @@ -207,11 +209,12 @@ Returns extra information of a miRNA. - Error Response: - Code: 404 - - Content: - + - Content: `detail`: error description ### MiRNA aliases -Returns a paginated response with aliases of a miRNA. +Returns all associations between mirnas Accessions IDs (MIMAT) and miRNAs matures IDs from the miRBase database. +The main difference between MIMAT and mature miRNA IDs in MiRBase lies in their purpose and usage. MIMAT are unique identifiers that define miRNAs uniquely in MiRBase, allowing users to retrieve comprehensive information about specific miRNAs, including their names, sequences, species, versions, and families. On the other hand, mature miRNA IDs refer to the specific mature sequences of miRNAs, such as miR-17-5p and miR-17-3p, which are excised from hairpin precursors and represent different arms of the miRNA. While accession IDs serve as universal identifiers for miRNAs across different versions of MiRBase, mature miRNA IDs focus on the individual sequences of mature miRNAs and their relationships within the database. - URL: `/mirna-aliases` - Required query params: - @@ -223,8 +226,8 @@ Returns a paginated response with aliases of a miRNA. - Success Response: - Code: 200 - Content: - - `mirbase_accession_id`: miRNA mirBase accession ID (MIMAT). - - `mature_mirna`: previous ID (according to miRBase). + - `mirbase_accession_id`: mirBase accession ID (MIMAT) for the miRNA. + - `mature_mirna`: Mature mirna ID in miRBase database. - Example: - URL: - Response: @@ -282,7 +285,7 @@ Service that takes a string of any length and returns a list of miRNAs that cont ### miRNA codes -Searches for codes from a list of miRNA identifiers and returns the approved access identifier according to miRBase DB. +Searches for codes from a list of miRNA identifiers and returns the approved access identifier according to miRBase DB (MI or MIMAT ID). - URL: `/mirna-codes` - Method: POST diff --git a/modulector/files/.Rhistory b/modulector/files/.Rhistory new file mode 100644 index 0000000..099e01a --- /dev/null +++ b/modulector/files/.Rhistory @@ -0,0 +1,100 @@ +library(multiMiR) +db.ver = multimir_dbInfoVersions() # versiones de multimir +db.ver +# cambiar version a la ultima +vers_table <- multimir_dbInfoVersions() +curr_vers <- vers_table[1, "VERSION"] # current version +multimir_switchDBVersion(db_version = curr_vers) +db.tables = multimir_dbTables() # tablas de la db de multimir (dbs integradas) +db.tables +db.info = multimir_dbInfo() # informacion d elas dbs integradas +db.info +# Agrupadores de tablas. Nos interesa en principio "disease.drugs" +predicted_tables() +validated_tables() +diseasedrug_tables() +reverse_table_lookup("targetscan") +db.count = multimir_dbCount() # obtiene registros por base de datos intergadas a multimir +db.count +apply(db.count[,-1], 2, sum) +db.tables = multimir_dbTables() # tablas de la db de multimir (dbs integradas) +db.tables +db.info = multimir_dbInfo() # informacion d elas dbs integradas +db.info +diseasedrug_tables() +db.count = multimir_dbCount() # obtiene registros por base de datos intergadas a multimir +db.count +apply(db.count[,-1], 2, sum) +# Otener listado de todos los genes, drogas, enfermedades y mirnas: +miRNAs = list_multimir("mirna") +genes = list_multimir("gene") +head(drugs) +drugs = list_multimir("drug") +diseases = list_multimir("disease") +head(drugs) +head(diseases) +# Ejemplo: obtener informacion para un mirna: +example1 <- get_multimir(mirna = 'hsa-miR-18a-3p', summary = TRUE) +View(example1) +View(example1@data) +# Pruebas Mauri +miRNAs = list_multimir("mirna") # obtengo todos los mirnas +human_miRNAs <- subset(miRNAs, org == "hsa") # filtro los mirnas humanos +all_mirna_drugs <- list() # aca guardo resultados +# Itero por cada mirna humano para obtener informacion de drogas +for (mirna in human_miRNAs$mature_mirna_id) { +print(mirna) +mirna_drugs <- get_multimir(mirna=mirna, table="disease.drug", summary = FALSE) # table="all" tampoco da lo que necesitmos +# Store drugs for this miRNA +all_mirna_drugs[[mirna]] <- mirna_drugs@data$disease_drug +} +View(mirna_drugs) +View(mirna_drugs@data) +mirna_drugs <- get_multimir(mirna='hsa-miR-18a-3p', table="disease.drug", summary = FALSE) # table="all" tampoco da lo que necesitmos +View(mirna_drugs@data) +# Intento de otra forma: +drugs = list_multimir("drug") # Obtengo todas las drogas dispnibles +all_mirna_drugs <- list() # aca guardo resultados +all_mirna_drugs <- list() # aca guardo resultados +# Itero por cada droga para obtener informacion de mirnas +for (d in drugs$drug) { +mirna_drugs <- get_multimir(disease.drug = d, table = 'disease.drug', summary = TRUE) # table="all" tampoco da lo que necesitmos +# Store drugs for this miRNA +all_mirna_drugs[[d]] <- mirna_drugs@data$mature_mirna_id +} +# Itero por cada droga para obtener informacion de mirnas +for (d in drugs$drug) { +mirna_drugs <- get_multimir(disease.drug = d, table = 'disease.drug', summary = FALSE) # table="all" tampoco da lo que necesitmos +# Store drugs for this miRNA +all_mirna_drugs[[d]] <- mirna_drugs@data$mature_mirna_id +} +# Intento de otra forma: +drugs = list_multimir("drug") # Obtengo todas las drogas dispnibles +all_mirna_drugs <- list() # aca guardo resultados +# Itero por cada droga para obtener informacion de mirnas +for (d in drugs$drug) { +mirna_drugs <- get_multimir(disease.drug = d, table = 'disease.drug', summary = FALSE) # table="all" tampoco da lo que necesitmos +# Store drugs for this miRNA +all_mirna_drugs[[d]] <- mirna_drugs@data$mature_mirna_id +} +# Itero por cada droga para obtener informacion de mirnas +for (d in drugs$drug) { +mirna_drugs <- get_multimir(disease.drug = d, table = 'disease.drug', summary = FALSE) # table="all" tampoco da lo que necesitmos +# Store drugs for this miRNA +# all_mirna_drugs[[d]] <- mirna_drugs@data$mature_mirna_id +} +View(mirna_drugs@data) +# Ejemplo: obtener infoamcion acerca de la droga cisplatin +example2 <- get_multimir(disease.drug = 'cisplatin', table = 'disease.drug') +View(example2) +View(example2@data) +# Ejemplo: obtener infoamcion acerca de la droga cisplatin +example2 <- get_multimir(disease.drug = 'cisplatin', table = 'disease.drug', summary = TRUE) +View(example2@summary) +mirna_drugs <- get_multimir(mirna='hsa-miR-18a-3p', table="all", summary = TRUE) # table="all" tampoco da lo que necesitmos +View(mirna_drugs) +View(mirna_drugs@data) +View(mirna_drugs@summary) +mirna_drugs <- get_multimir(mirna='hsa-miR-18a-3p', table="disease.drug", summary = FALSE) # table="all" tampoco da lo que necesitmos +View(mirna_drugs) +View(mirna_drugs@data) diff --git a/modulector/files/aliases.txt b/modulector/files/aliases.txt new file mode 100644 index 0000000..2752e10 --- /dev/null +++ b/modulector/files/aliases.txt @@ -0,0 +1,88831 @@ +MI0000001 cel-let-7L;cel-let-7; +MI0000002 cel-lin-4L;cel-lin-4; +MI0000003 cel-mir-1; +MI0000004 cel-mir-2; +MI0000005 cel-mir-34; +MI0000006 cel-mir-35; +MI0000007 cel-mir-36; +MI0000008 cel-mir-37; +MI0000009 cel-mir-38; +MI0000010 cel-mir-39; +MI0000011 cel-mir-40; +MI0000012 cel-mir-41; +MI0000013 cel-mir-42; +MI0000014 cel-mir-43; +MI0000015 cel-mir-44; +MI0000016 cel-mir-45; +MI0000017 cel-mir-46; +MI0000018 cel-mir-47; +MI0000019 cel-mir-48; +MI0000020 cel-mir-49; +MI0000021 cel-mir-50; +MI0000022 cel-mir-51; +MI0000023 cel-mir-52; +MI0000024 cel-mir-53; +MI0000025 cel-mir-54; +MI0000026 cel-mir-55; +MI0000027 cel-mir-56; +MI0000028 cel-mir-57; +MI0000029 cel-mir-58;cel-mir-58a; +MI0000030 cel-mir-59; +MI0000031 cel-mir-60; +MI0000032 cel-mir-61; +MI0000033 cel-mir-62; +MI0000034 cel-mir-63; +MI0000035 cel-mir-64; +MI0000036 cel-mir-65; +MI0000037 cel-mir-66; +MI0000038 cel-mir-67; +MI0000039 cel-mir-68; +MI0000040 cel-mir-69; +MI0000041 cel-mir-70; +MI0000042 cel-mir-71; +MI0000043 cel-mir-72; +MI0000044 cel-mir-73; +MI0000045 cel-mir-74; +MI0000046 cel-mir-75; +MI0000047 cel-mir-76; +MI0000048 cel-mir-77; +MI0000049 cel-mir-78; +MI0000050 cel-mir-79; +MI0000051 cel-mir-80; +MI0000052 cel-mir-81; +MI0000053 cel-mir-82; +MI0000054 cel-mir-83; +MI0000055 cel-mir-84; +MI0000056 cel-mir-85; +MI0000057 cel-mir-86; +MI0000058 cel-mir-87; +MI0000059 cel-mir-90; +MI0000060 hsa-let-7a-1L;hsa-let-7a-1; +MI0000061 hsa-let-7a-2L;hsa-let-7a-2; +MI0000062 hsa-let-7a-3L;hsa-let-7a-3; +MI0000063 hsa-let-7bL;hsa-let-7b; +MI0000064 hsa-let-7cL;hsa-let-7c; +MI0000065 hsa-let-7dL;hsa-let-7d; +MI0000066 hsa-let-7eL;hsa-let-7e; +MI0000067 hsa-let-7f-1L;hsa-let-7f-1; +MI0000068 hsa-let-7f-2L;hsa-let-7f-2; +MI0000069 hsa-mir-15;hsa-mir-15a; +MI0000070 hsa-mir-16-13;hsa-mir-16;hsa-mir-16-1; +MI0000071 hsa-mir-17; +MI0000072 hsa-mir-18;hsa-mir-18a; +MI0000073 hsa-mir-19a; +MI0000074 hsa-mir-19b-1; +MI0000075 hsa-mir-19b-2; +MI0000076 hsa-mir-20;hsa-mir-20a; +MI0000077 hsa-mir-21; +MI0000078 hsa-mir-22; +MI0000079 hsa-mir-23;hsa-mir-23a; +MI0000080 hsa-mir-24-1; +MI0000081 hsa-mir-24-2; +MI0000082 hsa-mir-25; +MI0000083 hsa-mir-26a;hsa-mir-26a-1; +MI0000084 hsa-mir-26b; +MI0000085 hsa-mir-27;hsa-mir-27a; +MI0000086 hsa-mir-28; +MI0000087 hsa-mir-29;hsa-mir-29a; +MI0000088 hsa-mir-30;hsa-mir-30a; +MI0000089 hsa-mir-31; +MI0000090 hsa-mir-32; +MI0000091 hsa-mir-33;hsa-mir-33a; +MI0000092 hsa-mir-91-13;hsa-mir-91; +MI0000093 hsa-mir-92-13;hsa-mir-92-1;hsa-mir-92a-1; +MI0000094 hsa-mir-92-X;hsa-mir-92-2;hsa-mir-92a-2; +MI0000095 hsa-mir-93-7.1;hsa-mir-93-1;hsa-mir-93; +MI0000096 hsa-mir-93-7.2;hsa-mir-93-2; +MI0000097 hsa-mir-95-4;hsa-mir-95; +MI0000098 hsa-mir-96-7;hsa-mir-96; +MI0000099 hsa-mir-97-6; +MI0000100 hsa-mir-98-X;hsa-mir-98; +MI0000101 hsa-mir-99-21;hsa-mir-99;hsa-mir-99a; +MI0000102 hsa-mir-100-11;hsa-mir-100; +MI0000103 hsa-mir-101-1;hsa-mir-101;hsa-mir-101-1; +MI0000104 hsa-mir-101-9; +MI0000105 hsa-mir-102-7.1;hsa-mir-102-2;hsa-mir-29b-2;hsa-mir-29b-1; +MI0000106 hsa-mir-102-7.2;hsa-mir-102-3;hsa-mir-29b-3; +MI0000107 hsa-mir-102-1;hsa-mir-29b-1;hsa-mir-29b-2; +MI0000108 hsa-mir-103-20;hsa-mir-103-2;hsa-mir-103a-2; +MI0000109 hsa-mir-103-5;hsa-mir-103-1;hsa-mir-103a-1; +MI0000110 hsa-mir-104-17;hsa-mir-104; +MI0000111 hsa-mir-105-X.1;hsa-mir-105-1; +MI0000112 hsa-mir-105-X.2;hsa-mir-105-2; +MI0000113 hsa-mir-106-X;hsa-mir-106;hsa-mir-106a; +MI0000114 hsa-mir-107-10;hsa-mir-107; +MI0000115 hsa-mir-16-3;hsa-mir-16-2; +MI0000116 dme-mir-1; +MI0000117 dme-mir-2a-1; +MI0000118 dme-mir-2a-2; +MI0000119 dme-mir-2b-1; +MI0000120 dme-mir-2b-2; +MI0000121 dme-mir-3; +MI0000122 dme-mir-4; +MI0000123 dme-mir-5; +MI0000124 dme-mir-6-1; +MI0000125 dme-mir-6-2; +MI0000126 dme-mir-6-3; +MI0000127 dme-mir-7; +MI0000128 dme-mir-8; +MI0000129 dme-mir-9;dme-mir-9a; +MI0000130 dme-mir-10; +MI0000131 dme-mir-11; +MI0000132 dme-mir-12; +MI0000133 dme-mir-13a; +MI0000134 dme-mir-13b-1; +MI0000135 dme-mir-13b-2; +MI0000136 dme-mir-14; +MI0000137 mmu-let-7gL;mmu-let-7g; +MI0000138 mmu-let-7iL;mmu-let-7i; +MI0000139 mmu-mir-1d;mmu-mir-1-1;mmu-mir-1a-1; +MI0000140 mmu-mir-15b; +MI0000141 mmu-mir-23b; +MI0000142 mmu-mir-27b; +MI0000143 mmu-mir-29b;mmu-mir-29b-1; +MI0000144 mmu-mir-30a; +MI0000145 mmu-mir-30b; +MI0000146 mmu-mir-99a; +MI0000147 mmu-mir-99b; +MI0000148 mmu-mir-101;mmu-mir-101a; +MI0000149 mmu-mir-123; +MI0000150 mmu-mir-124a;mmu-mir-124a-3;mmu-mir-124-3; +MI0000151 mmu-mir-125a; +MI0000152 mmu-mir-125b;mmu-mir-125b-2; +MI0000153 mmu-mir-126;mmu-mir-126a; +MI0000154 mmu-mir-127; +MI0000155 mmu-mir-128;mmu-mir-128a;mmu-mir-128-1; +MI0000156 mmu-mir-130;mmu-mir-130a; +MI0000157 mmu-mir-131;mmu-mir-9;mmu-mir-9-2; +MI0000158 mmu-mir-132; +MI0000159 mmu-mir-133;mmu-mir-133a-1; +MI0000160 mmu-mir-134; +MI0000161 mmu-mir-135;mmu-mir-135-1;mmu-mir-135a-1; +MI0000162 mmu-mir-136; +MI0000163 mmu-mir-137; +MI0000164 mmu-mir-138;mmu-mir-138-2; +MI0000165 mmu-mir-140; +MI0000166 mmu-mir-141; +MI0000167 mmu-mir-142;mmu-mir-142a; +MI0000168 mmu-mir-144; +MI0000169 mmu-mir-145;mmu-mir-145a; +MI0000170 mmu-mir-146;mmu-mir-146a; +MI0000171 mmu-mir-149; +MI0000172 mmu-mir-150; +MI0000173 mmu-mir-151; +MI0000174 mmu-mir-152; +MI0000175 mmu-mir-153; +MI0000176 mmu-mir-154; +MI0000177 mmu-mir-155; +MI0000178 ath-MIR156a; +MI0000179 ath-MIR156b; +MI0000180 ath-MIR156c; +MI0000181 ath-MIR156d; +MI0000182 ath-MIR156e; +MI0000183 ath-MIR156f; +MI0000184 ath-MIR157a; +MI0000185 ath-MIR157b; +MI0000186 ath-MIR157c; +MI0000187 ath-MIR157d; +MI0000188 ath-MIR158;ath-MIR158a; +MI0000189 ath-MIR159;ath-MIR159a; +MI0000190 ath-MIR160a; +MI0000191 ath-MIR160b; +MI0000192 ath-MIR160c; +MI0000193 ath-MIR161; +MI0000194 ath-MIR162a; +MI0000195 ath-MIR162b; +MI0000196 ath-MIR163; +MI0000197 ath-MIR164a; +MI0000198 ath-MIR164b; +MI0000199 ath-MIR165a; +MI0000200 ath-MIR165b; +MI0000201 ath-MIR166a; +MI0000202 ath-MIR166b; +MI0000203 ath-MIR166c; +MI0000204 ath-MIR166d; +MI0000205 ath-MIR166e; +MI0000206 ath-MIR166f; +MI0000207 ath-MIR166g; +MI0000208 ath-MIR167a; +MI0000209 ath-MIR167b; +MI0000210 ath-MIR168a; +MI0000211 ath-MIR168b; +MI0000212 ath-MIR169;ath-MIR169a; +MI0000213 ath-MIR170; +MI0000214 ath-MIR171;ath-MIR171a; +MI0000215 ath-MIR172a1;ath-MIR172a; +MI0000216 ath-MIR172a2;ath-MIR172b; +MI0000217 ath-MIR173; +MI0000218 ath-MIR159b; +MI0000219 ath-MIR180a; +MI0000220 ath-MIR180b; +MI0000221 mmu-mir-10b; +MI0000222 mmu-mir-129b;mmu-mir-129-1; +MI0000223 mmu-mir-181;mmu-mir-181a;mmu-mir-181a-2; +MI0000224 mmu-mir-182; +MI0000225 mmu-mir-183; +MI0000226 mmu-mir-184; +MI0000227 mmu-mir-185; +MI0000228 mmu-mir-186; +MI0000229 mmu-mir-187; +MI0000230 mmu-mir-188; +MI0000231 mmu-mir-189;mmu-mir-24-1; +MI0000232 mmu-mir-190;mmu-mir-190a; +MI0000233 mmu-mir-191; +MI0000234 hsa-mir-192; +MI0000235 mmu-mir-193;mmu-mir-193a; +MI0000236 mmu-mir-194;mmu-mir-194-1; +MI0000237 mmu-mir-195;mmu-mir-195a; +MI0000238 hsa-mir-196;hsa-mir-196-1;hsa-mir-196a-1; +MI0000239 hsa-mir-197; +MI0000240 hsa-mir-198; +MI0000241 mmu-mir-199-as;mmu-mir-199;mmu-mir-199a-1; +MI0000242 hsa-mir-199-s;hsa-mir-199a-1; +MI0000243 mmu-mir-200b; +MI0000244 mmu-mir-201; +MI0000245 mmu-mir-202; +MI0000246 mmu-mir-203; +MI0000247 mmu-mir-204; +MI0000248 mmu-mir-205; +MI0000249 mmu-mir-206; +MI0000250 mmu-mir-207; +MI0000251 hsa-mir-208;hsa-mir-208a; +MI0000252 hsa-mir-129;hsa-mir-129a;hsa-mir-129-1; +MI0000253 hsa-mir-148;hsa-mir-148a; +MI0000254 hsa-mir-30c;hsa-mir-30c-2; +MI0000255 hsa-mir-30d; +MI0000256 mmu-mir-122a;mmu-mir-122; +MI0000257 mmu-mir-143; +MI0000258 mmu-mir-1b; +MI0000259 mmu-mir-30e; +MI0000260 hsa-mir-124b; +MI0000261 hsa-mir-139; +MI0000262 hsa-mir-147;hsa-mir-147a; +MI0000263 hsa-mir-7-1; +MI0000264 hsa-mir-7-2; +MI0000265 hsa-mir-7-3; +MI0000266 hsa-mir-10a; +MI0000267 hsa-mir-10b; +MI0000268 hsa-mir-34;hsa-mir-34a; +MI0000269 hsa-mir-181a;hsa-mir-181a-2; +MI0000270 hsa-mir-181b;hsa-mir-181b-1; +MI0000271 hsa-mir-181c; +MI0000272 hsa-mir-182-as;hsa-mir-182; +MI0000273 hsa-mir-183; +MI0000274 hsa-mir-187; +MI0000278 hsa-mir-196-1; +MI0000279 hsa-mir-196-2;hsa-mir-196a-2; +MI0000280 hsa-mir-199a-1; +MI0000281 hsa-mir-199a-2; +MI0000282 hsa-mir-199b; +MI0000283 hsa-mir-203;hsa-mir-203a; +MI0000284 hsa-mir-204; +MI0000285 hsa-mir-205; +MI0000286 hsa-mir-210; +MI0000287 hsa-mir-211; +MI0000288 hsa-mir-212; +MI0000289 hsa-mir-213;hsa-mir-181a-1; +MI0000290 hsa-mir-214; +MI0000291 hsa-mir-215; +MI0000292 hsa-mir-216;hsa-mir-216a; +MI0000293 hsa-mir-217; +MI0000294 hsa-mir-218-1; +MI0000295 hsa-mir-218-2; +MI0000296 hsa-mir-219;hsa-mir-219-1;hsa-mir-219a-1; +MI0000297 hsa-mir-220;hsa-mir-220a; +MI0000298 hsa-mir-221; +MI0000299 hsa-mir-222; +MI0000300 hsa-mir-223; +MI0000301 hsa-mir-224; +MI0000302 cel-mir-124; +MI0000303 cel-mir-228; +MI0000304 cel-mir-229; +MI0000305 cel-mir-230; +MI0000306 cel-mir-231; +MI0000307 cel-mir-232; +MI0000308 cel-mir-233; +MI0000309 cel-mir-234; +MI0000310 cel-mir-235; +MI0000311 cel-mir-236; +MI0000312 cel-mir-237; +MI0000313 cel-mir-238; +MI0000314 cel-mir-239a; +MI0000315 cel-mir-239b; +MI0000316 cel-mir-240; +MI0000317 cel-mir-241; +MI0000318 cel-mir-242; +MI0000319 cel-mir-243; +MI0000320 cel-mir-244; +MI0000321 cel-mir-245; +MI0000322 cel-mir-246; +MI0000323 cel-mir-247; +MI0000324 cel-mir-248; +MI0000325 cel-mir-249; +MI0000326 cel-mir-250; +MI0000327 cel-mir-251; +MI0000328 cel-mir-252; +MI0000329 cel-mir-253; +MI0000330 cel-mir-254; +MI0000331 cel-mir-255; +MI0000332 cel-mir-227; +MI0000333 cel-mir-256; +MI0000334 cel-mir-257; +MI0000335 cel-mir-258;cel-mir-258-1; +MI0000336 cel-mir-259; +MI0000337 cel-mir-260; +MI0000338 cel-mir-261; +MI0000339 cel-mir-262; +MI0000342 hsa-mir-200b; +MI0000343 dme-mir-263;dme-mir-263a; +MI0000344 cel-mir-264; +MI0000345 cel-mir-265; +MI0000346 cel-mir-266; +MI0000347 cel-mir-267; +MI0000348 cel-mir-268; +MI0000349 cel-mir-269; +MI0000350 cel-mir-270; +MI0000351 cel-mir-271; +MI0000352 cel-mir-272; +MI0000353 cel-mir-273; +MI0000354 dme-mir-184; +MI0000355 dme-mir-274; +MI0000356 dme-mir-275; +MI0000357 dme-mir-92a; +MI0000358 dme-mir-219; +MI0000359 dme-mir-276a; +MI0000360 dme-mir-277; +MI0000361 dme-mir-278; +MI0000362 dme-mir-133; +MI0000363 dme-mir-279; +MI0000364 dme-mir-33; +MI0000365 dme-mir-280; +MI0000366 dme-mir-281-1; +MI0000367 dme-mir-282; +MI0000368 dme-mir-283; +MI0000369 dme-mir-284; +MI0000370 dme-mir-281-2; +MI0000371 dme-mir-34; +MI0000372 dme-mir-263a; +MI0000373 dme-mir-124; +MI0000374 dme-mir-79; +MI0000375 dme-mir-276b; +MI0000376 dme-mir-210; +MI0000377 dme-mir-285; +MI0000378 dme-mir-100; +MI0000379 dme-mir-92b; +MI0000380 dme-mir-286; +MI0000381 dme-mir-287; +MI0000382 dme-mir-87; +MI0000383 dme-mir-263b; +MI0000384 dme-mir-288; +MI0000385 dme-mir-289; +MI0000387 dme-bantam;bantam;dme-bantam; +MI0000388 mmu-mir-290;mmu-mir-290a; +MI0000389 mmu-mir-291;mmu-mir-291a; +MI0000390 mmu-mir-292;mmu-mir-292a; +MI0000391 mmu-mir-293; +MI0000392 mmu-mir-294; +MI0000393 mmu-mir-295; +MI0000394 mmu-mir-296; +MI0000395 mmu-mir-297-1;mmu-mir-297a-1; +MI0000396 mmu-mir-297-2; +MI0000397 mmu-mir-297-3;mmu-mir-297-2;mmu-mir-297a-2; +MI0000398 mmu-mir-298; +MI0000399 mmu-mir-299;mmu-mir-299a; +MI0000400 mmu-mir-300; +MI0000401 mmu-mir-301;mmu-mir-301a; +MI0000402 mmu-mir-302;mmu-mir-302a; +MI0000403 mmu-mir-34a;mmu-mir-34c; +MI0000404 mmu-mir-34b; +MI0000405 mmu-let-7d; +MI0000406 mmu-mir-106a; +MI0000407 mmu-mir-106b; +MI0000408 mmu-mir-130b; +MI0000409 dme-mir-303; +MI0000410 dme-mir-31b; +MI0000411 dme-mir-304; +MI0000412 dme-mir-305; +MI0000413 dme-mir-9c; +MI0000414 dme-mir-306; +MI0000415 dme-mir-9b; +MI0000416 dme-let-7L;dme-let-7; +MI0000417 dme-mir-125; +MI0000418 dme-mir-307;dme-mir-307a; +MI0000419 dme-mir-308; +MI0000420 dme-mir-31a; +MI0000421 dme-mir-309; +MI0000422 dme-mir-310; +MI0000423 dme-mir-311; +MI0000424 dme-mir-312; +MI0000425 dme-mir-313; +MI0000426 dme-mir-314; +MI0000427 dme-mir-315; +MI0000428 dme-mir-316; +MI0000429 dme-mir-317; +MI0000430 dme-mir-318; +MI0000431 dme-mir-2c; +MI0000432 dme-mir-iab-4; +MI0000433 hsa-let-7g; +MI0000434 hsa-let-7i; +MI0000435 hsa-mir-1b-1; +MI0000436 hsa-mir-1b-2; +MI0000437 hsa-mir-1d;hsa-mir-1-2; +MI0000438 hsa-mir-15b; +MI0000439 hsa-mir-23b; +MI0000440 hsa-mir-27b; +MI0000441 hsa-mir-30b; +MI0000442 hsa-mir-122a;hsa-mir-122; +MI0000443 hsa-mir-124a-1;hsa-mir-124-1; +MI0000444 hsa-mir-124a-2;hsa-mir-124-2; +MI0000445 hsa-mir-124a-3;hsa-mir-124-3; +MI0000446 hsa-mir-125b-1; +MI0000447 hsa-mir-128a;hsa-mir-128-1; +MI0000448 hsa-mir-130a; +MI0000449 hsa-mir-132; +MI0000450 hsa-mir-133a-1; +MI0000451 hsa-mir-133a-2; +MI0000452 hsa-mir-135-1;hsa-mir-135a-1; +MI0000453 hsa-mir-135-2;hsa-mir-135a-2; +MI0000454 hsa-mir-137; +MI0000455 hsa-mir-138-2; +MI0000456 hsa-mir-140; +MI0000457 hsa-mir-141; +MI0000458 hsa-mir-142; +MI0000459 hsa-mir-143; +MI0000460 hsa-mir-144; +MI0000461 hsa-mir-145; +MI0000462 hsa-mir-152; +MI0000463 hsa-mir-153-1; +MI0000464 hsa-mir-153-2; +MI0000465 hsa-mir-191; +MI0000466 hsa-mir-9-1; +MI0000467 hsa-mir-9-2; +MI0000468 hsa-mir-9-3; +MI0000469 hsa-mir-125a; +MI0000470 hsa-mir-125b-2; +MI0000471 hsa-mir-126; +MI0000472 hsa-mir-127; +MI0000473 hsa-mir-129b;hsa-mir-129-2; +MI0000474 hsa-mir-134; +MI0000475 hsa-mir-136; +MI0000476 hsa-mir-138-1; +MI0000477 hsa-mir-146;hsa-mir-146a; +MI0000478 hsa-mir-149; +MI0000479 hsa-mir-150; +MI0000480 hsa-mir-154; +MI0000481 hsa-mir-184; +MI0000482 hsa-mir-185; +MI0000483 hsa-mir-186; +MI0000484 hsa-mir-188; +MI0000485 hsa-mir-189; +MI0000486 hsa-mir-190;hsa-mir-190a; +MI0000487 hsa-mir-193;hsa-mir-193a; +MI0000488 hsa-mir-194;hsa-mir-194-1; +MI0000489 hsa-mir-195; +MI0000490 hsa-mir-206; +MI0000491 cbr-let-7; +MI0000492 cbr-lin-4; +MI0000493 cbr-mir-1; +MI0000494 cbr-mir-34; +MI0000495 cbr-mir-42; +MI0000496 cbr-mir-43; +MI0000497 cbr-mir-44; +MI0000498 cbr-mir-45-1; +MI0000499 cbr-mir-45-2; +MI0000500 cbr-mir-46; +MI0000501 cbr-mir-47; +MI0000502 cbr-mir-48; +MI0000503 cbr-mir-49; +MI0000504 cbr-mir-50; +MI0000505 cbr-mir-52; +MI0000506 cbr-mir-53; +MI0000507 cbr-mir-57; +MI0000508 cbr-mir-58;cbr-mir-58a; +MI0000509 cbr-mir-60; +MI0000510 cbr-mir-67; +MI0000511 cbr-mir-71; +MI0000512 cbr-mir-73;cbr-mir-73a; +MI0000513 cbr-mir-74;cbr-mir-74a; +MI0000514 cbr-mir-75; +MI0000515 cbr-mir-77;cbr-mir-77-1; +MI0000516 cbr-mir-77; +MI0000517 cbr-mir-79; +MI0000518 cbr-mir-80; +MI0000519 cbr-mir-81; +MI0000520 cbr-mir-82; +MI0000521 cbr-mir-85; +MI0000522 cbr-mir-86; +MI0000523 cbr-mir-87; +MI0000524 cbr-mir-90;cbr-mir-90a; +MI0000525 cbr-mir-124;cbr-mir-124a; +MI0000526 cbr-mir-228; +MI0000527 cbr-mir-230; +MI0000528 cbr-mir-232;cbr-mir-232-1; +MI0000529 cbr-mir-232; +MI0000530 cbr-mir-233; +MI0000531 cbr-mir-234; +MI0000532 cbr-mir-236; +MI0000533 cbr-mir-241; +MI0000534 cbr-mir-244; +MI0000535 cbr-mir-245; +MI0000536 cbr-mir-248; +MI0000537 cbr-mir-250; +MI0000538 cbr-mir-251; +MI0000539 cbr-mir-252; +MI0000540 cbr-mir-259; +MI0000541 cbr-mir-268; +MI0000542 hsa-mir-320;hsa-mir-320a; +MI0000543 hsa-mir-321; +MI0000544 ath-MIR319a; +MI0000545 ath-MIR319b; +MI0000546 mmu-mir-19b;mmu-mir-19b-2; +MI0000547 mmu-mir-30c-1; +MI0000548 mmu-mir-30c-2; +MI0000549 mmu-mir-30d; +MI0000550 mmu-mir-148;mmu-mir-148a; +MI0000551 mmu-mir-192; +MI0000552 mmu-mir-196-1;mmu-mir-196a-1; +MI0000553 mmu-mir-196-2;mmu-mir-196a-2; +MI0000554 mmu-mir-200a; +MI0000555 mmu-mir-208;mmu-mir-208a; +MI0000556 mmu-let-7a-1; +MI0000557 mmu-let-7a-2; +MI0000558 mmu-let-7b; +MI0000559 mmu-let-7c-1; +MI0000560 mmu-let-7c-2; +MI0000561 mmu-let-7e; +MI0000562 mmu-let-7f-1; +MI0000563 mmu-let-7f-2; +MI0000564 mmu-mir-15a; +MI0000565 mmu-mir-16-1; +MI0000566 mmu-mir-16-2; +MI0000567 mmu-mir-18;mmu-mir-18a; +MI0000568 mmu-mir-20;mmu-mir-20a; +MI0000569 mmu-mir-21;mmu-mir-21a; +MI0000570 mmu-mir-22; +MI0000571 mmu-mir-23a; +MI0000572 mmu-mir-24-2; +MI0000573 mmu-mir-26a-1; +MI0000574 mmu-mir-26a-2; +MI0000575 mmu-mir-26b; +MI0000576 mmu-mir-29a; +MI0000577 mmu-mir-29c; +MI0000578 mmu-mir-27a; +MI0000579 mmu-mir-31; +MI0000580 mmu-mir-92;mmu-mir-92-2;mmu-mir-92a-2; +MI0000581 mmu-mir-93; +MI0000583 mmu-mir-96; +MI0000584 mmu-mir-172;mmu-mir-34c;mmu-mir-34a; +MI0000585 mmu-mir-129-2; +MI0000586 mmu-mir-98; +MI0000587 mmu-mir-103-1; +MI0000588 mmu-mir-103-2; +MI0000589 rno-mir-322;rno-mir-322-1; +MI0000590 mmu-mir-322; +MI0000591 rno-mir-323; +MI0000592 mmu-mir-323; +MI0000593 rno-mir-301;rno-mir-301a; +MI0000594 rno-mir-324; +MI0000595 mmu-mir-324; +MI0000596 rno-mir-325; +MI0000597 mmu-mir-325; +MI0000598 mmu-mir-326; +MI0000599 rno-mir-326; +MI0000600 rno-mir-327; +MI0000601 rno-let-7d; +MI0000602 rno-mir-328;rno-mir-328a; +MI0000603 mmu-mir-328; +MI0000604 rno-mir-329; +MI0000605 mmu-mir-329; +MI0000606 rno-mir-330; +MI0000607 mmu-mir-330; +MI0000608 rno-mir-331; +MI0000609 mmu-mir-331; +MI0000610 rno-mir-333; +MI0000611 rno-mir-140; +MI0000612 rno-mir-335; +MI0000613 rno-mir-336; +MI0000614 rno-mir-337; +MI0000615 mmu-mir-337; +MI0000616 rno-mir-148b; +MI0000617 mmu-mir-148b; +MI0000618 rno-mir-338; +MI0000619 mmu-mir-338; +MI0000620 rno-mir-339; +MI0000621 mmu-mir-339; +MI0000622 rno-mir-340;rno-mir-340-1; +MI0000623 mmu-mir-340; +MI0000624 rno-mir-341; +MI0000625 mmu-mir-341; +MI0000626 rno-mir-342; +MI0000627 mmu-mir-342; +MI0000628 rno-mir-343; +MI0000629 rno-mir-344;rno-mir-344-1;rno-mir-344a-1; +MI0000630 mmu-mir-344;mmu-mir-344-1; +MI0000631 rno-mir-345; +MI0000632 mmu-mir-345; +MI0000633 rno-mir-346; +MI0000634 mmu-mir-346; +MI0000635 rno-mir-347; +MI0000636 rno-mir-349; +MI0000637 rno-mir-129;rno-mir-129-2; +MI0000638 rno-mir-20;rno-mir-20a; +MI0000639 rno-mir-350;rno-mir-350-1; +MI0000640 mmu-mir-350; +MI0000641 rno-mir-7;rno-mir-7-1;rno-mir-7a-1; +MI0000642 rno-mir-351;rno-mir-351-1; +MI0000643 mmu-mir-351; +MI0000644 rno-mir-352; +MI0000645 rno-mir-135b; +MI0000646 mmu-mir-135b; +MI0000647 rno-mir-151; +MI0000648 rno-mir-101b; +MI0000649 mmu-mir-101b; +MI0000650 hsa-mir-200c; +MI0000651 hsa-mir-1b;hsa-mir-1-1; +MI0000652 mmu-mir-1b;mmu-mir-1-2;mmu-mir-1a-2; +MI0000653 osa-MIR156a; +MI0000654 osa-MIR156b; +MI0000655 osa-MIR156c; +MI0000656 osa-MIR156d; +MI0000657 osa-MIR156e; +MI0000658 osa-MIR156f; +MI0000659 osa-MIR156g; +MI0000660 osa-MIR156h; +MI0000661 osa-MIR156i; +MI0000662 osa-MIR156j; +MI0000663 osa-MIR160a; +MI0000664 osa-MIR160b; +MI0000665 osa-MIR160c; +MI0000666 osa-MIR160d; +MI0000667 osa-MIR162;osa-MIR162a; +MI0000668 osa-MIR164a; +MI0000669 osa-MIR164b; +MI0000670 osa-MIR166a; +MI0000671 osa-MIR166b; +MI0000672 osa-MIR166c; +MI0000673 osa-MIR166d; +MI0000674 osa-MIR166e; +MI0000675 osa-MIR166f; +MI0000676 osa-MIR167a; +MI0000677 osa-MIR167b; +MI0000678 osa-MIR167c; +MI0000679 osa-MIR169;osa-MIR169a; +MI0000680 osa-MIR171;osa-MIR171a; +MI0000681 hsa-mir-155; +MI0000683 hsa-mir-181b-2; +MI0000684 mmu-mir-107; +MI0000685 mmu-mir-10a-1;mmu-mir-10a; +MI0000686 mmu-mir-10a-2; +MI0000687 mmu-mir-17; +MI0000688 mmu-mir-19a; +MI0000689 mmu-mir-25; +MI0000690 mmu-mir-28;mmu-mir-28a; +MI0000691 mmu-mir-32; +MI0000692 mmu-mir-100; +MI0000693 mmu-mir-139; +MI0000694 mmu-mir-200c; +MI0000695 mmu-mir-210; +MI0000696 mmu-mir-212; +MI0000697 mmu-mir-213;mmu-mir-181a-1; +MI0000698 mmu-mir-214; +MI0000699 mmu-mir-216;mmu-mir-216a; +MI0000700 mmu-mir-218-1; +MI0000701 mmu-mir-218-2; +MI0000702 mmu-mir-219-1;mmu-mir-219a-1; +MI0000703 mmu-mir-223; +MI0000704 mmu-mir-320; +MI0000705 mmu-mir-321; +MI0000706 mmu-mir-26a-2; +MI0000707 mmu-mir-33; +MI0000708 mmu-mir-211; +MI0000709 mmu-mir-221; +MI0000710 mmu-mir-222; +MI0000711 mmu-mir-224; +MI0000712 mmu-mir-29b-2; +MI0000713 mmu-mir-199a-2; +MI0000714 mmu-mir-199b; +MI0000715 mmu-mir-135-2;mmu-mir-135a-2; +MI0000716 mmu-mir-124a-1;mmu-mir-124-1; +MI0000717 mmu-mir-124a-2;mmu-mir-124-2; +MI0000718 mmu-mir-19b-1; +MI0000719 mmu-mir-92-1;mmu-mir-92a-1; +MI0000720 mmu-mir-9-1; +MI0000721 mmu-mir-9-3; +MI0000722 mmu-mir-138-1; +MI0000723 mmu-mir-181b;mmu-mir-181b-1; +MI0000724 mmu-mir-181c; +MI0000725 mmu-mir-125b-1; +MI0000726 mmu-mir-128b;mmu-mir-128-2; +MI0000727 hsa-mir-128b;hsa-mir-128-2; +MI0000728 mmu-mir-7-1;mmu-mir-7a-1; +MI0000729 mmu-mir-7-2;mmu-mir-7a-2; +MI0000730 mmu-mir-7b; +MI0000731 mmu-mir-217; +MI0000732 hsa-mir-194-2; +MI0000733 mmu-mir-194-2; +MI0000734 hsa-mir-106b; +MI0000735 hsa-mir-29c; +MI0000736 hsa-mir-30c-1; +MI0000737 hsa-mir-200a; +MI0000738 hsa-mir-302;hsa-mir-302a; +MI0000739 hsa-mir-101-2; +MI0000740 hsa-mir-219-2;hsa-mir-219a-2; +MI0000741 mmu-mir-219-2;mmu-mir-219a-2; +MI0000742 hsa-mir-34b; +MI0000743 hsa-mir-34c; +MI0000744 hsa-mir-299; +MI0000745 hsa-mir-301;hsa-mir-301a; +MI0000746 hsa-mir-99b; +MI0000747 hsa-mir-296; +MI0000748 hsa-mir-130b; +MI0000749 hsa-mir-30e; +MI0000750 hsa-mir-26a-2; +MI0000751 cbr-mir-72; +MI0000752 cel-mir-353; +MI0000753 cel-mir-354; +MI0000754 cel-mir-355; +MI0000755 cel-mir-356;cel-mir-356a; +MI0000756 cel-mir-357; +MI0000757 cel-mir-358; +MI0000758 cel-mir-359; +MI0000759 cel-mir-360; +MI0000760 hsa-mir-361; +MI0000761 mmu-mir-361; +MI0000762 hsa-mir-362; +MI0000763 mmu-mir-362; +MI0000764 hsa-mir-363; +MI0000765 mmu-mir-363; +MI0000767 hsa-mir-365-1;hsa-mir-365a; +MI0000768 mmu-mir-365-1; +MI0000769 hsa-mir-365-2;hsa-mir-365b; +MI0000772 hsa-mir-302b; +MI0000773 hsa-mir-302c; +MI0000774 hsa-mir-302d; +MI0000775 hsa-mir-367; +MI0000776 hsa-mir-368;hsa-mir-376c; +MI0000777 hsa-mir-369; +MI0000778 hsa-mir-370; +MI0000779 hsa-mir-371;hsa-mir-371a; +MI0000780 hsa-mir-372; +MI0000781 hsa-mir-373; +MI0000782 hsa-mir-374;hsa-mir-374a; +MI0000783 hsa-mir-375; +MI0000784 hsa-mir-376a;hsa-mir-376a-1; +MI0000785 hsa-mir-377; +MI0000786 hsa-mir-378;hsa-mir-378a; +MI0000787 hsa-mir-379; +MI0000788 hsa-mir-380; +MI0000789 hsa-mir-381; +MI0000790 hsa-mir-382; +MI0000791 hsa-mir-383; +MI0000792 mmu-mir-375; +MI0000793 mmu-mir-376a; +MI0000794 mmu-mir-377; +MI0000795 mmu-mir-378;mmu-mir-378a; +MI0000796 mmu-mir-379; +MI0000797 mmu-mir-380; +MI0000798 mmu-mir-381; +MI0000799 mmu-mir-382; +MI0000800 mmu-mir-383; +MI0000801 cel-lsy-6; +MI0000802 hsa-mir-340; +MI0000803 hsa-mir-330; +MI0000804 hsa-mir-328; +MI0000805 hsa-mir-342; +MI0000806 hsa-mir-337; +MI0000807 hsa-mir-323;hsa-mir-323a; +MI0000808 hsa-mir-326; +MI0000809 hsa-mir-151;hsa-mir-151a; +MI0000810 hsa-mir-135b; +MI0000811 hsa-mir-148b; +MI0000812 hsa-mir-331; +MI0000813 hsa-mir-324; +MI0000814 hsa-mir-338; +MI0000815 hsa-mir-339; +MI0000816 hsa-mir-335; +MI0000817 mmu-mir-335; +MI0000818 cbr-lsy-6; +MI0000819 cel-mir-392; +MI0000820 mmu-mir-133a-2; +MI0000821 mmu-mir-133b; +MI0000822 hsa-mir-133b; +MI0000823 mmu-mir-181b-2; +MI0000824 hsa-mir-325; +MI0000825 hsa-mir-345; +MI0000826 hsa-mir-346; +MI0000827 rno-let-7a-1; +MI0000828 rno-let-7a-2; +MI0000829 rno-let-7b; +MI0000830 rno-let-7c-1; +MI0000831 rno-let-7c-2; +MI0000832 rno-let-7e; +MI0000833 rno-let-7f-1; +MI0000834 rno-let-7f-2; +MI0000835 rno-let-7i; +MI0000836 rno-mir-7-2;rno-mir-7a-2; +MI0000837 rno-mir-7b; +MI0000838 rno-mir-9-1;rno-mir-9a-1; +MI0000839 rno-mir-9-3;rno-mir-9a-3; +MI0000840 rno-mir-9-2;rno-mir-9a-2; +MI0000841 rno-mir-10a; +MI0000842 rno-mir-10b; +MI0000843 rno-mir-15b; +MI0000844 rno-mir-16; +MI0000845 rno-mir-17;rno-mir-17-1; +MI0000846 rno-mir-18;rno-mir-18a; +MI0000847 rno-mir-19b-1; +MI0000848 rno-mir-19b-2; +MI0000849 rno-mir-19a; +MI0000850 rno-mir-21; +MI0000851 rno-mir-22; +MI0000852 rno-mir-23a; +MI0000853 rno-mir-23b; +MI0000854 rno-mir-24-1; +MI0000855 rno-mir-24-2; +MI0000856 rno-mir-25; +MI0000857 rno-mir-26a; +MI0000858 rno-mir-26b; +MI0000859 rno-mir-27b; +MI0000860 rno-mir-27a; +MI0000861 rno-mir-28; +MI0000862 rno-mir-29b-2; +MI0000863 rno-mir-29a; +MI0000864 rno-mir-29b-1; +MI0000865 rno-mir-29c;rno-mir-29c-1; +MI0000866 rno-mir-30c-1; +MI0000867 rno-mir-30e; +MI0000868 rno-mir-30b; +MI0000869 rno-mir-30d; +MI0000870 rno-mir-30a; +MI0000871 rno-mir-30c-2; +MI0000872 rno-mir-31;rno-mir-31a; +MI0000873 rno-mir-32; +MI0000874 rno-mir-33; +MI0000875 rno-mir-34b; +MI0000876 rno-mir-34c; +MI0000877 rno-mir-34a; +MI0000878 rno-mir-92-1;rno-mir-92a-1; +MI0000879 rno-mir-92-2;rno-mir-92a-2; +MI0000880 rno-mir-93; +MI0000881 rno-mir-96; +MI0000882 rno-mir-98; +MI0000883 rno-mir-99a; +MI0000884 rno-mir-99b; +MI0000885 rno-mir-100; +MI0000886 rno-mir-101;rno-mir-101a; +MI0000887 rno-mir-103-2; +MI0000888 rno-mir-103-1; +MI0000889 rno-mir-106b; +MI0000890 rno-mir-107; +MI0000891 rno-mir-122a;rno-mir-122; +MI0000892 rno-mir-124a-3;rno-mir-124-3; +MI0000893 rno-mir-124a-1;rno-mir-124-1; +MI0000894 rno-mir-124a-2;rno-mir-124-2; +MI0000895 rno-mir-125a; +MI0000896 rno-mir-125b-1; +MI0000897 rno-mir-125b-2; +MI0000898 rno-mir-126;rno-mir-126a; +MI0000899 rno-mir-127; +MI0000900 rno-mir-128a;rno-mir-128-1; +MI0000901 rno-mir-128b;rno-mir-128-2; +MI0000902 rno-mir-129-1; +MI0000903 rno-mir-130a; +MI0000904 rno-mir-130b; +MI0000905 rno-mir-132; +MI0000906 rno-mir-133a; +MI0000907 rno-mir-134; +MI0000908 rno-mir-135a; +MI0000909 rno-mir-136; +MI0000910 rno-mir-137; +MI0000911 rno-mir-138-2; +MI0000912 rno-mir-138-1; +MI0000913 rno-mir-139; +MI0000914 rno-mir-141; +MI0000915 rno-mir-142; +MI0000916 rno-mir-143; +MI0000917 rno-mir-144; +MI0000918 rno-mir-145; +MI0000919 rno-mir-146;rno-mir-146a; +MI0000920 rno-mir-150; +MI0000921 rno-mir-152; +MI0000922 rno-mir-153; +MI0000923 rno-mir-154; +MI0000924 rno-mir-181c; +MI0000925 rno-mir-181a;rno-mir-181a-2; +MI0000926 rno-mir-181b-1; +MI0000927 rno-mir-181b-2; +MI0000928 rno-mir-183; +MI0000929 rno-mir-184; +MI0000930 rno-mir-185; +MI0000931 rno-mir-186; +MI0000932 rno-mir-187; +MI0000933 rno-mir-190;rno-mir-190a;rno-mir-190a-1; +MI0000934 rno-mir-191;rno-mir-191a; +MI0000935 rno-mir-192; +MI0000936 rno-mir-193;rno-mir-193a; +MI0000937 rno-mir-194-1; +MI0000938 rno-mir-194-2; +MI0000939 rno-mir-195; +MI0000940 rno-mir-196;rno-mir-196a; +MI0000941 rno-mir-199a; +MI0000942 rno-mir-200c; +MI0000943 rno-mir-200a; +MI0000944 rno-mir-200b; +MI0000945 rno-mir-203;rno-mir-203a; +MI0000946 rno-mir-204; +MI0000947 rno-mir-205; +MI0000948 rno-mir-206; +MI0000949 rno-mir-208;rno-mir-208a; +MI0000950 rno-mir-210; +MI0000951 rno-mir-211; +MI0000952 rno-mir-212; +MI0000953 rno-mir-213;rno-mir-181a-1; +MI0000954 rno-mir-214; +MI0000955 rno-mir-216;rno-mir-216a; +MI0000956 rno-mir-217; +MI0000957 rno-mir-218-2;rno-mir-218a-2; +MI0000958 rno-mir-218-1;rno-mir-218a-1; +MI0000959 rno-mir-219-1;rno-mir-219a-1; +MI0000960 rno-mir-219-2;rno-mir-219a-2; +MI0000961 rno-mir-221; +MI0000962 rno-mir-222; +MI0000963 rno-mir-223; +MI0000964 rno-mir-290; +MI0000965 rno-mir-291;rno-mir-291a; +MI0000966 rno-mir-292; +MI0000967 rno-mir-296; +MI0000968 rno-mir-297; +MI0000969 rno-mir-298; +MI0000970 rno-mir-299;rno-mir-299a; +MI0000971 rno-mir-300; +MI0000972 rno-mir-320; +MI0000973 rno-mir-321; +MI0000974 mmu-mir-215; +MI0000975 ath-MIR167d; +MI0000976 ath-MIR169b; +MI0000977 ath-MIR169c; +MI0000978 ath-MIR169d; +MI0000979 ath-MIR169e; +MI0000980 ath-MIR169f; +MI0000981 ath-MIR169g; +MI0000982 ath-MIR169h; +MI0000983 ath-MIR169i; +MI0000984 ath-MIR169j; +MI0000985 ath-MIR169k; +MI0000986 ath-MIR169l; +MI0000987 ath-MIR169m; +MI0000988 ath-MIR169n; +MI0000989 ath-MIR171b; +MI0000990 ath-MIR171c; +MI0000991 ath-MIR172c; +MI0000992 ath-MIR172d; +MI0001000 ath-MIR390a; +MI0001001 ath-MIR390b; +MI0001002 ath-MIR391; +MI0001003 ath-MIR393a; +MI0001004 ath-MIR393b; +MI0001005 ath-MIR394a; +MI0001006 ath-MIR394b; +MI0001007 ath-MIR395a; +MI0001008 ath-MIR395b; +MI0001009 ath-MIR395c; +MI0001010 ath-MIR395d; +MI0001011 ath-MIR395e; +MI0001012 ath-MIR395f; +MI0001013 ath-MIR396a; +MI0001014 ath-MIR396b; +MI0001015 ath-MIR397a; +MI0001016 ath-MIR397b; +MI0001017 ath-MIR398a; +MI0001018 ath-MIR398b; +MI0001019 ath-MIR398c; +MI0001020 ath-MIR399a; +MI0001021 ath-MIR399b; +MI0001022 ath-MIR399c; +MI0001023 ath-MIR399d; +MI0001024 ath-MIR399e; +MI0001025 ath-MIR399f; +MI0001026 osa-MIR393;osa-MIR393a; +MI0001027 osa-MIR394; +MI0001028 osa-MIR395b; +MI0001029 osa-MIR395d; +MI0001030 osa-MIR395e; +MI0001031 osa-MIR395g; +MI0001032 osa-MIR395h; +MI0001033 osa-MIR395i; +MI0001034 osa-MIR395j; +MI0001035 osa-MIR395k; +MI0001036 osa-MIR395l; +MI0001037 osa-MIR395m;osa-MIR395s; +MI0001038 osa-MIR395n;osa-MIR395t; +MI0001039 osa-MIR395o; +MI0001040 osa-MIR395r; +MI0001041 osa-MIR395q;osa-MIR395c; +MI0001042 osa-MIR395c;osa-MIR395a; +MI0001043 osa-MIR395a;osa-MIR395f; +MI0001044 osa-MIR395f;osa-MIR395u; +MI0001045 osa-MIR395p; +MI0001046 osa-MIR396a; +MI0001047 osa-MIR396b; +MI0001048 osa-MIR396c; +MI0001049 osa-MIR397a; +MI0001050 osa-MIR397b; +MI0001051 osa-MIR398a; +MI0001052 osa-MIR398b; +MI0001053 osa-MIR399a; +MI0001054 osa-MIR399b; +MI0001055 osa-MIR399c; +MI0001056 osa-MIR399d; +MI0001057 osa-MIR399e; +MI0001058 osa-MIR399f; +MI0001059 osa-MIR399g; +MI0001060 osa-MIR399h; +MI0001061 osa-MIR399i; +MI0001062 osa-MIR399j; +MI0001063 osa-MIR399k; +MI0001064 ebv-mir-BHRF1-1; +MI0001065 ebv-mir-BHRF1-2; +MI0001066 ebv-mir-BHRF1-3; +MI0001067 ebv-mir-BART1; +MI0001068 ebv-mir-BART2; +MI0001069 ath-MIR400; +MI0001070 ath-MIR401; +MI0001071 ath-MIR402; +MI0001072 ath-MIR403; +MI0001073 ath-MIR404; +MI0001074 ath-MIR405a; +MI0001075 ath-MIR405b; +MI0001077 ath-MIR405d; +MI0001078 ath-MIR406; +MI0001079 ath-MIR407; +MI0001080 ath-MIR408; +MI0001082 ath-MIR156g; +MI0001083 ath-MIR156h; +MI0001084 ath-MIR158b; +MI0001085 ath-MIR159c; +MI0001086 ath-MIR319c; +MI0001087 ath-MIR164c; +MI0001088 ath-MIR167c; +MI0001089 ath-MIR172e; +MI0001090 osa-MIR156k; +MI0001091 osa-MIR156l; +MI0001092 osa-MIR159a; +MI0001093 osa-MIR159b; +MI0001094 osa-MIR159c; +MI0001095 osa-MIR159d; +MI0001096 osa-MIR159e; +MI0001097 osa-MIR159f; +MI0001098 osa-MIR319a; +MI0001099 osa-MIR319b; +MI0001100 osa-MIR160e; +MI0001101 osa-MIR160f; +MI0001102 osa-MIR162b; +MI0001103 osa-MIR164c; +MI0001104 osa-MIR164d; +MI0001105 osa-MIR164e; +MI0001106 osa-MIR166j; +MI0001107 osa-MIR166k; +MI0001108 osa-MIR166l; +MI0001109 osa-MIR167d; +MI0001110 osa-MIR167e; +MI0001111 osa-MIR167f; +MI0001112 osa-MIR167g; +MI0001113 osa-MIR167h; +MI0001114 osa-MIR167i; +MI0001115 osa-MIR168a; +MI0001116 osa-MIR168b; +MI0001117 osa-MIR169b; +MI0001118 osa-MIR169c; +MI0001119 osa-MIR169d; +MI0001120 osa-MIR169e; +MI0001121 osa-MIR169f; +MI0001122 osa-MIR169g; +MI0001123 osa-MIR169h; +MI0001124 osa-MIR169i; +MI0001125 osa-MIR169j; +MI0001126 osa-MIR169k; +MI0001127 osa-MIR169l; +MI0001128 osa-MIR169m; +MI0001129 osa-MIR169n; +MI0001130 osa-MIR169o; +MI0001131 osa-MIR169p; +MI0001132 osa-MIR169q; +MI0001133 osa-MIR171b; +MI0001134 osa-MIR171c; +MI0001135 osa-MIR171d; +MI0001136 osa-MIR171e; +MI0001137 osa-MIR171f; +MI0001138 osa-MIR171g; +MI0001139 osa-MIR172a; +MI0001140 osa-MIR172b; +MI0001141 osa-MIR172c; +MI0001142 osa-MIR166g; +MI0001143 osa-MIR166h; +MI0001144 osa-MIR166i; +MI0001145 hsa-mir-384; +MI0001146 mmu-mir-384; +MI0001147 osa-MIR171h; +MI0001148 osa-MIR393b; +MI0001149 osa-MIR408; +MI0001150 hsa-mir-196b; +MI0001151 mmu-mir-196b; +MI0001152 rno-mir-196b;rno-mir-196b-1; +MI0001153 osa-MIR395s; +MI0001154 osa-MIR172d; +MI0001155 osa-MIR171i; +MI0001156 osa-MIR167j; +MI0001157 osa-MIR166m; +MI0001158 osa-MIR166n;osa-MIR166j; +MI0001159 osa-MIR164f; +MI0001160 mmu-mir-409; +MI0001161 mmu-mir-410; +MI0001162 mmu-mir-376b; +MI0001163 mmu-mir-411; +MI0001164 mmu-mir-412; +MI0001165 mmu-mir-370; +MI0001166 gga-mir-29a; +MI0001167 gga-mir-29b-1; +MI0001168 gga-let-7i; +MI0001169 gga-mir-135a-2; +MI0001170 gga-mir-33;gga-mir-33-1;gga-mir-33;gga-mir-33-1; +MI0001171 gga-let-7a-3; +MI0001172 gga-let-7b; +MI0001173 gga-mir-99a; +MI0001174 gga-let-7c; +MI0001175 gga-mir-125b;gga-mir-125b-2; +MI0001176 gga-mir-155; +MI0001177 gga-mir-222a;gga-mir-222;gga-mir-222-1;gga-mir-222a; +MI0001178 gga-mir-221; +MI0001179 gga-mir-92;gga-mir-92-1; +MI0001180 gga-mir-19b; +MI0001181 gga-mir-20;gga-mir-20a; +MI0001182 gga-mir-19a; +MI0001183 gga-mir-18a; +MI0001184 gga-mir-17; +MI0001185 gga-mir-16-1; +MI0001186 gga-mir-15a; +MI0001187 gga-mir-26a; +MI0001188 gga-mir-153; +MI0001189 gga-mir-148a; +MI0001190 gga-mir-196-2; +MI0001191 gga-mir-138-1; +MI0001192 gga-mir-128b;gga-mir-128-2; +MI0001193 gga-mir-187; +MI0001194 gga-mir-32; +MI0001195 gga-mir-133a-1; +MI0001196 gga-mir-1-2;gga-mir-1a-2; +MI0001197 gga-mir-124a; +MI0001198 gga-mir-30d; +MI0001199 gga-mir-30b; +MI0001200 gga-mir-216;gga-mir-216a; +MI0001201 gga-mir-217; +MI0001202 gga-mir-194; +MI0001203 gga-mir-215; +MI0001204 gga-mir-30a; +MI0001205 gga-mir-30c-2; +MI0001206 gga-mir-133b; +MI0001207 gga-mir-206; +MI0001208 gga-mir-223; +MI0001209 gga-mir-18b; +MI0001210 gga-mir-106; +MI0001211 gga-mir-302;gga-mir-302a; +MI0001212 gga-mir-218-1; +MI0001213 gga-mir-103-2; +MI0001214 gga-mir-203;gga-mir-203a; +MI0001215 gga-mir-107; +MI0001216 gga-mir-10b; +MI0001217 gga-mir-128a;gga-mir-128-1; +MI0001218 gga-mir-213;gga-mir-181a-1; +MI0001219 gga-mir-181b-1; +MI0001220 gga-mir-199a-1;gga-mir-199a-2;gga-mir-199-2; +MI0001221 gga-mir-137; +MI0001222 gga-mir-16-2; +MI0001223 gga-mir-15b; +MI0001224 gga-mir-190;gga-mir-190a; +MI0001225 gga-mir-204-2; +MI0001226 gga-mir-7-2; +MI0001227 gga-mir-184; +MI0001228 gga-mir-138-2; +MI0001229 gga-mir-140; +MI0001230 gga-let-7g; +MI0001231 gga-mir-135a-1; +MI0001232 gga-let-7d; +MI0001233 gga-let-7f; +MI0001234 gga-let-7a-1; +MI0001235 gga-mir-146;gga-mir-146a; +MI0001236 gga-mir-103-1; +MI0001237 gga-mir-218-2; +MI0001238 gga-mir-205b; +MI0001239 gga-mir-130b; +MI0001240 gga-mir-301;gga-mir-301a; +MI0001241 gga-mir-130a; +MI0001242 gga-mir-181b-2; +MI0001243 gga-mir-181a;gga-mir-181a-2; +MI0001244 gga-mir-126; +MI0001245 gga-mir-199a-2;gga-mir-199a-1;gga-mir-199-1; +MI0001246 gga-mir-219;gga-mir-219a; +MI0001247 gga-mir-1-1;gga-mir-1a-1; +MI0001248 gga-mir-133a-2; +MI0001249 gga-mir-200a; +MI0001250 gga-mir-200b; +MI0001251 gga-mir-34a; +MI0001252 gga-mir-124b-1;gga-mir-124b; +MI0001253 gga-mir-124b-2; +MI0001254 gga-mir-1b; +MI0001255 gga-mir-133a-3;gga-mir-133c; +MI0001256 gga-mir-30e; +MI0001257 gga-mir-30c-1; +MI0001258 gga-mir-100; +MI0001259 gga-let-7a-2; +MI0001260 gga-mir-34b; +MI0001261 gga-mir-34c; +MI0001262 gga-let-7j; +MI0001263 gga-let-7k; +MI0001264 gga-mir-135a-3; +MI0001265 gga-mir-29c; +MI0001266 gga-mir-29b-2; +MI0001267 gga-mir-205a; +MI0001268 gga-mir-196-1; +MI0001269 gga-mir-7-3; +MI0001270 gga-mir-101;gga-mir-101-1; +MI0001271 gga-mir-204-1; +MI0001272 gga-mir-7-1; +MI0001273 gga-mir-23b; +MI0001274 gga-mir-27b; +MI0001275 gga-mir-24; +MI0001276 gga-mir-31; +MI0001277 gga-mir-122a-1;gga-mir-122-1; +MI0001278 gga-mir-183; +MI0001279 gga-mir-7b-1;gga-mir-7b; +MI0001280 gga-mir-122a-2;gga-mir-122-2; +MI0001281 gga-mir-142; +MI0001282 gga-mir-196-3; +MI0001283 gga-mir-9;gga-mir-9-2; +MI0001284 gga-mir-218-3; +MI0001285 gga-mir-222b; +MI0001286 gga-mir-7b-2; +MI0001287 dps-bantam; +MI0001288 dps-let-7; +MI0001289 dps-mir-1; +MI0001290 dps-mir-2a-1; +MI0001291 dps-mir-2a-2; +MI0001292 dps-mir-2b-1; +MI0001293 dps-mir-2b-2; +MI0001294 dps-mir-2c; +MI0001295 dps-mir-3; +MI0001296 dps-mir-4; +MI0001297 dps-mir-iab-4; +MI0001298 dps-mir-5; +MI0001299 dps-mir-6-1; +MI0001300 dps-mir-6-3; +MI0001301 dps-mir-6-2; +MI0001302 dps-mir-7; +MI0001303 dps-mir-8; +MI0001304 dps-mir-9a; +MI0001305 dps-mir-9b; +MI0001306 dps-mir-9c; +MI0001307 dps-mir-10; +MI0001308 dps-mir-11; +MI0001309 dps-mir-12; +MI0001310 dps-mir-13a; +MI0001311 dps-mir-13b-1; +MI0001312 dps-mir-13b-2; +MI0001313 dps-mir-14; +MI0001314 dps-mir-31a; +MI0001315 dps-mir-31b; +MI0001316 dps-mir-33; +MI0001317 dps-mir-34; +MI0001318 dps-mir-79; +MI0001319 dps-mir-87; +MI0001320 dps-mir-92a; +MI0001321 dps-mir-92b; +MI0001322 dps-mir-100; +MI0001323 dps-mir-124; +MI0001324 dps-mir-125; +MI0001325 dps-mir-133; +MI0001326 dps-mir-184; +MI0001327 dps-mir-210;dps-mir-210a; +MI0001328 dps-mir-219; +MI0001329 dps-mir-263a; +MI0001330 dps-mir-263b; +MI0001331 dps-mir-274; +MI0001332 dps-mir-275; +MI0001333 dps-mir-276a; +MI0001334 dps-mir-276b; +MI0001335 dps-mir-277; +MI0001336 dps-mir-278; +MI0001337 dps-mir-279; +MI0001338 dps-mir-280; +MI0001339 dps-mir-281-1; +MI0001340 dps-mir-281-2; +MI0001341 dps-mir-282; +MI0001342 dps-mir-283; +MI0001343 dps-mir-284; +MI0001344 dps-mir-285; +MI0001345 dps-mir-286; +MI0001346 dps-mir-287; +MI0001347 dps-mir-288; +MI0001348 dps-mir-289; +MI0001349 dps-mir-304; +MI0001350 dps-mir-305; +MI0001351 dps-mir-306; +MI0001352 dps-mir-307;dps-mir-307a; +MI0001353 dps-mir-308; +MI0001354 dps-mir-309; +MI0001355 dps-mir-314; +MI0001356 dps-mir-315; +MI0001357 dps-mir-316; +MI0001358 dps-mir-317; +MI0001359 dps-mir-318; +MI0001360 dre-mir-7b; +MI0001361 dre-mir-7-1;dre-mir-7a-1; +MI0001362 dre-mir-7-2;dre-mir-7a-2; +MI0001363 dre-mir-10a; +MI0001364 dre-mir-10b;dre-mir-10b-1; +MI0001365 dre-mir-34a;dre-mir-34;dre-mir-34a; +MI0001366 dre-mir-181b-1; +MI0001367 dre-mir-181b-2; +MI0001368 dre-mir-182; +MI0001369 dre-mir-183; +MI0001370 dre-mir-187;dre-mir-187-1;dre-mir-187; +MI0001371 dre-mir-192; +MI0001372 dre-mir-196a;dre-mir-196a-1; +MI0001373 dre-mir-199a-1;dre-mir-199-1; +MI0001374 dre-mir-199a-2;dre-mir-199-2; +MI0001375 dre-mir-199a-3;dre-mir-199-3; +MI0001376 dre-mir-203;dre-mir-203a; +MI0001377 dre-mir-204;dre-mir-204-1; +MI0001378 dre-mir-205;dre-mir-205-1;dre-mir-205; +MI0001379 dre-mir-210; +MI0001380 dre-mir-213;dre-mir-181a-1; +MI0001381 dre-mir-214; +MI0001382 dre-mir-216;dre-mir-216a-1;dre-mir-216a; +MI0001383 dre-mir-217;dre-mir-217-1;dre-mir-217; +MI0001384 dre-mir-219-1; +MI0001385 dre-mir-219-2; +MI0001386 dre-mir-220; +MI0001387 dre-mir-221; +MI0001388 dre-mir-222;dre-mir-222a; +MI0001389 dre-mir-223;dre-mir-223-1;dre-mir-223; +MI0001390 cbr-mir-353; +MI0001392 cbr-mir-64;cbr-mir-64a; +MI0001394 cbr-mir-231; +MI0001395 cbr-mir-356; +MI0001396 cbr-mir-83; +MI0001397 cbr-mir-246; +MI0001398 cbr-mir-51; +MI0001400 cbr-mir-357;cbr-mir-357-1; +MI0001401 cbr-mir-253; +MI0001402 cbr-mir-70; +MI0001403 cbr-mir-358; +MI0001404 cbr-mir-61; +MI0001405 cbr-mir-360; +MI0001406 cbr-mir-239a; +MI0001407 cbr-mir-249; +MI0001408 cbr-mir-240; +MI0001409 cbr-mir-254; +MI0001410 cbr-mir-239b; +MI0001411 cbr-mir-62; +MI0001412 cbr-mir-55; +MI0001413 cbr-mir-84; +MI0001414 cbr-mir-354; +MI0001415 cbr-mir-35;cbr-mir-35a; +MI0001416 cbr-mir-36; +MI0001418 cbr-mir-38; +MI0001419 cbr-mir-39; +MI0001420 cbr-mir-40; +MI0001421 cbr-mir-41;cbr-mir-41a; +MI0001422 cbr-mir-355; +MI0001423 rno-mir-421; +MI0001424 ath-MIR413; +MI0001425 ath-MIR414; +MI0001426 ath-MIR415; +MI0001427 ath-MIR416; +MI0001428 ath-MIR417; +MI0001429 ath-MIR418; +MI0001430 ath-MIR419; +MI0001431 ath-MIR420; +MI0001432 hsa-mir-108; +MI0001433 osa-MIR413; +MI0001434 osa-MIR414; +MI0001435 osa-MIR415; +MI0001436 osa-MIR416; +MI0001437 osa-MIR417; +MI0001438 osa-MIR418; +MI0001439 osa-MIR419; +MI0001440 osa-MIR420; +MI0001441 ath-MIR426; +MI0001442 osa-MIR426; +MI0001444 hsa-mir-422a; +MI0001445 hsa-mir-423; +MI0001446 hsa-mir-424; +MI0001447 mmu-mir-425; +MI0001448 hsa-mir-425; +MI0001449 xla-mir-427; +MI0001450 xla-mir-428; +MI0001451 xla-mir-429; +MI0001452 xla-mir-19b; +MI0001453 xla-mir-20; +MI0001454 xla-mir-18;xla-mir-18a-1; +MI0001455 xla-mir-133a; +MI0001456 zma-MIR156d; +MI0001457 zma-MIR156f; +MI0001458 zma-MIR156g; +MI0001459 zma-MIR156b; +MI0001460 zma-MIR156c; +MI0001461 zma-MIR156e; +MI0001462 zma-MIR156a; +MI0001463 zma-MIR156h; +MI0001464 zma-MIR156i; +MI0001465 zma-MIR160a; +MI0001466 zma-MIR160c; +MI0001467 zma-MIR160d; +MI0001468 zma-MIR160b; +MI0001469 zma-MIR164a; +MI0001470 zma-MIR164d; +MI0001471 zma-MIR164b; +MI0001472 zma-MIR164c; +MI0001473 zma-MIR169a; +MI0001474 zma-MIR169b; +MI0001475 zma-MIR167a; +MI0001476 zma-MIR167b; +MI0001477 zma-MIR167d; +MI0001478 zma-MIR167c; +MI0001479 zma-MIR160e; +MI0001480 zma-MIR166a; +MI0001481 zma-MIR162; +MI0001482 zma-MIR166h; +MI0001483 zma-MIR166e; +MI0001485 zma-MIR166i; +MI0001486 zma-MIR166f; +MI0001487 zma-MIR166g; +MI0001488 zma-MIR166b; +MI0001489 zma-MIR166c; +MI0001490 zma-MIR166d; +MI0001491 zma-MIR171a; +MI0001492 zma-MIR171b; +MI0001493 zma-MIR172a; +MI0001494 zma-MIR172d; +MI0001495 zma-MIR172b; +MI0001496 zma-MIR172c; +MI0001497 sbi-MIR166d; +MI0001498 sbi-MIR166c; +MI0001499 sbi-MIR166b; +MI0001500 sbi-MIR166a; +MI0001501 sbi-MIR172b; +MI0001502 sbi-MIR172c; +MI0001503 sbi-MIR172a; +MI0001504 sbi-MIR156a; +MI0001505 sbi-MIR156c; +MI0001506 sbi-MIR156b; +MI0001507 sbi-MIR160d; +MI0001508 sbi-MIR160a; +MI0001509 sbi-MIR160c; +MI0001510 sbi-MIR160b; +MI0001511 sbi-MIR160e; +MI0001512 sbi-MIR164;sbi-MIR164a; +MI0001513 sbi-MIR167a; +MI0001514 sbi-MIR167b; +MI0001515 sbi-MIR169b; +MI0001516 sbi-MIR169a; +MI0001517 gga-mir-20b; +MI0001518 hsa-mir-18b; +MI0001519 hsa-mir-20b; +MI0001520 oar-mir-431; +MI0001521 oar-mir-127; +MI0001522 oar-mir-432; +MI0001523 oar-mir-136; +MI0001524 mmu-mir-431; +MI0001525 mmu-mir-433; +MI0001526 mmu-mir-434; +MI0001527 dre-mir-430a;dre-mir-430a-1; +MI0001528 dre-mir-430b;dre-mir-430b-1; +MI0001529 dre-mir-430c;dre-mir-430c-1; +MI0001530 sbi-MIR393;sbi-MIR393a; +MI0001531 sbi-MIR394a; +MI0001532 sbi-MIR394b; +MI0001533 sbi-MIR395b; +MI0001534 sbi-MIR395a; +MI0001535 sbi-MIR395c; +MI0001536 sbi-MIR395d; +MI0001537 sbi-MIR395e; +MI0001538 sbi-MIR396b; +MI0001539 sbi-MIR396a; +MI0001540 sbi-MIR396c; +MI0001541 sbi-MIR399a; +MI0001542 sbi-MIR399c; +MI0001543 sbi-MIR399d; +MI0001544 sbi-MIR399e; +MI0001545 sbi-MIR399f; +MI0001546 sbi-MIR399b; +MI0001547 sbi-MIR399g; +MI0001548 sbi-MIR156d; +MI0001549 sbi-MIR164b; +MI0001550 sbi-MIR166e; +MI0001551 sbi-MIR167d; +MI0001552 sbi-MIR167f; +MI0001553 sbi-MIR167g; +MI0001554 sbi-MIR167e; +MI0001555 sbi-MIR167c; +MI0001556 sbi-MIR168; +MI0001557 sbi-MIR169c; +MI0001558 sbi-MIR169d; +MI0001559 sbi-MIR169e; +MI0001560 sbi-MIR169f; +MI0001561 sbi-MIR169g; +MI0001562 sbi-MIR169h; +MI0001563 sbi-MIR169i; +MI0001564 sbi-MIR171b; +MI0001565 sbi-MIR171d; +MI0001566 sbi-MIR171a; +MI0001567 sbi-MIR171c; +MI0001568 sbi-MIR172e; +MI0001569 sbi-MIR166f; +MI0001570 sbi-MIR171e; +MI0001571 sbi-MIR172d; +MI0001572 sbi-MIR159;sbi-MIR159a; +MI0001573 sbi-MIR319;sbi-MIR319a; +MI0001574 ame-bantam; +MI0001575 ame-mir-1;ame-mir-1-1; +MI0001576 ame-mir-12; +MI0001577 ame-mir-124; +MI0001578 ame-mir-125; +MI0001579 ame-mir-133; +MI0001580 ame-mir-184; +MI0001581 ame-mir-210; +MI0001582 ame-mir-219; +MI0001583 ame-mir-263;ame-mir-263a; +MI0001584 ame-mir-276; +MI0001585 ame-mir-277; +MI0001586 ame-mir-278; +MI0001587 ame-mir-281; +MI0001588 ame-mir-282; +MI0001589 ame-mir-2-1; +MI0001590 ame-mir-2-2; +MI0001591 ame-mir-305; +MI0001592 ame-mir-315; +MI0001593 ame-mir-317; +MI0001594 ame-mir-7; +MI0001595 ame-mir-8; +MI0001596 ame-mir-9a; +MI0001597 ame-mir-9b; +MI0001598 ame-mir-iab-4; +MI0001599 aga-bantam; +MI0001600 aga-let-7; +MI0001601 aga-mir-1; +MI0001602 aga-mir-10; +MI0001603 aga-mir-100; +MI0001604 aga-mir-124; +MI0001605 aga-mir-125; +MI0001606 aga-mir-133; +MI0001607 aga-mir-13b; +MI0001608 aga-mir-14; +MI0001609 aga-mir-184; +MI0001610 aga-mir-210; +MI0001611 aga-mir-219; +MI0001612 aga-mir-263;aga-mir-263a; +MI0001613 aga-mir-275; +MI0001614 aga-mir-276; +MI0001615 aga-mir-277; +MI0001616 aga-mir-278; +MI0001617 aga-mir-279; +MI0001618 aga-mir-281; +MI0001619 aga-mir-282; +MI0001620 aga-mir-283; +MI0001621 aga-mir-2b;aga-mir-2-1; +MI0001622 aga-mir-2c;aga-mir-2-2; +MI0001623 aga-mir-305; +MI0001624 aga-mir-307; +MI0001625 aga-mir-308; +MI0001626 aga-mir-315; +MI0001627 aga-mir-317; +MI0001628 aga-mir-7; +MI0001629 aga-mir-79; +MI0001630 aga-mir-8; +MI0001631 aga-mir-9a; +MI0001632 aga-mir-92a; +MI0001633 aga-mir-92b; +MI0001634 aga-mir-9b; +MI0001635 aga-mir-9c; +MI0001636 aga-mir-iab-4; +MI0001637 hsa-mir-448; +MI0001638 mmu-mir-448; +MI0001639 rno-mir-448; +MI0001640 cfa-mir-448; +MI0001641 hsa-mir-429; +MI0001642 mmu-mir-429; +MI0001643 rno-mir-429; +MI0001644 cfa-mir-429; +MI0001645 mmu-mir-365-2; +MI0001647 cfa-mir-365-2; +MI0001648 hsa-mir-449;hsa-mir-449a; +MI0001649 mmu-mir-449;mmu-mir-449a; +MI0001650 rno-mir-449;rno-mir-449a; +MI0001651 cfa-mir-449;cfa-mir-449a; +MI0001652 hsa-mir-450;hsa-mir-450-1;hsa-mir-450a-1; +MI0001653 mmu-mir-450;mmu-mir-450-1;mmu-mir-450a-1; +MI0001654 rno-mir-450;rno-mir-450a; +MI0001655 cfa-mir-450;cfa-mir-450a; +MI0001656 rno-mir-365; +MI0001657 cfa-mir-365-1; +MI0001658 khv-miR-K12-1a; +MI0001659 khv-miR-K12-1b; +MI0001660 khv-miR-K12-2; +MI0001661 khv-miR-K12-3; +MI0001662 khv-miR-K12-4; +MI0001663 khv-miR-K12-5; +MI0001664 khv-miR-K12-6; +MI0001665 khv-miR-K12-7; +MI0001666 khv-miR-K12-8; +MI0001667 khv-miR-K12-9; +MI0001668 khv-miR-K12-10; +MI0001669 mhv-miR-M1-1;mghv-mir-M1-1; +MI0001670 mhv-miR-M1-2;mghv-mir-M1-2; +MI0001671 mhv-miR-M1-3;mghv-mir-M1-3; +MI0001672 mhv-miR-M1-4;mghv-mir-M1-4; +MI0001673 mhv-miR-M1-5;mghv-mir-M1-5; +MI0001674 mhv-miR-M1-6;mghv-mir-M1-6; +MI0001675 mhv-miR-M1-7;mghv-mir-M1-7; +MI0001676 mhv-miR-M1-8;mghv-mir-M1-8; +MI0001677 mhv-miR-M1-9;mghv-mir-M1-9; +MI0001678 hcv-miR-UL22A-1;hcmv-mir-UL22A-1;hcmv-mir-UL22A; +MI0001679 hcv-miR-UL36-1;hcmv-mir-UL36-1;hcmv-mir-UL36; +MI0001680 hcv-miR-UL112-1;hcmv-mir-UL112-1;hcmv-mir-UL112; +MI0001681 hcv-miR-UL148D-1;hcmv-mir-UL148D-1;hcmv-mir-UL148D; +MI0001682 hcv-miR-US5-1;hcmv-mir-US5-1; +MI0001683 hcv-miR-US5-2;hcmv-mir-US5-2; +MI0001684 hcv-miR-US25-1;hcmv-mir-US25-1; +MI0001685 hcv-miR-US25-2;hcmv-mir-US25-2; +MI0001686 hcv-miR-US33-1;hcmv-mir-US33-1;hcmv-mir-US33; +MI0001687 osa-MIR435; +MI0001688 osa-MIR437; +MI0001689 osa-MIR438; +MI0001690 osa-MIR390; +MI0001691 osa-MIR439a; +MI0001692 osa-MIR439b; +MI0001693 osa-MIR439c; +MI0001694 osa-MIR439d; +MI0001695 osa-MIR439e; +MI0001696 osa-MIR439f; +MI0001697 osa-MIR439g; +MI0001698 osa-MIR439h; +MI0001699 osa-MIR439i; +MI0001700 osa-MIR439j;osa-MIR439i; +MI0001701 osa-MIR440; +MI0001702 osa-MIR396d; +MI0001703 osa-MIR396e; +MI0001704 osa-MIR441a; +MI0001705 osa-MIR441b; +MI0001706 osa-MIR441c; +MI0001707 osa-MIR442; +MI0001708 osa-MIR443; +MI0001709 osa-MIR445a; +MI0001710 osa-MIR445b; +MI0001711 osa-MIR445c; +MI0001712 osa-MIR445d; +MI0001713 osa-MIR445e; +MI0001714 osa-MIR445f; +MI0001715 osa-MIR445g; +MI0001716 osa-MIR445h; +MI0001717 osa-MIR445i; +MI0001718 osa-MIR446; +MI0001719 osa-MIR444;osa-MIR444a; +MI0001720 dre-mir-429;dre-mir-429a; +MI0001721 hsa-mir-431; +MI0001722 rno-mir-431; +MI0001723 hsa-mir-433; +MI0001724 rno-mir-433; +MI0001725 hsa-mir-329-1; +MI0001726 hsa-mir-329-2; +MI0001727 hsa-mir-453; +MI0001729 hsa-mir-451;hsa-mir-451a; +MI0001730 mmu-mir-451;mmu-mir-451a; +MI0001731 rno-mir-451; +MI0001732 dre-mir-451; +MI0001733 hsa-mir-452; +MI0001734 mmu-mir-452; +MI0001735 hsa-mir-409; +MI0001738 mtr-MIR162; +MI0001739 mtr-MIR160;mtr-MIR160a; +MI0001740 mtr-MIR166;mtr-MIR166a; +MI0001741 mtr-MIR169a; +MI0001742 mtr-MIR169b; +MI0001743 mtr-MIR399b; +MI0001744 mtr-MIR399d; +MI0001745 mtr-MIR393;mtr-MIR393a; +MI0001746 mtr-MIR395a; +MI0001747 mtr-MIR395b; +MI0001748 mtr-MIR399c; +MI0001749 mtr-MIR399a; +MI0001750 mtr-MIR399e; +MI0001751 mtr-MIR319;mtr-MIR319a; +MI0001752 mtr-MIR156;mtr-MIR156a; +MI0001753 mtr-MIR171;mtr-MIR171a; +MI0001754 sof-MIR156; +MI0001755 sof-MIR396; +MI0001756 sof-MIR159a; +MI0001757 sof-MIR159b; +MI0001758 sof-MIR159d; +MI0001759 sof-MIR159e; +MI0001760 sof-MIR159c; +MI0001761 sof-MIR167a; +MI0001762 sof-MIR167b; +MI0001763 sof-MIR168a; +MI0001764 sof-MIR168b; +MI0001765 sof-MIR408a; +MI0001766 sof-MIR408b; +MI0001767 sof-MIR408c; +MI0001768 sof-MIR408d; +MI0001769 sof-MIR408e; +MI0001770 gma-MIR156d; +MI0001771 gma-MIR156e; +MI0001772 gma-MIR156c; +MI0001773 gma-MIR159;gma-MIR159a; +MI0001774 gma-MIR160;gma-MIR160a; +MI0001775 gma-MIR166a; +MI0001776 gma-MIR166b; +MI0001777 gma-MIR167a; +MI0001778 gma-MIR167b; +MI0001779 gma-MIR168;gma-MIR168a; +MI0001780 gma-MIR172a; +MI0001781 gma-MIR172b; +MI0001782 gma-MIR319a; +MI0001783 gma-MIR319b; +MI0001784 gma-MIR156a; +MI0001785 gma-MIR396a; +MI0001786 gma-MIR396b; +MI0001787 gma-MIR398a; +MI0001788 gma-MIR398b; +MI0001789 gma-MIR319c; +MI0001790 gma-MIR156b; +MI0001791 gma-MIR169;gma-MIR169a; +MI0001792 zma-MIR171d; +MI0001793 zma-MIR171f; +MI0001794 zma-MIR394a; +MI0001795 zma-MIR394b; +MI0001796 zma-MIR395b; +MI0001797 zma-MIR395c; +MI0001798 zma-MIR395d;zma-MIR395c; +MI0001799 zma-MIR395a; +MI0001800 zma-MIR396b; +MI0001801 zma-MIR396a; +MI0001802 zma-MIR399a; +MI0001803 zma-MIR399c; +MI0001804 zma-MIR399b; +MI0001805 zma-MIR399d; +MI0001806 zma-MIR399e; +MI0001807 zma-MIR399f; +MI0001808 zma-MIR156j; +MI0001809 zma-MIR159a; +MI0001810 zma-MIR159b; +MI0001811 zma-MIR159c; +MI0001812 zma-MIR159d; +MI0001813 zma-MIR319a; +MI0001814 zma-MIR319c; +MI0001815 zma-MIR319b; +MI0001816 zma-MIR319d; +MI0001817 zma-MIR166k; +MI0001818 zma-MIR166j; +MI0001819 zma-MIR167e; +MI0001820 zma-MIR167f; +MI0001821 zma-MIR167g; +MI0001822 zma-MIR167h; +MI0001823 zma-MIR167i; +MI0001824 zma-MIR168a; +MI0001825 zma-MIR168b; +MI0001826 zma-MIR169c; +MI0001827 zma-MIR169f; +MI0001828 zma-MIR169g; +MI0001829 zma-MIR169h; +MI0001830 zma-MIR169i; +MI0001831 zma-MIR169k; +MI0001832 zma-MIR169j; +MI0001833 zma-MIR169d; +MI0001834 zma-MIR169e; +MI0001835 zma-MIR171c; +MI0001836 zma-MIR171j; +MI0001837 zma-MIR171e; +MI0001838 zma-MIR171i; +MI0001839 zma-MIR171g; +MI0001840 zma-MIR172e; +MI0001841 zma-MIR166l; +MI0001842 zma-MIR166m; +MI0001843 zma-MIR171k; +MI0001844 zma-MIR171h; +MI0001845 zma-MIR393;zma-MIR393a; +MI0001846 zma-MIR408;zma-MIR408a; +MI0001847 zma-MIR156k; +MI0001848 zma-MIR160f; +MI0001849 sbi-MIR399h; +MI0001850 sbi-MIR399i; +MI0001851 sbi-MIR159b; +MI0001852 sbi-MIR164c; +MI0001853 sbi-MIR166g; +MI0001854 sbi-MIR171f; +MI0001855 sbi-MIR395f; +MI0001856 sbi-MIR156e; +MI0001857 dre-let-7a-1; +MI0001858 dre-let-7a-2; +MI0001859 dre-let-7a-3; +MI0001860 dre-let-7a-4;dre-let-7a-3; +MI0001861 dre-let-7a-5;dre-let-7a-4; +MI0001862 dre-let-7a-6;dre-let-7a-5; +MI0001863 dre-let-7a-7;dre-let-7a-6; +MI0001864 dre-let-7b-1; +MI0001865 dre-let-7b-2;dre-let-7b; +MI0001866 dre-let-7c-1; +MI0001867 dre-let-7c-2; +MI0001868 dre-let-7d-1; +MI0001869 dre-let-7d-2; +MI0001870 dre-let-7d-3;dre-let-7d-2; +MI0001871 dre-let-7e;dre-let-7e-1;dre-let-7e; +MI0001872 dre-let-7f; +MI0001873 dre-let-7g-1; +MI0001874 dre-let-7g-2; +MI0001875 dre-let-7h; +MI0001876 dre-let-7i; +MI0001877 dre-mir-1-2; +MI0001878 dre-mir-1-1; +MI0001879 dre-mir-7a-3; +MI0001880 dre-mir-9-1; +MI0001881 dre-mir-9-2; +MI0001882 dre-mir-9-4; +MI0001883 dre-mir-9-3; +MI0001884 dre-mir-9-5; +MI0001885 dre-mir-9-6; +MI0001886 dre-mir-9-7; +MI0001887 dre-mir-10b-2; +MI0001888 dre-mir-10c; +MI0001889 dre-mir-10d-1;dre-mir-10d; +MI0001890 dre-mir-10d-2; +MI0001891 dre-mir-15a-1; +MI0001892 dre-mir-15a-2; +MI0001893 dre-mir-15b; +MI0001894 dre-mir-16a; +MI0001895 dre-mir-16b; +MI0001896 dre-mir-16c; +MI0001897 dre-mir-17a-1; +MI0001898 dre-mir-17a-2; +MI0001899 dre-mir-20b; +MI0001900 dre-mir-18a; +MI0001901 dre-mir-18b; +MI0001902 dre-mir-18c; +MI0001903 dre-mir-19a; +MI0001904 dre-mir-19b; +MI0001905 dre-mir-19c; +MI0001906 dre-mir-19d; +MI0001907 dre-mir-20a; +MI0001908 dre-mir-21-1; +MI0001909 dre-mir-21-2; +MI0001910 dre-mir-22a-1;dre-mir-22a; +MI0001911 dre-mir-22a-2; +MI0001912 dre-mir-22b; +MI0001913 dre-mir-23a-1; +MI0001914 dre-mir-23a-2; +MI0001915 dre-mir-23a-3;dre-mir-23a-2; +MI0001916 dre-mir-23a-4;dre-mir-23a-3; +MI0001917 dre-mir-23b; +MI0001918 dre-mir-24-4; +MI0001919 dre-mir-24-2; +MI0001920 dre-mir-24-3; +MI0001921 dre-mir-24-1; +MI0001922 dre-mir-25; +MI0001923 dre-mir-26a-1; +MI0001924 dre-mir-26a-2; +MI0001925 dre-mir-26a-3;dre-mir-26a-2; +MI0001926 dre-mir-26a-4;dre-mir-26a-3; +MI0001927 dre-mir-26b; +MI0001928 dre-mir-27a; +MI0001929 dre-mir-27b; +MI0001930 dre-mir-27c;dre-mir-27c-1;dre-mir-27c; +MI0001931 dre-mir-27d; +MI0001932 dre-mir-27e; +MI0001933 dre-mir-29b-1; +MI0001934 dre-mir-29b-2; +MI0001935 dre-mir-29b-3; +MI0001936 dre-mir-29b-4;dre-mir-29b-3; +MI0001937 dre-mir-29b-5; +MI0001938 dre-mir-29a-1;dre-mir-29a; +MI0001939 dre-mir-29a-2; +MI0001940 dre-mir-30a; +MI0001941 dre-mir-30b-1;dre-mir-30b; +MI0001942 dre-mir-30b-2; +MI0001943 dre-mir-30b-3; +MI0001944 dre-mir-30c-1;dre-mir-30c; +MI0001945 dre-mir-30c-2; +MI0001946 dre-mir-30d-1;dre-mir-30d; +MI0001947 dre-mir-30d-2; +MI0001948 dre-mir-30d-3; +MI0001949 dre-mir-30e-1; +MI0001950 dre-mir-30e-2; +MI0001951 dre-mir-92a-1; +MI0001952 dre-mir-92a-2; +MI0001953 dre-mir-92b; +MI0001954 dre-mir-93; +MI0001955 dre-mir-96; +MI0001956 dre-mir-99-1; +MI0001957 dre-mir-99-2; +MI0001958 dre-mir-100-1; +MI0001959 dre-mir-100-2; +MI0001960 dre-mir-101a; +MI0001961 dre-mir-101b; +MI0001962 dre-mir-103; +MI0001963 dre-mir-107-1;dre-mir-107;dre-mir-107a; +MI0001964 dre-mir-107-2; +MI0001965 dre-mir-122; +MI0001966 dre-mir-124-1; +MI0001967 dre-mir-124-2; +MI0001968 dre-mir-124-3; +MI0001969 dre-mir-124-4; +MI0001970 dre-mir-124-5; +MI0001971 dre-mir-124-6; +MI0001972 dre-mir-125a-1; +MI0001973 dre-mir-125a-2; +MI0001974 dre-mir-125a-3; +MI0001975 dre-mir-125b-1; +MI0001976 dre-mir-125b-2; +MI0001977 dre-mir-125b-3; +MI0001978 dre-mir-125c; +MI0001979 dre-mir-126;dre-mir-126a; +MI0001980 dre-mir-128-1; +MI0001981 dre-mir-128-2; +MI0001982 dre-mir-129-2; +MI0001983 dre-mir-129-1; +MI0001984 dre-mir-130a-1;dre-mir-130a; +MI0001985 dre-mir-130a-2; +MI0001986 dre-mir-130b; +MI0001987 dre-mir-130c-1; +MI0001988 dre-mir-130c-2; +MI0001989 dre-mir-132-1; +MI0001990 dre-mir-132-2; +MI0001991 dre-mir-132-3;dre-mir-132-2; +MI0001992 dre-mir-133a-2; +MI0001993 dre-mir-133a-1; +MI0001994 dre-mir-133b; +MI0001995 dre-mir-133c; +MI0001996 dre-mir-135-1;dre-mir-135c-1; +MI0001997 dre-mir-135-2;dre-mir-135c-2; +MI0001998 dre-mir-135-3;dre-mir-135c-3; +MI0001999 dre-mir-135-4; +MI0002000 dre-mir-137-1; +MI0002001 dre-mir-137-2; +MI0002002 dre-mir-138;dre-mir-138-1; +MI0002003 dre-mir-140; +MI0002004 dre-mir-141; +MI0002005 dre-mir-142a; +MI0002006 dre-mir-142b; +MI0002007 dre-mir-143-1;dre-mir-143; +MI0002008 dre-mir-143-2; +MI0002009 dre-mir-144; +MI0002010 dre-mir-145-1;dre-mir-145; +MI0002011 dre-mir-145-2; +MI0002012 dre-mir-146a; +MI0002013 dre-mir-146b-1;dre-mir-146b; +MI0002014 dre-mir-146b-2; +MI0002015 dre-mir-148; +MI0002016 dre-mir-150; +MI0002017 dre-mir-152-1;dre-mir-152; +MI0002018 dre-mir-152-2; +MI0002019 dre-mir-153b-1;dre-mir-153b; +MI0002020 dre-mir-153b-2; +MI0002021 dre-mir-153a; +MI0002022 dre-mir-153c; +MI0002023 dre-mir-155; +MI0002024 dre-mir-181c-1;dre-mir-181c; +MI0002025 dre-mir-181c-2; +MI0002026 dre-mir-184;dre-mir-184-1; +MI0002027 dre-mir-190;dre-mir-190a; +MI0002028 dre-mir-462; +MI0002029 dre-mir-193a-1; +MI0002030 dre-mir-193a-2; +MI0002031 dre-mir-193a-3; +MI0002032 dre-mir-193b; +MI0002033 dre-mir-194a; +MI0002034 dre-mir-194b; +MI0002035 dre-mir-196a-2; +MI0002036 dre-mir-196b; +MI0002037 dre-mir-200a; +MI0002038 dre-mir-200b; +MI0002039 dre-mir-200c; +MI0002040 dre-mir-202; +MI0002041 dre-mir-203b; +MI0002042 dre-mir-204-2; +MI0002043 dre-mir-204-3; +MI0002044 dre-mir-205-2; +MI0002045 dre-mir-206-1; +MI0002046 dre-mir-206-2; +MI0002047 dre-mir-216a-2; +MI0002048 dre-mir-216b-1;dre-mir-216b; +MI0002049 dre-mir-216b-2; +MI0002050 dre-mir-217-2; +MI0002051 dre-mir-218a-1; +MI0002052 dre-mir-218a-2; +MI0002053 dre-mir-218b; +MI0002054 dre-mir-219-3; +MI0002055 dre-mir-219-4; +MI0002056 dre-mir-219-5; +MI0002057 dre-mir-219-6; +MI0002058 dre-mir-223-2; +MI0002059 dre-mir-301a-1;dre-mir-301a; +MI0002060 dre-mir-301a-2; +MI0002061 dre-mir-301b; +MI0002062 dre-mir-301c; +MI0002063 dre-mir-338-1; +MI0002064 dre-mir-338-2; +MI0002065 dre-mir-338-3; +MI0002066 dre-mir-338-4; +MI0002067 dre-mir-363; +MI0002068 dre-mir-365-1; +MI0002069 dre-mir-365-2; +MI0002070 dre-mir-365-3; +MI0002071 dre-mir-365-4; +MI0002072 dre-mir-375-1; +MI0002073 dre-mir-375-2; +MI0002074 dre-mir-454a-1;dre-mir-454a; +MI0002075 dre-mir-454a-2; +MI0002076 dre-mir-454b; +MI0002077 dre-mir-455-1;dre-mir-455;dre-mir-455a;dre-mir-455-1; +MI0002078 dre-mir-455-2; +MI0002079 dre-mir-430c-2; +MI0002080 dre-mir-430c-3; +MI0002081 dre-mir-430c-4; +MI0002082 dre-mir-430c-5; +MI0002083 dre-mir-430c-6; +MI0002084 dre-mir-430c-7; +MI0002085 dre-mir-430c-8; +MI0002086 dre-mir-430c-9; +MI0002087 dre-mir-430c-10;dre-mir-430c-7; +MI0002088 dre-mir-430c-11;dre-mir-430c-8; +MI0002089 dre-mir-430c-12;dre-mir-430c-9; +MI0002090 dre-mir-430c-13;dre-mir-430c-10; +MI0002091 dre-mir-430c-14;dre-mir-430c-11; +MI0002092 dre-mir-430c-15;dre-mir-430c-12; +MI0002093 dre-mir-430c-16;dre-mir-430c-13; +MI0002094 dre-mir-430c-17;dre-mir-430c-14; +MI0002095 dre-mir-430c-18;dre-mir-430c-15; +MI0002096 dre-mir-430c-19;dre-mir-430c-16; +MI0002097 dre-mir-430c-20;dre-mir-430c-17; +MI0002098 dre-mir-430c-21;dre-mir-430c-18; +MI0002099 dre-mir-430c-22;dre-mir-430c-19; +MI0002100 dre-mir-430c-23;dre-mir-430c-20; +MI0002101 dre-mir-430c-24;dre-mir-430c-21; +MI0002102 dre-mir-430c-25; +MI0002103 dre-mir-430c-26; +MI0002104 dre-mir-430c-27; +MI0002105 dre-mir-430c-28; +MI0002106 dre-mir-430c-29; +MI0002107 dre-mir-430c-30; +MI0002108 dre-mir-430c-31; +MI0002109 dre-mir-430c-32; +MI0002110 dre-mir-430c-33; +MI0002111 dre-mir-430a-2; +MI0002112 dre-mir-430a-3; +MI0002113 dre-mir-430a-4; +MI0002114 dre-mir-430a-5; +MI0002115 dre-mir-430a-6; +MI0002116 dre-mir-430a-7; +MI0002117 dre-mir-430a-8; +MI0002118 dre-mir-430a-9; +MI0002119 dre-mir-430a-10; +MI0002120 dre-mir-430a-11; +MI0002121 dre-mir-430a-12; +MI0002122 dre-mir-430a-13; +MI0002123 dre-mir-430a-14; +MI0002124 dre-mir-430a-15; +MI0002125 dre-mir-430a-16; +MI0002126 dre-mir-430a-17; +MI0002127 dre-mir-430a-18; +MI0002128 dre-mir-430a-19; +MI0002129 dre-mir-430a-20; +MI0002130 dre-mir-430a-21; +MI0002131 dre-mir-430a-22;dre-mir-430a-18; +MI0002132 dre-mir-430a-23;dre-mir-430a-19; +MI0002133 dre-mir-430a-24;dre-mir-430a-20; +MI0002134 dre-mir-430a-25;dre-mir-430a-21; +MI0002135 dre-mir-430a-26;dre-mir-430a-22; +MI0002136 dre-mir-430a-27; +MI0002137 dre-mir-430a-28; +MI0002138 dre-mir-430a-29;dre-mir-430a-23; +MI0002139 dre-mir-430i-1; +MI0002140 dre-mir-430i-2; +MI0002141 dre-mir-430i-3; +MI0002142 dre-mir-430b-2; +MI0002143 dre-mir-430b-3; +MI0002144 dre-mir-430b-4; +MI0002145 dre-mir-430b-5; +MI0002146 dre-mir-430b-6; +MI0002147 dre-mir-430b-7; +MI0002148 dre-mir-430b-8; +MI0002149 dre-mir-430b-9; +MI0002150 dre-mir-430b-10; +MI0002151 dre-mir-430b-11; +MI0002152 dre-mir-430b-12; +MI0002153 dre-mir-430b-13; +MI0002154 dre-mir-430b-14; +MI0002155 dre-mir-430b-15; +MI0002156 dre-mir-430b-16; +MI0002157 dre-mir-430b-17; +MI0002158 dre-mir-430b-18; +MI0002159 dre-mir-430b-19; +MI0002160 dre-mir-430b-20; +MI0002161 dre-mir-430b-21; +MI0002162 dre-mir-430b-22; +MI0002163 dre-mir-430b-23; +MI0002164 dre-mir-430b-24; +MI0002165 dre-mir-430b-25; +MI0002166 dre-mir-430b-26;dre-mir-430b-5; +MI0002167 dre-mir-430b-27; +MI0002168 dre-mir-430b-28; +MI0002169 dre-mir-430b-29; +MI0002170 dre-mir-430b-30;dre-mir-430b-19; +MI0002171 dre-mir-430b-31;dre-mir-430b-20; +MI0002172 dre-mir-430b-32;dre-mir-430b-21; +MI0002173 dre-mir-430b-33;dre-mir-430b-22; +MI0002174 dre-mir-430b-34;dre-mir-430b-23; +MI0002175 dre-mir-430j; +MI0002176 dre-mir-456; +MI0002177 dre-mir-457a; +MI0002178 dre-mir-457b; +MI0002179 dre-mir-458; +MI0002180 dre-mir-459; +MI0002181 dre-mir-460-1;dre-mir-460; +MI0002182 dre-mir-460-2; +MI0002183 dre-mir-461; +MI0002184 ptc-MIR156a; +MI0002185 ptc-MIR156b; +MI0002186 ptc-MIR156c; +MI0002187 ptc-MIR156d; +MI0002188 ptc-MIR156e; +MI0002189 ptc-MIR156f; +MI0002190 ptc-MIR156g; +MI0002191 ptc-MIR156h; +MI0002192 ptc-MIR156i; +MI0002193 ptc-MIR156j; +MI0002194 ptc-MIR156k; +MI0002195 ptc-MIR159a; +MI0002196 ptc-MIR159b; +MI0002197 ptc-MIR159c; +MI0002198 ptc-MIR159d; +MI0002199 ptc-MIR159e; +MI0002200 ptc-MIR159f;ptc-MIR159c; +MI0002201 ptc-MIR160a; +MI0002202 ptc-MIR160b; +MI0002203 ptc-MIR160c; +MI0002204 ptc-MIR160d; +MI0002205 ptc-MIR160e; +MI0002206 ptc-MIR160f; +MI0002207 ptc-MIR160g; +MI0002208 ptc-MIR160h; +MI0002209 ptc-MIR162a; +MI0002210 ptc-MIR162b; +MI0002211 ptc-MIR162c; +MI0002212 ptc-MIR164a; +MI0002213 ptc-MIR164b; +MI0002214 ptc-MIR164c; +MI0002215 ptc-MIR164d; +MI0002216 ptc-MIR164e; +MI0002217 ptc-MIR164f; +MI0002218 ptc-MIR166a; +MI0002219 ptc-MIR166b; +MI0002220 ptc-MIR166c; +MI0002221 ptc-MIR166d; +MI0002222 ptc-MIR166e; +MI0002223 ptc-MIR166f; +MI0002224 ptc-MIR166g; +MI0002225 ptc-MIR166h; +MI0002226 ptc-MIR166i; +MI0002227 ptc-MIR166j; +MI0002228 ptc-MIR166k; +MI0002229 ptc-MIR166l; +MI0002230 ptc-MIR166m; +MI0002231 ptc-MIR166n; +MI0002232 ptc-MIR166o; +MI0002233 ptc-MIR166p; +MI0002234 ptc-MIR166q; +MI0002235 ptc-MIR167a; +MI0002236 ptc-MIR167b; +MI0002237 ptc-MIR167c; +MI0002238 ptc-MIR167d; +MI0002239 ptc-MIR167e; +MI0002240 ptc-MIR167f; +MI0002241 ptc-MIR167g; +MI0002242 ptc-MIR167h; +MI0002243 ptc-MIR168a; +MI0002244 ptc-MIR168b; +MI0002245 ptc-MIR169a; +MI0002246 ptc-MIR169aa; +MI0002247 ptc-MIR169ab; +MI0002248 ptc-MIR169ac; +MI0002249 ptc-MIR169ad; +MI0002250 ptc-MIR169ae; +MI0002251 ptc-MIR169af; +MI0002252 ptc-MIR169b; +MI0002253 ptc-MIR169c; +MI0002254 ptc-MIR169d; +MI0002255 ptc-MIR169e; +MI0002256 ptc-MIR169f; +MI0002257 ptc-MIR169g; +MI0002258 ptc-MIR169h; +MI0002259 ptc-MIR169i; +MI0002260 ptc-MIR169j; +MI0002261 ptc-MIR169k; +MI0002262 ptc-MIR169l; +MI0002263 ptc-MIR169m; +MI0002264 ptc-MIR169n; +MI0002265 ptc-MIR169o; +MI0002266 ptc-MIR169p; +MI0002267 ptc-MIR169q; +MI0002268 ptc-MIR169r; +MI0002269 ptc-MIR169s; +MI0002270 ptc-MIR169t; +MI0002271 ptc-MIR169u; +MI0002272 ptc-MIR169v; +MI0002273 ptc-MIR169w; +MI0002274 ptc-MIR169x; +MI0002275 ptc-MIR169y; +MI0002276 ptc-MIR169z; +MI0002277 ptc-MIR171a; +MI0002278 ptc-MIR171b; +MI0002279 ptc-MIR171c; +MI0002280 ptc-MIR171d; +MI0002281 ptc-MIR171e; +MI0002282 ptc-MIR171f; +MI0002283 ptc-MIR171g; +MI0002284 ptc-MIR171h; +MI0002285 ptc-MIR171i; +MI0002286 ptc-MIR171j; +MI0002287 ptc-MIR172a; +MI0002288 ptc-MIR172b; +MI0002289 ptc-MIR172c; +MI0002290 ptc-MIR172d; +MI0002291 ptc-MIR172e; +MI0002292 ptc-MIR172f; +MI0002293 ptc-MIR172g; +MI0002294 ptc-MIR172h; +MI0002295 ptc-MIR172i; +MI0002296 ptc-MIR319a; +MI0002297 ptc-MIR319b; +MI0002298 ptc-MIR319c; +MI0002299 ptc-MIR319d; +MI0002300 ptc-MIR319e; +MI0002301 ptc-MIR319f; +MI0002302 ptc-MIR319g; +MI0002303 ptc-MIR319h; +MI0002304 ptc-MIR319i; +MI0002305 ptc-MIR390a; +MI0002306 ptc-MIR390b; +MI0002307 ptc-MIR390c; +MI0002308 ptc-MIR390d; +MI0002309 ptc-MIR393a; +MI0002310 ptc-MIR393b; +MI0002311 ptc-MIR393c; +MI0002312 ptc-MIR393d; +MI0002313 ptc-MIR394a; +MI0002314 ptc-MIR394b; +MI0002315 ptc-MIR395a; +MI0002316 ptc-MIR395b; +MI0002317 ptc-MIR395c; +MI0002318 ptc-MIR395d; +MI0002319 ptc-MIR395e; +MI0002320 ptc-MIR395f; +MI0002321 ptc-MIR395g; +MI0002322 ptc-MIR395h; +MI0002323 ptc-MIR395i; +MI0002324 ptc-MIR395j; +MI0002325 ptc-MIR396a; +MI0002326 ptc-MIR396b; +MI0002327 ptc-MIR396c; +MI0002328 ptc-MIR396d; +MI0002329 ptc-MIR396e; +MI0002330 ptc-MIR396f; +MI0002331 ptc-MIR396g; +MI0002332 ptc-MIR397a; +MI0002333 ptc-MIR397b; +MI0002334 ptc-MIR397c; +MI0002335 ptc-MIR398a; +MI0002336 ptc-MIR398b; +MI0002337 ptc-MIR398c; +MI0002338 ptc-MIR399a; +MI0002339 ptc-MIR399b; +MI0002340 ptc-MIR399c; +MI0002341 ptc-MIR399d; +MI0002342 ptc-MIR399e; +MI0002343 ptc-MIR399f; +MI0002344 ptc-MIR399g; +MI0002345 ptc-MIR399h; +MI0002346 ptc-MIR399i; +MI0002347 ptc-MIR399j; +MI0002348 ptc-MIR399k;ptc-MIR399c; +MI0002349 ptc-MIR399l;ptc-MIR399e; +MI0002350 ptc-MIR403a; +MI0002351 ptc-MIR403b; +MI0002352 ptc-MIR408; +MI0002354 ptc-MIR472a; +MI0002355 ptc-MIR472b; +MI0002356 ptc-MIR473a;ptc-MIR477e; +MI0002357 ptc-MIR473b;ptc-MIR477f; +MI0002358 ptc-MIR474a; +MI0002359 ptc-MIR474b; +MI0002360 ptc-MIR474c; +MI0002361 ptc-MIR475a; +MI0002362 ptc-MIR475b; +MI0002363 ptc-MIR475c; +MI0002364 ptc-MIR475d; +MI0002365 ptc-MIR476a; +MI0002366 ptc-MIR476b; +MI0002367 ptc-MIR476c; +MI0002368 ptc-MIR477a; +MI0002369 ptc-MIR477b; +MI0002370 ptc-MIR478a; +MI0002371 ptc-MIR478b; +MI0002372 ptc-MIR478c; +MI0002373 ptc-MIR478d; +MI0002374 ptc-MIR478e; +MI0002375 ptc-MIR478f; +MI0002376 ptc-MIR478h; +MI0002377 ptc-MIR478i; +MI0002378 ptc-MIR478j; +MI0002379 ptc-MIR478k; +MI0002380 ptc-MIR478l; +MI0002381 ptc-MIR478m; +MI0002382 ptc-MIR478n; +MI0002383 ptc-MIR478o; +MI0002384 ptc-MIR478p; +MI0002385 ptc-MIR478q; +MI0002386 ptc-MIR478r; +MI0002387 ptc-MIR478s; +MI0002388 ptc-MIR478u;ptc-MIR478n; +MI0002389 ptc-MIR479; +MI0002390 ptc-MIR480a;ptc-MIR480; +MI0002391 ptc-MIR480b; +MI0002392 ptc-MIR481a; +MI0002393 ptc-MIR481b; +MI0002394 ptc-MIR481c; +MI0002395 ptc-MIR481d; +MI0002396 ptc-MIR481e;ptc-MIR481d; +MI0002397 ptc-MIR482;ptc-MIR482a; +MI0002398 mmu-mir-463; +MI0002399 mmu-mir-464; +MI0002400 mmu-mir-465;mmu-mir-465a; +MI0002401 mmu-mir-466;mmu-mir-466a; +MI0002402 mmu-mir-467;mmu-mir-467a;mmu-mir-467a-1; +MI0002403 mmu-mir-468; +MI0002404 mmu-mir-469; +MI0002405 mmu-mir-470; +MI0002406 mmu-mir-471; +MI0002407 ath-MIR447a; +MI0002408 ath-MIR447b; +MI0002409 ath-MIR447c; +MI0002410 ssc-mir-105-1; +MI0002411 ssc-mir-105-2; +MI0002412 ssc-mir-106a; +MI0002413 ssc-mir-122a;ssc-mir-122; +MI0002414 ssc-mir-125b;ssc-mir-125b-2; +MI0002415 ssc-mir-135a-1;ssc-mir-135-1; +MI0002416 ssc-mir-135a-2;ssc-mir-135-2; +MI0002417 ssc-mir-145; +MI0002418 ssc-mir-148a; +MI0002419 ssc-mir-15b; +MI0002420 ssc-mir-181b;ssc-mir-181b-2; +MI0002421 ssc-mir-184; +MI0002422 ssc-mir-19a; +MI0002423 ssc-mir-20;ssc-mir-20a; +MI0002424 ssc-mir-216;ssc-mir-216-1; +MI0002425 ssc-mir-217;ssc-mir-217-1; +MI0002426 ssc-mir-224; +MI0002427 ssc-mir-23a; +MI0002428 ssc-mir-24;ssc-mir-24-1; +MI0002429 ssc-mir-26a; +MI0002430 ssc-mir-28; +MI0002431 ssc-mir-29b;ssc-mir-29b-1; +MI0002432 ssc-mir-301; +MI0002433 ssc-mir-323; +MI0002434 ssc-mir-326; +MI0002435 ssc-mir-7;ssc-mir-7-2; +MI0002436 ssc-mir-95; +MI0002437 ssc-mir-140; +MI0002438 ssc-mir-181c; +MI0002439 ssc-mir-183; +MI0002440 ssc-mir-205; +MI0002441 ssc-mir-214; +MI0002442 ssc-mir-27a; +MI0002443 ssc-mir-32; +MI0002444 ssc-mir-325; +MI0002445 ssc-let-7c; +MI0002446 ssc-let-7f;ssc-let-7f-1; +MI0002447 ssc-let-7i; +MI0002448 ssc-mir-103;ssc-mir-103-1; +MI0002449 ssc-mir-107; +MI0002450 ssc-mir-124a;ssc-mir-124a-2; +MI0002451 ssc-mir-128a;ssc-mir-128;ssc-mir-128-1; +MI0002452 ssc-mir-136; +MI0002453 ssc-mir-139; +MI0002454 ssc-mir-153; +MI0002455 ssc-mir-18;ssc-mir-18a; +MI0002456 ssc-mir-186; +MI0002457 ssc-mir-196;ssc-mir-196a;ssc-mir-196a-2; +MI0002458 ssc-mir-204; +MI0002459 ssc-mir-21; +MI0002460 ssc-mir-29c; +MI0002461 ssc-mir-30c;ssc-mir-30c-2; +MI0002462 ssc-mir-9-1; +MI0002463 ssc-mir-9-2; +MI0002464 hsa-mir-412; +MI0002465 hsa-mir-410; +MI0002466 hsa-mir-376b; +MI0002467 hsa-mir-483; +MI0002468 hsa-mir-484; +MI0002469 hsa-mir-485; +MI0002470 hsa-mir-486;hsa-mir-486-1; +MI0002471 hsa-mir-487;hsa-mir-487a; +MI0002472 kshv-mir-K12-10a; +MI0002473 kshv-mir-K12-10b; +MI0002474 kshv-mir-K12-11; +MI0002475 kshv-mir-K12-1; +MI0002476 kshv-miR-K12-2; +MI0002477 kshv-mir-K12-9; +MI0002478 kshv-mir-K12-8; +MI0002479 kshv-mir-K12-7; +MI0002480 kshv-mir-K12-6; +MI0002481 kshv-mir-K12-5; +MI0002482 kshv-mir-K12-4; +MI0002483 kshv-mir-K12-3; +MI0002484 mml-mir-200c; +MI0002485 mml-mir-141; +MI0002486 ggo-mir-200c; +MI0002487 ggo-mir-141; +MI0002488 ppy-mir-200c; +MI0002489 ppy-mir-141; +MI0002490 ppa-mir-141; +MI0002491 ggo-mir-15b; +MI0002492 age-mir-15b; +MI0002493 ppa-mir-15b; +MI0002494 ppy-mir-15b; +MI0002495 ptr-mir-15b; +MI0002496 mml-mir-15b; +MI0002497 lla-mir-15b; +MI0002498 mne-mir-15b; +MI0002499 ptr-mir-23b; +MI0002500 ppy-mir-23b; +MI0002501 ppa-mir-23b; +MI0002502 mml-mir-30b; +MI0002503 ptr-mir-30b; +MI0002504 ggo-mir-30b; +MI0002505 lla-mir-30b; +MI0002506 mne-mir-30b; +MI0002507 age-mir-30b; +MI0002508 ppa-mir-30b; +MI0002509 ggo-mir-125b-1; +MI0002510 age-mir-125b-1; +MI0002511 ppa-mir-125b; +MI0002512 ppy-mir-125b-1; +MI0002513 ptr-mir-125b-1; +MI0002514 mml-mir-125b-1; +MI0002515 sla-mir-125b; +MI0002516 lla-mir-125b-1; +MI0002517 mne-mir-125b-1; +MI0002518 mml-mir-128a;mml-mir-128;mml-mir-128a; +MI0002519 ptr-mir-128a;ptr-mir-128;ptr-mir-128-1; +MI0002520 ppy-mir-128a;ppy-mir-128;ppy-mir-128-1; +MI0002521 sla-mir-128a;sla-mir-128; +MI0002522 age-mir-128a;age-mir-128; +MI0002523 ppa-mir-128a;ppa-mir-128; +MI0002524 mml-mir-130a; +MI0002525 ggo-mir-130a; +MI0002526 mne-mir-130a; +MI0002527 ppa-mir-130a; +MI0002528 ggo-mir-133a; +MI0002529 age-mir-133a; +MI0002530 ppa-mir-133a; +MI0002531 ppy-mir-133a; +MI0002532 ptr-mir-133a;ptr-mir-133a-1; +MI0002533 mml-mir-133a; +MI0002534 sla-mir-133a; +MI0002535 lla-mir-133a; +MI0002536 mne-mir-133a; +MI0002537 lla-mir-135-1; +MI0002538 age-mir-135-1; +MI0002539 ppa-mir-135-1; +MI0002540 mml-mir-135;mml-mir-135a-2; +MI0002541 ptr-mir-135;ptr-mir-135a-2; +MI0002542 ggo-mir-135;ggo-mir-135a; +MI0002543 ppy-mir-135;ppy-mir-135a-2; +MI0002544 lla-mir-135-2; +MI0002545 age-mir-135-2; +MI0002546 ppa-mir-135-2; +MI0002547 ptr-mir-140; +MI0002548 mne-mir-140; +MI0002549 ptr-mir-143; +MI0002550 ggo-mir-143; +MI0002551 ppy-mir-143; +MI0002552 lla-mir-143; +MI0002553 ppa-mir-143; +MI0002554 ptr-mir-144; +MI0002555 ppy-mir-144; +MI0002556 mne-mir-144; +MI0002557 ppa-mir-144; +MI0002558 mml-mir-145; +MI0002559 ptr-mir-145; +MI0002560 ggo-mir-145; +MI0002561 ppy-mir-145; +MI0002562 mne-mir-145; +MI0002563 mml-mir-153-1; +MI0002564 ppy-mir-153;ppy-mir-153-1; +MI0002565 mne-mir-153-1; +MI0002566 mml-mir-153-2; +MI0002567 ggo-mir-153; +MI0002568 mne-mir-153-2; +MI0002569 ptr-mir-9;ptr-mir-9-2; +MI0002570 ggo-mir-9; +MI0002571 lla-mir-9; +MI0002572 mne-mir-9; +MI0002573 age-mir-9; +MI0002574 ggo-mir-125b-2; +MI0002575 age-mir-125b-2; +MI0002576 lca-mir-125b; +MI0002577 ppy-mir-125b-2; +MI0002578 ptr-mir-125b-2; +MI0002579 mml-mir-125b-2; +MI0002580 lla-mir-125b-2; +MI0002581 mne-mir-125b-2; +MI0002582 mml-mir-127; +MI0002583 ptr-mir-127; +MI0002584 ppy-mir-127; +MI0002585 sla-mir-127; +MI0002586 lla-mir-127; +MI0002587 mne-mir-127; +MI0002588 age-mir-127; +MI0002589 ggo-mir-134; +MI0002590 ppy-mir-134; +MI0002591 mne-mir-134; +MI0002592 ppa-mir-134; +MI0002593 ptr-mir-136; +MI0002594 ggo-mir-136; +MI0002595 ppy-mir-136; +MI0002596 ppa-mir-136; +MI0002597 ptr-mir-154; +MI0002598 ggo-mir-154; +MI0002599 ppy-mir-154; +MI0002600 mne-mir-154; +MI0002601 ppa-mir-154; +MI0002602 ptr-mir-184; +MI0002603 ppy-mir-184; +MI0002604 mne-mir-184; +MI0002605 ptr-mir-186; +MI0002606 ggo-mir-186; +MI0002607 ppa-mir-186; +MI0002608 mml-mir-188; +MI0002609 ptr-mir-188; +MI0002610 ppy-mir-188; +MI0002611 mne-mir-188; +MI0002612 ppa-mir-188; +MI0002613 mml-mir-190;mml-mir-190a; +MI0002614 ptr-mir-190;ptr-mir-190a; +MI0002615 ggo-mir-190;ggo-mir-190a; +MI0002616 ppa-mir-190; +MI0002617 ggo-mir-195; +MI0002618 ppa-mir-195; +MI0002619 ppy-mir-206; +MI0002620 mne-mir-206; +MI0002621 mml-mir-21; +MI0002622 ptr-mir-21; +MI0002623 ggo-mir-21; +MI0002624 ppy-mir-21; +MI0002625 mne-mir-21; +MI0002626 age-mir-21; +MI0002627 ppa-mir-21; +MI0002628 age-mir-22; +MI0002629 ppa-mir-22; +MI0002630 lca-mir-22; +MI0002631 mml-mir-22; +MI0002632 ppy-mir-22; +MI0002633 ptr-mir-22; +MI0002634 sla-mir-22; +MI0002635 lla-mir-22; +MI0002636 mne-mir-22; +MI0002637 mml-mir-24-1; +MI0002638 ppy-mir-24-1; +MI0002639 mne-mir-24-1; +MI0002640 ppa-mir-24-1; +MI0002641 ptr-mir-26a;ptr-mir-26a-1; +MI0002642 ggo-mir-26a; +MI0002643 ppy-mir-26a; +MI0002644 lla-mir-26a; +MI0002645 mne-mir-26a; +MI0002646 mml-mir-26a;mml-mir-26a-1; +MI0002647 ppa-mir-26a; +MI0002648 age-mir-28; +MI0002649 mml-mir-28; +MI0002650 ptr-mir-28; +MI0002651 ggo-mir-28; +MI0002652 ppy-mir-28; +MI0002653 mne-mir-28; +MI0002654 sla-mir-28; +MI0002655 lla-mir-28; +MI0002656 ppa-mir-28; +MI0002657 ggo-mir-29a; +MI0002658 age-mir-29a; +MI0002659 ppa-mir-29a; +MI0002660 ppy-mir-29a; +MI0002661 ptr-mir-29a; +MI0002662 mml-mir-29a; +MI0002663 sla-mir-29a; +MI0002664 lla-mir-29a; +MI0002665 mne-mir-29a; +MI0002666 mml-mir-30a; +MI0002667 ptr-mir-30a; +MI0002668 ggo-mir-30a; +MI0002669 ppy-mir-30a; +MI0002670 ppa-mir-30a; +MI0002671 mml-mir-31; +MI0002672 ptr-mir-31; +MI0002673 ggo-mir-31; +MI0002674 ppy-mir-31; +MI0002675 mne-mir-31; +MI0002676 ppa-mir-31; +MI0002677 mml-mir-32; +MI0002678 ptr-mir-32; +MI0002679 ggo-mir-32; +MI0002680 ppy-mir-32; +MI0002681 sla-mir-32; +MI0002682 mne-mir-32; +MI0002683 ppa-mir-32; +MI0002684 mml-mir-33;mml-mir-33a; +MI0002685 ptr-mir-33;ptr-mir-33a; +MI0002686 ggo-mir-33; +MI0002687 ppy-mir-33;ppy-mir-33a; +MI0002688 mne-mir-33; +MI0002689 ppa-mir-33; +MI0002690 ptr-mir-95; +MI0002691 ggo-mir-95; +MI0002692 ppy-mir-95; +MI0002693 sla-mir-95; +MI0002694 lla-mir-95; +MI0002695 ppa-mir-95; +MI0002696 mml-mir-98; +MI0002697 ptr-mir-98; +MI0002698 ggo-mir-98; +MI0002699 ppy-mir-98; +MI0002700 age-mir-98; +MI0002701 ppa-mir-98; +MI0002702 mml-mir-99a; +MI0002703 ptr-mir-99a; +MI0002704 ggo-mir-99a; +MI0002705 ppy-mir-99a; +MI0002706 lla-mir-99a; +MI0002707 mne-mir-99a; +MI0002708 ppa-mir-99a; +MI0002709 ggo-mir-100; +MI0002710 age-mir-100; +MI0002711 ppa-mir-100; +MI0002712 ppy-mir-100; +MI0002713 ptr-mir-100; +MI0002714 mml-mir-100; +MI0002715 sla-mir-100; +MI0002716 lla-mir-100; +MI0002717 ggo-mir-101; +MI0002718 sla-mir-101; +MI0002719 age-mir-101; +MI0002720 ppa-mir-101; +MI0002721 ppy-mir-101;ppy-mir-101-3; +MI0002722 ptr-mir-101;ptr-mir-101-1; +MI0002723 mml-mir-101;mml-mir-101-1; +MI0002724 lla-mir-101; +MI0002725 mne-mir-101; +MI0002726 ppy-mir-29b-1; +MI0002727 ptr-mir-29b-1; +MI0002728 ggo-mir-29b-1; +MI0002729 lla-mir-29b; +MI0002730 age-mir-29b; +MI0002731 ppa-mir-29b-1; +MI0002732 ptr-mir-29b-2; +MI0002733 ggo-mir-29b-2; +MI0002734 ppy-mir-29b-2; +MI0002735 sla-mir-29b; +MI0002736 mne-mir-29b; +MI0002737 ppa-mir-29b-2; +MI0002738 age-mir-103; +MI0002739 ggo-mir-103; +MI0002740 ppa-mir-103; +MI0002741 ppy-mir-103;ppy-mir-103-1; +MI0002742 ptr-mir-103;ptr-mir-103-1; +MI0002743 mml-mir-103;mml-mir-103-1; +MI0002744 lla-mir-103; +MI0002745 mne-mir-103; +MI0002746 ppy-mir-105;ppy-mir-105-1; +MI0002747 ggo-mir-105; +MI0002748 ppa-mir-105; +MI0002749 ptr-mir-105; +MI0002750 mml-mir-105;mml-mir-105-1; +MI0002751 sla-mir-105; +MI0002752 lla-mir-105; +MI0002753 mne-mir-105; +MI0002754 mml-mir-107; +MI0002755 ptr-mir-107; +MI0002756 ggo-mir-107; +MI0002757 ppy-mir-107; +MI0002758 lla-mir-107; +MI0002759 mne-mir-107; +MI0002760 ppa-mir-107; +MI0002761 ggo-mir-124a; +MI0002762 age-mir-124a; +MI0002763 ppa-mir-124a; +MI0002764 ppy-mir-124a; +MI0002765 ptr-mir-124a; +MI0002766 mml-mir-124a;mml-mir-124a-1; +MI0002767 lla-mir-124a; +MI0002768 lla-mir-139; +MI0002769 ppa-mir-139; +MI0002770 ptr-mir-147;ptr-mir-147a; +MI0002771 ppy-mir-147;ppy-mir-147a; +MI0002772 sla-mir-147; +MI0002773 mne-mir-147; +MI0002774 ppa-mir-147; +MI0002775 ggo-mir-7-1; +MI0002776 ppy-mir-7-1; +MI0002777 sla-mir-7; +MI0002778 lla-mir-7; +MI0002779 mne-mir-7-1; +MI0002780 ppa-mir-7-1; +MI0002781 ggo-mir-7-2; +MI0002782 ppy-mir-7-2; +MI0002783 mne-mir-7-2; +MI0002784 ppa-mir-7-2; +MI0002785 ptr-mir-7;ptr-mir-7-3; +MI0002786 ggo-mir-7-3; +MI0002787 ppa-mir-7-3; +MI0002788 ggo-mir-10a; +MI0002789 ppy-mir-10a; +MI0002790 sla-mir-10a; +MI0002791 age-mir-10a; +MI0002792 ppa-mir-10a; +MI0002793 ggo-mir-10b; +MI0002794 mne-mir-10b; +MI0002795 ppa-mir-10b; +MI0002796 ggo-mir-34a; +MI0002797 age-mir-34a; +MI0002798 ppa-mir-34a; +MI0002799 ppy-mir-34a; +MI0002800 ptr-mir-34a; +MI0002801 mml-mir-34a; +MI0002802 sla-mir-34a; +MI0002803 lla-mir-34a; +MI0002804 mne-mir-34a; +MI0002805 ggo-mir-181a;ggo-mir-181a-2; +MI0002806 ppa-mir-181a;ppa-mir-181a-2; +MI0002807 ptr-mir-181a;ptr-mir-181a-2; +MI0002808 mml-mir-181a;mml-mir-181a-2; +MI0002809 sla-mir-181a;sla-mir-181a-2; +MI0002810 mne-mir-181a;mne-mir-181a-2; +MI0002811 mml-mir-181c; +MI0002812 ptr-mir-181c; +MI0002813 ggo-mir-181c; +MI0002814 ppa-mir-181c; +MI0002815 mml-mir-182; +MI0002816 ppy-mir-182; +MI0002817 ggo-mir-187; +MI0002818 ppy-mir-187; +MI0002819 mne-mir-187; +MI0002820 ppa-mir-187; +MI0002821 mml-mir-196;mml-mir-196a-1; +MI0002822 ggo-mir-196-1; +MI0002823 ppy-mir-196-1; +MI0002824 ptr-mir-196;ptr-mir-196a-2; +MI0002825 ggo-mir-196-2; +MI0002826 ppy-mir-196-2; +MI0002827 lla-mir-196; +MI0002828 age-mir-196; +MI0002829 ppa-mir-196; +MI0002830 ggo-mir-199a; +MI0002831 ppa-mir-199a; +MI0002832 ppy-mir-199a; +MI0002833 ptr-mir-199a;ptr-mir-199a-2; +MI0002834 mml-mir-199a;mml-mir-199a-1; +MI0002835 sla-mir-199a; +MI0002836 lla-mir-199a; +MI0002837 mne-mir-199a; +MI0002838 ptr-mir-204; +MI0002839 ggo-mir-204; +MI0002840 ppy-mir-204; +MI0002841 sla-mir-204; +MI0002842 mne-mir-204; +MI0002843 ppa-mir-204; +MI0002844 ggo-mir-205; +MI0002845 age-mir-205; +MI0002846 ppa-mir-205; +MI0002847 ptr-mir-205; +MI0002848 lla-mir-205; +MI0002849 mne-mir-205; +MI0002850 mml-mir-211; +MI0002851 ppy-mir-211; +MI0002852 mne-mir-211; +MI0002853 ggo-mir-214; +MI0002854 age-mir-214; +MI0002855 ppa-mir-214; +MI0002856 ppy-mir-214; +MI0002857 ptr-mir-214; +MI0002858 mml-mir-214; +MI0002859 sla-mir-214; +MI0002860 mne-mir-214; +MI0002861 lca-mir-216; +MI0002862 ptr-mir-216;ptr-mir-216a; +MI0002863 ggo-mir-216; +MI0002864 ppy-mir-216;ppy-mir-216a; +MI0002865 ppa-mir-216; +MI0002866 ggo-mir-217; +MI0002867 ppa-mir-217; +MI0002868 ggo-mir-218; +MI0002869 age-mir-218; +MI0002870 ppa-mir-218-1; +MI0002871 lca-mir-218; +MI0002872 ppy-mir-218-1; +MI0002873 ptr-mir-218-1; +MI0002874 sla-mir-218-1; +MI0002875 lla-mir-218-1; +MI0002876 mne-mir-218-1; +MI0002877 ppa-mir-218-2; +MI0002878 ppy-mir-218-2; +MI0002879 ptr-mir-218-2; +MI0002880 mml-mir-218;mml-mir-218-2; +MI0002881 sla-mir-218-2; +MI0002882 lla-mir-218-2; +MI0002883 mne-mir-218-2; +MI0002884 mml-mir-219;mml-mir-219-1; +MI0002885 ggo-mir-219; +MI0002886 ppy-mir-219;ppy-mir-219-1; +MI0002887 mml-mir-220;mml-mir-220a; +MI0002888 ptr-mir-220;ptr-mir-220a; +MI0002889 ggo-mir-220; +MI0002890 mne-mir-220; +MI0002891 ppa-mir-220; +MI0002892 mml-mir-221; +MI0002893 ggo-mir-221; +MI0002894 ppy-mir-221; +MI0002895 ppa-mir-221; +MI0002896 age-mir-222; +MI0002897 mml-mir-223; +MI0002898 ptr-mir-223; +MI0002899 ggo-mir-223; +MI0002900 ppy-mir-223; +MI0002901 sla-mir-223; +MI0002902 ppa-mir-223; +MI0002903 mml-mir-224; +MI0002904 ptr-mir-224; +MI0002905 ggo-mir-224; +MI0002906 ppy-mir-224; +MI0002907 mne-mir-224; +MI0002908 ppa-mir-224; +MI0002909 ptr-mir-197; +MI0002910 ppy-mir-197; +MI0002911 mne-mir-197; +MI0002912 age-mir-197; +MI0002913 ppa-mir-197; +MI0002914 ggo-mir-198; +MI0002915 age-mir-198; +MI0002916 ppa-mir-198; +MI0002917 ppy-mir-198; +MI0002918 ptr-mir-198; +MI0002919 mml-mir-198; +MI0002920 sla-mir-198; +MI0002921 lla-mir-198; +MI0002922 mne-mir-198; +MI0002923 ptr-mir-30c;ptr-mir-30c-2; +MI0002924 lla-mir-30c; +MI0002925 mne-mir-30c; +MI0002926 ptr-mir-30d; +MI0002927 ggo-mir-30d; +MI0002928 mne-mir-30d; +MI0002929 ppa-mir-30d; +MI0002930 ppa-mir-1; +MI0002931 mml-mir-213;mml-mir-181a-1; +MI0002932 mml-mir-181b;mml-mir-181b-1; +MI0002933 ptr-mir-213;ptr-mir-181a-1; +MI0002934 ptr-mir-181b;ptr-mir-181b-1; +MI0002935 ppy-mir-213;ppy-mir-181a-1; +MI0002936 ppy-mir-181b; +MI0002937 ggo-mir-213;ggo-mir-181a-1; +MI0002938 ggo-mir-181b; +MI0002939 lla-mir-213;lla-mir-181a-1; +MI0002940 lla-mir-181b; +MI0002941 mne-mir-213;mne-mir-181a-1; +MI0002942 mne-mir-181b; +MI0002943 ppa-mir-213;ppa-mir-181a-1; +MI0002944 ppa-mir-181b; +MI0002945 age-mir-15a; +MI0002946 age-mir-16; +MI0002947 ggo-mir-15a; +MI0002948 ggo-mir-16; +MI0002949 mne-mir-15a; +MI0002950 mne-mir-16; +MI0002951 sla-mir-15a; +MI0002952 sla-mir-16; +MI0002953 ppa-mir-15a; +MI0002954 ppa-mir-16; +MI0002955 lca-mir-15a; +MI0002956 lca-mir-16; +MI0002957 mml-mir-15a; +MI0002958 mml-mir-16;mml-mir-16-1; +MI0002959 ppy-mir-15a; +MI0002960 ppy-mir-16;ppy-mir-16-1; +MI0002961 ptr-mir-15a; +MI0002962 ptr-mir-16;ptr-mir-16-1; +MI0002963 lla-mir-15a; +MI0002964 lla-mir-16; +MI0002965 ggo-mir-17; +MI0002966 ggo-mir-18;ggo-mir-18a; +MI0002967 ggo-mir-19a; +MI0002968 ggo-mir-20;ggo-mir-20a; +MI0002969 ggo-mir-19b-1; +MI0002970 ggo-mir-92-1; +MI0002971 lca-mir-17; +MI0002972 lca-mir-18; +MI0002973 lca-mir-19a; +MI0002974 lca-mir-20; +MI0002975 lca-mir-19b-1; +MI0002976 lca-mir-92-1; +MI0002977 age-mir-17; +MI0002978 age-mir-18; +MI0002979 age-mir-19a; +MI0002980 age-mir-20; +MI0002981 age-mir-19b-1; +MI0002982 age-mir-92-1; +MI0002983 ppa-mir-17; +MI0002984 ppa-mir-18; +MI0002985 ppa-mir-19a; +MI0002986 ppa-mir-20; +MI0002987 ppa-mir-19b-1; +MI0002988 ppa-mir-92-1;ppa-mir-92a-1; +MI0002989 ppy-mir-17; +MI0002990 ppy-mir-18;ppy-mir-18a; +MI0002991 ppy-mir-19a; +MI0002992 ppy-mir-20;ppy-mir-20a; +MI0002993 ppy-mir-19b-1; +MI0002994 ppy-mir-92-1; +MI0002995 ptr-mir-17; +MI0002996 ptr-mir-18;ptr-mir-18a; +MI0002997 ptr-mir-19a; +MI0002998 ptr-mir-20;ptr-mir-20a; +MI0002999 ptr-mir-19b-1; +MI0003000 ptr-mir-92-1; +MI0003001 mml-mir-17; +MI0003002 mml-mir-18;mml-mir-18a; +MI0003003 mml-mir-19a; +MI0003004 mml-mir-20;mml-mir-20a; +MI0003005 mml-mir-19b-1; +MI0003006 mml-mir-92;mml-mir-92a-1; +MI0003007 sla-mir-17; +MI0003008 sla-mir-18; +MI0003009 sla-mir-19a; +MI0003010 sla-mir-20; +MI0003011 sla-mir-19b-1; +MI0003012 sla-mir-92-1; +MI0003013 lla-mir-17; +MI0003014 lla-mir-18; +MI0003015 lla-mir-19a; +MI0003016 lla-mir-20; +MI0003017 lla-mir-19b-1; +MI0003018 lla-mir-92-1; +MI0003019 mne-mir-17; +MI0003020 mne-mir-18; +MI0003021 mne-mir-19a; +MI0003022 mne-mir-20; +MI0003023 mne-mir-19b-1; +MI0003024 mml-mir-194;mml-mir-194-1; +MI0003025 mml-mir-215; +MI0003026 ptr-mir-194; +MI0003027 ptr-mir-215; +MI0003028 ppy-mir-194; +MI0003029 ppy-mir-215; +MI0003030 ggo-mir-194; +MI0003031 ggo-mir-215; +MI0003032 mne-mir-194; +MI0003033 mne-mir-215; +MI0003034 age-mir-194; +MI0003035 ggo-mir-23a; +MI0003036 ggo-mir-27a; +MI0003037 ggo-mir-24; +MI0003038 age-mir-23a; +MI0003039 age-mir-27a; +MI0003040 ppa-mir-23a; +MI0003041 ppa-mir-27a; +MI0003042 ppa-mir-24-2; +MI0003043 lca-mir-23a; +MI0003044 lca-mir-27a; +MI0003045 ppy-mir-23a; +MI0003046 ppy-mir-27a; +MI0003047 ppy-mir-24-2; +MI0003048 ptr-mir-23a; +MI0003049 ptr-mir-27a; +MI0003050 ptr-mir-24;ptr-mir-24-2; +MI0003051 mml-mir-23a; +MI0003052 mml-mir-27a; +MI0003053 mml-mir-24-2; +MI0003054 sla-mir-23a; +MI0003055 sla-mir-27a; +MI0003056 mne-mir-23a; +MI0003057 mne-mir-27a; +MI0003058 mne-mir-24-2; +MI0003059 ggo-mir-106b; +MI0003060 ggo-mir-93; +MI0003061 ggo-mir-25; +MI0003062 age-mir-106b; +MI0003063 age-mir-93; +MI0003064 ppa-mir-106b; +MI0003065 ppa-mir-93; +MI0003066 ppa-mir-25; +MI0003067 ppy-mir-106b; +MI0003068 ppy-mir-93; +MI0003069 ppy-mir-25; +MI0003070 ptr-mir-106b; +MI0003071 ptr-mir-93; +MI0003072 ptr-mir-25; +MI0003073 mml-mir-106b; +MI0003074 mml-mir-93; +MI0003075 mml-mir-25; +MI0003076 sla-mir-106b; +MI0003077 sla-mir-93; +MI0003078 lla-mir-106b; +MI0003079 lla-mir-93; +MI0003080 lla-mir-25; +MI0003081 mne-mir-106b; +MI0003082 mne-mir-93; +MI0003083 mne-mir-25; +MI0003084 mml-mir-183; +MI0003085 mml-mir-96; +MI0003086 ptr-mir-183; +MI0003087 ptr-mir-96; +MI0003088 ggo-mir-183; +MI0003089 ggo-mir-96; +MI0003090 sla-mir-183; +MI0003091 sla-mir-96; +MI0003092 mne-mir-183; +MI0003093 mne-mir-96; +MI0003094 ppa-mir-183; +MI0003095 ppa-mir-96; +MI0003096 ggo-mir-106a; +MI0003097 ggo-mir-19b-2; +MI0003098 ggo-mir-92-2; +MI0003099 age-mir-106a; +MI0003100 age-mir-19b-2; +MI0003101 age-mir-92-2; +MI0003102 ppa-mir-106a; +MI0003103 ppa-mir-19b-2; +MI0003104 ppa-mir-92-2;ppa-mir-92a-2; +MI0003105 lca-mir-19b-2; +MI0003106 lca-mir-92-2; +MI0003107 mml-mir-106a; +MI0003108 mml-mir-19b-2; +MI0003109 ppy-mir-106a; +MI0003110 ppy-mir-19b-2; +MI0003111 ppy-mir-92-2; +MI0003112 ptr-mir-106a; +MI0003113 ptr-mir-19b-2; +MI0003114 ptr-mir-92-2; +MI0003115 sla-mir-106a; +MI0003116 sla-mir-19b-2; +MI0003117 sla-mir-92-2; +MI0003118 lla-mir-19b-2; +MI0003119 lla-mir-92-2; +MI0003120 mne-mir-106a; +MI0003121 mne-mir-19b-2; +MI0003122 mne-mir-92; +MI0003123 hsa-mir-488; +MI0003124 hsa-mir-489; +MI0003125 hsa-mir-490; +MI0003126 hsa-mir-491; +MI0003127 hsa-mir-511-1;hsa-mir-511; +MI0003128 hsa-mir-511-2; +MI0003129 hsa-mir-146b; +MI0003130 hsa-mir-202; +MI0003131 hsa-mir-492; +MI0003132 hsa-mir-493; +MI0003133 hsa-mir-432; +MI0003134 hsa-mir-494; +MI0003135 hsa-mir-495; +MI0003136 hsa-mir-496; +MI0003137 hsa-mir-193b; +MI0003138 hsa-mir-497; +MI0003139 hsa-mir-181d; +MI0003140 hsa-mir-512-1; +MI0003141 hsa-mir-512-2; +MI0003142 hsa-mir-498; +MI0003143 hsa-mir-520e; +MI0003144 hsa-mir-515-1; +MI0003145 hsa-mir-519e; +MI0003146 hsa-mir-520f; +MI0003147 hsa-mir-515-2; +MI0003148 hsa-mir-519c; +MI0003149 hsa-mir-520a; +MI0003150 hsa-mir-526b; +MI0003151 hsa-mir-519b; +MI0003152 hsa-mir-525; +MI0003153 hsa-mir-523; +MI0003154 hsa-mir-518f; +MI0003155 hsa-mir-520b; +MI0003156 hsa-mir-518b; +MI0003157 hsa-mir-526a-1; +MI0003158 hsa-mir-520c; +MI0003159 hsa-mir-518c; +MI0003160 hsa-mir-524; +MI0003161 hsa-mir-517a; +MI0003162 hsa-mir-519d; +MI0003163 hsa-mir-521-2; +MI0003164 hsa-mir-520d; +MI0003165 hsa-mir-517b; +MI0003166 hsa-mir-520g; +MI0003167 hsa-mir-516-3;hsa-mir-516b-2; +MI0003168 hsa-mir-526a-2; +MI0003169 hsa-mir-518e; +MI0003170 hsa-mir-518a-1; +MI0003171 hsa-mir-518d; +MI0003172 hsa-mir-516-4;hsa-mir-516b-1; +MI0003173 hsa-mir-518a-2; +MI0003174 hsa-mir-517c; +MI0003175 hsa-mir-520h; +MI0003176 hsa-mir-521-1; +MI0003177 hsa-mir-522; +MI0003178 hsa-mir-519a-1; +MI0003179 hsa-mir-527; +MI0003180 hsa-mir-516-1;hsa-mir-516a-1; +MI0003181 hsa-mir-516-2;hsa-mir-516a-2; +MI0003182 hsa-mir-519a-2; +MI0003183 hsa-mir-499;hsa-mir-499a; +MI0003184 hsa-mir-500;hsa-mir-500a; +MI0003185 hsa-mir-501; +MI0003186 hsa-mir-502; +MI0003187 hsa-mir-450-2;hsa-mir-450a-2; +MI0003188 hsa-mir-503; +MI0003189 hsa-mir-504; +MI0003190 hsa-mir-505; +MI0003191 hsa-mir-513-1;hsa-mir-513a-1; +MI0003192 hsa-mir-513-2;hsa-mir-513a-2; +MI0003193 hsa-mir-506; +MI0003194 hsa-mir-507; +MI0003195 hsa-mir-508; +MI0003196 hsa-mir-509;hsa-mir-509-1; +MI0003197 hsa-mir-510; +MI0003198 hsa-mir-514-1;hsa-mir-514a-1; +MI0003199 hsa-mir-514-2;hsa-mir-514a-2; +MI0003200 hsa-mir-514-3;hsa-mir-514a-3; +MI0003201 osa-MIR528; +MI0003202 osa-MIR529;osa-MIR529a; +MI0003203 osa-MIR530; +MI0003204 osa-MIR531;osa-MIR531a; +MI0003205 hsa-mir-532; +MI0003206 mmu-mir-532; +MI0003207 fru-let-7h; +MI0003208 tni-let-7h; +MI0003209 fru-mir-223; +MI0003210 tni-mir-223; +MI0003211 fru-mir-124-3; +MI0003212 tni-mir-124-3; +MI0003213 fru-let-7e; +MI0003214 tni-let-7e; +MI0003215 fru-mir-219-2; +MI0003216 tni-mir-219-2; +MI0003217 fru-mir-101a; +MI0003218 tni-mir-101a; +MI0003219 fru-mir-222; +MI0003220 tni-mir-222; +MI0003221 fru-mir-221; +MI0003222 tni-mir-221; +MI0003223 fru-mir-142a;fru-mir-142; +MI0003224 tni-mir-142a; +MI0003225 fru-mir-9-1; +MI0003226 tni-mir-9-1; +MI0003227 fru-mir-23a-2; +MI0003228 tni-mir-23a-2; +MI0003229 fru-mir-25; +MI0003230 tni-mir-25; +MI0003231 fru-mir-17-1; +MI0003232 tni-mir-17-1; +MI0003233 fru-mir-18; +MI0003234 tni-mir-18; +MI0003235 fru-mir-19a; +MI0003236 tni-mir-19a; +MI0003237 fru-mir-19b; +MI0003238 tni-mir-19b; +MI0003239 fru-mir-92-2; +MI0003240 tni-mir-92-2; +MI0003241 fru-mir-184; +MI0003242 tni-mir-184; +MI0003243 dre-mir-184-2; +MI0003244 fru-let-7a-3; +MI0003245 tni-let-7a-3; +MI0003246 fru-mir-187; +MI0003247 tni-mir-187; +MI0003248 fru-mir-137; +MI0003249 tni-mir-137; +MI0003250 fru-mir-204b; +MI0003251 tni-mir-204b; +MI0003252 fru-mir-458; +MI0003253 tni-mir-458; +MI0003254 fru-mir-489; +MI0003255 tni-mir-489; +MI0003256 dre-mir-489; +MI0003257 fru-mir-192; +MI0003258 tni-mir-192; +MI0003259 fru-mir-194; +MI0003260 tni-mir-194; +MI0003261 fru-mir-142b; +MI0003262 tni-mir-142b; +MI0003263 fru-mir-30b; +MI0003264 tni-mir-30b; +MI0003265 fru-mir-30d; +MI0003266 tni-mir-30d; +MI0003267 fru-mir-27b; +MI0003268 tni-mir-27b; +MI0003269 fru-mir-23b; +MI0003270 tni-mir-23b; +MI0003271 fru-mir-196a-2; +MI0003272 tni-mir-196a-2; +MI0003273 fru-mir-126; +MI0003274 tni-mir-126; +MI0003275 fru-mir-199-3; +MI0003276 tni-mir-199-3; +MI0003277 fru-mir-148; +MI0003278 tni-mir-148; +MI0003279 fru-mir-10b-1; +MI0003280 tni-mir-10b-2; +MI0003281 fru-mir-205; +MI0003282 tni-mir-205; +MI0003283 fru-mir-365; +MI0003284 tni-mir-365; +MI0003285 fru-mir-193; +MI0003286 tni-mir-193; +MI0003287 fru-mir-124-1; +MI0003288 tni-mir-124-1; +MI0003289 fru-mir-217; +MI0003290 tni-mir-217; +MI0003291 fru-mir-216a; +MI0003292 tni-mir-216a; +MI0003293 fru-mir-216b; +MI0003294 tni-mir-216b; +MI0003295 fru-let-7i; +MI0003296 tni-let-7i; +MI0003297 fru-mir-10b-2; +MI0003298 tni-mir-10b-1; +MI0003299 fru-mir-196a-1; +MI0003300 tni-mir-196a-1; +MI0003301 fru-mir-429; +MI0003302 tni-mir-429; +MI0003303 fru-mir-200a; +MI0003304 tni-mir-200a; +MI0003305 fru-mir-200b; +MI0003306 tni-mir-200b; +MI0003307 fru-mir-218b; +MI0003308 tni-mir-218b; +MI0003309 fru-mir-301; +MI0003310 tni-mir-301; +MI0003311 fru-mir-130; +MI0003312 tni-mir-130; +MI0003313 fru-let-7a-2; +MI0003314 tni-let-7a-2; +MI0003315 fru-mir-122; +MI0003316 tni-mir-122; +MI0003317 fru-mir-218a-1; +MI0003318 tni-mir-218a-1; +MI0003319 fru-let-7d; +MI0003320 tni-let-7d; +MI0003321 fru-mir-9-2; +MI0003322 tni-mir-9-2; +MI0003323 fru-mir-460; +MI0003324 tni-mir-460; +MI0003325 fru-mir-21; +MI0003326 tni-mir-21; +MI0003327 fru-mir-153b; +MI0003328 tni-mir-153b; +MI0003329 fru-mir-199-2; +MI0003330 tni-mir-199-2; +MI0003331 fru-mir-181b-1;fru-mir-181b; +MI0003332 tni-mir-181b-1; +MI0003333 fru-mir-213;fru-mir-181a-1; +MI0003334 tni-mir-213;tni-mir-181a-1; +MI0003335 fru-mir-338; +MI0003336 tni-mir-338; +MI0003337 fru-mir-7; +MI0003338 tni-mir-7; +MI0003339 fru-mir-153a; +MI0003340 tni-mir-153a; +MI0003341 fru-let-7j; +MI0003342 tni-let-7j; +MI0003343 dre-let-7j; +MI0003344 fru-let-7b; +MI0003345 tni-let-7b; +MI0003346 fru-mir-128-2; +MI0003347 tni-mir-128-2; +MI0003348 fru-mir-144; +MI0003349 tni-mir-144; +MI0003350 fru-mir-30c; +MI0003351 tni-mir-30c; +MI0003352 fru-mir-140; +MI0003353 tni-mir-140; +MI0003354 fru-mir-124-2; +MI0003355 tni-mir-124-2; +MI0003356 fru-mir-214; +MI0003357 tni-mir-214; +MI0003358 fru-mir-199-1; +MI0003359 tni-mir-199-1; +MI0003360 fru-mir-455; +MI0003361 tni-mir-455; +MI0003362 fru-mir-135b; +MI0003363 tni-mir-135b; +MI0003364 dre-mir-135b; +MI0003365 fru-mir-196b; +MI0003366 tni-mir-196b; +MI0003367 fru-mir-129-1; +MI0003368 tni-mir-129-1; +MI0003369 fru-mir-26; +MI0003370 tni-mir-26; +MI0003371 fru-mir-101b; +MI0003372 tni-mir-101b; +MI0003373 fru-mir-9-4; +MI0003374 tni-mir-9-4; +MI0003375 fru-mir-181b-2; +MI0003376 tni-mir-181b-2; +MI0003377 fru-mir-103; +MI0003378 tni-mir-103; +MI0003379 fru-mir-107; +MI0003380 tni-mir-107; +MI0003381 fru-mir-22b; +MI0003382 tni-mir-22b; +MI0003383 fru-mir-212; +MI0003384 tni-mir-212; +MI0003385 dre-mir-212; +MI0003386 tni-mir-181a;tni-mir-181a-2; +MI0003387 dre-mir-181a;dre-mir-181a-2; +MI0003388 fru-mir-135a; +MI0003389 tni-mir-135a; +MI0003390 fru-mir-218a-2; +MI0003391 tni-mir-218a-2; +MI0003392 fru-mir-29a-1; +MI0003393 tni-mir-29a-1; +MI0003394 dre-mir-29a-3;dre-mir-29a-2; +MI0003395 fru-mir-29b-2; +MI0003396 tni-mir-29b-2; +MI0003397 fru-mir-133; +MI0003398 tni-mir-133; +MI0003399 fru-mir-132; +MI0003400 tni-mir-132; +MI0003401 fru-mir-125b; +MI0003402 tni-mir-125b; +MI0003403 fru-mir-29a-2; +MI0003404 tni-mir-29a-2; +MI0003405 fru-mir-29b-1; +MI0003406 tni-mir-29b-1; +MI0003407 fru-let-7a-1; +MI0003408 tni-let-7a-1; +MI0003409 fru-mir-100; +MI0003410 tni-mir-100; +MI0003411 fru-mir-219-1; +MI0003412 tni-mir-219-1; +MI0003413 fru-mir-24-1; +MI0003414 tni-mir-24-1; +MI0003415 fru-mir-23a-1; +MI0003416 tni-mir-23a-1; +MI0003417 fru-mir-27e; +MI0003418 tni-mir-27e; +MI0003419 fru-mir-375;fru-mir-375-1; +MI0003420 tni-mir-375; +MI0003421 fru-mir-128-1; +MI0003422 tni-mir-128-1; +MI0003423 fru-mir-1; +MI0003424 tni-mir-1; +MI0003425 fru-mir-202; +MI0003426 tni-mir-202; +MI0003427 fru-mir-203; +MI0003428 tni-mir-203; +MI0003429 fru-mir-23a-3; +MI0003430 tni-mir-23a-3; +MI0003431 fru-mir-27c; +MI0003432 tni-mir-27c; +MI0003433 fru-mir-24-2; +MI0003434 tni-mir-24-2; +MI0003435 fru-mir-138; +MI0003436 tni-mir-138; +MI0003437 fru-mir-129-2; +MI0003438 tni-mir-129-2; +MI0003439 fru-mir-125a; +MI0003440 tni-mir-125a; +MI0003441 fru-mir-17-2; +MI0003442 tni-mir-17-2; +MI0003443 fru-mir-20; +MI0003444 tni-mir-20; +MI0003445 fru-mir-92-1; +MI0003446 tni-mir-92-1; +MI0003447 fru-mir-15b; +MI0003448 tni-mir-15b; +MI0003449 fru-mir-10c; +MI0003450 tni-mir-10c; +MI0003451 fru-mir-9-3; +MI0003452 tni-mir-9-3; +MI0003453 fru-mir-183; +MI0003454 tni-mir-183; +MI0003455 fru-mir-96; +MI0003456 tni-mir-96; +MI0003457 fru-mir-182; +MI0003458 tni-mir-182; +MI0003459 fru-mir-210; +MI0003460 tni-mir-210; +MI0003461 fru-let-7g; +MI0003462 tni-let-7g; +MI0003463 fru-mir-22a; +MI0003464 tni-mir-22a; +MI0003465 fru-mir-204a;fru-mir-204;fru-mir-204a; +MI0003466 tni-mir-204a; +MI0003467 fru-mir-152; +MI0003468 tni-mir-152; +MI0003469 fru-mir-15a; +MI0003470 tni-mir-15a; +MI0003471 fru-mir-16; +MI0003472 tni-mir-16; +MI0003473 fru-mir-190; +MI0003474 tni-mir-190; +MI0003475 fru-mir-181a;fru-mir-181a-2; +MI0003476 mmu-mir-489; +MI0003477 rno-mir-489; +MI0003478 rno-mir-383; +MI0003479 rno-mir-207; +MI0003480 rno-mir-501; +MI0003481 rno-mir-361; +MI0003482 rno-mir-215; +MI0003483 rno-mir-224; +MI0003484 mmu-mir-483; +MI0003485 rno-mir-483; +MI0003486 rno-mir-370; +MI0003487 rno-mir-377; +MI0003488 rno-mir-412; +MI0003489 rno-mir-1; +MI0003490 rno-mir-133b; +MI0003491 mmu-mir-484; +MI0003492 mmu-mir-485; +MI0003493 mmu-mir-486;mmu-mir-486a; +MI0003494 ppt-MIR390a; +MI0003495 ppt-MIR390b; +MI0003496 ppt-MIR319a; +MI0003497 ppt-MIR319b; +MI0003498 ppt-MIR319c; +MI0003499 ppt-MIR319d; +MI0003500 ppt-MIR533;ppt-MIR533a; +MI0003501 ppt-MIR534;ppt-MIR534a; +MI0003502 ppt-MIR535a; +MI0003503 ppt-MIR535b; +MI0003504 ppt-MIR535c; +MI0003505 osa-MIR535; +MI0003506 ppt-MIR156a; +MI0003507 ppt-MIR536;ppt-MIR536a; +MI0003508 ppt-MIR537a; +MI0003509 ppt-MIR537b; +MI0003510 ppt-MIR538a; +MI0003511 ppt-MIR538b; +MI0003512 ppt-MIR538c; +MI0003513 hsa-mir-455; +MI0003514 hsa-mir-539; +MI0003515 hsa-mir-544;hsa-mir-544a; +MI0003516 hsa-mir-545; +MI0003517 mmu-mir-546; +MI0003518 mmu-mir-540; +MI0003519 mmu-mir-543; +MI0003520 mmu-mir-539; +MI0003521 mmu-mir-541; +MI0003522 mmu-mir-542; +MI0003523 mmu-mir-547; +MI0003524 rno-mir-540; +MI0003525 rno-mir-543; +MI0003526 rno-mir-539; +MI0003527 rno-mir-541; +MI0003528 rno-mir-542;rno-mir-542-1; +MI0003529 hsa-mir-376a-2; +MI0003530 hsa-mir-487b; +MI0003531 mmu-mir-367; +MI0003532 mmu-mir-494; +MI0003533 mmu-mir-376c; +MI0003534 mmu-mir-487b; +MI0003535 mmu-mir-369; +MI0003536 mmu-mir-20b; +MI0003537 mmu-mir-450-2;mmu-mir-450a-2; +MI0003538 mmu-mir-503; +MI0003539 mmu-mir-291b; +MI0003540 rno-mir-493; +MI0003541 rno-mir-379; +MI0003542 rno-mir-494; +MI0003543 rno-mir-376c; +MI0003544 rno-mir-376b; +MI0003545 rno-mir-376a; +MI0003546 rno-mir-381; +MI0003547 rno-mir-487b; +MI0003548 rno-mir-382; +MI0003549 rno-mir-485; +MI0003550 rno-mir-409;rno-mir-409a; +MI0003551 rno-mir-369; +MI0003552 rno-mir-374; +MI0003553 rno-mir-363; +MI0003554 rno-mir-20b; +MI0003555 rno-mir-503;rno-mir-503-1; +MI0003556 hsa-mir-551a; +MI0003557 hsa-mir-552; +MI0003558 hsa-mir-553; +MI0003559 hsa-mir-554; +MI0003560 hsa-mir-92b; +MI0003561 hsa-mir-555; +MI0003562 hsa-mir-556; +MI0003563 hsa-mir-557; +MI0003564 hsa-mir-558; +MI0003565 hsa-mir-559; +MI0003566 hsa-mir-560; +MI0003567 hsa-mir-561; +MI0003568 hsa-mir-562; +MI0003569 hsa-mir-563; +MI0003570 hsa-mir-564; +MI0003571 hsa-mir-565; +MI0003572 hsa-mir-566; +MI0003573 hsa-mir-567; +MI0003574 hsa-mir-568; +MI0003575 hsa-mir-551b; +MI0003576 hsa-mir-569; +MI0003577 hsa-mir-570; +MI0003578 hsa-mir-571; +MI0003579 hsa-mir-572; +MI0003580 hsa-mir-573; +MI0003581 hsa-mir-574; +MI0003582 hsa-mir-575; +MI0003583 hsa-mir-576; +MI0003584 hsa-mir-577; +MI0003585 hsa-mir-578; +MI0003586 hsa-mir-579; +MI0003587 hsa-mir-580; +MI0003588 hsa-mir-581; +MI0003589 hsa-mir-582; +MI0003590 hsa-mir-583; +MI0003591 hsa-mir-584; +MI0003592 hsa-mir-585; +MI0003593 hsa-mir-548a-1; +MI0003594 hsa-mir-586; +MI0003595 hsa-mir-587; +MI0003596 hsa-mir-548b; +MI0003597 hsa-mir-588; +MI0003598 hsa-mir-548a-2; +MI0003599 hsa-mir-589; +MI0003600 hsa-mir-550-1;hsa-mir-550a-1; +MI0003601 hsa-mir-550-2;hsa-mir-550a-2; +MI0003602 hsa-mir-590; +MI0003603 hsa-mir-591; +MI0003604 hsa-mir-592; +MI0003605 hsa-mir-593; +MI0003606 hsa-mir-594; +MI0003607 hsa-mir-595; +MI0003608 hsa-mir-596; +MI0003609 hsa-mir-597; +MI0003610 hsa-mir-598; +MI0003611 hsa-mir-599; +MI0003612 hsa-mir-548a-3; +MI0003613 hsa-mir-600; +MI0003614 hsa-mir-601; +MI0003615 hsa-mir-602; +MI0003616 hsa-mir-603; +MI0003617 hsa-mir-604; +MI0003618 hsa-mir-605; +MI0003619 hsa-mir-606; +MI0003620 hsa-mir-607; +MI0003621 hsa-mir-608; +MI0003622 hsa-mir-609; +MI0003623 hsa-mir-610; +MI0003624 hsa-mir-611; +MI0003625 hsa-mir-612; +MI0003626 hsa-mir-613; +MI0003627 hsa-mir-614; +MI0003628 hsa-mir-615; +MI0003629 hsa-mir-616; +MI0003630 hsa-mir-548c; +MI0003631 hsa-mir-617; +MI0003632 hsa-mir-618; +MI0003633 hsa-mir-619; +MI0003634 hsa-mir-620; +MI0003635 hsa-mir-621; +MI0003636 hsa-mir-622; +MI0003637 hsa-mir-623; +MI0003638 hsa-mir-624; +MI0003639 hsa-mir-625; +MI0003640 hsa-mir-626; +MI0003641 hsa-mir-627; +MI0003642 hsa-mir-628; +MI0003643 hsa-mir-629; +MI0003644 hsa-mir-630; +MI0003645 hsa-mir-631; +MI0003646 hsa-mir-33b; +MI0003647 hsa-mir-632; +MI0003648 hsa-mir-633; +MI0003649 hsa-mir-634; +MI0003650 hsa-mir-635; +MI0003651 hsa-mir-636; +MI0003652 hsa-mir-637; +MI0003653 hsa-mir-638; +MI0003654 hsa-mir-639; +MI0003655 hsa-mir-640; +MI0003656 hsa-mir-641; +MI0003657 hsa-mir-642;hsa-mir-642a; +MI0003658 hsa-mir-643; +MI0003659 hsa-mir-644;hsa-mir-644a; +MI0003660 hsa-mir-645; +MI0003661 hsa-mir-646; +MI0003662 hsa-mir-647; +MI0003663 hsa-mir-648; +MI0003664 hsa-mir-649; +MI0003665 hsa-mir-650; +MI0003666 hsa-mir-651; +MI0003667 hsa-mir-652; +MI0003668 hsa-mir-548d-1; +MI0003669 hsa-mir-661; +MI0003670 hsa-mir-662; +MI0003671 hsa-mir-548d-2; +MI0003672 hsa-mir-663;hsa-mir-663a; +MI0003673 hsa-mir-449b; +MI0003674 hsa-mir-653; +MI0003675 hsa-mir-411; +MI0003676 hsa-mir-654; +MI0003677 hsa-mir-655; +MI0003678 hsa-mir-656; +MI0003679 hsa-mir-549;hsa-mir-549a; +MI0003681 hsa-mir-657; +MI0003682 hsa-mir-658; +MI0003683 hsa-mir-659; +MI0003684 hsa-mir-660; +MI0003685 hsa-mir-421; +MI0003686 hsa-mir-542; +MI0003687 hcmv-mir-US4; +MI0003688 hcmv-mir-UL70; +MI0003689 sv40-mir-S1; +MI0003690 dre-mir-34b; +MI0003691 dre-mir-31; +MI0003692 dre-mir-135a; +MI0003693 dre-mir-139; +MI0003694 gga-mir-9-1; +MI0003695 gga-mir-146b; +MI0003696 gga-mir-147-1;gga-mir-147; +MI0003697 gga-mir-147-2; +MI0003698 gga-mir-193;gga-mir-193b; +MI0003699 gga-mir-202; +MI0003700 gga-mir-302b; +MI0003701 gga-mir-302c; +MI0003702 gga-mir-302d; +MI0003703 gga-mir-365-1; +MI0003704 gga-mir-365-2; +MI0003705 gga-mir-375; +MI0003706 gga-mir-383; +MI0003707 gga-mir-455; +MI0003708 gga-mir-489; +MI0003709 gga-mir-490; +MI0003710 gga-mir-499; +MI0003711 gga-mir-211; +MI0003712 gga-mir-367; +MI0003713 gga-mir-466; +MI0003714 gga-mir-429; +MI0003715 gga-mir-449;gga-mir-449a; +MI0003716 mmu-mir-302b; +MI0003717 mmu-mir-302c; +MI0003718 mmu-mir-302d; +MI0003719 rno-mir-378;rno-mir-378a; +MI0003720 rno-mir-505; +MI0003721 rno-mir-499; +MI0003722 rno-mir-664-1; +MI0003723 rno-mir-664-2; +MI0003724 rno-mir-497; +MI0003725 ebv-mir-BART3; +MI0003726 ebv-mir-BART4; +MI0003727 ebv-mir-BART5; +MI0003728 ebv-mir-BART6; +MI0003729 ebv-mir-BART7; +MI0003730 ebv-mir-BART8; +MI0003731 ebv-mir-BART9; +MI0003732 ebv-mir-BART10; +MI0003733 ebv-mir-BART11; +MI0003734 ebv-mir-BART12; +MI0003735 ebv-mir-BART13; +MI0003736 ebv-mir-BART14; +MI0003737 rlcv-mir-rL1-1; +MI0003738 rlcv-mir-rL1-2; +MI0003739 rlcv-mir-rL1-3; +MI0003740 rlcv-mir-rL1-4; +MI0003741 rlcv-mir-rL1-5; +MI0003742 rlcv-mir-rL1-6; +MI0003743 rlcv-mir-rL1-7; +MI0003744 rlcv-mir-rL1-8; +MI0003745 rlcv-mir-rL1-9; +MI0003746 rlcv-mir-rL1-10; +MI0003747 rlcv-mir-rL1-11; +MI0003748 rlcv-mir-rL1-12; +MI0003749 rlcv-mir-rL1-13; +MI0003750 rlcv-mir-rL1-14;rlcv-mir-rL1-14-1; +MI0003751 rlcv-mir-rL1-15; +MI0003752 rlcv-mir-rL1-16; +MI0003757 hsa-mir-758; +MI0003758 hsa-mir-1264; +MI0003760 hsa-mir-671; +MI0003761 hsa-mir-668; +MI0003762 hsa-mir-550a-3; +MI0003763 hsa-mir-767; +MI0003764 hsa-mir-1224; +MI0003772 hsa-mir-151b; +MI0003776 hsa-mir-320b-1; +MI0003778 hsa-mir-320c-1; +MI0003780 hsa-mir-1296; +MI0003782 hsa-mir-1468; +MI0003786 hsa-mir-1323; +MI0003814 hsa-mir-1271; +MI0003815 hsa-mir-1301; +MI0003820 hsa-mir-454; +MI0003821 hsa-mir-1185-2; +MI0003823 hsa-mir-449c; +MI0003832 hsa-mir-1283-1; +MI0003833 hsa-mir-675b; +MI0003834 hsa-mir-769; +MI0003836 hsa-mir-766; +MI0003839 hsa-mir-320b-2; +MI0003840 hsa-mir-378d-2; +MI0003844 hsa-mir-1185-1; +MI0003892 hsa-mir-762; +MI0003906 hsa-mir-802; +MI0003933 hsa-mir-670; +MI0003938 hsa-mir-1298; +MI0003939 hsa-mir-2113; +MI0003941 hsa-mir-761; +MI0003944 hsa-mir-764; +MI0004065 hsa-mir-759; +MI0004118 mmu-mir-1224; +MI0004120 mmu-mir-1247; +MI0004122 mmu-mir-301b; +MI0004123 mmu-mir-675; +MI0004124 mmu-mir-744; +MI0004125 mmu-mir-374;mmu-mir-374b; +MI0004126 mmu-mir-216b; +MI0004127 mmu-mir-592; +MI0004129 mmu-mir-758; +MI0004130 mmu-mir-1264; +MI0004131 mmu-mir-551b; +MI0004132 mmu-mir-1249; +MI0004133 mmu-mir-671; +MI0004134 mmu-mir-668; +MI0004155 mmu-mir-1843;mmu-mir-1843a; +MI0004171 mmu-mir-665; +MI0004196 mmu-mir-667; +MI0004203 mmu-mir-770; +MI0004215 mmu-mir-762; +MI0004220 mmu-mir-3475; +MI0004227 mmu-mir-344d-3; +MI0004249 mmu-mir-802; +MI0004258 mmu-mir-672; +MI0004295 mmu-mir-670; +MI0004300 mmu-mir-1298; +MI0004306 mmu-mir-761; +MI0004310 mmu-mir-764; +MI0004412 mmu-mir-3059; +MI0004418 mmu-mir-3058; +MI0004485 mmu-mir-3099; +MI0004486 mmu-mir-3106; +MI0004516 mmu-mir-763; +MI0004523 mmu-mir-669a-1; +MI0004524 mmu-mir-344d-1; +MI0004553 mmu-mir-666; +MI0004554 mmu-mir-759; +MI0004589 mmu-mir-496;mmu-mir-496a; +MI0004601 mmu-mir-673; +MI0004605 mmu-mir-760; +MI0004611 mmu-mir-674; +MI0004619 mmu-mir-344d-2; +MI0004633 mmu-mir-488; +MI0004634 mmu-mir-677; +MI0004635 mmu-mir-678; +MI0004636 mmu-mir-497;mmu-mir-497a; +MI0004637 mmu-mir-423; +MI0004638 mmu-mir-679; +MI0004639 mmu-mir-495; +MI0004640 mmu-mir-680-1; +MI0004641 mmu-mir-680-2; +MI0004642 mmu-mir-680-3; +MI0004643 mmu-mir-681; +MI0004644 mmu-mir-682; +MI0004645 mmu-mir-449b;mmu-mir-449c; +MI0004646 mmu-mir-683;mmu-mir-683-1; +MI0004647 mmu-mir-684-1; +MI0004648 mmu-mir-684-2; +MI0004649 mmu-mir-685; +MI0004650 mmu-mir-686; +MI0004651 mmu-mir-719; +MI0004652 mmu-mir-687; +MI0004653 mmu-mir-688; +MI0004654 mmu-mir-689-1; +MI0004655 mmu-mir-689-2; +MI0004658 mmu-mir-690; +MI0004659 mmu-mir-691; +MI0004660 mmu-mir-692-1; +MI0004661 mmu-mir-692-2; +MI0004662 mmu-mir-693; +MI0004664 mmu-mir-694; +MI0004665 mmu-mir-146b; +MI0004666 mmu-mir-669b; +MI0004667 mmu-mir-669a-2; +MI0004668 mmu-mir-669a-3; +MI0004671 mmu-mir-467b; +MI0004673 mmu-mir-669c; +MI0004674 mmu-mir-297b; +MI0004675 mmu-mir-695; +MI0004676 mmu-mir-499; +MI0004677 mmu-mir-696; +MI0004678 mmu-mir-720; +MI0004679 mmu-mir-455; +MI0004680 mmu-mir-491; +MI0004681 mmu-mir-697; +MI0004682 mmu-mir-698; +MI0004683 mmu-mir-699; +MI0004684 mmu-mir-700; +MI0004685 mmu-mir-701; +MI0004686 mmu-mir-702; +MI0004687 mmu-mir-703; +MI0004688 mmu-mir-704; +MI0004689 mmu-mir-705; +MI0004690 mmu-mir-706; +MI0004691 mmu-mir-707; +MI0004692 mmu-mir-708; +MI0004693 mmu-mir-709; +MI0004694 mmu-mir-710; +MI0004695 mmu-mir-711; +MI0004696 mmu-mir-712; +MI0004698 mmu-mir-713; +MI0004699 mmu-mir-714; +MI0004700 mmu-mir-715; +MI0004702 mmu-mir-500; +MI0004703 mmu-mir-501; +MI0004704 mmu-mir-717; +MI0004705 mmu-mir-450b; +MI0004706 mmu-mir-505; +MI0004707 mmu-mir-718; +MI0004708 mmu-mir-721; +MI0004709 ppt-MIR1210; +MI0004710 ppt-MIR1211; +MI0004711 ppt-MIR1212; +MI0004712 ppt-MIR1213; +MI0004713 ppt-MIR1214; +MI0004714 ppt-MIR1215; +MI0004715 ppt-MIR1216; +MI0004716 ppt-MIR1217; +MI0004717 ppt-MIR1218; +MI0004718 ppt-MIR1219a; +MI0004719 ppt-MIR1219b; +MI0004720 ppt-MIR1219c; +MI0004721 ppt-MIR1219d; +MI0004722 ppt-MIR1220a; +MI0004723 ppt-MIR1220b; +MI0004724 ppt-MIR533b; +MI0004725 ppt-MIR535d; +MI0004726 ppt-MIR1221; +MI0004727 ppt-MIR1222;ppt-MIR1222a; +MI0004728 ppt-MIR1223;ppt-MIR1223a; +MI0004729 ppt-MIR390c; +MI0004730 hsv1-mir-H1; +MI0004731 bta-mir-26a;bta-mir-26a-2; +MI0004732 bta-mir-18b; +MI0004733 bta-mir-29a; +MI0004734 bta-let-7f;bta-let-7f-2; +MI0004735 bta-mir-101;bta-mir-101-2; +MI0004736 bta-mir-103;bta-mir-103-1; +MI0004737 bta-mir-148a; +MI0004738 bta-mir-151; +MI0004739 bta-mir-16;bta-mir-16b; +MI0004740 bta-mir-18a; +MI0004741 bta-mir-20a; +MI0004742 bta-mir-21; +MI0004743 bta-mir-221; +MI0004744 bta-mir-222; +MI0004745 bta-mir-26b; +MI0004746 bta-mir-27a; +MI0004747 bta-mir-30d; +MI0004748 bta-mir-320;bta-mir-320a-2; +MI0004749 bta-mir-484; +MI0004750 bta-mir-499; +MI0004751 bta-mir-99a; +MI0004752 bta-mir-125a; +MI0004753 bta-mir-125b;bta-mir-125b-1; +MI0004754 bta-mir-126; +MI0004755 bta-mir-128a;bta-mir-128;bta-mir-128-1; +MI0004756 bta-mir-145; +MI0004757 bta-mir-181a-2;bta-mir-181a;bta-mir-181a-2; +MI0004758 bta-mir-199a;bta-mir-199a-1; +MI0004759 bta-mir-205; +MI0004760 bta-mir-27b; +MI0004761 bta-mir-30b; +MI0004762 bta-mir-31; +MI0004763 bta-mir-34b; +MI0004764 dre-mir-190b; +MI0004765 dre-mir-722; +MI0004766 dre-mir-499; +MI0004767 dre-mir-723; +MI0004768 dre-mir-724; +MI0004769 dre-mir-725;dre-mir-725-1;dre-mir-725; +MI0004770 dre-mir-726; +MI0004771 dre-mir-727; +MI0004772 dre-mir-728; +MI0004773 dre-mir-729; +MI0004774 dre-mir-34c; +MI0004775 dre-mir-730; +MI0004776 dre-mir-731; +MI0004777 dre-mir-732; +MI0004778 dre-mir-733; +MI0004779 dre-mir-15c; +MI0004780 dre-mir-734; +MI0004781 dre-mir-735; +MI0004782 dre-mir-736; +MI0004783 dre-mir-737; +MI0004784 dre-mir-738; +MI0004785 dre-mir-739; +MI0004786 dre-mir-740; +MI0004787 xtr-let-7b; +MI0004788 xtr-mir-1a-2; +MI0004789 xtr-mir-1a-1; +MI0004790 xtr-mir-7-1; +MI0004791 xtr-mir-7-3; +MI0004792 xtr-mir-7-2; +MI0004793 xtr-mir-9a-1; +MI0004794 xtr-mir-9a-2; +MI0004795 xtr-mir-9b; +MI0004796 xtr-mir-10a; +MI0004797 xtr-mir-10b; +MI0004798 xtr-mir-10c; +MI0004799 xtr-mir-15a; +MI0004800 xtr-mir-15b; +MI0004801 xtr-mir-16c; +MI0004802 xtr-mir-16a; +MI0004803 xtr-mir-17; +MI0004804 xtr-mir-19a; +MI0004805 xtr-mir-19b-2; +MI0004806 xtr-mir-23a-2; +MI0004807 xtr-mir-26-1; +MI0004808 xtr-mir-26-2; +MI0004809 xtr-mir-27a; +MI0004810 xtr-mir-27b; +MI0004811 xtr-mir-29d; +MI0004812 xtr-mir-29b; +MI0004813 xtr-mir-30a; +MI0004814 xtr-mir-30b; +MI0004815 xtr-mir-30c-1; +MI0004816 xtr-mir-34a; +MI0004817 xtr-mir-34b-2; +MI0004818 xtr-mir-34b-4; +MI0004819 xtr-mir-92a-2; +MI0004820 xtr-mir-98; +MI0004821 xtr-mir-99; +MI0004822 xtr-mir-106; +MI0004823 xtr-mir-107; +MI0004824 xtr-mir-122; +MI0004825 xtr-mir-125b-1; +MI0004826 xtr-mir-125b-2; +MI0004827 xtr-mir-126; +MI0004828 xtr-mir-128-2; +MI0004829 xtr-mir-129-1; +MI0004830 xtr-mir-129-2; +MI0004831 xtr-mir-130a; +MI0004832 xtr-mir-130c; +MI0004833 xtr-mir-130b; +MI0004834 xtr-mir-132; +MI0004835 xtr-mir-133c; +MI0004836 xtr-mir-133d; +MI0004837 xtr-mir-133b; +MI0004838 xtr-mir-135-1; +MI0004839 xtr-mir-138; +MI0004840 xtr-mir-139; +MI0004841 xtr-mir-140; +MI0004842 xtr-mir-142-1; +MI0004843 xtr-mir-142-2; +MI0004844 xtr-mir-146;xtr-mir-146a; +MI0004845 xtr-mir-148b; +MI0004846 xtr-mir-150; +MI0004847 xtr-mir-153-1; +MI0004848 xtr-mir-155; +MI0004849 xtr-mir-181b-1; +MI0004850 xtr-mir-181b-2; +MI0004851 xtr-mir-182; +MI0004852 xtr-mir-183; +MI0004853 xtr-mir-184; +MI0004854 xtr-mir-187; +MI0004855 xtr-mir-192; +MI0004856 xtr-mir-193; +MI0004857 xtr-mir-194-1; +MI0004858 xtr-mir-194-2; +MI0004859 xtr-mir-199a; +MI0004860 xtr-mir-202-1; +MI0004861 xtr-mir-202-2; +MI0004862 xtr-mir-205b; +MI0004863 xtr-mir-206; +MI0004864 xtr-mir-210; +MI0004865 xtr-mir-181a-1; +MI0004866 xtr-mir-181a-2; +MI0004867 xtr-mir-214; +MI0004868 xtr-mir-215; +MI0004869 xtr-mir-216; +MI0004870 xtr-mir-217; +MI0004871 xtr-mir-218-1; +MI0004872 xtr-mir-218-2; +MI0004873 xtr-mir-219; +MI0004874 xtr-mir-222; +MI0004875 xtr-mir-223; +MI0004876 xtr-mir-301-1; +MI0004877 xtr-mir-301-2; +MI0004878 xtr-mir-302; +MI0004879 xtr-mir-365-1; +MI0004880 xtr-mir-367; +MI0004881 xtr-mir-383; +MI0004882 xtr-mir-425; +MI0004883 xtr-mir-455; +MI0004884 xtr-mir-489; +MI0004885 xtr-mir-499; +MI0004886 xtr-let-7c; +MI0004887 xtr-let-7f; +MI0004888 xtr-let-7g; +MI0004889 xtr-let-7i; +MI0004890 xtr-mir-1b; +MI0004891 xtr-mir-9-3; +MI0004892 xtr-mir-15c; +MI0004893 xtr-mir-18a; +MI0004894 xtr-mir-23a-1; +MI0004895 xtr-mir-24a; +MI0004896 xtr-mir-24b; +MI0004897 xtr-mir-29a; +MI0004898 xtr-mir-30d; +MI0004899 xtr-mir-92b; +MI0004900 xtr-mir-93a; +MI0004901 xtr-mir-93b; +MI0004902 xtr-mir-96; +MI0004903 xtr-mir-101a-2; +MI0004904 xtr-mir-103-1; +MI0004905 xtr-mir-148a; +MI0004906 xtr-mir-338-1; +MI0004907 xtr-let-7e-1; +MI0004908 xtr-let-7a; +MI0004909 xtr-let-7e-2; +MI0004910 xtr-mir-16b; +MI0004911 xtr-mir-20a; +MI0004912 xtr-mir-22; +MI0004913 xtr-mir-23b; +MI0004914 xtr-mir-25-1; +MI0004915 xtr-mir-25-2; +MI0004916 xtr-mir-27c-1; +MI0004917 xtr-mir-27c-2; +MI0004918 xtr-mir-29c; +MI0004919 xtr-mir-30c-2; +MI0004920 xtr-mir-30e; +MI0004921 xtr-mir-31;xtr-mir-31a; +MI0004922 xtr-mir-33a; +MI0004923 xtr-mir-33b; +MI0004924 xtr-mir-34b-3; +MI0004925 xtr-mir-34b-1; +MI0004926 xtr-mir-92a-1; +MI0004927 xtr-mir-100; +MI0004928 xtr-mir-101a-1; +MI0004929 xtr-mir-103-2; +MI0004930 xtr-mir-124; +MI0004931 xtr-mir-125a; +MI0004932 xtr-mir-128-1; +MI0004933 xtr-mir-135-2; +MI0004934 xtr-mir-137-1; +MI0004935 xtr-mir-137-2; +MI0004936 xtr-mir-137-3; +MI0004937 xtr-mir-143; +MI0004938 xtr-mir-144; +MI0004939 xtr-mir-145; +MI0004940 xtr-mir-153-2; +MI0004941 xtr-mir-191; +MI0004942 xtr-mir-196a; +MI0004943 xtr-mir-196b; +MI0004944 xtr-mir-199b; +MI0004945 xtr-mir-200a; +MI0004946 xtr-mir-200b; +MI0004947 xtr-mir-203; +MI0004948 xtr-mir-204-2; +MI0004949 xtr-mir-204-1; +MI0004950 xtr-mir-205a; +MI0004951 xtr-mir-208; +MI0004952 xtr-mir-212; +MI0004953 xtr-mir-221; +MI0004954 xtr-mir-338-2; +MI0004955 xtr-mir-363; +MI0004956 xtr-mir-429; +MI0004957 xtr-mir-449;xtr-mir-449a; +MI0004958 xtr-mir-451; +MI0004959 xtr-mir-18b; +MI0004960 xtr-mir-19b-1; +MI0004961 xtr-mir-20b; +MI0004962 xtr-mir-133a; +MI0004963 xtr-mir-428;xtr-mir-428a; +MI0004965 mmu-mir-652; +MI0004966 tni-mir-10d; +MI0004967 fru-mir-10d; +MI0004968 bmo-let-7; +MI0004969 bmo-mir-1;bmo-mir-1a; +MI0004970 bmo-mir-7; +MI0004971 bmo-mir-8; +MI0004972 bmo-mir-9;bmo-mir-9a; +MI0004973 bmo-mir-10; +MI0004974 bmo-mir-14; +MI0004975 bmo-mir-34; +MI0004976 bmo-mir-124; +MI0004977 bmo-mir-263b; +MI0004978 bmo-mir-263a; +MI0004979 bmo-mir-275; +MI0004980 bmo-mir-276; +MI0004981 bmo-mir-277; +MI0004982 bmo-mir-279;bmo-mir-279a; +MI0004983 bmo-mir-282; +MI0004984 bmo-mir-283; +MI0004985 bmo-mir-305; +MI0004986 bmo-mir-307; +MI0004987 kshv-mir-K12-12; +MI0004988 ebv-mir-BART15; +MI0004989 ebv-mir-BART16; +MI0004990 ebv-mir-BART17; +MI0004991 ebv-mir-BART18; +MI0004992 ebv-mir-BART19; +MI0004993 ebv-mir-BART20; +MI0004994 gga-mir-21; +MI0004995 gga-mir-451; +MI0004996 gga-mir-144; +MI0004997 gga-mir-456; +MI0004998 gga-mir-460;gga-mir-460a; +MI0004999 gga-mir-757-1;gga-mir-757; +MI0005000 gga-mir-757-2; +MI0005001 gga-mir-757-3; +MI0005002 mmu-mir-490; +MI0005003 mmu-mir-676; +MI0005004 mmu-mir-615; +MI0005005 bta-mir-106;bta-mir-106a; +MI0005006 bta-mir-107; +MI0005007 bta-mir-10a; +MI0005008 bta-mir-127; +MI0005009 bta-mir-139; +MI0005010 bta-mir-140; +MI0005011 bta-mir-142; +MI0005012 bta-mir-15b; +MI0005013 bta-mir-181b;bta-mir-181b-2; +MI0005014 bta-mir-193a; +MI0005015 bta-mir-20b; +MI0005016 bta-mir-215; +MI0005017 bta-mir-218;bta-mir-218-2; +MI0005018 bta-mir-30e; +MI0005019 bta-mir-345; +MI0005020 bta-mir-369; +MI0005021 bta-mir-380; +MI0005022 bta-mir-487a; +MI0005023 bta-mir-545; +MI0005024 bta-mir-92;bta-mir-92a-2; +MI0005025 bta-mir-98; +MI0005026 bta-let-7d; +MI0005027 bta-mir-124a;bta-mir-124a-1; +MI0005028 bta-mir-132; +MI0005029 bta-mir-138;bta-mir-138-2; +MI0005030 bta-mir-148b; +MI0005031 bta-mir-17; +MI0005032 bta-mir-181c; +MI0005033 bta-mir-186; +MI0005034 bta-mir-191; +MI0005035 bta-mir-192; +MI0005036 bta-mir-199b; +MI0005037 bta-mir-200a; +MI0005038 bta-mir-200c; +MI0005039 bta-mir-210; +MI0005040 bta-mir-214; +MI0005041 bta-mir-22; +MI0005042 bta-mir-23a; +MI0005043 bta-mir-29b;bta-mir-29b-2; +MI0005044 bta-mir-29c; +MI0005045 bta-mir-361; +MI0005046 bta-mir-423; +MI0005047 bta-mir-425; +MI0005048 bta-mir-450;bta-mir-450a-2; +MI0005049 bta-mir-455; +MI0005050 bta-mir-93; +MI0005051 bta-let-7g; +MI0005052 bta-mir-10b; +MI0005053 bta-mir-24;bta-mir-24-2; +MI0005054 bta-mir-30a; +MI0005055 bta-mir-200b; +MI0005056 bta-mir-7;bta-mir-7-3; +MI0005057 bta-let-7a;bta-let-7a-1; +MI0005058 bta-mir-150; +MI0005059 bta-mir-342; +MI0005060 bta-mir-487b; +MI0005061 bta-mir-532; +MI0005062 bta-let-7f-1; +MI0005063 bta-mir-122a;bta-mir-122; +MI0005064 bta-mir-30c; +MI0005065 bta-let-7i; +MI0005066 bta-mir-23b; +MI0005067 bta-mir-25; +MI0005068 bta-mir-34c; +MI0005069 bta-mir-363; +MI0005070 mtr-MIR395c; +MI0005071 mtr-MIR395d; +MI0005072 mtr-MIR395e; +MI0005073 mtr-MIR395f; +MI0005074 mtr-MIR395g; +MI0005075 mtr-MIR395h; +MI0005076 mtr-MIR395i; +MI0005077 mtr-MIR395j; +MI0005078 mtr-MIR395k; +MI0005079 mtr-MIR395l; +MI0005080 mtr-MIR395m; +MI0005081 mtr-MIR395n; +MI0005082 mtr-MIR395o; +MI0005083 mtr-MIR395p;mtr-MIR395k; +MI0005084 osa-MIR395m; +MI0005085 osa-MIR395n; +MI0005086 osa-MIR395o; +MI0005087 osa-MIR395p; +MI0005088 osa-MIR395q; +MI0005090 osa-MIR395v; +MI0005091 osa-MIR395w; +MI0005092 osa-MIR395r; +MI0005093 mdv-mir-M1;mdv1-mir-M1; +MI0005094 mdv-mir-M2;mdv1-mir-M2; +MI0005095 mdv-mir-M3;mdv1-mir-M3; +MI0005096 mdv-mir-M4;mdv1-mir-M4; +MI0005097 mdv-mir-M5;mdv1-mir-M5; +MI0005098 mdv-mir-M6;mdv1-mir-M6; +MI0005099 mdv-mir-M7;mdv1-mir-M7; +MI0005100 mdv-mir-M8;mdv1-mir-M8; +MI0005101 ath-MIR771; +MI0005102 ath-MIR772;ath-MIR472; +MI0005103 ath-MIR773;ath-MIR773a; +MI0005104 ath-MIR774;ath-MIR774a; +MI0005105 ath-MIR775; +MI0005106 ath-MIR776; +MI0005107 ath-MIR777; +MI0005108 ath-MIR778; +MI0005109 ath-MIR779; +MI0005110 ath-MIR780; +MI0005111 ath-MIR781;ath-MIR781a; +MI0005112 ath-MIR782; +MI0005113 ath-MIR783; +MI0005114 ptc-MIR171k; +MI0005115 ptc-MIR403c; +MI0005116 hsa-mir-765; +MI0005117 hsa-mir-768; +MI0005118 hsa-mir-770; +MI0005119 sme-bantam-a; +MI0005120 sme-bantam-b; +MI0005121 sme-bantam-c;sme-bantam-c-1; +MI0005122 sme-let-7a; +MI0005123 sme-let-7b; +MI0005124 sme-let-7c; +MI0005125 sme-lin-4; +MI0005128 sme-mir-1a; +MI0005129 sme-mir-1b; +MI0005130 sme-mir-1c; +MI0005131 sme-mir-2a-1; +MI0005132 sme-mir-2a-2; +MI0005133 sme-mir-2b; +MI0005134 sme-mir-2c; +MI0005135 sme-mir-2d; +MI0005136 sme-mir-7a; +MI0005137 sme-mir-7b; +MI0005138 sme-mir-7c; +MI0005139 sme-mir-8;sme-mir-8a; +MI0005140 sme-mir-10;sme-mir-10b; +MI0005141 sme-mir-12; +MI0005142 sme-mir-13; +MI0005143 sme-mir-745; +MI0005144 sme-mir-746; +MI0005145 sme-mir-31a; +MI0005146 sme-mir-31b;sme-mir-31b-1; +MI0005147 sme-mir-36;sme-mir-36a; +MI0005148 sme-mir-61;sme-mir-61a; +MI0005149 sme-mir-71a-1; +MI0005150 sme-mir-71a-2; +MI0005151 sme-mir-71b; +MI0005152 sme-mir-71c; +MI0005153 sme-mir-79; +MI0005154 sme-mir-87a; +MI0005155 sme-mir-87b; +MI0005156 sme-mir-92; +MI0005157 sme-mir-124a; +MI0005158 sme-mir-124b; +MI0005159 sme-mir-124c;sme-mir-124c-1; +MI0005160 sme-mir-125a; +MI0005161 sme-mir-125b; +MI0005162 sme-mir-133;sme-mir-133b; +MI0005163 sme-mir-184; +MI0005164 sme-mir-190a; +MI0005165 sme-mir-190b; +MI0005166 sme-mir-747; +MI0005167 sme-mir-219; +MI0005168 sme-mir-277a; +MI0005169 sme-mir-277b; +MI0005170 sme-mir-277c; +MI0005171 sme-mir-278; +MI0005172 sme-mir-281; +MI0005173 sme-mir-67; +MI0005174 sme-mir-748; +MI0005175 sme-mir-749; +MI0005176 sme-mir-750; +MI0005177 sme-mir-751; +MI0005178 sme-mir-752; +MI0005179 sme-mir-753;sme-mir-753a; +MI0005180 sme-mir-754;sme-mir-754a; +MI0005181 sme-mir-755; +MI0005182 sme-mir-756; +MI0005183 sme-mir-277d; +MI0005184 cel-mir-784; +MI0005185 cel-mir-785; +MI0005186 cel-mir-786; +MI0005187 cel-mir-787; +MI0005188 cel-mir-788; +MI0005189 cel-mir-789-1; +MI0005190 cel-mir-789-2; +MI0005191 cel-mir-790; +MI0005192 cel-mir-791; +MI0005193 cel-mir-792; +MI0005194 cel-mir-793; +MI0005195 cel-mir-794; +MI0005196 cel-mir-795; +MI0005197 cel-mir-796; +MI0005198 cel-mir-797; +MI0005199 cel-mir-798; +MI0005200 cel-mir-799; +MI0005201 cel-mir-800; +MI0005202 hsa-mir-801; +MI0005203 mmu-mir-804; +MI0005204 mmu-mir-805; +MI0005205 mmu-mir-741; +MI0005206 mmu-mir-742; +MI0005207 mmu-mir-743;mmu-mir-743a; +MI0005209 osa-MIR807a; +MI0005210 osa-MIR806a; +MI0005211 osa-MIR806b; +MI0005212 osa-MIR806c; +MI0005213 osa-MIR806d; +MI0005214 osa-MIR806e; +MI0005215 osa-MIR806f; +MI0005216 osa-MIR806g; +MI0005217 osa-MIR806h; +MI0005218 osa-MIR807b; +MI0005219 osa-MIR807c; +MI0005220 osa-MIR808; +MI0005221 osa-MIR809a; +MI0005222 osa-MIR809b; +MI0005223 osa-MIR809c; +MI0005224 osa-MIR809d; +MI0005225 osa-MIR809e; +MI0005226 osa-MIR809f; +MI0005227 osa-MIR809g; +MI0005228 osa-MIR809h; +MI0005229 osa-MIR810;osa-MIR810a; +MI0005230 osa-MIR811a; +MI0005231 osa-MIR811b; +MI0005232 osa-MIR811c; +MI0005233 osa-MIR812a; +MI0005234 osa-MIR812b; +MI0005235 osa-MIR812c; +MI0005236 osa-MIR812d; +MI0005237 osa-MIR812e; +MI0005238 osa-MIR813; +MI0005239 osa-MIR814a; +MI0005240 osa-MIR814b; +MI0005241 osa-MIR814c; +MI0005242 osa-MIR815a; +MI0005243 osa-MIR815b; +MI0005244 osa-MIR815c; +MI0005245 osa-MIR816; +MI0005246 osa-MIR817; +MI0005247 osa-MIR818a; +MI0005248 osa-MIR818b; +MI0005249 osa-MIR818c; +MI0005250 osa-MIR818d; +MI0005251 osa-MIR818e; +MI0005252 osa-MIR819a; +MI0005253 osa-MIR819b; +MI0005254 osa-MIR819c; +MI0005255 osa-MIR819d; +MI0005256 osa-MIR819e; +MI0005257 osa-MIR819f; +MI0005258 osa-MIR819g; +MI0005259 osa-MIR819h; +MI0005260 osa-MIR819i; +MI0005261 osa-MIR819j; +MI0005262 osa-MIR819k; +MI0005263 osa-MIR820a; +MI0005264 osa-MIR820b; +MI0005265 osa-MIR820c; +MI0005266 osa-MIR821a; +MI0005267 osa-MIR821b; +MI0005268 osa-MIR821c; +MI0005269 mdo-mir-1;mdo-mir-1-1; +MI0005270 mdo-mir-7; +MI0005271 mdo-mir-9-2;mdo-mir-9a-2; +MI0005272 mdo-mir-9-1;mdo-mir-9a-1; +MI0005273 mdo-mir-10a; +MI0005274 mdo-mir-10b; +MI0005275 mdo-mir-21; +MI0005276 mdo-mir-22; +MI0005277 mdo-mir-30a; +MI0005278 mdo-mir-31; +MI0005279 mdo-mir-32; +MI0005280 mdo-mir-34a; +MI0005281 mdo-mir-100; +MI0005282 mdo-mir-101-2; +MI0005283 mdo-mir-101-1; +MI0005284 mdo-mir-103-1; +MI0005285 mdo-mir-103-2; +MI0005286 mdo-mir-107; +MI0005287 mdo-mir-122a;mdo-mir-122; +MI0005288 mdo-mir-124a-1; +MI0005289 mdo-mir-124a-2; +MI0005290 mdo-mir-124a-3; +MI0005291 mdo-mir-125b-1; +MI0005292 mdo-mir-125b-2; +MI0005293 mdo-mir-128b;mdo-mir-128;mdo-mir-128a; +MI0005294 mdo-mir-129; +MI0005295 mdo-mir-130a; +MI0005296 mdo-mir-133a;mdo-mir-133a-1; +MI0005297 mdo-mir-135a; +MI0005298 mdo-mir-135b; +MI0005299 mdo-mir-137;mdo-mir-137a; +MI0005300 mdo-mir-138; +MI0005301 mdo-mir-142; +MI0005302 mdo-mir-143; +MI0005303 mdo-mir-144; +MI0005304 mdo-mir-451; +MI0005305 mdo-mir-145; +MI0005306 mdo-mir-152; +MI0005307 mdo-mir-182; +MI0005308 mdo-mir-184; +MI0005309 mdo-mir-187; +MI0005310 mdo-mir-181c;mdo-mir-181a-3; +MI0005311 mdo-mir-186; +MI0005312 mdo-mir-193;mdo-mir-193a; +MI0005313 mdo-mir-196b; +MI0005314 mdo-mir-199b;mdo-mir-199b-1; +MI0005315 mdo-mir-203; +MI0005316 mdo-mir-204; +MI0005317 mdo-mir-206; +MI0005318 mdo-mir-208;mdo-mir-208a; +MI0005319 mdo-mir-214; +MI0005320 mdo-mir-216; +MI0005321 mdo-mir-217; +MI0005322 mdo-mir-218;mdo-mir-218-1; +MI0005323 mdo-mir-219;mdo-mir-219-1; +MI0005324 mdo-mir-223; +MI0005325 mdo-mir-338; +MI0005326 mdo-mir-365; +MI0005327 mdo-mir-375; +MI0005328 mdo-mir-383; +MI0005329 mdo-mir-449;mdo-mir-449a; +MI0005330 mdo-let-7a-2; +MI0005331 mdo-let-7g; +MI0005332 mdo-let-7i; +MI0005333 mdo-mir-15a; +MI0005334 mdo-mir-16;mdo-mir-16-1; +MI0005335 mdo-mir-183; +MI0005336 mdo-mir-96; +MI0005337 mdo-mir-212; +MI0005338 mdo-mir-132; +MI0005339 mdo-mir-200c; +MI0005340 mdo-mir-141; +MI0005341 mdo-mir-191; +MI0005342 mdo-mir-425; +MI0005343 mdo-mir-181a;mdo-mir-181a-1; +MI0005344 mdo-mir-181b;mdo-mir-181b-1; +MI0005345 mdo-mir-200b; +MI0005346 mdo-mir-200a; +MI0005347 mdo-mir-222a; +MI0005348 mdo-mir-221; +MI0005349 mdo-let-7f-2; +MI0005350 mdo-let-7a-3; +MI0005351 mdo-let-7b; +MI0005352 mdo-mir-29b;mdo-mir-29b-1; +MI0005353 mdo-mir-29a;mdo-mir-29a-1; +MI0005354 mdo-mir-17; +MI0005355 mdo-mir-18;mdo-mir-18a; +MI0005356 mdo-mir-19a; +MI0005357 mdo-mir-20;mdo-mir-20a; +MI0005358 mdo-mir-19b;mdo-mir-19b-1; +MI0005359 mdo-mir-92;mdo-mir-92a-1; +MI0005360 mdo-let-7a-1; +MI0005361 mdo-let-7f-1; +MI0005362 mdo-let-7d; +MI0005363 mdo-mir-23a; +MI0005364 mdo-mir-27a; +MI0005365 mdo-mir-24-2; +MI0005366 mdo-mir-23b; +MI0005367 mdo-mir-27b; +MI0005368 mdo-mir-24-1; +MI0005369 mdo-mir-93; +MI0005370 mdo-mir-25; +MI0005371 mdo-mir-302b; +MI0005372 mdo-mir-302c; +MI0005373 mdo-mir-302a; +MI0005374 mdo-mir-302d; +MI0005375 mdo-mir-367; +MI0005376 mmu-mir-801; +MI0005377 bmo-mir-31; +MI0005378 bmo-mir-71; +MI0005379 ath-MIR822; +MI0005380 ath-MIR823; +MI0005381 ath-MIR825; +MI0005382 ath-MIR826;ath-MIR826a; +MI0005383 ath-MIR827; +MI0005384 ath-MIR828; +MI0005385 ath-MIR829; +MI0005386 ath-MIR830; +MI0005387 ath-MIR831; +MI0005388 ath-MIR832; +MI0005389 ath-MIR833;ath-MIR833a; +MI0005390 ath-MIR834; +MI0005391 ath-MIR835; +MI0005392 ath-MIR836; +MI0005393 ath-MIR837; +MI0005394 ath-MIR838; +MI0005395 ath-MIR839; +MI0005396 ath-MIR840; +MI0005397 ath-MIR841;ath-MIR841a; +MI0005398 ath-MIR842; +MI0005399 ath-MIR843; +MI0005400 ath-MIR844; +MI0005401 ath-MIR845a; +MI0005402 ath-MIR846; +MI0005403 ath-MIR848; +MI0005404 ath-MIR849; +MI0005405 ath-MIR850; +MI0005406 ath-MIR851; +MI0005407 ath-MIR852; +MI0005408 ath-MIR853; +MI0005409 ath-MIR824; +MI0005410 ath-MIR847; +MI0005411 ath-MIR855; +MI0005412 ath-MIR854a; +MI0005413 ath-MIR854b; +MI0005414 ath-MIR854c; +MI0005415 ath-MIR854d; +MI0005416 hsa-mir-675; +MI0005417 cbr-mir-784; +MI0005418 cbr-mir-785;cbr-mir-785a; +MI0005419 cbr-mir-786; +MI0005420 cbr-mir-787; +MI0005421 cbr-mir-788; +MI0005422 cbr-mir-789a; +MI0005423 cbr-mir-789b;cbr-mir-789; +MI0005424 cbr-mir-790-1; +MI0005425 cbr-mir-790-2; +MI0005426 cbr-mir-791; +MI0005427 cbr-mir-792; +MI0005428 cbr-mir-235;cbr-mir-235a; +MI0005429 cbr-mir-242; +MI0005430 cbr-mir-255; +MI0005431 cbr-mir-359; +MI0005432 cbr-mir-392; +MI0005433 ath-MIR856; +MI0005434 ath-MIR857; +MI0005435 ath-MIR858;ath-MIR858a; +MI0005436 ath-MIR859; +MI0005437 ath-MIR860; +MI0005438 ath-MIR861; +MI0005439 ath-MIR862; +MI0005440 ath-MIR863; +MI0005441 ath-MIR864; +MI0005442 ath-MIR865; +MI0005443 ath-MIR866; +MI0005444 ath-MIR845b; +MI0005445 ath-MIR867; +MI0005446 ath-MIR868; +MI0005447 ath-MIR869; +MI0005448 ath-MIR870; +MI0005450 mmu-mir-181d; +MI0005451 bta-let-7a-2; +MI0005452 bta-let-7a-3; +MI0005453 bta-let-7b; +MI0005454 bta-let-7c; +MI0005455 bta-let-7e; +MI0005456 bta-mir-103-2; +MI0005457 bta-mir-125b-2; +MI0005458 bta-mir-15a; +MI0005459 bta-mir-195; +MI0005460 bta-mir-19a; +MI0005461 bta-mir-19b; +MI0005462 bta-mir-204; +MI0005463 bta-mir-331; +MI0005464 bta-mir-34a; +MI0005465 bta-mir-365;bta-mir-365-1; +MI0005466 bta-mir-374;bta-mir-374a; +MI0005467 bta-mir-497; +MI0005468 bta-mir-660; +MI0005469 bta-mir-99b; +MI0005470 mmu-mir-743b; +MI0005471 mmu-mir-871; +MI0005472 mmu-mir-879; +MI0005473 mmu-mir-880; +MI0005474 mmu-mir-881; +MI0005475 mmu-mir-882; +MI0005476 mmu-mir-883a; +MI0005477 mmu-mir-883b; +MI0005478 mmu-mir-190b; +MI0005479 mmu-mir-874; +MI0005480 mmu-mir-876; +MI0005481 mmu-mir-105; +MI0005482 mmu-mir-147; +MI0005483 mmu-mir-18b; +MI0005484 mmu-mir-193b; +MI0005485 mmu-mir-197; +MI0005487 mmu-mir-220; +MI0005488 mmu-mir-297a-3; +MI0005489 mmu-mir-297a-4; +MI0005490 mmu-mir-297a-5; +MI0005491 mmu-mir-297a-6; +MI0005492 mmu-mir-297c; +MI0005493 mmu-mir-327; +MI0005494 mmu-mir-343; +MI0005495 mmu-mir-344-2; +MI0005496 mmu-mir-421; +MI0005497 mmu-mir-453; +MI0005498 mmu-mir-465b-1; +MI0005499 mmu-mir-465b-2; +MI0005500 mmu-mir-465c-1; +MI0005501 mmu-mir-465c-2; +MI0005502 mmu-mir-466b-1; +MI0005503 mmu-mir-466b-2; +MI0005504 mmu-mir-466b-3; +MI0005505 mmu-mir-466c;mmu-mir-466c-1; +MI0005506 mmu-mir-466e; +MI0005507 mmu-mir-466f-1; +MI0005508 mmu-mir-466f-2; +MI0005509 mmu-mir-466f-3; +MI0005510 mmu-mir-466g; +MI0005511 mmu-mir-466h; +MI0005512 mmu-mir-467c; +MI0005513 mmu-mir-467d; +MI0005514 mmu-mir-493; +MI0005515 mmu-mir-504; +MI0005516 mmu-mir-509; +MI0005517 mmu-mir-568; +MI0005518 mmu-mir-574; +MI0005519 mmu-mir-590; +MI0005520 mmu-mir-654; +MI0005521 mmu-mir-92b; +MI0005522 hsa-mir-672; +MI0005523 hsa-mir-298; +MI0005524 hsa-mir-891a; +MI0005525 hsa-mir-300; +MI0005526 hsa-mir-871; +MI0005527 hsa-mir-886; +MI0005528 hsa-mir-892a; +MI0005529 hsa-mir-220b; +MI0005530 hsa-mir-509-2; +MI0005531 hsa-mir-450b; +MI0005532 hsa-mir-874; +MI0005533 hsa-mir-890; +MI0005534 hsa-mir-891b; +MI0005535 hsa-mir-674; +MI0005536 hsa-mir-220c; +MI0005537 hsa-mir-888; +MI0005538 hsa-mir-892b; +MI0005539 hsa-mir-541; +MI0005540 hsa-mir-889; +MI0005541 hsa-mir-875; +MI0005542 hsa-mir-876; +MI0005543 hsa-mir-708; +MI0005544 hsa-mir-147b; +MI0005545 hsa-mir-190b; +MI0005546 mmu-mir-466d; +MI0005547 mmu-mir-449b; +MI0005548 mmu-mir-878; +MI0005549 mmu-mir-872; +MI0005550 mmu-mir-873;mmu-mir-873a; +MI0005551 mmu-mir-875; +MI0005552 mmu-mir-208b; +MI0005553 mmu-mir-877; +MI0005554 mmu-mir-511; +MI0005555 mmu-mir-544; +MI0005556 mmu-mir-598; +MI0005557 mmu-mir-653; +MI0005558 hsa-mir-872; +MI0005559 hsa-mir-744; +MI0005560 hsa-mir-885; +MI0005561 hsa-mir-877; +MI0005562 hsa-mir-887; +MI0005563 hsa-mir-665; +MI0005564 hsa-mir-873; +MI0005565 hsa-mir-543; +MI0005566 hsa-mir-374b; +MI0005567 hsa-mir-760; +MI0005568 hsa-mir-301b; +MI0005569 hsa-mir-216b; +MI0005570 hsa-mir-208b; +MI0005571 mtr-MIR156b; +MI0005572 mtr-MIR167;mtr-MIR167a; +MI0005573 mtr-MIR164a; +MI0005574 mtr-MIR160b; +MI0005575 mtr-MIR166b; +MI0005576 mtr-MIR160c; +MI0005577 mtr-MIR169c; +MI0005578 mtr-MIR169d; +MI0005579 mtr-MIR169e; +MI0005580 mtr-MIR171b; +MI0005581 mtr-MIR166c; +MI0005582 mtr-MIR166d; +MI0005583 mtr-MIR169f; +MI0005584 mtr-MIR156c; +MI0005585 mtr-MIR156d; +MI0005586 mtr-MIR390; +MI0005587 mtr-MIR399f; +MI0005588 mtr-MIR399g; +MI0005589 mtr-MIR399h; +MI0005590 mtr-MIR399i; +MI0005591 mtr-MIR399j; +MI0005592 mtr-MIR399k; +MI0005594 mtr-MIR166e; +MI0005595 mtr-MIR156e; +MI0005596 mtr-MIR319b; +MI0005597 mtr-MIR171c; +MI0005598 mtr-MIR395q; +MI0005599 mtr-MIR398a; +MI0005600 mtr-MIR172;mtr-MIR172a; +MI0005601 mtr-MIR393b; +MI0005602 mtr-MIR398b; +MI0005603 mtr-MIR168;mtr-MIR168a; +MI0005604 mtr-MIR169g; +MI0005605 mtr-MIR156f; +MI0005606 mtr-MIR399l; +MI0005607 mtr-MIR156g; +MI0005608 mtr-MIR399m; +MI0005609 mtr-MIR399n; +MI0005610 mtr-MIR399o; +MI0005611 mtr-MIR398c; +MI0005612 mtr-MIR164b; +MI0005613 mtr-MIR156h; +MI0005614 mtr-MIR166f; +MI0005615 mtr-MIR160d; +MI0005616 mtr-MIR164c; +MI0005617 mtr-MIR164d; +MI0005618 mtr-MIR166g; +MI0005619 mtr-MIR171d; +MI0005620 mtr-MIR171e; +MI0005621 mtr-MIR396a; +MI0005622 mtr-MIR396b; +MI0005623 mtr-MIR169h; +MI0005624 mtr-MIR169i; +MI0005625 mtr-MIR169j;mtr-MIR169b; +MI0005626 mtr-MIR156i; +MI0005627 mtr-MIR171f; +MI0005628 mtr-MIR166h; +MI0005629 mtr-MIR160e; +MI0005630 mtr-MIR169m; +MI0005631 mtr-MIR169l; +MI0005632 mtr-MIR169k; +MI0005633 mtr-MIR395r; +MI0005634 mtr-MIR399p; +MI0005635 mtr-MIR171g; +MI0005636 mtr-MIR169n; +MI0005637 mtr-MIR169o; +MI0005638 ghr-MIR156a; +MI0005639 ghr-MIR156b; +MI0005640 ghr-MIR156c; +MI0005641 ghr-MIR156d; +MI0005642 gra-MIR157a; +MI0005643 gra-MIR157b; +MI0005644 ghr-MIR162a; +MI0005645 ghr-MIR166b; +MI0005646 ghb-MIR169a; +MI0005647 ghr-MIR390a; +MI0005648 ghr-MIR390b; +MI0005649 ghr-MIR390c; +MI0005650 ghr-MIR396a; +MI0005651 ghr-MIR396b; +MI0005652 ghr-MIR399a; +MI0005653 ghr-MIR399b; +MI0005654 ppt-MIR156c; +MI0005655 ppt-MIR160a; +MI0005656 ppt-MIR160b; +MI0005657 ppt-MIR160c; +MI0005658 ppt-MIR160d; +MI0005659 ppt-MIR166b; +MI0005660 ppt-MIR166a; +MI0005661 ppt-MIR167; +MI0005665 ppt-MIR319e; +MI0005667 ppt-MIR395; +MI0005668 ppt-MIR408;ppt-MIR408a; +MI0005669 ppt-MIR414; +MI0005670 ppt-MIR419; +MI0005671 ppt-MIR473a;ppt-MIR477c; +MI0005672 ppt-MIR473b;ppt-MIR477a; +MI0005673 ppt-MIR477a;ppt-MIR477f; +MI0005674 ppt-MIR477b;ppt-MIR477g; +MI0005675 ppt-MIR534b; +MI0005676 ppt-MIR893; +MI0005677 ppt-MIR894; +MI0005678 ppt-MIR895; +MI0005680 ppt-MIR896; +MI0005681 ppt-MIR897; +MI0005682 ppt-MIR899; +MI0005683 ppt-MIR900; +MI0005684 ppt-MIR901; +MI0005685 ppt-MIR902a; +MI0005686 ppt-MIR902b; +MI0005687 ppt-MIR536c; +MI0005688 ppt-MIR171a; +MI0005689 ppt-MIR171b; +MI0005690 ppt-MIR903; +MI0005691 ppt-MIR536b; +MI0005692 ppt-MIR904a; +MI0005693 ppt-MIR904b; +MI0005694 ppt-MIR898b; +MI0005695 ppt-MIR898a; +MI0005696 ppt-MIR156b; +MI0005697 cre-MIR918; +MI0005698 cre-MIR905; +MI0005699 cre-MIR906; +MI0005700 cre-MIR907; +MI0005701 cre-MIR908; +MI0005702 cre-MIR909; +MI0005703 cre-MIR910; +MI0005704 cre-MIR911; +MI0005705 cre-MIR912; +MI0005706 cre-MIR913; +MI0005707 cre-MIR914; +MI0005708 cre-MIR915; +MI0005709 cre-MIR919; +MI0005710 cre-MIR917; +MI0005711 cre-MIR916; +MI0005712 hsa-mir-920; +MI0005713 hsa-mir-921; +MI0005714 hsa-mir-922; +MI0005715 hsa-mir-923; +MI0005716 hsa-mir-924; +MI0005717 hsa-mir-509-3; +MI0005718 rrv-miR-rR1-1; +MI0005719 rrv-miR-rR1-2; +MI0005720 rrv-miR-rR1-3; +MI0005721 rrv-miR-rR1-4; +MI0005722 rrv-miR-rR1-5; +MI0005723 rrv-miR-rR1-6; +MI0005724 rrv-miR-rR1-7; +MI0005725 cgr-mir-21; +MI0005726 ame-let-7; +MI0005727 ame-mir-10;ame-mir-10-1;ame-mir-10; +MI0005728 ame-mir-100; +MI0005729 ame-mir-137; +MI0005730 ame-mir-13a; +MI0005731 ame-mir-14; +MI0005732 ame-mir-2-3; +MI0005733 ame-mir-275; +MI0005734 ame-mir-279;ame-mir-279a; +MI0005735 ame-mir-283; +MI0005736 ame-mir-29b; +MI0005737 ame-mir-31a; +MI0005738 ame-mir-33; +MI0005739 ame-mir-34; +MI0005740 ame-mir-375; +MI0005741 ame-mir-71; +MI0005742 ame-mir-79; +MI0005743 ame-mir-87-1; +MI0005744 ame-mir-87-2; +MI0005745 ame-mir-92a; +MI0005746 ame-mir-925; +MI0005747 ame-mir-926; +MI0005748 ame-mir-927;ame-mir-927a; +MI0005749 ame-mir-928; +MI0005750 ame-mir-190; +MI0005751 ame-mir-929; +MI0005752 ame-mir-930; +MI0005753 ame-mir-931; +MI0005754 ame-mir-932; +MI0005755 hsa-mir-933; +MI0005756 hsa-mir-934; +MI0005757 hsa-mir-935; +MI0005758 hsa-mir-936; +MI0005759 hsa-mir-937; +MI0005760 hsa-mir-938; +MI0005761 hsa-mir-939; +MI0005762 hsa-mir-940; +MI0005763 hsa-mir-941-1; +MI0005764 hsa-mir-941-2; +MI0005765 hsa-mir-941-3; +MI0005766 hsa-mir-941-4; +MI0005767 hsa-mir-942; +MI0005768 hsa-mir-943; +MI0005769 hsa-mir-944; +MI0005770 bna-MIR156a; +MI0005771 bna-MIR171;bna-MIR171g; +MI0005772 bna-MIR393; +MI0005773 bna-MIR396a; +MI0005774 bna-MIR399;bna-MIR399a; +MI0005775 hsa-mir-297; +MI0005776 pta-MIR156a; +MI0005777 pta-MIR156b; +MI0005778 pta-MIR159a; +MI0005779 pta-MIR159b; +MI0005780 pta-MIR159c; +MI0005782 pta-MIR166a; +MI0005783 pta-MIR166b; +MI0005784 pta-MIR166c; +MI0005785 pta-MIR171; +MI0005786 pta-MIR319; +MI0005787 pta-MIR390; +MI0005788 pta-MIR396; +MI0005789 pta-MIR398; +MI0005790 pta-MIR408; +MI0005791 pta-MIR482a; +MI0005792 pta-MIR482b; +MI0005793 pta-MIR783; +MI0005794 pta-MIR946a; +MI0005795 pta-MIR946b; +MI0005796 pta-MIR947; +MI0005797 pta-MIR948; +MI0005798 pta-MIR949; +MI0005799 pta-MIR950a; +MI0005800 pta-MIR950b; +MI0005801 pta-MIR951; +MI0005802 pta-MIR952a; +MI0005803 pta-MIR952b; +MI0005804 osa-MIR529b; +MI0005805 dme-mir-iab4as;dme-mir-iab-4as;dme-mir-iab-8; +MI0005806 dme-mir-954; +MI0005807 dme-mir-955; +MI0005808 dme-mir-190; +MI0005809 dme-mir-193; +MI0005810 dme-mir-956; +MI0005811 dme-mir-957; +MI0005812 dme-mir-958; +MI0005813 dme-mir-375; +MI0005814 dme-mir-959; +MI0005815 dme-mir-960; +MI0005816 dme-mir-961; +MI0005817 dme-mir-962; +MI0005818 dme-mir-963; +MI0005819 dme-mir-964; +MI0005820 dme-mir-932; +MI0005821 dme-mir-965; +MI0005822 dme-mir-966; +MI0005823 dme-mir-967; +MI0005824 dme-mir-1002; +MI0005825 dme-mir-968; +MI0005826 dme-mir-969; +MI0005827 dme-mir-970; +MI0005828 dme-mir-971; +MI0005829 dme-mir-972; +MI0005830 dme-mir-973; +MI0005831 dme-mir-974; +MI0005832 dme-mir-975; +MI0005833 dme-mir-976; +MI0005834 dme-mir-977; +MI0005835 dme-mir-978; +MI0005836 dme-mir-979; +MI0005837 dme-mir-980; +MI0005838 dme-mir-981; +MI0005839 dme-mir-982; +MI0005840 dme-mir-983-1; +MI0005841 dme-mir-983-2; +MI0005842 dme-mir-984; +MI0005843 dme-mir-927; +MI0005844 dme-mir-985; +MI0005845 dme-mir-986; +MI0005846 dme-mir-987; +MI0005847 dme-mir-988; +MI0005848 dme-mir-989; +MI0005849 dme-mir-137; +MI0005850 dme-mir-990; +MI0005851 dme-mir-991; +MI0005852 dme-mir-992; +MI0005853 dme-mir-929; +MI0005854 dme-mir-993; +MI0005855 dme-mir-994; +MI0005856 dme-mir-995; +MI0005857 dme-mir-996; +MI0005858 dme-mir-252; +MI0005859 dme-mir-997; +MI0005860 dme-mir-998; +MI0005861 dme-mir-999; +MI0005862 dme-mir-1000; +MI0005863 dme-mir-1001; +MI0005864 dme-mir-1003; +MI0005865 dme-mir-1004; +MI0005866 dme-mir-1005; +MI0005867 dme-mir-1006; +MI0005868 dme-mir-1007; +MI0005869 dme-mir-1008; +MI0005870 dme-mir-1009; +MI0005871 dme-mir-1010; +MI0005872 dme-mir-1011; +MI0005873 dme-mir-1012; +MI0005874 dme-mir-1013; +MI0005875 dme-mir-1014; +MI0005876 dme-mir-1015; +MI0005877 dme-mir-1016; +MI0005878 dme-mir-1017; +MI0005879 cel-mir-1018; +MI0005880 cel-mir-1019; +MI0005881 cel-mir-1020; +MI0005882 mdv2-mir-M14; +MI0005883 mdv2-mir-M15; +MI0005884 mdv2-mir-M16; +MI0005885 mdv2-mir-M17; +MI0005886 mdv2-mir-M18; +MI0005887 mdv2-mir-M19; +MI0005888 mdv2-mir-M20; +MI0005889 mdv2-mir-M21; +MI0005890 mdv2-mir-M22; +MI0005891 mdv2-mir-M23; +MI0005892 mdv2-mir-M24; +MI0005893 mdv2-mir-M25; +MI0005894 mdv2-mir-M26; +MI0005895 mdv2-mir-M27; +MI0005896 mdv2-mir-M28; +MI0005897 mdv2-mir-M29; +MI0005898 mdv2-mir-M30; +MI0005899 cel-mir-1021; +MI0005900 cel-mir-1022; +MI0005901 ppt-MIR160e; +MI0005902 ppt-MIR160f; +MI0005903 ppt-MIR160g; +MI0005904 ppt-MIR160h; +MI0005905 ppt-MIR160i; +MI0005906 ppt-MIR166c; +MI0005907 ppt-MIR166d; +MI0005908 ppt-MIR166e; +MI0005909 ppt-MIR166f; +MI0005910 ppt-MIR166g; +MI0005911 ppt-MIR166h; +MI0005912 ppt-MIR166i; +MI0005913 ppt-MIR166j; +MI0005914 ppt-MIR166k; +MI0005915 ppt-MIR166l; +MI0005916 ppt-MIR166m; +MI0005917 ppt-MIR408b; +MI0005918 ppt-MIR477d; +MI0005919 ppt-MIR477e; +MI0005920 ppt-MIR477h; +MI0005921 ppt-MIR529a; +MI0005922 ppt-MIR529b; +MI0005923 ppt-MIR529c; +MI0005924 ppt-MIR529d; +MI0005925 ppt-MIR529e; +MI0005926 ppt-MIR529f; +MI0005927 ppt-MIR529g; +MI0005928 ppt-MIR533c; +MI0005929 ppt-MIR533d; +MI0005930 ppt-MIR533e; +MI0005932 ppt-MIR536d; +MI0005933 ppt-MIR536e; +MI0005934 ppt-MIR536f; +MI0005935 ppt-MIR537c; +MI0005936 ppt-MIR537d; +MI0005937 ppt-MIR902c; +MI0005938 ppt-MIR902d; +MI0005939 ppt-MIR902e; +MI0005940 ppt-MIR902f; +MI0005941 ppt-MIR902g; +MI0005942 ppt-MIR902h; +MI0005943 ppt-MIR902i; +MI0005944 ppt-MIR902j; +MI0005945 ppt-MIR902k; +MI0005946 ppt-MIR902l; +MI0005947 ppt-MIR1222b; +MI0005948 ppt-MIR1222c; +MI0005949 ppt-MIR1222d; +MI0005950 ppt-MIR1222e; +MI0005951 ppt-MIR1223b; +MI0005952 ppt-MIR1223c; +MI0005953 ppt-MIR1223d; +MI0005954 ppt-MIR1223e; +MI0005955 ppt-MIR1223f; +MI0005956 ppt-MIR1223g; +MI0005957 ppt-MIR1223h; +MI0005958 ppt-MIR1223i; +MI0005959 ppt-MIR1223j; +MI0005960 ppt-MIR1023a; +MI0005961 ppt-MIR1023b; +MI0005962 ppt-MIR1023c; +MI0005963 ppt-MIR1023d; +MI0005964 ppt-MIR1024a; +MI0005965 ppt-MIR1024b; +MI0005966 ppt-MIR1025; +MI0005967 ppt-MIR1026a; +MI0005968 ppt-MIR1026b; +MI0005969 ppt-MIR1027a; +MI0005970 ppt-MIR1027b; +MI0005971 ppt-MIR1028a; +MI0005972 ppt-MIR1028b; +MI0005973 ppt-MIR1028c; +MI0005974 ppt-MIR1029; +MI0005975 ppt-MIR1030a; +MI0005976 ppt-MIR1030b; +MI0005977 ppt-MIR1030c; +MI0005978 ppt-MIR1030d; +MI0005979 ppt-MIR1030e; +MI0005980 ppt-MIR1030f; +MI0005981 ppt-MIR1030g; +MI0005982 ppt-MIR1030h; +MI0005983 ppt-MIR1030i; +MI0005984 ppt-MIR1030j; +MI0005985 ppt-MIR1031a; +MI0005986 ppt-MIR1031b; +MI0005987 ppt-MIR1032; +MI0005988 ppt-MIR1033a; +MI0005989 ppt-MIR1033b; +MI0005990 ppt-MIR1033c; +MI0005991 ppt-MIR1033d; +MI0005992 ppt-MIR1033e; +MI0005993 ppt-MIR1034; +MI0005994 ppt-MIR1035; +MI0005995 ppt-MIR1036; +MI0005996 ppt-MIR1037; +MI0005997 ppt-MIR1038; +MI0005998 ppt-MIR1039; +MI0005999 ppt-MIR1040; +MI0006000 ppt-MIR1041; +MI0006001 ppt-MIR1042; +MI0006002 ppt-MIR1043; +MI0006003 ppt-MIR1044; +MI0006004 ppt-MIR1045; +MI0006005 ppt-MIR1046; +MI0006006 ppt-MIR1047; +MI0006007 ppt-MIR1048; +MI0006008 ppt-MIR1049; +MI0006009 ppt-MIR1050; +MI0006010 ppt-MIR1051; +MI0006011 ppt-MIR1052; +MI0006012 ppt-MIR1053; +MI0006013 ppt-MIR1054; +MI0006014 ppt-MIR1055; +MI0006015 ppt-MIR1056; +MI0006016 ppt-MIR1057; +MI0006017 ppt-MIR1058; +MI0006018 ppt-MIR1059; +MI0006019 ppt-MIR1060; +MI0006020 ppt-MIR1061; +MI0006021 ppt-MIR1062; +MI0006022 ppt-MIR1063a; +MI0006023 ppt-MIR1063b; +MI0006024 ppt-MIR1063c; +MI0006025 ppt-MIR1063d; +MI0006026 ppt-MIR1063e; +MI0006027 ppt-MIR1063f; +MI0006028 ppt-MIR1063g; +MI0006029 ppt-MIR1063h; +MI0006030 ppt-MIR1064; +MI0006031 ppt-MIR1065; +MI0006032 ppt-MIR1066; +MI0006033 ppt-MIR1067; +MI0006034 ppt-MIR1068; +MI0006035 ppt-MIR1069; +MI0006036 ppt-MIR1070; +MI0006037 ppt-MIR1071; +MI0006038 ppt-MIR1072; +MI0006039 ppt-MIR1073; +MI0006040 ppt-MIR1074; +MI0006041 ppt-MIR1075; +MI0006042 ppt-MIR1076; +MI0006043 ppt-MIR1077; +MI0006044 ppt-MIR1078; +MI0006045 ppt-MIR1079; +MI0006046 smo-MIR156a; +MI0006047 smo-MIR156b; +MI0006048 smo-MIR156c; +MI0006049 smo-MIR156d; +MI0006050 smo-MIR159; +MI0006051 smo-MIR160a; +MI0006052 smo-MIR160b; +MI0006053 smo-MIR166a; +MI0006054 smo-MIR166b; +MI0006055 smo-MIR166c; +MI0006056 smo-MIR171a; +MI0006057 smo-MIR171b; +MI0006058 smo-MIR171c; +MI0006059 smo-MIR171d; +MI0006060 smo-MIR396; +MI0006061 smo-MIR408; +MI0006062 smo-MIR536; +MI0006063 smo-MIR1080; +MI0006064 smo-MIR1081; +MI0006065 smo-MIR1082a; +MI0006066 smo-MIR1082b; +MI0006067 smo-MIR1083; +MI0006068 smo-MIR1084; +MI0006069 smo-MIR1085; +MI0006070 smo-MIR1086; +MI0006071 smo-MIR1087; +MI0006072 smo-MIR1088; +MI0006073 smo-MIR1089; +MI0006074 smo-MIR1090; +MI0006075 smo-MIR1091; +MI0006076 smo-MIR1092; +MI0006077 smo-MIR1093; +MI0006078 smo-MIR1094a; +MI0006079 smo-MIR1094b; +MI0006080 smo-MIR1094c; +MI0006081 smo-MIR1095a; +MI0006082 smo-MIR1095b; +MI0006083 smo-MIR1096; +MI0006084 smo-MIR1097; +MI0006085 smo-MIR1098; +MI0006086 smo-MIR1099; +MI0006087 smo-MIR1100; +MI0006088 smo-MIR1101; +MI0006089 smo-MIR1102; +MI0006090 smo-MIR319; +MI0006091 smo-MIR1104; +MI0006092 smo-MIR1105; +MI0006093 smo-MIR1106; +MI0006094 smo-MIR1107; +MI0006095 smo-MIR1108; +MI0006096 smo-MIR1109; +MI0006097 smo-MIR1110; +MI0006098 smo-MIR1111; +MI0006099 smo-MIR1112; +MI0006100 smo-MIR1113; +MI0006101 smo-MIR1114; +MI0006102 smo-MIR1115; +MI0006103 smo-MIR1103; +MI0006104 hiv1-mir-N367; +MI0006105 hsv1-mir-LAT; +MI0006106 hiv1-mir-H1; +MI0006112 rno-mir-466b-1; +MI0006113 rno-mir-466b-2; +MI0006114 rno-mir-466c; +MI0006115 rno-mir-743b; +MI0006116 rno-mir-871; +MI0006117 rno-mir-872; +MI0006118 rno-mir-874; +MI0006119 rno-mir-877; +MI0006120 rno-mir-878; +MI0006121 rno-mir-879; +MI0006122 rno-mir-880; +MI0006123 rno-mir-881; +MI0006126 rno-mir-883; +MI0006127 mmu-mir-582; +MI0006128 mmu-mir-467e; +MI0006130 rno-mir-147; +MI0006131 rno-mir-17-2; +MI0006132 rno-mir-181d; +MI0006133 rno-mir-182; +MI0006134 rno-mir-188; +MI0006135 rno-mir-190b; +MI0006136 rno-mir-196c; +MI0006137 rno-mir-301b; +MI0006140 rno-mir-375; +MI0006141 rno-mir-380; +MI0006142 rno-mir-384; +MI0006143 rno-mir-410; +MI0006144 rno-mir-411; +MI0006145 rno-mir-423; +MI0006146 rno-mir-425; +MI0006147 rno-mir-434;rno-mir-434-1; +MI0006148 rno-mir-455; +MI0006149 rno-mir-463; +MI0006150 rno-mir-471; +MI0006151 rno-mir-484; +MI0006152 rno-mir-495; +MI0006153 rno-mir-500; +MI0006154 rno-mir-532; +MI0006155 rno-mir-598;rno-mir-598-1; +MI0006156 rno-mir-671; +MI0006157 rno-mir-672; +MI0006158 rno-mir-673; +MI0006159 rno-mir-674; +MI0006160 rno-mir-708; +MI0006161 rno-mir-742; +MI0006162 rno-mir-743a; +MI0006163 rno-mir-758; +MI0006164 rno-mir-760; +MI0006165 rno-mir-770; +MI0006166 rno-mir-873; +MI0006167 rno-mir-92b; +MI0006168 rno-mir-488; +MI0006169 rno-mir-652; +MI0006170 tae-miR159a;tae-MIR159a; +MI0006171 tae-MIR159b; +MI0006172 tae-MIR160; +MI0006173 tae-MIR164; +MI0006174 tae-MIR167;tae-MIR167a; +MI0006175 tae-MIR171;tae-MIR171a; +MI0006176 tae-MIR399; +MI0006177 tae-MIR408; +MI0006178 tae-MIR444;tae-MIR444a; +MI0006179 tae-MIR1117; +MI0006180 tae-MIR1118; +MI0006181 tae-MIR1119; +MI0006182 tae-MIR1120;tae-MIR1120a; +MI0006183 tae-MIR1121; +MI0006184 tae-MIR1122;tae-MIR1122a; +MI0006185 tae-MIR1123; +MI0006186 tae-MIR1124; +MI0006187 tae-MIR1125; +MI0006188 tae-MIR1126; +MI0006189 tae-MIR1127;tae-MIR1127a; +MI0006190 tae-MIR1128; +MI0006191 tae-MIR1129; +MI0006192 tae-MIR1130;tae-MIR1130a; +MI0006193 tae-MIR1131; +MI0006194 tae-MIR1132; +MI0006195 tae-MIR1133; +MI0006196 tae-MIR1134; +MI0006197 tae-MIR1135; +MI0006198 tae-MIR1136; +MI0006199 tae-MIR1137;tae-MIR1137a; +MI0006200 tae-MIR1138; +MI0006201 tae-MIR1139; +MI0006202 ppt-MIR477b; +MI0006203 cre-MIR1142; +MI0006204 cre-MIR1143; +MI0006205 cre-MIR1144a; +MI0006206 cre-MIR1145; +MI0006207 cre-MIR1146; +MI0006208 cre-MIR1147; +MI0006209 cre-MIR1148; +MI0006210 cre-MIR1149; +MI0006211 cre-MIR1150; +MI0006212 cre-MIR1151a; +MI0006213 cre-MIR1151b; +MI0006214 cre-MIR1152; +MI0006215 cre-MIR1153; +MI0006216 cre-MIR1154; +MI0006217 cre-MIR1155; +MI0006218 cre-MIR1156; +MI0006219 cre-MIR1157; +MI0006220 cre-MIR1158; +MI0006221 cre-MIR1160; +MI0006222 cre-MIR1161;cre-MIR1161a; +MI0006223 cre-MIR1162; +MI0006224 cre-MIR1163; +MI0006225 cre-MIR1164; +MI0006226 cre-MIR1165; +MI0006227 cre-MIR1166; +MI0006228 cre-MIR1168; +MI0006229 cre-MIR1169; +MI0006230 cre-MIR1170; +MI0006231 cre-MIR1171; +MI0006232 cre-MIR1173; +MI0006233 cre-MIR1172; +MI0006234 cre-MIR1167; +MI0006235 cre-MIR1144b; +MI0006236 cre-MIR1159; +MI0006237 aga-mir-1174; +MI0006238 aga-mir-1175; +MI0006239 aga-mir-34; +MI0006240 aga-mir-12; +MI0006241 aga-mir-996; +MI0006242 aga-mir-989; +MI0006243 aga-mir-306; +MI0006244 ddi-mir-1176; +MI0006245 ddi-mir-1177; +MI0006246 mcmv-mir-m01-1; +MI0006247 mcmv-mir-m01-2; +MI0006248 mcmv-mir-m01-3; +MI0006249 mcmv-mir-m01-4; +MI0006250 mcmv-mir-m21-1; +MI0006251 mcmv-mir-m22-1; +MI0006252 mcmv-mir-M23-1; +MI0006253 mcmv-mir-M23-2; +MI0006254 mcmv-mir-M44-1; +MI0006255 mcmv-mir-M55-1; +MI0006256 mcmv-mir-m59-1; +MI0006257 mcmv-mir-m59-2; +MI0006258 mcmv-mir-M87-1; +MI0006259 mcmv-mir-m88-1; +MI0006260 mcmv-mir-M95-1; +MI0006261 mcmv-mir-m107-1; +MI0006262 mcmv-mir-m108-1; +MI0006263 mcmv-mir-m108-2; +MI0006264 xtr-mir-31b; +MI0006265 xtr-mir-146b; +MI0006266 xtr-mir-320; +MI0006267 xtr-mir-375; +MI0006268 xtr-mir-427-1; +MI0006269 xtr-mir-427-2; +MI0006270 xtr-mir-427-3; +MI0006271 hsa-mir-1178; +MI0006272 hsa-mir-1179; +MI0006273 hsa-mir-1180; +MI0006274 hsa-mir-1181; +MI0006275 hsa-mir-1182; +MI0006276 hsa-mir-1183; +MI0006277 hsa-mir-1184;hsa-mir-1184-1; +MI0006278 mmu-mir-466l; +MI0006279 mmu-mir-669k; +MI0006280 mmu-mir-669g; +MI0006281 mmu-mir-669d; +MI0006282 mmu-mir-466i; +MI0006283 mmu-mir-1-2-as;mmu-mir-1b; +MI0006284 mmu-mir-1186;mmu-mir-1186a; +MI0006285 mmu-mir-1187; +MI0006286 mmu-mir-669j; +MI0006287 mmu-mir-669f; +MI0006288 mmu-mir-669i; +MI0006289 mmu-mir-669h; +MI0006290 mmu-mir-1188; +MI0006291 mmu-mir-466f-4; +MI0006292 mmu-mir-466k; +MI0006293 mmu-mir-467f; +MI0006294 mmu-mir-1190; +MI0006295 mmu-mir-466j; +MI0006296 mmu-mir-1191;mmu-mir-1191a; +MI0006297 mmu-mir-1192; +MI0006298 mmu-mir-1193; +MI0006299 mmu-mir-1194; +MI0006300 mmu-mir-669e; +MI0006301 mmu-mir-467g; +MI0006302 mmu-mir-467h; +MI0006303 mmu-mir-1195; +MI0006304 mmu-mir-1196; +MI0006305 mmu-mir-1197; +MI0006306 mmu-mir-1198; +MI0006307 mmu-mir-1199; +MI0006308 cpa-MIR162a; +MI0006309 ptr-mir-1224; +MI0006310 mml-mir-1224; +MI0006311 hsa-mir-1225; +MI0006312 mml-mir-1225; +MI0006313 hsa-mir-1226; +MI0006314 ptr-mir-1226; +MI0006315 mml-mir-1226; +MI0006316 hsa-mir-1227; +MI0006317 mml-mir-1227; +MI0006318 hsa-mir-1228; +MI0006319 hsa-mir-1229; +MI0006320 mml-mir-1230; +MI0006321 hsa-mir-1231; +MI0006322 mml-mir-1232; +MI0006323 hsa-mir-1233;hsa-mir-1233-1; +MI0006324 hsa-mir-1234; +MI0006325 mml-mir-1235; +MI0006326 hsa-mir-1236; +MI0006327 hsa-mir-1237; +MI0006328 hsa-mir-1238; +MI0006329 mml-mir-1239; +MI0006330 mml-mir-1240; +MI0006331 mml-mir-1241; +MI0006332 hsa-mir-1200; +MI0006333 hsa-mir-1201; +MI0006334 hsa-mir-1202; +MI0006335 hsa-mir-1203; +MI0006336 hsa-mir-663b; +MI0006337 hsa-mir-1204; +MI0006338 hsa-mir-1205; +MI0006339 hsa-mir-1206; +MI0006340 hsa-mir-1207; +MI0006341 hsa-mir-1208; +MI0006342 rno-mir-146b; +MI0006343 rno-mir-551b; +MI0006344 hsa-mir-548e; +MI0006345 hsa-mir-548j; +MI0006346 hsa-mir-1285-1; +MI0006347 hsa-mir-1285-2; +MI0006348 hsa-mir-1286; +MI0006349 hsa-mir-1287; +MI0006350 hsa-mir-1289-1; +MI0006351 hsa-mir-1289-2; +MI0006352 hsa-mir-1290; +MI0006353 hsa-mir-1291; +MI0006354 hsa-mir-548k; +MI0006355 hsa-mir-1293; +MI0006356 hsa-mir-1294; +MI0006357 hsa-mir-1295;hsa-mir-1295a; +MI0006358 hsa-mir-1297; +MI0006359 hsa-mir-1299; +MI0006360 hsa-mir-1300; +MI0006361 hsa-mir-548l; +MI0006362 hsa-mir-1302-1; +MI0006363 hsa-mir-1302-2; +MI0006364 hsa-mir-1302-3; +MI0006365 hsa-mir-1302-4; +MI0006366 hsa-mir-1302-5; +MI0006367 hsa-mir-1302-6; +MI0006368 hsa-mir-1302-7; +MI0006369 hsa-mir-1302-8; +MI0006370 hsa-mir-1303; +MI0006371 hsa-mir-1304; +MI0006372 hsa-mir-1305; +MI0006373 hsa-mir-1243; +MI0006374 hsa-mir-548f-1; +MI0006375 hsa-mir-548f-2; +MI0006376 hsa-mir-548f-3; +MI0006377 hsa-mir-548f-4; +MI0006378 hsa-mir-548f-5; +MI0006379 hsa-mir-1244;hsa-mir-1244-1; +MI0006380 hsa-mir-1245;hsa-mir-1245a; +MI0006381 hsa-mir-1246; +MI0006382 hsa-mir-1247; +MI0006383 hsa-mir-1248; +MI0006384 hsa-mir-1249; +MI0006385 hsa-mir-1250; +MI0006386 hsa-mir-1251; +MI0006387 hsa-mir-1253; +MI0006388 hsa-mir-1254;hsa-mir-1254-1; +MI0006389 hsa-mir-1255a; +MI0006390 hsa-mir-1256; +MI0006391 hsa-mir-1257; +MI0006392 hsa-mir-1258; +MI0006393 hsa-mir-1259; +MI0006394 hsa-mir-1260;hsa-mir-1260a; +MI0006395 hsa-mir-548g; +MI0006396 hsa-mir-1261; +MI0006397 hsa-mir-1262; +MI0006398 hsa-mir-1263; +MI0006399 hsa-mir-548n; +MI0006400 hsa-mir-548m; +MI0006401 hsa-mir-1265; +MI0006402 hsa-mir-548o; +MI0006403 hsa-mir-1266; +MI0006404 hsa-mir-1267; +MI0006405 hsa-mir-1268;hsa-mir-1268a; +MI0006406 hsa-mir-1269;hsa-mir-1269a; +MI0006407 hsa-mir-1270;hsa-mir-1270-1;hsa-mir-1270; +MI0006408 hsa-mir-1272; +MI0006409 hsa-mir-1273;hsa-mir-1273a; +MI0006410 hsa-mir-1274a; +MI0006411 hsa-mir-548h-1; +MI0006412 hsa-mir-548h-2; +MI0006413 hsa-mir-548h-3; +MI0006414 hsa-mir-548h-4; +MI0006415 hsa-mir-1275; +MI0006416 hsa-mir-1276; +MI0006417 hsa-mir-302e; +MI0006418 hsa-mir-302f; +MI0006419 hsa-mir-1277; +MI0006420 hsa-mir-548p; +MI0006421 hsa-mir-548i-1; +MI0006422 hsa-mir-548i-2; +MI0006423 hsa-mir-548i-3; +MI0006424 hsa-mir-548i-4; +MI0006425 hsa-mir-1278; +MI0006426 hsa-mir-1279; +MI0006427 hsa-mir-1274b; +MI0006428 hsa-mir-1281; +MI0006429 hsa-mir-1282; +MI0006430 hsa-mir-1283-2; +MI0006431 hsa-mir-1284; +MI0006432 hsa-mir-1288; +MI0006433 hsa-mir-1292; +MI0006434 hsa-mir-1252; +MI0006435 hsa-mir-1255b-1; +MI0006436 hsa-mir-1255b-2; +MI0006437 hsa-mir-1280; +MI0006438 bol-MIR824; +MI0006439 bra-MIR824; +MI0006440 bna-MIR824; +MI0006441 hsa-mir-1308; +MI0006442 hsa-mir-664;hsa-mir-664a; +MI0006443 hsa-mir-1306; +MI0006444 hsa-mir-1307; +MI0006445 bna-MIR397a; +MI0006446 bna-MIR397b; +MI0006447 bna-MIR390a; +MI0006448 bna-MIR390b; +MI0006449 bna-MIR390c; +MI0006450 bna-MIR171a; +MI0006451 bna-MIR171b; +MI0006452 bna-MIR171c; +MI0006453 bna-MIR171d; +MI0006454 bna-MIR171e; +MI0006455 bna-MIR171f; +MI0006456 bna-MIR171g; +MI0006457 bna-MIR169a; +MI0006458 bna-MIR169b; +MI0006459 bna-MIR169c; +MI0006460 bna-MIR169d; +MI0006461 bna-MIR169e; +MI0006462 bna-MIR169f; +MI0006463 bna-MIR169g; +MI0006464 bna-MIR169h; +MI0006465 bna-MIR169i; +MI0006466 bna-MIR169j; +MI0006467 bna-MIR169k; +MI0006468 bna-MIR169l; +MI0006469 bna-MIR169m; +MI0006470 bna-MIR168;bna-MIR168a; +MI0006471 bna-MIR167a; +MI0006472 bna-MIR167b; +MI0006473 bna-MIR167c; +MI0006474 bna-MIR166a; +MI0006475 bna-MIR166b; +MI0006476 bna-MIR166c; +MI0006477 bna-MIR166d; +MI0006478 bna-MIR164;bna-MIR164a; +MI0006479 bna-MIR161; +MI0006480 bna-MIR159; +MI0006481 bna-MIR156b; +MI0006482 bna-MIR1140a;bna-MIR1140; +MI0006483 bna-MIR1140b; +MI0006484 bna-MIR156c; +MI0006485 vvi-MIR156a; +MI0006486 vvi-MIR156b; +MI0006487 vvi-MIR156c; +MI0006488 vvi-MIR156d; +MI0006489 vvi-MIR156e; +MI0006490 vvi-MIR156f; +MI0006491 vvi-MIR156g; +MI0006492 vvi-MIR156i; +MI0006493 vvi-MIR159a; +MI0006494 vvi-MIR159b; +MI0006495 vvi-MIR159c; +MI0006496 vvi-MIR160a; +MI0006497 vvi-MIR160b; +MI0006498 vvi-MIR160c; +MI0006499 vvi-MIR160d; +MI0006500 vvi-MIR160e; +MI0006501 vvi-MIR160f;vvi-MIR160e; +MI0006502 vvi-MIR162; +MI0006503 vvi-MIR164a; +MI0006504 vvi-MIR164b; +MI0006505 vvi-MIR164c; +MI0006506 vvi-MIR164d; +MI0006507 vvi-MIR166a; +MI0006508 vvi-MIR166b; +MI0006509 vvi-MIR166c; +MI0006510 vvi-MIR166d; +MI0006511 vvi-MIR166e; +MI0006512 vvi-MIR166f; +MI0006513 vvi-MIR166g; +MI0006514 vvi-MIR166h; +MI0006515 vvi-MIR167a; +MI0006516 vvi-MIR167b; +MI0006517 vvi-MIR167c; +MI0006518 vvi-MIR167d; +MI0006519 vvi-MIR167e; +MI0006520 vvi-MIR168; +MI0006521 vvi-MIR169a; +MI0006522 vvi-MIR169y; +MI0006523 vvi-MIR169c; +MI0006524 vvi-MIR169d; +MI0006525 vvi-MIR169e; +MI0006526 vvi-MIR169f; +MI0006527 vvi-MIR169g; +MI0006528 vvi-MIR169j; +MI0006529 vvi-MIR169k; +MI0006530 vvi-MIR169m; +MI0006531 vvi-MIR169p; +MI0006532 vvi-MIR169r; +MI0006533 vvi-MIR169s; +MI0006534 vvi-MIR169t; +MI0006535 vvi-MIR169u; +MI0006536 vvi-MIR171a; +MI0006537 vvi-MIR171b; +MI0006538 vvi-MIR171c; +MI0006539 vvi-MIR171d; +MI0006540 vvi-MIR171e; +MI0006541 vvi-MIR171f; +MI0006542 vvi-MIR171h; +MI0006543 vvi-MIR171i; +MI0006544 vvi-MIR172a; +MI0006545 vvi-MIR172b; +MI0006546 vvi-MIR172c; +MI0006547 vvi-MIR172d; +MI0006548 vvi-MIR319b; +MI0006549 vvi-MIR319c; +MI0006550 vvi-MIR319f; +MI0006551 vvi-MIR319g; +MI0006552 vvi-MIR390; +MI0006553 vvi-MIR393b; +MI0006554 vvi-MIR394a; +MI0006555 vvi-MIR394b; +MI0006556 vvi-MIR395a; +MI0006557 vvi-MIR395b; +MI0006558 vvi-MIR395c; +MI0006559 vvi-MIR395d; +MI0006560 vvi-MIR395e; +MI0006561 vvi-MIR395f; +MI0006562 vvi-MIR395g; +MI0006563 vvi-MIR395h; +MI0006564 vvi-MIR395i; +MI0006565 vvi-MIR395j; +MI0006566 vvi-MIR395k; +MI0006567 vvi-MIR395l; +MI0006568 vvi-MIR395m; +MI0006569 vvi-MIR396a; +MI0006570 vvi-MIR396b; +MI0006571 vvi-MIR396d; +MI0006572 vvi-MIR398a; +MI0006573 vvi-MIR399a; +MI0006574 vvi-MIR399b; +MI0006575 vvi-MIR399e; +MI0006576 vvi-MIR399g; +MI0006577 vvi-MIR399h; +MI0006578 vvi-MIR408; +MI0006579 vvi-MIR479; +MI0006580 vvi-MIR535a; +MI0006581 vvi-MIR535b; +MI0006582 vvi-MIR535c; +MI0006583 vvi-MIR535d;vvi-MIR535c; +MI0006584 vvi-MIR535e; +MI0006585 age-mir-506; +MI0006586 age-mir-507; +MI0006587 age-mir-508; +MI0006588 age-mir-509a; +MI0006589 age-mir-509b; +MI0006590 age-mir-510; +MI0006591 age-mir-513b; +MI0006592 age-mir-513c-1; +MI0006593 age-mir-513a-1; +MI0006594 age-mir-513d; +MI0006595 age-mir-513e-2; +MI0006596 age-mir-513a-2; +MI0006597 age-mir-513c-2; +MI0006598 age-mir-514; +MI0006599 ssy-mir-506; +MI0006600 ssy-mir-507; +MI0006601 ssy-mir-508; +MI0006602 ssy-mir-509a; +MI0006603 ssy-mir-509b; +MI0006604 ssy-mir-510; +MI0006605 ssy-mir-513c; +MI0006606 ssy-mir-513b-1; +MI0006607 ssy-mir-513a; +MI0006608 ssy-mir-513b-2; +MI0006609 ssy-mir-514; +MI0006610 mml-mir-506; +MI0006611 mml-mir-507; +MI0006612 mml-mir-508; +MI0006613 mml-mir-509-1; +MI0006614 mml-mir-509-2; +MI0006615 mml-mir-510; +MI0006616 mml-mir-513b-1; +MI0006617 mml-mir-513b-2; +MI0006618 mml-mir-513a-1; +MI0006619 mml-mir-513a-2; +MI0006620 mml-mir-513a-3; +MI0006621 mml-mir-514;mml-mir-514-1;mml-mir-514;mml-mir-514a; +MI0006622 ptr-mir-506; +MI0006623 ptr-mir-507; +MI0006624 ptr-mir-508; +MI0006625 ptr-mir-509a-1; +MI0006626 ptr-mir-509b; +MI0006627 ptr-mir-509a-2; +MI0006628 ptr-mir-510; +MI0006629 ptr-mir-513a-1; +MI0006630 ptr-mir-513b; +MI0006631 ptr-mir-513a-2; +MI0006632 ptr-mir-513a-3; +MI0006633 ptr-mir-514-1; +MI0006634 ptr-mir-514-2; +MI0006635 ptr-mir-514-3; +MI0006636 ptr-mir-514-4; +MI0006637 pbi-mir-506; +MI0006638 pbi-mir-507; +MI0006639 pbi-mir-508; +MI0006640 pbi-mir-509; +MI0006641 pbi-mir-510; +MI0006642 pbi-mir-513a-1; +MI0006643 pbi-mir-513b; +MI0006644 pbi-mir-513c-1; +MI0006645 pbi-mir-513a-2; +MI0006646 pbi-mir-513c-2; +MI0006647 pbi-mir-514; +MI0006648 hsa-mir-513b; +MI0006649 hsa-mir-513c; +MI0006650 age-mir-513e-1; +MI0006652 hsa-mir-1321; +MI0006653 hsa-mir-1322; +MI0006654 hsa-mir-720; +MI0006656 hsa-mir-1197; +MI0006657 hsa-mir-1324; +MI0006658 oan-mir-9;oan-mir-9-1; +MI0006659 oan-mir-1325; +MI0006660 oan-mir-1326; +MI0006661 oan-mir-1327; +MI0006662 oan-mir-1328; +MI0006663 oan-mir-1329; +MI0006664 oan-mir-1330; +MI0006665 oan-mir-129; +MI0006666 oan-mir-96; +MI0006667 oan-mir-183; +MI0006668 oan-mir-29a-1; +MI0006669 oan-mir-29b;oan-mir-29b-1; +MI0006670 oan-mir-490; +MI0006671 oan-mir-140; +MI0006672 oan-mir-1331; +MI0006673 oan-mir-218;oan-mir-218-1; +MI0006674 oan-mir-33a; +MI0006675 oan-mir-1332; +MI0006676 oan-mir-193; +MI0006677 oan-mir-365;oan-mir-365-1; +MI0006678 oan-mir-1333; +MI0006679 oan-mir-122; +MI0006680 oan-mir-1334; +MI0006681 oan-mir-1335; +MI0006682 oan-mir-1336; +MI0006683 oan-mir-875; +MI0006684 oan-mir-1337; +MI0006685 oan-mir-181a;oan-mir-181a-1; +MI0006686 oan-mir-181b;oan-mir-181b-1; +MI0006687 oan-mir-137a; +MI0006688 oan-mir-1338; +MI0006689 oan-mir-204; +MI0006690 oan-mir-190a; +MI0006691 oan-mir-15c; +MI0006692 oan-mir-16c; +MI0006693 oan-mir-106; +MI0006694 oan-mir-18; +MI0006695 oan-mir-20b; +MI0006696 oan-mir-19b;oan-mir-19b-1; +MI0006697 oan-mir-92a-1; +MI0006698 oan-mir-363; +MI0006699 oan-mir-1339; +MI0006700 oan-mir-1a; +MI0006701 oan-mir-133a;oan-mir-133a-1; +MI0006702 oan-mir-29a-2; +MI0006703 oan-mir-205; +MI0006704 oan-mir-1340; +MI0006705 oan-mir-135b;oan-mir-135b-1; +MI0006706 oan-mir-1341; +MI0006707 oan-mir-1342; +MI0006708 oan-mir-1343; +MI0006709 oan-mir-196a; +MI0006710 oan-mir-137b; +MI0006711 oan-mir-1422a; +MI0006712 oan-mir-1422e; +MI0006713 oan-mir-1422h; +MI0006714 oan-mir-1422b-1; +MI0006715 oan-mir-1422f; +MI0006716 oan-mir-1422g; +MI0006717 oan-mir-1422c; +MI0006718 oan-mir-1422i; +MI0006719 oan-mir-1422k; +MI0006720 oan-let-7b; +MI0006721 oan-mir-219; +MI0006722 oan-mir-451; +MI0006723 oan-mir-144; +MI0006724 oan-mir-139; +MI0006725 oan-mir-1344; +MI0006726 oan-mir-130c; +MI0006727 oan-mir-301; +MI0006728 oan-mir-30c;oan-mir-30c-2; +MI0006729 oan-mir-30a; +MI0006730 oan-mir-460; +MI0006731 oan-mir-1345; +MI0006732 oan-mir-92b; +MI0006733 oan-mir-1346; +MI0006734 oan-mir-208; +MI0006735 oan-mir-1420a; +MI0006736 oan-mir-1420b; +MI0006737 oan-mir-1420c; +MI0006738 oan-mir-1420d; +MI0006739 oan-mir-1420e; +MI0006740 oan-mir-1347; +MI0006741 oan-mir-186; +MI0006742 oan-mir-1348; +MI0006743 oan-mir-1349; +MI0006744 oan-mir-200a; +MI0006745 oan-mir-200b; +MI0006746 oan-mir-1422l; +MI0006747 oan-mir-1350; +MI0006748 oan-mir-103-2; +MI0006749 oan-mir-1351; +MI0006750 oan-mir-1420f; +MI0006751 oan-mir-1352; +MI0006752 oan-mir-1353; +MI0006753 oan-mir-1354; +MI0006754 oan-mir-499; +MI0006755 oan-mir-1355; +MI0006756 oan-mir-1356; +MI0006757 oan-mir-24;oan-mir-24-1; +MI0006758 oan-mir-27b; +MI0006759 oan-mir-23b; +MI0006760 oan-mir-1357; +MI0006761 oan-mir-22; +MI0006762 oan-mir-1421a; +MI0006763 oan-mir-1421b; +MI0006764 oan-mir-1421c; +MI0006765 oan-mir-1421d; +MI0006766 oan-mir-1421e; +MI0006767 oan-mir-1421f; +MI0006768 oan-mir-1421g-1; +MI0006769 oan-mir-1421h; +MI0006770 oan-mir-1421i-1; +MI0006771 oan-mir-1421j; +MI0006772 oan-mir-142; +MI0006773 oan-let-7e; +MI0006774 oan-mir-7-2; +MI0006775 oan-mir-155; +MI0006776 oan-mir-1358; +MI0006777 oan-mir-26;oan-mir-26-1; +MI0006778 oan-mir-1359; +MI0006779 oan-mir-206; +MI0006780 oan-mir-133b; +MI0006781 oan-mir-190b; +MI0006782 oan-mir-194-1; +MI0006783 oan-mir-215; +MI0006784 oan-mir-1360; +MI0006785 oan-mir-147; +MI0006786 oan-mir-153;oan-mir-153-1; +MI0006787 oan-mir-128-1; +MI0006788 oan-mir-146b; +MI0006789 oan-mir-458; +MI0006790 oan-mir-101-1; +MI0006791 oan-mir-449c; +MI0006792 oan-mir-449b; +MI0006793 oan-mir-449a; +MI0006794 oan-mir-192; +MI0006795 oan-mir-194-2; +MI0006796 oan-mir-223; +MI0006797 oan-mir-1361; +MI0006798 oan-mir-1362; +MI0006799 oan-mir-1363; +MI0006800 oan-mir-1364; +MI0006801 oan-mir-1365; +MI0006802 oan-mir-1366; +MI0006803 oan-mir-1367; +MI0006804 oan-mir-1368; +MI0006805 oan-mir-1369; +MI0006806 oan-mir-1370; +MI0006807 oan-mir-1371; +MI0006808 oan-mir-30f; +MI0006809 oan-let-7g; +MI0006810 oan-mir-1372; +MI0006811 oan-mir-33b; +MI0006812 oan-mir-30d; +MI0006813 oan-mir-30b; +MI0006814 oan-mir-184; +MI0006815 oan-mir-100; +MI0006816 oan-mir-125; +MI0006818 oan-mir-15b; +MI0006819 oan-mir-16b; +MI0006820 oan-mir-1373; +MI0006821 oan-mir-1374; +MI0006822 oan-mir-222b;oan-mir-222b-1; +MI0006823 oan-mir-181c; +MI0006824 oan-mir-23a; +MI0006825 oan-mir-27a; +MI0006826 oan-mir-1375; +MI0006827 oan-mir-1421k-1; +MI0006828 oan-mir-1421l-1; +MI0006829 oan-mir-1419a; +MI0006830 oan-mir-1421m; +MI0006831 oan-mir-1421n-1; +MI0006832 oan-mir-1421o; +MI0006833 oan-mir-1421p-1; +MI0006834 oan-mir-1421q; +MI0006835 oan-mir-1421r; +MI0006836 oan-mir-1421s; +MI0006837 oan-mir-1421t; +MI0006838 oan-mir-1421n-2; +MI0006839 oan-mir-1421u; +MI0006840 oan-mir-150; +MI0006841 oan-mir-1422j; +MI0006842 oan-mir-1422d; +MI0006843 oan-mir-590; +MI0006844 oan-mir-130a; +MI0006845 oan-mir-1422m; +MI0006846 oan-mir-1422n; +MI0006847 oan-mir-1422o; +MI0006848 oan-mir-1376; +MI0006849 oan-mir-1377; +MI0006850 oan-mir-34;oan-mir-34a; +MI0006852 oan-mir-1378; +MI0006853 oan-mir-31; +MI0006854 oan-mir-124;oan-mir-124a-1; +MI0006855 oan-mir-1379; +MI0006856 oan-mir-1380; +MI0006857 oan-mir-107; +MI0006858 oan-mir-1381; +MI0006859 oan-mir-10a; +MI0006860 oan-mir-1382; +MI0006861 oan-mir-126; +MI0006862 oan-mir-429; +MI0006863 oan-mir-551; +MI0006864 oan-mir-1383; +MI0006865 oan-mir-222a; +MI0006866 oan-mir-221; +MI0006867 oan-mir-1384; +MI0006868 oan-mir-148; +MI0006869 oan-mir-196b; +MI0006870 oan-mir-145; +MI0006871 oan-mir-143; +MI0006872 oan-mir-20a-1; +MI0006873 oan-mir-19a; +MI0006874 oan-mir-20a-2; +MI0006875 oan-mir-92a-2; +MI0006876 oan-mir-1b; +MI0006877 oan-mir-133c; +MI0006878 oan-mir-1385; +MI0006879 oan-mir-191; +MI0006880 oan-mir-425; +MI0006881 oan-mir-454; +MI0006882 oan-mir-130b; +MI0006883 oan-mir-21; +MI0006884 oan-mir-1386; +MI0006885 oan-mir-1387; +MI0006886 oan-mir-15a; +MI0006887 oan-mir-16a; +MI0006888 oan-mir-1388; +MI0006889 oan-mir-214; +MI0006890 oan-mir-199; +MI0006891 oan-mir-1389; +MI0006892 oan-mir-128-2; +MI0006893 oan-mir-1390; +MI0006894 oan-mir-98; +MI0006895 oan-let-7f-2; +MI0006896 oan-mir-802; +MI0006897 oan-mir-99; +MI0006898 oan-mir-1391; +MI0006899 oan-mir-1392; +MI0006900 oan-mir-383; +MI0006901 oan-mir-1393; +MI0006902 oan-mir-135a; +MI0006903 oan-mir-302-2; +MI0006904 oan-mir-302-1; +MI0006905 oan-mir-1394; +MI0006906 oan-mir-1395; +MI0006907 oan-mir-1396; +MI0006908 oan-mir-1397; +MI0006909 oan-mir-1398; +MI0006910 oan-mir-1399; +MI0006911 oan-mir-30e; +MI0006912 oan-mir-1400; +MI0006913 oan-mir-1401; +MI0006914 oan-mir-1402; +MI0006915 oan-mir-1403; +MI0006916 oan-mir-1404; +MI0006917 oan-mir-1405; +MI0006918 oan-mir-1406; +MI0006919 oan-mir-138-1; +MI0006920 oan-mir-1407; +MI0006921 oan-mir-10b; +MI0006922 oan-mir-138-2; +MI0006923 oan-mir-217; +MI0006924 oan-mir-216;oan-mir-216a; +MI0006925 oan-mir-1408; +MI0006926 oan-mir-7-1; +MI0006927 oan-mir-1409; +MI0006928 oan-mir-1410; +MI0006929 oan-mir-1411; +MI0006930 oan-mir-103-1; +MI0006931 oan-mir-146a; +MI0006932 oan-mir-1412; +MI0006933 oan-mir-1413; +MI0006934 oan-let-7d; +MI0006935 oan-mir-1421v; +MI0006936 oan-mir-1421w; +MI0006937 oan-mir-1419b-1; +MI0006938 oan-mir-1421x; +MI0006939 oan-mir-1421y-1; +MI0006940 oan-mir-1421z; +MI0006941 oan-mir-1419c-1; +MI0006942 oan-mir-1421aa; +MI0006943 oan-mir-1421ab-1; +MI0006944 oan-mir-1419d; +MI0006945 oan-mir-1414; +MI0006946 oan-mir-1421ac-1; +MI0006947 oan-mir-1421ad; +MI0006948 oan-mir-1421ae; +MI0006949 oan-mir-1419e; +MI0006950 oan-mir-1421af; +MI0006951 oan-mir-187; +MI0006952 oan-mir-32; +MI0006953 oan-mir-1415; +MI0006954 oan-mir-1416; +MI0006955 oan-mir-101-2; +MI0006956 oan-mir-873; +MI0006957 oan-mir-1417; +MI0006959 oan-mir-1418; +MI0006960 oan-mir-17; +MI0006961 oan-mir-7-3; +MI0006962 oan-let-7f-1; +MI0006963 osa-MIR1423;osa-MIR1423a;osa-MIR1423; +MI0006964 osa-MIR1424; +MI0006965 osa-MIR1425; +MI0006966 osa-MIR1426; +MI0006967 osa-MIR1427; +MI0006968 osa-MIR1428;osa-MIR1428a; +MI0006969 osa-MIR1429; +MI0006970 osa-MIR1430; +MI0006971 osa-MIR1431; +MI0006972 osa-MIR1432; +MI0006973 osa-MIR1433;osa-MIR169r; +MI0006974 osa-MIR444b; +MI0006975 osa-MIR444c; +MI0006976 osa-MIR444d; +MI0006977 osa-MIR444e; +MI0006978 osa-MIR444f; +MI0006979 gga-mir-1329; +MI0006980 gga-mir-1397; +MI0006981 gga-mir-1416; +MI0006982 gga-mir-22; +MI0006983 gga-mir-551; +MI0006984 gga-mir-454; +MI0006985 gga-mir-33-2; +MI0006986 osa-MIR810b; +MI0006987 mdv1-mir-M9; +MI0006988 mdv1-mir-M10; +MI0006989 mdv1-mir-M11; +MI0006990 mdv1-mir-M12; +MI0006991 mdv1-mir-M13; +MI0006992 gga-mir-1434; +MI0006993 oan-mir-1421y-2; +MI0006994 oan-mir-1421y-3; +MI0006995 oan-mir-1419c-2; +MI0006996 oan-mir-1419c-3; +MI0006997 oan-mir-1421ag-1; +MI0006998 oan-mir-1419b-2; +MI0006999 oan-mir-1421ab-2; +MI0007000 oan-mir-1421ac-2; +MI0007001 oan-mir-1421ah; +MI0007002 oan-mir-1421ai; +MI0007003 oan-mir-1421aj; +MI0007004 oan-mir-1422b-2; +MI0007005 oan-mir-1421g-2; +MI0007006 oan-mir-1421g-3; +MI0007007 oan-mir-1421i-2; +MI0007008 oan-mir-1421i-3; +MI0007009 oan-mir-1421k-2; +MI0007010 oan-mir-1421k-3; +MI0007011 oan-mir-1421l-2; +MI0007012 oan-mir-1421p-2; +MI0007013 oan-mir-1421ak; +MI0007014 oan-mir-1421al; +MI0007015 oan-mir-1421am; +MI0007016 oan-mir-1422p; +MI0007017 oan-mir-1422q; +MI0007018 oan-mir-1420g; +MI0007019 oan-mir-1419f; +MI0007020 oan-mir-1419g; +MI0007021 osa-MIR1435; +MI0007022 osa-MIR1436; +MI0007024 osa-MIR1437;osa-MIR1437a; +MI0007025 osa-MIR1438; +MI0007028 osa-MIR1440;osa-MIR1440a; +MI0007029 osa-MIR1441; +MI0007030 osa-MIR1442; +MI0007031 osa-MIR1439; +MI0007032 ptc-MIR171l; +MI0007033 ptc-MIR171m; +MI0007034 ptc-MIR171n;ptc-MIR171j; +MI0007035 ptc-MIR530a; +MI0007036 ptc-MIR530b; +MI0007037 ptc-MIR1444a; +MI0007038 ptc-MIR1444b; +MI0007039 ptc-MIR1444c; +MI0007040 ptc-MIR1445; +MI0007041 ptc-MIR827; +MI0007042 ptc-MIR1446a; +MI0007043 ptc-MIR1446b; +MI0007044 ptc-MIR1446c; +MI0007045 ptc-MIR1446d; +MI0007046 ptc-MIR1446e; +MI0007047 ptc-MIR1447; +MI0007048 ptc-MIR1448; +MI0007049 ptc-MIR1449; +MI0007050 ptc-MIR1450; +MI0007051 osa-MIR827;osa-MIR827c; +MI0007052 pta-MIR482c; +MI0007053 pta-MIR482d; +MI0007054 gga-mir-1451; +MI0007055 gga-mir-460b; +MI0007056 gga-mir-1452; +MI0007057 gga-mir-1306; +MI0007058 gga-mir-1453; +MI0007059 gga-mir-1454; +MI0007060 gga-mir-1455; +MI0007061 gga-mir-1456; +MI0007062 gga-mir-1457; +MI0007063 gga-mir-1458; +MI0007064 gga-mir-1459; +MI0007065 gga-mir-1460; +MI0007066 gga-mir-1461;gga-mir-216c; +MI0007067 gga-mir-1462; +MI0007068 gga-mir-1463; +MI0007069 gga-mir-1464; +MI0007070 gga-mir-1465; +MI0007071 gga-mir-1466; +MI0007072 gga-mir-1467;gga-mir-1467-1; +MI0007073 hiv1-mir-TAR; +MI0007074 hsa-mir-1469; +MI0007075 hsa-mir-1470; +MI0007076 hsa-mir-1471; +MI0007077 ssc-mir-99b; +MI0007078 oan-mir-1421ag-2; +MI0007079 odi-mir-1468; +MI0007080 odi-mir-1469; +MI0007081 odi-mir-1470; +MI0007082 odi-mir-1471; +MI0007083 odi-mir-1472; +MI0007084 odi-mir-1473; +MI0007085 odi-mir-1474; +MI0007086 odi-mir-1475; +MI0007087 odi-mir-1476; +MI0007088 odi-mir-1477; +MI0007089 odi-mir-1478; +MI0007090 odi-mir-1479; +MI0007091 odi-mir-1480; +MI0007092 odi-mir-1481; +MI0007093 odi-mir-1482; +MI0007094 odi-mir-1483; +MI0007095 odi-mir-1484; +MI0007096 odi-mir-1485; +MI0007097 odi-mir-1486; +MI0007098 odi-mir-1487; +MI0007099 odi-mir-1489; +MI0007100 odi-mir-1490a-1; +MI0007101 odi-mir-1490a-2; +MI0007102 odi-mir-1490b; +MI0007103 odi-mir-1491; +MI0007104 odi-mir-1492; +MI0007105 odi-mir-1493-1; +MI0007106 odi-mir-1493-2; +MI0007107 odi-mir-1494; +MI0007108 odi-mir-1495; +MI0007109 odi-mir-1496; +MI0007110 odi-mir-1497a; +MI0007111 odi-mir-1497b; +MI0007112 odi-mir-1497c; +MI0007113 odi-mir-1497d-1; +MI0007114 odi-mir-1497d-2; +MI0007115 odi-mir-1497e; +MI0007116 odi-mir-1497f-1; +MI0007117 odi-mir-1497f-2; +MI0007118 odi-mir-1497g; +MI0007119 odi-mir-1497h; +MI0007120 odi-mir-1498; +MI0007121 odi-mir-1499; +MI0007122 odi-mir-1500; +MI0007123 odi-mir-1501; +MI0007124 odi-mir-1502; +MI0007125 odi-mir-1503; +MI0007126 odi-mir-1504; +MI0007127 odi-mir-1505; +MI0007128 odi-mir-1506; +MI0007129 cin-mir-1473; +MI0007130 cin-mir-1497; +MI0007131 csa-mir-1473; +MI0007132 csa-mir-1497; +MI0007133 odi-mir-1a; +MI0007134 odi-mir-1b; +MI0007135 odi-mir-1c; +MI0007136 odi-let-7a; +MI0007137 odi-let-7b; +MI0007138 odi-let-7c; +MI0007139 odi-let-7d; +MI0007140 odi-mir-7-1; +MI0007141 odi-mir-7-2; +MI0007142 odi-mir-31; +MI0007143 odi-mir-92a; +MI0007144 odi-mir-92b; +MI0007145 odi-mir-124a; +MI0007146 odi-mir-124b; +MI0007147 odi-mir-219; +MI0007148 odi-mir-281; +MI0007149 cin-let-7a-1; +MI0007150 cin-let-7a-2; +MI0007151 cin-let-7b; +MI0007152 cin-let-7c; +MI0007153 cin-let-7d; +MI0007154 cin-let-7e; +MI0007155 cin-mir-7; +MI0007156 cin-mir-31; +MI0007157 cin-mir-33; +MI0007158 cin-mir-34; +MI0007159 cin-mir-78; +MI0007160 cin-mir-92a; +MI0007161 cin-mir-92b; +MI0007162 cin-mir-92c; +MI0007163 cin-mir-101; +MI0007164 cin-mir-124-1; +MI0007165 cin-mir-124-2; +MI0007166 cin-mir-126; +MI0007167 cin-mir-133; +MI0007168 cin-mir-141; +MI0007169 cin-mir-153; +MI0007170 cin-mir-155; +MI0007171 cin-mir-181; +MI0007172 cin-mir-183; +MI0007173 cin-mir-184; +MI0007174 cin-mir-199; +MI0007175 cin-mir-200; +MI0007176 cin-mir-216; +MI0007177 cin-mir-217; +MI0007178 cin-mir-219; +MI0007179 cin-mir-281; +MI0007180 cin-mir-672; +MI0007181 csa-let-7a; +MI0007182 csa-let-7b; +MI0007183 csa-let-7c-1; +MI0007184 csa-let-7c-2; +MI0007185 csa-let-7d; +MI0007186 csa-mir-7; +MI0007187 csa-mir-31; +MI0007188 csa-mir-34; +MI0007189 csa-mir-92a; +MI0007190 csa-mir-92b; +MI0007191 csa-mir-92c; +MI0007192 csa-mir-124-1; +MI0007193 csa-mir-124-2; +MI0007194 csa-mir-126; +MI0007195 csa-mir-133; +MI0007196 csa-mir-141; +MI0007197 csa-mir-153; +MI0007198 csa-mir-155; +MI0007199 csa-mir-183; +MI0007200 csa-mir-200; +MI0007201 csa-mir-216a; +MI0007202 csa-mir-216b; +MI0007203 csa-mir-217; +MI0007204 csa-mir-219; +MI0007205 csa-mir-281; +MI0007206 gma-MIR159b; +MI0007207 gma-MIR159c; +MI0007208 gma-MIR162;gma-MIR162a; +MI0007209 gma-MIR164;gma-MIR164a; +MI0007210 gma-MIR167c; +MI0007211 gma-MIR169b; +MI0007212 gma-MIR169c; +MI0007213 gma-MIR171a; +MI0007214 gma-MIR390a; +MI0007215 gma-MIR390b; +MI0007216 gma-MIR393;gma-MIR393a; +MI0007217 gma-MIR171b; +MI0007218 gma-MIR482;gma-MIR482a; +MI0007219 gma-MIR1507;gma-MIR1507a; +MI0007220 gma-MIR1508;gma-MIR1508a; +MI0007221 gma-MIR1509;gma-MIR1509a; +MI0007222 gma-MIR1510;gma-MIR1510a; +MI0007223 gma-MIR1511; +MI0007224 gma-MIR1512;gma-MIR1512a; +MI0007225 gma-MIR1513;gma-MIR1513a; +MI0007226 gma-MIR1514a; +MI0007227 gma-MIR1514b; +MI0007228 gma-MIR1515;gma-MIR1515a; +MI0007229 gma-MIR1516;gma-MIR1516a; +MI0007230 gma-MIR1517; +MI0007231 gma-MIR1518; +MI0007232 gma-MIR1519; +MI0007233 gma-MIR1520d; +MI0007234 gma-MIR1536; +MI0007235 gma-MIR1520a; +MI0007236 gma-MIR1521;gma-MIR1521a; +MI0007237 gma-MIR1522; +MI0007240 gma-MIR1523;gma-MIR1523a; +MI0007241 gma-MIR1524; +MI0007242 gma-MIR1525; +MI0007243 gma-MIR1520b; +MI0007244 gma-MIR1526; +MI0007245 gma-MIR1527; +MI0007246 gma-MIR1528; +MI0007248 gma-MIR1529; +MI0007249 gma-MIR1530; +MI0007250 gma-MIR1531; +MI0007251 gma-MIR1532; +MI0007252 gma-MIR1520c; +MI0007253 gma-MIR1533; +MI0007254 gma-MIR1534; +MI0007257 gma-MIR1535;gma-MIR1535a; +MI0007258 hsa-mir-1537; +MI0007259 hsa-mir-1538; +MI0007260 hsa-mir-1539; +MI0007261 hsa-mir-103-1-as;hsa-mir-103b-1; +MI0007262 hsa-mir-103-2-as;hsa-mir-103b-2; +MI0007263 mdo-mir-1540;mdo-mir-1540a; +MI0007264 mdo-mir-1541; +MI0007265 mdo-mir-1542-1; +MI0007266 mdo-mir-1542-2; +MI0007267 mdo-mir-1543; +MI0007268 mdo-mir-340; +MI0007269 mdo-mir-1544;mdo-mir-1544a; +MI0007270 mdo-mir-1545;mdo-mir-1545a; +MI0007271 mdo-mir-1546; +MI0007272 mdo-mir-1547; +MI0007273 mdo-mir-1548; +MI0007274 mdo-mir-1549; +MI0007275 gga-mir-1550; +MI0007276 gga-mir-1551; +MI0007277 gga-mir-1552; +MI0007278 gga-mir-1553; +MI0007279 gga-mir-1554; +MI0007280 gga-mir-1555; +MI0007281 gga-mir-1556; +MI0007282 gga-mir-1557; +MI0007283 gga-mir-1558; +MI0007284 gga-mir-1559; +MI0007285 gga-mir-1560; +MI0007286 gga-mir-1561; +MI0007287 gga-mir-1562; +MI0007288 gga-mir-1563; +MI0007289 gga-mir-1564; +MI0007290 gga-mir-1565; +MI0007291 gga-mir-1566; +MI0007292 gga-mir-1567; +MI0007293 gga-mir-1568; +MI0007294 gga-mir-1569-1; +MI0007295 gga-mir-1569-2;gga-mir-1569; +MI0007296 gga-mir-1570; +MI0007297 gga-mir-1571; +MI0007298 gga-mir-1572; +MI0007299 gga-mir-1573; +MI0007300 gga-mir-1574; +MI0007301 gga-mir-1575; +MI0007302 gga-mir-1576; +MI0007303 gga-mir-1577; +MI0007304 gga-mir-1578; +MI0007305 gga-mir-1579; +MI0007306 gga-mir-1580; +MI0007307 gga-mir-1581; +MI0007308 gga-mir-1582; +MI0007309 gga-mir-1583; +MI0007310 gga-mir-1584; +MI0007311 gga-mir-1354; +MI0007312 gga-mir-1585; +MI0007313 gga-mir-1586; +MI0007314 gga-mir-1587; +MI0007315 gga-mir-1588; +MI0007316 gga-mir-1589; +MI0007317 gga-mir-1590; +MI0007318 gga-mir-1591; +MI0007319 gga-mir-1592; +MI0007320 gga-mir-1593; +MI0007321 gga-mir-1594; +MI0007322 gga-mir-1595; +MI0007323 gga-mir-1596; +MI0007324 gga-mir-1597; +MI0007325 gga-mir-1598; +MI0007326 gga-mir-1599; +MI0007327 gga-mir-1600; +MI0007328 gga-mir-1601; +MI0007329 gga-mir-1602; +MI0007330 gga-mir-1603; +MI0007331 gga-mir-1604; +MI0007332 gga-mir-1605; +MI0007333 gga-mir-1606; +MI0007334 gga-mir-1607; +MI0007335 gga-mir-1608; +MI0007336 gga-mir-1609-1;gga-mir-1609; +MI0007337 gga-mir-1609-2; +MI0007338 gga-mir-1610; +MI0007339 gga-mir-1611; +MI0007340 gga-mir-1612; +MI0007341 gga-mir-1613-1;gga-mir-1613; +MI0007342 gga-mir-1613-2; +MI0007343 gga-mir-1614; +MI0007344 gga-mir-1615; +MI0007345 gga-mir-1616; +MI0007346 gga-mir-1617; +MI0007347 gga-mir-1618; +MI0007348 gga-mir-1619; +MI0007349 gga-mir-1620; +MI0007350 gga-mir-1621; +MI0007351 gga-mir-1622; +MI0007352 gga-mir-1623; +MI0007353 gga-mir-1624; +MI0007354 gga-mir-1625; +MI0007355 gga-mir-1626; +MI0007356 gga-mir-1627; +MI0007357 gga-mir-1628; +MI0007358 gga-mir-1629; +MI0007359 gga-mir-1630; +MI0007360 gga-mir-1631; +MI0007361 gga-mir-1c; +MI0007362 gga-mir-1632; +MI0007363 gga-mir-1633; +MI0007364 gga-mir-1634;gga-mir-1634-1; +MI0007365 gga-mir-1635; +MI0007366 gga-mir-1636; +MI0007367 gga-mir-1637; +MI0007368 gga-mir-1638; +MI0007369 gga-mir-1815; +MI0007370 gga-mir-1814; +MI0007371 gga-mir-1639; +MI0007372 gga-mir-1640; +MI0007373 gga-mir-1641; +MI0007374 gga-mir-1642; +MI0007375 gga-mir-1643; +MI0007376 gga-mir-1644; +MI0007377 gga-mir-1645; +MI0007378 gga-mir-1646; +MI0007379 gga-mir-1647; +MI0007380 gga-mir-1648; +MI0007381 gga-mir-1649; +MI0007382 gga-mir-1650; +MI0007383 gga-mir-1651; +MI0007384 gga-mir-1652; +MI0007385 gga-mir-1653; +MI0007386 gga-mir-1654-1;gga-mir-1654; +MI0007387 gga-mir-1654-2; +MI0007388 gga-mir-1655; +MI0007389 gga-mir-1656; +MI0007390 gga-mir-135b; +MI0007391 gga-mir-1657; +MI0007392 gga-mir-1658; +MI0007393 gga-mir-1659; +MI0007394 gga-mir-1660; +MI0007395 gga-mir-1661; +MI0007396 gga-mir-1662; +MI0007397 gga-mir-1663; +MI0007398 gga-mir-1664; +MI0007399 gga-mir-1665; +MI0007400 gga-mir-1666; +MI0007401 gga-mir-1667; +MI0007402 gga-mir-1668; +MI0007403 gga-mir-1669; +MI0007404 gga-mir-1670; +MI0007405 gga-mir-1671; +MI0007406 gga-mir-1672; +MI0007407 gga-mir-1673; +MI0007408 gga-mir-1674; +MI0007409 gga-mir-1675; +MI0007410 gga-mir-1676; +MI0007411 gga-mir-1677; +MI0007412 gga-mir-1678; +MI0007413 gga-mir-1679; +MI0007414 gga-mir-1680; +MI0007415 gga-mir-1681; +MI0007416 gga-mir-1682; +MI0007417 gga-mir-1683; +MI0007418 gga-mir-1684;gga-mir-1684a; +MI0007419 gga-mir-1685; +MI0007420 gga-mir-1686; +MI0007421 gga-mir-1687; +MI0007422 gga-mir-1688; +MI0007423 gga-mir-1689; +MI0007424 gga-mir-1690; +MI0007425 gga-mir-1691; +MI0007426 gga-mir-199b; +MI0007427 gga-mir-1692; +MI0007428 gga-mir-1693; +MI0007429 gga-mir-1694; +MI0007430 gga-mir-1695; +MI0007431 gga-mir-1696; +MI0007432 gga-mir-1697; +MI0007433 gga-mir-1698;gga-mir-1698-1; +MI0007434 gga-mir-1699; +MI0007435 gga-mir-1700; +MI0007436 gga-mir-1701; +MI0007437 gga-mir-1702; +MI0007438 gga-mir-1703; +MI0007439 gga-mir-1704; +MI0007440 gga-mir-1705; +MI0007441 gga-mir-1706; +MI0007442 gga-mir-1707; +MI0007443 gga-mir-1813-2; +MI0007444 gga-mir-1708; +MI0007445 gga-mir-449c; +MI0007446 gga-mir-1709; +MI0007447 gga-mir-1710; +MI0007448 gga-mir-1711; +MI0007449 gga-mir-1712; +MI0007450 gga-mir-1713; +MI0007451 gga-mir-1714; +MI0007452 gga-mir-1715; +MI0007453 gga-mir-1716; +MI0007454 gga-mir-1717; +MI0007455 gga-mir-1718; +MI0007456 gga-mir-1719; +MI0007457 gga-mir-1720; +MI0007458 gga-mir-1721; +MI0007459 gga-mir-1722; +MI0007460 gga-mir-1723; +MI0007461 gga-mir-1724; +MI0007462 gga-mir-1725; +MI0007463 gga-mir-1726; +MI0007464 gga-mir-1727-1;gga-mir-1727; +MI0007465 gga-mir-1727-2; +MI0007466 gga-mir-1728; +MI0007467 gga-mir-1813-1; +MI0007468 gga-mir-1729; +MI0007469 gga-mir-1730; +MI0007470 gga-mir-1731; +MI0007471 gga-mir-1732;gga-mir-1732-1; +MI0007472 gga-mir-1733; +MI0007473 gga-mir-1734; +MI0007474 gga-mir-1735; +MI0007475 gga-mir-1736; +MI0007476 gga-mir-1737; +MI0007477 gga-mir-1738; +MI0007478 gga-mir-1739; +MI0007479 gga-mir-1740; +MI0007480 gga-mir-1741; +MI0007481 gga-mir-1742; +MI0007482 gga-mir-1743; +MI0007483 gga-mir-1744; +MI0007484 gga-mir-1745-1;gga-mir-1745; +MI0007485 gga-mir-1745-2; +MI0007486 gga-mir-1746; +MI0007487 gga-mir-1747; +MI0007488 gga-mir-1748; +MI0007489 gga-mir-1749; +MI0007490 gga-mir-1816; +MI0007491 gga-mir-1750; +MI0007492 gga-mir-1751; +MI0007493 gga-mir-1752; +MI0007494 gga-mir-1753-1;gga-mir-1753; +MI0007495 gga-mir-1753-2; +MI0007496 gga-mir-1754; +MI0007497 gga-mir-1755; +MI0007498 gga-mir-1756a; +MI0007499 gga-mir-1757; +MI0007500 gga-mir-1758; +MI0007501 gga-mir-1759; +MI0007502 gga-mir-1760; +MI0007503 gga-mir-1761; +MI0007504 gga-mir-1762; +MI0007505 gga-mir-1763; +MI0007506 gga-mir-1764; +MI0007507 gga-mir-1765; +MI0007508 gga-mir-1766-1;gga-mir-1766; +MI0007509 gga-mir-1766-2; +MI0007510 gga-mir-1767; +MI0007511 gga-mir-1768; +MI0007512 gga-mir-1769; +MI0007513 gga-mir-1770; +MI0007514 gga-mir-1771; +MI0007515 gga-mir-1772; +MI0007516 gga-mir-1773; +MI0007517 gga-mir-1774; +MI0007518 gga-mir-1775; +MI0007519 gga-mir-1776; +MI0007520 gga-mir-1777; +MI0007521 gga-mir-1778; +MI0007522 gga-mir-1779; +MI0007523 gga-mir-1780; +MI0007524 gga-mir-1781; +MI0007525 gga-mir-1782; +MI0007526 gga-mir-1783; +MI0007527 gga-mir-1784; +MI0007528 gga-mir-1785; +MI0007529 gga-mir-1786; +MI0007530 gga-mir-1787; +MI0007531 gga-mir-1788; +MI0007532 gga-mir-1789; +MI0007533 gga-mir-1790; +MI0007534 gga-mir-1791; +MI0007535 gga-mir-1792; +MI0007536 gga-mir-1793; +MI0007537 gga-mir-1794; +MI0007538 gga-mir-1795; +MI0007539 gga-mir-1796; +MI0007540 gga-mir-1797; +MI0007541 gga-mir-1756b; +MI0007542 gga-mir-1798; +MI0007543 gga-mir-1799; +MI0007544 gga-mir-1800; +MI0007545 gga-mir-1801; +MI0007546 gga-mir-1802; +MI0007547 gga-mir-122b; +MI0007548 gga-mir-1803; +MI0007549 gga-mir-1804; +MI0007550 gga-mir-1805; +MI0007551 gga-mir-1806; +MI0007552 gga-mir-1807; +MI0007553 gga-mir-1808; +MI0007554 gga-mir-1809; +MI0007555 gga-mir-1810; +MI0007556 gga-mir-1811; +MI0007557 gga-mir-1812; +MI0007558 gga-mir-101-2; +MI0007559 gga-mir-10a; +MI0007560 gga-mir-130c; +MI0007561 gga-mir-146c;gga-mir-146c-1;gga-mir-146c; +MI0007562 gga-mir-15c; +MI0007563 gga-mir-16c; +MI0007564 gga-mir-193a; +MI0007565 gga-mir-301b; +MI0007566 gga-mir-449b; +MI0007567 gga-mir-458;gga-mir-458a; +MI0007568 mml-mir-1-1; +MI0007569 mml-mir-1-2; +MI0007570 mml-let-7a-1; +MI0007571 mml-let-7a-2; +MI0007572 mml-let-7a-3; +MI0007573 mml-let-7b; +MI0007574 mml-let-7c; +MI0007575 mml-let-7d; +MI0007576 mml-let-7e; +MI0007577 mml-let-7f-1; +MI0007578 mml-let-7f-2; +MI0007579 mml-let-7g; +MI0007580 mml-let-7i; +MI0007581 mml-mir-7-1; +MI0007582 mml-mir-7-2; +MI0007583 mml-mir-7-3; +MI0007584 mml-mir-9-1; +MI0007585 mml-mir-9-2; +MI0007586 mml-mir-9-3; +MI0007587 mml-mir-10a; +MI0007588 mml-mir-10b; +MI0007589 mml-mir-16-2; +MI0007590 mml-mir-18b; +MI0007591 mml-mir-20b; +MI0007592 mml-mir-23b; +MI0007593 mml-mir-26a-2; +MI0007594 mml-mir-26b; +MI0007595 mml-mir-27b; +MI0007596 mml-mir-29b-1; +MI0007597 mml-mir-29b-2; +MI0007598 mml-mir-29c; +MI0007599 mml-mir-30c-1; +MI0007600 mml-mir-30c-2; +MI0007601 mml-mir-30d; +MI0007602 mml-mir-30e; +MI0007603 mml-mir-33b; +MI0007604 mml-mir-34b; +MI0007605 mml-mir-34c; +MI0007606 mml-mir-92a-2; +MI0007607 mml-mir-92b; +MI0007608 mml-mir-95; +MI0007609 mml-mir-99b; +MI0007610 mml-mir-101-2; +MI0007611 mml-mir-103-2; +MI0007612 mml-mir-105-2; +MI0007613 mml-mir-122a; +MI0007614 mml-mir-124a-2; +MI0007615 mml-mir-125a; +MI0007616 mml-mir-126; +MI0007617 mml-mir-128b; +MI0007618 mml-mir-129;mml-mir-129-1; +MI0007619 mml-mir-130b; +MI0007620 mml-mir-132; +MI0007621 mml-mir-133c; +MI0007622 mml-mir-133b; +MI0007623 mml-mir-134; +MI0007624 mml-mir-135a-1; +MI0007625 mml-mir-135b; +MI0007626 mml-mir-136; +MI0007627 mml-mir-137; +MI0007628 mml-mir-138; +MI0007629 mml-mir-139; +MI0007630 mml-mir-140; +MI0007631 mml-mir-142; +MI0007632 mml-mir-143; +MI0007633 mml-mir-144; +MI0007634 mml-mir-146a; +MI0007635 mml-mir-146b; +MI0007636 mml-mir-147a; +MI0007637 mml-mir-147b; +MI0007638 mml-mir-148a; +MI0007639 mml-mir-148b; +MI0007640 mml-mir-149; +MI0007641 mml-mir-150; +MI0007642 mml-mir-151; +MI0007643 mml-mir-152; +MI0007644 mml-mir-154; +MI0007645 mml-mir-155; +MI0007646 mml-mir-181b-2; +MI0007647 mml-mir-181d; +MI0007648 mml-mir-184; +MI0007649 mml-mir-185; +MI0007650 mml-mir-186; +MI0007651 mml-mir-187; +MI0007652 mml-mir-190b; +MI0007653 mml-mir-191; +MI0007654 mml-mir-192; +MI0007655 mml-mir-193a; +MI0007656 mml-mir-193b; +MI0007657 mml-mir-194-2; +MI0007658 mml-mir-195; +MI0007659 mml-mir-196a-2; +MI0007660 mml-mir-196b; +MI0007661 mml-mir-197; +MI0007662 mml-mir-199a-2; +MI0007663 mml-mir-200a; +MI0007664 mml-mir-203; +MI0007665 mml-mir-204; +MI0007666 mml-mir-205; +MI0007667 mml-mir-206; +MI0007668 mml-mir-208a; +MI0007669 mml-mir-208b; +MI0007670 mml-mir-210; +MI0007671 mml-mir-212; +MI0007672 mml-mir-216a; +MI0007673 mml-mir-216b; +MI0007674 mml-mir-217;mml-mir-217a;mml-mir-217; +MI0007675 mml-mir-218-1; +MI0007676 mml-mir-219-2; +MI0007677 mml-mir-220b; +MI0007678 mml-mir-220c; +MI0007679 mml-mir-220d; +MI0007680 mml-mir-222; +MI0007681 mml-mir-296; +MI0007682 mml-mir-297; +MI0007683 mml-mir-298; +MI0007684 mml-mir-299; +MI0007685 mml-mir-301a; +MI0007686 mml-mir-301b; +MI0007687 mml-mir-302a; +MI0007688 mml-mir-302b; +MI0007689 mml-mir-302c; +MI0007690 mml-mir-302d; +MI0007691 mml-mir-320;mml-mir-320a; +MI0007692 mml-mir-323;mml-mir-323a; +MI0007693 mml-mir-324; +MI0007694 mml-mir-325; +MI0007695 mml-mir-329-1; +MI0007696 mml-mir-329-2; +MI0007697 mml-mir-330; +MI0007698 mml-mir-331; +MI0007699 mml-mir-335; +MI0007700 mml-mir-337; +MI0007701 mml-mir-338; +MI0007702 mml-mir-339; +MI0007703 mml-mir-340; +MI0007704 mml-mir-342; +MI0007705 mml-mir-345; +MI0007706 mml-mir-346; +MI0007707 mml-mir-361; +MI0007708 mml-mir-362; +MI0007709 mml-mir-363; +MI0007710 mml-mir-365-1; +MI0007711 mml-mir-365-2; +MI0007712 mml-mir-367; +MI0007713 mml-mir-369; +MI0007714 mml-mir-370; +MI0007715 mml-mir-371;mml-mir-371-1;mml-mir-371; +MI0007716 mml-mir-372; +MI0007717 mml-mir-373; +MI0007718 mml-mir-374a; +MI0007719 mml-mir-374b; +MI0007720 mml-mir-375; +MI0007721 mml-mir-376a-1; +MI0007722 mml-mir-376a-2; +MI0007723 mml-mir-376b; +MI0007724 mml-mir-376c; +MI0007725 mml-mir-377; +MI0007726 mml-mir-378;mml-mir-378a; +MI0007727 mml-mir-379; +MI0007728 mml-mir-380; +MI0007729 mml-mir-381; +MI0007730 mml-mir-382; +MI0007731 mml-mir-383; +MI0007732 mml-mir-384; +MI0007733 mml-mir-409; +MI0007734 mml-mir-410; +MI0007735 mml-mir-411; +MI0007736 mml-mir-412; +MI0007737 mml-mir-421; +MI0007738 mml-mir-422a; +MI0007739 mml-mir-423; +MI0007740 mml-mir-424; +MI0007741 mml-mir-425; +MI0007742 mml-mir-429; +MI0007743 mml-mir-431; +MI0007744 mml-mir-432; +MI0007745 mml-mir-433; +MI0007746 mml-mir-448; +MI0007747 mml-mir-449a; +MI0007748 mml-mir-449b; +MI0007749 mml-mir-450a-1; +MI0007750 mml-mir-450a-2; +MI0007751 mml-mir-450b; +MI0007752 mml-mir-451; +MI0007753 mml-mir-452; +MI0007754 mml-mir-453; +MI0007755 mml-mir-454; +MI0007756 mml-mir-455; +MI0007757 mml-mir-484; +MI0007758 mml-mir-485; +MI0007759 mml-mir-486; +MI0007760 mml-mir-487a; +MI0007761 mml-mir-487b; +MI0007762 mml-mir-488; +MI0007763 mml-mir-489; +MI0007764 mml-mir-490; +MI0007765 mml-mir-491; +MI0007766 mml-mir-492; +MI0007767 mml-mir-493; +MI0007768 mml-mir-494; +MI0007769 mml-mir-495; +MI0007770 mml-mir-496; +MI0007771 mml-mir-497; +MI0007772 mml-mir-498; +MI0007773 mml-mir-499; +MI0007774 mml-mir-500;mml-mir-500a; +MI0007775 mml-mir-501; +MI0007776 mml-mir-502; +MI0007777 mml-mir-503; +MI0007778 mml-mir-504; +MI0007779 mml-mir-505; +MI0007780 mml-mir-511-1;mml-mir-511; +MI0007781 mml-mir-511-2; +MI0007782 mml-mir-512-1;mml-mir-512; +MI0007783 mml-mir-512-2; +MI0007784 mml-mir-514-2; +MI0007785 mml-mir-516a-1; +MI0007786 mml-mir-516a-2; +MI0007787 mml-mir-517a;mml-mir-517;mml-mir-517a; +MI0007788 mml-mir-517b; +MI0007789 mml-mir-518a;mml-mir-518a-1; +MI0007790 mml-mir-518b; +MI0007791 mml-mir-518c; +MI0007792 mml-mir-518d; +MI0007793 mml-mir-518e; +MI0007794 mml-mir-518f; +MI0007795 mml-mir-519a; +MI0007796 mml-mir-519b; +MI0007797 mml-mir-519c; +MI0007798 mml-mir-519d; +MI0007799 mml-mir-520a; +MI0007800 mml-mir-520b; +MI0007801 mml-mir-520c; +MI0007802 mml-mir-520d; +MI0007803 mml-mir-520e; +MI0007804 mml-mir-520f; +MI0007805 mml-mir-520g; +MI0007806 mml-mir-520h; +MI0007807 mml-mir-521; +MI0007808 mml-mir-522; +MI0007809 mml-mir-523a; +MI0007810 mml-mir-523b; +MI0007811 mml-mir-523c-1; +MI0007812 mml-mir-523c-2; +MI0007813 mml-mir-525; +MI0007814 mml-mir-532; +MI0007815 mml-mir-539; +MI0007816 mml-mir-542; +MI0007817 mml-mir-544; +MI0007818 mml-mir-545; +MI0007819 mml-mir-548a; +MI0007820 mml-mir-548b; +MI0007821 mml-mir-548c; +MI0007822 mml-mir-548d; +MI0007823 mml-mir-548e; +MI0007824 mml-mir-548f; +MI0007825 mml-mir-549;mml-mir-549a; +MI0007826 mml-mir-550; +MI0007827 mml-mir-551a; +MI0007828 mml-mir-551b; +MI0007829 mml-mir-552; +MI0007830 mml-mir-553; +MI0007831 mml-mir-554; +MI0007832 mml-mir-556; +MI0007833 mml-mir-557; +MI0007834 mml-mir-558; +MI0007835 mml-mir-562; +MI0007836 mml-mir-563; +MI0007837 mml-mir-567; +MI0007838 mml-mir-568; +MI0007839 mml-mir-569; +MI0007840 mml-mir-570; +MI0007841 mml-mir-572; +MI0007842 mml-mir-573; +MI0007843 mml-mir-576; +MI0007844 mml-mir-577; +MI0007845 mml-mir-578; +MI0007846 mml-mir-579; +MI0007847 mml-mir-580; +MI0007848 mml-mir-581; +MI0007849 mml-mir-582; +MI0007850 mml-mir-583; +MI0007851 mml-mir-584; +MI0007852 mml-mir-586; +MI0007853 mml-mir-587; +MI0007854 mml-mir-589; +MI0007855 mml-mir-590; +MI0007856 mml-mir-592; +MI0007857 mml-mir-593; +MI0007858 mml-mir-597; +MI0007859 mml-mir-598; +MI0007860 mml-mir-599; +MI0007861 mml-mir-600; +MI0007862 mml-mir-601; +MI0007863 mml-mir-604; +MI0007864 mml-mir-605; +MI0007865 mml-mir-607; +MI0007866 mml-mir-609; +MI0007867 mml-mir-611; +MI0007868 mml-mir-612; +MI0007869 mml-mir-615; +MI0007870 mml-mir-616; +MI0007871 mml-mir-618; +MI0007872 mml-mir-619; +MI0007873 mml-mir-624; +MI0007874 mml-mir-625; +MI0007875 mml-mir-626; +MI0007876 mml-mir-627; +MI0007877 mml-mir-628; +MI0007878 mml-mir-631; +MI0007879 mml-mir-632; +MI0007880 mml-mir-633; +MI0007881 mml-mir-636; +MI0007882 mml-mir-638; +MI0007883 mml-mir-639; +MI0007884 mml-mir-640; +MI0007885 mml-mir-642; +MI0007886 mml-mir-643; +MI0007887 mml-mir-644; +MI0007888 mml-mir-648; +MI0007889 mml-mir-649; +MI0007890 mml-mir-650a-1; +MI0007891 mml-mir-650a-2; +MI0007892 mml-mir-650b; +MI0007893 mml-mir-650c; +MI0007894 mml-mir-650d; +MI0007895 mml-mir-651; +MI0007896 mml-mir-652; +MI0007897 mml-mir-653; +MI0007898 mml-mir-654; +MI0007899 mml-mir-656; +MI0007900 mml-mir-657; +MI0007901 mml-mir-660; +MI0007902 mml-mir-661; +MI0007903 mml-mir-662; +MI0007904 mml-mir-663;mml-mir-663-1; +MI0007905 mml-mir-664; +MI0007906 mml-mir-668; +MI0007907 mml-mir-671; +MI0007908 mml-mir-675; +MI0007909 mml-mir-758; +MI0007910 mml-mir-765; +MI0007911 mml-mir-767; +MI0007912 mml-mir-768; +MI0007913 mml-mir-770; +MI0007914 mml-mir-802; +MI0007915 mml-mir-874; +MI0007916 mml-mir-875; +MI0007917 mml-mir-876; +MI0007918 mml-mir-877; +MI0007919 mml-mir-885; +MI0007920 mml-mir-886; +MI0007921 mml-mir-887; +MI0007922 mml-mir-888; +MI0007923 mml-mir-889; +MI0007924 mml-mir-890; +MI0007925 mml-mir-891;mml-mir-891a; +MI0007926 mml-mir-892;mml-mir-892a; +MI0007927 mml-mir-920; +MI0007928 mml-mir-922; +MI0007929 mml-mir-924; +MI0007930 mml-mir-933; +MI0007931 mml-mir-934; +MI0007932 mml-mir-936; +MI0007933 mml-mir-937; +MI0007934 mml-mir-938; +MI0007935 mml-mir-939; +MI0007936 mml-mir-940; +MI0007937 mml-mir-942; +MI0007938 mml-mir-944; +MI0007939 vvi-MIR156h; +MI0007940 vvi-MIR169b; +MI0007941 vvi-MIR169h; +MI0007942 vvi-MIR169i; +MI0007943 vvi-MIR169l; +MI0007944 vvi-MIR169n; +MI0007945 vvi-MIR169o; +MI0007946 vvi-MIR169q; +MI0007947 vvi-MIR169v; +MI0007948 vvi-MIR169w; +MI0007949 vvi-MIR169x; +MI0007950 vvi-MIR171g; +MI0007951 vvi-MIR319e; +MI0007952 vvi-MIR393a; +MI0007953 vvi-MIR394c; +MI0007954 vvi-MIR395n; +MI0007955 vvi-MIR396c; +MI0007956 vvi-MIR397a; +MI0007957 vvi-MIR397b; +MI0007958 vvi-MIR398b; +MI0007959 vvi-MIR398c; +MI0007960 vvi-MIR399c; +MI0007961 vvi-MIR399d; +MI0007962 vvi-MIR399f; +MI0007963 vvi-MIR399i; +MI0007964 vvi-MIR403a; +MI0007965 vvi-MIR403b; +MI0007966 vvi-MIR403c; +MI0007967 vvi-MIR403d; +MI0007968 vvi-MIR403e; +MI0007969 vvi-MIR403f; +MI0007970 vvi-MIR477;vvi-MIR477a; +MI0007971 vvi-MIR482; +MI0007972 vvi-MIR828a; +MI0007973 vvi-MIR828b; +MI0007974 vvi-MIR845a; +MI0007975 vvi-MIR845b; +MI0007976 vvi-MIR845c; +MI0007977 vvi-MIR845d; +MI0007978 vvi-MIR845e; +MI0007979 cel-mir-1817; +MI0007980 cel-mir-1818; +MI0007981 cel-mir-1819; +MI0007982 cel-mir-1820; +MI0007983 cel-mir-1821; +MI0007984 cel-mir-1822; +MI0007985 cel-mir-1823; +MI0007986 cel-mir-1824; +MI0007987 cfa-mir-216;cfa-mir-216b; +MI0007988 cfa-mir-33;cfa-mir-33a; +MI0007989 cfa-let-7a;cfa-let-7a-1; +MI0007990 cfa-mir-26a-2; +MI0007991 cfa-mir-1835; +MI0007992 cfa-mir-32; +MI0007993 cfa-mir-204; +MI0007994 cfa-mir-31; +MI0007995 cfa-mir-101-2; +MI0007996 cfa-mir-371; +MI0007997 cfa-mir-491; +MI0007998 cfa-mir-150; +MI0007999 cfa-mir-455; +MI0008000 cfa-mir-30a; +MI0008001 cfa-mir-30c-2; +MI0008002 cfa-mir-206; +MI0008003 cfa-mir-99b; +MI0008004 cfa-let-7e; +MI0008005 cfa-mir-125a; +MI0008006 cfa-let-7f; +MI0008007 cfa-mir-219-1; +MI0008008 cfa-mir-23b; +MI0008009 cfa-mir-27b; +MI0008010 cfa-mir-24-1; +MI0008011 cfa-mir-151; +MI0008012 cfa-mir-30d; +MI0008013 cfa-mir-30b; +MI0008014 cfa-mir-1836; +MI0008015 cfa-mir-122; +MI0008016 cfa-mir-196b; +MI0008017 cfa-mir-183; +MI0008018 cfa-mir-148a; +MI0008019 cfa-mir-129-1; +MI0008020 cfa-mir-335; +MI0008021 cfa-mir-29b-1; +MI0008022 cfa-mir-29a; +MI0008023 cfa-mir-30e; +MI0008024 cfa-mir-30c-1; +MI0008025 cfa-mir-135;cfa-mir-135a-2; +MI0008026 cfa-mir-383; +MI0008027 cfa-mir-486; +MI0008028 cfa-mir-1837;cfa-mir-1837-1; +MI0008029 cfa-mir-130a; +MI0008030 cfa-mir-129-2; +MI0008031 cfa-mir-192; +MI0008032 cfa-mir-128-1; +MI0008033 cfa-mir-7-1; +MI0008034 cfa-mir-181c; +MI0008035 cfa-mir-181d; +MI0008036 cfa-let-7g; +MI0008037 cfa-mir-191; +MI0008038 cfa-mir-425; +MI0008039 cfa-mir-23a; +MI0008040 cfa-mir-27a; +MI0008041 cfa-mir-24-2; +MI0008042 cfa-mir-199-1; +MI0008043 cfa-mir-708; +MI0008044 cfa-mir-1838; +MI0008045 cfa-mir-139; +MI0008047 cfa-mir-138b; +MI0008048 cfa-mir-15a; +MI0008049 cfa-mir-16-1; +MI0008050 cfa-mir-17; +MI0008051 cfa-mir-19a; +MI0008052 cfa-mir-20;cfa-mir-20a; +MI0008054 cfa-mir-19b-1; +MI0008055 cfa-mir-92a-1; +MI0008056 cfa-mir-138a; +MI0008057 cfa-mir-128-2; +MI0008058 cfa-mir-26a-1; +MI0008059 cfa-mir-499; +MI0008060 cfa-mir-1-1; +MI0008061 cfa-mir-124-5;cfa-mir-124-3; +MI0008062 cfa-mir-124-1; +MI0008063 cfa-mir-320; +MI0008064 cfa-mir-130b; +MI0008065 cfa-mir-185; +MI0008066 cfa-mir-1306; +MI0008068 cfa-mir-196a;cfa-mir-196a-2; +MI0008069 cfa-mir-148b; +MI0008070 cfa-mir-200c; +MI0008071 cfa-mir-1307; +MI0008072 cfa-mir-107; +MI0008073 cfa-mir-146b; +MI0008074 cfa-mir-124-2; +MI0008075 cfa-mir-99a-1; +MI0008076 cfa-let-7c; +MI0008077 cfa-mir-125b-2; +MI0008078 cfa-mir-155; +MI0008079 cfa-mir-218-1; +MI0008080 cfa-mir-574; +MI0008081 cfa-mir-9-2; +MI0008082 cfa-mir-28; +MI0008083 cfa-mir-15b; +MI0008084 cfa-mir-16-2; +MI0008085 cfa-mir-7-2; +MI0008086 cfa-mir-9-3; +MI0008087 cfa-mir-1839; +MI0008088 cfa-mir-26b; +MI0008089 cfa-mir-1840; +MI0008090 cfa-mir-664; +MI0008091 cfa-mir-194; +MI0008092 cfa-mir-143; +MI0008093 cfa-mir-378; +MI0008094 cfa-mir-146a; +MI0008095 cfa-mir-1271; +MI0008096 cfa-mir-1841; +MI0008097 cfa-mir-218-2; +MI0008098 cfa-mir-103;cfa-mir-103-1; +MI0008099 cfa-mir-328; +MI0008100 cfa-mir-140; +MI0008101 cfa-mir-34a; +MI0008102 cfa-mir-99a-2; +MI0008103 cfa-mir-125b-1; +MI0008104 cfa-mir-497; +MI0008105 cfa-mir-195; +MI0008106 cfa-mir-34c; +MI0008107 cfa-mir-101-1; +MI0008108 cfa-mir-186; +MI0008109 cfa-mir-106b; +MI0008110 cfa-mir-93; +MI0008111 cfa-mir-25; +MI0008112 cfa-mir-197; +MI0008113 cfa-mir-193b; +MI0008114 cfa-mir-590; +MI0008115 cfa-mir-339-1; +MI0008116 cfa-mir-1842; +MI0008117 cfa-mir-137; +MI0008118 cfa-mir-1-2; +MI0008119 cfa-mir-92b; +MI0008120 cfa-mir-350; +MI0008121 cfa-mir-29b-2; +MI0008122 cfa-mir-29c;cfa-mir-29c-1; +MI0008123 cfa-mir-1843; +MI0008124 cfa-mir-199-2; +MI0008125 cfa-mir-9-1; +MI0008126 cfa-mir-181a-1; +MI0008127 cfa-mir-181b-1; +MI0008128 cfa-mir-342; +MI0008129 cfa-mir-345; +MI0008130 cfa-mir-493; +MI0008131 cfa-mir-433; +MI0008132 cfa-mir-127; +MI0008133 cfa-mir-136; +MI0008134 cfa-mir-379; +MI0008135 cfa-mir-411; +MI0008136 cfa-mir-380; +MI0008137 cfa-mir-323; +MI0008138 cfa-mir-329;cfa-mir-329a; +MI0008139 cfa-mir-543; +MI0008140 cfa-mir-495; +MI0008141 cfa-mir-376-3;cfa-mir-376a-3; +MI0008142 cfa-mir-376-2;cfa-mir-376a-2; +MI0008143 cfa-mir-376-1;cfa-mir-376a-1; +MI0008144 cfa-mir-487;cfa-mir-487b; +MI0008145 cfa-mir-382; +MI0008146 cfa-mir-485; +MI0008147 cfa-mir-409; +MI0008148 cfa-mir-369; +MI0008149 cfa-mir-410; +MI0008150 cfa-mir-219-2; +MI0008151 cfa-mir-199-3; +MI0008152 cfa-mir-181a-2; +MI0008153 cfa-mir-181b-2; +MI0008154 cfa-mir-126; +MI0008155 cfa-mir-212; +MI0008156 cfa-mir-132; +MI0008157 cfa-mir-22; +MI0008158 cfa-mir-144; +MI0008159 cfa-mir-193a; +MI0008160 cfa-mir-142; +MI0008161 cfa-mir-10;cfa-mir-10a; +MI0008162 cfa-mir-152; +MI0008163 cfa-mir-338; +MI0008164 cfa-mir-1844; +MI0008165 cfa-mir-21; +MI0008166 cfa-mir-423a; +MI0008167 cfa-mir-652; +MI0008168 cfa-mir-224; +MI0008169 cfa-mir-424; +MI0008170 cfa-mir-503; +MI0008171 cfa-mir-542; +MI0008172 cfa-mir-450b; +MI0008173 cfa-mir-106a; +MI0008174 cfa-mir-19b-2; +MI0008175 cfa-mir-92a-2; +MI0008176 cfa-mir-363; +MI0008177 cfa-mir-361; +MI0008178 cfa-mir-384; +MI0008179 cfa-mir-374a; +MI0008180 cfa-mir-374b; +MI0008181 cfa-mir-421; +MI0008182 cfa-mir-98; +MI0008183 cfa-mir-221; +MI0008184 cfa-mir-532; +MI0008185 cfa-mir-500; +MI0008186 cfa-mir-660; +MI0008187 cfa-mir-502; +MI0008188 cfa-mir-676; +MI0008189 cfa-let-7j; +MI0008190 hsa-mir-320d-1; +MI0008191 hsa-mir-320c-2; +MI0008192 hsa-mir-320d-2; +MI0008193 hsa-mir-1825; +MI0008194 hsa-mir-1826; +MI0008195 hsa-mir-1827; +MI0008196 cel-mir-1828; +MI0008197 cel-mir-1829a; +MI0008198 cel-mir-1829b; +MI0008199 cel-mir-1829c; +MI0008200 cel-mir-1830; +MI0008201 cel-mir-1831; +MI0008202 cel-mir-1832;cel-mir-1832a; +MI0008203 cel-mir-1833; +MI0008204 cel-mir-1834;cel-mir-58b; +MI0008205 gga-mir-216b; +MI0008206 gga-mir-1845; +MI0008207 gga-mir-739; +MI0008208 gga-mir-214; +MI0008209 gga-mir-762; +MI0008210 gga-mir-124a-2; +MI0008211 ssc-mir-15a; +MI0008212 ssc-mir-16-1;ssc-mir-16-2; +MI0008213 ssc-mir-16-2;ssc-mir-16-1; +MI0008214 ssc-mir-17; +MI0008215 ssc-mir-30b; +MI0008216 ssc-mir-34a; +MI0008217 ssc-mir-130a; +MI0008218 ssc-mir-185; +MI0008219 ssc-mir-199b; +MI0008220 ssc-mir-210; +MI0008221 ssc-mir-221; +MI0008222 osa-MIR531b; +MI0008223 osa-MIR1846d; +MI0008224 osa-MIR1847; +MI0008225 osa-MIR1848; +MI0008226 osa-MIR1849; +MI0008227 osa-MIR1850; +MI0008228 osa-MIR1851; +MI0008229 osa-MIR1852; +MI0008230 osa-MIR1853; +MI0008231 osa-MIR1854; +MI0008232 osa-MIR1855; +MI0008233 osa-MIR1856; +MI0008234 osa-MIR1857; +MI0008235 osa-MIR1428b; +MI0008237 osa-MIR1428c; +MI0008238 osa-MIR1428d; +MI0008239 osa-MIR1428e; +MI0008240 osa-MIR1858a; +MI0008241 osa-MIR1858b; +MI0008242 osa-MIR1846a; +MI0008243 osa-MIR1846b; +MI0008244 osa-MIR1859; +MI0008245 osa-MIR1860; +MI0008246 osa-MIR1884a; +MI0008247 osa-MIR1861a; +MI0008248 osa-MIR1861b; +MI0008249 osa-MIR1861c; +MI0008250 osa-MIR1861d; +MI0008251 osa-MIR1861e; +MI0008252 osa-MIR1861f; +MI0008253 osa-MIR1861g; +MI0008254 osa-MIR1861h; +MI0008255 osa-MIR1861i; +MI0008256 osa-MIR1861j; +MI0008257 osa-MIR1861k; +MI0008258 osa-MIR1861l; +MI0008259 osa-MIR1861m; +MI0008260 osa-MIR1861n; +MI0008261 osa-MIR1862a; +MI0008262 osa-MIR1862b; +MI0008263 osa-MIR1862c; +MI0008264 osa-MIR1863;osa-MIR1863a; +MI0008265 osa-MIR1864; +MI0008266 osa-MIR1865; +MI0008267 osa-MIR1866; +MI0008268 osa-MIR1867; +MI0008269 osa-MIR1423b; +MI0008270 osa-MIR1868; +MI0008271 osa-MIR812f; +MI0008272 osa-MIR1869; +MI0008273 osa-MIR1870; +MI0008274 osa-MIR1871; +MI0008275 osa-MIR1872; +MI0008276 osa-MIR1873; +MI0008277 osa-MIR1874; +MI0008278 osa-MIR1875; +MI0008279 osa-MIR1862d; +MI0008280 osa-MIR1876; +MI0008281 osa-MIR1884b; +MI0008282 osa-MIR1862e; +MI0008283 osa-MIR1877; +MI0008284 osa-MIR1878; +MI0008285 osa-MIR1879; +MI0008286 osa-MIR1880; +MI0008287 osa-MIR1881; +MI0008288 osa-MIR1882a; +MI0008289 osa-MIR1882b; +MI0008290 osa-MIR1882c; +MI0008291 osa-MIR1882d; +MI0008292 osa-MIR1882e; +MI0008293 osa-MIR1882f; +MI0008294 osa-MIR1882g; +MI0008295 osa-MIR1882h; +MI0008296 osa-MIR812g; +MI0008297 osa-MIR812h; +MI0008298 osa-MIR812i; +MI0008299 osa-MIR812j; +MI0008300 osa-MIR1883a; +MI0008301 osa-MIR1883b; +MI0008302 bra-MIR1885;bra-MIR1885a; +MI0008303 ath-MIR1886; +MI0008304 ath-MIR1887; +MI0008305 ath-MIR1888;ath-MIR1888a; +MI0008306 aga-mir-11; +MI0008307 aga-mir-981; +MI0008308 aga-mir-87; +MI0008309 aga-mir-1889; +MI0008310 aga-mir-375;aga-mir-375-1;aga-mir-375; +MI0008311 aga-mir-1890; +MI0008312 aga-mir-1891; +MI0008313 mmu-mir-1902; +MI0008314 mmu-mir-1897; +MI0008315 mmu-mir-1905; +MI0008316 mmu-mir-1895; +MI0008317 mmu-mir-1903; +MI0008318 mmu-mir-1899; +MI0008319 mmu-mir-1900; +MI0008320 mmu-mir-1892; +MI0008321 mmu-mir-1906;mmu-mir-1906-1; +MI0008322 mmu-mir-1896; +MI0008323 mmu-mir-1904; +MI0008324 mmu-mir-1898; +MI0008325 mmu-mir-1907; +MI0008326 mmu-mir-1894; +MI0008327 mmu-mir-1893; +MI0008328 mmu-mir-1901; +MI0008329 hsa-mir-1908; +MI0008330 hsa-mir-1909; +MI0008331 hsa-mir-1910; +MI0008332 hsa-mir-1911; +MI0008333 hsa-mir-1912; +MI0008334 hsa-mir-1913; +MI0008335 hsa-mir-1914; +MI0008336 hsa-mir-1915; +MI0008337 mdv1-miR-M31;mdv1-mir-M31; +MI0008338 bmo-mir-2a-1; +MI0008339 bmo-mir-2a-2; +MI0008340 bmo-mir-2b; +MI0008341 bmo-mir-13a; +MI0008342 bmo-mir-13b; +MI0008343 bmo-mir-79; +MI0008344 bmo-mir-87; +MI0008345 bmo-mir-133; +MI0008346 bmo-mir-184; +MI0008347 bmo-mir-210; +MI0008348 bmo-mir-281; +MI0008349 bmo-mir-317; +MI0008350 bmo-bantam; +MI0008351 sly-MIR1916; +MI0008352 sly-MIR1917; +MI0008353 sly-MIR1918; +MI0008354 sly-MIR1919a; +MI0008355 sly-MIR1919b; +MI0008356 sly-MIR1919c; +MI0008357 sly-MIR160a; +MI0008358 sly-MIR166a; +MI0008359 sly-MIR166b; +MI0008360 sly-MIR167;sly-MIR167a; +MI0008361 sly-MIR169a; +MI0008362 sly-MIR169b; +MI0008363 sly-MIR169c; +MI0008364 sly-MIR169d; +MI0008365 sly-MIR171a; +MI0008366 sly-MIR171b; +MI0008367 sly-MIR171c; +MI0008368 sly-MIR171d; +MI0008369 sly-MIR395a; +MI0008370 sly-MIR395b; +MI0008371 sly-MIR397; +MI0008372 xla-mir-1b; +MI0008374 xla-mir-1306; +MI0008375 xla-mir-133b; +MI0008376 xla-mir-133d; +MI0008377 xla-mir-142; +MI0008378 xla-mir-15c; +MI0008379 xla-mir-194; +MI0008380 xla-mir-205; +MI0008381 xla-mir-220c; +MI0008382 xla-mir-223; +MI0008383 xla-mir-23a; +MI0008384 xla-mir-24b;xla-mir-24b-1; +MI0008385 xla-mir-363; +MI0008386 xla-mir-703; +MI0008388 xla-mir-92a-1; +MI0008389 xla-mir-92a-2; +MI0008390 bmo-mir-1920; +MI0008391 bmo-mir-1921; +MI0008392 bmo-mir-1922; +MI0008393 bmo-mir-1923; +MI0008394 bmo-mir-1926; +MI0008395 bmo-mir-1924; +MI0008396 bmo-mir-1925; +MI0008397 ptr-let-7a-1; +MI0008398 ptr-let-7a-2; +MI0008399 ptr-let-7a-3; +MI0008400 ptr-let-7b; +MI0008401 ptr-let-7c; +MI0008402 ptr-let-7d; +MI0008403 ptr-let-7e; +MI0008404 ptr-let-7f-1; +MI0008405 ptr-let-7f-2; +MI0008406 ptr-let-7g; +MI0008407 ptr-let-7i; +MI0008408 ptr-mir-101-2; +MI0008409 ptr-mir-103-2; +MI0008410 ptr-mir-10a; +MI0008411 ptr-mir-10b; +MI0008412 ptr-mir-1-1; +MI0008413 ptr-mir-1178; +MI0008414 ptr-mir-1179; +MI0008415 ptr-mir-1181; +MI0008416 ptr-mir-1182; +MI0008417 ptr-mir-1183; +MI0008418 ptr-mir-1184;ptr-mir-1184-1; +MI0008419 ptr-mir-1185-1; +MI0008420 ptr-mir-1185-2; +MI0008421 ptr-mir-1197; +MI0008422 ptr-mir-1-2; +MI0008423 ptr-mir-1201; +MI0008424 ptr-mir-1202; +MI0008425 ptr-mir-1203; +MI0008426 ptr-mir-1204; +MI0008427 ptr-mir-1205; +MI0008428 ptr-mir-1206; +MI0008429 ptr-mir-1207; +MI0008430 ptr-mir-1208; +MI0008431 ptr-mir-122; +MI0008432 ptr-mir-1225; +MI0008433 ptr-mir-1227; +MI0008434 ptr-mir-1233-1; +MI0008435 ptr-mir-1233-2; +MI0008436 ptr-mir-1233-3; +MI0008437 ptr-mir-1234; +MI0008438 ptr-mir-1236; +MI0008439 ptr-mir-1237; +MI0008440 ptr-mir-1244-1; +MI0008441 ptr-mir-1244-2; +MI0008442 ptr-mir-1244-3; +MI0008443 ptr-mir-1244-4; +MI0008444 ptr-mir-1244-5; +MI0008445 ptr-mir-1244-6; +MI0008446 ptr-mir-1244-7; +MI0008447 ptr-mir-1244-8; +MI0008448 ptr-mir-1244-9; +MI0008449 ptr-mir-1244-10; +MI0008450 ptr-mir-1244-11; +MI0008451 ptr-mir-1245; +MI0008452 ptr-mir-1246; +MI0008453 ptr-mir-1247; +MI0008454 ptr-mir-1248; +MI0008455 ptr-mir-1249; +MI0008456 ptr-mir-1250; +MI0008457 ptr-mir-1251; +MI0008458 ptr-mir-1253; +MI0008459 ptr-mir-1254; +MI0008460 ptr-mir-1255b; +MI0008461 ptr-mir-1256; +MI0008462 ptr-mir-1258; +MI0008463 ptr-mir-1259; +MI0008464 ptr-mir-125a; +MI0008465 ptr-mir-126; +MI0008466 ptr-mir-1262; +MI0008467 ptr-mir-1263; +MI0008468 ptr-mir-1264; +MI0008469 ptr-mir-1265; +MI0008470 ptr-mir-1266; +MI0008471 ptr-mir-1267; +MI0008472 ptr-mir-1271; +MI0008473 ptr-mir-1272; +MI0008474 ptr-mir-1273; +MI0008475 ptr-mir-1274b; +MI0008476 ptr-mir-1275; +MI0008477 ptr-mir-1276; +MI0008478 ptr-mir-1278; +MI0008479 ptr-mir-1280; +MI0008480 ptr-mir-1281; +MI0008481 ptr-mir-1282-1; +MI0008482 ptr-mir-128-2; +MI0008483 ptr-mir-1282-2; +MI0008484 ptr-mir-1283;ptr-mir-1283a; +MI0008485 ptr-mir-1284; +MI0008486 ptr-mir-1285; +MI0008487 ptr-mir-1286; +MI0008488 ptr-mir-1288; +MI0008489 ptr-mir-1289-1; +MI0008490 ptr-mir-1289-2; +MI0008491 ptr-mir-1290; +MI0008492 ptr-mir-1291; +MI0008493 ptr-mir-129-1; +MI0008494 ptr-mir-129-2; +MI0008495 ptr-mir-1292; +MI0008496 ptr-mir-1293; +MI0008497 ptr-mir-1294; +MI0008498 ptr-mir-1295; +MI0008499 ptr-mir-1296; +MI0008500 ptr-mir-1297-1;ptr-mir-1297; +MI0008501 ptr-mir-1297-2; +MI0008502 ptr-mir-1298; +MI0008503 ptr-mir-1299; +MI0008504 ptr-mir-1300b; +MI0008505 ptr-mir-1300a-3; +MI0008506 ptr-mir-1300a-4; +MI0008507 ptr-mir-1300a-1; +MI0008508 ptr-mir-1300a-5; +MI0008509 ptr-mir-1300a-6; +MI0008510 ptr-mir-1300a-7; +MI0008511 ptr-mir-1300a-8; +MI0008512 ptr-mir-1300a-9; +MI0008513 ptr-mir-1300a-10; +MI0008514 ptr-mir-1300a-11; +MI0008515 ptr-mir-1300a-2; +MI0008516 ptr-mir-1302-1; +MI0008517 ptr-mir-1302-2; +MI0008518 ptr-mir-1302-3; +MI0008519 ptr-mir-1302-4; +MI0008520 ptr-mir-1302-5; +MI0008521 ptr-mir-1302-6; +MI0008522 ptr-mir-1302-7; +MI0008523 ptr-mir-1302-8; +MI0008524 ptr-mir-1303; +MI0008525 ptr-mir-1306; +MI0008526 ptr-mir-1307; +MI0008527 ptr-mir-130a; +MI0008528 ptr-mir-130b; +MI0008529 ptr-mir-1322; +MI0008530 ptr-mir-1323; +MI0008531 ptr-mir-1324-1;ptr-mir-1324; +MI0008532 ptr-mir-1324-2; +MI0008533 ptr-mir-133a-2; +MI0008534 ptr-mir-133b; +MI0008535 ptr-mir-134; +MI0008536 ptr-mir-135a-1; +MI0008537 ptr-mir-135b; +MI0008538 ptr-mir-137; +MI0008539 ptr-mir-138; +MI0008540 ptr-mir-139; +MI0008541 ptr-mir-141-1;ptr-mir-141; +MI0008542 ptr-mir-141-2; +MI0008543 ptr-mir-142; +MI0008544 ptr-mir-146a; +MI0008545 ptr-mir-146b; +MI0008546 ptr-mir-147b; +MI0008547 ptr-mir-148a; +MI0008548 ptr-mir-148b; +MI0008549 ptr-mir-149; +MI0008550 ptr-mir-150; +MI0008551 ptr-mir-151; +MI0008552 ptr-mir-152; +MI0008553 ptr-mir-153; +MI0008554 ptr-mir-155; +MI0008555 ptr-mir-16-2; +MI0008556 ptr-mir-181b-2; +MI0008557 ptr-mir-181d; +MI0008558 ptr-mir-182; +MI0008559 ptr-mir-1825; +MI0008560 ptr-mir-1827; +MI0008561 ptr-mir-185; +MI0008562 ptr-mir-18b; +MI0008563 ptr-mir-190b; +MI0008564 ptr-mir-191; +MI0008565 ptr-mir-192; +MI0008566 ptr-mir-193a; +MI0008567 ptr-mir-193b; +MI0008568 ptr-mir-195; +MI0008569 ptr-mir-196a-1; +MI0008570 ptr-mir-196b; +MI0008571 ptr-mir-199a-1; +MI0008572 ptr-mir-199b; +MI0008573 ptr-mir-200a; +MI0008574 ptr-mir-202; +MI0008575 ptr-mir-203; +MI0008576 ptr-mir-206; +MI0008577 ptr-mir-208a; +MI0008578 ptr-mir-208b; +MI0008579 ptr-mir-20b; +MI0008580 ptr-mir-210; +MI0008581 ptr-mir-211; +MI0008582 ptr-mir-216b; +MI0008583 ptr-mir-217; +MI0008584 ptr-mir-219-1; +MI0008585 ptr-mir-219-2; +MI0008586 ptr-mir-220b; +MI0008587 ptr-mir-221; +MI0008588 ptr-mir-24-1; +MI0008589 ptr-mir-26a-2; +MI0008590 ptr-mir-26b; +MI0008591 ptr-mir-27b; +MI0008592 ptr-mir-296; +MI0008593 ptr-mir-297; +MI0008594 ptr-mir-298; +MI0008595 ptr-mir-29c; +MI0008596 ptr-mir-300; +MI0008597 ptr-mir-301a; +MI0008598 ptr-mir-301b; +MI0008599 ptr-mir-302a; +MI0008600 ptr-mir-302b; +MI0008601 ptr-mir-302c; +MI0008602 ptr-mir-302d; +MI0008603 ptr-mir-302e; +MI0008604 ptr-mir-302f; +MI0008605 ptr-mir-30c-1; +MI0008606 ptr-mir-30e; +MI0008607 ptr-mir-320a; +MI0008608 ptr-mir-320b-1; +MI0008609 ptr-mir-320b-2; +MI0008610 ptr-mir-320c-1; +MI0008611 ptr-mir-320c-2; +MI0008612 ptr-mir-320d-1; +MI0008613 ptr-mir-320d-2; +MI0008614 ptr-mir-320d-3; +MI0008615 ptr-mir-323; +MI0008616 ptr-mir-324; +MI0008617 ptr-mir-326; +MI0008618 ptr-mir-328; +MI0008619 ptr-mir-329-1; +MI0008620 ptr-mir-329-2; +MI0008621 ptr-mir-330; +MI0008622 ptr-mir-331; +MI0008623 ptr-mir-335; +MI0008624 ptr-mir-337; +MI0008625 ptr-mir-338; +MI0008626 ptr-mir-339; +MI0008627 ptr-mir-33b; +MI0008628 ptr-mir-340; +MI0008629 ptr-mir-342; +MI0008630 ptr-mir-345; +MI0008631 ptr-mir-346; +MI0008632 ptr-mir-34b; +MI0008633 ptr-mir-34c; +MI0008634 ptr-mir-361; +MI0008635 ptr-mir-362; +MI0008636 ptr-mir-365-1; +MI0008637 ptr-mir-365-2; +MI0008638 ptr-mir-367; +MI0008639 ptr-mir-369; +MI0008640 ptr-mir-370; +MI0008641 ptr-mir-371; +MI0008642 ptr-mir-372; +MI0008643 ptr-mir-374a; +MI0008644 ptr-mir-374b; +MI0008645 ptr-mir-375; +MI0008646 ptr-mir-376a-1; +MI0008647 ptr-mir-376a-2; +MI0008648 ptr-mir-376b; +MI0008649 ptr-mir-376c; +MI0008650 ptr-mir-377; +MI0008651 ptr-mir-378;ptr-mir-378a; +MI0008652 ptr-mir-379; +MI0008653 ptr-mir-380; +MI0008654 ptr-mir-381; +MI0008655 ptr-mir-382; +MI0008656 ptr-mir-383; +MI0008657 ptr-mir-409; +MI0008658 ptr-mir-410; +MI0008659 ptr-mir-411; +MI0008660 ptr-mir-412; +MI0008661 ptr-mir-421; +MI0008662 ptr-mir-422a; +MI0008663 ptr-mir-423; +MI0008664 ptr-mir-424; +MI0008665 ptr-mir-425; +MI0008666 ptr-mir-431; +MI0008667 ptr-mir-432; +MI0008668 ptr-mir-433; +MI0008669 ptr-mir-448; +MI0008670 ptr-mir-449a; +MI0008671 ptr-mir-449b; +MI0008672 ptr-mir-450a-1; +MI0008673 ptr-mir-450a-2; +MI0008674 ptr-mir-450b; +MI0008675 ptr-mir-451; +MI0008676 ptr-mir-452; +MI0008677 ptr-mir-453; +MI0008678 ptr-mir-454; +MI0008679 ptr-mir-455; +MI0008680 ptr-mir-484; +MI0008681 ptr-mir-485; +MI0008682 ptr-mir-486; +MI0008683 ptr-mir-487a; +MI0008684 ptr-mir-487b; +MI0008685 ptr-mir-488; +MI0008686 ptr-mir-489; +MI0008687 ptr-mir-490; +MI0008688 ptr-mir-491; +MI0008689 ptr-mir-492; +MI0008690 ptr-mir-494; +MI0008691 ptr-mir-495; +MI0008692 ptr-mir-496; +MI0008693 ptr-mir-498; +MI0008694 ptr-mir-499; +MI0008695 ptr-mir-500;ptr-mir-500-1; +MI0008696 ptr-mir-501; +MI0008697 ptr-mir-502; +MI0008698 ptr-mir-503; +MI0008699 ptr-mir-504; +MI0008700 ptr-mir-505; +MI0008701 ptr-mir-511; +MI0008702 ptr-mir-512; +MI0008703 ptr-mir-515-1; +MI0008704 ptr-mir-515-2; +MI0008705 ptr-mir-516a-1; +MI0008706 ptr-mir-516a-2; +MI0008707 ptr-mir-516b-1; +MI0008708 ptr-mir-516b-2; +MI0008709 ptr-mir-517a; +MI0008710 ptr-mir-517b-1; +MI0008711 ptr-mir-517b-2; +MI0008712 ptr-mir-518a; +MI0008713 ptr-mir-518b; +MI0008714 ptr-mir-518c; +MI0008715 ptr-mir-518d; +MI0008716 ptr-mir-518e; +MI0008717 ptr-mir-518f; +MI0008718 ptr-mir-519a; +MI0008719 ptr-mir-519b; +MI0008720 ptr-mir-519c; +MI0008721 ptr-mir-519d; +MI0008722 ptr-mir-519e; +MI0008723 ptr-mir-520a; +MI0008724 ptr-mir-520b; +MI0008725 ptr-mir-520c; +MI0008726 ptr-mir-520d; +MI0008727 ptr-mir-520e; +MI0008728 ptr-mir-520f; +MI0008729 ptr-mir-520g; +MI0008730 ptr-mir-520h; +MI0008731 ptr-mir-521-1; +MI0008732 ptr-mir-521-2; +MI0008733 ptr-mir-522; +MI0008734 ptr-mir-523; +MI0008735 ptr-mir-524; +MI0008736 ptr-mir-525; +MI0008737 ptr-mir-526a-1; +MI0008738 ptr-mir-526a-2; +MI0008739 ptr-mir-526b; +MI0008740 ptr-mir-527; +MI0008741 ptr-mir-532; +MI0008742 ptr-mir-539; +MI0008743 ptr-mir-543; +MI0008744 ptr-mir-544; +MI0008745 ptr-mir-545; +MI0008746 ptr-mir-548a-1; +MI0008747 ptr-mir-548a-2; +MI0008748 ptr-mir-548b; +MI0008749 ptr-mir-548c; +MI0008750 ptr-mir-548f-1; +MI0008751 ptr-mir-548f-2; +MI0008752 ptr-mir-548h; +MI0008753 ptr-mir-548i-1; +MI0008754 ptr-mir-548i-2; +MI0008755 ptr-mir-548i-3; +MI0008756 ptr-mir-548i-4; +MI0008757 ptr-mir-548i-5; +MI0008758 ptr-mir-548i-6; +MI0008759 ptr-mir-548j; +MI0008760 ptr-mir-548k; +MI0008761 ptr-mir-548l; +MI0008762 ptr-mir-548n; +MI0008763 ptr-mir-548p; +MI0008764 ptr-mir-549; +MI0008765 ptr-mir-550-1; +MI0008766 ptr-mir-550-2; +MI0008767 ptr-mir-550-3; +MI0008768 ptr-mir-551a; +MI0008769 ptr-mir-551b; +MI0008770 ptr-mir-552; +MI0008771 ptr-mir-553; +MI0008772 ptr-mir-554; +MI0008773 ptr-mir-555; +MI0008774 ptr-mir-556; +MI0008775 ptr-mir-557; +MI0008776 ptr-mir-558; +MI0008777 ptr-mir-559; +MI0008778 ptr-mir-561; +MI0008779 ptr-mir-562; +MI0008780 ptr-mir-564; +MI0008781 ptr-mir-566; +MI0008782 ptr-mir-567; +MI0008783 ptr-mir-568; +MI0008784 ptr-mir-569; +MI0008785 ptr-mir-572; +MI0008786 ptr-mir-575; +MI0008787 ptr-mir-576; +MI0008788 ptr-mir-577; +MI0008789 ptr-mir-579; +MI0008790 ptr-mir-580; +MI0008791 ptr-mir-581; +MI0008792 ptr-mir-582; +MI0008793 ptr-mir-583; +MI0008794 ptr-mir-584; +MI0008795 ptr-mir-586; +MI0008796 ptr-mir-587; +MI0008797 ptr-mir-588; +MI0008798 ptr-mir-590; +MI0008799 ptr-mir-591; +MI0008800 ptr-mir-592; +MI0008801 ptr-mir-593; +MI0008802 ptr-mir-595; +MI0008803 ptr-mir-597; +MI0008804 ptr-mir-598; +MI0008805 ptr-mir-599; +MI0008806 ptr-mir-600; +MI0008807 ptr-mir-601; +MI0008808 ptr-mir-605; +MI0008809 ptr-mir-609; +MI0008810 ptr-mir-610; +MI0008811 ptr-mir-612; +MI0008812 ptr-mir-613; +MI0008813 ptr-mir-614; +MI0008814 ptr-mir-615; +MI0008815 ptr-mir-616; +MI0008816 ptr-mir-617; +MI0008817 ptr-mir-618; +MI0008818 ptr-mir-619; +MI0008819 ptr-mir-621; +MI0008820 ptr-mir-622; +MI0008821 ptr-mir-624; +MI0008822 ptr-mir-626; +MI0008823 ptr-mir-627; +MI0008824 ptr-mir-628; +MI0008825 ptr-mir-630; +MI0008826 ptr-mir-632; +MI0008827 ptr-mir-633; +MI0008828 ptr-mir-634; +MI0008829 ptr-mir-635; +MI0008830 ptr-mir-637; +MI0008831 ptr-mir-640; +MI0008832 ptr-mir-641; +MI0008833 ptr-mir-642; +MI0008834 ptr-mir-643; +MI0008835 ptr-mir-645; +MI0008836 ptr-mir-646; +MI0008837 ptr-mir-649; +MI0008838 ptr-mir-650; +MI0008839 ptr-mir-652; +MI0008840 ptr-mir-653; +MI0008841 ptr-mir-654; +MI0008842 ptr-mir-656; +MI0008843 ptr-mir-657; +MI0008844 ptr-mir-658; +MI0008845 ptr-mir-660; +MI0008846 ptr-mir-663a; +MI0008847 ptr-mir-663b; +MI0008848 ptr-mir-664;ptr-mir-664a; +MI0008849 ptr-mir-665; +MI0008850 ptr-mir-668; +MI0008851 ptr-mir-671; +MI0008852 ptr-mir-708; +MI0008853 ptr-mir-7-1; +MI0008854 ptr-mir-7-2; +MI0008855 ptr-mir-720; +MI0008856 ptr-mir-744; +MI0008857 ptr-mir-758; +MI0008858 ptr-mir-760; +MI0008859 ptr-mir-765; +MI0008860 ptr-mir-766; +MI0008861 ptr-mir-770; +MI0008862 ptr-mir-802; +MI0008863 ptr-mir-873; +MI0008864 ptr-mir-874; +MI0008865 ptr-mir-875; +MI0008866 ptr-mir-876; +MI0008867 ptr-mir-885; +MI0008868 ptr-mir-886; +MI0008869 ptr-mir-887; +MI0008870 ptr-mir-889; +MI0008871 ptr-mir-890; +MI0008872 ptr-mir-891a; +MI0008873 ptr-mir-891b; +MI0008874 ptr-mir-892a; +MI0008875 ptr-mir-9-1; +MI0008876 ptr-mir-920; +MI0008877 ptr-mir-922; +MI0008878 ptr-mir-923; +MI0008879 ptr-mir-924; +MI0008880 ptr-mir-933; +MI0008881 ptr-mir-934; +MI0008882 ptr-mir-935; +MI0008883 ptr-mir-936; +MI0008884 ptr-mir-937; +MI0008885 ptr-mir-938; +MI0008886 ptr-mir-939; +MI0008887 ptr-mir-940; +MI0008888 ptr-mir-942; +MI0008889 ptr-mir-943; +MI0008890 ptr-mir-944; +MI0008891 ptr-mir-99b; +MI0008892 tca-mir-1; +MI0008893 tca-mir-2-3;tca-mir-2c;tca-mir-2-3; +MI0008894 tca-mir-2-1;tca-mir-2a;tca-mir-2-1; +MI0008895 tca-mir-2-2;tca-mir-2b;tca-mir-2-2; +MI0008896 tca-let-7; +MI0008897 tca-mir-7; +MI0008898 tca-mir-8; +MI0008899 tca-mir-10; +MI0008900 tca-mir-12; +MI0008901 tca-mir-13a; +MI0008902 tca-mir-13b; +MI0008903 tca-mir-14; +MI0008904 tca-mir-31a;tca-mir-31; +MI0008905 tca-mir-33; +MI0008906 tca-mir-34; +MI0008907 tca-mir-71; +MI0008908 tca-mir-87;tca-mir-87a; +MI0008909 tca-mir-92a; +MI0008910 tca-mir-92b; +MI0008911 tca-mir-100; +MI0008912 tca-mir-124; +MI0008913 tca-mir-125; +MI0008914 tca-mir-133; +MI0008915 tca-mir-137; +MI0008916 tca-mir-184; +MI0008917 tca-mir-190; +MI0008918 tca-mir-210; +MI0008919 tca-mir-219; +MI0008920 tca-mir-263b; +MI0008921 tca-mir-275; +MI0008922 tca-mir-276; +MI0008923 tca-mir-277; +MI0008924 tca-mir-279;tca-mir-279a; +MI0008925 tca-mir-281; +MI0008926 tca-mir-282; +MI0008927 tca-mir-283; +MI0008928 tca-mir-305; +MI0008929 tca-mir-307; +MI0008930 tca-mir-317; +MI0008931 tca-mir-927;tca-mir-927a; +MI0008932 tca-mir-932; +MI0008933 tca-mir-iab-4; +MI0008934 tca-mir-929; +MI0008935 tca-mir-9b; +MI0008936 tca-mir-9a; +MI0008937 hsv1-mir-H2; +MI0008938 hsv1-mir-H3; +MI0008939 hsv1-mir-H4; +MI0008940 hsv1-mir-H5; +MI0008941 hsv1-mir-H6; +MI0008942 dan-mir-92b; +MI0008943 dan-mir-288; +MI0008944 dan-mir-277; +MI0008945 dan-mir-8; +MI0008946 dan-bantam; +MI0008947 dan-mir-7; +MI0008948 dan-mir-87; +MI0008949 dan-mir-92a; +MI0008950 dan-mir-304; +MI0008951 dan-mir-2a-2; +MI0008952 dan-mir-284; +MI0008953 dan-mir-9b; +MI0008954 dan-mir-2b; +MI0008955 dan-mir-12; +MI0008956 dan-mir-285; +MI0008957 dan-mir-13a; +MI0008958 dan-mir-308; +MI0008959 dan-mir-312; +MI0008960 dan-mir-3; +MI0008961 dan-mir-287; +MI0008962 dan-mir-310; +MI0008963 dan-mir-13b-1; +MI0008964 dan-mir-4; +MI0008965 dan-mir-281-2; +MI0008966 dan-mir-79; +MI0008967 dan-mir-124; +MI0008968 dan-mir-1; +MI0008969 dan-mir-210; +MI0008970 dan-mir-307; +MI0008971 dan-mir-184; +MI0008972 dan-mir-283; +MI0008973 dan-mir-280; +MI0008974 dan-mir-34; +MI0008975 dan-mir-iab-4; +MI0008976 dan-mir-2c; +MI0008977 dan-mir-263a; +MI0008978 dan-mir-286; +MI0008979 dan-mir-282; +MI0008980 dan-mir-276b; +MI0008981 dan-mir-263b; +MI0008982 dan-mir-274; +MI0008983 dan-mir-316; +MI0008984 dan-mir-306; +MI0008985 dan-mir-275; +MI0008986 dan-mir-2a-1; +MI0008987 dan-mir-281-1; +MI0008988 dan-mir-317; +MI0008989 dan-mir-13b-2; +MI0008990 dan-mir-309; +MI0008991 dan-mir-279; +MI0008992 dan-mir-276a; +MI0008993 dan-mir-9c; +MI0008994 dan-mir-5; +MI0008995 dan-mir-9a; +MI0008996 dan-mir-315; +MI0008997 dan-mir-14; +MI0008998 dan-mir-33; +MI0008999 dan-mir-6-1; +MI0009000 dan-mir-318; +MI0009001 dan-mir-305; +MI0009002 dan-mir-314; +MI0009003 dan-mir-289; +MI0009004 dan-let-7; +MI0009005 dan-mir-133; +MI0009006 dan-mir-31b; +MI0009007 dan-mir-278; +MI0009008 dan-mir-311a; +MI0009009 dan-mir-11; +MI0009010 dan-mir-6-3; +MI0009011 dan-mir-125; +MI0009012 dan-mir-219; +MI0009013 dan-mir-311b; +MI0009014 dan-mir-10; +MI0009015 dan-mir-6-2; +MI0009016 dan-mir-31a; +MI0009017 dan-mir-100; +MI0009018 der-mir-308; +MI0009019 der-mir-283; +MI0009020 der-mir-31b; +MI0009021 der-mir-5; +MI0009022 der-mir-287; +MI0009023 der-mir-13b-2; +MI0009024 der-mir-310b; +MI0009025 der-let-7; +MI0009026 der-mir-309; +MI0009027 der-mir-100; +MI0009028 der-mir-311a; +MI0009029 der-mir-133; +MI0009030 der-mir-286; +MI0009031 der-mir-280; +MI0009032 der-mir-92a; +MI0009033 der-mir-306; +MI0009034 der-mir-316; +MI0009035 der-mir-307; +MI0009036 der-mir-14; +MI0009037 der-mir-8; +MI0009038 der-mir-11; +MI0009039 der-mir-13b-1; +MI0009040 der-mir-281-2; +MI0009041 der-mir-275; +MI0009042 der-mir-6-3; +MI0009043 der-mir-9a; +MI0009044 der-mir-263a; +MI0009045 der-mir-9b; +MI0009046 der-mir-34; +MI0009047 der-mir-282; +MI0009048 der-mir-6-2; +MI0009049 der-mir-2a-2; +MI0009050 der-mir-184; +MI0009051 der-mir-6-1; +MI0009052 der-mir-284; +MI0009053 der-mir-285; +MI0009054 der-mir-279; +MI0009055 der-mir-263b; +MI0009056 der-mir-277; +MI0009057 der-mir-318; +MI0009058 der-mir-31a; +MI0009059 der-mir-2a-1; +MI0009060 der-mir-311b-1; +MI0009061 der-mir-274; +MI0009062 der-mir-311c; +MI0009063 der-mir-iab-4; +MI0009064 der-mir-79; +MI0009065 der-mir-311b-2; +MI0009066 der-mir-125; +MI0009067 der-mir-305; +MI0009068 der-mir-281-1; +MI0009069 der-mir-314; +MI0009070 der-mir-276a; +MI0009071 der-mir-278; +MI0009072 der-mir-12; +MI0009073 der-mir-4; +MI0009074 der-bantam; +MI0009075 der-mir-1; +MI0009076 der-mir-2b-1; +MI0009077 der-mir-312-1; +MI0009078 der-mir-7; +MI0009079 der-mir-3; +MI0009080 der-mir-315; +MI0009081 der-mir-2c; +MI0009082 der-mir-317; +MI0009083 der-mir-276b; +MI0009084 der-mir-92b; +MI0009085 der-mir-87; +MI0009086 der-mir-33; +MI0009087 der-mir-210; +MI0009088 der-mir-124; +MI0009089 der-mir-312-2; +MI0009090 der-mir-304; +MI0009091 der-mir-10; +MI0009092 der-mir-13a; +MI0009093 der-mir-288; +MI0009094 der-mir-219; +MI0009095 der-mir-310a; +MI0009096 der-mir-2b-2; +MI0009097 der-mir-9c; +MI0009098 der-mir-289; +MI0009099 dgr-mir-277; +MI0009100 dgr-mir-100; +MI0009101 dgr-mir-305; +MI0009102 dgr-bantam; +MI0009103 dgr-mir-12; +MI0009104 dgr-mir-219; +MI0009105 dgr-mir-307; +MI0009106 dgr-mir-287-1; +MI0009107 dgr-mir-263b; +MI0009108 dgr-mir-308; +MI0009109 dgr-mir-184; +MI0009110 dgr-mir-2b; +MI0009111 dgr-mir-6-2; +MI0009112 dgr-mir-5-1; +MI0009113 dgr-mir-92a; +MI0009114 dgr-mir-6-4; +MI0009115 dgr-mir-11; +MI0009116 dgr-mir-276b; +MI0009117 dgr-mir-276a; +MI0009118 dgr-mir-309-1; +MI0009119 dgr-mir-iab-4; +MI0009120 dgr-mir-3-1; +MI0009121 dgr-mir-285; +MI0009122 dgr-mir-9b; +MI0009123 dgr-mir-79; +MI0009124 dgr-mir-318; +MI0009125 dgr-mir-31a; +MI0009126 dgr-mir-317; +MI0009127 dgr-mir-3-2; +MI0009128 dgr-mir-281-1; +MI0009129 dgr-mir-9a; +MI0009130 dgr-mir-6-6; +MI0009131 dgr-mir-286-2; +MI0009132 dgr-mir-316; +MI0009133 dgr-mir-306; +MI0009134 dgr-mir-8; +MI0009135 dgr-mir-4-2; +MI0009136 dgr-mir-286-1; +MI0009137 dgr-mir-304; +MI0009138 dgr-let-7-1; +MI0009139 dgr-mir-6-1; +MI0009140 dgr-mir-278; +MI0009141 dgr-mir-314; +MI0009142 dgr-mir-309-2; +MI0009143 dgr-mir-279; +MI0009144 dgr-mir-287-2; +MI0009145 dgr-mir-288; +MI0009146 dgr-mir-10; +MI0009147 dgr-mir-14; +MI0009148 dgr-mir-6-5; +MI0009149 dgr-mir-33; +MI0009150 dgr-mir-315; +MI0009151 dgr-mir-13b-1; +MI0009152 dgr-mir-9c; +MI0009153 dgr-mir-2a-1; +MI0009154 dgr-mir-87; +MI0009155 dgr-mir-1; +MI0009156 dgr-mir-125-1; +MI0009157 dgr-mir-284; +MI0009158 dgr-mir-6-3; +MI0009159 dgr-mir-4-1; +MI0009160 dgr-mir-31b; +MI0009161 dgr-mir-210; +MI0009162 dgr-mir-125-2; +MI0009163 dgr-mir-282; +MI0009164 dgr-mir-124; +MI0009165 dgr-mir-2a-2; +MI0009166 dgr-mir-13b-2; +MI0009167 dgr-mir-280; +MI0009168 dgr-mir-13a; +MI0009169 dgr-mir-283; +MI0009170 dgr-mir-34; +MI0009171 dgr-mir-133; +MI0009172 dgr-mir-263a; +MI0009173 dgr-mir-7; +MI0009174 dgr-mir-274; +MI0009175 dgr-mir-5-2; +MI0009176 dgr-let-7-2; +MI0009177 dgr-mir-281-2; +MI0009178 dgr-mir-92b; +MI0009179 dgr-mir-275; +MI0009180 dgr-mir-2c; +MI0009181 dmo-mir-316; +MI0009182 dmo-mir-284; +MI0009183 dmo-mir-4; +MI0009184 dmo-mir-12; +MI0009185 dmo-mir-276b; +MI0009186 dmo-mir-14; +MI0009187 dmo-mir-92a; +MI0009188 dmo-bantam; +MI0009189 dmo-mir-6-1; +MI0009190 dmo-mir-13b-2; +MI0009191 dmo-mir-100; +MI0009192 dmo-mir-219; +MI0009193 dmo-mir-31b; +MI0009194 dmo-mir-283; +MI0009195 dmo-mir-281-1; +MI0009196 dmo-mir-286; +MI0009197 dmo-mir-314; +MI0009198 dmo-mir-282; +MI0009199 dmo-mir-305; +MI0009200 dmo-mir-281-2; +MI0009201 dmo-mir-8; +MI0009202 dmo-mir-306; +MI0009203 dmo-mir-2b; +MI0009204 dmo-mir-285; +MI0009205 dmo-mir-2c; +MI0009206 dmo-mir-263a; +MI0009207 dmo-mir-276a; +MI0009208 dmo-mir-274; +MI0009209 dmo-mir-34; +MI0009210 dmo-mir-304; +MI0009211 dmo-mir-92b; +MI0009212 dmo-mir-287; +MI0009213 dmo-mir-309; +MI0009214 dmo-mir-13a; +MI0009215 dmo-mir-87; +MI0009216 dmo-mir-280; +MI0009217 dmo-mir-275; +MI0009218 dmo-mir-307; +MI0009219 dmo-mir-9b; +MI0009220 dmo-mir-210; +MI0009221 dmo-mir-3; +MI0009222 dmo-mir-125; +MI0009223 dmo-mir-9a; +MI0009224 dmo-mir-317; +MI0009225 dmo-mir-2a-2; +MI0009226 dmo-mir-6-3; +MI0009227 dmo-mir-184; +MI0009228 dmo-mir-288; +MI0009229 dmo-mir-278; +MI0009230 dmo-mir-31a; +MI0009231 dmo-mir-133; +MI0009232 dmo-mir-6-2; +MI0009233 dmo-mir-11; +MI0009234 dmo-mir-iab-4; +MI0009235 dmo-mir-279; +MI0009236 dmo-mir-9c; +MI0009237 dmo-mir-318; +MI0009238 dmo-mir-277; +MI0009239 dmo-let-7; +MI0009240 dmo-mir-315; +MI0009241 dmo-mir-124; +MI0009242 dmo-mir-2a-1; +MI0009243 dmo-mir-308; +MI0009244 dmo-mir-79; +MI0009245 dmo-mir-5; +MI0009246 dmo-mir-7; +MI0009247 dmo-mir-10; +MI0009248 dmo-mir-1; +MI0009249 dmo-mir-33; +MI0009250 dmo-mir-313; +MI0009251 dmo-mir-13b-1; +MI0009252 dpe-mir-307; +MI0009253 dpe-mir-3; +MI0009254 dpe-let-7-1; +MI0009255 dpe-mir-184; +MI0009256 dpe-mir-277; +MI0009257 dpe-mir-14; +MI0009258 dpe-mir-210; +MI0009259 dpe-mir-276a; +MI0009260 dpe-mir-13a; +MI0009261 dpe-mir-6-3; +MI0009262 dpe-mir-284; +MI0009263 dpe-mir-286; +MI0009264 dpe-mir-8; +MI0009265 dpe-mir-13b-2; +MI0009266 dpe-mir-133; +MI0009267 dpe-mir-283; +MI0009268 dpe-mir-5; +MI0009269 dpe-mir-34; +MI0009270 dpe-mir-282; +MI0009271 dpe-mir-9a; +MI0009272 dpe-mir-100-2; +MI0009273 dpe-mir-219; +MI0009274 dpe-mir-314; +MI0009275 dpe-bantam; +MI0009276 dpe-mir-280; +MI0009277 dpe-mir-31a; +MI0009278 dpe-mir-1; +MI0009279 dpe-mir-125-2; +MI0009280 dpe-mir-278; +MI0009281 dpe-mir-281-1; +MI0009282 dpe-mir-2a-2; +MI0009283 dpe-mir-315; +MI0009284 dpe-mir-124; +MI0009285 dpe-mir-308; +MI0009286 dpe-mir-125-1; +MI0009287 dpe-mir-87; +MI0009288 dpe-mir-279; +MI0009289 dpe-mir-263b; +MI0009290 dpe-mir-2c; +MI0009291 dpe-mir-13b-1; +MI0009292 dpe-mir-11; +MI0009293 dpe-mir-2b; +MI0009294 dpe-mir-317-2; +MI0009295 dpe-mir-125-3; +MI0009296 dpe-mir-iab-4; +MI0009297 dpe-mir-7; +MI0009298 dpe-mir-2a-1; +MI0009299 dpe-mir-33; +MI0009300 dpe-mir-275; +MI0009301 dpe-mir-9b; +MI0009302 dpe-mir-317-1; +MI0009303 dpe-mir-9c; +MI0009304 dpe-mir-79; +MI0009305 dpe-mir-289; +MI0009306 dpe-mir-318; +MI0009307 dpe-mir-276b; +MI0009308 dpe-mir-4; +MI0009309 dpe-mir-31b; +MI0009310 dpe-mir-288; +MI0009311 dpe-mir-10; +MI0009312 dpe-mir-281-2; +MI0009313 dpe-mir-305; +MI0009314 dpe-mir-92b; +MI0009315 dpe-mir-287; +MI0009316 dpe-let-7-2; +MI0009317 dpe-mir-6-1; +MI0009318 dpe-mir-274; +MI0009319 dpe-mir-306; +MI0009320 dpe-mir-309; +MI0009321 dpe-mir-263a; +MI0009322 dpe-mir-6-2; +MI0009323 dpe-mir-12; +MI0009324 dpe-mir-100-1; +MI0009325 dpe-mir-92a; +MI0009326 dpe-mir-316; +MI0009327 dse-mir-6-1; +MI0009328 dse-mir-12; +MI0009329 dse-mir-280; +MI0009330 dse-mir-263a; +MI0009331 dse-mir-79; +MI0009332 dse-mir-287; +MI0009333 dse-mir-7; +MI0009334 dse-mir-8; +MI0009335 dse-mir-87; +MI0009336 dse-mir-92b; +MI0009337 dse-bantam; +MI0009338 dse-mir-210; +MI0009339 dse-mir-2c; +MI0009340 dse-mir-276b; +MI0009341 dse-mir-310; +MI0009342 dse-mir-2b-1; +MI0009343 dse-mir-278; +MI0009344 dse-mir-281-2; +MI0009345 dse-mir-2b-2; +MI0009346 dse-mir-10; +MI0009347 dse-mir-92a; +MI0009348 dse-mir-13a; +MI0009349 dse-mir-34; +MI0009350 dse-mir-11; +MI0009351 dse-mir-317; +MI0009352 dse-mir-305; +MI0009353 dse-mir-276a; +MI0009354 dse-mir-282; +MI0009355 dse-mir-308; +MI0009356 dse-mir-277; +MI0009357 dse-mir-314; +MI0009358 dse-mir-100; +MI0009359 dse-mir-286; +MI0009360 dse-mir-284; +MI0009361 dse-mir-311; +MI0009362 dse-mir-9a; +MI0009363 dse-mir-304; +MI0009364 dse-mir-33; +MI0009365 dse-mir-281-1; +MI0009366 dse-mir-309; +MI0009367 dse-mir-306; +MI0009368 dse-mir-288; +MI0009369 dse-mir-289; +MI0009370 dse-mir-279; +MI0009371 dse-mir-285; +MI0009372 dse-mir-312; +MI0009373 dse-mir-307; +MI0009374 dse-mir-9c; +MI0009375 dse-mir-14; +MI0009376 dse-mir-1; +MI0009377 dse-mir-315; +MI0009378 dse-mir-13b-2; +MI0009379 dse-mir-318; +MI0009380 dse-mir-13b-1; +MI0009381 dse-mir-316; +MI0009382 dse-mir-2a-3; +MI0009383 dse-mir-275; +MI0009384 dse-mir-184; +MI0009385 dse-mir-31b; +MI0009386 dse-mir-219; +MI0009387 dse-mir-31a; +MI0009388 dse-mir-125; +MI0009389 dse-mir-9b; +MI0009390 dse-mir-274; +MI0009391 dse-mir-5; +MI0009392 dse-mir-2a-2; +MI0009393 dse-mir-263b; +MI0009394 dse-mir-313; +MI0009395 dse-mir-iab-4; +MI0009396 dse-mir-133; +MI0009397 dse-mir-2a-1; +MI0009398 dse-mir-4; +MI0009399 dse-mir-3; +MI0009400 dse-let-7; +MI0009401 dse-mir-283; +MI0009402 dse-mir-124; +MI0009403 dse-mir-6-2; +MI0009404 dse-mir-6-3; +MI0009405 dsi-mir-34; +MI0009406 dsi-mir-310; +MI0009407 dsi-mir-4; +MI0009408 dsi-mir-9a; +MI0009409 dsi-mir-87; +MI0009410 dsi-mir-13b-2; +MI0009411 dsi-mir-125; +MI0009412 dsi-mir-124; +MI0009413 dsi-mir-14; +MI0009414 dsi-mir-210; +MI0009415 dsi-mir-277; +MI0009416 dsi-mir-263a; +MI0009417 dsi-mir-12; +MI0009418 dsi-mir-2a-1; +MI0009419 dsi-mir-2c; +MI0009420 dsi-mir-iab-4; +MI0009421 dsi-mir-13b-1; +MI0009422 dsi-mir-311; +MI0009423 dsi-mir-2b-1; +MI0009424 dsi-mir-286; +MI0009425 dsi-mir-305; +MI0009426 dsi-bantam; +MI0009427 dsi-mir-3; +MI0009428 dsi-mir-317; +MI0009429 dsi-mir-314; +MI0009430 dsi-mir-11; +MI0009431 dsi-mir-33; +MI0009432 dsi-mir-1; +MI0009433 dsi-mir-219; +MI0009434 dsi-mir-316; +MI0009435 dsi-mir-315; +MI0009436 dsi-mir-263b; +MI0009437 dsi-mir-100; +MI0009438 dsi-mir-289; +MI0009439 dsi-mir-313; +MI0009440 dsi-mir-312; +MI0009441 dsi-let-7; +MI0009442 dsi-mir-308; +MI0009443 dsi-mir-2a-2; +MI0009444 dsi-mir-31b; +MI0009445 dsi-mir-92b; +MI0009446 dsi-mir-275; +MI0009447 dsi-mir-13a; +MI0009448 dsi-mir-304; +MI0009449 dsi-mir-282; +MI0009450 dsi-mir-307; +MI0009451 dsi-mir-2b-2; +MI0009452 dsi-mir-6-1; +MI0009453 dsi-mir-31a; +MI0009454 dsi-mir-10; +MI0009455 dsi-mir-285; +MI0009456 dsi-mir-8; +MI0009457 dsi-mir-5; +MI0009458 dsi-mir-278; +MI0009459 dsi-mir-276a; +MI0009460 dsi-mir-283; +MI0009461 dsi-mir-309; +MI0009462 dsi-mir-276b; +MI0009463 dsi-mir-279; +MI0009464 dsi-mir-288; +MI0009465 dsi-mir-92a; +MI0009466 dsi-mir-287; +MI0009467 dsi-mir-6-3; +MI0009468 dsi-mir-133; +MI0009469 dsi-mir-7; +MI0009470 dsi-mir-284; +MI0009471 dsi-mir-184; +MI0009472 dsi-mir-281; +MI0009473 dsi-mir-6-2; +MI0009474 dsi-mir-318; +MI0009475 dvi-mir-314; +MI0009476 dvi-mir-2a-2; +MI0009477 dvi-mir-2a-1; +MI0009478 dvi-mir-2c; +MI0009479 dvi-mir-12; +MI0009480 dvi-mir-13a; +MI0009481 dvi-mir-306; +MI0009482 dvi-mir-279; +MI0009483 dvi-mir-11; +MI0009484 dvi-mir-125; +MI0009485 dvi-mir-313; +MI0009486 dvi-mir-263a; +MI0009487 dvi-mir-274; +MI0009488 dvi-mir-263b; +MI0009489 dvi-mir-318; +MI0009490 dvi-mir-6-2; +MI0009491 dvi-mir-9c; +MI0009492 dvi-mir-9b; +MI0009493 dvi-mir-281-2; +MI0009494 dvi-mir-210; +MI0009495 dvi-mir-9a; +MI0009496 dvi-mir-287; +MI0009497 dvi-mir-7; +MI0009498 dvi-mir-282; +MI0009499 dvi-mir-315b; +MI0009500 dvi-mir-310; +MI0009501 dvi-mir-283; +MI0009502 dvi-mir-133; +MI0009503 dvi-mir-278; +MI0009504 dvi-mir-13b-1; +MI0009505 dvi-mir-124; +MI0009506 dvi-mir-305; +MI0009507 dvi-mir-33; +MI0009508 dvi-mir-276b; +MI0009509 dvi-mir-276a; +MI0009510 dvi-mir-315a; +MI0009511 dvi-mir-6-3; +MI0009512 dvi-mir-316; +MI0009513 dvi-mir-277; +MI0009514 dvi-mir-281-1; +MI0009515 dvi-mir-317; +MI0009516 dvi-mir-184; +MI0009517 dvi-mir-286; +MI0009518 dvi-mir-2b; +MI0009519 dvi-mir-288; +MI0009520 dvi-mir-307; +MI0009521 dvi-mir-13b-2; +MI0009522 dvi-mir-8; +MI0009523 dvi-mir-34; +MI0009524 dvi-mir-4; +MI0009525 dvi-mir-3; +MI0009526 dvi-mir-309; +MI0009527 dvi-mir-1; +MI0009528 dvi-mir-10; +MI0009529 dvi-mir-5; +MI0009530 dvi-mir-92b; +MI0009531 dvi-mir-iab-4; +MI0009532 dvi-mir-280; +MI0009533 dvi-bantam; +MI0009534 dvi-mir-31a; +MI0009535 dvi-mir-308; +MI0009536 dvi-mir-285; +MI0009537 dvi-mir-6-1; +MI0009538 dvi-mir-275; +MI0009539 dvi-mir-14; +MI0009540 dvi-mir-31b; +MI0009541 dvi-mir-100; +MI0009542 dvi-mir-87; +MI0009543 dvi-mir-79; +MI0009544 dvi-mir-304; +MI0009545 dvi-mir-284; +MI0009546 dvi-mir-219; +MI0009547 dvi-mir-92a; +MI0009548 dvi-let-7; +MI0009549 dwi-mir-79-2; +MI0009550 dwi-mir-87-2; +MI0009551 dwi-mir-34; +MI0009552 dwi-mir-285; +MI0009553 dwi-bantam; +MI0009554 dwi-mir-306-1; +MI0009555 dwi-mir-1; +MI0009556 dwi-mir-184; +MI0009557 dwi-mir-13b-1; +MI0009558 dwi-mir-92b; +MI0009559 dwi-mir-9c-1; +MI0009560 dwi-mir-284; +MI0009561 dwi-mir-281-2; +MI0009562 dwi-let-7; +MI0009563 dwi-mir-305; +MI0009564 dwi-mir-92a; +MI0009565 dwi-mir-286; +MI0009566 dwi-mir-316; +MI0009567 dwi-mir-279; +MI0009568 dwi-mir-263b; +MI0009569 dwi-mir-287; +MI0009570 dwi-mir-iab-4; +MI0009571 dwi-mir-2a-2; +MI0009572 dwi-mir-276a; +MI0009573 dwi-mir-7; +MI0009574 dwi-mir-306-2; +MI0009575 dwi-mir-2a-1; +MI0009576 dwi-mir-11; +MI0009577 dwi-mir-304; +MI0009578 dwi-mir-219; +MI0009579 dwi-mir-79-1; +MI0009580 dwi-mir-8; +MI0009581 dwi-mir-283; +MI0009582 dwi-mir-318-2; +MI0009583 dwi-mir-2b; +MI0009584 dwi-mir-12; +MI0009585 dwi-mir-276b; +MI0009586 dwi-mir-210; +MI0009587 dwi-mir-309; +MI0009588 dwi-mir-6-3; +MI0009589 dwi-mir-274; +MI0009590 dwi-mir-317; +MI0009591 dwi-mir-9c-2; +MI0009592 dwi-mir-314; +MI0009593 dwi-mir-282; +MI0009594 dwi-mir-124; +MI0009595 dwi-mir-280; +MI0009596 dwi-mir-278; +MI0009597 dwi-mir-13a; +MI0009598 dwi-mir-307; +MI0009599 dwi-mir-125; +MI0009600 dwi-mir-10; +MI0009601 dwi-mir-9a; +MI0009602 dwi-mir-318-1; +MI0009603 dwi-mir-2c; +MI0009604 dwi-mir-315; +MI0009605 dwi-mir-31b; +MI0009606 dwi-mir-13b-2; +MI0009607 dwi-mir-308; +MI0009608 dwi-mir-87-1; +MI0009609 dwi-mir-6-2; +MI0009610 dwi-mir-263a; +MI0009611 dwi-mir-6-1; +MI0009612 dwi-mir-277; +MI0009613 dwi-mir-5; +MI0009614 dwi-mir-33; +MI0009615 dwi-mir-14; +MI0009616 dwi-mir-31a; +MI0009617 dwi-mir-275; +MI0009618 dwi-mir-3; +MI0009619 dwi-mir-9b-1; +MI0009620 dwi-mir-281-1; +MI0009621 dwi-mir-9b-2; +MI0009622 dwi-mir-100; +MI0009623 dwi-mir-4; +MI0009624 dwi-mir-288; +MI0009625 dwi-mir-133; +MI0009626 dya-mir-274; +MI0009627 dya-mir-87; +MI0009628 dya-mir-307; +MI0009629 dya-mir-317; +MI0009630 dya-mir-13b-2; +MI0009631 dya-bantam; +MI0009632 dya-mir-4; +MI0009633 dya-mir-100; +MI0009634 dya-mir-281-2; +MI0009635 dya-mir-279; +MI0009636 dya-mir-33; +MI0009637 dya-mir-283; +MI0009638 dya-mir-280; +MI0009639 dya-mir-8; +MI0009640 dya-mir-305; +MI0009641 dya-mir-306; +MI0009642 dya-mir-9a-1;dya-mir-9a; +MI0009643 dya-mir-282; +MI0009644 dya-mir-133; +MI0009645 dya-mir-304; +MI0009646 dya-mir-3; +MI0009647 dya-mir-2b-2; +MI0009648 dya-mir-14; +MI0009649 dya-mir-314; +MI0009650 dya-mir-6-3; +MI0009651 dya-mir-318; +MI0009652 dya-mir-316-1;dya-mir-316; +MI0009653 dya-mir-34; +MI0009654 dya-mir-10; +MI0009655 dya-mir-1; +MI0009656 dya-mir-315-2; +MI0009657 dya-mir-309; +MI0009658 dya-mir-13b-1; +MI0009659 dya-mir-278; +MI0009660 dya-mir-284; +MI0009661 dya-mir-285; +MI0009662 dya-mir-2b-1; +MI0009663 dya-mir-iab-4; +MI0009664 dya-mir-311a; +MI0009665 dya-mir-310; +MI0009666 dya-mir-281-1; +MI0009667 dya-mir-13a; +MI0009668 dya-mir-288; +MI0009669 dya-mir-210; +MI0009670 dya-mir-125; +MI0009671 dya-mir-6-1; +MI0009672 dya-mir-2c; +MI0009673 dya-let-7; +MI0009674 dya-mir-277; +MI0009675 dya-mir-308; +MI0009676 dya-mir-5; +MI0009677 dya-mir-287; +MI0009678 dya-mir-31a; +MI0009679 dya-mir-31b; +MI0009680 dya-mir-124; +MI0009681 dya-mir-2a-2; +MI0009682 dya-mir-219; +MI0009683 dya-mir-312; +MI0009684 dya-mir-286; +MI0009685 dya-mir-315-1;dya-mir-315; +MI0009686 dya-mir-9a-2; +MI0009687 dya-mir-263b-1;dya-mir-263b; +MI0009688 dya-mir-92a; +MI0009689 dya-mir-9c; +MI0009690 dya-mir-2a-1; +MI0009691 dya-mir-9b; +MI0009692 dya-mir-263a; +MI0009693 dya-mir-275; +MI0009694 dya-mir-6-2; +MI0009695 dya-mir-316-2; +MI0009696 dya-mir-311b; +MI0009697 dya-mir-276a; +MI0009698 dya-mir-289; +MI0009699 dya-mir-263b-2; +MI0009700 dya-mir-7; +MI0009701 dya-mir-92b; +MI0009702 dya-mir-184; +MI0009703 dya-mir-11; +MI0009704 dya-mir-79; +MI0009705 dya-mir-276b; +MI0009706 pta-MIR1309; +MI0009707 pta-MIR1310; +MI0009708 pta-MIR1311; +MI0009709 pta-MIR1312; +MI0009710 pta-MIR1313; +MI0009711 pta-MIR1314; +MI0009712 pta-MIR1315; +MI0009713 pta-MIR1316; +MI0009714 osa-MIR1317; +MI0009715 osa-MIR1318; +MI0009716 osa-MIR1319;osa-MIR1319a; +MI0009717 osa-MIR1320; +MI0009718 bta-mir-1-2; +MI0009719 bta-mir-1-1; +MI0009720 bta-mir-100; +MI0009721 bta-mir-101-1; +MI0009722 bta-mir-105b; +MI0009723 bta-mir-105a; +MI0009724 bta-mir-106b; +MI0009725 bta-mir-104-2;bta-mir-124a-2; +MI0009726 bta-mir-104-3;bta-mir-124b; +MI0009727 bta-mir-128-2; +MI0009728 bta-mir-129-1; +MI0009729 bta-mir-129-2; +MI0009730 bta-mir-130a; +MI0009731 bta-mir-130b; +MI0009732 bta-mir-133a-2; +MI0009733 bta-mir-133a-1; +MI0009734 bta-mir-133b; +MI0009735 bta-mir-134; +MI0009736 bta-mir-135a-2; +MI0009737 bta-mir-135a-1; +MI0009738 bta-mir-135b; +MI0009739 bta-mir-136; +MI0009740 bta-mir-137; +MI0009741 bta-mir-138-1; +MI0009742 bta-mir-141; +MI0009743 bta-mir-143; +MI0009744 bta-mir-144; +MI0009745 bta-mir-146b; +MI0009746 bta-mir-146a; +MI0009747 bta-mir-147; +MI0009748 bta-mir-152; +MI0009749 bta-mir-153-1; +MI0009750 bta-mir-153-2; +MI0009751 bta-mir-154;bta-mir-154a; +MI0009752 bta-mir-155; +MI0009753 bta-mir-16a; +MI0009754 bta-mir-181d; +MI0009755 bta-mir-182; +MI0009756 bta-mir-183; +MI0009757 bta-mir-184; +MI0009758 bta-mir-185; +MI0009759 bta-mir-187; +MI0009760 bta-mir-188; +MI0009761 bta-mir-24-1; +MI0009762 bta-mir-190a; +MI0009763 bta-mir-190b; +MI0009764 bta-mir-193b; +MI0009765 bta-mir-194;bta-mir-194-2; +MI0009766 bta-mir-196a-2; +MI0009767 bta-mir-196a-1; +MI0009768 bta-mir-196b; +MI0009769 bta-mir-197; +MI0009770 bta-mir-199a-2; +MI0009771 bta-mir-202; +MI0009772 bta-mir-206; +MI0009773 bta-mir-208a; +MI0009774 bta-mir-208b; +MI0009775 bta-mir-211; +MI0009776 bta-mir-212; +MI0009777 bta-mir-216a; +MI0009778 bta-mir-216b; +MI0009779 bta-mir-217; +MI0009780 bta-mir-218a;bta-mir-218-1; +MI0009781 bta-mir-219;bta-mir-219-1;bta-mir-219;bta-mir-219-1; +MI0009782 bta-mir-223; +MI0009783 bta-mir-224; +MI0009784 bta-mir-26a-1; +MI0009785 bta-mir-28; +MI0009786 bta-mir-296; +MI0009787 bta-mir-299; +MI0009788 bta-mir-29d; +MI0009789 bta-mir-301a; +MI0009790 bta-mir-301b; +MI0009791 bta-mir-302a; +MI0009792 bta-mir-302d; +MI0009793 bta-mir-302b; +MI0009794 bta-mir-302c; +MI0009795 bta-mir-30f; +MI0009796 bta-mir-32; +MI0009797 bta-mir-323; +MI0009798 bta-mir-324; +MI0009799 bta-mir-326; +MI0009800 bta-mir-328; +MI0009801 bta-mir-329a; +MI0009802 bta-mir-329b; +MI0009803 bta-mir-330; +MI0009804 bta-mir-335; +MI0009805 bta-mir-338; +MI0009806 bta-mir-339;bta-mir-339a; +MI0009807 bta-mir-33a; +MI0009808 bta-mir-33b; +MI0009809 bta-mir-340; +MI0009810 bta-mir-346; +MI0009811 bta-mir-362; +MI0009812 bta-mir-365-2; +MI0009813 bta-mir-367; +MI0009814 bta-mir-370; +MI0009815 bta-mir-292;bta-mir-371; +MI0009816 bta-mir-374b; +MI0009817 bta-mir-375; +MI0009818 bta-mir-377; +MI0009819 bta-mir-378;bta-mir-378-1; +MI0009820 bta-mir-379; +MI0009821 bta-mir-381; +MI0009822 bta-mir-382; +MI0009823 bta-mir-383; +MI0009824 bta-mir-409;bta-mir-409a; +MI0009825 bta-mir-410; +MI0009826 bta-mir-411;bta-mir-411a; +MI0009827 bta-mir-412; +MI0009828 bta-mir-421; +MI0009829 bta-mir-429; +MI0009830 bta-mir-431; +MI0009831 bta-mir-432; +MI0009832 bta-mir-433; +MI0009833 bta-mir-448; +MI0009834 bta-mir-449a; +MI0009835 bta-mir-449b; +MI0009836 bta-mir-449c; +MI0009837 bta-mir-451; +MI0009838 bta-mir-452; +MI0009839 bta-mir-453; +MI0009840 bta-mir-454; +MI0009841 bta-mir-483; +MI0009842 bta-mir-485; +MI0009843 bta-mir-486; +MI0009844 bta-mir-488; +MI0009845 bta-mir-490; +MI0009846 bta-mir-491; +MI0009847 bta-mir-493; +MI0009848 bta-mir-494; +MI0009849 bta-mir-495; +MI0009850 bta-mir-496; +MI0009851 bta-mir-500; +MI0009852 bta-mir-502a-1; +MI0009853 bta-mir-502a-2; +MI0009854 bta-mir-502b; +MI0009855 bta-mir-504; +MI0009856 bta-mir-505; +MI0009857 bta-mir-539; +MI0009858 bta-mir-541; +MI0009859 bta-mir-543; +MI0009860 bta-mir-544b-1; +MI0009861 bta-mir-544b-2; +MI0009862 bta-mir-544a; +MI0009863 bta-mir-551a; +MI0009864 bta-mir-551b; +MI0009865 bta-mir-562; +MI0009866 bta-mir-568; +MI0009867 bta-mir-582; +MI0009868 bta-mir-584-2; +MI0009869 bta-mir-584-3; +MI0009870 bta-mir-584-4; +MI0009871 bta-mir-584-5; +MI0009872 bta-mir-584-6; +MI0009873 bta-mir-584-7; +MI0009874 bta-mir-584-1; +MI0009875 bta-mir-592; +MI0009876 bta-mir-599; +MI0009877 bta-mir-615; +MI0009878 bta-mir-628; +MI0009879 bta-mir-631; +MI0009880 bta-mir-653; +MI0009881 bta-mir-654; +MI0009882 bta-mir-655; +MI0009883 bta-mir-656; +MI0009884 bta-mir-658; +MI0009885 bta-mir-665; +MI0009886 bta-mir-670; +MI0009887 bta-mir-671; +MI0009888 bta-mir-685; +MI0009889 bta-mir-708; +MI0009891 bta-mir-744; +MI0009892 bta-mir-758; +MI0009893 bta-mir-759; +MI0009894 bta-mir-760; +MI0009895 bta-mir-761; +MI0009896 bta-mir-763; +MI0009897 bta-mir-767; +MI0009898 bta-mir-769; +MI0009899 bta-mir-873; +MI0009900 bta-mir-874; +MI0009901 bta-mir-875; +MI0009902 bta-mir-876; +MI0009903 bta-mir-877; +MI0009904 bta-mir-885; +MI0009905 bta-mir-92a;bta-mir-92a-1; +MI0009906 bta-mir-92b; +MI0009908 bta-mir-935; +MI0009909 bta-mir-940; +MI0009910 bta-mir-95; +MI0009911 bta-mir-96; +MI0009912 bta-mir-9-1; +MI0009913 bta-mir-9-2; +MI0009914 mmu-mir-1927; +MI0009917 mmu-mir-1928; +MI0009918 mmu-mir-1929; +MI0009919 mmu-mir-1930; +MI0009920 mmu-mir-1931; +MI0009921 mmu-mir-1932; +MI0009922 mmu-mir-1933; +MI0009923 mmu-mir-1934; +MI0009924 mmu-mir-1935; +MI0009925 mmu-mir-1936; +MI0009926 mmu-mir-1937a; +MI0009927 mmu-mir-1938; +MI0009928 mmu-mir-1939; +MI0009929 mmu-mir-1940; +MI0009930 mmu-mir-1941; +MI0009931 mmu-mir-1942; +MI0009932 mmu-mir-1943; +MI0009933 mmu-mir-1944; +MI0009934 mmu-mir-1945; +MI0009935 mmu-mir-1306; +MI0009936 mmu-mir-1946a; +MI0009937 mmu-mir-1947; +MI0009938 mmu-mir-1937b;mmu-mir-1937b-1; +MI0009939 mmu-mir-1948; +MI0009940 mmu-mir-1949; +MI0009941 mmu-mir-1950; +MI0009942 mmu-mir-669l; +MI0009943 mmu-mir-669m-1; +MI0009944 mmu-mir-669m-2; +MI0009945 mmu-mir-669o; +MI0009946 mmu-mir-1951; +MI0009947 mmu-mir-1952; +MI0009948 mmu-mir-1953; +MI0009949 mmu-mir-1954; +MI0009950 mmu-mir-1955; +MI0009951 mmu-mir-669n; +MI0009952 mmu-mir-1956; +MI0009953 mmu-mir-1937c; +MI0009954 mmu-mir-1957;mmu-mir-1957a; +MI0009955 mmu-mir-1958; +MI0009956 mmu-mir-1959; +MI0009957 mmu-mir-1960; +MI0009958 mmu-mir-1961; +MI0009959 mmu-mir-1962; +MI0009960 mmu-mir-1963; +MI0009961 mmu-mir-1964; +MI0009962 mmu-mir-1965; +MI0009963 mmu-mir-1966; +MI0009964 mmu-mir-1967; +MI0009965 mmu-mir-1968; +MI0009966 mmu-mir-1969; +MI0009967 mmu-mir-1946b; +MI0009968 mmu-mir-1970; +MI0009969 mmu-mir-1274a; +MI0009970 mmu-mir-1971; +MI0009971 sly-MIR156a; +MI0009972 sly-MIR156b; +MI0009973 sly-MIR156c; +MI0009974 sly-MIR159; +MI0009975 sly-MIR162; +MI0009976 sly-MIR172a; +MI0009977 sly-MIR172b; +MI0009978 sly-MIR319;sly-MIR319a; +MI0009979 sly-MIR399; +MI0009980 jcv-mir-J1; +MI0009981 bkv-mir-B1; +MI0009982 hsa-mir-1972;hsa-mir-1972-1; +MI0009983 hsa-mir-1973; +MI0009984 hsa-mir-1974; +MI0009985 hsa-mir-1975; +MI0009986 hsa-mir-1976; +MI0009987 hsa-mir-1977; +MI0009988 hsa-mir-1978; +MI0009989 hsa-mir-1979; +MI0009990 mmu-mir-1983; +MI0009991 mmu-mir-1839; +MI0009992 mmu-mir-1981; +MI0009993 mmu-mir-1982; +MI0009994 bmo-mir-12; +MI0009995 bmo-mir-137; +MI0009996 bmo-mir-190; +MI0009997 bmo-mir-285; +MI0009998 bmo-mir-92;bmo-mir-92b; +MI0009999 bmo-mir-925; +MI0010000 bmo-mir-927; +MI0010001 bmo-mir-929; +MI0010002 bmo-mir-930; +MI0010003 bmo-mir-932; +MI0010004 bmo-mir-9b; +MI0010005 bmo-mir-iab-4; +MI0010006 bmo-mir-278; +MI0010007 bfl-let-7-2;bfl-let-7a-2; +MI0010008 bfl-mir-1; +MI0010009 bfl-mir-7; +MI0010011 bfl-mir-10a; +MI0010012 bfl-mir-10b; +MI0010013 bfl-mir-10c; +MI0010014 bfl-mir-22; +MI0010015 bfl-mir-29a; +MI0010016 bfl-mir-29b; +MI0010017 bfl-mir-31; +MI0010018 bfl-mir-33-2; +MI0010019 bfl-mir-34;bfl-mir-34a; +MI0010020 bfl-mir-71; +MI0010021 bfl-mir-79; +MI0010022 bfl-mir-92a-1; +MI0010023 bfl-mir-92b; +MI0010024 bfl-mir-96; +MI0010025 bfl-mir-100; +MI0010026 bfl-mir-124; +MI0010027 bfl-mir-125;bfl-mir-125a; +MI0010028 bfl-mir-133; +MI0010029 bfl-mir-137; +MI0010030 bfl-mir-182;bfl-mir-182a; +MI0010031 bfl-mir-183; +MI0010032 bfl-mir-184; +MI0010033 bfl-mir-190; +MI0010034 bfl-mir-193;bfl-mir-193a; +MI0010035 bfl-mir-200a; +MI0010036 bfl-mir-200b; +MI0010037 bfl-mir-200c; +MI0010038 bfl-mir-210; +MI0010039 bfl-mir-216; +MI0010040 bfl-mir-217; +MI0010041 bfl-mir-242; +MI0010042 bfl-mir-252a; +MI0010043 bfl-mir-252b; +MI0010044 bfl-mir-281; +MI0010045 bfl-mir-375; +MI0010046 cap-mir-1;cte-mir-1; +MI0010047 cap-mir-2a;cte-mir-2a; +MI0010048 cap-mir-2b;cte-mir-2b; +MI0010049 cap-mir-2c;cte-mir-2c; +MI0010050 cap-mir-7;cte-mir-7; +MI0010051 cap-mir-8;cte-mir-8; +MI0010052 cap-mir-9;cte-mir-9; +MI0010053 cap-mir-10a;cte-mir-10a; +MI0010054 cap-mir-10b;cte-mir-10b; +MI0010055 cap-mir-10c;cte-mir-10c; +MI0010056 cap-mir-12;cte-mir-12; +MI0010057 cap-mir-29a;cte-mir-29a; +MI0010058 cap-mir-29b;cte-mir-29b; +MI0010059 cap-mir-31;cte-mir-31; +MI0010060 cap-mir-34;cte-mir-34; +MI0010061 cap-mir-71;cte-mir-71; +MI0010062 cap-mir-87a;cte-mir-87a; +MI0010063 cap-mir-87b;cte-mir-87b; +MI0010064 cap-mir-92a;cte-mir-92a; +MI0010065 cap-mir-92b;cte-mir-92b; +MI0010066 cap-mir-92c;cte-mir-92c; +MI0010067 cap-mir-96;cte-mir-96; +MI0010068 cap-mir-100;cte-mir-100; +MI0010069 cap-mir-125;cte-mir-125; +MI0010070 cap-mir-133;cte-mir-133; +MI0010071 cap-mir-137;cte-mir-137; +MI0010072 cap-mir-153;cte-mir-153; +MI0010073 cap-mir-182;cte-mir-182;cte-mir-263; +MI0010074 cap-mir-184a;cte-mir-184a; +MI0010075 cap-mir-184b;cte-mir-184b; +MI0010076 cap-mir-190;cte-mir-190; +MI0010077 cap-mir-193;cte-mir-193; +MI0010078 cap-mir-210;cte-mir-210;cte-mir-210a; +MI0010079 cap-mir-216a;cte-mir-216a; +MI0010080 cap-mir-252a;cte-mir-252a; +MI0010081 cap-mir-252b;cte-mir-252b; +MI0010082 cap-mir-278;cte-mir-278; +MI0010083 cap-mir-279;cte-mir-279; +MI0010084 cap-mir-281;cte-mir-281; +MI0010085 cap-mir-315;cte-mir-315; +MI0010086 cap-mir-317;cte-mir-317; +MI0010087 cap-mir-365;cte-mir-365; +MI0010088 cap-mir-375;cte-mir-375; +MI0010089 cap-mir-745a;cte-mir-745a; +MI0010090 cap-mir-745b;cte-mir-745b; +MI0010091 cap-mir-750;cte-mir-750; +MI0010092 cap-mir-981;cte-mir-981; +MI0010093 cap-mir-1175;cte-mir-1175; +MI0010094 cap-bantam;cte-bantam; +MI0010095 cap-let-7;cte-let-7; +MI0010096 cap-mir-33;cte-mir-33; +MI0010097 cap-mir-79;cte-mir-79; +MI0010098 cap-mir-124;cte-mir-124; +MI0010099 cap-mir-219;cte-mir-219; +MI0010100 lgi-mir-1; +MI0010101 lgi-mir-2c; +MI0010102 lgi-mir-2d; +MI0010103 lgi-mir-7; +MI0010104 lgi-mir-8; +MI0010105 lgi-mir-9; +MI0010106 lgi-mir-10; +MI0010107 lgi-mir-12; +MI0010108 lgi-mir-29; +MI0010109 lgi-mir-31; +MI0010110 lgi-mir-33; +MI0010111 lgi-mir-34; +MI0010112 lgi-mir-67; +MI0010113 lgi-mir-71; +MI0010114 lgi-mir-79; +MI0010115 lgi-mir-87; +MI0010116 lgi-mir-92; +MI0010117 lgi-mir-96a; +MI0010118 lgi-mir-96b; +MI0010119 lgi-mir-100; +MI0010120 lgi-mir-124; +MI0010121 lgi-mir-133; +MI0010122 lgi-mir-137; +MI0010123 lgi-mir-153; +MI0010124 lgi-mir-182;lgi-mir-263a; +MI0010125 lgi-mir-183;lgi-mir-263b; +MI0010126 lgi-mir-184; +MI0010127 lgi-mir-190; +MI0010128 lgi-mir-193; +MI0010129 lgi-mir-216a; +MI0010130 lgi-mir-216b; +MI0010131 lgi-mir-242;lgi-mir-242a; +MI0010132 lgi-mir-252;lgi-mir-252a; +MI0010133 lgi-mir-278; +MI0010134 lgi-mir-279; +MI0010135 lgi-mir-281; +MI0010136 lgi-mir-315; +MI0010137 lgi-mir-317; +MI0010138 lgi-mir-745a; +MI0010139 lgi-mir-745b; +MI0010140 lgi-mir-750; +MI0010141 lgi-mir-981; +MI0010142 lgi-mir-1175; +MI0010143 lgi-let-7; +MI0010144 nve-mir-100; +MI0010145 sko-mir-1; +MI0010146 sko-mir-7; +MI0010147 sko-mir-200; +MI0010148 sko-mir-9; +MI0010149 sko-mir-10; +MI0010150 sko-mir-29a; +MI0010151 sko-mir-29b; +MI0010152 sko-mir-31; +MI0010153 sko-mir-33; +MI0010154 sko-mir-34; +MI0010155 sko-mir-71; +MI0010156 sko-mir-79; +MI0010157 sko-mir-92a; +MI0010158 sko-mir-92b; +MI0010159 sko-mir-92c; +MI0010160 sko-mir-96; +MI0010161 sko-mir-100; +MI0010162 sko-mir-124; +MI0010163 sko-mir-125;sko-mir-125a; +MI0010164 sko-mir-133; +MI0010165 sko-mir-137; +MI0010166 sko-mir-153; +MI0010167 sko-mir-182; +MI0010168 sko-mir-183; +MI0010169 sko-mir-184; +MI0010170 sko-mir-190; +MI0010171 sko-mir-193;sko-mir-193a; +MI0010172 sko-mir-210; +MI0010173 sko-mir-242; +MI0010174 sko-mir-252a; +MI0010175 sko-mir-252b; +MI0010176 sko-mir-278; +MI0010177 sko-mir-281; +MI0010178 sko-mir-315; +MI0010179 sko-mir-365; +MI0010180 sko-let-7; +MI0010181 spu-mir-137; +MI0010182 spu-mir-210; +MI0010183 spu-mir-242; +MI0010184 spu-mir-375; +MI0010185 spu-let-7; +MI0010186 spu-mir-1; +MI0010187 spu-mir-7; +MI0010188 spu-mir-200; +MI0010189 spu-mir-9; +MI0010190 spu-mir-10; +MI0010191 spu-mir-22; +MI0010192 spu-mir-29;spu-mir-29a; +MI0010193 spu-mir-31; +MI0010194 spu-mir-33; +MI0010195 spu-mir-34; +MI0010196 spu-mir-71; +MI0010197 spu-mir-79; +MI0010198 spu-mir-92a; +MI0010199 spu-mir-92b; +MI0010200 spu-mir-92c; +MI0010201 spu-mir-96; +MI0010202 spu-mir-124; +MI0010203 spu-mir-125; +MI0010204 spu-mir-133; +MI0010205 spu-mir-153; +MI0010206 spu-mir-182; +MI0010207 spu-mir-184; +MI0010208 spu-mir-252a; +MI0010209 spu-mir-252b; +MI0010210 spu-mir-278; +MI0010211 cap-mir-67;cte-mir-67; +MI0010212 lgi-mir-375; +MI0010213 sko-mir-193b; +MI0010214 cap-mir-2d;cte-mir-2d;cte-mir-2d-1; +MI0010215 cap-mir-216b;cte-mir-216b; +MI0010216 cap-mir-242;cte-mir-242; +MI0010217 lgi-mir-242b; +MI0010218 lgi-mir-252b; +MI0010219 sko-mir-375; +MI0010220 spu-mir-183; +MI0010221 spu-mir-219; +MI0010222 aqu-mir-2014; +MI0010223 aqu-mir-2015; +MI0010224 aqu-mir-2016; +MI0010225 aqu-mir-2017; +MI0010226 aqu-mir-2018; +MI0010227 aqu-mir-2019; +MI0010228 aqu-mir-2020; +MI0010229 cap-mir-1992;cte-mir-1992; +MI0010230 cap-mir-1993;cte-mir-1993; +MI0010231 cap-mir-1994;cte-mir-1994; +MI0010232 cap-mir-1987;cte-mir-1987; +MI0010233 cap-mir-1989;cte-mir-1989; +MI0010234 cap-mir-2001;cte-mir-2001; +MI0010235 cap-mir-1995;cte-mir-1995; +MI0010236 cap-mir-1996a;cte-mir-1996a; +MI0010237 cap-mir-1997;cte-mir-1997; +MI0010238 cap-mir-1998;cte-mir-1998; +MI0010239 cap-mir-1999;cte-mir-1999; +MI0010240 cap-mir-2000;cte-mir-2000; +MI0010241 cap-mir-1996b;cte-mir-1996b; +MI0010242 cla-mir-1992; +MI0010243 cla-mir-1994; +MI0010244 hru-mir-1984; +MI0010245 hru-mir-1985; +MI0010246 hru-mir-1986; +MI0010247 hru-mir-1990; +MI0010248 hru-mir-1991; +MI0010249 hma-mir-2022; +MI0010250 isc-mir-2001; +MI0010251 lgi-mir-1992; +MI0010252 lgi-mir-1993; +MI0010253 lgi-mir-1994a; +MI0010254 lgi-mir-1994b; +MI0010255 lgi-mir-1984; +MI0010256 lgi-mir-1985; +MI0010257 lgi-mir-1986; +MI0010258 lgi-mir-1988; +MI0010259 lgi-mir-1989; +MI0010260 lgi-mir-2001; +MI0010261 lgi-mir-1990; +MI0010262 lgi-mir-1991; +MI0010263 nve-mir-2022; +MI0010264 sko-mir-2001; +MI0010265 sko-mir-2012; +MI0010266 sko-mir-2013; +MI0010267 sko-mir-2008; +MI0010268 sko-mir-2011; +MI0010269 spu-mir-2001; +MI0010270 spu-mir-2012; +MI0010271 spu-mir-2013; +MI0010272 spu-mir-2002; +MI0010273 spu-mir-2003; +MI0010274 spu-mir-2004; +MI0010275 spu-mir-2005; +MI0010276 spu-mir-2006; +MI0010277 spu-mir-2007; +MI0010278 spu-mir-2008; +MI0010279 spu-mir-2009; +MI0010280 spu-mir-2010; +MI0010281 spu-mir-2011; +MI0010282 aqu-mir-2021; +MI0010283 nve-mir-2023; +MI0010284 nve-mir-2024a;nve-mir-2024a-1; +MI0010285 nve-mir-2025; +MI0010286 nve-mir-2024b; +MI0010287 nve-mir-2024c; +MI0010288 nve-mir-2024d; +MI0010289 nve-mir-2024e;nve-mir-2024e-1; +MI0010290 nve-mir-2024f; +MI0010291 nve-mir-2026; +MI0010292 nve-mir-2027; +MI0010293 nve-mir-2024g;nve-mir-2024g-1; +MI0010294 nve-mir-2028; +MI0010295 nve-mir-2029; +MI0010296 nve-mir-2030; +MI0010297 nve-mir-2031; +MI0010298 nve-mir-2032a; +MI0010299 nve-mir-2032b;nve-mir-2032b-1; +MI0010300 nve-mir-2033; +MI0010301 nve-mir-2034; +MI0010302 nve-mir-2035;nve-mir-2035-1; +MI0010303 nve-mir-2036; +MI0010304 nve-mir-2037; +MI0010305 nve-mir-2038; +MI0010306 nve-mir-2039; +MI0010307 nve-mir-2040a;nve-mir-2040a-1; +MI0010308 nve-mir-2041;nve-mir-2041a; +MI0010309 nve-mir-2042; +MI0010310 nve-mir-2040b; +MI0010311 nve-mir-2043a;nve-mir-2043-1; +MI0010312 nve-mir-2044; +MI0010313 nve-mir-2045; +MI0010314 nve-mir-2046; +MI0010315 nve-mir-2047; +MI0010316 nve-mir-2048; +MI0010317 nve-mir-2049; +MI0010318 nve-mir-2050; +MI0010319 nve-mir-2043b;nve-mir-2043-2; +MI0010320 nve-mir-2051; +MI0010321 osa-MIR1846c; +MI0010322 cfa-mir-20b; +MI0010323 cfa-mir-18b; +MI0010324 cfa-mir-18a; +MI0010325 cfa-mir-133c; +MI0010326 cfa-mir-133a; +MI0010327 cfa-mir-133b; +MI0010328 cfa-let-7a-2; +MI0010329 cfa-let-7b; +MI0010330 cfa-mir-7-3; +MI0010331 cfa-mir-10b; +MI0010332 cfa-mir-34b; +MI0010333 cfa-mir-135a-1; +MI0010334 cfa-mir-135b; +MI0010335 cfa-mir-153; +MI0010336 cfa-mir-182; +MI0010337 cfa-mir-184; +MI0010338 cfa-mir-187; +MI0010339 cfa-mir-202; +MI0010340 cfa-mir-205; +MI0010341 cfa-mir-210; +MI0010342 cfa-mir-214; +MI0010343 cfa-mir-215; +MI0010344 cfa-mir-216a; +MI0010345 cfa-mir-217; +MI0010346 cfa-mir-222; +MI0010347 cfa-mir-223; +MI0010348 cfa-mir-301a; +MI0010349 cfa-mir-301b; +MI0010350 cfa-mir-302a; +MI0010351 cfa-mir-302b; +MI0010352 cfa-mir-302c; +MI0010353 cfa-mir-302d; +MI0010354 cfa-mir-367; +MI0010355 cfa-mir-489; +MI0010356 cfa-mir-96; +MI0010357 cfa-mir-103-2; +MI0010358 cfa-mir-33b; +MI0010359 cfa-mir-145; +MI0010360 cfa-mir-196a-1; +MI0010361 cfa-mir-200b; +MI0010362 cfa-mir-200a; +MI0010363 cfa-mir-203; +MI0010365 cfa-mir-208a; +MI0010366 cfa-mir-208b; +MI0010367 cfa-mir-451; +MI0010368 cfa-mir-375; +MI0010369 cfa-mir-190a; +MI0010370 cfa-mir-190b; +MI0010371 cfa-mir-147; +MI0010372 cfa-mir-490; +MI0010373 cfa-mir-211; +MI0010374 cfa-mir-141; +MI0010375 cfa-mir-514; +MI0010376 cfa-mir-95; +MI0010377 cfa-mir-105a; +MI0010378 cfa-mir-105b; +MI0010379 cfa-mir-188; +MI0010380 cfa-mir-220b; +MI0010381 cfa-mir-220a; +MI0010382 cfa-mir-134; +MI0010383 cfa-mir-149; +MI0010384 cfa-mir-299; +MI0010385 cfa-mir-362; +MI0010386 cfa-mir-376b; +MI0010387 cfa-mir-376c; +MI0010388 cfa-mir-370; +MI0010389 cfa-mir-377; +MI0010390 cfa-mir-381; +MI0010391 cfa-mir-340; +MI0010392 cfa-mir-330; +MI0010393 cfa-mir-326; +MI0010394 cfa-mir-331; +MI0010395 cfa-mir-324; +MI0010396 cfa-mir-325; +MI0010397 cfa-mir-346; +MI0010398 cfa-mir-329b; +MI0010399 cfa-mir-452; +MI0010400 cfa-mir-483; +MI0010401 cfa-mir-487a; +MI0010402 cfa-mir-488; +MI0010403 cfa-mir-432; +MI0010404 cfa-mir-494; +MI0010405 cfa-mir-496; +MI0010406 cfa-mir-504; +MI0010407 cfa-mir-505; +MI0010408 cfa-mir-539; +MI0010409 cfa-mir-544; +MI0010410 cfa-mir-545; +MI0010411 cfa-mir-551a; +MI0010412 cfa-mir-551b; +MI0010413 cfa-mir-568; +MI0010414 cfa-mir-578; +MI0010415 cfa-mir-582; +MI0010416 cfa-mir-589; +MI0010417 cfa-mir-592; +MI0010418 cfa-mir-599; +MI0010419 cfa-mir-615; +MI0010420 cfa-mir-628; +MI0010421 cfa-mir-631; +MI0010422 cfa-mir-632; +MI0010423 cfa-mir-653; +MI0010424 cfa-mir-758; +MI0010425 cfa-mir-671; +MI0010426 cfa-mir-454; +MI0010427 cfa-mir-802; +MI0010428 cfa-mir-300; +MI0010429 cfa-mir-874; +MI0010430 cfa-mir-875; +MI0010431 cfa-mir-876; +MI0010432 cfa-mir-885; +MI0010433 cfa-mir-665; +MI0010434 cfa-mir-207; +MI0010435 cfa-mir-761; +MI0010436 cfa-mir-764; +MI0010437 cfa-mir-759; +MI0010438 cfa-mir-718; +MI0010439 cfa-mir-872; +MI0010441 bta-mir-489; +MI0010442 bta-mir-220d; +MI0010443 bta-mir-1224; +MI0010444 bta-mir-376b; +MI0010445 bta-mir-376d; +MI0010446 bta-mir-376c; +MI0010447 bta-mir-764; +MI0010448 bta-mir-220e; +MI0010449 bta-mir-220c-2; +MI0010450 bta-mir-220b; +MI0010451 bta-mir-220c-1; +MI0010452 bta-mir-1225; +MI0010453 bta-mir-584-8; +MI0010454 bta-mir-29e; +MI0010455 bta-mir-1282; +MI0010456 bta-mir-1284; +MI0010457 bta-mir-376a; +MI0010458 bta-mir-1291; +MI0010459 bta-mir-1179; +MI0010460 bta-mir-1301; +MI0010461 bta-mir-220a; +MI0010462 bta-mir-7-2; +MI0010463 bta-mir-1256; +MI0010464 bta-mir-29b-1; +MI0010465 bta-mir-1835; +MI0010466 bta-mir-1281; +MI0010467 bta-mir-1251; +MI0010468 bta-mir-1296; +MI0010469 bta-mir-1193; +MI0010470 bta-mir-1197; +MI0010471 bta-mir-7-1; +MI0010472 bta-mir-1300a; +MI0010473 bta-mir-1839; +MI0010474 bta-mir-1307; +MI0010475 bta-mir-1298; +MI0010476 bta-mir-1287; +MI0010477 bta-mir-1248-1; +MI0010478 bta-mir-1185; +MI0010479 bta-mir-1306; +MI0010480 bta-mir-1271; +MI0010481 bta-mir-1249; +MI0010482 bta-mir-1300b; +MI0010483 bta-mir-1248-2; +MI0010484 bta-mir-181a-1; +MI0010485 bta-mir-181b-1; +MI0010486 hsa-mir-2052; +MI0010487 hsa-mir-2053; +MI0010488 hsa-mir-2054; +MI0010489 osa-MIR2055; +MI0010490 osa-MIR827a;osa-MIR827; +MI0010491 bfl-mir-2056; +MI0010492 bfl-mir-2057; +MI0010493 bfl-mir-2058; +MI0010494 bfl-mir-2059; +MI0010495 bfl-mir-2060; +MI0010496 bfl-mir-2061; +MI0010497 bfl-mir-2062; +MI0010498 bfl-mir-2063; +MI0010499 bfl-mir-2064; +MI0010500 bfl-mir-2013; +MI0010501 bfl-mir-135a-1; +MI0010502 bfl-mir-135a-2; +MI0010503 bfl-mir-2065; +MI0010504 bfl-mir-2066; +MI0010505 bfl-mir-2067; +MI0010506 bfl-mir-2068; +MI0010507 bfl-mir-2069; +MI0010508 bfl-mir-2070; +MI0010509 bfl-mir-2071; +MI0010510 bfl-mir-2072; +MI0010511 bfl-mir-2073; +MI0010512 bfl-mir-34b; +MI0010513 bfl-mir-2074; +MI0010514 bfl-mir-2075; +MI0010515 bfl-mir-2076; +MI0010516 bfl-let-7-1;bfl-let-7a-1; +MI0010517 bfl-let-7-1-as;bfl-let-7b; +MI0010518 bfl-mir-125b-as;bfl-mir-125b; +MI0010519 bfl-mir-129;bfl-mir-129a; +MI0010520 bfl-mir-9-1; +MI0010521 bfl-mir-9-2; +MI0010522 bfl-mir-92a-2; +MI0010523 bfl-mir-92a-3; +MI0010524 bfl-mir-92c; +MI0010525 bfl-mir-33-1; +MI0010526 bfl-mir-19; +MI0010527 bfl-mir-219; +MI0010528 bfl-mir-705; +MI0010529 ppt-MIR2077; +MI0010530 ppt-MIR2078; +MI0010531 ppt-MIR2079; +MI0010532 ppt-MIR2080; +MI0010533 ppt-MIR2084; +MI0010534 ppt-MIR2085; +MI0010535 ppt-MIR2081; +MI0010536 ppt-MIR2082; +MI0010537 ppt-MIR2083; +MI0010538 ppt-MIR1023e; +MI0010539 mtr-MIR2086; +MI0010540 mtr-MIR1510b; +MI0010541 mtr-MIR1507; +MI0010542 mtr-MIR1510a; +MI0010543 mtr-MIR1509;mtr-MIR1509a; +MI0010544 mtr-MIR2087; +MI0010545 mtr-MIR2088;mtr-MIR2088a;mtr-MIR2088; +MI0010546 mtr-MIR2089; +MI0010547 osa-MIR1846e; +MI0010548 osa-MIR1428f; +MI0010549 osa-MIR1428g; +MI0010550 osa-MIR2090; +MI0010551 osa-MIR2091; +MI0010552 osa-MIR2092; +MI0010553 osa-MIR2093; +MI0010554 osa-MIR2094; +MI0010555 osa-MIR2095; +MI0010556 osa-MIR2096; +MI0010557 osa-MIR2097; +MI0010558 osa-MIR2098; +MI0010559 osa-MIR2099; +MI0010560 osa-MIR2100; +MI0010561 osa-MIR2101; +MI0010562 osa-MIR2102; +MI0010563 osa-MIR396f; +MI0010564 osa-MIR2103; +MI0010565 osa-MIR2104; +MI0010566 osa-MIR2105; +MI0010567 osa-MIR2106; +MI0010568 osa-MIR827b; +MI0010569 zma-MIR396c; +MI0010570 zma-MIR396d; +MI0010571 gma-MIR167d; +MI0010572 gma-MIR396c; +MI0010573 gma-MIR1507b; +MI0010574 gma-MIR1508b; +MI0010575 gma-MIR1510b; +MI0010576 gma-MIR2107; +MI0010577 gma-MIR2108a; +MI0010578 gma-MIR2108b; +MI0010579 gma-MIR2109; +MI0010580 lja-MIR167; +MI0010581 lja-MIR396; +MI0010582 vun-MIR1507;vun-MIR1507a; +MI0010583 tca-mir-9a; +MI0010584 tca-bantam; +MI0010585 tca-mir-970; +MI0010586 tca-mir-263a; +MI0010587 tca-mir-279b; +MI0010588 tca-mir-993; +MI0010589 tca-mir-965; +MI0010590 tca-mir-315; +MI0010591 tca-mir-1000; +MI0010592 tca-mir-981; +MI0010593 tca-mir-304; +MI0010594 aga-mir-190; +MI0010595 aga-mir-929; +MI0010596 aga-mir-927; +MI0010597 aga-mir-993; +MI0010598 aga-mir-988; +MI0010599 aga-mir-970; +MI0010600 aga-mir-957; +MI0010601 aga-mir-137; +MI0010602 aga-mir-965-1; +MI0010603 aga-mir-965-2; +MI0010604 aga-mir-1000; +MI0010605 aga-mir-286; +MI0010606 aga-mir-263b; +MI0010607 aga-mir-309; +MI0010608 ame-mir-252;ame-mir-252a; +MI0010609 ame-mir-13b; +MI0010610 ame-mir-996; +MI0010611 ame-mir-263b; +MI0010612 ame-mir-92b-1; +MI0010613 ame-mir-92b-2; +MI0010614 ame-mir-985; +MI0010616 ame-mir-1000; +MI0010617 ame-mir-1006; +MI0010618 ame-mir-981; +MI0010619 ame-mir-316; +MI0010620 ame-mir-993; +MI0010621 bmo-mir-252; +MI0010622 bmo-mir-970; +MI0010623 bmo-mir-965; +MI0010624 bmo-mir-274; +MI0010625 bmo-mir-993b; +MI0010626 bmo-mir-993a; +MI0010627 ebv-mir-BART21; +MI0010628 ebv-mir-BART22; +MI0010629 hsa-mir-2110; +MI0010630 ath-MIR2111a; +MI0010631 ath-MIR2111b; +MI0010632 ath-MIR2112; +MI0010633 hsa-mir-2114; +MI0010634 hsa-mir-2115; +MI0010635 hsa-mir-2116; +MI0010636 hsa-mir-2117; +MI0010637 hsa-mir-548q; +MI0010639 bfl-mir-278; +MI0010640 lmi-mir-307; +MI0010641 lmi-mir-276; +MI0010642 lmi-mir-281; +MI0010643 lmi-mir-210; +MI0010644 lmi-mir-10; +MI0010645 lmi-mir-9a; +MI0010646 lmi-mir-8; +MI0010647 mcv-mir-M1;mcpv-mir-P1; +MI0010648 bra-MIR157a; +MI0010649 bra-MIR159a; +MI0010650 bra-MIR160a; +MI0010651 bra-MIR164a; +MI0010652 bra-MIR167a; +MI0010653 bra-MIR167b; +MI0010654 bra-MIR167c; +MI0010655 bra-MIR167d; +MI0010656 bra-MIR171a; +MI0010657 bra-MIR171b; +MI0010658 bra-MIR171c; +MI0010659 bra-MIR171d; +MI0010660 bra-MIR171e; +MI0010661 bra-MIR172a; +MI0010662 bra-MIR172b; +MI0010663 bol-MIR157a; +MI0010664 bol-MIR171a; +MI0010665 bol-MIR172a; +MI0010666 bol-MIR172b; +MI0010667 bol-MIR398a; +MI0010668 sja-let-7; +MI0010669 sja-mir-71;sja-mir-71a; +MI0010670 sja-bantam; +MI0010671 sja-mir-125a; +MI0010672 sja-mir-125b; +MI0010673 sma-let-7; +MI0010674 sma-mir-71;sma-mir-71a; +MI0010675 sma-bantam; +MI0010676 sma-mir-125a; +MI0010677 sma-mir-125b; +MI0010678 ssc-mir-101a-1;ssc-mir-101-1; +MI0010679 ssc-mir-101a-2;ssc-mir-101-2; +MI0010680 ssc-mir-124a-1; +MI0010681 ssc-mir-133a;ssc-mir-133a-1; +MI0010682 ssc-mir-1a;ssc-mir-1; +MI0010683 ssc-mir-450;ssc-mir-450a; +MI0010684 ssc-mir-503; +MI0010685 ssc-mir-146b; +MI0010686 ssc-mir-181a;ssc-mir-181a-1; +MI0010687 ssc-mir-215; +MI0010688 ssc-mir-30a; +MI0010689 bfl-mir-135b;bfl-mir-135b-1; +MI0010690 mmu-mir-683-2; +MI0010691 cel-mir-258-2; +MI0010692 hsv2-mir-H3; +MI0010693 hsv2-mir-H4; +MI0010694 hsv2-mir-H2; +MI0010695 mdm-MIR482;mdm-MIR482a; +MI0010696 mtr-MIR159a; +MI0010697 gma-MIR2119; +MI0010698 mtr-MIR2119; +MI0010699 pvu-MIR2118; +MI0010700 pvu-MIR159a; +MI0010701 pvu-MIR1514a; +MI0010702 pvu-MIR482; +MI0010703 pvu-MIR2119; +MI0010704 pvu-MIR166a; +MI0010705 pvu-MIR319c; +MI0010706 pvu-MIR399a; +MI0010707 vun-MIR1507b; +MI0010708 osa-MIR2120; +MI0010709 osa-MIR2121a; +MI0010710 osa-MIR2121b; +MI0010711 osa-MIR2122; +MI0010712 osa-MIR2123a; +MI0010713 osa-MIR2123b; +MI0010714 osa-MIR2123c; +MI0010715 osa-MIR2124a; +MI0010716 osa-MIR2124b; +MI0010717 osa-MIR2124c; +MI0010718 osa-MIR2124d; +MI0010719 osa-MIR2124e; +MI0010720 osa-MIR2124f; +MI0010721 osa-MIR2124g; +MI0010722 osa-MIR2124i; +MI0010723 osa-MIR2125; +MI0010724 osa-MIR2124h; +MI0010725 gma-MIR167e; +MI0010726 gma-MIR167f; +MI0010727 gma-MIR172c; +MI0010728 gma-MIR172d; +MI0010729 gma-MIR172e; +MI0010730 gma-MIR1509b; +MI0010731 gga-mir-2126; +MI0010732 gga-mir-2127; +MI0010733 gga-mir-2128; +MI0010734 gga-mir-2129; +MI0010735 gga-mir-2130; +MI0010736 gga-mir-2131; +MI0010737 mmu-mir-2132; +MI0010738 mmu-mir-2133-1; +MI0010739 mmu-mir-2133-2; +MI0010740 mmu-mir-2134-1; +MI0010741 mmu-mir-2134-2; +MI0010742 mmu-mir-2134-3; +MI0010743 mmu-mir-2134-4; +MI0010744 mmu-mir-2135-1; +MI0010745 mmu-mir-2135-4; +MI0010746 mmu-mir-2135-5; +MI0010747 mmu-mir-2135-2; +MI0010748 mmu-mir-2135-3; +MI0010749 mmu-mir-2136; +MI0010750 mmu-mir-2137; +MI0010751 mmu-mir-2138; +MI0010752 mmu-mir-2139; +MI0010753 mmu-mir-2140; +MI0010754 mmu-mir-2141; +MI0010755 mmu-mir-2142; +MI0010756 mmu-mir-2143-1; +MI0010757 mmu-mir-2143-2; +MI0010758 mmu-mir-2143-3; +MI0010759 mmu-mir-2144; +MI0010760 mmu-mir-2145-1; +MI0010761 mmu-mir-2145-2; +MI0010762 mmu-mir-2146; +MI0010763 sme-mir-10a; +MI0010764 sme-mir-2148; +MI0010765 sme-let-7d; +MI0010766 sme-mir-753b; +MI0010767 sme-mir-61b; +MI0010768 sme-mir-87c; +MI0010769 sme-mir-2149; +MI0010770 sme-mir-2147a; +MI0010771 sme-mir-2150; +MI0010772 sme-mir-2151; +MI0010773 sme-mir-2152; +MI0010774 sme-mir-2153; +MI0010775 sme-mir-87d; +MI0010776 sme-mir-754b-1; +MI0010777 sme-mir-754c-1; +MI0010778 sme-mir-124d; +MI0010779 sme-mir-124e; +MI0010780 sme-mir-8b; +MI0010781 sme-mir-1993; +MI0010782 sme-mir-36b; +MI0010783 sme-mir-1992; +MI0010784 sme-mir-2154-1; +MI0010785 sme-mir-216; +MI0010786 sme-mir-2156a; +MI0010787 sme-mir-9b; +MI0010788 sme-mir-9a; +MI0010789 sme-mir-1175; +MI0010790 sme-mir-2157; +MI0010791 sme-mir-2158; +MI0010792 sme-mir-2159; +MI0010793 sme-mir-7d; +MI0010794 sme-mir-2160-1; +MI0010795 sme-mir-2161; +MI0010796 sme-mir-2162; +MI0010797 sme-mir-2163; +MI0010799 sme-mir-133a; +MI0010800 sme-mir-2164; +MI0010801 sme-mir-2165; +MI0010802 sme-mir-36c; +MI0010803 sme-mir-96a; +MI0010804 sme-mir-2166; +MI0010805 sme-mir-2167; +MI0010806 sme-mir-2147b; +MI0010807 sme-mir-2168; +MI0010808 sme-mir-2169; +MI0010810 sme-mir-754d; +MI0010811 sme-mir-2170; +MI0010813 sme-mir-2147c; +MI0010814 sme-mir-2171; +MI0010815 sme-mir-2172; +MI0010817 sme-mir-96b; +MI0010818 sme-mir-2173; +MI0010819 sme-mir-2174; +MI0010820 sme-mir-2175; +MI0010822 sme-mir-753c; +MI0010823 sme-mir-2176; +MI0010825 sme-mir-2177; +MI0010826 sme-mir-2178; +MI0010827 sme-mir-2179; +MI0010828 sme-mir-315; +MI0010829 sme-mir-2180; +MI0010830 sme-mir-2181; +MI0010831 sme-mir-2155; +MI0010832 mmu-mir-2182; +MI0010833 mmu-mir-2183; +MI0010834 dre-mir-2184; +MI0010835 dre-mir-2185;dre-mir-2185-1; +MI0010836 dre-mir-429b; +MI0010837 dre-mir-1388; +MI0010838 dre-mir-1788; +MI0010839 dre-mir-2187; +MI0010840 dre-mir-196c; +MI0010841 dre-mir-2190;dre-mir-2190-1; +MI0010842 dre-mir-2191; +MI0010843 dre-mir-107b; +MI0010844 dre-mir-455b;dre-mir-455-2; +MI0010845 dre-mir-222b; +MI0010846 dre-mir-2196; +MI0010847 dre-mir-2198; +MI0010848 dre-mir-126b; +MI0010849 dre-mir-2186; +MI0010850 dre-mir-2188; +MI0010851 dre-mir-2189; +MI0010852 dre-mir-2192; +MI0010853 dre-mir-196d; +MI0010854 dre-mir-2193; +MI0010855 dre-mir-2194; +MI0010856 dre-mir-2195; +MI0010857 dre-mir-2197; +MI0010858 mtr-MIR2118; +MI0010859 mtr-MIR2199; +MI0010860 sbi-MIR156f; +MI0010861 sbi-MIR156g; +MI0010862 sbi-MIR156h; +MI0010863 sbi-MIR156i; +MI0010864 sbi-MIR160f; +MI0010865 sbi-MIR164d; +MI0010866 sbi-MIR164e; +MI0010867 sbi-MIR166h; +MI0010868 sbi-MIR166i; +MI0010869 sbi-MIR166j; +MI0010870 sbi-MIR166k; +MI0010871 sbi-MIR167h; +MI0010872 sbi-MIR167i; +MI0010873 sbi-MIR169e; +MI0010874 sbi-MIR169h; +MI0010875 sbi-MIR169j; +MI0010876 sbi-MIR169k; +MI0010877 sbi-MIR169l; +MI0010878 sbi-MIR169m; +MI0010879 sbi-MIR169n; +MI0010880 sbi-MIR171g; +MI0010881 sbi-MIR171h; +MI0010882 sbi-MIR171i; +MI0010883 sbi-MIR171j; +MI0010884 sbi-MIR171k; +MI0010885 sbi-MIR172d; +MI0010886 sbi-MIR319b; +MI0010887 sbi-MIR390; +MI0010888 sbi-MIR393b; +MI0010889 sbi-MIR394b; +MI0010890 sbi-MIR395c; +MI0010891 sbi-MIR395g; +MI0010892 sbi-MIR395h; +MI0010893 sbi-MIR395i; +MI0010894 sbi-MIR395j; +MI0010895 sbi-MIR395k; +MI0010896 sbi-MIR395l; +MI0010897 sbi-MIR396d; +MI0010898 sbi-MIR396e; +MI0010899 sbi-MIR397; +MI0010900 sbi-MIR399j; +MI0010901 sbi-MIR408; +MI0010902 sbi-MIR437a; +MI0010903 sbi-MIR437b; +MI0010904 sbi-MIR437c; +MI0010905 sbi-MIR437d; +MI0010906 sbi-MIR437e; +MI0010907 sbi-MIR437f; +MI0010908 sbi-MIR437g; +MI0010909 sbi-MIR437i; +MI0010910 sbi-MIR437j; +MI0010911 sbi-MIR437k; +MI0010912 sbi-MIR437l; +MI0010913 sbi-MIR437m; +MI0010914 sbi-MIR437n; +MI0010915 sbi-MIR437o; +MI0010916 sbi-MIR437p; +MI0010917 sbi-MIR437q; +MI0010918 sbi-MIR437r; +MI0010919 sbi-MIR437s; +MI0010920 sbi-MIR437t; +MI0010921 sbi-MIR437u; +MI0010922 sbi-MIR437v; +MI0010923 sbi-MIR437w; +MI0010924 sbi-MIR529; +MI0010925 sbi-MIR821a; +MI0010926 sbi-MIR821b; +MI0010927 sbi-MIR821c; +MI0010928 sbi-MIR821d; +MI0010929 sbi-MIR821e; +MI0010930 sbi-MIR1432; +MI0010931 sbi-MIR1435a; +MI0010932 sbi-MIR1435b; +MI0010933 sme-mir-2156b; +MI0010934 sme-mir-753e; +MI0010935 sme-mir-76; +MI0010936 sme-mir-124c-2; +MI0010937 sme-mir-2204; +MI0010938 sme-mir-2e; +MI0010939 sme-mir-2206; +MI0010940 sme-mir-753d; +MI0010941 sme-mir-2147d; +MI0010942 sme-mir-2205; +MI0010943 sme-mir-2f; +MI0010944 sme-mir-2154-2; +MI0010945 sme-mir-31b-2; +MI0010946 sme-mir-754c-2; +MI0010947 sme-mir-754b-2; +MI0010948 sme-mir-2160-2; +MI0010949 sme-mir-2202; +MI0010950 sme-mir-2203; +MI0010951 sme-mir-2200; +MI0010952 sme-mir-2201; +MI0010953 sme-bantam-c-2; +MI0010954 sme-mir-31b-3; +MI0010955 cel-mir-2207; +MI0010956 cel-mir-2208a; +MI0010957 cel-mir-2208b; +MI0010958 cel-mir-2209a; +MI0010959 cel-mir-2209c; +MI0010960 cel-mir-2210; +MI0010961 cel-mir-2211; +MI0010962 cel-mir-2212; +MI0010963 cel-mir-2213; +MI0010964 cel-mir-2214; +MI0010965 cel-mir-2215; +MI0010966 cel-mir-2216; +MI0010967 cel-mir-1832b; +MI0010968 cel-mir-2217;cel-mir-2217a; +MI0010969 cel-mir-2209b; +MI0010970 cel-mir-2218a; +MI0010971 cel-mir-2218b; +MI0010972 cel-mir-2219; +MI0010973 cel-mir-2220; +MI0010974 cel-mir-2221; +MI0010975 cbr-mir-73b; +MI0010976 cbr-mir-238; +MI0010977 cbr-mir-76; +MI0010978 cbr-mir-35c-1; +MI0010979 cbr-mir-35e; +MI0010980 cbr-mir-35c-2; +MI0010981 cbr-mir-35d; +MI0010982 cbr-mir-90b; +MI0010983 cbr-mir-235b; +MI0010984 cbr-mir-56; +MI0010985 cbr-mir-54a; +MI0010986 cbr-mir-237; +MI0010987 cbr-mir-1822; +MI0010988 cbr-mir-1834;cbr-mir-58b; +MI0010989 cbr-mir-35b-1; +MI0010990 cbr-mir-35b-2; +MI0010991 cbr-mir-35b-3; +MI0010992 cbr-mir-35b-4; +MI0010993 cbr-mir-35b-5; +MI0010994 cbr-mir-35b-6; +MI0010995 cbr-mir-35b-7; +MI0010996 cbr-mir-35b-8; +MI0010997 cbr-mir-35b-9; +MI0010998 cbr-mir-35b-10; +MI0010999 cbr-mir-35b-11; +MI0011000 cbr-mir-35b-12; +MI0011001 cbr-mir-35b-13; +MI0011002 cbr-mir-65; +MI0011003 cbr-mir-1817; +MI0011004 cbr-mir-2222-1; +MI0011005 cbr-mir-2227; +MI0011006 cbr-mir-41b; +MI0011007 cbr-mir-2222-2; +MI0011008 cbr-mir-64b; +MI0011009 cbr-mir-2214; +MI0011010 cbr-mir-2223; +MI0011011 cbr-mir-2224; +MI0011012 cbr-mir-54b; +MI0011013 cbr-mir-54c; +MI0011014 cbr-mir-54d; +MI0011015 cbr-mir-2225; +MI0011016 cbr-mir-2226; +MI0011017 cbr-mir-74b; +MI0011018 crm-mir-786; +MI0011019 crm-mir-41; +MI0011020 crm-mir-40; +MI0011021 crm-mir-39; +MI0011022 crm-mir-77-2; +MI0011023 crm-mir-49; +MI0011024 crm-mir-57; +MI0011025 crm-mir-35a-1; +MI0011026 crm-mir-35b; +MI0011027 crm-mir-35c-1; +MI0011028 crm-mir-35d-1; +MI0011029 crm-mir-35e-1; +MI0011030 crm-mir-35f; +MI0011031 crm-mir-35e-2; +MI0011032 crm-mir-83; +MI0011033 crm-mir-77-1; +MI0011034 crm-mir-232-1; +MI0011035 crm-mir-228; +MI0011036 crm-mir-90; +MI0011037 crm-let-7; +MI0011038 crm-mir-238; +MI0011039 crm-mir-75; +MI0011040 crm-mir-74a; +MI0011041 crm-mir-74b; +MI0011042 crm-mir-73; +MI0011043 crm-mir-76; +MI0011044 crm-mir-61; +MI0011045 crm-mir-242; +MI0011046 crm-mir-70; +MI0011047 crm-mir-249; +MI0011048 crm-mir-231; +MI0011049 crm-mir-85; +MI0011050 crm-mir-42; +MI0011051 crm-mir-43; +MI0011052 crm-mir-252; +MI0011053 crm-mir-355; +MI0011054 crm-mir-239b; +MI0011055 crm-mir-232-2; +MI0011056 crm-mir-787; +MI0011057 crm-mir-34; +MI0011058 crm-mir-82; +MI0011059 crm-mir-233; +MI0011060 crm-mir-124;crm-mir-124a; +MI0011061 crm-mir-47; +MI0011062 crm-mir-790-2; +MI0011063 crm-mir-248; +MI0011064 crm-mir-58a; +MI0011065 crm-mir-236; +MI0011066 crm-mir-35a-2; +MI0011067 crm-mir-35c-2; +MI0011068 crm-mir-230; +MI0011069 crm-mir-52-1; +MI0011070 crm-mir-55; +MI0011071 crm-mir-237; +MI0011072 crm-mir-79; +MI0011073 crm-mir-235; +MI0011074 crm-mir-84; +MI0011075 crm-mir-60; +MI0011076 crm-mir-48; +MI0011077 crm-mir-1; +MI0011078 crm-mir-72; +MI0011079 crm-mir-81; +MI0011080 crm-mir-52-2; +MI0011081 crm-mir-246-1; +MI0011082 crm-mir-2; +MI0011083 crm-mir-784; +MI0011084 crm-mir-45; +MI0011085 crm-mir-250; +MI0011086 crm-mir-87; +MI0011087 crm-mir-244; +MI0011088 crm-mir-86; +MI0011089 crm-mir-44; +MI0011090 crm-mir-50; +MI0011091 crm-mir-64c; +MI0011092 crm-mir-64d; +MI0011093 crm-mir-67; +MI0011094 crm-mir-46; +MI0011095 crm-lin-4; +MI0011096 crm-mir-246-2; +MI0011097 crm-mir-247; +MI0011098 crm-mir-785; +MI0011099 crm-mir-38; +MI0011100 crm-mir-357; +MI0011101 crm-mir-35g; +MI0011102 crm-mir-35d-2; +MI0011103 crm-mir-59; +MI0011104 crm-mir-259; +MI0011105 crm-mir-790-1; +MI0011106 crm-mir-788; +MI0011107 crm-mir-253; +MI0011108 crm-mir-245; +MI0011109 crm-mir-356; +MI0011110 crm-mir-241; +MI0011111 crm-mir-35c-3; +MI0011112 crm-mir-58b; +MI0011113 crm-mir-239a; +MI0011114 crm-mir-71; +MI0011115 crm-mir-80; +MI0011116 crm-mir-63; +MI0011117 crm-mir-2227; +MI0011118 crm-mir-2228; +MI0011119 crm-mir-62; +MI0011120 crm-mir-2229; +MI0011121 crm-mir-64e; +MI0011122 crm-mir-2230; +MI0011123 crm-mir-2231; +MI0011124 crm-mir-64a; +MI0011125 crm-mir-66; +MI0011126 crm-mir-64b; +MI0011127 ppc-mir-1; +MI0011128 ppc-mir-45; +MI0011129 ppc-mir-42a; +MI0011130 ppc-mir-63g; +MI0011131 ppc-mir-2232-1; +MI0011132 ppc-mir-87; +MI0011133 ppc-mir-124; +MI0011134 ppc-mir-239-1; +MI0011135 ppc-mir-37; +MI0011136 ppc-lin-4; +MI0011137 ppc-mir-252; +MI0011138 ppc-mir-63b; +MI0011139 ppc-mir-63c-1; +MI0011140 ppc-mir-63c-2; +MI0011141 ppc-mir-63c-3; +MI0011142 ppc-mir-63c-4; +MI0011143 ppc-mir-79; +MI0011144 ppc-mir-84b; +MI0011145 ppc-mir-42b; +MI0011146 ppc-mir-239-2; +MI0011147 ppc-mir-46; +MI0011148 ppc-mir-81; +MI0011149 ppc-let-7; +MI0011150 ppc-mir-63a; +MI0011151 ppc-mir-71;ppc-mir-71a; +MI0011152 ppc-mir-63d; +MI0011153 ppc-mir-2232-2; +MI0011154 ppc-mir-72; +MI0011155 ppc-mir-86; +MI0011156 ppc-mir-242; +MI0011157 ppc-mir-63f; +MI0011158 ppc-mir-65; +MI0011159 ppc-mir-84a; +MI0011160 ppc-mir-2252; +MI0011161 ppc-mir-2257;ppc-mir-2253b; +MI0011162 ppc-mir-2258; +MI0011163 ppc-mir-2234a; +MI0011164 ppc-mir-2234b; +MI0011165 ppc-mir-236; +MI0011166 ppc-mir-2244; +MI0011167 ppc-mir-2248; +MI0011168 ppc-mir-2253;ppc-mir-2253a; +MI0011169 ppc-mir-2254; +MI0011170 ppc-mir-63e; +MI0011171 ppc-mir-63h; +MI0011172 ppc-mir-2255; +MI0011173 ppc-mir-2256; +MI0011174 ppc-mir-2235-1;ppc-mir-2235a-1; +MI0011175 ppc-mir-2235-2;ppc-mir-2235a-2; +MI0011176 ppc-mir-2235-3;ppc-mir-2235a-3; +MI0011177 ppc-mir-2235-4;ppc-mir-2235a-4; +MI0011178 ppc-mir-2235-5;ppc-mir-2235a-5; +MI0011179 ppc-mir-2235-6;ppc-mir-2235a-6; +MI0011180 ppc-mir-2235-7;ppc-mir-2235a-7; +MI0011181 ppc-mir-2235-8;ppc-mir-2235a-8; +MI0011182 ppc-mir-2238b-1; +MI0011183 ppc-mir-2236a; +MI0011184 ppc-mir-2236b; +MI0011185 ppc-mir-2259; +MI0011186 ppc-mir-2260; +MI0011187 ppc-mir-2261; +MI0011188 ppc-mir-2262; +MI0011189 ppc-mir-2240b; +MI0011190 ppc-mir-2240a-1; +MI0011191 ppc-mir-2240a-2; +MI0011192 ppc-mir-2240c; +MI0011193 ppc-mir-2238a-1; +MI0011194 ppc-mir-2238a-2; +MI0011195 ppc-mir-2238a-3; +MI0011196 ppc-mir-2238c; +MI0011197 ppc-mir-234; +MI0011198 ppc-mir-54; +MI0011199 ppc-mir-55b; +MI0011200 ppc-mir-2263; +MI0011201 ppc-mir-2264; +MI0011202 ppc-mir-232; +MI0011203 ppc-mir-2265; +MI0011204 ppc-mir-2266; +MI0011205 ppc-mir-2237a; +MI0011206 ppc-mir-2237b; +MI0011207 ppc-mir-2267; +MI0011208 ppc-mir-312;ppc-mir-312a; +MI0011209 ppc-mir-2243; +MI0011210 ppc-mir-2242-1; +MI0011211 ppc-mir-2242-2; +MI0011212 ppc-mir-2245; +MI0011213 ppc-mir-2238d; +MI0011214 ppc-mir-2246; +MI0011215 ppc-mir-2249; +MI0011216 ppc-mir-67; +MI0011217 ppc-mir-2238b-2; +MI0011218 ppc-mir-38; +MI0011219 ppc-mir-2250; +MI0011220 ppc-mir-55a; +MI0011221 ppc-mir-56; +MI0011222 ppc-mir-993; +MI0011223 ppc-mir-2238e; +MI0011224 ppc-mir-2238a-4; +MI0011225 ppc-mir-2251;ppc-mir-2251a; +MI0011226 ppc-mir-2;ppc-mir-2b; +MI0011227 ppc-mir-2268; +MI0011228 ppc-mir-240; +MI0011229 ppc-mir-2269; +MI0011230 ppc-mir-2270; +MI0011231 ppc-mir-2271; +MI0011232 ppc-mir-2239-1; +MI0011233 ppc-mir-2237c; +MI0011234 ppc-mir-2272; +MI0011235 ppc-mir-2273; +MI0011236 ppc-mir-2241a-3; +MI0011237 ppc-mir-2241b-2; +MI0011238 ppc-mir-2241a-4; +MI0011239 ppc-mir-2241b-3; +MI0011240 ppc-mir-2241a-5; +MI0011241 ppc-mir-2274; +MI0011242 ppc-mir-2233; +MI0011243 ppc-mir-2247; +MI0011244 ppc-mir-279; +MI0011245 ppc-mir-2239-2; +MI0011246 ppc-mir-2241a-1; +MI0011247 ppc-mir-2241a-2; +MI0011248 ppc-mir-9; +MI0011249 ppc-mir-2241c; +MI0011250 ppc-mir-2241b-1; +MI0011251 osa-MIR2118a; +MI0011252 osa-MIR2118b; +MI0011253 osa-MIR2118c; +MI0011254 osa-MIR2118d; +MI0011255 osa-MIR2118e; +MI0011256 osa-MIR2118f; +MI0011257 osa-MIR2118g; +MI0011258 osa-MIR2118h; +MI0011259 osa-MIR2118i; +MI0011260 osa-MIR2118j; +MI0011261 osa-MIR2118k; +MI0011262 osa-MIR2118l; +MI0011263 osa-MIR2118m; +MI0011264 osa-MIR2118n; +MI0011265 osa-MIR2118o; +MI0011266 osa-MIR2118p; +MI0011267 osa-MIR2118q; +MI0011268 osa-MIR2118r; +MI0011269 osa-MIR2275a; +MI0011270 osa-MIR2275b; +MI0011271 zma-MIR2118a; +MI0011272 zma-MIR2118b; +MI0011273 zma-MIR2118c; +MI0011274 zma-MIR2118d; +MI0011275 zma-MIR2118e; +MI0011276 zma-MIR2118f; +MI0011277 zma-MIR2118g; +MI0011278 zma-MIR2275a; +MI0011279 zma-MIR2275b; +MI0011280 zma-MIR2275c; +MI0011281 zma-MIR2275d; +MI0011282 hsa-mir-2276; +MI0011284 hsa-mir-2277; +MI0011285 hsa-mir-2278; +MI0011287 bna-MIR2111b; +MI0011288 bna-MIR2111a; +MI0011289 dme-mir-2279; +MI0011290 dme-mir-2280; +MI0011291 dme-mir-2281; +MI0011292 dme-mir-2282; +MI0011293 dme-mir-2283; +MI0011294 bta-mir-2284i; +MI0011295 bta-mir-2286; +MI0011296 bta-mir-2287; +MI0011297 bta-mir-2288; +MI0011298 bta-mir-2289; +MI0011299 bta-mir-2285a; +MI0011300 bta-mir-2290; +MI0011301 bta-mir-2291; +MI0011302 bta-mir-2292; +MI0011303 bta-mir-2293; +MI0011304 bta-mir-2294; +MI0011305 bta-mir-2295; +MI0011306 bta-mir-2296; +MI0011307 bta-mir-2297; +MI0011308 bta-mir-2298; +MI0011309 bta-mir-2299; +MI0011310 bta-mir-2300a; +MI0011311 bta-mir-2300b; +MI0011312 bta-mir-2284s; +MI0011313 bta-mir-2301; +MI0011314 bta-mir-2302; +MI0011315 bta-mir-2303; +MI0011316 bta-mir-2285d; +MI0011317 bta-mir-2304; +MI0011318 bta-mir-2305; +MI0011319 bta-mir-2306; +MI0011320 bta-mir-2307; +MI0011321 bta-mir-2308; +MI0011322 bta-mir-2309; +MI0011323 bta-mir-2310; +MI0011324 bta-mir-1603; +MI0011325 bta-mir-2284l; +MI0011326 bta-mir-2489; +MI0011327 bta-mir-2311; +MI0011328 bta-mir-2284j; +MI0011329 bta-mir-2312; +MI0011330 bta-mir-2313; +MI0011331 bta-mir-2284t; +MI0011332 bta-mir-2285b;bta-mir-2285b-1; +MI0011333 bta-mir-2314; +MI0011334 bta-mir-2315; +MI0011335 bta-mir-2284d; +MI0011336 bta-mir-2316; +MI0011337 bta-mir-2317; +MI0011338 bta-mir-1343; +MI0011339 bta-mir-2318; +MI0011340 bta-mir-2319a; +MI0011341 bta-mir-2319b; +MI0011342 bta-mir-2320; +MI0011343 bta-mir-2284n; +MI0011344 bta-mir-2284g; +MI0011345 bta-mir-2321; +MI0011346 bta-mir-1721; +MI0011347 bta-mir-2322; +MI0011348 bta-mir-2323; +MI0011349 bta-mir-2324; +MI0011350 bta-mir-2325a; +MI0011351 bta-mir-2326; +MI0011352 bta-mir-2327; +MI0011353 bta-mir-2328; +MI0011354 bta-mir-2329-1; +MI0011355 bta-mir-2329-2; +MI0011356 bta-mir-2330; +MI0011357 bta-mir-2331; +MI0011358 bta-mir-2332; +MI0011359 bta-mir-2333; +MI0011360 bta-mir-2334; +MI0011361 bta-mir-2335; +MI0011362 bta-mir-2336; +MI0011363 bta-mir-2337; +MI0011364 bta-mir-199c; +MI0011365 bta-mir-2338; +MI0011366 bta-mir-2339; +MI0011367 bta-mir-1814a; +MI0011368 bta-mir-2340; +MI0011369 bta-mir-2341; +MI0011370 bta-mir-2342; +MI0011371 bta-mir-2343; +MI0011372 bta-mir-2344; +MI0011373 bta-mir-2345; +MI0011374 bta-mir-2346; +MI0011375 bta-mir-2347; +MI0011376 bta-mir-2348; +MI0011377 bta-mir-2349; +MI0011378 bta-mir-2284p; +MI0011379 bta-mir-2350; +MI0011380 bta-mir-2351; +MI0011381 bta-mir-2352; +MI0011382 bta-mir-2353; +MI0011383 bta-mir-2354; +MI0011384 bta-mir-2355; +MI0011385 bta-mir-2356; +MI0011386 bta-mir-2357; +MI0011387 bta-mir-2284u; +MI0011388 bta-mir-2358; +MI0011389 bta-mir-2359; +MI0011390 bta-mir-2360; +MI0011391 bta-mir-2361; +MI0011392 bta-mir-2362; +MI0011393 bta-mir-2363-1; +MI0011394 bta-mir-2363-2; +MI0011395 bta-mir-2364; +MI0011396 bta-mir-2365; +MI0011397 bta-mir-2366; +MI0011398 bta-mir-2284f; +MI0011399 bta-mir-2284a; +MI0011400 bta-mir-2284k; +MI0011401 bta-mir-1814b; +MI0011402 bta-mir-2367; +MI0011403 bta-mir-2368; +MI0011404 bta-mir-2369; +MI0011405 bta-mir-2370; +MI0011406 bta-mir-2371; +MI0011407 bta-mir-2372; +MI0011408 bta-mir-2373; +MI0011409 bta-mir-2374; +MI0011410 bta-mir-2375; +MI0011411 bta-mir-2376; +MI0011412 bta-mir-2377; +MI0011413 bta-mir-2378; +MI0011414 bta-mir-2379; +MI0011415 bta-mir-2284c; +MI0011416 bta-mir-2325b; +MI0011417 bta-mir-2380; +MI0011418 bta-mir-2381; +MI0011419 bta-mir-2382; +MI0011420 bta-mir-2383; +MI0011421 bta-mir-2384-1;bta-mir-2384; +MI0011422 bta-mir-2384-2; +MI0011423 bta-mir-2325c; +MI0011424 bta-mir-2385; +MI0011425 bta-mir-2284v; +MI0011426 bta-mir-2386; +MI0011427 bta-mir-2387; +MI0011428 bta-mir-2388; +MI0011429 bta-mir-2389; +MI0011430 bta-mir-2390; +MI0011431 bta-mir-2391; +MI0011432 bta-mir-2392; +MI0011433 bta-mir-2393; +MI0011434 bta-mir-2394; +MI0011435 bta-mir-2395; +MI0011436 bta-mir-2396; +MI0011437 bta-mir-2285c; +MI0011438 bta-mir-2397; +MI0011439 bta-mir-2398; +MI0011440 bta-mir-2399; +MI0011441 bta-mir-2400; +MI0011442 bta-mir-2284q; +MI0011443 bta-mir-2401; +MI0011444 bta-mir-2402; +MI0011445 bta-mir-2403; +MI0011446 bta-mir-2404-1; +MI0011447 bta-mir-449d; +MI0011448 bta-mir-2405; +MI0011449 bta-mir-2406; +MI0011450 bta-mir-2407; +MI0011451 bta-mir-2408; +MI0011452 bta-mir-2409; +MI0011453 bta-mir-2410; +MI0011454 bta-mir-1584; +MI0011455 bta-mir-1940; +MI0011456 bta-mir-2411; +MI0011457 bta-mir-2412; +MI0011458 bta-mir-2413; +MI0011459 bta-mir-2284m; +MI0011460 bta-mir-2414; +MI0011461 bta-mir-2415; +MI0011462 bta-mir-2416; +MI0011463 bta-mir-2417; +MI0011464 bta-mir-2418; +MI0011465 bta-mir-2284b; +MI0011466 bta-mir-1814c; +MI0011467 bta-mir-2419; +MI0011468 bta-mir-2420; +MI0011469 bta-mir-2421; +MI0011470 bta-mir-2422; +MI0011471 bta-mir-1843; +MI0011472 bta-mir-320b; +MI0011473 bta-mir-2423; +MI0011474 bta-mir-2424-1;bta-mir-2424; +MI0011475 bta-mir-2425; +MI0011476 bta-mir-2426; +MI0011477 bta-mir-2427; +MI0011478 bta-mir-2428; +MI0011479 bta-mir-2429; +MI0011480 bta-mir-2430; +MI0011481 bta-mir-2431; +MI0011482 bta-mir-677; +MI0011483 bta-mir-2432; +MI0011484 bta-mir-2433; +MI0011485 bta-mir-2434; +MI0011486 bta-mir-2435; +MI0011487 bta-mir-2436; +MI0011488 bta-mir-2284r; +MI0011489 bta-mir-2424-2; +MI0011490 bta-mir-2437; +MI0011491 bta-mir-2438; +MI0011492 bta-mir-2439; +MI0011493 bta-mir-2440; +MI0011494 bta-mir-2441; +MI0011495 bta-mir-2442; +MI0011496 bta-mir-2443; +MI0011497 bta-mir-2284h; +MI0011498 bta-mir-2444; +MI0011499 bta-mir-2445; +MI0011500 bta-mir-2446; +MI0011501 bta-mir-2447; +MI0011502 bta-mir-2448; +MI0011503 bta-mir-2449; +MI0011504 bta-mir-2450c; +MI0011505 bta-mir-2450b; +MI0011506 bta-mir-2450a; +MI0011507 bta-mir-2451; +MI0011508 bta-mir-1777a; +MI0011509 bta-mir-2452; +MI0011510 bta-mir-2453; +MI0011511 bta-mir-2454; +MI0011512 bta-mir-2455; +MI0011513 bta-mir-339b; +MI0011514 bta-mir-1434; +MI0011515 bta-mir-2456; +MI0011516 bta-mir-2457; +MI0011517 bta-mir-2458; +MI0011518 bta-mir-2459; +MI0011519 bta-mir-2460; +MI0011520 bta-mir-1777b; +MI0011521 bta-mir-2461; +MI0011522 bta-mir-2462; +MI0011523 bta-mir-2463; +MI0011524 bta-mir-2464; +MI0011525 bta-mir-2465; +MI0011526 bta-mir-2466; +MI0011527 bta-mir-2467; +MI0011528 bta-mir-2468; +MI0011529 bta-mir-2469; +MI0011530 bta-mir-2470; +MI0011531 bta-mir-2471; +MI0011532 bta-mir-2472; +MI0011533 bta-mir-2473; +MI0011534 bta-mir-2474; +MI0011535 bta-mir-2404-2; +MI0011536 bta-mir-2475; +MI0011537 bta-mir-2476; +MI0011538 bta-mir-2284o; +MI0011539 bta-mir-2477; +MI0011540 bta-mir-2478; +MI0011541 bta-mir-2479; +MI0011542 bta-mir-2480; +MI0011543 bta-mir-2481; +MI0011544 bta-mir-2482; +MI0011545 bta-mir-2483; +MI0011546 bta-mir-2484; +MI0011547 bta-mir-664;bta-mir-664a; +MI0011548 bta-mir-2485; +MI0011549 bta-mir-2284e; +MI0011550 bta-mir-2486; +MI0011551 bta-mir-2487; +MI0011552 bta-mir-2488; +MI0011553 xtr-mir-2184; +MI0011554 xtr-mir-2188; +MI0011555 hbv-mir-B2RC; +MI0011556 hbv-mir-B4; +MI0011557 hbv-mir-B20; +MI0011558 bdi-MIR444;bdi-MIR444a; +MI0011559 bdi-MIR171a; +MI0011560 bdi-MIR408; +MI0011561 bdi-MIR167;bdi-MIR167a; +MI0011562 bdi-MIR1139; +MI0011563 bdi-MIR160; +MI0011564 bdi-MIR169a; +MI0011565 bdi-MIR397;bdi-MIR397a; +MI0011566 bdi-MIR156;bdi-MIR156a; +MI0011567 bdi-MIR172d; +MI0011568 bdi-MIR1122; +MI0011569 bdi-MIR171d; +MI0011570 bdi-MIR166;bdi-MIR166a; +MI0011571 bdi-MIR171c; +MI0011572 bdi-MIR399;bdi-MIR399a; +MI0011573 bdi-MIR437; +MI0011574 bdi-MIR169b; +MI0011575 bdi-MIR1127; +MI0011576 bdi-MIR1135; +MI0011577 dme-mir-307-as;dme-mir-307b; +MI0011578 dme-mir-2489; +MI0011579 dme-mir-2490; +MI0011580 dme-mir-2491; +MI0011581 dme-mir-2492; +MI0011582 dme-mir-2493; +MI0011583 dme-mir-2494; +MI0011584 dme-mir-2495; +MI0011585 dme-mir-2496; +MI0011586 dme-mir-2497; +MI0011587 dme-mir-2498; +MI0011588 dme-mir-2499; +MI0011589 dme-mir-2500; +MI0011590 dme-mir-2501; +MI0011591 dps-mir-989; +MI0011592 dps-mir-981; +MI0011593 dps-mir-970; +MI0011594 dps-mir-980; +MI0011595 dps-mir-971; +MI0011596 dps-mir-190; +MI0011597 dps-mir-957; +MI0011598 dps-mir-958; +MI0011599 dps-mir-988; +MI0011600 dps-mir-987; +MI0011601 dps-mir-137; +MI0011602 dps-mir-994; +MI0011603 dps-mir-311; +MI0011604 dps-mir-92c; +MI0011605 dps-mir-968; +MI0011606 dps-mir-1002; +MI0011607 dps-mir-965; +MI0011608 dps-mir-1006; +MI0011609 dps-mir-375; +MI0011610 dps-mir-964; +MI0011611 dps-mir-959; +MI0011612 dps-mir-932; +MI0011613 dps-mir-252; +MI0011614 dps-mir-993; +MI0011615 dps-mir-1000; +MI0011616 dps-mir-929; +MI0011617 dps-mir-927; +MI0011618 dps-mir-995; +MI0011619 dps-mir-1010; +MI0011620 dps-mir-969; +MI0011621 dps-mir-193; +MI0011622 dps-mir-986; +MI0011623 dps-mir-307-as;dps-mir-307b; +MI0011624 dps-mir-263a-as;dps-mir-3983; +MI0011625 dps-mir-210-as;dps-mir-210b; +MI0011626 dps-mir-iab-4-as;dps-mir-iab-8; +MI0011627 dps-mir-2502; +MI0011628 dps-mir-2503; +MI0011629 dps-mir-2504; +MI0011630 dps-mir-2505; +MI0011631 dps-mir-2506; +MI0011632 dps-mir-2507a; +MI0011633 dps-mir-2508; +MI0011634 dps-mir-276c; +MI0011635 dps-mir-2509; +MI0011636 dps-mir-2510; +MI0011637 dps-mir-2511-1; +MI0011638 dps-mir-2511-2; +MI0011639 dps-mir-2512; +MI0011640 dps-mir-2513a; +MI0011641 dps-mir-2514; +MI0011642 dps-mir-2515; +MI0011643 dps-mir-2518-3; +MI0011644 dps-mir-2518-2; +MI0011645 dps-mir-2518-4; +MI0011646 dps-mir-2513b; +MI0011647 dps-mir-2516; +MI0011648 dps-mir-2517b;dps-mir-2517-4; +MI0011649 dps-mir-2518-1; +MI0011650 dps-mir-2574b; +MI0011651 dps-mir-2528-2; +MI0011652 dps-mir-2519; +MI0011653 dps-mir-2520; +MI0011654 dps-mir-2521; +MI0011655 dps-mir-2522a; +MI0011656 dps-mir-2523; +MI0011657 dps-mir-2524; +MI0011658 dps-mir-2525; +MI0011659 dps-mir-2526; +MI0011660 dps-mir-2545b; +MI0011661 dps-mir-2527; +MI0011662 dps-mir-2528-1; +MI0011663 dps-mir-2529; +MI0011664 dps-mir-2530; +MI0011665 dps-mir-2531; +MI0011666 dps-mir-2532; +MI0011667 dps-mir-2533; +MI0011668 dps-mir-2534; +MI0011669 dps-mir-2535; +MI0011670 dps-mir-2536; +MI0011671 dps-mir-2537; +MI0011672 dps-mir-2538; +MI0011673 dps-mir-2522b; +MI0011674 dps-mir-2539; +MI0011675 dps-mir-2540; +MI0011676 dps-mir-2541; +MI0011677 dps-mir-2542-1; +MI0011678 dps-mir-2517a-1;dps-mir-2517-1; +MI0011679 dps-mir-2543a-1; +MI0011680 dps-mir-2542-2; +MI0011681 dps-mir-2517a-2;dps-mir-2517-2; +MI0011682 dps-mir-2543b-2; +MI0011683 dps-mir-2542-3; +MI0011684 dps-mir-2544; +MI0011685 dps-mir-2517a-4; +MI0011686 dps-mir-2543b-1; +MI0011687 dps-mir-2545a; +MI0011688 dps-mir-2546; +MI0011689 dps-mir-2547; +MI0011690 dps-mir-2548; +MI0011691 dps-mir-2549; +MI0011692 dps-mir-2550; +MI0011693 dps-mir-2551; +MI0011694 dps-mir-2552; +MI0011695 dps-mir-2553; +MI0011696 dps-mir-2554; +MI0011697 dps-mir-2507b; +MI0011698 dps-mir-2555; +MI0011699 dps-mir-2556; +MI0011700 dps-mir-2557; +MI0011701 dps-mir-2558-1; +MI0011702 dps-mir-2558-2; +MI0011703 dps-mir-2559; +MI0011704 dps-mir-2560; +MI0011705 dps-mir-2561; +MI0011706 dps-mir-2562; +MI0011707 dps-mir-2563; +MI0011708 dps-mir-2564; +MI0011709 dps-mir-2565; +MI0011710 dps-mir-2566a-1; +MI0011711 dps-mir-2567a; +MI0011712 dps-mir-2566a-2; +MI0011713 dps-mir-2567c; +MI0011714 dps-mir-2566b; +MI0011715 dps-mir-2567b; +MI0011716 dps-mir-2568a; +MI0011717 dps-mir-2569; +MI0011718 dps-mir-2568b; +MI0011719 dps-mir-2570; +MI0011720 dps-mir-2571; +MI0011721 dps-mir-2572; +MI0011722 dps-mir-2573; +MI0011723 dps-mir-2574a; +MI0011724 dps-mir-2543a-2; +MI0011725 dps-mir-2517a-3;dps-mir-2517-3; +MI0011726 dps-mir-2575; +MI0011727 dps-mir-2576-1; +MI0011728 dps-mir-2576-2; +MI0011729 dsi-mir-977; +MI0011730 dsi-mir-978;dsi-mir-978a; +MI0011731 dsi-mir-1012; +MI0011732 dsi-mir-1003; +MI0011733 dsi-mir-991; +MI0011734 dsi-mir-986; +MI0011735 dsi-mir-987-1;dsi-mir-987; +MI0011736 dsi-mir-988; +MI0011737 dsi-mir-967; +MI0011738 dsi-mir-1002; +MI0011739 dsi-mir-968; +MI0011740 dsi-mir-1006; +MI0011741 dsi-mir-958; +MI0011742 dsi-mir-955; +MI0011743 dsi-mir-190; +MI0011744 dsi-mir-193; +MI0011745 dsi-mir-995; +MI0011746 dsi-mir-999; +MI0011747 dsi-mir-1000; +MI0011748 dsi-mir-929; +MI0011749 dsi-mir-993; +MI0011750 dsi-mir-1010; +MI0011751 dsi-mir-252; +MI0011752 dsi-mir-1005; +MI0011753 dsi-mir-961; +MI0011754 dsi-mir-965; +MI0011755 dsi-mir-963; +MI0011756 dsi-mir-964; +MI0011757 dsi-mir-932; +MI0011758 dsi-mir-969; +MI0011759 dsi-mir-980; +MI0011760 dsi-mir-927; +MI0011761 dsi-mir-981; +MI0011762 dsi-mir-970; +MI0011763 dsi-mir-375; +MI0011764 dsi-mir-992; +MI0011765 dsi-mir-137; +MI0011766 dsi-mir-960; +MI0011767 dsi-mir-962; +MI0011768 dsi-mir-989; +MI0011769 dsi-mir-957; +MI0011770 dsi-mir-1013; +MI0011771 dsi-mir-1011; +MI0011772 dsi-mir-975; +MI0011773 dsi-mir-976; +MI0011774 dsi-mir-978-as;dsi-mir-978b; +MI0011775 dsi-mir-iab-4-as;dsi-mir-iab-8; +MI0011776 dsi-mir-1001; +MI0011777 dsi-mir-959; +MI0011778 dsi-mir-2577; +MI0011779 dsi-mir-2489; +MI0011780 dsi-mir-2578; +MI0011781 dsi-mir-2579; +MI0011782 dsi-mir-982c; +MI0011783 dsi-mir-982b; +MI0011784 dsi-mir-982a; +MI0011785 dsi-mir-303; +MI0011786 dsi-mir-2580; +MI0011787 dsi-mir-2581; +MI0011788 dsi-mir-2582a; +MI0011789 dsi-mir-2494; +MI0011790 dsi-mir-2582b; +MI0011791 dsi-mir-983;dsi-mir-983a; +MI0011792 dsi-mir-2583; +MI0011793 dsi-mir-2584; +MI0011794 dsi-mir-987-2; +MI0011795 mtr-MIR169p;mtr-MIR169k; +MI0011796 mtr-MIR2585a; +MI0011797 mtr-MIR2585b; +MI0011798 mtr-MIR2586;mtr-MIR2586a; +MI0011799 mtr-MIR2587a; +MI0011800 mtr-MIR2587b; +MI0011801 mtr-MIR2587c; +MI0011802 mtr-MIR2587d; +MI0011803 mtr-MIR2587e; +MI0011804 mtr-MIR2587f; +MI0011805 mtr-MIR2588a; +MI0011806 mtr-MIR2588b; +MI0011807 mtr-MIR2589; +MI0011808 mtr-MIR2590a; +MI0011809 mtr-MIR2590b; +MI0011810 mtr-MIR2590c; +MI0011811 mtr-MIR2590d; +MI0011812 mtr-MIR2590e; +MI0011813 mtr-MIR2590f; +MI0011814 mtr-MIR2591; +MI0011815 mtr-MIR2592b; +MI0011816 mtr-MIR2592c; +MI0011817 mtr-MIR2592d; +MI0011818 mtr-MIR2592e; +MI0011819 mtr-MIR2592f; +MI0011820 mtr-MIR2592i; +MI0011821 mtr-MIR2592j; +MI0011822 mtr-MIR2592o; +MI0011823 mtr-MIR2592p; +MI0011824 mtr-MIR2592q; +MI0011825 mtr-MIR2592r; +MI0011826 mtr-MIR2592s; +MI0011827 mtr-MIR2593a; +MI0011828 mtr-MIR2593b; +MI0011829 mtr-MIR2593c; +MI0011830 mtr-MIR2594a;mtr-MIR2594; +MI0011831 mtr-MIR2594b; +MI0011832 mtr-MIR2595; +MI0011833 mtr-MIR2596; +MI0011834 mtr-MIR2597; +MI0011835 mtr-MIR2111g; +MI0011836 mtr-MIR2111h;mtr-MIR2111c; +MI0011837 mtr-MIR2111i; +MI0011838 mtr-MIR2111j;mtr-MIR2111d; +MI0011839 mtr-MIR2111k;mtr-MIR2111e; +MI0011840 mtr-MIR2111l; +MI0011841 mtr-MIR2111m;mtr-MIR2111g; +MI0011842 mtr-MIR2111n;mtr-MIR2111h; +MI0011843 mtr-MIR2111o;mtr-MIR2111i; +MI0011844 mtr-MIR2111p;mtr-MIR2111m; +MI0011845 mtr-MIR2111q; +MI0011846 mtr-MIR2111r;mtr-MIR2111n; +MI0011847 mtr-MIR2111s;mtr-MIR2111o; +MI0011848 mtr-MIR2598; +MI0011849 mtr-MIR2599; +MI0011850 mtr-MIR2600;mtr-MIR2600a; +MI0011851 mtr-MIR2601; +MI0011852 mtr-MIR2602a; +MI0011853 mtr-MIR2602b; +MI0011854 mtr-MIR2603; +MI0011855 mtr-MIR2604; +MI0011856 mtr-MIR2605; +MI0011857 mtr-MIR2606a; +MI0011858 mtr-MIR2606b; +MI0011859 mtr-MIR2606c; +MI0011860 mtr-MIR2607; +MI0011861 mtr-MIR2608; +MI0011862 mtr-MIR2609a; +MI0011863 mtr-MIR2609b; +MI0011864 mtr-MIR2609c; +MI0011865 mtr-MIR2610a; +MI0011866 mtr-MIR2610b; +MI0011867 mtr-MIR2611; +MI0011868 mtr-MIR169q;mtr-MIR169j; +MI0011869 mtr-MIR2585c; +MI0011870 mtr-MIR2585d; +MI0011871 mtr-MIR2585e; +MI0011872 mtr-MIR2612a;mtr-MIR2612; +MI0011873 mtr-MIR2612b; +MI0011874 mtr-MIR2613; +MI0011875 mtr-MIR2614; +MI0011876 mtr-MIR2615a; +MI0011877 mtr-MIR2615b; +MI0011878 mtr-MIR2615c; +MI0011879 mtr-MIR2616; +MI0011880 mtr-MIR1509b; +MI0011881 mtr-MIR2617a; +MI0011882 mtr-MIR2617c; +MI0011883 mtr-MIR2617b; +MI0011884 mtr-MIR2618a; +MI0011885 mtr-MIR2618b; +MI0011886 mtr-MIR2619;mtr-MIR2619a; +MI0011887 mtr-MIR2620; +MI0011888 mtr-MIR2621; +MI0011889 mtr-MIR2622; +MI0011890 mtr-MIR2623; +MI0011891 mtr-MIR2624a;mtr-MIR2624; +MI0011892 mtr-MIR2624b; +MI0011893 mtr-MIR2625; +MI0011894 mtr-MIR2626; +MI0011895 mtr-MIR2627; +MI0011896 mtr-MIR2592a; +MI0011897 mtr-MIR2592g; +MI0011898 mtr-MIR2592h; +MI0011899 mtr-MIR2592k; +MI0011900 mtr-MIR2592l; +MI0011901 mtr-MIR2592m; +MI0011902 mtr-MIR2592n; +MI0011903 mtr-MIR2111a; +MI0011904 mtr-MIR2111b; +MI0011905 mtr-MIR2111c;mtr-MIR2111b; +MI0011906 mtr-MIR2111d; +MI0011907 mtr-MIR2111e;mtr-MIR2111j; +MI0011908 mtr-MIR2111f;mtr-MIR2111k; +MI0011909 mtr-MIR2628; +MI0011910 mtr-MIR2629a; +MI0011911 mtr-MIR2629d; +MI0011912 mtr-MIR2629e; +MI0011913 mtr-MIR2629b; +MI0011914 mtr-MIR2629c; +MI0011915 mtr-MIR2629f; +MI0011916 mtr-MIR2629g; +MI0011917 mtr-MIR2630a; +MI0011918 mtr-MIR2630b; +MI0011919 mtr-MIR2630c; +MI0011920 mtr-MIR2630w; +MI0011921 mtr-MIR2630x; +MI0011922 mtr-MIR2630y; +MI0011923 mtr-MIR2630d; +MI0011924 mtr-MIR2630e; +MI0011925 mtr-MIR2630f; +MI0011926 mtr-MIR2630g; +MI0011927 mtr-MIR2630h; +MI0011928 mtr-MIR2630i; +MI0011929 mtr-MIR2630j; +MI0011930 mtr-MIR2630k; +MI0011931 mtr-MIR2630l; +MI0011932 mtr-MIR2630m; +MI0011933 mtr-MIR2630n; +MI0011934 mtr-MIR2630o; +MI0011935 mtr-MIR2630p; +MI0011936 mtr-MIR2630q; +MI0011937 mtr-MIR2630r; +MI0011938 mtr-MIR2630s; +MI0011939 mtr-MIR2630t; +MI0011940 mtr-MIR2630u; +MI0011941 mtr-MIR2630v; +MI0011942 mtr-MIR2631; +MI0011943 mtr-MIR2632a; +MI0011944 mtr-MIR2632b; +MI0011945 mtr-MIR2632c; +MI0011946 mtr-MIR2633; +MI0011947 mtr-MIR2634; +MI0011948 mtr-MIR2635; +MI0011949 mtr-MIR2636; +MI0011950 mtr-MIR2637; +MI0011951 mtr-MIR2638a; +MI0011952 mtr-MIR2638b; +MI0011953 mtr-MIR2639; +MI0011954 mtr-MIR2640a;mtr-MIR2640; +MI0011955 mtr-MIR2640b; +MI0011956 mtr-MIR2641; +MI0011957 mtr-MIR2642; +MI0011958 mtr-MIR2643;mtr-MIR2643a; +MI0011959 mtr-MIR2644a;mtr-MIR2644; +MI0011960 mtr-MIR2644b; +MI0011961 mtr-MIR2645; +MI0011962 mtr-MIR2646a; +MI0011963 mtr-MIR2646b; +MI0011964 mtr-MIR2647a; +MI0011965 mtr-MIR2647b; +MI0011966 mtr-MIR2647c; +MI0011967 mtr-MIR2648; +MI0011968 mtr-MIR2649; +MI0011969 mtr-MIR2650; +MI0011970 mtr-MIR2651; +MI0011971 mtr-MIR2652a; +MI0011972 mtr-MIR2652b; +MI0011973 mtr-MIR2652c; +MI0011974 mtr-MIR2652d; +MI0011975 mtr-MIR2652e; +MI0011976 mtr-MIR2652f; +MI0011977 mtr-MIR2652g; +MI0011978 mtr-MIR2652h; +MI0011979 mtr-MIR2652i; +MI0011980 mtr-MIR2652j; +MI0011981 mtr-MIR2652k; +MI0011982 mtr-MIR2652l; +MI0011983 mtr-MIR2653a; +MI0011984 mtr-MIR2653b; +MI0011985 mtr-MIR2653c; +MI0011986 mtr-MIR2654; +MI0011987 mtr-MIR2655a; +MI0011988 mtr-MIR2655b; +MI0011989 mtr-MIR2655c; +MI0011990 mtr-MIR2655d; +MI0011991 mtr-MIR2655e; +MI0011992 mtr-MIR2655f; +MI0011993 mtr-MIR2655g; +MI0011994 mtr-MIR2655h; +MI0011995 mtr-MIR2655i; +MI0011996 mtr-MIR2655j; +MI0011997 mtr-MIR2655k; +MI0011998 mtr-MIR2655l; +MI0011999 mtr-MIR2655m; +MI0012000 mtr-MIR2655n; +MI0012001 mtr-MIR2655o; +MI0012002 mtr-MIR2656a; +MI0012003 mtr-MIR2656b; +MI0012004 mtr-MIR2657a;mtr-MIR2657; +MI0012005 mtr-MIR2657b; +MI0012006 mtr-MIR2658; +MI0012007 mtr-MIR2659a; +MI0012008 mtr-MIR2659b; +MI0012009 mtr-MIR2659c; +MI0012010 mtr-MIR2659d; +MI0012011 mtr-MIR2659e; +MI0012012 mtr-MIR2659f; +MI0012013 mtr-MIR2660a;mtr-MIR2660; +MI0012014 mtr-MIR2660b; +MI0012015 mtr-MIR2661; +MI0012016 mtr-MIR2662; +MI0012017 mtr-MIR2663; +MI0012018 mtr-MIR2664;mtr-MIR2664a; +MI0012019 mtr-MIR2665; +MI0012020 mtr-MIR2666; +MI0012021 mtr-MIR2667;mtr-MIR2667a; +MI0012022 mtr-MIR2668; +MI0012023 mtr-MIR2669;mtr-MIR2669a; +MI0012024 mtr-MIR399q; +MI0012025 mtr-MIR2670a; +MI0012026 mtr-MIR2670b; +MI0012027 mtr-MIR2670c; +MI0012028 mtr-MIR2670d; +MI0012029 mtr-MIR2671j; +MI0012030 mtr-MIR2671a; +MI0012031 mtr-MIR2671b; +MI0012032 mtr-MIR2671c; +MI0012033 mtr-MIR2671d; +MI0012034 mtr-MIR2671e; +MI0012035 mtr-MIR2671f; +MI0012036 mtr-MIR2671g; +MI0012037 mtr-MIR2671h; +MI0012038 mtr-MIR2671i; +MI0012039 mtr-MIR2672; +MI0012040 mtr-MIR2673a; +MI0012041 mtr-MIR2673b; +MI0012042 mtr-MIR2674; +MI0012043 mtr-MIR2675a;mtr-MIR2675; +MI0012044 mtr-MIR2675b; +MI0012045 mtr-MIR2676a; +MI0012046 mtr-MIR2676b; +MI0012047 mtr-MIR2676c; +MI0012048 mtr-MIR2676d; +MI0012049 mtr-MIR2676e; +MI0012050 mtr-MIR2676f; +MI0012051 mtr-MIR2088b; +MI0012052 mtr-MIR2677; +MI0012053 mtr-MIR2678; +MI0012054 mtr-MIR2679a; +MI0012055 mtr-MIR2679b; +MI0012056 mtr-MIR2679c; +MI0012057 mtr-MIR2680a; +MI0012058 mtr-MIR2680b; +MI0012059 mtr-MIR2680c; +MI0012060 mtr-MIR2680d; +MI0012061 mtr-MIR2680e; +MI0012062 hsa-mir-2681; +MI0012063 hsa-mir-2682; +MI0012068 aqc-MIR156b; +MI0012069 aqc-MIR156a; +MI0012070 aqc-MIR159; +MI0012071 aqc-MIR160a; +MI0012072 aqc-MIR160b; +MI0012073 aqc-MIR166e; +MI0012074 aqc-MIR166a; +MI0012075 aqc-MIR166b; +MI0012076 aqc-MIR166c; +MI0012077 aqc-MIR166d; +MI0012078 aqc-MIR167; +MI0012079 aqc-MIR168; +MI0012080 aqc-MIR169c; +MI0012081 aqc-MIR169a; +MI0012082 aqc-MIR169b; +MI0012083 aqc-MIR171f; +MI0012084 aqc-MIR171a; +MI0012085 aqc-MIR171b; +MI0012086 aqc-MIR171c; +MI0012087 aqc-MIR171d; +MI0012088 aqc-MIR171e; +MI0012089 aqc-MIR172a; +MI0012090 aqc-MIR172b; +MI0012091 aqc-MIR319; +MI0012092 aqc-MIR395b; +MI0012093 aqc-MIR395a; +MI0012094 aqc-MIR396a; +MI0012095 aqc-MIR396b; +MI0012096 aqc-MIR398a; +MI0012097 aqc-MIR398b; +MI0012098 aqc-MIR399; +MI0012099 aqc-MIR408; +MI0012100 aqc-MIR477g; +MI0012101 aqc-MIR477f; +MI0012102 aqc-MIR477e; +MI0012103 aqc-MIR477a; +MI0012104 aqc-MIR477b; +MI0012105 aqc-MIR477c; +MI0012106 aqc-MIR477d; +MI0012107 aqc-MIR482a; +MI0012108 aqc-MIR482b; +MI0012109 aqc-MIR482c; +MI0012110 aqc-MIR529; +MI0012111 aqc-MIR530; +MI0012112 aqc-MIR535; +MI0012113 cte-mir-2e;cte-mir-2e-1; +MI0012114 cte-mir-2f; +MI0012115 cte-mir-993; +MI0012116 cte-mir-36; +MI0012117 cte-mir-277a; +MI0012118 cte-mir-2685; +MI0012119 cte-mir-10c-as;cte-mir-10d; +MI0012120 cte-mir-2686a; +MI0012121 cte-mir-2686b; +MI0012122 cte-mir-2686c; +MI0012123 cte-mir-2687; +MI0012124 cte-mir-2688; +MI0012125 cte-mir-2689; +MI0012126 cte-mir-2690; +MI0012127 cte-mir-2691; +MI0012128 cte-mir-1990a; +MI0012129 cte-mir-1990b; +MI0012130 cte-mir-1990c; +MI0012131 cte-mir-2692; +MI0012132 cte-mir-2693; +MI0012133 cte-mir-1991; +MI0012134 cte-mir-996; +MI0012135 cte-mir-2694;cte-mir-2694-1; +MI0012136 cte-mir-2720; +MI0012137 cte-mir-2695; +MI0012138 cte-mir-2696; +MI0012139 cte-mir-2697; +MI0012140 cte-mir-2g; +MI0012141 cte-mir-2698; +MI0012142 cte-mir-2699; +MI0012143 cte-mir-2700; +MI0012144 cte-mir-2701; +MI0012145 cte-mir-2702; +MI0012146 cte-mir-2703;cte-mir-2703-1; +MI0012147 cte-mir-2704; +MI0012148 cte-mir-216c; +MI0012149 cte-mir-2705; +MI0012150 cte-mir-210b; +MI0012151 cte-mir-2706; +MI0012152 cte-mir-2707; +MI0012153 cte-mir-277b; +MI0012154 cte-mir-2708; +MI0012155 cte-mir-2721; +MI0012156 cte-mir-2709; +MI0012157 cte-mir-2710; +MI0012158 cte-mir-2711; +MI0012159 cte-mir-2712; +MI0012160 cte-mir-2713; +MI0012161 cte-mir-2714; +MI0012162 cte-mir-2715;cte-mir-2715-1; +MI0012163 cte-mir-2716; +MI0012164 cte-mir-2717; +MI0012165 cte-mir-2718; +MI0012166 cte-mir-2719; +MI0012167 hsv1-miR-H7;hsv1-mir-H7; +MI0012168 hsv1-miR-H8;hsv1-mir-H8; +MI0012169 lgi-mir-2722; +MI0012170 bmo-mir-2723; +MI0012171 bmo-mir-2724; +MI0012172 bmo-mir-2725; +MI0012173 bmo-mir-2726; +MI0012174 bmo-mir-2727; +MI0012175 bmo-mir-2753; +MI0012176 bmo-mir-2728; +MI0012177 bmo-mir-2729; +MI0012178 bmo-mir-2730; +MI0012179 bmo-mir-2731a;bmo-mir-2731-1; +MI0012180 bmo-mir-2731b;bmo-mir-2731-2; +MI0012181 bmo-mir-2732; +MI0012182 bmo-mir-2733a;bmo-mir-2733a-1; +MI0012183 bmo-mir-2734; +MI0012184 bmo-mir-2735; +MI0012185 bmo-mir-2736; +MI0012186 bmo-mir-2737; +MI0012187 bmo-mir-2738; +MI0012188 bmo-mir-2739; +MI0012189 bmo-mir-2740; +MI0012190 bmo-mir-2733b;bmo-mir-2733b-1; +MI0012191 bmo-mir-2741; +MI0012192 bmo-mir-2742; +MI0012193 bmo-mir-9c; +MI0012194 bmo-mir-2743; +MI0012195 bmo-mir-2744; +MI0012196 bmo-mir-2745; +MI0012197 bmo-mir-2746; +MI0012198 bmo-mir-2747; +MI0012199 bmo-mir-2748; +MI0012200 bmo-mir-2749; +MI0012201 bmo-mir-306;bmo-mir-306a; +MI0012202 bmo-mir-2750; +MI0012203 bmo-mir-2751; +MI0012204 bmo-mir-2752; +MI0012205 bmo-mir-989;bmo-mir-989a; +MI0012206 bta-mir-1388; +MI0012207 bta-mir-1468; +MI0012208 bta-mir-194-1; +MI0012209 bta-mir-19b-2; +MI0012210 bta-mir-219-2; +MI0012211 bta-mir-320-1;bta-mir-320a-1; +MI0012212 bta-mir-424; +MI0012213 bta-mir-450-1;bta-mir-450a-1; +MI0012214 bta-mir-542; +MI0012215 dpu-bantam; +MI0012216 dpu-mir-1; +MI0012217 dpu-mir-10; +MI0012218 dpu-mir-100; +MI0012219 dpu-mir-12; +MI0012220 dpu-mir-124; +MI0012221 dpu-mir-133; +MI0012222 dpu-mir-137; +MI0012223 dpu-mir-153; +MI0012224 dpu-mir-193; +MI0012225 dpu-mir-283; +MI0012226 dpu-mir-219; +MI0012227 dpu-mir-745; +MI0012228 dpu-mir-252a; +MI0012229 dpu-mir-252b; +MI0012230 dpu-mir-263a; +MI0012231 dpu-mir-263b; +MI0012232 dpu-mir-275; +MI0012233 dpu-mir-276; +MI0012234 dpu-mir-278; +MI0012235 dpu-mir-279;dpu-mir-279a; +MI0012236 dpu-mir-281; +MI0012237 dpu-mir-285; +MI0012238 dpu-mir-2a;dpu-mir-2-1; +MI0012239 dpu-mir-2b;dpu-mir-2-2; +MI0012240 dpu-mir-31; +MI0012241 dpu-mir-315; +MI0012242 dpu-mir-317; +MI0012243 dpu-mir-33; +MI0012244 dpu-mir-34; +MI0012245 dpu-mir-375; +MI0012246 dpu-mir-307; +MI0012247 dpu-mir-7; +MI0012248 dpu-mir-71; +MI0012249 dpu-mir-79; +MI0012250 dpu-mir-8; +MI0012251 dpu-mir-87; +MI0012252 dpu-mir-9; +MI0012253 dpu-mir-92; +MI0012254 dpu-mir-96; +MI0012255 dpu-mir-965; +MI0012256 dpu-mir-981; +MI0012257 dpu-mir-993; +MI0012258 dpu-mir-iab-4; +MI0012259 isc-bantam; +MI0012260 isc-let-7; +MI0012261 isc-mir-1; +MI0012262 isc-mir-10; +MI0012263 isc-mir-100; +MI0012264 isc-mir-12; +MI0012265 isc-mir-124; +MI0012266 isc-mir-133; +MI0012267 isc-mir-137; +MI0012268 isc-mir-153; +MI0012269 isc-mir-184; +MI0012270 isc-mir-219; +MI0012271 isc-mir-252b; +MI0012272 isc-mir-263a; +MI0012273 isc-mir-275; +MI0012274 isc-mir-279; +MI0012275 isc-mir-285; +MI0012276 isc-mir-2a; +MI0012277 isc-mir-2b; +MI0012278 isc-mir-315; +MI0012279 isc-mir-317; +MI0012280 isc-mir-375; +MI0012281 isc-mir-307; +MI0012282 isc-mir-7; +MI0012283 isc-mir-71; +MI0012284 isc-mir-750; +MI0012285 isc-mir-79; +MI0012286 isc-mir-8; +MI0012287 isc-mir-87; +MI0012288 isc-mir-96; +MI0012289 isc-mir-993; +MI0012291 bmo-mir-100; +MI0012292 bmo-mir-316; +MI0012293 bmo-mir-33; +MI0012294 bmo-mir-11; +MI0012295 bmo-mir-998; +MI0012296 bmo-mir-308; +MI0012297 bmo-mir-279d; +MI0012298 bmo-mir-279b; +MI0012299 bmo-mir-279c; +MI0012300 bmo-mir-1175; +MI0012301 bmo-mir-2754; +MI0012302 bmo-mir-2755; +MI0012303 bmo-mir-2733e-2; +MI0012304 bmo-mir-2733e-1; +MI0012305 bmo-mir-2733d; +MI0012306 bmo-mir-2733c; +MI0012307 bmo-mir-9d; +MI0012308 bmo-mir-2807c; +MI0012309 bmo-mir-2756; +MI0012310 bmo-mir-745; +MI0012311 bmo-mir-2757; +MI0012312 bmo-mir-2758; +MI0012313 bmo-mir-2759; +MI0012314 bmo-mir-2760; +MI0012315 bmo-mir-2761; +MI0012316 bmo-mir-2762; +MI0012317 bmo-mir-2763; +MI0012318 bmo-mir-2764; +MI0012319 bmo-mir-2765; +MI0012320 bmo-mir-2766; +MI0012321 bmo-mir-2767; +MI0012322 bmo-mir-750; +MI0012323 bmo-mir-2768; +MI0012324 bmo-mir-375; +MI0012325 bmo-mir-2769; +MI0012326 bmo-mir-2770; +MI0012327 bmo-mir-2772b; +MI0012328 bmo-mir-2771; +MI0012329 bmo-mir-2772a-1; +MI0012331 bmo-mir-2774a-1; +MI0012332 bmo-mir-2774a-3; +MI0012333 bmo-mir-2775a; +MI0012334 bmo-mir-2776; +MI0012335 bmo-mir-2774b-1; +MI0012336 bmo-mir-2777; +MI0012337 bmo-mir-2774a-4; +MI0012338 bmo-mir-2778a-1; +MI0012339 bmo-mir-2778c; +MI0012340 bmo-mir-2778a-3; +MI0012341 bmo-mir-2774b-2; +MI0012344 bmo-mir-2779; +MI0012345 bmo-mir-2780a-1; +MI0012346 bmo-mir-2808c; +MI0012347 bmo-mir-2774a-2; +MI0012348 bmo-mir-2781; +MI0012349 bmo-mir-2778d; +MI0012350 bmo-mir-2772a-2; +MI0012351 bmo-mir-2778b; +MI0012352 bmo-mir-2778a-2; +MI0012353 bmo-mir-2778a-4; +MI0012355 bmo-mir-2782; +MI0012356 bmo-mir-2783; +MI0012357 bmo-mir-2784; +MI0012358 bmo-mir-2785; +MI0012359 bmo-mir-2786; +MI0012360 bmo-mir-2787; +MI0012361 bmo-mir-2788; +MI0012362 bmo-mir-2789; +MI0012363 bmo-mir-2790; +MI0012364 bmo-mir-2791; +MI0012365 bmo-mir-2792; +MI0012367 bmo-mir-2794; +MI0012368 bmo-mir-2795; +MI0012369 bmo-mir-2796; +MI0012370 bmo-mir-2797a; +MI0012371 bmo-mir-2797b; +MI0012372 bmo-mir-2797c; +MI0012373 bmo-mir-2797d; +MI0012374 bmo-mir-2798; +MI0012375 bmo-mir-2799; +MI0012376 bmo-mir-2800; +MI0012377 bmo-mir-2801; +MI0012379 bmo-mir-2803; +MI0012380 bmo-mir-2804-1; +MI0012381 bmo-mir-2808a-2; +MI0012382 bmo-mir-2805; +MI0012385 bmo-mir-2807a-1; +MI0012386 bmo-mir-2780a-2; +MI0012388 bmo-mir-2808a-1; +MI0012389 bmo-mir-2809; +MI0012390 bmo-mir-2810; +MI0012391 bmo-mir-2804-2; +MI0012393 bmo-mir-2812; +MI0012394 bmo-mir-2813-1; +MI0012395 bmo-mir-2807a-5; +MI0012396 bmo-mir-2807a-2; +MI0012400 bmo-mir-2816-1; +MI0012401 bmo-mir-2817; +MI0012402 bmo-mir-2818-1; +MI0012403 bmo-mir-2819; +MI0012404 bmo-mir-2820-1; +MI0012405 bmo-mir-2821; +MI0012406 bmo-mir-2780a-3; +MI0012407 bmo-mir-2780b-2; +MI0012408 bmo-mir-2822-1; +MI0012409 bmo-mir-2814-2; +MI0012410 bmo-mir-2804-3; +MI0012411 bmo-mir-2816-2; +MI0012413 bmo-mir-2816-3; +MI0012414 bmo-mir-2818-2; +MI0012415 bmo-mir-2780b-1; +MI0012416 bmo-mir-2807a-6; +MI0012419 bmo-mir-2824; +MI0012420 bmo-mir-2825; +MI0012421 bmo-mir-2826; +MI0012422 bmo-mir-2827; +MI0012423 bmo-mir-2808b; +MI0012424 bmo-mir-2828; +MI0012426 bmo-mir-2807b; +MI0012427 bmo-mir-2830-1; +MI0012428 bmo-mir-2831-1; +MI0012429 bmo-mir-2775b; +MI0012430 bmo-mir-2832; +MI0012433 bmo-mir-2833-1; +MI0012434 bmo-mir-2831-2; +MI0012435 bmo-mir-2834-1; +MI0012436 bmo-mir-2813-2; +MI0012437 bmo-mir-2835; +MI0012438 bmo-mir-2836; +MI0012439 bmo-mir-2822-2; +MI0012440 bmo-mir-2820-2; +MI0012441 bmo-mir-2837; +MI0012444 bmo-mir-2807a-3; +MI0012445 bmo-mir-2838; +MI0012446 bmo-mir-2839; +MI0012448 bmo-mir-2840; +MI0012449 bmo-mir-2841; +MI0012450 bmo-mir-2774c; +MI0012451 bmo-mir-2780c; +MI0012452 bmo-mir-2807a-4; +MI0012453 bmo-mir-2833-2; +MI0012454 bmo-mir-2842; +MI0012455 bmo-mir-2806-2; +MI0012456 bmo-mir-2843-1; +MI0012457 bmo-mir-2814-3; +MI0012460 bmo-mir-2834-2; +MI0012461 bmo-mir-2830-2; +MI0012462 bmo-mir-2780d; +MI0012463 bmo-mir-2804-4; +MI0012464 bmo-mir-2843-2; +MI0012465 bmo-mir-2845; +MI0012466 bmo-mir-2846; +MI0012467 bmo-mir-2847; +MI0012468 bmo-mir-2849-1; +MI0012469 bmo-mir-2848; +MI0012471 bmo-mir-2849-2; +MI0012472 bmo-mir-2849-3; +MI0012473 hvt-mir-H1; +MI0012474 hvt-mir-H2; +MI0012475 hvt-mir-H3; +MI0012476 hvt-mir-H4; +MI0012477 hvt-mir-H5; +MI0012478 hvt-mir-H7; +MI0012479 hvt-mir-H8; +MI0012480 hvt-mir-H9; +MI0012481 iltv-mir-I1; +MI0012482 iltv-mir-I2; +MI0012483 iltv-mir-I3; +MI0012484 iltv-mir-I4; +MI0012485 iltv-mir-I5; +MI0012486 iltv-mir-I6; +MI0012487 mdv2-mir-M32; +MI0012488 hsa-mir-711; +MI0012489 hsa-mir-718; +MI0012490 mdo-mir-26-2; +MI0012491 mdo-mir-26-3; +MI0012492 mdo-mir-26-1; +MI0012493 mdo-mir-148; +MI0012494 mdo-mir-153-2; +MI0012495 mdo-mir-301; +MI0012496 mdo-mir-190a; +MI0012497 mdo-mir-429; +MI0012498 mdo-mir-106; +MI0012499 mdo-mir-126; +MI0012500 mdo-mir-139; +MI0012501 mdo-mir-140; +MI0012502 mdo-mir-146a; +MI0012503 mdo-mir-146b; +MI0012504 mdo-mir-150; +MI0012505 mdo-mir-153-1; +MI0012506 mdo-mir-205a; +MI0012507 mdo-mir-210; +MI0012508 mdo-mir-215; +MI0012509 mdo-mir-455; +MI0012510 mdo-mir-499; +MI0012511 mdo-mir-33; +MI0012512 mdo-mir-363; +MI0012513 mdo-mir-190b; +MI0012514 mdo-mir-147b; +MI0012515 mdo-mir-460; +MI0012516 mdo-mir-28; +MI0012517 mdo-mir-195; +MI0012518 mdo-mir-151; +MI0012519 mdo-mir-497; +MI0012520 mdo-mir-551a; +MI0012521 mdo-mir-551b; +MI0012522 mdo-mir-599; +MI0012523 mdo-mir-875; +MI0012524 mdo-mir-885; +MI0012525 mdo-mir-761; +MI0012526 mdo-mir-759; +MI0012527 mdo-mir-739; +MI0012528 mmu-mir-432; +MI0012529 mmu-mir-599; +MI0012530 mmu-mir-767; +MI0012531 mmu-mir-664; +MI0012532 mml-mir-129-2; +MI0012533 mml-mir-526b; +MI0012534 mml-mir-524; +MI0012535 mml-mir-516;mml-mir-516b; +MI0012536 mml-mir-571; +MI0012537 mml-mir-595; +MI0012538 mml-mir-603; +MI0012539 mml-mir-622; +MI0012540 mml-mir-892b; +MI0012541 mml-mir-541; +MI0012542 mml-mir-708; +MI0012543 mml-mir-665; +MI0012544 mml-mir-543; +MI0012545 mml-mir-760; +MI0012546 mml-mir-1233; +MI0012547 mml-mir-1234; +MI0012548 mml-mir-762;mml-mir-762-1; +MI0012549 mml-mir-670; +MI0012550 mml-mir-761; +MI0012551 mml-mir-764; +MI0012552 mml-mir-759; +MI0012553 mml-mir-711; +MI0012554 oan-mir-29b-2; +MI0012555 oan-mir-92c; +MI0012556 oan-mir-92d; +MI0012557 oan-mir-9-2; +MI0012558 oan-mir-182; +MI0012559 oan-mir-218-2; +MI0012560 ptr-mir-500-2; +MI0012561 ptr-mir-892b; +MI0012562 ptr-mir-664b; +MI0012563 ptr-mir-299; +MI0012564 ptr-mir-373; +MI0012565 ptr-mir-497; +MI0012566 ptr-mir-570; +MI0012567 ptr-mir-571;ptr-mir-571-1; +MI0012568 ptr-mir-589; +MI0012569 ptr-mir-596; +MI0012570 ptr-mir-602; +MI0012571 ptr-mir-604; +MI0012572 ptr-mir-606; +MI0012573 ptr-mir-623; +MI0012574 ptr-mir-631; +MI0012575 ptr-mir-651; +MI0012576 ptr-mir-661; +MI0012577 ptr-mir-762; +MI0012578 ptr-mir-670; +MI0012579 ptr-mir-761; +MI0012580 ptr-mir-764; +MI0012581 ptr-mir-759; +MI0012582 ptr-mir-711; +MI0012583 ptr-mir-718; +MI0012584 rno-mir-202; +MI0012585 rno-mir-490; +MI0012586 rno-mir-513; +MI0012587 rno-mir-105; +MI0012588 rno-mir-220;rno-mir-220-1; +MI0012589 rno-mir-1224; +MI0012590 rno-mir-362; +MI0012591 rno-mir-511; +MI0012592 rno-mir-504; +MI0012593 rno-mir-544; +MI0012594 rno-mir-568; +MI0012595 rno-mir-582; +MI0012596 rno-mir-592; +MI0012597 rno-mir-615; +MI0012598 rno-mir-628; +MI0012599 rno-mir-632; +MI0012600 rno-mir-653; +MI0012601 rno-mir-668; +MI0012602 rno-mir-802; +MI0012603 rno-mir-675; +MI0012604 rno-mir-875; +MI0012605 rno-mir-876; +MI0012606 rno-mir-665; +MI0012607 rno-mir-935; +MI0012608 rno-mir-201; +MI0012609 rno-mir-293; +MI0012610 rno-mir-294; +MI0012611 rno-mir-295;rno-mir-295-1; +MI0012612 rno-mir-465; +MI0012613 rno-mir-547; +MI0012614 rno-mir-667; +MI0012615 rno-mir-761; +MI0012616 rno-mir-764; +MI0012617 rno-mir-666; +MI0012618 rno-mir-759; +MI0012619 rno-mir-678; +MI0012620 rno-mir-685; +MI0012621 rno-mir-711; +MI0012622 rno-mir-496; +MI0012623 iltv-mir-I7; +MI0012624 hvt-mir-H10; +MI0012625 hvt-mir-H12; +MI0012626 hvt-mir-H13; +MI0012627 hvt-mir-H14; +MI0012628 hvt-mir-H15; +MI0012629 hvt-mir-H16; +MI0012630 hvt-mir-H17; +MI0012631 hvt-mir-H18; +MI0012632 hvt-mir-H11; +MI0012633 peu-MIR2910; +MI0012634 peu-MIR2911; +MI0012635 peu-MIR2912a; +MI0012636 peu-MIR2912b; +MI0012637 peu-MIR2913; +MI0012638 peu-MIR2914; +MI0012639 peu-MIR2915; +MI0012640 peu-MIR2916; +MI0012641 bta-mir-9-3; +MI0012642 bta-mir-2917; +MI0012643 eca-mir-107b; +MI0012644 eca-mir-1179; +MI0012645 eca-mir-1244; +MI0012646 eca-mir-1282; +MI0012647 eca-mir-1296; +MI0012648 eca-mir-146b; +MI0012649 eca-mir-1839; +MI0012650 eca-mir-184; +MI0012651 eca-mir-1892; +MI0012652 eca-mir-190;eca-mir-190a; +MI0012653 eca-mir-1905a; +MI0012654 eca-mir-204a; +MI0012655 eca-mir-208a; +MI0012656 eca-mir-208b; +MI0012657 eca-mir-211; +MI0012658 eca-mir-346; +MI0012659 eca-mir-628a; +MI0012660 eca-mir-685; +MI0012661 eca-mir-7;eca-mir-7-1; +MI0012662 eca-mir-124;eca-mir-124-1; +MI0012663 eca-mir-1302-1; +MI0012664 eca-mir-147b; +MI0012665 eca-mir-200a; +MI0012666 eca-mir-200b; +MI0012667 eca-mir-302a; +MI0012668 eca-mir-302b; +MI0012669 eca-mir-302c; +MI0012670 eca-mir-302d; +MI0012671 eca-mir-30c; +MI0012672 eca-mir-30e; +MI0012673 eca-mir-34;eca-mir-34a; +MI0012674 eca-mir-367; +MI0012675 eca-mir-429; +MI0012676 eca-mir-492;eca-mir-492-1; +MI0012677 eca-mir-551a; +MI0012678 eca-mir-598; +MI0012679 eca-mir-761; +MI0012680 eca-mir-1261; +MI0012681 eca-mir-138;eca-mir-138-1; +MI0012682 eca-mir-140; +MI0012683 eca-mir-218;eca-mir-218-1; +MI0012684 eca-mir-328; +MI0012685 eca-mir-684; +MI0012686 eca-mir-95; +MI0012687 eca-mir-129a; +MI0012688 eca-mir-1302b-2; +MI0012689 eca-mir-148a; +MI0012690 eca-mir-153;eca-mir-153-1; +MI0012691 eca-mir-182; +MI0012692 eca-mir-183; +MI0012693 eca-mir-196b; +MI0012694 eca-mir-29a; +MI0012695 eca-mir-29b; +MI0012696 eca-mir-335; +MI0012697 eca-mir-489; +MI0012698 eca-mir-490; +MI0012699 eca-mir-592; +MI0012700 eca-mir-653; +MI0012701 eca-mir-671; +MI0012702 eca-mir-96; +MI0012703 eca-mir-101;eca-mir-101-1; +MI0012704 eca-mir-135b; +MI0012705 eca-mir-137; +MI0012706 eca-mir-15b; +MI0012707 eca-mir-16;eca-mir-16-1; +MI0012708 eca-mir-186; +MI0012709 eca-mir-1905b; +MI0012710 eca-mir-190b; +MI0012711 eca-mir-197; +MI0012712 eca-mir-199a; +MI0012713 eca-mir-205; +MI0012714 eca-mir-214; +MI0012715 eca-mir-29b-2; +MI0012716 eca-mir-29c; +MI0012717 eca-mir-29c-2; +MI0012718 eca-mir-488; +MI0012719 eca-mir-92b; +MI0012720 eca-mir-9a; +MI0012721 eca-mir-1291a; +MI0012722 eca-mir-1302d-4; +MI0012723 eca-mir-141; +MI0012724 eca-mir-148b; +MI0012725 eca-mir-149; +MI0012726 eca-mir-153-2; +MI0012727 eca-mir-200c; +MI0012728 eca-mir-26a; +MI0012729 eca-mir-615; +MI0012730 eca-mir-763; +MI0012731 eca-let-7a; +MI0012732 eca-mir-100; +MI0012733 eca-mir-125b; +MI0012734 eca-mir-1302c-5; +MI0012735 eca-mir-139; +MI0012736 eca-mir-1905c; +MI0012737 eca-mir-23a; +MI0012738 eca-mir-24;eca-mir-24-1; +MI0012739 eca-mir-27a; +MI0012740 eca-mir-326; +MI0012741 eca-mir-34b; +MI0012742 eca-mir-34c; +MI0012743 eca-mir-492-2; +MI0012744 eca-mir-7-2; +MI0012745 eca-mir-708; +MI0012746 eca-mir-1;eca-mir-1-1; +MI0012747 eca-mir-122; +MI0012748 eca-mir-130b; +MI0012749 eca-mir-133a; +MI0012750 eca-mir-1597; +MI0012751 eca-mir-187; +MI0012752 eca-mir-301b; +MI0012753 eca-mir-703; +MI0012754 eca-mir-1204; +MI0012755 eca-mir-124-2; +MI0012756 eca-mir-151; +MI0012757 eca-mir-30b; +MI0012758 eca-mir-30d; +MI0012759 eca-let-7e; +MI0012760 eca-mir-125a; +MI0012761 eca-mir-1302e-6; +MI0012762 eca-mir-150; +MI0012763 eca-mir-330; +MI0012764 eca-mir-371; +MI0012765 eca-mir-769;eca-mir-769a; +MI0012766 eca-mir-769b; +MI0012767 eca-mir-99b; +MI0012768 eca-mir-10a; +MI0012769 eca-mir-1180; +MI0012770 eca-mir-132; +MI0012771 eca-mir-142; +MI0012772 eca-mir-144; +MI0012773 eca-mir-193a; +MI0012774 eca-mir-195; +MI0012775 eca-mir-196a; +MI0012776 eca-mir-21; +MI0012777 eca-mir-212; +MI0012778 eca-mir-22; +MI0012779 eca-mir-301a; +MI0012780 eca-mir-324; +MI0012781 eca-mir-338; +MI0012782 eca-mir-33b; +MI0012783 eca-mir-365;eca-mir-365-1; +MI0012784 eca-mir-423; +MI0012785 eca-mir-451; +MI0012786 eca-mir-454; +MI0012787 eca-mir-497; +MI0012788 eca-mir-632; +MI0012789 eca-mir-129b; +MI0012790 eca-mir-130a; +MI0012791 eca-mir-1902; +MI0012792 eca-mir-192; +MI0012793 eca-mir-194;eca-mir-194-1; +MI0012794 eca-mir-493a; +MI0012795 eca-mir-670; +MI0012796 eca-mir-675; +MI0012797 eca-mir-106b; +MI0012798 eca-mir-1302e-7; +MI0012799 eca-mir-1842; +MI0012800 eca-mir-193b; +MI0012801 eca-mir-25; +MI0012802 eca-mir-365-2; +MI0012803 eca-mir-590; +MI0012804 eca-mir-93; +MI0012805 eca-mir-107a; +MI0012806 eca-mir-1271;eca-mir-1271a; +MI0012807 eca-mir-143; +MI0012808 eca-mir-145; +MI0012809 eca-mir-146a; +MI0012810 eca-mir-218-2; +MI0012811 eca-mir-340; +MI0012812 eca-mir-378; +MI0012813 eca-mir-874; +MI0012814 eca-mir-9a-2; +MI0012815 eca-mir-1301; +MI0012816 eca-mir-1461; +MI0012817 eca-mir-216a; +MI0012818 eca-mir-216b; +MI0012819 eca-mir-217; +MI0012820 eca-let-7g; +MI0012821 eca-mir-128;eca-mir-128-1; +MI0012822 eca-mir-1289; +MI0012823 eca-mir-135a; +MI0012824 eca-mir-138-2; +MI0012825 eca-mir-191;eca-mir-191a; +MI0012826 eca-mir-26a-2; +MI0012827 eca-mir-711; +MI0012828 eca-mir-885; +MI0012829 eca-mir-15a; +MI0012830 eca-mir-16-2; +MI0012831 eca-mir-17; +MI0012832 eca-mir-18a; +MI0012833 eca-mir-19a; +MI0012834 eca-mir-19b; +MI0012835 eca-mir-20a; +MI0012836 eca-mir-92a; +MI0012837 eca-mir-10b; +MI0012838 eca-mir-128-2; +MI0012839 eca-mir-1248; +MI0012840 eca-mir-28; +MI0012841 eca-mir-551b; +MI0012842 eca-mir-568; +MI0012843 eca-mir-1291b; +MI0012844 eca-mir-133b; +MI0012845 eca-mir-206-2; +MI0012846 eca-mir-219;eca-mir-219-1; +MI0012847 eca-mir-220b; +MI0012848 eca-mir-220b-2; +MI0012849 eca-mir-30c-2; +MI0012850 eca-mir-1898; +MI0012851 eca-mir-449a; +MI0012852 eca-mir-582; +MI0012853 eca-mir-1-2; +MI0012854 eca-mir-103; +MI0012855 eca-mir-1255b; +MI0012856 eca-mir-133a-2; +MI0012857 eca-mir-296; +MI0012858 eca-mir-499; +MI0012859 eca-let-7d; +MI0012860 eca-let-7f; +MI0012861 eca-mir-101-2; +MI0012862 eca-mir-204b-2; +MI0012863 eca-mir-23b; +MI0012864 eca-mir-24-2; +MI0012865 eca-mir-27b; +MI0012866 eca-mir-31; +MI0012867 eca-mir-491; +MI0012868 eca-mir-544b; +MI0012869 eca-mir-7-3; +MI0012870 eca-mir-872; +MI0012871 eca-mir-873; +MI0012872 eca-mir-876; +MI0012873 eca-mir-1185; +MI0012874 eca-mir-1193; +MI0012875 eca-mir-1197; +MI0012876 eca-mir-127; +MI0012877 eca-mir-134; +MI0012878 eca-mir-136; +MI0012879 eca-mir-154;eca-mir-154a; +MI0012880 eca-mir-299; +MI0012881 eca-mir-323; +MI0012882 eca-mir-329;eca-mir-329a; +MI0012883 eca-mir-337; +MI0012884 eca-mir-342; +MI0012885 eca-mir-345; +MI0012886 eca-mir-369; +MI0012887 eca-mir-370; +MI0012888 eca-mir-376a; +MI0012889 eca-mir-376b; +MI0012890 eca-mir-376c; +MI0012891 eca-mir-377; +MI0012892 eca-mir-379; +MI0012893 eca-mir-380; +MI0012894 eca-mir-381; +MI0012895 eca-mir-382; +MI0012896 eca-mir-409; +MI0012897 eca-mir-410; +MI0012898 eca-mir-411; +MI0012899 eca-mir-412; +MI0012900 eca-mir-431; +MI0012901 eca-mir-432; +MI0012902 eca-mir-433; +MI0012903 eca-mir-485; +MI0012904 eca-mir-487a; +MI0012905 eca-mir-487b; +MI0012906 eca-mir-493b; +MI0012907 eca-mir-494; +MI0012908 eca-mir-495; +MI0012909 eca-mir-496; +MI0012910 eca-mir-539; +MI0012911 eca-mir-541; +MI0012912 eca-mir-543; +MI0012913 eca-mir-544-2; +MI0012914 eca-mir-655; +MI0012915 eca-mir-656; +MI0012916 eca-mir-758; +MI0012917 eca-mir-770; +MI0012918 eca-mir-889; +MI0012919 eca-mir-126; +MI0012920 eca-mir-181a; +MI0012921 eca-mir-181b; +MI0012922 eca-mir-199b; +MI0012923 eca-mir-219-2; +MI0012924 eca-mir-32; +MI0012925 eca-let-7c; +MI0012926 eca-mir-125b-2; +MI0012927 eca-mir-155; +MI0012928 eca-mir-802; +MI0012929 eca-mir-99a-2; +MI0012930 eca-mir-383; +MI0012931 eca-mir-486; +MI0012932 eca-let-7a-2; +MI0012933 eca-mir-135a-2; +MI0012934 eca-mir-331; +MI0012935 eca-mir-33a; +MI0012936 eca-mir-181a-2; +MI0012937 eca-mir-194-2; +MI0012938 eca-mir-215; +MI0012939 eca-mir-350; +MI0012940 eca-mir-664; +MI0012941 eca-mir-105; +MI0012942 eca-mir-106a; +MI0012943 eca-mir-1264; +MI0012944 eca-mir-1298; +MI0012945 eca-mir-1468; +MI0012946 eca-mir-188; +MI0012947 eca-mir-18b; +MI0012948 eca-mir-1912; +MI0012949 eca-mir-19b-2; +MI0012950 eca-mir-20b; +MI0012951 eca-mir-221; +MI0012952 eca-mir-222; +MI0012953 eca-mir-223; +MI0012954 eca-mir-224; +MI0012955 eca-mir-322; +MI0012956 eca-mir-361; +MI0012957 eca-mir-362; +MI0012958 eca-mir-363; +MI0012959 eca-mir-374a; +MI0012960 eca-mir-374b; +MI0012961 eca-mir-384; +MI0012962 eca-mir-421; +MI0012963 eca-mir-424; +MI0012964 eca-mir-448; +MI0012965 eca-mir-450a; +MI0012966 eca-mir-450b; +MI0012967 eca-mir-451a;eca-mir-450c; +MI0012968 eca-mir-500;eca-mir-500-1; +MI0012969 eca-mir-500-2; +MI0012970 eca-mir-501; +MI0012971 eca-mir-502; +MI0012972 eca-mir-503; +MI0012973 eca-mir-504; +MI0012974 eca-mir-505; +MI0012975 eca-mir-507;eca-mir-507a; +MI0012976 eca-mir-508; +MI0012977 eca-mir-509;eca-mir-509a; +MI0012978 eca-mir-514; +MI0012979 eca-mir-532; +MI0012980 eca-mir-542; +MI0012981 eca-mir-545; +MI0012982 eca-mir-652; +MI0012983 eca-mir-660; +MI0012984 eca-mir-672; +MI0012985 eca-mir-764; +MI0012986 eca-mir-767; +MI0012987 eca-mir-92a-2; +MI0012988 eca-mir-98; +MI0012989 bmo-mir-306-as;bmo-mir-306b; +MI0012990 bmo-mir-2851-2; +MI0012991 bmo-mir-2851-1; +MI0012992 bmo-mir-2852; +MI0012994 bmo-mir-1-as;bmo-mir-1b; +MI0012995 bmo-mir-2854; +MI0012996 bmo-mir-2855; +MI0012997 bmo-mir-2833b; +MI0012998 bmo-mir-2856-1; +MI0012999 bmo-mir-2856-2; +MI0013000 bmo-mir-2857; +MI0013002 bmo-mir-2859; +MI0013003 bmo-mir-2860; +MI0013006 hsa-mir-2861; +MI0013007 mmu-mir-2861; +MI0013008 ola-mir-430a-1; +MI0013009 ola-mir-430c-1; +MI0013010 ola-mir-430b-1; +MI0013011 ola-mir-430c-2; +MI0013012 ola-mir-430c-3; +MI0013013 ola-mir-430d-1; +MI0013014 ola-mir-430a-2; +MI0013015 ola-mir-430c-4; +MI0013016 ola-mir-430d-2; +MI0013017 ola-mir-430a-3; +MI0013018 ola-mir-430a-4; +MI0013019 ola-mir-430c-5; +MI0013020 ola-mir-430d-3; +MI0013021 ola-mir-430b-2; +MI0013022 ola-mir-430c-6; +MI0013023 ola-mir-430c-7; +MI0013024 osa-MIR2862; +MI0013025 osa-MIR2863a; +MI0013026 osa-MIR2864; +MI0013027 osa-MIR2865; +MI0013028 osa-MIR2866; +MI0013029 osa-MIR2867; +MI0013030 osa-MIR2868; +MI0013031 osa-MIR2869; +MI0013032 osa-MIR2870; +MI0013033 osa-MIR2863b; +MI0013034 osa-MIR2905; +MI0013035 osa-MIR2871a; +MI0013036 osa-MIR2871b; +MI0013037 osa-MIR2872; +MI0013038 osa-MIR2873;osa-MIR2873a; +MI0013039 osa-MIR2874; +MI0013040 osa-MIR2875; +MI0013041 osa-MIR2876; +MI0013042 osa-MIR2877; +MI0013043 osa-MIR2878; +MI0013044 osa-MIR1863c; +MI0013045 osa-MIR2879; +MI0013046 osa-MIR2880; +MI0013047 osa-MIR396g; +MI0013048 osa-MIR396h; +MI0013049 osa-MIR396i;osa-MIR396d; +MI0013050 osa-MIR1863b; +MI0013051 bta-mir-193a-2; +MI0013052 bta-mir-378-2; +MI0013053 bta-mir-669; +MI0013054 bta-mir-2881; +MI0013055 bta-mir-2882; +MI0013056 bta-mir-2883; +MI0013057 bta-mir-2884; +MI0013058 bta-mir-2885; +MI0013059 bta-mir-2886; +MI0013060 bta-mir-2887-1; +MI0013061 bta-mir-2887-2; +MI0013062 bta-mir-2888-1; +MI0013063 bta-mir-2888-2; +MI0013064 bta-mir-2889; +MI0013065 bta-mir-2890; +MI0013066 bta-mir-2891; +MI0013067 bta-mir-2892; +MI0013068 bta-mir-2893; +MI0013069 bta-mir-2894; +MI0013070 bta-mir-2895; +MI0013071 bta-mir-2896; +MI0013072 bta-mir-2897; +MI0013073 bta-mir-2898; +MI0013074 bta-mir-2899; +MI0013075 bta-mir-2900; +MI0013076 bta-mir-2901; +MI0013077 bta-mir-2902-1;bta-mir-2902; +MI0013078 bta-mir-2902-2; +MI0013079 bta-mir-2903; +MI0013080 bta-mir-2904-1; +MI0013081 bta-mir-2904-2; +MI0013082 bta-mir-2904-3; +MI0013083 hsa-mir-2909; +MI0013084 ssc-mir-206; +MI0013085 ssc-let-7a;ssc-let-7a-1; +MI0013086 ssc-let-7e; +MI0013087 ssc-let-7g; +MI0013088 ssc-mir-378;ssc-mir-378-1; +MI0013089 ssc-mir-133b; +MI0013090 ssc-mir-29a; +MI0013091 ssc-mir-30d; +MI0013092 ssc-mir-30e; +MI0013093 ssc-mir-199a;ssc-mir-199a-2; +MI0013094 ssc-mir-128-2; +MI0013095 ssc-mir-191; +MI0013096 ssc-mir-499; +MI0013097 ssc-mir-320; +MI0013098 ssc-mir-143; +MI0013099 ssc-mir-423; +MI0013100 ssc-mir-151; +MI0013101 ssc-mir-10a; +MI0013102 ssc-mir-10b; +MI0013103 ssc-mir-486;ssc-mir-486-1; +MI0013104 ssc-mir-152; +MI0013105 ssc-mir-103-2; +MI0013106 ssc-mir-181a-2; +MI0013107 ssc-mir-181b-1; +MI0013108 ssc-mir-181d; +MI0013109 ssc-mir-27b; +MI0013110 ssc-mir-340;ssc-mir-340-1; +MI0013111 ssc-mir-24-2; +MI0013112 ssc-mir-23b; +MI0013113 ssc-mir-193a; +MI0013114 ssc-mir-99a; +MI0013115 ssc-mir-125a; +MI0013116 ssc-mir-1308; +MI0013117 ssc-mir-345;ssc-mir-345-1; +MI0013118 ssc-mir-148b; +MI0013119 ssc-mir-885; +MI0013120 ssc-mir-365-2; +MI0013121 ssc-mir-365-1; +MI0013122 ssc-mir-98; +MI0013123 ssc-mir-664; +MI0013124 ssc-mir-92a-2; +MI0013125 ssc-mir-92a-1; +MI0013126 ssc-mir-92b; +MI0013127 ssc-mir-192; +MI0013128 ssc-mir-100; +MI0013129 ssc-mir-208b; +MI0013130 ssc-mir-374a; +MI0013131 ssc-mir-374b; +MI0013132 ssc-mir-34c;ssc-mir-34c-1; +MI0013133 ssc-mir-425; +MI0013134 ssc-mir-142; +MI0013135 ssc-mir-424; +MI0013136 ssc-mir-130b; +MI0013137 ssc-mir-196b;ssc-mir-196b-1; +MI0013138 ssc-mir-542; +MI0013139 ssc-mir-497; +MI0013140 ssc-mir-450b; +MI0013141 ssc-mir-195; +MI0013142 ssc-mir-331; +MI0013143 ssc-mir-504; +MI0013144 ssc-mir-127; +MI0013145 ssc-mir-361; +MI0013146 ssc-mir-1277; +MI0013147 ssc-mir-1307; +MI0013148 ssc-mir-1306; +MI0013149 ssc-mir-339;ssc-mir-339-1; +MI0013150 ssc-mir-532; +MI0013151 ssc-mir-222; +MI0013152 ssc-mir-676;ssc-mir-676-1; +MI0013153 ssc-mir-342; +MI0013154 ssc-mir-708; +MI0013155 ssc-mir-432; +MI0013156 ssc-mir-935; +MI0013157 ssc-mir-202; +MI0013158 ssc-mir-328; +MI0013159 ssc-mir-19b-2; +MI0013160 ssc-mir-19b-1; +MI0013161 ssc-mir-574; +MI0013162 ssc-mir-1839; +MI0013163 ssc-mir-628; +MI0013164 ssc-mir-1285; +MI0013165 ssc-mir-335; +MI0013166 ssc-mir-500; +MI0013167 ssc-mir-324; +MI0013168 ssc-mir-769; +MI0013169 ssc-mir-129;ssc-mir-129a; +MI0013170 ssc-mir-455; +MI0013171 ssc-mir-505; +MI0013172 ssc-mir-125b-1; +MI0013173 bhv1-mir-B1; +MI0013174 bhv1-mir-B2; +MI0013175 bhv1-mir-B3; +MI0013176 bhv1-mir-B4; +MI0013177 bhv1-mir-B5; +MI0013178 bhv1-mir-B6; +MI0013179 bhv1-mir-B7; +MI0013180 bhv1-mir-B8; +MI0013181 bhv1-mir-B9; +MI0013182 mmu-mir-2134-5; +MI0013183 mmu-mir-2134-6; +MI0013184 zma-MIR156l; +MI0013185 zma-MIR159e; +MI0013186 zma-MIR159f; +MI0013187 zma-MIR159g; +MI0013188 zma-MIR159h; +MI0013189 zma-MIR159i; +MI0013190 zma-MIR159j; +MI0013191 zma-MIR159k; +MI0013192 zma-MIR160g; +MI0013193 zma-MIR164e; +MI0013194 zma-MIR164f; +MI0013195 zma-MIR164g; +MI0013196 zma-MIR164h; +MI0013197 zma-MIR166n; +MI0013198 zma-MIR167j; +MI0013199 zma-MIR169l; +MI0013200 zma-MIR169m; +MI0013201 zma-MIR169n; +MI0013202 zma-MIR169o; +MI0013203 zma-MIR169p; +MI0013204 zma-MIR169q; +MI0013205 zma-MIR169r; +MI0013206 zma-MIR171l; +MI0013207 zma-MIR171m; +MI0013208 zma-MIR171n; +MI0013209 zma-MIR390a; +MI0013210 zma-MIR393b; +MI0013211 zma-MIR393c; +MI0013212 zma-MIR395d; +MI0013213 zma-MIR395e; +MI0013214 zma-MIR395f; +MI0013215 zma-MIR395g; +MI0013216 zma-MIR395h; +MI0013217 zma-MIR395i; +MI0013218 zma-MIR395j; +MI0013219 zma-MIR395k; +MI0013220 zma-MIR395l; +MI0013221 zma-MIR395m; +MI0013222 zma-MIR395n; +MI0013223 zma-MIR395o; +MI0013224 zma-MIR395p; +MI0013225 zma-MIR396e; +MI0013226 zma-MIR396f; +MI0013227 zma-MIR396g; +MI0013228 zma-MIR396h; +MI0013229 zma-MIR397a; +MI0013230 zma-MIR397b; +MI0013231 zma-MIR398a; +MI0013232 zma-MIR398b; +MI0013233 zma-MIR399g; +MI0013234 zma-MIR399h; +MI0013235 zma-MIR399i; +MI0013236 zma-MIR399j; +MI0013237 zma-MIR408b; +MI0013238 zma-MIR482; +MI0013239 zma-MIR528a; +MI0013240 zma-MIR528b; +MI0013241 zma-MIR529; +MI0013242 zma-MIR827; +MI0013243 zma-MIR1432; +MI0013244 zma-MIR390b; +MI0013245 osa-MIR2906a; +MI0013246 osa-MIR2906b; +MI0013247 osa-MIR2907a; +MI0013248 osa-MIR2907b; +MI0013249 osa-MIR2907c; +MI0013250 osa-MIR2907d; +MI0013252 sbi-MIR162; +MI0013253 sbi-MIR169o; +MI0013254 sbi-MIR169p; +MI0013255 sbi-MIR169q; +MI0013256 sbi-MIR172f; +MI0013257 sbi-MIR398; +MI0013258 sbi-MIR399k; +MI0013259 sbi-MIR528; +MI0013260 osa-MIR2918; +MI0013261 osa-MIR2919; +MI0013262 osa-MIR2920; +MI0013263 osa-MIR2921; +MI0013264 osa-MIR2922; +MI0013265 osa-MIR2923; +MI0013266 osa-MIR2924; +MI0013267 osa-MIR2925; +MI0013268 osa-MIR2926; +MI0013269 osa-MIR2927; +MI0013270 osa-MIR2928; +MI0013271 osa-MIR2929; +MI0013272 osa-MIR2930; +MI0013273 osa-MIR2931; +MI0013274 osa-MIR2932; +MI0013275 rlcv-mir-rL1-14-2; +MI0013276 rlcv-mir-rL1-17; +MI0013277 rlcv-mir-rL1-18; +MI0013278 rlcv-mir-rL1-19; +MI0013279 rlcv-mir-rL1-20; +MI0013280 rlcv-mir-rL1-21; +MI0013281 rlcv-mir-rL1-22; +MI0013282 rlcv-mir-rL1-23; +MI0013283 rlcv-mir-rL1-24; +MI0013284 rlcv-mir-rL1-25; +MI0013285 rlcv-mir-rL1-26; +MI0013286 rlcv-mir-rL1-27; +MI0013287 rlcv-mir-rL1-28; +MI0013288 rlcv-mir-rL1-29; +MI0013289 rlcv-mir-rL1-30; +MI0013290 rlcv-mir-rL1-31; +MI0013291 rlcv-mir-rL1-32; +MI0013292 rlcv-mir-rL1-33; +MI0013293 ctr-MIR156; +MI0013294 csi-MIR160;csi-MIR160a; +MI0013295 csi-MIR164;csi-MIR164a; +MI0013296 csi-MIR166;csi-MIR166e; +MI0013297 ctr-MIR166; +MI0013298 ccl-MIR167a; +MI0013299 ccl-MIR168; +MI0013300 csi-MIR169;csi-MIR169a; +MI0013301 ccl-MIR171; +MI0013302 csi-MIR172;csi-MIR172a; +MI0013303 ctr-MIR319; +MI0013304 ccl-MIR396; +MI0013305 csi-MIR398;csi-MIR398a; +MI0013306 ctr-MIR164; +MI0013307 ctr-MIR167; +MI0013308 ctr-MIR171; +MI0013309 ccl-MIR167b; +MI0013310 crt-MIR166a; +MI0013311 crt-MIR166b; +MI0013312 crt-MIR168; +MI0013313 crt-MIR171; +MI0013314 csi-MIR162; +MI0013315 csi-MIR166a; +MI0013316 csi-MIR166b; +MI0013317 csi-MIR390;csi-MIR390a; +MI0013318 bma-bantam;bma-mir-81; +MI0013319 bma-let-7; +MI0013320 bma-lin-4; +MI0013321 bma-mir-2a; +MI0013322 bma-mir-2b-1; +MI0013323 bma-mir-2b-2; +MI0013324 bma-mir-2c; +MI0013325 bma-mir-7; +MI0013326 bma-mir-9; +MI0013327 bma-mir-34; +MI0013328 bma-mir-36a;bma-mir-36c; +MI0013329 bma-mir-36b; +MI0013330 bma-mir-50; +MI0013331 bma-mir-57; +MI0013332 bma-mir-71; +MI0013333 bma-mir-72; +MI0013334 bma-mir-79; +MI0013335 bma-mir-87a; +MI0013336 bma-mir-87b; +MI0013337 bma-mir-92; +MI0013338 bma-mir-100a; +MI0013339 bma-mir-100b; +MI0013340 bma-mir-100c; +MI0013341 bma-mir-100d; +MI0013342 bma-mir-124; +MI0013343 bma-mir-133; +MI0013344 bma-mir-137;bma-mir-234; +MI0013345 bma-mir-153; +MI0013346 bma-mir-228; +MI0013347 bma-mir-236;bma-mir-236-1; +MI0013348 bma-mir-279; +MI0013349 bma-mir-281; +MI0013350 osa-MIR395x; +MI0013351 osa-MIR395y; +MI0013352 api-mir-137; +MI0013353 api-mir-190; +MI0013354 api-mir-10; +MI0013355 api-mir-iab-4; +MI0013356 api-bantam; +MI0013357 api-mir-1923; +MI0013358 api-mir-184;api-mir-184a; +MI0013359 api-mir-276; +MI0013360 api-mir-281; +MI0013361 api-mir-993; +MI0013362 ath-MIR2933a; +MI0013363 ath-MIR2933b; +MI0013364 ath-MIR2934; +MI0013365 ath-MIR2935; +MI0013366 ath-MIR2936; +MI0013367 ath-MIR2937; +MI0013368 ath-MIR2938; +MI0013369 ath-MIR2939; +MI0013370 rco-MIR156a; +MI0013371 rco-MIR156b; +MI0013372 rco-MIR156c; +MI0013373 rco-MIR156d; +MI0013374 rco-MIR156e; +MI0013375 rco-MIR156f; +MI0013376 rco-MIR156g; +MI0013377 rco-MIR156h; +MI0013378 rco-MIR159; +MI0013379 rco-MIR160a; +MI0013380 rco-MIR160b; +MI0013381 rco-MIR162; +MI0013382 rco-MIR164a; +MI0013383 rco-MIR164b; +MI0013384 rco-MIR164c; +MI0013385 rco-MIR164d; +MI0013386 rco-MIR166a; +MI0013387 rco-MIR166b; +MI0013388 rco-MIR166c; +MI0013389 rco-MIR166d; +MI0013390 rco-MIR166e; +MI0013391 rco-MIR167a; +MI0013392 rco-MIR167b; +MI0013393 rco-MIR167c; +MI0013394 rco-MIR168; +MI0013395 rco-MIR169a; +MI0013396 rco-MIR169b; +MI0013397 rco-MIR169c; +MI0013398 rco-MIR171a; +MI0013399 rco-MIR171b; +MI0013400 rco-MIR171c; +MI0013401 rco-MIR171d; +MI0013402 rco-MIR171e; +MI0013403 rco-MIR171f; +MI0013404 rco-MIR171g; +MI0013405 rco-MIR172; +MI0013406 rco-MIR319a; +MI0013407 rco-MIR319b; +MI0013408 rco-MIR319c; +MI0013409 rco-MIR319d; +MI0013410 rco-MIR390a; +MI0013411 rco-MIR390b; +MI0013412 rco-MIR393; +MI0013413 rco-MIR395a; +MI0013414 rco-MIR395b; +MI0013415 rco-MIR395c; +MI0013416 rco-MIR395d; +MI0013417 rco-MIR395e; +MI0013418 rco-MIR396; +MI0013419 rco-MIR397; +MI0013420 rco-MIR398a; +MI0013421 rco-MIR398b; +MI0013422 rco-MIR399a; +MI0013423 rco-MIR399b; +MI0013424 rco-MIR399c; +MI0013425 rco-MIR399d; +MI0013426 rco-MIR399e; +MI0013427 rco-MIR399f; +MI0013428 rco-MIR403a; +MI0013429 rco-MIR403b; +MI0013430 rco-MIR408; +MI0013431 rco-MIR535; +MI0013432 rco-MIR160c; +MI0013433 aae-mir-184; +MI0013434 aae-mir-275; +MI0013435 aae-mir-277; +MI0013436 aae-mir-9;aae-mir-9c; +MI0013437 aae-mir-8; +MI0013438 aae-mir-252; +MI0013439 aae-bantam; +MI0013440 aae-mir-71; +MI0013441 aae-mir-276-1; +MI0013442 aae-mir-317-1; +MI0013443 aae-mir-2a; +MI0013444 aae-mir-998; +MI0013445 aae-mir-92a; +MI0013446 aae-mir-306; +MI0013447 aae-mir-281; +MI0013448 aae-mir-1889; +MI0013449 aae-mir-980; +MI0013450 aae-mir-278; +MI0013451 aae-mir-989; +MI0013452 aae-mir-14; +MI0013453 aae-mir-11; +MI0013454 aae-mir-190; +MI0013455 aae-mir-1; +MI0013456 aae-mir-34; +MI0013457 aae-mir-1890; +MI0013458 aae-mir-957; +MI0013459 aae-mir-305; +MI0013460 aae-mir-996; +MI0013461 aae-mir-87; +MI0013462 aae-mir-12; +MI0013463 aae-mir-13; +MI0013464 aae-mir-999; +MI0013465 aae-mir-125; +MI0013466 aae-mir-308; +MI0013467 aae-mir-315; +MI0013468 aae-mir-1891-1; +MI0013469 aae-mir-1891-2; +MI0013470 aae-mir-1175; +MI0013471 aae-mir-1174; +MI0013472 aae-mir-993; +MI0013473 aae-mir-981; +MI0013474 aae-mir-965; +MI0013475 aae-mir-932; +MI0013476 aae-mir-927; +MI0013477 aae-mir-309a-1; +MI0013478 aae-mir-309a-2; +MI0013479 aae-mir-285; +MI0013480 aae-mir-137-1; +MI0013481 aae-mir-137-2; +MI0013482 aae-mir-133; +MI0013483 aae-mir-31; +MI0013484 aae-mir-10; +MI0013485 aae-mir-iab-4-1; +MI0013486 aae-mir-283; +MI0013487 aae-mir-988; +MI0013488 aae-mir-124; +MI0013489 aae-mir-2940; +MI0013490 aae-mir-2765; +MI0013491 aae-mir-2941-1; +MI0013492 aae-mir-2941-2; +MI0013493 aae-mir-33; +MI0013494 aae-mir-279; +MI0013495 aae-mir-263a; +MI0013496 aae-mir-7; +MI0013497 aae-mir-100; +MI0013498 aae-mir-970; +MI0013499 aae-mir-210; +MI0013500 aae-mir-79; +MI0013501 aae-mir-307; +MI0013502 aae-mir-1000-1; +MI0013503 aae-mir-1000-2; +MI0013504 aae-mir-375; +MI0013505 aae-let-7; +MI0013506 aae-mir-2942; +MI0013507 aae-mir-2943-1; +MI0013508 aae-mir-2943-2; +MI0013509 aae-mir-2944a; +MI0013510 aae-mir-2944b; +MI0013511 aae-mir-193; +MI0013512 aae-mir-2b; +MI0013513 aae-mir-219; +MI0013514 aae-mir-2c; +MI0013515 aae-mir-263b; +MI0013516 aae-mir-276-2; +MI0013517 aae-mir-282-1; +MI0013518 aae-mir-282-2; +MI0013519 aae-mir-286b-1; +MI0013520 aae-mir-286b-2; +MI0013521 aae-mir-286a; +MI0013522 aae-mir-2945; +MI0013523 aae-mir-316; +MI0013524 aae-mir-317-2; +MI0013526 aae-mir-309b; +MI0013527 aae-mir-92b; +MI0013528 aae-mir-9a-1; +MI0013529 aae-mir-9a-2; +MI0013530 aae-mir-9b; +MI0013531 aae-mir-iab-4-2; +MI0013532 aae-mir-2946; +MI0013533 bmo-mir-1000; +MI0013534 bmo-mir-iab-4as;bmo-mir-iab-8; +MI0013535 gra-MIR398; +MI0013536 gra-MIR482; +MI0013537 gar-MIR2947; +MI0013538 ghr-MIR164; +MI0013539 ghr-MIR167;ghr-MIR167a; +MI0013540 ghr-MIR172; +MI0013541 ghr-MIR393; +MI0013542 ghr-MIR394b; +MI0013543 ghr-MIR394a; +MI0013544 ghr-MIR398; +MI0013545 ghr-MIR479; +MI0013546 ghr-MIR482a; +MI0013547 ghr-MIR482b; +MI0013548 ghr-MIR827a; +MI0013549 ghr-MIR827b; +MI0013550 ghr-MIR827c; +MI0013551 ghr-MIR2948; +MI0013552 ghr-MIR2949a; +MI0013553 ghr-MIR2949b; +MI0013554 ghr-MIR2949c; +MI0013555 ghr-MIR2950; +MI0013556 ghr-MIR399c; +MI0013557 ghr-MIR399d; +MI0013558 hsv2-mir-H7; +MI0013559 hsv2-mir-H9; +MI0013560 hsv2-miR-H10; +MI0013561 cqu-mir-1174; +MI0013562 cqu-mir-125; +MI0013563 cqu-mir-iab-4; +MI0013564 cqu-mir-281;cqu-mir-281-1; +MI0013565 cqu-mir-124; +MI0013566 cqu-mir-1; +MI0013567 cqu-mir-988; +MI0013568 cqu-mir-275; +MI0013569 cqu-mir-315; +MI0013570 cqu-let-7; +MI0013571 cqu-mir-13; +MI0013572 cqu-mir-957; +MI0013573 cqu-mir-999; +MI0013574 cqu-mir-277; +MI0013575 cqu-mir-965; +MI0013576 cqu-mir-252;cqu-mir-252-1; +MI0013577 cqu-mir-993; +MI0013578 cqu-mir-278; +MI0013579 cqu-mir-970; +MI0013580 cqu-mir-283; +MI0013581 cqu-mir-9; +MI0013582 cqu-mir-305; +MI0013583 cqu-mir-317;cqu-mir-317-1; +MI0013584 cqu-mir-981; +MI0013585 cqu-mir-100; +MI0013586 cqu-mir-989; +MI0013587 cqu-mir-1175; +MI0013588 cqu-mir-276-1; +MI0013589 cqu-mir-276-2; +MI0013590 cqu-mir-276-3; +MI0013591 cqu-mir-12; +MI0013592 cqu-mir-210; +MI0013593 cqu-mir-263; +MI0013594 cqu-mir-92-1;cqu-mir-92; +MI0013595 cqu-mir-92-2; +MI0013596 cqu-mir-71; +MI0013597 cqu-mir-190-2; +MI0013598 cqu-mir-190-1; +MI0013599 cqu-mir-1000; +MI0013600 cqu-mir-10; +MI0013601 cqu-mir-11; +MI0013602 cqu-mir-8; +MI0013603 cqu-mir-285; +MI0013604 cqu-mir-2; +MI0013605 cqu-mir-137; +MI0013606 cqu-mir-932; +MI0013607 cqu-mir-14; +MI0013608 cqu-mir-279; +MI0013609 cqu-mir-996; +MI0013610 cqu-bantam; +MI0013611 cqu-mir-1891; +MI0013612 cqu-mir-7; +MI0013613 cqu-mir-184; +MI0013614 cqu-mir-31; +MI0013615 cqu-mir-1890-1;cqu-mir-1890; +MI0013616 cqu-mir-1890-2; +MI0013617 cqu-mir-980; +MI0013618 cqu-mir-308; +MI0013619 cqu-mir-79; +MI0013620 cqu-mir-33; +MI0013621 cqu-mir-2951; +MI0013622 cqu-mir-2941-1; +MI0013623 cqu-mir-2941-2; +MI0013624 cqu-mir-2952; +MI0013625 cqu-mir-133; +MI0013626 cqu-mir-306; +MI0013627 cqu-mir-87; +MI0013628 cqu-mir-1889; +MI0013629 cqu-mir-316; +MI0013630 cqu-mir-375;cqu-mir-375-1; +MI0013631 cqu-mir-309; +MI0013632 cqu-mir-998; +MI0013633 cel-mir-2953; +MI0013634 gga-mir-2954; +MI0013635 tgu-mir-1329; +MI0013636 tgu-mir-2955; +MI0013637 tgu-mir-1451; +MI0013638 tgu-mir-1677; +MI0013639 tgu-mir-1805; +MI0013640 tgu-mir-2956-1; +MI0013641 tgu-mir-2956-2; +MI0013642 tgu-mir-2957;tgu-mir-148b; +MI0013643 tgu-mir-2958; +MI0013644 tgu-mir-1784; +MI0013645 tgu-mir-2959; +MI0013646 tgu-mir-1662; +MI0013647 tgu-mir-2960; +MI0013648 tgu-mir-2961; +MI0013649 tgu-mir-2962; +MI0013650 tgu-mir-2963; +MI0013651 tgu-mir-2964;tgu-mir-219b; +MI0013652 tgu-mir-146a; +MI0013653 tgu-mir-458; +MI0013654 tgu-mir-1729; +MI0013655 tgu-mir-2965; +MI0013656 tgu-mir-456; +MI0013657 tgu-mir-425; +MI0013658 tgu-mir-1803; +MI0013659 tgu-mir-2966; +MI0013660 tgu-mir-2954; +MI0013661 tgu-mir-2967; +MI0013662 tgu-mir-460b; +MI0013663 tgu-mir-2968; +MI0013664 tgu-mir-2969; +MI0013665 tgu-mir-2970; +MI0013666 tgu-mir-2188; +MI0013667 tgu-mir-2971; +MI0013668 tgu-mir-2972; +MI0013669 tgu-mir-2973; +MI0013670 tgu-mir-2974; +MI0013671 tgu-mir-2975; +MI0013672 tgu-mir-2976-1; +MI0013673 tgu-mir-2976-3; +MI0013674 tgu-mir-2976-2; +MI0013675 tgu-mir-2977; +MI0013676 tgu-mir-2978; +MI0013677 tgu-mir-2979-1; +MI0013678 tgu-mir-2980-1; +MI0013679 tgu-mir-2981; +MI0013680 tgu-mir-2982; +MI0013681 tgu-mir-2983; +MI0013682 tgu-mir-2984; +MI0013683 tgu-mir-2985-1; +MI0013684 tgu-mir-2985-2; +MI0013685 tgu-mir-2986; +MI0013686 tgu-mir-2987; +MI0013687 tgu-mir-2988; +MI0013688 tgu-mir-129; +MI0013689 tgu-mir-139; +MI0013690 tgu-mir-363; +MI0013691 tgu-mir-9-2; +MI0013692 tgu-mir-9-1; +MI0013693 tgu-mir-148;tgu-mir-148a; +MI0013694 tgu-let-7i; +MI0013695 tgu-mir-125-1; +MI0013696 tgu-mir-125-2; +MI0013697 tgu-mir-30b; +MI0013698 tgu-mir-124-1; +MI0013699 tgu-mir-124-2; +MI0013700 tgu-mir-124-3; +MI0013701 tgu-mir-101-1; +MI0013702 tgu-mir-101-2; +MI0013703 tgu-let-7b; +MI0013704 tgu-mir-7-1; +MI0013705 tgu-mir-7-2; +MI0013706 tgu-mir-7-3; +MI0013707 tgu-mir-7-4; +MI0013708 tgu-mir-100-1; +MI0013709 tgu-mir-100-2; +MI0013710 tgu-mir-221; +MI0013711 tgu-mir-128-2; +MI0013712 tgu-mir-128-1; +MI0013713 tgu-mir-222-1; +MI0013714 tgu-mir-222-2; +MI0013715 tgu-mir-138-1; +MI0013716 tgu-mir-138-2; +MI0013717 tgu-mir-26-1; +MI0013718 tgu-mir-26-2; +MI0013719 tgu-mir-19b-1; +MI0013720 tgu-mir-19b-2; +MI0013721 tgu-let-7e; +MI0013722 tgu-let-7a-1; +MI0013723 tgu-let-7a-3; +MI0013724 tgu-let-7a-2; +MI0013725 tgu-let-7a-4; +MI0013726 tgu-let-7c-1; +MI0013727 tgu-let-7c-2; +MI0013728 tgu-mir-30c; +MI0013729 tgu-mir-218-1; +MI0013730 tgu-mir-218-2; +MI0013731 tgu-mir-103-1; +MI0013732 tgu-mir-103-2; +MI0013733 tgu-mir-103-3; +MI0013734 tgu-mir-99-1; +MI0013735 tgu-mir-99-2; +MI0013736 tgu-mir-2989-1; +MI0013737 tgu-mir-2989-2; +MI0013738 tgu-mir-1559; +MI0013739 tgu-mir-21; +MI0013740 tgu-let-7g-1; +MI0013741 tgu-let-7g-2; +MI0013742 tgu-mir-122; +MI0013743 tgu-let-7f; +MI0013744 tgu-mir-383; +MI0013745 tgu-mir-29a-1; +MI0013746 tgu-mir-29a-2; +MI0013747 tgu-mir-451; +MI0013748 tgu-mir-27; +MI0013749 tgu-mir-30a; +MI0013750 tgu-let-7d; +MI0013751 tgu-mir-34b; +MI0013752 tgu-mir-33; +MI0013753 tgu-mir-24; +MI0013755 tgu-mir-551; +MI0013756 tgu-mir-338; +MI0013757 tgu-mir-137; +MI0013758 tgu-mir-126; +MI0013759 tgu-mir-200a; +MI0013760 tgu-mir-181a-1; +MI0013761 tgu-mir-181a-2; +MI0013762 tgu-mir-2991; +MI0013763 tgu-mir-490-1; +MI0013764 tgu-mir-490-2; +MI0013765 tgu-mir-2992; +MI0013766 tgu-mir-2993; +MI0013767 tgu-mir-2994; +MI0013768 tgu-mir-153-1; +MI0013769 tgu-mir-153-2; +MI0013770 tgu-mir-20a; +MI0013771 tgu-mir-142; +MI0013772 tgu-mir-15a; +MI0013773 tgu-mir-107; +MI0013774 tgu-mir-140; +MI0013775 tgu-mir-194-1; +MI0013776 tgu-mir-194-2; +MI0013777 tgu-mir-135a-1; +MI0013778 tgu-mir-135b; +MI0013779 tgu-mir-184; +MI0013780 tgu-mir-1-2; +MI0013781 tgu-mir-1-1; +MI0013782 tgu-mir-181b-1; +MI0013783 tgu-mir-181b-2; +MI0013784 tgu-mir-17a; +MI0013785 tgu-mir-202-1; +MI0013786 tgu-mir-202-2; +MI0013787 tgu-mir-23; +MI0013788 tgu-mir-187; +MI0013789 tgu-mir-219;tgu-mir-219a; +MI0013790 tgu-mir-2995; +MI0013791 tgu-mir-204-1; +MI0013792 tgu-mir-204-2; +MI0013793 tgu-mir-204-3; +MI0013794 tgu-mir-204-4; +MI0013795 tgu-mir-133-1; +MI0013796 tgu-mir-133-2; +MI0013797 tgu-mir-133-3; +MI0013798 tgu-mir-375; +MI0013799 tgu-mir-130a; +MI0013800 tgu-mir-92-1; +MI0013801 tgu-mir-92-2; +MI0013802 tgu-mir-199-1; +MI0013803 tgu-mir-216a; +MI0013804 tgu-mir-215; +MI0013805 tgu-mir-130b; +MI0013806 tgu-mir-217; +MI0013807 tgu-mir-454; +MI0013808 tgu-mir-130c; +MI0013809 tgu-mir-365-1; +MI0013810 tgu-mir-365-2; +MI0013811 tgu-mir-16a; +MI0013812 tgu-mir-32; +MI0013813 tgu-mir-193a; +MI0013814 tgu-mir-16c; +MI0013815 tgu-mir-18a; +MI0013816 tgu-mir-16b; +MI0013817 tgu-mir-190; +MI0013818 tgu-mir-106; +MI0013819 tgu-mir-20b; +MI0013820 tgu-mir-200b; +MI0013821 tgu-mir-216b; +MI0013822 tgu-mir-1388; +MI0013823 tgu-mir-301; +MI0013824 tgu-mir-144; +MI0013825 tgu-mir-15b; +MI0013826 tgu-mir-34a; +MI0013827 tgu-mir-223; +MI0013828 tgu-mir-2996-1; +MI0013829 tgu-mir-2996-2; +MI0013830 tgu-mir-29b-1; +MI0013831 tgu-mir-29b-2; +MI0013832 tgu-mir-146b; +MI0013833 tgu-mir-214; +MI0013834 tgu-mir-2997; +MI0013835 tgu-mir-203; +MI0013836 tgu-mir-147; +MI0013837 tgu-mir-18b; +MI0013838 tgu-mir-193b; +MI0013839 tgu-mir-146c; +MI0013840 tgu-mir-455; +MI0013841 tgu-mir-19a; +MI0013842 tgu-mir-155; +MI0013843 tgu-mir-30d; +MI0013844 tgu-mir-460a; +MI0013845 tgu-mir-31; +MI0013846 tgu-mir-205; +MI0013847 tgu-mir-199-2; +MI0013848 tgu-mir-135a-2; +MI0013849 tgu-mir-489; +MI0013850 tgu-mir-15c; +MI0013852 tgu-mir-2979-2; +MI0013853 tgu-mir-2980-2; +MI0013854 bmo-mir-2998; +MI0013855 bmo-mir-2999; +MI0013856 bmo-mir-2733f; +MI0013857 bmo-mir-2733g; +MI0013858 bmo-mir-2733a-2; +MI0013859 bmo-mir-2733h; +MI0013860 bmo-mir-3000; +MI0013861 bmo-mir-3001; +MI0013862 hma-mir-3002; +MI0013863 hma-mir-3003a; +MI0013864 hma-mir-3003b; +MI0013865 hma-mir-3004; +MI0013866 hma-mir-3005; +MI0013867 hma-mir-3006; +MI0013868 hma-mir-3007; +MI0013869 hma-mir-3008; +MI0013870 hma-mir-3009; +MI0013871 hma-mir-3010; +MI0013872 hma-mir-3011; +MI0013873 hma-mir-3012a; +MI0013874 hma-mir-3012b; +MI0013875 hma-mir-3013; +MI0013876 hma-mir-3014; +MI0013877 hma-mir-2030; +MI0013878 api-mir-100; +MI0013885 hsv1-mir-H11; +MI0013886 hsv1-mir-H12; +MI0013887 hsv1-mir-H13; +MI0013888 hsv1-mir-H14; +MI0013889 hsv1-mir-H15; +MI0013890 hsv1-mir-H16; +MI0013891 hsv1-mir-H17; +MI0013892 hsv1-mir-H18; +MI0013898 hsv2-mir-H11; +MI0013899 hsv2-mir-H12; +MI0013900 hsv2-mir-H13; +MI0013901 hsv2-mir-H19; +MI0013902 hsv2-mir-H20; +MI0013903 hsv2-mir-H21; +MI0013904 hsv2-mir-H22; +MI0013905 hsv2-mir-H23; +MI0013906 hsv2-mir-H24; +MI0013907 hsv2-mir-H25; +MI0013908 api-let-7; +MI0013909 api-mir-1; +MI0013910 api-mir-1000; +MI0013911 api-mir-124; +MI0013912 api-mir-13a; +MI0013913 api-mir-14; +MI0013914 api-mir-184b; +MI0013915 api-mir-210-1;api-mir-210; +MI0013916 api-mir-210-2; +MI0013917 api-mir-219; +MI0013918 api-mir-263a; +MI0013919 api-mir-252a; +MI0013920 api-mir-263b; +MI0013921 api-mir-275; +MI0013922 api-mir-277; +MI0013923 api-mir-278; +MI0013924 api-mir-279a; +MI0013925 api-mir-279b; +MI0013926 api-mir-29; +MI0013927 api-mir-2a; +MI0013928 api-mir-2b; +MI0013929 api-mir-2c; +MI0013930 api-mir-307-1;api-mir-307; +MI0013931 api-mir-307-2; +MI0013932 api-mir-315; +MI0013933 api-mir-316; +MI0013934 api-mir-317; +MI0013935 api-mir-34; +MI0013936 api-mir-7; +MI0013937 api-mir-71; +MI0013938 api-mir-981; +MI0013939 api-mir-8; +MI0013940 api-mir-87b; +MI0013941 api-mir-87a; +MI0013942 api-mir-927; +MI0013943 api-mir-929; +MI0013944 api-mir-92a-1; +MI0013945 api-mir-92a-2; +MI0013946 api-mir-92b-1; +MI0013947 api-mir-92b-2; +MI0013948 api-mir-965; +MI0013949 api-mir-971-1;api-mir-971; +MI0013950 api-mir-971-2; +MI0013951 api-mir-996-1;api-mir-996; +MI0013952 api-mir-996-2; +MI0013953 api-mir-998; +MI0013954 api-mir-9a; +MI0013955 api-mir-9b; +MI0013956 api-mir-3015a-1; +MI0013957 api-mir-3015a-2; +MI0013958 api-mir-3016; +MI0013959 api-mir-3017a; +MI0013960 api-mir-3015b; +MI0013961 api-mir-3018; +MI0013962 api-mir-3019; +MI0013963 api-mir-3020; +MI0013964 api-mir-3021;api-mir-3021-1; +MI0013965 api-mir-3022; +MI0013966 api-mir-3023; +MI0013967 api-mir-3024; +MI0013968 api-mir-3025; +MI0013969 api-mir-3026; +MI0013970 api-mir-3027; +MI0013971 api-mir-3028; +MI0013972 api-mir-3029; +MI0013973 api-mir-3030; +MI0013974 api-mir-3031; +MI0013975 api-mir-3032; +MI0013976 api-mir-3033; +MI0013977 api-mir-3034-1;api-mir-3034; +MI0013978 api-mir-3034-2; +MI0013979 api-mir-3035-1; +MI0013980 api-mir-3035-2; +MI0013981 api-mir-252b; +MI0013982 api-mir-3036-1; +MI0013983 api-mir-3036-2; +MI0013984 api-mir-3036-3; +MI0013985 api-mir-3036-4; +MI0013986 api-mir-3036-5; +MI0013987 api-mir-3037; +MI0013988 api-mir-3038; +MI0013989 api-mir-306; +MI0013990 api-mir-3039; +MI0013991 api-mir-3040; +MI0013992 api-mir-3041; +MI0013993 api-mir-3042; +MI0013994 api-mir-3043-1; +MI0013995 api-mir-3043-2; +MI0013996 api-mir-3043-3; +MI0013997 api-mir-3044; +MI0013998 api-mir-3017b-1; +MI0013999 api-mir-3017b-2; +MI0014000 api-mir-3017b-3; +MI0014001 api-mir-3045a; +MI0014002 api-mir-3046; +MI0014003 api-mir-3047-1; +MI0014004 api-mir-3047-2; +MI0014005 api-mir-2765; +MI0014006 api-mir-3048; +MI0014007 api-mir-3049; +MI0014008 api-mir-2796; +MI0014009 api-mir-3050; +MI0014010 api-mir-3051-1; +MI0014011 api-mir-3051-2; +MI0014012 api-mir-3052; +MI0014013 api-mir-3015c-1;api-mir-3015c; +MI0014014 api-mir-3015c-2; +MI0014015 api-mir-3053; +MI0014016 api-mir-3045b; +MI0014017 api-mir-3054; +MI0014018 api-mir-3055;api-mir-3055-1; +MI0014019 api-mir-3056; +MI0014020 mmu-mir-3057; +MI0014021 mmu-mir-1251; +MI0014022 mmu-mir-3060; +MI0014023 mmu-mir-3061; +MI0014024 mmu-mir-3062; +MI0014025 mmu-mir-3063; +MI0014026 mmu-mir-3064; +MI0014027 mmu-mir-3065; +MI0014028 mmu-mir-3066; +MI0014029 mmu-mir-3067; +MI0014030 mmu-mir-3068; +MI0014031 mmu-mir-3069; +MI0014032 mmu-mir-3070a;mmu-mir-3070-1; +MI0014033 mmu-mir-3070b;mmu-mir-3070-2; +MI0014034 mmu-mir-3071; +MI0014035 mmu-mir-3072; +MI0014036 mmu-mir-3073;mmu-mir-3073a; +MI0014037 mmu-mir-3074-1; +MI0014038 mmu-mir-3075; +MI0014039 mmu-mir-3076; +MI0014040 mmu-mir-3077; +MI0014041 mmu-mir-3078; +MI0014042 mmu-mir-3079; +MI0014043 mmu-mir-3080; +MI0014044 mmu-mir-3081; +MI0014045 mmu-mir-3082; +MI0014046 mmu-mir-3083; +MI0014047 mmu-mir-3084;mmu-mir-3084-1; +MI0014048 mmu-mir-3085; +MI0014049 mmu-mir-3086; +MI0014050 mmu-mir-466m; +MI0014051 mmu-mir-669d-2; +MI0014052 mmu-mir-466o; +MI0014053 mmu-mir-467a-2; +MI0014054 mmu-mir-669a-4; +MI0014055 mmu-mir-669a-5; +MI0014056 mmu-mir-467a-3; +MI0014057 mmu-mir-466c-2; +MI0014058 mmu-mir-669a-6; +MI0014059 mmu-mir-467a-4; +MI0014060 mmu-mir-466b-4; +MI0014061 mmu-mir-669a-7; +MI0014062 mmu-mir-467a-5; +MI0014063 mmu-mir-466b-5; +MI0014064 mmu-mir-669p-1; +MI0014065 mmu-mir-467a-6; +MI0014066 mmu-mir-669a-8; +MI0014067 mmu-mir-466b-6; +MI0014068 mmu-mir-669a-9; +MI0014069 mmu-mir-467a-7; +MI0014070 mmu-mir-466b-7; +MI0014071 mmu-mir-669p-2; +MI0014072 mmu-mir-467a-8; +MI0014073 mmu-mir-669a-10; +MI0014074 mmu-mir-467a-9; +MI0014075 mmu-mir-669a-11; +MI0014076 mmu-mir-467a-10; +MI0014077 mmu-mir-669a-12; +MI0014078 mmu-mir-466p; +MI0014079 mmu-mir-466n; +MI0014080 mmu-mir-3087; +MI0014081 mmu-mir-3088; +MI0014082 mmu-mir-3089; +MI0014083 mmu-mir-3090; +MI0014084 mmu-mir-3091; +MI0014085 mmu-mir-3092; +MI0014086 mmu-mir-3093; +MI0014087 mmu-mir-3094; +MI0014088 mmu-mir-3095; +MI0014089 mmu-mir-3096;mmu-mir-3096a; +MI0014090 mmu-mir-3097; +MI0014091 mmu-mir-3098; +MI0014092 mmu-mir-3100; +MI0014093 mmu-mir-3101; +MI0014094 mmu-mir-344e; +MI0014095 mmu-mir-344b; +MI0014096 mmu-mir-344c; +MI0014097 mmu-mir-344g; +MI0014098 mmu-mir-344f; +MI0014099 mmu-mir-3102; +MI0014100 mmu-mir-3103; +MI0014101 mmu-mir-3104; +MI0014102 mmu-mir-3105; +MI0014103 mmu-mir-3107;mmu-mir-486b; +MI0014104 mmu-mir-3074-2; +MI0014105 mmu-mir-3108; +MI0014106 mmu-mir-3109; +MI0014107 mmu-mir-3110; +MI0014108 mmu-mir-374c; +MI0014109 mmu-mir-3112; +MI0014110 mmu-mir-1912; +MI0014111 mmu-mir-3113; +MI0014112 mmu-mir-466b-8; +MI0014113 oar-let-7b; +MI0014114 oar-let-7c; +MI0014116 oar-mir-21; +MI0014117 oar-mir-29a; +MI0014121 oar-mir-125b; +MI0014122 oar-mir-133; +MI0014123 oar-mir-181a-1; +MI0014127 hsa-mir-3115; +MI0014128 hsa-mir-3116-1; +MI0014129 hsa-mir-3116-2; +MI0014130 hsa-mir-3117; +MI0014131 hsa-mir-3118-1; +MI0014132 hsa-mir-3118-2; +MI0014133 hsa-mir-3118-3; +MI0014134 hsa-mir-3119-1; +MI0014135 hsa-mir-3119-2; +MI0014136 hsa-mir-3120; +MI0014137 hsa-mir-3121; +MI0014138 hsa-mir-3122; +MI0014139 hsa-mir-3123; +MI0014140 hsa-mir-3124; +MI0014141 hsa-mir-548s; +MI0014142 hsa-mir-3125; +MI0014143 hsa-mir-3126; +MI0014144 hsa-mir-3127; +MI0014145 hsa-mir-3128; +MI0014146 hsa-mir-3129; +MI0014147 hsa-mir-3130-1; +MI0014148 hsa-mir-3130-2; +MI0014149 hsa-mir-3130-3; +MI0014150 hsa-mir-3130-4; +MI0014151 hsa-mir-3131; +MI0014152 hsa-mir-3132; +MI0014153 hsa-mir-3133; +MI0014154 hsa-mir-378b; +MI0014155 hsa-mir-3134; +MI0014156 hsa-mir-3135;hsa-mir-3135a; +MI0014157 hsa-mir-466; +MI0014158 hsa-mir-3136; +MI0014159 hsa-mir-544b; +MI0014160 hsa-mir-3137; +MI0014161 hsa-mir-3138; +MI0014162 hsa-mir-3139; +MI0014163 hsa-mir-3140; +MI0014164 hsa-mir-548t; +MI0014165 hsa-mir-3141; +MI0014166 hsa-mir-3142; +MI0014167 hsa-mir-3143; +MI0014168 hsa-mir-548u; +MI0014169 hsa-mir-3144; +MI0014170 hsa-mir-3145; +MI0014171 hsa-mir-1273c; +MI0014172 hsa-mir-3146; +MI0014173 hsa-mir-3147; +MI0014174 hsa-mir-548v; +MI0014175 hsa-mir-3148; +MI0014176 hsa-mir-3149; +MI0014177 hsa-mir-3150;hsa-mir-3150a; +MI0014178 hsa-mir-3151; +MI0014179 hsa-mir-3152; +MI0014180 hsa-mir-3153; +MI0014181 hsa-mir-3074; +MI0014182 hsa-mir-3154; +MI0014183 hsa-mir-3155;hsa-mir-3155a; +MI0014184 hsa-mir-3156-1; +MI0014185 hsa-mir-3157; +MI0014186 hsa-mir-3158-1; +MI0014187 hsa-mir-3158-2; +MI0014188 hsa-mir-3159; +MI0014189 hsa-mir-3160-1; +MI0014190 hsa-mir-3160-2; +MI0014191 hsa-mir-3161; +MI0014192 hsa-mir-3162; +MI0014193 hsa-mir-3163; +MI0014194 hsa-mir-3164; +MI0014195 hsa-mir-3165; +MI0014196 hsa-mir-3166; +MI0014197 hsa-mir-1260b; +MI0014198 hsa-mir-3167; +MI0014199 hsa-mir-3168; +MI0014200 hsa-mir-3169; +MI0014201 hsa-mir-3170; +MI0014202 hsa-mir-3171; +MI0014203 hsa-mir-3172; +MI0014204 hsa-mir-3173; +MI0014205 hsa-mir-1193; +MI0014206 hsa-mir-323b; +MI0014207 hsa-mir-3118-4; +MI0014208 hsa-mir-3174; +MI0014209 hsa-mir-3175; +MI0014210 hsa-mir-3176; +MI0014211 hsa-mir-3177; +MI0014212 hsa-mir-3178; +MI0014213 hsa-mir-3179-1; +MI0014214 hsa-mir-3180-1; +MI0014215 hsa-mir-3180-2; +MI0014216 hsa-mir-3179-2; +MI0014217 hsa-mir-3180-3; +MI0014221 hsa-mir-3179-3; +MI0014222 hsa-mir-548w; +MI0014223 hsa-mir-3181; +MI0014224 hsa-mir-3182; +MI0014225 hsa-mir-3183; +MI0014226 hsa-mir-3184; +MI0014227 hsa-mir-3185; +MI0014228 hsa-mir-3065; +MI0014229 hsa-mir-3186; +MI0014230 hsa-mir-3156-2; +MI0014231 hsa-mir-3187; +MI0014232 hsa-mir-3188; +MI0014233 hsa-mir-3189; +MI0014234 hsa-mir-320e; +MI0014235 hsa-mir-3190; +MI0014236 hsa-mir-3191; +MI0014237 hsa-mir-3192; +MI0014238 hsa-mir-3193; +MI0014239 hsa-mir-3194; +MI0014240 hsa-mir-3195; +MI0014241 hsa-mir-3196; +MI0014242 hsa-mir-3156-3; +MI0014243 hsa-mir-3118-5; +MI0014244 hsa-mir-548x; +MI0014245 hsa-mir-3197; +MI0014246 hsa-mir-3198;hsa-mir-3198-1; +MI0014247 hsa-mir-3199-1; +MI0014248 hsa-mir-3199-2; +MI0014249 hsa-mir-3200; +MI0014250 hsa-mir-3201; +MI0014251 hsa-mir-514b; +MI0014252 hsa-mir-3202-1; +MI0014253 hsa-mir-3202-2; +MI0014254 hsa-mir-1273d; +MI0014255 bmo-mir-3203; +MI0014256 bmo-mir-3204a; +MI0014257 bmo-mir-3205; +MI0014258 bmo-mir-3206; +MI0014259 bmo-mir-3207; +MI0014260 bmo-mir-2808d; +MI0014261 bmo-mir-3208; +MI0014262 bmo-mir-3209; +MI0014263 bmo-mir-3210; +MI0014264 bmo-mir-3211; +MI0014265 bmo-mir-3212; +MI0014266 bmo-mir-3213; +MI0014267 bmo-mir-3214; +MI0014268 bmo-mir-3215; +MI0014269 bmo-mir-3216; +MI0014270 bmo-mir-3217; +MI0014271 bmo-mir-3218; +MI0014272 bmo-mir-3219; +MI0014273 bmo-mir-3220; +MI0014274 bmo-mir-3221; +MI0014275 bmo-mir-3222; +MI0014276 bmo-mir-3223; +MI0014277 bmo-mir-3224; +MI0014278 bmo-mir-279e; +MI0014279 bmo-mir-3225; +MI0014280 bmo-mir-3226; +MI0014281 bmo-mir-3227; +MI0014282 bmo-mir-3228; +MI0014283 bmo-mir-3229; +MI0014284 bmo-mir-3230; +MI0014285 bmo-mir-3231; +MI0014286 bmo-mir-3232; +MI0014287 bmo-mir-3233; +MI0014288 bmo-mir-3234; +MI0014289 bmo-mir-2808e; +MI0014290 bmo-mir-3235; +MI0014291 bmo-mir-3236; +MI0014292 bmo-mir-3237; +MI0014293 bmo-mir-3238; +MI0014294 bmo-mir-3239; +MI0014296 bmo-mir-3241; +MI0014297 bmo-mir-3242; +MI0014298 bmo-mir-3243; +MI0014299 bmo-mir-3244; +MI0014300 bmo-mir-3245; +MI0014301 bmo-mir-3246; +MI0014302 bmo-mir-3247; +MI0014303 bmo-mir-3248; +MI0014304 bmo-mir-3249; +MI0014305 bmo-mir-3250; +MI0014306 bmo-mir-2807d; +MI0014307 bmo-mir-3251; +MI0014308 bmo-mir-3252; +MI0014309 bmo-mir-3253; +MI0014310 bmo-mir-3254; +MI0014311 bmo-mir-3255; +MI0014312 bmo-mir-3256; +MI0014313 bmo-mir-3257; +MI0014314 bmo-mir-3258; +MI0014315 bmo-mir-3259; +MI0014316 bmo-mir-3260; +MI0014317 bmo-mir-3261; +MI0014318 bmo-mir-3262; +MI0014319 bmo-mir-3263; +MI0014320 bmo-mir-3264; +MI0014321 bmo-mir-3265; +MI0014322 bmo-mir-3266; +MI0014323 bmo-mir-3267a; +MI0014324 bmo-mir-3268; +MI0014325 bmo-mir-3269; +MI0014326 bmo-mir-3270; +MI0014327 bmo-mir-3271; +MI0014328 bmo-mir-3272; +MI0014329 bmo-mir-3273; +MI0014330 bmo-mir-3274; +MI0014331 bmo-mir-3275; +MI0014332 bmo-mir-3276; +MI0014333 bmo-mir-3277; +MI0014334 bmo-mir-3278; +MI0014335 bmo-mir-3279; +MI0014336 bmo-mir-3280; +MI0014337 bmo-mir-3281; +MI0014338 bmo-mir-3267b; +MI0014339 bmo-mir-3282; +MI0014340 bmo-mir-3283; +MI0014341 bmo-mir-3284; +MI0014342 bmo-mir-3285; +MI0014343 bmo-mir-3286; +MI0014344 bmo-mir-3287; +MI0014345 bmo-mir-3288; +MI0014346 bmo-mir-3289; +MI0014347 bmo-mir-3290; +MI0014348 bmo-mir-3291; +MI0014349 bmo-mir-3292; +MI0014350 bmo-mir-3293; +MI0014351 bmo-mir-3294; +MI0014352 bmo-mir-3295; +MI0014353 bmo-mir-3296; +MI0014354 bmo-mir-3297; +MI0014355 bmo-mir-3298; +MI0014356 bmo-mir-3299; +MI0014358 bmo-mir-3301; +MI0014359 bmo-mir-3302; +MI0014360 bmo-mir-3303; +MI0014361 bmo-mir-3304a; +MI0014362 bmo-mir-3305; +MI0014363 bmo-mir-3306; +MI0014364 bmo-mir-3307; +MI0014365 bmo-mir-3308; +MI0014366 bmo-mir-3309; +MI0014367 bmo-mir-3310; +MI0014368 bmo-mir-3311; +MI0014369 bmo-mir-3312; +MI0014372 bmo-mir-3314; +MI0014373 bmo-mir-3315; +MI0014374 bmo-mir-3316; +MI0014375 bmo-mir-3317; +MI0014376 bmo-mir-3318; +MI0014377 bmo-mir-3319; +MI0014379 bmo-mir-3321; +MI0014380 bmo-mir-3322; +MI0014381 bmo-mir-3323; +MI0014382 bmo-mir-3324; +MI0014383 bmo-mir-3325; +MI0014384 bmo-mir-3326; +MI0014385 bmo-mir-3327; +MI0014386 bmo-mir-3328; +MI0014387 bmo-mir-3329; +MI0014388 bmo-mir-3330; +MI0014390 bmo-mir-3332; +MI0014391 bmo-mir-3333; +MI0014392 bmo-mir-3334; +MI0014393 bmo-mir-3335; +MI0014394 bmo-mir-3336; +MI0014395 bmo-mir-3337; +MI0014396 bmo-mir-3338; +MI0014397 bmo-mir-3339; +MI0014398 bmo-mir-3340; +MI0014400 bmo-mir-3342; +MI0014401 bmo-mir-3343; +MI0014402 bmo-mir-3344; +MI0014403 bmo-mir-3345; +MI0014405 bmo-mir-3347a; +MI0014406 bmo-mir-3348; +MI0014408 bmo-mir-3350; +MI0014409 bmo-mir-3351; +MI0014410 bmo-mir-3352; +MI0014411 bmo-mir-3353; +MI0014412 bmo-mir-2733j; +MI0014413 bmo-mir-2733b-2; +MI0014414 bmo-mir-3354; +MI0014415 bmo-mir-3355; +MI0014416 bmo-mir-3356; +MI0014417 bmo-mir-3357; +MI0014418 bmo-mir-3358; +MI0014419 bmo-mir-3359; +MI0014420 bmo-mir-3360; +MI0014421 bmo-mir-3361; +MI0014422 bmo-mir-3362; +MI0014423 bmo-mir-3363; +MI0014424 bmo-mir-3364; +MI0014425 bmo-mir-3365; +MI0014426 bmo-mir-3366; +MI0014427 bmo-mir-3367; +MI0014428 bmo-mir-3368; +MI0014429 bmo-mir-3369; +MI0014430 bmo-mir-3267c; +MI0014431 bmo-mir-3370; +MI0014432 bmo-mir-3371; +MI0014433 bmo-mir-3372; +MI0014434 bmo-mir-3373; +MI0014435 bmo-mir-3374; +MI0014436 bmo-mir-3375; +MI0014438 bmo-mir-3377; +MI0014439 bmo-mir-3378; +MI0014440 bmo-mir-3379; +MI0014442 bmo-mir-3381; +MI0014443 bmo-mir-3382; +MI0014444 bmo-mir-3383; +MI0014445 bmo-mir-3384; +MI0014446 bmo-mir-3385; +MI0014447 bmo-mir-3386; +MI0014448 bmo-mir-3387; +MI0014449 bmo-mir-3388; +MI0014450 bmo-mir-3389; +MI0014452 bmo-mir-2733i; +MI0014453 bmo-mir-2733a-3; +MI0014454 bmo-mir-3391; +MI0014455 bmo-mir-3392; +MI0014456 bmo-mir-3393; +MI0014457 bmo-mir-3394; +MI0014458 bmo-mir-3395; +MI0014459 bmo-mir-3396; +MI0014460 bmo-mir-3397; +MI0014461 bmo-mir-3398; +MI0014462 bmo-mir-3399; +MI0014463 bmo-mir-3400; +MI0014464 bmo-mir-3401; +MI0014465 bmo-mir-3402; +MI0014466 bmo-mir-3403; +MI0014467 bmo-mir-3347b; +MI0014468 bmo-mir-3404; +MI0014469 bmo-mir-3405; +MI0014470 bmo-mir-3406; +MI0014471 bmo-mir-3407; +MI0014472 bmo-mir-3408; +MI0014473 bmo-mir-3409; +MI0014474 bmo-mir-3410; +MI0014475 bmo-mir-3411; +MI0014476 bmo-mir-3412; +MI0014477 bmo-mir-3413; +MI0014478 bmo-mir-3414; +MI0014479 bmo-mir-3415; +MI0014480 bmo-mir-3416; +MI0014481 bmo-mir-3417; +MI0014482 bmo-mir-3418; +MI0014483 bmo-mir-3419; +MI0014484 bmo-mir-989b; +MI0014485 bmo-mir-3420; +MI0014486 bmo-mir-3421; +MI0014487 bmo-mir-3422; +MI0014488 bmo-mir-3423; +MI0014489 bmo-mir-3424; +MI0014490 bmo-mir-3425; +MI0014491 bmo-mir-3426; +MI0014492 bmo-mir-3427; +MI0014493 bmo-mir-3428; +MI0014494 bmo-mir-3429; +MI0014495 bmo-mir-3204b; +MI0014496 bmo-mir-3430; +MI0014497 bta-mir-2284w; +MI0014498 bta-mir-3431; +MI0014499 bta-mir-2284x; +MI0014500 bta-mir-3432-1;bta-mir-3432a-1; +MI0014501 bta-mir-3432-2;bta-mir-3432a-2; +MI0014502 aly-MIR156a; +MI0014503 aly-MIR156b; +MI0014504 aly-MIR156c; +MI0014505 aly-MIR156d; +MI0014506 aly-MIR156e; +MI0014507 aly-MIR156f; +MI0014508 aly-MIR156g; +MI0014509 aly-MIR156h; +MI0014510 aly-MIR157a; +MI0014511 aly-MIR157b; +MI0014512 aly-MIR157c; +MI0014513 aly-MIR157d; +MI0014514 aly-MIR158a; +MI0014515 aly-MIR159a; +MI0014516 aly-MIR159b; +MI0014517 aly-MIR159c; +MI0014518 aly-MIR319a; +MI0014519 aly-MIR319b; +MI0014520 aly-MIR319c; +MI0014521 aly-MIR160a; +MI0014522 aly-MIR160b; +MI0014523 aly-MIR160c; +MI0014524 aly-MIR161; +MI0014525 aly-MIR162a; +MI0014526 aly-MIR162b; +MI0014527 aly-MIR164a; +MI0014528 aly-MIR164b; +MI0014529 aly-MIR164c; +MI0014530 aly-MIR165a; +MI0014531 aly-MIR165b; +MI0014532 aly-MIR166a; +MI0014533 aly-MIR166b; +MI0014534 aly-MIR166c; +MI0014535 aly-MIR166d; +MI0014536 aly-MIR166e; +MI0014537 aly-MIR166f; +MI0014538 aly-MIR166g; +MI0014539 aly-MIR167a; +MI0014540 aly-MIR167b; +MI0014541 aly-MIR167c; +MI0014542 aly-MIR167d; +MI0014543 aly-MIR168a; +MI0014544 aly-MIR168b; +MI0014545 aly-MIR169a; +MI0014546 aly-MIR169b; +MI0014547 aly-MIR169c; +MI0014548 aly-MIR169d; +MI0014549 aly-MIR169e; +MI0014550 aly-MIR169f; +MI0014551 aly-MIR169g; +MI0014552 aly-MIR169h; +MI0014553 aly-MIR169i; +MI0014554 aly-MIR169j; +MI0014555 aly-MIR169k; +MI0014556 aly-MIR169l; +MI0014557 aly-MIR169m; +MI0014558 aly-MIR169n; +MI0014559 aly-MIR170; +MI0014560 aly-MIR171a; +MI0014561 aly-MIR171b; +MI0014562 aly-MIR171c; +MI0014563 aly-MIR172a; +MI0014564 aly-MIR172b; +MI0014565 aly-MIR172c; +MI0014566 aly-MIR172d; +MI0014567 aly-MIR172e; +MI0014568 aly-MIR173;aly-MIR173a; +MI0014569 aly-MIR390a; +MI0014570 aly-MIR390b; +MI0014571 aly-MIR391; +MI0014572 aly-MIR393a; +MI0014573 aly-MIR393b; +MI0014574 aly-MIR394a; +MI0014575 aly-MIR394b; +MI0014576 aly-MIR395b; +MI0014577 aly-MIR395c; +MI0014578 aly-MIR395d; +MI0014579 aly-MIR395e; +MI0014580 aly-MIR395f; +MI0014581 aly-MIR396a; +MI0014582 aly-MIR396b; +MI0014583 aly-MIR397a; +MI0014584 aly-MIR397b; +MI0014585 aly-MIR398a; +MI0014586 aly-MIR398b; +MI0014587 aly-MIR398c; +MI0014588 aly-MIR399a; +MI0014589 aly-MIR399b; +MI0014590 aly-MIR399c; +MI0014591 aly-MIR399d; +MI0014592 aly-MIR399e; +MI0014593 aly-MIR399f; +MI0014594 aly-MIR400; +MI0014595 aly-MIR403;aly-MIR403a; +MI0014596 aly-MIR408; +MI0014597 aly-MIR472; +MI0014598 aly-MIR771; +MI0014599 aly-MIR774;aly-MIR774a; +MI0014600 aly-MIR781; +MI0014601 aly-MIR822; +MI0014602 aly-MIR823; +MI0014603 aly-MIR824; +MI0014604 aly-MIR825; +MI0014605 aly-MIR827; +MI0014606 aly-MIR828; +MI0014607 aly-MIR829; +MI0014608 aly-MIR831; +MI0014609 aly-MIR833; +MI0014610 aly-MIR834; +MI0014611 aly-MIR835; +MI0014612 aly-MIR838; +MI0014613 aly-MIR839; +MI0014614 aly-MIR840; +MI0014615 aly-MIR842; +MI0014616 aly-MIR844; +MI0014617 aly-MIR845a; +MI0014618 aly-MIR845b; +MI0014619 aly-MIR846; +MI0014620 aly-MIR847; +MI0014621 aly-MIR852; +MI0014622 aly-MIR856; +MI0014623 aly-MIR857; +MI0014624 aly-MIR858; +MI0014625 aly-MIR859; +MI0014626 aly-MIR860; +MI0014627 aly-MIR861; +MI0014628 aly-MIR862; +MI0014629 aly-MIR868; +MI0014630 aly-MIR2111a; +MI0014631 aly-MIR2111b; +MI0014632 aly-MIR2112; +MI0014633 aly-MIR319d; +MI0014634 aly-MIR395g; +MI0014635 aly-MIR395h; +MI0014636 aly-MIR399g; +MI0014637 aly-MIR399h; +MI0014638 aly-MIR399i; +MI0014639 aly-MIR158b; +MI0014640 aly-MIR163; +MI0014641 aly-MIR402; +MI0014642 aly-MIR773b; +MI0014643 aly-MIR3433; +MI0014644 aly-MIR837; +MI0014645 aly-MIR848; +MI0014646 aly-MIR851; +MI0014647 aly-MIR853; +MI0014648 aly-MIR869; +MI0014649 aly-MIR3434; +MI0014650 aly-MIR774b; +MI0014651 aly-MIR3435; +MI0014652 aly-MIR3436; +MI0014653 aly-MIR3437; +MI0014654 aly-MIR3438; +MI0014655 aly-MIR3439; +MI0014656 aly-MIR3440; +MI0014657 aly-MIR3441; +MI0014658 aly-MIR3442; +MI0014659 aly-MIR3443; +MI0014660 aly-MIR3444;aly-MIR3444a; +MI0014661 aly-MIR3445; +MI0014662 aly-MIR3446; +MI0014663 aly-MIR3447; +MI0014664 aly-MIR3448; +MI0014665 aly-MIR3449; +MI0014666 ath-MIR773b; +MI0014667 ath-MIR3434; +MI0014668 ath-MIR774b; +MI0014669 ath-MIR841b; +MI0014670 esi-MIR3464; +MI0014671 esi-MIR3454g; +MI0014672 esi-MIR3454a; +MI0014673 esi-MIR3466; +MI0014674 esi-MIR3454c; +MI0014675 esi-MIR3454f; +MI0014676 esi-MIR3455; +MI0014677 esi-MIR3450; +MI0014678 esi-MIR3454b; +MI0014679 esi-MIR3460; +MI0014680 esi-MIR3469; +MI0014681 esi-MIR3461; +MI0014682 esi-MIR3463; +MI0014683 esi-MIR3454e; +MI0014684 esi-MIR3457; +MI0014685 esi-MIR3467; +MI0014686 esi-MIR3459; +MI0014687 esi-MIR3462; +MI0014688 esi-MIR3453; +MI0014689 esi-MIR3451; +MI0014690 esi-MIR3454d; +MI0014691 esi-MIR3456; +MI0014692 esi-MIR3452; +MI0014693 esi-MIR3468; +MI0014694 esi-MIR3465; +MI0014695 esi-MIR3458; +MI0014696 mmu-mir-3470a; +MI0014697 mmu-mir-3470b; +MI0014698 mmu-mir-1937b-2; +MI0014699 mmu-mir-3471-1; +MI0014700 mmu-mir-1937b-3; +MI0014701 mmu-mir-3471-2; +MI0014702 mmu-mir-1937b-4; +MI0014703 mmu-mir-1937b-5; +MI0014704 mmu-mir-3472; +MI0014705 mmu-mir-1186b; +MI0014706 mmu-mir-3473;mmu-mir-3473a; +MI0014707 mmu-mir-3474; +MI0014709 aae-mir-9c; +MI0014710 aae-mir-929-1; +MI0014711 aae-mir-929-2; +MI0014712 bhv1-mir-B10; +MI0014713 hsv2-mir-H5; +MI0014714 hsv2-mir-H6; +MI0014715 ghr-MIR3476; +MI0014716 nvi-mir-14; +MI0014717 nvi-mir-29b; +MI0014718 nvi-mir-33; +MI0014719 nvi-mir-281; +MI0014720 nvi-mir-7; +MI0014721 nvi-mir-137; +MI0014722 nvi-mir-31a; +MI0014723 nvi-mir-71; +MI0014724 nvi-mir-2c; +MI0014725 nvi-mir-13a; +MI0014726 nvi-mir-13b; +MI0014727 nvi-mir-2a; +MI0014728 nvi-mir-2b; +MI0014729 nvi-mir-92a; +MI0014730 nvi-mir-283; +MI0014731 nvi-mir-12; +MI0014732 nvi-mir-184; +MI0014733 nvi-mir-929; +MI0014734 nvi-mir-190; +MI0014735 nvi-mir-iab-4as;nvi-mir-iab-8; +MI0014736 nvi-mir-iab-4; +MI0014737 nvi-mir-10; +MI0014738 nvi-mir-100; +MI0014739 nvi-let-7; +MI0014740 nvi-mir-125; +MI0014741 nvi-mir-2796; +MI0014742 nvi-mir-279; +MI0014743 nvi-mir-34; +MI0014744 nvi-mir-277; +MI0014745 nvi-mir-317; +MI0014746 nvi-mir-275; +MI0014747 nvi-mir-305; +MI0014748 nvi-mir-276; +MI0014749 nvi-mir-124; +MI0014750 nvi-mir-315; +MI0014751 nvi-mir-219; +MI0014752 nvi-mir-133; +MI0014753 nvi-mir-1; +MI0014754 nvi-mir-282; +MI0014755 nvi-mir-307; +MI0014756 nvi-mir-210; +MI0014757 nvi-bantam; +MI0014758 nvi-mir-9a; +MI0014759 nvi-mir-8; +MI0014760 nvi-mir-375; +MI0014761 nvi-mir-927; +MI0014762 nvi-mir-252; +MI0014763 nvi-mir-932; +MI0014764 nvi-mir-263b; +MI0014765 nvi-mir-993; +MI0014766 nvi-mir-928; +MI0014767 nvi-mir-3477; +MI0014768 nvi-mir-3478; +MI0014769 ssc-mir-744; +MI0014770 ssc-mir-22; +MI0014771 ssc-mir-363;ssc-mir-363-1; +MI0014772 ssc-mir-299; +MI0014773 ssc-mir-338; +MI0014774 ssc-mir-369; +MI0014775 ssc-mir-376a; +MI0014776 ssc-mir-450c; +MI0014777 ssc-mir-758; +MI0014778 ppy-mir-1-1; +MI0014779 ppy-let-7a-1; +MI0014780 ppy-let-7a-2; +MI0014781 ppy-let-7a-3; +MI0014782 ppy-let-7b; +MI0014783 ppy-let-7c; +MI0014784 ppy-let-7d; +MI0014785 ppy-let-7e; +MI0014786 ppy-let-7f-1; +MI0014787 ppy-let-7f-2; +MI0014788 ppy-let-7g; +MI0014789 ppy-let-7i; +MI0014790 ppy-mir-7-3; +MI0014791 ppy-mir-9-1; +MI0014792 ppy-mir-9-2; +MI0014793 ppy-mir-9-3; +MI0014794 ppy-mir-10b; +MI0014795 ppy-mir-16-2; +MI0014796 ppy-mir-18b; +MI0014797 ppy-mir-20b; +MI0014798 ppy-mir-26a-2; +MI0014799 ppy-mir-26b; +MI0014800 ppy-mir-27b; +MI0014801 ppy-mir-29c; +MI0014802 ppy-mir-30b; +MI0014803 ppy-mir-30c-1; +MI0014804 ppy-mir-30d; +MI0014805 ppy-mir-30e; +MI0014806 ppy-mir-33b; +MI0014807 ppy-mir-34b; +MI0014808 ppy-mir-34c; +MI0014809 ppy-mir-92b; +MI0014810 ppy-mir-96; +MI0014811 ppy-mir-101-1; +MI0014812 ppy-mir-101-2; +MI0014813 ppy-mir-103-2; +MI0014814 ppy-mir-105-2; +MI0014815 ppy-mir-122; +MI0014816 ppy-mir-124-2; +MI0014817 ppy-mir-125a; +MI0014818 ppy-mir-126; +MI0014819 ppy-mir-128-2; +MI0014820 ppy-mir-129-1; +MI0014821 ppy-mir-129-2; +MI0014822 ppy-mir-130a; +MI0014823 ppy-mir-130b; +MI0014824 ppy-mir-132; +MI0014825 ppy-mir-133c; +MI0014826 ppy-mir-133b; +MI0014827 ppy-mir-135a-1; +MI0014828 ppy-mir-135b; +MI0014829 ppy-mir-137; +MI0014830 ppy-mir-138-2; +MI0014831 ppy-mir-139; +MI0014832 ppy-mir-140; +MI0014833 ppy-mir-142; +MI0014834 ppy-mir-146a; +MI0014835 ppy-mir-146b; +MI0014836 ppy-mir-147b; +MI0014837 ppy-mir-148a; +MI0014838 ppy-mir-148b; +MI0014839 ppy-mir-149; +MI0014840 ppy-mir-150; +MI0014841 ppy-mir-151;ppy-mir-151a; +MI0014842 ppy-mir-153-2; +MI0014843 ppy-mir-155; +MI0014844 ppy-mir-181a-2; +MI0014845 ppy-mir-181b-2; +MI0014846 ppy-mir-181c; +MI0014847 ppy-mir-181d; +MI0014848 ppy-mir-183; +MI0014849 ppy-mir-185; +MI0014850 ppy-mir-186; +MI0014851 ppy-mir-190;ppy-mir-190a; +MI0014852 ppy-mir-190b; +MI0014853 ppy-mir-191; +MI0014854 ppy-mir-192; +MI0014855 ppy-mir-193a; +MI0014856 ppy-mir-193b; +MI0014857 ppy-mir-195; +MI0014858 ppy-mir-196b; +MI0014859 ppy-mir-199a-2; +MI0014860 ppy-mir-199b; +MI0014861 ppy-mir-200a; +MI0014862 ppy-mir-203; +MI0014863 ppy-mir-205; +MI0014864 ppy-mir-208a; +MI0014865 ppy-mir-208b; +MI0014866 ppy-mir-210; +MI0014867 ppy-mir-216b; +MI0014868 ppy-mir-217; +MI0014869 ppy-mir-219-2; +MI0014870 ppy-mir-220a; +MI0014871 ppy-mir-220b; +MI0014872 ppy-mir-220c; +MI0014873 ppy-mir-222; +MI0014874 ppy-mir-296; +MI0014875 ppy-mir-297; +MI0014876 ppy-mir-298; +MI0014877 ppy-mir-299; +MI0014878 ppy-mir-300; +MI0014879 ppy-mir-301b; +MI0014880 ppy-mir-302b; +MI0014881 ppy-mir-302c; +MI0014882 ppy-mir-302d; +MI0014883 ppy-mir-302e; +MI0014884 ppy-mir-320a; +MI0014885 ppy-mir-320b-1; +MI0014886 ppy-mir-320b-2; +MI0014887 ppy-mir-320c-1; +MI0014888 ppy-mir-320c-2; +MI0014889 ppy-mir-320d-1; +MI0014890 ppy-mir-320d-2; +MI0014891 ppy-mir-323; +MI0014892 ppy-mir-324; +MI0014893 ppy-mir-325; +MI0014894 ppy-mir-326; +MI0014895 ppy-mir-328; +MI0014896 ppy-mir-329-1; +MI0014897 ppy-mir-329-2; +MI0014898 ppy-mir-330; +MI0014899 ppy-mir-331; +MI0014900 ppy-mir-335; +MI0014901 ppy-mir-337; +MI0014902 ppy-mir-338; +MI0014903 ppy-mir-339; +MI0014904 ppy-mir-340; +MI0014905 ppy-mir-342; +MI0014906 ppy-mir-345; +MI0014907 ppy-mir-346; +MI0014908 ppy-mir-361; +MI0014909 ppy-mir-362; +MI0014910 ppy-mir-363; +MI0014911 ppy-mir-365-1; +MI0014912 ppy-mir-365-2; +MI0014913 ppy-mir-367; +MI0014914 ppy-mir-369; +MI0014915 ppy-mir-370; +MI0014916 ppy-mir-371; +MI0014917 ppy-mir-372; +MI0014918 ppy-mir-373; +MI0014919 ppy-mir-374a; +MI0014920 ppy-mir-375; +MI0014921 ppy-mir-376a-1; +MI0014922 ppy-mir-376a-2; +MI0014923 ppy-mir-376b; +MI0014924 ppy-mir-376c; +MI0014925 ppy-mir-377; +MI0014926 ppy-mir-378;ppy-mir-378a; +MI0014927 ppy-mir-379; +MI0014928 ppy-mir-380; +MI0014929 ppy-mir-381; +MI0014930 ppy-mir-382; +MI0014931 ppy-mir-383; +MI0014932 ppy-mir-384; +MI0014933 ppy-mir-409; +MI0014934 ppy-mir-410; +MI0014935 ppy-mir-411; +MI0014936 ppy-mir-412; +MI0014937 ppy-mir-421; +MI0014938 ppy-mir-422a; +MI0014939 ppy-mir-423; +MI0014940 ppy-mir-424; +MI0014941 ppy-mir-425; +MI0014942 ppy-mir-429; +MI0014943 ppy-mir-431; +MI0014944 ppy-mir-432; +MI0014945 ppy-mir-433; +MI0014946 ppy-mir-448; +MI0014947 ppy-mir-449a; +MI0014948 ppy-mir-449b; +MI0014949 ppy-mir-450a-1; +MI0014950 ppy-mir-450a-2; +MI0014951 ppy-mir-450b; +MI0014952 ppy-mir-451; +MI0014953 ppy-mir-452; +MI0014954 ppy-mir-453; +MI0014955 ppy-mir-455; +MI0014956 ppy-mir-484; +MI0014957 ppy-mir-485; +MI0014958 ppy-mir-486; +MI0014959 ppy-mir-487a; +MI0014960 ppy-mir-487b; +MI0014961 ppy-mir-488; +MI0014962 ppy-mir-489; +MI0014963 ppy-mir-490; +MI0014964 ppy-mir-491; +MI0014965 ppy-mir-492; +MI0014966 ppy-mir-493; +MI0014967 ppy-mir-494; +MI0014968 ppy-mir-495; +MI0014969 ppy-mir-496; +MI0014970 ppy-mir-497; +MI0014971 ppy-mir-498; +MI0014972 ppy-mir-499; +MI0014973 ppy-mir-500; +MI0014974 ppy-mir-501; +MI0014975 ppy-mir-502; +MI0014976 ppy-mir-503; +MI0014977 ppy-mir-504; +MI0014978 ppy-mir-505; +MI0014979 ppy-mir-506; +MI0014980 ppy-mir-507; +MI0014981 ppy-mir-508; +MI0014982 ppy-mir-509-1;ppy-mir-509; +MI0014983 ppy-mir-509-2; +MI0014984 ppy-mir-509-3; +MI0014985 ppy-mir-510; +MI0014986 ppy-mir-511-1;ppy-mir-511; +MI0014987 ppy-mir-511-2; +MI0014988 ppy-mir-512-1; +MI0014989 ppy-mir-512-2; +MI0014990 ppy-mir-513a-1; +MI0014991 ppy-mir-513a-2; +MI0014992 ppy-mir-513b; +MI0014993 ppy-mir-513c; +MI0014994 ppy-mir-514-1;ppy-mir-514; +MI0014995 ppy-mir-514-2; +MI0014996 ppy-mir-514-3; +MI0014997 ppy-mir-515-1; +MI0014998 ppy-mir-515-2; +MI0014999 ppy-mir-516a-1; +MI0015000 ppy-mir-516a-2; +MI0015001 ppy-mir-516b-1; +MI0015002 ppy-mir-516b-2; +MI0015003 ppy-mir-517a; +MI0015004 ppy-mir-517b; +MI0015005 ppy-mir-517c; +MI0015006 ppy-mir-518a-1; +MI0015007 ppy-mir-518a-2; +MI0015008 ppy-mir-518b; +MI0015009 ppy-mir-518c; +MI0015010 ppy-mir-518d; +MI0015011 ppy-mir-518e;ppy-mir-518f-2; +MI0015012 ppy-mir-518f;ppy-mir-518f-1; +MI0015013 ppy-mir-519a;ppy-mir-519b; +MI0015014 ppy-mir-519f;ppy-mir-519a; +MI0015015 ppy-mir-519b; +MI0015016 ppy-mir-519c; +MI0015017 ppy-mir-519d; +MI0015018 ppy-mir-519e; +MI0015019 ppy-mir-520a; +MI0015020 ppy-mir-520b; +MI0015021 ppy-mir-520c; +MI0015022 ppy-mir-520d; +MI0015023 ppy-mir-520e; +MI0015024 ppy-mir-520f; +MI0015025 ppy-mir-520g; +MI0015026 ppy-mir-520h; +MI0015027 ppy-mir-521-1; +MI0015028 ppy-mir-521-2; +MI0015029 ppy-mir-522; +MI0015030 ppy-mir-523; +MI0015031 ppy-mir-524; +MI0015032 ppy-mir-525; +MI0015033 ppy-mir-526a-1; +MI0015034 ppy-mir-526a-2;ppy-mir-526a; +MI0015035 ppy-mir-526b; +MI0015036 ppy-mir-527; +MI0015037 ppy-mir-532; +MI0015038 ppy-mir-539; +MI0015039 ppy-mir-541; +MI0015040 ppy-mir-542; +MI0015041 ppy-mir-543; +MI0015042 ppy-mir-544; +MI0015043 ppy-mir-545; +MI0015044 ppy-mir-549; +MI0015045 ppy-mir-551a; +MI0015046 ppy-mir-551b; +MI0015047 ppy-mir-553; +MI0015048 ppy-mir-554; +MI0015049 ppy-mir-555; +MI0015050 ppy-mir-556; +MI0015051 ppy-mir-557; +MI0015052 ppy-mir-558; +MI0015053 ppy-mir-559; +MI0015054 ppy-mir-562; +MI0015055 ppy-mir-563; +MI0015056 ppy-mir-564; +MI0015057 ppy-mir-566; +MI0015058 ppy-mir-567; +MI0015059 ppy-mir-568; +MI0015060 ppy-mir-569; +MI0015061 ppy-mir-571; +MI0015062 ppy-mir-573; +MI0015063 ppy-mir-575; +MI0015064 ppy-mir-576; +MI0015065 ppy-mir-577; +MI0015066 ppy-mir-578; +MI0015067 ppy-mir-579; +MI0015068 ppy-mir-580; +MI0015069 ppy-mir-581; +MI0015070 ppy-mir-582; +MI0015071 ppy-mir-583; +MI0015072 ppy-mir-584; +MI0015073 ppy-mir-586; +MI0015074 ppy-mir-587; +MI0015075 ppy-mir-588; +MI0015076 ppy-mir-589; +MI0015077 ppy-mir-590; +MI0015078 ppy-mir-591; +MI0015079 ppy-mir-592; +MI0015080 ppy-mir-593; +MI0015081 ppy-mir-595; +MI0015082 ppy-mir-596; +MI0015083 ppy-mir-597; +MI0015084 ppy-mir-598; +MI0015085 ppy-mir-599; +MI0015086 ppy-mir-600; +MI0015087 ppy-mir-601; +MI0015088 ppy-mir-602; +MI0015089 ppy-mir-603; +MI0015090 ppy-mir-604; +MI0015091 ppy-mir-605; +MI0015092 ppy-mir-606; +MI0015093 ppy-mir-608; +MI0015094 ppy-mir-609; +MI0015095 ppy-mir-610; +MI0015096 ppy-mir-611; +MI0015097 ppy-mir-612; +MI0015098 ppy-mir-613; +MI0015099 ppy-mir-614; +MI0015100 ppy-mir-615; +MI0015101 ppy-mir-616; +MI0015102 ppy-mir-617; +MI0015103 ppy-mir-618; +MI0015104 ppy-mir-619; +MI0015105 ppy-mir-621; +MI0015106 ppy-mir-622; +MI0015107 ppy-mir-623; +MI0015108 ppy-mir-624; +MI0015109 ppy-mir-626; +MI0015110 ppy-mir-628; +MI0015111 ppy-mir-630; +MI0015112 ppy-mir-631; +MI0015113 ppy-mir-632; +MI0015114 ppy-mir-633; +MI0015115 ppy-mir-634; +MI0015116 ppy-mir-636; +MI0015117 ppy-mir-637; +MI0015118 ppy-mir-638; +MI0015119 ppy-mir-639; +MI0015120 ppy-mir-640; +MI0015121 ppy-mir-645; +MI0015122 ppy-mir-646; +MI0015123 ppy-mir-647; +MI0015124 ppy-mir-648; +MI0015125 ppy-mir-650; +MI0015126 ppy-mir-651; +MI0015127 ppy-mir-652; +MI0015128 ppy-mir-653; +MI0015129 ppy-mir-654; +MI0015130 ppy-mir-655; +MI0015131 ppy-mir-656; +MI0015132 ppy-mir-658; +MI0015133 ppy-mir-660; +MI0015134 ppy-mir-663b; +MI0015135 ppy-mir-664; +MI0015136 ppy-mir-668; +MI0015137 ppy-mir-671; +MI0015138 ppy-mir-675a; +MI0015139 ppy-mir-675b; +MI0015140 ppy-mir-708; +MI0015141 ppy-mir-720; +MI0015142 ppy-mir-744; +MI0015143 ppy-mir-758; +MI0015144 ppy-mir-760; +MI0015145 ppy-mir-765; +MI0015146 ppy-mir-766; +MI0015147 ppy-mir-767; +MI0015148 ppy-mir-770; +MI0015149 ppy-mir-802; +MI0015150 ppy-mir-873; +MI0015151 ppy-mir-874; +MI0015152 ppy-mir-875; +MI0015153 ppy-mir-876; +MI0015154 ppy-mir-877; +MI0015155 ppy-mir-885; +MI0015156 ppy-mir-886; +MI0015157 ppy-mir-887; +MI0015158 ppy-mir-888; +MI0015159 ppy-mir-889; +MI0015160 ppy-mir-890; +MI0015161 ppy-mir-891a; +MI0015162 ppy-mir-891b; +MI0015163 ppy-mir-892a; +MI0015164 ppy-mir-892b; +MI0015165 ppy-mir-920; +MI0015166 ppy-mir-921; +MI0015167 ppy-mir-922; +MI0015168 ppy-mir-924; +MI0015169 ppy-mir-933; +MI0015170 ppy-mir-934; +MI0015171 ppy-mir-936; +MI0015172 ppy-mir-937; +MI0015173 ppy-mir-938; +MI0015174 ppy-mir-939; +MI0015175 ppy-mir-942; +MI0015176 ppy-mir-943; +MI0015177 ppy-mir-944; +MI0015178 ppy-mir-1178; +MI0015179 ppy-mir-1179; +MI0015180 ppy-mir-1180; +MI0015181 ppy-mir-1181; +MI0015182 ppy-mir-1183; +MI0015183 ppy-mir-1185-1; +MI0015184 ppy-mir-1185-2; +MI0015185 ppy-mir-1197; +MI0015186 ppy-mir-1200; +MI0015187 ppy-mir-1201; +MI0015188 ppy-mir-1202; +MI0015189 ppy-mir-1204; +MI0015190 ppy-mir-1205; +MI0015191 ppy-mir-1207; +MI0015192 ppy-mir-1208; +MI0015193 ppy-mir-1224; +MI0015194 ppy-mir-1225; +MI0015195 ppy-mir-1226; +MI0015196 ppy-mir-1227; +MI0015197 ppy-mir-1228; +MI0015198 ppy-mir-1233; +MI0015199 ppy-mir-1236; +MI0015200 ppy-mir-1237; +MI0015201 ppy-mir-1238; +MI0015202 ppy-mir-1244; +MI0015203 ppy-mir-1245; +MI0015204 ppy-mir-1246; +MI0015205 ppy-mir-1247; +MI0015206 ppy-mir-1248; +MI0015207 ppy-mir-1249; +MI0015208 ppy-mir-1250; +MI0015209 ppy-mir-1251; +MI0015210 ppy-mir-1252; +MI0015211 ppy-mir-1253; +MI0015212 ppy-mir-1254; +MI0015213 ppy-mir-1255a; +MI0015214 ppy-mir-1255b-1; +MI0015215 ppy-mir-1255b-2; +MI0015216 ppy-mir-1256; +MI0015217 ppy-mir-1257; +MI0015218 ppy-mir-1260;ppy-mir-1260a; +MI0015219 ppy-mir-1261; +MI0015220 ppy-mir-1262; +MI0015221 ppy-mir-1263; +MI0015222 ppy-mir-1264; +MI0015223 ppy-mir-1265; +MI0015224 ppy-mir-1266; +MI0015225 ppy-mir-1267; +MI0015226 ppy-mir-1268; +MI0015227 ppy-mir-1269; +MI0015228 ppy-mir-1270; +MI0015229 ppy-mir-1271; +MI0015230 ppy-mir-1273;ppy-mir-1273a; +MI0015231 ppy-mir-1274a; +MI0015232 ppy-mir-1274b; +MI0015233 ppy-mir-1275; +MI0015234 ppy-mir-1277; +MI0015235 ppy-mir-1280; +MI0015236 ppy-mir-1281; +MI0015237 ppy-mir-1282; +MI0015238 ppy-mir-1283a; +MI0015239 ppy-mir-1283b; +MI0015240 ppy-mir-1284; +MI0015241 ppy-mir-1285a; +MI0015242 ppy-mir-1285b; +MI0015243 ppy-mir-1286; +MI0015244 ppy-mir-1287; +MI0015245 ppy-mir-1289-1; +MI0015246 ppy-mir-1290; +MI0015247 ppy-mir-1291; +MI0015248 ppy-mir-1292; +MI0015249 ppy-mir-1293; +MI0015250 ppy-mir-1295; +MI0015251 ppy-mir-1296; +MI0015252 ppy-mir-1297; +MI0015253 ppy-mir-1298; +MI0015254 ppy-mir-1299; +MI0015255 ppy-mir-1301; +MI0015256 ppy-mir-1302-1; +MI0015257 ppy-mir-1302-2; +MI0015258 ppy-mir-1302-3; +MI0015259 ppy-mir-1302-4; +MI0015260 ppy-mir-1302-5;ppy-mir-1302-2; +MI0015261 ppy-mir-1303; +MI0015262 ppy-mir-1304; +MI0015263 ppy-mir-1305; +MI0015264 ppy-mir-1306; +MI0015265 ppy-mir-1307; +MI0015266 ppy-mir-1322; +MI0015267 ppy-mir-1323; +MI0015268 ppy-mir-1324; +MI0015269 ppy-mir-1468; +MI0015270 ppy-mir-1469; +MI0015271 ppy-mir-1471; +MI0015272 ppy-mir-1537; +MI0015273 ppy-mir-1538; +MI0015274 ppy-mir-1827; +MI0015275 ppy-mir-1908; +MI0015276 ppy-mir-1909; +MI0015277 ppy-mir-1910; +MI0015278 ppy-mir-1912; +MI0015279 ppy-mir-1913; +MI0015280 ppy-mir-1914; +MI0015281 ppy-mir-1915; +MI0015282 sja-mir-1; +MI0015283 sja-mir-2a; +MI0015284 sja-mir-2b; +MI0015285 sja-mir-7; +MI0015286 sja-mir-8; +MI0015287 sja-mir-10; +MI0015288 sja-mir-31; +MI0015289 sja-mir-36; +MI0015290 sja-mir-61; +MI0015291 sja-mir-71b; +MI0015292 sja-mir-124; +MI0015293 sja-mir-133; +MI0015294 sja-mir-190; +MI0015295 sja-mir-219; +MI0015296 sja-mir-277; +MI0015297 sja-mir-307; +MI0015298 sja-mir-310; +MI0015299 sja-mir-2162; +MI0015300 sja-mir-3479; +MI0015301 sja-mir-2c; +MI0015302 sja-mir-2d; +MI0015303 sja-mir-3480; +MI0015304 sja-mir-3481; +MI0015305 sja-mir-3482; +MI0015306 sja-mir-3483; +MI0015307 sja-mir-3484; +MI0015308 sja-mir-3485; +MI0015309 sja-mir-3486; +MI0015310 sja-mir-2e; +MI0015311 sja-mir-3487; +MI0015312 sja-mir-3488; +MI0015313 sja-mir-3489; +MI0015314 sja-mir-3490; +MI0015315 sja-mir-3491; +MI0015316 sja-mir-3492; +MI0015317 sja-mir-3493; +MI0015318 sja-mir-3494; +MI0015319 sja-mir-3495; +MI0015320 sja-mir-3496; +MI0015321 sja-mir-3497; +MI0015322 sja-mir-3498; +MI0015323 sja-mir-3499; +MI0015324 sja-mir-3500; +MI0015325 sja-mir-3501; +MI0015326 sja-mir-3502; +MI0015327 sja-mir-3503; +MI0015328 sja-mir-3504; +MI0015329 sja-mir-3505; +MI0015330 sja-mir-3506; +MI0015331 sja-mir-3507; +MI0015332 ahy-MIR156a; +MI0015333 ahy-MIR156b; +MI0015334 ahy-MIR156c; +MI0015335 ahy-MIR159; +MI0015336 ahy-MIR160; +MI0015337 ahy-MIR167; +MI0015338 ahy-MIR394; +MI0015339 ahy-MIR398; +MI0015340 ahy-MIR408; +MI0015341 ahy-MIR3508; +MI0015342 ahy-MIR3509; +MI0015343 ahy-MIR3510; +MI0015344 ahy-MIR3511; +MI0015345 ahy-MIR3512; +MI0015346 ahy-MIR3513; +MI0015347 ahy-MIR3514; +MI0015348 ahy-MIR3515; +MI0015349 ahy-MIR3516; +MI0015350 ahy-MIR3517; +MI0015351 ahy-MIR3518; +MI0015352 ahy-MIR3519; +MI0015353 ahy-MIR3520; +MI0015354 ahy-MIR3521; +MI0015355 rlcv-mir-rL1-34; +MI0015356 rlcv-mir-rL1-35; +MI0015357 gso-MIR167a; +MI0015358 gso-MIR1508a; +MI0015359 gso-MIR482a; +MI0015360 gso-MIR482b; +MI0015361 gso-MIR1510b; +MI0015362 gso-MIR1510a; +MI0015363 gso-MIR1507a; +MI0015364 gso-MIR1507b; +MI0015365 gso-MIR3522a; +MI0015366 gso-MIR3522b; +MI0015367 gso-MIR2218; +MI0015368 gso-MIR1509a; +MI0015369 gso-MIR2109; +MI0015370 vvi-MIR2111; +MI0015371 lja-MIR2111; +MI0015372 bra-MIR2111a; +MI0015373 bra-MIR2111b; +MI0015374 gga-mir-2188; +MI0015375 gga-mir-3523; +MI0015376 gga-mir-3524;gga-mir-3524a; +MI0015377 gga-mir-3526; +MI0015378 gga-mir-3527; +MI0015379 gga-mir-3528; +MI0015380 gga-mir-3529; +MI0015381 gga-mir-3530; +MI0015382 gga-mir-2964;gga-mir-219b; +MI0015383 gga-mir-3531; +MI0015384 gga-mir-3525; +MI0015385 gga-mir-3532; +MI0015386 gga-mir-3533; +MI0015387 gga-mir-3534; +MI0015388 gga-mir-3535; +MI0015389 gga-mir-3536; +MI0015390 gga-mir-3537; +MI0015391 gga-mir-3538-1;gga-mir-3538; +MI0015392 gga-mir-3538-2; +MI0015393 gga-mir-3539; +MI0015394 gga-mir-3540; +MI0015395 rno-mir-3541; +MI0015396 rno-mir-3542;rno-mir-3542-1; +MI0015397 rno-mir-3543;rno-mir-3543-1; +MI0015398 rno-mir-3544; +MI0015399 rno-mir-3545;rno-mir-203b; +MI0015400 rno-mir-3546; +MI0015401 rno-mir-3547; +MI0015402 rno-mir-449c; +MI0015403 rno-mir-3085; +MI0015404 rno-mir-3548; +MI0015405 rno-mir-3549; +MI0015406 rno-mir-3550; +MI0015407 rno-mir-3551; +MI0015408 rno-mir-344b-2; +MI0015409 rno-mir-3552; +MI0015410 rno-mir-3553; +MI0015411 rno-mir-3074; +MI0015412 rno-mir-3554;rno-mir-31b; +MI0015413 rno-mir-3555;rno-mir-191b; +MI0015414 rno-mir-3556b;rno-mir-3556b-1; +MI0015415 rno-mir-3557; +MI0015416 rno-mir-3556a; +MI0015417 rno-mir-291b; +MI0015418 rno-mir-3596d; +MI0015419 rno-mir-466d; +MI0015420 rno-mir-3558; +MI0015421 rno-mir-3559; +MI0015422 rno-mir-3560; +MI0015423 rno-mir-3561; +MI0015424 rno-mir-3562; +MI0015425 rno-mir-3563;rno-mir-299b; +MI0015426 rno-mir-3597-3;rno-mir-9b-3; +MI0015427 rno-mir-3564; +MI0015428 rno-mir-3565;rno-mir-218b; +MI0015429 rno-mir-3065; +MI0015430 rno-mir-3597-1;rno-mir-9b-1; +MI0015431 rno-mir-3566; +MI0015432 rno-mir-344a-2; +MI0015433 rno-mir-3567;rno-mir-126b; +MI0015434 rno-mir-208b; +MI0015435 rno-mir-216b; +MI0015436 rno-mir-3568; +MI0015437 rno-mir-3569; +MI0015438 rno-mir-3570; +MI0015439 rno-mir-3597-2;rno-mir-9b-2; +MI0015440 rno-mir-3571; +MI0015441 rno-mir-1949; +MI0015442 rno-mir-3572; +MI0015443 rno-mir-1188; +MI0015444 rno-mir-3573; +MI0015445 rno-mir-1193; +MI0015446 rno-mir-3574; +MI0015447 rno-mir-3575; +MI0015448 rno-mir-3576; +MI0015449 rno-mir-3577; +MI0015450 rno-mir-1912; +MI0015451 rno-mir-3578; +MI0015452 rno-mir-3579; +MI0015453 rno-mir-3580; +MI0015454 rno-mir-3581;rno-mir-409b; +MI0015455 rno-mir-3596b; +MI0015456 rno-mir-3582;rno-mir-133c; +MI0015457 rno-mir-3583; +MI0015458 rno-mir-3584;rno-mir-3584-1; +MI0015459 rno-mir-3596c; +MI0015460 rno-mir-3585; +MI0015461 rno-mir-3586; +MI0015462 rno-mir-2964;rno-mir-219b; +MI0015463 rno-mir-3587; +MI0015464 rno-mir-702; +MI0015465 rno-mir-3596a; +MI0015466 rno-mir-3588; +MI0015467 rno-mir-3589; +MI0015468 rno-mir-3590; +MI0015469 rno-mir-2985; +MI0015470 rno-mir-1249; +MI0015471 rno-mir-3591;rno-mir-122b; +MI0015472 rno-mir-344b-1; +MI0015473 rno-mir-3592; +MI0015474 rno-mir-3593; +MI0015475 rno-mir-3594; +MI0015476 rno-mir-3120; +MI0015477 rno-mir-741; +MI0015478 rno-mir-3595; +MI0015479 rno-mir-328b; +MI0015480 cin-mir-1; +MI0015481 cin-mir-3575; +MI0015482 cin-mir-9; +MI0015483 cin-mir-15; +MI0015484 cin-mir-3598; +MI0015485 cin-mir-29; +MI0015486 cin-mir-96; +MI0015487 cin-mir-125; +MI0015488 cin-mir-3599; +MI0015489 cin-mir-135; +MI0015490 cin-mir-182; +MI0015491 cin-mir-196; +MI0015492 cin-mir-367; +MI0015493 cin-mir-375; +MI0015494 cin-mir-4220; +MI0015495 cin-mir-92e; +MI0015496 cin-mir-92d; +MI0015497 cin-mir-132-2; +MI0015498 cin-mir-4000c; +MI0015499 cin-mir-4000d; +MI0015500 cin-mir-4000a-1; +MI0015501 cin-mir-4000b-1; +MI0015502 cin-mir-4000e; +MI0015503 cin-mir-4000a-3; +MI0015504 cin-mir-4000a-2; +MI0015505 cin-mir-4000f; +MI0015506 cin-mir-4000g; +MI0015507 cin-mir-4000h; +MI0015508 cin-mir-4000b-2; +MI0015509 cin-mir-4000i; +MI0015510 cin-mir-4001a-1; +MI0015511 cin-mir-4001i; +MI0015512 cin-mir-4002; +MI0015513 cin-mir-4001a-2; +MI0015514 cin-mir-4001c; +MI0015515 cin-mir-4001d; +MI0015516 cin-mir-4001e; +MI0015517 cin-mir-4001f; +MI0015518 cin-mir-4001g; +MI0015519 cin-mir-4001b-1; +MI0015520 cin-mir-4001h; +MI0015521 cin-mir-4001b-2; +MI0015522 cin-mir-4003a-1; +MI0015523 cin-mir-4005a; +MI0015524 cin-mir-4003c; +MI0015525 cin-mir-4003a-2; +MI0015526 cin-mir-4003a-3; +MI0015527 cin-mir-4005b; +MI0015528 cin-mir-4003a-4; +MI0015529 cin-mir-4003b; +MI0015530 cin-mir-4004; +MI0015531 cin-mir-4006b; +MI0015532 cin-mir-4006c; +MI0015533 cin-mir-4006d; +MI0015534 cin-mir-4006a-1; +MI0015535 cin-mir-4006e; +MI0015536 cin-mir-4006a-2; +MI0015537 cin-mir-4006a-3; +MI0015538 cin-mir-4006f; +MI0015539 cin-mir-4006g; +MI0015540 cin-mir-4007; +MI0015541 cin-mir-1502a; +MI0015542 cin-mir-1502b; +MI0015543 cin-mir-1502c; +MI0015544 cin-mir-1502d; +MI0015545 cin-mir-4008a; +MI0015546 cin-mir-4008b; +MI0015547 cin-mir-4008c; +MI0015548 cin-mir-4009a; +MI0015549 cin-mir-4009b; +MI0015550 cin-mir-4009c; +MI0015551 cin-mir-4010-1;cin-mir-4010; +MI0015552 cin-mir-4010-2; +MI0015553 cin-mir-4011a; +MI0015554 cin-mir-4011b; +MI0015555 cin-mir-4012-1; +MI0015556 cin-mir-4012-2; +MI0015557 cin-mir-4013a; +MI0015558 cin-mir-4013b; +MI0015559 cin-mir-4014-1; +MI0015560 cin-mir-4014-2; +MI0015561 cin-mir-4015-1; +MI0015562 cin-mir-4015-2; +MI0015563 cin-mir-4016-1; +MI0015564 cin-mir-4016-2; +MI0015565 cin-mir-4017-1; +MI0015566 cin-mir-4017-2; +MI0015567 cin-mir-4019; +MI0015568 cin-mir-4018a; +MI0015569 cin-mir-4018b; +MI0015570 cin-mir-4020a; +MI0015571 cin-mir-4020b; +MI0015572 cin-mir-4021; +MI0015573 cin-mir-4022; +MI0015574 cin-mir-4023; +MI0015575 cin-mir-4024; +MI0015576 cin-mir-4025; +MI0015577 cin-mir-4026; +MI0015578 cin-mir-4027; +MI0015579 cin-mir-4028; +MI0015580 cin-mir-4029; +MI0015581 cin-mir-4030; +MI0015582 cin-mir-4031; +MI0015583 cin-mir-4032; +MI0015584 cin-mir-4033; +MI0015585 cin-mir-4034; +MI0015586 cin-mir-4035; +MI0015587 cin-mir-4036; +MI0015588 cin-mir-4037; +MI0015589 cin-mir-4038; +MI0015590 cin-mir-4039; +MI0015591 cin-mir-4040; +MI0015592 cin-mir-4041; +MI0015593 cin-mir-4042; +MI0015594 cin-mir-4043; +MI0015595 cin-mir-4044; +MI0015596 cin-mir-4045; +MI0015597 cin-mir-4046; +MI0015598 cin-mir-4047; +MI0015599 cin-mir-4048; +MI0015600 cin-mir-4049; +MI0015601 cin-mir-4050; +MI0015602 cin-mir-4051; +MI0015603 cin-mir-4052; +MI0015604 cin-mir-4053; +MI0015605 cin-mir-4054; +MI0015606 cin-mir-4055; +MI0015607 cin-mir-4056; +MI0015608 cin-mir-4057; +MI0015609 cin-mir-4058; +MI0015610 cin-mir-4059; +MI0015611 cin-mir-4060; +MI0015612 cin-mir-4061; +MI0015613 cin-mir-4062; +MI0015614 cin-mir-4063; +MI0015615 cin-mir-4064; +MI0015616 cin-mir-4065; +MI0015617 cin-mir-4066; +MI0015618 cin-mir-4067; +MI0015619 cin-mir-4068; +MI0015620 cin-mir-4069; +MI0015621 cin-mir-4070; +MI0015622 cin-mir-4071; +MI0015623 cin-mir-4072; +MI0015624 cin-mir-4073; +MI0015625 cin-mir-4074; +MI0015626 cin-mir-4075; +MI0015627 cin-mir-4076; +MI0015628 cin-mir-4077a; +MI0015629 cin-mir-4077b; +MI0015630 cin-mir-4077c; +MI0015631 cin-mir-4078; +MI0015632 cin-mir-4079; +MI0015633 cin-mir-4080; +MI0015634 cin-mir-4081; +MI0015635 cin-mir-4082; +MI0015636 cin-mir-4083; +MI0015637 cin-mir-4084; +MI0015638 cin-mir-4085; +MI0015639 cin-mir-4086; +MI0015640 cin-mir-4087; +MI0015641 cin-mir-4088; +MI0015642 cin-mir-4089; +MI0015643 cin-mir-4090; +MI0015644 cin-mir-4091; +MI0015645 cin-mir-4092; +MI0015646 cin-mir-4093; +MI0015647 cin-mir-4094; +MI0015648 cin-mir-4095; +MI0015649 cin-mir-4096; +MI0015650 cin-mir-4097; +MI0015651 cin-mir-4098; +MI0015652 cin-mir-4099; +MI0015653 cin-mir-4100; +MI0015654 cin-mir-4101; +MI0015655 cin-mir-4102; +MI0015656 cin-mir-4077d; +MI0015657 cin-mir-4103; +MI0015658 cin-mir-4104; +MI0015659 cin-mir-4105; +MI0015660 cin-mir-4106; +MI0015661 cin-mir-4107; +MI0015662 cin-mir-4108; +MI0015663 cin-mir-4109; +MI0015664 cin-mir-4110; +MI0015665 cin-mir-4111; +MI0015666 cin-mir-4112; +MI0015667 cin-mir-4113; +MI0015668 cin-mir-4114; +MI0015669 cin-mir-4115; +MI0015670 cin-mir-4116; +MI0015671 cin-mir-4117; +MI0015672 cin-mir-4118; +MI0015673 cin-mir-4119; +MI0015674 cin-mir-4120; +MI0015675 cin-mir-4121; +MI0015676 cin-mir-4122; +MI0015677 cin-mir-4123; +MI0015678 cin-mir-4003d; +MI0015679 cin-mir-4124; +MI0015680 cin-mir-4125; +MI0015681 cin-mir-4126; +MI0015682 cin-mir-4127; +MI0015683 cin-mir-4128; +MI0015684 cin-mir-4129; +MI0015685 cin-mir-4130; +MI0015686 cin-mir-4131; +MI0015687 cin-mir-4132; +MI0015688 cin-mir-4133; +MI0015689 cin-mir-4134; +MI0015690 cin-mir-4135; +MI0015691 cin-mir-4136; +MI0015692 cin-mir-4137; +MI0015693 cin-mir-4138; +MI0015694 cin-mir-4139; +MI0015695 cin-mir-4140; +MI0015696 cin-mir-4141; +MI0015697 cin-mir-4142; +MI0015698 cin-mir-4143; +MI0015699 cin-mir-4144; +MI0015700 cin-mir-4145; +MI0015701 cin-mir-4146; +MI0015702 cin-mir-4147; +MI0015703 cin-mir-4148; +MI0015704 cin-mir-4149; +MI0015705 cin-mir-4150; +MI0015706 cin-mir-4151; +MI0015707 cin-mir-4152; +MI0015708 cin-mir-4153; +MI0015709 cin-mir-4154; +MI0015710 cin-mir-4155; +MI0015711 cin-mir-4156; +MI0015712 cin-mir-4157; +MI0015713 cin-mir-4158; +MI0015714 cin-mir-4159; +MI0015715 cin-mir-4160; +MI0015716 cin-mir-4161; +MI0015717 cin-mir-4162; +MI0015718 cin-mir-4163; +MI0015719 cin-mir-4164; +MI0015720 cin-mir-4165; +MI0015721 cin-mir-4166; +MI0015722 cin-mir-4167; +MI0015723 cin-mir-4168; +MI0015724 cin-mir-4169; +MI0015725 cin-mir-4170; +MI0015726 cin-mir-4171; +MI0015727 cin-mir-4172; +MI0015728 cin-mir-4173; +MI0015729 cin-mir-4174; +MI0015730 cin-mir-4175; +MI0015731 cin-mir-4176; +MI0015732 cin-mir-4177; +MI0015733 cin-mir-4178a; +MI0015734 cin-mir-4178b; +MI0015735 cin-mir-4179;cin-mir-4179a; +MI0015736 cin-mir-4180; +MI0015737 cin-mir-4181; +MI0015738 cin-mir-4182; +MI0015739 cin-mir-4183; +MI0015740 cin-mir-4184; +MI0015741 cin-mir-4005c; +MI0015742 cin-mir-4185; +MI0015743 cin-mir-4186; +MI0015744 cin-mir-4187; +MI0015745 cin-mir-4188; +MI0015746 cin-mir-4189; +MI0015747 cin-mir-4190; +MI0015748 cin-mir-4191; +MI0015749 cin-mir-4192; +MI0015750 cin-mir-4193; +MI0015751 cin-mir-4194; +MI0015752 cin-mir-4195; +MI0015753 cin-mir-4196; +MI0015754 cin-mir-4197; +MI0015755 cin-mir-4198; +MI0015756 cin-mir-4199; +MI0015757 cin-mir-4200; +MI0015758 cin-mir-4201; +MI0015759 cin-mir-4202; +MI0015760 cin-mir-4203; +MI0015761 cin-mir-4204; +MI0015762 cin-mir-4205; +MI0015763 cin-mir-4206; +MI0015764 cin-mir-4207; +MI0015765 cin-mir-4208; +MI0015766 cin-mir-4209; +MI0015767 cin-mir-4210; +MI0015768 cin-mir-4211; +MI0015769 cin-mir-4212; +MI0015770 cin-mir-4213; +MI0015771 cin-mir-4214; +MI0015772 cin-mir-4215; +MI0015773 cin-mir-4216; +MI0015774 cin-mir-4217; +MI0015775 cin-mir-4218; +MI0015776 cin-mir-4219; +MI0015777 cin-let-7f; +MI0015778 aly-MIR395i; +MI0015779 aly-MIR399j; +MI0015780 aly-MIR841; +MI0015781 aly-MIR1887; +MI0015782 aly-MIR4221; +MI0015783 aly-MIR4222; +MI0015784 aly-MIR4223; +MI0015785 aly-MIR4224; +MI0015786 aly-MIR4225; +MI0015787 aly-MIR4226; +MI0015788 aly-MIR4227; +MI0015789 aly-MIR4228; +MI0015790 aly-MIR4229; +MI0015791 aly-MIR4230; +MI0015792 aly-MIR4231; +MI0015793 aly-MIR3444b; +MI0015794 aly-MIR4232; +MI0015795 aly-MIR4233; +MI0015796 aly-MIR4234; +MI0015797 aly-MIR4235; +MI0015798 aly-MIR4236; +MI0015799 aly-MIR4237; +MI0015800 aly-MIR4238; +MI0015801 aly-MIR4239; +MI0015802 aly-MIR4240; +MI0015803 aly-MIR4241; +MI0015804 aly-MIR4242; +MI0015805 aly-MIR4243; +MI0015806 aly-MIR4244; +MI0015807 aly-MIR4245; +MI0015808 aly-MIR4246; +MI0015809 aly-MIR4247; +MI0015810 aly-MIR4248a; +MI0015811 aly-MIR4248b; +MI0015812 aly-MIR4248c; +MI0015813 aly-MIR4249; +MI0015814 aly-MIR4250; +MI0015815 ath-MIR4221; +MI0015816 ath-MIR4227; +MI0015817 ath-MIR4228; +MI0015818 ath-MIR3440b; +MI0015819 ath-MIR4239; +MI0015820 ath-MIR4240; +MI0015821 ath-MIR4243; +MI0015822 hsa-mir-4295; +MI0015823 hsa-mir-4296; +MI0015824 hsa-mir-4297; +MI0015825 hsa-mir-378c; +MI0015826 hsa-mir-4293; +MI0015827 hsa-mir-4294; +MI0015828 hsa-mir-4301; +MI0015829 hsa-mir-4299; +MI0015830 hsa-mir-4298; +MI0015831 hsa-mir-4300; +MI0015832 hsa-mir-4304; +MI0015833 hsa-mir-4302; +MI0015834 hsa-mir-4303; +MI0015835 hsa-mir-4305; +MI0015836 hsa-mir-4306; +MI0015837 hsa-mir-4309; +MI0015838 hsa-mir-4307; +MI0015839 hsa-mir-4308; +MI0015840 hsa-mir-4310; +MI0015841 hsa-mir-4311; +MI0015842 hsa-mir-4312; +MI0015843 hsa-mir-4313; +MI0015844 hsa-mir-4315-1; +MI0015845 hsa-mir-4316; +MI0015846 hsa-mir-4314; +MI0015847 hsa-mir-4318; +MI0015848 hsa-mir-4319; +MI0015849 hsa-mir-4320; +MI0015850 hsa-mir-4317; +MI0015851 hsa-mir-4322; +MI0015852 hsa-mir-4321; +MI0015853 hsa-mir-4323; +MI0015854 hsa-mir-4324; +MI0015855 hsa-mir-4256; +MI0015856 hsa-mir-4257; +MI0015857 hsa-mir-4258; +MI0015858 hsa-mir-4259; +MI0015859 hsa-mir-4260; +MI0015860 hsa-mir-4253; +MI0015861 hsa-mir-4251; +MI0015862 hsa-mir-4254; +MI0015863 hsa-mir-4255; +MI0015864 hsa-mir-4252; +MI0015865 hsa-mir-4325; +MI0015866 hsa-mir-4326; +MI0015867 hsa-mir-4327; +MI0015868 hsa-mir-4261; +MI0015869 hsa-mir-4265; +MI0015870 hsa-mir-4266; +MI0015871 hsa-mir-4267; +MI0015872 hsa-mir-4262; +MI0015873 hsa-mir-2355; +MI0015874 hsa-mir-4268; +MI0015875 hsa-mir-4269; +MI0015876 hsa-mir-4263; +MI0015877 hsa-mir-4264; +MI0015878 hsa-mir-4270; +MI0015879 hsa-mir-4271; +MI0015880 hsa-mir-4272; +MI0015881 hsa-mir-4273; +MI0015882 hsa-mir-4276; +MI0015883 hsa-mir-4275; +MI0015884 hsa-mir-4274; +MI0015885 hsa-mir-4281; +MI0015886 hsa-mir-4277; +MI0015887 hsa-mir-4279; +MI0015888 hsa-mir-4278; +MI0015889 hsa-mir-4280; +MI0015890 hsa-mir-4282; +MI0015891 hsa-mir-4285; +MI0015892 hsa-mir-4283-1; +MI0015893 hsa-mir-4284; +MI0015894 hsa-mir-4286; +MI0015895 hsa-mir-4287; +MI0015896 hsa-mir-4288; +MI0015897 hsa-mir-4292; +MI0015898 hsa-mir-4289; +MI0015899 hsa-mir-4290; +MI0015900 hsa-mir-4291; +MI0015901 hsa-mir-4329; +MI0015902 hsa-mir-4330; +MI0015903 hsa-mir-500b; +MI0015904 hsa-mir-4328; +MI0015905 ssc-mir-194;ssc-mir-194b; +MI0015906 ssc-mir-296; +MI0015907 ssc-mir-155; +MI0015908 ssc-mir-411; +MI0015909 ssc-mir-133a-2; +MI0015910 ssc-mir-4331;ssc-mir-4331-1; +MI0015911 ssc-mir-382; +MI0015912 ssc-mir-381; +MI0015913 ssc-mir-362; +MI0015914 ssc-mir-490;ssc-mir-490-1; +MI0015915 ssc-mir-376c; +MI0015916 ssc-mir-376b; +MI0015917 ssc-mir-4332; +MI0015918 ssc-mir-4333; +MI0015919 ssc-mir-652; +MI0015920 ssc-mir-1224; +MI0015921 ssc-mir-4334; +MI0015922 ssc-mir-1271; +MI0015923 ssc-mir-4335; +MI0015924 ssc-mir-218;ssc-mir-218-1; +MI0015925 ssc-mir-421; +MI0015926 ssc-mir-146a; +MI0015927 ssc-mir-383; +MI0015928 ssc-mir-487b; +MI0015929 ssc-mir-484; +MI0015930 ssc-mir-4336; +MI0015931 ssc-mir-1296; +MI0015932 ssc-mir-4337; +MI0015933 ssc-mir-4338; +MI0015934 ssc-mir-494; +MI0015935 ssc-mir-4339; +MI0015936 bmo-mir-92a; +MI0015937 bmo-mir-2733e-3; +MI0015938 tgu-mir-204-5; +MI0015939 tgu-mir-34c-1; +MI0015940 isc-mir-1993; +MI0015941 isc-mir-278; +MI0015942 bta-mir-3114; +MI0015943 bta-mir-3600; +MI0015944 bta-mir-2957;bta-mir-148c; +MI0015945 bta-mir-3578; +MI0015946 bta-mir-3581;bta-mir-409b; +MI0015947 bta-mir-3601; +MI0015948 bta-mir-3602; +MI0015949 bta-mir-3603;bta-mir-26c; +MI0015950 bta-mir-3604-1; +MI0015951 bta-mir-3604-2; +MI0015952 bta-mir-3596; +MI0015953 aga-mir-375-2; +MI0015954 ame-mir-10-2; +MI0015955 ame-mir-1-2; +MI0015956 ath-MIR8543;ath-MIR854e; +MI0015957 cbr-mir-232-2; +MI0015958 cbr-mir-357-2; +MI0015959 cbr-mir-77-2; +MI0015960 cfa-mir-29c-2; +MI0015961 cfa-mir-1837-2; +MI0015962 cfa-mir-1837-3; +MI0015963 cfa-mir-1837-4; +MI0015964 cre-MIR1161b; +MI0015965 gga-mir-146c-2; +MI0015966 gga-mir-222-2; +MI0015967 rno-mir-220-2; +MI0015968 rno-mir-295-2; +MI0015969 tgu-mir-34c-2; +MI0015970 dre-let-7e-2; +MI0015971 hsa-mir-1184-2; +MI0015972 hsa-mir-1184-3; +MI0015973 hsa-mir-1233-2; +MI0015974 hsa-mir-1244-2; +MI0015975 hsa-mir-1244-3; +MI0015976 hsa-mir-1270-2; +MI0015977 hsa-mir-1972-2; +MI0015978 hsa-mir-1302-9; +MI0015979 hsa-mir-1302-10; +MI0015980 hsa-mir-1302-11; +MI0015981 hsa-mir-3118-6; +MI0015982 hsa-mir-4283-2; +MI0015983 hsa-mir-4315-2; +MI0015984 mmu-mir-1906-2; +MI0015985 nve-mir-2024e-2; +MI0015986 nve-mir-2024e-3; +MI0015987 nve-mir-2032b-2; +MI0015988 nve-mir-2040a-2; +MI0015989 nve-mir-2035-2; +MI0015990 nve-mir-2024a-2; +MI0015991 nve-mir-2024a-3; +MI0015992 nve-mir-2024g-2; +MI0015993 nve-mir-2024g-3; +MI0015994 bfl-mir-135b-2; +MI0015995 hsa-mir-3605; +MI0015996 hsa-mir-3606; +MI0015997 hsa-mir-3607; +MI0015999 hsa-mir-3609; +MI0016000 hsa-mir-3610; +MI0016001 hsa-mir-3611; +MI0016002 hsa-mir-3612; +MI0016003 hsa-mir-3613; +MI0016004 hsa-mir-3614; +MI0016005 hsa-mir-3615; +MI0016006 hsa-mir-3616; +MI0016007 hsa-mir-3617; +MI0016008 hsa-mir-3618; +MI0016009 hsa-mir-3619; +MI0016010 hsa-mir-23c; +MI0016011 hsa-mir-3620; +MI0016012 hsa-mir-3621; +MI0016013 hsa-mir-3622a; +MI0016014 hsa-mir-3622b; +MI0016015 vvi-MIR3623; +MI0016016 vvi-MIR2950; +MI0016017 vvi-MIR3624; +MI0016018 vvi-MIR3625; +MI0016019 vvi-MIR3626; +MI0016020 vvi-MIR3627; +MI0016021 vvi-MIR3628; +MI0016022 vvi-MIR3629a; +MI0016023 vvi-MIR3629b; +MI0016024 vvi-MIR3629c; +MI0016025 vvi-MIR447b;vvi-MIR477b; +MI0016026 vvi-MIR3630; +MI0016027 vvi-MIR3631a; +MI0016028 vvi-MIR3631b; +MI0016029 vvi-MIR3631c; +MI0016030 vvi-MIR3631d; +MI0016031 vvi-MIR3632; +MI0016032 vvi-MIR3633a; +MI0016033 vvi-MIR3634; +MI0016034 vvi-MIR3633b; +MI0016035 vvi-MIR3635; +MI0016036 vvi-MIR3636; +MI0016037 vvi-MIR3637; +MI0016038 vvi-MIR3638; +MI0016039 vvi-MIR3639; +MI0016040 vvi-MIR3640; +MI0016041 dme-mir-3641; +MI0016042 dme-mir-3642; +MI0016043 dme-mir-3643; +MI0016044 dme-mir-3644; +MI0016045 dme-mir-3645; +MI0016046 hsa-mir-3646; +MI0016047 hsa-mir-3647; +MI0016048 hsa-mir-3648;hsa-mir-3648-1; +MI0016049 hsa-mir-3649; +MI0016050 hsa-mir-3650; +MI0016051 hsa-mir-3651; +MI0016052 hsa-mir-3652; +MI0016053 hsa-mir-3653; +MI0016054 hsa-mir-3654; +MI0016055 hsa-mir-3655; +MI0016056 hsa-mir-3656; +MI0016057 hsa-mir-3657; +MI0016058 hsa-mir-3658; +MI0016059 hsa-mir-1273e; +MI0016060 hsa-mir-3659; +MI0016061 hsa-mir-3660; +MI0016062 hsa-mir-3661; +MI0016063 hsa-mir-3662; +MI0016064 hsa-mir-3663; +MI0016065 hsa-mir-3664; +MI0016066 hsa-mir-3665; +MI0016067 hsa-mir-3666; +MI0016068 hsa-mir-3667; +MI0016069 hsa-mir-3668; +MI0016070 hsa-mir-3669; +MI0016071 hsa-mir-3670;hsa-mir-3670-1; +MI0016072 hsa-mir-3671; +MI0016073 hsa-mir-3672; +MI0016074 hsa-mir-3673; +MI0016075 hsa-mir-3674; +MI0016076 hsa-mir-3675; +MI0016077 hsa-mir-3676; +MI0016078 hsa-mir-3677; +MI0016079 hsa-mir-3678; +MI0016080 hsa-mir-3679; +MI0016081 hsa-mir-3680;hsa-mir-3680-1; +MI0016082 hsa-mir-3681; +MI0016083 hsa-mir-3682; +MI0016084 hsa-mir-3683; +MI0016085 hsa-mir-3684; +MI0016086 hsa-mir-3685; +MI0016087 hsa-mir-3686; +MI0016088 hsa-mir-3687;hsa-mir-3687-1; +MI0016089 hsa-mir-3688;hsa-mir-3688-1; +MI0016090 hsa-mir-3689a; +MI0016091 hsa-mir-3690;hsa-mir-3690-1; +MI0016092 hsa-mir-3691; +MI0016093 hsa-mir-3692; +MI0016094 pab-MIR950;pab-MIR950a; +MI0016095 pab-MIR3693; +MI0016096 pab-MIR3694; +MI0016097 pab-MIR3695;pab-MIR3695d; +MI0016098 pab-MIR3696; +MI0016099 pab-MIR3697;pab-MIR3697b; +MI0016100 pab-MIR3698; +MI0016101 pab-MIR3699; +MI0016102 pab-MIR3700; +MI0016103 pab-MIR3701;pab-MIR3701b; +MI0016104 pab-MIR3702; +MI0016105 pab-MIR3703; +MI0016106 pab-MIR3704; +MI0016107 pab-MIR3705; +MI0016108 pab-MIR3706; +MI0016109 pab-MIR3707; +MI0016110 pab-MIR3708; +MI0016111 pab-MIR3709a; +MI0016112 pab-MIR3709b; +MI0016113 pab-MIR3710; +MI0016114 pab-MIR3711; +MI0016115 pab-MIR3712; +MI0016116 pab-MIR160a; +MI0016117 pab-MIR160b; +MI0016118 pab-MIR166a; +MI0016119 pab-MIR166b; +MI0016120 pab-MIR482d; +MI0016121 pab-MIR395; +MI0016122 pab-MIR396a; +MI0016123 pab-MIR396b; +MI0016124 pab-MIR396c; +MI0016125 pab-MIR397;pab-MIR397b; +MI0016126 pab-MIR482a; +MI0016127 pab-MIR482b; +MI0016128 pab-MIR482c; +MI0016129 pab-MIR535;pab-MIR535e; +MI0016130 pab-MIR947; +MI0016131 pab-MIR951; +MI0016132 pab-MIR1311;pab-MIR1311a; +MI0016133 pab-MIR1863; +MI0016134 hsa-mir-3713; +MI0016135 hsa-mir-3714; +MI0016136 ame-mir-11; +MI0016137 ame-mir-1175; +MI0016138 ame-mir-193; +MI0016139 ame-mir-307; +MI0016140 ame-mir-2788; +MI0016141 ame-mir-989; +MI0016142 ame-mir-3717; +MI0016143 ame-mir-3745; +MI0016144 ame-mir-3746; +MI0016145 ame-mir-3747a; +MI0016146 ame-mir-3747b; +MI0016147 ame-mir-3748; +MI0016148 ame-mir-3749; +MI0016149 ame-mir-3750; +MI0016150 ame-mir-3718a; +MI0016151 ame-mir-3751; +MI0016152 ame-mir-3752; +MI0016153 ame-mir-3753; +MI0016154 ame-mir-3754; +MI0016155 ame-mir-3755; +MI0016156 ame-mir-3718b; +MI0016157 ame-mir-3756; +MI0016158 ame-mir-3049; +MI0016159 ame-mir-3757; +MI0016160 ame-mir-3758; +MI0016161 ame-mir-3719; +MI0016162 ame-mir-3759; +MI0016163 ame-mir-3760; +MI0016164 ame-mir-3761; +MI0016165 ame-mir-3762; +MI0016166 ame-mir-3763; +MI0016167 ame-mir-3764; +MI0016168 ame-mir-3720; +MI0016169 ame-mir-3765; +MI0016170 ame-mir-3766; +MI0016171 ame-mir-3767; +MI0016172 ame-mir-3768; +MI0016173 ame-mir-3769; +MI0016174 ame-mir-971; +MI0016175 ame-mir-3770; +MI0016176 ame-mir-3721; +MI0016177 ame-mir-3771; +MI0016178 ame-mir-3772; +MI0016179 ame-mir-3773; +MI0016180 ame-mir-3722; +MI0016181 ame-mir-3774; +MI0016182 ame-mir-3775; +MI0016183 ame-mir-3776; +MI0016184 ame-mir-3777; +MI0016185 ame-mir-3778; +MI0016186 ame-mir-3779; +MI0016187 ame-mir-965; +MI0016188 ame-mir-3780; +MI0016189 ame-mir-3781; +MI0016190 ame-mir-3782; +MI0016191 ame-mir-3783; +MI0016192 ame-mir-3716b; +MI0016193 ame-mir-3784; +MI0016194 ame-mir-3785; +MI0016195 ame-mir-3786; +MI0016196 ame-mir-3787; +MI0016197 ame-mir-3788; +MI0016198 ame-mir-3789; +MI0016199 ame-mir-3790; +MI0016200 ame-mir-3791; +MI0016201 ame-mir-279b; +MI0016202 ame-mir-9c; +MI0016203 ame-mir-2944; +MI0016204 ame-mir-318; +MI0016205 ame-mir-3792; +MI0016206 ame-mir-927b; +MI0016207 ame-mir-3793; +MI0016208 ame-mir-3794; +MI0016209 ame-mir-306; +MI0016210 ame-mir-3795; +MI0016211 ame-mir-3796; +MI0016212 ame-mir-3797; +MI0016213 ame-mir-3477; +MI0016214 ame-mir-3798; +MI0016215 ame-mir-3799; +MI0016216 ame-mir-279c; +MI0016217 ame-mir-3800; +MI0016218 ame-mir-3801; +MI0016219 ame-mir-3723; +MI0016220 ame-mir-3724; +MI0016221 ame-mir-2796; +MI0016222 ame-mir-3725; +MI0016223 ame-mir-3726; +MI0016224 ame-mir-3727; +MI0016225 ame-mir-3728; +MI0016226 ame-mir-3729; +MI0016227 ame-mir-3715; +MI0016228 ame-mir-3730; +MI0016229 ame-mir-3731; +MI0016230 ame-mir-3732; +MI0016231 ame-mir-3716a; +MI0016232 ame-mir-3733; +MI0016233 ame-mir-3734; +MI0016234 ame-mir-3735; +MI0016235 ame-mir-3736; +MI0016236 ame-mir-3737; +MI0016237 ame-mir-3738; +MI0016238 ame-mir-3739; +MI0016239 ame-mir-3740; +MI0016240 ame-mir-3741; +MI0016241 ame-mir-3742; +MI0016242 ame-mir-3743; +MI0016243 ame-mir-3744; +MI0016244 ame-mir-980; +MI0016245 ame-mir-750; +MI0016246 tgu-mir-25; +MI0016247 tgu-mir-192; +MI0016248 tgu-mir-10a; +MI0016249 tgu-mir-132; +MI0016250 mghv-mir-M1-10; +MI0016251 mghv-mir-M1-11; +MI0016252 mghv-mir-M1-12; +MI0016253 mghv-mir-M1-13; +MI0016254 mghv-mir-M1-14; +MI0016255 mghv-mir-M1-15; +MI0016256 tca-mir-3802; +MI0016257 tca-mir-3803; +MI0016258 tca-mir-3804a; +MI0016259 tca-mir-3804b; +MI0016260 tca-mir-995; +MI0016261 tca-mir-2765; +MI0016262 tca-mir-3805a; +MI0016263 tca-mir-3806; +MI0016264 tca-mir-3807; +MI0016265 tca-mir-3808; +MI0016266 tca-mir-3809; +MI0016267 tca-mir-3810; +MI0016268 tca-mir-3811c-1;tca-mir-3811a-2; +MI0016269 tca-mir-3812; +MI0016270 tca-mir-3813; +MI0016271 tca-mir-3811d;tca-mir-3811a-3; +MI0016272 tca-mir-3814; +MI0016273 tca-mir-3815; +MI0016274 tca-mir-3816; +MI0016275 tca-mir-3817; +MI0016276 tca-mir-3811c-2;tca-mir-3811a-4; +MI0016277 tca-mir-3818; +MI0016278 tca-mir-3805b; +MI0016279 tca-mir-3811e;tca-mir-3811a-5; +MI0016280 tca-mir-3820; +MI0016281 tca-mir-3821; +MI0016282 tca-mir-3822; +MI0016283 tca-mir-3823; +MI0016284 tca-mir-3824; +MI0016285 tca-mir-3811b; +MI0016286 tca-mir-3825; +MI0016287 tca-mir-3826; +MI0016288 tca-mir-3827; +MI0016289 tca-mir-3811a;tca-mir-3811a-1; +MI0016290 tca-mir-3828; +MI0016291 tca-mir-3829; +MI0016292 tca-mir-3830; +MI0016293 tca-mir-3831; +MI0016294 tca-mir-3832; +MI0016295 tca-mir-3833; +MI0016296 tca-mir-iab-8; +MI0016297 tca-mir-3834; +MI0016298 tca-mir-3835; +MI0016299 tca-mir-3836a; +MI0016300 tca-mir-308; +MI0016301 tca-mir-3837; +MI0016302 tca-mir-3836b; +MI0016303 tca-mir-2796; +MI0016304 tca-mir-9c; +MI0016305 tca-mir-316; +MI0016306 tca-mir-2944a; +MI0016307 tca-mir-3838; +MI0016308 tca-mir-3839; +MI0016309 tca-mir-3840; +MI0016310 tca-mir-3841; +MI0016311 tca-mir-3842; +MI0016312 tca-mir-279c; +MI0016313 tca-mir-3843; +MI0016314 tca-mir-3844; +MI0016315 tca-mir-3477; +MI0016316 tca-mir-3845; +MI0016317 tca-mir-3846; +MI0016318 tca-mir-3847; +MI0016319 tca-mir-3848; +MI0016320 tca-mir-2944b; +MI0016321 tca-mir-9d; +MI0016322 tca-mir-309a; +MI0016323 tca-mir-3849; +MI0016324 tca-mir-3850; +MI0016325 tca-mir-3851b; +MI0016326 tca-mir-3851a-1; +MI0016327 tca-mir-3852; +MI0016328 tca-mir-3853; +MI0016329 tca-mir-3854; +MI0016330 tca-mir-3851a-2; +MI0016331 tca-mir-3855; +MI0016332 tca-mir-87b; +MI0016333 tca-mir-3856; +MI0016334 tca-mir-3851c; +MI0016335 tca-mir-3857; +MI0016336 tca-mir-3049; +MI0016337 tca-mir-3851d;tca-mir-3851d-1; +MI0016338 tca-mir-3851e; +MI0016339 tca-mir-3858; +MI0016340 tca-mir-3851f; +MI0016341 tca-mir-92c; +MI0016342 tca-mir-279d; +MI0016343 tca-mir-3859; +MI0016344 tca-mir-3860; +MI0016345 tca-mir-375; +MI0016346 tca-mir-3861; +MI0016347 tca-mir-2788; +MI0016348 tca-mir-3862; +MI0016349 tca-mir-29; +MI0016350 tca-mir-252a; +MI0016351 tca-mir-252b; +MI0016352 tca-mir-3863; +MI0016353 tca-mir-2944c; +MI0016354 tca-mir-3864; +MI0016355 tca-mir-3865; +MI0016356 tca-mir-279e; +MI0016357 tca-mir-1175; +MI0016358 tca-mir-750; +MI0016359 tca-mir-989; +MI0016360 tca-mir-3866; +MI0016361 tca-mir-3867; +MI0016362 tca-mir-3868; +MI0016363 tca-mir-3869; +MI0016364 tca-mir-3870; +MI0016365 tca-mir-3871; +MI0016366 tca-mir-3872; +MI0016367 tca-mir-3873; +MI0016368 tca-mir-3874; +MI0016369 tca-mir-3875; +MI0016370 tca-mir-3876; +MI0016371 tca-mir-3877; +MI0016372 tca-mir-3878; +MI0016373 tca-mir-3879; +MI0016374 tca-mir-998; +MI0016375 tca-mir-11; +MI0016376 tca-mir-3880; +MI0016377 tca-mir-3881; +MI0016378 tca-mir-3882; +MI0016379 tca-mir-3883; +MI0016380 tca-mir-980; +MI0016381 tca-mir-3884; +MI0016382 tca-mir-3885; +MI0016383 tca-mir-3886; +MI0016384 tca-mir-3887; +MI0016385 tca-mir-3888; +MI0016386 tca-mir-3889; +MI0016387 tca-mir-3890; +MI0016388 tca-mir-3891; +MI0016389 tca-mir-3791; +MI0016390 tca-mir-3892; +MI0016391 tca-mir-309b; +MI0016392 tca-mir-3893; +MI0016393 tca-mir-3894; +MI0016394 tca-mir-3895; +MI0016395 tca-mir-3896; +MI0016396 tca-mir-193; +MI0016397 tca-mir-3897; +MI0016398 tca-mir-3898; +MI0016399 tca-mir-3899; +MI0016400 tca-mir-3900; +MI0016401 tca-mir-3901; +MI0016402 tca-mir-3902; +MI0016403 tca-mir-3903; +MI0016404 tca-mir-3904; +MI0016405 tca-mir-3905; +MI0016406 tca-mir-3819; +MI0016407 dre-mir-3906; +MI0016408 hsa-mir-3180-4; +MI0016409 hsa-mir-3180-5; +MI0016410 hsa-mir-3907; +MI0016411 hsa-mir-3689b; +MI0016412 hsa-mir-3908; +MI0016413 hsa-mir-3909; +MI0016414 hsa-mir-3910-1; +MI0016415 hsa-mir-3911; +MI0016416 hsa-mir-3912; +MI0016417 hsa-mir-3913-1; +MI0016418 hsa-mir-3913-2; +MI0016419 hsa-mir-3914-1; +MI0016420 hsa-mir-3915; +MI0016421 hsa-mir-3914-2; +MI0016422 hsa-mir-3916; +MI0016423 hsa-mir-3917; +MI0016424 hsa-mir-3918; +MI0016425 hsa-mir-3919; +MI0016426 hsa-mir-3150b; +MI0016427 hsa-mir-3920; +MI0016428 hsa-mir-3921; +MI0016429 hsa-mir-3922; +MI0016430 hsa-mir-3923; +MI0016431 hsa-mir-3910-2; +MI0016432 hsa-mir-3924; +MI0016433 hsa-mir-3925; +MI0016434 hsa-mir-3926-1; +MI0016435 hsa-mir-3927; +MI0016436 hsa-mir-676; +MI0016437 hsa-mir-3926-2; +MI0016438 hsa-mir-3928; +MI0016439 hsa-mir-3929; +MI0016440 smr-mir-282; +MI0016441 smr-mir-965; +MI0016442 smr-mir-3930; +MI0016443 isc-mir-276; +MI0016444 isc-mir-305; +MI0016445 isc-mir-iab-4; +MI0016446 smr-mir-3931; +MI0016447 dpu-mir-279b; +MI0016448 dpu-mir-305; +MI0016449 hvu-MIR156;hvu-MIR156a; +MI0016450 tae-MIR156; +MI0016451 hvu-MIR159b; +MI0016452 hvu-MIR159a; +MI0016453 tae-MIR319; +MI0016454 ttu-MIR160; +MI0016455 hvu-MIR166;hvu-MIR166a; +MI0016456 tae-MIR167b; +MI0016457 hvu-MIR168; +MI0016458 ata-MIR169; +MI0016459 hvu-MIR169; +MI0016460 tae-MIR1433;tae-MIR169; +MI0016461 hvu-MIR171; +MI0016462 ata-MIR172; +MI0016463 tae-MIR395a; +MI0016464 tae-MIR395b; +MI0016465 hvu-MIR397;hvu-MIR397a; +MI0016466 tae-MIR398; +MI0016467 tae-MIR444b; +MI0016468 tae-MIR171b; +MI0016469 gma-MIR4340; +MI0016470 gma-MIR4341; +MI0016471 gma-MIR4342; +MI0016472 gma-MIR4343a; +MI0016473 gma-MIR4344; +MI0016474 gma-MIR4345; +MI0016475 gma-MIR4364b; +MI0016476 gma-MIR4346; +MI0016477 gma-MIR4347; +MI0016478 gma-MIR4348;gma-MIR4348a; +MI0016479 gma-MIR4349; +MI0016480 gma-MIR4350; +MI0016481 gma-MIR4351; +MI0016482 gma-MIR4352a; +MI0016483 gma-MIR4353; +MI0016484 gma-MIR1520e; +MI0016485 gma-MIR1520f; +MI0016486 gma-MIR1520g; +MI0016487 gma-MIR4354; +MI0016488 gma-MIR4355; +MI0016489 gma-MIR4356; +MI0016490 gma-MIR4357; +MI0016491 gma-MIR4358; +MI0016492 gma-MIR4359a; +MI0016493 gma-MIR4360; +MI0016494 gma-MIR4359b; +MI0016495 gma-MIR4387c; +MI0016496 gma-MIR1520h; +MI0016497 gma-MIR4361; +MI0016498 gma-MIR1520i; +MI0016499 gma-MIR4362; +MI0016500 gma-MIR4363; +MI0016501 gma-MIR4364a; +MI0016502 gma-MIR4380a; +MI0016503 gma-MIR396d; +MI0016504 gma-MIR1520j; +MI0016505 gma-MIR4365; +MI0016506 gma-MIR4366; +MI0016507 gma-MIR4367; +MI0016508 gma-MIR4368a; +MI0016509 gma-MIR4371c; +MI0016510 gma-MIR4368b; +MI0016511 gma-MIR4369; +MI0016512 gma-MIR4370; +MI0016513 gma-MIR4387b; +MI0016514 gma-MIR4371a; +MI0016515 gma-MIR4371b; +MI0016516 gma-MIR4372;gma-MIR4372a; +MI0016517 gma-MIR4352b; +MI0016518 gma-MIR4373; +MI0016519 gma-MIR4374a; +MI0016520 gma-MIR4375; +MI0016521 gma-MIR4376;gma-MIR391; +MI0016522 gma-MIR4377; +MI0016523 gma-MIR4374b; +MI0016524 gma-MIR4378a; +MI0016525 gma-MIR4378b; +MI0016526 gma-MIR4379; +MI0016527 gma-MIR482b; +MI0016528 gma-MIR4380b; +MI0016529 gma-MIR4381; +MI0016530 gma-MIR4382; +MI0016531 gma-MIR4383; +MI0016532 gma-MIR1520k; +MI0016533 gma-MIR1520l; +MI0016534 gma-MIR1520m; +MI0016535 gma-MIR4384; +MI0016536 gma-MIR1520n; +MI0016537 gma-MIR1520o; +MI0016538 gma-MIR4385; +MI0016539 gma-MIR4386; +MI0016540 gma-MIR4387a; +MI0016541 gma-MIR4388; +MI0016542 gma-MIR4387d; +MI0016543 gma-MIR4389; +MI0016544 gma-MIR4390; +MI0016545 gma-MIR4391; +MI0016546 gma-MIR4392; +MI0016547 gma-MIR4343b; +MI0016548 gma-MIR167g; +MI0016549 gma-MIR4393a; +MI0016550 gma-MIR4394; +MI0016551 gma-MIR4395; +MI0016552 gma-MIR4396; +MI0016553 gma-MIR4397; +MI0016554 gma-MIR1520r; +MI0016555 gma-MIR4398; +MI0016556 gma-MIR4399; +MI0016557 gma-MIR4400; +MI0016558 gma-MIR4393b; +MI0016559 gma-MIR156f; +MI0016560 gma-MIR4401;gma-MIR4401a; +MI0016561 gma-MIR4402; +MI0016562 gma-MIR4403; +MI0016563 gma-MIR1520p; +MI0016564 gma-MIR4404; +MI0016565 gma-MIR4405; +MI0016566 gma-MIR4406; +MI0016567 gma-MIR4407; +MI0016568 gma-MIR4408; +MI0016569 gma-MIR4409; +MI0016570 gma-MIR4410; +MI0016571 gma-MIR169d; +MI0016572 gma-MIR4411; +MI0016573 gma-MIR1520q; +MI0016574 gma-MIR172f; +MI0016575 gma-MIR171c; +MI0016576 gma-MIR169e; +MI0016577 gma-MIR394b; +MI0016578 gma-MIR4412; +MI0016579 gma-MIR4413;gma-MIR4413a; +MI0016580 gma-MIR156g; +MI0016581 gma-MIR159d; +MI0016582 gma-MIR394a; +MI0016583 gma-MIR4414;gma-MIR4414a; +MI0016584 gma-MIR4415;gma-MIR4415a; +MI0016585 gma-MIR4416;gma-MIR4416a; +MI0016586 gma-MIR396e; +MI0016587 ath-MIR3932a; +MI0016588 ath-MIR3932b; +MI0016589 ath-MIR3933; +MI0016590 hsa-mir-3934; +MI0016591 hsa-mir-3935; +MI0016592 hsa-mir-3936; +MI0016593 hsa-mir-3937; +MI0016594 hsa-mir-3938; +MI0016595 hsa-mir-548y; +MI0016596 hsa-mir-3939; +MI0016597 hsa-mir-3940; +MI0016598 hsa-mir-3941; +MI0016599 hsa-mir-3942; +MI0016600 hsa-mir-3943; +MI0016601 hsa-mir-3944; +MI0016602 hsa-mir-3945; +MI0016603 far-MIR159; +MI0016604 far-MIR160; +MI0016605 far-MIR171; +MI0016606 far-MIR1119; +MI0016607 far-MIR1122; +MI0016608 far-MIR1134; +MI0016609 far-MIR156a; +MI0016610 far-MIR396; +MI0016611 far-MIR164a; +MI0016612 far-MIR169; +MI0016613 far-MIR437; +MI0016614 far-MIR529; +MI0016615 far-MIR156b; +MI0016616 far-MIR166; +MI0016617 far-MIR164b; +MI0016618 ssc-mir-30c-1; +MI0016619 ssc-mir-126; +MI0016620 ssc-mir-149; +MI0016621 ssc-mir-199a-1; +MI0016622 ssc-mir-378-2; +MI0016623 ssc-mir-451; +MI0016624 ngi-mir-iab-4as;ngi-mir-iab-8; +MI0016625 ngi-mir-375; +MI0016626 ngi-mir-1; +MI0016627 ngi-mir-275; +MI0016628 ngi-mir-31a; +MI0016629 ngi-mir-281; +MI0016630 ngi-mir-14; +MI0016631 ngi-mir-34; +MI0016632 ngi-mir-219; +MI0016633 ngi-mir-283; +MI0016634 ngi-mir-2; +MI0016635 ngi-mir-927; +MI0016636 ngi-mir-263b; +MI0016637 ngi-mir-13a; +MI0016638 ngi-mir-137; +MI0016639 ngi-mir-184; +MI0016640 ngi-mir-210; +MI0016641 ngi-mir-277; +MI0016642 ngi-mir-29b; +MI0016643 ngi-mir-100; +MI0016644 ngi-mir-305; +MI0016645 ngi-mir-932; +MI0016646 ngi-mir-9a; +MI0016647 ngi-mir-276; +MI0016648 ngi-mir-92a; +MI0016649 ngi-mir-317; +MI0016650 ngi-mir-993; +MI0016651 ngi-mir-252; +MI0016652 ngi-mir-iab-4; +MI0016653 ngi-mir-133; +MI0016654 ngi-let-7; +MI0016655 ngi-mir-929; +MI0016656 nlo-mir-281; +MI0016657 nlo-mir-10; +MI0016658 nlo-mir-929; +MI0016659 nlo-mir-282; +MI0016660 nlo-mir-263b; +MI0016661 nlo-mir-12; +MI0016662 nlo-mir-125; +MI0016663 nlo-mir-133; +MI0016664 nlo-mir-137; +MI0016665 nlo-mir-13a; +MI0016666 nlo-mir-184; +MI0016667 nlo-mir-219; +MI0016668 nlo-mir-2; +MI0016669 nlo-mir-252; +MI0016670 nlo-mir-275; +MI0016671 nlo-mir-276; +MI0016672 nlo-mir-277; +MI0016673 nlo-mir-305; +MI0016674 nlo-mir-315; +MI0016675 nlo-mir-31a; +MI0016676 nlo-mir-34; +MI0016677 nlo-mir-7; +MI0016678 nlo-mir-8; +MI0016679 nlo-mir-927; +MI0016680 nlo-mir-92a; +MI0016681 nlo-mir-932; +MI0016682 nlo-mir-993; +MI0016683 nlo-mir-9a; +MI0016684 hsa-mir-374c; +MI0016685 hsa-mir-642b; +MI0016686 hsa-mir-550b-1; +MI0016687 hsa-mir-550b-2; +MI0016688 hsa-mir-548z; +MI0016689 hsa-mir-548aa-1; +MI0016690 hsa-mir-548aa-2; +MI0016691 csi-MIR156;csi-MIR156a; +MI0016692 csi-MIR3946; +MI0016693 csi-MIR159;csi-MIR159a; +MI0016694 csi-MIR166c; +MI0016695 csi-MIR166d; +MI0016696 csi-MIR167c; +MI0016697 csi-MIR167b; +MI0016698 csi-MIR171b; +MI0016699 csi-MIR171a; +MI0016700 csi-MIR172b; +MI0016701 csi-MIR172c; +MI0016702 csi-MIR319;csi-MIR159d; +MI0016703 csi-MIR393;csi-MIR393a; +MI0016704 csi-MIR394;csi-MIR394a; +MI0016705 csi-MIR395;csi-MIR395a; +MI0016706 csi-MIR396a; +MI0016707 csi-MIR396b; +MI0016708 csi-MIR397; +MI0016709 csi-MIR399e; +MI0016710 csi-MIR399c; +MI0016711 csi-MIR399d; +MI0016712 csi-MIR399a; +MI0016713 csi-MIR399b; +MI0016714 csi-MIR403;csi-MIR403a; +MI0016715 csi-MIR408; +MI0016716 csi-MIR472;csi-MIR482f; +MI0016717 csi-MIR473;csi-MIR477c; +MI0016718 csi-MIR477a; +MI0016719 csi-MIR477b; +MI0016720 csi-MIR477c; +MI0016721 csi-MIR479; +MI0016722 csi-MIR482a; +MI0016723 csi-MIR482b; +MI0016724 csi-MIR530a; +MI0016725 csi-MIR530b; +MI0016726 csi-MIR535;csi-MIR535a; +MI0016727 csi-MIR827; +MI0016728 csi-MIR857; +MI0016729 csi-MIR3947; +MI0016730 csi-MIR3948; +MI0016731 csi-MIR1515;csi-MIR1515a; +MI0016732 csi-MIR3949; +MI0016733 csi-MIR3950; +MI0016734 csi-MIR3951;csi-MIR3951a; +MI0016735 csi-MIR396c; +MI0016736 csi-MIR3952; +MI0016737 csi-MIR482c; +MI0016738 csi-MIR3953; +MI0016739 csi-MIR3954; +MI0016740 csi-MIR167a; +MI0016741 hvu-MIR1120; +MI0016742 hvu-MIR166b; +MI0016743 hvu-MIR1436; +MI0016744 hvu-MIR1126; +MI0016745 hvu-MIR444;hvu-MIR444a; +MI0016746 hsa-mir-548o-2; +MI0016747 hsa-mir-1254-2; +MI0016748 hsa-mir-1268b; +MI0016749 hsa-mir-378d-1; +MI0016750 hsa-mir-378e; +MI0016751 hsa-mir-548h-5; +MI0016752 hsa-mir-548ab; +MI0016753 hsa-mir-4417; +MI0016754 hsa-mir-4418; +MI0016755 hsa-mir-4419a; +MI0016756 hsa-mir-378f; +MI0016757 hsa-mir-4420; +MI0016758 hsa-mir-4421; +MI0016759 hsa-mir-4422; +MI0016760 hsa-mir-4423; +MI0016761 hsa-mir-378g; +MI0016762 hsa-mir-548ac; +MI0016763 hsa-mir-4424; +MI0016764 hsa-mir-4425; +MI0016765 hsa-mir-4426; +MI0016766 hsa-mir-4427; +MI0016767 hsa-mir-4428; +MI0016768 hsa-mir-4429; +MI0016769 hsa-mir-4430; +MI0016770 hsa-mir-548ad; +MI0016771 hsa-mir-4431; +MI0016772 hsa-mir-4432; +MI0016773 hsa-mir-4433;hsa-mir-4433a; +MI0016774 hsa-mir-4434; +MI0016775 hsa-mir-4435-1; +MI0016776 hsa-mir-4436a; +MI0016777 hsa-mir-4435-2; +MI0016778 hsa-mir-4437; +MI0016779 hsa-mir-548ae-1; +MI0016780 hsa-mir-548ae-2; +MI0016781 hsa-mir-4438; +MI0016782 hsa-mir-4439; +MI0016783 hsa-mir-4440; +MI0016784 hsa-mir-4441; +MI0016785 hsa-mir-4442; +MI0016786 hsa-mir-4443; +MI0016787 hsa-mir-4444;hsa-mir-4444-1; +MI0016788 hsa-mir-4445; +MI0016789 hsa-mir-4446; +MI0016790 hsa-mir-4447; +MI0016791 hsa-mir-4448; +MI0016792 hsa-mir-4449; +MI0016793 hsa-mir-548ag-1; +MI0016794 hsa-mir-548ag-2; +MI0016795 hsa-mir-4450; +MI0016796 hsa-mir-548ah; +MI0016797 hsa-mir-4451; +MI0016798 hsa-mir-4452; +MI0016799 hsa-mir-4453; +MI0016800 hsa-mir-4454; +MI0016801 hsa-mir-4455; +MI0016802 hsa-mir-4456; +MI0016803 hsa-mir-4457; +MI0016804 hsa-mir-4458; +MI0016805 hsa-mir-4459; +MI0016806 hsa-mir-4460; +MI0016807 hsa-mir-4461; +MI0016808 hsa-mir-378h; +MI0016809 hsa-mir-3135b; +MI0016810 hsa-mir-4462; +MI0016811 hsa-mir-4463; +MI0016812 hsa-mir-4464; +MI0016813 hsa-mir-548ai; +MI0016814 hsa-mir-548aj-1; +MI0016815 hsa-mir-548aj-2; +MI0016816 hsa-mir-4465; +MI0016817 hsa-mir-4466; +MI0016818 hsa-mir-4467; +MI0016819 hsa-mir-4468; +MI0016820 hsa-mir-4469; +MI0016821 hsa-mir-4470; +MI0016822 hsa-mir-4471; +MI0016823 hsa-mir-4472-1; +MI0016824 hsa-mir-4472-2; +MI0016825 hsa-mir-4473; +MI0016826 hsa-mir-4474; +MI0016827 hsa-mir-4475; +MI0016828 hsa-mir-4476; +MI0016829 hsa-mir-4477a; +MI0016830 hsa-mir-4477b; +MI0016831 hsa-mir-4478; +MI0016832 hsa-mir-3689c; +MI0016833 hsa-mir-548x-2; +MI0016834 hsa-mir-3689d-1; +MI0016835 hsa-mir-3689d-2; +MI0016836 hsa-mir-3689e; +MI0016837 hsa-mir-3689f; +MI0016838 hsa-mir-4479; +MI0016839 hsa-mir-3155b; +MI0016840 hsa-mir-548ak; +MI0016841 hsa-mir-4480; +MI0016842 hsa-mir-4481; +MI0016843 hsa-mir-4482;hsa-mir-4482-1;hsa-mir-4482; +MI0016844 hsa-mir-4483; +MI0016845 hsa-mir-4484; +MI0016846 hsa-mir-4485; +MI0016847 hsa-mir-4486; +MI0016848 hsa-mir-4487; +MI0016849 hsa-mir-4488; +MI0016850 hsa-mir-4489; +MI0016851 hsa-mir-548al; +MI0016852 hsa-mir-4490; +MI0016853 hsa-mir-4491; +MI0016854 hsa-mir-4492; +MI0016855 hsa-mir-4493; +MI0016856 hsa-mir-4494; +MI0016857 hsa-mir-4495; +MI0016858 hsa-mir-4496; +MI0016859 hsa-mir-4497; +MI0016860 hsa-mir-4498; +MI0016861 hsa-mir-4419b; +MI0016862 hsa-mir-4499; +MI0016863 hsa-mir-4500; +MI0016864 hsa-mir-4501; +MI0016865 hsa-mir-4502; +MI0016866 hsa-mir-4503; +MI0016867 hsa-mir-4504; +MI0016868 hsa-mir-4505; +MI0016869 hsa-mir-4506; +MI0016870 hsa-mir-2392; +MI0016871 hsa-mir-4507; +MI0016872 hsa-mir-4508; +MI0016873 hsa-mir-4509-1; +MI0016874 hsa-mir-4509-2; +MI0016875 hsa-mir-4509-3; +MI0016876 hsa-mir-4510; +MI0016877 hsa-mir-4511; +MI0016878 hsa-mir-4512; +MI0016879 hsa-mir-4513; +MI0016880 hsa-mir-4514; +MI0016881 hsa-mir-4515; +MI0016882 hsa-mir-4516; +MI0016883 hsa-mir-4517; +MI0016884 hsa-mir-4518; +MI0016885 hsa-mir-4519; +MI0016886 hsa-mir-4520a;hsa-mir-4520-1; +MI0016887 hsa-mir-4521; +MI0016888 hsa-mir-1269b; +MI0016889 hsa-mir-4522; +MI0016890 hsa-mir-4523; +MI0016891 hsa-mir-4524;hsa-mir-4524a; +MI0016892 hsa-mir-4525; +MI0016893 hsa-mir-4526; +MI0016894 hsa-mir-4527; +MI0016895 hsa-mir-4528; +MI0016896 hsa-mir-4529; +MI0016897 hsa-mir-4530; +MI0016898 hsa-mir-4531; +MI0016899 hsa-mir-4532; +MI0016900 hsa-mir-4533; +MI0016901 hsa-mir-4534; +MI0016902 hsa-mir-378i; +MI0016903 hsa-mir-4535; +MI0016904 hsa-mir-548am; +MI0016905 hsa-mir-1587; +MI0016906 hsa-mir-4536;hsa-mir-4536-1; +MI0016907 hsa-mir-548an; +MI0016908 hsa-mir-4537; +MI0016909 hsa-mir-4538; +MI0016910 hsa-mir-4539; +MI0016911 hsa-mir-4540; +MI0016912 oar-mir-493; +MI0016913 oar-mir-665; +MI0016914 oar-mir-433; +MI0016915 oar-mir-370; +MI0016916 oar-mir-3955; +MI0016917 oar-mir-379; +MI0016918 oar-mir-411a; +MI0016919 oar-mir-299; +MI0016920 oar-mir-380; +MI0016921 oar-mir-411b; +MI0016922 oar-mir-1197; +MI0016923 oar-mir-323a; +MI0016924 oar-mir-758; +MI0016925 oar-mir-329b; +MI0016926 oar-mir-329a; +MI0016927 oar-mir-494; +MI0016928 oar-mir-1193; +MI0016929 oar-mir-543; +MI0016930 oar-mir-495; +MI0016931 oar-mir-3958; +MI0016932 oar-mir-376e; +MI0016933 oar-mir-376c; +MI0016934 oar-mir-376d; +MI0016935 oar-mir-654; +MI0016936 oar-mir-376b; +MI0016937 oar-mir-376a; +MI0016938 oar-mir-1185; +MI0016939 oar-mir-3956; +MI0016940 oar-mir-381; +MI0016941 oar-mir-487b; +MI0016942 oar-mir-539; +MI0016943 oar-mir-544; +MI0016944 oar-mir-655; +MI0016945 oar-mir-3959; +MI0016946 oar-mir-487a; +MI0016947 oar-mir-382; +MI0016948 oar-mir-134; +MI0016949 oar-mir-668; +MI0016950 oar-mir-485; +MI0016951 oar-mir-323b; +MI0016952 oar-mir-154a; +MI0016953 oar-mir-154b; +MI0016954 oar-mir-496; +MI0016955 oar-mir-377; +MI0016956 oar-mir-541; +MI0016957 oar-mir-3957; +MI0016958 oar-mir-409; +MI0016959 oar-mir-412; +MI0016960 oar-mir-369; +MI0016961 oar-mir-410; +MI0016962 oar-mir-323c; +MI0016963 mmu-mir-3960; +MI0016964 hsa-mir-3960; +MI0016965 mmu-mir-3961; +MI0016966 mmu-mir-28c; +MI0016967 mmu-mir-3962; +MI0016968 mmu-mir-3963; +MI0016969 mmu-mir-3096b; +MI0016970 mmu-mir-3964; +MI0016971 mmu-mir-1843b; +MI0016972 mmu-mir-3965; +MI0016973 mmu-mir-378b; +MI0016974 mmu-mir-101c; +MI0016975 mmu-mir-3966; +MI0016976 mmu-mir-3967; +MI0016977 mmu-mir-3968; +MI0016978 mmu-mir-3969; +MI0016979 mmu-mir-28b; +MI0016980 mmu-mir-3970; +MI0016981 mmu-mir-3971; +MI0016982 bgy-MIR156; +MI0016983 bgy-MIR396a; +MI0016984 bgy-MIR396b; +MI0016985 bgy-MIR529; +MI0016986 bcy-MIR156; +MI0016987 bcy-MIR396a; +MI0016988 bcy-MIR396b; +MI0016989 bcy-MIR529; +MI0016990 hsa-mir-3972; +MI0016991 hsa-mir-3973; +MI0016992 hsa-mir-3974; +MI0016993 hsa-mir-3975; +MI0016994 hsa-mir-3976; +MI0016995 hsa-mir-3977; +MI0016996 hsa-mir-3978; +MI0016997 mmu-mir-3473b; +MI0016998 cgr-mir-7;cgr-mir-7a; +MI0016999 pma-mir-1a; +MI0017000 pma-mir-1b; +MI0017001 pma-mir-1c; +MI0017002 pma-mir-1d; +MI0017003 pma-mir-7a-1; +MI0017004 pma-mir-7a-2; +MI0017005 pma-mir-7b; +MI0017006 pma-mir-9a-1; +MI0017007 pma-mir-9a-2; +MI0017008 pma-mir-9b; +MI0017009 pma-mir-10b; +MI0017010 pma-mir-10a; +MI0017011 pma-mir-15a; +MI0017012 pma-mir-15b; +MI0017013 pma-mir-16; +MI0017014 pma-mir-17a; +MI0017015 pma-mir-17b; +MI0017016 pma-mir-17c; +MI0017017 pma-mir-18a; +MI0017018 pma-mir-18b; +MI0017019 pma-mir-19a; +MI0017020 pma-mir-19b; +MI0017021 pma-mir-19c; +MI0017022 pma-mir-20a; +MI0017023 pma-mir-20b; +MI0017024 pma-mir-22a; +MI0017025 pma-mir-22b; +MI0017026 pma-mir-23a; +MI0017027 pma-mir-23b; +MI0017028 pma-mir-24; +MI0017029 pma-mir-25b; +MI0017030 pma-mir-26a-1; +MI0017031 pma-mir-26a-2; +MI0017032 pma-mir-26b; +MI0017033 pma-mir-27a; +MI0017034 pma-mir-27b; +MI0017035 pma-mir-29a; +MI0017036 pma-mir-29b; +MI0017037 pma-mir-29c; +MI0017038 pma-mir-29d; +MI0017039 pma-mir-30a; +MI0017040 pma-mir-30b; +MI0017041 pma-mir-30c; +MI0017042 pma-mir-30d; +MI0017043 pma-mir-30e; +MI0017044 pma-mir-30f-1; +MI0017045 pma-mir-30f-2; +MI0017046 pma-mir-30g; +MI0017047 pma-mir-31; +MI0017048 pma-mir-33a; +MI0017049 pma-mir-33b; +MI0017050 pma-mir-92a; +MI0017051 pma-mir-96a; +MI0017052 pma-mir-100a; +MI0017053 pma-mir-100b; +MI0017054 pma-mir-100c; +MI0017055 pma-mir-103a; +MI0017056 pma-mir-103b; +MI0017057 pma-mir-124; +MI0017058 pma-mir-125; +MI0017059 pma-mir-126; +MI0017060 pma-mir-128-1; +MI0017061 pma-mir-128-2; +MI0017062 pma-mir-129a; +MI0017063 pma-mir-130d; +MI0017064 pma-mir-130e; +MI0017065 pma-mir-130a; +MI0017066 pma-mir-130b; +MI0017067 pma-mir-130c; +MI0017068 pma-mir-132; +MI0017069 pma-mir-133a; +MI0017070 pma-mir-133b; +MI0017071 pma-mir-135a; +MI0017072 pma-mir-135b; +MI0017073 pma-mir-137-1; +MI0017074 pma-mir-137-2; +MI0017075 pma-mir-138a; +MI0017076 pma-mir-138b; +MI0017077 pma-mir-140; +MI0017078 pma-mir-143; +MI0017079 pma-mir-144; +MI0017080 pma-mir-145; +MI0017081 pma-mir-146; +MI0017082 pma-mir-147; +MI0017083 pma-mir-152a; +MI0017084 pma-mir-152b; +MI0017085 pma-mir-153-1; +MI0017086 pma-mir-153-2; +MI0017087 pma-mir-153-3; +MI0017088 pma-mir-155; +MI0017089 pma-mir-181a; +MI0017090 pma-mir-181b-1; +MI0017091 pma-mir-182; +MI0017092 pma-mir-183; +MI0017093 pma-mir-184; +MI0017094 pma-mir-190a; +MI0017095 pma-mir-190b; +MI0017096 pma-mir-192; +MI0017097 pma-mir-193; +MI0017098 pma-mir-194; +MI0017099 pma-mir-196a; +MI0017100 pma-mir-196b; +MI0017101 pma-mir-199a; +MI0017102 pma-mir-199b; +MI0017103 pma-mir-200b; +MI0017104 pma-mir-203a; +MI0017105 pma-mir-203b; +MI0017106 pma-mir-204; +MI0017107 pma-mir-205a; +MI0017108 pma-mir-205b; +MI0017109 pma-mir-208; +MI0017110 pma-mir-210; +MI0017111 pma-mir-212; +MI0017112 pma-mir-216a; +MI0017113 pma-mir-216b; +MI0017114 pma-mir-217a; +MI0017115 pma-mir-218a-1; +MI0017116 pma-mir-218a-2; +MI0017117 pma-mir-218b; +MI0017118 pma-mir-221; +MI0017119 pma-mir-222; +MI0017120 pma-mir-281a; +MI0017121 pma-mir-301a; +MI0017122 pma-mir-301b; +MI0017123 pma-mir-302; +MI0017124 pma-mir-315; +MI0017125 pma-mir-338b; +MI0017126 pma-mir-373;pma-mir-430f; +MI0017127 pma-mir-375a; +MI0017128 pma-mir-375b; +MI0017129 pma-mir-429; +MI0017130 pma-mir-430a; +MI0017131 pma-mir-430b; +MI0017132 pma-mir-430c; +MI0017133 pma-mir-430d; +MI0017134 pma-mir-430e; +MI0017135 pma-mir-451; +MI0017136 pma-mir-456; +MI0017137 pma-mir-459; +MI0017138 pma-mir-497; +MI0017139 pma-mir-551; +MI0017140 pma-mir-875; +MI0017141 pma-mir-1329; +MI0017142 pma-mir-1788a; +MI0017143 pma-mir-1788b; +MI0017144 pma-let-7a-1; +MI0017145 pma-let-7a-2; +MI0017146 pma-let-7a-3; +MI0017147 pma-let-7a-4; +MI0017148 pma-let-7b; +MI0017149 pma-let-7c; +MI0017150 pma-let-7d; +MI0017151 pma-mir-4541; +MI0017152 pma-mir-4542; +MI0017153 pma-mir-4543; +MI0017154 pma-mir-4544; +MI0017155 pma-mir-4545; +MI0017156 pma-mir-4546; +MI0017157 pma-mir-4547; +MI0017158 pma-mir-4548; +MI0017159 pma-mir-4549; +MI0017160 pma-mir-4550; +MI0017161 pma-mir-4551; +MI0017162 pma-mir-4552; +MI0017163 pma-mir-4553; +MI0017164 pma-mir-4554; +MI0017165 pma-mir-4555; +MI0017166 pma-mir-4556; +MI0017167 pma-mir-4557; +MI0017168 pma-mir-4558; +MI0017169 pma-mir-4559; +MI0017170 pma-mir-4560; +MI0017171 pma-mir-4561; +MI0017172 pma-mir-4562; +MI0017173 pma-mir-4563; +MI0017174 pma-mir-4564; +MI0017175 pma-mir-4565; +MI0017176 pma-mir-4566; +MI0017177 pma-mir-4567; +MI0017178 pma-mir-4568; +MI0017179 pma-mir-4569; +MI0017180 pma-mir-4570; +MI0017181 pma-mir-4571; +MI0017182 pma-mir-4572; +MI0017183 pma-mir-4573; +MI0017184 pma-mir-4574; +MI0017185 pma-mir-4575; +MI0017186 pma-mir-4576; +MI0017187 pma-mir-4577; +MI0017188 pma-mir-4578; +MI0017189 pma-mir-4579; +MI0017190 pma-mir-4580; +MI0017191 pma-mir-4581; +MI0017192 pma-mir-4582; +MI0017193 pma-mir-4583; +MI0017194 pma-mir-4584; +MI0017195 pma-mir-4585; +MI0017196 pma-mir-4586; +MI0017197 pma-mir-4587; +MI0017198 pma-mir-4588; +MI0017199 pma-mir-4589; +MI0017200 pma-mir-4590; +MI0017201 pma-mir-4591; +MI0017202 pma-mir-4592; +MI0017203 pma-mir-4593; +MI0017204 pma-mir-4594; +MI0017205 pma-mir-4595; +MI0017206 pma-mir-4596; +MI0017207 pma-mir-4597; +MI0017208 pma-mir-4598; +MI0017209 pma-mir-4599a; +MI0017210 pma-mir-4599b; +MI0017211 pma-mir-4600; +MI0017212 pma-mir-4601; +MI0017213 pma-mir-4602; +MI0017214 pma-mir-4603; +MI0017215 pma-mir-4604; +MI0017216 pma-mir-4605; +MI0017217 pma-mir-4606; +MI0017218 pma-mir-4607; +MI0017219 pma-mir-4608; +MI0017220 pma-mir-4609; +MI0017221 pma-mir-4610; +MI0017222 pma-mir-4611; +MI0017223 pma-mir-4612; +MI0017224 pma-mir-4613; +MI0017225 pma-mir-4614; +MI0017226 pma-mir-4615; +MI0017227 pma-mir-4616; +MI0017228 pma-mir-4617; +MI0017229 pma-mir-4618; +MI0017230 pma-mir-4619; +MI0017231 pma-mir-4620; +MI0017232 pma-mir-4621; +MI0017233 pma-mir-4622; +MI0017234 pma-mir-4623; +MI0017235 pma-mir-4624; +MI0017236 pma-mir-4625; +MI0017237 pma-mir-4626; +MI0017238 pma-mir-4627; +MI0017239 pma-mir-4628; +MI0017240 pma-mir-4629; +MI0017241 pma-mir-4630; +MI0017242 pma-mir-4631; +MI0017245 osa-MIR812k; +MI0017246 osa-MIR812l; +MI0017247 osa-MIR812m; +MI0017248 osa-MIR1862f; +MI0017249 osa-MIR1862g; +MI0017250 osa-MIR811d; +MI0017251 osa-MIR3979; +MI0017252 osa-MIR3980a; +MI0017253 osa-MIR3980b; +MI0017254 osa-MIR812n; +MI0017255 osa-MIR812o; +MI0017256 osa-MIR3981; +MI0017257 osa-MIR2873b; +MI0017258 osa-MIR3982; +MI0017259 hsa-mir-4632; +MI0017260 hsa-mir-4633; +MI0017261 hsa-mir-4634; +MI0017262 hsa-mir-4635; +MI0017263 hsa-mir-4636; +MI0017264 hsa-mir-4637; +MI0017265 hsa-mir-4638; +MI0017266 hsa-mir-4639; +MI0017267 hsa-mir-4640; +MI0017268 hsa-mir-4641; +MI0017269 hsa-mir-4642; +MI0017270 hsa-mir-4643; +MI0017271 hsa-mir-4644; +MI0017272 hsa-mir-4645; +MI0017273 hsa-mir-4646; +MI0017274 hsa-mir-4647; +MI0017275 hsa-mir-4648; +MI0017276 hsa-mir-4649; +MI0017277 hsa-mir-4650-1; +MI0017278 hsa-mir-4650-2; +MI0017279 hsa-mir-4651; +MI0017280 hsa-mir-4652; +MI0017281 hsa-mir-4653; +MI0017282 hsa-mir-4654; +MI0017283 hsa-mir-4655; +MI0017284 hsa-mir-4656; +MI0017285 hsa-mir-4657; +MI0017286 hsa-mir-4658; +MI0017287 hsa-mir-4659a; +MI0017288 hsa-mir-4660; +MI0017289 hsa-mir-4661; +MI0017290 hsa-mir-4662a; +MI0017291 hsa-mir-4659b; +MI0017292 hsa-mir-4663; +MI0017293 hsa-mir-4662b; +MI0017294 hsa-mir-4664; +MI0017295 hsa-mir-4665; +MI0017296 hsa-mir-4666;hsa-mir-4666a; +MI0017297 hsa-mir-4667; +MI0017298 hsa-mir-4668; +MI0017299 hsa-mir-2964a;hsa-mir-219b; +MI0017300 hsa-mir-4669; +MI0017301 hsa-mir-4670; +MI0017302 hsa-mir-4671; +MI0017303 hsa-mir-4672; +MI0017304 hsa-mir-4673; +MI0017305 hsa-mir-4674; +MI0017306 hsa-mir-4675; +MI0017307 hsa-mir-4676; +MI0017308 hsa-mir-4677; +MI0017309 hsa-mir-4678; +MI0017310 hsa-mir-4679-1; +MI0017311 hsa-mir-4679-2; +MI0017312 hsa-mir-4680; +MI0017313 hsa-mir-4681; +MI0017314 hsa-mir-4682; +MI0017315 hsa-mir-4683; +MI0017316 hsa-mir-4684; +MI0017317 hsa-mir-4685; +MI0017318 hsa-mir-4686; +MI0017319 hsa-mir-4687; +MI0017320 hsa-mir-1343; +MI0017321 hsa-mir-4688; +MI0017322 hsa-mir-4689; +MI0017323 hsa-mir-4690; +MI0017324 hsa-mir-4691; +MI0017325 hsa-mir-4692; +MI0017326 hsa-mir-4693; +MI0017327 hsa-mir-4694; +MI0017328 hsa-mir-4695; +MI0017329 hsa-mir-4696; +MI0017330 hsa-mir-4697; +MI0017331 hsa-mir-4698; +MI0017332 hsa-mir-4699; +MI0017333 hsa-mir-4700; +MI0017334 hsa-mir-4701; +MI0017335 hsa-mir-3198-2; +MI0017336 hsa-mir-4703; +MI0017337 hsa-mir-4704; +MI0017338 hsa-mir-4705; +MI0017339 hsa-mir-4706; +MI0017340 hsa-mir-4707; +MI0017341 hsa-mir-4708; +MI0017342 hsa-mir-4709; +MI0017343 hsa-mir-3545;hsa-mir-203b; +MI0017344 hsa-mir-4710; +MI0017345 hsa-mir-4711; +MI0017346 hsa-mir-4712; +MI0017347 hsa-mir-4713; +MI0017348 hsa-mir-4714; +MI0017349 hsa-mir-4715; +MI0017350 hsa-mir-4716; +MI0017351 hsa-mir-3529; +MI0017352 hsa-mir-4717; +MI0017353 hsa-mir-4718; +MI0017354 hsa-mir-4719; +MI0017355 hsa-mir-4720; +MI0017356 hsa-mir-4721; +MI0017357 hsa-mir-4722; +MI0017358 hsa-mir-4520b;hsa-mir-4520-2; +MI0017359 hsa-mir-4723; +MI0017360 hsa-mir-451b; +MI0017361 hsa-mir-4724; +MI0017362 hsa-mir-4725; +MI0017363 hsa-mir-4726; +MI0017364 hsa-mir-4727; +MI0017365 hsa-mir-4728; +MI0017366 hsa-mir-4729; +MI0017367 hsa-mir-4730; +MI0017368 hsa-mir-4731; +MI0017369 hsa-mir-4732; +MI0017370 hsa-mir-4733; +MI0017371 hsa-mir-4734; +MI0017372 hsa-mir-4735; +MI0017373 hsa-mir-4736; +MI0017374 hsa-mir-4737; +MI0017375 hsa-mir-3064; +MI0017376 hsa-mir-4738; +MI0017377 hsa-mir-4739; +MI0017378 hsa-mir-4740; +MI0017379 hsa-mir-4741; +MI0017380 hsa-mir-4742; +MI0017381 hsa-mir-4743; +MI0017382 hsa-mir-4744; +MI0017383 hsa-mir-3591;hsa-mir-122b; +MI0017384 hsa-mir-4745; +MI0017385 hsa-mir-4746; +MI0017386 hsa-mir-4747; +MI0017387 hsa-mir-4748; +MI0017388 hsa-mir-4749; +MI0017389 hsa-mir-4750; +MI0017390 hsa-mir-4751; +MI0017391 hsa-mir-4752; +MI0017392 hsa-mir-4753; +MI0017393 hsa-mir-371b; +MI0017394 hsa-mir-4754; +MI0017395 hsa-mir-4755; +MI0017396 hsa-mir-499a;hsa-mir-499b; +MI0017397 hsa-mir-4756; +MI0017398 hsa-mir-4757; +MI0017399 hsa-mir-4758; +MI0017400 hsa-mir-4759; +MI0017401 hsa-mir-4760; +MI0017402 hsa-mir-4761; +MI0017403 hsa-mir-4762; +MI0017404 hsa-mir-4763; +MI0017405 hsa-mir-4764; +MI0017406 hsa-mir-4765; +MI0017407 hsa-mir-4766; +MI0017408 hsa-mir-4767; +MI0017409 hsa-mir-4768; +MI0017410 hsa-mir-4769; +MI0017411 hsa-mir-4770; +MI0017412 hsa-mir-4771-1; +MI0017413 hsa-mir-4771-2; +MI0017414 hsa-mir-4772; +MI0017415 hsa-mir-4773-1; +MI0017416 hsa-mir-4773-2; +MI0017417 hsa-mir-4774; +MI0017418 hsa-mir-4775; +MI0017419 hsa-mir-4776-1; +MI0017420 hsa-mir-4776-2; +MI0017421 hsa-mir-4777; +MI0017422 hsa-mir-4778; +MI0017423 hsa-mir-4779; +MI0017424 hsa-mir-4780; +MI0017425 hsa-mir-4436b;hsa-mir-4436b-1; +MI0017426 hsa-mir-4781; +MI0017427 hsa-mir-4782; +MI0017428 hsa-mir-4783; +MI0017429 hsa-mir-4784; +MI0017430 hsa-mir-4785; +MI0017431 hsa-mir-1245b; +MI0017432 hsa-mir-2467; +MI0017433 hsa-mir-4786; +MI0017434 hsa-mir-4787; +MI0017435 hsa-mir-4788; +MI0017436 hsa-mir-4789; +MI0017437 hsa-mir-4790; +MI0017438 hsa-mir-4791; +MI0017439 hsa-mir-4792; +MI0017440 hsa-mir-4793; +MI0017441 hsa-mir-4794; +MI0017442 hsa-mir-4795; +MI0017443 hsa-mir-4796; +MI0017444 hsa-mir-4797; +MI0017445 hsa-mir-4798; +MI0017446 hsa-mir-4799; +MI0017447 hsa-mir-3688-2; +MI0017448 hsa-mir-4800; +MI0017449 hsa-mir-4801; +MI0017450 hsa-mir-4802; +MI0017451 hsa-mir-4803; +MI0017452 hsa-mir-4804; +MI0017453 tcc-MIR156a; +MI0017454 tcc-MIR156b; +MI0017455 tcc-MIR156c; +MI0017456 tcc-MIR156d; +MI0017457 tcc-MIR156e; +MI0017458 tcc-MIR156f; +MI0017459 tcc-MIR156g; +MI0017460 tcc-MIR160a; +MI0017461 tcc-MIR160b; +MI0017462 tcc-MIR160c; +MI0017463 tcc-MIR162; +MI0017464 tcc-MIR164a; +MI0017465 tcc-MIR164b; +MI0017466 tcc-MIR164c; +MI0017467 tcc-MIR166a; +MI0017468 tcc-MIR166b; +MI0017469 tcc-MIR166c; +MI0017470 tcc-MIR166d; +MI0017471 tcc-MIR167a; +MI0017472 tcc-MIR167b; +MI0017473 tcc-MIR167c; +MI0017474 tcc-MIR168; +MI0017475 tcc-MIR169a; +MI0017476 tcc-MIR169b; +MI0017477 tcc-MIR169c; +MI0017478 tcc-MIR169d; +MI0017479 tcc-MIR169e; +MI0017480 tcc-MIR169f; +MI0017481 tcc-MIR169g; +MI0017482 tcc-MIR169h; +MI0017483 tcc-MIR169i; +MI0017484 tcc-MIR169j; +MI0017485 tcc-MIR169k; +MI0017486 tcc-MIR169l; +MI0017487 tcc-MIR169m; +MI0017488 tcc-MIR169n; +MI0017489 tcc-MIR171a; +MI0017490 tcc-MIR171b; +MI0017491 tcc-MIR171c; +MI0017492 tcc-MIR171d; +MI0017493 tcc-MIR171e; +MI0017494 tcc-MIR171f; +MI0017495 tcc-MIR171g; +MI0017496 tcc-MIR171h; +MI0017497 tcc-MIR172a; +MI0017498 tcc-MIR172b; +MI0017499 tcc-MIR172c; +MI0017500 tcc-MIR172d; +MI0017501 tcc-MIR172e; +MI0017502 tcc-MIR319; +MI0017503 tcc-MIR390a; +MI0017504 tcc-MIR390b; +MI0017505 tcc-MIR393a; +MI0017506 tcc-MIR393b; +MI0017507 tcc-MIR394a; +MI0017508 tcc-MIR394b; +MI0017509 tcc-MIR395a; +MI0017510 tcc-MIR395b; +MI0017511 tcc-MIR396a; +MI0017512 tcc-MIR396b; +MI0017513 tcc-MIR396c; +MI0017514 tcc-MIR396d; +MI0017515 tcc-MIR396e; +MI0017516 tcc-MIR397; +MI0017517 tcc-MIR398a; +MI0017518 tcc-MIR398b; +MI0017519 tcc-MIR399a; +MI0017520 tcc-MIR399b; +MI0017521 tcc-MIR399c; +MI0017522 tcc-MIR399d; +MI0017523 tcc-MIR399e; +MI0017524 tcc-MIR399f; +MI0017525 tcc-MIR399g; +MI0017526 tcc-MIR399h; +MI0017527 tcc-MIR399i; +MI0017528 tcc-MIR403a; +MI0017529 tcc-MIR403b; +MI0017530 tcc-MIR530a; +MI0017531 tcc-MIR530b; +MI0017532 tcc-MIR535; +MI0017533 tcc-MIR827; +MI0017534 tcc-MIR2111; +MI0017535 cel-mir-4805; +MI0017536 cel-mir-4806; +MI0017537 cel-mir-4807; +MI0017538 cel-mir-4808; +MI0017539 cel-mir-4809; +MI0017540 cel-mir-4810;cel-mir-4810a; +MI0017541 cel-mir-4811; +MI0017542 cel-mir-4812; +MI0017543 cel-mir-4813; +MI0017544 cel-mir-4814; +MI0017545 cel-mir-4815; +MI0017546 cel-mir-4816; +MI0017547 sko-mir-125b; +MI0017548 sko-mir-4817; +MI0017549 sko-mir-4818a; +MI0017550 sko-mir-4818b; +MI0017551 sko-mir-4818c; +MI0017552 sko-mir-4818d; +MI0017553 sko-mir-4818e; +MI0017554 sko-mir-4818f; +MI0017555 sko-mir-4818g; +MI0017556 sko-mir-4819; +MI0017557 sko-mir-4820; +MI0017558 sko-mir-4821; +MI0017559 sko-mir-2007; +MI0017560 sko-mir-4822; +MI0017561 sko-mir-4823; +MI0017562 sko-mir-4824; +MI0017563 sko-mir-4825; +MI0017564 sko-mir-4826; +MI0017565 sko-mir-4827a; +MI0017566 sko-mir-4827b; +MI0017567 sko-mir-4828a; +MI0017568 sko-mir-4828b; +MI0017569 sko-mir-4829a; +MI0017570 sko-mir-4829b; +MI0017571 sko-mir-4829c; +MI0017572 sko-mir-4830a; +MI0017573 sko-mir-4830b; +MI0017574 sko-mir-4830c; +MI0017575 sko-mir-4831; +MI0017576 sko-mir-4832; +MI0017577 sko-mir-2006; +MI0017578 sko-mir-4833; +MI0017579 sko-mir-4834; +MI0017580 sko-mir-4835; +MI0017581 sko-mir-4836; +MI0017582 sko-mir-4837; +MI0017583 sko-mir-4830d; +MI0017584 sko-mir-4838; +MI0017585 sko-mir-4839; +MI0017586 sko-mir-4840; +MI0017587 sko-mir-4841-1; +MI0017588 sko-mir-4841-2; +MI0017589 sko-mir-4842; +MI0017590 sko-mir-4843; +MI0017591 sko-mir-4844; +MI0017592 sko-mir-4845; +MI0017593 sko-mir-4846; +MI0017594 spu-mir-29b; +MI0017595 spu-mir-981; +MI0017596 spu-mir-4847; +MI0017597 spu-mir-4848a; +MI0017598 spu-mir-4848b; +MI0017599 spu-mir-4849; +MI0017600 spu-mir-4850; +MI0017601 spu-mir-4851; +MI0017602 spu-mir-4852; +MI0017603 spu-mir-4853;spu-mir-4853-1; +MI0017604 spu-mir-4854; +MI0017605 spu-mir-4855; +MI0017606 bfl-mir-92d; +MI0017607 bfl-mir-129b; +MI0017608 bfl-mir-182b; +MI0017609 bfl-mir-4856a; +MI0017610 bfl-mir-4857; +MI0017611 bfl-mir-4858; +MI0017612 bfl-mir-4859; +MI0017613 bfl-mir-4860; +MI0017614 bfl-mir-4861; +MI0017615 bfl-mir-4862a;bfl-mir-4862; +MI0017616 bfl-mir-4862b; +MI0017617 bfl-mir-4856b; +MI0017618 bfl-mir-4863; +MI0017619 bfl-mir-4864; +MI0017620 bfl-mir-4865; +MI0017621 bfl-mir-4866; +MI0017622 bfl-mir-4867; +MI0017623 bfl-mir-4868a; +MI0017624 bfl-mir-4868b; +MI0017625 bfl-mir-4868c; +MI0017626 bfl-mir-4869; +MI0017627 bfl-mir-4870; +MI0017628 bfl-mir-193b; +MI0017629 bfl-mir-4871; +MI0017630 bfl-mir-4872a; +MI0017631 bfl-mir-4872b; +MI0017632 bfl-mir-4872c-1; +MI0017633 bfl-mir-4872c-2; +MI0017634 bfl-mir-4928; +MI0017635 bfl-mir-34c;bfl-mir-34c-1; +MI0017636 bfl-mir-4873; +MI0017637 bfl-mir-4874; +MI0017638 bfl-mir-4875a; +MI0017639 bfl-mir-4875b; +MI0017640 bfl-mir-4875c; +MI0017641 bfl-mir-4875d; +MI0017642 bfl-mir-4876; +MI0017643 bfl-mir-4877; +MI0017644 bfl-mir-4878; +MI0017645 bfl-mir-4879; +MI0017646 bfl-mir-4880; +MI0017647 bfl-mir-4881; +MI0017648 bfl-mir-4057;bfl-mir-4057-1; +MI0017649 bfl-mir-4882a; +MI0017650 bfl-mir-4882b; +MI0017651 bfl-mir-4882c; +MI0017652 bfl-mir-4883; +MI0017653 bfl-mir-4884; +MI0017654 bfl-mir-4885a;bfl-mir-4885; +MI0017655 bfl-mir-4885b; +MI0017656 bfl-mir-4886; +MI0017657 bfl-mir-4887; +MI0017658 bfl-mir-4888; +MI0017659 bfl-mir-4889a; +MI0017660 bfl-mir-4889b; +MI0017661 bfl-mir-182c; +MI0017662 bfl-mir-4890; +MI0017663 bfl-mir-4891; +MI0017664 bfl-mir-4892; +MI0017665 bfl-mir-4893; +MI0017666 bfl-mir-182d; +MI0017667 bfl-mir-4894; +MI0017668 bfl-mir-4895; +MI0017669 bfl-mir-4896; +MI0017670 bfl-mir-4897a;bfl-mir-4897; +MI0017671 bfl-mir-4897b; +MI0017672 bfl-mir-4898; +MI0017673 bfl-mir-4899; +MI0017674 bfl-mir-4900a;bfl-mir-4900a-1; +MI0017675 bfl-mir-4900b;bfl-mir-4900b-1; +MI0017676 bfl-mir-4901; +MI0017677 bfl-mir-4902; +MI0017678 bfl-mir-34d; +MI0017679 bfl-mir-34e; +MI0017680 bfl-mir-4903; +MI0017681 bfl-mir-4904; +MI0017682 bfl-mir-4905; +MI0017683 bfl-mir-4906; +MI0017684 xbo-mir-92a; +MI0017685 xbo-mir-2013; +MI0017686 xbo-mir-124; +MI0017687 xbo-mir-137; +MI0017688 xbo-mir-219; +MI0017689 xbo-mir-2012; +MI0017690 xbo-mir-4907; +MI0017691 xbo-mir-92b; +MI0017692 dme-mir-4910; +MI0017693 dme-mir-4911; +MI0017694 dme-mir-4912; +MI0017695 dme-mir-4913; +MI0017696 dme-mir-4914; +MI0017697 dme-mir-4915; +MI0017698 dme-mir-4916; +MI0017699 dme-mir-2535b; +MI0017700 dme-mir-4917; +MI0017701 dme-mir-4918; +MI0017702 dme-mir-4919; +MI0017703 dme-mir-4908; +MI0017704 dme-mir-4909; +MI0017705 cel-mir-4920; +MI0017706 cel-mir-4921; +MI0017707 cel-mir-4922-1; +MI0017708 cel-mir-4922-2; +MI0017709 cel-mir-4923a; +MI0017710 cel-mir-4924; +MI0017711 cel-mir-4923b; +MI0017712 cel-mir-4925; +MI0017713 cel-mir-4926; +MI0017714 cel-mir-4927; +MI0017715 cel-mir-4929; +MI0017716 cel-mir-4930; +MI0017717 cel-mir-4931; +MI0017718 cel-mir-4932; +MI0017719 cel-mir-4933; +MI0017720 cel-mir-4934; +MI0017721 cel-mir-4935; +MI0017722 cel-mir-4936; +MI0017723 cel-mir-4937; +MI0017724 cel-mir-4938; +MI0017725 dme-mir-4939; +MI0017726 dme-mir-4940; +MI0017727 dme-mir-4941; +MI0017728 dme-mir-4942; +MI0017729 dme-mir-4943; +MI0017730 dme-mir-4944; +MI0017731 dme-mir-4945; +MI0017732 dme-mir-4946; +MI0017733 dme-mir-4947; +MI0017734 dme-mir-4948; +MI0017735 dme-mir-4949; +MI0017736 dme-mir-4950; +MI0017737 dme-mir-4951; +MI0017738 dme-mir-4952; +MI0017739 dme-mir-4953; +MI0017740 dme-mir-4954; +MI0017741 dme-mir-4955; +MI0017742 dme-mir-4956; +MI0017743 dme-mir-4957; +MI0017744 dme-mir-4958; +MI0017745 dme-mir-4959; +MI0017746 dme-mir-4960; +MI0017747 dme-mir-4961; +MI0017748 dme-mir-4962; +MI0017749 dme-mir-4963; +MI0017750 dme-mir-4964; +MI0017751 dme-mir-4965; +MI0017752 dme-mir-4966; +MI0017753 dme-mir-4967; +MI0017754 dme-mir-4968; +MI0017755 dme-mir-4969; +MI0017756 dme-mir-4970; +MI0017757 dme-mir-4971; +MI0017758 dme-mir-4972; +MI0017759 dme-mir-4973; +MI0017760 dme-mir-4974; +MI0017761 dme-mir-4975; +MI0017762 dme-mir-4976; +MI0017763 dme-mir-4977; +MI0017764 dme-mir-4978; +MI0017765 dme-mir-4979; +MI0017766 dme-mir-4980; +MI0017767 dme-mir-4981; +MI0017768 dme-mir-4982; +MI0017769 dme-mir-4983; +MI0017770 dme-mir-4984; +MI0017771 dme-mir-4985; +MI0017772 dme-mir-4986; +MI0017773 dme-mir-4987; +MI0017774 egr-let-7; +MI0017775 egr-mir-1; +MI0017776 egr-mir-2a; +MI0017777 egr-mir-2b; +MI0017778 egr-mir-2c; +MI0017779 egr-mir-7; +MI0017780 egr-mir-8; +MI0017781 egr-mir-9; +MI0017782 egr-mir-10;egr-mir-10a; +MI0017783 egr-mir-71; +MI0017784 egr-mir-87; +MI0017785 egr-mir-124a; +MI0017786 egr-mir-124b; +MI0017787 egr-mir-125; +MI0017788 egr-mir-153; +MI0017789 egr-mir-190; +MI0017790 egr-mir-219; +MI0017791 egr-mir-277;egr-mir-277a; +MI0017792 egr-mir-745; +MI0017793 egr-mir-4988;egr-mir-184; +MI0017794 egr-mir-4989; +MI0017795 egr-mir-4990; +MI0017796 egr-mir-4991; +MI0017797 emu-let-7; +MI0017798 emu-mir-1; +MI0017799 emu-mir-2a; +MI0017800 emu-mir-2b; +MI0017801 emu-mir-2c; +MI0017802 emu-mir-7; +MI0017803 emu-mir-8; +MI0017804 emu-mir-9; +MI0017805 emu-mir-10; +MI0017806 emu-mir-71; +MI0017807 emu-mir-87; +MI0017808 emu-mir-96; +MI0017809 emu-mir-124a; +MI0017810 emu-mir-124b; +MI0017811 emu-mir-125; +MI0017812 emu-mir-153; +MI0017813 emu-mir-190; +MI0017814 emu-mir-219; +MI0017815 emu-mir-277;emu-mir-277a; +MI0017816 emu-mir-745; +MI0017817 emu-mir-4988;emu-mir-184; +MI0017818 emu-mir-4989; +MI0017819 gma-MIR156h; +MI0017820 gma-MIR156i; +MI0017821 gma-MIR160b; +MI0017822 gma-MIR160c; +MI0017823 gma-MIR160d; +MI0017824 gma-MIR160e; +MI0017825 gma-MIR162b; +MI0017826 gma-MIR164b; +MI0017827 gma-MIR164c; +MI0017828 gma-MIR164d; +MI0017829 gma-MIR166c; +MI0017830 gma-MIR166d; +MI0017831 gma-MIR166e; +MI0017832 gma-MIR166f; +MI0017833 gma-MIR166g; +MI0017834 gma-MIR166h; +MI0017835 gma-MIR168b; +MI0017836 gma-MIR169f; +MI0017837 gma-MIR169g; +MI0017838 gma-MIR171d; +MI0017839 gma-MIR171e; +MI0017840 gma-MIR171f; +MI0017841 gma-MIR171g; +MI0017842 gma-MIR319d; +MI0017843 gma-MIR319e; +MI0017844 gma-MIR319f; +MI0017845 gma-MIR390c; +MI0017846 gma-MIR394c; +MI0017847 gma-MIR398c; +MI0017848 gma-MIR408;gma-MIR408d; +MI0017849 gma-MIR2118a; +MI0017850 gma-MIR2118b; +MI0017851 gma-MIR482c; +MI0017852 gma-MIR530;gma-MIR530a; +MI0017853 gma-MIR862a; +MI0017854 gma-MIR1507c; +MI0017855 gma-MIR1508c; +MI0017856 gma-MIR1513b; +MI0017857 gma-MIR1535b; +MI0017858 gma-MIR4992; +MI0017859 gma-MIR4993; +MI0017860 gma-MIR4994; +MI0017861 gma-MIR4995; +MI0017862 gma-MIR4996; +MI0017863 gma-MIR4997; +MI0017864 gma-MIR4998; +MI0017865 hsa-mir-4999; +MI0017866 hsa-mir-5000; +MI0017867 hsa-mir-5001; +MI0017868 hsa-mir-5002; +MI0017869 hsa-mir-5003; +MI0017870 hsa-mir-5004; +MI0017871 hsa-mir-548ao; +MI0017872 hsa-mir-4482-2; +MI0017873 hsa-mir-5006; +MI0017874 hsa-mir-5007; +MI0017875 hsa-mir-548ap; +MI0017876 hsa-mir-5008; +MI0017877 hsa-mir-5009; +MI0017878 hsa-mir-5010; +MI0017879 hsa-mir-5011; +MI0017880 ath-MIR5012; +MI0017881 ath-MIR5013; +MI0017882 ath-MIR5014;ath-MIR5014a; +MI0017883 ath-MIR5015a;ath-MIR5015; +MI0017884 ath-MIR5016; +MI0017885 ath-MIR5017; +MI0017886 ath-MIR5018; +MI0017887 ath-MIR5019; +MI0017888 ath-MIR5020a; +MI0017889 ath-MIR5021; +MI0017890 ath-MIR5015b; +MI0017891 ath-MIR5022; +MI0017892 ath-MIR5023; +MI0017893 ath-MIR5020b; +MI0017894 ath-MIR5024; +MI0017895 ath-MIR5025; +MI0017896 ath-MIR5026; +MI0017897 ath-MIR5027; +MI0017898 ath-MIR5028; +MI0017899 ath-MIR5029; +MI0017900 gma-MIR5030; +MI0017901 gma-MIR5031; +MI0017902 gma-MIR1523b; +MI0017903 gma-MIR5032; +MI0017904 gma-MIR5033; +MI0017905 gma-MIR171h; +MI0017906 gma-MIR5034; +MI0017907 gma-MIR171i; +MI0017908 gma-MIR5035; +MI0017909 gma-MIR5036; +MI0017910 gma-MIR5037;gma-MIR5037a; +MI0017911 gma-MIR1516b; +MI0017912 gma-MIR169h; +MI0017913 gma-MIR5038a; +MI0017914 gma-MIR167h; +MI0017915 gma-MIR1521b; +MI0017916 gma-MIR5039; +MI0017917 gma-MIR5040; +MI0017918 gma-MIR169i; +MI0017919 gma-MIR396f; +MI0017920 gma-MIR5041; +MI0017921 gma-MIR396g; +MI0017922 gma-MIR5042; +MI0017923 gma-MIR4372b; +MI0017924 gma-MIR5043; +MI0017925 gma-MIR5044; +MI0017926 gma-MIR167i; +MI0017927 hme-mir-2788; +MI0017928 hme-mir-193; +MI0017929 gpy-mir-5045; +MI0017930 tre-mir-5045; +MI0017931 mmu-mir-5046; +MI0017932 hsa-mir-5047; +MI0017933 hvu-MIR399; +MI0017934 hvu-MIR444b; +MI0017935 hvu-MIR5048;hvu-MIR5048a; +MI0017936 hvu-MIR5049;hvu-MIR5049a; +MI0017937 hvu-MIR5050; +MI0017938 hvu-MIR5051; +MI0017939 hvu-MIR5052; +MI0017940 hvu-MIR5053; +MI0017941 bdi-MIR408; +MI0017942 osa-MIR5071; +MI0017943 osa-MIR5072; +MI0017944 bdi-MIR5055; +MI0017945 bdi-MIR5056; +MI0017946 osa-MIR5073; +MI0017947 bdi-MIR5057; +MI0017948 bdi-MIR5058; +MI0017949 tae-MIR5086; +MI0017950 osa-MIR5074; +MI0017951 bdi-MIR5059; +MI0017952 osa-MIR5075; +MI0017953 bdi-MIR5060; +MI0017954 bdi-MIR5061; +MI0017955 osa-MIR5076; +MI0017956 bdi-MIR1878; +MI0017957 tae-MIR5084; +MI0017958 tae-MIR5085; +MI0017959 bdi-MIR5062a; +MI0017960 bdi-MIR5062b; +MI0017961 bdi-MIR5063; +MI0017962 bdi-MIR5064; +MI0017963 bdi-MIR5065; +MI0017964 bdi-MIR5066; +MI0017965 osa-MIR5077; +MI0017966 osa-MIR5078; +MI0017967 bdi-MIR5067; +MI0017968 bdi-MIR5068; +MI0017969 osa-MIR5079;osa-MIR5079a; +MI0017970 osa-MIR5080; +MI0017971 bdi-MIR5069; +MI0017972 osa-MIR5081; +MI0017973 osa-MIR5082; +MI0017974 osa-MIR5083; +MI0017975 bdi-MIR5070; +MI0017976 hsa-mir-5087; +MI0017977 hsa-mir-5088; +MI0017978 hsa-mir-5089; +MI0017979 hsa-mir-5090; +MI0017980 hsa-mir-5091; +MI0017981 hsa-mir-5092; +MI0017982 hsa-mir-5093; +MI0017983 hsa-mir-5094; +MI0017984 ssc-let-7a-2; +MI0017985 ssc-mir-18b; +MI0017986 ssc-mir-129b; +MI0017987 ssc-mir-187; +MI0017988 ssc-mir-190;ssc-mir-190b; +MI0017989 ssc-mir-218b; +MI0017990 ssc-mir-219;ssc-mir-219a; +MI0017991 ssc-mir-429; +MI0017992 ssc-mir-486-2; +MI0017993 ssc-mir-491; +MI0017994 ssc-mir-545; +MI0017995 ssc-mir-615; +MI0017996 ssc-mir-1343; +MI0017997 ssc-mir-2320; +MI0017998 ssc-mir-2476-1; +MI0017999 ssc-mir-2476-2; +MI0018000 ssc-mir-2476-3; +MI0018001 hsa-mir-5095; +MI0018002 hsa-mir-1273f; +MI0018003 hsa-mir-1273g; +MI0018004 hsa-mir-5096; +MI0018005 mmu-mir-5097; +MI0018006 mmu-mir-5098; +MI0018007 mmu-mir-5099; +MI0018008 mmu-mir-5100; +MI0018009 mmu-mir-5101; +MI0018010 mmu-mir-5102; +MI0018011 mmu-mir-5103; +MI0018012 mmu-mir-5104; +MI0018013 mmu-mir-5105; +MI0018014 mmu-mir-5106; +MI0018015 mmu-mir-3473c; +MI0018016 mmu-mir-5107; +MI0018017 mmu-mir-5108; +MI0018018 mmu-mir-5109; +MI0018019 mmu-mir-5110; +MI0018020 mmu-mir-5111; +MI0018021 mmu-mir-5112; +MI0018022 mmu-mir-5113; +MI0018023 mmu-mir-5114; +MI0018024 mmu-mir-5115; +MI0018025 mmu-mir-5116; +MI0018026 mmu-mir-5117; +MI0018027 mmu-mir-5118; +MI0018028 mmu-mir-5119; +MI0018029 mmu-mir-5120; +MI0018030 mmu-mir-5121; +MI0018031 mmu-mir-5122; +MI0018032 mmu-mir-466q; +MI0018033 mmu-mir-3473d; +MI0018034 mmu-mir-5123; +MI0018035 mmu-mir-5124;mmu-mir-5124a; +MI0018036 mmu-mir-5125; +MI0018037 mmu-mir-3572; +MI0018038 mmu-mir-5126; +MI0018039 mmu-mir-5127; +MI0018040 mmu-mir-5128; +MI0018041 mmu-mir-5129; +MI0018042 mmu-mir-5130; +MI0018043 mmu-mir-5131; +MI0018044 mmu-mir-5132; +MI0018045 mmu-mir-5133; +MI0018046 mmu-mir-5134; +MI0018047 mmu-mir-5135; +MI0018048 mmu-mir-5136; +MI0018049 rgl-MIR5137; +MI0018050 rgl-MIR5138; +MI0018051 rgl-MIR5139; +MI0018052 rgl-MIR5140; +MI0018053 rgl-MIR5141; +MI0018054 rgl-MIR5142; +MI0018055 osa-MIR5143;osa-MIR5143a; +MI0018056 osa-MIR5144; +MI0018057 osa-MIR5145; +MI0018058 osa-MIR5146; +MI0018059 osa-MIR5147; +MI0018060 osa-MIR2863c; +MI0018061 osa-MIR5148a; +MI0018062 osa-MIR5148b; +MI0018063 osa-MIR5148c; +MI0018064 osa-MIR5149; +MI0018065 osa-MIR5150; +MI0018066 osa-MIR5151; +MI0018067 osa-MIR5152; +MI0018068 osa-MIR5153; +MI0018069 osa-MIR5154; +MI0018070 osa-MIR5155; +MI0018071 osa-MIR5156; +MI0018072 osa-MIR5157a; +MI0018073 osa-MIR5157b; +MI0018074 osa-MIR5158; +MI0018075 osa-MIR5159; +MI0018076 osa-MIR5160; +MI0018077 osa-MIR5161; +MI0018078 osa-MIR5162; +MI0018079 bdi-MIR169d; +MI0018080 bdi-MIR169i; +MI0018081 bdi-MIR395a; +MI0018082 bdi-MIR169j; +MI0018083 bdi-MIR166f; +MI0018084 bdi-MIR171b; +MI0018085 bdi-MIR390;bdi-MIR390a; +MI0018086 bdi-MIR160a; +MI0018087 bdi-MIR528; +MI0018088 bdi-MIR395b; +MI0018089 bdi-MIR166d; +MI0018090 bdi-MIR171d; +MI0018091 bdi-MIR167b; +MI0018092 bdi-MIR166b; +MI0018093 bdi-MIR160b; +MI0018094 bdi-MIR164b; +MI0018095 bdi-MIR167c; +MI0018096 bdi-MIR396d; +MI0018097 bdi-MIR169k; +MI0018098 bdi-MIR168; +MI0018099 bdi-MIR397b; +MI0018100 bdi-MIR160c; +MI0018101 bdi-MIR396c; +MI0018102 bdi-MIR167d; +MI0018103 bdi-MIR399b; +MI0018104 bdi-MIR156b; +MI0018105 bdi-MIR169g; +MI0018106 bdi-MIR160d; +MI0018107 bdi-MIR160e; +MI0018108 bdi-MIR396e; +MI0018109 bdi-MIR156c; +MI0018110 bdi-MIR172a; +MI0018111 bdi-MIR396a; +MI0018112 bdi-MIR166e; +MI0018113 bdi-MIR166c; +MI0018114 bdi-MIR169e; +MI0018115 bdi-MIR394; +MI0018116 bdi-MIR398a; +MI0018117 bdi-MIR159;bdi-MIR159a; +MI0018118 bdi-MIR164a; +MI0018119 bdi-MIR393a; +MI0018120 bdi-MIR169a; +MI0018121 bdi-MIR172b; +MI0018122 bdi-MIR156d; +MI0018123 bdi-MIR393b; +MI0018124 bdi-MIR169h; +MI0018125 bdi-MIR396b; +MI0018126 bdi-MIR169c; +MI0018127 bdi-MIR395c; +MI0018128 bdi-MIR827; +MI0018129 bdi-MIR5163;bdi-MIR5163a; +MI0018130 bdi-MIR5181b; +MI0018131 bdi-MIR5164; +MI0018132 bdi-MIR5165; +MI0018133 bdi-MIR5166; +MI0018134 bdi-MIR5167;bdi-MIR5167a; +MI0018135 bdi-MIR5168;bdi-MIR166g; +MI0018136 bdi-MIR5169;bdi-MIR5169a; +MI0018137 bdi-MIR319;bdi-MIR319a; +MI0018138 bdi-MIR5180b; +MI0018139 bdi-MIR5170; +MI0018140 bdi-MIR5171;bdi-MIR5171a; +MI0018141 bdi-MIR5172; +MI0018142 bdi-MIR5173; +MI0018143 bdi-MIR5174;bdi-MIR5174a; +MI0018144 bdi-MIR5175a; +MI0018145 bdi-MIR5176; +MI0018146 bdi-MIR5175b; +MI0018147 bdi-MIR395d; +MI0018148 bdi-MIR5177; +MI0018149 bdi-MIR5178; +MI0018150 bdi-MIR398b; +MI0018151 bdi-MIR5179; +MI0018152 bdi-MIR164c; +MI0018153 bdi-MIR5180a; +MI0018154 bdi-MIR5181a; +MI0018155 bdi-MIR5182; +MI0018156 bdi-MIR5183; +MI0018157 bdi-MIR5184; +MI0018158 bdi-MIR5185a; +MI0018159 bdi-MIR5185b; +MI0018160 bdi-MIR169f; +MI0018161 xtr-mir-449b; +MI0018162 xtr-mir-449c; +MI0018163 cme-MIR164;cme-MIR164a; +MI0018164 cme-MIR390;cme-MIR390b; +MI0018165 hsa-mir-5186; +MI0018166 hsa-mir-5187; +MI0018167 hsa-mir-5188; +MI0018168 hsa-mir-5189; +MI0018169 hsa-mir-5190; +MI0018170 hsa-mir-5191; +MI0018171 hsa-mir-5192; +MI0018172 hsa-mir-5193; +MI0018173 hsa-mir-5194; +MI0018174 hsa-mir-5195; +MI0018175 hsa-mir-5196; +MI0018176 hsa-mir-5197; +MI0018177 cme-MIR168; +MI0018178 bpcv1-mir-B1; +MI0018179 bpcv2-mir-B1; +MI0018180 ssp-MIR169; +MI0018181 ssp-MIR827; +MI0018182 ssp-MIR437a; +MI0018183 ssp-MIR437b; +MI0018184 ssp-MIR437c; +MI0018185 ssp-MIR444a; +MI0018186 ssp-MIR444b; +MI0018187 ssp-MIR444c; +MI0018188 ssp-MIR528; +MI0018189 ssp-MIR1128; +MI0018190 ssp-MIR1432; +MI0018191 ssp-MIR156; +MI0018192 ssp-MIR159a; +MI0018193 ssp-MIR167b; +MI0018194 ssp-MIR168a; +MI0018195 ssp-MIR396; +MI0018196 ssp-MIR408d; +MI0018197 ssp-MIR408a; +MI0018199 mml-mir-371-2; +MI0018200 mml-mir-762-2; +MI0018201 mml-mir-762-3; +MI0018202 mml-mir-663-2; +MI0018203 mml-mir-663-3; +MI0018204 mml-mir-663-4; +MI0018205 mml-mir-663-5; +MI0018206 mml-mir-663-6; +MI0018207 mml-mir-663-7; +MI0018208 mml-mir-663-8; +MI0018209 mml-mir-663-9; +MI0018210 mml-mir-663-10; +MI0018211 mml-mir-663-11; +MI0018212 hvu-MIR166c; +MI0018213 bdi-MIR162; +MI0018214 bdi-MIR164d; +MI0018215 bdi-MIR164e; +MI0018216 bdi-MIR164f; +MI0018217 bdi-MIR390b; +MI0018218 bdi-MIR395i; +MI0018219 bdi-MIR395m; +MI0018220 bdi-MIR395e; +MI0018221 bdi-MIR395f; +MI0018222 bdi-MIR395g; +MI0018223 bdi-MIR395h; +MI0018224 bdi-MIR395j; +MI0018225 bdi-MIR395k; +MI0018226 bdi-MIR395l; +MI0018227 bdi-MIR395n; +MI0018228 bdi-MIR398c; +MI0018229 bdi-MIR529; +MI0018230 bdi-MIR5198; +MI0018231 bdi-MIR5199; +MI0018232 bdi-MIR5200;bdi-MIR5200c; +MI0018233 bdi-MIR5201; +MI0018234 bdi-MIR5202; +MI0018235 bdi-MIR5203;bdi-MIR5181d; +MI0018236 bdi-MIR319b; +MI0018237 bdi-MIR396f; +MI0018238 bdi-MIR5054; +MI0018239 mtr-MIR5204; +MI0018240 mtr-MIR5205a; +MI0018241 mtr-MIR5205b; +MI0018242 mtr-MIR5205c; +MI0018243 mtr-MIR5205d; +MI0018244 mtr-MIR5206;mtr-MIR5206a; +MI0018245 mtr-MIR5207; +MI0018246 mtr-MIR5208a; +MI0018247 mtr-MIR5208b; +MI0018248 mtr-MIR5208c; +MI0018249 mtr-MIR5209; +MI0018250 mtr-MIR5210; +MI0018251 mtr-MIR5211; +MI0018252 mtr-MIR5212; +MI0018253 mtr-MIR5213; +MI0018254 mtr-MIR5214; +MI0018255 mtr-MIR2592t; +MI0018256 mtr-MIR5215; +MI0018257 mtr-MIR2592u; +MI0018258 mtr-MIR2592v; +MI0018259 mtr-MIR2592w; +MI0018260 mtr-MIR2592x; +MI0018261 mtr-MIR2592y; +MI0018262 mtr-MIR2592z; +MI0018263 mtr-MIR2592aa; +MI0018264 mtr-MIR2592ab; +MI0018265 mtr-MIR2592ac; +MI0018266 mtr-MIR2592ad; +MI0018267 mtr-MIR2592ae; +MI0018268 mtr-MIR2592af; +MI0018269 mtr-MIR2592ag; +MI0018270 mtr-MIR2592ah; +MI0018271 mtr-MIR2592ai; +MI0018272 mtr-MIR2592aj; +MI0018273 mtr-MIR2592ak; +MI0018274 mtr-MIR2592al; +MI0018275 mtr-MIR2592am; +MI0018276 mtr-MIR2592an; +MI0018277 mtr-MIR2592ao; +MI0018278 mtr-MIR2586b; +MI0018279 mtr-MIR5216a; +MI0018280 mtr-MIR5216b; +MI0018281 mtr-MIR5217; +MI0018282 mtr-MIR5218; +MI0018283 mtr-MIR5219a;mtr-MIR5219; +MI0018284 mtr-MIR5221; +MI0018285 mtr-MIR5222; +MI0018286 mtr-MIR5223a;mtr-MIR5223; +MI0018287 mtr-MIR5223b; +MI0018288 mtr-MIR5224a; +MI0018289 mtr-MIR5225;mtr-MIR5225a; +MI0018290 mtr-MIR5226; +MI0018291 mtr-MIR5224b; +MI0018292 mtr-MIR5227; +MI0018293 mtr-MIR2592ap; +MI0018294 mtr-MIR2592aq; +MI0018295 mtr-MIR2592ar; +MI0018296 mtr-MIR2592as; +MI0018297 mtr-MIR2592at; +MI0018298 mtr-MIR2592au; +MI0018299 mtr-MIR2592av; +MI0018300 mtr-MIR2592aw; +MI0018301 mtr-MIR2592ax; +MI0018302 mtr-MIR2592ay; +MI0018303 mtr-MIR2592az; +MI0018304 mtr-MIR2592ba; +MI0018305 mtr-MIR2592bb; +MI0018306 mtr-MIR2592bc; +MI0018307 mtr-MIR2592bd; +MI0018308 mtr-MIR2592be; +MI0018309 mtr-MIR2592bf; +MI0018310 mtr-MIR2592bg; +MI0018311 mtr-MIR2592bh; +MI0018312 mtr-MIR4414a; +MI0018313 mtr-MIR2670e; +MI0018314 mtr-MIR2670f; +MI0018315 mtr-MIR2670g; +MI0018316 mtr-MIR4414b; +MI0018317 mtr-MIR5228; +MI0018318 mtr-MIR5229a; +MI0018319 mtr-MIR5229b; +MI0018320 mtr-MIR5230; +MI0018321 mtr-MIR5231; +MI0018322 mtr-MIR5232; +MI0018323 mtr-MIR5233; +MI0018324 mtr-MIR5234; +MI0018325 mtr-MIR5235a; +MI0018326 mtr-MIR5235b; +MI0018327 mtr-MIR5236a; +MI0018328 mtr-MIR5236b; +MI0018329 mtr-MIR5236c; +MI0018330 mtr-MIR5236d; +MI0018331 mtr-MIR5236e; +MI0018332 mtr-MIR5237; +MI0018333 mtr-MIR5238; +MI0018334 mtr-MIR2592bi; +MI0018335 mtr-MIR2592bj; +MI0018336 mtr-MIR2592bk; +MI0018337 mtr-MIR482; +MI0018338 mtr-MIR5239; +MI0018339 mtr-MIR5240; +MI0018340 mtr-MIR5241a; +MI0018341 mtr-MIR5241b; +MI0018342 mtr-MIR5241c; +MI0018343 mtr-MIR5242; +MI0018344 mtr-MIR5243; +MI0018345 mtr-MIR5244; +MI0018346 mtr-MIR5245; +MI0018347 mtr-MIR5246; +MI0018348 mtr-MIR5247; +MI0018349 mtr-MIR5248; +MI0018350 mtr-MIR5249; +MI0018351 mtr-MIR5250; +MI0018352 mtr-MIR5251; +MI0018353 mtr-MIR5252; +MI0018354 mtr-MIR2643b; +MI0018355 mtr-MIR5253; +MI0018356 mtr-MIR5254; +MI0018357 mtr-MIR5255; +MI0018358 mtr-MIR5256; +MI0018359 mtr-MIR2111t;mtr-MIR2111l; +MI0018360 mtr-MIR2111u;mtr-MIR2111f; +MI0018361 mtr-MIR5257; +MI0018362 mtr-MIR5258; +MI0018363 mtr-MIR5259; +MI0018364 mtr-MIR5260; +MI0018365 mtr-MIR5261; +MI0018366 mtr-MIR5262; +MI0018367 mtr-MIR5263; +MI0018368 mtr-MIR172b; +MI0018369 mtr-MIR172c; +MI0018370 mtr-MIR159b; +MI0018371 mtr-MIR160f; +MI0018372 mtr-MIR171h; +MI0018373 mtr-MIR168b; +MI0018374 mtr-MIR399r; +MI0018375 mtr-MIR156j; +MI0018376 mtr-MIR5264; +MI0018377 mtr-MIR5265; +MI0018378 mtr-MIR5266; +MI0018379 mtr-MIR5267a; +MI0018380 mtr-MIR5267b; +MI0018381 mtr-MIR5267c; +MI0018382 mtr-MIR5267d; +MI0018383 mtr-MIR5267e; +MI0018384 mtr-MIR5267f; +MI0018385 mtr-MIR5267g; +MI0018386 mtr-MIR5267h; +MI0018387 mtr-MIR5267i; +MI0018388 mtr-MIR5267j; +MI0018389 mtr-MIR5267k; +MI0018390 mtr-MIR5267l; +MI0018391 mtr-MIR5267m; +MI0018392 mtr-MIR5267n; +MI0018393 mtr-MIR5267o; +MI0018394 mtr-MIR5268a; +MI0018395 mtr-MIR5268b; +MI0018396 mtr-MIR5269a; +MI0018397 mtr-MIR5269b; +MI0018398 mtr-MIR5270a; +MI0018399 mtr-MIR5270b; +MI0018400 mtr-MIR5271a; +MI0018401 mtr-MIR5271b; +MI0018402 mtr-MIR5271c; +MI0018403 mtr-MIR5271d; +MI0018404 mtr-MIR5271e; +MI0018405 mtr-MIR5272a; +MI0018406 mtr-MIR5272b; +MI0018407 mtr-MIR5272c; +MI0018408 mtr-MIR5272d; +MI0018409 mtr-MIR5272e; +MI0018410 mtr-MIR5272f; +MI0018411 mtr-MIR5273; +MI0018412 mtr-MIR2590g; +MI0018413 mtr-MIR2629h; +MI0018414 mtr-MIR5274;mtr-MIR5274a; +MI0018415 mtr-MIR2606d;mtr-MIR2606c; +MI0018416 mtr-MIR5275; +MI0018417 mtr-MIR5276; +MI0018418 mtr-MIR5208d; +MI0018419 mtr-MIR5277; +MI0018420 mtr-MIR5278; +MI0018421 mtr-MIR5279; +MI0018422 mtr-MIR5280; +MI0018423 mtr-MIR5281a; +MI0018424 mtr-MIR5281b; +MI0018425 mtr-MIR5281c; +MI0018426 mtr-MIR5281d; +MI0018427 mtr-MIR5281e; +MI0018428 mtr-MIR5281f; +MI0018429 mtr-MIR5282; +MI0018430 mtr-MIR5283; +MI0018431 mtr-MIR2600b; +MI0018432 mtr-MIR2600c; +MI0018433 mtr-MIR2600d; +MI0018434 mtr-MIR2600e; +MI0018435 mtr-MIR2590h; +MI0018436 mtr-MIR2590i; +MI0018437 mtr-MIR2590j; +MI0018438 mtr-MIR5284a; +MI0018439 mtr-MIR5284b; +MI0018440 mtr-MIR5284c; +MI0018441 mtr-MIR5284d; +MI0018442 mtr-MIR5284e; +MI0018443 mtr-MIR5284f; +MI0018444 mtr-MIR5284g; +MI0018445 mtr-MIR5284h; +MI0018446 mtr-MIR5285a; +MI0018447 mtr-MIR5285b; +MI0018448 mtr-MIR5285c; +MI0018449 mtr-MIR5286a; +MI0018450 mtr-MIR5287a; +MI0018451 mtr-MIR5287b; +MI0018452 mtr-MIR5288; +MI0018453 mtr-MIR5289a; +MI0018454 mtr-MIR5289b; +MI0018455 mtr-MIR5286b; +MI0018456 mtr-MIR5290; +MI0018457 mtr-MIR5291a; +MI0018458 mtr-MIR5291b; +MI0018459 mtr-MIR5291c; +MI0018460 mtr-MIR5292a; +MI0018461 mtr-MIR5292b; +MI0018462 mtr-MIR5293; +MI0018463 mtr-MIR5294a; +MI0018464 mtr-MIR5294b; +MI0018465 mtr-MIR5294c; +MI0018466 mtr-MIR5295a; +MI0018467 mtr-MIR5295b; +MI0018468 mtr-MIR5295c; +MI0018469 mtr-MIR5295d; +MI0018470 mtr-MIR5296; +MI0018471 mtr-MIR5297; +MI0018472 mtr-MIR5298a; +MI0018473 mtr-MIR5298b; +MI0018474 mtr-MIR5298c; +MI0018475 mtr-MIR5298d; +MI0018476 mtr-MIR5299; +MI0018477 sly-MIR5300; +MI0018478 sly-MIR5301;sly-MIR482e; +MI0018479 sly-MIR5302;sly-MIR5302a; +MI0018480 sly-MIR5303; +MI0018481 sly-MIR5304; +MI0018482 sly-MIR482;sly-MIR482a; +MI0018483 mtr-MIR5219b; +MI0018484 isc-mir-5305; +MI0018485 isc-mir-5306; +MI0018486 isc-mir-5307; +MI0018487 isc-mir-5308; +MI0018488 isc-mir-5309; +MI0018489 isc-mir-3931; +MI0018490 isc-mir-5310; +MI0018491 isc-mir-5311; +MI0018492 isc-mir-5312; +MI0018493 isc-mir-5313; +MI0018494 isc-mir-5314; +MI0018495 isc-mir-5315; +MI0018496 rmi-mir-5316a; +MI0018497 rmi-mir-5316b; +MI0018498 rmi-mir-5317a; +MI0018499 rmi-mir-5318; +MI0018500 rmi-mir-5317b; +MI0018501 rmi-mir-5319; +MI0018502 rmi-mir-5320; +MI0018503 rmi-mir-5321; +MI0018504 rmi-mir-5322; +MI0018505 rmi-mir-5323; +MI0018506 rmi-mir-5324; +MI0018507 rmi-mir-5325; +MI0018508 rmi-mir-5326; +MI0018509 rmi-mir-5327; +MI0018510 rmi-mir-5328; +MI0018511 rmi-mir-5329; +MI0018512 rmi-mir-5330; +MI0018513 rmi-mir-5331; +MI0018514 rmi-mir-5332; +MI0018515 rmi-mir-5333; +MI0018516 rmi-mir-5334; +MI0018517 rmi-mir-5335; +MI0018518 rmi-mir-5336; +MI0018519 osa-MIR5337;osa-MIR5337a; +MI0018520 osa-MIR5338; +MI0018521 osa-MIR5339; +MI0018522 osa-MIR5340; +MI0018523 rmi-mir-5341; +MI0018524 asu-lin-4; +MI0018525 asu-let-7; +MI0018526 asu-mir-81b; +MI0018527 asu-mir-81c; +MI0018528 asu-mir-1; +MI0018529 asu-mir-2a; +MI0018530 asu-mir-2b; +MI0018531 asu-mir-7; +MI0018532 asu-mir-9; +MI0018533 asu-mir-43d; +MI0018534 asu-mir-43e; +MI0018535 asu-mir-34; +MI0018536 asu-mir-36a; +MI0018537 asu-mir-36b; +MI0018538 asu-mir-36c; +MI0018539 asu-mir-36d; +MI0018540 asu-mir-36e; +MI0018541 asu-mir-43a; +MI0018542 asu-mir-43b; +MI0018543 asu-mir-43c-1; +MI0018544 asu-mir-43c-2; +MI0018545 asu-mir-44a; +MI0018546 asu-mir-46; +MI0018547 asu-mir-49; +MI0018548 asu-mir-50; +MI0018549 asu-mir-56; +MI0018550 asu-mir-57; +MI0018551 asu-mir-71; +MI0018552 asu-mir-72; +MI0018553 asu-mir-76; +MI0018554 asu-mir-79; +MI0018555 asu-mir-81a; +MI0018556 asu-mir-83; +MI0018557 asu-mir-84; +MI0018558 asu-mir-86; +MI0018559 asu-mir-87a; +MI0018560 asu-mir-87b; +MI0018561 asu-mir-92; +MI0018562 asu-mir-100a-1; +MI0018563 asu-mir-100a-2; +MI0018564 asu-mir-100b; +MI0018565 asu-mir-100c; +MI0018566 asu-mir-100d; +MI0018567 asu-mir-124; +MI0018568 asu-mir-133; +MI0018569 asu-mir-137;asu-mir-234; +MI0018570 asu-mir-184; +MI0018571 asu-mir-228; +MI0018572 asu-mir-236; +MI0018573 asu-mir-250; +MI0018574 asu-mir-252; +MI0018575 asu-mir-279a; +MI0018576 asu-mir-279b; +MI0018577 asu-mir-279c; +MI0018578 asu-mir-5342; +MI0018579 asu-mir-5343;asu-mir-283; +MI0018580 asu-mir-5344;asu-mir-239; +MI0018581 asu-mir-67; +MI0018582 asu-mir-375; +MI0018583 asu-mir-750; +MI0018584 asu-mir-791; +MI0018585 asu-mir-993; +MI0018586 asu-mir-1175; +MI0018587 asu-mir-1822; +MI0018588 asu-mir-5345a; +MI0018589 asu-mir-5345b; +MI0018590 asu-mir-5346; +MI0018591 asu-mir-100e; +MI0018592 asu-mir-5347; +MI0018593 asu-mir-36f; +MI0018594 asu-mir-5348; +MI0018595 asu-mir-5349; +MI0018596 asu-mir-5350a; +MI0018597 asu-mir-5350b; +MI0018598 asu-mir-5350c; +MI0018599 asu-mir-5350d; +MI0018600 asu-mir-5351; +MI0018601 asu-mir-5352; +MI0018602 asu-mir-44b; +MI0018603 asu-mir-5353; +MI0018604 asu-mir-5354; +MI0018605 asu-mir-5355; +MI0018606 asu-mir-5356a; +MI0018607 asu-mir-5356b; +MI0018608 asu-mir-5357; +MI0018609 asu-mir-5358a; +MI0018610 asu-mir-5359; +MI0018611 asu-mir-5360; +MI0018612 asu-mir-5361; +MI0018613 asu-mir-5362; +MI0018614 asu-mir-5363; +MI0018615 asu-mir-5364; +MI0018616 asu-mir-5365a; +MI0018617 asu-mir-5366; +MI0018618 asu-mir-5365b; +MI0018619 asu-mir-5358b; +MI0018620 asu-mir-5367; +MI0018621 gma-MIR5368; +MI0018622 gma-MIR5369; +MI0018623 gma-MIR862b; +MI0018624 gma-MIR5037b; +MI0018625 gma-MIR5037c; +MI0018626 gma-MIR5370; +MI0018627 gma-MIR5371; +MI0018628 gma-MIR5372; +MI0018629 gma-MIR5373; +MI0018630 gma-MIR5038b; +MI0018631 gma-MIR403a; +MI0018632 gma-MIR403b; +MI0018633 gma-MIR5374; +MI0018634 gma-MIR5375; +MI0018635 gma-MIR5376; +MI0018636 gma-MIR5377; +MI0018637 gma-MIR5378; +MI0018638 gma-MIR5379; +MI0018639 gma-MIR5380a; +MI0018640 gma-MIR5380b; +MI0018641 gma-MIR171j; +MI0018642 gma-MIR395a; +MI0018643 gma-MIR395b; +MI0018644 gma-MIR395c; +MI0018645 gma-MIR397a; +MI0018646 gma-MIR397b; +MI0018647 gma-MIR408a; +MI0018648 gma-MIR408b; +MI0018649 gma-MIR408c; +MI0018650 gma-MIR3522; +MI0018651 gma-MIR156j; +MI0018652 gma-MIR156k; +MI0018653 gma-MIR156l; +MI0018654 gma-MIR156m; +MI0018655 gma-MIR156n; +MI0018656 gma-MIR156o; +MI0018657 gma-MIR159e; +MI0018658 gma-MIR159f; +MI0018659 gma-MIR162c; +MI0018660 gma-MIR166i; +MI0018661 gma-MIR166j; +MI0018662 gma-MIR169j; +MI0018663 gma-MIR169k; +MI0018664 gma-MIR169l; +MI0018665 gma-MIR169m; +MI0018666 gma-MIR169n; +MI0018667 gma-MIR171k; +MI0018668 gma-MIR172g; +MI0018669 gma-MIR172h; +MI0018670 gma-MIR172i; +MI0018671 gma-MIR172j; +MI0018672 gma-MIR319g; +MI0018673 gma-MIR319h; +MI0018674 gma-MIR319i; +MI0018675 gma-MIR319j; +MI0018676 gma-MIR319k; +MI0018677 gma-MIR319l; +MI0018678 gma-MIR319m; +MI0018679 gma-MIR396h; +MI0018680 gma-MIR396i; +MI0018681 gma-MIR482d; +MI0018682 gma-MIR1512b; +MI0018683 gma-MIR1513c; +MI0018684 gma-MIR4413b; +MI0018685 gma-MIR4415b; +MI0018686 gma-MIR167j; +MI0018687 gma-MIR171l; +MI0018688 sbi-MIR5381; +MI0018689 sbi-MIR5382; +MI0018690 sbi-MIR5383; +MI0018691 sbi-MIR5384; +MI0018692 sbi-MIR5385; +MI0018693 sbi-MIR5386; +MI0018694 sbi-MIR5387;sbi-MIR5387a; +MI0018695 sbi-MIR5388; +MI0018696 sbi-MIR5389; +MI0018697 aca-mir-5390; +MI0018698 aca-mir-5391; +MI0018699 aca-mir-5392; +MI0018700 aca-mir-5393; +MI0018701 aca-let-7a; +MI0018702 aca-let-7b; +MI0018703 aca-let-7c-1; +MI0018704 aca-let-7c-2; +MI0018705 aca-let-7d; +MI0018706 aca-let-7e; +MI0018707 aca-let-7f-1; +MI0018708 aca-let-7f-2; +MI0018709 aca-let-7g; +MI0018710 aca-let-7i; +MI0018711 aca-mir-100; +MI0018712 aca-mir-101-1; +MI0018713 aca-mir-101-2; +MI0018714 aca-mir-107; +MI0018715 aca-mir-103; +MI0018716 aca-mir-10a; +MI0018717 aca-mir-10b; +MI0018718 aca-mir-10c; +MI0018719 aca-mir-122; +MI0018720 aca-mir-124a-1; +MI0018721 aca-mir-124a-2; +MI0018722 aca-mir-124a-3; +MI0018723 aca-mir-124b; +MI0018724 aca-mir-125a; +MI0018725 aca-mir-125b-1; +MI0018726 aca-mir-125b-2; +MI0018727 aca-mir-126; +MI0018728 aca-mir-128-1; +MI0018729 aca-mir-128-2; +MI0018730 aca-mir-129a; +MI0018731 aca-mir-129b; +MI0018732 aca-mir-1306; +MI0018733 aca-mir-130a-1; +MI0018734 aca-mir-130a-2; +MI0018735 aca-mir-130b; +MI0018736 aca-mir-130c; +MI0018737 aca-mir-132; +MI0018738 aca-mir-1329; +MI0018739 aca-mir-133a-1; +MI0018740 aca-mir-133a-2; +MI0018741 aca-mir-135-1; +MI0018742 aca-mir-135-2; +MI0018743 aca-mir-135-3; +MI0018744 aca-mir-137a; +MI0018745 aca-mir-137b; +MI0018746 aca-mir-138-1; +MI0018747 aca-mir-138-2; +MI0018748 aca-mir-1388; +MI0018749 aca-mir-139; +MI0018750 aca-mir-1397; +MI0018751 aca-mir-140; +MI0018752 aca-mir-142; +MI0018753 aca-mir-143; +MI0018754 aca-mir-144; +MI0018755 aca-mir-145; +MI0018756 aca-mir-146a; +MI0018757 aca-mir-146b; +MI0018758 aca-mir-147; +MI0018759 aca-mir-148a; +MI0018760 aca-mir-148b; +MI0018761 aca-mir-150; +MI0018762 aca-mir-153-1; +MI0018763 aca-mir-153-2; +MI0018764 aca-mir-155; +MI0018765 aca-mir-15b; +MI0018766 aca-mir-15a; +MI0018767 aca-mir-1662; +MI0018768 aca-mir-1677a; +MI0018769 aca-mir-1677b; +MI0018770 aca-mir-16a; +MI0018771 aca-mir-16b; +MI0018772 aca-mir-17; +MI0018773 aca-mir-1788; +MI0018774 aca-mir-1805; +MI0018775 aca-mir-181a-1; +MI0018776 aca-mir-181a-2; +MI0018777 aca-mir-181a-3; +MI0018778 aca-mir-181b-1; +MI0018779 aca-mir-181b-2; +MI0018780 aca-mir-182; +MI0018781 aca-mir-184; +MI0018782 aca-mir-187; +MI0018783 aca-mir-18a; +MI0018784 aca-mir-18b; +MI0018785 aca-mir-190a; +MI0018786 aca-mir-190b; +MI0018787 aca-mir-191; +MI0018788 aca-mir-193; +MI0018789 aca-mir-194-1; +MI0018790 aca-mir-194-2; +MI0018791 aca-mir-196a-1; +MI0018792 aca-mir-196a-2; +MI0018793 aca-mir-196c; +MI0018794 aca-mir-199a-1; +MI0018795 aca-mir-199a-2; +MI0018796 aca-mir-199b; +MI0018797 aca-mir-19a; +MI0018798 aca-mir-19b; +MI0018799 aca-mir-1a-1; +MI0018800 aca-mir-1a-2; +MI0018801 aca-mir-1b; +MI0018802 aca-mir-200a; +MI0018803 aca-mir-200b; +MI0018804 aca-mir-202; +MI0018805 aca-mir-203; +MI0018806 aca-mir-204a-1; +MI0018807 aca-mir-204a-2; +MI0018808 aca-mir-205a; +MI0018809 aca-mir-205b; +MI0018810 aca-mir-206; +MI0018811 aca-mir-208; +MI0018812 aca-mir-20a; +MI0018813 aca-mir-20b; +MI0018814 aca-mir-21; +MI0018815 aca-mir-210; +MI0018816 aca-mir-212; +MI0018817 aca-mir-214; +MI0018818 aca-mir-215; +MI0018819 aca-mir-216a; +MI0018820 aca-mir-216b; +MI0018821 aca-mir-217; +MI0018822 aca-mir-218-1; +MI0018823 aca-mir-218-2; +MI0018824 aca-mir-2188; +MI0018825 aca-mir-219-1; +MI0018826 aca-mir-219-2; +MI0018827 aca-mir-22; +MI0018828 aca-mir-221; +MI0018829 aca-mir-222;aca-mir-222a; +MI0018830 aca-mir-223; +MI0018831 aca-mir-23a; +MI0018832 aca-mir-23b; +MI0018833 aca-mir-24-1; +MI0018834 aca-mir-24-2; +MI0018835 aca-mir-26-1; +MI0018836 aca-mir-26-2; +MI0018837 aca-mir-27a; +MI0018838 aca-mir-27b; +MI0018839 aca-mir-2970; +MI0018840 aca-mir-29a-1; +MI0018841 aca-mir-29a-2; +MI0018842 aca-mir-29b-1; +MI0018843 aca-mir-29b-2; +MI0018844 aca-mir-301a; +MI0018845 aca-mir-301b; +MI0018846 aca-mir-302;aca-mir-302b; +MI0018847 aca-mir-30a; +MI0018848 aca-mir-30b; +MI0018849 aca-mir-30c;aca-mir-30c-1; +MI0018850 aca-mir-30d; +MI0018851 aca-mir-30e; +MI0018852 aca-mir-31; +MI0018853 aca-mir-32; +MI0018854 aca-mir-33-1; +MI0018855 aca-mir-33-2; +MI0018856 aca-mir-338; +MI0018857 aca-mir-34a; +MI0018858 aca-mir-34b; +MI0018859 aca-mir-34c; +MI0018860 aca-mir-363; +MI0018861 aca-mir-365; +MI0018862 aca-mir-367; +MI0018863 aca-mir-375; +MI0018864 aca-mir-383; +MI0018865 aca-mir-425; +MI0018866 aca-mir-429; +MI0018867 aca-mir-449a; +MI0018868 aca-mir-449b; +MI0018869 aca-mir-451; +MI0018870 aca-mir-454; +MI0018871 aca-mir-455; +MI0018872 aca-mir-456; +MI0018873 aca-mir-457; +MI0018874 aca-mir-458; +MI0018875 aca-mir-460a; +MI0018876 aca-mir-460b; +MI0018877 aca-mir-489; +MI0018878 aca-mir-490; +MI0018879 aca-mir-497; +MI0018880 aca-mir-499; +MI0018881 aca-mir-551; +MI0018882 aca-mir-7-1; +MI0018883 aca-mir-7-2; +MI0018884 aca-mir-7-3; +MI0018885 aca-mir-726; +MI0018886 aca-mir-727; +MI0018887 aca-mir-875; +MI0018888 aca-mir-9-1; +MI0018889 aca-mir-9-2; +MI0018890 aca-mir-9-3; +MI0018891 aca-mir-92a-1; +MI0018892 aca-mir-92a-2; +MI0018893 aca-mir-98; +MI0018894 aca-mir-99a; +MI0018895 aca-mir-99b; +MI0018896 aca-mir-5394; +MI0018897 aca-mir-5395; +MI0018898 aca-mir-5396;aca-mir-5396a; +MI0018899 aca-mir-5397; +MI0018900 aca-mir-5398; +MI0018901 aca-mir-5399; +MI0018902 aca-mir-5400; +MI0018903 aca-mir-5401; +MI0018904 aca-mir-5402; +MI0018905 aca-mir-449c; +MI0018906 aca-mir-5403; +MI0018907 aca-mir-5404; +MI0018908 aca-mir-5405; +MI0018909 aca-mir-5406; +MI0018910 aca-mir-5407; +MI0018911 aca-mir-5408a; +MI0018912 aca-mir-5409; +MI0018913 aca-mir-5410; +MI0018914 aca-mir-5411; +MI0018915 aca-mir-5412; +MI0018916 aca-mir-5413; +MI0018917 aca-mir-5414; +MI0018918 aca-mir-5415; +MI0018919 aca-mir-5416; +MI0018920 aca-mir-5417; +MI0018921 aca-mir-5418; +MI0018922 aca-mir-5419; +MI0018923 aca-mir-5420; +MI0018924 aca-mir-5421; +MI0018925 aca-mir-5422; +MI0018926 aca-mir-5423; +MI0018927 aca-mir-5424; +MI0018928 aca-mir-5425; +MI0018929 aca-mir-5426; +MI0018930 aca-mir-5427; +MI0018931 aca-mir-5428; +MI0018932 aca-mir-5429; +MI0018933 aca-mir-5430; +MI0018934 aca-mir-5431; +MI0018935 aca-mir-5432; +MI0018936 aca-mir-5433; +MI0018937 aca-mir-5434; +MI0018938 aca-mir-5435a; +MI0018939 aca-mir-5436; +MI0018940 aca-mir-5437; +MI0018941 aca-mir-5438; +MI0018942 aca-mir-5439; +MI0018943 aca-mir-5440; +MI0018944 aca-mir-5441; +MI0018945 aca-mir-5442; +MI0018946 aca-mir-5443; +MI0018947 aca-mir-5444a; +MI0018948 aca-mir-5445; +MI0018949 aca-mir-5446; +MI0018950 aca-mir-5447; +MI0018951 aca-mir-5448; +MI0018952 aca-mir-5449; +MI0018953 aca-mir-5450; +MI0018954 aca-mir-5408b; +MI0018955 aca-mir-5451; +MI0018956 aca-mir-5452; +MI0018957 aca-mir-5408c; +MI0018958 aca-mir-5453; +MI0018959 aca-mir-5454; +MI0018960 aca-mir-5455; +MI0018961 aca-mir-5456; +MI0018962 aca-mir-5457; +MI0018963 aca-mir-5458; +MI0018964 aca-mir-5459; +MI0018965 aca-mir-5444b; +MI0018966 aca-mir-5460; +MI0018967 aca-mir-5461; +MI0018968 aca-mir-5435b; +MI0018969 aca-mir-5435c; +MI0018970 aca-mir-5462; +MI0018971 aca-mir-5463; +MI0018972 aca-mir-5464; +MI0018973 aca-mir-5465; +MI0018974 aca-mir-5466; +MI0018975 aca-mir-5467; +MI0018976 aca-mir-5468; +MI0018977 aca-mir-5469; +MI0018978 aca-mir-5470; +MI0018979 aau-MIR160; +MI0018980 aau-MIR172; +MI0018981 aau-MIR396; +MI0018982 aau-MIR319; +MI0018983 aau-MIR2086; +MI0018984 aau-MIR162; +MI0018985 aau-MIR168; +MI0018986 amg-MIR319; +MI0018987 amg-MIR396; +MI0018988 amg-MIR2086; +MI0018989 pti-MIR5471; +MI0018990 pti-MIR5472; +MI0018991 pti-MIR5473; +MI0018992 pti-MIR5474; +MI0018993 pti-MIR5475; +MI0018994 pti-MIR5476; +MI0018995 pti-MIR5477; +MI0018996 pti-MIR5478; +MI0018997 pti-MIR5479; +MI0018998 pti-MIR5480; +MI0018999 pti-MIR5481; +MI0019000 pti-MIR5482; +MI0019001 pti-MIR5483; +MI0019002 osa-MIR5484; +MI0019003 osa-MIR5485; +MI0019004 osa-MIR5486; +MI0019005 osa-MIR5487; +MI0019006 osa-MIR5488; +MI0019007 osa-MIR5489; +MI0019008 osa-MIR5490; +MI0019009 osa-MIR5491; +MI0019010 osa-MIR5492; +MI0019011 osa-MIR5493; +MI0019012 osa-MIR5494; +MI0019013 osa-MIR5495; +MI0019014 osa-MIR5496; +MI0019015 osa-MIR5497; +MI0019016 osa-MIR5498; +MI0019017 osa-MIR5499; +MI0019018 osa-MIR5500; +MI0019019 osa-MIR5501; +MI0019020 osa-MIR5502; +MI0019021 osa-MIR5503; +MI0019022 osa-MIR5504; +MI0019023 osa-MIR5505; +MI0019024 osa-MIR5506; +MI0019025 osa-MIR5507; +MI0019026 osa-MIR5508; +MI0019027 osa-MIR5509; +MI0019028 osa-MIR5510; +MI0019029 osa-MIR5511; +MI0019030 osa-MIR5512;osa-MIR5512a; +MI0019031 osa-MIR5513; +MI0019032 osa-MIR2275c; +MI0019033 osa-MIR5514; +MI0019034 osa-MIR5515; +MI0019035 osa-MIR5516;osa-MIR5516a; +MI0019036 osa-MIR5517; +MI0019037 osa-MIR5518; +MI0019038 osa-MIR5519; +MI0019039 osa-MIR5520; +MI0019040 osa-MIR5521; +MI0019041 osa-MIR5522; +MI0019042 osa-MIR5523; +MI0019043 osa-MIR2275d; +MI0019044 osa-MIR5524; +MI0019045 osa-MIR5525; +MI0019046 osa-MIR5526; +MI0019047 osa-MIR5527; +MI0019048 osa-MIR5528; +MI0019049 osa-MIR5529; +MI0019050 osa-MIR5530; +MI0019051 osa-MIR5531; +MI0019052 osa-MIR5532; +MI0019053 osa-MIR5533; +MI0019054 osa-MIR5534a; +MI0019055 osa-MIR5534b; +MI0019056 osa-MIR5535; +MI0019057 osa-MIR5536; +MI0019058 osa-MIR5537; +MI0019059 osa-MIR5538; +MI0019060 osa-MIR5539;osa-MIR5539a; +MI0019061 osa-MIR5540; +MI0019062 osa-MIR5541; +MI0019063 osa-MIR5542; +MI0019064 osa-MIR5543; +MI0019065 osa-MIR5544; +MI0019066 cel-mir-5545; +MI0019067 cel-mir-5546; +MI0019068 cel-mir-5547; +MI0019069 cel-mir-5548; +MI0019070 cel-mir-5549; +MI0019071 cel-mir-5550; +MI0019072 cel-mir-5551; +MI0019073 cel-mir-5552; +MI0019074 cel-mir-5553; +MI0019075 mtr-MIR5554a; +MI0019076 mtr-MIR5555; +MI0019077 mtr-MIR2619b; +MI0019078 mtr-MIR2592bl; +MI0019079 mtr-MIR5554b; +MI0019080 mtr-MIR5274b; +MI0019081 mtr-MIR5556; +MI0019082 mtr-MIR2592bm; +MI0019083 mtr-MIR5557; +MI0019084 mtr-MIR2592bn; +MI0019085 mtr-MIR5558; +MI0019086 mtr-MIR5559; +MI0019087 mtr-MIR5560; +MI0019088 mtr-MIR5554c; +MI0019089 mtr-MIR5561; +MI0019090 mtr-MIR5562; +MI0019091 mtr-MIR5563; +MI0019092 mtr-MIR167b; +MI0019093 mtr-MIR168c; +MI0019094 mtr-MIR408; +MI0019095 mtr-MIR2111v;mtr-MIR2111a; +MI0019096 sbi-MIR5564a; +MI0019097 sbi-MIR5564b; +MI0019098 sbi-MIR5565e; +MI0019099 sbi-MIR5565f; +MI0019100 sbi-MIR5566; +MI0019101 sbi-MIR5567; +MI0019102 sbi-MIR5565c; +MI0019103 sbi-MIR5568;sbi-MIR5568a; +MI0019104 sbi-MIR5387b; +MI0019105 sbi-MIR5569; +MI0019106 sbi-MIR5570; +MI0019107 sbi-MIR5565a; +MI0019108 sbi-MIR5565b; +MI0019109 sbi-MIR5565d; +MI0019110 hsa-mir-4436b-2; +MI0019111 hsa-mir-4444-2; +MI0019112 hsa-mir-3670-2; +MI0019113 hsa-mir-3680-2; +MI0019114 hsa-mir-4524b; +MI0019115 hsa-mir-5571; +MI0019116 hsa-mir-5100; +MI0019117 hsa-mir-5572; +MI0019118 rgl-MIR5573; +MI0019119 rgl-MIR5574; +MI0019120 rgl-MIR5575; +MI0019121 rgl-MIR5576; +MI0019122 rgl-MIR5577; +MI0019123 rgl-MIR5578; +MI0019124 rgl-MIR164; +MI0019125 hvsa-miR-HSUR5; +MI0019126 hvsa-miR-HSUR4; +MI0019127 hvsa-miR-HSUR2; +MI0019128 zma-MIR444a; +MI0019129 zma-MIR444b; +MI0019130 hsa-mir-548aq; +MI0019131 hsa-mir-548ar; +MI0019132 hsa-mir-548as; +MI0019133 hsa-mir-5579; +MI0019134 hsa-mir-644b;hsa-mir-664b; +MI0019135 hsa-mir-5580; +MI0019136 hsa-mir-5581; +MI0019137 hsa-mir-548at; +MI0019138 hsa-mir-5582; +MI0019139 hsa-mir-5583-1; +MI0019140 hsa-mir-5583-2; +MI0019141 hsa-mir-5584; +MI0019142 hsa-mir-5585; +MI0019143 hsa-mir-5586; +MI0019144 hsa-mir-5587; +MI0019145 hsa-mir-548au; +MI0019146 hsa-mir-1295b; +MI0019147 hsa-mir-5588; +MI0019148 hsa-mir-5589; +MI0019149 hsa-mir-4536-2; +MI0019150 hsa-mir-5590; +MI0019151 hsa-mir-5591; +MI0019152 hsa-mir-548av; +MI0019153 cel-mir-5592-1; +MI0019154 cel-mir-5592-2; +MI0019155 cel-mir-5593-1; +MI0019156 cel-mir-5593-2; +MI0019157 cel-mir-5594; +MI0019158 cel-mir-356b; +MI0019159 cel-mir-5595; +MI0019160 cin-mir-5596a; +MI0019161 cin-mir-5597; +MI0019162 cin-mir-5598; +MI0019163 cin-mir-5599; +MI0019164 cin-mir-5600; +MI0019165 cin-mir-5601; +MI0019166 cin-mir-5596b; +MI0019167 cin-mir-5602; +MI0019168 cin-mir-5603; +MI0019169 cin-mir-5604; +MI0019170 cin-mir-4179b; +MI0019171 cin-mir-5605; +MI0019172 cin-mir-5606; +MI0019173 cin-mir-5607; +MI0019174 cin-mir-5608; +MI0019175 cin-mir-5609; +MI0019176 cin-mir-5610; +MI0019177 cin-mir-5611; +MI0019178 cin-mir-5612; +MI0019179 mmu-mir-3544; +MI0019180 mmu-mir-299b; +MI0019181 mmu-mir-5615-1; +MI0019182 mmu-mir-5615-2; +MI0019183 mmu-mir-1231; +MI0019184 mmu-mir-5616; +MI0019185 mmu-mir-5617; +MI0019186 mmu-mir-5618; +MI0019187 mmu-mir-5619; +MI0019188 mmu-mir-5620; +MI0019189 mmu-mir-5621; +MI0019190 mmu-mir-5622; +MI0019191 mmu-mir-5623; +MI0019192 mmu-mir-3073b; +MI0019193 mmu-mir-5624; +MI0019194 mmu-mir-5625; +MI0019195 mmu-mir-5626; +MI0019196 mmu-mir-344h-1; +MI0019197 mmu-mir-344h-2; +MI0019198 mmu-mir-5627; +MI0019199 ath-MIR5628; +MI0019200 ath-MIR5629; +MI0019201 ath-MIR5630a; +MI0019202 ath-MIR5631; +MI0019203 ath-MIR5020c; +MI0019204 ath-MIR5632; +MI0019205 ath-MIR5633; +MI0019206 ath-MIR5634; +MI0019207 ath-MIR5635a; +MI0019208 ath-MIR5636; +MI0019209 ath-MIR5637; +MI0019210 ath-MIR5638a; +MI0019211 ath-MIR5630b; +MI0019212 ath-MIR5639; +MI0019213 ath-MIR5640; +MI0019214 ath-MIR5641; +MI0019215 ath-MIR5642a; +MI0019216 ath-MIR5643a; +MI0019217 ath-MIR5635d; +MI0019218 ath-MIR5644; +MI0019219 ath-MIR5638b; +MI0019220 ath-MIR5645a; +MI0019221 ath-MIR5645b; +MI0019222 ath-MIR5646; +MI0019223 ath-MIR5647; +MI0019224 ath-MIR5648; +MI0019225 ath-MIR5645c; +MI0019226 ath-MIR5649a; +MI0019227 ath-MIR5650; +MI0019228 ath-MIR858b; +MI0019229 ath-MIR5635b; +MI0019230 ath-MIR833b; +MI0019231 ath-MIR781b; +MI0019232 ath-MIR156i; +MI0019233 ath-MIR5651; +MI0019234 ath-MIR156j; +MI0019235 ath-MIR5652; +MI0019236 ath-MIR5653; +MI0019237 ath-MIR5654; +MI0019238 ath-MIR5655; +MI0019239 ath-MIR5635c; +MI0019240 ath-MIR5656; +MI0019241 ath-MIR5657; +MI0019242 ath-MIR5658; +MI0019243 ath-MIR5659; +MI0019244 ath-MIR5645d; +MI0019245 ath-MIR5660; +MI0019246 ath-MIR5642b; +MI0019247 ath-MIR1888b; +MI0019248 ath-MIR5649b; +MI0019249 ath-MIR5661; +MI0019250 ath-MIR5662; +MI0019251 ath-MIR5663; +MI0019252 ath-MIR5645f; +MI0019253 ath-MIR5664; +MI0019254 ath-MIR5665; +MI0019255 ath-MIR5666; +MI0019256 ath-MIR5643b; +MI0019257 ath-MIR5645e; +MI0019258 sly-MIR4376;sly-MIR391; +MI0019259 meu-mir-15c; +MI0019260 meu-mir-16c; +MI0019261 gma-MIR5667; +MI0019262 gma-MIR5668; +MI0019263 gma-MIR5669; +MI0019264 gma-MIR5670;gma-MIR5670a; +MI0019265 gma-MIR5671;gma-MIR5671a; +MI0019266 gma-MIR5672; +MI0019267 gma-MIR5037d; +MI0019268 gma-MIR5673; +MI0019269 gma-MIR2111;gma-MIR2111a; +MI0019270 gma-MIR1512c; +MI0019271 gma-MIR5674;gma-MIR5674a; +MI0019272 gma-MIR5675; +MI0019273 gma-MIR4401b; +MI0019274 gma-MIR5676; +MI0019275 gma-MIR530b; +MI0019276 gma-MIR4387e; +MI0019277 gma-MIR5677; +MI0019278 gma-MIR5678; +MI0019279 gma-MIR5679; +MI0019280 hsa-mir-5680; +MI0019281 hsa-mir-5681a; +MI0019282 hsa-mir-5682; +MI0019283 hsa-mir-548aw; +MI0019284 hsa-mir-5683; +MI0019285 hsa-mir-5684; +MI0019286 hsa-mir-548ax; +MI0019287 hsa-mir-5685; +MI0019288 hsa-mir-5692c-1; +MI0019289 hsa-mir-5692c-2; +MI0019290 hsa-mir-5686; +MI0019291 hsa-mir-5687; +MI0019292 hsa-mir-5688; +MI0019293 hsa-mir-5681b; +MI0019294 hsa-mir-5689; +MI0019295 hsa-mir-5690; +MI0019296 hsa-mir-5691; +MI0019297 hsa-mir-5692a-1; +MI0019298 hsa-mir-5692a-2; +MI0019299 hsa-mir-4666b; +MI0019300 hsa-mir-5693; +MI0019301 hsa-mir-5694; +MI0019302 hsa-mir-5695; +MI0019303 hsa-mir-5696; +MI0019304 hsa-mir-5697; +MI0019305 hsa-mir-5698; +MI0019306 hsa-mir-5699; +MI0019307 hsa-mir-5700; +MI0019308 hsa-mir-5701-1; +MI0019309 hsa-mir-5702; +MI0019310 hsa-mir-5703; +MI0019311 hsa-mir-5692b; +MI0019312 hsa-mir-5704; +MI0019313 hsa-mir-5705; +MI0019314 hsa-mir-5706; +MI0019315 hsa-mir-5707; +MI0019316 hsa-mir-5708; +MI0019317 mmu-mir-344i; +MI0019318 mmu-mir-5709; +MI0019319 mmu-mir-5710; +MI0019320 bra-MIR5711; +MI0019321 bra-MIR5654a; +MI0019322 bra-MIR5654b; +MI0019323 bra-MIR5712; +MI0019324 bra-MIR5713; +MI0019325 bra-MIR5714; +MI0019326 bra-MIR5715; +MI0019327 bra-MIR5716; +MI0019328 bra-MIR5717; +MI0019329 bra-MIR1885b; +MI0019330 bra-MIR5718; +MI0019331 bra-MIR5719; +MI0019332 bra-MIR5720; +MI0019333 bra-MIR5721; +MI0019334 bra-MIR5722; +MI0019335 bra-MIR1140; +MI0019336 bra-MIR5723; +MI0019337 bra-MIR5724; +MI0019338 bra-MIR5725; +MI0019339 bra-MIR5726; +MI0019340 ssl-MIR156; +MI0019341 ssl-MIR164a; +MI0019342 ssl-MIR164b; +MI0019343 ssl-MIR166a; +MI0019344 ssl-MIR166b; +MI0019345 ssl-MIR169; +MI0019346 ssl-MIR171a; +MI0019347 ssl-MIR171b; +MI0019348 ssl-MIR172; +MI0019349 ssl-MIR394; +MI0019350 ssl-MIR395; +MI0019351 ssl-MIR396; +MI0019352 ssl-MIR397; +MI0019353 ssl-MIR398; +MI0019354 ssl-MIR399; +MI0019355 ssl-MIR828; +MI0019356 ssl-MIR948; +MI0019357 ssl-MIR1078; +MI0019358 tur-mir-10; +MI0019359 tur-mir-5727; +MI0019360 tur-mir-278; +MI0019361 tur-mir-5728-2; +MI0019362 tur-mir-276; +MI0019363 tur-mir-7; +MI0019364 tur-mir-5729b; +MI0019365 tur-mir-71-1; +MI0019366 tur-mir-2-1; +MI0019367 tur-mir-12b; +MI0019368 tur-mir-281; +MI0019369 tur-mir-745; +MI0019370 tur-mir-5730; +MI0019371 tur-mir-993b; +MI0019372 tur-mir-5729a; +MI0019373 tur-mir-5731; +MI0019374 tur-mir-993a-1; +MI0019375 tur-mir-317; +MI0019376 tur-mir-5732; +MI0019377 tur-mir-5733; +MI0019378 tur-mir-87; +MI0019379 tur-mir-307; +MI0019380 tur-mir-210-1; +MI0019381 tur-mir-993a-2; +MI0019382 tur-mir-184; +MI0019383 tur-mir-5734; +MI0019384 tur-mir-252; +MI0019385 tur-mir-5736b; +MI0019386 tur-mir-133; +MI0019387 tur-mir-5728-1; +MI0019388 tur-mir-9-1; +MI0019389 tur-mir-190; +MI0019390 tur-mir-9-2; +MI0019391 tur-mir-92; +MI0019392 tur-mir-124-2; +MI0019393 tur-mir-3931; +MI0019394 tur-mir-5735; +MI0019395 tur-mir-1; +MI0019396 tur-mir-34; +MI0019397 tur-mir-71-2; +MI0019398 tur-mir-137; +MI0019399 tur-mir-5736a; +MI0019400 tur-mir-12a; +MI0019401 tur-mir-5737; +MI0019402 tur-mir-124-1; +MI0019403 tur-mir-279; +MI0019404 tur-mir-263b; +MI0019405 tur-mir-5738; +MI0019406 tur-mir-2-2; +MI0019407 tur-mir-210-2; +MI0019408 tur-mir-263a; +MI0019409 tur-mir-305; +MI0019410 dme-mir-5613; +MI0019411 dme-mir-5614; +MI0019412 hsa-mir-5739; +MI0019413 ola-mir-193a; +MI0019414 ola-mir-218a-1; +MI0019415 ola-mir-221; +MI0019416 ola-mir-222; +MI0019417 ola-mir-18-1; +MI0019418 ola-mir-20a-1; +MI0019419 ola-mir-92a-2; +MI0019420 ola-mir-184-1; +MI0019421 ola-mir-9a-2; +MI0019422 ola-mir-199a-1; +MI0019423 ola-mir-181b-1; +MI0019424 ola-mir-101a; +MI0019425 ola-mir-27b; +MI0019426 ola-mir-24a-1; +MI0019427 ola-mir-9b-1; +MI0019428 ola-mir-135a-1; +MI0019429 ola-mir-499; +MI0019430 ola-let-7a-1; +MI0019431 ola-let-7b-1; +MI0019432 ola-mir-184-2; +MI0019433 ola-mir-9a-3; +MI0019434 ola-mir-140; +MI0019435 ola-mir-138; +MI0019436 ola-mir-183-1; +MI0019437 ola-mir-1-1; +MI0019438 ola-mir-133-2; +MI0019439 ola-mir-462; +MI0019440 ola-mir-731; +MI0019441 ola-let-7g; +MI0019442 ola-mir-196a; +MI0019443 ola-let-7e; +MI0019444 ola-let-7a-2; +MI0019445 ola-mir-1388; +MI0019446 ola-mir-29b-1; +MI0019447 ola-mir-29a; +MI0019448 ola-mir-200a; +MI0019449 ola-mir-200b; +MI0019450 ola-mir-124-1; +MI0019451 ola-mir-135a-2; +MI0019452 ola-mir-124-2; +MI0019453 ola-mir-205; +MI0019454 ola-mir-26-1; +MI0019455 ola-mir-199a-2; +MI0019456 ola-mir-33; +MI0019457 ola-mir-137; +MI0019458 ola-mir-152; +MI0019459 ola-mir-338-1; +MI0019460 ola-mir-24a-2; +MI0019461 ola-mir-27c; +MI0019462 ola-mir-23a-1; +MI0019463 ola-mir-150; +MI0019464 ola-mir-24c; +MI0019465 ola-mir-181a-1; +MI0019466 ola-mir-181b-2; +MI0019467 ola-mir-24a-3; +MI0019468 ola-mir-23b; +MI0019469 ola-mir-9a-4; +MI0019470 ola-mir-204; +MI0019471 ola-mir-1306; +MI0019472 ola-mir-218a-2; +MI0019473 ola-mir-106a; +MI0019474 ola-mir-19d; +MI0019475 ola-mir-103-1; +MI0019476 ola-mir-19b-2; +MI0019477 ola-mir-458; +MI0019478 ola-mir-187; +MI0019479 ola-mir-30e; +MI0019480 ola-mir-30c; +MI0019481 ola-mir-30d; +MI0019482 ola-mir-128; +MI0019483 ola-mir-126; +MI0019484 ola-mir-122; +MI0019485 ola-mir-199a-3; +MI0019486 ola-mir-101b; +MI0019487 ola-mir-455; +MI0019488 ola-mir-218b; +MI0019489 ola-mir-301b; +MI0019490 ola-mir-130c; +MI0019491 ola-mir-16; +MI0019492 ola-mir-100-1; +MI0019493 ola-mir-125c; +MI0019494 ola-mir-139; +MI0019495 ola-mir-132; +MI0019496 ola-mir-22-1; +MI0019497 ola-mir-21-1; +MI0019498 ola-mir-301a; +MI0019499 ola-mir-194; +MI0019500 ola-mir-192; +MI0019501 ola-mir-144; +MI0019502 ola-mir-21-2; +MI0019503 ola-mir-125b-2; +MI0019504 ola-let-7c; +MI0019505 ola-mir-99; +MI0019506 ola-mir-22-2; +MI0019507 ola-mir-125b-1; +MI0019508 ola-let-7a-4; +MI0019509 ola-mir-100-2; +MI0019510 ola-mir-223; +MI0019511 ola-mir-142; +MI0019512 ola-mir-107; +MI0019513 ola-mir-10d; +MI0019514 ola-mir-146a; +MI0019515 ola-mir-9a-1; +MI0019516 ola-mir-92b; +MI0019517 ola-mir-125a; +MI0019518 ola-mir-199a-4; +MI0019519 ola-mir-214; +MI0019520 ola-mir-7; +MI0019521 ola-mir-26-2; +MI0019522 ola-mir-9b-2; +MI0019523 ola-mir-460; +MI0019524 ola-mir-133-1; +MI0019525 ola-mir-1-2; +MI0019526 ola-mir-24b; +MI0019527 ola-mir-27a; +MI0019528 ola-mir-23a-2; +MI0019529 ola-mir-27d; +MI0019530 ola-mir-31; +MI0019531 ola-mir-338-2; +MI0019532 ola-mir-26-3; +MI0019533 ola-mir-124-3; +MI0019534 ola-mir-15a; +MI0019535 ola-mir-10b; +MI0019536 ola-mir-148; +MI0019537 ola-mir-92a-1; +MI0019538 ola-mir-19b-1; +MI0019539 ola-mir-20a-2; +MI0019540 ola-mir-19a; +MI0019541 ola-mir-18-2; +MI0019542 ola-mir-17; +MI0019543 ola-mir-203; +MI0019544 ola-mir-103-2; +MI0019545 ola-mir-29b-2; +MI0019546 ola-mir-29c; +MI0019547 ola-mir-135b; +MI0019548 ola-mir-183-2; +MI0019549 ola-mir-182; +MI0019550 ola-let-7b-2; +MI0019551 ola-let-7a-3; +MI0019552 ola-mir-206; +MI0019553 ola-mir-133-3; +MI0019554 ola-mir-210; +MI0019555 ola-mir-729; +MI0019556 ola-mir-190b; +MI0019557 ola-mir-9a-5; +MI0019558 ola-mir-459; +MI0019559 ola-mir-30a; +MI0019560 ola-mir-181a-2; +MI0019561 ola-mir-143; +MI0019562 ola-mir-145; +MI0019563 ola-mir-338-3; +MI0019564 ola-mir-1788; +MI0019565 vun-MIR156a; +MI0019566 vun-MIR156b; +MI0019567 vun-MIR319b; +MI0019568 vun-MIR160; +MI0019569 vun-MIR162; +MI0019570 vun-MIR164; +MI0019571 vun-MIR168; +MI0019572 vun-MIR169; +MI0019573 vun-MIR172; +MI0019574 vun-MIR319a; +MI0019575 vun-MIR395; +MI0019576 vun-MIR399a; +MI0019577 vun-MIR399b; +MI0019578 vun-MIR408; +MI0019579 vun-MIR482; +MI0019580 vun-MIR2118; +MI0019581 dre-mir-132-3; +MI0019582 dre-mir-137-3; +MI0019583 dre-mir-187-2; +MI0019584 dre-mir-2185-2; +MI0019585 dre-mir-2185-3; +MI0019586 dre-mir-2190-2; +MI0019587 dre-mir-2190-3; +MI0019588 dre-mir-2190-4; +MI0019589 dre-mir-27c-2; +MI0019590 dre-mir-725-2; +MI0019591 dre-mir-23a-4; +MI0019592 dre-mir-24-5; +MI0019593 hsa-mir-5701-2; +MI0019594 sko-mir-219; +MI0019595 sha-mir-190; +MI0019596 sha-mir-181a-2; +MI0019597 sha-mir-138-1; +MI0019598 sha-mir-352; +MI0019599 sha-mir-1329; +MI0019600 sha-mir-716a; +MI0019601 sha-mir-340; +MI0019602 sha-mir-216b; +MI0019603 sha-mir-216a; +MI0019604 sha-mir-140; +MI0019605 sha-mir-126; +MI0019606 sha-mir-202; +MI0019607 sha-mir-1540; +MI0019608 sha-mir-5105; +MI0019609 sha-mir-9; +MI0019610 sha-mir-133a; +MI0019611 sha-mir-199a; +MI0019612 sha-mir-23a; +MI0019613 sha-mir-24-2; +MI0019614 sha-mir-23b; +MI0019615 sha-mir-27b; +MI0019616 sha-mir-24-1; +MI0019617 sha-mir-204; +MI0019618 sha-mir-716b; +MI0019619 sha-mir-193; +MI0019620 sha-mir-7; +MI0019621 sha-let-7g; +MI0019622 sha-mir-1546; +MI0019623 sha-mir-222; +MI0019624 sha-mir-221; +MI0019625 sha-mir-128; +MI0019626 sha-mir-10b; +MI0019627 sha-mir-100; +MI0019628 sha-let-7a; +MI0019629 sha-mir-125a; +MI0019630 sha-mir-139; +MI0019631 sha-mir-200b; +MI0019632 sha-mir-200a; +MI0019633 sha-mir-150; +MI0019634 sha-mir-30e; +MI0019635 sha-mir-30c; +MI0019636 sha-mir-19b; +MI0019637 sha-mir-125b; +MI0019638 sha-mir-101; +MI0019639 sha-mir-181a-1; +MI0019640 sha-mir-205; +MI0019641 sha-mir-21; +MI0019642 sha-mir-130b; +MI0019643 sha-mir-454; +MI0019644 sha-mir-142; +MI0019645 sha-mir-10a; +MI0019646 sha-mir-338; +MI0019647 sha-mir-93; +MI0019648 sha-mir-25; +MI0019649 sha-mir-497; +MI0019650 sha-let-7i; +MI0019651 sha-mir-135a; +MI0019652 sha-mir-1549; +MI0019653 sha-mir-200c; +MI0019654 sha-mir-141; +MI0019655 sha-mir-129; +MI0019656 sha-mir-138-2; +MI0019657 sha-mir-26a; +MI0019658 sha-mir-383; +MI0019659 sha-mir-130a; +MI0019660 sha-mir-363; +MI0019661 sha-mir-92a; +MI0019662 mtr-MIR5740; +MI0019663 mtr-MIR5741a; +MI0019664 mtr-MIR396c; +MI0019665 mtr-MIR5742; +MI0019666 mtr-MIR5743a; +MI0019667 mtr-MIR5743b; +MI0019668 mtr-MIR5741b; +MI0019669 mtr-MIR5744; +MI0019670 mtr-MIR5745a; +MI0019671 mtr-MIR5746; +MI0019672 mtr-MIR5747; +MI0019673 mtr-MIR5748; +MI0019674 mtr-MIR5749; +MI0019675 mtr-MIR5750; +MI0019676 mtr-MIR5751; +MI0019677 mtr-MIR171i;mtr-MIR171g; +MI0019678 mtr-MIR5752a; +MI0019679 mtr-MIR5752b; +MI0019680 mtr-MIR5753; +MI0019681 mtr-MIR5754; +MI0019682 mtr-MIR5755; +MI0019683 mtr-MIR169r; +MI0019684 mtr-MIR5741c; +MI0019685 mtr-MIR5756; +MI0019686 mtr-MIR5757; +MI0019687 mtr-MIR5225b; +MI0019688 mtr-MIR5225c; +MI0019689 mtr-MIR5758; +MI0019690 mtr-MIR5745b; +MI0019691 mtr-MIR5759; +MI0019692 mtr-MIR5741d; +MI0019693 mtr-MIR2593e; +MI0019694 mtr-MIR5760; +MI0019695 mtr-MIR5037a; +MI0019696 mtr-MIR5037b; +MI0019697 mtr-MIR5206b; +MI0019698 mtr-MIR5037c; +MI0019699 mtr-MIR2593d; +MI0019700 mtr-MIR5741e; +MI0019701 mtr-MIR530; +MI0019702 gma-MIR5761a; +MI0019703 gma-MIR5762; +MI0019704 gma-MIR5763a; +MI0019705 gma-MIR5763b; +MI0019706 gma-MIR5764; +MI0019707 gma-MIR5765; +MI0019708 gma-MIR5766; +MI0019709 gma-MIR5767; +MI0019710 gma-MIR5768; +MI0019711 gma-MIR5769; +MI0019712 gma-MIR5770a; +MI0019713 gma-MIR5559; +MI0019714 gma-MIR5225; +MI0019715 gma-MIR393b; +MI0019716 gma-MIR5771; +MI0019717 gma-MIR4416c; +MI0019718 gma-MIR5761b; +MI0019719 gma-MIR5772; +MI0019720 gma-MIR5773; +MI0019721 gma-MIR5774a; +MI0019722 gma-MIR4416b; +MI0019723 gma-MIR1516c; +MI0019724 gma-MIR5775; +MI0019725 gma-MIR1513d; +MI0019726 gma-MIR5776; +MI0019727 gma-MIR5777; +MI0019728 gma-MIR5778; +MI0019729 gma-MIR5779; +MI0019730 gma-MIR5780;gma-MIR5780a; +MI0019731 gma-MIR5781; +MI0019732 gma-MIR5782; +MI0019733 gma-MIR5783; +MI0019734 gma-MIR5770b; +MI0019735 gma-MIR5784; +MI0019736 gma-MIR5785; +MI0019737 gma-MIR5763c; +MI0019738 gma-MIR5774b; +MI0019739 gma-MIR399a; +MI0019740 gma-MIR828a; +MI0019741 gma-MIR156p; +MI0019742 gma-MIR530c; +MI0019743 gma-MIR828b; +MI0019744 gma-MIR530d; +MI0019745 gma-MIR171m; +MI0019746 gma-MIR172k; +MI0019747 gma-MIR171n; +MI0019748 gma-MIR156q; +MI0019749 gma-MIR171o; +MI0019750 gma-MIR172l; +MI0019751 gma-MIR169o; +MI0019752 gma-MIR319n; +MI0019753 gma-MIR171p; +MI0019754 gma-MIR530e; +MI0019755 gma-MIR394d; +MI0019756 gma-MIR169p; +MI0019757 gma-MIR156r; +MI0019758 gma-MIR399b; +MI0019759 gma-MIR396j; +MI0019760 gma-MIR171q; +MI0019761 gma-MIR156s; +MI0019762 gma-MIR169r; +MI0019763 gma-MIR169s; +MI0019764 gma-MIR396k; +MI0019765 gma-MIR2111b; +MI0019766 gma-MIR2111c; +MI0019767 gma-MIR5786; +MI0019768 gma-MIR166k; +MI0019769 gma-MIR2111d; +MI0019770 gma-MIR156t; +MI0019771 gma-MIR2606a; +MI0019772 gma-MIR482e; +MI0019773 gma-MIR399c; +MI0019774 gma-MIR171r; +MI0019775 gma-MIR394e; +MI0019776 gma-MIR399d; +MI0019777 gma-MIR399e; +MI0019778 gma-MIR169t; +MI0019779 gma-MIR171s; +MI0019780 gma-MIR166l; +MI0019781 gma-MIR171t; +MI0019782 gma-MIR2111e; +MI0019783 gma-MIR2111f; +MI0019784 gma-MIR394f; +MI0019785 gma-MIR171u; +MI0019786 gma-MIR399f; +MI0019787 gma-MIR399g; +MI0019788 gma-MIR395d; +MI0019789 gma-MIR395e; +MI0019790 gma-MIR395f; +MI0019791 gma-MIR395g; +MI0019792 gma-MIR166m; +MI0019793 gma-MIR5674b; +MI0019794 gma-MIR169u; +MI0019795 gma-MIR2606b; +MI0019796 gma-MIR399h; +MI0019797 hsa-mir-5787; +MI0019798 osa-MIR5788; +MI0019799 osa-MIR812p; +MI0019800 osa-MIR812q; +MI0019801 osa-MIR5789; +MI0019802 osa-MIR5790; +MI0019803 osa-MIR5791; +MI0019804 osa-MIR5792; +MI0019805 osa-MIR5793; +MI0019806 osa-MIR5794; +MI0019807 osa-MIR812r; +MI0019808 osa-MIR5795; +MI0019809 osa-MIR5796; +MI0019810 osa-MIR5797; +MI0019811 osa-MIR5798; +MI0019812 osa-MIR812s; +MI0019813 osa-MIR5799; +MI0019814 osa-MIR5800; +MI0019815 osa-MIR5801;osa-MIR5801a; +MI0019816 osa-MIR5802; +MI0019817 osa-MIR812t; +MI0019818 osa-MIR812u; +MI0019819 osa-MIR5803; +MI0019820 osa-MIR5804; +MI0019821 osa-MIR5805; +MI0019822 osa-MIR5806; +MI0019823 osa-MIR812v; +MI0019824 osa-MIR5807; +MI0019825 osa-MIR5808;osa-MIR5801b; +MI0019826 osa-MIR5809; +MI0019827 osa-MIR5810; +MI0019828 osa-MIR5811; +MI0019829 osa-MIR5812; +MI0019830 osa-MIR5813; +MI0019831 osa-MIR5814; +MI0019832 osa-MIR5815; +MI0019833 osa-MIR5816; +MI0019834 osa-MIR5143b; +MI0019835 osa-MIR5817; +MI0019836 osa-MIR5818; +MI0019837 osa-MIR5819; +MI0019838 osa-MIR5820; +MI0019839 osa-MIR5821; +MI0019840 osa-MIR5822; +MI0019841 osa-MIR5823; +MI0019842 osa-MIR5824; +MI0019843 osa-MIR1319b; +MI0019844 osa-MIR5825; +MI0019845 osa-MIR5826; +MI0019846 osa-MIR5827; +MI0019847 osa-MIR5828; +MI0019848 osa-MIR5829; +MI0019849 osa-MIR5830; +MI0019850 osa-MIR5831; +MI0019851 osa-MIR5179; +MI0019852 osa-MIR5832; +MI0019853 osa-MIR5833; +MI0019854 osa-MIR5834; +MI0019855 osa-MIR5835; +MI0019856 osa-MIR2873c; +MI0019857 osa-MIR5836; +MI0019858 osa-MIR5837; +MI0019859 osa-MIR5516b; +MI0019992 hco-mir-5884; +MI0019993 hco-mir-133; +MI0019994 hco-mir-63a; +MI0019995 hco-mir-5885a; +MI0019996 hco-mir-5886a; +MI0019997 hco-mir-5887; +MI0019998 hco-mir-5888; +MI0019999 hco-mir-40b; +MI0020000 hco-mir-5889; +MI0020001 hco-mir-5890a; +MI0020002 hco-mir-79; +MI0020003 hco-mir-46; +MI0020004 hco-mir-5891; +MI0020005 hco-mir-50; +MI0020006 hco-mir-250; +MI0020007 hco-mir-5892a; +MI0020008 hco-mir-5893; +MI0020009 hco-mir-259; +MI0020010 hco-mir-5894a; +MI0020011 hco-mir-61; +MI0020012 hco-mir-43; +MI0020013 hco-mir-5895; +MI0020014 hco-mir-124; +MI0020015 hco-mir-45; +MI0020016 hco-mir-5896; +MI0020017 hco-mir-5897a; +MI0020018 hco-mir-5898; +MI0020019 hco-mir-5899; +MI0020020 hco-lin-4; +MI0020021 hco-mir-5900; +MI0020022 hco-mir-87a; +MI0020023 hco-mir-9; +MI0020024 hco-mir-87b; +MI0020025 hco-mir-86; +MI0020026 hco-mir-5901; +MI0020027 hco-mir-5902; +MI0020028 hco-mir-5903; +MI0020029 hco-mir-83; +MI0020030 hco-mir-59; +MI0020031 hco-mir-5904a; +MI0020032 hco-mir-71; +MI0020033 hco-mir-5905; +MI0020034 hco-mir-5906; +MI0020035 hco-mir-5907; +MI0020036 hco-mir-5908; +MI0020037 hco-mir-5897b; +MI0020038 hco-mir-5909; +MI0020039 hco-mir-5910; +MI0020040 hco-mir-5911a; +MI0020041 hco-mir-84a; +MI0020042 hco-mir-242; +MI0020043 hco-mir-5890b; +MI0020044 hco-mir-252; +MI0020045 hco-mir-5904b; +MI0020046 hco-mir-790; +MI0020047 hco-mir-137;hco-mir-234; +MI0020048 hco-mir-5912a; +MI0020049 hco-mir-277; +MI0020050 hco-mir-5890c; +MI0020051 hco-mir-236; +MI0020052 hco-mir-5897c; +MI0020053 hco-mir-5352; +MI0020054 hco-mir-5913; +MI0020055 hco-mir-5914; +MI0020056 hco-mir-5915; +MI0020057 hco-mir-5916; +MI0020058 hco-mir-5911b; +MI0020059 hco-mir-7; +MI0020060 hco-mir-235; +MI0020061 hco-mir-228; +MI0020062 hco-mir-5917; +MI0020063 hco-mir-5918a; +MI0020064 hco-mir-5919; +MI0020065 hco-mir-5890d; +MI0020066 hco-mir-5920; +MI0020067 hco-mir-5921; +MI0020068 hco-mir-5911c; +MI0020069 hco-mir-5922; +MI0020070 hco-mir-5923; +MI0020071 hco-mir-5894b; +MI0020072 hco-mir-1; +MI0020073 hco-mir-5890e; +MI0020074 hco-mir-5924a;hco-mir-5924-1; +MI0020075 hco-mir-5925; +MI0020076 hco-mir-5926; +MI0020077 hco-mir-307; +MI0020078 hco-mir-5927; +MI0020079 hco-mir-5890f; +MI0020080 hco-mir-255; +MI0020081 hco-mir-5928a; +MI0020082 hco-mir-993; +MI0020083 hco-mir-5929; +MI0020084 hco-mir-2; +MI0020085 hco-mir-5930; +MI0020086 hco-mir-5885b; +MI0020087 hco-mir-5904c; +MI0020088 hco-mir-5924b;hco-mir-5924-2; +MI0020089 hco-mir-5931; +MI0020090 hco-mir-5918b; +MI0020091 hco-mir-5918c; +MI0020092 hco-mir-5912b; +MI0020093 hco-mir-5932; +MI0020094 hco-mir-5933; +MI0020095 hco-mir-5934; +MI0020096 hco-mir-5935; +MI0020097 hco-mir-40e; +MI0020098 hco-mir-40c; +MI0020099 hco-mir-40d; +MI0020100 hco-mir-5936; +MI0020101 hco-mir-5937; +MI0020102 hco-mir-5938; +MI0020103 hco-mir-5939; +MI0020104 hco-mir-5940; +MI0020105 hco-mir-5941; +MI0020106 hco-mir-5942; +MI0020107 hco-mir-5928b; +MI0020108 hco-mir-5943; +MI0020109 hco-mir-63b; +MI0020110 hco-mir-55; +MI0020111 hco-mir-5918d; +MI0020112 hco-mir-5944; +MI0020113 hco-mir-40a; +MI0020114 hco-mir-5928c; +MI0020115 hco-mir-5945; +MI0020116 hco-mir-5946a; +MI0020117 hco-mir-5947; +MI0020118 hco-mir-5948; +MI0020119 hco-mir-5949; +MI0020120 hco-mir-5950; +MI0020121 hco-mir-5951; +MI0020122 hco-mir-5952; +MI0020123 hco-mir-5953; +MI0020124 hco-mir-5928d; +MI0020125 hco-mir-5954; +MI0020126 hco-mir-5955; +MI0020127 hco-mir-5956; +MI0020128 hco-mir-5957; +MI0020129 hco-mir-5958; +MI0020130 hco-mir-5886b; +MI0020131 hco-mir-5959; +MI0020132 hco-mir-5960; +MI0020133 hco-mir-5961; +MI0020134 hco-mir-5962; +MI0020135 hco-mir-5963; +MI0020136 hco-mir-60; +MI0020137 hco-mir-5964; +MI0020138 hco-mir-5946b; +MI0020139 hco-mir-5946c; +MI0020140 hco-mir-5965; +MI0020141 hco-mir-5966; +MI0020142 hco-mir-5967; +MI0020143 hco-mir-5968; +MI0020144 hco-mir-5969; +MI0020145 hco-mir-5970; +MI0020146 hco-mir-5971; +MI0020147 hco-mir-5972; +MI0020148 hco-mir-5973; +MI0020149 hco-mir-5928e; +MI0020150 hco-mir-5974; +MI0020151 hco-mir-5975; +MI0020152 hco-mir-5885c; +MI0020153 hco-mir-5976; +MI0020154 hco-mir-5892b; +MI0020155 hco-mir-5977; +MI0020156 hco-mir-5978; +MI0020157 hco-mir-5979; +MI0020158 hco-mir-5980; +MI0020159 hco-mir-5981; +MI0020160 hco-mir-5982; +MI0020161 hco-mir-5983; +MI0020162 hco-mir-5984a; +MI0020163 hco-mir-5984b; +MI0020164 hco-mir-76; +MI0020165 hco-mir-5985-1; +MI0020166 hco-mir-5985-2; +MI0020167 hco-mir-72; +MI0020168 hco-mir-5986; +MI0020169 hco-mir-5991; +MI0020170 hco-mir-5987; +MI0020171 hco-mir-190; +MI0020172 hco-mir-5988; +MI0020173 hco-mir-87c; +MI0020174 hco-mir-5989; +MI0020175 hco-mir-5990; +MI0020176 hco-mir-84b; +MI0020177 hco-mir-265; +MI0020178 hco-mir-2159; +MI0020179 hhv6b-mir-Ro6-1; +MI0020180 hhv6b-mir-Ro6-2; +MI0020181 hhv6b-mir-Ro6-3; +MI0020182 hhv6b-mir-Ro6-4; +MI0020183 spu-mir-92d; +MI0020184 spu-mir-92e; +MI0020185 spu-mir-5992;spu-mir-5992-1; +MI0020186 spu-mir-5993; +MI0020187 spu-mir-5994; +MI0020188 ath-MIR5595a; +MI0020189 ath-MIR5995b; +MI0020190 ath-MIR5996; +MI0020191 ath-MIR5997; +MI0020192 ath-MIR5998a; +MI0020193 ath-MIR5998b; +MI0020194 ath-MIR4245; +MI0020195 ath-MIR5014b; +MI0020196 ath-MIR5999; +MI0020197 dpr-MIR156a; +MI0020198 dpr-MIR156b; +MI0020199 dpr-MIR160; +MI0020200 dpr-MIR166a; +MI0020201 dpr-MIR166b; +MI0020202 dpr-MIR167a; +MI0020203 dpr-MIR167b; +MI0020204 dpr-MIR167c; +MI0020205 dpr-MIR172a; +MI0020206 dpr-MIR172b; +MI0020207 dpr-MIR396; +MI0020208 dpr-MIR397; +MI0020209 dpr-MIR408; +MI0020210 ame-mir-6000a; +MI0020211 ame-mir-6001; +MI0020212 ame-mir-6002; +MI0020213 ame-mir-6003; +MI0020214 ame-mir-6004; +MI0020215 ame-mir-6005; +MI0020216 ame-mir-2765; +MI0020217 ame-mir-6006; +MI0020218 tca-mir-6007; +MI0020219 tca-mir-6008; +MI0020220 tca-mir-6009; +MI0020221 tca-mir-6010; +MI0020222 tca-mir-6011; +MI0020223 tca-mir-6012; +MI0020224 tca-mir-6013; +MI0020225 tca-mir-6014; +MI0020226 tca-mir-6015; +MI0020227 tca-mir-6016; +MI0020228 tca-mir-6017; +MI0020229 tca-mir-6018; +MI0020230 tca-mir-927b; +MI0020231 tca-mir-9e; +MI0020232 nta-MIR6019a; +MI0020233 nta-MIR6020a; +MI0020234 nta-MIR6019b; +MI0020235 nta-MIR6020b; +MI0020236 nta-MIR6021; +MI0020237 stu-MIR6022; +MI0020238 sly-MIR6022; +MI0020239 stu-MIR6023; +MI0020240 sly-MIR6023; +MI0020241 stu-MIR6024; +MI0020242 sly-MIR6024; +MI0020243 nta-MIR6024; +MI0020244 stu-MIR482c; +MI0020245 stu-MIR482b; +MI0020246 stu-MIR482a; +MI0020247 nta-MIR482a; +MI0020248 stu-MIR482d; +MI0020249 stu-MIR482e; +MI0020250 sly-MIR482b; +MI0020251 sly-MIR482c; +MI0020252 nta-MIR482b; +MI0020253 nta-MIR6025a; +MI0020254 nta-MIR6025b; +MI0020255 stu-MIR6025; +MI0020256 stu-MIR6026; +MI0020257 sly-MIR6026; +MI0020258 sly-MIR6027; +MI0020259 stu-MIR6027; +MI0020260 bna-MIR156d; +MI0020261 bna-MIR156e; +MI0020262 bna-MIR156f; +MI0020263 bna-MIR156g; +MI0020264 bna-MIR160a; +MI0020265 bna-MIR160b; +MI0020266 bna-MIR160c; +MI0020267 bna-MIR160d; +MI0020268 bna-MIR162a; +MI0020269 bna-MIR164b; +MI0020270 bna-MIR164c; +MI0020271 bna-MIR164d; +MI0020272 bna-MIR166f; +MI0020273 bna-MIR166e; +MI0020274 bna-MIR167d; +MI0020275 bna-MIR168b; +MI0020276 bna-MIR169n; +MI0020277 bna-MIR172d; +MI0020278 bna-MIR172b; +MI0020279 bna-MIR172c; +MI0020280 bna-MIR172a; +MI0020281 bna-MIR394a; +MI0020282 bna-MIR394b; +MI0020283 bna-MIR395a; +MI0020284 bna-MIR395b; +MI0020285 bna-MIR395c; +MI0020286 bna-MIR395d; +MI0020287 bna-MIR395e; +MI0020288 bna-MIR395f; +MI0020289 bna-MIR399b; +MI0020290 bna-MIR399c; +MI0020291 bna-MIR403; +MI0020292 bna-MIR860; +MI0020293 bna-MIR2111d; +MI0020294 bna-MIR2111c; +MI0020295 bna-MIR6028; +MI0020296 bna-MIR6029; +MI0020297 bna-MIR6030; +MI0020298 bna-MIR6031; +MI0020299 bna-MIR6032; +MI0020300 bna-MIR6033; +MI0020301 bna-MIR6034; +MI0020302 bna-MIR6035; +MI0020303 bna-MIR6036; +MI0020304 ame-mir-6037; +MI0020305 ame-mir-6038; +MI0020306 ame-mir-6039; +MI0020307 ame-mir-6040; +MI0020308 ame-mir-6000b; +MI0020309 ame-mir-252b; +MI0020310 ame-mir-6041; +MI0020311 ame-mir-6042; +MI0020312 ame-mir-6043; +MI0020313 ame-mir-6044; +MI0020314 ame-mir-6045; +MI0020315 ame-mir-92c; +MI0020316 ame-mir-6046; +MI0020317 ame-mir-6012; +MI0020318 ame-mir-6047a; +MI0020319 ame-mir-6048; +MI0020320 ame-mir-6049; +MI0020321 ame-mir-6050; +MI0020322 ame-mir-6051; +MI0020323 ame-mir-6052; +MI0020324 ame-mir-6053; +MI0020325 ame-mir-6054; +MI0020326 ame-mir-6055; +MI0020327 ame-mir-6056; +MI0020328 ame-mir-6057; +MI0020329 ame-mir-6058; +MI0020330 ame-mir-6059; +MI0020331 ame-mir-6060; +MI0020332 ame-mir-6061; +MI0020333 ame-mir-6062; +MI0020334 ame-mir-6063; +MI0020335 ame-mir-6047b; +MI0020336 ame-mir-6064; +MI0020337 ame-mir-6065; +MI0020338 ame-mir-6066; +MI0020339 ame-mir-6067; +MI0020340 hsa-mir-1199; +MI0020341 ppy-mir-1199; +MI0020342 cfa-mir-1199; +MI0020343 rno-mir-1199; +MI0020344 ptr-mir-1199; +MI0020345 hsa-mir-6068; +MI0020346 hsa-mir-6069; +MI0020347 hsa-mir-6070; +MI0020348 hsa-mir-6071; +MI0020349 hsa-mir-6072; +MI0020350 hsa-mir-6073; +MI0020351 hsa-mir-6074; +MI0020352 hsa-mir-6075; +MI0020353 hsa-mir-6076; +MI0020354 hsa-mir-6077-1;hsa-mir-6077; +MI0020355 hsa-mir-6078; +MI0020356 hsa-mir-6079; +MI0020357 hsa-mir-6080; +MI0020358 hsa-mir-6081; +MI0020359 hsa-mir-6082; +MI0020360 hsa-mir-6083; +MI0020361 hsa-mir-6084; +MI0020362 hsa-mir-6085; +MI0020363 hsa-mir-6086; +MI0020364 hsa-mir-6087; +MI0020365 hsa-mir-6088; +MI0020366 hsa-mir-6089-1; +MI0020367 hsa-mir-6090; +MI0020368 cgr-let-7a;cgr-let-7a-1; +MI0020369 cgr-let-7b; +MI0020370 cgr-let-7c;cgr-let-7c-1; +MI0020371 cgr-let-7d; +MI0020372 cgr-let-7f; +MI0020373 cgr-let-7g; +MI0020374 cgr-let-7i; +MI0020375 cgr-mir-1; +MI0020376 cgr-mir-100; +MI0020377 cgr-mir-101b; +MI0020378 cgr-mir-103; +MI0020379 cgr-mir-106b; +MI0020380 cgr-mir-107; +MI0020381 cgr-mir-10a; +MI0020382 cgr-mir-10b; +MI0020383 cgr-mir-122; +MI0020384 cgr-mir-124; +MI0020385 cgr-mir-125a; +MI0020386 cgr-mir-125b; +MI0020387 cgr-mir-126;cgr-mir-126a; +MI0020388 cgr-mir-1260; +MI0020389 cgr-mir-1271; +MI0020390 cgr-mir-1285; +MI0020391 cgr-mir-128; +MI0020392 cgr-mir-129; +MI0020393 cgr-mir-1306; +MI0020394 cgr-mir-130a; +MI0020395 cgr-mir-130b; +MI0020396 cgr-mir-132; +MI0020397 cgr-mir-134; +MI0020398 cgr-mir-1343; +MI0020399 cgr-mir-137; +MI0020400 cgr-mir-138; +MI0020401 cgr-mir-139; +MI0020402 cgr-mir-140; +MI0020403 cgr-mir-141; +MI0020404 cgr-mir-142; +MI0020405 cgr-mir-143; +MI0020406 cgr-mir-144; +MI0020407 cgr-mir-146a; +MI0020408 cgr-mir-146b; +MI0020409 cgr-mir-147; +MI0020410 cgr-mir-148b; +MI0020411 cgr-mir-149; +MI0020412 cgr-mir-151; +MI0020413 cgr-mir-152; +MI0020414 cgr-mir-154; +MI0020415 cgr-mir-155; +MI0020416 cgr-mir-15a; +MI0020417 cgr-mir-15b; +MI0020418 cgr-mir-16; +MI0020419 cgr-mir-17; +MI0020420 cgr-mir-181a; +MI0020421 cgr-mir-181b; +MI0020422 cgr-mir-181c; +MI0020423 cgr-mir-181d; +MI0020424 cgr-mir-182; +MI0020425 cgr-mir-183; +MI0020426 cgr-mir-1839; +MI0020427 cgr-mir-184; +MI0020428 cgr-mir-1843; +MI0020429 cgr-mir-185; +MI0020430 cgr-mir-186; +MI0020431 cgr-mir-187; +MI0020432 cgr-mir-188; +MI0020433 cgr-mir-18a; +MI0020434 cgr-mir-190a; +MI0020435 cgr-mir-1903; +MI0020436 cgr-mir-190b; +MI0020437 cgr-mir-191; +MI0020438 cgr-mir-192; +MI0020439 cgr-mir-193b; +MI0020440 cgr-mir-194; +MI0020441 cgr-mir-1949; +MI0020442 cgr-mir-195; +MI0020443 cgr-mir-1956; +MI0020444 cgr-mir-196a; +MI0020445 cgr-mir-196b; +MI0020446 cgr-mir-196c; +MI0020447 cgr-mir-1973; +MI0020448 cgr-mir-199a; +MI0020449 cgr-mir-199b; +MI0020450 cgr-mir-19a; +MI0020451 cgr-mir-19b; +MI0020452 cgr-mir-200b; +MI0020453 cgr-mir-200c; +MI0020454 cgr-mir-204; +MI0020455 cgr-mir-205; +MI0020456 cgr-mir-206; +MI0020457 cgr-mir-20a; +MI0020458 cgr-mir-210; +MI0020459 cgr-mir-212; +MI0020460 cgr-mir-214; +MI0020461 cgr-mir-215; +MI0020462 cgr-mir-218a; +MI0020463 cgr-mir-22; +MI0020464 cgr-mir-221; +MI0020465 cgr-mir-222; +MI0020466 cgr-mir-23a; +MI0020467 cgr-mir-23b; +MI0020468 cgr-mir-24; +MI0020469 cgr-mir-2424; +MI0020470 cgr-mir-25; +MI0020471 cgr-mir-26a;cgr-mir-26a-2; +MI0020472 cgr-mir-26b; +MI0020473 cgr-mir-27a; +MI0020474 cgr-mir-27b; +MI0020475 cgr-mir-28; +MI0020476 cgr-mir-296; +MI0020477 cgr-mir-298; +MI0020478 cgr-mir-29a; +MI0020479 cgr-mir-29b; +MI0020480 cgr-mir-29c; +MI0020481 cgr-mir-300; +MI0020482 cgr-mir-301a; +MI0020483 cgr-mir-3072; +MI0020484 cgr-mir-30a; +MI0020485 cgr-mir-30b; +MI0020486 cgr-mir-30c;cgr-mir-30c-2; +MI0020487 cgr-mir-30d; +MI0020488 cgr-mir-30e; +MI0020489 cgr-mir-31; +MI0020490 cgr-mir-32; +MI0020491 cgr-mir-320a; +MI0020492 cgr-mir-322; +MI0020493 cgr-mir-324; +MI0020494 cgr-mir-325; +MI0020495 cgr-mir-326; +MI0020496 cgr-mir-328; +MI0020497 cgr-mir-33; +MI0020498 cgr-mir-331; +MI0020499 cgr-mir-338; +MI0020500 cgr-mir-339; +MI0020501 cgr-mir-340; +MI0020502 cgr-mir-342; +MI0020503 cgr-mir-344; +MI0020504 cgr-mir-345; +MI0020505 cgr-mir-34a; +MI0020506 cgr-mir-34b; +MI0020507 cgr-mir-34c; +MI0020508 cgr-mir-350; +MI0020509 cgr-mir-361; +MI0020510 cgr-mir-362; +MI0020511 cgr-mir-365; +MI0020512 cgr-mir-369; +MI0020513 cgr-mir-374; +MI0020514 cgr-mir-377; +MI0020515 cgr-mir-378; +MI0020516 cgr-mir-379; +MI0020517 cgr-mir-381; +MI0020518 cgr-mir-382; +MI0020519 cgr-mir-384; +MI0020520 cgr-mir-409; +MI0020521 cgr-mir-410; +MI0020522 cgr-mir-412; +MI0020523 cgr-mir-423; +MI0020524 cgr-mir-425; +MI0020525 cgr-mir-429; +MI0020526 cgr-mir-450a; +MI0020527 cgr-mir-450b; +MI0020528 cgr-mir-455; +MI0020529 cgr-mir-484; +MI0020530 cgr-mir-486; +MI0020531 cgr-mir-496; +MI0020532 cgr-mir-497; +MI0020533 cgr-mir-499; +MI0020534 cgr-mir-500; +MI0020535 cgr-mir-501; +MI0020536 cgr-mir-503; +MI0020537 cgr-mir-504; +MI0020538 cgr-mir-505; +MI0020539 cgr-mir-532; +MI0020540 cgr-mir-542; +MI0020541 cgr-mir-582; +MI0020542 cgr-mir-598; +MI0020543 cgr-mir-615; +MI0020544 cgr-mir-628; +MI0020545 cgr-mir-632; +MI0020546 cgr-mir-652; +MI0020547 cgr-mir-653; +MI0020548 cgr-mir-664; +MI0020549 cgr-mir-671; +MI0020550 cgr-mir-672; +MI0020551 cgr-mir-674; +MI0020552 cgr-mir-702; +MI0020553 cgr-mir-708; +MI0020555 cgr-mir-744; +MI0020556 cgr-mir-7b; +MI0020557 cgr-mir-872; +MI0020558 cgr-mir-874; +MI0020559 cgr-mir-9; +MI0020560 cgr-mir-92a; +MI0020561 cgr-mir-92b; +MI0020562 cgr-mir-93; +MI0020563 cgr-mir-98; +MI0020564 cgr-mir-99a; +MI0020565 cgr-mir-6091; +MI0020566 cgr-mir-6092; +MI0020567 egu-MIR172a; +MI0020568 egu-MIR172b; +MI0020569 egu-MIR172c; +MI0020570 egu-MIR172d; +MI0020571 egu-MIR172e; +MI0020572 egu-MIR172f; +MI0020573 ptr-mir-222; +MI0020574 ptr-mir-4510; +MI0020575 ptr-mir-92b; +MI0020576 ptr-mir-4446; +MI0020577 ptr-mir-320e; +MI0020578 ptr-mir-3151; +MI0020579 ptr-mir-767; +MI0020580 ptr-mir-655; +MI0020581 ptr-mir-3173; +MI0020582 ptr-mir-4660; +MI0020583 ptr-mir-3200; +MI0020584 ptr-mir-2392; +MI0020585 ptr-mir-3127; +MI0020586 ptr-mir-1252; +MI0020587 ptr-mir-3660; +MI0020588 ptr-mir-3129; +MI0020589 ptr-mir-3192; +MI0020590 ptr-mir-4742; +MI0020591 ptr-mir-378b; +MI0020592 ptr-mir-4743; +MI0020593 ptr-mir-3943; +MI0020594 ptr-mir-3138; +MI0020595 ptr-mir-23c; +MI0020596 ptr-mir-676; +MI0020597 ptr-mir-3117; +MI0020598 ptr-mir-200c; +MI0020599 ptr-mir-4536; +MI0020600 ptr-mir-4654; +MI0020601 ptr-mir-548o; +MI0020602 ptr-mir-3937; +MI0020603 ptr-mir-3149; +MI0020604 ptr-mir-548e; +MI0020605 ptr-mir-3132; +MI0020606 ptr-mir-4524a; +MI0020607 ptr-mir-4667; +MI0020608 ptr-mir-3121; +MI0020609 ptr-mir-3193; +MI0020610 ptr-mir-3664; +MI0020611 ptr-mir-3136; +MI0020612 ptr-mir-4504; +MI0020613 ptr-mir-1260b; +MI0020614 ptr-mir-378e; +MI0020615 ptr-mir-4423; +MI0020616 ptr-mir-4428; +MI0020617 ptr-mir-3165; +MI0020618 ptr-mir-449c; +MI0020619 ptr-mir-2114; +MI0020620 ggo-let-7f; +MI0020621 ggo-let-7a; +MI0020622 ggo-let-7c; +MI0020623 ggo-let-7g; +MI0020624 ggo-let-7b; +MI0020625 ggo-mir-1; +MI0020626 ggo-let-7e; +MI0020627 ggo-mir-320a; +MI0020628 ggo-mir-140; +MI0020629 ggo-mir-128; +MI0020630 ggo-let-7i; +MI0020631 ggo-mir-29c; +MI0020632 ggo-mir-423; +MI0020633 ggo-mir-185; +MI0020634 ggo-mir-340; +MI0020635 ggo-mir-330; +MI0020636 ggo-mir-598; +MI0020637 ggo-mir-129; +MI0020638 ggo-mir-26b; +MI0020639 ggo-mir-222; +MI0020640 ggo-mir-191; +MI0020641 ggo-mir-127; +MI0020642 ggo-mir-23b; +MI0020643 ggo-mir-146b; +MI0020644 ggo-mir-22; +MI0020645 ggo-mir-138; +MI0020646 ggo-mir-152; +MI0020647 ggo-mir-181d; +MI0020648 ggo-mir-342; +MI0020649 ggo-mir-485; +MI0020650 ggo-mir-378a; +MI0020651 ggo-mir-495; +MI0020652 ggo-mir-487b; +MI0020653 ggo-mir-139; +MI0020654 ggo-mir-151a; +MI0020655 ggo-mir-148b; +MI0020656 ggo-mir-4510; +MI0020657 ggo-mir-379; +MI0020658 ggo-mir-30c; +MI0020659 ggo-mir-27b; +MI0020660 ggo-mir-433; +MI0020661 ggo-mir-885; +MI0020662 ggo-mir-889; +MI0020663 ggo-mir-383; +MI0020664 ggo-mir-432; +MI0020665 ggo-mir-499a; +MI0020666 ggo-mir-192; +MI0020667 ggo-mir-92b; +MI0020668 ggo-mir-410; +MI0020669 ggo-mir-335; +MI0020670 ggo-mir-34c; +MI0020671 ggo-mir-30e; +MI0020672 ggo-mir-338; +MI0020673 ggo-mir-374b; +MI0020674 ggo-mir-584; +MI0020675 ggo-mir-331; +MI0020676 ggo-mir-4446; +MI0020677 ggo-mir-324; +MI0020678 ggo-mir-532; +MI0020679 ggo-mir-760; +MI0020680 ggo-mir-125a; +MI0020681 ggo-mir-323a; +MI0020682 ggo-mir-146a; +MI0020683 ggo-mir-361; +MI0020684 ggo-mir-376c; +MI0020685 ggo-mir-193b; +MI0020686 ggo-mir-769; +MI0020687 ggo-mir-874; +MI0020688 ggo-mir-148a; +MI0020689 ggo-mir-299; +MI0020690 ggo-mir-497; +MI0020691 ggo-mir-149; +MI0020692 ggo-mir-487a; +MI0020693 ggo-mir-210; +MI0020694 ggo-mir-543; +MI0020695 ggo-mir-411; +MI0020696 ggo-mir-486; +MI0020697 ggo-mir-365a; +MI0020698 ggo-mir-424; +MI0020699 ggo-mir-4488; +MI0020700 ggo-mir-652; +MI0020701 ggo-mir-655; +MI0020702 ggo-mir-877; +MI0020703 ggo-mir-130b; +MI0020704 ggo-mir-363; +MI0020705 ggo-mir-1301; +MI0020706 ggo-mir-376a; +MI0020707 ggo-mir-494; +MI0020708 ggo-mir-339; +MI0020709 ggo-mir-574; +MI0020710 ggo-mir-504; +MI0020711 ggo-mir-660; +MI0020712 ggo-mir-577; +MI0020713 ggo-mir-328; +MI0020714 ggo-mir-873; +MI0020715 ggo-mir-421; +MI0020716 ggo-mir-374a; +MI0020717 ggo-mir-409; +MI0020718 ggo-mir-323b; +MI0020719 ggo-mir-1296; +MI0020720 ggo-mir-1185; +MI0020721 ggo-mir-193a; +MI0020722 ggo-mir-1277; +MI0020723 ggo-mir-1255a; +MI0020724 ggo-mir-142; +MI0020725 ggo-mir-329b; +MI0020726 ggo-mir-122; +MI0020727 ggo-mir-197; +MI0020728 ggo-mir-206; +MI0020729 ggo-mir-370; +MI0020730 ggo-mir-656; +MI0020731 ggo-mir-431; +MI0020732 ggo-mir-628; +MI0020733 ggo-mir-551a; +MI0020734 ggo-mir-502a; +MI0020735 ggo-mir-551b; +MI0020736 ggo-mir-375; +MI0020737 ggo-mir-346; +MI0020738 ggo-mir-483; +MI0020739 ggo-mir-1271; +MI0020740 ggo-mir-376b; +MI0020741 ggo-mir-629; +MI0020742 ggo-mir-380; +MI0020743 ggo-mir-491; +MI0020744 ggo-mir-4524a; +MI0020745 ggo-mir-592; +MI0020746 ggo-mir-4660; +MI0020747 ggo-mir-484; +MI0020748 ggo-mir-377; +MI0020749 ggo-mir-582; +MI0020750 ggo-mir-503; +MI0020751 ggo-mir-887; +MI0020752 ggo-mir-490; +MI0020753 ggo-mir-590; +MI0020754 ggo-mir-345; +MI0020755 ggo-mir-1291; +MI0020756 ggo-mir-448; +MI0020757 ggo-mir-3943; +MI0020758 ggo-mir-452; +MI0020759 ggo-mir-767; +MI0020760 ggo-mir-940; +MI0020761 ggo-mir-1180; +MI0020762 ggo-mir-326; +MI0020763 ggo-mir-320b; +MI0020764 ggo-mir-150; +MI0020765 ggo-mir-1179; +MI0020766 ggo-mir-144; +MI0020767 ggo-mir-381; +MI0020768 ggo-mir-155; +MI0020769 ggo-mir-455; +MI0020770 ggo-mir-496; +MI0020771 ggo-mir-766; +MI0020772 ggo-mir-1306; +MI0020773 ggo-mir-34b; +MI0020774 ggo-mir-20b; +MI0020775 ggo-mir-505; +MI0020776 ggo-mir-1228; +MI0020777 ggo-mir-488; +MI0020778 ggo-mir-542; +MI0020779 ggo-mir-1298; +MI0020780 ggo-mir-1287; +MI0020781 ggo-mir-509; +MI0020782 ggo-mir-1250; +MI0020783 ggo-mir-3605; +MI0020784 ggo-mir-450a; +MI0020785 ggo-mir-654; +MI0020786 ggo-mir-589; +MI0020787 ggo-mir-1260b; +MI0020788 ggo-mir-362; +MI0020789 ggo-mir-378b; +MI0020790 ggo-mir-337; +MI0020791 ggo-mir-23c; +MI0020792 ggo-mir-1197; +MI0020793 ggo-mir-4520b; +MI0020794 ggo-mir-1249; +MI0020796 ggo-mir-4429; +MI0020797 ggo-mir-493; +MI0020798 ggo-mir-2110; +MI0020799 ggo-mir-1252; +MI0020800 ggo-mir-668; +MI0020801 ggo-mir-135b; +MI0020802 ggo-mir-517c; +MI0020803 ggo-mir-4743; +MI0020804 ggo-mir-1193; +MI0020805 ggo-mir-1343; +MI0020806 ggo-mir-3612; +MI0020807 ggo-mir-3151; +MI0020808 ggo-mir-548b; +MI0020809 ggo-mir-3126; +MI0020810 ggo-mir-641; +MI0020811 ggo-mir-4529; +MI0020812 ggo-mir-203b; +MI0020813 ggo-mir-3129; +MI0020814 ggo-mir-548c; +MI0020815 ggo-mir-371b; +MI0020816 ggo-mir-1266; +MI0020817 ggo-mir-3127; +MI0020818 ggo-mir-190b; +MI0020819 ggo-mir-3138; +MI0020820 ggo-mir-133b; +MI0020821 ggo-mir-676; +MI0020822 ggo-mir-651; +MI0020823 ggo-mir-3173; +MI0020824 ggo-mir-548e; +MI0020825 ggo-mir-188; +MI0020826 ggo-mir-548a; +MI0020827 ggo-mir-671; +MI0020828 ggo-mir-454; +MI0020829 ggo-mir-3615; +MI0020830 ggo-mir-1289; +MI0020831 ggo-mir-1278; +MI0020832 ggo-mir-4738; +MI0020833 ggo-mir-508; +MI0020834 ggo-mir-1264; +MI0020835 ggo-mir-556; +MI0020836 ggo-mir-548d; +MI0020837 ggo-mir-1273c; +MI0020838 ggo-mir-296; +MI0020839 ggo-mir-1286; +MI0020840 ggo-mir-516b;ggo-mir-516b-1; +MI0020841 ggo-mir-4536; +MI0020842 ggo-mir-548f; +MI0020843 ggo-mir-3923; +MI0020844 ggo-mir-450b; +MI0020845 ggo-mir-202; +MI0020846 ggo-mir-182; +MI0020847 ggo-mir-200b; +MI0020848 ggo-mir-200a; +MI0020849 ggo-mir-609; +MI0020850 ggo-mir-624; +MI0020851 ggo-mir-378e; +MI0020852 ggo-mir-429; +MI0020853 ggo-mir-675b; +MI0020854 ggo-mir-3927; +MI0020855 ggo-mir-4484; +MI0020856 ggo-mir-502b; +MI0020857 ggo-mir-18b; +MI0020858 mml-mir-4446; +MI0020859 mml-mir-873; +MI0020860 mml-mir-320b; +MI0020861 mml-mir-378d; +MI0020862 mml-mir-1185;mml-mir-1185-1; +MI0020863 mml-mir-1271; +MI0020864 mml-mir-1298; +MI0020865 mml-mir-1277; +MI0020866 mml-mir-3151; +MI0020867 mml-mir-1260b; +MI0020868 mml-mir-1255a; +MI0020869 mml-mir-1262; +MI0020870 mml-mir-1258; +MI0020871 mml-mir-3200; +MI0020872 mml-mir-1249; +MI0020873 mml-mir-676;mml-mir-676-1; +MI0020874 mml-mir-320c; +MI0020875 mml-mir-4743; +MI0020876 mml-mir-1296; +MI0020877 mml-mir-1179; +MI0020878 mml-mir-4803; +MI0020879 mml-mir-3173; +MI0020880 mml-mir-4536; +MI0020881 mml-mir-4667; +MI0020882 mml-mir-1250; +MI0020883 mml-mir-891b; +MI0020884 mml-mir-3146; +MI0020885 mml-mir-4716; +MI0020886 mml-mir-1243; +MI0020887 mml-mir-1304; +MI0020888 mml-mir-3122; +MI0020889 mml-mir-4796; +MI0020890 mml-mir-1255b; +MI0020891 mml-mir-1284; +MI0020892 mml-mir-4650; +MI0020893 mml-mir-2114; +MI0020894 mml-mir-1323; +MI0020895 mml-mir-3140; +MI0020896 mml-mir-514b; +MI0020897 mml-mir-3145; +MI0020898 mml-mir-3927; +MI0020899 mml-mir-517c; +MI0020900 mml-mir-1283; +MI0020901 mml-mir-519e; +MI0020902 mml-mir-217b; +MI0020903 mml-mir-518d;mml-mir-518d-1; +MI0020904 ppy-mir-152; +MI0020905 ppy-mir-4446; +MI0020906 ppy-mir-320e; +MI0020907 ppy-mir-202; +MI0020908 ppy-mir-378d; +MI0020909 ppy-mir-548e; +MI0020910 ppy-mir-4451; +MI0020911 ppy-mir-3943; +MI0020912 ppy-mir-378b; +MI0020913 ppy-mir-676; +MI0020914 ppy-mir-4743; +MI0020915 ppy-mir-454; +MI0020916 ppy-mir-3155a; +MI0020917 ppy-mir-1193; +MI0020918 ppy-mir-1260b; +MI0020919 ppy-mir-3660; +MI0020920 ppy-mir-3617; +MI0020921 ppy-mir-548a; +MI0020922 ppy-mir-4798; +MI0020923 ppy-mir-3934; +MI0020924 ppy-mir-4782; +MI0020925 ppy-mir-548h; +MI0020926 ppy-mir-548f; +MI0020927 ppy-mir-548c; +MI0020928 ppy-mir-4791; +MI0020929 ppy-mir-3940; +MI0020930 ppy-mir-4774; +MI0020931 ppy-mir-4484; +MI0020932 ppy-mir-4515; +MI0020933 ppy-mir-1273e; +MI0020934 ppy-mir-4667; +MI0020935 ppy-mir-3912; +MI0020936 ppy-mir-3661; +MI0020937 ppy-mir-4520a; +MI0020938 ppy-mir-4637; +MI0020939 ppy-mir-3938; +MI0020940 ppy-mir-4529; +MI0020941 ppy-mir-4526; +MI0020942 ppy-mir-151b; +MI0020943 ppy-mir-3173; +MI0020944 ppy-mir-3121; +MI0020945 ppy-mir-3170; +MI0020946 ppy-mir-4672; +MI0020947 ppy-mir-4796; +MI0020948 ppy-mir-4427; +MI0020949 ppy-mir-3188; +MI0020950 ppy-mir-3154; +MI0020951 ppy-mir-3145; +MI0020952 ppy-mir-1976; +MI0020953 ppy-mir-2861; +MI0020954 ppy-mir-2278; +MI0020955 ppy-mir-3174; +MI0020956 ppy-mir-4788; +MI0020957 ppy-mir-378e; +MI0020958 mmu-mir-3084-2; +MI0020959 mes-MIR159;mes-MIR159a; +MI0020960 mes-MIR160; +MI0020961 mes-MIR166; +MI0020962 mes-MIR167;mes-MIR167a; +MI0020963 mes-MIR168;mes-MIR168a; +MI0020964 mes-MIR171;mes-MIR171a; +MI0020965 mes-MIR172;mes-MIR172a; +MI0020966 mes-MIR394;mes-MIR394a; +MI0020967 mes-MIR399;mes-MIR399a; +MI0020968 mes-MIR408; +MI0020969 mse-mir-210; +MI0020970 mse-mir-3286; +MI0020971 mse-mir-11; +MI0020972 mse-mir-998; +MI0020973 mse-mir-190; +MI0020974 mse-mir-2779; +MI0020975 mse-mir-7; +MI0020976 mse-mir-279b; +MI0020977 mse-mir-965; +MI0020978 mse-mir-33; +MI0020979 mse-mir-275; +MI0020980 mse-mir-989; +MI0020981 mse-mir-3338; +MI0020982 mse-mir-981-2; +MI0020983 mse-mir-316; +MI0020984 mse-mir-87; +MI0020985 mse-mir-285; +MI0020986 mse-let-7a; +MI0020987 mse-mir-100; +MI0020988 mse-mir-193; +MI0020989 mse-mir-276; +MI0020990 mse-mir-1000; +MI0020991 mse-mir-2755; +MI0020992 mse-mir-277; +MI0020993 mse-mir-282; +MI0020994 mse-mir-745; +MI0020995 mse-mir-281; +MI0020996 mse-mir-31; +MI0020997 mse-mir-307; +MI0020998 mse-mir-10a; +MI0020999 mse-mir-279c; +MI0021000 mse-mir-278; +MI0021001 mse-bantam; +MI0021002 mse-mir-970; +MI0021003 mse-mir-932; +MI0021004 mse-mir-279a; +MI0021005 mse-mir-8; +MI0021006 mse-mir-750; +MI0021007 mse-mir-137; +MI0021008 mse-mir-iab-4; +MI0021009 mse-mir-2768; +MI0021010 mse-mir-2796; +MI0021011 mse-mir-133; +MI0021012 mse-mir-14; +MI0021013 mse-mir-317; +MI0021014 mse-mir-252; +MI0021015 mse-mir-12; +MI0021016 mse-mir-993; +MI0021017 mse-mir-263a; +MI0021018 mse-mir-283; +MI0021019 mse-mir-2765; +MI0021020 mse-mir-92a; +MI0021021 mse-mir-79; +MI0021022 mse-mir-9a; +MI0021023 mse-mir-981-1;mse-mir-981; +MI0021024 mse-mir-124; +MI0021025 mse-mir-34; +MI0021026 mse-mir-9b; +MI0021027 mse-mir-184; +MI0021028 mse-mir-308; +MI0021029 mse-mir-2a; +MI0021030 mse-mir-2b; +MI0021031 mse-mir-71; +MI0021032 mse-mir-2766; +MI0021033 mse-mir-1a; +MI0021034 mse-mir-263b; +MI0021035 mse-mir-279d; +MI0021036 mse-mir-306; +MI0021037 mse-mir-92b; +MI0021038 mse-mir-2767; +MI0021039 mse-mir-2763; +MI0021040 mse-mir-10b;mse-mir-10b-1; +MI0021041 mse-mir-10c;mse-mir-10b-2; +MI0021042 mse-mir-2788; +MI0021043 mse-mir-1b; +MI0021044 mse-mir-1926; +MI0021045 mse-mir-2565; +MI0021046 mse-mir-3389; +MI0021047 mse-mir-450; +MI0021048 mse-mir-929;mse-mir-929a; +MI0021049 mse-mir-2797a; +MI0021050 mse-mir-2797b; +MI0021051 mse-mir-6093; +MI0021052 mse-mir-6094; +MI0021053 mse-mir-6095-1; +MI0021054 mse-mir-6095-2; +MI0021055 mse-mir-6095-3; +MI0021056 mse-mir-6096-1; +MI0021057 mse-mir-6096-2; +MI0021058 mse-mir-6096-3; +MI0021059 mse-mir-6097; +MI0021060 mse-mir-6098; +MI0021061 mse-mir-6099; +MI0021062 mse-mir-6100; +MI0021063 mse-mir-6101; +MI0021064 cca-MIR156a; +MI0021065 cca-MIR156b; +MI0021066 cca-MIR156c; +MI0021067 cca-MIR160a; +MI0021068 cca-MIR160b; +MI0021069 cca-MIR164; +MI0021070 cca-MIR167; +MI0021071 cca-MIR168a; +MI0021072 cca-MIR169a; +MI0021073 cca-MIR169b; +MI0021074 cca-MIR171; +MI0021075 cca-MIR172; +MI0021076 cca-MIR319; +MI0021077 cca-MIR390; +MI0021078 cca-MIR393; +MI0021079 cca-MIR394; +MI0021080 cca-MIR395a; +MI0021081 cca-MIR395b; +MI0021082 cca-MIR395c; +MI0021083 cca-MIR396a; +MI0021084 cca-MIR396b; +MI0021085 cca-MIR398; +MI0021086 cca-MIR399; +MI0021087 cca-MIR408; +MI0021088 cca-MIR6103; +MI0021089 cca-MIR6104; +MI0021090 cca-MIR6105a; +MI0021091 cca-MIR6106; +MI0021092 cca-MIR6107; +MI0021093 cca-MIR6105b; +MI0021094 cca-MIR6108a; +MI0021095 cca-MIR6108g; +MI0021096 cca-MIR6108b; +MI0021097 cca-MIR6109; +MI0021098 cca-MIR6110; +MI0021099 cca-MIR6111; +MI0021100 cca-MIR6112; +MI0021101 cca-MIR6113; +MI0021102 cca-MIR6114; +MI0021103 cca-MIR6108c; +MI0021104 cca-MIR6108d; +MI0021105 cca-MIR6108e; +MI0021106 cca-MIR6108f; +MI0021107 cca-MIR6115; +MI0021108 cca-MIR396c; +MI0021109 cca-MIR6116; +MI0021110 cca-MIR6117; +MI0021111 cca-MIR6118; +MI0021112 bta-mir-1246; +MI0021113 bta-mir-1260b; +MI0021114 bta-mir-1277; +MI0021115 bta-mir-149; +MI0021116 bta-mir-3120; +MI0021117 bta-mir-3141; +MI0021118 bta-mir-3613;bta-mir-3613a; +MI0021119 bta-mir-4286-1; +MI0021120 bta-mir-4286-2; +MI0021121 bta-mir-450b; +MI0021122 bta-mir-574; +MI0021123 bta-mir-652; +MI0021125 bta-mir-2284y-1; +MI0021126 bta-mir-2285e-1; +MI0021127 bta-mir-2285e-2; +MI0021128 bta-mir-2285f-1; +MI0021129 bta-mir-2285f-2; +MI0021130 bta-mir-2285g;bta-mir-2285g-1; +MI0021131 bta-mir-2285h; +MI0021132 bta-mir-2285i; +MI0021133 bta-mir-2285j-1; +MI0021134 bta-mir-2285j-2; +MI0021135 bta-mir-2285k-1; +MI0021136 bta-mir-2285l; +MI0021137 bta-mir-6119; +MI0021138 bta-mir-6120; +MI0021139 bta-mir-6121; +MI0021140 bta-mir-6122; +MI0021141 bta-mir-6123; +MI0021142 lus-MIR171a; +MI0021143 lus-MIR319a; +MI0021144 lus-MIR167a; +MI0021145 lus-MIR169a; +MI0021146 lus-MIR169b; +MI0021147 lus-MIR169c; +MI0021148 lus-MIR169d; +MI0021149 lus-MIR164a; +MI0021150 lus-MIR319b; +MI0021151 lus-MIR167b; +MI0021152 lus-MIR395a; +MI0021153 lus-MIR395b; +MI0021154 lus-MIR171b; +MI0021155 lus-MIR172a; +MI0021156 lus-MIR395c; +MI0021157 lus-MIR160a; +MI0021158 lus-MIR164b; +MI0021159 lus-MIR169e; +MI0021160 lus-MIR171c; +MI0021161 lus-MIR394a; +MI0021162 lus-MIR164c; +MI0021163 lus-MIR172b; +MI0021164 lus-MIR172c; +MI0021165 lus-MIR395d; +MI0021166 lus-MIR171d; +MI0021167 lus-MIR398a; +MI0021168 lus-MIR169f; +MI0021169 lus-MIR171e; +MI0021170 lus-MIR160b; +MI0021171 lus-MIR160c; +MI0021172 lus-MIR399a; +MI0021173 lus-MIR399b; +MI0021174 lus-MIR399c; +MI0021175 lus-MIR399d; +MI0021176 lus-MIR399e; +MI0021177 lus-MIR399f; +MI0021178 lus-MIR167c; +MI0021179 lus-MIR167d; +MI0021180 lus-MIR398b; +MI0021181 lus-MIR156b; +MI0021182 lus-MIR530a; +MI0021183 lus-MIR171f; +MI0021184 lus-MIR172d; +MI0021185 lus-MIR167e; +MI0021186 lus-MIR162a; +MI0021187 lus-MIR390a; +MI0021188 lus-MIR166a; +MI0021189 lus-MIR530b; +MI0021190 lus-MIR397a; +MI0021191 lus-MIR160d; +MI0021192 lus-MIR166b; +MI0021193 lus-MIR393a; +MI0021194 lus-MIR172e; +MI0021195 lus-MIR167f; +MI0021196 lus-MIR167g; +MI0021197 lus-MIR167h; +MI0021198 lus-MIR156i; +MI0021199 lus-MIR156c; +MI0021200 lus-MIR156d; +MI0021201 lus-MIR397b; +MI0021202 lus-MIR159a; +MI0021203 lus-MIR164d; +MI0021204 lus-MIR156e; +MI0021205 lus-MIR168a; +MI0021206 lus-MIR156f; +MI0021207 lus-MIR162b; +MI0021208 lus-MIR399g; +MI0021209 lus-MIR160e; +MI0021210 lus-MIR167i; +MI0021211 lus-MIR390b; +MI0021212 lus-MIR166c; +MI0021213 lus-MIR171g; +MI0021214 lus-MIR394b; +MI0021215 lus-MIR160f; +MI0021216 lus-MIR169g; +MI0021217 lus-MIR390c; +MI0021218 lus-MIR169h; +MI0021219 lus-MIR169i; +MI0021220 lus-MIR169j; +MI0021221 lus-MIR156g; +MI0021222 lus-MIR160g; +MI0021223 lus-MIR390d; +MI0021224 lus-MIR166d; +MI0021225 lus-MIR172f; +MI0021226 lus-MIR168b; +MI0021227 lus-MIR396a; +MI0021228 lus-MIR395e; +MI0021229 lus-MIR169k; +MI0021230 lus-MIR408a; +MI0021231 lus-MIR160h; +MI0021232 lus-MIR396b; +MI0021233 lus-MIR396c; +MI0021234 lus-MIR398c; +MI0021235 lus-MIR169l; +MI0021236 lus-MIR156a; +MI0021237 lus-MIR166e; +MI0021238 lus-MIR393b; +MI0021239 lus-MIR171h; +MI0021240 lus-MIR828a; +MI0021241 lus-MIR166f; +MI0021242 lus-MIR160i; +MI0021243 lus-MIR166g; +MI0021244 lus-MIR171i; +MI0021245 lus-MIR160j; +MI0021246 lus-MIR172g; +MI0021247 lus-MIR164e; +MI0021248 lus-MIR172h; +MI0021249 lus-MIR393c; +MI0021250 lus-MIR172i; +MI0021251 lus-MIR166h; +MI0021252 lus-MIR393d; +MI0021253 lus-MIR159b; +MI0021254 lus-MIR172j; +MI0021255 lus-MIR159c; +MI0021256 lus-MIR166i; +MI0021257 lus-MIR396d; +MI0021258 hsa-mir-6124; +MI0021259 hsa-mir-6125; +MI0021260 hsa-mir-6126; +MI0021261 ptr-mir-6127; +MI0021262 ptr-mir-6128; +MI0021263 ptr-mir-378j; +MI0021264 ptr-mir-6129; +MI0021265 ptr-mir-6130; +MI0021266 ptr-mir-6131; +MI0021267 ptr-mir-6132; +MI0021268 ptr-mir-6133; +MI0021269 ptr-mir-3154; +MI0021270 ptr-mir-6134; +MI0021271 hsa-mir-6127; +MI0021272 hsa-mir-6128; +MI0021273 hsa-mir-378j; +MI0021274 hsa-mir-6129; +MI0021275 hsa-mir-6130; +MI0021276 hsa-mir-6131; +MI0021277 hsa-mir-6132; +MI0021278 hsa-mir-6133; +MI0021279 hsa-mir-6134; +MI0021280 mml-mir-6127; +MI0021281 mml-mir-6128; +MI0021282 mml-mir-378j; +MI0021283 mml-mir-6129; +MI0021284 mml-mir-6130; +MI0021285 mml-mir-6131; +MI0021286 mml-mir-6132; +MI0021287 mml-mir-6133; +MI0021288 mml-mir-3154; +MI0021289 mml-mir-6134; +MI0021290 pgi-MIR482a; +MI0021291 pgi-MIR482b; +MI0021292 pgi-MIR2118; +MI0021293 pgi-MIR6135a; +MI0021294 pgi-MIR6135b; +MI0021295 pgi-MIR6135c; +MI0021296 pgi-MIR6135d; +MI0021297 pgi-MIR6135e; +MI0021298 pgi-MIR6135f; +MI0021299 pgi-MIR6135g; +MI0021300 pgi-MIR6135h; +MI0021301 pgi-MIR6135i; +MI0021302 pgi-MIR6135j; +MI0021303 pgi-MIR4376;pgi-MIR391; +MI0021304 pgi-MIR6136a; +MI0021305 pgi-MIR6136b; +MI0021306 pgi-MIR6135k; +MI0021307 pgi-MIR6137a; +MI0021308 pgi-MIR6137b; +MI0021309 pgi-MIR6138; +MI0021310 pgi-MIR6139; +MI0021311 pgi-MIR6140a; +MI0021312 pgi-MIR6140b; +MI0021313 pgi-MIR6140c; +MI0021314 pgi-MIR6140d; +MI0021315 pgi-MIR6141; +MI0021316 pgi-MIR6142; +MI0021317 pgi-MIR6143a; +MI0021318 pgi-MIR6143b; +MI0021319 nta-MIR156a; +MI0021320 nta-MIR156b; +MI0021321 nta-MIR156c; +MI0021322 nta-MIR156d; +MI0021323 nta-MIR156e; +MI0021324 nta-MIR156f; +MI0021325 nta-MIR156g; +MI0021326 nta-MIR156h; +MI0021327 nta-MIR156i; +MI0021328 nta-MIR156j; +MI0021329 nta-MIR159; +MI0021330 nta-MIR160a; +MI0021331 nta-MIR160b; +MI0021332 nta-MIR160c; +MI0021333 nta-MIR160d; +MI0021334 nta-MIR162a; +MI0021335 nta-MIR162b; +MI0021336 nta-MIR164a; +MI0021337 nta-MIR164b; +MI0021338 nta-MIR164c; +MI0021339 nta-MIR166a; +MI0021340 nta-MIR166b; +MI0021341 nta-MIR166c; +MI0021342 nta-MIR166d; +MI0021343 nta-MIR166e; +MI0021344 nta-MIR166f; +MI0021345 nta-MIR166g; +MI0021346 nta-MIR166h; +MI0021347 nta-MIR167a; +MI0021348 nta-MIR167b; +MI0021349 nta-MIR167c; +MI0021350 nta-MIR167d; +MI0021351 nta-MIR167e; +MI0021352 nta-MIR168a; +MI0021353 nta-MIR168b; +MI0021354 nta-MIR168c; +MI0021355 nta-MIR168d; +MI0021356 nta-MIR168e; +MI0021357 nta-MIR169a; +MI0021358 nta-MIR169b; +MI0021359 nta-MIR169c; +MI0021360 nta-MIR169d; +MI0021361 nta-MIR169e; +MI0021362 nta-MIR169f; +MI0021363 nta-MIR169g; +MI0021364 nta-MIR169h; +MI0021365 nta-MIR169i; +MI0021366 nta-MIR169j; +MI0021367 nta-MIR169k; +MI0021368 nta-MIR169l; +MI0021369 nta-MIR169m; +MI0021370 nta-MIR169o; +MI0021371 nta-MIR169p; +MI0021372 nta-MIR169q; +MI0021373 nta-MIR169r; +MI0021374 nta-MIR169s; +MI0021375 nta-MIR169t; +MI0021376 nta-MIR171a; +MI0021377 nta-MIR171b; +MI0021378 nta-MIR171c; +MI0021379 nta-MIR172a; +MI0021380 nta-MIR172b; +MI0021381 nta-MIR172c; +MI0021382 nta-MIR172d; +MI0021383 nta-MIR172e; +MI0021384 nta-MIR172f; +MI0021385 nta-MIR172g; +MI0021386 nta-MIR172h; +MI0021387 nta-MIR172i; +MI0021388 nta-MIR172j; +MI0021389 nta-MIR319a; +MI0021390 nta-MIR319b; +MI0021391 nta-MIR390a; +MI0021392 nta-MIR390b; +MI0021393 nta-MIR390c; +MI0021394 nta-MIR394; +MI0021395 nta-MIR395a; +MI0021396 nta-MIR395b; +MI0021397 nta-MIR395c; +MI0021398 nta-MIR396a; +MI0021399 nta-MIR396b; +MI0021400 nta-MIR396c; +MI0021401 nta-MIR397; +MI0021402 nta-MIR398; +MI0021403 nta-MIR399a; +MI0021404 nta-MIR399b; +MI0021405 nta-MIR399c; +MI0021406 nta-MIR399d; +MI0021407 nta-MIR399e; +MI0021408 nta-MIR399f; +MI0021409 nta-MIR399g; +MI0021410 nta-MIR408; +MI0021411 nta-MIR477a; +MI0021412 nta-MIR477b; +MI0021413 nta-MIR479a; +MI0021414 nta-MIR479b; +MI0021415 nta-MIR827; +MI0021416 nta-MIR1919; +MI0021417 nta-MIR482c; +MI0021418 nta-MIR2911; +MI0021419 nta-MIR6144; +MI0021420 nta-MIR6025c; +MI0021421 nta-MIR6145a; +MI0021422 nta-MIR6025d; +MI0021423 nta-MIR6025e; +MI0021424 nta-MIR6146a; +MI0021425 nta-MIR6146b; +MI0021426 nta-MIR6147; +MI0021427 nta-MIR6148a; +MI0021428 nta-MIR6148b; +MI0021429 nta-MIR6149a; +MI0021430 nta-MIR6149b; +MI0021431 nta-MIR6150; +MI0021432 nta-MIR6151a; +MI0021433 nta-MIR6151b; +MI0021434 nta-MIR6151c; +MI0021435 nta-MIR6151d; +MI0021436 nta-MIR6151e; +MI0021437 nta-MIR6151f; +MI0021438 nta-MIR6151g; +MI0021439 nta-MIR6151h; +MI0021440 nta-MIR6151i; +MI0021441 nta-MIR6152a; +MI0021442 nta-MIR6152b; +MI0021443 nta-MIR6145b; +MI0021444 nta-MIR6153; +MI0021445 nta-MIR6154a; +MI0021446 nta-MIR6154b; +MI0021447 nta-MIR6155; +MI0021448 nta-MIR6145c; +MI0021449 nta-MIR6156; +MI0021450 nta-MIR6157; +MI0021451 nta-MIR5303a; +MI0021452 nta-MIR5303b; +MI0021453 nta-MIR1446; +MI0021454 nta-MIR6145d; +MI0021455 nta-MIR6145e; +MI0021456 nta-MIR6158a; +MI0021457 nta-MIR6158b; +MI0021458 nta-MIR6158c; +MI0021459 nta-MIR6159; +MI0021460 nta-MIR5303c; +MI0021461 nta-MIR6145f; +MI0021462 nta-MIR6160; +MI0021463 nta-MIR6161d; +MI0021464 nta-MIR6161a; +MI0021465 nta-MIR6161b; +MI0021466 nta-MIR482d; +MI0021467 nta-MIR6162; +MI0021468 nta-MIR6161c; +MI0021469 nta-MIR6163; +MI0021470 nta-MIR6164a; +MI0021471 nta-MIR6164b; +MI0021472 hsa-mir-6165; +MI0021473 hbr-MIR6166; +MI0021474 hbr-MIR2118; +MI0021475 hbr-MIR6167; +MI0021476 hbr-MIR6168; +MI0021477 hbr-MIR482;hbr-MIR482a; +MI0021478 hbr-MIR6169; +MI0021479 hbr-MIR6170; +MI0021480 hbr-MIR6171; +MI0021481 hbr-MIR396a; +MI0021482 hbr-MIR6172; +MI0021483 hbr-MIR6173; +MI0021484 hbr-MIR398; +MI0021485 hbr-MIR6174; +MI0021486 hbr-MIR6175; +MI0021487 hvu-MIR5049b; +MI0021488 hvu-MIR1130; +MI0021489 hvu-MIR6176; +MI0021490 hvu-MIR6177; +MI0021491 hvu-MIR6178; +MI0021492 hvu-MIR6179; +MI0021493 hvu-MIR5049c; +MI0021494 hvu-MIR6180; +MI0021495 hvu-MIR6181; +MI0021496 hvu-MIR6182; +MI0021497 hvu-MIR6183; +MI0021498 hvu-MIR6184; +MI0021499 hvu-MIR6185; +MI0021500 hvu-MIR6186; +MI0021501 hvu-MIR6187; +MI0021502 hvu-MIR6188; +MI0021503 hvu-MIR5049d; +MI0021504 hvu-MIR6189; +MI0021505 hvu-MIR6190; +MI0021506 hvu-MIR6191; +MI0021507 hvu-MIR5048b; +MI0021508 hvu-MIR6192; +MI0021509 hvu-MIR6193; +MI0021510 hvu-MIR6194; +MI0021511 hvu-MIR6195; +MI0021512 hvu-MIR6196; +MI0021513 hvu-MIR6197; +MI0021514 hvu-MIR6198; +MI0021515 hvu-MIR6199; +MI0021516 hvu-MIR5049e; +MI0021517 hvu-MIR6200; +MI0021518 hvu-MIR6201; +MI0021519 hvu-MIR5049f; +MI0021520 hvu-MIR6202; +MI0021521 hvu-MIR6203; +MI0021522 hvu-MIR6204; +MI0021523 hvu-MIR6205; +MI0021524 hvu-MIR6206; +MI0021525 hvu-MIR6207; +MI0021526 hvu-MIR6208; +MI0021527 hvu-MIR6209; +MI0021528 hvu-MIR6210; +MI0021529 hvu-MIR6211; +MI0021530 hvu-MIR6212; +MI0021531 hvu-MIR6213; +MI0021532 hvu-MIR6214; +MI0021533 rno-mir-1839; +MI0021534 rno-mir-3068; +MI0021535 rno-mir-1843;rno-mir-1843a; +MI0021536 rno-mir-509; +MI0021537 rno-mir-1306; +MI0021538 rno-mir-3473; +MI0021539 rno-mir-6215; +MI0021540 rno-mir-378b; +MI0021541 rno-mir-6216; +MI0021583 mmu-mir-6236; +MI0021584 mmu-mir-6237; +MI0021585 mmu-mir-6238; +MI0021586 mmu-mir-6239; +MI0021587 mmu-mir-6240; +MI0021588 mmu-mir-6241; +MI0021590 mmu-mir-6243; +MI0021591 mmu-mir-6244; +MI0021592 osa-MIR6245; +MI0021593 osa-MIR1440b; +MI0021594 osa-MIR6246; +MI0021595 osa-MIR6247; +MI0021596 osa-MIR6248; +MI0021597 osa-MIR5337b; +MI0021598 osa-MIR6249;osa-MIR6249a; +MI0021599 osa-MIR5512b; +MI0021600 osa-MIR6250; +MI0021601 osa-MIR6251; +MI0021602 osa-MIR6252; +MI0021603 osa-MIR6253; +MI0021604 osa-MIR6254; +MI0021605 osa-MIR6255; +MI0021606 osa-MIR6256; +MI0021607 ppe-MIR6257; +MI0021608 ppe-MIR6258; +MI0021609 ppe-MIR482a; +MI0021610 ppe-MIR482b; +MI0021611 ppe-MIR171f; +MI0021612 ppe-MIR6259; +MI0021613 ppe-MIR6260; +MI0021614 ppe-MIR6261; +MI0021615 ppe-MIR6262; +MI0021616 ppe-MIR394a; +MI0021617 ppe-MIR6263; +MI0021618 ppe-MIR6264; +MI0021619 ppe-MIR828; +MI0021620 ppe-MIR482c; +MI0021621 ppe-MIR6265; +MI0021622 ppe-MIR171h; +MI0021623 ppe-MIR171a; +MI0021624 ppe-MIR477a; +MI0021625 ppe-MIR477b; +MI0021626 ppe-MIR171e; +MI0021627 ppe-MIR6266a; +MI0021628 ppe-MIR6267a; +MI0021629 ppe-MIR169e; +MI0021630 ppe-MIR6269; +MI0021631 ppe-MIR398a; +MI0021632 ppe-MIR6270; +MI0021633 ppe-MIR6271; +MI0021634 ppe-MIR6267b; +MI0021635 ppe-MIR6272; +MI0021636 ppe-MIR6273; +MI0021637 ppe-MIR319a; +MI0021638 ppe-MIR6274;ppe-MIR6274a; +MI0021639 ppe-MIR6275; +MI0021640 ppe-MIR319b; +MI0021641 ppe-MIR171g; +MI0021642 ppe-MIR6276; +MI0021643 ppe-MIR6277; +MI0021644 ppe-MIR6278; +MI0021645 ppe-MIR6279; +MI0021646 ppe-MIR171b; +MI0021647 ppe-MIR6280; +MI0021648 ppe-MIR6281; +MI0021649 ppe-MIR6282; +MI0021650 ppe-MIR6283; +MI0021651 ppe-MIR6284; +MI0021652 ppe-MIR482d; +MI0021653 ppe-MIR6285; +MI0021654 ppe-MIR6286; +MI0021655 ppe-MIR482e; +MI0021656 ppe-MIR6287; +MI0021657 ppe-MIR6288;ppe-MIR6288a; +MI0021659 ppe-MIR6289; +MI0021660 ppe-MIR171c; +MI0021661 ppe-MIR6266b; +MI0021662 ppe-MIR6290; +MI0021663 ppe-MIR6291a; +MI0021664 ppe-MIR6292; +MI0021665 ppe-MIR398b; +MI0021666 ppe-MIR6293; +MI0021667 ppe-MIR6294; +MI0021668 ppe-MIR6295; +MI0021669 ppe-MIR6296; +MI0021670 ppe-MIR6291b; +MI0021671 ppe-MIR6266c; +MI0021672 ppe-MIR6297a; +MI0021673 ppe-MIR6297b; +MI0021674 gma-MIR156u; +MI0021675 gma-MIR156v; +MI0021676 gma-MIR156w; +MI0021677 gma-MIR156x; +MI0021678 gma-MIR156y; +MI0021679 gma-MIR156z; +MI0021680 gma-MIR156aa; +MI0021681 gma-MIR156ab; +MI0021682 gma-MIR160f; +MI0021683 gma-MIR164e; +MI0021684 gma-MIR164f; +MI0021685 gma-MIR164g; +MI0021686 gma-MIR164h; +MI0021687 gma-MIR164i; +MI0021688 gma-MIR164j; +MI0021689 gma-MIR164k; +MI0021690 gma-MIR166n; +MI0021691 gma-MIR166o; +MI0021692 gma-MIR166p; +MI0021693 gma-MIR166q; +MI0021694 gma-MIR166r; +MI0021695 gma-MIR166s; +MI0021696 gma-MIR166t; +MI0021697 gma-MIR166u; +MI0021699 gma-MIR169v; +MI0021700 gma-MIR390d; +MI0021701 gma-MIR390e; +MI0021702 gma-MIR390f; +MI0021703 gma-MIR390g; +MI0021704 gma-MIR393c; +MI0021705 gma-MIR393d; +MI0021706 gma-MIR393e; +MI0021707 gma-MIR393f; +MI0021708 gma-MIR393g; +MI0021709 gma-MIR393h; +MI0021710 gma-MIR393i; +MI0021711 gma-MIR393j; +MI0021712 gma-MIR393k; +MI0021713 gma-MIR394g; +MI0021714 gma-MIR395h; +MI0021715 gma-MIR395i; +MI0021716 gma-MIR395j; +MI0021717 gma-MIR395k; +MI0021718 gma-MIR395l; +MI0021719 gma-MIR395m; +MI0021720 gma-MIR1515b; +MI0021721 gma-MIR1516d; +MI0021723 gma-MIR6299; +MI0021724 gma-MIR6300; +MI0021725 hme-bantam; +MI0021726 hme-let-7; +MI0021727 hme-mir-10; +MI0021728 hme-mir-1000; +MI0021729 hme-mir-11; +MI0021730 hme-mir-1175; +MI0021731 hme-mir-12; +MI0021732 hme-mir-124; +MI0021733 hme-mir-133; +MI0021734 hme-mir-137; +MI0021735 hme-mir-13a; +MI0021736 hme-mir-13b; +MI0021737 hme-mir-14; +MI0021738 hme-mir-184; +MI0021739 hme-mir-190; +MI0021740 hme-mir-1b; +MI0021741 hme-mir-1a; +MI0021742 hme-mir-210; +MI0021743 hme-mir-252; +MI0021744 hme-mir-263a; +MI0021745 hme-mir-263b; +MI0021746 hme-mir-2733; +MI0021747 hme-mir-2755; +MI0021748 hme-mir-2756; +MI0021749 hme-mir-276; +MI0021750 hme-mir-2763; +MI0021751 hme-mir-2765; +MI0021752 hme-mir-2767; +MI0021753 hme-mir-2768; +MI0021754 hme-mir-277; +MI0021755 hme-mir-278; +MI0021756 hme-mir-279a; +MI0021757 hme-mir-2796; +MI0021758 hme-mir-2797; +MI0021759 hme-mir-279b; +MI0021760 hme-mir-279d; +MI0021761 hme-mir-279c; +MI0021762 hme-mir-281; +MI0021763 hme-mir-282; +MI0021764 hme-mir-283; +MI0021765 hme-mir-285; +MI0021766 hme-mir-2a; +MI0021767 hme-mir-2b; +MI0021768 hme-mir-2c; +MI0021769 hme-mir-305; +MI0021770 hme-mir-306; +MI0021771 hme-mir-307; +MI0021772 hme-mir-308; +MI0021773 hme-mir-316; +MI0021774 hme-mir-3286; +MI0021775 hme-mir-33-1; +MI0021776 hme-mir-33-2; +MI0021777 hme-mir-3327; +MI0021778 hme-mir-3338; +MI0021779 hme-mir-34-1; +MI0021780 hme-mir-34-2; +MI0021781 hme-mir-7; +MI0021782 hme-mir-71; +MI0021783 hme-mir-745; +MI0021784 hme-mir-79; +MI0021785 hme-mir-8; +MI0021786 hme-mir-87; +MI0021787 hme-mir-927; +MI0021788 hme-mir-928; +MI0021789 hme-mir-929; +MI0021790 hme-mir-92a; +MI0021791 hme-mir-92b; +MI0021792 hme-mir-932; +MI0021793 hme-mir-965; +MI0021794 hme-mir-970; +MI0021795 hme-mir-971; +MI0021796 hme-mir-981; +MI0021797 hme-mir-993; +MI0021798 hme-mir-998; +MI0021799 hme-mir-9b; +MI0021800 hme-mir-9a; +MI0021801 hme-mir-6301-1; +MI0021802 hme-mir-6301-2; +MI0021803 hme-mir-6302-1; +MI0021804 hme-mir-6302-2; +MI0021805 hme-mir-6303; +MI0021806 hme-mir-6304; +MI0021807 hme-mir-6305; +MI0021808 hme-mir-6306; +MI0021809 hme-mir-6307; +MI0021810 hme-mir-6308; +MI0021811 hme-mir-6309; +MI0021812 hme-mir-6310; +MI0021813 hme-mir-6311; +MI0021814 hme-mir-6312; +MI0021815 meu-mir-6313; +MI0021816 hsv1-mir-H26; +MI0021817 sma-mir-10; +MI0021818 sma-mir-124;sma-mir-124a; +MI0021819 sma-mir-190; +MI0021820 sma-mir-2a; +MI0021821 sma-mir-2b; +MI0021822 sma-mir-2c; +MI0021823 sma-mir-2d; +MI0021824 sma-mir-2e; +MI0021825 sma-mir-31; +MI0021826 sma-mir-3479; +MI0021827 sma-mir-3492; +MI0021828 sma-mir-36;sma-mir-36a; +MI0021829 sma-mir-61; +MI0021830 sma-mir-71b; +MI0021831 sma-mir-8; +MI0021832 rno-mir-6314; +MI0021833 rno-mir-3099; +MI0021834 rno-mir-344i; +MI0021835 rno-mir-6315; +MI0021836 rno-mir-3102; +MI0021837 rno-mir-344g; +MI0021838 rno-mir-6316; +MI0021839 rno-mir-6317;rno-mir-6317-1; +MI0021840 rno-mir-6318; +MI0021841 rno-mir-6319;rno-mir-6319-1; +MI0021842 rno-mir-3075; +MI0021843 rno-mir-6320; +MI0021844 rno-mir-6321; +MI0021845 rno-mir-1298; +MI0021846 rno-mir-6322; +MI0021847 rno-mir-6323; +MI0021848 rno-mir-6324; +MI0021849 rno-mir-6325; +MI0021850 rno-mir-6326; +MI0021851 rno-mir-6327; +MI0021852 rno-mir-6328; +MI0021853 rno-mir-6329; +MI0021854 rno-mir-6330; +MI0021855 rno-mir-6331; +MI0021856 rno-mir-3072; +MI0021857 rno-mir-679; +MI0021858 rno-mir-6332; +MI0021859 rno-mir-6333; +MI0021860 rno-mir-6334; +MI0021861 mmu-mir-195b; +MI0021862 mmu-mir-6335; +MI0021863 mmu-mir-133c; +MI0021864 mmu-mir-6336; +MI0021865 mmu-mir-6337; +MI0021866 mmu-mir-6338; +MI0021867 mmu-mir-6339; +MI0021868 mmu-mir-6340; +MI0021869 mmu-mir-6341; +MI0021870 mmu-mir-6342; +MI0021871 mmu-mir-6343; +MI0021872 mmu-mir-6344; +MI0021873 mmu-mir-6345; +MI0021874 mmu-mir-6346; +MI0021875 mmu-mir-6347; +MI0021876 mmu-mir-6348; +MI0021877 mmu-mir-6349; +MI0021878 mmu-mir-6350; +MI0021879 mmu-mir-6351; +MI0021880 mmu-mir-6352; +MI0021881 mmu-mir-6353; +MI0021882 mmu-mir-6354; +MI0021883 mmu-mir-6355; +MI0021884 mmu-mir-6356; +MI0021885 mmu-mir-6357; +MI0021886 mmu-mir-6358; +MI0021887 mmu-mir-6359; +MI0021888 mmu-mir-6360; +MI0021889 mmu-mir-6361; +MI0021890 mmu-mir-145b; +MI0021891 mmu-mir-6362; +MI0021892 mmu-mir-6363; +MI0021893 mmu-mir-6364; +MI0021894 mmu-mir-6365; +MI0021895 mmu-mir-6366; +MI0021896 mmu-mir-6367; +MI0021897 mmu-mir-6368; +MI0021898 mmu-mir-6369; +MI0021899 mmu-mir-6370; +MI0021900 mmu-mir-6371; +MI0021901 mmu-mir-6372; +MI0021902 mmu-mir-6373; +MI0021903 mmu-mir-6374; +MI0021904 mmu-mir-6375; +MI0021905 mmu-mir-6376; +MI0021906 mmu-mir-21b; +MI0021907 mmu-mir-6377; +MI0021908 mmu-let-7j; +MI0021909 mmu-mir-6378; +MI0021910 mmu-mir-6379; +MI0021911 mmu-mir-6380; +MI0021912 mmu-mir-6381; +MI0021913 mmu-mir-6382; +MI0021914 mmu-mir-6383; +MI0021915 mmu-mir-6384; +MI0021916 mmu-mir-6385; +MI0021917 mmu-mir-130c; +MI0021918 mmu-mir-6386; +MI0021919 mmu-mir-6387; +MI0021920 mmu-mir-6388; +MI0021921 mmu-mir-5124b; +MI0021922 mmu-mir-6389; +MI0021923 mmu-mir-378c; +MI0021924 mmu-mir-6390; +MI0021925 mmu-mir-6391; +MI0021926 mmu-mir-6392; +MI0021927 mmu-mir-6393; +MI0021928 mmu-mir-6394; +MI0021929 mmu-mir-1957b; +MI0021930 mmu-mir-6395; +MI0021931 mmu-mir-6396; +MI0021932 mmu-mir-21c; +MI0021933 mmu-mir-6397; +MI0021934 mmu-mir-6398; +MI0021935 mmu-mir-6399; +MI0021936 mmu-mir-6400; +MI0021937 mmu-mir-6401; +MI0021938 mmu-mir-6402; +MI0021939 mmu-mir-6403; +MI0021940 mmu-mir-6404; +MI0021941 mmu-mir-6405; +MI0021942 mmu-mir-496b; +MI0021943 mmu-mir-6406; +MI0021944 mmu-mir-6407; +MI0021945 mmu-mir-6408; +MI0021946 mmu-mir-6409; +MI0021947 mmu-mir-6410; +MI0021948 mmu-mir-6411; +MI0021949 mmu-mir-6412; +MI0021950 mmu-mir-6413; +MI0021951 mmu-mir-378d; +MI0021952 mmu-mir-6414; +MI0021953 mmu-mir-6415; +MI0021954 mmu-mir-6416; +MI0021955 mmu-mir-6417; +MI0021956 mmu-mir-6418; +MI0021957 mmu-mir-6419; +MI0021958 mmu-mir-6420; +MI0021959 mmu-mir-873b; +MI0021960 mmu-mir-451b; +MI0021961 mmu-mir-30f; +MI0021962 ptc-MIR6421; +MI0021963 ptc-MIR6458; +MI0021964 ptc-MIR6440b; +MI0021965 ptc-MIR6459;ptc-MIR6459a; +MI0021966 ptc-MIR6460; +MI0021967 ptc-MIR6461; +MI0021968 ptc-MIR6462a; +MI0021969 ptc-MIR6463; +MI0021970 ptc-MIR6425a; +MI0021971 ptc-MIR6464; +MI0021972 ptc-MIR6465; +MI0021973 ptc-MIR6466; +MI0021974 ptc-MIR6467; +MI0021975 ptc-MIR6438b; +MI0021976 ptc-MIR6425b; +MI0021977 ptc-MIR6440c; +MI0021978 ptc-MIR6468; +MI0021979 ptc-MIR6469; +MI0021980 ptc-MIR6457b; +MI0021981 ptc-MIR6462b; +MI0021982 ptc-MIR6462c; +MI0021983 ptc-MIR6425c; +MI0021984 ptc-MIR6470; +MI0021985 ptc-MIR6471; +MI0021986 ptc-MIR6472; +MI0021987 ptc-MIR6473; +MI0021988 ptc-MIR6474; +MI0021989 ptc-MIR6425d; +MI0021990 ptc-MIR6475; +MI0021991 ptc-MIR6476;ptc-MIR6476a; +MI0021992 ptc-MIR6477; +MI0021993 ptc-MIR6425e; +MI0021994 ptc-MIR6478; +MI0021995 ptc-MIR6426a; +MI0021996 ptc-MIR6479; +MI0021997 ptc-MIR6480; +MI0021998 ptc-MIR6462d; +MI0021999 ptc-MIR6437b; +MI0022000 ptc-MIR6440d; +MI0022001 ptc-MIR6427; +MI0022002 ptc-MIR6428; +MI0022003 ptc-MIR6429; +MI0022004 ptc-MIR6430; +MI0022005 ptc-MIR6431; +MI0022006 ptc-MIR6432; +MI0022007 ptc-MIR6433;ptc-MIR482d; +MI0022008 ptc-MIR6422; +MI0022009 ptc-MIR6434; +MI0022010 ptc-MIR6435; +MI0022011 ptc-MIR6436; +MI0022012 ptc-MIR6437a; +MI0022013 ptc-MIR6438a; +MI0022014 ptc-MIR6439a; +MI0022015 ptc-MIR6440a; +MI0022016 ptc-MIR6441; +MI0022017 ptc-MIR6442; +MI0022018 ptc-MIR6443; +MI0022019 ptc-MIR6444; +MI0022020 ptc-MIR6445a; +MI0022021 ptc-MIR6446; +MI0022022 ptc-MIR6447; +MI0022023 ptc-MIR6448; +MI0022024 ptc-MIR6423; +MI0022025 ptc-MIR6449; +MI0022026 ptc-MIR6450a; +MI0022027 ptc-MIR6451; +MI0022028 ptc-MIR6445b; +MI0022029 ptc-MIR477c; +MI0022030 ptc-MIR6439b; +MI0022031 ptc-MIR6426b; +MI0022032 ptc-MIR6424;ptc-MIR536; +MI0022033 ptc-MIR6450b; +MI0022034 ptc-MIR6452; +MI0022035 ptc-MIR6453;ptc-MIR3627a; +MI0022036 ptc-MIR6454; +MI0022037 ptc-MIR6455; +MI0022038 ptc-MIR6456; +MI0022039 ptc-MIR6457a; +MI0022040 ptc-MIR156l; +MI0022041 ptc-MIR169ag; +MI0022042 ptc-MIR2111a; +MI0022043 ptc-MIR482b; +MI0022044 ptc-MIR2111b; +MI0022045 ptc-MIR395k; +MI0022046 ptc-MIR403d; +MI0022047 ptc-MIR477d; +MI0022048 ptc-MIR482c; +MI0022049 ptc-MIR828a; +MI0022050 ptc-MIR828b; +MI0022051 mmu-mir-6481; +MI0022052 hbr-MIR156; +MI0022053 hbr-MIR159a; +MI0022054 hbr-MIR166a; +MI0022055 hbr-MIR166b; +MI0022056 hbr-MIR319; +MI0022057 hbr-MIR396b; +MI0022058 hbr-MIR408a; +MI0022059 hbr-MIR408b; +MI0022060 hbr-MIR476; +MI0022061 hbr-MIR6482; +MI0022062 hbr-MIR6483; +MI0022063 hbr-MIR6484; +MI0022064 hbr-MIR159b; +MI0022065 hbr-MIR6485; +MI0022066 mja-mir-6489; +MI0022067 mja-mir-6490; +MI0022068 mja-mir-6491; +MI0022069 mja-mir-6492; +MI0022070 mja-mir-6493; +MI0022071 mja-mir-6494; +MI0022072 prv-mir-LLT1; +MI0022073 prv-mir-LLT2; +MI0022074 prv-mir-LLT3; +MI0022075 prv-mir-LLT4; +MI0022076 prv-mir-LLT5; +MI0022077 prv-mir-LLT6; +MI0022078 prv-mir-LLT7; +MI0022079 prv-mir-LLT8; +MI0022080 prv-mir-LLT9; +MI0022081 prv-mir-LLT10a; +MI0022082 prv-mir-LLT10b; +MI0022083 prv-mir-LLT11a; +MI0022084 prv-mir-LLT11b; +MI0022085 bmo-mir-6495; +MI0022086 bmo-mir-6496; +MI0022087 bmo-mir-6497; +MI0022088 bmo-mir-6498; +MI0022089 pde-MIR159; +MI0022090 pde-MIR162; +MI0022091 pde-MIR166a; +MI0022092 pde-MIR166b; +MI0022093 pde-MIR169; +MI0022094 pde-MIR171; +MI0022095 pde-MIR390; +MI0022096 pde-MIR396; +MI0022097 pde-MIR482a; +MI0022098 pde-MIR482b; +MI0022099 pde-MIR482c; +MI0022100 pde-MIR482d; +MI0022101 pde-MIR783; +MI0022102 pde-MIR946; +MI0022103 pde-MIR947; +MI0022104 pde-MIR949a; +MI0022105 pde-MIR949b; +MI0022106 pde-MIR950; +MI0022107 pde-MIR951; +MI0022108 pde-MIR952a; +MI0022109 pde-MIR952b; +MI0022110 pde-MIR952c; +MI0022111 pde-MIR1310; +MI0022112 pde-MIR1311; +MI0022113 pde-MIR1312; +MI0022114 pde-MIR1313; +MI0022115 pde-MIR1314; +MI0022116 pde-MIR3701; +MI0022117 pde-MIR3704a; +MI0022118 pde-MIR3704b; +MI0022119 pde-MIR3712; +MI0022120 ssc-let-7d; +MI0022121 ssc-let-7f-2; +MI0022122 ssc-mir-7-1; +MI0022123 ssc-mir-9-3; +MI0022124 ssc-mir-20b-1; +MI0022125 ssc-mir-20b-2; +MI0022126 ssc-mir-29b-2; +MI0022127 ssc-mir-31; +MI0022128 ssc-mir-34c-2; +MI0022129 ssc-mir-132; +MI0022130 ssc-mir-137; +MI0022131 ssc-mir-138; +MI0022132 ssc-mir-144; +MI0022133 ssc-mir-150-1; +MI0022134 ssc-mir-150-2; +MI0022135 ssc-mir-182; +MI0022136 ssc-mir-190a; +MI0022137 ssc-mir-194a; +MI0022138 ssc-mir-196a-1; +MI0022139 ssc-mir-196b-2; +MI0022140 ssc-mir-212; +MI0022141 ssc-mir-216-2; +MI0022142 ssc-mir-217-2; +MI0022143 ssc-mir-218-2; +MI0022144 ssc-mir-339-2; +MI0022145 ssc-mir-340-2; +MI0022146 ssc-mir-345-2; +MI0022147 ssc-mir-363-2; +MI0022148 ssc-mir-370; +MI0022149 ssc-mir-452; +MI0022150 ssc-mir-489; +MI0022151 ssc-mir-490-2; +MI0022152 ssc-mir-493; +MI0022153 ssc-mir-551a; +MI0022154 ssc-mir-582; +MI0022155 ssc-mir-671; +MI0022156 ssc-mir-676-2; +MI0022157 ssc-mir-874; +MI0022158 ssc-mir-1249-1; +MI0022159 ssc-mir-1249-2; +MI0022160 ssc-mir-1468; +MI0022161 ssc-mir-3613; +MI0022162 ssc-mir-2366-1; +MI0022163 ssc-mir-2366-2; +MI0022164 ssc-mir-2411; +MI0022167 ssc-mir-2483; +MI0022168 bfl-mir-153; +MI0022169 xtr-mir-190; +MI0022170 tgu-mir-183; +MI0022171 tgu-mir-196; +MI0022172 tgu-mir-367; +MI0022173 tgu-mir-499; +MI0022174 tgu-mir-1397; +MI0022175 tgu-mir-1460; +MI0022176 tgu-mir-1467;tgu-mir-1467-1; +MI0022177 tgu-mir-1641; +MI0022178 tgu-mir-1669; +MI0022179 tgu-mir-1743; +MI0022180 tgu-mir-1744; +MI0022181 tgu-mit-1756;tgu-mir-1756; +MI0022182 tgu-mir-1759; +MI0022183 tgu-mir-1781; +MI0022184 tgu-mir-1788; +MI0022185 tgu-mir-1789; +MI0022186 tgu-mir-1791; +MI0022187 tgu-mir-2131; +MI0022188 tgu-mir-30e; +MI0022189 pol-mir-1; +MI0022190 pol-let-7b; +MI0022191 pol-let-7a; +MI0022192 pol-let-7d; +MI0022193 pol-mir-9b; +MI0022194 pol-mir-10b; +MI0022195 pol-mir-21; +MI0022196 pol-mir-22; +MI0022197 pol-mir-122; +MI0022198 pol-mir-124; +MI0022199 pol-mir-133; +MI0022200 pol-mir-140; +MI0022201 pol-mir-144; +MI0022202 pol-mir-182; +MI0022203 pol-mir-199a-1; +MI0022204 pol-mir-199a-2; +MI0022205 pol-mir-203; +MI0022206 pol-mir-206; +MI0022207 pol-mir-219; +MI0022208 pol-mir-221; +MI0022209 hsa-mir-6499; +MI0022210 hsa-mir-548ay; +MI0022211 hsa-mir-6500; +MI0022212 hsa-mir-548az; +MI0022213 hsa-mir-6501; +MI0022214 hsa-mir-6502; +MI0022215 hsa-mir-6503; +MI0022216 hsa-mir-6504; +MI0022217 hsa-mir-6505; +MI0022218 hsa-mir-6506; +MI0022219 hsa-mir-6507; +MI0022220 hsa-mir-6508; +MI0022221 hsa-mir-6509; +MI0022222 hsa-mir-6510; +MI0022223 hsa-mir-6511a-1; +MI0022224 hsa-mir-6512; +MI0022225 hsa-mir-6513; +MI0022226 hsa-mir-6514; +MI0022227 hsa-mir-6515; +MI0022228 han-MIR156a; +MI0022229 han-MIR156b; +MI0022230 hci-MIR156a; +MI0022231 hci-MIR156b; +MI0022232 htu-MIR156a; +MI0022233 har-MIR156a; +MI0022234 hpa-MIR156a; +MI0022235 har-MIR156c; +MI0022236 han-MIR156c; +MI0022237 htu-MIR159a; +MI0022238 han-MIR160a; +MI0022239 htu-MIR160a; +MI0022240 htu-MIR162a; +MI0022241 hpe-MIR162a; +MI0022242 hci-MIR164a; +MI0022243 hpa-MIR166a; +MI0022244 hpe-MIR166a; +MI0022245 hpa-MIR171a; +MI0022246 htu-MIR171a; +MI0022247 htu-MIR171b; +MI0022248 htu-MIR171c; +MI0022249 hex-MIR390a; +MI0022250 hex-MIR390b; +MI0022251 htu-MIR393a; +MI0022252 htu-MIR393b; +MI0022253 htu-MIR393c; +MI0022254 htu-MIR403a; +MI0022255 htu-MIR403b; +MI0022256 htu-MIR403c; +MI0022257 htu-MIR403d; +MI0022258 htu-MIR403e; +MI0022259 har-MIR403a; +MI0022260 hpe-MIR403a; +MI0022261 htu-MIR530; +MI0022262 han-MIR1310; +MI0022263 han-MIR2911; +MI0022264 han-MIR3440; +MI0022265 han-MIR3630; +MI0022266 mmu-mir-6516; +MI0022267 hhi-mir-147b; +MI0022268 bta-mir-6517; +MI0022269 bta-mir-3154; +MI0022270 bta-mir-2285o-1; +MI0022271 bta-mir-2285o-2; +MI0022272 bta-mir-2285n-1; +MI0022273 bta-mir-2285n-2; +MI0022274 bta-mir-2285p; +MI0022275 bta-mir-2285m-1; +MI0022276 bta-mir-2285m-2; +MI0022277 bta-mir-2284y-2; +MI0022279 bta-mir-378b; +MI0022280 bta-mir-6518; +MI0022281 bta-mir-6519; +MI0022282 bta-mir-6520; +MI0022283 bta-mir-6521; +MI0022284 bta-mir-2285n-3; +MI0022285 bta-mir-2285n-4; +MI0022286 bta-mir-2284y-3; +MI0022287 bta-mir-6522; +MI0022288 bta-mir-411b; +MI0022289 bta-mir-154c; +MI0022290 bta-mir-376e; +MI0022291 bta-mir-3956; +MI0022292 bta-mir-411c; +MI0022293 bta-mir-154b; +MI0022294 bta-mir-3957; +MI0022295 bta-mir-1247; +MI0022296 bta-mir-2285o-3; +MI0022297 bta-mir-2285o-4; +MI0022298 bta-mir-2285m-3; +MI0022299 bta-mir-378c; +MI0022300 bta-mir-2284y-4; +MI0022301 bta-mir-6523;bta-mir-6523a; +MI0022302 bta-mir-6524; +MI0022303 bta-mir-2284y-5; +MI0022304 bta-mir-6525; +MI0022305 bta-mir-2284y-6; +MI0022306 bta-mir-2285m-4; +MI0022307 bta-mir-2285o-5; +MI0022308 bta-mir-3660; +MI0022309 bta-mir-2285m-5; +MI0022310 bta-mir-2285n-5; +MI0022311 bta-mir-2285n-6; +MI0022313 bta-mir-6526-1; +MI0022314 bta-mir-6526-2; +MI0022315 bta-mir-503; +MI0022317 bta-mir-2284y-7; +MI0022318 bta-mir-6526-3; +MI0022319 bta-mir-2285n-7; +MI0022320 bta-mir-2284z-1; +MI0022321 bta-mir-2284aa-1; +MI0022322 bta-mir-2285k-2; +MI0022323 bta-mir-6527; +MI0022324 bta-mir-6528; +MI0022325 bta-mir-2284z-3; +MI0022326 bta-mir-2284aa-2; +MI0022327 bta-mir-2284aa-3; +MI0022328 bta-mir-6529;bta-mir-6529a; +MI0022329 bta-mir-2285k-3; +MI0022330 bta-mir-6530; +MI0022331 bta-mir-6531; +MI0022332 bta-mir-2285k-4; +MI0022333 bta-mir-6532; +MI0022334 bta-mir-6533; +MI0022335 bta-mir-6534; +MI0022336 bta-mir-2284z-4; +MI0022337 bta-mir-2285k-5; +MI0022338 bta-mir-2284z-5; +MI0022339 bta-mir-2284z-6; +MI0022340 bta-mir-6535; +MI0022341 bta-mir-2284z-7; +MI0022342 bta-mir-6536-1; +MI0022343 bta-mir-2284aa-4; +MI0022344 bta-mir-6536-2; +MI0022345 bta-mir-2285q; +MI0022346 bta-mir-2285r; +MI0022347 bta-mir-2285s; +MI0022348 bta-mir-2285t; +MI0022349 bta-mir-2285u;bta-mir-2285b-2; +MI0022350 bta-mir-2285v; +MI0022351 bta-mir-2284z-2; +MI0022352 mmu-let-7k; +MI0022353 mmu-mir-6537; +MI0022354 mmu-mir-6538; +MI0022355 mmu-mir-6539; +MI0022356 mmu-mir-6540; +MI0022357 mmu-mir-3473e; +MI0022358 mmu-mir-6541; +MI0022359 gga-mir-6542; +MI0022360 gga-mir-6544; +MI0022361 gga-mir-6545; +MI0022362 gga-mir-6546; +MI0022363 gga-mir-6547; +MI0022364 gga-mir-124c; +MI0022365 gga-mir-6548; +MI0022366 gga-mir-6549; +MI0022367 gga-mir-6550; +MI0022368 gga-mir-3607; +MI0022369 gga-mir-6551; +MI0022370 gga-mir-6552; +MI0022371 gga-mir-6553; +MI0022372 gga-mir-6554; +MI0022373 gga-mir-222b; +MI0022374 gga-mir-6555; +MI0022375 gga-mir-6556; +MI0022376 gga-mir-6558; +MI0022377 gga-mir-6559; +MI0022378 gga-mir-6560; +MI0022379 gga-mir-6561; +MI0022380 gga-mir-3064; +MI0022381 gga-mir-6564; +MI0022382 gga-mir-6565; +MI0022383 gga-mir-6566; +MI0022384 gga-mir-6567; +MI0022385 gga-mir-3594; +MI0022386 gga-mir-6568; +MI0022387 gga-mir-6569; +MI0022388 gga-mir-6570; +MI0022389 gga-mir-6571; +MI0022390 gga-mir-6572; +MI0022391 gga-mir-6573; +MI0022392 gga-mir-6574; +MI0022393 gga-mir-6575; +MI0022394 gga-mir-6576; +MI0022395 gga-mir-6577; +MI0022396 gga-mir-6578; +MI0022397 gga-mir-6579-1; +MI0022398 gga-mir-6579-2; +MI0022399 gga-mir-6580; +MI0022400 gga-mir-6581; +MI0022401 gga-mir-6582; +MI0022402 gga-mir-6583; +MI0022403 gga-mir-365b; +MI0022404 gga-mir-6584; +MI0022405 gga-mir-6585; +MI0022406 gga-mir-6586; +MI0022407 gga-mir-6587; +MI0022408 gga-mir-6588; +MI0022409 gga-mir-6589; +MI0022410 gga-mir-6590; +MI0022411 gga-mir-6591; +MI0022412 gga-mir-6592; +MI0022413 gga-mir-6593; +MI0022414 gga-mir-6594; +MI0022415 gga-mir-6595; +MI0022416 gga-mir-6596; +MI0022417 gga-mir-6597; +MI0022418 gga-mir-6598; +MI0022419 gga-mir-6600; +MI0022420 gga-mir-6601; +MI0022421 gga-mir-6602; +MI0022422 gga-mir-6603; +MI0022423 gga-mir-6604; +MI0022424 gga-mir-6605; +MI0022425 gga-mir-6606; +MI0022426 gga-mir-6607; +MI0022427 gga-mir-6608-1; +MI0022428 gga-mir-6609; +MI0022429 gga-mir-6610; +MI0022430 gga-mir-6611; +MI0022431 gga-mir-6612; +MI0022432 gga-mir-6613; +MI0022433 gga-mir-6614; +MI0022434 gga-mir-6615; +MI0022435 gga-mir-6616; +MI0022436 gga-mir-6617; +MI0022437 gga-mir-6618; +MI0022438 gga-mir-6619; +MI0022439 gga-mir-6620; +MI0022440 gga-mir-4732; +MI0022441 gga-mir-6621; +MI0022442 gga-mir-6623; +MI0022443 gga-mir-6624; +MI0022444 gga-mir-6625; +MI0022445 gga-mir-6626; +MI0022446 gga-mir-6627; +MI0022447 gga-mir-6628; +MI0022448 gga-mir-6629; +MI0022449 gga-mir-6630; +MI0022450 gga-mir-6631; +MI0022451 gga-mir-6632; +MI0022452 gga-mir-6633; +MI0022453 gga-mir-6634; +MI0022454 gga-mir-6635-1; +MI0022455 gga-mir-6635-2; +MI0022456 gga-mir-6637-1; +MI0022457 gga-mir-6637-2; +MI0022458 gga-mir-6639; +MI0022459 gga-mir-6640; +MI0022460 gga-mir-6641; +MI0022461 gga-mir-6642; +MI0022462 gga-mir-6643; +MI0022463 gga-mir-6645; +MI0022464 gga-mir-6646-1; +MI0022465 gga-mir-6647; +MI0022466 gga-mir-6644-2; +MI0022467 gga-mir-6648-1; +MI0022468 gga-mir-6649; +MI0022469 gga-mir-6650; +MI0022470 gga-mir-6651; +MI0022471 gga-mir-6652; +MI0022472 gga-mir-3524b; +MI0022473 gga-mir-6653; +MI0022474 gga-mir-6654; +MI0022475 gga-mir-6655; +MI0022476 gga-mir-6656; +MI0022477 gga-mir-6657; +MI0022478 gga-mir-6658; +MI0022479 gga-mir-6659; +MI0022480 gga-mir-6660; +MI0022481 gga-mir-6661; +MI0022482 gga-mir-6662; +MI0022483 gga-mir-6663; +MI0022484 gga-mir-6664; +MI0022485 gga-mir-6665; +MI0022486 gga-mir-6666; +MI0022487 gga-mir-6667; +MI0022488 gga-mir-6668; +MI0022489 gga-mir-6669; +MI0022490 gga-mir-6670; +MI0022491 gga-mir-6671; +MI0022492 gga-mir-6672; +MI0022493 gga-mir-6673; +MI0022494 gga-mir-6674; +MI0022495 gga-mir-6675; +MI0022496 gga-mir-6676; +MI0022497 gga-mir-6677; +MI0022498 gga-mir-6678; +MI0022499 gga-mir-6679; +MI0022500 gga-mir-6680; +MI0022501 gga-mir-1684b; +MI0022502 gga-mir-6681; +MI0022503 gga-mir-6682; +MI0022504 gga-mir-6683; +MI0022505 gga-mir-6684; +MI0022506 gga-mir-6685; +MI0022507 gga-mir-6686; +MI0022508 gga-mir-6687; +MI0022509 gga-mir-6688; +MI0022510 gga-mir-6689; +MI0022511 gga-mir-6690; +MI0022512 gga-mir-6691-1; +MI0022513 gga-mir-6692; +MI0022514 gga-mir-6693; +MI0022515 gga-mir-6694; +MI0022516 gga-mir-6695; +MI0022517 gga-mir-6696; +MI0022518 gga-mir-6697; +MI0022519 gga-mir-6698; +MI0022520 gga-mir-6516; +MI0022521 gga-mir-6699; +MI0022522 gga-mir-6700; +MI0022523 gga-mir-6701; +MI0022524 gga-mir-6702; +MI0022525 gga-mir-6703; +MI0022526 gga-mir-6704; +MI0022527 gga-mir-6705; +MI0022528 gga-mir-6706; +MI0022529 gga-mir-6707; +MI0022530 gga-mir-6708; +MI0022531 gga-mir-6709; +MI0022532 gga-mir-6710; +MI0022533 gga-mir-6711; +MI0022534 gga-mir-6712; +MI0022535 gga-mir-6713; +MI0022536 gga-mir-6714; +MI0022537 gga-mir-6622; +MI0022538 gga-mir-6644-1; +MI0022539 gga-mir-6543; +MI0022540 gga-mir-6557; +MI0022541 gga-mir-458b; +MI0022542 gga-mir-6562; +MI0022543 gga-mir-6563; +MI0022544 gga-mir-6599; +MI0022545 ghr-MIR167b; +MI0022546 ghr-MIR169;ghr-MIR169a; +MI0022547 ghr-MIR399e; +MI0022548 hsa-mir-6715a; +MI0022549 hsa-mir-6715b; +MI0022550 hsa-mir-6716; +MI0022551 hsa-mir-6717; +MI0022552 hsa-mir-6511b-1; +MI0022553 hsa-mir-6718; +MI0022554 hsa-mir-6719; +MI0022555 hsa-mir-6720; +MI0022556 hsa-mir-6721; +MI0022557 hsa-mir-6722; +MI0022558 hsa-mir-6723; +MI0022559 hsa-mir-6724;hsa-mir-6724-1; +MI0022560 hsa-mir-892c; +MI0022561 blv-mir-B1; +MI0022562 blv-mir-B2; +MI0022563 blv-mir-B3; +MI0022564 blv-mir-B4; +MI0022565 blv-mir-B5; +MI0022566 cln-MIR162; +MI0022567 cln-MIR164; +MI0022568 cln-MIR166; +MI0022569 cln-MIR1310; +MI0022570 cln-MIR6725; +MI0022571 hsa-mir-6726; +MI0022572 hsa-mir-6727; +MI0022573 hsa-mir-6728; +MI0022574 hsa-mir-6729; +MI0022575 hsa-mir-6730; +MI0022576 hsa-mir-6731; +MI0022577 hsa-mir-6732; +MI0022578 hsa-mir-6733; +MI0022579 hsa-mir-6734; +MI0022580 hsa-mir-6735; +MI0022581 hsa-mir-6736; +MI0022582 hsa-mir-6737; +MI0022583 hsa-mir-6738; +MI0022584 hsa-mir-6739; +MI0022585 hsa-mir-6740; +MI0022586 hsa-mir-6741; +MI0022587 hsa-mir-6742; +MI0022588 hsa-mir-6743; +MI0022589 hsa-mir-6744; +MI0022590 hsa-mir-6745; +MI0022591 hsa-mir-6746; +MI0022592 hsa-mir-6747; +MI0022593 hsa-mir-6748; +MI0022594 hsa-mir-6749; +MI0022595 hsa-mir-6750; +MI0022596 hsa-mir-6751; +MI0022597 hsa-mir-6752; +MI0022598 hsa-mir-6753; +MI0022599 hsa-mir-6754; +MI0022600 hsa-mir-6755; +MI0022601 hsa-mir-6756; +MI0022602 hsa-mir-6757; +MI0022603 hsa-mir-6758; +MI0022604 hsa-mir-6759; +MI0022605 hsa-mir-6760; +MI0022606 hsa-mir-6761; +MI0022607 hsa-mir-6762; +MI0022608 hsa-mir-6763; +MI0022609 hsa-mir-6764; +MI0022610 hsa-mir-6765; +MI0022611 hsa-mir-6766; +MI0022612 hsa-mir-6767; +MI0022613 hsa-mir-6768; +MI0022614 hsa-mir-6769a; +MI0022615 hsa-mir-6770-1; +MI0022616 hsa-mir-6771; +MI0022617 hsa-mir-6772; +MI0022618 hsa-mir-6773; +MI0022619 hsa-mir-6774; +MI0022620 hsa-mir-6775; +MI0022621 hsa-mir-6776; +MI0022622 hsa-mir-6777; +MI0022623 hsa-mir-6778; +MI0022624 hsa-mir-6779; +MI0022625 hsa-mir-6780a; +MI0022626 hsa-mir-6781; +MI0022627 hsa-mir-6782; +MI0022628 hsa-mir-6783; +MI0022629 hsa-mir-6784; +MI0022630 hsa-mir-6785; +MI0022631 hsa-mir-6786; +MI0022632 hsa-mir-6787; +MI0022633 hsa-mir-6788; +MI0022634 hsa-mir-6789; +MI0022635 hsa-mir-6790; +MI0022636 hsa-mir-6791; +MI0022637 hsa-mir-6792; +MI0022638 hsa-mir-6793; +MI0022639 hsa-mir-6794; +MI0022640 hsa-mir-6795; +MI0022641 hsa-mir-6796; +MI0022642 hsa-mir-6797; +MI0022643 hsa-mir-6798; +MI0022644 hsa-mir-6799; +MI0022645 hsa-mir-6800; +MI0022646 hsa-mir-6801; +MI0022647 hsa-mir-6802; +MI0022648 hsa-mir-6803; +MI0022649 hsa-mir-6804; +MI0022650 hsa-mir-6805; +MI0022651 hsa-mir-6806; +MI0022652 hsa-mir-6807; +MI0022653 hsa-mir-6808; +MI0022654 hsa-mir-6809; +MI0022655 hsa-mir-6810; +MI0022656 hsa-mir-6811; +MI0022657 hsa-mir-6812; +MI0022658 hsa-mir-6813; +MI0022659 hsa-mir-6814; +MI0022660 hsa-mir-6815; +MI0022661 hsa-mir-6816; +MI0022662 hsa-mir-6817; +MI0022663 hsa-mir-6818; +MI0022664 hsa-mir-6819; +MI0022665 hsa-mir-6820; +MI0022666 hsa-mir-6821; +MI0022667 hsa-mir-6822; +MI0022668 hsa-mir-6823; +MI0022669 hsa-mir-6824; +MI0022670 hsa-mir-6825; +MI0022671 hsa-mir-6826; +MI0022672 hsa-mir-6827; +MI0022673 hsa-mir-6828; +MI0022674 hsa-mir-6829; +MI0022675 hsa-mir-6830; +MI0022676 hsa-mir-6831; +MI0022677 hsa-mir-6832; +MI0022678 hsa-mir-6833; +MI0022679 hsa-mir-6834; +MI0022680 hsa-mir-6835; +MI0022681 hsa-mir-6780b; +MI0022682 hsa-mir-6836; +MI0022683 hsa-mir-6837; +MI0022684 hsa-mir-6838; +MI0022685 hsa-mir-6839; +MI0022686 hsa-mir-6840; +MI0022687 hsa-mir-6841; +MI0022688 hsa-mir-6842; +MI0022689 hsa-mir-6843; +MI0022690 hsa-mir-6844; +MI0022691 hsa-mir-6845; +MI0022692 hsa-mir-6846; +MI0022693 hsa-mir-6847; +MI0022694 hsa-mir-6848; +MI0022695 hsa-mir-6849; +MI0022696 hsa-mir-6850; +MI0022697 hsa-mir-6851; +MI0022698 hsa-mir-6852; +MI0022699 hsa-mir-6853; +MI0022700 hsa-mir-6854; +MI0022701 hsa-mir-6855; +MI0022702 hsa-mir-6856; +MI0022703 hsa-mir-6857; +MI0022704 hsa-mir-6858; +MI0022705 hsa-mir-6859-1; +MI0022706 hsa-mir-6769b; +MI0022707 hsa-mir-6860; +MI0022708 hsa-mir-6861; +MI0022709 hsa-mir-6862-1; +MI0022710 hsa-mir-6863; +MI0022711 hsa-mir-6864; +MI0022712 hsa-mir-6865; +MI0022713 hsa-mir-6866; +MI0022714 hsa-mir-6867; +MI0022715 hsa-mir-6868; +MI0022716 hsa-mir-6869; +MI0022717 hsa-mir-6870; +MI0022718 hsa-mir-6871; +MI0022719 hsa-mir-6872; +MI0022720 hsa-mir-6873; +MI0022721 hsa-mir-6874; +MI0022722 hsa-mir-6875; +MI0022723 hsa-mir-6876; +MI0022724 hsa-mir-6877; +MI0022725 hsa-mir-6878; +MI0022726 hsa-mir-6879; +MI0022727 hsa-mir-6880; +MI0022728 hsa-mir-6881; +MI0022729 hsa-mir-6882; +MI0022730 hsa-mir-6883; +MI0022731 hsa-mir-6884; +MI0022732 hsa-mir-6885; +MI0022733 hsa-mir-6886; +MI0022734 hsa-mir-6887; +MI0022735 hsa-mir-6888; +MI0022736 hsa-mir-6889; +MI0022737 hsa-mir-6890; +MI0022738 hsa-mir-6891; +MI0022739 hsa-mir-6892; +MI0022740 hsa-mir-6893; +MI0022741 hsa-mir-6894; +MI0022742 hsa-mir-6895; +MI0022743 mmu-mir-6896; +MI0022744 mmu-mir-6897; +MI0022745 mmu-mir-6898; +MI0022746 mmu-mir-6899; +MI0022747 mmu-mir-6900; +MI0022748 mmu-mir-6901; +MI0022749 mmu-mir-6902; +MI0022750 mmu-mir-6903; +MI0022751 mmu-mir-6904; +MI0022752 mmu-mir-6905; +MI0022753 mmu-mir-6906; +MI0022754 mmu-mir-6907; +MI0022755 mmu-mir-6908; +MI0022756 mmu-mir-6909; +MI0022757 mmu-mir-6910; +MI0022758 mmu-mir-6911; +MI0022759 mmu-mir-6912; +MI0022760 mmu-mir-6913; +MI0022761 mmu-mir-6914; +MI0022762 mmu-mir-6915; +MI0022763 mmu-mir-6916; +MI0022764 mmu-mir-6917; +MI0022765 mmu-mir-6918; +MI0022766 mmu-mir-6919; +MI0022767 mmu-mir-6920; +MI0022768 mmu-mir-6921; +MI0022769 mmu-mir-6922; +MI0022770 mmu-mir-6923; +MI0022771 mmu-mir-6924; +MI0022772 mmu-mir-6925; +MI0022773 mmu-mir-6926; +MI0022774 mmu-mir-6927; +MI0022775 mmu-mir-6928; +MI0022776 mmu-mir-6929; +MI0022777 mmu-mir-6930; +MI0022778 mmu-mir-6931; +MI0022779 mmu-mir-6932; +MI0022780 mmu-mir-6933; +MI0022781 mmu-mir-6934; +MI0022782 mmu-mir-6935; +MI0022783 mmu-mir-6936; +MI0022784 mmu-mir-6937; +MI0022785 mmu-mir-6938; +MI0022786 mmu-mir-6939; +MI0022787 mmu-mir-6940; +MI0022788 mmu-mir-6941; +MI0022789 mmu-mir-6942; +MI0022790 mmu-mir-6943; +MI0022791 mmu-mir-6944; +MI0022792 mmu-mir-6945; +MI0022793 mmu-mir-6946; +MI0022794 mmu-mir-6947; +MI0022795 mmu-mir-6948; +MI0022796 mmu-mir-6949; +MI0022797 mmu-mir-6950; +MI0022798 mmu-mir-6951; +MI0022799 mmu-mir-6952; +MI0022800 mmu-mir-6953; +MI0022801 mmu-mir-6954; +MI0022802 mmu-mir-6955; +MI0022803 mmu-mir-6956; +MI0022804 mmu-mir-6957; +MI0022805 mmu-mir-6958; +MI0022806 mmu-mir-6959; +MI0022807 mmu-mir-6960; +MI0022808 mmu-mir-6961; +MI0022809 mmu-mir-6962; +MI0022810 mmu-mir-6963; +MI0022811 mmu-mir-6964; +MI0022812 mmu-mir-6965; +MI0022813 mmu-mir-3547; +MI0022814 mmu-mir-6966; +MI0022815 mmu-mir-6967;mmu-mir-6967-1; +MI0022816 mmu-mir-6968; +MI0022817 mmu-mir-6969; +MI0022818 mmu-mir-6970; +MI0022819 mmu-mir-6971; +MI0022820 mmu-mir-6972; +MI0022821 mmu-mir-6973a; +MI0022822 mmu-mir-6974; +MI0022823 mmu-mir-6975; +MI0022824 mmu-mir-6976; +MI0022825 mmu-mir-6977; +MI0022826 mmu-mir-6978; +MI0022827 mmu-mir-6979; +MI0022828 mmu-mir-6980; +MI0022829 mmu-mir-6981; +MI0022830 mmu-mir-6982; +MI0022831 mmu-mir-6983; +MI0022832 mmu-mir-6984; +MI0022833 mmu-mir-6985; +MI0022834 mmu-mir-6986; +MI0022835 mmu-mir-6987; +MI0022836 mmu-mir-6988; +MI0022837 mmu-mir-6989; +MI0022838 mmu-mir-6990; +MI0022839 mmu-mir-6991; +MI0022840 mmu-mir-6992; +MI0022841 mmu-mir-6993; +MI0022842 mmu-mir-6994; +MI0022843 mmu-mir-6995; +MI0022844 mmu-mir-6996; +MI0022845 mmu-mir-6997; +MI0022846 mmu-mir-6998; +MI0022847 mmu-mir-6999; +MI0022848 mmu-mir-7000; +MI0022849 mmu-mir-7001; +MI0022850 mmu-mir-7002; +MI0022851 mmu-mir-6973b; +MI0022852 mmu-mir-7003; +MI0022853 mmu-mir-7004; +MI0022854 mmu-mir-7005; +MI0022855 mmu-mir-7006; +MI0022856 mmu-mir-7007; +MI0022857 mmu-mir-7008; +MI0022858 mmu-mir-7009; +MI0022859 mmu-mir-7010; +MI0022860 mmu-mir-7011; +MI0022861 mmu-mir-7012; +MI0022862 mmu-mir-7013; +MI0022863 mmu-mir-7014; +MI0022864 mmu-mir-7015; +MI0022865 mmu-mir-7016; +MI0022866 mmu-mir-7017; +MI0022867 mmu-mir-7018; +MI0022868 mmu-mir-7019; +MI0022869 mmu-mir-7020; +MI0022870 mmu-mir-7021; +MI0022871 mmu-mir-7022; +MI0022872 mmu-mir-7023; +MI0022873 mmu-mir-7024; +MI0022874 mmu-mir-7025; +MI0022875 mmu-mir-7026; +MI0022876 mmu-mir-7027; +MI0022877 mmu-mir-7028; +MI0022878 mmu-mir-7029; +MI0022879 mmu-mir-7030; +MI0022880 mmu-mir-7031; +MI0022881 mmu-mir-7032; +MI0022882 mmu-mir-7033; +MI0022883 mmu-mir-7034; +MI0022884 mmu-mir-7035; +MI0022885 mmu-mir-7036;mmu-mir-7036a; +MI0022886 mmu-mir-7037; +MI0022887 mmu-mir-7038; +MI0022888 mmu-mir-7039; +MI0022889 mmu-mir-7040; +MI0022890 mmu-mir-7041; +MI0022891 mmu-mir-7042; +MI0022892 mmu-mir-7043; +MI0022893 mmu-mir-7044; +MI0022894 mmu-mir-7045; +MI0022895 mmu-mir-7046; +MI0022896 mmu-mir-7047; +MI0022897 mmu-mir-7048; +MI0022898 mmu-mir-7049; +MI0022899 mmu-mir-7050; +MI0022900 mmu-mir-7051; +MI0022901 mmu-mir-7052; +MI0022902 mmu-mir-7053; +MI0022903 mmu-mir-7054; +MI0022904 mmu-mir-7055; +MI0022905 mmu-mir-7056; +MI0022906 mmu-mir-7057; +MI0022907 mmu-mir-7058; +MI0022908 mmu-mir-7059; +MI0022909 mmu-mir-7060; +MI0022910 mmu-mir-7061; +MI0022911 mmu-mir-7062; +MI0022912 mmu-mir-7063; +MI0022913 mmu-mir-7064; +MI0022914 mmu-mir-7065; +MI0022915 mmu-mir-7066; +MI0022916 mmu-mir-7067; +MI0022917 mmu-mir-6769b; +MI0022918 mmu-mir-7068; +MI0022919 mmu-mir-7069; +MI0022920 mmu-mir-7070; +MI0022921 mmu-mir-7071; +MI0022922 mmu-mir-7072; +MI0022923 mmu-mir-7073; +MI0022924 mmu-mir-7074; +MI0022925 mmu-mir-7075; +MI0022926 mmu-mir-7076; +MI0022927 mmu-mir-7077; +MI0022928 mmu-mir-7078; +MI0022929 mmu-mir-7079; +MI0022930 mmu-mir-7080; +MI0022931 mmu-mir-7081; +MI0022932 mmu-mir-7082; +MI0022933 mmu-mir-7083; +MI0022934 mmu-mir-7084; +MI0022935 mmu-mir-7085; +MI0022936 mmu-mir-7086; +MI0022937 mmu-mir-7087; +MI0022938 mmu-mir-7088; +MI0022939 mmu-mir-7089; +MI0022940 mmu-mir-7090; +MI0022941 mmu-mir-7091; +MI0022942 mmu-mir-7092; +MI0022943 mmu-mir-7093; +MI0022944 mmu-mir-7094-1; +MI0022945 mmu-mir-7094-2; +MI0022946 ddi-mir-7095; +MI0022947 ddi-mir-7096; +MI0022948 ddi-mir-7097; +MI0022949 ddi-mir-7098; +MI0022950 ddi-mir-7099; +MI0022951 ddi-mir-7100; +MI0022952 ddi-mir-7101; +MI0022953 ddi-mir-7102; +MI0022954 ddi-mir-7103; +MI0022955 ddi-mir-7104; +MI0022956 ddi-mir-7105; +MI0022957 hsa-mir-7106; +MI0022958 hsa-mir-7107; +MI0022959 hsa-mir-7108; +MI0022960 hsa-mir-7109; +MI0022961 hsa-mir-7110; +MI0022962 hsa-mir-7111; +MI0022963 hsa-mir-7112-1;hsa-mir-7112; +MI0022964 hsa-mir-7113; +MI0022965 hsa-mir-7114; +MI0022966 mmu-mir-7115; +MI0022967 mmu-mir-7116; +MI0022968 mmu-mir-7117; +MI0022969 mmu-mir-7118; +MI0022970 mmu-mir-7119; +MI0022971 mdm-MIR156a; +MI0022972 mdm-MIR156b; +MI0022973 mdm-MIR156c; +MI0022974 mdm-MIR156d; +MI0022975 mdm-MIR156e; +MI0022976 mdm-MIR156f; +MI0022977 mdm-MIR156g; +MI0022978 mdm-MIR156h; +MI0022979 mdm-MIR156i; +MI0022980 mdm-MIR156j; +MI0022981 mdm-MIR156k; +MI0022982 mdm-MIR156l; +MI0022983 mdm-MIR156m; +MI0022984 mdm-MIR156n; +MI0022985 mdm-MIR156o; +MI0022986 mdm-MIR156p; +MI0022987 mdm-MIR156q; +MI0022988 mdm-MIR156r; +MI0022989 mdm-MIR156s; +MI0022990 mdm-MIR156t; +MI0022991 mdm-MIR156u; +MI0022992 mdm-MIR156v; +MI0022993 mdm-MIR156w; +MI0022994 mdm-MIR156x; +MI0022995 mdm-MIR156y; +MI0022996 mdm-MIR156z; +MI0022997 mdm-MIR156aa; +MI0022998 mdm-MIR156ab; +MI0022999 mdm-MIR156ac; +MI0023000 mdm-MIR156ad; +MI0023001 mdm-MIR156ae; +MI0023002 mdm-MIR159a; +MI0023003 mdm-MIR159b; +MI0023004 mdm-MIR160a; +MI0023005 mdm-MIR160b; +MI0023006 mdm-MIR160c; +MI0023007 mdm-MIR160d; +MI0023008 mdm-MIR160e; +MI0023009 mdm-MIR162a; +MI0023010 mdm-MIR162b; +MI0023011 mdm-MIR164a; +MI0023012 mdm-MIR164b; +MI0023013 mdm-MIR164c; +MI0023014 mdm-MIR164d; +MI0023015 mdm-MIR164e; +MI0023016 mdm-MIR164f; +MI0023017 mdm-MIR166a; +MI0023018 mdm-MIR166b; +MI0023019 mdm-MIR166c; +MI0023020 mdm-MIR166d; +MI0023021 mdm-MIR166e; +MI0023022 mdm-MIR166f; +MI0023023 mdm-MIR166g; +MI0023024 mdm-MIR166h; +MI0023025 mdm-MIR166i; +MI0023026 mdm-MIR167a; +MI0023027 mdm-MIR167b; +MI0023028 mdm-MIR167c; +MI0023029 mdm-MIR167d; +MI0023030 mdm-MIR167e; +MI0023031 mdm-MIR167f; +MI0023032 mdm-MIR167g; +MI0023033 mdm-MIR167h; +MI0023034 mdm-MIR167i; +MI0023035 mdm-MIR167j; +MI0023036 mdm-MIR168a; +MI0023037 mdm-MIR168b; +MI0023038 mdm-MIR169a; +MI0023039 mdm-MIR169b; +MI0023040 mdm-MIR169c; +MI0023041 mdm-MIR169d; +MI0023042 mdm-MIR171a; +MI0023043 mdm-MIR171b; +MI0023044 mdm-MIR171c; +MI0023045 mdm-MIR171d; +MI0023046 mdm-MIR171e; +MI0023047 mdm-MIR171f; +MI0023048 mdm-MIR171g; +MI0023049 mdm-MIR171h; +MI0023050 mdm-MIR171i; +MI0023051 mdm-MIR171j; +MI0023052 mdm-MIR171k; +MI0023053 mdm-MIR171l; +MI0023054 mdm-MIR171m; +MI0023055 mdm-MIR171n; +MI0023056 mdm-MIR172a; +MI0023057 mdm-MIR172b; +MI0023058 mdm-MIR172c; +MI0023059 mdm-MIR172d; +MI0023060 mdm-MIR172e; +MI0023061 mdm-MIR172f; +MI0023062 mdm-MIR172g; +MI0023063 mdm-MIR172h; +MI0023064 mdm-MIR172i; +MI0023065 mdm-MIR172j; +MI0023066 mdm-MIR172k; +MI0023067 mdm-MIR172l; +MI0023068 mdm-MIR172m; +MI0023069 mdm-MIR172n; +MI0023070 mdm-MIR172o; +MI0023071 mdm-MIR319a; +MI0023072 mdm-MIR319b; +MI0023073 mdm-MIR390a; +MI0023074 mdm-MIR390b; +MI0023075 mdm-MIR390c; +MI0023076 mdm-MIR390d; +MI0023077 mdm-MIR390e; +MI0023078 mdm-MIR390f; +MI0023079 mdm-MIR393a; +MI0023080 mdm-MIR393b; +MI0023081 mdm-MIR393c; +MI0023082 mdm-MIR394a; +MI0023083 mdm-MIR394b; +MI0023084 mdm-MIR395a; +MI0023085 mdm-MIR395b; +MI0023086 mdm-MIR395c; +MI0023087 mdm-MIR395d; +MI0023088 mdm-MIR395e; +MI0023089 mdm-MIR395f; +MI0023090 mdm-MIR395g; +MI0023091 mdm-MIR395h; +MI0023092 mdm-MIR395i; +MI0023093 mdm-MIR396a; +MI0023094 mdm-MIR396b; +MI0023095 mdm-MIR396c; +MI0023096 mdm-MIR396d; +MI0023097 mdm-MIR396e; +MI0023098 mdm-MIR396f; +MI0023099 mdm-MIR396g; +MI0023100 mdm-MIR397a; +MI0023101 mdm-MIR397b; +MI0023102 mdm-MIR398a; +MI0023103 mdm-MIR398b; +MI0023104 mdm-MIR398c; +MI0023105 mdm-MIR399a; +MI0023106 mdm-MIR399b; +MI0023107 mdm-MIR399c; +MI0023108 mdm-MIR399d; +MI0023109 mdm-MIR399e; +MI0023110 mdm-MIR399f; +MI0023111 mdm-MIR399g; +MI0023112 mdm-MIR399h; +MI0023113 mdm-MIR399i; +MI0023114 mdm-MIR399j; +MI0023115 mdm-MIR403a; +MI0023116 mdm-MIR403b; +MI0023117 mdm-MIR408a; +MI0023118 mdm-MIR2111a; +MI0023119 mdm-MIR2111b; +MI0023120 mdm-MIR3627a; +MI0023121 mdm-MIR3627b; +MI0023122 mdm-MIR3627c; +MI0023123 mdm-MIR391; +MI0023124 mdm-MIR447;mdm-MIR477b; +MI0023125 mdm-MIR477;mdm-MIR477a; +MI0023126 mdm-MIR482b; +MI0023127 mdm-MIR482c; +MI0023128 mdm-MIR535a; +MI0023129 mdm-MIR535b; +MI0023130 mdm-MIR535c; +MI0023131 mdm-MIR535d; +MI0023132 mdm-MIR827; +MI0023133 mdm-MIR828a; +MI0023134 mdm-MIR828b; +MI0023135 mdm-MIR408b; +MI0023136 mdm-MIR408c; +MI0023137 mdm-MIR408d; +MI0023138 mdm-MIR2118a; +MI0023139 mdm-MIR2118b; +MI0023140 mdm-MIR2118c; +MI0023141 mdm-MIR7120a; +MI0023142 mdm-MIR7120b; +MI0023143 mdm-MIR482d; +MI0023144 mdm-MIR7121a; +MI0023145 mdm-MIR7121b; +MI0023146 mdm-MIR7121c; +MI0023147 mdm-MIR7121d; +MI0023148 mdm-MIR7121e; +MI0023149 mdm-MIR7121f; +MI0023150 mdm-MIR7121g; +MI0023151 mdm-MIR7121h; +MI0023152 mdm-MIR7122a; +MI0023153 mdm-MIR7122b; +MI0023154 mdm-MIR7123a; +MI0023155 mdm-MIR7123b; +MI0023156 mdm-MIR5225c; +MI0023157 mdm-MIR159c; +MI0023158 mdm-MIR7124a; +MI0023159 mdm-MIR7124b; +MI0023160 mdm-MIR5225a; +MI0023161 mdm-MIR5225b; +MI0023162 mdm-MIR319c; +MI0023163 mdm-MIR7125; +MI0023164 mdm-MIR7126; +MI0023165 mdm-MIR393d; +MI0023166 mdm-MIR393e; +MI0023167 mdm-MIR393f; +MI0023168 mdm-MIR7127a; +MI0023169 mdm-MIR7127b; +MI0023170 mdm-MIR171o; +MI0023171 mdm-MIR169e; +MI0023172 mdm-MIR169f; +MI0023173 mdm-MIR7128; +MI0023174 mdm-MIR858; +MI0023175 cme-MIR156a; +MI0023176 cme-MIR160a; +MI0023177 cme-MIR169q; +MI0023178 cme-MIR169s; +MI0023179 cme-MIR169p; +MI0023180 cme-MIR169o; +MI0023181 cme-MIR169d; +MI0023182 cme-MIR399d; +MI0023183 cme-MIR169k; +MI0023184 cme-MIR162; +MI0023185 cme-MIR169c; +MI0023186 cme-MIR399e; +MI0023187 cme-MIR858; +MI0023188 cme-MIR845; +MI0023189 cme-MIR171i; +MI0023190 cme-MIR164c; +MI0023191 cme-MIR399f; +MI0023192 cme-MIR164b; +MI0023193 cme-MIR477a; +MI0023194 cme-MIR164d; +MI0023195 cme-MIR166i; +MI0023196 cme-MIR169m; +MI0023197 cme-MIR169j; +MI0023198 cme-MIR169b; +MI0023199 cme-MIR169a; +MI0023200 cme-MIR169i; +MI0023201 cme-MIR166c; +MI0023202 cme-MIR169l; +MI0023203 cme-MIR172f; +MI0023204 cme-MIR854; +MI0023205 cme-MIR1863; +MI0023206 cme-MIR477b; +MI0023207 cme-MIR166b; +MI0023208 cme-MIR530b; +MI0023209 cme-MIR156i; +MI0023210 cme-MIR396a; +MI0023211 cme-MIR166d; +MI0023212 cme-MIR166h; +MI0023213 cme-MIR166f; +MI0023214 cme-MIR166a; +MI0023215 cme-MIR156d; +MI0023216 cme-MIR167a; +MI0023217 cme-MIR167b; +MI0023218 cme-MIR169h; +MI0023219 cme-MIR169f; +MI0023220 cme-MIR169n; +MI0023221 cme-MIR169e; +MI0023222 cme-MIR171e; +MI0023223 cme-MIR171a; +MI0023224 cme-MIR171g; +MI0023225 cme-MIR156c; +MI0023226 cme-MIR171d; +MI0023227 cme-MIR171b; +MI0023228 cme-MIR172b; +MI0023229 cme-MIR172c; +MI0023230 cme-MIR172e; +MI0023231 cme-MIR172d; +MI0023232 cme-MIR319b; +MI0023233 cme-MIR319a; +MI0023234 cme-MIR319c; +MI0023235 cme-MIR156b; +MI0023236 cme-MIR319d; +MI0023237 cme-MIR390d; +MI0023238 cme-MIR390a; +MI0023239 cme-MIR390c; +MI0023240 cme-MIR393a; +MI0023241 cme-MIR393b; +MI0023242 cme-MIR393c; +MI0023243 cme-MIR394b; +MI0023244 cme-MIR394a; +MI0023245 cme-MIR395a; +MI0023246 cme-MIR395e; +MI0023247 cme-MIR395d; +MI0023248 cme-MIR395f; +MI0023249 cme-MIR396b; +MI0023250 cme-MIR396c; +MI0023251 cme-MIR396d; +MI0023252 cme-MIR397; +MI0023253 cme-MIR398b; +MI0023254 cme-MIR399a; +MI0023255 cme-MIR156f; +MI0023256 cme-MIR399c; +MI0023257 cme-MIR408; +MI0023258 cme-MIR171c; +MI0023259 cme-MIR2111a; +MI0023260 cme-MIR156e; +MI0023261 cme-MIR395b; +MI0023262 cme-MIR156h; +MI0023263 cme-MIR156g; +MI0023264 cme-MIR159a; +MI0023265 cme-MIR828; +MI0023266 cme-MIR396e; +MI0023267 cme-MIR167d; +MI0023268 cme-MIR167f; +MI0023269 cme-MIR166g; +MI0023270 cme-MIR171f; +MI0023271 cme-MIR399b; +MI0023272 cme-MIR159b; +MI0023273 cme-MIR2111b; +MI0023274 cme-MIR395c; +MI0023275 cme-MIR160b; +MI0023276 cme-MIR169g; +MI0023277 cme-MIR171h; +MI0023278 cme-MIR398a; +MI0023279 cme-MIR169r; +MI0023280 cme-MIR167c; +MI0023281 cme-MIR167e; +MI0023282 cme-MIR160d; +MI0023283 cme-MIR166e; +MI0023284 cme-MIR160c; +MI0023285 cme-MIR172a; +MI0023286 cme-MIR530a; +MI0023287 cme-MIR7129; +MI0023288 cme-MIR7130; +MI0023289 cme-MIR399g; +MI0023290 cme-MIR156j; +MI0023291 cme-MIR169t; +MI0023292 mdm-MIR1511; +MI0023293 ddi-mir-7131a; +MI0023294 ddi-mir-7131d; +MI0023295 ddi-mir-7131b; +MI0023296 ddi-mir-7131c; +MI0023297 ccr-let-7a; +MI0023298 ccr-let-7b; +MI0023299 ccr-let-7g; +MI0023300 ccr-let-7i; +MI0023301 ccr-let-7j; +MI0023302 ccr-mir-1; +MI0023303 ccr-mir-100; +MI0023304 ccr-mir-101a; +MI0023305 ccr-mir-101b; +MI0023306 ccr-mir-103; +MI0023307 ccr-mir-107; +MI0023308 ccr-mir-10b; +MI0023309 ccr-mir-10c; +MI0023310 ccr-mir-10d; +MI0023311 ccr-mir-122; +MI0023312 ccr-mir-125b; +MI0023313 ccr-mir-125c; +MI0023314 ccr-mir-126; +MI0023315 ccr-mir-128; +MI0023316 ccr-mir-129; +MI0023317 ccr-mir-130a; +MI0023318 ccr-mir-130b; +MI0023319 ccr-mir-130c; +MI0023320 ccr-mir-132a; +MI0023321 ccr-mir-133a; +MI0023322 ccr-mir-135c; +MI0023323 ccr-mir-137; +MI0023324 ccr-mir-138; +MI0023325 ccr-mir-139; +MI0023326 ccr-mir-140; +MI0023327 ccr-mir-142-1; +MI0023328 ccr-mir-142-2; +MI0023329 ccr-mir-143; +MI0023330 ccr-mir-144; +MI0023331 ccr-mir-146a; +MI0023332 ccr-mir-148; +MI0023333 ccr-mir-15a-1; +MI0023334 ccr-mir-153b; +MI0023335 ccr-mir-153c; +MI0023336 ccr-mir-155; +MI0023337 ccr-mir-15a-2; +MI0023338 ccr-mir-15b; +MI0023339 ccr-mir-16a; +MI0023340 ccr-mir-16b; +MI0023341 ccr-mir-16c; +MI0023342 ccr-mir-17; +MI0023343 ccr-mir-181a; +MI0023344 ccr-mir-181b; +MI0023345 ccr-mir-181c; +MI0023346 ccr-mir-182; +MI0023347 ccr-mir-183; +MI0023348 ccr-mir-184; +MI0023349 ccr-mir-187; +MI0023350 ccr-mir-18a; +MI0023351 ccr-mir-18b; +MI0023352 ccr-mir-18c; +MI0023353 ccr-mir-190; +MI0023354 ccr-mir-192; +MI0023355 ccr-mir-193a; +MI0023356 ccr-mir-194; +MI0023357 ccr-mir-196a; +MI0023358 ccr-mir-196b; +MI0023359 ccr-mir-199; +MI0023360 ccr-mir-19d; +MI0023361 ccr-mir-200a; +MI0023362 ccr-mir-200b; +MI0023363 ccr-mir-203a; +MI0023364 ccr-mir-203b; +MI0023365 ccr-mir-205; +MI0023366 ccr-mir-206; +MI0023367 ccr-mir-20a; +MI0023368 ccr-mir-21; +MI0023369 ccr-mir-210; +MI0023370 ccr-mir-214; +MI0023371 ccr-mir-217; +MI0023372 ccr-mir-218a; +MI0023373 ccr-mir-218b; +MI0023374 ccr-mir-221; +MI0023375 ccr-mir-222; +MI0023376 ccr-mir-22a; +MI0023377 ccr-mir-22b; +MI0023378 ccr-mir-23a; +MI0023379 ccr-mir-23b; +MI0023380 ccr-mir-24; +MI0023381 ccr-mir-25; +MI0023382 ccr-mir-26a; +MI0023383 ccr-mir-27a; +MI0023384 ccr-mir-27c; +MI0023385 ccr-mir-27d; +MI0023386 ccr-mir-29a; +MI0023387 ccr-mir-29b; +MI0023388 ccr-mir-301a; +MI0023389 ccr-mir-30b; +MI0023390 ccr-mir-30d; +MI0023391 ccr-mir-338; +MI0023392 ccr-mir-34; +MI0023393 ccr-mir-363; +MI0023394 ccr-mir-365; +MI0023395 ccr-mir-375; +MI0023396 ccr-mir-738; +MI0023397 ccr-mir-429; +MI0023398 ccr-mir-430; +MI0023399 ccr-mir-454a; +MI0023400 ccr-mir-454b; +MI0023401 ccr-mir-455; +MI0023402 ccr-mir-457a; +MI0023403 ccr-mir-457b; +MI0023404 ccr-mir-459; +MI0023405 ccr-mir-460; +MI0023406 ccr-mir-489; +MI0023407 ccr-mir-499; +MI0023408 ccr-mir-722; +MI0023409 ccr-mir-724; +MI0023410 ccr-mir-725; +MI0023411 ccr-mir-726; +MI0023412 ccr-mir-727; +MI0023413 ccr-mir-729; +MI0023414 ccr-mir-730; +MI0023415 ccr-mir-734; +MI0023416 ccr-mir-7a; +MI0023417 ccr-mir-7b; +MI0023418 ccr-mir-9; +MI0023419 ccr-mir-92a; +MI0023420 ccr-mir-92b; +MI0023421 ccr-mir-93; +MI0023422 ccr-mir-96; +MI0023423 ccr-mir-99; +MI0023424 ccr-mir-2192; +MI0023425 ccr-mir-551; +MI0023426 ccr-mir-132b; +MI0023427 ccr-mir-124a; +MI0023428 ccr-mir-7132; +MI0023429 ccr-mir-7133; +MI0023430 ccr-mir-124b; +MI0023431 hsa-mir-6511b-2; +MI0023432 osa-MIR818f; +MI0023433 bma-mir-5838;bma-mir-5838-1; +MI0023434 bma-mir-5839; +MI0023435 bma-mir-5840-1;bma-mir-5840; +MI0023436 bma-mir-5840-2; +MI0023437 bma-mir-5841; +MI0023438 bma-mir-5842; +MI0023439 bma-mir-5843; +MI0023440 bma-mir-5844; +MI0023441 bma-mir-5845; +MI0023442 bma-mir-5846;bma-mir-5846-1; +MI0023443 bma-mir-5847-1; +MI0023444 bma-mir-5847-2; +MI0023445 bma-mir-5847-3; +MI0023446 bma-mir-5848; +MI0023447 bma-mir-5849; +MI0023448 bma-mir-5850;bma-mir-2i; +MI0023449 bma-mir-5851; +MI0023450 bma-mir-5852; +MI0023451 bma-mir-5853; +MI0023452 bma-mir-5854; +MI0023453 bma-mir-5855; +MI0023454 bma-mir-5856a; +MI0023455 bma-mir-5856b; +MI0023456 bma-mir-5857; +MI0023457 bma-mir-5858; +MI0023458 bma-mir-5859; +MI0023459 bma-mir-5860;bma-mir-2g; +MI0023460 bma-mir-5861-1;bma-mir-5861; +MI0023461 bma-mir-5861-2; +MI0023462 bma-mir-5862-1;bma-mir-5862; +MI0023463 bma-mir-5862-2; +MI0023464 bma-mir-5863-1;bma-mir-5863; +MI0023465 bma-mir-5863-2; +MI0023466 bma-mir-5864; +MI0023467 bma-mir-5865; +MI0023468 bma-mir-5866; +MI0023469 bma-mir-5867; +MI0023470 bma-mir-5868; +MI0023471 bma-mir-5869; +MI0023472 bma-mir-5870;bma-mir-2e; +MI0023473 bma-mir-5871; +MI0023474 bma-mir-5872-1;bma-mir-5872; +MI0023475 bma-mir-5872-2; +MI0023476 bma-mir-5872-3; +MI0023477 bma-mir-5872-4; +MI0023478 bma-mir-5872-5; +MI0023479 bma-mir-5872-6; +MI0023480 bma-mir-5873-1;bma-mir-5873; +MI0023481 bma-mir-5873-2; +MI0023482 bma-mir-5873-3; +MI0023483 bma-mir-5874; +MI0023484 bma-mir-5875; +MI0023485 bma-mir-5876; +MI0023486 bma-mir-5877-1;bma-mir-5877; +MI0023487 bma-mir-5877-2; +MI0023488 bma-mir-5878; +MI0023489 bma-mir-5879a; +MI0023490 bma-mir-5879b; +MI0023491 bma-mir-5880a; +MI0023492 bma-mir-5880b; +MI0023493 bma-mir-5881a; +MI0023494 bma-mir-5881b; +MI0023495 bma-mir-5881c; +MI0023496 bma-mir-5882a-1; +MI0023497 bma-mir-5882a-2; +MI0023498 bma-mir-5882a-3; +MI0023499 bma-mir-5882b-1; +MI0023500 bma-mir-5882b-2; +MI0023501 bma-mir-5882b-3; +MI0023502 bma-mir-5883-1; +MI0023503 bma-mir-5883-2; +MI0023504 bma-mir-5883-3; +MI0023506 sbi-MIR5568g; +MI0023507 sbi-MIR5564c; +MI0023508 sbi-MIR6217a; +MI0023509 sbi-MIR6217b; +MI0023510 sbi-MIR6218; +MI0023511 sbi-MIR5565g; +MI0023512 sbi-MIR5568b; +MI0023513 sbi-MIR5568c; +MI0023514 sbi-MIR6219; +MI0023515 sbi-MIR6220; +MI0023516 sbi-MIR437x; +MI0023517 sbi-MIR6221; +MI0023518 sbi-MIR6222; +MI0023519 sbi-MIR6223; +MI0023520 sbi-MIR6224a; +MI0023521 sbi-MIR6224b; +MI0023522 sbi-MIR6224c; +MI0023523 sbi-MIR6225; +MI0023524 sbi-MIR5568d; +MI0023525 sbi-MIR6226; +MI0023526 sbi-MIR2118; +MI0023527 sbi-MIR6227; +MI0023528 sbi-MIR169r; +MI0023529 sbi-MIR6228; +MI0023530 sbi-MIR6229; +MI0023531 sbi-MIR6230; +MI0023532 sbi-MIR5568e; +MI0023533 sbi-MIR6231; +MI0023534 sbi-MIR5568f; +MI0023535 sbi-MIR6232a; +MI0023536 sbi-MIR6232b; +MI0023537 sbi-MIR6233; +MI0023538 sbi-MIR6234a; +MI0023539 sbi-MIR6234b; +MI0023540 sbi-MIR6235; +MI0023541 mmu-mir-692-3; +MI0023542 bfl-mir-4057-2; +MI0023543 bfl-mir-34c-2; +MI0023544 bfl-mir-4900a-2; +MI0023545 bfl-mir-4900b-2; +MI0023546 cqu-mir-252-2; +MI0023547 cqu-mir-281-2; +MI0023548 cqu-mir-317-2; +MI0023549 cqu-mir-375-2; +MI0023550 gga-mir-1467-2; +MI0023551 gga-mir-1634-2; +MI0023552 gga-mir-1698-2; +MI0023553 gga-mir-6608-2; +MI0023554 gga-mir-6646-2; +MI0023555 gga-mir-6648-2; +MI0023556 gga-mir-6691-2; +MI0023557 gga-mir-1732-2; +MI0023558 gga-mir-1732-3; +MI0023559 gga-mir-196-4; +MI0023560 gga-mir-196-5; +MI0023561 hsa-mir-3690-2; +MI0023562 hsa-mir-6077-2; +MI0023563 hsa-mir-6089-2; +MI0023564 hsa-mir-6511a-2; +MI0023565 hsa-mir-6511a-3; +MI0023566 hsa-mir-6511a-4; +MI0023567 ssc-mir-7134; +MI0023568 ssc-mir-7135; +MI0023569 ssc-mir-7136; +MI0023570 ssc-mir-7137; +MI0023571 ssc-mir-7138; +MI0023572 ssc-mir-7139; +MI0023573 ssc-mir-7140; +MI0023574 ssc-mir-7141; +MI0023575 ssc-mir-7142; +MI0023576 ssc-mir-7143; +MI0023577 ssc-mir-7144; +MI0023578 hcmv-mir-US22; +MI0023579 hcmv-mir-US29; +MI0023580 dev-mir-D1; +MI0023581 dev-mir-D2; +MI0023582 dev-mir-D3; +MI0023583 dev-mir-D4; +MI0023584 dev-mir-D5; +MI0023585 dev-mir-D6; +MI0023586 dev-mir-D7; +MI0023587 dev-mir-D8; +MI0023588 dev-mir-D9; +MI0023589 dev-mir-D10; +MI0023590 dev-mir-D11; +MI0023591 dev-mir-D12; +MI0023592 dev-mir-D13; +MI0023593 dev-mir-D14; +MI0023594 dev-mir-D15; +MI0023595 dev-mir-D16; +MI0023596 dev-mir-D17; +MI0023597 dev-mir-D18; +MI0023598 dev-mir-D19; +MI0023599 dev-mir-D20; +MI0023600 dev-mir-D21; +MI0023601 dev-mir-D22; +MI0023602 dev-mir-D23; +MI0023603 dev-mir-D24; +MI0023604 dre-mir-7145; +MI0023605 dre-mir-7146; +MI0023606 dre-mir-7147; +MI0023607 dre-mir-7148; +MI0023608 dre-mir-7149; +MI0023609 dre-mir-1306; +MI0023610 hsa-mir-7150; +MI0023611 hsa-mir-7151; +MI0023612 hsa-mir-7152; +MI0023613 hsa-mir-7153; +MI0023614 hsa-mir-7154; +MI0023615 hsa-mir-7155; +MI0023616 hsa-mir-7156; +MI0023617 hsa-mir-7157; +MI0023618 hsa-mir-7158; +MI0023619 hsa-mir-7161; +MI0023620 hsa-mir-7159; +MI0023621 hsa-mir-7160; +MI0023622 hsa-mir-486-2; +MI0023623 hsa-mir-7162; +MI0023624 mml-mir-500b; +MI0023625 mml-mir-4766; +MI0023626 mml-mir-1306; +MI0023627 mml-mir-1251; +MI0023628 mml-mir-7163; +MI0023629 mml-mir-3059; +MI0023630 mml-mir-6505; +MI0023631 mml-mir-1245; +MI0023632 mml-mir-7164; +MI0023633 mml-mir-548g; +MI0023634 mml-mir-548h; +MI0023635 mml-mir-3577; +MI0023636 mml-mir-3167; +MI0023637 mml-mir-7165; +MI0023638 mml-mir-1180; +MI0023639 mml-mir-7166; +MI0023640 mml-mir-7167; +MI0023641 mml-mir-7168; +MI0023642 mml-mir-7169; +MI0023643 mml-mir-7170; +MI0023644 mml-mir-7171; +MI0023645 mml-mir-4703; +MI0023646 mml-mir-133d; +MI0023647 mml-mir-7172; +MI0023648 mml-mir-7173; +MI0023649 mml-mir-7174; +MI0023650 mml-mir-6790; +MI0023651 mml-mir-7175; +MI0023652 mml-mir-7176; +MI0023653 mml-mir-6794; +MI0023654 mml-mir-518d-2; +MI0023655 mml-mir-518g; +MI0023656 mml-mir-518a-2; +MI0023658 mml-mir-7177; +MI0023659 mml-mir-7178; +MI0023660 mml-mir-7179; +MI0023661 mml-mir-7180; +MI0023662 mml-mir-4677; +MI0023663 mml-mir-7181; +MI0023664 mml-mir-7182; +MI0023665 mml-mir-6827; +MI0023666 mml-mir-6529; +MI0023667 mml-mir-3938; +MI0023668 mml-mir-7183; +MI0023669 mml-mir-7184; +MI0023670 mml-mir-548i; +MI0023671 mml-mir-7185; +MI0023672 mml-mir-676-2; +MI0023673 mml-mir-7186; +MI0023674 mml-mir-7187; +MI0023675 mml-mir-7188; +MI0023676 mml-mir-548j; +MI0023677 mml-mir-769; +MI0023678 mml-mir-7189; +MI0023679 mml-mir-7190; +MI0023680 mml-mir-7191; +MI0023681 mml-mir-7192; +MI0023682 mml-mir-549b; +MI0023683 mml-mir-7193; +MI0023684 mml-mir-7194; +MI0023685 mml-mir-7195; +MI0023686 mml-mir-7196; +MI0023687 mml-mir-1185-2; +MI0023688 mml-mir-323b; +MI0023689 mml-mir-7197; +MI0023690 mml-mir-1247; +MI0023691 mml-mir-7198; +MI0023692 mml-mir-7199; +MI0023693 mml-mir-7200; +MI0023694 mml-mir-7201; +MI0023695 mml-mir-7202; +MI0023696 mml-mir-7203; +MI0023697 mml-mir-7204; +MI0023698 mml-mir-1911; +MI0023699 mml-mir-7205; +MI0023700 mml-mir-7206; +MI0023701 mml-mir-7207; +MI0023702 mml-mir-7208; +MI0023703 mml-mir-892c; +MI0023705 mmu-mir-7210; +MI0023706 mmu-mir-7211; +MI0023707 mmu-mir-7212; +MI0023708 mmu-mir-7213; +MI0023709 mmu-mir-7214; +MI0023710 mmu-mir-7215; +MI0023711 mmu-mir-7216; +MI0023712 mmu-mir-7217; +MI0023713 mmu-mir-7218; +MI0023714 mmu-mir-7219; +MI0023715 mmu-mir-7220; +MI0023716 mmu-mir-7221; +MI0023717 mmu-mir-7222; +MI0023718 mmu-mir-7223; +MI0023719 mmu-mir-7224; +MI0023720 mmu-mir-7225; +MI0023721 mmu-mir-7226; +MI0023722 mmu-mir-7227; +MI0023723 mmu-mir-7228; +MI0023724 mmu-mir-7229; +MI0023725 mmu-mir-7230; +MI0023726 mmu-mir-7231; +MI0023727 mmu-mir-7232; +MI0023728 mmu-mir-7233; +MI0023729 mmu-mir-7234; +MI0023730 mmu-mir-7235; +MI0023731 mmu-mir-7236; +MI0023732 mmu-mir-7237; +MI0023733 mmu-mir-7238; +MI0023734 mmu-mir-7239; +MI0023735 mmu-mir-7240; +MI0023736 mmu-mir-7241; +MI0023737 mmu-mir-7242; +MI0023739 mdo-mir-7244; +MI0023740 mdo-mir-7245; +MI0023741 mdo-mir-7246; +MI0023742 mdo-mir-7247; +MI0023743 mdo-mir-7248; +MI0023744 mdo-mir-7249; +MI0023745 mdo-mir-7250; +MI0023746 mdo-mir-7251; +MI0023747 mdo-mir-7252; +MI0023748 mdo-mir-7253; +MI0023749 mdo-mir-7254; +MI0023750 mdo-mir-7255; +MI0023751 mdo-mir-7256; +MI0023752 mdo-mir-181a-2; +MI0023753 mdo-mir-181b-2; +MI0023754 mdo-mir-7257; +MI0023755 mdo-mir-7258; +MI0023756 mdo-mir-7259; +MI0023757 mdo-mir-7260; +MI0023758 mdo-mir-7261; +MI0023759 mdo-mir-29a-2; +MI0023760 mdo-mir-29b-2; +MI0023761 mdo-mir-7262a; +MI0023762 mdo-mir-9a-3; +MI0023763 mdo-mir-7263; +MI0023764 mdo-mir-196a; +MI0023765 mdo-mir-7264; +MI0023766 mdo-mir-7265; +MI0023767 mdo-mir-7266; +MI0023768 mdo-mir-30c-1; +MI0023769 mdo-mir-7267; +MI0023770 mdo-mir-7268; +MI0023771 mdo-mir-7269; +MI0023772 mdo-mir-7270; +MI0023773 mdo-mir-7271; +MI0023774 mdo-mir-130c-1; +MI0023775 mdo-mir-7272; +MI0023776 mdo-mir-92b; +MI0023777 mdo-mir-7273; +MI0023778 mdo-mir-7274; +MI0023779 mdo-mir-7275; +MI0023780 mdo-mir-7276; +MI0023781 mdo-mir-7277; +MI0023782 mdo-mir-7278; +MI0023783 mdo-mir-219-2; +MI0023784 mdo-mir-7279; +MI0023785 mdo-mir-7280; +MI0023786 mdo-mir-7281; +MI0023787 mdo-mir-7282; +MI0023788 mdo-mir-7283; +MI0023789 mdo-mir-7284; +MI0023790 mdo-mir-7262b; +MI0023791 mdo-mir-199b-2; +MI0023792 mdo-mir-7285; +MI0023793 mdo-mir-7286; +MI0023794 mdo-mir-30b; +MI0023795 mdo-mir-137b; +MI0023796 mdo-mir-181b-3; +MI0023797 mdo-mir-9b; +MI0023798 mdo-mir-7287; +MI0023799 mdo-mir-7288; +MI0023800 mdo-mir-7289; +MI0023801 mdo-mir-7290; +MI0023802 mdo-mir-130b; +MI0023803 mdo-mir-130c-2; +MI0023804 mdo-mir-7291; +MI0023805 mdo-mir-7292; +MI0023806 mdo-mir-7293; +MI0023807 mdo-mir-199b-3; +MI0023808 mdo-mir-7294; +MI0023809 mdo-mir-7295; +MI0023810 mdo-mir-7296; +MI0023811 mdo-mir-7297; +MI0023812 mdo-mir-449c; +MI0023813 mdo-mir-449b; +MI0023814 mdo-mir-7298; +MI0023815 mdo-mir-34c; +MI0023816 mdo-mir-34b; +MI0023817 mdo-mir-7299; +MI0023818 mdo-mir-7300; +MI0023820 mdo-mir-1643a; +MI0023821 mdo-mir-7302; +MI0023822 mdo-mir-1643b; +MI0023823 mdo-mir-7303; +MI0023824 mdo-mir-7304; +MI0023825 mdo-mir-7305; +MI0023826 mdo-mir-7306; +MI0023827 mdo-mir-128b; +MI0023828 mdo-mir-7307; +MI0023829 mdo-mir-208b; +MI0023830 mdo-mir-7308; +MI0023831 mdo-mir-7309; +MI0023832 mdo-mir-7310; +MI0023833 mdo-mir-7311; +MI0023834 mdo-mir-30d; +MI0023835 mdo-mir-30c-2; +MI0023836 mdo-mir-7312; +MI0023837 mdo-mir-7313; +MI0023838 mdo-mir-7314; +MI0023839 mdo-mir-7315; +MI0023840 mdo-mir-7316; +MI0023841 mdo-mir-7317; +MI0023842 mdo-mir-7318; +MI0023843 mdo-mir-7319; +MI0023844 mdo-mir-7320; +MI0023845 mdo-mir-7321; +MI0023846 mdo-mir-7322; +MI0023847 mdo-mir-7323; +MI0023848 mdo-mir-7324; +MI0023849 mdo-mir-7325; +MI0023850 mdo-mir-193b; +MI0023851 mdo-mir-7326; +MI0023852 mdo-mir-7327; +MI0023853 mdo-mir-7328; +MI0023854 mdo-mir-7329; +MI0023855 mdo-mir-505; +MI0023856 mdo-mir-873; +MI0023857 mdo-mir-7330; +MI0023858 mdo-mir-7331-1; +MI0023859 mdo-mir-7331-2; +MI0023860 mdo-mir-218-2; +MI0023861 mdo-mir-2970; +MI0023862 mdo-mir-7332; +MI0023863 mdo-mir-7333; +MI0023864 mdo-mir-7334; +MI0023865 mdo-mir-7335; +MI0023866 mdo-mir-7336; +MI0023867 mdo-mir-7337; +MI0023868 mdo-mir-7338; +MI0023869 mdo-mir-7339; +MI0023870 mdo-mir-7340; +MI0023871 mdo-mir-1805; +MI0023872 mdo-mir-7341; +MI0023873 mdo-mir-7342; +MI0023874 mdo-mir-7343; +MI0023875 mdo-mir-16-2; +MI0023876 mdo-mir-7344; +MI0023877 mdo-mir-1251; +MI0023878 mdo-mir-7345-1; +MI0023879 mdo-mir-7345-2; +MI0023880 mdo-mir-7346; +MI0023881 mdo-mir-7347; +MI0023882 mdo-mir-7348; +MI0023883 mdo-mir-7349; +MI0023884 mdo-mir-7350; +MI0023885 mdo-mir-7351; +MI0023886 mdo-mir-7352; +MI0023887 mdo-mir-7353; +MI0023888 mdo-mir-7354; +MI0023889 mdo-mir-7355; +MI0023890 mdo-mir-7356; +MI0023891 mdo-mir-7357; +MI0023892 mdo-mir-7358; +MI0023893 mdo-mir-7359a-1; +MI0023894 mdo-mir-7359a-2; +MI0023895 mdo-mir-7359a-3; +MI0023896 mdo-mir-7359a-4; +MI0023897 mdo-mir-7359a-5; +MI0023898 mdo-mir-7360-1; +MI0023899 mdo-mir-7360-2; +MI0023900 mdo-mir-7360-3; +MI0023901 mdo-mir-7360-4; +MI0023902 mdo-mir-7360-5; +MI0023903 mdo-mir-7360-6; +MI0023904 mdo-mir-7360-7; +MI0023905 mdo-mir-7360-8; +MI0023906 mdo-mir-7359b-1; +MI0023907 mdo-mir-7359b-2; +MI0023908 mdo-mir-7359b-3; +MI0023909 mdo-mir-7359b-4; +MI0023910 mdo-mir-7360-9; +MI0023911 mdo-mir-7361; +MI0023912 mdo-mir-7362; +MI0023913 mdo-mir-7363; +MI0023914 mdo-mir-7364; +MI0023915 mdo-mir-7365; +MI0023916 mdo-mir-1544b; +MI0023917 mdo-mir-1544c-1; +MI0023918 mdo-mir-1544c-2; +MI0023919 mdo-mir-1544c-3; +MI0023920 mdo-mir-1544c-4; +MI0023921 mdo-mir-1544c-5; +MI0023922 mdo-mir-1544c-6; +MI0023923 mdo-mir-1544e-1; +MI0023924 mdo-mir-1544e-2; +MI0023925 mdo-mir-7366; +MI0023926 mdo-mir-1545b-1; +MI0023927 mdo-mir-1545b-2; +MI0023928 mdo-mir-1544e-3; +MI0023929 mdo-mir-1545b-3; +MI0023930 mdo-mir-1545c; +MI0023931 mdo-mir-1544d; +MI0023932 mdo-mir-7367; +MI0023933 mdo-mir-7368; +MI0023934 mdo-mir-7369; +MI0023935 mdo-mir-7370; +MI0023936 mdo-mir-92a-2; +MI0023937 mdo-mir-19b-2; +MI0023938 mdo-mir-20b; +MI0023939 mdo-mir-18b; +MI0023940 mdo-mir-15c; +MI0023941 mdo-mir-7370i; +MI0023942 mdo-mir-7371a; +MI0023943 mdo-mir-7371b-1; +MI0023944 mdo-mir-7372; +MI0023945 mdo-mir-7371c; +MI0023946 mdo-mir-7371d; +MI0023947 mdo-mir-7371e; +MI0023948 mdo-mir-7371f; +MI0023949 mdo-mir-7371g; +MI0023950 mdo-mir-7371h; +MI0023951 mdo-mir-7371b-2; +MI0023952 mdo-mir-7371j; +MI0023953 mdo-mir-7373a-1; +MI0023954 mdo-mir-7373a-2; +MI0023955 mdo-mir-7374a; +MI0023956 mdo-mir-7375; +MI0023957 mdo-mir-7374c; +MI0023958 mdo-mir-7374b; +MI0023959 mdo-mir-7373b; +MI0023960 mdo-mir-7373c; +MI0023961 mdo-mir-7373d; +MI0023962 mdo-mir-7376; +MI0023963 mdo-mir-7377; +MI0023964 mdo-mir-7378; +MI0023965 mdo-mir-7379; +MI0023966 mdo-mir-7380; +MI0023967 mdo-mir-7381; +MI0023968 mdo-mir-7382; +MI0023969 mdo-mir-7383-1; +MI0023970 mdo-mir-7383-2; +MI0023971 mdo-mir-7383-3; +MI0023972 mdo-mir-7383-4; +MI0023973 mdo-mir-7383-5; +MI0023974 mdo-mir-7384; +MI0023975 mdo-mir-7385a; +MI0023976 mdo-mir-7385b; +MI0023977 mdo-mir-7385c; +MI0023978 mdo-mir-7385d; +MI0023979 mdo-mir-7386a-1; +MI0023980 mdo-mir-7386a-2; +MI0023981 mdo-mir-7386a-3; +MI0023982 mdo-mir-7386b; +MI0023983 mdo-mir-7387; +MI0023984 mdo-mir-7386h; +MI0023985 mdo-mir-7386c; +MI0023986 mdo-mir-7386i; +MI0023987 mdo-mir-7386j; +MI0023988 mdo-mir-7386k; +MI0023989 mdo-mir-7386d; +MI0023990 mdo-mir-7386e; +MI0023991 mdo-mir-7386l; +MI0023992 mdo-mir-7386f; +MI0023993 mdo-mir-7385e; +MI0023994 mdo-mir-7386g; +MI0023995 mdo-mir-7386m; +MI0023996 mdo-mir-7386n; +MI0023997 mdo-mir-7386o; +MI0023998 mdo-mir-7388a; +MI0023999 mdo-mir-133a-2; +MI0024000 mdo-mir-7389; +MI0024001 mdo-mir-7388b; +MI0024002 mdo-mir-7388c; +MI0024003 mdo-mir-7390; +MI0024004 mdo-mir-7385f; +MI0024005 mdo-mir-7391; +MI0024006 mdo-mir-1-2; +MI0024007 mdo-mir-7392-1; +MI0024008 mdo-mir-7392-2; +MI0024009 mdo-mir-7393; +MI0024010 mdo-mir-7394a; +MI0024011 mdo-mir-7395; +MI0024012 mdo-mir-7396; +MI0024013 mdo-mir-7397; +MI0024014 mdo-mir-7394b; +MI0024015 mdo-mir-7398e; +MI0024016 mdo-mir-7398f; +MI0024017 mdo-mir-7398a-1; +MI0024018 mdo-mir-7398r; +MI0024019 mdo-mir-7398n; +MI0024020 mdo-mir-7398k-1; +MI0024021 mdo-mir-7398k-2; +MI0024022 mdo-mir-7398o; +MI0024023 mdo-mir-7398l; +MI0024024 mdo-mir-7398m; +MI0024025 mdo-mir-7398c; +MI0024026 mdo-mir-7398b; +MI0024027 mdo-mir-7398a-2; +MI0024028 mdo-mir-7398a-3; +MI0024029 mdo-mir-7398a-4; +MI0024030 mdo-mir-7398a-5; +MI0024031 mdo-mir-7398p; +MI0024032 mdo-mir-7398q; +MI0024033 mdo-mir-7398d; +MI0024034 mdo-mir-7398s; +MI0024035 mdo-mir-7398u; +MI0024036 mdo-mir-7398j; +MI0024037 mdo-mir-7398g; +MI0024038 mdo-mir-7398h; +MI0024039 mdo-mir-7398t; +MI0024040 mdo-mir-7398i; +MI0024041 mdo-mir-1540b; +MI0024042 mdo-mir-7399; +MI0024043 oan-mir-7400; +MI0024044 oan-mir-7401; +MI0024045 oan-mir-7402; +MI0024046 oan-mir-7403; +MI0024047 oan-mir-133a-2; +MI0024048 oan-mir-7404-1; +MI0024049 oan-mir-7404-2; +MI0024050 oan-mir-7405; +MI0024051 oan-mir-7406; +MI0024052 oan-mir-2985; +MI0024053 oan-let-7c-1; +MI0024054 oan-let-7c-2; +MI0024055 oan-mir-7407-1; +MI0024056 oan-mir-7407-2; +MI0024057 oan-mir-7408; +MI0024058 oan-mir-7409; +MI0024059 oan-mir-7410; +MI0024060 oan-mir-7411; +MI0024061 oan-mir-7412; +MI0024062 oan-mir-1421an; +MI0024063 oan-mir-135b-2; +MI0024064 oan-mir-7413; +MI0024065 oan-mir-7414; +MI0024066 oan-mir-7415; +MI0024067 oan-mir-181b-2; +MI0024068 oan-mir-181a-2; +MI0024069 oan-mir-365-2; +MI0024070 oan-mir-7416; +MI0024071 oan-mir-222b-2; +MI0024072 oan-mir-181a-3; +MI0024073 oan-mir-7417; +MI0024074 oan-mir-24-2; +MI0024075 oan-mir-7418; +MI0024076 oan-mir-124a-2; +MI0024077 oan-mir-7419; +MI0024078 oan-mir-34b; +MI0024079 oan-mir-7420; +MI0024080 oan-mir-26-2; +MI0024081 oan-mir-7421; +MI0024082 oan-mir-7422a; +MI0024083 oan-mir-7423; +MI0024084 oan-mir-7424; +MI0024085 oan-mir-7425; +MI0024086 oan-mir-153-2; +MI0024087 oan-mir-7426; +MI0024088 oan-mir-19b-2; +MI0024089 oan-mir-7427; +MI0024090 oan-mir-7428; +MI0024091 oan-mir-7429; +MI0024092 oan-mir-7430; +MI0024093 oan-mir-30c-1; +MI0024094 oan-mir-7431; +MI0024095 oan-mir-7432; +MI0024096 oan-mir-7433; +MI0024097 oan-mir-7434; +MI0024098 oan-mir-216b; +MI0024099 oan-mir-7422b; +MI0024100 oan-mir-7435; +MI0024101 oan-mir-7436; +MI0024103 gga-mir-7437; +MI0024104 gga-mir-7438; +MI0024105 gga-mir-7439; +MI0024106 gga-mir-7440; +MI0024107 gga-mir-7441; +MI0024108 gga-mir-7442; +MI0024109 gga-mir-7443; +MI0024110 gga-mir-7444; +MI0024111 gga-mir-7445-1; +MI0024113 gga-mir-7446; +MI0024114 gga-mir-7447; +MI0024115 gga-mir-7448; +MI0024116 gga-mir-7445-2; +MI0024117 gga-mir-7449; +MI0024118 gga-mir-7450; +MI0024121 gga-mir-7451; +MI0024122 gga-mir-7452; +MI0024123 gga-mir-7453; +MI0024124 gga-mir-7454; +MI0024125 gga-mir-7455; +MI0024126 gga-mir-7456; +MI0024127 gga-mir-7457; +MI0024128 gga-mir-7458;gga-mir-7458-1; +MI0024129 gga-mir-7459; +MI0024130 gga-mir-7460; +MI0024131 gga-mir-7461; +MI0024135 gga-mir-7462; +MI0024136 gga-mir-7463; +MI0024137 gga-mir-7464; +MI0024138 gga-mir-7465; +MI0024139 gga-mir-7466; +MI0024140 gga-mir-7467; +MI0024141 gga-mir-7468; +MI0024142 gga-mir-7469; +MI0024143 gga-mir-7470; +MI0024144 gga-mir-7471; +MI0024145 gga-mir-7472; +MI0024146 gga-mir-7473; +MI0024147 gga-mir-7474; +MI0024148 gga-mir-7475; +MI0024149 gga-mir-7476; +MI0024150 gga-mir-7477; +MI0024151 gga-mir-7478; +MI0024156 gga-mir-7479-1; +MI0024157 gga-mir-7479-2; +MI0024158 gga-mir-7479-3; +MI0024159 gga-mir-7480-1; +MI0024160 gga-mir-7480-2; +MI0024161 gga-mir-7481; +MI0024162 gga-mir-7482;gga-mir-7482-1; +MI0024163 gga-mir-7483; +MI0024164 hcmv-mir-UL59; +MI0024165 hcmv-mir-UL69; +MI0024166 ghr-MIR7484a; +MI0024167 ghr-MIR7484b; +MI0024168 ghr-MIR7485; +MI0024169 ghr-MIR7486a; +MI0024170 ghr-MIR7486b; +MI0024171 ghr-MIR7487; +MI0024172 ghr-MIR7488; +MI0024173 ghr-MIR7489; +MI0024174 ghr-MIR7490; +MI0024175 ghr-MIR7491; +MI0024176 ghr-MIR7492a; +MI0024177 ghr-MIR7492b; +MI0024178 ghr-MIR7492c; +MI0024179 ghr-MIR160; +MI0024180 ghr-MIR7493; +MI0024181 ghr-MIR7494; +MI0024182 ghr-MIR7495a; +MI0024183 ghr-MIR7495b; +MI0024184 ghr-MIR7496a; +MI0024185 ghr-MIR7496b; +MI0024186 ghr-MIR7497; +MI0024187 ghr-MIR7498; +MI0024188 ghr-MIR7499; +MI0024189 ghr-MIR7500; +MI0024190 ghr-MIR7501; +MI0024191 ghr-MIR7502; +MI0024192 ghr-MIR7503; +MI0024193 ghr-MIR7504a; +MI0024194 ghr-MIR7505; +MI0024195 ghr-MIR7506; +MI0024196 ghr-MIR7507; +MI0024197 ghr-MIR7508; +MI0024198 ghr-MIR7509; +MI0024199 ghr-MIR169b; +MI0024200 ghr-MIR7510a; +MI0024201 ghr-MIR7504b; +MI0024202 ghr-MIR7511; +MI0024203 ghr-MIR7512; +MI0024204 ghr-MIR7513; +MI0024205 ghr-MIR7510b; +MI0024206 ghr-MIR7514; +MI0024207 mes-MIR156a; +MI0024208 mes-MIR156b; +MI0024209 mes-MIR156c; +MI0024210 mes-MIR156d; +MI0024211 mes-MIR156e; +MI0024212 mes-MIR156f; +MI0024213 mes-MIR156g; +MI0024214 mes-MIR156h; +MI0024215 mes-MIR156i; +MI0024216 mes-MIR156j; +MI0024217 mes-MIR156k; +MI0024218 mes-MIR159b; +MI0024219 mes-MIR159c; +MI0024220 mes-MIR159d; +MI0024221 mes-MIR160a; +MI0024222 mes-MIR160b; +MI0024223 mes-MIR160c; +MI0024224 mes-MIR160d; +MI0024225 mes-MIR160e; +MI0024226 mes-MIR160f; +MI0024227 mes-MIR160g; +MI0024228 mes-MIR160h; +MI0024229 mes-MIR162; +MI0024230 mes-MIR164a; +MI0024231 mes-MIR164b; +MI0024232 mes-MIR164c; +MI0024233 mes-MIR164d; +MI0024234 mes-MIR166a; +MI0024235 mes-MIR166b; +MI0024236 mes-MIR166c; +MI0024237 mes-MIR166d; +MI0024238 mes-MIR166e; +MI0024239 mes-MIR166f; +MI0024240 mes-MIR166g; +MI0024241 mes-MIR166h; +MI0024242 mes-MIR166i; +MI0024243 mes-MIR166j; +MI0024244 mes-MIR167b; +MI0024245 mes-MIR167c; +MI0024246 mes-MIR167d; +MI0024247 mes-MIR167e; +MI0024248 mes-MIR167f; +MI0024249 mes-MIR167g; +MI0024250 mes-MIR167h; +MI0024251 mes-MIR169a; +MI0024252 mes-MIR169b; +MI0024253 mes-MIR169c; +MI0024254 mes-MIR169d; +MI0024255 mes-MIR169e; +MI0024256 mes-MIR169f; +MI0024257 mes-MIR169g; +MI0024258 mes-MIR169h; +MI0024259 mes-MIR169i; +MI0024260 mes-MIR169j; +MI0024261 mes-MIR169k; +MI0024262 mes-MIR169l; +MI0024263 mes-MIR169m; +MI0024264 mes-MIR169n; +MI0024265 mes-MIR169o; +MI0024266 mes-MIR169p; +MI0024267 mes-MIR169q; +MI0024268 mes-MIR169r; +MI0024269 mes-MIR169s; +MI0024270 mes-MIR169t; +MI0024271 mes-MIR169u; +MI0024272 mes-MIR169v; +MI0024273 mes-MIR169w; +MI0024274 mes-MIR169x; +MI0024275 mes-MIR169y; +MI0024276 mes-MIR169z; +MI0024277 mes-MIR169aa; +MI0024278 mes-MIR169ab; +MI0024279 mes-MIR169ac; +MI0024280 mes-MIR171b; +MI0024281 mes-MIR171c; +MI0024282 mes-MIR171d; +MI0024283 mes-MIR171e; +MI0024284 mes-MIR171f; +MI0024285 mes-MIR171g; +MI0024286 mes-MIR171h; +MI0024287 mes-MIR171i; +MI0024288 mes-MIR171j; +MI0024289 mes-MIR171k; +MI0024290 mes-MIR172b; +MI0024291 mes-MIR172c; +MI0024292 mes-MIR172d; +MI0024293 mes-MIR172e; +MI0024294 mes-MIR172f; +MI0024295 mes-MIR319a; +MI0024296 mes-MIR319b; +MI0024297 mes-MIR319c; +MI0024298 mes-MIR319d; +MI0024299 mes-MIR319e; +MI0024300 mes-MIR319f; +MI0024301 mes-MIR319g; +MI0024302 mes-MIR319h; +MI0024303 mes-MIR390; +MI0024304 mes-MIR393a; +MI0024305 mes-MIR393b; +MI0024306 mes-MIR393c; +MI0024307 mes-MIR393d; +MI0024308 mes-MIR394b; +MI0024309 mes-MIR394c; +MI0024310 mes-MIR395a; +MI0024311 mes-MIR395b; +MI0024312 mes-MIR395c; +MI0024313 mes-MIR395d; +MI0024314 mes-MIR395e; +MI0024315 mes-MIR396a; +MI0024316 mes-MIR396b; +MI0024317 mes-MIR396c; +MI0024318 mes-MIR396d; +MI0024319 mes-MIR396e; +MI0024320 mes-MIR396f; +MI0024321 mes-MIR397; +MI0024322 mes-MIR399b; +MI0024323 mes-MIR399c; +MI0024324 mes-MIR399d; +MI0024325 mes-MIR399e; +MI0024326 mes-MIR399f; +MI0024327 mes-MIR399g; +MI0024328 mes-MIR403a; +MI0024329 mes-MIR403b; +MI0024330 mes-MIR477h; +MI0024331 mes-MIR477i; +MI0024332 mes-MIR477a; +MI0024333 mes-MIR477b; +MI0024334 mes-MIR477c; +MI0024335 mes-MIR477d; +MI0024336 mes-MIR477e; +MI0024337 mes-MIR477f; +MI0024338 mes-MIR477g; +MI0024339 mes-MIR482; +MI0024340 mes-MIR530a; +MI0024341 mes-MIR530b; +MI0024342 mes-MIR535a; +MI0024343 mes-MIR535b; +MI0024344 mes-MIR827; +MI0024345 mes-MIR828a; +MI0024346 mes-MIR828b; +MI0024347 mes-MIR1446; +MI0024348 mes-MIR2111a; +MI0024349 mes-MIR2111b; +MI0024350 mes-MIR2275; +MI0024351 mes-MIR2950; +MI0024352 sly-MIR168a; +MI0024353 sly-MIR168b; +MI0024354 hsa-mir-7515; +MI0024355 aja-mir-1893; +MI0024356 aja-mir-3596; +MI0024357 aja-mir-29b; +MI0024358 aja-mir-142; +MI0024359 aja-mir-144; +MI0024360 aja-mir-145; +MI0024361 aja-mir-671; +MI0024362 aja-mir-21; +MI0024363 aja-mir-22; +MI0024364 aja-mir-25; +MI0024365 aja-mir-7; +MI0024366 aja-mir-214; +MI0024367 aja-mir-3074; +MI0024368 aja-mir-3120; +MI0024369 aja-mir-143; +MI0024370 aja-mir-3618; +MI0024371 aja-mir-29c; +MI0024372 aja-mir-331; +MI0024373 aja-let-7i; +MI0024374 lja-MIR167a; +MI0024375 lja-MIR167b; +MI0024376 lja-MIR167c; +MI0024377 lja-MIR171a; +MI0024378 lja-MIR171b; +MI0024379 lja-MIR171c; +MI0024380 lja-MIR171d; +MI0024381 lja-MIR172a; +MI0024382 lja-MIR172b; +MI0024383 lja-MIR172c; +MI0024384 lja-MIR390a; +MI0024385 lja-MIR390b; +MI0024386 lja-MIR397; +MI0024387 lja-MIR408; +MI0024388 lja-MIR7516; +MI0024389 lja-MIR1507a; +MI0024390 lja-MIR1507b; +MI0024391 lja-MIR7517; +MI0024392 lja-MIR7518; +MI0024393 lja-MIR7519; +MI0024394 lja-MIR7520; +MI0024395 lja-MIR7521; +MI0024396 lja-MIR7522; +MI0024397 lja-MIR7523a; +MI0024398 lja-MIR7523b; +MI0024399 lja-MIR7524; +MI0024400 lja-MIR7525; +MI0024401 lja-MIR7526a; +MI0024402 lja-MIR7526b; +MI0024403 lja-MIR7526c; +MI0024404 lja-MIR7526d; +MI0024405 lja-MIR7526e; +MI0024406 lja-MIR7526f; +MI0024407 lja-MIR7526g; +MI0024408 lja-MIR7526h; +MI0024409 lja-MIR7527; +MI0024410 lja-MIR7528; +MI0024411 lja-MIR7529; +MI0024412 lja-MIR7530; +MI0024413 lja-MIR7531; +MI0024414 lja-MIR7532a; +MI0024415 lja-MIR7532b; +MI0024416 lja-MIR7533a; +MI0024417 lja-MIR7533b; +MI0024418 lja-MIR7534; +MI0024419 lja-MIR7535; +MI0024420 lja-MIR7536a; +MI0024421 lja-MIR7536b; +MI0024422 lja-MIR7537; +MI0024423 lja-MIR7538; +MI0024424 lja-MIR7539; +MI0024425 lja-MIR7540a; +MI0024426 lja-MIR7540b; +MI0024427 lja-MIR7541; +MI0024428 lja-MIR7542; +MI0024429 lja-MIR7543; +MI0024430 lja-MIR7544; +MI0024431 lja-MIR7545; +MI0024432 lja-MIR7546; +MI0024433 ipu-let-7a-7; +MI0024434 ipu-let-7a-1; +MI0024435 ipu-let-7a-3; +MI0024436 ipu-let-7a-5; +MI0024437 ipu-let-7a-6; +MI0024438 ipu-let-7a-4; +MI0024439 ipu-let-7a-2; +MI0024440 ipu-let-7b-2; +MI0024441 ipu-let-7b-1; +MI0024442 ipu-let-7c-1; +MI0024443 ipu-let-7c-2; +MI0024444 ipu-let-7d-2; +MI0024445 ipu-let-7d-1; +MI0024446 ipu-let-7e-2; +MI0024447 ipu-let-7e-1; +MI0024448 ipu-let-7f; +MI0024449 ipu-let-7g-1; +MI0024450 ipu-let-7g-2; +MI0024451 ipu-let-7h; +MI0024452 ipu-let-7i; +MI0024453 ipu-let-7j-1; +MI0024454 ipu-let-7j-2; +MI0024455 ipu-mir-1-1; +MI0024456 ipu-mir-100-1; +MI0024457 ipu-mir-100-2; +MI0024458 ipu-mir-101a; +MI0024459 ipu-mir-101b; +MI0024460 ipu-mir-103-1; +MI0024461 ipu-mir-103-2; +MI0024462 ipu-mir-107a; +MI0024463 ipu-mir-107b; +MI0024464 ipu-mir-10a; +MI0024465 ipu-mir-10b-1; +MI0024466 ipu-mir-10b-2; +MI0024467 ipu-mir-10c; +MI0024468 ipu-mir-10d; +MI0024469 ipu-mir-122; +MI0024470 ipu-mir-124a-5; +MI0024471 ipu-mir-124a-4; +MI0024472 ipu-mir-124a-2; +MI0024473 ipu-mir-124a-1; +MI0024474 ipu-mir-124a-3; +MI0024475 ipu-mir-125a-2; +MI0024476 ipu-mir-125a-1; +MI0024477 ipu-mir-125b-1; +MI0024478 ipu-mir-125b-2; +MI0024479 ipu-mir-125b-3; +MI0024480 ipu-mir-125c; +MI0024481 ipu-mir-126a; +MI0024482 ipu-mir-126b; +MI0024483 ipu-mir-128-2; +MI0024484 ipu-mir-128-1; +MI0024485 ipu-mir-129-1; +MI0024486 ipu-mir-129-3; +MI0024487 ipu-mir-129-4; +MI0024488 ipu-mir-129-2; +MI0024489 ipu-mir-130c-1; +MI0024490 ipu-mir-130c-2; +MI0024491 ipu-mir-132a; +MI0024492 ipu-mir-132b; +MI0024493 ipu-mir-133a; +MI0024494 ipu-mir-133b; +MI0024495 ipu-mir-133c; +MI0024496 ipu-mir-135a; +MI0024497 ipu-mir-135b; +MI0024498 ipu-mir-135c-1; +MI0024499 ipu-mir-135c-2; +MI0024500 ipu-mir-137; +MI0024501 ipu-mir-138-1; +MI0024502 ipu-mir-138-2; +MI0024503 ipu-mir-1388; +MI0024504 ipu-mir-139; +MI0024505 ipu-mir-140; +MI0024506 ipu-mir-141; +MI0024507 ipu-mir-142-1; +MI0024508 ipu-mir-142-2; +MI0024509 ipu-mir-143; +MI0024510 ipu-mir-144; +MI0024511 ipu-mir-145; +MI0024512 ipu-mir-146a; +MI0024513 ipu-mir-146b; +MI0024514 ipu-mir-148; +MI0024515 ipu-mir-150; +MI0024516 ipu-mir-152; +MI0024517 ipu-mir-153b; +MI0024518 ipu-mir-155; +MI0024519 ipu-mir-15a-1; +MI0024520 ipu-mir-15a-2; +MI0024521 ipu-mir-15b; +MI0024522 ipu-mir-16b; +MI0024523 ipu-mir-1788; +MI0024524 ipu-mir-17a; +MI0024525 ipu-mir-17b; +MI0024526 ipu-mir-181a-1; +MI0024527 ipu-mir-181a-2; +MI0024528 ipu-mir-181a-3; +MI0024529 ipu-mir-181a-4; +MI0024530 ipu-mir-181a-5; +MI0024531 ipu-mir-181b-2; +MI0024532 ipu-mir-181b-1; +MI0024533 ipu-mir-181c; +MI0024534 ipu-mir-182; +MI0024535 ipu-mir-183; +MI0024536 ipu-mir-184; +MI0024537 ipu-mir-187; +MI0024538 ipu-mir-18a; +MI0024539 ipu-mir-190a; +MI0024540 ipu-mir-190b; +MI0024541 ipu-mir-192; +MI0024542 ipu-mir-194a; +MI0024543 ipu-mir-196a-1; +MI0024544 ipu-mir-196a-2; +MI0024545 ipu-mir-196d-1; +MI0024546 ipu-mir-196d-2; +MI0024547 ipu-mir-199a-1; +MI0024548 ipu-mir-199a-2; +MI0024549 ipu-mir-199a-4; +MI0024550 ipu-mir-199a-3; +MI0024551 ipu-mir-19a-1; +MI0024552 ipu-mir-19a-2; +MI0024553 ipu-mir-19b; +MI0024554 ipu-mir-200a; +MI0024555 ipu-mir-200b; +MI0024556 ipu-mir-200c; +MI0024557 ipu-mir-202; +MI0024558 ipu-mir-203a; +MI0024559 ipu-mir-203b; +MI0024560 ipu-mir-204-2; +MI0024561 ipu-mir-204-3; +MI0024562 ipu-mir-204-1; +MI0024563 ipu-mir-205; +MI0024564 ipu-mir-206-1; +MI0024565 ipu-mir-206-2; +MI0024566 ipu-mir-20a; +MI0024567 ipu-mir-21-1; +MI0024568 ipu-mir-21-2; +MI0024569 ipu-mir-210; +MI0024570 ipu-mir-212-1; +MI0024571 ipu-mir-212-2; +MI0024572 ipu-mir-214; +MI0024573 ipu-mir-216a; +MI0024574 ipu-mir-216b; +MI0024575 ipu-mir-217; +MI0024576 ipu-mir-2187; +MI0024577 ipu-mir-2188; +MI0024578 ipu-mir-218a-1; +MI0024579 ipu-mir-218a-2; +MI0024580 ipu-mir-218b; +MI0024581 ipu-mir-219a-2; +MI0024582 ipu-mir-219a-1; +MI0024583 ipu-mir-219b; +MI0024584 ipu-mir-221-1; +MI0024585 ipu-mir-221-2; +MI0024586 ipu-mir-221-3; +MI0024587 ipu-mir-222a; +MI0024588 ipu-mir-223; +MI0024589 ipu-mir-22a; +MI0024590 ipu-mir-22b; +MI0024591 ipu-mir-23a-2; +MI0024592 ipu-mir-23a-3; +MI0024593 ipu-mir-23a-1; +MI0024594 ipu-mir-23b-2; +MI0024595 ipu-mir-23b-1; +MI0024596 ipu-mir-24-2; +MI0024597 ipu-mir-24-1; +MI0024598 ipu-mir-24-3; +MI0024599 ipu-mir-25; +MI0024600 ipu-mir-26a-2; +MI0024601 ipu-mir-26a-3; +MI0024602 ipu-mir-26a-1; +MI0024603 ipu-mir-26b; +MI0024604 ipu-mir-27a; +MI0024605 ipu-mir-27b; +MI0024606 ipu-mir-27c; +MI0024607 ipu-mir-27d; +MI0024608 ipu-mir-27e; +MI0024609 ipu-mir-29c; +MI0024610 ipu-mir-29b; +MI0024611 ipu-mir-301a; +MI0024612 ipu-mir-301c; +MI0024613 ipu-mir-30a; +MI0024614 ipu-mir-30b; +MI0024615 ipu-mir-30c; +MI0024616 ipu-mir-30d; +MI0024617 ipu-mir-30e; +MI0024618 ipu-mir-31; +MI0024619 ipu-mir-338-3; +MI0024620 ipu-mir-338-1; +MI0024621 ipu-mir-338-2; +MI0024622 ipu-mir-34a; +MI0024623 ipu-mir-34b; +MI0024624 ipu-mir-34c; +MI0024625 ipu-mir-363; +MI0024626 ipu-mir-365-1; +MI0024627 ipu-mir-365-2; +MI0024628 ipu-mir-375-1; +MI0024629 ipu-mir-375-2; +MI0024630 ipu-mir-429a; +MI0024631 ipu-mir-429b; +MI0024632 ipu-mir-454b; +MI0024633 ipu-mir-455a; +MI0024634 ipu-mir-455b; +MI0024635 ipu-mir-456; +MI0024636 ipu-mir-457a; +MI0024637 ipu-mir-458; +MI0024638 ipu-mir-459; +MI0024639 ipu-mir-460; +MI0024640 ipu-mir-462; +MI0024641 ipu-mir-489; +MI0024642 ipu-mir-499-2; +MI0024643 ipu-mir-499-1; +MI0024644 ipu-mir-724-1; +MI0024645 ipu-mir-724-2; +MI0024646 ipu-mir-728-1; +MI0024647 ipu-mir-728-2; +MI0024648 ipu-mir-730-1; +MI0024649 ipu-mir-730-2; +MI0024650 ipu-mir-737; +MI0024651 ipu-mir-7a-4; +MI0024652 ipu-mir-7a-2; +MI0024653 ipu-mir-7a-1; +MI0024654 ipu-mir-7a-3; +MI0024655 ipu-mir-7a-5; +MI0024656 ipu-mir-7b; +MI0024657 ipu-mir-9-4; +MI0024658 ipu-mir-9-2; +MI0024659 ipu-mir-9-6; +MI0024660 ipu-mir-9-1; +MI0024661 ipu-mir-9-3; +MI0024662 ipu-mir-9-7; +MI0024663 ipu-mir-9-5; +MI0024664 ipu-mir-92a-2; +MI0024665 ipu-mir-92a-1; +MI0024666 ipu-mir-92b; +MI0024667 ipu-mir-96; +MI0024668 ipu-mir-99a; +MI0024669 ipu-mir-99b; +MI0024670 ipu-mir-24b; +MI0024671 ipu-mir-7547; +MI0024672 ipu-mir-7147; +MI0024673 ipu-mir-29a; +MI0024674 ipu-mir-16c; +MI0024675 ipu-mir-199b; +MI0024676 ipu-mir-7548; +MI0024677 ipu-mir-203c; +MI0024678 ipu-mir-551; +MI0024679 ipu-mir-7549; +MI0024680 ipu-mir-129b; +MI0024681 ipu-mir-7550; +MI0024682 ipu-mir-3618; +MI0024683 ipu-mir-7551; +MI0024684 ipu-mir-7552; +MI0024685 ipu-mir-7553; +MI0024686 ipu-mir-7554; +MI0024687 ipu-mir-7555; +MI0024688 ipu-mir-7556; +MI0024689 ipu-mir-7557; +MI0024690 ipu-mir-7558a; +MI0024691 ipu-mir-7559; +MI0024692 ipu-mir-7560; +MI0024693 ipu-mir-7558b; +MI0024694 ipu-mir-7561; +MI0024695 ipu-mir-7562; +MI0024696 ipu-mir-7563a; +MI0024697 ipu-mir-7563b; +MI0024698 ipu-mir-7563c; +MI0024699 ipu-mir-7564; +MI0024700 ipu-mir-7565; +MI0024701 ipu-mir-7566; +MI0024702 ipu-mir-7567; +MI0024703 ipu-mir-7568; +MI0024704 ipu-mir-7569; +MI0024705 ipu-mir-7570; +MI0024706 ipu-mir-7571; +MI0024707 ipu-mir-7572; +MI0024708 ipu-mir-7573; +MI0024709 ipu-mir-7574; +MI0024710 ipu-mir-7575; +MI0024711 ipu-mir-7576; +MI0024712 ipu-mir-7577; +MI0024713 ipu-mir-457b; +MI0024714 mmu-mir-7578; +MI0024715 rno-mir-7578; +MI0024716 cbr-mir-7579; +MI0024717 cbr-mir-7580-1; +MI0024718 cbr-mir-7580-2; +MI0024719 cbr-mir-7581; +MI0024720 cbr-mir-7582; +MI0024721 cbr-mir-7583a; +MI0024722 cbr-mir-7583b; +MI0024723 cbr-mir-7584; +MI0024724 cbr-mir-7585; +MI0024725 cbr-mir-7586; +MI0024726 cbr-mir-7587; +MI0024727 cbr-mir-7583d; +MI0024728 cbr-mir-7588; +MI0024729 cbr-mir-7583c; +MI0024730 cbr-mir-7589; +MI0024731 cbr-mir-7590; +MI0024732 cbr-mir-7591; +MI0024733 cbr-mir-7592; +MI0024734 cbr-mir-7593; +MI0024735 cbr-mir-7594a-1; +MI0024736 cbr-mir-7594a-2; +MI0024737 cbr-mir-7594b-1; +MI0024738 cbr-mir-7594b-2; +MI0024739 cbr-mir-7595; +MI0024740 cbr-mir-64c; +MI0024741 cbr-mir-7596; +MI0024742 cbr-mir-247; +MI0024743 cbr-mir-2; +MI0024744 cbr-mir-124b; +MI0024745 cbr-mir-124c; +MI0024746 cbr-mir-785b; +MI0024747 crm-mir-7579; +MI0024748 crm-mir-1822; +MI0024749 crm-mir-7597; +MI0024750 crm-mir-1817b; +MI0024751 crm-mir-358; +MI0024752 crm-mir-7598; +MI0024753 crm-mir-7599-1; +MI0024754 crm-mir-7599-2; +MI0024755 crm-mir-7599-3; +MI0024756 crm-mir-7600; +MI0024757 crm-mir-7601; +MI0024758 crm-mir-7602; +MI0024759 crm-mir-7603; +MI0024760 crm-mir-7604; +MI0024761 crm-mir-7605; +MI0024762 crm-mir-54; +MI0024763 crm-mir-7606; +MI0024764 crm-mir-7607; +MI0024765 crm-mir-7608; +MI0024766 crm-mir-7609; +MI0024767 crm-mir-7610; +MI0024768 crm-mir-240; +MI0024769 crm-mir-7611; +MI0024770 crm-mir-7582; +MI0024771 crm-mir-392; +MI0024772 crm-mir-7594; +MI0024773 crm-mir-7612; +MI0024774 crm-mir-56; +MI0024775 crm-mir-51;crm-mir-51-1; +MI0024776 crm-mir-58c; +MI0024777 crm-mir-58d; +MI0024778 crm-mir-7613; +MI0024779 crm-mir-2225; +MI0024780 crm-mir-2254; +MI0024781 crm-mir-1824; +MI0024782 crm-mir-251; +MI0024783 crm-mir-124b; +MI0024784 crm-mir-234; +MI0024785 crm-mir-254; +MI0024786 crm-mir-359; +MI0024787 crm-mir-2229a; +MI0024788 crm-mir-2229b; +MI0024789 cbn-mir-7579-1; +MI0024790 cbn-mir-7579-2; +MI0024791 cbn-mir-1822-1; +MI0024792 cbn-mir-1822-2; +MI0024793 cbn-mir-7614; +MI0024794 cbn-mir-7597; +MI0024795 cbn-mir-7615-1; +MI0024796 cbn-mir-7615-2; +MI0024797 cbn-mir-7616-1; +MI0024798 cbn-mir-7616-2; +MI0024799 cbn-mir-7617-1; +MI0024800 cbn-mir-7617-2; +MI0024801 cbn-mir-7618; +MI0024802 cbn-mir-7619; +MI0024803 cbn-mir-7620a; +MI0024804 cbn-mir-7621a; +MI0024805 cbn-mir-7621b; +MI0024806 cbn-mir-7622; +MI0024807 cbn-mir-789b; +MI0024808 cbn-mir-789a; +MI0024809 cbn-mir-7623; +MI0024810 cbn-mir-7624; +MI0024811 cbn-mir-7625; +MI0024812 cbn-mir-7626; +MI0024813 cbn-mir-7627; +MI0024814 cbn-mir-7628; +MI0024815 cbn-mir-7629; +MI0024816 cbn-mir-7630; +MI0024817 cbn-mir-7631; +MI0024818 cbn-mir-230; +MI0024819 cbn-mir-7632; +MI0024820 cbn-mir-7633; +MI0024821 cbn-mir-7634; +MI0024822 cbn-mir-7635; +MI0024823 cbn-mir-356; +MI0024824 cbn-mir-7636; +MI0024825 cbn-mir-84; +MI0024826 cbn-let-7; +MI0024827 cbn-mir-48-1; +MI0024828 cbn-mir-48-2; +MI0024829 cbn-mir-7637-1; +MI0024830 cbn-mir-7637-2; +MI0024831 cbn-mir-241-1; +MI0024832 cbn-mir-241-2; +MI0024833 cbn-mir-52-1; +MI0024834 cbn-mir-52-2; +MI0024835 cbn-mir-54; +MI0024836 cbn-mir-55; +MI0024837 cbn-mir-56; +MI0024838 cbn-mir-51-1; +MI0024839 cbn-mir-51-2; +MI0024840 cbn-mir-80; +MI0024841 cbn-mir-81; +MI0024842 cbn-mir-58a-1; +MI0024843 cbn-mir-58a-2; +MI0024844 cbn-mir-82; +MI0024845 cbn-mir-58b; +MI0024846 cbn-mir-63; +MI0024847 cbn-mir-64m; +MI0024848 cbn-mir-64j-1; +MI0024849 cbn-mir-64f; +MI0024850 cbn-mir-64b-1; +MI0024851 cbn-mir-64h-1; +MI0024852 cbn-mir-64a-1; +MI0024853 cbn-mir-64d-1; +MI0024854 cbn-mir-64e; +MI0024855 cbn-mir-64b-2; +MI0024856 cbn-mir-64c-1; +MI0024857 cbn-mir-64a-2; +MI0024858 cbn-mir-64i-1; +MI0024859 cbn-mir-64g-1; +MI0024860 cbn-mir-64k-1; +MI0024861 cbn-mir-64l; +MI0024862 cbn-mir-64k-2; +MI0024863 cbn-mir-64g-2; +MI0024864 cbn-mir-64i-2; +MI0024865 cbn-mir-64a-3; +MI0024866 cbn-mir-64c-2; +MI0024867 cbn-mir-64a-4; +MI0024868 cbn-mir-64d-2; +MI0024869 cbn-mir-64a-5; +MI0024870 cbn-mir-64h-2; +MI0024871 cbn-mir-64j-2; +MI0024872 cbn-mir-1-1; +MI0024873 cbn-mir-1-2; +MI0024874 cbn-mir-44-1; +MI0024875 cbn-mir-44-2; +MI0024876 cbn-mir-44-3; +MI0024877 cbn-mir-61-1; +MI0024878 cbn-mir-61-2; +MI0024879 cbn-mir-74c; +MI0024880 cbn-mir-72a; +MI0024881 cbn-mir-73a; +MI0024882 cbn-mir-74b; +MI0024883 cbn-mir-72b; +MI0024884 cbn-mir-74a; +MI0024885 cbn-mir-73b; +MI0024886 cbn-mir-74d-1; +MI0024887 cbn-mir-74d-2; +MI0024888 cbn-mir-87-1; +MI0024889 cbn-mir-87-2; +MI0024890 cbn-mir-233; +MI0024891 cbn-mir-2-1; +MI0024892 cbn-mir-2-2; +MI0024893 cbn-mir-43-1; +MI0024894 cbn-mir-43-2; +MI0024895 cbn-mir-250-1; +MI0024896 cbn-mir-250-2; +MI0024897 cbn-mir-238; +MI0024898 cbn-mir-239b; +MI0024899 cbn-mir-239a; +MI0024900 cbn-mir-239c-1; +MI0024901 cbn-mir-239c-2; +MI0024902 cbn-mir-239d-1; +MI0024903 cbn-mir-239d-2; +MI0024904 cbn-mir-50; +MI0024905 cbn-mir-90; +MI0024906 cbn-mir-62; +MI0024907 cbn-lin-4-1; +MI0024908 cbn-lin-4-2; +MI0024909 cbn-mir-237; +MI0024910 cbn-mir-1824a-1; +MI0024911 cbn-mir-1824a-2; +MI0024912 cbn-mir-1824b; +MI0024913 cbn-mir-7638; +MI0024914 cbn-mir-231; +MI0024915 cbn-mir-787; +MI0024916 cbn-mir-251a-1; +MI0024917 cbn-mir-251b-1; +MI0024918 cbn-mir-251b-2; +MI0024919 cbn-mir-357-1; +MI0024920 cbn-mir-357-2; +MI0024921 cbn-mir-46; +MI0024922 cbn-mir-47; +MI0024923 cbn-mir-49; +MI0024924 cbn-mir-83-1; +MI0024925 cbn-mir-83-2; +MI0024926 cbn-mir-75; +MI0024927 cbn-mir-79-1; +MI0024928 cbn-mir-79-2; +MI0024929 cbn-mir-790-1; +MI0024930 cbn-mir-790-2; +MI0024931 cbn-mir-86; +MI0024932 cbn-mir-785; +MI0024933 cbn-mir-124-1; +MI0024934 cbn-mir-124-2; +MI0024935 cbn-mir-228-1; +MI0024936 cbn-mir-228-2; +MI0024937 cbn-mir-7639; +MI0024938 cbn-mir-232; +MI0024939 cbn-mir-234-1; +MI0024940 cbn-mir-234-2; +MI0024941 cbn-mir-235; +MI0024942 cbn-mir-7620b; +MI0024943 cbn-mir-236-1; +MI0024944 cbn-mir-236-2; +MI0024945 cbn-mir-242; +MI0024946 cbn-mir-244; +MI0024947 cbn-mir-245-1; +MI0024948 cbn-mir-245-2; +MI0024949 cbn-mir-7640-1; +MI0024950 cbn-mir-7640-2; +MI0024951 cbn-mir-246-1; +MI0024952 cbn-mir-246-2; +MI0024953 cbn-mir-248; +MI0024954 cbn-mir-249; +MI0024955 cbn-mir-254; +MI0024956 cbn-mir-255-1; +MI0024957 cbn-mir-255-2; +MI0024958 cbn-mir-259; +MI0024959 cbn-mir-34; +MI0024960 cbn-mir-355-1; +MI0024961 cbn-mir-355-2; +MI0024962 cbn-mir-359; +MI0024963 cbn-mir-57-1; +MI0024964 cbn-mir-57-2; +MI0024965 cbn-mir-60-1; +MI0024966 cbn-mir-60-2; +MI0024967 cbn-mir-67; +MI0024968 cbn-mir-70; +MI0024969 cbn-mir-76; +MI0024970 cbn-mir-77; +MI0024971 cbn-mir-784; +MI0024972 cbn-mir-85; +MI0024973 cbn-mir-59-1; +MI0024974 cbn-mir-59-2; +MI0024975 hsa-mir-7641-1; +MI0024976 hsa-mir-7641-2; +MI0024977 hsv1-mir-H27; +MI0024978 sci-mir-7642; +MI0024979 lco-mir-7642; +MI0024980 tgu-mir-7643; +MI0024981 tgu-mir-7644; +MI0024982 tgu-mir-7645; +MI0024983 mmu-mir-6546; +MI0024984 mmu-mir-7646; +MI0024985 mmu-mir-7647; +MI0024986 mmu-mir-7648; +MI0024987 mmu-mir-7649; +MI0024988 mmu-mir-7650; +MI0024989 mmu-mir-7651; +MI0024990 mmu-mir-219b; +MI0024991 mmu-mir-7036b; +MI0024992 mmu-mir-7652; +MI0024993 mmu-mir-7653; +MI0024994 mmu-mir-7654; +MI0024995 mmu-mir-7655; +MI0024996 mmu-mir-7656; +MI0024997 mmu-mir-7657; +MI0024998 mmu-mir-7658; +MI0024999 mmu-mir-7659; +MI0025000 mmu-mir-7660; +MI0025001 mmu-mir-7661; +MI0025002 mmu-mir-7662; +MI0025003 mmu-mir-7663; +MI0025004 mmu-mir-7664; +MI0025005 mmu-mir-7665; +MI0025006 mmu-mir-7666; +MI0025007 mmu-mir-7667; +MI0025008 mmu-mir-7668; +MI0025009 mmu-mir-7669; +MI0025010 mmu-mir-7670; +MI0025011 mmu-mir-7671; +MI0025012 mmu-mir-7672; +MI0025013 mmu-mir-7673; +MI0025014 mmu-mir-3569; +MI0025015 mmu-mir-7674; +MI0025016 mmu-mir-7675; +MI0025017 mmu-mir-7676-1; +MI0025018 mmu-mir-7676-2; +MI0025019 mmu-mir-129b; +MI0025020 mmu-mir-292b; +MI0025021 mmu-mir-1191b; +MI0025022 mmu-mir-7677; +MI0025023 mmu-mir-7678; +MI0025024 mmu-mir-7679; +MI0025025 mmu-mir-7680; +MI0025026 mmu-mir-6715; +MI0025027 mmu-mir-3620; +MI0025028 mmu-mir-465d; +MI0025029 mmu-mir-7681; +MI0025030 mmu-mir-7682; +MI0025031 mmu-mir-7683; +MI0025032 mmu-mir-216c; +MI0025033 mmu-mir-7684; +MI0025034 mmu-mir-219c; +MI0025035 mmu-mir-126b; +MI0025036 mmu-mir-7685; +MI0025037 mmu-mir-7686; +MI0025038 mmu-mir-290b; +MI0025039 mmu-mir-7687; +MI0025040 mmu-mir-1258; +MI0025041 mmu-mir-7688; +MI0025042 mmu-mir-7689; +MI0025043 mmu-mir-7243; +MI0025044 mml-mir-5697; +MI0025045 mdo-mir-7301; +MI0025046 cbr-mir-4813; +MI0025047 cbr-mir-2231; +MI0025048 cbr-mir-35f; +MI0025049 cbr-mir-35g-1; +MI0025050 cbr-mir-35g-2; +MI0025051 cbr-mir-35g-3; +MI0025052 crm-mir-35h; +MI0025053 crm-mir-36; +MI0025054 crm-mir-255; +MI0025055 crm-mir-360; +MI0025056 crm-mir-35i; +MI0025057 cbn-mir-39-1; +MI0025058 cbn-mir-38-1; +MI0025059 cbn-mir-36-1; +MI0025060 cbn-mir-35a; +MI0025061 cbn-mir-35b-1; +MI0025062 cbn-mir-35c-1; +MI0025063 cbn-mir-35d; +MI0025064 cbn-mir-35e; +MI0025065 cbn-mir-35f-1; +MI0025066 cbn-mir-35g; +MI0025067 cbn-mir-35h; +MI0025068 cbn-mir-35i; +MI0025069 cbn-mir-35b-2; +MI0025070 cbn-mir-35j; +MI0025071 cbn-mir-35c-2; +MI0025072 cbn-mir-35k; +MI0025073 cbn-mir-35l; +MI0025074 cbn-mir-35b-3; +MI0025075 cbn-mir-35f-2; +MI0025076 cbn-mir-35b-4; +MI0025077 cbn-mir-35b-5; +MI0025078 cbn-mir-35m; +MI0025079 cbn-mir-35n; +MI0025080 cbn-mir-39-2; +MI0025081 cbn-mir-38-2; +MI0025082 cbn-mir-36-2; +MI0025083 cbn-mir-7690; +MI0025084 cbn-mir-360; +MI0025085 pmi-let-7; +MI0025086 pmi-mir-1; +MI0025087 pmi-mir-7; +MI0025088 pmi-mir-9; +MI0025089 pmi-mir-10; +MI0025090 pmi-mir-22; +MI0025091 pmi-mir-29a; +MI0025092 pmi-mir-29b; +MI0025093 pmi-mir-31-1; +MI0025094 pmi-mir-31-2; +MI0025095 pmi-mir-31-3; +MI0025096 pmi-mir-33; +MI0025097 pmi-mir-34; +MI0025098 pmi-mir-71; +MI0025099 pmi-mir-92a; +MI0025100 pmi-mir-92b; +MI0025101 pmi-mir-92c; +MI0025102 pmi-mir-92d; +MI0025103 pmi-mir-96; +MI0025104 pmi-mir-100; +MI0025105 pmi-mir-124; +MI0025106 pmi-mir-125; +MI0025107 pmi-mir-133; +MI0025108 pmi-mir-137; +MI0025109 pmi-mir-153; +MI0025110 pmi-mir-182;pmi-mir-263; +MI0025111 pmi-mir-184; +MI0025112 pmi-mir-193; +MI0025113 pmi-mir-200; +MI0025114 pmi-mir-210; +MI0025115 pmi-mir-219; +MI0025116 pmi-mir-242; +MI0025117 pmi-mir-252a; +MI0025118 pmi-mir-252b; +MI0025119 pmi-mir-278; +MI0025120 pmi-mir-375; +MI0025121 pmi-mir-981; +MI0025122 pmi-mir-2001; +MI0025123 pmi-mir-2002; +MI0025124 pmi-mir-2004; +MI0025125 pmi-mir-2005; +MI0025126 pmi-mir-2006; +MI0025127 pmi-mir-2007; +MI0025128 pmi-mir-2008; +MI0025129 pmi-mir-2009; +MI0025130 pmi-mir-2010; +MI0025131 pmi-mir-2011; +MI0025132 pmi-mir-2012; +MI0025133 pmi-mir-2013; +MI0025134 lva-let-7; +MI0025135 lva-mir-1; +MI0025136 lva-mir-7; +MI0025137 lva-mir-9; +MI0025138 lva-mir-10; +MI0025139 lva-mir-22; +MI0025140 lva-mir-29a; +MI0025141 lva-mir-29b; +MI0025142 lva-mir-31; +MI0025143 lva-mir-33; +MI0025144 lva-mir-34; +MI0025145 lva-mir-71; +MI0025146 lva-mir-92a; +MI0025147 lva-mir-92b-1; +MI0025148 lva-mir-92b-2; +MI0025149 lva-mir-96; +MI0025150 lva-mir-124; +MI0025151 lva-mir-125; +MI0025152 lva-mir-133; +MI0025153 lva-mir-137; +MI0025154 lva-mir-153; +MI0025155 lva-mir-182; +MI0025156 lva-mir-183; +MI0025157 lva-mir-184; +MI0025158 lva-mir-193; +MI0025159 lva-mir-200; +MI0025160 lva-mir-210; +MI0025161 lva-mir-219; +MI0025162 lva-mir-242; +MI0025163 lva-mir-252a; +MI0025164 lva-mir-252b; +MI0025165 lva-mir-278; +MI0025166 lva-mir-375; +MI0025167 lva-mir-981; +MI0025168 lva-mir-2001; +MI0025169 lva-mir-2002; +MI0025170 lva-mir-2003; +MI0025171 lva-mir-2004; +MI0025172 lva-mir-2005; +MI0025173 lva-mir-2006; +MI0025174 lva-mir-2007; +MI0025175 lva-mir-2008; +MI0025176 lva-mir-2009; +MI0025177 lva-mir-2010; +MI0025178 lva-mir-2011; +MI0025179 lva-mir-2012; +MI0025180 lva-mir-2013; +MI0025181 lva-mir-4847; +MI0025182 lva-mir-4850; +MI0025183 lva-mir-4854; +MI0025184 bta-mir-2285g-2; +MI0025185 bta-mir-2285g-3; +MI0025186 bta-mir-2285af-1; +MI0025187 bta-mir-2285af-2; +MI0025188 bta-mir-2285y; +MI0025189 bta-mir-2285w; +MI0025190 bta-mir-2285x; +MI0025191 bta-mir-6529b; +MI0025192 bta-mir-3613b; +MI0025193 bta-mir-133c; +MI0025194 bta-mir-2285z; +MI0025195 bta-mir-6523b; +MI0025196 bta-mir-7691; +MI0025197 bta-mir-2285u; +MI0025198 osa-MIR1437b; +MI0025199 osa-MIR7692; +MI0025200 osa-MIR7693; +MI0025201 osa-MIR7694; +MI0025202 osa-MIR7695; +MI0025203 mtr-MIR169i; +MI0025204 mtr-MIR2587g; +MI0025205 mtr-MIR2652m; +MI0025206 mtr-MIR2653d; +MI0025207 mtr-MIR2656c; +MI0025208 mtr-MIR2656d; +MI0025209 mtr-MIR2656e; +MI0025210 mtr-MIR2659g; +MI0025211 mtr-MIR2659h; +MI0025212 mtr-MIR2659i; +MI0025213 mtr-MIR2659j; +MI0025214 mtr-MIR2659k; +MI0025215 mtr-MIR2664b; +MI0025216 mtr-MIR2667b; +MI0025217 mtr-MIR2669b; +MI0025218 mtr-MIR172d; +MI0025219 mtr-MIR319c; +MI0025220 mtr-MIR319d; +MI0025221 mtr-MIR397; +MI0025222 mtr-MIR7696a; +MI0025223 mtr-MIR7696b; +MI0025224 mtr-MIR7696c; +MI0025225 mtr-MIR7696d; +MI0025226 mtr-MIR7697; +MI0025227 mtr-MIR7698; +MI0025228 mtr-MIR7699; +MI0025229 mtr-MIR7700; +MI0025230 mtr-MIR169l; +MI0025231 mtr-MIR399s; +MI0025232 mtr-MIR399t; +MI0025233 mtr-MIR2592bo; +MI0025234 mtr-MIR2592bp; +MI0025235 mtr-MIR2592bq; +MI0025236 mtr-MIR2592br; +MI0025237 mtr-MIR7701; +MI0025238 hsa-mir-7702; +MI0025239 hsa-mir-7703; +MI0025240 hsa-mir-7704; +MI0025241 hsa-mir-7705; +MI0025242 hsa-mir-7706; +MI0025243 oar-let-7a; +MI0025244 oar-let-7d; +MI0025245 oar-let-7f; +MI0025246 oar-let-7g; +MI0025247 oar-let-7i; +MI0025248 oar-mir-103; +MI0025249 oar-mir-106b; +MI0025250 oar-mir-107; +MI0025251 oar-mir-10a; +MI0025252 oar-mir-10b; +MI0025253 oar-mir-143; +MI0025254 oar-mir-148a; +MI0025255 oar-mir-150; +MI0025256 oar-mir-152; +MI0025257 oar-mir-16b; +MI0025258 oar-mir-17; +MI0025259 oar-mir-181a-2; +MI0025260 oar-mir-191; +MI0025261 oar-mir-194; +MI0025262 oar-mir-199a; +MI0025263 oar-mir-19b; +MI0025264 oar-mir-200a; +MI0025265 oar-mir-200b; +MI0025266 oar-mir-200c; +MI0025267 oar-mir-218a; +MI0025268 oar-mir-22; +MI0025269 oar-mir-221; +MI0025270 oar-mir-23a; +MI0025271 oar-mir-23b; +MI0025272 oar-mir-25; +MI0025273 oar-mir-26a; +MI0025274 oar-mir-26b; +MI0025275 oar-mir-27a; +MI0025276 oar-mir-29b;oar-mir-29b-1; +MI0025277 oar-mir-30a; +MI0025278 oar-mir-30b; +MI0025279 oar-mir-30c; +MI0025280 oar-mir-30d; +MI0025281 oar-mir-362; +MI0025282 oar-mir-106a; +MI0025283 oar-mir-374a; +MI0025284 oar-mir-374b; +MI0025285 oar-mir-99a; +MI0025286 ama-MIR156; +MI0025287 ama-MIR396; +MI0025288 bdi-MIR397b; +MI0025289 bdi-MIR5174e; +MI0025290 bdi-MIR156e; +MI0025291 bdi-MIR156f; +MI0025292 bdi-MIR156g; +MI0025293 bdi-MIR156h; +MI0025294 bdi-MIR156i; +MI0025295 bdi-MIR159b; +MI0025296 bdi-MIR166h; +MI0025297 bdi-MIR166i; +MI0025298 bdi-MIR167e; +MI0025299 bdi-MIR395o; +MI0025300 bdi-MIR395p; +MI0025301 bdi-MIR5163b; +MI0025302 bdi-MIR5167b; +MI0025303 bdi-MIR5174b; +MI0025304 bdi-MIR5174c; +MI0025305 bdi-MIR5174d; +MI0025306 bdi-MIR5181c; +MI0025307 bdi-MIR5185c; +MI0025308 bdi-MIR5185d; +MI0025309 bdi-MIR5185e; +MI0025310 bdi-MIR5185f; +MI0025311 bdi-MIR5185g; +MI0025312 bdi-MIR5185h; +MI0025313 bdi-MIR5185i; +MI0025314 bdi-MIR5185j; +MI0025315 bdi-MIR5185k; +MI0025316 bdi-MIR5185l; +MI0025317 bdi-MIR5185m; +MI0025318 bdi-MIR7707; +MI0025319 bdi-MIR7708a; +MI0025320 bdi-MIR7709; +MI0025321 bdi-MIR7710; +MI0025322 bdi-MIR7711; +MI0025323 bdi-MIR7712; +MI0025324 bdi-MIR7713; +MI0025325 bdi-MIR7714; +MI0025326 bdi-MIR7715; +MI0025327 bdi-MIR7716; +MI0025328 bdi-MIR7717a; +MI0025329 bdi-MIR7718; +MI0025330 bdi-MIR7719; +MI0025331 bdi-MIR5049; +MI0025332 bdi-MIR7720; +MI0025333 bdi-MIR7721; +MI0025334 bdi-MIR7717b; +MI0025335 bdi-MIR7722; +MI0025336 bdi-MIR7723a; +MI0025337 bdi-MIR7724a; +MI0025338 bdi-MIR7724b; +MI0025339 bdi-MIR7725a; +MI0025340 bdi-MIR7725b; +MI0025341 bdi-MIR7726a; +MI0025342 bdi-MIR7727; +MI0025343 bdi-MIR7728; +MI0025344 bdi-MIR7729a; +MI0025345 bdi-MIR7729b; +MI0025346 bdi-MIR7730; +MI0025347 bdi-MIR7731; +MI0025348 bdi-MIR7732; +MI0025349 bdi-MIR7733; +MI0025350 bdi-MIR7734; +MI0025351 bdi-MIR7717c; +MI0025352 bdi-MIR7735; +MI0025353 bdi-MIR7736; +MI0025354 bdi-MIR7737; +MI0025355 bdi-MIR7738; +MI0025356 bdi-MIR7739; +MI0025357 bdi-MIR7740; +MI0025358 bdi-MIR7726b; +MI0025359 bdi-MIR7741; +MI0025360 bdi-MIR7742; +MI0025361 bdi-MIR7743; +MI0025362 bdi-MIR7744; +MI0025363 bdi-MIR7745; +MI0025364 bdi-MIR7746; +MI0025365 bdi-MIR7747; +MI0025366 bdi-MIR7748a; +MI0025367 bdi-MIR7749; +MI0025368 bdi-MIR7750; +MI0025369 bdi-MIR7751; +MI0025370 bdi-MIR7752; +MI0025371 bdi-MIR7753; +MI0025372 bdi-MIR7748b; +MI0025373 bdi-MIR7754; +MI0025374 bdi-MIR7755; +MI0025375 bdi-MIR7723b; +MI0025376 bdi-MIR7756; +MI0025377 bdi-MIR7757; +MI0025378 bdi-MIR7758; +MI0025379 bdi-MIR7759; +MI0025380 bdi-MIR7760; +MI0025381 bdi-MIR7761; +MI0025382 bdi-MIR7762; +MI0025383 bdi-MIR7763; +MI0025384 bdi-MIR7764; +MI0025385 bdi-MIR7708b; +MI0025386 bdi-MIR7765; +MI0025387 bdi-MIR7766; +MI0025388 bdi-MIR7767; +MI0025389 bdi-MIR7768a; +MI0025390 bdi-MIR7768b; +MI0025391 bdi-MIR7769; +MI0025392 bdi-MIR7770; +MI0025393 bdi-MIR7771; +MI0025394 bdi-MIR7772; +MI0025395 bdi-MIR7773; +MI0025396 bdi-MIR7774; +MI0025397 bdi-MIR7775; +MI0025398 bdi-MIR7776; +MI0025399 bdi-MIR7777; +MI0025400 bdi-MIR7778; +MI0025401 bdi-MIR7779; +MI0025402 bdi-MIR7780; +MI0025403 bdi-MIR7781; +MI0025404 bdi-MIR7782; +MI0025405 bdi-MIR7783; +MI0025406 bdi-MIR7784a; +MI0025407 bdi-MIR7784b; +MI0025408 bdi-MIR7785; +MI0025409 bdi-MIR7786; +MI0025410 bdi-MIR7787; +MI0025411 hhi-mir-7788; +MI0025412 hhi-mir-7789; +MI0025413 hhi-mir-7790; +MI0025414 hhi-mir-723; +MI0025415 hhi-mir-7791; +MI0025416 hhi-mir-7792; +MI0025417 hhi-mir-7793; +MI0025418 hhi-mir-7794; +MI0025419 hhi-mir-449; +MI0025420 hhi-mir-430a-1; +MI0025421 hhi-mir-7795; +MI0025422 hhi-mir-7796; +MI0025423 hhi-mir-7641; +MI0025424 hhi-let-7c; +MI0025425 hhi-let-7j; +MI0025426 hhi-mir-1; +MI0025427 hhi-mir-10d; +MI0025428 hhi-mir-129b; +MI0025429 hhi-mir-129a; +MI0025430 hhi-mir-1788; +MI0025431 hhi-mir-181b; +MI0025432 hhi-mir-182; +MI0025433 hhi-mir-183; +MI0025434 hhi-mir-187; +MI0025435 hhi-mir-196; +MI0025436 hhi-mir-199a; +MI0025437 hhi-mir-21; +MI0025438 hhi-mir-23a; +MI0025439 hhi-mir-26-1; +MI0025440 hhi-mir-26-2; +MI0025441 hhi-mir-301; +MI0025442 hhi-mir-430a-3; +MI0025443 hhi-mir-430a-2; +MI0025444 hhi-mir-430b-1; +MI0025445 hhi-mir-430b-2; +MI0025446 hhi-mir-728; +MI0025447 hhi-mir-96; +MI0025448 hhi-mir-15a; +MI0025449 hhi-mir-737; +MI0025450 rgl-MIR7797a; +MI0025451 rgl-MIR7798; +MI0025452 rgl-MIR7799; +MI0025453 rgl-MIR7800; +MI0025454 rgl-MIR7801; +MI0025455 rgl-MIR7802; +MI0025456 rgl-MIR7803a; +MI0025457 rgl-MIR7804; +MI0025458 rgl-MIR7805; +MI0025459 rgl-MIR7806; +MI0025460 rgl-MIR7807a; +MI0025461 rgl-MIR7803b; +MI0025462 rgl-MIR7808; +MI0025463 rgl-MIR7809; +MI0025464 rgl-MIR7810; +MI0025465 rgl-MIR7811; +MI0025466 rgl-MIR7807b; +MI0025467 rgl-MIR7797b; +MI0025468 ptc-MIR6476b; +MI0025469 ptc-MIR6476c; +MI0025470 ptc-MIR403d; +MI0025471 ptc-MIR7812; +MI0025472 ptc-MIR7814; +MI0025473 ptc-MIR7815; +MI0025474 ptc-MIR7816; +MI0025475 ptc-MIR6462e; +MI0025476 ptc-MIR6462f; +MI0025477 ptc-MIR7817a; +MI0025478 ptc-MIR7818; +MI0025479 ptc-MIR7817b; +MI0025480 ptc-MIR7820; +MI0025481 ptc-MIR7822; +MI0025482 ptc-MIR7823; +MI0025483 ptc-MIR7824; +MI0025484 ptc-MIR7825; +MI0025485 ptc-MIR1444d; +MI0025486 ptc-MIR1444e; +MI0025487 ptc-MIR7826; +MI0025488 ptc-MIR7828; +MI0025489 ptc-MIR7830; +MI0025490 ptc-MIR7831; +MI0025491 ptc-MIR3627b; +MI0025492 ptc-MIR7833; +MI0025493 ptc-MIR7837; +MI0025494 ptc-MIR7838; +MI0025495 ptc-MIR7839; +MI0025496 ptc-MIR6459b; +MI0025497 ptc-MIR7840; +MI0025498 ptc-MIR7841; +MI0025499 ptc-MIR7842; +MI0025500 ptc-MIR7813; +MI0025501 ptc-MIR7819; +MI0025502 ptc-MIR7821; +MI0025503 ptc-MIR7827; +MI0025504 ptc-MIR7829; +MI0025505 ptc-MIR7832; +MI0025506 ptc-MIR7834; +MI0025507 ptc-MIR7835; +MI0025508 ptc-MIR7836; +MI0025509 rno-mir-155; +MI0025510 hsa-mir-7843; +MI0025511 hsa-mir-4433b; +MI0025512 hsa-mir-1273h; +MI0025513 hsa-mir-6516; +MI0025514 hsa-mir-7844; +MI0025515 hsa-mir-7845; +MI0025516 hsa-mir-7846; +MI0025517 hsa-mir-7847; +MI0025518 hsa-mir-7848; +MI0025519 hsa-mir-7849; +MI0025520 hsa-mir-7850; +MI0025521 hsa-mir-7851; +MI0025522 hsa-mir-7852; +MI0025523 hsa-mir-7853; +MI0025524 hsa-mir-7854; +MI0025525 hsa-mir-7855; +MI0025526 hsa-mir-7856; +MI0025527 bta-mir-7857;bta-mir-7857-1; +MI0025528 bta-mir-7858; +MI0025529 bta-mir-7859; +MI0025530 bta-mir-2285aa; +MI0025531 bta-mir-2285ab; +MI0025532 bta-mir-2284ab; +MI0025533 bta-mir-664b; +MI0025534 bta-mir-7860; +MI0025535 bta-mir-2285ac; +MI0025536 bta-mir-7861; +MI0025537 bta-mir-7862; +MI0025538 bta-mir-6516; +MI0025539 bta-mir-219-2; +MI0025540 bta-mir-7863; +MI0025541 bta-mir-2285ad; +MI0025542 bta-mir-2284ac; +MI0025543 bta-mir-2285ae; +MI0025544 bta-mir-7864; +MI0025545 bta-mir-7865; +MI0025546 ssp-MIR166; +MI0025547 prd-mir-7865; +MI0025548 prd-mir-100; +MI0025549 prd-lin-4; +MI0025550 prd-mir-7866; +MI0025551 prd-mir-71; +MI0025552 prd-mir-239; +MI0025553 prd-mir-5960; +MI0025554 prd-mir-86; +MI0025555 prd-mir-5359; +MI0025556 prd-mir-84; +MI0025557 prd-mir-7867; +MI0025558 prd-let-7; +MI0025559 prd-mir-7868; +MI0025560 prd-mir-72; +MI0025561 prd-mir-7869; +MI0025562 prd-mir-50; +MI0025563 prd-mir-7870; +MI0025564 prd-mir-7871; +MI0025565 prd-mir-7872; +MI0025566 prd-mir-7873a; +MI0025567 prd-mir-7874; +MI0025568 prd-mir-34; +MI0025569 prd-mir-7875; +MI0025570 prd-mir-5360; +MI0025571 prd-mir-9a; +MI0025572 prd-mir-1175; +MI0025573 prd-mir-7876; +MI0025574 prd-mir-7877; +MI0025575 prd-mir-46; +MI0025576 prd-mir-35b; +MI0025577 prd-mir-7878; +MI0025578 prd-mir-7879; +MI0025579 prd-mir-242; +MI0025580 prd-mir-7880;prd-mir-7880a; +MI0025581 prd-mir-7881; +MI0025582 prd-mir-7882; +MI0025583 prd-mir-252; +MI0025584 prd-mir-7883a; +MI0025585 prd-mir-7883b; +MI0025586 prd-mir-36; +MI0025587 prd-mir-7884; +MI0025588 prd-mir-5358a; +MI0025589 prd-mir-7940c; +MI0025590 prd-mir-7885; +MI0025591 prd-mir-360; +MI0025592 prd-mir-7886; +MI0025593 prd-mir-7887; +MI0025594 prd-mir-7927a; +MI0025595 prd-mir-7888; +MI0025596 prd-mir-7889; +MI0025597 prd-mir-7873b; +MI0025598 prd-mir-7890; +MI0025599 prd-mir-7940b; +MI0025600 prd-mir-2; +MI0025601 prd-mir-58; +MI0025602 prd-mir-7911c;prd-mir-7911c-1; +MI0025603 prd-mir-7891; +MI0025604 prd-mir-37; +MI0025605 prd-mir-7892; +MI0025606 prd-mir-7893; +MI0025607 prd-mir-5358b; +MI0025608 prd-mir-7894; +MI0025609 prd-mir-9b; +MI0025610 prd-mir-61; +MI0025611 prd-mir-7895; +MI0025612 prd-mir-7896; +MI0025613 prd-mir-5841;prd-mir-7880b; +MI0025614 prd-mir-7897; +MI0025615 prd-mir-60; +MI0025616 prd-mir-7898;prd-mir-7880c; +MI0025617 prd-mir-240; +MI0025618 prd-mir-7899; +MI0025619 prd-mir-7966a; +MI0025620 prd-mir-7900; +MI0025621 prd-mir-7901; +MI0025622 prd-mir-235; +MI0025623 prd-mir-4816; +MI0025624 prd-mir-7918a; +MI0025625 prd-mir-7918b; +MI0025626 prd-mir-7927c; +MI0025627 prd-mir-7927d; +MI0025628 prd-mir-7902; +MI0025629 prd-mir-993; +MI0025630 prd-mir-7903; +MI0025631 prd-mir-7904; +MI0025632 prd-mir-7905; +MI0025633 prd-mir-7906; +MI0025634 prd-mir-7907a; +MI0025635 prd-mir-7908; +MI0025636 prd-mir-7579; +MI0025637 prd-mir-7939c; +MI0025638 prd-mir-7909; +MI0025639 prd-mir-7939i; +MI0025640 prd-mir-7910a; +MI0025641 prd-mir-7939f; +MI0025642 prd-mir-7939d; +MI0025643 prd-mir-7927b; +MI0025644 prd-mir-7911a; +MI0025645 prd-mir-7911b; +MI0025646 prd-mir-7912; +MI0025647 prd-mir-7939e; +MI0025648 prd-mir-7913; +MI0025649 prd-mir-87; +MI0025650 prd-mir-7914; +MI0025651 prd-mir-7948c; +MI0025652 prd-mir-7939h; +MI0025653 prd-mir-7915; +MI0025654 prd-mir-7916; +MI0025655 prd-mir-7957b; +MI0025656 prd-mir-7917; +MI0025657 prd-mir-7907b; +MI0025658 prd-mir-7918e; +MI0025659 prd-mir-7918f; +MI0025660 prd-mir-7919; +MI0025661 prd-mir-40; +MI0025662 prd-mir-7920; +MI0025663 prd-mir-7921; +MI0025664 prd-mir-7922; +MI0025665 prd-mir-81; +MI0025666 prd-mir-7923; +MI0025667 prd-mir-7924; +MI0025668 prd-mir-7948b; +MI0025669 prd-mir-7883c; +MI0025670 prd-mir-7925; +MI0025671 prd-mir-7926; +MI0025672 prd-mir-7927e; +MI0025673 prd-mir-7928; +MI0025674 prd-mir-7929; +MI0025675 prd-mir-7930; +MI0025676 prd-mir-7931; +MI0025677 prd-mir-7950c; +MI0025678 prd-mir-35a; +MI0025679 prd-mir-7932; +MI0025680 prd-mir-7933; +MI0025681 prd-mir-1; +MI0025682 prd-mir-7934; +MI0025683 prd-mir-7910b; +MI0025684 prd-mir-7935; +MI0025685 prd-mir-7948a; +MI0025686 prd-mir-7936; +MI0025687 prd-mir-7937; +MI0025688 prd-mir-7938; +MI0025689 prd-mir-7939j; +MI0025690 prd-mir-7940a; +MI0025691 prd-mir-49; +MI0025692 prd-mir-7941; +MI0025693 prd-mir-7942; +MI0025694 prd-mir-7943; +MI0025695 prd-mir-7944; +MI0025696 prd-mir-7945; +MI0025697 prd-mir-7946; +MI0025698 prd-mir-67; +MI0025699 prd-mir-236; +MI0025700 prd-mir-7947; +MI0025701 prd-mir-255; +MI0025702 prd-mir-7939b; +MI0025703 prd-mir-5594; +MI0025704 prd-mir-7948d; +MI0025705 prd-mir-7949; +MI0025706 prd-mir-7950a-1; +MI0025707 prd-mir-7950a-2; +MI0025708 prd-mir-7939g; +MI0025709 prd-mir-7951; +MI0025710 prd-mir-7957a; +MI0025711 prd-mir-7952; +MI0025712 prd-mir-7918d; +MI0025713 prd-mir-7918c; +MI0025714 prd-mir-44; +MI0025715 prd-mir-124; +MI0025716 prd-mir-184; +MI0025717 prd-mir-7953; +MI0025718 prd-mir-234; +MI0025719 prd-mir-7954; +MI0025720 prd-mir-7955; +MI0025721 prd-mir-7956; +MI0025722 prd-mir-7957d; +MI0025723 prd-mir-7958; +MI0025724 prd-mir-7959b; +MI0025725 prd-mir-7939a; +MI0025726 prd-mir-7959a; +MI0025727 prd-mir-277; +MI0025728 prd-mir-39; +MI0025729 prd-mir-7960; +MI0025730 prd-mir-7950b; +MI0025731 prd-mir-76; +MI0025732 prd-mir-7961-1; +MI0025733 prd-mir-7961-2; +MI0025734 prd-mir-7957c; +MI0025735 prd-mir-7962; +MI0025736 prd-mir-7963; +MI0025737 prd-mir-7964a; +MI0025738 prd-mir-7965; +MI0025739 prd-mir-7964b; +MI0025740 prd-mir-7966b; +MI0025741 prd-mir-7967; +MI0025742 prd-mir-7968; +MI0025743 prd-mir-7969; +MI0025744 prd-mir-7970; +MI0025745 prd-mir-7971; +MI0025746 rgl-MIR7972; +MI0025747 hsa-mir-548ba; +MI0025748 hsa-mir-7973-1; +MI0025749 hsa-mir-7973-2; +MI0025750 hsa-mir-7974; +MI0025751 hsa-mir-7975; +MI0025752 hsa-mir-7976; +MI0025753 hsa-mir-7977; +MI0025754 hsa-mir-7978; +MI0025755 stu-MIR7979; +MI0025756 stu-MIR7980a; +MI0025757 stu-MIR7981; +MI0025758 stu-MIR7982a; +MI0025759 stu-MIR7982b; +MI0025760 stu-MIR7983; +MI0025761 stu-MIR7984a; +MI0025762 stu-MIR7984b; +MI0025763 stu-MIR7985; +MI0025764 stu-MIR5303c; +MI0025765 stu-MIR5303a; +MI0025766 stu-MIR5303b; +MI0025767 stu-MIR5303d; +MI0025768 stu-MIR7986; +MI0025769 stu-MIR7987; +MI0025770 stu-MIR7984c; +MI0025771 stu-MIR7988; +MI0025772 stu-MIR7989; +MI0025773 stu-MIR7990a; +MI0025774 stu-MIR7991a; +MI0025775 stu-MIR7991b; +MI0025776 stu-MIR7991c; +MI0025777 stu-MIR7992; +MI0025778 stu-MIR1886a; +MI0025779 stu-MIR1886b; +MI0025780 stu-MIR1886c; +MI0025781 stu-MIR1886d; +MI0025782 stu-MIR1886e; +MI0025783 stu-MIR1886f; +MI0025784 stu-MIR7993a; +MI0025785 stu-MIR7993b; +MI0025786 stu-MIR7993c; +MI0025787 stu-MIR7993d; +MI0025788 stu-MIR7994a; +MI0025789 stu-MIR7994b; +MI0025790 stu-MIR7995; +MI0025791 stu-MIR7996a; +MI0025792 stu-MIR7996b; +MI0025793 stu-MIR7996c; +MI0025794 stu-MIR7997a; +MI0025795 stu-MIR7997b; +MI0025796 stu-MIR7997c; +MI0025797 stu-MIR7998; +MI0025798 stu-MIR7999; +MI0025799 stu-MIR8000; +MI0025800 stu-MIR8001a; +MI0025801 stu-MIR8002; +MI0025802 stu-MIR8003; +MI0025803 stu-MIR8004; +MI0025804 stu-MIR8005a; +MI0025805 stu-MIR8005b; +MI0025806 stu-MIR8005c; +MI0025807 stu-MIR8006; +MI0025808 stu-MIR8007a; +MI0025809 stu-MIR1886g; +MI0025810 stu-MIR8008a; +MI0025811 stu-MIR8009; +MI0025812 stu-MIR5303e; +MI0025813 stu-MIR5303f; +MI0025814 stu-MIR1886h; +MI0025815 stu-MIR8010; +MI0025816 stu-MIR8011a; +MI0025817 stu-MIR8012; +MI0025818 stu-MIR8013; +MI0025819 stu-MIR8014; +MI0025820 stu-MIR8007b; +MI0025821 stu-MIR8015; +MI0025822 stu-MIR8016; +MI0025823 stu-MIR8017; +MI0025824 stu-MIR8018; +MI0025825 stu-MIR8019; +MI0025826 stu-MIR8001b; +MI0025827 stu-MIR7990b; +MI0025828 stu-MIR8020; +MI0025829 stu-MIR8021; +MI0025830 stu-MIR8022; +MI0025831 stu-MIR8023; +MI0025832 stu-MIR8024a; +MI0025833 stu-MIR8024b; +MI0025834 stu-MIR1886i; +MI0025835 stu-MIR8025; +MI0025836 stu-MIR8026; +MI0025837 stu-MIR7984d; +MI0025838 stu-MIR8027; +MI0025839 stu-MIR7980b; +MI0025840 stu-MIR8008b; +MI0025841 stu-MIR8028; +MI0025842 stu-MIR8029; +MI0025843 stu-MIR8030; +MI0025844 stu-MIR8031; +MI0025845 stu-MIR8032a; +MI0025846 stu-MIR8032b; +MI0025847 stu-MIR8032c; +MI0025848 stu-MIR8032d; +MI0025849 stu-MIR8032e; +MI0025850 stu-MIR8032f; +MI0025851 stu-MIR8032g; +MI0025852 stu-MIR8033; +MI0025853 stu-MIR8034; +MI0025854 stu-MIR8035; +MI0025855 stu-MIR8036; +MI0025856 stu-MIR8037; +MI0025857 stu-MIR8038a; +MI0025858 stu-MIR8038b; +MI0025859 stu-MIR8011b; +MI0025860 stu-MIR8039; +MI0025861 stu-MIR319; +MI0025862 stu-MIR8040; +MI0025863 stu-MIR8041a; +MI0025864 stu-MIR8041b; +MI0025865 stu-MIR8042; +MI0025866 stu-MIR8043; +MI0025867 stu-MIR8044; +MI0025868 stu-MIR8045; +MI0025869 stu-MIR7122; +MI0025870 stu-MIR8046; +MI0025871 stu-MIR8047; +MI0025872 stu-MIR6149; +MI0025873 stu-MIR399a; +MI0025874 stu-MIR399b; +MI0025875 stu-MIR399c; +MI0025876 stu-MIR399d; +MI0025877 stu-MIR399e; +MI0025878 stu-MIR399f; +MI0025879 stu-MIR399g; +MI0025880 stu-MIR399h; +MI0025881 stu-MIR8048; +MI0025882 stu-MIR164; +MI0025883 stu-MIR5304; +MI0025884 stu-MIR8049; +MI0025885 stu-MIR8050; +MI0025886 stu-MIR1919; +MI0025887 stu-MIR8051; +MI0025888 hsa-mir-8052; +MI0025889 hsa-mir-8053; +MI0025890 hsa-mir-8054; +MI0025891 hsa-mir-8055; +MI0025892 hsa-mir-8056; +MI0025893 hsa-mir-8057; +MI0025894 hsa-mir-8058; +MI0025895 hsa-mir-8059; +MI0025896 hsa-mir-8060; +MI0025897 hsa-mir-8061; +MI0025898 hsa-mir-8062; +MI0025899 hsa-mir-8063; +MI0025900 hsa-mir-8064; +MI0025901 hsa-mir-8065; +MI0025902 hsa-mir-8066; +MI0025903 hsa-mir-8067; +MI0025904 hsa-mir-8068; +MI0025905 hsa-mir-8069;hsa-mir-8069-1; +MI0025906 hsa-mir-8070; +MI0025907 hsa-mir-8071-1; +MI0025908 hsa-mir-8072; +MI0025909 hsa-mir-8073; +MI0025910 hsa-mir-8074; +MI0025911 hsa-mir-8075; +MI0025912 hsa-mir-8076; +MI0025913 hsa-mir-8077; +MI0025914 hsa-mir-8078; +MI0025915 hsa-mir-8079; +MI0025916 hsa-mir-8080; +MI0025917 hsa-mir-8081; +MI0025918 hsa-mir-8082; +MI0025919 hsa-mir-8083; +MI0025920 hsa-mir-8084; +MI0025921 hsa-mir-8085; +MI0025922 hsa-mir-8086; +MI0025923 hsa-mir-8087; +MI0025924 hsa-mir-8088; +MI0025925 hsa-mir-8089; +MI0025926 stu-MIR5303j; +MI0025927 stu-MIR5303g; +MI0025928 stu-MIR5303h; +MI0025929 stu-MIR5303i; +MI0025930 stu-MIR3627; +MI0025931 stu-MIR171b; +MI0025932 stu-MIR166a; +MI0025933 stu-MIR166b; +MI0025934 stu-MIR166c; +MI0025935 stu-MIR166d; +MI0025936 stu-MIR171a; +MI0025937 stu-MIR171c; +MI0025938 stu-MIR399i; +MI0025939 stu-MIR395a; +MI0025940 stu-MIR395b; +MI0025941 stu-MIR395c; +MI0025942 stu-MIR395d; +MI0025943 stu-MIR395e; +MI0025944 stu-MIR395f; +MI0025945 stu-MIR395g; +MI0025946 stu-MIR395h; +MI0025947 stu-MIR395i; +MI0025948 stu-MIR395j; +MI0025949 stu-MIR827; +MI0025950 stu-MIR4376;stu-MIR391; +MI0025951 stu-MIR319b; +MI0025952 stu-MIR319a; +MI0025953 stu-MIR162a; +MI0025954 stu-MIR162b; +MI0025955 stu-MIR160a; +MI0025956 stu-MIR160b; +MI0025957 stu-MIR172b; +MI0025958 stu-MIR172c; +MI0025959 stu-MIR172a; +MI0025960 stu-MIR172d; +MI0025961 stu-MIR172e; +MI0025962 stu-MIR156a; +MI0025963 stu-MIR156b; +MI0025964 stu-MIR156c; +MI0025965 stu-MIR156d; +MI0025966 stu-MIR171d; +MI0025967 stu-MIR167c; +MI0025968 stu-MIR167b; +MI0025969 stu-MIR167a; +MI0025970 stu-MIR167d; +MI0025971 stu-MIR479; +MI0025972 stu-MIR399j; +MI0025973 stu-MIR399k; +MI0025974 stu-MIR399l; +MI0025975 stu-MIR399m; +MI0025976 stu-MIR399n; +MI0025977 stu-MIR399o; +MI0025978 stu-MIR393; +MI0025979 stu-MIR477a; +MI0025980 stu-MIR477b; +MI0025981 stu-MIR530; +MI0025982 stu-MIR398a; +MI0025983 stu-MIR398b; +MI0025984 stu-MIR396; +MI0025985 stu-MIR408a; +MI0025986 stu-MIR408b; +MI0025987 stu-MIR397; +MI0025988 stu-MIR390; +MI0025989 stu-MIR171e; +MI0025990 stu-MIR156e; +MI0025991 stu-MIR156f; +MI0025992 stu-MIR156g; +MI0025993 stu-MIR156h; +MI0025994 stu-MIR156i; +MI0025995 stu-MIR156j; +MI0025996 stu-MIR156k; +MI0025997 stu-MIR169a; +MI0025998 stu-MIR169b; +MI0025999 stu-MIR169c; +MI0026000 stu-MIR169d; +MI0026001 stu-MIR169e; +MI0026002 stu-MIR169f; +MI0026003 stu-MIR169g; +MI0026004 stu-MIR169h; +MI0026005 stu-MIR384; +MI0026006 osa-MIR1861o; +MI0026007 osa-MIR5079b; +MI0026008 osa-MIR5539b; +MI0026009 osa-MIR6249b; +MI0026010 osa-MIR531c; +MI0026011 aly-MIR172f; +MI0026012 aly-MIR166h; +MI0026013 aly-MIR2111c; +MI0026014 aly-MIR403b; +MI0026015 aly-MIR173b; +MI0026016 mmu-mir-3473f; +MI0026017 mmu-mir-8090; +MI0026018 mmu-mir-8091; +MI0026019 mmu-mir-8092; +MI0026020 mmu-mir-8093; +MI0026021 mmu-mir-8094; +MI0026022 mmu-mir-8095; +MI0026023 mmu-mir-1291; +MI0026024 mmu-mir-8096; +MI0026025 mmu-mir-8097; +MI0026026 mmu-mir-8098; +MI0026027 mmu-mir-8099-1; +MI0026028 mmu-mir-142b; +MI0026029 mmu-mir-8100; +MI0026030 mmu-mir-497b; +MI0026031 mmu-mir-8101; +MI0026032 mmu-mir-8102; +MI0026033 mmu-mir-8103; +MI0026034 mmu-mir-8104; +MI0026035 mmu-mir-8105; +MI0026036 mmu-mir-3535; +MI0026037 mmu-mir-8106; +MI0026038 mmu-mir-8107; +MI0026039 mmu-mir-8108; +MI0026040 mmu-mir-1668; +MI0026041 mmu-mir-8109; +MI0026042 mmu-mir-8110; +MI0026043 mmu-mir-8111; +MI0026044 mmu-mir-8112; +MI0026045 mmu-mir-8113; +MI0026046 mmu-mir-8114; +MI0026047 mmu-mir-8115; +MI0026048 mmu-mir-8116; +MI0026049 mmu-mir-8117; +MI0026050 mmu-mir-8118; +MI0026051 mmu-mir-8119; +MI0026052 mmu-mir-8120; +MI0026053 mmu-mir-8099-2; +MI0026054 mmu-mir-3473g; +MI0026055 ath-MIR8121; +MI0026056 ppe-MIR156a; +MI0026057 ppe-MIR156b; +MI0026058 ppe-MIR156c; +MI0026059 ppe-MIR156d; +MI0026060 ppe-MIR156e; +MI0026061 ppe-MIR156f; +MI0026062 ppe-MIR156g; +MI0026063 ppe-MIR156h; +MI0026064 ppe-MIR156i; +MI0026065 ppe-MIR159; +MI0026066 ppe-MIR160a; +MI0026067 ppe-MIR160b; +MI0026068 ppe-MIR162; +MI0026069 ppe-MIR164a; +MI0026070 ppe-MIR164b; +MI0026071 ppe-MIR164c; +MI0026072 ppe-MIR164d; +MI0026073 ppe-MIR166a; +MI0026074 ppe-MIR166b; +MI0026075 ppe-MIR166c; +MI0026076 ppe-MIR166d; +MI0026077 ppe-MIR166e; +MI0026078 ppe-MIR167a; +MI0026079 ppe-MIR167b; +MI0026080 ppe-MIR167c; +MI0026081 ppe-MIR167d; +MI0026082 ppe-MIR168; +MI0026083 ppe-MIR169a; +MI0026084 ppe-MIR169b; +MI0026085 ppe-MIR169c; +MI0026086 ppe-MIR169d; +MI0026087 ppe-MIR169f; +MI0026088 ppe-MIR169g; +MI0026089 ppe-MIR169h; +MI0026090 ppe-MIR169i; +MI0026091 ppe-MIR169j; +MI0026092 ppe-MIR169k; +MI0026093 ppe-MIR169l; +MI0026094 ppe-MIR171d; +MI0026095 ppe-MIR172a; +MI0026096 ppe-MIR172b; +MI0026097 ppe-MIR172c; +MI0026098 ppe-MIR172d; +MI0026099 ppe-MIR390; +MI0026100 ppe-MIR393a; +MI0026101 ppe-MIR393b; +MI0026102 ppe-MIR394b; +MI0026103 ppe-MIR395a; +MI0026104 ppe-MIR395b; +MI0026105 ppe-MIR395c; +MI0026106 ppe-MIR395d; +MI0026107 ppe-MIR395e; +MI0026108 ppe-MIR395f; +MI0026109 ppe-MIR395g; +MI0026110 ppe-MIR395h; +MI0026111 ppe-MIR395i; +MI0026112 ppe-MIR395j; +MI0026113 ppe-MIR395k; +MI0026114 ppe-MIR395l; +MI0026115 ppe-MIR395m; +MI0026116 ppe-MIR395n; +MI0026117 ppe-MIR395o; +MI0026118 ppe-MIR396a; +MI0026119 ppe-MIR396b; +MI0026120 ppe-MIR397; +MI0026121 ppe-MIR399a; +MI0026122 ppe-MIR399b; +MI0026123 ppe-MIR399c; +MI0026124 ppe-MIR399d; +MI0026125 ppe-MIR399e; +MI0026126 ppe-MIR399f; +MI0026127 ppe-MIR399g; +MI0026128 ppe-MIR399h; +MI0026129 ppe-MIR399i; +MI0026130 ppe-MIR399j; +MI0026131 ppe-MIR399k; +MI0026132 ppe-MIR399l; +MI0026133 ppe-MIR399m; +MI0026134 ppe-MIR399n; +MI0026135 ppe-MIR403; +MI0026136 ppe-MIR482f; +MI0026137 ppe-MIR530; +MI0026138 ppe-MIR535a; +MI0026139 ppe-MIR535b; +MI0026140 ppe-MIR827; +MI0026141 ppe-MIR2111a; +MI0026142 ppe-MIR2111b; +MI0026143 ppe-MIR2111c; +MI0026144 ppe-MIR2111d; +MI0026145 ppe-MIR1511; +MI0026146 ppe-MIR8122; +MI0026147 ppe-MIR8123; +MI0026148 ppe-MIR7122a; +MI0026149 ppe-MIR7122b; +MI0026150 ppe-MIR8124; +MI0026151 ppe-MIR8125; +MI0026152 ppe-MIR3627; +MI0026153 ppe-MIR7125; +MI0026154 ppe-MIR8126; +MI0026155 ppe-MIR477; +MI0026156 ppe-MIR6267c; +MI0026157 ppe-MIR6291c; +MI0026158 ppe-MIR8127; +MI0026159 ppe-MIR5225; +MI0026160 ppe-MIR8128; +MI0026161 ppe-MIR6274b; +MI0026162 ppe-MIR8129; +MI0026163 ppe-MIR8130; +MI0026164 ppe-MIR8131; +MI0026165 ppe-MIR6288b; +MI0026166 ppe-MIR8132; +MI0026167 ppe-MIR8133; +MI0026168 ppe-MIR6288c; +MI0026169 ppe-MIR858; +MI0026170 bbe-let-7a-1; +MI0026171 bbe-let-7a-2; +MI0026172 bbe-mir-100; +MI0026173 bbe-mir-10a; +MI0026174 bbe-mir-10b; +MI0026175 bbe-mir-10c; +MI0026176 bbe-mir-124; +MI0026177 bbe-mir-125a; +MI0026178 bbe-mir-125b; +MI0026179 bbe-mir-129a; +MI0026180 bbe-mir-129b; +MI0026181 bbe-mir-133; +MI0026182 bbe-mir-135a; +MI0026183 bbe-mir-135b; +MI0026184 bbe-mir-137; +MI0026185 bbe-mir-1; +MI0026186 bbe-mir-153; +MI0026187 bbe-mir-182a; +MI0026188 bbe-mir-182b; +MI0026189 bbe-mir-182c; +MI0026190 bbe-mir-182d; +MI0026191 bbe-mir-183; +MI0026192 bbe-mir-184; +MI0026193 bbe-mir-190; +MI0026194 bbe-mir-193b; +MI0026195 bbe-mir-200a; +MI0026196 bbe-mir-200b; +MI0026197 bbe-mir-200c; +MI0026198 bbe-mir-2013; +MI0026199 bbe-mir-2056; +MI0026200 bbe-mir-2057; +MI0026201 bbe-mir-2058; +MI0026202 bbe-mir-2059; +MI0026203 bbe-mir-2060a; +MI0026204 bbe-mir-2060b; +MI0026205 bbe-mir-2061; +MI0026206 bbe-mir-2062; +MI0026207 bbe-mir-2063; +MI0026208 bbe-mir-2064; +MI0026209 bbe-mir-2066; +MI0026210 bbe-mir-2067; +MI0026211 bbe-mir-2068; +MI0026212 bbe-mir-2069-1; +MI0026213 bbe-mir-2069-2; +MI0026214 bbe-mir-2069-3; +MI0026215 bbe-mir-2070; +MI0026216 bbe-mir-2071-1; +MI0026217 bbe-mir-2071-2; +MI0026218 bbe-mir-2072; +MI0026219 bbe-mir-2076; +MI0026220 bbe-mir-210; +MI0026221 bbe-mir-216; +MI0026222 bbe-mir-217; +MI0026223 bbe-mir-219-1; +MI0026224 bbe-mir-219-2; +MI0026225 bbe-mir-22; +MI0026226 bbe-mir-242; +MI0026227 bbe-mir-252a; +MI0026228 bbe-mir-252b; +MI0026229 bbe-mir-278; +MI0026230 bbe-mir-281; +MI0026231 bbe-mir-29a; +MI0026232 bbe-mir-29b; +MI0026233 bbe-mir-31; +MI0026234 bbe-mir-33-1; +MI0026235 bbe-mir-33-2; +MI0026236 bbe-mir-34a; +MI0026237 bbe-mir-34b; +MI0026238 bbe-mir-34c; +MI0026239 bbe-mir-34d; +MI0026240 bbe-mir-34f; +MI0026241 bbe-mir-375; +MI0026242 bbe-mir-4057; +MI0026243 bbe-mir-4859; +MI0026244 bbe-mir-4860; +MI0026245 bbe-mir-4861; +MI0026246 bbe-mir-4863; +MI0026247 bbe-mir-4864; +MI0026248 bbe-mir-4865; +MI0026249 bbe-mir-4866; +MI0026250 bbe-mir-4867; +MI0026251 bbe-mir-4868a; +MI0026252 bbe-mir-4868b; +MI0026253 bbe-mir-4868c; +MI0026254 bbe-mir-4873; +MI0026255 bbe-mir-4874; +MI0026256 bbe-mir-4876; +MI0026257 bbe-mir-4877; +MI0026258 bbe-mir-4878; +MI0026259 bbe-mir-4879; +MI0026260 bbe-mir-4880; +MI0026261 bbe-mir-4887; +MI0026262 bbe-mir-4888; +MI0026263 bbe-mir-4889b; +MI0026264 bbe-mir-4890; +MI0026265 bbe-mir-4891; +MI0026266 bbe-mir-4899; +MI0026267 bbe-mir-4904; +MI0026268 bbe-mir-4928; +MI0026269 bbe-mir-7; +MI0026270 bbe-mir-705; +MI0026271 bbe-mir-71; +MI0026272 bbe-mir-92a-1; +MI0026273 bbe-mir-92a-2; +MI0026274 bbe-mir-92b; +MI0026275 bbe-mir-92c; +MI0026276 bbe-mir-92d; +MI0026277 bbe-mir-9; +MI0026278 bbe-mir-96; +MI0026279 bbe-mir-34g; +MI0026280 bbe-mir-34h; +MI0026281 bbe-mir-2060c-1; +MI0026282 bbe-mir-2060c-2; +MI0026283 bbe-mir-2060c-3; +MI0026284 bbe-mir-2060c-4; +MI0026285 bbe-mir-4856a; +MI0026286 bbe-mir-4857; +MI0026287 bbe-mir-4869; +MI0026288 bma-mir-1175; +MI0026289 bma-mir-1822; +MI0026290 bma-mir-232; +MI0026291 bma-mir-239; +MI0026292 bma-mir-250; +MI0026293 bma-mir-252; +MI0026294 bma-mir-268-1;bma-mir-268; +MI0026295 bma-mir-268-2; +MI0026296 bma-mir-268-3; +MI0026297 bma-mir-283; +MI0026298 bma-mir-2d; +MI0026299 bma-mir-307; +MI0026300 bma-mir-36-1;bma-mir-36a-1; +MI0026301 bma-mir-36-2;bma-mir-36a-2; +MI0026302 bma-mir-36-3; +MI0026303 bma-mir-36-4; +MI0026304 bma-mir-36-5; +MI0026305 bma-mir-45; +MI0026306 bma-mir-49; +MI0026307 bma-mir-5360; +MI0026308 bma-mir-5361; +MI0026309 bma-mir-5363; +MI0026310 bma-mir-5364; +MI0026311 bma-mir-5365a; +MI0026312 bma-mir-5365b; +MI0026313 bma-mir-5366; +MI0026314 bma-mir-60; +MI0026315 bma-mir-750; +MI0026316 bma-mir-84-1; +MI0026317 bma-mir-84-2; +MI0026318 bma-mir-86; +MI0026319 hbv-mir-B2; +MI0026320 hbv-mir-B3RC; +MI0026321 hbv-mir-B7; +MI0026322 hbv-mir-B8; +MI0026323 hbv-mir-B19; +MI0026324 hbv-mir-B21RC; +MI0026325 hbv-mir-B26; +MI0026326 hbv-mir-B14RC; +MI0026327 hbv-mir-B22; +MI0026328 cpa-MIR156a; +MI0026329 cpa-MIR156b; +MI0026330 cpa-MIR156c; +MI0026331 cpa-MIR156d; +MI0026332 cpa-MIR156e; +MI0026333 cpa-MIR156f; +MI0026334 cpa-MIR159a; +MI0026335 cpa-MIR159b; +MI0026336 cpa-MIR319; +MI0026337 cpa-MIR160a; +MI0026338 cpa-MIR160b; +MI0026339 cpa-MIR160c; +MI0026340 cpa-MIR160d; +MI0026341 cpa-MIR160e; +MI0026342 cpa-MIR160f; +MI0026343 cpa-MIR164a; +MI0026344 cpa-MIR164b; +MI0026345 cpa-MIR164c; +MI0026346 cpa-MIR164d; +MI0026347 cpa-MIR164e; +MI0026348 cpa-MIR166a; +MI0026349 cpa-MIR166b; +MI0026350 cpa-MIR166c; +MI0026351 cpa-MIR166d; +MI0026352 cpa-MIR166e; +MI0026353 cpa-MIR167a; +MI0026354 cpa-MIR167b; +MI0026355 cpa-MIR167c; +MI0026356 cpa-MIR167d; +MI0026357 cpa-MIR169; +MI0026358 cpa-MIR171a; +MI0026359 cpa-MIR171b; +MI0026360 cpa-MIR171c; +MI0026361 cpa-MIR171d; +MI0026362 cpa-MIR172a; +MI0026363 cpa-MIR172b; +MI0026364 cpa-MIR390a; +MI0026365 cpa-MIR390b; +MI0026366 cpa-MIR393; +MI0026367 cpa-MIR394a; +MI0026368 cpa-MIR394b; +MI0026369 cpa-MIR395a; +MI0026370 cpa-MIR395b; +MI0026371 cpa-MIR395c; +MI0026372 cpa-MIR395d; +MI0026373 cpa-MIR395e; +MI0026374 cpa-MIR396; +MI0026375 cpa-MIR408; +MI0026376 cpa-MIR535; +MI0026377 cpa-MIR8134; +MI0026378 cpa-MIR398; +MI0026379 cpa-MIR8135; +MI0026380 cpa-MIR477; +MI0026381 cpa-MIR8136; +MI0026382 cpa-MIR8137; +MI0026383 cpa-MIR8138; +MI0026384 cpa-MIR8139a; +MI0026385 cpa-MIR8139b; +MI0026386 cpa-MIR8139c; +MI0026387 cpa-MIR8139d; +MI0026388 cpa-MIR8139e; +MI0026389 cpa-MIR8140; +MI0026390 cpa-MIR8141; +MI0026391 cpa-MIR8142; +MI0026392 cpa-MIR8143; +MI0026393 cpa-MIR8144; +MI0026394 cpa-MIR8145; +MI0026395 cpa-MIR8146; +MI0026396 cpa-MIR8147; +MI0026397 cpa-MIR8148; +MI0026398 cpa-MIR8149; +MI0026399 cpa-MIR8150; +MI0026400 cpa-MIR8151; +MI0026401 cpa-MIR8152; +MI0026402 cpa-MIR8153; +MI0026403 cpa-MIR5211; +MI0026404 cpa-MIR8154; +MI0026405 cpa-MIR8155; +MI0026406 lus-MIR156h; +MI0026407 lus-MIR166j; +MI0026408 lus-MIR166k; +MI0026409 lus-MIR171j; +MI0026410 lus-MIR396e; +MI0026411 lus-MIR398d; +MI0026412 lus-MIR398e; +MI0026413 lus-MIR398f; +MI0026414 hsa-mir-7112-2; +MI0026415 hsa-mir-6862-2; +MI0026417 hsa-mir-8071-2; +MI0026418 hsa-mir-6770-2; +MI0026419 hsa-mir-6770-3; +MI0026420 hsa-mir-6859-2; +MI0026421 hsa-mir-6859-3; +MI0026422 ssa-let-7j; +MI0026423 ssa-let-7c-1; +MI0026424 ssa-let-7c-2; +MI0026425 ssa-let-7f; +MI0026426 ssa-let-7g-1; +MI0026427 ssa-let-7g-2; +MI0026428 ssa-let-7h; +MI0026429 ssa-let-7i-1; +MI0026430 ssa-let-7i-2; +MI0026431 ssa-mir-100a-1; +MI0026432 ssa-mir-100a-2; +MI0026433 ssa-mir-101a-1; +MI0026434 ssa-mir-101a-2; +MI0026435 ssa-mir-101b-1; +MI0026436 ssa-mir-101b-2; +MI0026437 ssa-mir-103; +MI0026438 ssa-mir-106a-1; +MI0026439 ssa-mir-106a-2; +MI0026440 ssa-mir-106b; +MI0026441 ssa-mir-107; +MI0026442 ssa-mir-10a-1; +MI0026443 ssa-mir-10a-2; +MI0026444 ssa-mir-10b-1; +MI0026445 ssa-mir-10b-2; +MI0026446 ssa-mir-10b-3; +MI0026447 ssa-mir-10b-4; +MI0026448 ssa-mir-10d-1; +MI0026449 ssa-mir-10d-2; +MI0026450 ssa-mir-122-1; +MI0026451 ssa-mir-122-2; +MI0026452 ssa-mir-125a-1; +MI0026453 ssa-mir-125a-2; +MI0026454 ssa-mir-125b-1; +MI0026455 ssa-mir-125b-2; +MI0026456 ssa-mir-125b-3; +MI0026457 ssa-mir-126-1; +MI0026458 ssa-mir-126-2; +MI0026459 ssa-mir-126-3; +MI0026460 ssa-mir-126-4; +MI0026461 ssa-mir-128-1; +MI0026462 ssa-mir-128-2; +MI0026463 ssa-mir-128-3; +MI0026464 ssa-mir-128-4; +MI0026465 ssa-mir-129-1; +MI0026466 ssa-mir-129-2; +MI0026467 ssa-mir-129-3; +MI0026468 ssa-mir-130a-1; +MI0026469 ssa-mir-130a-2; +MI0026470 ssa-mir-130b-1; +MI0026471 ssa-mir-130b-2; +MI0026472 ssa-mir-130d-1; +MI0026473 ssa-mir-130d-2; +MI0026474 ssa-mir-130d-3; +MI0026475 ssa-mir-132-1; +MI0026476 ssa-mir-132-2; +MI0026477 ssa-mir-132-3; +MI0026478 ssa-mir-132-4; +MI0026479 ssa-mir-1338; +MI0026480 ssa-mir-133a-1; +MI0026481 ssa-mir-133b-1; +MI0026482 ssa-mir-133b-2; +MI0026483 ssa-mir-133a-3; +MI0026484 ssa-mir-133a-2; +MI0026485 ssa-mir-135a; +MI0026486 ssa-mir-135b-1; +MI0026487 ssa-mir-135b-2; +MI0026488 ssa-mir-135b-3; +MI0026489 ssa-mir-135c-1; +MI0026490 ssa-mir-135c-2; +MI0026491 ssa-mir-137-1; +MI0026492 ssa-mir-137-2; +MI0026493 ssa-mir-138-1; +MI0026494 ssa-mir-138-2; +MI0026495 ssa-mir-138-3; +MI0026496 ssa-mir-138-4; +MI0026497 ssa-mir-139-1; +MI0026498 ssa-mir-139-2; +MI0026499 ssa-mir-140; +MI0026500 ssa-mir-142a-1; +MI0026501 ssa-mir-142a-2; +MI0026502 ssa-mir-142b; +MI0026503 ssa-mir-143; +MI0026504 ssa-mir-144; +MI0026505 ssa-mir-145-1; +MI0026506 ssa-mir-145-2; +MI0026507 ssa-mir-146a-1; +MI0026508 ssa-mir-146a-2; +MI0026509 ssa-mir-146a-3; +MI0026510 ssa-mir-146b; +MI0026511 ssa-mir-146d-1; +MI0026512 ssa-mir-146d-2; +MI0026513 ssa-mir-148a; +MI0026514 ssa-mir-148b; +MI0026515 ssa-mir-150; +MI0026516 ssa-mir-152; +MI0026517 ssa-mir-153a-1; +MI0026518 ssa-mir-153a-2; +MI0026519 ssa-mir-153b; +MI0026520 ssa-mir-155-1; +MI0026521 ssa-mir-155-2; +MI0026522 ssa-mir-15a; +MI0026523 ssa-mir-15b; +MI0026524 ssa-mir-15c-1; +MI0026525 ssa-mir-15c-2; +MI0026526 ssa-mir-15d; +MI0026527 ssa-mir-15e; +MI0026528 ssa-mir-16a-1; +MI0026529 ssa-mir-16a-2; +MI0026530 ssa-mir-16b; +MI0026531 ssa-mir-16c; +MI0026532 ssa-mir-1788; +MI0026533 ssa-mir-17-3; +MI0026534 ssa-mir-17-2; +MI0026535 ssa-mir-17-1; +MI0026536 ssa-mir-181a-1; +MI0026537 ssa-mir-181a-2; +MI0026538 ssa-mir-181a-3; +MI0026539 ssa-mir-181a-4; +MI0026540 ssa-mir-181a-5; +MI0026541 ssa-mir-181b; +MI0026542 ssa-mir-181c; +MI0026543 ssa-mir-182; +MI0026544 ssa-mir-183-1; +MI0026545 ssa-mir-183-2; +MI0026546 ssa-mir-183-3; +MI0026547 ssa-mir-18a; +MI0026548 ssa-mir-18b; +MI0026549 ssa-mir-190a; +MI0026550 ssa-mir-190b; +MI0026551 ssa-mir-192a-1; +MI0026552 ssa-mir-192a-2; +MI0026553 ssa-mir-192b; +MI0026554 ssa-mir-193; +MI0026555 ssa-mir-194a-1; +MI0026556 ssa-mir-194a-2; +MI0026557 ssa-mir-194b; +MI0026558 ssa-mir-194c; +MI0026559 ssa-mir-196a-1; +MI0026560 ssa-mir-196a-2; +MI0026561 ssa-mir-196a-3; +MI0026562 ssa-mir-196a-4; +MI0026563 ssa-mir-196b-1; +MI0026564 ssa-mir-196b-2; +MI0026565 ssa-mir-199a-1; +MI0026566 ssa-mir-199a-2; +MI0026567 ssa-mir-199a-3; +MI0026568 ssa-mir-199a-4; +MI0026569 ssa-mir-19a-1; +MI0026570 ssa-mir-19a-3; +MI0026571 ssa-mir-19a-2; +MI0026572 ssa-mir-19c-1; +MI0026573 ssa-mir-19c-2; +MI0026574 ssa-mir-19c-3; +MI0026575 ssa-mir-19c-4; +MI0026576 ssa-mir-19d; +MI0026577 ssa-mir-1-3; +MI0026578 ssa-mir-1-2; +MI0026579 ssa-mir-1-1; +MI0026580 ssa-mir-1-4; +MI0026581 ssa-mir-200a-1; +MI0026582 ssa-mir-200a-2; +MI0026583 ssa-mir-200a-3; +MI0026584 ssa-mir-200b-1; +MI0026585 ssa-mir-200b-2; +MI0026586 ssa-mir-202; +MI0026587 ssa-mir-203a-1; +MI0026588 ssa-mir-203a-2; +MI0026589 ssa-mir-203b; +MI0026590 ssa-mir-204-1; +MI0026591 ssa-mir-204-2; +MI0026592 ssa-mir-204-3; +MI0026593 ssa-mir-204-4; +MI0026594 ssa-mir-205a-1; +MI0026595 ssa-mir-205a-2; +MI0026596 ssa-mir-205b-1; +MI0026597 ssa-mir-205b-2; +MI0026598 ssa-mir-205b-3; +MI0026599 ssa-mir-205b-4; +MI0026600 ssa-mir-206; +MI0026601 ssa-mir-20a-1; +MI0026602 ssa-mir-20a-2; +MI0026603 ssa-mir-20a-3; +MI0026604 ssa-mir-20b; +MI0026605 ssa-mir-210-1; +MI0026606 ssa-mir-210-2; +MI0026607 ssa-mir-212a-1; +MI0026608 ssa-mir-212a-2; +MI0026609 ssa-mir-212b-1; +MI0026610 ssa-mir-212b-2; +MI0026611 ssa-mir-214-1; +MI0026612 ssa-mir-214-2; +MI0026613 ssa-mir-214-3; +MI0026614 ssa-mir-216a; +MI0026615 ssa-mir-216b; +MI0026616 ssa-mir-2187; +MI0026617 ssa-mir-2188; +MI0026618 ssa-mir-218-1; +MI0026619 ssa-mir-218-2; +MI0026620 ssa-mir-219a-1; +MI0026621 ssa-mir-219a-2; +MI0026622 ssa-mir-219b-1; +MI0026623 ssa-mir-219b-2; +MI0026624 ssa-mir-219c-1; +MI0026625 ssa-mir-219c-2; +MI0026626 ssa-mir-21a-1; +MI0026627 ssa-mir-21a-2; +MI0026628 ssa-mir-21b; +MI0026629 ssa-mir-221; +MI0026630 ssa-mir-222a-1; +MI0026631 ssa-mir-222a-2; +MI0026632 ssa-mir-222b; +MI0026633 ssa-mir-22a; +MI0026634 ssa-mir-22b-1; +MI0026635 ssa-mir-22b-2; +MI0026636 ssa-mir-23a-3; +MI0026637 ssa-mir-23a-4; +MI0026638 ssa-mir-23a-1; +MI0026639 ssa-mir-23a-2; +MI0026640 ssa-mir-23b; +MI0026641 ssa-mir-24a-4; +MI0026642 ssa-mir-24a-2; +MI0026643 ssa-mir-24a-3; +MI0026644 ssa-mir-24a-1; +MI0026645 ssa-mir-24b; +MI0026646 ssa-mir-25-1; +MI0026647 ssa-mir-25-2; +MI0026648 ssa-mir-25-3; +MI0026649 ssa-mir-26a-1; +MI0026650 ssa-mir-26a-2; +MI0026651 ssa-mir-26a-3; +MI0026652 ssa-mir-26a-4; +MI0026653 ssa-mir-26a-5; +MI0026654 ssa-mir-26a-6; +MI0026655 ssa-mir-26b; +MI0026656 ssa-mir-26d; +MI0026657 ssa-mir-27a-1; +MI0026658 ssa-mir-27a-2; +MI0026659 ssa-mir-27b-1; +MI0026660 ssa-mir-27b-2; +MI0026661 ssa-mir-27c-1; +MI0026662 ssa-mir-27c-2; +MI0026663 ssa-mir-27d; +MI0026664 ssa-mir-29a; +MI0026665 ssa-mir-29b-1; +MI0026666 ssa-mir-29b-2; +MI0026667 ssa-mir-29b-3; +MI0026668 ssa-mir-29b-4; +MI0026669 ssa-mir-29c; +MI0026670 ssa-mir-301a-1; +MI0026671 ssa-mir-301b; +MI0026672 ssa-mir-301c; +MI0026673 ssa-mir-301d; +MI0026674 ssa-mir-30a-3; +MI0026675 ssa-mir-30a-4; +MI0026676 ssa-mir-30a-1; +MI0026677 ssa-mir-30a-2; +MI0026678 ssa-mir-30b; +MI0026679 ssa-mir-30c-1; +MI0026680 ssa-mir-30c-2; +MI0026681 ssa-mir-30d-1; +MI0026682 ssa-mir-30d-2; +MI0026683 ssa-mir-30e-1; +MI0026684 ssa-mir-30e-2; +MI0026685 ssa-mir-30e-3; +MI0026686 ssa-mir-338a-3; +MI0026687 ssa-mir-338a-2; +MI0026688 ssa-mir-338a-1; +MI0026689 ssa-mir-338a-4; +MI0026690 ssa-mir-33a-1; +MI0026691 ssa-mir-33a-2; +MI0026692 ssa-mir-33b; +MI0026693 ssa-mir-365-1; +MI0026694 ssa-mir-365-2; +MI0026695 ssa-mir-375-1; +MI0026696 ssa-mir-375-2; +MI0026697 ssa-mir-375-3; +MI0026698 ssa-mir-429; +MI0026699 ssa-mir-430a; +MI0026700 ssa-mir-430b; +MI0026701 ssa-mir-430c; +MI0026702 ssa-mir-449a; +MI0026703 ssa-mir-449b; +MI0026704 ssa-mir-454; +MI0026705 ssa-mir-455; +MI0026706 ssa-mir-456-1; +MI0026707 ssa-mir-456-2; +MI0026708 ssa-mir-458; +MI0026709 ssa-mir-459; +MI0026710 ssa-mir-460-1; +MI0026711 ssa-mir-460-2; +MI0026712 ssa-mir-462a; +MI0026713 ssa-mir-462b; +MI0026714 ssa-mir-489-1; +MI0026715 ssa-mir-489-2; +MI0026716 ssa-mir-499a; +MI0026717 ssa-mir-499b-1; +MI0026718 ssa-mir-499b-2; +MI0026719 ssa-mir-499b-3; +MI0026720 ssa-mir-551; +MI0026721 ssa-mir-7132a; +MI0026722 ssa-mir-722-1; +MI0026723 ssa-mir-722-2; +MI0026724 ssa-mir-723-1; +MI0026725 ssa-mir-723-2; +MI0026726 ssa-mir-724-1; +MI0026727 ssa-mir-724-2; +MI0026728 ssa-mir-724-3; +MI0026729 ssa-mir-724-4; +MI0026730 ssa-mir-725-1; +MI0026731 ssa-mir-725-2; +MI0026732 ssa-mir-727-1; +MI0026733 ssa-mir-727-2; +MI0026734 ssa-mir-729; +MI0026735 ssa-mir-730a-1; +MI0026736 ssa-mir-730a-2; +MI0026737 ssa-mir-731; +MI0026738 ssa-mir-736; +MI0026739 ssa-mir-737; +MI0026740 ssa-let-7a-1; +MI0026741 ssa-let-7a-3; +MI0026742 ssa-let-7a-2; +MI0026743 ssa-let-7a-4; +MI0026744 ssa-let-7a-5; +MI0026745 ssa-mir-7a-1; +MI0026746 ssa-mir-7a-2; +MI0026747 ssa-mir-7a-3; +MI0026748 ssa-mir-7a-4; +MI0026749 ssa-mir-7a-5; +MI0026750 ssa-mir-7a-6; +MI0026751 ssa-mir-7a-7; +MI0026752 ssa-let-7b-1; +MI0026753 ssa-let-7b-2; +MI0026754 ssa-let-7d-1; +MI0026755 ssa-let-7d-2; +MI0026756 ssa-let-7e-1; +MI0026757 ssa-let-7e-2; +MI0026758 ssa-mir-92a-1; +MI0026759 ssa-mir-92a-2; +MI0026760 ssa-mir-92a-3; +MI0026761 ssa-mir-92a-4; +MI0026762 ssa-mir-92b; +MI0026763 ssa-mir-93a-1; +MI0026764 ssa-mir-93a-2; +MI0026765 ssa-mir-96-1; +MI0026766 ssa-mir-96-2; +MI0026767 ssa-mir-99-1; +MI0026768 ssa-mir-99-2; +MI0026769 ssa-mir-9a-1; +MI0026770 ssa-mir-9a-2; +MI0026771 ssa-mir-9a-3; +MI0026772 ssa-mir-9a-4; +MI0026773 ssa-mir-9a-5; +MI0026774 ssa-mir-9a-6; +MI0026775 ssa-mir-9a-7; +MI0026776 ssa-mir-9a-8; +MI0026777 ssa-mir-9b; +MI0026778 ssa-mir-7132b; +MI0026779 ssa-mir-8156; +MI0026780 ssa-mir-8157; +MI0026781 ssa-mir-734; +MI0026782 ssa-mir-8158; +MI0026783 ssa-mir-8159; +MI0026784 ssa-mir-2184; +MI0026785 ssa-mir-8160;ssa-mir-8160-1; +MI0026786 ssa-mir-8161;ssa-mir-8160-2; +MI0026787 ssa-mir-7552b; +MI0026788 ssa-mir-7552a-1; +MI0026789 ssa-mir-7552a-2; +MI0026790 ssa-mir-8162; +MI0026791 ssa-mir-8163; +MI0026792 ssa-mir-8164; +MI0026793 ath-MIR8165; +MI0026794 ath-MIR8166; +MI0026795 ath-MIR8167a; +MI0026796 ath-MIR8167b; +MI0026797 ath-MIR8167c; +MI0026798 ath-MIR8168; +MI0026799 ath-MIR8169; +MI0026800 ath-MIR8170; +MI0026801 ath-MIR8171; +MI0026802 ath-MIR8172; +MI0026803 ath-MIR8173; +MI0026804 ath-MIR8174; +MI0026805 ath-MIR8175; +MI0026806 ath-MIR8176; +MI0026807 ath-MIR8177; +MI0026808 ath-MIR8178; +MI0026809 ath-MIR8179; +MI0026810 ath-MIR8180; +MI0026811 ath-MIR8181; +MI0026812 ath-MIR8182; +MI0026813 ath-MIR8183; +MI0026814 ath-MIR8184; +MI0026815 sja-mir-8185; +MI0026816 cel-mir-8186-1; +MI0026817 cel-mir-8186-2; +MI0026818 cel-mir-8187; +MI0026819 cel-mir-8188; +MI0026820 cel-mir-8189; +MI0026821 cel-mir-8190; +MI0026822 cel-mir-8191; +MI0026823 cel-mir-8192; +MI0026824 cel-mir-8193; +MI0026825 cel-mir-8194; +MI0026826 cel-mir-8195; +MI0026827 cel-mir-8196a; +MI0026828 cel-mir-8197; +MI0026829 cel-mir-8198; +MI0026830 cel-mir-8199; +MI0026831 cel-mir-8200; +MI0026832 cel-mir-8201; +MI0026833 cel-mir-8202; +MI0026834 cel-mir-8203; +MI0026835 cel-mir-4810b; +MI0026836 cel-mir-8204; +MI0026837 cel-mir-8196b; +MI0026838 cel-mir-8205; +MI0026839 cel-mir-8206; +MI0026840 cel-mir-8207; +MI0026841 cel-mir-8208; +MI0026842 cel-mir-8209; +MI0026843 cel-mir-8210; +MI0026844 cel-mir-2217b-1; +MI0026845 cel-mir-2217b-2; +MI0026846 cel-mir-2217b-3; +MI0026847 cel-mir-8211; +MI0026848 cel-mir-8212; +MI0026849 cel-mir-2217b-4; +MI0026850 ppc-mir-228; +MI0026851 ppc-mir-2251b; +MI0026852 ppc-mir-2235b; +MI0026853 ppc-mir-8213; +MI0026854 ppc-mir-235; +MI0026855 ppc-mir-2238f; +MI0026856 ppc-mir-8214; +MI0026857 ppc-mir-8215a; +MI0026858 ppc-mir-8216; +MI0026859 ppc-mir-8217; +MI0026860 ppc-mir-8218a; +MI0026861 ppc-mir-63i; +MI0026862 ppc-mir-8219; +MI0026863 ppc-mir-2a; +MI0026864 ppc-mir-8220; +MI0026865 ppc-mir-8221; +MI0026866 ppc-mir-8222; +MI0026867 ppc-mir-8215b; +MI0026868 ppc-mir-36; +MI0026869 ppc-mir-8223; +MI0026870 ppc-mir-83; +MI0026871 ppc-mir-42c; +MI0026872 ppc-mir-8224; +MI0026873 ppc-mir-8225; +MI0026874 ppc-mir-2238g; +MI0026875 ppc-mir-8226; +MI0026876 ppc-mir-8227; +MI0026877 ppc-mir-8228; +MI0026878 ppc-mir-8229a; +MI0026879 ppc-mir-59; +MI0026880 ppc-mir-8230; +MI0026881 ppc-mir-8231; +MI0026882 ppc-mir-8364d; +MI0026883 ppc-mir-8232; +MI0026884 ppc-mir-133; +MI0026885 ppc-mir-63j; +MI0026886 ppc-mir-8233; +MI0026887 ppc-mir-84d; +MI0026888 ppc-mir-8234; +MI0026889 ppc-mir-8235; +MI0026890 ppc-mir-8236; +MI0026891 ppc-mir-8237; +MI0026892 ppc-mir-2238h; +MI0026893 ppc-mir-8238; +MI0026894 ppc-mir-8239; +MI0026895 ppc-mir-8240; +MI0026896 ppc-mir-8241; +MI0026897 ppc-mir-2238i; +MI0026898 ppc-mir-8242; +MI0026899 ppc-mir-312b; +MI0026900 ppc-mir-8243; +MI0026901 ppc-mir-8244; +MI0026902 ppc-mir-2235c; +MI0026903 ppc-mir-2235d; +MI0026904 ppc-mir-8245a; +MI0026905 ppc-mir-8246; +MI0026906 ppc-mir-8247; +MI0026907 ppc-mir-8248; +MI0026908 ppc-mir-8249; +MI0026909 ppc-mir-8250a-1; +MI0026910 ppc-mir-2238j; +MI0026911 ppc-mir-8251; +MI0026912 ppc-mir-84c; +MI0026913 ppc-mir-8252a; +MI0026914 ppc-mir-8253; +MI0026915 ppc-mir-8254; +MI0026916 ppc-mir-8255; +MI0026917 ppc-mir-8256; +MI0026918 ppc-mir-8257; +MI0026919 ppc-mir-8258; +MI0026920 ppc-mir-8259; +MI0026921 ppc-mir-8250a-2; +MI0026922 ppc-mir-8260; +MI0026923 ppc-mir-8250c; +MI0026924 ppc-mir-8250d; +MI0026925 ppc-mir-8261; +MI0026926 ppc-mir-2237d; +MI0026927 ppc-mir-57; +MI0026928 ppc-mir-2253c; +MI0026929 ppc-mir-2253d; +MI0026930 ppc-mir-2235a-10; +MI0026931 ppc-mir-71b; +MI0026932 ppc-mir-8262; +MI0026933 ppc-mir-8263; +MI0026934 ppc-mir-8264; +MI0026935 ppc-mir-8265; +MI0026936 ppc-mir-8266; +MI0026937 ppc-mir-63k; +MI0026938 ppc-mir-8267; +MI0026939 ppc-mir-8268; +MI0026940 ppc-mir-8269; +MI0026941 ppc-mir-8364j; +MI0026942 ppc-mir-8364k; +MI0026943 ppc-mir-8364c-2; +MI0026944 ppc-mir-8270; +MI0026945 ppc-mir-2235a-11; +MI0026946 ppc-mir-8271; +MI0026947 ppc-mir-2238k; +MI0026948 ppc-mir-84e; +MI0026949 ppc-mir-8272; +MI0026950 ppc-mir-8273; +MI0026951 ppc-mir-8364n; +MI0026952 ppc-mir-8274; +MI0026953 ppc-mir-8275; +MI0026954 ppc-mir-8276; +MI0026955 ppc-mir-8277; +MI0026956 ppc-mir-8278; +MI0026957 ppc-mir-8279; +MI0026958 ppc-mir-8364q; +MI0026959 ppc-mir-8280; +MI0026960 ppc-mir-8364h; +MI0026961 ppc-mir-8281; +MI0026962 ppc-mir-8282a; +MI0026963 ppc-mir-8283; +MI0026964 ppc-mir-8284; +MI0026965 ppc-mir-8304b; +MI0026966 ppc-mir-8285; +MI0026967 ppc-mir-8286a; +MI0026968 ppc-mir-2238l; +MI0026969 ppc-mir-8364b-1; +MI0026970 ppc-mir-8287; +MI0026971 ppc-mir-8288; +MI0026972 ppc-mir-76; +MI0026973 ppc-mir-8317a; +MI0026974 ppc-mir-8289; +MI0026975 ppc-mir-8364b-2; +MI0026976 ppc-mir-8290; +MI0026977 ppc-mir-8291; +MI0026978 ppc-mir-8292; +MI0026979 ppc-mir-8293; +MI0026980 ppc-mir-8294; +MI0026981 ppc-mir-8295; +MI0026982 ppc-mir-8296; +MI0026983 ppc-mir-8364v; +MI0026984 ppc-mir-8364f; +MI0026985 ppc-mir-8297; +MI0026986 ppc-mir-8298; +MI0026987 ppc-mir-8299; +MI0026988 ppc-mir-8300; +MI0026989 ppc-mir-8364g; +MI0026990 ppc-mir-8301; +MI0026991 ppc-mir-8364u; +MI0026992 ppc-mir-8302; +MI0026993 ppc-mir-8303-1; +MI0026994 ppc-mir-360; +MI0026995 ppc-mir-8303-2; +MI0026996 ppc-mir-8304a; +MI0026997 ppc-mir-8305; +MI0026998 ppc-mir-8306; +MI0026999 ppc-mir-8364o; +MI0027000 ppc-mir-8307; +MI0027001 ppc-mir-8229b; +MI0027002 ppc-mir-8356b; +MI0027003 ppc-mir-8308; +MI0027004 ppc-mir-8309; +MI0027005 ppc-mir-8310; +MI0027006 ppc-mir-8311; +MI0027007 ppc-mir-8312; +MI0027008 ppc-mir-8313; +MI0027009 ppc-mir-8364c-1; +MI0027010 ppc-mir-8364p; +MI0027011 ppc-mir-8364w; +MI0027012 ppc-mir-8314; +MI0027013 ppc-mir-8338-1; +MI0027014 ppc-mir-8315-1; +MI0027015 ppc-mir-8316; +MI0027016 ppc-mir-8315-2; +MI0027017 ppc-mir-8317b; +MI0027018 ppc-mir-8318; +MI0027019 ppc-mir-8364a; +MI0027020 ppc-mir-8319; +MI0027021 ppc-mir-8320; +MI0027022 ppc-mir-8321; +MI0027023 ppc-mir-8322; +MI0027024 ppc-mir-8245b; +MI0027025 ppc-mir-8364m; +MI0027026 ppc-mir-8323; +MI0027027 ppc-mir-8324; +MI0027028 ppc-mir-8325; +MI0027029 ppc-mir-8326; +MI0027030 ppc-mir-8327; +MI0027031 ppc-mir-8328; +MI0027032 ppc-mir-8329; +MI0027033 ppc-mir-8330; +MI0027034 ppc-mir-8331; +MI0027035 ppc-mir-8332; +MI0027036 ppc-mir-8333; +MI0027037 ppc-mir-8334; +MI0027038 ppc-mir-8335; +MI0027039 ppc-mir-8364i; +MI0027040 ppc-mir-8336; +MI0027041 ppc-mir-8337; +MI0027042 ppc-mir-8338-2; +MI0027043 ppc-mir-8339; +MI0027044 ppc-mir-8340; +MI0027045 ppc-mir-8341; +MI0027046 ppc-mir-8342; +MI0027047 ppc-mir-8343; +MI0027048 ppc-mir-2235a-9; +MI0027049 ppc-mir-8344; +MI0027050 ppc-mir-8345; +MI0027051 ppc-mir-8346; +MI0027052 ppc-mir-8286b; +MI0027053 ppc-mir-8347; +MI0027054 ppc-mir-8348; +MI0027055 ppc-mir-8349; +MI0027056 ppc-mir-8218b; +MI0027057 ppc-mir-8282b; +MI0027058 ppc-mir-8350; +MI0027059 ppc-mir-8351; +MI0027060 ppc-mir-8352; +MI0027061 ppc-mir-8282c; +MI0027062 ppc-mir-8364e; +MI0027063 ppc-mir-8364r; +MI0027064 ppc-mir-8364l; +MI0027065 ppc-mir-8353; +MI0027066 ppc-mir-8354; +MI0027067 ppc-mir-8364s; +MI0027068 ppc-mir-8355; +MI0027069 ppc-mir-8356a; +MI0027070 ppc-mir-8357; +MI0027071 ppc-mir-8358; +MI0027072 ppc-mir-8359; +MI0027073 ppc-mir-8360; +MI0027074 ppc-mir-8364t; +MI0027075 ppc-mir-84f; +MI0027076 ppc-mir-8361; +MI0027077 ppc-mir-8362; +MI0027078 ppc-mir-8363; +MI0027079 ppc-mir-8252b; +MI0027080 str-mir-1; +MI0027081 str-mir-7880a; +MI0027082 str-mir-50; +MI0027083 str-mir-8365; +MI0027084 str-mir-7880b-1; +MI0027085 str-mir-8366a; +MI0027086 str-mir-7880b-2; +MI0027087 str-mir-7880b-3; +MI0027088 str-mir-7880b-4; +MI0027089 str-mir-7880c; +MI0027090 str-bantam; +MI0027091 str-mir-7880d; +MI0027092 str-mir-71; +MI0027093 str-mir-7880e-1; +MI0027094 str-mir-7880f; +MI0027095 str-mir-7880g; +MI0027096 str-mir-252a; +MI0027097 str-mir-7880h; +MI0027098 str-mir-7880i; +MI0027099 str-mir-81a; +MI0027100 str-mir-8367; +MI0027101 str-mir-7880e-2; +MI0027102 str-lin-4; +MI0027103 str-mir-8368; +MI0027104 str-mir-236; +MI0027105 str-mir-81b; +MI0027106 str-mir-81c; +MI0027107 str-mir-72; +MI0027108 str-mir-8369; +MI0027109 str-mir-7880j; +MI0027110 str-mir-5359; +MI0027111 str-mir-86; +MI0027112 str-mir-92; +MI0027113 str-mir-7880k; +MI0027114 str-mir-8370; +MI0027115 str-mir-7880l; +MI0027116 str-mir-7880m; +MI0027117 str-mir-8371; +MI0027118 str-mir-7880n; +MI0027119 str-mir-252b; +MI0027120 str-mir-7880o; +MI0027121 str-mir-7880p; +MI0027122 str-mir-1175; +MI0027123 str-mir-7880q; +MI0027124 str-mir-8372; +MI0027125 str-mir-8373; +MI0027126 str-mir-8366b; +MI0027127 str-mir-7880r; +MI0027128 str-mir-7880s; +MI0027129 str-mir-8374; +MI0027130 str-mir-8375; +MI0027131 str-mir-8376; +MI0027132 str-mir-7880t; +MI0027133 str-mir-9; +MI0027134 str-mir-8377; +MI0027135 str-mir-87a; +MI0027136 str-mir-47; +MI0027137 str-mir-7880u; +MI0027138 str-mir-8378; +MI0027139 str-mir-84; +MI0027140 str-mir-8379a; +MI0027141 str-mir-76; +MI0027142 str-mir-8380; +MI0027143 str-mir-8381; +MI0027144 str-mir-8382; +MI0027145 str-mir-7880v; +MI0027146 str-mir-8383; +MI0027147 str-mir-7880w; +MI0027148 str-mir-8384; +MI0027149 str-mir-8385; +MI0027150 str-mir-8386; +MI0027151 str-mir-8387; +MI0027152 str-mir-40; +MI0027153 str-mir-124; +MI0027154 str-mir-184; +MI0027155 str-mir-8388; +MI0027156 str-mir-8389; +MI0027157 str-mir-240; +MI0027158 str-mir-8390; +MI0027159 str-mir-8391; +MI0027160 str-mir-8392; +MI0027161 str-mir-37a; +MI0027162 str-mir-255; +MI0027163 str-mir-8393; +MI0027164 str-mir-360; +MI0027165 str-mir-8394; +MI0027166 str-mir-58; +MI0027167 str-mir-37b; +MI0027168 str-mir-8379b; +MI0027169 str-mir-279; +MI0027170 str-mir-87b; +MI0027171 str-mir-2; +MI0027172 str-mir-234; +MI0027173 str-mir-7880x; +MI0027174 str-mir-8395; +MI0027175 str-mir-8396; +MI0027176 str-mir-34a; +MI0027177 str-mir-34b; +MI0027178 str-mir-8397; +MI0027179 str-mir-8398; +MI0027180 str-mir-8399; +MI0027181 str-mir-8400; +MI0027182 str-mir-8401; +MI0027183 str-mir-7880y; +MI0027184 str-mir-8402; +MI0027185 str-mir-34c; +MI0027193 sma-mir-219; +MI0027194 sma-mir-8403; +MI0027195 sma-mir-8404; +MI0027196 sma-mir-125c; +MI0027197 sma-mir-8405; +MI0027198 sma-mir-36b; +MI0027199 sma-mir-8406; +MI0027200 sma-mir-8407; +MI0027201 sma-mir-8408; +MI0027202 sma-mir-8409; +MI0027203 sma-mir-8410; +MI0027204 sma-mir-8411; +MI0027205 sma-mir-8412; +MI0027206 sma-mir-8413; +MI0027207 sma-mir-8414; +MI0027208 sma-mir-8415; +MI0027209 sma-mir-8416; +MI0027210 sma-mir-8417; +MI0027211 sma-mir-8418; +MI0027212 sma-mir-8419; +MI0027213 sma-mir-8420; +MI0027214 sma-mir-8421; +MI0027215 sma-mir-8422; +MI0027216 sma-mir-8423; +MI0027217 sma-mir-8424; +MI0027218 sma-mir-8425; +MI0027219 sma-mir-8426; +MI0027220 sma-mir-8427; +MI0027221 sma-mir-8428; +MI0027222 sma-mir-8429; +MI0027223 sma-mir-8430; +MI0027224 sma-mir-8431; +MI0027225 sma-mir-8432; +MI0027226 sma-mir-8433; +MI0027227 sma-mir-8434; +MI0027228 sma-mir-8435; +MI0027229 sma-mir-8436; +MI0027230 sma-mir-8437; +MI0027231 sma-mir-8438; +MI0027232 sma-mir-8439; +MI0027233 sma-mir-8440; +MI0027234 sma-mir-8441; +MI0027235 sma-mir-745; +MI0027236 sma-mir-8442; +MI0027237 sma-mir-281; +MI0027238 sma-mir-8443; +MI0027239 sma-mir-8444; +MI0027240 sma-mir-7; +MI0027241 sma-mir-8445; +MI0027242 sma-mir-8446; +MI0027243 sma-mir-8447; +MI0027244 sma-mir-8448; +MI0027245 sma-mir-8449; +MI0027246 sma-mir-8450; +MI0027247 sma-mir-8451; +MI0027248 sma-mir-8452; +MI0027249 sma-mir-8453; +MI0027250 sma-mir-124b; +MI0027251 sma-mir-8454; +MI0027252 sma-mir-8455; +MI0027253 sma-mir-8456; +MI0027254 sma-mir-8457; +MI0027255 sma-mir-8458; +MI0027256 sma-mir-1a; +MI0027257 sma-mir-755; +MI0027258 sma-mir-8459; +MI0027259 sma-mir-96; +MI0027260 sma-mir-8460; +MI0027261 sma-mir-8461; +MI0027262 sma-mir-1b; +MI0027263 sma-mir-8462; +MI0027264 sma-mir-8463; +MI0027265 sma-mir-8464; +MI0027266 sma-mir-8465; +MI0027267 sma-mir-8466; +MI0027268 sma-mir-8467; +MI0027269 sma-mir-8468; +MI0027270 sma-mir-8469; +MI0027271 sma-mir-8470; +MI0027272 sma-mir-8471; +MI0027273 sma-mir-8472; +MI0027274 sma-mir-2162; +MI0027275 sma-mir-8473; +MI0027276 sma-mir-8474; +MI0027277 sma-mir-8475; +MI0027278 sma-mir-8476; +MI0027279 sma-mir-8477; +MI0027280 sma-mir-8478; +MI0027281 sma-mir-8479; +MI0027282 sma-mir-8480; +MI0027283 sma-mir-8481; +MI0027284 sma-mir-8482; +MI0027285 sma-mir-8483; +MI0027286 sma-mir-8484; +MI0027287 sma-mir-2f; +MI0027288 hsa-mir-8485; +MI0027289 pxy-mir-8486; +MI0027290 pxy-mir-8487; +MI0027291 pxy-mir-8488; +MI0027292 pxy-mir-8489a; +MI0027293 pxy-mir-8490; +MI0027294 pxy-mir-8491; +MI0027295 pxy-mir-8492; +MI0027296 pxy-mir-8493; +MI0027297 pxy-mir-8494; +MI0027298 pxy-mir-8495; +MI0027299 pxy-mir-8496; +MI0027300 pxy-mir-8497; +MI0027301 pxy-mir-8498; +MI0027302 pxy-mir-8499a; +MI0027303 pxy-mir-8499b; +MI0027304 pxy-mir-8499c; +MI0027305 pxy-mir-8501; +MI0027306 pxy-mir-252; +MI0027307 pxy-mir-8502; +MI0027308 pxy-mir-8503; +MI0027309 pxy-mir-8504; +MI0027310 pxy-mir-2a; +MI0027311 pxy-mir-965; +MI0027312 pxy-mir-8505; +MI0027313 pxy-mir-8537a;pxy-mir-8537-1; +MI0027314 pxy-mir-8506; +MI0027315 pxy-mir-308; +MI0027316 pxy-mir-8507; +MI0027317 pxy-bantam; +MI0027318 pxy-mir-184; +MI0027319 pxy-mir-8508; +MI0027320 pxy-mir-2733a; +MI0027321 pxy-mir-7b; +MI0027322 pxy-mir-8509; +MI0027323 pxy-mir-8510a-5; +MI0027324 pxy-mir-8510a-4; +MI0027325 pxy-mir-8510b; +MI0027326 pxy-mir-750; +MI0027327 pxy-mir-8512-1; +MI0027328 pxy-mir-263; +MI0027329 pxy-mir-8511; +MI0027330 pxy-mir-2733b; +MI0027331 pxy-mir-8515-1; +MI0027332 pxy-mir-8517a; +MI0027333 pxy-mir-8512-2; +MI0027334 pxy-mir-8513; +MI0027335 pxy-mir-8514; +MI0027336 pxy-mir-8528a; +MI0027337 pxy-mir-2756; +MI0027338 pxy-mir-8515-2; +MI0027339 pxy-mir-929; +MI0027340 pxy-mir-8521b-10; +MI0027341 pxy-mir-8521a-3; +MI0027342 pxy-mir-8516; +MI0027343 pxy-mir-8521a-1; +MI0027344 pxy-mir-8521a-2; +MI0027345 pxy-mir-8521b-11; +MI0027346 pxy-mir-8517b; +MI0027347 pxy-mir-279a; +MI0027348 pxy-mir-8518; +MI0027349 pxy-mir-8521b-8; +MI0027350 pxy-mir-8521b-3; +MI0027351 pxy-mir-8521b-1; +MI0027352 pxy-mir-8519; +MI0027353 pxy-mir-8520; +MI0027354 pxy-mir-8500; +MI0027355 pxy-mir-6497; +MI0027356 pxy-mir-8521b-4; +MI0027357 pxy-mir-7a; +MI0027358 pxy-mir-8522; +MI0027359 pxy-mir-8523; +MI0027360 pxy-mir-8524-1; +MI0027361 pxy-mir-8524-2; +MI0027362 pxy-mir-8525; +MI0027363 pxy-mir-8526; +MI0027364 pxy-mir-8510a-7; +MI0027365 pxy-mir-8527; +MI0027366 pxy-mir-8528b; +MI0027367 pxy-mir-8529; +MI0027368 pxy-mir-8530; +MI0027369 pxy-mir-8531; +MI0027370 pxy-mir-8489b; +MI0027371 pxy-mir-9a; +MI0027372 pxy-mir-8532; +MI0027373 pxy-mir-8533; +MI0027374 pxy-mir-8534; +MI0027375 pxy-mir-193; +MI0027376 pxy-mir-8535-1; +MI0027377 pxy-mir-8535-2; +MI0027378 pxy-mir-277; +MI0027379 pxy-mir-8510a-2; +MI0027380 pxy-mir-283; +MI0027381 pxy-mir-306-1; +MI0027382 pxy-mir-306-2; +MI0027383 pxy-mir-3286; +MI0027384 pxy-mir-8536b; +MI0027385 pxy-mir-8537b;pxy-mir-8537-2; +MI0027386 pxy-mir-10; +MI0027387 pxy-mir-8538; +MI0027388 pxy-mir-8539-1; +MI0027389 pxy-mir-8539-2; +MI0027390 pxy-mir-8540; +MI0027391 pxy-mir-6307; +MI0027392 pxy-mir-8541; +MI0027393 pxy-mir-745; +MI0027394 pxy-mir-8521b-5; +MI0027395 pxy-mir-8521a-5; +MI0027396 pxy-mir-8510a-8; +MI0027397 pxy-mir-8510a-1; +MI0027398 pxy-mir-8510a-3; +MI0027399 pxy-mir-2b; +MI0027400 pxy-mir-281; +MI0027401 pxy-mir-8542; +MI0027402 pxy-mir-8543; +MI0027403 pxy-mir-9b-1; +MI0027404 pxy-mir-9b-2; +MI0027405 pxy-mir-2525-1; +MI0027406 pxy-mir-2525-2; +MI0027407 pxy-mir-8544-1; +MI0027408 pxy-mir-8544-2; +MI0027409 pxy-mir-8545; +MI0027410 pxy-mir-274; +MI0027411 pxy-mir-8521b-6; +MI0027412 pxy-mir-8521a-4; +MI0027413 pxy-mir-8510a-6; +MI0027414 pxy-mir-8546; +MI0027415 pxy-mir-8536a; +MI0027416 pxy-mir-8521b-7; +MI0027417 pxy-mir-8521b-2; +MI0027418 pxy-mir-8521b-9; +MI0027419 pxy-mir-8547; +MI0027420 pxy-mir-2767; +MI0027421 pxy-mir-279b; +MI0027422 bta-mir-8548; +MI0027423 bta-mir-8549; +MI0027424 bta-mir-8550; +MI0027425 atr-MIR8551; +MI0027426 atr-MIR8552a; +MI0027427 atr-MIR8553a; +MI0027428 atr-MIR8554; +MI0027429 atr-MIR8555; +MI0027430 atr-MIR8556; +MI0027431 atr-MIR8553b; +MI0027432 atr-MIR8557; +MI0027433 atr-MIR8558a; +MI0027434 atr-MIR8559; +MI0027435 atr-MIR8617; +MI0027436 atr-MIR8560; +MI0027437 atr-MIR8561; +MI0027438 atr-MIR8562a; +MI0027439 atr-MIR8562b; +MI0027440 atr-MIR8562c; +MI0027441 atr-MIR8563; +MI0027442 atr-MIR8564; +MI0027443 atr-MIR8565g; +MI0027444 atr-MIR8566; +MI0027445 atr-MIR8567; +MI0027446 atr-MIR8568; +MI0027447 atr-MIR8569; +MI0027448 atr-MIR8565a; +MI0027449 atr-MIR8565b; +MI0027450 atr-MIR8565c; +MI0027451 atr-MIR8565d; +MI0027452 atr-MIR8565e; +MI0027453 atr-MIR8565f; +MI0027454 atr-MIR8570; +MI0027455 atr-MIR8571; +MI0027456 atr-MIR8552b; +MI0027457 atr-MIR8572; +MI0027458 atr-MIR8573; +MI0027459 atr-MIR8574; +MI0027460 atr-MIR8575; +MI0027461 atr-MIR8576; +MI0027462 atr-MIR8577; +MI0027463 atr-MIR8578; +MI0027464 atr-MIR8579; +MI0027465 atr-MIR8580; +MI0027466 atr-MIR8581; +MI0027467 atr-MIR8552c; +MI0027468 atr-MIR8582; +MI0027469 atr-MIR8583; +MI0027470 atr-MIR8584; +MI0027471 atr-MIR8552d; +MI0027472 atr-MIR8585; +MI0027473 atr-MIR8586; +MI0027474 atr-MIR8616; +MI0027475 atr-MIR8587; +MI0027476 atr-MIR8588; +MI0027477 atr-MIR8589; +MI0027478 atr-MIR8590; +MI0027479 atr-MIR8591; +MI0027480 atr-MIR8592; +MI0027481 atr-MIR8593; +MI0027482 atr-MIR8565h; +MI0027483 atr-MIR8594; +MI0027484 atr-MIR8595; +MI0027485 atr-MIR8596; +MI0027486 atr-MIR8597; +MI0027487 atr-MIR8598; +MI0027488 atr-MIR8599; +MI0027489 atr-MIR8600; +MI0027490 atr-MIR8601; +MI0027491 atr-MIR8602; +MI0027492 atr-MIR8603; +MI0027493 atr-MIR8604; +MI0027494 atr-MIR8605; +MI0027495 atr-MIR8606; +MI0027496 atr-MIR8607; +MI0027497 atr-MIR2111; +MI0027498 atr-MIR8608; +MI0027499 atr-MIR8609; +MI0027500 atr-MIR8610; +MI0027501 atr-MIR8611; +MI0027502 atr-MIR8612; +MI0027503 atr-MIR8613; +MI0027504 atr-MIR8614; +MI0027505 atr-MIR156a; +MI0027506 atr-MIR156b; +MI0027507 atr-MIR156c; +MI0027508 atr-MIR156d; +MI0027509 atr-MIR159; +MI0027510 atr-MIR160; +MI0027511 atr-MIR164a; +MI0027512 atr-MIR164b; +MI0027513 atr-MIR166a; +MI0027514 atr-MIR166b; +MI0027515 atr-MIR166c; +MI0027516 atr-MIR166d; +MI0027517 atr-MIR167; +MI0027518 atr-MIR168; +MI0027519 atr-MIR169a; +MI0027520 atr-MIR169b; +MI0027521 atr-MIR169c; +MI0027522 atr-MIR171a; +MI0027523 atr-MIR171b; +MI0027524 atr-MIR171c; +MI0027525 atr-MIR172; +MI0027526 atr-MIR319a; +MI0027527 atr-MIR319b; +MI0027528 atr-MIR319c; +MI0027529 atr-MIR319d; +MI0027530 atr-MIR319e; +MI0027531 atr-MIR390; +MI0027532 atr-MIR393; +MI0027533 atr-MIR394; +MI0027534 atr-MIR395; +MI0027535 atr-MIR396a; +MI0027536 atr-MIR396b; +MI0027537 atr-MIR396c; +MI0027538 atr-MIR396d; +MI0027539 atr-MIR396e; +MI0027540 atr-MIR397a; +MI0027541 atr-MIR397b; +MI0027542 atr-MIR398; +MI0027543 atr-MIR477; +MI0027544 atr-MIR535; +MI0027545 atr-MIR828; +MI0027546 atr-MIR8558b; +MI0027547 atr-MIR8615; +MI0027548 atr-MIR2950; +MI0027549 esi-MIR8618a; +MI0027550 esi-MIR8618b; +MI0027551 esi-MIR8619; +MI0027552 esi-MIR8620; +MI0027553 esi-MIR8621; +MI0027554 esi-MIR8622a; +MI0027555 esi-MIR8623c; +MI0027556 esi-MIR8622b; +MI0027557 esi-MIR8623a; +MI0027558 esi-MIR8624a; +MI0027559 esi-MIR8625; +MI0027560 esi-MIR8622c; +MI0027561 esi-MIR8626; +MI0027562 esi-MIR8627; +MI0027563 esi-MIR8628; +MI0027564 esi-MIR8629; +MI0027565 esi-MIR8623d; +MI0027566 esi-MIR8630; +MI0027567 esi-MIR8631; +MI0027568 esi-MIR8624b; +MI0027569 esi-MIR8623b; +MI0027570 sly-MIR164a; +MI0027571 sly-MIR164b; +MI0027572 gra-MIR7505b; +MI0027573 gra-MIR8632; +MI0027574 gra-MIR8633; +MI0027575 gra-MIR3267; +MI0027576 gra-MIR8634; +MI0027577 gra-MIR3476; +MI0027578 gra-MIR167a; +MI0027579 gra-MIR167b; +MI0027580 gra-MIR8635; +MI0027581 gra-MIR8636; +MI0027582 gra-MIR8637; +MI0027583 gra-MIR172a; +MI0027584 gra-MIR8639a; +MI0027585 gra-MIR8639b; +MI0027586 gra-MIR8639c; +MI0027587 gra-MIR8639f; +MI0027588 gra-MIR8639g; +MI0027589 gra-MIR8639h; +MI0027590 gra-MIR8639i; +MI0027591 gra-MIR8640; +MI0027592 gra-MIR7486e; +MI0027593 gra-MIR8642; +MI0027594 gra-MIR8643a; +MI0027595 gra-MIR8643b; +MI0027596 gra-MIR8663a; +MI0027597 gra-MIR8644; +MI0027598 gra-MIR8645; +MI0027599 gra-MIR8646; +MI0027600 gra-MIR8647; +MI0027601 gra-MIR8648; +MI0027602 gra-MIR8649; +MI0027603 gra-MIR8650; +MI0027604 gra-MIR5741; +MI0027605 gra-MIR8651; +MI0027606 gra-MIR8652; +MI0027607 gra-MIR8653a; +MI0027608 gra-MIR7502b; +MI0027609 gra-MIR7502c; +MI0027610 gra-MIR8709a; +MI0027611 gra-MIR7492d; +MI0027612 gra-MIR8654a; +MI0027613 gra-MIR8654b; +MI0027614 gra-MIR8654c; +MI0027615 gra-MIR8655; +MI0027616 gra-MIR8656; +MI0027617 gra-MIR8657a; +MI0027618 gra-MIR8657c; +MI0027619 gra-MIR8657d; +MI0027620 gra-MIR8657e; +MI0027621 gra-MIR8658; +MI0027622 gra-MIR7504c; +MI0027623 gra-MIR8659a; +MI0027624 gra-MIR8659b; +MI0027625 gra-MIR8660; +MI0027626 gra-MIR8661; +MI0027627 gra-MIR8662; +MI0027628 gra-MIR8663b; +MI0027629 gra-MIR8664; +MI0027630 gra-MIR7486d; +MI0027631 gra-MIR8665; +MI0027632 gra-MIR8666; +MI0027633 gra-MIR8667; +MI0027634 gra-MIR8668; +MI0027635 gra-MIR8669; +MI0027636 gra-MIR7503b; +MI0027637 gra-MIR1446; +MI0027638 gra-MIR8671; +MI0027639 gra-MIR8672; +MI0027640 gra-MIR8673; +MI0027641 gra-MIR8675a; +MI0027642 gra-MIR8676; +MI0027643 gra-MIR8677; +MI0027644 gra-MIR8678; +MI0027645 gra-MIR8679; +MI0027646 gra-MIR8680; +MI0027647 gra-MIR8681; +MI0027648 gra-MIR8682; +MI0027649 gra-MIR8683; +MI0027650 gra-MIR7484c; +MI0027651 gra-MIR7484d; +MI0027652 gra-MIR8684; +MI0027653 gra-MIR8685; +MI0027654 gra-MIR8686; +MI0027655 gra-MIR8687; +MI0027656 gra-MIR8688; +MI0027657 gra-MIR7494b; +MI0027658 gra-MIR8690; +MI0027659 gra-MIR8691; +MI0027660 gra-MIR8692; +MI0027661 gra-MIR7504d; +MI0027662 gra-MIR7504e; +MI0027663 gra-MIR7504f; +MI0027664 gra-MIR7504g; +MI0027665 gra-MIR7504h; +MI0027666 gra-MIR7584e; +MI0027667 gra-MIR7504n; +MI0027668 gra-MIR8693; +MI0027669 gra-MIR8694a; +MI0027670 gra-MIR8694b; +MI0027671 gra-MIR8695; +MI0027672 gra-MIR8696; +MI0027673 gra-MIR8697; +MI0027674 gra-MIR8698; +MI0027675 gra-MIR8699; +MI0027676 gra-MIR8700; +MI0027677 gra-MIR8701; +MI0027678 gra-MIR8702; +MI0027679 gra-MIR8675b; +MI0027680 gra-MIR8675c; +MI0027681 gra-MIR530a; +MI0027682 gra-MIR530b; +MI0027683 gra-MIR8703a; +MI0027684 gra-MIR8703b; +MI0027685 gra-MIR8703c; +MI0027686 gra-MIR8705; +MI0027687 gra-MIR8706a; +MI0027688 gra-MIR8706b; +MI0027689 gra-MIR8707; +MI0027690 gra-MIR8708; +MI0027691 gra-MIR8709c; +MI0027692 gra-MIR8710a; +MI0027693 gra-MIR8710b; +MI0027694 gra-MIR8711; +MI0027695 gra-MIR8712; +MI0027696 gra-MIR7504i; +MI0027697 gra-MIR8713; +MI0027698 gra-MIR8714; +MI0027699 gra-MIR7494c; +MI0027700 gra-MIR8715; +MI0027701 gra-MIR8716; +MI0027702 gra-MIR7484e; +MI0027703 gra-MIR8719; +MI0027704 gra-MIR8720; +MI0027705 gra-MIR7486j; +MI0027706 gra-MIR8721a; +MI0027707 gra-MIR8721b; +MI0027708 gra-MIR164a; +MI0027709 gra-MIR8722; +MI0027710 gra-MIR7492e; +MI0027711 gra-MIR8723b; +MI0027712 gra-MIR8724; +MI0027713 gra-MIR8725; +MI0027714 gra-MIR477; +MI0027715 gra-MIR8726; +MI0027716 gra-MIR7486f; +MI0027717 gra-MIR7486g; +MI0027718 gra-MIR8727; +MI0027719 gra-MIR7492g; +MI0027720 gra-MIR7492h; +MI0027721 gra-MIR7492i; +MI0027722 gra-MIR7492j; +MI0027723 gra-MIR7492k; +MI0027724 gra-MIR8729; +MI0027725 gra-MIR8730; +MI0027726 gra-MIR8731; +MI0027727 gra-MIR7492l; +MI0027728 gra-MIR7492m; +MI0027729 gra-MIR7506b; +MI0027730 gra-MIR5207; +MI0027731 gra-MIR7502d; +MI0027732 gra-MIR8732; +MI0027733 gra-MIR8733; +MI0027734 gra-MIR8734; +MI0027735 gra-MIR7484o; +MI0027736 gra-MIR172b; +MI0027737 gra-MIR7486i; +MI0027738 gra-MIR8771a; +MI0027739 gra-MIR8771b; +MI0027740 gra-MIR8771e; +MI0027741 gra-MIR399; +MI0027742 gra-MIR8735; +MI0027743 gra-MIR8736; +MI0027744 gra-MIR8737; +MI0027745 gra-MIR8738a; +MI0027746 gra-MIR8738b; +MI0027747 gra-MIR8740; +MI0027748 gra-MIR8741; +MI0027749 gra-MIR8771c; +MI0027750 gra-MIR7492n; +MI0027751 gra-MIR166c; +MI0027752 gra-MIR7484f; +MI0027753 gra-MIR8742a; +MI0027754 gra-MIR8742b; +MI0027755 gra-MIR8743c; +MI0027756 gra-MIR8743d; +MI0027757 gra-MIR8743e; +MI0027758 gra-MIR8743a; +MI0027759 gra-MIR8781a; +MI0027760 gra-MIR8744; +MI0027761 gra-MIR8745; +MI0027762 gra-MIR167c; +MI0027763 gra-MIR7494d; +MI0027764 gra-MIR8709b; +MI0027765 gra-MIR8746; +MI0027766 gra-MIR8747; +MI0027767 gra-MIR8748; +MI0027768 gra-MIR7494e; +MI0027769 gra-MIR7494f; +MI0027770 gra-MIR8749; +MI0027771 gra-MIR8750; +MI0027772 gra-MIR8751a; +MI0027773 gra-MIR8751b; +MI0027774 gra-MIR8752; +MI0027775 gra-MIR166d; +MI0027776 gra-MIR8753; +MI0027777 gra-MIR8771d; +MI0027778 gra-MIR8754; +MI0027779 gra-MIR8755; +MI0027780 gra-MIR8756; +MI0027781 gra-MIR8757a; +MI0027782 gra-MIR8758; +MI0027783 gra-MIR8757b; +MI0027784 gra-MIR8759; +MI0027785 gra-MIR8760; +MI0027786 gra-MIR8761; +MI0027787 gra-MIR8762a; +MI0027788 gra-MIR7502e; +MI0027789 gra-MIR8762b; +MI0027790 gra-MIR8763; +MI0027791 gra-MIR8674a; +MI0027792 gra-MIR8674b; +MI0027793 gra-MIR8764; +MI0027794 gra-MIR8765; +MI0027795 gra-MIR8766; +MI0027796 gra-MIR8653b; +MI0027797 gra-MIR8767a; +MI0027798 gra-MIR8767b; +MI0027799 gra-MIR8768; +MI0027800 gra-MIR482c; +MI0027801 gra-MIR7484g; +MI0027802 gra-MIR8769; +MI0027803 gra-MIR8770; +MI0027804 gra-MIR8771f; +MI0027805 gra-MIR8772; +MI0027806 gra-MIR8773; +MI0027807 gra-MIR8774; +MI0027808 gra-MIR8775; +MI0027809 gra-MIR8762d; +MI0027810 gra-MIR7484h; +MI0027811 gra-MIR7484i; +MI0027812 gra-MIR7484j; +MI0027813 gra-MIR7484k; +MI0027814 gra-MIR8776a; +MI0027815 gra-MIR8776b; +MI0027816 gra-MIR8776c; +MI0027817 gra-MIR8776d; +MI0027818 gra-MIR8777; +MI0027819 gra-MIR482d; +MI0027820 gra-MIR7504k; +MI0027821 gra-MIR7504l; +MI0027822 gra-MIR7504m; +MI0027823 gra-MIR8779; +MI0027824 gra-MIR7484l; +MI0027825 gra-MIR8780; +MI0027826 gra-MIR8743b; +MI0027827 gra-MIR8782; +MI0027828 gra-MIR8783; +MI0027829 gra-MIR7484m; +MI0027830 gra-MIR7486c; +MI0027831 gra-MIR8784; +MI0027832 gra-MIR8785; +MI0027833 gra-MIR8786a; +MI0027834 gra-MIR8786b; +MI0027835 gra-MIR8767c; +MI0027836 gra-MIR8787; +MI0027837 gra-MIR8762e; +MI0027838 gra-MIR8762c; +MI0027839 gra-MIR8670a; +MI0027840 gra-MIR8670b; +MI0027841 gra-MIR8657b; +MI0027842 gra-MIR7504j; +MI0027843 gra-MIR8717; +MI0027844 gra-MIR7492f; +MI0027845 gra-MIR8723a; +MI0027846 gra-MIR7492o; +MI0027847 gra-MIR8704; +MI0027848 gra-MIR8674c; +MI0027849 gra-MIR8781b; +MI0027850 gra-MIR7486h; +MI0027851 gra-MIR7493b; +MI0027852 gra-MIR8739; +MI0027853 gra-MIR7484n; +MI0027854 gra-MIR8728; +MI0027855 gra-MIR8778; +MI0027856 gra-MIR8718; +MI0027857 gra-MIR8641; +MI0027858 gra-MIR8639d; +MI0027859 gra-MIR8639e; +MI0027860 gra-MIR8689; +MI0027861 gra-MIR8638; +MI0027862 gra-MIR7502f; +MI0027863 pin-MIR8788; +MI0027864 psj-MIR8788a; +MI0027865 psj-MIR8788b; +MI0027866 pra-MIR8788a; +MI0027867 pra-MIR8788b; +MI0027868 cfa-mir-6529; +MI0027869 cfa-mir-8789; +MI0027870 cfa-mir-8790; +MI0027871 cfa-mir-8791a; +MI0027872 cfa-mir-8792; +MI0027873 cfa-mir-8793-1; +MI0027874 cfa-mir-8794-1; +MI0027875 cfa-mir-8795; +MI0027876 cfa-mir-8796; +MI0027877 cfa-mir-8797; +MI0027878 cfa-mir-8798; +MI0027879 cfa-mir-8799a; +MI0027880 cfa-mir-8800; +MI0027881 cfa-mir-8801; +MI0027882 cfa-mir-8802; +MI0027883 cfa-mir-8803; +MI0027884 cfa-mir-8804; +MI0027885 cfa-mir-8805; +MI0027886 cfa-mir-8806; +MI0027887 cfa-mir-8807; +MI0027888 cfa-mir-8808; +MI0027889 cfa-mir-8809; +MI0027890 cfa-mir-8810; +MI0027891 cfa-mir-8811; +MI0027892 cfa-mir-8812; +MI0027893 cfa-mir-8813-1; +MI0027894 cfa-mir-8814; +MI0027895 cfa-mir-8815-1; +MI0027896 cfa-mir-8816; +MI0027897 cfa-mir-8815-2; +MI0027898 cfa-mir-8817; +MI0027899 cfa-mir-8818; +MI0027900 cfa-mir-8819; +MI0027901 cfa-mir-8820; +MI0027902 cfa-mir-8821; +MI0027903 cfa-mir-8822; +MI0027904 cfa-mir-8823; +MI0027905 cfa-mir-8824; +MI0027906 cfa-mir-8825; +MI0027907 cfa-mir-8799b; +MI0027908 cfa-mir-8826; +MI0027909 cfa-mir-8799c; +MI0027910 cfa-mir-8827; +MI0027911 cfa-mir-8828; +MI0027912 cfa-mir-1249; +MI0027913 cfa-mir-8829; +MI0027914 cfa-mir-8830-1; +MI0027915 cfa-mir-8830-2; +MI0027916 cfa-mir-8831; +MI0027917 cfa-mir-8830-3; +MI0027918 cfa-mir-8832; +MI0027919 cfa-mir-8833; +MI0027920 cfa-mir-8834a-1; +MI0027921 cfa-mir-8835; +MI0027922 cfa-mir-8836; +MI0027923 cfa-mir-8837; +MI0027924 cfa-mir-8838; +MI0027925 cfa-mir-8839; +MI0027926 cfa-mir-8840; +MI0027927 cfa-mir-8841-1; +MI0027928 cfa-mir-8842; +MI0027929 cfa-mir-8843; +MI0027930 cfa-mir-1301; +MI0027931 cfa-mir-8844; +MI0027932 cfa-mir-8845; +MI0027933 cfa-mir-8846; +MI0027934 cfa-mir-8799d; +MI0027935 cfa-mir-8794-2; +MI0027936 cfa-mir-8847; +MI0027937 cfa-mir-8848; +MI0027938 cfa-mir-8793-2; +MI0027939 cfa-mir-8793-3; +MI0027940 cfa-mir-8849; +MI0027941 cfa-mir-8850; +MI0027942 cfa-mir-8851; +MI0027943 cfa-mir-8852; +MI0027944 cfa-mir-8853; +MI0027945 cfa-mir-8854; +MI0027946 cfa-mir-8855; +MI0027947 cfa-mir-8856; +MI0027948 cfa-mir-8857; +MI0027949 cfa-mir-8858; +MI0027950 cfa-mir-8859a; +MI0027951 cfa-mir-8860; +MI0027952 cfa-mir-8861; +MI0027953 cfa-mir-1343; +MI0027954 cfa-mir-8859b; +MI0027955 cfa-mir-8862; +MI0027956 cfa-mir-8863; +MI0027957 cfa-mir-8864-1; +MI0027958 cfa-mir-8865; +MI0027959 cfa-mir-8866; +MI0027960 cfa-mir-8867; +MI0027961 cfa-mir-8868; +MI0027962 cfa-mir-8869; +MI0027963 cfa-mir-8870; +MI0027964 cfa-mir-8871; +MI0027965 cfa-mir-8872; +MI0027966 cfa-mir-2387; +MI0027967 cfa-mir-8799e-1; +MI0027968 cfa-mir-8799f; +MI0027969 cfa-mir-8873a; +MI0027970 cfa-mir-8874; +MI0027971 cfa-mir-8875; +MI0027972 cfa-mir-8876; +MI0027973 cfa-mir-8877; +MI0027974 cfa-mir-8878; +MI0027975 cfa-mir-8879; +MI0027976 cfa-mir-8799e-2; +MI0027977 cfa-mir-8880; +MI0027978 cfa-mir-8881; +MI0027979 cfa-mir-7180; +MI0027980 cfa-mir-1185; +MI0027981 cfa-mir-8882; +MI0027982 cfa-mir-8883; +MI0027983 cfa-mir-8884; +MI0027984 cfa-mir-889; +MI0027985 cfa-mir-3958; +MI0027986 cfa-mir-8841-2; +MI0027987 cfa-mir-8885; +MI0027988 cfa-mir-8886; +MI0027989 cfa-mir-8887; +MI0027990 cfa-mir-8888; +MI0027991 cfa-mir-6516; +MI0027992 cfa-mir-8889; +MI0027993 cfa-mir-8873b; +MI0027994 cfa-let-7d; +MI0027995 cfa-mir-8890; +MI0027996 cfa-mir-8891; +MI0027997 cfa-mir-8892; +MI0027998 cfa-mir-769; +MI0027999 cfa-mir-8893; +MI0028000 cfa-mir-8894; +MI0028001 cfa-mir-8864-4; +MI0028002 cfa-mir-8864-3; +MI0028003 cfa-mir-8813-2; +MI0028004 cfa-mir-8895; +MI0028005 cfa-mir-8896; +MI0028006 cfa-mir-8897; +MI0028007 cfa-mir-449b; +MI0028008 cfa-mir-8799g; +MI0028009 cfa-mir-8898; +MI0028010 cfa-mir-8899; +MI0028011 cfa-mir-8900; +MI0028012 cfa-mir-8901; +MI0028013 cfa-mir-8902; +MI0028014 cfa-mir-1296; +MI0028015 cfa-mir-8903; +MI0028016 cfa-mir-8908b; +MI0028017 cfa-mir-507b; +MI0028018 cfa-mir-8904a; +MI0028019 cfa-mir-8908f; +MI0028020 cfa-mir-508a; +MI0028021 cfa-mir-8908d-2; +MI0028022 cfa-mir-8908d-3; +MI0028023 cfa-mir-2483; +MI0028024 cfa-mir-506; +MI0028025 cfa-mir-1468; +MI0028026 cfa-mir-8904b; +MI0028027 cfa-mir-508b; +MI0028028 cfa-mir-8908e; +MI0028029 cfa-mir-2114; +MI0028030 cfa-mir-8908a-1; +MI0028031 cfa-mir-8834a-2; +MI0028032 cfa-mir-8791b; +MI0028033 cfa-mir-8834b; +MI0028034 cfa-mir-8908a-2; +MI0028035 cfa-mir-507a; +MI0028036 cfa-mir-8908d-1; +MI0028037 cfa-mir-8908c; +MI0028038 cfa-mir-8908a-3; +MI0028039 cfa-mir-8908a-4; +MI0028040 cfa-mir-8864-2; +MI0028041 cfa-mir-8906; +MI0028042 cfa-mir-8907; +MI0028043 cfa-mir-8905; +MI0028044 eca-mir-8909; +MI0028045 eca-mir-8910; +MI0028046 eca-mir-8911; +MI0028047 eca-mir-8912; +MI0028048 eca-mir-8913; +MI0028049 eca-mir-8914; +MI0028050 eca-mir-8915; +MI0028051 eca-mir-8916; +MI0028052 eca-mir-8917; +MI0028053 eca-mir-8918; +MI0028054 eca-mir-8919; +MI0028055 eca-mir-8920; +MI0028056 eca-mir-8921-1; +MI0028057 eca-mir-8922; +MI0028058 eca-mir-8923-1; +MI0028059 eca-mir-8924-1; +MI0028060 eca-mir-8925; +MI0028061 eca-mir-8926; +MI0028062 eca-mir-8927-1; +MI0028063 eca-mir-8928; +MI0028064 eca-mir-8929-1; +MI0028065 eca-mir-8921-2; +MI0028066 eca-mir-8930; +MI0028067 eca-mir-8931; +MI0028068 eca-mir-8929-2; +MI0028069 eca-mir-8932-1; +MI0028070 eca-mir-185; +MI0028071 eca-mir-8933-1; +MI0028072 eca-mir-8934-1; +MI0028073 eca-mir-8921-3; +MI0028074 eca-mir-8935-1; +MI0028075 eca-mir-8936; +MI0028076 eca-mir-8924-2; +MI0028077 eca-mir-8937-1; +MI0028078 eca-mir-8938; +MI0028079 eca-mir-8923-2; +MI0028080 eca-mir-8939; +MI0028081 eca-mir-8923-3; +MI0028082 eca-mir-8940-1; +MI0028083 eca-mir-8935-2; +MI0028084 eca-mir-8933-2; +MI0028085 eca-mir-8941-1; +MI0028086 eca-mir-8942; +MI0028087 eca-mir-8927-2; +MI0028088 eca-mir-8923-4; +MI0028089 eca-mir-8943; +MI0028090 eca-mir-8944; +MI0028091 eca-mir-8945; +MI0028092 eca-mir-8941-2; +MI0028093 eca-mir-8946; +MI0028094 eca-mir-8947; +MI0028095 eca-mir-8948; +MI0028096 eca-mir-8949; +MI0028097 eca-mir-8950; +MI0028098 eca-mir-8951; +MI0028099 eca-mir-8952; +MI0028100 eca-mir-8953; +MI0028101 eca-mir-8954; +MI0028102 eca-mir-3959; +MI0028103 eca-mir-8955; +MI0028104 eca-mir-3958; +MI0028105 eca-mir-8940-2; +MI0028106 eca-mir-329b; +MI0028107 eca-mir-8956; +MI0028108 eca-mir-154b; +MI0028109 eca-mir-449b; +MI0028110 eca-mir-8957; +MI0028111 eca-mir-8958; +MI0028112 eca-mir-8959; +MI0028113 eca-mir-8960; +MI0028114 eca-mir-8961; +MI0028115 eca-mir-1388; +MI0028116 eca-mir-8962; +MI0028117 eca-mir-8963; +MI0028118 eca-mir-8964; +MI0028119 eca-mir-8965; +MI0028120 eca-mir-8966; +MI0028121 eca-mir-8967; +MI0028122 eca-mir-8968; +MI0028123 eca-mir-7177a; +MI0028124 eca-mir-7045; +MI0028125 eca-mir-8969; +MI0028126 eca-mir-8970; +MI0028127 eca-mir-8971; +MI0028128 eca-mir-8972; +MI0028129 eca-mir-8973; +MI0028130 eca-mir-8974; +MI0028131 eca-mir-8975; +MI0028132 eca-mir-8976; +MI0028133 eca-mir-8977; +MI0028134 eca-mir-8978; +MI0028135 eca-mir-8979; +MI0028136 eca-mir-8980; +MI0028137 eca-mir-8981; +MI0028138 eca-mir-8982; +MI0028139 eca-mir-8983; +MI0028140 eca-mir-8984; +MI0028141 eca-mir-8985; +MI0028142 eca-mir-8986a; +MI0028143 eca-mir-8987; +MI0028144 eca-mir-8988; +MI0028145 eca-mir-8989; +MI0028146 eca-mir-8990; +MI0028147 eca-mir-8991; +MI0028148 eca-mir-8992; +MI0028149 eca-mir-1271b; +MI0028150 eca-mir-8993-1; +MI0028151 eca-mir-8986b; +MI0028152 eca-mir-8994; +MI0028153 eca-mir-8995; +MI0028154 eca-mir-8996; +MI0028155 eca-mir-8997; +MI0028156 eca-mir-7143; +MI0028157 eca-mir-8998; +MI0028158 eca-mir-8999; +MI0028159 eca-mir-9000; +MI0028160 eca-mir-8993-2; +MI0028161 eca-mir-9001; +MI0028162 eca-mir-9002-1; +MI0028163 eca-mir-9003; +MI0028164 eca-mir-9004; +MI0028165 eca-mir-9005; +MI0028166 eca-mir-9006; +MI0028167 eca-mir-9002-2; +MI0028168 eca-mir-9007; +MI0028169 eca-mir-9008; +MI0028170 eca-mir-9009; +MI0028171 eca-mir-9010; +MI0028172 eca-mir-3200; +MI0028173 eca-mir-9011; +MI0028174 eca-mir-9012; +MI0028175 eca-mir-9013; +MI0028176 eca-mir-9014-1; +MI0028177 eca-mir-9015; +MI0028178 eca-mir-9016; +MI0028179 eca-mir-8924-3; +MI0028180 eca-mir-9017; +MI0028181 eca-mir-9018; +MI0028182 eca-mir-9019; +MI0028183 eca-mir-9020; +MI0028184 eca-mir-9021; +MI0028185 eca-mir-1249; +MI0028186 eca-mir-9022; +MI0028187 eca-mir-9023; +MI0028188 eca-mir-9024; +MI0028189 eca-mir-9025; +MI0028190 eca-mir-9026; +MI0028191 eca-mir-9027; +MI0028192 eca-mir-9028; +MI0028193 eca-mir-9029; +MI0028194 eca-mir-9030; +MI0028195 eca-mir-9031; +MI0028196 eca-mir-9032; +MI0028197 eca-mir-9033-1; +MI0028198 eca-mir-9034; +MI0028199 eca-mir-9035; +MI0028200 eca-mir-9036; +MI0028201 eca-mir-9037; +MI0028202 eca-mir-9038; +MI0028203 eca-mir-9039; +MI0028204 eca-mir-9040; +MI0028205 eca-mir-9033-2; +MI0028206 eca-mir-9041; +MI0028207 eca-mir-9042; +MI0028208 eca-mir-7667; +MI0028209 eca-mir-8935-3; +MI0028210 eca-mir-9043; +MI0028211 eca-mir-9044; +MI0028212 eca-mir-9045; +MI0028213 eca-mir-1307; +MI0028214 eca-mir-9046; +MI0028215 eca-mir-9047; +MI0028216 eca-mir-9048; +MI0028217 eca-mir-8935-4; +MI0028218 eca-mir-8935-5; +MI0028219 eca-mir-9049; +MI0028220 eca-mir-9050; +MI0028221 eca-mir-9051; +MI0028222 eca-mir-9052-1; +MI0028223 eca-mir-8935-6; +MI0028224 eca-mir-9053; +MI0028225 eca-mir-9054; +MI0028226 eca-mir-9055; +MI0028227 eca-mir-9056; +MI0028228 eca-mir-9057; +MI0028229 eca-mir-9052-2; +MI0028230 eca-mir-9058a; +MI0028231 eca-mir-3548; +MI0028232 eca-mir-9059; +MI0028233 eca-mir-9060; +MI0028234 eca-mir-9061; +MI0028235 eca-mir-9062; +MI0028236 eca-mir-9063; +MI0028237 eca-mir-9064; +MI0028238 eca-mir-9065; +MI0028239 eca-mir-9066; +MI0028240 eca-mir-9067; +MI0028241 eca-mir-9068; +MI0028242 eca-mir-9069; +MI0028243 eca-mir-9070; +MI0028244 eca-mir-9071; +MI0028245 eca-mir-9072; +MI0028246 eca-mir-9073; +MI0028247 eca-mir-9074; +MI0028248 eca-mir-9075; +MI0028249 eca-mir-9076; +MI0028250 eca-mir-9077; +MI0028251 eca-mir-9078; +MI0028252 eca-mir-9079; +MI0028253 eca-mir-9080; +MI0028254 eca-mir-9081; +MI0028255 eca-mir-9082; +MI0028256 eca-mir-9083; +MI0028257 eca-mir-9084; +MI0028258 eca-mir-9085; +MI0028259 eca-mir-9086; +MI0028260 eca-mir-9087; +MI0028261 eca-mir-9088; +MI0028262 eca-mir-9089-1; +MI0028263 eca-mir-9090; +MI0028264 eca-mir-9091; +MI0028265 eca-mir-9092; +MI0028266 eca-mir-9093; +MI0028267 eca-mir-372; +MI0028268 eca-mir-9094; +MI0028269 eca-mir-9014-2; +MI0028270 eca-mir-9089-2; +MI0028271 eca-mir-9095; +MI0028272 eca-mir-9096; +MI0028273 eca-mir-9097; +MI0028274 eca-mir-744; +MI0028275 eca-mir-9098; +MI0028276 eca-mir-9099; +MI0028277 eca-mir-9100; +MI0028278 eca-mir-9101; +MI0028279 eca-mir-9102; +MI0028280 eca-mir-9103; +MI0028281 eca-mir-9104; +MI0028282 eca-mir-9105; +MI0028283 eca-mir-9106; +MI0028284 eca-mir-7035; +MI0028285 eca-mir-9107; +MI0028286 eca-mir-9108; +MI0028287 eca-mir-9109; +MI0028288 eca-mir-3065; +MI0028289 eca-mir-9110; +MI0028290 eca-mir-9111; +MI0028291 eca-mir-9112; +MI0028292 eca-mir-8934-2; +MI0028293 eca-mir-9113; +MI0028294 eca-mir-9114; +MI0028295 eca-mir-9115; +MI0028296 eca-mir-9116; +MI0028297 eca-mir-9117; +MI0028298 eca-mir-9118; +MI0028299 eca-mir-9119; +MI0028300 eca-mir-9120; +MI0028301 eca-mir-483; +MI0028302 eca-mir-9121; +MI0028303 eca-mir-9122; +MI0028304 eca-mir-9123; +MI0028305 eca-mir-1379; +MI0028306 eca-mir-9124; +MI0028307 eca-mir-9125; +MI0028308 eca-mir-9126; +MI0028309 eca-mir-9127; +MI0028310 eca-mir-9128-1; +MI0028311 eca-mir-9129; +MI0028312 eca-mir-9128-2; +MI0028313 eca-mir-9130; +MI0028314 eca-mir-9131; +MI0028315 eca-mir-9132; +MI0028316 eca-mir-9133; +MI0028317 eca-mir-9134; +MI0028318 eca-mir-9135; +MI0028319 eca-mir-9136; +MI0028320 eca-mir-9137; +MI0028321 eca-mir-9138; +MI0028322 eca-mir-9139; +MI0028323 eca-mir-7177b; +MI0028324 eca-mir-9140; +MI0028325 eca-mir-9141; +MI0028326 eca-mir-8908k-1; +MI0028327 eca-mir-9142; +MI0028328 eca-mir-8908c-1; +MI0028329 eca-mir-8908b-1; +MI0028330 eca-mir-8908d-1; +MI0028331 eca-mir-507b; +MI0028332 eca-mir-8908b-5; +MI0028333 eca-mir-2483; +MI0028334 eca-mir-8908f-2; +MI0028335 eca-mir-8908b-2; +MI0028336 eca-mir-8908e; +MI0028337 eca-mir-8908b-3; +MI0028338 eca-mir-8908f-3; +MI0028339 eca-mir-8908n; +MI0028340 eca-mir-8908d-2; +MI0028341 eca-mir-1911; +MI0028342 eca-mir-676; +MI0028343 eca-mir-514b; +MI0028344 eca-mir-8908k-2; +MI0028345 eca-mir-506a; +MI0028346 eca-mir-8908g-2; +MI0028347 eca-mir-509b; +MI0028348 eca-mir-8908h; +MI0028349 eca-mir-8908b-4; +MI0028350 eca-mir-8908j; +MI0028351 eca-mir-8908l-1; +MI0028352 eca-mir-8908a-1; +MI0028353 eca-mir-8908g-1; +MI0028354 eca-mir-2114; +MI0028355 eca-mir-8908l-2; +MI0028356 eca-mir-8908f-1; +MI0028357 eca-mir-514a; +MI0028358 eca-mir-9143; +MI0028359 eca-mir-8908m; +MI0028360 eca-mir-8908c-3; +MI0028361 eca-mir-8908a-2; +MI0028362 eca-mir-8908f-4; +MI0028363 eca-mir-8908c-2; +MI0028364 eca-mir-9058b; +MI0028365 eca-mir-8908i; +MI0028366 eca-mir-9144; +MI0028367 eca-mir-9145; +MI0028368 eca-mir-9146; +MI0028369 eca-mir-9147; +MI0028370 eca-mir-9148; +MI0028371 eca-mir-8923-5; +MI0028372 eca-mir-9149; +MI0028373 eca-mir-9150; +MI0028374 eca-mir-9151; +MI0028375 eca-mir-9152; +MI0028376 eca-mir-9153; +MI0028377 eca-mir-9154; +MI0028378 eca-mir-9155; +MI0028379 eca-mir-9156; +MI0028380 eca-mir-1543; +MI0028381 eca-mir-9157; +MI0028382 eca-mir-9158; +MI0028383 eca-mir-9159; +MI0028384 eca-mir-9160; +MI0028385 eca-mir-9161; +MI0028386 eca-mir-9162; +MI0028387 eca-mir-9163; +MI0028388 eca-mir-9164; +MI0028389 eca-mir-3613; +MI0028390 eca-mir-9165; +MI0028391 eca-mir-9166; +MI0028392 eca-mir-9167; +MI0028393 eca-mir-9168-1; +MI0028394 eca-mir-9168-2; +MI0028395 eca-mir-9169; +MI0028396 eca-mir-9170; +MI0028397 eca-mir-425; +MI0028398 eca-mir-191b; +MI0028399 eca-mir-9171; +MI0028400 eca-mir-9172; +MI0028401 eca-mir-9173; +MI0028402 eca-mir-9174; +MI0028403 eca-mir-9175; +MI0028404 eca-mir-9176; +MI0028405 eca-mir-9177; +MI0028406 eca-mir-8923-6; +MI0028407 eca-mir-9178; +MI0028408 eca-mir-9179; +MI0028409 eca-mir-6529; +MI0028410 eca-mir-9180; +MI0028411 eca-mir-9181; +MI0028412 eca-mir-9182; +MI0028413 eca-mir-9183; +MI0028414 eca-mir-9184; +MI0028415 eca-mir-8932-2; +MI0028416 eca-mir-8937-2; +MI0028417 eca-mir-9185; +MI0028418 efu-mir-9187; +MI0028419 efu-mir-9188a; +MI0028420 efu-mir-9189e; +MI0028421 efu-mir-9190; +MI0028422 efu-mir-9191-1; +MI0028423 efu-mir-9191-2; +MI0028424 efu-mir-9192; +MI0028425 efu-mir-9193-1; +MI0028426 efu-mir-9193-2; +MI0028427 efu-mir-9194; +MI0028428 efu-mir-9195-1; +MI0028429 efu-mir-9195-2; +MI0028430 efu-mir-9195-3; +MI0028431 efu-mir-9196; +MI0028432 efu-mir-9197; +MI0028433 efu-mir-9203b; +MI0028434 efu-mir-9198a; +MI0028435 efu-mir-9198b-1; +MI0028436 efu-mir-9198b-2; +MI0028437 efu-mir-9198b-3; +MI0028438 efu-mir-9198b-4; +MI0028439 efu-mir-9198c; +MI0028440 efu-mir-9198d; +MI0028441 efu-mir-9198b-5; +MI0028442 efu-mir-9198e; +MI0028443 efu-mir-9199; +MI0028444 efu-mir-9201a-1; +MI0028445 efu-mir-9201a-2; +MI0028446 efu-mir-9200b; +MI0028447 efu-mir-9201a-3; +MI0028448 efu-mir-9201b; +MI0028449 efu-mir-9201a-4; +MI0028450 efu-mir-9201a-5; +MI0028451 efu-mir-9202; +MI0028452 efu-mir-9203a; +MI0028453 efu-mir-9188b; +MI0028454 efu-mir-9204; +MI0028455 efu-mir-9205; +MI0028456 efu-mir-9243b; +MI0028457 efu-mir-9206; +MI0028458 efu-mir-9207; +MI0028459 efu-mir-9209c; +MI0028460 efu-mir-9209d; +MI0028461 efu-mir-9208; +MI0028462 efu-mir-9209a; +MI0028463 efu-mir-9209b; +MI0028464 efu-mir-9210; +MI0028465 efu-mir-9211; +MI0028466 efu-mir-9212; +MI0028467 efu-mir-9213; +MI0028468 efu-mir-9214-1; +MI0028469 efu-mir-9215a-1; +MI0028470 efu-mir-9215b; +MI0028471 efu-mir-9215a-2; +MI0028472 efu-mir-9216; +MI0028473 efu-mir-9215a-3; +MI0028474 efu-mir-9215a-4; +MI0028475 efu-mir-9217; +MI0028476 efu-mir-9215a-5; +MI0028477 efu-mir-9214-2; +MI0028478 efu-mir-9218; +MI0028479 efu-mir-9219; +MI0028480 efu-mir-9220; +MI0028481 efu-mir-378; +MI0028482 efu-mir-9221; +MI0028483 efu-mir-9222; +MI0028484 efu-mir-9223a; +MI0028485 efu-mir-9223f; +MI0028486 efu-mir-9223c-2; +MI0028487 efu-mir-9223e; +MI0028488 efu-mir-9223b-2; +MI0028489 efu-mir-9223g; +MI0028490 efu-mir-9223d; +MI0028491 efu-mir-9223h; +MI0028492 efu-mir-9223c-1; +MI0028493 efu-mir-9223b-1; +MI0028494 efu-mir-9223i; +MI0028495 efu-mir-9242-2; +MI0028496 efu-mir-9224; +MI0028497 efu-mir-9225; +MI0028498 efu-mir-9226; +MI0028499 efu-mir-9227; +MI0028500 efu-mir-9228-1; +MI0028501 efu-mir-9229a-1; +MI0028502 efu-mir-9230a; +MI0028503 efu-mir-9229b-2; +MI0028504 efu-mir-9230b; +MI0028505 efu-mir-9237b; +MI0028506 efu-mir-9231; +MI0028507 efu-mir-9229a-2; +MI0028508 efu-mir-9230c; +MI0028509 efu-mir-9232; +MI0028510 efu-mir-9229d; +MI0028511 efu-mir-9228-2; +MI0028512 efu-mir-9237c; +MI0028513 efu-mir-9229c; +MI0028514 efu-mir-9229b-1; +MI0028515 efu-mir-9233; +MI0028516 efu-mir-9234a;efu-mir-9234a-1; +MI0028517 efu-mir-9235a; +MI0028518 efu-mir-9236a; +MI0028519 efu-mir-9229e-2; +MI0028520 efu-mir-9229f; +MI0028521 efu-mir-9234b; +MI0028522 efu-mir-9236b; +MI0028523 efu-mir-9235b; +MI0028524 efu-mir-9236c; +MI0028525 efu-mir-9234c;efu-mir-9234a-2; +MI0028526 efu-mir-9237a; +MI0028527 efu-mir-9238; +MI0028528 efu-mir-9229e-1; +MI0028529 efu-mir-9239; +MI0028530 efu-mir-9240; +MI0028531 efu-mir-9241; +MI0028532 efu-mir-9242-1; +MI0028533 efu-mir-9243a; +MI0028534 efu-mir-9244; +MI0028535 efu-mir-9246a; +MI0028536 efu-mir-9245; +MI0028537 efu-mir-9246b; +MI0028538 efu-mir-9246c; +MI0028539 efu-mir-9247; +MI0028540 efu-mir-9248; +MI0028541 efu-mir-9249; +MI0028542 efu-mir-9250-1; +MI0028543 efu-mir-9250-2; +MI0028544 efu-mir-9251; +MI0028545 efu-mir-9256a-1; +MI0028546 efu-mir-9252; +MI0028547 efu-mir-9253; +MI0028548 efu-mir-9254; +MI0028549 efu-mir-9255; +MI0028550 efu-mir-9243c; +MI0028551 efu-mir-9256a-2; +MI0028552 efu-mir-9256b-1; +MI0028553 efu-mir-9256b-2; +MI0028554 efu-mir-9256b-3; +MI0028555 efu-mir-9256b-4; +MI0028556 efu-mir-9256b-5; +MI0028557 efu-mir-9256b-6; +MI0028558 efu-mir-9257; +MI0028559 efu-mir-9258; +MI0028560 efu-mir-544; +MI0028561 efu-mir-9259; +MI0028562 efu-mir-9260; +MI0028563 efu-mir-9261-1; +MI0028564 efu-mir-9261-2; +MI0028565 efu-mir-9261-3; +MI0028566 efu-mir-9262; +MI0028567 efu-mir-9263; +MI0028568 efu-mir-9189d; +MI0028569 efu-mir-9189g; +MI0028570 efu-mir-9189c; +MI0028571 efu-mir-9189f; +MI0028572 efu-mir-9189a; +MI0028573 efu-mir-9189b; +MI0028574 efu-mir-9189h; +MI0028575 efu-mir-34b; +MI0028576 efu-mir-9264; +MI0028577 efu-mir-452; +MI0028578 efu-mir-1249; +MI0028579 efu-mir-9265; +MI0028580 efu-mir-9266; +MI0028581 efu-mir-9267; +MI0028582 efu-mir-9268; +MI0028583 efu-mir-23b; +MI0028584 efu-mir-27b; +MI0028585 efu-mir-9269; +MI0028586 efu-mir-9270; +MI0028587 efu-mir-9271; +MI0028588 efu-mir-9186l; +MI0028589 efu-mir-9272; +MI0028590 efu-mir-191; +MI0028591 efu-mir-9186p-4; +MI0028592 efu-mir-9186f-2; +MI0028593 efu-mir-9186f-4; +MI0028594 efu-mir-490; +MI0028595 efu-mir-9273; +MI0028596 efu-mir-9274; +MI0028597 efu-mir-9275; +MI0028598 efu-mir-101; +MI0028599 efu-mir-9276; +MI0028600 efu-mir-9277; +MI0028601 efu-mir-9278; +MI0028602 efu-mir-9279a-1; +MI0028603 efu-mir-9280; +MI0028604 efu-mir-125b; +MI0028605 efu-mir-10; +MI0028606 efu-mir-33; +MI0028607 efu-mir-128a; +MI0028608 efu-mir-9281; +MI0028609 efu-mir-194-1; +MI0028610 efu-mir-215; +MI0028611 efu-mir-9279a-2; +MI0028612 efu-mir-9186g-1; +MI0028613 efu-mir-330; +MI0028614 efu-mir-337; +MI0028615 efu-mir-493; +MI0028616 efu-mir-9282; +MI0028617 efu-mir-370; +MI0028618 efu-mir-136; +MI0028619 efu-mir-127; +MI0028620 efu-mir-9283; +MI0028621 efu-mir-9284; +MI0028622 efu-mir-9285; +MI0028623 efu-mir-9-2; +MI0028624 efu-mir-26a; +MI0028625 efu-mir-9286; +MI0028626 efu-mir-29c; +MI0028627 efu-mir-9287; +MI0028628 efu-let-7c; +MI0028629 efu-mir-99a; +MI0028630 efu-mir-9288; +MI0028631 efu-mir-199-2; +MI0028632 efu-mir-9289; +MI0028633 efu-mir-9290; +MI0028634 efu-mir-28; +MI0028635 efu-mir-9291; +MI0028636 efu-mir-9186h-1; +MI0028637 efu-mir-9292; +MI0028638 efu-mir-9293; +MI0028639 efu-mir-107; +MI0028640 efu-mir-9294; +MI0028641 efu-mir-9295; +MI0028642 efu-mir-9296; +MI0028643 efu-mir-9297; +MI0028644 efu-mir-9186q; +MI0028645 efu-mir-9186m; +MI0028646 efu-mir-9298; +MI0028647 efu-mir-9186n; +MI0028648 efu-mir-9299; +MI0028649 efu-mir-211; +MI0028650 efu-mir-499; +MI0028651 efu-mir-342; +MI0028652 efu-mir-1307; +MI0028653 efu-mir-9300-1; +MI0028654 efu-mir-9301; +MI0028655 efu-mir-135; +MI0028656 efu-mir-513; +MI0028657 efu-mir-148; +MI0028658 efu-mir-30a; +MI0028659 efu-mir-2683; +MI0028660 efu-mir-9302; +MI0028661 efu-mir-9303; +MI0028662 efu-mir-9304; +MI0028663 efu-mir-9305; +MI0028664 efu-mir-9306; +MI0028665 efu-mir-9307; +MI0028666 efu-mir-9308; +MI0028667 efu-mir-9309; +MI0028668 efu-mir-9310; +MI0028669 efu-mir-9311; +MI0028670 efu-mir-4667; +MI0028671 efu-mir-9312; +MI0028672 efu-mir-497; +MI0028673 efu-mir-9313; +MI0028674 efu-mir-9314; +MI0028675 efu-mir-1271; +MI0028676 efu-mir-9315; +MI0028677 efu-mir-130; +MI0028678 efu-mir-9316; +MI0028679 efu-mir-19; +MI0028680 efu-mir-92a; +MI0028681 efu-mir-20; +MI0028682 efu-mir-18; +MI0028683 efu-mir-92c; +MI0028684 efu-mir-17; +MI0028685 efu-mir-9317; +MI0028686 efu-mir-129a; +MI0028687 efu-mir-132; +MI0028688 efu-mir-9318a; +MI0028689 efu-mir-7b; +MI0028690 efu-mir-128b; +MI0028691 efu-mir-26c; +MI0028692 efu-mir-181e; +MI0028693 efu-mir-181f; +MI0028694 efu-mir-9319; +MI0028695 efu-mir-9320; +MI0028696 efu-mir-103a; +MI0028697 efu-mir-200b; +MI0028698 efu-mir-200a; +MI0028699 efu-mir-429; +MI0028700 efu-mir-1388; +MI0028701 efu-let-7d; +MI0028702 efu-let-7f; +MI0028703 efu-mir-9321; +MI0028704 efu-mir-9279b; +MI0028705 efu-mir-146; +MI0028706 efu-mir-149; +MI0028707 efu-mir-9186b-6; +MI0028708 efu-mir-9318b; +MI0028709 efu-mir-423; +MI0028710 efu-mir-1193; +MI0028711 efu-mir-376; +MI0028712 efu-mir-299; +MI0028713 efu-mir-494; +MI0028714 efu-mir-411; +MI0028715 efu-mir-323; +MI0028716 efu-mir-495; +MI0028717 efu-mir-379; +MI0028718 efu-mir-3958; +MI0028719 efu-mir-138b; +MI0028720 efu-mir-383; +MI0028721 efu-mir-218a; +MI0028722 efu-mir-34a; +MI0028723 efu-mir-485; +MI0028724 efu-mir-154; +MI0028725 efu-mir-382; +MI0028726 efu-mir-409; +MI0028727 efu-mir-487; +MI0028728 efu-mir-412; +MI0028729 efu-mir-133-1; +MI0028730 efu-mir-34c; +MI0028731 efu-mir-9279a-3; +MI0028732 efu-mir-9186b-2; +MI0028733 efu-mir-9186a; +MI0028734 efu-mir-9186p-2; +MI0028735 efu-mir-9186d-2; +MI0028736 efu-mir-9322; +MI0028737 efu-mir-9323; +MI0028738 efu-mir-324; +MI0028739 efu-mir-9324; +MI0028740 efu-mir-125a; +MI0028741 efu-mir-181a; +MI0028742 efu-mir-181b; +MI0028743 efu-mir-219; +MI0028744 efu-mir-202; +MI0028745 efu-mir-361; +MI0028746 efu-mir-335; +MI0028747 efu-mir-486; +MI0028748 efu-mir-155; +MI0028749 efu-mir-9325; +MI0028750 efu-mir-138a; +MI0028751 efu-mir-31; +MI0028752 efu-mir-9326; +MI0028753 efu-mir-9327; +MI0028754 efu-mir-9186k; +MI0028755 efu-mir-218b; +MI0028756 efu-mir-9186g-2; +MI0028757 efu-mir-9328; +MI0028758 efu-mir-9329; +MI0028759 efu-mir-30d; +MI0028760 efu-mir-9330; +MI0028761 efu-mir-185; +MI0028762 efu-mir-507c; +MI0028763 efu-mir-8908; +MI0028764 efu-mir-26b; +MI0028765 efu-mir-9186b-4; +MI0028766 efu-mir-9186p-3; +MI0028767 efu-mir-150; +MI0028768 efu-mir-214; +MI0028769 efu-mir-199-1; +MI0028770 efu-mir-9331; +MI0028771 efu-mir-9332; +MI0028772 efu-mir-9333; +MI0028773 efu-mir-9186b-1; +MI0028774 efu-mir-9334; +MI0028775 efu-mir-103b; +MI0028776 efu-mir-9335; +MI0028777 efu-mir-455; +MI0028778 efu-mir-151; +MI0028779 efu-mir-16-1; +MI0028780 efu-mir-652; +MI0028781 efu-mir-204; +MI0028782 efu-mir-9336; +MI0028783 efu-mir-9186o-2; +MI0028784 efu-mir-9337; +MI0028785 efu-mir-9186d-1; +MI0028786 efu-mir-381; +MI0028787 efu-mir-1185; +MI0028788 efu-mir-9186c; +MI0028789 efu-mir-200c; +MI0028790 efu-mir-141; +MI0028791 efu-mir-338; +MI0028792 efu-mir-9300-2; +MI0028793 efu-mir-365-1; +MI0028794 efu-mir-193b; +MI0028795 efu-mir-9338-1; +MI0028796 efu-mir-874; +MI0028797 efu-mir-9339; +MI0028798 efu-mir-9340; +MI0028799 efu-mir-129b; +MI0028800 efu-mir-9186b-5; +MI0028801 efu-mir-153-2; +MI0028802 efu-mir-9338-2; +MI0028803 efu-mir-182; +MI0028804 efu-mir-449; +MI0028805 efu-mir-9341; +MI0028806 efu-mir-9342; +MI0028807 efu-mir-9343; +MI0028808 efu-mir-574-1; +MI0028809 efu-mir-9344; +MI0028810 efu-mir-9279a-4; +MI0028811 efu-mir-9345; +MI0028812 efu-mir-22; +MI0028813 efu-mir-9186f-3; +MI0028814 efu-mir-9186p-1; +MI0028815 efu-mir-9346; +MI0028816 efu-mir-9347; +MI0028817 efu-mir-9348; +MI0028818 efu-mir-9-3; +MI0028819 efu-mir-582; +MI0028820 efu-mir-507b; +MI0028821 efu-mir-196; +MI0028822 efu-mir-145; +MI0028823 efu-mir-143; +MI0028824 efu-mir-9349; +MI0028825 efu-mir-199-3; +MI0028826 efu-mir-9350; +MI0028827 efu-mir-424; +MI0028828 efu-mir-503; +MI0028829 efu-mir-450; +MI0028830 efu-mir-133-2; +MI0028831 efu-mir-1-1; +MI0028832 efu-mir-9351; +MI0028833 efu-mir-124-1; +MI0028834 efu-mir-181c; +MI0028835 efu-mir-181d; +MI0028836 efu-mir-152; +MI0028837 efu-mir-9186b-3; +MI0028838 efu-mir-30c; +MI0028839 efu-mir-30e; +MI0028840 efu-mir-1842; +MI0028841 efu-mir-9352; +MI0028842 efu-mir-628; +MI0028843 efu-mir-9353; +MI0028844 efu-mir-9354; +MI0028845 efu-mir-193a; +MI0028846 efu-mir-365-2; +MI0028847 efu-mir-9338-3; +MI0028848 efu-mir-9186j; +MI0028849 efu-mir-9186i; +MI0028850 efu-mir-9355; +MI0028851 efu-mir-21; +MI0028852 efu-mir-210; +MI0028853 efu-mir-331; +MI0028854 efu-mir-9356; +MI0028855 efu-mir-9357; +MI0028856 efu-mir-188; +MI0028857 efu-mir-500; +MI0028858 efu-mir-532; +MI0028859 efu-mir-660; +MI0028860 efu-mir-502; +MI0028861 efu-mir-205; +MI0028862 efu-mir-7a; +MI0028863 efu-mir-192; +MI0028864 efu-mir-194-2; +MI0028865 efu-mir-592; +MI0028866 efu-mir-153-1; +MI0028867 efu-mir-92b; +MI0028868 efu-mir-23a; +MI0028869 efu-mir-27a; +MI0028870 efu-mir-139; +MI0028871 efu-mir-9186o-1; +MI0028872 efu-mir-106; +MI0028873 efu-mir-93; +MI0028874 efu-mir-25; +MI0028875 efu-mir-9186f-1; +MI0028876 efu-mir-9186e; +MI0028877 efu-mir-9358; +MI0028878 efu-mir-126; +MI0028879 efu-mir-9359; +MI0028880 efu-mir-9360; +MI0028881 efu-mir-9361; +MI0028882 efu-mir-9362; +MI0028883 efu-mir-124-3; +MI0028884 efu-mir-206; +MI0028885 efu-mir-29b; +MI0028886 efu-mir-29a; +MI0028887 efu-mir-1-2; +MI0028888 efu-mir-9363; +MI0028889 efu-mir-1343; +MI0028890 efu-mir-8915; +MI0028891 efu-mir-375; +MI0028892 efu-mir-9364; +MI0028893 efu-mir-9365; +MI0028894 efu-mir-9-1; +MI0028895 efu-mir-506; +MI0028896 efu-mir-507a; +MI0028897 efu-mir-99b; +MI0028898 efu-let-7e; +MI0028899 efu-mir-7c; +MI0028900 efu-mir-15; +MI0028901 efu-mir-16-2; +MI0028902 efu-mir-339; +MI0028903 efu-mir-124-2; +MI0028904 efu-mir-320; +MI0028905 efu-mir-9366; +MI0028906 efu-mir-30b; +MI0028907 efu-mir-140; +MI0028908 efu-mir-9367; +MI0028909 efu-mir-9368; +MI0028910 efu-mir-574-2; +MI0028911 efu-mir-221; +MI0028912 efu-mir-222; +MI0028913 efu-mir-9186h-2; +MI0028914 efu-mir-9186h-3; +MI0028915 efu-mir-223; +MI0028916 efu-mir-504; +MI0028917 efu-mir-142; +MI0028918 dme-mir-9369; +MI0028919 dme-mir-9370; +MI0028920 dme-mir-9371; +MI0028921 dme-mir-9372; +MI0028922 dme-mir-9373; +MI0028923 dme-mir-9374; +MI0028924 dme-mir-9375; +MI0028925 dme-mir-9376; +MI0028926 dme-mir-9377; +MI0028927 dme-mir-9378; +MI0028928 dme-mir-9379; +MI0028929 dme-mir-9380; +MI0028930 dme-mir-9381; +MI0028931 dme-mir-9382; +MI0028932 dme-mir-9383; +MI0028933 dme-mir-9384; +MI0028934 dme-mir-9385; +MI0028935 hbr-MIR9386; +MI0028936 hbr-MIR9387; +MI0028937 hbr-MIR482b; +MI0028938 dme-mir-9388; +MI0028939 gsa-mir-1; +MI0028940 gsa-mir-87; +MI0028941 gsa-mir-279; +MI0028942 gsa-mir-71a; +MI0028943 gsa-mir-184a; +MI0028944 gsa-mir-71b; +MI0028945 gsa-mir-190; +MI0028946 gsa-mir-1175; +MI0028947 gsa-mir-96a; +MI0028948 gsa-mir-36; +MI0028949 gsa-let-7; +MI0028950 gsa-mir-67; +MI0028951 gsa-mir-219; +MI0028952 gsa-mir-2a; +MI0028953 gsa-mir-281; +MI0028954 gsa-mir-96b; +MI0028955 gsa-mir-2b; +MI0028956 gsa-mir-124a; +MI0028957 gsa-mir-2c; +MI0028958 gsa-mir-10a; +MI0028959 gsa-mir-2001; +MI0028960 gsa-mir-7; +MI0028961 gsa-mir-8; +MI0028962 gsa-mir-76a; +MI0028963 gsa-mir-9; +MI0028964 gsa-bantam; +MI0028965 gsa-mir-124b; +MI0028966 gsa-mir-278; +MI0028967 gsa-mir-277a; +MI0028968 gsa-mir-2d; +MI0028969 gsa-mir-1993; +MI0028970 gsa-mir-184b; +MI0028971 gsa-mir-993; +MI0028972 gsa-lin-4; +MI0028973 gsa-mir-10b; +MI0028974 gsa-mir-277b; +MI0028975 gsa-mir-1992; +MI0028976 gsa-mir-31; +MI0028977 gsa-mir-153; +MI0028978 gsa-mir-9389; +MI0028979 gsa-mir-71c; +MI0028980 gsa-mir-9390; +MI0028981 gsa-mir-184c; +MI0028982 gsa-mir-9391; +MI0028983 gsa-mir-9392; +MI0028984 gsa-mir-9393; +MI0028985 gsa-mir-9394a; +MI0028986 gsa-mir-76b; +MI0028987 gsa-mir-9395; +MI0028988 gsa-mir-9396; +MI0028989 gsa-mir-9397; +MI0028990 gsa-mir-9398; +MI0028991 gsa-mir-9399; +MI0028992 gsa-mir-9400; +MI0028993 gsa-mir-9394b; +MI0028994 gsa-mir-9401; +MI0028995 gsa-mir-9402; +MI0028996 gsa-mir-9403; +MI0028997 gsa-mir-9404; +MI0028998 gsa-mir-9405; +MI0028999 xtr-mir-9406; +MI0029000 xtr-mir-9407; +MI0029001 xtr-mir-428b; +MI0029002 bol-MIR9408; +MI0029003 bol-MIR9409; +MI0029004 bol-MIR9410; +MI0029005 bol-MIR9411; +MI0029006 nve-mir-9412-1; +MI0029007 nve-mir-9412-2; +MI0029008 nve-mir-9412-3; +MI0029009 nve-mir-9412-4; +MI0029010 nve-mir-9412-5; +MI0029011 nve-mir-9412-6; +MI0029012 nve-mir-9412-7; +MI0029013 nve-mir-9413-1; +MI0029014 nve-mir-9413-2; +MI0029015 nve-mir-9414; +MI0029016 nve-mir-9415-1; +MI0029017 nve-mir-9415-2; +MI0029018 nve-mir-9416-1; +MI0029019 nve-mir-9416-2; +MI0029020 nve-mir-9417; +MI0029021 nve-mir-9418-1; +MI0029022 nve-mir-9418-2; +MI0029023 nve-mir-9419; +MI0029024 nve-mir-9420; +MI0029025 nve-mir-9421; +MI0029026 nve-mir-9422; +MI0029027 nve-mir-9423; +MI0029028 nve-mir-2041b-1; +MI0029029 nve-mir-2041b-2; +MI0029030 nve-mir-2041b-3; +MI0029031 nve-mir-2041b-4; +MI0029032 nve-mir-9424a; +MI0029033 nve-mir-9425; +MI0029034 nve-mir-9426; +MI0029035 nve-mir-9427; +MI0029036 nve-mir-9428-1; +MI0029037 nve-mir-9428-2; +MI0029038 nve-mir-9428-3; +MI0029039 nve-mir-9429; +MI0029040 nve-mir-9430; +MI0029041 nve-mir-9431; +MI0029042 nve-mir-9424b; +MI0029043 nve-mir-9432; +MI0029044 nve-mir-9433; +MI0029045 nve-mir-9434; +MI0029046 nve-mir-9435; +MI0029047 nve-mir-9436-1; +MI0029048 nve-mir-9436-2; +MI0029049 nve-mir-9437-1; +MI0029050 nve-mir-9437-2; +MI0029051 nve-mir-9437-3; +MI0029052 nve-mir-9438; +MI0029053 nve-mir-9439; +MI0029054 nve-mir-9440-1; +MI0029055 nve-mir-9440-2; +MI0029056 nve-mir-9440-3; +MI0029057 nve-mir-9440-4; +MI0029058 nve-mir-9441-1; +MI0029059 nve-mir-9441-2; +MI0029060 nve-mir-9442; +MI0029061 nve-mir-9443; +MI0029062 nve-mir-9444; +MI0029063 nve-mir-9445-1; +MI0029064 nve-mir-9445-2; +MI0029065 nve-mir-9446; +MI0029066 nve-mir-9447-1; +MI0029067 nve-mir-9447-2; +MI0029068 nve-mir-9448; +MI0029069 nve-mir-9449-1; +MI0029070 nve-mir-9449-2; +MI0029071 nve-mir-9450; +MI0029072 nve-mir-9451; +MI0029073 nve-mir-9452; +MI0029074 nve-mir-9453; +MI0029075 nve-mir-9454; +MI0029076 nve-mir-9455; +MI0029077 nve-mir-9456-1; +MI0029078 nve-mir-9456-2; +MI0029079 nve-mir-9457-1; +MI0029080 nve-mir-9457-2; +MI0029081 nve-mir-9458; +MI0029082 nve-mir-9459; +MI0029083 nve-mir-9460-1; +MI0029084 nve-mir-9460-2; +MI0029085 nve-mir-9460-3; +MI0029086 nve-mir-9460-4; +MI0029087 nve-mir-9460-5; +MI0029088 nve-mir-9461-1; +MI0029089 nve-mir-9461-2; +MI0029090 nve-mir-9462; +MI0029091 nve-mir-9465-1; +MI0029092 nve-mir-9465-2; +MI0029093 nve-mir-9466; +MI0029094 nve-mir-9467; +MI0029095 nve-mir-9468; +MI0029096 nve-mir-9463; +MI0029097 nve-mir-9464; +MI0029098 sly-MIR319b; +MI0029099 sly-MIR319c; +MI0029100 sly-MIR403; +MI0029101 sly-MIR9469; +MI0029102 sly-MIR394; +MI0029103 sly-MIR9470; +MI0029104 sly-MIR9471b; +MI0029105 sly-MIR166c; +MI0029106 sly-MIR5302b; +MI0029107 sly-MIR9471a; +MI0029108 sly-MIR9472; +MI0029109 sly-MIR156d; +MI0029110 sly-MIR156e; +MI0029111 sly-MIR396a; +MI0029112 sly-MIR167b; +MI0029113 sly-MIR482d; +MI0029114 sly-MIR9473; +MI0029115 sly-MIR9474; +MI0029116 sly-MIR9475; +MI0029117 sly-MIR390a; +MI0029118 sly-MIR9476; +MI0029119 sly-MIR9477; +MI0029120 sly-MIR9478; +MI0029121 sly-MIR169e; +MI0029122 sly-MIR9479; +MI0029123 sly-MIR390b; +MI0029124 sly-MIR396b; +MI0029125 sly-MIR171e; +MI0029126 sly-MIR477; +MI0029127 bdi-MIR9480a; +MI0029128 bdi-MIR9480b; +MI0029129 bdi-MIR9481a; +MI0029130 bdi-MIR9482; +MI0029131 bdi-MIR9483a; +MI0029132 bdi-MIR9483b; +MI0029133 bdi-MIR9484; +MI0029134 bdi-MIR9485; +MI0029135 bdi-MIR9486a; +MI0029136 bdi-MIR9487; +MI0029137 bdi-MIR9488; +MI0029138 bdi-MIR9489; +MI0029139 bdi-MIR9486b; +MI0029140 bdi-MIR9490; +MI0029141 bdi-MIR9481b; +MI0029142 bdi-MIR9491; +MI0029143 bdi-MIR9492; +MI0029144 bdi-MIR9493; +MI0029145 bdi-MIR9494; +MI0029146 bdi-MIR9495; +MI0029147 bdi-MIR9496; +MI0029148 bdi-MIR9497; +MI0029149 bdi-MIR9498; +MI0029150 bdi-MIR9499; +MI0029151 bdi-MIR156j; +MI0029152 bdi-MIR159c; +MI0029153 bdi-MIR160f; +MI0029154 bdi-MIR166j; +MI0029155 bdi-MIR167f; +MI0029156 bdi-MIR167g; +MI0029157 bdi-MIR169l; +MI0029158 bdi-MIR169m; +MI0029159 bdi-MIR169n; +MI0029160 bdi-MIR171e; +MI0029161 bdi-MIR171f; +MI0029162 bdi-MIR395q; +MI0029163 bdi-MIR399c; +MI0029164 bdi-MIR399d; +MI0029165 bdi-MIR444b; +MI0029166 bdi-MIR444c; +MI0029167 bdi-MIR444d; +MI0029168 bdi-MIR530a; +MI0029169 bdi-MIR530b; +MI0029170 bdi-MIR531; +MI0029171 bdi-MIR845; +MI0029172 bdi-MIR1432; +MI0029173 bdi-MIR2118a; +MI0029174 bdi-MIR2118b; +MI0029175 bdi-MIR2275a; +MI0029176 bdi-MIR2275b; +MI0029177 bdi-MIR2275c; +MI0029178 bdi-MIR5169b; +MI0029179 bdi-MIR5171b; +MI0029180 bdi-MIR5174f; +MI0029181 bdi-MIR5281b; +MI0029183 bdi-MIR5281a; +MI0029184 bdi-MIR5181e; +MI0029185 hsa-mir-9500; +MI0029186 bma-mir-236-2; +MI0029187 bma-mir-5838-2; +MI0029188 bma-mir-5846-2; +MI0029189 bma-mir-9501; +MI0029190 bma-mir-2f; +MI0029191 bma-mir-36a-3; +MI0029192 bma-mir-36d; +MI0029193 bma-mir-9502; +MI0029194 bma-mir-9503; +MI0029195 bma-mir-9504; +MI0029196 bma-mir-9505; +MI0029197 bma-mir-9506; +MI0029198 bma-mir-9507; +MI0029199 bma-mir-9508; +MI0029200 bma-mir-9509; +MI0029201 bma-mir-9510; +MI0029202 bma-mir-9511; +MI0029203 bma-mir-9512; +MI0029204 bma-mir-9513; +MI0029205 bma-mir-9514; +MI0029206 bma-mir-9515; +MI0029207 bma-mir-9516; +MI0029208 bma-mir-9517; +MI0029209 bma-mir-9518; +MI0029210 bma-mir-9519; +MI0029211 bma-mir-9520; +MI0029212 bma-mir-9521; +MI0029213 bma-mir-9522; +MI0029214 bma-mir-9523-1; +MI0029215 bma-mir-9523-2; +MI0029216 bma-mir-9525; +MI0029217 bma-mir-9526; +MI0029218 bma-mir-9527; +MI0029219 bma-mir-9528; +MI0029220 bma-mir-9529; +MI0029221 bma-mir-9530; +MI0029222 bma-mir-9531; +MI0029223 bma-mir-9532; +MI0029224 bma-mir-9533; +MI0029225 bma-mir-9534; +MI0029226 bma-mir-2h-1; +MI0029227 bma-mir-2h-2; +MI0029228 bma-mir-9535; +MI0029229 bma-mir-9536; +MI0029230 bma-mir-9537; +MI0029231 ath-MIR826b; +MI0029233 bdi-MIR5200a; +MI0029234 bdi-MIR5200b; +MI0029235 dvi-mir-1000; +MI0029236 dvi-mir-1002; +MI0029237 dvi-mir-1003; +MI0029238 dvi-mir-1006; +MI0029239 dvi-mir-1007; +MI0029240 dvi-mir-1010; +MI0029241 dvi-mir-1017; +MI0029242 dvi-mir-137; +MI0029243 dvi-mir-190; +MI0029244 dvi-mir-193; +MI0029245 dvi-mir-252; +MI0029246 dvi-mir-311; +MI0029247 dvi-mir-375; +MI0029248 dvi-mir-927; +MI0029249 dvi-mir-929; +MI0029250 dvi-mir-932; +MI0029251 dvi-mir-955; +MI0029252 dvi-mir-956; +MI0029253 dvi-mir-957; +MI0029254 dvi-mir-958; +MI0029255 dvi-mir-962; +MI0029256 dvi-mir-963; +MI0029257 dvi-mir-964; +MI0029258 dvi-mir-965; +MI0029259 dvi-mir-968; +MI0029260 dvi-mir-969; +MI0029261 dvi-mir-970; +MI0029262 dvi-mir-971; +MI0029263 dvi-mir-973; +MI0029264 dvi-mir-976; +MI0029265 dvi-mir-980; +MI0029266 dvi-mir-981; +MI0029267 dvi-mir-987; +MI0029268 dvi-mir-988; +MI0029269 dvi-mir-989; +MI0029270 dvi-mir-993; +MI0029271 dvi-mir-994; +MI0029272 dvi-mir-995; +MI0029273 dvi-mir-996; +MI0029274 dvi-mir-998; +MI0029275 dvi-mir-999; +MI0029276 dvi-mir-iab-8; +MI0029277 dvi-mir-9538; +MI0029278 dvi-mir-9539; +MI0029279 dvi-mir-9540; +MI0029280 dvi-mir-9542a; +MI0029281 dvi-mir-9543a; +MI0029282 dvi-mir-9544a; +MI0029283 dvi-mir-9545; +MI0029284 dvi-mir-9541; +MI0029285 dvi-mir-9547; +MI0029286 dvi-mir-9546; +MI0029287 dvi-mir-9548; +MI0029288 dvi-mir-9550; +MI0029289 dvi-mir-9549; +MI0029290 dvi-mir-974-1; +MI0029291 dvi-mir-974-2; +MI0029292 dvi-mir-975; +MI0029293 dvi-mir-977; +MI0029294 dvi-mir-986; +MI0029295 hco-mir-9551; +MI0029296 bra-MIR9552a; +MI0029297 bra-MIR9552b; +MI0029298 bra-MIR9408; +MI0029299 bra-MIR9553; +MI0029300 bra-MIR9554; +MI0029301 bra-MIR9555a; +MI0029302 bra-MIR9556; +MI0029303 bra-MIR9557; +MI0029304 bra-MIR9558; +MI0029305 bra-MIR9559; +MI0029306 bra-MIR9560a; +MI0029307 bra-MIR9560b; +MI0029308 bra-MIR9561; +MI0029309 bra-MIR9555b; +MI0029310 bra-MIR9562; +MI0029311 bra-MIR408; +MI0029312 bra-MIR9563a; +MI0029313 bra-MIR9564; +MI0029314 bra-MIR9565; +MI0029315 bra-MIR9566; +MI0029316 bra-MIR9567; +MI0029317 bra-MIR9563b; +MI0029318 bra-MIR9568; +MI0029319 bra-MIR9569; +MI0029320 bra-MIR158; +MI0029321 hsa-mir-548bb; +MI0029322 mse-mir-929b; +MI0029323 mse-mir-9570; +MI0029324 mse-mir-9571a; +MI0029325 mse-mir-9571b; +MI0029326 bhv5-mir-B12; +MI0029327 bhv5-mir-B13; +MI0029328 bhv5-mir-B14; +MI0029329 bhv5-mir-B8; +MI0029330 bhv5-mir-B11; +MI0029331 gga-mir-9-3; +MI0029332 gga-mir-19b-2; +MI0029333 gga-mir-26a-2; +MI0029334 gga-mir-33-2; +MI0029335 gga-mir-92-2; +MI0029336 gga-mir-96; +MI0029337 gga-mir-125b-1; +MI0029338 gga-mir-145; +MI0029339 gga-mir-182; +MI0029340 gga-mir-190b; +MI0029341 gga-mir-203b; +MI0029342 gga-mir-210a; +MI0029343 gga-mir-338; +MI0029344 gga-mir-363; +MI0029345 gga-mir-1388a; +MI0029346 aca-let-7c-3; +MI0029347 aca-let-7a-3; +MI0029348 aca-let-7a-2; +MI0029349 aca-mir-19c; +MI0029350 aca-mir-26-3; +MI0029351 aca-mir-30c-2; +MI0029352 aca-mir-106; +MI0029353 aca-mir-133a-3; +MI0029354 aca-mir-133b; +MI0029355 aca-mir-181c; +MI0029356 aca-mir-222b; +MI0029357 aca-mir-302a; +MI0029358 aca-mir-737; +MI0029359 aca-mir-1641; +MI0029360 aca-mir-9572; +MI0029361 aca-mir-9573; +MI0029362 aca-mir-5396b; +MI0029363 aca-mir-9574; +MI0029364 aca-mir-9575; +MI0029365 aca-mir-9576; +MI0029366 aca-mir-9577; +MI0029367 xtr-mir-454; +MI0029368 xtr-mir-460a; +MI0029369 xtr-mir-460b; +MI0029370 xtr-mir-551b; +MI0029371 cpi-let-7a-1; +MI0029372 cpi-let-7a-2; +MI0029373 cpi-let-7a-3; +MI0029374 cpi-let-7a-4; +MI0029375 cpi-let-7b; +MI0029376 cpi-let-7c-1; +MI0029377 cpi-let-7c-2; +MI0029378 cpi-let-7d; +MI0029379 cpi-let-7e; +MI0029380 cpi-let-7f-1; +MI0029381 cpi-let-7f-2; +MI0029382 cpi-let-7g; +MI0029383 cpi-let-7i; +MI0029384 cpi-mir-1a-1; +MI0029385 cpi-mir-1a-2; +MI0029386 cpi-mir-1b; +MI0029387 cpi-mir-7a-1; +MI0029388 cpi-mir-7a-2; +MI0029389 cpi-mir-7a-3; +MI0029390 cpi-mir-7b; +MI0029391 cpi-mir-9-1; +MI0029392 cpi-mir-9-2; +MI0029393 cpi-mir-9-3; +MI0029394 cpi-mir-9-4; +MI0029395 cpi-mir-10a; +MI0029396 cpi-mir-10b; +MI0029397 cpi-mir-10c; +MI0029398 cpi-mir-15a; +MI0029399 cpi-mir-15b; +MI0029400 cpi-mir-16a; +MI0029401 cpi-mir-16c; +MI0029402 cpi-mir-18a; +MI0029403 cpi-mir-18b; +MI0029404 cpi-mir-19a; +MI0029405 cpi-mir-19b-1; +MI0029406 cpi-mir-19b-2; +MI0029407 cpi-mir-20a; +MI0029408 cpi-mir-20b; +MI0029409 cpi-mir-21; +MI0029410 cpi-mir-22; +MI0029411 cpi-mir-23a; +MI0029412 cpi-mir-23b; +MI0029413 cpi-mir-24-1; +MI0029414 cpi-mir-24-2; +MI0029415 cpi-mir-26-1; +MI0029416 cpi-mir-26-2; +MI0029417 cpi-mir-26-3; +MI0029418 cpi-mir-27a; +MI0029419 cpi-mir-27b; +MI0029420 cpi-mir-29a-1; +MI0029421 cpi-mir-29a-2; +MI0029422 cpi-mir-29b-1; +MI0029423 cpi-mir-29b-2; +MI0029424 cpi-mir-30a; +MI0029425 cpi-mir-30b; +MI0029426 cpi-mir-30c-1; +MI0029427 cpi-mir-30c-2; +MI0029428 cpi-mir-30d; +MI0029429 cpi-mir-30e; +MI0029430 cpi-mir-31; +MI0029431 cpi-mir-32; +MI0029432 cpi-mir-33-1; +MI0029433 cpi-mir-33-2; +MI0029434 cpi-mir-34a; +MI0029435 cpi-mir-34b; +MI0029436 cpi-mir-34c; +MI0029437 cpi-mir-92a-1; +MI0029438 cpi-mir-92a-2; +MI0029439 cpi-mir-92b; +MI0029440 cpi-mir-92c; +MI0029441 cpi-mir-93; +MI0029442 cpi-mir-96; +MI0029443 cpi-mir-98; +MI0029444 cpi-mir-99a; +MI0029445 cpi-mir-99b; +MI0029446 cpi-mir-100; +MI0029447 cpi-mir-101-1; +MI0029448 cpi-mir-101-2; +MI0029449 cpi-mir-103-1; +MI0029450 cpi-mir-103-2; +MI0029451 cpi-mir-106a; +MI0029452 cpi-mir-106b; +MI0029453 cpi-mir-107; +MI0029454 cpi-mir-122; +MI0029455 cpi-mir-124-1; +MI0029456 cpi-mir-124-2; +MI0029457 cpi-mir-124-3; +MI0029458 cpi-mir-124-4; +MI0029459 cpi-mir-125a; +MI0029460 cpi-mir-125b-1; +MI0029461 cpi-mir-125b-2; +MI0029462 cpi-mir-126; +MI0029463 cpi-mir-128-1; +MI0029464 cpi-mir-128-2; +MI0029465 cpi-mir-129-1; +MI0029466 cpi-mir-129-2; +MI0029467 cpi-mir-130a; +MI0029468 cpi-mir-130b; +MI0029469 cpi-mir-130c; +MI0029470 cpi-mir-130d; +MI0029471 cpi-mir-132; +MI0029472 cpi-mir-133a-1; +MI0029473 cpi-mir-133a-2; +MI0029474 cpi-mir-133b; +MI0029475 cpi-mir-133c; +MI0029476 cpi-mir-135-1; +MI0029477 cpi-mir-135-2; +MI0029478 cpi-mir-135-3; +MI0029479 cpi-mir-137a; +MI0029480 cpi-mir-137b; +MI0029481 cpi-mir-138; +MI0029482 cpi-mir-139; +MI0029483 cpi-mir-140; +MI0029484 cpi-mir-142-1; +MI0029485 cpi-mir-142-2; +MI0029486 cpi-mir-143; +MI0029487 cpi-mir-144; +MI0029488 cpi-mir-145; +MI0029489 cpi-mir-146a; +MI0029490 cpi-mir-146b; +MI0029491 cpi-mir-146c; +MI0029492 cpi-mir-147; +MI0029493 cpi-mir-148a; +MI0029494 cpi-mir-148b; +MI0029495 cpi-mir-152; +MI0029496 cpi-mir-153-1; +MI0029497 cpi-mir-153-2; +MI0029498 cpi-mir-155a; +MI0029499 cpi-mir-155b; +MI0029500 cpi-mir-181a-1; +MI0029501 cpi-mir-181a-2; +MI0029502 cpi-mir-181a-3; +MI0029503 cpi-mir-181b-1; +MI0029504 cpi-mir-181b-2; +MI0029505 cpi-mir-181b-3; +MI0029506 cpi-mir-182; +MI0029507 cpi-mir-183; +MI0029508 cpi-mir-184; +MI0029509 cpi-mir-187; +MI0029510 cpi-mir-190a; +MI0029511 cpi-mir-190b; +MI0029512 cpi-mir-191; +MI0029513 cpi-mir-192; +MI0029514 cpi-mir-193a; +MI0029515 cpi-mir-193b; +MI0029516 cpi-mir-194-1; +MI0029517 cpi-mir-194-2; +MI0029518 cpi-mir-196-1; +MI0029519 cpi-mir-196-2; +MI0029520 cpi-mir-196-3; +MI0029521 cpi-mir-199-1; +MI0029522 cpi-mir-199-2; +MI0029523 cpi-mir-199-3; +MI0029524 cpi-mir-200a; +MI0029525 cpi-mir-200b; +MI0029526 cpi-mir-202; +MI0029527 cpi-mir-203; +MI0029528 cpi-mir-204-1; +MI0029529 cpi-mir-204-2; +MI0029530 cpi-mir-204-3; +MI0029531 cpi-mir-205a; +MI0029532 cpi-mir-205b; +MI0029533 cpi-mir-206; +MI0029534 cpi-mir-208; +MI0029535 cpi-mir-210; +MI0029536 cpi-mir-212; +MI0029537 cpi-mir-214; +MI0029538 cpi-mir-215; +MI0029539 cpi-mir-216a; +MI0029540 cpi-mir-216b; +MI0029541 cpi-mir-217; +MI0029542 cpi-mir-218-1; +MI0029543 cpi-mir-218-2; +MI0029544 cpi-mir-219-1; +MI0029545 cpi-mir-219-2; +MI0029546 cpi-mir-221; +MI0029547 cpi-mir-222a; +MI0029548 cpi-mir-222b; +MI0029549 cpi-mir-223; +MI0029550 cpi-mir-301a; +MI0029551 cpi-mir-301b; +MI0029552 cpi-mir-302a; +MI0029553 cpi-mir-302b; +MI0029554 cpi-mir-302c; +MI0029555 cpi-mir-302d; +MI0029556 cpi-mir-338a; +MI0029557 cpi-mir-338b; +MI0029558 cpi-mir-363; +MI0029559 cpi-mir-365-1; +MI0029560 cpi-mir-365-2; +MI0029561 cpi-mir-367; +MI0029562 cpi-mir-375; +MI0029563 cpi-mir-383; +MI0029564 cpi-mir-425; +MI0029565 cpi-mir-429; +MI0029566 cpi-mir-449a; +MI0029567 cpi-mir-449b; +MI0029568 cpi-mir-449c; +MI0029569 cpi-mir-449d; +MI0029570 cpi-mir-451; +MI0029571 cpi-mir-454; +MI0029572 cpi-mir-455; +MI0029573 cpi-mir-456; +MI0029574 cpi-mir-458; +MI0029575 cpi-mir-459; +MI0029576 cpi-mir-460a; +MI0029577 cpi-mir-460b; +MI0029578 cpi-mir-489; +MI0029579 cpi-mir-490; +MI0029580 cpi-mir-499; +MI0029581 cpi-mir-551-1; +MI0029582 cpi-mir-551-2; +MI0029583 cpi-mir-599; +MI0029584 cpi-mir-726; +MI0029585 cpi-mir-737; +MI0029586 cpi-mir-875; +MI0029587 cpi-mir-1306; +MI0029588 cpi-mir-1329; +MI0029589 cpi-mir-1388; +MI0029590 cpi-mir-1397; +MI0029591 cpi-mir-1416; +MI0029592 cpi-mir-1641; +MI0029593 cpi-mir-1662; +MI0029594 cpi-mir-1677a; +MI0029595 cpi-mir-1677b; +MI0029596 cpi-mir-1677c; +MI0029597 cpi-mir-1677d; +MI0029598 cpi-mir-1677e; +MI0029599 cpi-mir-1677f; +MI0029600 cpi-mir-1677g-1; +MI0029601 cpi-mir-1677g-2; +MI0029602 cpi-mir-1677h; +MI0029603 cpi-mir-1720; +MI0029604 cpi-mir-1784; +MI0029605 cpi-mir-1788; +MI0029606 cpi-mir-1791; +MI0029607 cpi-mir-1805; +MI0029608 cpi-mir-2184; +MI0029609 cpi-mir-2188; +MI0029610 cpi-mir-2970; +MI0029611 cpi-mir-2984; +MI0029612 cpi-mir-3064; +MI0029613 cpi-mir-3618; +MI0029614 cpi-mir-9578; +MI0029615 cpi-mir-9579; +MI0029616 cpi-mir-1729; +MI0029617 cpi-mir-9580; +MI0029618 cpi-mir-9581; +MI0029619 cpi-mir-9582; +MI0029620 cpi-mir-9583; +MI0029621 cpi-mir-9584; +MI0029622 cpi-mir-9585; +MI0029623 cpi-mir-9586; +MI0029624 cpi-mir-9587; +MI0029625 cpi-mir-9588; +MI0029626 cpi-mir-9589; +MI0029627 cpi-mir-9590; +MI0029628 cpi-mir-9591; +MI0029629 cpi-mir-9592; +MI0029630 cpi-mir-9593; +MI0029631 cpi-mir-9594; +MI0029632 cpi-mir-9595; +MI0029633 cpi-mir-9596; +MI0029634 cpi-mir-9597; +MI0029635 cpi-mir-15c; +MI0029636 cpi-mir-16b; +MI0029637 cpi-mir-17; +MI0029638 cpi-mir-727; +MI0029639 ami-let-7a-1; +MI0029640 ami-let-7a-2; +MI0029641 ami-let-7a-3; +MI0029642 ami-let-7a-4; +MI0029643 ami-let-7b; +MI0029644 ami-let-7c-1; +MI0029645 ami-let-7c-2; +MI0029646 ami-let-7d; +MI0029647 ami-let-7e; +MI0029648 ami-let-7f-1; +MI0029649 ami-let-7f-2; +MI0029650 ami-let-7g; +MI0029651 ami-let-7i; +MI0029652 ami-mir-1a-1; +MI0029653 ami-mir-1a-2; +MI0029654 ami-mir-1b; +MI0029655 ami-mir-7a-1; +MI0029656 ami-mir-7a-2; +MI0029657 ami-mir-7a-3; +MI0029658 ami-mir-7b; +MI0029659 ami-mir-9-1; +MI0029660 ami-mir-9-2; +MI0029661 ami-mir-9-3; +MI0029662 ami-mir-9-4; +MI0029663 ami-mir-10a; +MI0029664 ami-mir-10b; +MI0029665 ami-mir-10c; +MI0029666 ami-mir-15a; +MI0029667 ami-mir-15b; +MI0029668 ami-mir-15c; +MI0029669 ami-mir-16a-1; +MI0029670 ami-mir-16a-2; +MI0029671 ami-mir-16b; +MI0029672 ami-mir-17; +MI0029673 ami-mir-18; +MI0029674 ami-mir-19a; +MI0029675 ami-mir-19b; +MI0029676 ami-mir-20a; +MI0029677 ami-mir-21; +MI0029678 ami-mir-23a; +MI0029679 ami-mir-23b; +MI0029680 ami-mir-24-1; +MI0029681 ami-mir-24-2; +MI0029682 ami-mir-26-1; +MI0029683 ami-mir-26-2; +MI0029684 ami-mir-27a; +MI0029685 ami-mir-27b; +MI0029686 ami-mir-29a-1; +MI0029687 ami-mir-29a-2; +MI0029688 ami-mir-29b-1; +MI0029689 ami-mir-29b-2; +MI0029690 ami-mir-30a; +MI0029691 ami-mir-30b; +MI0029692 ami-mir-30c-1; +MI0029693 ami-mir-30c-2; +MI0029694 ami-mir-30d; +MI0029695 ami-mir-30e; +MI0029696 ami-mir-31; +MI0029697 ami-mir-32; +MI0029698 ami-mir-33-1; +MI0029699 ami-mir-33-2; +MI0029700 ami-mir-34a; +MI0029701 ami-mir-34b; +MI0029702 ami-mir-34c; +MI0029703 ami-mir-92a; +MI0029704 ami-mir-92b; +MI0029705 ami-mir-93; +MI0029706 ami-mir-96; +MI0029707 ami-mir-98; +MI0029708 ami-mir-99a; +MI0029709 ami-mir-99b; +MI0029710 ami-mir-100; +MI0029711 ami-mir-101-1; +MI0029712 ami-mir-101-2; +MI0029713 ami-mir-103; +MI0029714 ami-mir-106; +MI0029715 ami-mir-107; +MI0029716 ami-mir-122; +MI0029717 ami-mir-124-1; +MI0029718 ami-mir-124-2; +MI0029719 ami-mir-124-3; +MI0029720 ami-mir-124-4; +MI0029721 ami-mir-125a; +MI0029722 ami-mir-125b-1; +MI0029723 ami-mir-125b-2; +MI0029724 ami-mir-126; +MI0029725 ami-mir-128-1; +MI0029726 ami-mir-128-2; +MI0029727 ami-mir-129a; +MI0029728 ami-mir-129b; +MI0029729 ami-mir-130a; +MI0029730 ami-mir-130b; +MI0029731 ami-mir-130c; +MI0029732 ami-mir-132; +MI0029733 ami-mir-133a-1; +MI0029734 ami-mir-133a-2; +MI0029735 ami-mir-133a-3; +MI0029736 ami-mir-133b; +MI0029737 ami-mir-135-1; +MI0029738 ami-mir-135-2; +MI0029739 ami-mir-135-3; +MI0029740 ami-mir-137a; +MI0029741 ami-mir-137b; +MI0029742 ami-mir-138-1; +MI0029743 ami-mir-138-2; +MI0029744 ami-mir-139; +MI0029745 ami-mir-140; +MI0029746 ami-mir-142-1; +MI0029747 ami-mir-142-2; +MI0029748 ami-mir-143; +MI0029749 ami-mir-144; +MI0029750 ami-mir-145; +MI0029751 ami-mir-146a; +MI0029752 ami-mir-146b; +MI0029753 ami-mir-146c; +MI0029754 ami-mir-147; +MI0029755 ami-mir-148b; +MI0029756 ami-mir-150; +MI0029757 ami-mir-152; +MI0029758 ami-mir-153-1; +MI0029759 ami-mir-153-2; +MI0029760 ami-mir-155; +MI0029761 ami-mir-181a-1; +MI0029762 ami-mir-181a-2; +MI0029763 ami-mir-181a-3; +MI0029764 ami-mir-181b-1; +MI0029765 ami-mir-181b-2; +MI0029766 ami-mir-181b-3; +MI0029767 ami-mir-182; +MI0029768 ami-mir-183; +MI0029769 ami-mir-184; +MI0029770 ami-mir-187; +MI0029771 ami-mir-190a; +MI0029772 ami-mir-190b; +MI0029773 ami-mir-191; +MI0029774 ami-mir-192; +MI0029775 ami-mir-193a; +MI0029776 ami-mir-193b; +MI0029777 ami-mir-194-1; +MI0029778 ami-mir-194-2; +MI0029779 ami-mir-196-1; +MI0029780 ami-mir-196-2; +MI0029781 ami-mir-196-3; +MI0029782 ami-mir-199-1; +MI0029783 ami-mir-199-2; +MI0029784 ami-mir-199-3; +MI0029785 ami-mir-200a; +MI0029786 ami-mir-200b; +MI0029787 ami-mir-202; +MI0029788 ami-mir-203; +MI0029789 ami-mir-204-1; +MI0029790 ami-mir-204-2; +MI0029791 ami-mir-205a; +MI0029792 ami-mir-205b; +MI0029793 ami-mir-206; +MI0029794 ami-mir-208; +MI0029795 ami-mir-210; +MI0029796 ami-mir-212; +MI0029797 ami-mir-214; +MI0029798 ami-mir-215; +MI0029799 ami-mir-216a; +MI0029800 ami-mir-216b; +MI0029801 ami-mir-217; +MI0029802 ami-mir-218-1; +MI0029803 ami-mir-218-2; +MI0029804 ami-mir-219a; +MI0029805 ami-mir-219b; +MI0029806 ami-mir-221; +MI0029807 ami-mir-222a; +MI0029808 ami-mir-222b; +MI0029809 ami-mir-223; +MI0029810 ami-mir-301a; +MI0029811 ami-mir-301b; +MI0029812 ami-mir-302a; +MI0029813 ami-mir-302b; +MI0029814 ami-mir-302c; +MI0029815 ami-mir-302d; +MI0029816 ami-mir-338-1; +MI0029817 ami-mir-338-2; +MI0029818 ami-mir-365-1; +MI0029819 ami-mir-365-2; +MI0029820 ami-mir-367; +MI0029821 ami-mir-375; +MI0029822 ami-mir-383; +MI0029823 ami-mir-425; +MI0029824 ami-mir-429; +MI0029825 ami-mir-449a; +MI0029826 ami-mir-449b; +MI0029827 ami-mir-449c; +MI0029828 ami-mir-449d; +MI0029829 ami-mir-454; +MI0029830 ami-mir-455; +MI0029831 ami-mir-456; +MI0029832 ami-mir-458; +MI0029833 ami-mir-459; +MI0029834 ami-mir-460a; +MI0029835 ami-mir-460b; +MI0029836 ami-mir-489; +MI0029837 ami-mir-490; +MI0029838 ami-mir-497; +MI0029839 ami-mir-499; +MI0029840 ami-mir-551-1; +MI0029841 ami-mir-551-2; +MI0029842 ami-mir-599; +MI0029843 ami-mir-737; +MI0029844 ami-mir-875; +MI0029845 ami-mir-1306; +MI0029846 ami-mir-1329; +MI0029847 ami-mir-1388; +MI0029848 ami-mir-1397; +MI0029849 ami-mir-1416; +MI0029850 ami-mir-1641; +MI0029851 ami-mir-1662; +MI0029852 ami-mir-1677a; +MI0029853 ami-mir-1677b; +MI0029854 ami-mir-1677c; +MI0029855 ami-mir-1720; +MI0029856 ami-mir-1788; +MI0029857 ami-mir-1791; +MI0029858 ami-mir-1805; +MI0029859 ami-mir-2184; +MI0029860 ami-mir-2188; +MI0029861 ami-mir-2970; +MI0029862 ami-mir-2984; +MI0029863 ami-mir-3064; +MI0029864 ami-mir-3618; +MI0029865 ami-mir-9598; +MI0029866 ami-mir-9599; +MI0029867 ami-mir-9600; +MI0029868 ami-mir-9601; +MI0029869 ami-mir-9602; +MI0029870 ami-mir-9603; +MI0029871 ami-mir-9604; +MI0029872 ami-mir-9605; +MI0029873 ami-mir-9606; +MI0029874 ami-mir-9607; +MI0029875 ami-mir-9608; +MI0029876 ami-mir-9609; +MI0029877 ami-mir-9610; +MI0029878 ami-mir-9611; +MI0029879 ami-mir-9612; +MI0029880 ami-mir-9613; +MI0029882 cli-let-7a-1; +MI0029883 cli-let-7a-2; +MI0029884 cli-let-7a-3; +MI0029885 cli-let-7a-4; +MI0029886 cli-let-7b; +MI0029887 cli-let-7c; +MI0029888 cli-let-7d; +MI0029889 cli-let-7e; +MI0029890 cli-let-7f; +MI0029891 cli-let-7g; +MI0029892 cli-let-7i; +MI0029893 cli-mir-1a-1; +MI0029894 cli-mir-1a-2; +MI0029895 cli-mir-1b; +MI0029896 cli-mir-7a-1; +MI0029897 cli-mir-7a-2; +MI0029898 cli-mir-7a-3; +MI0029899 cli-mir-7b; +MI0029900 cli-mir-9-1; +MI0029901 cli-mir-9-2; +MI0029902 cli-mir-9-3; +MI0029903 cli-mir-10a; +MI0029904 cli-mir-10b; +MI0029905 cli-mir-10c; +MI0029906 cli-mir-15a; +MI0029907 cli-mir-15b; +MI0029908 cli-mir-15c; +MI0029909 cli-mir-16a-1; +MI0029910 cli-mir-16a-2; +MI0029911 cli-mir-16b; +MI0029912 cli-mir-17; +MI0029913 cli-mir-18a; +MI0029914 cli-mir-18b; +MI0029915 cli-mir-19a; +MI0029916 cli-mir-19b-1; +MI0029917 cli-mir-19b-2; +MI0029918 cli-mir-20a; +MI0029919 cli-mir-20b; +MI0029920 cli-mir-21; +MI0029921 cli-mir-22; +MI0029922 cli-mir-23b; +MI0029923 cli-mir-26-1; +MI0029924 cli-mir-26-2; +MI0029925 cli-mir-27b; +MI0029926 cli-mir-29a-1; +MI0029927 cli-mir-29a-2; +MI0029928 cli-mir-29b-1; +MI0029929 cli-mir-29b-2; +MI0029930 cli-mir-30a; +MI0029931 cli-mir-30c-1; +MI0029932 cli-mir-30c-2; +MI0029933 cli-mir-30d; +MI0029934 cli-mir-30e; +MI0029935 cli-mir-31; +MI0029936 cli-mir-32; +MI0029937 cli-mir-33-1; +MI0029938 cli-mir-33-2; +MI0029939 cli-mir-34a; +MI0029940 cli-mir-34b; +MI0029941 cli-mir-34c; +MI0029942 cli-mir-92-1; +MI0029943 cli-mir-92-2; +MI0029944 cli-mir-96; +MI0029945 cli-mir-99; +MI0029946 cli-mir-100-1; +MI0029947 cli-mir-101-1; +MI0029948 cli-mir-101-2; +MI0029949 cli-mir-103-1; +MI0029950 cli-mir-103-2; +MI0029951 cli-mir-106; +MI0029952 cli-mir-107; +MI0029953 cli-mir-122; +MI0029954 cli-mir-124-1; +MI0029955 cli-mir-124-2; +MI0029956 cli-mir-125-1; +MI0029957 cli-mir-125-2; +MI0029958 cli-mir-126; +MI0029959 cli-mir-128-1; +MI0029960 cli-mir-128-2; +MI0029961 cli-mir-129; +MI0029962 cli-mir-130a; +MI0029963 cli-mir-130c; +MI0029964 cli-mir-133a-1; +MI0029965 cli-mir-133a-2; +MI0029966 cli-mir-133b; +MI0029967 cli-mir-133c; +MI0029968 cli-mir-135-1; +MI0029969 cli-mir-135-2; +MI0029970 cli-mir-135-3; +MI0029971 cli-mir-137a; +MI0029972 cli-mir-137b; +MI0029973 cli-mir-138-1; +MI0029974 cli-mir-138-2; +MI0029975 cli-mir-139; +MI0029976 cli-mir-140; +MI0029977 cli-mir-142; +MI0029978 cli-mir-143; +MI0029979 cli-mir-145; +MI0029980 cli-mir-146a; +MI0029981 cli-mir-146b; +MI0029982 cli-mir-146c; +MI0029983 cli-mir-147; +MI0029984 cli-mir-148a; +MI0029985 cli-mir-148b; +MI0029986 cli-mir-153a; +MI0029987 cli-mir-153b; +MI0029988 cli-mir-155; +MI0029989 cli-mir-181a-1; +MI0029990 cli-mir-181a-2; +MI0029991 cli-mir-181b-1; +MI0029992 cli-mir-181b-2; +MI0029993 cli-mir-182; +MI0029994 cli-mir-183; +MI0029995 cli-mir-184; +MI0029996 cli-mir-187; +MI0029997 cli-mir-190; +MI0029998 cli-mir-193; +MI0029999 cli-mir-194; +MI0030000 cli-mir-196-1; +MI0030001 cli-mir-196-2; +MI0030002 cli-mir-196-3; +MI0030003 cli-mir-199-1; +MI0030004 cli-mir-199-2; +MI0030005 cli-mir-200a; +MI0030006 cli-mir-200b; +MI0030007 cli-mir-202; +MI0030008 cli-mir-204-1; +MI0030009 cli-mir-204-2; +MI0030010 cli-mir-204-3; +MI0030011 cli-mir-205a; +MI0030012 cli-mir-205b; +MI0030013 cli-mir-206; +MI0030014 cli-mir-210; +MI0030015 cli-mir-214; +MI0030016 cli-mir-215; +MI0030017 cli-mir-216a; +MI0030018 cli-mir-216b; +MI0030019 cli-mir-217; +MI0030020 cli-mir-218-1; +MI0030021 cli-mir-218-2; +MI0030022 cli-mir-221; +MI0030023 cli-mir-222a; +MI0030024 cli-mir-222b; +MI0030025 cli-mir-223; +MI0030026 cli-mir-301a; +MI0030027 cli-mir-301b; +MI0030028 cli-mir-302a; +MI0030029 cli-mir-302b-1; +MI0030030 cli-mir-302b-2; +MI0030031 cli-mir-302c; +MI0030032 cli-mir-338a; +MI0030033 cli-mir-338b; +MI0030034 cli-mir-363; +MI0030035 cli-mir-365-1; +MI0030036 cli-mir-365-2; +MI0030037 cli-mir-367; +MI0030038 cli-mir-375; +MI0030039 cli-mir-383; +MI0030040 cli-mir-425; +MI0030041 cli-mir-429; +MI0030042 cli-mir-449a; +MI0030043 cli-mir-449b; +MI0030044 cli-mir-449c; +MI0030045 cli-mir-449d; +MI0030046 cli-mir-451; +MI0030047 cli-mir-454; +MI0030048 cli-mir-455; +MI0030049 cli-mir-456; +MI0030050 cli-mir-458; +MI0030051 cli-mir-459; +MI0030052 cli-mir-460a; +MI0030053 cli-mir-460b; +MI0030054 cli-mir-489; +MI0030055 cli-mir-490; +MI0030056 cli-mir-499; +MI0030057 cli-mir-551a; +MI0030058 cli-mir-551b; +MI0030059 cli-mir-599; +MI0030060 cli-mir-737; +MI0030061 cli-mir-875; +MI0030062 cli-mir-1306; +MI0030063 cli-mir-1329; +MI0030064 cli-mir-1388; +MI0030065 cli-mir-1416; +MI0030066 cli-mir-1451; +MI0030067 cli-mir-1467; +MI0030068 cli-mir-1550; +MI0030069 cli-mir-1552; +MI0030070 cli-mir-1559; +MI0030071 cli-mir-1641; +MI0030072 cli-mir-1655; +MI0030073 cli-mir-1662; +MI0030074 cli-mir-1677; +MI0030075 cli-mir-1720; +MI0030076 cli-mir-1729; +MI0030077 cli-mir-1781; +MI0030078 cli-mir-1782; +MI0030079 cli-mir-1784; +MI0030080 cli-mir-1788; +MI0030081 cli-mir-1791; +MI0030082 cli-mir-1803-1; +MI0030083 cli-mir-1803-2; +MI0030084 cli-mir-1805; +MI0030085 cli-mir-2131; +MI0030086 cli-mir-2188; +MI0030087 cli-mir-2954; +MI0030088 cli-mir-2970; +MI0030089 cli-mir-2984; +MI0030090 cli-mir-3064; +MI0030091 cli-mir-3618; +MI0030092 cli-mir-9615; +MI0030093 cli-mir-9616; +MI0030094 cli-mir-9617; +MI0030095 cli-mir-9618; +MI0030096 cli-mir-9619; +MI0030097 cli-mir-9620; +MI0030098 cli-mir-9621; +MI0030099 cli-mir-1756b; +MI0030101 cli-mir-9622; +MI0030102 cli-mir-9623; +MI0030103 cli-mir-9624; +MI0030104 cli-mir-9625; +MI0030105 cli-mir-9626; +MI0030106 cli-mir-9627; +MI0030107 cli-mir-9628; +MI0030108 cli-mir-9629; +MI0030109 cli-mir-9630; +MI0030110 cli-mir-9631; +MI0030111 cli-mir-9632; +MI0030112 cli-mir-9633; +MI0030113 cli-mir-8993; +MI0030114 cli-mir-9634; +MI0030115 cli-mir-9635; +MI0030116 cli-mir-9636; +MI0030117 cli-mir-9637; +MI0030118 cli-mir-9638; +MI0030119 cli-mir-9639; +MI0030120 cli-mir-9640; +MI0030121 cli-mir-9641; +MI0030122 cli-mir-9642; +MI0030123 cli-mir-9643; +MI0030124 cli-mir-9644; +MI0030125 cli-mir-9645; +MI0030126 cli-mir-9646; +MI0030127 cli-mir-9647; +MI0030128 cli-mir-9648; +MI0030129 cli-mir-9649; +MI0030130 pbv-let-7a-1; +MI0030131 pbv-let-7a-2; +MI0030132 pbv-let-7a-3; +MI0030133 pbv-let-7b; +MI0030134 pbv-let-7c-1; +MI0030135 pbv-let-7c-2; +MI0030136 pbv-let-7c-3; +MI0030137 pbv-let-7d; +MI0030138 pbv-let-7e; +MI0030139 pbv-let-7f-1; +MI0030140 pbv-let-7f-2; +MI0030141 pbv-let-7g; +MI0030142 pbv-let-7i; +MI0030143 pbv-mir-1a-1; +MI0030144 pbv-mir-1a-2; +MI0030145 pbv-mir-1b; +MI0030146 pbv-mir-7-1; +MI0030147 pbv-mir-7-2; +MI0030148 pbv-mir-7-3; +MI0030149 pbv-mir-9-1; +MI0030150 pbv-mir-9-2; +MI0030151 pbv-mir-9-3; +MI0030152 pbv-mir-9-4; +MI0030153 pbv-mir-10a; +MI0030154 pbv-mir-10b-1; +MI0030155 pbv-mir-10b-2; +MI0030156 pbv-mir-15a; +MI0030157 pbv-mir-15b; +MI0030158 pbv-mir-16a; +MI0030159 pbv-mir-16b; +MI0030160 pbv-mir-16c; +MI0030161 pbv-mir-17; +MI0030162 pbv-mir-18a; +MI0030163 pbv-mir-18b; +MI0030164 pbv-mir-19a; +MI0030165 pbv-mir-19b; +MI0030166 pbv-mir-20a; +MI0030167 pbv-mir-20b; +MI0030168 pbv-mir-21; +MI0030169 pbv-mir-22; +MI0030170 pbv-mir-23a; +MI0030171 pbv-mir-23b; +MI0030172 pbv-mir-24-1; +MI0030173 pbv-mir-24-2; +MI0030174 pbv-mir-26-1; +MI0030175 pbv-mir-26-2; +MI0030176 pbv-mir-26-3; +MI0030177 pbv-mir-27a; +MI0030178 pbv-mir-27b; +MI0030179 pbv-mir-29a-1; +MI0030180 pbv-mir-29a-2; +MI0030181 pbv-mir-29b-1; +MI0030182 pbv-mir-29b-2; +MI0030183 pbv-mir-30a; +MI0030184 pbv-mir-30b; +MI0030185 pbv-mir-30c-1; +MI0030186 pbv-mir-30c-2; +MI0030187 pbv-mir-30d; +MI0030188 pbv-mir-30e; +MI0030189 pbv-mir-31; +MI0030190 pbv-mir-32; +MI0030191 pbv-mir-33-1; +MI0030192 pbv-mir-33-2; +MI0030193 pbv-mir-34a; +MI0030194 pbv-mir-34b; +MI0030195 pbv-mir-34c; +MI0030196 pbv-mir-92a-1; +MI0030197 pbv-mir-92a-2; +MI0030198 pbv-mir-92b; +MI0030199 pbv-mir-96; +MI0030200 pbv-mir-98; +MI0030201 pbv-mir-99a; +MI0030202 pbv-mir-99b; +MI0030203 pbv-mir-100; +MI0030204 pbv-mir-101-1; +MI0030205 pbv-mir-101-2; +MI0030206 pbv-mir-103-1; +MI0030207 pbv-mir-103-2; +MI0030208 pbv-mir-106; +MI0030209 pbv-mir-107; +MI0030210 pbv-mir-122; +MI0030211 pbv-mir-124b; +MI0030212 pbv-mir-124a-1; +MI0030213 pbv-mir-124a-2; +MI0030214 pbv-mir-124a-3; +MI0030215 pbv-mir-125a; +MI0030216 pbv-mir-125b-1; +MI0030217 pbv-mir-125b-2; +MI0030218 pbv-mir-126; +MI0030219 pbv-mir-128-1; +MI0030220 pbv-mir-128-2; +MI0030221 pbv-mir-129a; +MI0030222 pbv-mir-129b; +MI0030223 pbv-mir-130a; +MI0030224 pbv-mir-130b; +MI0030225 pbv-mir-130c; +MI0030226 pbv-mir-130d; +MI0030227 pbv-mir-132; +MI0030228 pbv-mir-133a-1; +MI0030229 pbv-mir-133a-2; +MI0030230 pbv-mir-133b; +MI0030231 pbv-mir-133c; +MI0030232 pbv-mir-135-1; +MI0030233 pbv-mir-135-2; +MI0030234 pbv-mir-135-3; +MI0030235 pbv-mir-137a; +MI0030236 pbv-mir-137b; +MI0030237 pbv-mir-138-1; +MI0030238 pbv-mir-138-2; +MI0030239 pbv-mir-139; +MI0030240 pbv-mir-142; +MI0030241 pbv-mir-143; +MI0030242 pbv-mir-144; +MI0030243 pbv-mir-145; +MI0030244 pbv-mir-146a; +MI0030245 pbv-mir-146b; +MI0030246 pbv-mir-147; +MI0030247 pbv-mir-148a; +MI0030248 pbv-mir-148b; +MI0030249 pbv-mir-150; +MI0030250 pbv-mir-153-1; +MI0030251 pbv-mir-153-2; +MI0030252 pbv-mir-155a; +MI0030253 pbv-mir-155b; +MI0030254 pbv-mir-181a-2; +MI0030255 pbv-mir-181a-1; +MI0030256 pbv-mir-181b-1; +MI0030257 pbv-mir-181b-2; +MI0030258 pbv-mir-181c; +MI0030259 pbv-mir-182; +MI0030260 pbv-mir-183; +MI0030261 pbv-mir-184; +MI0030262 pbv-mir-190a; +MI0030263 pbv-mir-190b; +MI0030264 pbv-mir-191; +MI0030265 pbv-mir-193a; +MI0030266 pbv-mir-193b; +MI0030267 pbv-mir-194-1; +MI0030268 pbv-mir-194-2; +MI0030269 pbv-mir-196a; +MI0030270 pbv-mir-196c; +MI0030271 pbv-mir-199-1; +MI0030272 pbv-mir-199-2; +MI0030273 pbv-mir-199-3; +MI0030274 pbv-mir-200a; +MI0030275 pbv-mir-200b; +MI0030276 pbv-mir-202; +MI0030277 pbv-mir-203; +MI0030278 pbv-mir-204-1; +MI0030279 pbv-mir-204-2; +MI0030280 pbv-mir-204-3; +MI0030281 pbv-mir-205a; +MI0030282 pbv-mir-205b; +MI0030283 pbv-mir-206; +MI0030284 pbv-mir-208; +MI0030285 pbv-mir-210; +MI0030286 pbv-mir-212; +MI0030287 pbv-mir-214; +MI0030288 pbv-mir-215; +MI0030289 pbv-mir-216a; +MI0030290 pbv-mir-216b; +MI0030291 pbv-mir-217; +MI0030292 pbv-mir-218-1; +MI0030293 pbv-mir-218-2; +MI0030294 pbv-mir-219-1; +MI0030295 pbv-mir-219-2; +MI0030296 pbv-mir-221; +MI0030297 pbv-mir-222a; +MI0030298 pbv-mir-222b; +MI0030299 pbv-mir-223; +MI0030300 pbv-mir-301a; +MI0030301 pbv-mir-301b; +MI0030302 pbv-mir-338; +MI0030303 pbv-mir-363; +MI0030304 pbv-mir-365-1; +MI0030305 pbv-mir-365-2; +MI0030306 pbv-mir-375; +MI0030307 pbv-mir-383; +MI0030308 pbv-mir-425; +MI0030309 pbv-mir-429; +MI0030310 pbv-mir-449a; +MI0030311 pbv-mir-449b; +MI0030312 pbv-mir-449c; +MI0030313 pbv-mir-449d; +MI0030314 pbv-mir-454; +MI0030315 pbv-mir-455; +MI0030316 pbv-mir-456; +MI0030317 pbv-mir-458; +MI0030318 pbv-mir-489; +MI0030319 pbv-mir-490; +MI0030320 pbv-mir-499; +MI0030321 pbv-mir-551a; +MI0030322 pbv-mir-551b; +MI0030323 pbv-mir-599; +MI0030324 pbv-mir-737; +MI0030325 pbv-mir-875; +MI0030326 pbv-mir-1306; +MI0030327 pbv-mir-1329; +MI0030328 pbv-mir-1388; +MI0030329 pbv-mir-1397; +MI0030330 pbv-mir-1641; +MI0030331 pbv-mir-1662; +MI0030332 pbv-mir-1677; +MI0030333 pbv-mir-1788; +MI0030334 pbv-mir-1805; +MI0030335 pbv-mir-2188; +MI0030336 pbv-mir-2970; +MI0030337 pbv-mir-3064; +MI0030338 pbv-mir-3618; +MI0030339 pbv-mir-5420; +MI0030340 pbv-mir-9650; +MI0030341 pbv-mir-9651; +MI0030342 cli-mir-1756a; +MI0030343 mmu-mir-3154; +MI0030344 mmu-mir-3552; +MI0030345 mmu-mir-3618; +MI0030346 mmu-mir-935; +MI0030347 rno-let-7g; +MI0030348 rno-mir-1247; +MI0030349 rno-mir-1297; +MI0030350 rno-mir-148a; +MI0030351 rno-mir-149; +MI0030352 rno-mir-15a; +MI0030353 rno-mir-1843b; +MI0030354 rno-mir-1896; +MI0030355 rno-mir-193b; +MI0030356 rno-mir-1956; +MI0030357 rno-mir-3064; +MI0030358 rno-mir-3084a;rno-mir-3084a-1; +MI0030359 rno-mir-3084b-1;rno-mir-3084a-2; +MI0030360 rno-mir-3084c;rno-mir-3084b; +MI0030361 rno-mir-3084d;rno-mir-3084a-3; +MI0030362 rno-mir-450b-1; +MI0030363 rno-mir-452; +MI0030364 rno-mir-5132; +MI0030365 rno-mir-762; +MI0030366 bfv-miR-BF1; +MI0030367 bfv-miR-BF2; +MI0030368 tae-MIR1122b; +MI0030369 tae-MIR9652; +MI0030370 tae-MIR9653a; +MI0030371 tae-MIR9654a; +MI0030372 tae-MIR9655; +MI0030373 tae-MIR9656; +MI0030374 tae-MIR9654b; +MI0030375 tae-MIR9657a; +MI0030376 tae-MIR9658; +MI0030377 tae-MIR9659; +MI0030378 tae-MIR9660; +MI0030379 tae-MIR1127b; +MI0030380 tae-MIR9661; +MI0030381 tae-MIR396; +MI0030382 tae-MIR9662a; +MI0030383 tae-MIR9663; +MI0030384 tae-MIR1137b; +MI0030385 tae-MIR9664; +MI0030386 tae-MIR9665; +MI0030387 tae-MIR2275; +MI0030388 tae-MIR9666a; +MI0030389 tae-MIR9667; +MI0030390 tae-MIR9662b; +MI0030391 tae-MIR5062; +MI0030392 tae-MIR9668; +MI0030393 tae-MIR9669; +MI0030394 tae-MIR9666c; +MI0030395 tae-MIR9670; +MI0030396 tae-MIR1847; +MI0030397 tae-MIR9671; +MI0030398 tae-MIR1122c; +MI0030399 tae-MIR167c; +MI0030400 tae-MIR9672a; +MI0030401 tae-MIR9673; +MI0030402 tae-MIR5175; +MI0030403 tae-MIR9674a; +MI0030404 tae-MIR1120b; +MI0030405 tae-MIR397; +MI0030406 tae-MIR1130b; +MI0030407 tae-MIR5384; +MI0030408 tae-MIR9675; +MI0030409 tae-MIR1120c; +MI0030410 tae-MIR7757; +MI0030411 tae-MIR9674b; +MI0030412 tae-MIR9676; +MI0030413 tae-MIR5048; +MI0030414 tae-MIR9677a; +MI0030415 tae-MIR9678; +MI0030416 tae-MIR6197; +MI0030417 tae-MIR9657c; +MI0030418 tae-MIR9679; +MI0030419 tae-MIR5049; +MI0030420 tae-MIR9657b; +MI0030421 tae-MIR9666b; +MI0030545 hvu-MIR397b; +MI0030546 hvu-MIR156b; +MI0030547 bra-MIR156a; +MI0030548 bra-MIR156b; +MI0030549 bra-MIR156c; +MI0030550 bra-MIR156d; +MI0030551 bra-MIR156e; +MI0030552 bra-MIR156f; +MI0030553 bra-MIR156g; +MI0030554 bra-MIR162; +MI0030555 bra-MIR168b; +MI0030556 bra-MIR168c; +MI0030557 bra-MIR168a; +MI0030558 bra-MIR319; +MI0030559 bra-MIR390; +MI0030560 bra-MIR391; +MI0030561 bra-MIR395d; +MI0030562 bra-MIR395b; +MI0030563 bra-MIR395c; +MI0030564 bra-MIR395a; +MI0030565 bra-MIR396; +MI0030566 bra-MIR398; +MI0030567 bra-MIR400; +MI0030568 bra-MIR403; +MI0030569 bra-MIR860; +MI0030570 bra-MIR6032; +MI0030571 bra-MIR164b; +MI0030572 bra-MIR164d; +MI0030573 bra-MIR164c; +MI0030574 bra-MIR164e; +MI0030575 bra-MIR172c; +MI0030576 bra-MIR2111; +MI0030577 bra-MIR172d; +MI0030578 bra-MIR161; +MI0030579 chi-let-7a; +MI0030580 chi-let-7b; +MI0030581 chi-let-7c; +MI0030582 chi-let-7d; +MI0030583 chi-let-7e; +MI0030584 chi-let-7f; +MI0030585 chi-let-7g; +MI0030586 chi-let-7i; +MI0030587 chi-mir-1; +MI0030588 chi-mir-100; +MI0030589 chi-mir-101; +MI0030590 chi-mir-103; +MI0030591 chi-mir-105a; +MI0030592 chi-mir-105b; +MI0030593 chi-mir-106a; +MI0030594 chi-mir-106b; +MI0030595 chi-mir-107; +MI0030596 chi-mir-10a; +MI0030597 chi-mir-10b; +MI0030598 chi-mir-1185; +MI0030599 chi-mir-1197; +MI0030600 chi-mir-122; +MI0030601 chi-mir-1224; +MI0030602 chi-mir-1248; +MI0030603 chi-mir-1249; +MI0030604 chi-mir-124a; +MI0030605 chi-mir-125a; +MI0030606 chi-mir-125b; +MI0030607 chi-mir-126; +MI0030608 chi-mir-127; +MI0030609 chi-mir-1271; +MI0030610 chi-mir-128; +MI0030611 chi-mir-1291; +MI0030612 chi-mir-129; +MI0030613 chi-mir-1296; +MI0030614 chi-mir-1306; +MI0030615 chi-mir-1307; +MI0030616 chi-mir-130a; +MI0030617 chi-mir-130b; +MI0030618 chi-mir-133a; +MI0030619 chi-mir-133b; +MI0030620 chi-mir-1343; +MI0030621 chi-mir-134; +MI0030622 chi-mir-135a; +MI0030623 chi-mir-135b; +MI0030624 chi-mir-136; +MI0030625 chi-mir-137; +MI0030626 chi-mir-1388; +MI0030627 chi-mir-140; +MI0030628 chi-mir-141; +MI0030629 chi-mir-143; +MI0030630 chi-mir-144; +MI0030631 chi-mir-145; +MI0030632 chi-mir-1468; +MI0030633 chi-mir-146a; +MI0030634 chi-mir-146b; +MI0030635 chi-mir-147; +MI0030636 chi-mir-148a; +MI0030637 chi-mir-148b; +MI0030638 chi-mir-150; +MI0030639 chi-mir-151; +MI0030640 chi-mir-153; +MI0030641 chi-mir-154a; +MI0030642 chi-mir-154b; +MI0030643 chi-mir-155; +MI0030644 chi-mir-15a; +MI0030645 chi-mir-15b; +MI0030646 chi-mir-16a; +MI0030647 chi-mir-16b; +MI0030648 chi-mir-17; +MI0030649 chi-mir-1814; +MI0030650 chi-mir-181b; +MI0030651 chi-mir-181c; +MI0030652 chi-mir-181d; +MI0030653 chi-mir-182; +MI0030654 chi-mir-183; +MI0030655 chi-mir-1839; +MI0030656 chi-mir-184; +MI0030657 chi-mir-186; +MI0030658 chi-mir-187; +MI0030659 chi-mir-188; +MI0030660 chi-mir-18a; +MI0030661 chi-mir-18b; +MI0030662 chi-mir-190a; +MI0030663 chi-mir-190b; +MI0030664 chi-mir-191; +MI0030665 chi-mir-192; +MI0030666 chi-mir-193a; +MI0030667 chi-mir-193b; +MI0030668 chi-mir-194; +MI0030670 chi-mir-195; +MI0030671 chi-mir-196a; +MI0030672 chi-mir-196b; +MI0030673 chi-mir-197; +MI0030674 chi-mir-199a; +MI0030675 chi-mir-199b; +MI0030676 chi-mir-199c; +MI0030677 chi-mir-19a; +MI0030678 chi-mir-19b; +MI0030679 chi-mir-200a; +MI0030680 chi-mir-200b; +MI0030681 chi-mir-200c; +MI0030682 chi-mir-202; +MI0030683 chi-mir-204; +MI0030684 chi-mir-206; +MI0030685 chi-mir-208b; +MI0030686 chi-mir-20a; +MI0030687 chi-mir-20b; +MI0030688 chi-mir-211; +MI0030689 chi-mir-214; +MI0030690 chi-mir-215; +MI0030691 chi-mir-21; +MI0030692 chi-mir-216b; +MI0030693 chi-mir-217; +MI0030694 chi-mir-218; +MI0030695 chi-mir-219; +MI0030696 chi-mir-221; +MI0030697 chi-mir-222; +MI0030698 chi-mir-223; +MI0030699 chi-mir-224; +MI0030700 chi-mir-22; +MI0030701 chi-mir-2284a; +MI0030702 chi-mir-2284b; +MI0030703 chi-mir-2284c; +MI0030704 chi-mir-2284d; +MI0030705 chi-mir-2290; +MI0030706 chi-mir-2318; +MI0030707 chi-mir-2320; +MI0030708 chi-mir-2331; +MI0030709 chi-mir-2332; +MI0030710 chi-mir-2335; +MI0030711 chi-mir-23a; +MI0030712 chi-mir-23b; +MI0030713 chi-mir-24; +MI0030714 chi-mir-2404; +MI0030715 chi-mir-2411; +MI0030716 chi-mir-2432; +MI0030717 chi-mir-2284e; +MI0030718 chi-mir-2483; +MI0030719 chi-mir-25; +MI0030720 chi-mir-26a; +MI0030721 chi-mir-26b; +MI0030722 chi-mir-27a; +MI0030723 chi-mir-27b; +MI0030724 chi-mir-28; +MI0030725 chi-mir-296; +MI0030726 chi-mir-29a; +MI0030727 chi-mir-29b; +MI0030728 chi-mir-29c; +MI0030729 chi-mir-301a; +MI0030730 chi-mir-301b; +MI0030731 chi-mir-30a; +MI0030732 chi-mir-30b; +MI0030733 chi-mir-30c; +MI0030734 chi-mir-30d; +MI0030735 chi-mir-30e; +MI0030736 chi-mir-30f; +MI0030737 chi-mir-320; +MI0030738 chi-mir-323a; +MI0030739 chi-mir-323b; +MI0030740 chi-mir-324; +MI0030741 chi-mir-326; +MI0030742 chi-mir-328; +MI0030743 chi-mir-329a; +MI0030744 chi-mir-329b; +MI0030745 chi-mir-330; +MI0030746 chi-mir-331; +MI0030747 chi-mir-335; +MI0030748 chi-mir-338; +MI0030749 chi-mir-33a; +MI0030750 chi-mir-33b; +MI0030751 chi-mir-340; +MI0030752 chi-mir-342; +MI0030753 chi-mir-3431; +MI0030754 chi-mir-3432; +MI0030755 chi-mir-345; +MI0030756 chi-mir-346; +MI0030757 chi-mir-34a; +MI0030758 chi-mir-34b; +MI0030759 chi-mir-34c; +MI0030760 chi-mir-361; +MI0030761 chi-mir-362; +MI0030762 chi-mir-363; +MI0030763 chi-mir-365; +MI0030764 chi-mir-369; +MI0030765 chi-mir-374a; +MI0030766 chi-mir-374b; +MI0030767 chi-mir-376a; +MI0030768 chi-mir-376b; +MI0030769 chi-mir-376c; +MI0030770 chi-mir-376d; +MI0030771 chi-mir-376e; +MI0030772 chi-mir-377; +MI0030773 chi-mir-378; +MI0030774 chi-mir-379; +MI0030775 chi-mir-380; +MI0030776 chi-mir-381; +MI0030777 chi-mir-382; +MI0030778 chi-mir-383; +MI0030779 chi-mir-3955; +MI0030780 chi-mir-3958; +MI0030781 chi-mir-3959; +MI0030782 chi-mir-409; +MI0030783 chi-mir-410; +MI0030784 chi-mir-411a; +MI0030785 chi-mir-411b; +MI0030786 chi-mir-412; +MI0030787 chi-mir-421; +MI0030788 chi-mir-423; +MI0030789 chi-mir-424; +MI0030790 chi-mir-425; +MI0030791 chi-mir-429; +MI0030792 chi-mir-432; +MI0030793 chi-mir-433; +MI0030794 chi-mir-449a; +MI0030795 chi-mir-449b; +MI0030796 chi-mir-449c; +MI0030797 chi-mir-450; +MI0030798 chi-mir-451; +MI0030799 chi-mir-454; +MI0030800 chi-mir-455; +MI0030801 chi-mir-483; +MI0030802 chi-mir-485; +MI0030803 chi-mir-487a; +MI0030804 chi-mir-487b; +MI0030805 chi-mir-490; +MI0030806 chi-mir-491; +MI0030807 chi-mir-493; +MI0030808 chi-mir-494; +MI0030809 chi-mir-495; +MI0030810 chi-mir-496; +MI0030811 chi-mir-497; +MI0030812 chi-mir-499; +MI0030813 chi-mir-500; +MI0030814 chi-mir-502a; +MI0030815 chi-mir-502b; +MI0030816 chi-mir-504; +MI0030817 chi-mir-505; +MI0030818 chi-mir-532; +MI0030819 chi-mir-542; +MI0030820 chi-mir-543; +MI0030821 chi-mir-544; +MI0030822 chi-mir-545; +MI0030823 chi-mir-582; +MI0030824 chi-mir-592; +MI0030825 chi-mir-628; +MI0030826 chi-mir-655; +MI0030827 chi-mir-656; +MI0030828 chi-mir-660; +MI0030829 chi-mir-665; +MI0030830 chi-mir-671; +MI0030831 chi-mir-7; +MI0030832 chi-mir-708; +MI0030833 chi-mir-758; +MI0030834 chi-mir-767; +MI0030835 chi-mir-873; +MI0030836 chi-mir-874; +MI0030837 chi-mir-876; +MI0030838 chi-mir-877; +MI0030839 chi-mir-92a; +MI0030840 chi-mir-92b; +MI0030841 chi-mir-93; +MI0030842 chi-mir-9; +MI0030843 chi-mir-96; +MI0030844 chi-mir-98; +MI0030845 chi-mir-99a; +MI0030846 chi-mir-99b; +MI0030848 dsi-mir-2498a; +MI0030849 dsi-mir-2498c; +MI0030850 dsi-mir-2498b; +MI0030851 dsi-mir-983b; +MI0030853 dsi-mir-9680; +MI0030854 dsi-mir-972; +MI0030855 dsi-mir-973; +MI0030857 dsi-mir-4966-1; +MI0030858 dsi-mir-4966-2; +MI0030859 dsi-mir-4966-3; +MI0030860 dsi-mir-9369; +MI0030861 dsi-mir-974; +MI0030862 dsi-mir-2499; +MI0030863 dse-mir-2498b; +MI0030865 dse-mir-2498a; +MI0030867 dse-mir-991; +MI0030868 dse-mir-992; +MI0030869 dse-mir-982c-1; +MI0030870 dse-mir-982c-2; +MI0030872 dse-mir-303; +MI0030873 dse-mir-982b-1; +MI0030874 dse-mir-982b-2; +MI0030875 dse-mir-2582-1; +MI0030876 dse-mir-2582-2; +MI0030877 dse-mir-983; +MI0030878 dse-mir-973; +MI0030879 dse-mir-976; +MI0030880 dse-mir-4966-1; +MI0030882 dse-mir-4966-2; +MI0030885 dse-mir-975; +MI0030886 dse-mir-974; +MI0030887 dse-mir-2499; +MI0030888 dse-mir-978a; +MI0030889 dse-mir-978b; +MI0030890 dse-mir-977; +MI0030891 dse-mir-9680; +MI0030892 dse-mir-9369; +MI0030893 dse-mir-9685; +MI0030894 dya-mir-992; +MI0030895 dya-mir-2498; +MI0030897 dya-mir-9681; +MI0030898 dya-mir-991; +MI0030900 dya-mir-9682; +MI0030903 dya-mir-303; +MI0030904 dya-mir-9683; +MI0030906 dya-mir-975; +MI0030907 dya-mir-978; +MI0030908 dya-mir-2499; +MI0030909 dya-mir-976; +MI0030910 dya-mir-9690; +MI0030911 dya-mir-977; +MI0030912 der-mir-9681; +MI0030913 der-mir-991-1; +MI0030914 der-mir-991-2; +MI0030915 der-mir-992-1; +MI0030916 der-mir-2498a; +MI0030917 der-mir-2498b; +MI0030918 der-mir-992-2; +MI0030919 der-mir-9691; +MI0030921 der-mir-983a; +MI0030922 der-mir-983b; +MI0030923 der-mir-9682; +MI0030924 der-mir-2499; +MI0030925 der-mir-975; +MI0030926 der-mir-977; +MI0030927 der-mir-978; +MI0030928 der-mir-974; +MI0030929 der-mir-976; +MI0030930 der-mir-973; +MI0030931 der-mir-9683; +MI0030932 der-mir-9680; +MI0030933 dvi-mir-9692; +MI0030934 dvi-mir-9693; +MI0030935 dvi-mir-9694; +MI0030936 dvi-mir-9695; +MI0030937 dvi-mir-9696a; +MI0030938 dvi-mir-9696b; +MI0030939 dvi-mir-9697; +MI0030940 dvi-mir-9698; +MI0030941 dvi-mir-9699; +MI0030943 dvi-mir-9538b; +MI0030944 dvi-mir-9700a; +MI0030945 dvi-mir-9700b; +MI0030946 dvi-mir-9701a; +MI0030947 dvi-mir-9701b; +MI0030948 dvi-mir-9702; +MI0030949 dvi-mir-9703; +MI0030950 dvi-mir-9704-1; +MI0030951 dvi-mir-9705-2; +MI0030952 dvi-mir-9706a-1; +MI0030953 dvi-mir-9706b-1; +MI0030954 dvi-mir-9707-1; +MI0030955 dvi-mir-9704-2; +MI0030956 dvi-mir-9705-1; +MI0030959 dvi-mir-9707-2; +MI0030960 dvi-mir-9708a; +MI0030961 dvi-mir-9708b; +MI0030962 dvi-mir-9708c; +MI0030963 dvi-mir-9708d; +MI0030964 dvi-mir-9544c; +MI0030965 dvi-mir-9544b; +MI0030966 dvi-mir-9709; +MI0030967 dvi-mir-9541b; +MI0030968 dvi-mir-9541a; +MI0030969 dvi-mir-9710; +MI0030971 dvi-mir-9711; +MI0030972 dvi-mir-9712; +MI0030973 dvi-mir-9713; +MI0030974 dvi-mir-9714; +MI0030975 dvi-mir-9542d; +MI0030977 dvi-mir-9542b; +MI0030978 dvi-mir-9542e; +MI0030979 dvi-mir-9542c; +MI0030980 dvi-mir-9716; +MI0030981 dvi-mir-9717; +MI0030982 mmu-mir-9718; +MI0030983 hsa-mir-9718; +MI0030984 dvi-mir-9719; +MI0030985 dvi-mir-9720; +MI0030986 dvi-mir-9721; +MI0030987 ocu-mir-302b; +MI0030988 ocu-mir-302c; +MI0030989 ocu-mir-302a; +MI0030990 ocu-mir-302d; +MI0030991 ocu-mir-367; +MI0030992 ocu-mir-294;ocu-mir-373; +MI0030993 ocu-mir-290;ocu-mir-371; +MI0030994 ocu-mir-520e; +MI0030995 ocu-mir-498; +MI0030996 ocu-mir-512a; +MI0030997 ocu-mir-512b; +MI0030998 ocu-mir-191; +MI0030999 gma-MIR9722; +MI0031000 gma-MIR9723; +MI0031001 gma-MIR9724; +MI0031002 gma-MIR9725; +MI0031003 gma-MIR5780b; +MI0031004 gma-MIR9726; +MI0031005 gma-MIR398d; +MI0031006 gma-MIR4348b; +MI0031007 gma-MIR9727; +MI0031008 gma-MIR9728; +MI0031009 gma-MIR9729; +MI0031010 gma-MIR5671b; +MI0031011 gma-MIR9730; +MI0031012 gma-MIR9731; +MI0031013 gma-MIR9732; +MI0031014 gma-MIR5780c; +MI0031015 gma-MIR9733; +MI0031016 gma-MIR9734; +MI0031017 gma-MIR9735; +MI0031018 gma-MIR9736; +MI0031019 gma-MIR9737; +MI0031020 gma-MIR9738; +MI0031021 gma-MIR9739; +MI0031022 gma-MIR9740; +MI0031023 gma-MIR9741; +MI0031024 gma-MIR9742; +MI0031025 gma-MIR9743; +MI0031026 gma-MIR9744; +MI0031027 gma-MIR9745; +MI0031028 gma-MIR9746a; +MI0031029 gma-MIR9746b; +MI0031030 gma-MIR9746c; +MI0031031 gma-MIR9746d; +MI0031032 gma-MIR9746e; +MI0031033 gma-MIR9746f; +MI0031034 gma-MIR9746g; +MI0031035 gma-MIR9746h; +MI0031036 gma-MIR9747; +MI0031037 gma-MIR9748; +MI0031038 gma-MIR9749; +MI0031039 gma-MIR319o; +MI0031040 gma-MIR9750; +MI0031041 gma-MIR319p; +MI0031042 gma-MIR9751; +MI0031043 gma-MIR9752; +MI0031044 gma-MIR399i; +MI0031045 gma-MIR9746i; +MI0031046 gma-MIR9753; +MI0031047 gma-MIR9754; +MI0031048 gma-MIR9755; +MI0031049 gma-MIR9756; +MI0031050 gma-MIR167k; +MI0031051 gma-MIR4348c; +MI0031052 gma-MIR9757; +MI0031053 gma-MIR5380c; +MI0031054 gma-MIR9758; +MI0031055 gma-MIR5670b; +MI0031056 gma-MIR9759; +MI0031057 gma-MIR9760; +MI0031058 gma-MIR5780d; +MI0031059 gma-MIR9761; +MI0031060 gma-MIR319q; +MI0031061 gma-MIR9762; +MI0031062 gma-MIR9763; +MI0031063 gma-MIR9764; +MI0031064 gma-MIR9765; +MI0031065 gma-MIR9766; +MI0031066 gma-MIR9767; +MI0031067 ggo-mir-515-1; +MI0031068 ggo-mir-519e; +MI0031069 ggo-mir-520f; +MI0031070 ggo-mir-515-2; +MI0031071 ggo-mir-519c-1; +MI0031072 ggo-mir-525; +MI0031073 ggo-mir-523; +MI0031074 ggo-mir-518f; +MI0031075 ggo-mir-519b; +MI0031076 ggo-mir-518b; +MI0031077 ggo-mir-520c; +MI0031078 ggo-mir-518c; +MI0031079 ggo-mir-524; +MI0031080 ggo-mir-519d; +MI0031081 ggo-mir-526a; +MI0031082 ggo-mir-518e; +MI0031083 ggo-mir-518d; +MI0031084 ggo-mir-1283-1; +MI0031085 ggo-mir-517c-2; +MI0031086 ggo-mir-520g; +MI0031087 ggo-mir-519c-2; +MI0031088 ggo-mir-521; +MI0031089 ggo-mir-522; +MI0031090 ggo-mir-519a-1; +MI0031091 ggo-mir-1283-2; +MI0031092 ggo-mir-516a-1; +MI0031093 ggo-mir-1283-3; +MI0031094 ggo-mir-516a-2; +MI0031095 ggo-mir-516b-2; +MI0031096 ggo-mir-519a-2; +MI0031097 mml-mir-519a-2; +MI0031098 mml-mir-518a-3; +MI0031099 mml-mir-518a-4; +MI0031100 mml-mir-517b; +MI0031101 ppy-mir-515-3; +MI0031102 ppy-mir-517c-2; +MI0031103 ppy-mir-517c-3;ppy-mir-517c-1; +MI0031104 ppy-mir-518g;ppy-mir-518e; +MI0031105 ppy-mir-520i; +MI0031106 ppy-mir-521-3; +MI0031107 ppy-mir-516a-3;ppy-mir-516a-2; +MI0031108 ppy-mir-518a-3;ppy-mir-518a-2; +MI0031109 ptr-mir-518g; +MI0031110 ptr-mir-519f; +MI0031111 ptr-mir-1283b; +MI0031112 gga-mir-6635-3; +MI0031113 gga-mir-7458-2; +MI0031114 gga-mir-7480-3; +MI0031115 gga-mir-7482-2; +MI0031116 gga-mir-7482-3; +MI0031117 gga-mir-7482-4; +MI0031118 gga-mir-7482-5; +MI0031119 gga-mir-7482-6; +MI0031120 mmu-mir-9768; +MI0031121 mmu-mir-9769; +MI0031122 tch-mir-181a-1; +MI0031123 tch-mir-210; +MI0031124 tch-mir-7-1; +MI0031125 tch-mir-200a; +MI0031126 tch-mir-1277; +MI0031127 tch-mir-33a; +MI0031128 tch-mir-9771a; +MI0031129 tch-mir-142; +MI0031130 tch-mir-10b-1; +MI0031131 tch-mir-155; +MI0031132 tch-mir-200c; +MI0031133 tch-mir-125a; +MI0031134 tch-mir-450a-1; +MI0031135 tch-mir-143; +MI0031136 tch-mir-9771b; +MI0031137 tch-mir-592; +MI0031138 tch-mir-199b; +MI0031139 tch-mir-103a-1; +MI0031140 tch-mir-6529; +MI0031141 tch-mir-9771c; +MI0031142 tch-let-7a; +MI0031143 tch-mir-32; +MI0031144 tch-mir-95; +MI0031145 tch-mir-342; +MI0031146 tch-mir-26a-1; +MI0031147 tch-mir-141; +MI0031148 tch-mir-411; +MI0031149 tch-mir-188; +MI0031150 tch-mir-184; +MI0031151 tch-mir-29b-1; +MI0031152 tch-mir-424; +MI0031153 tch-mir-1306; +MI0031154 tch-mir-365b; +MI0031155 tch-mir-505; +MI0031156 tch-mir-92a-1; +MI0031157 tch-mir-103a-2; +MI0031158 tch-mir-190b; +MI0031159 tch-mir-409; +MI0031160 tch-mir-30b; +MI0031161 tch-mir-296; +MI0031162 tch-mir-539; +MI0031163 tch-mir-129-1; +MI0031164 tch-mir-101; +MI0031165 tch-mir-450a-2; +MI0031166 tch-mir-107; +MI0031167 tch-mir-499a; +MI0031168 tch-mir-34a-1; +MI0031169 tch-mir-29a; +MI0031170 tch-mir-147b; +MI0031171 tch-mir-9771d; +MI0031172 tch-mir-218-1; +MI0031173 tch-mir-376c; +MI0031174 tch-mir-17; +MI0031175 tch-mir-361; +MI0031176 tch-mir-135b; +MI0031177 tch-let-7g; +MI0031178 tch-mir-23b; +MI0031179 tch-mir-19b-1; +MI0031180 tch-mir-9771e; +MI0031181 tch-mir-221; +MI0031182 tch-mir-9-1; +MI0031183 tch-mir-7-2; +MI0031184 tch-mir-423; +MI0031185 tch-mir-181c; +MI0031186 tch-let-7f; +MI0031187 tch-mir-181d; +MI0031188 tch-mir-199a; +MI0031189 tch-mir-122; +MI0031190 tch-mir-136; +MI0031191 tch-mir-193b; +MI0031192 tch-mir-378a; +MI0031193 tch-mir-148b; +MI0031194 tch-mir-27b; +MI0031195 tch-mir-432; +MI0031196 tch-mir-376a-1; +MI0031197 tch-mir-885; +MI0031198 tch-mir-9771f; +MI0031199 tch-mir-139; +MI0031200 tch-mir-128; +MI0031201 tch-mir-9771g; +MI0031202 tch-mir-7-3; +MI0031203 tch-mir-181b; +MI0031204 tch-mir-369; +MI0031205 tch-mir-152; +MI0031206 tch-mir-29c; +MI0031207 tch-mir-9771h; +MI0031208 tch-mir-365a-1; +MI0031209 tch-mir-195; +MI0031210 tch-mir-26b; +MI0031211 tch-mir-219; +MI0031212 tch-mir-15b; +MI0031213 tch-mir-486; +MI0031214 tch-mir-100; +MI0031215 tch-mir-9771i; +MI0031216 tch-mir-656; +MI0031217 tch-mir-9771j; +MI0031218 tch-mir-497; +MI0031219 tch-mir-127; +MI0031220 tch-mir-140; +MI0031221 tch-mir-15a; +MI0031222 tch-mir-30a; +MI0031223 tch-mir-99a; +MI0031224 tch-mir-92a-2; +MI0031225 tch-mir-185; +MI0031226 tch-mir-28; +MI0031227 tch-mir-19b-2; +MI0031228 tch-mir-129-2; +MI0031229 tch-mir-491; +MI0031230 tch-mir-146a; +MI0031231 tch-mir-381; +MI0031232 tch-mir-20a; +MI0031233 tch-mir-98; +MI0031234 tch-mir-191; +MI0031235 tch-mir-425; +MI0031236 tch-mir-183; +MI0031237 tch-mir-330; +MI0031238 tch-mir-9-2; +MI0031239 tch-mir-34c; +MI0031240 tch-mir-652; +MI0031241 tch-mir-130a; +MI0031242 tch-mir-9771k; +MI0031243 tch-mir-671; +MI0031244 tch-mir-190a; +MI0031245 tch-mir-328; +MI0031246 tch-mir-99b; +MI0031247 tch-mir-374b; +MI0031248 tch-mir-193a-1; +MI0031249 tch-mir-10b-2; +MI0031250 tch-mir-9-3; +MI0031251 tch-mir-30c; +MI0031252 tch-mir-363; +MI0031253 tch-mir-708; +MI0031254 tch-mir-22; +MI0031255 tch-mir-374a; +MI0031256 tch-mir-25; +MI0031257 tch-mir-532; +MI0031258 tch-mir-21; +MI0031259 tch-mir-125b; +MI0031260 tch-mir-1247; +MI0031261 tch-mir-135a; +MI0031262 tch-mir-324; +MI0031263 tch-mir-9771l; +MI0031264 tch-mir-1301; +MI0031265 tch-mir-9771m; +MI0031266 tch-mir-365a-2; +MI0031267 tch-mir-222; +MI0031268 tch-mir-193a-2; +MI0031269 tch-mir-326; +MI0031270 tch-mir-26a-2; +MI0031271 tch-mir-19a; +MI0031272 tch-let-7i; +MI0031273 tch-mir-29b-2; +MI0031274 tch-mir-504; +MI0031275 tch-mir-27a; +MI0031276 tch-mir-503; +MI0031277 tch-mir-455; +MI0031278 tch-mir-376b; +MI0031279 tch-mir-376a-2; +MI0031280 tch-mir-9771n; +MI0031281 tch-mir-148a; +MI0031282 tch-mir-200b; +MI0031283 tch-mir-542; +MI0031284 tch-mir-9771o; +MI0031285 tch-mir-181a-2; +MI0031286 tch-mir-9770; +MI0031287 tch-mir-192; +MI0031288 tch-mir-7-4; +MI0031289 tch-mir-218-2; +MI0031290 tch-mir-93; +MI0031291 tch-mir-335; +MI0031292 tch-mir-9771p; +MI0031293 tch-let-7e; +MI0031294 tch-mir-628; +MI0031295 tch-mir-186; +MI0031296 tch-mir-34a-2; +MI0031297 tch-mir-196a; +MI0031298 tch-mir-194; +MI0031299 oha-let-7a-1; +MI0031300 oha-let-7a-2; +MI0031301 oha-let-7f-1; +MI0031302 oha-let-7c-1; +MI0031303 oha-let-7c-2; +MI0031304 oha-let-7c-3; +MI0031305 oha-let-7b; +MI0031306 oha-let-7d; +MI0031307 oha-let-7f-2; +MI0031308 oha-let-7a-3; +MI0031309 oha-let-7g; +MI0031310 oha-let-7i; +MI0031311 oha-let-7e; +MI0031312 oha-mir-1a; +MI0031313 oha-mir-100; +MI0031314 oha-mir-101a; +MI0031315 oha-mir-101b; +MI0031316 oha-mir-107; +MI0031317 oha-mir-103a; +MI0031318 oha-mir-103b; +MI0031319 oha-mir-10a; +MI0031320 oha-mir-10b; +MI0031321 oha-mir-10c; +MI0031322 oha-mir-122; +MI0031323 oha-mir-124-1; +MI0031324 oha-mir-124-2; +MI0031325 oha-mir-124-4; +MI0031326 oha-mir-124-3; +MI0031327 oha-mir-125a; +MI0031328 oha-mir-125b; +MI0031329 oha-mir-126; +MI0031330 oha-mir-128; +MI0031331 oha-mir-129a; +MI0031332 oha-mir-129b-2; +MI0031333 oha-mir-129b-1; +MI0031334 oha-mir-1306; +MI0031335 oha-mir-130a; +MI0031336 oha-mir-130b; +MI0031337 oha-mir-130c; +MI0031338 oha-mir-130d; +MI0031339 oha-mir-132; +MI0031340 oha-mir-1329; +MI0031341 oha-mir-133a-1; +MI0031342 oha-mir-133a-2; +MI0031343 oha-mir-133b; +MI0031344 oha-mir-133a-3; +MI0031345 oha-mir-135-1; +MI0031346 oha-mir-135-2; +MI0031347 oha-mir-135-3; +MI0031348 oha-mir-137; +MI0031349 oha-mir-138-1; +MI0031350 oha-mir-138-2; +MI0031351 oha-mir-1388; +MI0031352 oha-mir-139; +MI0031353 oha-mir-1397; +MI0031354 oha-mir-140; +MI0031355 oha-mir-142; +MI0031356 oha-mir-143; +MI0031357 oha-mir-144; +MI0031358 oha-mir-145; +MI0031359 oha-mir-146b; +MI0031360 oha-mir-147-1; +MI0031361 oha-mir-148a; +MI0031362 oha-mir-148b; +MI0031363 oha-mir-150; +MI0031364 oha-mir-153-1; +MI0031365 oha-mir-153-2; +MI0031366 oha-mir-15a; +MI0031367 oha-mir-15b; +MI0031368 oha-mir-16a; +MI0031369 oha-mir-16b; +MI0031370 oha-mir-1641; +MI0031371 oha-mir-1677b; +MI0031372 oha-mir-17; +MI0031373 oha-mir-1788; +MI0031374 oha-mir-1805; +MI0031375 oha-mir-181a-1; +MI0031376 oha-mir-181a-2; +MI0031377 oha-mir-181c; +MI0031378 oha-mir-181b; +MI0031379 oha-mir-182; +MI0031380 oha-mir-183; +MI0031381 oha-mir-18a; +MI0031382 oha-mir-18b; +MI0031383 oha-mir-190a; +MI0031384 oha-mir-1905; +MI0031385 oha-mir-190b; +MI0031386 oha-mir-191; +MI0031387 oha-mir-193; +MI0031388 oha-mir-194-1; +MI0031389 oha-mir-196a; +MI0031390 oha-mir-196b; +MI0031391 oha-mir-196c; +MI0031392 oha-mir-199a; +MI0031393 oha-mir-199b; +MI0031394 oha-mir-199c; +MI0031395 oha-mir-19a; +MI0031396 oha-mir-19b; +MI0031397 oha-mir-1b; +MI0031398 oha-mir-1c; +MI0031399 oha-mir-1d; +MI0031400 oha-mir-20b; +MI0031401 oha-mir-200a; +MI0031402 oha-mir-202; +MI0031403 oha-mir-203; +MI0031404 oha-mir-204-1; +MI0031405 oha-mir-204-2; +MI0031406 oha-mir-205a; +MI0031407 oha-mir-205b; +MI0031408 oha-mir-206; +MI0031409 oha-mir-208; +MI0031410 oha-mir-20a; +MI0031411 oha-mir-21; +MI0031412 oha-mir-210; +MI0031413 oha-mir-204-3; +MI0031414 oha-mir-212; +MI0031415 oha-mir-3120; +MI0031416 oha-mir-215; +MI0031417 oha-mir-216; +MI0031418 oha-mir-217; +MI0031419 oha-mir-218-1; +MI0031420 oha-mir-218-2; +MI0031421 oha-mir-2188; +MI0031422 oha-mir-219-1; +MI0031423 oha-mir-219-2; +MI0031424 oha-mir-22b; +MI0031425 oha-mir-22a; +MI0031426 oha-mir-221; +MI0031427 oha-mir-222a; +MI0031428 oha-mir-222b; +MI0031429 oha-mir-223; +MI0031430 oha-mir-23a; +MI0031431 oha-mir-23b; +MI0031432 oha-mir-24-1; +MI0031433 oha-mir-24-2; +MI0031434 oha-mir-26-1; +MI0031435 oha-mir-26-2; +MI0031436 oha-mir-26-3; +MI0031437 oha-mir-27a; +MI0031438 oha-mir-27b; +MI0031439 oha-mir-2970; +MI0031440 oha-mir-2985a-2; +MI0031441 oha-mir-2985a-1; +MI0031442 oha-mir-2985b; +MI0031443 oha-mir-29a-1; +MI0031444 oha-mir-29b-1; +MI0031445 oha-mir-29b-2; +MI0031446 oha-mir-29a-2; +MI0031447 oha-mir-301b; +MI0031448 oha-mir-301a; +MI0031449 oha-mir-30e; +MI0031450 oha-mir-30a; +MI0031451 oha-mir-30b; +MI0031452 oha-mir-30c-2; +MI0031453 oha-mir-30c-1; +MI0031454 oha-mir-30d; +MI0031455 oha-mir-31; +MI0031456 oha-mir-32-1; +MI0031457 oha-mir-33-2; +MI0031458 oha-mir-338; +MI0031459 oha-mir-33a; +MI0031460 oha-mir-34a; +MI0031461 oha-mir-34c; +MI0031462 oha-mir-3618; +MI0031463 oha-mir-363; +MI0031464 oha-mir-365a-1; +MI0031465 oha-mir-365a-2; +MI0031466 oha-mir-375; +MI0031467 oha-mir-383; +MI0031468 oha-mir-425; +MI0031469 oha-mir-429; +MI0031470 oha-mir-449a; +MI0031471 oha-mir-449c; +MI0031472 oha-mir-451; +MI0031473 oha-mir-455; +MI0031474 oha-mir-456; +MI0031475 oha-mir-458; +MI0031476 oha-mir-490; +MI0031477 oha-mir-499; +MI0031478 oha-mir-5391; +MI0031479 oha-mir-5470; +MI0031480 oha-mir-551b; +MI0031481 oha-mir-599; +MI0031482 oha-mir-7-1; +MI0031483 oha-mir-7-2; +MI0031484 oha-mir-7-3; +MI0031485 oha-mir-737; +MI0031486 oha-mir-875; +MI0031487 oha-mir-9-1; +MI0031488 oha-mir-9-2; +MI0031489 oha-mir-9-3; +MI0031490 oha-mir-9-4; +MI0031491 oha-mir-92a-1; +MI0031492 oha-mir-92a-2; +MI0031493 oha-mir-96; +MI0031494 oha-mir-98; +MI0031495 oha-mir-99a; +MI0031496 oha-mir-99b; +MI0031497 gra-MIR827b; +MI0031498 bta-mir-1842; +MI0031499 bta-mir-4657; +MI0031500 bta-mir-4523; +MI0031501 bta-mir-378d; +MI0031502 bta-mir-4449; +MI0031503 bta-mir-3064; +MI0031504 bta-mir-3533; +MI0031505 bta-mir-3432b; +MI0031506 bta-mir-2450d; +MI0031507 bta-mir-4444; +MI0031508 bta-mir-4680; +MI0031509 efu-mir-9200a; +MI0031510 hsa-mir-3179-4; +MI0031511 hsa-mir-1244-4; +MI0031512 hsa-mir-3648-2; +MI0031513 hsa-mir-3670-3; +MI0031514 hsa-mir-3670-4; +MI0031515 hsa-mir-3687-2; +MI0031516 hsa-mir-6724-2; +MI0031517 hsa-mir-6724-3; +MI0031518 hsa-mir-6724-4; +MI0031519 hsa-mir-8069-2; +MI0031520 hsa-mir-941-5; +MI0031521 hsa-mir-6859-4; +MI0031522 hsa-mir-5701-3; +MI0031523 tae-MIR531; +MI0031524 tae-MIR9772; +MI0031525 tae-MIR9773; +MI0031526 tae-MIR9672b; +MI0031527 tae-MIR9774; +MI0031528 tae-MIR9775; +MI0031529 tae-MIR530; +MI0031530 tae-MIR9776; +MI0031531 tae-MIR5050; +MI0031532 tae-MIR9777; +MI0031533 tae-MIR9778; +MI0031534 tae-MIR6201; +MI0031535 tae-MIR9779; +MI0031536 tae-MIR9780; +MI0031537 tae-MIR9781; +MI0031538 tae-MIR9653b; +MI0031539 tae-MIR9782; +MI0031540 tae-MIR9677b; +MI0031541 tae-MIR9783; +MI0031542 tae-MIR5200; +MI0031543 ssc-mir-9784-1; +MI0031544 ssc-mir-9784-2; +MI0031545 ssc-mir-9785; +MI0031546 ssc-mir-9786-1; +MI0031547 ssc-mir-9786-2; +MI0031548 ssc-mir-9787; +MI0031549 ssc-mir-9788-1; +MI0031550 ssc-mir-9788-2; +MI0031551 ssc-mir-9789; +MI0031552 ssc-mir-7857; +MI0031553 ssc-mir-9790; +MI0031554 ssc-mir-9791-1; +MI0031555 ssc-mir-9791-2; +MI0031556 ssc-mir-9792; +MI0031557 ssc-mir-9793; +MI0031558 ssc-mir-9794; +MI0031559 ssc-mir-9795; +MI0031560 ssc-mir-9796; +MI0031561 ssc-mir-9797; +MI0031562 ssc-mir-9798; +MI0031563 ssc-mir-9799; +MI0031564 ssc-mir-9800; +MI0031565 ssc-mir-9801; +MI0031566 ssc-mir-9802; +MI0031567 ssc-mir-9803; +MI0031568 ssc-mir-9804; +MI0031569 ssc-mir-9805; +MI0031570 ssc-mir-9806-1; +MI0031571 ssc-mir-9806-2; +MI0031572 ssc-mir-9806-3; +MI0031573 ssc-mir-9806-4; +MI0031574 ssc-mir-9807; +MI0031575 ssc-mir-9808; +MI0031576 ssc-mir-9809; +MI0031577 ssc-mir-9810; +MI0031578 ssc-mir-9811; +MI0031579 ssc-mir-9812; +MI0031580 ssc-mir-9813; +MI0031581 ssc-mir-9814; +MI0031582 ssc-mir-9815; +MI0031583 ssc-mir-9816; +MI0031584 ssc-mir-9817; +MI0031585 ssc-mir-9818; +MI0031586 ssc-mir-9819; +MI0031587 ssc-mir-9820; +MI0031588 ssc-mir-9821; +MI0031589 ssc-mir-9822; +MI0031590 ssc-mir-9823; +MI0031591 ssc-mir-9824; +MI0031592 ssc-mir-9825; +MI0031593 ssc-mir-9826; +MI0031594 ssc-mir-9827; +MI0031595 ssc-mir-9828-1; +MI0031596 ssc-mir-9828-2; +MI0031597 ssc-mir-9828-3; +MI0031598 ssc-mir-9829; +MI0031599 ssc-mir-9830; +MI0031600 ssc-mir-9831; +MI0031601 ssc-mir-9832; +MI0031602 ssc-mir-9833; +MI0031603 ssc-mir-9834; +MI0031604 ssc-mir-9835; +MI0031605 ssc-mir-9836; +MI0031606 ssc-mir-9837; +MI0031607 ssc-mir-9838; +MI0031608 ssc-mir-9839; +MI0031609 ssc-mir-9840; +MI0031610 ssc-mir-9841; +MI0031611 ssc-mir-9842; +MI0031612 ssc-mir-9843; +MI0031613 ssc-mir-9844; +MI0031614 ssc-mir-9845-1; +MI0031615 ssc-mir-9845-2; +MI0031616 ssc-mir-9845-3; +MI0031617 ssc-mir-9845-4; +MI0031618 ssc-mir-9845-5; +MI0031619 ssc-mir-9845-6; +MI0031620 ssc-mir-6782; +MI0031621 ssc-mir-9846; +MI0031622 ssc-mir-9847-1; +MI0031623 ssc-mir-9847-2; +MI0031624 ssc-mir-9848; +MI0031625 ssc-mir-9849; +MI0031626 ssc-mir-9850; +MI0031627 ssc-mir-9851; +MI0031628 ssc-mir-9852; +MI0031629 ssc-mir-9853-1; +MI0031630 ssc-mir-9853-2; +MI0031631 ssc-mir-9854; +MI0031632 ssc-mir-9855-1; +MI0031633 ssc-mir-9855-2; +MI0031634 ssc-mir-9856; +MI0031635 ssc-mir-9857; +MI0031636 ssc-mir-9858; +MI0031637 ssc-mir-9859; +MI0031638 ssc-mir-9860; +MI0031639 ssc-mir-9861; +MI0031640 ssc-mir-371; +MI0031641 ssc-mir-378b; +MI0031642 ssc-mir-219b; +MI0031643 ssc-mir-9862; +MI0031644 ssc-mir-96; +MI0031645 ata-MIR169g; +MI0031646 ata-MIR167c; +MI0031647 ata-MIR396a; +MI0031648 ata-MIR167a; +MI0031649 ata-MIR156d; +MI0031650 ata-MIR393; +MI0031651 ata-MIR5070; +MI0031652 ata-MIR171c; +MI0031653 ata-MIR160b; +MI0031654 ata-MIR9863a; +MI0031655 ata-MIR9772a; +MI0031656 ata-MIR167e; +MI0031657 ata-MIR2275a; +MI0031658 ata-MIR166a; +MI0031659 ata-MIR2118c; +MI0031660 ata-MIR169e; +MI0031661 ata-MIR395e; +MI0031662 ata-MIR156c; +MI0031663 ata-MIR166e; +MI0031664 ata-MIR156a; +MI0031665 ata-MIR2275b; +MI0031666 ata-MIR166b; +MI0031667 ata-MIR9672; +MI0031668 ata-MIR5168; +MI0031669 ata-MIR156b; +MI0031670 ata-MIR172a; +MI0031671 ata-MIR169c; +MI0031672 ata-MIR5200; +MI0031673 ata-MIR390; +MI0031674 ata-MIR169j; +MI0031675 ata-MIR5181; +MI0031676 ata-MIR169b; +MI0031677 ata-MIR172b; +MI0031678 ata-MIR395b; +MI0031679 ata-MIR168; +MI0031680 ata-MIR9772b; +MI0031681 ata-MIR160a; +MI0031682 ata-MIR166d; +MI0031683 ata-MIR396d; +MI0031684 ata-MIR395a; +MI0031685 ata-MIR395d; +MI0031686 ata-MIR169i; +MI0031687 ata-MIR396e; +MI0031688 ata-MIR396c; +MI0031689 ata-MIR6201; +MI0031690 ata-MIR167b; +MI0031691 ata-MIR398f; +MI0031692 ata-MIR169f; +MI0031693 ata-MIR2118a; +MI0031694 ata-MIR396b; +MI0031695 ata-MIR395f; +MI0031696 ata-MIR5062a; +MI0031697 ata-MIR408; +MI0031698 ata-MIR171a; +MI0031699 ata-MIR528; +MI0031700 ata-MIR9674c; +MI0031701 ata-MIR167f; +MI0031702 ata-MIR399b; +MI0031703 ata-MIR160c; +MI0031704 ata-MIR5062b; +MI0031705 ata-MIR9674a; +MI0031706 ata-MIR169d; +MI0031707 ata-MIR169a; +MI0031708 ata-MIR395c; +MI0031709 ata-MIR164a; +MI0031710 ata-MIR1432; +MI0031711 ata-MIR9776; +MI0031712 ata-MIR164b; +MI0031713 ata-MIR2118b; +MI0031714 ata-MIR172c; +MI0031715 ata-MIR9677; +MI0031716 ata-MIR2275c; +MI0031717 ata-MIR171d; +MI0031718 ata-MIR398g; +MI0031719 ata-MIR167d; +MI0031720 ata-MIR394; +MI0031721 ata-MIR9863b; +MI0031722 ata-MIR156e; +MI0031723 ata-MIR399a; +MI0031724 ata-MIR164c; +MI0031725 ata-MIR319; +MI0031726 ata-MIR9783; +MI0031727 ata-MIR166c; +MI0031728 ata-MIR171b; +MI0031729 ata-MIR169h; +MI0031730 ata-MIR5084; +MI0031731 ata-MIR9674b; +MI0031732 api-mir-3055-2; +MI0031733 api-mir-3055-3; +MI0031734 api-mir-3055-4; +MI0031735 api-mir-3055-5; +MI0031736 api-mir-3021-2; +MI0031737 api-mir-3021-3; +MI0031738 ata-MIR2118d; +MI0031739 ath-MIR8167d; +MI0031740 ath-MIR8167e; +MI0031741 ath-MIR8167f; +MI0031742 oar-mir-29b-2; +MI0031743 vvi-MIR171j; +MI0031744 crm-mir-51-2; +MI0031745 fru-mir-375-2; +MI0031746 fru-mir-124-4; +MI0031747 ptr-mir-1184-2; +MI0031748 tgu-mir-1467-2; +MI0031749 spu-mir-4853-2; +MI0031750 spu-mir-5992-2; +MI0031751 ptr-mir-571-2; +MI0031752 mmu-mir-6967-2; +MI0031753 mmu-mir-466c-3; +MI0031754 cte-mir-2694-2; +MI0031755 cte-mir-2703-2; +MI0031756 cte-mir-2715-2; +MI0031757 cte-mir-2d-2; +MI0031758 cte-mir-2e-2; +MI0031759 rno-mir-190a-2; +MI0031760 rno-mir-196b-2; +MI0031761 rno-mir-29c-2; +MI0031762 rno-mir-3084b-2;rno-mir-3084a-4; +MI0031763 rno-mir-322-2; +MI0031764 rno-mir-340-2; +MI0031765 rno-mir-350-2; +MI0031766 rno-mir-351-2; +MI0031767 rno-mir-3542-2; +MI0031768 rno-mir-3543-2; +MI0031769 rno-mir-3556b-2; +MI0031770 rno-mir-3584-2; +MI0031771 rno-mir-434-2; +MI0031772 rno-mir-450b-2; +MI0031773 rno-mir-503-2; +MI0031774 rno-mir-598-2; +MI0031775 rno-mir-6317-2; +MI0031776 rno-mir-6319-2; +MI0031777 rno-mir-29b-3; +MI0031778 rno-mir-344b-3; +MI0031779 rno-mir-466b-3; +MI0031780 rno-mir-466b-4; +MI0031781 rno-mir-542-2; +MI0031782 rno-mir-542-3; +MI0031783 efu-mir-9338-4; +MI0031784 prd-mir-7911c-2; +MI0031785 rno-mir-1b; +MI0031786 rno-mir-676; +MI0031787 rno-mir-486; +MI0031788 ame-mir-9864; +MI0031789 ame-mir-279d; +MI0031790 ame-mir-3718c; +MI0031791 ame-mir-9865; +MI0031792 ame-mir-9866; +MI0031793 ame-mir-9867; +MI0031794 ame-mir-9868; +MI0031795 ame-mir-9869; +MI0031796 ame-mir-9870; +MI0031797 ame-mir-9871; +MI0031798 ame-mir-9872; +MI0031799 ame-mir-9873; +MI0031800 ame-mir-9874; +MI0031801 ame-mir-9875; +MI0031802 ame-mir-9876; +MI0031803 ame-mir-9877; +MI0031804 ame-mir-9878; +MI0031805 ame-mir-9879; +MI0031806 ame-mir-9880; +MI0031807 ame-mir-9881; +MI0031808 ame-mir-9882; +MI0031809 ame-mir-9883; +MI0031810 ame-mir-9884; +MI0031811 ame-mir-9885; +MI0031812 ame-mir-9886; +MI0031813 ame-mir-9887; +MI0031814 ame-mir-2b; +MI0031815 ame-mir-9888; +MI0031816 ame-mir-9889; +MI0031817 ame-mir-9890; +MI0031818 ame-mir-9891; +MI0031819 ame-mir-9892; +MI0031820 ame-mir-9893; +MI0031821 ame-mir-9894; +MI0031822 ame-mir-9895; +MI0031823 ame-mir-9896; +MI0031824 ame-mir-3478; +MI0031825 cre-MIR9897; +MI0031826 hsa-mir-9898; +MI0031827 hsa-mir-9899; +MI0031828 hsa-mir-9900; +MI0031829 hsa-mir-9901; +MI0031830 hsa-mir-9902-1; +MI0031831 hsa-mir-9903; +MI0031832 cja-let-7a-1; +MI0031833 cja-let-7a-2; +MI0031834 cja-let-7b; +MI0031835 cja-let-7g; +MI0031836 cja-mir-523; +MI0031837 cja-mir-519a; +MI0031838 cja-mir-372; +MI0031839 cja-mir-371a; +MI0031840 cja-mir-1323; +MI0031841 cja-mir-513b-1; +MI0031842 cja-mir-513b-2; +MI0031843 cja-mir-513a-1; +MI0031844 cja-mir-513a-2; +MI0031845 cja-mir-513a-3; +MI0031846 cja-mir-513c-1; +MI0031847 cja-mir-513c-2; +MI0031848 cja-mir-320-1; +MI0031849 cja-mir-320-2; +MI0031850 cja-mir-548e; +MI0031851 cja-mir-495; +MI0031852 cja-mir-543; +MI0031853 cja-mir-451; +MI0031854 cja-mir-338; +MI0031855 cja-mir-216b; +MI0031856 cja-mir-329; +MI0031857 cja-mir-181c; +MI0031858 cja-mir-181a-1; +MI0031859 cja-mir-181a-2; +MI0031860 cja-mir-181b-1; +MI0031861 cja-mir-181b-2; +MI0031862 cja-mir-181d; +MI0031863 cja-mir-99; +MI0031864 cja-mir-193; +MI0031865 cja-mir-452; +MI0031866 cja-mir-708; +MI0031867 cja-mir-369; +MI0031868 cja-mir-410; +MI0031869 cja-mir-656; +MI0031870 cja-mir-487a; +MI0031871 cja-mir-154; +MI0031872 cja-mir-652a; +MI0031873 cja-mir-363; +MI0031874 cja-mir-214; +MI0031875 cja-mir-199-1; +MI0031876 cja-mir-199-2; +MI0031877 cja-mir-665; +MI0031878 cja-mir-1249; +MI0031879 cja-mir-1251; +MI0031880 cja-mir-9904; +MI0031881 cja-mir-219; +MI0031882 cja-mir-485; +MI0031883 cja-mir-383a; +MI0031884 cja-mir-103a-1; +MI0031885 cja-mir-103a-3; +MI0031886 cja-mir-103a-2; +MI0031887 cja-mir-222-2; +MI0031888 cja-mir-222-1; +MI0031889 cja-mir-671; +MI0031890 cja-mir-31; +MI0031891 cja-mir-34c; +MI0031892 cja-mir-296; +MI0031893 cja-mir-491; +MI0031894 cja-mir-655; +MI0031895 cja-mir-374b; +MI0031896 cja-mir-421; +MI0031897 cja-mir-377; +MI0031898 cja-mir-23b; +MI0031899 cja-mir-539; +MI0031900 cja-mir-376a-1; +MI0031901 cja-mir-376a-2; +MI0031903 cja-mir-376b; +MI0031904 cja-mir-215; +MI0031905 cja-mir-628; +MI0031906 cja-mir-2355; +MI0031907 cja-mir-186; +MI0031908 cja-mir-20b; +MI0031909 cja-mir-93; +MI0031910 cja-mir-17; +MI0031911 cja-mir-191; +MI0031912 cja-mir-224; +MI0031913 cja-mir-548m; +MI0031914 cja-mir-3120; +MI0031915 cja-mir-424; +MI0031916 cja-mir-130b; +MI0031917 cja-mir-1298; +MI0031918 cja-mir-532; +MI0031919 cja-mir-1306; +MI0031920 cja-mir-323; +MI0031921 cja-mir-324; +MI0031922 cja-mir-1247; +MI0031923 cja-mir-1468; +MI0031924 cja-mir-328; +MI0031925 cja-mir-675; +MI0031926 cja-mir-374a; +MI0031927 cja-mir-129-2; +MI0031928 cja-mir-129-1; +MI0031929 cja-mir-382; +MI0031930 cja-mir-503; +MI0031931 cja-mir-551; +MI0031932 cja-mir-345; +MI0031933 cja-mir-144; +MI0031934 cja-mir-145; +MI0031935 cja-mir-203; +MI0031936 cja-mir-887; +MI0031937 cja-mir-33; +MI0031938 cja-mir-1327; +MI0031939 cja-mir-548l; +MI0031940 cja-mir-20a; +MI0031941 cja-mir-141; +MI0031942 cja-mir-132; +MI0031943 cja-mir-582; +MI0031944 cja-mir-124-1; +MI0031945 cja-mir-124-2; +MI0031946 cja-mir-200c; +MI0031947 cja-mir-429; +MI0031948 cja-mir-216a; +MI0031949 cja-mir-365-1; +MI0031950 cja-mir-365-2; +MI0031951 cja-mir-101-1; +MI0031952 cja-mir-140; +MI0031953 cja-mir-660; +MI0031954 cja-mir-10b; +MI0031955 cja-mir-10a; +MI0031956 cja-mir-598; +MI0031957 cja-mir-217; +MI0031958 cja-mir-29b-1; +MI0031959 cja-mir-29b-2; +MI0031960 cja-mir-29c; +MI0031961 cja-mir-15b; +MI0031962 cja-mir-16-2; +MI0031963 cja-mir-16-1; +MI0031964 cja-mir-21; +MI0031965 cja-mir-449c; +MI0031966 cja-mir-196a; +MI0031967 cja-mir-196b; +MI0031968 cja-mir-411; +MI0031969 cja-mir-381; +MI0031970 cja-mir-3688; +MI0031971 cja-mir-183; +MI0031972 cja-mir-135; +MI0031973 cja-mir-654; +MI0031974 cja-mir-455; +MI0031975 cja-mir-32; +MI0031976 cja-mir-92b; +MI0031977 cja-mir-92a-1; +MI0031978 cja-mir-92a-2; +MI0031979 cja-mir-105; +MI0031980 cja-mir-335; +MI0031981 cja-mir-128-2; +MI0031982 cja-mir-128-1; +MI0031983 cja-mir-483; +MI0031984 cja-mir-3065; +MI0031985 cja-mir-148a; +MI0031986 cja-mir-148b; +MI0031987 cja-mir-152; +MI0031988 cja-mir-885; +MI0031989 cja-mir-125; +MI0031990 cja-mir-615; +MI0031991 cja-mir-205; +MI0031992 cja-mir-151; +MI0031993 cja-mir-127; +MI0031994 cja-mir-126; +MI0031995 cja-mir-187; +MI0031996 cja-mir-139; +MI0031997 cja-mir-342; +MI0031998 cja-mir-150; +MI0031999 cja-mir-9-1; +MI0032000 cja-mir-9-2; +MI0032001 cja-mir-494; +MI0032002 cja-mir-146b; +MI0032003 cja-mir-146a; +MI0032004 cja-mir-769; +MI0032005 cja-mir-143; +MI0032006 cja-mir-2114; +MI0032007 cja-mir-339; +MI0032008 cja-mir-423; +MI0032009 cja-mir-1911; +MI0032010 cja-mir-190a; +MI0032011 cja-mir-190b; +MI0032012 cja-mir-767; +MI0032013 cja-mir-7; +MI0032014 cja-mir-1a-1; +MI0032015 cja-mir-1a-2; +MI0032016 cja-mir-206; +MI0032017 cja-mir-184; +MI0032018 cja-mir-185; +MI0032019 cja-mir-876; +MI0032020 cja-mir-449a; +MI0032021 cja-mir-34a; +MI0032022 cja-mir-24-1; +MI0032023 cja-mir-24-2; +MI0032024 cja-mir-379; +MI0032025 cja-mir-412; +MI0032026 cja-mir-541; +MI0032027 cja-mir-30d; +MI0032028 cja-mir-30b; +MI0032029 cja-mir-30a; +MI0032030 cja-mir-30e; +MI0032031 cja-mir-194; +MI0032032 cja-mir-223; +MI0032033 cja-mir-934; +MI0032034 cja-mir-134; +MI0032035 cja-mir-19b-2; +MI0032036 cja-mir-19b-1; +MI0032037 cja-mir-499a; +MI0032038 cja-mir-155; +MI0032039 cja-mir-1296; +MI0032040 cja-mir-361; +MI0032041 cja-mir-137; +MI0032042 cja-mir-95; +MI0032043 cja-mir-26a-1; +MI0032044 cja-mir-26a-2; +MI0032045 cja-mir-26b; +MI0032046 cja-mir-27a; +MI0032047 cja-mir-27b; +MI0032048 cja-mir-197; +MI0032049 cja-mir-204; +MI0032050 cja-mir-211; +MI0032051 cja-mir-202; +MI0032052 cja-mir-488; +MI0032053 cja-mir-9905; +MI0032054 cja-mir-1301; +MI0032055 cja-mir-153-1; +MI0032056 cja-mir-153-2; +MI0032057 cja-mir-448; +MI0032058 cja-mir-133a-1; +MI0032059 cja-mir-133a-2; +MI0032060 cja-mir-493; +MI0032061 cja-mir-218; +MI0032062 cja-mir-670; +MI0032063 cja-mir-182; +MI0032064 cja-mir-96; +MI0032065 cja-mir-133b; +MI0032066 cja-mir-450a; +MI0032067 cja-mir-450b; +MI0032068 cja-mir-497; +MI0032069 cja-mir-373; +MI0032070 cja-mir-383b; +MI0032071 cja-mir-518a; +MI0032072 cja-mir-510a; +MI0032073 cja-mir-513d-1; +MI0032074 cja-mir-513d-2; +MI0032075 cja-mir-5191; +MI0032076 cja-mir-1258a; +MI0032077 cja-mir-3135; +MI0032078 cja-mir-548a; +MI0032079 cja-mir-34b; +MI0032080 cja-mir-548b; +MI0032081 cja-mir-548n-1; +MI0032082 cja-mir-548n-2; +MI0032083 cja-mir-9906; +MI0032084 cja-mir-9907; +MI0032085 cja-mir-9908; +MI0032086 cja-mir-330; +MI0032087 cja-mir-676; +MI0032088 cja-mir-504; +MI0032089 cja-mir-9909; +MI0032090 cja-mir-1258b; +MI0032091 cja-mir-9910; +MI0032092 cja-mir-142; +MI0032093 cja-mir-505; +MI0032094 cja-mir-299; +MI0032095 cja-mir-616; +MI0032096 cja-mir-337; +MI0032097 cja-mir-891b-1; +MI0032098 cja-mir-891b-2; +MI0032099 cja-mir-617; +MI0032100 cja-mir-770; +MI0032101 cja-mir-3074-2; +MI0032102 cja-mir-3074-1; +MI0032103 cja-mir-542; +MI0032104 cja-mir-371b; +MI0032105 cja-mir-514a; +MI0032106 cja-mir-508; +MI0032107 cja-mir-548q-2; +MI0032108 cja-mir-548q-1; +MI0032109 cja-mir-548f; +MI0032110 cja-mir-548x; +MI0032111 cja-mir-548o-1; +MI0032112 cja-mir-548o-2; +MI0032113 cja-mir-548d-2; +MI0032114 cja-mir-548d-1; +MI0032115 cja-mir-561; +MI0032116 cja-mir-499b; +MI0032117 cja-mir-548s; +MI0032118 cja-mir-622; +MI0032119 cja-mir-466a; +MI0032120 cja-mir-367; +MI0032121 cja-mir-302a; +MI0032122 cja-mir-302b; +MI0032123 cja-mir-302d; +MI0032124 cja-mir-631-1; +MI0032125 cja-mir-631-2; +MI0032126 cja-mir-631-3; +MI0032127 cja-mir-138; +MI0032128 cja-mir-1898; +MI0032129 cja-mir-569; +MI0032130 cja-mir-3546; +MI0032131 cja-mir-208b; +MI0032132 cja-mir-208a-1; +MI0032133 cja-mir-208a-2; +MI0032134 cja-mir-4790; +MI0032135 cja-mir-3152; +MI0032136 cja-mir-548h; +MI0032137 cja-mir-548p; +MI0032138 cja-mir-548j; +MI0032139 cja-mir-548c-2; +MI0032140 cja-mir-548c-1; +MI0032141 cja-mir-1264; +MI0032142 cja-mir-3940; +MI0032143 cja-mir-763; +MI0032144 cja-mir-875; +MI0032145 cja-mir-4762; +MI0032146 cja-mir-556; +MI0032147 cja-mir-759; +MI0032148 cja-mir-761; +MI0032149 cja-mir-489; +MI0032150 cja-mir-559; +MI0032151 cja-mir-302c; +MI0032152 cja-mir-1b; +MI0032153 cja-mir-466b; +MI0032154 cja-mir-548v; +MI0032155 cja-mir-1193; +MI0032156 cja-mir-586; +MI0032157 cja-mir-103b-2; +MI0032158 cja-mir-103b-1; +MI0032159 cja-mir-1282; +MI0032160 cja-mir-2968; +MI0032161 cja-mir-581; +MI0032162 cja-mir-548y-2; +MI0032163 cja-mir-548y-1; +MI0032164 cja-mir-589; +MI0032165 cja-mir-4745; +MI0032166 cja-mir-4683; +MI0032167 cja-mir-122; +MI0032168 cja-mir-1294; +MI0032169 cja-mir-651; +MI0032170 cja-mir-2053; +MI0032171 cja-mir-1302; +MI0032172 cja-mir-544; +MI0032173 cja-mir-2338; +MI0032174 cja-mir-4460; +MI0032175 cja-mir-4679; +MI0032176 cja-mir-4780; +MI0032177 cja-mir-1240; +MI0032178 cja-mir-557; +MI0032179 cja-mir-612; +MI0032180 cja-mir-1305; +MI0032181 cja-mir-545; +MI0032182 cja-mir-548t; +MI0032183 cja-mir-580; +MI0032184 cja-mir-3118; +MI0032185 cja-mir-3576; +MI0032186 cja-mir-4503; +MI0032187 cja-mir-4512; +MI0032188 cja-mir-4772; +MI0032189 cja-mir-548g; +MI0032190 cja-mir-548r; +MI0032191 cja-mir-548i-1; +MI0032192 cja-mir-548i-2; +MI0032193 cja-mir-638; +MI0032194 cja-mir-1253; +MI0032195 cja-mir-1895; +MI0032196 cja-mir-9911; +MI0032197 cja-mir-9912; +MI0032198 cja-mir-548u; +MI0032199 cja-mir-548k; +MI0032200 cja-mir-498; +MI0032201 cja-mir-518b-1; +MI0032202 cja-mir-518b-2; +MI0032203 cja-mir-518b-3; +MI0032204 cja-mir-518b-4; +MI0032205 cja-mir-519b; +MI0032206 cja-mir-521; +MI0032207 cja-mir-519c; +MI0032208 cja-mir-513g; +MI0032209 cja-mir-514b; +MI0032210 cja-mir-506; +MI0032211 cja-mir-513f-1; +MI0032212 cja-mir-513f-2; +MI0032213 cja-mir-513f-3; +MI0032214 cja-mir-513h; +MI0032215 cja-mir-510b; +MI0032216 cja-mir-509; +MI0032217 cja-mir-513e; +MI0032218 cja-mir-9913; +MI0032219 cja-mir-9914; +MI0032220 cja-mir-9915; +MI0032221 cja-mir-9916; +MI0032222 cja-mir-9917-1; +MI0032223 cja-mir-9917-2; +MI0032224 cja-mir-9918; +MI0032225 cja-mir-9919; +MI0032227 cja-mir-9921; +MI0032228 cja-mir-652b; +MI0032229 cja-mir-9922; +MI0032230 cja-mir-9923; +MI0032231 cja-mir-9924; +MI0032232 cja-mir-9952b; +MI0032233 cja-mir-9925; +MI0032234 cja-mir-9926; +MI0032235 cja-mir-9952c; +MI0032236 cja-mir-3544; +MI0032237 cja-mir-9927; +MI0032238 cja-mir-9928; +MI0032239 cja-mir-9929; +MI0032240 cja-mir-9930; +MI0032241 cja-mir-9931; +MI0032242 cja-mir-9932; +MI0032243 cja-mir-1185; +MI0032244 cja-mir-9933; +MI0032245 cja-mir-548w; +MI0032246 cja-mir-9934; +MI0032247 cja-mir-584; +MI0032248 cja-mir-9935; +MI0032249 cja-mir-507; +MI0032250 cja-mir-9936-1; +MI0032251 cja-mir-9936-2; +MI0032252 cja-mir-9937; +MI0032253 cja-mir-9938; +MI0032254 cja-mir-9939; +MI0032255 cja-mir-9940; +MI0032256 cja-mir-9941; +MI0032257 cja-mir-9942; +MI0032258 cja-mir-9943; +MI0032259 cja-mir-9948a; +MI0032260 cja-mir-9944; +MI0032261 cja-mir-891c; +MI0032262 cja-mir-9945; +MI0032263 cja-mir-9946; +MI0032264 cja-mir-6529; +MI0032265 cja-mir-942; +MI0032266 cja-mir-9947; +MI0032267 cja-mir-9948b; +MI0032268 cja-mir-9949; +MI0032269 cja-mir-577; +MI0032270 cja-mir-9950; +MI0032271 cja-mir-9951; +MI0032272 cja-mir-9952a-1; +MI0032273 cja-mir-9952a-2; +MI0032274 cja-mir-9953; +MI0032275 cja-mir-9954; +MI0032276 cja-mir-9955; +MI0032277 cja-mir-9956; +MI0032278 cja-mir-9957-1; +MI0032279 cja-mir-9957-2; +MI0032280 cja-mir-9958; +MI0032281 cja-mir-9959; +MI0032282 cja-mir-9960; +MI0032283 cja-mir-9961; +MI0032284 cja-mir-9962; +MI0032285 cja-mir-9963; +MI0032286 cja-mir-9964; +MI0032287 cja-mir-9965; +MI0032288 cja-mir-9966; +MI0032289 cja-mir-9967; +MI0032290 cja-mir-9968; +MI0032291 cja-mir-9969; +MI0032292 cja-mir-891d; +MI0032293 cja-mir-9970; +MI0032294 cja-mir-9971; +MI0032295 cja-mir-9972; +MI0032297 cja-mir-9973; +MI0032298 cja-mir-9974; +MI0032299 cja-mir-9975; +MI0032300 cja-mir-9976-1; +MI0032301 cja-mir-9976-2; +MI0032302 cja-mir-9977; +MI0032303 cja-mir-9978; +MI0032304 cja-mir-653; +MI0032305 cja-mir-9979; +MI0032306 cja-mir-9980; +MI0032307 cja-mir-9981; +MI0032308 cja-mir-9982; +MI0032309 cja-mir-9983; +MI0032310 cja-mir-9984-1; +MI0032311 cja-mir-9984-2; +MI0032312 cja-mir-487b; +MI0032313 hsa-mir-9985; +MI0032314 hsa-mir-1843; +MI0032315 hsa-mir-548bc; +MI0032316 hsa-mir-9986; +MI0032317 pal-mir-1-1; +MI0032318 pal-mir-1-2; +MI0032319 pal-let-7f; +MI0032320 pal-let-7a-1; +MI0032321 pal-let-7g; +MI0032322 pal-mir-122; +MI0032323 pal-mir-140; +MI0032324 pal-mir-143; +MI0032325 pal-mir-378; +MI0032326 pal-let-7e; +MI0032327 pal-let-7i; +MI0032328 pal-mir-199-1; +MI0032329 pal-mir-199-2; +MI0032330 pal-mir-199-3; +MI0032331 pal-mir-34c; +MI0032332 pal-mir-128; +MI0032333 pal-mir-21; +MI0032334 pal-mir-206; +MI0032335 pal-mir-30a; +MI0032336 pal-mir-29a; +MI0032337 pal-mir-26a-2; +MI0032338 pal-mir-192; +MI0032339 pal-mir-3958; +MI0032340 pal-mir-27b; +MI0032341 pal-mir-191; +MI0032342 pal-mir-672; +MI0032343 pal-mir-181a-2; +MI0032344 pal-mir-181a-1; +MI0032345 pal-mir-148a; +MI0032346 pal-mir-499a; +MI0032347 pal-mir-25; +MI0032348 pal-mir-30d; +MI0032349 pal-mir-10a; +MI0032350 pal-mir-215; +MI0032351 pal-mir-423; +MI0032352 pal-mir-30e; +MI0032353 pal-mir-99b; +MI0032354 pal-mir-124; +MI0032355 pal-mir-92a-2; +MI0032356 pal-mir-185; +MI0032357 pal-mir-221; +MI0032358 pal-mir-181b-2; +MI0032359 pal-mir-486a-1; +MI0032360 pal-mir-99a; +MI0032361 pal-mir-486a-2; +MI0032362 pal-mir-125b-2; +MI0032363 pal-mir-181b-1; +MI0032364 pal-mir-125b-1; +MI0032365 pal-mir-129a; +MI0032366 pal-mir-23a; +MI0032367 pal-mir-27a; +MI0032368 pal-mir-22; +MI0032369 pal-mir-202; +MI0032370 pal-mir-200b; +MI0032371 pal-mir-200a; +MI0032372 pal-mir-148b; +MI0032373 pal-mir-23b; +MI0032374 pal-mir-129b; +MI0032375 pal-mir-133a-1; +MI0032376 pal-mir-133a-2; +MI0032377 pal-mir-363; +MI0032378 pal-mir-485; +MI0032379 pal-mir-30c; +MI0032380 pal-mir-98; +MI0032381 pal-mir-9-1; +MI0032382 pal-mir-379; +MI0032383 pal-mir-9-2; +MI0032384 pal-mir-34b; +MI0032385 pal-mir-28; +MI0032386 pal-mir-16-1; +MI0032387 pal-mir-16-2; +MI0032388 pal-mir-130; +MI0032389 pal-mir-194b; +MI0032390 pal-mir-10b; +MI0032391 pal-mir-532; +MI0032392 pal-mir-186; +MI0032393 pal-mir-15b; +MI0032394 pal-mir-92b; +MI0032395 pal-mir-126; +MI0032396 pal-mir-200c; +MI0032397 pal-mir-8908b; +MI0032398 pal-mir-382; +MI0032399 pal-mir-7b-1; +MI0032400 pal-mir-424; +MI0032401 pal-mir-323; +MI0032402 pal-mir-411; +MI0032403 pal-mir-139; +MI0032404 pal-mir-219a-2; +MI0032405 pal-mir-146b; +MI0032406 pal-mir-193a; +MI0032407 pal-mir-506; +MI0032408 pal-mir-106b; +MI0032409 pal-mir-93; +MI0032410 pal-mir-449a; +MI0032411 pal-mir-15a; +MI0032412 pal-mir-493; +MI0032413 pal-mir-30b; +MI0032414 pal-mir-138-1; +MI0032415 pal-mir-500-1; +MI0032416 pal-mir-500-2; +MI0032417 pal-mir-9987; +MI0032418 pal-mir-9988; +MI0032419 pal-mir-509b; +MI0032420 pal-mir-100; +MI0032421 pal-mir-17; +MI0032422 pal-mir-144; +MI0032423 pal-mir-365b; +MI0032424 pal-mir-204; +MI0032425 pal-mir-193b; +MI0032426 pal-mir-664a-1; +MI0032427 pal-mir-299a; +MI0032428 pal-mir-1185; +MI0032429 pal-mir-155; +MI0032430 pal-mir-1388; +MI0032431 pal-mir-212; +MI0032432 pal-mir-345; +MI0032433 pal-mir-425; +MI0032434 pal-mir-135-1; +MI0032435 pal-mir-8908a-2; +MI0032436 pal-mir-374b; +MI0032437 pal-mir-132; +MI0032438 pal-mir-331; +MI0032439 pal-mir-150; +MI0032440 pal-mir-660; +MI0032441 pal-mir-7140; +MI0032442 pal-mir-136; +MI0032443 pal-mir-708; +MI0032444 pal-mir-20b; +MI0032445 pal-mir-181c; +MI0032446 pal-mir-196b; +MI0032447 pal-mir-504; +MI0032448 pal-mir-664b; +MI0032449 pal-mir-337; +MI0032450 pal-mir-885; +MI0032451 pal-mir-487b; +MI0032452 pal-mir-574; +MI0032453 pal-mir-369; +MI0032454 pal-mir-208a-1; +MI0032455 pal-mir-208a-2; +MI0032456 pal-mir-224; +MI0032457 pal-mir-194a; +MI0032458 pal-mir-490; +MI0032459 pal-mir-873; +MI0032460 pal-mir-338; +MI0032461 pal-mir-34a; +MI0032462 pal-mir-361; +MI0032463 pal-mir-652; +MI0032464 pal-mir-218-2; +MI0032465 pal-mir-301a; +MI0032466 pal-mir-380; +MI0032467 pal-mir-137; +MI0032468 pal-mir-216b; +MI0032469 pal-mir-370; +MI0032470 pal-mir-454; +MI0032471 pal-mir-9989; +MI0032472 pal-mir-329b; +MI0032473 pal-mir-9990; +MI0032474 pal-mir-8908e; +MI0032475 pal-mir-153-1; +MI0032476 pal-mir-214; +MI0032477 pal-mir-503; +MI0032478 pal-mir-219a-1; +MI0032479 pal-mir-26a-1; +MI0032480 pal-mir-320; +MI0032481 pal-mir-296; +MI0032482 pal-mir-497; +MI0032483 pal-mir-151; +MI0032484 pal-mir-33a; +MI0032485 pal-mir-195; +MI0032486 pal-mir-342; +MI0032487 pal-mir-432; +MI0032488 pal-mir-133b; +MI0032489 pal-mir-502; +MI0032490 pal-mir-760; +MI0032491 pal-mir-330; +MI0032492 pal-mir-141; +MI0032493 pal-mir-429; +MI0032494 pal-mir-101-2; +MI0032495 pal-mir-8908a-1; +MI0032496 pal-mir-196a; +MI0032497 pal-mir-152; +MI0032498 pal-mir-125a; +MI0032499 pal-mir-205; +MI0032500 pal-mir-7a; +MI0032501 pal-mir-412; +MI0032502 pal-mir-26b; +MI0032503 pal-mir-1180; +MI0032504 pal-mir-375; +MI0032505 pal-mir-450b; +MI0032506 pal-mir-222; +MI0032507 pal-mir-409; +MI0032508 pal-mir-323b; +MI0032509 pal-mir-142; +MI0032510 pal-mir-1224; +MI0032511 pal-mir-96; +MI0032512 pal-mir-31; +MI0032513 pal-mir-20a; +MI0032514 pal-let-7c; +MI0032515 pal-mir-181d; +MI0032516 pal-mir-183; +MI0032517 pal-mir-127; +MI0032518 pal-let-7a-2; +MI0032519 pal-mir-9991; +MI0032520 pal-mir-410; +MI0032521 pal-mir-138-2; +MI0032522 pal-mir-381; +MI0032523 pal-mir-9992; +MI0032524 pal-mir-145; +MI0032525 pal-mir-92a-1; +MI0032526 pal-mir-335; +MI0032527 pal-mir-7b-2; +MI0032528 pal-mir-184; +MI0032529 pal-mir-19-1; +MI0032530 pal-mir-19-2; +MI0032531 pal-mir-452; +MI0032532 pal-mir-383; +MI0032533 pal-mir-9993a; +MI0032534 pal-mir-29b-1; +MI0032535 pal-mir-9994; +MI0032536 pal-mir-802; +MI0032537 pal-mir-146a; +MI0032538 pal-mir-542; +MI0032539 pal-mir-495; +MI0032540 pal-mir-9995; +MI0032541 pal-mir-551b; +MI0032542 pal-mir-340; +MI0032543 pal-mir-103a; +MI0032544 pal-mir-6529; +MI0032545 pal-mir-29c; +MI0032546 pal-mir-450a-1; +MI0032547 pal-mir-107a; +MI0032548 pal-mir-29b-2; +MI0032549 pal-mir-106a; +MI0032550 pal-mir-103b; +MI0032551 pal-mir-376d; +MI0032552 pal-mir-450a-2; +MI0032553 pal-mir-544; +MI0032554 pal-mir-3959; +MI0032555 pal-mir-101-1; +MI0032556 pal-mir-1301; +MI0032557 pal-mir-543; +MI0032558 pal-mir-9996; +MI0032559 pal-mir-18a; +MI0032560 pal-mir-196c; +MI0032561 pal-mir-889; +MI0032562 pal-mir-8908g; +MI0032563 pal-mir-376c; +MI0032564 pal-mir-105-1; +MI0032565 pal-mir-9997; +MI0032566 pal-mir-376b; +MI0032567 pal-mir-8908f; +MI0032568 pal-mir-6119; +MI0032569 pal-mir-628; +MI0032570 pal-mir-9998; +MI0032571 pal-mir-218-1; +MI0032572 pal-mir-8908c; +MI0032573 pal-mir-135-2; +MI0032574 pal-mir-758; +MI0032575 pal-mir-458; +MI0032576 pal-mir-4646; +MI0032577 pal-mir-3120; +MI0032578 pal-mir-208b; +MI0032579 pal-mir-9999; +MI0032580 pal-mir-665; +MI0032581 pal-mir-10000; +MI0032582 pal-mir-1379; +MI0032583 pal-mir-10001; +MI0032584 pal-mir-10002; +MI0032585 pal-mir-541; +MI0032586 pal-mir-154b; +MI0032587 pal-mir-9993b; +MI0032588 pal-mir-9226; +MI0032589 pal-mir-486a-3; +MI0032590 pal-mir-282; +MI0032591 pal-mir-339a; +MI0032592 pal-mir-10003; +MI0032593 pal-mir-421; +MI0032594 pal-mir-10004; +MI0032595 pal-mir-10005; +MI0032596 pal-mir-9287; +MI0032597 pal-mir-10006-1; +MI0032598 pal-mir-10006-2; +MI0032599 pal-mir-433; +MI0032600 pal-mir-33b; +MI0032601 pal-mir-182; +MI0032602 pal-mir-10007; +MI0032603 pal-mir-874; +MI0032604 pal-mir-10008; +MI0032605 pal-mir-8908d; +MI0032606 pal-mir-10009; +MI0032607 pal-mir-219b; +MI0032608 pal-mir-1307; +MI0032609 pal-mir-10010; +MI0032610 pal-mir-10011; +MI0032611 pal-mir-324; +MI0032612 pal-mir-10012; +MI0032613 pal-mir-153-2; +MI0032614 pal-mir-10013; +MI0032615 pal-mir-10014; +MI0032616 pal-mir-513; +MI0032617 pal-mir-301b; +MI0032618 pal-mir-211; +MI0032619 pal-mir-876; +MI0032620 pal-mir-10015; +MI0032621 pal-mir-346; +MI0032622 pal-mir-9298; +MI0032623 pal-mir-188; +MI0032624 pal-mir-1296; +MI0032625 pal-mir-4657; +MI0032626 pal-mir-378d; +MI0032627 pal-mir-378e; +MI0032628 pal-mir-376a; +MI0032629 pal-mir-32; +MI0032630 pal-mir-507; +MI0032631 pal-mir-1249; +MI0032632 pal-mir-10016; +MI0032633 pal-mir-3085; +MI0032634 pal-mir-656; +MI0032635 pal-mir-378c; +MI0032636 pal-mir-187; +MI0032637 pal-mir-3059; +MI0032638 pal-mir-487a; +MI0032639 pal-mir-371; +MI0032640 pal-mir-10017-1; +MI0032641 pal-mir-1306; +MI0032642 pal-mir-10018; +MI0032643 pal-mir-10017-2; +MI0032644 pal-mir-190b; +MI0032645 pal-mir-362; +MI0032646 pal-mir-10019-1; +MI0032647 pal-mir-10019-2; +MI0032648 pal-mir-339b; +MI0032649 pal-mir-1911; +MI0032650 pal-mir-1839; +MI0032651 pal-mir-107b; +MI0032652 pal-mir-18b; +MI0032653 pal-mir-422c; +MI0032654 pal-mir-3064; +MI0032655 pal-mir-449c; +MI0032656 pal-mir-299b; +MI0032657 pal-mir-599; +MI0032658 pal-mir-377; +MI0032659 pal-mir-484; +MI0032660 pal-mir-668; +MI0032661 pal-mir-664a-2; +MI0032666 bta-mir-10020; +MI0032667 hpo-mir-100; +MI0032668 hpo-mir-71; +MI0032669 hpo-mir-10021; +MI0032670 hpo-mir-5885a; +MI0032671 hpo-mir-81; +MI0032672 hpo-mir-54a; +MI0032673 hpo-mir-5899a; +MI0032674 hpo-mir-83; +MI0032675 hpo-mir-60a; +MI0032676 hpo-mir-5885b; +MI0032677 hpo-mir-5885c; +MI0032678 hpo-let-7; +MI0032679 hpo-mir-10022; +MI0032680 hpo-mir-79; +MI0032681 hpo-mir-10023; +MI0032682 hpo-mir-55; +MI0032683 hpo-mir-233; +MI0032684 hpo-mir-84a; +MI0032685 hpo-mir-5908; +MI0032686 hpo-mir-228; +MI0032687 hpo-mir-5899b; +MI0032688 hpo-lin-4; +MI0032689 hpo-mir-1; +MI0032690 hpo-mir-240; +MI0032691 hpo-mir-54b; +MI0032692 hpo-mir-259; +MI0032693 hpo-mir-63a; +MI0032694 hpo-mir-63b; +MI0032695 hpo-mir-9; +MI0032696 hpo-mir-87b; +MI0032697 hpo-mir-34; +MI0032698 hpo-mir-87a; +MI0032699 hpo-mir-236; +MI0032700 hpo-mir-993; +MI0032701 hpo-mir-250; +MI0032702 hpo-mir-59; +MI0032703 hpo-mir-86; +MI0032704 hpo-mir-10024; +MI0032705 hpo-mir-10025; +MI0032706 hpo-mir-50; +MI0032707 hpo-mir-61a; +MI0032708 hpo-mir-43a; +MI0032709 hpo-mir-5884; +MI0032710 hpo-mir-45; +MI0032711 hpo-mir-60b; +MI0032712 hpo-mir-5895; +MI0032713 hpo-mir-750; +MI0032714 hpo-mir-61b; +MI0032715 hpo-mir-235; +MI0032716 hpo-mir-307; +MI0032717 hpo-mir-232a; +MI0032718 hpo-mir-2; +MI0032719 hpo-mir-252; +MI0032720 hpo-mir-5976; +MI0032721 hpo-mir-5896; +MI0032722 hpo-mir-232b; +MI0032723 hpo-mir-234; +MI0032724 hpo-mir-5948; +MI0032725 hpo-mir-10026; +MI0032726 hpo-mir-46; +MI0032727 hpo-mir-1175; +MI0032728 hpo-mir-10027; +MI0032729 hpo-mir-124; +MI0032730 hpo-mir-277; +MI0032731 hpo-mir-36a; +MI0032732 hpo-mir-72; +MI0032733 hpo-mir-5352; +MI0032734 hpo-mir-10028; +MI0032735 hpo-mir-790; +MI0032736 hpo-mir-10029; +MI0032737 hpo-mir-5983; +MI0032738 hpo-mir-37; +MI0032739 hpo-mir-5906; +MI0032740 hpo-mir-7; +MI0032741 hpo-mir-43b; +MI0032742 hpo-mir-10030; +MI0032743 hpo-mir-40a; +MI0032744 hpo-mir-40b; +MI0032745 hpo-mir-10031b; +MI0032746 hpo-mir-10032; +MI0032747 hpo-mir-76; +MI0032748 hpo-mir-10033; +MI0032749 hpo-mir-10034-1; +MI0032750 hpo-mir-10034-2; +MI0032751 hpo-mir-10035; +MI0032752 hpo-mir-40c; +MI0032753 hpo-mir-10036-1; +MI0032754 hpo-mir-10036-2; +MI0032755 hpo-mir-10037; +MI0032756 hpo-mir-10038; +MI0032757 hpo-mir-40d; +MI0032758 hpo-mir-10039; +MI0032759 hpo-mir-10040; +MI0032760 hpo-mir-10041; +MI0032761 hpo-mir-10042; +MI0032762 hpo-mir-10043a; +MI0032763 hpo-mir-10044; +MI0032764 hpo-mir-10045; +MI0032765 hpo-mir-10046; +MI0032766 hpo-mir-10134-2; +MI0032767 hpo-mir-10047; +MI0032768 hpo-mir-10048; +MI0032769 hpo-mir-40e; +MI0032770 hpo-mir-10049; +MI0032771 hpo-mir-10050; +MI0032772 hpo-mir-10051; +MI0032773 hpo-mir-10031a-2; +MI0032774 hpo-mir-10052; +MI0032775 hpo-mir-10053; +MI0032776 hpo-mir-10063a; +MI0032777 hpo-mir-10054; +MI0032778 hpo-mir-5932; +MI0032779 hpo-mir-10055; +MI0032780 hpo-mir-5897; +MI0032781 hpo-mir-10056; +MI0032782 hpo-mir-10057; +MI0032783 hpo-mir-10065b-2; +MI0032784 hpo-mir-10072b; +MI0032785 hpo-mir-10058; +MI0032786 hpo-mir-10059; +MI0032787 hpo-mir-10043b; +MI0032788 hpo-mir-10060; +MI0032789 hpo-mir-10061; +MI0032790 hpo-mir-10031c; +MI0032791 hpo-mir-10062; +MI0032792 hpo-mir-40f; +MI0032793 hpo-mir-1822; +MI0032794 hpo-mir-10031a-1; +MI0032795 hpo-mir-10063b; +MI0032796 hpo-mir-10064; +MI0032797 hpo-mir-10065a; +MI0032798 hpo-mir-10065b-1; +MI0032799 hpo-mir-10066; +MI0032800 hpo-mir-10067; +MI0032801 hpo-mir-10068; +MI0032802 hpo-mir-10069; +MI0032803 hpo-mir-10031d; +MI0032804 hpo-mir-10043c; +MI0032805 hpo-mir-10070; +MI0032806 hpo-mir-10071; +MI0032807 hpo-mir-10072a; +MI0032808 hpo-mir-10073; +MI0032809 hpo-mir-10043d; +MI0032810 hpo-mir-10074; +MI0032811 hpo-mir-10075a; +MI0032812 hpo-mir-10098a; +MI0032813 hpo-mir-10076; +MI0032814 hpo-mir-10077; +MI0032815 hpo-mir-36b; +MI0032816 hpo-mir-10078; +MI0032817 hpo-mir-10079; +MI0032818 hpo-mir-10080; +MI0032819 hpo-mir-10081; +MI0032820 hpo-mir-10137a; +MI0032821 hpo-mir-10082; +MI0032822 hpo-mir-10075b; +MI0032823 hpo-mir-10083; +MI0032824 hpo-mir-10084; +MI0032825 hpo-mir-10085; +MI0032826 hpo-mir-10086; +MI0032827 hpo-mir-10087; +MI0032828 hpo-mir-10088; +MI0032829 hpo-mir-10089; +MI0032830 hpo-mir-10090; +MI0032831 hpo-mir-10091; +MI0032832 hpo-mir-5898; +MI0032833 hpo-mir-10092; +MI0032834 hpo-mir-255; +MI0032835 hpo-mir-40g; +MI0032836 hpo-mir-10156a; +MI0032837 hpo-mir-10093; +MI0032838 hpo-mir-10094; +MI0032839 hpo-mir-10095; +MI0032840 hpo-mir-40h; +MI0032841 hpo-mir-10096; +MI0032842 hpo-mir-10097; +MI0032843 hpo-mir-10098b; +MI0032844 hpo-mir-10099; +MI0032845 hpo-mir-10100; +MI0032846 hpo-mir-10101; +MI0032847 hpo-mir-10102; +MI0032848 hpo-mir-5902; +MI0032849 hpo-mir-10103; +MI0032850 hpo-mir-10043e; +MI0032851 hpo-mir-10104; +MI0032852 hpo-mir-5915; +MI0032853 hpo-mir-10105; +MI0032854 hpo-mir-10106; +MI0032855 hpo-mir-10107; +MI0032856 hpo-mir-10108; +MI0032857 hpo-mir-10109; +MI0032858 hpo-mir-10110; +MI0032859 hpo-mir-10111; +MI0032860 hpo-mir-10112; +MI0032861 hpo-mir-10113; +MI0032862 hpo-mir-10114; +MI0032863 hpo-mir-10115; +MI0032864 hpo-mir-10116; +MI0032865 hpo-mir-10117; +MI0032866 hpo-mir-10118; +MI0032867 hpo-mir-10119; +MI0032868 hpo-mir-10120; +MI0032869 hpo-mir-10121; +MI0032870 hpo-mir-10122; +MI0032871 hpo-mir-10123; +MI0032872 hpo-mir-10124; +MI0032873 hpo-mir-10125; +MI0032874 hpo-mir-10126; +MI0032875 hpo-mir-10127; +MI0032876 hpo-mir-10128; +MI0032877 hpo-mir-10129; +MI0032878 hpo-mir-10130; +MI0032879 hpo-mir-10131; +MI0032880 hpo-mir-10132; +MI0032881 hpo-mir-10133; +MI0032882 hpo-mir-10134-1; +MI0032883 hpo-mir-10135; +MI0032884 hpo-mir-10136; +MI0032885 hpo-mir-10137b; +MI0032886 hpo-mir-10138; +MI0032887 hpo-mir-10031e; +MI0032888 hpo-mir-10139; +MI0032889 hpo-mir-10140; +MI0032890 hpo-mir-10141; +MI0032891 hpo-mir-10142; +MI0032892 hpo-mir-10143; +MI0032893 hpo-mir-10144; +MI0032894 hpo-mir-10145; +MI0032895 hpo-mir-10146; +MI0032896 hpo-mir-10157; +MI0032897 hpo-mir-10147; +MI0032898 hpo-mir-10148; +MI0032899 hpo-mir-10149; +MI0032900 hpo-mir-10150; +MI0032901 hpo-mir-10151; +MI0032902 hpo-mir-10152; +MI0032903 hpo-mir-10153; +MI0032904 hpo-mir-10154; +MI0032905 hpo-mir-10043f; +MI0032906 hpo-mir-2709; +MI0032907 hpo-mir-10155; +MI0032908 hpo-mir-10156b; +MI0032909 hpo-mir-10158a; +MI0032910 hpo-mir-10158b; +MI0032911 hpo-mir-10159; +MI0032912 hpo-mir-10160; +MI0032913 bta-mir-10161; +MI0032914 bta-mir-10162; +MI0032915 bta-mir-10163; +MI0032916 bta-mir-10164; +MI0032917 bta-mir-10165; +MI0032918 bta-mir-10166; +MI0032919 bta-mir-10167; +MI0032920 bta-mir-507; +MI0032921 bta-mir-10168; +MI0032922 bta-mir-10169; +MI0032923 bta-mir-10170; +MI0032924 bta-mir-10171; +MI0032925 bta-mir-10172; +MI0032926 bta-mir-10173; +MI0032927 bta-mir-2285ag; +MI0032928 bta-mir-7857-2; +MI0032929 bta-mir-219b; +MI0032930 bta-mir-10174; +MI0032931 bta-mir-10175; +MI0032932 bta-mir-10176; +MI0032933 bta-mir-10177; +MI0032934 bta-mir-10178; +MI0032935 bta-mir-194b; +MI0032936 bta-mir-323b; +MI0032937 bta-mir-668; +MI0032938 bta-mir-10179; +MI0032939 bta-mir-10180; +MI0032940 bta-mir-10181; +MI0032941 bta-mir-10182; +MI0032942 bta-mir-10183; +MI0032943 bta-mir-10184; +MI0032944 bta-mir-10185; +MI0032945 bta-mir-2285ah; +MI0032946 bta-mir-2285ai; +MI0032947 bta-mir-2285aj; +MI0032948 bta-mir-2285ak; +MI0032949 bta-mir-2285al; +MI0032950 bta-mir-2285am; +MI0032951 gma-MIR10186a; +MI0032952 gma-MIR10187; +MI0032953 gma-MIR10188; +MI0032954 gma-MIR10189; +MI0032955 gma-MIR10190; +MI0032956 gma-MIR10191; +MI0032957 gma-MIR5030b; +MI0032958 gma-MIR10192; +MI0032959 gma-MIR5770c; +MI0032960 gma-MIR10193a; +MI0032961 gma-MIR10194; +MI0032962 gma-MIR10195; +MI0032963 gma-MIR10196; +MI0032964 gma-MIR10197; +MI0032965 gma-MIR10198; +MI0032966 gma-MIR10199; +MI0032967 gma-MIR10200; +MI0032968 gma-MIR1446; +MI0032969 gma-MIR10201; +MI0032970 gma-MIR4392b; +MI0032971 ttv-mir-T1; +MI0032972 sfv-mir-S1; +MI0032973 sfv-mir-S2; +MI0032974 sfv-mir-S3; +MI0032975 sfv-mir-S4; +MI0032976 sfv-mir-S5; +MI0032977 sfv-mir-S6; +MI0032978 sfv-mir-S7; +MI0032979 vca-MIR156a; +MI0032980 vca-MIR156b; +MI0032981 vca-MIR159; +MI0032982 vca-MIR160; +MI0032983 vca-MIR166a; +MI0032984 vca-MIR166b; +MI0032985 vca-MIR166c; +MI0032986 vca-MIR167a; +MI0032987 vca-MIR167b; +MI0032988 vca-MIR168a; +MI0032989 vca-MIR168b; +MI0032990 vca-MIR172a; +MI0032991 vca-MIR172b; +MI0032992 vca-MIR393; +MI0032993 vca-MIR396; +MI0032994 vca-MIR397; +MI0032995 vca-MIR408; +MI0032996 vca-MIR528; +MI0032997 vca-MIR535; +MI0032998 vca-MIR10202a; +MI0032999 vca-MIR10202b; +MI0033000 vca-MIR10203; +MI0033001 vca-MIR10204; +MI0033002 vca-MIR10205; +MI0033003 vca-MIR10206a; +MI0033004 vca-MIR10206b; +MI0033005 vca-MIR10207; +MI0033006 vca-MIR10208; +MI0033007 vca-MIR10209; +MI0033008 vca-MIR391; +MI0033009 vca-MIR10210; +MI0033010 vca-MIR396b; +MI0033011 vca-MIR1432; +MI0033013 eun-MIR159; +MI0033014 eun-MIR160; +MI0033015 eun-MIR162; +MI0033016 eun-MIR166; +MI0033017 eun-MIR167a; +MI0033018 eun-MIR167b; +MI0033019 eun-MIR167c; +MI0033020 eun-MIR167d; +MI0033021 eun-MIR172a; +MI0033022 eun-MIR172b; +MI0033023 eun-MIR172c; +MI0033024 eun-MIR395; +MI0033025 eun-MIR396a; +MI0033026 eun-MIR396b; +MI0033027 eun-MIR397a; +MI0033028 eun-MIR397b; +MI0033029 eun-MIR482a; +MI0033030 eun-MIR482b; +MI0033031 eun-MIR482c; +MI0033032 eun-MIR530; +MI0033033 eun-MIR535a; +MI0033034 eun-MIR535b; +MI0033035 eun-MIR827; +MI0033036 eun-MIR10211a; +MI0033037 eun-MIR10211b; +MI0033038 eun-MIR10212; +MI0033039 eun-MIR10213; +MI0033040 eun-MIR10214a; +MI0033041 eun-MIR10214b; +MI0033042 eun-MIR10215; +MI0033043 eun-MIR10216; +MI0033044 eun-MIR10217; +MI0033045 eun-MIR10218; +MI0033046 eun-MIR10219; +MI0033047 eun-MIR10220; +MI0033048 eun-MIR10221; +MI0033049 eun-MIR10222; +MI0033050 eun-MIR10223; +MI0033051 eun-MIR10224; +MI0033053 prv-mir-LLT12; +MI0033054 bta-mir-10225a; +MI0033055 bta-mir-10225b; +MI0033056 hsa-mir-10226; +MI0033057 cgr-mir-200a; +MI0033058 cgr-let-7a-2; +MI0033059 cgr-let-7c-2; +MI0033060 cgr-let-7e; +MI0033061 cgr-mir-148a; +MI0033062 cgr-mir-194-2; +MI0033063 cgr-mir-217; +MI0033064 cgr-mir-219b; +MI0033065 cgr-mir-26a-1; +MI0033066 cgr-mir-301b; +MI0033067 cgr-mir-3154; +MI0033069 cgr-mir-449a; +MI0033070 cgr-mir-451a; +MI0033071 cgr-mir-574; +MI0033072 cgr-mir-125b-2; +MI0033073 cgr-mir-29b-2; +MI0033074 cgr-mir-101a; +MI0033075 cgr-mir-1224; +MI0033076 cgr-mir-1249; +MI0033077 cgr-mir-126b; +MI0033078 cgr-mir-127; +MI0033079 cgr-mir-150; +MI0033080 cgr-mir-16-2; +MI0033081 cgr-mir-193a; +MI0033082 cgr-mir-199a-2; +MI0033083 cgr-mir-1b; +MI0033084 cgr-mir-202; +MI0033085 cgr-mir-211; +MI0033086 cgr-mir-216b; +MI0033087 cgr-mir-24-1; +MI0033088 cgr-mir-3068; +MI0033089 cgr-mir-3074-2; +MI0033090 cgr-mir-3074-1; +MI0033091 cgr-mir-30c-1; +MI0033092 cgr-mir-3102; +MI0033093 cgr-mir-3535; +MI0033094 cgr-mir-365-2; +MI0033095 cgr-mir-497b; +MI0033096 cgr-mir-760; +MI0033097 cgr-mir-99b; +MI0033098 cgr-mir-128-2; +MI0033099 cgr-mir-330; +MI0033100 cgr-mir-802; +MI0033101 cgr-mir-18b; +MI0033102 cgr-mir-20b; +MI0033103 egr-bantam; +MI0033104 egr-mir-61; +MI0033105 egr-mir-31; +MI0033106 egr-mir-10227a; +MI0033107 egr-mir-2162; +MI0033108 egr-mir-3479a; +MI0033109 egr-mir-10228; +MI0033110 egr-mir-281; +MI0033111 egr-mir-10229a; +MI0033112 egr-mir-36a; +MI0033113 egr-mir-10227b; +MI0033114 egr-mir-133; +MI0033115 egr-mir-1992; +MI0033116 egr-mir-10229b; +MI0033117 egr-mir-10227c; +MI0033118 egr-mir-10230; +MI0033119 egr-mir-10231; +MI0033120 egr-mir-10232; +MI0033121 egr-mir-10233; +MI0033122 egr-mir-10234; +MI0033123 egr-mir-10235; +MI0033124 egr-mir-10236; +MI0033125 egr-mir-10237; +MI0033126 egr-mir-10238; +MI0033127 egr-mir-10239; +MI0033128 egr-mir-10240; +MI0033129 egr-mir-10241; +MI0033130 egr-mir-10227d; +MI0033131 egr-mir-10242; +MI0033132 egr-mir-10243; +MI0033133 egr-mir-10244; +MI0033134 egr-mir-10245; +MI0033135 egr-mir-36b; +MI0033136 egr-mir-10247; +MI0033137 egr-mir-10248; +MI0033138 egr-mir-10249; +MI0033139 egr-mir-10227e; +MI0033140 egr-mir-10250; +MI0033141 egr-mir-10251; +MI0033142 egr-mir-10252; +MI0033143 egr-mir-2d; +MI0033144 egr-mir-10253; +MI0033145 egr-mir-10254; +MI0033146 egr-mir-10255; +MI0033147 egr-mir-10256; +MI0033148 egr-mir-10257; +MI0033149 egr-mir-10258; +MI0033150 egr-mir-10259; +MI0033151 egr-mir-10260; +MI0033152 egr-mir-10261; +MI0033153 egr-mir-10262; +MI0033154 egr-mir-10263; +MI0033155 egr-mir-10264; +MI0033156 egr-mir-10265; +MI0033157 egr-mir-10266; +MI0033158 egr-mir-10267; +MI0033159 egr-mir-10268; +MI0033160 egr-mir-10269; +MI0033161 egr-mir-10270; +MI0033162 egr-mir-10271; +MI0033163 egr-mir-10272; +MI0033164 egr-mir-10273; +MI0033165 egr-mir-10274; +MI0033166 egr-mir-10275; +MI0033167 egr-mir-10276; +MI0033168 egr-mir-10277; +MI0033169 egr-mir-10278; +MI0033170 egr-mir-10279; +MI0033171 egr-mir-10280; +MI0033172 egr-mir-10281; +MI0033173 egr-mir-10282; +MI0033174 egr-mir-10283; +MI0033175 egr-mir-10284; +MI0033176 egr-mir-10285; +MI0033177 egr-mir-10286; +MI0033178 egr-mir-10287; +MI0033179 egr-mir-10288; +MI0033180 egr-mir-10289; +MI0033181 egr-mir-10290; +MI0033182 egr-mir-10291; +MI0033183 egr-mir-10292; +MI0033184 egr-mir-307; +MI0033185 egr-mir-10293; +MI0033186 tcf-bantam; +MI0033187 tcf-let-7; +MI0033188 tcf-mir-1; +MI0033189 tcf-mir-2a-1; +MI0033190 tcf-mir-2a-2; +MI0033191 tcf-mir-2b; +MI0033192 tcf-mir-7; +MI0033193 tcf-mir-8; +MI0033194 tcf-mir-9a; +MI0033195 tcf-mir-9b; +MI0033196 tcf-mir-10; +MI0033197 tcf-mir-12; +MI0033198 tcf-mir-13; +MI0033199 tcf-mir-31; +MI0033200 tcf-mir-33; +MI0033201 tcf-mir-34; +MI0033202 tcf-mir-279f; +MI0033203 tcf-mir-71; +MI0033204 tcf-mir-87; +MI0033205 tcf-mir-92a; +MI0033206 tcf-mir-92b; +MI0033207 tcf-mir-96; +MI0033208 tcf-mir-100; +MI0033209 tcf-mir-124; +MI0033210 tcf-mir-125; +MI0033211 tcf-mir-133; +MI0033212 tcf-mir-137; +MI0033213 tcf-mir-153; +MI0033214 tcf-mir-184; +MI0033215 tcf-mir-190; +MI0033216 tcf-mir-193; +MI0033217 tcf-mir-210; +MI0033218 tcf-mir-219; +MI0033219 tcf-mir-252a; +MI0033220 tcf-mir-252b; +MI0033221 tcf-mir-263a; +MI0033222 tcf-mir-263b; +MI0033223 tcf-mir-275; +MI0033224 tcf-mir-276; +MI0033225 tcf-mir-277; +MI0033226 tcf-mir-278; +MI0033227 tcf-mir-279a; +MI0033228 tcf-mir-279b; +MI0033229 tcf-mir-279c; +MI0033230 tcf-mir-279d; +MI0033231 tcf-mir-279e; +MI0033232 tcf-mir-281; +MI0033233 tcf-mir-282; +MI0033234 tcf-mir-283; +MI0033235 tcf-mir-285; +MI0033236 tcf-mir-305; +MI0033237 tcf-mir-307; +MI0033238 tcf-mir-315; +MI0033239 tcf-mir-317; +MI0033240 tcf-mir-375; +MI0033241 tcf-mir-745; +MI0033242 tcf-mir-750; +MI0033243 tcf-mir-965; +MI0033244 tcf-mir-981; +MI0033245 tcf-mir-993; +MI0033246 tcf-mir-995; +MI0033247 tcf-mir-996; +MI0033248 tcf-mir-998; +MI0033249 tcf-mir-1175; +MI0033250 tcf-mir-2788; +MI0033251 tcf-mir-2944a; +MI0033252 tcf-mir-3477; +MI0033253 tcf-mir-3791; +MI0033254 tcf-mir-iab-4; +MI0033255 tcf-mir-iab-8; +MI0033256 tcf-mir-10294; +MI0033257 tcf-mir-10295; +MI0033258 tcf-mir-10296; +MI0033259 tcf-mir-10297; +MI0033260 tcf-mir-10298a; +MI0033261 tcf-mir-10299; +MI0033262 tcf-mir-10300; +MI0033263 tcf-mir-2944b; +MI0033264 tcf-mir-10301; +MI0033265 tcf-mir-10302; +MI0033266 tcf-mir-10303a; +MI0033267 tcf-mir-316; +MI0033268 tcf-mir-10304; +MI0033269 tcf-mir-10305; +MI0033270 tcf-mir-79; +MI0033271 tcf-mir-309; +MI0033272 tcf-mir-318; +MI0033273 tcf-mir-10306; +MI0033274 tcf-mir-10307; +MI0033275 tcf-mir-10402; +MI0033276 tcf-mir-10403; +MI0033277 tcf-mir-10308; +MI0033278 tcf-mir-10309; +MI0033279 tcf-mir-10310-1; +MI0033280 tcf-mir-10310-2; +MI0033281 tcf-mir-10311; +MI0033282 tcf-mir-10312; +MI0033283 tcf-mir-10313; +MI0033284 tcf-mir-10314; +MI0033285 tcf-mir-10303b; +MI0033286 tcf-mir-10315a; +MI0033287 tcf-mir-10316a; +MI0033288 tcf-mir-10315b; +MI0033289 tcf-mir-10317; +MI0033290 tcf-mir-10318; +MI0033291 tcf-mir-10319; +MI0033292 tcf-mir-10320; +MI0033293 tcf-mir-10321; +MI0033294 tcf-mir-10322; +MI0033295 tcf-mir-10323; +MI0033296 tcf-mir-10324; +MI0033297 tcf-mir-10325; +MI0033298 tcf-mir-10326; +MI0033299 tcf-mir-10327; +MI0033300 tcf-mir-10328; +MI0033301 tcf-mir-10329; +MI0033302 tcf-mir-10330; +MI0033303 tcf-mir-10331; +MI0033304 tcf-mir-10332; +MI0033305 tcf-mir-10333; +MI0033306 tcf-mir-10334; +MI0033307 tcf-mir-10335; +MI0033308 tcf-mir-10336; +MI0033309 tcf-mir-10337; +MI0033310 tcf-mir-10338; +MI0033311 tcf-mir-10339; +MI0033312 tcf-mir-10340; +MI0033313 tcf-mir-10316b; +MI0033314 tcf-mir-10341-1; +MI0033315 tcf-mir-10341-2; +MI0033316 tcf-mir-10342; +MI0033317 tcf-mir-10343; +MI0033318 tcf-mir-10344; +MI0033319 tcf-mir-10345; +MI0033320 tcf-mir-10346-1; +MI0033321 tcf-mir-10346-2; +MI0033322 tcf-mir-10316c; +MI0033323 tcf-mir-10347-1; +MI0033324 tcf-mir-10347-2; +MI0033325 tcf-mir-10348; +MI0033326 tcf-mir-10349; +MI0033327 tcf-mir-10350; +MI0033328 tcf-mir-10351; +MI0033329 tcf-mir-10352; +MI0033330 tcf-mir-10298b; +MI0033331 tcf-mir-10353; +MI0033332 tcf-mir-10354; +MI0033333 tcf-mir-87b; +MI0033334 aga-mir-998; +MI0033335 aga-mir-10355; +MI0033336 aga-mir-2944a-1; +MI0033337 aga-mir-2944a-2; +MI0033338 aga-mir-10361b; +MI0033339 aga-mir-2944b; +MI0033340 aga-mir-10356-1; +MI0033341 aga-mir-10356-2; +MI0033342 aga-mir-10357; +MI0033343 aga-mir-10358-1; +MI0033344 aga-mir-10358-2; +MI0033345 aga-mir-10358-3; +MI0033346 aga-mir-10358-4; +MI0033347 aga-mir-10358-5; +MI0033348 aga-mir-2945; +MI0033349 aga-mir-10359; +MI0033350 aga-mir-285; +MI0033351 aga-mir-10360; +MI0033352 aga-mir-33; +MI0033353 aga-mir-10361a-1; +MI0033354 aga-mir-10361a-2; +MI0033355 aga-mir-10361a-3; +MI0033356 aga-mir-10362; +MI0033357 aga-mir-10363; +MI0033358 aga-mir-10364; +MI0033359 aga-mir-2796; +MI0033360 aga-mir-10365; +MI0033361 aga-mir-980; +MI0033362 aga-mir-10366a-1; +MI0033363 aga-mir-10367; +MI0033364 aga-mir-10366b; +MI0033365 aga-mir-932; +MI0033366 aga-mir-10366a-2; +MI0033367 aga-mir-10368; +MI0033368 aga-mir-10369; +MI0033369 aga-mir-10370-1; +MI0033370 aga-mir-10370-2; +MI0033371 aga-mir-10371; +MI0033372 aga-mir-10372a; +MI0033373 aga-mir-10373; +MI0033374 aga-mir-10372b; +MI0033375 aga-mir-10374; +MI0033376 aga-mir-2b; +MI0033377 aga-mir-286b; +MI0033378 aga-mir-31; +MI0033379 aga-mir-10375a; +MI0033380 aga-mir-10375b-1; +MI0033381 aga-mir-10375b-2; +MI0033382 aga-mir-10375b-3; +MI0033383 aga-mir-10376; +MI0033384 aga-mir-10377a; +MI0033385 aga-mir-2c; +MI0033386 aga-mir-10377b; +MI0033387 aga-mir-10378; +MI0033388 aga-mir-10379; +MI0033389 aga-mir-10380; +MI0033390 aga-mir-10381; +MI0033391 ssc-mir-10382; +MI0033392 ssc-mir-1388; +MI0033393 ssc-mir-10383; +MI0033394 ssc-mir-10384-1; +MI0033395 ssc-mir-10384-2; +MI0033396 ssc-mir-1842; +MI0033397 ssc-mir-26b; +MI0033398 ssc-mir-670; +MI0033399 ssc-mir-10386; +MI0033400 ssc-mir-10387; +MI0033401 ssc-mir-10388; +MI0033402 ssc-mir-330; +MI0033403 ssc-mir-10389; +MI0033404 ssc-mir-10390; +MI0033405 ssc-mir-10391; +MI0033406 ssc-mir-141; +MI0033407 ssc-mir-200b; +MI0033408 ssc-mir-223; +MI0033409 ssc-mir-375; +MI0033410 ssc-mir-454; +MI0033411 ssc-mir-6516; +MI0033412 ssc-mir-6529; +MI0033413 ssc-mir-660; +MI0033414 ssc-mir-802; +MI0033415 ssc-mir-4331-2; +MI0033416 hsa-mir-10392; +MI0033417 hsa-mir-10393; +MI0033418 hsa-mir-10394; +MI0033419 hsa-mir-10395; +MI0033420 hsa-mir-10396a; +MI0033421 hsa-mir-10397; +MI0033422 hsa-mir-10398; +MI0033423 hsa-mir-10399; +MI0033424 hsa-mir-10400; +MI0033425 hsa-mir-10401; +MI0033426 hsa-mir-10396b; +MI0033427 dme-mir-10404; +MI0033431 gma-MIR10405a; +MI0033432 gma-MIR4348d; +MI0033433 gma-MIR10406a; +MI0033434 gma-MIR10186b; +MI0033435 gma-MIR10407a; +MI0033436 gma-MIR10408; +MI0033437 gma-MIR10186c; +MI0033438 gma-MIR10409; +MI0033439 gma-MIR10410a; +MI0033440 gma-MIR10411; +MI0033441 gma-MIR10412; +MI0033442 gma-MIR10407c; +MI0033443 gma-MIR10413a; +MI0033444 gma-MIR10414; +MI0033445 gma-MIR10186d; +MI0033446 gma-MIR167l; +MI0033447 gma-MIR10407d; +MI0033448 gma-MIR10415; +MI0033449 gma-MIR10405e; +MI0033450 gma-MIR10416; +MI0033451 gma-MIR10413b; +MI0033452 gma-MIR10417; +MI0033453 gma-MIR10418; +MI0033454 gma-MIR4405b; +MI0033455 gma-MIR10193e; +MI0033456 gma-MIR399j; +MI0033457 gma-MIR10419; +MI0033458 gma-MIR10420; +MI0033459 gma-MIR10421; +MI0033460 gma-MIR10186e; +MI0033461 gma-MIR10422; +MI0033462 gma-MIR10423; +MI0033463 gma-MIR10424a; +MI0033464 gma-MIR399k; +MI0033465 gma-MIR10405b; +MI0033466 gma-MIR10405c; +MI0033467 gma-MIR10425; +MI0033468 gma-MIR169w; +MI0033469 gma-MIR10186f; +MI0033470 gma-MIR399l; +MI0033471 gma-MIR10410b; +MI0033472 gma-MIR4374c; +MI0033473 gma-MIR399m; +MI0033474 gma-MIR10426; +MI0033475 gma-MIR10193b; +MI0033476 gma-MIR10427a; +MI0033477 gma-MIR10406b; +MI0033478 gma-MIR10186g; +MI0033479 gma-MIR9724b; +MI0033480 gma-MIR4414b; +MI0033481 gma-MIR10424b; +MI0033482 gma-MIR10428; +MI0033483 gma-MIR4997b; +MI0033484 gma-MIR10429; +MI0033485 gma-MIR5377b; +MI0033486 gma-MIR10427b; +MI0033487 gma-MIR10430; +MI0033488 gma-MIR10186h; +MI0033489 gma-MIR10431; +MI0033490 gma-MIR10432; +MI0033491 gma-MIR10186i; +MI0033492 gma-MIR10433; +MI0033493 gma-MIR5764b; +MI0033494 gma-MIR10434; +MI0033495 gma-MIR10435; +MI0033496 gma-MIR10405d; +MI0033497 gma-MIR10410c; +MI0033498 gma-MIR10407b; +MI0033499 gma-MIR10436; +MI0033500 gma-MIR399n; +MI0033501 gma-MIR10437; +MI0033502 gma-MIR10438; +MI0033503 gma-MIR10439; +MI0033504 gma-MIR10424c; +MI0033505 gma-MIR10440; +MI0033506 gma-MIR10441; +MI0033507 gma-MIR10442; +MI0033508 gma-MIR10193c; +MI0033509 gma-MIR10193d; +MI0033510 gma-MIR10186j; +MI0033511 gma-MIR10186k; +MI0033512 gma-MIR10186l; +MI0033513 gma-MIR10443; +MI0033514 gma-MIR10424d; +MI0033515 gma-MIR10444; +MI0033516 gma-MIR10445; +MI0033517 gma-MIR10193f; +MI0033518 gma-MIR10446; +MI0033519 gma-MIR10447; +MI0033520 gma-MIR399o; +MI0033521 gma-MIR10448; +MI0033522 egr-mir-3479b; +MI0033523 egr-mir-10450; +MI0033524 egr-mir-277b; +MI0033525 emu-bantam; +MI0033526 emu-mir-31; +MI0033527 emu-mir-36a; +MI0033528 emu-mir-36b; +MI0033529 emu-mir-61; +MI0033530 emu-mir-133; +MI0033531 emu-mir-281; +MI0033532 emu-mir-307; +MI0033533 emu-mir-1992; +MI0033534 emu-mir-2162; +MI0033535 emu-mir-3479a; +MI0033536 emu-mir-3479b; +MI0033537 emu-mir-10293; +MI0033538 emu-mir-277b; +MI0033539 sfr-mir-2c; +MI0033540 sfr-mir-210; +MI0033541 sfr-mir-10451; +MI0033542 sfr-mir-10452; +MI0033543 sfr-mir-10453; +MI0033544 sfr-mir-10454a-1; +MI0033545 sfr-mir-10454a-2; +MI0033546 sfr-mir-10455; +MI0033547 sfr-mir-10456; +MI0033548 sfr-mir-10457; +MI0033549 sfr-mir-10458; +MI0033550 sfr-mir-10459; +MI0033551 sfr-mir-10460; +MI0033552 sfr-mir-10461a; +MI0033553 sfr-mir-10454b; +MI0033554 sfr-mir-10454c; +MI0033555 sfr-mir-10462-1; +MI0033556 sfr-mir-10462-2; +MI0033557 sfr-mir-10463; +MI0033558 sfr-mir-10464; +MI0033559 sfr-mir-10465-1; +MI0033560 sfr-mir-10466; +MI0033561 sfr-mir-10467; +MI0033562 sfr-mir-10468; +MI0033563 sfr-mir-10454d; +MI0033564 sfr-mir-10454e; +MI0033565 sfr-mir-10454f; +MI0033566 sfr-mir-10469; +MI0033567 sfr-mir-3286; +MI0033568 sfr-mir-277-1; +MI0033569 sfr-mir-279c; +MI0033570 sfr-mir-10470; +MI0033571 sfr-mir-10471; +MI0033572 sfr-mir-10472; +MI0033573 sfr-mir-10473; +MI0033574 sfr-mir-10454g; +MI0033575 sfr-mir-10474; +MI0033576 sfr-mir-10475; +MI0033577 sfr-mir-10476; +MI0033578 sfr-mir-10477; +MI0033579 sfr-mir-10465-2; +MI0033580 sfr-mir-10492c; +MI0033581 sfr-mir-10478; +MI0033582 sfr-mir-10454h; +MI0033583 sfr-mir-10461b; +MI0033584 sfr-mir-10508b; +MI0033585 sfr-mir-10479; +MI0033586 sfr-mir-10480; +MI0033587 sfr-mir-10481; +MI0033588 sfr-mir-10482; +MI0033589 sfr-mir-10483-1; +MI0033590 sfr-mir-10483-2; +MI0033591 sfr-mir-279a; +MI0033592 sfr-mir-92a; +MI0033593 sfr-mir-307; +MI0033594 sfr-mir-10484; +MI0033595 sfr-mir-277-2; +MI0033596 sfr-mir-2a; +MI0033597 sfr-mir-10485; +MI0033598 sfr-mir-10486; +MI0033599 sfr-mir-2b; +MI0033600 sfr-mir-34; +MI0033601 sfr-mir-11; +MI0033602 sfr-mir-375; +MI0033603 sfr-mir-317; +MI0033604 sfr-mir-10487; +MI0033605 sfr-mir-10488; +MI0033606 sfr-mir-316; +MI0033607 sfr-mir-13b; +MI0033608 sfr-mir-6094; +MI0033609 sfr-mir-10489; +MI0033610 sfr-mir-281; +MI0033611 sfr-mir-10490; +MI0033612 sfr-mir-2765; +MI0033613 sfr-mir-10491; +MI0033614 sfr-mir-13a; +MI0033615 sfr-mir-2756; +MI0033616 sfr-mir-10492a; +MI0033617 sfr-mir-932; +MI0033618 sfr-mir-10493; +MI0033619 sfr-mir-2766; +MI0033620 sfr-mir-10494; +MI0033621 sfr-mir-10495-1; +MI0033622 sfr-mir-10495-2; +MI0033623 sfr-mir-10495-3; +MI0033624 sfr-mir-7; +MI0033625 sfr-mir-10496; +MI0033626 sfr-mir-10497; +MI0033627 sfr-mir-10498; +MI0033628 sfr-mir-10499a-1; +MI0033629 sfr-mir-10; +MI0033630 sfr-mir-10499a-2; +MI0033631 sfr-mir-10499a-3; +MI0033632 sfr-mir-10499a-4; +MI0033633 sfr-mir-10499a-5; +MI0033634 sfr-mir-10500; +MI0033635 sfr-mir-10501; +MI0033636 sfr-mir-274; +MI0033637 sfr-mir-10502; +MI0033638 sfr-mir-10503; +MI0033639 sfr-mir-10504; +MI0033640 sfr-mir-14; +MI0033641 sfr-mir-10505-1; +MI0033642 sfr-mir-10505-2; +MI0033643 sfr-mir-10506; +MI0033644 sfr-mir-10507-1; +MI0033645 sfr-mir-10507-2; +MI0033646 sfr-mir-2755; +MI0033647 sfr-mir-10508a-1; +MI0033648 sfr-mir-10508a-2; +MI0033649 sfr-mir-10509; +MI0033650 sfr-mir-10492b; +MI0033651 sfr-mir-285; +MI0033652 sfr-mir-279b; +MI0033653 sfr-mir-10510; +MI0033654 sfr-mir-10499b-1; +MI0033655 sfr-mir-10499b-2; +MI0033656 sfr-mir-10511; +MI0033657 sfr-mir-10512; +MI0033658 sfr-mir-10513; +MI0033659 sfr-mir-10514; +MI0033660 sfr-mir-263b; +MI0033661 ath-MIR10515; +MI0033662 tae-MIR10516; +MI0033663 tae-MIR10517; +MI0033664 tae-MIR10518; +MI0033665 tae-MIR10519; +MI0033666 tae-MIR10520; +MI0033667 tae-MIR10521; +MI0033668 hsa-mir-10522; +MI0033669 hsa-mir-10523; +MI0033670 hsa-mir-9983; +MI0033671 hsa-mir-10524; +MI0033672 hsa-mir-10525; +MI0033673 hsa-mir-10526; +MI0033674 hsa-mir-10527; +MI0033675 ptvpv2a-mir-P1; +MI0033676 gggpv1-mir-P1; +MI0033677 racpv-mir-P1; +MI0033678 sly-MIR172c; +MI0033679 sly-MIR408; +MI0033680 sly-MIR10528; +MI0033681 sly-MIR319d; +MI0033682 sly-MIR172d; +MI0033683 sly-MIR10529; +MI0033684 sly-MIR827; +MI0033685 sly-MIR530; +MI0033686 sly-MIR393; +MI0033687 sly-MIR10530; +MI0033688 sly-MIR398a; +MI0033689 sly-MIR7981e; +MI0033690 sly-MIR399b; +MI0033691 sly-MIR10531; +MI0033692 sly-MIR10532; +MI0033693 sly-MIR10533; +MI0033694 sly-MIR10534; +MI0033695 sly-MIR7981c; +MI0033696 sly-MIR10535a; +MI0033697 sly-MIR6025; +MI0033698 sly-MIR10536; +MI0033699 sly-MIR10537; +MI0033700 sly-MIR7981f; +MI0033701 sly-MIR10535b; +MI0033702 sly-MIR169f; +MI0033703 sly-MIR7981a; +MI0033704 sly-MIR7981b; +MI0033705 sly-MIR7981d; +MI0033706 sly-MIR10538; +MI0033707 sly-MIR10539; +MI0033708 sly-MIR10540; +MI0033709 sly-MIR10541; +MI0033710 sly-MIR159b; +MI0033711 sly-MIR10542; +MI0033712 sly-MIR171f; +MI0033713 abu-mir-10a-2; +MI0033714 abu-mir-183-2; +MI0033715 abu-mir-183-1; +MI0033716 abu-mir-100-1; +MI0033717 abu-mir-100-2; +MI0033718 abu-mir-192; +MI0033719 abu-mir-10b; +MI0033720 abu-mir-182; +MI0033721 abu-mir-9-1; +MI0033722 abu-mir-204-1; +MI0033723 abu-mir-143; +MI0033724 abu-mir-204-2; +MI0033725 abu-mir-204-3; +MI0033726 abu-mir-9-2; +MI0033727 abu-mir-21-2; +MI0033728 abu-mir-21-1; +MI0033729 abu-mir-9-3; +MI0033730 abu-mir-9-4; +MI0033731 abu-mir-9-5; +MI0033732 abu-mir-9-6; +MI0033733 abu-mir-199-2; +MI0033734 abu-mir-199-1; +MI0033735 abu-mir-199-3; +MI0033736 abu-mir-26a-4; +MI0033737 abu-mir-26a-1; +MI0033738 abu-mir-26a-2; +MI0033739 abu-mir-26a-3; +MI0033740 abu-mir-199-4; +MI0033741 abu-mir-92a-1; +MI0033742 abu-mir-92a-2; +MI0033743 abu-mir-184a; +MI0033744 abu-mir-133a-1; +MI0033745 abu-mir-133a-2; +MI0033746 abu-let-7a-2; +MI0033747 abu-let-7a-3; +MI0033748 abu-let-7a-4; +MI0033749 abu-let-7a-5; +MI0033750 abu-let-7a-1; +MI0033751 abu-mir-30a-1; +MI0033752 abu-mir-30a-2; +MI0033753 abu-mir-27b; +MI0033754 abu-mir-203-1; +MI0033755 abu-mir-203-2; +MI0033756 abu-mir-140; +MI0033757 abu-mir-205-1; +MI0033758 abu-mir-22a; +MI0033759 abu-mir-462; +MI0033760 abu-mir-126; +MI0033761 abu-mir-25; +MI0033762 abu-mir-184b; +MI0033763 abu-mir-2188; +MI0033764 abu-let-7d-1; +MI0033765 abu-let-7d-2; +MI0033766 abu-mir-30b; +MI0033767 abu-mir-99b; +MI0033768 abu-mir-221-1; +MI0033769 abu-mir-148a; +MI0033770 abu-mir-30c; +MI0033771 abu-mir-135a; +MI0033772 abu-mir-222-1; +MI0033773 abu-let-7g-1; +MI0033774 abu-mir-153a-2; +MI0033775 abu-mir-153a-1; +MI0033776 abu-let-7g-2; +MI0033777 abu-mir-222-2; +MI0033778 abu-let-7e; +MI0033779 abu-mir-221-2; +MI0033780 abu-mir-190b; +MI0033781 abu-mir-30d; +MI0033782 abu-mir-22b; +MI0033783 abu-mir-1388; +MI0033784 abu-let-7i; +MI0033785 abu-mir-103-2; +MI0033786 abu-mir-144; +MI0033787 abu-mir-26b; +MI0033788 abu-mir-125b-2; +MI0033789 abu-mir-133b; +MI0033790 abu-mir-214-1; +MI0033791 abu-mir-206; +MI0033792 abu-mir-214-2; +MI0033793 abu-mir-125a-1; +MI0033794 abu-mir-125a-2; +MI0033795 abu-mir-455-1; +MI0033796 abu-mir-200b; +MI0033797 abu-mir-724-1; +MI0033798 abu-mir-724-2; +MI0033799 abu-mir-27e-1; +MI0033800 abu-mir-125b-3; +MI0033801 abu-mir-125b-1; +MI0033802 abu-mir-19b-1; +MI0033803 abu-mir-218a-2; +MI0033804 abu-mir-16b; +MI0033805 abu-mir-142-1; +MI0033806 abu-mir-142-2; +MI0033807 abu-mir-96-1; +MI0033808 abu-mir-96-2; +MI0033809 abu-mir-92b; +MI0033810 abu-mir-194a; +MI0033811 abu-mir-200a; +MI0033812 abu-mir-27a; +MI0033813 abu-mir-456; +MI0033814 abu-mir-301b-1; +MI0033815 abu-mir-101a; +MI0033816 abu-mir-17-1; +MI0033817 abu-mir-17-2; +MI0033818 abu-let-7c; +MI0033819 abu-mir-1-1; +MI0033820 abu-mir-338-3; +MI0033821 abu-mir-338-1; +MI0033822 abu-mir-338-2; +MI0033823 abu-mir-122; +MI0033824 abu-mir-128-1; +MI0033825 abu-mir-1-2; +MI0033826 abu-mir-128-2; +MI0033827 abu-mir-19d; +MI0033828 abu-mir-129-1; +MI0033829 abu-mir-129-2; +MI0033830 abu-mir-216b; +MI0033831 abu-mir-129-3; +MI0033832 abu-mir-23a-2; +MI0033833 abu-mir-130-1; +MI0033834 abu-mir-130-2; +MI0033835 abu-mir-460; +MI0033836 abu-mir-375-1; +MI0033837 abu-mir-107; +MI0033838 abu-let-7h; +MI0033839 abu-mir-20a; +MI0033840 abu-mir-19a-1; +MI0033841 abu-mir-27d; +MI0033842 abu-mir-135b-1; +MI0033843 abu-mir-135b-2; +MI0033844 abu-mir-138-1; +MI0033845 abu-mir-138-2; +MI0033846 abu-mir-138-3; +MI0033847 abu-mir-23b; +MI0033848 abu-mir-15a; +MI0033849 abu-mir-499; +MI0033850 abu-mir-18a; +MI0033851 abu-let-7b-1; +MI0033852 abu-mir-7-1; +MI0033853 abu-mir-7-2; +MI0033854 abu-mir-24a-3; +MI0033855 abu-mir-93; +MI0033856 abu-mir-132-1; +MI0033857 abu-mir-7-3; +MI0033858 abu-mir-106; +MI0033859 abu-mir-190a-1; +MI0033860 abu-mir-190a-2; +MI0033861 abu-mir-196a-1; +MI0033862 abu-mir-34; +MI0033863 abu-mir-139; +MI0033864 abu-mir-489; +MI0033865 abu-mir-22c; +MI0033866 abu-mir-24a-4; +MI0033867 abu-mir-101b; +MI0033868 abu-mir-219-1; +MI0033869 abu-mir-20b; +MI0033870 abu-mir-365; +MI0033871 abu-mir-155; +MI0033872 abu-mir-135c; +MI0033873 abu-mir-187-1; +MI0033874 abu-mir-219-2; +MI0033875 abu-mir-730; +MI0033876 abu-mir-193; +MI0033877 abu-mir-153b; +MI0033878 abu-mir-33-2; +MI0033879 abu-mir-2187a; +MI0033880 abu-mir-219-3; +MI0033881 abu-mir-29a-3; +MI0033882 abu-mir-729; +MI0033883 abu-mir-736; +MI0033884 abu-mir-29b-1; +MI0033885 abu-mir-24a-1; +MI0033886 abu-mir-29b-2; +MI0033887 abu-mir-23a-1; +MI0033888 abu-mir-301b-2; +MI0033889 abu-mir-218a-1; +MI0033890 abu-mir-23a-3; +MI0033891 abu-mir-196a-2; +MI0033892 abu-mir-9-7; +MI0033893 abu-mir-16a; +MI0033894 abu-mir-124-1; +MI0033895 abu-mir-10a-1; +MI0033896 abu-mir-124-2; +MI0033897 abu-mir-218b; +MI0033898 abu-mir-7-4; +MI0033899 abu-mir-205-2; +MI0033900 abu-mir-103-1; +MI0033901 abu-mir-19b-2; +MI0033902 abu-mir-219-4; +MI0033903 abu-mir-429b; +MI0033904 abu-mir-727a; +MI0033905 abu-mir-727b; +MI0033906 abu-mir-29a-2; +MI0033907 abu-mir-24a-2; +MI0033908 abu-mir-19a-2; +MI0033909 abu-mir-124-3; +MI0033910 abu-mir-124-4; +MI0033911 abu-mir-27e-2; +MI0033912 abu-mir-124-5; +MI0033913 abu-mir-10c; +MI0033914 abu-mir-29a-1; +MI0033915 abu-mir-458; +MI0033916 abu-mir-731; +MI0033917 abu-mir-132-2; +MI0033918 abu-mir-15b; +MI0033919 abu-mir-24b; +MI0033920 abu-mir-301a; +MI0033921 abu-mir-23c; +MI0033922 abu-mir-734; +MI0033923 abu-mir-194b; +MI0033924 abu-mir-726; +MI0033925 abu-mir-722-1; +MI0033926 abu-mir-722-2; +MI0033927 abu-let-7f; +MI0033928 abu-mir-137-1; +MI0033929 abu-mir-137-2; +MI0033930 abu-mir-216a; +MI0033931 abu-mir-135d; +MI0033932 abu-mir-196b; +MI0033933 abu-mir-457; +MI0033934 abu-mir-153c; +MI0033935 abu-mir-19c; +MI0033936 abu-mir-31; +MI0033937 abu-mir-15c; +MI0033938 abu-mir-2187b; +MI0033939 abu-mir-723a; +MI0033940 abu-mir-551; +MI0033941 abu-mir-147; +MI0033942 abu-mir-1788; +MI0033943 abu-mir-728a; +MI0033944 abu-mir-18b; +MI0033945 abu-mir-10d; +MI0033946 abu-mir-723b; +MI0033947 abu-mir-181a; +MI0033948 abu-mir-181b; +MI0033949 abu-mir-430-1; +MI0033950 abu-mir-212-1; +MI0033951 abu-mir-212-2; +MI0033952 abu-mir-99a; +MI0033953 abu-mir-33-1; +MI0033954 abu-mir-7132a; +MI0033955 abu-mir-7133-2; +MI0033956 abu-mir-7133-3; +MI0033957 abu-mir-7132b; +MI0033958 abu-mir-29c; +MI0033959 abu-mir-725; +MI0033960 abu-mir-449b; +MI0033961 abu-mir-449a; +MI0033962 abu-mir-10543; +MI0033963 abu-mir-8160b; +MI0033964 abu-mir-10544; +MI0033965 abu-mir-3120; +MI0033966 abu-mir-10545; +MI0033967 abu-mir-8160a; +MI0033968 abu-mir-430-2; +MI0033969 abu-mir-10546-1; +MI0033970 abu-mir-10546-2; +MI0033971 abu-mir-10547; +MI0033972 abu-mir-7147; +MI0033973 abu-mir-10548; +MI0033974 abu-mir-148b; +MI0033975 abu-mir-10549; +MI0033976 abu-mir-10550; +MI0033977 abu-mir-10551; +MI0033978 abu-mir-10552; +MI0033979 abu-mir-10553; +MI0033980 abu-mir-454b; +MI0033981 abu-mir-150; +MI0033982 abu-mir-29d; +MI0033983 abu-mir-146; +MI0033984 abu-mir-451; +MI0033985 abu-mir-124-6; +MI0033986 abu-mir-145; +MI0033987 abu-mir-181c; +MI0033988 abu-mir-152; +MI0033989 abu-mir-27c; +MI0033990 abu-mir-210; +MI0033991 abu-mir-728b; +MI0033992 abu-mir-24c; +MI0033993 abu-mir-737; +MI0033994 abu-mir-202; +MI0033995 abu-mir-10554-1; +MI0033996 abu-mir-10554-2; +MI0033997 abu-mir-10555; +MI0033998 abu-mir-16c; +MI0033999 abu-mir-10556a; +MI0034000 abu-mir-10557; +MI0034001 abu-mir-10558; +MI0034002 abu-mir-10559; +MI0034003 abu-mir-10560; +MI0034004 abu-mir-10561; +MI0034005 abu-mir-10562; +MI0034006 abu-mir-10563; +MI0034007 abu-mir-10564; +MI0034008 abu-mir-10556b; +MI0034009 abu-mir-7552; +MI0034010 abu-mir-10565; +MI0034011 mze-mir-10a; +MI0034012 mze-mir-10b; +MI0034013 mze-mir-192; +MI0034014 mze-mir-183-2; +MI0034015 mze-mir-183-1; +MI0034016 mze-mir-182; +MI0034017 mze-mir-10c; +MI0034018 mze-mir-21-1; +MI0034019 mze-mir-21-2; +MI0034020 mze-mir-92a-1; +MI0034021 mze-mir-92a-2; +MI0034022 mze-mir-9-1; +MI0034023 mze-mir-9-2; +MI0034024 mze-mir-184a; +MI0034025 mze-mir-146; +MI0034026 mze-mir-9-3; +MI0034027 mze-mir-9-4; +MI0034028 mze-mir-9-5; +MI0034029 mze-mir-9-6; +MI0034030 mze-mir-199-2; +MI0034031 mze-mir-199-1; +MI0034032 mze-mir-199-3; +MI0034033 mze-mir-100-2; +MI0034034 mze-mir-26a-4; +MI0034035 mze-mir-26a-1; +MI0034036 mze-mir-26a-2; +MI0034037 mze-mir-26a-3; +MI0034038 mze-mir-199-4; +MI0034039 mze-mir-100-1; +MI0034040 mze-mir-204-1; +MI0034041 mze-mir-204-2; +MI0034042 mze-let-7a-2; +MI0034043 mze-let-7a-3; +MI0034044 mze-let-7a-6; +MI0034045 mze-let-7a-4; +MI0034046 mze-mir-27b; +MI0034047 mze-let-7a-1; +MI0034048 mze-let-7a-5; +MI0034049 mze-mir-462; +MI0034050 mze-mir-140; +MI0034051 mze-mir-30a-1; +MI0034052 mze-mir-30a-2; +MI0034053 mze-mir-205-1; +MI0034054 mze-mir-203-1; +MI0034055 mze-mir-203-2; +MI0034056 mze-mir-133a-2; +MI0034057 mze-mir-133a-1; +MI0034058 mze-mir-22a; +MI0034059 mze-mir-25; +MI0034060 mze-let-7d-2; +MI0034061 mze-let-7d-1; +MI0034062 mze-mir-184b; +MI0034063 mze-mir-126; +MI0034064 mze-mir-2188; +MI0034065 mze-mir-92b; +MI0034066 mze-mir-30c; +MI0034067 mze-mir-222-1; +MI0034068 mze-mir-222-2; +MI0034069 mze-let-7g-1; +MI0034070 mze-let-7g-2; +MI0034071 mze-mir-16a; +MI0034072 mze-mir-125a-1; +MI0034073 mze-mir-125a-2; +MI0034074 mze-mir-103; +MI0034075 mze-let-7i-1; +MI0034076 mze-let-7i-2; +MI0034077 mze-mir-455-1; +MI0034078 mze-mir-30b; +MI0034079 mze-mir-153a-1; +MI0034080 mze-mir-153a-2; +MI0034081 mze-mir-221-1; +MI0034082 mze-mir-218a-2; +MI0034083 mze-mir-26b; +MI0034084 mze-let-7e-1; +MI0034085 mze-mir-221-2; +MI0034086 mze-let-7e-2; +MI0034087 mze-mir-214-1; +MI0034088 mze-mir-216b; +MI0034089 mze-mir-135a; +MI0034090 mze-mir-214-2; +MI0034091 mze-mir-125b-2; +MI0034092 mze-mir-301b-1; +MI0034093 mze-mir-1388; +MI0034094 mze-mir-125b-1; +MI0034095 mze-mir-27d; +MI0034096 mze-mir-99b; +MI0034097 mze-mir-133b; +MI0034098 mze-mir-128-1; +MI0034099 mze-mir-724-1; +MI0034100 mze-mir-724-2; +MI0034101 mze-mir-206; +MI0034102 mze-mir-130-2; +MI0034103 mze-mir-130-1; +MI0034104 mze-mir-194a; +MI0034105 mze-mir-128-2; +MI0034106 mze-mir-200b; +MI0034107 mze-let-7c; +MI0034108 mze-mir-27a; +MI0034109 mze-mir-142-1; +MI0034110 mze-mir-30d; +MI0034111 mze-mir-142-2; +MI0034112 mze-mir-17; +MI0034113 mze-mir-190b; +MI0034114 mze-mir-731; +MI0034115 mze-mir-200a; +MI0034116 mze-mir-16b; +MI0034117 mze-mir-144; +MI0034118 mze-mir-218b; +MI0034119 mze-mir-429b; +MI0034120 mze-mir-138-1; +MI0034121 mze-mir-122; +MI0034122 mze-mir-27e-1; +MI0034123 mze-mir-107; +MI0034124 mze-mir-460; +MI0034125 mze-mir-101a; +MI0034126 mze-mir-23b; +MI0034127 mze-mir-19b-1; +MI0034128 mze-mir-19b-2; +MI0034129 mze-mir-19d; +MI0034130 mze-let-7h; +MI0034131 mze-mir-20a-1; +MI0034132 mze-mir-20a-2; +MI0034133 mze-mir-1-1; +MI0034134 mze-mir-338-1; +MI0034135 mze-mir-338-3; +MI0034136 mze-mir-338-2; +MI0034137 mze-mir-129-1; +MI0034138 mze-mir-129-2; +MI0034139 mze-mir-129-3; +MI0034140 mze-mir-129-4; +MI0034141 mze-mir-18a; +MI0034142 mze-mir-15a; +MI0034143 mze-mir-135b-1; +MI0034144 mze-mir-135b-2; +MI0034145 mze-mir-96-1; +MI0034146 mze-mir-106; +MI0034147 mze-mir-96-2; +MI0034148 mze-mir-93; +MI0034149 mze-mir-19a; +MI0034150 mze-mir-24a-2; +MI0034151 mze-mir-24a-1; +MI0034152 mze-mir-7a-2; +MI0034153 mze-mir-132a; +MI0034154 mze-mir-22c; +MI0034155 mze-mir-489; +MI0034156 mze-mir-196a; +MI0034157 mze-mir-7a-1; +MI0034158 mze-mir-24a-4; +MI0034159 mze-mir-499; +MI0034160 mze-let-7b-1; +MI0034161 mze-mir-7b; +MI0034162 mze-mir-101b; +MI0034163 mze-mir-190a-1; +MI0034164 mze-mir-190a-2; +MI0034165 mze-mir-139; +MI0034166 mze-mir-212a; +MI0034167 mze-mir-20b; +MI0034168 mze-mir-727; +MI0034169 mze-mir-365; +MI0034170 mze-mir-187-1; +MI0034171 mze-mir-730; +MI0034172 mze-mir-33b; +MI0034173 mze-mir-135c; +MI0034174 mze-mir-2187a; +MI0034175 mze-mir-193; +MI0034176 mze-mir-29a-3; +MI0034177 mze-mir-219a-1; +MI0034178 mze-mir-219a-2; +MI0034179 mze-mir-138-2; +MI0034180 mze-mir-301b-2; +MI0034181 mze-mir-456; +MI0034182 mze-mir-218a-1; +MI0034183 mze-mir-22b; +MI0034184 mze-mir-23a-1; +MI0034185 mze-mir-23a-2; +MI0034186 mze-mir-138-3; +MI0034187 mze-mir-23a-3; +MI0034188 mze-mir-155; +MI0034189 mze-mir-9-7; +MI0034190 mze-mir-34; +MI0034191 mze-mir-205-2; +MI0034192 mze-mir-124-3; +MI0034193 mze-mir-7a-3; +MI0034194 mze-mir-204-3; +MI0034195 mze-mir-124-1; +MI0034196 mze-mir-375; +MI0034197 mze-mir-29a-2; +MI0034198 mze-mir-124-4; +MI0034199 mze-mir-153b; +MI0034200 mze-mir-27e-2; +MI0034201 mze-mir-124-2; +MI0034202 mze-mir-124-5; +MI0034203 mze-mir-1-2; +MI0034204 mze-mir-29a-1; +MI0034205 mze-mir-29b-2; +MI0034206 mze-mir-29b-1; +MI0034207 mze-mir-181b; +MI0034208 mze-mir-458; +MI0034209 mze-mir-132b; +MI0034210 mze-mir-15b; +MI0034211 mze-mir-23c; +MI0034212 mze-mir-18b; +MI0034213 mze-mir-24b; +MI0034214 mze-mir-216a; +MI0034215 mze-mir-734; +MI0034216 mze-mir-137-1; +MI0034217 mze-mir-137-2; +MI0034218 mze-mir-722-1; +MI0034219 mze-mir-722-2; +MI0034220 mze-mir-196b; +MI0034221 mze-mir-194b; +MI0034222 mze-mir-150; +MI0034223 mze-mir-135d; +MI0034224 mze-mir-31; +MI0034225 mze-mir-19c; +MI0034226 mze-mir-726; +MI0034227 mze-mir-153c; +MI0034228 mze-mir-551; +MI0034229 mze-mir-147; +MI0034230 mze-mir-723a; +MI0034231 mze-mir-728; +MI0034232 mze-mir-457; +MI0034233 mze-mir-301a; +MI0034234 mze-mir-181a; +MI0034235 mze-mir-10d; +MI0034236 mze-mir-723b; +MI0034237 mze-mir-2187b; +MI0034238 mze-mir-125c; +MI0034239 mze-mir-212b; +MI0034240 mze-mir-219c; +MI0034241 mze-mir-219b; +MI0034242 mze-mir-33a; +MI0034243 mze-mir-7132b; +MI0034244 mze-mir-99a; +MI0034245 mze-mir-148; +MI0034246 mze-mir-7132a; +MI0034247 mze-mir-15c; +MI0034248 mze-mir-7133-2; +MI0034249 mze-mir-7133-3; +MI0034250 mze-mir-725; +MI0034251 mze-mir-449b; +MI0034252 mze-mir-449a; +MI0034253 mze-mir-8159; +MI0034254 mze-mir-8160b; +MI0034255 mze-mir-10566; +MI0034256 mze-mir-7147; +MI0034257 mze-mir-10544; +MI0034258 mze-mir-10554-1; +MI0034259 mze-mir-10567; +MI0034260 mze-mir-3120; +MI0034261 mze-mir-10552; +MI0034262 mze-mir-10554-2; +MI0034263 mze-mir-10545; +MI0034264 mze-mir-10554-3; +MI0034265 mze-mir-10553; +MI0034266 mze-mir-24a-3; +MI0034267 nbr-mir-10568; +MI0034268 nbr-mir-10569; +MI0034269 nbr-mir-10570; +MI0034270 nbr-mir-10571; +MI0034271 nbr-mir-10572; +MI0034272 nbr-mir-10a-1; +MI0034273 nbr-mir-10a-2; +MI0034274 nbr-mir-10b; +MI0034275 nbr-mir-183-2; +MI0034276 nbr-mir-183-1; +MI0034277 nbr-mir-192; +MI0034278 nbr-mir-182; +MI0034279 nbr-mir-9-1; +MI0034280 nbr-mir-9-2; +MI0034281 nbr-mir-92a-1; +MI0034282 nbr-mir-92a-2; +MI0034283 nbr-mir-21-2; +MI0034284 nbr-mir-21-1; +MI0034285 nbr-mir-9-3; +MI0034286 nbr-mir-9-4; +MI0034287 nbr-mir-9-5; +MI0034288 nbr-mir-9-6; +MI0034289 nbr-mir-204-1; +MI0034290 nbr-mir-204-2; +MI0034291 nbr-mir-199-2; +MI0034292 nbr-mir-199-1; +MI0034293 nbr-mir-199-3; +MI0034294 nbr-mir-100-2; +MI0034295 nbr-mir-100-1; +MI0034296 nbr-mir-199-4; +MI0034297 nbr-mir-26a-4; +MI0034298 nbr-mir-26a-1; +MI0034299 nbr-mir-26a-3; +MI0034300 nbr-mir-184a; +MI0034301 nbr-mir-30a; +MI0034302 nbr-mir-27b; +MI0034303 nbr-mir-140; +MI0034304 nbr-mir-203-1; +MI0034305 nbr-mir-203-2; +MI0034306 nbr-mir-25; +MI0034307 nbr-let-7a-2; +MI0034308 nbr-let-7a-3; +MI0034309 nbr-let-7a-6; +MI0034310 nbr-let-7a-4; +MI0034311 nbr-let-7a-5; +MI0034312 nbr-let-7a-1; +MI0034313 nbr-mir-205-1; +MI0034314 nbr-mir-22a; +MI0034315 nbr-mir-133a-1; +MI0034316 nbr-mir-133a-2; +MI0034317 nbr-mir-462; +MI0034318 nbr-mir-2188; +MI0034319 nbr-mir-126; +MI0034320 nbr-mir-222-2; +MI0034321 nbr-mir-222-1; +MI0034322 nbr-mir-135a; +MI0034323 nbr-mir-153a-1; +MI0034324 nbr-mir-218b; +MI0034325 nbr-mir-153a-2; +MI0034326 nbr-mir-184b; +MI0034327 nbr-mir-221-1; +MI0034328 nbr-mir-30c; +MI0034329 nbr-mir-92b; +MI0034330 nbr-mir-125a-1; +MI0034331 nbr-mir-125a-2; +MI0034332 nbr-mir-125b-2; +MI0034333 nbr-let-7d-1; +MI0034334 nbr-let-7d-2; +MI0034335 nbr-mir-221-2; +MI0034336 nbr-let-7g-1; +MI0034337 nbr-let-7g-2; +MI0034338 nbr-mir-103; +MI0034339 nbr-mir-19b-1; +MI0034340 nbr-mir-301b-2; +MI0034341 nbr-mir-99b; +MI0034342 nbr-mir-455; +MI0034343 nbr-mir-30b; +MI0034344 nbr-mir-206; +MI0034345 nbr-mir-125b-3; +MI0034346 nbr-mir-724-1; +MI0034347 nbr-mir-724-2; +MI0034348 nbr-mir-214-1; +MI0034349 nbr-mir-125b-1; +MI0034350 nbr-mir-26b; +MI0034351 nbr-mir-190b; +MI0034352 nbr-mir-216b; +MI0034353 nbr-mir-133b; +MI0034354 nbr-let-7i-1; +MI0034355 nbr-let-7i-2; +MI0034356 nbr-mir-731; +MI0034357 nbr-mir-200b; +MI0034358 nbr-let-7e-1; +MI0034359 nbr-let-7e-2; +MI0034360 nbr-mir-19d; +MI0034361 nbr-mir-1388; +MI0034362 nbr-mir-130-2; +MI0034363 nbr-mir-130-1; +MI0034364 nbr-mir-17-1; +MI0034365 nbr-mir-17-2; +MI0034366 nbr-mir-16b; +MI0034367 nbr-mir-200a; +MI0034368 nbr-mir-144; +MI0034369 nbr-mir-19a; +MI0034370 nbr-mir-30d; +MI0034371 nbr-mir-96-1; +MI0034372 nbr-mir-138-1; +MI0034373 nbr-mir-138-2; +MI0034374 nbr-mir-96-2; +MI0034375 nbr-mir-27a; +MI0034376 nbr-mir-142-1; +MI0034377 nbr-mir-142-2; +MI0034378 nbr-let-7c; +MI0034379 nbr-mir-101a; +MI0034380 nbr-mir-194a; +MI0034381 nbr-mir-23b; +MI0034382 nbr-mir-107; +MI0034383 nbr-mir-18a; +MI0034384 nbr-mir-135b-1; +MI0034385 nbr-mir-20a-1; +MI0034386 nbr-mir-135b-2; +MI0034387 nbr-mir-27e-1; +MI0034388 nbr-mir-460; +MI0034389 nbr-mir-23a-2; +MI0034390 nbr-mir-1-1; +MI0034391 nbr-mir-20a-2; +MI0034392 nbr-mir-1-2; +MI0034393 nbr-mir-338-1; +MI0034394 nbr-mir-338-3; +MI0034395 nbr-mir-338-2; +MI0034396 nbr-mir-132a; +MI0034397 nbr-mir-129-2; +MI0034398 nbr-mir-129-1; +MI0034399 nbr-mir-129-3; +MI0034400 nbr-mir-27d; +MI0034401 nbr-mir-7-1; +MI0034402 nbr-mir-129-4; +MI0034403 nbr-mir-7-4; +MI0034404 nbr-mir-7-2; +MI0034405 nbr-mir-196a-1; +MI0034406 nbr-mir-122; +MI0034407 nbr-mir-93; +MI0034408 nbr-mir-7-3; +MI0034409 nbr-mir-15a; +MI0034410 nbr-mir-190a-1; +MI0034411 nbr-mir-190a-2; +MI0034412 nbr-mir-499; +MI0034413 nbr-let-7h; +MI0034414 nbr-mir-489; +MI0034415 nbr-mir-20b; +MI0034416 nbr-mir-24a-2; +MI0034417 nbr-mir-24a-1; +MI0034418 nbr-mir-139; +MI0034419 nbr-mir-22c; +MI0034420 nbr-mir-101b; +MI0034421 nbr-mir-187; +MI0034422 nbr-let-7b-1; +MI0034423 nbr-mir-2187a; +MI0034424 nbr-mir-727; +MI0034425 nbr-mir-24c; +MI0034426 nbr-mir-365; +MI0034427 nbr-mir-219c-1; +MI0034428 nbr-mir-730; +MI0034429 nbr-mir-155; +MI0034430 nbr-mir-33b; +MI0034431 nbr-mir-193; +MI0034432 nbr-mir-26a-2; +MI0034433 nbr-mir-456; +MI0034434 nbr-mir-23a-1; +MI0034435 nbr-mir-218a-1; +MI0034436 nbr-mir-214-2; +MI0034437 nbr-mir-301b-1; +MI0034438 nbr-mir-22b; +MI0034439 nbr-mir-138-3; +MI0034440 nbr-mir-124-6; +MI0034441 nbr-mir-23a-3; +MI0034442 nbr-mir-218a-2; +MI0034443 nbr-mir-196a-2; +MI0034444 nbr-mir-9-7; +MI0034445 nbr-mir-16a; +MI0034446 nbr-mir-34; +MI0034447 nbr-mir-205-2; +MI0034448 nbr-mir-204-3; +MI0034449 nbr-mir-124-1; +MI0034450 nbr-mir-429b; +MI0034451 nbr-mir-19b-2; +MI0034452 nbr-mir-219c-2; +MI0034453 nbr-mir-375; +MI0034454 nbr-mir-124-4; +MI0034455 nbr-mir-153b; +MI0034456 nbr-mir-124-3; +MI0034457 nbr-mir-124-2; +MI0034458 nbr-mir-27e-2; +MI0034459 nbr-mir-124-5; +MI0034460 nbr-let-7b-2; +MI0034461 nbr-mir-10c; +MI0034462 nbr-mir-29a; +MI0034463 nbr-mir-199-5; +MI0034464 nbr-mir-29b; +MI0034465 nbr-mir-10d; +MI0034466 nbr-mir-181b; +MI0034467 nbr-mir-132b; +MI0034468 nbr-mir-458; +MI0034469 nbr-mir-301a; +MI0034470 nbr-mir-734; +MI0034471 nbr-mir-196b; +MI0034472 nbr-mir-24b; +MI0034473 nbr-mir-18b; +MI0034474 nbr-mir-137-1; +MI0034475 nbr-mir-137-2; +MI0034476 nbr-mir-216a; +MI0034477 nbr-mir-23c; +MI0034478 nbr-mir-150; +MI0034479 nbr-mir-722-2; +MI0034480 nbr-mir-722-1; +MI0034481 nbr-mir-135d; +MI0034482 nbr-mir-723b; +MI0034483 nbr-mir-19c; +MI0034484 nbr-mir-194b; +MI0034485 nbr-mir-31; +MI0034486 nbr-mir-153c; +MI0034487 nbr-mir-15c; +MI0034488 nbr-mir-723a; +MI0034489 nbr-mir-551; +MI0034490 nbr-mir-726; +MI0034491 nbr-mir-7133; +MI0034492 nbr-mir-147; +MI0034493 nbr-mir-728; +MI0034494 nbr-mir-181a; +MI0034495 nbr-mir-457; +MI0034496 nbr-mir-15b; +MI0034497 nbr-mir-2187b; +MI0034498 nbr-mir-212a; +MI0034499 nbr-mir-212b; +MI0034500 nbr-mir-219a; +MI0034501 nbr-mir-219b; +MI0034502 nbr-mir-7132a; +MI0034503 nbr-mir-33a; +MI0034504 nbr-mir-99a; +MI0034505 nbr-mir-148; +MI0034506 nbr-mir-135c; +MI0034507 nbr-mir-29c; +MI0034508 nbr-mir-7132b; +MI0034509 nbr-mir-725; +MI0034510 nbr-mir-449b; +MI0034511 nbr-mir-449a; +MI0034512 nbr-mir-7147; +MI0034513 nbr-mir-10544; +MI0034514 nbr-mir-3120; +MI0034515 nbr-mir-10553; +MI0034516 nbr-mir-8159; +MI0034517 nbr-mir-8160; +MI0034518 oni-mir-10a-1; +MI0034519 oni-mir-10a-2; +MI0034520 oni-mir-10b; +MI0034521 oni-mir-192; +MI0034522 oni-mir-183-2; +MI0034523 oni-mir-183-1; +MI0034524 oni-mir-182; +MI0034525 oni-mir-143; +MI0034526 oni-mir-204a-1; +MI0034527 oni-mir-204a-2; +MI0034528 oni-mir-204a-3; +MI0034529 oni-mir-21-1; +MI0034530 oni-mir-21-2; +MI0034531 oni-mir-199a-1; +MI0034532 oni-mir-199a-2; +MI0034533 oni-mir-199a-3; +MI0034534 oni-mir-26a-4; +MI0034535 oni-mir-26a-1; +MI0034536 oni-mir-26a-2; +MI0034537 oni-mir-26a-3; +MI0034538 oni-mir-92a-1; +MI0034539 oni-mir-30a-2; +MI0034540 oni-mir-30a-1; +MI0034541 oni-mir-92a-2; +MI0034542 oni-mir-199a-4; +MI0034543 oni-mir-100-2; +MI0034544 oni-mir-9a-2; +MI0034545 oni-mir-100-1; +MI0034546 oni-mir-27b; +MI0034547 oni-mir-9a-3; +MI0034548 oni-mir-9a-1; +MI0034549 oni-mir-9a-5; +MI0034550 oni-mir-9a-6; +MI0034551 oni-let-7a-2; +MI0034552 oni-let-7a-3; +MI0034553 oni-let-7a-6; +MI0034554 oni-let-7a-4; +MI0034555 oni-let-7a-5; +MI0034556 oni-let-7a-1; +MI0034557 oni-mir-140; +MI0034558 oni-let-7d-1; +MI0034559 oni-let-7d-2; +MI0034560 oni-mir-462; +MI0034561 oni-mir-133a-1; +MI0034562 oni-mir-133a-2; +MI0034563 oni-mir-30c; +MI0034564 oni-mir-184b; +MI0034565 oni-mir-22a; +MI0034566 oni-mir-2188; +MI0034567 oni-mir-205-1; +MI0034568 oni-mir-25; +MI0034569 oni-mir-222-2; +MI0034570 oni-mir-222-1; +MI0034571 oni-let-7g-1; +MI0034572 oni-let-7g-2; +MI0034573 oni-mir-125b-2; +MI0034574 oni-mir-126; +MI0034575 oni-mir-30b; +MI0034576 oni-mir-221-1; +MI0034577 oni-mir-125a-1; +MI0034578 oni-mir-125a-2; +MI0034579 oni-mir-103-2; +MI0034580 oni-mir-221-2; +MI0034581 oni-mir-144a; +MI0034582 oni-mir-125b-3; +MI0034583 oni-mir-125b-1; +MI0034584 oni-mir-218a-2; +MI0034585 oni-let-7e-1; +MI0034586 oni-let-7e-2; +MI0034587 oni-mir-22b; +MI0034588 oni-let-7i-1; +MI0034589 oni-let-7i-2; +MI0034590 oni-mir-1388; +MI0034591 oni-mir-19b-2; +MI0034592 oni-mir-19b-1; +MI0034593 oni-mir-214-1; +MI0034594 oni-mir-724-1; +MI0034595 oni-mir-724-2; +MI0034596 oni-mir-16a; +MI0034597 oni-mir-190b; +MI0034598 oni-mir-455-1; +MI0034599 oni-mir-135a; +MI0034600 oni-mir-26b; +MI0034601 oni-mir-153a-1; +MI0034602 oni-mir-133b; +MI0034603 oni-mir-92b; +MI0034604 oni-mir-99b; +MI0034605 oni-mir-206; +MI0034606 oni-let-7c; +MI0034607 oni-mir-218b; +MI0034608 oni-mir-301b-1; +MI0034609 oni-mir-194a; +MI0034610 oni-mir-142-1; +MI0034611 oni-mir-142-2; +MI0034612 oni-mir-128-1; +MI0034613 oni-mir-128-2; +MI0034614 oni-mir-17a-2; +MI0034615 oni-mir-17a-1; +MI0034616 oni-mir-130a-1; +MI0034617 oni-mir-130a-2; +MI0034618 oni-mir-19d; +MI0034619 oni-mir-200b; +MI0034620 oni-mir-30d; +MI0034621 oni-mir-16b; +MI0034622 oni-mir-27e-2; +MI0034623 oni-mir-27e-1; +MI0034624 oni-mir-27a; +MI0034625 oni-mir-19a; +MI0034626 oni-mir-200a; +MI0034627 oni-mir-23b; +MI0034628 oni-mir-138-1; +MI0034629 oni-mir-138-2; +MI0034630 oni-mir-107; +MI0034631 oni-mir-216b; +MI0034632 oni-mir-460; +MI0034633 oni-mir-217; +MI0034634 oni-mir-20-1; +MI0034635 oni-mir-101a; +MI0034636 oni-mir-27d; +MI0034637 oni-mir-20-2; +MI0034638 oni-mir-129-1; +MI0034639 oni-mir-129-2; +MI0034640 oni-mir-129-3; +MI0034641 oni-mir-338-1; +MI0034642 oni-mir-338-3; +MI0034643 oni-mir-96-1; +MI0034644 oni-mir-96-2; +MI0034645 oni-mir-18a-1; +MI0034646 oni-mir-129-4; +MI0034647 oni-mir-338-2; +MI0034648 oni-mir-122; +MI0034649 oni-mir-1-1; +MI0034650 oni-mir-196a-1; +MI0034651 oni-let-7h; +MI0034652 oni-mir-135b-1; +MI0034653 oni-mir-135b-2; +MI0034654 oni-mir-489; +MI0034655 oni-mir-24a-2; +MI0034656 oni-mir-24a-1; +MI0034657 oni-mir-106; +MI0034658 oni-mir-22c; +MI0034659 oni-mir-93; +MI0034660 oni-mir-7-1; +MI0034661 oni-mir-15a; +MI0034662 oni-mir-499; +MI0034663 oni-mir-132a; +MI0034664 oni-mir-7-2; +MI0034665 oni-mir-190a-1; +MI0034666 oni-mir-190a-2; +MI0034667 oni-mir-139; +MI0034668 oni-mir-7-3; +MI0034669 oni-let-7b-1; +MI0034670 oni-mir-24a-3; +MI0034671 oni-mir-34; +MI0034672 oni-mir-212b; +MI0034673 oni-mir-101b; +MI0034674 oni-mir-153c; +MI0034675 oni-mir-365; +MI0034676 oni-mir-727a; +MI0034677 oni-mir-155; +MI0034678 oni-mir-2187a; +MI0034679 oni-mir-33b; +MI0034680 oni-mir-730; +MI0034681 oni-mir-135c; +MI0034682 oni-mir-187; +MI0034683 oni-mir-219b-1; +MI0034684 oni-mir-729; +MI0034685 oni-mir-153b; +MI0034686 oni-mir-193; +MI0034687 oni-mir-137a; +MI0034688 oni-mir-29a-3; +MI0034689 oni-mir-736-1; +MI0034690 oni-mir-29b-1; +MI0034691 oni-mir-456; +MI0034692 oni-mir-138-3; +MI0034693 oni-mir-23a-1; +MI0034694 oni-mir-218a-1; +MI0034695 oni-mir-214-2; +MI0034696 oni-mir-23a-3; +MI0034697 oni-mir-301b-2; +MI0034698 oni-mir-196a-2; +MI0034699 oni-mir-23a-2; +MI0034700 oni-mir-219b-2; +MI0034701 oni-mir-9a-4; +MI0034702 oni-mir-124a-1; +MI0034703 oni-mir-205-2; +MI0034704 oni-mir-103-1; +MI0034705 oni-mir-24a-4; +MI0034706 oni-mir-124a-2; +MI0034707 oni-mir-124a-3; +MI0034708 oni-mir-7-4; +MI0034709 oni-mir-429b; +MI0034710 oni-mir-124a-4; +MI0034711 oni-mir-184a; +MI0034712 oni-mir-375; +MI0034713 oni-let-7b-2; +MI0034714 oni-mir-29a-2; +MI0034715 oni-mir-124a-5; +MI0034716 oni-mir-124a-6; +MI0034717 oni-mir-10c; +MI0034718 oni-mir-1-2; +MI0034719 oni-mir-29a-1; +MI0034720 oni-mir-29b-2; +MI0034721 oni-mir-129-5; +MI0034722 oni-mir-10d; +MI0034723 oni-mir-9a-7; +MI0034724 oni-mir-203a-1; +MI0034725 oni-mir-203a-2; +MI0034726 oni-mir-181a; +MI0034727 oni-mir-725; +MI0034728 oni-mir-731; +MI0034729 oni-mir-181b; +MI0034730 oni-mir-132b; +MI0034731 oni-mir-15b; +MI0034732 oni-mir-458; +MI0034733 oni-mir-150; +MI0034734 oni-mir-24b; +MI0034735 oni-mir-31; +MI0034736 oni-mir-734; +MI0034737 oni-mir-194b; +MI0034738 oni-mir-23c; +MI0034739 oni-mir-196b; +MI0034740 oni-mir-137b-1; +MI0034741 oni-mir-137b-2; +MI0034742 oni-mir-216a; +MI0034743 oni-mir-722-1; +MI0034744 oni-mir-722-2; +MI0034745 oni-mir-135d; +MI0034746 oni-mir-18b; +MI0034747 oni-mir-723a; +MI0034748 oni-mir-147; +MI0034749 oni-mir-2187b; +MI0034750 oni-mir-728a; +MI0034751 oni-mir-457; +MI0034752 oni-mir-301a; +MI0034753 oni-mir-551; +MI0034754 oni-mir-726; +MI0034755 oni-mir-19c; +MI0034756 oni-mir-723b; +MI0034757 oni-mir-212a; +MI0034758 oni-mir-7132a; +MI0034759 oni-mir-219a; +MI0034760 oni-mir-219c; +MI0034761 oni-mir-99a; +MI0034762 oni-mir-33a; +MI0034763 oni-mir-7132b; +MI0034764 oni-mir-148; +MI0034765 oni-mir-130b; +MI0034766 oni-mir-7133-1; +MI0034767 oni-mir-15c; +MI0034768 oni-mir-29c; +MI0034769 oni-mir-449b; +MI0034770 oni-mir-449a; +MI0034771 oni-mir-8160a; +MI0034772 oni-mir-10544; +MI0034773 oni-mir-3120-1; +MI0034774 oni-mir-8159; +MI0034775 oni-mir-10573a; +MI0034776 oni-mir-10553; +MI0034777 oni-mir-10574; +MI0034778 oni-mir-10575-1; +MI0034779 oni-mir-10575-2; +MI0034780 oni-mir-10573b; +MI0034781 oni-mir-10576; +MI0034782 oni-mir-10577; +MI0034783 oni-mir-7147; +MI0034784 oni-mir-10578; +MI0034785 oni-mir-10579; +MI0034786 oni-mir-10580; +MI0034787 oni-mir-10551; +MI0034788 oni-mir-10545; +MI0034789 oni-mir-10555; +MI0034790 pny-mir-10a-1; +MI0034791 pny-mir-10a-2; +MI0034792 pny-mir-10b; +MI0034793 pny-mir-192; +MI0034794 pny-mir-183-2; +MI0034795 pny-mir-183-1; +MI0034796 pny-mir-182; +MI0034797 pny-mir-92-1; +MI0034798 pny-mir-92-2; +MI0034799 pny-mir-21-1; +MI0034800 pny-mir-21-2; +MI0034801 pny-mir-184a; +MI0034802 pny-mir-100-2; +MI0034803 pny-mir-146; +MI0034804 pny-mir-462; +MI0034805 pny-mir-100-1; +MI0034806 pny-mir-204-1; +MI0034807 pny-mir-140; +MI0034808 pny-mir-204-2; +MI0034809 pny-mir-26a-1; +MI0034810 pny-mir-26a-4; +MI0034811 pny-mir-26a-2; +MI0034812 pny-mir-26a-3; +MI0034813 pny-mir-199-2; +MI0034814 pny-mir-199-1; +MI0034815 pny-mir-199-3; +MI0034816 pny-mir-199-4; +MI0034817 pny-mir-27b; +MI0034818 pny-mir-184b; +MI0034819 pny-mir-30c; +MI0034820 pny-mir-30a-2; +MI0034821 pny-mir-30a-1; +MI0034822 pny-let-7a-2; +MI0034823 pny-let-7a-3; +MI0034824 pny-let-7a-6; +MI0034825 pny-let-7a-4; +MI0034826 pny-let-7a-5; +MI0034827 pny-let-7a-1; +MI0034828 pny-mir-25; +MI0034829 pny-mir-205-1; +MI0034830 pny-mir-222-1; +MI0034831 pny-mir-22a; +MI0034832 pny-mir-135a; +MI0034833 pny-mir-222-2; +MI0034834 pny-let-7d-2; +MI0034835 pny-let-7d-1; +MI0034836 pny-mir-30b; +MI0034837 pny-mir-126; +MI0034838 pny-mir-214-1; +MI0034839 pny-mir-125a-1; +MI0034840 pny-mir-2188; +MI0034841 pny-mir-125a-2; +MI0034842 pny-mir-214-2; +MI0034843 pny-let-7g-1; +MI0034844 pny-let-7g-2; +MI0034845 pny-mir-1388; +MI0034846 pny-mir-103-2; +MI0034847 pny-mir-724-1; +MI0034848 pny-mir-724-2; +MI0034849 pny-mir-19b-1; +MI0034850 pny-mir-99b; +MI0034851 pny-mir-221-1; +MI0034852 pny-mir-125b-3; +MI0034853 pny-mir-455; +MI0034854 pny-mir-153a-1; +MI0034855 pny-mir-153a-2; +MI0034856 pny-mir-17-2; +MI0034857 pny-mir-17-1; +MI0034858 pny-mir-221-2; +MI0034859 pny-mir-122; +MI0034860 pny-let-7e-1; +MI0034861 pny-let-7e-2; +MI0034862 pny-mir-125b-1; +MI0034863 pny-mir-124-1; +MI0034864 pny-mir-124-2; +MI0034865 pny-mir-124-3; +MI0034866 pny-mir-206; +MI0034867 pny-let-7i-1; +MI0034868 pny-let-7i-2; +MI0034869 pny-mir-130a-1; +MI0034870 pny-mir-130a-2; +MI0034871 pny-mir-26b; +MI0034872 pny-mir-133-1; +MI0034873 pny-mir-19d; +MI0034874 pny-mir-128-1; +MI0034875 pny-mir-124-4; +MI0034876 pny-mir-124-5; +MI0034877 pny-mir-124-6; +MI0034878 pny-mir-216b; +MI0034879 pny-mir-30d; +MI0034880 pny-mir-144; +MI0034881 pny-mir-128-2; +MI0034882 pny-mir-190b; +MI0034883 pny-mir-20a-1; +MI0034884 pny-mir-20a-2; +MI0034885 pny-mir-107; +MI0034886 pny-mir-16b; +MI0034887 pny-mir-301b-1; +MI0034888 pny-let-7c; +MI0034889 pny-mir-200a; +MI0034890 pny-mir-27a; +MI0034891 pny-mir-15a; +MI0034892 pny-mir-138-1; +MI0034893 pny-mir-142-1; +MI0034894 pny-mir-138-3; +MI0034895 pny-mir-142-2; +MI0034896 pny-mir-19a-1; +MI0034897 pny-mir-27e-1; +MI0034898 pny-mir-106; +MI0034899 pny-mir-200b; +MI0034900 pny-mir-19a-2; +MI0034901 pny-mir-135b-1; +MI0034902 pny-mir-18a; +MI0034903 pny-mir-23b; +MI0034904 pny-mir-375; +MI0034905 pny-mir-101a; +MI0034906 pny-mir-194a; +MI0034907 pny-mir-93; +MI0034908 pny-mir-218b; +MI0034909 pny-mir-460; +MI0034910 pny-mir-96-1; +MI0034911 pny-let-7h; +MI0034912 pny-mir-196a; +MI0034913 pny-mir-499; +MI0034914 pny-mir-24a-2; +MI0034915 pny-mir-24a-1; +MI0034916 pny-mir-139; +MI0034917 pny-mir-7-1; +MI0034918 pny-mir-129-1; +MI0034919 pny-mir-489; +MI0034920 pny-mir-129-2; +MI0034921 pny-mir-129-3; +MI0034922 pny-mir-338-3; +MI0034923 pny-mir-7-2; +MI0034924 pny-mir-338-1; +MI0034925 pny-mir-190a-1; +MI0034926 pny-mir-190a-2; +MI0034927 pny-mir-7-3; +MI0034928 pny-mir-22c; +MI0034929 pny-mir-20b; +MI0034930 pny-mir-338-2; +MI0034931 pny-mir-132-1; +MI0034932 pny-mir-24a-4; +MI0034933 pny-let-7b-1; +MI0034934 pny-mir-212-1; +MI0034935 pny-mir-365; +MI0034936 pny-mir-187; +MI0034937 pny-mir-135c; +MI0034938 pny-mir-730; +MI0034939 pny-mir-219b-1; +MI0034940 pny-mir-29a-3; +MI0034941 pny-mir-138-2; +MI0034942 pny-mir-23a-1; +MI0034943 pny-mir-22b; +MI0034944 pny-mir-218a-1; +MI0034945 pny-mir-456; +MI0034946 pny-mir-23a-2; +MI0034947 pny-mir-301b-2; +MI0034948 pny-mir-1-1; +MI0034949 pny-mir-23a-3; +MI0034950 pny-mir-218a-2; +MI0034951 pny-mir-155; +MI0034952 pny-mir-34; +MI0034953 pny-mir-729; +MI0034954 pny-mir-16a; +MI0034955 pny-mir-204-3; +MI0034956 pny-mir-205-2; +MI0034957 pny-mir-7-4; +MI0034958 pny-mir-219b-2; +MI0034959 pny-mir-96-2; +MI0034960 pny-mir-429b; +MI0034961 pny-mir-19b-2; +MI0034962 pny-mir-24a-3; +MI0034963 pny-let-7b-2; +MI0034964 pny-mir-153b; +MI0034965 pny-mir-133-3; +MI0034966 pny-mir-27e-2; +MI0034967 pny-mir-10c; +MI0034968 pny-mir-135b-2; +MI0034969 pny-mir-1-2; +MI0034970 pny-mir-29a-2; +MI0034971 pny-mir-29a-1; +MI0034972 pny-mir-29b; +MI0034973 pny-mir-10d; +MI0034974 pny-mir-203-1; +MI0034975 pny-mir-203-2; +MI0034976 pny-mir-731; +MI0034977 pny-mir-181b; +MI0034978 pny-mir-23c; +MI0034979 pny-mir-15b; +MI0034980 pny-mir-458; +MI0034981 pny-mir-18b; +MI0034982 pny-mir-24b; +MI0034983 pny-mir-132-2; +MI0034984 pny-mir-196b; +MI0034985 pny-mir-734; +MI0034986 pny-mir-216a; +MI0034987 pny-mir-31; +MI0034988 pny-mir-137-1; +MI0034989 pny-mir-137-2; +MI0034990 pny-mir-101b; +MI0034991 pny-mir-135d; +MI0034992 pny-mir-150; +MI0034993 pny-mir-722-2; +MI0034994 pny-mir-19c; +MI0034995 pny-mir-194b; +MI0034996 pny-mir-551; +MI0034997 pny-mir-723a; +MI0034998 pny-mir-147; +MI0034999 pny-mir-2187a; +MI0035000 pny-let-7f; +MI0035001 pny-mir-301a; +MI0035002 pny-mir-457; +MI0035003 pny-mir-153c; +MI0035004 pny-mir-726; +MI0035005 pny-mir-728; +MI0035006 pny-mir-723b; +MI0035007 pny-mir-722-1; +MI0035008 pny-mir-2187b; +MI0035009 pny-mir-181a; +MI0035010 pny-mir-430a-1; +MI0035011 pny-mir-430a-2; +MI0035012 pny-mir-125c; +MI0035013 pny-mir-212-2; +MI0035014 pny-mir-219a; +MI0035015 pny-mir-7132a; +MI0035016 pny-mir-33; +MI0035017 pny-mir-7132b; +MI0035018 pny-mir-99a; +MI0035019 pny-mir-27d; +MI0035020 pny-mir-148; +MI0035021 pny-mir-130b; +MI0035022 pny-mir-15c; +MI0035023 pny-mir-7133-2; +MI0035024 pny-mir-7133-1; +MI0035025 pny-mir-725; +MI0035026 pny-mir-449a; +MI0035027 pny-mir-8160b; +MI0035028 pny-mir-10566; +MI0035029 pny-mir-7147; +MI0035030 pny-mir-3120; +MI0035031 pny-mir-10553; +MI0035032 pny-mir-8159; +MI0035033 pny-mir-10549; +MI0035034 pny-mir-10544; +MI0035035 pny-mir-430b; +MI0035036 pny-mir-10555; +MI0035037 pny-mir-129-4; +MI0035038 pny-mir-103-1; +MI0035039 pny-mir-133-2; +MI0035040 egr-mir-96; +MI0035041 egr-mir-7b; +MI0035042 oni-mir-430a; +MI0035043 oni-mir-455-2; +MI0035044 oni-mir-454b; +MI0035045 oni-mir-8160b; +MI0035046 oni-let-7f; +MI0035047 oni-mir-2184; +MI0035048 oni-mir-430b; +MI0035049 oni-mir-18a-2; +MI0035050 oni-mir-96-3; +MI0035051 oni-mir-10558; +MI0035052 oni-mir-10547b; +MI0035053 oni-mir-10581a; +MI0035054 oni-mir-10582; +MI0035055 oni-mir-10552; +MI0035056 oni-mir-7552; +MI0035057 oni-mir-10583; +MI0035058 oni-mir-183-3; +MI0035059 oni-mir-10584; +MI0035060 oni-mir-10581c; +MI0035061 oni-mir-10573d; +MI0035062 oni-mir-10581d; +MI0035063 oni-mir-10585; +MI0035064 oni-mir-10586; +MI0035065 oni-mir-10587; +MI0035066 oni-mir-10588; +MI0035067 oni-mir-10589; +MI0035068 oni-mir-10590; +MI0035069 oni-mir-10591; +MI0035070 oni-mir-10581b; +MI0035071 oni-mir-26c; +MI0035072 oni-mir-10547d-1; +MI0035073 oni-mir-7133-2; +MI0035074 oni-mir-7133-3; +MI0035075 oni-mir-7133-4; +MI0035076 oni-mir-10547d-2; +MI0035077 oni-mir-10592; +MI0035078 oni-mir-10593; +MI0035079 oni-mir-10594a-1; +MI0035080 oni-mir-10594a-2; +MI0035081 oni-mir-10595; +MI0035082 oni-mir-10596-1; +MI0035083 oni-mir-10548b; +MI0035084 oni-mir-10597a; +MI0035085 oni-mir-10598; +MI0035086 oni-mir-736-2; +MI0035087 oni-mir-10599; +MI0035088 oni-mir-10600; +MI0035089 oni-mir-10601; +MI0035090 oni-mir-10602; +MI0035091 oni-mir-199c; +MI0035092 oni-mir-10603a; +MI0035093 oni-mir-10604; +MI0035094 oni-mir-10605; +MI0035095 oni-mir-10596-2; +MI0035096 oni-mir-10606; +MI0035097 oni-mir-9b-1; +MI0035098 oni-mir-10607; +MI0035099 oni-mir-10608a; +MI0035100 oni-mir-10609; +MI0035101 oni-mir-728b; +MI0035102 oni-mir-10610a; +MI0035103 oni-mir-10611; +MI0035104 oni-mir-10612; +MI0035105 oni-mir-9b-2; +MI0035106 oni-mir-10613; +MI0035107 oni-mir-26d; +MI0035108 oni-mir-10614; +MI0035109 oni-mir-10615a; +MI0035110 oni-mir-10616a; +MI0035111 oni-mir-6960; +MI0035112 oni-mir-10603b; +MI0035113 oni-mir-202; +MI0035114 oni-mir-10617; +MI0035115 oni-mir-10618; +MI0035116 oni-mir-451b; +MI0035117 oni-mir-10619; +MI0035118 oni-mir-10620; +MI0035119 oni-mir-10610b-1; +MI0035120 oni-mir-10621a; +MI0035121 oni-mir-10622-1; +MI0035122 oni-mir-10622-2; +MI0035123 oni-mir-10622-3; +MI0035124 oni-mir-10623; +MI0035125 oni-mir-9b-3; +MI0035126 oni-mir-9b-4; +MI0035127 oni-mir-10624; +MI0035128 oni-mir-10625-1; +MI0035129 oni-mir-10625-2; +MI0035130 oni-mir-449c; +MI0035131 oni-mir-10626; +MI0035132 oni-mir-10627; +MI0035133 oni-mir-10628; +MI0035134 oni-mir-10629-1; +MI0035135 oni-mir-10629-2; +MI0035136 oni-mir-10630; +MI0035137 oni-mir-9b-5; +MI0035138 oni-mir-10631; +MI0035139 oni-mir-10632-1; +MI0035140 oni-mir-10632-2; +MI0035141 oni-mir-10632-3; +MI0035142 oni-mir-29d; +MI0035143 oni-mir-10633; +MI0035144 oni-mir-10634; +MI0035145 oni-mir-10635; +MI0035146 oni-mir-27f; +MI0035147 oni-mir-10636; +MI0035148 oni-mir-10637; +MI0035149 oni-mir-10638; +MI0035150 oni-mir-10639; +MI0035151 oni-mir-10640; +MI0035152 oni-mir-10641; +MI0035153 oni-mir-10642; +MI0035154 oni-mir-10643; +MI0035155 oni-mir-10556a; +MI0035156 oni-mir-10644; +MI0035157 oni-mir-10645; +MI0035158 oni-mir-10646a; +MI0035159 oni-mir-10647; +MI0035160 oni-mir-10646b; +MI0035161 oni-mir-10648; +MI0035162 oni-mir-10649; +MI0035163 oni-mir-10650; +MI0035164 oni-mir-199b-2; +MI0035165 oni-mir-10651; +MI0035166 oni-mir-10615b; +MI0035167 oni-mir-204b; +MI0035168 oni-mir-10652; +MI0035169 oni-mir-10653-1; +MI0035170 oni-mir-10654; +MI0035171 oni-mir-10655; +MI0035172 oni-mir-10656; +MI0035173 oni-mir-10657; +MI0035174 oni-mir-10658; +MI0035175 oni-mir-10659; +MI0035176 oni-mir-10660; +MI0035177 oni-mir-10661; +MI0035178 oni-mir-10662; +MI0035179 oni-mir-10663; +MI0035180 oni-mir-10664; +MI0035181 oni-mir-7565; +MI0035182 oni-mir-10665; +MI0035183 oni-mir-10666; +MI0035184 oni-mir-10667-1; +MI0035185 oni-mir-10667-2; +MI0035186 oni-mir-10668; +MI0035187 oni-mir-10669; +MI0035188 oni-mir-10670; +MI0035189 oni-mir-1788; +MI0035190 oni-mir-10671; +MI0035191 oni-mir-10672; +MI0035192 oni-mir-726b; +MI0035193 oni-mir-10673; +MI0035194 oni-mir-10674; +MI0035195 oni-mir-10675; +MI0035196 oni-mir-10676; +MI0035197 oni-mir-10677; +MI0035198 oni-mir-10678; +MI0035199 oni-mir-10679; +MI0035200 oni-mir-132c; +MI0035201 oni-mir-10548c; +MI0035202 oni-mir-10680; +MI0035203 oni-mir-10681; +MI0035204 oni-mir-10682; +MI0035205 oni-mir-10683; +MI0035206 oni-mir-10684; +MI0035207 oni-mir-10685; +MI0035208 oni-mir-10686-1; +MI0035209 oni-mir-10686-2; +MI0035210 oni-mir-10687; +MI0035211 oni-mir-10688; +MI0035212 oni-mir-34b; +MI0035213 oni-mir-10689; +MI0035214 oni-mir-10690; +MI0035215 oni-mir-10691; +MI0035216 oni-mir-10692-1; +MI0035217 oni-mir-10692-2; +MI0035218 oni-mir-10693; +MI0035219 oni-mir-10621b; +MI0035220 oni-mir-10694; +MI0035221 oni-mir-10695; +MI0035222 oni-mir-10696; +MI0035223 oni-mir-10697a-1; +MI0035224 oni-mir-10698; +MI0035225 oni-mir-10699; +MI0035226 oni-mir-10700; +MI0035227 oni-mir-10701; +MI0035228 oni-mir-10702; +MI0035229 oni-mir-10703; +MI0035230 oni-mir-10704; +MI0035231 oni-mir-10705; +MI0035232 oni-mir-10706; +MI0035233 oni-mir-10707; +MI0035234 oni-mir-10708; +MI0035235 oni-mir-10709; +MI0035236 oni-mir-10710; +MI0035237 oni-mir-10711; +MI0035238 oni-mir-10712; +MI0035239 oni-mir-10713; +MI0035240 oni-mir-10714; +MI0035241 oni-mir-10715; +MI0035242 oni-mir-10716; +MI0035243 oni-mir-10717; +MI0035244 oni-mir-10718; +MI0035245 oni-mir-10719; +MI0035246 oni-mir-10720-1; +MI0035247 oni-mir-10721; +MI0035248 oni-mir-142b; +MI0035249 oni-mir-10720-2; +MI0035250 oni-mir-10594c; +MI0035251 oni-mir-10722; +MI0035252 oni-mir-144b; +MI0035253 oni-mir-10723; +MI0035254 oni-mir-10724; +MI0035255 oni-mir-10725; +MI0035256 oni-mir-10726; +MI0035257 oni-mir-10727; +MI0035258 oni-mir-10728; +MI0035259 oni-mir-10729; +MI0035260 oni-mir-10730; +MI0035261 oni-mir-10731; +MI0035262 oni-mir-10732; +MI0035263 oni-mir-10733; +MI0035264 oni-mir-10734; +MI0035265 oni-mir-10735; +MI0035266 oni-mir-10610c; +MI0035267 oni-mir-10736; +MI0035268 oni-mir-10737; +MI0035269 oni-mir-10738; +MI0035270 oni-mir-10739; +MI0035271 oni-mir-219d-1; +MI0035272 oni-mir-10740; +MI0035273 oni-mir-10741; +MI0035274 oni-mir-10742; +MI0035275 oni-mir-10743; +MI0035276 oni-mir-10744; +MI0035277 oni-mir-10745; +MI0035278 oni-mir-10746; +MI0035279 oni-mir-132d; +MI0035280 oni-mir-10747; +MI0035281 oni-mir-7144; +MI0035282 oni-mir-10748; +MI0035283 oni-mir-10749; +MI0035284 oni-mir-10750; +MI0035285 oni-mir-10751; +MI0035286 oni-mir-10697b-1; +MI0035287 oni-mir-10752; +MI0035288 oni-mir-10697b-2; +MI0035289 oni-mir-10753; +MI0035290 oni-mir-10754; +MI0035291 oni-mir-10755; +MI0035292 oni-mir-10756; +MI0035293 oni-mir-10757; +MI0035294 oni-mir-10758; +MI0035295 oni-mir-10759; +MI0035296 oni-mir-10760; +MI0035297 oni-mir-10761; +MI0035298 oni-mir-10762; +MI0035299 oni-mir-10763; +MI0035300 oni-mir-10764; +MI0035301 oni-mir-10765; +MI0035302 oni-mir-10766; +MI0035303 oni-mir-10767; +MI0035304 oni-mir-10768; +MI0035305 oni-mir-10769; +MI0035306 oni-mir-10770; +MI0035307 oni-mir-10771; +MI0035308 oni-mir-10772; +MI0035309 oni-mir-10773; +MI0035310 oni-mir-10774; +MI0035311 oni-mir-10775; +MI0035312 oni-mir-10776; +MI0035313 oni-mir-10777; +MI0035314 oni-mir-10778; +MI0035315 oni-mir-10779; +MI0035316 oni-mir-10780; +MI0035317 oni-mir-10781; +MI0035318 oni-mir-10782; +MI0035319 oni-mir-10783; +MI0035320 oni-mir-10784; +MI0035321 oni-mir-10785; +MI0035322 oni-mir-10786; +MI0035323 oni-mir-10787; +MI0035324 oni-mir-10788; +MI0035325 oni-mir-10789; +MI0035326 oni-mir-10790; +MI0035327 oni-mir-10791; +MI0035328 oni-mir-10792; +MI0035329 oni-mir-10793; +MI0035330 oni-mir-10794; +MI0035331 oni-mir-10795; +MI0035332 oni-mir-10796; +MI0035333 oni-mir-10797; +MI0035334 oni-mir-10798; +MI0035335 oni-mir-10799; +MI0035336 oni-mir-10800; +MI0035337 oni-mir-10801; +MI0035338 oni-mir-10802; +MI0035339 oni-mir-10803; +MI0035340 oni-mir-10563; +MI0035341 oni-mir-10804; +MI0035342 oni-mir-10805; +MI0035343 oni-mir-10806; +MI0035344 oni-mir-10807; +MI0035345 oni-mir-10808; +MI0035346 oni-mir-10809; +MI0035347 oni-mir-10810; +MI0035348 oni-mir-10811; +MI0035349 oni-mir-10812; +MI0035350 oni-mir-10813-1; +MI0035351 oni-mir-10813-2; +MI0035352 oni-mir-10814; +MI0035353 oni-mir-10815; +MI0035354 oni-mir-10559; +MI0035355 oni-mir-10816; +MI0035356 oni-mir-10817; +MI0035357 oni-mir-10818; +MI0035358 oni-mir-10819; +MI0035359 oni-mir-10820; +MI0035360 oni-mir-10821; +MI0035361 oni-mir-10822; +MI0035362 oni-mir-10823; +MI0035363 oni-mir-10824; +MI0035364 oni-mir-10825; +MI0035365 oni-mir-9c; +MI0035366 oni-mir-124b-1; +MI0035367 oni-mir-124b-2; +MI0035368 oni-mir-10826; +MI0035369 oni-mir-10827; +MI0035370 oni-mir-10828; +MI0035371 oni-mir-10829; +MI0035372 oni-mir-10830; +MI0035373 oni-mir-10831a; +MI0035374 oni-mir-10832; +MI0035375 oni-mir-10573c; +MI0035376 oni-mir-10833; +MI0035377 oni-mir-10834-1; +MI0035378 oni-mir-10835; +MI0035379 oni-mir-10836; +MI0035380 oni-mir-10837; +MI0035381 oni-mir-10838; +MI0035382 oni-mir-10839-1; +MI0035383 oni-mir-10840-1; +MI0035384 oni-mir-10840-2; +MI0035385 oni-mir-10841-1; +MI0035386 oni-mir-10839-2; +MI0035387 oni-mir-10842; +MI0035388 oni-mir-10556b; +MI0035389 oni-mir-10834-2; +MI0035390 oni-mir-10843; +MI0035391 oni-mir-10844; +MI0035392 oni-mir-10616b; +MI0035393 oni-mir-10834-3; +MI0035394 oni-mir-10845; +MI0035395 oni-mir-10831b; +MI0035396 oni-mir-10846-1; +MI0035397 oni-mir-10847; +MI0035398 oni-mir-3120-2; +MI0035399 oni-mir-10848; +MI0035400 oni-mir-4585; +MI0035401 oni-mir-10846-2; +MI0035402 oni-mir-10841-2; +MI0035403 oni-mir-10569; +MI0035404 oni-mir-10849; +MI0035405 oni-mir-10547c; +MI0035406 oni-mir-10850; +MI0035407 oni-mir-10851-1; +MI0035408 oni-mir-10852; +MI0035409 oni-mir-10853; +MI0035410 oni-mir-10854; +MI0035411 oni-mir-10851-2; +MI0035412 oni-mir-10855; +MI0035413 oni-mir-10856; +MI0035414 oni-mir-10857; +MI0035415 oni-mir-10858; +MI0035416 oni-mir-27c; +MI0035417 oni-mir-199b-1; +MI0035418 oni-mir-10859; +MI0035419 oni-mir-10860; +MI0035420 oni-mir-10861; +MI0035421 oni-mir-10862; +MI0035422 oni-mir-10863; +MI0035423 oni-mir-10864; +MI0035424 oni-mir-10865; +MI0035425 oni-mir-10866; +MI0035426 oni-mir-10867; +MI0035427 oni-mir-10868; +MI0035428 oni-mir-10869; +MI0035429 oni-mir-10870-1; +MI0035430 oni-mir-10871; +MI0035431 oni-mir-10548a-2; +MI0035432 oni-mir-145; +MI0035433 oni-mir-153d; +MI0035434 oni-mir-10872; +MI0035435 oni-mir-10608b; +MI0035436 oni-mir-10873; +MI0035437 oni-mir-10874; +MI0035438 oni-mir-10875; +MI0035439 oni-mir-10547a-3; +MI0035440 oni-mir-10876; +MI0035441 oni-mir-10877; +MI0035442 oni-mir-10878; +MI0035443 oni-mir-10594b; +MI0035444 oni-mir-10879; +MI0035445 oni-mir-10603c; +MI0035446 oni-mir-10548a-1; +MI0035447 oni-mir-10880; +MI0035448 oni-mir-10881; +MI0035449 oni-mir-10697a-2; +MI0035450 oni-mir-10882; +MI0035451 oni-mir-10883; +MI0035452 oni-mir-10548d; +MI0035453 oni-mir-10884; +MI0035454 oni-mir-10610b-2; +MI0035455 oni-mir-10885; +MI0035456 oni-mir-10886; +MI0035457 oni-mir-10887; +MI0035458 oni-mir-10888; +MI0035459 oni-mir-10889; +MI0035460 oni-mir-10890; +MI0035461 oni-mir-10891; +MI0035462 oni-mir-10892; +MI0035463 oni-mir-10549; +MI0035464 oni-mir-10893; +MI0035465 oni-mir-10894; +MI0035466 oni-mir-10895; +MI0035467 oni-mir-727b; +MI0035468 oni-mir-181c-1; +MI0035469 oni-mir-10896; +MI0035470 oni-mir-10897; +MI0035471 oni-mir-10898; +MI0035472 oni-mir-10597b; +MI0035473 oni-mir-10899; +MI0035474 oni-mir-10900a; +MI0035475 oni-mir-10901; +MI0035476 oni-mir-10902; +MI0035477 oni-mir-10903; +MI0035478 oni-mir-34c; +MI0035479 oni-mir-10904; +MI0035480 oni-mir-10905-1; +MI0035481 oni-mir-10905-2; +MI0035482 oni-mir-10597c; +MI0035483 oni-mir-10906; +MI0035484 oni-mir-10907; +MI0035485 oni-mir-10562; +MI0035486 oni-mir-184c; +MI0035487 oni-mir-10597d; +MI0035488 oni-mir-10908; +MI0035489 oni-mir-10909; +MI0035490 oni-mir-10910; +MI0035491 oni-mir-10547a-1; +MI0035492 oni-mir-10547a-2; +MI0035493 oni-mir-3553-1; +MI0035494 oni-mir-10870-2; +MI0035495 oni-mir-10912; +MI0035496 oni-mir-10913; +MI0035497 oni-mir-10914; +MI0035498 oni-mir-181c-2; +MI0035499 oni-mir-10915; +MI0035500 oni-mir-10916; +MI0035501 oni-mir-3553-2; +MI0035502 oni-mir-10917; +MI0035503 oni-mir-10918; +MI0035504 oni-mir-10919; +MI0035505 oni-mir-10920; +MI0035506 oni-mir-10900b; +MI0035507 oni-mir-199b-3; +MI0035508 oni-mir-10921; +MI0035509 oni-mir-210; +MI0035510 oni-mir-10922; +MI0035511 oni-mir-10923; +MI0035512 oni-mir-10924; +MI0035513 oni-mir-301c; +MI0035514 oni-mir-10925; +MI0035515 oni-mir-10926; +MI0035516 oni-mir-10927; +MI0035517 oni-mir-10928; +MI0035518 oni-mir-10929; +MI0035519 oni-mir-10930; +MI0035520 oni-mir-10931; +MI0035521 oni-mir-10932; +MI0035522 oni-mir-10933; +MI0035523 oni-mir-10934; +MI0035524 oni-mir-10935; +MI0035525 oni-mir-10936; +MI0035526 oni-mir-23d; +MI0035527 oni-mir-10937; +MI0035528 oni-mir-10938; +MI0035529 oni-mir-10939-1; +MI0035530 oni-mir-10940; +MI0035531 oni-mir-10939-2; +MI0035532 oni-mir-3553-3; +MI0035533 oni-mir-10941; +MI0035534 oni-mir-10942; +MI0035535 oni-mir-10943; +MI0035536 oni-mir-10944; +MI0035537 oni-mir-10653-2; +MI0035538 oni-mir-181c-3; +MI0035539 oni-mir-10946; +MI0035540 oni-mir-10947; +MI0035541 oni-mir-219d-2; +MI0035542 oni-mir-10948; +MI0035543 oni-mir-10949; +MI0035544 oni-mir-10939-3; +MI0035545 oni-mir-10950; +MI0035546 oni-mir-7550; +MI0035547 oni-mir-10951; +MI0035548 oni-mir-10952; +MI0035549 oni-mir-10953; +MI0035550 oni-mir-17b-1; +MI0035551 oni-mir-10954; +MI0035552 oni-mir-10955; +MI0035553 oni-mir-10956; +MI0035554 oni-mir-10957; +MI0035555 oni-mir-10958; +MI0035556 oni-mir-10959; +MI0035557 oni-mir-10960; +MI0035558 oni-mir-10961; +MI0035559 oni-mir-10962; +MI0035560 oni-mir-184d; +MI0035561 oni-mir-10963; +MI0035562 oni-mir-10939-4; +MI0035563 oni-mir-10964; +MI0035564 oni-mir-10965; +MI0035565 oni-mir-10966; +MI0035566 oni-mir-10967-1; +MI0035567 oni-mir-203b; +MI0035568 oni-mir-10968; +MI0035569 oni-mir-10969; +MI0035570 oni-mir-10967-2; +MI0035571 oni-mir-10970; +MI0035572 oni-mir-17b-2; +MI0035573 oni-mir-10971; +MI0035574 oni-mir-10972; +MI0035575 oni-mir-10973; +MI0035576 oni-mir-10974; +MI0035577 oni-mir-10975; +MI0035578 oni-mir-10976; +MI0035579 oni-mir-181d; +MI0035580 oni-mir-10977; +MI0035581 oni-mir-153a-2; +MI0035582 mdm-MIR10978a; +MI0035583 mdm-MIR10978b; +MI0035584 mdm-MIR10979; +MI0035585 mdm-MIR10980a; +MI0035586 mdm-MIR10980b; +MI0035587 mdm-MIR10981a; +MI0035588 mdm-MIR10981b; +MI0035589 mdm-MIR3627d; +MI0035590 mdm-MIR10982a; +MI0035591 mdm-MIR10982b; +MI0035592 mdm-MIR10982c; +MI0035593 mdm-MIR10982d; +MI0035594 mdm-MIR159d; +MI0035595 mdm-MIR159e; +MI0035596 mdm-MIR159f; +MI0035597 mdm-MIR530a; +MI0035598 mdm-MIR530b; +MI0035599 mdm-MIR530c; +MI0035600 mdm-MIR166j; +MI0035601 mdm-MIR10983; +MI0035602 mdm-MIR10984a; +MI0035603 mdm-MIR10985; +MI0035604 mdm-MIR399k; +MI0035605 mdm-MIR10986; +MI0035606 mdm-MIR319d; +MI0035607 mdm-MIR10987; +MI0035608 mdm-MIR10988; +MI0035609 mdm-MIR10989a; +MI0035610 mdm-MIR10989b; +MI0035611 mdm-MIR10989c; +MI0035612 mdm-MIR10989d; +MI0035613 mdm-MIR10989e; +MI0035614 mdm-MIR10990; +MI0035615 mdm-MIR10991a; +MI0035616 mdm-MIR10991b; +MI0035617 mdm-MIR10991c; +MI0035618 mdm-MIR10991d; +MI0035619 mdm-MIR10991e; +MI0035620 mdm-MIR10992; +MI0035621 mdm-MIR319e; +MI0035622 mdm-MIR319f; +MI0035623 mdm-MIR319g; +MI0035624 mdm-MIR10993a; +MI0035625 mdm-MIR10993b; +MI0035626 mdm-MIR10994; +MI0035627 mdm-MIR395j; +MI0035628 mdm-MIR169g; +MI0035629 mdm-MIR169h; +MI0035630 mdm-MIR169i; +MI0035631 mdm-MIR169j; +MI0035632 mdm-MIR10995; +MI0035633 mdm-MIR10996a; +MI0035634 mdm-MIR10997; +MI0035635 mdm-MIR171p; +MI0035636 mdm-MIR393g; +MI0035637 mdm-MIR393h; +MI0035638 mdm-MIR10998; +MI0035639 mdm-MIR395k; +MI0035640 mdm-MIR10993c; +MI0035641 mdm-MIR10993d; +MI0035642 mdm-MIR10993e; +MI0035643 mdm-MIR10993f; +MI0035644 mdm-MIR10999a; +MI0035645 mdm-MIR10999b; +MI0035646 mdm-MIR10981c; +MI0035647 mdm-MIR10981d; +MI0035648 mdm-MIR319h; +MI0035649 mdm-MIR11002c; +MI0035650 mdm-MIR11000; +MI0035651 mdm-MIR11001; +MI0035652 mdm-MIR11002a; +MI0035653 mdm-MIR11002b; +MI0035654 mdm-MIR11003; +MI0035655 mdm-MIR11004; +MI0035656 mdm-MIR11005; +MI0035657 mdm-MIR171q; +MI0035658 mdm-MIR11006; +MI0035659 mdm-MIR11007; +MI0035660 mdm-MIR11008; +MI0035661 mdm-MIR10984b; +MI0035662 mdm-MIR11009; +MI0035663 mdm-MIR11010; +MI0035664 mdm-MIR11011a; +MI0035665 mdm-MIR11012a; +MI0035666 mdm-MIR11012b; +MI0035667 mdm-MIR169k; +MI0035668 mdm-MIR169l; +MI0035669 mdm-MIR169m; +MI0035670 mdm-MIR169n; +MI0035671 mdm-MIR172p; +MI0035672 mdm-MIR11013; +MI0035673 mdm-MIR10996b; +MI0035674 mdm-MIR11014; +MI0035675 mdm-MIR11015; +MI0035676 mdm-MIR11016; +MI0035677 mdm-MIR395l; +MI0035678 mdm-MIR11017; +MI0035679 mdm-MIR11018; +MI0035680 mdm-MIR11019; +MI0035681 mdm-MIR11011b; +MI0035682 mdm-MIR11020; +MI0035683 mdm-MIR169o; +MI0035684 seu-MIR11021; +MI0035685 seu-MIR11022; +MI0035686 seu-MIR11023; +MI0035687 seu-MIR11024; +MI0035688 seu-MIR11025; +MI0035689 seu-MIR11026; +MI0035690 seu-MIR11027; +MI0035691 seu-MIR11028; +MI0035692 seu-MIR11029; +MI0035693 seu-MIR11030a; +MI0035694 seu-MIR11030b; +MI0035695 seu-MIR11031; +MI0035696 seu-MIR11032; +MI0035697 seu-MIR11033; +MI0035698 seu-MIR319; +MI0035699 seu-MIR11034; +MI0035700 seu-MIR11035; +MI0035701 seu-MIR11036; +MI0035702 seu-MIR11037; +MI0035703 seu-MIR11038; +MI0035704 seu-MIR11039; +MI0035705 seu-MIR11040; +MI0035706 seu-MIR11041; +MI0035707 seu-MIR11042; +MI0035708 seu-MIR11043; +MI0035709 seu-MIR11044; +MI0035710 seu-MIR11045; +MI0035711 seu-MIR11046; +MI0035712 seu-MIR11047; +MI0035713 seu-MIR11048; +MI0035714 seu-MIR11049; +MI0035715 eel-mir-11050; +MI0035716 eel-mir-11051; +MI0035717 eel-mir-11052; +MI0035718 eel-mir-11053; +MI0035719 eel-mir-8160; +MI0035720 eel-mir-11054; +MI0035721 eel-mir-11055; +MI0035722 eel-mir-7132; +MI0035723 eel-mir-11056; +MI0035724 eel-mir-11057; +MI0035725 eel-mir-11058; +MI0035726 eel-mir-11059; +MI0035727 eel-mir-11060; +MI0035728 eel-mir-11061; +MI0035729 eel-mir-11062; +MI0035730 eel-mir-11063; +MI0035731 eel-mir-11064; +MI0035732 eel-mir-7552-1; +MI0035733 eel-mir-7552-2; +MI0035734 eel-mir-11065; +MI0035735 lja-MIR11066; +MI0035736 lja-MIR7533c; +MI0035737 lja-MIR11067; +MI0035738 lja-MIR11068a; +MI0035739 lja-MIR11068b; +MI0035740 lja-MIR11068c; +MI0035741 lja-MIR11069; +MI0035742 lja-MIR11070; +MI0035743 lja-MIR11071; +MI0035744 lja-MIR11072a; +MI0035745 lja-MIR11073; +MI0035746 lja-MIR11074; +MI0035747 lja-MIR11075a; +MI0035748 lja-MIR11076; +MI0035749 lja-MIR11077a; +MI0035750 lja-MIR11078a; +MI0035751 lja-MIR11078b; +MI0035752 lja-MIR11078c; +MI0035753 lja-MIR11078d; +MI0035754 lja-MIR11079; +MI0035755 lja-MIR164; +MI0035756 lja-MIR11080; +MI0035757 lja-MIR11072c; +MI0035758 lja-MIR11072d; +MI0035759 lja-MIR11072e; +MI0035760 lja-MIR11072h; +MI0035761 lja-MIR11072f; +MI0035762 lja-MIR11072g; +MI0035763 lja-MIR11081; +MI0035764 lja-MIR11082a; +MI0035765 lja-MIR11082b; +MI0035766 lja-MIR11082c; +MI0035767 lja-MIR11082d; +MI0035768 lja-MIR11082e; +MI0035769 lja-MIR11082f; +MI0035770 lja-MIR11082g; +MI0035771 lja-MIR11082h; +MI0035772 lja-MIR11082i; +MI0035773 lja-MIR11082j; +MI0035774 lja-MIR11082k; +MI0035775 lja-MIR11083a; +MI0035776 lja-MIR11083b; +MI0035777 lja-MIR11083c; +MI0035778 lja-MIR11078e; +MI0035779 lja-MIR11072b; +MI0035780 lja-MIR11068d; +MI0035781 lja-MIR11072i; +MI0035782 lja-MIR11075b; +MI0035783 lja-MIR7526i; +MI0035784 lja-MIR7526j; +MI0035785 lja-MIR7526k; +MI0035786 lja-MIR11084; +MI0035787 lja-MIR11085; +MI0035788 lja-MIR11086; +MI0035789 lja-MIR11097c; +MI0035790 lja-MIR11087; +MI0035791 lja-MIR11088a; +MI0035792 lja-MIR11089a; +MI0035793 lja-MIR11068e; +MI0035794 lja-MIR11108c; +MI0035795 lja-MIR11090a; +MI0035796 lja-MIR11090b; +MI0035797 lja-MIR11090c; +MI0035798 lja-MIR11090d; +MI0035799 lja-MIR11091; +MI0035800 lja-MIR11092; +MI0035801 lja-MIR11093; +MI0035802 lja-MIR11089b; +MI0035803 lja-MIR11094; +MI0035804 lja-MIR11095; +MI0035805 lja-MIR11096a; +MI0035806 lja-MIR11096b; +MI0035807 lja-MIR11097a; +MI0035808 lja-MIR11108e; +MI0035809 lja-MIR11098; +MI0035810 lja-MIR11099; +MI0035811 lja-MIR11100; +MI0035812 lja-MIR11101a; +MI0035813 lja-MIR11101b; +MI0035814 lja-MIR11077b; +MI0035815 lja-MIR11102; +MI0035816 lja-MIR11103a; +MI0035817 lja-MIR7533d; +MI0035818 lja-MIR11077c; +MI0035819 lja-MIR11077d; +MI0035820 lja-MIR11104; +MI0035821 lja-MIR11105a; +MI0035822 lja-MIR11105b; +MI0035823 lja-MIR11105c; +MI0035824 lja-MIR11105d; +MI0035825 lja-MIR11106; +MI0035826 lja-MIR11107a; +MI0035827 lja-MIR11107b; +MI0035828 lja-MIR11107c; +MI0035829 lja-MIR7526l; +MI0035830 lja-MIR11082l; +MI0035831 lja-MIR11108a; +MI0035832 lja-MIR11108b; +MI0035833 lja-MIR11109; +MI0035834 lja-MIR11110a; +MI0035835 lja-MIR11110b; +MI0035836 lja-MIR477; +MI0035837 lja-MIR11111; +MI0035838 lja-MIR11112; +MI0035839 lja-MIR11097e; +MI0035840 lja-MIR11113; +MI0035841 lja-MIR11078f; +MI0035842 lja-MIR11114; +MI0035843 lja-MIR11108j; +MI0035844 lja-MIR11115; +MI0035845 lja-MIR11072j; +MI0035846 lja-MIR11116; +MI0035847 lja-MIR11097i; +MI0035848 lja-MIR11097g; +MI0035849 lja-MIR11097h; +MI0035850 lja-MIR11117a; +MI0035851 lja-MIR11117b; +MI0035852 lja-MIR11118; +MI0035853 lja-MIR11119; +MI0035854 lja-MIR11103b; +MI0035855 lja-MIR11103c; +MI0035856 lja-MIR11120; +MI0035857 lja-MIR398; +MI0035858 lja-MIR11121; +MI0035859 lja-MIR11122; +MI0035860 lja-MIR5287a; +MI0035861 lja-MIR11123; +MI0035862 lja-MIR11124; +MI0035863 lja-MIR11088b; +MI0035864 lja-MIR11108g; +MI0035865 lja-MIR11108h; +MI0035866 lja-MIR11108k; +MI0035867 lja-MIR11108l; +MI0035868 lja-MIR11125; +MI0035869 lja-MIR11097d; +MI0035870 lja-MIR11108s; +MI0035871 lja-MIR11126; +MI0035872 lja-MIR11097b; +MI0035873 lja-MIR11127; +MI0035874 lja-MIR11068f; +MI0035875 lja-MIR11128; +MI0035876 lja-MIR11129; +MI0035877 lja-MIR11108d; +MI0035878 lja-MIR168; +MI0035879 lja-MIR11130; +MI0035880 lja-MIR11131; +MI0035881 lja-MIR11108r; +MI0035882 lja-MIR11132; +MI0035883 lja-MIR11133; +MI0035884 lja-MIR11134; +MI0035885 lja-MIR11108m; +MI0035886 lja-MIR11108n; +MI0035887 lja-MIR11108t; +MI0035888 lja-MIR11108u; +MI0035889 lja-MIR11135a; +MI0035890 lja-MIR11135b; +MI0035891 lja-MIR11135c; +MI0035892 lja-MIR11136; +MI0035893 lja-MIR11137; +MI0035894 lja-MIR11138; +MI0035895 lja-MIR11139; +MI0035896 lja-MIR11082m; +MI0035897 lja-MIR11140; +MI0035898 lja-MIR11108x; +MI0035899 lja-MIR11108q; +MI0035900 lja-MIR11141; +MI0035901 lja-MIR11142; +MI0035902 lja-MIR11143; +MI0035903 lja-MIR11090e; +MI0035904 lja-MIR11144; +MI0035905 lja-MIR11075c; +MI0035906 lja-MIR11145a; +MI0035907 lja-MIR11145b; +MI0035908 lja-MIR11145c; +MI0035909 lja-MIR11146; +MI0035910 lja-MIR11147; +MI0035911 lja-MIR11083d; +MI0035912 lja-MIR11083e; +MI0035913 lja-MIR11083f; +MI0035914 lja-MIR11148; +MI0035915 lja-MIR11108i; +MI0035916 lja-MIR11149a; +MI0035917 lja-MIR5287b; +MI0035918 lja-MIR11108v; +MI0035919 lja-MIR11108f; +MI0035920 lja-MIR11103d; +MI0035921 lja-MIR395; +MI0035922 lja-MIR11150; +MI0035923 lja-MIR11151; +MI0035924 lja-MIR11152; +MI0035925 lja-MIR11153; +MI0035926 lja-MIR11154; +MI0035927 lja-MIR11155a; +MI0035928 lja-MIR1511; +MI0035929 lja-MIR11156; +MI0035930 lja-MIR11155b; +MI0035931 lja-MIR11149b; +MI0035932 lja-MIR11157; +MI0035933 lja-MIR11158; +MI0035934 lja-MIR11159; +MI0035935 lja-MIR11103e; +MI0035936 lja-MIR11160; +MI0035937 lja-MIR11161; +MI0035938 lja-MIR11162; +MI0035939 lja-MIR11163; +MI0035940 lja-MIR11145d; +MI0035941 lja-MIR11155d; +MI0035942 lja-MIR11089c; +MI0035943 lja-MIR11164; +MI0035944 lja-MIR11108w; +MI0035945 lja-MIR166; +MI0035946 lja-MIR11165; +MI0035947 lja-MIR11166; +MI0035948 lja-MIR11135d; +MI0035949 lja-MIR11167; +MI0035950 lja-MIR11168; +MI0035951 lja-MIR1120; +MI0035952 lja-MIR11169; +MI0035953 lja-MIR11170; +MI0035954 lja-MIR11108o; +MI0035955 lja-MIR11108p; +MI0035956 lja-MIR5287c; +MI0035957 lja-MIR11171; +MI0035958 lja-MIR11078g; +MI0035959 lja-MIR11172; +MI0035960 lja-MIR11155c; +MI0035961 lja-MIR11173; +MI0035962 lja-MIR11174; +MI0035963 lja-MIR11175; +MI0035964 lja-MIR11176; +MI0035965 lja-MIR11177; +MI0035966 lja-MIR11178; +MI0035967 lja-MIR11179; +MI0035968 lja-MIR11097f; +MI0035969 lja-MIR5287d; +MI0035970 lja-MIR11155e; +MI0035971 lja-MIR11180; +MI0035972 hsa-mir-11181; +MI0035973 dme-mir-11182; +MI0035974 gmo-mir-29b-1; +MI0035975 gmo-mir-722-1; +MI0035976 gmo-mir-187; +MI0035977 gmo-mir-23a-2; +MI0035978 gmo-mir-723-2; +MI0035979 gmo-mir-27b; +MI0035980 gmo-mir-458; +MI0035981 gmo-mir-301c; +MI0035982 gmo-mir-2188; +MI0035983 gmo-mir-124-3; +MI0035984 gmo-mir-218a-2; +MI0035985 gmo-mir-152; +MI0035986 gmo-mir-23b; +MI0035987 gmo-mir-221-2; +MI0035988 gmo-mir-489; +MI0035989 gmo-mir-199-4; +MI0035990 gmo-mir-144; +MI0035991 gmo-mir-204-3; +MI0035992 gmo-mir-222-2; +MI0035993 gmo-mir-221-1; +MI0035994 gmo-mir-21-2; +MI0035995 gmo-mir-100a; +MI0035996 gmo-mir-22b; +MI0035997 gmo-mir-217; +MI0035998 gmo-mir-1-1; +MI0035999 gmo-mir-375; +MI0036000 gmo-mir-142-2; +MI0036001 gmo-mir-24a-4; +MI0036002 gmo-mir-103-2; +MI0036003 gmo-mir-130a; +MI0036004 gmo-mir-135b; +MI0036005 gmo-mir-139; +MI0036006 gmo-mir-137-1; +MI0036007 gmo-mir-196b; +MI0036008 gmo-mir-155; +MI0036009 gmo-mir-430e-1; +MI0036010 gmo-mir-430b; +MI0036011 gmo-mir-122; +MI0036012 gmo-mir-223b; +MI0036013 gmo-mir-430c; +MI0036014 gmo-mir-8159; +MI0036015 gmo-mir-430f-1; +MI0036016 gmo-mir-128-1; +MI0036017 gmo-mir-29b-2; +MI0036018 gmo-mir-29a-2; +MI0036019 gmo-mir-129-3; +MI0036020 gmo-mir-9-1; +MI0036021 gmo-mir-301b; +MI0036022 gmo-mir-430e-2; +MI0036023 gmo-mir-430d; +MI0036024 gmo-mir-430f-2; +MI0036025 gmo-let-7a-3; +MI0036026 gmo-mir-202; +MI0036027 gmo-let-7a-4; +MI0036028 gmo-mir-128-2; +MI0036029 gmo-mir-23a-1; +MI0036030 gmo-mir-148; +MI0036031 gmo-mir-10a-1; +MI0036032 gmo-mir-181a-4; +MI0036033 gmo-mir-181c; +MI0036034 gmo-let-7a-2; +MI0036035 gmo-mir-125b-1; +MI0036036 gmo-mir-30e-1; +MI0036037 gmo-mir-30b; +MI0036038 gmo-mir-30d; +MI0036039 gmo-mir-30e-2; +MI0036040 gmo-mir-31; +MI0036041 gmo-mir-24a-1; +MI0036042 gmo-mir-27a-2; +MI0036043 gmo-mir-23a-3; +MI0036044 gmo-mir-200b; +MI0036045 gmo-mir-200a; +MI0036046 gmo-mir-429; +MI0036047 gmo-mir-728a; +MI0036048 gmo-mir-2187a; +MI0036049 gmo-mir-7133; +MI0036050 gmo-mir-462; +MI0036051 gmo-mir-731; +MI0036052 gmo-mir-219-1; +MI0036053 gmo-mir-24a-3; +MI0036054 gmo-mir-153b; +MI0036055 gmo-mir-101a; +MI0036056 gmo-mir-132-1; +MI0036057 gmo-mir-7a-1; +MI0036058 gmo-mir-1788; +MI0036059 gmo-mir-137-2; +MI0036060 gmo-mir-205-1; +MI0036061 gmo-mir-29a-1; +MI0036062 gmo-mir-124-4; +MI0036063 gmo-mir-135c-2; +MI0036064 gmo-mir-22a-1; +MI0036065 gmo-mir-181a-1; +MI0036066 gmo-mir-181b-1; +MI0036067 gmo-mir-205-2; +MI0036068 gmo-let-7j; +MI0036069 gmo-mir-7132b; +MI0036070 gmo-mir-8825; +MI0036071 gmo-mir-30c; +MI0036072 gmo-mir-30a; +MI0036073 gmo-mir-196a; +MI0036074 gmo-mir-33b-1; +MI0036075 gmo-mir-29d; +MI0036076 gmo-mir-29a-3; +MI0036077 gmo-mir-338-2; +MI0036078 gmo-mir-10a-2; +MI0036079 gmo-let-7f; +MI0036080 gmo-mir-124-5; +MI0036081 gmo-mir-16a; +MI0036082 gmo-mir-15b; +MI0036083 gmo-mir-725; +MI0036084 gmo-mir-9-4; +MI0036085 gmo-mir-9-5; +MI0036086 gmo-mir-203b; +MI0036087 gmo-mir-26a-3; +MI0036088 gmo-let-7h-2; +MI0036089 gmo-let-7g-1; +MI0036090 gmo-mir-11183; +MI0036091 gmo-mir-11184a; +MI0036092 gmo-mir-737; +MI0036093 gmo-mir-27a-1; +MI0036094 gmo-mir-24b; +MI0036095 gmo-mir-204-2; +MI0036096 gmo-mir-184-2; +MI0036097 gmo-mir-338-1; +MI0036098 gmo-mir-135c-1; +MI0036099 gmo-let-7e-1; +MI0036100 gmo-let-7a-5; +MI0036101 gmo-mir-9-7; +MI0036102 gmo-mir-210; +MI0036103 gmo-mir-734; +MI0036104 gmo-mir-19c; +MI0036105 gmo-mir-190b; +MI0036106 gmo-mir-10b; +MI0036107 gmo-mir-103-1; +MI0036108 gmo-mir-199-2; +MI0036109 gmo-mir-129-4; +MI0036110 gmo-mir-430e-3; +MI0036111 gmo-mir-430a; +MI0036112 gmo-mir-430g; +MI0036113 gmo-mir-125a-2; +MI0036114 gmo-let-7d-2; +MI0036115 gmo-mir-499; +MI0036116 gmo-mir-206; +MI0036117 gmo-mir-133b; +MI0036118 gmo-mir-7a-2; +MI0036119 gmo-let-7g-2; +MI0036120 gmo-let-7h-1; +MI0036121 gmo-mir-129-1; +MI0036122 gmo-mir-551; +MI0036123 gmo-mir-203a; +MI0036124 gmo-mir-26b; +MI0036125 gmo-mir-199-1; +MI0036126 gmo-mir-214-1; +MI0036127 gmo-mir-124-1; +MI0036128 gmo-mir-153a-1; +MI0036129 gmo-mir-153a-2; +MI0036130 gmo-mir-736; +MI0036131 gmo-mir-26a-2; +MI0036132 gmo-mir-455; +MI0036133 gmo-mir-126; +MI0036134 gmo-mir-9-3; +MI0036135 gmo-mir-7b; +MI0036136 gmo-mir-727; +MI0036137 gmo-mir-728b; +MI0036138 gmo-mir-218a-1; +MI0036139 gmo-mir-138-3; +MI0036140 gmo-mir-10c; +MI0036141 gmo-mir-219-2; +MI0036142 gmo-mir-218b; +MI0036143 gmo-mir-130b; +MI0036144 gmo-mir-101b; +MI0036145 gmo-mir-194b; +MI0036146 gmo-mir-181d; +MI0036147 gmo-mir-181a-3; +MI0036148 gmo-mir-9-6; +MI0036149 gmo-mir-7c; +MI0036150 gmo-mir-1338; +MI0036151 gmo-mir-25; +MI0036152 gmo-mir-19d; +MI0036153 gmo-mir-93; +MI0036154 gmo-mir-20a-3; +MI0036155 gmo-mir-1-2; +MI0036156 gmo-mir-460; +MI0036157 gmo-mir-7132a; +MI0036158 gmo-mir-190a-1; +MI0036159 gmo-mir-184-1; +MI0036160 gmo-mir-730; +MI0036161 gmo-mir-29c; +MI0036162 gmo-mir-135d; +MI0036163 gmo-mir-183; +MI0036164 gmo-mir-96; +MI0036165 gmo-mir-182; +MI0036166 gmo-mir-129-2; +MI0036167 gmo-mir-7a-3; +MI0036168 gmo-mir-15a; +MI0036169 gmo-mir-16b; +MI0036170 gmo-mir-9-2; +MI0036171 gmo-mir-99; +MI0036172 gmo-let-7c; +MI0036173 gmo-mir-125b-2; +MI0036174 gmo-let-7a-1; +MI0036175 gmo-mir-100b; +MI0036176 gmo-mir-22a-2; +MI0036177 gmo-mir-192; +MI0036178 gmo-mir-194a; +MI0036179 gmo-mir-212-1; +MI0036180 gmo-mir-132-2; +MI0036181 gmo-mir-454; +MI0036182 gmo-mir-301a; +MI0036183 gmo-mir-142-1; +MI0036184 gmo-mir-21-1; +MI0036185 gmo-mir-449a; +MI0036186 gmo-mir-449b; +MI0036187 gmo-mir-193a; +MI0036188 gmo-mir-365; +MI0036189 gmo-mir-24a-2; +MI0036190 gmo-let-7i-2; +MI0036191 gmo-mir-34; +MI0036192 gmo-mir-146; +MI0036193 gmo-mir-140; +MI0036194 gmo-mir-17-1; +MI0036195 gmo-mir-19a-1; +MI0036196 gmo-mir-20a-1; +MI0036197 gmo-mir-19b-2; +MI0036198 gmo-mir-204-1; +MI0036199 gmo-mir-10d; +MI0036200 gmo-mir-199-3; +MI0036201 gmo-mir-138-1; +MI0036202 gmo-mir-338-3; +MI0036203 gmo-mir-150; +MI0036204 gmo-mir-456; +MI0036205 gmo-mir-219-3; +MI0036206 gmo-mir-125a-1; +MI0036207 gmo-let-7d-1; +MI0036208 gmo-mir-26a-1; +MI0036209 gmo-mir-723-1; +MI0036210 gmo-mir-181a-2; +MI0036211 gmo-mir-181b-2; +MI0036212 gmo-let-7i-1; +MI0036213 gmo-mir-724-1; +MI0036214 gmo-mir-138-2; +MI0036215 gmo-mir-17-2; +MI0036216 gmo-mir-18a-1; +MI0036217 gmo-mir-19a-2; +MI0036218 gmo-mir-20a-2; +MI0036219 gmo-mir-19b-1; +MI0036220 gmo-mir-92-1; +MI0036221 gmo-mir-222-1; +MI0036222 gmo-mir-124-2; +MI0036223 gmo-mir-135a; +MI0036224 gmo-mir-216a; +MI0036225 gmo-mir-216b; +MI0036226 gmo-mir-27c; +MI0036227 gmo-mir-128-3; +MI0036228 gmo-mir-145; +MI0036229 gmo-mir-143; +MI0036230 gmo-mir-92-2; +MI0036231 gmo-mir-363; +MI0036232 gmo-mir-20b; +MI0036233 gmo-mir-18b; +MI0036234 gmo-mir-11185; +MI0036235 gmo-mir-11186; +MI0036236 gmo-mir-11187; +MI0036237 gmo-mir-11188; +MI0036238 gmo-mir-11189; +MI0036239 gmo-mir-11190; +MI0036240 gmo-mir-11191; +MI0036241 gmo-mir-11192; +MI0036242 gmo-mir-11193; +MI0036243 gmo-mir-10545; +MI0036244 gmo-mir-11194; +MI0036245 gmo-mir-11195; +MI0036246 gmo-mir-8160a; +MI0036247 gmo-mir-11196; +MI0036248 gmo-mir-11197; +MI0036249 gmo-mir-11198; +MI0036250 gmo-mir-11199; +MI0036251 gmo-mir-11200; +MI0036252 gmo-mir-11201; +MI0036253 gmo-mir-11202; +MI0036254 gmo-mir-11203; +MI0036255 gmo-mir-11204a; +MI0036256 gmo-mir-11205; +MI0036257 gmo-mir-11206; +MI0036258 gmo-mir-11207; +MI0036259 gmo-mir-10585; +MI0036260 gmo-mir-11208; +MI0036261 gmo-mir-11209; +MI0036262 gmo-mir-11210; +MI0036263 gmo-mir-11211; +MI0036264 gmo-mir-11212; +MI0036265 gmo-mir-11213; +MI0036266 gmo-mir-11214; +MI0036267 gmo-mir-7552-1; +MI0036268 gmo-mir-11215; +MI0036269 gmo-mir-11204b; +MI0036270 gmo-mir-11216; +MI0036271 gmo-mir-11217; +MI0036272 gmo-mir-11218; +MI0036273 gmo-mir-11219; +MI0036274 gmo-mir-11220a; +MI0036275 gmo-mir-11221; +MI0036276 gmo-mir-11222; +MI0036277 gmo-mir-11223; +MI0036278 gmo-mir-11224a; +MI0036279 gmo-mir-11225; +MI0036280 gmo-mir-11226; +MI0036281 gmo-mir-11227; +MI0036282 gmo-mir-11228; +MI0036283 gmo-mir-11229; +MI0036284 gmo-mir-11230; +MI0036285 gmo-mir-11231; +MI0036286 gmo-mir-11220b; +MI0036287 gmo-mir-11232; +MI0036288 gmo-mir-11233; +MI0036289 gmo-mir-11234; +MI0036290 gmo-mir-11235; +MI0036291 gmo-mir-11184b; +MI0036292 gmo-mir-11236; +MI0036293 gmo-mir-11237; +MI0036294 gmo-mir-8160b; +MI0036295 gmo-mir-11238; +MI0036296 gmo-mir-10544; +MI0036297 gmo-mir-11239; +MI0036298 gmo-mir-11240; +MI0036299 gmo-mir-11241; +MI0036300 gmo-mir-11242; +MI0036301 gmo-mir-11243; +MI0036302 gmo-mir-11244; +MI0036303 gmo-mir-11245; +MI0036304 gmo-mir-11246; +MI0036305 gmo-mir-11247; +MI0036306 gmo-mir-7550; +MI0036307 gmo-mir-11248; +MI0036308 gmo-mir-11249; +MI0036309 gmo-mir-11250; +MI0036310 gmo-mir-11251; +MI0036311 gmo-mir-11252; +MI0036312 gmo-mir-11204c; +MI0036313 gmo-mir-11253; +MI0036314 gmo-mir-11254; +MI0036315 gmo-mir-11255; +MI0036316 gmo-mir-11256; +MI0036317 gmo-mir-11257; +MI0036318 gmo-mir-11258; +MI0036319 gmo-mir-11259; +MI0036320 gmo-mir-11260; +MI0036321 gmo-mir-11261; +MI0036322 gmo-mir-11262; +MI0036323 gmo-mir-11263; +MI0036324 gmo-mir-11264; +MI0036325 gmo-mir-11265; +MI0036326 gmo-mir-11266a; +MI0036327 gmo-mir-11266b; +MI0036328 gmo-mir-11267; +MI0036329 gmo-mir-11268; +MI0036330 gmo-mir-11269; +MI0036331 gmo-mir-11270; +MI0036332 gmo-mir-11271; +MI0036333 gmo-mir-11272; +MI0036334 gmo-mir-11273; +MI0036335 gmo-mir-11274; +MI0036336 gmo-mir-11275; +MI0036337 gmo-mir-11276; +MI0036338 gmo-mir-11277; +MI0036339 gmo-mir-11278; +MI0036340 gmo-mir-11279; +MI0036341 gmo-mir-11280; +MI0036342 gmo-mir-11281; +MI0036343 gmo-mir-11204d; +MI0036344 gmo-mir-11282; +MI0036345 rno-mir-709; +MI0036346 fve-MIR11283; +MI0036347 fve-MIR11284; +MI0036348 fve-MIR11285; +MI0036349 fve-MIR1511; +MI0036350 fve-MIR156b; +MI0036351 fve-MIR156a; +MI0036352 fve-MIR156c; +MI0036353 fve-MIR156e; +MI0036354 fve-MIR156d; +MI0036355 fve-MIR156f; +MI0036356 fve-MIR156g; +MI0036357 fve-MIR156h; +MI0036358 fve-MIR156i; +MI0036359 fve-MIR156j; +MI0036360 fve-MIR159a; +MI0036361 fve-MIR159b; +MI0036362 fve-MIR159c; +MI0036363 fve-MIR160b; +MI0036364 fve-MIR160a; +MI0036365 fve-MIR162; +MI0036366 fve-MIR164a; +MI0036367 fve-MIR164b; +MI0036368 fve-MIR164c; +MI0036369 fve-MIR166e; +MI0036370 fve-MIR166a; +MI0036371 fve-MIR166b; +MI0036372 fve-MIR166d; +MI0036373 fve-MIR166c; +MI0036374 fve-MIR166f; +MI0036375 fve-MIR167d; +MI0036376 fve-MIR167b; +MI0036377 fve-MIR167c; +MI0036378 fve-MIR167a; +MI0036379 fve-MIR168; +MI0036380 fve-MIR169a; +MI0036381 fve-MIR169b; +MI0036382 fve-MIR169c; +MI0036383 fve-MIR169d; +MI0036384 fve-MIR169e; +MI0036385 fve-MIR169f; +MI0036386 fve-MIR171a; +MI0036387 fve-MIR171d; +MI0036388 fve-MIR171e; +MI0036389 fve-MIR171g; +MI0036390 fve-MIR171c; +MI0036391 fve-MIR171h; +MI0036392 fve-MIR171b; +MI0036393 fve-MIR171f; +MI0036394 fve-MIR172b; +MI0036395 fve-MIR172c; +MI0036396 fve-MIR172a; +MI0036397 fve-MIR2109; +MI0036398 fve-MIR2111c; +MI0036399 fve-MIR2111a; +MI0036400 fve-MIR2111b; +MI0036401 fve-MIR319; +MI0036402 fve-MIR3627a; +MI0036403 fve-MIR3627b; +MI0036404 fve-MIR390a; +MI0036405 fve-MIR390b; +MI0036406 fve-MIR393b; +MI0036407 fve-MIR393a; +MI0036408 fve-MIR394; +MI0036409 fve-MIR396b; +MI0036410 fve-MIR396a; +MI0036411 fve-MIR396c; +MI0036412 fve-MIR396d; +MI0036413 fve-MIR396e; +MI0036414 fve-MIR397; +MI0036415 fve-MIR399a; +MI0036416 fve-MIR399b; +MI0036417 fve-MIR408; +MI0036418 fve-MIR477a; +MI0036419 fve-MIR482a; +MI0036420 fve-MIR482b; +MI0036421 fve-MIR482c; +MI0036422 fve-MIR482d; +MI0036423 fve-MIR5225; +MI0036424 fve-MIR530; +MI0036425 fve-MIR535a; +MI0036426 fve-MIR535b; +MI0036427 fve-MIR827; +MI0036428 fve-MIR845; +MI0036429 fve-MIR11286; +MI0036430 fve-MIR11287; +MI0036431 fve-MIR11288c; +MI0036432 fve-MIR11289; +MI0036433 fve-MIR11290; +MI0036434 fve-MIR11288a; +MI0036435 fve-MIR11291; +MI0036436 fve-MIR11292; +MI0036437 fve-MIR11293; +MI0036438 fve-MIR11294; +MI0036439 fve-MIR11295; +MI0036440 fve-MIR11296; +MI0036441 fve-MIR11297; +MI0036442 fve-MIR11298; +MI0036443 fve-MIR11299; +MI0036444 fve-MIR11300; +MI0036445 fve-MIR11301; +MI0036446 fve-MIR11302; +MI0036447 fve-MIR11303; +MI0036448 fve-MIR11304; +MI0036449 fve-MIR11305; +MI0036450 fve-MIR11306; +MI0036451 fve-MIR11307; +MI0036452 fve-MIR11308; +MI0036453 fve-MIR11309; +MI0036454 fve-MIR11310; +MI0036455 fve-MIR11311; +MI0036456 fve-MIR11312; +MI0036457 fve-MIR477b; +MI0036458 fve-MIR11313; +MI0036459 fve-MIR11314; +MI0036460 fve-MIR11288b; +MI0036461 fve-MIR11288d; +MI0036462 fve-MIR11288e; +MI0036463 fve-MIR11315; +MI0036464 ppt-MIR11316; +MI0036465 ppt-MIR11317; +MI0036466 ppt-MIR11318; +MI0036467 ppt-MIR11319; +MI0036468 ppt-MIR11320; +MI0036469 ppt-MIR11321; +MI0036470 ppt-MIR11322; +MI0036471 ppt-MIR11323; +MI0036472 ppt-MIR11324; +MI0036473 ppt-MIR11325; +MI0036474 ppt-MIR11326; +MI0036475 ppt-MIR11327; +MI0036476 ppt-MIR11328; +MI0036477 ppt-MIR11329; +MI0036478 ppt-MIR11330; +MI0036479 ppt-MIR1027c; +MI0036480 ppt-MIR1034b; +MI0036481 ppt-MIR1049b; +MI0036482 cst-MIR11331; +MI0036483 cst-MIR11332; +MI0036484 cst-MIR11333; +MI0036485 cst-MIR11334; +MI0036486 cst-MIR11335; +MI0036487 osa-MIR11336; +MI0036488 osa-MIR11337; +MI0036489 osa-MIR11338; +MI0036490 osa-MIR11339; +MI0036491 osa-MIR11340; +MI0036492 osa-MIR11341; +MI0036493 osa-MIR11342; +MI0036494 osa-MIR11343; +MI0036495 osa-MIR11344; +MI0036496 osa-MIR2120b; +MI0036497 osa-MIR5801c; +MI0036498 osa-MIR6245b; +MI0036517 esi-MIR3455b; +MI0036547 esi-MIR3469b; +MI0036557 ssc-mir-33b; +MI0036558 hsa-mir-11399; +MI0036559 hsa-mir-11400; +MI0036560 hsa-mir-11401; +MI0036561 pab-MIR156a; +MI0036562 pab-MIR156b; +MI0036563 pab-MIR156c; +MI0036564 pab-MIR156d; +MI0036565 pab-MIR156e; +MI0036566 pab-MIR156f; +MI0036567 pab-MIR156g; +MI0036568 pab-MIR156h; +MI0036569 pab-MIR156i; +MI0036570 pab-MIR156j; +MI0036571 pab-MIR156k; +MI0036572 pab-MIR156l; +MI0036573 pab-MIR156m; +MI0036574 pab-MIR156n; +MI0036575 pab-MIR156p; +MI0036576 pab-MIR156q; +MI0036577 pab-MIR156r; +MI0036578 pab-MIR156s; +MI0036579 pab-MIR156t; +MI0036580 pab-MIR156u; +MI0036581 pab-MIR156v; +MI0036582 pab-MIR156w; +MI0036583 pab-MIR156x; +MI0036584 pab-MIR156y; +MI0036585 pab-MIR156ab; +MI0036586 pab-MIR156aa; +MI0036587 pab-MIR159a; +MI0036588 pab-MIR159b; +MI0036589 pab-MIR159c; +MI0036590 pab-MIR159d; +MI0036591 pab-MIR159e; +MI0036592 pab-MIR160c; +MI0036593 pab-MIR160d; +MI0036594 pab-MIR160e; +MI0036595 pab-MIR160f; +MI0036596 pab-MIR162a; +MI0036597 pab-MIR162b; +MI0036598 pab-MIR162c; +MI0036599 pab-MIR164a; +MI0036600 pab-MIR164b; +MI0036601 pab-MIR166c; +MI0036602 pab-MIR166d; +MI0036603 pab-MIR166e; +MI0036604 pab-MIR166f; +MI0036605 pab-MIR166g; +MI0036606 pab-MIR166h; +MI0036607 pab-MIR166i; +MI0036608 pab-MIR166j; +MI0036609 pab-MIR167a; +MI0036610 pab-MIR167b; +MI0036611 pab-MIR168a; +MI0036612 pab-MIR168b; +MI0036613 pab-MIR169a; +MI0036614 pab-MIR169b; +MI0036615 pab-MIR169c; +MI0036616 pab-MIR169d; +MI0036617 pab-MIR169e; +MI0036618 pab-MIR171a; +MI0036619 pab-MIR171b; +MI0036620 pab-MIR171c; +MI0036621 pab-MIR171d; +MI0036622 pab-MIR171e; +MI0036623 pab-MIR319a; +MI0036624 pab-MIR319b; +MI0036625 pab-MIR319c; +MI0036626 pab-MIR319d; +MI0036627 pab-MIR319e; +MI0036628 pab-MIR319f; +MI0036629 pab-MIR319g; +MI0036630 pab-MIR319h; +MI0036631 pab-MIR319j; +MI0036632 pab-MIR390a; +MI0036633 pab-MIR390b; +MI0036634 pab-MIR393a; +MI0036635 pab-MIR393b; +MI0036636 pab-MIR393c; +MI0036637 pab-MIR393d; +MI0036638 pab-MIR394a; +MI0036639 pab-MIR394b; +MI0036640 pab-MIR394c; +MI0036641 pab-MIR395a; +MI0036642 pab-MIR395b; +MI0036643 pab-MIR395c; +MI0036644 pab-MIR395d; +MI0036645 pab-MIR395e; +MI0036646 pab-MIR395f; +MI0036647 pab-MIR395g; +MI0036648 pab-MIR395h; +MI0036649 pab-MIR395i; +MI0036650 pab-MIR396d; +MI0036651 pab-MIR396e; +MI0036652 pab-MIR396f; +MI0036653 pab-MIR396g; +MI0036654 pab-MIR396h; +MI0036655 pab-MIR396i; +MI0036656 pab-MIR396j; +MI0036657 pab-MIR396k; +MI0036658 pab-MIR396l; +MI0036659 pab-MIR396m; +MI0036660 pab-MIR396n; +MI0036661 pab-MIR396o; +MI0036662 pab-MIR396p; +MI0036663 pab-MIR396q; +MI0036664 pab-MIR396r; +MI0036665 pab-MIR396s; +MI0036666 pab-MIR396t; +MI0036667 pab-MIR396u; +MI0036668 pab-MIR397a; +MI0036669 pab-MIR397c; +MI0036670 pab-MIR397d; +MI0036671 pab-MIR397e; +MI0036672 pab-MIR397f; +MI0036673 pab-MIR397g; +MI0036674 pab-MIR397h; +MI0036675 pab-MIR397i; +MI0036676 pab-MIR397j; +MI0036677 pab-MIR397k; +MI0036678 pab-MIR397l; +MI0036679 pab-MIR397m; +MI0036680 pab-MIR397n; +MI0036681 pab-MIR397o; +MI0036682 pab-MIR397p; +MI0036683 pab-MIR397q; +MI0036684 pab-MIR397r; +MI0036685 pab-MIR397s; +MI0036686 pab-MIR397t; +MI0036687 pab-MIR397u; +MI0036688 pab-MIR398a; +MI0036689 pab-MIR398b; +MI0036690 pab-MIR399a; +MI0036691 pab-MIR399b; +MI0036692 pab-MIR399c; +MI0036693 pab-MIR399d; +MI0036694 pab-MIR399e; +MI0036695 pab-MIR399f; +MI0036696 pab-MIR399g; +MI0036697 pab-MIR399h; +MI0036698 pab-MIR472; +MI0036699 pab-MIR1083; +MI0036700 pab-MIR1311b; +MI0036701 pab-MIR1312a; +MI0036702 pab-MIR1312b; +MI0036703 pab-MIR1314; +MI0036704 pab-MIR1313a; +MI0036705 pab-MIR1313b; +MI0036706 pab-MIR1313c; +MI0036707 pab-MIR1313d; +MI0036708 pab-MIR11402; +MI0036709 pab-MIR11403; +MI0036710 pab-MIR2111; +MI0036711 pab-MIR2950a; +MI0036712 pab-MIR2950b; +MI0036713 pab-MIR3627a; +MI0036714 pab-MIR3627b; +MI0036715 pab-MIR3695a; +MI0036716 pab-MIR3695b; +MI0036717 pab-MIR3695c; +MI0036718 pab-MIR3697a; +MI0036719 pab-MIR3697c; +MI0036720 pab-MIR3701a; +MI0036721 pab-MIR3701c; +MI0036722 pab-MIR3701d; +MI0036723 pab-MIR3701e; +MI0036724 pab-MIR3701j; +MI0036725 pab-MIR3701f; +MI0036726 pab-MIR3701g; +MI0036727 pab-MIR3701h; +MI0036728 pab-MIR3701i; +MI0036729 pab-MIR3710b; +MI0036730 pab-MIR3710c; +MI0036731 pab-MIR3710d; +MI0036732 pab-MIR3710e; +MI0036733 pab-MIR3710f; +MI0036734 pab-MIR3710g; +MI0036735 pab-MIR3710h; +MI0036736 pab-MIR11404; +MI0036737 pab-MIR408; +MI0036738 pab-MIR391a; +MI0036739 pab-MIR391b; +MI0036740 pab-MIR391c; +MI0036741 pab-MIR391d; +MI0036742 pab-MIR391e; +MI0036743 pab-MIR391f; +MI0036744 pab-MIR391g; +MI0036745 pab-MIR391h; +MI0036746 pab-MIR391i; +MI0036747 pab-MIR4414; +MI0036748 pab-MIR482t; +MI0036749 pab-MIR482u; +MI0036750 pab-MIR482v; +MI0036751 pab-MIR482e; +MI0036752 pab-MIR482f; +MI0036753 pab-MIR482g; +MI0036754 pab-MIR482i; +MI0036755 pab-MIR482k; +MI0036756 pab-MIR482l; +MI0036757 pab-MIR482m; +MI0036758 pab-MIR482n; +MI0036759 pab-MIR482o; +MI0036760 pab-MIR482p; +MI0036761 pab-MIR482r; +MI0036762 pab-MIR482s; +MI0036763 pab-MIR11405; +MI0036764 pab-MIR11406; +MI0036765 pab-MIR529a; +MI0036766 pab-MIR529b; +MI0036767 pab-MIR529c; +MI0036768 pab-MIR529d; +MI0036769 pab-MIR529e; +MI0036770 pab-MIR529f; +MI0036771 pab-MIR529g; +MI0036772 pab-MIR529h; +MI0036773 pab-MIR529i; +MI0036774 pab-MIR529j; +MI0036775 pab-MIR529k; +MI0036776 pab-MIR529l; +MI0036777 pab-MIR529m; +MI0036778 pab-MIR529n; +MI0036779 pab-MIR529o; +MI0036780 pab-MIR529p; +MI0036781 pab-MIR535a; +MI0036782 pab-MIR535b; +MI0036783 pab-MIR535c; +MI0036784 pab-MIR535d; +MI0036785 pab-MIR536a; +MI0036786 pab-MIR536b; +MI0036787 pab-MIR946a; +MI0036788 pab-MIR946b; +MI0036789 pab-MIR946c; +MI0036790 pab-MIR946d; +MI0036791 pab-MIR946e; +MI0036792 pab-MIR946f; +MI0036793 pab-MIR946g; +MI0036794 pab-MIR946h; +MI0036795 pab-MIR949b; +MI0036796 pab-MIR949a; +MI0036797 pab-MIR950b; +MI0036798 pab-MIR950c; +MI0036799 pab-MIR950d; +MI0036800 pab-MIR950e; +MI0036801 pab-MIR950f; +MI0036802 pab-MIR950g; +MI0036803 pab-MIR950h; +MI0036804 pab-MIR950i; +MI0036805 pab-MIR11407a; +MI0036806 pab-MIR11408a; +MI0036807 pab-MIR11409a; +MI0036808 pab-MIR159f; +MI0036809 pab-MIR159g; +MI0036810 pab-MIR159h; +MI0036811 pab-MIR159i; +MI0036812 pab-MIR11410; +MI0036813 pab-MIR11411a; +MI0036814 pab-MIR11412; +MI0036815 pab-MIR11413a; +MI0036816 pab-MIR11413b; +MI0036817 pab-MIR482h; +MI0036818 pab-MIR11414; +MI0036819 pab-MIR11415; +MI0036820 pab-MIR11416; +MI0036821 pab-MIR11417; +MI0036822 pab-MIR11418; +MI0036823 pab-MIR11419; +MI0036824 pab-MIR3627c; +MI0036825 pab-MIR11420a; +MI0036826 pab-MIR11421; +MI0036827 pab-MIR11422a; +MI0036828 pab-MIR11422b; +MI0036829 pab-MIR11423a; +MI0036830 pab-MIR11424; +MI0036831 pab-MIR11425a; +MI0036832 pab-MIR11425b; +MI0036833 pab-MIR11425c; +MI0036834 pab-MIR11425d; +MI0036835 pab-MIR11425e; +MI0036836 pab-MIR11425f; +MI0036837 pab-MIR11426a; +MI0036838 pab-MIR11426b; +MI0036839 pab-MIR11427a; +MI0036840 pab-MIR11427b; +MI0036841 pab-MIR11428; +MI0036842 pab-MIR11429a; +MI0036843 pab-MIR11429b; +MI0036844 pab-MIR11429c; +MI0036845 pab-MIR11429d; +MI0036846 pab-MIR11430; +MI0036847 pab-MIR11431a; +MI0036848 pab-MIR11432; +MI0036849 pab-MIR11433; +MI0036850 pab-MIR3627d; +MI0036851 pab-MIR11434; +MI0036852 pab-MIR3693j; +MI0036853 pab-MIR3693k; +MI0036854 pab-MIR11409b; +MI0036855 pab-MIR11409c; +MI0036856 pab-MIR11435; +MI0036857 pab-MIR11436a; +MI0036858 pab-MIR11436b; +MI0036859 pab-MIR11436c; +MI0036860 pab-MIR11436d; +MI0036861 pab-MIR11437; +MI0036862 pab-MIR11438; +MI0036863 pab-MIR11439; +MI0036864 pab-MIR11440a; +MI0036865 pab-MIR11440b; +MI0036866 pab-MIR11441a; +MI0036867 pab-MIR11441b; +MI0036868 pab-MIR11442; +MI0036869 pab-MIR11443; +MI0036870 pab-MIR11444; +MI0036871 pab-MIR11445a; +MI0036872 pab-MIR11445b; +MI0036873 pab-MIR11445c; +MI0036874 pab-MIR11446; +MI0036875 pab-MIR11447; +MI0036876 pab-MIR11448; +MI0036877 pab-MIR11449; +MI0036878 pab-MIR11450; +MI0036879 pab-MIR11451; +MI0036880 pab-MIR11452; +MI0036881 pab-MIR11453; +MI0036882 pab-MIR11454a; +MI0036883 pab-MIR11454b; +MI0036884 pab-MIR3710i; +MI0036885 pab-MIR11455; +MI0036886 pab-MIR11456; +MI0036887 pab-MIR11457; +MI0036888 pab-MIR11408b; +MI0036889 pab-MIR11409d; +MI0036890 pab-MIR11458; +MI0036891 pab-MIR11459; +MI0036892 pab-MIR11423b; +MI0036893 pab-MIR11423c; +MI0036894 pab-MIR11460; +MI0036895 pab-MIR11461; +MI0036896 pab-MIR949c; +MI0036897 pab-MIR11462; +MI0036898 pab-MIR11423d; +MI0036899 pab-MIR11423e; +MI0036900 pab-MIR11423f; +MI0036901 pab-MIR11423g; +MI0036902 pab-MIR11423h; +MI0036903 pab-MIR11423i; +MI0036904 pab-MIR11423j; +MI0036905 pab-MIR11423k; +MI0036906 pab-MIR11463; +MI0036907 pab-MIR11464a; +MI0036908 pab-MIR11465; +MI0036909 pab-MIR11466a; +MI0036910 pab-MIR11467a; +MI0036911 pab-MIR11467b; +MI0036912 pab-MIR11468; +MI0036913 pab-MIR11469; +MI0036914 pab-MIR11470; +MI0036915 pab-MIR11471; +MI0036916 pab-MIR11472; +MI0036917 pab-MIR11473; +MI0036918 pab-MIR11474; +MI0036919 pab-MIR11475; +MI0036920 pab-MIR11476a; +MI0036921 pab-MIR11476b; +MI0036922 pab-MIR11477; +MI0036923 pab-MIR11478; +MI0036924 pab-MIR11479; +MI0036925 pab-MIR11480; +MI0036926 pab-MIR11420b; +MI0036927 pab-MIR11411b; +MI0036928 pab-MIR11481a; +MI0036929 pab-MIR3627g; +MI0036930 pab-MIR3627h; +MI0036931 pab-MIR3627i; +MI0036932 pab-MIR11482; +MI0036933 pab-MIR11483; +MI0036934 pab-MIR11431b; +MI0036935 pab-MIR11431c; +MI0036936 pab-MIR11408c; +MI0036937 pab-MIR11484; +MI0036938 pab-MIR3693h; +MI0036939 pab-MIR3693i; +MI0036940 pab-MIR1312c; +MI0036941 pab-MIR11485; +MI0036942 pab-MIR11486; +MI0036943 pab-MIR11487a; +MI0036944 pab-MIR11488; +MI0036945 pab-MIR11489; +MI0036946 pab-MIR11490a; +MI0036947 pab-MIR11490b; +MI0036948 pab-MIR11491; +MI0036949 pab-MIR11492; +MI0036950 pab-MIR11493a; +MI0036951 pab-MIR11493b; +MI0036952 pab-MIR11493c; +MI0036953 pab-MIR11494; +MI0036954 pab-MIR11495; +MI0036955 pab-MIR11496; +MI0036956 pab-MIR11497; +MI0036957 pab-MIR11498a; +MI0036958 pab-MIR11499a; +MI0036959 pab-MIR11499b; +MI0036960 pab-MIR11500; +MI0036961 pab-MIR11501; +MI0036962 pab-MIR11502; +MI0036963 pab-MIR11503; +MI0036964 pab-MIR11504; +MI0036965 pab-MIR11505; +MI0036966 pab-MIR11506; +MI0036967 pab-MIR11507; +MI0036968 pab-MIR11508; +MI0036969 pab-MIR3693b; +MI0036970 pab-MIR3693c; +MI0036971 pab-MIR11498b; +MI0036972 pab-MIR11498c; +MI0036973 pab-MIR11509; +MI0036974 pab-MIR11510; +MI0036975 pab-MIR11511; +MI0036976 pab-MIR11466b; +MI0036977 pab-MIR11512; +MI0036978 pab-MIR11513; +MI0036979 pab-MIR11481b; +MI0036980 pab-MIR11481c; +MI0036981 pab-MIR11514; +MI0036982 pab-MIR11407b; +MI0036983 pab-MIR11515a; +MI0036984 pab-MIR11516; +MI0036985 pab-MIR11423l; +MI0036986 pab-MIR11517; +MI0036987 pab-MIR11420c; +MI0036988 pab-MIR11518; +MI0036989 pab-MIR11519; +MI0036990 pab-MIR11520; +MI0036991 pab-MIR11466c; +MI0036992 pab-MIR11466d; +MI0036993 pab-MIR11521; +MI0036994 pab-MIR11522; +MI0036995 pab-MIR11523a; +MI0036996 pab-MIR11523b; +MI0036997 pab-MIR11523c; +MI0036998 pab-MIR11523d; +MI0036999 pab-MIR11524; +MI0037000 pab-MIR11525a; +MI0037001 pab-MIR11525b; +MI0037002 pab-MIR11526; +MI0037003 pab-MIR11527; +MI0037004 pab-MIR11528; +MI0037005 pab-MIR11529a; +MI0037006 pab-MIR11529b; +MI0037007 pab-MIR11529c; +MI0037008 pab-MIR11530; +MI0037009 pab-MIR11531; +MI0037010 pab-MIR11411c; +MI0037011 pab-MIR11411d; +MI0037012 pab-MIR11464b; +MI0037013 pab-MIR11532; +MI0037014 pab-MIR482w; +MI0037015 pab-MIR482x; +MI0037016 pab-MIR11487b; +MI0037017 pab-MIR11487c; +MI0037018 pab-MIR11533a; +MI0037019 pab-MIR11534; +MI0037020 pab-MIR11535; +MI0037021 pab-MIR11536; +MI0037022 pab-MIR11533b; +MI0037023 pab-MIR11537; +MI0037024 pab-MIR11538; +MI0037025 pab-MIR11539a; +MI0037026 pab-MIR11540; +MI0037027 pab-MIR11541; +MI0037028 pab-MIR3627f; +MI0037029 pab-MIR11542; +MI0037030 pab-MIR11539b; +MI0037031 pab-MIR3627e; +MI0037032 pab-MIR11543; +MI0037033 pab-MIR11544; +MI0037034 pab-MIR3627j; +MI0037035 pab-MIR11545; +MI0037036 pab-MIR11546a; +MI0037037 pab-MIR11546b; +MI0037038 pab-MIR11546c; +MI0037039 pab-MIR11546d; +MI0037040 pab-MIR11546e; +MI0037041 pab-MIR11547; +MI0037042 pab-MIR11548; +MI0037043 pab-MIR11549; +MI0037044 pab-MIR11550; +MI0037045 pab-MIR11551a; +MI0037046 pab-MIR11552; +MI0037047 pab-MIR11553; +MI0037048 pab-MIR11554; +MI0037049 pab-MIR11409e; +MI0037050 pab-MIR11555; +MI0037051 pab-MIR11556; +MI0037052 pab-MIR11557; +MI0037053 pab-MIR11558; +MI0037054 pab-MIR11559; +MI0037055 pab-MIR11466e; +MI0037056 pab-MIR11560; +MI0037057 pab-MIR11561; +MI0037058 pab-MIR11562a; +MI0037059 pab-MIR11562b; +MI0037060 pab-MIR11562c; +MI0037061 pab-MIR11563; +MI0037062 pab-MIR3693d; +MI0037063 pab-MIR3693e; +MI0037064 pab-MIR3693f; +MI0037065 pab-MIR3693g; +MI0037066 pab-MIR11546f; +MI0037067 pab-MIR11564a; +MI0037068 pab-MIR11564b; +MI0037069 pab-MIR11565; +MI0037070 pab-MIR11409f; +MI0037071 pab-MIR11566; +MI0037072 pab-MIR11409g; +MI0037073 pab-MIR11567; +MI0037074 pab-MIR11568; +MI0037075 pab-MIR11569; +MI0037076 pab-MIR11570a; +MI0037077 pab-MIR11570b; +MI0037078 pab-MIR11570c; +MI0037079 pab-MIR11571; +MI0037080 pab-MIR11572; +MI0037081 pab-MIR11573a; +MI0037082 pab-MIR11573b; +MI0037083 pab-MIR11420d; +MI0037084 pab-MIR11420e; +MI0037085 pab-MIR11420f; +MI0037086 pab-MIR11420g; +MI0037087 pab-MIR11574; +MI0037088 pab-MIR11515b; +MI0037089 pab-MIR11575; +MI0037090 pab-MIR11576; +MI0037091 pab-MIR11577; +MI0037092 pab-MIR11578; +MI0037093 pab-MIR11579; +MI0037094 pab-MIR11580; +MI0037095 pab-MIR11581; +MI0037096 pab-MIR11582; +MI0037097 pab-MIR11551b; +MI0037098 pab-MIR11583a; +MI0037099 pab-MIR11583b; +MI0037100 fhe-bantam; +MI0037101 fhe-mir-1; +MI0037102 fhe-mir-61; +MI0037103 fhe-mir-190; +MI0037104 fhe-mir-219; +MI0037105 fhe-mir-745a; +MI0037106 fhe-mir-750; +MI0037107 fhe-mir-2a; +MI0037108 fhe-mir-2b; +MI0037109 fhe-mir-2c; +MI0037110 fhe-mir-2d; +MI0037111 fhe-mir-2e; +MI0037112 fhe-mir-2f; +MI0037113 fhe-mir-8; +MI0037114 fhe-mir-9; +MI0037115 fhe-mir-10; +MI0037116 fhe-mir-31; +MI0037117 fhe-mir-36a; +MI0037118 fhe-mir-46; +MI0037119 fhe-mir-745b; +MI0037120 fhe-mir-71a; +MI0037121 fhe-mir-71b; +MI0037122 fhe-mir-87; +MI0037123 fhe-mir-96; +MI0037124 fhe-mir-124; +MI0037125 fhe-mir-125a; +MI0037126 fhe-mir-125b; +MI0037127 fhe-mir-277; +MI0037128 fhe-mir-307; +MI0037129 fhe-mir-3479; +MI0037130 fhe-let-7; +MI0037131 fhe-mir-7; +MI0037132 fhe-mir-2162; +MI0037133 fhe-mir-11584; +MI0037134 fhe-mir-11585; +MI0037135 fhe-mir-11586; +MI0037136 fhe-mir-11587; +MI0037137 fhe-mir-36b; +MI0037138 apl-mir-11588; +MI0037139 apl-mir-11589; +MI0037140 apl-mir-11590; +MI0037141 apl-mir-11591; +MI0037142 pab-MIR3698b; +MI0037143 pab-MIR482j; +MI0037144 pab-MIR828; +MI0037145 pab-MIR858a; +MI0037146 pab-MIR858b; +MI0037147 pab-MIR156z; +MI0037148 pab-MIR156o; +MI0037149 pab-MIR159j; +MI0037150 pab-MIR159k; +MI0037151 pab-MIR319i; +MI0037152 pab-MIR319k; +MI0037153 pab-MIR319l; +MI0037154 pab-MIR319m; +MI0037155 pab-MIR319n; +MI0037156 pab-MIR482q; +MI0037157 bib-mir-2788; +MI0037158 bib-mir-193; +MI0037159 cas-MIR158b; +MI0037160 cas-MIR827b; +MI0037161 cas-MIR159c; +MI0037162 cas-MIR156a; +MI0037163 cas-MIR156b; +MI0037164 cas-MIR156c; +MI0037165 cas-MIR156d; +MI0037166 cas-MIR156e; +MI0037167 cas-MIR156f; +MI0037168 cas-MIR156g; +MI0037169 cas-MIR156h; +MI0037170 cas-MIR156i; +MI0037171 cas-MIR156j; +MI0037172 cas-MIR156k; +MI0037173 cas-MIR157a; +MI0037174 cas-MIR157b; +MI0037175 cas-MIR157c; +MI0037176 cas-MIR157d; +MI0037177 cas-MIR158a; +MI0037178 cas-MIR159b; +MI0037179 cas-MIR159a; +MI0037180 cas-MIR160a; +MI0037181 cas-MIR160b; +MI0037182 cas-MIR161; +MI0037183 cas-MIR162a; +MI0037184 cas-MIR164; +MI0037185 cas-MIR165a; +MI0037186 cas-MIR165b; +MI0037187 cas-MIR166a; +MI0037188 cas-MIR166b; +MI0037189 cas-MIR166c; +MI0037190 cas-MIR166d; +MI0037191 cas-MIR166e; +MI0037192 cas-MIR166f; +MI0037193 cas-MIR167a; +MI0037194 cas-MIR167b; +MI0037195 cas-MIR167c; +MI0037196 cas-MIR168; +MI0037197 cas-MIR169a; +MI0037198 cas-MIR169b; +MI0037199 cas-MIR169c; +MI0037200 cas-MIR169d; +MI0037201 cas-MIR169e; +MI0037202 cas-MIR169f; +MI0037203 cas-MIR169g; +MI0037204 cas-MIR170; +MI0037205 cas-MIR171a; +MI0037206 cas-MIR171b; +MI0037207 cas-MIR171c; +MI0037208 cas-MIR172a; +MI0037209 cas-MIR172b; +MI0037210 cas-MIR172c; +MI0037211 cas-MIR172d; +MI0037212 cas-MIR173; +MI0037213 cas-MIR319a; +MI0037214 cas-MIR319b; +MI0037215 cas-MIR319c; +MI0037216 cas-MIR390a; +MI0037217 cas-MIR390b; +MI0037218 cas-MIR393; +MI0037219 cas-MIR394; +MI0037220 cas-MIR395a; +MI0037221 cas-MIR395b; +MI0037222 cas-MIR395c; +MI0037223 cas-MIR395d; +MI0037224 cas-MIR396a; +MI0037225 cas-MIR396b; +MI0037226 cas-MIR397; +MI0037227 cas-MIR398a; +MI0037228 cas-MIR398b; +MI0037229 cas-MIR399a; +MI0037230 cas-MIR399b; +MI0037231 cas-MIR400; +MI0037232 cas-MIR403; +MI0037233 cas-MIR408; +MI0037234 cas-MIR472; +MI0037235 cas-MIR825; +MI0037236 cas-MIR827a; +MI0037237 cas-MIR828; +MI0037238 cas-MIR845; +MI0037239 cas-MIR857; +MI0037240 cas-MIR858; +MI0037241 cas-MIR860; +MI0037242 cas-MIR2111a; +MI0037243 cas-MIR2111b; +MI0037244 cas-MIR3435; +MI0037245 cas-MIR5139; +MI0037246 cas-MIR8171; +MI0037247 cas-MIR9560; +MI0037248 cas-MIR11592; +MI0037249 cas-MIR162b; +MI0037250 bdo-mir-2c; +MI0037251 bdo-mir-307; +MI0037252 bdo-mir-996; +MI0037253 bdo-mir-929; +MI0037254 bdo-mir-932; +MI0037255 bdo-mir-998; +MI0037256 bdo-mir-988; +MI0037257 bdo-mir-971; +MI0037258 bdo-mir-283; +MI0037259 bdo-mir-263a; +MI0037260 bdo-mir-193; +MI0037261 bdo-mir-9b; +MI0037262 bdo-mir-92b; +MI0037263 bdo-mir-100; +MI0037264 bdo-mir-8; +MI0037265 bdo-mir-276b; +MI0037266 bdo-mir-7; +MI0037267 bdo-mir-315; +MI0037268 bdo-mir-993; +MI0037269 bdo-let-7; +MI0037270 bdo-mir-276a; +MI0037271 bdo-mir-275; +MI0037272 bdo-mir-124; +MI0037273 bdo-mir-iab-4; +MI0037274 bdo-mir-9c; +MI0037275 bdo-mir-999; +MI0037276 bdo-mir-981; +MI0037277 bdo-mir-970; +MI0037278 bdo-mir-79; +MI0037279 bdo-mir-305; +MI0037280 bdo-mir-2a-1; +MI0037281 bdo-mir-263b; +MI0037282 bdo-mir-219; +MI0037283 bdo-mir-190; +MI0037284 bdo-mir-184; +MI0037285 bdo-mir-137; +MI0037286 bdo-mir-13b; +MI0037287 bdo-mir-13a; +MI0037288 bdo-mir-125; +MI0037289 bdo-mir-1000; +MI0037290 bdo-mir-10; +MI0037291 bdo-mir-1; +MI0037292 bdo-bantam; +MI0037293 bdo-mir-2b-2; +MI0037294 bdo-mir-2a-2; +MI0037295 bdo-mir-281; +MI0037296 bdo-mir-iab-8; +MI0037297 bdo-mir-5b-1; +MI0037298 bdo-mir-4; +MI0037299 bdo-mir-5a; +MI0037300 bdo-mir-12; +MI0037301 bdo-mir-927; +MI0037302 bdo-mir-87; +MI0037303 bdo-mir-308; +MI0037304 bdo-mir-994; +MI0037305 bdo-mir-5b-2; +MI0037306 bdo-mir-316; +MI0037307 bdo-mir-284; +MI0037308 bdo-mir-282; +MI0037309 bdo-mir-210; +MI0037310 bdo-mir-14; +MI0037311 bdo-mir-286; +MI0037312 bdo-mir-11; +MI0037313 bdo-mir-252; +MI0037314 bdo-mir-995; +MI0037315 bdo-mir-318; +MI0037316 bdo-mir-375; +MI0037317 bdo-mir-2b-1; +MI0037318 bdo-mir-306; +MI0037319 bdo-mir-958; +MI0037320 bdo-mir-11593; +MI0037321 bdo-mir-304; +MI0037322 bdo-mir-11594; +MI0037323 bdo-mir-980; +MI0037324 bdo-mir-11595; +MI0037325 bdo-mir-6; +MI0037326 bdo-mir-309b; +MI0037327 bdo-mir-309a; +MI0037328 bdo-mir-11596; +MI0037329 bdo-mir-11597; +MI0037330 pla-MIR11598; +MI0037331 pla-MIR11599; +MI0037332 pla-MIR11600; +MI0037333 pla-MIR11601; +MI0037334 pla-MIR11602; +MI0037335 pla-MIR11603; +MI0037336 pla-MIR11604; +MI0037337 pla-MIR11605; +MI0037338 pla-MIR11606; +MI0037339 pla-MIR11607; +MI0037340 pla-MIR11608; +MI0037341 pla-MIR11609; +MI0037342 pla-MIR11610; +MI0037343 pla-MIR11611; +MI0037344 pla-MIR11612; +MI0037345 tca-mir-3851m-1; +MI0037346 tca-mir-11614; +MI0037347 tca-mir-11615; +MI0037348 tca-mir-3806b-1; +MI0037349 tca-mir-3806b-2; +MI0037350 tca-mir-3806b-3; +MI0037351 tca-mir-3806b-4; +MI0037352 tca-mir-11617b; +MI0037353 tca-mir-3851l-1; +MI0037354 tca-mir-11617c; +MI0037355 tca-mir-3836c-1; +MI0037356 tca-mir-3851n-1; +MI0037357 tca-mir-11617a-1; +MI0037358 tca-mir-3836d; +MI0037359 tca-mir-3836c-2; +MI0037360 tca-mir-11618a-1; +MI0037361 tca-mir-3851o-2; +MI0037362 tca-mir-3851k-1; +MI0037363 tca-mir-11618b-1; +MI0037364 tca-mir-3836e; +MI0037365 tca-mir-11619e; +MI0037366 tca-mir-3836c-3; +MI0037367 tca-mir-11618a-4; +MI0037368 tca-mir-3851o-1; +MI0037369 tca-mir-3851l-2; +MI0037370 tca-mir-11618b-2; +MI0037371 tca-mir-3836f; +MI0037372 tca-mir-11619f; +MI0037373 tca-mir-11620; +MI0037374 tca-mir-3851k-2; +MI0037375 tca-mir-11619b; +MI0037376 tca-mir-11621; +MI0037377 tca-mir-11619a-3; +MI0037378 tca-mir-11617a-2; +MI0037379 tca-mir-11622; +MI0037380 tca-mir-11623; +MI0037381 tca-mir-3851g-1; +MI0037382 tca-mir-11624a-1; +MI0037383 tca-mir-11624a-2; +MI0037384 tca-mir-11624a-3; +MI0037385 tca-mir-309c; +MI0037386 tca-mir-11624b-1; +MI0037387 tca-mir-3851h; +MI0037388 tca-mir-11624d; +MI0037389 tca-mir-3851i; +MI0037390 tca-mir-3851j; +MI0037391 tca-mir-11625a; +MI0037392 tca-mir-11626a; +MI0037393 tca-mir-11626b; +MI0037394 tca-mir-11624c; +MI0037395 tca-mir-11627; +MI0037396 tca-mir-11628; +MI0037397 tca-mir-11629; +MI0037398 tca-mir-11630; +MI0037399 tca-mir-3851n-2; +MI0037400 tca-mir-3851l-3; +MI0037401 tca-mir-3851k-3; +MI0037402 tca-mir-11618b-3; +MI0037403 tca-mir-11618a-3; +MI0037404 tca-mir-3851m-3; +MI0037405 tca-mir-11617a-3; +MI0037406 tca-mir-11619a-1; +MI0037407 tca-mir-3851m-2; +MI0037408 tca-mir-11618b-4; +MI0037409 tca-mir-3851k-4; +MI0037410 tca-mir-11619a-2; +MI0037411 tca-mir-11617a-4; +MI0037412 tca-mir-11618a-2; +MI0037413 tca-mir-971b; +MI0037414 tca-mir-11619c; +MI0037415 tca-mir-11619d; +MI0037416 tca-mir-3851q; +MI0037417 tca-mir-11625b; +MI0037418 tca-mir-3851g-2; +MI0037419 tca-mir-11631; +MI0037420 tca-mir-3858a-2; +MI0037421 tca-mir-3851d-2; +MI0037422 tca-mir-3858b; +MI0037423 tca-mir-11632; +MI0037424 tca-mir-11633; +MI0037425 tca-mir-3836g-1; +MI0037426 tca-mir-3851m-4; +MI0037427 tca-mir-3851r; +MI0037428 tca-mir-3836c-4; +MI0037429 tca-mir-11634; +MI0037430 tca-mir-3836c-5; +MI0037431 tca-mir-11635; +MI0037432 tca-mir-11636; +MI0037433 tca-mir-3806c; +MI0037434 tca-mir-11637; +MI0037435 tca-mir-11638; +MI0037436 tca-mir-3836h; +MI0037437 tca-mir-11639; +MI0037438 tca-mir-11617d-1; +MI0037439 tca-mir-11617e; +MI0037440 tca-mir-11617f-1; +MI0037441 tca-mir-3836i-1; +MI0037442 tca-mir-11617f-2; +MI0037443 tca-mir-3836i-2; +MI0037444 tca-mir-11641; +MI0037445 tca-mir-276b; +MI0037446 tca-mir-3851g-3; +MI0037447 tca-mir-11642; +MI0037448 tca-mir-11624b-2; +MI0037449 tca-mir-11643; +MI0037450 tca-mir-6016b; +MI0037451 tca-mir-11644; +MI0037452 tca-mir-307b; +MI0037453 tca-mir-927c; +MI0037454 tca-mir-11645; +MI0037455 tca-mir-11646; +MI0037456 tca-mir-11647; +MI0037457 tca-mir-11648; +MI0037458 tca-mir-3851p; +MI0037459 tca-mir-11617d-2; +MI0037460 tca-mir-3836j; +MI0037461 tca-mir-11617d-3; +MI0037462 tca-mir-11649; +MI0037463 tca-mir-11650; +MI0037464 dqu-bantam; +MI0037465 dqu-let-7; +MI0037466 dqu-iab-4; +MI0037467 dqu-mir-1a; +MI0037468 dqu-mir-1b; +MI0037469 dqu-mir-2a; +MI0037470 dqu-mir-2b; +MI0037471 dqu-mir-7; +MI0037472 dqu-mir-8; +MI0037473 dqu-mir-9; +MI0037474 dqu-mir-10; +MI0037475 dqu-mir-11; +MI0037476 dqu-mir-12; +MI0037477 dqu-mir-13a; +MI0037478 dqu-mir-13b; +MI0037479 dqu-mir-14; +MI0037480 dqu-mir-29; +MI0037481 dqu-mir-31; +MI0037482 dqu-mir-33; +MI0037483 dqu-mir-34; +MI0037484 dqu-mir-71; +MI0037485 dqu-mir-79; +MI0037486 dqu-mir-87; +MI0037487 dqu-mir-92a-1; +MI0037488 dqu-mir-92a-2; +MI0037489 dqu-mir-92b; +MI0037490 dqu-mir-92c; +MI0037491 dqu-mir-100; +MI0037492 dqu-mir-124; +MI0037493 dqu-mir-125; +MI0037494 dqu-mir-133; +MI0037495 dqu-mir-137; +MI0037496 dqu-mir-184; +MI0037497 dqu-mir-190; +MI0037498 dqu-mir-193; +MI0037499 dqu-mir-210; +MI0037500 dqu-mir-219; +MI0037501 dqu-mir-252a; +MI0037502 dqu-mir-252b; +MI0037503 dqu-mir-263a; +MI0037504 dqu-mir-263b; +MI0037505 dqu-mir-275; +MI0037506 dqu-mir-276; +MI0037507 dqu-mir-277; +MI0037508 dqu-mir-278; +MI0037509 dqu-mir-279a; +MI0037510 dqu-mir-279b; +MI0037511 dqu-mir-279c; +MI0037512 dqu-mir-281; +MI0037513 dqu-mir-282; +MI0037514 dqu-mir-283; +MI0037515 dqu-mir-305; +MI0037516 dqu-mir-306; +MI0037517 dqu-mir-307; +MI0037518 dqu-mir-315; +MI0037519 dqu-mir-316; +MI0037520 dqu-mir-317; +MI0037521 dqu-mir-375; +MI0037522 dqu-mir-750; +MI0037523 dqu-mir-927a; +MI0037524 dqu-mir-927b; +MI0037525 dqu-mir-929; +MI0037526 dqu-mir-932; +MI0037527 dqu-mir-965; +MI0037528 dqu-mir-971; +MI0037529 dqu-mir-980; +MI0037530 dqu-mir-981; +MI0037531 dqu-mir-993; +MI0037532 dqu-mir-995; +MI0037533 dqu-mir-996; +MI0037534 dqu-mir-1000; +MI0037535 dqu-mir-1175; +MI0037536 dqu-mir-2765; +MI0037537 dqu-mir-2788; +MI0037538 dqu-mir-2796; +MI0037539 dqu-mir-11651; +MI0037540 dqu-mir-3477; +MI0037541 dqu-mir-3715; +MI0037542 dqu-mir-3759; +MI0037543 dqu-mir-3770; +MI0037544 dqu-mir-3782; +MI0037545 dqu-mir-3783; +MI0037546 dqu-mir-3785; +MI0037547 dqu-mir-3786; +MI0037548 dqu-mir-6001; +MI0037549 dqu-mir-6037; +MI0037550 dqu-mir-6038; +MI0037551 dqu-mir-6039; +MI0037552 dqu-mir-6060; +MI0037553 dqu-mir-6065; +MI0037554 dqu-mir-6067; +MI0037555 dqu-mir-11652; +MI0037556 dqu-mir-11653; +MI0037557 dqu-mir-11654; +MI0037558 dqu-mir-11655; +MI0037559 dqu-mir-11656; +MI0037560 dqu-mir-11657; +MI0037561 dqu-mir-11658; +MI0037562 dqu-mir-11659; +MI0037563 dqu-mir-11660; +MI0037564 dqu-mir-11661; +MI0037565 dqu-mir-11662; +MI0037566 pca-bantam; +MI0037567 pca-let-7; +MI0037568 pca-iab-4; +MI0037569 pca-mir-1; +MI0037570 pca-mir-7; +MI0037571 pca-mir-8; +MI0037572 pca-mir-9; +MI0037573 pca-mir-11; +MI0037574 pca-mir-12; +MI0037575 pca-mir-13a; +MI0037576 pca-mir-13b; +MI0037577 pca-mir-14; +MI0037578 pca-mir-29; +MI0037579 pca-mir-31; +MI0037580 pca-mir-33; +MI0037581 pca-mir-34; +MI0037582 pca-mir-71; +MI0037583 pca-mir-92c; +MI0037584 pca-mir-100; +MI0037585 pca-mir-124; +MI0037586 pca-mir-133; +MI0037587 pca-mir-137; +MI0037588 pca-mir-184; +MI0037589 pca-mir-190; +MI0037590 pca-mir-210; +MI0037591 pca-mir-219; +MI0037592 pca-mir-252; +MI0037593 pca-mir-263b; +MI0037594 pca-mir-275; +MI0037595 pca-mir-276; +MI0037596 pca-mir-277; +MI0037597 pca-mir-278; +MI0037598 pca-mir-279b; +MI0037599 pca-mir-279c; +MI0037600 pca-mir-281; +MI0037601 pca-mir-282; +MI0037602 pca-mir-283; +MI0037603 pca-mir-305; +MI0037604 pca-mir-306; +MI0037605 pca-mir-315; +MI0037606 pca-mir-316; +MI0037607 pca-mir-317; +MI0037608 pca-mir-750; +MI0037609 pca-mir-927a; +MI0037610 pca-mir-927b; +MI0037611 pca-mir-929; +MI0037612 pca-mir-932; +MI0037613 pca-mir-965; +MI0037614 pca-mir-971; +MI0037615 pca-mir-980; +MI0037616 pca-mir-981; +MI0037617 pca-mir-995; +MI0037618 pca-mir-1000; +MI0037619 pca-mir-1175; +MI0037620 pca-mir-2765; +MI0037621 pca-mir-2796; +MI0037622 pca-mir-3049; +MI0037623 pca-mir-3736; +MI0037624 pca-mir-3759; +MI0037625 pca-mir-3770; +MI0037626 pca-mir-3782; +MI0037627 pca-mir-3783; +MI0037628 pca-mir-3785; +MI0037629 pca-mir-3786; +MI0037630 pca-mir-6001; +MI0037631 pca-mir-6038; +MI0037632 pca-mir-6039; +MI0037633 pca-mir-6065; +MI0037634 pca-mir-6067; +MI0037635 pca-mir-11663; +MI0037636 pca-mir-11664a; +MI0037637 pca-mir-11664b; +MI0037638 pca-mir-11665; +MI0037639 tca-mir-11618a-5; +MI0037640 tca-mir-3836g-2; +MI0037641 tca-mir-3851l-4; +MI0037904 mes-MIR171l; +MI0037905 mes-MIR390b; +MI0037906 mes-MIR397b; +MI0037907 mes-MIR398; +MI0037908 mes-MIR399h; +MI0037909 mes-MIR477j; +MI0037910 mes-MIR477k; +MI0037911 mes-MIR2118; +MI0037912 mes-MIR482b; +MI0037913 mes-MIR482c; +MI0037914 mes-MIR482d; +MI0037915 mes-MIR482e; +MI0037916 mes-MIR535c; +MI0037917 mes-MIR535d; +MI0037918 mes-MIR1446b; +MI0037919 mes-MIR3627; +MI0037920 mes-MIR6445; +MI0037921 mes-MIR9386; +MI0037922 mes-MIR169ad; +MI0037923 mes-MIR11891; +MI0037924 mes-MIR11892; +MI0037925 aae-mir-11893-1; +MI0037926 aae-mir-11893-2; +MI0037927 aae-mir-11894a-1; +MI0037928 aae-mir-11894a-2; +MI0037929 aae-mir-11894a-3; +MI0037930 aae-mir-11894b-1; +MI0037931 aae-mir-11894b-2; +MI0037932 aae-mir-11895-1; +MI0037933 aae-mir-11895-2; +MI0037934 aae-mir-10365; +MI0037935 aae-mir-11896; +MI0037936 aae-mir-11897a; +MI0037937 aae-mir-11898; +MI0037938 aae-mir-11897b; +MI0037939 aae-mir-11899-1; +MI0037940 aae-mir-11899-2; +MI0037941 aae-mir-11900; +MI0037942 aae-mir-11901; +MI0037943 aae-mir-11902; +MI0037944 aae-mir-11903a; +MI0037945 aae-mir-11904; +MI0037946 aae-mir-11905; +MI0037947 aae-mir-11906; +MI0037948 aae-mir-11907; +MI0037949 aae-mir-11908-1; +MI0037950 aae-mir-11908-2; +MI0037951 aae-mir-11909-1; +MI0037952 aae-mir-11909-2; +MI0037953 aae-mir-11910; +MI0037954 aae-mir-11911; +MI0037955 aae-mir-11912; +MI0037956 aae-mir-11913; +MI0037957 aae-mir-11914-1; +MI0037958 aae-mir-11914-2; +MI0037959 aae-mir-11914-3; +MI0037960 aae-mir-11903b; +MI0037961 aae-mir-11915; +MI0037962 aae-mir-11916; +MI0037963 aae-mir-11917; +MI0037964 aae-mir-11918; +MI0037965 aae-mir-11919; +MI0037966 aae-mir-11920-1; +MI0037967 aae-mir-11920-2; +MI0037968 aae-mir-11920-3; +MI0037969 aae-mir-11920-4; +MI0037970 aae-mir-11921; +MI0037971 aae-mir-11922; +MI0037972 aae-mir-11923; +MI0037973 aae-mir-11924; +MI0037974 aae-mir-11925; +MI0037975 aae-mir-11926-1; +MI0037976 aae-mir-11926-2; +MI0037977 aae-mir-11927; +MI0037978 aae-mir-11928; +MI0037979 gmo-let-7e-2; +MI0037980 gmo-mir-133a-1; +MI0037981 gmo-mir-133a-2; +MI0037982 gmo-mir-18a-2; +MI0037983 gmo-mir-190a-2; +MI0037984 gmo-mir-212-2; +MI0037985 gmo-mir-214-2; +MI0037986 gmo-mir-2184; +MI0037987 gmo-mir-2187b; +MI0037988 gmo-mir-223a; +MI0037989 gmo-mir-26a-4; +MI0037990 gmo-mir-27d; +MI0037991 gmo-mir-33b-2; +MI0037992 gmo-mir-451; +MI0037993 gmo-mir-459; +MI0037994 gmo-mir-722-2; +MI0037995 gmo-mir-724-2; +MI0037996 gmo-mir-727b; +MI0037997 gmo-mir-7552-2; +MI0037998 gmo-mir-11224b; +MI0037999 gmo-mir-11929; +MI0038000 gmo-mir-11930; +MI0038001 gmo-mir-11931-1; +MI0038002 gmo-mir-11932; +MI0038003 gmo-mir-11933; +MI0038004 gmo-mir-11931-2; +MI0038005 gmo-mir-11934; +MI0038006 gmo-mir-11935; +MI0038007 gmo-mir-11936; +MI0038008 gmo-mir-11937; +MI0038009 pte-bantam; +MI0038010 pte-iab-4-1; +MI0038011 pte-iab-4-2; +MI0038012 pte-iab-8-1; +MI0038013 pte-iab-8-2; +MI0038014 pte-let-7; +MI0038015 pte-mir-1; +MI0038016 pte-mir-10; +MI0038017 pte-mir-100a; +MI0038018 pte-mir-100b; +MI0038019 pte-mir-125a; +MI0038020 pte-mir-125b; +MI0038021 pte-mir-184-1; +MI0038022 pte-mir-184-2; +MI0038023 pte-mir-190; +MI0038024 pte-mir-193a; +MI0038025 pte-mir-193b; +MI0038026 pte-mir-210; +MI0038027 pte-mir-263a; +MI0038028 pte-mir-263b; +MI0038029 pte-mir-275; +MI0038030 pte-mir-276-1; +MI0038031 pte-mir-276-2; +MI0038032 pte-mir-277a; +MI0038033 pte-mir-277b; +MI0038034 pte-mir-278a; +MI0038035 pte-mir-278b; +MI0038036 pte-mir-35a; +MI0038037 pte-mir-279; +MI0038038 pte-mir-35b; +MI0038039 pte-mir-281; +MI0038040 pte-mir-29a; +MI0038041 pte-mir-29b; +MI0038042 pte-mir-2a; +MI0038043 pte-mir-2b-1; +MI0038044 pte-mir-2b-2; +MI0038045 pte-mir-2c; +MI0038046 pte-mir-2d; +MI0038047 pte-mir-2e; +MI0038048 pte-mir-2f; +MI0038049 pte-mir-2g-1; +MI0038050 pte-mir-2g-2; +MI0038051 pte-mir-11938; +MI0038052 pte-mir-305; +MI0038053 pte-mir-315; +MI0038054 pte-mir-317; +MI0038055 pte-mir-34; +MI0038056 pte-mir-35c; +MI0038057 pte-mir-35o-1; +MI0038058 pte-mir-35q-1; +MI0038059 pte-mir-35t; +MI0038060 pte-mir-35n-1; +MI0038061 pte-mir-35n-2; +MI0038062 pte-mir-35k; +MI0038063 pte-mir-35d; +MI0038064 pte-mir-35j-1; +MI0038065 pte-mir-35j-2; +MI0038066 pte-mir-35e-1; +MI0038067 pte-mir-35f; +MI0038068 pte-mir-35g; +MI0038069 pte-mir-35h; +MI0038070 pte-mir-35i; +MI0038071 pte-mir-35s; +MI0038072 pte-mir-35m; +MI0038073 pte-mir-35z; +MI0038074 pte-mir-35u; +MI0038075 pte-mir-35e-2; +MI0038076 pte-mir-35p; +MI0038077 pte-mir-35w; +MI0038078 pte-mir-35l; +MI0038079 pte-mir-35x; +MI0038080 pte-mir-35y; +MI0038081 pte-mir-35v; +MI0038082 pte-mir-35r-1; +MI0038083 pte-mir-35r-2; +MI0038084 pte-mir-35r-3; +MI0038085 pte-mir-35q-2; +MI0038086 pte-mir-35o-2; +MI0038087 pte-mir-35q-3; +MI0038088 pte-mir-375-1; +MI0038089 pte-mir-375-2; +MI0038090 pte-mir-3931; +MI0038091 pte-mir-7; +MI0038092 pte-mir-71-1; +MI0038093 pte-mir-71-2; +MI0038094 pte-mir-745; +MI0038095 pte-mir-8; +MI0038096 pte-mir-87a; +MI0038097 pte-mir-87b; +MI0038098 pte-mir-87c; +MI0038099 pte-mir-9; +MI0038100 pte-mir-92a; +MI0038101 pte-mir-92b-1; +MI0038102 pte-mir-92c; +MI0038103 pte-mir-92b-2; +MI0038104 pte-mir-96; +MI0038105 pte-mir-981; +MI0038106 pte-mir-993a; +MI0038107 pte-mir-993b-1; +MI0038108 pte-mir-993b-2; +MI0038109 pte-mir-11939; +MI0038110 pte-mir-11940; +MI0038111 pte-mir-11941; +MI0038112 pte-mir-11942a; +MI0038113 pte-mir-11942b; +MI0038114 pte-mir-11942c; +MI0038115 pte-mir-11942d; +MI0038116 pte-mir-11943; +MI0038117 pte-mir-14; +MI0038118 pte-mir-11944; +MI0038119 pte-mir-11945; +MI0038120 pte-mir-11946; +MI0038121 pte-mir-11947a-1; +MI0038122 pte-mir-11947a-2; +MI0038123 pte-mir-11948; +MI0038124 pte-mir-11949; +MI0038125 pte-mir-11950; +MI0038126 pte-mir-11951a; +MI0038127 pte-mir-11951b; +MI0038128 pte-mir-11952; +MI0038129 pte-mir-3477; +MI0038130 pte-mir-11953; +MI0038131 pte-mir-11954; +MI0038132 pte-mir-11955; +MI0038133 pte-mir-11956; +MI0038134 pte-mir-11947b-1; +MI0038135 pte-mir-11947b-2; +MI0038136 pte-mir-11957; +MI0038137 pte-mir-11958; +MI0038138 pte-mir-11959-1; +MI0038139 pte-mir-11959-2; +MI0038140 pte-mir-11960; +MI0038141 pte-mir-11961a; +MI0038142 pte-mir-11961b; +MI0038143 pte-mir-11961c; +MI0038144 pte-mir-11962a; +MI0038145 pte-mir-11962b; +MI0038146 pte-mir-11965-3; +MI0038147 pte-mir-11963a; +MI0038148 pte-mir-11963b-1; +MI0038149 pte-mir-11963b-2; +MI0038150 pte-mir-11964; +MI0038151 pte-mir-11965-1; +MI0038152 pte-mir-11965-2; +MI0038153 pte-mir-11966; +MI0038154 pte-mir-11967; +MI0038155 pte-mir-11968-1; +MI0038156 pte-mir-11968-2; +MI0038157 zma-MIR11969; +MI0038158 zma-MIR11970; +MI0038159 bta-mir-11971; +MI0038160 bta-mir-2285ar; +MI0038161 bta-mir-2285as-1; +MI0038162 bta-mir-2285as-2; +MI0038163 bta-mir-2285as-3; +MI0038164 bta-mir-11972; +MI0038165 bta-mir-2285at-1; +MI0038166 bta-mir-2285at-2; +MI0038167 bta-mir-2285at-3; +MI0038168 bta-mir-2285at-4; +MI0038169 bta-mir-2285au; +MI0038170 bta-mir-2285av; +MI0038171 bta-mir-2285aw; +MI0038172 bta-mir-11973; +MI0038173 bta-mir-2285ax-1; +MI0038174 bta-mir-2285ax-2; +MI0038175 bta-mir-2285ax-3; +MI0038176 bta-mir-11974; +MI0038177 bta-mir-11975; +MI0038178 bta-mir-2285ay; +MI0038179 bta-mir-2285az; +MI0038180 bta-mir-11976-1; +MI0038181 bta-mir-11976-2; +MI0038182 bta-mir-2285an; +MI0038183 bta-mir-11977; +MI0038184 bta-mir-2285ao-1; +MI0038185 bta-mir-2285ao-2; +MI0038186 bta-mir-2285ap; +MI0038187 bta-mir-2285ao-3; +MI0038188 bta-mir-11978; +MI0038189 bta-mir-2285aq-1; +MI0038190 bta-mir-2285aq-2; +MI0038191 bta-mir-11979; +MI0038192 bta-mir-11980; +MI0038193 bta-mir-6715; +MI0038194 bta-mir-11981; +MI0038195 bta-mir-9851; +MI0038196 bta-mir-11982; +MI0038197 bta-mir-2285ba-1; +MI0038198 bta-mir-2285ba-2; +MI0038199 bta-mir-2285bb; +MI0038200 bta-mir-11983; +MI0038201 bta-mir-2285bc; +MI0038202 bta-mir-11984; +MI0038203 bta-mir-2285bd; +MI0038204 bta-mir-2285be; +MI0038205 bta-mir-11985; +MI0038206 bta-mir-2285bf-1; +MI0038207 bta-mir-2285bf-2; +MI0038208 bta-mir-2285bf-3; +MI0038209 bta-mir-11986; +MI0038210 bta-mir-2285bg; +MI0038211 bta-mir-11987; +MI0038212 bta-mir-2285bh; +MI0038213 bta-mir-2285bi-1; +MI0038214 bta-mir-2285bi-2; +MI0038215 bta-mir-2285bj-1; +MI0038216 bta-mir-2285bj-2; +MI0038217 bta-mir-11988; +MI0038218 bta-mir-374c; +MI0038219 xla-let-7a; +MI0038220 xla-let-7b; +MI0038221 xla-let-7c; +MI0038222 xla-let-7e; +MI0038223 xla-let-7f; +MI0038224 xla-let-7j; +MI0038225 xla-let-7i; +MI0038226 xla-mir-100-2; +MI0038227 xla-mir-100-1; +MI0038228 xla-mir-101; +MI0038229 xla-mir-103a; +MI0038230 xla-mir-103b; +MI0038231 xla-mir-106; +MI0038232 xla-mir-107; +MI0038233 xla-mir-10a; +MI0038234 xla-mir-10b; +MI0038235 xla-mir-122; +MI0038236 xla-mir-124-2; +MI0038237 xla-mir-124-1; +MI0038238 xla-mir-125a; +MI0038239 xla-mir-125b; +MI0038240 xla-mir-126-1; +MI0038241 xla-mir-126-2; +MI0038242 xla-mir-128-2; +MI0038243 xla-mir-128-1; +MI0038244 xla-mir-130a; +MI0038245 xla-mir-130b; +MI0038246 xla-mir-130c-1; +MI0038247 xla-mir-130c-2; +MI0038248 xla-mir-135; +MI0038249 xla-mir-138-2; +MI0038250 xla-mir-138-1; +MI0038251 xla-mir-140-1; +MI0038252 xla-mir-140-2; +MI0038253 xla-mir-142-2; +MI0038254 xla-mir-143; +MI0038255 xla-mir-144; +MI0038256 xla-mir-145; +MI0038257 xla-mir-146a; +MI0038258 xla-mir-146b; +MI0038259 xla-mir-148a; +MI0038260 xla-mir-148b; +MI0038261 xla-mir-15a; +MI0038262 xla-mir-15b; +MI0038263 xla-mir-15c-2; +MI0038264 xla-mir-16b; +MI0038265 xla-mir-16a; +MI0038266 xla-mir-16c; +MI0038267 xla-mir-17-1; +MI0038268 xla-mir-17-2; +MI0038269 xla-mir-181a; +MI0038270 xla-mir-181b-1; +MI0038271 xla-mir-181b-2; +MI0038272 xla-mir-182-1; +MI0038273 xla-mir-182-2; +MI0038274 xla-mir-183; +MI0038275 xla-mir-184; +MI0038276 xla-mir-18b; +MI0038277 xla-mir-18a-2; +MI0038278 xla-mir-190; +MI0038279 xla-mir-191; +MI0038280 xla-mir-192; +MI0038281 xla-mir-193; +MI0038282 xla-mir-194-2; +MI0038283 xla-mir-199; +MI0038284 xla-mir-19a; +MI0038285 xla-mir-19b-2; +MI0038286 xla-mir-1a; +MI0038287 xla-mir-200a-1; +MI0038288 xla-mir-200a-2; +MI0038289 xla-mir-200b; +MI0038290 xla-mir-202; +MI0038291 xla-mir-203; +MI0038292 xla-mir-206; +MI0038293 xla-mir-20a; +MI0038294 xla-mir-210; +MI0038295 xla-mir-212; +MI0038296 xla-mir-214-1; +MI0038297 xla-mir-214-2; +MI0038298 xla-mir-216; +MI0038299 xla-mir-217; +MI0038300 xla-mir-22; +MI0038301 xla-mir-221; +MI0038302 xla-mir-222; +MI0038303 xla-mir-23a-2; +MI0038304 xla-mir-23b; +MI0038305 xla-mir-24a-2; +MI0038306 xla-mir-24a-1; +MI0038307 xla-mir-24b-2; +MI0038308 xla-mir-25; +MI0038309 xla-mir-26-1; +MI0038310 xla-mir-26-2; +MI0038311 xla-mir-27a; +MI0038312 xla-mir-27b; +MI0038313 xla-mir-29b; +MI0038314 xla-mir-29c; +MI0038315 xla-mir-301-1; +MI0038316 xla-mir-301-2; +MI0038317 xla-mir-30a; +MI0038318 xla-mir-30b; +MI0038319 xla-mir-30c; +MI0038320 xla-mir-30d; +MI0038321 xla-mir-30e; +MI0038322 xla-mir-338; +MI0038323 xla-mir-33a; +MI0038324 xla-mir-33b; +MI0038325 xla-mir-34a; +MI0038326 xla-mir-34b; +MI0038327 xla-mir-363-2; +MI0038328 xla-mir-375; +MI0038329 xla-mir-425-1; +MI0038330 xla-mir-425-2; +MI0038331 xla-mir-427-2; +MI0038332 xla-mir-428a-2; +MI0038333 xla-mir-428b; +MI0038334 xla-mir-429-2; +MI0038335 xla-mir-449; +MI0038336 xla-mir-455; +MI0038337 xla-mir-499; +MI0038338 xla-mir-92a-3; +MI0038339 xla-mir-92a-4; +MI0038340 xla-mir-92b; +MI0038341 xla-mir-93; +MI0038342 xla-mir-96; +MI0038343 xla-mir-98; +MI0038344 xla-mir-99; +MI0038345 bta-mir-11986b; +MI0038346 bta-mir-2285bk; +MI0038347 bta-mir-2285bl; +MI0038348 bta-mir-2285bm; +MI0038349 bta-mir-2285bn; +MI0038350 bta-mir-7180; +MI0038351 bta-mir-2285bo; +MI0038352 bta-mir-11989; +MI0038353 bta-mir-11990; +MI0038354 bta-mir-1911; +MI0038355 bta-mir-11991; +MI0038356 bta-mir-11992; +MI0038357 bta-mir-2285bp; +MI0038358 bta-mir-11993; +MI0038359 bta-mir-2285bq; +MI0038360 bta-mir-2285br; +MI0038361 bta-mir-2285bs; +MI0038362 bta-mir-11986c; +MI0038363 bta-mir-2285bt; +MI0038364 bta-mir-2285bu-1; +MI0038365 bta-mir-2285bu-2; +MI0038366 bta-mir-2285bv; +MI0038367 bta-mir-2285bw; +MI0038368 bta-mir-2285bx; +MI0038369 bta-mir-2285by; +MI0038370 bta-mir-2285bz; +MI0038371 bta-mir-11994; +MI0038372 bta-mir-11995; +MI0038373 bta-mir-11996; +MI0038374 bta-mir-2285ca; +MI0038375 bta-mir-2285cb; +MI0038376 bta-mir-2285cc; +MI0038377 bta-mir-11997; +MI0038378 bta-mir-11998; +MI0038379 bta-mir-2285cd; +MI0038380 bta-mir-1264; +MI0038381 bta-mir-2285ce; +MI0038382 bta-mir-11999; +MI0038383 bta-mir-12000; +MI0038384 bta-mir-12001; +MI0038385 bta-mir-12002a; +MI0038386 bta-mir-12003; +MI0038387 bta-mir-2285cf; +MI0038388 bta-mir-12004; +MI0038389 bta-mir-2285cg; +MI0038390 bta-mir-12005-1; +MI0038391 bta-mir-12005-2; +MI0038392 bta-mir-12006; +MI0038393 bta-mir-12007; +MI0038394 bta-mir-299-2; +MI0038395 bta-mir-148d; +MI0038396 bta-mir-2285ch; +MI0038397 bta-mir-2285ci; +MI0038398 bta-mir-6775; +MI0038399 bta-mir-2285cj; +MI0038400 bta-mir-12008; +MI0038401 bta-mir-2285ck; +MI0038402 bta-mir-12009; +MI0038403 bta-mir-12010; +MI0038404 bta-mir-12011; +MI0038405 bta-mir-12012; +MI0038406 bta-mir-2285cl; +MI0038407 bta-mir-2285cm; +MI0038408 bta-mir-2285cn; +MI0038409 bta-mir-12013; +MI0038410 bta-mir-6501; +MI0038411 bta-mir-2285co; +MI0038412 bta-mir-2285cp; +MI0038413 bta-mir-2285cq; +MI0038414 bta-mir-12014; +MI0038415 bta-mir-12015; +MI0038416 bta-mir-2285cr-1; +MI0038417 bta-mir-2285cr-2; +MI0038418 bta-mir-2285cs; +MI0038419 bta-mir-12002b; +MI0038420 bta-mir-2285ct; +MI0038421 bta-mir-12016; +MI0038422 bta-mir-12017; +MI0038423 bta-mir-2285cu; +MI0038424 bta-mir-2285cv-1; +MI0038425 bta-mir-2285cv-2; +MI0038426 bta-mir-12018; +MI0038427 bta-mir-2285cw-1; +MI0038428 bta-mir-2285cw-2; +MI0038429 bta-mir-2285cx; +MI0038430 bta-mir-2285cy; +MI0038431 bta-mir-2285cz; +MI0038432 bta-mir-2285da; +MI0038433 bta-mir-12019; +MI0038434 bta-mir-2285db; +MI0038435 bta-mir-2285dc; +MI0038436 bta-mir-12020; +MI0038437 bta-mir-2285dd; +MI0038438 bta-mir-2285de; +MI0038439 bta-mir-12021; +MI0038440 bta-mir-12022; +MI0038441 bta-mir-12023; +MI0038442 bta-mir-12024; +MI0038443 bta-mir-12025; +MI0038444 bta-mir-12026-1; +MI0038445 bta-mir-12026-2; +MI0038446 bta-mir-12027; +MI0038447 bta-mir-12028; +MI0038448 bta-mir-12029; +MI0038449 bta-mir-12030; +MI0038450 bta-mir-12031; +MI0038451 bta-mir-12032; +MI0038452 bta-mir-12033; +MI0038453 bta-mir-12034; +MI0038454 bta-mir-12035; +MI0038455 bta-mir-2285df; +MI0038456 bta-mir-194b-2; +MI0038457 bta-mir-12036; +MI0038458 bta-mir-12037; +MI0038459 bta-mir-12038; +MI0038460 bta-mir-12039; +MI0038461 bta-mir-12040; +MI0038462 bta-mir-2285dg; +MI0038463 bta-mir-12041; +MI0038464 bta-mir-191b; +MI0038465 bta-mir-12042; +MI0038466 bta-mir-12043; +MI0038467 bta-mir-3065; +MI0038468 bta-mir-12044; +MI0038469 bta-mir-12045; +MI0038470 bta-mir-507b; +MI0038471 bta-mir-2285dh; +MI0038472 bta-mir-2285di; +MI0038473 bta-mir-2285dj; +MI0038474 bta-mir-12046; +MI0038475 bta-mir-2285dk; +MI0038476 bta-mir-12047; +MI0038477 bta-mir-12048; +MI0038478 bta-mir-12049; +MI0038479 bta-mir-12050; +MI0038480 bta-mir-12051; +MI0038481 bta-mir-1949; +MI0038482 bta-mir-2285dl-1; +MI0038483 bta-mir-2285dl-2; +MI0038484 bta-mir-2285dm; +MI0038485 bta-mir-12052; +MI0038486 bta-mir-12053; +MI0038487 bta-mir-12054; +MI0038488 bta-mir-12055; +MI0038489 bta-mir-12056; +MI0038490 bta-mir-12057; +MI0038491 bta-mir-12058; +MI0038492 bta-mir-12059; +MI0038493 bta-mir-12060; +MI0038494 bta-mir-12061; +MI0038495 bta-mir-12062; +MI0038496 bta-mir-12063; +MI0038497 bta-mir-12064; +MI0038498 mco-bantam; +MI0038499 mco-let-7; +MI0038500 mco-mir-1; +MI0038501 mco-mir-2a; +MI0038502 mco-mir-2b; +MI0038503 mco-mir-2c; +MI0038504 mco-mir-7a; +MI0038505 mco-mir-7b; +MI0038506 mco-mir-9; +MI0038507 mco-mir-10; +MI0038508 mco-mir-31; +MI0038509 mco-mir-36a; +MI0038510 mco-mir-36b; +MI0038511 mco-mir-61; +MI0038512 mco-mir-71; +MI0038513 mco-mir-87; +MI0038514 mco-mir-96; +MI0038515 mco-mir-124a; +MI0038516 mco-mir-124b; +MI0038517 mco-mir-125; +MI0038518 mco-mir-133; +MI0038519 mco-mir-153; +MI0038520 mco-mir-184; +MI0038521 mco-mir-190; +MI0038522 mco-mir-12065; +MI0038523 mco-mir-12066; +MI0038524 mco-mir-219; +MI0038525 mco-mir-277; +MI0038526 mco-mir-277b; +MI0038527 mco-mir-281; +MI0038528 mco-mir-307; +MI0038529 mco-mir-745; +MI0038530 mco-mir-2162; +MI0038531 mco-mir-3479a; +MI0038532 mco-mir-3479b; +MI0038533 mco-mir-4989; +MI0038534 mco-mir-10293; +MI0038535 mco-mir-12067; +MI0038536 mco-mir-12068; +MI0038537 mco-mir-12069; +MI0038538 mco-mir-12070; +MI0038539 mco-mir-12071; +MI0038540 cpo-let-7a-1; +MI0038541 cpo-let-7a-2; +MI0038542 cpo-let-7a-3; +MI0038543 cpo-let-7b; +MI0038544 cpo-let-7c; +MI0038545 cpo-let-7d; +MI0038546 cpo-let-7e; +MI0038547 cpo-let-7f-1; +MI0038548 cpo-let-7f-2; +MI0038549 cpo-let-7g; +MI0038550 cpo-let-7i; +MI0038551 cpo-mir-1b; +MI0038552 cpo-mir-1a; +MI0038553 cpo-mir-7-1; +MI0038554 cpo-mir-7-2; +MI0038555 cpo-mir-7-3; +MI0038556 cpo-mir-9-1; +MI0038557 cpo-mir-9-2; +MI0038558 cpo-mir-9-3; +MI0038559 cpo-mir-10a; +MI0038560 cpo-mir-10b; +MI0038561 cpo-mir-15a; +MI0038562 cpo-mir-15b; +MI0038563 cpo-mir-16a; +MI0038564 cpo-mir-16b; +MI0038565 cpo-mir-17; +MI0038566 cpo-mir-18a; +MI0038567 cpo-mir-18b; +MI0038568 cpo-mir-19a; +MI0038569 cpo-mir-19b-1; +MI0038570 cpo-mir-19b-2; +MI0038571 cpo-mir-20a; +MI0038572 cpo-mir-20b; +MI0038573 cpo-mir-21; +MI0038574 cpo-mir-22; +MI0038575 cpo-mir-23a; +MI0038576 cpo-mir-23b; +MI0038577 cpo-mir-24-1; +MI0038578 cpo-mir-24-2; +MI0038579 cpo-mir-25; +MI0038580 cpo-mir-26a-1; +MI0038581 cpo-mir-26a-2; +MI0038582 cpo-mir-26b; +MI0038583 cpo-mir-27a; +MI0038584 cpo-mir-27b; +MI0038585 cpo-mir-28; +MI0038586 cpo-mir-29a; +MI0038587 cpo-mir-29b-1; +MI0038588 cpo-mir-29b-2; +MI0038589 cpo-mir-29c; +MI0038590 cpo-mir-30a; +MI0038591 cpo-mir-30b; +MI0038592 cpo-mir-30c-1; +MI0038593 cpo-mir-30c-2; +MI0038594 cpo-mir-30d; +MI0038595 cpo-mir-30e; +MI0038596 cpo-mir-31; +MI0038597 cpo-mir-32; +MI0038598 cpo-mir-33a; +MI0038599 cpo-mir-33b; +MI0038600 cpo-mir-34a; +MI0038601 cpo-mir-34b; +MI0038602 cpo-mir-34c; +MI0038603 cpo-mir-92a-1; +MI0038604 cpo-mir-92a-2; +MI0038605 cpo-mir-92b; +MI0038606 cpo-mir-93; +MI0038607 cpo-mir-95; +MI0038608 cpo-mir-96; +MI0038609 cpo-mir-98; +MI0038610 cpo-mir-99a; +MI0038611 cpo-mir-99b; +MI0038612 cpo-mir-100; +MI0038613 cpo-mir-101-1; +MI0038614 cpo-mir-101-2; +MI0038615 cpo-mir-103-1; +MI0038616 cpo-mir-103-2; +MI0038617 cpo-mir-105; +MI0038618 cpo-mir-106a; +MI0038619 cpo-mir-106b; +MI0038620 cpo-mir-107; +MI0038621 cpo-mir-122; +MI0038622 cpo-mir-124-1; +MI0038623 cpo-mir-124-2; +MI0038624 cpo-mir-125a; +MI0038625 cpo-mir-125b-1; +MI0038626 cpo-mir-125b-2; +MI0038627 cpo-mir-126; +MI0038628 cpo-mir-127; +MI0038629 cpo-mir-128-1; +MI0038630 cpo-mir-128-2; +MI0038631 cpo-mir-129-1; +MI0038632 cpo-mir-129-2; +MI0038633 cpo-mir-130a; +MI0038634 cpo-mir-130b; +MI0038635 cpo-mir-132; +MI0038636 cpo-mir-133a-1; +MI0038637 cpo-mir-133a-2; +MI0038638 cpo-mir-133b; +MI0038639 cpo-mir-134; +MI0038640 cpo-mir-135a-1; +MI0038641 cpo-mir-135a-2; +MI0038642 cpo-mir-135b; +MI0038643 cpo-mir-136; +MI0038644 cpo-mir-138-1; +MI0038645 cpo-mir-138-2; +MI0038646 cpo-mir-139; +MI0038647 cpo-mir-140; +MI0038648 cpo-mir-141; +MI0038649 cpo-mir-142; +MI0038650 cpo-mir-143; +MI0038651 cpo-mir-144; +MI0038652 cpo-mir-145; +MI0038653 cpo-mir-146a; +MI0038654 cpo-mir-146b; +MI0038655 cpo-mir-147; +MI0038656 cpo-mir-148a; +MI0038657 cpo-mir-148b; +MI0038658 cpo-mir-149; +MI0038659 cpo-mir-150; +MI0038660 cpo-mir-151; +MI0038661 cpo-mir-152; +MI0038662 cpo-mir-153; +MI0038663 cpo-mir-154; +MI0038664 cpo-mir-155; +MI0038665 cpo-mir-181a-1; +MI0038666 cpo-mir-181a-2; +MI0038667 cpo-mir-181b-1; +MI0038668 cpo-mir-181b-2; +MI0038669 cpo-mir-181c; +MI0038670 cpo-mir-182; +MI0038671 cpo-mir-183; +MI0038672 cpo-mir-184; +MI0038673 cpo-mir-185; +MI0038674 cpo-mir-186; +MI0038675 cpo-mir-187; +MI0038676 cpo-mir-188; +MI0038677 cpo-mir-190a; +MI0038678 cpo-mir-190b; +MI0038679 cpo-mir-191; +MI0038680 cpo-mir-192; +MI0038681 cpo-mir-193a; +MI0038682 cpo-mir-193b; +MI0038683 cpo-mir-194; +MI0038684 cpo-mir-195; +MI0038685 cpo-mir-196a; +MI0038686 cpo-mir-196c; +MI0038687 cpo-mir-196b; +MI0038688 cpo-mir-197; +MI0038689 cpo-mir-199-1; +MI0038690 cpo-mir-199-2; +MI0038691 cpo-mir-199-3; +MI0038692 cpo-mir-200a; +MI0038693 cpo-mir-200b; +MI0038694 cpo-mir-200c; +MI0038695 cpo-mir-202; +MI0038696 cpo-mir-203; +MI0038697 cpo-mir-204; +MI0038698 cpo-mir-205; +MI0038699 cpo-mir-206; +MI0038700 cpo-mir-208a; +MI0038701 cpo-mir-208b; +MI0038702 cpo-mir-210; +MI0038703 cpo-mir-211; +MI0038704 cpo-mir-212; +MI0038705 cpo-mir-214; +MI0038706 cpo-mir-215; +MI0038707 cpo-mir-216a; +MI0038708 cpo-mir-216b; +MI0038709 cpo-mir-217; +MI0038710 cpo-mir-218-1; +MI0038711 cpo-mir-218-2; +MI0038712 cpo-mir-219b; +MI0038713 cpo-mir-221; +MI0038714 cpo-mir-222; +MI0038715 cpo-mir-223; +MI0038716 cpo-mir-224; +MI0038717 cpo-mir-296; +MI0038718 cpo-mir-299; +MI0038719 cpo-mir-301a; +MI0038720 cpo-mir-301b; +MI0038721 cpo-mir-302a; +MI0038722 cpo-mir-302b; +MI0038723 cpo-mir-302c; +MI0038724 cpo-mir-302d; +MI0038725 cpo-mir-323a; +MI0038726 cpo-mir-323b; +MI0038727 cpo-mir-324; +MI0038728 cpo-mir-326; +MI0038729 cpo-mir-328; +MI0038730 cpo-mir-329; +MI0038731 cpo-mir-330; +MI0038732 cpo-mir-331; +MI0038733 cpo-mir-335; +MI0038734 cpo-mir-337; +MI0038735 cpo-mir-338; +MI0038736 cpo-mir-339; +MI0038737 cpo-mir-340; +MI0038738 cpo-mir-342; +MI0038739 cpo-mir-345; +MI0038740 cpo-mir-346; +MI0038741 cpo-mir-350; +MI0038742 cpo-mir-361; +MI0038743 cpo-mir-362; +MI0038744 cpo-mir-363; +MI0038745 cpo-mir-365-1; +MI0038746 cpo-mir-365-2; +MI0038747 cpo-mir-367; +MI0038748 cpo-mir-369; +MI0038749 cpo-mir-370; +MI0038750 cpo-mir-290; +MI0038751 cpo-mir-374; +MI0038752 cpo-mir-375; +MI0038753 cpo-mir-376a; +MI0038754 cpo-mir-376b; +MI0038755 cpo-mir-376c; +MI0038756 cpo-mir-376d; +MI0038757 cpo-mir-377; +MI0038758 cpo-mir-378; +MI0038759 cpo-mir-379; +MI0038760 cpo-mir-380; +MI0038761 cpo-mir-381; +MI0038762 cpo-mir-382; +MI0038763 cpo-mir-383; +MI0038764 cpo-mir-892; +MI0038765 cpo-mir-409; +MI0038766 cpo-mir-410; +MI0038767 cpo-mir-411; +MI0038768 cpo-mir-412; +MI0038769 cpo-mir-423; +MI0038770 cpo-mir-424; +MI0038771 cpo-mir-425; +MI0038772 cpo-mir-429; +MI0038773 cpo-mir-431; +MI0038774 cpo-mir-432; +MI0038775 cpo-mir-433; +MI0038776 cpo-mir-448; +MI0038777 cpo-mir-449a; +MI0038778 cpo-mir-449c; +MI0038779 cpo-mir-450a-1; +MI0038780 cpo-mir-450a-2; +MI0038781 cpo-mir-450b; +MI0038782 cpo-mir-451; +MI0038783 cpo-mir-452; +MI0038784 cpo-mir-454; +MI0038785 cpo-mir-455; +MI0038786 cpo-mir-483; +MI0038787 cpo-mir-485; +MI0038788 cpo-mir-486; +MI0038789 cpo-mir-487a; +MI0038790 cpo-mir-487b; +MI0038791 cpo-mir-490; +MI0038792 cpo-mir-491; +MI0038793 cpo-mir-493; +MI0038794 cpo-mir-494; +MI0038795 cpo-mir-495; +MI0038796 cpo-mir-496; +MI0038797 cpo-mir-497; +MI0038798 cpo-mir-499; +MI0038799 cpo-mir-500a; +MI0038800 cpo-mir-500b; +MI0038801 cpo-mir-501; +MI0038802 cpo-mir-502a; +MI0038803 cpo-mir-503; +MI0038804 cpo-mir-504; +MI0038805 cpo-mir-505; +MI0038806 cpo-mir-506; +MI0038807 cpo-mir-507a; +MI0038808 cpo-mir-507b; +MI0038809 cpo-mir-507c; +MI0038810 cpo-mir-509a; +MI0038811 cpo-mir-509b; +MI0038812 cpo-mir-509c; +MI0038813 cpo-mir-509d; +MI0038814 cpo-mir-509e; +MI0038815 cpo-mir-511; +MI0038816 cpo-mir-509f; +MI0038817 cpo-mir-532; +MI0038818 cpo-mir-539; +MI0038819 cpo-mir-541; +MI0038820 cpo-mir-542; +MI0038821 cpo-mir-543; +MI0038822 cpo-mir-545; +MI0038823 cpo-mir-551; +MI0038824 cpo-mir-574; +MI0038825 cpo-mir-582; +MI0038826 cpo-mir-615; +MI0038827 cpo-mir-652; +MI0038828 cpo-mir-653; +MI0038829 cpo-mir-654; +MI0038830 cpo-mir-655; +MI0038831 cpo-mir-656; +MI0038832 cpo-mir-660; +MI0038833 cpo-mir-670; +MI0038834 cpo-mir-671; +MI0038835 cpo-mir-672; +MI0038836 cpo-mir-675; +MI0038837 cpo-mir-676; +MI0038838 cpo-mir-708; +MI0038839 cpo-mir-744; +MI0038840 cpo-mir-758; +MI0038841 cpo-mir-760; +MI0038842 cpo-mir-769; +MI0038843 cpo-mir-802; +MI0038844 cpo-mir-872; +MI0038845 cpo-mir-873; +MI0038846 cpo-mir-874; +MI0038847 cpo-mir-885; +MI0038848 cpo-mir-889; +MI0038849 cpo-mir-1185; +MI0038850 cpo-mir-1193; +MI0038851 cpo-mir-1197; +MI0038852 cpo-mir-1247; +MI0038853 cpo-mir-1251; +MI0038854 cpo-mir-1264; +MI0038855 cpo-mir-1271; +MI0038856 cpo-mir-1277; +MI0038857 cpo-mir-1296; +MI0038858 cpo-mir-1298; +MI0038859 cpo-mir-1301; +MI0038860 cpo-mir-1343; +MI0038861 cpo-mir-1379; +MI0038862 cpo-mir-1388; +MI0038863 cpo-mir-1842; +MI0038864 cpo-mir-2355; +MI0038865 cpo-mir-2387; +MI0038866 cpo-mir-3059; +MI0038867 cpo-mir-3085; +MI0038868 cpo-mir-513; +MI0038869 cpo-mir-3613; +MI0038870 cpo-mir-3959; +MI0038871 cpo-mir-6529; +MI0038872 cpo-mir-12072; +MI0038873 cpo-mir-12073; +MI0038874 cpo-mir-12074; +MI0038875 cpo-mir-12075; +MI0038876 cpo-mir-12076; +MI0038877 cpo-mir-12077; +MI0038878 cpo-mir-12078; +MI0038879 cpo-mir-526; +MI0038880 cpo-mir-12079; +MI0038881 cpo-mir-12080; +MI0038882 cpo-mir-12081; +MI0038883 cpo-mir-12082; +MI0038884 cpo-mir-12083; +MI0038885 cpo-mir-12084; +MI0038886 dno-let-7a; +MI0038887 dno-let-7c-2; +MI0038888 dno-let-7b; +MI0038889 dno-let-7c-1; +MI0038890 dno-let-7d; +MI0038891 dno-let-7f-1; +MI0038892 dno-let-7f-2; +MI0038893 dno-let-7g; +MI0038894 dno-let-7i; +MI0038895 dno-mir-1-1; +MI0038896 dno-mir-1-2; +MI0038897 dno-mir-7-1; +MI0038898 dno-mir-7-2; +MI0038899 dno-mir-7-3; +MI0038900 dno-mir-9-1; +MI0038901 dno-mir-9-2; +MI0038902 dno-mir-9-3; +MI0038903 dno-mir-10a; +MI0038904 dno-mir-10b; +MI0038905 dno-mir-15a; +MI0038906 dno-mir-15b; +MI0038907 dno-mir-16a; +MI0038908 dno-mir-16b; +MI0038909 dno-mir-17; +MI0038910 dno-mir-18a; +MI0038911 dno-mir-18b; +MI0038912 dno-mir-19a; +MI0038913 dno-mir-19b-1; +MI0038914 dno-mir-19b-2; +MI0038915 dno-mir-20a; +MI0038916 dno-mir-20b; +MI0038917 dno-mir-21; +MI0038918 dno-mir-22; +MI0038919 dno-mir-23a; +MI0038920 dno-mir-23b; +MI0038921 dno-mir-24a; +MI0038922 dno-mir-24b; +MI0038923 dno-mir-25; +MI0038924 dno-mir-26a-1; +MI0038925 dno-mir-26a-2; +MI0038926 dno-mir-26b; +MI0038927 dno-mir-27a; +MI0038928 dno-mir-27b; +MI0038929 dno-mir-28; +MI0038930 dno-mir-29a; +MI0038931 dno-mir-29b-1; +MI0038932 dno-mir-29b-2; +MI0038933 dno-mir-29c; +MI0038934 dno-mir-30a; +MI0038935 dno-mir-30b; +MI0038936 dno-mir-30c-1; +MI0038937 dno-mir-30c-2; +MI0038938 dno-mir-30d; +MI0038939 dno-mir-30e; +MI0038940 dno-mir-31; +MI0038941 dno-mir-32; +MI0038942 dno-mir-33a; +MI0038943 dno-mir-33b; +MI0038944 dno-mir-34a; +MI0038945 dno-mir-34b; +MI0038946 dno-mir-34c; +MI0038947 dno-mir-92a-1; +MI0038948 dno-mir-92a-2; +MI0038949 dno-mir-92b; +MI0038950 dno-mir-93; +MI0038951 dno-mir-95; +MI0038952 dno-mir-96; +MI0038953 dno-mir-98; +MI0038954 dno-mir-99a; +MI0038955 dno-mir-100; +MI0038956 dno-mir-101-1; +MI0038957 dno-mir-101-2; +MI0038958 dno-mir-103a-1; +MI0038959 dno-mir-103a-2; +MI0038960 dno-mir-106a; +MI0038961 dno-mir-106b; +MI0038962 dno-mir-107; +MI0038963 dno-mir-122; +MI0038964 dno-mir-124-1; +MI0038965 dno-mir-124-2; +MI0038966 dno-mir-125b-1; +MI0038967 dno-mir-125b-2; +MI0038968 dno-mir-126; +MI0038969 dno-mir-127; +MI0038970 dno-mir-128-1; +MI0038971 dno-mir-128-2; +MI0038972 dno-mir-129-1; +MI0038973 dno-mir-129-2; +MI0038974 dno-mir-130a; +MI0038975 dno-mir-130b; +MI0038976 dno-mir-132; +MI0038977 dno-mir-133a-1; +MI0038978 dno-mir-133a-2; +MI0038979 dno-mir-133b; +MI0038980 dno-mir-134; +MI0038981 dno-mir-135a-1; +MI0038982 dno-mir-135a-2; +MI0038983 dno-mir-135b; +MI0038984 dno-mir-136; +MI0038985 dno-mir-137; +MI0038986 dno-mir-138-1; +MI0038987 dno-mir-138-2; +MI0038988 dno-mir-139; +MI0038989 dno-mir-140; +MI0038990 dno-mir-141; +MI0038991 dno-mir-142; +MI0038992 dno-mir-143; +MI0038993 dno-mir-144; +MI0038994 dno-mir-146a; +MI0038995 dno-mir-146b; +MI0038996 dno-mir-147; +MI0038997 dno-mir-148a; +MI0038998 dno-mir-148b; +MI0038999 dno-mir-149; +MI0039000 dno-mir-150; +MI0039001 dno-mir-151; +MI0039002 dno-mir-153a; +MI0039003 dno-mir-153b; +MI0039004 dno-mir-154a; +MI0039005 dno-mir-154b; +MI0039006 dno-mir-155; +MI0039007 dno-mir-181a-1; +MI0039008 dno-mir-181a-2; +MI0039009 dno-mir-181b-1; +MI0039010 dno-mir-181b-2; +MI0039011 dno-mir-181c; +MI0039012 dno-mir-181d; +MI0039013 dno-mir-182; +MI0039014 dno-mir-183; +MI0039015 dno-mir-184; +MI0039016 dno-mir-185; +MI0039017 dno-mir-186; +MI0039018 dno-mir-187; +MI0039019 dno-mir-188; +MI0039020 dno-mir-190a; +MI0039021 dno-mir-190b; +MI0039022 dno-mir-191; +MI0039023 dno-mir-192; +MI0039024 dno-mir-193a; +MI0039025 dno-mir-193b; +MI0039026 dno-mir-194; +MI0039027 dno-mir-195; +MI0039028 dno-mir-196a; +MI0039029 dno-mir-196b; +MI0039030 dno-mir-196c; +MI0039031 dno-mir-197; +MI0039032 dno-mir-199-1; +MI0039033 dno-mir-199-2; +MI0039034 dno-mir-200b; +MI0039035 dno-mir-202; +MI0039036 dno-mir-204; +MI0039037 dno-mir-205; +MI0039038 dno-mir-206; +MI0039039 dno-mir-208a; +MI0039040 dno-mir-208b; +MI0039041 dno-mir-210; +MI0039042 dno-mir-211; +MI0039043 dno-mir-214; +MI0039044 dno-mir-215; +MI0039045 dno-mir-216a; +MI0039046 dno-mir-216b; +MI0039047 dno-mir-217; +MI0039048 dno-mir-218-1; +MI0039049 dno-mir-218-2; +MI0039050 dno-mir-219a; +MI0039051 dno-mir-219b; +MI0039052 dno-mir-221; +MI0039053 dno-mir-222; +MI0039054 dno-mir-223; +MI0039055 dno-mir-224; +MI0039056 dno-mir-296; +MI0039057 dno-mir-299; +MI0039058 dno-mir-301a; +MI0039059 dno-mir-301b; +MI0039060 dno-mir-302a; +MI0039061 dno-mir-302b; +MI0039062 dno-mir-302c; +MI0039063 dno-mir-302d; +MI0039064 dno-mir-323a; +MI0039065 dno-mir-323b; +MI0039066 dno-mir-324; +MI0039067 dno-mir-326; +MI0039068 dno-mir-328; +MI0039069 dno-mir-329; +MI0039070 dno-mir-330; +MI0039071 dno-mir-331; +MI0039072 dno-mir-335; +MI0039073 dno-mir-337; +MI0039074 dno-mir-338; +MI0039075 dno-mir-339; +MI0039076 dno-mir-340; +MI0039077 dno-mir-342; +MI0039078 dno-mir-345; +MI0039079 dno-mir-361; +MI0039080 dno-mir-362; +MI0039081 dno-mir-363; +MI0039082 dno-mir-365-1; +MI0039083 dno-mir-365-2; +MI0039084 dno-mir-367; +MI0039085 dno-mir-369; +MI0039086 dno-mir-371; +MI0039087 dno-mir-372; +MI0039088 dno-mir-374a; +MI0039089 dno-mir-375; +MI0039090 dno-mir-376a; +MI0039091 dno-mir-376b; +MI0039092 dno-mir-376d; +MI0039093 dno-mir-377; +MI0039094 dno-mir-378; +MI0039095 dno-mir-379; +MI0039096 dno-mir-380; +MI0039097 dno-mir-381; +MI0039098 dno-mir-382; +MI0039099 dno-mir-383; +MI0039100 dno-mir-409; +MI0039101 dno-mir-410; +MI0039102 dno-mir-411; +MI0039103 dno-mir-412; +MI0039104 dno-mir-421; +MI0039105 dno-mir-423; +MI0039106 dno-mir-424; +MI0039107 dno-mir-425; +MI0039108 dno-mir-429; +MI0039109 dno-mir-432; +MI0039110 dno-mir-433; +MI0039111 dno-mir-449a; +MI0039112 dno-mir-449b; +MI0039113 dno-mir-449c; +MI0039114 dno-mir-450a; +MI0039115 dno-mir-450b; +MI0039116 dno-mir-450c; +MI0039117 dno-mir-451; +MI0039118 dno-mir-454; +MI0039119 dno-mir-455; +MI0039120 dno-mir-483; +MI0039121 dno-mir-485; +MI0039122 dno-mir-486; +MI0039123 dno-mir-487a; +MI0039124 dno-mir-487b; +MI0039125 dno-mir-488; +MI0039126 dno-mir-489; +MI0039127 dno-mir-490; +MI0039128 dno-mir-491; +MI0039129 dno-mir-493; +MI0039130 dno-mir-494; +MI0039131 dno-mir-495; +MI0039132 dno-mir-496; +MI0039133 dno-mir-497; +MI0039134 dno-mir-499; +MI0039135 dno-mir-500a; +MI0039136 dno-mir-500b; +MI0039137 dno-mir-502; +MI0039138 dno-mir-503; +MI0039139 dno-mir-504; +MI0039140 dno-mir-505; +MI0039141 dno-mir-506; +MI0039142 dno-mir-507; +MI0039143 dno-mir-508; +MI0039144 dno-mir-509a-1; +MI0039145 dno-mir-509a-2; +MI0039146 dno-mir-509b; +MI0039147 dno-mir-512; +MI0039148 dno-mir-532; +MI0039149 dno-mir-539; +MI0039150 dno-mir-541; +MI0039151 dno-mir-542; +MI0039152 dno-mir-543; +MI0039153 dno-mir-545; +MI0039154 dno-mir-551a; +MI0039155 dno-mir-551b; +MI0039156 dno-mir-574; +MI0039157 dno-mir-582; +MI0039158 dno-mir-590; +MI0039159 dno-mir-628; +MI0039160 dno-mir-652; +MI0039161 dno-mir-653; +MI0039162 dno-mir-654; +MI0039163 dno-mir-656; +MI0039164 dno-mir-660; +MI0039165 dno-mir-670; +MI0039166 dno-mir-671; +MI0039167 dno-mir-672; +MI0039168 dno-mir-675; +MI0039169 dno-mir-676; +MI0039170 dno-mir-708; +MI0039171 dno-mir-744; +MI0039172 dno-mir-758; +MI0039173 dno-mir-760; +MI0039174 dno-mir-802; +MI0039175 dno-mir-873; +MI0039176 dno-mir-874; +MI0039177 dno-mir-885; +MI0039178 dno-mir-889; +MI0039179 dno-mir-1185-1; +MI0039180 dno-mir-1185-2; +MI0039181 dno-mir-1193; +MI0039182 dno-mir-1197; +MI0039183 dno-mir-1249; +MI0039184 dno-mir-1251; +MI0039185 dno-mir-1271; +MI0039186 dno-mir-1277; +MI0039187 dno-mir-1296; +MI0039188 dno-mir-1298; +MI0039189 dno-mir-1301; +MI0039190 dno-mir-1307; +MI0039191 dno-mir-1343; +MI0039192 dno-mir-1388; +MI0039193 dno-mir-1842; +MI0039194 dno-mir-2114; +MI0039195 dno-mir-2355; +MI0039196 dno-mir-2483; +MI0039197 dno-mir-3059; +MI0039198 dno-mir-3085; +MI0039199 dno-mir-3613; +MI0039200 dno-mir-3959; +MI0039201 dno-mir-6529; +MI0039202 dno-mir-12085; +MI0039203 dno-mir-12086; +MI0039204 dno-mir-12087; +MI0039205 ocu-let-7a-1; +MI0039206 ocu-let-7a-2; +MI0039207 ocu-let-7a-3; +MI0039208 ocu-let-7b; +MI0039209 ocu-let-7c; +MI0039210 ocu-let-7d; +MI0039211 ocu-let-7f-1; +MI0039212 ocu-let-7f-2; +MI0039213 ocu-let-7g; +MI0039214 ocu-let-7i; +MI0039215 ocu-mir-1-2; +MI0039216 ocu-mir-7a; +MI0039217 ocu-mir-9-1; +MI0039218 ocu-mir-9-2; +MI0039219 ocu-mir-10a; +MI0039220 ocu-mir-10b; +MI0039221 ocu-mir-15a; +MI0039222 ocu-mir-15b; +MI0039223 ocu-mir-16a; +MI0039224 ocu-mir-16b; +MI0039225 ocu-mir-17; +MI0039226 ocu-mir-18a; +MI0039227 ocu-mir-18b; +MI0039228 ocu-mir-19a; +MI0039229 ocu-mir-19b-1; +MI0039230 ocu-mir-19b-2; +MI0039231 ocu-mir-20a; +MI0039232 ocu-mir-20b; +MI0039233 ocu-mir-21; +MI0039234 ocu-mir-22; +MI0039235 ocu-mir-23b; +MI0039236 ocu-mir-24-1; +MI0039237 ocu-mir-24-2; +MI0039238 ocu-mir-25; +MI0039239 ocu-mir-26a; +MI0039240 ocu-mir-26b; +MI0039241 ocu-mir-27b; +MI0039242 ocu-mir-28; +MI0039243 ocu-mir-29a; +MI0039244 ocu-mir-29b-1; +MI0039245 ocu-mir-29b-2; +MI0039246 ocu-mir-29c; +MI0039247 ocu-mir-30a; +MI0039248 ocu-mir-30b; +MI0039249 ocu-mir-30c-1; +MI0039250 ocu-mir-30c-2; +MI0039251 ocu-mir-30d; +MI0039252 ocu-mir-30e; +MI0039253 ocu-mir-31; +MI0039254 ocu-mir-32; +MI0039255 ocu-mir-33a; +MI0039256 ocu-mir-34a; +MI0039257 ocu-mir-34b; +MI0039258 ocu-mir-34c; +MI0039259 ocu-mir-92a-1; +MI0039260 ocu-mir-92a-2; +MI0039261 ocu-mir-93; +MI0039262 ocu-mir-96; +MI0039263 ocu-mir-98; +MI0039264 ocu-mir-99a; +MI0039265 ocu-mir-100; +MI0039266 ocu-mir-101-1; +MI0039267 ocu-mir-101-2; +MI0039268 ocu-mir-103a-1; +MI0039269 ocu-mir-103a-2; +MI0039270 ocu-mir-105a-1; +MI0039271 ocu-mir-105a-2; +MI0039272 ocu-mir-106a; +MI0039273 ocu-mir-106b; +MI0039274 ocu-mir-107; +MI0039275 ocu-mir-122; +MI0039276 ocu-mir-124-1; +MI0039277 ocu-mir-124-2; +MI0039278 ocu-mir-125b-1; +MI0039279 ocu-mir-125b-2; +MI0039280 ocu-mir-127; +MI0039281 ocu-mir-128a; +MI0039282 ocu-mir-128b; +MI0039283 ocu-mir-129-1; +MI0039284 ocu-mir-129-2; +MI0039285 ocu-mir-130a; +MI0039286 ocu-mir-130b; +MI0039287 ocu-mir-133a; +MI0039288 ocu-mir-133b; +MI0039289 ocu-mir-134; +MI0039290 ocu-mir-135a-1; +MI0039291 ocu-mir-135a-2; +MI0039292 ocu-mir-135b; +MI0039293 ocu-mir-136; +MI0039294 ocu-mir-137; +MI0039295 ocu-mir-138-1; +MI0039296 ocu-mir-138-2; +MI0039297 ocu-mir-139; +MI0039298 ocu-mir-140; +MI0039299 ocu-mir-141; +MI0039300 ocu-mir-142; +MI0039301 ocu-mir-143; +MI0039302 ocu-mir-144; +MI0039303 ocu-mir-145; +MI0039304 ocu-mir-146a; +MI0039305 ocu-mir-146b; +MI0039306 ocu-mir-147; +MI0039307 ocu-mir-148a; +MI0039308 ocu-mir-148b; +MI0039309 ocu-mir-150; +MI0039310 ocu-mir-151; +MI0039311 ocu-mir-152; +MI0039312 ocu-mir-153; +MI0039313 ocu-mir-154; +MI0039314 ocu-mir-155; +MI0039315 ocu-mir-181a-1; +MI0039316 ocu-mir-181a-2; +MI0039317 ocu-mir-181b-1; +MI0039318 ocu-mir-181b-2; +MI0039319 ocu-mir-181c; +MI0039320 ocu-mir-181d; +MI0039321 ocu-mir-182; +MI0039322 ocu-mir-183; +MI0039323 ocu-mir-184; +MI0039324 ocu-mir-185; +MI0039325 ocu-mir-186; +MI0039326 ocu-mir-187; +MI0039327 ocu-mir-188; +MI0039328 ocu-mir-190a; +MI0039329 ocu-mir-190b; +MI0039330 ocu-mir-193a; +MI0039331 ocu-mir-193b; +MI0039332 ocu-mir-194; +MI0039333 ocu-mir-195; +MI0039334 ocu-mir-196a-1; +MI0039335 ocu-mir-196a-2; +MI0039336 ocu-mir-196b; +MI0039337 ocu-mir-197; +MI0039338 ocu-mir-199a-1; +MI0039339 ocu-mir-199a-2; +MI0039340 ocu-mir-200c; +MI0039341 ocu-mir-204; +MI0039342 ocu-mir-205; +MI0039343 ocu-mir-206; +MI0039344 ocu-mir-208a; +MI0039345 ocu-mir-208b; +MI0039346 ocu-mir-211; +MI0039347 ocu-mir-212; +MI0039348 ocu-mir-214; +MI0039349 ocu-mir-215; +MI0039350 ocu-mir-216a; +MI0039351 ocu-mir-216b; +MI0039352 ocu-mir-217; +MI0039353 ocu-mir-218-1; +MI0039354 ocu-mir-218-2; +MI0039355 ocu-mir-219a; +MI0039356 ocu-mir-219b; +MI0039357 ocu-mir-221; +MI0039358 ocu-mir-222; +MI0039359 ocu-mir-223; +MI0039360 ocu-mir-224; +MI0039361 ocu-mir-299; +MI0039362 ocu-mir-301a; +MI0039363 ocu-mir-301b; +MI0039364 ocu-mir-323a; +MI0039365 ocu-mir-324; +MI0039366 ocu-mir-325; +MI0039367 ocu-mir-326; +MI0039368 ocu-mir-328; +MI0039369 ocu-mir-329; +MI0039370 ocu-mir-331; +MI0039371 ocu-mir-335; +MI0039372 ocu-mir-337; +MI0039373 ocu-mir-340; +MI0039374 ocu-mir-342; +MI0039375 ocu-mir-346; +MI0039376 ocu-mir-350; +MI0039377 ocu-mir-361; +MI0039378 ocu-mir-362; +MI0039379 ocu-mir-363; +MI0039380 ocu-mir-365-1; +MI0039381 ocu-mir-365-2; +MI0039382 ocu-mir-369; +MI0039383 ocu-mir-370; +MI0039384 ocu-mir-374a; +MI0039385 ocu-mir-374b; +MI0039386 ocu-mir-375; +MI0039387 ocu-mir-376a; +MI0039388 ocu-mir-376b; +MI0039389 ocu-mir-376c-1; +MI0039390 ocu-mir-376c-2; +MI0039391 ocu-mir-377; +MI0039392 ocu-mir-378; +MI0039393 ocu-mir-379; +MI0039394 ocu-mir-381; +MI0039395 ocu-mir-382; +MI0039396 ocu-mir-383; +MI0039397 ocu-mir-384; +MI0039398 ocu-mir-409; +MI0039399 ocu-mir-410; +MI0039400 ocu-mir-411; +MI0039401 ocu-mir-421; +MI0039402 ocu-mir-423; +MI0039403 ocu-mir-424; +MI0039404 ocu-mir-425; +MI0039405 ocu-mir-432; +MI0039406 ocu-mir-433; +MI0039407 ocu-mir-448; +MI0039408 ocu-mir-449a; +MI0039409 ocu-mir-449b; +MI0039410 ocu-mir-450a-1; +MI0039411 ocu-mir-450a-2; +MI0039412 ocu-mir-450b; +MI0039413 ocu-mir-451; +MI0039414 ocu-mir-452; +MI0039415 ocu-mir-455; +MI0039416 ocu-mir-485; +MI0039417 ocu-mir-486; +MI0039418 ocu-mir-487a; +MI0039419 ocu-mir-487b; +MI0039420 ocu-mir-488; +MI0039421 ocu-mir-489; +MI0039422 ocu-mir-490; +MI0039423 ocu-mir-491; +MI0039424 ocu-mir-495; +MI0039425 ocu-mir-496; +MI0039426 ocu-mir-497; +MI0039427 ocu-mir-499; +MI0039428 ocu-mir-500; +MI0039429 ocu-mir-501; +MI0039430 ocu-mir-502a; +MI0039431 ocu-mir-502b; +MI0039432 ocu-mir-503; +MI0039433 ocu-mir-504; +MI0039434 ocu-mir-505; +MI0039435 ocu-mir-506; +MI0039436 ocu-mir-507; +MI0039437 ocu-mir-508; +MI0039438 ocu-mir-509a; +MI0039439 ocu-mir-513; +MI0039440 ocu-mir-509b; +MI0039441 ocu-mir-509c; +MI0039442 ocu-mir-532; +MI0039443 ocu-mir-539; +MI0039444 ocu-mir-541; +MI0039445 ocu-mir-542; +MI0039446 ocu-mir-545; +MI0039447 ocu-mir-551b; +MI0039448 ocu-mir-574; +MI0039449 ocu-mir-582; +MI0039450 ocu-mir-590; +MI0039451 ocu-mir-599; +MI0039452 ocu-mir-628; +MI0039453 ocu-mir-652; +MI0039454 ocu-mir-653; +MI0039455 ocu-mir-654; +MI0039456 ocu-mir-655; +MI0039457 ocu-mir-656; +MI0039458 ocu-mir-660; +MI0039459 ocu-mir-670; +MI0039460 ocu-mir-671; +MI0039461 ocu-mir-672; +MI0039462 ocu-mir-676; +MI0039463 ocu-mir-708; +MI0039464 ocu-mir-744; +MI0039465 ocu-mir-758; +MI0039466 ocu-mir-760; +MI0039467 ocu-mir-802; +MI0039468 ocu-mir-872; +MI0039469 ocu-mir-873; +MI0039470 ocu-mir-874; +MI0039471 ocu-mir-875; +MI0039472 ocu-mir-885; +MI0039473 ocu-mir-889; +MI0039474 ocu-mir-1197; +MI0039475 ocu-mir-1249; +MI0039476 ocu-mir-1251; +MI0039477 ocu-mir-1264; +MI0039478 ocu-mir-1277; +MI0039479 ocu-mir-1296; +MI0039480 ocu-mir-1298; +MI0039481 ocu-mir-1307; +MI0039482 ocu-mir-1343; +MI0039483 ocu-mir-1911; +MI0039484 ocu-mir-2355; +MI0039485 ocu-mir-2387; +MI0039486 ocu-mir-3059; +MI0039487 ocu-mir-3085; +MI0039488 ocu-mir-3613; +MI0039489 ocu-mir-6529; +MI0039490 ocu-mir-7180; +MI0039491 ocu-mir-9851; +MI0039492 ocu-mir-12090; +MI0039493 ocu-mir-12091; +MI0039494 ocu-mir-12092; +MI0039495 ocu-mir-12093; +MI0039496 ocu-mir-12094; +MI0039497 ocu-mir-105b; +MI0039498 ocu-mir-12095; +MI0039499 hsa-mir-3059; +MI0039500 hsa-mir-3085; +MI0039501 hsa-mir-6529; +MI0039502 hsa-mir-9851; +MI0039503 mmu-mir-1271; +MI0039504 mmu-mir-1911; +MI0039505 gga-mir-143; +MI0039506 gga-mir-449d; +MI0039507 dre-mir-129-3; +MI0039508 dre-mir-129-4; +MI0039509 dre-mir-212-2; +MI0039510 dre-mir-138-2; +MI0039511 dre-mir-181a-4; +MI0039512 dre-mir-181a-3; +MI0039513 dre-mir-181a-5; +MI0039514 dre-mir-181b-3; +MI0039515 dre-mir-181d; +MI0039516 dre-mir-204-3; +MI0039517 dre-mir-23b-2; +MI0039518 dre-mir-24b; +MI0039519 dre-mir-7133; +MI0039520 dre-mir-128-3; +MI0039521 dre-mir-29b3; +MI0039522 dre-mir-7132; +MI0039523 gga-mir-9-4; +MI0039524 dre-mir-338-3; +MI0039525 mle-bantam; +MI0039526 mle-let-7; +MI0039527 mle-mir-1; +MI0039528 mle-mir-2a; +MI0039529 mle-mir-2b; +MI0039530 mle-mir-2c; +MI0039531 mle-mir-2d; +MI0039532 mle-mir-2e; +MI0039533 mle-mir-2f; +MI0039534 mle-mir-2g; +MI0039535 mle-mir-2h; +MI0039536 mle-mir-2i; +MI0039537 mle-mir-2j; +MI0039538 mle-mir-2k; +MI0039539 mle-mir-7; +MI0039540 mle-mir-8; +MI0039541 mle-mir-9; +MI0039542 mle-mir-10a; +MI0039543 mle-mir-10b; +MI0039544 mle-mir-12; +MI0039545 mle-mir-745a; +MI0039546 mle-mir-745b; +MI0039547 mle-mir-29a; +MI0039548 mle-mir-29b; +MI0039549 mle-mir-31; +MI0039550 mle-mir-33; +MI0039551 mle-mir-34; +MI0039552 mle-mir-67; +MI0039553 mle-mir-71; +MI0039554 mle-mir-981; +MI0039555 mle-mir-87; +MI0039556 mle-mir-92a; +MI0039557 mle-mir-92b; +MI0039558 mle-mir-92c; +MI0039559 mle-mir-96a; +MI0039560 mle-mir-96b; +MI0039561 mle-mir-100; +MI0039562 mle-mir-124; +MI0039563 mle-mir-125; +MI0039564 mle-mir-133; +MI0039565 mle-mir-137; +MI0039566 mle-mir-153; +MI0039567 mle-mir-263b; +MI0039568 mle-mir-263a; +MI0039569 mle-mir-184; +MI0039570 mle-mir-190; +MI0039571 mle-mir-193; +MI0039572 mle-mir-210; +MI0039573 mle-mir-216a; +MI0039574 mle-mir-216b; +MI0039575 mle-mir-219; +MI0039576 mle-mir-242; +MI0039577 mle-mir-252a; +MI0039578 mle-mir-252b; +MI0039579 mle-mir-277; +MI0039580 mle-mir-279; +MI0039581 mle-mir-281; +MI0039582 mle-mir-315; +MI0039583 mle-mir-317; +MI0039584 mle-mir-365; +MI0039585 mle-mir-375; +MI0039586 mle-mir-750; +MI0039587 mle-mir-1175; +MI0039588 mle-mir-1984; +MI0039589 mle-mir-1985; +MI0039590 mle-mir-1986; +MI0039591 mle-mir-1988a; +MI0039592 mle-mir-1988b; +MI0039593 mle-mir-1989a; +MI0039594 mle-mir-1989b; +MI0039595 mle-mir-1990; +MI0039596 mle-mir-1991; +MI0039597 mle-mir-1992; +MI0039598 mle-mir-1993; +MI0039599 mle-mir-1994a; +MI0039600 mle-mir-1994b; +MI0039601 mle-mir-2001; +MI0039602 mle-mir-2722; +MI0039603 mle-mir-12096a; +MI0039604 mle-mir-12096b; +MI0039605 mle-mir-12097; +MI0039606 mle-mir-12098; +MI0039607 mle-mir-12099; +MI0039608 mle-mir-12100; +MI0039609 mle-mir-29c; +MI0039610 mle-mir-12101-1; +MI0039611 mle-mir-12101-2; +MI0039612 mle-mir-12102; +MI0039613 mle-mir-12103; +MI0039614 mle-mir-12104; +MI0039615 csi-MIR156b; +MI0039616 csi-MIR156c; +MI0039617 csi-MIR156d; +MI0039618 csi-MIR156e; +MI0039619 csi-MIR156f; +MI0039620 csi-MIR156g; +MI0039621 csi-MIR159b; +MI0039622 csi-MIR159c; +MI0039623 csi-MIR160b; +MI0039624 csi-MIR160c; +MI0039625 csi-MIR164b; +MI0039626 csi-MIR164c; +MI0039627 csi-MIR166b; +MI0039628 csi-MIR166d; +MI0039629 csi-MIR166f; +MI0039630 csi-MIR166g; +MI0039631 csi-MIR166h; +MI0039632 csi-MIR166i; +MI0039633 csi-MIR166j; +MI0039634 csi-MIR166k; +MI0039635 csi-MIR167d; +MI0039636 csi-MIR167e; +MI0039637 csi-MIR169b; +MI0039638 csi-MIR169c; +MI0039639 csi-MIR169d; +MI0039640 csi-MIR169e; +MI0039641 csi-MIR169f; +MI0039642 csi-MIR169g; +MI0039643 csi-MIR169h; +MI0039644 csi-MIR169i; +MI0039645 csi-MIR169j; +MI0039646 csi-MIR169k; +MI0039647 csi-MIR169l; +MI0039648 csi-MIR169m; +MI0039649 csi-MIR169n; +MI0039650 csi-MIR171c; +MI0039651 csi-MIR171d; +MI0039652 csi-MIR171e; +MI0039653 csi-MIR171f; +MI0039654 csi-MIR171g; +MI0039655 csi-MIR171h; +MI0039656 csi-MIR171i; +MI0039657 csi-MIR172b; +MI0039658 csi-MIR172d; +MI0039659 csi-MIR390b; +MI0039660 csi-MIR393b; +MI0039661 csi-MIR393c; +MI0039662 csi-MIR394b; +MI0039663 csi-MIR395b; +MI0039664 csi-MIR395c; +MI0039665 csi-MIR396d; +MI0039666 csi-MIR396e; +MI0039667 csi-MIR396f; +MI0039668 csi-MIR398b; +MI0039669 csi-MIR399e; +MI0039670 csi-MIR399f; +MI0039671 csi-MIR403b; +MI0039672 csi-MIR477d; +MI0039673 csi-MIR477e; +MI0039674 csi-MIR482d; +MI0039675 csi-MIR535b; +MI0039676 csi-MIR535c; +MI0039677 csi-MIR858; +MI0039678 csi-MIR2275a; +MI0039679 csi-MIR2275b; +MI0039680 csi-MIR3627a; +MI0039681 csi-MIR3627b; +MI0039682 csi-MIR3627c; +MI0039683 csi-MIR391; +MI0039684 csi-MIR1515b; +MI0039685 csi-MIR3952b; +MI0039686 csi-MIR3954b; +MI0039687 csi-MIR12105; +MI0039688 csi-MIR536; +MI0039689 csi-MIR12106; +MI0039690 csi-MIR12107; +MI0039692 csi-MIR482e; +MI0039694 csi-MIR12108; +MI0039695 csi-MIR12109; +MI0039696 csi-MIR9560; +MI0039697 csi-MIR12110; +MI0039698 csi-MIR12111; +MI0039699 csi-MIR168; +MI0039700 csi-MIR482g; +MI0039701 csi-MIR156h; +MI0039702 csi-MIR156i; +MI0039703 csi-MIR156j; +MI0039704 csi-MIR164d; +MI0039705 csi-MIR169o; +MI0039706 csi-MIR169p; +MI0039707 csi-MIR169q; +MI0039708 csi-MIR535d; +MI0039709 csi-MIR535e; +MI0039710 csi-MIR535f; +MI0039711 csi-MIR2111; +MI0039712 csi-MIR3951b; +MI0039713 csi-MIR169r; +MI0039714 smi-MIR12112; +MI0039715 hsa-mir-12113; +MI0039716 hsa-mir-12114; +MI0039717 hsa-mir-12115; +MI0039718 hsa-mir-12116; +MI0039719 hsa-mir-12117; +MI0039720 hsa-mir-12118; +MI0039721 hsa-mir-12119; +MI0039722 hsa-mir-12120; +MI0039723 hsa-mir-12121; +MI0039724 hsa-mir-12122; +MI0039725 hsa-mir-12123; +MI0039726 hsa-mir-12124; +MI0039727 hsa-mir-12125; +MI0039728 hsa-mir-12126; +MI0039729 hsa-mir-12127; +MI0039730 hsa-mir-12128; +MI0039731 hsa-mir-12129; +MI0039732 hsa-mir-12130; +MI0039733 hsa-mir-12131; +MI0039734 hsa-mir-12132; +MI0039735 hsa-mir-12133; +MI0039736 cel-mir-12134; +MI0039737 cel-mir-55b; +MI0039738 cel-mir-58c; +MI0039739 hsa-mir-12135; +MI0039740 hsa-mir-12136; +MI0039741 ppa-mir-410; +MI0039742 ppa-mir-369; +MI0039743 ppa-mir-412; +MI0039744 ppa-mir-409; +MI0039745 ppa-mir-485; +MI0039746 ppa-mir-382; +MI0039747 ppa-mir-889; +MI0039748 ppa-mir-381; +MI0039749 ppa-mir-654; +MI0039750 ppa-mir-376c; +MI0039751 ppa-mir-494; +MI0039752 ppa-mir-323; +MI0039753 ppa-mir-299; +MI0039754 ppa-mir-411a; +MI0039755 ppa-mir-379; +MI0039756 ppa-mir-370; +MI0039757 ppa-mir-432; +MI0039758 ppa-mir-127; +MI0039759 ppa-mir-665; +MI0039760 ppa-mir-493; +MI0039761 ppa-mir-342; +MI0039762 ppa-mir-193b; +MI0039763 ppa-mir-574; +MI0039764 ppa-mir-615; +MI0039765 ppa-mir-145; +MI0039766 ppa-mir-378a; +MI0039767 ppa-mir-192; +MI0039768 ppa-mir-152; +MI0039769 ppa-mir-1307; +MI0039770 ppa-mir-146b; +MI0039771 ppa-let-7i; +MI0039772 ppa-mir-421; +MI0039773 ppa-mir-320a; +MI0039774 ppa-mir-486-2; +MI0039775 ppa-mir-486-1; +MI0039776 ppa-mir-199b; +MI0039777 ppa-mir-887; +MI0039778 ppa-mir-2355; +MI0039779 ppa-let-7a-2; +MI0039780 ppa-mir-151; +MI0039781 ppa-mir-155; +MI0039782 ppa-let-7c; +MI0039783 ppa-let-7g; +MI0039784 ppa-mir-26b; +MI0039785 ppa-mir-629; +MI0039786 ppa-mir-191; +MI0039787 ppa-mir-769; +MI0039788 ppa-mir-92b; +MI0039789 ppa-mir-30e; +MI0039790 ppa-mir-320b-2; +MI0039791 ppa-mir-181d; +MI0039792 ppa-mir-140; +MI0039793 ppa-mir-424; +MI0039794 ppa-mir-542; +MI0039795 ppa-mir-450a-2; +MI0039796 ppa-mir-450a-1; +MI0039797 ppa-mir-1304; +MI0039798 ppa-mir-125a; +MI0039799 ppa-let-7e; +MI0039800 ppa-mir-423; +MI0039801 ppa-let-7a-1; +MI0039802 ppa-let-7b; +MI0039803 ppa-mir-328; +MI0039804 ppa-mir-193a; +MI0039805 ppa-mir-27b; +MI0039806 ppa-mir-549-1; +MI0039807 ppa-mir-549-2; +MI0039808 ppa-mir-222; +MI0039809 ppa-mir-148a; +MI0039810 ppa-let-7f; +MI0039811 ppa-mir-148b; +MI0039812 ppa-mir-320b-1; +MI0039813 ppa-mir-210; +MI0039814 ppa-mir-532; +MI0039815 ppa-mir-660; +MI0039816 ppa-mir-34c; +MI0039817 ppa-mir-484; +MI0039818 ppa-mir-340; +MI0039819 ptr-mir-877; +MI0039820 ptr-mir-2355; +MI0039821 ptr-mir-4677; +MI0039822 ggo-mir-196b; +MI0039823 ggo-mir-301a; +MI0039824 ggo-mir-2355; +MI0039825 ggo-mir-561; +MI0039826 ggo-mir-369; +MI0039827 ggo-mir-541; +MI0039828 ggo-mir-382; +MI0039829 ggo-mir-539; +MI0039830 ggo-mir-758; +MI0039831 ggo-mir-615; +MI0039832 ggo-mir-1304; +MI0039833 ggo-mir-1307; +MI0039834 ggo-mir-320a-2; +MI0039835 mml-mir-574; +MI0039836 mml-mir-328; +MI0039837 mmr-mir-615; +MI0039838 mmr-mir-204; +MI0039839 mmr-mir-130a; +MI0039840 mmr-mir-1839-1; +MI0039841 mmr-mir-146a; +MI0039842 mmr-mir-29b-1; +MI0039843 mmr-mir-29a; +MI0039844 mmr-mir-100; +MI0039845 mmr-let-7a-2; +MI0039846 mmr-mir-125a; +MI0039847 mmr-mir-218b; +MI0039848 mmr-mir-1307; +MI0039849 mmr-mir-708; +MI0039850 mmr-mir-1839-2; +MI0039851 mmr-mir-15a; +MI0039852 mmr-mir-126; +MI0039853 mmr-mir-26a-1; +MI0039854 mmr-mir-138-2; +MI0039855 mmr-mir-29b-2; +MI0039856 mmr-mir-29c; +MI0039857 mmr-mir-103a; +MI0039858 mmr-mir-221; +MI0039859 mmr-mir-26b; +MI0039860 mmr-mir-28; +MI0039861 mmr-let-7a-1; +MI0039862 mmr-mir-152; +MI0039863 mmr-mir-211; +MI0039864 mmr-mir-455; +MI0039865 mmr-mir-320a-4; +MI0039866 mmr-let-7g; +MI0039867 mmr-mir-872; +MI0039868 mmr-mir-301a; +MI0039869 mmr-mir-181a; +MI0039870 mmr-mir-186; +MI0039871 mmr-mir-136; +MI0039872 mmr-mir-188; +MI0039873 mmr-mir-532; +MI0039874 mmr-mir-1839-3; +MI0039875 mmr-mir-340; +MI0039876 mmr-mir-107; +MI0039877 mmr-mir-6313-1; +MI0039878 mmr-mir-1388; +MI0039879 mmr-mir-98; +MI0039880 mmr-mir-374a; +MI0039881 mmr-mir-101-1; +MI0039882 mmr-mir-342; +MI0039883 mmr-mir-365-1; +MI0039884 mmr-mir-193; +MI0039885 mmr-mir-103b; +MI0039886 mmr-mir-486; +MI0039887 mmr-let-7f; +MI0039888 mmr-mir-365-2; +MI0039889 mmr-mir-361; +MI0039890 mmr-mir-1839-4; +MI0039891 mmr-mir-497; +MI0039892 mmr-mir-590; +MI0039893 mmr-mir-34c; +MI0039894 mmr-mir-34b; +MI0039895 mmr-mir-324; +MI0039896 mmr-mir-34a; +MI0039897 mmr-mir-199-3; +MI0039898 mmr-mir-502a; +MI0039899 mmr-mir-660; +MI0039900 mmr-mir-500; +MI0039901 mmr-mir-502b; +MI0039902 mmr-mir-320a-2; +MI0039903 mmr-mir-22; +MI0039904 mmr-mir-19b-2; +MI0039905 mmr-mir-92b; +MI0039906 mmr-let-7b; +MI0039907 mmr-mir-187; +MI0039908 mmr-mir-410; +MI0039909 mmr-mir-409; +MI0039910 mmr-mir-3959; +MI0039911 mmr-mir-381; +MI0039912 mmr-mir-411b; +MI0039913 mmr-mir-411a; +MI0039914 mmr-mir-92a; +MI0039915 mmr-mir-19b-1; +MI0039916 mmr-mir-20; +MI0039917 mmr-mir-18; +MI0039918 mmr-mir-17; +MI0039919 mmr-mir-21; +MI0039920 mmr-mir-146b; +MI0039921 mmr-let-7c; +MI0039922 mmr-mir-99a; +MI0039923 mmr-mir-140; +MI0039924 mmr-mir-328; +MI0039925 mmr-mir-212; +MI0039926 mmr-mir-26a-2; +MI0039927 mmr-mir-138-1; +MI0039928 mmr-mir-10; +MI0039929 mmr-mir-101-2; +MI0039930 mmr-mir-222; +MI0039931 mmr-mir-145; +MI0039932 mmr-mir-148b; +MI0039933 mmr-mir-320a-1; +MI0039934 mmr-mir-214; +MI0039935 mmr-mir-199-1; +MI0039936 mmr-mir-10a; +MI0039937 mmr-mir-425; +MI0039938 mmr-mir-191; +MI0039939 mmr-mir-31; +MI0039940 mmr-mir-199-2; +MI0039941 mmr-mir-218a; +MI0039942 mmr-mir-182; +MI0039943 mmr-mir-30a; +MI0039944 mmr-mir-30c; +MI0039945 mmr-mir-320a-3; +MI0039946 mmr-mir-128; +MI0039947 mmr-mir-30e; +MI0039948 mmr-mir-151; +MI0039949 mmr-mir-196b; +MI0039950 mmr-mir-424; +MI0039951 mmr-mir-542; +MI0039952 mmr-mir-296; +MI0039953 mmr-mir-24; +MI0039954 mmr-mir-27b; +MI0039955 mmr-mir-23b; +MI0039956 mmr-mir-6313-2; +MI0039957 mmr-mir-132; +MI0039958 mmr-mir-484; +MI0039959 mmr-mir-197; +MI0039960 mmr-mir-345; +MI0039961 mmr-mir-195; +MI0039962 dma-mir-1388; +MI0039963 dma-let-7a-1; +MI0039964 dma-mir-140; +MI0039965 dma-mir-193; +MI0039966 dma-mir-26b; +MI0039967 dma-mir-532; +MI0039968 dma-mir-10a; +MI0039969 dma-mir-30c; +MI0039970 dma-mir-409; +MI0039971 dma-mir-877; +MI0039972 dma-mir-340; +MI0039973 dma-mir-92a-2; +MI0039974 dma-mir-19b-2; +MI0039975 dma-mir-432; +MI0039976 dma-mir-127; +MI0039977 dma-mir-22; +MI0039978 dma-mir-196; +MI0039979 dma-let-7f; +MI0039980 dma-mir-100; +MI0039981 dma-mir-130a; +MI0039982 dma-mir-125b-2; +MI0039983 dma-mir-143; +MI0039984 dma-mir-145; +MI0039985 dma-mir-28; +MI0039986 dma-let-7b; +MI0039987 dma-mir-103a; +MI0039988 dma-mir-1307; +MI0039989 dma-mir-101-1; +MI0039990 dma-mir-708; +MI0039991 dma-mir-30a; +MI0039992 dma-mir-26a-2; +MI0039993 dma-mir-107; +MI0039994 dma-mir-181a-1; +MI0039995 dma-mir-181b-1; +MI0039996 dma-mir-660; +MI0039997 dma-mir-502b; +MI0039998 dma-mir-125b-1; +MI0039999 dma-mir-31; +MI0040000 dma-mir-186; +MI0040001 dma-mir-214; +MI0040002 dma-mir-199; +MI0040003 dma-let-7c; +MI0040004 dma-mir-103b; +MI0040005 dma-mir-26a-1; +MI0040006 dma-mir-16; +MI0040007 dma-mir-222; +MI0040008 dma-mir-221; +MI0040009 dma-mir-101-2; +MI0040010 dma-mir-23b; +MI0040011 dma-mir-27b; +MI0040012 dma-mir-24; +MI0040013 dma-mir-30e; +MI0040014 dma-mir-381; +MI0040015 dma-mir-25; +MI0040016 dma-mir-93; +MI0040017 dma-mir-106b; +MI0040018 dma-mir-29a; +MI0040019 dma-mir-296; +MI0040020 dma-mir-6529; +MI0040021 dma-mir-19b-1; +MI0040022 dma-mir-92a-1; +MI0040023 dma-let-7g; +MI0040024 dma-mir-21; +MI0040025 dma-mir-98; +MI0040026 dma-mir-151; +MI0040027 dma-mir-181b-2; +MI0040028 dma-mir-181a-2; +MI0040029 dma-mir-148b; +MI0040030 dma-mir-191; +MI0040031 dma-mir-181c; +MI0040032 dma-mir-10; +MI0040033 dma-mir-423; +MI0040034 dma-mir-339; +MI0040035 dma-let-7a-2; +MI0040036 dma-mir-125a; +MI0040037 cja-mir-450c; +MI0040038 cja-mir-98; +MI0040039 cja-mir-502b; +MI0040040 cja-mir-331; +MI0040041 cja-let-7i; +MI0040042 cja-mir-29a; +MI0040043 cja-mir-301a; +MI0040044 cja-mir-22; +MI0040045 cja-mir-30c; +MI0040046 cja-mir-23a; +MI0040047 cja-mir-125a; +MI0040048 cja-let-7e; +MI0040049 cja-mir-125b; +MI0040050 cja-let-7c; +MI0040051 cja-mir-340; +MI0040052 cja-mir-378; +MI0040053 cja-mir-25; +MI0040054 cja-mir-106b; +MI0040055 cja-mir-28; +MI0040056 cja-mir-484; +MI0040057 cja-mir-1307; +MI0040058 cja-mir-100; +MI0040059 cja-mir-130a; +MI0040060 cja-mir-409; +MI0040061 cja-mir-889; +MI0040062 cja-mir-432; +MI0040063 cja-let-7d; +MI0040064 cja-let-7f; +MI0040065 cja-mir-19a; +MI0040066 cja-mir-873; +MI0040067 cja-mir-101-2; +MI0040068 ppy-mir-3136; +MI0040069 ppy-mir-6529; +MI0040070 ppy-mir-2355; +MI0040071 ppy-mir-301a; +MI0040072 nle-mir-324; +MI0040073 nle-mir-153-2; +MI0040074 nle-mir-484; +MI0040075 nle-mir-210; +MI0040076 nle-mir-5699; +MI0040077 nle-mir-365-2; +MI0040078 nle-mir-126; +MI0040079 nle-mir-340; +MI0040080 nle-mir-2467; +MI0040081 nle-mir-149-1; +MI0040082 nle-mir-149-2; +MI0040083 nle-mir-10a; +MI0040084 nle-mir-152; +MI0040085 nle-let-7a-1; +MI0040086 nle-mir-21; +MI0040087 nle-mir-106b; +MI0040088 nle-mir-93; +MI0040089 nle-mir-25; +MI0040090 nle-mir-212; +MI0040091 nle-mir-132; +MI0040092 nle-mir-22; +MI0040093 nle-mir-769; +MI0040094 nle-mir-4714; +MI0040095 nle-mir-423; +MI0040096 nle-mir-3925; +MI0040097 nle-mir-502a; +MI0040098 nle-mir-660; +MI0040099 nle-mir-501; +MI0040100 nle-mir-502b; +MI0040101 nle-mir-532; +MI0040102 nle-mir-151; +MI0040103 nle-mir-98; +MI0040104 nle-mir-30d; +MI0040105 nle-mir-30b; +MI0040106 nle-mir-410; +MI0040107 nle-mir-409; +MI0040108 nle-mir-381; +MI0040109 nle-mir-136; +MI0040110 nle-mir-127; +MI0040111 nle-mir-24-2; +MI0040112 nle-mir-199a-1; +MI0040113 nle-mir-181c; +MI0040114 nle-mir-549-1; +MI0040115 nle-mir-549-2; +MI0040116 nle-mir-345; +MI0040117 nle-mir-130a; +MI0040118 nle-mir-320b-2; +MI0040119 nle-mir-497; +MI0040120 nle-mir-195; +MI0040121 nle-mir-34a; +MI0040122 nle-mir-192; +MI0040123 nle-mir-101-2; +MI0040124 nle-mir-30e; +MI0040125 nle-mir-29b-2; +MI0040126 nle-mir-29c; +MI0040127 nle-mir-320a; +MI0040128 nle-mir-505; +MI0040129 nle-mir-424; +MI0040130 nle-mir-542; +MI0040131 nle-mir-450a-2; +MI0040132 nle-mir-450a-1; +MI0040133 nle-mir-450b; +MI0040134 nle-mir-19b; +MI0040135 nle-mir-92a-1; +MI0040136 nle-mir-153-1; +MI0040137 nle-mir-301a; +MI0040138 nle-mir-454; +MI0040139 nle-mir-877; +MI0040140 nle-mir-224; +MI0040141 nle-mir-30a; +MI0040142 nle-mir-30c; +MI0040143 nle-mir-222; +MI0040144 nle-mir-221; +MI0040145 nle-mir-671; +MI0040146 nle-mir-196b; +MI0040147 nle-mir-148a; +MI0040148 nle-mir-15a; +MI0040149 nle-mir-16-1; +MI0040150 nle-mir-125a; +MI0040151 nle-let-7e; +MI0040152 nle-mir-365-1; +MI0040153 nle-mir-193b; +MI0040154 nle-mir-361; +MI0040155 nle-mir-374a; +MI0040156 nle-mir-421; +MI0040157 nle-mir-218-2; +MI0040158 nle-mir-103a; +MI0040159 nle-mir-146a; +MI0040160 nle-mir-378d-2; +MI0040161 nle-mir-942; +MI0040162 nle-mir-320b-1; +MI0040163 nle-mir-128-1; +MI0040164 nle-mir-7180; +MI0040165 nle-mir-190; +MI0040166 nle-mir-628; +MI0040167 nle-mir-378a; +MI0040168 nle-mir-145; +MI0040169 nle-mir-143; +MI0040170 nle-mir-582; +MI0040171 nle-mir-101-1; +MI0040172 nle-mir-181a-1; +MI0040173 nle-mir-181b-1; +MI0040174 nle-mir-199b; +MI0040175 nle-mir-181b-2; +MI0040176 nle-mir-181a-2; +MI0040177 nle-mir-455; +MI0040178 nle-mir-155; +MI0040179 nle-mir-125b-2; +MI0040180 nle-let-7c; +MI0040181 nle-mir-99a; +MI0040182 nle-mir-887; +MI0040183 nle-mir-140; +MI0040184 nle-mir-138; +MI0040185 nle-mir-320c-1; +MI0040186 nle-mir-320c-2; +MI0040187 nle-mir-29b-1; +MI0040188 nle-mir-29a; +MI0040189 nle-mir-182; +MI0040190 nle-mir-4670; +MI0040191 nle-mir-31; +MI0040192 nle-mir-24-1; +MI0040193 nle-mir-27b; +MI0040194 nle-mir-23b; +MI0040195 nle-let-7f; +MI0040196 nle-mir-186; +MI0040197 nle-mir-331; +MI0040198 nle-mir-199a-2; +MI0040199 nle-mir-214; +MI0040200 nle-mir-92b; +MI0040201 nle-mir-218-1; +MI0040202 nle-mir-378d-1; +MI0040203 nle-mir-1296; +MI0040204 nle-mir-92a-2; +MI0040205 nle-mir-20; +MI0040206 nle-mir-19a; +MI0040207 nle-mir-17; +MI0040208 nle-let-7g; +MI0040209 nle-mir-191; +MI0040210 nle-mir-26a-1; +MI0040211 nle-mir-128-2; +MI0040212 nle-mir-28; +MI0040213 nle-mir-16-2; +MI0040214 nle-mir-15b; +MI0040215 nle-mir-1307; +MI0040216 nle-mir-107; +MI0040217 nle-mir-146b; +MI0040218 nle-mir-561; +MI0040219 nle-mir-10b; +MI0040220 nle-mir-100; +MI0040221 nle-let-7a-2; +MI0040222 nle-mir-125b-1; +MI0040223 nle-mir-34c; +MI0040224 nle-mir-1260b; +MI0040225 nle-mir-148b; +MI0040226 nle-let-7i; +MI0040227 nle-mir-26a-2; +MI0040228 sbo-let-7e; +MI0040229 sbo-mir-125a; +MI0040230 sbo-mir-486b; +MI0040231 sbo-mir-16-1; +MI0040232 sbo-mir-151; +MI0040233 sbo-mir-199-1; +MI0040234 sbo-mir-24-1; +MI0040235 sbo-mir-27a; +MI0040236 sbo-mir-127; +MI0040237 sbo-mir-181a-2; +MI0040238 sbo-mir-199-3; +MI0040239 sbo-mir-221; +MI0040240 sbo-mir-181a-1; +MI0040241 sbo-let-7f; +MI0040242 sbo-mir-24-2; +MI0040243 sbo-mir-27b; +MI0040244 sbo-mir-191; +MI0040245 sbo-mir-6529; +MI0040246 sbo-mir-148a; +MI0040247 sbo-mir-125b-2; +MI0040248 sbo-mir-99a; +MI0040249 sbo-mir-143; +MI0040250 sbo-let-7b; +MI0040251 sbo-mir-10a; +MI0040252 sbo-mir-423; +MI0040253 sbo-mir-424; +MI0040254 sbo-mir-92a-1; +MI0040255 sbo-mir-26a-1; +MI0040256 sbo-mir-22; +MI0040257 sbo-mir-21; +MI0040258 sbo-mir-92a-2; +MI0040259 sbo-mir-28; +MI0040260 sbo-mir-26a-2; +MI0040261 sbo-mir-214; +MI0040262 sbo-mir-199-2; +MI0040263 sbo-mir-16-2; +MI0040264 sbo-mir-125b-1; +MI0040265 sbo-let-7a; +MI0040266 sbo-mir-100; +MI0040267 sbo-mir-146b; +MI0040268 sbo-mir-10b; +MI0040269 sbo-mir-186; +MI0040270 sbo-mir-29a; +MI0040271 sbo-mir-486a; +MI0040272 pha-let-7a-1; +MI0040273 pha-let-7b; +MI0040274 pha-mir-103b; +MI0040275 pha-mir-769; +MI0040276 pha-mir-361; +MI0040277 pha-mir-423; +MI0040278 pha-mir-145; +MI0040279 pha-mir-143; +MI0040280 pha-mir-186; +MI0040281 pha-let-7e; +MI0040282 pha-mir-125a; +MI0040283 pha-mir-193a; +MI0040284 pha-mir-181b-2; +MI0040285 pha-mir-181a-2; +MI0040286 pha-mir-125b-1; +MI0040287 pha-let-7a-2; +MI0040288 pha-mir-100; +MI0040289 pha-mir-101-1; +MI0040290 pha-mir-24-2; +MI0040291 pha-mir-27b; +MI0040292 pha-mir-23b; +MI0040293 pha-mir-152; +MI0040294 pha-mir-320b-2; +MI0040295 pha-mir-199-2; +MI0040296 pha-mir-130a; +MI0040297 pha-mir-31-1; +MI0040298 pha-mir-378; +MI0040299 pha-mir-23a; +MI0040300 pha-mir-27a; +MI0040301 pha-mir-24-1; +MI0040302 pha-mir-181c; +MI0040303 pha-mir-29a; +MI0040304 pha-mir-92a-2; +MI0040305 pha-mir-19b-1; +MI0040306 pha-mir-30d; +MI0040307 pha-mir-10a; +MI0040308 pha-mir-196a-1; +MI0040309 pha-mir-148a; +MI0040310 pha-mir-107; +MI0040311 pha-mir-660; +MI0040312 pha-mir-582; +MI0040313 pha-mir-877; +MI0040314 pha-mir-196a-2; +MI0040315 pha-mir-1307; +MI0040316 pha-mir-26a-2; +MI0040317 pha-mir-30e; +MI0040318 pha-mir-130b; +MI0040319 pha-mir-106b; +MI0040320 pha-mir-93; +MI0040321 pha-mir-25; +MI0040322 pha-mir-26b; +MI0040323 pha-mir-16-1; +MI0040324 pha-mir-92a-1; +MI0040325 pha-mir-19b-2; +MI0040326 pha-mir-340; +MI0040327 pha-mir-148b; +MI0040328 pha-mir-155; +MI0040329 pha-mir-221; +MI0040330 pha-mir-222; +MI0040331 pha-mir-151; +MI0040332 pha-mir-132; +MI0040333 pha-let-7f; +MI0040334 pha-mir-502b; +MI0040335 pha-mir-532; +MI0040336 pha-mir-191; +MI0040337 pha-mir-193b; +MI0040338 pha-mir-21; +MI0040339 pha-mir-199-3; +MI0040340 pha-mir-98; +MI0040341 pha-mir-146b; +MI0040342 pha-let-7i; +MI0040343 pha-mir-708; +MI0040344 pha-mir-146a; +MI0040345 pha-mir-181a-1; +MI0040346 pha-mir-181b-1; +MI0040347 pha-mir-320b-1; +MI0040348 pha-mir-101-2; +MI0040349 pha-let-7g; +MI0040350 pha-mir-210-1; +MI0040351 pha-mir-409; +MI0040352 pha-mir-381; +MI0040353 pha-mir-299; +MI0040354 pha-mir-411a; +MI0040355 pha-mir-127; +MI0040356 pha-mir-214; +MI0040357 pha-mir-199-1; +MI0040358 pha-mir-16-2; +MI0040359 pha-mir-30a; +MI0040360 pha-mir-30c; +MI0040361 pha-mir-26a-1; +MI0040362 pha-mir-760; +MI0040363 pha-mir-103a; +MI0040364 pha-mir-22; +MI0040365 pha-mir-320a; +MI0040366 pha-mir-887; +MI0040367 pha-mir-125b-2; +MI0040368 pha-let-7c; +MI0040369 pha-mir-99a; +MI0040370 pha-mir-140; +MI0040371 pha-mir-10b; +MI0040372 pha-mir-31-2; +MI0040373 pha-mir-210-2; +MI0040374 oga-mir-301a; +MI0040375 oga-mir-21; +MI0040376 oga-mir-760; +MI0040377 oga-mir-197; +MI0040378 oga-mir-101; +MI0040379 oga-mir-186; +MI0040380 oga-mir-6529; +MI0040381 oga-let-7f; +MI0040382 oga-mir-34c; +MI0040383 oga-mir-34b; +MI0040384 oga-mir-138-1; +MI0040385 oga-mir-99a; +MI0040386 oga-let-7c; +MI0040387 oga-mir-125b-2; +MI0040388 oga-mir-155; +MI0040389 oga-mir-128-1; +MI0040390 oga-mir-16-2; +MI0040391 oga-mir-15b; +MI0040392 oga-mir-320a; +MI0040393 oga-mir-107; +MI0040394 oga-mir-1296; +MI0040395 oga-mir-218a; +MI0040396 oga-mir-34a; +MI0040397 oga-mir-30b; +MI0040398 oga-mir-30d; +MI0040399 oga-mir-151; +MI0040400 oga-let-7a-1; +MI0040401 oga-let-7b; +MI0040402 oga-mir-28a; +MI0040403 oga-mir-138-2; +MI0040404 oga-mir-181b-1; +MI0040405 oga-mir-181a-1; +MI0040406 oga-mir-29b-2; +MI0040407 oga-mir-23b; +MI0040408 oga-mir-27b; +MI0040409 oga-mir-24-1; +MI0040410 oga-mir-872; +MI0040411 oga-mir-31; +MI0040412 oga-mir-29a; +MI0040413 oga-mir-29b-1; +MI0040414 oga-mir-10; +MI0040415 oga-mir-140; +MI0040416 oga-mir-195; +MI0040417 oga-mir-497; +MI0040418 oga-mir-26a-2; +MI0040419 oga-mir-148b; +MI0040420 oga-mir-615; +MI0040421 oga-mir-196; +MI0040422 oga-mir-582; +MI0040423 oga-mir-374a; +MI0040424 oga-mir-421; +MI0040425 oga-mir-30a; +MI0040426 oga-mir-30c; +MI0040427 oga-mir-92a-2; +MI0040428 oga-mir-19b-1; +MI0040429 oga-mir-19a; +MI0040430 oga-mir-18; +MI0040431 oga-mir-17; +MI0040432 oga-let-7g; +MI0040433 oga-mir-182; +MI0040434 oga-mir-125a; +MI0040435 oga-let-7e; +MI0040436 oga-mir-99b; +MI0040437 oga-mir-98; +MI0040438 oga-mir-196b; +MI0040439 oga-mir-148a; +MI0040440 oga-mir-222; +MI0040441 oga-mir-221; +MI0040442 oga-mir-28b; +MI0040443 oga-mir-210; +MI0040444 oga-mir-365-1; +MI0040445 oga-mir-193b; +MI0040446 oga-mir-103b; +MI0040447 oga-mir-1388; +MI0040448 oga-mir-185; +MI0040449 oga-mir-130a; +MI0040450 oga-mir-143; +MI0040451 oga-mir-145; +MI0040452 oga-mir-378; +MI0040453 oga-mir-103a; +MI0040454 oga-mir-486; +MI0040455 oga-mir-1247; +MI0040456 oga-mir-410; +MI0040457 oga-mir-409; +MI0040458 oga-mir-381; +MI0040459 oga-mir-411a; +MI0040460 oga-mir-136; +MI0040461 oga-mir-127; +MI0040462 oga-mir-493; +MI0040463 oga-mir-342; +MI0040464 oga-mir-224; +MI0040465 oga-mir-361; +MI0040466 oga-mir-16-1; +MI0040467 oga-mir-15a; +MI0040468 oga-mir-574; +MI0040469 oga-mir-191; +MI0040470 oga-mir-196a; +MI0040471 oga-mir-10a; +MI0040472 oga-mir-152; +MI0040473 oga-mir-660; +MI0040474 oga-mir-500; +MI0040475 oga-mir-502b; +MI0040476 oga-mir-532; +MI0040477 oga-mir-330; +MI0040478 oga-mir-214; +MI0040479 oga-mir-199-1; +MI0040480 oga-mir-340; +MI0040481 oga-mir-22; +MI0040482 oga-mir-132; +MI0040483 oga-mir-212; +MI0040484 oga-mir-30e; +MI0040485 oga-mir-25; +MI0040486 oga-mir-93; +MI0040487 oga-mir-106b; +MI0040488 oga-mir-192; +MI0040489 oga-let-7i; +MI0040490 oga-mir-149; +MI0040491 oga-mir-199-2; +MI0040492 oga-mir-181e; +MI0040493 oga-mir-181a-2; +MI0040494 oga-mir-455; +MI0040495 oga-mir-181c; +MI0040496 oga-mir-181d; +MI0040497 oga-mir-24-2; +MI0040498 oga-mir-27a; +MI0040499 oga-mir-23a; +MI0040500 oga-mir-26b; +MI0040501 oga-mir-505; +MI0040502 oga-mir-423; +MI0040503 oga-mir-365-2; +MI0040504 oga-mir-193a; +MI0040505 oga-mir-19b-2; +MI0040506 oga-mir-92a-1; +MI0040507 oga-mir-125b-1; +MI0040508 oga-let-7a-2; +MI0040509 oga-mir-100; +MI0040510 oga-mir-184; +MI0040511 oga-mir-190; +MI0040512 oga-mir-26a-1; +MI0040513 oga-mir-128-2; +MI0040514 aof-MIR12137; +MI0040515 aof-MIR12138; +MI0040516 aof-MIR12139; +MI0040517 aof-MIR12140; +MI0040518 aof-MIR12141; +MI0040519 aof-MIR12142; +MI0040520 aof-MIR12143; +MI0040521 aof-MIR12144; +MI0040522 aof-MIR12145; +MI0040523 aof-MIR12146; +MI0040524 aof-MIR12147; +MI0040525 aof-MIR12148; +MI0040526 aof-MIR12149; +MI0040527 aof-MIR12150; +MI0040528 aof-MIR12151; +MI0040529 aof-MIR12152; +MI0040530 aof-MIR12153; +MI0040531 aof-MIR12154; +MI0040532 aof-MIR12155; +MI0040533 aof-MIR12156; +MI0040534 aof-MIR12157; +MI0040535 aof-MIR12158; +MI0040536 aof-MIR12159; +MI0040537 aof-MIR12160; +MI0040538 aof-MIR12161; +MI0040539 aof-MIR12162; +MI0040540 aof-MIR12163; +MI0040541 aof-MIR2275d; +MI0040542 aof-MIR482c; +MI0040543 aof-MIR12164; +MI0040544 aof-MIR12165; +MI0040545 aof-MIR12166; +MI0040546 aof-MIR12167; +MI0040547 aof-MIR12168; +MI0040548 aof-MIR12169; +MI0040549 aof-MIR12170; +MI0040550 aof-MIR12171; +MI0040551 aof-MIR12172; +MI0040552 aof-MIR477b; +MI0040553 aof-MIR12173; +MI0040554 aof-MIR399c; +MI0040555 aof-MIR12174; +MI0040556 aof-MIR12175; +MI0040557 aof-MIR12176; +MI0040558 aof-MIR12177; +MI0040559 aof-MIR156a; +MI0040560 aof-MIR156b; +MI0040561 aof-MIR156c; +MI0040562 aof-MIR159; +MI0040563 aof-MIR160a; +MI0040564 aof-MIR160b; +MI0040565 aof-MIR160c; +MI0040566 aof-MIR164; +MI0040567 aof-MIR166a; +MI0040568 aof-MIR166b; +MI0040569 aof-MIR166c; +MI0040570 aof-MIR166d; +MI0040571 aof-MIR167a; +MI0040572 aof-MIR167b; +MI0040573 aof-MIR167c; +MI0040574 aof-MIR168a; +MI0040575 aof-MIR168b; +MI0040576 aof-MIR169a; +MI0040577 aof-MIR169b; +MI0040578 aof-MIR169c; +MI0040579 aof-MIR171a; +MI0040580 aof-MIR171b; +MI0040581 aof-MIR171c; +MI0040582 aof-MIR172; +MI0040583 aof-MIR2118b; +MI0040584 aof-MIR2118c; +MI0040585 aof-MIR2118a; +MI0040586 aof-MIR2275a; +MI0040587 aof-MIR2275b; +MI0040588 aof-MIR2275c; +MI0040589 aof-MIR319a; +MI0040590 aof-MIR319b; +MI0040591 aof-MIR390; +MI0040592 aof-MIR393a; +MI0040593 aof-MIR393b; +MI0040594 aof-MIR394; +MI0040595 aof-MIR395a; +MI0040596 aof-MIR395b; +MI0040597 aof-MIR396a; +MI0040598 aof-MIR396b; +MI0040599 aof-MIR398; +MI0040600 aof-MIR399a; +MI0040601 aof-MIR399b; +MI0040602 aof-MIR408; +MI0040603 aof-MIR391; +MI0040604 aof-MIR477a; +MI0040605 aof-MIR479; +MI0040606 aof-MIR482a; +MI0040607 aof-MIR482b; +MI0040608 aof-MIR5139a; +MI0040609 aof-MIR535; +MI0040610 aof-MIR536; +MI0040611 aof-MIR8155; +MI0040612 aof-MIR5139b; +MI0040613 aof-MIR827; +MI0040614 aof-MIR828; +MI0040615 mmu-mir-5104b; +MI0040616 mmu-mir-12178; +MI0040617 mmu-mir-12179; +MI0040618 mmu-mir-12180; +MI0040619 mmu-mir-12181; +MI0040620 mmu-mir-12182; +MI0040621 mmu-mir-12183; +MI0040622 mmu-mir-203b; +MI0040623 mmu-mir-12184; +MI0040624 mmu-mir-9b-2; +MI0040625 mmu-mir-12185; +MI0040626 mmu-mir-12186; +MI0040627 mmu-mir-12187; +MI0040628 mmu-mir-1970b; +MI0040629 mmu-mir-12188; +MI0040630 mmu-mir-3083b; +MI0040631 mmu-mir-12189; +MI0040632 mmu-mir-12190; +MI0040633 mmu-mir-12191; +MI0040634 mmu-mir-122b; +MI0040635 mmu-mir-12192; +MI0040636 mmu-mir-12193; +MI0040637 mmu-mir-124b; +MI0040638 mmu-mir-12194; +MI0040639 mmu-mir-12195; +MI0040640 mmu-mir-9b-1; +MI0040641 mmu-mir-3473h; +MI0040642 mmu-mir-12196; +MI0040643 mmu-mir-12197; +MI0040644 mmu-mir-12198; +MI0040645 mmu-mir-12199; +MI0040646 mmu-mir-12200; +MI0040647 mmu-mir-12201; +MI0040648 mmu-mir-12202; +MI0040649 mmu-mir-9b-3; +MI0040650 mmu-mir-12203; +MI0040651 mmu-mir-12204; +MI0040652 mmu-mir-1970c; +MI0040653 mmu-mir-12205; +MI0040654 mmu-mir-12206; +MI0040655 gga-mir-12207; +MI0040656 gga-mir-12208; +MI0040657 gga-mir-12209; +MI0040658 gga-mir-12210; +MI0040659 gga-mir-12211; +MI0040660 gga-mir-12212; +MI0040661 gga-mir-12213; +MI0040662 gga-mir-2984; +MI0040663 gga-mir-12214; +MI0040664 gga-mir-2985-1; +MI0040665 gga-mir-12215; +MI0040666 gga-mir-12216; +MI0040667 gga-mir-9b-1; +MI0040668 gga-mir-12217; +MI0040669 gga-mir-184b; +MI0040670 gga-mir-12218; +MI0040671 gga-mir-12219; +MI0040672 gga-mir-12220; +MI0040673 gga-mir-12221-1; +MI0040674 gga-mir-12221-2; +MI0040675 gga-mir-191; +MI0040676 gga-mir-425; +MI0040677 gga-mir-12222; +MI0040678 gga-mir-12223; +MI0040679 gga-mir-12224; +MI0040680 gga-mir-12225; +MI0040681 gga-mir-12226; +MI0040682 gga-mir-12227; +MI0040683 gga-mir-12228; +MI0040684 gga-mir-12229; +MI0040685 gga-mir-12230; +MI0040686 gga-mir-12231; +MI0040687 gga-mir-12232; +MI0040688 gga-mir-12233; +MI0040689 gga-mir-12234; +MI0040690 gga-mir-2184b; +MI0040691 gga-mir-2184a; +MI0040692 gga-mir-132a; +MI0040693 gga-mir-132b; +MI0040694 gga-mir-212; +MI0040695 gga-mir-132c; +MI0040696 gga-mir-12235; +MI0040697 gga-mir-12236; +MI0040698 gga-mir-12237; +MI0040699 gga-mir-10585; +MI0040700 gga-mir-12238; +MI0040701 gga-mir-12239; +MI0040702 gga-mir-12240; +MI0040703 gga-mir-12241; +MI0040704 gga-mir-12242; +MI0040705 gga-mir-1388b; +MI0040706 gga-mir-12243; +MI0040707 gga-mir-12244; +MI0040708 gga-mir-12245; +MI0040709 gga-mir-12246; +MI0040710 gga-mir-12247-1; +MI0040711 gga-mir-12247-2; +MI0040712 gga-mir-12248; +MI0040713 gga-mir-12249; +MI0040714 gga-mir-12250; +MI0040715 gga-mir-12251; +MI0040716 gga-mir-12252; +MI0040717 gga-mir-205c; +MI0040718 gga-mir-12253; +MI0040719 gga-mir-12254; +MI0040720 gga-mir-12255; +MI0040721 gga-mir-12256; +MI0040722 gga-mir-12257; +MI0040723 gga-mir-12258; +MI0040724 gga-mir-12259; +MI0040725 gga-mir-12260; +MI0040726 gga-mir-12261; +MI0040727 gga-mir-12262; +MI0040728 gga-mir-12263; +MI0040729 gga-mir-12264; +MI0040730 gga-mir-12265; +MI0040731 gga-mir-12266-1; +MI0040732 gga-mir-10c; +MI0040733 gga-mir-148b; +MI0040734 gga-mir-12267; +MI0040735 gga-mir-12268; +MI0040736 gga-mir-12269; +MI0040737 gga-mir-12270; +MI0040738 gga-mir-12271; +MI0040739 gga-mir-2985-2; +MI0040740 gga-mir-12272; +MI0040741 gga-mir-12273; +MI0040742 gga-mir-12274; +MI0040743 gga-mir-12275; +MI0040744 gga-mir-12276; +MI0040745 gga-mir-12277; +MI0040746 gga-mir-12278; +MI0040747 gga-mir-12279; +MI0040748 gga-mir-210b; +MI0040749 gga-mir-129-1; +MI0040750 gga-mir-1763b; +MI0040751 gga-mir-12280; +MI0040752 gga-mir-214b; +MI0040753 gga-mir-12281; +MI0040754 gga-mir-12282; +MI0040755 gga-mir-12283; +MI0040756 gga-mir-12284; +MI0040757 gga-mir-12285; +MI0040758 gga-mir-12286; +MI0040759 gga-mir-12287; +MI0040760 gga-mir-12288; +MI0040761 gga-mir-12289-1; +MI0040762 gga-let-7l-1; +MI0040763 gga-mir-12289-2; +MI0040764 gga-mir-129-2; +MI0040765 gga-mir-12290; +MI0040766 gga-mir-726; +MI0040767 gga-mir-12291; +MI0040768 gga-mir-129-3; +MI0040769 gga-let-7l-2; +MI0040770 gga-mir-12292; +MI0040771 gga-mir-12293; +MI0040772 gga-mir-122b-1; +MI0040773 gga-mir-12266-2; +MI0040774 gga-mir-12266-3; +MI0040775 gga-mir-12294; +MI0040776 gga-mir-12295; +MI0040777 gga-mir-9b-2; +MI0040778 gga-mir-122b-2; +MI0040779 mdo-mir-12296; +MI0040780 mdo-mir-12298; +MI0040781 mdo-mir-9c-3; +MI0040782 mdo-mir-12299-1; +MI0040783 mdo-mir-12297g-3; +MI0040784 mdo-mir-12297g-1; +MI0040785 mdo-mir-12297d; +MI0040786 mdo-mir-12297g-2; +MI0040787 mdo-mir-12297j; +MI0040788 mdo-mir-12300; +MI0040789 mdo-mir-325; +MI0040790 mdo-mir-12301; +MI0040791 mdo-mir-12302; +MI0040792 mdo-mir-12303; +MI0040793 mdo-mir-12304-1; +MI0040794 mdo-mir-12304-2; +MI0040795 mdo-mir-12305; +MI0040796 mdo-mir-7356b; +MI0040797 mdo-mir-12306; +MI0040798 mdo-mir-12307; +MI0040799 mdo-mir-12308a; +MI0040800 mdo-mir-1388; +MI0040801 mdo-mir-352; +MI0040802 mdo-mir-12309; +MI0040803 mdo-mir-12310; +MI0040804 mdo-mir-12311; +MI0040805 mdo-mir-12312; +MI0040806 mdo-mir-1329; +MI0040807 mdo-mir-12313; +MI0040808 mdo-mir-7286b; +MI0040809 mdo-mir-12314; +MI0040810 mdo-mir-12315; +MI0040811 mdo-mir-12316; +MI0040812 mdo-mir-12317; +MI0040813 mdo-mir-7284b; +MI0040814 mdo-mir-12318; +MI0040815 mdo-mir-12319; +MI0040816 mdo-mir-12320; +MI0040817 mdo-mir-205b; +MI0040818 mdo-mir-12321; +MI0040819 mdo-mir-9c-1; +MI0040820 mdo-mir-12322; +MI0040821 mdo-mir-12323; +MI0040822 mdo-mir-12324a; +MI0040823 mdo-mir-12325; +MI0040824 mdo-mir-12326; +MI0040825 mdo-mir-12327-1; +MI0040826 mdo-mir-12327-2; +MI0040827 mdo-mir-12328; +MI0040828 mdo-mir-133b; +MI0040829 mdo-mir-7262c; +MI0040830 mdo-mir-12329; +MI0040831 mdo-mir-12330; +MI0040832 mdo-mir-7262d; +MI0040833 mdo-mir-12331; +MI0040834 mdo-mir-12332; +MI0040835 mdo-mir-12324b; +MI0040836 mdo-mir-3600; +MI0040837 mdo-mir-12333; +MI0040838 mdo-mir-12334; +MI0040839 mdo-mir-12335-1; +MI0040840 mdo-mir-12335-2; +MI0040841 mdo-mir-12336; +MI0040842 mdo-mir-7262e; +MI0040843 mdo-mir-12297c-2; +MI0040844 mdo-mir-12337; +MI0040845 mdo-mir-12338; +MI0040846 mdo-mir-9c-2; +MI0040847 mdo-mir-7262k; +MI0040848 mdo-mir-12297e-3; +MI0040849 mdo-mir-122b; +MI0040850 mdo-mir-12339; +MI0040851 mdo-mir-30e; +MI0040852 mdo-mir-12340; +MI0040853 mdo-mir-12341; +MI0040854 mdo-mir-12342; +MI0040855 mdo-mir-12343; +MI0040856 mdo-mir-12344; +MI0040857 mdo-mir-12345; +MI0040858 mdo-mir-1306; +MI0040859 mdo-mir-12346; +MI0040860 mdo-mir-1546b; +MI0040861 mdo-mir-7312b; +MI0040862 mdo-mir-12297c-1; +MI0040863 mdo-mir-12297c-3; +MI0040864 mdo-mir-12308b; +MI0040865 mdo-mir-12347; +MI0040866 mdo-mir-7262g; +MI0040867 mdo-mir-12348; +MI0040868 mdo-mir-12349; +MI0040869 mdo-mir-12350; +MI0040870 mdo-mir-12351; +MI0040871 mdo-mir-34d; +MI0040872 mdo-mir-2985-1; +MI0040873 mdo-mir-12352; +MI0040874 mdo-mir-12353; +MI0040875 mdo-mir-12354; +MI0040876 mdo-mir-12297a; +MI0040877 mdo-mir-12355; +MI0040878 mdo-mir-12356; +MI0040879 mdo-mir-12357; +MI0040880 mdo-mir-12297h; +MI0040881 mdo-mir-12358; +MI0040882 mdo-mir-12359; +MI0040883 mdo-mir-12360; +MI0040884 mdo-mir-12361; +MI0040885 mdo-mir-7323b; +MI0040886 mdo-mir-12362; +MI0040887 mdo-mir-12363; +MI0040888 mdo-mir-2985-2; +MI0040889 mdo-mir-7262j; +MI0040890 mdo-mir-12364; +MI0040891 mdo-mir-12365; +MI0040892 mdo-mir-7262l; +MI0040893 mdo-mir-12366a; +MI0040894 mdo-mir-12367; +MI0040895 mdo-mir-12297e-1; +MI0040896 mdo-mir-7262m; +MI0040897 mdo-mir-12368; +MI0040898 mdo-mir-12297i; +MI0040899 mdo-mir-7320b; +MI0040900 mdo-mir-12369; +MI0040901 mdo-mir-12370; +MI0040902 mdo-mir-12371; +MI0040903 mdo-mir-12372; +MI0040904 mdo-mir-12373; +MI0040905 mdo-mir-12374; +MI0040906 mdo-mir-12375; +MI0040907 mdo-mir-12376; +MI0040908 mdo-mir-12377; +MI0040909 mdo-mir-12378; +MI0040910 mdo-mir-12379; +MI0040911 mdo-mir-12299-2; +MI0040912 mdo-mir-12380; +MI0040913 mdo-mir-12381; +MI0040914 mdo-mir-12382; +MI0040915 mdo-mir-12383; +MI0040916 mdo-mir-12384; +MI0040917 mdo-mir-12297f; +MI0040918 mdo-mir-12385; +MI0040919 mdo-mir-12386; +MI0040920 mdo-mir-12387; +MI0040921 mdo-mir-551c; +MI0040922 mdo-mir-12388; +MI0040923 mdo-mir-12389; +MI0040924 mdo-mir-12297b; +MI0040925 mdo-mir-12390; +MI0040926 mdo-mir-12297e-2; +MI0040927 mdo-mir-12391; +MI0040928 mdo-mir-12392; +MI0040929 mdo-mir-7262h; +MI0040930 mdo-mir-12393; +MI0040931 mdo-mir-12394; +MI0040932 mdo-mir-12395; +MI0040933 mdo-mir-12396; +MI0040934 mdo-mir-12397; +MI0040935 mdo-mir-12398; +MI0040936 mdo-mir-210b; +MI0040937 mdo-mir-1549b; +MI0040938 mdo-mir-7345b; +MI0040939 mdo-mir-12399; +MI0040940 mdo-mir-12400; +MI0040941 mdo-mir-7385i-2; +MI0040942 mdo-mir-7385h; +MI0040943 mdo-mir-7385i-1; +MI0040944 mdo-mir-7385g-3; +MI0040945 mdo-mir-12401; +MI0040946 mdo-mir-1544f; +MI0040947 mdo-mir-1545d-1; +MI0040948 mdo-mir-1545g-1; +MI0040949 mdo-mir-1545e-1; +MI0040950 mdo-mir-1545e-2; +MI0040951 mdo-mir-1545f; +MI0040952 mdo-mir-1545d-3; +MI0040953 mdo-mir-1545d-4; +MI0040954 mdo-mir-1545g-2; +MI0040955 mdo-mir-1545g-3; +MI0040956 mdo-mir-1544g; +MI0040957 mdo-mir-1545d-2; +MI0040958 mdo-mir-7262f; +MI0040959 mdo-mir-12402-1; +MI0040960 mdo-mir-12402-2; +MI0040961 mdo-mir-16b; +MI0040962 mdo-mir-7386p; +MI0040963 mdo-mir-7371o; +MI0040964 mdo-mir-7371n; +MI0040965 mdo-mir-7371q; +MI0040966 mdo-mir-7371m; +MI0040967 mdo-mir-7371k; +MI0040968 mdo-mir-7386q; +MI0040969 mdo-mir-7371l; +MI0040970 mdo-mir-7371p; +MI0040971 mdo-mir-7373e; +MI0040972 mdo-mir-12403; +MI0040973 mdo-mir-7375c-4; +MI0040974 mdo-mir-7375c-3; +MI0040975 mdo-mir-7375c-1; +MI0040976 mdo-mir-7375e; +MI0040977 mdo-mir-7375d; +MI0040978 mdo-mir-7375c-2; +MI0040979 mdo-mir-7374d; +MI0040980 mdo-mir-7373f; +MI0040981 mdo-mir-7262i; +MI0040982 mdo-mir-7394c; +MI0040983 mdo-mir-7398v; +MI0040984 mdo-mir-7398w; +MI0040985 mdo-mir-7398x; +MI0040986 mdo-mir-7398y; +MI0040987 mdo-mir-12404; +MI0040988 mdo-mir-12405; +MI0040989 mdo-mir-12406; +MI0040990 mdo-mir-12407; +MI0040991 mdo-mir-12408; +MI0040992 mdo-mir-12409; +MI0040993 mdo-mir-12366b; +MI0040994 mdo-mir-12410; +MI0040995 mdo-mir-12411; +MI0040996 mdo-mir-12412; +MI0040997 aga-mir-12413; +MI0040998 aga-mir-12414; +MI0040999 aga-mir-12415; +MI0041000 aga-mir-12416; +MI0041001 aga-mir-12417; +MI0041002 aga-mir-12418; +MI0041003 aga-mir-12419; +MI0041063 smc-mir-12455-1; +MI0041064 smc-mir-12456; +MI0041065 smc-mir-12457; +MI0041066 smc-mir-12455-2; +MI0041067 smc-mir-12458; +MI0041068 smc-mir-12459; +MI0041069 smc-mir-12460; +MI0041070 smc-mir-12461; +MI0041071 hsa-mir-9902-2; +MI0041072 gga-mir-1784b; +MI0041073 mdo-mir-7385g-1; +MI0041074 mdo-mir-7385g-2; +MIMAT0000001 cel-let-7;cel-let-7-5p; +MIMAT0000002 cel-lin-4;cel-lin-4-5p; +MIMAT0000003 cel-miR-1;cel-miR-1-3p; +MIMAT0000004 cel-miR-2;cel-miR-2-3p; +MIMAT0000005 cel-miR-34;cel-miR-34-5p; +MIMAT0000006 cel-miR-35;cel-miR-35-3p; +MIMAT0000007 cel-miR-36;cel-miR-36-3p; +MIMAT0000008 cel-miR-37;cel-miR-37-3p; +MIMAT0000009 cel-miR-38;cel-miR-38-3p; +MIMAT0000010 cel-miR-39;cel-miR-39-3p; +MIMAT0000011 cel-miR-40;cel-miR-40-3p; +MIMAT0000012 cel-miR-41;cel-miR-41-3p; +MIMAT0000013 cel-miR-42;cel-miR-42-3p; +MIMAT0000014 cel-miR-43;cel-miR-43-3p; +MIMAT0000015 cel-miR-44;cel-miR-44-3p; +MIMAT0000016 cel-miR-45;cel-miR-45-3p; +MIMAT0000017 cel-miR-46;cel-miR-46-3p; +MIMAT0000018 cel-miR-47;cel-miR-47-3p; +MIMAT0000019 cel-miR-48;cel-miR-48-5p; +MIMAT0000020 cel-miR-49;cel-miR-49-3p; +MIMAT0000021 cel-miR-50;cel-miR-50-5p; +MIMAT0000022 cel-miR-51;cel-miR-51-5p; +MIMAT0000023 cel-miR-52;cel-miR-52-5p; +MIMAT0000024 cel-miR-53;cel-miR-53-5p; +MIMAT0000025 cel-miR-54;cel-miR-54-3p; +MIMAT0000026 cel-miR-55;cel-miR-55-3p; +MIMAT0000027 cel-miR-56*;cel-miR-56-5p; +MIMAT0000028 cel-miR-56;cel-miR-56-3p; +MIMAT0000029 cel-miR-57;cel-miR-57-5p; +MIMAT0000030 cel-miR-58;cel-miR-58-3p;cel-miR-58a-3p; +MIMAT0000031 cel-miR-59;cel-miR-59-3p; +MIMAT0000032 cel-miR-60;cel-miR-60-3p; +MIMAT0000033 cel-miR-61;cel-miR-61-3p; +MIMAT0000034 cel-miR-62; +MIMAT0000035 cel-miR-63;cel-miR-63-3p; +MIMAT0000036 cel-miR-64;cel-miR-64-5p; +MIMAT0000037 cel-miR-65;cel-miR-65-5p; +MIMAT0000038 cel-miR-66;cel-miR-66-5p; +MIMAT0000039 cel-miR-67;cel-miR-67-3p; +MIMAT0000040 cel-miR-68; +MIMAT0000041 cel-miR-69; +MIMAT0000042 cel-miR-70;cel-miR-70-3p; +MIMAT0000043 cel-miR-71;cel-miR-71-5p; +MIMAT0000044 cel-miR-72;cel-miR-72-5p; +MIMAT0000045 cel-miR-73;cel-miR-73-3p; +MIMAT0000046 cel-miR-74;cel-miR-74-3p; +MIMAT0000047 cel-miR-75;cel-miR-75-3p; +MIMAT0000048 cel-miR-76;cel-miR-76-3p; +MIMAT0000049 cel-miR-77;cel-miR-77-3p; +MIMAT0000050 cel-miR-78; +MIMAT0000051 cel-miR-79;cel-miR-79-3p; +MIMAT0000052 cel-miR-227;cel-miR-80-5p; +MIMAT0000053 cel-miR-80;cel-miR-80-3p; +MIMAT0000054 cel-miR-81;cel-miR-81-3p; +MIMAT0000055 cel-miR-82;cel-miR-82-3p; +MIMAT0000056 cel-miR-83;cel-miR-83-3p; +MIMAT0000057 cel-miR-84;cel-miR-84-5p; +MIMAT0000058 cel-miR-85;cel-miR-85-3p; +MIMAT0000059 cel-miR-86;cel-miR-86-5p; +MIMAT0000060 cel-miR-87;cel-miR-87-3p; +MIMAT0000061 cel-miR-90;cel-miR-90-3p; +MIMAT0000062 hsa-let-7a;hsa-let-7a-5p; +MIMAT0000063 hsa-let-7b;hsa-let-7b-5p; +MIMAT0000064 hsa-let-7c;hsa-let-7c-5p; +MIMAT0000065 hsa-let-7d;hsa-let-7d-5p; +MIMAT0000066 hsa-let-7e;hsa-let-7e-5p; +MIMAT0000067 hsa-let-7f;hsa-let-7f-5p; +MIMAT0000068 hsa-miR-15a;hsa-miR-15a-5p; +MIMAT0000069 hsa-miR-16;hsa-miR-16-5p; +MIMAT0000070 hsa-miR-17-5p;hsa-miR-17;hsa-miR-17-5p; +MIMAT0000071 hsa-miR-17-3p;hsa-miR-17*;hsa-miR-17-3p; +MIMAT0000072 hsa-miR-18;hsa-miR-18a;hsa-miR-18a-5p; +MIMAT0000073 hsa-miR-19a;hsa-miR-19a-3p; +MIMAT0000074 hsa-miR-19b;hsa-miR-19b-3p; +MIMAT0000075 hsa-miR-20;hsa-miR-20a;hsa-miR-20a-5p; +MIMAT0000076 hsa-miR-21;hsa-miR-21-5p; +MIMAT0000077 hsa-miR-22;hsa-miR-22-3p; +MIMAT0000078 hsa-miR-23a;hsa-miR-23a-3p; +MIMAT0000079 hsa-miR-189;hsa-miR-24-1*;hsa-miR-24-1-5p; +MIMAT0000080 hsa-miR-24;hsa-miR-24-3p; +MIMAT0000081 hsa-miR-25;hsa-miR-25-3p; +MIMAT0000082 hsa-miR-26a;hsa-miR-26a-5p; +MIMAT0000083 hsa-miR-26b;hsa-miR-26b-5p; +MIMAT0000084 hsa-miR-27a;hsa-miR-27a-3p; +MIMAT0000085 hsa-miR-28;hsa-miR-28-5p; +MIMAT0000086 hsa-miR-29a;hsa-miR-29a-3p; +MIMAT0000087 hsa-miR-30a-5p;hsa-miR-30a;hsa-miR-30a-5p; +MIMAT0000088 hsa-miR-30a-3p;hsa-miR-30a*;hsa-miR-30a-3p; +MIMAT0000089 hsa-miR-31;hsa-miR-31-5p; +MIMAT0000090 hsa-miR-32;hsa-miR-32-5p; +MIMAT0000091 hsa-miR-33;hsa-miR-33a;hsa-miR-33a-5p; +MIMAT0000092 hsa-miR-92;hsa-miR-92a;hsa-miR-92a-3p; +MIMAT0000093 hsa-miR-93;hsa-miR-93-5p; +MIMAT0000094 hsa-miR-95;hsa-miR-95-3p; +MIMAT0000095 hsa-miR-96;hsa-miR-96-5p; +MIMAT0000096 hsa-miR-98;hsa-miR-98-5p; +MIMAT0000097 hsa-miR-99a;hsa-miR-99a-5p; +MIMAT0000098 hsa-miR-100;hsa-miR-100-5p; +MIMAT0000099 hsa-miR-101;hsa-miR-101-3p; +MIMAT0000100 hsa-miR-29b;hsa-miR-29b-3p; +MIMAT0000101 hsa-miR-103;hsa-miR-103a;hsa-miR-103a-3p; +MIMAT0000102 hsa-miR-105;hsa-miR-105-5p; +MIMAT0000103 hsa-miR-106a;hsa-miR-106a-5p; +MIMAT0000104 hsa-miR-107; +MIMAT0000105 dme-miR-1;dme-miR-1-3p; +MIMAT0000106 dme-miR-2a;dme-miR-2a-3p; +MIMAT0000107 dme-miR-2b;dme-miR-2b-3p; +MIMAT0000108 dme-miR-3;dme-miR-3-3p; +MIMAT0000109 dme-miR-4;dme-miR-4-3p; +MIMAT0000110 dme-miR-5;dme-miR-5-5p; +MIMAT0000111 dme-miR-6;dme-miR-6-3p; +MIMAT0000112 dme-miR-7;dme-miR-7-5p; +MIMAT0000113 dme-miR-8;dme-miR-8-3p; +MIMAT0000114 dme-miR-9a;dme-miR-9a-5p; +MIMAT0000115 dme-miR-10;dme-miR-10*;dme-miR-10-5p; +MIMAT0000116 dme-miR-11;dme-miR-11-3p; +MIMAT0000117 dme-miR-12;dme-miR-12-5p; +MIMAT0000118 dme-miR-13a;dme-miR-13a-3p; +MIMAT0000119 dme-miR-13b;dme-miR-13b-3p; +MIMAT0000120 dme-miR-14;dme-miR-14-3p; +MIMAT0000121 mmu-let-7g;mmu-let-7g-5p; +MIMAT0000122 mmu-let-7i;mmu-let-7i-5p; +MIMAT0000123 mmu-miR-1;mmu-miR-1a;mmu-miR-1a-3p; +MIMAT0000124 mmu-miR-15b;mmu-miR-15b-5p; +MIMAT0000125 mmu-miR-23b;mmu-miR-23b-3p; +MIMAT0000126 mmu-miR-27b;mmu-miR-27b-3p; +MIMAT0000127 mmu-miR-29b;mmu-miR-29b-3p; +MIMAT0000128 mmu-miR-30a-5p;mmu-miR-30a;mmu-miR-30a-5p; +MIMAT0000129 mmu-miR-30a-3p;mmu-miR-30a*;mmu-miR-30a-3p; +MIMAT0000130 mmu-miR-30b;mmu-miR-30b-5p; +MIMAT0000131 mmu-miR-99a;mmu-miR-99a-5p; +MIMAT0000132 mmu-miR-99b;mmu-miR-99b-5p; +MIMAT0000133 mmu-miR-101a;mmu-miR-101a-3p; +MIMAT0000134 mmu-miR-124a;mmu-miR-124;mmu-miR-124-3p; +MIMAT0000135 mmu-miR-125a;mmu-miR-125a-5p; +MIMAT0000136 mmu-miR-125b;mmu-miR-125b-5p; +MIMAT0000137 mmu-miR-126-5p;mmu-miR-126a-5p; +MIMAT0000138 mmu-miR-126-3p;mmu-miR-126a-3p; +MIMAT0000139 mmu-miR-127;mmu-miR-127-3p; +MIMAT0000140 mmu-miR-128a;mmu-miR-128;mmu-miR-128-3p; +MIMAT0000141 mmu-miR-130a;mmu-miR-130a-3p; +MIMAT0000142 mmu-miR-9;mmu-miR-9-5p; +MIMAT0000143 mmu-miR-9*;mmu-miR-9-3p; +MIMAT0000144 mmu-miR-132;mmu-miR-132-3p; +MIMAT0000145 mmu-miR-133a;mmu-miR-133a-3p; +MIMAT0000146 mmu-miR-134;mmu-miR-134-5p; +MIMAT0000147 mmu-miR-135a;mmu-miR-135a-5p; +MIMAT0000148 mmu-miR-136;mmu-miR-136-5p; +MIMAT0000149 mmu-miR-137;mmu-miR-137-3p; +MIMAT0000150 mmu-miR-138;mmu-miR-138-5p; +MIMAT0000151 mmu-miR-140;mmu-miR-140-5p; +MIMAT0000152 mmu-miR-140*;mmu-miR-140-3p; +MIMAT0000153 mmu-miR-141;mmu-miR-141-3p; +MIMAT0000154 mmu-miR-142-5p;mmu-miR-142a-5p; +MIMAT0000155 mmu-miR-142-3p;mmu-miR-142a-3p; +MIMAT0000156 mmu-miR-144;mmu-miR-144-3p; +MIMAT0000157 mmu-miR-145;mmu-miR-145-5p;mmu-miR-145a-5p; +MIMAT0000158 mmu-miR-146;mmu-miR-146a;mmu-miR-146a-5p; +MIMAT0000159 mmu-miR-149;mmu-miR-149-5p; +MIMAT0000160 mmu-miR-150;mmu-miR-150-5p; +MIMAT0000161 mmu-miR-151;mmu-miR-151-3p; +MIMAT0000162 mmu-miR-152;mmu-miR-152-3p; +MIMAT0000163 mmu-miR-153;mmu-miR-153-3p; +MIMAT0000164 mmu-miR-154;mmu-miR-154-5p; +MIMAT0000165 mmu-miR-155;mmu-miR-155-5p; +MIMAT0000166 ath-miR156a;ath-miR156a-5p; +MIMAT0000167 ath-miR156b;ath-miR156b-5p; +MIMAT0000168 ath-miR156c;ath-miR156c-5p; +MIMAT0000169 ath-miR156d;ath-miR156d-5p; +MIMAT0000170 ath-miR156e; +MIMAT0000171 ath-miR156f;ath-miR156f-5p; +MIMAT0000172 ath-miR157a;ath-miR157a-5p; +MIMAT0000173 ath-miR157b;ath-miR157b-5p; +MIMAT0000174 ath-miR157c;ath-miR157c-5p; +MIMAT0000175 ath-miR157d; +MIMAT0000176 ath-miR158a;ath-miR158a-3p; +MIMAT0000177 ath-miR159a; +MIMAT0000178 ath-miR160a;ath-miR160a-5p; +MIMAT0000179 ath-miR160b; +MIMAT0000180 ath-miR160c;ath-miR160c-5p; +MIMAT0000181 ath-miR161;ath-miR161.1; +MIMAT0000182 ath-miR162a;ath-miR162a-3p; +MIMAT0000183 ath-miR162b;ath-miR162b-3p; +MIMAT0000184 ath-miR163; +MIMAT0000185 ath-miR164a; +MIMAT0000186 ath-miR164b;ath-miR164b-5p; +MIMAT0000187 ath-miR165a;ath-miR165a-3p; +MIMAT0000188 ath-miR165b; +MIMAT0000189 ath-miR166a;ath-miR166a-3p; +MIMAT0000190 ath-miR166b;ath-miR166b-3p; +MIMAT0000191 ath-miR166c; +MIMAT0000192 ath-miR166d; +MIMAT0000193 ath-miR166e;ath-miR166e-3p; +MIMAT0000194 ath-miR166f; +MIMAT0000195 ath-miR166g; +MIMAT0000196 ath-miR167a;ath-miR167a-5p; +MIMAT0000197 ath-miR167b; +MIMAT0000198 ath-miR168a;ath-miR168a-5p; +MIMAT0000199 ath-miR168b;ath-miR168b-5p; +MIMAT0000200 ath-miR169a;ath-miR169a-5p; +MIMAT0000201 ath-miR170;ath-miR170-3p; +MIMAT0000202 ath-miR171a;ath-miR171a-3p; +MIMAT0000203 ath-miR172a; +MIMAT0000204 ath-miR172b*;ath-miR172b-5p; +MIMAT0000205 ath-miR172b;ath-miR172b-3p; +MIMAT0000206 ath-miR173;ath-miR173-5p; +MIMAT0000207 ath-miR159b;ath-miR159b-3p; +MIMAT0000208 mmu-miR-10b;mmu-miR-10b-5p; +MIMAT0000209 mmu-miR-129;mmu-miR-129-5p; +MIMAT0000210 mmu-miR-181a;mmu-miR-181a-5p; +MIMAT0000211 mmu-miR-182;mmu-miR-182-5p; +MIMAT0000212 mmu-miR-183;mmu-miR-183-5p; +MIMAT0000213 mmu-miR-184;mmu-miR-184-3p; +MIMAT0000214 mmu-miR-185;mmu-miR-185-5p; +MIMAT0000215 mmu-miR-186;mmu-miR-186-5p; +MIMAT0000216 mmu-miR-187;mmu-miR-187-3p; +MIMAT0000217 mmu-miR-188;mmu-miR-188-5p; +MIMAT0000218 mmu-miR-189;mmu-miR-24*;mmu-miR-24-1*;mmu-miR-24-1-5p; +MIMAT0000219 mmu-miR-24;mmu-miR-24-3p; +MIMAT0000220 mmu-miR-190;mmu-miR-190-5p;mmu-miR-190a-5p; +MIMAT0000221 mmu-miR-191;mmu-miR-191-5p; +MIMAT0000222 hsa-miR-192;hsa-miR-192-5p; +MIMAT0000223 mmu-miR-193;mmu-miR-193-3p;mmu-miR-193a-3p; +MIMAT0000224 mmu-miR-194;mmu-miR-194-5p; +MIMAT0000225 mmu-miR-195;mmu-miR-195-5p;mmu-miR-195a-5p; +MIMAT0000226 hsa-miR-196a;hsa-miR-196a-5p; +MIMAT0000227 hsa-miR-197;hsa-miR-197-3p; +MIMAT0000228 hsa-miR-198; +MIMAT0000229 mmu-miR-199a;mmu-miR-199a-5p; +MIMAT0000230 mmu-miR-199a*;mmu-miR-199a-3p; +MIMAT0000231 hsa-miR-199a;hsa-miR-199a-5p; +MIMAT0000232 hsa-miR-199a*;hsa-miR-199a-3p; +MIMAT0000233 mmu-miR-200b;mmu-miR-200b-3p; +MIMAT0000234 mmu-miR-201;mmu-miR-201-5p; +MIMAT0000235 mmu-miR-202;mmu-miR-202-3p; +MIMAT0000236 mmu-miR-203;mmu-miR-203-3p; +MIMAT0000237 mmu-miR-204;mmu-miR-204-5p; +MIMAT0000238 mmu-miR-205;mmu-miR-205-5p; +MIMAT0000239 mmu-miR-206;mmu-miR-206-3p; +MIMAT0000240 mmu-miR-207; +MIMAT0000241 hsa-miR-208;hsa-miR-208a;hsa-miR-208a-3p; +MIMAT0000242 hsa-miR-129;hsa-miR-129-5p; +MIMAT0000243 hsa-miR-148a;hsa-miR-148a-3p; +MIMAT0000244 hsa-miR-30c;hsa-miR-30c-5p; +MIMAT0000245 hsa-miR-30d;hsa-miR-30d-5p; +MIMAT0000246 mmu-miR-122a;mmu-miR-122;mmu-miR-122-5p; +MIMAT0000247 mmu-miR-143;mmu-miR-143-3p; +MIMAT0000248 mmu-miR-30e;mmu-miR-30e-5p; +MIMAT0000249 mmu-miR-30e*;mmu-miR-30e-3p; +MIMAT0000250 hsa-miR-139;hsa-miR-139-5p; +MIMAT0000251 hsa-miR-147;hsa-miR-147a; +MIMAT0000252 hsa-miR-7;hsa-miR-7-5p; +MIMAT0000253 hsa-miR-10a;hsa-miR-10a-5p; +MIMAT0000254 hsa-miR-10b;hsa-miR-10b-5p; +MIMAT0000255 hsa-miR-34a;hsa-miR-34a-5p; +MIMAT0000256 hsa-miR-181a;hsa-miR-181a-5p; +MIMAT0000257 hsa-miR-181b;hsa-miR-181b-5p; +MIMAT0000258 hsa-miR-181c;hsa-miR-181c-5p; +MIMAT0000259 hsa-miR-182;hsa-miR-182-5p; +MIMAT0000260 hsa-miR-182*;hsa-miR-182-3p; +MIMAT0000261 hsa-miR-183;hsa-miR-183-5p; +MIMAT0000262 hsa-miR-187;hsa-miR-187-3p; +MIMAT0000263 hsa-miR-199b;hsa-miR-199b-5p; +MIMAT0000264 hsa-miR-203;hsa-miR-203a;hsa-miR-203a-3p; +MIMAT0000265 hsa-miR-204;hsa-miR-204-5p; +MIMAT0000266 hsa-miR-205;hsa-miR-205-5p; +MIMAT0000267 hsa-miR-210;hsa-miR-210-3p; +MIMAT0000268 hsa-miR-211;hsa-miR-211-5p; +MIMAT0000269 hsa-miR-212;hsa-miR-212-3p; +MIMAT0000270 hsa-miR-213;hsa-miR-181a*;hsa-miR-181a-3p; +MIMAT0000271 hsa-miR-214;hsa-miR-214-3p; +MIMAT0000272 hsa-miR-215;hsa-miR-215-5p; +MIMAT0000273 hsa-miR-216;hsa-miR-216a;hsa-miR-216a-5p; +MIMAT0000274 hsa-miR-217;hsa-miR-217-5p; +MIMAT0000275 hsa-miR-218;hsa-miR-218-5p; +MIMAT0000276 hsa-miR-219;hsa-miR-219-5p;hsa-miR-219a-5p; +MIMAT0000277 hsa-miR-220;hsa-miR-220a; +MIMAT0000278 hsa-miR-221;hsa-miR-221-3p; +MIMAT0000279 hsa-miR-222;hsa-miR-222-3p; +MIMAT0000280 hsa-miR-223;hsa-miR-223-3p; +MIMAT0000281 hsa-miR-224;hsa-miR-224-5p; +MIMAT0000282 cel-miR-124;cel-miR-124-3p; +MIMAT0000283 cel-miR-228;cel-miR-228-5p; +MIMAT0000284 cel-miR-229;cel-miR-229-5p; +MIMAT0000285 cel-miR-230;cel-miR-230-3p; +MIMAT0000286 cel-miR-231;cel-miR-231-3p; +MIMAT0000287 cel-miR-232;cel-miR-232-3p; +MIMAT0000288 cel-miR-233;cel-miR-233-3p; +MIMAT0000289 cel-miR-234;cel-miR-234-3p; +MIMAT0000290 cel-miR-235;cel-miR-235-3p; +MIMAT0000291 cel-miR-236;cel-miR-236-3p; +MIMAT0000292 cel-miR-237;cel-miR-237-5p; +MIMAT0000293 cel-miR-238;cel-miR-238-3p; +MIMAT0000294 cel-miR-239a;cel-miR-239a-5p; +MIMAT0000295 cel-miR-239b;cel-miR-239b-5p; +MIMAT0000296 cel-miR-240;cel-miR-240-3p; +MIMAT0000297 cel-miR-241;cel-miR-241-5p; +MIMAT0000298 cel-miR-242; +MIMAT0000299 cel-miR-243;cel-miR-243-3p; +MIMAT0000300 cel-miR-244;cel-miR-244-5p; +MIMAT0000301 cel-miR-245;cel-miR-245-3p; +MIMAT0000302 cel-miR-246;cel-miR-246-3p; +MIMAT0000303 cel-miR-247;cel-miR-247-3p; +MIMAT0000304 cel-miR-248; +MIMAT0000305 cel-miR-249;cel-miR-249-3p; +MIMAT0000306 cel-miR-250;cel-miR-250-3p; +MIMAT0000307 cel-miR-251; +MIMAT0000308 cel-miR-252;cel-miR-252-5p; +MIMAT0000309 cel-miR-253;cel-miR-253*;cel-miR-253-5p; +MIMAT0000310 cel-miR-254;cel-miR-254-3p; +MIMAT0000311 cel-miR-256; +MIMAT0000312 cel-miR-257; +MIMAT0000313 cel-miR-258; +MIMAT0000314 cel-miR-259;cel-miR-259-5p; +MIMAT0000315 cel-miR-260; +MIMAT0000316 cel-miR-261; +MIMAT0000317 cel-miR-262; +MIMAT0000318 hsa-miR-200b;hsa-miR-200b-3p; +MIMAT0000319 dme-miR-263a;dme-miR-263a-5p; +MIMAT0000320 cel-miR-264; +MIMAT0000321 cel-miR-265; +MIMAT0000322 cel-miR-266; +MIMAT0000323 cel-miR-267; +MIMAT0000324 cel-miR-268; +MIMAT0000325 cel-miR-269; +MIMAT0000326 cel-miR-270; +MIMAT0000327 cel-miR-271; +MIMAT0000328 cel-miR-272; +MIMAT0000329 cel-miR-273; +MIMAT0000330 dme-miR-184*;dme-miR-184-5p; +MIMAT0000331 dme-miR-184;dme-miR-184-3p; +MIMAT0000332 dme-miR-274;dme-miR-274-5p; +MIMAT0000333 dme-miR-275;dme-miR-275-3p; +MIMAT0000334 dme-miR-92a;dme-miR-92a-3p; +MIMAT0000335 dme-miR-219;dme-miR-219-5p; +MIMAT0000336 dme-miR-276a*;dme-miR-276*;dme-miR-276a-5p; +MIMAT0000337 dme-miR-276a;dme-miR-276a-3p; +MIMAT0000338 dme-miR-277;dme-miR-277-3p; +MIMAT0000339 dme-miR-278;dme-miR-278-3p; +MIMAT0000340 dme-miR-133;dme-miR-133-3p; +MIMAT0000341 dme-miR-279;dme-miR-279-3p; +MIMAT0000342 dme-miR-33;dme-miR-33-5p; +MIMAT0000343 dme-miR-280;dme-miR-280-5p; +MIMAT0000344 dme-miR-281-1*;dme-miR-281-1-5p; +MIMAT0000345 dme-miR-281;dme-miR-281-3p; +MIMAT0000346 dme-miR-282;dme-miR-282-5p; +MIMAT0000347 dme-miR-283;dme-miR-283-5p; +MIMAT0000348 dme-miR-284;dme-miR-284-3p; +MIMAT0000349 dme-miR-281-2*;dme-miR-281-2-5p; +MIMAT0000350 dme-miR-34;dme-miR-34-5p; +MIMAT0000351 dme-miR-124;dme-miR-124-3p; +MIMAT0000352 dme-miR-79;dme-miR-79-3p; +MIMAT0000353 dme-miR-276b*; +MIMAT0000354 dme-miR-276b;dme-miR-276b-3p; +MIMAT0000355 dme-miR-210;dme-miR-210-3p; +MIMAT0000356 dme-miR-285;dme-miR-285-3p; +MIMAT0000357 dme-miR-100;dme-miR-100-5p; +MIMAT0000358 dme-miR-92b;dme-miR-92b-3p; +MIMAT0000359 dme-miR-286;dme-miR-286-3p; +MIMAT0000360 dme-miR-287;dme-miR-287-3p; +MIMAT0000361 dme-miR-87;dme-miR-87-3p; +MIMAT0000362 dme-miR-263b;dme-miR-263b-5p; +MIMAT0000363 dme-miR-288;dme-miR-288-3p; +MIMAT0000364 dme-miR-289;dme-miR-289-5p; +MIMAT0000365 dme-bantam;dme-bantam-3p; +MIMAT0000366 mmu-miR-290;mmu-miR-290-5p;mmu-miR-290a-5p; +MIMAT0000367 mmu-miR-291-5p;mmu-miR-291a-5p; +MIMAT0000368 mmu-miR-291-3p;mmu-miR-291a-3p; +MIMAT0000369 mmu-miR-292-5p;mmu-miR-292a-5p; +MIMAT0000370 mmu-miR-292-3p;mmu-miR-292a-3p; +MIMAT0000371 mmu-miR-293;mmu-miR-293-3p; +MIMAT0000372 mmu-miR-294;mmu-miR-294-3p; +MIMAT0000373 mmu-miR-295;mmu-miR-295-3p; +MIMAT0000374 mmu-miR-296;mmu-miR-296-5p; +MIMAT0000375 mmu-miR-297;mmu-miR-297a;mmu-miR-297a-5p; +MIMAT0000376 mmu-miR-298;mmu-miR-298-5p; +MIMAT0000377 mmu-miR-299;mmu-miR-299*;mmu-miR-299-5p;mmu-miR-299a-5p; +MIMAT0000378 mmu-miR-300;mmu-miR-300-3p; +MIMAT0000379 mmu-miR-301;mmu-miR-301a;mmu-miR-301a-3p; +MIMAT0000380 mmu-miR-302;mmu-miR-302a;mmu-miR-302a-3p; +MIMAT0000381 mmu-miR-34c;mmu-miR-34c-5p; +MIMAT0000382 mmu-miR-34b;mmu-miR-34b-5p; +MIMAT0000383 mmu-let-7d;mmu-let-7d-5p; +MIMAT0000384 mmu-let-7d*;mmu-let-7d-3p; +MIMAT0000385 mmu-miR-106a;mmu-miR-106a-5p; +MIMAT0000386 mmu-miR-106b;mmu-miR-106b-5p; +MIMAT0000387 mmu-miR-130b;mmu-miR-130b-3p; +MIMAT0000388 dme-miR-303;dme-miR-303-5p; +MIMAT0000389 dme-miR-31b;dme-miR-31b-5p; +MIMAT0000390 dme-miR-304;dme-miR-304-5p; +MIMAT0000391 dme-miR-305;dme-miR-305-5p; +MIMAT0000392 dme-miR-9c;dme-miR-9c-5p; +MIMAT0000393 dme-miR-306;dme-miR-306-5p; +MIMAT0000394 dme-miR-306*;dme-miR-306-3p; +MIMAT0000395 dme-miR-9b;dme-miR-9b-5p; +MIMAT0000396 dme-let-7;dme-let-7-5p; +MIMAT0000397 dme-miR-125;dme-miR-125-5p; +MIMAT0000398 dme-miR-307;dme-miR-307a-3p; +MIMAT0000399 dme-miR-308;dme-miR-308-3p; +MIMAT0000400 dme-miR-31a;dme-miR-31a-5p; +MIMAT0000401 dme-miR-309;dme-miR-309-3p; +MIMAT0000402 dme-miR-310;dme-miR-310-3p; +MIMAT0000403 dme-miR-311;dme-miR-311-3p; +MIMAT0000404 dme-miR-312;dme-miR-312-3p; +MIMAT0000405 dme-miR-313;dme-miR-313-3p; +MIMAT0000406 dme-miR-314;dme-miR-314-3p; +MIMAT0000407 dme-miR-315;dme-miR-315-5p; +MIMAT0000408 dme-miR-316;dme-miR-316-5p; +MIMAT0000409 dme-miR-317;dme-miR-317-3p; +MIMAT0000410 dme-miR-318;dme-miR-318-3p; +MIMAT0000411 dme-miR-2c;dme-miR-2c-3p; +MIMAT0000412 dme-miR-iab-4-5p; +MIMAT0000413 dme-miR-iab-4-3p; +MIMAT0000414 hsa-let-7g;hsa-let-7g-5p; +MIMAT0000415 hsa-let-7i;hsa-let-7i-5p; +MIMAT0000416 hsa-miR-1;hsa-miR-1-3p; +MIMAT0000417 hsa-miR-15b;hsa-miR-15b-5p; +MIMAT0000418 hsa-miR-23b;hsa-miR-23b-3p; +MIMAT0000419 hsa-miR-27b;hsa-miR-27b-3p; +MIMAT0000420 hsa-miR-30b;hsa-miR-30b-5p; +MIMAT0000421 hsa-miR-122a;hsa-miR-122;hsa-miR-122-5p; +MIMAT0000422 hsa-miR-124a;hsa-miR-124;hsa-miR-124-3p; +MIMAT0000423 hsa-miR-125b;hsa-miR-125b-5p; +MIMAT0000424 hsa-miR-128a;hsa-miR-128;hsa-miR-128-3p; +MIMAT0000425 hsa-miR-130a;hsa-miR-130a-3p; +MIMAT0000426 hsa-miR-132;hsa-miR-132-3p; +MIMAT0000427 hsa-miR-133a;hsa-miR-133a-3p; +MIMAT0000428 hsa-miR-135a;hsa-miR-135a-5p; +MIMAT0000429 hsa-miR-137;hsa-miR-137-3p; +MIMAT0000430 hsa-miR-138;hsa-miR-138-5p; +MIMAT0000431 hsa-miR-140;hsa-miR-140-5p; +MIMAT0000432 hsa-miR-141;hsa-miR-141-3p; +MIMAT0000433 hsa-miR-142-5p; +MIMAT0000434 hsa-miR-142-3p; +MIMAT0000435 hsa-miR-143;hsa-miR-143-3p; +MIMAT0000436 hsa-miR-144;hsa-miR-144-3p; +MIMAT0000437 hsa-miR-145;hsa-miR-145-5p; +MIMAT0000438 hsa-miR-152;hsa-miR-152-3p; +MIMAT0000439 hsa-miR-153;hsa-miR-153-3p; +MIMAT0000440 hsa-miR-191;hsa-miR-191-5p; +MIMAT0000441 hsa-miR-9;hsa-miR-9-5p; +MIMAT0000442 hsa-miR-9*;hsa-miR-9-3p; +MIMAT0000443 hsa-miR-125a;hsa-miR-125a-5p; +MIMAT0000444 hsa-miR-126*;hsa-miR-126-5p; +MIMAT0000445 hsa-miR-126;hsa-miR-126-3p; +MIMAT0000446 hsa-miR-127;hsa-miR-127-3p; +MIMAT0000447 hsa-miR-134;hsa-miR-134-5p; +MIMAT0000448 hsa-miR-136;hsa-miR-136-5p; +MIMAT0000449 hsa-miR-146;hsa-miR-146a;hsa-miR-146a-5p; +MIMAT0000450 hsa-miR-149;hsa-miR-149-5p; +MIMAT0000451 hsa-miR-150;hsa-miR-150-5p; +MIMAT0000452 hsa-miR-154;hsa-miR-154-5p; +MIMAT0000453 hsa-miR-154*;hsa-miR-154-3p; +MIMAT0000454 hsa-miR-184; +MIMAT0000455 hsa-miR-185;hsa-miR-185-5p; +MIMAT0000456 hsa-miR-186;hsa-miR-186-5p; +MIMAT0000457 hsa-miR-188;hsa-miR-188-5p; +MIMAT0000458 hsa-miR-190;hsa-miR-190a;hsa-miR-190a-5p; +MIMAT0000459 hsa-miR-193;hsa-miR-193a;hsa-miR-193a-3p; +MIMAT0000460 hsa-miR-194;hsa-miR-194-5p; +MIMAT0000461 hsa-miR-195;hsa-miR-195-5p; +MIMAT0000462 hsa-miR-206; +MIMAT0000463 cbr-let-7; +MIMAT0000464 cbr-lin-4; +MIMAT0000465 cbr-miR-1; +MIMAT0000466 cbr-miR-34; +MIMAT0000467 cbr-miR-42; +MIMAT0000468 cbr-miR-43; +MIMAT0000469 cbr-miR-44; +MIMAT0000470 cbr-miR-45; +MIMAT0000471 cbr-miR-46; +MIMAT0000472 cbr-miR-47; +MIMAT0000473 cbr-miR-48; +MIMAT0000474 cbr-miR-49; +MIMAT0000475 cbr-miR-50; +MIMAT0000476 cbr-miR-52; +MIMAT0000477 cbr-miR-57; +MIMAT0000478 cbr-miR-58;cbr-miR-58a; +MIMAT0000479 cbr-miR-60; +MIMAT0000480 cbr-miR-67; +MIMAT0000481 cbr-miR-71; +MIMAT0000482 cbr-miR-73;cbr-miR-73a; +MIMAT0000483 cbr-miR-74;cbr-miR-74a; +MIMAT0000484 cbr-miR-75; +MIMAT0000485 cbr-miR-77; +MIMAT0000486 cbr-miR-79; +MIMAT0000487 cbr-miR-80; +MIMAT0000488 cbr-miR-81; +MIMAT0000489 cbr-miR-82; +MIMAT0000490 cbr-miR-85; +MIMAT0000491 cbr-miR-86; +MIMAT0000492 cbr-miR-87; +MIMAT0000493 cbr-miR-90;cbr-miR-90a; +MIMAT0000494 cbr-miR-124;cbr-miR-124a; +MIMAT0000495 cbr-miR-228; +MIMAT0000496 cbr-miR-230; +MIMAT0000497 cbr-miR-232; +MIMAT0000498 cbr-miR-233; +MIMAT0000499 cbr-miR-234; +MIMAT0000500 cbr-miR-236; +MIMAT0000501 cbr-miR-241; +MIMAT0000502 cbr-miR-244; +MIMAT0000503 cbr-miR-245; +MIMAT0000504 cbr-miR-248; +MIMAT0000505 cbr-miR-250; +MIMAT0000506 cbr-miR-251; +MIMAT0000507 cbr-miR-252; +MIMAT0000508 cbr-miR-259; +MIMAT0000509 cbr-miR-268; +MIMAT0000510 hsa-miR-320;hsa-miR-320a;hsa-miR-320a-3p; +MIMAT0000511 ath-miR319a; +MIMAT0000512 ath-miR319b; +MIMAT0000513 mmu-miR-19b;mmu-miR-19b-3p; +MIMAT0000514 mmu-miR-30c;mmu-miR-30c-5p; +MIMAT0000515 mmu-miR-30d;mmu-miR-30d-5p; +MIMAT0000516 mmu-miR-148a;mmu-miR-148a-3p; +MIMAT0000517 mmu-miR-192;mmu-miR-192-5p; +MIMAT0000518 mmu-miR-196a;mmu-miR-196a-5p; +MIMAT0000519 mmu-miR-200a;mmu-miR-200a-3p; +MIMAT0000520 mmu-miR-208;mmu-miR-208a;mmu-miR-208a-3p; +MIMAT0000521 mmu-let-7a;mmu-let-7a-5p; +MIMAT0000522 mmu-let-7b;mmu-let-7b-5p; +MIMAT0000523 mmu-let-7c;mmu-let-7c-5p; +MIMAT0000524 mmu-let-7e;mmu-let-7e-5p; +MIMAT0000525 mmu-let-7f;mmu-let-7f-5p; +MIMAT0000526 mmu-miR-15a;mmu-miR-15a-5p; +MIMAT0000527 mmu-miR-16;mmu-miR-16-5p; +MIMAT0000528 mmu-miR-18;mmu-miR-18a;mmu-miR-18a-5p; +MIMAT0000529 mmu-miR-20;mmu-miR-20a;mmu-miR-20a-5p; +MIMAT0000530 mmu-miR-21;mmu-miR-21-5p;mmu-miR-21a-5p; +MIMAT0000531 mmu-miR-22;mmu-miR-22-3p; +MIMAT0000532 mmu-miR-23a;mmu-miR-23a-3p; +MIMAT0000533 mmu-miR-26a;mmu-miR-26a-5p; +MIMAT0000534 mmu-miR-26b;mmu-miR-26b-5p; +MIMAT0000535 mmu-miR-29a;mmu-miR-29a-3p; +MIMAT0000536 mmu-miR-29c;mmu-miR-29c-3p; +MIMAT0000537 mmu-miR-27a;mmu-miR-27a-3p; +MIMAT0000538 mmu-miR-31;mmu-miR-31-5p; +MIMAT0000539 mmu-miR-92;mmu-miR-92a;mmu-miR-92a-3p; +MIMAT0000540 mmu-miR-93;mmu-miR-93-5p; +MIMAT0000541 mmu-miR-96;mmu-miR-96-5p; +MIMAT0000542 mmu-miR-34a;mmu-miR-34a-5p; +MIMAT0000543 mmu-miR-129-5p; +MIMAT0000544 mmu-miR-129-3p;mmu-miR-129-2-3p; +MIMAT0000545 mmu-miR-98;mmu-miR-98-5p; +MIMAT0000546 mmu-miR-103;mmu-miR-103-3p; +MIMAT0000547 rno-miR-322;rno-miR-322*;rno-miR-322-3p; +MIMAT0000548 mmu-miR-322-5p;mmu-miR-424;mmu-miR-322;mmu-miR-322-5p; +MIMAT0000549 mmu-miR-322-3p;mmu-miR-322;mmu-miR-322*;mmu-miR-322-3p; +MIMAT0000550 rno-miR-323;rno-miR-323-3p; +MIMAT0000551 mmu-miR-323;mmu-miR-323-3p; +MIMAT0000552 rno-miR-301;rno-miR-301a;rno-miR-301a-3p; +MIMAT0000553 rno-miR-324-5p; +MIMAT0000554 rno-miR-324-3p; +MIMAT0000555 mmu-miR-324-5p; +MIMAT0000556 mmu-miR-324-3p; +MIMAT0000557 rno-miR-325;rno-miR-325-5p; +MIMAT0000558 mmu-miR-325;mmu-miR-325*;mmu-miR-325-5p; +MIMAT0000559 mmu-miR-326;mmu-miR-326-3p; +MIMAT0000560 rno-miR-326;rno-miR-326-3p; +MIMAT0000561 rno-miR-327; +MIMAT0000562 rno-let-7d;rno-let-7d-5p; +MIMAT0000563 rno-let-7d*;rno-let-7d-3p; +MIMAT0000564 rno-miR-328;rno-miR-328a;rno-miR-328a-3p; +MIMAT0000565 mmu-miR-328;mmu-miR-328-3p; +MIMAT0000566 rno-miR-329;rno-miR-329-3p; +MIMAT0000567 mmu-miR-329;mmu-miR-329-3p; +MIMAT0000568 rno-miR-330;rno-miR-330*;rno-miR-330-3p; +MIMAT0000569 mmu-miR-330;mmu-miR-330*;mmu-miR-330-3p; +MIMAT0000570 rno-miR-331;rno-miR-331-3p; +MIMAT0000571 mmu-miR-331;mmu-miR-331-3p; +MIMAT0000572 rno-miR-333; +MIMAT0000573 rno-miR-140;rno-miR-140-5p; +MIMAT0000574 rno-miR-140*;rno-miR-140-3p; +MIMAT0000575 rno-miR-335; +MIMAT0000576 rno-miR-336;rno-miR-336-5p; +MIMAT0000577 rno-miR-337;rno-miR-337-3p; +MIMAT0000578 mmu-miR-337;mmu-miR-337-3p; +MIMAT0000579 rno-miR-148b;rno-miR-148b-3p; +MIMAT0000580 mmu-miR-148b;mmu-miR-148b-3p; +MIMAT0000581 rno-miR-338;rno-miR-338-3p; +MIMAT0000582 mmu-miR-338;mmu-miR-338-3p; +MIMAT0000583 rno-miR-339;rno-miR-339-5p; +MIMAT0000584 mmu-miR-339;mmu-miR-339-5p; +MIMAT0000585 rno-miR-340;rno-miR-340-3p; +MIMAT0000586 mmu-miR-340;mmu-miR-340-3p; +MIMAT0000587 rno-miR-341; +MIMAT0000588 mmu-miR-341;mmu-miR-341-3p; +MIMAT0000589 rno-miR-342;rno-miR-342-3p; +MIMAT0000590 mmu-miR-342;mmu-miR-342-3p; +MIMAT0000591 rno-miR-343; +MIMAT0000592 rno-miR-344;rno-miR-344-3p;rno-miR-344a-3p; +MIMAT0000593 mmu-miR-344;mmu-miR-344-3p; +MIMAT0000594 rno-miR-345;rno-miR-345-5p; +MIMAT0000595 mmu-miR-345;mmu-miR-345-5p; +MIMAT0000596 rno-miR-346; +MIMAT0000597 mmu-miR-346;mmu-miR-346-5p; +MIMAT0000598 rno-miR-347; +MIMAT0000599 rno-miR-349; +MIMAT0000600 rno-miR-129;rno-miR-129-5p; +MIMAT0000601 rno-miR-129*;rno-miR-129-2*;rno-miR-129-2-3p; +MIMAT0000602 rno-miR-20;rno-miR-20a;rno-miR-20a-5p; +MIMAT0000603 rno-miR-20*;rno-miR-20a*;rno-miR-20a-3p; +MIMAT0000604 rno-miR-350; +MIMAT0000605 mmu-miR-350;mmu-miR-350-3p; +MIMAT0000606 rno-miR-7;rno-miR-7a;rno-miR-7a-5p; +MIMAT0000607 rno-miR-7*;rno-miR-7a*;rno-miR-7a-1*;rno-miR-7a-1-3p; +MIMAT0000608 rno-miR-351;rno-miR-351-5p; +MIMAT0000609 mmu-miR-351;mmu-miR-351-5p; +MIMAT0000610 rno-miR-352; +MIMAT0000611 rno-miR-135b;rno-miR-135b-5p; +MIMAT0000612 mmu-miR-135b;mmu-miR-135b-5p; +MIMAT0000613 rno-miR-151*;rno-miR-151;rno-miR-151-5p; +MIMAT0000614 rno-miR-151;rno-miR-151*;rno-miR-151-3p; +MIMAT0000615 rno-miR-101b;rno-miR-101b-3p; +MIMAT0000616 mmu-miR-101b;mmu-miR-101b-3p; +MIMAT0000617 hsa-miR-200c;hsa-miR-200c-3p; +MIMAT0000618 osa-miR156a; +MIMAT0000619 osa-miR156b;osa-miR156b-5p; +MIMAT0000620 osa-miR156c;osa-miR156c-5p; +MIMAT0000621 osa-miR156d; +MIMAT0000622 osa-miR156e; +MIMAT0000623 osa-miR156f;osa-miR156f-5p; +MIMAT0000624 osa-miR156g;osa-miR156g-5p; +MIMAT0000625 osa-miR156h;osa-miR156h-5p; +MIMAT0000626 osa-miR156i; +MIMAT0000627 osa-miR156j;osa-miR156j-5p; +MIMAT0000628 osa-miR160a;osa-miR160a-5p; +MIMAT0000629 osa-miR160b;osa-miR160b-5p; +MIMAT0000630 osa-miR160c;osa-miR160c-5p; +MIMAT0000631 osa-miR160d;osa-miR160d-5p; +MIMAT0000632 osa-miR162a; +MIMAT0000633 osa-miR164a; +MIMAT0000634 osa-miR164b; +MIMAT0000635 osa-miR166a;osa-miR166a-3p; +MIMAT0000636 osa-miR166b;osa-miR166b-3p; +MIMAT0000637 osa-miR166c;osa-miR166c-3p; +MIMAT0000638 osa-miR166d;osa-miR166d-3p; +MIMAT0000639 osa-miR166e;osa-miR166e-3p; +MIMAT0000640 osa-miR166f; +MIMAT0000641 osa-miR167a;osa-miR167a-5p; +MIMAT0000642 osa-miR167b; +MIMAT0000643 osa-miR167c;osa-miR167c-5p; +MIMAT0000644 osa-miR169a; +MIMAT0000645 osa-miR171a; +MIMAT0000646 hsa-miR-155;hsa-miR-155-5p; +MIMAT0000647 mmu-miR-107;mmu-miR-107-3p; +MIMAT0000648 mmu-miR-10a;mmu-miR-10a-5p; +MIMAT0000649 mmu-miR-17-5p;mmu-miR-17;mmu-miR-17-5p; +MIMAT0000650 mmu-miR-17-3p;mmu-miR-17*;mmu-miR-17-3p; +MIMAT0000651 mmu-miR-19a;mmu-miR-19a-3p; +MIMAT0000652 mmu-miR-25;mmu-miR-25-3p; +MIMAT0000653 mmu-miR-28;mmu-miR-28-5p;mmu-miR-28a-5p; +MIMAT0000654 mmu-miR-32;mmu-miR-32-5p; +MIMAT0000655 mmu-miR-100;mmu-miR-100-5p; +MIMAT0000656 mmu-miR-139;mmu-miR-139-5p; +MIMAT0000657 mmu-miR-200c;mmu-miR-200c-3p; +MIMAT0000658 mmu-miR-210;mmu-miR-210-3p; +MIMAT0000659 mmu-miR-212;mmu-miR-212-3p; +MIMAT0000660 mmu-miR-213;mmu-miR-181a*;mmu-miR-181a-1*;mmu-miR-181a-1-3p; +MIMAT0000661 mmu-miR-214;mmu-miR-214-3p; +MIMAT0000662 mmu-miR-216;mmu-miR-216a;mmu-miR-216a-5p; +MIMAT0000663 mmu-miR-218;mmu-miR-218-5p; +MIMAT0000664 mmu-miR-219;mmu-miR-219-5p;mmu-miR-219a-5p; +MIMAT0000665 mmu-miR-223;mmu-miR-223-3p; +MIMAT0000666 mmu-miR-320;mmu-miR-320-3p; +MIMAT0000667 mmu-miR-33;mmu-miR-33-5p; +MIMAT0000668 mmu-miR-211;mmu-miR-211-5p; +MIMAT0000669 mmu-miR-221;mmu-miR-221-3p; +MIMAT0000670 mmu-miR-222;mmu-miR-222-3p; +MIMAT0000671 mmu-miR-224;mmu-miR-224-5p; +MIMAT0000672 mmu-miR-199b;mmu-miR-199b*;mmu-miR-199b-5p; +MIMAT0000673 mmu-miR-181b;mmu-miR-181b-5p; +MIMAT0000674 mmu-miR-181c;mmu-miR-181c-5p; +MIMAT0000675 mmu-miR-128b; +MIMAT0000676 hsa-miR-128b; +MIMAT0000677 mmu-miR-7;mmu-miR-7a;mmu-miR-7a-5p; +MIMAT0000678 mmu-miR-7b;mmu-miR-7b-5p; +MIMAT0000679 mmu-miR-217;mmu-miR-217-5p; +MIMAT0000680 hsa-miR-106b;hsa-miR-106b-5p; +MIMAT0000681 hsa-miR-29c;hsa-miR-29c-3p; +MIMAT0000682 hsa-miR-200a;hsa-miR-200a-3p; +MIMAT0000683 hsa-miR-302a*;hsa-miR-302a-5p; +MIMAT0000684 hsa-miR-302a;hsa-miR-302a-3p; +MIMAT0000685 hsa-miR-34b;hsa-miR-34b*;hsa-miR-34b-5p; +MIMAT0000686 hsa-miR-34c;hsa-miR-34c-5p; +MIMAT0000687 hsa-miR-299;hsa-miR-299-5p;hsa-miR-299-3p; +MIMAT0000688 hsa-miR-301;hsa-miR-301a;hsa-miR-301a-3p; +MIMAT0000689 hsa-miR-99b;hsa-miR-99b-5p; +MIMAT0000690 hsa-miR-296;hsa-miR-296-5p; +MIMAT0000691 hsa-miR-130b;hsa-miR-130b-3p; +MIMAT0000692 hsa-miR-30e-5p;hsa-miR-30e;hsa-miR-30e-5p; +MIMAT0000693 hsa-miR-30e-3p;hsa-miR-30e*;hsa-miR-30e-3p; +MIMAT0000694 cbr-miR-72; +MIMAT0000695 cel-miR-353; +MIMAT0000696 cel-miR-354;cel-miR-354-3p; +MIMAT0000697 cel-miR-355;cel-miR-355-5p; +MIMAT0000698 cel-miR-356;cel-miR-356a; +MIMAT0000699 cel-miR-357;cel-miR-357-3p; +MIMAT0000700 cel-miR-358;cel-miR-358-3p; +MIMAT0000701 cel-miR-359; +MIMAT0000702 cel-miR-360;cel-miR-360-3p; +MIMAT0000703 hsa-miR-361;hsa-miR-361-5p; +MIMAT0000704 mmu-miR-361;mmu-miR-361-5p; +MIMAT0000705 hsa-miR-362;hsa-miR-362-5p; +MIMAT0000706 mmu-miR-362;mmu-miR-362-5p; +MIMAT0000707 hsa-miR-363;hsa-miR-363-3p; +MIMAT0000708 mmu-miR-363;mmu-miR-363-3p; +MIMAT0000710 hsa-miR-365;hsa-miR-365a-3p; +MIMAT0000711 mmu-miR-365;mmu-miR-365-3p; +MIMAT0000714 hsa-miR-302b*;hsa-miR-302b-5p; +MIMAT0000715 hsa-miR-302b;hsa-miR-302b-3p; +MIMAT0000716 hsa-miR-302c*;hsa-miR-302c-5p; +MIMAT0000717 hsa-miR-302c;hsa-miR-302c-3p; +MIMAT0000718 hsa-miR-302d;hsa-miR-302d-3p; +MIMAT0000719 hsa-miR-367;hsa-miR-367-3p; +MIMAT0000720 hsa-miR-368;hsa-miR-376c;hsa-miR-376c-3p; +MIMAT0000721 hsa-miR-369;hsa-miR-369-3p; +MIMAT0000722 hsa-miR-370;hsa-miR-370-3p; +MIMAT0000723 hsa-miR-371;hsa-miR-371-3p;hsa-miR-371a-3p; +MIMAT0000724 hsa-miR-372;hsa-miR-372-3p; +MIMAT0000725 hsa-miR-373*;hsa-miR-373-5p; +MIMAT0000726 hsa-miR-373;hsa-miR-373-3p; +MIMAT0000727 hsa-miR-374;hsa-miR-374a;hsa-miR-374a-5p; +MIMAT0000728 hsa-miR-375;hsa-miR-375-3p; +MIMAT0000729 hsa-miR-376a;hsa-miR-376a-3p; +MIMAT0000730 hsa-miR-377;hsa-miR-377-3p; +MIMAT0000731 hsa-miR-378;hsa-miR-378*;hsa-miR-378a-5p; +MIMAT0000732 hsa-miR-422b;hsa-miR-378;hsa-miR-378a-3p; +MIMAT0000733 hsa-miR-379;hsa-miR-379-5p; +MIMAT0000734 hsa-miR-380-5p;hsa-miR-380*;hsa-miR-380-5p; +MIMAT0000735 hsa-miR-380-3p;hsa-miR-380;hsa-miR-380-3p; +MIMAT0000736 hsa-miR-381;hsa-miR-381-3p; +MIMAT0000737 hsa-miR-382;hsa-miR-382-5p; +MIMAT0000738 hsa-miR-383;hsa-miR-383-5p; +MIMAT0000739 mmu-miR-375;mmu-miR-375-3p; +MIMAT0000740 mmu-miR-376a;mmu-miR-376a-3p; +MIMAT0000741 mmu-miR-377;mmu-miR-377-3p; +MIMAT0000742 mmu-miR-378;mmu-miR-378*;mmu-miR-378-5p;mmu-miR-378a-5p; +MIMAT0000743 mmu-miR-379;mmu-miR-379-5p; +MIMAT0000744 mmu-miR-380-5p; +MIMAT0000745 mmu-miR-380-3p; +MIMAT0000746 mmu-miR-381;mmu-miR-381-3p; +MIMAT0000747 mmu-miR-382;mmu-miR-382-5p; +MIMAT0000748 mmu-miR-383;mmu-miR-383-5p; +MIMAT0000749 cel-lsy-6;cel-lsy-6-3p; +MIMAT0000750 hsa-miR-340;hsa-miR-340*;hsa-miR-340-3p; +MIMAT0000751 hsa-miR-330;hsa-miR-330-3p; +MIMAT0000752 hsa-miR-328;hsa-miR-328-3p; +MIMAT0000753 hsa-miR-342;hsa-miR-342-3p; +MIMAT0000754 hsa-miR-337;hsa-miR-337-3p; +MIMAT0000755 hsa-miR-323;hsa-miR-323-3p;hsa-miR-323a-3p; +MIMAT0000756 hsa-miR-326; +MIMAT0000757 hsa-miR-151;hsa-miR-151-3p;hsa-miR-151a-3p; +MIMAT0000758 hsa-miR-135b;hsa-miR-135b-5p; +MIMAT0000759 hsa-miR-148b;hsa-miR-148b-3p; +MIMAT0000760 hsa-miR-331;hsa-miR-331-3p; +MIMAT0000761 hsa-miR-324-5p; +MIMAT0000762 hsa-miR-324-3p; +MIMAT0000763 hsa-miR-338;hsa-miR-338-3p; +MIMAT0000764 hsa-miR-339;hsa-miR-339-5p; +MIMAT0000765 hsa-miR-335;hsa-miR-335-5p; +MIMAT0000766 mmu-miR-335;mmu-miR-335-5p; +MIMAT0000767 cbr-lsy-6; +MIMAT0000768 cel-miR-392;cel-miR-392-3p; +MIMAT0000769 mmu-miR-133b;mmu-miR-133b-3p; +MIMAT0000770 hsa-miR-133b; +MIMAT0000771 hsa-miR-325; +MIMAT0000772 hsa-miR-345;hsa-miR-345-5p; +MIMAT0000773 hsa-miR-346; +MIMAT0000774 rno-let-7a;rno-let-7a-5p; +MIMAT0000775 rno-let-7b;rno-let-7b-5p; +MIMAT0000776 rno-let-7c;rno-let-7c-5p; +MIMAT0000777 rno-let-7e;rno-let-7e-5p; +MIMAT0000778 rno-let-7f;rno-let-7f-5p; +MIMAT0000779 rno-let-7i;rno-let-7i-5p; +MIMAT0000780 rno-miR-7b; +MIMAT0000781 rno-miR-9;rno-miR-9a-5p; +MIMAT0000782 rno-miR-10a;rno-miR-10a-5p; +MIMAT0000783 rno-miR-10b;rno-miR-10b-5p; +MIMAT0000784 rno-miR-15b;rno-miR-15b-5p; +MIMAT0000785 rno-miR-16;rno-miR-16-5p; +MIMAT0000786 rno-miR-17;rno-miR-17-5p; +MIMAT0000787 rno-miR-18;rno-miR-18a;rno-miR-18a-5p; +MIMAT0000788 rno-miR-19b;rno-miR-19b-3p; +MIMAT0000789 rno-miR-19a;rno-miR-19a-3p; +MIMAT0000790 rno-miR-21;rno-miR-21-5p; +MIMAT0000791 rno-miR-22;rno-miR-22-3p; +MIMAT0000792 rno-miR-23a;rno-miR-23a-3p; +MIMAT0000793 rno-miR-23b;rno-miR-23b-3p; +MIMAT0000794 rno-miR-24;rno-miR-24-3p; +MIMAT0000795 rno-miR-25;rno-miR-25-3p; +MIMAT0000796 rno-miR-26a;rno-miR-26a-5p; +MIMAT0000797 rno-miR-26b;rno-miR-26b-5p; +MIMAT0000798 rno-miR-27b;rno-miR-27b-3p; +MIMAT0000799 rno-miR-27a;rno-miR-27a-3p; +MIMAT0000800 rno-miR-28;rno-miR-28-5p; +MIMAT0000801 rno-miR-29b;rno-miR-29b-3p; +MIMAT0000802 rno-miR-29a;rno-miR-29a-3p; +MIMAT0000803 rno-miR-29c;rno-miR-29c-3p; +MIMAT0000804 rno-miR-30c;rno-miR-30c-5p; +MIMAT0000805 rno-miR-30e;rno-miR-30e-5p; +MIMAT0000806 rno-miR-30b;rno-miR-30b-5p; +MIMAT0000807 rno-miR-30d;rno-miR-30d-5p; +MIMAT0000808 rno-miR-30a-5p;rno-miR-30a;rno-miR-30a-5p; +MIMAT0000809 rno-miR-30a-3p;rno-miR-30a*;rno-miR-30a-3p; +MIMAT0000810 rno-miR-31;rno-miR-31a-5p; +MIMAT0000811 rno-miR-32;rno-miR-32-5p; +MIMAT0000812 rno-miR-33;rno-miR-33-5p; +MIMAT0000813 rno-miR-34b;rno-miR-34b-5p; +MIMAT0000814 rno-miR-34c;rno-miR-34c-5p; +MIMAT0000815 rno-miR-34a;rno-miR-34a-5p; +MIMAT0000816 rno-miR-92;rno-miR-92a;rno-miR-92a-3p; +MIMAT0000817 rno-miR-93;rno-miR-93-5p; +MIMAT0000818 rno-miR-96;rno-miR-96-5p; +MIMAT0000819 rno-miR-98;rno-miR-98-5p; +MIMAT0000820 rno-miR-99a;rno-miR-99a-5p; +MIMAT0000821 rno-miR-99b;rno-miR-99b-5p; +MIMAT0000822 rno-miR-100;rno-miR-100-5p; +MIMAT0000823 rno-miR-101;rno-miR-101a;rno-miR-101a-3p; +MIMAT0000824 rno-miR-103;rno-miR-103-3p; +MIMAT0000825 rno-miR-106b;rno-miR-106b-5p; +MIMAT0000826 rno-miR-107;rno-miR-107-3p; +MIMAT0000827 rno-miR-122a;rno-miR-122;rno-miR-122-5p; +MIMAT0000828 rno-miR-124a;rno-miR-124;rno-miR-124-3p; +MIMAT0000829 rno-miR-125a;rno-miR-125a-5p; +MIMAT0000830 rno-miR-125b;rno-miR-125b-5p; +MIMAT0000831 rno-miR-126*;rno-miR-126a-5p; +MIMAT0000832 rno-miR-126;rno-miR-126a-3p; +MIMAT0000833 rno-miR-127;rno-miR-127-3p; +MIMAT0000834 rno-miR-128a;rno-miR-128;rno-miR-128-3p; +MIMAT0000835 rno-miR-128b; +MIMAT0000836 rno-miR-130a;rno-miR-130a-3p; +MIMAT0000837 rno-miR-130b;rno-miR-130b-3p; +MIMAT0000838 rno-miR-132;rno-miR-132-3p; +MIMAT0000839 rno-miR-133a;rno-miR-133a-3p; +MIMAT0000840 rno-miR-134;rno-miR-134-5p; +MIMAT0000841 rno-miR-135a;rno-miR-135a-5p; +MIMAT0000842 rno-miR-136;rno-miR-136-5p; +MIMAT0000843 rno-miR-137;rno-miR-137-3p; +MIMAT0000844 rno-miR-138;rno-miR-138-5p; +MIMAT0000845 rno-miR-139;rno-miR-139-5p; +MIMAT0000846 rno-miR-141;rno-miR-141-3p; +MIMAT0000847 rno-miR-142-5p; +MIMAT0000848 rno-miR-142-3p; +MIMAT0000849 rno-miR-143;rno-miR-143-3p; +MIMAT0000850 rno-miR-144;rno-miR-144-3p; +MIMAT0000851 rno-miR-145;rno-miR-145-5p; +MIMAT0000852 rno-miR-146;rno-miR-146a;rno-miR-146a-5p; +MIMAT0000853 rno-miR-150;rno-miR-150-5p; +MIMAT0000854 rno-miR-152;rno-miR-152-3p; +MIMAT0000855 rno-miR-153;rno-miR-153-3p; +MIMAT0000856 rno-miR-154;rno-miR-154-5p; +MIMAT0000857 rno-miR-181c;rno-miR-181c-5p; +MIMAT0000858 rno-miR-181a;rno-miR-181a-5p; +MIMAT0000859 rno-miR-181b;rno-miR-181b-5p; +MIMAT0000860 rno-miR-183;rno-miR-183-5p; +MIMAT0000861 rno-miR-184; +MIMAT0000862 rno-miR-185;rno-miR-185-5p; +MIMAT0000863 rno-miR-186;rno-miR-186-5p; +MIMAT0000864 rno-miR-187;rno-miR-187-3p; +MIMAT0000865 rno-miR-190;rno-miR-190a-5p; +MIMAT0000866 rno-miR-191;rno-miR-191a-5p; +MIMAT0000867 rno-miR-192;rno-miR-192-5p; +MIMAT0000868 rno-miR-193;rno-miR-193-3p;rno-miR-193a-3p; +MIMAT0000869 rno-miR-194;rno-miR-194-5p; +MIMAT0000870 rno-miR-195;rno-miR-195-5p; +MIMAT0000871 rno-miR-196a;rno-miR-196a-5p; +MIMAT0000872 rno-miR-199a;rno-miR-199a-5p; +MIMAT0000873 rno-miR-200c;rno-miR-200c-3p; +MIMAT0000874 rno-miR-200a;rno-miR-200a-3p; +MIMAT0000875 rno-miR-200b;rno-miR-200b-3p; +MIMAT0000876 rno-miR-203;rno-miR-203a-3p; +MIMAT0000877 rno-miR-204;rno-miR-204-5p; +MIMAT0000878 rno-miR-205; +MIMAT0000879 rno-miR-206;rno-miR-206-3p; +MIMAT0000880 rno-miR-208;rno-miR-208a-3p; +MIMAT0000881 rno-miR-210;rno-miR-210-3p; +MIMAT0000882 rno-miR-211;rno-miR-211-5p; +MIMAT0000883 rno-miR-212;rno-miR-212-3p; +MIMAT0000884 rno-miR-213;rno-miR-181a*;rno-miR-181a-1*;rno-miR-181a-1-3p; +MIMAT0000885 rno-miR-214;rno-miR-214-3p; +MIMAT0000886 rno-miR-216;rno-miR-216a;rno-miR-216a-5p; +MIMAT0000887 rno-miR-217;rno-miR-217-5p; +MIMAT0000888 rno-miR-218;rno-miR-218a;rno-miR-218a-5p; +MIMAT0000889 rno-miR-219;rno-miR-219-5p;rno-miR-219a-5p; +MIMAT0000890 rno-miR-221;rno-miR-221-3p; +MIMAT0000891 rno-miR-222;rno-miR-222-3p; +MIMAT0000892 rno-miR-223;rno-miR-223-3p; +MIMAT0000893 rno-miR-290; +MIMAT0000894 rno-miR-291-5p;rno-miR-291a-5p; +MIMAT0000895 rno-miR-291-3p;rno-miR-291a-3p; +MIMAT0000896 rno-miR-292-5p; +MIMAT0000897 rno-miR-292-3p; +MIMAT0000898 rno-miR-296;rno-miR-296*;rno-miR-296-5p; +MIMAT0000899 rno-miR-297; +MIMAT0000900 rno-miR-298;rno-miR-298-5p; +MIMAT0000901 rno-miR-299;rno-miR-299a-5p; +MIMAT0000902 rno-miR-300;rno-miR-300-3p; +MIMAT0000903 rno-miR-320;rno-miR-320-3p; +MIMAT0000904 mmu-miR-215;mmu-miR-215-5p; +MIMAT0000905 ath-miR167d; +MIMAT0000906 ath-miR169b;ath-miR169b-5p; +MIMAT0000907 ath-miR169c; +MIMAT0000908 ath-miR169d; +MIMAT0000909 ath-miR169e; +MIMAT0000910 ath-miR169f;ath-miR169f-5p; +MIMAT0000911 ath-miR169g;ath-miR169g-5p; +MIMAT0000912 ath-miR169g*;ath-miR169g-3p; +MIMAT0000913 ath-miR169h; +MIMAT0000914 ath-miR169i; +MIMAT0000915 ath-miR169j; +MIMAT0000916 ath-miR169k; +MIMAT0000917 ath-miR169l; +MIMAT0000918 ath-miR169m; +MIMAT0000919 ath-miR169n; +MIMAT0000920 ath-miR171b;ath-miR171b-3p; +MIMAT0000921 ath-miR171c;ath-miR171c-3p; +MIMAT0000922 ath-miR172c; +MIMAT0000923 ath-miR172d;ath-miR172d-3p; +MIMAT0000931 ath-miR390a;ath-miR390a-5p; +MIMAT0000932 ath-miR390b;ath-miR390b-5p; +MIMAT0000933 ath-miR391;ath-miR391-5p; +MIMAT0000934 ath-miR393a;ath-miR393a-5p; +MIMAT0000935 ath-miR393b;ath-miR393b-5p; +MIMAT0000936 ath-miR394a; +MIMAT0000937 ath-miR394b;ath-miR394b-5p; +MIMAT0000938 ath-miR395a; +MIMAT0000939 ath-miR395b; +MIMAT0000940 ath-miR395c; +MIMAT0000941 ath-miR395d; +MIMAT0000942 ath-miR395e; +MIMAT0000943 ath-miR395f; +MIMAT0000944 ath-miR396a;ath-miR396a-5p; +MIMAT0000945 ath-miR396b;ath-miR396b-5p; +MIMAT0000946 ath-miR397a; +MIMAT0000947 ath-miR397b; +MIMAT0000948 ath-miR398a;ath-miR398a-3p; +MIMAT0000949 ath-miR398b;ath-miR398b-3p; +MIMAT0000950 ath-miR398c;ath-miR398c-3p; +MIMAT0000951 ath-miR399a; +MIMAT0000952 ath-miR399b; +MIMAT0000953 ath-miR399c;ath-miR399c-3p; +MIMAT0000954 ath-miR399d; +MIMAT0000955 ath-miR399e; +MIMAT0000956 ath-miR399f; +MIMAT0000957 osa-miR393;osa-miR393a; +MIMAT0000958 osa-miR394; +MIMAT0000959 osa-miR395b; +MIMAT0000960 osa-miR395d; +MIMAT0000961 osa-miR395e; +MIMAT0000962 osa-miR395g; +MIMAT0000963 osa-miR395h; +MIMAT0000964 osa-miR395i; +MIMAT0000965 osa-miR395j; +MIMAT0000966 osa-miR395k; +MIMAT0000967 osa-miR395l; +MIMAT0000968 osa-miR395m;osa-miR395s; +MIMAT0000969 osa-miR395n;osa-miR395t; +MIMAT0000970 osa-miR395o; +MIMAT0000971 osa-miR395r; +MIMAT0000972 osa-miR395q;osa-miR395c; +MIMAT0000973 osa-miR395c;osa-miR395a; +MIMAT0000974 osa-miR395a;osa-miR395f; +MIMAT0000975 osa-miR395f;osa-miR395u; +MIMAT0000976 osa-miR395p; +MIMAT0000977 osa-miR396a;osa-miR396a-5p; +MIMAT0000978 osa-miR396b;osa-miR396b-5p; +MIMAT0000979 osa-miR396c;osa-miR396c-5p; +MIMAT0000980 osa-miR397a; +MIMAT0000981 osa-miR397b; +MIMAT0000982 osa-miR398a; +MIMAT0000983 osa-miR398b; +MIMAT0000984 osa-miR399a; +MIMAT0000985 osa-miR399b; +MIMAT0000986 osa-miR399c; +MIMAT0000987 osa-miR399d; +MIMAT0000988 osa-miR399e; +MIMAT0000989 osa-miR399f; +MIMAT0000990 osa-miR399g; +MIMAT0000991 osa-miR399h; +MIMAT0000992 osa-miR399i; +MIMAT0000993 osa-miR399j; +MIMAT0000994 osa-miR399k; +MIMAT0000995 ebv-miR-BHRF1-1; +MIMAT0000996 ebv-miR-BHRF1-2*;ebv-miR-BHRF1-2-5p; +MIMAT0000997 ebv-miR-BHRF1-2;ebv-miR-BHRF1-2-3p; +MIMAT0000998 ebv-miR-BHRF1-3; +MIMAT0000999 ebv-miR-BART1;ebv-miR-BART1-5p; +MIMAT0001000 ebv-miR-BART2;ebv-miR-BART2-5p; +MIMAT0001001 ath-miR400; +MIMAT0001002 ath-miR401; +MIMAT0001003 ath-miR402; +MIMAT0001004 ath-miR403;ath-miR403-3p; +MIMAT0001005 ath-miR404; +MIMAT0001006 ath-miR405a; +MIMAT0001007 ath-miR405b; +MIMAT0001008 ath-miR405d; +MIMAT0001009 ath-miR406; +MIMAT0001010 ath-miR407; +MIMAT0001011 ath-miR408;ath-miR408-3p; +MIMAT0001012 ath-miR156g; +MIMAT0001013 ath-miR156h; +MIMAT0001014 ath-miR158b; +MIMAT0001015 ath-miR159c; +MIMAT0001016 ath-miR319c; +MIMAT0001017 ath-miR164c;ath-miR164c-5p; +MIMAT0001018 ath-miR167c;ath-miR167c-5p; +MIMAT0001019 ath-miR172e;ath-miR172e-3p; +MIMAT0001020 osa-miR156k; +MIMAT0001021 osa-miR156l;osa-miR156l-5p; +MIMAT0001022 osa-miR159a;osa-miR159a.1; +MIMAT0001023 osa-miR159b; +MIMAT0001024 osa-miR159c; +MIMAT0001025 osa-miR159d; +MIMAT0001026 osa-miR159e; +MIMAT0001027 osa-miR159f; +MIMAT0001028 osa-miR319a;osa-miR319a-3p.2;osa-miR319a-3p.2-3p; +MIMAT0001029 osa-miR319b; +MIMAT0001030 osa-miR160e;osa-miR160e-5p; +MIMAT0001031 osa-miR160f;osa-miR160f-5p; +MIMAT0001032 osa-miR162b; +MIMAT0001033 osa-miR164c; +MIMAT0001034 osa-miR164d; +MIMAT0001035 osa-miR164e; +MIMAT0001036 osa-miR166j;osa-miR166j-3p; +MIMAT0001037 osa-miR166k;osa-miR166k-3p; +MIMAT0001038 osa-miR166l;osa-miR166l-3p; +MIMAT0001039 osa-miR167d;osa-miR167d-5p; +MIMAT0001040 osa-miR167e;osa-miR167e-5p; +MIMAT0001041 osa-miR167f; +MIMAT0001042 osa-miR167g; +MIMAT0001043 osa-miR167h;osa-miR167h-5p; +MIMAT0001044 osa-miR167i;osa-miR167i-5p; +MIMAT0001045 osa-miR168a;osa-miR168a-5p; +MIMAT0001046 osa-miR168b; +MIMAT0001047 osa-miR169b; +MIMAT0001048 osa-miR169c; +MIMAT0001049 osa-miR169d; +MIMAT0001050 osa-miR169e; +MIMAT0001051 osa-miR169f;osa-miR169f.1; +MIMAT0001052 osa-miR169g; +MIMAT0001053 osa-miR169h; +MIMAT0001054 osa-miR169i;osa-miR169i.1;osa-miR169i-5p.1; +MIMAT0001055 osa-miR169j; +MIMAT0001056 osa-miR169k; +MIMAT0001057 osa-miR169l; +MIMAT0001058 osa-miR169m; +MIMAT0001059 osa-miR169n; +MIMAT0001060 osa-miR169o; +MIMAT0001061 osa-miR169p; +MIMAT0001062 osa-miR169q; +MIMAT0001063 osa-miR171b; +MIMAT0001064 osa-miR171c;osa-miR171c-3p; +MIMAT0001065 osa-miR171d;osa-miR171d-3p; +MIMAT0001066 osa-miR171e;osa-miR171e-3p; +MIMAT0001067 osa-miR171f;osa-miR171f-3p; +MIMAT0001068 osa-miR171g; +MIMAT0001069 osa-miR172a; +MIMAT0001070 osa-miR172b; +MIMAT0001071 osa-miR172c; +MIMAT0001072 osa-miR166g;osa-miR166g-3p; +MIMAT0001073 osa-miR166h;osa-miR166h-3p; +MIMAT0001074 osa-miR166i;osa-miR166i-3p; +MIMAT0001075 hsa-miR-384; +MIMAT0001076 mmu-miR-384;mmu-miR-384-3p; +MIMAT0001077 osa-miR171h; +MIMAT0001078 osa-miR393b;osa-miR393b-5p; +MIMAT0001079 osa-miR408;osa-miR408-3p; +MIMAT0001080 hsa-miR-196b;hsa-miR-196b-5p; +MIMAT0001081 mmu-miR-196b;mmu-miR-196b-5p; +MIMAT0001082 rno-miR-196b;rno-miR-196b-5p; +MIMAT0001083 osa-miR395s; +MIMAT0001084 osa-miR172d;osa-miR172d-3p; +MIMAT0001085 osa-miR171i;osa-miR171i-3p; +MIMAT0001086 osa-miR167j; +MIMAT0001087 osa-miR166m; +MIMAT0001088 osa-miR166n;osa-miR166n-3p;osa-miR166j-3p; +MIMAT0001089 osa-miR164f; +MIMAT0001090 mmu-miR-409;mmu-miR-409-3p; +MIMAT0001091 mmu-miR-410;mmu-miR-410-3p; +MIMAT0001092 mmu-miR-376b;mmu-miR-376b-3p; +MIMAT0001093 mmu-miR-411;mmu-miR-411*;mmu-miR-411-3p; +MIMAT0001094 mmu-miR-412;mmu-miR-412-3p; +MIMAT0001095 mmu-miR-370;mmu-miR-370-3p; +MIMAT0001096 gga-miR-29a;gga-miR-29a-3p; +MIMAT0001097 gga-miR-29b;gga-miR-29b-3p; +MIMAT0001098 gga-let-7i; +MIMAT0001099 gga-miR-135a;gga-miR-135a-5p; +MIMAT0001100 gga-miR-33;gga-miR-33-5p; +MIMAT0001101 gga-let-7a;gga-let-7a-5p; +MIMAT0001102 gga-let-7b; +MIMAT0001103 gga-miR-99a;gga-miR-99a-5p; +MIMAT0001104 gga-let-7c;gga-let-7c-5p; +MIMAT0001105 gga-miR-125b;gga-miR-125b-5p; +MIMAT0001106 gga-miR-155; +MIMAT0001107 gga-miR-222a;gga-miR-222;gga-miR-222a; +MIMAT0001108 gga-miR-221;gga-miR-221-3p; +MIMAT0001109 gga-miR-92;gga-miR-92-3p; +MIMAT0001110 gga-miR-19b;gga-miR-19b-3p; +MIMAT0001111 gga-miR-20a;gga-miR-20a-5p; +MIMAT0001112 gga-miR-19a;gga-miR-19a-3p; +MIMAT0001113 gga-miR-18a;gga-miR-18a-5p; +MIMAT0001114 gga-miR-17-5p; +MIMAT0001115 gga-miR-17-3p; +MIMAT0001116 gga-miR-16;gga-miR-16-5p; +MIMAT0001117 gga-miR-15a; +MIMAT0001118 gga-miR-26a;gga-miR-26a-5p; +MIMAT0001119 gga-miR-153;gga-miR-153-3p; +MIMAT0001120 gga-miR-148a;gga-miR-148a-3p; +MIMAT0001121 gga-miR-196;gga-miR-196-5p; +MIMAT0001122 gga-miR-138;gga-miR-138-5p; +MIMAT0001123 gga-miR-128b;gga-miR-128;gga-miR-128-3p; +MIMAT0001124 gga-miR-187;gga-miR-187-3p; +MIMAT0001125 gga-miR-32;gga-miR-32-5p; +MIMAT0001126 gga-miR-133a;gga-miR-133a-3p; +MIMAT0001127 gga-miR-1;gga-miR-1a;gga-miR-1a-3p; +MIMAT0001128 gga-miR-124a;gga-miR-124a-3p; +MIMAT0001129 gga-miR-30d; +MIMAT0001130 gga-miR-30b;gga-miR-30b-5p; +MIMAT0001131 gga-miR-216;gga-miR-216a; +MIMAT0001132 gga-miR-217;gga-miR-217-5p; +MIMAT0001133 gga-miR-194; +MIMAT0001134 gga-miR-215;gga-miR-215-5p; +MIMAT0001135 gga-miR-30a-5p; +MIMAT0001136 gga-miR-30a-3p; +MIMAT0001137 gga-miR-30c;gga-miR-30c-5p; +MIMAT0001138 gga-miR-133b; +MIMAT0001139 gga-miR-206; +MIMAT0001140 gga-miR-223; +MIMAT0001141 gga-miR-18b;gga-miR-18b-5p; +MIMAT0001142 gga-miR-106;gga-miR-106-5p; +MIMAT0001143 gga-miR-302;gga-miR-302a; +MIMAT0001144 gga-miR-218;gga-miR-218-5p; +MIMAT0001145 gga-miR-103;gga-miR-103-3p; +MIMAT0001146 gga-miR-203;gga-miR-203a; +MIMAT0001147 gga-miR-107;gga-miR-107-3p; +MIMAT0001148 gga-miR-10b;gga-miR-10b-5p; +MIMAT0001149 gga-miR-128a; +MIMAT0001150 gga-miR-213;gga-miR-181a*;gga-miR-181a-3p; +MIMAT0001151 gga-miR-181b;gga-miR-181b-5p; +MIMAT0001152 gga-miR-199a;gga-miR-199;gga-miR-199-5p; +MIMAT0001153 gga-miR-137;gga-miR-137-3p; +MIMAT0001154 gga-miR-15b;gga-miR-15b-5p; +MIMAT0001155 gga-miR-190;gga-miR-190-5p;gga-miR-190a-5p; +MIMAT0001156 gga-miR-204; +MIMAT0001157 gga-miR-7; +MIMAT0001158 gga-miR-184;gga-miR-184-3p; +MIMAT0001159 gga-miR-140;gga-miR-140-5p; +MIMAT0001160 gga-let-7g;gga-let-7g-5p; +MIMAT0001161 gga-let-7d; +MIMAT0001162 gga-let-7f;gga-let-7f-5p; +MIMAT0001163 gga-miR-146;gga-miR-146a;gga-miR-146a-5p; +MIMAT0001164 gga-miR-205b; +MIMAT0001165 gga-miR-130b;gga-miR-130b-3p; +MIMAT0001166 gga-miR-301;gga-miR-301a;gga-miR-301a-3p; +MIMAT0001167 gga-miR-130a;gga-miR-130a-3p; +MIMAT0001168 gga-miR-181a;gga-miR-181a-5p; +MIMAT0001169 gga-miR-126;gga-miR-126-3p; +MIMAT0001170 gga-miR-219;gga-miR-219a; +MIMAT0001171 gga-miR-200a;gga-miR-200a-3p; +MIMAT0001172 gga-miR-200b;gga-miR-200b-3p; +MIMAT0001173 gga-miR-34a;gga-miR-34a-5p; +MIMAT0001174 gga-miR-124b; +MIMAT0001175 gga-miR-1b;gga-miR-1b-3p; +MIMAT0001176 gga-miR-133c;gga-miR-133c-3p; +MIMAT0001177 gga-miR-30e;gga-miR-30e-5p; +MIMAT0001178 gga-miR-100;gga-miR-100-5p; +MIMAT0001179 gga-miR-34b;gga-miR-34b-5p; +MIMAT0001180 gga-miR-34c;gga-miR-34c-5p; +MIMAT0001181 gga-let-7j;gga-let-7j-5p; +MIMAT0001182 gga-let-7k;gga-let-7k-5p; +MIMAT0001183 gga-miR-29c;gga-miR-29c-3p; +MIMAT0001184 gga-miR-205a; +MIMAT0001185 gga-miR-101;gga-miR-101-3p; +MIMAT0001186 gga-miR-23b;gga-miR-23b-3p; +MIMAT0001187 gga-miR-27b;gga-miR-27b-3p; +MIMAT0001188 gga-miR-24;gga-miR-24-3p; +MIMAT0001189 gga-miR-31;gga-miR-31-5p; +MIMAT0001190 gga-miR-122a;gga-miR-122;gga-miR-122-5p; +MIMAT0001191 gga-miR-183; +MIMAT0001192 gga-miR-7b; +MIMAT0001193 gga-miR-142-5p; +MIMAT0001194 gga-miR-142-3p; +MIMAT0001195 gga-miR-9;gga-miR-9-5p; +MIMAT0001196 gga-miR-222b; +MIMAT0001197 dps-bantam; +MIMAT0001198 dps-let-7; +MIMAT0001199 dps-miR-1; +MIMAT0001200 dps-miR-2a; +MIMAT0001201 dps-miR-2b; +MIMAT0001202 dps-miR-2c; +MIMAT0001203 dps-miR-3; +MIMAT0001204 dps-miR-4; +MIMAT0001205 dps-miR-iab-4-5p; +MIMAT0001206 dps-miR-iab-4-3p; +MIMAT0001207 dps-miR-5; +MIMAT0001208 dps-miR-6; +MIMAT0001209 dps-miR-7; +MIMAT0001210 dps-miR-8; +MIMAT0001211 dps-miR-9a; +MIMAT0001212 dps-miR-9b; +MIMAT0001213 dps-miR-9c; +MIMAT0001214 dps-miR-10; +MIMAT0001215 dps-miR-11; +MIMAT0001216 dps-miR-12; +MIMAT0001217 dps-miR-13a; +MIMAT0001218 dps-miR-13b; +MIMAT0001219 dps-miR-14; +MIMAT0001220 dps-miR-31a; +MIMAT0001221 dps-miR-31b; +MIMAT0001222 dps-miR-33; +MIMAT0001223 dps-miR-34; +MIMAT0001224 dps-miR-79; +MIMAT0001225 dps-miR-87; +MIMAT0001226 dps-miR-92a; +MIMAT0001227 dps-miR-92b; +MIMAT0001228 dps-miR-100; +MIMAT0001229 dps-miR-124; +MIMAT0001230 dps-miR-125; +MIMAT0001231 dps-miR-133; +MIMAT0001232 dps-miR-184; +MIMAT0001233 dps-miR-210;dps-miR-210a; +MIMAT0001234 dps-miR-219; +MIMAT0001235 dps-miR-263a; +MIMAT0001236 dps-miR-263b; +MIMAT0001237 dps-miR-274; +MIMAT0001238 dps-miR-275; +MIMAT0001239 dps-miR-276a; +MIMAT0001240 dps-miR-276b; +MIMAT0001241 dps-miR-277; +MIMAT0001242 dps-miR-278; +MIMAT0001243 dps-miR-279; +MIMAT0001244 dps-miR-280; +MIMAT0001245 dps-miR-281; +MIMAT0001246 dps-miR-282; +MIMAT0001247 dps-miR-283; +MIMAT0001248 dps-miR-284; +MIMAT0001249 dps-miR-285; +MIMAT0001250 dps-miR-286; +MIMAT0001251 dps-miR-287; +MIMAT0001252 dps-miR-288; +MIMAT0001253 dps-miR-289; +MIMAT0001254 dps-miR-304; +MIMAT0001255 dps-miR-305; +MIMAT0001256 dps-miR-306; +MIMAT0001257 dps-miR-307;dps-miR-307a; +MIMAT0001258 dps-miR-308; +MIMAT0001259 dps-miR-309; +MIMAT0001260 dps-miR-314; +MIMAT0001261 dps-miR-315; +MIMAT0001262 dps-miR-316; +MIMAT0001263 dps-miR-317; +MIMAT0001264 dps-miR-318; +MIMAT0001265 dre-miR-7b; +MIMAT0001266 dre-miR-7;dre-miR-7a; +MIMAT0001267 dre-miR-10a;dre-miR-10a-5p; +MIMAT0001268 dre-miR-10b;dre-miR-10b-5p; +MIMAT0001269 dre-miR-34a;dre-miR-34;dre-miR-34a; +MIMAT0001270 dre-miR-181b;dre-miR-181b-5p; +MIMAT0001271 dre-miR-182;dre-miR-182-5p; +MIMAT0001272 dre-miR-182*;dre-miR-182-3p; +MIMAT0001273 dre-miR-183;dre-miR-183-5p; +MIMAT0001274 dre-miR-187; +MIMAT0001275 dre-miR-192; +MIMAT0001276 dre-miR-196a;dre-miR-196a-5p; +MIMAT0001277 dre-miR-199a;dre-miR-199;dre-miR-199-5p; +MIMAT0001278 dre-miR-203;dre-miR-203a;dre-miR-203a-3p; +MIMAT0001279 dre-miR-204;dre-miR-204-5p; +MIMAT0001280 dre-miR-205;dre-miR-205-5p; +MIMAT0001281 dre-miR-210;dre-miR-210-3p; +MIMAT0001282 dre-miR-213;dre-miR-181a*;dre-miR-181a-3p; +MIMAT0001283 dre-miR-214; +MIMAT0001284 dre-miR-216;dre-miR-216a; +MIMAT0001285 dre-miR-217; +MIMAT0001286 dre-miR-219;dre-miR-219-5p; +MIMAT0001287 dre-miR-220; +MIMAT0001288 dre-miR-221;dre-miR-221-3p; +MIMAT0001289 dre-miR-222;dre-miR-222a;dre-miR-222a-3p; +MIMAT0001290 dre-miR-223; +MIMAT0001291 cbr-miR-353; +MIMAT0001292 cbr-miR-64;cbr-miR-64a; +MIMAT0001293 cbr-miR-231; +MIMAT0001294 cbr-miR-356; +MIMAT0001295 cbr-miR-83; +MIMAT0001296 cbr-miR-246; +MIMAT0001297 cbr-miR-51; +MIMAT0001298 cbr-miR-357; +MIMAT0001299 cbr-miR-253; +MIMAT0001300 cbr-miR-70; +MIMAT0001301 cbr-miR-358; +MIMAT0001302 cbr-miR-61; +MIMAT0001303 cbr-miR-360; +MIMAT0001304 cbr-miR-239a; +MIMAT0001305 cbr-miR-249; +MIMAT0001306 cbr-miR-240; +MIMAT0001307 cbr-miR-254; +MIMAT0001308 cbr-miR-239b; +MIMAT0001309 cbr-miR-62; +MIMAT0001310 cbr-miR-55; +MIMAT0001311 cbr-miR-84; +MIMAT0001312 cbr-miR-354; +MIMAT0001313 cbr-miR-35;cbr-miR-35a; +MIMAT0001314 cbr-miR-36; +MIMAT0001315 cbr-miR-38; +MIMAT0001316 cbr-miR-39; +MIMAT0001317 cbr-miR-40; +MIMAT0001318 cbr-miR-41;cbr-miR-41a; +MIMAT0001319 cbr-miR-355; +MIMAT0001320 rno-miR-421;rno-miR-421-5p; +MIMAT0001321 ath-miR413; +MIMAT0001322 ath-miR414; +MIMAT0001323 ath-miR415; +MIMAT0001324 ath-miR416; +MIMAT0001325 ath-miR417; +MIMAT0001326 ath-miR418; +MIMAT0001327 ath-miR419; +MIMAT0001328 ath-miR420; +MIMAT0001329 osa-miR413; +MIMAT0001330 osa-miR414; +MIMAT0001331 osa-miR415; +MIMAT0001332 osa-miR416; +MIMAT0001333 osa-miR417; +MIMAT0001334 osa-miR418; +MIMAT0001335 osa-miR419; +MIMAT0001336 osa-miR420; +MIMAT0001337 ath-miR426; +MIMAT0001338 osa-miR426; +MIMAT0001339 hsa-miR-422a; +MIMAT0001340 hsa-miR-423;hsa-miR-423-3p; +MIMAT0001341 hsa-miR-424;hsa-miR-424-5p; +MIMAT0001342 mmu-miR-425;mmu-miR-425*;mmu-miR-425-3p; +MIMAT0001343 hsa-miR-425;hsa-miR-425-3p;hsa-miR-425*;hsa-miR-425-3p; +MIMAT0001344 xla-miR-427; +MIMAT0001345 xla-miR-428; +MIMAT0001346 xla-miR-429; +MIMAT0001347 xla-miR-19b; +MIMAT0001348 xla-miR-20; +MIMAT0001349 xla-miR-18;xla-miR-18a-5p; +MIMAT0001350 xla-miR-133a; +MIMAT0001351 zma-miR156d;zma-miR156d-5p; +MIMAT0001352 zma-miR156f;zma-miR156f-5p; +MIMAT0001353 zma-miR156g;zma-miR156g-5p; +MIMAT0001354 zma-miR156b;zma-miR156b-5p; +MIMAT0001355 zma-miR156c; +MIMAT0001356 zma-miR156e;zma-miR156e-5p; +MIMAT0001357 zma-miR156a;zma-miR156a-5p; +MIMAT0001358 zma-miR156h;zma-miR156h-5p; +MIMAT0001359 zma-miR156i;zma-miR156i-5p; +MIMAT0001360 zma-miR160a;zma-miR160a-5p; +MIMAT0001361 zma-miR160c;zma-miR160c-5p; +MIMAT0001362 zma-miR160d;zma-miR160d-5p; +MIMAT0001363 zma-miR160b;zma-miR160b-5p; +MIMAT0001364 zma-miR164a;zma-miR164a-5p; +MIMAT0001365 zma-miR164d;zma-miR164d-5p; +MIMAT0001366 zma-miR164b;zma-miR164b-5p; +MIMAT0001367 zma-miR164c;zma-miR164c-5p; +MIMAT0001368 zma-miR169a;zma-miR169a-5p; +MIMAT0001369 zma-miR169b;zma-miR169b-5p; +MIMAT0001370 zma-miR167a;zma-miR167a-5p; +MIMAT0001371 zma-miR167b;zma-miR167b-5p; +MIMAT0001372 zma-miR167d;zma-miR167d-5p; +MIMAT0001373 zma-miR167c;zma-miR167c-5p; +MIMAT0001374 zma-miR160e; +MIMAT0001375 zma-miR166a;zma-miR166a-3p; +MIMAT0001376 zma-miR162;zma-miR162-3p; +MIMAT0001377 zma-miR166h;zma-miR166h-3p; +MIMAT0001378 zma-miR166e; +MIMAT0001379 zma-miR166i;zma-miR166i-3p; +MIMAT0001380 zma-miR166f; +MIMAT0001381 zma-miR166g;zma-miR166g-3p; +MIMAT0001382 zma-miR166b;zma-miR166b-3p; +MIMAT0001383 zma-miR166c;zma-miR166c-3p; +MIMAT0001384 zma-miR166d;zma-miR166d-3p; +MIMAT0001385 zma-miR171a;zma-miR171a-3p; +MIMAT0001386 zma-miR171b;zma-miR171b-3p; +MIMAT0001387 zma-miR172a; +MIMAT0001388 zma-miR172d;zma-miR172d-3p; +MIMAT0001389 zma-miR172b;zma-miR172b-3p; +MIMAT0001390 zma-miR172c;zma-miR172c-3p; +MIMAT0001391 sbi-miR166d; +MIMAT0001392 sbi-miR166c; +MIMAT0001393 sbi-miR166b; +MIMAT0001394 sbi-miR166a; +MIMAT0001395 sbi-miR172b; +MIMAT0001396 sbi-miR172c; +MIMAT0001397 sbi-miR172a; +MIMAT0001398 sbi-miR156a; +MIMAT0001399 sbi-miR156c; +MIMAT0001400 sbi-miR156b; +MIMAT0001401 sbi-miR160d; +MIMAT0001402 sbi-miR160a; +MIMAT0001403 sbi-miR160c; +MIMAT0001404 sbi-miR160b; +MIMAT0001405 sbi-miR160e; +MIMAT0001406 sbi-miR164;sbi-miR164a; +MIMAT0001407 sbi-miR167a; +MIMAT0001408 sbi-miR167b; +MIMAT0001409 sbi-miR169b; +MIMAT0001410 sbi-miR169a; +MIMAT0001411 gga-miR-20b;gga-miR-20b-5p; +MIMAT0001412 hsa-miR-18b;hsa-miR-18b-5p; +MIMAT0001413 hsa-miR-20b;hsa-miR-20b-5p; +MIMAT0001414 oar-miR-431; +MIMAT0001415 oar-miR-127; +MIMAT0001416 oar-miR-432; +MIMAT0001417 oar-miR-136; +MIMAT0001418 mmu-miR-431;mmu-miR-431-5p; +MIMAT0001419 mmu-miR-433-5p;mmu-miR-433*;mmu-miR-433-5p; +MIMAT0001420 mmu-miR-433-3p;mmu-miR-433;mmu-miR-433-3p; +MIMAT0001421 mmu-miR-434-5p; +MIMAT0001422 mmu-miR-434-3p; +MIMAT0001423 dre-miR-430a;dre-miR-430a-3p; +MIMAT0001424 dre-miR-430b;dre-miR-430b-3p; +MIMAT0001425 dre-miR-430c;dre-miR-430c-3p; +MIMAT0001426 sbi-MIR393;sbi-miR393;sbi-miR393a; +MIMAT0001427 sbi-MIR394a;sbi-miR394a; +MIMAT0001428 sbi-MIR394b;sbi-miR394b; +MIMAT0001429 sbi-MIR395b;sbi-miR395b; +MIMAT0001430 sbi-MIR395a;sbi-miR395a; +MIMAT0001431 sbi-MIR395c;sbi-miR395c; +MIMAT0001432 sbi-MIR395d;sbi-miR395d; +MIMAT0001433 sbi-MIR395e;sbi-miR395e; +MIMAT0001434 sbi-MIR396b;sbi-miR396b; +MIMAT0001435 sbi-MIR396a;sbi-miR396a; +MIMAT0001436 sbi-MIR396c;sbi-miR396c; +MIMAT0001437 sbi-MIR399a;sbi-miR399a; +MIMAT0001438 sbi-MIR399c;sbi-miR399c; +MIMAT0001439 sbi-MIR399d;sbi-miR399d; +MIMAT0001440 sbi-MIR399e;sbi-miR399e; +MIMAT0001441 sbi-MIR399f;sbi-miR399f; +MIMAT0001442 sbi-MIR399b;sbi-miR399b; +MIMAT0001443 sbi-MIR399g;sbi-miR399g; +MIMAT0001444 sbi-MIR156d;sbi-miR156d; +MIMAT0001445 sbi-MIR164b;sbi-miR164b; +MIMAT0001446 sbi-MIR166e;sbi-miR166e; +MIMAT0001447 sbi-MIR167d;sbi-miR167d; +MIMAT0001448 sbi-MIR167f;sbi-miR167f; +MIMAT0001449 sbi-MIR167g;sbi-miR167g; +MIMAT0001450 sbi-MIR167e;sbi-miR167e; +MIMAT0001451 sbi-MIR167c;sbi-miR167c; +MIMAT0001452 sbi-MIR168;sbi-miR168; +MIMAT0001453 sbi-MIR169c;sbi-miR169c; +MIMAT0001454 sbi-MIR169d;sbi-miR169d;sbi-miR169d-5p; +MIMAT0001455 sbi-MIR169e;sbi-miR169e; +MIMAT0001456 sbi-MIR169f;sbi-miR169f; +MIMAT0001457 sbi-MIR169g;sbi-miR169g; +MIMAT0001458 sbi-MIR169h;sbi-miR169h; +MIMAT0001459 sbi-MIR169i;sbi-miR169i; +MIMAT0001460 sbi-MIR171b;sbi-miR171b; +MIMAT0001461 sbi-MIR171d;sbi-miR171d; +MIMAT0001462 sbi-MIR171a;sbi-miR171a; +MIMAT0001463 sbi-MIR171c;sbi-miR171c; +MIMAT0001464 sbi-MIR172e;sbi-miR172e; +MIMAT0001465 sbi-MIR166f;sbi-miR166f; +MIMAT0001466 sbi-MIR171e;sbi-miR171e; +MIMAT0001467 sbi-MIR172d;sbi-miR172d; +MIMAT0001468 sbi-MIR159;sbi-miR159;sbi-miR159a; +MIMAT0001469 sbi-MIR319;sbi-miR319;sbi-miR319a; +MIMAT0001470 ame-bantam;ame-bantam-3p; +MIMAT0001471 ame-miR-1;ame-miR-1-3p; +MIMAT0001472 ame-miR-12;ame-miR-12-5p; +MIMAT0001473 ame-miR-124;ame-miR-124-3p; +MIMAT0001474 ame-miR-125;ame-miR-125-5p; +MIMAT0001475 ame-miR-133;ame-miR-133-3p; +MIMAT0001476 ame-miR-184;ame-miR-184-3p; +MIMAT0001477 ame-miR-210;ame-miR-210-3p; +MIMAT0001478 ame-miR-219;ame-miR-219-5p; +MIMAT0001479 ame-miR-263;ame-miR-263a;ame-miR-263a-5p; +MIMAT0001480 ame-miR-276;ame-miR-276-3p; +MIMAT0001481 ame-miR-277;ame-miR-277-3p; +MIMAT0001482 ame-miR-278;ame-miR-278-3p; +MIMAT0001483 ame-miR-281;ame-miR-281-3p; +MIMAT0001484 ame-miR-282;ame-miR-282-5p; +MIMAT0001485 ame-miR-2;ame-miR-2-3p; +MIMAT0001486 ame-miR-305;ame-miR-305-5p; +MIMAT0001487 ame-miR-315;ame-miR-315-5p; +MIMAT0001488 ame-miR-317;ame-miR-317-3p; +MIMAT0001489 ame-miR-7;ame-miR-7-5p; +MIMAT0001490 ame-miR-8;ame-miR-8-3p; +MIMAT0001491 ame-miR-9a;ame-miR-9a-5p; +MIMAT0001492 ame-miR-9b;ame-miR-9b-5p; +MIMAT0001493 ame-miR-iab-4;ame-miR-iab-4-5p; +MIMAT0001494 aga-bantam; +MIMAT0001495 aga-let-7; +MIMAT0001496 aga-miR-1; +MIMAT0001497 aga-miR-10; +MIMAT0001498 aga-miR-100; +MIMAT0001499 aga-miR-124; +MIMAT0001500 aga-miR-125; +MIMAT0001501 aga-miR-133; +MIMAT0001502 aga-miR-13b; +MIMAT0001503 aga-miR-14; +MIMAT0001504 aga-miR-184; +MIMAT0001505 aga-miR-210; +MIMAT0001506 aga-miR-219; +MIMAT0001507 aga-miR-263;aga-miR-263a; +MIMAT0001508 aga-miR-275; +MIMAT0001509 aga-miR-276;aga-miR-276-5p; +MIMAT0001510 aga-miR-277; +MIMAT0001511 aga-miR-278; +MIMAT0001512 aga-miR-279; +MIMAT0001513 aga-miR-281; +MIMAT0001514 aga-miR-282; +MIMAT0001515 aga-miR-283; +MIMAT0001516 aga-miR-2b;aga-miR-2; +MIMAT0001517 aga-miR-2c; +MIMAT0001518 aga-miR-305; +MIMAT0001519 aga-miR-307; +MIMAT0001520 aga-miR-308; +MIMAT0001521 aga-miR-315; +MIMAT0001522 aga-miR-317; +MIMAT0001523 aga-miR-7; +MIMAT0001524 aga-miR-79; +MIMAT0001525 aga-miR-8; +MIMAT0001526 aga-miR-9a; +MIMAT0001527 aga-miR-92a; +MIMAT0001528 aga-miR-92b; +MIMAT0001529 aga-miR-9b; +MIMAT0001530 aga-miR-9c; +MIMAT0001531 aga-miR-iab-4; +MIMAT0001532 hsa-miR-448; +MIMAT0001533 mmu-miR-448;mmu-miR-448-3p; +MIMAT0001534 rno-miR-448;rno-miR-448-3p; +MIMAT0001535 cfa-miR-448; +MIMAT0001536 hsa-miR-429; +MIMAT0001537 mmu-miR-429;mmu-miR-429-3p; +MIMAT0001538 rno-miR-429; +MIMAT0001539 cfa-miR-429; +MIMAT0001540 cfa-miR-365; +MIMAT0001541 hsa-miR-449;hsa-miR-449a; +MIMAT0001542 mmu-miR-449;mmu-miR-449a;mmu-miR-449a-5p; +MIMAT0001543 rno-miR-449;rno-miR-449a;rno-miR-449a-5p; +MIMAT0001544 cfa-miR-449;cfa-miR-449a; +MIMAT0001545 hsa-miR-450;hsa-miR-450a;hsa-miR-450a-5p; +MIMAT0001546 mmu-miR-450;mmu-miR-450a-5p;mmu-miR-450a;mmu-miR-450a-5p; +MIMAT0001547 rno-miR-450;rno-miR-450a;rno-miR-450a-5p; +MIMAT0001548 cfa-miR-450;cfa-miR-450a; +MIMAT0001549 rno-miR-365;rno-miR-365-3p; +MIMAT0001550 khv-miR-K12-1a; +MIMAT0001551 khv-miR-K12-1b; +MIMAT0001552 khv-miR-K12-2*; +MIMAT0001553 khv-miR-K12-2; +MIMAT0001554 khv-miR-K12-3; +MIMAT0001555 khv-miR-K12-4; +MIMAT0001556 khv-miR-K12-5; +MIMAT0001557 khv-miR-K12-6-5p; +MIMAT0001558 khv-miR-K12-6-3p; +MIMAT0001559 khv-miR-K12-7; +MIMAT0001560 khv-miR-K12-8-5p; +MIMAT0001561 khv-miR-K12-9; +MIMAT0001562 khv-miR-K12-9*; +MIMAT0001563 khv-miR-K12-10; +MIMAT0001564 mhv-miR-M1-1;mghv-miR-M1-1;mghv-miR-M1-1-3p; +MIMAT0001565 mhv-miR-M1-2;mghv-miR-M1-2;mghv-miR-M1-2-3p; +MIMAT0001566 mhv-miR-M1-3;mghv-miR-M1-3;mghv-miR-M1-3-3p; +MIMAT0001567 mhv-miR-M1-4;mghv-miR-M1-4;mghv-miR-M1-4-5p; +MIMAT0001568 mhv-miR-M1-5;mghv-miR-M1-5;mghv-miR-M1-5-5p; +MIMAT0001569 mhv-miR-M1-6;mghv-miR-M1-6;mghv-miR-M1-6-3p; +MIMAT0001570 mhv-miR-M1-7-5p;mghv-miR-M1-7-5p; +MIMAT0001571 mhv-miR-M1-7-3p;mghv-miR-M1-7-3p; +MIMAT0001572 mhv-miR-M1-8;mghv-miR-M1-8;mghv-miR-M1-8-5p; +MIMAT0001573 mhv-miR-M1-9;mghv-miR-M1-9; +MIMAT0001574 hcv-miR-UL22A-1;hcmv-miR-UL22A-1;hcmv-miR-UL22A;hcmv-miR-UL22A-5p; +MIMAT0001575 hcv-miR-UL22A-1*;hcmv-miR-UL22A-1*;hcmv-miR-UL22A*;hcmv-miR-UL22A-3p; +MIMAT0001576 hcv-miR-UL36-1;hcmv-miR-UL36-1;hcmv-miR-UL36;hcmv-miR-UL36-5p; +MIMAT0001577 hcv-miR-UL112-1;hcmv-miR-UL112-1;hcmv-miR-UL112;hcmv-miR-UL112-3p; +MIMAT0001578 hcv-miR-UL148D-1;hcmv-miR-UL148D-1;hcmv-miR-UL148D; +MIMAT0001579 hcv-miR-US5-1;hcmv-miR-US5-1; +MIMAT0001580 hcv-miR-US5-2;hcmv-miR-US5-2;hcmv-miR-US5-2-3p; +MIMAT0001581 hcv-miR-US25-1;hcmv-miR-US25-1;hcmv-miR-US25-1-5p; +MIMAT0001582 hcv-miR-US25-2-5p;hcmv-miR-US25-2-5p; +MIMAT0001583 hcv-miR-US25-2-3p;hcmv-miR-US25-2-3p; +MIMAT0001584 hcv-miR-US33-1;hcmv-miR-US33-1;hcmv-miR-US33;hcmv-miR-US33-5p; +MIMAT0001585 osa-MIR435;osa-miR435; +MIMAT0001586 osa-MIR437;osa-miR437; +MIMAT0001587 osa-MIR438;osa-miR438; +MIMAT0001588 osa-MIR390;osa-miR390;osa-miR390-5p; +MIMAT0001589 osa-MIR439a;osa-miR439a; +MIMAT0001590 osa-MIR439b;osa-miR439b; +MIMAT0001591 osa-MIR439c;osa-miR439c; +MIMAT0001592 osa-MIR439d;osa-miR439d; +MIMAT0001593 osa-MIR439e;osa-miR439e; +MIMAT0001594 osa-MIR439f;osa-miR439f; +MIMAT0001595 osa-MIR439g;osa-miR439g; +MIMAT0001596 osa-MIR439h;osa-miR439h; +MIMAT0001597 osa-MIR439i;osa-miR439i; +MIMAT0001598 osa-MIR439j;osa-miR439j;osa-miR439i; +MIMAT0001599 osa-MIR440;osa-miR440; +MIMAT0001600 osa-MIR396d;osa-miR396d; +MIMAT0001601 osa-MIR396e;osa-miR396e;osa-miR396e-5p; +MIMAT0001602 osa-MIR441a;osa-miR441a; +MIMAT0001603 osa-MIR441b;osa-miR441b; +MIMAT0001604 osa-MIR441c;osa-miR441c; +MIMAT0001605 osa-MIR442;osa-miR442; +MIMAT0001606 osa-MIR443;osa-miR443; +MIMAT0001607 osa-MIR445a;osa-miR445a; +MIMAT0001608 osa-MIR445b;osa-miR445b; +MIMAT0001609 osa-MIR445c;osa-miR445c; +MIMAT0001610 osa-MIR445d;osa-miR445d; +MIMAT0001611 osa-MIR445e;osa-miR445e; +MIMAT0001612 osa-MIR445f;osa-miR445f; +MIMAT0001613 osa-MIR445g;osa-miR445g; +MIMAT0001614 osa-MIR445h;osa-miR445h; +MIMAT0001615 osa-MIR445i;osa-miR445i; +MIMAT0001616 osa-MIR446;osa-miR446; +MIMAT0001617 osa-MIR444;osa-miR444;osa-miR444a.1;osa-miR444a-3p.1; +MIMAT0001618 hsa-miR-191*;hsa-miR-191-3p; +MIMAT0001619 rno-miR-424;rno-miR-322;rno-miR-322-5p; +MIMAT0001620 hsa-miR-200a*;hsa-miR-200a-5p; +MIMAT0001621 hsa-miR-369-5p; +MIMAT0001622 gga-miR-181a; +MIMAT0001623 dre-miR-181a;dre-miR-181a-5p; +MIMAT0001624 dre-miR-429;dre-miR-429a; +MIMAT0001625 hsa-miR-431;hsa-miR-431-5p; +MIMAT0001626 rno-miR-431; +MIMAT0001627 hsa-miR-433;hsa-miR-433-3p; +MIMAT0001628 rno-miR-433;rno-miR-433-3p; +MIMAT0001629 hsa-miR-329;hsa-miR-329-3p; +MIMAT0001630 hsa-miR-453;hsa-miR-323b-5p; +MIMAT0001631 hsa-miR-451;hsa-miR-451a; +MIMAT0001632 mmu-miR-451;mmu-miR-451a; +MIMAT0001633 rno-miR-451;rno-miR-451-5p; +MIMAT0001634 dre-miR-451; +MIMAT0001635 hsa-miR-452;hsa-miR-452-5p; +MIMAT0001636 hsa-miR-452*;hsa-miR-452-3p; +MIMAT0001637 mmu-miR-452;mmu-miR-452-5p; +MIMAT0001638 hsa-miR-409-5p; +MIMAT0001639 hsa-miR-409-3p; +MIMAT0001640 mtr-miR162; +MIMAT0001641 mtr-miR160;mtr-miR160a; +MIMAT0001642 mtr-miR166;mtr-miR166a; +MIMAT0001643 mtr-miR169a; +MIMAT0001644 mtr-miR169b; +MIMAT0001645 mtr-miR399b; +MIMAT0001646 mtr-miR399d; +MIMAT0001647 mtr-miR393;mtr-miR393a; +MIMAT0001648 mtr-miR395a; +MIMAT0001649 mtr-miR395b; +MIMAT0001650 mtr-miR399c; +MIMAT0001651 mtr-miR399a; +MIMAT0001652 mtr-miR399e; +MIMAT0001653 mtr-miR319;mtr-miR319a;mtr-miR319a-3p; +MIMAT0001654 mtr-miR156;mtr-miR156a; +MIMAT0001655 mtr-miR171;mtr-miR171a; +MIMAT0001656 sof-miR156; +MIMAT0001657 sof-miR396; +MIMAT0001658 sof-miR159a; +MIMAT0001659 sof-miR159b; +MIMAT0001660 sof-miR159d; +MIMAT0001661 sof-miR159e; +MIMAT0001662 sof-miR159c; +MIMAT0001663 sof-miR167a; +MIMAT0001664 sof-miR167b; +MIMAT0001665 sof-miR168a; +MIMAT0001666 sof-miR168b; +MIMAT0001667 sof-miR408a; +MIMAT0001668 sof-miR408b; +MIMAT0001669 sof-miR408c; +MIMAT0001670 sof-miR408d; +MIMAT0001671 sof-miR408e; +MIMAT0001672 gma-miR156d; +MIMAT0001673 gma-miR156e; +MIMAT0001674 gma-miR156c; +MIMAT0001675 gma-miR159;gma-miR159a;gma-miR159a-3p; +MIMAT0001676 gma-miR160;gma-miR160a-5p; +MIMAT0001677 gma-miR166a;gma-miR166a-3p; +MIMAT0001678 gma-miR166b; +MIMAT0001679 gma-miR167a; +MIMAT0001680 gma-miR167b; +MIMAT0001681 gma-miR168;gma-miR168a; +MIMAT0001682 gma-miR172a; +MIMAT0001683 gma-miR172b;gma-miR172b-3p; +MIMAT0001684 gma-miR319a; +MIMAT0001685 gma-miR319b; +MIMAT0001686 gma-miR156a; +MIMAT0001687 gma-miR396a;gma-miR396a-5p; +MIMAT0001688 gma-miR396b;gma-miR396b-5p; +MIMAT0001689 gma-miR398a; +MIMAT0001690 gma-miR398b;gma-miR398b-3p; +MIMAT0001691 gma-miR319c; +MIMAT0001692 gma-miR156b; +MIMAT0001693 gma-miR169;gma-miR169a; +MIMAT0001694 zma-miR171d;zma-miR171d-3p; +MIMAT0001695 zma-miR171f;zma-miR171f-3p; +MIMAT0001696 zma-miR394a;zma-miR394a-5p; +MIMAT0001697 zma-miR394b;zma-miR394b-5p; +MIMAT0001698 zma-miR395b;zma-miR395b-3p; +MIMAT0001699 zma-miR395c; +MIMAT0001700 zma-miR395d;zma-miR395c;zma-miR395c-3p; +MIMAT0001701 zma-miR395a;zma-miR395a-3p; +MIMAT0001702 zma-miR396b;zma-miR396b-5p; +MIMAT0001703 zma-miR396a;zma-miR396a-5p; +MIMAT0001704 zma-miR399a;zma-miR399a-3p; +MIMAT0001705 zma-miR399c;zma-miR399c-3p; +MIMAT0001706 zma-miR399b;zma-miR399b-3p; +MIMAT0001707 zma-miR399d;zma-miR399d-3p; +MIMAT0001708 zma-miR399e;zma-miR399e-3p; +MIMAT0001709 zma-miR399f;zma-miR399f-3p; +MIMAT0001710 zma-miR156j;zma-miR156j-5p; +MIMAT0001711 zma-miR159a;zma-miR159a-3p; +MIMAT0001712 zma-miR159b;zma-miR159b-3p; +MIMAT0001713 zma-miR159c;zma-miR159c-3p; +MIMAT0001714 zma-miR159d;zma-miR159d-3p; +MIMAT0001715 zma-miR319a;zma-miR319a-3p; +MIMAT0001716 zma-miR319c;zma-miR319c-3p; +MIMAT0001717 zma-miR319b;zma-miR319b-3p; +MIMAT0001718 zma-miR319d;zma-miR319d-3p; +MIMAT0001719 zma-miR166k;zma-miR166k-3p; +MIMAT0001720 zma-miR166j;zma-miR166j-3p; +MIMAT0001721 zma-miR167e;zma-miR167e-5p; +MIMAT0001722 zma-miR167f;zma-miR167f-5p; +MIMAT0001723 zma-miR167g;zma-miR167g-5p; +MIMAT0001724 zma-miR167h;zma-miR167h-5p; +MIMAT0001725 zma-miR167i;zma-miR167i-5p; +MIMAT0001726 zma-miR168a;zma-miR168a-5p; +MIMAT0001727 zma-miR168b;zma-miR168b-5p; +MIMAT0001728 zma-miR169c;zma-miR169c-5p; +MIMAT0001729 zma-miR169f;zma-miR169f-5p; +MIMAT0001730 zma-miR169g; +MIMAT0001731 zma-miR169h; +MIMAT0001732 zma-miR169i;zma-miR169i-5p; +MIMAT0001733 zma-miR169k;zma-miR169k-5p; +MIMAT0001734 zma-miR169j;zma-miR169j-5p; +MIMAT0001735 zma-miR169d; +MIMAT0001736 zma-miR169e; +MIMAT0001737 zma-miR171c;zma-miR171c-3p; +MIMAT0001738 zma-miR171j;zma-miR171j-3p; +MIMAT0001739 zma-miR171e;zma-miR171e-3p; +MIMAT0001740 zma-miR171i;zma-miR171i-3p; +MIMAT0001741 zma-miR171g;zma-miR171g-3p; +MIMAT0001742 zma-miR172e; +MIMAT0001743 zma-miR166l;zma-miR166l-3p; +MIMAT0001744 zma-miR166m;zma-miR166m-3p; +MIMAT0001745 zma-miR171k;zma-miR171k-3p; +MIMAT0001746 zma-miR171h;zma-miR171h-3p; +MIMAT0001747 zma-miR393;zma-miR393a;zma-miR393a-5p; +MIMAT0001748 zma-miR408;zma-miR408a; +MIMAT0001749 zma-miR156k;zma-miR156k-5p; +MIMAT0001750 zma-miR160f;zma-miR160f-5p; +MIMAT0001751 sbi-miR399h; +MIMAT0001752 sbi-miR399i; +MIMAT0001753 sbi-miR159b; +MIMAT0001754 sbi-miR164c; +MIMAT0001755 sbi-miR166g; +MIMAT0001756 sbi-miR171f; +MIMAT0001757 sbi-miR395f; +MIMAT0001758 sbi-miR156e; +MIMAT0001759 dre-let-7a; +MIMAT0001760 dre-let-7b; +MIMAT0001761 dre-let-7c;dre-let-7c-5p; +MIMAT0001762 dre-let-7d;dre-let-7d-5p; +MIMAT0001763 dre-let-7e; +MIMAT0001764 dre-let-7f; +MIMAT0001765 dre-let-7g; +MIMAT0001766 dre-let-7h; +MIMAT0001767 dre-let-7i; +MIMAT0001768 dre-miR-1; +MIMAT0001769 dre-miR-9;dre-miR-9-5p; +MIMAT0001770 dre-miR-10c;dre-miR-10c-5p; +MIMAT0001771 dre-miR-10d;dre-miR-10d-5p; +MIMAT0001772 dre-miR-15a;dre-miR-15a-5p; +MIMAT0001773 dre-miR-15b;dre-miR-15b-5p; +MIMAT0001774 dre-miR-16a; +MIMAT0001775 dre-miR-16b; +MIMAT0001776 dre-miR-16c;dre-miR-16c-5p; +MIMAT0001777 dre-miR-17a;dre-miR-17a-5p; +MIMAT0001778 dre-miR-20b;dre-miR-20b-5p; +MIMAT0001779 dre-miR-18a; +MIMAT0001780 dre-miR-18b;dre-miR-18b-5p; +MIMAT0001781 dre-miR-18c; +MIMAT0001782 dre-miR-19a;dre-miR-19a-3p; +MIMAT0001783 dre-miR-19b;dre-miR-19b-3p; +MIMAT0001784 dre-miR-19c;dre-miR-19c-3p; +MIMAT0001785 dre-miR-19d;dre-miR-19d-3p; +MIMAT0001786 dre-miR-20a;dre-miR-20a-5p; +MIMAT0001787 dre-miR-21; +MIMAT0001788 dre-miR-22a;dre-miR-22a-3p; +MIMAT0001789 dre-miR-22b;dre-miR-22b-3p; +MIMAT0001790 dre-miR-23a;dre-miR-23a-3p; +MIMAT0001791 dre-miR-23b; +MIMAT0001792 dre-miR-24; +MIMAT0001793 dre-miR-25;dre-miR-25-3p; +MIMAT0001794 dre-miR-26a;dre-miR-26a-5p; +MIMAT0001795 dre-miR-26b; +MIMAT0001796 dre-miR-27a;dre-miR-27a-3p; +MIMAT0001797 dre-miR-27b;dre-miR-27b-3p; +MIMAT0001798 dre-miR-27c;dre-miR-27c-3p; +MIMAT0001799 dre-miR-27d; +MIMAT0001800 dre-miR-27e; +MIMAT0001801 dre-miR-29b; +MIMAT0001802 dre-miR-29a; +MIMAT0001803 dre-miR-30a;dre-miR-30a-5p; +MIMAT0001804 dre-miR-30b; +MIMAT0001805 dre-miR-30c;dre-miR-30c-5p; +MIMAT0001806 dre-miR-30d; +MIMAT0001807 dre-miR-30e;dre-miR-30e-5p; +MIMAT0001808 dre-miR-92a;dre-miR-92a-3p; +MIMAT0001809 dre-miR-92b;dre-miR-92b-3p; +MIMAT0001810 dre-miR-93; +MIMAT0001811 dre-miR-96;dre-miR-96-5p; +MIMAT0001812 dre-miR-99; +MIMAT0001813 dre-miR-100;dre-miR-100-5p; +MIMAT0001814 dre-miR-101a; +MIMAT0001815 dre-miR-101b; +MIMAT0001816 dre-miR-103; +MIMAT0001817 dre-miR-107;dre-miR-107a;dre-miR-107a-3p; +MIMAT0001818 dre-miR-122; +MIMAT0001819 dre-miR-124;dre-miR-124-3p; +MIMAT0001820 dre-miR-125a; +MIMAT0001821 dre-miR-125b;dre-miR-125b-5p; +MIMAT0001822 dre-miR-125c;dre-miR-125c-5p; +MIMAT0001823 dre-miR-126;dre-miR-126a;dre-miR-126a-3p; +MIMAT0001824 dre-miR-128;dre-miR-128-3p; +MIMAT0001825 dre-miR-129;dre-miR-129-5p; +MIMAT0001826 dre-miR-130a; +MIMAT0001827 dre-miR-130b; +MIMAT0001828 dre-miR-130c;dre-miR-130c-3p; +MIMAT0001829 dre-miR-132;dre-miR-132-3p; +MIMAT0001830 dre-miR-133a;dre-miR-133a-3p; +MIMAT0001831 dre-miR-133b;dre-miR-133b-3p; +MIMAT0001832 dre-miR-133c;dre-miR-133c-3p; +MIMAT0001833 dre-miR-135;dre-miR-135c; +MIMAT0001834 dre-miR-137;dre-miR-137-3p; +MIMAT0001835 dre-miR-138;dre-miR-138-5p; +MIMAT0001836 dre-miR-140;dre-miR-140-5p; +MIMAT0001837 dre-miR-141;dre-miR-141-3p; +MIMAT0001838 dre-miR-142a-5p; +MIMAT0001839 dre-miR-142b-5p; +MIMAT0001840 dre-miR-143; +MIMAT0001841 dre-miR-144;dre-miR-144-3p; +MIMAT0001842 dre-miR-145;dre-miR-145-5p; +MIMAT0001843 dre-miR-146a; +MIMAT0001844 dre-miR-146b; +MIMAT0001845 dre-miR-148; +MIMAT0001846 dre-miR-150; +MIMAT0001847 dre-miR-152; +MIMAT0001848 dre-miR-153b;dre-miR-153b-3p; +MIMAT0001849 dre-miR-153a;dre-miR-153a-3p; +MIMAT0001850 dre-miR-153c;dre-miR-153c-3p; +MIMAT0001851 dre-miR-155; +MIMAT0001852 dre-miR-181c;dre-miR-181c-5p; +MIMAT0001853 dre-miR-184; +MIMAT0001854 dre-miR-190;dre-miR-190a; +MIMAT0001855 dre-miR-462; +MIMAT0001856 dre-miR-193a;dre-miR-193a-3p; +MIMAT0001857 dre-miR-193b;dre-miR-193b-3p; +MIMAT0001858 dre-miR-194a; +MIMAT0001859 dre-miR-194b; +MIMAT0001860 dre-miR-196b; +MIMAT0001861 dre-miR-200a;dre-miR-200a-3p; +MIMAT0001862 dre-miR-200b;dre-miR-200b-3p; +MIMAT0001863 dre-miR-200c;dre-miR-200c-3p; +MIMAT0001864 dre-miR-202;dre-miR-202-3p; +MIMAT0001865 dre-miR-203b;dre-miR-203b-3p; +MIMAT0001866 dre-miR-206;dre-miR-206-3p; +MIMAT0001867 dre-miR-216b; +MIMAT0001868 dre-miR-218a; +MIMAT0001869 dre-miR-218b; +MIMAT0001870 dre-miR-301a; +MIMAT0001871 dre-miR-301b;dre-miR-301b-3p; +MIMAT0001872 dre-miR-301c;dre-miR-301c-3p; +MIMAT0001873 dre-miR-338; +MIMAT0001874 dre-miR-363;dre-miR-363-3p; +MIMAT0001875 dre-miR-365; +MIMAT0001876 dre-miR-375; +MIMAT0001877 dre-miR-454a; +MIMAT0001878 dre-miR-454b; +MIMAT0001879 dre-miR-455;dre-miR-455a;dre-miR-455-5p; +MIMAT0001880 dre-miR-430i;dre-miR-430i-3p; +MIMAT0001881 dre-miR-430j; +MIMAT0001882 dre-miR-456; +MIMAT0001883 dre-miR-457a; +MIMAT0001884 dre-miR-457b;dre-miR-457b-5p; +MIMAT0001885 dre-miR-458;dre-miR-458-3p; +MIMAT0001886 dre-miR-459;dre-miR-459-5p; +MIMAT0001887 dre-miR-460-5p; +MIMAT0001888 dre-miR-460-3p; +MIMAT0001889 dre-miR-461; +MIMAT0001890 ptc-miR156a; +MIMAT0001891 ptc-miR156b; +MIMAT0001892 ptc-miR156c; +MIMAT0001893 ptc-miR156d; +MIMAT0001894 ptc-miR156e; +MIMAT0001895 ptc-miR156f; +MIMAT0001896 ptc-miR156g; +MIMAT0001897 ptc-miR156h; +MIMAT0001898 ptc-miR156i; +MIMAT0001899 ptc-miR156j; +MIMAT0001900 ptc-miR156k; +MIMAT0001901 ptc-miR159a; +MIMAT0001902 ptc-miR159b; +MIMAT0001903 ptc-miR159c; +MIMAT0001904 ptc-miR159d; +MIMAT0001905 ptc-miR159e; +MIMAT0001906 ptc-miR159f;ptc-miR159c; +MIMAT0001907 ptc-miR160a; +MIMAT0001908 ptc-miR160b;ptc-miR160b-5p; +MIMAT0001909 ptc-miR160c;ptc-miR160c-5p; +MIMAT0001910 ptc-miR160d; +MIMAT0001911 ptc-miR160e;ptc-miR160e-5p; +MIMAT0001912 ptc-miR160f; +MIMAT0001913 ptc-miR160g; +MIMAT0001914 ptc-miR160h; +MIMAT0001915 ptc-miR162a; +MIMAT0001916 ptc-miR162b; +MIMAT0001917 ptc-miR162c; +MIMAT0001918 ptc-miR164a; +MIMAT0001919 ptc-miR164b; +MIMAT0001920 ptc-miR164c; +MIMAT0001921 ptc-miR164d; +MIMAT0001922 ptc-miR164e; +MIMAT0001923 ptc-miR164f; +MIMAT0001924 ptc-miR166a; +MIMAT0001925 ptc-miR166b; +MIMAT0001926 ptc-miR166c; +MIMAT0001927 ptc-miR166d; +MIMAT0001928 ptc-miR166e; +MIMAT0001929 ptc-miR166f; +MIMAT0001930 ptc-miR166g; +MIMAT0001931 ptc-miR166h; +MIMAT0001932 ptc-miR166i; +MIMAT0001933 ptc-miR166j; +MIMAT0001934 ptc-miR166k; +MIMAT0001935 ptc-miR166l; +MIMAT0001936 ptc-miR166m; +MIMAT0001937 ptc-miR166n; +MIMAT0001938 ptc-miR166o; +MIMAT0001939 ptc-miR166p; +MIMAT0001940 ptc-miR166q; +MIMAT0001941 ptc-miR167a; +MIMAT0001942 ptc-miR167b; +MIMAT0001943 ptc-miR167c; +MIMAT0001944 ptc-miR167d; +MIMAT0001945 ptc-miR167e; +MIMAT0001946 ptc-miR167f;ptc-miR167f-5p; +MIMAT0001947 ptc-miR167g;ptc-miR167g-5p; +MIMAT0001948 ptc-miR167h;ptc-miR167h-5p; +MIMAT0001949 ptc-miR168a;ptc-miR168a-5p; +MIMAT0001950 ptc-miR168b;ptc-miR168b-5p; +MIMAT0001951 ptc-miR169a; +MIMAT0001952 ptc-miR169aa; +MIMAT0001953 ptc-miR169ab; +MIMAT0001954 ptc-miR169ac; +MIMAT0001955 ptc-miR169ad; +MIMAT0001956 ptc-miR169ae; +MIMAT0001957 ptc-miR169af; +MIMAT0001958 ptc-miR169b;ptc-miR169b-5p; +MIMAT0001959 ptc-miR169c; +MIMAT0001960 ptc-miR169d; +MIMAT0001961 ptc-miR169e; +MIMAT0001962 ptc-miR169f; +MIMAT0001963 ptc-miR169g; +MIMAT0001964 ptc-miR169h; +MIMAT0001965 ptc-miR169i; +MIMAT0001966 ptc-miR169j; +MIMAT0001967 ptc-miR169k; +MIMAT0001968 ptc-miR169l; +MIMAT0001969 ptc-miR169m; +MIMAT0001970 ptc-miR169n;ptc-miR169n-5p; +MIMAT0001971 ptc-miR169o; +MIMAT0001972 ptc-miR169p; +MIMAT0001973 ptc-miR169q; +MIMAT0001974 ptc-miR169r; +MIMAT0001975 ptc-miR169s; +MIMAT0001976 ptc-miR169t; +MIMAT0001977 ptc-miR169u;ptc-miR169u-5p; +MIMAT0001978 ptc-miR169v; +MIMAT0001979 ptc-miR169w; +MIMAT0001980 ptc-miR169x; +MIMAT0001981 ptc-miR169y; +MIMAT0001982 ptc-miR169z; +MIMAT0001983 ptc-miR171a;ptc-miR171a-3p; +MIMAT0001984 ptc-miR171b; +MIMAT0001985 ptc-miR171c; +MIMAT0001986 ptc-miR171d; +MIMAT0001987 ptc-miR171e; +MIMAT0001988 ptc-miR171f; +MIMAT0001989 ptc-miR171g;ptc-miR171g-3p; +MIMAT0001990 ptc-miR171h;ptc-miR171h-3p; +MIMAT0001991 ptc-miR171i; +MIMAT0001992 ptc-miR171j; +MIMAT0001993 ptc-miR172a; +MIMAT0001994 ptc-miR172b;ptc-miR172b-3p; +MIMAT0001995 ptc-miR172c; +MIMAT0001996 ptc-miR172d; +MIMAT0001997 ptc-miR172e; +MIMAT0001998 ptc-miR172f; +MIMAT0001999 ptc-miR172g;ptc-miR172g-3p; +MIMAT0002000 ptc-miR172h;ptc-miR172h-3p; +MIMAT0002001 ptc-miR172i; +MIMAT0002002 ptc-miR319a; +MIMAT0002003 ptc-miR319b; +MIMAT0002004 ptc-miR319c; +MIMAT0002005 ptc-miR319d; +MIMAT0002006 ptc-miR319e; +MIMAT0002007 ptc-miR319f; +MIMAT0002008 ptc-miR319g; +MIMAT0002009 ptc-miR319h; +MIMAT0002010 ptc-miR319i; +MIMAT0002011 ptc-miR390a; +MIMAT0002012 ptc-miR390b; +MIMAT0002013 ptc-miR390c; +MIMAT0002014 ptc-miR390d;ptc-miR390d-5p; +MIMAT0002015 ptc-miR393a;ptc-miR393a-5p; +MIMAT0002016 ptc-miR393b;ptc-miR393b-5p; +MIMAT0002017 ptc-miR393c; +MIMAT0002018 ptc-miR393d; +MIMAT0002019 ptc-miR394a;ptc-miR394a-5p; +MIMAT0002020 ptc-miR394b;ptc-miR394b-5p; +MIMAT0002021 ptc-miR395a; +MIMAT0002022 ptc-miR395b; +MIMAT0002023 ptc-miR395c; +MIMAT0002024 ptc-miR395d; +MIMAT0002025 ptc-miR395e; +MIMAT0002026 ptc-miR395f; +MIMAT0002027 ptc-miR395g; +MIMAT0002028 ptc-miR395h; +MIMAT0002029 ptc-miR395i; +MIMAT0002030 ptc-miR395j; +MIMAT0002031 ptc-miR396a; +MIMAT0002032 ptc-miR396b; +MIMAT0002033 ptc-miR396c; +MIMAT0002034 ptc-miR396d; +MIMAT0002035 ptc-miR396e;ptc-miR396e-5p; +MIMAT0002036 ptc-miR396f; +MIMAT0002037 ptc-miR396g;ptc-miR396g-5p; +MIMAT0002038 ptc-miR397a; +MIMAT0002039 ptc-miR397b; +MIMAT0002040 ptc-miR397c; +MIMAT0002041 ptc-miR398a; +MIMAT0002042 ptc-miR398b; +MIMAT0002043 ptc-miR398c;ptc-miR398c-3p; +MIMAT0002044 ptc-miR399a; +MIMAT0002045 ptc-miR399b; +MIMAT0002046 ptc-miR399c; +MIMAT0002047 ptc-miR399d; +MIMAT0002048 ptc-miR399e; +MIMAT0002049 ptc-miR399f; +MIMAT0002050 ptc-miR399g; +MIMAT0002051 ptc-miR399h; +MIMAT0002052 ptc-miR399i; +MIMAT0002053 ptc-miR399j; +MIMAT0002054 ptc-miR399k;ptc-miR399c; +MIMAT0002055 ptc-miR399l;ptc-miR399e; +MIMAT0002056 ptc-miR403a; +MIMAT0002057 ptc-miR403b; +MIMAT0002058 ptc-miR408;ptc-miR408-3p; +MIMAT0002060 ptc-miR472a; +MIMAT0002061 ptc-miR472b; +MIMAT0002062 ptc-miR473a;ptc-miR473a-5p;ptc-miR477e-5p; +MIMAT0002063 ptc-miR473b;ptc-miR477f; +MIMAT0002064 ptc-miR474a; +MIMAT0002065 ptc-miR474b; +MIMAT0002066 ptc-miR474c; +MIMAT0002067 ptc-miR475a;ptc-miR475a-3p; +MIMAT0002068 ptc-miR475b;ptc-miR475b-3p; +MIMAT0002069 ptc-miR475c; +MIMAT0002070 ptc-miR475d;ptc-miR475d-3p; +MIMAT0002071 ptc-miR476a; +MIMAT0002072 ptc-miR476b; +MIMAT0002073 ptc-miR476c; +MIMAT0002074 ptc-miR477a;ptc-miR477a-5p; +MIMAT0002075 ptc-miR477b; +MIMAT0002076 ptc-miR478a; +MIMAT0002077 ptc-miR478b; +MIMAT0002078 ptc-miR478c; +MIMAT0002079 ptc-miR478d; +MIMAT0002080 ptc-miR478e; +MIMAT0002081 ptc-miR478f; +MIMAT0002082 ptc-miR478h; +MIMAT0002083 ptc-miR478i; +MIMAT0002084 ptc-miR478j; +MIMAT0002085 ptc-miR478k; +MIMAT0002086 ptc-miR478l; +MIMAT0002087 ptc-miR478m; +MIMAT0002088 ptc-miR478n; +MIMAT0002089 ptc-miR478o; +MIMAT0002090 ptc-miR478p; +MIMAT0002091 ptc-miR478q; +MIMAT0002092 ptc-miR478r; +MIMAT0002093 ptc-miR478s; +MIMAT0002094 ptc-miR478u;ptc-miR478n; +MIMAT0002095 ptc-miR479;ptc-miR171l-5p; +MIMAT0002096 ptc-miR480a;ptc-miR480; +MIMAT0002097 ptc-miR480b; +MIMAT0002098 ptc-miR481a; +MIMAT0002099 ptc-miR481b; +MIMAT0002100 ptc-miR481c; +MIMAT0002101 ptc-miR481d; +MIMAT0002102 ptc-miR481e;ptc-miR481d; +MIMAT0002103 ptc-miR482;ptc-miR482.1;ptc-miR482a.1; +MIMAT0002104 mmu-miR-463;mmu-miR-463*;mmu-miR-463-5p; +MIMAT0002105 mmu-miR-464; +MIMAT0002106 mmu-miR-465;mmu-miR-465-5p;mmu-miR-465a-5p; +MIMAT0002107 mmu-miR-466;mmu-miR-466a-3p; +MIMAT0002108 mmu-miR-467;mmu-miR-467a;mmu-miR-467a*;mmu-miR-467a-1*;mmu-miR-467a*;mmu-miR-467a-3p; +MIMAT0002109 mmu-miR-468;mmu-miR-468-3p; +MIMAT0002110 mmu-miR-469; +MIMAT0002111 mmu-miR-470;mmu-miR-470-5p; +MIMAT0002112 mmu-miR-471;mmu-miR-471-5p; +MIMAT0002113 ath-miR447a;ath-miR447a-3p; +MIMAT0002114 ath-miR447b; +MIMAT0002115 ath-miR447c;ath-miR447c-3p; +MIMAT0002116 ssc-miR-105-1; +MIMAT0002117 ssc-miR-105-2; +MIMAT0002118 ssc-miR-106a; +MIMAT0002119 ssc-miR-122a;ssc-miR-122;ssc-miR-122-5p; +MIMAT0002120 ssc-miR-125b; +MIMAT0002121 ssc-miR-135a-1;ssc-miR-135; +MIMAT0002122 ssc-miR-135a-2;ssc-miR-135; +MIMAT0002123 ssc-miR-145;ssc-miR-145-5p; +MIMAT0002124 ssc-miR-148a;ssc-miR-148a-3p; +MIMAT0002125 ssc-miR-15b; +MIMAT0002126 ssc-miR-181b; +MIMAT0002127 ssc-miR-184; +MIMAT0002128 ssc-miR-19a; +MIMAT0002129 ssc-miR-20;ssc-miR-20a;ssc-miR-20a-5p; +MIMAT0002130 ssc-miR-216; +MIMAT0002131 ssc-miR-217; +MIMAT0002132 ssc-miR-224; +MIMAT0002133 ssc-miR-23a; +MIMAT0002134 ssc-miR-24;ssc-miR-24-3p; +MIMAT0002135 ssc-miR-26a; +MIMAT0002136 ssc-miR-28;ssc-miR-28-5p; +MIMAT0002137 ssc-miR-29b; +MIMAT0002138 ssc-miR-301; +MIMAT0002139 ssc-miR-323; +MIMAT0002140 ssc-miR-326; +MIMAT0002141 ssc-miR-7;ssc-miR-7-5p; +MIMAT0002142 ssc-miR-95; +MIMAT0002143 ssc-miR-140;ssc-miR-140-5p; +MIMAT0002144 ssc-miR-181c; +MIMAT0002145 ssc-miR-183; +MIMAT0002146 ssc-miR-205; +MIMAT0002147 ssc-miR-214;ssc-miR-214-3p; +MIMAT0002148 ssc-miR-27a; +MIMAT0002149 ssc-miR-32; +MIMAT0002150 ssc-miR-325; +MIMAT0002151 ssc-let-7c; +MIMAT0002152 ssc-let-7f;ssc-let-7f-5p; +MIMAT0002153 ssc-let-7i;ssc-let-7i-5p; +MIMAT0002154 ssc-miR-103; +MIMAT0002155 ssc-miR-107; +MIMAT0002156 ssc-miR-124a; +MIMAT0002157 ssc-miR-128a;ssc-miR-128; +MIMAT0002158 ssc-miR-136;ssc-miR-136-5p; +MIMAT0002159 ssc-miR-139;ssc-miR-139-5p; +MIMAT0002160 ssc-miR-153; +MIMAT0002161 ssc-miR-18;ssc-miR-18a; +MIMAT0002162 ssc-miR-186;ssc-miR-186-5p; +MIMAT0002163 ssc-miR-196;ssc-miR-196a; +MIMAT0002164 ssc-miR-204; +MIMAT0002165 ssc-miR-21;ssc-miR-21-5p; +MIMAT0002166 ssc-miR-29c; +MIMAT0002167 ssc-miR-30c;ssc-miR-30c-5p; +MIMAT0002168 ssc-miR-9-1; +MIMAT0002169 ssc-miR-9-2; +MIMAT0002170 hsa-miR-412;hsa-miR-412-3p; +MIMAT0002171 hsa-miR-410;hsa-miR-410-3p; +MIMAT0002172 hsa-miR-376b;hsa-miR-376b-3p; +MIMAT0002173 hsa-miR-483;hsa-miR-483-3p; +MIMAT0002174 hsa-miR-484; +MIMAT0002175 hsa-miR-485-5p; +MIMAT0002176 hsa-miR-485-3p; +MIMAT0002177 hsa-miR-486;hsa-miR-486-5p; +MIMAT0002178 hsa-miR-487;hsa-miR-487a;hsa-miR-487a-3p; +MIMAT0002179 kshv-miR-K12-10a;kshv-miR-K12-10a-3p; +MIMAT0002180 kshv-miR-K12-10b; +MIMAT0002181 kshv-miR-K12-11;kshv-miR-K12-11-3p; +MIMAT0002182 kshv-miR-K12-1;kshv-miR-K12-1-5p; +MIMAT0002183 kshv-miR-K12-2;kshv-miR-K12-2-5p; +MIMAT0002184 kshv-miR-K12-9*;kshv-miR-K12-9-5p; +MIMAT0002185 kshv-miR-K12-9;kshv-miR-K12-9-3p; +MIMAT0002186 kshv-miR-K12-8;kshv-miR-K12-8-3p; +MIMAT0002187 kshv-miR-K12-7;kshv-miR-K12-7-3p; +MIMAT0002188 kshv-miR-K12-6-5p; +MIMAT0002189 kshv-miR-K12-6-3p; +MIMAT0002190 kshv-miR-K12-5;kshv-miR-K12-5-3p; +MIMAT0002191 kshv-miR-K12-4-5p; +MIMAT0002192 kshv-miR-K12-4-3p; +MIMAT0002193 kshv-miR-K12-3;kshv-miR-K12-3-5p; +MIMAT0002194 kshv-miR-K12-3*;kshv-miR-K12-3-3p; +MIMAT0002195 mml-miR-200c;mml-miR-200c-3p; +MIMAT0002196 mml-miR-141;mml-miR-141-3p; +MIMAT0002197 ggo-miR-200c; +MIMAT0002198 ggo-miR-141; +MIMAT0002199 ppy-miR-200c; +MIMAT0002200 ppy-miR-141; +MIMAT0002201 ppa-miR-141; +MIMAT0002202 ggo-miR-15b; +MIMAT0002203 age-miR-15b; +MIMAT0002204 ppa-miR-15b; +MIMAT0002205 ppy-miR-15b; +MIMAT0002206 ptr-miR-15b; +MIMAT0002207 mml-miR-15b;mml-miR-15b-5p; +MIMAT0002208 lla-miR-15b; +MIMAT0002209 mne-miR-15b; +MIMAT0002210 ptr-miR-23b; +MIMAT0002211 ppy-miR-23b; +MIMAT0002212 ppa-miR-23b; +MIMAT0002213 mml-miR-30b;mml-miR-30b-5p; +MIMAT0002214 ptr-miR-30b; +MIMAT0002215 ggo-miR-30b; +MIMAT0002216 lla-miR-30b; +MIMAT0002217 mne-miR-30b; +MIMAT0002218 age-miR-30b; +MIMAT0002219 ppa-miR-30b; +MIMAT0002220 ggo-miR-125b; +MIMAT0002221 age-miR-125b; +MIMAT0002222 ppa-miR-125b; +MIMAT0002223 ppy-miR-125b; +MIMAT0002224 ptr-miR-125b; +MIMAT0002225 mml-miR-125b;mml-miR-125b-5p; +MIMAT0002226 sla-miR-125b; +MIMAT0002227 lla-miR-125b; +MIMAT0002228 mne-miR-125b; +MIMAT0002229 mml-miR-128a;mml-miR-128;mml-miR-128a;mml-miR-128a-3p; +MIMAT0002230 ptr-miR-128a;ptr-miR-128; +MIMAT0002231 ppy-miR-128a;ppy-miR-128; +MIMAT0002232 sla-miR-128a;sla-miR-128; +MIMAT0002233 age-miR-128a;age-miR-128; +MIMAT0002234 ppa-miR-128a;ppa-miR-128; +MIMAT0002235 mml-miR-130a;mml-miR-130a-3p; +MIMAT0002236 ggo-miR-130a; +MIMAT0002237 mne-miR-130a; +MIMAT0002238 ppa-miR-130a; +MIMAT0002239 ggo-miR-133a; +MIMAT0002240 age-miR-133a; +MIMAT0002241 ppa-miR-133a; +MIMAT0002242 ppy-miR-133a; +MIMAT0002243 ptr-miR-133a; +MIMAT0002244 mml-miR-133a; +MIMAT0002245 sla-miR-133a; +MIMAT0002246 lla-miR-133a; +MIMAT0002247 mne-miR-133a; +MIMAT0002248 lla-miR-135; +MIMAT0002249 age-miR-135; +MIMAT0002250 ppa-miR-135; +MIMAT0002251 mml-miR-135;mml-miR-135a;mml-miR-135a-5p; +MIMAT0002252 ptr-miR-135;ptr-miR-135a; +MIMAT0002253 ggo-miR-135;ggo-miR-135a; +MIMAT0002254 ppy-miR-135; +MIMAT0002255 ptr-miR-140; +MIMAT0002256 mne-miR-140; +MIMAT0002257 ptr-miR-143; +MIMAT0002258 ggo-miR-143; +MIMAT0002259 ppy-miR-143; +MIMAT0002260 lla-miR-143; +MIMAT0002261 ppa-miR-143; +MIMAT0002262 ptr-miR-144; +MIMAT0002263 ppy-miR-144; +MIMAT0002264 mne-miR-144; +MIMAT0002265 ppa-miR-144; +MIMAT0002266 mml-miR-145;mml-miR-145-5p; +MIMAT0002267 ptr-miR-145; +MIMAT0002268 ggo-miR-145; +MIMAT0002269 ppy-miR-145; +MIMAT0002270 mne-miR-145; +MIMAT0002271 mml-miR-153;mml-miR-153-3p; +MIMAT0002272 ppy-miR-153; +MIMAT0002273 mne-miR-153; +MIMAT0002274 ggo-miR-153; +MIMAT0002275 ptr-miR-9; +MIMAT0002276 ggo-miR-9; +MIMAT0002277 lla-miR-9; +MIMAT0002278 mne-miR-9; +MIMAT0002279 age-miR-9; +MIMAT0002280 lca-miR-125b; +MIMAT0002281 mml-miR-127;mml-miR-127-3p; +MIMAT0002282 ptr-miR-127; +MIMAT0002283 ppy-miR-127; +MIMAT0002284 sla-miR-127; +MIMAT0002285 lla-miR-127; +MIMAT0002286 mne-miR-127; +MIMAT0002287 age-miR-127; +MIMAT0002288 ggo-miR-134; +MIMAT0002289 ppy-miR-134; +MIMAT0002290 mne-miR-134; +MIMAT0002291 ppa-miR-134; +MIMAT0002292 ptr-miR-136; +MIMAT0002293 ggo-miR-136; +MIMAT0002294 ppy-miR-136; +MIMAT0002295 ppa-miR-136; +MIMAT0002296 ptr-miR-154; +MIMAT0002297 ggo-miR-154; +MIMAT0002298 ppy-miR-154; +MIMAT0002299 mne-miR-154; +MIMAT0002300 ppa-miR-154; +MIMAT0002301 ptr-miR-184; +MIMAT0002302 ppy-miR-184; +MIMAT0002303 mne-miR-184; +MIMAT0002304 ptr-miR-186; +MIMAT0002305 ggo-miR-186; +MIMAT0002306 ppa-miR-186; +MIMAT0002307 mml-miR-188;mml-miR-188-5p; +MIMAT0002308 ptr-miR-188; +MIMAT0002309 ppy-miR-188; +MIMAT0002310 mne-miR-188; +MIMAT0002311 ppa-miR-188; +MIMAT0002312 mml-miR-190;mml-miR-190a;mml-miR-190a-5p; +MIMAT0002313 ptr-miR-190;ptr-miR-190a; +MIMAT0002314 ggo-miR-190;ggo-miR-190a; +MIMAT0002315 ppa-miR-190; +MIMAT0002316 ggo-miR-195; +MIMAT0002317 ppa-miR-195; +MIMAT0002318 ppy-miR-206; +MIMAT0002319 mne-miR-206; +MIMAT0002320 mml-miR-21;mml-miR-21-5p; +MIMAT0002321 ptr-miR-21; +MIMAT0002322 ggo-miR-21; +MIMAT0002323 ppy-miR-21; +MIMAT0002324 mne-miR-21; +MIMAT0002325 age-miR-21; +MIMAT0002326 ppa-miR-21; +MIMAT0002327 age-miR-22; +MIMAT0002328 ppa-miR-22; +MIMAT0002329 lca-miR-22; +MIMAT0002330 mml-miR-22; +MIMAT0002331 ppy-miR-22; +MIMAT0002332 ptr-miR-22; +MIMAT0002333 sla-miR-22; +MIMAT0002334 lla-miR-22; +MIMAT0002335 mne-miR-22; +MIMAT0002336 mml-miR-189;mml-miR-24*;mml-miR-24-5p; +MIMAT0002337 mml-miR-24;mml-miR-24-3p; +MIMAT0002338 ppy-miR-189;ppy-miR-24*;ppy-miR-24-5p; +MIMAT0002339 ppy-miR-24;ppy-miR-24-3p; +MIMAT0002340 mne-miR-189;mne-miR-24*;mne-miR-24-5p; +MIMAT0002341 mne-miR-24;mne-miR-24-3p; +MIMAT0002342 ppa-miR-189;ppa-miR-24*;ppa-miR-24-5p; +MIMAT0002343 ppa-miR-24;ppa-miR-24-3p; +MIMAT0002344 ptr-miR-26a; +MIMAT0002345 ggo-miR-26a; +MIMAT0002346 ppy-miR-26a; +MIMAT0002347 lla-miR-26a; +MIMAT0002348 mne-miR-26a; +MIMAT0002349 mml-miR-26a;mml-miR-26a-5p; +MIMAT0002350 ppa-miR-26a; +MIMAT0002351 age-miR-28; +MIMAT0002352 mml-miR-28;mml-miR-28-5p; +MIMAT0002353 ptr-miR-28; +MIMAT0002354 ggo-miR-28; +MIMAT0002355 ppy-miR-28; +MIMAT0002356 mne-miR-28; +MIMAT0002357 sla-miR-28; +MIMAT0002358 lla-miR-28; +MIMAT0002359 ppa-miR-28; +MIMAT0002360 ggo-miR-29a; +MIMAT0002361 age-miR-29a; +MIMAT0002362 ppa-miR-29a; +MIMAT0002363 ppy-miR-29a; +MIMAT0002364 ptr-miR-29a; +MIMAT0002365 mml-miR-29a;mml-miR-29a-3p; +MIMAT0002366 sla-miR-29a; +MIMAT0002367 lla-miR-29a; +MIMAT0002368 mne-miR-29a; +MIMAT0002369 mml-miR-30a-5p; +MIMAT0002370 mml-miR-30a-3p; +MIMAT0002371 ptr-miR-30a-5p; +MIMAT0002372 ptr-miR-30a-3p; +MIMAT0002373 ggo-miR-30a-5p; +MIMAT0002374 ggo-miR-30a-3p; +MIMAT0002375 ppy-miR-30a-5p; +MIMAT0002376 ppy-miR-30a-3p; +MIMAT0002377 ppa-miR-30a-5p; +MIMAT0002378 ppa-miR-30a-3p; +MIMAT0002379 mml-miR-31;mml-miR-31-5p; +MIMAT0002380 ptr-miR-31; +MIMAT0002381 ggo-miR-31; +MIMAT0002382 ppy-miR-31; +MIMAT0002383 mne-miR-31; +MIMAT0002384 ppa-miR-31; +MIMAT0002385 mml-miR-32;mml-miR-32-5p; +MIMAT0002386 ptr-miR-32; +MIMAT0002387 ggo-miR-32; +MIMAT0002388 ppy-miR-32; +MIMAT0002389 sla-miR-32; +MIMAT0002390 mne-miR-32; +MIMAT0002391 ppa-miR-32; +MIMAT0002392 mml-miR-33;mml-miR-33a; +MIMAT0002393 ptr-miR-33;ptr-miR-33a; +MIMAT0002394 ggo-miR-33; +MIMAT0002395 ppy-miR-33;ppy-miR-33a; +MIMAT0002396 mne-miR-33; +MIMAT0002397 ppa-miR-33; +MIMAT0002398 ptr-miR-95; +MIMAT0002399 ggo-miR-95; +MIMAT0002400 ppy-miR-95; +MIMAT0002401 sla-miR-95; +MIMAT0002402 lla-miR-95; +MIMAT0002403 ppa-miR-95; +MIMAT0002404 mml-miR-98; +MIMAT0002405 ptr-miR-98; +MIMAT0002406 ggo-miR-98; +MIMAT0002407 ppy-miR-98; +MIMAT0002408 age-miR-98; +MIMAT0002409 ppa-miR-98; +MIMAT0002410 mml-miR-99a;mml-miR-99a-5p; +MIMAT0002411 ptr-miR-99a; +MIMAT0002412 ggo-miR-99a; +MIMAT0002413 ppy-miR-99a; +MIMAT0002414 lla-miR-99a; +MIMAT0002415 mne-miR-99a; +MIMAT0002416 ppa-miR-99a; +MIMAT0002417 ggo-miR-100; +MIMAT0002418 age-miR-100; +MIMAT0002419 ppa-miR-100; +MIMAT0002420 ppy-miR-100; +MIMAT0002421 ptr-miR-100; +MIMAT0002422 mml-miR-100;mml-miR-100-5p; +MIMAT0002423 sla-miR-100; +MIMAT0002424 lla-miR-100; +MIMAT0002425 ggo-miR-101; +MIMAT0002426 sla-miR-101; +MIMAT0002427 age-miR-101; +MIMAT0002428 ppa-miR-101; +MIMAT0002429 ppy-miR-101; +MIMAT0002430 ptr-miR-101; +MIMAT0002431 mml-miR-101;mml-miR-101-3p; +MIMAT0002432 lla-miR-101; +MIMAT0002433 mne-miR-101; +MIMAT0002434 ppy-miR-29b; +MIMAT0002435 ptr-miR-29b; +MIMAT0002436 ggo-miR-29b; +MIMAT0002437 lla-miR-29b; +MIMAT0002438 age-miR-29b; +MIMAT0002439 ppa-miR-29b; +MIMAT0002440 sla-miR-29b; +MIMAT0002441 mne-miR-29b; +MIMAT0002442 age-miR-103; +MIMAT0002443 ggo-miR-103; +MIMAT0002444 ppa-miR-103; +MIMAT0002445 ppy-miR-103; +MIMAT0002446 ptr-miR-103; +MIMAT0002447 mml-miR-103;mml-miR-103-3p; +MIMAT0002448 lla-miR-103; +MIMAT0002449 mne-miR-103; +MIMAT0002450 ppy-miR-105; +MIMAT0002451 ggo-miR-105; +MIMAT0002452 ppa-miR-105; +MIMAT0002453 ptr-miR-105; +MIMAT0002454 mml-miR-105;mml-miR-105-5p; +MIMAT0002455 sla-miR-105; +MIMAT0002456 lla-miR-105; +MIMAT0002457 mne-miR-105; +MIMAT0002458 mml-miR-107;mml-miR-107-3p; +MIMAT0002459 ptr-miR-107; +MIMAT0002460 ggo-miR-107; +MIMAT0002461 ppy-miR-107; +MIMAT0002462 lla-miR-107; +MIMAT0002463 mne-miR-107; +MIMAT0002464 ppa-miR-107; +MIMAT0002465 ggo-miR-124a; +MIMAT0002466 age-miR-124a; +MIMAT0002467 ppa-miR-124a; +MIMAT0002468 ppy-miR-124a; +MIMAT0002469 ptr-miR-124a; +MIMAT0002470 mml-miR-124a;mml-miR-124a-3p; +MIMAT0002471 lla-miR-124a; +MIMAT0002472 lla-miR-139; +MIMAT0002473 ppa-miR-139; +MIMAT0002474 ptr-miR-147;ptr-miR-147a; +MIMAT0002475 ppy-miR-147;ppy-miR-147a; +MIMAT0002476 sla-miR-147; +MIMAT0002477 mne-miR-147; +MIMAT0002478 ppa-miR-147; +MIMAT0002479 ggo-miR-7; +MIMAT0002480 ppy-miR-7; +MIMAT0002481 sla-miR-7; +MIMAT0002482 lla-miR-7; +MIMAT0002483 mne-miR-7; +MIMAT0002484 ppa-miR-7; +MIMAT0002485 ptr-miR-7; +MIMAT0002486 ggo-miR-10a; +MIMAT0002487 ppy-miR-10a; +MIMAT0002488 sla-miR-10a; +MIMAT0002489 age-miR-10a; +MIMAT0002490 ppa-miR-10a; +MIMAT0002491 ggo-miR-10b; +MIMAT0002492 mne-miR-10b; +MIMAT0002493 ppa-miR-10b; +MIMAT0002494 ggo-miR-34a; +MIMAT0002495 age-miR-34a; +MIMAT0002496 ppa-miR-34a; +MIMAT0002497 ppy-miR-34a; +MIMAT0002498 ptr-miR-34a; +MIMAT0002499 mml-miR-34a;mml-miR-34a-5p; +MIMAT0002500 sla-miR-34a; +MIMAT0002501 lla-miR-34a; +MIMAT0002502 mne-miR-34a; +MIMAT0002503 ggo-miR-181a;ggo-miR-181a-5p; +MIMAT0002504 ppa-miR-181a;ppa-miR-181a-5p; +MIMAT0002505 ptr-miR-181a;ptr-miR-181a-5p; +MIMAT0002506 mml-miR-181a;mml-miR-181a-5p; +MIMAT0002507 sla-miR-181a; +MIMAT0002508 mne-miR-181a;mne-miR-181a-5p; +MIMAT0002509 mml-miR-181c;mml-miR-181c-5p; +MIMAT0002510 ptr-miR-181c; +MIMAT0002511 ggo-miR-181c; +MIMAT0002512 ppa-miR-181c; +MIMAT0002513 mml-miR-182; +MIMAT0002514 ppy-miR-182; +MIMAT0002515 ggo-miR-187; +MIMAT0002516 ppy-miR-187; +MIMAT0002517 mne-miR-187; +MIMAT0002518 ppa-miR-187; +MIMAT0002519 mml-miR-196;mml-miR-196a;mml-miR-196a-5p; +MIMAT0002520 ggo-miR-196; +MIMAT0002521 ppy-miR-196; +MIMAT0002522 ptr-miR-196;ptr-miR-196a; +MIMAT0002523 ppy-miR-196-2; +MIMAT0002524 lla-miR-196; +MIMAT0002525 age-miR-196; +MIMAT0002526 ppa-miR-196; +MIMAT0002527 ggo-miR-199a; +MIMAT0002528 ppa-miR-199a; +MIMAT0002529 ppy-miR-199a; +MIMAT0002530 ptr-miR-199a;ptr-miR-199a-5p; +MIMAT0002531 mml-miR-199a; +MIMAT0002532 sla-miR-199a; +MIMAT0002533 lla-miR-199a; +MIMAT0002534 mne-miR-199a; +MIMAT0002535 ptr-miR-204; +MIMAT0002536 ggo-miR-204; +MIMAT0002537 ppy-miR-204; +MIMAT0002538 sla-miR-204; +MIMAT0002539 mne-miR-204; +MIMAT0002540 ppa-miR-204; +MIMAT0002541 ggo-miR-205; +MIMAT0002542 age-miR-205; +MIMAT0002543 ppa-miR-205; +MIMAT0002544 ptr-miR-205; +MIMAT0002545 lla-miR-205; +MIMAT0002546 mne-miR-205; +MIMAT0002547 mml-miR-211; +MIMAT0002548 ppy-miR-211; +MIMAT0002549 mne-miR-211; +MIMAT0002550 ggo-miR-214; +MIMAT0002551 age-miR-214; +MIMAT0002552 ppa-miR-214; +MIMAT0002553 ppy-miR-214; +MIMAT0002554 ptr-miR-214; +MIMAT0002555 mml-miR-214;mml-miR-214-3p; +MIMAT0002556 sla-miR-214; +MIMAT0002557 mne-miR-214; +MIMAT0002558 lca-miR-216; +MIMAT0002559 ptr-miR-216;ptr-miR-216a; +MIMAT0002560 ggo-miR-216; +MIMAT0002561 ppy-miR-216;ppy-miR-216a; +MIMAT0002562 ppa-miR-216; +MIMAT0002563 ggo-miR-217; +MIMAT0002564 ppa-miR-217; +MIMAT0002565 ggo-miR-218; +MIMAT0002566 age-miR-218; +MIMAT0002567 ppa-miR-218; +MIMAT0002568 lca-miR-218; +MIMAT0002569 ppy-miR-218; +MIMAT0002570 ptr-miR-218; +MIMAT0002571 sla-miR-218; +MIMAT0002572 lla-miR-218; +MIMAT0002573 mne-miR-218; +MIMAT0002574 mml-miR-218;mml-miR-218-5p; +MIMAT0002575 mml-miR-219; +MIMAT0002576 ggo-miR-219; +MIMAT0002577 ppy-miR-219; +MIMAT0002578 mml-miR-220;mml-miR-220a; +MIMAT0002579 ptr-miR-220;ptr-miR-220a; +MIMAT0002580 ggo-miR-220; +MIMAT0002581 mne-miR-220; +MIMAT0002582 ppa-miR-220; +MIMAT0002583 mml-miR-221;mml-miR-221-3p; +MIMAT0002584 ggo-miR-221; +MIMAT0002585 ppy-miR-221; +MIMAT0002586 ppa-miR-221; +MIMAT0002587 age-miR-222; +MIMAT0002588 mml-miR-223; +MIMAT0002589 ptr-miR-223; +MIMAT0002590 ggo-miR-223; +MIMAT0002591 ppy-miR-223; +MIMAT0002592 sla-miR-223; +MIMAT0002593 ppa-miR-223; +MIMAT0002594 mml-miR-224;mml-miR-224-5p; +MIMAT0002595 ptr-miR-224; +MIMAT0002596 ggo-miR-224; +MIMAT0002597 ppy-miR-224; +MIMAT0002598 mne-miR-224; +MIMAT0002599 ppa-miR-224; +MIMAT0002600 ptr-miR-197; +MIMAT0002601 ppy-miR-197; +MIMAT0002602 mne-miR-197; +MIMAT0002603 age-miR-197; +MIMAT0002604 ppa-miR-197; +MIMAT0002605 ggo-miR-198; +MIMAT0002606 age-miR-198; +MIMAT0002607 ppa-miR-198; +MIMAT0002608 ppy-miR-198; +MIMAT0002609 ptr-miR-198; +MIMAT0002610 mml-miR-198; +MIMAT0002611 sla-miR-198; +MIMAT0002612 lla-miR-198; +MIMAT0002613 mne-miR-198; +MIMAT0002614 ptr-miR-30c; +MIMAT0002615 lla-miR-30c; +MIMAT0002616 mne-miR-30c; +MIMAT0002617 ptr-miR-30d; +MIMAT0002618 ggo-miR-30d; +MIMAT0002619 mne-miR-30d; +MIMAT0002620 ppa-miR-30d; +MIMAT0002621 ppa-miR-1; +MIMAT0002622 mml-miR-213;mml-miR-181a*;mml-miR-181a-3p; +MIMAT0002623 mml-miR-181b;mml-miR-181b-5p; +MIMAT0002624 ptr-miR-213;ptr-miR-181a*;ptr-miR-181a-3p; +MIMAT0002625 ptr-miR-181b; +MIMAT0002626 ppy-miR-181a;ppy-miR-181a-5p; +MIMAT0002627 ppy-miR-213;ppy-miR-181a*;ppy-miR-181a-3p; +MIMAT0002628 ppy-miR-181b; +MIMAT0002629 ggo-miR-213;ggo-miR-181a*;ggo-miR-181a-3p; +MIMAT0002630 ggo-miR-181b; +MIMAT0002631 lla-miR-181a;lla-miR-181a-5p; +MIMAT0002632 lla-miR-213;lla-miR-181a*;lla-miR-181a-3p; +MIMAT0002633 lla-miR-181b; +MIMAT0002634 mne-miR-213;mne-miR-181a*;mne-miR-181a-3p; +MIMAT0002635 mne-miR-181b; +MIMAT0002636 ppa-miR-213;ppa-miR-181a*;ppa-miR-181a-3p; +MIMAT0002637 ppa-miR-181b; +MIMAT0002638 age-miR-15a; +MIMAT0002639 age-miR-16; +MIMAT0002640 ggo-miR-15a; +MIMAT0002641 ggo-miR-16; +MIMAT0002642 mne-miR-15a; +MIMAT0002643 mne-miR-16; +MIMAT0002644 sla-miR-15a; +MIMAT0002645 sla-miR-16; +MIMAT0002646 ppa-miR-15a; +MIMAT0002647 ppa-miR-16; +MIMAT0002648 lca-miR-15a; +MIMAT0002649 lca-miR-16; +MIMAT0002650 mml-miR-15a;mml-miR-15a-5p; +MIMAT0002651 mml-miR-16;mml-miR-16-5p; +MIMAT0002652 ppy-miR-15a; +MIMAT0002653 ppy-miR-16; +MIMAT0002654 ptr-miR-15a; +MIMAT0002655 ptr-miR-16; +MIMAT0002656 lla-miR-15a; +MIMAT0002657 lla-miR-16; +MIMAT0002658 ggo-miR-17-5p; +MIMAT0002659 ggo-miR-17-3p; +MIMAT0002660 ggo-miR-18;ggo-miR-18a; +MIMAT0002661 ggo-miR-19a; +MIMAT0002662 ggo-miR-20;ggo-miR-20a; +MIMAT0002663 ggo-miR-19b; +MIMAT0002664 ggo-miR-92; +MIMAT0002665 lca-miR-17-5p; +MIMAT0002666 lca-miR-17-3p; +MIMAT0002667 lca-miR-18; +MIMAT0002668 lca-miR-19a; +MIMAT0002669 lca-miR-20; +MIMAT0002670 lca-miR-19b; +MIMAT0002671 lca-miR-92; +MIMAT0002672 age-miR-17-5p; +MIMAT0002673 age-miR-17-3p; +MIMAT0002674 age-miR-18; +MIMAT0002675 age-miR-19a; +MIMAT0002676 age-miR-20; +MIMAT0002677 age-miR-19b; +MIMAT0002678 age-miR-92; +MIMAT0002679 ppa-miR-17-5p; +MIMAT0002680 ppa-miR-17-3p; +MIMAT0002681 ppa-miR-18; +MIMAT0002682 ppa-miR-19a; +MIMAT0002683 ppa-miR-20; +MIMAT0002684 ppa-miR-19b; +MIMAT0002685 ppa-miR-92;ppa-miR-92a; +MIMAT0002686 ppy-miR-17-5p; +MIMAT0002687 ppy-miR-17-3p; +MIMAT0002688 ppy-miR-18;ppy-miR-18a; +MIMAT0002689 ppy-miR-19a; +MIMAT0002690 ppy-miR-20;ppy-miR-20a; +MIMAT0002691 ppy-miR-19b; +MIMAT0002692 ppy-miR-92; +MIMAT0002693 ptr-miR-17-5p; +MIMAT0002694 ptr-miR-17-3p; +MIMAT0002695 ptr-miR-18;ptr-miR-18a; +MIMAT0002696 ptr-miR-19a; +MIMAT0002697 ptr-miR-20;ptr-miR-20a; +MIMAT0002698 ptr-miR-19b; +MIMAT0002699 ptr-miR-92; +MIMAT0002700 mml-miR-17-5p; +MIMAT0002701 mml-miR-17-3p; +MIMAT0002702 mml-miR-18;mml-miR-18a;mml-miR-18a-5p; +MIMAT0002703 mml-miR-19a;mml-miR-19a-3p; +MIMAT0002704 mml-miR-20;mml-miR-20a;mml-miR-20a-5p; +MIMAT0002705 mml-miR-19b; +MIMAT0002706 mml-miR-92;mml-miR-92a;mml-miR-92a-3p; +MIMAT0002707 sla-miR-17-5p; +MIMAT0002708 sla-miR-17-3p; +MIMAT0002709 sla-miR-18; +MIMAT0002710 sla-miR-19a; +MIMAT0002711 sla-miR-20; +MIMAT0002712 sla-miR-19b; +MIMAT0002713 sla-miR-92; +MIMAT0002714 lla-miR-17-5p; +MIMAT0002715 lla-miR-17-3p; +MIMAT0002716 lla-miR-18; +MIMAT0002717 lla-miR-19a; +MIMAT0002718 lla-miR-20; +MIMAT0002719 lla-miR-19b; +MIMAT0002720 lla-miR-92; +MIMAT0002721 mne-miR-17-5p; +MIMAT0002722 mne-miR-17-3p; +MIMAT0002723 mne-miR-18; +MIMAT0002724 mne-miR-19a; +MIMAT0002725 mne-miR-20; +MIMAT0002726 mne-miR-19b; +MIMAT0002727 mml-miR-194;mml-miR-194-5p; +MIMAT0002728 mml-miR-215;mml-miR-215-5p; +MIMAT0002729 ptr-miR-194; +MIMAT0002730 ptr-miR-215; +MIMAT0002731 ppy-miR-194; +MIMAT0002732 ppy-miR-215; +MIMAT0002733 ggo-miR-194; +MIMAT0002734 ggo-miR-215; +MIMAT0002735 mne-miR-194; +MIMAT0002736 mne-miR-215; +MIMAT0002737 age-miR-194; +MIMAT0002738 ggo-miR-23a; +MIMAT0002739 ggo-miR-27a; +MIMAT0002740 ggo-miR-24; +MIMAT0002741 age-miR-23a; +MIMAT0002742 age-miR-27a; +MIMAT0002743 ppa-miR-23a; +MIMAT0002744 ppa-miR-27a; +MIMAT0002745 lca-miR-23a; +MIMAT0002746 lca-miR-27a; +MIMAT0002747 ppy-miR-23a; +MIMAT0002748 ppy-miR-27a; +MIMAT0002749 ptr-miR-23a; +MIMAT0002750 ptr-miR-27a; +MIMAT0002751 ptr-miR-24; +MIMAT0002752 mml-miR-23a;mml-miR-23a-3p; +MIMAT0002753 mml-miR-27a;mml-miR-27a-3p; +MIMAT0002754 sla-miR-23a; +MIMAT0002755 sla-miR-27a; +MIMAT0002756 mne-miR-23a; +MIMAT0002757 mne-miR-27a; +MIMAT0002758 ggo-miR-106b; +MIMAT0002759 ggo-miR-93; +MIMAT0002760 ggo-miR-25; +MIMAT0002761 age-miR-106b; +MIMAT0002762 age-miR-93; +MIMAT0002763 ppa-miR-106b; +MIMAT0002764 ppa-miR-93; +MIMAT0002765 ppa-miR-25; +MIMAT0002766 ppy-miR-106b; +MIMAT0002767 ppy-miR-93; +MIMAT0002768 ppy-miR-25; +MIMAT0002769 ptr-miR-106b; +MIMAT0002770 ptr-miR-93; +MIMAT0002771 ptr-miR-25; +MIMAT0002772 mml-miR-106b;mml-miR-106b-5p; +MIMAT0002773 mml-miR-93;mml-miR-93-5p; +MIMAT0002774 mml-miR-25; +MIMAT0002775 sla-miR-106b; +MIMAT0002776 sla-miR-93; +MIMAT0002777 lla-miR-106b; +MIMAT0002778 lla-miR-93; +MIMAT0002779 lla-miR-25; +MIMAT0002780 mne-miR-106b; +MIMAT0002781 mne-miR-93; +MIMAT0002782 mne-miR-25; +MIMAT0002783 mml-miR-183;mml-miR-183-5p; +MIMAT0002784 mml-miR-96; +MIMAT0002785 ptr-miR-183; +MIMAT0002786 ptr-miR-96; +MIMAT0002787 ggo-miR-183; +MIMAT0002788 ggo-miR-96; +MIMAT0002789 sla-miR-183; +MIMAT0002790 sla-miR-96; +MIMAT0002791 mne-miR-183; +MIMAT0002792 mne-miR-96; +MIMAT0002793 ppa-miR-183; +MIMAT0002794 ppa-miR-96; +MIMAT0002795 ggo-miR-106a; +MIMAT0002796 age-miR-106a; +MIMAT0002797 ppa-miR-106a; +MIMAT0002798 mml-miR-106a;mml-miR-106a-5p; +MIMAT0002799 ppy-miR-106a; +MIMAT0002800 ptr-miR-106a; +MIMAT0002801 sla-miR-106a; +MIMAT0002802 mne-miR-106a; +MIMAT0002803 mne-miR-92; +MIMAT0002804 hsa-miR-488;hsa-miR-488*;hsa-miR-488-5p; +MIMAT0002805 hsa-miR-489;hsa-miR-489-3p; +MIMAT0002806 hsa-miR-490;hsa-miR-490-3p; +MIMAT0002807 hsa-miR-491;hsa-miR-491-5p; +MIMAT0002808 hsa-miR-511;hsa-miR-511-5p; +MIMAT0002809 hsa-miR-146b;hsa-miR-146b-5p; +MIMAT0002810 hsa-miR-202*;hsa-miR-202-5p; +MIMAT0002811 hsa-miR-202;hsa-miR-202-3p; +MIMAT0002812 hsa-miR-492; +MIMAT0002813 hsa-miR-493;hsa-miR-493-5p;hsa-miR-493*;hsa-miR-493-5p; +MIMAT0002814 hsa-miR-432;hsa-miR-432-5p; +MIMAT0002815 hsa-miR-432*;hsa-miR-432-3p; +MIMAT0002816 hsa-miR-494;hsa-miR-494-3p; +MIMAT0002817 hsa-miR-495;hsa-miR-495-3p; +MIMAT0002818 hsa-miR-496; +MIMAT0002819 hsa-miR-193b;hsa-miR-193b-3p; +MIMAT0002820 hsa-miR-497;hsa-miR-497-5p; +MIMAT0002821 hsa-miR-181d;hsa-miR-181d-5p; +MIMAT0002822 hsa-miR-512-5p; +MIMAT0002823 hsa-miR-512-3p; +MIMAT0002824 hsa-miR-498;hsa-miR-498-5p; +MIMAT0002825 hsa-miR-520e;hsa-miR-520e-3p; +MIMAT0002826 hsa-miR-515-5p; +MIMAT0002827 hsa-miR-515-3p; +MIMAT0002828 hsa-miR-519e*;hsa-miR-519e-5p; +MIMAT0002829 hsa-miR-519e;hsa-miR-519e-3p; +MIMAT0002830 hsa-miR-520f;hsa-miR-520f-3p; +MIMAT0002831 hsa-miR-526c;hsa-miR-519c-5p; +MIMAT0002832 hsa-miR-519c;hsa-miR-519c-3p; +MIMAT0002833 hsa-miR-520a*;hsa-miR-520a-5p; +MIMAT0002834 hsa-miR-520a;hsa-miR-520a-3p; +MIMAT0002835 hsa-miR-526b;hsa-miR-526b-5p; +MIMAT0002836 hsa-miR-526b*;hsa-miR-526b-3p; +MIMAT0002837 hsa-miR-519b;hsa-miR-519b-3p; +MIMAT0002838 hsa-miR-525;hsa-miR-525-5p; +MIMAT0002839 hsa-miR-525*;hsa-miR-525-3p; +MIMAT0002840 hsa-miR-523;hsa-miR-523-3p; +MIMAT0002841 hsa-miR-518f*;hsa-miR-518f-5p; +MIMAT0002842 hsa-miR-518f;hsa-miR-518f-3p; +MIMAT0002843 hsa-miR-520b;hsa-miR-520b-3p; +MIMAT0002844 hsa-miR-518b; +MIMAT0002845 hsa-miR-526a;hsa-miR-526a-5p; +MIMAT0002846 hsa-miR-520c;hsa-miR-520c-3p; +MIMAT0002847 hsa-miR-518c*;hsa-miR-518c-5p; +MIMAT0002848 hsa-miR-518c;hsa-miR-518c-3p; +MIMAT0002849 hsa-miR-524*;hsa-miR-524-5p; +MIMAT0002850 hsa-miR-524;hsa-miR-524-3p; +MIMAT0002851 hsa-miR-517*;hsa-miR-517-5p; +MIMAT0002852 hsa-miR-517a;hsa-miR-517a-3p; +MIMAT0002853 hsa-miR-519d;hsa-miR-519d-3p; +MIMAT0002854 hsa-miR-521; +MIMAT0002855 hsa-miR-520d*;hsa-miR-520d-5p; +MIMAT0002856 hsa-miR-520d;hsa-miR-520d-3p; +MIMAT0002857 hsa-miR-517b;hsa-miR-517b-3p; +MIMAT0002858 hsa-miR-520g;hsa-miR-520g-3p; +MIMAT0002859 hsa-miR-516-5p;hsa-miR-516b;hsa-miR-516b-5p; +MIMAT0002860 hsa-miR-516-3p;hsa-miR-516b*;hsa-miR-516a-3p;hsa-miR-516b*;hsa-miR-516a-3p;hsa-miR-516b*;hsa-miR-516b-3p; +MIMAT0002861 hsa-miR-518e;hsa-miR-518e-3p; +MIMAT0002862 hsa-miR-527; +MIMAT0002863 hsa-miR-518a;hsa-miR-518a-3p; +MIMAT0002864 hsa-miR-518d;hsa-miR-518d-3p; +MIMAT0002865 hsa-miR-518a-2*; +MIMAT0002866 hsa-miR-517c;hsa-miR-517c-3p; +MIMAT0002867 hsa-miR-520h; +MIMAT0002868 hsa-miR-522;hsa-miR-522-3p; +MIMAT0002869 hsa-miR-519a;hsa-miR-519a-3p; +MIMAT0002870 hsa-miR-499;hsa-miR-499-5p;hsa-miR-499a-5p; +MIMAT0002871 hsa-miR-500;hsa-miR-500*;hsa-miR-500a*;hsa-miR-500a-3p; +MIMAT0002872 hsa-miR-501;hsa-miR-501-5p; +MIMAT0002873 hsa-miR-502;hsa-miR-502-5p; +MIMAT0002874 hsa-miR-503;hsa-miR-503-5p; +MIMAT0002875 hsa-miR-504;hsa-miR-504-5p; +MIMAT0002876 hsa-miR-505;hsa-miR-505-3p; +MIMAT0002877 hsa-miR-513;hsa-miR-513-5p;hsa-miR-513a-5p; +MIMAT0002878 hsa-miR-506;hsa-miR-506-3p; +MIMAT0002879 hsa-miR-507; +MIMAT0002880 hsa-miR-508;hsa-miR-508-3p; +MIMAT0002881 hsa-miR-509;hsa-miR-509-3p; +MIMAT0002882 hsa-miR-510;hsa-miR-510-5p; +MIMAT0002883 hsa-miR-514;hsa-miR-514a-3p; +MIMAT0002884 osa-miR528;osa-miR528-5p; +MIMAT0002885 osa-miR529;osa-miR529a; +MIMAT0002886 osa-miR530;osa-miR530-3p; +MIMAT0002887 osa-miR531;osa-miR531a; +MIMAT0002888 hsa-miR-532;hsa-miR-532-5p; +MIMAT0002889 mmu-miR-532;mmu-miR-532-5p; +MIMAT0002890 hsa-miR-299-5p; +MIMAT0002891 hsa-miR-18a*;hsa-miR-18a-3p; +MIMAT0002892 fru-let-7h; +MIMAT0002893 tni-let-7h; +MIMAT0002894 fru-miR-223; +MIMAT0002895 tni-miR-223; +MIMAT0002896 fru-miR-124; +MIMAT0002897 tni-miR-124; +MIMAT0002898 fru-let-7e; +MIMAT0002899 tni-let-7e; +MIMAT0002900 fru-miR-219; +MIMAT0002901 tni-miR-219; +MIMAT0002902 fru-miR-101a; +MIMAT0002903 tni-miR-101a; +MIMAT0002904 fru-miR-222; +MIMAT0002905 tni-miR-222; +MIMAT0002906 fru-miR-221; +MIMAT0002907 tni-miR-221; +MIMAT0002908 fru-miR-142a;fru-miR-142; +MIMAT0002909 tni-miR-142a; +MIMAT0002910 fru-miR-9; +MIMAT0002911 tni-miR-9; +MIMAT0002912 fru-miR-23a; +MIMAT0002913 tni-miR-23a; +MIMAT0002914 fru-miR-25; +MIMAT0002915 tni-miR-25; +MIMAT0002916 fru-miR-17; +MIMAT0002917 tni-miR-17; +MIMAT0002918 fru-miR-18; +MIMAT0002919 tni-miR-18; +MIMAT0002920 fru-miR-19a; +MIMAT0002921 tni-miR-19a; +MIMAT0002922 fru-miR-19b; +MIMAT0002923 tni-miR-19b; +MIMAT0002924 fru-miR-92; +MIMAT0002925 tni-miR-92; +MIMAT0002926 fru-miR-184; +MIMAT0002927 tni-miR-184; +MIMAT0002928 fru-let-7a; +MIMAT0002929 tni-let-7a; +MIMAT0002930 fru-miR-187; +MIMAT0002931 tni-miR-187; +MIMAT0002932 fru-miR-137; +MIMAT0002933 tni-miR-137; +MIMAT0002934 fru-miR-204b; +MIMAT0002935 tni-miR-204b; +MIMAT0002936 fru-miR-458; +MIMAT0002937 tni-miR-458; +MIMAT0002938 fru-miR-489; +MIMAT0002939 tni-miR-489; +MIMAT0002940 dre-miR-489; +MIMAT0002941 fru-miR-192; +MIMAT0002942 tni-miR-192; +MIMAT0002943 fru-miR-194; +MIMAT0002944 tni-miR-194; +MIMAT0002945 fru-miR-142b; +MIMAT0002946 tni-miR-142b; +MIMAT0002947 fru-miR-30b; +MIMAT0002948 tni-miR-30b; +MIMAT0002949 fru-miR-30d; +MIMAT0002950 tni-miR-30d; +MIMAT0002951 fru-miR-27b; +MIMAT0002952 tni-miR-27b; +MIMAT0002953 fru-miR-23b; +MIMAT0002954 tni-miR-23b; +MIMAT0002955 fru-miR-196a; +MIMAT0002956 tni-miR-196a; +MIMAT0002957 fru-miR-126; +MIMAT0002958 tni-miR-126; +MIMAT0002959 fru-miR-199; +MIMAT0002960 tni-miR-199; +MIMAT0002961 fru-miR-148; +MIMAT0002962 tni-miR-148; +MIMAT0002963 fru-miR-10b; +MIMAT0002964 tni-miR-10b; +MIMAT0002965 fru-miR-205; +MIMAT0002966 tni-miR-205; +MIMAT0002967 fru-miR-365; +MIMAT0002968 tni-miR-365; +MIMAT0002969 fru-miR-193; +MIMAT0002970 tni-miR-193; +MIMAT0002971 fru-miR-217; +MIMAT0002972 tni-miR-217; +MIMAT0002973 fru-miR-216a; +MIMAT0002974 tni-miR-216a; +MIMAT0002975 fru-miR-216b; +MIMAT0002976 tni-miR-216b; +MIMAT0002977 fru-let-7i; +MIMAT0002978 tni-let-7i; +MIMAT0002979 fru-miR-429; +MIMAT0002980 tni-miR-429; +MIMAT0002981 fru-miR-200a; +MIMAT0002982 tni-miR-200a; +MIMAT0002983 fru-miR-200b; +MIMAT0002984 tni-miR-200b; +MIMAT0002985 fru-miR-218b; +MIMAT0002986 tni-miR-218b; +MIMAT0002987 fru-miR-301; +MIMAT0002988 tni-miR-301; +MIMAT0002989 fru-miR-130; +MIMAT0002990 tni-miR-130; +MIMAT0002991 fru-miR-122; +MIMAT0002992 tni-miR-122; +MIMAT0002993 fru-miR-218a; +MIMAT0002994 tni-miR-218a; +MIMAT0002995 fru-let-7d; +MIMAT0002996 tni-let-7d; +MIMAT0002997 fru-miR-460; +MIMAT0002998 tni-miR-460; +MIMAT0002999 fru-miR-21; +MIMAT0003000 tni-miR-21; +MIMAT0003001 fru-miR-153b; +MIMAT0003002 tni-miR-153b; +MIMAT0003003 fru-miR-181b; +MIMAT0003004 tni-miR-181b; +MIMAT0003005 fru-miR-213;fru-miR-181a*;fru-miR-181a-3p; +MIMAT0003006 tni-miR-213;tni-miR-181a*;tni-miR-181a-3p; +MIMAT0003007 fru-miR-338; +MIMAT0003008 tni-miR-338; +MIMAT0003009 fru-miR-7; +MIMAT0003010 tni-miR-7; +MIMAT0003011 fru-miR-153a; +MIMAT0003012 tni-miR-153a; +MIMAT0003013 fru-let-7j; +MIMAT0003014 tni-let-7j; +MIMAT0003015 dre-let-7j; +MIMAT0003016 fru-let-7b; +MIMAT0003017 tni-let-7b; +MIMAT0003018 fru-miR-128; +MIMAT0003019 tni-miR-128; +MIMAT0003020 fru-miR-144; +MIMAT0003021 tni-miR-144; +MIMAT0003022 fru-miR-30c; +MIMAT0003023 tni-miR-30c; +MIMAT0003024 fru-miR-140; +MIMAT0003025 tni-miR-140; +MIMAT0003026 fru-miR-214; +MIMAT0003027 tni-miR-214; +MIMAT0003028 fru-miR-455; +MIMAT0003029 tni-miR-455; +MIMAT0003030 fru-miR-135b; +MIMAT0003031 tni-miR-135b; +MIMAT0003032 dre-miR-135b;dre-miR-135b-5p; +MIMAT0003033 fru-miR-196b; +MIMAT0003034 tni-miR-196b; +MIMAT0003035 fru-miR-129; +MIMAT0003036 tni-miR-129; +MIMAT0003037 fru-miR-26; +MIMAT0003038 tni-miR-26; +MIMAT0003039 fru-miR-101b; +MIMAT0003040 tni-miR-101b; +MIMAT0003041 fru-miR-103; +MIMAT0003042 tni-miR-103; +MIMAT0003043 fru-miR-107; +MIMAT0003044 tni-miR-107; +MIMAT0003045 fru-miR-22b; +MIMAT0003046 tni-miR-22b; +MIMAT0003047 fru-miR-212; +MIMAT0003048 tni-miR-212; +MIMAT0003049 dre-miR-212; +MIMAT0003050 tni-miR-181a;tni-miR-181a-5p; +MIMAT0003051 fru-miR-135a; +MIMAT0003052 tni-miR-135a; +MIMAT0003053 fru-miR-29a; +MIMAT0003054 tni-miR-29a; +MIMAT0003055 fru-miR-29b; +MIMAT0003056 tni-miR-29b; +MIMAT0003057 fru-miR-133; +MIMAT0003058 tni-miR-133; +MIMAT0003059 fru-miR-132; +MIMAT0003060 tni-miR-132; +MIMAT0003061 fru-miR-125b; +MIMAT0003062 tni-miR-125b; +MIMAT0003063 fru-miR-100; +MIMAT0003064 tni-miR-100; +MIMAT0003065 fru-miR-24;fru-miR-24-3p; +MIMAT0003066 tni-miR-24; +MIMAT0003067 fru-miR-27e; +MIMAT0003068 tni-miR-27e; +MIMAT0003069 fru-miR-375; +MIMAT0003070 tni-miR-375; +MIMAT0003071 fru-miR-1; +MIMAT0003072 tni-miR-1; +MIMAT0003073 fru-miR-202; +MIMAT0003074 tni-miR-202; +MIMAT0003075 fru-miR-203; +MIMAT0003076 tni-miR-203; +MIMAT0003077 fru-miR-27c; +MIMAT0003078 tni-miR-27c; +MIMAT0003079 fru-miR-138; +MIMAT0003080 tni-miR-138; +MIMAT0003081 fru-miR-125a; +MIMAT0003082 tni-miR-125a; +MIMAT0003083 fru-miR-20; +MIMAT0003084 tni-miR-20; +MIMAT0003085 fru-miR-15b; +MIMAT0003086 tni-miR-15b; +MIMAT0003087 fru-miR-10c; +MIMAT0003088 tni-miR-10c; +MIMAT0003089 fru-miR-183; +MIMAT0003090 tni-miR-183; +MIMAT0003091 fru-miR-96; +MIMAT0003092 tni-miR-96; +MIMAT0003093 fru-miR-182; +MIMAT0003094 tni-miR-182; +MIMAT0003095 fru-miR-210; +MIMAT0003096 tni-miR-210; +MIMAT0003097 fru-let-7g; +MIMAT0003098 tni-let-7g; +MIMAT0003099 fru-miR-22a; +MIMAT0003100 tni-miR-22a; +MIMAT0003101 fru-miR-204a;fru-miR-204;fru-miR-204a; +MIMAT0003102 tni-miR-204a; +MIMAT0003103 fru-miR-152; +MIMAT0003104 tni-miR-152; +MIMAT0003105 fru-miR-15a; +MIMAT0003106 tni-miR-15a; +MIMAT0003107 fru-miR-16; +MIMAT0003108 tni-miR-16; +MIMAT0003109 fru-miR-190; +MIMAT0003110 tni-miR-190; +MIMAT0003111 fru-miR-181a;fru-miR-181a-5p; +MIMAT0003112 mmu-miR-489;mmu-miR-489-3p; +MIMAT0003113 rno-miR-489;rno-miR-489-3p; +MIMAT0003114 rno-miR-383;rno-miR-383-5p; +MIMAT0003115 rno-miR-207; +MIMAT0003116 rno-miR-501;rno-miR-501-5p; +MIMAT0003117 rno-miR-361;rno-miR-361-5p; +MIMAT0003118 rno-miR-215; +MIMAT0003119 rno-miR-224;rno-miR-224-5p; +MIMAT0003120 mmu-miR-483;mmu-miR-483*;mmu-miR-483-3p; +MIMAT0003121 rno-miR-483;rno-miR-483-3p; +MIMAT0003122 rno-miR-370;rno-miR-370-3p; +MIMAT0003123 rno-miR-377;rno-miR-377-3p; +MIMAT0003124 rno-miR-412;rno-miR-412-3p; +MIMAT0003125 rno-miR-1;rno-miR-1-3p; +MIMAT0003126 rno-miR-133b;rno-miR-133b-3p; +MIMAT0003127 mmu-miR-484; +MIMAT0003128 mmu-miR-485-5p;mmu-miR-485;mmu-miR-485-5p; +MIMAT0003129 mmu-miR-485-3p;mmu-miR-485*;mmu-miR-485-3p; +MIMAT0003130 mmu-miR-486;mmu-miR-486-5p;mmu-miR-486a-5p; +MIMAT0003131 ppt-miR390a; +MIMAT0003132 ppt-miR390b; +MIMAT0003133 ppt-miR319a; +MIMAT0003134 ppt-miR319b; +MIMAT0003135 ppt-miR319c; +MIMAT0003136 ppt-miR319d;ppt-miR319d-3p; +MIMAT0003137 ppt-miR533;ppt-miR533a;ppt-miR533a*;ppt-miR533a-5p; +MIMAT0003138 ppt-miR534;ppt-miR534a; +MIMAT0003139 ppt-miR535a; +MIMAT0003140 ppt-miR535b; +MIMAT0003141 ppt-miR535c; +MIMAT0003142 osa-miR535;osa-miR535-5p; +MIMAT0003143 ppt-miR156a; +MIMAT0003144 ppt-miR536;ppt-miR536a; +MIMAT0003145 ppt-miR537a; +MIMAT0003146 ppt-miR537b; +MIMAT0003147 ppt-miR538a; +MIMAT0003148 ppt-miR538b; +MIMAT0003149 ppt-miR538c; +MIMAT0003150 hsa-miR-455;hsa-miR-455-5p; +MIMAT0003151 mmu-miR-422b;mmu-miR-378;mmu-miR-378-3p;mmu-miR-378a-3p; +MIMAT0003152 rno-miR-22*;rno-miR-22-5p; +MIMAT0003153 rno-miR-189;rno-miR-24-1*;rno-miR-24-1-5p; +MIMAT0003154 rno-miR-29c*;rno-miR-29c-5p; +MIMAT0003155 dre-miR-199*;dre-miR-199-3p; +MIMAT0003156 dre-miR-9*;dre-miR-9-3p; +MIMAT0003157 dre-miR-126*;dre-miR-126a*;dre-miR-126a-5p; +MIMAT0003158 dre-miR-129*;dre-miR-129-3p; +MIMAT0003159 dre-miR-140*;dre-miR-140-3p; +MIMAT0003160 dre-miR-142a-3p; +MIMAT0003161 hsa-miR-493-3p;hsa-miR-493;hsa-miR-493-3p; +MIMAT0003162 rno-miR-1*;rno-miR-1-5p; +MIMAT0003163 hsa-miR-539;hsa-miR-539-5p; +MIMAT0003164 hsa-miR-544;hsa-miR-544a; +MIMAT0003165 hsa-miR-545;hsa-miR-545-3p; +MIMAT0003166 mmu-miR-546; +MIMAT0003167 mmu-miR-540;mmu-miR-540-3p; +MIMAT0003168 mmu-miR-543;mmu-miR-543-3p; +MIMAT0003169 mmu-miR-539;mmu-miR-539-5p; +MIMAT0003170 mmu-miR-541;mmu-miR-541-5p; +MIMAT0003171 mmu-miR-542-5p; +MIMAT0003172 mmu-miR-542-3p; +MIMAT0003173 mmu-miR-547;mmu-miR-547-3p; +MIMAT0003174 rno-miR-540;rno-miR-540-3p; +MIMAT0003175 rno-miR-543;rno-miR-543*;rno-miR-543-3p; +MIMAT0003176 rno-miR-539;rno-miR-539-5p; +MIMAT0003177 rno-miR-541;rno-miR-541-5p; +MIMAT0003178 rno-miR-542-5p; +MIMAT0003179 rno-miR-542-3p; +MIMAT0003180 hsa-miR-487b;hsa-miR-487b-3p; +MIMAT0003181 mmu-miR-367;mmu-miR-367-3p; +MIMAT0003182 mmu-miR-494;mmu-miR-494-3p; +MIMAT0003183 mmu-miR-376c;mmu-miR-376c-3p; +MIMAT0003184 mmu-miR-487b;mmu-miR-487b-3p; +MIMAT0003185 mmu-miR-369-5p; +MIMAT0003186 mmu-miR-369-3p; +MIMAT0003187 mmu-miR-20b;mmu-miR-20b-5p; +MIMAT0003188 mmu-miR-503;mmu-miR-503-5p; +MIMAT0003189 mmu-miR-291b-5p; +MIMAT0003190 mmu-miR-291b-3p; +MIMAT0003191 rno-miR-493;rno-miR-493-3p; +MIMAT0003192 rno-miR-379;rno-miR-379-5p; +MIMAT0003193 rno-miR-494;rno-miR-494-3p; +MIMAT0003194 rno-miR-376c;rno-miR-376c-3p; +MIMAT0003195 rno-miR-376b*;rno-miR-376b-5p; +MIMAT0003196 rno-miR-376b;rno-miR-376b-3p; +MIMAT0003197 rno-miR-376a*;rno-miR-376a-5p; +MIMAT0003198 rno-miR-376a;rno-miR-376a-3p; +MIMAT0003199 rno-miR-381;rno-miR-381-3p; +MIMAT0003200 rno-miR-487b;rno-miR-487b-3p; +MIMAT0003201 rno-miR-382;rno-miR-382-5p; +MIMAT0003202 rno-miR-382*;rno-miR-382-3p; +MIMAT0003203 rno-miR-485;rno-miR-485-5p; +MIMAT0003204 rno-miR-409-5p;rno-miR-409a-5p; +MIMAT0003205 rno-miR-409-3p;rno-miR-409a-3p; +MIMAT0003206 rno-miR-369-5p; +MIMAT0003207 rno-miR-369-3p; +MIMAT0003208 rno-miR-374;rno-miR-374-5p; +MIMAT0003209 rno-miR-363-5p;rno-miR-363*;rno-miR-363-5p; +MIMAT0003210 rno-miR-363-3p;rno-miR-363;rno-miR-363-3p; +MIMAT0003211 rno-miR-20b;rno-miR-20b-5p; +MIMAT0003212 rno-miR-20b*;rno-miR-20b-3p; +MIMAT0003213 rno-miR-503;rno-miR-503-5p; +MIMAT0003214 hsa-miR-551a; +MIMAT0003215 hsa-miR-552;hsa-miR-552-3p; +MIMAT0003216 hsa-miR-553; +MIMAT0003217 hsa-miR-554; +MIMAT0003218 hsa-miR-92b;hsa-miR-92b-3p; +MIMAT0003219 hsa-miR-555; +MIMAT0003220 hsa-miR-556;hsa-miR-556-5p; +MIMAT0003221 hsa-miR-557; +MIMAT0003222 hsa-miR-558; +MIMAT0003223 hsa-miR-559; +MIMAT0003224 hsa-miR-560; +MIMAT0003225 hsa-miR-561;hsa-miR-561-3p; +MIMAT0003226 hsa-miR-562; +MIMAT0003227 hsa-miR-563; +MIMAT0003228 hsa-miR-564; +MIMAT0003229 hsa-miR-565; +MIMAT0003230 hsa-miR-566; +MIMAT0003231 hsa-miR-567; +MIMAT0003232 hsa-miR-568; +MIMAT0003233 hsa-miR-551b;hsa-miR-551b-3p; +MIMAT0003234 hsa-miR-569; +MIMAT0003235 hsa-miR-570;hsa-miR-570-3p; +MIMAT0003236 hsa-miR-571; +MIMAT0003237 hsa-miR-572; +MIMAT0003238 hsa-miR-573; +MIMAT0003239 hsa-miR-574;hsa-miR-574-3p; +MIMAT0003240 hsa-miR-575; +MIMAT0003241 hsa-miR-576;hsa-miR-576-5p; +MIMAT0003242 hsa-miR-577; +MIMAT0003243 hsa-miR-578; +MIMAT0003244 hsa-miR-579;hsa-miR-579-3p; +MIMAT0003245 hsa-miR-580;hsa-miR-580-3p; +MIMAT0003246 hsa-miR-581; +MIMAT0003247 hsa-miR-582;hsa-miR-582-5p; +MIMAT0003248 hsa-miR-583; +MIMAT0003249 hsa-miR-584;hsa-miR-584-5p; +MIMAT0003250 hsa-miR-585;hsa-miR-585-3p; +MIMAT0003251 hsa-miR-548a;hsa-miR-548a-3p; +MIMAT0003252 hsa-miR-586; +MIMAT0003253 hsa-miR-587; +MIMAT0003254 hsa-miR-548b;hsa-miR-548b-3p; +MIMAT0003255 hsa-miR-588; +MIMAT0003256 hsa-miR-589;hsa-miR-589*;hsa-miR-589-3p; +MIMAT0003257 hsa-miR-550;hsa-miR-550*;hsa-miR-550a*;hsa-miR-550a-3p; +MIMAT0003258 hsa-miR-590;hsa-miR-590-5p; +MIMAT0003259 hsa-miR-591; +MIMAT0003260 hsa-miR-592; +MIMAT0003261 hsa-miR-593;hsa-miR-593*;hsa-miR-593-5p; +MIMAT0003262 hsa-miR-594; +MIMAT0003263 hsa-miR-595; +MIMAT0003264 hsa-miR-596; +MIMAT0003265 hsa-miR-597;hsa-miR-597-5p; +MIMAT0003266 hsa-miR-598;hsa-miR-598-3p; +MIMAT0003267 hsa-miR-599; +MIMAT0003268 hsa-miR-600; +MIMAT0003269 hsa-miR-601; +MIMAT0003270 hsa-miR-602; +MIMAT0003271 hsa-miR-603; +MIMAT0003272 hsa-miR-604; +MIMAT0003273 hsa-miR-605;hsa-miR-605-5p; +MIMAT0003274 hsa-miR-606; +MIMAT0003275 hsa-miR-607; +MIMAT0003276 hsa-miR-608; +MIMAT0003277 hsa-miR-609; +MIMAT0003278 hsa-miR-610; +MIMAT0003279 hsa-miR-611; +MIMAT0003280 hsa-miR-612; +MIMAT0003281 hsa-miR-613; +MIMAT0003282 hsa-miR-614; +MIMAT0003283 hsa-miR-615;hsa-miR-615-3p; +MIMAT0003284 hsa-miR-616;hsa-miR-616*;hsa-miR-616-5p; +MIMAT0003285 hsa-miR-548c;hsa-miR-548c-3p; +MIMAT0003286 hsa-miR-617; +MIMAT0003287 hsa-miR-618; +MIMAT0003288 hsa-miR-619;hsa-miR-619-3p; +MIMAT0003289 hsa-miR-620; +MIMAT0003290 hsa-miR-621; +MIMAT0003291 hsa-miR-622; +MIMAT0003292 hsa-miR-623; +MIMAT0003293 hsa-miR-624;hsa-miR-624*;hsa-miR-624-5p; +MIMAT0003294 hsa-miR-625;hsa-miR-625-5p; +MIMAT0003295 hsa-miR-626; +MIMAT0003296 hsa-miR-627;hsa-miR-627-5p; +MIMAT0003297 hsa-miR-628;hsa-miR-628-3p; +MIMAT0003298 hsa-miR-629;hsa-miR-629*;hsa-miR-629-3p; +MIMAT0003299 hsa-miR-630; +MIMAT0003300 hsa-miR-631; +MIMAT0003301 hsa-miR-33b;hsa-miR-33b-5p; +MIMAT0003302 hsa-miR-632; +MIMAT0003303 hsa-miR-633; +MIMAT0003304 hsa-miR-634; +MIMAT0003305 hsa-miR-635; +MIMAT0003306 hsa-miR-636; +MIMAT0003307 hsa-miR-637; +MIMAT0003308 hsa-miR-638; +MIMAT0003309 hsa-miR-639; +MIMAT0003310 hsa-miR-640; +MIMAT0003311 hsa-miR-641; +MIMAT0003312 hsa-miR-642;hsa-miR-642a;hsa-miR-642a-5p; +MIMAT0003313 hsa-miR-643; +MIMAT0003314 hsa-miR-644;hsa-miR-644a; +MIMAT0003315 hsa-miR-645; +MIMAT0003316 hsa-miR-646; +MIMAT0003317 hsa-miR-647; +MIMAT0003318 hsa-miR-648; +MIMAT0003319 hsa-miR-649; +MIMAT0003320 hsa-miR-650; +MIMAT0003321 hsa-miR-651;hsa-miR-651-5p; +MIMAT0003322 hsa-miR-652;hsa-miR-652-3p; +MIMAT0003323 hsa-miR-548d;hsa-miR-548d-3p; +MIMAT0003324 hsa-miR-661; +MIMAT0003325 hsa-miR-662; +MIMAT0003326 hsa-miR-663;hsa-miR-663a; +MIMAT0003327 hsa-miR-449b;hsa-miR-449b-5p; +MIMAT0003328 hsa-miR-653;hsa-miR-653-5p; +MIMAT0003329 hsa-miR-411;hsa-miR-411-5p; +MIMAT0003330 hsa-miR-654;hsa-miR-654-5p; +MIMAT0003331 hsa-miR-655;hsa-miR-655-3p; +MIMAT0003332 hsa-miR-656;hsa-miR-656-3p; +MIMAT0003333 hsa-miR-549;hsa-miR-549a;hsa-miR-549a-3p; +MIMAT0003335 hsa-miR-657; +MIMAT0003336 hsa-miR-658; +MIMAT0003337 hsa-miR-659;hsa-miR-659-3p; +MIMAT0003338 hsa-miR-660;hsa-miR-660-5p; +MIMAT0003339 hsa-miR-421; +MIMAT0003340 hsa-miR-542-5p; +MIMAT0003341 hcmv-miR-US4;hcmv-miR-US4-5p; +MIMAT0003342 hcmv-miR-UL70-5p; +MIMAT0003343 hcmv-miR-UL70-3p; +MIMAT0003344 sv40-miR-S1-5p; +MIMAT0003345 sv40-miR-S1-3p; +MIMAT0003346 dre-miR-34b; +MIMAT0003347 dre-miR-31; +MIMAT0003348 dre-miR-135a; +MIMAT0003349 dre-miR-139;dre-miR-139-5p; +MIMAT0003350 gga-miR-9*;gga-miR-9-3p; +MIMAT0003351 gga-miR-146b;gga-miR-146b-5p; +MIMAT0003352 gga-miR-147; +MIMAT0003353 gga-miR-193;gga-miR-193b;gga-miR-193b-3p; +MIMAT0003354 gga-miR-202*;gga-miR-202-5p; +MIMAT0003355 gga-miR-202;gga-miR-202-3p; +MIMAT0003356 gga-miR-302b*;gga-miR-302b-5p; +MIMAT0003357 gga-miR-302b;gga-miR-302b-3p; +MIMAT0003358 gga-miR-302c*;gga-miR-302c-5p; +MIMAT0003359 gga-miR-302c;gga-miR-302c-3p; +MIMAT0003360 gga-miR-302d; +MIMAT0003361 gga-miR-365;gga-miR-365-3p; +MIMAT0003362 gga-miR-375; +MIMAT0003363 gga-miR-383;gga-miR-383-5p; +MIMAT0003364 gga-miR-455;gga-miR-455-5p; +MIMAT0003365 gga-miR-489;gga-miR-489-3p; +MIMAT0003366 gga-miR-490;gga-miR-490-3p; +MIMAT0003367 gga-miR-499;gga-miR-499-5p; +MIMAT0003368 gga-miR-211; +MIMAT0003369 gga-miR-367; +MIMAT0003370 gga-miR-466; +MIMAT0003371 gga-miR-429;gga-miR-429-3p; +MIMAT0003372 gga-miR-449;gga-miR-449a; +MIMAT0003373 mmu-miR-302b*;mmu-miR-302b-5p; +MIMAT0003374 mmu-miR-302b;mmu-miR-302b-3p; +MIMAT0003375 mmu-miR-302c*;mmu-miR-302c-5p; +MIMAT0003376 mmu-miR-302c;mmu-miR-302c-3p; +MIMAT0003377 mmu-miR-302d;mmu-miR-302d-3p; +MIMAT0003378 rno-miR-378;rno-miR-378*;rno-miR-378a-5p; +MIMAT0003379 rno-miR-422b;rno-miR-378;rno-miR-378a-3p; +MIMAT0003380 rno-miR-505;rno-miR-505-3p; +MIMAT0003381 rno-miR-499;rno-miR-499-5p; +MIMAT0003382 rno-miR-664;rno-miR-664-3p; +MIMAT0003383 rno-miR-497;rno-miR-497-5p; +MIMAT0003384 fru-miR-189;fru-miR-24-5p; +MIMAT0003385 hsa-miR-363*;hsa-miR-363-5p; +MIMAT0003386 hsa-miR-376a*;hsa-miR-376a-5p; +MIMAT0003387 mmu-miR-376a*;mmu-miR-376a-5p; +MIMAT0003388 mmu-miR-376b*;mmu-miR-376b-5p; +MIMAT0003389 hsa-miR-542-3p; +MIMAT0003390 ebv-miR-BART1-3p; +MIMAT0003391 dre-miR-10a*;dre-miR-10a-3p; +MIMAT0003392 dre-miR-210*;dre-miR-210-5p; +MIMAT0003393 hsa-miR-425-5p;hsa-miR-425;hsa-miR-425-5p; +MIMAT0003394 dre-miR-10d*;dre-miR-10d-3p; +MIMAT0003395 dre-miR-15a*;dre-miR-15a-3p; +MIMAT0003396 dre-miR-17a*;dre-miR-17a-3p; +MIMAT0003397 dre-miR-18b*;dre-miR-18b-3p; +MIMAT0003398 dre-miR-19a*;dre-miR-19a-5p; +MIMAT0003399 dre-miR-19b*;dre-miR-19b-5p; +MIMAT0003400 dre-miR-20a*;dre-miR-20a-3p; +MIMAT0003401 dre-miR-27c*;dre-miR-27c-5p; +MIMAT0003402 dre-miR-30e*;dre-miR-30e-3p; +MIMAT0003403 dre-miR-132*;dre-miR-132-5p; +MIMAT0003404 dre-miR-133a*;dre-miR-133a-5p; +MIMAT0003405 dre-miR-133b*;dre-miR-133b-5p; +MIMAT0003406 dre-miR-202*;dre-miR-202-5p; +MIMAT0003407 dre-miR-203b*;dre-miR-203b-5p; +MIMAT0003408 dre-miR-459*;dre-miR-459-3p; +MIMAT0003409 mmu-miR-467*;mmu-miR-467a;mmu-miR-467a-5p; +MIMAT0003410 ebv-miR-BART3-5p;ebv-miR-BART3*;ebv-miR-BART3-5p; +MIMAT0003411 ebv-miR-BART3-3p;ebv-miR-BART3;ebv-miR-BART3-3p; +MIMAT0003412 ebv-miR-BART4;ebv-miR-BART4-5p; +MIMAT0003413 ebv-miR-BART5;ebv-miR-BART5-5p; +MIMAT0003414 ebv-miR-BART6-5p; +MIMAT0003415 ebv-miR-BART6-3p; +MIMAT0003416 ebv-miR-BART7;ebv-miR-BART7-3p; +MIMAT0003417 ebv-miR-BART8-5p;ebv-miR-BART8;ebv-miR-BART8-5p; +MIMAT0003418 ebv-miR-BART8-3p;ebv-miR-BART8*;ebv-miR-BART8-3p; +MIMAT0003419 ebv-miR-BART9;ebv-miR-BART9-3p; +MIMAT0003420 ebv-miR-BART10;ebv-miR-BART10-3p; +MIMAT0003421 ebv-miR-BART11-5p; +MIMAT0003422 ebv-miR-BART11-3p; +MIMAT0003423 ebv-miR-BART12; +MIMAT0003424 ebv-miR-BART13;ebv-miR-BART13-3p; +MIMAT0003425 ebv-miR-BART14-5p;ebv-miR-BART14*;ebv-miR-BART14-5p; +MIMAT0003426 ebv-miR-BART14-3p;ebv-miR-BART14;ebv-miR-BART14-3p; +MIMAT0003427 rlcv-miR-rL1-1;rlcv-miR-rL1-1-5p; +MIMAT0003428 rlcv-miR-rL1-2;rlcv-miR-rL1-2-3p; +MIMAT0003429 rlcv-miR-rL1-3;rlcv-miR-rL1-3-3p; +MIMAT0003430 rlcv-miR-rL1-4-5p; +MIMAT0003431 rlcv-miR-rL1-4-3p; +MIMAT0003432 rlcv-miR-rL1-5-5p; +MIMAT0003433 rlcv-miR-rL1-5-3p; +MIMAT0003434 rlcv-miR-rL1-6-5p; +MIMAT0003435 rlcv-miR-rL1-6-3p;rlcv-miR-rL1-6;rlcv-miR-rL1-6-3p; +MIMAT0003436 rlcv-miR-rL1-7;rlcv-miR-rL1-7-5p; +MIMAT0003437 rlcv-miR-rL1-8;rlcv-miR-rL1-8-5p; +MIMAT0003438 rlcv-miR-rL1-9;rlcv-miR-rL1-9-3p; +MIMAT0003439 rlcv-miR-rL1-10;rlcv-miR-rL1-10-3p; +MIMAT0003440 rlcv-miR-rL1-11;rlcv-miR-rL1-11-3p; +MIMAT0003441 rlcv-miR-rL1-12-5p; +MIMAT0003442 rlcv-miR-rL1-12-3p; +MIMAT0003443 rlcv-miR-rL1-13;rlcv-miR-rL1-13-3p; +MIMAT0003444 rlcv-miR-rL1-14-5p; +MIMAT0003445 rlcv-miR-rL1-14-3p; +MIMAT0003446 rlcv-miR-rL1-15;rlcv-miR-rL1-15-3p; +MIMAT0003447 rlcv-miR-rL1-16-5p; +MIMAT0003448 rlcv-miR-rL1-16-3p; +MIMAT0003449 mmu-miR-488;mmu-miR-488*;mmu-miR-488-5p; +MIMAT0003450 mmu-miR-488*;mmu-miR-488;mmu-miR-488-3p; +MIMAT0003451 mmu-miR-677;mmu-miR-677-5p; +MIMAT0003452 mmu-miR-678; +MIMAT0003453 mmu-miR-497;mmu-miR-497-5p;mmu-miR-497a-5p; +MIMAT0003454 mmu-miR-423;mmu-miR-423-3p; +MIMAT0003455 mmu-miR-679;mmu-miR-679-5p; +MIMAT0003456 mmu-miR-495;mmu-miR-495-3p; +MIMAT0003457 mmu-miR-680; +MIMAT0003458 mmu-miR-681; +MIMAT0003459 mmu-miR-682; +MIMAT0003460 mmu-miR-449b;mmu-miR-449c;mmu-miR-449c-5p; +MIMAT0003461 mmu-miR-683; +MIMAT0003462 mmu-miR-684; +MIMAT0003463 mmu-miR-685; +MIMAT0003464 mmu-miR-686; +MIMAT0003465 mmu-miR-719; +MIMAT0003466 mmu-miR-687; +MIMAT0003467 mmu-miR-688; +MIMAT0003468 mmu-miR-689; +MIMAT0003469 mmu-miR-690; +MIMAT0003470 mmu-miR-691; +MIMAT0003471 mmu-miR-692; +MIMAT0003472 mmu-miR-693;mmu-miR-693-5p; +MIMAT0003473 mmu-miR-133a*;mmu-miR-133a-5p; +MIMAT0003474 mmu-miR-694; +MIMAT0003475 mmu-miR-146b;mmu-miR-146b-5p; +MIMAT0003476 mmu-miR-669b;mmu-miR-669b-5p; +MIMAT0003477 mmu-miR-669a;mmu-miR-669a-5p; +MIMAT0003478 mmu-miR-467b;mmu-miR-467b*;mmu-miR-467b-3p; +MIMAT0003479 mmu-miR-669c;mmu-miR-669c-5p; +MIMAT0003480 mmu-miR-297b;mmu-miR-297b-5p; +MIMAT0003481 mmu-miR-695; +MIMAT0003482 mmu-miR-499;mmu-miR-499-5p; +MIMAT0003483 mmu-miR-696; +MIMAT0003484 mmu-miR-720; +MIMAT0003485 mmu-miR-455;mmu-miR-455-5p;mmu-miR-455*;mmu-miR-455-5p; +MIMAT0003486 mmu-miR-491;mmu-miR-491-5p; +MIMAT0003487 mmu-miR-697; +MIMAT0003488 mmu-miR-698;mmu-miR-698-3p; +MIMAT0003489 mmu-miR-699; +MIMAT0003490 mmu-miR-700;mmu-miR-700-3p; +MIMAT0003491 mmu-miR-701;mmu-miR-701-5p; +MIMAT0003492 mmu-miR-702;mmu-miR-702-3p; +MIMAT0003493 mmu-miR-703; +MIMAT0003494 mmu-miR-704; +MIMAT0003495 mmu-miR-705; +MIMAT0003496 mmu-miR-706; +MIMAT0003497 mmu-miR-707; +MIMAT0003498 mmu-miR-708;mmu-miR-708*;mmu-miR-708-3p; +MIMAT0003499 mmu-miR-709; +MIMAT0003500 mmu-miR-710; +MIMAT0003501 mmu-miR-711; +MIMAT0003502 mmu-miR-712;mmu-miR-712-5p; +MIMAT0003504 mmu-miR-713; +MIMAT0003505 mmu-miR-714; +MIMAT0003506 mmu-miR-715; +MIMAT0003507 mmu-miR-500;mmu-miR-500-3p; +MIMAT0003508 mmu-miR-501;mmu-miR-501-5p; +MIMAT0003509 mmu-miR-501*;mmu-miR-501-3p; +MIMAT0003510 mmu-miR-717; +MIMAT0003511 mmu-miR-450b;mmu-miR-450b-5p; +MIMAT0003512 mmu-miR-450b*;mmu-miR-450b-3p; +MIMAT0003513 mmu-miR-505;mmu-miR-505-3p; +MIMAT0003514 mmu-miR-718; +MIMAT0003515 mmu-miR-721; +MIMAT0003516 bta-miR-26a; +MIMAT0003517 bta-miR-18b; +MIMAT0003518 bta-miR-29a; +MIMAT0003519 bta-let-7f; +MIMAT0003520 bta-miR-101; +MIMAT0003521 bta-miR-103; +MIMAT0003522 bta-miR-148a; +MIMAT0003523 bta-miR-151*;bta-miR-151-5p; +MIMAT0003524 bta-miR-151;bta-miR-151-3p; +MIMAT0003525 bta-miR-16;bta-miR-16b; +MIMAT0003526 bta-miR-18a; +MIMAT0003527 bta-miR-20a; +MIMAT0003528 bta-miR-21;bta-miR-21-5p; +MIMAT0003529 bta-miR-221; +MIMAT0003530 bta-miR-222; +MIMAT0003531 bta-miR-26b; +MIMAT0003532 bta-miR-27a;bta-miR-27a-3p; +MIMAT0003533 bta-miR-30d; +MIMAT0003534 bta-miR-320;bta-miR-320a; +MIMAT0003535 bta-miR-484; +MIMAT0003536 bta-miR-499; +MIMAT0003537 bta-miR-99a;bta-miR-99a-5p; +MIMAT0003538 bta-miR-125a; +MIMAT0003539 bta-miR-125b; +MIMAT0003540 bta-miR-126;bta-miR-126-3p; +MIMAT0003541 bta-miR-128a;bta-miR-128; +MIMAT0003542 bta-miR-145; +MIMAT0003543 bta-miR-181a; +MIMAT0003544 bta-miR-199a;bta-miR-199a-5p; +MIMAT0003545 bta-miR-205; +MIMAT0003546 bta-miR-27b; +MIMAT0003547 bta-miR-30b;bta-miR-30b-5p; +MIMAT0003548 bta-miR-31; +MIMAT0003549 bta-miR-34b; +MIMAT0003550 xtr-let-7b; +MIMAT0003551 xtr-miR-1a; +MIMAT0003552 xtr-miR-7; +MIMAT0003553 xtr-miR-9a;xtr-miR-9a-5p; +MIMAT0003554 xtr-miR-9a*;xtr-miR-9a-3p; +MIMAT0003555 xtr-miR-9b;xtr-miR-9b-5p; +MIMAT0003556 xtr-miR-9b*;xtr-miR-9b-3p; +MIMAT0003557 xtr-miR-10a; +MIMAT0003558 xtr-miR-10b; +MIMAT0003559 xtr-miR-10c; +MIMAT0003560 xtr-miR-15a; +MIMAT0003561 xtr-miR-15b; +MIMAT0003562 xtr-miR-16c; +MIMAT0003563 xtr-miR-16a; +MIMAT0003564 xtr-miR-17-5p; +MIMAT0003565 xtr-miR-17-3p; +MIMAT0003566 xtr-miR-19a; +MIMAT0003567 xtr-miR-19b; +MIMAT0003568 xtr-miR-23a; +MIMAT0003569 xtr-miR-26; +MIMAT0003570 xtr-miR-27a; +MIMAT0003571 xtr-miR-27b; +MIMAT0003572 xtr-miR-29d; +MIMAT0003573 xtr-miR-29b; +MIMAT0003574 xtr-miR-30a-5p; +MIMAT0003575 xtr-miR-30a-3p; +MIMAT0003576 xtr-miR-30b; +MIMAT0003577 xtr-miR-30c; +MIMAT0003578 xtr-miR-34a; +MIMAT0003579 xtr-miR-34b; +MIMAT0003580 xtr-miR-92a; +MIMAT0003581 xtr-miR-98; +MIMAT0003582 xtr-miR-99; +MIMAT0003583 xtr-miR-106; +MIMAT0003584 xtr-miR-107; +MIMAT0003585 xtr-miR-122; +MIMAT0003586 xtr-miR-125b; +MIMAT0003587 xtr-miR-126*;xtr-miR-126-5p; +MIMAT0003588 xtr-miR-126;xtr-miR-126-3p; +MIMAT0003589 xtr-miR-128; +MIMAT0003590 xtr-miR-129; +MIMAT0003591 xtr-miR-130a; +MIMAT0003592 xtr-miR-130c; +MIMAT0003593 xtr-miR-130b; +MIMAT0003594 xtr-miR-132; +MIMAT0003595 xtr-miR-133c; +MIMAT0003596 xtr-miR-133d; +MIMAT0003597 xtr-miR-133b; +MIMAT0003598 xtr-miR-135; +MIMAT0003599 xtr-miR-138; +MIMAT0003600 xtr-miR-139; +MIMAT0003601 xtr-miR-140; +MIMAT0003602 xtr-miR-142-5p; +MIMAT0003603 xtr-miR-142-3p; +MIMAT0003604 xtr-miR-146;xtr-miR-146a; +MIMAT0003605 xtr-miR-148b; +MIMAT0003606 xtr-miR-150; +MIMAT0003607 xtr-miR-153; +MIMAT0003608 xtr-miR-155; +MIMAT0003609 xtr-miR-181b; +MIMAT0003610 xtr-miR-182;xtr-miR-182-5p; +MIMAT0003611 xtr-miR-182*;xtr-miR-182-3p; +MIMAT0003612 xtr-miR-183; +MIMAT0003613 xtr-miR-184; +MIMAT0003614 xtr-miR-187; +MIMAT0003615 xtr-miR-192; +MIMAT0003616 xtr-miR-193; +MIMAT0003617 xtr-miR-194; +MIMAT0003618 xtr-miR-199a;xtr-miR-199a-5p; +MIMAT0003619 xtr-miR-199a*;xtr-miR-199a-3p; +MIMAT0003620 xtr-miR-202*;xtr-miR-202-5p; +MIMAT0003621 xtr-miR-202;xtr-miR-202-3p; +MIMAT0003622 xtr-miR-205b; +MIMAT0003623 xtr-miR-206; +MIMAT0003624 xtr-miR-210; +MIMAT0003625 xtr-miR-181a;xtr-miR-181a-5p; +MIMAT0003626 xtr-miR-181a*;xtr-miR-181a-1*;xtr-miR-181a-1-3p; +MIMAT0003627 xtr-miR-214; +MIMAT0003628 xtr-miR-215; +MIMAT0003629 xtr-miR-216; +MIMAT0003630 xtr-miR-217; +MIMAT0003631 xtr-miR-218; +MIMAT0003632 xtr-miR-219; +MIMAT0003633 xtr-miR-222; +MIMAT0003634 xtr-miR-223; +MIMAT0003635 xtr-miR-301; +MIMAT0003636 xtr-miR-302; +MIMAT0003637 xtr-miR-365; +MIMAT0003638 xtr-miR-367; +MIMAT0003639 xtr-miR-383; +MIMAT0003640 xtr-miR-425-5p; +MIMAT0003641 xtr-miR-455; +MIMAT0003642 xtr-miR-489; +MIMAT0003643 xtr-miR-499; +MIMAT0003644 xtr-let-7c; +MIMAT0003645 xtr-let-7f; +MIMAT0003646 xtr-let-7g; +MIMAT0003647 xtr-let-7i; +MIMAT0003648 xtr-miR-1b; +MIMAT0003649 xtr-miR-9;xtr-miR-9-5p; +MIMAT0003650 xtr-miR-9*;xtr-miR-9-3p; +MIMAT0003651 xtr-miR-15c; +MIMAT0003652 xtr-miR-18a;xtr-miR-18a-5p; +MIMAT0003653 xtr-miR-189;xtr-miR-24a-5p; +MIMAT0003654 xtr-miR-24a;xtr-miR-24a-3p; +MIMAT0003655 xtr-miR-24b; +MIMAT0003656 xtr-miR-29a; +MIMAT0003657 xtr-miR-30d; +MIMAT0003658 xtr-miR-92b; +MIMAT0003659 xtr-miR-93a; +MIMAT0003660 xtr-miR-93b; +MIMAT0003661 xtr-miR-96; +MIMAT0003662 xtr-miR-101a; +MIMAT0003663 xtr-miR-103; +MIMAT0003664 xtr-miR-148a; +MIMAT0003665 xtr-miR-338; +MIMAT0003666 xtr-let-7e; +MIMAT0003667 xtr-let-7a; +MIMAT0003668 xtr-miR-16b; +MIMAT0003669 xtr-miR-20a;xtr-miR-20a-5p; +MIMAT0003670 xtr-miR-20a*;xtr-miR-20a-3p; +MIMAT0003671 xtr-miR-22*;xtr-miR-22-5p; +MIMAT0003672 xtr-miR-22;xtr-miR-22-3p; +MIMAT0003673 xtr-miR-23b; +MIMAT0003674 xtr-miR-25; +MIMAT0003675 xtr-miR-27c; +MIMAT0003676 xtr-miR-29c*;xtr-miR-29c-5p; +MIMAT0003677 xtr-miR-29c;xtr-miR-29c-3p; +MIMAT0003678 xtr-miR-30e; +MIMAT0003679 xtr-miR-31;xtr-miR-31a; +MIMAT0003680 xtr-miR-33a; +MIMAT0003681 xtr-miR-33b; +MIMAT0003682 xtr-miR-100; +MIMAT0003683 xtr-miR-124; +MIMAT0003684 xtr-miR-125a; +MIMAT0003685 xtr-miR-137; +MIMAT0003686 xtr-miR-143; +MIMAT0003687 xtr-miR-144; +MIMAT0003688 xtr-miR-145; +MIMAT0003689 xtr-miR-191; +MIMAT0003690 xtr-miR-196a; +MIMAT0003691 xtr-miR-196b; +MIMAT0003692 xtr-miR-199b; +MIMAT0003693 xtr-miR-200a; +MIMAT0003694 xtr-miR-200b; +MIMAT0003695 xtr-miR-203; +MIMAT0003696 xtr-miR-204; +MIMAT0003697 xtr-miR-205a; +MIMAT0003698 xtr-miR-208; +MIMAT0003699 xtr-miR-212; +MIMAT0003700 xtr-miR-221; +MIMAT0003701 xtr-miR-363-5p; +MIMAT0003702 xtr-miR-363-3p; +MIMAT0003703 xtr-miR-429; +MIMAT0003704 xtr-miR-449;xtr-miR-449a-5p; +MIMAT0003705 xtr-miR-451; +MIMAT0003706 xtr-miR-18b; +MIMAT0003707 xtr-miR-20b; +MIMAT0003708 xtr-miR-133a; +MIMAT0003709 xtr-miR-428;xtr-miR-428a; +MIMAT0003711 mmu-miR-652;mmu-miR-652-3p; +MIMAT0003712 kshv-miR-K12;kshv-miR-K12-12;kshv-miR-K12-12*;kshv-miR-K12-12-5p; +MIMAT0003713 ebv-miR-BART15; +MIMAT0003714 ebv-miR-BART16; +MIMAT0003715 ebv-miR-BART17-5p; +MIMAT0003716 ebv-miR-BART17-3p; +MIMAT0003717 ebv-miR-BART18;ebv-miR-BART18-5p; +MIMAT0003718 ebv-miR-BART19;ebv-miR-BART19-3p; +MIMAT0003719 ebv-miR-BART20-5p; +MIMAT0003720 ebv-miR-BART20-3p; +MIMAT0003721 gga-miR-199*;gga-miR-199-3p; +MIMAT0003722 gga-miR-140*;gga-miR-140-3p; +MIMAT0003723 gga-miR-126*;gga-miR-126-5p; +MIMAT0003724 gga-miR-146b*;gga-miR-146b-3p; +MIMAT0003725 mmu-miR-675-5p; +MIMAT0003726 mmu-miR-675-3p; +MIMAT0003727 mmu-miR-374-5p;mmu-miR-374;mmu-miR-374-5p;mmu-miR-374b-5p; +MIMAT0003728 mmu-miR-374-3p;mmu-miR-374*;mmu-miR-374-3p;mmu-miR-374b-3p; +MIMAT0003729 mmu-miR-216b;mmu-miR-216b-5p; +MIMAT0003730 mmu-miR-592;mmu-miR-592-5p; +MIMAT0003731 mmu-miR-671;mmu-miR-671-5p; +MIMAT0003732 mmu-miR-668;mmu-miR-668-3p; +MIMAT0003733 mmu-miR-665;mmu-miR-665-3p; +MIMAT0003734 mmu-miR-667;mmu-miR-667-3p; +MIMAT0003735 mmu-miR-672;mmu-miR-672-5p; +MIMAT0003736 mmu-miR-670;mmu-miR-670-5p; +MIMAT0003737 mmu-miR-666;mmu-miR-666-5p; +MIMAT0003738 mmu-miR-496;mmu-miR-496-3p;mmu-miR-496a-3p; +MIMAT0003739 mmu-miR-673;mmu-miR-673-5p; +MIMAT0003740 mmu-miR-674-5p;mmu-miR-674;mmu-miR-674-5p; +MIMAT0003741 mmu-miR-674-3p;mmu-miR-674*;mmu-miR-674-3p; +MIMAT0003742 mmu-miR-455-3p;mmu-miR-455;mmu-miR-455-3p; +MIMAT0003743 mmu-miR-712*;mmu-miR-712-3p; +MIMAT0003744 hsv1-miR-H1;hsv1-miR-H1-5p; +MIMAT0003745 bta-miR-21*;bta-miR-21-3p; +MIMAT0003746 bta-miR-199a*;bta-miR-199a-3p; +MIMAT0003747 dre-miR-190b; +MIMAT0003748 dre-miR-722; +MIMAT0003749 dre-miR-499;dre-miR-499-5p; +MIMAT0003750 dre-miR-723*;dre-miR-723-5p; +MIMAT0003751 dre-miR-723;dre-miR-723-3p; +MIMAT0003752 dre-miR-724; +MIMAT0003753 dre-miR-725;dre-miR-725-3p; +MIMAT0003754 dre-miR-726; +MIMAT0003755 dre-miR-727*;dre-miR-727-5p; +MIMAT0003756 dre-miR-727;dre-miR-727-3p; +MIMAT0003757 dre-miR-728; +MIMAT0003758 dre-miR-729; +MIMAT0003759 dre-miR-34c;dre-miR-34c-5p; +MIMAT0003760 dre-miR-730; +MIMAT0003761 dre-miR-731; +MIMAT0003762 dre-miR-732; +MIMAT0003763 dre-miR-733; +MIMAT0003764 dre-miR-15c; +MIMAT0003765 dre-miR-734; +MIMAT0003766 dre-miR-735;dre-miR-735-3p; +MIMAT0003767 dre-miR-736; +MIMAT0003768 dre-miR-737;dre-miR-737-3p; +MIMAT0003769 dre-miR-738; +MIMAT0003770 dre-miR-739; +MIMAT0003771 dre-miR-740; +MIMAT0003772 tni-miR-10d; +MIMAT0003773 fru-miR-10d; +MIMAT0003774 gga-miR-21;gga-miR-21-5p; +MIMAT0003775 gga-miR-451; +MIMAT0003776 gga-miR-144;gga-miR-144-3p; +MIMAT0003777 gga-miR-456;gga-miR-456-3p; +MIMAT0003778 gga-miR-460;gga-miR-460a;gga-miR-460a-5p; +MIMAT0003779 gga-miR-757; +MIMAT0003780 mmu-miR-490;mmu-miR-490-3p; +MIMAT0003781 mmu-miR-676*;mmu-miR-676-5p; +MIMAT0003782 mmu-miR-676;mmu-miR-676-3p; +MIMAT0003783 mmu-miR-615;mmu-miR-615-3p; +MIMAT0003784 bta-miR-106;bta-miR-106a; +MIMAT0003785 bta-miR-107; +MIMAT0003786 bta-miR-10a; +MIMAT0003787 bta-miR-127; +MIMAT0003788 bta-miR-139; +MIMAT0003789 bta-miR-140; +MIMAT0003790 bta-miR-142;bta-miR-142-5p; +MIMAT0003791 bta-miR-142*;bta-miR-142-3p; +MIMAT0003792 bta-miR-15b; +MIMAT0003793 bta-miR-181b; +MIMAT0003794 bta-miR-193a*;bta-miR-193a-5p; +MIMAT0003795 bta-miR-193a;bta-miR-193a-3p; +MIMAT0003796 bta-miR-20b; +MIMAT0003797 bta-miR-215; +MIMAT0003798 bta-miR-218; +MIMAT0003799 bta-miR-30e-5p; +MIMAT0003800 bta-miR-345;bta-miR-345-5p; +MIMAT0003801 bta-miR-369-5p; +MIMAT0003802 bta-miR-369-3p; +MIMAT0003803 bta-miR-380-5p; +MIMAT0003804 bta-miR-380-3p; +MIMAT0003805 bta-miR-487a; +MIMAT0003806 bta-miR-545*;bta-miR-545-5p; +MIMAT0003807 bta-miR-545-3p;bta-miR-545;bta-miR-545-3p; +MIMAT0003808 bta-miR-92; +MIMAT0003809 bta-miR-98; +MIMAT0003810 bta-let-7d; +MIMAT0003811 bta-miR-124a; +MIMAT0003812 bta-miR-132; +MIMAT0003813 bta-miR-138; +MIMAT0003814 bta-miR-148b; +MIMAT0003815 bta-miR-17-5p; +MIMAT0003816 bta-miR-17-3p; +MIMAT0003817 bta-miR-181c; +MIMAT0003818 bta-miR-186; +MIMAT0003819 bta-miR-191; +MIMAT0003820 bta-miR-192; +MIMAT0003821 bta-miR-199b; +MIMAT0003822 bta-miR-200a; +MIMAT0003823 bta-miR-200c; +MIMAT0003824 bta-miR-210; +MIMAT0003825 bta-miR-214; +MIMAT0003826 bta-miR-22-5p; +MIMAT0003827 bta-miR-23a; +MIMAT0003828 bta-miR-29b; +MIMAT0003829 bta-miR-29c; +MIMAT0003830 bta-miR-361; +MIMAT0003831 bta-miR-423;bta-miR-423-3p; +MIMAT0003832 bta-miR-425-5p; +MIMAT0003833 bta-miR-425-3p; +MIMAT0003834 bta-miR-450;bta-miR-450a; +MIMAT0003835 bta-miR-455;bta-miR-455-5p; +MIMAT0003836 bta-miR-455*;bta-miR-455-3p; +MIMAT0003837 bta-miR-93; +MIMAT0003838 bta-let-7g; +MIMAT0003839 bta-miR-10b; +MIMAT0003840 bta-miR-24;bta-miR-24-3p; +MIMAT0003841 bta-miR-30a-5p; +MIMAT0003842 bta-miR-200b; +MIMAT0003843 bta-miR-7; +MIMAT0003844 bta-let-7a;bta-let-7a-5p; +MIMAT0003845 bta-miR-150; +MIMAT0003846 bta-miR-342; +MIMAT0003847 bta-miR-487b; +MIMAT0003848 bta-miR-532; +MIMAT0003849 bta-miR-122a;bta-miR-122; +MIMAT0003850 bta-miR-30c; +MIMAT0003851 bta-let-7i; +MIMAT0003852 bta-miR-23b;bta-miR-23b-3p; +MIMAT0003853 bta-miR-25; +MIMAT0003854 bta-miR-34c; +MIMAT0003855 bta-miR-363; +MIMAT0003856 mtr-miR395c; +MIMAT0003857 mtr-miR395d; +MIMAT0003858 mtr-miR395e; +MIMAT0003859 mtr-miR395f; +MIMAT0003860 mtr-miR395g; +MIMAT0003861 mtr-miR395h; +MIMAT0003862 mtr-miR395i; +MIMAT0003863 mtr-miR395j; +MIMAT0003864 mtr-miR395k; +MIMAT0003865 mtr-miR395l; +MIMAT0003866 mtr-miR395m; +MIMAT0003867 mtr-miR395n; +MIMAT0003868 mtr-miR395o; +MIMAT0003869 mtr-miR395p;mtr-miR395k; +MIMAT0003870 osa-miR395m; +MIMAT0003871 osa-miR395n; +MIMAT0003872 osa-miR395o; +MIMAT0003873 osa-miR395p; +MIMAT0003874 osa-miR395q; +MIMAT0003876 osa-miR395v; +MIMAT0003877 osa-miR395w; +MIMAT0003878 osa-miR395r; +MIMAT0003879 hsa-miR-758;hsa-miR-758-3p; +MIMAT0003880 hsa-miR-671;hsa-miR-671-5p; +MIMAT0003881 hsa-miR-668;hsa-miR-668-3p; +MIMAT0003882 hsa-miR-767-5p; +MIMAT0003883 hsa-miR-767-3p; +MIMAT0003884 hsa-miR-454-5p;hsa-miR-454*;hsa-miR-454-5p; +MIMAT0003885 hsa-miR-454-3p;hsa-miR-454;hsa-miR-454-3p; +MIMAT0003886 hsa-miR-769-5p; +MIMAT0003887 hsa-miR-769-3p; +MIMAT0003888 hsa-miR-766;hsa-miR-766-3p; +MIMAT0003889 mmu-miR-758;mmu-miR-758-3p; +MIMAT0003890 mmu-miR-551b;mmu-miR-551b-3p; +MIMAT0003891 mmu-miR-770-3p; +MIMAT0003892 mmu-miR-762; +MIMAT0003893 mmu-miR-761; +MIMAT0003894 mmu-miR-764-5p; +MIMAT0003895 mmu-miR-764-3p; +MIMAT0003896 mmu-miR-763; +MIMAT0003897 mmu-miR-759; +MIMAT0003898 mmu-miR-760;mmu-miR-760-3p; +MIMAT0003899 ppt-miR1210;ppt-miR477a-3p; +MIMAT0003900 ppt-miR1211;ppt-miR1211*;ppt-miR1211-5p; +MIMAT0003901 ppt-miR1212; +MIMAT0003902 ppt-miR1213;ppt-miR477g-3p; +MIMAT0003903 ppt-miR1214; +MIMAT0003904 ppt-miR1215; +MIMAT0003905 ppt-miR1216; +MIMAT0003906 ppt-miR1217;ppt-miR1217-3p; +MIMAT0003907 ppt-miR1218; +MIMAT0003908 ppt-miR1219a; +MIMAT0003909 ppt-miR1219b; +MIMAT0003910 ppt-miR1219c; +MIMAT0003911 ppt-miR1219d; +MIMAT0003912 ppt-miR1220a; +MIMAT0003913 ppt-miR1220b; +MIMAT0003914 ppt-miR533b;ppt-miR533b-5p; +MIMAT0003915 ppt-miR535d; +MIMAT0003916 ppt-miR1221;ppt-miR1221-5p; +MIMAT0003917 ppt-miR1222;ppt-miR1222a; +MIMAT0003918 ppt-miR1223;ppt-miR1223a; +MIMAT0003919 ppt-miR390c;ppt-miR390c-5p; +MIMAT0003920 mdv-miR-M1;mdv1-miR-M1;mdv1-miR-M1-5p; +MIMAT0003921 mdv-miR-M2;mdv1-miR-M2;mdv1-miR-M2-5p; +MIMAT0003922 mdv-miR-M2*;mdv1-miR-M2*;mdv1-miR-M2-3p; +MIMAT0003923 mdv-miR-M3;mdv1-miR-M3;mdv1-miR-M3-5p; +MIMAT0003924 mdv-miR-M4;mdv1-miR-M4;mdv1-miR-M4-5p; +MIMAT0003925 mdv-miR-M4*;mdv1-miR-M4*;mdv1-miR-M4-3p; +MIMAT0003926 mdv-miR-M5;mdv1-miR-M5;mdv1-miR-M5-3p; +MIMAT0003927 mdv-miR-M6;mdv1-miR-M6;mdv1-miR-M6*;mdv1-miR-M6-3p; +MIMAT0003928 mdv-miR-M7;mdv1-miR-M7;mdv1-miR-M7*;mdv1-miR-M7;mdv1-miR-M7-3p; +MIMAT0003929 mdv-miR-M8;mdv1-miR-M8;mdv1-miR-M8-3p; +MIMAT0003930 ath-miR771; +MIMAT0003931 ath-miR772;ath-miR472;ath-miR472-3p; +MIMAT0003932 ath-miR773;ath-miR773a; +MIMAT0003933 ath-miR774;ath-miR774a; +MIMAT0003934 ath-miR775; +MIMAT0003935 ath-miR776; +MIMAT0003936 ath-miR777; +MIMAT0003937 ath-miR778; +MIMAT0003938 ath-miR779;ath-miR779.1; +MIMAT0003939 ath-miR780;ath-miR780.2; +MIMAT0003940 ath-miR781;ath-miR781a; +MIMAT0003941 ath-miR782; +MIMAT0003942 ath-miR783; +MIMAT0003943 ptc-miR171k; +MIMAT0003944 ptc-miR403c;ptc-miR403c-3p; +MIMAT0003945 hsa-miR-765; +MIMAT0003946 hsa-miR-768-5p; +MIMAT0003947 hsa-miR-768-3p; +MIMAT0003948 hsa-miR-770-5p; +MIMAT0003949 sme-bantam-a; +MIMAT0003950 sme-bantam-b;sme-bantam-b-3p; +MIMAT0003951 sme-bantam-c;sme-bantam-c-3p; +MIMAT0003952 sme-let-7a;sme-let-7a-5p; +MIMAT0003953 sme-let-7b;sme-let-7b-5p; +MIMAT0003954 sme-let-7b*;sme-let-7b-3p; +MIMAT0003955 sme-let-7c;sme-let-7c-5p; +MIMAT0003956 sme-lin-4;sme-lin-4-5p; +MIMAT0003960 sme-miR-1a;sme-miR-1a-3p; +MIMAT0003961 sme-miR-1b;sme-miR-1b-3p; +MIMAT0003962 sme-miR-1c;sme-miR-1c-3p; +MIMAT0003963 sme-miR-2a;sme-miR-2a-3p; +MIMAT0003964 sme-miR-2a*;sme-miR-2a-1*;sme-miR-2a-1-5p; +MIMAT0003965 sme-miR-2b*;sme-miR-2b-5p; +MIMAT0003966 sme-miR-2b;sme-miR-2b-3p; +MIMAT0003967 sme-miR-2c;sme-miR-2c-3p; +MIMAT0003968 sme-miR-2d;sme-miR-2d-3p; +MIMAT0003969 sme-miR-7a;sme-miR-7a-5p; +MIMAT0003970 sme-miR-7b;sme-miR-7b-5p; +MIMAT0003971 sme-miR-7c;sme-miR-7c-5p; +MIMAT0003972 sme-miR-8;sme-miR-8a;sme-miR-8a-3p; +MIMAT0003973 sme-miR-10;sme-miR-10b;sme-miR-10b-5p; +MIMAT0003974 sme-miR-10*;sme-miR-10b*;sme-miR-10b-3p; +MIMAT0003975 sme-miR-12;sme-miR-12-5p; +MIMAT0003976 sme-miR-13;sme-miR-13-3p; +MIMAT0003977 sme-miR-745;sme-miR-745-3p; +MIMAT0003978 sme-miR-746;sme-miR-746-3p; +MIMAT0003979 sme-miR-31a;sme-miR-31a-5p; +MIMAT0003980 sme-miR-31b;sme-miR-31b-5p; +MIMAT0003981 sme-miR-36*;sme-miR-36a*;sme-miR-36a-5p; +MIMAT0003982 sme-miR-36;sme-miR-36a;sme-miR-36a-3p; +MIMAT0003983 sme-miR-61;sme-miR-61a;sme-miR-61a-3p; +MIMAT0003984 sme-miR-71a;sme-miR-71a-5p; +MIMAT0003985 sme-miR-71b;sme-miR-71b-5p; +MIMAT0003986 sme-miR-71b*;sme-miR-71b-3p; +MIMAT0003987 sme-miR-71c;sme-miR-71c-5p; +MIMAT0003988 sme-miR-79;sme-miR-79-3p; +MIMAT0003989 sme-miR-87a;sme-miR-87a-3p; +MIMAT0003990 sme-miR-87b;sme-miR-87b-3p; +MIMAT0003991 sme-miR-92;sme-miR-92-3p; +MIMAT0003992 sme-miR-124a;sme-miR-124a-3p; +MIMAT0003993 sme-miR-124b;sme-miR-124b-3p; +MIMAT0003994 sme-miR-124c*;sme-miR-124c-1*;sme-miR-124c-1-5p; +MIMAT0003995 sme-miR-124c;sme-miR-124c-3p; +MIMAT0003996 sme-miR-125a;sme-miR-125a-5p; +MIMAT0003997 sme-miR-125a*;sme-miR-125a-3p; +MIMAT0003998 sme-miR-125b;sme-miR-125b-5p; +MIMAT0003999 sme-miR-133;sme-miR-133b-3p; +MIMAT0004000 sme-miR-184;sme-miR-184-3p; +MIMAT0004001 sme-miR-190a;sme-miR-190a-5p; +MIMAT0004002 sme-miR-190a*;sme-miR-190a-3p; +MIMAT0004003 sme-miR-190b;sme-miR-190b-5p; +MIMAT0004004 sme-miR-190b*;sme-miR-190b-3p; +MIMAT0004005 sme-miR-747;sme-miR-747-5p; +MIMAT0004006 sme-miR-219;sme-miR-219-5p; +MIMAT0004007 sme-miR-277a;sme-miR-277a-3p; +MIMAT0004008 sme-miR-277b*;sme-miR-277b-5p; +MIMAT0004009 sme-miR-277b;sme-miR-277b-3p; +MIMAT0004010 sme-miR-277c;sme-miR-277c-3p; +MIMAT0004011 sme-miR-278;sme-miR-278-3p; +MIMAT0004012 sme-miR-281*;sme-miR-281-5p; +MIMAT0004013 sme-miR-281;sme-miR-281-3p; +MIMAT0004014 sme-miR-67;sme-miR-67-3p; +MIMAT0004015 sme-miR-748;sme-miR-748-3p; +MIMAT0004016 sme-miR-749; +MIMAT0004017 sme-miR-750;sme-miR-750-3p; +MIMAT0004018 sme-miR-751; +MIMAT0004019 sme-miR-752;sme-miR-752-3p; +MIMAT0004020 sme-miR-753;sme-miR-753a; +MIMAT0004021 sme-miR-754;sme-miR-754a; +MIMAT0004022 sme-miR-755;sme-miR-755-5p; +MIMAT0004023 sme-miR-756;sme-miR-756-5p; +MIMAT0004024 sme-miR-277d;sme-miR-277d-3p; +MIMAT0004025 osa-miR807a; +MIMAT0004026 osa-miR806a; +MIMAT0004027 osa-miR806b; +MIMAT0004028 osa-miR806c; +MIMAT0004029 osa-miR806d; +MIMAT0004030 osa-miR806e; +MIMAT0004031 osa-miR806f; +MIMAT0004032 osa-miR806g; +MIMAT0004033 osa-miR806h; +MIMAT0004034 osa-miR807b; +MIMAT0004035 osa-miR807c; +MIMAT0004036 osa-miR808; +MIMAT0004037 osa-miR809a; +MIMAT0004038 osa-miR809b; +MIMAT0004039 osa-miR809c; +MIMAT0004040 osa-miR809d; +MIMAT0004041 osa-miR809e; +MIMAT0004042 osa-miR809f; +MIMAT0004043 osa-miR809g; +MIMAT0004044 osa-miR809h; +MIMAT0004045 osa-miR810;osa-miR810a; +MIMAT0004046 osa-miR811a; +MIMAT0004047 osa-miR811b; +MIMAT0004048 osa-miR811c; +MIMAT0004049 osa-miR812a; +MIMAT0004050 osa-miR812b; +MIMAT0004051 osa-miR812c; +MIMAT0004052 osa-miR812d; +MIMAT0004053 osa-miR812e; +MIMAT0004054 osa-miR813; +MIMAT0004055 osa-miR814a; +MIMAT0004056 osa-miR814b; +MIMAT0004057 osa-miR814c; +MIMAT0004058 osa-miR815a; +MIMAT0004059 osa-miR815b; +MIMAT0004060 osa-miR815c; +MIMAT0004061 osa-miR816; +MIMAT0004062 osa-miR817; +MIMAT0004063 osa-miR818a; +MIMAT0004064 osa-miR818b; +MIMAT0004065 osa-miR818c; +MIMAT0004066 osa-miR818d; +MIMAT0004067 osa-miR818e; +MIMAT0004068 osa-miR819a;osa-miR819a-5p; +MIMAT0004069 osa-miR819b; +MIMAT0004070 osa-miR819c;osa-miR819c-5p; +MIMAT0004071 osa-miR819d;osa-miR819d-5p; +MIMAT0004072 osa-miR819e;osa-miR819e-5p; +MIMAT0004073 osa-miR819f; +MIMAT0004074 osa-miR819g; +MIMAT0004075 osa-miR819h;osa-miR819h-5p; +MIMAT0004076 osa-miR819i; +MIMAT0004077 osa-miR819j;osa-miR819j-5p; +MIMAT0004078 osa-miR819k;osa-miR819k-5p; +MIMAT0004079 osa-miR820a; +MIMAT0004080 osa-miR820b; +MIMAT0004081 osa-miR820c; +MIMAT0004082 osa-miR821a; +MIMAT0004083 osa-miR821b; +MIMAT0004084 osa-miR821c; +MIMAT0004085 mdo-miR-1;mdo-miR-1-3p; +MIMAT0004086 mdo-miR-7; +MIMAT0004087 mdo-miR-9;mdo-miR-9-5p;mdo-miR-9a-5p; +MIMAT0004088 mdo-miR-9*;mdo-miR-9-3p;mdo-miR-9a-3p; +MIMAT0004089 mdo-miR-10a;mdo-miR-10a-5p; +MIMAT0004090 mdo-miR-10b;mdo-miR-10b-5p; +MIMAT0004091 mdo-miR-21;mdo-miR-21-5p; +MIMAT0004092 mdo-miR-22;mdo-miR-22-3p; +MIMAT0004093 mdo-miR-30a;mdo-miR-30a-5p; +MIMAT0004094 mdo-miR-31;mdo-miR-31-5p; +MIMAT0004095 mdo-miR-32;mdo-miR-32-5p; +MIMAT0004096 mdo-miR-34a;mdo-miR-34a-5p; +MIMAT0004097 mdo-miR-100;mdo-miR-100-5p; +MIMAT0004098 mdo-miR-101;mdo-miR-101-3p; +MIMAT0004099 mdo-miR-103;mdo-miR-103-3p; +MIMAT0004100 mdo-miR-107; +MIMAT0004101 mdo-miR-122a;mdo-miR-122;mdo-miR-122-5p; +MIMAT0004102 mdo-miR-124a;mdo-miR-124a-3p; +MIMAT0004103 mdo-miR-125b;mdo-miR-125b-5p; +MIMAT0004104 mdo-miR-128b;mdo-miR-128;mdo-miR-128a-3p; +MIMAT0004105 mdo-miR-129;mdo-miR-129-5p; +MIMAT0004106 mdo-miR-130a;mdo-miR-130a-3p; +MIMAT0004107 mdo-miR-133a;mdo-miR-133a-3p; +MIMAT0004108 mdo-miR-135a;mdo-miR-135a-5p; +MIMAT0004109 mdo-miR-135b;mdo-miR-135b-5p; +MIMAT0004110 mdo-miR-137;mdo-miR-137a; +MIMAT0004111 mdo-miR-138; +MIMAT0004112 mdo-miR-142; +MIMAT0004113 mdo-miR-143;mdo-miR-143-3p; +MIMAT0004114 mdo-miR-144;mdo-miR-144-3p; +MIMAT0004115 mdo-miR-451; +MIMAT0004116 mdo-miR-145;mdo-miR-145-5p; +MIMAT0004117 mdo-miR-152;mdo-miR-152-3p; +MIMAT0004118 mdo-miR-182;mdo-miR-182-5p; +MIMAT0004119 mdo-miR-184;mdo-miR-184-3p; +MIMAT0004120 mdo-miR-187;mdo-miR-187-3p; +MIMAT0004121 mdo-miR-181c; +MIMAT0004122 mdo-miR-186;mdo-miR-186-5p; +MIMAT0004123 mdo-miR-193;mdo-miR-193a-3p; +MIMAT0004124 mdo-miR-196b; +MIMAT0004125 mdo-miR-199b;mdo-miR-199b-1-5p; +MIMAT0004126 mdo-miR-203; +MIMAT0004127 mdo-miR-204; +MIMAT0004128 mdo-miR-206; +MIMAT0004129 mdo-miR-208;mdo-miR-208a; +MIMAT0004130 mdo-miR-214;mdo-miR-214-3p; +MIMAT0004131 mdo-miR-216; +MIMAT0004132 mdo-miR-217; +MIMAT0004133 mdo-miR-218;mdo-miR-218-5p; +MIMAT0004134 mdo-miR-219;mdo-miR-219-5p; +MIMAT0004135 mdo-miR-223;mdo-miR-223-3p; +MIMAT0004136 mdo-miR-338; +MIMAT0004137 mdo-miR-365;mdo-miR-365-3p; +MIMAT0004138 mdo-miR-375; +MIMAT0004139 mdo-miR-383;mdo-miR-383-5p; +MIMAT0004140 mdo-miR-449;mdo-miR-449a-5p; +MIMAT0004141 mdo-let-7a;mdo-let-7a-5p; +MIMAT0004142 mdo-let-7g;mdo-let-7g-5p; +MIMAT0004143 mdo-let-7i;mdo-let-7i-5p; +MIMAT0004144 mdo-miR-15a;mdo-miR-15a-5p; +MIMAT0004145 mdo-miR-16;mdo-miR-16-5p; +MIMAT0004146 mdo-miR-183;mdo-miR-183-5p; +MIMAT0004147 mdo-miR-96; +MIMAT0004148 mdo-miR-212;mdo-miR-212-3p; +MIMAT0004149 mdo-miR-132;mdo-miR-132-3p; +MIMAT0004150 mdo-miR-200c;mdo-miR-200c-3p; +MIMAT0004151 mdo-miR-141;mdo-miR-141-3p; +MIMAT0004152 mdo-miR-191;mdo-miR-191-5p; +MIMAT0004153 mdo-miR-425;mdo-miR-425-3p; +MIMAT0004154 mdo-miR-181a;mdo-miR-181a-5p; +MIMAT0004155 mdo-miR-181b;mdo-miR-181b-5p; +MIMAT0004156 mdo-miR-200b;mdo-miR-200b-3p; +MIMAT0004157 mdo-miR-200a*;mdo-miR-200a-5p; +MIMAT0004158 mdo-miR-200a;mdo-miR-200a-3p; +MIMAT0004159 mdo-miR-222a; +MIMAT0004160 mdo-miR-221;mdo-miR-221-3p; +MIMAT0004161 mdo-let-7f;mdo-let-7f-5p; +MIMAT0004162 mdo-let-7b; +MIMAT0004163 mdo-miR-29b;mdo-miR-29b-3p; +MIMAT0004164 mdo-miR-29a;mdo-miR-29a-3p; +MIMAT0004165 mdo-miR-17-5p; +MIMAT0004166 mdo-miR-17-3p; +MIMAT0004167 mdo-miR-18;mdo-miR-18a-5p; +MIMAT0004168 mdo-miR-19a;mdo-miR-19a-3p; +MIMAT0004169 mdo-miR-20;mdo-miR-20a-5p; +MIMAT0004170 mdo-miR-19b;mdo-miR-19b-3p; +MIMAT0004171 mdo-miR-92;mdo-miR-92a-3p; +MIMAT0004172 mdo-let-7d; +MIMAT0004173 mdo-miR-23a;mdo-miR-23a-3p; +MIMAT0004174 mdo-miR-27a;mdo-miR-27a-3p; +MIMAT0004175 mdo-miR-24;mdo-miR-24-3p; +MIMAT0004176 mdo-miR-23b;mdo-miR-23b-3p; +MIMAT0004177 mdo-miR-27b;mdo-miR-27b-3p; +MIMAT0004178 mdo-miR-93;mdo-miR-93-5p; +MIMAT0004179 mdo-miR-25; +MIMAT0004180 mdo-miR-302b; +MIMAT0004181 mdo-miR-302c; +MIMAT0004182 mdo-miR-302a; +MIMAT0004183 mdo-miR-302d; +MIMAT0004184 mdo-miR-367; +MIMAT0004185 hsa-miR-802; +MIMAT0004186 mmu-miR-301b;mmu-miR-301b-3p; +MIMAT0004187 mmu-miR-744;mmu-miR-744-5p; +MIMAT0004188 mmu-miR-802;mmu-miR-802-5p; +MIMAT0004189 mmu-miR-693-3p; +MIMAT0004190 bmo-let-7;bmo-let-7-5p; +MIMAT0004191 bmo-miR-1;bmo-miR-1a;bmo-miR-1a-3p; +MIMAT0004192 bmo-miR-7;bmo-miR-7-5p; +MIMAT0004193 bmo-miR-8;bmo-miR-8-3p; +MIMAT0004194 bmo-miR-9;bmo-miR-9a;bmo-miR-9a-5p; +MIMAT0004195 bmo-miR-10;bmo-miR-10-5p; +MIMAT0004196 bmo-miR-14;bmo-miR-14-3p; +MIMAT0004197 bmo-miR-34;bmo-miR-34-5p; +MIMAT0004198 bmo-miR-124; +MIMAT0004199 bmo-miR-263b;bmo-miR-263b-5p; +MIMAT0004200 bmo-miR-263a;bmo-miR-263a-5p; +MIMAT0004201 bmo-miR-275;bmo-miR-275-3p; +MIMAT0004202 bmo-miR-276;bmo-miR-276-5p; +MIMAT0004203 bmo-miR-277;bmo-miR-277-3p; +MIMAT0004204 bmo-miR-279;bmo-miR-279a; +MIMAT0004205 bmo-miR-282;bmo-miR-282-5p; +MIMAT0004206 bmo-miR-283;bmo-miR-283-5p; +MIMAT0004207 bmo-miR-305;bmo-miR-305-5p; +MIMAT0004208 bmo-miR-307;bmo-miR-307-3p; +MIMAT0004209 hsa-miR-801; +MIMAT0004210 mmu-miR-804; +MIMAT0004211 mmu-miR-805; +MIMAT0004212 mmu-miR-801; +MIMAT0004213 bmo-miR-31;bmo-miR-31-5p; +MIMAT0004214 bmo-miR-71;bmo-miR-71-5p; +MIMAT0004215 cel-miR-253;cel-miR-253-3p; +MIMAT0004216 cel-miR-255;cel-miR-255-3p; +MIMAT0004217 mmu-miR-465-3p;mmu-miR-465a-3p; +MIMAT0004218 ath-miR780.1; +MIMAT0004219 cel-miR-784;cel-miR-784-5p; +MIMAT0004220 cel-miR-785;cel-miR-785-3p; +MIMAT0004221 cel-miR-786;cel-miR-786-3p; +MIMAT0004222 cel-miR-787;cel-miR-787-3p; +MIMAT0004223 cel-miR-788;cel-miR-788-5p; +MIMAT0004224 cel-miR-789;cel-miR-789-3p; +MIMAT0004225 cel-miR-790;cel-miR-790-5p; +MIMAT0004226 cel-miR-791;cel-miR-791-3p; +MIMAT0004227 cel-miR-792;cel-miR-792-3p; +MIMAT0004228 cel-miR-793; +MIMAT0004229 cel-miR-794;cel-miR-794-5p; +MIMAT0004230 cel-miR-795;cel-miR-795-5p; +MIMAT0004231 cel-miR-796; +MIMAT0004232 cel-miR-797;cel-miR-797-5p; +MIMAT0004233 cel-miR-798; +MIMAT0004234 cel-miR-799; +MIMAT0004235 cel-miR-800;cel-miR-800-3p; +MIMAT0004236 mmu-miR-741;mmu-miR-741-3p; +MIMAT0004237 mmu-miR-742;mmu-miR-742-3p; +MIMAT0004238 mmu-miR-743;mmu-miR-743a;mmu-miR-743a-3p; +MIMAT0004239 ath-miR822;ath-miR822-5p; +MIMAT0004240 ath-miR823; +MIMAT0004241 ath-miR825; +MIMAT0004242 ath-miR826;ath-miR826a; +MIMAT0004243 ath-miR827; +MIMAT0004244 ath-miR828; +MIMAT0004245 ath-miR829.1;ath-miR829-3p.1; +MIMAT0004246 ath-miR829.2;ath-miR829-3p.2; +MIMAT0004247 ath-miR830*;ath-miR830-5p; +MIMAT0004248 ath-miR830;ath-miR830-3p; +MIMAT0004249 ath-miR831;ath-miR831-3p; +MIMAT0004250 ath-miR832-5p; +MIMAT0004251 ath-miR832-3p; +MIMAT0004252 ath-miR833-5p;ath-miR833a-5p; +MIMAT0004253 ath-miR833-3p;ath-miR833a-3p; +MIMAT0004254 ath-miR834; +MIMAT0004255 ath-miR835-5p; +MIMAT0004256 ath-miR835-3p; +MIMAT0004257 ath-miR836; +MIMAT0004258 ath-miR837-5p; +MIMAT0004259 ath-miR837-3p; +MIMAT0004260 ath-miR838; +MIMAT0004261 ath-miR839;ath-miR839-5p; +MIMAT0004262 ath-miR840;ath-miR840-5p; +MIMAT0004263 ath-miR841;ath-miR841a;ath-miR841a-5p; +MIMAT0004264 ath-miR842; +MIMAT0004265 ath-miR843; +MIMAT0004266 ath-miR844;ath-miR844-5p; +MIMAT0004267 ath-miR844*;ath-miR844-3p; +MIMAT0004268 ath-miR845a; +MIMAT0004269 ath-miR846;ath-miR846-3p; +MIMAT0004270 ath-miR848; +MIMAT0004271 ath-miR849; +MIMAT0004272 ath-miR850; +MIMAT0004273 ath-miR851-5p; +MIMAT0004274 ath-miR851-3p; +MIMAT0004275 ath-miR852; +MIMAT0004276 ath-miR853; +MIMAT0004277 ath-miR824;ath-miR824-5p; +MIMAT0004278 ath-miR847; +MIMAT0004279 ath-miR855; +MIMAT0004280 ath-miR854a; +MIMAT0004281 ath-miR854b; +MIMAT0004282 ath-miR854c; +MIMAT0004283 ath-miR854d;ath-miR854e;ath-miR854d; +MIMAT0004284 hsa-miR-675;hsa-miR-675-5p; +MIMAT0004285 cbr-miR-784; +MIMAT0004286 cbr-miR-785;cbr-miR-785a; +MIMAT0004287 cbr-miR-786; +MIMAT0004288 cbr-miR-787; +MIMAT0004289 cbr-miR-788; +MIMAT0004290 cbr-miR-789a; +MIMAT0004291 cbr-miR-789b;cbr-miR-789; +MIMAT0004292 cbr-miR-790; +MIMAT0004293 cbr-miR-791; +MIMAT0004294 cbr-miR-792; +MIMAT0004295 cbr-miR-235;cbr-miR-235a; +MIMAT0004296 cbr-miR-242; +MIMAT0004297 cbr-miR-255; +MIMAT0004298 cbr-miR-359; +MIMAT0004299 cbr-miR-392; +MIMAT0004300 ath-miR856; +MIMAT0004301 ath-miR857; +MIMAT0004302 ath-miR858;ath-miR858a; +MIMAT0004303 ath-miR859; +MIMAT0004304 ath-miR860; +MIMAT0004305 ath-miR861-5p; +MIMAT0004306 ath-miR861-3p; +MIMAT0004307 ath-miR862-5p; +MIMAT0004308 ath-miR862-3p; +MIMAT0004309 ath-miR863-5p; +MIMAT0004310 ath-miR863-3p; +MIMAT0004311 ath-miR864-5p; +MIMAT0004312 ath-miR864-3p; +MIMAT0004313 ath-miR865-5p; +MIMAT0004314 ath-miR865-3p; +MIMAT0004315 ath-miR866-5p; +MIMAT0004316 ath-miR866-3p; +MIMAT0004317 ath-miR845b; +MIMAT0004318 ath-miR867; +MIMAT0004319 ath-miR868;ath-miR868-3p; +MIMAT0004320 ath-miR869.1; +MIMAT0004321 ath-miR869.2; +MIMAT0004322 ath-miR870;ath-miR870-3p; +MIMAT0004324 mmu-miR-181d;mmu-miR-181d-5p; +MIMAT0004325 ppt-miR319d.1*;ppt-miR319d-5p.1; +MIMAT0004326 ppt-miR319d.2*;ppt-miR319d-5p.2; +MIMAT0004327 ppt-miR390c*;ppt-miR390c-3p; +MIMAT0004328 bta-miR-126*;bta-miR-126-5p; +MIMAT0004329 ath-miR779.2; +MIMAT0004330 bta-let-7a*;bta-let-7a-3p; +MIMAT0004331 bta-let-7b; +MIMAT0004332 bta-let-7c; +MIMAT0004333 bta-let-7e; +MIMAT0004334 bta-miR-15a; +MIMAT0004335 bta-miR-195; +MIMAT0004336 bta-miR-19a; +MIMAT0004337 bta-miR-19b; +MIMAT0004338 bta-miR-204; +MIMAT0004339 bta-miR-331;bta-miR-331-3p; +MIMAT0004340 bta-miR-34a; +MIMAT0004341 bta-miR-365;bta-miR-365-3p; +MIMAT0004342 bta-miR-374;bta-miR-374a; +MIMAT0004343 bta-miR-497; +MIMAT0004344 bta-miR-660; +MIMAT0004345 bta-miR-99b; +MIMAT0004346 ppt-miR156c; +MIMAT0004347 ppt-miR160a; +MIMAT0004348 ppt-miR160b; +MIMAT0004349 ppt-miR160c; +MIMAT0004350 ppt-miR160d; +MIMAT0004351 ppt-miR166b; +MIMAT0004352 ppt-miR166a; +MIMAT0004353 ppt-miR167; +MIMAT0004354 ppt-miR319e; +MIMAT0004355 ppt-miR395; +MIMAT0004356 ppt-miR408;ppt-miR408a; +MIMAT0004357 ppt-miR414; +MIMAT0004358 ppt-miR419; +MIMAT0004359 ppt-miR473a;ppt-miR477c; +MIMAT0004360 ppt-miR473b;ppt-miR477a-5p; +MIMAT0004361 ppt-miR477a;ppt-miR477f; +MIMAT0004362 ppt-miR477b;ppt-miR477g-5p; +MIMAT0004363 ppt-miR534b; +MIMAT0004364 ppt-miR893; +MIMAT0004365 ppt-miR894; +MIMAT0004366 ppt-miR895; +MIMAT0004367 ppt-miR896; +MIMAT0004368 ppt-miR897; +MIMAT0004369 ppt-miR899; +MIMAT0004370 ppt-miR900;ppt-miR900-3p; +MIMAT0004371 ppt-miR901; +MIMAT0004372 ppt-miR902a;ppt-miR902a-3p; +MIMAT0004373 ppt-miR902b;ppt-miR902b-3p; +MIMAT0004374 ppt-miR536c; +MIMAT0004375 ppt-miR171a; +MIMAT0004376 ppt-miR171b; +MIMAT0004377 ppt-miR903; +MIMAT0004378 ppt-miR536b; +MIMAT0004379 ppt-miR904a; +MIMAT0004380 ppt-miR904b; +MIMAT0004381 ppt-miR898b; +MIMAT0004382 ppt-miR898a-5p;ppt-miR898a;ppt-miR898a-5p; +MIMAT0004383 ppt-miR898a-3p;ppt-miR898a*;ppt-miR898a-3p; +MIMAT0004384 ppt-miR156b; +MIMAT0004385 cre-miR918; +MIMAT0004386 cre-miR905;cre-miR905-3p; +MIMAT0004387 cre-miR906-5p; +MIMAT0004388 cre-miR906-3p; +MIMAT0004389 cre-miR907; +MIMAT0004390 cre-miR908;cre-miR908.2; +MIMAT0004391 cre-miR909-5p;cre-miR909.2; +MIMAT0004392 cre-miR909-3p;cre-miR909.3; +MIMAT0004393 cre-miR910; +MIMAT0004394 cre-miR911; +MIMAT0004395 cre-miR912; +MIMAT0004396 cre-miR913;cre-miR913*;cre-miR913-3p; +MIMAT0004397 cre-miR914; +MIMAT0004398 cre-miR915; +MIMAT0004399 cre-miR919-5p.1;cre-miR919.2; +MIMAT0004400 cre-miR919-5p.2; +MIMAT0004401 cre-miR919-5p.3; +MIMAT0004402 cre-miR919-3p.1; +MIMAT0004403 cre-miR919-3p.2; +MIMAT0004404 cre-miR917; +MIMAT0004405 cre-miR916; +MIMAT0004406 rrv-miR-rR1-1;rrv-miR-rR1-1-5p; +MIMAT0004407 rrv-miR-rR1-1*;rrv-miR-rR1-1-3p; +MIMAT0004408 rrv-miR-rR1-2; +MIMAT0004409 rrv-miR-rR1-3; +MIMAT0004410 rrv-miR-rR1-4;rrv-miR-rR1-4-5p; +MIMAT0004411 rrv-miR-rR1-4*;rrv-miR-rR1-4-3p; +MIMAT0004412 rrv-miR-rR1-5; +MIMAT0004413 rrv-miR-rR1-6;rrv-miR-rR1-6-5p; +MIMAT0004414 rrv-miR-rR1-6*;rrv-miR-rR1-6-3p; +MIMAT0004415 rrv-miR-rR1-7-5p; +MIMAT0004416 rrv-miR-rR1-7-3p; +MIMAT0004417 cgr-miR-21;cgr-miR-21-5p; +MIMAT0004418 ame-let-7;ame-let-7-5p; +MIMAT0004419 ame-miR-10;ame-miR-10-5p; +MIMAT0004420 ame-miR-100;ame-miR-100-5p; +MIMAT0004421 ame-miR-137;ame-miR-137-3p; +MIMAT0004422 ame-miR-13a;ame-miR-13a-3p; +MIMAT0004423 ame-miR-14;ame-miR-14-3p; +MIMAT0004424 ame-miR-275;ame-miR-275-3p; +MIMAT0004425 ame-miR-279;ame-miR-279a;ame-miR-279a-3p; +MIMAT0004426 ame-miR-283;ame-miR-283-5p; +MIMAT0004427 ame-miR-29b;ame-miR-29b-3p; +MIMAT0004428 ame-miR-31a;ame-miR-31a-5p; +MIMAT0004429 ame-miR-33;ame-miR-33-5p; +MIMAT0004430 ame-miR-34;ame-miR-34-5p; +MIMAT0004431 ame-miR-375;ame-miR-375-3p; +MIMAT0004432 ame-miR-71;ame-miR-71-5p; +MIMAT0004433 ame-miR-79;ame-miR-79-3p; +MIMAT0004434 ame-miR-87;ame-miR-87-3p; +MIMAT0004435 ame-miR-92a;ame-miR-92a-3p; +MIMAT0004436 ame-miR-925; +MIMAT0004437 ame-miR-926; +MIMAT0004438 ame-miR-927;ame-miR-927a;ame-miR-927a-5p; +MIMAT0004439 ame-miR-928;ame-miR-928-5p; +MIMAT0004440 ame-miR-190;ame-miR-190-5p; +MIMAT0004441 ame-miR-929;ame-miR-929-5p; +MIMAT0004442 ame-miR-930; +MIMAT0004443 ame-miR-931; +MIMAT0004444 ame-miR-932;ame-miR-932-5p; +MIMAT0004445 bna-miR156a; +MIMAT0004446 bna-miR171;bna-miR171g; +MIMAT0004447 bna-miR393; +MIMAT0004448 bna-miR396a; +MIMAT0004449 bna-miR399;bna-miR399a; +MIMAT0004450 hsa-miR-297; +MIMAT0004451 mdv2-miR-M14-5p; +MIMAT0004452 mdv2-miR-M14-3p; +MIMAT0004453 mdv2-miR-M15*;mdv2-miR-M15-5p; +MIMAT0004454 mdv2-miR-M15;mdv2-miR-M15-3p; +MIMAT0004455 mdv2-miR-M16;mdv2-miR-M16-5p; +MIMAT0004456 mdv2-miR-M17*;mdv2-miR-M17-5p; +MIMAT0004457 mdv2-miR-M17;mdv2-miR-M17-3p; +MIMAT0004458 mdv2-miR-M18-5p; +MIMAT0004459 mdv2-miR-M18-3p; +MIMAT0004460 mdv2-miR-M19;mdv2-miR-M19-3p; +MIMAT0004461 mdv2-miR-M20*;mdv2-miR-M20-5p; +MIMAT0004462 mdv2-miR-M20;mdv2-miR-M20-3p; +MIMAT0004463 mdv2-miR-M21*;mdv2-miR-M21-5p; +MIMAT0004464 mdv2-miR-M21;mdv2-miR-M21-3p; +MIMAT0004465 mdv2-miR-M22;mdv2-miR-M22-5p; +MIMAT0004466 mdv2-miR-M22*;mdv2-miR-M22-3p; +MIMAT0004467 mdv2-miR-M23;mdv2-miR-M23-5p; +MIMAT0004468 mdv2-miR-M24;mdv2-miR-M24-3p; +MIMAT0004469 mdv2-miR-M25-5p; +MIMAT0004470 mdv2-miR-M25-3p; +MIMAT0004471 mdv2-miR-M26;mdv2-miR-M26-5p; +MIMAT0004472 mdv2-miR-M27-5p; +MIMAT0004473 mdv2-miR-M27-3p; +MIMAT0004474 mdv2-miR-M28;mdv2-miR-M28-5p; +MIMAT0004475 mdv2-miR-M28*;mdv2-miR-M28-3p; +MIMAT0004476 mdv2-miR-M29;mdv2-miR-M29-5p; +MIMAT0004477 mdv2-miR-M30;mdv2-miR-M30-5p; +MIMAT0004478 hiv1-miR-N367; +MIMAT0004479 hsv1-miR-LAT; +MIMAT0004480 hiv1-miR-H1; +MIMAT0004481 hsa-let-7a*;hsa-let-7a-3p; +MIMAT0004482 hsa-let-7b*;hsa-let-7b-3p; +MIMAT0004483 hsa-let-7c*; +MIMAT0004484 hsa-let-7d*;hsa-let-7d-3p; +MIMAT0004485 hsa-let-7e*;hsa-let-7e-3p; +MIMAT0004486 hsa-let-7f-1*;hsa-let-7f-1-3p; +MIMAT0004487 hsa-let-7f-2*;hsa-let-7f-2-3p; +MIMAT0004488 hsa-miR-15a*;hsa-miR-15a-3p; +MIMAT0004489 hsa-miR-16-1*;hsa-miR-16-1-3p; +MIMAT0004490 hsa-miR-19a*;hsa-miR-19a-5p; +MIMAT0004491 hsa-miR-19b-1*;hsa-miR-19b-1-5p; +MIMAT0004492 hsa-miR-19b-2*;hsa-miR-19b-2-5p; +MIMAT0004493 hsa-miR-20a*;hsa-miR-20a-3p; +MIMAT0004494 hsa-miR-21*;hsa-miR-21-3p; +MIMAT0004495 hsa-miR-22*;hsa-miR-22-5p; +MIMAT0004496 hsa-miR-23a*;hsa-miR-23a-5p; +MIMAT0004497 hsa-miR-24-2*;hsa-miR-24-2-5p; +MIMAT0004498 hsa-miR-25*;hsa-miR-25-5p; +MIMAT0004499 hsa-miR-26a-1*;hsa-miR-26a-1-3p; +MIMAT0004500 hsa-miR-26b*;hsa-miR-26b-3p; +MIMAT0004501 hsa-miR-27a*;hsa-miR-27a-5p; +MIMAT0004502 hsa-miR-28-3p; +MIMAT0004503 hsa-miR-29a*;hsa-miR-29a-5p; +MIMAT0004504 hsa-miR-31*;hsa-miR-31-3p; +MIMAT0004505 hsa-miR-32*;hsa-miR-32-3p; +MIMAT0004506 hsa-miR-33a*;hsa-miR-33a-3p; +MIMAT0004507 hsa-miR-92a-1*;hsa-miR-92a-1-5p; +MIMAT0004508 hsa-miR-92a-2*;hsa-miR-92a-2-5p; +MIMAT0004509 hsa-miR-93*;hsa-miR-93-3p; +MIMAT0004510 hsa-miR-96*;hsa-miR-96-3p; +MIMAT0004511 hsa-miR-99a*;hsa-miR-99a-3p; +MIMAT0004512 hsa-miR-100*;hsa-miR-100-3p; +MIMAT0004513 hsa-miR-101*;hsa-miR-101-5p; +MIMAT0004514 hsa-miR-29b-1*;hsa-miR-29b-1-5p; +MIMAT0004515 hsa-miR-29b-2*;hsa-miR-29b-2-5p; +MIMAT0004516 hsa-miR-105*;hsa-miR-105-3p; +MIMAT0004517 hsa-miR-106a*;hsa-miR-106a-3p; +MIMAT0004518 hsa-miR-16-2*;hsa-miR-16-2-3p; +MIMAT0004519 mmu-let-7g*;mmu-let-7g-3p; +MIMAT0004520 mmu-let-7i*;mmu-let-7i-3p; +MIMAT0004521 mmu-miR-15b*;mmu-miR-15b-3p; +MIMAT0004522 mmu-miR-27b*;mmu-miR-27b-5p; +MIMAT0004523 mmu-miR-29b*;mmu-miR-29b-1*;mmu-miR-29b-1-5p; +MIMAT0004524 mmu-miR-30b*;mmu-miR-30b-3p; +MIMAT0004525 mmu-miR-99b*;mmu-miR-99b-3p; +MIMAT0004526 mmu-miR-101a*;mmu-miR-101a-5p; +MIMAT0004527 mmu-miR-124*;mmu-miR-124-5p; +MIMAT0004528 mmu-miR-125a-3p; +MIMAT0004529 mmu-miR-125b*;mmu-miR-125b-2-3p; +MIMAT0004530 mmu-miR-127*;mmu-miR-127-5p; +MIMAT0004531 mmu-miR-135a*;mmu-miR-135a-1*;mmu-miR-135a-1-3p; +MIMAT0004532 mmu-miR-136*;mmu-miR-136-3p; +MIMAT0004533 mmu-miR-141*;mmu-miR-141-5p; +MIMAT0004534 mmu-miR-145*;mmu-miR-145-3p;mmu-miR-145a-3p; +MIMAT0004535 mmu-miR-150*;mmu-miR-150-3p; +MIMAT0004536 mmu-miR-151-5p; +MIMAT0004537 mmu-miR-154*;mmu-miR-154-3p; +MIMAT0004538 mmu-miR-10b*;mmu-miR-10b-3p; +MIMAT0004539 mmu-miR-183*;mmu-miR-183-3p; +MIMAT0004540 mmu-miR-186*;mmu-miR-186-3p; +MIMAT0004541 mmu-miR-188-3p; +MIMAT0004542 mmu-miR-191*;mmu-miR-191-3p; +MIMAT0004543 hsa-miR-192*;hsa-miR-192-3p; +MIMAT0004544 mmu-miR-193*;mmu-miR-193-5p;mmu-miR-193a-5p; +MIMAT0004545 mmu-miR-200b*;mmu-miR-200b-5p; +MIMAT0004546 mmu-miR-202-5p; +MIMAT0004547 mmu-miR-203*;mmu-miR-203-5p; +MIMAT0004548 hsa-miR-129*;hsa-miR-129-1-3p; +MIMAT0004549 hsa-miR-148a*;hsa-miR-148a-5p; +MIMAT0004550 hsa-miR-30c-2*;hsa-miR-30c-2-3p; +MIMAT0004551 hsa-miR-30d*;hsa-miR-30d-3p; +MIMAT0004552 hsa-miR-139-3p; +MIMAT0004553 hsa-miR-7-1*;hsa-miR-7-1-3p; +MIMAT0004554 hsa-miR-7-2*;hsa-miR-7-2-3p; +MIMAT0004555 hsa-miR-10a*;hsa-miR-10a-3p; +MIMAT0004556 hsa-miR-10b*;hsa-miR-10b-3p; +MIMAT0004557 hsa-miR-34a*;hsa-miR-34a-3p; +MIMAT0004558 hsa-miR-181a-2*;hsa-miR-181a-2-3p; +MIMAT0004559 hsa-miR-181c*;hsa-miR-181c-3p; +MIMAT0004560 hsa-miR-183*;hsa-miR-183-3p; +MIMAT0004561 hsa-miR-187*;hsa-miR-187-5p; +MIMAT0004562 hsa-miR-196a*;hsa-miR-196a-3p; +MIMAT0004563 hsa-miR-199b-3p; +MIMAT0004564 hsa-miR-214*;hsa-miR-214-5p; +MIMAT0004565 hsa-miR-218-1*;hsa-miR-218-1-3p; +MIMAT0004566 hsa-miR-218-2*;hsa-miR-218-2-3p; +MIMAT0004567 hsa-miR-219-1-3p;hsa-miR-219a-1-3p; +MIMAT0004568 hsa-miR-221*;hsa-miR-221-5p; +MIMAT0004569 hsa-miR-222*;hsa-miR-222-5p; +MIMAT0004570 hsa-miR-223*;hsa-miR-223-5p; +MIMAT0004571 hsa-miR-200b*;hsa-miR-200b-5p; +MIMAT0004572 mmu-miR-290-3p;mmu-miR-290a-3p; +MIMAT0004573 mmu-miR-293*;mmu-miR-293-5p; +MIMAT0004574 mmu-miR-294*;mmu-miR-294-5p; +MIMAT0004575 mmu-miR-295*;mmu-miR-295-5p; +MIMAT0004576 mmu-miR-296-3p; +MIMAT0004577 mmu-miR-299;mmu-miR-299-3p;mmu-miR-299a-3p; +MIMAT0004578 mmu-miR-300*;mmu-miR-300-5p; +MIMAT0004579 mmu-miR-302a*;mmu-miR-302a-5p; +MIMAT0004580 mmu-miR-34c*;mmu-miR-34c-3p; +MIMAT0004581 mmu-miR-34b-3p; +MIMAT0004582 mmu-miR-106b*;mmu-miR-106b-3p; +MIMAT0004583 mmu-miR-130b*;mmu-miR-130b-5p; +MIMAT0004584 hsa-let-7g*;hsa-let-7g-3p; +MIMAT0004585 hsa-let-7i*;hsa-let-7i-3p; +MIMAT0004586 hsa-miR-15b*;hsa-miR-15b-3p; +MIMAT0004587 hsa-miR-23b*;hsa-miR-23b-5p; +MIMAT0004588 hsa-miR-27b*;hsa-miR-27b-5p; +MIMAT0004589 hsa-miR-30b*;hsa-miR-30b-3p; +MIMAT0004590 hsa-miR-122*;hsa-miR-122-3p; +MIMAT0004591 hsa-miR-124*;hsa-miR-124-5p; +MIMAT0004592 hsa-miR-125b-1*;hsa-miR-125b-1-3p; +MIMAT0004593 hsa-miR-130a*;hsa-miR-130a-5p; +MIMAT0004594 hsa-miR-132*;hsa-miR-132-5p; +MIMAT0004595 hsa-miR-135a*;hsa-miR-135a-3p; +MIMAT0004596 hsa-miR-138-2*;hsa-miR-138-2-3p; +MIMAT0004597 hsa-miR-140-3p; +MIMAT0004598 hsa-miR-141*;hsa-miR-141-5p; +MIMAT0004599 hsa-miR-143*;hsa-miR-143-5p; +MIMAT0004600 hsa-miR-144*;hsa-miR-144-5p; +MIMAT0004601 hsa-miR-145*;hsa-miR-145-3p; +MIMAT0004602 hsa-miR-125a-3p; +MIMAT0004603 hsa-miR-125b-2*;hsa-miR-125b-2-3p; +MIMAT0004604 hsa-miR-127-5p; +MIMAT0004605 hsa-miR-129-3p;hsa-miR-129-2-3p; +MIMAT0004606 hsa-miR-136*;hsa-miR-136-3p; +MIMAT0004607 hsa-miR-138-1*;hsa-miR-138-1-3p; +MIMAT0004608 hsa-miR-146a*;hsa-miR-146a-3p; +MIMAT0004609 hsa-miR-149*;hsa-miR-149-3p; +MIMAT0004610 hsa-miR-150*;hsa-miR-150-3p; +MIMAT0004611 hsa-miR-185*;hsa-miR-185-3p; +MIMAT0004612 hsa-miR-186*;hsa-miR-186-3p; +MIMAT0004613 hsa-miR-188-3p; +MIMAT0004614 hsa-miR-193a-5p; +MIMAT0004615 hsa-miR-195*;hsa-miR-195-3p; +MIMAT0004616 mmu-miR-30c-1*;mmu-miR-30c-1-3p; +MIMAT0004617 mmu-miR-148a*;mmu-miR-148a-5p; +MIMAT0004618 mmu-miR-196a*;mmu-miR-196a-2*;mmu-miR-196a-2-3p; +MIMAT0004619 mmu-miR-200a*;mmu-miR-200a-5p; +MIMAT0004620 mmu-let-7a*;mmu-let-7a-1*;mmu-let-7a-1-3p; +MIMAT0004621 mmu-let-7b*;mmu-let-7b-3p; +MIMAT0004622 mmu-let-7c-1*;mmu-let-7c-1-3p; +MIMAT0004623 mmu-let-7f*;mmu-let-7f-1*;mmu-let-7f-1-3p; +MIMAT0004624 mmu-miR-15a*;mmu-miR-15a-3p; +MIMAT0004625 mmu-miR-16*;mmu-miR-16-1*;mmu-miR-16-1-3p; +MIMAT0004626 mmu-miR-18a*;mmu-miR-18a-3p; +MIMAT0004627 mmu-miR-20a*;mmu-miR-20a-3p; +MIMAT0004628 mmu-miR-21*;mmu-miR-21-3p;mmu-miR-21a-3p; +MIMAT0004629 mmu-miR-22*;mmu-miR-22-5p; +MIMAT0004630 mmu-miR-26b*;mmu-miR-26b-3p; +MIMAT0004631 mmu-miR-29a*;mmu-miR-29a-5p; +MIMAT0004632 mmu-miR-29c*;mmu-miR-29c-5p; +MIMAT0004633 mmu-miR-27a*;mmu-miR-27a-5p; +MIMAT0004634 mmu-miR-31*;mmu-miR-31-3p; +MIMAT0004635 mmu-miR-92a*;mmu-miR-92a-2*;mmu-miR-92a-2-5p; +MIMAT0004636 mmu-miR-93*;mmu-miR-93-3p; +MIMAT0004637 rno-miR-323*;rno-miR-323-5p; +MIMAT0004638 mmu-miR-323-5p; +MIMAT0004639 rno-miR-325-3p; +MIMAT0004640 mmu-miR-325;mmu-miR-325-3p; +MIMAT0004641 rno-miR-330;rno-miR-330-5p; +MIMAT0004642 mmu-miR-330;mmu-miR-330-5p; +MIMAT0004643 mmu-miR-331-5p; +MIMAT0004644 mmu-miR-337-5p; +MIMAT0004645 rno-miR-148b-5p; +MIMAT0004646 rno-miR-338*;rno-miR-338-5p; +MIMAT0004647 mmu-miR-338-5p; +MIMAT0004648 rno-miR-339-3p; +MIMAT0004649 mmu-miR-339-3p; +MIMAT0004650 rno-miR-340-5p; +MIMAT0004651 mmu-miR-340-5p; +MIMAT0004652 rno-miR-342-5p; +MIMAT0004653 mmu-miR-342-5p; +MIMAT0004654 rno-miR-344-5p;rno-miR-344a-5p; +MIMAT0004655 rno-miR-345-3p; +MIMAT0004656 mmu-miR-345-3p; +MIMAT0004657 hsa-miR-200c*;hsa-miR-200c-5p; +MIMAT0004658 hsa-miR-155*;hsa-miR-155-3p; +MIMAT0004659 mmu-miR-10a*;mmu-miR-10a-3p; +MIMAT0004660 mmu-miR-19a*;mmu-miR-19a-5p; +MIMAT0004661 mmu-miR-28*;mmu-miR-28-3p;mmu-miR-28a-3p; +MIMAT0004662 mmu-miR-139-3p; +MIMAT0004663 mmu-miR-200c*;mmu-miR-200c-5p; +MIMAT0004664 mmu-miR-214*;mmu-miR-214-5p; +MIMAT0004665 mmu-miR-218-1*;mmu-miR-218-1-3p; +MIMAT0004666 mmu-miR-33*;mmu-miR-33-3p; +MIMAT0004667 mmu-miR-199b;mmu-miR-199b-3p; +MIMAT0004668 mmu-miR-138*;mmu-miR-138-1*;mmu-miR-138-1-3p; +MIMAT0004669 mmu-miR-125b-3p;mmu-miR-125b-1-3p; +MIMAT0004670 mmu-miR-7a*;mmu-miR-7a-1*;mmu-miR-7a-1-3p; +MIMAT0004671 hsa-miR-194*;hsa-miR-194-3p; +MIMAT0004672 hsa-miR-106b*;hsa-miR-106b-3p; +MIMAT0004673 hsa-miR-29c*;hsa-miR-29c-5p; +MIMAT0004674 hsa-miR-30c-1*;hsa-miR-30c-1-3p; +MIMAT0004675 hsa-miR-219-2-3p;hsa-miR-219a-2-3p; +MIMAT0004676 hsa-miR-34b;hsa-miR-34b-3p; +MIMAT0004677 hsa-miR-34c-3p; +MIMAT0004678 hsa-miR-99b*;hsa-miR-99b-3p; +MIMAT0004679 hsa-miR-296-3p; +MIMAT0004680 hsa-miR-130b*;hsa-miR-130b-5p; +MIMAT0004681 hsa-miR-26a-2*;hsa-miR-26a-2-3p; +MIMAT0004682 hsa-miR-361-3p; +MIMAT0004683 hsa-miR-362-3p; +MIMAT0004684 mmu-miR-362-3p; +MIMAT0004685 hsa-miR-302d*;hsa-miR-302d-5p; +MIMAT0004686 hsa-miR-367*;hsa-miR-367-5p; +MIMAT0004687 hsa-miR-371-5p;hsa-miR-371a-5p; +MIMAT0004688 hsa-miR-374a*;hsa-miR-374a-3p; +MIMAT0004689 hsa-miR-377*;hsa-miR-377-5p; +MIMAT0004690 hsa-miR-379*;hsa-miR-379-3p; +MIMAT0004691 mmu-miR-382*;mmu-miR-382-3p; +MIMAT0004692 hsa-miR-340;hsa-miR-340-5p; +MIMAT0004693 hsa-miR-330-5p; +MIMAT0004694 hsa-miR-342-5p; +MIMAT0004695 hsa-miR-337-5p; +MIMAT0004696 hsa-miR-323-5p;hsa-miR-323a-5p; +MIMAT0004697 hsa-miR-151-5p;hsa-miR-151a-5p; +MIMAT0004698 hsa-miR-135b*;hsa-miR-135b-3p; +MIMAT0004699 hsa-miR-148b*;hsa-miR-148b-5p; +MIMAT0004700 hsa-miR-331-5p; +MIMAT0004701 hsa-miR-338-5p; +MIMAT0004702 hsa-miR-339-3p; +MIMAT0004703 hsa-miR-335*;hsa-miR-335-3p; +MIMAT0004704 mmu-miR-335-3p; +MIMAT0004705 rno-let-7b*;rno-let-7b-3p; +MIMAT0004706 rno-let-7e*;rno-let-7e-3p; +MIMAT0004707 rno-let-7i*;rno-let-7i-3p; +MIMAT0004708 rno-miR-9*;rno-miR-9a-3p; +MIMAT0004709 rno-miR-10a-3p; +MIMAT0004710 rno-miR-17-3p;rno-miR-17-1-3p; +MIMAT0004711 rno-miR-21*;rno-miR-21-3p; +MIMAT0004712 rno-miR-23a*;rno-miR-23a-5p; +MIMAT0004713 rno-miR-25*;rno-miR-25-5p; +MIMAT0004714 rno-miR-26b*;rno-miR-26b-3p; +MIMAT0004715 rno-miR-27a*;rno-miR-27a-5p; +MIMAT0004716 rno-miR-28*;rno-miR-28-3p; +MIMAT0004717 rno-miR-29b-2*;rno-miR-29b-2-5p;rno-miR-29b-5p; +MIMAT0004718 rno-miR-29a*;rno-miR-29a-5p; +MIMAT0004719 rno-miR-30c-1*;rno-miR-30c-1-3p; +MIMAT0004720 rno-miR-30e*;rno-miR-30e-3p; +MIMAT0004721 rno-miR-30b-3p; +MIMAT0004722 rno-miR-30d*;rno-miR-30d-3p; +MIMAT0004723 rno-miR-34c*;rno-miR-34c-3p; +MIMAT0004724 rno-miR-99a*;rno-miR-99a-3p; +MIMAT0004725 rno-miR-99b*;rno-miR-99b-3p; +MIMAT0004726 rno-miR-101a*;rno-miR-101a-5p; +MIMAT0004727 rno-miR-106b*;rno-miR-106b-3p; +MIMAT0004728 rno-miR-124*;rno-miR-124-5p; +MIMAT0004729 rno-miR-125a-3p; +MIMAT0004730 rno-miR-125b-3p;rno-miR-125b-1-3p; +MIMAT0004731 rno-miR-125b*; +MIMAT0004732 rno-miR-135a*;rno-miR-135a-3p; +MIMAT0004733 rno-miR-136*;rno-miR-136-3p; +MIMAT0004734 rno-miR-138*;rno-miR-138-1*;rno-miR-138-1-3p; +MIMAT0004735 rno-miR-139-3p; +MIMAT0004736 rno-miR-193*;rno-miR-193-5p;rno-miR-193a-5p; +MIMAT0004737 rno-miR-196a*;rno-miR-196a-3p; +MIMAT0004738 rno-miR-199a-3p; +MIMAT0004739 rno-miR-204*;rno-miR-204-3p; +MIMAT0004740 rno-miR-218*;rno-miR-218-2*;rno-miR-218a-2*;rno-miR-218a-2-3p; +MIMAT0004741 rno-miR-219-1-3p;rno-miR-219a-1-3p; +MIMAT0004742 rno-miR-296;rno-miR-296-3p; +MIMAT0004743 rno-miR-300-5p; +MIMAT0004744 ebv-miR-BART2-3p; +MIMAT0004745 mmu-miR-384-5p; +MIMAT0004746 mmu-miR-409-5p; +MIMAT0004747 mmu-miR-411;mmu-miR-411-5p; +MIMAT0004748 hsa-miR-423-5p; +MIMAT0004749 hsa-miR-424*;hsa-miR-424-3p; +MIMAT0004750 mmu-miR-425;mmu-miR-425-5p; +MIMAT0004751 hsa-miR-18b*;hsa-miR-18b-3p; +MIMAT0004752 hsa-miR-20b*;hsa-miR-20b-3p; +MIMAT0004753 mmu-miR-431*;mmu-miR-431-3p; +MIMAT0004754 hcmv-miR-UL36*;hcmv-miR-UL36-3p; +MIMAT0004755 hcmv-miR-US25-1*;hcmv-miR-US25-1-3p; +MIMAT0004756 hcmv-miR-US33-3p; +MIMAT0004757 hsa-miR-431*;hsa-miR-431-3p; +MIMAT0004758 mmu-miR-463;mmu-miR-463-3p; +MIMAT0004759 mmu-miR-466a-5p; +MIMAT0004760 mmu-miR-470*;mmu-miR-470-3p; +MIMAT0004761 hsa-miR-483-5p; +MIMAT0004762 hsa-miR-486-3p; +MIMAT0004763 hsa-miR-488;hsa-miR-488-3p; +MIMAT0004764 hsa-miR-490-5p; +MIMAT0004765 hsa-miR-491-3p; +MIMAT0004766 hsa-miR-146b-3p; +MIMAT0004767 hsa-miR-193b*;hsa-miR-193b-5p; +MIMAT0004768 hsa-miR-497*;hsa-miR-497-3p; +MIMAT0004770 hsa-miR-516a-5p; +MIMAT0004771 hsa-miR-516a-5p; +MIMAT0004772 hsa-miR-499-3p;hsa-miR-499a-3p; +MIMAT0004773 hsa-miR-500;hsa-miR-500a;hsa-miR-500a-5p; +MIMAT0004774 hsa-miR-501-3p; +MIMAT0004775 hsa-miR-502-3p; +MIMAT0004776 hsa-miR-505*;hsa-miR-505-5p; +MIMAT0004777 hsa-miR-513-3p;hsa-miR-513a-3p; +MIMAT0004778 hsa-miR-508-5p; +MIMAT0004779 hsa-miR-509-5p; +MIMAT0004780 hsa-miR-532-3p; +MIMAT0004781 mmu-miR-532-3p; +MIMAT0004782 mmu-miR-483;mmu-miR-483-5p; +MIMAT0004783 ppt-miR533a;ppt-miR533a-3p; +MIMAT0004784 hsa-miR-455-3p; +MIMAT0004785 hsa-miR-545*;hsa-miR-545-5p; +MIMAT0004786 mmu-miR-540-5p; +MIMAT0004787 rno-miR-543;rno-miR-543-5p; +MIMAT0004788 mmu-miR-20b*;mmu-miR-20b-3p; +MIMAT0004789 mmu-miR-450a-3p;mmu-miR-450a-2*;mmu-miR-450a-2-3p; +MIMAT0004790 mmu-miR-503*;mmu-miR-503-3p; +MIMAT0004791 rno-miR-379*;rno-miR-379-3p; +MIMAT0004792 hsa-miR-92b*;hsa-miR-92b-5p; +MIMAT0004793 hsa-miR-556-3p; +MIMAT0004794 hsa-miR-551b*;hsa-miR-551b-5p; +MIMAT0004795 hsa-miR-574-5p; +MIMAT0004796 hsa-miR-576-3p; +MIMAT0004797 hsa-miR-582-3p; +MIMAT0004798 hsa-miR-548b-5p; +MIMAT0004799 hsa-miR-589;hsa-miR-589-5p; +MIMAT0004800 hsa-miR-550;hsa-miR-550a;hsa-miR-550a-5p; +MIMAT0004801 hsa-miR-590-3p; +MIMAT0004802 hsa-miR-593;hsa-miR-593-3p; +MIMAT0004803 hsa-miR-548a-5p; +MIMAT0004804 hsa-miR-615-5p; +MIMAT0004805 hsa-miR-616;hsa-miR-616-3p; +MIMAT0004806 hsa-miR-548c-5p; +MIMAT0004807 hsa-miR-624;hsa-miR-624-3p; +MIMAT0004808 hsa-miR-625*;hsa-miR-625-3p; +MIMAT0004809 hsa-miR-628-5p; +MIMAT0004810 hsa-miR-629;hsa-miR-629-5p; +MIMAT0004811 hsa-miR-33b*;hsa-miR-33b-3p; +MIMAT0004812 hsa-miR-548d-5p; +MIMAT0004813 hsa-miR-411*;hsa-miR-411-3p; +MIMAT0004814 hsa-miR-654-3p; +MIMAT0004815 ebv-miR-BART7*;ebv-miR-BART7-5p; +MIMAT0004816 ebv-miR-BART9*;ebv-miR-BART9-5p; +MIMAT0004817 ebv-miR-BART10*;ebv-miR-BART10-5p; +MIMAT0004818 ebv-miR-BART13*;ebv-miR-BART13-5p; +MIMAT0004819 hsa-miR-671-3p; +MIMAT0004820 mmu-miR-744*;mmu-miR-744-3p; +MIMAT0004821 mmu-miR-671-3p; +MIMAT0004822 mmu-miR-770-5p; +MIMAT0004823 mmu-miR-666-3p; +MIMAT0004824 mmu-miR-673-3p; +MIMAT0004825 mmu-miR-423-5p; +MIMAT0004826 mmu-miR-146b*;mmu-miR-146b-3p; +MIMAT0004827 mmu-miR-297b-3p; +MIMAT0004828 mmu-miR-708;mmu-miR-708-5p; +MIMAT0004829 ppt-miR1211;ppt-miR1211-3p; +MIMAT0004830 ppt-miR1217-5p; +MIMAT0004831 ppt-miR1220a; +MIMAT0004832 ppt-miR1220b; +MIMAT0004833 ppt-miR533b-3p; +MIMAT0004834 ppt-miR1221-3p; +MIMAT0004835 ebv-miR-BART18-3p; +MIMAT0004836 ebv-miR-BART19-5p; +MIMAT0004837 mmu-miR-615-5p; +MIMAT0004838 mmu-miR-742*;mmu-miR-742-5p; +MIMAT0004839 mmu-miR-743b-5p; +MIMAT0004840 mmu-miR-743b-3p; +MIMAT0004841 mmu-miR-871;mmu-miR-871-5p; +MIMAT0004842 mmu-miR-879;mmu-miR-879-5p; +MIMAT0004843 mmu-miR-879*;mmu-miR-879-3p; +MIMAT0004844 mmu-miR-880;mmu-miR-880-3p; +MIMAT0004845 mmu-miR-881*;mmu-miR-881-5p; +MIMAT0004846 mmu-miR-881;mmu-miR-881-3p; +MIMAT0004847 mmu-miR-882; +MIMAT0004848 mmu-miR-883a-5p; +MIMAT0004849 mmu-miR-883a-3p; +MIMAT0004850 mmu-miR-883b-5p; +MIMAT0004851 mmu-miR-883b-3p; +MIMAT0004852 mmu-miR-190b;mmu-miR-190b-5p; +MIMAT0004853 mmu-miR-874;mmu-miR-874-3p; +MIMAT0004854 mmu-miR-876-5p; +MIMAT0004855 mmu-miR-876-3p; +MIMAT0004856 mmu-miR-105; +MIMAT0004857 mmu-miR-147;mmu-miR-147-3p; +MIMAT0004858 mmu-miR-18b;mmu-miR-18b-5p; +MIMAT0004859 mmu-miR-193b;mmu-miR-193b-3p; +MIMAT0004860 mmu-miR-197; +MIMAT0004861 mmu-miR-877;mmu-miR-877-5p; +MIMAT0004862 mmu-miR-877*;mmu-miR-877-3p; +MIMAT0004863 mmu-miR-220; +MIMAT0004864 mmu-miR-297a*;mmu-miR-297a-3p; +MIMAT0004865 mmu-miR-297c;mmu-miR-297c-5p; +MIMAT0004866 mmu-miR-297c*;mmu-miR-297c-3p; +MIMAT0004867 mmu-miR-327; +MIMAT0004868 mmu-miR-343; +MIMAT0004869 mmu-miR-421;mmu-miR-421-3p; +MIMAT0004870 mmu-miR-453; +MIMAT0004871 mmu-miR-465b-5p; +MIMAT0004872 mmu-miR-465b-3p; +MIMAT0004873 mmu-miR-465c-5p; +MIMAT0004874 mmu-miR-465c-3p; +MIMAT0004875 mmu-miR-466b-5p; +MIMAT0004876 mmu-miR-466b-3p; +MIMAT0004877 mmu-miR-466c-5p; +MIMAT0004878 mmu-miR-466c-3p; +MIMAT0004879 mmu-miR-466e-5p; +MIMAT0004880 mmu-miR-466e-3p; +MIMAT0004881 mmu-miR-466f-5p; +MIMAT0004882 mmu-miR-466f-3p; +MIMAT0004883 mmu-miR-466g; +MIMAT0004884 mmu-miR-466h;mmu-miR-466h-5p; +MIMAT0004885 mmu-miR-467c;mmu-miR-467c-5p; +MIMAT0004886 mmu-miR-467d;mmu-miR-467d-5p; +MIMAT0004887 mmu-miR-467d*;mmu-miR-467d-3p; +MIMAT0004888 mmu-miR-493;mmu-miR-493-3p; +MIMAT0004889 mmu-miR-504;mmu-miR-504-5p; +MIMAT0004890 mmu-miR-509-5p; +MIMAT0004891 mmu-miR-509-3p; +MIMAT0004892 mmu-miR-568; +MIMAT0004893 mmu-miR-574-5p; +MIMAT0004894 mmu-miR-574-3p; +MIMAT0004895 mmu-miR-590-5p; +MIMAT0004896 mmu-miR-590-3p; +MIMAT0004897 mmu-miR-654-5p; +MIMAT0004898 mmu-miR-654-3p; +MIMAT0004899 mmu-miR-92b;mmu-miR-92b-3p; +MIMAT0004900 hsa-miR-672; +MIMAT0004901 hsa-miR-298; +MIMAT0004902 hsa-miR-891a;hsa-miR-891a-5p; +MIMAT0004903 hsa-miR-300; +MIMAT0004904 hsa-miR-871; +MIMAT0004905 hsa-miR-886-5p; +MIMAT0004906 hsa-miR-886-3p; +MIMAT0004907 hsa-miR-892a; +MIMAT0004908 hsa-miR-220b; +MIMAT0004909 hsa-miR-450b-5p; +MIMAT0004910 hsa-miR-450b-3p; +MIMAT0004911 hsa-miR-874;hsa-miR-874-3p; +MIMAT0004912 hsa-miR-890; +MIMAT0004913 hsa-miR-891b; +MIMAT0004914 hsa-miR-674; +MIMAT0004915 hsa-miR-220c; +MIMAT0004916 hsa-miR-888;hsa-miR-888-5p; +MIMAT0004917 hsa-miR-888*;hsa-miR-888-3p; +MIMAT0004918 hsa-miR-892b; +MIMAT0004919 hsa-miR-541*;hsa-miR-541-5p; +MIMAT0004920 hsa-miR-541;hsa-miR-541-3p; +MIMAT0004921 hsa-miR-889;hsa-miR-889-3p; +MIMAT0004922 hsa-miR-875-5p; +MIMAT0004923 hsa-miR-875-3p; +MIMAT0004924 hsa-miR-876-5p; +MIMAT0004925 hsa-miR-876-3p; +MIMAT0004926 hsa-miR-708;hsa-miR-708-5p; +MIMAT0004927 hsa-miR-708*;hsa-miR-708-3p; +MIMAT0004928 hsa-miR-147b;hsa-miR-147b-3p; +MIMAT0004929 hsa-miR-190b;hsa-miR-190b-5p; +MIMAT0004930 mmu-miR-466d-5p; +MIMAT0004931 mmu-miR-466d-3p; +MIMAT0004932 mmu-miR-878-5p; +MIMAT0004933 mmu-miR-878-3p; +MIMAT0004934 mmu-miR-872;mmu-miR-872-5p; +MIMAT0004935 mmu-miR-872*;mmu-miR-872-3p; +MIMAT0004936 mmu-miR-873;mmu-miR-873-5p;mmu-miR-873a-5p; +MIMAT0004937 mmu-miR-875-5p; +MIMAT0004938 mmu-miR-875-3p; +MIMAT0004939 mmu-miR-208b;mmu-miR-208b-3p; +MIMAT0004940 mmu-miR-511;mmu-miR-511-5p; +MIMAT0004941 mmu-miR-544;mmu-miR-544-3p; +MIMAT0004942 mmu-miR-598;mmu-miR-598-3p; +MIMAT0004943 mmu-miR-653;mmu-miR-653-5p; +MIMAT0004944 hsa-miR-872; +MIMAT0004945 hsa-miR-744;hsa-miR-744-5p; +MIMAT0004946 hsa-miR-744*;hsa-miR-744-3p; +MIMAT0004947 hsa-miR-885-5p; +MIMAT0004948 hsa-miR-885-3p; +MIMAT0004949 hsa-miR-877;hsa-miR-877-5p; +MIMAT0004950 hsa-miR-877*;hsa-miR-877-3p; +MIMAT0004951 hsa-miR-887;hsa-miR-887-3p; +MIMAT0004952 hsa-miR-665; +MIMAT0004953 hsa-miR-873;hsa-miR-873-5p; +MIMAT0004954 hsa-miR-543; +MIMAT0004955 hsa-miR-374b;hsa-miR-374b-5p; +MIMAT0004956 hsa-miR-374b*;hsa-miR-374b-3p; +MIMAT0004957 hsa-miR-760; +MIMAT0004958 hsa-miR-301b;hsa-miR-301b-3p; +MIMAT0004959 hsa-miR-216b;hsa-miR-216b-5p; +MIMAT0004960 hsa-miR-208b;hsa-miR-208b-3p; +MIMAT0004961 ppt-miR900-5p; +MIMAT0004962 ppt-miR902a-5p; +MIMAT0004963 ppt-miR902b-5p; +MIMAT0004964 cre-miR905*;cre-miR905-5p; +MIMAT0004965 cre-miR908.1; +MIMAT0004966 cre-miR908.3; +MIMAT0004967 cre-miR909.1; +MIMAT0004968 cre-miR913;cre-miR913-5p; +MIMAT0004969 cre-miR919.1; +MIMAT0004970 hsa-miR-920; +MIMAT0004971 hsa-miR-921; +MIMAT0004972 hsa-miR-922; +MIMAT0004973 hsa-miR-923; +MIMAT0004974 hsa-miR-924; +MIMAT0004975 hsa-miR-509-3-5p; +MIMAT0004976 hsa-miR-933; +MIMAT0004977 hsa-miR-934; +MIMAT0004978 hsa-miR-935; +MIMAT0004979 hsa-miR-936; +MIMAT0004980 hsa-miR-937;hsa-miR-937-3p; +MIMAT0004981 hsa-miR-938; +MIMAT0004982 hsa-miR-939;hsa-miR-939-5p; +MIMAT0004983 hsa-miR-940; +MIMAT0004984 hsa-miR-941; +MIMAT0004985 hsa-miR-942;hsa-miR-942-5p; +MIMAT0004986 hsa-miR-943; +MIMAT0004987 hsa-miR-944; +MIMAT0004988 pta-miR156a; +MIMAT0004989 pta-miR156b; +MIMAT0004990 pta-miR159a; +MIMAT0004991 pta-miR159b; +MIMAT0004992 pta-miR159c; +MIMAT0004993 pta-miR166a; +MIMAT0004994 pta-miR166b; +MIMAT0004995 pta-miR166c; +MIMAT0004996 pta-miR171; +MIMAT0004997 pta-miR319; +MIMAT0004998 pta-miR390; +MIMAT0004999 pta-miR396; +MIMAT0005000 pta-miR398; +MIMAT0005001 pta-miR408; +MIMAT0005002 pta-miR482a; +MIMAT0005003 pta-miR482b; +MIMAT0005004 pta-miR783; +MIMAT0005005 pta-miR946a;pta-miR946a-3p; +MIMAT0005006 pta-miR946b; +MIMAT0005007 pta-miR947; +MIMAT0005008 pta-miR948; +MIMAT0005009 pta-miR949; +MIMAT0005010 pta-miR950a; +MIMAT0005011 pta-miR950b; +MIMAT0005012 pta-miR951; +MIMAT0005013 pta-miR952a; +MIMAT0005014 pta-miR952b; +MIMAT0005015 osa-miR529b; +MIMAT0005016 dme-miR-1003;dme-miR-1003-3p; +MIMAT0005017 dme-miR-1004;dme-miR-1004-3p; +MIMAT0005018 dme-miR-1005;dme-miR-1005-3p; +MIMAT0005019 dme-miR-1006;dme-miR-1006-3p; +MIMAT0005020 dme-miR-1007;dme-miR-1007-3p; +MIMAT0005021 dme-miR-1008;dme-miR-1008-3p; +MIMAT0005022 dme-miR-1009;dme-miR-1009-3p; +MIMAT0005023 dme-miR-1010;dme-miR-1010-3p; +MIMAT0005024 dme-miR-1011;dme-miR-1011-3p; +MIMAT0005025 dme-miR-1012;dme-miR-1012-3p; +MIMAT0005026 dme-miR-1013;dme-miR-1013-3p; +MIMAT0005027 dme-miR-1014;dme-miR-1014-3p; +MIMAT0005028 dme-miR-1015;dme-miR-1015-3p; +MIMAT0005029 dme-miR-1016;dme-miR-1016-3p; +MIMAT0005030 dme-miR-1017;dme-miR-1017-3p; +MIMAT0005031 cel-miR-1018; +MIMAT0005032 cel-miR-1019;cel-miR-1019-3p; +MIMAT0005033 cel-miR-1020;cel-miR-1020-3p; +MIMAT0005034 ppt-miR160e; +MIMAT0005035 ppt-miR160f; +MIMAT0005036 ppt-miR160g; +MIMAT0005037 ppt-miR160h; +MIMAT0005038 ppt-miR160i; +MIMAT0005039 ppt-miR166c; +MIMAT0005040 ppt-miR166d; +MIMAT0005041 ppt-miR166e; +MIMAT0005042 ppt-miR166f; +MIMAT0005043 ppt-miR166g; +MIMAT0005044 ppt-miR166h; +MIMAT0005045 ppt-miR166i; +MIMAT0005046 ppt-miR166j; +MIMAT0005047 ppt-miR166k; +MIMAT0005048 ppt-miR166l; +MIMAT0005049 ppt-miR166m; +MIMAT0005050 ppt-miR408b; +MIMAT0005051 ppt-miR477d; +MIMAT0005052 ppt-miR477e; +MIMAT0005053 ppt-miR477h; +MIMAT0005054 ppt-miR529a; +MIMAT0005055 ppt-miR529b; +MIMAT0005056 ppt-miR529c; +MIMAT0005057 ppt-miR529d; +MIMAT0005058 ppt-miR529e; +MIMAT0005059 ppt-miR529f; +MIMAT0005060 ppt-miR529g; +MIMAT0005061 ppt-miR533c; +MIMAT0005062 ppt-miR533d; +MIMAT0005063 ppt-miR533e; +MIMAT0005064 ppt-miR536d; +MIMAT0005065 ppt-miR536e; +MIMAT0005066 ppt-miR536f; +MIMAT0005067 ppt-miR537c; +MIMAT0005068 ppt-miR537d; +MIMAT0005069 ppt-miR902c-5p; +MIMAT0005070 ppt-miR902c-3p; +MIMAT0005071 ppt-miR902d-5p; +MIMAT0005072 ppt-miR902d-3p; +MIMAT0005073 ppt-miR902e-5p; +MIMAT0005074 ppt-miR902e-3p; +MIMAT0005075 ppt-miR902f-5p; +MIMAT0005076 ppt-miR902f-3p; +MIMAT0005077 ppt-miR902g-5p; +MIMAT0005078 ppt-miR902g-3p; +MIMAT0005079 ppt-miR902h-5p; +MIMAT0005080 ppt-miR902h-3p; +MIMAT0005081 ppt-miR902i-5p; +MIMAT0005082 ppt-miR902i-3p; +MIMAT0005083 ppt-miR902j-5p; +MIMAT0005084 ppt-miR902j-3p; +MIMAT0005085 ppt-miR902k-5p; +MIMAT0005086 ppt-miR902k-3p; +MIMAT0005087 ppt-miR902l-5p; +MIMAT0005088 ppt-miR902l-3p; +MIMAT0005089 ppt-miR1222b; +MIMAT0005090 ppt-miR1222c; +MIMAT0005091 ppt-miR1222d; +MIMAT0005092 ppt-miR1222e; +MIMAT0005093 ppt-miR1223b; +MIMAT0005094 ppt-miR1223c; +MIMAT0005095 ppt-miR1223d; +MIMAT0005096 ppt-miR1223e; +MIMAT0005097 ppt-miR1223f; +MIMAT0005098 ppt-miR1223g; +MIMAT0005099 ppt-miR1223h; +MIMAT0005100 ppt-miR1223i; +MIMAT0005101 ppt-miR1223j; +MIMAT0005102 ppt-miR1023a-5p; +MIMAT0005103 ppt-miR1023a-3p; +MIMAT0005104 ppt-miR1023b-5p; +MIMAT0005105 ppt-miR1023b-3p; +MIMAT0005106 ppt-miR1023c-5p; +MIMAT0005107 ppt-miR1023c-3p; +MIMAT0005108 ppt-miR1023d-5p; +MIMAT0005109 ppt-miR1024a; +MIMAT0005110 ppt-miR1024b; +MIMAT0005111 ppt-miR1025; +MIMAT0005112 ppt-miR1026a; +MIMAT0005113 ppt-miR1026b; +MIMAT0005114 ppt-miR1027a; +MIMAT0005115 ppt-miR1027b; +MIMAT0005116 ppt-miR1028a-5p; +MIMAT0005117 ppt-miR1028a-3p; +MIMAT0005118 ppt-miR1028b-5p; +MIMAT0005119 ppt-miR1028b-3p; +MIMAT0005120 ppt-miR1028c-5p; +MIMAT0005121 ppt-miR1028c-3p; +MIMAT0005122 ppt-miR1029; +MIMAT0005123 ppt-miR1030a; +MIMAT0005124 ppt-miR1030b; +MIMAT0005125 ppt-miR1030c; +MIMAT0005126 ppt-miR1030d; +MIMAT0005127 ppt-miR1030e; +MIMAT0005128 ppt-miR1030f; +MIMAT0005129 ppt-miR1030g; +MIMAT0005130 ppt-miR1030h; +MIMAT0005131 ppt-miR1030i; +MIMAT0005132 ppt-miR1030j; +MIMAT0005133 ppt-miR1031a; +MIMAT0005134 ppt-miR1031b; +MIMAT0005135 ppt-miR1032; +MIMAT0005136 ppt-miR1033a; +MIMAT0005137 ppt-miR1033b; +MIMAT0005138 ppt-miR1033c; +MIMAT0005139 ppt-miR1033d; +MIMAT0005140 ppt-miR1033e; +MIMAT0005141 ppt-miR1034; +MIMAT0005142 ppt-miR1035; +MIMAT0005143 ppt-miR1036-5p; +MIMAT0005144 ppt-miR1036-3p; +MIMAT0005145 ppt-miR1037; +MIMAT0005146 ppt-miR1038-5p; +MIMAT0005147 ppt-miR1038-3p; +MIMAT0005148 ppt-miR1039-5p; +MIMAT0005149 ppt-miR1039-3p; +MIMAT0005150 ppt-miR1040; +MIMAT0005151 ppt-miR1041; +MIMAT0005152 ppt-miR1042-5p; +MIMAT0005153 ppt-miR1042-3p; +MIMAT0005154 ppt-miR1043-5p; +MIMAT0005155 ppt-miR1043-3p; +MIMAT0005156 ppt-miR1044-5p; +MIMAT0005157 ppt-miR1044-3p; +MIMAT0005158 ppt-miR1045; +MIMAT0005159 ppt-miR1046-5p; +MIMAT0005160 ppt-miR1046-3p; +MIMAT0005161 ppt-miR1047-5p; +MIMAT0005162 ppt-miR1047-3p; +MIMAT0005163 ppt-miR1048-5p; +MIMAT0005164 ppt-miR1048-3p; +MIMAT0005165 ppt-miR1049; +MIMAT0005166 ppt-miR1050; +MIMAT0005167 ppt-miR1051-5p; +MIMAT0005168 ppt-miR1051-3p; +MIMAT0005169 ppt-miR1052; +MIMAT0005170 ppt-miR1053-5p; +MIMAT0005171 ppt-miR1053-3p; +MIMAT0005172 ppt-miR1054; +MIMAT0005173 ppt-miR1055; +MIMAT0005174 ppt-miR1056; +MIMAT0005175 ppt-miR1057; +MIMAT0005176 ppt-miR1058; +MIMAT0005177 ppt-miR1059; +MIMAT0005178 ppt-miR1060; +MIMAT0005179 ppt-miR1061-5p; +MIMAT0005180 ppt-miR1061-3p; +MIMAT0005181 ppt-miR1062; +MIMAT0005182 ppt-miR1063a; +MIMAT0005183 ppt-miR1063b; +MIMAT0005184 ppt-miR1063c; +MIMAT0005185 ppt-miR1063d; +MIMAT0005186 ppt-miR1063e; +MIMAT0005187 ppt-miR1063f; +MIMAT0005188 ppt-miR1063g; +MIMAT0005189 ppt-miR1063h; +MIMAT0005190 ppt-miR1064-5p; +MIMAT0005191 ppt-miR1064-3p; +MIMAT0005192 ppt-miR1065; +MIMAT0005193 ppt-miR1066; +MIMAT0005194 ppt-miR1067; +MIMAT0005195 ppt-miR1068; +MIMAT0005196 ppt-miR1069-5p; +MIMAT0005197 ppt-miR1069-3p; +MIMAT0005198 ppt-miR1070; +MIMAT0005199 ppt-miR1071-5p; +MIMAT0005200 ppt-miR1071-3p; +MIMAT0005201 ppt-miR1072; +MIMAT0005202 ppt-miR1073-5p; +MIMAT0005203 ppt-miR1073-3p; +MIMAT0005204 ppt-miR1074; +MIMAT0005205 ppt-miR1075; +MIMAT0005206 ppt-miR1076-5p; +MIMAT0005207 ppt-miR1076-3p; +MIMAT0005208 ppt-miR1077-5p; +MIMAT0005209 ppt-miR1077-3p; +MIMAT0005210 ppt-miR1078; +MIMAT0005211 ppt-miR1079-5p; +MIMAT0005212 ppt-miR1079-3p; +MIMAT0005213 smo-miR156a; +MIMAT0005214 smo-miR156b; +MIMAT0005215 smo-miR156c; +MIMAT0005216 smo-miR156d; +MIMAT0005217 smo-miR159; +MIMAT0005218 smo-miR160a; +MIMAT0005219 smo-miR160b; +MIMAT0005220 smo-miR166a; +MIMAT0005221 smo-miR166b; +MIMAT0005222 smo-miR166c; +MIMAT0005223 smo-miR171a; +MIMAT0005224 smo-miR171b; +MIMAT0005225 smo-miR171c; +MIMAT0005226 smo-miR171d; +MIMAT0005227 smo-miR396; +MIMAT0005228 smo-miR408; +MIMAT0005229 smo-miR536; +MIMAT0005230 smo-miR1080; +MIMAT0005231 smo-miR1081; +MIMAT0005232 smo-miR1082a; +MIMAT0005233 smo-miR1082b; +MIMAT0005234 smo-miR1083; +MIMAT0005235 smo-miR1084; +MIMAT0005236 smo-miR1085-5p; +MIMAT0005237 smo-miR1085-3p; +MIMAT0005238 smo-miR1086; +MIMAT0005239 smo-miR1087; +MIMAT0005240 smo-miR1088-5p; +MIMAT0005241 smo-miR1088-3p; +MIMAT0005242 smo-miR1089; +MIMAT0005243 smo-miR1090; +MIMAT0005244 smo-miR1091; +MIMAT0005245 smo-miR1092; +MIMAT0005246 smo-miR1093; +MIMAT0005247 smo-miR1094a; +MIMAT0005248 smo-miR1094b; +MIMAT0005249 smo-miR1094c; +MIMAT0005250 smo-miR1095a; +MIMAT0005251 smo-miR1095b; +MIMAT0005252 smo-miR1096; +MIMAT0005253 smo-miR1097; +MIMAT0005254 smo-miR1098; +MIMAT0005255 smo-miR1099; +MIMAT0005256 smo-miR1100; +MIMAT0005257 smo-miR1101-5p; +MIMAT0005258 smo-miR1101-3p; +MIMAT0005259 smo-miR1102; +MIMAT0005260 smo-miR319; +MIMAT0005261 smo-miR1104; +MIMAT0005262 smo-miR1105; +MIMAT0005263 smo-miR1106; +MIMAT0005264 smo-miR1107; +MIMAT0005265 smo-miR1108; +MIMAT0005266 smo-miR1109; +MIMAT0005267 smo-miR1110; +MIMAT0005268 smo-miR1111; +MIMAT0005269 smo-miR1112-5p; +MIMAT0005270 smo-miR1112-3p; +MIMAT0005271 smo-miR1113; +MIMAT0005272 smo-miR1114; +MIMAT0005273 smo-miR1115-5p; +MIMAT0005274 smo-miR1115-3p; +MIMAT0005275 smo-miR1103-5p; +MIMAT0005276 smo-miR1103-3p; +MIMAT0005278 rno-miR-466b;rno-miR-466b-5p; +MIMAT0005279 rno-miR-466c;rno-miR-466c-5p; +MIMAT0005280 rno-miR-743b;rno-miR-743b-3p; +MIMAT0005281 rno-miR-871;rno-miR-871-5p; +MIMAT0005282 rno-miR-872;rno-miR-872-5p; +MIMAT0005283 rno-miR-872*;rno-miR-872-3p; +MIMAT0005284 rno-miR-874;rno-miR-874-3p; +MIMAT0005285 rno-miR-877; +MIMAT0005286 rno-miR-878; +MIMAT0005287 rno-miR-879;rno-miR-879-5p; +MIMAT0005288 rno-miR-880;rno-miR-880-3p; +MIMAT0005289 rno-miR-881;rno-miR-881-3p; +MIMAT0005290 rno-miR-883;rno-miR-883-3p; +MIMAT0005291 mmu-miR-582-5p; +MIMAT0005292 mmu-miR-582-3p; +MIMAT0005293 mmu-miR-467e;mmu-miR-467e-5p; +MIMAT0005294 mmu-miR-467e*;mmu-miR-467e-3p; +MIMAT0005295 mmu-miR-376c*;mmu-miR-376c-5p; +MIMAT0005297 rno-miR-147; +MIMAT0005298 rno-miR-17; +MIMAT0005299 rno-miR-181d;rno-miR-181d-5p; +MIMAT0005300 rno-miR-182; +MIMAT0005301 rno-miR-188;rno-miR-188-5p; +MIMAT0005302 rno-miR-190b;rno-miR-190b-5p; +MIMAT0005303 rno-miR-196c;rno-miR-196c-5p; +MIMAT0005304 rno-miR-301b;rno-miR-301b-3p; +MIMAT0005307 rno-miR-375;rno-miR-375-3p; +MIMAT0005308 rno-miR-380;rno-miR-380-5p; +MIMAT0005309 rno-miR-384-5p; +MIMAT0005310 rno-miR-384-3p; +MIMAT0005311 rno-miR-410;rno-miR-410-3p; +MIMAT0005312 rno-miR-411;rno-miR-411-5p; +MIMAT0005313 rno-miR-423;rno-miR-423-3p; +MIMAT0005314 rno-miR-425;rno-miR-425-5p; +MIMAT0005315 rno-miR-434;rno-miR-434-3p; +MIMAT0005316 rno-miR-455;rno-miR-455-5p; +MIMAT0005317 rno-miR-463;rno-miR-463-3p; +MIMAT0005318 rno-miR-471;rno-miR-471-5p; +MIMAT0005319 rno-miR-484; +MIMAT0005320 rno-miR-495; +MIMAT0005321 rno-miR-500;rno-miR-500-3p; +MIMAT0005322 rno-miR-532-5p; +MIMAT0005323 rno-miR-532-3p; +MIMAT0005324 rno-miR-598-5p; +MIMAT0005325 rno-miR-598-3p; +MIMAT0005326 rno-miR-671; +MIMAT0005327 rno-miR-672;rno-miR-672-5p; +MIMAT0005328 rno-miR-673;rno-miR-673-5p; +MIMAT0005329 rno-miR-674-5p; +MIMAT0005330 rno-miR-674-3p; +MIMAT0005331 rno-miR-708;rno-miR-708-5p; +MIMAT0005332 rno-miR-708*;rno-miR-708-3p; +MIMAT0005333 rno-miR-742;rno-miR-742-3p; +MIMAT0005334 rno-miR-743a;rno-miR-743a-3p; +MIMAT0005335 rno-miR-758;rno-miR-758-3p; +MIMAT0005336 rno-miR-760-5p; +MIMAT0005337 rno-miR-760-3p; +MIMAT0005338 rno-miR-770;rno-miR-770-5p; +MIMAT0005339 rno-miR-873;rno-miR-873-5p; +MIMAT0005340 rno-miR-92b;rno-miR-92b-3p; +MIMAT0005341 rno-miR-488;rno-miR-488-3p; +MIMAT0005342 rno-miR-652;rno-miR-652-3p; +MIMAT0005343 tae-miR159a; +MIMAT0005344 tae-miR159b; +MIMAT0005345 tae-miR160; +MIMAT0005346 tae-miR164; +MIMAT0005347 tae-miR167;tae-miR167a; +MIMAT0005348 tae-miR171;tae-miR171a; +MIMAT0005349 tae-miR399; +MIMAT0005350 tae-miR408; +MIMAT0005351 tae-miR444;tae-miR444a; +MIMAT0005352 tae-miR1117; +MIMAT0005353 tae-miR1118; +MIMAT0005354 tae-miR1119; +MIMAT0005355 tae-miR1120;tae-miR1120a; +MIMAT0005356 tae-miR1121; +MIMAT0005357 tae-miR1122;tae-miR1122a; +MIMAT0005358 tae-miR1123; +MIMAT0005359 tae-miR1124; +MIMAT0005360 tae-miR1125; +MIMAT0005361 tae-miR1126; +MIMAT0005362 tae-miR1127;tae-miR1127a; +MIMAT0005363 tae-miR1128; +MIMAT0005364 tae-miR1129; +MIMAT0005365 tae-miR1130;tae-miR1130a; +MIMAT0005366 tae-miR1131; +MIMAT0005367 tae-miR1132; +MIMAT0005368 tae-miR1133; +MIMAT0005369 tae-miR1134; +MIMAT0005370 tae-miR1135; +MIMAT0005371 tae-miR1136; +MIMAT0005372 tae-miR1137;tae-miR1137a; +MIMAT0005373 tae-miR1138; +MIMAT0005374 tae-miR1139; +MIMAT0005375 ppt-miR477b; +MIMAT0005376 cre-miR1142; +MIMAT0005377 cre-miR1143*;cre-miR1143-5p; +MIMAT0005378 cre-miR1143;cre-miR1143-3p; +MIMAT0005379 cre-miR1144a.2; +MIMAT0005380 cre-miR1144a.1; +MIMAT0005381 cre-miR1145.2; +MIMAT0005382 cre-miR1145.1; +MIMAT0005383 cre-miR1146; +MIMAT0005384 cre-miR1147.1; +MIMAT0005385 cre-miR1147.2; +MIMAT0005386 cre-miR1148.1; +MIMAT0005387 cre-miR1148.2; +MIMAT0005388 cre-miR1149.1; +MIMAT0005389 cre-miR1149.2; +MIMAT0005390 cre-miR1150.3; +MIMAT0005391 cre-miR1150.2; +MIMAT0005392 cre-miR1150.1; +MIMAT0005393 cre-miR1151a;cre-miR1151a-5p; +MIMAT0005394 cre-miR1151a*;cre-miR1151a-3p; +MIMAT0005395 cre-miR1151b;cre-miR1151b-5p; +MIMAT0005396 cre-miR1151b*;cre-miR1151b-3p; +MIMAT0005397 cre-miR1152; +MIMAT0005398 cre-miR1153.1;cre-miR1153-5p.1; +MIMAT0005399 cre-miR1153.2*;cre-miR1153-5p.2; +MIMAT0005400 cre-miR1153.2;cre-miR1153-3p.2; +MIMAT0005401 cre-miR1153.1*;cre-miR1153-3p.1; +MIMAT0005402 cre-miR1154;cre-miR1154-5p; +MIMAT0005403 cre-miR1154*;cre-miR1154-3p; +MIMAT0005404 cre-miR1155; +MIMAT0005405 cre-miR1156.1; +MIMAT0005406 cre-miR1156.2; +MIMAT0005407 cre-miR1157*;cre-miR1157-5p; +MIMAT0005408 cre-miR1157;cre-miR1157-3p; +MIMAT0005409 cre-miR1158; +MIMAT0005410 cre-miR1160.2; +MIMAT0005411 cre-miR1160.1; +MIMAT0005412 cre-miR1160.3; +MIMAT0005413 cre-miR1161;cre-miR1161a;cre-miR1161b;cre-miR1161a; +MIMAT0005415 cre-miR1162*;cre-miR1162-5p; +MIMAT0005416 cre-miR1162;cre-miR1162-3p; +MIMAT0005417 cre-miR1163.2; +MIMAT0005418 cre-miR1163.1; +MIMAT0005419 cre-miR1164; +MIMAT0005420 cre-miR1165;cre-miR1165-5p; +MIMAT0005421 cre-miR1165*;cre-miR1165-3p; +MIMAT0005422 cre-miR1166.1; +MIMAT0005423 cre-miR1166.2; +MIMAT0005424 cre-miR1168.1; +MIMAT0005425 cre-miR1168.2; +MIMAT0005426 cre-miR1169*;cre-miR1169-5p; +MIMAT0005427 cre-miR1169;cre-miR1169-3p; +MIMAT0005428 cre-miR1170.2; +MIMAT0005429 cre-miR1170.1; +MIMAT0005430 cre-miR1171; +MIMAT0005431 cre-miR1173; +MIMAT0005432 cre-miR1172.2; +MIMAT0005433 cre-miR1172.1; +MIMAT0005434 cre-miR1167; +MIMAT0005435 cre-miR1144b; +MIMAT0005436 cre-miR1159.2; +MIMAT0005437 cre-miR1159.1; +MIMAT0005438 mmu-miR-30c-2*;mmu-miR-30c-2-3p; +MIMAT0005439 mmu-let-7c-2*;mmu-let-7c-2-3p; +MIMAT0005440 mmu-miR-24-2*;mmu-miR-24-2-5p; +MIMAT0005441 rno-miR-24-2*;rno-miR-24-2-5p; +MIMAT0005442 rno-miR-30c-2*;rno-miR-30c-2-3p; +MIMAT0005443 mmu-miR-181a-2*;mmu-miR-181a-2-3p; +MIMAT0005444 mmu-miR-218-2*;mmu-miR-218-2-3p; +MIMAT0005445 rno-miR-29b-1*;rno-miR-29b-1-5p; +MIMAT0005446 rno-miR-219-2-3p;rno-miR-219a-2-3p; +MIMAT0005447 mmu-miR-449b; +MIMAT0005448 mmu-miR-467b;mmu-miR-467b-5p; +MIMAT0005449 hsa-miR-523*;hsa-miR-523-5p; +MIMAT0005450 hsa-miR-518e*;hsa-miR-518e-5p; +MIMAT0005451 hsa-miR-522*;hsa-miR-522-5p; +MIMAT0005452 hsa-miR-519a*;hsa-miR-519a-5p; +MIMAT0005453 mmu-miR-466b-3-3p; +MIMAT0005454 hsa-miR-519b-5p; +MIMAT0005455 hsa-miR-520c-5p; +MIMAT0005456 hsa-miR-518d-5p; +MIMAT0005457 hsa-miR-518a-5p; +MIMAT0005458 hsa-miR-1224-5p; +MIMAT0005459 hsa-miR-1224-3p; +MIMAT0005460 mmu-miR-1224;mmu-miR-1224-5p; +MIMAT0005461 xtr-miR-181a-2*;xtr-miR-181a-2-3p; +MIMAT0005462 xtr-miR-18a*;xtr-miR-18a-3p; +MIMAT0005463 dme-miR-iab4as-5p;dme-miR-iab-4as-5p;dme-miR-iab-8-5p; +MIMAT0005464 dme-miR-iab4as-3p;dme-miR-iab-4as-3p;dme-miR-iab-8-3p; +MIMAT0005465 dme-miR-954;dme-miR-954-5p; +MIMAT0005466 dme-miR-955;dme-miR-955-5p; +MIMAT0005467 dme-miR-190;dme-miR-190-5p; +MIMAT0005468 dme-miR-193;dme-miR-193-3p; +MIMAT0005469 dme-miR-956;dme-miR-956-3p; +MIMAT0005470 dme-miR-957;dme-miR-957-3p; +MIMAT0005471 dme-miR-958;dme-miR-958-3p; +MIMAT0005472 dme-miR-375;dme-miR-375-3p; +MIMAT0005473 dme-miR-959;dme-miR-959-3p; +MIMAT0005474 dme-miR-960;dme-miR-960-5p; +MIMAT0005475 dme-miR-961;dme-miR-961-5p; +MIMAT0005476 dme-miR-962;dme-miR-962-5p; +MIMAT0005477 dme-miR-963;dme-miR-963-5p; +MIMAT0005478 dme-miR-964;dme-miR-964-5p; +MIMAT0005479 dme-miR-932;dme-miR-932-5p; +MIMAT0005480 dme-miR-965;dme-miR-965-3p; +MIMAT0005481 dme-miR-966;dme-miR-966-5p; +MIMAT0005482 dme-miR-967;dme-miR-967-5p; +MIMAT0005483 dme-miR-1002;dme-miR-1002-5p; +MIMAT0005484 dme-miR-968;dme-miR-968-5p; +MIMAT0005485 dme-miR-969;dme-miR-969-5p; +MIMAT0005486 dme-miR-970;dme-miR-970-3p; +MIMAT0005487 dme-miR-971;dme-miR-971-3p; +MIMAT0005488 dme-miR-972;dme-miR-972-3p; +MIMAT0005489 dme-miR-973;dme-miR-973-5p; +MIMAT0005490 dme-miR-974;dme-miR-974-5p; +MIMAT0005491 dme-miR-975;dme-miR-975-5p; +MIMAT0005492 dme-miR-976;dme-miR-976-3p; +MIMAT0005493 dme-miR-977;dme-miR-977-3p; +MIMAT0005494 dme-miR-978;dme-miR-978-3p; +MIMAT0005495 dme-miR-979;dme-miR-979-3p; +MIMAT0005496 dme-miR-980;dme-miR-980-3p; +MIMAT0005497 dme-miR-981;dme-miR-981-3p; +MIMAT0005498 dme-miR-982;dme-miR-982-5p; +MIMAT0005499 dme-miR-983;dme-miR-983-5p; +MIMAT0005500 dme-miR-984;dme-miR-984-5p; +MIMAT0005501 dme-miR-927;dme-miR-927-5p; +MIMAT0005502 dme-miR-985;dme-miR-985-3p; +MIMAT0005503 dme-miR-986;dme-miR-986-5p; +MIMAT0005504 dme-miR-987;dme-miR-987-5p; +MIMAT0005505 dme-miR-988;dme-miR-988-3p; +MIMAT0005506 dme-miR-989;dme-miR-989-3p; +MIMAT0005507 dme-miR-137;dme-miR-137-3p; +MIMAT0005508 dme-miR-990;dme-miR-990-5p; +MIMAT0005509 dme-miR-991;dme-miR-991-3p; +MIMAT0005510 dme-miR-992;dme-miR-992-3p; +MIMAT0005511 dme-miR-929;dme-miR-929-3p; +MIMAT0005512 dme-miR-993;dme-miR-993-3p; +MIMAT0005513 dme-miR-994;dme-miR-994-5p; +MIMAT0005514 dme-miR-995;dme-miR-995-3p; +MIMAT0005515 dme-miR-996;dme-miR-996-3p; +MIMAT0005516 dme-miR-252;dme-miR-252-5p; +MIMAT0005517 dme-miR-997;dme-miR-997-5p; +MIMAT0005518 dme-miR-998;dme-miR-998-3p; +MIMAT0005519 dme-miR-999;dme-miR-999-3p; +MIMAT0005520 dme-miR-1000;dme-miR-1000-5p; +MIMAT0005521 dme-miR-1001;dme-miR-1001-5p; +MIMAT0005522 cel-miR-1021; +MIMAT0005523 cel-miR-1022;cel-miR-1022-5p; +MIMAT0005524 aga-miR-1174; +MIMAT0005525 aga-miR-1175; +MIMAT0005526 aga-miR-34; +MIMAT0005527 aga-miR-12; +MIMAT0005528 aga-miR-996; +MIMAT0005529 aga-miR-989; +MIMAT0005530 aga-miR-306; +MIMAT0005531 ddi-miR-1176; +MIMAT0005532 ddi-miR-1177; +MIMAT0005533 mcmv-miR-m01-1; +MIMAT0005534 mcmv-miR-m01-2;mcmv-miR-m01-2-5p; +MIMAT0005535 mcmv-miR-m01-2*;mcmv-miR-m01-2-3p; +MIMAT0005536 mcmv-miR-m01-3;mcmv-miR-m01-3-5p; +MIMAT0005537 mcmv-miR-m01-3*;mcmv-miR-m01-3-3p; +MIMAT0005538 mcmv-miR-m01-4;mcmv-miR-m01-4-5p; +MIMAT0005539 mcmv-miR-m01-4*;mcmv-miR-m01-4-3p; +MIMAT0005540 mcmv-miR-m21-1; +MIMAT0005541 mcmv-miR-m22-1; +MIMAT0005542 mcmv-miR-M23-1-5p; +MIMAT0005543 mcmv-miR-M23-1-3p; +MIMAT0005544 mcmv-miR-M23-2*;mcmv-miR-M23-2-5p; +MIMAT0005545 mcmv-miR-M23-2;mcmv-miR-M23-2-3p; +MIMAT0005546 mcmv-miR-M44-1; +MIMAT0005547 mcmv-miR-M55-1; +MIMAT0005548 mcmv-miR-m59-1; +MIMAT0005549 mcmv-miR-m59-2; +MIMAT0005550 mcmv-miR-M87-1; +MIMAT0005551 mcmv-miR-m88-1*;mcmv-miR-m88-1-5p; +MIMAT0005552 mcmv-miR-m88-1;mcmv-miR-m88-1-3p; +MIMAT0005553 mcmv-miR-M95-1-5p; +MIMAT0005554 mcmv-miR-M95-1-3p; +MIMAT0005555 mcmv-miR-m107-1-5p; +MIMAT0005556 mcmv-miR-m107-1-3p; +MIMAT0005557 mcmv-miR-m108-1*;mcmv-miR-m108-1-5p; +MIMAT0005558 mcmv-miR-m108-1;mcmv-miR-m108-1-3p; +MIMAT0005559 mcmv-miR-m108-2-5p.2; +MIMAT0005560 mcmv-miR-m108-2-5p.1; +MIMAT0005561 mcmv-miR-m108-2-3p; +MIMAT0005562 xtr-miR-31b; +MIMAT0005563 xtr-miR-146b; +MIMAT0005564 xtr-miR-320; +MIMAT0005565 xtr-miR-375; +MIMAT0005566 xtr-miR-427; +MIMAT0005567 cpa-miR162a; +MIMAT0005568 ptr-miR-1224-5p; +MIMAT0005569 ptr-miR-1224-3p; +MIMAT0005570 mml-miR-1224;mml-miR-1224-5p; +MIMAT0005571 mml-miR-1224*;mml-miR-1224-3p; +MIMAT0005572 hsa-miR-1225-5p; +MIMAT0005573 hsa-miR-1225-3p; +MIMAT0005574 mml-miR-1225-5p; +MIMAT0005575 mml-miR-1225-3p; +MIMAT0005576 hsa-miR-1226*;hsa-miR-1226-5p; +MIMAT0005577 hsa-miR-1226;hsa-miR-1226-3p; +MIMAT0005578 ptr-miR-1226; +MIMAT0005579 mml-miR-1226; +MIMAT0005580 hsa-miR-1227;hsa-miR-1227-3p; +MIMAT0005581 mml-miR-1227; +MIMAT0005582 hsa-miR-1228*;hsa-miR-1228-5p; +MIMAT0005583 hsa-miR-1228;hsa-miR-1228-3p; +MIMAT0005584 hsa-miR-1229;hsa-miR-1229-3p; +MIMAT0005585 mml-miR-1230; +MIMAT0005586 hsa-miR-1231; +MIMAT0005587 mml-miR-1232; +MIMAT0005588 hsa-miR-1233;hsa-miR-1233-3p; +MIMAT0005589 hsa-miR-1234;hsa-miR-1234-3p; +MIMAT0005590 mml-miR-1235; +MIMAT0005591 hsa-miR-1236;hsa-miR-1236-3p; +MIMAT0005592 hsa-miR-1237;hsa-miR-1237-3p; +MIMAT0005593 hsa-miR-1238;hsa-miR-1238-3p; +MIMAT0005594 mml-miR-1239; +MIMAT0005595 rno-miR-146b;rno-miR-146b-5p; +MIMAT0005596 rno-miR-551b;rno-miR-551b-3p; +MIMAT0005597 bol-miR824; +MIMAT0005598 bra-miR824; +MIMAT0005599 bna-miR824; +MIMAT0005600 bna-miR397a; +MIMAT0005601 bna-miR397b; +MIMAT0005602 bna-miR390a; +MIMAT0005603 bna-miR390b; +MIMAT0005604 bna-miR390c; +MIMAT0005605 bna-miR171a; +MIMAT0005606 bna-miR171b; +MIMAT0005607 bna-miR171c; +MIMAT0005608 bna-miR171d; +MIMAT0005609 bna-miR171e; +MIMAT0005610 bna-miR171f; +MIMAT0005611 bna-miR171g; +MIMAT0005612 bna-miR169a; +MIMAT0005613 bna-miR169b; +MIMAT0005614 bna-miR169c; +MIMAT0005615 bna-miR169d; +MIMAT0005616 bna-miR169e; +MIMAT0005617 bna-miR169f; +MIMAT0005618 bna-miR169g; +MIMAT0005619 bna-miR169h; +MIMAT0005620 bna-miR169i; +MIMAT0005621 bna-miR169j; +MIMAT0005622 bna-miR169k; +MIMAT0005623 bna-miR169l; +MIMAT0005624 bna-miR169m; +MIMAT0005625 bna-miR168;bna-miR168a; +MIMAT0005626 bna-miR167a; +MIMAT0005627 bna-miR167b; +MIMAT0005628 bna-miR167c; +MIMAT0005629 bna-miR166a; +MIMAT0005630 bna-miR166b; +MIMAT0005631 bna-miR166c; +MIMAT0005632 bna-miR166d; +MIMAT0005633 bna-miR164;bna-miR164a; +MIMAT0005634 bna-miR161; +MIMAT0005635 bna-miR159; +MIMAT0005636 bna-miR156b; +MIMAT0005637 bna-miR1140a;bna-miR1140; +MIMAT0005638 bna-miR1140b; +MIMAT0005639 bna-miR156c; +MIMAT0005640 vvi-miR156a; +MIMAT0005641 vvi-miR156b; +MIMAT0005642 vvi-miR156c; +MIMAT0005643 vvi-miR156d; +MIMAT0005644 vvi-miR156e; +MIMAT0005645 vvi-miR156f; +MIMAT0005646 vvi-miR156g; +MIMAT0005647 vvi-miR156i; +MIMAT0005648 vvi-miR159a; +MIMAT0005649 vvi-miR159b; +MIMAT0005650 vvi-miR159c; +MIMAT0005651 vvi-miR160a; +MIMAT0005652 vvi-miR160b; +MIMAT0005653 vvi-miR160c; +MIMAT0005654 vvi-miR160d; +MIMAT0005655 vvi-miR160e; +MIMAT0005656 vvi-miR160f;vvi-miR160e; +MIMAT0005657 vvi-miR162; +MIMAT0005658 vvi-miR164a; +MIMAT0005659 vvi-miR164b; +MIMAT0005660 vvi-miR164c; +MIMAT0005661 vvi-miR164d; +MIMAT0005662 vvi-miR166a; +MIMAT0005663 vvi-miR166b; +MIMAT0005664 vvi-miR166c; +MIMAT0005665 vvi-miR166d; +MIMAT0005666 vvi-miR166e; +MIMAT0005667 vvi-miR166f; +MIMAT0005668 vvi-miR166g; +MIMAT0005669 vvi-miR166h; +MIMAT0005670 vvi-miR167a; +MIMAT0005671 vvi-miR167b; +MIMAT0005672 vvi-miR167c; +MIMAT0005673 vvi-miR167d; +MIMAT0005674 vvi-miR167e; +MIMAT0005675 vvi-miR168; +MIMAT0005676 vvi-miR169a; +MIMAT0005677 vvi-miR169y; +MIMAT0005678 vvi-miR169c; +MIMAT0005679 vvi-miR169d; +MIMAT0005680 vvi-miR169e; +MIMAT0005681 vvi-miR169f; +MIMAT0005682 vvi-miR169g; +MIMAT0005683 vvi-miR169j; +MIMAT0005684 vvi-miR169k; +MIMAT0005685 vvi-miR169m; +MIMAT0005686 vvi-miR169p; +MIMAT0005687 vvi-miR169r; +MIMAT0005688 vvi-miR169s; +MIMAT0005689 vvi-miR169t; +MIMAT0005690 vvi-miR169u; +MIMAT0005691 vvi-miR171a; +MIMAT0005692 vvi-miR171b; +MIMAT0005693 vvi-miR171c; +MIMAT0005694 vvi-miR171d; +MIMAT0005695 vvi-miR171e; +MIMAT0005696 vvi-miR171f; +MIMAT0005697 vvi-miR171h; +MIMAT0005698 vvi-miR171i; +MIMAT0005699 vvi-miR172a; +MIMAT0005700 vvi-miR172b; +MIMAT0005701 vvi-miR172c; +MIMAT0005702 vvi-miR172d; +MIMAT0005703 vvi-miR319b; +MIMAT0005704 vvi-miR319c; +MIMAT0005705 vvi-miR319f; +MIMAT0005706 vvi-miR319g; +MIMAT0005707 vvi-miR390; +MIMAT0005708 vvi-miR393b; +MIMAT0005709 vvi-miR394a; +MIMAT0005710 vvi-miR394b; +MIMAT0005711 vvi-miR395a; +MIMAT0005712 vvi-miR395b; +MIMAT0005713 vvi-miR395c; +MIMAT0005714 vvi-miR395d; +MIMAT0005715 vvi-miR395e; +MIMAT0005716 vvi-miR395f; +MIMAT0005717 vvi-miR395g; +MIMAT0005718 vvi-miR395h; +MIMAT0005719 vvi-miR395i; +MIMAT0005720 vvi-miR395j; +MIMAT0005721 vvi-miR395k; +MIMAT0005722 vvi-miR395l; +MIMAT0005723 vvi-miR395m; +MIMAT0005724 vvi-miR396a; +MIMAT0005725 vvi-miR396b; +MIMAT0005726 vvi-miR396d; +MIMAT0005727 vvi-miR398a; +MIMAT0005728 vvi-miR399a; +MIMAT0005729 vvi-miR399b; +MIMAT0005730 vvi-miR399e; +MIMAT0005731 vvi-miR399g; +MIMAT0005732 vvi-miR399h; +MIMAT0005733 vvi-miR408; +MIMAT0005734 vvi-miR479; +MIMAT0005735 vvi-miR535a; +MIMAT0005736 vvi-miR535b; +MIMAT0005737 vvi-miR535c; +MIMAT0005738 vvi-miR535d;vvi-miR535c; +MIMAT0005739 vvi-miR535e; +MIMAT0005740 age-miR-506; +MIMAT0005741 age-miR-507; +MIMAT0005742 age-miR-508; +MIMAT0005743 age-miR-509a; +MIMAT0005744 age-miR-509b; +MIMAT0005745 age-miR-510; +MIMAT0005746 age-miR-513b; +MIMAT0005747 age-miR-513c; +MIMAT0005748 age-miR-513a; +MIMAT0005749 age-miR-513d; +MIMAT0005750 age-miR-513e; +MIMAT0005751 age-miR-514; +MIMAT0005752 ssy-miR-506; +MIMAT0005753 ssy-miR-507; +MIMAT0005754 ssy-miR-508; +MIMAT0005755 ssy-miR-509a; +MIMAT0005756 ssy-miR-509b; +MIMAT0005757 ssy-miR-510; +MIMAT0005758 ssy-miR-513c; +MIMAT0005759 ssy-miR-513b; +MIMAT0005760 ssy-miR-513a; +MIMAT0005761 ssy-miR-514; +MIMAT0005762 mml-miR-506;mml-miR-506-3p; +MIMAT0005763 mml-miR-507; +MIMAT0005764 mml-miR-508;mml-miR-508-3p; +MIMAT0005765 mml-miR-509; +MIMAT0005766 mml-miR-510;mml-miR-510-5p; +MIMAT0005767 mml-miR-513b; +MIMAT0005768 mml-miR-513a; +MIMAT0005769 mml-miR-514;mml-miR-514a;mml-miR-514a-3p; +MIMAT0005770 ptr-miR-506; +MIMAT0005771 ptr-miR-507; +MIMAT0005772 ptr-miR-508; +MIMAT0005773 ptr-miR-509a; +MIMAT0005774 ptr-miR-509b; +MIMAT0005775 ptr-miR-510; +MIMAT0005776 ptr-miR-513a; +MIMAT0005777 ptr-miR-513b; +MIMAT0005778 ptr-miR-514; +MIMAT0005779 pbi-miR-506; +MIMAT0005780 pbi-miR-507; +MIMAT0005781 pbi-miR-508; +MIMAT0005782 pbi-miR-509; +MIMAT0005783 pbi-miR-510; +MIMAT0005784 pbi-miR-513a; +MIMAT0005785 pbi-miR-513b; +MIMAT0005786 pbi-miR-513c; +MIMAT0005787 pbi-miR-514; +MIMAT0005788 hsa-miR-513b;hsa-miR-513b-5p; +MIMAT0005789 hsa-miR-513c;hsa-miR-513c-5p; +MIMAT0005790 osa-miR444a.2;osa-miR444a-3p.2; +MIMAT0005791 hsa-miR-1264; +MIMAT0005792 hsa-miR-320b; +MIMAT0005793 hsa-miR-320c; +MIMAT0005794 hsa-miR-1296;hsa-miR-1296-5p; +MIMAT0005795 hsa-miR-1323; +MIMAT0005796 hsa-miR-1271;hsa-miR-1271-5p; +MIMAT0005797 hsa-miR-1301;hsa-miR-1301-3p; +MIMAT0005798 hsa-miR-1185;hsa-miR-1185-5p; +MIMAT0005799 hsa-miR-1283; +MIMAT0005800 hsa-miR-1298;hsa-miR-1298-5p; +MIMAT0005801 mdv1-miR-M1*;mdv1-miR-M1-3p; +MIMAT0005802 mdv1-miR-M5*;mdv1-miR-M5-5p; +MIMAT0005803 mdv1-miR-M6;mdv1-miR-M6-5p; +MIMAT0005804 mdv1-miR-M7;mdv1-miR-M7*;mdv1-miR-M7-5p; +MIMAT0005805 mdv1-miR-M8-5p; +MIMAT0005806 ghr-miR156a; +MIMAT0005807 ghr-miR156b; +MIMAT0005808 ghr-miR156c; +MIMAT0005809 ghr-miR156d; +MIMAT0005810 gra-miR157a; +MIMAT0005811 gra-miR157b; +MIMAT0005812 ghr-miR162a; +MIMAT0005813 ghr-miR166b; +MIMAT0005814 ghb-miR169a; +MIMAT0005815 ghr-miR390a; +MIMAT0005816 ghr-miR390b; +MIMAT0005817 ghr-miR390c; +MIMAT0005818 ghr-miR396a; +MIMAT0005819 ghr-miR396b; +MIMAT0005820 ghr-miR399a; +MIMAT0005821 ghr-miR399b; +MIMAT0005822 cel-miR-1019*;cel-miR-1019-5p; +MIMAT0005823 hsa-miR-1178;hsa-miR-1178-3p; +MIMAT0005824 hsa-miR-1179; +MIMAT0005825 hsa-miR-1180;hsa-miR-1180-3p; +MIMAT0005826 hsa-miR-1181; +MIMAT0005827 hsa-miR-1182; +MIMAT0005828 hsa-miR-1183; +MIMAT0005829 hsa-miR-1184; +MIMAT0005830 mmu-miR-466l;mmu-miR-466l-3p; +MIMAT0005831 mmu-miR-669k;mmu-miR-669k-3p; +MIMAT0005832 mmu-miR-669g; +MIMAT0005833 mmu-miR-669d;mmu-miR-669d-5p; +MIMAT0005834 mmu-miR-466i;mmu-miR-466i-3p; +MIMAT0005835 mmu-miR-1-2-as;mmu-miR-1-2-as-5p;mmu-miR-1b-5p; +MIMAT0005836 mmu-miR-1186;mmu-miR-1186a; +MIMAT0005837 mmu-miR-1187; +MIMAT0005838 mmu-miR-669j; +MIMAT0005839 mmu-miR-669f;mmu-miR-669f-3p; +MIMAT0005840 mmu-miR-669i; +MIMAT0005841 mmu-miR-669h-5p; +MIMAT0005842 mmu-miR-669h-3p; +MIMAT0005843 mmu-miR-1188;mmu-miR-1188-5p; +MIMAT0005844 mmu-miR-466f; +MIMAT0005845 mmu-miR-466k; +MIMAT0005846 mmu-miR-467f; +MIMAT0005847 mmu-miR-1190; +MIMAT0005848 mmu-miR-466j; +MIMAT0005849 mmu-miR-1191;mmu-miR-1191a; +MIMAT0005850 mmu-miR-1192; +MIMAT0005851 mmu-miR-1193;mmu-miR-1193-3p; +MIMAT0005852 mmu-miR-1194; +MIMAT0005853 mmu-miR-669e;mmu-miR-669e-5p; +MIMAT0005854 mmu-miR-467g; +MIMAT0005855 mmu-miR-467h; +MIMAT0005856 mmu-miR-1195; +MIMAT0005857 mmu-miR-1196;mmu-miR-1196-5p; +MIMAT0005858 mmu-miR-1197;mmu-miR-1197-3p; +MIMAT0005859 mmu-miR-1198;mmu-miR-1198-5p; +MIMAT0005860 mmu-miR-1199;mmu-miR-1199-5p; +MIMAT0005861 mml-miR-1240; +MIMAT0005862 mml-miR-1241; +MIMAT0005863 hsa-miR-1200; +MIMAT0005864 hsa-miR-1201; +MIMAT0005865 hsa-miR-1202; +MIMAT0005866 hsa-miR-1203; +MIMAT0005867 hsa-miR-663b; +MIMAT0005868 hsa-miR-1204; +MIMAT0005869 hsa-miR-1205; +MIMAT0005870 hsa-miR-1206; +MIMAT0005871 hsa-miR-1207-5p; +MIMAT0005872 hsa-miR-1207-3p; +MIMAT0005873 hsa-miR-1208; +MIMAT0005874 hsa-miR-548e;hsa-miR-548e-3p; +MIMAT0005875 hsa-miR-548j;hsa-miR-548j-5p; +MIMAT0005876 hsa-miR-1285;hsa-miR-1285-3p; +MIMAT0005877 hsa-miR-1286; +MIMAT0005878 hsa-miR-1287;hsa-miR-1287-5p; +MIMAT0005879 hsa-miR-1289; +MIMAT0005880 hsa-miR-1290; +MIMAT0005881 hsa-miR-1291; +MIMAT0005882 hsa-miR-548k; +MIMAT0005883 hsa-miR-1293; +MIMAT0005884 hsa-miR-1294; +MIMAT0005885 hsa-miR-1295;hsa-miR-1295a; +MIMAT0005886 hsa-miR-1297; +MIMAT0005887 hsa-miR-1299; +MIMAT0005888 hsa-miR-1300; +MIMAT0005889 hsa-miR-548l; +MIMAT0005890 hsa-miR-1302; +MIMAT0005891 hsa-miR-1303; +MIMAT0005892 hsa-miR-1304;hsa-miR-1304-5p; +MIMAT0005893 hsa-miR-1305; +MIMAT0005894 hsa-miR-1243; +MIMAT0005895 hsa-miR-548f;hsa-miR-548f-3p; +MIMAT0005896 hsa-miR-1244; +MIMAT0005897 hsa-miR-1245;hsa-miR-1245a; +MIMAT0005898 hsa-miR-1246; +MIMAT0005899 hsa-miR-1247;hsa-miR-1247-5p; +MIMAT0005900 hsa-miR-1248; +MIMAT0005901 hsa-miR-1249;hsa-miR-1249-3p; +MIMAT0005902 hsa-miR-1250;hsa-miR-1250-5p; +MIMAT0005903 hsa-miR-1251;hsa-miR-1251-5p; +MIMAT0005904 hsa-miR-1253; +MIMAT0005905 hsa-miR-1254; +MIMAT0005906 hsa-miR-1255a; +MIMAT0005907 hsa-miR-1256; +MIMAT0005908 hsa-miR-1257; +MIMAT0005909 hsa-miR-1258; +MIMAT0005910 hsa-miR-1259; +MIMAT0005911 hsa-miR-1260;hsa-miR-1260a; +MIMAT0005912 hsa-miR-548g;hsa-miR-548g-3p; +MIMAT0005913 hsa-miR-1261; +MIMAT0005914 hsa-miR-1262; +MIMAT0005915 hsa-miR-1263; +MIMAT0005916 hsa-miR-548n; +MIMAT0005917 hsa-miR-548m; +MIMAT0005918 hsa-miR-1265; +MIMAT0005919 hsa-miR-548o;hsa-miR-548o-3p; +MIMAT0005920 hsa-miR-1266;hsa-miR-1266-5p; +MIMAT0005921 hsa-miR-1267; +MIMAT0005922 hsa-miR-1268;hsa-miR-1268a; +MIMAT0005923 hsa-miR-1269;hsa-miR-1269a; +MIMAT0005924 hsa-miR-1270; +MIMAT0005925 hsa-miR-1272; +MIMAT0005926 hsa-miR-1273;hsa-miR-1273a; +MIMAT0005927 hsa-miR-1274a; +MIMAT0005928 hsa-miR-548h;hsa-miR-548h-5p; +MIMAT0005929 hsa-miR-1275; +MIMAT0005930 hsa-miR-1276; +MIMAT0005931 hsa-miR-302e; +MIMAT0005932 hsa-miR-302f; +MIMAT0005933 hsa-miR-1277;hsa-miR-1277-3p; +MIMAT0005934 hsa-miR-548p; +MIMAT0005935 hsa-miR-548i; +MIMAT0005936 hsa-miR-1278; +MIMAT0005937 hsa-miR-1279; +MIMAT0005938 hsa-miR-1274b; +MIMAT0005939 hsa-miR-1281; +MIMAT0005940 hsa-miR-1282; +MIMAT0005941 hsa-miR-1284; +MIMAT0005942 hsa-miR-1288;hsa-miR-1288-3p; +MIMAT0005943 hsa-miR-1292;hsa-miR-1292-5p; +MIMAT0005944 hsa-miR-1252;hsa-miR-1252-5p; +MIMAT0005945 hsa-miR-1255b;hsa-miR-1255b-5p; +MIMAT0005946 hsa-miR-1280; +MIMAT0005947 hsa-miR-1308; +MIMAT0005948 hsa-miR-664*;hsa-miR-664-5p;hsa-miR-664a-5p; +MIMAT0005949 hsa-miR-664;hsa-miR-664-3p;hsa-miR-664a-3p; +MIMAT0005950 hsa-miR-1306;hsa-miR-1306-3p; +MIMAT0005951 hsa-miR-1307;hsa-miR-1307-3p; +MIMAT0005952 hsa-miR-1321; +MIMAT0005953 hsa-miR-1322; +MIMAT0005954 hsa-miR-720; +MIMAT0005955 hsa-miR-1197; +MIMAT0005956 hsa-miR-1324; +MIMAT0005957 osa-miR1423;osa-miR1423a-3p;osa-miR1423-3p; +MIMAT0005958 osa-miR1424; +MIMAT0005959 osa-miR1425;osa-miR1425-5p; +MIMAT0005960 osa-miR1426; +MIMAT0005961 osa-miR1427; +MIMAT0005962 osa-miR1428;osa-miR1428a-5p; +MIMAT0005963 osa-miR1429;osa-miR1429-3p; +MIMAT0005964 osa-miR1430; +MIMAT0005965 osa-miR1431; +MIMAT0005966 osa-miR1432;osa-miR1432-5p; +MIMAT0005967 osa-miR1433;osa-miR169r-3p; +MIMAT0005968 osa-miR444b.2; +MIMAT0005969 osa-miR444b.1; +MIMAT0005970 osa-miR444c.2; +MIMAT0005971 osa-miR444c.1; +MIMAT0005972 osa-miR444d.3; +MIMAT0005973 osa-miR444d.2; +MIMAT0005974 osa-miR444d.1; +MIMAT0005975 osa-miR444e; +MIMAT0005976 osa-miR444f; +MIMAT0005977 osa-miR810b.1; +MIMAT0005978 osa-miR810b.2; +MIMAT0005979 mdv1-miR-M9;mdv1-miR-M9-5p; +MIMAT0005980 mdv1-miR-M9*;mdv1-miR-M9-3p; +MIMAT0005981 mdv1-miR-M10;mdv1-miR-M10-3p; +MIMAT0005982 mdv1-miR-M11-5p; +MIMAT0005983 mdv1-miR-M11-3p; +MIMAT0005984 mdv1-miR-M12;mdv1-miR-M12-3p; +MIMAT0005985 mdv1-miR-M13; +MIMAT0005986 osa-miR1435; +MIMAT0005987 osa-miR1436; +MIMAT0005988 osa-miR1437;osa-miR1437a; +MIMAT0005989 osa-miR1438; +MIMAT0005990 osa-miR1440;osa-miR1440a; +MIMAT0005991 osa-miR1441; +MIMAT0005992 osa-miR1442; +MIMAT0005993 osa-miR1439; +MIMAT0005994 ptc-miR171l;ptc-miR171l-3p; +MIMAT0005995 ptc-miR171m; +MIMAT0005996 ptc-miR171n;ptc-miR171j; +MIMAT0005997 ptc-miR530a; +MIMAT0005998 ptc-miR530b; +MIMAT0005999 ptc-miR1444a; +MIMAT0006000 ptc-miR1444b; +MIMAT0006001 ptc-miR1444c; +MIMAT0006002 ptc-miR1445; +MIMAT0006003 ptc-miR827; +MIMAT0006004 ptc-miR1446a; +MIMAT0006005 ptc-miR1446b; +MIMAT0006006 ptc-miR1446c; +MIMAT0006007 ptc-miR1446d; +MIMAT0006008 ptc-miR1446e; +MIMAT0006009 ptc-miR1447; +MIMAT0006010 ptc-miR1448; +MIMAT0006011 ptc-miR1449; +MIMAT0006012 ptc-miR1450; +MIMAT0006013 osa-miR827;osa-miR827c; +MIMAT0006014 pta-miR482c; +MIMAT0006015 pta-miR482d; +MIMAT0006016 hiv1-miR-TAR-5p; +MIMAT0006017 hiv1-miR-TAR-3p; +MIMAT0006018 ssc-miR-99b; +MIMAT0006019 odi-miR-1468; +MIMAT0006020 odi-miR-1469; +MIMAT0006021 odi-miR-1470; +MIMAT0006022 odi-miR-1471; +MIMAT0006023 odi-miR-1472; +MIMAT0006024 odi-miR-1473; +MIMAT0006025 odi-miR-1474; +MIMAT0006026 odi-miR-1475; +MIMAT0006027 odi-miR-1476-5p; +MIMAT0006028 odi-miR-1476-3p; +MIMAT0006029 odi-miR-1477; +MIMAT0006030 odi-miR-1478; +MIMAT0006031 odi-miR-1479; +MIMAT0006032 odi-miR-1480; +MIMAT0006033 odi-miR-1481; +MIMAT0006034 odi-miR-1482; +MIMAT0006035 odi-miR-1483-5p; +MIMAT0006036 odi-miR-1483-3p; +MIMAT0006037 odi-miR-1484; +MIMAT0006038 odi-miR-1485; +MIMAT0006039 odi-miR-1486; +MIMAT0006040 odi-miR-1487; +MIMAT0006041 odi-miR-1489; +MIMAT0006042 odi-miR-1490a; +MIMAT0006043 odi-miR-1490b; +MIMAT0006044 odi-miR-1491; +MIMAT0006045 odi-miR-1492; +MIMAT0006046 odi-miR-1493; +MIMAT0006047 odi-miR-1494; +MIMAT0006048 odi-miR-1495; +MIMAT0006049 odi-miR-1496; +MIMAT0006050 odi-miR-1497a; +MIMAT0006051 odi-miR-1497b; +MIMAT0006052 odi-miR-1497c; +MIMAT0006053 odi-miR-1497d; +MIMAT0006054 odi-miR-1497e; +MIMAT0006055 odi-miR-1497f; +MIMAT0006056 odi-miR-1497g; +MIMAT0006057 odi-miR-1497h; +MIMAT0006058 odi-miR-1498; +MIMAT0006059 odi-miR-1499; +MIMAT0006060 odi-miR-1500; +MIMAT0006061 odi-miR-1501; +MIMAT0006062 odi-miR-1502; +MIMAT0006063 odi-miR-1503; +MIMAT0006064 odi-miR-1504; +MIMAT0006065 odi-miR-1505; +MIMAT0006066 odi-miR-1506; +MIMAT0006067 cin-miR-1473;cin-miR-1473-3p; +MIMAT0006068 cin-miR-1497;cin-miR-1497-3p; +MIMAT0006069 csa-miR-1473; +MIMAT0006070 csa-miR-1497; +MIMAT0006071 odi-miR-1a; +MIMAT0006072 odi-miR-1b; +MIMAT0006073 odi-miR-1c; +MIMAT0006074 odi-let-7a; +MIMAT0006075 odi-let-7b; +MIMAT0006076 odi-let-7c; +MIMAT0006077 odi-let-7d; +MIMAT0006078 odi-miR-7; +MIMAT0006079 odi-miR-31; +MIMAT0006080 odi-miR-92a; +MIMAT0006081 odi-miR-92b; +MIMAT0006082 odi-miR-124a; +MIMAT0006083 odi-miR-124b; +MIMAT0006084 odi-miR-219; +MIMAT0006085 odi-miR-281; +MIMAT0006086 cin-let-7a;cin-let-7a-5p; +MIMAT0006087 cin-let-7b;cin-let-7b-5p; +MIMAT0006088 cin-let-7c; +MIMAT0006089 cin-let-7d;cin-let-7d-5p; +MIMAT0006090 cin-let-7e; +MIMAT0006091 cin-miR-7;cin-miR-7-5p; +MIMAT0006092 cin-miR-31; +MIMAT0006093 cin-miR-33; +MIMAT0006094 cin-miR-34;cin-miR-34-5p; +MIMAT0006095 cin-miR-78; +MIMAT0006096 cin-miR-92a;cin-miR-92a-3p; +MIMAT0006097 cin-miR-92b;cin-miR-92b-3p; +MIMAT0006098 cin-miR-92c;cin-miR-92c-3p; +MIMAT0006099 cin-miR-101; +MIMAT0006100 cin-miR-124;cin-miR-124-3p; +MIMAT0006101 cin-miR-126;cin-miR-126-3p; +MIMAT0006102 cin-miR-133;cin-miR-133-3p; +MIMAT0006103 cin-miR-141;cin-miR-141-3p; +MIMAT0006104 cin-miR-153;cin-miR-153-3p; +MIMAT0006105 cin-miR-155; +MIMAT0006106 cin-miR-181; +MIMAT0006107 cin-miR-183;cin-miR-183-5p; +MIMAT0006108 cin-miR-184; +MIMAT0006109 cin-miR-199-3p; +MIMAT0006110 cin-miR-200;cin-miR-200-3p; +MIMAT0006111 cin-miR-216; +MIMAT0006112 cin-miR-217; +MIMAT0006113 cin-miR-219;cin-miR-219-5p; +MIMAT0006114 cin-miR-281;cin-miR-281-3p; +MIMAT0006115 cin-miR-672; +MIMAT0006116 csa-let-7a; +MIMAT0006117 csa-let-7b; +MIMAT0006118 csa-let-7c; +MIMAT0006119 csa-let-7d; +MIMAT0006120 csa-miR-7; +MIMAT0006121 csa-miR-31; +MIMAT0006122 csa-miR-34; +MIMAT0006123 csa-miR-92a; +MIMAT0006124 csa-miR-92b; +MIMAT0006125 csa-miR-92c; +MIMAT0006126 csa-miR-124; +MIMAT0006127 csa-miR-126; +MIMAT0006128 csa-miR-133; +MIMAT0006129 csa-miR-141; +MIMAT0006130 csa-miR-153; +MIMAT0006131 csa-miR-155; +MIMAT0006132 csa-miR-183; +MIMAT0006133 csa-miR-200; +MIMAT0006134 csa-miR-216a; +MIMAT0006135 csa-miR-216b; +MIMAT0006136 csa-miR-217; +MIMAT0006137 csa-miR-219; +MIMAT0006138 csa-miR-281; +MIMAT0006139 mdo-miR-1540;mdo-miR-1540a; +MIMAT0006140 mdo-miR-1541; +MIMAT0006141 mdo-miR-1542;mdo-miR-1542-3p; +MIMAT0006142 mdo-miR-1543; +MIMAT0006143 mdo-miR-340;mdo-miR-340-5p; +MIMAT0006144 mdo-miR-1544;mdo-miR-1544a-5p; +MIMAT0006145 mdo-miR-1545;mdo-miR-1545a-3p; +MIMAT0006146 mdo-miR-1546;mdo-miR-1546-5p; +MIMAT0006147 mdo-miR-1547;mdo-miR-1547-5p; +MIMAT0006148 mdo-miR-1548;mdo-miR-1548-3p; +MIMAT0006149 mdo-miR-1549;mdo-miR-1549-3p; +MIMAT0006150 mml-miR-1;mml-miR-1-3p; +MIMAT0006151 mml-let-7a;mml-let-7a-5p; +MIMAT0006152 mml-let-7b;mml-let-7b-5p; +MIMAT0006153 mml-let-7c;mml-let-7c-5p; +MIMAT0006154 mml-let-7d; +MIMAT0006155 mml-let-7e;mml-let-7e-5p; +MIMAT0006156 mml-let-7f;mml-let-7f-5p; +MIMAT0006157 mml-let-7g;mml-let-7g-5p; +MIMAT0006158 mml-let-7i;mml-let-7i-5p; +MIMAT0006159 mml-miR-7; +MIMAT0006160 mml-miR-9;mml-miR-9-5p; +MIMAT0006161 mml-miR-10a;mml-miR-10a-5p; +MIMAT0006162 mml-miR-10b;mml-miR-10b-5p; +MIMAT0006163 mml-miR-18b; +MIMAT0006164 mml-miR-20b;mml-miR-20b-5p; +MIMAT0006165 mml-miR-23b;mml-miR-23b-3p; +MIMAT0006166 mml-miR-26b;mml-miR-26b-5p; +MIMAT0006167 mml-miR-27b;mml-miR-27b-3p; +MIMAT0006168 mml-miR-29b;mml-miR-29b-3p; +MIMAT0006169 mml-miR-29c;mml-miR-29c-3p; +MIMAT0006170 mml-miR-30c;mml-miR-30c-5p; +MIMAT0006171 mml-miR-30d;mml-miR-30d-5p; +MIMAT0006172 mml-miR-30e;mml-miR-30e-5p; +MIMAT0006173 mml-miR-33b;mml-miR-33b-5p; +MIMAT0006174 mml-miR-34b; +MIMAT0006175 mml-miR-34c-5p; +MIMAT0006176 mml-miR-34c-3p; +MIMAT0006177 mml-miR-92b;mml-miR-92b-3p; +MIMAT0006178 mml-miR-95;mml-miR-95-3p; +MIMAT0006179 mml-miR-99b;mml-miR-99b-5p; +MIMAT0006180 mml-miR-122a;mml-miR-122a-5p; +MIMAT0006181 mml-miR-125a-5p; +MIMAT0006182 mml-miR-125a-3p; +MIMAT0006183 mml-miR-126; +MIMAT0006184 mml-miR-128b;mml-miR-128b-3p; +MIMAT0006185 mml-miR-129-5p; +MIMAT0006186 mml-miR-129-3p;mml-miR-129-1-3p; +MIMAT0006187 mml-miR-130b;mml-miR-130b-3p; +MIMAT0006188 mml-miR-132;mml-miR-132-3p; +MIMAT0006189 mml-miR-133b;mml-miR-133b-3p; +MIMAT0006190 mml-miR-134;mml-miR-134-5p; +MIMAT0006191 mml-miR-135b;mml-miR-135b-5p; +MIMAT0006192 mml-miR-136; +MIMAT0006193 mml-miR-137;mml-miR-137-3p; +MIMAT0006194 mml-miR-138;mml-miR-138-5p; +MIMAT0006195 mml-miR-139-5p; +MIMAT0006196 mml-miR-139-3p; +MIMAT0006197 mml-miR-140-5p; +MIMAT0006198 mml-miR-140-3p; +MIMAT0006199 mml-miR-142-5p; +MIMAT0006200 mml-miR-142-3p; +MIMAT0006201 mml-miR-143;mml-miR-143-3p; +MIMAT0006202 mml-miR-144; +MIMAT0006203 mml-miR-146a;mml-miR-146a-5p; +MIMAT0006204 mml-miR-146b-5p; +MIMAT0006205 mml-miR-146b-3p; +MIMAT0006206 mml-miR-147a; +MIMAT0006207 mml-miR-147b; +MIMAT0006208 mml-miR-148a;mml-miR-148a-3p; +MIMAT0006209 mml-miR-148b;mml-miR-148b-3p; +MIMAT0006210 mml-miR-149;mml-miR-149-5p; +MIMAT0006211 mml-miR-150;mml-miR-150-5p; +MIMAT0006212 mml-miR-151-5p; +MIMAT0006213 mml-miR-151-3p; +MIMAT0006214 mml-miR-152;mml-miR-152-3p; +MIMAT0006215 mml-miR-154;mml-miR-154-5p; +MIMAT0006216 mml-miR-155; +MIMAT0006217 mml-miR-181d; +MIMAT0006218 mml-miR-184; +MIMAT0006219 mml-miR-185;mml-miR-185-5p; +MIMAT0006220 mml-miR-186;mml-miR-186-5p; +MIMAT0006221 mml-miR-187;mml-miR-187-3p; +MIMAT0006222 mml-miR-190b; +MIMAT0006223 mml-miR-191;mml-miR-191-5p; +MIMAT0006224 mml-miR-192;mml-miR-192-5p; +MIMAT0006225 mml-miR-193a-5p; +MIMAT0006226 mml-miR-193a-3p; +MIMAT0006227 mml-miR-193b;mml-miR-193b-3p; +MIMAT0006228 mml-miR-195;mml-miR-195-5p; +MIMAT0006229 mml-miR-196b;mml-miR-196b-5p; +MIMAT0006230 mml-miR-197;mml-miR-197-3p; +MIMAT0006231 mml-miR-199a-5p; +MIMAT0006232 mml-miR-199a-3p; +MIMAT0006233 mml-miR-200a;mml-miR-200a-3p; +MIMAT0006234 mml-miR-203; +MIMAT0006235 mml-miR-204;mml-miR-204-5p; +MIMAT0006236 mml-miR-205; +MIMAT0006237 mml-miR-206; +MIMAT0006238 mml-miR-208a;mml-miR-208a-3p; +MIMAT0006239 mml-miR-208b;mml-miR-208b-3p; +MIMAT0006240 mml-miR-210;mml-miR-210-3p; +MIMAT0006241 mml-miR-212;mml-miR-212-3p; +MIMAT0006242 mml-miR-216a;mml-miR-216a-5p; +MIMAT0006243 mml-miR-216b; +MIMAT0006244 mml-miR-217;mml-miR-217a;mml-miR-217; +MIMAT0006245 mml-miR-219-5p; +MIMAT0006246 mml-miR-219-3p; +MIMAT0006247 mml-miR-220b; +MIMAT0006248 mml-miR-220c; +MIMAT0006249 mml-miR-220d; +MIMAT0006250 mml-miR-222;mml-miR-222-3p; +MIMAT0006251 mml-miR-296-5p; +MIMAT0006252 mml-miR-296-3p; +MIMAT0006253 mml-miR-297; +MIMAT0006254 mml-miR-298; +MIMAT0006255 mml-miR-299-5p; +MIMAT0006256 mml-miR-299-3p; +MIMAT0006257 mml-miR-301a;mml-miR-301a-3p; +MIMAT0006258 mml-miR-301b; +MIMAT0006259 mml-miR-302a;mml-miR-302a-3p; +MIMAT0006260 mml-miR-302b; +MIMAT0006261 mml-miR-302c; +MIMAT0006262 mml-miR-302d; +MIMAT0006263 mml-miR-320;mml-miR-320a; +MIMAT0006264 mml-miR-323-5p;mml-miR-323a-5p; +MIMAT0006265 mml-miR-323-3p;mml-miR-323a-3p; +MIMAT0006266 mml-miR-324-5p; +MIMAT0006267 mml-miR-324-3p; +MIMAT0006268 mml-miR-325; +MIMAT0006269 mml-miR-329;mml-miR-329-3p; +MIMAT0006270 mml-miR-330-5p; +MIMAT0006271 mml-miR-330-3p; +MIMAT0006272 mml-miR-331-5p; +MIMAT0006273 mml-miR-331-3p; +MIMAT0006274 mml-miR-335;mml-miR-335-5p; +MIMAT0006275 mml-miR-337-5p; +MIMAT0006276 mml-miR-337-3p; +MIMAT0006277 mml-miR-338-5p; +MIMAT0006278 mml-miR-338-3p; +MIMAT0006279 mml-miR-339-5p; +MIMAT0006280 mml-miR-339-3p; +MIMAT0006281 mml-miR-340;mml-miR-340-5p; +MIMAT0006282 mml-miR-342-5p; +MIMAT0006283 mml-miR-342-3p; +MIMAT0006284 mml-miR-345; +MIMAT0006285 mml-miR-346; +MIMAT0006286 mml-miR-361-5p; +MIMAT0006287 mml-miR-361-3p; +MIMAT0006288 mml-miR-362-5p; +MIMAT0006289 mml-miR-362-3p; +MIMAT0006290 mml-miR-363;mml-miR-363-3p; +MIMAT0006291 mml-miR-365;mml-miR-365-3p; +MIMAT0006292 mml-miR-367; +MIMAT0006293 mml-miR-369-5p; +MIMAT0006294 mml-miR-369-3p; +MIMAT0006295 mml-miR-370;mml-miR-370-3p; +MIMAT0006296 mml-miR-371-5p; +MIMAT0006297 mml-miR-371-3p; +MIMAT0006298 mml-miR-372;mml-miR-372-3p; +MIMAT0006299 mml-miR-373; +MIMAT0006300 mml-miR-374a;mml-miR-374a-5p; +MIMAT0006301 mml-miR-374b;mml-miR-374b-5p; +MIMAT0006302 mml-miR-375; +MIMAT0006303 mml-miR-376a;mml-miR-376a-3p; +MIMAT0006304 mml-miR-376b;mml-miR-376b-3p; +MIMAT0006305 mml-miR-376c;mml-miR-376c-3p; +MIMAT0006306 mml-miR-377;mml-miR-377-3p; +MIMAT0006307 mml-miR-378;mml-miR-378a; +MIMAT0006308 mml-miR-379;mml-miR-379-5p; +MIMAT0006309 mml-miR-380;mml-miR-380-3p; +MIMAT0006310 mml-miR-381;mml-miR-381-3p; +MIMAT0006311 mml-miR-382;mml-miR-382-5p; +MIMAT0006312 mml-miR-383; +MIMAT0006313 mml-miR-384; +MIMAT0006314 mml-miR-409-5p; +MIMAT0006315 mml-miR-409-3p; +MIMAT0006316 mml-miR-410;mml-miR-410-3p; +MIMAT0006317 mml-miR-411;mml-miR-411-5p; +MIMAT0006318 mml-miR-412;mml-miR-412-3p; +MIMAT0006319 mml-miR-421; +MIMAT0006320 mml-miR-422a; +MIMAT0006321 mml-miR-423-5p; +MIMAT0006322 mml-miR-423-3p; +MIMAT0006323 mml-miR-424;mml-miR-424-5p; +MIMAT0006324 mml-miR-425; +MIMAT0006325 mml-miR-429;mml-miR-429-3p; +MIMAT0006326 mml-miR-431; +MIMAT0006327 mml-miR-432;mml-miR-432-5p; +MIMAT0006328 mml-miR-433;mml-miR-433-3p; +MIMAT0006329 mml-miR-448; +MIMAT0006330 mml-miR-449a;mml-miR-449a-5p; +MIMAT0006331 mml-miR-449b;mml-miR-449b-5p; +MIMAT0006332 mml-miR-450a;mml-miR-450a-5p; +MIMAT0006333 mml-miR-450b-5p; +MIMAT0006334 mml-miR-450b-3p; +MIMAT0006335 mml-miR-451; +MIMAT0006336 mml-miR-452;mml-miR-452-5p; +MIMAT0006337 mml-miR-453; +MIMAT0006338 mml-miR-454;mml-miR-454-3p; +MIMAT0006339 mml-miR-455-5p; +MIMAT0006340 mml-miR-455-3p; +MIMAT0006341 mml-miR-484; +MIMAT0006342 mml-miR-485-5p; +MIMAT0006343 mml-miR-485-3p; +MIMAT0006344 mml-miR-486-5p; +MIMAT0006345 mml-miR-486-3p; +MIMAT0006346 mml-miR-487a; +MIMAT0006347 mml-miR-487b;mml-miR-487b-3p; +MIMAT0006348 mml-miR-488;mml-miR-488-3p; +MIMAT0006349 mml-miR-489;mml-miR-489-3p; +MIMAT0006350 mml-miR-490-5p; +MIMAT0006351 mml-miR-490-3p; +MIMAT0006352 mml-miR-491-5p; +MIMAT0006353 mml-miR-491-3p; +MIMAT0006354 mml-miR-492; +MIMAT0006355 mml-miR-493;mml-miR-493-3p; +MIMAT0006356 mml-miR-494;mml-miR-494-3p; +MIMAT0006357 mml-miR-495;mml-miR-495-3p; +MIMAT0006358 mml-miR-496; +MIMAT0006359 mml-miR-497;mml-miR-497-5p; +MIMAT0006360 mml-miR-498; +MIMAT0006361 mml-miR-499-5p; +MIMAT0006362 mml-miR-499-3p; +MIMAT0006363 mml-miR-500;mml-miR-500a-5p; +MIMAT0006364 mml-miR-501;mml-miR-501-5p; +MIMAT0006365 mml-miR-502-5p; +MIMAT0006366 mml-miR-502-3p; +MIMAT0006367 mml-miR-503;mml-miR-503-5p; +MIMAT0006368 mml-miR-504;mml-miR-504-5p; +MIMAT0006369 mml-miR-505;mml-miR-505-3p; +MIMAT0006370 mml-miR-511;mml-miR-511-5p; +MIMAT0006371 mml-miR-512-5p; +MIMAT0006372 mml-miR-512-3p; +MIMAT0006373 mml-miR-516a-5p; +MIMAT0006374 mml-miR-516a-3p; +MIMAT0006375 mml-miR-517a;mml-miR-517;mml-miR-517a; +MIMAT0006376 mml-miR-517b; +MIMAT0006377 mml-miR-518a-5p; +MIMAT0006378 mml-miR-518a-3p; +MIMAT0006379 mml-miR-518b; +MIMAT0006380 mml-miR-518c;mml-miR-518c-3p; +MIMAT0006381 mml-miR-518d; +MIMAT0006382 mml-miR-518e; +MIMAT0006383 mml-miR-518f; +MIMAT0006384 mml-miR-519a;mml-miR-519a-3p; +MIMAT0006385 mml-miR-519b; +MIMAT0006386 mml-miR-519c; +MIMAT0006387 mml-miR-519d; +MIMAT0006388 mml-miR-520a;mml-miR-520a-3p; +MIMAT0006389 mml-miR-520b; +MIMAT0006390 mml-miR-520c; +MIMAT0006391 mml-miR-520d-5p; +MIMAT0006392 mml-miR-520d-3p; +MIMAT0006393 mml-miR-520e; +MIMAT0006394 mml-miR-520f; +MIMAT0006395 mml-miR-520g; +MIMAT0006396 mml-miR-520h; +MIMAT0006397 mml-miR-521; +MIMAT0006398 mml-miR-522; +MIMAT0006399 mml-miR-523a; +MIMAT0006400 mml-miR-523b; +MIMAT0006401 mml-miR-523c; +MIMAT0006402 mml-miR-525; +MIMAT0006403 mml-miR-532-5p; +MIMAT0006404 mml-miR-532-3p; +MIMAT0006405 mml-miR-539; +MIMAT0006406 mml-miR-542-5p; +MIMAT0006407 mml-miR-542-3p; +MIMAT0006408 mml-miR-544; +MIMAT0006409 mml-miR-545; +MIMAT0006410 mml-miR-548a; +MIMAT0006411 mml-miR-548b; +MIMAT0006412 mml-miR-548c; +MIMAT0006413 mml-miR-548d-5p; +MIMAT0006414 mml-miR-548d-3p; +MIMAT0006415 mml-miR-548e; +MIMAT0006416 mml-miR-548f; +MIMAT0006417 mml-miR-549;mml-miR-549a; +MIMAT0006418 mml-miR-550;mml-miR-550-5p; +MIMAT0006419 mml-miR-551a; +MIMAT0006420 mml-miR-551b;mml-miR-551b-3p; +MIMAT0006421 mml-miR-552; +MIMAT0006422 mml-miR-553; +MIMAT0006423 mml-miR-554; +MIMAT0006424 mml-miR-556-5p; +MIMAT0006425 mml-miR-556-3p; +MIMAT0006426 mml-miR-557; +MIMAT0006427 mml-miR-558; +MIMAT0006428 mml-miR-562; +MIMAT0006429 mml-miR-563; +MIMAT0006430 mml-miR-567; +MIMAT0006431 mml-miR-568; +MIMAT0006432 mml-miR-569; +MIMAT0006433 mml-miR-570; +MIMAT0006434 mml-miR-572; +MIMAT0006435 mml-miR-573; +MIMAT0006436 mml-miR-576-5p; +MIMAT0006437 mml-miR-576-3p; +MIMAT0006438 mml-miR-577;mml-miR-577-5p; +MIMAT0006439 mml-miR-578; +MIMAT0006440 mml-miR-579; +MIMAT0006441 mml-miR-580; +MIMAT0006442 mml-miR-581; +MIMAT0006443 mml-miR-582-5p; +MIMAT0006444 mml-miR-582-3p; +MIMAT0006445 mml-miR-583; +MIMAT0006446 mml-miR-584;mml-miR-584-5p; +MIMAT0006447 mml-miR-586; +MIMAT0006448 mml-miR-587; +MIMAT0006449 mml-miR-589; +MIMAT0006450 mml-miR-590-5p; +MIMAT0006451 mml-miR-590-3p; +MIMAT0006452 mml-miR-592;mml-miR-592-5p; +MIMAT0006453 mml-miR-593; +MIMAT0006454 mml-miR-597; +MIMAT0006455 mml-miR-598;mml-miR-598-3p; +MIMAT0006456 mml-miR-599;mml-miR-599-3p; +MIMAT0006457 mml-miR-600; +MIMAT0006458 mml-miR-601; +MIMAT0006459 mml-miR-604; +MIMAT0006460 mml-miR-605; +MIMAT0006461 mml-miR-607; +MIMAT0006462 mml-miR-609; +MIMAT0006463 mml-miR-611; +MIMAT0006464 mml-miR-612; +MIMAT0006465 mml-miR-615-5p; +MIMAT0006466 mml-miR-615-3p; +MIMAT0006467 mml-miR-616; +MIMAT0006468 mml-miR-618; +MIMAT0006469 mml-miR-619; +MIMAT0006470 mml-miR-624; +MIMAT0006471 mml-miR-625; +MIMAT0006472 mml-miR-626; +MIMAT0006473 mml-miR-627;mml-miR-627-3p; +MIMAT0006474 mml-miR-628-5p; +MIMAT0006475 mml-miR-628-3p; +MIMAT0006476 mml-miR-631; +MIMAT0006477 mml-miR-632; +MIMAT0006478 mml-miR-633; +MIMAT0006479 mml-miR-636; +MIMAT0006480 mml-miR-638; +MIMAT0006481 mml-miR-639; +MIMAT0006482 mml-miR-640; +MIMAT0006483 mml-miR-642; +MIMAT0006484 mml-miR-643; +MIMAT0006485 mml-miR-644; +MIMAT0006486 mml-miR-648; +MIMAT0006487 mml-miR-649; +MIMAT0006488 mml-miR-650a; +MIMAT0006489 mml-miR-650b; +MIMAT0006490 mml-miR-650c; +MIMAT0006491 mml-miR-650d; +MIMAT0006492 mml-miR-651; +MIMAT0006493 mml-miR-652; +MIMAT0006494 mml-miR-653;mml-miR-653-5p; +MIMAT0006495 mml-miR-654-5p; +MIMAT0006496 mml-miR-654-3p; +MIMAT0006497 mml-miR-656;mml-miR-656-3p; +MIMAT0006498 mml-miR-657; +MIMAT0006499 mml-miR-660;mml-miR-660-5p; +MIMAT0006500 mml-miR-661; +MIMAT0006501 mml-miR-662; +MIMAT0006502 mml-miR-663; +MIMAT0006503 mml-miR-664; +MIMAT0006504 mml-miR-668; +MIMAT0006505 mml-miR-671-5p; +MIMAT0006506 mml-miR-671-3p; +MIMAT0006507 mml-miR-675;mml-miR-675-5p; +MIMAT0006508 mml-miR-758;mml-miR-758-3p; +MIMAT0006509 mml-miR-765; +MIMAT0006510 mml-miR-767-5p; +MIMAT0006511 mml-miR-767-3p; +MIMAT0006512 mml-miR-768-5p; +MIMAT0006513 mml-miR-768-3p; +MIMAT0006514 mml-miR-770-5p; +MIMAT0006515 mml-miR-802; +MIMAT0006516 mml-miR-874;mml-miR-874-3p; +MIMAT0006517 mml-miR-875-5p; +MIMAT0006518 mml-miR-875-3p; +MIMAT0006519 mml-miR-876-5p; +MIMAT0006520 mml-miR-876-3p; +MIMAT0006521 mml-miR-877;mml-miR-877-5p; +MIMAT0006522 mml-miR-885-5p; +MIMAT0006523 mml-miR-885-3p; +MIMAT0006524 mml-miR-886-5p; +MIMAT0006525 mml-miR-886-3p; +MIMAT0006526 mml-miR-887; +MIMAT0006527 mml-miR-888; +MIMAT0006528 mml-miR-889;mml-miR-889-3p; +MIMAT0006529 mml-miR-890;mml-miR-890-5p; +MIMAT0006530 mml-miR-891;mml-miR-891a; +MIMAT0006531 mml-miR-892;mml-miR-892a; +MIMAT0006532 mml-miR-920; +MIMAT0006533 mml-miR-922; +MIMAT0006534 mml-miR-924; +MIMAT0006535 mml-miR-933; +MIMAT0006536 mml-miR-934;mml-miR-934-5p; +MIMAT0006537 mml-miR-936; +MIMAT0006538 mml-miR-937; +MIMAT0006539 mml-miR-938; +MIMAT0006540 mml-miR-939; +MIMAT0006541 mml-miR-940; +MIMAT0006542 mml-miR-942;mml-miR-942-5p; +MIMAT0006543 mml-miR-944; +MIMAT0006544 vvi-miR156h; +MIMAT0006545 vvi-miR169b; +MIMAT0006546 vvi-miR169h; +MIMAT0006547 vvi-miR169i; +MIMAT0006548 vvi-miR169l; +MIMAT0006549 vvi-miR169n; +MIMAT0006550 vvi-miR169o; +MIMAT0006551 vvi-miR169q; +MIMAT0006552 vvi-miR169v; +MIMAT0006553 vvi-miR169w; +MIMAT0006554 vvi-miR169x; +MIMAT0006555 vvi-miR171g; +MIMAT0006556 vvi-miR319e; +MIMAT0006557 vvi-miR393a; +MIMAT0006558 vvi-miR394c; +MIMAT0006559 vvi-miR395n; +MIMAT0006560 vvi-miR396c; +MIMAT0006561 vvi-miR397a; +MIMAT0006562 vvi-miR397b; +MIMAT0006563 vvi-miR398b; +MIMAT0006564 vvi-miR398c; +MIMAT0006565 vvi-miR399c; +MIMAT0006566 vvi-miR399d; +MIMAT0006567 vvi-miR399f; +MIMAT0006568 vvi-miR399i; +MIMAT0006569 vvi-miR403a; +MIMAT0006570 vvi-miR403b; +MIMAT0006571 vvi-miR403c; +MIMAT0006572 vvi-miR403d; +MIMAT0006573 vvi-miR403e; +MIMAT0006574 vvi-miR403f; +MIMAT0006575 vvi-miR477;vvi-miR477a; +MIMAT0006576 vvi-miR482; +MIMAT0006577 vvi-miR828a; +MIMAT0006578 vvi-miR828b; +MIMAT0006579 vvi-miR845a; +MIMAT0006580 vvi-miR845b; +MIMAT0006581 vvi-miR845c; +MIMAT0006582 vvi-miR845d; +MIMAT0006583 vvi-miR845e; +MIMAT0006584 cel-miR-1817; +MIMAT0006585 cel-miR-1818; +MIMAT0006586 cel-miR-1819;cel-miR-1819-3p; +MIMAT0006587 cel-miR-1820;cel-miR-1820-5p; +MIMAT0006588 cel-miR-1821;cel-miR-1821-3p; +MIMAT0006589 cel-miR-1822;cel-miR-1822-3p; +MIMAT0006590 cel-miR-1823;cel-miR-1823-3p; +MIMAT0006591 cel-miR-1824;cel-miR-1824-5p; +MIMAT0006592 cfa-miR-216;cfa-miR-216b; +MIMAT0006593 cfa-miR-33;cfa-miR-33a; +MIMAT0006594 cfa-let-7a; +MIMAT0006595 cfa-miR-26a; +MIMAT0006596 cfa-miR-1835; +MIMAT0006597 cfa-miR-32; +MIMAT0006598 cfa-miR-204; +MIMAT0006599 cfa-miR-31; +MIMAT0006600 cfa-miR-101; +MIMAT0006601 cfa-miR-491; +MIMAT0006602 cfa-miR-150; +MIMAT0006603 cfa-miR-455; +MIMAT0006604 cfa-miR-30a; +MIMAT0006605 cfa-miR-30c; +MIMAT0006606 cfa-miR-206; +MIMAT0006607 cfa-miR-99b; +MIMAT0006608 cfa-let-7e; +MIMAT0006609 cfa-miR-125a; +MIMAT0006610 cfa-let-7f; +MIMAT0006611 cfa-miR-219;cfa-miR-219-5p; +MIMAT0006612 cfa-miR-23b; +MIMAT0006613 cfa-miR-27b; +MIMAT0006614 cfa-miR-24; +MIMAT0006615 cfa-miR-151; +MIMAT0006616 cfa-miR-30d; +MIMAT0006617 cfa-miR-30b; +MIMAT0006618 cfa-miR-1836; +MIMAT0006619 cfa-miR-122; +MIMAT0006620 cfa-miR-196b; +MIMAT0006621 cfa-miR-183; +MIMAT0006622 cfa-miR-148a; +MIMAT0006623 cfa-miR-129; +MIMAT0006624 cfa-miR-335; +MIMAT0006625 cfa-miR-29b; +MIMAT0006626 cfa-miR-29a; +MIMAT0006627 cfa-miR-30e; +MIMAT0006628 cfa-miR-135;cfa-miR-135a-3p; +MIMAT0006629 cfa-miR-383; +MIMAT0006630 cfa-miR-1837; +MIMAT0006631 cfa-miR-130a; +MIMAT0006632 cfa-miR-192; +MIMAT0006633 cfa-miR-128; +MIMAT0006634 cfa-miR-7; +MIMAT0006635 cfa-miR-181c; +MIMAT0006636 cfa-miR-181d; +MIMAT0006637 cfa-let-7g; +MIMAT0006638 cfa-miR-191; +MIMAT0006639 cfa-miR-425; +MIMAT0006640 cfa-miR-23a; +MIMAT0006641 cfa-miR-27a; +MIMAT0006642 cfa-miR-199; +MIMAT0006643 cfa-miR-708; +MIMAT0006644 cfa-miR-1838; +MIMAT0006645 cfa-miR-139; +MIMAT0006646 cfa-miR-138b; +MIMAT0006647 cfa-miR-15a; +MIMAT0006648 cfa-miR-16; +MIMAT0006649 cfa-miR-17; +MIMAT0006650 cfa-miR-19a; +MIMAT0006651 cfa-miR-20;cfa-miR-20a; +MIMAT0006652 cfa-miR-19b; +MIMAT0006653 cfa-miR-92a; +MIMAT0006654 cfa-miR-138a; +MIMAT0006655 cfa-miR-499; +MIMAT0006656 cfa-miR-1; +MIMAT0006657 cfa-miR-124; +MIMAT0006658 cfa-miR-320; +MIMAT0006659 cfa-miR-130b; +MIMAT0006660 cfa-miR-185; +MIMAT0006661 cfa-miR-1306; +MIMAT0006662 cfa-miR-196a; +MIMAT0006663 cfa-miR-148b; +MIMAT0006664 cfa-miR-200c; +MIMAT0006665 cfa-miR-1307; +MIMAT0006666 cfa-miR-107; +MIMAT0006667 cfa-miR-146b; +MIMAT0006668 cfa-miR-99a; +MIMAT0006669 cfa-let-7c; +MIMAT0006670 cfa-miR-125b; +MIMAT0006671 cfa-miR-155; +MIMAT0006672 cfa-miR-218; +MIMAT0006673 cfa-miR-574; +MIMAT0006674 cfa-miR-9; +MIMAT0006675 cfa-miR-28; +MIMAT0006676 cfa-miR-15b; +MIMAT0006677 cfa-miR-1839; +MIMAT0006678 cfa-miR-26b; +MIMAT0006679 cfa-miR-1840; +MIMAT0006680 cfa-miR-664; +MIMAT0006681 cfa-miR-194; +MIMAT0006682 cfa-miR-143; +MIMAT0006683 cfa-miR-378; +MIMAT0006684 cfa-miR-146a; +MIMAT0006685 cfa-miR-1271; +MIMAT0006686 cfa-miR-1841; +MIMAT0006687 cfa-miR-103; +MIMAT0006688 cfa-miR-328; +MIMAT0006689 cfa-miR-140; +MIMAT0006690 cfa-miR-34a; +MIMAT0006691 cfa-miR-497; +MIMAT0006692 cfa-miR-195; +MIMAT0006693 cfa-miR-34c; +MIMAT0006694 cfa-miR-186; +MIMAT0006695 cfa-miR-106b; +MIMAT0006696 cfa-miR-93; +MIMAT0006697 cfa-miR-25; +MIMAT0006698 cfa-miR-197; +MIMAT0006699 cfa-miR-193b; +MIMAT0006700 cfa-miR-590; +MIMAT0006701 cfa-miR-1842; +MIMAT0006702 cfa-miR-137; +MIMAT0006703 cfa-miR-92b; +MIMAT0006704 cfa-miR-350; +MIMAT0006705 cfa-miR-29c; +MIMAT0006706 cfa-miR-1843; +MIMAT0006707 cfa-miR-181a; +MIMAT0006708 cfa-miR-181b; +MIMAT0006709 cfa-miR-342; +MIMAT0006710 cfa-miR-345; +MIMAT0006711 cfa-miR-493; +MIMAT0006712 cfa-miR-433; +MIMAT0006713 cfa-miR-127; +MIMAT0006714 cfa-miR-136; +MIMAT0006715 cfa-miR-379; +MIMAT0006716 cfa-miR-411; +MIMAT0006717 cfa-miR-380; +MIMAT0006718 cfa-miR-323; +MIMAT0006719 cfa-miR-329;cfa-miR-329a; +MIMAT0006720 cfa-miR-543; +MIMAT0006721 cfa-miR-495; +MIMAT0006722 cfa-miR-376;cfa-miR-376a; +MIMAT0006723 cfa-miR-487;cfa-miR-487b; +MIMAT0006724 cfa-miR-382; +MIMAT0006725 cfa-miR-485; +MIMAT0006726 cfa-miR-409; +MIMAT0006727 cfa-miR-369; +MIMAT0006728 cfa-miR-410; +MIMAT0006729 cfa-miR-219*;cfa-miR-219-3p; +MIMAT0006730 cfa-miR-126; +MIMAT0006731 cfa-miR-212; +MIMAT0006732 cfa-miR-132; +MIMAT0006733 cfa-miR-22; +MIMAT0006734 cfa-miR-144; +MIMAT0006735 cfa-miR-193a; +MIMAT0006736 cfa-miR-142; +MIMAT0006737 cfa-miR-10;cfa-miR-10a; +MIMAT0006738 cfa-miR-152; +MIMAT0006739 cfa-miR-338; +MIMAT0006740 cfa-miR-1844; +MIMAT0006741 cfa-miR-21; +MIMAT0006742 cfa-miR-423a; +MIMAT0006743 cfa-miR-652; +MIMAT0006744 cfa-miR-224; +MIMAT0006745 cfa-miR-424; +MIMAT0006746 cfa-miR-503; +MIMAT0006747 cfa-miR-542; +MIMAT0006748 cfa-miR-450b; +MIMAT0006749 cfa-miR-106a; +MIMAT0006750 cfa-miR-363; +MIMAT0006751 cfa-miR-361; +MIMAT0006752 cfa-miR-384; +MIMAT0006753 cfa-miR-374a; +MIMAT0006754 cfa-miR-374b; +MIMAT0006755 cfa-miR-421; +MIMAT0006756 cfa-miR-98; +MIMAT0006757 cfa-miR-221; +MIMAT0006758 cfa-miR-532; +MIMAT0006759 cfa-miR-500; +MIMAT0006760 cfa-miR-660; +MIMAT0006761 cfa-miR-502; +MIMAT0006762 cfa-miR-676; +MIMAT0006763 cfa-let-7j; +MIMAT0006764 hsa-miR-320d; +MIMAT0006765 hsa-miR-1825; +MIMAT0006766 hsa-miR-1826; +MIMAT0006767 hsa-miR-1827; +MIMAT0006768 cel-miR-1828; +MIMAT0006769 cel-miR-1829a;cel-miR-1829a-3p; +MIMAT0006770 cel-miR-1829b;cel-miR-1829b-5p; +MIMAT0006771 cel-miR-1829c;cel-miR-1829c-5p; +MIMAT0006772 cel-miR-1830;cel-miR-1830-5p; +MIMAT0006773 cel-miR-1831; +MIMAT0006774 cel-miR-1832;cel-miR-1832a;cel-miR-1832a-3p; +MIMAT0006775 cel-miR-1833; +MIMAT0006776 cel-miR-1834;cel-miR-1834-3p;cel-miR-58b-3p; +MIMAT0006777 mml-miR-133c;mml-miR-133c-3p; +MIMAT0006778 hsa-miR-516a-3p; +MIMAT0006779 ath-miR161.2; +MIMAT0006780 osa-miR167a*;osa-miR167a-3p; +MIMAT0006781 gga-miR-99a*;gga-miR-99a-3p; +MIMAT0006782 aga-miR-276-3p; +MIMAT0006783 ptc-miR394a-3p; +MIMAT0006784 ptc-miR394b-3p; +MIMAT0006785 ptc-miR482.2;ptc-miR482a.2; +MIMAT0006786 ssc-miR-140*;ssc-miR-140-3p; +MIMAT0006787 osa-miR530-5p; +MIMAT0006788 gga-miR-455-3p; +MIMAT0006789 hsa-miR-1468;hsa-miR-1468-5p; +MIMAT0006790 hsa-miR-675b;hsa-miR-675*;hsa-miR-675-3p; +MIMAT0006791 pta-miR946a*;pta-miR946a-5p; +MIMAT0006792 oan-miR-9;oan-miR-9-5p; +MIMAT0006793 oan-miR-9*;oan-miR-9-3p; +MIMAT0006794 oan-miR-1325; +MIMAT0006795 oan-miR-1326; +MIMAT0006796 oan-miR-1327;oan-miR-1327-5p; +MIMAT0006797 oan-miR-1328; +MIMAT0006798 oan-miR-1329;oan-miR-1329-5p; +MIMAT0006799 oan-miR-1329*;oan-miR-1329-3p; +MIMAT0006800 oan-miR-1330; +MIMAT0006801 oan-miR-129;oan-miR-129-5p; +MIMAT0006802 oan-miR-129*;oan-miR-129-3p; +MIMAT0006803 oan-miR-96;oan-miR-96-5p; +MIMAT0006804 oan-miR-96*;oan-miR-96-3p; +MIMAT0006805 oan-miR-183; +MIMAT0006806 oan-miR-29a-1*;oan-miR-29a-1-5p; +MIMAT0006807 oan-miR-29a;oan-miR-29a-3p; +MIMAT0006808 oan-miR-29b*;oan-miR-29b-5p; +MIMAT0006809 oan-miR-29b;oan-miR-29b-3p; +MIMAT0006810 oan-miR-490;oan-miR-490-5p; +MIMAT0006811 oan-miR-490*;oan-miR-490-3p; +MIMAT0006812 oan-miR-140*;oan-miR-140-5p; +MIMAT0006813 oan-miR-140;oan-miR-140-3p; +MIMAT0006814 oan-miR-1331; +MIMAT0006815 oan-miR-218;oan-miR-218-5p; +MIMAT0006816 oan-miR-218*;oan-miR-218-3p; +MIMAT0006817 oan-miR-33-5p; +MIMAT0006818 oan-miR-33a-3p; +MIMAT0006819 oan-miR-1332;oan-miR-1332-3p; +MIMAT0006820 oan-miR-193*;oan-miR-193-5p; +MIMAT0006821 oan-miR-193;oan-miR-193-3p; +MIMAT0006822 oan-miR-365*;oan-miR-365-5p;oan-miR-365-1-5p; +MIMAT0006823 oan-miR-365;oan-miR-365-3p; +MIMAT0006824 oan-miR-1333; +MIMAT0006825 oan-miR-122;oan-miR-122-5p; +MIMAT0006826 oan-miR-122*;oan-miR-122-3p; +MIMAT0006827 oan-miR-1334; +MIMAT0006828 oan-miR-1335; +MIMAT0006829 oan-miR-1336; +MIMAT0006830 oan-miR-875;oan-miR-875-5p; +MIMAT0006831 oan-miR-875*;oan-miR-875-3p; +MIMAT0006832 oan-miR-1337; +MIMAT0006833 oan-miR-181a;oan-miR-181a-5p; +MIMAT0006834 oan-miR-181a*;oan-miR-181a-3p;oan-miR-181a-1-3p; +MIMAT0006835 oan-miR-181b;oan-miR-181b-5p; +MIMAT0006836 oan-miR-181b*;oan-miR-181b-3p;oan-miR-181b-1-3p; +MIMAT0006837 oan-miR-137a*;oan-miR-137a-5p; +MIMAT0006838 oan-miR-137a;oan-miR-137a-3p; +MIMAT0006839 oan-miR-1338*;oan-miR-1338-5p; +MIMAT0006840 oan-miR-1338;oan-miR-1338-3p; +MIMAT0006841 oan-miR-204;oan-miR-204-5p; +MIMAT0006842 oan-miR-204*;oan-miR-204-3p; +MIMAT0006843 oan-miR-190a;oan-miR-190a-5p; +MIMAT0006844 oan-miR-190a*;oan-miR-190a-3p; +MIMAT0006845 oan-miR-15c;oan-miR-15c-5p; +MIMAT0006846 oan-miR-15c*;oan-miR-15c-3p; +MIMAT0006847 oan-miR-16c;oan-miR-16c-5p; +MIMAT0006848 oan-miR-16c*;oan-miR-16c-3p; +MIMAT0006849 oan-miR-106;oan-miR-106-5p; +MIMAT0006850 oan-miR-106*;oan-miR-106-3p; +MIMAT0006851 oan-miR-18;oan-miR-18-5p; +MIMAT0006852 oan-miR-18*;oan-miR-18-3p; +MIMAT0006853 oan-miR-20b;oan-miR-20b-5p; +MIMAT0006854 oan-miR-20b*;oan-miR-20b-3p; +MIMAT0006855 oan-miR-19b*;oan-miR-19b-5p;oan-miR-19b-1-5p; +MIMAT0006856 oan-miR-19b;oan-miR-19b-3p; +MIMAT0006857 oan-miR-92a-1*;oan-miR-92a-1-5p; +MIMAT0006858 oan-miR-92a;oan-miR-92a-3p; +MIMAT0006859 oan-miR-363*;oan-miR-363-5p; +MIMAT0006860 oan-miR-363;oan-miR-363-3p; +MIMAT0006861 oan-miR-1339;oan-miR-1339-5p; +MIMAT0006862 oan-miR-1339*;oan-miR-1339-3p; +MIMAT0006863 oan-miR-1a;oan-miR-1a-3p; +MIMAT0006864 oan-miR-133a*;oan-miR-133a-5p; +MIMAT0006865 oan-miR-133a;oan-miR-133a-3p; +MIMAT0006866 oan-miR-205;oan-miR-205-5p; +MIMAT0006867 oan-miR-205*;oan-miR-205-3p; +MIMAT0006868 oan-miR-1340*;oan-miR-1340-5p; +MIMAT0006869 oan-miR-1340;oan-miR-1340-3p; +MIMAT0006870 oan-miR-135b;oan-miR-135b-5p; +MIMAT0006871 oan-miR-135b*;oan-miR-135b-3p;oan-miR-135b-1-3p; +MIMAT0006872 oan-miR-1341; +MIMAT0006873 oan-miR-1342; +MIMAT0006874 oan-miR-1343;oan-miR-1343-5p; +MIMAT0006875 oan-miR-1343*;oan-miR-1343-3p; +MIMAT0006876 oan-miR-196a;oan-miR-196a-5p; +MIMAT0006877 oan-miR-196a*;oan-miR-196a-3p; +MIMAT0006878 oan-miR-137b;oan-miR-137b-3p; +MIMAT0006879 oan-miR-1422a*;oan-miR-1422a-5p; +MIMAT0006880 oan-miR-1422a;oan-miR-1422a-3p; +MIMAT0006881 oan-miR-1422e;oan-miR-1422e-5p; +MIMAT0006882 oan-miR-1422e*;oan-miR-1422e-3p; +MIMAT0006883 oan-miR-1422h*;oan-miR-1422h-5p; +MIMAT0006884 oan-miR-1422h;oan-miR-1422h-3p; +MIMAT0006885 oan-miR-1422b-1*;oan-miR-1422b-1-5p; +MIMAT0006886 oan-miR-1422b;oan-miR-1422b-3p; +MIMAT0006887 oan-miR-1422f;oan-miR-1422f-5p; +MIMAT0006888 oan-miR-1422f*;oan-miR-1422f-3p; +MIMAT0006889 oan-miR-1422g;oan-miR-1422g-5p; +MIMAT0006890 oan-miR-1422g*;oan-miR-1422g-3p; +MIMAT0006891 oan-miR-1422c*;oan-miR-1422c-5p; +MIMAT0006892 oan-miR-1422c;oan-miR-1422c-3p; +MIMAT0006893 oan-miR-1422i*;oan-miR-1422i-5p; +MIMAT0006894 oan-miR-1422i;oan-miR-1422i-3p; +MIMAT0006895 oan-miR-1422k-5p; +MIMAT0006896 oan-miR-1422k-3p; +MIMAT0006897 oan-let-7b;oan-let-7b-5p; +MIMAT0006898 oan-let-7b*;oan-let-7b-3p; +MIMAT0006899 oan-miR-219*;oan-miR-219-5p; +MIMAT0006900 oan-miR-219;oan-miR-219-3p; +MIMAT0006901 oan-miR-451; +MIMAT0006902 oan-miR-144*;oan-miR-144-5p; +MIMAT0006903 oan-miR-144;oan-miR-144-3p; +MIMAT0006904 oan-miR-139;oan-miR-139-5p; +MIMAT0006905 oan-miR-139*;oan-miR-139-3p; +MIMAT0006906 oan-miR-1344; +MIMAT0006907 oan-miR-130c*;oan-miR-130c-5p; +MIMAT0006908 oan-miR-130c;oan-miR-130c-3p; +MIMAT0006909 oan-miR-301*;oan-miR-301-5p; +MIMAT0006910 oan-miR-301;oan-miR-301-3p; +MIMAT0006911 oan-miR-30c;oan-miR-30c-5p; +MIMAT0006912 oan-miR-30c*;oan-miR-30c-3p;oan-miR-30c-2-3p; +MIMAT0006913 oan-miR-30a;oan-miR-30a-5p; +MIMAT0006914 oan-miR-30a*;oan-miR-30a-3p; +MIMAT0006915 oan-miR-460;oan-miR-460-5p; +MIMAT0006916 oan-miR-460*;oan-miR-460-3p; +MIMAT0006917 oan-miR-1345; +MIMAT0006918 oan-miR-92b; +MIMAT0006919 oan-miR-1346; +MIMAT0006920 oan-miR-208*;oan-miR-208-5p; +MIMAT0006921 oan-miR-208;oan-miR-208-3p; +MIMAT0006922 oan-miR-1420a*;oan-miR-1420a-5p; +MIMAT0006923 oan-miR-1420a;oan-miR-1420a-3p; +MIMAT0006924 oan-miR-1420b*;oan-miR-1420b-5p; +MIMAT0006925 oan-miR-1420b;oan-miR-1420b-3p; +MIMAT0006926 oan-miR-1420c;oan-miR-1420c-3p; +MIMAT0006927 oan-miR-1420d*;oan-miR-1420d-5p; +MIMAT0006928 oan-miR-1420d;oan-miR-1420d-3p; +MIMAT0006929 oan-miR-1420e;oan-miR-1420e-3p; +MIMAT0006930 oan-miR-1347; +MIMAT0006931 oan-miR-186;oan-miR-186-5p; +MIMAT0006932 oan-miR-186*;oan-miR-186-3p; +MIMAT0006933 oan-miR-1348; +MIMAT0006934 oan-miR-1349; +MIMAT0006935 oan-miR-200a*;oan-miR-200a-5p; +MIMAT0006936 oan-miR-200a;oan-miR-200a-3p; +MIMAT0006937 oan-miR-200b*;oan-miR-200b-5p; +MIMAT0006938 oan-miR-200b;oan-miR-200b-3p; +MIMAT0006939 oan-miR-1422l; +MIMAT0006940 oan-miR-1350; +MIMAT0006941 oan-miR-103*;oan-miR-103-5p;oan-miR-103-2-5p; +MIMAT0006942 oan-miR-103;oan-miR-103-3p; +MIMAT0006943 oan-miR-1351;oan-miR-1351-5p; +MIMAT0006944 oan-miR-1420f; +MIMAT0006945 oan-miR-1352; +MIMAT0006946 oan-miR-1353; +MIMAT0006947 oan-miR-1354;oan-miR-1354-5p; +MIMAT0006948 oan-miR-1354*;oan-miR-1354-3p; +MIMAT0006949 oan-miR-499;oan-miR-499-5p; +MIMAT0006950 oan-miR-499*;oan-miR-499-3p; +MIMAT0006951 oan-miR-1355;oan-miR-1355-5p; +MIMAT0006952 oan-miR-1355*;oan-miR-1355-3p; +MIMAT0006953 oan-miR-1356; +MIMAT0006954 oan-miR-24*;oan-miR-24-5p;oan-miR-24-1-5p; +MIMAT0006955 oan-miR-24;oan-miR-24-3p; +MIMAT0006956 oan-miR-27b*;oan-miR-27b-5p; +MIMAT0006957 oan-miR-27b;oan-miR-27b-3p; +MIMAT0006958 oan-miR-23b*;oan-miR-23b-5p; +MIMAT0006959 oan-miR-23b;oan-miR-23b-3p; +MIMAT0006960 oan-miR-1357; +MIMAT0006961 oan-miR-22*;oan-miR-22-5p; +MIMAT0006962 oan-miR-22;oan-miR-22-3p; +MIMAT0006963 oan-miR-1421a;oan-miR-1421a-5p; +MIMAT0006964 oan-miR-1421a*;oan-miR-1421a-3p; +MIMAT0006965 oan-miR-1421b*;oan-miR-1421b-5p; +MIMAT0006966 oan-miR-1421b;oan-miR-1421b-3p; +MIMAT0006967 oan-miR-1421c;oan-miR-1421c-5p; +MIMAT0006968 oan-miR-1421c*;oan-miR-1421c-3p; +MIMAT0006969 oan-miR-1421d;oan-miR-1421d-5p; +MIMAT0006970 oan-miR-1421d*;oan-miR-1421d-3p; +MIMAT0006971 oan-miR-1421e*;oan-miR-1421e-5p; +MIMAT0006972 oan-miR-1421e;oan-miR-1421e-3p; +MIMAT0006973 oan-miR-1421f;oan-miR-1421f-5p; +MIMAT0006974 oan-miR-1421f*;oan-miR-1421f-3p; +MIMAT0006975 oan-miR-1421g;oan-miR-1421g-5p; +MIMAT0006976 oan-miR-1421g-1*;oan-miR-1421g-1-3p; +MIMAT0006977 oan-miR-1421h;oan-miR-1421h-5p; +MIMAT0006978 oan-miR-1421h*;oan-miR-1421h-3p; +MIMAT0006979 oan-miR-1421i;oan-miR-1421i-5p; +MIMAT0006980 oan-miR-1421i-1*;oan-miR-1421i-1-3p; +MIMAT0006981 oan-miR-1421j;oan-miR-1421j-5p; +MIMAT0006982 oan-miR-142;oan-miR-142-5p; +MIMAT0006983 oan-miR-142*;oan-miR-142-3p; +MIMAT0006984 oan-let-7e;oan-let-7e-5p; +MIMAT0006985 oan-let-7e*;oan-let-7e-3p; +MIMAT0006986 oan-miR-7;oan-miR-7-5p; +MIMAT0006987 oan-miR-7*;oan-miR-7-3p; +MIMAT0006988 oan-miR-155;oan-miR-155-5p; +MIMAT0006989 oan-miR-155*;oan-miR-155-3p; +MIMAT0006990 oan-miR-1358; +MIMAT0006991 oan-miR-26;oan-miR-26-5p; +MIMAT0006992 oan-miR-26*;oan-miR-26-3p;oan-miR-26-1-3p; +MIMAT0006993 oan-miR-1359; +MIMAT0006994 oan-miR-206*;oan-miR-206-5p; +MIMAT0006995 oan-miR-206;oan-miR-206-3p; +MIMAT0006996 oan-miR-133b*;oan-miR-133b-5p; +MIMAT0006997 oan-miR-133b;oan-miR-133b-3p; +MIMAT0006998 oan-miR-190b; +MIMAT0006999 oan-miR-194;oan-miR-194-5p; +MIMAT0007000 oan-miR-215;oan-miR-215-5p; +MIMAT0007001 oan-miR-215*;oan-miR-215-3p; +MIMAT0007002 oan-miR-1360; +MIMAT0007003 oan-miR-147; +MIMAT0007004 oan-miR-153*;oan-miR-153-5p;oan-miR-153-1-5p; +MIMAT0007005 oan-miR-153;oan-miR-153-3p; +MIMAT0007006 oan-miR-128;oan-miR-128-3p; +MIMAT0007007 oan-miR-146b;oan-miR-146b-5p; +MIMAT0007008 oan-miR-146b*;oan-miR-146b-3p; +MIMAT0007009 oan-miR-458*;oan-miR-458-5p; +MIMAT0007010 oan-miR-458;oan-miR-458-3p; +MIMAT0007011 oan-miR-101; +MIMAT0007012 oan-miR-449c; +MIMAT0007013 oan-miR-449b;oan-miR-449b-5p; +MIMAT0007014 oan-miR-449b*;oan-miR-449b-3p; +MIMAT0007015 oan-miR-449a; +MIMAT0007016 oan-miR-192;oan-miR-192-5p; +MIMAT0007017 oan-miR-192*;oan-miR-192-3p; +MIMAT0007018 oan-miR-194*;oan-miR-194-3p; +MIMAT0007019 oan-miR-223*;oan-miR-223-5p; +MIMAT0007020 oan-miR-223;oan-miR-223-3p; +MIMAT0007021 oan-miR-1361*;oan-miR-1361-5p; +MIMAT0007022 oan-miR-1361;oan-miR-1361-3p; +MIMAT0007023 oan-miR-1362;oan-miR-1362-5p; +MIMAT0007024 oan-miR-1362*;oan-miR-1362-3p; +MIMAT0007025 oan-miR-1363;oan-miR-1363-5p; +MIMAT0007026 oan-miR-1363*;oan-miR-1363-3p; +MIMAT0007027 oan-miR-1364; +MIMAT0007028 oan-miR-1365;oan-miR-1365-5p; +MIMAT0007029 oan-miR-1365*;oan-miR-1365-3p; +MIMAT0007030 oan-miR-1366; +MIMAT0007031 oan-miR-1367*;oan-miR-1367-5p; +MIMAT0007032 oan-miR-1367;oan-miR-1367-3p; +MIMAT0007033 oan-miR-1368; +MIMAT0007034 oan-miR-1369; +MIMAT0007035 oan-miR-1370; +MIMAT0007036 oan-miR-1371; +MIMAT0007037 oan-miR-30f; +MIMAT0007038 oan-let-7g;oan-let-7g-5p; +MIMAT0007039 oan-let-7g*;oan-let-7g-3p; +MIMAT0007040 oan-miR-1372; +MIMAT0007041 oan-miR-30d;oan-miR-30d-5p; +MIMAT0007042 oan-miR-30d*;oan-miR-30d-3p; +MIMAT0007043 oan-miR-30b;oan-miR-30b-5p; +MIMAT0007044 oan-miR-30b*;oan-miR-30b-3p; +MIMAT0007045 oan-miR-184; +MIMAT0007046 oan-miR-100;oan-miR-100-5p; +MIMAT0007047 oan-miR-100*;oan-miR-100-3p; +MIMAT0007048 oan-miR-125;oan-miR-125-5p; +MIMAT0007049 oan-miR-125*;oan-miR-125-3p; +MIMAT0007050 oan-miR-15b;oan-miR-15b-5p; +MIMAT0007051 oan-miR-15b*;oan-miR-15b-3p; +MIMAT0007052 oan-miR-16b;oan-miR-16b-5p; +MIMAT0007053 oan-miR-16b*;oan-miR-16b-3p; +MIMAT0007054 oan-miR-1373; +MIMAT0007055 oan-miR-1374; +MIMAT0007056 oan-miR-222b*;oan-miR-222b-5p; +MIMAT0007057 oan-miR-222b;oan-miR-222b-3p; +MIMAT0007058 oan-miR-181c;oan-miR-181c-5p; +MIMAT0007059 oan-miR-181c*;oan-miR-181c-3p; +MIMAT0007060 oan-miR-23a*;oan-miR-23a-5p; +MIMAT0007061 oan-miR-23a;oan-miR-23a-3p; +MIMAT0007062 oan-miR-27a*;oan-miR-27a-5p; +MIMAT0007063 oan-miR-27a;oan-miR-27a-3p; +MIMAT0007064 oan-miR-1375;oan-miR-1375-5p; +MIMAT0007065 oan-miR-1375*;oan-miR-1375-3p; +MIMAT0007066 oan-miR-1421k;oan-miR-1421k-5p; +MIMAT0007067 oan-miR-1421k-1*;oan-miR-1421k-1-3p; +MIMAT0007068 oan-miR-1421l;oan-miR-1421l-5p; +MIMAT0007069 oan-miR-1421l-1*;oan-miR-1421l-1-3p; +MIMAT0007070 oan-miR-1419a*;oan-miR-1419a-5p; +MIMAT0007071 oan-miR-1419a;oan-miR-1419a-3p; +MIMAT0007072 oan-miR-1421m;oan-miR-1421m-5p; +MIMAT0007073 oan-miR-1421m*;oan-miR-1421m-3p; +MIMAT0007074 oan-miR-1421n;oan-miR-1421n-5p; +MIMAT0007075 oan-miR-1421n-1*;oan-miR-1421n-1-3p; +MIMAT0007076 oan-miR-1421o;oan-miR-1421o-5p; +MIMAT0007077 oan-miR-1421o*;oan-miR-1421o-3p; +MIMAT0007078 oan-miR-1421p;oan-miR-1421p-5p; +MIMAT0007079 oan-miR-1421p*;oan-miR-1421p-3p; +MIMAT0007080 oan-miR-1421q;oan-miR-1421q-5p; +MIMAT0007081 oan-miR-1421q*;oan-miR-1421q-3p; +MIMAT0007082 oan-miR-1421r;oan-miR-1421r-5p; +MIMAT0007083 oan-miR-1421r*;oan-miR-1421r-3p; +MIMAT0007084 oan-miR-1421s;oan-miR-1421s-5p; +MIMAT0007085 oan-miR-1421s*;oan-miR-1421s-3p; +MIMAT0007086 oan-miR-1421t;oan-miR-1421t-5p; +MIMAT0007087 oan-miR-1421t*;oan-miR-1421t-3p; +MIMAT0007088 oan-miR-1421u;oan-miR-1421u-5p; +MIMAT0007089 oan-miR-1421u*; +MIMAT0007090 oan-miR-150;oan-miR-150-5p; +MIMAT0007091 oan-miR-150*;oan-miR-150-3p; +MIMAT0007092 oan-miR-1422j*;oan-miR-1422j-5p; +MIMAT0007093 oan-miR-1422j;oan-miR-1422j-3p; +MIMAT0007094 oan-miR-1422d;oan-miR-1422d-3p; +MIMAT0007095 oan-miR-1422d*; +MIMAT0007096 oan-miR-590*;oan-miR-590-5p; +MIMAT0007097 oan-miR-590;oan-miR-590-3p; +MIMAT0007098 oan-miR-130a; +MIMAT0007099 oan-miR-1422m;oan-miR-1422m-5p; +MIMAT0007100 oan-miR-1422m*;oan-miR-1422m-3p; +MIMAT0007101 oan-miR-1422n*;oan-miR-1422n-5p; +MIMAT0007102 oan-miR-1422n;oan-miR-1422n-3p; +MIMAT0007103 oan-miR-1422o*;oan-miR-1422o-5p; +MIMAT0007104 oan-miR-1422o;oan-miR-1422o-3p; +MIMAT0007105 oan-miR-1376*;oan-miR-1376-5p; +MIMAT0007106 oan-miR-1376;oan-miR-1376-3p; +MIMAT0007107 oan-miR-1377; +MIMAT0007108 oan-miR-34;oan-miR-34-5p;oan-miR-34a-5p; +MIMAT0007109 oan-miR-34*;oan-miR-34-3p;oan-miR-34a-3p; +MIMAT0007110 oan-miR-1378; +MIMAT0007111 oan-miR-31;oan-miR-31-5p; +MIMAT0007112 oan-miR-31*;oan-miR-31-3p; +MIMAT0007113 oan-miR-124*;oan-miR-124-5p;oan-miR-124a-5p; +MIMAT0007114 oan-miR-124;oan-miR-124-3p;oan-miR-124a-1-3p; +MIMAT0007115 oan-miR-1379; +MIMAT0007116 oan-miR-1380*;oan-miR-1380-5p; +MIMAT0007117 oan-miR-1380;oan-miR-1380-3p; +MIMAT0007118 oan-miR-107*;oan-miR-107-5p; +MIMAT0007119 oan-miR-107;oan-miR-107-3p; +MIMAT0007120 oan-miR-1381*;oan-miR-1381-5p; +MIMAT0007121 oan-miR-1381;oan-miR-1381-3p; +MIMAT0007122 oan-miR-10a;oan-miR-10a-5p; +MIMAT0007123 oan-miR-10a*;oan-miR-10a-3p; +MIMAT0007124 oan-miR-1382; +MIMAT0007125 oan-miR-126*;oan-miR-126-5p; +MIMAT0007126 oan-miR-126;oan-miR-126-3p; +MIMAT0007127 oan-miR-429*;oan-miR-429-5p; +MIMAT0007128 oan-miR-429;oan-miR-429-3p; +MIMAT0007129 oan-miR-551*;oan-miR-551-5p; +MIMAT0007130 oan-miR-551;oan-miR-551-3p; +MIMAT0007131 oan-miR-1383; +MIMAT0007132 oan-miR-222a*;oan-miR-222a-5p; +MIMAT0007133 oan-miR-222a;oan-miR-222a-3p; +MIMAT0007134 oan-miR-221*;oan-miR-221-5p; +MIMAT0007135 oan-miR-221;oan-miR-221-3p; +MIMAT0007136 oan-miR-1384; +MIMAT0007137 oan-miR-148*;oan-miR-148-5p; +MIMAT0007138 oan-miR-148;oan-miR-148-3p; +MIMAT0007139 oan-miR-196b;oan-miR-196b-5p; +MIMAT0007140 oan-miR-196b*;oan-miR-196b-3p; +MIMAT0007141 oan-miR-145;oan-miR-145-5p; +MIMAT0007142 oan-miR-145*;oan-miR-145-3p; +MIMAT0007143 oan-miR-143*;oan-miR-143-5p; +MIMAT0007144 oan-miR-143;oan-miR-143-3p; +MIMAT0007145 oan-miR-20a;oan-miR-20a-5p; +MIMAT0007146 oan-miR-20a-1*;oan-miR-20a-1-3p; +MIMAT0007147 oan-miR-19a*;oan-miR-19a-5p; +MIMAT0007148 oan-miR-19a;oan-miR-19a-3p; +MIMAT0007149 oan-miR-1b; +MIMAT0007150 oan-miR-133c; +MIMAT0007151 oan-miR-1385; +MIMAT0007152 oan-miR-191;oan-miR-191-5p; +MIMAT0007153 oan-miR-191*;oan-miR-191-3p; +MIMAT0007154 oan-miR-425;oan-miR-425-5p; +MIMAT0007155 oan-miR-425*;oan-miR-425-3p; +MIMAT0007156 oan-miR-454*;oan-miR-454-5p; +MIMAT0007157 oan-miR-454;oan-miR-454-3p; +MIMAT0007158 oan-miR-130b*;oan-miR-130b-5p; +MIMAT0007159 oan-miR-130b;oan-miR-130b-3p; +MIMAT0007160 oan-miR-21;oan-miR-21-5p; +MIMAT0007161 oan-miR-21*;oan-miR-21-3p; +MIMAT0007162 oan-miR-1386; +MIMAT0007163 oan-miR-1387; +MIMAT0007164 oan-miR-15a;oan-miR-15a-5p; +MIMAT0007165 oan-miR-15a*;oan-miR-15a-3p; +MIMAT0007166 oan-miR-16a;oan-miR-16a-5p; +MIMAT0007167 oan-miR-16a*;oan-miR-16a-3p; +MIMAT0007168 oan-miR-1388*;oan-miR-1388-5p; +MIMAT0007169 oan-miR-1388;oan-miR-1388-3p; +MIMAT0007170 oan-miR-214*;oan-miR-214-5p; +MIMAT0007171 oan-miR-214;oan-miR-214-3p; +MIMAT0007172 oan-miR-199*;oan-miR-199-5p; +MIMAT0007173 oan-miR-199;oan-miR-199-3p; +MIMAT0007174 oan-miR-1389;oan-miR-1389-3p; +MIMAT0007175 oan-miR-128*;oan-miR-128-5p; +MIMAT0007176 oan-miR-1390;oan-miR-1390-5p; +MIMAT0007177 oan-miR-1390*;oan-miR-1390-3p; +MIMAT0007178 oan-miR-98; +MIMAT0007179 oan-let-7f;oan-let-7f-5p; +MIMAT0007180 oan-let-7f-1*;oan-let-7f-1-3p; +MIMAT0007181 oan-miR-802;oan-miR-802-5p; +MIMAT0007182 oan-miR-802*;oan-miR-802-3p; +MIMAT0007183 oan-miR-99;oan-miR-99-5p; +MIMAT0007184 oan-miR-99*;oan-miR-99-3p; +MIMAT0007185 oan-miR-1391*;oan-miR-1391-5p; +MIMAT0007186 oan-miR-1391;oan-miR-1391-3p; +MIMAT0007187 oan-miR-1392;oan-miR-1392-5p; +MIMAT0007188 oan-miR-1392*;oan-miR-1392-3p; +MIMAT0007189 oan-miR-383;oan-miR-383-5p; +MIMAT0007190 oan-miR-383*;oan-miR-383-3p; +MIMAT0007191 oan-miR-1393; +MIMAT0007192 oan-miR-135a*; +MIMAT0007193 oan-miR-135a;oan-miR-135a-3p; +MIMAT0007194 oan-miR-302*;oan-miR-302-5p; +MIMAT0007195 oan-miR-302;oan-miR-302-3p; +MIMAT0007196 oan-miR-1394; +MIMAT0007197 oan-miR-1395;oan-miR-1395-3p; +MIMAT0007198 oan-miR-1396; +MIMAT0007199 oan-miR-1397;oan-miR-1397-5p; +MIMAT0007200 oan-miR-1397*;oan-miR-1397-3p; +MIMAT0007201 oan-miR-1398;oan-miR-1398-5p; +MIMAT0007202 oan-miR-1399; +MIMAT0007203 oan-miR-30e;oan-miR-30e-5p; +MIMAT0007204 oan-miR-30e*;oan-miR-30e-3p; +MIMAT0007205 oan-miR-1400*;oan-miR-1400-5p; +MIMAT0007206 oan-miR-1400;oan-miR-1400-3p; +MIMAT0007207 oan-miR-1401;oan-miR-1401-5p; +MIMAT0007208 oan-miR-1401*;oan-miR-1401-3p; +MIMAT0007209 oan-miR-1402; +MIMAT0007210 oan-miR-1403; +MIMAT0007211 oan-miR-1404; +MIMAT0007212 oan-miR-1405*;oan-miR-1405-5p; +MIMAT0007213 oan-miR-1405;oan-miR-1405-3p; +MIMAT0007214 oan-miR-1406;oan-miR-1406-5p; +MIMAT0007215 oan-miR-1406*;oan-miR-1406-3p; +MIMAT0007216 oan-miR-138;oan-miR-138-5p; +MIMAT0007217 oan-miR-1407; +MIMAT0007218 oan-miR-10b;oan-miR-10b-5p; +MIMAT0007219 oan-miR-10b*;oan-miR-10b-3p; +MIMAT0007220 oan-miR-138*;oan-miR-138-3p; +MIMAT0007221 oan-miR-217;oan-miR-217-5p; +MIMAT0007222 oan-miR-217*;oan-miR-217-3p; +MIMAT0007223 oan-miR-216;oan-miR-216-5p;oan-miR-216a-5p; +MIMAT0007224 oan-miR-216*;oan-miR-216-3p;oan-miR-216a-3p; +MIMAT0007225 oan-miR-1408; +MIMAT0007226 oan-miR-1409;oan-miR-1409-5p; +MIMAT0007227 oan-miR-1409*;oan-miR-1409-3p; +MIMAT0007228 oan-miR-1410; +MIMAT0007229 oan-miR-1411; +MIMAT0007230 oan-miR-146a;oan-miR-146a-5p; +MIMAT0007231 oan-miR-146a*;oan-miR-146a-3p; +MIMAT0007232 oan-miR-1412; +MIMAT0007233 oan-miR-1413;oan-miR-1413-3p; +MIMAT0007234 oan-let-7d;oan-let-7d-5p; +MIMAT0007235 oan-let-7d*;oan-let-7d-3p; +MIMAT0007236 oan-miR-1421v;oan-miR-1421v-5p; +MIMAT0007237 oan-miR-1421v*;oan-miR-1421v-3p; +MIMAT0007238 oan-miR-1421w*;oan-miR-1421w-5p; +MIMAT0007239 oan-miR-1421w;oan-miR-1421w-3p; +MIMAT0007240 oan-miR-1419b;oan-miR-1419b-5p; +MIMAT0007241 oan-miR-1419b-1*;oan-miR-1419b-1-3p; +MIMAT0007242 oan-miR-1421x;oan-miR-1421x-5p; +MIMAT0007243 oan-miR-1421x*;oan-miR-1421x-3p; +MIMAT0007244 oan-miR-1421y;oan-miR-1421y-5p; +MIMAT0007245 oan-miR-1421z;oan-miR-1421z-5p; +MIMAT0007246 oan-miR-1421z*;oan-miR-1421z-3p; +MIMAT0007247 oan-miR-1419c;oan-miR-1419c-5p; +MIMAT0007248 oan-miR-1419c*;oan-miR-1419c-3p; +MIMAT0007249 oan-miR-1421aa;oan-miR-1421aa-5p; +MIMAT0007250 oan-miR-1421aa*;oan-miR-1421aa-3p; +MIMAT0007251 oan-miR-1421ab;oan-miR-1421ab-5p; +MIMAT0007252 oan-miR-1421ab*;oan-miR-1421ab-3p; +MIMAT0007253 oan-miR-1419d;oan-miR-1419d-5p; +MIMAT0007254 oan-miR-1419d*;oan-miR-1419d-3p; +MIMAT0007255 oan-miR-1414;oan-miR-1414-5p; +MIMAT0007256 oan-miR-1414*;oan-miR-1414-3p; +MIMAT0007257 oan-miR-1421ac;oan-miR-1421ac-5p; +MIMAT0007258 oan-miR-1421ac*;oan-miR-1421ac-3p; +MIMAT0007259 oan-miR-1421ad;oan-miR-1421ad-5p; +MIMAT0007260 oan-miR-1421ad*;oan-miR-1421ad-3p; +MIMAT0007261 oan-miR-1421ae; +MIMAT0007262 oan-miR-1419e;oan-miR-1419e-5p; +MIMAT0007263 oan-miR-1419e*;oan-miR-1419e-3p; +MIMAT0007264 oan-miR-1421af;oan-miR-1421af-5p; +MIMAT0007265 oan-miR-1421af*;oan-miR-1421af-3p; +MIMAT0007266 oan-miR-187*;oan-miR-187-5p; +MIMAT0007267 oan-miR-187;oan-miR-187-3p; +MIMAT0007268 oan-miR-32;oan-miR-32-5p; +MIMAT0007269 oan-miR-32*;oan-miR-32-3p; +MIMAT0007270 oan-miR-1415; +MIMAT0007271 oan-miR-1416; +MIMAT0007272 oan-miR-873;oan-miR-873-5p; +MIMAT0007273 oan-miR-873*;oan-miR-873-3p; +MIMAT0007274 oan-miR-1417;oan-miR-1417-5p; +MIMAT0007275 oan-miR-1417*;oan-miR-1417-3p; +MIMAT0007276 oan-miR-1418;oan-miR-1418-5p; +MIMAT0007277 oan-miR-1418*;oan-miR-1418-3p; +MIMAT0007278 oan-miR-17;oan-miR-17-5p; +MIMAT0007279 oan-miR-17*;oan-miR-17-3p; +MIMAT0007280 osa-miR1428a-3p; +MIMAT0007281 gga-miR-1329;gga-miR-1329-5p; +MIMAT0007282 gga-miR-1329*;gga-miR-1329-3p; +MIMAT0007283 gga-miR-1397;gga-miR-1397-5p; +MIMAT0007284 gga-miR-1397*;gga-miR-1397-3p; +MIMAT0007285 gga-miR-1416;gga-miR-1416-5p; +MIMAT0007286 gga-miR-1416*;gga-miR-1416-3p; +MIMAT0007287 gga-miR-22*;gga-miR-22-5p; +MIMAT0007288 gga-miR-22;gga-miR-22-3p; +MIMAT0007289 gga-miR-551*;gga-miR-551-5p; +MIMAT0007290 gga-miR-551;gga-miR-551-3p; +MIMAT0007291 gga-miR-454*;gga-miR-454-5p; +MIMAT0007292 gga-miR-454;gga-miR-454-3p; +MIMAT0007293 gga-miR-33*; +MIMAT0007294 mdv1-miR-M10-5p; +MIMAT0007295 gga-miR-1434; +MIMAT0007297 oan-miR-1421ag*;oan-miR-1421ag-5p; +MIMAT0007298 oan-miR-1421ag;oan-miR-1421ag-3p; +MIMAT0007300 oan-miR-1421ab-2*;oan-miR-1421ab-2-3p; +MIMAT0007302 oan-miR-1421ac-2*;oan-miR-1421ac-2-3p; +MIMAT0007303 oan-miR-1421ah;oan-miR-1421ah-5p; +MIMAT0007304 oan-miR-1421ah*;oan-miR-1421ah-3p; +MIMAT0007305 oan-miR-1421ai;oan-miR-1421ai-5p; +MIMAT0007306 oan-miR-1421ai*;oan-miR-1421ai-3p; +MIMAT0007307 oan-miR-1421aj;oan-miR-1421aj-5p; +MIMAT0007308 oan-miR-1421aj*;oan-miR-1421aj-3p; +MIMAT0007309 oan-miR-1421ak;oan-miR-1421ak-5p; +MIMAT0007310 oan-miR-1421ak*;oan-miR-1421ak-3p; +MIMAT0007311 oan-miR-1421al;oan-miR-1421al-5p; +MIMAT0007312 oan-miR-1421al*;oan-miR-1421al-3p; +MIMAT0007313 oan-miR-1421am; +MIMAT0007314 oan-miR-1422p*;oan-miR-1422p-5p; +MIMAT0007315 oan-miR-1422p;oan-miR-1422p-3p; +MIMAT0007316 oan-miR-1422q;oan-miR-1422q-5p; +MIMAT0007317 oan-miR-1422q*;oan-miR-1422q-3p; +MIMAT0007318 oan-miR-1420g;oan-miR-1420g-5p; +MIMAT0007319 oan-miR-1420g*;oan-miR-1420g-3p; +MIMAT0007320 oan-miR-1419f*;oan-miR-1419f-5p; +MIMAT0007321 oan-miR-1419f;oan-miR-1419f-3p; +MIMAT0007322 oan-miR-1419g;oan-miR-1419g-5p; +MIMAT0007323 oan-miR-1419g*;oan-miR-1419g-3p; +MIMAT0007324 gga-miR-1451;gga-miR-1451-5p; +MIMAT0007325 gga-miR-1451*;gga-miR-1451-3p; +MIMAT0007326 gga-miR-460b-5p; +MIMAT0007327 gga-miR-460b-3p; +MIMAT0007328 gga-miR-1452; +MIMAT0007329 gga-miR-1306;gga-miR-1306-3p; +MIMAT0007330 gga-miR-1453; +MIMAT0007331 gga-miR-1454; +MIMAT0007332 gga-miR-1455; +MIMAT0007333 gga-miR-1456;gga-miR-1456-5p; +MIMAT0007334 gga-miR-1456*;gga-miR-1456-3p; +MIMAT0007335 gga-miR-1457; +MIMAT0007336 gga-miR-1458; +MIMAT0007337 gga-miR-1459; +MIMAT0007338 gga-miR-1460; +MIMAT0007339 gga-miR-1461;gga-miR-216c; +MIMAT0007340 gga-miR-1462;gga-miR-1462-5p; +MIMAT0007341 gga-miR-1463; +MIMAT0007342 gga-miR-1464; +MIMAT0007343 gga-miR-1465; +MIMAT0007344 gga-miR-1466; +MIMAT0007345 gga-miR-1467;gga-miR-1467-5p; +MIMAT0007346 gga-miR-1467*;gga-miR-1467-3p; +MIMAT0007347 hsa-miR-1469; +MIMAT0007348 hsa-miR-1470; +MIMAT0007349 hsa-miR-1471; +MIMAT0007351 gma-miR159b;gma-miR159b-3p; +MIMAT0007352 gma-miR159c; +MIMAT0007353 gma-miR162;gma-miR162a; +MIMAT0007354 gma-miR164;gma-miR164a; +MIMAT0007355 gma-miR167c; +MIMAT0007356 gma-miR169b; +MIMAT0007357 gma-miR169c; +MIMAT0007358 gma-miR171a; +MIMAT0007359 gma-miR390a-5p; +MIMAT0007360 gma-miR390a-3p; +MIMAT0007361 gma-miR390b;gma-miR390b-5p; +MIMAT0007362 gma-miR393;gma-miR393a; +MIMAT0007363 gma-miR171b;gma-miR171b-3p; +MIMAT0007364 gma-miR482;gma-miR482a-3p; +MIMAT0007365 gma-miR1507;gma-miR1507a; +MIMAT0007366 gma-miR1508;gma-miR1508a; +MIMAT0007367 gma-miR1509;gma-miR1509a; +MIMAT0007368 gma-miR1510;gma-miR1510a;gma-miR1510a-3p; +MIMAT0007369 gma-miR1511; +MIMAT0007370 gma-miR1512;gma-miR1512a;gma-miR1512a-5p; +MIMAT0007371 gma-miR1513;gma-miR1513a-5p; +MIMAT0007372 gma-miR1514a;gma-miR1514a-5p; +MIMAT0007373 gma-miR1514b;gma-miR1514b-5p; +MIMAT0007374 gma-miR1515;gma-miR1515a; +MIMAT0007375 gma-miR1516;gma-miR1516a-3p; +MIMAT0007376 gma-miR1517; +MIMAT0007377 gma-miR1518; +MIMAT0007378 gma-miR1519; +MIMAT0007379 gma-miR1520d; +MIMAT0007380 gma-miR1536; +MIMAT0007381 gma-miR1520a; +MIMAT0007382 gma-miR1521;gma-miR1521a; +MIMAT0007383 gma-miR1522; +MIMAT0007384 gma-miR1523;gma-miR1523a; +MIMAT0007385 gma-miR1524; +MIMAT0007386 gma-miR1525; +MIMAT0007387 gma-miR1520b; +MIMAT0007388 gma-miR1526; +MIMAT0007389 gma-miR1527; +MIMAT0007390 gma-miR1528; +MIMAT0007391 gma-miR1529; +MIMAT0007392 gma-miR1530; +MIMAT0007393 gma-miR1531;gma-miR1531-3p; +MIMAT0007394 gma-miR1532; +MIMAT0007395 gma-miR1520c; +MIMAT0007396 gma-miR1533; +MIMAT0007397 gma-miR1534; +MIMAT0007398 gma-miR1535;gma-miR1535a; +MIMAT0007399 hsa-miR-1537;hsa-miR-1537-3p; +MIMAT0007400 hsa-miR-1538; +MIMAT0007401 hsa-miR-1539; +MIMAT0007402 hsa-miR-103-as;hsa-miR-103b; +MIMAT0007403 gga-miR-1550-5p; +MIMAT0007404 gga-miR-1550-3p; +MIMAT0007405 gga-miR-1551;gga-miR-1551-5p; +MIMAT0007406 gga-miR-1551*;gga-miR-1551-3p; +MIMAT0007407 gga-miR-1552-5p; +MIMAT0007408 gga-miR-1552-3p; +MIMAT0007409 gga-miR-1553*;gga-miR-1553-5p; +MIMAT0007410 gga-miR-1553;gga-miR-1553-3p; +MIMAT0007411 gga-miR-1554; +MIMAT0007412 gga-miR-1555;gga-miR-1555-3p; +MIMAT0007413 gga-miR-1556; +MIMAT0007414 gga-miR-1557; +MIMAT0007415 gga-miR-1558; +MIMAT0007416 gga-miR-1559;gga-miR-1559-5p; +MIMAT0007417 gga-miR-1560*;gga-miR-1560-5p; +MIMAT0007418 gga-miR-1560;gga-miR-1560-3p; +MIMAT0007419 gga-miR-1561; +MIMAT0007420 gga-miR-1562;gga-miR-1562-5p; +MIMAT0007421 gga-miR-1562*;gga-miR-1562-3p; +MIMAT0007422 gga-miR-1563; +MIMAT0007423 gga-miR-1564;gga-miR-1564-5p; +MIMAT0007424 gga-miR-1564*;gga-miR-1564-3p; +MIMAT0007425 gga-miR-1565; +MIMAT0007426 gga-miR-1566; +MIMAT0007427 gga-miR-1567; +MIMAT0007428 gga-miR-1568; +MIMAT0007429 gga-miR-1569; +MIMAT0007430 gga-miR-1570; +MIMAT0007431 gga-miR-1571; +MIMAT0007432 gga-miR-1572; +MIMAT0007433 gga-miR-1573; +MIMAT0007434 gga-miR-1574*;gga-miR-1574-5p; +MIMAT0007435 gga-miR-1574;gga-miR-1574-3p; +MIMAT0007436 gga-miR-1575; +MIMAT0007437 gga-miR-1576; +MIMAT0007438 gga-miR-1577; +MIMAT0007439 gga-miR-1578; +MIMAT0007440 gga-miR-1579; +MIMAT0007441 gga-miR-1580; +MIMAT0007442 gga-miR-1581; +MIMAT0007443 gga-miR-1582; +MIMAT0007444 gga-miR-1583; +MIMAT0007445 gga-miR-1584; +MIMAT0007446 gga-miR-1354; +MIMAT0007447 gga-miR-1585; +MIMAT0007448 gga-miR-1586; +MIMAT0007449 gga-miR-1587; +MIMAT0007450 gga-miR-1588; +MIMAT0007451 gga-miR-1589; +MIMAT0007452 gga-miR-1590; +MIMAT0007453 gga-miR-1591*;gga-miR-1591-5p; +MIMAT0007454 gga-miR-1591;gga-miR-1591-3p; +MIMAT0007455 gga-miR-1592; +MIMAT0007456 gga-miR-1593; +MIMAT0007457 gga-miR-1594; +MIMAT0007458 gga-miR-1595;gga-miR-1595-5p; +MIMAT0007459 gga-miR-1595*;gga-miR-1595-3p; +MIMAT0007460 gga-miR-1596;gga-miR-1596-5p; +MIMAT0007461 gga-miR-1596*;gga-miR-1596-3p; +MIMAT0007462 gga-miR-1597*;gga-miR-1597-5p; +MIMAT0007463 gga-miR-1597;gga-miR-1597-3p; +MIMAT0007464 gga-miR-1598; +MIMAT0007465 gga-miR-1599; +MIMAT0007466 gga-miR-1600; +MIMAT0007467 gga-miR-1601; +MIMAT0007468 gga-miR-1602; +MIMAT0007469 gga-miR-1603; +MIMAT0007470 gga-miR-1604; +MIMAT0007471 gga-miR-1605; +MIMAT0007472 gga-miR-1606; +MIMAT0007473 gga-miR-1607; +MIMAT0007474 gga-miR-1608; +MIMAT0007475 gga-miR-1609; +MIMAT0007476 gga-miR-1610; +MIMAT0007477 gga-miR-1611; +MIMAT0007478 gga-miR-1612; +MIMAT0007479 gga-miR-1613; +MIMAT0007480 gga-miR-1614;gga-miR-1614-5p; +MIMAT0007481 gga-miR-1614*;gga-miR-1614-3p; +MIMAT0007482 gga-miR-1615; +MIMAT0007483 gga-miR-1616; +MIMAT0007484 gga-miR-1617; +MIMAT0007485 gga-miR-1618;gga-miR-1618-3p; +MIMAT0007486 gga-miR-1619; +MIMAT0007487 gga-miR-1620; +MIMAT0007488 gga-miR-1621;gga-miR-1621-5p; +MIMAT0007489 gga-miR-1621*;gga-miR-1621-3p; +MIMAT0007490 gga-miR-1622; +MIMAT0007491 gga-miR-1623; +MIMAT0007492 gga-miR-1624; +MIMAT0007493 gga-miR-1625;gga-miR-1625-5p; +MIMAT0007494 gga-miR-1625*;gga-miR-1625-3p; +MIMAT0007495 gga-miR-1626*;gga-miR-1626-5p; +MIMAT0007496 gga-miR-1626;gga-miR-1626-3p; +MIMAT0007497 gga-miR-1627*;gga-miR-1627-5p; +MIMAT0007498 gga-miR-1627;gga-miR-1627-3p; +MIMAT0007499 gga-miR-1628; +MIMAT0007500 gga-miR-1629; +MIMAT0007501 gga-miR-1630; +MIMAT0007502 gga-miR-1631; +MIMAT0007503 gga-miR-1c; +MIMAT0007504 gga-miR-1632;gga-miR-1632-5p; +MIMAT0007505 gga-miR-1632*;gga-miR-1632-3p; +MIMAT0007506 gga-miR-1633; +MIMAT0007507 gga-miR-1634; +MIMAT0007508 gga-miR-1635; +MIMAT0007509 gga-miR-1636; +MIMAT0007510 gga-miR-1637; +MIMAT0007511 gga-miR-1638; +MIMAT0007512 gga-miR-1815; +MIMAT0007513 gga-miR-1814; +MIMAT0007514 gga-miR-1639; +MIMAT0007515 gga-miR-1640; +MIMAT0007516 gga-miR-1641; +MIMAT0007517 gga-miR-1642; +MIMAT0007518 gga-miR-1643*;gga-miR-1643-5p; +MIMAT0007519 gga-miR-1643;gga-miR-1643-3p; +MIMAT0007520 gga-miR-1644; +MIMAT0007521 gga-miR-1645; +MIMAT0007522 gga-miR-1646; +MIMAT0007523 gga-miR-1647; +MIMAT0007524 gga-miR-1648;gga-miR-1648-5p; +MIMAT0007525 gga-miR-1648*;gga-miR-1648-3p; +MIMAT0007526 gga-miR-1649;gga-miR-1649-5p; +MIMAT0007527 gga-miR-1649*;gga-miR-1649-3p; +MIMAT0007528 gga-miR-1650; +MIMAT0007529 gga-miR-1651;gga-miR-1651-5p; +MIMAT0007530 gga-miR-1651*;gga-miR-1651-3p; +MIMAT0007531 gga-miR-1652; +MIMAT0007532 gga-miR-1653; +MIMAT0007533 gga-miR-1654; +MIMAT0007534 gga-miR-1655;gga-miR-1655-5p; +MIMAT0007535 gga-miR-1656; +MIMAT0007536 gga-miR-135b; +MIMAT0007537 gga-miR-1657; +MIMAT0007538 gga-miR-1658;gga-miR-1658-5p; +MIMAT0007539 gga-miR-1658*;gga-miR-1658-3p; +MIMAT0007540 gga-miR-1659; +MIMAT0007541 gga-miR-1660; +MIMAT0007542 gga-miR-1661; +MIMAT0007543 gga-miR-1662; +MIMAT0007544 gga-miR-1663*;gga-miR-1663-5p; +MIMAT0007545 gga-miR-1663;gga-miR-1663-3p; +MIMAT0007546 gga-miR-1664*;gga-miR-1664-5p; +MIMAT0007547 gga-miR-1664;gga-miR-1664-3p; +MIMAT0007548 gga-miR-1665; +MIMAT0007549 gga-miR-1666; +MIMAT0007550 gga-miR-1667;gga-miR-1667-3p; +MIMAT0007551 gga-miR-1668*;gga-miR-1668-5p; +MIMAT0007552 gga-miR-1668;gga-miR-1668-3p; +MIMAT0007553 gga-miR-1669; +MIMAT0007554 gga-miR-1670; +MIMAT0007555 gga-miR-1671; +MIMAT0007556 gga-miR-1672; +MIMAT0007557 gga-miR-1673; +MIMAT0007558 gga-miR-1674; +MIMAT0007559 gga-miR-1675; +MIMAT0007560 gga-miR-1676*;gga-miR-1676-5p; +MIMAT0007561 gga-miR-1676;gga-miR-1676-3p; +MIMAT0007562 gga-miR-1677*;gga-miR-1677-5p; +MIMAT0007563 gga-miR-1677;gga-miR-1677-3p; +MIMAT0007564 gga-miR-1678; +MIMAT0007565 gga-miR-1679; +MIMAT0007566 gga-miR-1680*;gga-miR-1680-5p; +MIMAT0007567 gga-miR-1680;gga-miR-1680-3p; +MIMAT0007568 gga-miR-1681; +MIMAT0007569 gga-miR-1682; +MIMAT0007570 gga-miR-1683; +MIMAT0007571 gga-miR-1684*;gga-miR-1684a-5p; +MIMAT0007572 gga-miR-1684;gga-miR-1684a-3p; +MIMAT0007573 gga-miR-1685*;gga-miR-1685-5p; +MIMAT0007574 gga-miR-1685;gga-miR-1685-3p; +MIMAT0007575 gga-miR-1686; +MIMAT0007576 gga-miR-1687;gga-miR-1687-5p; +MIMAT0007577 gga-miR-1687*;gga-miR-1687-3p; +MIMAT0007578 gga-miR-1688; +MIMAT0007579 gga-miR-1689*;gga-miR-1689-5p; +MIMAT0007580 gga-miR-1689;gga-miR-1689-3p; +MIMAT0007581 gga-miR-1690*;gga-miR-1690-5p; +MIMAT0007582 gga-miR-1691; +MIMAT0007583 gga-miR-199b; +MIMAT0007584 gga-miR-1692; +MIMAT0007585 gga-miR-1693; +MIMAT0007586 gga-miR-1694; +MIMAT0007587 gga-miR-1695; +MIMAT0007588 gga-miR-1696; +MIMAT0007589 gga-miR-1697; +MIMAT0007590 gga-miR-1698; +MIMAT0007591 gga-miR-1699; +MIMAT0007592 gga-miR-1700; +MIMAT0007593 gga-miR-1701; +MIMAT0007594 gga-miR-1702; +MIMAT0007595 gga-miR-1703;gga-miR-1703-5p; +MIMAT0007596 gga-miR-1704; +MIMAT0007597 gga-miR-1705; +MIMAT0007598 gga-miR-1706; +MIMAT0007599 gga-miR-1707; +MIMAT0007600 gga-miR-1813; +MIMAT0007601 gga-miR-1708; +MIMAT0007602 gga-miR-449c;gga-miR-449c-5p; +MIMAT0007603 gga-miR-449c*;gga-miR-449c-3p; +MIMAT0007604 gga-miR-1709; +MIMAT0007605 gga-miR-1710; +MIMAT0007606 gga-miR-1711; +MIMAT0007607 gga-miR-1712*;gga-miR-1712-5p; +MIMAT0007608 gga-miR-1712;gga-miR-1712-3p; +MIMAT0007609 gga-miR-1713; +MIMAT0007610 gga-miR-1714; +MIMAT0007611 gga-miR-1715;gga-miR-1715-5p; +MIMAT0007612 gga-miR-1715*;gga-miR-1715-3p; +MIMAT0007613 gga-miR-1716; +MIMAT0007614 gga-miR-1717; +MIMAT0007615 gga-miR-1718; +MIMAT0007616 gga-miR-1719; +MIMAT0007617 gga-miR-1720*;gga-miR-1720-5p; +MIMAT0007618 gga-miR-1720;gga-miR-1720-3p; +MIMAT0007619 gga-miR-1721; +MIMAT0007620 gga-miR-1722;gga-miR-1722-5p; +MIMAT0007621 gga-miR-1722*;gga-miR-1722-3p; +MIMAT0007622 gga-miR-1723; +MIMAT0007623 gga-miR-1724; +MIMAT0007624 gga-miR-1725; +MIMAT0007625 gga-miR-1726; +MIMAT0007626 gga-miR-1727; +MIMAT0007627 gga-miR-1728-5p; +MIMAT0007628 gga-miR-1728-3p; +MIMAT0007629 gga-miR-1729;gga-miR-1729-5p; +MIMAT0007630 gga-miR-1729*;gga-miR-1729-3p; +MIMAT0007631 gga-miR-1730*;gga-miR-1730-5p; +MIMAT0007632 gga-miR-1730;gga-miR-1730-3p; +MIMAT0007633 gga-miR-1731;gga-miR-1731-5p; +MIMAT0007634 gga-miR-1732; +MIMAT0007635 gga-miR-1733; +MIMAT0007636 gga-miR-1734; +MIMAT0007637 gga-miR-1735; +MIMAT0007638 gga-miR-1736*;gga-miR-1736-5p; +MIMAT0007639 gga-miR-1736;gga-miR-1736-3p; +MIMAT0007640 gga-miR-1737; +MIMAT0007641 gga-miR-1738; +MIMAT0007642 gga-miR-1739; +MIMAT0007643 gga-miR-1740;gga-miR-1740-5p; +MIMAT0007644 gga-miR-1740*;gga-miR-1740-3p; +MIMAT0007645 gga-miR-1741; +MIMAT0007646 gga-miR-1742; +MIMAT0007647 gga-miR-1743; +MIMAT0007648 gga-miR-1744*;gga-miR-1744-5p; +MIMAT0007649 gga-miR-1744;gga-miR-1744-3p; +MIMAT0007650 gga-miR-1745; +MIMAT0007651 gga-miR-1746; +MIMAT0007652 gga-miR-1747;gga-miR-1747-5p; +MIMAT0007653 gga-miR-1748; +MIMAT0007654 gga-miR-1749;gga-miR-1749-5p; +MIMAT0007655 gga-miR-1749*;gga-miR-1749-3p; +MIMAT0007656 gga-miR-1816; +MIMAT0007657 gga-miR-1750; +MIMAT0007658 gga-miR-1751*;gga-miR-1751-5p; +MIMAT0007659 gga-miR-1752; +MIMAT0007660 gga-miR-1753; +MIMAT0007661 gga-miR-1754;gga-miR-1754-5p; +MIMAT0007662 gga-miR-1755; +MIMAT0007663 gga-miR-1756a; +MIMAT0007664 gga-miR-1757; +MIMAT0007665 gga-miR-1758; +MIMAT0007666 gga-miR-1759;gga-miR-1759-5p; +MIMAT0007667 gga-miR-1760; +MIMAT0007668 gga-miR-1761; +MIMAT0007669 gga-miR-1762; +MIMAT0007670 gga-miR-1763; +MIMAT0007671 gga-miR-1764*;gga-miR-1764-5p; +MIMAT0007672 gga-miR-1764;gga-miR-1764-3p; +MIMAT0007673 gga-miR-1765; +MIMAT0007674 gga-miR-1766; +MIMAT0007675 gga-miR-1767; +MIMAT0007676 gga-miR-1768; +MIMAT0007677 gga-miR-1769*;gga-miR-1769-5p; +MIMAT0007678 gga-miR-1769;gga-miR-1769-3p; +MIMAT0007679 gga-miR-1770; +MIMAT0007680 gga-miR-1771; +MIMAT0007681 gga-miR-1772*;gga-miR-1772-5p; +MIMAT0007682 gga-miR-1772;gga-miR-1772-3p; +MIMAT0007683 gga-miR-1773*;gga-miR-1773-5p; +MIMAT0007684 gga-miR-1773;gga-miR-1773-3p; +MIMAT0007685 gga-miR-1774; +MIMAT0007686 gga-miR-1775;gga-miR-1775-3p; +MIMAT0007687 gga-miR-1776; +MIMAT0007688 gga-miR-1777; +MIMAT0007689 gga-miR-1778; +MIMAT0007690 gga-miR-1779; +MIMAT0007691 gga-miR-1780; +MIMAT0007692 gga-miR-1781*;gga-miR-1781-5p; +MIMAT0007693 gga-miR-1781;gga-miR-1781-3p; +MIMAT0007694 gga-miR-1782; +MIMAT0007695 gga-miR-1783; +MIMAT0007696 gga-miR-1784*;gga-miR-1784-5p; +MIMAT0007697 gga-miR-1785; +MIMAT0007698 gga-miR-1786; +MIMAT0007699 gga-miR-1787; +MIMAT0007700 gga-miR-1788-5p; +MIMAT0007701 gga-miR-1788-3p; +MIMAT0007702 gga-miR-1789; +MIMAT0007703 gga-miR-1790; +MIMAT0007704 gga-miR-1791*;gga-miR-1791-5p; +MIMAT0007705 gga-miR-1791;gga-miR-1791-3p; +MIMAT0007706 gga-miR-1792; +MIMAT0007707 gga-miR-1793; +MIMAT0007708 gga-miR-1794; +MIMAT0007709 gga-miR-1795; +MIMAT0007710 gga-miR-1796; +MIMAT0007711 gga-miR-1797; +MIMAT0007712 gga-miR-1756b; +MIMAT0007713 gga-miR-1798*;gga-miR-1798-5p; +MIMAT0007714 gga-miR-1798;gga-miR-1798-3p; +MIMAT0007715 gga-miR-1799; +MIMAT0007716 gga-miR-1800; +MIMAT0007717 gga-miR-1801; +MIMAT0007718 gga-miR-1802; +MIMAT0007719 gga-miR-122b; +MIMAT0007720 gga-miR-1803; +MIMAT0007721 gga-miR-1804; +MIMAT0007722 gga-miR-1805-5p; +MIMAT0007723 gga-miR-1805-3p; +MIMAT0007724 gga-miR-1806; +MIMAT0007725 gga-miR-1807; +MIMAT0007726 gga-miR-1808; +MIMAT0007727 gga-miR-1809; +MIMAT0007728 gga-miR-1810; +MIMAT0007729 gga-miR-1811; +MIMAT0007730 gga-miR-1812;gga-miR-1812-5p; +MIMAT0007731 gga-miR-10a;gga-miR-10a-5p; +MIMAT0007732 gga-miR-10a*;gga-miR-10a-3p; +MIMAT0007733 gga-miR-130c*;gga-miR-130c-5p; +MIMAT0007734 gga-miR-130c;gga-miR-130c-3p; +MIMAT0007735 gga-miR-146c;gga-miR-146c-5p; +MIMAT0007736 gga-miR-146c*;gga-miR-146c-3p; +MIMAT0007737 gga-miR-15c;gga-miR-15c-5p; +MIMAT0007738 gga-miR-15c*;gga-miR-15c-3p; +MIMAT0007739 gga-miR-16c;gga-miR-16c-5p; +MIMAT0007740 gga-miR-193a;gga-miR-193a-3p; +MIMAT0007741 gga-miR-301b-5p; +MIMAT0007742 gga-miR-301b-3p; +MIMAT0007743 gga-miR-449b;gga-miR-449b-5p; +MIMAT0007744 gga-miR-449b*;gga-miR-449b-3p; +MIMAT0007745 gga-miR-458*;gga-miR-458a-5p; +MIMAT0007746 gga-miR-458;gga-miR-458a-3p; +MIMAT0007747 cfa-miR-371; +MIMAT0007748 gga-miR-216b; +MIMAT0007749 gga-miR-1845; +MIMAT0007750 gga-miR-739; +MIMAT0007751 gga-miR-214; +MIMAT0007752 gga-miR-762; +MIMAT0007753 ssc-miR-15a; +MIMAT0007754 ssc-miR-16; +MIMAT0007755 ssc-miR-17;ssc-miR-17-5p; +MIMAT0007756 ssc-miR-30b;ssc-miR-30b-5p; +MIMAT0007757 ssc-miR-34a; +MIMAT0007758 ssc-miR-130a; +MIMAT0007759 ssc-miR-185; +MIMAT0007760 ssc-miR-199b*;ssc-miR-199b-3p; +MIMAT0007761 ssc-miR-210; +MIMAT0007762 ssc-miR-221;ssc-miR-221-3p; +MIMAT0007763 osa-miR531b; +MIMAT0007764 osa-miR1846d-5p; +MIMAT0007765 osa-miR1846d-3p; +MIMAT0007766 osa-miR1847.1; +MIMAT0007767 osa-miR1847.2; +MIMAT0007768 osa-miR1848; +MIMAT0007769 osa-miR1849; +MIMAT0007770 osa-miR1850;osa-miR1850.1; +MIMAT0007771 osa-miR1851; +MIMAT0007772 osa-miR1852; +MIMAT0007773 osa-miR1853-5p; +MIMAT0007774 osa-miR1853-3p; +MIMAT0007775 osa-miR1854-5p; +MIMAT0007776 osa-miR1854-3p; +MIMAT0007777 osa-miR1855; +MIMAT0007778 osa-miR1856; +MIMAT0007779 osa-miR1857-5p; +MIMAT0007780 osa-miR1857-3p; +MIMAT0007781 osa-miR1428b; +MIMAT0007782 osa-miR1428c; +MIMAT0007783 osa-miR1428d; +MIMAT0007784 osa-miR1428e-5p; +MIMAT0007785 osa-miR1428e-3p; +MIMAT0007786 osa-miR1858a; +MIMAT0007787 osa-miR1858b; +MIMAT0007788 osa-miR1846a-5p; +MIMAT0007789 osa-miR1846a-3p; +MIMAT0007790 osa-miR1846b-5p; +MIMAT0007791 osa-miR1846b-3p; +MIMAT0007792 osa-miR1859; +MIMAT0007793 osa-miR1860-5p; +MIMAT0007794 osa-miR1860-3p; +MIMAT0007795 osa-miR1884a; +MIMAT0007796 osa-miR1861a; +MIMAT0007797 osa-miR1861b; +MIMAT0007798 osa-miR1861c; +MIMAT0007799 osa-miR1861d; +MIMAT0007800 osa-miR1861e; +MIMAT0007801 osa-miR1861f; +MIMAT0007802 osa-miR1861g; +MIMAT0007803 osa-miR1861h; +MIMAT0007804 osa-miR1861i; +MIMAT0007805 osa-miR1861j; +MIMAT0007806 osa-miR1861k; +MIMAT0007807 osa-miR1861l; +MIMAT0007808 osa-miR1861m; +MIMAT0007809 osa-miR1861n; +MIMAT0007810 osa-miR1862a; +MIMAT0007811 osa-miR1862b; +MIMAT0007812 osa-miR1862c; +MIMAT0007813 osa-miR1863;osa-miR1863a; +MIMAT0007814 osa-miR1864; +MIMAT0007815 osa-miR1865-5p; +MIMAT0007816 osa-miR1865-3p; +MIMAT0007817 osa-miR1866;osa-miR1866-5p; +MIMAT0007818 osa-miR1867; +MIMAT0007819 osa-miR1423b; +MIMAT0007820 osa-miR1868; +MIMAT0007821 osa-miR812f; +MIMAT0007822 osa-miR1869; +MIMAT0007823 osa-miR1870;osa-miR1870-5p; +MIMAT0007824 osa-miR1871; +MIMAT0007825 osa-miR1872; +MIMAT0007826 osa-miR1873; +MIMAT0007827 osa-miR1874-5p; +MIMAT0007828 osa-miR1874-3p; +MIMAT0007829 osa-miR1875; +MIMAT0007830 osa-miR1862d; +MIMAT0007831 osa-miR1876; +MIMAT0007832 osa-miR1884b;osa-miR1884b-5p; +MIMAT0007833 osa-miR1862e; +MIMAT0007834 osa-miR1877; +MIMAT0007835 osa-miR1878; +MIMAT0007836 osa-miR1879; +MIMAT0007837 osa-miR1880; +MIMAT0007838 osa-miR1881; +MIMAT0007839 osa-miR1882a; +MIMAT0007840 osa-miR1882b; +MIMAT0007841 osa-miR1882c; +MIMAT0007842 osa-miR1882d; +MIMAT0007843 osa-miR1882e;osa-miR1882e-5p; +MIMAT0007844 osa-miR1882f; +MIMAT0007845 osa-miR1882g; +MIMAT0007846 osa-miR1882h; +MIMAT0007847 osa-miR812g; +MIMAT0007848 osa-miR812h; +MIMAT0007849 osa-miR812i; +MIMAT0007850 osa-miR812j; +MIMAT0007851 osa-miR1883a; +MIMAT0007852 osa-miR1883b; +MIMAT0007853 ath-miR1886;ath-miR1886.1; +MIMAT0007854 ath-miR1887; +MIMAT0007855 ath-miR1888;ath-miR1888a; +MIMAT0007856 aga-miR-11; +MIMAT0007857 aga-miR-981; +MIMAT0007858 aga-miR-87; +MIMAT0007859 aga-miR-1889; +MIMAT0007860 aga-miR-375; +MIMAT0007861 aga-miR-1890; +MIMAT0007862 aga-miR-1891; +MIMAT0007863 mmu-miR-1902; +MIMAT0007864 mmu-miR-1897-5p; +MIMAT0007865 mmu-miR-1897-3p; +MIMAT0007866 mmu-miR-1905; +MIMAT0007867 mmu-miR-1895; +MIMAT0007868 mmu-miR-1903; +MIMAT0007869 mmu-miR-1899; +MIMAT0007870 mmu-miR-1900; +MIMAT0007871 mmu-miR-1892; +MIMAT0007872 mmu-miR-1906; +MIMAT0007873 mmu-miR-1896; +MIMAT0007874 mmu-miR-1904; +MIMAT0007875 mmu-miR-1898; +MIMAT0007876 mmu-miR-1907; +MIMAT0007877 mmu-miR-1894-5p; +MIMAT0007878 mmu-miR-1894-3p; +MIMAT0007879 mmu-miR-1893; +MIMAT0007880 mmu-miR-1901; +MIMAT0007881 hsa-miR-1908;hsa-miR-1908-5p; +MIMAT0007882 hsa-miR-1909*;hsa-miR-1909-5p; +MIMAT0007883 hsa-miR-1909;hsa-miR-1909-3p; +MIMAT0007884 hsa-miR-1910;hsa-miR-1910-5p; +MIMAT0007885 hsa-miR-1911;hsa-miR-1911-5p; +MIMAT0007886 hsa-miR-1911*;hsa-miR-1911-3p; +MIMAT0007887 hsa-miR-1912;hsa-miR-1912-3p; +MIMAT0007888 hsa-miR-1913; +MIMAT0007889 hsa-miR-1914;hsa-miR-1914-5p; +MIMAT0007890 hsa-miR-1914*;hsa-miR-1914-3p; +MIMAT0007891 hsa-miR-1915*;hsa-miR-1915-5p; +MIMAT0007892 hsa-miR-1915;hsa-miR-1915-3p; +MIMAT0007893 mdv1-miR-M31; +MIMAT0007894 bmo-miR-2a;bmo-miR-2a-3p; +MIMAT0007895 bmo-miR-2b;bmo-miR-2b-3p; +MIMAT0007896 bmo-miR-13a*;bmo-miR-13a-5p; +MIMAT0007897 bmo-miR-13a;bmo-miR-13a-3p; +MIMAT0007898 bmo-miR-13b;bmo-miR-13b-3p; +MIMAT0007899 bmo-miR-79;bmo-miR-79-3p; +MIMAT0007900 bmo-miR-87; +MIMAT0007901 bmo-miR-133; +MIMAT0007902 bmo-miR-184;bmo-miR-184-3p; +MIMAT0007903 bmo-miR-210; +MIMAT0007904 bmo-miR-281*;bmo-miR-281-5p; +MIMAT0007905 bmo-miR-281;bmo-miR-281-3p; +MIMAT0007906 bmo-miR-317;bmo-miR-317-3p; +MIMAT0007907 bmo-bantam;bmo-bantam-3p; +MIMAT0007908 sly-miR1916; +MIMAT0007909 sly-miR1917; +MIMAT0007910 sly-miR1918; +MIMAT0007911 sly-miR1919a; +MIMAT0007912 sly-miR1919b; +MIMAT0007913 sly-miR1919c;sly-miR1919c-3p; +MIMAT0007914 sly-miR160a; +MIMAT0007915 sly-miR166a; +MIMAT0007916 sly-miR166b; +MIMAT0007917 sly-miR167;sly-miR167a; +MIMAT0007918 sly-miR169a; +MIMAT0007919 sly-miR169b; +MIMAT0007920 sly-miR169c; +MIMAT0007921 sly-miR169d; +MIMAT0007922 sly-miR171a; +MIMAT0007923 sly-miR171b;sly-miR171b-3p; +MIMAT0007924 sly-miR171c; +MIMAT0007925 sly-miR171d; +MIMAT0007926 sly-miR395a; +MIMAT0007927 sly-miR395b; +MIMAT0007928 sly-miR397;sly-miR397-5p; +MIMAT0007929 bmo-miR-1920; +MIMAT0007930 bmo-miR-1921; +MIMAT0007931 bmo-miR-1922; +MIMAT0007932 bmo-miR-1923; +MIMAT0007933 bmo-miR-1926; +MIMAT0007934 bmo-miR-1924; +MIMAT0007935 bmo-miR-1925; +MIMAT0007936 ptr-let-7a; +MIMAT0007937 ptr-let-7b; +MIMAT0007938 ptr-let-7c; +MIMAT0007939 ptr-let-7d; +MIMAT0007940 ptr-let-7e; +MIMAT0007941 ptr-let-7f; +MIMAT0007942 ptr-let-7g; +MIMAT0007943 ptr-let-7i; +MIMAT0007944 ptr-miR-10a; +MIMAT0007945 ptr-miR-10b; +MIMAT0007946 ptr-miR-1; +MIMAT0007947 ptr-miR-1178; +MIMAT0007948 ptr-miR-1179; +MIMAT0007949 ptr-miR-1181; +MIMAT0007950 ptr-miR-1182; +MIMAT0007951 ptr-miR-1183; +MIMAT0007952 ptr-miR-1184; +MIMAT0007953 ptr-miR-1185; +MIMAT0007954 ptr-miR-1197; +MIMAT0007955 ptr-miR-1201; +MIMAT0007956 ptr-miR-1202; +MIMAT0007957 ptr-miR-1203; +MIMAT0007958 ptr-miR-1204; +MIMAT0007959 ptr-miR-1205; +MIMAT0007960 ptr-miR-1206; +MIMAT0007961 ptr-miR-1207; +MIMAT0007962 ptr-miR-1208; +MIMAT0007963 ptr-miR-122; +MIMAT0007964 ptr-miR-1225; +MIMAT0007965 ptr-miR-1227; +MIMAT0007966 ptr-miR-1233; +MIMAT0007967 ptr-miR-1234; +MIMAT0007968 ptr-miR-1236; +MIMAT0007969 ptr-miR-1237; +MIMAT0007970 ptr-miR-1244; +MIMAT0007971 ptr-miR-1245; +MIMAT0007972 ptr-miR-1246; +MIMAT0007973 ptr-miR-1247; +MIMAT0007974 ptr-miR-1248; +MIMAT0007975 ptr-miR-1249; +MIMAT0007976 ptr-miR-1250; +MIMAT0007977 ptr-miR-1251; +MIMAT0007978 ptr-miR-1253; +MIMAT0007979 ptr-miR-1254; +MIMAT0007980 ptr-miR-1255b; +MIMAT0007981 ptr-miR-1256; +MIMAT0007982 ptr-miR-1258; +MIMAT0007983 ptr-miR-1259; +MIMAT0007984 ptr-miR-125a; +MIMAT0007985 ptr-miR-126; +MIMAT0007986 ptr-miR-1262; +MIMAT0007987 ptr-miR-1263; +MIMAT0007988 ptr-miR-1264; +MIMAT0007989 ptr-miR-1265; +MIMAT0007990 ptr-miR-1266; +MIMAT0007991 ptr-miR-1267; +MIMAT0007992 ptr-miR-1271; +MIMAT0007993 ptr-miR-1272; +MIMAT0007994 ptr-miR-1273; +MIMAT0007995 ptr-miR-1274b; +MIMAT0007996 ptr-miR-1275; +MIMAT0007997 ptr-miR-1276; +MIMAT0007998 ptr-miR-1278; +MIMAT0007999 ptr-miR-1280; +MIMAT0008000 ptr-miR-1281; +MIMAT0008001 ptr-miR-1282; +MIMAT0008002 ptr-miR-1283;ptr-miR-1283a; +MIMAT0008003 ptr-miR-1284; +MIMAT0008004 ptr-miR-1285; +MIMAT0008005 ptr-miR-1286; +MIMAT0008006 ptr-miR-1288; +MIMAT0008007 ptr-miR-1289; +MIMAT0008008 ptr-miR-1290; +MIMAT0008009 ptr-miR-1291; +MIMAT0008010 ptr-miR-129; +MIMAT0008011 ptr-miR-1292; +MIMAT0008012 ptr-miR-1293; +MIMAT0008013 ptr-miR-1294; +MIMAT0008014 ptr-miR-1295; +MIMAT0008015 ptr-miR-1296; +MIMAT0008016 ptr-miR-1297; +MIMAT0008017 ptr-miR-1298; +MIMAT0008018 ptr-miR-1299; +MIMAT0008019 ptr-miR-1300b; +MIMAT0008020 ptr-miR-1300a; +MIMAT0008021 ptr-miR-1302; +MIMAT0008022 ptr-miR-1303; +MIMAT0008023 ptr-miR-1306; +MIMAT0008024 ptr-miR-1307; +MIMAT0008025 ptr-miR-130a; +MIMAT0008026 ptr-miR-130b; +MIMAT0008027 ptr-miR-1322; +MIMAT0008028 ptr-miR-1323; +MIMAT0008029 ptr-miR-1324; +MIMAT0008030 ptr-miR-133b; +MIMAT0008031 ptr-miR-134; +MIMAT0008032 ptr-miR-135b; +MIMAT0008033 ptr-miR-137; +MIMAT0008034 ptr-miR-138; +MIMAT0008035 ptr-miR-139; +MIMAT0008036 ptr-miR-141; +MIMAT0008037 ptr-miR-142; +MIMAT0008038 ptr-miR-146a; +MIMAT0008039 ptr-miR-146b; +MIMAT0008040 ptr-miR-147b; +MIMAT0008041 ptr-miR-148a; +MIMAT0008042 ptr-miR-148b; +MIMAT0008043 ptr-miR-149; +MIMAT0008044 ptr-miR-150; +MIMAT0008045 ptr-miR-151; +MIMAT0008046 ptr-miR-152; +MIMAT0008047 ptr-miR-153; +MIMAT0008048 ptr-miR-155; +MIMAT0008049 ptr-miR-181d; +MIMAT0008050 ptr-miR-182; +MIMAT0008051 ptr-miR-1825; +MIMAT0008052 ptr-miR-1827; +MIMAT0008053 ptr-miR-185; +MIMAT0008054 ptr-miR-18b; +MIMAT0008055 ptr-miR-190b; +MIMAT0008056 ptr-miR-191; +MIMAT0008057 ptr-miR-192; +MIMAT0008058 ptr-miR-193a; +MIMAT0008059 ptr-miR-193b; +MIMAT0008060 ptr-miR-195; +MIMAT0008061 ptr-miR-196b; +MIMAT0008062 ptr-miR-199b; +MIMAT0008063 ptr-miR-200a; +MIMAT0008064 ptr-miR-202; +MIMAT0008065 ptr-miR-203; +MIMAT0008066 ptr-miR-206; +MIMAT0008067 ptr-miR-208a; +MIMAT0008068 ptr-miR-208b; +MIMAT0008069 ptr-miR-20b; +MIMAT0008070 ptr-miR-210; +MIMAT0008071 ptr-miR-211; +MIMAT0008072 ptr-miR-216b; +MIMAT0008073 ptr-miR-217; +MIMAT0008074 ptr-miR-219-1-3p; +MIMAT0008075 ptr-miR-220b; +MIMAT0008076 ptr-miR-221; +MIMAT0008077 ptr-miR-26b; +MIMAT0008078 ptr-miR-27b; +MIMAT0008079 ptr-miR-296; +MIMAT0008080 ptr-miR-297; +MIMAT0008081 ptr-miR-298; +MIMAT0008082 ptr-miR-29c; +MIMAT0008083 ptr-miR-300; +MIMAT0008084 ptr-miR-301a; +MIMAT0008085 ptr-miR-301b; +MIMAT0008086 ptr-miR-302a; +MIMAT0008087 ptr-miR-302b; +MIMAT0008088 ptr-miR-302c; +MIMAT0008089 ptr-miR-302d; +MIMAT0008090 ptr-miR-302e; +MIMAT0008091 ptr-miR-302f; +MIMAT0008092 ptr-miR-30e; +MIMAT0008093 ptr-miR-320a; +MIMAT0008094 ptr-miR-320b; +MIMAT0008095 ptr-miR-320c; +MIMAT0008096 ptr-miR-320d; +MIMAT0008097 ptr-miR-323; +MIMAT0008098 ptr-miR-324; +MIMAT0008099 ptr-miR-326; +MIMAT0008100 ptr-miR-328; +MIMAT0008101 ptr-miR-329; +MIMAT0008102 ptr-miR-330; +MIMAT0008103 ptr-miR-331; +MIMAT0008104 ptr-miR-335; +MIMAT0008105 ptr-miR-337; +MIMAT0008106 ptr-miR-338; +MIMAT0008107 ptr-miR-339; +MIMAT0008108 ptr-miR-33b; +MIMAT0008109 ptr-miR-340; +MIMAT0008110 ptr-miR-342; +MIMAT0008111 ptr-miR-345; +MIMAT0008112 ptr-miR-346; +MIMAT0008113 ptr-miR-34b; +MIMAT0008114 ptr-miR-34c; +MIMAT0008115 ptr-miR-361; +MIMAT0008116 ptr-miR-362; +MIMAT0008117 ptr-miR-365; +MIMAT0008118 ptr-miR-367; +MIMAT0008119 ptr-miR-369; +MIMAT0008120 ptr-miR-370; +MIMAT0008121 ptr-miR-371; +MIMAT0008122 ptr-miR-372; +MIMAT0008123 ptr-miR-374a; +MIMAT0008124 ptr-miR-374b; +MIMAT0008125 ptr-miR-375; +MIMAT0008126 ptr-miR-376a; +MIMAT0008127 ptr-miR-376b; +MIMAT0008128 ptr-miR-376c; +MIMAT0008129 ptr-miR-377; +MIMAT0008130 ptr-miR-378;ptr-miR-378a; +MIMAT0008131 ptr-miR-379; +MIMAT0008132 ptr-miR-380; +MIMAT0008133 ptr-miR-381; +MIMAT0008134 ptr-miR-382; +MIMAT0008135 ptr-miR-383; +MIMAT0008136 ptr-miR-409; +MIMAT0008137 ptr-miR-410; +MIMAT0008138 ptr-miR-411; +MIMAT0008139 ptr-miR-412; +MIMAT0008140 ptr-miR-421; +MIMAT0008141 ptr-miR-422a; +MIMAT0008142 ptr-miR-423; +MIMAT0008143 ptr-miR-424; +MIMAT0008144 ptr-miR-425; +MIMAT0008145 ptr-miR-431; +MIMAT0008146 ptr-miR-432; +MIMAT0008147 ptr-miR-433; +MIMAT0008148 ptr-miR-448; +MIMAT0008149 ptr-miR-449a; +MIMAT0008150 ptr-miR-449b; +MIMAT0008151 ptr-miR-450a; +MIMAT0008152 ptr-miR-450b; +MIMAT0008153 ptr-miR-451; +MIMAT0008154 ptr-miR-452; +MIMAT0008155 ptr-miR-453; +MIMAT0008156 ptr-miR-454; +MIMAT0008157 ptr-miR-455; +MIMAT0008158 ptr-miR-484; +MIMAT0008159 ptr-miR-485; +MIMAT0008160 ptr-miR-486; +MIMAT0008161 ptr-miR-487a; +MIMAT0008162 ptr-miR-487b; +MIMAT0008163 ptr-miR-488; +MIMAT0008164 ptr-miR-489; +MIMAT0008165 ptr-miR-490; +MIMAT0008166 ptr-miR-491; +MIMAT0008167 ptr-miR-492; +MIMAT0008168 ptr-miR-494; +MIMAT0008169 ptr-miR-495; +MIMAT0008170 ptr-miR-496; +MIMAT0008171 ptr-miR-498; +MIMAT0008172 ptr-miR-499; +MIMAT0008173 ptr-miR-500; +MIMAT0008174 ptr-miR-501; +MIMAT0008175 ptr-miR-502; +MIMAT0008176 ptr-miR-503; +MIMAT0008177 ptr-miR-504; +MIMAT0008178 ptr-miR-505; +MIMAT0008179 ptr-miR-511; +MIMAT0008180 ptr-miR-512; +MIMAT0008181 ptr-miR-515; +MIMAT0008182 ptr-miR-516a; +MIMAT0008183 ptr-miR-516b; +MIMAT0008184 ptr-miR-517a; +MIMAT0008185 ptr-miR-517b; +MIMAT0008186 ptr-miR-518a; +MIMAT0008187 ptr-miR-518b; +MIMAT0008188 ptr-miR-518c; +MIMAT0008189 ptr-miR-518d; +MIMAT0008190 ptr-miR-518e; +MIMAT0008191 ptr-miR-518f; +MIMAT0008192 ptr-miR-519a; +MIMAT0008193 ptr-miR-519b; +MIMAT0008194 ptr-miR-519c; +MIMAT0008195 ptr-miR-519d; +MIMAT0008196 ptr-miR-519e; +MIMAT0008197 ptr-miR-520a; +MIMAT0008198 ptr-miR-520b; +MIMAT0008199 ptr-miR-520c; +MIMAT0008200 ptr-miR-520d; +MIMAT0008201 ptr-miR-520e; +MIMAT0008202 ptr-miR-520f; +MIMAT0008203 ptr-miR-520g; +MIMAT0008204 ptr-miR-520h; +MIMAT0008205 ptr-miR-521; +MIMAT0008206 ptr-miR-522; +MIMAT0008207 ptr-miR-523; +MIMAT0008208 ptr-miR-524; +MIMAT0008209 ptr-miR-525; +MIMAT0008210 ptr-miR-526a; +MIMAT0008211 ptr-miR-526b; +MIMAT0008212 ptr-miR-527; +MIMAT0008213 ptr-miR-532; +MIMAT0008214 ptr-miR-539; +MIMAT0008215 ptr-miR-543; +MIMAT0008216 ptr-miR-544; +MIMAT0008217 ptr-miR-545; +MIMAT0008218 ptr-miR-548a; +MIMAT0008219 ptr-miR-548b; +MIMAT0008220 ptr-miR-548c; +MIMAT0008221 ptr-miR-548f; +MIMAT0008222 ptr-miR-548h; +MIMAT0008223 ptr-miR-548i; +MIMAT0008224 ptr-miR-548j; +MIMAT0008225 ptr-miR-548k; +MIMAT0008226 ptr-miR-548l; +MIMAT0008227 ptr-miR-548n; +MIMAT0008228 ptr-miR-548p; +MIMAT0008229 ptr-miR-549; +MIMAT0008230 ptr-miR-550; +MIMAT0008231 ptr-miR-551a; +MIMAT0008232 ptr-miR-551b; +MIMAT0008233 ptr-miR-552; +MIMAT0008234 ptr-miR-553; +MIMAT0008235 ptr-miR-554; +MIMAT0008236 ptr-miR-555; +MIMAT0008237 ptr-miR-556; +MIMAT0008238 ptr-miR-557; +MIMAT0008239 ptr-miR-558; +MIMAT0008240 ptr-miR-559; +MIMAT0008241 ptr-miR-561; +MIMAT0008242 ptr-miR-562; +MIMAT0008243 ptr-miR-564; +MIMAT0008244 ptr-miR-566; +MIMAT0008245 ptr-miR-567; +MIMAT0008246 ptr-miR-568; +MIMAT0008247 ptr-miR-569; +MIMAT0008248 ptr-miR-572; +MIMAT0008249 ptr-miR-575; +MIMAT0008250 ptr-miR-576; +MIMAT0008251 ptr-miR-577; +MIMAT0008252 ptr-miR-579; +MIMAT0008253 ptr-miR-580; +MIMAT0008254 ptr-miR-581; +MIMAT0008255 ptr-miR-582; +MIMAT0008256 ptr-miR-583; +MIMAT0008257 ptr-miR-584; +MIMAT0008258 ptr-miR-586; +MIMAT0008259 ptr-miR-587; +MIMAT0008260 ptr-miR-588; +MIMAT0008261 ptr-miR-590; +MIMAT0008262 ptr-miR-591; +MIMAT0008263 ptr-miR-592; +MIMAT0008264 ptr-miR-593; +MIMAT0008265 ptr-miR-595; +MIMAT0008266 ptr-miR-597; +MIMAT0008267 ptr-miR-598; +MIMAT0008268 ptr-miR-599; +MIMAT0008269 ptr-miR-600; +MIMAT0008270 ptr-miR-601; +MIMAT0008271 ptr-miR-605; +MIMAT0008272 ptr-miR-609; +MIMAT0008273 ptr-miR-610; +MIMAT0008274 ptr-miR-612; +MIMAT0008275 ptr-miR-613; +MIMAT0008276 ptr-miR-614; +MIMAT0008277 ptr-miR-615; +MIMAT0008278 ptr-miR-616; +MIMAT0008279 ptr-miR-617; +MIMAT0008280 ptr-miR-618; +MIMAT0008281 ptr-miR-619; +MIMAT0008282 ptr-miR-621; +MIMAT0008283 ptr-miR-622; +MIMAT0008284 ptr-miR-624; +MIMAT0008285 ptr-miR-626; +MIMAT0008286 ptr-miR-627; +MIMAT0008287 ptr-miR-628; +MIMAT0008288 ptr-miR-630; +MIMAT0008289 ptr-miR-632; +MIMAT0008290 ptr-miR-633; +MIMAT0008291 ptr-miR-634; +MIMAT0008292 ptr-miR-635; +MIMAT0008293 ptr-miR-637; +MIMAT0008294 ptr-miR-640; +MIMAT0008295 ptr-miR-641; +MIMAT0008296 ptr-miR-642; +MIMAT0008297 ptr-miR-643; +MIMAT0008298 ptr-miR-645; +MIMAT0008299 ptr-miR-646; +MIMAT0008300 ptr-miR-649; +MIMAT0008301 ptr-miR-650; +MIMAT0008302 ptr-miR-652; +MIMAT0008303 ptr-miR-653; +MIMAT0008304 ptr-miR-654; +MIMAT0008305 ptr-miR-656; +MIMAT0008306 ptr-miR-657; +MIMAT0008307 ptr-miR-658; +MIMAT0008308 ptr-miR-660; +MIMAT0008309 ptr-miR-663a; +MIMAT0008310 ptr-miR-663b; +MIMAT0008311 ptr-miR-664;ptr-miR-664a; +MIMAT0008312 ptr-miR-665; +MIMAT0008313 ptr-miR-668; +MIMAT0008314 ptr-miR-671; +MIMAT0008315 ptr-miR-708; +MIMAT0008316 ptr-miR-720; +MIMAT0008317 ptr-miR-744; +MIMAT0008318 ptr-miR-758; +MIMAT0008319 ptr-miR-760; +MIMAT0008320 ptr-miR-765; +MIMAT0008321 ptr-miR-766; +MIMAT0008322 ptr-miR-770; +MIMAT0008323 ptr-miR-802; +MIMAT0008324 ptr-miR-873; +MIMAT0008325 ptr-miR-874; +MIMAT0008326 ptr-miR-875; +MIMAT0008327 ptr-miR-876; +MIMAT0008328 ptr-miR-885; +MIMAT0008329 ptr-miR-886; +MIMAT0008330 ptr-miR-887; +MIMAT0008331 ptr-miR-889; +MIMAT0008332 ptr-miR-890; +MIMAT0008333 ptr-miR-891a; +MIMAT0008334 ptr-miR-891b; +MIMAT0008335 ptr-miR-892a; +MIMAT0008336 ptr-miR-920; +MIMAT0008337 ptr-miR-922; +MIMAT0008338 ptr-miR-923; +MIMAT0008339 ptr-miR-924; +MIMAT0008340 ptr-miR-933; +MIMAT0008341 ptr-miR-934; +MIMAT0008342 ptr-miR-935; +MIMAT0008343 ptr-miR-936; +MIMAT0008344 ptr-miR-937; +MIMAT0008345 ptr-miR-938; +MIMAT0008346 ptr-miR-939; +MIMAT0008347 ptr-miR-940; +MIMAT0008348 ptr-miR-942; +MIMAT0008349 ptr-miR-943; +MIMAT0008350 ptr-miR-944; +MIMAT0008351 ptr-miR-99b; +MIMAT0008352 tca-miR-1;tca-miR-1-3p; +MIMAT0008353 tca-miR-2;tca-miR-2c-3p;tca-miR-2-3p; +MIMAT0008354 tca-let-7;tca-let-7-5p; +MIMAT0008355 tca-miR-7;tca-miR-7-5p; +MIMAT0008356 tca-miR-8;tca-miR-8-3p; +MIMAT0008357 tca-miR-10;tca-miR-10-5p; +MIMAT0008358 tca-miR-12;tca-miR-12-5p; +MIMAT0008359 tca-miR-13a;tca-miR-13a-3p; +MIMAT0008360 tca-miR-13b;tca-miR-13b-3p; +MIMAT0008361 tca-miR-14;tca-miR-14-3p; +MIMAT0008362 tca-miR-31a;tca-miR-31-5p; +MIMAT0008363 tca-miR-33;tca-miR-33-5p; +MIMAT0008364 tca-miR-34;tca-miR-34-5p; +MIMAT0008365 tca-miR-71;tca-miR-71-5p; +MIMAT0008366 tca-miR-87;tca-miR-87a-3p; +MIMAT0008367 tca-miR-92a;tca-miR-92a-3p; +MIMAT0008368 tca-miR-92b;tca-miR-92b-3p; +MIMAT0008369 tca-miR-100;tca-miR-100-5p; +MIMAT0008370 tca-miR-124;tca-miR-124-3p; +MIMAT0008371 tca-miR-125;tca-miR-125-5p; +MIMAT0008372 tca-miR-133;tca-miR-133-3p; +MIMAT0008373 tca-miR-137;tca-miR-137-3p; +MIMAT0008374 tca-miR-184;tca-miR-184-3p; +MIMAT0008375 tca-miR-190;tca-miR-190-5p; +MIMAT0008376 tca-miR-210;tca-miR-210-3p; +MIMAT0008377 tca-miR-219;tca-miR-219-5p; +MIMAT0008378 tca-miR-263b;tca-miR-263b-5p; +MIMAT0008379 tca-miR-275;tca-miR-275-3p; +MIMAT0008380 tca-miR-276*;tca-miR-276-5p; +MIMAT0008381 tca-miR-276;tca-miR-276-3p; +MIMAT0008382 tca-miR-277;tca-miR-277-3p; +MIMAT0008383 tca-miR-279;tca-miR-279a;tca-miR-279a-3p; +MIMAT0008384 tca-miR-281*;tca-miR-281-5p; +MIMAT0008385 tca-miR-281;tca-miR-281-3p; +MIMAT0008386 tca-miR-282;tca-miR-282-5p; +MIMAT0008387 tca-miR-283;tca-miR-283-5p; +MIMAT0008388 tca-miR-305;tca-miR-305-5p; +MIMAT0008389 tca-miR-307;tca-miR-307-3p; +MIMAT0008390 tca-miR-317;tca-miR-317-3p; +MIMAT0008391 tca-miR-927;tca-miR-927-5p;tca-miR-927a-5p; +MIMAT0008392 tca-miR-932;tca-miR-932-5p; +MIMAT0008393 tca-miR-iab-4-5p; +MIMAT0008394 tca-miR-iab-4-3p; +MIMAT0008395 tca-miR-929;tca-miR-929-5p; +MIMAT0008396 tca-miR-9b; +MIMAT0008397 tca-miR-9a; +MIMAT0008398 hsv1-miR-H2-5p;hsv1-miR-H2*;hsv1-miR-H2-5p; +MIMAT0008399 hsv1-miR-H2-3p;hsv1-miR-H2;hsv1-miR-H2-3p; +MIMAT0008400 hsv1-miR-H3;hsv1-miR-H3-3p; +MIMAT0008401 hsv1-miR-H4-5p;hsv1-miR-H4;hsv1-miR-H4-5p; +MIMAT0008402 hsv1-miR-H4-3p;hsv1-miR-H4*;hsv1-miR-H4-3p; +MIMAT0008403 hsv1-miR-H5;hsv1-miR-H5-3p; +MIMAT0008404 hsv1-miR-H6;hsv1-miR-H6-3p; +MIMAT0008405 dan-miR-92b; +MIMAT0008406 dan-miR-288; +MIMAT0008407 dan-miR-277; +MIMAT0008408 dan-miR-8; +MIMAT0008409 dan-bantam; +MIMAT0008410 dan-miR-7; +MIMAT0008411 dan-miR-87; +MIMAT0008412 dan-miR-92a; +MIMAT0008413 dan-miR-304; +MIMAT0008414 dan-miR-2a; +MIMAT0008415 dan-miR-284; +MIMAT0008416 dan-miR-9b; +MIMAT0008417 dan-miR-2b; +MIMAT0008418 dan-miR-12; +MIMAT0008419 dan-miR-285; +MIMAT0008420 dan-miR-13a; +MIMAT0008421 dan-miR-308; +MIMAT0008422 dan-miR-312; +MIMAT0008423 dan-miR-3; +MIMAT0008424 dan-miR-287; +MIMAT0008425 dan-miR-310; +MIMAT0008426 dan-miR-13b; +MIMAT0008427 dan-miR-4; +MIMAT0008428 dan-miR-281-1*;dan-miR-281-1-5p; +MIMAT0008429 dan-miR-281;dan-miR-281-3p; +MIMAT0008430 dan-miR-79; +MIMAT0008431 dan-miR-124; +MIMAT0008432 dan-miR-1; +MIMAT0008433 dan-miR-210; +MIMAT0008434 dan-miR-307; +MIMAT0008435 dan-miR-184*;dan-miR-184-5p; +MIMAT0008436 dan-miR-184;dan-miR-184-3p; +MIMAT0008437 dan-miR-283; +MIMAT0008438 dan-miR-280; +MIMAT0008439 dan-miR-34; +MIMAT0008440 dan-miR-iab-4-5p; +MIMAT0008441 dan-miR-iab-4-3p; +MIMAT0008442 dan-miR-2c; +MIMAT0008443 dan-miR-263a; +MIMAT0008444 dan-miR-286; +MIMAT0008445 dan-miR-282; +MIMAT0008446 dan-miR-276b; +MIMAT0008447 dan-miR-263b; +MIMAT0008448 dan-miR-274; +MIMAT0008449 dan-miR-316; +MIMAT0008450 dan-miR-306; +MIMAT0008451 dan-miR-275; +MIMAT0008452 dan-miR-317; +MIMAT0008453 dan-miR-309; +MIMAT0008454 dan-miR-279; +MIMAT0008455 dan-miR-276a; +MIMAT0008456 dan-miR-9c; +MIMAT0008457 dan-miR-5; +MIMAT0008458 dan-miR-9a; +MIMAT0008459 dan-miR-315; +MIMAT0008460 dan-miR-14; +MIMAT0008461 dan-miR-33; +MIMAT0008462 dan-miR-6; +MIMAT0008463 dan-miR-318; +MIMAT0008464 dan-miR-305; +MIMAT0008465 dan-miR-314; +MIMAT0008466 dan-miR-289; +MIMAT0008467 dan-let-7; +MIMAT0008468 dan-miR-133; +MIMAT0008469 dan-miR-31b; +MIMAT0008470 dan-miR-278; +MIMAT0008471 dan-miR-311a; +MIMAT0008472 dan-miR-11; +MIMAT0008473 dan-miR-125; +MIMAT0008474 dan-miR-219; +MIMAT0008475 dan-miR-311b; +MIMAT0008476 dan-miR-10; +MIMAT0008477 dan-miR-31a; +MIMAT0008478 dan-miR-100; +MIMAT0008479 der-miR-308; +MIMAT0008480 der-miR-283; +MIMAT0008481 der-miR-31b; +MIMAT0008482 der-miR-5; +MIMAT0008483 der-miR-287; +MIMAT0008484 der-miR-13b; +MIMAT0008485 der-miR-310b;der-miR-310b-3p; +MIMAT0008486 der-let-7; +MIMAT0008487 der-miR-309; +MIMAT0008488 der-miR-100; +MIMAT0008489 der-miR-311a;der-miR-311a-3p; +MIMAT0008490 der-miR-133; +MIMAT0008491 der-miR-286; +MIMAT0008492 der-miR-280; +MIMAT0008493 der-miR-92a; +MIMAT0008494 der-miR-306;der-miR-306-5p; +MIMAT0008495 der-miR-306*;der-miR-306-3p; +MIMAT0008496 der-miR-316; +MIMAT0008497 der-miR-307; +MIMAT0008498 der-miR-14; +MIMAT0008499 der-miR-8; +MIMAT0008500 der-miR-11; +MIMAT0008501 der-miR-281-1*;der-miR-281-1-5p; +MIMAT0008502 der-miR-281;der-miR-281-3p; +MIMAT0008503 der-miR-275; +MIMAT0008504 der-miR-6; +MIMAT0008505 der-miR-9a; +MIMAT0008506 der-miR-263a; +MIMAT0008507 der-miR-9b; +MIMAT0008508 der-miR-34; +MIMAT0008509 der-miR-282; +MIMAT0008510 der-miR-2a; +MIMAT0008511 der-miR-184*;der-miR-184-5p; +MIMAT0008512 der-miR-184;der-miR-184-3p; +MIMAT0008513 der-miR-284; +MIMAT0008514 der-miR-285; +MIMAT0008515 der-miR-279; +MIMAT0008516 der-miR-263b; +MIMAT0008517 der-miR-277; +MIMAT0008518 der-miR-318; +MIMAT0008519 der-miR-31a; +MIMAT0008520 der-miR-311b;der-miR-311b-3p; +MIMAT0008521 der-miR-274; +MIMAT0008522 der-miR-311c;der-miR-311c-3p; +MIMAT0008523 der-miR-iab-4-5p; +MIMAT0008524 der-miR-iab-4-3p; +MIMAT0008525 der-miR-79; +MIMAT0008526 der-miR-125; +MIMAT0008527 der-miR-305; +MIMAT0008528 der-miR-314; +MIMAT0008529 der-miR-276a; +MIMAT0008530 der-miR-278; +MIMAT0008531 der-miR-12; +MIMAT0008532 der-miR-4; +MIMAT0008533 der-bantam; +MIMAT0008534 der-miR-1; +MIMAT0008535 der-miR-2b; +MIMAT0008536 der-miR-312;der-miR-312-3p; +MIMAT0008537 der-miR-7; +MIMAT0008538 der-miR-3; +MIMAT0008539 der-miR-315; +MIMAT0008540 der-miR-2c; +MIMAT0008541 der-miR-317; +MIMAT0008542 der-miR-276b; +MIMAT0008543 der-miR-92b; +MIMAT0008544 der-miR-87; +MIMAT0008545 der-miR-33; +MIMAT0008546 der-miR-210; +MIMAT0008547 der-miR-124; +MIMAT0008548 der-miR-304; +MIMAT0008549 der-miR-10; +MIMAT0008550 der-miR-13a; +MIMAT0008551 der-miR-288; +MIMAT0008552 der-miR-219; +MIMAT0008553 der-miR-310a;der-miR-310a-3p; +MIMAT0008554 der-miR-9c; +MIMAT0008555 der-miR-289; +MIMAT0008556 dgr-miR-277; +MIMAT0008557 dgr-miR-100; +MIMAT0008558 dgr-miR-305; +MIMAT0008559 dgr-bantam; +MIMAT0008560 dgr-miR-12; +MIMAT0008561 dgr-miR-219; +MIMAT0008562 dgr-miR-307; +MIMAT0008563 dgr-miR-287; +MIMAT0008564 dgr-miR-263b; +MIMAT0008565 dgr-miR-308; +MIMAT0008566 dgr-miR-184*;dgr-miR-184-5p; +MIMAT0008567 dgr-miR-184;dgr-miR-184-3p; +MIMAT0008568 dgr-miR-2b; +MIMAT0008569 dgr-miR-6; +MIMAT0008570 dgr-miR-5; +MIMAT0008571 dgr-miR-92a; +MIMAT0008572 dgr-miR-11; +MIMAT0008573 dgr-miR-276b*;dgr-miR-276b-5p; +MIMAT0008574 dgr-miR-276b;dgr-miR-276b-3p; +MIMAT0008575 dgr-miR-276a*;dgr-miR-276a-5p; +MIMAT0008576 dgr-miR-276a;dgr-miR-276a-3p; +MIMAT0008577 dgr-miR-309; +MIMAT0008578 dgr-miR-iab-4-5p; +MIMAT0008579 dgr-miR-iab-4-3p; +MIMAT0008580 dgr-miR-3; +MIMAT0008581 dgr-miR-285; +MIMAT0008582 dgr-miR-9b; +MIMAT0008583 dgr-miR-79; +MIMAT0008584 dgr-miR-318; +MIMAT0008585 dgr-miR-31a; +MIMAT0008586 dgr-miR-317; +MIMAT0008587 dgr-miR-281-1*;dgr-miR-281-1-5p; +MIMAT0008588 dgr-miR-281;dgr-miR-281-3p; +MIMAT0008589 dgr-miR-9a; +MIMAT0008590 dgr-miR-286; +MIMAT0008591 dgr-miR-316; +MIMAT0008592 dgr-miR-306; +MIMAT0008593 dgr-miR-8; +MIMAT0008594 dgr-miR-4; +MIMAT0008595 dgr-miR-304; +MIMAT0008596 dgr-let-7; +MIMAT0008597 dgr-miR-278; +MIMAT0008598 dgr-miR-314; +MIMAT0008599 dgr-miR-279; +MIMAT0008600 dgr-miR-288; +MIMAT0008601 dgr-miR-10; +MIMAT0008602 dgr-miR-14; +MIMAT0008603 dgr-miR-33; +MIMAT0008604 dgr-miR-315; +MIMAT0008605 dgr-miR-13b; +MIMAT0008606 dgr-miR-9c; +MIMAT0008607 dgr-miR-2a; +MIMAT0008608 dgr-miR-87; +MIMAT0008609 dgr-miR-1; +MIMAT0008610 dgr-miR-125; +MIMAT0008611 dgr-miR-284; +MIMAT0008612 dgr-miR-31b; +MIMAT0008613 dgr-miR-210; +MIMAT0008614 dgr-miR-282; +MIMAT0008615 dgr-miR-124; +MIMAT0008616 dgr-miR-280; +MIMAT0008617 dgr-miR-13a; +MIMAT0008618 dgr-miR-283; +MIMAT0008619 dgr-miR-34; +MIMAT0008620 dgr-miR-133; +MIMAT0008621 dgr-miR-263a; +MIMAT0008622 dgr-miR-7; +MIMAT0008623 dgr-miR-274; +MIMAT0008624 dgr-miR-92b; +MIMAT0008625 dgr-miR-275; +MIMAT0008626 dgr-miR-2c; +MIMAT0008627 dmo-miR-316; +MIMAT0008628 dmo-miR-284; +MIMAT0008629 dmo-miR-4; +MIMAT0008630 dmo-miR-12; +MIMAT0008631 dmo-miR-276b; +MIMAT0008632 dmo-miR-14; +MIMAT0008633 dmo-miR-92a; +MIMAT0008634 dmo-bantam; +MIMAT0008635 dmo-miR-6; +MIMAT0008636 dmo-miR-13b; +MIMAT0008637 dmo-miR-100; +MIMAT0008638 dmo-miR-219; +MIMAT0008639 dmo-miR-31b; +MIMAT0008640 dmo-miR-283; +MIMAT0008641 dmo-miR-281-1*;dmo-miR-281-1-5p; +MIMAT0008642 dmo-miR-281;dmo-miR-281-3p; +MIMAT0008643 dmo-miR-286; +MIMAT0008644 dmo-miR-314; +MIMAT0008645 dmo-miR-282; +MIMAT0008646 dmo-miR-305; +MIMAT0008647 dmo-miR-8; +MIMAT0008648 dmo-miR-306;dmo-miR-306-5p; +MIMAT0008649 dmo-miR-306*;dmo-miR-306-3p; +MIMAT0008650 dmo-miR-2b; +MIMAT0008651 dmo-miR-285; +MIMAT0008652 dmo-miR-2c; +MIMAT0008653 dmo-miR-263a; +MIMAT0008654 dmo-miR-276a; +MIMAT0008655 dmo-miR-274; +MIMAT0008656 dmo-miR-34; +MIMAT0008657 dmo-miR-304; +MIMAT0008658 dmo-miR-92b; +MIMAT0008659 dmo-miR-287; +MIMAT0008660 dmo-miR-309; +MIMAT0008661 dmo-miR-13a; +MIMAT0008662 dmo-miR-87; +MIMAT0008663 dmo-miR-280; +MIMAT0008664 dmo-miR-275; +MIMAT0008665 dmo-miR-307; +MIMAT0008666 dmo-miR-9b; +MIMAT0008667 dmo-miR-210; +MIMAT0008668 dmo-miR-3; +MIMAT0008669 dmo-miR-125; +MIMAT0008670 dmo-miR-9a; +MIMAT0008671 dmo-miR-317; +MIMAT0008672 dmo-miR-2a; +MIMAT0008673 dmo-miR-184*;dmo-miR-184-5p; +MIMAT0008674 dmo-miR-184;dmo-miR-184-3p; +MIMAT0008675 dmo-miR-288; +MIMAT0008676 dmo-miR-278; +MIMAT0008677 dmo-miR-31a; +MIMAT0008678 dmo-miR-133; +MIMAT0008679 dmo-miR-11; +MIMAT0008680 dmo-miR-iab-4-5p; +MIMAT0008681 dmo-miR-iab-4-3p; +MIMAT0008682 dmo-miR-279; +MIMAT0008683 dmo-miR-9c; +MIMAT0008684 dmo-miR-318; +MIMAT0008685 dmo-miR-277; +MIMAT0008686 dmo-let-7; +MIMAT0008687 dmo-miR-315; +MIMAT0008688 dmo-miR-124; +MIMAT0008689 dmo-miR-308; +MIMAT0008690 dmo-miR-79; +MIMAT0008691 dmo-miR-5; +MIMAT0008692 dmo-miR-7; +MIMAT0008693 dmo-miR-10; +MIMAT0008694 dmo-miR-1; +MIMAT0008695 dmo-miR-33; +MIMAT0008696 dmo-miR-313; +MIMAT0008697 dpe-miR-307; +MIMAT0008698 dpe-miR-3; +MIMAT0008699 dpe-let-7; +MIMAT0008700 dpe-miR-184*;dpe-miR-184-5p; +MIMAT0008701 dpe-miR-184;dpe-miR-184-3p; +MIMAT0008702 dpe-miR-277; +MIMAT0008703 dpe-miR-14; +MIMAT0008704 dpe-miR-210; +MIMAT0008705 dpe-miR-276a; +MIMAT0008706 dpe-miR-13a; +MIMAT0008707 dpe-miR-6; +MIMAT0008708 dpe-miR-284; +MIMAT0008709 dpe-miR-286; +MIMAT0008710 dpe-miR-8; +MIMAT0008711 dpe-miR-13b; +MIMAT0008712 dpe-miR-133; +MIMAT0008713 dpe-miR-283; +MIMAT0008714 dpe-miR-5; +MIMAT0008715 dpe-miR-34; +MIMAT0008716 dpe-miR-282; +MIMAT0008717 dpe-miR-9a; +MIMAT0008718 dpe-miR-100; +MIMAT0008719 dpe-miR-219; +MIMAT0008720 dpe-miR-314; +MIMAT0008721 dpe-bantam; +MIMAT0008722 dpe-miR-280; +MIMAT0008723 dpe-miR-31a; +MIMAT0008724 dpe-miR-1; +MIMAT0008725 dpe-miR-125; +MIMAT0008726 dpe-miR-278; +MIMAT0008727 dpe-miR-281-1*;dpe-miR-281-1-5p; +MIMAT0008728 dpe-miR-281;dpe-miR-281-3p; +MIMAT0008729 dpe-miR-2a; +MIMAT0008730 dpe-miR-315; +MIMAT0008731 dpe-miR-124; +MIMAT0008732 dpe-miR-308; +MIMAT0008733 dpe-miR-87; +MIMAT0008734 dpe-miR-279; +MIMAT0008735 dpe-miR-263b; +MIMAT0008736 dpe-miR-2c; +MIMAT0008737 dpe-miR-11; +MIMAT0008738 dpe-miR-2b; +MIMAT0008739 dpe-miR-317; +MIMAT0008740 dpe-miR-iab-4-5p; +MIMAT0008741 dpe-miR-iab-4-3p; +MIMAT0008742 dpe-miR-7; +MIMAT0008743 dpe-miR-33; +MIMAT0008744 dpe-miR-275; +MIMAT0008745 dpe-miR-9b; +MIMAT0008746 dpe-miR-9c; +MIMAT0008747 dpe-miR-79; +MIMAT0008748 dpe-miR-289; +MIMAT0008749 dpe-miR-318; +MIMAT0008750 dpe-miR-276b; +MIMAT0008751 dpe-miR-4; +MIMAT0008752 dpe-miR-31b; +MIMAT0008753 dpe-miR-288; +MIMAT0008754 dpe-miR-10; +MIMAT0008755 dpe-miR-305; +MIMAT0008756 dpe-miR-92b; +MIMAT0008757 dpe-miR-287; +MIMAT0008758 dpe-miR-274; +MIMAT0008759 dpe-miR-306; +MIMAT0008760 dpe-miR-309; +MIMAT0008761 dpe-miR-263a; +MIMAT0008762 dpe-miR-12; +MIMAT0008763 dpe-miR-92a; +MIMAT0008764 dpe-miR-316; +MIMAT0008765 dse-miR-6; +MIMAT0008766 dse-miR-12; +MIMAT0008767 dse-miR-280; +MIMAT0008768 dse-miR-263a; +MIMAT0008769 dse-miR-79; +MIMAT0008770 dse-miR-287; +MIMAT0008771 dse-miR-7; +MIMAT0008772 dse-miR-8; +MIMAT0008773 dse-miR-87; +MIMAT0008774 dse-miR-92b; +MIMAT0008775 dse-bantam; +MIMAT0008776 dse-miR-210; +MIMAT0008777 dse-miR-2c; +MIMAT0008778 dse-miR-276b; +MIMAT0008779 dse-miR-310;dse-miR-310-3p; +MIMAT0008780 dse-miR-2b; +MIMAT0008781 dse-miR-278; +MIMAT0008782 dse-miR-281-1*;dse-miR-281-1-5p; +MIMAT0008783 dse-miR-281;dse-miR-281-3p; +MIMAT0008784 dse-miR-10; +MIMAT0008785 dse-miR-92a; +MIMAT0008786 dse-miR-13a; +MIMAT0008787 dse-miR-34; +MIMAT0008788 dse-miR-11; +MIMAT0008789 dse-miR-317; +MIMAT0008790 dse-miR-305; +MIMAT0008791 dse-miR-276a; +MIMAT0008792 dse-miR-282; +MIMAT0008793 dse-miR-308; +MIMAT0008794 dse-miR-277; +MIMAT0008795 dse-miR-314; +MIMAT0008796 dse-miR-100; +MIMAT0008797 dse-miR-286; +MIMAT0008798 dse-miR-284; +MIMAT0008799 dse-miR-311;dse-miR-311-3p; +MIMAT0008800 dse-miR-9a; +MIMAT0008801 dse-miR-304; +MIMAT0008802 dse-miR-33; +MIMAT0008803 dse-miR-309; +MIMAT0008804 dse-miR-306;dse-miR-306-5p; +MIMAT0008805 dse-miR-306*;dse-miR-306-3p; +MIMAT0008806 dse-miR-288; +MIMAT0008807 dse-miR-289; +MIMAT0008808 dse-miR-279; +MIMAT0008809 dse-miR-285; +MIMAT0008810 dse-miR-312;dse-miR-312-3p; +MIMAT0008811 dse-miR-307; +MIMAT0008812 dse-miR-9c; +MIMAT0008813 dse-miR-14; +MIMAT0008814 dse-miR-1; +MIMAT0008815 dse-miR-315; +MIMAT0008816 dse-miR-13b; +MIMAT0008817 dse-miR-318; +MIMAT0008818 dse-miR-316; +MIMAT0008819 dse-miR-2a; +MIMAT0008820 dse-miR-275; +MIMAT0008821 dse-miR-184*;dse-miR-184-5p; +MIMAT0008822 dse-miR-184;dse-miR-184-3p; +MIMAT0008823 dse-miR-31b; +MIMAT0008824 dse-miR-219; +MIMAT0008825 dse-miR-31a; +MIMAT0008826 dse-miR-125; +MIMAT0008827 dse-miR-9b; +MIMAT0008828 dse-miR-274; +MIMAT0008829 dse-miR-5; +MIMAT0008830 dse-miR-263b; +MIMAT0008831 dse-miR-313;dse-miR-313-3p; +MIMAT0008832 dse-miR-iab-4-5p; +MIMAT0008833 dse-miR-iab-4-3p; +MIMAT0008834 dse-miR-133; +MIMAT0008835 dse-miR-4; +MIMAT0008836 dse-miR-3; +MIMAT0008837 dse-let-7; +MIMAT0008838 dse-miR-283; +MIMAT0008839 dse-miR-124; +MIMAT0008840 dsi-miR-34; +MIMAT0008841 dsi-miR-310;dsi-miR-310-3p; +MIMAT0008842 dsi-miR-4; +MIMAT0008843 dsi-miR-9a; +MIMAT0008844 dsi-miR-87; +MIMAT0008845 dsi-miR-13b; +MIMAT0008846 dsi-miR-125; +MIMAT0008847 dsi-miR-124; +MIMAT0008848 dsi-miR-14; +MIMAT0008849 dsi-miR-210; +MIMAT0008850 dsi-miR-277; +MIMAT0008851 dsi-miR-263a; +MIMAT0008852 dsi-miR-12; +MIMAT0008853 dsi-miR-2a; +MIMAT0008854 dsi-miR-2c; +MIMAT0008855 dsi-miR-iab-4-5p; +MIMAT0008856 dsi-miR-iab-4-3p; +MIMAT0008857 dsi-miR-311;dsi-miR-311-3p; +MIMAT0008858 dsi-miR-2b; +MIMAT0008859 dsi-miR-286; +MIMAT0008860 dsi-miR-305; +MIMAT0008861 dsi-bantam; +MIMAT0008862 dsi-miR-3; +MIMAT0008863 dsi-miR-317; +MIMAT0008864 dsi-miR-314; +MIMAT0008865 dsi-miR-11; +MIMAT0008866 dsi-miR-33; +MIMAT0008867 dsi-miR-1; +MIMAT0008868 dsi-miR-219; +MIMAT0008869 dsi-miR-316; +MIMAT0008870 dsi-miR-315; +MIMAT0008871 dsi-miR-263b; +MIMAT0008872 dsi-miR-100; +MIMAT0008873 dsi-miR-289; +MIMAT0008874 dsi-miR-313;dsi-miR-313-3p; +MIMAT0008875 dsi-miR-312;dsi-miR-312-3p; +MIMAT0008876 dsi-let-7; +MIMAT0008877 dsi-miR-308; +MIMAT0008878 dsi-miR-31b; +MIMAT0008879 dsi-miR-92b; +MIMAT0008880 dsi-miR-275; +MIMAT0008881 dsi-miR-13a; +MIMAT0008882 dsi-miR-304; +MIMAT0008883 dsi-miR-282; +MIMAT0008884 dsi-miR-307; +MIMAT0008885 dsi-miR-6;dsi-miR-6-3p; +MIMAT0008886 dsi-miR-31a; +MIMAT0008887 dsi-miR-10; +MIMAT0008888 dsi-miR-285; +MIMAT0008889 dsi-miR-8; +MIMAT0008890 dsi-miR-5; +MIMAT0008891 dsi-miR-278; +MIMAT0008892 dsi-miR-276a; +MIMAT0008893 dsi-miR-283; +MIMAT0008894 dsi-miR-309; +MIMAT0008895 dsi-miR-276b; +MIMAT0008896 dsi-miR-279; +MIMAT0008897 dsi-miR-288; +MIMAT0008898 dsi-miR-92a; +MIMAT0008899 dsi-miR-287; +MIMAT0008900 dsi-miR-133; +MIMAT0008901 dsi-miR-7; +MIMAT0008902 dsi-miR-284; +MIMAT0008903 dsi-miR-184*;dsi-miR-184-5p; +MIMAT0008904 dsi-miR-184;dsi-miR-184-3p; +MIMAT0008905 dsi-miR-281*;dsi-miR-281-5p; +MIMAT0008906 dsi-miR-281;dsi-miR-281-3p; +MIMAT0008907 dsi-miR-318; +MIMAT0008908 dvi-miR-314;dvi-miR-314-3p; +MIMAT0008909 dvi-miR-2a;dvi-miR-2a-3p; +MIMAT0008910 dvi-miR-2c;dvi-miR-2c-3p; +MIMAT0008911 dvi-miR-12;dvi-miR-12-5p; +MIMAT0008912 dvi-miR-13a;dvi-miR-13a-3p; +MIMAT0008913 dvi-miR-306;dvi-miR-306-5p; +MIMAT0008914 dvi-miR-306*;dvi-miR-306-3p; +MIMAT0008915 dvi-miR-279;dvi-miR-279-3p; +MIMAT0008916 dvi-miR-11;dvi-miR-11-3p; +MIMAT0008917 dvi-miR-125;dvi-miR-125-5p; +MIMAT0008918 dvi-miR-313;dvi-miR-313-3p; +MIMAT0008919 dvi-miR-263a;dvi-miR-263a-5p; +MIMAT0008920 dvi-miR-274; +MIMAT0008921 dvi-miR-263b;dvi-miR-263b-5p; +MIMAT0008922 dvi-miR-318; +MIMAT0008923 dvi-miR-6;dvi-miR-6-3p; +MIMAT0008924 dvi-miR-9c;dvi-miR-9c-5p; +MIMAT0008925 dvi-miR-9b;dvi-miR-9b-5p; +MIMAT0008926 dvi-miR-281-1*;dvi-miR-281-1-5p; +MIMAT0008927 dvi-miR-281;dvi-miR-281-3p; +MIMAT0008928 dvi-miR-210;dvi-miR-210-3p; +MIMAT0008929 dvi-miR-9a;dvi-miR-9a-5p; +MIMAT0008930 dvi-miR-287; +MIMAT0008931 dvi-miR-7;dvi-miR-7-5p; +MIMAT0008932 dvi-miR-282;dvi-miR-282-5p; +MIMAT0008933 dvi-miR-315b; +MIMAT0008934 dvi-miR-310;dvi-miR-310-3p; +MIMAT0008935 dvi-miR-283;dvi-miR-283-5p; +MIMAT0008936 dvi-miR-133;dvi-miR-133-3p; +MIMAT0008937 dvi-miR-278;dvi-miR-278-3p; +MIMAT0008938 dvi-miR-13b;dvi-miR-13b-3p; +MIMAT0008939 dvi-miR-124;dvi-miR-124-3p; +MIMAT0008940 dvi-miR-305;dvi-miR-305-5p; +MIMAT0008941 dvi-miR-33;dvi-miR-33-5p; +MIMAT0008942 dvi-miR-276b;dvi-miR-276b-3p; +MIMAT0008943 dvi-miR-276a;dvi-miR-276a-3p; +MIMAT0008944 dvi-miR-315a; +MIMAT0008945 dvi-miR-316;dvi-miR-316-5p; +MIMAT0008946 dvi-miR-277;dvi-miR-277-3p; +MIMAT0008947 dvi-miR-317;dvi-miR-317-3p; +MIMAT0008948 dvi-miR-184*;dvi-miR-184-5p; +MIMAT0008949 dvi-miR-184;dvi-miR-184-3p; +MIMAT0008950 dvi-miR-286;dvi-miR-286-3p; +MIMAT0008951 dvi-miR-2b;dvi-miR-2b-3p; +MIMAT0008952 dvi-miR-288; +MIMAT0008953 dvi-miR-307; +MIMAT0008954 dvi-miR-8;dvi-miR-8-3p; +MIMAT0008955 dvi-miR-34;dvi-miR-34-5p; +MIMAT0008956 dvi-miR-4;dvi-miR-4-3p; +MIMAT0008957 dvi-miR-3;dvi-miR-3-3p; +MIMAT0008958 dvi-miR-309;dvi-miR-309-3p; +MIMAT0008959 dvi-miR-1;dvi-miR-1-3p; +MIMAT0008960 dvi-miR-10;dvi-miR-10-5p; +MIMAT0008961 dvi-miR-5;dvi-miR-5-5p; +MIMAT0008962 dvi-miR-92b;dvi-miR-92b-3p; +MIMAT0008963 dvi-miR-iab-4-5p; +MIMAT0008964 dvi-miR-iab-4-3p; +MIMAT0008965 dvi-miR-280; +MIMAT0008966 dvi-bantam;dvi-bantam-3p; +MIMAT0008967 dvi-miR-31a;dvi-miR-31a-5p; +MIMAT0008968 dvi-miR-308;dvi-miR-308-3p; +MIMAT0008969 dvi-miR-285;dvi-miR-285-3p; +MIMAT0008970 dvi-miR-275;dvi-miR-275-3p; +MIMAT0008971 dvi-miR-14;dvi-miR-14-3p; +MIMAT0008972 dvi-miR-31b; +MIMAT0008973 dvi-miR-100;dvi-miR-100-5p; +MIMAT0008974 dvi-miR-87;dvi-miR-87-3p; +MIMAT0008975 dvi-miR-79;dvi-miR-79-3p; +MIMAT0008976 dvi-miR-304;dvi-miR-304-5p; +MIMAT0008977 dvi-miR-284;dvi-miR-284-3p; +MIMAT0008978 dvi-miR-219;dvi-miR-219-5p; +MIMAT0008979 dvi-miR-92a;dvi-miR-92a-3p; +MIMAT0008980 dvi-let-7; +MIMAT0008981 dwi-miR-79; +MIMAT0008982 dwi-miR-87; +MIMAT0008983 dwi-miR-34; +MIMAT0008984 dwi-miR-285; +MIMAT0008985 dwi-bantam; +MIMAT0008986 dwi-miR-306; +MIMAT0008987 dwi-miR-1; +MIMAT0008988 dwi-miR-184*;dwi-miR-184-5p; +MIMAT0008989 dwi-miR-184;dwi-miR-184-3p; +MIMAT0008990 dwi-miR-13b; +MIMAT0008991 dwi-miR-92b; +MIMAT0008992 dwi-miR-9c; +MIMAT0008993 dwi-miR-284; +MIMAT0008994 dwi-miR-281-1*;dwi-miR-281-1-5p; +MIMAT0008995 dwi-miR-281;dwi-miR-281-3p; +MIMAT0008996 dwi-let-7; +MIMAT0008997 dwi-miR-305; +MIMAT0008998 dwi-miR-92a; +MIMAT0008999 dwi-miR-286; +MIMAT0009000 dwi-miR-316; +MIMAT0009001 dwi-miR-279; +MIMAT0009002 dwi-miR-263b; +MIMAT0009003 dwi-miR-287; +MIMAT0009004 dwi-miR-iab-4-5p; +MIMAT0009005 dwi-miR-iab-4-3p; +MIMAT0009006 dwi-miR-2a; +MIMAT0009007 dwi-miR-276a*;dwi-miR-276a-5p; +MIMAT0009008 dwi-miR-276a;dwi-miR-276a-3p; +MIMAT0009009 dwi-miR-7; +MIMAT0009010 dwi-miR-11; +MIMAT0009011 dwi-miR-304; +MIMAT0009012 dwi-miR-219; +MIMAT0009013 dwi-miR-8; +MIMAT0009014 dwi-miR-283; +MIMAT0009015 dwi-miR-318; +MIMAT0009016 dwi-miR-2b; +MIMAT0009017 dwi-miR-12; +MIMAT0009018 dwi-miR-276b*;dwi-miR-276b-5p; +MIMAT0009019 dwi-miR-276b;dwi-miR-276b-3p; +MIMAT0009020 dwi-miR-210; +MIMAT0009021 dwi-miR-309; +MIMAT0009022 dwi-miR-6; +MIMAT0009023 dwi-miR-274; +MIMAT0009024 dwi-miR-317; +MIMAT0009025 dwi-miR-314; +MIMAT0009026 dwi-miR-282; +MIMAT0009027 dwi-miR-124; +MIMAT0009028 dwi-miR-280; +MIMAT0009029 dwi-miR-278; +MIMAT0009030 dwi-miR-13a; +MIMAT0009031 dwi-miR-307; +MIMAT0009032 dwi-miR-125; +MIMAT0009033 dwi-miR-10; +MIMAT0009034 dwi-miR-9a; +MIMAT0009035 dwi-miR-2c; +MIMAT0009036 dwi-miR-315; +MIMAT0009037 dwi-miR-31b; +MIMAT0009038 dwi-miR-308; +MIMAT0009039 dwi-miR-263a; +MIMAT0009040 dwi-miR-277; +MIMAT0009041 dwi-miR-5; +MIMAT0009042 dwi-miR-33; +MIMAT0009043 dwi-miR-14; +MIMAT0009044 dwi-miR-31a; +MIMAT0009045 dwi-miR-275; +MIMAT0009046 dwi-miR-3; +MIMAT0009047 dwi-miR-9b; +MIMAT0009048 dwi-miR-100; +MIMAT0009049 dwi-miR-4; +MIMAT0009050 dwi-miR-288; +MIMAT0009051 dwi-miR-133; +MIMAT0009052 dya-miR-274; +MIMAT0009053 dya-miR-87; +MIMAT0009054 dya-miR-307; +MIMAT0009055 dya-miR-317; +MIMAT0009056 dya-miR-13b; +MIMAT0009057 dya-bantam; +MIMAT0009058 dya-miR-4; +MIMAT0009059 dya-miR-100; +MIMAT0009060 dya-miR-281-1*;dya-miR-281-1-5p; +MIMAT0009061 dya-miR-281;dya-miR-281-3p; +MIMAT0009062 dya-miR-279; +MIMAT0009063 dya-miR-33; +MIMAT0009064 dya-miR-283; +MIMAT0009065 dya-miR-280; +MIMAT0009066 dya-miR-8; +MIMAT0009067 dya-miR-305; +MIMAT0009068 dya-miR-306;dya-miR-306-5p; +MIMAT0009069 dya-miR-306*;dya-miR-306-3p; +MIMAT0009070 dya-miR-9a; +MIMAT0009071 dya-miR-282; +MIMAT0009072 dya-miR-133; +MIMAT0009073 dya-miR-304; +MIMAT0009074 dya-miR-3; +MIMAT0009075 dya-miR-2b; +MIMAT0009076 dya-miR-14; +MIMAT0009077 dya-miR-314; +MIMAT0009078 dya-miR-6; +MIMAT0009079 dya-miR-318; +MIMAT0009080 dya-miR-316; +MIMAT0009081 dya-miR-34; +MIMAT0009082 dya-miR-10; +MIMAT0009083 dya-miR-1; +MIMAT0009084 dya-miR-315; +MIMAT0009085 dya-miR-309; +MIMAT0009086 dya-miR-278; +MIMAT0009087 dya-miR-284; +MIMAT0009088 dya-miR-285; +MIMAT0009089 dya-miR-iab-4-5p; +MIMAT0009090 dya-miR-iab-4-3p; +MIMAT0009091 dya-miR-311a;dya-miR-311a-3p; +MIMAT0009092 dya-miR-310;dya-miR-310-3p; +MIMAT0009093 dya-miR-13a; +MIMAT0009094 dya-miR-288; +MIMAT0009095 dya-miR-210; +MIMAT0009096 dya-miR-125; +MIMAT0009097 dya-miR-2c; +MIMAT0009098 dya-let-7; +MIMAT0009099 dya-miR-277; +MIMAT0009100 dya-miR-308; +MIMAT0009101 dya-miR-5; +MIMAT0009102 dya-miR-287; +MIMAT0009103 dya-miR-31a; +MIMAT0009104 dya-miR-31b; +MIMAT0009105 dya-miR-124; +MIMAT0009106 dya-miR-2a; +MIMAT0009107 dya-miR-219; +MIMAT0009108 dya-miR-312;dya-miR-312-3p; +MIMAT0009109 dya-miR-286; +MIMAT0009110 dya-miR-263b; +MIMAT0009111 dya-miR-92a; +MIMAT0009112 dya-miR-9c; +MIMAT0009113 dya-miR-9b; +MIMAT0009114 dya-miR-263a; +MIMAT0009115 dya-miR-275; +MIMAT0009116 dya-miR-311b;dya-miR-311b-3p; +MIMAT0009117 dya-miR-276a; +MIMAT0009118 dya-miR-289; +MIMAT0009119 dya-miR-7; +MIMAT0009120 dya-miR-92b; +MIMAT0009121 dya-miR-184*;dya-miR-184-5p; +MIMAT0009122 dya-miR-184;dya-miR-184-3p; +MIMAT0009123 dya-miR-11; +MIMAT0009124 dya-miR-79; +MIMAT0009125 dya-miR-276b; +MIMAT0009126 pta-miR1309; +MIMAT0009127 pta-miR1310; +MIMAT0009128 pta-miR1311; +MIMAT0009129 pta-miR1312; +MIMAT0009130 pta-miR1313; +MIMAT0009131 pta-miR1314; +MIMAT0009132 pta-miR1315; +MIMAT0009133 pta-miR1316; +MIMAT0009134 osa-miR1317;osa-miR1317-5p; +MIMAT0009135 osa-miR1318;osa-miR1318-5p; +MIMAT0009136 osa-miR1319;osa-miR1319a; +MIMAT0009137 osa-miR1320;osa-miR1320-5p; +MIMAT0009138 sly-miR156a; +MIMAT0009139 sly-miR156b; +MIMAT0009140 sly-miR156c; +MIMAT0009141 sly-miR159; +MIMAT0009142 sly-miR162; +MIMAT0009143 sly-miR172a; +MIMAT0009144 sly-miR172b; +MIMAT0009145 sly-miR319;sly-miR319a; +MIMAT0009146 sly-miR399; +MIMAT0009147 jcv-miR-J1-5p; +MIMAT0009148 jcv-miR-J1-3p; +MIMAT0009149 bkv-miR-B1-5p; +MIMAT0009150 bkv-miR-B1-3p; +MIMAT0009151 bmo-miR-12; +MIMAT0009152 bmo-miR-137; +MIMAT0009153 bmo-miR-190;bmo-miR-190-5p; +MIMAT0009154 bmo-miR-285; +MIMAT0009155 bmo-miR-92;bmo-miR-92b; +MIMAT0009156 bmo-miR-925; +MIMAT0009157 bmo-miR-927;bmo-miR-927-5p; +MIMAT0009158 bmo-miR-929;bmo-miR-929-5p; +MIMAT0009159 bmo-miR-930; +MIMAT0009160 bmo-miR-932; +MIMAT0009161 bmo-miR-9b;bmo-miR-9b-5p; +MIMAT0009162 bmo-miR-iab-4-5p; +MIMAT0009163 bmo-miR-iab-4-3p; +MIMAT0009164 bmo-miR-278;bmo-miR-278-3p; +MIMAT0009165 osa-miR1846c-5p; +MIMAT0009166 osa-miR1846c-3p; +MIMAT0009167 oan-miR-29a-2*;oan-miR-29a-2-5p; +MIMAT0009168 oan-miR-1421n-2*;oan-miR-1421n-2-3p; +MIMAT0009169 oan-miR-20a-2*;oan-miR-20a-2-3p; +MIMAT0009170 oan-miR-92a-2*;oan-miR-92a-2-5p; +MIMAT0009171 oan-let-7f-2*;oan-let-7f-2-3p; +MIMAT0009172 oan-miR-1421y-2*;oan-miR-1421y-2-3p; +MIMAT0009173 oan-miR-1421y-3*;oan-miR-1421y-3-3p; +MIMAT0009174 oan-miR-1419b-2*;oan-miR-1419b-2-3p; +MIMAT0009175 oan-miR-1422b-2*;oan-miR-1422b-2-5p; +MIMAT0009176 oan-miR-1421g-2*;oan-miR-1421g-2-3p; +MIMAT0009177 oan-miR-1421i-2*;oan-miR-1421i-2-3p; +MIMAT0009178 oan-miR-1421i-3*;oan-miR-1421i-3-3p; +MIMAT0009179 oan-miR-1421k-2*;oan-miR-1421k-2-3p;oan-miR-1421k-3p; +MIMAT0009180 oan-miR-1421k-3*;oan-miR-1421k-3-3p; +MIMAT0009181 oan-miR-1421l-2*;oan-miR-1421l-2-3p; +MIMAT0009182 dan-miR-281-2*;dan-miR-281-2-5p; +MIMAT0009183 der-miR-281-2*;der-miR-281-2-5p; +MIMAT0009184 dgr-miR-281-2*;dgr-miR-281-2-5p; +MIMAT0009185 dmo-miR-281-2*;dmo-miR-281-2-5p; +MIMAT0009186 dpe-miR-281-2*;dpe-miR-281-2-5p; +MIMAT0009187 dse-miR-281-2*;dse-miR-281-2-5p; +MIMAT0009188 dvi-miR-281-2*;dvi-miR-281-2-5p; +MIMAT0009189 dwi-miR-281-2*;dwi-miR-281-2-5p; +MIMAT0009190 dya-miR-281-2*;dya-miR-281-2-5p; +MIMAT0009191 oan-miR-33b-3p; +MIMAT0009192 ptr-miR-199a-3p; +MIMAT0009193 ptr-miR-219-5p; +MIMAT0009194 ptr-miR-219-2-3p; +MIMAT0009195 oan-miR-7-1*;oan-miR-7-1-3p; +MIMAT0009196 hsa-miR-103-2*;hsa-miR-103a-2*;hsa-miR-103a-2-5p; +MIMAT0009197 hsa-miR-205*;hsa-miR-205-3p; +MIMAT0009198 hsa-miR-224*;hsa-miR-224-3p; +MIMAT0009199 hsa-miR-365*;hsa-miR-365a-5p; +MIMAT0009200 osa-miR159a.2; +MIMAT0009201 hsa-miR-196b*;hsa-miR-196b-3p; +MIMAT0009202 aga-miR-2; +MIMAT0009203 hsa-miR-449b*;hsa-miR-449b-3p; +MIMAT0009204 ebv-miR-BART4*;ebv-miR-BART4-3p; +MIMAT0009205 ebv-miR-BART5*;ebv-miR-BART5-3p; +MIMAT0009206 hsa-miR-2113; +MIMAT0009207 mdv1-miR-M3*;mdv1-miR-M3-3p; +MIMAT0009208 osa-miR1429-5p; +MIMAT0009209 mdv1-miR-M12*;mdv1-miR-M12-5p; +MIMAT0009210 osa-miR1850.2; +MIMAT0009211 osa-miR1850.3; +MIMAT0009212 osa-miR1866-3p; +MIMAT0009213 bra-miR1885;bra-miR1885a; +MIMAT0009214 bta-miR-1; +MIMAT0009215 bta-miR-100; +MIMAT0009216 bta-miR-105b; +MIMAT0009217 bta-miR-105a; +MIMAT0009218 bta-miR-106b; +MIMAT0009219 bta-miR-104; +MIMAT0009220 bta-miR-129; +MIMAT0009221 bta-miR-129-5p; +MIMAT0009222 bta-miR-129-3p; +MIMAT0009223 bta-miR-130a; +MIMAT0009224 bta-miR-130b; +MIMAT0009225 bta-miR-133a; +MIMAT0009226 bta-miR-133b; +MIMAT0009227 bta-miR-134; +MIMAT0009228 bta-miR-135a; +MIMAT0009229 bta-miR-135b; +MIMAT0009230 bta-miR-136; +MIMAT0009231 bta-miR-137; +MIMAT0009232 bta-miR-141; +MIMAT0009233 bta-miR-143; +MIMAT0009234 bta-miR-144; +MIMAT0009235 bta-miR-146b; +MIMAT0009236 bta-miR-146a; +MIMAT0009237 bta-miR-147; +MIMAT0009238 bta-miR-152; +MIMAT0009239 bta-miR-153; +MIMAT0009240 bta-miR-154;bta-miR-154a; +MIMAT0009241 bta-miR-155; +MIMAT0009242 bta-miR-16a; +MIMAT0009243 bta-miR-181d; +MIMAT0009244 bta-miR-182; +MIMAT0009245 bta-miR-183; +MIMAT0009246 bta-miR-184; +MIMAT0009247 bta-miR-185; +MIMAT0009248 bta-miR-187; +MIMAT0009249 bta-miR-188; +MIMAT0009250 bta-miR-24; +MIMAT0009251 bta-miR-190a; +MIMAT0009252 bta-miR-190b; +MIMAT0009253 bta-miR-193b; +MIMAT0009254 bta-miR-194; +MIMAT0009255 bta-miR-196a; +MIMAT0009256 bta-miR-196b; +MIMAT0009257 bta-miR-197; +MIMAT0009259 bta-miR-202; +MIMAT0009260 bta-miR-206; +MIMAT0009261 bta-miR-208a; +MIMAT0009262 bta-miR-208b; +MIMAT0009263 bta-miR-211; +MIMAT0009264 bta-miR-212; +MIMAT0009265 bta-miR-216a; +MIMAT0009266 bta-miR-216b; +MIMAT0009267 bta-miR-217; +MIMAT0009268 bta-miR-218a; +MIMAT0009269 bta-miR-219;bta-miR-219-5p; +MIMAT0009270 bta-miR-223; +MIMAT0009271 bta-miR-224; +MIMAT0009272 bta-miR-28; +MIMAT0009273 bta-miR-296;bta-miR-296-3p; +MIMAT0009274 bta-miR-299; +MIMAT0009275 bta-miR-29d;bta-miR-29d-3p; +MIMAT0009276 bta-miR-301a; +MIMAT0009277 bta-miR-301b; +MIMAT0009278 bta-miR-302a; +MIMAT0009279 bta-miR-302d; +MIMAT0009280 bta-miR-302b; +MIMAT0009281 bta-miR-302c; +MIMAT0009282 bta-miR-30f; +MIMAT0009283 bta-miR-32; +MIMAT0009284 bta-miR-323; +MIMAT0009285 bta-miR-324; +MIMAT0009286 bta-miR-326; +MIMAT0009287 bta-miR-328; +MIMAT0009288 bta-miR-329a; +MIMAT0009289 bta-miR-329b; +MIMAT0009290 bta-miR-330; +MIMAT0009291 bta-miR-335; +MIMAT0009292 bta-miR-338; +MIMAT0009293 bta-miR-339;bta-miR-339a; +MIMAT0009294 bta-miR-33a; +MIMAT0009295 bta-miR-33b; +MIMAT0009296 bta-miR-340; +MIMAT0009297 bta-miR-346; +MIMAT0009298 bta-miR-362;bta-miR-362-5p; +MIMAT0009299 bta-miR-367; +MIMAT0009300 bta-miR-370; +MIMAT0009301 bta-miR-292;bta-miR-371; +MIMAT0009302 bta-miR-374b; +MIMAT0009303 bta-miR-375; +MIMAT0009304 bta-miR-377; +MIMAT0009305 bta-miR-378; +MIMAT0009306 bta-miR-379; +MIMAT0009307 bta-miR-381; +MIMAT0009308 bta-miR-382; +MIMAT0009309 bta-miR-383; +MIMAT0009310 bta-miR-409;bta-miR-409a; +MIMAT0009311 bta-miR-410; +MIMAT0009312 bta-miR-411;bta-miR-411a; +MIMAT0009313 bta-miR-412; +MIMAT0009314 bta-miR-421; +MIMAT0009315 bta-miR-429; +MIMAT0009316 bta-miR-431; +MIMAT0009317 bta-miR-432; +MIMAT0009318 bta-miR-433; +MIMAT0009319 bta-miR-448; +MIMAT0009320 bta-miR-449a; +MIMAT0009321 bta-miR-449b; +MIMAT0009322 bta-miR-449c; +MIMAT0009323 bta-miR-451; +MIMAT0009324 bta-miR-452; +MIMAT0009325 bta-miR-453; +MIMAT0009326 bta-miR-454; +MIMAT0009327 bta-miR-483; +MIMAT0009328 bta-miR-485; +MIMAT0009329 bta-miR-486; +MIMAT0009330 bta-miR-488; +MIMAT0009331 bta-miR-490; +MIMAT0009332 bta-miR-491; +MIMAT0009333 bta-miR-493; +MIMAT0009334 bta-miR-494; +MIMAT0009335 bta-miR-495; +MIMAT0009336 bta-miR-496; +MIMAT0009337 bta-miR-500; +MIMAT0009338 bta-miR-502a; +MIMAT0009339 bta-miR-502b; +MIMAT0009340 bta-miR-504; +MIMAT0009341 bta-miR-505; +MIMAT0009342 bta-miR-539; +MIMAT0009343 bta-miR-541; +MIMAT0009344 bta-miR-543; +MIMAT0009345 bta-miR-544b; +MIMAT0009346 bta-miR-544a; +MIMAT0009347 bta-miR-551a; +MIMAT0009348 bta-miR-551b; +MIMAT0009349 bta-miR-562; +MIMAT0009350 bta-miR-568; +MIMAT0009351 bta-miR-582; +MIMAT0009352 bta-miR-584; +MIMAT0009353 bta-miR-592; +MIMAT0009354 bta-miR-599; +MIMAT0009355 bta-miR-615; +MIMAT0009356 bta-miR-628; +MIMAT0009357 bta-miR-631; +MIMAT0009358 bta-miR-653; +MIMAT0009359 bta-miR-654; +MIMAT0009360 bta-miR-655; +MIMAT0009361 bta-miR-656; +MIMAT0009362 bta-miR-658; +MIMAT0009363 bta-miR-665; +MIMAT0009364 bta-miR-670; +MIMAT0009365 bta-miR-671; +MIMAT0009366 bta-miR-685; +MIMAT0009367 bta-miR-708; +MIMAT0009369 bta-miR-744; +MIMAT0009370 bta-miR-758; +MIMAT0009371 bta-miR-759; +MIMAT0009372 bta-miR-760;bta-miR-760-5p; +MIMAT0009373 bta-miR-761; +MIMAT0009374 bta-miR-763; +MIMAT0009375 bta-miR-767; +MIMAT0009376 bta-miR-769; +MIMAT0009377 bta-miR-873; +MIMAT0009378 bta-miR-874; +MIMAT0009379 bta-miR-875; +MIMAT0009380 bta-miR-876; +MIMAT0009381 bta-miR-877; +MIMAT0009382 bta-miR-885; +MIMAT0009383 bta-miR-92a; +MIMAT0009384 bta-miR-92b; +MIMAT0009385 bta-miR-935; +MIMAT0009386 bta-miR-940; +MIMAT0009387 bta-miR-95; +MIMAT0009388 bta-miR-96; +MIMAT0009389 bta-miR-9;bta-miR-9-5p; +MIMAT0009390 mmu-miR-1927; +MIMAT0009391 mmu-miR-1928; +MIMAT0009392 mmu-miR-1929;mmu-miR-1929-5p; +MIMAT0009393 mmu-miR-1930;mmu-miR-1930-5p; +MIMAT0009394 mmu-miR-1931; +MIMAT0009395 mmu-miR-1932; +MIMAT0009396 mmu-miR-1933-5p; +MIMAT0009397 mmu-miR-1933-3p; +MIMAT0009398 mmu-miR-1934;mmu-miR-1934-5p; +MIMAT0009399 mmu-miR-1935; +MIMAT0009400 mmu-miR-1936; +MIMAT0009401 mmu-miR-1937a; +MIMAT0009402 mmu-miR-1938; +MIMAT0009403 mmu-miR-1939; +MIMAT0009404 mmu-miR-1940; +MIMAT0009405 mmu-miR-1941-5p; +MIMAT0009406 mmu-miR-1941-3p; +MIMAT0009407 mmu-miR-1942; +MIMAT0009408 mmu-miR-1943;mmu-miR-1943-5p; +MIMAT0009409 mmu-miR-1944; +MIMAT0009410 mmu-miR-1945; +MIMAT0009411 mmu-miR-1306;mmu-miR-1306-3p; +MIMAT0009412 mmu-miR-1946a; +MIMAT0009413 mmu-miR-1947;mmu-miR-1947-5p; +MIMAT0009414 mmu-miR-1937b; +MIMAT0009415 mmu-miR-1948;mmu-miR-1948-3p; +MIMAT0009416 mmu-miR-1949; +MIMAT0009417 mmu-miR-1950; +MIMAT0009418 mmu-miR-669l;mmu-miR-669l-5p; +MIMAT0009419 mmu-miR-669m;mmu-miR-669m-3p; +MIMAT0009421 mmu-miR-669o;mmu-miR-669o-5p; +MIMAT0009422 mmu-miR-1951; +MIMAT0009423 mmu-miR-1952; +MIMAT0009424 mmu-miR-1953; +MIMAT0009425 mmu-miR-1954; +MIMAT0009426 mmu-miR-1955;mmu-miR-1955-5p; +MIMAT0009427 mmu-miR-669n; +MIMAT0009428 mmu-miR-1956; +MIMAT0009429 mmu-miR-1937c; +MIMAT0009430 mmu-miR-1957;mmu-miR-1957a; +MIMAT0009431 mmu-miR-1958; +MIMAT0009432 mmu-miR-1959; +MIMAT0009433 mmu-miR-1960; +MIMAT0009434 mmu-miR-1961; +MIMAT0009435 mmu-miR-1962; +MIMAT0009436 mmu-miR-1963; +MIMAT0009437 mmu-miR-1964;mmu-miR-1964-3p; +MIMAT0009438 mmu-miR-1965; +MIMAT0009439 mmu-miR-1966;mmu-miR-1966-5p; +MIMAT0009440 mmu-miR-1967; +MIMAT0009441 mmu-miR-1968;mmu-miR-1968-5p; +MIMAT0009442 mmu-miR-1969; +MIMAT0009443 mmu-miR-1946b; +MIMAT0009444 mmu-miR-1970; +MIMAT0009445 mmu-miR-1274a; +MIMAT0009446 mmu-miR-1971; +MIMAT0009447 hsa-miR-1972; +MIMAT0009448 hsa-miR-1973; +MIMAT0009449 hsa-miR-1974; +MIMAT0009450 hsa-miR-1975; +MIMAT0009451 hsa-miR-1976; +MIMAT0009452 hsa-miR-1977; +MIMAT0009453 hsa-miR-1978; +MIMAT0009454 hsa-miR-1979; +MIMAT0009455 mmu-miR-1983; +MIMAT0009456 mmu-miR-1839-5p; +MIMAT0009457 mmu-miR-1839-3p; +MIMAT0009458 mmu-miR-1981;mmu-miR-1981-5p; +MIMAT0009459 mmu-miR-1982*;mmu-miR-1982-5p; +MIMAT0009460 mmu-miR-1982.1;mmu-miR-1982.1-3p;mmu-miR-1982-3p; +MIMAT0009461 mmu-miR-1982.2;mmu-miR-1982.2-3p; +MIMAT0009462 bfl-let-7;bfl-let-7a;bfl-let-7a-5p; +MIMAT0009463 bfl-miR-1;bfl-miR-1-3p; +MIMAT0009464 bfl-miR-7; +MIMAT0009465 bfl-miR-9;bfl-miR-9-5p; +MIMAT0009466 bfl-miR-10a;bfl-miR-10a-5p; +MIMAT0009467 bfl-miR-10a*;bfl-miR-10a-3p; +MIMAT0009468 bfl-miR-10b; +MIMAT0009469 bfl-miR-10c; +MIMAT0009470 bfl-miR-22;bfl-miR-22-3p; +MIMAT0009471 bfl-miR-29a;bfl-miR-29a-3p; +MIMAT0009472 bfl-miR-29b;bfl-miR-29b-3p; +MIMAT0009473 bfl-miR-31;bfl-miR-31-5p; +MIMAT0009474 bfl-miR-33; +MIMAT0009475 bfl-miR-34;bfl-miR-34a; +MIMAT0009476 bfl-miR-71;bfl-miR-71-5p; +MIMAT0009477 bfl-miR-79;bfl-miR-9-3p; +MIMAT0009478 bfl-miR-92a; +MIMAT0009479 bfl-miR-92b;bfl-miR-92b-3p; +MIMAT0009480 bfl-miR-96;bfl-miR-96-5p; +MIMAT0009481 bfl-miR-100;bfl-miR-100-5p; +MIMAT0009482 bfl-miR-124;bfl-miR-124-3p; +MIMAT0009483 bfl-miR-125;bfl-miR-125a;bfl-miR-125a-5p; +MIMAT0009484 bfl-miR-133; +MIMAT0009485 bfl-miR-137; +MIMAT0009486 bfl-miR-182;bfl-miR-182a; +MIMAT0009487 bfl-miR-183; +MIMAT0009488 bfl-miR-184;bfl-miR-184-3p; +MIMAT0009489 bfl-miR-190; +MIMAT0009490 bfl-miR-193;bfl-miR-193a; +MIMAT0009491 bfl-miR-200a; +MIMAT0009492 bfl-miR-200b; +MIMAT0009493 bfl-miR-200c; +MIMAT0009494 bfl-miR-210;bfl-miR-210-3p; +MIMAT0009495 bfl-miR-216;bfl-miR-216-5p; +MIMAT0009496 bfl-miR-217; +MIMAT0009497 bfl-miR-242; +MIMAT0009498 bfl-miR-252a; +MIMAT0009499 bfl-miR-252b;bfl-miR-252b-5p; +MIMAT0009500 bfl-miR-281; +MIMAT0009501 bfl-miR-375; +MIMAT0009502 cap-miR-1;cte-miR-1; +MIMAT0009503 cap-miR-2a;cte-miR-2a; +MIMAT0009504 cap-miR-2b;cte-miR-2b; +MIMAT0009505 cap-miR-2c;cte-miR-2c; +MIMAT0009506 cap-miR-7;cte-miR-7; +MIMAT0009507 cap-miR-8;cte-miR-8; +MIMAT0009508 cap-miR-9;cte-miR-9;cte-miR-9-5p; +MIMAT0009509 cap-miR-10a;cte-miR-10a; +MIMAT0009510 cap-miR-10b;cte-miR-10b; +MIMAT0009511 cap-miR-10c;cte-miR-10c; +MIMAT0009512 cap-miR-12;cte-miR-12; +MIMAT0009513 cap-miR-29a;cte-miR-29a; +MIMAT0009514 cap-miR-29b;cte-miR-29b; +MIMAT0009515 cap-miR-31;cte-miR-31; +MIMAT0009516 cap-miR-34;cte-miR-34; +MIMAT0009517 cap-miR-71;cte-miR-71; +MIMAT0009518 cap-miR-87a;cte-miR-87a; +MIMAT0009519 cap-miR-87b;cte-miR-87b; +MIMAT0009520 cap-miR-92a;cte-miR-92a; +MIMAT0009521 cap-miR-92b;cte-miR-92b; +MIMAT0009522 cap-miR-92c;cte-miR-92c; +MIMAT0009523 cap-miR-96;cte-miR-96; +MIMAT0009524 cap-miR-100;cte-miR-100; +MIMAT0009525 cap-miR-125;cte-miR-125; +MIMAT0009526 cap-miR-133;cte-miR-133; +MIMAT0009527 cap-miR-137;cte-miR-137; +MIMAT0009528 cap-miR-153;cte-miR-153; +MIMAT0009529 cap-miR-182;cte-miR-182;cte-miR-263; +MIMAT0009530 cap-miR-184a;cte-miR-184a; +MIMAT0009531 cap-miR-184b;cte-miR-184b; +MIMAT0009532 cap-miR-190;cte-miR-190; +MIMAT0009533 cap-miR-193;cte-miR-193; +MIMAT0009534 cap-miR-210;cte-miR-210;cte-miR-210a; +MIMAT0009535 cap-miR-216a;cte-miR-216a; +MIMAT0009536 cap-miR-252a;cte-miR-252a; +MIMAT0009537 cap-miR-252b;cte-miR-252b; +MIMAT0009538 cap-miR-278;cte-miR-278; +MIMAT0009539 cap-miR-279;cte-miR-279; +MIMAT0009540 cap-miR-281;cte-miR-281; +MIMAT0009541 cap-miR-315;cte-miR-315; +MIMAT0009542 cap-miR-317;cte-miR-317; +MIMAT0009543 cap-miR-365;cte-miR-365; +MIMAT0009544 cap-miR-375;cte-miR-375; +MIMAT0009545 cap-miR-745a;cte-miR-745a; +MIMAT0009546 cap-miR-745b;cte-miR-745b; +MIMAT0009547 cap-miR-750;cte-miR-750; +MIMAT0009548 cap-miR-981;cte-miR-981; +MIMAT0009549 cap-miR-1175*;cte-miR-1175*;cte-miR-1175-5p; +MIMAT0009550 cap-miR-1175;cte-miR-1175;cte-miR-1175-3p; +MIMAT0009551 cap-bantam;cte-bantam; +MIMAT0009552 cap-let-7;cte-let-7; +MIMAT0009553 cap-miR-33;cte-miR-33; +MIMAT0009554 cap-miR-79;cte-miR-79;cte-miR-9-3p; +MIMAT0009555 cap-miR-124;cte-miR-124; +MIMAT0009556 cap-miR-219;cte-miR-219; +MIMAT0009557 lgi-miR-1; +MIMAT0009558 lgi-miR-2c; +MIMAT0009559 lgi-miR-2d; +MIMAT0009560 lgi-miR-7; +MIMAT0009561 lgi-miR-8; +MIMAT0009562 lgi-miR-9;lgi-miR-9-5p; +MIMAT0009563 lgi-miR-10; +MIMAT0009564 lgi-miR-12; +MIMAT0009565 lgi-miR-29; +MIMAT0009566 lgi-miR-31; +MIMAT0009567 lgi-miR-33;lgi-miR-33-5p; +MIMAT0009568 lgi-miR-33*;lgi-miR-33-3p; +MIMAT0009569 lgi-miR-34; +MIMAT0009570 lgi-miR-67; +MIMAT0009571 lgi-miR-71; +MIMAT0009572 lgi-miR-79;lgi-miR-9-3p; +MIMAT0009573 lgi-miR-87; +MIMAT0009574 lgi-miR-92; +MIMAT0009575 lgi-miR-96a; +MIMAT0009576 lgi-miR-96b; +MIMAT0009577 lgi-miR-100; +MIMAT0009578 lgi-miR-124; +MIMAT0009579 lgi-miR-133*;lgi-miR-133-5p; +MIMAT0009580 lgi-miR-133;lgi-miR-133-3p; +MIMAT0009581 lgi-miR-137; +MIMAT0009582 lgi-miR-153; +MIMAT0009583 lgi-miR-182;lgi-miR-263a; +MIMAT0009584 lgi-miR-183;lgi-miR-263b; +MIMAT0009585 lgi-miR-184; +MIMAT0009586 lgi-miR-190; +MIMAT0009587 lgi-miR-193; +MIMAT0009588 lgi-miR-216a; +MIMAT0009589 lgi-miR-216b; +MIMAT0009590 lgi-miR-242;lgi-miR-242a; +MIMAT0009591 lgi-miR-252;lgi-miR-252a; +MIMAT0009592 lgi-miR-278; +MIMAT0009593 lgi-miR-279; +MIMAT0009594 lgi-miR-281*;lgi-miR-281-5p; +MIMAT0009595 lgi-miR-281;lgi-miR-281-3p; +MIMAT0009596 lgi-miR-315; +MIMAT0009597 lgi-miR-317; +MIMAT0009598 lgi-miR-745a; +MIMAT0009599 lgi-miR-745b; +MIMAT0009600 lgi-miR-750; +MIMAT0009601 lgi-miR-981; +MIMAT0009602 lgi-miR-1175*;lgi-miR-1175-5p; +MIMAT0009603 lgi-miR-1175;lgi-miR-1175-3p; +MIMAT0009604 lgi-let-7; +MIMAT0009605 nve-miR-100;nve-miR-100-5p; +MIMAT0009606 nve-miR-100*;nve-miR-100-3p; +MIMAT0009607 sko-miR-1;sko-miR-1-3p; +MIMAT0009608 sko-miR-7;sko-miR-7-5p; +MIMAT0009609 sko-miR-200; +MIMAT0009610 sko-miR-9;sko-miR-9-5p; +MIMAT0009611 sko-miR-10; +MIMAT0009612 sko-miR-29a; +MIMAT0009613 sko-miR-29b;sko-miR-29b-3p; +MIMAT0009614 sko-miR-31; +MIMAT0009615 sko-miR-33*;sko-miR-33-3p; +MIMAT0009616 sko-miR-34;sko-miR-34-5p; +MIMAT0009617 sko-miR-71; +MIMAT0009618 sko-miR-79;sko-miR-9-3p; +MIMAT0009619 sko-miR-92a; +MIMAT0009620 sko-miR-92b; +MIMAT0009621 sko-miR-92c; +MIMAT0009622 sko-miR-96;sko-miR-96-5p; +MIMAT0009623 sko-miR-100; +MIMAT0009624 sko-miR-124*;sko-miR-124-5p; +MIMAT0009625 sko-miR-124;sko-miR-124-3p; +MIMAT0009626 sko-miR-125;sko-miR-125a; +MIMAT0009627 sko-miR-133; +MIMAT0009628 sko-miR-137; +MIMAT0009629 sko-miR-153; +MIMAT0009630 sko-miR-182; +MIMAT0009631 sko-miR-183; +MIMAT0009632 sko-miR-184*;sko-miR-184-5p; +MIMAT0009633 sko-miR-184;sko-miR-184-3p; +MIMAT0009634 sko-miR-190; +MIMAT0009635 sko-miR-193;sko-miR-193a;sko-miR-193a-3p; +MIMAT0009636 sko-miR-210;sko-miR-210-3p; +MIMAT0009637 sko-miR-242; +MIMAT0009638 sko-miR-252a; +MIMAT0009639 sko-miR-252b; +MIMAT0009640 sko-miR-278; +MIMAT0009641 sko-miR-281; +MIMAT0009642 sko-miR-315; +MIMAT0009643 sko-miR-365;sko-miR-365-3p; +MIMAT0009644 sko-let-7; +MIMAT0009645 spu-miR-137; +MIMAT0009646 spu-miR-210; +MIMAT0009647 spu-miR-242; +MIMAT0009648 spu-miR-375; +MIMAT0009649 spu-let-7; +MIMAT0009650 spu-miR-1; +MIMAT0009651 spu-miR-7; +MIMAT0009652 spu-miR-200;spu-miR-200-3p; +MIMAT0009653 spu-miR-9;spu-miR-9-5p; +MIMAT0009654 spu-miR-10; +MIMAT0009655 spu-miR-22; +MIMAT0009656 spu-miR-29;spu-miR-29a; +MIMAT0009657 spu-miR-31; +MIMAT0009658 spu-miR-33; +MIMAT0009659 spu-miR-34; +MIMAT0009660 spu-miR-71; +MIMAT0009661 spu-miR-79;spu-miR-9-3p; +MIMAT0009662 spu-miR-92a; +MIMAT0009663 spu-miR-92b;spu-miR-92b-3p; +MIMAT0009664 spu-miR-92c; +MIMAT0009665 spu-miR-96; +MIMAT0009666 spu-miR-124; +MIMAT0009667 spu-miR-125;spu-miR-125-5p; +MIMAT0009668 spu-miR-133; +MIMAT0009669 spu-miR-153;spu-miR-153-3p; +MIMAT0009670 spu-miR-182; +MIMAT0009671 spu-miR-184; +MIMAT0009672 spu-miR-252a; +MIMAT0009673 spu-miR-252b; +MIMAT0009674 spu-miR-278;spu-miR-278-3p; +MIMAT0009675 cap-miR-67;cte-miR-67; +MIMAT0009676 lgi-miR-375; +MIMAT0009677 sko-miR-193b; +MIMAT0009678 cap-miR-2d;cte-miR-2d; +MIMAT0009679 cap-miR-216b;cte-miR-216b; +MIMAT0009680 cap-miR-242;cte-miR-242; +MIMAT0009681 lgi-miR-242b; +MIMAT0009682 lgi-miR-252b; +MIMAT0009683 sko-miR-375; +MIMAT0009684 spu-miR-183; +MIMAT0009685 spu-miR-219;spu-miR-219-5p; +MIMAT0009686 aqu-miR-2014*;aqu-miR-2014-5p; +MIMAT0009687 aqu-miR-2014;aqu-miR-2014-3p; +MIMAT0009688 aqu-miR-2015*;aqu-miR-2015-5p; +MIMAT0009689 aqu-miR-2015;aqu-miR-2015-3p; +MIMAT0009690 aqu-miR-2016;aqu-miR-2016-5p; +MIMAT0009691 aqu-miR-2016*;aqu-miR-2016-3p; +MIMAT0009692 aqu-miR-2017*;aqu-miR-2017-5p; +MIMAT0009693 aqu-miR-2017;aqu-miR-2017-3p; +MIMAT0009694 aqu-miR-2018;aqu-miR-2018-5p; +MIMAT0009695 aqu-miR-2018*;aqu-miR-2018-3p; +MIMAT0009696 aqu-miR-2019;aqu-miR-2019-5p; +MIMAT0009697 aqu-miR-2019*;aqu-miR-2019-3p; +MIMAT0009698 aqu-miR-2020;aqu-miR-2020-5p; +MIMAT0009699 aqu-miR-2020*;aqu-miR-2020-3p; +MIMAT0009700 cap-miR-1992;cte-miR-1992; +MIMAT0009701 cap-miR-1993;cte-miR-1993; +MIMAT0009702 cap-miR-1994;cte-miR-1994; +MIMAT0009703 cap-miR-1987;cte-miR-1987; +MIMAT0009704 cap-miR-1989;cte-miR-1989; +MIMAT0009705 cap-miR-2001;cte-miR-2001; +MIMAT0009706 cap-miR-1995;cte-miR-1995; +MIMAT0009707 cap-miR-1996a;cte-miR-1996a; +MIMAT0009708 cap-miR-1997;cte-miR-1997; +MIMAT0009709 cap-miR-1998;cte-miR-1998; +MIMAT0009710 cap-miR-1999;cte-miR-1999; +MIMAT0009711 cap-miR-2000;cte-miR-2000; +MIMAT0009712 cap-miR-1996b;cte-miR-1996b; +MIMAT0009713 cla-miR-1992; +MIMAT0009714 cla-miR-1994; +MIMAT0009715 hru-miR-1984; +MIMAT0009716 hru-miR-1985; +MIMAT0009717 hru-miR-1986; +MIMAT0009718 hru-miR-1990; +MIMAT0009719 hru-miR-1991; +MIMAT0009720 hma-miR-2022; +MIMAT0009721 isc-miR-2001; +MIMAT0009722 lgi-miR-1992; +MIMAT0009723 lgi-miR-1993; +MIMAT0009724 lgi-miR-1994a; +MIMAT0009725 lgi-miR-1994b; +MIMAT0009726 lgi-miR-1984; +MIMAT0009727 lgi-miR-1985; +MIMAT0009728 lgi-miR-1986; +MIMAT0009729 lgi-miR-1988; +MIMAT0009730 lgi-miR-1989; +MIMAT0009731 lgi-miR-2001; +MIMAT0009732 lgi-miR-1990; +MIMAT0009733 lgi-miR-1991; +MIMAT0009734 nve-miR-2022;nve-miR-2022-3p; +MIMAT0009735 sko-miR-2001; +MIMAT0009736 sko-miR-2012;sko-miR-2012-5p; +MIMAT0009737 sko-miR-2013; +MIMAT0009738 sko-miR-2008; +MIMAT0009739 sko-miR-2011; +MIMAT0009740 spu-miR-2001; +MIMAT0009741 spu-miR-2012; +MIMAT0009742 spu-miR-2013; +MIMAT0009743 spu-miR-2002;spu-miR-2002-3p; +MIMAT0009744 spu-miR-2003;spu-miR-2003-5p; +MIMAT0009745 spu-miR-2004; +MIMAT0009746 spu-miR-2005; +MIMAT0009747 spu-miR-2006; +MIMAT0009748 spu-miR-2007; +MIMAT0009749 spu-miR-2008; +MIMAT0009750 spu-miR-2009; +MIMAT0009751 spu-miR-2010; +MIMAT0009752 spu-miR-2011; +MIMAT0009753 aqu-miR-2021*;aqu-miR-2021-5p; +MIMAT0009754 aqu-miR-2021;aqu-miR-2021-3p; +MIMAT0009755 nve-miR-2023*;nve-miR-2023-5p; +MIMAT0009756 nve-miR-2023;nve-miR-2023-3p; +MIMAT0009757 nve-miR-2024a*;nve-miR-2024a-5p; +MIMAT0009758 nve-miR-2024a;nve-miR-2024a-3p; +MIMAT0009759 nve-miR-2025*;nve-miR-2025-5p; +MIMAT0009760 nve-miR-2025;nve-miR-2025-3p; +MIMAT0009761 nve-miR-2024b*;nve-miR-2024b-5p; +MIMAT0009762 nve-miR-2024b;nve-miR-2024b-3p; +MIMAT0009763 nve-miR-2024c*;nve-miR-2024c-5p; +MIMAT0009764 nve-miR-2024c;nve-miR-2024c-3p; +MIMAT0009765 nve-miR-2024d; +MIMAT0009766 nve-miR-2024e*;nve-miR-2024e-5p; +MIMAT0009767 nve-miR-2024e;nve-miR-2024e-3p; +MIMAT0009768 nve-miR-2024f*;nve-miR-2024f-5p; +MIMAT0009769 nve-miR-2024f;nve-miR-2024f-3p; +MIMAT0009770 nve-miR-2026;nve-miR-2026-5p; +MIMAT0009771 nve-miR-2026*;nve-miR-2026-3p; +MIMAT0009772 nve-miR-2027*;nve-miR-2027-5p; +MIMAT0009773 nve-miR-2027;nve-miR-2027-3p; +MIMAT0009774 nve-miR-2024g*;nve-miR-2024g-5p; +MIMAT0009775 nve-miR-2024g;nve-miR-2024g-3p; +MIMAT0009776 nve-miR-2028;nve-miR-2028-5p; +MIMAT0009777 nve-miR-2028*;nve-miR-2028-3p; +MIMAT0009778 nve-miR-2029;nve-miR-2029-5p; +MIMAT0009779 nve-miR-2029*;nve-miR-2029-3p; +MIMAT0009780 nve-miR-2030;nve-miR-2030-5p; +MIMAT0009781 nve-miR-2030*;nve-miR-2030-3p; +MIMAT0009782 nve-miR-2031;nve-miR-2031-5p; +MIMAT0009783 nve-miR-2031*;nve-miR-2031-3p; +MIMAT0009784 nve-miR-2032a;nve-miR-2032a-5p; +MIMAT0009785 nve-miR-2032a*;nve-miR-2032a-3p; +MIMAT0009786 nve-miR-2032b;nve-miR-2032b-5p; +MIMAT0009787 nve-miR-2032b*;nve-miR-2032b-3p; +MIMAT0009788 nve-miR-2033;nve-miR-2033-5p; +MIMAT0009789 nve-miR-2033*;nve-miR-2033-3p; +MIMAT0009790 nve-miR-2034*;nve-miR-2034-5p; +MIMAT0009791 nve-miR-2034;nve-miR-2034-3p; +MIMAT0009792 nve-miR-2035;nve-miR-2035-5p; +MIMAT0009793 nve-miR-2035*;nve-miR-2035-3p; +MIMAT0009794 nve-miR-2036*;nve-miR-2036-5p; +MIMAT0009795 nve-miR-2036;nve-miR-2036-3p; +MIMAT0009796 nve-miR-2037*;nve-miR-2037-5p; +MIMAT0009797 nve-miR-2037;nve-miR-2037-3p; +MIMAT0009798 nve-miR-2038*;nve-miR-2038-5p; +MIMAT0009799 nve-miR-2038;nve-miR-2038-3p; +MIMAT0009800 nve-miR-2039*;nve-miR-2039-5p; +MIMAT0009801 nve-miR-2039;nve-miR-2039-3p; +MIMAT0009802 nve-miR-2040a*;nve-miR-2040a-5p; +MIMAT0009803 nve-miR-2040a;nve-miR-2040a-3p; +MIMAT0009804 nve-miR-2041*;nve-miR-2041-5p;nve-miR-2041a-5p; +MIMAT0009805 nve-miR-2041;nve-miR-2041-3p;nve-miR-2041a-3p; +MIMAT0009806 nve-miR-2042;nve-miR-2042-5p; +MIMAT0009807 nve-miR-2042*;nve-miR-2042-3p; +MIMAT0009808 nve-miR-2040b*;nve-miR-2040b-5p; +MIMAT0009809 nve-miR-2040b;nve-miR-2040b-3p; +MIMAT0009810 nve-miR-2043a*;nve-miR-2043a-5p;nve-miR-2043-5p; +MIMAT0009811 nve-miR-2043a;nve-miR-2043a-3p;nve-miR-2043-3p; +MIMAT0009812 nve-miR-2044*;nve-miR-2044-5p; +MIMAT0009813 nve-miR-2044;nve-miR-2044-3p; +MIMAT0009814 nve-miR-2045;nve-miR-2045-5p; +MIMAT0009815 nve-miR-2045*;nve-miR-2045-3p; +MIMAT0009816 nve-miR-2046;nve-miR-2046-5p; +MIMAT0009817 nve-miR-2046*;nve-miR-2046-3p; +MIMAT0009818 nve-miR-2047;nve-miR-2047-5p; +MIMAT0009819 nve-miR-2047*;nve-miR-2047-3p; +MIMAT0009820 nve-miR-2048*;nve-miR-2048-5p; +MIMAT0009821 nve-miR-2048;nve-miR-2048-3p; +MIMAT0009822 nve-miR-2049;nve-miR-2049-5p; +MIMAT0009823 nve-miR-2049*;nve-miR-2049-3p; +MIMAT0009824 nve-miR-2050*;nve-miR-2050-5p; +MIMAT0009825 nve-miR-2050;nve-miR-2050-3p; +MIMAT0009826 nve-miR-2043b*;nve-miR-2043b-5p; +MIMAT0009827 nve-miR-2043b;nve-miR-2043b-3p;nve-miR-2043-2-3p; +MIMAT0009828 nve-miR-2051*;nve-miR-2051-5p; +MIMAT0009829 nve-miR-2051;nve-miR-2051-3p; +MIMAT0009830 cfa-miR-20b; +MIMAT0009831 cfa-miR-18b; +MIMAT0009832 cfa-miR-18a; +MIMAT0009833 cfa-miR-133c; +MIMAT0009834 cfa-miR-133a; +MIMAT0009835 cfa-miR-133b; +MIMAT0009836 cfa-let-7b; +MIMAT0009837 cfa-miR-10b; +MIMAT0009838 cfa-miR-34b; +MIMAT0009839 cfa-miR-135b; +MIMAT0009840 cfa-miR-153; +MIMAT0009841 cfa-miR-182; +MIMAT0009842 cfa-miR-184; +MIMAT0009843 cfa-miR-187; +MIMAT0009844 cfa-miR-202; +MIMAT0009845 cfa-miR-205; +MIMAT0009846 cfa-miR-210; +MIMAT0009847 cfa-miR-214; +MIMAT0009848 cfa-miR-215; +MIMAT0009849 cfa-miR-216a; +MIMAT0009850 cfa-miR-217; +MIMAT0009851 cfa-miR-222; +MIMAT0009852 cfa-miR-223; +MIMAT0009853 cfa-miR-301a; +MIMAT0009854 cfa-miR-301b; +MIMAT0009855 cfa-miR-302a; +MIMAT0009856 cfa-miR-302b; +MIMAT0009857 cfa-miR-302c; +MIMAT0009858 cfa-miR-302d; +MIMAT0009859 cfa-miR-367; +MIMAT0009860 cfa-miR-489; +MIMAT0009861 cfa-miR-96; +MIMAT0009862 cfa-miR-33b; +MIMAT0009863 cfa-miR-145; +MIMAT0009864 cfa-miR-200b; +MIMAT0009865 cfa-miR-200a; +MIMAT0009866 cfa-miR-203; +MIMAT0009867 cfa-miR-211; +MIMAT0009868 cfa-miR-208a; +MIMAT0009869 cfa-miR-208b; +MIMAT0009870 cfa-miR-451; +MIMAT0009871 cfa-miR-375; +MIMAT0009872 cfa-miR-190a; +MIMAT0009873 cfa-miR-190b; +MIMAT0009874 cfa-miR-147; +MIMAT0009875 cfa-miR-490; +MIMAT0009876 cfa-miR-141; +MIMAT0009877 cfa-miR-514; +MIMAT0009878 cfa-miR-95; +MIMAT0009879 cfa-miR-105a; +MIMAT0009880 cfa-miR-188; +MIMAT0009881 cfa-miR-220b; +MIMAT0009882 cfa-miR-220a; +MIMAT0009883 cfa-miR-134; +MIMAT0009884 cfa-miR-149; +MIMAT0009885 cfa-miR-299; +MIMAT0009886 cfa-miR-362; +MIMAT0009887 cfa-miR-376b; +MIMAT0009888 cfa-miR-376c; +MIMAT0009889 cfa-miR-370; +MIMAT0009890 cfa-miR-377; +MIMAT0009891 cfa-miR-381; +MIMAT0009892 cfa-miR-340; +MIMAT0009893 cfa-miR-330; +MIMAT0009894 cfa-miR-326; +MIMAT0009895 cfa-miR-331; +MIMAT0009896 cfa-miR-324; +MIMAT0009897 cfa-miR-325; +MIMAT0009898 cfa-miR-346; +MIMAT0009899 cfa-miR-329b; +MIMAT0009900 cfa-miR-452; +MIMAT0009901 cfa-miR-483; +MIMAT0009902 cfa-miR-487a; +MIMAT0009903 cfa-miR-488; +MIMAT0009904 cfa-miR-432; +MIMAT0009905 cfa-miR-494; +MIMAT0009906 cfa-miR-496; +MIMAT0009907 cfa-miR-504; +MIMAT0009908 cfa-miR-505; +MIMAT0009909 cfa-miR-539; +MIMAT0009910 cfa-miR-544; +MIMAT0009911 cfa-miR-545; +MIMAT0009912 cfa-miR-551a; +MIMAT0009913 cfa-miR-551b; +MIMAT0009914 cfa-miR-568; +MIMAT0009915 cfa-miR-578; +MIMAT0009916 cfa-miR-582; +MIMAT0009917 cfa-miR-589; +MIMAT0009918 cfa-miR-592; +MIMAT0009919 cfa-miR-599; +MIMAT0009920 cfa-miR-615; +MIMAT0009921 cfa-miR-628; +MIMAT0009922 cfa-miR-631; +MIMAT0009923 cfa-miR-632; +MIMAT0009924 cfa-miR-653; +MIMAT0009925 cfa-miR-758; +MIMAT0009926 cfa-miR-671; +MIMAT0009927 cfa-miR-454; +MIMAT0009928 cfa-miR-802; +MIMAT0009929 cfa-miR-300; +MIMAT0009930 cfa-miR-874; +MIMAT0009931 cfa-miR-875; +MIMAT0009932 cfa-miR-876; +MIMAT0009933 cfa-miR-885; +MIMAT0009934 cfa-miR-665; +MIMAT0009935 cfa-miR-207; +MIMAT0009936 cfa-miR-761; +MIMAT0009937 cfa-miR-764; +MIMAT0009938 cfa-miR-759; +MIMAT0009939 cfa-miR-718; +MIMAT0009940 cfa-miR-872; +MIMAT0009942 bta-miR-489; +MIMAT0009943 bta-miR-220d; +MIMAT0009944 bta-miR-1224; +MIMAT0009945 bta-miR-376b; +MIMAT0009946 bta-miR-376a; +MIMAT0009947 bta-miR-376c; +MIMAT0009948 bta-miR-764; +MIMAT0009949 bta-miR-220e; +MIMAT0009950 bta-miR-220c; +MIMAT0009951 bta-miR-220b; +MIMAT0009952 bta-miR-1225-3p; +MIMAT0009953 bta-miR-29e; +MIMAT0009954 bta-miR-1282; +MIMAT0009955 bta-miR-1284; +MIMAT0009956 bta-miR-1291; +MIMAT0009957 bta-miR-1179; +MIMAT0009958 bta-miR-1301; +MIMAT0009959 bta-miR-220a; +MIMAT0009960 bta-miR-1256; +MIMAT0009961 bta-miR-1835; +MIMAT0009962 bta-miR-1281; +MIMAT0009963 bta-miR-1251; +MIMAT0009964 bta-miR-1296; +MIMAT0009965 bta-miR-1193; +MIMAT0009966 bta-miR-1197; +MIMAT0009967 bta-miR-1300a; +MIMAT0009968 bta-miR-1839; +MIMAT0009969 bta-miR-1307; +MIMAT0009970 bta-miR-1298; +MIMAT0009971 bta-miR-1287; +MIMAT0009972 bta-miR-1248; +MIMAT0009973 bta-miR-1185; +MIMAT0009974 bta-miR-1306; +MIMAT0009975 bta-miR-1271; +MIMAT0009976 bta-miR-1249; +MIMAT0009977 hsa-miR-2052; +MIMAT0009978 hsa-miR-2053; +MIMAT0009979 hsa-miR-2054; +MIMAT0009980 osa-miR2055; +MIMAT0009981 osa-miR827a;osa-miR827; +MIMAT0009982 bfl-miR-2056; +MIMAT0009983 bfl-miR-2057; +MIMAT0009984 bfl-miR-2058;bfl-miR-2058-5p; +MIMAT0009985 bfl-miR-2059;bfl-miR-2059-3p; +MIMAT0009986 bfl-miR-2060; +MIMAT0009987 bfl-miR-2061; +MIMAT0009988 bfl-miR-2062;bfl-miR-2062-5p; +MIMAT0009989 bfl-miR-2063; +MIMAT0009990 bfl-miR-2064; +MIMAT0009991 bfl-miR-2013; +MIMAT0009992 bfl-miR-135a; +MIMAT0009993 bfl-miR-2065; +MIMAT0009994 bfl-miR-2066; +MIMAT0009995 bfl-miR-2067; +MIMAT0009996 bfl-miR-2068;bfl-miR-2068-5p; +MIMAT0009997 bfl-miR-2069; +MIMAT0009998 bfl-miR-2070;bfl-miR-2070-5p; +MIMAT0009999 bfl-miR-2071;bfl-miR-2071-3p; +MIMAT0010000 bfl-miR-2072;bfl-miR-2072-5p; +MIMAT0010001 bfl-miR-2073; +MIMAT0010002 bfl-miR-34b;bfl-miR-34b-3p; +MIMAT0010003 bfl-miR-2074; +MIMAT0010004 bfl-miR-2075; +MIMAT0010005 bfl-miR-2076;bfl-miR-2076-5p; +MIMAT0010006 bfl-let-7-1-as;bfl-let-7b; +MIMAT0010007 bfl-miR-125b-as;bfl-miR-125b; +MIMAT0010008 bfl-miR-129;bfl-miR-129a;bfl-miR-129a-5p; +MIMAT0010009 bfl-miR-129*;bfl-miR-129a-3p; +MIMAT0010010 bfl-miR-92c; +MIMAT0010011 bfl-miR-19*;bfl-miR-19-3p; +MIMAT0010012 bfl-miR-219; +MIMAT0010013 bfl-miR-705; +MIMAT0010014 ppt-miR2077; +MIMAT0010015 ppt-miR2078; +MIMAT0010016 ppt-miR2079; +MIMAT0010017 ppt-miR2080; +MIMAT0010018 ppt-miR2084; +MIMAT0010019 ppt-miR2085; +MIMAT0010020 ppt-miR2081; +MIMAT0010021 ppt-miR2082; +MIMAT0010022 ppt-miR2083-5p; +MIMAT0010023 ppt-miR2083-3p; +MIMAT0010024 ppt-miR1023e-5p; +MIMAT0010025 ppt-miR1023e-3p; +MIMAT0010026 mtr-miR2086*;mtr-miR2086-5p; +MIMAT0010027 mtr-miR2086;mtr-miR2086-3p; +MIMAT0010028 mtr-miR1510b*;mtr-miR1510b-5p; +MIMAT0010029 mtr-miR1510b;mtr-miR1510b-3p; +MIMAT0010030 mtr-miR1507*;mtr-miR1507-5p; +MIMAT0010031 mtr-miR1507;mtr-miR1507-3p; +MIMAT0010032 mtr-miR1510a*;mtr-miR1510a-5p; +MIMAT0010033 mtr-miR1510a;mtr-miR1510a-3p; +MIMAT0010034 mtr-miR1509;mtr-miR1509a-5p; +MIMAT0010035 mtr-miR1509*;mtr-miR1509a-3p; +MIMAT0010036 mtr-miR2087;mtr-miR2087-5p; +MIMAT0010037 mtr-miR2087*;mtr-miR2087-3p; +MIMAT0010038 mtr-miR2088;mtr-miR2088a;mtr-miR2088a-5p;mtr-miR2088-5p; +MIMAT0010039 mtr-miR2088*;mtr-miR2088a*;mtr-miR2088a-3p;mtr-miR2088-3p; +MIMAT0010040 mtr-miR2089;mtr-miR2089-5p; +MIMAT0010041 mtr-miR2089*;mtr-miR2089-3p; +MIMAT0010042 osa-miR1846e; +MIMAT0010043 osa-miR1428f-5p; +MIMAT0010044 osa-miR1428g-5p; +MIMAT0010045 osa-miR2090; +MIMAT0010046 osa-miR2091-5p; +MIMAT0010047 osa-miR2091-3p; +MIMAT0010048 osa-miR2092-5p; +MIMAT0010049 osa-miR2092-3p; +MIMAT0010050 osa-miR2093-5p; +MIMAT0010051 osa-miR2093-3p; +MIMAT0010052 osa-miR2094-5p; +MIMAT0010053 osa-miR2094-3p; +MIMAT0010054 osa-miR2095-5p; +MIMAT0010055 osa-miR2095-3p; +MIMAT0010056 osa-miR2096-5p; +MIMAT0010057 osa-miR2096-3p; +MIMAT0010058 osa-miR2097-5p; +MIMAT0010059 osa-miR2097-3p; +MIMAT0010060 osa-miR2098-5p; +MIMAT0010061 osa-miR2098-3p; +MIMAT0010062 osa-miR2099-5p; +MIMAT0010063 osa-miR2099-3p; +MIMAT0010064 osa-miR2100-5p; +MIMAT0010065 osa-miR2100-3p; +MIMAT0010066 osa-miR2101-5p; +MIMAT0010067 osa-miR2101-3p; +MIMAT0010068 osa-miR2102-5p; +MIMAT0010069 osa-miR2102-3p; +MIMAT0010070 osa-miR396f;osa-miR396f-5p; +MIMAT0010071 osa-miR2103; +MIMAT0010072 osa-miR2104; +MIMAT0010073 osa-miR2105; +MIMAT0010074 osa-miR2106; +MIMAT0010075 osa-miR827b; +MIMAT0010076 zma-miR396c; +MIMAT0010077 zma-miR396d; +MIMAT0010078 gma-miR167d; +MIMAT0010079 gma-miR396c; +MIMAT0010080 gma-miR1507b; +MIMAT0010081 gma-miR1508b; +MIMAT0010082 gma-miR1510b;gma-miR1510b-3p; +MIMAT0010083 gma-miR2107; +MIMAT0010084 gma-miR2108a; +MIMAT0010085 gma-miR2108b; +MIMAT0010086 gma-miR2109;gma-miR2109-5p; +MIMAT0010087 lja-miR167; +MIMAT0010088 lja-miR396; +MIMAT0010089 vun-miR1507;vun-miR1507a; +MIMAT0010090 tca-miR-9a;tca-miR-9a-5p; +MIMAT0010091 tca-bantam;tca-bantam-3p; +MIMAT0010092 tca-miR-970;tca-miR-970-3p; +MIMAT0010093 tca-miR-263a;tca-miR-263a-5p; +MIMAT0010094 tca-miR-993;tca-miR-993-3p; +MIMAT0010095 tca-miR-965;tca-miR-965-3p; +MIMAT0010096 tca-miR-315; +MIMAT0010097 tca-miR-1000;tca-miR-1000-5p; +MIMAT0010098 tca-miR-981; +MIMAT0010099 tca-miR-304; +MIMAT0010100 aga-miR-190; +MIMAT0010101 aga-miR-929; +MIMAT0010102 aga-miR-927; +MIMAT0010103 aga-miR-993; +MIMAT0010104 aga-miR-988; +MIMAT0010105 aga-miR-970; +MIMAT0010106 aga-miR-957; +MIMAT0010107 aga-miR-137; +MIMAT0010108 aga-miR-965;aga-miR-965-3p; +MIMAT0010109 aga-miR-1000; +MIMAT0010110 aga-miR-286; +MIMAT0010111 aga-miR-263b; +MIMAT0010112 aga-miR-309; +MIMAT0010113 ame-miR-252;ame-miR-252a;ame-miR-252a-5p; +MIMAT0010114 ame-miR-13b;ame-miR-13b-3p; +MIMAT0010115 ame-miR-996;ame-miR-996-3p; +MIMAT0010116 ame-miR-263b;ame-miR-263b-5p; +MIMAT0010117 ame-miR-92b;ame-miR-92b-3p; +MIMAT0010118 ame-miR-985;ame-miR-985-3p; +MIMAT0010119 ame-miR-1000;ame-miR-1000-5p; +MIMAT0010120 ame-miR-1006;ame-miR-1006-3p; +MIMAT0010121 ame-miR-981;ame-miR-981-3p; +MIMAT0010122 ame-miR-316;ame-miR-316-5p; +MIMAT0010123 ame-miR-993;ame-miR-993-3p; +MIMAT0010124 bmo-miR-252;bmo-miR-252-5p; +MIMAT0010125 bmo-miR-970;bmo-miR-970-3p; +MIMAT0010126 bmo-miR-965;bmo-miR-965*;bmo-miR-965-3p; +MIMAT0010127 bmo-miR-274;bmo-miR-274-5p; +MIMAT0010128 bmo-miR-993b;bmo-miR-993b-3p; +MIMAT0010129 bmo-miR-993a;bmo-miR-993a-3p; +MIMAT0010130 ebv-miR-BART21-5p; +MIMAT0010131 ebv-miR-BART21-3p; +MIMAT0010132 ebv-miR-BART22; +MIMAT0010133 hsa-miR-2110; +MIMAT0010135 bfl-miR-278; +MIMAT0010136 lmi-miR-307*;lmi-miR-307-5p; +MIMAT0010137 lmi-miR-307;lmi-miR-307-3p; +MIMAT0010138 lmi-miR-276*;lmi-miR-276-5p; +MIMAT0010139 lmi-miR-276;lmi-miR-276-3p; +MIMAT0010140 lmi-miR-281*;lmi-miR-281-5p; +MIMAT0010141 lmi-miR-281;lmi-miR-281-3p; +MIMAT0010142 lmi-miR-210*;lmi-miR-210-5p; +MIMAT0010143 lmi-miR-210;lmi-miR-210-3p; +MIMAT0010144 lmi-miR-10;lmi-miR-10-5p; +MIMAT0010145 lmi-miR-10*;lmi-miR-10-3p; +MIMAT0010146 lmi-miR-9a;lmi-miR-9a-5p; +MIMAT0010147 lmi-miR-9a*;lmi-miR-9a-3p; +MIMAT0010148 lmi-miR-8*;lmi-miR-8-5p; +MIMAT0010149 lmi-miR-8;lmi-miR-8-3p; +MIMAT0010150 mcv-miR-M1-5p;mcpv-miR-P1-5p; +MIMAT0010151 mcv-miR-M1-3p;mcpv-miR-P1-3p; +MIMAT0010152 bra-miR157a; +MIMAT0010153 bra-miR159a; +MIMAT0010154 bra-miR160a;bra-miR160a-5p; +MIMAT0010155 bra-miR160a*;bra-miR160a-3p; +MIMAT0010156 bra-miR164a; +MIMAT0010157 bra-miR167a; +MIMAT0010158 bra-miR167b; +MIMAT0010159 bra-miR167c; +MIMAT0010160 bra-miR167d; +MIMAT0010161 bra-miR171a; +MIMAT0010162 bra-miR171b; +MIMAT0010163 bra-miR171c; +MIMAT0010164 bra-miR171d; +MIMAT0010165 bra-miR171e; +MIMAT0010166 bra-miR172a; +MIMAT0010167 bra-miR172b*;bra-miR172b-5p; +MIMAT0010168 bra-miR172b;bra-miR172b-3p; +MIMAT0010169 bol-miR157a; +MIMAT0010170 bol-miR171a; +MIMAT0010171 bol-miR172a; +MIMAT0010172 bol-miR172b; +MIMAT0010173 bol-miR398a*;bol-miR398a-5p; +MIMAT0010174 bol-miR398a;bol-miR398a-3p; +MIMAT0010175 sja-let-7; +MIMAT0010176 sja-miR-71;sja-miR-71a; +MIMAT0010177 sja-bantam; +MIMAT0010178 sja-miR-125a; +MIMAT0010179 sja-miR-125b; +MIMAT0010180 sma-let-7;sma-let-7-5p; +MIMAT0010181 sma-miR-71;sma-miR-71a;sma-miR-71a-5p; +MIMAT0010182 sma-bantam;sma-bantam-3p; +MIMAT0010183 sma-miR-125a;sma-miR-125a-5p; +MIMAT0010184 sma-miR-125b; +MIMAT0010185 ssc-miR-101a;ssc-miR-101; +MIMAT0010186 ssc-miR-133a;ssc-miR-133a-3p; +MIMAT0010187 ssc-miR-1a;ssc-miR-1; +MIMAT0010188 ssc-miR-450;ssc-miR-450a; +MIMAT0010189 ssc-miR-503; +MIMAT0010190 ssc-miR-146b; +MIMAT0010191 ssc-miR-181a; +MIMAT0010192 ssc-miR-215; +MIMAT0010193 ssc-miR-30a;ssc-miR-30a-5p; +MIMAT0010194 bfl-miR-135b; +MIMAT0010195 hsa-let-7a-2*;hsa-let-7a-2-3p; +MIMAT0010196 cfa-miR-135a-5p; +MIMAT0010198 cfa-miR-105b; +MIMAT0010199 bta-miR-376d; +MIMAT0010200 bta-miR-1300b; +MIMAT0010201 tca-miR-279b;tca-miR-279b-3p; +MIMAT0010202 hsv2-miR-H3; +MIMAT0010203 hsv2-miR-H4-5p; +MIMAT0010204 hsv2-miR-H4-3p; +MIMAT0010205 hsv2-miR-H2; +MIMAT0010206 dme-miR-995*;dme-miR-995-5p; +MIMAT0010214 hsa-miR-151b; +MIMAT0010251 hsa-miR-449c;hsa-miR-449c-5p; +MIMAT0010313 hsa-miR-762; +MIMAT0010357 hsa-miR-670;hsa-miR-670-5p; +MIMAT0010364 hsa-miR-761; +MIMAT0010367 hsa-miR-764; +MIMAT0010497 hsa-miR-759; +MIMAT0010560 mmu-miR-1249;mmu-miR-1249-3p; +MIMAT0011057 mtr-miR156b;mtr-miR156b-5p; +MIMAT0011058 mtr-miR167;mtr-miR167a; +MIMAT0011059 mtr-miR164a; +MIMAT0011060 mtr-miR160b; +MIMAT0011061 mtr-miR166b; +MIMAT0011062 mtr-miR160c; +MIMAT0011063 mtr-miR169c; +MIMAT0011064 mtr-miR169d;mtr-miR169d-5p; +MIMAT0011065 mtr-miR169e;mtr-miR169e-5p; +MIMAT0011066 mtr-miR171b; +MIMAT0011067 mtr-miR166c; +MIMAT0011068 mtr-miR166d; +MIMAT0011069 mtr-miR169f; +MIMAT0011070 mtr-miR156c;mtr-miR156c-5p; +MIMAT0011071 mtr-miR156d;mtr-miR156d-5p; +MIMAT0011072 mtr-miR390; +MIMAT0011073 mtr-miR399f; +MIMAT0011074 mtr-miR399g; +MIMAT0011075 mtr-miR399h; +MIMAT0011076 mtr-miR399i; +MIMAT0011077 mtr-miR399j; +MIMAT0011078 mtr-miR399k; +MIMAT0011080 mtr-miR166e;mtr-miR166e-3p; +MIMAT0011081 mtr-miR156e; +MIMAT0011082 mtr-miR319b;mtr-miR319b-3p; +MIMAT0011083 mtr-miR171c; +MIMAT0011084 mtr-miR395q; +MIMAT0011085 mtr-miR398a;mtr-miR398a-3p; +MIMAT0011086 mtr-miR172;mtr-miR172a; +MIMAT0011087 mtr-miR393b;mtr-miR393b-5p; +MIMAT0011088 mtr-miR398b; +MIMAT0011089 mtr-miR168;mtr-miR168a; +MIMAT0011090 mtr-miR169g; +MIMAT0011091 mtr-miR156f; +MIMAT0011092 mtr-miR399l; +MIMAT0011093 mtr-miR156g;mtr-miR156g-5p; +MIMAT0011094 mtr-miR399m; +MIMAT0011095 mtr-miR399n; +MIMAT0011096 mtr-miR399o; +MIMAT0011097 mtr-miR398c; +MIMAT0011098 mtr-miR164b; +MIMAT0011099 mtr-miR156h;mtr-miR156h-5p; +MIMAT0011100 mtr-miR166f; +MIMAT0011101 mtr-miR160d; +MIMAT0011102 mtr-miR164c; +MIMAT0011103 mtr-miR164d; +MIMAT0011104 mtr-miR166g;mtr-miR166g-3p; +MIMAT0011105 mtr-miR171d; +MIMAT0011106 mtr-miR171e;mtr-miR171e-3p; +MIMAT0011107 mtr-miR396a;mtr-miR396a-5p; +MIMAT0011108 mtr-miR396b;mtr-miR396b-5p; +MIMAT0011109 mtr-miR169h; +MIMAT0011110 mtr-miR169i; +MIMAT0011111 mtr-miR169j;mtr-miR169b; +MIMAT0011112 mtr-miR156i;mtr-miR156i-5p; +MIMAT0011113 mtr-miR171f; +MIMAT0011114 mtr-miR166h; +MIMAT0011115 mtr-miR160e; +MIMAT0011116 mtr-miR169m; +MIMAT0011117 mtr-miR169l; +MIMAT0011118 mtr-miR169k; +MIMAT0011119 mtr-miR395r; +MIMAT0011120 mtr-miR399p; +MIMAT0011121 mtr-miR171g; +MIMAT0011122 mtr-miR169n; +MIMAT0011123 mtr-miR169o; +MIMAT0011132 cfa-miR-486; +MIMAT0011134 cfa-miR-339; +MIMAT0011135 xla-miR-1b; +MIMAT0011136 xla-miR-1306; +MIMAT0011137 xla-miR-133b; +MIMAT0011138 xla-miR-133d; +MIMAT0011139 xla-miR-142; +MIMAT0011140 xla-miR-15c; +MIMAT0011141 xla-miR-194; +MIMAT0011142 xla-miR-205; +MIMAT0011143 xla-miR-220c; +MIMAT0011144 xla-miR-223; +MIMAT0011145 xla-miR-23a; +MIMAT0011146 xla-miR-24b;xla-miR-24b-3p; +MIMAT0011147 xla-miR-363; +MIMAT0011148 xla-miR-703; +MIMAT0011149 xla-miR-92a;xla-miR-92a-3p; +MIMAT0011150 ath-miR2111a;ath-miR2111a-5p; +MIMAT0011151 ath-miR2111a*;ath-miR2111a-3p; +MIMAT0011152 ath-miR2111b;ath-miR2111b-5p; +MIMAT0011153 ath-miR2111b*;ath-miR2111b-3p; +MIMAT0011154 ath-miR2112-5p; +MIMAT0011155 ath-miR2112-3p; +MIMAT0011156 hsa-miR-2114;hsa-miR-2114-5p; +MIMAT0011157 hsa-miR-2114*;hsa-miR-2114-3p; +MIMAT0011158 hsa-miR-2115;hsa-miR-2115-5p; +MIMAT0011159 hsa-miR-2115*;hsa-miR-2115-3p; +MIMAT0011160 hsa-miR-2116;hsa-miR-2116-5p; +MIMAT0011161 hsa-miR-2116*;hsa-miR-2116-3p; +MIMAT0011162 hsa-miR-2117; +MIMAT0011163 hsa-miR-548q; +MIMAT0011164 mdm-miR482*;mdm-miR482a-5p; +MIMAT0011165 mdm-miR482;mdm-miR482a-3p; +MIMAT0011166 mtr-miR159a; +MIMAT0011167 gma-miR2119; +MIMAT0011168 mtr-miR2119; +MIMAT0011169 pvu-miR2118; +MIMAT0011170 pvu-miR159a;pvu-miR159a.2; +MIMAT0011171 pvu-miR1514a; +MIMAT0011172 pvu-miR482*;pvu-miR482-5p; +MIMAT0011173 pvu-miR482;pvu-miR482-3p; +MIMAT0011174 pvu-miR2119; +MIMAT0011175 pvu-miR166a; +MIMAT0011176 pvu-miR319c; +MIMAT0011177 pvu-miR399a; +MIMAT0011178 vun-miR1507b; +MIMAT0011179 osa-miR2120; +MIMAT0011180 osa-miR2121a; +MIMAT0011181 osa-miR2121b; +MIMAT0011182 osa-miR2122; +MIMAT0011183 osa-miR2123a; +MIMAT0011184 osa-miR2123b; +MIMAT0011185 osa-miR2123c; +MIMAT0011186 osa-miR2124a; +MIMAT0011187 osa-miR2124b; +MIMAT0011188 osa-miR2124c; +MIMAT0011189 osa-miR2124d; +MIMAT0011190 osa-miR2124e; +MIMAT0011191 osa-miR2124f; +MIMAT0011192 osa-miR2124g; +MIMAT0011193 osa-miR2124i; +MIMAT0011194 osa-miR2125; +MIMAT0011195 osa-miR2124h; +MIMAT0011196 gma-miR167e; +MIMAT0011197 gma-miR167f; +MIMAT0011198 gma-miR172c; +MIMAT0011199 gma-miR172d; +MIMAT0011200 gma-miR172e; +MIMAT0011201 gma-miR1509b; +MIMAT0011202 gga-miR-2126; +MIMAT0011203 gga-miR-2127; +MIMAT0011204 gga-miR-2128; +MIMAT0011205 gga-miR-2129; +MIMAT0011206 gga-miR-2130; +MIMAT0011207 gga-miR-2131;gga-miR-2131-5p; +MIMAT0011208 mmu-miR-2132; +MIMAT0011209 mmu-miR-2133; +MIMAT0011210 mmu-miR-2134; +MIMAT0011211 mmu-miR-2135; +MIMAT0011212 mmu-miR-2136; +MIMAT0011213 mmu-miR-2137; +MIMAT0011214 mmu-miR-2138; +MIMAT0011215 mmu-miR-2139; +MIMAT0011216 mmu-miR-2140; +MIMAT0011217 mmu-miR-2141; +MIMAT0011218 mmu-miR-2142; +MIMAT0011219 mmu-miR-2143; +MIMAT0011220 mmu-miR-2144; +MIMAT0011221 mmu-miR-2145; +MIMAT0011222 mmu-miR-2146; +MIMAT0011223 sme-miR-10a-5p; +MIMAT0011224 sme-miR-2148;sme-miR-2148-5p; +MIMAT0011225 sme-let-7d; +MIMAT0011226 sme-miR-753b-3p; +MIMAT0011227 sme-miR-61b-3p; +MIMAT0011228 sme-miR-87c;sme-miR-87c-3p; +MIMAT0011229 sme-miR-2149-5p; +MIMAT0011230 sme-miR-2147a; +MIMAT0011231 sme-miR-2150; +MIMAT0011232 sme-miR-2151;sme-miR-2151-3p; +MIMAT0011233 sme-miR-2152; +MIMAT0011234 sme-miR-2153; +MIMAT0011235 sme-miR-87d;sme-miR-87d-3p; +MIMAT0011236 sme-miR-754b;sme-miR-754b-5p; +MIMAT0011237 sme-miR-754c;sme-miR-754c-5p; +MIMAT0011238 sme-miR-124d;sme-miR-124d-3p; +MIMAT0011239 sme-miR-124e;sme-miR-124e-3p; +MIMAT0011240 sme-miR-8b;sme-miR-8b-3p; +MIMAT0011241 sme-miR-1993;sme-miR-1993-3p; +MIMAT0011242 sme-miR-36b;sme-miR-36b-3p; +MIMAT0011243 sme-miR-1992-3p; +MIMAT0011244 sme-miR-2154;sme-miR-2154-5p; +MIMAT0011245 sme-miR-216-5p; +MIMAT0011246 sme-miR-2156a;sme-miR-2156a-3p; +MIMAT0011247 sme-miR-9b;sme-miR-9b-5p; +MIMAT0011248 sme-miR-9a;sme-miR-9a-5p; +MIMAT0011249 sme-miR-1175*;sme-miR-1175-3p; +MIMAT0011250 sme-miR-2157;sme-miR-2157-5p; +MIMAT0011251 sme-miR-2158-5p; +MIMAT0011252 sme-miR-2159-5p; +MIMAT0011253 sme-miR-7d;sme-miR-7d-5p; +MIMAT0011254 sme-miR-2160;sme-miR-2160-5p; +MIMAT0011255 sme-miR-2161;sme-miR-2161-3p; +MIMAT0011256 sme-miR-2162-5p; +MIMAT0011257 sme-miR-2163-3p; +MIMAT0011258 sme-miR-133a;sme-miR-133a-3p; +MIMAT0011259 sme-miR-2164-3p; +MIMAT0011260 sme-miR-2165-3p; +MIMAT0011261 sme-miR-36c;sme-miR-36c-3p; +MIMAT0011262 sme-miR-96a;sme-miR-96a-5p; +MIMAT0011263 sme-miR-2166; +MIMAT0011264 sme-miR-2167; +MIMAT0011265 sme-miR-2147b; +MIMAT0011266 sme-miR-2168-5p; +MIMAT0011267 sme-miR-2169-5p; +MIMAT0011268 sme-miR-754d; +MIMAT0011269 sme-miR-2170; +MIMAT0011270 sme-miR-2147c; +MIMAT0011271 sme-miR-2171; +MIMAT0011272 sme-miR-2172-3p; +MIMAT0011273 sme-miR-96b;sme-miR-96b-5p; +MIMAT0011274 sme-miR-2173;sme-miR-2173-3p; +MIMAT0011275 sme-miR-2174; +MIMAT0011276 sme-miR-2175; +MIMAT0011277 sme-miR-753c; +MIMAT0011278 sme-miR-2176; +MIMAT0011279 sme-miR-2177-3p; +MIMAT0011280 sme-miR-2178; +MIMAT0011281 sme-miR-2179;sme-miR-2179-3p; +MIMAT0011282 sme-miR-315;sme-miR-315-5p; +MIMAT0011283 sme-miR-2180; +MIMAT0011284 sme-miR-2181; +MIMAT0011285 sme-miR-2155; +MIMAT0011286 mmu-miR-2182; +MIMAT0011287 mmu-miR-2183; +MIMAT0011288 dre-miR-2184; +MIMAT0011289 dre-miR-2185;dre-miR-2185-5p; +MIMAT0011290 dre-miR-2185*;dre-miR-2185-3p; +MIMAT0011291 dre-miR-429b; +MIMAT0011292 dre-miR-1388*;dre-miR-1388-5p; +MIMAT0011293 dre-miR-1388;dre-miR-1388-3p; +MIMAT0011294 dre-miR-1788;dre-miR-1788-5p; +MIMAT0011295 dre-miR-1788*;dre-miR-1788-3p; +MIMAT0011296 dre-miR-2187*;dre-miR-2187-5p; +MIMAT0011297 dre-miR-2187;dre-miR-2187-3p; +MIMAT0011298 dre-miR-196c; +MIMAT0011299 dre-miR-2190; +MIMAT0011300 dre-miR-2191; +MIMAT0011301 dre-miR-107b; +MIMAT0011302 dre-miR-455b;dre-miR-455-2-5p; +MIMAT0011303 dre-miR-222b; +MIMAT0011304 dre-miR-2196; +MIMAT0011305 dre-miR-2198; +MIMAT0011306 dre-miR-126b;dre-miR-126b-3p; +MIMAT0011307 dre-miR-126b*;dre-miR-126b-5p; +MIMAT0011308 dre-miR-2186; +MIMAT0011309 dre-miR-2188;dre-miR-2188-5p; +MIMAT0011310 dre-miR-2188*;dre-miR-2188-3p; +MIMAT0011311 dre-miR-2189; +MIMAT0011312 dre-miR-2192; +MIMAT0011313 dre-miR-196d; +MIMAT0011314 dre-miR-2193; +MIMAT0011315 dre-miR-2194; +MIMAT0011316 dre-miR-2195; +MIMAT0011317 dre-miR-2197; +MIMAT0011318 mtr-miR2118; +MIMAT0011319 mtr-miR2199; +MIMAT0011320 sbi-miR156f; +MIMAT0011321 sbi-miR156g; +MIMAT0011322 sbi-miR156h; +MIMAT0011323 sbi-miR156i; +MIMAT0011324 sbi-miR160f; +MIMAT0011325 sbi-miR164d; +MIMAT0011326 sbi-miR164e; +MIMAT0011327 sbi-miR166h; +MIMAT0011328 sbi-miR166i; +MIMAT0011329 sbi-miR166j; +MIMAT0011330 sbi-miR166k; +MIMAT0011331 sbi-miR167h; +MIMAT0011332 sbi-miR167i; +MIMAT0011333 sbi-miR169e; +MIMAT0011334 sbi-miR169h; +MIMAT0011335 sbi-miR169j; +MIMAT0011336 sbi-miR169k; +MIMAT0011337 sbi-miR169l; +MIMAT0011338 sbi-miR169m; +MIMAT0011339 sbi-miR169n; +MIMAT0011340 sbi-miR171g; +MIMAT0011341 sbi-miR171h; +MIMAT0011342 sbi-miR171i; +MIMAT0011343 sbi-miR171j; +MIMAT0011344 sbi-miR171k; +MIMAT0011345 sbi-miR172d; +MIMAT0011346 sbi-miR319b; +MIMAT0011347 sbi-miR390; +MIMAT0011348 sbi-miR393b; +MIMAT0011349 sbi-miR394b; +MIMAT0011350 sbi-miR395c; +MIMAT0011351 sbi-miR395g; +MIMAT0011352 sbi-miR395h; +MIMAT0011353 sbi-miR395i; +MIMAT0011354 sbi-miR395j; +MIMAT0011355 sbi-miR395k; +MIMAT0011356 sbi-miR395l; +MIMAT0011357 sbi-miR396d; +MIMAT0011358 sbi-miR396e; +MIMAT0011359 sbi-miR397;sbi-miR397-5p; +MIMAT0011360 sbi-miR399j; +MIMAT0011361 sbi-miR408; +MIMAT0011362 sbi-miR437a; +MIMAT0011363 sbi-miR437b; +MIMAT0011364 sbi-miR437c; +MIMAT0011365 sbi-miR437d; +MIMAT0011366 sbi-miR437e; +MIMAT0011367 sbi-miR437f; +MIMAT0011368 sbi-miR437g; +MIMAT0011369 sbi-miR437i; +MIMAT0011370 sbi-miR437j; +MIMAT0011371 sbi-miR437k; +MIMAT0011372 sbi-miR437l; +MIMAT0011373 sbi-miR437m; +MIMAT0011374 sbi-miR437n; +MIMAT0011375 sbi-miR437o; +MIMAT0011376 sbi-miR437p; +MIMAT0011377 sbi-miR437q; +MIMAT0011378 sbi-miR437r; +MIMAT0011379 sbi-miR437s; +MIMAT0011380 sbi-miR437t; +MIMAT0011381 sbi-miR437u; +MIMAT0011382 sbi-miR437v; +MIMAT0011383 sbi-miR437w; +MIMAT0011384 sbi-miR529; +MIMAT0011385 sbi-miR821a; +MIMAT0011386 sbi-miR821b; +MIMAT0011387 sbi-miR821c; +MIMAT0011388 sbi-miR821d; +MIMAT0011389 sbi-miR821e; +MIMAT0011390 sbi-miR1432; +MIMAT0011391 sbi-miR1435a; +MIMAT0011392 sbi-miR1435b; +MIMAT0011393 sme-miR-2156b*;sme-miR-2156b-5p; +MIMAT0011394 sme-miR-2156b;sme-miR-2156b-3p; +MIMAT0011395 sme-miR-753b-5p; +MIMAT0011396 sme-miR-76*;sme-miR-76-5p; +MIMAT0011397 sme-miR-76;sme-miR-76-3p; +MIMAT0011398 sme-miR-2204-5p; +MIMAT0011399 sme-miR-2204-3p; +MIMAT0011400 sme-miR-2e-5p; +MIMAT0011401 sme-miR-2e-3p; +MIMAT0011402 sme-miR-2206-5p; +MIMAT0011403 sme-miR-2206-3p; +MIMAT0011404 sme-miR-753d-5p; +MIMAT0011405 sme-miR-753d-3p; +MIMAT0011406 sme-miR-2147d-5p; +MIMAT0011407 sme-miR-2147d-3p; +MIMAT0011408 sme-miR-2205;sme-miR-2205-5p; +MIMAT0011409 sme-miR-2205*;sme-miR-2205-3p; +MIMAT0011410 sme-miR-2f;sme-miR-2f-5p; +MIMAT0011411 sme-miR-2f*;sme-miR-2f-3p; +MIMAT0011412 sme-miR-2154*;sme-miR-2154-3p; +MIMAT0011413 sme-miR-31b-1*;sme-miR-31b-1-3p; +MIMAT0011414 sme-miR-754c-1*;sme-miR-754c-1-3p; +MIMAT0011415 sme-miR-754b*;sme-miR-754b-3p; +MIMAT0011416 sme-miR-2160-1*;sme-miR-2160-1-3p; +MIMAT0011417 sme-miR-2202;sme-miR-2202-5p; +MIMAT0011418 sme-miR-2202*;sme-miR-2202-3p; +MIMAT0011419 sme-miR-2203*;sme-miR-2203-5p; +MIMAT0011420 sme-miR-2203;sme-miR-2203-3p; +MIMAT0011421 sme-miR-2200;sme-miR-2200-5p; +MIMAT0011422 sme-miR-2200*;sme-miR-2200-3p; +MIMAT0011423 sme-miR-2201*;sme-miR-2201-5p; +MIMAT0011424 sme-miR-2201;sme-miR-2201-3p; +MIMAT0011425 cel-miR-2207;cel-miR-2207-5p; +MIMAT0011426 cel-miR-2207*;cel-miR-2207-3p; +MIMAT0011427 cel-miR-2208a;cel-miR-2208a-5p; +MIMAT0011428 cel-miR-2208a*;cel-miR-2208a-3p; +MIMAT0011429 cel-miR-2208b-5p; +MIMAT0011430 cel-miR-2208b-3p; +MIMAT0011431 cel-miR-2209a*;cel-miR-2209a-5p; +MIMAT0011432 cel-miR-2209a;cel-miR-2209a-3p; +MIMAT0011433 cel-miR-2209c*;cel-miR-2209c-5p; +MIMAT0011434 cel-miR-2209c;cel-miR-2209c-3p; +MIMAT0011435 cel-miR-2210;cel-miR-2210-5p; +MIMAT0011436 cel-miR-2210*;cel-miR-2210-3p; +MIMAT0011437 cel-miR-2211*;cel-miR-2211-5p; +MIMAT0011438 cel-miR-2211;cel-miR-2211-3p; +MIMAT0011439 cel-miR-2212;cel-miR-2212-5p; +MIMAT0011440 cel-miR-2212*;cel-miR-2212-3p; +MIMAT0011441 cel-miR-2213*;cel-miR-2213-5p; +MIMAT0011442 cel-miR-2213;cel-miR-2213-3p; +MIMAT0011443 cel-miR-2214*;cel-miR-2214-5p; +MIMAT0011444 cel-miR-2214;cel-miR-2214-3p; +MIMAT0011445 cel-miR-2215*;cel-miR-2215-5p; +MIMAT0011446 cel-miR-2215;cel-miR-2215-3p; +MIMAT0011447 cel-miR-2216;cel-miR-2216-5p; +MIMAT0011448 cel-miR-2216*;cel-miR-2216-3p; +MIMAT0011449 cel-miR-1832b*;cel-miR-1832b-5p; +MIMAT0011450 cel-miR-1832b;cel-miR-1832b-3p; +MIMAT0011451 cel-miR-2217*;cel-miR-2217-5p;cel-miR-2217a-5p; +MIMAT0011452 cel-miR-2217;cel-miR-2217-3p;cel-miR-2217a-3p; +MIMAT0011453 cel-miR-2209b*;cel-miR-2209b-5p; +MIMAT0011454 cel-miR-2209b;cel-miR-2209b-3p; +MIMAT0011455 cel-miR-2218a;cel-miR-2218a-5p; +MIMAT0011456 cel-miR-2218a*;cel-miR-2218a-3p; +MIMAT0011457 cel-miR-2218b;cel-miR-2218b-5p; +MIMAT0011458 cel-miR-2218b*;cel-miR-2218b-3p; +MIMAT0011459 cel-miR-2219*;cel-miR-2219-5p; +MIMAT0011460 cel-miR-2219;cel-miR-2219-3p; +MIMAT0011461 cel-miR-2220*;cel-miR-2220-5p; +MIMAT0011462 cel-miR-2220;cel-miR-2220-3p; +MIMAT0011463 cel-miR-2221; +MIMAT0011464 cbr-miR-73b; +MIMAT0011465 cbr-miR-238; +MIMAT0011466 cbr-miR-76; +MIMAT0011467 cbr-miR-35c; +MIMAT0011468 cbr-miR-35e; +MIMAT0011469 cbr-miR-35d*;cbr-miR-35d-5p; +MIMAT0011470 cbr-miR-35d;cbr-miR-35d-3p; +MIMAT0011471 cbr-miR-90b*;cbr-miR-90b-5p; +MIMAT0011472 cbr-miR-90b;cbr-miR-90b-3p; +MIMAT0011473 cbr-miR-235b*;cbr-miR-235b-5p; +MIMAT0011474 cbr-miR-235b;cbr-miR-235b-3p; +MIMAT0011475 cbr-miR-56*;cbr-miR-56-5p; +MIMAT0011476 cbr-miR-56;cbr-miR-56-3p; +MIMAT0011477 cbr-miR-54a;cbr-miR-54a-5p; +MIMAT0011478 cbr-miR-54a*;cbr-miR-54a-3p; +MIMAT0011479 cbr-miR-237;cbr-miR-237-5p; +MIMAT0011480 cbr-miR-237*;cbr-miR-237-3p; +MIMAT0011481 cbr-miR-1822; +MIMAT0011482 cbr-miR-1834;cbr-miR-58b; +MIMAT0011483 cbr-miR-35b; +MIMAT0011484 cbr-miR-65;cbr-miR-65-5p; +MIMAT0011485 cbr-miR-65*;cbr-miR-65-3p; +MIMAT0011486 cbr-miR-1817; +MIMAT0011487 cbr-miR-2222; +MIMAT0011488 cbr-miR-2227; +MIMAT0011489 cbr-miR-41b; +MIMAT0011490 cbr-miR-64b; +MIMAT0011491 cbr-miR-2214; +MIMAT0011492 cbr-miR-2223; +MIMAT0011493 cbr-miR-2224; +MIMAT0011494 cbr-miR-54b; +MIMAT0011495 cbr-miR-54c; +MIMAT0011496 cbr-miR-54d; +MIMAT0011497 cbr-miR-2225*;cbr-miR-2225-5p; +MIMAT0011498 cbr-miR-2225;cbr-miR-2225-3p; +MIMAT0011499 cbr-miR-2226;cbr-miR-2226-5p; +MIMAT0011500 cbr-miR-2226*;cbr-miR-2226-3p; +MIMAT0011501 cbr-miR-74b*;cbr-miR-74b-5p; +MIMAT0011502 cbr-miR-74b;cbr-miR-74b-3p; +MIMAT0011503 crm-miR-786; +MIMAT0011504 crm-miR-41; +MIMAT0011505 crm-miR-40; +MIMAT0011506 crm-miR-39; +MIMAT0011507 crm-miR-77; +MIMAT0011508 crm-miR-49; +MIMAT0011509 crm-miR-57; +MIMAT0011510 crm-miR-35a; +MIMAT0011511 crm-miR-35b; +MIMAT0011512 crm-miR-35c;crm-miR-35c-3p; +MIMAT0011513 crm-miR-35e; +MIMAT0011514 crm-miR-35f; +MIMAT0011515 crm-miR-83; +MIMAT0011516 crm-miR-232; +MIMAT0011517 crm-miR-228; +MIMAT0011518 crm-miR-90; +MIMAT0011519 crm-let-7; +MIMAT0011520 crm-miR-238; +MIMAT0011521 crm-miR-75; +MIMAT0011522 crm-miR-74a; +MIMAT0011523 crm-miR-74b; +MIMAT0011524 crm-miR-73; +MIMAT0011525 crm-miR-76; +MIMAT0011526 crm-miR-61; +MIMAT0011527 crm-miR-242; +MIMAT0011528 crm-miR-70; +MIMAT0011529 crm-miR-249; +MIMAT0011530 crm-miR-231; +MIMAT0011531 crm-miR-85; +MIMAT0011532 crm-miR-42; +MIMAT0011533 crm-miR-43; +MIMAT0011534 crm-miR-252; +MIMAT0011535 crm-miR-355; +MIMAT0011536 crm-miR-239b; +MIMAT0011537 crm-miR-787; +MIMAT0011538 crm-miR-34; +MIMAT0011539 crm-miR-82; +MIMAT0011540 crm-miR-233; +MIMAT0011541 crm-miR-124;crm-miR-124a; +MIMAT0011542 crm-miR-47; +MIMAT0011543 crm-miR-790; +MIMAT0011544 crm-miR-248; +MIMAT0011545 crm-miR-58a; +MIMAT0011546 crm-miR-236; +MIMAT0011547 crm-miR-230*;crm-miR-230-5p; +MIMAT0011548 crm-miR-230;crm-miR-230-3p; +MIMAT0011549 crm-miR-52;crm-miR-52-5p; +MIMAT0011550 crm-miR-52*;crm-miR-52-3p; +MIMAT0011551 crm-miR-55*;crm-miR-55-5p; +MIMAT0011552 crm-miR-55;crm-miR-55-3p; +MIMAT0011553 crm-miR-237;crm-miR-237-5p; +MIMAT0011554 crm-miR-237*;crm-miR-237-3p; +MIMAT0011555 crm-miR-79*;crm-miR-79-5p; +MIMAT0011556 crm-miR-79;crm-miR-79-3p; +MIMAT0011557 crm-miR-235*;crm-miR-235-5p; +MIMAT0011558 crm-miR-235;crm-miR-235-3p; +MIMAT0011559 crm-miR-84;crm-miR-84-5p; +MIMAT0011560 crm-miR-84*;crm-miR-84-3p; +MIMAT0011561 crm-miR-60*;crm-miR-60-5p; +MIMAT0011562 crm-miR-60;crm-miR-60-3p; +MIMAT0011563 crm-miR-48;crm-miR-48-5p; +MIMAT0011564 crm-miR-48*;crm-miR-48-3p; +MIMAT0011565 crm-miR-1*;crm-miR-1-5p; +MIMAT0011566 crm-miR-1;crm-miR-1-3p; +MIMAT0011567 crm-miR-72;crm-miR-72-5p; +MIMAT0011568 crm-miR-72*;crm-miR-72-3p; +MIMAT0011569 crm-miR-81*;crm-miR-81-5p; +MIMAT0011570 crm-miR-81;crm-miR-81-3p; +MIMAT0011571 crm-miR-246;crm-miR-246-5p; +MIMAT0011572 crm-miR-246*;crm-miR-246-3p; +MIMAT0011573 crm-miR-2*;crm-miR-2-5p; +MIMAT0011574 crm-miR-2;crm-miR-2-3p; +MIMAT0011575 crm-miR-784*;crm-miR-784-5p; +MIMAT0011576 crm-miR-784;crm-miR-784-3p; +MIMAT0011577 crm-miR-45*;crm-miR-45-5p; +MIMAT0011578 crm-miR-45;crm-miR-45-3p; +MIMAT0011579 crm-miR-250*;crm-miR-250-5p; +MIMAT0011580 crm-miR-250;crm-miR-250-3p; +MIMAT0011581 crm-miR-87*;crm-miR-87-5p; +MIMAT0011582 crm-miR-87;crm-miR-87-3p; +MIMAT0011583 crm-miR-244;crm-miR-244-5p; +MIMAT0011584 crm-miR-244*;crm-miR-244-3p; +MIMAT0011585 crm-miR-86;crm-miR-86-5p; +MIMAT0011586 crm-miR-86*;crm-miR-86-3p; +MIMAT0011587 crm-miR-44*;crm-miR-44-5p; +MIMAT0011588 crm-miR-44;crm-miR-44-3p; +MIMAT0011589 crm-miR-50;crm-miR-50-5p; +MIMAT0011590 crm-miR-50*;crm-miR-50-3p; +MIMAT0011591 crm-miR-64c;crm-miR-64c-5p; +MIMAT0011592 crm-miR-64c*;crm-miR-64c-3p; +MIMAT0011593 crm-miR-64d;crm-miR-64d-5p; +MIMAT0011594 crm-miR-64d*;crm-miR-64d-3p; +MIMAT0011595 crm-miR-67*;crm-miR-67-5p; +MIMAT0011596 crm-miR-67;crm-miR-67-3p; +MIMAT0011597 crm-miR-46*;crm-miR-46-5p; +MIMAT0011598 crm-miR-46;crm-miR-46-3p; +MIMAT0011599 crm-lin-4;crm-lin-4-5p; +MIMAT0011600 crm-lin-4*;crm-lin-4-3p; +MIMAT0011601 crm-miR-247; +MIMAT0011602 crm-miR-785; +MIMAT0011603 crm-miR-38; +MIMAT0011604 crm-miR-357; +MIMAT0011605 crm-miR-35g; +MIMAT0011606 crm-miR-59; +MIMAT0011607 crm-miR-259; +MIMAT0011608 crm-miR-788; +MIMAT0011609 crm-miR-253; +MIMAT0011610 crm-miR-245; +MIMAT0011611 crm-miR-356; +MIMAT0011612 crm-miR-241; +MIMAT0011613 crm-miR-35c*;crm-miR-35c-5p; +MIMAT0011614 crm-miR-58b*;crm-miR-58b-5p; +MIMAT0011615 crm-miR-58b;crm-miR-58b-3p; +MIMAT0011616 crm-miR-239a;crm-miR-239a-5p; +MIMAT0011617 crm-miR-239a*;crm-miR-239a-3p; +MIMAT0011618 crm-miR-71;crm-miR-71-5p; +MIMAT0011619 crm-miR-71*;crm-miR-71-3p; +MIMAT0011620 crm-miR-80*;crm-miR-80-5p; +MIMAT0011621 crm-miR-80;crm-miR-80-3p; +MIMAT0011622 crm-miR-63;crm-miR-63-5p; +MIMAT0011623 crm-miR-63*;crm-miR-63-3p; +MIMAT0011624 crm-miR-2227; +MIMAT0011625 crm-miR-2228; +MIMAT0011626 crm-miR-62; +MIMAT0011627 crm-miR-2229; +MIMAT0011628 crm-miR-64e; +MIMAT0011629 crm-miR-2230*;crm-miR-2230-5p; +MIMAT0011630 crm-miR-2230;crm-miR-2230-3p; +MIMAT0011631 crm-miR-2231*;crm-miR-2231-5p; +MIMAT0011632 crm-miR-2231;crm-miR-2231-3p; +MIMAT0011633 crm-miR-64a;crm-miR-64a-5p; +MIMAT0011634 crm-miR-64a*;crm-miR-64a-3p; +MIMAT0011635 crm-miR-66;crm-miR-66-5p; +MIMAT0011636 crm-miR-66*;crm-miR-66-3p; +MIMAT0011637 crm-miR-64b;crm-miR-64b-5p; +MIMAT0011638 crm-miR-64b*;crm-miR-64b-3p; +MIMAT0011639 ppc-miR-1; +MIMAT0011640 ppc-miR-45; +MIMAT0011641 ppc-miR-42a; +MIMAT0011642 ppc-miR-63g; +MIMAT0011643 ppc-miR-2232; +MIMAT0011644 ppc-miR-87; +MIMAT0011645 ppc-miR-124; +MIMAT0011646 ppc-miR-239; +MIMAT0011647 ppc-miR-37; +MIMAT0011648 ppc-lin-4; +MIMAT0011649 ppc-miR-252; +MIMAT0011650 ppc-miR-63b; +MIMAT0011651 ppc-miR-63c; +MIMAT0011652 ppc-miR-79; +MIMAT0011653 ppc-miR-84b; +MIMAT0011654 ppc-miR-42b; +MIMAT0011655 ppc-miR-46; +MIMAT0011656 ppc-miR-81; +MIMAT0011657 ppc-let-7; +MIMAT0011658 ppc-miR-63a; +MIMAT0011659 ppc-miR-71;ppc-miR-71a; +MIMAT0011660 ppc-miR-63d; +MIMAT0011661 ppc-miR-72; +MIMAT0011662 ppc-miR-86; +MIMAT0011663 ppc-miR-242; +MIMAT0011664 ppc-miR-63f; +MIMAT0011665 ppc-miR-65; +MIMAT0011666 ppc-miR-84a; +MIMAT0011667 ppc-miR-2252; +MIMAT0011668 ppc-miR-2257;ppc-miR-2253b; +MIMAT0011669 ppc-miR-2258; +MIMAT0011670 ppc-miR-2234a; +MIMAT0011671 ppc-miR-2234b; +MIMAT0011672 ppc-miR-236; +MIMAT0011673 ppc-miR-2244; +MIMAT0011674 ppc-miR-2248; +MIMAT0011675 ppc-miR-2253;ppc-miR-2253a; +MIMAT0011676 ppc-miR-2254; +MIMAT0011677 ppc-miR-63e; +MIMAT0011678 ppc-miR-63h; +MIMAT0011679 ppc-miR-2255; +MIMAT0011680 ppc-miR-2256; +MIMAT0011681 ppc-miR-2235;ppc-miR-2235a-3p; +MIMAT0011682 ppc-miR-2238b; +MIMAT0011683 ppc-miR-2236a; +MIMAT0011684 ppc-miR-2236b; +MIMAT0011685 ppc-miR-2259; +MIMAT0011686 ppc-miR-2260; +MIMAT0011687 ppc-miR-2261; +MIMAT0011688 ppc-miR-2262; +MIMAT0011689 ppc-miR-2240b; +MIMAT0011690 ppc-miR-2240a; +MIMAT0011691 ppc-miR-2240c; +MIMAT0011692 ppc-miR-2238a; +MIMAT0011693 ppc-miR-2238c; +MIMAT0011694 ppc-miR-234; +MIMAT0011695 ppc-miR-54; +MIMAT0011696 ppc-miR-55b; +MIMAT0011697 ppc-miR-2263; +MIMAT0011698 ppc-miR-2264; +MIMAT0011699 ppc-miR-232; +MIMAT0011700 ppc-miR-2265; +MIMAT0011701 ppc-miR-2266; +MIMAT0011702 ppc-miR-2237a; +MIMAT0011703 ppc-miR-2237b; +MIMAT0011704 ppc-miR-2267; +MIMAT0011705 ppc-miR-312;ppc-miR-312a; +MIMAT0011706 ppc-miR-2243; +MIMAT0011707 ppc-miR-2242; +MIMAT0011709 ppc-miR-2245; +MIMAT0011710 ppc-miR-2238d; +MIMAT0011711 ppc-miR-2246; +MIMAT0011712 ppc-miR-2249; +MIMAT0011713 ppc-miR-67; +MIMAT0011714 ppc-miR-38; +MIMAT0011715 ppc-miR-2250; +MIMAT0011716 ppc-miR-55a; +MIMAT0011717 ppc-miR-56; +MIMAT0011718 ppc-miR-993; +MIMAT0011719 ppc-miR-2238e; +MIMAT0011720 ppc-miR-2251;ppc-miR-2251a; +MIMAT0011721 ppc-miR-2;ppc-miR-2b; +MIMAT0011722 ppc-miR-2268; +MIMAT0011723 ppc-miR-240; +MIMAT0011724 ppc-miR-2269; +MIMAT0011725 ppc-miR-2270; +MIMAT0011726 ppc-miR-2271; +MIMAT0011727 ppc-miR-2239; +MIMAT0011728 ppc-miR-2237c; +MIMAT0011729 ppc-miR-2272; +MIMAT0011730 ppc-miR-2273; +MIMAT0011731 ppc-miR-2241a; +MIMAT0011732 ppc-miR-2241b; +MIMAT0011733 ppc-miR-2274; +MIMAT0011734 ppc-miR-2233; +MIMAT0011735 ppc-miR-2247; +MIMAT0011736 ppc-miR-279; +MIMAT0011737 ppc-miR-9; +MIMAT0011738 ppc-miR-2241c; +MIMAT0011739 crm-miR-35d; +MIMAT0011740 osa-miR2118a; +MIMAT0011741 osa-miR2118b; +MIMAT0011742 osa-miR2118c; +MIMAT0011743 osa-miR2118d; +MIMAT0011744 osa-miR2118e; +MIMAT0011745 osa-miR2118f; +MIMAT0011746 osa-miR2118g; +MIMAT0011747 osa-miR2118h; +MIMAT0011748 osa-miR2118i; +MIMAT0011749 osa-miR2118j; +MIMAT0011750 osa-miR2118k; +MIMAT0011751 osa-miR2118l; +MIMAT0011752 osa-miR2118m; +MIMAT0011753 osa-miR2118n; +MIMAT0011754 osa-miR2118o; +MIMAT0011755 osa-miR2118p; +MIMAT0011756 osa-miR2118q; +MIMAT0011757 osa-miR2118r; +MIMAT0011758 osa-miR2275a; +MIMAT0011759 osa-miR2275b; +MIMAT0011760 zma-miR2118a; +MIMAT0011761 zma-miR2118b; +MIMAT0011762 zma-miR2118c; +MIMAT0011763 zma-miR2118d; +MIMAT0011764 zma-miR2118e; +MIMAT0011765 zma-miR2118f; +MIMAT0011766 zma-miR2118g; +MIMAT0011767 zma-miR2275a-5p; +MIMAT0011768 zma-miR2275a-3p; +MIMAT0011769 zma-miR2275b-5p; +MIMAT0011770 zma-miR2275b-3p; +MIMAT0011771 zma-miR2275c-5p; +MIMAT0011772 zma-miR2275c-3p; +MIMAT0011773 zma-miR2275d-5p; +MIMAT0011774 zma-miR2275d-3p; +MIMAT0011775 hsa-miR-2276;hsa-miR-2276-3p; +MIMAT0011777 hsa-miR-2277;hsa-miR-2277-3p; +MIMAT0011778 hsa-miR-2278; +MIMAT0011780 bna-miR2111b;bna-miR2111b-5p; +MIMAT0011781 bna-miR2111b*;bna-miR2111b-3p; +MIMAT0011782 bna-miR2111a;bna-miR2111a-5p; +MIMAT0011783 bna-miR2111a*;bna-miR2111a-3p; +MIMAT0011784 dme-miR-2279*;dme-miR-2279-5p; +MIMAT0011785 dme-miR-2279;dme-miR-2279-3p; +MIMAT0011786 dme-miR-2280;dme-miR-2280-5p; +MIMAT0011787 dme-miR-2280*;dme-miR-2280-3p; +MIMAT0011788 dme-miR-2281*;dme-miR-2281-5p; +MIMAT0011789 dme-miR-2281;dme-miR-2281-3p; +MIMAT0011790 dme-miR-2282;dme-miR-2282-3p; +MIMAT0011791 dme-miR-2283;dme-miR-2283-5p; +MIMAT0011792 bta-miR-2284i; +MIMAT0011793 bta-miR-2286; +MIMAT0011794 bta-miR-2287; +MIMAT0011795 bta-miR-2288; +MIMAT0011796 bta-miR-2289; +MIMAT0011797 bta-miR-2285a; +MIMAT0011798 bta-miR-2290; +MIMAT0011799 bta-miR-2291; +MIMAT0011800 bta-miR-2292; +MIMAT0011801 bta-miR-2293; +MIMAT0011802 bta-miR-2294; +MIMAT0011803 bta-miR-2295; +MIMAT0011804 bta-miR-2296; +MIMAT0011805 bta-miR-2297; +MIMAT0011806 bta-miR-2298; +MIMAT0011807 bta-miR-2299-5p; +MIMAT0011808 bta-miR-2299-3p; +MIMAT0011809 bta-miR-2300a-5p; +MIMAT0011810 bta-miR-2300b-3p; +MIMAT0011811 bta-miR-2284s; +MIMAT0011812 bta-miR-2301; +MIMAT0011813 bta-miR-2302; +MIMAT0011814 bta-miR-2303; +MIMAT0011815 bta-miR-2285d; +MIMAT0011816 bta-miR-2304; +MIMAT0011817 bta-miR-2305; +MIMAT0011818 bta-miR-2306; +MIMAT0011819 bta-miR-2307; +MIMAT0011820 bta-miR-2308; +MIMAT0011821 bta-miR-2309; +MIMAT0011822 bta-miR-2310; +MIMAT0011823 bta-miR-1603; +MIMAT0011824 bta-miR-2284l; +MIMAT0011825 bta-miR-2489; +MIMAT0011826 bta-miR-2311; +MIMAT0011827 bta-miR-2284j; +MIMAT0011828 bta-miR-2312; +MIMAT0011829 bta-miR-2313;bta-miR-2313-5p; +MIMAT0011830 bta-miR-2313*;bta-miR-2313-3p; +MIMAT0011831 bta-miR-2284t*;bta-miR-2284t-5p; +MIMAT0011832 bta-miR-2284t;bta-miR-2284t-3p; +MIMAT0011833 bta-miR-2285b; +MIMAT0011834 bta-miR-2314; +MIMAT0011835 bta-miR-2315; +MIMAT0011836 bta-miR-2284d; +MIMAT0011837 bta-miR-2316; +MIMAT0011838 bta-miR-2317; +MIMAT0011839 bta-miR-1343;bta-miR-1343-5p; +MIMAT0011840 bta-miR-1343*;bta-miR-1343-3p; +MIMAT0011841 bta-miR-2318; +MIMAT0011842 bta-miR-2319a; +MIMAT0011843 bta-miR-2319b; +MIMAT0011844 bta-miR-2320;bta-miR-2320-5p; +MIMAT0011845 bta-miR-2320*;bta-miR-2320-3p; +MIMAT0011846 bta-miR-2284n; +MIMAT0011847 bta-miR-2284g; +MIMAT0011848 bta-miR-2321; +MIMAT0011849 bta-miR-1721; +MIMAT0011850 bta-miR-2322;bta-miR-2322-5p; +MIMAT0011851 bta-miR-2322*;bta-miR-2322-3p; +MIMAT0011852 bta-miR-2323; +MIMAT0011853 bta-miR-2324; +MIMAT0011854 bta-miR-2325a; +MIMAT0011855 bta-miR-2326; +MIMAT0011856 bta-miR-2327; +MIMAT0011857 bta-miR-2328;bta-miR-2328-5p; +MIMAT0011858 bta-miR-2328*;bta-miR-2328-3p; +MIMAT0011859 bta-miR-2329-3p; +MIMAT0011860 bta-miR-2329-5p; +MIMAT0011861 bta-miR-2330;bta-miR-2330-5p; +MIMAT0011862 bta-miR-2330*;bta-miR-2330-3p; +MIMAT0011863 bta-miR-2331;bta-miR-2331-5p; +MIMAT0011864 bta-miR-2331*;bta-miR-2331-3p; +MIMAT0011865 bta-miR-2332; +MIMAT0011866 bta-miR-2333; +MIMAT0011867 bta-miR-2334; +MIMAT0011868 bta-miR-2335; +MIMAT0011869 bta-miR-2336; +MIMAT0011870 bta-miR-2337; +MIMAT0011871 bta-miR-199c; +MIMAT0011872 bta-miR-2338; +MIMAT0011873 bta-miR-2339; +MIMAT0011874 bta-miR-1814a; +MIMAT0011875 bta-miR-2340; +MIMAT0011876 bta-miR-2341; +MIMAT0011877 bta-miR-2342; +MIMAT0011878 bta-miR-2343; +MIMAT0011879 bta-miR-2344; +MIMAT0011880 bta-miR-2345; +MIMAT0011881 bta-miR-2346; +MIMAT0011882 bta-miR-2347; +MIMAT0011883 bta-miR-2348; +MIMAT0011884 bta-miR-2349; +MIMAT0011885 bta-miR-2284p; +MIMAT0011886 bta-miR-2350; +MIMAT0011887 bta-miR-2351; +MIMAT0011888 bta-miR-2352; +MIMAT0011889 bta-miR-2353; +MIMAT0011890 bta-miR-2354; +MIMAT0011891 bta-miR-2355*;bta-miR-2355-5p; +MIMAT0011892 bta-miR-2355;bta-miR-2355-3p; +MIMAT0011893 bta-miR-2356; +MIMAT0011894 bta-miR-2357; +MIMAT0011895 bta-miR-2284u; +MIMAT0011896 bta-miR-2358; +MIMAT0011897 bta-miR-2359; +MIMAT0011898 bta-miR-2360; +MIMAT0011899 bta-miR-2361; +MIMAT0011900 bta-miR-2362; +MIMAT0011901 bta-miR-2363; +MIMAT0011902 bta-miR-2364; +MIMAT0011903 bta-miR-2365; +MIMAT0011904 bta-miR-2366; +MIMAT0011905 bta-miR-2284f; +MIMAT0011906 bta-miR-2284a; +MIMAT0011907 bta-miR-2284k; +MIMAT0011908 bta-miR-1814b; +MIMAT0011909 bta-miR-2367;bta-miR-2367-5p; +MIMAT0011910 bta-miR-2367*;bta-miR-2367-3p; +MIMAT0011911 bta-miR-2368;bta-miR-2368-5p; +MIMAT0011912 bta-miR-2368*;bta-miR-2368-3p; +MIMAT0011913 bta-miR-2369; +MIMAT0011914 bta-miR-2370;bta-miR-2370-5p; +MIMAT0011915 bta-miR-2370*;bta-miR-2370-3p; +MIMAT0011916 bta-miR-2371; +MIMAT0011917 bta-miR-2372; +MIMAT0011918 bta-miR-2373;bta-miR-2373-5p; +MIMAT0011919 bta-miR-2373*;bta-miR-2373-3p; +MIMAT0011920 bta-miR-2374; +MIMAT0011921 bta-miR-2375; +MIMAT0011922 bta-miR-2376; +MIMAT0011923 bta-miR-2377; +MIMAT0011924 bta-miR-2378; +MIMAT0011925 bta-miR-2379; +MIMAT0011926 bta-miR-2284c; +MIMAT0011927 bta-miR-2325b; +MIMAT0011928 bta-miR-2380; +MIMAT0011929 bta-miR-2381; +MIMAT0011930 bta-miR-2382;bta-miR-2382-5p; +MIMAT0011931 bta-miR-2382*;bta-miR-2382-3p; +MIMAT0011932 bta-miR-2383; +MIMAT0011933 bta-miR-2384; +MIMAT0011934 bta-miR-2325c; +MIMAT0011935 bta-miR-2385-5p; +MIMAT0011936 bta-miR-2385-3p; +MIMAT0011937 bta-miR-2284v; +MIMAT0011938 bta-miR-2386; +MIMAT0011939 bta-miR-2387; +MIMAT0011940 bta-miR-2388*;bta-miR-2388-5p; +MIMAT0011941 bta-miR-2388;bta-miR-2388-3p; +MIMAT0011942 bta-miR-2389; +MIMAT0011943 bta-miR-2390; +MIMAT0011944 bta-miR-2391; +MIMAT0011945 bta-miR-2392; +MIMAT0011946 bta-miR-2393; +MIMAT0011947 bta-miR-2394; +MIMAT0011948 bta-miR-2395; +MIMAT0011949 bta-miR-2396; +MIMAT0011950 bta-miR-2285c; +MIMAT0011951 bta-miR-2397*;bta-miR-2397-5p; +MIMAT0011952 bta-miR-2397;bta-miR-2397-3p; +MIMAT0011953 bta-miR-2398; +MIMAT0011954 bta-miR-2399;bta-miR-2399-5p; +MIMAT0011955 bta-miR-2399*;bta-miR-2399-3p; +MIMAT0011956 bta-miR-2400; +MIMAT0011957 bta-miR-2284q; +MIMAT0011958 bta-miR-2401; +MIMAT0011959 bta-miR-2402; +MIMAT0011960 bta-miR-2403; +MIMAT0011961 bta-miR-2404; +MIMAT0011962 bta-miR-449d; +MIMAT0011963 bta-miR-2405; +MIMAT0011964 bta-miR-2406; +MIMAT0011965 bta-miR-2407; +MIMAT0011966 bta-miR-2408; +MIMAT0011967 bta-miR-2409; +MIMAT0011968 bta-miR-2410; +MIMAT0011969 bta-miR-1584;bta-miR-1584-5p; +MIMAT0011970 bta-miR-1584*;bta-miR-1584-3p; +MIMAT0011971 bta-miR-1940; +MIMAT0011972 bta-miR-2411;bta-miR-2411-5p; +MIMAT0011973 bta-miR-2411*;bta-miR-2411-3p; +MIMAT0011974 bta-miR-2412; +MIMAT0011975 bta-miR-2413; +MIMAT0011976 bta-miR-2284m; +MIMAT0011977 bta-miR-2414; +MIMAT0011978 bta-miR-2415*;bta-miR-2415-5p; +MIMAT0011979 bta-miR-2415;bta-miR-2415-3p; +MIMAT0011980 bta-miR-2416; +MIMAT0011981 bta-miR-2417; +MIMAT0011982 bta-miR-2418; +MIMAT0011983 bta-miR-2284b; +MIMAT0011984 bta-miR-1814c; +MIMAT0011985 bta-miR-2419;bta-miR-2419-5p; +MIMAT0011986 bta-miR-2419*;bta-miR-2419-3p; +MIMAT0011987 bta-miR-2420; +MIMAT0011988 bta-miR-2421; +MIMAT0011989 bta-miR-2422; +MIMAT0011990 bta-miR-1843; +MIMAT0011991 bta-miR-320b; +MIMAT0011992 bta-miR-2423; +MIMAT0011993 bta-miR-2424; +MIMAT0011994 bta-miR-2425;bta-miR-2425-5p; +MIMAT0011995 bta-miR-2425*;bta-miR-2425-3p; +MIMAT0011996 bta-miR-2426; +MIMAT0011997 bta-miR-2427; +MIMAT0011998 bta-miR-2428; +MIMAT0011999 bta-miR-2429; +MIMAT0012000 bta-miR-2430; +MIMAT0012001 bta-miR-2431*;bta-miR-2431-5p; +MIMAT0012002 bta-miR-2431;bta-miR-2431-3p; +MIMAT0012003 bta-miR-677; +MIMAT0012004 bta-miR-2432; +MIMAT0012005 bta-miR-2433; +MIMAT0012006 bta-miR-2434; +MIMAT0012007 bta-miR-2435; +MIMAT0012008 bta-miR-2436-5p; +MIMAT0012009 bta-miR-2436-3p; +MIMAT0012010 bta-miR-2284r; +MIMAT0012011 bta-miR-2437; +MIMAT0012012 bta-miR-2438; +MIMAT0012013 bta-miR-2439*;bta-miR-2439-5p; +MIMAT0012014 bta-miR-2439;bta-miR-2439-3p; +MIMAT0012015 bta-miR-2440; +MIMAT0012016 bta-miR-2441; +MIMAT0012017 bta-miR-2442; +MIMAT0012018 bta-miR-2443; +MIMAT0012019 bta-miR-2284h;bta-miR-2284h-5p; +MIMAT0012020 bta-miR-2284h*;bta-miR-2284h-3p; +MIMAT0012021 bta-miR-2444; +MIMAT0012022 bta-miR-2445; +MIMAT0012023 bta-miR-2446; +MIMAT0012024 bta-miR-2447; +MIMAT0012025 bta-miR-2448*;bta-miR-2448-5p; +MIMAT0012026 bta-miR-2448;bta-miR-2448-3p; +MIMAT0012027 bta-miR-2449; +MIMAT0012028 bta-miR-2450c; +MIMAT0012029 bta-miR-2450b; +MIMAT0012030 bta-miR-2450a; +MIMAT0012031 bta-miR-2451; +MIMAT0012032 bta-miR-1777a; +MIMAT0012033 bta-miR-2452; +MIMAT0012034 bta-miR-2453; +MIMAT0012035 bta-miR-2454;bta-miR-2454-5p; +MIMAT0012036 bta-miR-2454*;bta-miR-2454-3p; +MIMAT0012037 bta-miR-2455; +MIMAT0012038 bta-miR-339b; +MIMAT0012039 bta-miR-1434*;bta-miR-1434-5p; +MIMAT0012040 bta-miR-1434;bta-miR-1434-3p; +MIMAT0012041 bta-miR-2456; +MIMAT0012042 bta-miR-2457; +MIMAT0012043 bta-miR-2458; +MIMAT0012044 bta-miR-2459; +MIMAT0012045 bta-miR-2460; +MIMAT0012046 bta-miR-1777b; +MIMAT0012047 bta-miR-2461-5p; +MIMAT0012048 bta-miR-2461-3p; +MIMAT0012049 bta-miR-2462; +MIMAT0012050 bta-miR-2463; +MIMAT0012051 bta-miR-2464-5p; +MIMAT0012052 bta-miR-2464-3p; +MIMAT0012053 bta-miR-2465; +MIMAT0012054 bta-miR-2466-5p; +MIMAT0012055 bta-miR-2466-3p; +MIMAT0012056 bta-miR-2467*;bta-miR-2467-5p; +MIMAT0012057 bta-miR-2467;bta-miR-2467-3p; +MIMAT0012058 bta-miR-2468; +MIMAT0012059 bta-miR-2469; +MIMAT0012060 bta-miR-2470; +MIMAT0012061 bta-miR-2471;bta-miR-2471-5p; +MIMAT0012062 bta-miR-2471*;bta-miR-2471-3p; +MIMAT0012063 bta-miR-2472; +MIMAT0012064 bta-miR-2473; +MIMAT0012065 bta-miR-2474; +MIMAT0012066 bta-miR-2475; +MIMAT0012067 bta-miR-2476; +MIMAT0012068 bta-miR-2284o; +MIMAT0012069 bta-miR-2477; +MIMAT0012070 bta-miR-2478; +MIMAT0012071 bta-miR-2479; +MIMAT0012072 bta-miR-2480; +MIMAT0012073 bta-miR-2481; +MIMAT0012074 bta-miR-2482; +MIMAT0012075 bta-miR-2483*;bta-miR-2483-5p; +MIMAT0012076 bta-miR-2483;bta-miR-2483-3p; +MIMAT0012077 bta-miR-2484; +MIMAT0012078 bta-miR-664;bta-miR-664a; +MIMAT0012079 bta-miR-2485; +MIMAT0012080 bta-miR-2284e; +MIMAT0012081 bta-miR-2486;bta-miR-2486-5p; +MIMAT0012082 bta-miR-2486*;bta-miR-2486-3p; +MIMAT0012083 bta-miR-2487; +MIMAT0012084 bta-miR-2488; +MIMAT0012085 sme-bantam-b*;sme-bantam-b-5p; +MIMAT0012086 sme-bantam-c*;sme-bantam-c-5p; +MIMAT0012087 sme-let-7a*;sme-let-7a-3p; +MIMAT0012088 sme-let-7c*;sme-let-7c-3p; +MIMAT0012089 sme-lin-4-3p; +MIMAT0012090 sme-miR-1a*;sme-miR-1a-5p; +MIMAT0012091 sme-miR-1b*;sme-miR-1b-5p; +MIMAT0012092 sme-miR-1c*;sme-miR-1c-5p; +MIMAT0012093 sme-miR-2a-2*;sme-miR-2a-2-5p; +MIMAT0012094 sme-miR-2c-5p; +MIMAT0012095 sme-miR-2d-5p; +MIMAT0012096 sme-miR-7a-3p; +MIMAT0012097 sme-miR-7b*;sme-miR-7b-3p; +MIMAT0012098 sme-miR-7c*;sme-miR-7c-3p; +MIMAT0012099 sme-miR-8a*;sme-miR-8a-5p; +MIMAT0012100 sme-miR-12*;sme-miR-12-3p; +MIMAT0012101 sme-miR-13*;sme-miR-13-5p; +MIMAT0012102 sme-miR-745*;sme-miR-745-5p; +MIMAT0012103 sme-miR-746-5p; +MIMAT0012104 sme-miR-31a*;sme-miR-31a-3p; +MIMAT0012105 sme-miR-61a*;sme-miR-61a-5p; +MIMAT0012106 sme-miR-71a-1*;sme-miR-71a-1-3p; +MIMAT0012107 sme-miR-71c*;sme-miR-71c-3p; +MIMAT0012108 sme-miR-79-5p; +MIMAT0012109 sme-miR-87a-5p; +MIMAT0012110 sme-miR-87b-5p; +MIMAT0012111 sme-miR-92*;sme-miR-92-5p; +MIMAT0012112 sme-miR-124a*;sme-miR-124a-5p; +MIMAT0012113 sme-miR-124b*;sme-miR-124b-5p; +MIMAT0012114 sme-miR-125b*;sme-miR-125b-3p; +MIMAT0012115 sme-miR-133b-5p; +MIMAT0012116 sme-miR-184*;sme-miR-184-5p; +MIMAT0012117 sme-miR-747-3p; +MIMAT0012118 sme-miR-219*;sme-miR-219-3p; +MIMAT0012119 sme-miR-277a*;sme-miR-277a-5p; +MIMAT0012120 sme-miR-277c*;sme-miR-277c-5p; +MIMAT0012121 sme-miR-278*;sme-miR-278-5p; +MIMAT0012122 sme-miR-67-5p; +MIMAT0012123 sme-miR-748*;sme-miR-748-5p; +MIMAT0012124 sme-miR-750-5p; +MIMAT0012125 sme-miR-752-5p; +MIMAT0012126 sme-miR-755-3p; +MIMAT0012127 sme-miR-756*;sme-miR-756-3p; +MIMAT0012128 sme-miR-277d-5p; +MIMAT0012129 ath-miR1886.2; +MIMAT0012130 sme-miR-10a-3p; +MIMAT0012131 sme-miR-2148*;sme-miR-2148-3p; +MIMAT0012132 sme-miR-61b-5p; +MIMAT0012133 sme-miR-87c*;sme-miR-87c-5p; +MIMAT0012134 sme-miR-2149-3p; +MIMAT0012135 sme-miR-2151*;sme-miR-2151-5p; +MIMAT0012136 sme-miR-87d*;sme-miR-87d-5p; +MIMAT0012137 sme-miR-124d*;sme-miR-124d-5p; +MIMAT0012138 sme-miR-124e*;sme-miR-124e-5p; +MIMAT0012139 sme-miR-8b*;sme-miR-8b-5p; +MIMAT0012140 sme-miR-1993*;sme-miR-1993-5p; +MIMAT0012141 sme-miR-36b*;sme-miR-36b-5p; +MIMAT0012142 sme-miR-1992-5p; +MIMAT0012143 sme-miR-216-3p; +MIMAT0012144 sme-miR-2156a*;sme-miR-2156a-5p; +MIMAT0012145 sme-miR-9b*;sme-miR-9b-3p; +MIMAT0012146 sme-miR-9a*;sme-miR-9a-3p; +MIMAT0012147 sme-miR-1175;sme-miR-1175-5p; +MIMAT0012148 sme-miR-2157*;sme-miR-2157-3p; +MIMAT0012149 sme-miR-2158-3p; +MIMAT0012150 sme-miR-2159-3p; +MIMAT0012151 sme-miR-7d*;sme-miR-7d-3p; +MIMAT0012152 sme-miR-2161*;sme-miR-2161-5p; +MIMAT0012153 sme-miR-2162-3p; +MIMAT0012154 sme-miR-2163-5p; +MIMAT0012155 sme-miR-133a*;sme-miR-133a-5p; +MIMAT0012156 sme-miR-2164-5p; +MIMAT0012157 sme-miR-2165-5p; +MIMAT0012158 sme-miR-36c*;sme-miR-36c-5p; +MIMAT0012159 sme-miR-96a*;sme-miR-96a-3p; +MIMAT0012160 sme-miR-2168-3p; +MIMAT0012161 sme-miR-2169-3p; +MIMAT0012162 sme-miR-2172-5p; +MIMAT0012163 sme-miR-96b*;sme-miR-96b-3p; +MIMAT0012164 sme-miR-2173*;sme-miR-2173-5p; +MIMAT0012165 sme-miR-2177-5p; +MIMAT0012166 sme-miR-2179*;sme-miR-2179-5p; +MIMAT0012167 sme-miR-315*;sme-miR-315-3p; +MIMAT0012168 sme-miR-753e*;sme-miR-753e-5p; +MIMAT0012169 sme-miR-753e;sme-miR-753e-3p; +MIMAT0012170 hbv-miR-B2RC; +MIMAT0012171 hbv-miR-B4; +MIMAT0012172 hbv-miR-B20;hbv-miR-B20-5p; +MIMAT0012173 bdi-miR444;bdi-miR444a; +MIMAT0012174 bdi-miR171a; +MIMAT0012175 bdi-miR408; +MIMAT0012176 bdi-miR167;bdi-miR167a; +MIMAT0012177 bdi-miR1139; +MIMAT0012178 bdi-miR160; +MIMAT0012179 bdi-miR169a; +MIMAT0012180 bdi-miR397;bdi-miR397a; +MIMAT0012181 bdi-miR156;bdi-miR156a; +MIMAT0012182 bdi-miR172d; +MIMAT0012183 bdi-miR1122; +MIMAT0012184 bdi-miR171d; +MIMAT0012185 bdi-miR166;bdi-miR166a;bdi-miR166a-3p; +MIMAT0012186 bdi-miR171c;bdi-miR171c-3p; +MIMAT0012187 bdi-miR399;bdi-miR399a; +MIMAT0012188 bdi-miR437; +MIMAT0012189 bdi-miR169b; +MIMAT0012190 bdi-miR1127; +MIMAT0012191 bdi-miR1135; +MIMAT0012192 xtr-miR-2184; +MIMAT0012193 xtr-miR-2188; +MIMAT0012194 dme-miR-307-as*;dme-miR-307b-5p; +MIMAT0012195 dme-miR-307-as;dme-miR-307b-3p; +MIMAT0012196 dme-miR-2489;dme-miR-2489-3p; +MIMAT0012197 dme-miR-2490;dme-miR-2490-5p; +MIMAT0012198 dme-miR-2491;dme-miR-2491-5p; +MIMAT0012199 dme-miR-2492;dme-miR-2492-3p; +MIMAT0012200 dme-miR-2493*;dme-miR-2493-5p; +MIMAT0012201 dme-miR-2493;dme-miR-2493-3p; +MIMAT0012202 dme-miR-2494*;dme-miR-2494-5p; +MIMAT0012203 dme-miR-2494;dme-miR-2494-3p; +MIMAT0012204 dme-miR-2495;dme-miR-2495-5p; +MIMAT0012205 dme-miR-2495*;dme-miR-2495-3p; +MIMAT0012206 dme-miR-2496*;dme-miR-2496-5p; +MIMAT0012207 dme-miR-2496;dme-miR-2496-3p; +MIMAT0012208 dme-miR-2497*;dme-miR-2497-5p; +MIMAT0012209 dme-miR-2497;dme-miR-2497-3p; +MIMAT0012210 dme-miR-2498*;dme-miR-2498-5p; +MIMAT0012211 dme-miR-2498;dme-miR-2498-3p; +MIMAT0012212 dme-miR-2499*;dme-miR-2499-5p; +MIMAT0012213 dme-miR-2499;dme-miR-2499-3p; +MIMAT0012214 dme-miR-2500*;dme-miR-2500-5p; +MIMAT0012215 dme-miR-2500;dme-miR-2500-3p; +MIMAT0012216 dme-miR-2501;dme-miR-2501-5p; +MIMAT0012217 dme-miR-2501*;dme-miR-2501-3p; +MIMAT0012218 dps-miR-989; +MIMAT0012219 dps-miR-981*;dps-miR-981-5p; +MIMAT0012220 dps-miR-981;dps-miR-981-3p; +MIMAT0012221 dps-miR-970*;dps-miR-970-5p; +MIMAT0012222 dps-miR-970;dps-miR-970-3p; +MIMAT0012223 dps-miR-980*;dps-miR-980-5p; +MIMAT0012224 dps-miR-980;dps-miR-980-3p; +MIMAT0012225 dps-miR-971*;dps-miR-971-5p; +MIMAT0012226 dps-miR-971;dps-miR-971-3p; +MIMAT0012227 dps-miR-190*;dps-miR-190-5p; +MIMAT0012228 dps-miR-190;dps-miR-190-3p; +MIMAT0012229 dps-miR-957*;dps-miR-957-5p; +MIMAT0012230 dps-miR-957;dps-miR-957-3p; +MIMAT0012231 dps-miR-958;dps-miR-958-5p; +MIMAT0012232 dps-miR-958*;dps-miR-958-3p; +MIMAT0012233 dps-miR-988*;dps-miR-988-5p; +MIMAT0012234 dps-miR-988;dps-miR-988-3p; +MIMAT0012235 dps-miR-987;dps-miR-987-5p; +MIMAT0012236 dps-miR-987*;dps-miR-987-3p; +MIMAT0012237 dps-miR-137*;dps-miR-137-5p; +MIMAT0012238 dps-miR-137;dps-miR-137-3p; +MIMAT0012239 dps-miR-994;dps-miR-994-5p; +MIMAT0012240 dps-miR-994*;dps-miR-994-3p; +MIMAT0012241 dps-miR-311*;dps-miR-311-5p; +MIMAT0012242 dps-miR-311;dps-miR-311-3p; +MIMAT0012243 dps-miR-92c*;dps-miR-92c-5p; +MIMAT0012244 dps-miR-92c;dps-miR-92c-3p; +MIMAT0012245 dps-miR-968;dps-miR-968-5p; +MIMAT0012246 dps-miR-968*;dps-miR-968-3p; +MIMAT0012247 dps-miR-1002;dps-miR-1002-5p; +MIMAT0012248 dps-miR-1002*;dps-miR-1002-3p; +MIMAT0012249 dps-miR-965*;dps-miR-965-5p; +MIMAT0012250 dps-miR-965;dps-miR-965-3p; +MIMAT0012251 dps-miR-1006*;dps-miR-1006-5p; +MIMAT0012252 dps-miR-1006;dps-miR-1006-3p; +MIMAT0012253 dps-miR-375*;dps-miR-375-5p; +MIMAT0012254 dps-miR-375;dps-miR-375-3p; +MIMAT0012255 dps-miR-964*;dps-miR-964-5p; +MIMAT0012256 dps-miR-964;dps-miR-964-3p; +MIMAT0012257 dps-miR-959*;dps-miR-959-5p; +MIMAT0012258 dps-miR-959;dps-miR-959-3p; +MIMAT0012259 dps-miR-932;dps-miR-932-5p; +MIMAT0012260 dps-miR-932*;dps-miR-932-3p; +MIMAT0012261 dps-miR-252;dps-miR-252-5p; +MIMAT0012262 dps-miR-252*;dps-miR-252-3p; +MIMAT0012263 dps-miR-993*;dps-miR-993-5p; +MIMAT0012264 dps-miR-993;dps-miR-993-3p; +MIMAT0012265 dps-miR-1000;dps-miR-1000-5p; +MIMAT0012266 dps-miR-1000*;dps-miR-1000-3p; +MIMAT0012267 dps-miR-929;dps-miR-929-5p; +MIMAT0012268 dps-miR-929*;dps-miR-929-3p; +MIMAT0012269 dps-miR-927;dps-miR-927-5p; +MIMAT0012270 dps-miR-927*;dps-miR-927-3p; +MIMAT0012271 dps-miR-995*;dps-miR-995-5p; +MIMAT0012272 dps-miR-995;dps-miR-995-3p; +MIMAT0012273 dps-miR-1010*;dps-miR-1010-5p; +MIMAT0012274 dps-miR-1010;dps-miR-1010-3p; +MIMAT0012275 dps-miR-969*;dps-miR-969-5p; +MIMAT0012276 dps-miR-969;dps-miR-969-3p; +MIMAT0012277 dps-miR-193;dps-miR-193-5p; +MIMAT0012278 dps-miR-193*;dps-miR-193-3p; +MIMAT0012279 dps-miR-986;dps-miR-986-5p; +MIMAT0012280 dps-miR-986*;dps-miR-986-3p; +MIMAT0012281 dps-miR-307-as;dps-miR-307b; +MIMAT0012282 dps-miR-263a-as;dps-miR-3983; +MIMAT0012283 dps-miR-210-as;dps-miR-210b; +MIMAT0012284 dps-miR-iab-4-as;dps-miR-iab-8;dps-miR-iab-8-5p; +MIMAT0012285 dps-miR-iab-4-as*;dps-miR-iab-8*;dps-miR-iab-8-3p; +MIMAT0012286 dps-miR-2502; +MIMAT0012287 dps-miR-2503; +MIMAT0012288 dps-miR-2504; +MIMAT0012289 dps-miR-2505; +MIMAT0012290 dps-miR-2506; +MIMAT0012291 dps-miR-2507a; +MIMAT0012292 dps-miR-2508; +MIMAT0012293 dps-miR-276c; +MIMAT0012294 dps-miR-2509; +MIMAT0012295 dps-miR-2510; +MIMAT0012296 dps-miR-2511; +MIMAT0012297 dps-miR-2512; +MIMAT0012298 dps-miR-2513a; +MIMAT0012299 dps-miR-2514; +MIMAT0012300 dps-miR-2515; +MIMAT0012301 dps-miR-2518; +MIMAT0012302 dps-miR-2513b; +MIMAT0012303 dps-miR-2516; +MIMAT0012304 dps-miR-2517b; +MIMAT0012305 dps-miR-2574b; +MIMAT0012306 dps-miR-2528; +MIMAT0012307 dps-miR-2519; +MIMAT0012308 dps-miR-2520; +MIMAT0012309 dps-miR-2521; +MIMAT0012310 dps-miR-2522a; +MIMAT0012311 dps-miR-2523; +MIMAT0012312 dps-miR-2524; +MIMAT0012313 dps-miR-2525; +MIMAT0012314 dps-miR-2526*; +MIMAT0012315 dps-miR-2526;dps-miR-2526-3p; +MIMAT0012316 dps-miR-2545b; +MIMAT0012317 dps-miR-2527; +MIMAT0012318 dps-miR-2529; +MIMAT0012319 dps-miR-2530; +MIMAT0012320 dps-miR-2531; +MIMAT0012321 dps-miR-2532; +MIMAT0012322 dps-miR-2533; +MIMAT0012323 dps-miR-2534; +MIMAT0012324 dps-miR-2535*;dps-miR-2535-5p; +MIMAT0012325 dps-miR-2535;dps-miR-2535-3p; +MIMAT0012326 dps-miR-2536;dps-miR-2536-5p; +MIMAT0012327 dps-miR-2536*;dps-miR-2536-3p; +MIMAT0012328 dps-miR-2537*;dps-miR-2537-5p; +MIMAT0012329 dps-miR-2537;dps-miR-2537-3p; +MIMAT0012330 dps-miR-2538;dps-miR-2538-5p; +MIMAT0012331 dps-miR-2538*;dps-miR-2538-3p; +MIMAT0012332 dps-miR-2522b;dps-miR-2522b-5p; +MIMAT0012333 dps-miR-2522b*;dps-miR-2522b-3p; +MIMAT0012334 dps-miR-2539;dps-miR-2539-5p; +MIMAT0012335 dps-miR-2539*;dps-miR-2539-3p; +MIMAT0012336 dps-miR-2540*;dps-miR-2540-5p; +MIMAT0012337 dps-miR-2540;dps-miR-2540-3p; +MIMAT0012338 dps-miR-2541*;dps-miR-2541-5p; +MIMAT0012339 dps-miR-2541;dps-miR-2541-3p; +MIMAT0012340 dps-miR-2542;dps-miR-2542-5p; +MIMAT0012341 dps-miR-2542*;dps-miR-2542-3p; +MIMAT0012342 dps-miR-2517a*;dps-miR-2517a-5p;dps-miR-2517-5p; +MIMAT0012343 dps-miR-2517a;dps-miR-2517a-3p;dps-miR-2517-3p; +MIMAT0012344 dps-miR-2543a*;dps-miR-2543a-5p; +MIMAT0012345 dps-miR-2543a;dps-miR-2543a-3p; +MIMAT0012346 dps-miR-2543b*;dps-miR-2543b-5p; +MIMAT0012347 dps-miR-2543b;dps-miR-2543b-3p; +MIMAT0012348 dps-miR-2544*;dps-miR-2544-5p; +MIMAT0012349 dps-miR-2544;dps-miR-2544-3p; +MIMAT0012350 dps-miR-2545a;dps-miR-2545a-5p; +MIMAT0012351 dps-miR-2545a*;dps-miR-2545a-3p; +MIMAT0012352 dps-miR-2546*;dps-miR-2546-5p; +MIMAT0012353 dps-miR-2546;dps-miR-2546-3p; +MIMAT0012354 dps-miR-2547*;dps-miR-2547-5p; +MIMAT0012355 dps-miR-2547;dps-miR-2547-3p; +MIMAT0012356 dps-miR-2548*;dps-miR-2548-5p; +MIMAT0012357 dps-miR-2548;dps-miR-2548-3p; +MIMAT0012358 dps-miR-2549*;dps-miR-2549-5p; +MIMAT0012359 dps-miR-2549;dps-miR-2549-3p; +MIMAT0012360 dps-miR-2550*;dps-miR-2550-5p; +MIMAT0012361 dps-miR-2550;dps-miR-2550-3p; +MIMAT0012362 dps-miR-2551*;dps-miR-2551-5p; +MIMAT0012363 dps-miR-2551;dps-miR-2551-3p; +MIMAT0012364 dps-miR-2552;dps-miR-2552-5p; +MIMAT0012365 dps-miR-2552*;dps-miR-2552-3p; +MIMAT0012366 dps-miR-2553;dps-miR-2553-5p; +MIMAT0012367 dps-miR-2553*;dps-miR-2553-3p; +MIMAT0012368 dps-miR-2554;dps-miR-2554-5p; +MIMAT0012369 dps-miR-2554*;dps-miR-2554-3p; +MIMAT0012370 dps-miR-2507b;dps-miR-2507b-5p; +MIMAT0012371 dps-miR-2507b*;dps-miR-2507b-3p; +MIMAT0012372 dps-miR-2555*;dps-miR-2555-5p; +MIMAT0012373 dps-miR-2555;dps-miR-2555-3p; +MIMAT0012374 dps-miR-2556*;dps-miR-2556-5p; +MIMAT0012375 dps-miR-2556;dps-miR-2556-3p; +MIMAT0012376 dps-miR-2557*;dps-miR-2557-5p; +MIMAT0012377 dps-miR-2557;dps-miR-2557-3p; +MIMAT0012378 dps-miR-2558;dps-miR-2558-5p; +MIMAT0012379 dps-miR-2558*;dps-miR-2558-3p; +MIMAT0012380 dps-miR-2559*;dps-miR-2559-5p; +MIMAT0012381 dps-miR-2559;dps-miR-2559-3p; +MIMAT0012382 dps-miR-2560;dps-miR-2560-5p; +MIMAT0012383 dps-miR-2560*;dps-miR-2560-3p; +MIMAT0012384 dps-miR-2561;dps-miR-2561-5p; +MIMAT0012385 dps-miR-2561*;dps-miR-2561-3p; +MIMAT0012386 dps-miR-2562*;dps-miR-2562-5p; +MIMAT0012387 dps-miR-2562;dps-miR-2562-3p; +MIMAT0012388 dps-miR-2563;dps-miR-2563-5p; +MIMAT0012389 dps-miR-2563*;dps-miR-2563-3p; +MIMAT0012390 dps-miR-2564*;dps-miR-2564-5p; +MIMAT0012391 dps-miR-2564;dps-miR-2564-3p; +MIMAT0012392 dps-miR-2565*;dps-miR-2565-5p; +MIMAT0012393 dps-miR-2565;dps-miR-2565-3p; +MIMAT0012394 dps-miR-2566a-1*;dps-miR-2566a-1-5p; +MIMAT0012395 dps-miR-2566a;dps-miR-2566a-3p; +MIMAT0012396 dps-miR-2567a*;dps-miR-2567a-5p; +MIMAT0012397 dps-miR-2567a;dps-miR-2567a-3p; +MIMAT0012398 dps-miR-2567c*;dps-miR-2567c-5p; +MIMAT0012399 dps-miR-2567c;dps-miR-2567c-3p; +MIMAT0012400 dps-miR-2566b*;dps-miR-2566b-5p; +MIMAT0012401 dps-miR-2566b;dps-miR-2566b-3p; +MIMAT0012402 dps-miR-2567b*;dps-miR-2567b-5p; +MIMAT0012403 dps-miR-2567b;dps-miR-2567b-3p; +MIMAT0012404 dps-miR-2568a;dps-miR-2568a-5p; +MIMAT0012405 dps-miR-2568a*;dps-miR-2568a-3p; +MIMAT0012406 dps-miR-2569;dps-miR-2569-5p; +MIMAT0012407 dps-miR-2569*;dps-miR-2569-3p; +MIMAT0012408 dps-miR-2568b;dps-miR-2568b-5p; +MIMAT0012409 dps-miR-2568b*;dps-miR-2568b-3p; +MIMAT0012410 dps-miR-2570;dps-miR-2570-5p; +MIMAT0012411 dps-miR-2570*;dps-miR-2570-3p; +MIMAT0012412 dps-miR-2571*;dps-miR-2571-5p; +MIMAT0012413 dps-miR-2571;dps-miR-2571-3p; +MIMAT0012414 dps-miR-2572*;dps-miR-2572-5p; +MIMAT0012415 dps-miR-2572;dps-miR-2572-3p; +MIMAT0012416 dps-miR-2573*;dps-miR-2573-5p; +MIMAT0012417 dps-miR-2573;dps-miR-2573-3p; +MIMAT0012418 dps-miR-2574a;dps-miR-2574a-5p; +MIMAT0012419 dps-miR-2574a*;dps-miR-2574a-3p; +MIMAT0012420 dps-miR-2575;dps-miR-2575-5p; +MIMAT0012421 dps-miR-2575*;dps-miR-2575-3p; +MIMAT0012422 dps-miR-2576; +MIMAT0012423 dsi-miR-977;dsi-miR-977-3p; +MIMAT0012424 dsi-miR-978;dsi-miR-978a;dsi-miR-978a-3p; +MIMAT0012425 dsi-miR-1012;dsi-miR-1012-5p; +MIMAT0012426 dsi-miR-1012*;dsi-miR-1012-3p; +MIMAT0012427 dsi-miR-1003*;dsi-miR-1003-5p; +MIMAT0012428 dsi-miR-1003;dsi-miR-1003-3p; +MIMAT0012429 dsi-miR-991*;dsi-miR-991-5p; +MIMAT0012430 dsi-miR-991;dsi-miR-991-3p; +MIMAT0012431 dsi-miR-986;dsi-miR-986-5p; +MIMAT0012432 dsi-miR-986*;dsi-miR-986-3p; +MIMAT0012433 dsi-miR-987;dsi-miR-987-5p; +MIMAT0012434 dsi-miR-987*;dsi-miR-987-3p; +MIMAT0012435 dsi-miR-988*;dsi-miR-988-5p; +MIMAT0012436 dsi-miR-988;dsi-miR-988-3p; +MIMAT0012437 dsi-miR-967;dsi-miR-967-5p; +MIMAT0012438 dsi-miR-967*;dsi-miR-967-3p; +MIMAT0012439 dsi-miR-1002;dsi-miR-1002-5p; +MIMAT0012440 dsi-miR-1002*;dsi-miR-1002-3p; +MIMAT0012441 dsi-miR-968;dsi-miR-968-5p; +MIMAT0012442 dsi-miR-968*;dsi-miR-968-3p; +MIMAT0012443 dsi-miR-1006*;dsi-miR-1006-5p; +MIMAT0012444 dsi-miR-1006;dsi-miR-1006-3p; +MIMAT0012445 dsi-miR-958;dsi-miR-958-5p; +MIMAT0012446 dsi-miR-958*;dsi-miR-958-3p; +MIMAT0012447 dsi-miR-955;dsi-miR-955-5p; +MIMAT0012448 dsi-miR-955*;dsi-miR-955-3p; +MIMAT0012449 dsi-miR-190*;dsi-miR-190-5p; +MIMAT0012450 dsi-miR-190;dsi-miR-190-3p; +MIMAT0012451 dsi-miR-193*;dsi-miR-193-5p; +MIMAT0012452 dsi-miR-193;dsi-miR-193-3p; +MIMAT0012453 dsi-miR-995*;dsi-miR-995-5p; +MIMAT0012454 dsi-miR-995;dsi-miR-995-3p; +MIMAT0012455 dsi-miR-999*;dsi-miR-999-5p; +MIMAT0012456 dsi-miR-999;dsi-miR-999-3p; +MIMAT0012457 dsi-miR-1000;dsi-miR-1000-5p; +MIMAT0012458 dsi-miR-1000*;dsi-miR-1000-3p; +MIMAT0012459 dsi-miR-929;dsi-miR-929-5p; +MIMAT0012460 dsi-miR-929*;dsi-miR-929-3p; +MIMAT0012461 dsi-miR-993*;dsi-miR-993-5p; +MIMAT0012462 dsi-miR-993;dsi-miR-993-3p; +MIMAT0012463 dsi-miR-1010*;dsi-miR-1010-5p; +MIMAT0012464 dsi-miR-1010;dsi-miR-1010-3p; +MIMAT0012465 dsi-miR-252;dsi-miR-252-5p; +MIMAT0012466 dsi-miR-252*;dsi-miR-252-3p; +MIMAT0012467 dsi-miR-1005*;dsi-miR-1005-5p; +MIMAT0012468 dsi-miR-1005;dsi-miR-1005-3p; +MIMAT0012469 dsi-miR-961;dsi-miR-961-5p; +MIMAT0012470 dsi-miR-961*;dsi-miR-961-3p; +MIMAT0012471 dsi-miR-965;dsi-miR-965-5p; +MIMAT0012472 dsi-miR-965*;dsi-miR-965-3p; +MIMAT0012473 dsi-miR-963;dsi-miR-963-5p; +MIMAT0012474 dsi-miR-963*;dsi-miR-963-3p; +MIMAT0012475 dsi-miR-964;dsi-miR-964-5p; +MIMAT0012476 dsi-miR-964*;dsi-miR-964-3p; +MIMAT0012477 dsi-miR-932;dsi-miR-932-5p; +MIMAT0012478 dsi-miR-932*;dsi-miR-932-3p; +MIMAT0012479 dsi-miR-969*;dsi-miR-969-5p; +MIMAT0012480 dsi-miR-969;dsi-miR-969-3p; +MIMAT0012481 dsi-miR-980*;dsi-miR-980-5p; +MIMAT0012482 dsi-miR-980;dsi-miR-980-3p; +MIMAT0012483 dsi-miR-927;dsi-miR-927-5p; +MIMAT0012484 dsi-miR-927*;dsi-miR-927-3p; +MIMAT0012485 dsi-miR-981*;dsi-miR-981-5p; +MIMAT0012486 dsi-miR-981;dsi-miR-981-3p; +MIMAT0012487 dsi-miR-970*;dsi-miR-970-5p; +MIMAT0012488 dsi-miR-970;dsi-miR-970-3p; +MIMAT0012489 dsi-miR-375*;dsi-miR-375-5p; +MIMAT0012490 dsi-miR-375;dsi-miR-375-3p; +MIMAT0012491 dsi-miR-992*;dsi-miR-992-5p; +MIMAT0012492 dsi-miR-992;dsi-miR-992-3p; +MIMAT0012493 dsi-miR-137*;dsi-miR-137-5p; +MIMAT0012494 dsi-miR-137;dsi-miR-137-3p; +MIMAT0012495 dsi-miR-960; +MIMAT0012496 dsi-miR-962; +MIMAT0012497 dsi-miR-989; +MIMAT0012498 dsi-miR-957; +MIMAT0012499 dsi-miR-1013; +MIMAT0012500 dsi-miR-1011; +MIMAT0012501 dsi-miR-975;dsi-miR-975-5p; +MIMAT0012502 dsi-miR-976;dsi-miR-976-3p; +MIMAT0012503 dsi-miR-978-as;dsi-miR-978b;dsi-miR-978b-3p; +MIMAT0012504 dsi-miR-iab-4-as;dsi-miR-iab-8;dsi-miR-iab-8-5p; +MIMAT0012505 dsi-miR-iab-4-as*;dsi-miR-iab-8*;dsi-miR-iab-8-3p; +MIMAT0012506 dsi-miR-1001;dsi-miR-1001-5p; +MIMAT0012507 dsi-miR-1001*;dsi-miR-1001-3p; +MIMAT0012508 dsi-miR-959; +MIMAT0012509 dsi-miR-2577; +MIMAT0012510 dsi-miR-2489; +MIMAT0012511 dsi-miR-2578; +MIMAT0012512 dsi-miR-2579; +MIMAT0012513 dsi-miR-982c;dsi-miR-982c-3p; +MIMAT0012514 dsi-miR-982b;dsi-miR-982b-3p; +MIMAT0012515 dsi-miR-982a;dsi-miR-982a-5p; +MIMAT0012516 dsi-miR-303;dsi-miR-303-5p; +MIMAT0012517 dsi-miR-2580; +MIMAT0012518 dsi-miR-2581; +MIMAT0012519 dsi-miR-2582a;dsi-miR-2582a-5p; +MIMAT0012520 dsi-miR-2582a*;dsi-miR-2582a-3p; +MIMAT0012521 dsi-miR-2494;dsi-miR-2494-5p; +MIMAT0012522 dsi-miR-2494*;dsi-miR-2494-3p; +MIMAT0012523 dsi-miR-2582b*;dsi-miR-2582b-5p; +MIMAT0012524 dsi-miR-2582b;dsi-miR-2582b-3p; +MIMAT0012525 dsi-miR-983;dsi-miR-983-5p;dsi-miR-983a-5p; +MIMAT0012526 dsi-miR-983*;dsi-miR-983-3p;dsi-miR-983a-3p; +MIMAT0012527 dsi-miR-2583;dsi-miR-2583-5p; +MIMAT0012528 dsi-miR-2583*;dsi-miR-2583-3p; +MIMAT0012529 dsi-miR-2584*;dsi-miR-2584-5p; +MIMAT0012530 dsi-miR-2584;dsi-miR-2584-3p; +MIMAT0012531 dme-miR-10;dme-miR-10-3p; +MIMAT0012532 bta-miR-27a-5p; +MIMAT0012533 bta-miR-99a*;bta-miR-99a-3p; +MIMAT0012534 bta-miR-30b-3p; +MIMAT0012535 bta-miR-345-3p; +MIMAT0012536 bta-miR-22-3p; +MIMAT0012537 bta-miR-423-5p; +MIMAT0012538 bta-miR-23b-5p; +MIMAT0012539 bta-miR-365-5p; +MIMAT0012540 mdv2-miR-M16*;mdv2-miR-M16-3p; +MIMAT0012541 mdv2-miR-M19-5p; +MIMAT0012542 mdv2-miR-M23*;mdv2-miR-M23-3p; +MIMAT0012543 mdv2-miR-M24*;mdv2-miR-M24-5p; +MIMAT0012544 mdv2-miR-M26*;mdv2-miR-M26-3p; +MIMAT0012545 mdv2-miR-M29-3p; +MIMAT0012546 mdv2-miR-M30*;mdv2-miR-M30-3p; +MIMAT0012547 bta-miR-219-3p; +MIMAT0012548 bta-miR-362-3p; +MIMAT0012549 bta-miR-9*;bta-miR-9-3p; +MIMAT0012550 aqc-miR156b; +MIMAT0012551 aqc-miR156a; +MIMAT0012552 aqc-miR159; +MIMAT0012553 aqc-miR160a; +MIMAT0012554 aqc-miR160b; +MIMAT0012555 aqc-miR166e; +MIMAT0012556 aqc-miR166a; +MIMAT0012557 aqc-miR166b; +MIMAT0012558 aqc-miR166c; +MIMAT0012559 aqc-miR166d; +MIMAT0012560 aqc-miR167; +MIMAT0012561 aqc-miR168; +MIMAT0012562 aqc-miR169c; +MIMAT0012563 aqc-miR169a; +MIMAT0012564 aqc-miR169b; +MIMAT0012565 aqc-miR171f; +MIMAT0012566 aqc-miR171a; +MIMAT0012567 aqc-miR171b; +MIMAT0012568 aqc-miR171c; +MIMAT0012569 aqc-miR171d; +MIMAT0012570 aqc-miR171e; +MIMAT0012571 aqc-miR172a; +MIMAT0012572 aqc-miR172b; +MIMAT0012573 aqc-miR319; +MIMAT0012574 aqc-miR395b; +MIMAT0012575 aqc-miR395a; +MIMAT0012576 aqc-miR396a; +MIMAT0012577 aqc-miR396b; +MIMAT0012578 aqc-miR398a; +MIMAT0012579 aqc-miR398b; +MIMAT0012580 aqc-miR399; +MIMAT0012581 aqc-miR408; +MIMAT0012582 aqc-miR477g; +MIMAT0012583 aqc-miR477f; +MIMAT0012584 aqc-miR477e; +MIMAT0012585 aqc-miR477a; +MIMAT0012586 aqc-miR477b; +MIMAT0012587 aqc-miR477c; +MIMAT0012588 aqc-miR477d; +MIMAT0012589 aqc-miR482a; +MIMAT0012590 aqc-miR482b; +MIMAT0012591 aqc-miR482c; +MIMAT0012592 aqc-miR529; +MIMAT0012593 aqc-miR530; +MIMAT0012594 aqc-miR535; +MIMAT0012595 hsv1-miR-H7;hsv1-miR-H7-5p; +MIMAT0012596 hsv1-miR-H7*;hsv1-miR-H7-3p; +MIMAT0012597 hsv1-miR-H8;hsv1-miR-H8-5p; +MIMAT0012598 hsv1-miR-H8*;hsv1-miR-H8-3p; +MIMAT0012599 bmo-miR-2723; +MIMAT0012600 bmo-miR-2724; +MIMAT0012601 bmo-miR-2725; +MIMAT0012602 bmo-miR-2726; +MIMAT0012603 bmo-miR-2727; +MIMAT0012604 bmo-miR-2753; +MIMAT0012605 bmo-miR-2728; +MIMAT0012606 bmo-miR-2729; +MIMAT0012607 bmo-miR-2730; +MIMAT0012608 bmo-miR-2731a;bmo-miR-2731; +MIMAT0012609 bmo-miR-2731b; +MIMAT0012610 bmo-miR-2732; +MIMAT0012611 bmo-miR-2733a;bmo-miR-2733a-5p; +MIMAT0012612 bmo-miR-2734; +MIMAT0012613 bmo-miR-2735; +MIMAT0012614 bmo-miR-2736; +MIMAT0012615 bmo-miR-2737; +MIMAT0012616 bmo-miR-2738; +MIMAT0012617 bmo-miR-2739; +MIMAT0012618 bmo-miR-2740; +MIMAT0012619 bmo-miR-2741; +MIMAT0012620 bmo-miR-2742; +MIMAT0012621 bmo-miR-9c;bmo-miR-9c-3p; +MIMAT0012622 bmo-miR-2743; +MIMAT0012623 bmo-miR-2744; +MIMAT0012624 bmo-miR-2745; +MIMAT0012625 bmo-miR-2746; +MIMAT0012626 bmo-miR-2747; +MIMAT0012627 bmo-miR-2748; +MIMAT0012628 bmo-miR-2749; +MIMAT0012629 bmo-miR-306;bmo-miR-306a;bmo-miR-306a-5p; +MIMAT0012630 bmo-miR-2750; +MIMAT0012631 bmo-miR-2751; +MIMAT0012632 bmo-miR-2752; +MIMAT0012633 bmo-miR-989;bmo-miR-989a; +MIMAT0012634 dpu-bantam; +MIMAT0012635 dpu-miR-1; +MIMAT0012636 dpu-miR-10; +MIMAT0012637 dpu-miR-100; +MIMAT0012638 dpu-miR-12; +MIMAT0012639 dpu-miR-124; +MIMAT0012640 dpu-miR-133; +MIMAT0012641 dpu-miR-137; +MIMAT0012642 dpu-miR-153; +MIMAT0012643 dpu-miR-193; +MIMAT0012644 dpu-miR-283; +MIMAT0012645 dpu-miR-219; +MIMAT0012646 dpu-miR-745; +MIMAT0012647 dpu-miR-252a; +MIMAT0012648 dpu-miR-252b; +MIMAT0012649 dpu-miR-263a; +MIMAT0012650 dpu-miR-263b; +MIMAT0012651 dpu-miR-275; +MIMAT0012652 dpu-miR-276; +MIMAT0012653 dpu-miR-278; +MIMAT0012654 dpu-miR-279;dpu-miR-279a; +MIMAT0012655 dpu-miR-281; +MIMAT0012656 dpu-miR-285; +MIMAT0012657 dpu-miR-2a;dpu-miR-2; +MIMAT0012658 dpu-miR-2b; +MIMAT0012659 dpu-miR-31; +MIMAT0012660 dpu-miR-315; +MIMAT0012661 dpu-miR-317; +MIMAT0012662 dpu-miR-33; +MIMAT0012663 dpu-miR-34; +MIMAT0012664 dpu-miR-375; +MIMAT0012665 dpu-miR-307; +MIMAT0012666 dpu-miR-7; +MIMAT0012667 dpu-miR-71; +MIMAT0012668 dpu-miR-79;dpu-miR-9-3p; +MIMAT0012669 dpu-miR-8; +MIMAT0012670 dpu-miR-87; +MIMAT0012671 dpu-miR-9;dpu-miR-9-5p; +MIMAT0012672 dpu-miR-92; +MIMAT0012673 dpu-miR-96; +MIMAT0012674 dpu-miR-965; +MIMAT0012675 dpu-miR-981; +MIMAT0012676 dpu-miR-993; +MIMAT0012677 dpu-miR-iab-4-5p; +MIMAT0012678 dpu-miR-iab-4-3p; +MIMAT0012679 isc-bantam; +MIMAT0012680 isc-let-7; +MIMAT0012681 isc-miR-1; +MIMAT0012682 isc-miR-10; +MIMAT0012683 isc-miR-100; +MIMAT0012684 isc-miR-12; +MIMAT0012685 isc-miR-124; +MIMAT0012686 isc-miR-133; +MIMAT0012687 isc-miR-137; +MIMAT0012688 isc-miR-153; +MIMAT0012689 isc-miR-184; +MIMAT0012690 isc-miR-219; +MIMAT0012691 isc-miR-252b; +MIMAT0012692 isc-miR-263a; +MIMAT0012693 isc-miR-275; +MIMAT0012694 isc-miR-279; +MIMAT0012695 isc-miR-285; +MIMAT0012696 isc-miR-2a; +MIMAT0012697 isc-miR-2b; +MIMAT0012698 isc-miR-315; +MIMAT0012699 isc-miR-317; +MIMAT0012700 isc-miR-375; +MIMAT0012701 isc-miR-307; +MIMAT0012702 isc-miR-7; +MIMAT0012703 isc-miR-71; +MIMAT0012704 isc-miR-750; +MIMAT0012705 isc-miR-79; +MIMAT0012706 isc-miR-8; +MIMAT0012707 isc-miR-87; +MIMAT0012708 isc-miR-96; +MIMAT0012709 isc-miR-993; +MIMAT0012710 hvt-miR-H1; +MIMAT0012711 hvt-miR-H2; +MIMAT0012712 hvt-miR-H3-5p; +MIMAT0012713 hvt-miR-H3-3p; +MIMAT0012714 hvt-miR-H4;hvt-miR-H4-5p; +MIMAT0012715 hvt-miR-H4*;hvt-miR-H4-3p; +MIMAT0012716 hvt-miR-H5;hvt-miR-H5-5p; +MIMAT0012717 hvt-miR-H5*;hvt-miR-H5-3p; +MIMAT0012718 hvt-miR-H7-5p; +MIMAT0012719 hvt-miR-H7-3p; +MIMAT0012720 hvt-miR-H8; +MIMAT0012721 hvt-miR-H9-5p; +MIMAT0012722 hvt-miR-H9-3p; +MIMAT0012723 iltv-miR-I1;iltv-miR-I1-5p; +MIMAT0012724 iltv-miR-I1*;iltv-miR-I1-3p; +MIMAT0012725 iltv-miR-I2; +MIMAT0012726 iltv-miR-I3; +MIMAT0012727 iltv-miR-I4; +MIMAT0012728 iltv-miR-I5*;iltv-miR-I5-5p; +MIMAT0012729 iltv-miR-I5;iltv-miR-I5-3p; +MIMAT0012730 iltv-miR-I6*;iltv-miR-I6-5p; +MIMAT0012731 iltv-miR-I6;iltv-miR-I6-3p; +MIMAT0012732 mdv2-miR-M32*;mdv2-miR-M32-5p; +MIMAT0012733 mdv2-miR-M32;mdv2-miR-M32-3p; +MIMAT0012734 hsa-miR-711; +MIMAT0012735 hsa-miR-718; +MIMAT0012736 mdo-miR-26;mdo-miR-26-5p; +MIMAT0012737 mdo-miR-148;mdo-miR-148-3p; +MIMAT0012738 mdo-miR-153;mdo-miR-153-3p; +MIMAT0012739 mdo-miR-301;mdo-miR-301-3p; +MIMAT0012740 mdo-miR-190a;mdo-miR-190a-5p; +MIMAT0012741 mdo-miR-429; +MIMAT0012742 mdo-miR-106;mdo-miR-106-5p; +MIMAT0012743 mdo-miR-126;mdo-miR-126-5p; +MIMAT0012744 mdo-miR-139;mdo-miR-139-5p; +MIMAT0012745 mdo-miR-140;mdo-miR-140-5p; +MIMAT0012746 mdo-miR-146a;mdo-miR-146a-5p; +MIMAT0012747 mdo-miR-146b;mdo-miR-146b-5p; +MIMAT0012748 mdo-miR-150;mdo-miR-150-5p; +MIMAT0012749 mdo-miR-205a; +MIMAT0012750 mdo-miR-210;mdo-miR-210-3p; +MIMAT0012751 mdo-miR-215; +MIMAT0012752 mdo-miR-455;mdo-miR-455-5p; +MIMAT0012753 mdo-miR-499;mdo-miR-499-5p; +MIMAT0012754 mdo-miR-33;mdo-miR-33-5p; +MIMAT0012755 mdo-miR-363; +MIMAT0012756 mdo-miR-190b; +MIMAT0012757 mdo-miR-147b; +MIMAT0012758 mdo-miR-460;mdo-miR-460-5p; +MIMAT0012759 mdo-miR-28; +MIMAT0012760 mdo-miR-195; +MIMAT0012761 mdo-miR-151; +MIMAT0012762 mdo-miR-497;mdo-miR-497-5p; +MIMAT0012763 mdo-miR-551a; +MIMAT0012764 mdo-miR-551b;mdo-miR-551b-3p; +MIMAT0012765 mdo-miR-599;mdo-miR-599-3p; +MIMAT0012766 mdo-miR-875;mdo-miR-875-5p; +MIMAT0012767 mdo-miR-885; +MIMAT0012768 mdo-miR-761; +MIMAT0012769 mdo-miR-759; +MIMAT0012770 mdo-miR-739; +MIMAT0012771 mmu-miR-432; +MIMAT0012772 mmu-miR-599; +MIMAT0012773 mmu-miR-767; +MIMAT0012774 mmu-miR-664;mmu-miR-664-3p; +MIMAT0012775 mml-miR-129; +MIMAT0012776 mml-miR-526b; +MIMAT0012777 mml-miR-524;mml-miR-524-5p; +MIMAT0012778 mml-miR-516;mml-miR-516b; +MIMAT0012779 mml-miR-571; +MIMAT0012780 mml-miR-595; +MIMAT0012781 mml-miR-603; +MIMAT0012782 mml-miR-622; +MIMAT0012783 mml-miR-892b; +MIMAT0012784 mml-miR-541;mml-miR-541-5p; +MIMAT0012785 mml-miR-708;mml-miR-708-5p; +MIMAT0012786 mml-miR-665; +MIMAT0012787 mml-miR-543;mml-miR-543-3p; +MIMAT0012788 mml-miR-760; +MIMAT0012789 mml-miR-1233; +MIMAT0012790 mml-miR-1234; +MIMAT0012791 mml-miR-762; +MIMAT0012792 mml-miR-670;mml-miR-670-5p; +MIMAT0012793 mml-miR-761; +MIMAT0012794 mml-miR-764; +MIMAT0012795 mml-miR-759; +MIMAT0012796 mml-miR-711; +MIMAT0012797 oan-miR-92c; +MIMAT0012798 oan-miR-182;oan-miR-182-5p; +MIMAT0012799 ptr-miR-892b; +MIMAT0012800 ptr-miR-664b; +MIMAT0012801 ptr-miR-299; +MIMAT0012802 ptr-miR-373; +MIMAT0012803 ptr-miR-497; +MIMAT0012804 ptr-miR-570; +MIMAT0012805 ptr-miR-571; +MIMAT0012806 ptr-miR-589; +MIMAT0012807 ptr-miR-596; +MIMAT0012808 ptr-miR-602; +MIMAT0012809 ptr-miR-604; +MIMAT0012810 ptr-miR-606; +MIMAT0012811 ptr-miR-623; +MIMAT0012812 ptr-miR-631; +MIMAT0012813 ptr-miR-651; +MIMAT0012814 ptr-miR-661; +MIMAT0012815 ptr-miR-762; +MIMAT0012816 ptr-miR-670; +MIMAT0012817 ptr-miR-761; +MIMAT0012818 ptr-miR-764; +MIMAT0012819 ptr-miR-759; +MIMAT0012820 ptr-miR-711; +MIMAT0012821 ptr-miR-718; +MIMAT0012822 rno-miR-202;rno-miR-202-5p; +MIMAT0012823 rno-miR-490;rno-miR-490-3p; +MIMAT0012824 rno-miR-513; +MIMAT0012825 rno-miR-105; +MIMAT0012826 rno-miR-220; +MIMAT0012827 rno-miR-1224; +MIMAT0012828 rno-miR-362;rno-miR-362-5p; +MIMAT0012829 rno-miR-511;rno-miR-511-5p; +MIMAT0012830 rno-miR-504; +MIMAT0012831 rno-miR-544;rno-miR-544-3p; +MIMAT0012832 rno-miR-568; +MIMAT0012833 rno-miR-582;rno-miR-582-5p; +MIMAT0012834 rno-miR-592; +MIMAT0012835 rno-miR-615; +MIMAT0012836 rno-miR-628; +MIMAT0012837 rno-miR-632; +MIMAT0012838 rno-miR-653;rno-miR-653-5p; +MIMAT0012839 rno-miR-668; +MIMAT0012840 rno-miR-802;rno-miR-802-5p; +MIMAT0012841 rno-miR-675;rno-miR-675-5p; +MIMAT0012842 rno-miR-875; +MIMAT0012843 rno-miR-876; +MIMAT0012844 rno-miR-665; +MIMAT0012845 rno-miR-935; +MIMAT0012846 rno-miR-201;rno-miR-201-5p; +MIMAT0012847 rno-miR-293;rno-miR-293-5p; +MIMAT0012848 rno-miR-294; +MIMAT0012849 rno-miR-295;rno-miR-295-5p; +MIMAT0012850 rno-miR-465;rno-miR-465-5p; +MIMAT0012851 rno-miR-547;rno-miR-547-3p; +MIMAT0012852 rno-miR-667;rno-miR-667-3p; +MIMAT0012853 rno-miR-761; +MIMAT0012854 rno-miR-764;rno-miR-764-5p; +MIMAT0012855 rno-miR-666;rno-miR-666-5p; +MIMAT0012856 rno-miR-759; +MIMAT0012857 rno-miR-678; +MIMAT0012858 rno-miR-685; +MIMAT0012859 rno-miR-711; +MIMAT0012860 rno-miR-496;rno-miR-496-3p; +MIMAT0012861 iltv-miR-I7; +MIMAT0012862 hvt-miR-H10; +MIMAT0012863 hvt-miR-H12-5p; +MIMAT0012864 hvt-miR-H12-3p; +MIMAT0012865 hvt-miR-H13; +MIMAT0012866 hvt-miR-H14;hvt-miR-H14-5p; +MIMAT0012867 hvt-miR-H14*;hvt-miR-H14-3p; +MIMAT0012868 hvt-miR-H15*;hvt-miR-H15-5p; +MIMAT0012869 hvt-miR-H15;hvt-miR-H15-3p; +MIMAT0012870 hvt-miR-H16-5p; +MIMAT0012871 hvt-miR-H16-3p; +MIMAT0012872 hvt-miR-H17*;hvt-miR-H17-5p; +MIMAT0012873 hvt-miR-H17;hvt-miR-H17-3p; +MIMAT0012874 hvt-miR-H18-5p; +MIMAT0012875 hvt-miR-H18-3p; +MIMAT0012876 hvt-miR-H11; +MIMAT0012877 peu-miR2910; +MIMAT0012878 peu-miR2911; +MIMAT0012879 peu-miR2912a; +MIMAT0012880 peu-miR2912b; +MIMAT0012881 peu-miR2913; +MIMAT0012882 peu-miR2914; +MIMAT0012883 peu-miR2915; +MIMAT0012884 peu-miR2916; +MIMAT0012885 bta-miR-2917; +MIMAT0012886 eca-miR-107b; +MIMAT0012887 eca-miR-1179; +MIMAT0012888 eca-miR-1244; +MIMAT0012889 eca-miR-1282; +MIMAT0012890 eca-miR-1296; +MIMAT0012891 eca-miR-146b-5p; +MIMAT0012892 eca-miR-146b-3p; +MIMAT0012893 eca-miR-1839; +MIMAT0012894 eca-miR-184; +MIMAT0012895 eca-miR-1892; +MIMAT0012896 eca-miR-190;eca-miR-190a; +MIMAT0012897 eca-miR-1905a; +MIMAT0012898 eca-miR-204a; +MIMAT0012899 eca-miR-208a; +MIMAT0012900 eca-miR-208b; +MIMAT0012901 eca-miR-211; +MIMAT0012902 eca-miR-346; +MIMAT0012903 eca-miR-628a; +MIMAT0012904 eca-miR-685; +MIMAT0012905 eca-miR-7; +MIMAT0012906 eca-miR-124; +MIMAT0012907 eca-miR-1302; +MIMAT0012908 eca-miR-147b; +MIMAT0012909 eca-miR-200a; +MIMAT0012910 eca-miR-200b; +MIMAT0012911 eca-miR-302a; +MIMAT0012912 eca-miR-302b; +MIMAT0012913 eca-miR-302c; +MIMAT0012914 eca-miR-302d; +MIMAT0012915 eca-miR-30c; +MIMAT0012916 eca-miR-30e; +MIMAT0012917 eca-miR-34;eca-miR-34a; +MIMAT0012918 eca-miR-367; +MIMAT0012919 eca-miR-429; +MIMAT0012920 eca-miR-492; +MIMAT0012921 eca-miR-551a; +MIMAT0012922 eca-miR-598; +MIMAT0012923 eca-miR-761; +MIMAT0012924 eca-miR-1261; +MIMAT0012925 eca-miR-138; +MIMAT0012926 eca-miR-140-5p; +MIMAT0012927 eca-miR-140-3p; +MIMAT0012928 eca-miR-218; +MIMAT0012929 eca-miR-328; +MIMAT0012930 eca-miR-684; +MIMAT0012931 eca-miR-95; +MIMAT0012932 eca-miR-129a-5p; +MIMAT0012933 eca-miR-129a-3p; +MIMAT0012934 eca-miR-1302b; +MIMAT0012935 eca-miR-148a; +MIMAT0012936 eca-miR-153; +MIMAT0012937 eca-miR-182; +MIMAT0012938 eca-miR-183; +MIMAT0012939 eca-miR-196b; +MIMAT0012940 eca-miR-29a; +MIMAT0012941 eca-miR-29b; +MIMAT0012942 eca-miR-335; +MIMAT0012943 eca-miR-489; +MIMAT0012944 eca-miR-490-5p; +MIMAT0012945 eca-miR-490-3p; +MIMAT0012946 eca-miR-592; +MIMAT0012947 eca-miR-653; +MIMAT0012948 eca-miR-671-5p; +MIMAT0012949 eca-miR-671-3p; +MIMAT0012950 eca-miR-96; +MIMAT0012951 eca-miR-101; +MIMAT0012952 eca-miR-135b; +MIMAT0012953 eca-miR-137; +MIMAT0012954 eca-miR-15b; +MIMAT0012955 eca-miR-16; +MIMAT0012956 eca-miR-186; +MIMAT0012957 eca-miR-1905b; +MIMAT0012958 eca-miR-190b; +MIMAT0012959 eca-miR-197; +MIMAT0012960 eca-miR-199a-5p; +MIMAT0012961 eca-miR-199a-3p; +MIMAT0012962 eca-miR-205; +MIMAT0012963 eca-miR-214; +MIMAT0012964 eca-miR-29c; +MIMAT0012965 eca-miR-488; +MIMAT0012966 eca-miR-92b; +MIMAT0012967 eca-miR-9a; +MIMAT0012968 eca-miR-1291a; +MIMAT0012969 eca-miR-1302d; +MIMAT0012970 eca-miR-141; +MIMAT0012971 eca-miR-148b-5p; +MIMAT0012972 eca-miR-148b-3p; +MIMAT0012973 eca-miR-149; +MIMAT0012974 eca-miR-200c; +MIMAT0012975 eca-miR-26a; +MIMAT0012976 eca-miR-615-5p; +MIMAT0012977 eca-miR-615-3p; +MIMAT0012978 eca-miR-763; +MIMAT0012979 eca-let-7a; +MIMAT0012980 eca-miR-100; +MIMAT0012981 eca-miR-125b-5p; +MIMAT0012982 eca-miR-1302c; +MIMAT0012983 eca-miR-139-5p; +MIMAT0012984 eca-miR-139-3p; +MIMAT0012985 eca-miR-1905c; +MIMAT0012986 eca-miR-23a; +MIMAT0012987 eca-miR-24; +MIMAT0012988 eca-miR-27a; +MIMAT0012989 eca-miR-326; +MIMAT0012990 eca-miR-34b-5p; +MIMAT0012991 eca-miR-34b-3p; +MIMAT0012992 eca-miR-34c; +MIMAT0012993 eca-miR-708; +MIMAT0012994 eca-miR-1; +MIMAT0012995 eca-miR-122; +MIMAT0012996 eca-miR-130b; +MIMAT0012997 eca-miR-133a; +MIMAT0012998 eca-miR-1597; +MIMAT0012999 eca-miR-187; +MIMAT0013000 eca-miR-301b-5p; +MIMAT0013001 eca-miR-301b-3p; +MIMAT0013002 eca-miR-703; +MIMAT0013003 eca-miR-1204; +MIMAT0013004 eca-miR-151-5p; +MIMAT0013005 eca-miR-30b; +MIMAT0013006 eca-miR-30d; +MIMAT0013007 eca-let-7e; +MIMAT0013008 eca-miR-125a-5p; +MIMAT0013009 eca-miR-125a-3p; +MIMAT0013010 eca-miR-1302e; +MIMAT0013011 eca-miR-150; +MIMAT0013012 eca-miR-330; +MIMAT0013013 eca-miR-371-5p; +MIMAT0013014 eca-miR-371-3p; +MIMAT0013015 eca-miR-769-5p;eca-miR-769a-5p; +MIMAT0013016 eca-miR-769-3p;eca-miR-769a-3p; +MIMAT0013017 eca-miR-769b; +MIMAT0013018 eca-miR-99b; +MIMAT0013019 eca-miR-10a; +MIMAT0013020 eca-miR-1180; +MIMAT0013021 eca-miR-132; +MIMAT0013022 eca-miR-142-5p; +MIMAT0013023 eca-miR-142-3p; +MIMAT0013024 eca-miR-144; +MIMAT0013025 eca-miR-193a-5p; +MIMAT0013026 eca-miR-193a-3p; +MIMAT0013027 eca-miR-195; +MIMAT0013028 eca-miR-196a; +MIMAT0013029 eca-miR-21; +MIMAT0013030 eca-miR-212; +MIMAT0013031 eca-miR-22; +MIMAT0013032 eca-miR-301a; +MIMAT0013033 eca-miR-324-5p; +MIMAT0013034 eca-miR-324-3p; +MIMAT0013035 eca-miR-338-5p; +MIMAT0013036 eca-miR-338-3p; +MIMAT0013037 eca-miR-33b; +MIMAT0013038 eca-miR-365; +MIMAT0013039 eca-miR-423-5p; +MIMAT0013040 eca-miR-423-3p; +MIMAT0013041 eca-miR-451; +MIMAT0013042 eca-miR-454; +MIMAT0013043 eca-miR-497; +MIMAT0013044 eca-miR-632; +MIMAT0013045 eca-miR-129b-5p; +MIMAT0013046 eca-miR-129b-3p; +MIMAT0013047 eca-miR-130a; +MIMAT0013048 eca-miR-1902; +MIMAT0013049 eca-miR-192; +MIMAT0013050 eca-miR-194; +MIMAT0013051 eca-miR-493a; +MIMAT0013052 eca-miR-670; +MIMAT0013053 eca-miR-675; +MIMAT0013054 eca-miR-106b; +MIMAT0013055 eca-miR-1842; +MIMAT0013056 eca-miR-193b; +MIMAT0013057 eca-miR-25; +MIMAT0013058 eca-miR-590-5p; +MIMAT0013059 eca-miR-590-3p; +MIMAT0013060 eca-miR-93; +MIMAT0013061 eca-miR-107a; +MIMAT0013062 eca-miR-1271;eca-miR-1271a; +MIMAT0013063 eca-miR-143; +MIMAT0013064 eca-miR-145; +MIMAT0013065 eca-miR-146a; +MIMAT0013066 eca-miR-340-5p; +MIMAT0013067 eca-miR-340-3p; +MIMAT0013068 eca-miR-378; +MIMAT0013069 eca-miR-874; +MIMAT0013070 eca-miR-1301; +MIMAT0013071 eca-miR-1461; +MIMAT0013072 eca-miR-216a; +MIMAT0013073 eca-miR-216b; +MIMAT0013074 eca-miR-217; +MIMAT0013075 eca-let-7g; +MIMAT0013076 eca-miR-128; +MIMAT0013077 eca-miR-1289; +MIMAT0013078 eca-miR-135a; +MIMAT0013079 eca-miR-191;eca-miR-191a; +MIMAT0013080 eca-miR-711; +MIMAT0013081 eca-miR-885-5p; +MIMAT0013082 eca-miR-885-3p; +MIMAT0013083 eca-miR-15a; +MIMAT0013084 eca-miR-17; +MIMAT0013085 eca-miR-18a; +MIMAT0013086 eca-miR-19a; +MIMAT0013087 eca-miR-19b; +MIMAT0013088 eca-miR-20a; +MIMAT0013089 eca-miR-92a; +MIMAT0013090 eca-miR-10b; +MIMAT0013091 eca-miR-1248; +MIMAT0013092 eca-miR-28-5p; +MIMAT0013093 eca-miR-28-3p; +MIMAT0013094 eca-miR-551b; +MIMAT0013095 eca-miR-568; +MIMAT0013096 eca-miR-1291b; +MIMAT0013097 eca-miR-133b; +MIMAT0013098 eca-miR-206; +MIMAT0013099 eca-miR-219-5p; +MIMAT0013100 eca-miR-220b; +MIMAT0013101 eca-miR-1898; +MIMAT0013102 eca-miR-449a; +MIMAT0013103 eca-miR-582-5p; +MIMAT0013104 eca-miR-582-3p; +MIMAT0013105 eca-miR-103; +MIMAT0013106 eca-miR-1255b; +MIMAT0013107 eca-miR-296; +MIMAT0013108 eca-miR-499-5p; +MIMAT0013109 eca-miR-499-3p; +MIMAT0013110 eca-let-7d; +MIMAT0013111 eca-let-7f; +MIMAT0013112 eca-miR-204b; +MIMAT0013113 eca-miR-23b; +MIMAT0013114 eca-miR-27b; +MIMAT0013115 eca-miR-31; +MIMAT0013116 eca-miR-491-5p; +MIMAT0013117 eca-miR-491-3p; +MIMAT0013118 eca-miR-544b; +MIMAT0013119 eca-miR-872; +MIMAT0013120 eca-miR-873; +MIMAT0013121 eca-miR-876-5p; +MIMAT0013122 eca-miR-876-3p; +MIMAT0013123 eca-miR-1185; +MIMAT0013124 eca-miR-1193; +MIMAT0013125 eca-miR-1197; +MIMAT0013126 eca-miR-127; +MIMAT0013127 eca-miR-134; +MIMAT0013128 eca-miR-136; +MIMAT0013129 eca-miR-154;eca-miR-154a; +MIMAT0013130 eca-miR-299; +MIMAT0013131 eca-miR-323-5p; +MIMAT0013132 eca-miR-323-3p; +MIMAT0013133 eca-miR-329;eca-miR-329a; +MIMAT0013134 eca-miR-337-5p; +MIMAT0013135 eca-miR-337-3p; +MIMAT0013136 eca-miR-342-5p; +MIMAT0013137 eca-miR-342-3p; +MIMAT0013138 eca-miR-345-5p; +MIMAT0013139 eca-miR-345-3p; +MIMAT0013140 eca-miR-369-5p; +MIMAT0013141 eca-miR-369-3p; +MIMAT0013142 eca-miR-370; +MIMAT0013143 eca-miR-376a; +MIMAT0013144 eca-miR-376b; +MIMAT0013145 eca-miR-376c; +MIMAT0013146 eca-miR-377; +MIMAT0013147 eca-miR-379; +MIMAT0013148 eca-miR-380; +MIMAT0013149 eca-miR-381; +MIMAT0013150 eca-miR-382; +MIMAT0013151 eca-miR-409-5p; +MIMAT0013152 eca-miR-409-3p; +MIMAT0013153 eca-miR-410; +MIMAT0013154 eca-miR-411; +MIMAT0013155 eca-miR-412; +MIMAT0013156 eca-miR-431; +MIMAT0013157 eca-miR-432; +MIMAT0013158 eca-miR-433; +MIMAT0013159 eca-miR-485-5p; +MIMAT0013160 eca-miR-485-3p; +MIMAT0013161 eca-miR-487a; +MIMAT0013162 eca-miR-487b; +MIMAT0013163 eca-miR-493b; +MIMAT0013164 eca-miR-494; +MIMAT0013165 eca-miR-495; +MIMAT0013166 eca-miR-496; +MIMAT0013167 eca-miR-539; +MIMAT0013168 eca-miR-541; +MIMAT0013169 eca-miR-543; +MIMAT0013170 eca-miR-544; +MIMAT0013171 eca-miR-655; +MIMAT0013172 eca-miR-656; +MIMAT0013173 eca-miR-758; +MIMAT0013174 eca-miR-770-5p; +MIMAT0013175 eca-miR-889; +MIMAT0013176 eca-miR-126-5p; +MIMAT0013177 eca-miR-126-3p; +MIMAT0013178 eca-miR-181a; +MIMAT0013179 eca-miR-181b; +MIMAT0013180 eca-miR-32; +MIMAT0013181 eca-let-7c; +MIMAT0013182 eca-miR-155; +MIMAT0013183 eca-miR-802; +MIMAT0013184 eca-miR-99a; +MIMAT0013185 eca-miR-383; +MIMAT0013186 eca-miR-486-5p; +MIMAT0013187 eca-miR-486-3p; +MIMAT0013188 eca-miR-331; +MIMAT0013189 eca-miR-33a; +MIMAT0013190 eca-miR-215; +MIMAT0013191 eca-miR-350; +MIMAT0013192 eca-miR-664; +MIMAT0013193 eca-miR-105; +MIMAT0013194 eca-miR-106a; +MIMAT0013195 eca-miR-1264; +MIMAT0013196 eca-miR-1298; +MIMAT0013197 eca-miR-1468; +MIMAT0013198 eca-miR-188-5p; +MIMAT0013199 eca-miR-188-3p; +MIMAT0013200 eca-miR-18b; +MIMAT0013201 eca-miR-1912; +MIMAT0013202 eca-miR-20b; +MIMAT0013203 eca-miR-221; +MIMAT0013204 eca-miR-222; +MIMAT0013205 eca-miR-223; +MIMAT0013206 eca-miR-224; +MIMAT0013207 eca-miR-322; +MIMAT0013208 eca-miR-361-5p; +MIMAT0013209 eca-miR-361-3p; +MIMAT0013210 eca-miR-362-5p; +MIMAT0013211 eca-miR-362-3p; +MIMAT0013212 eca-miR-363; +MIMAT0013213 eca-miR-374a; +MIMAT0013214 eca-miR-374b; +MIMAT0013215 eca-miR-384; +MIMAT0013216 eca-miR-421; +MIMAT0013217 eca-miR-424; +MIMAT0013218 eca-miR-448; +MIMAT0013219 eca-miR-450a; +MIMAT0013220 eca-miR-450b-5p; +MIMAT0013221 eca-miR-450b-3p; +MIMAT0013222 eca-miR-451a;eca-miR-450c; +MIMAT0013223 eca-miR-500; +MIMAT0013224 eca-miR-501-5p; +MIMAT0013225 eca-miR-502-5p; +MIMAT0013226 eca-miR-502-3p; +MIMAT0013227 eca-miR-503; +MIMAT0013228 eca-miR-504; +MIMAT0013229 eca-miR-505; +MIMAT0013230 eca-miR-507;eca-miR-507a; +MIMAT0013231 eca-miR-508-5p; +MIMAT0013232 eca-miR-508-3p; +MIMAT0013233 eca-miR-509-5p;eca-miR-509a-5p; +MIMAT0013234 eca-miR-514; +MIMAT0013235 eca-miR-532-5p; +MIMAT0013236 eca-miR-532-3p; +MIMAT0013237 eca-miR-542-5p; +MIMAT0013238 eca-miR-542-3p; +MIMAT0013239 eca-miR-545; +MIMAT0013240 eca-miR-652; +MIMAT0013241 eca-miR-660; +MIMAT0013242 eca-miR-672; +MIMAT0013243 eca-miR-764-5p; +MIMAT0013244 eca-miR-764-3p; +MIMAT0013245 eca-miR-767-5p; +MIMAT0013246 eca-miR-767-3p; +MIMAT0013247 eca-miR-98; +MIMAT0013248 mtr-miR169p;mtr-miR169k; +MIMAT0013249 mtr-miR2585a; +MIMAT0013250 mtr-miR2585b; +MIMAT0013251 mtr-miR2586;mtr-miR2586a; +MIMAT0013252 mtr-miR2587a; +MIMAT0013253 mtr-miR2587b; +MIMAT0013254 mtr-miR2587c; +MIMAT0013255 mtr-miR2587d; +MIMAT0013256 mtr-miR2587e; +MIMAT0013257 mtr-miR2587f; +MIMAT0013258 mtr-miR2588a; +MIMAT0013259 mtr-miR2588b; +MIMAT0013260 mtr-miR2589; +MIMAT0013261 mtr-miR2590a; +MIMAT0013262 mtr-miR2590b; +MIMAT0013263 mtr-miR2590c; +MIMAT0013264 mtr-miR2590d; +MIMAT0013265 mtr-miR2590e; +MIMAT0013266 mtr-miR2590f; +MIMAT0013267 mtr-miR2591; +MIMAT0013268 mtr-miR2592b;mtr-miR2592b-3p; +MIMAT0013269 mtr-miR2592c; +MIMAT0013270 mtr-miR2592d;mtr-miR2592d-3p; +MIMAT0013271 mtr-miR2592e;mtr-miR2592e-3p; +MIMAT0013272 mtr-miR2592f; +MIMAT0013273 mtr-miR2592i; +MIMAT0013274 mtr-miR2592j; +MIMAT0013275 mtr-miR2592o;mtr-miR2592o-3p; +MIMAT0013276 mtr-miR2592p; +MIMAT0013277 mtr-miR2592q;mtr-miR2592q-3p; +MIMAT0013278 mtr-miR2592r; +MIMAT0013279 mtr-miR2592s;mtr-miR2592s-3p; +MIMAT0013280 mtr-miR2593a; +MIMAT0013281 mtr-miR2593b; +MIMAT0013282 mtr-miR2593c; +MIMAT0013283 mtr-miR2594a;mtr-miR2594; +MIMAT0013284 mtr-miR2594b; +MIMAT0013285 mtr-miR2595; +MIMAT0013286 mtr-miR2596; +MIMAT0013287 mtr-miR2597; +MIMAT0013288 mtr-miR2111g;mtr-miR2111g-3p; +MIMAT0013289 mtr-miR2111h;mtr-miR2111c; +MIMAT0013290 mtr-miR2111i; +MIMAT0013291 mtr-miR2111j;mtr-miR2111d-5p; +MIMAT0013292 mtr-miR2111k;mtr-miR2111e-5p; +MIMAT0013293 mtr-miR2111l; +MIMAT0013294 mtr-miR2111m;mtr-miR2111g-5p; +MIMAT0013295 mtr-miR2111n;mtr-miR2111h; +MIMAT0013296 mtr-miR2111o;mtr-miR2111i; +MIMAT0013297 mtr-miR2111p;mtr-miR2111m-5p; +MIMAT0013298 mtr-miR2111q; +MIMAT0013299 mtr-miR2111r;mtr-miR2111n; +MIMAT0013300 mtr-miR2111s;mtr-miR2111o; +MIMAT0013301 mtr-miR2598; +MIMAT0013302 mtr-miR2599; +MIMAT0013303 mtr-miR2600;mtr-miR2600a; +MIMAT0013304 mtr-miR2601; +MIMAT0013305 mtr-miR2602a; +MIMAT0013306 mtr-miR2602b; +MIMAT0013307 mtr-miR2603; +MIMAT0013308 mtr-miR2604; +MIMAT0013309 mtr-miR2605; +MIMAT0013310 mtr-miR2606a; +MIMAT0013311 mtr-miR2606b; +MIMAT0013312 mtr-miR2606c; +MIMAT0013313 mtr-miR2607; +MIMAT0013314 mtr-miR2608; +MIMAT0013315 mtr-miR2609a; +MIMAT0013316 mtr-miR2609b; +MIMAT0013317 mtr-miR2609c; +MIMAT0013318 mtr-miR2610a; +MIMAT0013319 mtr-miR2610b; +MIMAT0013320 mtr-miR2611; +MIMAT0013321 mtr-miR169q;mtr-miR169j; +MIMAT0013322 mtr-miR2585c; +MIMAT0013323 mtr-miR2585d; +MIMAT0013324 mtr-miR2585e; +MIMAT0013325 mtr-miR2612a;mtr-miR2612; +MIMAT0013326 mtr-miR2612b; +MIMAT0013327 mtr-miR2613; +MIMAT0013328 mtr-miR2614; +MIMAT0013329 mtr-miR2615a; +MIMAT0013330 mtr-miR2615b; +MIMAT0013331 mtr-miR2615c; +MIMAT0013332 mtr-miR2616; +MIMAT0013333 mtr-miR1509b; +MIMAT0013334 mtr-miR2617a; +MIMAT0013335 mtr-miR2617c; +MIMAT0013336 mtr-miR2617b; +MIMAT0013337 mtr-miR2618a; +MIMAT0013338 mtr-miR2618b; +MIMAT0013339 mtr-miR2619;mtr-miR2619a; +MIMAT0013340 mtr-miR2620; +MIMAT0013341 mtr-miR2621; +MIMAT0013342 mtr-miR2622; +MIMAT0013343 mtr-miR2623; +MIMAT0013344 mtr-miR2624a;mtr-miR2624; +MIMAT0013345 mtr-miR2624b; +MIMAT0013346 mtr-miR2625; +MIMAT0013347 mtr-miR2626; +MIMAT0013348 mtr-miR2627; +MIMAT0013349 mtr-miR2592a;mtr-miR2592a.2;mtr-miR2592a.2-3p; +MIMAT0013350 mtr-miR2592g; +MIMAT0013351 mtr-miR2592h; +MIMAT0013352 mtr-miR2592k; +MIMAT0013353 mtr-miR2592l; +MIMAT0013354 mtr-miR2592m; +MIMAT0013355 mtr-miR2592n; +MIMAT0013356 mtr-miR2111a; +MIMAT0013357 mtr-miR2111b; +MIMAT0013358 mtr-miR2111c;mtr-miR2111b; +MIMAT0013359 mtr-miR2111d; +MIMAT0013360 mtr-miR2111e;mtr-miR2111j; +MIMAT0013361 mtr-miR2111f;mtr-miR2111k; +MIMAT0013362 mtr-miR2628; +MIMAT0013363 mtr-miR2629a; +MIMAT0013364 mtr-miR2629d; +MIMAT0013365 mtr-miR2629e; +MIMAT0013366 mtr-miR2629b; +MIMAT0013367 mtr-miR2629c; +MIMAT0013368 mtr-miR2629f; +MIMAT0013369 mtr-miR2629g; +MIMAT0013370 mtr-miR2630a; +MIMAT0013371 mtr-miR2630b; +MIMAT0013372 mtr-miR2630c; +MIMAT0013373 mtr-miR2630w; +MIMAT0013374 mtr-miR2630x; +MIMAT0013375 mtr-miR2630y; +MIMAT0013376 mtr-miR2630d; +MIMAT0013377 mtr-miR2630e; +MIMAT0013378 mtr-miR2630f; +MIMAT0013379 mtr-miR2630g; +MIMAT0013380 mtr-miR2630h; +MIMAT0013381 mtr-miR2630i; +MIMAT0013382 mtr-miR2630j; +MIMAT0013383 mtr-miR2630k; +MIMAT0013384 mtr-miR2630l; +MIMAT0013385 mtr-miR2630m; +MIMAT0013386 mtr-miR2630n; +MIMAT0013387 mtr-miR2630o; +MIMAT0013388 mtr-miR2630p; +MIMAT0013389 mtr-miR2630q; +MIMAT0013390 mtr-miR2630r; +MIMAT0013391 mtr-miR2630s; +MIMAT0013392 mtr-miR2630t; +MIMAT0013393 mtr-miR2630u; +MIMAT0013394 mtr-miR2630v; +MIMAT0013395 mtr-miR2631; +MIMAT0013396 mtr-miR2632a; +MIMAT0013397 mtr-miR2632b; +MIMAT0013398 mtr-miR2632c; +MIMAT0013399 mtr-miR2633; +MIMAT0013400 mtr-miR2634; +MIMAT0013401 mtr-miR2635; +MIMAT0013402 mtr-miR2636; +MIMAT0013403 mtr-miR2637; +MIMAT0013404 mtr-miR2638a; +MIMAT0013405 mtr-miR2638b; +MIMAT0013406 mtr-miR2639; +MIMAT0013407 mtr-miR2640a;mtr-miR2640; +MIMAT0013408 mtr-miR2640b; +MIMAT0013409 mtr-miR2641; +MIMAT0013410 mtr-miR2642; +MIMAT0013411 mtr-miR2643;mtr-miR2643a; +MIMAT0013412 mtr-miR2644a;mtr-miR2644; +MIMAT0013413 mtr-miR2644b; +MIMAT0013414 mtr-miR2645; +MIMAT0013415 mtr-miR2646a; +MIMAT0013416 mtr-miR2646b; +MIMAT0013417 mtr-miR2647a; +MIMAT0013418 mtr-miR2647b; +MIMAT0013419 mtr-miR2647c; +MIMAT0013420 mtr-miR2648; +MIMAT0013421 mtr-miR2649; +MIMAT0013422 mtr-miR2650; +MIMAT0013423 mtr-miR2651; +MIMAT0013424 mtr-miR2652a; +MIMAT0013425 mtr-miR2652b; +MIMAT0013426 mtr-miR2652c; +MIMAT0013427 mtr-miR2652d; +MIMAT0013428 mtr-miR2652e; +MIMAT0013429 mtr-miR2652f; +MIMAT0013430 mtr-miR2652g; +MIMAT0013431 mtr-miR2652h; +MIMAT0013432 mtr-miR2652i; +MIMAT0013433 mtr-miR2652j; +MIMAT0013434 mtr-miR2652k; +MIMAT0013435 mtr-miR2652l; +MIMAT0013436 mtr-miR2653a; +MIMAT0013437 mtr-miR2653b; +MIMAT0013438 mtr-miR2653c; +MIMAT0013439 mtr-miR2654; +MIMAT0013440 mtr-miR2655a; +MIMAT0013441 mtr-miR2655b; +MIMAT0013442 mtr-miR2655c; +MIMAT0013443 mtr-miR2655d; +MIMAT0013444 mtr-miR2655e; +MIMAT0013445 mtr-miR2655f; +MIMAT0013446 mtr-miR2655g; +MIMAT0013447 mtr-miR2655h; +MIMAT0013448 mtr-miR2655i; +MIMAT0013449 mtr-miR2655j; +MIMAT0013450 mtr-miR2655k; +MIMAT0013451 mtr-miR2655l; +MIMAT0013452 mtr-miR2655m; +MIMAT0013453 mtr-miR2655n; +MIMAT0013454 mtr-miR2655o; +MIMAT0013455 mtr-miR2656a; +MIMAT0013456 mtr-miR2656b; +MIMAT0013457 mtr-miR2657a;mtr-miR2657; +MIMAT0013458 mtr-miR2657b; +MIMAT0013459 mtr-miR2658; +MIMAT0013460 mtr-miR2659a; +MIMAT0013461 mtr-miR2659b; +MIMAT0013462 mtr-miR2659c; +MIMAT0013463 mtr-miR2659d; +MIMAT0013464 mtr-miR2659e; +MIMAT0013465 mtr-miR2659f; +MIMAT0013466 mtr-miR2660a;mtr-miR2660; +MIMAT0013467 mtr-miR2660b; +MIMAT0013468 mtr-miR2661; +MIMAT0013469 mtr-miR2662; +MIMAT0013470 mtr-miR2663; +MIMAT0013471 mtr-miR2664;mtr-miR2664a; +MIMAT0013472 mtr-miR2665; +MIMAT0013473 mtr-miR2666; +MIMAT0013474 mtr-miR2667;mtr-miR2667a; +MIMAT0013475 mtr-miR2668; +MIMAT0013476 mtr-miR2669;mtr-miR2669a; +MIMAT0013477 mtr-miR399q; +MIMAT0013478 mtr-miR2670a; +MIMAT0013479 mtr-miR2670b; +MIMAT0013480 mtr-miR2670c; +MIMAT0013481 mtr-miR2670d; +MIMAT0013482 mtr-miR2671j; +MIMAT0013483 mtr-miR2671a; +MIMAT0013484 mtr-miR2671b; +MIMAT0013485 mtr-miR2671c; +MIMAT0013486 mtr-miR2671d; +MIMAT0013487 mtr-miR2671e; +MIMAT0013488 mtr-miR2671f; +MIMAT0013489 mtr-miR2671g; +MIMAT0013490 mtr-miR2671h; +MIMAT0013491 mtr-miR2671i; +MIMAT0013492 mtr-miR2672; +MIMAT0013493 mtr-miR2673a; +MIMAT0013494 mtr-miR2673b; +MIMAT0013495 mtr-miR2674; +MIMAT0013496 mtr-miR2675a;mtr-miR2675; +MIMAT0013497 mtr-miR2675b; +MIMAT0013498 mtr-miR2676a; +MIMAT0013499 mtr-miR2676b; +MIMAT0013500 mtr-miR2676c; +MIMAT0013501 mtr-miR2676d; +MIMAT0013502 mtr-miR2676e; +MIMAT0013503 mtr-miR2676f; +MIMAT0013504 mtr-miR2088b; +MIMAT0013505 mtr-miR2677; +MIMAT0013506 mtr-miR2678; +MIMAT0013507 mtr-miR2679a; +MIMAT0013508 mtr-miR2679b; +MIMAT0013509 mtr-miR2679c; +MIMAT0013510 mtr-miR2680a; +MIMAT0013511 mtr-miR2680b; +MIMAT0013512 mtr-miR2680c; +MIMAT0013513 mtr-miR2680d; +MIMAT0013514 mtr-miR2680e; +MIMAT0013515 hsa-miR-2681*;hsa-miR-2681-5p; +MIMAT0013516 hsa-miR-2681;hsa-miR-2681-3p; +MIMAT0013517 hsa-miR-2682;hsa-miR-2682-5p; +MIMAT0013518 hsa-miR-2682*;hsa-miR-2682-3p; +MIMAT0013527 cte-miR-2e; +MIMAT0013528 cte-miR-2f; +MIMAT0013529 cte-miR-993; +MIMAT0013530 cte-miR-36; +MIMAT0013531 cte-miR-277a; +MIMAT0013532 cte-miR-2685*;cte-miR-2685-5p; +MIMAT0013533 cte-miR-2685;cte-miR-2685-3p; +MIMAT0013534 cte-miR-10c-as;cte-miR-10d; +MIMAT0013535 cte-miR-2686a*;cte-miR-2686a-5p; +MIMAT0013536 cte-miR-2686a;cte-miR-2686a-3p; +MIMAT0013537 cte-miR-2686b; +MIMAT0013538 cte-miR-2686c; +MIMAT0013539 cte-miR-2687; +MIMAT0013540 cte-miR-2688*;cte-miR-2688-5p; +MIMAT0013541 cte-miR-2688;cte-miR-2688-3p; +MIMAT0013542 cte-miR-2689; +MIMAT0013543 cte-miR-2690; +MIMAT0013544 cte-miR-2691*;cte-miR-2691-5p; +MIMAT0013545 cte-miR-2691;cte-miR-2691-3p; +MIMAT0013546 cte-miR-1990a; +MIMAT0013547 cte-miR-1990b; +MIMAT0013548 cte-miR-1990c*;cte-miR-1990c-3p; +MIMAT0013549 cte-miR-2692; +MIMAT0013550 cte-miR-2693; +MIMAT0013551 cte-miR-1991; +MIMAT0013552 cte-miR-996; +MIMAT0013553 cte-miR-2694; +MIMAT0013554 cte-miR-2720*;cte-miR-2720-5p; +MIMAT0013555 cte-miR-2720;cte-miR-2720-3p; +MIMAT0013556 cte-miR-2695; +MIMAT0013557 cte-miR-2696; +MIMAT0013558 cte-miR-2697; +MIMAT0013559 cte-miR-2g; +MIMAT0013560 cte-miR-2698; +MIMAT0013561 cte-miR-2699*;cte-miR-2699-5p; +MIMAT0013562 cte-miR-2699;cte-miR-2699-3p; +MIMAT0013563 cte-miR-2700; +MIMAT0013564 cte-miR-2701; +MIMAT0013565 cte-miR-2702;cte-miR-2702-5p; +MIMAT0013566 cte-miR-2702*;cte-miR-2702-3p; +MIMAT0013567 cte-miR-2703*;cte-miR-2703-5p; +MIMAT0013568 cte-miR-2703;cte-miR-2703-3p; +MIMAT0013569 cte-miR-2704; +MIMAT0013570 cte-miR-216c; +MIMAT0013571 cte-miR-2705; +MIMAT0013572 cte-miR-210b; +MIMAT0013573 cte-miR-2706; +MIMAT0013574 cte-miR-2707; +MIMAT0013575 cte-miR-277b; +MIMAT0013576 cte-miR-2708; +MIMAT0013577 cte-miR-2721; +MIMAT0013578 cte-miR-2709; +MIMAT0013579 cte-miR-2710; +MIMAT0013580 cte-miR-2711; +MIMAT0013581 cte-miR-2712; +MIMAT0013582 cte-miR-2713; +MIMAT0013583 cte-miR-2714; +MIMAT0013584 cte-miR-2715; +MIMAT0013585 cte-miR-2716; +MIMAT0013586 cte-miR-2717; +MIMAT0013587 cte-miR-2718; +MIMAT0013588 cte-miR-2719; +MIMAT0013589 lgi-miR-2722; +MIMAT0013590 bta-miR-1388-5p; +MIMAT0013591 bta-miR-1388-3p; +MIMAT0013592 bta-miR-1468; +MIMAT0013593 bta-miR-424;bta-miR-424-5p; +MIMAT0013594 bta-miR-542-5p; +MIMAT0013596 bmo-miR-100; +MIMAT0013597 bmo-miR-316*;bmo-miR-316-5p; +MIMAT0013598 bmo-miR-316;bmo-miR-316-3p; +MIMAT0013599 bmo-miR-33;bmo-miR-33-5p; +MIMAT0013600 bmo-miR-33*;bmo-miR-33-3p; +MIMAT0013601 bmo-miR-11*;bmo-miR-11-5p; +MIMAT0013602 bmo-miR-11;bmo-miR-11-3p; +MIMAT0013603 bmo-miR-998; +MIMAT0013604 bmo-miR-308*;bmo-miR-308-5p; +MIMAT0013605 bmo-miR-308;bmo-miR-308-3p; +MIMAT0013606 bmo-miR-279d*;bmo-miR-279d-5p; +MIMAT0013607 bmo-miR-279d;bmo-miR-279d-3p; +MIMAT0013608 bmo-miR-279b*;bmo-miR-279b-5p; +MIMAT0013609 bmo-miR-279b;bmo-miR-279b-3p; +MIMAT0013610 bmo-miR-279c*;bmo-miR-279c-5p; +MIMAT0013611 bmo-miR-279c;bmo-miR-279c-3p; +MIMAT0013612 bmo-miR-1175-5p; +MIMAT0013613 bmo-miR-1175-3p; +MIMAT0013614 bmo-miR-2754; +MIMAT0013615 bmo-miR-2755*;bmo-miR-2755-5p; +MIMAT0013616 bmo-miR-2755;bmo-miR-2755-3p; +MIMAT0013617 bmo-miR-2733e; +MIMAT0013618 bmo-miR-2733d; +MIMAT0013619 bmo-miR-2733c; +MIMAT0013620 bmo-miR-9d; +MIMAT0013621 bmo-miR-2807c;bmo-miR-2807c-5p; +MIMAT0013622 bmo-miR-2807c*;bmo-miR-2807c-3p; +MIMAT0013623 bmo-miR-2756;bmo-miR-2756-5p; +MIMAT0013624 bmo-miR-2756*;bmo-miR-2756-3p; +MIMAT0013625 bmo-miR-745*;bmo-miR-745-5p; +MIMAT0013626 bmo-miR-745;bmo-miR-745-3p; +MIMAT0013627 bmo-miR-2757;bmo-miR-2757-5p; +MIMAT0013628 bmo-miR-2757*;bmo-miR-2757-3p; +MIMAT0013629 bmo-miR-2758;bmo-miR-2758-5p; +MIMAT0013630 bmo-miR-2758*;bmo-miR-2758-3p; +MIMAT0013631 bmo-miR-2759; +MIMAT0013632 bmo-miR-2760*;bmo-miR-2760-5p; +MIMAT0013633 bmo-miR-2760;bmo-miR-2760-3p; +MIMAT0013634 bmo-miR-2761*;bmo-miR-2761-5p; +MIMAT0013635 bmo-miR-2761;bmo-miR-2761-3p; +MIMAT0013636 bmo-miR-2762; +MIMAT0013637 bmo-miR-2763*;bmo-miR-2763-5p; +MIMAT0013638 bmo-miR-2763;bmo-miR-2763-3p; +MIMAT0013639 bmo-miR-2764; +MIMAT0013640 bmo-miR-2765; +MIMAT0013641 bmo-miR-2766*;bmo-miR-2766-5p; +MIMAT0013642 bmo-miR-2766;bmo-miR-2766-3p; +MIMAT0013643 bmo-miR-2767; +MIMAT0013644 bmo-miR-750*;bmo-miR-750-5p; +MIMAT0013645 bmo-miR-750;bmo-miR-750-3p; +MIMAT0013646 bmo-miR-2768*;bmo-miR-2768-5p; +MIMAT0013647 bmo-miR-2768;bmo-miR-2768-3p; +MIMAT0013648 bmo-miR-375;bmo-miR-375-5p; +MIMAT0013649 bmo-miR-375*;bmo-miR-375-3p; +MIMAT0013650 bmo-miR-2769; +MIMAT0013651 bmo-miR-2770;bmo-miR-2770-5p; +MIMAT0013652 bmo-miR-2770*;bmo-miR-2770-3p; +MIMAT0013653 bmo-miR-2772b; +MIMAT0013654 bmo-miR-2771*;bmo-miR-2771-5p; +MIMAT0013655 bmo-miR-2771;bmo-miR-2771-3p; +MIMAT0013656 bmo-miR-2772a; +MIMAT0013658 bmo-miR-2774a; +MIMAT0013659 bmo-miR-2775a; +MIMAT0013660 bmo-miR-2776; +MIMAT0013661 bmo-miR-2774b; +MIMAT0013662 bmo-miR-2777;bmo-miR-2777-5p; +MIMAT0013663 bmo-miR-2777*;bmo-miR-2777-3p; +MIMAT0013664 bmo-miR-2778a*;bmo-miR-2778a-5p; +MIMAT0013665 bmo-miR-2778a;bmo-miR-2778a-3p; +MIMAT0013666 bmo-miR-2778c;bmo-miR-2778c-5p; +MIMAT0013667 bmo-miR-2778c*;bmo-miR-2778c-3p; +MIMAT0013668 bmo-miR-2779; +MIMAT0013669 bmo-miR-2780a;bmo-miR-2780a-5p; +MIMAT0013670 bmo-miR-2780a*;bmo-miR-2780a-3p; +MIMAT0013671 bmo-miR-2808c; +MIMAT0013672 bmo-miR-2781; +MIMAT0013673 bmo-miR-2778d;bmo-miR-2778d-5p; +MIMAT0013674 bmo-miR-2778d*;bmo-miR-2778d-3p; +MIMAT0013675 bmo-miR-2778b*;bmo-miR-2778b-5p; +MIMAT0013676 bmo-miR-2778b;bmo-miR-2778b-3p; +MIMAT0013678 bmo-miR-2782; +MIMAT0013679 bmo-miR-2783; +MIMAT0013680 bmo-miR-2784; +MIMAT0013681 bmo-miR-2785; +MIMAT0013682 bmo-miR-2786; +MIMAT0013683 bmo-miR-2787*;bmo-miR-2787-5p; +MIMAT0013684 bmo-miR-2787;bmo-miR-2787-3p; +MIMAT0013685 bmo-miR-2788; +MIMAT0013686 bmo-miR-2789; +MIMAT0013687 bmo-miR-2790*;bmo-miR-2790-5p; +MIMAT0013688 bmo-miR-2790;bmo-miR-2790-3p; +MIMAT0013689 bmo-miR-2791; +MIMAT0013690 bmo-miR-2792-5p; +MIMAT0013691 bmo-miR-2792-3p; +MIMAT0013694 bmo-miR-2794; +MIMAT0013695 bmo-miR-2795; +MIMAT0013696 bmo-miR-2796-5p; +MIMAT0013697 bmo-miR-2796-3p; +MIMAT0013698 bmo-miR-2797a; +MIMAT0013699 bmo-miR-2797b; +MIMAT0013700 bmo-miR-2797c; +MIMAT0013701 bmo-miR-2797d; +MIMAT0013702 bmo-miR-2798; +MIMAT0013703 bmo-miR-2799; +MIMAT0013704 bmo-miR-2800; +MIMAT0013705 bmo-miR-2801; +MIMAT0013708 bmo-miR-2803; +MIMAT0013709 bmo-miR-2804*;bmo-miR-2804-5p; +MIMAT0013710 bmo-miR-2804;bmo-miR-2804-3p; +MIMAT0013711 bmo-miR-2808a;bmo-miR-2808a-5p; +MIMAT0013712 bmo-miR-2808a*;bmo-miR-2808a-3p; +MIMAT0013713 bmo-miR-2805; +MIMAT0013715 bmo-miR-2806; +MIMAT0013716 bmo-miR-2807a; +MIMAT0013717 bmo-miR-2809; +MIMAT0013718 bmo-miR-2810; +MIMAT0013720 bmo-miR-2812; +MIMAT0013721 bmo-miR-2813; +MIMAT0013723 bmo-miR-2814; +MIMAT0013726 bmo-miR-2816; +MIMAT0013727 bmo-miR-2817; +MIMAT0013728 bmo-miR-2818; +MIMAT0013729 bmo-miR-2819; +MIMAT0013730 bmo-miR-2820; +MIMAT0013731 bmo-miR-2821; +MIMAT0013732 bmo-miR-2780b; +MIMAT0013733 bmo-miR-2822; +MIMAT0013735 bmo-miR-2824; +MIMAT0013736 bmo-miR-2825; +MIMAT0013737 bmo-miR-2826; +MIMAT0013738 bmo-miR-2827; +MIMAT0013739 bmo-miR-2808b; +MIMAT0013740 bmo-miR-2828; +MIMAT0013742 bmo-miR-2807b; +MIMAT0013743 bmo-miR-2830; +MIMAT0013744 bmo-miR-2831; +MIMAT0013745 bmo-miR-2775b; +MIMAT0013746 bmo-miR-2832; +MIMAT0013747 bmo-miR-2833; +MIMAT0013748 bmo-miR-2834; +MIMAT0013749 bmo-miR-2835; +MIMAT0013750 bmo-miR-2836; +MIMAT0013751 bmo-miR-2837; +MIMAT0013753 bmo-miR-2838; +MIMAT0013754 bmo-miR-2839*;bmo-miR-2839-5p; +MIMAT0013755 bmo-miR-2839;bmo-miR-2839-3p; +MIMAT0013757 bmo-miR-2840; +MIMAT0013758 bmo-miR-2841; +MIMAT0013759 bmo-miR-2774c; +MIMAT0013760 bmo-miR-2780c; +MIMAT0013761 bmo-miR-2842; +MIMAT0013762 bmo-miR-2843;bmo-miR-2843-5p; +MIMAT0013763 bmo-miR-2843-1*;bmo-miR-2843-1-3p; +MIMAT0013765 bmo-miR-2780d; +MIMAT0013766 bmo-miR-2845; +MIMAT0013767 bmo-miR-2846; +MIMAT0013768 bmo-miR-2847; +MIMAT0013769 bmo-miR-2849; +MIMAT0013770 bmo-miR-2848; +MIMAT0013771 hsa-miR-449c*;hsa-miR-449c-3p; +MIMAT0013772 sme-miR-71a-2*;sme-miR-71a-2-3p; +MIMAT0013773 ath-miR1886.3; +MIMAT0013774 bta-miR-124b; +MIMAT0013775 sme-miR-754c-2*;sme-miR-754c-2-3p; +MIMAT0013776 sme-miR-2160-2*;sme-miR-2160-2-3p; +MIMAT0013777 bmo-miR-2733b; +MIMAT0013778 sme-miR-124c-2*;sme-miR-124c-2-5p; +MIMAT0013779 sme-miR-31b*;sme-miR-31b-3p; +MIMAT0013780 eca-miR-199b-5p; +MIMAT0013781 eca-miR-199b-3p; +MIMAT0013782 bmo-miR-306-as;bmo-miR-306b; +MIMAT0013783 bmo-miR-2851; +MIMAT0013785 bmo-miR-2852; +MIMAT0013787 bmo-miR-1-as*;bmo-miR-1b*;bmo-miR-1b-5p; +MIMAT0013788 bmo-miR-1-as;bmo-miR-1;bmo-miR-1b-3p; +MIMAT0013789 bmo-miR-2854; +MIMAT0013790 bmo-miR-2855; +MIMAT0013791 bmo-miR-2833b; +MIMAT0013792 bmo-miR-2856*;bmo-miR-2856-5p; +MIMAT0013793 bmo-miR-2856;bmo-miR-2856-3p; +MIMAT0013796 bmo-miR-2857; +MIMAT0013799 bmo-miR-2859; +MIMAT0013800 bmo-miR-2860; +MIMAT0013801 spu-miR-200*;spu-miR-200-5p; +MIMAT0013802 hsa-miR-2861; +MIMAT0013803 mmu-miR-2861; +MIMAT0013804 ola-miR-430a; +MIMAT0013805 ola-miR-430c; +MIMAT0013806 ola-miR-430b; +MIMAT0013807 ola-miR-430d; +MIMAT0013808 osa-miR2862; +MIMAT0013809 osa-miR2863a; +MIMAT0013810 osa-miR2864.1; +MIMAT0013811 osa-miR2864.2; +MIMAT0013812 osa-miR2865; +MIMAT0013813 osa-miR2866; +MIMAT0013814 osa-miR2867;osa-miR2867-5p; +MIMAT0013815 osa-miR2868; +MIMAT0013816 osa-miR2869; +MIMAT0013817 osa-miR2870; +MIMAT0013818 osa-miR2863b; +MIMAT0013819 osa-miR2905; +MIMAT0013820 osa-miR2871a;osa-miR2871a-3p; +MIMAT0013821 osa-miR2871b;osa-miR2871b-3p; +MIMAT0013822 osa-miR2872; +MIMAT0013823 osa-miR2873;osa-miR2873a; +MIMAT0013824 osa-miR2874; +MIMAT0013825 osa-miR2875; +MIMAT0013826 osa-miR2876;osa-miR2876-3p; +MIMAT0013827 osa-miR2877; +MIMAT0013828 osa-miR2878-5p; +MIMAT0013829 osa-miR2878-3p; +MIMAT0013830 osa-miR1863c; +MIMAT0013831 osa-miR2879; +MIMAT0013832 osa-miR2880; +MIMAT0013833 osa-miR396g; +MIMAT0013834 osa-miR396h; +MIMAT0013835 osa-miR396i;osa-miR396d; +MIMAT0013836 osa-miR1863b; +MIMAT0013837 bta-miR-193a; +MIMAT0013838 bta-miR-669; +MIMAT0013839 bta-miR-2881; +MIMAT0013840 bta-miR-2882; +MIMAT0013841 bta-miR-2883; +MIMAT0013842 bta-miR-2884; +MIMAT0013843 bta-miR-2885; +MIMAT0013844 bta-miR-2886; +MIMAT0013845 bta-miR-2887; +MIMAT0013846 bta-miR-2888; +MIMAT0013847 bta-miR-2889; +MIMAT0013848 bta-miR-2890; +MIMAT0013849 bta-miR-2891; +MIMAT0013850 bta-miR-2892; +MIMAT0013851 bta-miR-2893; +MIMAT0013852 bta-miR-2894; +MIMAT0013853 bta-miR-2895; +MIMAT0013854 bta-miR-2896; +MIMAT0013855 bta-miR-2897; +MIMAT0013856 bta-miR-2898; +MIMAT0013857 bta-miR-2899; +MIMAT0013858 bta-miR-2900; +MIMAT0013859 bta-miR-2901; +MIMAT0013860 bta-miR-2902; +MIMAT0013861 bta-miR-2903; +MIMAT0013862 bta-miR-2904; +MIMAT0013863 hsa-miR-2909; +MIMAT0013864 ssc-miR-206; +MIMAT0013865 ssc-let-7a; +MIMAT0013866 ssc-let-7e; +MIMAT0013867 ssc-let-7g; +MIMAT0013868 ssc-miR-378; +MIMAT0013869 ssc-miR-133b; +MIMAT0013870 ssc-miR-29a;ssc-miR-29a-3p; +MIMAT0013871 ssc-miR-30d; +MIMAT0013872 ssc-miR-30e-5p; +MIMAT0013873 ssc-miR-30e-3p; +MIMAT0013874 ssc-miR-199a-5p; +MIMAT0013875 ssc-miR-199a-3p; +MIMAT0013876 ssc-miR-191; +MIMAT0013877 ssc-miR-499;ssc-miR-499-5p; +MIMAT0013878 ssc-miR-320; +MIMAT0013879 ssc-miR-143;ssc-miR-143-3p; +MIMAT0013880 ssc-miR-423-5p; +MIMAT0013881 ssc-miR-423-3p; +MIMAT0013882 ssc-miR-151-5p; +MIMAT0013883 ssc-miR-151-3p; +MIMAT0013884 ssc-miR-10a;ssc-miR-10a-5p; +MIMAT0013885 ssc-miR-10b; +MIMAT0013886 ssc-miR-486; +MIMAT0013887 ssc-miR-152; +MIMAT0013888 ssc-miR-181d;ssc-miR-181d-5p; +MIMAT0013889 ssc-miR-27b*;ssc-miR-27b-5p; +MIMAT0013890 ssc-miR-27b;ssc-miR-27b-3p; +MIMAT0013891 ssc-miR-340; +MIMAT0013893 ssc-miR-23b; +MIMAT0013894 ssc-miR-193a-5p; +MIMAT0013895 ssc-miR-193a-3p; +MIMAT0013896 ssc-miR-99a;ssc-miR-99a-5p; +MIMAT0013897 ssc-miR-125a; +MIMAT0013898 ssc-miR-1308; +MIMAT0013899 ssc-miR-345-5p; +MIMAT0013900 ssc-miR-345-3p; +MIMAT0013901 ssc-miR-148b;ssc-miR-148b-3p; +MIMAT0013902 ssc-miR-885-5p; +MIMAT0013903 ssc-miR-885-3p; +MIMAT0013904 ssc-miR-365;ssc-miR-365-3p; +MIMAT0013905 ssc-miR-98; +MIMAT0013906 ssc-miR-664-5p; +MIMAT0013907 ssc-miR-664-3p; +MIMAT0013908 ssc-miR-92a; +MIMAT0013909 ssc-miR-92b;ssc-miR-92b-3p; +MIMAT0013910 ssc-miR-192; +MIMAT0013911 ssc-miR-100; +MIMAT0013912 ssc-miR-208b; +MIMAT0013913 ssc-miR-374a;ssc-miR-374a-5p; +MIMAT0013914 ssc-miR-374a*;ssc-miR-374a-3p; +MIMAT0013915 ssc-miR-374b;ssc-miR-374b-5p; +MIMAT0013916 ssc-miR-34c; +MIMAT0013917 ssc-miR-425-5p; +MIMAT0013918 ssc-miR-425-3p; +MIMAT0013919 ssc-miR-142;ssc-miR-142-5p; +MIMAT0013920 ssc-miR-424;ssc-miR-424-5p; +MIMAT0013921 ssc-miR-424*;ssc-miR-424-3p; +MIMAT0013922 ssc-miR-130b;ssc-miR-130b-3p; +MIMAT0013923 ssc-miR-196b;ssc-miR-196b-5p; +MIMAT0013924 ssc-miR-542-5p; +MIMAT0013925 ssc-miR-542-3p; +MIMAT0013926 ssc-miR-497; +MIMAT0013927 ssc-miR-450b;ssc-miR-450b-5p; +MIMAT0013928 ssc-miR-195; +MIMAT0013929 ssc-miR-331-5p; +MIMAT0013930 ssc-miR-331-3p; +MIMAT0013931 ssc-miR-504; +MIMAT0013932 ssc-miR-127; +MIMAT0013933 ssc-miR-361-5p; +MIMAT0013934 ssc-miR-361-3p; +MIMAT0013935 ssc-miR-1277; +MIMAT0013936 ssc-miR-1307; +MIMAT0013937 ssc-miR-1306-5p; +MIMAT0013938 ssc-miR-1306-3p; +MIMAT0013939 ssc-miR-339;ssc-miR-339-5p; +MIMAT0013940 ssc-miR-532-5p; +MIMAT0013941 ssc-miR-532-3p; +MIMAT0013942 ssc-miR-222; +MIMAT0013943 ssc-miR-676;ssc-miR-676-3p; +MIMAT0013944 ssc-miR-342; +MIMAT0013945 ssc-miR-708;ssc-miR-708-5p; +MIMAT0013946 ssc-miR-432;ssc-miR-432-5p; +MIMAT0013947 ssc-miR-935; +MIMAT0013948 ssc-miR-202;ssc-miR-202-5p; +MIMAT0013949 ssc-miR-328; +MIMAT0013950 ssc-miR-19b; +MIMAT0013951 ssc-miR-574;ssc-miR-574-3p; +MIMAT0013952 ssc-miR-1839;ssc-miR-1839-5p; +MIMAT0013953 ssc-miR-628;ssc-miR-628-5p; +MIMAT0013954 ssc-miR-1285; +MIMAT0013955 ssc-miR-335; +MIMAT0013956 ssc-miR-500;ssc-miR-500-3p; +MIMAT0013957 ssc-miR-324; +MIMAT0013958 ssc-miR-769;ssc-miR-769-3p; +MIMAT0013959 ssc-miR-129;ssc-miR-129a;ssc-miR-129a-3p; +MIMAT0013960 ssc-miR-455;ssc-miR-455-3p; +MIMAT0013961 ssc-miR-505; +MIMAT0013962 bhv1-miR-B1; +MIMAT0013963 bhv1-miR-B2; +MIMAT0013964 bhv1-miR-B3; +MIMAT0013965 bhv1-miR-B4; +MIMAT0013966 bhv1-miR-B5; +MIMAT0013967 bhv1-miR-B6;bhv1-miR-B6-5p; +MIMAT0013968 bhv1-miR-B6*;bhv1-miR-B6-3p; +MIMAT0013969 bhv1-miR-B7; +MIMAT0013970 bhv1-miR-B8-5p; +MIMAT0013971 bhv1-miR-B8-3p; +MIMAT0013972 bhv1-miR-B9; +MIMAT0013973 zma-miR156l;zma-miR156l-5p; +MIMAT0013974 zma-miR159e;zma-miR159e-3p; +MIMAT0013975 zma-miR159f;zma-miR159f-3p; +MIMAT0013976 zma-miR159g;zma-miR159g-3p; +MIMAT0013977 zma-miR159h;zma-miR159h-3p; +MIMAT0013978 zma-miR159i;zma-miR159i-3p; +MIMAT0013979 zma-miR159j;zma-miR159j-3p; +MIMAT0013980 zma-miR159k;zma-miR159k-3p; +MIMAT0013981 zma-miR160g;zma-miR160g-5p; +MIMAT0013982 zma-miR164e;zma-miR164e-5p; +MIMAT0013983 zma-miR164f;zma-miR164f-5p; +MIMAT0013984 zma-miR164g;zma-miR164g-5p; +MIMAT0013985 zma-miR164h;zma-miR164h-5p; +MIMAT0013986 zma-miR166n;zma-miR166n-3p; +MIMAT0013987 zma-miR167j;zma-miR167j-5p; +MIMAT0013988 zma-miR169l;zma-miR169l-5p; +MIMAT0013989 zma-miR169m;zma-miR169m-5p; +MIMAT0013990 zma-miR169n;zma-miR169n-5p; +MIMAT0013991 zma-miR169o;zma-miR169o-5p; +MIMAT0013992 zma-miR169p;zma-miR169p-5p; +MIMAT0013993 zma-miR169q;zma-miR169q-5p; +MIMAT0013994 zma-miR169r;zma-miR169r-5p; +MIMAT0013995 zma-miR171l;zma-miR171l-3p; +MIMAT0013996 zma-miR171m;zma-miR171m-3p; +MIMAT0013997 zma-miR171n;zma-miR171n-3p; +MIMAT0013998 zma-miR390a;zma-miR390a-5p; +MIMAT0013999 zma-miR393b;zma-miR393b-5p; +MIMAT0014000 zma-miR393c;zma-miR393c-5p; +MIMAT0014001 zma-miR395d;zma-miR395d-3p; +MIMAT0014002 zma-miR395e;zma-miR395e-3p; +MIMAT0014003 zma-miR395f;zma-miR395f-3p; +MIMAT0014004 zma-miR395g;zma-miR395g-3p; +MIMAT0014005 zma-miR395h;zma-miR395h-3p; +MIMAT0014006 zma-miR395i;zma-miR395i-3p; +MIMAT0014007 zma-miR395j;zma-miR395j-3p; +MIMAT0014008 zma-miR395k;zma-miR395k-3p; +MIMAT0014009 zma-miR395l;zma-miR395l-3p; +MIMAT0014010 zma-miR395m;zma-miR395m-3p; +MIMAT0014011 zma-miR395n;zma-miR395n-3p; +MIMAT0014012 zma-miR395o;zma-miR395o-3p; +MIMAT0014013 zma-miR395p;zma-miR395p-3p; +MIMAT0014014 zma-miR396e;zma-miR396e-5p; +MIMAT0014015 zma-miR396f;zma-miR396f-5p; +MIMAT0014016 zma-miR396g;zma-miR396g-5p; +MIMAT0014017 zma-miR396h; +MIMAT0014018 zma-miR397a;zma-miR397a-5p; +MIMAT0014019 zma-miR397b;zma-miR397b-5p; +MIMAT0014020 zma-miR398a;zma-miR398a-3p; +MIMAT0014021 zma-miR398b;zma-miR398b-3p; +MIMAT0014022 zma-miR399g;zma-miR399g-3p; +MIMAT0014023 zma-miR399h;zma-miR399h-3p; +MIMAT0014024 zma-miR399i;zma-miR399i-3p; +MIMAT0014025 zma-miR399j;zma-miR399j-3p; +MIMAT0014026 zma-miR408b;zma-miR408b-3p; +MIMAT0014027 zma-miR482;zma-miR482-3p; +MIMAT0014028 zma-miR528a;zma-miR528a-5p; +MIMAT0014029 zma-miR528b;zma-miR528b-5p; +MIMAT0014030 zma-miR529;zma-miR529-5p; +MIMAT0014031 zma-miR827;zma-miR827-3p; +MIMAT0014032 zma-miR1432;zma-miR1432-5p; +MIMAT0014033 zma-miR390b;zma-miR390b-5p; +MIMAT0014034 osa-miR2906a; +MIMAT0014035 osa-miR2906b; +MIMAT0014036 osa-miR2907a; +MIMAT0014037 osa-miR2907b; +MIMAT0014038 osa-miR2907c; +MIMAT0014039 osa-miR2907d; +MIMAT0014041 sbi-miR162; +MIMAT0014042 sbi-miR169o; +MIMAT0014043 sbi-miR169p; +MIMAT0014044 sbi-miR169q; +MIMAT0014045 sbi-miR172f; +MIMAT0014046 sbi-miR398; +MIMAT0014047 sbi-miR399k; +MIMAT0014048 sbi-miR528; +MIMAT0014049 osa-miR2918; +MIMAT0014050 osa-miR2919; +MIMAT0014051 osa-miR2920; +MIMAT0014052 osa-miR2921; +MIMAT0014053 osa-miR2922; +MIMAT0014054 osa-miR2923; +MIMAT0014055 osa-miR2924; +MIMAT0014056 osa-miR2925; +MIMAT0014057 osa-miR2926; +MIMAT0014058 osa-miR2927; +MIMAT0014059 osa-miR2928; +MIMAT0014060 osa-miR2929; +MIMAT0014061 osa-miR2930; +MIMAT0014062 osa-miR2931; +MIMAT0014063 osa-miR2932; +MIMAT0014064 rlcv-miR-rL1-17;rlcv-miR-rL1-17-3p; +MIMAT0014065 rlcv-miR-rL1-20-5p; +MIMAT0014066 rlcv-miR-rL1-20-3p; +MIMAT0014067 ctr-miR156; +MIMAT0014068 csi-miR160;csi-miR160a-5p; +MIMAT0014069 csi-miR164;csi-miR164a-5p; +MIMAT0014070 csi-miR166;csi-miR166e;csi-miR166e-3p; +MIMAT0014071 ctr-miR166; +MIMAT0014072 ccl-miR167a; +MIMAT0014073 ccl-miR168; +MIMAT0014074 csi-miR169;csi-miR169a; +MIMAT0014075 ccl-miR171; +MIMAT0014076 csi-miR172;csi-miR172a;csi-miR172a-3p; +MIMAT0014077 ctr-miR319; +MIMAT0014078 ccl-miR396; +MIMAT0014079 csi-miR398;csi-miR398a-3p; +MIMAT0014080 ctr-miR164; +MIMAT0014081 ctr-miR167; +MIMAT0014082 ctr-miR171; +MIMAT0014083 ccl-miR167b; +MIMAT0014084 crt-miR166a; +MIMAT0014085 crt-miR166b; +MIMAT0014086 crt-miR168; +MIMAT0014087 crt-miR171; +MIMAT0014088 csi-miR162.5;csi-miR162;csi-miR162-3p; +MIMAT0014089 csi-miR162; +MIMAT0014090 csi-miR166a;csi-miR166a-3p; +MIMAT0014091 csi-miR166b; +MIMAT0014092 csi-miR390;csi-miR390a-5p; +MIMAT0014093 bma-bantam;bma-miR-81; +MIMAT0014094 bma-let-7; +MIMAT0014095 bma-lin-4; +MIMAT0014096 bma-miR-2a; +MIMAT0014097 bma-miR-2b;bma-miR-2b-3p; +MIMAT0014098 bma-miR-2c; +MIMAT0014099 bma-miR-7; +MIMAT0014100 bma-miR-9;bma-miR-9-5p; +MIMAT0014101 bma-miR-34; +MIMAT0014102 bma-miR-36a;bma-miR-36c;bma-miR-36c-3p; +MIMAT0014103 bma-miR-36b;bma-miR-36b-3p; +MIMAT0014104 bma-miR-50; +MIMAT0014105 bma-miR-57; +MIMAT0014106 bma-miR-71; +MIMAT0014107 bma-miR-72; +MIMAT0014108 bma-miR-79;bma-miR-9-3p; +MIMAT0014109 bma-miR-87a; +MIMAT0014110 bma-miR-87b; +MIMAT0014111 bma-miR-92; +MIMAT0014112 bma-miR-100a; +MIMAT0014113 bma-miR-100b; +MIMAT0014114 bma-miR-100c; +MIMAT0014115 bma-miR-100d; +MIMAT0014116 bma-miR-124; +MIMAT0014117 bma-miR-133; +MIMAT0014118 bma-miR-137;bma-miR-234; +MIMAT0014119 bma-miR-153; +MIMAT0014120 bma-miR-228; +MIMAT0014121 bma-miR-236; +MIMAT0014122 bma-miR-279; +MIMAT0014123 bma-miR-281;bma-miR-281-3p; +MIMAT0014124 osa-miR395x; +MIMAT0014125 osa-miR395y; +MIMAT0014126 api-miR-137; +MIMAT0014127 api-miR-190; +MIMAT0014128 api-miR-10; +MIMAT0014129 api-miR-iab-4; +MIMAT0014130 api-bantam; +MIMAT0014131 api-miR-1923; +MIMAT0014132 api-miR-184;api-miR-184a; +MIMAT0014133 api-miR-276; +MIMAT0014134 api-miR-281; +MIMAT0014135 api-miR-993; +MIMAT0014136 ath-miR2933a; +MIMAT0014137 ath-miR2933b; +MIMAT0014138 ath-miR2934;ath-miR2934-5p; +MIMAT0014139 ath-miR2935; +MIMAT0014140 ath-miR2936; +MIMAT0014141 ath-miR2937; +MIMAT0014142 ath-miR2938; +MIMAT0014143 ath-miR2939; +MIMAT0014144 rco-miR156a; +MIMAT0014145 rco-miR156b; +MIMAT0014146 rco-miR156c; +MIMAT0014147 rco-miR156d; +MIMAT0014148 rco-miR156e; +MIMAT0014149 rco-miR156f; +MIMAT0014150 rco-miR156g; +MIMAT0014151 rco-miR156h; +MIMAT0014152 rco-miR159; +MIMAT0014153 rco-miR160a; +MIMAT0014154 rco-miR160b; +MIMAT0014155 rco-miR162; +MIMAT0014156 rco-miR164a; +MIMAT0014157 rco-miR164b; +MIMAT0014158 rco-miR164c; +MIMAT0014159 rco-miR164d; +MIMAT0014160 rco-miR166a; +MIMAT0014161 rco-miR166b; +MIMAT0014162 rco-miR166c; +MIMAT0014163 rco-miR166d; +MIMAT0014164 rco-miR166e; +MIMAT0014165 rco-miR167a; +MIMAT0014166 rco-miR167b; +MIMAT0014167 rco-miR167c; +MIMAT0014168 rco-miR168; +MIMAT0014169 rco-miR169a; +MIMAT0014170 rco-miR169b; +MIMAT0014171 rco-miR169c; +MIMAT0014172 rco-miR171a; +MIMAT0014173 rco-miR171b; +MIMAT0014174 rco-miR171c; +MIMAT0014175 rco-miR171d; +MIMAT0014176 rco-miR171e; +MIMAT0014177 rco-miR171f; +MIMAT0014178 rco-miR171g; +MIMAT0014179 rco-miR172; +MIMAT0014180 rco-miR319a; +MIMAT0014181 rco-miR319b; +MIMAT0014182 rco-miR319c; +MIMAT0014183 rco-miR319d; +MIMAT0014184 rco-miR390a; +MIMAT0014185 rco-miR390b; +MIMAT0014186 rco-miR393; +MIMAT0014187 rco-miR395a; +MIMAT0014188 rco-miR395b; +MIMAT0014189 rco-miR395c; +MIMAT0014190 rco-miR395d; +MIMAT0014191 rco-miR395e; +MIMAT0014192 rco-miR396; +MIMAT0014193 rco-miR397; +MIMAT0014194 rco-miR398a; +MIMAT0014195 rco-miR398b; +MIMAT0014196 rco-miR399a; +MIMAT0014197 rco-miR399b; +MIMAT0014198 rco-miR399c; +MIMAT0014199 rco-miR399d; +MIMAT0014200 rco-miR399e; +MIMAT0014201 rco-miR399f; +MIMAT0014202 rco-miR403a; +MIMAT0014203 rco-miR403b; +MIMAT0014204 rco-miR408; +MIMAT0014205 rco-miR535; +MIMAT0014206 rco-miR160c; +MIMAT0014207 aae-miR-184; +MIMAT0014208 aae-miR-275*;aae-miR-275-5p; +MIMAT0014209 aae-miR-275;aae-miR-275-3p; +MIMAT0014210 aae-miR-277*;aae-miR-277-5p; +MIMAT0014211 aae-miR-277;aae-miR-277-3p; +MIMAT0014212 aae-miR-9;aae-miR-9c-5p; +MIMAT0014213 aae-miR-9*;aae-miR-9c-3p; +MIMAT0014214 aae-miR-8*;aae-miR-8-5p; +MIMAT0014215 aae-miR-8;aae-miR-8-3p; +MIMAT0014216 aae-miR-252;aae-miR-252-5p; +MIMAT0014217 aae-miR-252*;aae-miR-252-3p; +MIMAT0014218 aae-bantam-5p; +MIMAT0014219 aae-bantam-3p; +MIMAT0014220 aae-miR-71;aae-miR-71-5p; +MIMAT0014221 aae-miR-71*;aae-miR-71-3p; +MIMAT0014222 aae-miR-276*;aae-miR-276-5p; +MIMAT0014223 aae-miR-276;aae-miR-276-3p; +MIMAT0014224 aae-miR-317; +MIMAT0014225 aae-miR-2a*;aae-miR-2a-5p; +MIMAT0014226 aae-miR-2a;aae-miR-2a-3p; +MIMAT0014227 aae-miR-998; +MIMAT0014228 aae-miR-92a;aae-miR-92a-3p; +MIMAT0014229 aae-miR-306;aae-miR-306-5p; +MIMAT0014230 aae-miR-306*;aae-miR-306-3p; +MIMAT0014231 aae-miR-281;aae-miR-281-5p; +MIMAT0014232 aae-miR-281*;aae-miR-281-3p; +MIMAT0014233 aae-miR-1889*;aae-miR-1889-5p; +MIMAT0014234 aae-miR-1889;aae-miR-1889-3p; +MIMAT0014235 aae-miR-980*;aae-miR-980-5p; +MIMAT0014236 aae-miR-980;aae-miR-980-3p; +MIMAT0014237 aae-miR-278;aae-miR-278-5p; +MIMAT0014238 aae-miR-278*;aae-miR-278-3p; +MIMAT0014239 aae-miR-989; +MIMAT0014240 aae-miR-14; +MIMAT0014241 aae-miR-11*;aae-miR-11-5p; +MIMAT0014242 aae-miR-11;aae-miR-11-3p; +MIMAT0014243 aae-miR-190; +MIMAT0014244 aae-miR-1; +MIMAT0014245 aae-miR-34;aae-miR-34-5p; +MIMAT0014246 aae-miR-34*;aae-miR-34-3p; +MIMAT0014247 aae-miR-1890; +MIMAT0014248 aae-miR-957; +MIMAT0014249 aae-miR-305;aae-miR-305-5p; +MIMAT0014250 aae-miR-305*;aae-miR-305-3p; +MIMAT0014251 aae-miR-996; +MIMAT0014252 aae-miR-87; +MIMAT0014253 aae-miR-12;aae-miR-12-5p; +MIMAT0014254 aae-miR-12*;aae-miR-12-3p; +MIMAT0014255 aae-miR-13*;aae-miR-13-5p; +MIMAT0014256 aae-miR-13;aae-miR-13-3p; +MIMAT0014257 aae-miR-999; +MIMAT0014258 aae-miR-125;aae-miR-125-5p; +MIMAT0014259 aae-miR-125*; +MIMAT0014260 aae-miR-308;aae-miR-308-5p; +MIMAT0014261 aae-miR-308*;aae-miR-308-3p; +MIMAT0014262 aae-miR-315;aae-miR-315-5p; +MIMAT0014263 aae-miR-1891; +MIMAT0014264 aae-miR-1175;aae-miR-1175-5p; +MIMAT0014265 aae-miR-1174; +MIMAT0014266 aae-miR-993; +MIMAT0014267 aae-miR-981; +MIMAT0014268 aae-miR-965; +MIMAT0014269 aae-miR-932*;aae-miR-932-5p; +MIMAT0014270 aae-miR-932;aae-miR-932-3p; +MIMAT0014271 aae-miR-927; +MIMAT0014272 aae-miR-309a; +MIMAT0014273 aae-miR-285; +MIMAT0014274 aae-miR-137; +MIMAT0014275 aae-miR-133; +MIMAT0014276 aae-miR-31; +MIMAT0014277 aae-miR-10; +MIMAT0014278 aae-miR-iab-4-5p; +MIMAT0014279 aae-miR-283; +MIMAT0014280 aae-miR-988*;aae-miR-988-5p; +MIMAT0014281 aae-miR-988;aae-miR-988-3p; +MIMAT0014282 aae-miR-124; +MIMAT0014283 aae-miR-2940;aae-miR-2940-5p; +MIMAT0014284 aae-miR-2940*;aae-miR-2940-3p; +MIMAT0014285 aae-miR-2765; +MIMAT0014286 aae-miR-2941; +MIMAT0014287 aae-miR-33; +MIMAT0014288 aae-miR-279; +MIMAT0014289 aae-miR-263a;aae-miR-263a-5p; +MIMAT0014290 aae-miR-7; +MIMAT0014291 aae-miR-100; +MIMAT0014292 aae-miR-970; +MIMAT0014293 aae-miR-210; +MIMAT0014294 aae-miR-79;aae-miR-79-5p; +MIMAT0014295 aae-miR-79*;aae-miR-79-3p; +MIMAT0014296 aae-miR-307; +MIMAT0014297 aae-miR-1000; +MIMAT0014298 aae-miR-375; +MIMAT0014299 aae-let-7; +MIMAT0014300 aae-miR-2942; +MIMAT0014301 aae-miR-2943; +MIMAT0014302 aae-miR-2944a;aae-miR-2944a-5p; +MIMAT0014303 aae-miR-2944a*;aae-miR-2944a-3p; +MIMAT0014304 aae-miR-2944b;aae-miR-2944b-5p; +MIMAT0014305 aae-miR-193; +MIMAT0014306 aae-miR-2b; +MIMAT0014307 aae-miR-219; +MIMAT0014308 aae-miR-2c; +MIMAT0014309 aae-miR-263b;aae-miR-263b-5p; +MIMAT0014310 aae-miR-263b*;aae-miR-263b-3p; +MIMAT0014311 aae-miR-282;aae-miR-282-5p; +MIMAT0014312 aae-miR-282*;aae-miR-282-3p; +MIMAT0014313 aae-miR-286b; +MIMAT0014314 aae-miR-286a; +MIMAT0014315 aae-miR-2945*;aae-miR-2945-5p; +MIMAT0014316 aae-miR-2945;aae-miR-2945-3p; +MIMAT0014317 aae-miR-316; +MIMAT0014319 aae-miR-309b*;aae-miR-309b-5p; +MIMAT0014320 aae-miR-309b;aae-miR-309b-3p; +MIMAT0014321 aae-miR-92b*;aae-miR-92b-5p; +MIMAT0014322 aae-miR-92b;aae-miR-92b-3p; +MIMAT0014323 aae-miR-9a; +MIMAT0014324 aae-miR-9b; +MIMAT0014325 aae-miR-2946; +MIMAT0014326 bmo-miR-1000; +MIMAT0014327 bmo-miR-iab-4as;bmo-miR-iab-8; +MIMAT0014328 gra-miR398; +MIMAT0014329 gra-miR482; +MIMAT0014330 gar-miR2947; +MIMAT0014331 ghr-miR164; +MIMAT0014332 ghr-miR167;ghr-miR167a; +MIMAT0014333 ghr-miR172; +MIMAT0014334 ghr-miR393; +MIMAT0014335 ghr-miR394b; +MIMAT0014336 ghr-miR394a; +MIMAT0014337 ghr-miR398; +MIMAT0014338 ghr-miR479; +MIMAT0014339 ghr-miR482a; +MIMAT0014340 ghr-miR482b; +MIMAT0014341 ghr-miR827a; +MIMAT0014342 ghr-miR827b; +MIMAT0014343 ghr-miR827c; +MIMAT0014344 ghr-miR2948-5p; +MIMAT0014345 ghr-miR2949a;ghr-miR2949a-5p; +MIMAT0014346 ghr-miR2949b; +MIMAT0014347 ghr-miR2949c; +MIMAT0014348 ghr-miR2950; +MIMAT0014349 ghr-miR399c; +MIMAT0014350 ghr-miR399d; +MIMAT0014351 hsv2-miR-H7-5p; +MIMAT0014352 hsv2-miR-H9-3p; +MIMAT0014353 hsv2-miR-H10; +MIMAT0014354 cqu-miR-1174; +MIMAT0014355 cqu-miR-125;cqu-miR-125-5p; +MIMAT0014356 cqu-miR-125*;cqu-miR-125-3p; +MIMAT0014357 cqu-miR-iab-4; +MIMAT0014358 cqu-miR-281;cqu-miR-281-5p; +MIMAT0014359 cqu-miR-281*;cqu-miR-281-3p; +MIMAT0014360 cqu-miR-124; +MIMAT0014361 cqu-miR-1; +MIMAT0014362 cqu-miR-988*;cqu-miR-988-5p; +MIMAT0014363 cqu-miR-988;cqu-miR-988-3p; +MIMAT0014364 cqu-miR-275; +MIMAT0014365 cqu-miR-315; +MIMAT0014366 cqu-let-7;cqu-let-7-5p; +MIMAT0014367 cqu-let-7*;cqu-let-7-3p; +MIMAT0014368 cqu-miR-13; +MIMAT0014369 cqu-miR-957; +MIMAT0014370 cqu-miR-999; +MIMAT0014371 cqu-miR-277; +MIMAT0014372 cqu-miR-965; +MIMAT0014373 cqu-miR-252;cqu-miR-252-5p; +MIMAT0014374 cqu-miR-252*;cqu-miR-252-3p; +MIMAT0014375 cqu-miR-993;cqu-miR-993-5p; +MIMAT0014376 cqu-miR-993*;cqu-miR-993-3p; +MIMAT0014377 cqu-miR-278; +MIMAT0014378 cqu-miR-970; +MIMAT0014379 cqu-miR-283; +MIMAT0014380 cqu-miR-9;cqu-miR-9-5p; +MIMAT0014381 cqu-miR-9*;cqu-miR-9-3p; +MIMAT0014382 cqu-miR-305;cqu-miR-305-5p; +MIMAT0014383 cqu-miR-305*;cqu-miR-305-3p; +MIMAT0014384 cqu-miR-317*;cqu-miR-317-5p; +MIMAT0014385 cqu-miR-317;cqu-miR-317-3p; +MIMAT0014386 cqu-miR-981; +MIMAT0014387 cqu-miR-100;cqu-miR-100-5p; +MIMAT0014388 cqu-miR-100*;cqu-miR-100-3p; +MIMAT0014389 cqu-miR-989; +MIMAT0014390 cqu-miR-1175;cqu-miR-1175-5p; +MIMAT0014391 cqu-miR-1175*;cqu-miR-1175-3p; +MIMAT0014392 cqu-miR-276*;cqu-miR-276-5p; +MIMAT0014393 cqu-miR-276;cqu-miR-276-3p; +MIMAT0014394 cqu-miR-12*;cqu-miR-12-5p; +MIMAT0014395 cqu-miR-12;cqu-miR-12-3p; +MIMAT0014396 cqu-miR-210*;cqu-miR-210-5p; +MIMAT0014397 cqu-miR-210;cqu-miR-210-3p; +MIMAT0014398 cqu-miR-263; +MIMAT0014399 cqu-miR-92; +MIMAT0014400 cqu-miR-71;cqu-miR-71-5p; +MIMAT0014401 cqu-miR-71*;cqu-miR-71-3p; +MIMAT0014402 cqu-miR-190; +MIMAT0014403 cqu-miR-1000; +MIMAT0014404 cqu-miR-10*;cqu-miR-10-5p; +MIMAT0014405 cqu-miR-10;cqu-miR-10-3p; +MIMAT0014406 cqu-miR-11*;cqu-miR-11-5p; +MIMAT0014407 cqu-miR-11;cqu-miR-11-3p; +MIMAT0014408 cqu-miR-8*;cqu-miR-8-5p; +MIMAT0014409 cqu-miR-8;cqu-miR-8-3p; +MIMAT0014410 cqu-miR-285*;cqu-miR-285-5p; +MIMAT0014411 cqu-miR-285;cqu-miR-285-3p; +MIMAT0014412 cqu-miR-2; +MIMAT0014413 cqu-miR-137; +MIMAT0014414 cqu-miR-932*;cqu-miR-932-5p; +MIMAT0014415 cqu-miR-932;cqu-miR-932-3p; +MIMAT0014416 cqu-miR-14; +MIMAT0014417 cqu-miR-279*;cqu-miR-279-5p; +MIMAT0014418 cqu-miR-279;cqu-miR-279-3p; +MIMAT0014419 cqu-miR-996; +MIMAT0014420 cqu-bantam;cqu-bantam-5p; +MIMAT0014421 cqu-bantam*;cqu-bantam-3p; +MIMAT0014422 cqu-miR-1891; +MIMAT0014423 cqu-miR-7; +MIMAT0014424 cqu-miR-184; +MIMAT0014425 cqu-miR-31;cqu-miR-31-5p; +MIMAT0014426 cqu-miR-31*;cqu-miR-31-3p; +MIMAT0014427 cqu-miR-1890; +MIMAT0014428 cqu-miR-980; +MIMAT0014429 cqu-miR-308; +MIMAT0014430 cqu-miR-79; +MIMAT0014431 cqu-miR-33; +MIMAT0014432 cqu-miR-2951;cqu-miR-2951-5p; +MIMAT0014433 cqu-miR-2951*;cqu-miR-2951-3p; +MIMAT0014434 cqu-miR-2941-1*;cqu-miR-2941-1-5p; +MIMAT0014435 cqu-miR-2941;cqu-miR-2941-3p; +MIMAT0014436 cqu-miR-2952; +MIMAT0014437 cqu-miR-133; +MIMAT0014438 cqu-miR-306; +MIMAT0014439 cqu-miR-87; +MIMAT0014440 cqu-miR-1889;cqu-miR-1889-5p; +MIMAT0014441 cqu-miR-1889*;cqu-miR-1889-3p; +MIMAT0014442 cqu-miR-316; +MIMAT0014443 cqu-miR-375; +MIMAT0014444 cqu-miR-309; +MIMAT0014445 cqu-miR-998; +MIMAT0014446 cel-miR-2953-5p; +MIMAT0014447 cel-miR-2953-3p; +MIMAT0014448 gga-miR-2954; +MIMAT0014449 tgu-miR-1329;tgu-miR-1329-5p; +MIMAT0014450 tgu-miR-2955;tgu-miR-2955-3p; +MIMAT0014451 tgu-miR-1451;tgu-miR-1451-5p; +MIMAT0014452 tgu-miR-1677;tgu-miR-1677-5p; +MIMAT0014453 tgu-miR-1805;tgu-miR-1805-3p; +MIMAT0014454 tgu-miR-2956; +MIMAT0014455 tgu-miR-2957;tgu-miR-148b; +MIMAT0014456 tgu-miR-2958; +MIMAT0014457 tgu-miR-1784;tgu-miR-1784-3p; +MIMAT0014458 tgu-miR-2959; +MIMAT0014459 tgu-miR-1662; +MIMAT0014460 tgu-miR-2960; +MIMAT0014461 tgu-miR-2961; +MIMAT0014462 tgu-miR-2962;tgu-miR-2962-5p; +MIMAT0014463 tgu-miR-2963;tgu-miR-2963-3p; +MIMAT0014464 tgu-miR-2964;tgu-miR-219b; +MIMAT0014465 tgu-miR-146a;tgu-miR-146a-3p; +MIMAT0014466 tgu-miR-458;tgu-miR-458-3p; +MIMAT0014467 tgu-miR-1729;tgu-miR-1729-5p; +MIMAT0014468 tgu-miR-2965; +MIMAT0014469 tgu-miR-456;tgu-miR-456-3p; +MIMAT0014470 tgu-miR-425-5p; +MIMAT0014471 tgu-miR-425-3p; +MIMAT0014472 tgu-miR-1803;tgu-miR-1803-3p; +MIMAT0014473 tgu-miR-2966; +MIMAT0014474 tgu-miR-2954;tgu-miR-2954-3p; +MIMAT0014475 tgu-miR-2967; +MIMAT0014476 tgu-miR-460b;tgu-miR-460b-5p; +MIMAT0014477 tgu-miR-2968; +MIMAT0014478 tgu-miR-2969; +MIMAT0014479 tgu-miR-2970;tgu-miR-2970-5p; +MIMAT0014480 tgu-miR-2188;tgu-miR-2188-5p; +MIMAT0014481 tgu-miR-2971; +MIMAT0014482 tgu-miR-2972; +MIMAT0014483 tgu-miR-2973;tgu-miR-2973-5p; +MIMAT0014484 tgu-miR-2974; +MIMAT0014485 tgu-miR-2975; +MIMAT0014486 tgu-miR-2976; +MIMAT0014487 tgu-miR-2977; +MIMAT0014488 tgu-miR-2978; +MIMAT0014489 tgu-miR-2979;tgu-miR-2979-5p; +MIMAT0014490 tgu-miR-2980; +MIMAT0014491 tgu-miR-2981; +MIMAT0014492 tgu-miR-2982; +MIMAT0014493 tgu-miR-2983; +MIMAT0014494 tgu-miR-2984;tgu-miR-2984-5p; +MIMAT0014495 tgu-miR-2985; +MIMAT0014496 tgu-miR-2986; +MIMAT0014497 tgu-miR-2987;tgu-miR-2987-3p; +MIMAT0014498 tgu-miR-2988; +MIMAT0014499 tgu-miR-129;tgu-miR-129-3p; +MIMAT0014500 tgu-miR-139;tgu-miR-139-5p; +MIMAT0014501 tgu-miR-363;tgu-miR-363-3p; +MIMAT0014502 tgu-miR-9;tgu-miR-9-5p; +MIMAT0014503 tgu-miR-148;tgu-miR-148-3p;tgu-miR-148a-3p; +MIMAT0014504 tgu-let-7i;tgu-let-7i-5p; +MIMAT0014505 tgu-miR-125;tgu-miR-125-5p; +MIMAT0014506 tgu-miR-30b-5p; +MIMAT0014507 tgu-miR-124;tgu-miR-124-3p; +MIMAT0014508 tgu-miR-101;tgu-miR-101-3p; +MIMAT0014509 tgu-let-7b;tgu-let-7b-5p; +MIMAT0014510 tgu-miR-7;tgu-miR-7-5p; +MIMAT0014511 tgu-miR-100;tgu-miR-100-5p; +MIMAT0014512 tgu-miR-221;tgu-miR-221-3p; +MIMAT0014513 tgu-miR-128;tgu-miR-128-3p; +MIMAT0014514 tgu-miR-222;tgu-miR-222-3p; +MIMAT0014515 tgu-miR-138;tgu-miR-138-5p; +MIMAT0014516 tgu-miR-26;tgu-miR-26-5p; +MIMAT0014517 tgu-miR-19b;tgu-miR-19b-3p; +MIMAT0014518 tgu-let-7e;tgu-let-7e-5p; +MIMAT0014519 tgu-let-7a;tgu-let-7a-5p; +MIMAT0014520 tgu-let-7c;tgu-let-7c-5p; +MIMAT0014521 tgu-miR-30c-5p; +MIMAT0014522 tgu-miR-218;tgu-miR-218-5p; +MIMAT0014523 tgu-miR-103;tgu-miR-103-3p; +MIMAT0014524 tgu-miR-99;tgu-miR-99-5p; +MIMAT0014525 tgu-miR-2989; +MIMAT0014526 tgu-miR-1559; +MIMAT0014527 tgu-miR-21;tgu-miR-21-5p; +MIMAT0014528 tgu-let-7g;tgu-let-7g-5p; +MIMAT0014529 tgu-miR-122;tgu-miR-122-5p; +MIMAT0014530 tgu-let-7f;tgu-let-7f-5p; +MIMAT0014531 tgu-miR-383;tgu-miR-383-5p; +MIMAT0014532 tgu-miR-29a;tgu-miR-29a-3p; +MIMAT0014533 tgu-miR-451; +MIMAT0014534 tgu-miR-27;tgu-miR-27-3p; +MIMAT0014535 tgu-miR-30a-3p; +MIMAT0014536 tgu-let-7d;tgu-let-7d-5p; +MIMAT0014537 tgu-miR-34b; +MIMAT0014538 tgu-miR-33;tgu-miR-33-5p; +MIMAT0014539 tgu-miR-24;tgu-miR-24-3p; +MIMAT0014540 tgu-miR-128*;tgu-miR-128-5p; +MIMAT0014541 tgu-miR-551;tgu-miR-551-3p; +MIMAT0014542 tgu-miR-338;tgu-miR-338-3p; +MIMAT0014543 tgu-miR-137;tgu-miR-137-3p; +MIMAT0014544 tgu-miR-126;tgu-miR-126-3p; +MIMAT0014545 tgu-miR-200a;tgu-miR-200a-3p; +MIMAT0014546 tgu-miR-181a;tgu-miR-181a-5p; +MIMAT0014547 tgu-miR-2991; +MIMAT0014548 tgu-miR-490;tgu-miR-490-3p; +MIMAT0014549 tgu-miR-2992; +MIMAT0014550 tgu-miR-2993; +MIMAT0014551 tgu-miR-2994; +MIMAT0014552 tgu-miR-153;tgu-miR-153-3p; +MIMAT0014553 tgu-miR-20a;tgu-miR-20a-5p; +MIMAT0014554 tgu-miR-142;tgu-miR-142-5p; +MIMAT0014555 tgu-miR-15a;tgu-miR-15a-5p; +MIMAT0014556 tgu-miR-107; +MIMAT0014557 tgu-miR-140;tgu-miR-140-5p; +MIMAT0014558 tgu-miR-194;tgu-miR-194-5p; +MIMAT0014559 tgu-miR-135a;tgu-miR-135a-5p; +MIMAT0014560 tgu-miR-135b; +MIMAT0014561 tgu-miR-184; +MIMAT0014562 tgu-miR-1;tgu-miR-1-3p; +MIMAT0014563 tgu-miR-181b;tgu-miR-181b-5p; +MIMAT0014564 tgu-miR-17a;tgu-miR-17a-3p; +MIMAT0014565 tgu-miR-202; +MIMAT0014566 tgu-miR-23;tgu-miR-23-3p; +MIMAT0014567 tgu-miR-187;tgu-miR-187-3p; +MIMAT0014568 tgu-miR-219;tgu-miR-219a; +MIMAT0014569 tgu-miR-2995; +MIMAT0014570 tgu-miR-204; +MIMAT0014571 tgu-miR-133;tgu-miR-133-3p; +MIMAT0014572 tgu-miR-375; +MIMAT0014573 tgu-miR-130a;tgu-miR-130a-3p; +MIMAT0014574 tgu-miR-92;tgu-miR-92-3p; +MIMAT0014576 tgu-miR-216a;tgu-miR-216a-5p; +MIMAT0014577 tgu-miR-215;tgu-miR-215-5p; +MIMAT0014578 tgu-miR-130b;tgu-miR-130b-3p; +MIMAT0014579 tgu-miR-217;tgu-miR-217-5p; +MIMAT0014580 tgu-miR-454;tgu-miR-454-3p; +MIMAT0014581 tgu-miR-130c;tgu-miR-130c-3p; +MIMAT0014582 tgu-miR-365;tgu-miR-365-3p; +MIMAT0014583 tgu-miR-16a;tgu-miR-16a-5p; +MIMAT0014584 tgu-miR-32; +MIMAT0014585 tgu-miR-193a;tgu-miR-193a-3p; +MIMAT0014586 tgu-miR-16c; +MIMAT0014587 tgu-miR-18a; +MIMAT0014588 tgu-miR-16b;tgu-miR-16b-5p; +MIMAT0014589 tgu-miR-190;tgu-miR-190-5p; +MIMAT0014590 tgu-miR-106;tgu-miR-106-5p; +MIMAT0014591 tgu-miR-20b;tgu-miR-20b-5p; +MIMAT0014592 tgu-miR-200b;tgu-miR-200b-3p; +MIMAT0014593 tgu-miR-216b;tgu-miR-216b-5p; +MIMAT0014594 tgu-miR-1388;tgu-miR-1388-3p; +MIMAT0014595 tgu-miR-301;tgu-miR-301-3p; +MIMAT0014596 tgu-miR-144;tgu-miR-144-3p; +MIMAT0014597 tgu-miR-15b;tgu-miR-15b-5p; +MIMAT0014598 tgu-miR-34a; +MIMAT0014599 tgu-miR-223; +MIMAT0014600 tgu-miR-2996; +MIMAT0014601 tgu-miR-29b;tgu-miR-29b-3p; +MIMAT0014602 tgu-miR-146b;tgu-miR-146b-5p; +MIMAT0014603 tgu-miR-214;tgu-miR-214-3p; +MIMAT0014604 tgu-miR-2997;tgu-miR-2997-3p; +MIMAT0014605 tgu-miR-203;tgu-miR-203-3p; +MIMAT0014606 tgu-miR-147; +MIMAT0014607 tgu-miR-18b; +MIMAT0014608 tgu-miR-193b;tgu-miR-193b-3p; +MIMAT0014609 tgu-miR-146c; +MIMAT0014610 tgu-miR-455;tgu-miR-455-3p; +MIMAT0014611 tgu-miR-19a;tgu-miR-19a-3p; +MIMAT0014612 tgu-miR-155;tgu-miR-155-5p; +MIMAT0014613 tgu-miR-30d-3p; +MIMAT0014614 tgu-miR-460a;tgu-miR-460a-5p; +MIMAT0014615 tgu-miR-31; +MIMAT0014616 tgu-miR-205; +MIMAT0014617 tgu-miR-199-3p; +MIMAT0014618 tgu-miR-489;tgu-miR-489-3p; +MIMAT0014619 tgu-miR-15c;tgu-miR-15c-5p; +MIMAT0014620 tgu-miR-1805*;tgu-miR-1805-5p; +MIMAT0014621 tgu-miR-2962*;tgu-miR-2962-3p; +MIMAT0014622 tgu-miR-146a*;tgu-miR-146a-5p; +MIMAT0014623 tgu-miR-2954*;tgu-miR-2954-5p; +MIMAT0014624 tgu-miR-460b*;tgu-miR-460b-3p; +MIMAT0014625 tgu-miR-129*;tgu-miR-129-5p; +MIMAT0014626 tgu-miR-139*;tgu-miR-139-3p; +MIMAT0014627 tgu-miR-9*;tgu-miR-9-3p; +MIMAT0014628 tgu-miR-125-1*;tgu-miR-125-1-3p; +MIMAT0014629 tgu-miR-30b-3p; +MIMAT0014630 tgu-miR-124*;tgu-miR-124-5p; +MIMAT0014631 tgu-miR-101*;tgu-miR-101-5p;tgu-miR-101-2-5p; +MIMAT0014632 tgu-miR-7*;tgu-miR-7-3p;tgu-miR-7-1-3p; +MIMAT0014633 tgu-miR-100*;tgu-miR-100-3p; +MIMAT0014634 tgu-let-7a*;tgu-let-7a-3p;tgu-let-7a-2-3p; +MIMAT0014635 tgu-miR-99*;tgu-miR-99-3p; +MIMAT0014636 tgu-miR-21*;tgu-miR-21-3p; +MIMAT0014637 tgu-miR-30a-5p; +MIMAT0014638 tgu-miR-551*;tgu-miR-551-5p; +MIMAT0014639 tgu-miR-126*;tgu-miR-126-5p; +MIMAT0014640 tgu-miR-200a*;tgu-miR-200a-5p; +MIMAT0014641 tgu-miR-181a*;tgu-miR-181a-3p;tgu-miR-181a-1-3p; +MIMAT0014642 tgu-miR-140*;tgu-miR-140-3p; +MIMAT0014643 tgu-miR-135a*;tgu-miR-135a-3p;tgu-miR-135a-1-3p; +MIMAT0014644 tgu-miR-23*;tgu-miR-23-5p; +MIMAT0014645 tgu-miR-199-5p; +MIMAT0014646 tgu-miR-130b*;tgu-miR-130b-5p; +MIMAT0014647 tgu-miR-16a*;tgu-miR-16a-3p; +MIMAT0014648 tgu-miR-16b*;tgu-miR-16b-3p; +MIMAT0014649 tgu-miR-200b*;tgu-miR-200b-5p; +MIMAT0014650 tgu-miR-144*;tgu-miR-144-5p; +MIMAT0014651 tgu-miR-29b*;tgu-miR-29b-5p;tgu-miR-29b-2-5p; +MIMAT0014652 tgu-miR-146b*;tgu-miR-146b-3p; +MIMAT0014653 tgu-miR-2997*;tgu-miR-2997-5p; +MIMAT0014654 tgu-miR-193b*;tgu-miR-193b-5p; +MIMAT0014655 tgu-miR-455*;tgu-miR-455-5p; +MIMAT0014656 tgu-miR-155*;tgu-miR-155-3p; +MIMAT0014657 tgu-miR-30d-5p; +MIMAT0014658 tgu-miR-460a*;tgu-miR-460a-3p; +MIMAT0014659 bmo-miR-2998; +MIMAT0014660 bmo-miR-2999; +MIMAT0014661 bmo-miR-2733f; +MIMAT0014662 bmo-miR-2733g; +MIMAT0014663 bmo-miR-2733h; +MIMAT0014664 bmo-miR-3000; +MIMAT0014665 bmo-miR-3001; +MIMAT0014666 hma-miR-3002; +MIMAT0014667 hma-miR-3003a-5p; +MIMAT0014668 hma-miR-3003a-3p; +MIMAT0014669 hma-miR-3003b-5p; +MIMAT0014670 hma-miR-3003b-3p; +MIMAT0014671 hma-miR-3004; +MIMAT0014672 hma-miR-3005; +MIMAT0014673 hma-miR-3006; +MIMAT0014674 hma-miR-3007-5p; +MIMAT0014675 hma-miR-3007-3p; +MIMAT0014676 hma-miR-3008; +MIMAT0014677 hma-miR-3009; +MIMAT0014678 hma-miR-3010; +MIMAT0014679 hma-miR-3011; +MIMAT0014680 hma-miR-3012a; +MIMAT0014681 hma-miR-3012b; +MIMAT0014682 hma-miR-3013; +MIMAT0014683 hma-miR-3014; +MIMAT0014684 hma-miR-2030; +MIMAT0014685 tgu-miR-125-2*;tgu-miR-125-2-3p; +MIMAT0014686 tgu-miR-30c-3p; +MIMAT0014687 api-miR-100; +MIMAT0014688 hsv1-miR-H11; +MIMAT0014689 hsv1-miR-H12; +MIMAT0014690 hsv1-miR-H13; +MIMAT0014691 hsv1-miR-H14-5p; +MIMAT0014692 hsv1-miR-H14-3p; +MIMAT0014693 hsv1-miR-H15; +MIMAT0014694 hsv1-miR-H16; +MIMAT0014695 hsv1-miR-H17; +MIMAT0014696 hsv1-miR-H18; +MIMAT0014697 hsv2-miR-H11*;hsv2-miR-H11-5p; +MIMAT0014698 hsv2-miR-H11;hsv2-miR-H11-3p; +MIMAT0014699 hsv2-miR-H12; +MIMAT0014700 hsv2-miR-H13; +MIMAT0014701 hsv2-miR-H19; +MIMAT0014702 hsv2-miR-H20; +MIMAT0014703 hsv2-miR-H21; +MIMAT0014704 hsv2-miR-H22; +MIMAT0014705 hsv2-miR-H23;hsv2-miR-H23-5p; +MIMAT0014706 hsv2-miR-H23*;hsv2-miR-H23-3p; +MIMAT0014707 hsv2-miR-H24; +MIMAT0014708 hsv2-miR-H25; +MIMAT0014709 api-let-7; +MIMAT0014710 api-miR-1; +MIMAT0014711 api-miR-1000; +MIMAT0014712 api-miR-124; +MIMAT0014713 api-miR-13a; +MIMAT0014714 api-miR-14; +MIMAT0014715 api-miR-184b; +MIMAT0014716 api-miR-210; +MIMAT0014717 api-miR-219; +MIMAT0014718 api-miR-263a; +MIMAT0014719 api-miR-252a; +MIMAT0014720 api-miR-263b; +MIMAT0014721 api-miR-275; +MIMAT0014722 api-miR-277; +MIMAT0014723 api-miR-278; +MIMAT0014724 api-miR-279a; +MIMAT0014725 api-miR-279b; +MIMAT0014726 api-miR-29; +MIMAT0014727 api-miR-2a; +MIMAT0014728 api-miR-2c; +MIMAT0014729 api-miR-307; +MIMAT0014730 api-miR-315; +MIMAT0014731 api-miR-316; +MIMAT0014732 api-miR-317; +MIMAT0014733 api-miR-34; +MIMAT0014734 api-miR-7; +MIMAT0014735 api-miR-71; +MIMAT0014736 api-miR-981; +MIMAT0014737 api-miR-8; +MIMAT0014738 api-miR-87b; +MIMAT0014739 api-miR-87a; +MIMAT0014740 api-miR-927; +MIMAT0014741 api-miR-929; +MIMAT0014742 api-miR-92a; +MIMAT0014743 api-miR-92b; +MIMAT0014744 api-miR-965; +MIMAT0014745 api-miR-971; +MIMAT0014746 api-miR-996; +MIMAT0014747 api-miR-998; +MIMAT0014748 api-miR-9a; +MIMAT0014749 api-miR-9b; +MIMAT0014750 api-miR-3015a; +MIMAT0014751 api-miR-3016; +MIMAT0014752 api-miR-3017a; +MIMAT0014753 api-miR-3015b; +MIMAT0014754 api-miR-3018; +MIMAT0014755 api-miR-3019; +MIMAT0014756 api-miR-3020; +MIMAT0014757 api-miR-3021; +MIMAT0014758 api-miR-3022; +MIMAT0014759 api-miR-3023; +MIMAT0014760 api-miR-3024; +MIMAT0014761 api-miR-3025; +MIMAT0014762 api-miR-3026; +MIMAT0014763 api-miR-3027; +MIMAT0014764 api-miR-3028; +MIMAT0014765 api-miR-3029; +MIMAT0014766 api-miR-3030; +MIMAT0014767 api-miR-3031; +MIMAT0014768 api-miR-3032; +MIMAT0014769 api-miR-3033; +MIMAT0014770 api-miR-3034; +MIMAT0014771 api-miR-3035; +MIMAT0014772 api-miR-252b; +MIMAT0014773 api-miR-3036; +MIMAT0014774 api-miR-3037; +MIMAT0014775 api-miR-3038; +MIMAT0014776 api-miR-306; +MIMAT0014777 api-miR-3039; +MIMAT0014778 api-miR-3040; +MIMAT0014779 api-miR-3041; +MIMAT0014780 api-miR-3042; +MIMAT0014781 api-miR-3043; +MIMAT0014782 api-miR-3044; +MIMAT0014783 api-miR-3017b; +MIMAT0014784 api-miR-3045a; +MIMAT0014785 api-miR-3046; +MIMAT0014786 api-miR-3047; +MIMAT0014787 api-miR-2765; +MIMAT0014788 api-miR-3048; +MIMAT0014789 api-miR-3049; +MIMAT0014790 api-miR-2796; +MIMAT0014791 api-miR-3050; +MIMAT0014792 api-miR-3051; +MIMAT0014793 api-miR-3052; +MIMAT0014794 api-miR-3015c; +MIMAT0014795 api-miR-3053; +MIMAT0014796 api-miR-3045b; +MIMAT0014797 api-miR-3054; +MIMAT0014798 api-miR-3055; +MIMAT0014799 api-miR-3056; +MIMAT0014800 mmu-miR-1247;mmu-miR-1247-5p; +MIMAT0014801 mmu-miR-1247*;mmu-miR-1247-3p; +MIMAT0014802 mmu-miR-1264-5p; +MIMAT0014803 mmu-miR-1264-3p; +MIMAT0014804 mmu-miR-1249*;mmu-miR-1249-5p; +MIMAT0014805 mmu-miR-1843-5p;mmu-miR-1843a-5p; +MIMAT0014806 mmu-miR-1843-3p;mmu-miR-1843a-3p; +MIMAT0014807 mmu-miR-344d-3*;mmu-miR-344d-3-5p; +MIMAT0014808 mmu-miR-344d;mmu-miR-344d-3p; +MIMAT0014809 mmu-miR-1298;mmu-miR-1298-5p; +MIMAT0014810 mmu-miR-1298*;mmu-miR-1298-3p; +MIMAT0014811 mmu-miR-3059;mmu-miR-3059-5p; +MIMAT0014812 mmu-miR-3059*;mmu-miR-3059-3p; +MIMAT0014813 mmu-miR-3058;mmu-miR-3058-5p; +MIMAT0014814 mmu-miR-3058*;mmu-miR-3058-3p; +MIMAT0014815 mmu-miR-3099*;mmu-miR-3099-5p; +MIMAT0014816 mmu-miR-3099;mmu-miR-3099-3p; +MIMAT0014817 mmu-miR-3106;mmu-miR-3106-5p; +MIMAT0014818 mmu-miR-3106*;mmu-miR-3106-3p; +MIMAT0014819 mmu-miR-344d-1*;mmu-miR-344d-1-5p; +MIMAT0014821 api-miR-2b; +MIMAT0014822 mmu-miR-3057-5p; +MIMAT0014823 mmu-miR-3057-3p; +MIMAT0014824 mmu-miR-1251;mmu-miR-1251-5p; +MIMAT0014825 mmu-miR-1251*;mmu-miR-1251-3p; +MIMAT0014826 mmu-miR-3060*;mmu-miR-3060-5p; +MIMAT0014827 mmu-miR-3060;mmu-miR-3060-3p; +MIMAT0014828 mmu-miR-3061-5p; +MIMAT0014829 mmu-miR-3061-3p; +MIMAT0014830 mmu-miR-3062;mmu-miR-3062-5p; +MIMAT0014831 mmu-miR-3062*;mmu-miR-3062-3p; +MIMAT0014832 mmu-miR-3063*;mmu-miR-3063-5p; +MIMAT0014833 mmu-miR-3063;mmu-miR-3063-3p; +MIMAT0014834 mmu-miR-3064-5p; +MIMAT0014835 mmu-miR-3064-3p; +MIMAT0014836 mmu-miR-3065;mmu-miR-3065-5p; +MIMAT0014837 mmu-miR-3065*;mmu-miR-3065-3p; +MIMAT0014838 mmu-miR-3066;mmu-miR-3066-5p; +MIMAT0014839 mmu-miR-3066*;mmu-miR-3066-3p; +MIMAT0014840 mmu-miR-3067;mmu-miR-3067-5p; +MIMAT0014841 mmu-miR-3067*;mmu-miR-3067-3p; +MIMAT0014842 mmu-miR-3068;mmu-miR-3068-5p; +MIMAT0014843 mmu-miR-3068*;mmu-miR-3068-3p; +MIMAT0014844 mmu-miR-3069-5p; +MIMAT0014845 mmu-miR-3069-3p; +MIMAT0014846 mmu-miR-3070a*;mmu-miR-3070a-5p;mmu-miR-3070-5p; +MIMAT0014847 mmu-miR-3070a;mmu-miR-3070a-3p;mmu-miR-3070-3p; +MIMAT0014848 mmu-miR-3070b-5p; +MIMAT0014849 mmu-miR-3070b-3p;mmu-miR-3070-2-3p; +MIMAT0014850 mmu-miR-3071;mmu-miR-3071-5p; +MIMAT0014851 mmu-miR-3071*;mmu-miR-3071-3p; +MIMAT0014852 mmu-miR-3072*;mmu-miR-3072-5p; +MIMAT0014853 mmu-miR-3072;mmu-miR-3072-3p; +MIMAT0014854 mmu-miR-3073-5p;mmu-miR-3073a-5p; +MIMAT0014855 mmu-miR-3073-3p;mmu-miR-3073a-3p; +MIMAT0014856 mmu-miR-3074-5p; +MIMAT0014857 mmu-miR-3074-1-3p; +MIMAT0014858 mmu-miR-3075;mmu-miR-3075-5p; +MIMAT0014859 mmu-miR-3075*;mmu-miR-3075-3p; +MIMAT0014860 mmu-miR-3076-5p; +MIMAT0014861 mmu-miR-3076-3p; +MIMAT0014862 mmu-miR-3077*;mmu-miR-3077-5p; +MIMAT0014863 mmu-miR-3077;mmu-miR-3077-3p; +MIMAT0014864 mmu-miR-3078;mmu-miR-3078-5p; +MIMAT0014865 mmu-miR-3078*;mmu-miR-3078-3p; +MIMAT0014866 mmu-miR-3079-5p; +MIMAT0014867 mmu-miR-3079-3p; +MIMAT0014868 mmu-miR-3080-5p; +MIMAT0014869 mmu-miR-3080-3p; +MIMAT0014870 mmu-miR-3081*;mmu-miR-3081-5p; +MIMAT0014871 mmu-miR-3081;mmu-miR-3081-3p; +MIMAT0014872 mmu-miR-3082-5p; +MIMAT0014873 mmu-miR-3082-3p; +MIMAT0014874 mmu-miR-3083;mmu-miR-3083-5p; +MIMAT0014875 mmu-miR-3083*;mmu-miR-3083-3p; +MIMAT0014876 mmu-miR-3084*;mmu-miR-3084-5p; +MIMAT0014877 mmu-miR-3084;mmu-miR-3084-3p; +MIMAT0014878 mmu-miR-3085-5p; +MIMAT0014879 mmu-miR-3085-3p; +MIMAT0014880 mmu-miR-3086-5p; +MIMAT0014881 mmu-miR-3086-3p; +MIMAT0014882 mmu-miR-466m-5p; +MIMAT0014883 mmu-miR-466m-3p; +MIMAT0014884 mmu-miR-669d-2*;mmu-miR-669d-2-3p; +MIMAT0014885 mmu-miR-466o-5p; +MIMAT0014886 mmu-miR-466o-3p; +MIMAT0014889 mmu-miR-669p;mmu-miR-669p-5p; +MIMAT0014890 mmu-miR-669p*;mmu-miR-669p-3p; +MIMAT0014891 mmu-miR-466p-5p; +MIMAT0014892 mmu-miR-466p-3p; +MIMAT0014893 mmu-miR-466n-5p; +MIMAT0014894 mmu-miR-466n-3p; +MIMAT0014895 mmu-miR-3087*;mmu-miR-3087-5p; +MIMAT0014896 mmu-miR-3087;mmu-miR-3087-3p; +MIMAT0014897 mmu-miR-3088*;mmu-miR-3088-5p; +MIMAT0014898 mmu-miR-3088;mmu-miR-3088-3p; +MIMAT0014899 mmu-miR-3089-5p; +MIMAT0014900 mmu-miR-3089-3p; +MIMAT0014901 mmu-miR-3090*;mmu-miR-3090-5p; +MIMAT0014902 mmu-miR-3090;mmu-miR-3090-3p; +MIMAT0014903 mmu-miR-3091-5p; +MIMAT0014904 mmu-miR-3091-3p; +MIMAT0014905 mmu-miR-3092*;mmu-miR-3092-5p; +MIMAT0014906 mmu-miR-3092;mmu-miR-3092-3p; +MIMAT0014907 mmu-miR-3093-5p; +MIMAT0014908 mmu-miR-3093-3p; +MIMAT0014909 mmu-miR-3094;mmu-miR-3094-5p; +MIMAT0014910 mmu-miR-3094*;mmu-miR-3094-3p; +MIMAT0014911 mmu-miR-3095-5p; +MIMAT0014912 mmu-miR-3095-3p; +MIMAT0014913 mmu-miR-3096-5p;mmu-miR-3096a-5p; +MIMAT0014914 mmu-miR-3096-3p;mmu-miR-3096a-3p; +MIMAT0014915 mmu-miR-3097-5p; +MIMAT0014916 mmu-miR-3097-3p; +MIMAT0014917 mmu-miR-3098-5p; +MIMAT0014918 mmu-miR-3098-3p; +MIMAT0014919 mmu-miR-3100-5p; +MIMAT0014920 mmu-miR-3100-3p; +MIMAT0014921 mmu-miR-3101;mmu-miR-3101-5p; +MIMAT0014922 mmu-miR-3101*;mmu-miR-3101-3p; +MIMAT0014923 mmu-miR-344e*;mmu-miR-344e-5p; +MIMAT0014924 mmu-miR-344e;mmu-miR-344e-3p; +MIMAT0014925 mmu-miR-344b*;mmu-miR-344b-5p; +MIMAT0014926 mmu-miR-344b;mmu-miR-344b-3p; +MIMAT0014927 mmu-miR-344c*;mmu-miR-344c-5p; +MIMAT0014928 mmu-miR-344c;mmu-miR-344c-3p; +MIMAT0014929 mmu-miR-344g-5p; +MIMAT0014930 mmu-miR-344g-3p; +MIMAT0014931 mmu-miR-344f-5p; +MIMAT0014932 mmu-miR-344f-3p; +MIMAT0014933 mmu-miR-3102*;mmu-miR-3102-5p; +MIMAT0014934 mmu-miR-3102-5p.2;mmu-miR-3102-5p.2-5p; +MIMAT0014935 mmu-miR-3102-3p.2;mmu-miR-3102-3p.2-3p; +MIMAT0014936 mmu-miR-3102;mmu-miR-3102-3p; +MIMAT0014937 mmu-miR-3103*;mmu-miR-3103-5p; +MIMAT0014938 mmu-miR-3103;mmu-miR-3103-3p; +MIMAT0014939 mmu-miR-3104-5p; +MIMAT0014940 mmu-miR-3104-3p; +MIMAT0014941 mmu-miR-3105-5p; +MIMAT0014942 mmu-miR-3105-3p; +MIMAT0014943 mmu-miR-3107;mmu-miR-3107-5p;mmu-miR-486b-5p; +MIMAT0014944 mmu-miR-3107*;mmu-miR-3107-3p;mmu-miR-486b-3p; +MIMAT0014946 mmu-miR-3074-2-3p; +MIMAT0014947 mmu-miR-3108;mmu-miR-3108-5p; +MIMAT0014948 mmu-miR-3108*;mmu-miR-3108-3p; +MIMAT0014949 mmu-miR-3109*;mmu-miR-3109-5p; +MIMAT0014950 mmu-miR-3109;mmu-miR-3109-3p; +MIMAT0014951 mmu-miR-3110;mmu-miR-3110-5p; +MIMAT0014952 mmu-miR-3110*;mmu-miR-3110-3p; +MIMAT0014953 mmu-miR-374c;mmu-miR-374c-5p; +MIMAT0014954 mmu-miR-374c*;mmu-miR-374c-3p; +MIMAT0014955 mmu-miR-3112;mmu-miR-3112-5p; +MIMAT0014956 mmu-miR-3112*;mmu-miR-3112-3p; +MIMAT0014957 mmu-miR-1912*;mmu-miR-1912-5p; +MIMAT0014958 mmu-miR-1912;mmu-miR-1912-3p; +MIMAT0014959 mmu-miR-3113;mmu-miR-3113-5p; +MIMAT0014960 mmu-miR-3113*;mmu-miR-3113-3p; +MIMAT0014961 mmu-miR-344d-2*;mmu-miR-344d-2-5p; +MIMAT0014963 oar-let-7b; +MIMAT0014964 oar-let-7c; +MIMAT0014966 oar-miR-21; +MIMAT0014967 oar-miR-29a; +MIMAT0014971 oar-miR-125b; +MIMAT0014972 oar-miR-133; +MIMAT0014973 oar-miR-181a; +MIMAT0014977 hsa-miR-3115; +MIMAT0014978 hsa-miR-3116; +MIMAT0014979 hsa-miR-3117;hsa-miR-3117-3p; +MIMAT0014980 hsa-miR-3118; +MIMAT0014981 hsa-miR-3119; +MIMAT0014982 hsa-miR-3120;hsa-miR-3120-3p; +MIMAT0014983 hsa-miR-3121;hsa-miR-3121-3p; +MIMAT0014984 hsa-miR-3122; +MIMAT0014985 hsa-miR-3123; +MIMAT0014986 hsa-miR-3124;hsa-miR-3124-5p; +MIMAT0014987 hsa-miR-548s; +MIMAT0014988 hsa-miR-3125; +MIMAT0014989 hsa-miR-3126-5p; +MIMAT0014990 hsa-miR-3127;hsa-miR-3127-5p; +MIMAT0014991 hsa-miR-3128; +MIMAT0014992 hsa-miR-3129;hsa-miR-3129-5p; +MIMAT0014994 hsa-miR-3130-3p; +MIMAT0014995 hsa-miR-3130-5p; +MIMAT0014996 hsa-miR-3131; +MIMAT0014997 hsa-miR-3132; +MIMAT0014998 hsa-miR-3133; +MIMAT0014999 hsa-miR-378b; +MIMAT0015000 hsa-miR-3134; +MIMAT0015001 hsa-miR-3135;hsa-miR-3135a; +MIMAT0015002 hsa-miR-466; +MIMAT0015003 hsa-miR-3136;hsa-miR-3136-5p; +MIMAT0015004 hsa-miR-544b; +MIMAT0015005 hsa-miR-3137; +MIMAT0015006 hsa-miR-3138; +MIMAT0015007 hsa-miR-3139; +MIMAT0015008 hsa-miR-3140;hsa-miR-3140-3p; +MIMAT0015009 hsa-miR-548t;hsa-miR-548t-5p; +MIMAT0015010 hsa-miR-3141; +MIMAT0015011 hsa-miR-3142; +MIMAT0015012 hsa-miR-3143; +MIMAT0015013 hsa-miR-548u; +MIMAT0015014 hsa-miR-3144-5p; +MIMAT0015015 hsa-miR-3144-3p; +MIMAT0015016 hsa-miR-3145;hsa-miR-3145-3p; +MIMAT0015017 hsa-miR-1273c; +MIMAT0015018 hsa-miR-3146; +MIMAT0015019 hsa-miR-3147; +MIMAT0015020 hsa-miR-548v; +MIMAT0015021 hsa-miR-3148; +MIMAT0015022 hsa-miR-3149; +MIMAT0015023 hsa-miR-3150;hsa-miR-3150a-3p; +MIMAT0015024 hsa-miR-3151;hsa-miR-3151-5p; +MIMAT0015025 hsa-miR-3152;hsa-miR-3152-3p; +MIMAT0015026 hsa-miR-3153; +MIMAT0015027 hsa-miR-3074;hsa-miR-3074-3p; +MIMAT0015028 hsa-miR-3154; +MIMAT0015029 hsa-miR-3155;hsa-miR-3155a; +MIMAT0015030 hsa-miR-3156;hsa-miR-3156-5p; +MIMAT0015031 hsa-miR-3157;hsa-miR-3157-5p; +MIMAT0015032 hsa-miR-3158;hsa-miR-3158-3p; +MIMAT0015033 hsa-miR-3159; +MIMAT0015034 hsa-miR-3160;hsa-miR-3160-3p; +MIMAT0015035 hsa-miR-3161; +MIMAT0015036 hsa-miR-3162;hsa-miR-3162-5p; +MIMAT0015037 hsa-miR-3163; +MIMAT0015038 hsa-miR-3164; +MIMAT0015039 hsa-miR-3165; +MIMAT0015040 hsa-miR-3166; +MIMAT0015041 hsa-miR-1260b; +MIMAT0015042 hsa-miR-3167; +MIMAT0015043 hsa-miR-3168; +MIMAT0015044 hsa-miR-3169; +MIMAT0015045 hsa-miR-3170; +MIMAT0015046 hsa-miR-3171; +MIMAT0015047 hsa-miR-3172; +MIMAT0015048 hsa-miR-3173;hsa-miR-3173-3p; +MIMAT0015049 hsa-miR-1193; +MIMAT0015050 hsa-miR-323b-3p; +MIMAT0015051 hsa-miR-3174; +MIMAT0015052 hsa-miR-3175; +MIMAT0015053 hsa-miR-3176; +MIMAT0015054 hsa-miR-3177;hsa-miR-3177-3p; +MIMAT0015055 hsa-miR-3178; +MIMAT0015056 hsa-miR-3179; +MIMAT0015057 hsa-miR-3180-5p; +MIMAT0015058 hsa-miR-3180-3p; +MIMAT0015060 hsa-miR-548w; +MIMAT0015061 hsa-miR-3181; +MIMAT0015062 hsa-miR-3182; +MIMAT0015063 hsa-miR-3183; +MIMAT0015064 hsa-miR-3184;hsa-miR-3184-5p; +MIMAT0015065 hsa-miR-3185; +MIMAT0015066 hsa-miR-3065-5p; +MIMAT0015067 hsa-miR-3186-5p; +MIMAT0015068 hsa-miR-3186-3p; +MIMAT0015069 hsa-miR-3187;hsa-miR-3187-3p; +MIMAT0015070 hsa-miR-3188; +MIMAT0015071 hsa-miR-3189;hsa-miR-3189-3p; +MIMAT0015072 hsa-miR-320e; +MIMAT0015073 hsa-miR-3190-5p;hsa-miR-3190;hsa-miR-3190-5p; +MIMAT0015074 hsa-miR-3190-3p; +MIMAT0015075 hsa-miR-3191;hsa-miR-3191-3p; +MIMAT0015076 hsa-miR-3192;hsa-miR-3192-5p; +MIMAT0015077 hsa-miR-3193; +MIMAT0015078 hsa-miR-3194;hsa-miR-3194-5p; +MIMAT0015079 hsa-miR-3195; +MIMAT0015080 hsa-miR-3196; +MIMAT0015081 hsa-miR-548x;hsa-miR-548x-3p; +MIMAT0015082 hsa-miR-3197; +MIMAT0015083 hsa-miR-3198; +MIMAT0015084 hsa-miR-3199; +MIMAT0015085 hsa-miR-3200;hsa-miR-3200-3p; +MIMAT0015086 hsa-miR-3201; +MIMAT0015087 hsa-miR-514b-5p; +MIMAT0015088 hsa-miR-514b-3p; +MIMAT0015089 hsa-miR-3202; +MIMAT0015090 hsa-miR-1273d; +MIMAT0015091 cel-let-7*;cel-let-7-3p; +MIMAT0015092 cel-lin-4*;cel-lin-4-3p; +MIMAT0015093 cel-miR-34*;cel-miR-34-3p; +MIMAT0015094 cel-miR-37*;cel-miR-37-5p; +MIMAT0015095 cel-miR-42*;cel-miR-42-5p; +MIMAT0015096 cel-miR-46*;cel-miR-46-5p; +MIMAT0015097 cel-miR-47*;cel-miR-47-5p; +MIMAT0015098 cel-miR-48*;cel-miR-48-3p; +MIMAT0015099 cel-miR-51*;cel-miR-51-3p; +MIMAT0015100 cel-miR-58*;cel-miR-58-5p;cel-miR-58a-5p; +MIMAT0015101 cel-miR-59*;cel-miR-59-5p; +MIMAT0015102 cel-miR-60*;cel-miR-60-5p; +MIMAT0015103 cel-miR-61*;cel-miR-61-5p; +MIMAT0015104 cel-miR-63*;cel-miR-63-5p; +MIMAT0015105 cel-miR-64*;cel-miR-64-3p; +MIMAT0015106 cel-miR-65*;cel-miR-65-3p; +MIMAT0015107 cel-miR-71*;cel-miR-71-3p; +MIMAT0015108 cel-miR-75*;cel-miR-75-5p; +MIMAT0015109 cel-miR-81*;cel-miR-81-5p; +MIMAT0015110 cel-miR-84*;cel-miR-84-3p; +MIMAT0015111 cel-miR-124*;cel-miR-124-5p; +MIMAT0015112 cel-miR-229*;cel-miR-229-3p; +MIMAT0015113 cel-miR-230*;cel-miR-230-5p; +MIMAT0015114 cel-miR-238*;cel-miR-238-5p; +MIMAT0015115 cel-miR-239b*;cel-miR-239b-3p; +MIMAT0015116 cel-miR-240*;cel-miR-240-5p; +MIMAT0015117 cel-miR-243*;cel-miR-243-5p; +MIMAT0015118 cel-miR-244*;cel-miR-244-3p; +MIMAT0015119 cel-miR-247*;cel-miR-247-5p; +MIMAT0015120 cel-miR-358*;cel-miR-358-5p; +MIMAT0015121 cel-miR-360*;cel-miR-360-5p; +MIMAT0015122 osa-miR168a-3p; +MIMAT0015123 osa-miR393b-3p; +MIMAT0015124 zma-miR156d*;zma-miR156d-3p; +MIMAT0015125 zma-miR156f*;zma-miR156f-3p; +MIMAT0015126 zma-miR156g*;zma-miR156g-3p; +MIMAT0015127 zma-miR156b*;zma-miR156b-3p; +MIMAT0015128 zma-miR156e*;zma-miR156e-3p; +MIMAT0015129 zma-miR156a*;zma-miR156a-3p; +MIMAT0015130 zma-miR156h*;zma-miR156h-3p; +MIMAT0015131 zma-miR156i*;zma-miR156i-3p; +MIMAT0015132 zma-miR160a*;zma-miR160a-3p; +MIMAT0015133 zma-miR160c*;zma-miR160c-3p; +MIMAT0015134 zma-miR160d*;zma-miR160d-3p; +MIMAT0015135 zma-miR160b*;zma-miR160b-3p; +MIMAT0015136 zma-miR164a*;zma-miR164a-3p; +MIMAT0015137 zma-miR164d*;zma-miR164d-3p; +MIMAT0015138 zma-miR164b*;zma-miR164b-3p; +MIMAT0015139 zma-miR164c*;zma-miR164c-3p; +MIMAT0015140 zma-miR169a*;zma-miR169a-3p; +MIMAT0015141 zma-miR169b*;zma-miR169b-3p; +MIMAT0015142 zma-miR167a*;zma-miR167a-3p; +MIMAT0015143 zma-miR167b*;zma-miR167b-3p; +MIMAT0015144 zma-miR167d*;zma-miR167d-3p; +MIMAT0015145 zma-miR167c*;zma-miR167c-3p; +MIMAT0015146 zma-miR166a*;zma-miR166a-5p; +MIMAT0015147 zma-miR162*;zma-miR162-5p; +MIMAT0015148 zma-miR166h*;zma-miR166h-5p; +MIMAT0015149 zma-miR166i*;zma-miR166i-5p; +MIMAT0015150 zma-miR166g*;zma-miR166g-5p; +MIMAT0015151 zma-miR166b*;zma-miR166b-5p; +MIMAT0015152 zma-miR166c*;zma-miR166c-5p; +MIMAT0015153 zma-miR166d*;zma-miR166d-5p; +MIMAT0015154 zma-miR171a*;zma-miR171a-5p; +MIMAT0015155 zma-miR171b*;zma-miR171b-5p; +MIMAT0015156 zma-miR172d*;zma-miR172d-5p; +MIMAT0015157 zma-miR172b*;zma-miR172b-5p; +MIMAT0015158 zma-miR172c*;zma-miR172c-5p; +MIMAT0015159 osa-miR396e-3p; +MIMAT0015160 zma-miR171d*;zma-miR171d-5p; +MIMAT0015161 zma-miR171f*;zma-miR171f-5p; +MIMAT0015162 zma-miR394a*;zma-miR394a-3p; +MIMAT0015163 zma-miR394b*;zma-miR394b-3p; +MIMAT0015164 zma-miR395b*;zma-miR395b-5p; +MIMAT0015165 zma-miR395c*;zma-miR395c-5p; +MIMAT0015166 zma-miR395a*;zma-miR395a-5p; +MIMAT0015167 zma-miR396b*;zma-miR396b-3p; +MIMAT0015168 zma-miR396a*;zma-miR396a-3p; +MIMAT0015169 zma-miR399a*;zma-miR399a-5p; +MIMAT0015170 zma-miR399c*;zma-miR399c-5p; +MIMAT0015171 zma-miR399b*;zma-miR399b-5p; +MIMAT0015172 zma-miR399d*;zma-miR399d-5p; +MIMAT0015173 zma-miR399e*;zma-miR399e-5p; +MIMAT0015174 zma-miR399f*;zma-miR399f-5p; +MIMAT0015175 zma-miR156j*;zma-miR156j-3p; +MIMAT0015176 zma-miR159a*;zma-miR159a-5p; +MIMAT0015177 zma-miR159b*;zma-miR159b-5p; +MIMAT0015178 zma-miR159c*;zma-miR159c-5p; +MIMAT0015179 zma-miR159d*;zma-miR159d-5p; +MIMAT0015180 zma-miR319a*;zma-miR319a-5p; +MIMAT0015181 zma-miR319c*;zma-miR319c-5p; +MIMAT0015182 zma-miR319b*;zma-miR319b-5p; +MIMAT0015183 zma-miR319d*;zma-miR319d-5p; +MIMAT0015184 zma-miR166k*;zma-miR166k-5p; +MIMAT0015185 zma-miR166j*;zma-miR166j-5p; +MIMAT0015186 zma-miR167e*;zma-miR167e-3p; +MIMAT0015187 zma-miR167f*;zma-miR167f-3p; +MIMAT0015188 zma-miR167g*;zma-miR167g-3p; +MIMAT0015189 zma-miR167h*;zma-miR167h-3p; +MIMAT0015190 zma-miR167i*;zma-miR167i-3p; +MIMAT0015191 zma-miR168a*;zma-miR168a-3p; +MIMAT0015192 zma-miR168b*;zma-miR168b-3p; +MIMAT0015193 zma-miR169c*;zma-miR169c-3p; +MIMAT0015194 zma-miR169f*;zma-miR169f-3p; +MIMAT0015195 zma-miR169i*;zma-miR169i-3p; +MIMAT0015196 zma-miR169k*;zma-miR169k-3p; +MIMAT0015197 zma-miR169j*;zma-miR169j-3p; +MIMAT0015198 zma-miR171c*;zma-miR171c-5p; +MIMAT0015199 zma-miR171j*;zma-miR171j-5p; +MIMAT0015200 zma-miR171e*;zma-miR171e-5p; +MIMAT0015201 zma-miR171i*;zma-miR171i-5p; +MIMAT0015202 zma-miR171g*;zma-miR171g-5p; +MIMAT0015203 zma-miR166l*;zma-miR166l-5p; +MIMAT0015204 zma-miR166m*;zma-miR166m-5p; +MIMAT0015205 zma-miR171k*;zma-miR171k-5p; +MIMAT0015206 zma-miR171h*;zma-miR171h-5p; +MIMAT0015207 zma-miR393a*;zma-miR393a-3p; +MIMAT0015208 zma-miR156k*;zma-miR156k-3p; +MIMAT0015209 zma-miR160f*;zma-miR160f-3p; +MIMAT0015210 ssc-miR-24*;ssc-miR-24-1-5p; +MIMAT0015211 ssc-miR-28-3p; +MIMAT0015212 kshv-miR-K12-10a*;kshv-miR-K12-10a-5p; +MIMAT0015213 kshv-miR-K12-11*;kshv-miR-K12-11-5p; +MIMAT0015214 kshv-miR-K12-1*;kshv-miR-K12-1-3p; +MIMAT0015215 kshv-miR-K12-2*;kshv-miR-K12-2-3p; +MIMAT0015216 kshv-miR-K12-8*;kshv-miR-K12-8-5p; +MIMAT0015217 kshv-miR-K12-7*;kshv-miR-K12-7-5p; +MIMAT0015218 kshv-miR-K12-5*;kshv-miR-K12-5-5p; +MIMAT0015219 mmu-miR-3475;mmu-miR-3475-3p; +MIMAT0015220 hsv1-miR-H1*;hsv1-miR-H1-3p; +MIMAT0015221 bmo-let-7*;bmo-let-7-3p; +MIMAT0015222 bmo-miR-1*;bmo-miR-1a*;bmo-miR-1a-5p; +MIMAT0015223 bmo-miR-7*;bmo-miR-7-3p; +MIMAT0015224 bmo-miR-8*;bmo-miR-8-5p; +MIMAT0015225 bmo-miR-9a*;bmo-miR-9a-3p; +MIMAT0015226 bmo-miR-10*;bmo-miR-10-3p; +MIMAT0015227 bmo-miR-14*;bmo-miR-14-5p; +MIMAT0015228 bmo-miR-34*;bmo-miR-34-3p; +MIMAT0015229 bmo-miR-263b*;bmo-miR-263b-3p; +MIMAT0015230 bmo-miR-263a*;bmo-miR-263a-3p; +MIMAT0015231 bmo-miR-275*;bmo-miR-275-5p; +MIMAT0015232 bmo-miR-276*;bmo-miR-276-3p; +MIMAT0015233 bmo-miR-277*;bmo-miR-277-5p; +MIMAT0015234 bmo-miR-282*;bmo-miR-282-3p; +MIMAT0015235 bmo-miR-283*;bmo-miR-283-3p; +MIMAT0015236 bmo-miR-305*;bmo-miR-305-3p; +MIMAT0015237 bmo-miR-307*;bmo-miR-307-5p; +MIMAT0015238 kshv-miR-K12-12*;kshv-miR-K12-12;kshv-miR-K12-12-3p; +MIMAT0015239 cel-miR-786*;cel-miR-786-5p; +MIMAT0015240 cel-miR-788*;cel-miR-788-3p; +MIMAT0015241 cel-miR-797*;cel-miR-797-3p; +MIMAT0015242 bmo-miR-31*;bmo-miR-31-3p; +MIMAT0015243 bmo-miR-71*;bmo-miR-71-3p; +MIMAT0015244 osa-miR1423-5p.2;osa-miR1423a-5p;osa-miR1423-5p; +MIMAT0015245 cin-miR-1473*;cin-miR-1473-5p; +MIMAT0015246 cin-miR-1497*;cin-miR-1497-5p; +MIMAT0015247 cin-let-7a-1*;cin-let-7a-1-3p; +MIMAT0015248 cin-let-7a-2*;cin-let-7a-2-3p; +MIMAT0015249 cin-let-7b*;cin-let-7b-3p; +MIMAT0015250 cin-let-7d*;cin-let-7d-3p; +MIMAT0015251 cin-miR-7*;cin-miR-7-3p; +MIMAT0015252 cin-miR-34*;cin-miR-34-3p; +MIMAT0015253 cin-miR-92a*;cin-miR-92a-5p; +MIMAT0015254 cin-miR-92b*;cin-miR-92b-5p; +MIMAT0015255 cin-miR-92c*;cin-miR-92c-5p; +MIMAT0015256 cin-miR-124-1*;cin-miR-124-1-5p; +MIMAT0015257 cin-miR-124-2*;cin-miR-124-2-5p; +MIMAT0015258 cin-miR-126*;cin-miR-126-5p; +MIMAT0015259 cin-miR-133*;cin-miR-133-5p; +MIMAT0015260 cin-miR-141*;cin-miR-141-5p; +MIMAT0015261 cin-miR-153*;cin-miR-153-5p; +MIMAT0015262 cin-miR-183*;cin-miR-183-3p; +MIMAT0015263 cin-miR-200*;cin-miR-200-5p; +MIMAT0015264 cin-miR-219*;cin-miR-219-3p; +MIMAT0015265 cin-miR-281*;cin-miR-281-5p; +MIMAT0015266 cel-miR-1822*;cel-miR-1822-5p; +MIMAT0015267 cel-miR-1829a*;cel-miR-1829a-5p; +MIMAT0015268 ssc-miR-17-3p; +MIMAT0015269 ssc-miR-30b-3p; +MIMAT0015270 osa-miR1870-3p; +MIMAT0015271 bmo-miR-2a-1*;bmo-miR-2a-1-5p; +MIMAT0015272 bmo-miR-2a-2*;bmo-miR-2a-2-5p; +MIMAT0015273 bmo-miR-2b*;bmo-miR-2b-5p; +MIMAT0015274 bmo-miR-13b*;bmo-miR-13b-5p; +MIMAT0015275 bmo-miR-79*;bmo-miR-79-5p; +MIMAT0015276 bmo-miR-184*;bmo-miR-184-5p; +MIMAT0015277 bmo-miR-317*;bmo-miR-317-5p; +MIMAT0015278 bmo-bantam*;bmo-bantam-5p; +MIMAT0015279 hsv1-miR-H3*;hsv1-miR-H3-5p; +MIMAT0015280 hsv1-miR-H5-5p; +MIMAT0015281 hsv1-miR-H6-5p; +MIMAT0015282 dsi-miR-312*;dsi-miR-312-5p; +MIMAT0015283 dsi-miR-6*;dsi-miR-6-5p; +MIMAT0015284 osa-miR1317-5p.2;osa-miR1317-5p.2-5p; +MIMAT0015285 osa-miR1317-3p;osa-miR1882e-3p; +MIMAT0015286 osa-miR1320-3p; +MIMAT0015287 bmo-miR-190*;bmo-miR-190-3p; +MIMAT0015288 bmo-miR-927*;bmo-miR-927-3p; +MIMAT0015289 bmo-miR-929*;bmo-miR-929-3p; +MIMAT0015290 bmo-miR-9b*;bmo-miR-9b-3p; +MIMAT0015291 bmo-miR-278*;bmo-miR-278-5p; +MIMAT0015292 osa-miR396f-3p; +MIMAT0015293 bmo-miR-252*;bmo-miR-252-3p; +MIMAT0015294 bmo-miR-970*;bmo-miR-970-5p; +MIMAT0015295 bmo-miR-965;bmo-miR-965-5p; +MIMAT0015296 bmo-miR-274*;bmo-miR-274-3p; +MIMAT0015297 bmo-miR-993b*;bmo-miR-993b-5p; +MIMAT0015298 bmo-miR-993a*;bmo-miR-993a-5p; +MIMAT0015299 ssc-miR-133a*;ssc-miR-133a-5p; +MIMAT0015300 ssc-miR-30a-3p; +MIMAT0015301 pvu-miR159a.1; +MIMAT0015302 bmo-miR-9c*;bmo-miR-9c-5p; +MIMAT0015303 bmo-miR-306**;bmo-miR-306a*;bmo-miR-306a-3p; +MIMAT0015304 bta-miR-424*;bta-miR-424-3p; +MIMAT0015305 bmo-miR-2778a-2*;bmo-miR-2778a-2-5p; +MIMAT0015306 bmo-miR-2778a-4*;bmo-miR-2778a-4-5p; +MIMAT0015307 bmo-miR-2843-2*;bmo-miR-2843-2-3p; +MIMAT0015308 zma-miR156l*;zma-miR156l-3p; +MIMAT0015309 zma-miR159e*;zma-miR159e-5p; +MIMAT0015310 zma-miR159f*;zma-miR159f-5p; +MIMAT0015311 zma-miR159g*;zma-miR159g-5p; +MIMAT0015312 zma-miR159h*;zma-miR159h-5p; +MIMAT0015313 zma-miR159i*;zma-miR159i-5p; +MIMAT0015314 zma-miR159j*;zma-miR159j-5p; +MIMAT0015315 zma-miR159k*;zma-miR159k-5p; +MIMAT0015316 zma-miR160g*;zma-miR160g-3p; +MIMAT0015317 zma-miR164e*;zma-miR164e-3p; +MIMAT0015318 zma-miR164f*;zma-miR164f-3p; +MIMAT0015319 zma-miR164g*;zma-miR164g-3p; +MIMAT0015320 zma-miR164h*;zma-miR164h-3p; +MIMAT0015321 zma-miR166n*;zma-miR166n-5p; +MIMAT0015322 zma-miR167j*;zma-miR167j-3p; +MIMAT0015323 zma-miR169l*;zma-miR169l-3p; +MIMAT0015324 zma-miR169m*;zma-miR169m-3p; +MIMAT0015325 zma-miR169n*;zma-miR169n-3p; +MIMAT0015326 zma-miR169o*;zma-miR169o-3p; +MIMAT0015327 zma-miR169p*;zma-miR169p-3p; +MIMAT0015328 zma-miR169q*;zma-miR169q-3p; +MIMAT0015329 zma-miR169r*;zma-miR169r-3p; +MIMAT0015330 zma-miR171l*;zma-miR171l-5p; +MIMAT0015331 zma-miR171m*;zma-miR171m-5p; +MIMAT0015332 zma-miR171n*;zma-miR171n-5p; +MIMAT0015333 zma-miR390a*;zma-miR390a-3p; +MIMAT0015334 zma-miR393b*;zma-miR393b-3p; +MIMAT0015335 zma-miR393c*;zma-miR393c-3p; +MIMAT0015336 zma-miR395d*;zma-miR395d-5p; +MIMAT0015337 zma-miR395e*;zma-miR395e-5p; +MIMAT0015338 zma-miR395f*;zma-miR395f-5p; +MIMAT0015339 zma-miR395g*;zma-miR395g-5p; +MIMAT0015340 zma-miR395h*;zma-miR395h-5p; +MIMAT0015341 zma-miR395i*;zma-miR395i-5p; +MIMAT0015342 zma-miR395j*;zma-miR395j-5p; +MIMAT0015343 zma-miR395k*;zma-miR395k-5p; +MIMAT0015344 zma-miR395l*;zma-miR395l-5p; +MIMAT0015345 zma-miR395m*;zma-miR395m-5p; +MIMAT0015346 zma-miR395n*;zma-miR395n-5p; +MIMAT0015347 zma-miR395o*;zma-miR395o-5p; +MIMAT0015348 zma-miR395p*;zma-miR395p-5p; +MIMAT0015349 zma-miR396e*;zma-miR396e-3p; +MIMAT0015350 zma-miR396f*;zma-miR396f-3p; +MIMAT0015351 zma-miR396g*;zma-miR396g-3p; +MIMAT0015352 zma-miR397a*;zma-miR397a-3p; +MIMAT0015353 zma-miR397b*;zma-miR397b-3p; +MIMAT0015354 zma-miR398a*;zma-miR398a-5p; +MIMAT0015355 zma-miR398b*;zma-miR398b-5p; +MIMAT0015356 zma-miR399g*;zma-miR399g-5p; +MIMAT0015357 zma-miR399h*;zma-miR399h-5p; +MIMAT0015358 zma-miR399i*;zma-miR399i-5p; +MIMAT0015359 zma-miR399j*;zma-miR399j-5p; +MIMAT0015360 zma-miR408b*;zma-miR408b-5p; +MIMAT0015361 zma-miR482*;zma-miR482-5p; +MIMAT0015362 zma-miR528a*;zma-miR528a-3p; +MIMAT0015363 zma-miR528b*;zma-miR528b-3p; +MIMAT0015364 zma-miR529*;zma-miR529-3p; +MIMAT0015365 zma-miR827*;zma-miR827-5p; +MIMAT0015366 zma-miR1432*;zma-miR1432-3p; +MIMAT0015367 zma-miR390b*;zma-miR390b-3p; +MIMAT0015369 aae-miR-92a*;aae-miR-92a-5p; +MIMAT0015370 aae-miR-315*;aae-miR-315-3p; +MIMAT0015371 aae-miR-1175*;aae-miR-1175-3p; +MIMAT0015372 aae-miR-263a*;aae-miR-263a-3p; +MIMAT0015373 aae-miR-2944b*;aae-miR-2944b-3p; +MIMAT0015374 ghr-miR2949a*;ghr-miR2949a-3p; +MIMAT0015375 hsv2-miR-H7-3p; +MIMAT0015376 hsv2-miR-H9-5p; +MIMAT0015377 hsa-miR-3126-3p; +MIMAT0015378 hsa-miR-3065-3p; +MIMAT0015379 bmo-miR-3203*;bmo-miR-3203-5p; +MIMAT0015380 bmo-miR-3203;bmo-miR-3203-3p; +MIMAT0015381 bmo-miR-3204a;bmo-miR-3204a-5p; +MIMAT0015382 bmo-miR-3204a*;bmo-miR-3204a-3p; +MIMAT0015383 bmo-miR-3205; +MIMAT0015384 bmo-miR-3206; +MIMAT0015385 bmo-miR-3207; +MIMAT0015386 bmo-miR-2808d; +MIMAT0015387 bmo-miR-3208; +MIMAT0015388 bmo-miR-3209; +MIMAT0015389 bmo-miR-3210; +MIMAT0015390 bmo-miR-3211; +MIMAT0015391 bmo-miR-3212; +MIMAT0015392 bmo-miR-3213;bmo-miR-3213-5p; +MIMAT0015393 bmo-miR-3213*;bmo-miR-3213-3p; +MIMAT0015394 bmo-miR-3214; +MIMAT0015395 bmo-miR-3215; +MIMAT0015396 bmo-miR-3216; +MIMAT0015397 bmo-miR-3217; +MIMAT0015398 bmo-miR-3218; +MIMAT0015399 bmo-miR-3219; +MIMAT0015400 bmo-miR-3220; +MIMAT0015401 bmo-miR-3221; +MIMAT0015402 bmo-miR-3222; +MIMAT0015403 bmo-miR-3223;bmo-miR-3223-5p; +MIMAT0015404 bmo-miR-3223*;bmo-miR-3223-3p; +MIMAT0015405 bmo-miR-3224; +MIMAT0015406 bmo-miR-279e; +MIMAT0015407 bmo-miR-3225; +MIMAT0015408 bmo-miR-3226; +MIMAT0015409 bmo-miR-3227; +MIMAT0015410 bmo-miR-3228; +MIMAT0015411 bmo-miR-3229; +MIMAT0015412 bmo-miR-3230; +MIMAT0015413 bmo-miR-3231; +MIMAT0015414 bmo-miR-3232; +MIMAT0015415 bmo-miR-3233; +MIMAT0015416 bmo-miR-3234; +MIMAT0015417 bmo-miR-2808e; +MIMAT0015418 bmo-miR-3235; +MIMAT0015419 bmo-miR-3236; +MIMAT0015420 bmo-miR-3237; +MIMAT0015421 bmo-miR-3238; +MIMAT0015422 bmo-miR-3239; +MIMAT0015423 bmo-miR-3241; +MIMAT0015424 bmo-miR-3242; +MIMAT0015425 bmo-miR-3243; +MIMAT0015426 bmo-miR-3244; +MIMAT0015427 bmo-miR-3245; +MIMAT0015428 bmo-miR-3246; +MIMAT0015429 bmo-miR-3247; +MIMAT0015430 bmo-miR-3248; +MIMAT0015431 bmo-miR-3249; +MIMAT0015432 bmo-miR-3250; +MIMAT0015433 bmo-miR-2807d; +MIMAT0015434 bmo-miR-3251; +MIMAT0015435 bmo-miR-3252; +MIMAT0015436 bmo-miR-3253; +MIMAT0015437 bmo-miR-3254; +MIMAT0015438 bmo-miR-3255; +MIMAT0015439 bmo-miR-3256; +MIMAT0015440 bmo-miR-3257*;bmo-miR-3257-5p; +MIMAT0015441 bmo-miR-3257;bmo-miR-3257-3p; +MIMAT0015442 bmo-miR-3258; +MIMAT0015443 bmo-miR-3259; +MIMAT0015444 bmo-miR-3260; +MIMAT0015445 bmo-miR-3261; +MIMAT0015446 bmo-miR-3262; +MIMAT0015447 bmo-miR-3263; +MIMAT0015448 bmo-miR-3264; +MIMAT0015449 bmo-miR-3265; +MIMAT0015450 bmo-miR-3266; +MIMAT0015451 bmo-miR-3267a; +MIMAT0015452 bmo-miR-3268;bmo-miR-3268-5p; +MIMAT0015453 bmo-miR-3268*;bmo-miR-3268-3p; +MIMAT0015454 bmo-miR-3269; +MIMAT0015455 bmo-miR-3270; +MIMAT0015456 bmo-miR-3271; +MIMAT0015457 bmo-miR-3272; +MIMAT0015458 bmo-miR-3273; +MIMAT0015459 bmo-miR-3274; +MIMAT0015460 bmo-miR-3275; +MIMAT0015461 bmo-miR-3276; +MIMAT0015462 bmo-miR-3277; +MIMAT0015463 bmo-miR-3278; +MIMAT0015464 bmo-miR-3279; +MIMAT0015465 bmo-miR-3280; +MIMAT0015466 bmo-miR-3281; +MIMAT0015467 bmo-miR-3267b; +MIMAT0015468 bmo-miR-3282; +MIMAT0015469 bmo-miR-3283; +MIMAT0015470 bmo-miR-3284; +MIMAT0015471 bmo-miR-3285; +MIMAT0015472 bmo-miR-3286*;bmo-miR-3286-5p; +MIMAT0015473 bmo-miR-3286;bmo-miR-3286-3p; +MIMAT0015474 bmo-miR-3287; +MIMAT0015475 bmo-miR-3288; +MIMAT0015476 bmo-miR-3289; +MIMAT0015477 bmo-miR-3290; +MIMAT0015478 bmo-miR-3291; +MIMAT0015479 bmo-miR-3292; +MIMAT0015480 bmo-miR-3293; +MIMAT0015481 bmo-miR-3294; +MIMAT0015482 bmo-miR-3295; +MIMAT0015483 bmo-miR-3296*;bmo-miR-3296-5p; +MIMAT0015484 bmo-miR-3296;bmo-miR-3296-3p; +MIMAT0015485 bmo-miR-3297;bmo-miR-3297-5p; +MIMAT0015486 bmo-miR-3297*;bmo-miR-3297-3p; +MIMAT0015487 bmo-miR-3298; +MIMAT0015488 bmo-miR-3299; +MIMAT0015489 bmo-miR-3301; +MIMAT0015490 bmo-miR-3302; +MIMAT0015491 bmo-miR-3303; +MIMAT0015492 bmo-miR-3304a; +MIMAT0015493 bmo-miR-3305; +MIMAT0015494 bmo-miR-3306; +MIMAT0015495 bmo-miR-3307; +MIMAT0015496 bmo-miR-3308;bmo-miR-3308-5p; +MIMAT0015497 bmo-miR-3308*;bmo-miR-3308-3p; +MIMAT0015498 bmo-miR-3309; +MIMAT0015499 bmo-miR-3310; +MIMAT0015500 bmo-miR-3311; +MIMAT0015501 bmo-miR-3312; +MIMAT0015502 bmo-miR-3314; +MIMAT0015503 bmo-miR-3315; +MIMAT0015504 bmo-miR-3316; +MIMAT0015505 bmo-miR-3317; +MIMAT0015506 bmo-miR-3318; +MIMAT0015507 bmo-miR-3319; +MIMAT0015508 bmo-miR-3321; +MIMAT0015509 bmo-miR-3322; +MIMAT0015510 bmo-miR-3323; +MIMAT0015511 bmo-miR-3324; +MIMAT0015512 bmo-miR-3325; +MIMAT0015513 bmo-miR-3326; +MIMAT0015514 bmo-miR-3327;bmo-miR-3327-5p; +MIMAT0015515 bmo-miR-3327*;bmo-miR-3327-3p; +MIMAT0015516 bmo-miR-3328; +MIMAT0015517 bmo-miR-3329; +MIMAT0015518 bmo-miR-3330; +MIMAT0015519 bmo-miR-3332; +MIMAT0015520 bmo-miR-3333; +MIMAT0015521 bmo-miR-3334; +MIMAT0015522 bmo-miR-3335; +MIMAT0015523 bmo-miR-3336; +MIMAT0015524 bmo-miR-3337; +MIMAT0015525 bmo-miR-3338*;bmo-miR-3338-5p; +MIMAT0015526 bmo-miR-3338;bmo-miR-3338-3p; +MIMAT0015527 bmo-miR-3339; +MIMAT0015528 bmo-miR-3340; +MIMAT0015529 bmo-miR-3342; +MIMAT0015530 bmo-miR-3343; +MIMAT0015531 bmo-miR-3344; +MIMAT0015532 bmo-miR-3345; +MIMAT0015533 bmo-miR-3347a; +MIMAT0015534 bmo-miR-3348; +MIMAT0015535 bmo-miR-3350; +MIMAT0015536 bmo-miR-3351; +MIMAT0015537 bmo-miR-3352; +MIMAT0015538 bmo-miR-3353; +MIMAT0015539 bmo-miR-2733j; +MIMAT0015540 bmo-miR-3354; +MIMAT0015541 bmo-miR-3355; +MIMAT0015542 bmo-miR-3356; +MIMAT0015543 bmo-miR-3357; +MIMAT0015544 bmo-miR-3358; +MIMAT0015545 bmo-miR-3359; +MIMAT0015546 bmo-miR-3360; +MIMAT0015547 bmo-miR-3361; +MIMAT0015548 bmo-miR-3362; +MIMAT0015549 bmo-miR-3363; +MIMAT0015550 bmo-miR-3364; +MIMAT0015551 bmo-miR-3365; +MIMAT0015552 bmo-miR-3366; +MIMAT0015553 bmo-miR-3367; +MIMAT0015554 bmo-miR-3368; +MIMAT0015555 bmo-miR-3369; +MIMAT0015556 bmo-miR-3267c; +MIMAT0015557 bmo-miR-3370; +MIMAT0015558 bmo-miR-3371; +MIMAT0015559 bmo-miR-3372*;bmo-miR-3372-5p; +MIMAT0015560 bmo-miR-3372;bmo-miR-3372-3p; +MIMAT0015561 bmo-miR-3373;bmo-miR-3373-5p; +MIMAT0015562 bmo-miR-3373*;bmo-miR-3373-3p; +MIMAT0015563 bmo-miR-3374*;bmo-miR-3374-5p; +MIMAT0015564 bmo-miR-3374;bmo-miR-3374-3p; +MIMAT0015565 bmo-miR-3375*;bmo-miR-3375-5p; +MIMAT0015566 bmo-miR-3375;bmo-miR-3375-3p; +MIMAT0015567 bmo-miR-3377;bmo-miR-3377-5p; +MIMAT0015568 bmo-miR-3377*;bmo-miR-3377-3p; +MIMAT0015569 bmo-miR-3378;bmo-miR-3378-5p; +MIMAT0015570 bmo-miR-3378*;bmo-miR-3378-3p; +MIMAT0015571 bmo-miR-3379*; +MIMAT0015572 bmo-miR-3379; +MIMAT0015573 bmo-miR-3381;bmo-miR-3381-5p; +MIMAT0015574 bmo-miR-3381*;bmo-miR-3381-3p; +MIMAT0015575 bmo-miR-3382;bmo-miR-3382-5p; +MIMAT0015576 bmo-miR-3382*;bmo-miR-3382-3p; +MIMAT0015577 bmo-miR-3383*;bmo-miR-3383-5p; +MIMAT0015578 bmo-miR-3383;bmo-miR-3383-3p; +MIMAT0015579 bmo-miR-3384*;bmo-miR-3384-5p; +MIMAT0015580 bmo-miR-3384;bmo-miR-3384-3p; +MIMAT0015581 bmo-miR-3385*;bmo-miR-3385-5p; +MIMAT0015582 bmo-miR-3385;bmo-miR-3385-3p; +MIMAT0015583 bmo-miR-3386;bmo-miR-3386-5p; +MIMAT0015584 bmo-miR-3386*;bmo-miR-3386-3p; +MIMAT0015585 bmo-miR-3387*;bmo-miR-3387-5p; +MIMAT0015586 bmo-miR-3387;bmo-miR-3387-3p; +MIMAT0015587 bmo-miR-3388*;bmo-miR-3388-5p; +MIMAT0015588 bmo-miR-3388;bmo-miR-3388-3p; +MIMAT0015589 bmo-miR-3389;bmo-miR-3389-5p; +MIMAT0015590 bmo-miR-3389*;bmo-miR-3389-3p; +MIMAT0015591 bmo-miR-2733i*;bmo-miR-2733i-5p; +MIMAT0015592 bmo-miR-2733i;bmo-miR-2733i-3p; +MIMAT0015593 bmo-miR-2733a*;bmo-miR-2733a-3p; +MIMAT0015594 bmo-miR-3391*;bmo-miR-3391-5p; +MIMAT0015595 bmo-miR-3391;bmo-miR-3391-3p; +MIMAT0015596 bmo-miR-3392; +MIMAT0015597 bmo-miR-3393; +MIMAT0015598 bmo-miR-3394; +MIMAT0015599 bmo-miR-3395; +MIMAT0015600 bmo-miR-3396; +MIMAT0015601 bmo-miR-3397; +MIMAT0015602 bmo-miR-3398; +MIMAT0015603 bmo-miR-3399; +MIMAT0015604 bmo-miR-3400; +MIMAT0015605 bmo-miR-3401; +MIMAT0015606 bmo-miR-3402; +MIMAT0015607 bmo-miR-3403; +MIMAT0015608 bmo-miR-3347b; +MIMAT0015609 bmo-miR-3404; +MIMAT0015610 bmo-miR-3405; +MIMAT0015611 bmo-miR-3406;bmo-miR-3406-5p; +MIMAT0015612 bmo-miR-3406*;bmo-miR-3406-3p; +MIMAT0015613 bmo-miR-3407; +MIMAT0015614 bmo-miR-3408; +MIMAT0015615 bmo-miR-3409; +MIMAT0015616 bmo-miR-3410; +MIMAT0015617 bmo-miR-3411; +MIMAT0015618 bmo-miR-3412; +MIMAT0015619 bmo-miR-3413; +MIMAT0015620 bmo-miR-3414;bmo-miR-3414-5p; +MIMAT0015621 bmo-miR-3414*;bmo-miR-3414-3p; +MIMAT0015622 bmo-miR-3415; +MIMAT0015623 bmo-miR-3416; +MIMAT0015624 bmo-miR-3417; +MIMAT0015625 bmo-miR-3418; +MIMAT0015626 bmo-miR-3419; +MIMAT0015627 bmo-miR-989b; +MIMAT0015628 bmo-miR-3420; +MIMAT0015629 bmo-miR-3421; +MIMAT0015630 bmo-miR-3422; +MIMAT0015631 bmo-miR-3423; +MIMAT0015632 bmo-miR-3424; +MIMAT0015633 bmo-miR-3425; +MIMAT0015634 bmo-miR-3426; +MIMAT0015635 bmo-miR-3427; +MIMAT0015636 bmo-miR-3428; +MIMAT0015637 bmo-miR-3429; +MIMAT0015638 bmo-miR-3204b; +MIMAT0015639 bmo-miR-3430; +MIMAT0015640 mmu-miR-3470a; +MIMAT0015641 mmu-miR-3470b; +MIMAT0015642 mmu-miR-3471; +MIMAT0015643 mmu-miR-3472; +MIMAT0015644 mmu-miR-1186b; +MIMAT0015645 mmu-miR-3473;mmu-miR-3473a; +MIMAT0015646 mmu-miR-3474; +MIMAT0015647 aae-miR-9c; +MIMAT0015648 aae-miR-929; +MIMAT0015649 bhv1-miR-B10; +MIMAT0015650 hsv2-miR-H5; +MIMAT0015651 hsv2-miR-H6;hsv2-miR-H6-5p; +MIMAT0015652 hsv2-miR-H6*;hsv2-miR-H6-3p; +MIMAT0015653 ghr-miR3476;ghr-miR3476-5p; +MIMAT0015654 ghr-miR3476*;ghr-miR3476-3p; +MIMAT0015655 nvi-miR-14; +MIMAT0015656 nvi-miR-29b; +MIMAT0015657 nvi-miR-33; +MIMAT0015658 nvi-miR-281; +MIMAT0015659 nvi-miR-7; +MIMAT0015660 nvi-miR-137; +MIMAT0015661 nvi-miR-31a; +MIMAT0015662 nvi-miR-71; +MIMAT0015663 nvi-miR-2c; +MIMAT0015664 nvi-miR-13a; +MIMAT0015665 nvi-miR-13b; +MIMAT0015666 nvi-miR-2a; +MIMAT0015667 nvi-miR-2b; +MIMAT0015668 nvi-miR-92a; +MIMAT0015669 nvi-miR-283; +MIMAT0015670 nvi-miR-12; +MIMAT0015671 nvi-miR-184; +MIMAT0015672 nvi-miR-929; +MIMAT0015673 nvi-miR-190; +MIMAT0015674 nvi-miR-iab-4as;nvi-miR-iab-8; +MIMAT0015675 nvi-miR-iab-4; +MIMAT0015676 nvi-miR-10; +MIMAT0015677 nvi-miR-100; +MIMAT0015678 nvi-let-7; +MIMAT0015679 nvi-miR-125; +MIMAT0015680 nvi-miR-2796; +MIMAT0015681 nvi-miR-279; +MIMAT0015682 nvi-miR-34; +MIMAT0015683 nvi-miR-277; +MIMAT0015684 nvi-miR-317; +MIMAT0015685 nvi-miR-275; +MIMAT0015686 nvi-miR-305; +MIMAT0015687 nvi-miR-276; +MIMAT0015688 nvi-miR-124; +MIMAT0015689 nvi-miR-315; +MIMAT0015690 nvi-miR-219; +MIMAT0015691 nvi-miR-133; +MIMAT0015692 nvi-miR-1; +MIMAT0015693 nvi-miR-282; +MIMAT0015694 nvi-miR-307; +MIMAT0015695 nvi-miR-210; +MIMAT0015696 nvi-bantam; +MIMAT0015697 nvi-miR-9a; +MIMAT0015698 nvi-miR-8; +MIMAT0015699 nvi-miR-375; +MIMAT0015700 nvi-miR-927; +MIMAT0015701 nvi-miR-252; +MIMAT0015702 nvi-miR-932; +MIMAT0015703 nvi-miR-263b; +MIMAT0015704 nvi-miR-993; +MIMAT0015705 nvi-miR-928; +MIMAT0015706 nvi-miR-3477; +MIMAT0015707 nvi-miR-3478; +MIMAT0015708 ssc-miR-744; +MIMAT0015709 ssc-miR-22-5p; +MIMAT0015710 ssc-miR-22-3p; +MIMAT0015711 ssc-miR-363; +MIMAT0015712 ssc-miR-299; +MIMAT0015713 ssc-miR-338; +MIMAT0015714 ssc-miR-369; +MIMAT0015715 ssc-miR-376a*;ssc-miR-376a-5p; +MIMAT0015716 ssc-miR-376a;ssc-miR-376a-3p; +MIMAT0015717 ssc-miR-450c;ssc-miR-450c-5p; +MIMAT0015718 ssc-miR-450c*;ssc-miR-450c-3p; +MIMAT0015719 ssc-miR-758; +MIMAT0015720 ppy-miR-1; +MIMAT0015721 ppy-let-7a; +MIMAT0015722 ppy-let-7b; +MIMAT0015723 ppy-let-7c; +MIMAT0015724 ppy-let-7d; +MIMAT0015725 ppy-let-7e; +MIMAT0015726 ppy-let-7f; +MIMAT0015727 ppy-let-7g; +MIMAT0015728 ppy-let-7i; +MIMAT0015729 ppy-miR-9; +MIMAT0015730 ppy-miR-10b; +MIMAT0015731 ppy-miR-18b; +MIMAT0015732 ppy-miR-20b; +MIMAT0015733 ppy-miR-26b; +MIMAT0015734 ppy-miR-27b; +MIMAT0015735 ppy-miR-29c; +MIMAT0015736 ppy-miR-30b; +MIMAT0015737 ppy-miR-30c; +MIMAT0015738 ppy-miR-30d; +MIMAT0015739 ppy-miR-30e; +MIMAT0015740 ppy-miR-33b; +MIMAT0015741 ppy-miR-34b; +MIMAT0015742 ppy-miR-34c-5p; +MIMAT0015743 ppy-miR-34c-3p; +MIMAT0015744 ppy-miR-92b; +MIMAT0015745 ppy-miR-96; +MIMAT0015746 ppy-miR-122; +MIMAT0015747 ppy-miR-124; +MIMAT0015748 ppy-miR-125a-5p; +MIMAT0015749 ppy-miR-125a-3p; +MIMAT0015750 ppy-miR-126; +MIMAT0015751 ppy-miR-129;ppy-miR-129-5p; +MIMAT0015752 ppy-miR-129-1*;ppy-miR-129-1-3p; +MIMAT0015753 ppy-miR-130a; +MIMAT0015754 ppy-miR-130b; +MIMAT0015755 ppy-miR-132; +MIMAT0015756 ppy-miR-133b; +MIMAT0015757 ppy-miR-135a; +MIMAT0015758 ppy-miR-135b; +MIMAT0015759 ppy-miR-137; +MIMAT0015760 ppy-miR-138; +MIMAT0015761 ppy-miR-139-5p; +MIMAT0015762 ppy-miR-139-3p; +MIMAT0015763 ppy-miR-140-5p; +MIMAT0015764 ppy-miR-140-3p; +MIMAT0015765 ppy-miR-142-5p; +MIMAT0015766 ppy-miR-142-3p; +MIMAT0015767 ppy-miR-146a; +MIMAT0015768 ppy-miR-146b-5p; +MIMAT0015769 ppy-miR-146b-3p; +MIMAT0015770 ppy-miR-147b; +MIMAT0015771 ppy-miR-148a; +MIMAT0015772 ppy-miR-148b; +MIMAT0015773 ppy-miR-149; +MIMAT0015774 ppy-miR-150; +MIMAT0015775 ppy-miR-151-5p;ppy-miR-151a-5p; +MIMAT0015776 ppy-miR-151-3p;ppy-miR-151a-3p; +MIMAT0015777 ppy-miR-155; +MIMAT0015778 ppy-miR-181c; +MIMAT0015779 ppy-miR-181d; +MIMAT0015780 ppy-miR-183; +MIMAT0015781 ppy-miR-185; +MIMAT0015782 ppy-miR-186; +MIMAT0015783 ppy-miR-190;ppy-miR-190a; +MIMAT0015784 ppy-miR-190b; +MIMAT0015785 ppy-miR-191; +MIMAT0015786 ppy-miR-192; +MIMAT0015787 ppy-miR-193a-5p; +MIMAT0015788 ppy-miR-193a-3p; +MIMAT0015789 ppy-miR-193b; +MIMAT0015790 ppy-miR-195; +MIMAT0015791 ppy-miR-196b; +MIMAT0015792 ppy-miR-199a-5p; +MIMAT0015793 ppy-miR-199a-3p; +MIMAT0015794 ppy-miR-199b-5p; +MIMAT0015795 ppy-miR-199b-3p; +MIMAT0015796 ppy-miR-200a; +MIMAT0015797 ppy-miR-203; +MIMAT0015798 ppy-miR-205; +MIMAT0015799 ppy-miR-208a; +MIMAT0015800 ppy-miR-208b; +MIMAT0015801 ppy-miR-210; +MIMAT0015802 ppy-miR-216b; +MIMAT0015803 ppy-miR-217; +MIMAT0015804 ppy-miR-219-5p; +MIMAT0015805 ppy-miR-220a; +MIMAT0015806 ppy-miR-220b; +MIMAT0015807 ppy-miR-220c; +MIMAT0015808 ppy-miR-222; +MIMAT0015809 ppy-miR-296-5p; +MIMAT0015810 ppy-miR-296-3p; +MIMAT0015811 ppy-miR-297; +MIMAT0015812 ppy-miR-298; +MIMAT0015813 ppy-miR-299-5p; +MIMAT0015814 ppy-miR-299-3p; +MIMAT0015815 ppy-miR-300; +MIMAT0015816 ppy-miR-301b; +MIMAT0015817 ppy-miR-302b; +MIMAT0015818 ppy-miR-302c; +MIMAT0015819 ppy-miR-302d; +MIMAT0015820 ppy-miR-302e; +MIMAT0015821 ppy-miR-320a; +MIMAT0015822 ppy-miR-320b; +MIMAT0015823 ppy-miR-320c; +MIMAT0015824 ppy-miR-320d; +MIMAT0015825 ppy-miR-323-5p; +MIMAT0015826 ppy-miR-323-3p; +MIMAT0015827 ppy-miR-324-5p; +MIMAT0015828 ppy-miR-324-3p; +MIMAT0015829 ppy-miR-325; +MIMAT0015830 ppy-miR-326; +MIMAT0015831 ppy-miR-328; +MIMAT0015832 ppy-miR-329; +MIMAT0015833 ppy-miR-330-5p; +MIMAT0015834 ppy-miR-330-3p; +MIMAT0015835 ppy-miR-331-5p; +MIMAT0015836 ppy-miR-331-3p; +MIMAT0015837 ppy-miR-335; +MIMAT0015838 ppy-miR-337-5p; +MIMAT0015839 ppy-miR-337-3p; +MIMAT0015840 ppy-miR-338-5p; +MIMAT0015841 ppy-miR-338-3p; +MIMAT0015842 ppy-miR-339-5p; +MIMAT0015843 ppy-miR-340; +MIMAT0015844 ppy-miR-342-5p; +MIMAT0015845 ppy-miR-342-3p; +MIMAT0015846 ppy-miR-345; +MIMAT0015847 ppy-miR-346; +MIMAT0015848 ppy-miR-361-5p; +MIMAT0015849 ppy-miR-361-3p; +MIMAT0015850 ppy-miR-362-5p; +MIMAT0015851 ppy-miR-362-3p; +MIMAT0015852 ppy-miR-363; +MIMAT0015853 ppy-miR-365; +MIMAT0015854 ppy-miR-367; +MIMAT0015855 ppy-miR-369-5p; +MIMAT0015856 ppy-miR-369-3p; +MIMAT0015857 ppy-miR-370; +MIMAT0015858 ppy-miR-371-5p; +MIMAT0015859 ppy-miR-371-3p; +MIMAT0015860 ppy-miR-372; +MIMAT0015861 ppy-miR-373; +MIMAT0015862 ppy-miR-374a; +MIMAT0015863 ppy-miR-375; +MIMAT0015864 ppy-miR-376a; +MIMAT0015865 ppy-miR-376b; +MIMAT0015866 ppy-miR-376c; +MIMAT0015867 ppy-miR-377; +MIMAT0015868 ppy-miR-378;ppy-miR-378a; +MIMAT0015869 ppy-miR-379; +MIMAT0015870 ppy-miR-380; +MIMAT0015871 ppy-miR-381; +MIMAT0015872 ppy-miR-382; +MIMAT0015873 ppy-miR-383; +MIMAT0015874 ppy-miR-384; +MIMAT0015875 ppy-miR-409-5p; +MIMAT0015876 ppy-miR-409-3p; +MIMAT0015877 ppy-miR-410; +MIMAT0015878 ppy-miR-411; +MIMAT0015879 ppy-miR-412; +MIMAT0015880 ppy-miR-421; +MIMAT0015881 ppy-miR-422a; +MIMAT0015882 ppy-miR-423-5p; +MIMAT0015883 ppy-miR-423-3p; +MIMAT0015884 ppy-miR-424; +MIMAT0015885 ppy-miR-425; +MIMAT0015886 ppy-miR-429; +MIMAT0015887 ppy-miR-431; +MIMAT0015888 ppy-miR-432; +MIMAT0015889 ppy-miR-433; +MIMAT0015890 ppy-miR-448; +MIMAT0015891 ppy-miR-449a; +MIMAT0015892 ppy-miR-449b; +MIMAT0015893 ppy-miR-450a; +MIMAT0015894 ppy-miR-450b-5p; +MIMAT0015895 ppy-miR-450b-3p; +MIMAT0015896 ppy-miR-451; +MIMAT0015897 ppy-miR-452; +MIMAT0015898 ppy-miR-453; +MIMAT0015899 ppy-miR-455-5p; +MIMAT0015900 ppy-miR-455-3p; +MIMAT0015901 ppy-miR-484; +MIMAT0015902 ppy-miR-485-5p; +MIMAT0015903 ppy-miR-485-3p; +MIMAT0015904 ppy-miR-486-5p; +MIMAT0015905 ppy-miR-487a; +MIMAT0015906 ppy-miR-487b; +MIMAT0015907 ppy-miR-488; +MIMAT0015908 ppy-miR-489; +MIMAT0015909 ppy-miR-490-5p; +MIMAT0015910 ppy-miR-490-3p; +MIMAT0015911 ppy-miR-491-5p; +MIMAT0015912 ppy-miR-491-3p; +MIMAT0015913 ppy-miR-492; +MIMAT0015914 ppy-miR-493; +MIMAT0015915 ppy-miR-494; +MIMAT0015916 ppy-miR-495; +MIMAT0015917 ppy-miR-496; +MIMAT0015918 ppy-miR-497; +MIMAT0015919 ppy-miR-498; +MIMAT0015920 ppy-miR-499-5p; +MIMAT0015921 ppy-miR-499-3p; +MIMAT0015922 ppy-miR-500; +MIMAT0015923 ppy-miR-501-3p; +MIMAT0015924 ppy-miR-502-5p; +MIMAT0015925 ppy-miR-502-3p; +MIMAT0015926 ppy-miR-503; +MIMAT0015927 ppy-miR-504; +MIMAT0015928 ppy-miR-505; +MIMAT0015929 ppy-miR-506; +MIMAT0015930 ppy-miR-507; +MIMAT0015931 ppy-miR-508-5p; +MIMAT0015932 ppy-miR-508-3p; +MIMAT0015933 ppy-miR-509-5p; +MIMAT0015934 ppy-miR-509-3p; +MIMAT0015935 ppy-miR-510; +MIMAT0015936 ppy-miR-511; +MIMAT0015937 ppy-miR-512-3p; +MIMAT0015938 ppy-miR-513a-5p; +MIMAT0015939 ppy-miR-513a-1-3p; +MIMAT0015940 ppy-miR-513b; +MIMAT0015941 ppy-miR-513c; +MIMAT0015942 ppy-miR-514; +MIMAT0015943 ppy-miR-515-5p; +MIMAT0015944 ppy-miR-515-3p; +MIMAT0015945 ppy-miR-516a-5p; +MIMAT0015946 ppy-miR-516a-3p; +MIMAT0015947 ppy-miR-516b; +MIMAT0015948 ppy-miR-517a; +MIMAT0015949 ppy-miR-517b; +MIMAT0015950 ppy-miR-517c; +MIMAT0015951 ppy-miR-518a-5p; +MIMAT0015952 ppy-miR-518a-3p; +MIMAT0015953 ppy-miR-518b; +MIMAT0015954 ppy-miR-518c; +MIMAT0015955 ppy-miR-518d-5p; +MIMAT0015956 ppy-miR-518d-3p; +MIMAT0015957 ppy-miR-518e;ppy-miR-518f; +MIMAT0015958 ppy-miR-518f; +MIMAT0015959 ppy-miR-519a;ppy-miR-519b; +MIMAT0015960 ppy-miR-519f;ppy-miR-519a; +MIMAT0015961 ppy-miR-519b-5p; +MIMAT0015962 ppy-miR-519b-3p; +MIMAT0015963 ppy-miR-519c-5p; +MIMAT0015964 ppy-miR-519d; +MIMAT0015965 ppy-miR-519e; +MIMAT0015966 ppy-miR-520a-5p; +MIMAT0015967 ppy-miR-520a-3p; +MIMAT0015968 ppy-miR-520b; +MIMAT0015969 ppy-miR-520c-5p; +MIMAT0015970 ppy-miR-520c-3p; +MIMAT0015971 ppy-miR-520d-5p; +MIMAT0015972 ppy-miR-520d-3p; +MIMAT0015973 ppy-miR-520e; +MIMAT0015974 ppy-miR-520f; +MIMAT0015975 ppy-miR-520g; +MIMAT0015976 ppy-miR-520h; +MIMAT0015977 ppy-miR-521; +MIMAT0015978 ppy-miR-522; +MIMAT0015979 ppy-miR-523; +MIMAT0015980 ppy-miR-524-5p; +MIMAT0015981 ppy-miR-524-3p; +MIMAT0015982 ppy-miR-525-5p; +MIMAT0015983 ppy-miR-525-3p; +MIMAT0015984 ppy-miR-526a; +MIMAT0015985 ppy-miR-526b; +MIMAT0015986 ppy-miR-527; +MIMAT0015987 ppy-miR-532-5p; +MIMAT0015988 ppy-miR-532-3p; +MIMAT0015989 ppy-miR-539; +MIMAT0015990 ppy-miR-541; +MIMAT0015991 ppy-miR-542-5p; +MIMAT0015992 ppy-miR-542-3p; +MIMAT0015993 ppy-miR-543; +MIMAT0015994 ppy-miR-544; +MIMAT0015995 ppy-miR-545; +MIMAT0015996 ppy-miR-549; +MIMAT0015997 ppy-miR-551a; +MIMAT0015998 ppy-miR-551b; +MIMAT0015999 ppy-miR-553; +MIMAT0016000 ppy-miR-554; +MIMAT0016001 ppy-miR-555; +MIMAT0016002 ppy-miR-556-5p; +MIMAT0016003 ppy-miR-556-3p; +MIMAT0016004 ppy-miR-557; +MIMAT0016005 ppy-miR-558; +MIMAT0016006 ppy-miR-559; +MIMAT0016007 ppy-miR-562; +MIMAT0016008 ppy-miR-563; +MIMAT0016009 ppy-miR-564; +MIMAT0016010 ppy-miR-566; +MIMAT0016011 ppy-miR-567; +MIMAT0016012 ppy-miR-568; +MIMAT0016013 ppy-miR-569; +MIMAT0016014 ppy-miR-571; +MIMAT0016015 ppy-miR-573; +MIMAT0016016 ppy-miR-575; +MIMAT0016017 ppy-miR-576-5p; +MIMAT0016018 ppy-miR-576-3p; +MIMAT0016019 ppy-miR-577; +MIMAT0016020 ppy-miR-578; +MIMAT0016021 ppy-miR-579; +MIMAT0016022 ppy-miR-580; +MIMAT0016023 ppy-miR-581; +MIMAT0016024 ppy-miR-582-5p; +MIMAT0016025 ppy-miR-582-3p; +MIMAT0016026 ppy-miR-583; +MIMAT0016027 ppy-miR-584; +MIMAT0016028 ppy-miR-586; +MIMAT0016029 ppy-miR-587; +MIMAT0016030 ppy-miR-588; +MIMAT0016031 ppy-miR-589; +MIMAT0016032 ppy-miR-590-5p; +MIMAT0016033 ppy-miR-590-3p; +MIMAT0016034 ppy-miR-591; +MIMAT0016035 ppy-miR-592; +MIMAT0016036 ppy-miR-593; +MIMAT0016037 ppy-miR-595; +MIMAT0016038 ppy-miR-596; +MIMAT0016039 ppy-miR-597; +MIMAT0016040 ppy-miR-598; +MIMAT0016041 ppy-miR-599; +MIMAT0016042 ppy-miR-600; +MIMAT0016043 ppy-miR-601; +MIMAT0016044 ppy-miR-602; +MIMAT0016045 ppy-miR-603; +MIMAT0016046 ppy-miR-604; +MIMAT0016047 ppy-miR-605; +MIMAT0016048 ppy-miR-606; +MIMAT0016049 ppy-miR-608; +MIMAT0016050 ppy-miR-609; +MIMAT0016051 ppy-miR-610; +MIMAT0016052 ppy-miR-611; +MIMAT0016053 ppy-miR-612; +MIMAT0016054 ppy-miR-613; +MIMAT0016055 ppy-miR-614; +MIMAT0016056 ppy-miR-615-5p; +MIMAT0016057 ppy-miR-615-3p; +MIMAT0016058 ppy-miR-616; +MIMAT0016059 ppy-miR-617; +MIMAT0016060 ppy-miR-618; +MIMAT0016061 ppy-miR-619; +MIMAT0016062 ppy-miR-621; +MIMAT0016063 ppy-miR-622; +MIMAT0016064 ppy-miR-623; +MIMAT0016065 ppy-miR-624; +MIMAT0016066 ppy-miR-626; +MIMAT0016067 ppy-miR-628-5p; +MIMAT0016068 ppy-miR-628-3p; +MIMAT0016069 ppy-miR-630; +MIMAT0016070 ppy-miR-631; +MIMAT0016071 ppy-miR-632; +MIMAT0016072 ppy-miR-633; +MIMAT0016073 ppy-miR-634; +MIMAT0016074 ppy-miR-636; +MIMAT0016075 ppy-miR-637; +MIMAT0016076 ppy-miR-638; +MIMAT0016077 ppy-miR-639; +MIMAT0016078 ppy-miR-640; +MIMAT0016079 ppy-miR-645; +MIMAT0016080 ppy-miR-646; +MIMAT0016081 ppy-miR-647; +MIMAT0016082 ppy-miR-648; +MIMAT0016083 ppy-miR-650; +MIMAT0016084 ppy-miR-651; +MIMAT0016085 ppy-miR-652; +MIMAT0016086 ppy-miR-653; +MIMAT0016087 ppy-miR-654-5p; +MIMAT0016088 ppy-miR-654-3p; +MIMAT0016089 ppy-miR-655; +MIMAT0016090 ppy-miR-656; +MIMAT0016091 ppy-miR-658; +MIMAT0016092 ppy-miR-660; +MIMAT0016093 ppy-miR-663b; +MIMAT0016094 ppy-miR-664; +MIMAT0016095 ppy-miR-668; +MIMAT0016096 ppy-miR-671-5p; +MIMAT0016097 ppy-miR-671-3p; +MIMAT0016098 ppy-miR-675a; +MIMAT0016099 ppy-miR-675b; +MIMAT0016100 ppy-miR-708; +MIMAT0016101 ppy-miR-720; +MIMAT0016102 ppy-miR-744; +MIMAT0016103 ppy-miR-758; +MIMAT0016104 ppy-miR-760; +MIMAT0016105 ppy-miR-765; +MIMAT0016106 ppy-miR-766; +MIMAT0016107 ppy-miR-767-5p; +MIMAT0016108 ppy-miR-767-3p; +MIMAT0016109 ppy-miR-770-5p; +MIMAT0016110 ppy-miR-802; +MIMAT0016111 ppy-miR-873; +MIMAT0016112 ppy-miR-874; +MIMAT0016113 ppy-miR-875-5p; +MIMAT0016114 ppy-miR-875-3p; +MIMAT0016115 ppy-miR-876-5p; +MIMAT0016116 ppy-miR-876-3p; +MIMAT0016117 ppy-miR-877; +MIMAT0016118 ppy-miR-885-5p; +MIMAT0016119 ppy-miR-885-3p; +MIMAT0016120 ppy-miR-886-5p; +MIMAT0016121 ppy-miR-886-3p; +MIMAT0016122 ppy-miR-887; +MIMAT0016123 ppy-miR-888; +MIMAT0016124 ppy-miR-889; +MIMAT0016125 ppy-miR-890; +MIMAT0016126 ppy-miR-891a; +MIMAT0016127 ppy-miR-891b; +MIMAT0016128 ppy-miR-892a; +MIMAT0016129 ppy-miR-892b; +MIMAT0016130 ppy-miR-920; +MIMAT0016131 ppy-miR-921; +MIMAT0016132 ppy-miR-922; +MIMAT0016133 ppy-miR-924; +MIMAT0016134 ppy-miR-933; +MIMAT0016135 ppy-miR-934; +MIMAT0016136 ppy-miR-936; +MIMAT0016137 ppy-miR-937; +MIMAT0016138 ppy-miR-938; +MIMAT0016139 ppy-miR-939; +MIMAT0016140 ppy-miR-942; +MIMAT0016141 ppy-miR-943; +MIMAT0016142 ppy-miR-944; +MIMAT0016143 ppy-miR-1178; +MIMAT0016144 ppy-miR-1179; +MIMAT0016145 ppy-miR-1180; +MIMAT0016146 ppy-miR-1181; +MIMAT0016147 ppy-miR-1183; +MIMAT0016148 ppy-miR-1185; +MIMAT0016149 ppy-miR-1197; +MIMAT0016150 ppy-miR-1200; +MIMAT0016151 ppy-miR-1201; +MIMAT0016152 ppy-miR-1202; +MIMAT0016153 ppy-miR-1204; +MIMAT0016154 ppy-miR-1205; +MIMAT0016155 ppy-miR-1207-5p; +MIMAT0016156 ppy-miR-1207-3p; +MIMAT0016157 ppy-miR-1208; +MIMAT0016158 ppy-miR-1224-5p; +MIMAT0016159 ppy-miR-1224-3p; +MIMAT0016160 ppy-miR-1225-5p; +MIMAT0016161 ppy-miR-1225-3p; +MIMAT0016162 ppy-miR-1226; +MIMAT0016163 ppy-miR-1227; +MIMAT0016164 ppy-miR-1228; +MIMAT0016165 ppy-miR-1233; +MIMAT0016166 ppy-miR-1236; +MIMAT0016167 ppy-miR-1237; +MIMAT0016168 ppy-miR-1238; +MIMAT0016169 ppy-miR-1244; +MIMAT0016170 ppy-miR-1245; +MIMAT0016171 ppy-miR-1246; +MIMAT0016172 ppy-miR-1247; +MIMAT0016173 ppy-miR-1248; +MIMAT0016174 ppy-miR-1249; +MIMAT0016175 ppy-miR-1250; +MIMAT0016176 ppy-miR-1251; +MIMAT0016177 ppy-miR-1252; +MIMAT0016178 ppy-miR-1253; +MIMAT0016179 ppy-miR-1254; +MIMAT0016180 ppy-miR-1255a; +MIMAT0016181 ppy-miR-1255b; +MIMAT0016182 ppy-miR-1256; +MIMAT0016183 ppy-miR-1257; +MIMAT0016184 ppy-miR-1260;ppy-miR-1260a; +MIMAT0016185 ppy-miR-1261; +MIMAT0016186 ppy-miR-1262; +MIMAT0016187 ppy-miR-1263; +MIMAT0016188 ppy-miR-1264; +MIMAT0016189 ppy-miR-1265; +MIMAT0016190 ppy-miR-1266; +MIMAT0016191 ppy-miR-1267; +MIMAT0016192 ppy-miR-1268; +MIMAT0016193 ppy-miR-1269; +MIMAT0016194 ppy-miR-1270; +MIMAT0016195 ppy-miR-1271; +MIMAT0016196 ppy-miR-1273;ppy-miR-1273a; +MIMAT0016197 ppy-miR-1274a; +MIMAT0016198 ppy-miR-1274b; +MIMAT0016199 ppy-miR-1275; +MIMAT0016200 ppy-miR-1277; +MIMAT0016201 ppy-miR-1280; +MIMAT0016202 ppy-miR-1281; +MIMAT0016203 ppy-miR-1282; +MIMAT0016204 ppy-miR-1283a; +MIMAT0016205 ppy-miR-1283b; +MIMAT0016206 ppy-miR-1284; +MIMAT0016207 ppy-miR-1285a; +MIMAT0016208 ppy-miR-1285b; +MIMAT0016209 ppy-miR-1286; +MIMAT0016210 ppy-miR-1287; +MIMAT0016211 ppy-miR-1289; +MIMAT0016212 ppy-miR-1290; +MIMAT0016213 ppy-miR-1291; +MIMAT0016214 ppy-miR-1292; +MIMAT0016215 ppy-miR-1293; +MIMAT0016216 ppy-miR-1295; +MIMAT0016217 ppy-miR-1296; +MIMAT0016218 ppy-miR-1297; +MIMAT0016219 ppy-miR-1298; +MIMAT0016220 ppy-miR-1299; +MIMAT0016221 ppy-miR-1301; +MIMAT0016222 ppy-miR-1302; +MIMAT0016223 ppy-miR-1303; +MIMAT0016224 ppy-miR-1304; +MIMAT0016225 ppy-miR-1305; +MIMAT0016226 ppy-miR-1306; +MIMAT0016227 ppy-miR-1307; +MIMAT0016228 ppy-miR-1322; +MIMAT0016229 ppy-miR-1323; +MIMAT0016230 ppy-miR-1324; +MIMAT0016231 ppy-miR-1468; +MIMAT0016232 ppy-miR-1469; +MIMAT0016233 ppy-miR-1471; +MIMAT0016234 ppy-miR-1537; +MIMAT0016235 ppy-miR-1538; +MIMAT0016236 ppy-miR-1827; +MIMAT0016237 ppy-miR-1908; +MIMAT0016238 ppy-miR-1909; +MIMAT0016239 ppy-miR-1910; +MIMAT0016240 ppy-miR-1912; +MIMAT0016241 ppy-miR-1913; +MIMAT0016242 ppy-miR-1914; +MIMAT0016243 ppy-miR-1915; +MIMAT0016244 sja-miR-1; +MIMAT0016245 sja-miR-2a-5p; +MIMAT0016246 sja-miR-2a-3p; +MIMAT0016247 sja-miR-2b-5p; +MIMAT0016248 sja-miR-2b-3p; +MIMAT0016249 sja-miR-7-5p; +MIMAT0016250 sja-miR-7-3p; +MIMAT0016251 sja-miR-8-5p; +MIMAT0016252 sja-miR-8-3p; +MIMAT0016253 sja-miR-10-5p; +MIMAT0016254 sja-miR-10-3p; +MIMAT0016255 sja-miR-31-5p; +MIMAT0016256 sja-miR-31-3p; +MIMAT0016257 sja-miR-36-5p; +MIMAT0016258 sja-miR-36-3p; +MIMAT0016259 sja-miR-61; +MIMAT0016260 sja-miR-71b-5p; +MIMAT0016261 sja-miR-71b-3p; +MIMAT0016262 sja-miR-124-5p; +MIMAT0016263 sja-miR-124-3p; +MIMAT0016264 sja-miR-133; +MIMAT0016265 sja-miR-190-5p; +MIMAT0016266 sja-miR-190-3p; +MIMAT0016267 sja-miR-219-5p; +MIMAT0016268 sja-miR-219-3p; +MIMAT0016269 sja-miR-277; +MIMAT0016270 sja-miR-307; +MIMAT0016271 sja-miR-310; +MIMAT0016272 sja-miR-2162-5p; +MIMAT0016273 sja-miR-2162-3p; +MIMAT0016274 sja-miR-3479-5p; +MIMAT0016275 sja-miR-3479-3p; +MIMAT0016276 sja-miR-2c-5p; +MIMAT0016277 sja-miR-2c-3p; +MIMAT0016278 sja-miR-2d-5p; +MIMAT0016279 sja-miR-2d-3p; +MIMAT0016280 sja-miR-3480-5p; +MIMAT0016281 sja-miR-3480-3p; +MIMAT0016282 sja-miR-3481-5p; +MIMAT0016283 sja-miR-3481-3p; +MIMAT0016284 sja-miR-3482-5p; +MIMAT0016285 sja-miR-3482-3p; +MIMAT0016286 sja-miR-3483-5p; +MIMAT0016287 sja-miR-3483-3p; +MIMAT0016288 sja-miR-3484-5p; +MIMAT0016289 sja-miR-3484-3p; +MIMAT0016290 sja-miR-3485-5p; +MIMAT0016291 sja-miR-3485-3p; +MIMAT0016292 sja-miR-3486-5p; +MIMAT0016293 sja-miR-3486-3p; +MIMAT0016294 sja-miR-2e-5p; +MIMAT0016295 sja-miR-2e-3p; +MIMAT0016296 sja-miR-3487; +MIMAT0016297 sja-miR-3488; +MIMAT0016298 sja-miR-3489; +MIMAT0016299 sja-miR-3490; +MIMAT0016300 sja-miR-3491; +MIMAT0016301 sja-miR-3492; +MIMAT0016302 sja-miR-3493; +MIMAT0016303 sja-miR-3494; +MIMAT0016304 sja-miR-3495; +MIMAT0016305 sja-miR-3496; +MIMAT0016306 sja-miR-3497; +MIMAT0016307 sja-miR-3498; +MIMAT0016308 sja-miR-3499; +MIMAT0016309 sja-miR-3500; +MIMAT0016310 sja-miR-3501; +MIMAT0016311 sja-miR-3502; +MIMAT0016312 sja-miR-3503; +MIMAT0016313 sja-miR-3504; +MIMAT0016314 sja-miR-3505; +MIMAT0016315 sja-miR-3506; +MIMAT0016316 sja-miR-3507; +MIMAT0016317 ahy-miR156a; +MIMAT0016318 ahy-miR156b-5p; +MIMAT0016319 ahy-miR156b-3p; +MIMAT0016320 ahy-miR156c; +MIMAT0016321 ahy-miR159; +MIMAT0016322 ahy-miR160-5p; +MIMAT0016323 ahy-miR160-3p; +MIMAT0016324 ahy-miR167-5p; +MIMAT0016325 ahy-miR167-3p; +MIMAT0016326 ahy-miR394; +MIMAT0016327 ahy-miR398; +MIMAT0016328 ahy-miR408-5p; +MIMAT0016329 ahy-miR408-3p; +MIMAT0016330 ahy-miR3508; +MIMAT0016331 ahy-miR3509-5p; +MIMAT0016332 ahy-miR3509-3p; +MIMAT0016333 ahy-miR3510; +MIMAT0016334 ahy-miR3511-5p; +MIMAT0016335 ahy-miR3511-3p; +MIMAT0016336 ahy-miR3512; +MIMAT0016337 ahy-miR3513-5p; +MIMAT0016338 ahy-miR3513-3p; +MIMAT0016339 ahy-miR3514-5p; +MIMAT0016340 ahy-miR3514-3p; +MIMAT0016341 ahy-miR3515; +MIMAT0016342 ahy-miR3516; +MIMAT0016343 ahy-miR3517; +MIMAT0016344 ahy-miR3518; +MIMAT0016345 ahy-miR3519; +MIMAT0016346 ahy-miR3520-5p; +MIMAT0016347 ahy-miR3520-3p; +MIMAT0016348 ahy-miR3521; +MIMAT0016351 gso-miR167a; +MIMAT0016352 gso-miR1508a; +MIMAT0016353 gso-miR482a; +MIMAT0016354 gso-miR482b; +MIMAT0016355 gso-miR1510b; +MIMAT0016356 gso-miR1510a; +MIMAT0016357 gso-miR1507a; +MIMAT0016358 gso-miR1507b; +MIMAT0016359 gso-miR3522a; +MIMAT0016360 gso-miR3522b; +MIMAT0016361 gso-miR2218; +MIMAT0016362 gso-miR1509a; +MIMAT0016363 gso-miR2109; +MIMAT0016364 vvi-miR2111;vvi-miR2111-5p; +MIMAT0016365 vvi-miR2111*;vvi-miR2111-3p; +MIMAT0016366 lja-miR2111;lja-miR2111-5p; +MIMAT0016367 lja-miR2111*;lja-miR2111-3p; +MIMAT0016368 bra-miR2111a;bra-miR2111a-5p; +MIMAT0016369 bra-miR2111a*;bra-miR2111a-3p; +MIMAT0016370 bra-miR2111b;bra-miR2111b-5p; +MIMAT0016371 bra-miR2111b*;bra-miR2111b-3p; +MIMAT0016372 gga-miR-2188;gga-miR-2188-5p; +MIMAT0016373 gga-miR-3523; +MIMAT0016374 gga-miR-3524;gga-miR-3524a; +MIMAT0016375 gga-miR-3526; +MIMAT0016376 gga-miR-3527; +MIMAT0016377 gga-miR-3528; +MIMAT0016378 gga-miR-3529; +MIMAT0016379 gga-miR-3530;gga-miR-3530-3p; +MIMAT0016380 gga-miR-2964;gga-miR-219b; +MIMAT0016381 gga-miR-3531;gga-miR-3531-5p; +MIMAT0016382 gga-miR-3525; +MIMAT0016383 gga-miR-3532;gga-miR-3532-3p; +MIMAT0016384 gga-miR-3533; +MIMAT0016385 gga-miR-3534; +MIMAT0016386 gga-miR-3535; +MIMAT0016387 gga-miR-3536; +MIMAT0016388 gga-miR-3537; +MIMAT0016389 gga-miR-3538; +MIMAT0016390 gga-miR-3539; +MIMAT0016391 gga-miR-3540; +MIMAT0016392 cin-miR-1-5p; +MIMAT0016393 cin-miR-1-3p; +MIMAT0016394 cin-miR-3575-5p; +MIMAT0016395 cin-miR-3575-3p; +MIMAT0016396 cin-miR-9-5p; +MIMAT0016397 cin-miR-15-5p; +MIMAT0016398 cin-miR-15-3p; +MIMAT0016399 cin-miR-3598-5p; +MIMAT0016400 cin-miR-3598-3p; +MIMAT0016401 cin-miR-29-5p; +MIMAT0016402 cin-miR-29-3p; +MIMAT0016403 cin-miR-96-5p; +MIMAT0016404 cin-miR-96-3p; +MIMAT0016405 cin-miR-125-5p; +MIMAT0016406 cin-miR-125-3p; +MIMAT0016407 cin-miR-3599-5p; +MIMAT0016408 cin-miR-3599-3p; +MIMAT0016409 cin-miR-135-5p; +MIMAT0016410 cin-miR-135-3p; +MIMAT0016411 cin-miR-182-5p; +MIMAT0016412 cin-miR-182-3p; +MIMAT0016413 cin-miR-196-5p; +MIMAT0016414 cin-miR-196-3p; +MIMAT0016415 cin-miR-367-5p; +MIMAT0016416 cin-miR-367-3p; +MIMAT0016417 cin-miR-375-5p; +MIMAT0016418 cin-miR-375-3p; +MIMAT0016419 cin-miR-4220-5p; +MIMAT0016420 cin-miR-4220-3p; +MIMAT0016421 cin-miR-92e-5p; +MIMAT0016422 cin-miR-92e-3p; +MIMAT0016423 cin-miR-92d-5p; +MIMAT0016424 cin-miR-92d-3p; +MIMAT0016425 cin-miR-132-5p; +MIMAT0016426 cin-miR-4000c-5p; +MIMAT0016427 cin-miR-4000c-3p; +MIMAT0016428 cin-miR-4000d-5p; +MIMAT0016429 cin-miR-4000d-3p; +MIMAT0016430 cin-miR-4000a-5p; +MIMAT0016431 cin-miR-4000a-3p; +MIMAT0016432 cin-miR-4000b-5p; +MIMAT0016433 cin-miR-4000b-1-3p; +MIMAT0016434 cin-miR-4000e-5p; +MIMAT0016435 cin-miR-4000e-3p; +MIMAT0016436 cin-miR-4000f-5p; +MIMAT0016437 cin-miR-4000f-3p; +MIMAT0016438 cin-miR-4000g-5p; +MIMAT0016439 cin-miR-4000g-3p; +MIMAT0016440 cin-miR-4000h-5p; +MIMAT0016441 cin-miR-4000h-3p; +MIMAT0016442 cin-miR-4000i-5p; +MIMAT0016443 cin-miR-4000i-3p; +MIMAT0016444 cin-miR-4001a-5p; +MIMAT0016445 cin-miR-4001a-1-3p; +MIMAT0016446 cin-miR-4001b-5p; +MIMAT0016447 cin-miR-4001b-1-3p; +MIMAT0016448 cin-miR-4002-5p; +MIMAT0016449 cin-miR-4002-3p; +MIMAT0016450 cin-miR-4001c-5p; +MIMAT0016451 cin-miR-4001c-3p; +MIMAT0016452 cin-miR-4001d-5p; +MIMAT0016453 cin-miR-4001d-3p; +MIMAT0016454 cin-miR-4001e-5p; +MIMAT0016455 cin-miR-4001e-3p; +MIMAT0016456 cin-miR-4001f-5p; +MIMAT0016457 cin-miR-4001f-3p; +MIMAT0016458 cin-miR-4001g-3p; +MIMAT0016459 cin-miR-4001h-5p; +MIMAT0016460 cin-miR-4001h-3p; +MIMAT0016461 cin-miR-4003a-5p; +MIMAT0016462 cin-miR-4003a-3p; +MIMAT0016463 cin-miR-4005a-5p; +MIMAT0016464 cin-miR-4005a-3p; +MIMAT0016465 cin-miR-4003c-5p; +MIMAT0016466 cin-miR-4003c-3p; +MIMAT0016467 cin-miR-4005b-5p; +MIMAT0016468 cin-miR-4005b-3p; +MIMAT0016469 cin-miR-4003b-5p; +MIMAT0016470 cin-miR-4003b-3p; +MIMAT0016471 cin-miR-4004-5p; +MIMAT0016472 cin-miR-4006b-5p; +MIMAT0016473 cin-miR-4006b-3p; +MIMAT0016474 cin-miR-4006c-5p; +MIMAT0016475 cin-miR-4006c-3p; +MIMAT0016476 cin-miR-4006d-5p; +MIMAT0016477 cin-miR-4006d-3p; +MIMAT0016478 cin-miR-4006a-5p; +MIMAT0016479 cin-miR-4006a-1-3p; +MIMAT0016480 cin-miR-4006e-5p; +MIMAT0016481 cin-miR-4006e-3p; +MIMAT0016482 cin-miR-4006f-5p; +MIMAT0016483 cin-miR-4006f-3p; +MIMAT0016484 cin-miR-4006g-5p; +MIMAT0016485 cin-miR-4006g-3p; +MIMAT0016486 cin-miR-4007-5p; +MIMAT0016487 cin-miR-1502a-5p; +MIMAT0016488 cin-miR-1502a-3p; +MIMAT0016489 cin-miR-1502b-5p; +MIMAT0016490 cin-miR-1502b-3p; +MIMAT0016491 cin-miR-1502c-5p; +MIMAT0016492 cin-miR-1502c-3p; +MIMAT0016493 cin-miR-1502d-5p; +MIMAT0016494 cin-miR-1502d-3p; +MIMAT0016495 cin-miR-4008a-5p; +MIMAT0016496 cin-miR-4008a-3p; +MIMAT0016497 cin-miR-4008b-5p; +MIMAT0016498 cin-miR-4008b-3p; +MIMAT0016499 cin-miR-4008c-5p; +MIMAT0016500 cin-miR-4008c-3p; +MIMAT0016501 cin-miR-4009a-5p; +MIMAT0016502 cin-miR-4009a-3p; +MIMAT0016503 cin-miR-4009b-5p; +MIMAT0016504 cin-miR-4009b-3p; +MIMAT0016505 cin-miR-4009c-3p; +MIMAT0016506 cin-miR-4010-5p; +MIMAT0016507 cin-miR-4010-3p; +MIMAT0016508 cin-miR-4011a-5p; +MIMAT0016509 cin-miR-4011a-3p; +MIMAT0016510 cin-miR-4011b-5p; +MIMAT0016511 cin-miR-4011b-3p; +MIMAT0016512 cin-miR-4012-5p; +MIMAT0016513 cin-miR-4012-3p; +MIMAT0016514 cin-miR-4013a-5p; +MIMAT0016515 cin-miR-4013a-3p; +MIMAT0016516 cin-miR-4013b-5p; +MIMAT0016517 cin-miR-4013b-3p; +MIMAT0016518 cin-miR-4014-1-5p; +MIMAT0016519 cin-miR-4014-3p; +MIMAT0016520 cin-miR-4015-5p; +MIMAT0016521 cin-miR-4015-3p; +MIMAT0016522 cin-miR-4016-3p;cin-miR-4016; +MIMAT0016523 cin-miR-4016-5p; +MIMAT0016524 cin-miR-4017-5p; +MIMAT0016525 cin-miR-4017-3p; +MIMAT0016526 cin-miR-4019-5p; +MIMAT0016527 cin-miR-4019-3p; +MIMAT0016528 cin-miR-4018a-5p; +MIMAT0016529 cin-miR-4018a-3p; +MIMAT0016530 cin-miR-4018b-5p; +MIMAT0016531 cin-miR-4018b-3p; +MIMAT0016532 cin-miR-4020a-5p; +MIMAT0016533 cin-miR-4020b-5p; +MIMAT0016534 cin-miR-4020b-3p; +MIMAT0016535 cin-miR-4021-5p; +MIMAT0016536 cin-miR-4021-3p; +MIMAT0016537 cin-miR-4022-3p; +MIMAT0016538 cin-miR-4023-3p; +MIMAT0016539 cin-miR-4024-5p; +MIMAT0016540 cin-miR-4024-3p; +MIMAT0016541 cin-miR-4025-5p; +MIMAT0016542 cin-miR-4026-5p; +MIMAT0016543 cin-miR-4026-3p; +MIMAT0016544 cin-miR-4027-5p; +MIMAT0016545 cin-miR-4027-3p; +MIMAT0016546 cin-miR-4028-3p; +MIMAT0016547 cin-miR-4029-5p; +MIMAT0016548 cin-miR-4029-3p; +MIMAT0016549 cin-miR-4030-5p; +MIMAT0016550 cin-miR-4030-3p; +MIMAT0016551 cin-miR-4031-5p; +MIMAT0016552 cin-miR-4031-3p; +MIMAT0016553 cin-miR-4032-5p; +MIMAT0016554 cin-miR-4032-3p; +MIMAT0016555 cin-miR-4033-5p; +MIMAT0016556 cin-miR-4033-3p; +MIMAT0016557 cin-miR-4034-5p; +MIMAT0016558 cin-miR-4034-3p; +MIMAT0016559 cin-miR-4035-5p; +MIMAT0016560 cin-miR-4035-3p; +MIMAT0016561 cin-miR-4036-5p; +MIMAT0016562 cin-miR-4036-3p; +MIMAT0016563 cin-miR-4037-5p; +MIMAT0016564 cin-miR-4037-3p; +MIMAT0016565 cin-miR-4038-5p; +MIMAT0016566 cin-miR-4038-3p; +MIMAT0016567 cin-miR-4039-5p; +MIMAT0016568 cin-miR-4039-3p; +MIMAT0016569 cin-miR-4040-5p; +MIMAT0016570 cin-miR-4040-3p; +MIMAT0016571 cin-miR-4041-5p; +MIMAT0016572 cin-miR-4041-3p; +MIMAT0016573 cin-miR-4042-5p; +MIMAT0016574 cin-miR-4042-3p; +MIMAT0016575 cin-miR-4043-5p; +MIMAT0016576 cin-miR-4043-3p; +MIMAT0016577 cin-miR-4044-5p; +MIMAT0016578 cin-miR-4044-3p; +MIMAT0016579 cin-miR-4045-5p; +MIMAT0016580 cin-miR-4045-3p; +MIMAT0016581 cin-miR-4046-5p; +MIMAT0016582 cin-miR-4046-3p; +MIMAT0016583 cin-miR-4047-5p; +MIMAT0016584 cin-miR-4047-3p; +MIMAT0016585 cin-miR-4048-5p; +MIMAT0016586 cin-miR-4048-3p; +MIMAT0016587 cin-miR-4049-5p; +MIMAT0016588 cin-miR-4049-3p; +MIMAT0016589 cin-miR-4050-5p; +MIMAT0016590 cin-miR-4050-3p; +MIMAT0016591 cin-miR-4051-5p; +MIMAT0016592 cin-miR-4051-3p; +MIMAT0016593 cin-miR-4052-5p; +MIMAT0016594 cin-miR-4052-3p; +MIMAT0016595 cin-miR-4053-5p; +MIMAT0016596 cin-miR-4053-3p; +MIMAT0016597 cin-miR-4054-5p; +MIMAT0016598 cin-miR-4054-3p; +MIMAT0016599 cin-miR-4055-5p; +MIMAT0016600 cin-miR-4055-3p; +MIMAT0016601 cin-miR-4056-5p; +MIMAT0016602 cin-miR-4056-3p; +MIMAT0016603 cin-miR-4057-5p; +MIMAT0016604 cin-miR-4057-3p; +MIMAT0016605 cin-miR-4058-5p; +MIMAT0016606 cin-miR-4059-5p; +MIMAT0016607 cin-miR-4059-3p; +MIMAT0016608 cin-miR-4060-5p; +MIMAT0016609 cin-miR-4060-3p; +MIMAT0016610 cin-miR-4061-5p; +MIMAT0016611 cin-miR-4061-3p; +MIMAT0016612 cin-miR-4062-5p; +MIMAT0016613 cin-miR-4062-3p; +MIMAT0016614 cin-miR-4063-5p; +MIMAT0016615 cin-miR-4063-3p; +MIMAT0016616 cin-miR-4064-5p; +MIMAT0016617 cin-miR-4064-3p; +MIMAT0016618 cin-miR-4065-5p; +MIMAT0016619 cin-miR-4065-3p; +MIMAT0016620 cin-miR-4066-5p; +MIMAT0016621 cin-miR-4066-3p; +MIMAT0016622 cin-miR-4067-5p; +MIMAT0016623 cin-miR-4067-3p; +MIMAT0016624 cin-miR-4068-5p; +MIMAT0016625 cin-miR-4068-3p; +MIMAT0016626 cin-miR-4069-5p; +MIMAT0016627 cin-miR-4069-3p; +MIMAT0016628 cin-miR-4070-5p; +MIMAT0016629 cin-miR-4070-3p; +MIMAT0016630 cin-miR-4071-5p; +MIMAT0016631 cin-miR-4071-3p; +MIMAT0016632 cin-miR-4072-5p; +MIMAT0016633 cin-miR-4072-3p; +MIMAT0016634 cin-miR-4073-5p; +MIMAT0016635 cin-miR-4073-3p; +MIMAT0016636 cin-miR-4074-5p; +MIMAT0016637 cin-miR-4074-3p; +MIMAT0016638 cin-miR-4075-5p; +MIMAT0016639 cin-miR-4075-3p; +MIMAT0016640 cin-miR-4076-5p; +MIMAT0016641 cin-miR-4076-3p; +MIMAT0016642 cin-miR-4077a-5p; +MIMAT0016643 cin-miR-4077b-5p; +MIMAT0016644 cin-miR-4077c-5p; +MIMAT0016645 cin-miR-4078-5p; +MIMAT0016646 cin-miR-4078-3p; +MIMAT0016647 cin-miR-4079-5p; +MIMAT0016648 cin-miR-4079-3p; +MIMAT0016649 cin-miR-4080-5p; +MIMAT0016650 cin-miR-4080-3p; +MIMAT0016651 cin-miR-4081-5p; +MIMAT0016652 cin-miR-4081-3p; +MIMAT0016653 cin-miR-4082-5p; +MIMAT0016654 cin-miR-4082-3p; +MIMAT0016655 cin-miR-4083-5p; +MIMAT0016656 cin-miR-4083-3p; +MIMAT0016657 cin-miR-4084-5p; +MIMAT0016658 cin-miR-4084-3p; +MIMAT0016659 cin-miR-4085-5p; +MIMAT0016660 cin-miR-4085-3p; +MIMAT0016661 cin-miR-4086-3p; +MIMAT0016662 cin-miR-4087-5p; +MIMAT0016663 cin-miR-4087-3p; +MIMAT0016664 cin-miR-4088-5p; +MIMAT0016665 cin-miR-4088-3p; +MIMAT0016666 cin-miR-4089-5p; +MIMAT0016667 cin-miR-4090-3p; +MIMAT0016668 cin-miR-4091-5p; +MIMAT0016669 cin-miR-4091-3p; +MIMAT0016670 cin-miR-4092-5p; +MIMAT0016671 cin-miR-4092-3p; +MIMAT0016672 cin-miR-4093-5p; +MIMAT0016673 cin-miR-4093-3p; +MIMAT0016674 cin-miR-4094-5p; +MIMAT0016675 cin-miR-4094-3p; +MIMAT0016676 cin-miR-4095-5p; +MIMAT0016677 cin-miR-4096-3p; +MIMAT0016678 cin-miR-4097-5p; +MIMAT0016679 cin-miR-4097-3p; +MIMAT0016680 cin-miR-4098-5p; +MIMAT0016681 cin-miR-4098-3p; +MIMAT0016682 cin-miR-4099-5p; +MIMAT0016683 cin-miR-4099-3p; +MIMAT0016684 cin-miR-4100-5p; +MIMAT0016685 cin-miR-4100-3p; +MIMAT0016686 cin-miR-4101-3p; +MIMAT0016687 cin-miR-4102-5p; +MIMAT0016688 cin-miR-4102-3p; +MIMAT0016689 cin-miR-4077d-5p; +MIMAT0016690 cin-miR-4103-3p; +MIMAT0016691 cin-miR-4104-5p; +MIMAT0016692 cin-miR-4105-5p; +MIMAT0016693 cin-miR-4106-3p; +MIMAT0016694 cin-miR-4107-5p; +MIMAT0016695 cin-miR-4108-5p; +MIMAT0016696 cin-miR-4109-5p; +MIMAT0016697 cin-miR-4109-3p; +MIMAT0016698 cin-miR-4110-5p; +MIMAT0016699 cin-miR-4110-3p; +MIMAT0016700 cin-miR-4111-3p; +MIMAT0016701 cin-miR-4112-5p; +MIMAT0016702 cin-miR-4112-3p; +MIMAT0016703 cin-miR-4113-5p; +MIMAT0016704 cin-miR-4114-5p; +MIMAT0016705 cin-miR-4115-5p; +MIMAT0016706 cin-miR-4115-3p; +MIMAT0016707 cin-miR-4116-5p; +MIMAT0016708 cin-miR-4117-5p; +MIMAT0016709 cin-miR-4118-3p; +MIMAT0016710 cin-miR-4119-5p; +MIMAT0016711 cin-miR-4119-3p; +MIMAT0016712 cin-miR-4120-5p; +MIMAT0016713 cin-miR-4121-3p; +MIMAT0016714 cin-miR-4122-3p; +MIMAT0016715 cin-miR-4123-5p; +MIMAT0016716 cin-miR-4123-3p; +MIMAT0016717 cin-miR-4003d-3p; +MIMAT0016718 cin-miR-4124-5p; +MIMAT0016719 cin-miR-4125-5p; +MIMAT0016720 cin-miR-4126-5p; +MIMAT0016721 cin-miR-4127-5p; +MIMAT0016722 cin-miR-4127-3p; +MIMAT0016723 cin-miR-4128-3p; +MIMAT0016724 cin-miR-4129-3p; +MIMAT0016725 cin-miR-4130-3p; +MIMAT0016726 cin-miR-4131-5p; +MIMAT0016727 cin-miR-4131-3p; +MIMAT0016728 cin-miR-4132-5p; +MIMAT0016729 cin-miR-4132-3p; +MIMAT0016730 cin-miR-4133-3p; +MIMAT0016731 cin-miR-4134-5p; +MIMAT0016732 cin-miR-4135-3p; +MIMAT0016733 cin-miR-4136-3p; +MIMAT0016734 cin-miR-4137-3p; +MIMAT0016735 cin-miR-4138-5p; +MIMAT0016736 cin-miR-4139-5p; +MIMAT0016737 cin-miR-4139-3p; +MIMAT0016738 cin-miR-4140-5p; +MIMAT0016739 cin-miR-4140-3p; +MIMAT0016740 cin-miR-4141-5p; +MIMAT0016741 cin-miR-4141-3p; +MIMAT0016742 cin-miR-4142-5p; +MIMAT0016743 cin-miR-4142-3p; +MIMAT0016744 cin-miR-4143-5p; +MIMAT0016745 cin-miR-4143-3p; +MIMAT0016746 cin-miR-4144-5p; +MIMAT0016747 cin-miR-4144-3p; +MIMAT0016748 cin-miR-4145-3p; +MIMAT0016749 cin-miR-4146-3p; +MIMAT0016750 cin-miR-4147-3p; +MIMAT0016751 cin-miR-4148-5p; +MIMAT0016752 cin-miR-4149-5p; +MIMAT0016753 cin-miR-4150-5p; +MIMAT0016754 cin-miR-4151-5p; +MIMAT0016755 cin-miR-4151-3p; +MIMAT0016756 cin-miR-4152-5p; +MIMAT0016757 cin-miR-4153-3p; +MIMAT0016758 cin-miR-4154-3p; +MIMAT0016759 cin-miR-4155-5p; +MIMAT0016760 cin-miR-4155-3p; +MIMAT0016761 cin-miR-4156-5p; +MIMAT0016762 cin-miR-4156-3p; +MIMAT0016763 cin-miR-4157-5p; +MIMAT0016764 cin-miR-4158-5p; +MIMAT0016765 cin-miR-4159-3p; +MIMAT0016766 cin-miR-4160-3p; +MIMAT0016767 cin-miR-4161-3p; +MIMAT0016768 cin-miR-4162-5p; +MIMAT0016769 cin-miR-4162-3p; +MIMAT0016770 cin-miR-4163-5p; +MIMAT0016771 cin-miR-4163-3p; +MIMAT0016772 cin-miR-4164-3p; +MIMAT0016773 cin-miR-4165-3p; +MIMAT0016774 cin-miR-4166-5p; +MIMAT0016775 cin-miR-4167-5p; +MIMAT0016776 cin-miR-4168-3p; +MIMAT0016777 cin-miR-4169-3p; +MIMAT0016778 cin-miR-4170-5p; +MIMAT0016779 cin-miR-4171-5p; +MIMAT0016780 cin-miR-4172-3p; +MIMAT0016781 cin-miR-4173-5p; +MIMAT0016782 cin-miR-4173-3p; +MIMAT0016783 cin-miR-4174-3p; +MIMAT0016784 cin-miR-4175-3p; +MIMAT0016785 cin-miR-4176-5p; +MIMAT0016786 cin-miR-4177-5p; +MIMAT0016787 cin-miR-4177-3p; +MIMAT0016788 cin-miR-4178a-5p; +MIMAT0016789 cin-miR-4178b-5p; +MIMAT0016790 cin-miR-4179-5p;cin-miR-4179a-5p; +MIMAT0016791 cin-miR-4179-3p;cin-miR-4179a-3p; +MIMAT0016792 cin-miR-4180-5p; +MIMAT0016793 cin-miR-4180-3p; +MIMAT0016794 cin-miR-4181-5p; +MIMAT0016795 cin-miR-4181-3p; +MIMAT0016796 cin-miR-4182-5p; +MIMAT0016797 cin-miR-4182-3p; +MIMAT0016798 cin-miR-4183-5p; +MIMAT0016799 cin-miR-4183-3p; +MIMAT0016800 cin-miR-4184-3p; +MIMAT0016801 cin-miR-4005c-5p; +MIMAT0016802 cin-miR-4185-5p; +MIMAT0016803 cin-miR-4185-3p; +MIMAT0016804 cin-miR-4186-5p; +MIMAT0016805 cin-miR-4187-5p; +MIMAT0016806 cin-miR-4188-5p; +MIMAT0016807 cin-miR-4189-5p; +MIMAT0016808 cin-miR-4190-5p; +MIMAT0016809 cin-miR-4191-5p; +MIMAT0016810 cin-miR-4192-3p; +MIMAT0016811 cin-miR-4193-5p; +MIMAT0016812 cin-miR-4194-5p; +MIMAT0016813 cin-miR-4194-3p; +MIMAT0016814 cin-miR-4195-3p; +MIMAT0016815 cin-miR-4196-5p; +MIMAT0016816 cin-miR-4197-5p; +MIMAT0016817 cin-miR-4198-5p; +MIMAT0016818 cin-miR-4199-3p; +MIMAT0016819 cin-miR-4200-5p; +MIMAT0016820 cin-miR-4200-3p; +MIMAT0016821 cin-miR-4201-5p; +MIMAT0016822 cin-miR-4202-5p; +MIMAT0016823 cin-miR-4203-3p; +MIMAT0016824 cin-miR-4204-5p; +MIMAT0016825 cin-miR-4204-3p; +MIMAT0016826 cin-miR-4205-5p; +MIMAT0016827 cin-miR-4206-3p; +MIMAT0016828 cin-miR-4207-3p; +MIMAT0016829 cin-miR-4208-3p; +MIMAT0016830 cin-miR-4209-5p; +MIMAT0016831 cin-miR-4210-5p; +MIMAT0016832 cin-miR-4211-5p; +MIMAT0016833 cin-miR-4212-3p; +MIMAT0016834 cin-miR-4213-5p; +MIMAT0016835 cin-miR-4214-5p; +MIMAT0016836 cin-miR-4215-3p; +MIMAT0016837 cin-miR-4216-5p; +MIMAT0016838 cin-miR-4216-3p; +MIMAT0016839 cin-miR-4217-3p; +MIMAT0016840 cin-miR-4218-5p; +MIMAT0016841 cin-miR-4219-5p; +MIMAT0016842 cin-let-7f-5p; +MIMAT0016843 cin-let-7f-3p; +MIMAT0016844 hsa-miR-4295; +MIMAT0016845 hsa-miR-4296; +MIMAT0016846 hsa-miR-4297; +MIMAT0016847 hsa-miR-378c; +MIMAT0016848 hsa-miR-4293; +MIMAT0016849 hsa-miR-4294; +MIMAT0016850 hsa-miR-4301; +MIMAT0016851 hsa-miR-4299; +MIMAT0016852 hsa-miR-4298; +MIMAT0016853 hsa-miR-4300; +MIMAT0016854 hsa-miR-4304; +MIMAT0016855 hsa-miR-4302; +MIMAT0016856 hsa-miR-4303; +MIMAT0016857 hsa-miR-4305; +MIMAT0016858 hsa-miR-4306; +MIMAT0016859 hsa-miR-4309; +MIMAT0016860 hsa-miR-4307; +MIMAT0016861 hsa-miR-4308; +MIMAT0016862 hsa-miR-4310; +MIMAT0016863 hsa-miR-4311; +MIMAT0016864 hsa-miR-4312; +MIMAT0016865 hsa-miR-4313; +MIMAT0016866 hsa-miR-4315; +MIMAT0016867 hsa-miR-4316; +MIMAT0016868 hsa-miR-4314; +MIMAT0016869 hsa-miR-4318; +MIMAT0016870 hsa-miR-4319; +MIMAT0016871 hsa-miR-4320; +MIMAT0016872 hsa-miR-4317; +MIMAT0016873 hsa-miR-4322; +MIMAT0016874 hsa-miR-4321; +MIMAT0016875 hsa-miR-4323; +MIMAT0016876 hsa-miR-4324; +MIMAT0016877 hsa-miR-4256; +MIMAT0016878 hsa-miR-4257; +MIMAT0016879 hsa-miR-4258; +MIMAT0016880 hsa-miR-4259; +MIMAT0016881 hsa-miR-4260; +MIMAT0016882 hsa-miR-4253; +MIMAT0016883 hsa-miR-4251; +MIMAT0016884 hsa-miR-4254; +MIMAT0016885 hsa-miR-4255; +MIMAT0016886 hsa-miR-4252; +MIMAT0016887 hsa-miR-4325; +MIMAT0016888 hsa-miR-4326; +MIMAT0016889 hsa-miR-4327; +MIMAT0016890 hsa-miR-4261; +MIMAT0016891 hsa-miR-4265; +MIMAT0016892 hsa-miR-4266; +MIMAT0016893 hsa-miR-4267; +MIMAT0016894 hsa-miR-4262; +MIMAT0016895 hsa-miR-2355;hsa-miR-2355-5p; +MIMAT0016896 hsa-miR-4268; +MIMAT0016897 hsa-miR-4269; +MIMAT0016898 hsa-miR-4263; +MIMAT0016899 hsa-miR-4264; +MIMAT0016900 hsa-miR-4270; +MIMAT0016901 hsa-miR-4271; +MIMAT0016902 hsa-miR-4272; +MIMAT0016903 hsa-miR-4273; +MIMAT0016904 hsa-miR-4276; +MIMAT0016905 hsa-miR-4275; +MIMAT0016906 hsa-miR-4274; +MIMAT0016907 hsa-miR-4281; +MIMAT0016908 hsa-miR-4277; +MIMAT0016909 hsa-miR-4279; +MIMAT0016910 hsa-miR-4278; +MIMAT0016911 hsa-miR-4280; +MIMAT0016912 hsa-miR-4282; +MIMAT0016913 hsa-miR-4285; +MIMAT0016914 hsa-miR-4283; +MIMAT0016915 hsa-miR-4284; +MIMAT0016916 hsa-miR-4286; +MIMAT0016917 hsa-miR-4287; +MIMAT0016918 hsa-miR-4288; +MIMAT0016919 hsa-miR-4292; +MIMAT0016920 hsa-miR-4289; +MIMAT0016921 hsa-miR-4290; +MIMAT0016922 hsa-miR-4291; +MIMAT0016923 hsa-miR-4329; +MIMAT0016924 hsa-miR-4330; +MIMAT0016925 hsa-miR-500b;hsa-miR-500b-5p; +MIMAT0016926 hsa-miR-4328; +MIMAT0016927 bmo-miR-92a; +MIMAT0016928 tgu-miR-34c;tgu-miR-34c-5p; +MIMAT0016929 isc-miR-1993; +MIMAT0016930 isc-miR-278; +MIMAT0016931 bta-miR-3114; +MIMAT0016932 bta-miR-3600; +MIMAT0016933 bta-miR-2957;bta-miR-148c; +MIMAT0016934 bta-miR-3578; +MIMAT0016935 bta-miR-3581;bta-miR-409b; +MIMAT0016936 bta-miR-3601; +MIMAT0016937 bta-miR-3602; +MIMAT0016938 bta-miR-3603;bta-miR-26c; +MIMAT0016939 bta-miR-3604; +MIMAT0016940 bta-miR-3596; +MIMAT0016941 rlcv-miR-rL1-18;rlcv-miR-rL1-18-3p; +MIMAT0016942 rlcv-miR-rL1-19;rlcv-miR-rL1-19-5p; +MIMAT0016943 rlcv-miR-rL1-21;rlcv-miR-rL1-21-3p; +MIMAT0016944 rlcv-miR-rL1-22;rlcv-miR-rL1-22-3p; +MIMAT0016945 rlcv-miR-rL1-23-5p; +MIMAT0016946 rlcv-miR-rL1-23-3p; +MIMAT0016947 rlcv-miR-rL1-24-5p; +MIMAT0016948 rlcv-miR-rL1-24-3p; +MIMAT0016949 rlcv-miR-rL1-25;rlcv-miR-rL1-25-3p; +MIMAT0016950 rlcv-miR-rL1-26;rlcv-miR-rL1-26-3p; +MIMAT0016951 rlcv-miR-rL1-27;rlcv-miR-rL1-27-3p; +MIMAT0016952 rlcv-miR-rL1-28;rlcv-miR-rL1-28-3p; +MIMAT0016953 rlcv-miR-rL1-29;rlcv-miR-rL1-29-3p; +MIMAT0016954 rlcv-miR-rL1-30;rlcv-miR-rL1-30-3p; +MIMAT0016955 rlcv-miR-rL1-31-5p; +MIMAT0016956 rlcv-miR-rL1-31-3p; +MIMAT0016957 rlcv-miR-rL1-32-5p; +MIMAT0016958 rlcv-miR-rL1-32-3p; +MIMAT0016959 rlcv-miR-rL1-33;rlcv-miR-rL1-33-5p; +MIMAT0016960 rlcv-miR-rL1-34-5p; +MIMAT0016961 rlcv-miR-rL1-34-3p; +MIMAT0016962 rlcv-miR-rL1-35-5p; +MIMAT0016963 rlcv-miR-rL1-35-3p; +MIMAT0016964 cin-miR-4000a-3-3p; +MIMAT0016965 cin-miR-4000b-2-3p; +MIMAT0016966 cin-miR-4001i-5p; +MIMAT0016967 cin-miR-4001i-3p; +MIMAT0016968 cin-miR-4006a-2-3p; +MIMAT0016969 cin-miR-4006a-3-3p; +MIMAT0016970 dps-miR-2566a-2*;dps-miR-2566a-2-5p; +MIMAT0016971 cqu-miR-2941-2*;cqu-miR-2941-2-5p; +MIMAT0016972 ppy-miR-129-2*;ppy-miR-129-2-3p; +MIMAT0016973 ppy-miR-133c; +MIMAT0016974 cin-miR-4001a-2-3p; +MIMAT0016975 cin-miR-4001b-2-3p; +MIMAT0016976 cin-miR-4014-2-5p; +MIMAT0016977 aae-miR-iab-4-3p; +MIMAT0016978 ppy-miR-513a-2-3p; +MIMAT0016979 mmu-miR-1-1*;mmu-miR-1a-1*;mmu-miR-1a-1-5p; +MIMAT0016980 mmu-miR-23b*;mmu-miR-23b-5p; +MIMAT0016981 mmu-miR-99a*;mmu-miR-99a-3p; +MIMAT0016982 mmu-miR-128-1*;mmu-miR-128-1-5p; +MIMAT0016983 mmu-miR-130a*;mmu-miR-130a-5p; +MIMAT0016984 mmu-miR-132*;mmu-miR-132-5p; +MIMAT0016985 mmu-miR-134*;mmu-miR-134-3p; +MIMAT0016986 mmu-miR-137*;mmu-miR-137-5p; +MIMAT0016987 mmu-miR-138-2*;mmu-miR-138-2-3p; +MIMAT0016988 mmu-miR-144*;mmu-miR-144-5p; +MIMAT0016989 mmu-miR-146a*;mmu-miR-146a-3p; +MIMAT0016990 mmu-miR-149*;mmu-miR-149-3p; +MIMAT0016991 mmu-miR-152*;mmu-miR-152-5p; +MIMAT0016992 mmu-miR-153*;mmu-miR-153-5p; +MIMAT0016993 mmu-miR-155*;mmu-miR-155-3p; +MIMAT0016994 mmu-miR-129-1-3p; +MIMAT0016995 mmu-miR-182*;mmu-miR-182-3p; +MIMAT0016996 mmu-miR-185*;mmu-miR-185-3p; +MIMAT0016997 mmu-miR-187*;mmu-miR-187-5p; +MIMAT0016998 mmu-miR-190*;mmu-miR-190-3p;mmu-miR-190a-3p; +MIMAT0016999 mmu-miR-194-1*;mmu-miR-194-1-3p; +MIMAT0017000 mmu-miR-195*;mmu-miR-195-3p;mmu-miR-195a-3p; +MIMAT0017001 mmu-miR-201*;mmu-miR-201-3p; +MIMAT0017002 mmu-miR-204*;mmu-miR-204-3p; +MIMAT0017003 mmu-miR-205*;mmu-miR-205-3p; +MIMAT0017004 mmu-miR-206*;mmu-miR-206-5p; +MIMAT0017005 mmu-miR-122*;mmu-miR-122-3p; +MIMAT0017006 mmu-miR-143*;mmu-miR-143-5p; +MIMAT0017007 mmu-miR-298*;mmu-miR-298-3p; +MIMAT0017008 mmu-miR-301a*;mmu-miR-301a-5p; +MIMAT0017009 mmu-miR-106a*;mmu-miR-106a-3p; +MIMAT0017010 mmu-miR-19b-2*;mmu-miR-19b-2-5p; +MIMAT0017011 mmu-miR-30d*;mmu-miR-30d-3p; +MIMAT0017012 mmu-miR-192*;mmu-miR-192-3p; +MIMAT0017013 mmu-miR-196a-1*;mmu-miR-196a-1-3p; +MIMAT0017014 mmu-miR-208a-5p; +MIMAT0017015 mmu-let-7a-2*;mmu-let-7a-2-3p; +MIMAT0017016 mmu-let-7e*;mmu-let-7e-3p; +MIMAT0017017 mmu-let-7f-2*;mmu-let-7f-2-3p; +MIMAT0017018 mmu-miR-16-2*;mmu-miR-16-2-3p; +MIMAT0017019 mmu-miR-23a*;mmu-miR-23a-5p; +MIMAT0017020 mmu-miR-26a-1*;mmu-miR-26a-1-3p; +MIMAT0017021 mmu-miR-96*;mmu-miR-96-3p; +MIMAT0017022 mmu-miR-34a*;mmu-miR-34a-3p; +MIMAT0017023 mmu-miR-98*;mmu-miR-98-3p; +MIMAT0017024 mmu-miR-103-1*;mmu-miR-103-1-5p; +MIMAT0017025 mmu-miR-103-2*;mmu-miR-103-2-5p; +MIMAT0017026 rno-miR-301a*;rno-miR-301a-5p; +MIMAT0017027 mmu-miR-326*;mmu-miR-326-5p; +MIMAT0017028 rno-miR-326*;rno-miR-326-5p; +MIMAT0017029 rno-miR-328a*;rno-miR-328a-5p; +MIMAT0017030 mmu-miR-328*;mmu-miR-328-5p; +MIMAT0017031 rno-miR-329*;rno-miR-329-5p; +MIMAT0017032 mmu-miR-329*;mmu-miR-329-5p; +MIMAT0017033 rno-miR-331*;rno-miR-331-5p; +MIMAT0017034 rno-miR-336*;rno-miR-336-3p; +MIMAT0017035 rno-miR-337*;rno-miR-337-5p; +MIMAT0017036 mmu-miR-148b*;mmu-miR-148b-5p; +MIMAT0017037 mmu-miR-341*;mmu-miR-341-5p; +MIMAT0017038 mmu-miR-344*;mmu-miR-344-5p; +MIMAT0017039 mmu-miR-346*;mmu-miR-346-3p; +MIMAT0017040 mmu-miR-350*;mmu-miR-350-5p; +MIMAT0017041 rno-miR-351*;rno-miR-351-3p; +MIMAT0017042 mmu-miR-351*;mmu-miR-351-3p; +MIMAT0017043 rno-miR-135b*;rno-miR-135b-3p; +MIMAT0017044 mmu-miR-135b*;mmu-miR-135b-3p; +MIMAT0017045 rno-miR-101b*;rno-miR-101b-5p; +MIMAT0017046 mmu-miR-101b*;mmu-miR-101b-5p; +MIMAT0017047 mmu-miR-1-2*;mmu-miR-1a-2*;mmu-miR-1a-2-5p; +MIMAT0017048 mmu-miR-107*;mmu-miR-107-5p; +MIMAT0017049 mmu-miR-25*;mmu-miR-25-5p; +MIMAT0017050 mmu-miR-32*;mmu-miR-32-3p; +MIMAT0017051 mmu-miR-100*;mmu-miR-100-3p; +MIMAT0017052 mmu-miR-210*;mmu-miR-210-5p; +MIMAT0017053 mmu-miR-212-5p; +MIMAT0017054 mmu-miR-216a*;mmu-miR-216a-3p; +MIMAT0017055 mmu-miR-219-3p*;mmu-miR-219-1-3p;mmu-miR-219a-1-3p; +MIMAT0017056 mmu-miR-223*;mmu-miR-223-5p; +MIMAT0017057 mmu-miR-320*;mmu-miR-320-5p; +MIMAT0017058 mmu-miR-26a-2*;mmu-miR-26a-2-3p; +MIMAT0017059 mmu-miR-211*;mmu-miR-211-3p; +MIMAT0017060 mmu-miR-221*;mmu-miR-221-5p; +MIMAT0017061 mmu-miR-222*;mmu-miR-222-5p; +MIMAT0017062 mmu-miR-224*;mmu-miR-224-3p; +MIMAT0017063 mmu-miR-29b-2*;mmu-miR-29b-2-5p; +MIMAT0017064 mmu-miR-135a-2*;mmu-miR-135a-2-3p; +MIMAT0017065 mmu-miR-19b-1*;mmu-miR-19b-1-5p; +MIMAT0017066 mmu-miR-92a-1*;mmu-miR-92a-1-5p; +MIMAT0017067 mmu-miR-181b-1*;mmu-miR-181b-1-3p; +MIMAT0017068 mmu-miR-181c*;mmu-miR-181c-3p; +MIMAT0017069 mmu-miR-128-2*;mmu-miR-128-2-5p; +MIMAT0017070 mmu-miR-7a-2*;mmu-miR-7a-2-3p; +MIMAT0017071 mmu-miR-7b*;mmu-miR-7b-3p; +MIMAT0017072 mmu-miR-217*;mmu-miR-217-3p; +MIMAT0017073 mmu-miR-194-2*;mmu-miR-194-2-3p; +MIMAT0017074 mmu-miR-219-3p; +MIMAT0017075 mmu-miR-361*;mmu-miR-361-3p; +MIMAT0017076 mmu-miR-363-5p; +MIMAT0017077 mmu-miR-365-1*;mmu-miR-365-1-5p; +MIMAT0017078 mmu-miR-375*;mmu-miR-375-5p; +MIMAT0017079 mmu-miR-377*;mmu-miR-377-5p; +MIMAT0017080 mmu-miR-379*;mmu-miR-379-3p; +MIMAT0017081 mmu-miR-381*;mmu-miR-381-5p; +MIMAT0017082 mmu-miR-383*;mmu-miR-383-3p; +MIMAT0017083 mmu-miR-133b*;mmu-miR-133b-5p; +MIMAT0017084 mmu-miR-181b-2*;mmu-miR-181b-2-3p; +MIMAT0017085 rno-let-7a-1*;rno-let-7a-1-3p; +MIMAT0017086 rno-let-7a-2*;rno-let-7a-2-3p; +MIMAT0017087 rno-let-7c-1*;rno-let-7c-1-3p; +MIMAT0017088 rno-let-7c-2*;rno-let-7c-2-3p; +MIMAT0017089 rno-let-7f-1*;rno-let-7f-1-3p; +MIMAT0017090 rno-let-7f-2*;rno-let-7f-2-3p; +MIMAT0017091 rno-miR-7a-2*;rno-miR-7a-2-3p; +MIMAT0017092 rno-miR-10b*;rno-miR-10b-3p; +MIMAT0017093 rno-miR-15b*;rno-miR-15b-3p; +MIMAT0017094 rno-miR-16*;rno-miR-16-3p; +MIMAT0017095 rno-miR-18a*;rno-miR-18a-3p; +MIMAT0017096 rno-miR-19b-1*;rno-miR-19b-1-5p; +MIMAT0017097 rno-miR-19b-2*;rno-miR-19b-2-5p; +MIMAT0017098 rno-miR-19a*;rno-miR-19a-5p; +MIMAT0017099 rno-miR-23b*;rno-miR-23b-5p; +MIMAT0017100 rno-miR-26a*;rno-miR-26a-3p; +MIMAT0017101 rno-miR-27b*;rno-miR-27b-5p; +MIMAT0017102 rno-miR-31*;rno-miR-31a-3p; +MIMAT0017103 rno-miR-32*;rno-miR-32-3p; +MIMAT0017104 rno-miR-33*;rno-miR-33-3p; +MIMAT0017105 rno-miR-34b*;rno-miR-34b-3p; +MIMAT0017106 rno-miR-34a*;rno-miR-34a-3p; +MIMAT0017107 rno-miR-92a-1*;rno-miR-92a-1-5p; +MIMAT0017108 rno-miR-92a-2*;rno-miR-92a-2-5p; +MIMAT0017109 rno-miR-93*;rno-miR-93-3p; +MIMAT0017110 rno-miR-96*;rno-miR-96-3p; +MIMAT0017111 rno-miR-98*;rno-miR-98-3p; +MIMAT0017112 rno-miR-100*;rno-miR-100-3p; +MIMAT0017113 rno-miR-103-2*;rno-miR-103-2-5p; +MIMAT0017114 rno-miR-103-1*;rno-miR-103-1-5p; +MIMAT0017115 rno-miR-107*;rno-miR-107-5p; +MIMAT0017116 rno-miR-122*;rno-miR-122-3p; +MIMAT0017117 rno-miR-127*;rno-miR-127-5p; +MIMAT0017118 rno-miR-128-1*;rno-miR-128-1-5p; +MIMAT0017119 rno-miR-128-2*;rno-miR-128-2-5p; +MIMAT0017120 rno-miR-129-1*;rno-miR-129-1-3p; +MIMAT0017121 rno-miR-130a*;rno-miR-130a-5p; +MIMAT0017122 rno-miR-130b*;rno-miR-130b-5p; +MIMAT0017123 rno-miR-132*;rno-miR-132-5p; +MIMAT0017124 rno-miR-133a*;rno-miR-133a-5p; +MIMAT0017125 rno-miR-134*;rno-miR-134-3p; +MIMAT0017126 rno-miR-137*;rno-miR-137-5p; +MIMAT0017127 rno-miR-138-2*;rno-miR-138-2-3p; +MIMAT0017128 rno-miR-141*;rno-miR-141-5p; +MIMAT0017129 rno-miR-143*;rno-miR-143-5p; +MIMAT0017130 rno-miR-144*;rno-miR-144-5p; +MIMAT0017131 rno-miR-145*;rno-miR-145-3p; +MIMAT0017132 rno-miR-146a*;rno-miR-146a-3p; +MIMAT0017133 rno-miR-150*;rno-miR-150-3p; +MIMAT0017134 rno-miR-152*;rno-miR-152-5p; +MIMAT0017135 rno-miR-153*;rno-miR-153-5p; +MIMAT0017136 rno-miR-154*;rno-miR-154-3p; +MIMAT0017137 rno-miR-181c*;rno-miR-181c-3p; +MIMAT0017138 rno-miR-181a-2*;rno-miR-181a-2-3p; +MIMAT0017139 rno-miR-181b-1*;rno-miR-181b-1-3p; +MIMAT0017140 rno-miR-181b-2*;rno-miR-181b-2-3p; +MIMAT0017141 rno-miR-183*;rno-miR-183-3p; +MIMAT0017142 rno-miR-185*;rno-miR-185-3p; +MIMAT0017143 rno-miR-186*;rno-miR-186-3p; +MIMAT0017144 rno-miR-187*;rno-miR-187-5p; +MIMAT0017145 rno-miR-190*;rno-miR-190a-3p; +MIMAT0017146 rno-miR-191*;rno-miR-191a-3p; +MIMAT0017147 rno-miR-192*;rno-miR-192-3p; +MIMAT0017148 rno-miR-194*;rno-miR-194-3p; +MIMAT0017149 rno-miR-195*;rno-miR-195-3p; +MIMAT0017150 rno-miR-200c*;rno-miR-200c-5p; +MIMAT0017151 rno-miR-200a*;rno-miR-200a-5p; +MIMAT0017152 rno-miR-200b*;rno-miR-200b-5p; +MIMAT0017153 rno-miR-203*;rno-miR-203a-5p; +MIMAT0017154 rno-miR-206*;rno-miR-206-5p; +MIMAT0017155 rno-miR-208*;rno-miR-208a-5p; +MIMAT0017156 rno-miR-210*;rno-miR-210-5p; +MIMAT0017157 rno-miR-211*;rno-miR-211-3p; +MIMAT0017158 rno-miR-212*;rno-miR-212-5p; +MIMAT0017159 rno-miR-214*;rno-miR-214-5p; +MIMAT0017160 rno-miR-216a*;rno-miR-216a-3p; +MIMAT0017161 rno-miR-217*;rno-miR-217-3p; +MIMAT0017162 rno-miR-218-1*;rno-miR-218a-1*;rno-miR-218a-1-3p; +MIMAT0017163 rno-miR-221*;rno-miR-221-5p; +MIMAT0017164 rno-miR-222*;rno-miR-222-5p; +MIMAT0017165 rno-miR-223*;rno-miR-223-5p; +MIMAT0017166 rno-miR-298*;rno-miR-298-3p; +MIMAT0017167 rno-miR-299*;rno-miR-299a-3p; +MIMAT0017168 rno-miR-320*;rno-miR-320-5p; +MIMAT0017169 mmu-miR-215*;mmu-miR-215-3p; +MIMAT0017170 mmu-miR-196b*;mmu-miR-196b-3p; +MIMAT0017171 rno-miR-196b*;rno-miR-196b-3p; +MIMAT0017172 mmu-miR-410*;mmu-miR-410-5p; +MIMAT0017173 mmu-miR-412-5p; +MIMAT0017174 mmu-miR-370*;mmu-miR-370-5p; +MIMAT0017175 rno-miR-421*;rno-miR-421-3p; +MIMAT0017176 mmu-miR-448-5p; +MIMAT0017177 rno-miR-448*;rno-miR-448-5p; +MIMAT0017178 mmu-miR-429*;mmu-miR-429-5p; +MIMAT0017179 mmu-miR-365-2*;mmu-miR-365-2-5p; +MIMAT0017180 mmu-miR-449a*;mmu-miR-449a-3p; +MIMAT0017181 rno-miR-449a*;rno-miR-449a-3p; +MIMAT0017182 mmu-miR-450a-1*;mmu-miR-450a-1-3p; +MIMAT0017183 rno-miR-450a*;rno-miR-450a-3p; +MIMAT0017184 rno-miR-365*;rno-miR-365-5p; +MIMAT0017185 mghv-mir-M1-1*;mghv-miR-M1-1*;mghv-miR-M1-1-5p; +MIMAT0017186 mghv-mir-M1-2-5p;mghv-miR-M1-2-5p; +MIMAT0017187 mghv-mir-M1-3*;mghv-miR-M1-3*;mghv-miR-M1-3-5p; +MIMAT0017188 mghv-mir-M1-4*;mghv-miR-M1-4*;mghv-miR-M1-4-3p; +MIMAT0017189 mghv-mir-M1-5*;mghv-miR-M1-5*;mghv-miR-M1-5-3p; +MIMAT0017190 mghv-miR-M1-6*;mghv-miR-M1-6-5p; +MIMAT0017191 mghv-mir-M1-8*;mghv-miR-M1-8*;mghv-miR-M1-8-3p; +MIMAT0017192 rno-miR-433*;rno-miR-433-5p; +MIMAT0017193 rno-miR-451*;rno-miR-451-3p; +MIMAT0017194 mmu-miR-452-3p; +MIMAT0017195 mmu-miR-471-3p; +MIMAT0017196 rno-miR-489*;rno-miR-489-5p; +MIMAT0017197 rno-miR-383*;rno-miR-383-3p; +MIMAT0017198 rno-miR-501*;rno-miR-501-3p; +MIMAT0017199 rno-miR-361*;rno-miR-361-3p; +MIMAT0017200 rno-miR-224*;rno-miR-224-3p; +MIMAT0017201 rno-miR-483*;rno-miR-483-5p; +MIMAT0017202 rno-miR-370*;rno-miR-370-5p; +MIMAT0017203 rno-miR-377*;rno-miR-377-5p; +MIMAT0017204 rno-miR-412*;rno-miR-412-5p; +MIMAT0017205 rno-miR-133b*;rno-miR-133b-5p; +MIMAT0017206 mmu-miR-486*;mmu-miR-486-3p;mmu-miR-486a-3p; +MIMAT0017207 mmu-miR-543*;mmu-miR-543-5p; +MIMAT0017208 mmu-miR-539-3p; +MIMAT0017209 mmu-miR-541*;mmu-miR-541-3p; +MIMAT0017210 mmu-miR-547*;mmu-miR-547-5p; +MIMAT0017211 rno-miR-540*;rno-miR-540-5p; +MIMAT0017212 rno-miR-539*;rno-miR-539-3p; +MIMAT0017213 rno-miR-541*;rno-miR-541-3p; +MIMAT0017214 mmu-miR-367*;mmu-miR-367-5p; +MIMAT0017215 mmu-miR-494*;mmu-miR-494-5p; +MIMAT0017216 mmu-miR-487b*;mmu-miR-487b-5p; +MIMAT0017217 rno-miR-493*;rno-miR-493-5p; +MIMAT0017218 rno-miR-494*;rno-miR-494-5p; +MIMAT0017219 rno-miR-376c*;rno-miR-376c-5p; +MIMAT0017220 rno-miR-381*;rno-miR-381-5p; +MIMAT0017221 rno-miR-487b*;rno-miR-487b-5p; +MIMAT0017222 rno-miR-485*;rno-miR-485-3p; +MIMAT0017223 rno-miR-374*;rno-miR-374-3p; +MIMAT0017224 rno-miR-503*;rno-miR-503-3p; +MIMAT0017225 mmu-miR-302d*;mmu-miR-302d-5p; +MIMAT0017226 rno-miR-505*;rno-miR-505-5p; +MIMAT0017227 rno-miR-499*;rno-miR-499-3p; +MIMAT0017228 rno-miR-664-1*;rno-miR-664-1-5p; +MIMAT0017229 rno-miR-664-2*;rno-miR-664-2-5p; +MIMAT0017230 rno-miR-497*;rno-miR-497-3p; +MIMAT0017231 mmu-miR-1224*;mmu-miR-1224-3p; +MIMAT0017232 mmu-miR-301b*;mmu-miR-301b-5p; +MIMAT0017233 mmu-miR-216b*;mmu-miR-216b-3p; +MIMAT0017234 mmu-miR-592*;mmu-miR-592-3p; +MIMAT0017235 mmu-miR-758*;mmu-miR-758-5p; +MIMAT0017236 mmu-miR-551b*;mmu-miR-551b-5p; +MIMAT0017237 mmu-miR-668*;mmu-miR-668-5p; +MIMAT0017238 mmu-miR-665*;mmu-miR-665-5p; +MIMAT0017239 mmu-miR-667*;mmu-miR-667-5p; +MIMAT0017240 mmu-miR-802*;mmu-miR-802-3p; +MIMAT0017241 mmu-miR-672*;mmu-miR-672-3p; +MIMAT0017242 mmu-miR-670*;mmu-miR-670-3p; +MIMAT0017243 mmu-miR-669a-3p; +MIMAT0017244 mmu-miR-496*;mmu-miR-496-5p;mmu-miR-496a-5p; +MIMAT0017245 mmu-miR-760-5p; +MIMAT0017246 mmu-miR-677*;mmu-miR-677-3p; +MIMAT0017247 mmu-miR-497*;mmu-miR-497-3p;mmu-miR-497a-3p; +MIMAT0017248 mmu-miR-679-3p; +MIMAT0017249 mmu-miR-495*;mmu-miR-495-5p; +MIMAT0017250 mmu-miR-669b*;mmu-miR-669b-3p; +MIMAT0017251 mmu-miR-669a-3-3p; +MIMAT0017253 mmu-miR-669c*;mmu-miR-669c-3p; +MIMAT0017254 mmu-miR-499*;mmu-miR-499-3p; +MIMAT0017255 mmu-miR-491*;mmu-miR-491-3p; +MIMAT0017256 mmu-miR-700*;mmu-miR-700-5p; +MIMAT0017257 mmu-miR-701*;mmu-miR-701-3p; +MIMAT0017258 mmu-miR-500*;mmu-miR-500-5p; +MIMAT0017259 mmu-miR-505-5p; +MIMAT0017260 mmu-miR-652*;mmu-miR-652-5p; +MIMAT0017261 mmu-miR-490-5p; +MIMAT0017262 mmu-miR-741*;mmu-miR-741-5p; +MIMAT0017263 mmu-miR-743a*;mmu-miR-743a-5p; +MIMAT0017264 mmu-miR-181d*;mmu-miR-181d-3p; +MIMAT0017265 mmu-miR-871-3p; +MIMAT0017266 mmu-miR-880*;mmu-miR-880-5p; +MIMAT0017267 mmu-miR-190b*;mmu-miR-190b-3p; +MIMAT0017268 mmu-miR-874*;mmu-miR-874-5p; +MIMAT0017269 mmu-miR-147*;mmu-miR-147-5p; +MIMAT0017270 mmu-miR-18b*;mmu-miR-18b-3p; +MIMAT0017271 mmu-miR-193b*;mmu-miR-193b-5p; +MIMAT0017272 mmu-miR-297a-5*; +MIMAT0017273 mmu-miR-421*;mmu-miR-421-5p; +MIMAT0017274 mmu-miR-466h-3p; +MIMAT0017275 mmu-miR-467c*;mmu-miR-467c-3p; +MIMAT0017276 mmu-miR-493*;mmu-miR-493-5p; +MIMAT0017277 mmu-miR-504*;mmu-miR-504-3p; +MIMAT0017278 mmu-miR-92b*;mmu-miR-92b-5p; +MIMAT0017279 mmu-miR-873*;mmu-miR-873-3p;mmu-miR-873a-3p; +MIMAT0017280 mmu-miR-208b*;mmu-miR-208b-5p; +MIMAT0017281 mmu-miR-511-3p; +MIMAT0017282 mmu-miR-544-5p; +MIMAT0017283 mmu-miR-598*;mmu-miR-598-5p; +MIMAT0017284 mmu-miR-653*;mmu-miR-653-3p; +MIMAT0017285 rno-miR-466b-1*;rno-miR-466b-1-3p;rno-miR-466b-3p; +MIMAT0017286 rno-miR-466b-2*;rno-miR-466b-2-3p; +MIMAT0017287 rno-miR-466c*;rno-miR-466c-3p; +MIMAT0017288 rno-miR-743b*;rno-miR-743b-5p; +MIMAT0017289 rno-miR-871*;rno-miR-871-3p; +MIMAT0017290 rno-miR-874*;rno-miR-874-5p; +MIMAT0017291 rno-miR-879*;rno-miR-879-3p; +MIMAT0017292 rno-miR-880*;rno-miR-880-5p; +MIMAT0017293 rno-miR-881*;rno-miR-881-5p; +MIMAT0017294 rno-miR-883*;rno-miR-883-5p; +MIMAT0017295 rno-miR-17-2-3p; +MIMAT0017296 rno-miR-181d*;rno-miR-181d-3p; +MIMAT0017297 rno-miR-188*;rno-miR-188-3p; +MIMAT0017298 rno-miR-190b*;rno-miR-190b-3p; +MIMAT0017299 rno-miR-196c*;rno-miR-196c-3p; +MIMAT0017300 rno-miR-301b*;rno-miR-301b-5p; +MIMAT0017301 rno-miR-375*;rno-miR-375-5p; +MIMAT0017302 rno-miR-380*;rno-miR-380-3p; +MIMAT0017303 rno-miR-410*;rno-miR-410-5p; +MIMAT0017304 rno-miR-411*;rno-miR-411-3p; +MIMAT0017305 rno-miR-423*;rno-miR-423-5p; +MIMAT0017306 rno-miR-425*;rno-miR-425-3p; +MIMAT0017307 rno-miR-434*;rno-miR-434-5p; +MIMAT0017308 rno-miR-455*;rno-miR-455-3p; +MIMAT0017309 rno-miR-463*;rno-miR-463-5p; +MIMAT0017310 rno-miR-471*;rno-miR-471-3p; +MIMAT0017311 rno-miR-500*;rno-miR-500-5p; +MIMAT0017312 rno-miR-672*;rno-miR-672-3p; +MIMAT0017313 rno-miR-673*;rno-miR-673-3p; +MIMAT0017314 rno-miR-742*;rno-miR-742-5p; +MIMAT0017315 rno-miR-743a*;rno-miR-743a-5p; +MIMAT0017316 rno-miR-758*;rno-miR-758-5p; +MIMAT0017317 rno-miR-770*;rno-miR-770-3p; +MIMAT0017318 rno-miR-873*;rno-miR-873-3p; +MIMAT0017319 rno-miR-92b*;rno-miR-92b-5p; +MIMAT0017320 rno-miR-488*;rno-miR-488-5p; +MIMAT0017321 rno-miR-652*;rno-miR-652-5p; +MIMAT0017322 mmu-miR-466l-5p; +MIMAT0017323 mmu-miR-669k*;mmu-miR-669k-5p; +MIMAT0017324 mmu-miR-669d*;mmu-miR-669d-3p; +MIMAT0017325 mmu-miR-466i-5p; +MIMAT0017326 mmu-miR-1-2-as-3p;mmu-miR-1b-3p; +MIMAT0017327 mmu-miR-669f-5p; +MIMAT0017328 mmu-miR-1188*;mmu-miR-1188-3p; +MIMAT0017329 mmu-miR-1193-5p; +MIMAT0017330 mmu-miR-669e*;mmu-miR-669e-3p; +MIMAT0017331 mmu-miR-1197*;mmu-miR-1197-5p; +MIMAT0017332 mmu-miR-1198-3p; +MIMAT0017333 mmu-miR-1199*;mmu-miR-1199-3p; +MIMAT0017334 rno-miR-146b*;rno-miR-146b-3p; +MIMAT0017335 rno-miR-551b*;rno-miR-551b-5p; +MIMAT0017336 gma-miR171b-5p; +MIMAT0017337 gma-miR482a-5p; +MIMAT0017338 gma-miR1510a-5p; +MIMAT0017339 ssc-miR-199b;ssc-miR-199b-5p; +MIMAT0017340 mmu-miR-1930*;mmu-miR-1930-3p; +MIMAT0017341 mmu-miR-1934*;mmu-miR-1934-3p; +MIMAT0017342 mmu-miR-1943*;mmu-miR-1943-3p; +MIMAT0017343 mmu-miR-1947*;mmu-miR-1947-3p; +MIMAT0017344 mmu-miR-1948*;mmu-miR-1948-5p; +MIMAT0017345 mmu-miR-669l*;mmu-miR-669l-3p; +MIMAT0017346 mmu-miR-669m-5p; +MIMAT0017347 mmu-miR-669o-3p; +MIMAT0017348 mmu-miR-1955-3p; +MIMAT0017349 mmu-miR-1964-5p; +MIMAT0017350 mmu-miR-1968*;mmu-miR-1968-3p; +MIMAT0017351 mmu-miR-1981*;mmu-miR-1981-3p; +MIMAT0017352 hsa-miR-2277-5p; +MIMAT0017353 mmu-miR-664*;mmu-miR-664-5p; +MIMAT0017354 oan-miR-92d; +MIMAT0017355 rno-miR-202*;rno-miR-202-3p; +MIMAT0017356 rno-miR-490*;rno-miR-490-5p; +MIMAT0017357 rno-miR-362*;rno-miR-362-3p; +MIMAT0017358 rno-miR-511*;rno-miR-511-3p; +MIMAT0017359 rno-miR-544*;rno-miR-544-5p; +MIMAT0017360 rno-miR-582*;rno-miR-582-3p; +MIMAT0017361 rno-miR-653*;rno-miR-653-3p; +MIMAT0017362 rno-miR-802*;rno-miR-802-3p; +MIMAT0017363 rno-miR-675*;rno-miR-675-3p; +MIMAT0017364 rno-miR-201*;rno-miR-201-3p; +MIMAT0017365 rno-miR-293*;rno-miR-293-3p; +MIMAT0017366 rno-miR-295*;rno-miR-295-3p; +MIMAT0017367 rno-miR-465*;rno-miR-465-3p; +MIMAT0017368 rno-miR-547*;rno-miR-547-5p; +MIMAT0017369 rno-miR-667*;rno-miR-667-5p; +MIMAT0017370 rno-miR-764*;rno-miR-764-3p; +MIMAT0017371 rno-miR-666*;rno-miR-666-3p; +MIMAT0017372 rno-miR-496*;rno-miR-496-5p; +MIMAT0017373 ssc-miR-499-3p; +MIMAT0017374 ssc-miR-143-5p; +MIMAT0017375 ssc-miR-181d-3p; +MIMAT0017376 ssc-miR-365-5p; +MIMAT0017377 ssc-miR-92b-5p; +MIMAT0017378 ssc-miR-374b-3p; +MIMAT0017379 ssc-miR-196b-3p; +MIMAT0017380 ssc-miR-450b-3p; +MIMAT0017381 ssc-miR-339-3p; +MIMAT0017382 ssc-miR-676-5p; +MIMAT0017383 ssc-miR-708-3p; +MIMAT0017384 ssc-miR-432-3p; +MIMAT0017385 ssc-miR-1839-3p; +MIMAT0017386 csi-miR166e*;csi-miR166e-5p; +MIMAT0017387 csi-miR172a*;csi-miR172a-5p; +MIMAT0017388 csi-miR162*;csi-miR162-5p; +MIMAT0017389 tgu-miR-338-5p; +MIMAT0017390 tgu-miR-17a-5p; +MIMAT0017391 tgu-miR-301-5p; +MIMAT0017392 hsa-miR-3200-5p; +MIMAT0017393 bta-miR-2284w; +MIMAT0017394 bta-miR-3431; +MIMAT0017395 bta-miR-2284x; +MIMAT0017396 bta-miR-3432;bta-miR-3432a; +MIMAT0017397 aly-miR156a;aly-miR156a-5p; +MIMAT0017398 aly-miR156a*;aly-miR156a-3p; +MIMAT0017399 aly-miR156b;aly-miR156b-5p; +MIMAT0017400 aly-miR156b*;aly-miR156b-3p; +MIMAT0017401 aly-miR156c;aly-miR156c-5p; +MIMAT0017402 aly-miR156c*;aly-miR156c-3p; +MIMAT0017403 aly-miR156d;aly-miR156d-5p; +MIMAT0017404 aly-miR156d*;aly-miR156d-3p; +MIMAT0017405 aly-miR156e;aly-miR156e-5p; +MIMAT0017406 aly-miR156e*;aly-miR156e-3p; +MIMAT0017407 aly-miR156f;aly-miR156f-5p; +MIMAT0017408 aly-miR156f*;aly-miR156f-3p; +MIMAT0017409 aly-miR156g;aly-miR156g-5p; +MIMAT0017410 aly-miR156g*;aly-miR156g-3p; +MIMAT0017411 aly-miR156h;aly-miR156h-5p; +MIMAT0017412 aly-miR156h*;aly-miR156h-3p; +MIMAT0017413 aly-miR157a;aly-miR157a-5p; +MIMAT0017414 aly-miR157a*;aly-miR157a-3p; +MIMAT0017415 aly-miR157b;aly-miR157b-5p; +MIMAT0017416 aly-miR157b*;aly-miR157b-3p; +MIMAT0017417 aly-miR157c;aly-miR157c-5p; +MIMAT0017418 aly-miR157c*;aly-miR157c-3p; +MIMAT0017419 aly-miR157d;aly-miR157d-5p; +MIMAT0017420 aly-miR157d*;aly-miR157d-3p; +MIMAT0017421 aly-miR158a*;aly-miR158a-5p; +MIMAT0017422 aly-miR158a;aly-miR158a-3p; +MIMAT0017423 aly-miR159a*;aly-miR159a-5p; +MIMAT0017424 aly-miR159a;aly-miR159a-3p; +MIMAT0017425 aly-miR159b*;aly-miR159b-5p; +MIMAT0017426 aly-miR159b;aly-miR159b-3p; +MIMAT0017427 aly-miR159c*;aly-miR159c-5p; +MIMAT0017428 aly-miR159c;aly-miR159c-3p; +MIMAT0017429 aly-miR319a*;aly-miR319a-5p; +MIMAT0017430 aly-miR319a;aly-miR319a-3p; +MIMAT0017431 aly-miR319b*;aly-miR319b-5p; +MIMAT0017432 aly-miR319b;aly-miR319b-3p; +MIMAT0017433 aly-miR319c*;aly-miR319c-5p; +MIMAT0017434 aly-miR319c;aly-miR319c-3p; +MIMAT0017435 aly-miR160a;aly-miR160a-5p; +MIMAT0017436 aly-miR160a*;aly-miR160a-3p; +MIMAT0017437 aly-miR160b;aly-miR160b-5p; +MIMAT0017438 aly-miR160b*;aly-miR160b-3p; +MIMAT0017439 aly-miR160c;aly-miR160c-5p; +MIMAT0017440 aly-miR160c*;aly-miR160c-3p; +MIMAT0017441 aly-miR161.2;aly-miR161-5p.2; +MIMAT0017442 aly-miR161.1;aly-miR161-5p.1; +MIMAT0017443 aly-miR161.1*;aly-miR161-3p.1; +MIMAT0017444 aly-miR161.2*;aly-miR161-3p.2; +MIMAT0017445 aly-miR162a*;aly-miR162a-5p; +MIMAT0017446 aly-miR162a;aly-miR162a-3p; +MIMAT0017447 aly-miR162b*;aly-miR162b-5p; +MIMAT0017448 aly-miR162b;aly-miR162b-3p; +MIMAT0017449 aly-miR164a;aly-miR164a-5p; +MIMAT0017450 aly-miR164a*;aly-miR164a-3p; +MIMAT0017451 aly-miR164b;aly-miR164b-5p; +MIMAT0017452 aly-miR164b*;aly-miR164b-3p; +MIMAT0017453 aly-miR164c;aly-miR164c-5p; +MIMAT0017454 aly-miR164c*;aly-miR164c-3p; +MIMAT0017455 aly-miR165a*;aly-miR165a-5p; +MIMAT0017456 aly-miR165a;aly-miR165a-3p; +MIMAT0017457 aly-miR165b*;aly-miR165b-5p; +MIMAT0017458 aly-miR165b;aly-miR165b-3p; +MIMAT0017459 aly-miR166a*;aly-miR166a-5p; +MIMAT0017460 aly-miR166a;aly-miR166a-3p; +MIMAT0017461 aly-miR166b*;aly-miR166b-5p; +MIMAT0017462 aly-miR166b;aly-miR166b-3p; +MIMAT0017463 aly-miR166c*;aly-miR166c-5p; +MIMAT0017464 aly-miR166c;aly-miR166c-3p; +MIMAT0017465 aly-miR166d*;aly-miR166d-5p; +MIMAT0017466 aly-miR166d;aly-miR166d-3p; +MIMAT0017467 aly-miR166e*;aly-miR166e-5p; +MIMAT0017468 aly-miR166e;aly-miR166e-3p; +MIMAT0017469 aly-miR166f*;aly-miR166f-5p; +MIMAT0017470 aly-miR166f;aly-miR166f-3p; +MIMAT0017471 aly-miR166g*;aly-miR166g-5p; +MIMAT0017472 aly-miR166g;aly-miR166g-3p; +MIMAT0017473 aly-miR167a;aly-miR167a-5p; +MIMAT0017474 aly-miR167a*;aly-miR167a-3p; +MIMAT0017475 aly-miR167b;aly-miR167b-5p; +MIMAT0017476 aly-miR167b*;aly-miR167b-3p; +MIMAT0017477 aly-miR167c;aly-miR167c-5p; +MIMAT0017478 aly-miR167c*;aly-miR167c-3p; +MIMAT0017479 aly-miR167d;aly-miR167d-5p; +MIMAT0017480 aly-miR167d*;aly-miR167d-3p; +MIMAT0017481 aly-miR168a;aly-miR168a-5p; +MIMAT0017482 aly-miR168a*;aly-miR168a-3p; +MIMAT0017483 aly-miR168b;aly-miR168b-5p; +MIMAT0017484 aly-miR168b*;aly-miR168b-3p; +MIMAT0017485 aly-miR169a;aly-miR169a-5p; +MIMAT0017486 aly-miR169a*;aly-miR169a-3p; +MIMAT0017487 aly-miR169b;aly-miR169b-5p; +MIMAT0017488 aly-miR169b*;aly-miR169b-3p; +MIMAT0017489 aly-miR169c;aly-miR169c-5p; +MIMAT0017490 aly-miR169c*;aly-miR169c-3p; +MIMAT0017491 aly-miR169d;aly-miR169d-5p; +MIMAT0017492 aly-miR169d*;aly-miR169d-3p; +MIMAT0017493 aly-miR169e;aly-miR169e-5p; +MIMAT0017494 aly-miR169e*;aly-miR169e-3p; +MIMAT0017495 aly-miR169f;aly-miR169f-5p; +MIMAT0017496 aly-miR169f*;aly-miR169f-3p; +MIMAT0017497 aly-miR169g;aly-miR169g-5p; +MIMAT0017498 aly-miR169g*;aly-miR169g-3p; +MIMAT0017499 aly-miR169h;aly-miR169h-5p; +MIMAT0017500 aly-miR169h*;aly-miR169h-3p; +MIMAT0017501 aly-miR169i;aly-miR169i-5p; +MIMAT0017502 aly-miR169i*;aly-miR169i-3p; +MIMAT0017503 aly-miR169j;aly-miR169j-5p; +MIMAT0017504 aly-miR169j*;aly-miR169j-3p; +MIMAT0017505 aly-miR169k;aly-miR169k-5p; +MIMAT0017506 aly-miR169k*;aly-miR169k-3p; +MIMAT0017507 aly-miR169l;aly-miR169l-5p; +MIMAT0017508 aly-miR169l*;aly-miR169l-3p; +MIMAT0017509 aly-miR169m;aly-miR169m-5p; +MIMAT0017510 aly-miR169m*;aly-miR169m-3p; +MIMAT0017511 aly-miR169n;aly-miR169n-5p; +MIMAT0017512 aly-miR169n*;aly-miR169n-3p; +MIMAT0017513 aly-miR170*;aly-miR170-5p; +MIMAT0017514 aly-miR170;aly-miR170-3p; +MIMAT0017515 aly-miR171a*;aly-miR171a-5p; +MIMAT0017516 aly-miR171a;aly-miR171a-3p; +MIMAT0017517 aly-miR171b*;aly-miR171b-5p; +MIMAT0017518 aly-miR171b;aly-miR171b-3p; +MIMAT0017519 aly-miR171c*;aly-miR171c-5p; +MIMAT0017520 aly-miR171c;aly-miR171c-3p; +MIMAT0017521 aly-miR172a*;aly-miR172a-5p; +MIMAT0017522 aly-miR172a;aly-miR172a-3p; +MIMAT0017523 aly-miR172b*;aly-miR172b-5p; +MIMAT0017524 aly-miR172b;aly-miR172b-3p; +MIMAT0017525 aly-miR172c*;aly-miR172c-5p; +MIMAT0017526 aly-miR172c;aly-miR172c-3p; +MIMAT0017527 aly-miR172d*;aly-miR172d-5p; +MIMAT0017528 aly-miR172d;aly-miR172d-3p; +MIMAT0017529 aly-miR172e*;aly-miR172e-5p; +MIMAT0017530 aly-miR172e;aly-miR172e-3p; +MIMAT0017531 aly-miR173;aly-miR173-5p;aly-miR173a-5p; +MIMAT0017532 aly-miR173*;aly-miR173-3p;aly-miR173a-3p; +MIMAT0017533 aly-miR390a;aly-miR390a-5p; +MIMAT0017534 aly-miR390a*;aly-miR390a-3p; +MIMAT0017535 aly-miR390b;aly-miR390b-5p; +MIMAT0017536 aly-miR390b*;aly-miR390b-3p; +MIMAT0017537 aly-miR391;aly-miR391-5p; +MIMAT0017538 aly-miR391*;aly-miR391-3p; +MIMAT0017539 aly-miR393a;aly-miR393a-5p; +MIMAT0017540 aly-miR393a*;aly-miR393a-3p; +MIMAT0017541 aly-miR393b;aly-miR393b-5p; +MIMAT0017542 aly-miR393b*;aly-miR393b-3p; +MIMAT0017543 aly-miR394a;aly-miR394a-5p; +MIMAT0017544 aly-miR394a*;aly-miR394a-3p; +MIMAT0017545 aly-miR394b;aly-miR394b-5p; +MIMAT0017546 aly-miR394b*;aly-miR394b-3p; +MIMAT0017547 aly-miR395b*;aly-miR395b-5p; +MIMAT0017548 aly-miR395b;aly-miR395b-3p; +MIMAT0017549 aly-miR395c*;aly-miR395c-5p; +MIMAT0017550 aly-miR395c;aly-miR395c-3p; +MIMAT0017551 aly-miR395d*;aly-miR395d-5p; +MIMAT0017552 aly-miR395d;aly-miR395d-3p; +MIMAT0017553 aly-miR395e*;aly-miR395e-5p; +MIMAT0017554 aly-miR395e;aly-miR395e-3p; +MIMAT0017555 aly-miR395f*;aly-miR395f-5p; +MIMAT0017556 aly-miR395f;aly-miR395f-3p; +MIMAT0017557 aly-miR396a;aly-miR396a-5p; +MIMAT0017558 aly-miR396a*;aly-miR396a-3p; +MIMAT0017559 aly-miR396b;aly-miR396b-5p; +MIMAT0017560 aly-miR396b*;aly-miR396b-3p; +MIMAT0017561 aly-miR397a;aly-miR397a-5p; +MIMAT0017562 aly-miR397a*;aly-miR397a-3p; +MIMAT0017563 aly-miR397b;aly-miR397b-5p; +MIMAT0017564 aly-miR397b*;aly-miR397b-3p; +MIMAT0017565 aly-miR398a*;aly-miR398a-5p; +MIMAT0017566 aly-miR398a;aly-miR398a-3p; +MIMAT0017567 aly-miR398b*;aly-miR398b-5p; +MIMAT0017568 aly-miR398b;aly-miR398b-3p; +MIMAT0017569 aly-miR398c*;aly-miR398c-5p; +MIMAT0017570 aly-miR398c;aly-miR398c-3p; +MIMAT0017571 aly-miR399a*;aly-miR399a-5p; +MIMAT0017572 aly-miR399a;aly-miR399a-3p; +MIMAT0017573 aly-miR399b*;aly-miR399b-5p; +MIMAT0017574 aly-miR399b;aly-miR399b-3p; +MIMAT0017575 aly-miR399c*;aly-miR399c-5p; +MIMAT0017576 aly-miR399c;aly-miR399c-3p; +MIMAT0017577 aly-miR399d*;aly-miR399d-5p; +MIMAT0017578 aly-miR399d;aly-miR399d-3p; +MIMAT0017579 aly-miR399e*;aly-miR399e-5p; +MIMAT0017580 aly-miR399e;aly-miR399e-3p; +MIMAT0017581 aly-miR399f*;aly-miR399f-5p; +MIMAT0017582 aly-miR399f;aly-miR399f-3p; +MIMAT0017583 aly-miR400;aly-miR400-5p; +MIMAT0017584 aly-miR400*;aly-miR400-3p; +MIMAT0017585 aly-miR403*;aly-miR403-5p;aly-miR403a-5p; +MIMAT0017586 aly-miR403;aly-miR403-3p;aly-miR403a-3p; +MIMAT0017587 aly-miR408*;aly-miR408-5p; +MIMAT0017588 aly-miR408;aly-miR408-3p; +MIMAT0017589 aly-miR472*;aly-miR472-5p; +MIMAT0017590 aly-miR472;aly-miR472-3p; +MIMAT0017591 aly-miR771;aly-miR771-5p; +MIMAT0017592 aly-miR771*;aly-miR771-3p; +MIMAT0017593 aly-miR774.1;aly-miR774a-5p.1; +MIMAT0017594 aly-miR774.2;aly-miR774a-5p.2; +MIMAT0017595 aly-miR774.2*;aly-miR774a-3p.2; +MIMAT0017596 aly-miR774.1*;aly-miR774a-3p.1; +MIMAT0017597 aly-miR781;aly-miR781-5p; +MIMAT0017598 aly-miR781*;aly-miR781-3p; +MIMAT0017599 aly-miR822;aly-miR822-5p; +MIMAT0017600 aly-miR822*;aly-miR822-3p; +MIMAT0017601 aly-miR823*;aly-miR823-5p; +MIMAT0017602 aly-miR823;aly-miR823-3p; +MIMAT0017603 aly-miR824;aly-miR824-5p; +MIMAT0017604 aly-miR824*;aly-miR824-3p; +MIMAT0017605 aly-miR825*;aly-miR825-5p; +MIMAT0017606 aly-miR825;aly-miR825-3p; +MIMAT0017607 aly-miR827*;aly-miR827-5p; +MIMAT0017608 aly-miR827;aly-miR827-3p; +MIMAT0017609 aly-miR828;aly-miR828-5p; +MIMAT0017610 aly-miR828*;aly-miR828-3p; +MIMAT0017611 aly-miR829*;aly-miR829-5p; +MIMAT0017612 aly-miR829;aly-miR829-3p; +MIMAT0017613 aly-miR831*;aly-miR831-5p; +MIMAT0017614 aly-miR831;aly-miR831-3p; +MIMAT0017615 aly-miR833-5p; +MIMAT0017616 aly-miR833-3p; +MIMAT0017617 aly-miR834*;aly-miR834-5p; +MIMAT0017618 aly-miR834;aly-miR834-3p; +MIMAT0017619 aly-miR835-5p; +MIMAT0017620 aly-miR835-3p; +MIMAT0017621 aly-miR838*;aly-miR838-5p; +MIMAT0017622 aly-miR838;aly-miR838-3p; +MIMAT0017623 aly-miR839;aly-miR839-5p; +MIMAT0017624 aly-miR839*;aly-miR839-3p; +MIMAT0017625 aly-miR840;aly-miR840-5p; +MIMAT0017626 aly-miR840*;aly-miR840-3p; +MIMAT0017627 aly-miR842*;aly-miR842-5p; +MIMAT0017628 aly-miR842;aly-miR842-3p; +MIMAT0017629 aly-miR844;aly-miR844-5p; +MIMAT0017630 aly-miR844*;aly-miR844-3p; +MIMAT0017631 aly-miR845a*;aly-miR845a-5p; +MIMAT0017632 aly-miR845a;aly-miR845a-3p; +MIMAT0017633 aly-miR845b*;aly-miR845b-5p; +MIMAT0017634 aly-miR845b;aly-miR845b-3p; +MIMAT0017635 aly-miR846*;aly-miR846-5p; +MIMAT0017636 aly-miR846;aly-miR846-3p; +MIMAT0017637 aly-miR847*;aly-miR847-5p; +MIMAT0017638 aly-miR847;aly-miR847-3p; +MIMAT0017639 aly-miR852*;aly-miR852-5p; +MIMAT0017640 aly-miR852;aly-miR852-3p; +MIMAT0017641 aly-miR856;aly-miR856-5p; +MIMAT0017642 aly-miR856*;aly-miR856-3p; +MIMAT0017643 aly-miR857*;aly-miR857-5p; +MIMAT0017644 aly-miR857;aly-miR857-3p; +MIMAT0017645 aly-miR858;aly-miR858-5p; +MIMAT0017646 aly-miR858*;aly-miR858-3p; +MIMAT0017647 aly-miR859;aly-miR859-5p; +MIMAT0017648 aly-miR859*;aly-miR859-3p; +MIMAT0017649 aly-miR860*;aly-miR860-5p; +MIMAT0017650 aly-miR860;aly-miR860-3p; +MIMAT0017651 aly-miR861-5p; +MIMAT0017652 aly-miR861-3p; +MIMAT0017653 aly-miR862-5p; +MIMAT0017654 aly-miR862-3p; +MIMAT0017655 aly-miR868*;aly-miR868-5p; +MIMAT0017656 aly-miR868;aly-miR868-3p; +MIMAT0017657 aly-miR2111a;aly-miR2111a-5p; +MIMAT0017658 aly-miR2111a*;aly-miR2111a-3p; +MIMAT0017659 aly-miR2111b;aly-miR2111b-5p; +MIMAT0017660 aly-miR2111b*;aly-miR2111b-3p; +MIMAT0017661 aly-miR2112*;aly-miR2112-5p; +MIMAT0017662 aly-miR2112;aly-miR2112-3p; +MIMAT0017663 aly-miR319d*;aly-miR319d-5p; +MIMAT0017664 aly-miR319d;aly-miR319d-3p; +MIMAT0017665 aly-miR395g*;aly-miR395g-5p; +MIMAT0017666 aly-miR395g;aly-miR395g-3p; +MIMAT0017667 aly-miR395h*;aly-miR395h-5p; +MIMAT0017668 aly-miR395h;aly-miR395h-3p; +MIMAT0017669 aly-miR399g*;aly-miR399g-5p; +MIMAT0017670 aly-miR399g;aly-miR399g-3p; +MIMAT0017671 aly-miR399h*;aly-miR399h-5p; +MIMAT0017672 aly-miR399h;aly-miR399h-3p; +MIMAT0017673 aly-miR399i*;aly-miR399i-5p; +MIMAT0017674 aly-miR399i;aly-miR399i-3p; +MIMAT0017675 aly-miR158b*;aly-miR158b-5p; +MIMAT0017676 aly-miR158b;aly-miR158b-3p; +MIMAT0017677 aly-miR163.1*;aly-miR163-5p.1; +MIMAT0017678 aly-miR163.2*;aly-miR163-5p.2; +MIMAT0017679 aly-miR163.2;aly-miR163-3p.2; +MIMAT0017680 aly-miR163.1;aly-miR163-3p.1; +MIMAT0017681 aly-miR402;aly-miR402-5p; +MIMAT0017682 aly-miR402*;aly-miR402-3p; +MIMAT0017683 aly-miR773b;aly-miR773b-5p; +MIMAT0017684 aly-miR773b*;aly-miR773b-3p; +MIMAT0017685 aly-miR3433*;aly-miR3433-5p; +MIMAT0017686 aly-miR3433;aly-miR3433-3p; +MIMAT0017687 aly-miR837-5p; +MIMAT0017688 aly-miR837-3p; +MIMAT0017689 aly-miR848*;aly-miR848-5p; +MIMAT0017690 aly-miR848;aly-miR848-3p; +MIMAT0017691 aly-miR851*;aly-miR851-5p; +MIMAT0017692 aly-miR851;aly-miR851-3p; +MIMAT0017693 aly-miR853*;aly-miR853-5p; +MIMAT0017694 aly-miR853;aly-miR853-3p; +MIMAT0017695 aly-miR869*;aly-miR869-5p; +MIMAT0017696 aly-miR869;aly-miR869-3p; +MIMAT0017697 aly-miR3434*;aly-miR3434-5p; +MIMAT0017698 aly-miR3434;aly-miR3434-3p; +MIMAT0017699 aly-miR774b;aly-miR774b-5p; +MIMAT0017700 aly-miR774b*;aly-miR774b-3p; +MIMAT0017701 aly-miR3435*;aly-miR3435-5p; +MIMAT0017702 aly-miR3435;aly-miR3435-3p; +MIMAT0017703 aly-miR3436;aly-miR3436-5p; +MIMAT0017704 aly-miR3436*;aly-miR3436-3p; +MIMAT0017705 aly-miR3437;aly-miR3437-5p; +MIMAT0017706 aly-miR3437*;aly-miR3437-3p; +MIMAT0017707 aly-miR3438-3p; +MIMAT0017708 aly-miR3438-5p; +MIMAT0017709 aly-miR3439*;aly-miR3439-5p; +MIMAT0017710 aly-miR3439;aly-miR3439-3p; +MIMAT0017711 aly-miR3440*;aly-miR3440-5p; +MIMAT0017712 aly-miR3440;aly-miR3440-3p; +MIMAT0017713 aly-miR3441.2*;aly-miR3441-5p.2; +MIMAT0017714 aly-miR3441.1;aly-miR3441-5p.1; +MIMAT0017715 aly-miR3441.1*;aly-miR3441-3p.1; +MIMAT0017716 aly-miR3441.2;aly-miR3441-3p.2; +MIMAT0017717 aly-miR3442*;aly-miR3442-5p; +MIMAT0017718 aly-miR3442;aly-miR3442-3p; +MIMAT0017719 aly-miR3443;aly-miR3443-5p; +MIMAT0017720 aly-miR3443*;aly-miR3443-3p; +MIMAT0017721 aly-miR3444;aly-miR3444a-5p; +MIMAT0017722 aly-miR3444*;aly-miR3444a-3p; +MIMAT0017723 aly-miR3445.2*;aly-miR3445-5p.2; +MIMAT0017724 aly-miR3445.1*;aly-miR3445-5p.1; +MIMAT0017725 aly-miR3445.1;aly-miR3445-3p.1; +MIMAT0017726 aly-miR3445.2;aly-miR3445-3p.2; +MIMAT0017727 aly-miR3446;aly-miR3446-5p; +MIMAT0017728 aly-miR3446*;aly-miR3446-3p; +MIMAT0017729 aly-miR3447*;aly-miR3447-5p; +MIMAT0017730 aly-miR3447;aly-miR3447-3p; +MIMAT0017731 aly-miR3448*;aly-miR3448-5p; +MIMAT0017732 aly-miR3448;aly-miR3448-3p; +MIMAT0017733 aly-miR3449;aly-miR3449-5p; +MIMAT0017734 aly-miR3449*;aly-miR3449-3p; +MIMAT0017735 ath-miR773b*;ath-miR773b-5p; +MIMAT0017736 ath-miR773b;ath-miR773b-3p; +MIMAT0017737 ath-miR3434;ath-miR3434-5p; +MIMAT0017738 ath-miR3434*;ath-miR3434-3p; +MIMAT0017739 ath-miR774b;ath-miR774b-5p; +MIMAT0017740 ath-miR774b*;ath-miR774b-3p; +MIMAT0017741 ath-miR841b;ath-miR841b-5p; +MIMAT0017742 ath-miR841b*;ath-miR841b-3p; +MIMAT0017743 esi-miR3464;esi-miR3464-5p; +MIMAT0017744 esi-miR3464*;esi-miR3464-3p; +MIMAT0017745 esi-miR3454g*;esi-miR3454g-5p; +MIMAT0017746 esi-miR3454g;esi-miR3454g-3p; +MIMAT0017747 esi-miR3454a;esi-miR3454a-5p; +MIMAT0017748 esi-miR3454a*;esi-miR3454a-3p; +MIMAT0017749 esi-miR3466;esi-miR3466-5p; +MIMAT0017750 esi-miR3466*;esi-miR3466-3p; +MIMAT0017751 esi-miR3454c;esi-miR3454c-5p; +MIMAT0017752 esi-miR3454c*;esi-miR3454c-3p; +MIMAT0017753 esi-miR3454f;esi-miR3454f-5p; +MIMAT0017754 esi-miR3454f*;esi-miR3454f-3p; +MIMAT0017755 esi-miR3455*;esi-miR3455-5p; +MIMAT0017756 esi-miR3455;esi-miR3455-3p; +MIMAT0017757 esi-miR3450;esi-miR3450-5p; +MIMAT0017758 esi-miR3450*;esi-miR3450-3p; +MIMAT0017759 esi-miR3454b;esi-miR3454b-5p; +MIMAT0017760 esi-miR3454b*;esi-miR3454b-3p; +MIMAT0017761 esi-miR3460*;esi-miR3460-5p; +MIMAT0017762 esi-miR3460;esi-miR3460-3p; +MIMAT0017763 esi-miR3469;esi-miR3469-5p; +MIMAT0017764 esi-miR3469*;esi-miR3469-3p; +MIMAT0017765 esi-miR3461;esi-miR3461-5p; +MIMAT0017766 esi-miR3461*;esi-miR3461-3p; +MIMAT0017767 esi-miR3463;esi-miR3463-5p; +MIMAT0017768 esi-miR3463*;esi-miR3463-3p; +MIMAT0017769 esi-miR3454e;esi-miR3454e-5p; +MIMAT0017770 esi-miR3454e*;esi-miR3454e-3p; +MIMAT0017771 esi-miR3457*;esi-miR3457-5p; +MIMAT0017772 esi-miR3457;esi-miR3457-3p; +MIMAT0017773 esi-miR3467*;esi-miR3467-5p; +MIMAT0017774 esi-miR3467;esi-miR3467-3p; +MIMAT0017775 esi-miR3459*;esi-miR3459-5p; +MIMAT0017776 esi-miR3459;esi-miR3459-3p; +MIMAT0017777 esi-miR3462;esi-miR3462-5p; +MIMAT0017778 esi-miR3462*;esi-miR3462-3p; +MIMAT0017779 esi-miR3453;esi-miR3453-5p; +MIMAT0017780 esi-miR3453*;esi-miR3453-3p; +MIMAT0017781 esi-miR3451*;esi-miR3451-5p; +MIMAT0017782 esi-miR3451;esi-miR3451-3p; +MIMAT0017783 esi-miR3454d;esi-miR3454d-5p; +MIMAT0017784 esi-miR3454d*;esi-miR3454d-3p; +MIMAT0017785 esi-miR3456;esi-miR3456-5p; +MIMAT0017786 esi-miR3456*;esi-miR3456-3p; +MIMAT0017787 esi-miR3452;esi-miR3452-5p; +MIMAT0017788 esi-miR3452*;esi-miR3452-3p; +MIMAT0017789 esi-miR3468*;esi-miR3468-5p; +MIMAT0017790 esi-miR3468;esi-miR3468-3p; +MIMAT0017791 esi-miR3465*;esi-miR3465-5p; +MIMAT0017792 esi-miR3465;esi-miR3465-3p; +MIMAT0017793 esi-miR3458*;esi-miR3458-5p; +MIMAT0017794 esi-miR3458;esi-miR3458-3p; +MIMAT0017795 rno-miR-3541; +MIMAT0017796 rno-miR-3542; +MIMAT0017797 rno-miR-3543; +MIMAT0017798 rno-miR-3544; +MIMAT0017799 rno-miR-3545-5p;rno-miR-203b-5p; +MIMAT0017800 rno-miR-3545-3p;rno-miR-203b-3p; +MIMAT0017801 rno-miR-3546; +MIMAT0017802 rno-miR-3547; +MIMAT0017803 rno-miR-449c-5p; +MIMAT0017804 rno-miR-449c-3p; +MIMAT0017805 rno-miR-3085; +MIMAT0017806 rno-miR-3548; +MIMAT0017807 rno-miR-3549; +MIMAT0017808 rno-miR-3550; +MIMAT0017809 rno-miR-3551-5p; +MIMAT0017810 rno-miR-3551-3p; +MIMAT0017811 rno-miR-344b-5p; +MIMAT0017812 rno-miR-344b-2-3p;rno-miR-344b-3p; +MIMAT0017813 rno-miR-3552; +MIMAT0017814 rno-miR-3553; +MIMAT0017815 rno-miR-3074; +MIMAT0017816 rno-miR-3554;rno-miR-31b; +MIMAT0017817 rno-miR-3555;rno-miR-191b; +MIMAT0017818 rno-miR-3556b; +MIMAT0017819 rno-miR-3557-5p; +MIMAT0017820 rno-miR-3557-3p; +MIMAT0017821 rno-miR-3556a; +MIMAT0017822 rno-miR-291b; +MIMAT0017823 rno-miR-3596d; +MIMAT0017824 rno-miR-466d; +MIMAT0017825 rno-miR-3558-5p; +MIMAT0017826 rno-miR-3558-3p; +MIMAT0017827 rno-miR-3559-5p; +MIMAT0017828 rno-miR-3559-3p; +MIMAT0017829 rno-miR-3560; +MIMAT0017830 rno-miR-3561-5p; +MIMAT0017831 rno-miR-3561-3p; +MIMAT0017832 rno-miR-3562; +MIMAT0017833 rno-miR-3563-5p;rno-miR-299b-5p; +MIMAT0017834 rno-miR-3563-3p;rno-miR-299b-3p; +MIMAT0017835 rno-miR-3597-5p;rno-miR-9b-5p; +MIMAT0017836 rno-miR-3597-3p;rno-miR-9b-3p; +MIMAT0017837 rno-miR-3564; +MIMAT0017838 rno-miR-3565;rno-miR-218b; +MIMAT0017839 rno-miR-3065-5p; +MIMAT0017840 rno-miR-3065-3p; +MIMAT0017841 rno-miR-3566; +MIMAT0017842 rno-miR-344a; +MIMAT0017843 rno-miR-3567;rno-miR-126b; +MIMAT0017844 rno-miR-208b-5p; +MIMAT0017845 rno-miR-208b-3p; +MIMAT0017846 rno-miR-216b-5p; +MIMAT0017847 rno-miR-216b-3p; +MIMAT0017848 rno-miR-3568; +MIMAT0017849 rno-miR-3569; +MIMAT0017850 rno-miR-3570; +MIMAT0017851 rno-miR-3571; +MIMAT0017852 rno-miR-1949; +MIMAT0017853 rno-miR-3572; +MIMAT0017854 rno-miR-1188-5p; +MIMAT0017855 rno-miR-1188-3p; +MIMAT0017856 rno-miR-3573-5p; +MIMAT0017857 rno-miR-3573-3p; +MIMAT0017858 rno-miR-1193-5p; +MIMAT0017859 rno-miR-1193-3p; +MIMAT0017860 rno-miR-3574; +MIMAT0017861 rno-miR-3575; +MIMAT0017862 rno-miR-3576; +MIMAT0017863 rno-miR-3577; +MIMAT0017864 rno-miR-1912-5p; +MIMAT0017865 rno-miR-1912-3p; +MIMAT0017866 rno-miR-3578; +MIMAT0017867 rno-miR-3579; +MIMAT0017868 rno-miR-3580-5p; +MIMAT0017869 rno-miR-3580-3p; +MIMAT0017870 rno-miR-3581;rno-miR-409b; +MIMAT0017871 rno-miR-3596b; +MIMAT0017872 rno-miR-3582;rno-miR-133c; +MIMAT0017873 rno-miR-3583-5p; +MIMAT0017874 rno-miR-3583-3p; +MIMAT0017875 rno-miR-3584-5p; +MIMAT0017876 rno-miR-3584-3p; +MIMAT0017877 rno-miR-3596c; +MIMAT0017878 rno-miR-3585-5p; +MIMAT0017879 rno-miR-3585-3p; +MIMAT0017880 rno-miR-3586-5p; +MIMAT0017881 rno-miR-3586-3p; +MIMAT0017882 rno-miR-2964;rno-miR-219b; +MIMAT0017883 rno-miR-3587; +MIMAT0017884 rno-miR-702-5p; +MIMAT0017885 rno-miR-702-3p; +MIMAT0017886 rno-miR-3596a; +MIMAT0017887 rno-miR-3588; +MIMAT0017888 rno-miR-3589; +MIMAT0017889 rno-miR-3590-5p; +MIMAT0017890 rno-miR-3590-3p; +MIMAT0017891 rno-miR-2985; +MIMAT0017892 rno-miR-1249; +MIMAT0017893 rno-miR-3591;rno-miR-122b; +MIMAT0017894 rno-miR-344b-1-3p; +MIMAT0017895 rno-miR-3592; +MIMAT0017896 rno-miR-3593-5p; +MIMAT0017897 rno-miR-3593-3p; +MIMAT0017898 rno-miR-3594-5p; +MIMAT0017899 rno-miR-3594-3p; +MIMAT0017900 rno-miR-3120; +MIMAT0017901 rno-miR-741-5p; +MIMAT0017902 rno-miR-741-3p; +MIMAT0017903 rno-miR-3595; +MIMAT0017904 rno-miR-328b-3p; +MIMAT0017905 aly-miR395i; +MIMAT0017906 aly-miR399j; +MIMAT0017907 aly-miR841; +MIMAT0017908 aly-miR1887; +MIMAT0017909 aly-miR4221; +MIMAT0017910 aly-miR4222; +MIMAT0017911 aly-miR4223; +MIMAT0017912 aly-miR4224; +MIMAT0017913 aly-miR4225; +MIMAT0017914 aly-miR4226; +MIMAT0017915 aly-miR4227; +MIMAT0017916 aly-miR4228; +MIMAT0017917 aly-miR4229; +MIMAT0017918 aly-miR4230; +MIMAT0017919 aly-miR4231; +MIMAT0017920 aly-miR3444b; +MIMAT0017921 aly-miR4232; +MIMAT0017922 aly-miR4233; +MIMAT0017923 aly-miR4234; +MIMAT0017924 aly-miR4235; +MIMAT0017925 aly-miR4236; +MIMAT0017926 aly-miR4237; +MIMAT0017927 aly-miR4238; +MIMAT0017928 aly-miR4239; +MIMAT0017929 aly-miR4240; +MIMAT0017930 aly-miR4241; +MIMAT0017931 aly-miR4242; +MIMAT0017932 aly-miR4243; +MIMAT0017933 aly-miR4244; +MIMAT0017934 aly-miR4245; +MIMAT0017935 aly-miR4246; +MIMAT0017936 aly-miR4247; +MIMAT0017937 aly-miR4248a; +MIMAT0017938 aly-miR4248b; +MIMAT0017939 aly-miR4248c; +MIMAT0017940 aly-miR4249; +MIMAT0017941 aly-miR4250; +MIMAT0017942 ath-miR4221; +MIMAT0017943 ath-miR4227; +MIMAT0017944 ath-miR4228;ath-miR4228-5p; +MIMAT0017945 ath-miR3440b-5p; +MIMAT0017946 ath-miR3440b-3p; +MIMAT0017947 ath-miR4239; +MIMAT0017948 ath-miR4240; +MIMAT0017949 ath-miR4243; +MIMAT0017950 hsa-miR-2355-3p; +MIMAT0017951 ssc-miR-194;ssc-miR-194-3p;ssc-miR-194b-3p; +MIMAT0017952 ssc-miR-296;ssc-miR-296-5p; +MIMAT0017953 ssc-miR-155;ssc-miR-155-3p; +MIMAT0017954 ssc-miR-411; +MIMAT0017955 ssc-miR-4331;ssc-miR-4331-3p; +MIMAT0017956 ssc-miR-382; +MIMAT0017957 ssc-miR-381;ssc-miR-381-5p; +MIMAT0017958 ssc-miR-362; +MIMAT0017959 ssc-miR-490;ssc-miR-490-5p; +MIMAT0017960 ssc-miR-376c; +MIMAT0017961 ssc-miR-376b; +MIMAT0017962 ssc-miR-4332; +MIMAT0017963 ssc-miR-4333; +MIMAT0017964 ssc-miR-652; +MIMAT0017965 ssc-miR-1224; +MIMAT0017966 ssc-miR-4334;ssc-miR-4334-5p; +MIMAT0017967 ssc-miR-1271;ssc-miR-1271-3p; +MIMAT0017968 ssc-miR-4335; +MIMAT0017969 ssc-miR-218;ssc-miR-218-3p; +MIMAT0017970 ssc-miR-421;ssc-miR-421-5p; +MIMAT0017971 ssc-miR-146a;ssc-miR-146a-3p; +MIMAT0017972 ssc-miR-383; +MIMAT0017973 ssc-miR-487b; +MIMAT0017974 ssc-miR-484; +MIMAT0017975 ssc-miR-4336; +MIMAT0017976 ssc-miR-1296;ssc-miR-1296-3p; +MIMAT0017977 ssc-miR-4337; +MIMAT0017978 ssc-miR-4338; +MIMAT0017979 ssc-miR-494; +MIMAT0017980 ssc-miR-4339; +MIMAT0017981 hsa-miR-3605-5p; +MIMAT0017982 hsa-miR-3605-3p; +MIMAT0017983 hsa-miR-3606;hsa-miR-3606-5p; +MIMAT0017984 hsa-miR-3607-5p; +MIMAT0017985 hsa-miR-3607-3p; +MIMAT0017986 hsa-miR-3609; +MIMAT0017987 hsa-miR-3610; +MIMAT0017988 hsa-miR-3611; +MIMAT0017989 hsa-miR-3612; +MIMAT0017990 hsa-miR-3613-5p; +MIMAT0017991 hsa-miR-3613-3p; +MIMAT0017992 hsa-miR-3614-5p; +MIMAT0017993 hsa-miR-3614-3p; +MIMAT0017994 hsa-miR-3615; +MIMAT0017995 hsa-miR-3616-5p; +MIMAT0017996 hsa-miR-3616-3p; +MIMAT0017997 hsa-miR-3617;hsa-miR-3617-5p; +MIMAT0017998 hsa-miR-3618; +MIMAT0017999 hsa-miR-3619;hsa-miR-3619-5p; +MIMAT0018000 hsa-miR-23c; +MIMAT0018001 hsa-miR-3620;hsa-miR-3620-3p; +MIMAT0018002 hsa-miR-3621; +MIMAT0018003 hsa-miR-3622a-5p; +MIMAT0018004 hsa-miR-3622a-3p; +MIMAT0018005 hsa-miR-3622b-5p; +MIMAT0018006 hsa-miR-3622b-3p; +MIMAT0018007 vvi-miR3623*;vvi-miR3623-5p; +MIMAT0018008 vvi-miR3623;vvi-miR3623-3p; +MIMAT0018009 vvi-miR2950;vvi-miR2950-5p; +MIMAT0018010 vvi-miR2950*;vvi-miR2950-3p; +MIMAT0018011 vvi-miR3624*;vvi-miR3624-5p; +MIMAT0018012 vvi-miR3624;vvi-miR3624-3p; +MIMAT0018013 vvi-miR3625*;vvi-miR3625-5p; +MIMAT0018014 vvi-miR3625;vvi-miR3625-3p; +MIMAT0018015 vvi-miR3626;vvi-miR3626-5p; +MIMAT0018016 vvi-miR3626*;vvi-miR3626-3p; +MIMAT0018017 vvi-miR3627;vvi-miR3627-5p; +MIMAT0018018 vvi-miR3627*;vvi-miR3627-3p; +MIMAT0018019 vvi-miR3628*;vvi-miR3628-5p; +MIMAT0018020 vvi-miR3628;vvi-miR3628-3p; +MIMAT0018021 vvi-miR3629a*;vvi-miR3629a-5p; +MIMAT0018022 vvi-miR3629a;vvi-miR3629a-3p; +MIMAT0018023 vvi-miR3629b; +MIMAT0018024 vvi-miR3629c; +MIMAT0018025 vvi-miR447b;vvi-miR447b-5p;vvi-miR477b-5p; +MIMAT0018026 vvi-miR447b*;vvi-miR447b-3p;vvi-miR477b-3p; +MIMAT0018027 vvi-miR3630;vvi-miR3630-5p; +MIMAT0018028 vvi-miR3630*;vvi-miR3630-3p; +MIMAT0018029 vvi-miR3631a;vvi-miR3631a-5p; +MIMAT0018030 vvi-miR3631a*;vvi-miR3631a-3p; +MIMAT0018031 vvi-miR3631b;vvi-miR3631b-5p; +MIMAT0018032 vvi-miR3631b*;vvi-miR3631b-3p; +MIMAT0018033 vvi-miR3631c; +MIMAT0018034 vvi-miR3631d; +MIMAT0018035 vvi-miR3632*;vvi-miR3632-5p; +MIMAT0018036 vvi-miR3632;vvi-miR3632-3p; +MIMAT0018037 vvi-miR3633a;vvi-miR3633a-5p; +MIMAT0018038 vvi-miR3633a*;vvi-miR3633a-3p; +MIMAT0018039 vvi-miR3634*;vvi-miR3634-5p; +MIMAT0018040 vvi-miR3634;vvi-miR3634-3p; +MIMAT0018041 vvi-miR3633b;vvi-miR3633b-5p; +MIMAT0018042 vvi-miR3633b*;vvi-miR3633b-3p; +MIMAT0018043 vvi-miR3635;vvi-miR3635-5p; +MIMAT0018044 vvi-miR3635*;vvi-miR3635-3p; +MIMAT0018045 vvi-miR3636*;vvi-miR3636-5p; +MIMAT0018046 vvi-miR3636;vvi-miR3636-3p; +MIMAT0018047 vvi-miR3637*;vvi-miR3637-5p; +MIMAT0018048 vvi-miR3637;vvi-miR3637-3p; +MIMAT0018049 vvi-miR3638*;vvi-miR3638-5p; +MIMAT0018050 vvi-miR3638;vvi-miR3638-3p; +MIMAT0018051 vvi-miR3639;vvi-miR3639-5p; +MIMAT0018052 vvi-miR3639*;vvi-miR3639-3p; +MIMAT0018053 vvi-miR3640*;vvi-miR3640-5p; +MIMAT0018054 vvi-miR3640;vvi-miR3640-3p; +MIMAT0018055 dme-miR-3641*;dme-miR-3641-5p; +MIMAT0018056 dme-miR-3641;dme-miR-3641-3p; +MIMAT0018057 dme-miR-3642*;dme-miR-3642-5p; +MIMAT0018058 dme-miR-3642;dme-miR-3642-3p; +MIMAT0018059 dme-miR-3643*;dme-miR-3643-5p; +MIMAT0018060 dme-miR-3643;dme-miR-3643-3p; +MIMAT0018061 dme-miR-3644;dme-miR-3644-5p; +MIMAT0018062 dme-miR-3644*;dme-miR-3644-3p; +MIMAT0018063 dme-miR-3645*;dme-miR-3645-5p; +MIMAT0018064 dme-miR-3645;dme-miR-3645-3p; +MIMAT0018065 hsa-miR-3646; +MIMAT0018066 hsa-miR-3647-5p; +MIMAT0018067 hsa-miR-3647-3p; +MIMAT0018068 hsa-miR-3648; +MIMAT0018069 hsa-miR-3649; +MIMAT0018070 hsa-miR-3650; +MIMAT0018071 hsa-miR-3651; +MIMAT0018072 hsa-miR-3652; +MIMAT0018073 hsa-miR-3653;hsa-miR-3653-3p; +MIMAT0018074 hsa-miR-3654; +MIMAT0018075 hsa-miR-3655; +MIMAT0018076 hsa-miR-3656; +MIMAT0018077 hsa-miR-3657; +MIMAT0018078 hsa-miR-3658; +MIMAT0018079 hsa-miR-1273e; +MIMAT0018080 hsa-miR-3659; +MIMAT0018081 hsa-miR-3660; +MIMAT0018082 hsa-miR-3661; +MIMAT0018083 hsa-miR-3662; +MIMAT0018084 hsa-miR-3663-5p; +MIMAT0018085 hsa-miR-3663-3p; +MIMAT0018086 hsa-miR-3664;hsa-miR-3664-5p; +MIMAT0018087 hsa-miR-3665; +MIMAT0018088 hsa-miR-3666; +MIMAT0018089 hsa-miR-3667-5p; +MIMAT0018090 hsa-miR-3667-3p; +MIMAT0018091 hsa-miR-3668; +MIMAT0018092 hsa-miR-3669; +MIMAT0018093 hsa-miR-3670; +MIMAT0018094 hsa-miR-3671; +MIMAT0018095 hsa-miR-3672; +MIMAT0018096 hsa-miR-3673; +MIMAT0018097 hsa-miR-3674; +MIMAT0018098 hsa-miR-3675-5p; +MIMAT0018099 hsa-miR-3675-3p; +MIMAT0018100 hsa-miR-3676;hsa-miR-3676-3p; +MIMAT0018101 hsa-miR-3677;hsa-miR-3677-3p; +MIMAT0018102 hsa-miR-3678-5p; +MIMAT0018103 hsa-miR-3678-3p; +MIMAT0018104 hsa-miR-3679-5p; +MIMAT0018105 hsa-miR-3679-3p; +MIMAT0018106 hsa-miR-3680;hsa-miR-3680-5p; +MIMAT0018107 hsa-miR-3680*;hsa-miR-3680-3p; +MIMAT0018108 hsa-miR-3681;hsa-miR-3681-5p; +MIMAT0018109 hsa-miR-3681*;hsa-miR-3681-3p; +MIMAT0018110 hsa-miR-3682;hsa-miR-3682-3p; +MIMAT0018111 hsa-miR-3683; +MIMAT0018112 hsa-miR-3684; +MIMAT0018113 hsa-miR-3685; +MIMAT0018114 hsa-miR-3686; +MIMAT0018115 hsa-miR-3687; +MIMAT0018116 hsa-miR-3688;hsa-miR-3688-3p; +MIMAT0018117 hsa-miR-3689a-5p; +MIMAT0018118 hsa-miR-3689a-3p; +MIMAT0018119 hsa-miR-3690; +MIMAT0018120 hsa-miR-3691;hsa-miR-3691-5p; +MIMAT0018121 hsa-miR-3692*;hsa-miR-3692-5p; +MIMAT0018122 hsa-miR-3692;hsa-miR-3692-3p; +MIMAT0018123 pab-miR950-5p;pab-miR950a-5p; +MIMAT0018124 pab-miR950-3p;pab-miR950a-3p; +MIMAT0018125 pab-miR3693; +MIMAT0018126 pab-miR3694; +MIMAT0018127 pab-miR3695;pab-miR3695d-5p; +MIMAT0018128 pab-miR3696; +MIMAT0018129 pab-miR3697;pab-miR3697b; +MIMAT0018130 pab-miR3698; +MIMAT0018131 pab-miR3699; +MIMAT0018132 pab-miR3700; +MIMAT0018133 pab-miR3701;pab-miR3701b-3p; +MIMAT0018134 pab-miR3702; +MIMAT0018135 pab-miR3703; +MIMAT0018136 pab-miR3704; +MIMAT0018137 pab-miR3705; +MIMAT0018138 pab-miR3706; +MIMAT0018139 pab-miR3707; +MIMAT0018140 pab-miR3708; +MIMAT0018141 pab-miR3709a; +MIMAT0018142 pab-miR3709b; +MIMAT0018143 pab-miR3710; +MIMAT0018144 pab-miR3711; +MIMAT0018145 pab-miR3712; +MIMAT0018146 pab-miR160a; +MIMAT0018147 pab-miR160b; +MIMAT0018148 pab-miR166a; +MIMAT0018149 pab-miR166b; +MIMAT0018150 pab-miR482d;pab-miR482d-5p; +MIMAT0018151 pab-miR395; +MIMAT0018152 pab-miR396a;pab-miR396a-5p; +MIMAT0018153 pab-miR396b; +MIMAT0018154 pab-miR396c; +MIMAT0018155 pab-miR397;pab-miR397b; +MIMAT0018156 pab-miR482a; +MIMAT0018157 pab-miR482b; +MIMAT0018158 pab-miR482c; +MIMAT0018159 pab-miR535;pab-miR535e; +MIMAT0018160 pab-miR947; +MIMAT0018161 pab-miR951; +MIMAT0018162 pab-miR1311;pab-miR1311a-3p; +MIMAT0018163 pab-miR1863; +MIMAT0018164 hsa-miR-3713; +MIMAT0018165 hsa-miR-3714; +MIMAT0018166 mghv-miR-M1-10*;mghv-miR-M1-10-5p; +MIMAT0018167 mghv-miR-M1-10;mghv-miR-M1-10-3p; +MIMAT0018168 mghv-miR-M1-11-5p; +MIMAT0018169 mghv-miR-M1-11-3p; +MIMAT0018170 mghv-miR-M1-12*;mghv-miR-M1-12-5p; +MIMAT0018171 mghv-miR-M1-12;mghv-miR-M1-12-3p; +MIMAT0018172 mghv-miR-M1-13*;mghv-miR-M1-13-5p; +MIMAT0018173 mghv-miR-M1-13;mghv-miR-M1-13-3p; +MIMAT0018174 mghv-miR-M1-14*;mghv-miR-M1-14-5p; +MIMAT0018175 mghv-miR-M1-14;mghv-miR-M1-14-3p; +MIMAT0018176 mghv-miR-M1-15; +MIMAT0018177 dre-miR-3906; +MIMAT0018178 hsa-miR-3180; +MIMAT0018179 hsa-miR-3907; +MIMAT0018180 hsa-miR-3689b;hsa-miR-3689b-5p; +MIMAT0018181 hsa-miR-3689b*;hsa-miR-3689b-3p; +MIMAT0018182 hsa-miR-3908; +MIMAT0018183 hsa-miR-3909; +MIMAT0018184 hsa-miR-3910; +MIMAT0018185 hsa-miR-3911; +MIMAT0018186 hsa-miR-3912;hsa-miR-3912-3p; +MIMAT0018187 hsa-miR-3913;hsa-miR-3913-5p; +MIMAT0018188 hsa-miR-3914; +MIMAT0018189 hsa-miR-3915; +MIMAT0018190 hsa-miR-3916; +MIMAT0018191 hsa-miR-3917; +MIMAT0018192 hsa-miR-3918; +MIMAT0018193 hsa-miR-3919; +MIMAT0018194 hsa-miR-3150b;hsa-miR-3150b-3p; +MIMAT0018195 hsa-miR-3920; +MIMAT0018196 hsa-miR-3921; +MIMAT0018197 hsa-miR-3922;hsa-miR-3922-3p; +MIMAT0018198 hsa-miR-3923; +MIMAT0018199 hsa-miR-3924; +MIMAT0018200 hsa-miR-3925;hsa-miR-3925-5p; +MIMAT0018201 hsa-miR-3926; +MIMAT0018202 hsa-miR-3927;hsa-miR-3927-3p; +MIMAT0018203 hsa-miR-676*;hsa-miR-676-5p; +MIMAT0018204 hsa-miR-676;hsa-miR-676-3p; +MIMAT0018205 hsa-miR-3928;hsa-miR-3928-3p; +MIMAT0018206 hsa-miR-3929; +MIMAT0018207 hvu-miR156;hvu-miR156a; +MIMAT0018208 tae-miR156; +MIMAT0018209 hvu-miR159b; +MIMAT0018210 hvu-miR159a; +MIMAT0018211 tae-miR319; +MIMAT0018212 ttu-miR160; +MIMAT0018213 hvu-miR166;hvu-miR166a; +MIMAT0018214 tae-miR167b; +MIMAT0018215 hvu-miR168-5p; +MIMAT0018216 hvu-miR168-3p; +MIMAT0018217 ata-miR169; +MIMAT0018218 hvu-miR169; +MIMAT0018219 tae-miR1433;tae-miR169; +MIMAT0018220 hvu-miR171;hvu-miR171-3p; +MIMAT0018221 ata-miR172; +MIMAT0018222 tae-miR395a; +MIMAT0018223 tae-miR395b; +MIMAT0018224 hvu-miR397;hvu-miR397a; +MIMAT0018225 tae-miR398; +MIMAT0018226 tae-miR444b; +MIMAT0018227 tae-miR171b; +MIMAT0018228 gma-miR4340; +MIMAT0018229 gma-miR4341; +MIMAT0018230 gma-miR4342; +MIMAT0018231 gma-miR4343a; +MIMAT0018232 gma-miR4344; +MIMAT0018233 gma-miR4345; +MIMAT0018234 gma-miR4364b; +MIMAT0018235 gma-miR4346; +MIMAT0018236 gma-miR4347; +MIMAT0018237 gma-miR4348;gma-miR4348a;gma-miR4348a-5p; +MIMAT0018238 gma-miR4349;gma-miR4349-5p; +MIMAT0018239 gma-miR4350; +MIMAT0018240 gma-miR4351; +MIMAT0018241 gma-miR4352a; +MIMAT0018242 gma-miR4353; +MIMAT0018243 gma-miR1520e; +MIMAT0018244 gma-miR1520f;gma-miR1520f-3p; +MIMAT0018245 gma-miR1520g; +MIMAT0018246 gma-miR4354; +MIMAT0018247 gma-miR4355; +MIMAT0018248 gma-miR4356; +MIMAT0018249 gma-miR4357; +MIMAT0018250 gma-miR4358; +MIMAT0018251 gma-miR4359a; +MIMAT0018252 gma-miR4360; +MIMAT0018253 gma-miR4359b; +MIMAT0018254 gma-miR4387c; +MIMAT0018255 gma-miR1520h; +MIMAT0018256 gma-miR4361; +MIMAT0018257 gma-miR1520i; +MIMAT0018258 gma-miR4362; +MIMAT0018259 gma-miR4363; +MIMAT0018260 gma-miR4364a; +MIMAT0018261 gma-miR4380a; +MIMAT0018262 gma-miR396d; +MIMAT0018263 gma-miR1520j; +MIMAT0018264 gma-miR4365; +MIMAT0018265 gma-miR4366; +MIMAT0018266 gma-miR4367; +MIMAT0018267 gma-miR4368a; +MIMAT0018268 gma-miR4371c; +MIMAT0018269 gma-miR4368b; +MIMAT0018270 gma-miR4369; +MIMAT0018271 gma-miR4370; +MIMAT0018272 gma-miR4387b; +MIMAT0018273 gma-miR4371a; +MIMAT0018274 gma-miR4371b; +MIMAT0018275 gma-miR4372;gma-miR4372a; +MIMAT0018276 gma-miR4352b; +MIMAT0018277 gma-miR4373; +MIMAT0018278 gma-miR4374a; +MIMAT0018279 gma-miR4375; +MIMAT0018280 gma-miR4376;gma-miR4376-5p;gma-miR391-5p; +MIMAT0018281 gma-miR4377; +MIMAT0018282 gma-miR4374b; +MIMAT0018283 gma-miR4378a; +MIMAT0018284 gma-miR4378b; +MIMAT0018285 gma-miR4379; +MIMAT0018286 gma-miR482b;gma-miR482b-5p; +MIMAT0018287 gma-miR4380b; +MIMAT0018288 gma-miR4381; +MIMAT0018289 gma-miR4382; +MIMAT0018290 gma-miR4383; +MIMAT0018291 gma-miR1520k; +MIMAT0018292 gma-miR1520l; +MIMAT0018293 gma-miR1520m; +MIMAT0018294 gma-miR4384; +MIMAT0018295 gma-miR1520n; +MIMAT0018296 gma-miR1520o; +MIMAT0018297 gma-miR4385; +MIMAT0018298 gma-miR4386; +MIMAT0018299 gma-miR4387a; +MIMAT0018300 gma-miR4388; +MIMAT0018301 gma-miR4387d; +MIMAT0018302 gma-miR4389; +MIMAT0018303 gma-miR4390; +MIMAT0018304 gma-miR4391; +MIMAT0018305 gma-miR4392; +MIMAT0018306 gma-miR4343b; +MIMAT0018307 gma-miR167g; +MIMAT0018308 gma-miR4393a; +MIMAT0018309 gma-miR4394; +MIMAT0018310 gma-miR4395; +MIMAT0018311 gma-miR4396; +MIMAT0018312 gma-miR4397;gma-miR4397-3p; +MIMAT0018313 gma-miR1520r; +MIMAT0018314 gma-miR4398; +MIMAT0018315 gma-miR4399; +MIMAT0018316 gma-miR4400; +MIMAT0018317 gma-miR4393b; +MIMAT0018318 gma-miR156f; +MIMAT0018319 gma-miR4401;gma-miR4401a; +MIMAT0018320 gma-miR4402; +MIMAT0018321 gma-miR4403; +MIMAT0018322 gma-miR1520p; +MIMAT0018323 gma-miR4404; +MIMAT0018324 gma-miR4405; +MIMAT0018325 gma-miR4406; +MIMAT0018326 gma-miR4407; +MIMAT0018327 gma-miR4408; +MIMAT0018328 gma-miR4409; +MIMAT0018329 gma-miR4410; +MIMAT0018330 gma-miR169d; +MIMAT0018331 gma-miR4411; +MIMAT0018332 gma-miR1520q; +MIMAT0018333 gma-miR172f; +MIMAT0018334 gma-miR171c;gma-miR171c-5p; +MIMAT0018335 gma-miR169e; +MIMAT0018336 gma-miR394b;gma-miR394b-3p; +MIMAT0018337 gma-miR4412;gma-miR4412-3p; +MIMAT0018338 gma-miR4413;gma-miR4413a; +MIMAT0018339 gma-miR156g; +MIMAT0018340 gma-miR159d; +MIMAT0018341 gma-miR394a;gma-miR394a-3p; +MIMAT0018342 gma-miR4414;gma-miR4414-5p;gma-miR4414a-5p; +MIMAT0018343 gma-miR4415;gma-miR4415a-5p; +MIMAT0018344 gma-miR4416;gma-miR4416a; +MIMAT0018345 gma-miR396e; +MIMAT0018346 ath-miR3932a; +MIMAT0018347 ath-miR3932b;ath-miR3932b-3p; +MIMAT0018348 ath-miR3933; +MIMAT0018349 hsa-miR-3934;hsa-miR-3934-5p; +MIMAT0018350 hsa-miR-3935; +MIMAT0018351 hsa-miR-3936; +MIMAT0018352 hsa-miR-3937; +MIMAT0018353 hsa-miR-3938; +MIMAT0018354 hsa-miR-548y; +MIMAT0018355 hsa-miR-3939; +MIMAT0018356 hsa-miR-3940;hsa-miR-3940-3p; +MIMAT0018357 hsa-miR-3941; +MIMAT0018358 hsa-miR-3942;hsa-miR-3942-5p; +MIMAT0018359 hsa-miR-3943; +MIMAT0018360 hsa-miR-3944;hsa-miR-3944-3p; +MIMAT0018361 hsa-miR-3945; +MIMAT0018362 far-miR159; +MIMAT0018363 far-miR160; +MIMAT0018364 far-miR171; +MIMAT0018365 far-miR1119; +MIMAT0018366 far-miR1122; +MIMAT0018367 far-miR1134; +MIMAT0018368 far-miR156a; +MIMAT0018369 far-miR396; +MIMAT0018370 far-miR164a; +MIMAT0018371 far-miR169; +MIMAT0018372 far-miR437; +MIMAT0018373 far-miR529; +MIMAT0018374 far-miR156b; +MIMAT0018375 far-miR166; +MIMAT0018376 far-miR164b; +MIMAT0018377 ssc-miR-126*;ssc-miR-126-5p; +MIMAT0018378 ssc-miR-126;ssc-miR-126-3p; +MIMAT0018379 ssc-miR-149; +MIMAT0018380 ssc-miR-199a; +MIMAT0018381 ssc-miR-199a*; +MIMAT0018382 ssc-miR-451; +MIMAT0018383 ngi-miR-iab-4as;ngi-miR-iab-8; +MIMAT0018384 ngi-miR-375; +MIMAT0018385 ngi-miR-1; +MIMAT0018386 ngi-miR-275; +MIMAT0018387 ngi-miR-31a; +MIMAT0018388 ngi-miR-281; +MIMAT0018389 ngi-miR-14; +MIMAT0018390 ngi-miR-34; +MIMAT0018391 ngi-miR-219; +MIMAT0018392 ngi-miR-283; +MIMAT0018393 ngi-miR-2; +MIMAT0018394 ngi-miR-927; +MIMAT0018395 ngi-miR-263b; +MIMAT0018396 ngi-miR-13a; +MIMAT0018397 ngi-miR-137; +MIMAT0018398 ngi-miR-184; +MIMAT0018399 ngi-miR-210; +MIMAT0018400 ngi-miR-277; +MIMAT0018401 ngi-miR-29b; +MIMAT0018402 ngi-miR-100; +MIMAT0018403 ngi-miR-305; +MIMAT0018404 ngi-miR-932; +MIMAT0018405 ngi-miR-9a; +MIMAT0018406 ngi-miR-276; +MIMAT0018407 ngi-miR-92a; +MIMAT0018408 ngi-miR-317; +MIMAT0018409 ngi-miR-993; +MIMAT0018410 ngi-miR-252; +MIMAT0018411 ngi-miR-iab-4; +MIMAT0018412 ngi-miR-133; +MIMAT0018413 ngi-let-7; +MIMAT0018414 ngi-miR-929; +MIMAT0018415 nlo-miR-281; +MIMAT0018416 nlo-miR-10; +MIMAT0018417 nlo-miR-929; +MIMAT0018418 nlo-miR-282; +MIMAT0018419 nlo-miR-263b; +MIMAT0018420 nlo-miR-12; +MIMAT0018421 nlo-miR-125; +MIMAT0018422 nlo-miR-133; +MIMAT0018423 nlo-miR-137; +MIMAT0018424 nlo-miR-13a; +MIMAT0018425 nlo-miR-184; +MIMAT0018426 nlo-miR-219; +MIMAT0018427 nlo-miR-2; +MIMAT0018428 nlo-miR-252; +MIMAT0018429 nlo-miR-275; +MIMAT0018430 nlo-miR-276; +MIMAT0018431 nlo-miR-277; +MIMAT0018432 nlo-miR-305; +MIMAT0018433 nlo-miR-315; +MIMAT0018434 nlo-miR-31a; +MIMAT0018435 nlo-miR-34; +MIMAT0018436 nlo-miR-7; +MIMAT0018437 nlo-miR-8; +MIMAT0018438 nlo-miR-927; +MIMAT0018439 nlo-miR-92a; +MIMAT0018440 nlo-miR-932; +MIMAT0018441 nlo-miR-993; +MIMAT0018442 nlo-miR-9a; +MIMAT0018443 hsa-miR-374c;hsa-miR-374c-5p; +MIMAT0018444 hsa-miR-642b;hsa-miR-642b-3p; +MIMAT0018445 hsa-miR-550b;hsa-miR-550b-3p; +MIMAT0018446 hsa-miR-548z; +MIMAT0018447 hsa-miR-548aa; +MIMAT0018448 csi-miR156;csi-miR156a-5p; +MIMAT0018449 csi-miR3946; +MIMAT0018450 csi-miR159;csi-miR159a-3p; +MIMAT0018451 csi-miR166c;csi-miR166c-3p; +MIMAT0018452 csi-miR166d; +MIMAT0018453 csi-miR167c;csi-miR167c-5p; +MIMAT0018454 csi-miR167b;csi-miR167b-5p; +MIMAT0018455 csi-miR171b;csi-miR171b-3p; +MIMAT0018456 csi-miR171a; +MIMAT0018457 csi-miR172b; +MIMAT0018458 csi-miR172c;csi-miR172c-3p; +MIMAT0018459 csi-miR319;csi-miR159d; +MIMAT0018460 csi-miR393;csi-miR393a; +MIMAT0018461 csi-miR394;csi-miR394a; +MIMAT0018462 csi-miR395;csi-miR395a; +MIMAT0018463 csi-miR396a;csi-miR396a-5p; +MIMAT0018464 csi-miR396b;csi-miR396b-5p; +MIMAT0018465 csi-miR397;csi-miR397-5p; +MIMAT0018466 csi-miR399e; +MIMAT0018467 csi-miR399c;csi-miR399c-3p; +MIMAT0018468 csi-miR399d;csi-miR399d-3p; +MIMAT0018469 csi-miR399a;csi-miR399a-3p; +MIMAT0018470 csi-miR399b;csi-miR399b-3p; +MIMAT0018471 csi-miR403;csi-miR403a-3p; +MIMAT0018472 csi-miR408;csi-miR408-3p; +MIMAT0018473 csi-miR472;csi-miR482f-3p; +MIMAT0018474 csi-miR473;csi-miR477c-5p; +MIMAT0018475 csi-miR477a;csi-miR477a-5p; +MIMAT0018476 csi-miR477b;csi-miR477b-5p; +MIMAT0018477 csi-miR477c; +MIMAT0018478 csi-miR479; +MIMAT0018479 csi-miR482a*;csi-miR482a-5p; +MIMAT0018480 csi-miR482a;csi-miR482a-3p; +MIMAT0018481 csi-miR482b;csi-miR482b-3p; +MIMAT0018482 csi-miR530a;csi-miR530a-5p; +MIMAT0018483 csi-miR530b;csi-miR530b-5p; +MIMAT0018484 csi-miR535;csi-miR535a; +MIMAT0018485 csi-miR827; +MIMAT0018486 csi-miR857; +MIMAT0018487 csi-miR3947-5p; +MIMAT0018488 csi-miR3948; +MIMAT0018489 csi-miR1515;csi-miR1515a; +MIMAT0018490 csi-miR3949; +MIMAT0018491 csi-miR3950; +MIMAT0018492 csi-miR3951;csi-miR3951a-5p; +MIMAT0018493 csi-miR396c; +MIMAT0018494 csi-miR3952;csi-miR3952-3p; +MIMAT0018495 csi-miR482c;csi-miR482c-3p; +MIMAT0018496 csi-miR3953; +MIMAT0018497 csi-miR3954; +MIMAT0018498 csi-miR167a;csi-miR167a-5p; +MIMAT0018499 hvu-miR1120; +MIMAT0018500 hvu-miR166b; +MIMAT0018501 hvu-miR1436; +MIMAT0018502 hvu-miR1126; +MIMAT0018503 hvu-miR444;hvu-miR444a; +MIMAT0018504 ath-miR854e; +MIMAT0018505 cre-miR1161b; +MIMAT0018506 ame-miR-11;ame-miR-11-3p; +MIMAT0018507 ame-miR-1175;ame-miR-1175-3p; +MIMAT0018508 ame-miR-193;ame-miR-193-3p; +MIMAT0018509 ame-miR-307;ame-miR-307-3p; +MIMAT0018510 ame-miR-2788;ame-miR-2788-3p; +MIMAT0018511 ame-miR-989;ame-miR-989-3p; +MIMAT0018512 ame-miR-3717;ame-miR-3717-5p; +MIMAT0018513 ame-miR-3745;ame-miR-3745-3p; +MIMAT0018514 ame-miR-3746;ame-miR-3746-3p; +MIMAT0018515 ame-miR-3747a;ame-miR-3747a-5p; +MIMAT0018516 ame-miR-3747b;ame-miR-3747b-5p; +MIMAT0018517 ame-miR-3748;ame-miR-3748-3p; +MIMAT0018518 ame-miR-3749;ame-miR-3749-3p; +MIMAT0018519 ame-miR-3750;ame-miR-3750-5p; +MIMAT0018520 ame-miR-3718a;ame-miR-3718a-3p; +MIMAT0018521 ame-miR-3751;ame-miR-3751-3p; +MIMAT0018522 ame-miR-3752;ame-miR-3752-3p; +MIMAT0018523 ame-miR-3753;ame-miR-3753-5p; +MIMAT0018524 ame-miR-3754;ame-miR-3754-5p; +MIMAT0018525 ame-miR-3755;ame-miR-3755-5p; +MIMAT0018526 ame-miR-3718b;ame-miR-3718b-5p; +MIMAT0018527 ame-miR-3756;ame-miR-3756-5p; +MIMAT0018528 ame-miR-3049;ame-miR-3049-3p; +MIMAT0018529 ame-miR-3757;ame-miR-3757-3p; +MIMAT0018530 ame-miR-3758;ame-miR-3758-5p; +MIMAT0018531 ame-miR-3719;ame-miR-3719-3p; +MIMAT0018532 ame-miR-3759;ame-miR-3759-3p; +MIMAT0018533 ame-miR-3760;ame-miR-3760-5p; +MIMAT0018534 ame-miR-3761;ame-miR-3761-5p; +MIMAT0018535 ame-miR-3762;ame-miR-3762-5p; +MIMAT0018536 ame-miR-3763;ame-miR-3763-5p; +MIMAT0018537 ame-miR-3764;ame-miR-3764-3p; +MIMAT0018538 ame-miR-3720;ame-miR-3720-5p; +MIMAT0018539 ame-miR-3765;ame-miR-3765-5p; +MIMAT0018540 ame-miR-3766;ame-miR-3766-3p; +MIMAT0018541 ame-miR-3767;ame-miR-3767-3p; +MIMAT0018542 ame-miR-3768;ame-miR-3768-3p; +MIMAT0018543 ame-miR-3769;ame-miR-3769-3p; +MIMAT0018544 ame-miR-971;ame-miR-971-3p; +MIMAT0018545 ame-miR-3770;ame-miR-3770-5p; +MIMAT0018546 ame-miR-3721;ame-miR-3721-3p; +MIMAT0018547 ame-miR-3771;ame-miR-3771-3p; +MIMAT0018548 ame-miR-3772;ame-miR-3772-3p; +MIMAT0018549 ame-miR-3773;ame-miR-3773-3p; +MIMAT0018550 ame-miR-3722;ame-miR-3722-5p; +MIMAT0018551 ame-miR-3774;ame-miR-3774-3p; +MIMAT0018552 ame-miR-3775;ame-miR-3775-5p; +MIMAT0018553 ame-miR-3776;ame-miR-3776-5p; +MIMAT0018554 ame-miR-3777;ame-miR-3777-3p; +MIMAT0018555 ame-miR-3778;ame-miR-3778-3p; +MIMAT0018556 ame-miR-3779;ame-miR-3779-5p; +MIMAT0018557 ame-miR-965;ame-miR-965-5p; +MIMAT0018558 ame-miR-3780;ame-miR-3780-5p; +MIMAT0018559 ame-miR-3781;ame-miR-3781-3p; +MIMAT0018560 ame-miR-3782;ame-miR-3782-5p; +MIMAT0018561 ame-miR-3783;ame-miR-3783-3p; +MIMAT0018562 ame-miR-3716b;ame-miR-3716b-3p; +MIMAT0018563 ame-miR-3784;ame-miR-3784-3p; +MIMAT0018564 ame-miR-3785;ame-miR-3785-3p; +MIMAT0018565 ame-miR-3786;ame-miR-3786-5p; +MIMAT0018566 ame-miR-3787;ame-miR-3787-5p; +MIMAT0018567 ame-miR-3788;ame-miR-3788-5p; +MIMAT0018568 ame-miR-3789;ame-miR-3789-3p; +MIMAT0018569 ame-miR-3790;ame-miR-3790-5p; +MIMAT0018570 ame-miR-3791;ame-miR-3791-3p; +MIMAT0018571 ame-miR-279b;ame-miR-279b-3p; +MIMAT0018572 ame-miR-9c;ame-miR-9c-3p; +MIMAT0018573 ame-miR-2944;ame-miR-2944-3p; +MIMAT0018574 ame-miR-318;ame-miR-318-3p; +MIMAT0018575 ame-miR-3792;ame-miR-3792-5p; +MIMAT0018576 ame-miR-927b;ame-miR-927b-5p; +MIMAT0018577 ame-miR-3793;ame-miR-3793-5p; +MIMAT0018578 ame-miR-3794;ame-miR-3794-5p; +MIMAT0018579 ame-miR-306;ame-miR-306-5p; +MIMAT0018580 ame-miR-3795;ame-miR-3795-5p; +MIMAT0018581 ame-miR-3796;ame-miR-3796-3p; +MIMAT0018582 ame-miR-3797;ame-miR-3797-5p; +MIMAT0018583 ame-miR-3477;ame-miR-3477-5p; +MIMAT0018584 ame-miR-3798;ame-miR-3798-3p; +MIMAT0018585 ame-miR-3799;ame-miR-3799-5p; +MIMAT0018586 ame-miR-279c;ame-miR-279c-3p; +MIMAT0018587 ame-miR-3800;ame-miR-3800-3p; +MIMAT0018588 ame-miR-3801;ame-miR-3801-5p; +MIMAT0018589 ame-miR-3723;ame-miR-3723-5p; +MIMAT0018590 ame-miR-3724;ame-miR-3724-3p; +MIMAT0018591 ame-miR-2796;ame-miR-2796-3p; +MIMAT0018592 ame-miR-3725;ame-miR-3725-3p; +MIMAT0018593 ame-miR-3726;ame-miR-3726-5p; +MIMAT0018594 ame-miR-3727;ame-miR-3727-3p; +MIMAT0018595 ame-miR-3728;ame-miR-3728-5p; +MIMAT0018596 ame-miR-3729;ame-miR-3729-3p; +MIMAT0018597 ame-miR-3715;ame-miR-3715-5p; +MIMAT0018598 ame-miR-3730;ame-miR-3730-5p; +MIMAT0018599 ame-miR-3731;ame-miR-3731-5p; +MIMAT0018600 ame-miR-3732;ame-miR-3732-3p; +MIMAT0018601 ame-miR-3716a;ame-miR-3716a-3p; +MIMAT0018602 ame-miR-3733;ame-miR-3733-5p; +MIMAT0018603 ame-miR-3734;ame-miR-3734-3p; +MIMAT0018604 ame-miR-3735;ame-miR-3735-5p; +MIMAT0018605 ame-miR-3736;ame-miR-3736-5p; +MIMAT0018606 ame-miR-3737;ame-miR-3737-5p; +MIMAT0018607 ame-miR-3738;ame-miR-3738-5p; +MIMAT0018608 ame-miR-3739;ame-miR-3739-3p; +MIMAT0018609 ame-miR-3740;ame-miR-3740-5p; +MIMAT0018610 ame-miR-3741;ame-miR-3741-3p; +MIMAT0018611 ame-miR-3742;ame-miR-3742-5p; +MIMAT0018612 ame-miR-3743;ame-miR-3743-3p; +MIMAT0018613 ame-miR-3744;ame-miR-3744-5p; +MIMAT0018614 ame-miR-980;ame-miR-980-3p; +MIMAT0018615 ame-miR-750;ame-miR-750-3p; +MIMAT0018616 tgu-miR-25; +MIMAT0018617 tgu-miR-192; +MIMAT0018618 tgu-miR-10a;tgu-miR-10a-5p; +MIMAT0018619 tgu-miR-132; +MIMAT0018620 tca-miR-3802-5p; +MIMAT0018621 tca-miR-3802-3p; +MIMAT0018622 tca-miR-3803-5p; +MIMAT0018623 tca-miR-3803-3p; +MIMAT0018624 tca-miR-3804a-5p; +MIMAT0018625 tca-miR-3804a-3p; +MIMAT0018626 tca-miR-3804b-5p; +MIMAT0018627 tca-miR-3804b-3p; +MIMAT0018628 tca-miR-995-5p; +MIMAT0018629 tca-miR-995-3p; +MIMAT0018630 tca-miR-2765-5p; +MIMAT0018631 tca-miR-2765-3p; +MIMAT0018632 tca-miR-3805a-5p; +MIMAT0018633 tca-miR-3805a-3p; +MIMAT0018634 tca-miR-3806-5p; +MIMAT0018635 tca-miR-3806-3p; +MIMAT0018636 tca-miR-3807-5p; +MIMAT0018637 tca-miR-3807-3p; +MIMAT0018638 tca-miR-3808-5p; +MIMAT0018639 tca-miR-3808-3p; +MIMAT0018640 tca-miR-3809-5p; +MIMAT0018641 tca-miR-3809-3p; +MIMAT0018642 tca-miR-3810-5p; +MIMAT0018643 tca-miR-3810-3p; +MIMAT0018644 tca-miR-3811c-5p;tca-miR-3811a-5p; +MIMAT0018645 tca-miR-3811c-3p;tca-miR-3811a-3p; +MIMAT0018646 tca-miR-3812-5p; +MIMAT0018647 tca-miR-3812-3p; +MIMAT0018648 tca-miR-3813-5p; +MIMAT0018649 tca-miR-3813-3p; +MIMAT0018650 tca-miR-3811d-5p;tca-miR-3811a-3-5p; +MIMAT0018651 tca-miR-3811d-3p; +MIMAT0018652 tca-miR-3814-5p; +MIMAT0018653 tca-miR-3814-3p; +MIMAT0018654 tca-miR-3815-5p; +MIMAT0018655 tca-miR-3815-3p; +MIMAT0018656 tca-miR-3816-5p; +MIMAT0018657 tca-miR-3816-3p; +MIMAT0018658 tca-miR-3817-5p; +MIMAT0018659 tca-miR-3817-3p; +MIMAT0018660 tca-miR-3818-5p; +MIMAT0018661 tca-miR-3818-3p; +MIMAT0018662 tca-miR-3805b-5p; +MIMAT0018663 tca-miR-3805b-3p; +MIMAT0018664 tca-miR-3811e-5p;tca-miR-3811b-5p; +MIMAT0018665 tca-miR-3811e-3p;tca-miR-3811b-3p; +MIMAT0018666 tca-miR-3820-5p; +MIMAT0018667 tca-miR-3820-3p; +MIMAT0018668 tca-miR-3821-5p; +MIMAT0018669 tca-miR-3821-3p; +MIMAT0018670 tca-miR-3822-5p; +MIMAT0018671 tca-miR-3822-3p; +MIMAT0018672 tca-miR-3823-5p; +MIMAT0018673 tca-miR-3823-3p; +MIMAT0018674 tca-miR-3824-5p; +MIMAT0018675 tca-miR-3824-3p; +MIMAT0018676 tca-miR-3811b-5p;tca-miR-3811a-5-5p; +MIMAT0018677 tca-miR-3811b-3p; +MIMAT0018678 tca-miR-3825-5p; +MIMAT0018679 tca-miR-3825-3p; +MIMAT0018680 tca-miR-3826-5p; +MIMAT0018681 tca-miR-3826-3p; +MIMAT0018682 tca-miR-3827-5p; +MIMAT0018683 tca-miR-3827-3p; +MIMAT0018684 tca-miR-3811a-5p;tca-miR-3811a-1-5p; +MIMAT0018685 tca-miR-3811a-3p; +MIMAT0018686 tca-miR-3828-5p; +MIMAT0018687 tca-miR-3828-3p; +MIMAT0018688 tca-miR-3829-5p; +MIMAT0018689 tca-miR-3829-3p; +MIMAT0018690 tca-miR-3830-5p; +MIMAT0018691 tca-miR-3830-3p; +MIMAT0018692 tca-miR-3831-5p; +MIMAT0018693 tca-miR-3831-3p; +MIMAT0018694 tca-miR-3832-5p; +MIMAT0018695 tca-miR-3832-3p; +MIMAT0018696 tca-miR-3833-5p; +MIMAT0018697 tca-miR-3833-3p; +MIMAT0018698 tca-miR-iab-5p;tca-miR-iab-8-5p; +MIMAT0018699 tca-miR-iab-3p;tca-miR-iab-8-3p; +MIMAT0018700 tca-miR-3834-5p; +MIMAT0018701 tca-miR-3834-3p; +MIMAT0018702 tca-miR-3835-5p; +MIMAT0018703 tca-miR-3835-3p; +MIMAT0018704 tca-miR-3836a-5p; +MIMAT0018705 tca-miR-3836a-3p; +MIMAT0018706 tca-miR-308-5p; +MIMAT0018707 tca-miR-308-3p; +MIMAT0018708 tca-miR-3837-5p; +MIMAT0018709 tca-miR-3837-3p; +MIMAT0018710 tca-miR-3836b-5p; +MIMAT0018711 tca-miR-3836b-3p; +MIMAT0018712 tca-miR-2796-5p; +MIMAT0018713 tca-miR-2796-3p; +MIMAT0018714 tca-miR-9c-5p; +MIMAT0018715 tca-miR-9c-3p; +MIMAT0018716 tca-miR-316-5p; +MIMAT0018717 tca-miR-316-3p; +MIMAT0018718 tca-miR-2944a-5p; +MIMAT0018719 tca-miR-2944a-3p; +MIMAT0018720 tca-miR-3838-5p; +MIMAT0018721 tca-miR-3838-3p; +MIMAT0018722 tca-miR-3839-5p; +MIMAT0018723 tca-miR-3839-3p; +MIMAT0018724 tca-miR-3840-5p; +MIMAT0018725 tca-miR-3840-3p; +MIMAT0018726 tca-miR-3841-5p; +MIMAT0018727 tca-miR-3841-3p; +MIMAT0018728 tca-miR-3842-5p; +MIMAT0018729 tca-miR-3842-3p; +MIMAT0018730 tca-miR-279c-5p; +MIMAT0018731 tca-miR-279c-3p; +MIMAT0018732 tca-miR-3843-5p; +MIMAT0018733 tca-miR-3843-3p; +MIMAT0018734 tca-miR-3844-5p; +MIMAT0018735 tca-miR-3844-3p; +MIMAT0018736 tca-miR-3477-5p; +MIMAT0018737 tca-miR-3477-3p; +MIMAT0018738 tca-miR-3845-5p; +MIMAT0018739 tca-miR-3845-3p; +MIMAT0018740 tca-miR-3846-5p; +MIMAT0018741 tca-miR-3846-3p; +MIMAT0018742 tca-miR-3847-5p; +MIMAT0018743 tca-miR-3847-3p; +MIMAT0018744 tca-miR-3848-5p; +MIMAT0018745 tca-miR-3848-3p; +MIMAT0018746 tca-miR-2944b-5p; +MIMAT0018747 tca-miR-2944b-3p; +MIMAT0018748 tca-miR-9d-5p; +MIMAT0018749 tca-miR-9d-3p; +MIMAT0018750 tca-miR-309a-5p; +MIMAT0018751 tca-miR-309a-3p; +MIMAT0018752 tca-miR-3849-5p; +MIMAT0018753 tca-miR-3849-3p; +MIMAT0018754 tca-miR-3850-5p; +MIMAT0018755 tca-miR-3850-3p; +MIMAT0018756 tca-miR-3851b-5p; +MIMAT0018757 tca-miR-3851b-3p; +MIMAT0018758 tca-miR-3851a-5p; +MIMAT0018759 tca-miR-3851a-3p; +MIMAT0018760 tca-miR-3852-5p; +MIMAT0018761 tca-miR-3852-3p; +MIMAT0018762 tca-miR-3853-5p; +MIMAT0018763 tca-miR-3853-3p; +MIMAT0018764 tca-miR-3854-5p; +MIMAT0018765 tca-miR-3854-3p; +MIMAT0018766 tca-miR-3855-5p; +MIMAT0018767 tca-miR-3855-3p; +MIMAT0018768 tca-miR-87b-5p; +MIMAT0018769 tca-miR-87b-3p; +MIMAT0018770 tca-miR-3856-5p; +MIMAT0018771 tca-miR-3856-3p; +MIMAT0018772 tca-miR-3851c-5p; +MIMAT0018773 tca-miR-3851c-3p; +MIMAT0018774 tca-miR-3857-5p; +MIMAT0018775 tca-miR-3857-3p; +MIMAT0018776 tca-miR-3049-5p; +MIMAT0018777 tca-miR-3049-3p; +MIMAT0018778 tca-miR-3851d-5p; +MIMAT0018779 tca-miR-3851d-3p; +MIMAT0018780 tca-miR-3851e-5p; +MIMAT0018781 tca-miR-3851e-3p; +MIMAT0018782 tca-miR-3858-5p; +MIMAT0018783 tca-miR-3858-3p; +MIMAT0018784 tca-miR-3851f-5p; +MIMAT0018785 tca-miR-3851f-3p; +MIMAT0018786 tca-miR-92c-5p; +MIMAT0018787 tca-miR-92c-3p; +MIMAT0018788 tca-miR-279d-5p; +MIMAT0018789 tca-miR-279d-3p; +MIMAT0018790 tca-miR-3859-5p; +MIMAT0018791 tca-miR-3859-3p; +MIMAT0018792 tca-miR-3860-5p; +MIMAT0018793 tca-miR-3860-3p; +MIMAT0018794 tca-miR-375-5p; +MIMAT0018795 tca-miR-375-3p; +MIMAT0018796 tca-miR-3861-5p; +MIMAT0018797 tca-miR-3861-3p; +MIMAT0018798 tca-miR-2788-5p; +MIMAT0018799 tca-miR-2788-3p; +MIMAT0018800 tca-miR-3862-5p; +MIMAT0018801 tca-miR-3862-3p; +MIMAT0018802 tca-miR-29-5p; +MIMAT0018803 tca-miR-29-3p; +MIMAT0018804 tca-miR-252a-5p; +MIMAT0018805 tca-miR-252a-3p; +MIMAT0018806 tca-miR-252b-5p; +MIMAT0018807 tca-miR-252b-3p; +MIMAT0018808 tca-miR-3863-5p; +MIMAT0018809 tca-miR-3863-3p; +MIMAT0018810 tca-miR-2944c-5p; +MIMAT0018811 tca-miR-2944c-3p; +MIMAT0018812 tca-miR-3864-5p; +MIMAT0018813 tca-miR-3864-3p; +MIMAT0018814 tca-miR-3865-5p; +MIMAT0018815 tca-miR-3865-3p; +MIMAT0018816 tca-miR-279e-5p; +MIMAT0018817 tca-miR-279e-3p; +MIMAT0018818 tca-miR-1175-5p; +MIMAT0018819 tca-miR-1175-3p; +MIMAT0018820 tca-miR-750-5p; +MIMAT0018821 tca-miR-750-3p; +MIMAT0018822 tca-miR-989-5p; +MIMAT0018823 tca-miR-989-3p; +MIMAT0018824 tca-miR-3866-5p; +MIMAT0018825 tca-miR-3866-3p; +MIMAT0018826 tca-miR-3867-5p; +MIMAT0018827 tca-miR-3867-3p; +MIMAT0018828 tca-miR-3868-5p; +MIMAT0018829 tca-miR-3868-3p; +MIMAT0018830 tca-miR-3869-5p; +MIMAT0018831 tca-miR-3869-3p; +MIMAT0018832 tca-miR-3870-5p; +MIMAT0018833 tca-miR-3870-3p; +MIMAT0018834 tca-miR-3871-5p; +MIMAT0018835 tca-miR-3871-3p; +MIMAT0018836 tca-miR-3872-5p; +MIMAT0018837 tca-miR-3872-3p; +MIMAT0018838 tca-miR-3873-5p; +MIMAT0018839 tca-miR-3873-3p; +MIMAT0018840 tca-miR-3874-5p; +MIMAT0018841 tca-miR-3874-3p; +MIMAT0018842 tca-miR-3875-5p; +MIMAT0018843 tca-miR-3875-3p; +MIMAT0018844 tca-miR-3876-5p; +MIMAT0018845 tca-miR-3876-3p; +MIMAT0018846 tca-miR-3877-5p; +MIMAT0018847 tca-miR-3877-3p; +MIMAT0018848 tca-miR-3878-5p; +MIMAT0018849 tca-miR-3878-3p; +MIMAT0018850 tca-miR-3879-5p; +MIMAT0018851 tca-miR-3879-3p; +MIMAT0018852 tca-miR-998-5p; +MIMAT0018853 tca-miR-998-3p; +MIMAT0018854 tca-miR-11-5p; +MIMAT0018855 tca-miR-11-3p; +MIMAT0018856 tca-miR-3880-5p; +MIMAT0018857 tca-miR-3880-3p; +MIMAT0018858 tca-miR-3881-5p; +MIMAT0018859 tca-miR-3881-3p; +MIMAT0018860 tca-miR-3882-5p; +MIMAT0018861 tca-miR-3882-3p; +MIMAT0018862 tca-miR-3883-5p; +MIMAT0018863 tca-miR-3883-3p; +MIMAT0018864 tca-miR-980-5p; +MIMAT0018865 tca-miR-980-3p; +MIMAT0018866 tca-miR-3884-5p; +MIMAT0018867 tca-miR-3884-3p; +MIMAT0018868 tca-miR-3885-5p; +MIMAT0018869 tca-miR-3885-3p; +MIMAT0018870 tca-miR-3886-5p; +MIMAT0018871 tca-miR-3886-3p; +MIMAT0018872 tca-miR-3887-5p; +MIMAT0018873 tca-miR-3887-3p; +MIMAT0018874 tca-miR-3888-5p; +MIMAT0018875 tca-miR-3888-3p; +MIMAT0018876 tca-miR-3889-5p; +MIMAT0018877 tca-miR-3889-3p; +MIMAT0018878 tca-miR-3890-5p; +MIMAT0018879 tca-miR-3890-3p; +MIMAT0018880 tca-miR-3891-5p; +MIMAT0018881 tca-miR-3891-3p; +MIMAT0018882 tca-miR-3791-5p; +MIMAT0018883 tca-miR-3791-3p; +MIMAT0018884 tca-miR-3892-5p; +MIMAT0018885 tca-miR-3892-3p; +MIMAT0018886 tca-miR-309b-5p; +MIMAT0018887 tca-miR-309b-3p; +MIMAT0018888 tca-miR-3893-5p; +MIMAT0018889 tca-miR-3893-3p; +MIMAT0018890 tca-miR-3894-5p; +MIMAT0018891 tca-miR-3894-3p; +MIMAT0018892 tca-miR-3895-5p; +MIMAT0018893 tca-miR-3895-3p; +MIMAT0018894 tca-miR-3896-5p; +MIMAT0018895 tca-miR-3896-3p; +MIMAT0018896 tca-miR-193-5p; +MIMAT0018897 tca-miR-193-3p; +MIMAT0018898 tca-miR-3897-5p; +MIMAT0018899 tca-miR-3897-3p; +MIMAT0018900 tca-miR-3898-5p; +MIMAT0018901 tca-miR-3898-3p; +MIMAT0018902 tca-miR-3899-5p; +MIMAT0018903 tca-miR-3899-3p; +MIMAT0018904 tca-miR-3900-5p; +MIMAT0018905 tca-miR-3900-3p; +MIMAT0018906 tca-miR-3901-5p; +MIMAT0018907 tca-miR-3901-3p; +MIMAT0018908 tca-miR-3902-5p; +MIMAT0018909 tca-miR-3902-3p; +MIMAT0018910 tca-miR-3903-3p; +MIMAT0018911 tca-miR-3904-5p; +MIMAT0018912 tca-miR-3904-3p; +MIMAT0018913 tca-miR-3905-5p; +MIMAT0018914 tca-miR-3819-5p; +MIMAT0018915 smr-miR-282; +MIMAT0018916 smr-miR-965; +MIMAT0018917 smr-miR-3930;smr-miR-3930-5p; +MIMAT0018918 smr-miR-3930*;smr-miR-3930-3p; +MIMAT0018919 isc-miR-276; +MIMAT0018920 isc-miR-305; +MIMAT0018921 isc-miR-iab-4; +MIMAT0018922 smr-miR-3931; +MIMAT0018923 dpu-miR-279b; +MIMAT0018924 dpu-miR-305; +MIMAT0018925 hsa-miR-1268b; +MIMAT0018926 hsa-miR-378d; +MIMAT0018927 hsa-miR-378e; +MIMAT0018928 hsa-miR-548ab; +MIMAT0018929 hsa-miR-4417; +MIMAT0018930 hsa-miR-4418; +MIMAT0018931 hsa-miR-4419a; +MIMAT0018932 hsa-miR-378f; +MIMAT0018933 hsa-miR-4420; +MIMAT0018934 hsa-miR-4421; +MIMAT0018935 hsa-miR-4422; +MIMAT0018936 hsa-miR-4423-3p; +MIMAT0018937 hsa-miR-378g; +MIMAT0018938 hsa-miR-548ac; +MIMAT0018939 hsa-miR-4424; +MIMAT0018940 hsa-miR-4425; +MIMAT0018941 hsa-miR-4426; +MIMAT0018942 hsa-miR-4427; +MIMAT0018943 hsa-miR-4428; +MIMAT0018944 hsa-miR-4429; +MIMAT0018945 hsa-miR-4430; +MIMAT0018946 hsa-miR-548ad;hsa-miR-548ad-3p; +MIMAT0018947 hsa-miR-4431; +MIMAT0018948 hsa-miR-4432; +MIMAT0018949 hsa-miR-4433;hsa-miR-4433-3p;hsa-miR-4433a-3p; +MIMAT0018950 hsa-miR-4434; +MIMAT0018951 hsa-miR-4435; +MIMAT0018952 hsa-miR-4436a; +MIMAT0018953 hsa-miR-4437; +MIMAT0018954 hsa-miR-548ae;hsa-miR-548ae-3p; +MIMAT0018956 hsa-miR-4438; +MIMAT0018957 hsa-miR-4439; +MIMAT0018958 hsa-miR-4440; +MIMAT0018959 hsa-miR-4441; +MIMAT0018960 hsa-miR-4442; +MIMAT0018961 hsa-miR-4443; +MIMAT0018962 hsa-miR-4444; +MIMAT0018963 hsa-miR-4445;hsa-miR-4445-5p; +MIMAT0018964 hsa-miR-4445*;hsa-miR-4445-3p; +MIMAT0018965 hsa-miR-4446-3p; +MIMAT0018966 hsa-miR-4447; +MIMAT0018967 hsa-miR-4448; +MIMAT0018968 hsa-miR-4449; +MIMAT0018969 hsa-miR-548ag; +MIMAT0018971 hsa-miR-4450; +MIMAT0018972 hsa-miR-548ah;hsa-miR-548ah-5p; +MIMAT0018973 hsa-miR-4451; +MIMAT0018974 hsa-miR-4452; +MIMAT0018975 hsa-miR-4453; +MIMAT0018976 hsa-miR-4454; +MIMAT0018977 hsa-miR-4455; +MIMAT0018978 hsa-miR-4456; +MIMAT0018979 hsa-miR-4457; +MIMAT0018980 hsa-miR-4458; +MIMAT0018981 hsa-miR-4459; +MIMAT0018982 hsa-miR-4460; +MIMAT0018983 hsa-miR-4461; +MIMAT0018984 hsa-miR-378h; +MIMAT0018985 hsa-miR-3135b; +MIMAT0018986 hsa-miR-4462; +MIMAT0018987 hsa-miR-4463; +MIMAT0018988 hsa-miR-4464; +MIMAT0018989 hsa-miR-548ai; +MIMAT0018990 hsa-miR-548aj;hsa-miR-548aj-3p; +MIMAT0018992 hsa-miR-4465; +MIMAT0018993 hsa-miR-4466; +MIMAT0018994 hsa-miR-4467; +MIMAT0018995 hsa-miR-4468; +MIMAT0018996 hsa-miR-4469; +MIMAT0018997 hsa-miR-4470; +MIMAT0018998 hsa-miR-4471; +MIMAT0018999 hsa-miR-4472; +MIMAT0019000 hsa-miR-4473; +MIMAT0019001 hsa-miR-4474-3p; +MIMAT0019002 hsa-miR-4475; +MIMAT0019003 hsa-miR-4476; +MIMAT0019004 hsa-miR-4477a; +MIMAT0019005 hsa-miR-4477b; +MIMAT0019006 hsa-miR-4478; +MIMAT0019007 hsa-miR-3689c; +MIMAT0019008 hsa-miR-3689d; +MIMAT0019009 hsa-miR-3689e; +MIMAT0019010 hsa-miR-3689f; +MIMAT0019011 hsa-miR-4479; +MIMAT0019012 hsa-miR-3155b; +MIMAT0019013 hsa-miR-548ak; +MIMAT0019014 hsa-miR-4480; +MIMAT0019015 hsa-miR-4481; +MIMAT0019016 hsa-miR-4482;hsa-miR-4482-5p; +MIMAT0019017 hsa-miR-4483; +MIMAT0019018 hsa-miR-4484; +MIMAT0019019 hsa-miR-4485;hsa-miR-4485-3p; +MIMAT0019020 hsa-miR-4486; +MIMAT0019021 hsa-miR-4487; +MIMAT0019022 hsa-miR-4488; +MIMAT0019023 hsa-miR-4489; +MIMAT0019024 hsa-miR-548al; +MIMAT0019025 hsa-miR-4490; +MIMAT0019026 hsa-miR-4491; +MIMAT0019027 hsa-miR-4492; +MIMAT0019028 hsa-miR-4493; +MIMAT0019029 hsa-miR-4494; +MIMAT0019030 hsa-miR-4495; +MIMAT0019031 hsa-miR-4496; +MIMAT0019032 hsa-miR-4497; +MIMAT0019033 hsa-miR-4498; +MIMAT0019034 hsa-miR-4419b; +MIMAT0019035 hsa-miR-4499; +MIMAT0019036 hsa-miR-4500; +MIMAT0019037 hsa-miR-4501; +MIMAT0019038 hsa-miR-4502; +MIMAT0019039 hsa-miR-4503; +MIMAT0019040 hsa-miR-4504; +MIMAT0019041 hsa-miR-4505; +MIMAT0019042 hsa-miR-4506; +MIMAT0019043 hsa-miR-2392; +MIMAT0019044 hsa-miR-4507; +MIMAT0019045 hsa-miR-4508; +MIMAT0019046 hsa-miR-4509; +MIMAT0019047 hsa-miR-4510; +MIMAT0019048 hsa-miR-4511; +MIMAT0019049 hsa-miR-4512; +MIMAT0019050 hsa-miR-4513; +MIMAT0019051 hsa-miR-4514; +MIMAT0019052 hsa-miR-4515; +MIMAT0019053 hsa-miR-4516; +MIMAT0019054 hsa-miR-4517; +MIMAT0019055 hsa-miR-4518; +MIMAT0019056 hsa-miR-4519; +MIMAT0019057 hsa-miR-4520a-3p;hsa-miR-4520-3p; +MIMAT0019058 hsa-miR-4521; +MIMAT0019059 hsa-miR-1269b; +MIMAT0019060 hsa-miR-4522; +MIMAT0019061 hsa-miR-4523; +MIMAT0019062 hsa-miR-4524;hsa-miR-4524a-5p; +MIMAT0019063 hsa-miR-4524*;hsa-miR-4524a-3p; +MIMAT0019064 hsa-miR-4525; +MIMAT0019065 hsa-miR-4526; +MIMAT0019066 hsa-miR-4527; +MIMAT0019067 hsa-miR-4528; +MIMAT0019068 hsa-miR-4529-3p; +MIMAT0019069 hsa-miR-4530; +MIMAT0019070 hsa-miR-4531; +MIMAT0019071 hsa-miR-4532; +MIMAT0019072 hsa-miR-4533; +MIMAT0019073 hsa-miR-4534; +MIMAT0019074 hsa-miR-378i; +MIMAT0019075 hsa-miR-4535; +MIMAT0019076 hsa-miR-548am;hsa-miR-548am-3p; +MIMAT0019077 hsa-miR-1587; +MIMAT0019078 hsa-miR-4536;hsa-miR-4536-5p; +MIMAT0019079 hsa-miR-548an; +MIMAT0019080 hsa-miR-4537; +MIMAT0019081 hsa-miR-4538; +MIMAT0019082 hsa-miR-4539; +MIMAT0019083 hsa-miR-4540; +MIMAT0019084 rlcv-mir-rL1-1-3p;rlcv-miR-rL1-1-3p; +MIMAT0019085 rlcv-mir-rL1-2-5p;rlcv-miR-rL1-2-5p; +MIMAT0019086 rlcv-mir-rL1-7-3p;rlcv-miR-rL1-7-3p; +MIMAT0019087 rlcv-mir-rL1-8-3p;rlcv-miR-rL1-8-3p; +MIMAT0019088 rlcv-mir-rL1-10-5p;rlcv-miR-rL1-10-5p; +MIMAT0019089 rlcv-mir-rL1-11-5p;rlcv-miR-rL1-11-5p; +MIMAT0019090 rlcv-mir-rL1-13-5p;rlcv-miR-rL1-13-5p; +MIMAT0019091 rlcv-mir-rL1-15-5p;rlcv-miR-rL1-15-5p; +MIMAT0019092 tca-miR-1-5p; +MIMAT0019093 tca-miR-2c-5p;tca-miR-2-3-5p; +MIMAT0019094 tca-miR-2a-5p;tca-miR-2-1-5p; +MIMAT0019095 tca-miR-2a-3p; +MIMAT0019096 tca-miR-2b-5p;tca-miR-2-2-5p; +MIMAT0019097 tca-miR-2b-3p; +MIMAT0019098 tca-let-7-3p; +MIMAT0019099 tca-miR-7-3p; +MIMAT0019100 tca-miR-8-5p; +MIMAT0019101 tca-miR-10-3p; +MIMAT0019102 tca-miR-12-3p; +MIMAT0019103 tca-miR-13a-5p; +MIMAT0019104 tca-miR-13b-5p; +MIMAT0019105 tca-miR-14-5p; +MIMAT0019106 tca-miR-31-3p; +MIMAT0019107 tca-miR-33-3p; +MIMAT0019108 tca-miR-34-3p; +MIMAT0019109 tca-miR-71-3p; +MIMAT0019110 tca-miR-87a-5p; +MIMAT0019111 tca-miR-92a-5p; +MIMAT0019112 tca-miR-92b-5p; +MIMAT0019113 tca-miR-100-3p; +MIMAT0019114 tca-miR-124-5p; +MIMAT0019115 tca-miR-125-3p; +MIMAT0019116 tca-miR-133-5p; +MIMAT0019117 tca-miR-137-5p; +MIMAT0019118 tca-miR-184-5p; +MIMAT0019119 tca-miR-190-3p; +MIMAT0019120 tca-miR-210-5p; +MIMAT0019121 tca-miR-219-3p; +MIMAT0019122 tca-miR-263b-3p; +MIMAT0019123 tca-miR-275-5p; +MIMAT0019124 tca-miR-277-5p; +MIMAT0019125 tca-miR-279a-5p; +MIMAT0019126 tca-miR-282-3p; +MIMAT0019127 tca-miR-283-3p; +MIMAT0019128 tca-miR-305-3p; +MIMAT0019129 tca-miR-307-5p; +MIMAT0019130 tca-miR-317-5p; +MIMAT0019131 tca-miR-927-3p;tca-miR-927a-3p; +MIMAT0019132 tca-miR-932-3p; +MIMAT0019133 tca-miR-929-3p; +MIMAT0019134 tca-miR-9b-5p; +MIMAT0019135 tca-miR-9b-3p; +MIMAT0019136 mmu-miR-1306-5p; +MIMAT0019137 bfl-miR-1*;bfl-miR-1-5p; +MIMAT0019138 bfl-miR-22*;bfl-miR-22-5p; +MIMAT0019139 bfl-miR-29a*;bfl-miR-29a-5p; +MIMAT0019140 bfl-miR-29b*;bfl-miR-29b-5p; +MIMAT0019141 bfl-miR-31*;bfl-miR-31-3p; +MIMAT0019142 bfl-miR-71*;bfl-miR-71-3p; +MIMAT0019143 bfl-miR-92b*;bfl-miR-92b-5p; +MIMAT0019144 bfl-miR-96*;bfl-miR-96-3p; +MIMAT0019145 bfl-miR-100*;bfl-miR-100-3p; +MIMAT0019146 bfl-miR-124*;bfl-miR-124-5p; +MIMAT0019147 bfl-miR-125a*;bfl-miR-125a-3p; +MIMAT0019148 bfl-miR-184*;bfl-miR-184-5p; +MIMAT0019149 bfl-miR-210*;bfl-miR-210-5p; +MIMAT0019150 bfl-miR-216*;bfl-miR-216-3p; +MIMAT0019151 bfl-miR-252b*;bfl-miR-252b-3p; +MIMAT0019152 sko-miR-1*;sko-miR-1-5p; +MIMAT0019153 sko-miR-7*;sko-miR-7-3p; +MIMAT0019154 sko-miR-29b*;sko-miR-29b-5p; +MIMAT0019155 sko-miR-34*;sko-miR-34-3p; +MIMAT0019156 sko-miR-96*;sko-miR-96-3p; +MIMAT0019157 sko-miR-193a*;sko-miR-193a-5p; +MIMAT0019158 sko-miR-210*;sko-miR-210-5p; +MIMAT0019159 sko-miR-365*;sko-miR-365-5p; +MIMAT0019160 spu-miR-92b*;spu-miR-92b-5p; +MIMAT0019161 spu-miR-125*;spu-miR-125-3p; +MIMAT0019162 spu-miR-153*;spu-miR-153-5p; +MIMAT0019163 spu-miR-278*;spu-miR-278-5p; +MIMAT0019164 sko-miR-2012*;sko-miR-2012-3p; +MIMAT0019165 spu-miR-2002*;spu-miR-2002-5p; +MIMAT0019166 spu-miR-2003*;spu-miR-2003-3p; +MIMAT0019167 bfl-miR-2058*;bfl-miR-2058-3p; +MIMAT0019168 bfl-miR-2059-5p; +MIMAT0019169 bfl-miR-2062*;bfl-miR-2062-3p; +MIMAT0019170 bfl-miR-2068*;bfl-miR-2068-3p; +MIMAT0019171 bfl-miR-2070*;bfl-miR-2070-3p; +MIMAT0019172 bfl-miR-2071*;bfl-miR-2071-5p; +MIMAT0019173 bfl-miR-2072*;bfl-miR-2072-3p; +MIMAT0019174 bfl-miR-34b-5p; +MIMAT0019175 bfl-miR-2076*;bfl-miR-2076-3p; +MIMAT0019176 bfl-let-7a*;bfl-let-7a-3p; +MIMAT0019177 tca-miR-9a-3p; +MIMAT0019178 tca-bantam-5p; +MIMAT0019179 tca-miR-970-5p; +MIMAT0019180 tca-miR-263a-3p; +MIMAT0019181 tca-miR-279b-5p; +MIMAT0019182 tca-miR-993-5p; +MIMAT0019183 tca-miR-965-5p; +MIMAT0019184 tca-miR-1000-3p; +MIMAT0019185 rlcv-mir-rL1-17-5p;rlcv-miR-rL1-17-5p; +MIMAT0019186 rlcv-mir-rL1-18-5p;rlcv-miR-rL1-18-5p; +MIMAT0019187 rlcv-mir-rL1-19-3p;rlcv-miR-rL1-19-3p; +MIMAT0019188 rlcv-mir-rL1-21-5p;rlcv-miR-rL1-21-5p; +MIMAT0019189 rlcv-mir-rL1-22-5p;rlcv-miR-rL1-22-5p; +MIMAT0019190 rlcv-mir-rL1-25-5p;rlcv-miR-rL1-25-5p; +MIMAT0019191 rlcv-mir-rL1-26-5p;rlcv-miR-rL1-26-5p; +MIMAT0019192 rlcv-mir-rL1-27-5p;rlcv-miR-rL1-27-5p; +MIMAT0019193 rlcv-mir-rL1-28-5p;rlcv-miR-rL1-28-5p; +MIMAT0019194 rlcv-mir-rL1-29-5p;rlcv-miR-rL1-29-5p; +MIMAT0019195 rlcv-mir-rL1-30-5p;rlcv-miR-rL1-30-5p; +MIMAT0019196 rlcv-mir-rL1-33-3p;rlcv-miR-rL1-33-3p; +MIMAT0019197 hsa-miR-3117-5p; +MIMAT0019198 hsa-miR-3120-5p; +MIMAT0019199 hsa-miR-3121-5p; +MIMAT0019200 hsa-miR-3124-3p; +MIMAT0019201 hsa-miR-3127-3p; +MIMAT0019202 hsa-miR-3129-3p; +MIMAT0019203 hsa-miR-3136-3p; +MIMAT0019204 hsa-miR-3140-5p; +MIMAT0019205 hsa-miR-3145-5p; +MIMAT0019206 hsa-miR-3150a-5p; +MIMAT0019207 hsa-miR-3152-5p; +MIMAT0019208 hsa-miR-3074-5p; +MIMAT0019209 hsa-miR-3156-3p; +MIMAT0019210 hsa-miR-3157-3p; +MIMAT0019211 hsa-miR-3158-5p; +MIMAT0019212 hsa-miR-3160-5p; +MIMAT0019213 hsa-miR-3162-3p; +MIMAT0019214 hsa-miR-3173-5p; +MIMAT0019215 hsa-miR-3177-5p; +MIMAT0019216 hsa-miR-3187-5p; +MIMAT0019217 hsa-miR-3189-5p; +MIMAT0019218 hsa-miR-3194-3p; +MIMAT0019219 hsa-miR-3619-3p; +MIMAT0019220 hsa-miR-3664-3p; +MIMAT0019221 hsa-miR-3677-5p; +MIMAT0019222 hsa-miR-3682-5p; +MIMAT0019223 hsa-miR-3688-5p; +MIMAT0019224 hsa-miR-3691-3p; +MIMAT0019225 hsa-miR-3913-3p; +MIMAT0019226 hsa-miR-3150b-5p; +MIMAT0019227 hsa-miR-3922-5p; +MIMAT0019228 hsa-miR-3925-3p; +MIMAT0019229 hsa-miR-3940-5p; +MIMAT0019230 hsa-miR-3942-3p; +MIMAT0019231 hsa-miR-3944-5p; +MIMAT0019232 hsa-miR-4423-5p; +MIMAT0019233 hsa-miR-4446-5p; +MIMAT0019234 hsa-miR-4474-5p; +MIMAT0019235 hsa-miR-4520a-5p;hsa-miR-4520-5p; +MIMAT0019236 hsa-miR-4529-5p; +MIMAT0019237 oar-miR-493-5p; +MIMAT0019238 oar-miR-493-3p; +MIMAT0019239 oar-miR-665-5p; +MIMAT0019240 oar-miR-665-3p; +MIMAT0019241 oar-miR-433-5p; +MIMAT0019242 oar-miR-433-3p; +MIMAT0019243 oar-miR-370-5p; +MIMAT0019244 oar-miR-370-3p; +MIMAT0019245 oar-miR-3955-5p; +MIMAT0019246 oar-miR-3955-3p; +MIMAT0019247 oar-miR-379-5p; +MIMAT0019248 oar-miR-379-3p; +MIMAT0019249 oar-miR-411a-5p; +MIMAT0019250 oar-miR-411a-3p; +MIMAT0019251 oar-miR-299-5p; +MIMAT0019252 oar-miR-299-3p; +MIMAT0019253 oar-miR-380-5p; +MIMAT0019254 oar-miR-380-3p; +MIMAT0019255 oar-miR-411b-5p; +MIMAT0019256 oar-miR-411b-3p; +MIMAT0019257 oar-miR-1197-5p; +MIMAT0019258 oar-miR-1197-3p; +MIMAT0019259 oar-miR-323a-5p; +MIMAT0019260 oar-miR-323a-3p; +MIMAT0019261 oar-miR-758-5p; +MIMAT0019262 oar-miR-758-3p; +MIMAT0019263 oar-miR-329b-5p; +MIMAT0019264 oar-miR-329b-3p; +MIMAT0019265 oar-miR-329a-5p; +MIMAT0019266 oar-miR-329a-3p; +MIMAT0019267 oar-miR-494-5p; +MIMAT0019268 oar-miR-494-3p; +MIMAT0019269 oar-miR-1193-5p; +MIMAT0019270 oar-miR-1193-3p; +MIMAT0019271 oar-miR-543-5p; +MIMAT0019272 oar-miR-543-3p; +MIMAT0019273 oar-miR-495-5p; +MIMAT0019274 oar-miR-495-3p; +MIMAT0019275 oar-miR-3958-5p; +MIMAT0019276 oar-miR-3958-3p; +MIMAT0019277 oar-miR-376e-5p; +MIMAT0019278 oar-miR-376e-3p; +MIMAT0019279 oar-miR-376c-5p; +MIMAT0019280 oar-miR-376c-3p; +MIMAT0019281 oar-miR-376d; +MIMAT0019282 oar-miR-654-5p; +MIMAT0019283 oar-miR-654-3p; +MIMAT0019284 oar-miR-376b-5p; +MIMAT0019285 oar-miR-376b-3p; +MIMAT0019286 oar-miR-376a-5p; +MIMAT0019287 oar-miR-376a-3p; +MIMAT0019288 oar-miR-1185-5p; +MIMAT0019289 oar-miR-1185-3p; +MIMAT0019290 oar-miR-3956-5p; +MIMAT0019291 oar-miR-3956-3p; +MIMAT0019292 oar-miR-381-5p; +MIMAT0019293 oar-miR-381-3p; +MIMAT0019294 oar-miR-487b-5p; +MIMAT0019295 oar-miR-487b-3p; +MIMAT0019296 oar-miR-539-5p; +MIMAT0019297 oar-miR-539-3p; +MIMAT0019298 oar-miR-544-5p; +MIMAT0019299 oar-miR-544-3p; +MIMAT0019300 oar-miR-655-5p; +MIMAT0019301 oar-miR-655-3p; +MIMAT0019302 oar-miR-3959-5p; +MIMAT0019303 oar-miR-3959-3p; +MIMAT0019304 oar-miR-487a-5p; +MIMAT0019305 oar-miR-487a-3p; +MIMAT0019306 oar-miR-382-5p; +MIMAT0019307 oar-miR-382-3p; +MIMAT0019308 oar-miR-134-5p; +MIMAT0019309 oar-miR-134-3p; +MIMAT0019310 oar-miR-668-5p; +MIMAT0019311 oar-miR-668-3p; +MIMAT0019312 oar-miR-485-5p; +MIMAT0019313 oar-miR-485-3p; +MIMAT0019314 oar-miR-323b; +MIMAT0019315 oar-miR-154a-5p; +MIMAT0019316 oar-miR-154a-3p; +MIMAT0019317 oar-miR-154b-5p; +MIMAT0019318 oar-miR-154b-3p; +MIMAT0019319 oar-miR-496-5p; +MIMAT0019320 oar-miR-496-3p; +MIMAT0019321 oar-miR-377-5p; +MIMAT0019322 oar-miR-377-3p; +MIMAT0019323 oar-miR-541-5p; +MIMAT0019324 oar-miR-541-3p; +MIMAT0019325 oar-miR-3957-5p; +MIMAT0019326 oar-miR-3957-3p; +MIMAT0019327 oar-miR-409-5p; +MIMAT0019328 oar-miR-409-3p; +MIMAT0019329 oar-miR-412-3p; +MIMAT0019330 oar-miR-412-5p; +MIMAT0019331 oar-miR-369-5p; +MIMAT0019332 oar-miR-369-3p; +MIMAT0019333 oar-miR-410-5p; +MIMAT0019334 oar-miR-410-3p; +MIMAT0019335 oar-miR-323c; +MIMAT0019336 mmu-miR-3960; +MIMAT0019337 hsa-miR-3960; +MIMAT0019338 mmu-miR-3961; +MIMAT0019339 mmu-miR-28c; +MIMAT0019340 mmu-miR-3962; +MIMAT0019341 mmu-miR-3963; +MIMAT0019342 mmu-miR-3096b-5p; +MIMAT0019343 mmu-miR-3096b-3p; +MIMAT0019344 mmu-miR-3964; +MIMAT0019345 mmu-miR-1843b-5p; +MIMAT0019346 mmu-miR-1843b-3p; +MIMAT0019347 mmu-miR-3965; +MIMAT0019348 mmu-miR-378b; +MIMAT0019349 mmu-miR-101c; +MIMAT0019350 mmu-miR-3966; +MIMAT0019351 mmu-miR-3967; +MIMAT0019352 mmu-miR-3968; +MIMAT0019353 mmu-miR-3969; +MIMAT0019354 mmu-miR-28b; +MIMAT0019355 mmu-miR-3970; +MIMAT0019356 mmu-miR-3971; +MIMAT0019357 hsa-miR-3972; +MIMAT0019358 hsa-miR-3973; +MIMAT0019359 hsa-miR-3974; +MIMAT0019360 hsa-miR-3975; +MIMAT0019361 hsa-miR-3976; +MIMAT0019362 hsa-miR-3977; +MIMAT0019363 hsa-miR-3978; +MIMAT0019364 pma-miR-1a*;pma-miR-1a-5p; +MIMAT0019365 pma-miR-1a;pma-miR-1a-3p; +MIMAT0019366 pma-miR-1b; +MIMAT0019367 pma-miR-1c*;pma-miR-1c-5p; +MIMAT0019368 pma-miR-1c;pma-miR-1c-3p; +MIMAT0019369 pma-miR-1d; +MIMAT0019370 pma-miR-7a;pma-miR-7a-5p; +MIMAT0019371 pma-miR-7a*;pma-miR-7a-3p; +MIMAT0019372 pma-miR-7b; +MIMAT0019373 pma-miR-9a;pma-miR-9a-5p; +MIMAT0019374 pma-miR-9a*;pma-miR-9a-3p; +MIMAT0019375 pma-miR-9b; +MIMAT0019376 pma-miR-10b;pma-miR-10b-5p; +MIMAT0019377 pma-miR-10b*;pma-miR-10b-3p; +MIMAT0019378 pma-miR-10a; +MIMAT0019379 pma-miR-15a; +MIMAT0019380 pma-miR-15b; +MIMAT0019381 pma-miR-16;pma-miR-16-5p; +MIMAT0019382 pma-miR-16*;pma-miR-16-3p; +MIMAT0019383 pma-miR-17a;pma-miR-17a-5p; +MIMAT0019384 pma-miR-17a*;pma-miR-17a-3p; +MIMAT0019385 pma-miR-17b; +MIMAT0019386 pma-miR-17c; +MIMAT0019387 pma-miR-18a;pma-miR-18a-5p; +MIMAT0019388 pma-miR-18a*;pma-miR-18a-3p; +MIMAT0019389 pma-miR-18b;pma-miR-18b-5p; +MIMAT0019390 pma-miR-18b*;pma-miR-18b-3p; +MIMAT0019391 pma-miR-19a; +MIMAT0019392 pma-miR-19b*;pma-miR-19b-5p; +MIMAT0019393 pma-miR-19b;pma-miR-19b-3p; +MIMAT0019394 pma-miR-19c; +MIMAT0019395 pma-miR-20a;pma-miR-20a-5p; +MIMAT0019396 pma-miR-20a*;pma-miR-20a-3p; +MIMAT0019397 pma-miR-20b; +MIMAT0019398 pma-miR-22a*;pma-miR-22a-5p; +MIMAT0019399 pma-miR-22a;pma-miR-22a-3p; +MIMAT0019400 pma-miR-22b*;pma-miR-22b-5p; +MIMAT0019401 pma-miR-22b;pma-miR-22b-3p; +MIMAT0019402 pma-miR-23a*;pma-miR-23a-5p; +MIMAT0019403 pma-miR-23a;pma-miR-23a-3p; +MIMAT0019404 pma-miR-23b; +MIMAT0019405 pma-miR-24; +MIMAT0019406 pma-miR-25b*;pma-miR-25b-5p; +MIMAT0019407 pma-miR-25b;pma-miR-25b-3p; +MIMAT0019408 pma-miR-26a;pma-miR-26a-5p; +MIMAT0019409 pma-miR-26a-1*;pma-miR-26a-1-3p; +MIMAT0019410 pma-miR-26a-2*;pma-miR-26a-2-3p; +MIMAT0019411 pma-miR-26b;pma-miR-26b-5p; +MIMAT0019412 pma-miR-26b*;pma-miR-26b-3p; +MIMAT0019413 pma-miR-27a; +MIMAT0019414 pma-miR-27b*;pma-miR-27b-5p; +MIMAT0019415 pma-miR-27b;pma-miR-27b-3p; +MIMAT0019416 pma-miR-29a*;pma-miR-29a-5p; +MIMAT0019417 pma-miR-29a;pma-miR-29a-3p; +MIMAT0019418 pma-miR-29b; +MIMAT0019419 pma-miR-29c; +MIMAT0019420 pma-miR-29d*;pma-miR-29d-5p; +MIMAT0019421 pma-miR-29d;pma-miR-29d-3p; +MIMAT0019422 pma-miR-30a;pma-miR-30a-5p; +MIMAT0019423 pma-miR-30a*;pma-miR-30a-3p; +MIMAT0019424 pma-miR-30b; +MIMAT0019425 pma-miR-30c;pma-miR-30c-5p; +MIMAT0019426 pma-miR-30c*;pma-miR-30c-3p; +MIMAT0019427 pma-miR-30d; +MIMAT0019428 pma-miR-30e;pma-miR-30e-5p; +MIMAT0019429 pma-miR-30e*;pma-miR-30e-3p; +MIMAT0019430 pma-miR-30f; +MIMAT0019431 pma-miR-30g; +MIMAT0019432 pma-miR-31; +MIMAT0019433 pma-miR-33a; +MIMAT0019434 pma-miR-33b; +MIMAT0019435 pma-miR-92a; +MIMAT0019436 pma-miR-96a; +MIMAT0019437 pma-miR-100a;pma-miR-100a-5p; +MIMAT0019438 pma-miR-100a*;pma-miR-100a-3p; +MIMAT0019439 pma-miR-100b; +MIMAT0019440 pma-miR-100c; +MIMAT0019441 pma-miR-103a; +MIMAT0019442 pma-miR-103b*;pma-miR-103b-5p; +MIMAT0019443 pma-miR-103b;pma-miR-103b-3p; +MIMAT0019444 pma-miR-124*;pma-miR-124-5p; +MIMAT0019445 pma-miR-124;pma-miR-124-3p; +MIMAT0019446 pma-miR-125;pma-miR-125-5p; +MIMAT0019447 pma-miR-125*;pma-miR-125-3p; +MIMAT0019448 pma-miR-126; +MIMAT0019449 pma-miR-128; +MIMAT0019450 pma-miR-129a;pma-miR-129a-5p; +MIMAT0019451 pma-miR-129a*;pma-miR-129a-3p; +MIMAT0019452 pma-miR-130d; +MIMAT0019453 pma-miR-130e; +MIMAT0019454 pma-miR-130a*;pma-miR-130a-5p; +MIMAT0019455 pma-miR-130a;pma-miR-130a-3p; +MIMAT0019456 pma-miR-130b; +MIMAT0019457 pma-miR-130c; +MIMAT0019458 pma-miR-132*;pma-miR-132-5p; +MIMAT0019459 pma-miR-132;pma-miR-132-3p; +MIMAT0019460 pma-miR-133a; +MIMAT0019461 pma-miR-133b*;pma-miR-133b-5p; +MIMAT0019462 pma-miR-133b;pma-miR-133b-3p; +MIMAT0019463 pma-miR-135a;pma-miR-135a-5p; +MIMAT0019464 pma-miR-135a*;pma-miR-135a-3p; +MIMAT0019465 pma-miR-135b; +MIMAT0019466 pma-miR-137-1*;pma-miR-137-1-5p; +MIMAT0019467 pma-miR-137;pma-miR-137-3p; +MIMAT0019468 pma-miR-137-2*;pma-miR-137-2-5p; +MIMAT0019469 pma-miR-138a; +MIMAT0019470 pma-miR-138b; +MIMAT0019471 pma-miR-140; +MIMAT0019472 pma-miR-143*;pma-miR-143-5p; +MIMAT0019473 pma-miR-143;pma-miR-143-3p; +MIMAT0019474 pma-miR-144*;pma-miR-144-5p; +MIMAT0019475 pma-miR-144;pma-miR-144-3p; +MIMAT0019476 pma-miR-145;pma-miR-145-5p; +MIMAT0019477 pma-miR-145*;pma-miR-145-3p; +MIMAT0019478 pma-miR-146;pma-miR-146-5p; +MIMAT0019479 pma-miR-146*;pma-miR-146-3p; +MIMAT0019480 pma-miR-147; +MIMAT0019481 pma-miR-152a; +MIMAT0019482 pma-miR-152b; +MIMAT0019483 pma-miR-153*;pma-miR-153-5p; +MIMAT0019484 pma-miR-153;pma-miR-153-3p; +MIMAT0019485 pma-miR-155; +MIMAT0019486 pma-miR-181a;pma-miR-181a-5p; +MIMAT0019487 pma-miR-181a*;pma-miR-181a-3p; +MIMAT0019488 pma-miR-181b;pma-miR-181b-5p; +MIMAT0019489 pma-miR-181b*;pma-miR-181b-3p; +MIMAT0019490 pma-miR-182; +MIMAT0019491 pma-miR-183;pma-miR-183-5p; +MIMAT0019492 pma-miR-183*;pma-miR-183-3p; +MIMAT0019493 pma-miR-184; +MIMAT0019494 pma-miR-190a; +MIMAT0019495 pma-miR-190b;pma-miR-190b-5p; +MIMAT0019496 pma-miR-190b*;pma-miR-190b-3p; +MIMAT0019497 pma-miR-192;pma-miR-192-5p; +MIMAT0019498 pma-miR-192*;pma-miR-192-3p; +MIMAT0019499 pma-miR-193; +MIMAT0019500 pma-miR-194;pma-miR-194-5p; +MIMAT0019501 pma-miR-194*;pma-miR-194-3p; +MIMAT0019502 pma-miR-196a;pma-miR-196a-5p; +MIMAT0019503 pma-miR-196a*;pma-miR-196a-3p; +MIMAT0019504 pma-miR-196b; +MIMAT0019505 pma-miR-199a;pma-miR-199a-5p; +MIMAT0019506 pma-miR-199a*;pma-miR-199a-3p; +MIMAT0019507 pma-miR-199b;pma-miR-199b-5p; +MIMAT0019508 pma-miR-199b*;pma-miR-199b-3p; +MIMAT0019509 pma-miR-200b*;pma-miR-200b-5p; +MIMAT0019510 pma-miR-200b;pma-miR-200b-3p; +MIMAT0019511 pma-miR-203a*;pma-miR-203a-5p; +MIMAT0019512 pma-miR-203a;pma-miR-203a-3p; +MIMAT0019513 pma-miR-203b*;pma-miR-203b-5p; +MIMAT0019514 pma-miR-203b;pma-miR-203b-3p; +MIMAT0019515 pma-miR-204;pma-miR-204-5p; +MIMAT0019516 pma-miR-204*;pma-miR-204-3p; +MIMAT0019517 pma-miR-205a;pma-miR-205a-5p; +MIMAT0019518 pma-miR-205a*;pma-miR-205a-3p; +MIMAT0019519 pma-miR-205b; +MIMAT0019520 pma-miR-208*;pma-miR-208-5p; +MIMAT0019521 pma-miR-208;pma-miR-208-3p; +MIMAT0019522 pma-miR-210; +MIMAT0019523 pma-miR-212*;pma-miR-212-5p; +MIMAT0019524 pma-miR-212;pma-miR-212-3p; +MIMAT0019525 pma-miR-216a;pma-miR-216a-5p; +MIMAT0019526 pma-miR-216a*;pma-miR-216a-3p; +MIMAT0019527 pma-miR-216b; +MIMAT0019528 pma-miR-217a; +MIMAT0019529 pma-miR-218a;pma-miR-218a-5p; +MIMAT0019530 pma-miR-218a*;pma-miR-218a-3p; +MIMAT0019531 pma-miR-218b; +MIMAT0019532 pma-miR-221; +MIMAT0019533 pma-miR-222*;pma-miR-222-5p; +MIMAT0019534 pma-miR-222;pma-miR-222-3p; +MIMAT0019535 pma-miR-281a; +MIMAT0019536 pma-miR-301a; +MIMAT0019537 pma-miR-301b; +MIMAT0019538 pma-miR-302; +MIMAT0019539 pma-miR-315; +MIMAT0019540 pma-miR-338b; +MIMAT0019541 pma-miR-373;pma-miR-430f; +MIMAT0019542 pma-miR-375a*;pma-miR-375a-5p; +MIMAT0019543 pma-miR-375a;pma-miR-375a-3p; +MIMAT0019544 pma-miR-375b*;pma-miR-375b-5p; +MIMAT0019545 pma-miR-375b;pma-miR-375b-3p; +MIMAT0019546 pma-miR-429*;pma-miR-429-5p; +MIMAT0019547 pma-miR-429;pma-miR-429-3p; +MIMAT0019548 pma-miR-430a; +MIMAT0019549 pma-miR-430b; +MIMAT0019550 pma-miR-430c; +MIMAT0019551 pma-miR-430d; +MIMAT0019552 pma-miR-430e; +MIMAT0019553 pma-miR-451; +MIMAT0019554 pma-miR-456; +MIMAT0019555 pma-miR-459; +MIMAT0019556 pma-miR-497;pma-miR-497-5p; +MIMAT0019557 pma-miR-497*;pma-miR-497-3p; +MIMAT0019558 pma-miR-551; +MIMAT0019559 pma-miR-875; +MIMAT0019560 pma-miR-1329; +MIMAT0019561 pma-miR-1788a-5p; +MIMAT0019562 pma-miR-1788a-3p; +MIMAT0019563 pma-miR-1788b-3p; +MIMAT0019564 pma-let-7a; +MIMAT0019565 pma-let-7b;pma-let-7b-5p; +MIMAT0019566 pma-let-7b*;pma-let-7b-3p; +MIMAT0019567 pma-let-7c; +MIMAT0019568 pma-let-7d; +MIMAT0019569 pma-miR-4541; +MIMAT0019570 pma-miR-4542*;pma-miR-4542-5p; +MIMAT0019571 pma-miR-4542;pma-miR-4542-3p; +MIMAT0019572 pma-miR-4543; +MIMAT0019573 pma-miR-4544;pma-miR-4544-5p; +MIMAT0019574 pma-miR-4544*;pma-miR-4544-3p; +MIMAT0019575 pma-miR-4545*;pma-miR-4545-5p; +MIMAT0019576 pma-miR-4545;pma-miR-4545-3p; +MIMAT0019577 pma-miR-4546; +MIMAT0019578 pma-miR-4547;pma-miR-4547-5p; +MIMAT0019579 pma-miR-4547*;pma-miR-4547-3p; +MIMAT0019580 pma-miR-4548; +MIMAT0019581 pma-miR-4549; +MIMAT0019582 pma-miR-4550; +MIMAT0019583 pma-miR-4551; +MIMAT0019584 pma-miR-4552; +MIMAT0019585 pma-miR-4553; +MIMAT0019586 pma-miR-4554; +MIMAT0019587 pma-miR-4555; +MIMAT0019588 pma-miR-4556; +MIMAT0019589 pma-miR-4557; +MIMAT0019590 pma-miR-4558; +MIMAT0019591 pma-miR-4559; +MIMAT0019592 pma-miR-4560; +MIMAT0019593 pma-miR-4561; +MIMAT0019594 pma-miR-4562; +MIMAT0019595 pma-miR-4563; +MIMAT0019596 pma-miR-4564; +MIMAT0019597 pma-miR-4565; +MIMAT0019598 pma-miR-4566; +MIMAT0019599 pma-miR-4567; +MIMAT0019600 pma-miR-4568; +MIMAT0019601 pma-miR-4569; +MIMAT0019602 pma-miR-4570; +MIMAT0019603 pma-miR-4571-5p; +MIMAT0019604 pma-miR-4571-3p; +MIMAT0019605 pma-miR-4572; +MIMAT0019606 pma-miR-4573; +MIMAT0019607 pma-miR-4574; +MIMAT0019608 pma-miR-4575; +MIMAT0019609 pma-miR-4576; +MIMAT0019610 pma-miR-4577; +MIMAT0019611 pma-miR-4578; +MIMAT0019612 pma-miR-4579; +MIMAT0019613 pma-miR-4580; +MIMAT0019614 pma-miR-4581; +MIMAT0019615 pma-miR-4582; +MIMAT0019616 pma-miR-4583; +MIMAT0019617 pma-miR-4584; +MIMAT0019618 pma-miR-4585; +MIMAT0019619 pma-miR-4586; +MIMAT0019620 pma-miR-4587; +MIMAT0019621 pma-miR-4588; +MIMAT0019622 pma-miR-4589; +MIMAT0019623 pma-miR-4590; +MIMAT0019624 pma-miR-4591; +MIMAT0019625 pma-miR-4592; +MIMAT0019626 pma-miR-4593; +MIMAT0019627 pma-miR-4594; +MIMAT0019628 pma-miR-4595; +MIMAT0019629 pma-miR-4596; +MIMAT0019630 pma-miR-4597; +MIMAT0019631 pma-miR-4598; +MIMAT0019632 pma-miR-4599a; +MIMAT0019633 pma-miR-4599b; +MIMAT0019634 pma-miR-4600; +MIMAT0019635 pma-miR-4601; +MIMAT0019636 pma-miR-4602; +MIMAT0019637 pma-miR-4603; +MIMAT0019638 pma-miR-4604; +MIMAT0019639 pma-miR-4605; +MIMAT0019640 pma-miR-4606; +MIMAT0019641 pma-miR-4607; +MIMAT0019642 pma-miR-4608; +MIMAT0019643 pma-miR-4609; +MIMAT0019644 pma-miR-4610; +MIMAT0019645 pma-miR-4611; +MIMAT0019646 pma-miR-4612; +MIMAT0019647 pma-miR-4613; +MIMAT0019648 pma-miR-4614; +MIMAT0019649 pma-miR-4615; +MIMAT0019650 pma-miR-4616; +MIMAT0019651 pma-miR-4617; +MIMAT0019652 pma-miR-4618; +MIMAT0019653 pma-miR-4619; +MIMAT0019654 pma-miR-4620; +MIMAT0019655 pma-miR-4621; +MIMAT0019656 pma-miR-4622; +MIMAT0019657 pma-miR-4623; +MIMAT0019658 pma-miR-4624; +MIMAT0019659 pma-miR-4625; +MIMAT0019660 pma-miR-4626; +MIMAT0019661 pma-miR-4627; +MIMAT0019662 pma-miR-4628; +MIMAT0019663 pma-miR-4629; +MIMAT0019664 pma-miR-4630; +MIMAT0019665 pma-miR-4631; +MIMAT0019666 osa-miR812k; +MIMAT0019667 osa-miR812l; +MIMAT0019668 osa-miR812m; +MIMAT0019669 osa-miR1862f; +MIMAT0019670 osa-miR1862g; +MIMAT0019671 osa-miR811d.2; +MIMAT0019672 osa-miR811d.1; +MIMAT0019673 osa-miR3979-5p; +MIMAT0019674 osa-miR3979-3p; +MIMAT0019675 osa-miR3980a-5p; +MIMAT0019676 osa-miR3980a-3p; +MIMAT0019677 osa-miR3980b-5p; +MIMAT0019678 osa-miR3980b-3p; +MIMAT0019679 osa-miR812n-5p; +MIMAT0019680 osa-miR812n-3p; +MIMAT0019681 osa-miR812o-5p; +MIMAT0019682 osa-miR812o-3p; +MIMAT0019683 osa-miR3981-5p; +MIMAT0019684 osa-miR3981-3p; +MIMAT0019685 osa-miR2873b; +MIMAT0019686 osa-miR3982-5p; +MIMAT0019687 osa-miR3982-3p; +MIMAT0019688 hsa-miR-4632;hsa-miR-4632-3p; +MIMAT0019689 hsa-miR-4633-5p; +MIMAT0019690 hsa-miR-4633-3p; +MIMAT0019691 hsa-miR-4634; +MIMAT0019692 hsa-miR-4635; +MIMAT0019693 hsa-miR-4636; +MIMAT0019694 hsa-miR-4637; +MIMAT0019695 hsa-miR-4638-5p; +MIMAT0019696 hsa-miR-4638-3p; +MIMAT0019697 hsa-miR-4639-5p; +MIMAT0019698 hsa-miR-4639-3p; +MIMAT0019699 hsa-miR-4640-5p; +MIMAT0019700 hsa-miR-4640-3p; +MIMAT0019701 hsa-miR-4641; +MIMAT0019702 hsa-miR-4642; +MIMAT0019703 hsa-miR-4643; +MIMAT0019704 hsa-miR-4644; +MIMAT0019705 hsa-miR-4645-5p; +MIMAT0019706 hsa-miR-4645-3p; +MIMAT0019707 hsa-miR-4646-5p; +MIMAT0019708 hsa-miR-4646-3p; +MIMAT0019709 hsa-miR-4647; +MIMAT0019710 hsa-miR-4648; +MIMAT0019711 hsa-miR-4649-5p; +MIMAT0019712 hsa-miR-4649-3p; +MIMAT0019713 hsa-miR-4650-5p; +MIMAT0019714 hsa-miR-4650-3p; +MIMAT0019715 hsa-miR-4651; +MIMAT0019716 hsa-miR-4652-5p; +MIMAT0019717 hsa-miR-4652-3p; +MIMAT0019718 hsa-miR-4653-5p; +MIMAT0019719 hsa-miR-4653-3p; +MIMAT0019720 hsa-miR-4654; +MIMAT0019721 hsa-miR-4655-5p; +MIMAT0019722 hsa-miR-4655-3p; +MIMAT0019723 hsa-miR-4656; +MIMAT0019724 hsa-miR-4657; +MIMAT0019725 hsa-miR-4658; +MIMAT0019726 hsa-miR-4659a-5p; +MIMAT0019727 hsa-miR-4659a-3p; +MIMAT0019728 hsa-miR-4660; +MIMAT0019729 hsa-miR-4661-5p; +MIMAT0019730 hsa-miR-4661-3p; +MIMAT0019731 hsa-miR-4662a-5p; +MIMAT0019732 hsa-miR-4662a-3p; +MIMAT0019733 hsa-miR-4659b-5p; +MIMAT0019734 hsa-miR-4659b-3p; +MIMAT0019735 hsa-miR-4663; +MIMAT0019736 hsa-miR-4662b; +MIMAT0019737 hsa-miR-4664-5p; +MIMAT0019738 hsa-miR-4664-3p; +MIMAT0019739 hsa-miR-4665-5p; +MIMAT0019740 hsa-miR-4665-3p; +MIMAT0019741 hsa-miR-4666-5p;hsa-miR-4666a-5p; +MIMAT0019742 hsa-miR-4666-3p;hsa-miR-4666a-3p; +MIMAT0019743 hsa-miR-4667-5p; +MIMAT0019744 hsa-miR-4667-3p; +MIMAT0019745 hsa-miR-4668-5p; +MIMAT0019746 hsa-miR-4668-3p; +MIMAT0019747 hsa-miR-2964a-5p;hsa-miR-219b-5p; +MIMAT0019748 hsa-miR-2964a-3p;hsa-miR-219b-3p; +MIMAT0019749 hsa-miR-4669; +MIMAT0019750 hsa-miR-4670-5p; +MIMAT0019751 hsa-miR-4670-3p; +MIMAT0019752 hsa-miR-4671-5p; +MIMAT0019753 hsa-miR-4671-3p; +MIMAT0019754 hsa-miR-4672; +MIMAT0019755 hsa-miR-4673; +MIMAT0019756 hsa-miR-4674; +MIMAT0019757 hsa-miR-4675; +MIMAT0019758 hsa-miR-4676-5p; +MIMAT0019759 hsa-miR-4676-3p; +MIMAT0019760 hsa-miR-4677-5p; +MIMAT0019761 hsa-miR-4677-3p; +MIMAT0019762 hsa-miR-4678; +MIMAT0019763 hsa-miR-4679; +MIMAT0019764 hsa-miR-4680-5p; +MIMAT0019765 hsa-miR-4680-3p; +MIMAT0019766 hsa-miR-4681; +MIMAT0019767 hsa-miR-4682; +MIMAT0019768 hsa-miR-4683; +MIMAT0019769 hsa-miR-4684-5p; +MIMAT0019770 hsa-miR-4684-3p; +MIMAT0019771 hsa-miR-4685-5p; +MIMAT0019772 hsa-miR-4685-3p; +MIMAT0019773 hsa-miR-4686; +MIMAT0019774 hsa-miR-4687-5p; +MIMAT0019775 hsa-miR-4687-3p; +MIMAT0019776 hsa-miR-1343;hsa-miR-1343-3p; +MIMAT0019777 hsa-miR-4688; +MIMAT0019778 hsa-miR-4689; +MIMAT0019779 hsa-miR-4690-5p; +MIMAT0019780 hsa-miR-4690-3p; +MIMAT0019781 hsa-miR-4691-5p; +MIMAT0019782 hsa-miR-4691-3p; +MIMAT0019783 hsa-miR-4692; +MIMAT0019784 hsa-miR-4693-5p; +MIMAT0019785 hsa-miR-4693-3p; +MIMAT0019786 hsa-miR-4694-5p; +MIMAT0019787 hsa-miR-4694-3p; +MIMAT0019788 hsa-miR-4695-5p; +MIMAT0019789 hsa-miR-4695-3p; +MIMAT0019790 hsa-miR-4696; +MIMAT0019791 hsa-miR-4697-5p; +MIMAT0019792 hsa-miR-4697-3p; +MIMAT0019793 hsa-miR-4698; +MIMAT0019794 hsa-miR-4699-5p; +MIMAT0019795 hsa-miR-4699-3p; +MIMAT0019796 hsa-miR-4700-5p; +MIMAT0019797 hsa-miR-4700-3p; +MIMAT0019798 hsa-miR-4701-5p; +MIMAT0019799 hsa-miR-4701-3p; +MIMAT0019801 hsa-miR-4703-5p; +MIMAT0019802 hsa-miR-4703-3p; +MIMAT0019803 hsa-miR-4704-5p; +MIMAT0019804 hsa-miR-4704-3p; +MIMAT0019805 hsa-miR-4705; +MIMAT0019806 hsa-miR-4706; +MIMAT0019807 hsa-miR-4707-5p; +MIMAT0019808 hsa-miR-4707-3p; +MIMAT0019809 hsa-miR-4708-5p; +MIMAT0019810 hsa-miR-4708-3p; +MIMAT0019811 hsa-miR-4709-5p; +MIMAT0019812 hsa-miR-4709-3p; +MIMAT0019813 hsa-miR-3545-5p;hsa-miR-203b-5p; +MIMAT0019814 hsa-miR-3545-3p;hsa-miR-203b-3p; +MIMAT0019815 hsa-miR-4710; +MIMAT0019816 hsa-miR-4711-5p; +MIMAT0019817 hsa-miR-4711-3p; +MIMAT0019818 hsa-miR-4712-5p; +MIMAT0019819 hsa-miR-4712-3p; +MIMAT0019820 hsa-miR-4713-5p; +MIMAT0019821 hsa-miR-4713-3p; +MIMAT0019822 hsa-miR-4714-5p; +MIMAT0019823 hsa-miR-4714-3p; +MIMAT0019824 hsa-miR-4715-5p; +MIMAT0019825 hsa-miR-4715-3p; +MIMAT0019826 hsa-miR-4716-5p; +MIMAT0019827 hsa-miR-4716-3p; +MIMAT0019828 hsa-miR-3529;hsa-miR-3529-5p; +MIMAT0019829 hsa-miR-4717-5p; +MIMAT0019830 hsa-miR-4717-3p; +MIMAT0019831 hsa-miR-4718; +MIMAT0019832 hsa-miR-4719; +MIMAT0019833 hsa-miR-4720-5p; +MIMAT0019834 hsa-miR-4720-3p; +MIMAT0019835 hsa-miR-4721; +MIMAT0019836 hsa-miR-4722-5p; +MIMAT0019837 hsa-miR-4722-3p; +MIMAT0019838 hsa-miR-4723-5p; +MIMAT0019839 hsa-miR-4723-3p; +MIMAT0019840 hsa-miR-451b; +MIMAT0019841 hsa-miR-4724-5p; +MIMAT0019842 hsa-miR-4724-3p; +MIMAT0019843 hsa-miR-4725-5p; +MIMAT0019844 hsa-miR-4725-3p; +MIMAT0019845 hsa-miR-4726-5p; +MIMAT0019846 hsa-miR-4726-3p; +MIMAT0019847 hsa-miR-4727-5p; +MIMAT0019848 hsa-miR-4727-3p; +MIMAT0019849 hsa-miR-4728-5p; +MIMAT0019850 hsa-miR-4728-3p; +MIMAT0019851 hsa-miR-4729; +MIMAT0019852 hsa-miR-4730; +MIMAT0019853 hsa-miR-4731-5p; +MIMAT0019854 hsa-miR-4731-3p; +MIMAT0019855 hsa-miR-4732-5p; +MIMAT0019856 hsa-miR-4732-3p; +MIMAT0019857 hsa-miR-4733-5p; +MIMAT0019858 hsa-miR-4733-3p; +MIMAT0019859 hsa-miR-4734; +MIMAT0019860 hsa-miR-4735-5p; +MIMAT0019861 hsa-miR-4735-3p; +MIMAT0019862 hsa-miR-4736; +MIMAT0019863 hsa-miR-4737; +MIMAT0019864 hsa-miR-3064-5p; +MIMAT0019865 hsa-miR-3064-3p; +MIMAT0019866 hsa-miR-4738-5p; +MIMAT0019867 hsa-miR-4738-3p; +MIMAT0019868 hsa-miR-4739; +MIMAT0019869 hsa-miR-4740-5p; +MIMAT0019870 hsa-miR-4740-3p; +MIMAT0019871 hsa-miR-4741; +MIMAT0019872 hsa-miR-4742-5p; +MIMAT0019873 hsa-miR-4742-3p; +MIMAT0019874 hsa-miR-4743;hsa-miR-4743-5p; +MIMAT0019875 hsa-miR-4744; +MIMAT0019876 hsa-miR-3591-5p;hsa-miR-122b-5p; +MIMAT0019877 hsa-miR-3591-3p;hsa-miR-122b-3p; +MIMAT0019878 hsa-miR-4745-5p; +MIMAT0019879 hsa-miR-4745-3p; +MIMAT0019880 hsa-miR-4746-5p; +MIMAT0019881 hsa-miR-4746-3p; +MIMAT0019882 hsa-miR-4747-5p; +MIMAT0019883 hsa-miR-4747-3p; +MIMAT0019884 hsa-miR-4748; +MIMAT0019885 hsa-miR-4749-5p; +MIMAT0019886 hsa-miR-4749-3p; +MIMAT0019887 hsa-miR-4750;hsa-miR-4750-5p; +MIMAT0019888 hsa-miR-4751; +MIMAT0019889 hsa-miR-4752; +MIMAT0019890 hsa-miR-4753-5p; +MIMAT0019891 hsa-miR-4753-3p; +MIMAT0019892 hsa-miR-371b-5p; +MIMAT0019893 hsa-miR-371b-3p; +MIMAT0019894 hsa-miR-4754; +MIMAT0019895 hsa-miR-4755-5p; +MIMAT0019896 hsa-miR-4755-3p; +MIMAT0019897 hsa-miR-499a-5p;hsa-miR-499b-5p; +MIMAT0019898 hsa-miR-499a-3p;hsa-miR-499b-3p; +MIMAT0019899 hsa-miR-4756-5p; +MIMAT0019900 hsa-miR-4756-3p; +MIMAT0019901 hsa-miR-4757-5p; +MIMAT0019902 hsa-miR-4757-3p; +MIMAT0019903 hsa-miR-4758-5p; +MIMAT0019904 hsa-miR-4758-3p; +MIMAT0019905 hsa-miR-4759; +MIMAT0019906 hsa-miR-4760-5p; +MIMAT0019907 hsa-miR-4760-3p; +MIMAT0019908 hsa-miR-4761-5p; +MIMAT0019909 hsa-miR-4761-3p; +MIMAT0019910 hsa-miR-4762-5p; +MIMAT0019911 hsa-miR-4762-3p; +MIMAT0019912 hsa-miR-4763-5p; +MIMAT0019913 hsa-miR-4763-3p; +MIMAT0019914 hsa-miR-4764-5p; +MIMAT0019915 hsa-miR-4764-3p; +MIMAT0019916 hsa-miR-4765; +MIMAT0019917 hsa-miR-4766-5p; +MIMAT0019918 hsa-miR-4766-3p; +MIMAT0019919 hsa-miR-4767; +MIMAT0019920 hsa-miR-4768-5p; +MIMAT0019921 hsa-miR-4768-3p; +MIMAT0019922 hsa-miR-4769-5p; +MIMAT0019923 hsa-miR-4769-3p; +MIMAT0019924 hsa-miR-4770; +MIMAT0019925 hsa-miR-4771; +MIMAT0019926 hsa-miR-4772-5p; +MIMAT0019927 hsa-miR-4772-3p; +MIMAT0019928 hsa-miR-4773; +MIMAT0019929 hsa-miR-4774-5p; +MIMAT0019930 hsa-miR-4774-3p; +MIMAT0019931 hsa-miR-4775; +MIMAT0019932 hsa-miR-4776-5p; +MIMAT0019933 hsa-miR-4776-3p; +MIMAT0019934 hsa-miR-4777-5p; +MIMAT0019935 hsa-miR-4777-3p; +MIMAT0019936 hsa-miR-4778-5p; +MIMAT0019937 hsa-miR-4778-3p; +MIMAT0019938 hsa-miR-4779; +MIMAT0019939 hsa-miR-4780; +MIMAT0019940 hsa-miR-4436b-5p; +MIMAT0019941 hsa-miR-4436b-3p; +MIMAT0019942 hsa-miR-4781-5p; +MIMAT0019943 hsa-miR-4781-3p; +MIMAT0019944 hsa-miR-4782-5p; +MIMAT0019945 hsa-miR-4782-3p; +MIMAT0019946 hsa-miR-4783-5p; +MIMAT0019947 hsa-miR-4783-3p; +MIMAT0019948 hsa-miR-4784; +MIMAT0019949 hsa-miR-4785; +MIMAT0019950 hsa-miR-1245b-5p; +MIMAT0019951 hsa-miR-1245b-3p; +MIMAT0019952 hsa-miR-2467-5p; +MIMAT0019953 hsa-miR-2467-3p; +MIMAT0019954 hsa-miR-4786-5p; +MIMAT0019955 hsa-miR-4786-3p; +MIMAT0019956 hsa-miR-4787-5p; +MIMAT0019957 hsa-miR-4787-3p; +MIMAT0019958 hsa-miR-4788; +MIMAT0019959 hsa-miR-4789-5p; +MIMAT0019960 hsa-miR-4789-3p; +MIMAT0019961 hsa-miR-4790-5p; +MIMAT0019962 hsa-miR-4790-3p; +MIMAT0019963 hsa-miR-4791; +MIMAT0019964 hsa-miR-4792; +MIMAT0019965 hsa-miR-4793-5p; +MIMAT0019966 hsa-miR-4793-3p; +MIMAT0019967 hsa-miR-4794; +MIMAT0019968 hsa-miR-4795-5p; +MIMAT0019969 hsa-miR-4795-3p; +MIMAT0019970 hsa-miR-4796-5p; +MIMAT0019971 hsa-miR-4796-3p; +MIMAT0019972 hsa-miR-4797-5p; +MIMAT0019973 hsa-miR-4797-3p; +MIMAT0019974 hsa-miR-4798-5p; +MIMAT0019975 hsa-miR-4798-3p; +MIMAT0019976 hsa-miR-4799-5p; +MIMAT0019977 hsa-miR-4799-3p; +MIMAT0019978 hsa-miR-4800-5p; +MIMAT0019979 hsa-miR-4800-3p; +MIMAT0019980 hsa-miR-4801; +MIMAT0019981 hsa-miR-4802-5p; +MIMAT0019982 hsa-miR-4802-3p; +MIMAT0019983 hsa-miR-4803; +MIMAT0019984 hsa-miR-4804-5p; +MIMAT0019985 hsa-miR-4804-3p; +MIMAT0019986 cel-miR-4805*;cel-miR-4805-5p; +MIMAT0019987 cel-miR-4805;cel-miR-4805-3p; +MIMAT0019988 cel-miR-4806-5p; +MIMAT0019989 cel-miR-4806-3p; +MIMAT0019990 cel-miR-4807; +MIMAT0019991 cel-miR-4808*;cel-miR-4808-5p; +MIMAT0019992 cel-miR-4808;cel-miR-4808-3p; +MIMAT0019993 cel-miR-4809*;cel-miR-4809-5p; +MIMAT0019994 cel-miR-4809;cel-miR-4809-3p; +MIMAT0019995 cel-miR-4810;cel-miR-4810a; +MIMAT0019996 cel-miR-4811*;cel-miR-4811-5p; +MIMAT0019997 cel-miR-4811;cel-miR-4811-3p; +MIMAT0019998 cel-miR-4812;cel-miR-4812-5p; +MIMAT0019999 cel-miR-4812*;cel-miR-4812-3p; +MIMAT0020000 cel-miR-4813*;cel-miR-4813-5p; +MIMAT0020001 cel-miR-4813;cel-miR-4813-3p; +MIMAT0020002 cel-miR-4814*;cel-miR-4814-5p; +MIMAT0020003 cel-miR-4814;cel-miR-4814-3p; +MIMAT0020004 cel-miR-4815; +MIMAT0020005 cel-miR-4816;cel-miR-4816-5p; +MIMAT0020006 cel-miR-4816*;cel-miR-4816-3p; +MIMAT0020007 sko-miR-125b*;sko-miR-125b-3p; +MIMAT0020008 sko-miR-4817*;sko-miR-4817-5p; +MIMAT0020009 sko-miR-4818a; +MIMAT0020010 sko-miR-4818b*;sko-miR-4818b-5p; +MIMAT0020011 sko-miR-4818b;sko-miR-4818b-3p; +MIMAT0020012 sko-miR-4818c; +MIMAT0020013 sko-miR-4818d; +MIMAT0020014 sko-miR-4818e*;sko-miR-4818e-5p; +MIMAT0020015 sko-miR-4818e;sko-miR-4818e-3p; +MIMAT0020016 sko-miR-4818f; +MIMAT0020017 sko-miR-4818g*;sko-miR-4818g-5p; +MIMAT0020018 sko-miR-4818g;sko-miR-4818g-3p; +MIMAT0020019 sko-miR-4819;sko-miR-4819-5p; +MIMAT0020020 sko-miR-4819*;sko-miR-4819-3p; +MIMAT0020021 sko-miR-4820; +MIMAT0020022 sko-miR-4821; +MIMAT0020023 sko-miR-2007;sko-miR-2007-5p; +MIMAT0020024 sko-miR-2007*;sko-miR-2007-3p; +MIMAT0020025 sko-miR-4822*;sko-miR-4822-5p; +MIMAT0020026 sko-miR-4822;sko-miR-4822-3p; +MIMAT0020027 sko-miR-4823*;sko-miR-4823-5p; +MIMAT0020028 sko-miR-4823;sko-miR-4823-3p; +MIMAT0020029 sko-miR-4824; +MIMAT0020030 sko-miR-4825*;sko-miR-4825-5p; +MIMAT0020031 sko-miR-4825;sko-miR-4825-3p; +MIMAT0020032 sko-miR-4826;sko-miR-4826-5p; +MIMAT0020033 sko-miR-4826*;sko-miR-4826-3p; +MIMAT0020034 sko-miR-4827a; +MIMAT0020035 sko-miR-4827b; +MIMAT0020036 sko-miR-4828a; +MIMAT0020037 sko-miR-4828b; +MIMAT0020038 sko-miR-4829a; +MIMAT0020039 sko-miR-4829b; +MIMAT0020040 sko-miR-4829c; +MIMAT0020041 sko-miR-4830a; +MIMAT0020042 sko-miR-4830b;sko-miR-4830b-5p; +MIMAT0020043 sko-miR-4830b*;sko-miR-4830b-3p; +MIMAT0020044 sko-miR-4830c; +MIMAT0020045 sko-miR-4831; +MIMAT0020046 sko-miR-4832; +MIMAT0020047 sko-miR-2006*;sko-miR-2006-5p; +MIMAT0020048 sko-miR-2006;sko-miR-2006-3p; +MIMAT0020049 sko-miR-4833; +MIMAT0020050 sko-miR-4834; +MIMAT0020051 sko-miR-4835*;sko-miR-4835-5p; +MIMAT0020052 sko-miR-4835;sko-miR-4835-3p; +MIMAT0020053 sko-miR-4836*;sko-miR-4836-5p; +MIMAT0020054 sko-miR-4836;sko-miR-4836-3p; +MIMAT0020055 sko-miR-4837; +MIMAT0020056 sko-miR-4830d;sko-miR-4830d-5p; +MIMAT0020057 sko-miR-4830d*;sko-miR-4830d-3p; +MIMAT0020058 sko-miR-4838; +MIMAT0020059 sko-miR-4839; +MIMAT0020060 sko-miR-4840; +MIMAT0020061 sko-miR-4841; +MIMAT0020062 sko-miR-4842; +MIMAT0020063 sko-miR-4843; +MIMAT0020064 sko-miR-4844; +MIMAT0020065 sko-miR-4845; +MIMAT0020066 sko-miR-4846; +MIMAT0020067 spu-miR-29b; +MIMAT0020068 spu-miR-981; +MIMAT0020069 spu-miR-4847; +MIMAT0020070 spu-miR-4848a; +MIMAT0020071 spu-miR-4848b; +MIMAT0020072 spu-miR-4849; +MIMAT0020073 spu-miR-4850; +MIMAT0020074 spu-miR-4851; +MIMAT0020075 spu-miR-4852; +MIMAT0020076 spu-miR-4853; +MIMAT0020077 spu-miR-4854; +MIMAT0020078 spu-miR-4855; +MIMAT0020079 bfl-miR-92d*;bfl-miR-92d-5p; +MIMAT0020080 bfl-miR-129b; +MIMAT0020081 bfl-miR-182b*;bfl-miR-182b-3p; +MIMAT0020082 bfl-miR-4856a; +MIMAT0020083 bfl-miR-4857; +MIMAT0020084 bfl-miR-4858*;bfl-miR-4858-5p; +MIMAT0020085 bfl-miR-4858;bfl-miR-4858-3p; +MIMAT0020086 bfl-miR-4859*;bfl-miR-4859-5p; +MIMAT0020087 bfl-miR-4859;bfl-miR-4859-3p; +MIMAT0020088 bfl-miR-4860*;bfl-miR-4860-5p; +MIMAT0020089 bfl-miR-4860;bfl-miR-4860-3p; +MIMAT0020090 bfl-miR-4861; +MIMAT0020091 bfl-miR-4862a;bfl-miR-4862-5p; +MIMAT0020092 bfl-miR-4862b*;bfl-miR-4862-3p; +MIMAT0020093 bfl-miR-4856b;bfl-miR-4856b-5p; +MIMAT0020094 bfl-miR-4856b*;bfl-miR-4856b-3p; +MIMAT0020095 bfl-miR-4863;bfl-miR-4863-5p; +MIMAT0020096 bfl-miR-4863*;bfl-miR-4863-3p; +MIMAT0020097 bfl-miR-4864*;bfl-miR-4864-5p; +MIMAT0020098 bfl-miR-4864;bfl-miR-4864-3p; +MIMAT0020099 bfl-miR-4865*;bfl-miR-4865-5p; +MIMAT0020100 bfl-miR-4865;bfl-miR-4865-3p; +MIMAT0020101 bfl-miR-4866;bfl-miR-4866-5p; +MIMAT0020102 bfl-miR-4866*;bfl-miR-4866-3p; +MIMAT0020103 bfl-miR-4867; +MIMAT0020104 bfl-miR-4868a; +MIMAT0020105 bfl-miR-4868b; +MIMAT0020106 bfl-miR-4868c*;bfl-miR-4868c-5p; +MIMAT0020107 bfl-miR-4868c;bfl-miR-4868c-3p; +MIMAT0020108 bfl-miR-4869;bfl-miR-4869-5p; +MIMAT0020109 bfl-miR-4869*;bfl-miR-4869-3p; +MIMAT0020110 bfl-miR-4870; +MIMAT0020111 bfl-miR-193b; +MIMAT0020112 bfl-miR-4871*;bfl-miR-4871-5p; +MIMAT0020113 bfl-miR-4871;bfl-miR-4871-3p; +MIMAT0020114 bfl-miR-4872a; +MIMAT0020115 bfl-miR-4872b; +MIMAT0020116 bfl-miR-4872c; +MIMAT0020117 bfl-miR-4928; +MIMAT0020118 xbo-miR-92a; +MIMAT0020119 xbo-miR-2013; +MIMAT0020120 xbo-miR-124; +MIMAT0020121 xbo-miR-137; +MIMAT0020122 xbo-miR-219; +MIMAT0020123 xbo-miR-2012; +MIMAT0020124 xbo-miR-4907; +MIMAT0020125 xbo-miR-92b; +MIMAT0020126 cel-miR-4920; +MIMAT0020127 cel-miR-4921; +MIMAT0020128 cel-miR-4922; +MIMAT0020129 cel-miR-4923a; +MIMAT0020130 cel-miR-4924; +MIMAT0020131 cel-miR-4923b; +MIMAT0020132 cel-miR-4925; +MIMAT0020133 cel-miR-4926; +MIMAT0020134 cel-miR-4927; +MIMAT0020135 cel-miR-4929; +MIMAT0020136 cel-miR-4930; +MIMAT0020137 cel-miR-4931; +MIMAT0020138 cel-miR-4932; +MIMAT0020139 cel-miR-4933; +MIMAT0020140 cel-miR-4934; +MIMAT0020141 cel-miR-4935; +MIMAT0020142 cel-miR-4936; +MIMAT0020143 cel-miR-4937; +MIMAT0020144 cel-miR-4938; +MIMAT0020145 dme-miR-4939-3p; +MIMAT0020146 dme-miR-4940-5p; +MIMAT0020147 dme-miR-4940-3p; +MIMAT0020148 dme-miR-4941-5p; +MIMAT0020149 dme-miR-4941-3p; +MIMAT0020150 dme-miR-4942-3p; +MIMAT0020151 dme-miR-4943-5p; +MIMAT0020152 dme-miR-4943-3p; +MIMAT0020153 dme-miR-4944-5p; +MIMAT0020154 dme-miR-4944-3p; +MIMAT0020155 dme-miR-4945-5p; +MIMAT0020156 dme-miR-4946-5p; +MIMAT0020157 dme-miR-4947-5p; +MIMAT0020158 dme-miR-4948-5p; +MIMAT0020159 dme-miR-4948-3p; +MIMAT0020160 dme-miR-4949-5p; +MIMAT0020161 dme-miR-4949-3p; +MIMAT0020162 dme-miR-4950-5p; +MIMAT0020163 dme-miR-4950-3p; +MIMAT0020164 dme-miR-4951-5p; +MIMAT0020165 dme-miR-4951-3p; +MIMAT0020166 dme-miR-4952-5p; +MIMAT0020167 dme-miR-4952-3p; +MIMAT0020168 dme-miR-4953-3p; +MIMAT0020169 dme-miR-4954-5p; +MIMAT0020170 dme-miR-4954-3p; +MIMAT0020171 dme-miR-4955-5p; +MIMAT0020172 dme-miR-4955-3p; +MIMAT0020173 dme-miR-4956-5p; +MIMAT0020174 dme-miR-4956-3p; +MIMAT0020175 dme-miR-4957-5p; +MIMAT0020176 dme-miR-4957-3p; +MIMAT0020177 dme-miR-4958-5p; +MIMAT0020178 dme-miR-4958-3p; +MIMAT0020179 dme-miR-4959-5p; +MIMAT0020180 dme-miR-4960-3p; +MIMAT0020181 dme-miR-4961-5p; +MIMAT0020182 dme-miR-4961-3p; +MIMAT0020183 dme-miR-4962-5p; +MIMAT0020184 dme-miR-4962-3p; +MIMAT0020185 dme-miR-4963-5p; +MIMAT0020186 dme-miR-4963-3p; +MIMAT0020187 dme-miR-4964-3p; +MIMAT0020188 dme-miR-4965-5p; +MIMAT0020189 dme-miR-4965-3p; +MIMAT0020190 dme-miR-4966-5p; +MIMAT0020191 dme-miR-4966-3p; +MIMAT0020192 dme-miR-4967-5p; +MIMAT0020193 dme-miR-4967-3p; +MIMAT0020194 dme-miR-4968-5p; +MIMAT0020195 dme-miR-4969-5p; +MIMAT0020196 dme-miR-4969-3p; +MIMAT0020197 dme-miR-4970-5p; +MIMAT0020198 dme-miR-4971-5p; +MIMAT0020199 dme-miR-4972-5p; +MIMAT0020200 dme-miR-4972-3p; +MIMAT0020201 dme-miR-4973-5p; +MIMAT0020202 dme-miR-4973-3p; +MIMAT0020203 dme-miR-4974-5p; +MIMAT0020204 dme-miR-4974-3p; +MIMAT0020205 dme-miR-4975-5p; +MIMAT0020206 dme-miR-4976-5p; +MIMAT0020207 dme-miR-4976-3p; +MIMAT0020208 dme-miR-4977-5p; +MIMAT0020209 dme-miR-4977-3p; +MIMAT0020210 dme-miR-4978-5p; +MIMAT0020211 dme-miR-4979-5p; +MIMAT0020212 dme-miR-4979-3p; +MIMAT0020213 dme-miR-4980-3p; +MIMAT0020214 dme-miR-4981-3p; +MIMAT0020215 dme-miR-4982-5p; +MIMAT0020216 dme-miR-4982-3p; +MIMAT0020217 dme-miR-4983-5p; +MIMAT0020218 dme-miR-4983-3p; +MIMAT0020219 dme-miR-4984-5p; +MIMAT0020220 dme-miR-4984-3p; +MIMAT0020221 dme-miR-4985-5p; +MIMAT0020222 dme-miR-4985-3p; +MIMAT0020223 dme-miR-4986-5p; +MIMAT0020224 dme-miR-4986-3p; +MIMAT0020225 dme-miR-4987-5p; +MIMAT0020226 dme-miR-4987-3p; +MIMAT0020227 egr-let-7;egr-let-7-5p; +MIMAT0020228 egr-miR-1;egr-miR-1-5p; +MIMAT0020229 egr-miR-2a;egr-miR-2a-3p; +MIMAT0020230 egr-miR-2b;egr-miR-2b-3p; +MIMAT0020231 egr-miR-2c*;egr-miR-2c-5p; +MIMAT0020232 egr-miR-2c;egr-miR-2c-3p; +MIMAT0020233 egr-miR-7;egr-miR-7-5p; +MIMAT0020234 egr-miR-8;egr-miR-8-3p; +MIMAT0020235 egr-miR-9;egr-miR-9-5p; +MIMAT0020236 egr-miR-10;egr-miR-10a-5p; +MIMAT0020237 egr-miR-71;egr-miR-71-5p; +MIMAT0020238 egr-miR-87*;egr-miR-87-5p; +MIMAT0020239 egr-miR-87;egr-miR-87-3p; +MIMAT0020240 egr-miR-124a;egr-miR-124a-3p; +MIMAT0020241 egr-miR-124b*;egr-miR-124b-5p; +MIMAT0020242 egr-miR-124b;egr-miR-124b-3p; +MIMAT0020243 egr-miR-125;egr-miR-125-5p; +MIMAT0020244 egr-miR-153;egr-miR-153-3p; +MIMAT0020245 egr-miR-190;egr-miR-190-5p; +MIMAT0020246 egr-miR-219;egr-miR-219-5p; +MIMAT0020247 egr-miR-277;egr-miR-277a-3p; +MIMAT0020248 egr-miR-745;egr-miR-745-3p; +MIMAT0020249 egr-miR-4988;egr-miR-184-5p; +MIMAT0020250 egr-miR-4989;egr-miR-4989-3p; +MIMAT0020251 egr-miR-4990; +MIMAT0020252 egr-miR-4991; +MIMAT0020253 emu-let-7;emu-let-7-5p; +MIMAT0020254 emu-miR-1;emu-miR-1-3p; +MIMAT0020255 emu-miR-2a;emu-miR-2a-3p; +MIMAT0020256 emu-miR-2b;emu-miR-2b-3p; +MIMAT0020257 emu-miR-2c;emu-miR-2c-3p; +MIMAT0020258 emu-miR-2c*; +MIMAT0020259 emu-miR-7;emu-miR-7-5p; +MIMAT0020260 emu-miR-8;emu-miR-8-3p; +MIMAT0020261 emu-miR-9;emu-miR-9-5p; +MIMAT0020262 emu-miR-10;emu-miR-10-5p; +MIMAT0020263 emu-miR-71;emu-miR-71-5p; +MIMAT0020264 emu-miR-87;emu-miR-87-3p; +MIMAT0020265 emu-miR-96;emu-miR-96-5p; +MIMAT0020266 emu-miR-124a;emu-miR-124a-3p; +MIMAT0020267 emu-miR-124b;emu-miR-124b-3p; +MIMAT0020268 emu-miR-125;emu-miR-125-5p; +MIMAT0020269 emu-miR-153;emu-miR-153-3p; +MIMAT0020270 emu-miR-190;emu-miR-190-5p; +MIMAT0020271 emu-miR-219;emu-miR-219-5p; +MIMAT0020272 emu-miR-277;emu-miR-277a-3p; +MIMAT0020273 emu-miR-745;emu-miR-745-3p; +MIMAT0020274 emu-miR-4988;emu-miR-184-5p; +MIMAT0020275 emu-miR-4989;emu-miR-4989-3p; +MIMAT0020276 bpcv1-miR-B1; +MIMAT0020277 bpcv2-miR-B1; +MIMAT0020278 ssp-miR169; +MIMAT0020279 ssp-miR827; +MIMAT0020280 ssp-miR437a; +MIMAT0020281 ssp-miR437b; +MIMAT0020282 ssp-miR437c; +MIMAT0020283 ssp-miR444a; +MIMAT0020284 ssp-miR444b*;ssp-miR444b.1; +MIMAT0020285 ssp-miR444b;ssp-miR444b.2; +MIMAT0020286 ssp-miR444c;ssp-miR444c-3p; +MIMAT0020287 ssp-miR444c*; +MIMAT0020288 ssp-miR528; +MIMAT0020289 ssp-miR1128; +MIMAT0020290 ssp-miR1432; +MIMAT0020291 ssp-miR156; +MIMAT0020292 ssp-miR159a; +MIMAT0020293 ssp-miR167b; +MIMAT0020294 ssp-miR168a; +MIMAT0020295 ssp-miR396; +MIMAT0020296 ssp-miR408d; +MIMAT0020297 ssp-miR408a; +MIMAT0020299 hsa-miR-4520b-5p; +MIMAT0020300 hsa-miR-4520b-3p;hsa-miR-4520-2-3p; +MIMAT0020301 cel-miR-1*;cel-miR-1-5p; +MIMAT0020302 cel-miR-2*;cel-miR-2-5p; +MIMAT0020303 cel-miR-35*;cel-miR-35-5p; +MIMAT0020304 cel-miR-36*;cel-miR-36-5p; +MIMAT0020305 cel-miR-38*;cel-miR-38-5p; +MIMAT0020306 cel-miR-39*;cel-miR-39-5p; +MIMAT0020307 cel-miR-40*;cel-miR-40-5p; +MIMAT0020308 cel-miR-43*;cel-miR-43-5p; +MIMAT0020309 cel-miR-49*;cel-miR-49-5p; +MIMAT0020310 cel-miR-50*;cel-miR-50-3p; +MIMAT0020311 cel-miR-52*;cel-miR-52-3p; +MIMAT0020312 cel-miR-53*;cel-miR-53-3p; +MIMAT0020313 cel-miR-55*;cel-miR-55-5p; +MIMAT0020314 cel-miR-57*;cel-miR-57-3p; +MIMAT0020315 cel-miR-66*;cel-miR-66-3p; +MIMAT0020316 cel-miR-67*;cel-miR-67-5p; +MIMAT0020317 cel-miR-70*;cel-miR-70-5p; +MIMAT0020318 cel-miR-72*;cel-miR-72-3p; +MIMAT0020319 cel-miR-73*;cel-miR-73-5p; +MIMAT0020320 cel-miR-74*;cel-miR-74-5p; +MIMAT0020321 cel-miR-76*;cel-miR-76-5p; +MIMAT0020322 cel-miR-79*;cel-miR-79-5p; +MIMAT0020323 cel-miR-82*;cel-miR-82-5p; +MIMAT0020324 cel-miR-85*;cel-miR-85-5p; +MIMAT0020325 cel-miR-87*;cel-miR-87-5p; +MIMAT0020326 cel-miR-90*;cel-miR-90-5p; +MIMAT0020327 cel-miR-228*;cel-miR-228-3p; +MIMAT0020328 cel-miR-231*;cel-miR-231-5p; +MIMAT0020329 cel-miR-233*;cel-miR-233-5p; +MIMAT0020330 cel-miR-234*;cel-miR-234-5p; +MIMAT0020331 cel-miR-235*;cel-miR-235-5p; +MIMAT0020332 cel-miR-236*;cel-miR-236-5p; +MIMAT0020333 cel-miR-237*;cel-miR-237-3p; +MIMAT0020334 cel-miR-239a*;cel-miR-239a-3p; +MIMAT0020335 cel-miR-241*;cel-miR-241-3p; +MIMAT0020336 cel-miR-245*;cel-miR-245-5p; +MIMAT0020337 cel-miR-246*;cel-miR-246-5p; +MIMAT0020338 cel-miR-249*;cel-miR-249-5p; +MIMAT0020339 cel-miR-250*;cel-miR-250-5p; +MIMAT0020340 cel-miR-252*;cel-miR-252-3p; +MIMAT0020341 cel-miR-255*;cel-miR-255-5p; +MIMAT0020342 cel-miR-259*;cel-miR-259-3p; +MIMAT0020343 cel-miR-357*;cel-miR-357-5p; +MIMAT0020344 cel-miR-392*;cel-miR-392-5p; +MIMAT0020345 ath-miR447a.2;ath-miR447a.2-3p; +MIMAT0020346 ath-miR447c-5p; +MIMAT0020347 cel-miR-784*;cel-miR-784-3p; +MIMAT0020348 cel-miR-787*;cel-miR-787-5p; +MIMAT0020349 cel-miR-790*;cel-miR-790-3p; +MIMAT0020350 cel-miR-791*;cel-miR-791-5p; +MIMAT0020351 cel-miR-792*;cel-miR-792-5p; +MIMAT0020352 cel-miR-794*;cel-miR-794-3p; +MIMAT0020353 cel-miR-795*;cel-miR-795-3p; +MIMAT0020354 cel-miR-800*;cel-miR-800-5p; +MIMAT0020355 ath-miR868-5p; +MIMAT0020356 cel-miR-1020*;cel-miR-1020-5p; +MIMAT0020357 cel-miR-1022*;cel-miR-1022-3p; +MIMAT0020358 cel-miR-1819*;cel-miR-1819-5p; +MIMAT0020359 cel-miR-1820*;cel-miR-1820-3p; +MIMAT0020360 cel-miR-1824-3p; +MIMAT0020361 cel-miR-1834*;cel-miR-1834-5p;cel-miR-58b-5p; +MIMAT0020362 ssc-miR-142-3p; +MIMAT0020363 ssc-miR-769-5p; +MIMAT0020364 ath-miR2934-3p; +MIMAT0020365 ssc-miR-194-5p;ssc-miR-194b-5p; +MIMAT0020366 ssc-miR-4334-3p; +MIMAT0020367 mmu-miR-3473b; +MIMAT0020368 cgr-miR-7;cgr-miR-7a; +MIMAT0020369 tcc-miR156a; +MIMAT0020370 tcc-miR156b; +MIMAT0020371 tcc-miR156c; +MIMAT0020372 tcc-miR156d; +MIMAT0020373 tcc-miR156e; +MIMAT0020374 tcc-miR156f; +MIMAT0020375 tcc-miR156g; +MIMAT0020376 tcc-miR160a; +MIMAT0020377 tcc-miR160b; +MIMAT0020378 tcc-miR160c; +MIMAT0020379 tcc-miR162; +MIMAT0020380 tcc-miR164a; +MIMAT0020381 tcc-miR164b; +MIMAT0020382 tcc-miR164c; +MIMAT0020383 tcc-miR166a; +MIMAT0020384 tcc-miR166b; +MIMAT0020385 tcc-miR166c; +MIMAT0020386 tcc-miR166d; +MIMAT0020387 tcc-miR167a; +MIMAT0020388 tcc-miR167b; +MIMAT0020389 tcc-miR167c; +MIMAT0020390 tcc-miR168; +MIMAT0020391 tcc-miR169a; +MIMAT0020392 tcc-miR169b; +MIMAT0020393 tcc-miR169c; +MIMAT0020394 tcc-miR169d; +MIMAT0020395 tcc-miR169e; +MIMAT0020396 tcc-miR169f; +MIMAT0020397 tcc-miR169g; +MIMAT0020398 tcc-miR169h; +MIMAT0020399 tcc-miR169i; +MIMAT0020400 tcc-miR169j; +MIMAT0020401 tcc-miR169k; +MIMAT0020402 tcc-miR169l; +MIMAT0020403 tcc-miR169m; +MIMAT0020404 tcc-miR169n; +MIMAT0020405 tcc-miR171a; +MIMAT0020406 tcc-miR171b; +MIMAT0020407 tcc-miR171c; +MIMAT0020408 tcc-miR171d; +MIMAT0020409 tcc-miR171e; +MIMAT0020410 tcc-miR171f; +MIMAT0020411 tcc-miR171g; +MIMAT0020412 tcc-miR171h; +MIMAT0020413 tcc-miR172a; +MIMAT0020414 tcc-miR172b; +MIMAT0020415 tcc-miR172c; +MIMAT0020416 tcc-miR172d; +MIMAT0020417 tcc-miR172e; +MIMAT0020418 tcc-miR319; +MIMAT0020419 tcc-miR390a; +MIMAT0020420 tcc-miR390b; +MIMAT0020421 tcc-miR393a; +MIMAT0020422 tcc-miR393b; +MIMAT0020423 tcc-miR394a; +MIMAT0020424 tcc-miR394b; +MIMAT0020425 tcc-miR395a; +MIMAT0020426 tcc-miR395b; +MIMAT0020427 tcc-miR396a; +MIMAT0020428 tcc-miR396b; +MIMAT0020429 tcc-miR396c; +MIMAT0020430 tcc-miR396d; +MIMAT0020431 tcc-miR396e; +MIMAT0020432 tcc-miR397; +MIMAT0020433 tcc-miR398a; +MIMAT0020434 tcc-miR398b; +MIMAT0020435 tcc-miR399a; +MIMAT0020436 tcc-miR399b; +MIMAT0020437 tcc-miR399c; +MIMAT0020438 tcc-miR399d; +MIMAT0020439 tcc-miR399e; +MIMAT0020440 tcc-miR399f; +MIMAT0020441 tcc-miR399g; +MIMAT0020442 tcc-miR399h; +MIMAT0020443 tcc-miR399i; +MIMAT0020444 tcc-miR403a; +MIMAT0020445 tcc-miR403b; +MIMAT0020446 tcc-miR530a; +MIMAT0020447 tcc-miR530b; +MIMAT0020448 tcc-miR535; +MIMAT0020449 tcc-miR827; +MIMAT0020450 tcc-miR2111; +MIMAT0020451 bfl-miR-34c; +MIMAT0020452 bfl-miR-4873; +MIMAT0020453 bfl-miR-4874;bfl-miR-4874-5p; +MIMAT0020454 bfl-miR-4874*;bfl-miR-4874-3p; +MIMAT0020455 bfl-miR-4875a-5p; +MIMAT0020456 bfl-miR-4875b-5p; +MIMAT0020457 bfl-miR-4875c-3p; +MIMAT0020458 bfl-miR-4875d-3p; +MIMAT0020459 bfl-miR-4876; +MIMAT0020460 bfl-miR-4877; +MIMAT0020461 bfl-miR-4878; +MIMAT0020462 bfl-miR-4879; +MIMAT0020463 bfl-miR-4880; +MIMAT0020464 bfl-miR-4881; +MIMAT0020465 bfl-miR-4057; +MIMAT0020466 bfl-miR-4882a; +MIMAT0020467 bfl-miR-4882b; +MIMAT0020468 bfl-miR-4882c; +MIMAT0020469 bfl-miR-4883; +MIMAT0020470 bfl-miR-4884; +MIMAT0020471 bfl-miR-4885a;bfl-miR-4885; +MIMAT0020472 bfl-miR-4885b; +MIMAT0020473 bfl-miR-4886; +MIMAT0020474 bfl-miR-4887; +MIMAT0020475 bfl-miR-4888; +MIMAT0020476 bfl-miR-4889a; +MIMAT0020477 bfl-miR-4889b; +MIMAT0020478 bfl-miR-182c; +MIMAT0020479 bfl-miR-4890; +MIMAT0020480 bfl-miR-4891-5p; +MIMAT0020481 bfl-miR-4891-3p; +MIMAT0020482 bfl-miR-4892; +MIMAT0020483 bfl-miR-4893; +MIMAT0020484 bfl-miR-182d; +MIMAT0020485 bfl-miR-4894; +MIMAT0020486 bfl-miR-4895; +MIMAT0020487 bfl-miR-4896; +MIMAT0020488 bfl-miR-4897a;bfl-miR-4897; +MIMAT0020489 bfl-miR-4897b; +MIMAT0020490 bfl-miR-4898; +MIMAT0020491 bfl-miR-4899; +MIMAT0020492 bfl-miR-4900a; +MIMAT0020493 bfl-miR-4900b; +MIMAT0020494 bfl-miR-4901; +MIMAT0020495 bfl-miR-4902; +MIMAT0020496 bfl-miR-34d; +MIMAT0020497 bfl-miR-34e; +MIMAT0020498 bfl-miR-4903; +MIMAT0020499 bfl-miR-4904-5p; +MIMAT0020500 bfl-miR-4904-3p; +MIMAT0020501 bfl-miR-4905; +MIMAT0020502 bfl-miR-4906; +MIMAT0020503 dme-miR-4910-5p; +MIMAT0020504 dme-miR-4911-3p; +MIMAT0020505 dme-miR-4912-5p; +MIMAT0020506 dme-miR-4913-3p; +MIMAT0020507 dme-miR-4914-5p; +MIMAT0020508 dme-miR-4915-5p; +MIMAT0020509 dme-miR-4916-3p; +MIMAT0020510 dme-miR-2535b-3p; +MIMAT0020511 dme-miR-4917-3p; +MIMAT0020512 dme-miR-4918-5p; +MIMAT0020513 dme-miR-4919-5p; +MIMAT0020514 dme-miR-4908-3p; +MIMAT0020515 dme-miR-4909-3p; +MIMAT0020516 ath-miR5012; +MIMAT0020517 ath-miR5013; +MIMAT0020518 ath-miR5014;ath-miR5014-3p;ath-miR5014a-3p; +MIMAT0020519 ath-miR5015a;ath-miR5015; +MIMAT0020520 ath-miR5016; +MIMAT0020521 ath-miR5017;ath-miR5017-3p; +MIMAT0020522 ath-miR5018; +MIMAT0020523 ath-miR5019; +MIMAT0020524 ath-miR5020a; +MIMAT0020525 ath-miR5021; +MIMAT0020526 ath-miR5015b; +MIMAT0020527 ath-miR5022; +MIMAT0020528 ath-miR5023; +MIMAT0020529 ath-miR5020b; +MIMAT0020530 ath-miR5024;ath-miR5024-5p; +MIMAT0020531 ath-miR5025; +MIMAT0020532 ath-miR5026; +MIMAT0020533 ath-miR5027; +MIMAT0020534 ath-miR5028; +MIMAT0020535 ath-miR5029; +MIMAT0020536 hme-miR-2788;hme-miR-2788-5p; +MIMAT0020537 hme-miR-2788*;hme-miR-2788-3p; +MIMAT0020538 hme-miR-193*;hme-miR-193-5p; +MIMAT0020539 hme-miR-193;hme-miR-193-3p; +MIMAT0020540 mmu-miR-5046; +MIMAT0020541 hsa-miR-5047; +MIMAT0020542 hvu-miR399; +MIMAT0020543 hvu-miR444b; +MIMAT0020544 hvu-miR5048;hvu-miR5048a; +MIMAT0020545 hvu-miR5049;hvu-miR5049a; +MIMAT0020546 hvu-miR5050; +MIMAT0020547 hvu-miR5051; +MIMAT0020548 hvu-miR5052; +MIMAT0020549 hvu-miR5053; +MIMAT0020550 bdi-miR408;bdi-miR408-5p; +MIMAT0020551 osa-miR5071; +MIMAT0020552 osa-miR5072; +MIMAT0020553 bdi-miR5055; +MIMAT0020554 bdi-miR5056; +MIMAT0020555 osa-miR5073; +MIMAT0020556 bdi-miR5057; +MIMAT0020557 bdi-miR5058; +MIMAT0020558 tae-miR5086; +MIMAT0020559 osa-miR5074; +MIMAT0020560 bdi-miR5059; +MIMAT0020561 osa-miR5075; +MIMAT0020562 bdi-miR5060; +MIMAT0020563 bdi-miR5061; +MIMAT0020564 osa-miR5076; +MIMAT0020565 bdi-miR1878;bdi-miR1878-3p; +MIMAT0020566 tae-miR5084; +MIMAT0020567 tae-miR5085; +MIMAT0020568 bdi-miR5062a; +MIMAT0020569 bdi-miR5062b; +MIMAT0020570 bdi-miR5063; +MIMAT0020571 bdi-miR5064; +MIMAT0020572 bdi-miR5065; +MIMAT0020573 bdi-miR5066; +MIMAT0020574 osa-miR5077; +MIMAT0020575 osa-miR5078; +MIMAT0020576 bdi-miR5067; +MIMAT0020577 bdi-miR5068; +MIMAT0020578 osa-miR5079;osa-miR5079a; +MIMAT0020579 osa-miR5080; +MIMAT0020580 bdi-miR5069; +MIMAT0020581 osa-miR5081; +MIMAT0020582 osa-miR5082; +MIMAT0020583 osa-miR5083; +MIMAT0020584 bdi-miR5070; +MIMAT0020585 ssc-miR-18b; +MIMAT0020586 ssc-miR-129b; +MIMAT0020587 ssc-miR-187; +MIMAT0020588 ssc-miR-190;ssc-miR-190b; +MIMAT0020589 ssc-miR-218b; +MIMAT0020590 ssc-miR-219;ssc-miR-219a; +MIMAT0020591 ssc-miR-429; +MIMAT0020592 ssc-miR-491; +MIMAT0020593 ssc-miR-545*;ssc-miR-545-5p; +MIMAT0020594 ssc-miR-545;ssc-miR-545-3p; +MIMAT0020595 ssc-miR-615; +MIMAT0020596 ssc-miR-1343; +MIMAT0020597 ssc-miR-2320;ssc-miR-2320-5p; +MIMAT0020598 ssc-miR-2320*;ssc-miR-2320-3p; +MIMAT0020599 ssc-miR-2476; +MIMAT0020600 hsa-miR-5095; +MIMAT0020601 hsa-miR-1273f; +MIMAT0020602 hsa-miR-1273g;hsa-miR-1273g-5p; +MIMAT0020603 hsa-miR-5096; +MIMAT0020604 mmu-miR-5097; +MIMAT0020605 mmu-miR-5098; +MIMAT0020606 mmu-miR-5099; +MIMAT0020607 mmu-miR-5100; +MIMAT0020608 mmu-miR-5101; +MIMAT0020609 mmu-miR-5102; +MIMAT0020610 mmu-miR-5103; +MIMAT0020611 mmu-miR-5104; +MIMAT0020612 mmu-miR-5105; +MIMAT0020613 mmu-miR-5106; +MIMAT0020614 mmu-miR-3473c; +MIMAT0020615 mmu-miR-5107;mmu-miR-5107-5p; +MIMAT0020616 mmu-miR-5108; +MIMAT0020617 mmu-miR-5109; +MIMAT0020618 mmu-miR-5110; +MIMAT0020619 mmu-miR-5111;mmu-miR-5111-3p; +MIMAT0020620 mmu-miR-5112; +MIMAT0020621 mmu-miR-5113; +MIMAT0020622 mmu-miR-5114; +MIMAT0020623 mmu-miR-5115; +MIMAT0020624 mmu-miR-5116; +MIMAT0020625 mmu-miR-5117;mmu-miR-5117-5p; +MIMAT0020626 mmu-miR-5118; +MIMAT0020627 mmu-miR-5119; +MIMAT0020628 mmu-miR-5120; +MIMAT0020629 mmu-miR-5121; +MIMAT0020630 mmu-miR-5122; +MIMAT0020631 mmu-miR-466q; +MIMAT0020632 mmu-miR-3473d; +MIMAT0020633 mmu-miR-5123; +MIMAT0020634 mmu-miR-5124;mmu-miR-5124a; +MIMAT0020635 mmu-miR-5125; +MIMAT0020636 mmu-miR-3572;mmu-miR-3572-3p; +MIMAT0020637 mmu-miR-5126; +MIMAT0020638 mmu-miR-5127; +MIMAT0020639 mmu-miR-5128; +MIMAT0020640 mmu-miR-5129;mmu-miR-5129-5p; +MIMAT0020641 mmu-miR-5130; +MIMAT0020642 mmu-miR-5131; +MIMAT0020643 mmu-miR-5132;mmu-miR-5132-5p; +MIMAT0020644 mmu-miR-5133; +MIMAT0020645 mmu-miR-5134;mmu-miR-5134-5p; +MIMAT0020646 mmu-miR-5135; +MIMAT0020647 mmu-miR-5136; +MIMAT0020648 rgl-miR5137; +MIMAT0020649 rgl-miR5138; +MIMAT0020650 rgl-miR5139; +MIMAT0020651 rgl-miR5140; +MIMAT0020652 rgl-miR5141; +MIMAT0020653 rgl-miR5142; +MIMAT0020654 bdi-miR169d; +MIMAT0020655 bdi-miR169i; +MIMAT0020656 bdi-miR395a; +MIMAT0020657 bdi-miR169j;bdi-miR169j-5p; +MIMAT0020658 bdi-miR166f; +MIMAT0020659 bdi-miR171b; +MIMAT0020660 bdi-miR390;bdi-miR390a;bdi-miR390a-5p; +MIMAT0020661 bdi-miR160a;bdi-miR160a-5p; +MIMAT0020662 bdi-miR528;bdi-miR528-5p; +MIMAT0020663 bdi-miR395b; +MIMAT0020664 bdi-miR166d;bdi-miR166d-3p; +MIMAT0020665 bdi-miR171d;bdi-miR171d-3p; +MIMAT0020666 bdi-miR167b; +MIMAT0020667 bdi-miR166b;bdi-miR166b-3p; +MIMAT0020668 bdi-miR160b;bdi-miR160b-5p; +MIMAT0020669 bdi-miR164b; +MIMAT0020670 bdi-miR167c;bdi-miR167c-5p; +MIMAT0020671 bdi-miR396d;bdi-miR396d-5p; +MIMAT0020672 bdi-miR169k;bdi-miR169k-5p; +MIMAT0020673 bdi-miR168;bdi-miR168-5p; +MIMAT0020674 bdi-miR397b; +MIMAT0020675 bdi-miR160c;bdi-miR160c-5p; +MIMAT0020676 bdi-miR396c;bdi-miR396c-5p; +MIMAT0020677 bdi-miR167d;bdi-miR167d-5p; +MIMAT0020678 bdi-miR399b; +MIMAT0020679 bdi-miR156b;bdi-miR156b-5p; +MIMAT0020680 bdi-miR169g; +MIMAT0020681 bdi-miR160d;bdi-miR160d-5p; +MIMAT0020682 bdi-miR160e;bdi-miR160e-5p; +MIMAT0020683 bdi-miR396e;bdi-miR396e-5p; +MIMAT0020684 bdi-miR156c; +MIMAT0020685 bdi-miR172a;bdi-miR172a-3p; +MIMAT0020686 bdi-miR396a;bdi-miR396a-5p; +MIMAT0020687 bdi-miR166e;bdi-miR166e-3p; +MIMAT0020688 bdi-miR166c;bdi-miR166c-3p; +MIMAT0020689 bdi-miR169e;bdi-miR169e-5p; +MIMAT0020690 bdi-miR394; +MIMAT0020691 bdi-miR398a; +MIMAT0020692 bdi-miR159;bdi-miR159-3p;bdi-miR159a-3p; +MIMAT0020693 bdi-miR164a;bdi-miR164a-5p; +MIMAT0020694 bdi-miR393a; +MIMAT0020695 bdi-miR169a;bdi-miR169a-5p; +MIMAT0020696 bdi-miR172b; +MIMAT0020697 bdi-miR156d;bdi-miR156d-5p; +MIMAT0020698 bdi-miR393b;bdi-miR393b-5p; +MIMAT0020699 bdi-miR169h;bdi-miR169h-5p; +MIMAT0020700 bdi-miR396b;bdi-miR396b-5p; +MIMAT0020701 bdi-miR169c;bdi-miR169c-5p; +MIMAT0020702 bdi-miR395c;bdi-miR395c-3p; +MIMAT0020703 bdi-miR827;bdi-miR827-3p; +MIMAT0020704 bdi-miR5163;bdi-miR5163a-3p; +MIMAT0020705 bdi-miR5181b; +MIMAT0020706 bdi-miR5164; +MIMAT0020707 bdi-miR5165;bdi-miR5165-5p; +MIMAT0020708 bdi-miR5166; +MIMAT0020709 bdi-miR5167;bdi-miR5167-5p;bdi-miR5167a-5p; +MIMAT0020710 bdi-miR5168;bdi-miR166g;bdi-miR166g-3p; +MIMAT0020711 bdi-miR5169;bdi-miR5169a; +MIMAT0020712 bdi-miR319;bdi-miR319a; +MIMAT0020713 bdi-miR5180b; +MIMAT0020714 bdi-miR5170; +MIMAT0020715 bdi-miR5171;bdi-miR5171a; +MIMAT0020716 bdi-miR5172;bdi-miR5172-3p; +MIMAT0020717 bdi-miR5173;bdi-miR5173-5p; +MIMAT0020718 bdi-miR5174;bdi-miR5174a; +MIMAT0020719 bdi-miR5175a; +MIMAT0020720 bdi-miR5176-5p; +MIMAT0020721 bdi-miR5176-3p; +MIMAT0020722 bdi-miR5175b; +MIMAT0020723 bdi-miR395d;bdi-miR395d-3p; +MIMAT0020724 bdi-miR5177; +MIMAT0020725 bdi-miR5178;bdi-miR5178-3p; +MIMAT0020726 bdi-miR398b; +MIMAT0020727 bdi-miR5179; +MIMAT0020728 bdi-miR164c;bdi-miR164c-5p; +MIMAT0020729 bdi-miR5180a; +MIMAT0020730 bdi-miR5181a;bdi-miR5181a-5p; +MIMAT0020731 bdi-miR5182; +MIMAT0020732 bdi-miR5183; +MIMAT0020733 bdi-miR5184; +MIMAT0020734 bdi-miR5185a;bdi-miR5185a-5p; +MIMAT0020735 bdi-miR5185b;bdi-miR5185b-5p; +MIMAT0020736 bdi-miR169f; +MIMAT0020737 hvu-miR166c; +MIMAT0020738 bdi-miR162; +MIMAT0020739 bdi-miR164d; +MIMAT0020740 bdi-miR164e; +MIMAT0020741 bdi-miR164f; +MIMAT0020742 bdi-miR390b; +MIMAT0020743 bdi-miR395i; +MIMAT0020744 bdi-miR395m; +MIMAT0020745 bdi-miR395e;bdi-miR395e-3p; +MIMAT0020746 bdi-miR395f;bdi-miR395f-3p; +MIMAT0020747 bdi-miR395g;bdi-miR395g-3p; +MIMAT0020748 bdi-miR395h;bdi-miR395h-3p; +MIMAT0020749 bdi-miR395j;bdi-miR395j-3p; +MIMAT0020750 bdi-miR395k;bdi-miR395k-3p; +MIMAT0020751 bdi-miR395l;bdi-miR395l-3p; +MIMAT0020752 bdi-miR395n;bdi-miR395n-3p; +MIMAT0020753 bdi-miR398c; +MIMAT0020754 bdi-miR529;bdi-miR529-5p; +MIMAT0020755 bdi-miR5198; +MIMAT0020756 bdi-miR5199; +MIMAT0020757 bdi-miR5200;bdi-miR5200c; +MIMAT0020758 bdi-miR5201;bdi-miR5201-3p; +MIMAT0020759 bdi-miR5202; +MIMAT0020760 bdi-miR5203;bdi-miR5181d; +MIMAT0020761 bdi-miR319b;bdi-miR319b-3p; +MIMAT0020762 bdi-miR396f; +MIMAT0020763 bdi-miR5054; +MIMAT0020764 sly-miR5300; +MIMAT0020765 sly-miR5301;sly-miR482e-5p; +MIMAT0020766 sly-miR5302;sly-miR5302a; +MIMAT0020767 sly-miR5303; +MIMAT0020768 sly-miR5304; +MIMAT0020769 sly-miR482;sly-miR482a; +MIMAT0020770 cel-miR-41-5p; +MIMAT0020771 cel-miR-44-5p; +MIMAT0020772 cel-miR-45-5p; +MIMAT0020773 cel-miR-54-5p; +MIMAT0020774 cel-miR-77-5p; +MIMAT0020775 cel-miR-83-5p; +MIMAT0020776 cel-miR-86-3p; +MIMAT0020777 cel-miR-232-5p; +MIMAT0020778 cel-miR-1830-3p; +MIMAT0020779 dme-miR-1-5p; +MIMAT0020780 dme-miR-2a-1-5p; +MIMAT0020781 dme-miR-2a-2-5p; +MIMAT0020782 dme-miR-2b-1-5p; +MIMAT0020783 dme-miR-2b-2-5p; +MIMAT0020784 dme-miR-3-5p; +MIMAT0020785 dme-miR-4-5p; +MIMAT0020786 dme-miR-5-3p; +MIMAT0020787 dme-miR-6-1-5p; +MIMAT0020788 dme-miR-6-2-5p; +MIMAT0020789 dme-miR-6-3-5p; +MIMAT0020790 dme-miR-7-3p; +MIMAT0020791 dme-miR-8-5p; +MIMAT0020792 dme-miR-9a-3p; +MIMAT0020793 dme-miR-11-5p; +MIMAT0020794 dme-miR-12-3p; +MIMAT0020795 dme-miR-13a-5p; +MIMAT0020796 dme-miR-13b-1-5p; +MIMAT0020797 dme-miR-13b-2-5p; +MIMAT0020798 dme-miR-14-5p; +MIMAT0020799 dme-miR-263a-3p; +MIMAT0020800 dme-miR-274-3p; +MIMAT0020801 dme-miR-275-5p; +MIMAT0020802 dme-miR-92a-5p; +MIMAT0020803 dme-miR-219-3p; +MIMAT0020804 dme-miR-277-5p; +MIMAT0020805 dme-miR-278-5p; +MIMAT0020806 dme-miR-133-5p; +MIMAT0020807 dme-miR-279-5p; +MIMAT0020808 dme-miR-33-3p; +MIMAT0020809 dme-miR-282-3p; +MIMAT0020810 dme-miR-283-3p; +MIMAT0020811 dme-miR-284-5p; +MIMAT0020812 dme-miR-34-3p; +MIMAT0020813 dme-miR-124-5p; +MIMAT0020814 dme-miR-79-5p; +MIMAT0020815 dme-miR-276b-5p; +MIMAT0020816 dme-miR-210-5p; +MIMAT0020817 dme-miR-285-5p; +MIMAT0020818 dme-miR-100-3p; +MIMAT0020819 dme-miR-92b-5p; +MIMAT0020820 dme-miR-286-5p; +MIMAT0020821 dme-miR-87-5p; +MIMAT0020822 dme-miR-263b-3p; +MIMAT0020823 dme-bantam-5p; +MIMAT0020824 dme-miR-303-3p; +MIMAT0020825 dme-miR-31b-3p; +MIMAT0020826 dme-miR-304-3p; +MIMAT0020827 dme-miR-305-3p; +MIMAT0020828 dme-miR-9c-3p; +MIMAT0020829 dme-miR-9b-3p; +MIMAT0020830 dme-let-7-3p; +MIMAT0020831 dme-miR-125-3p; +MIMAT0020832 dme-miR-307a-5p; +MIMAT0020833 dme-miR-308-5p; +MIMAT0020834 dme-miR-31a-3p; +MIMAT0020835 dme-miR-309-5p; +MIMAT0020836 dme-miR-310-5p; +MIMAT0020837 dme-miR-311-5p; +MIMAT0020838 dme-miR-312-5p; +MIMAT0020839 dme-miR-313-5p; +MIMAT0020840 dme-miR-314-5p; +MIMAT0020841 dme-miR-315-3p; +MIMAT0020842 dme-miR-316-3p; +MIMAT0020843 dme-miR-317-5p; +MIMAT0020844 dme-miR-318-5p; +MIMAT0020845 dme-miR-2c-5p; +MIMAT0020846 dme-miR-954-3p; +MIMAT0020847 dme-miR-955-3p; +MIMAT0020848 dme-miR-190-3p; +MIMAT0020849 dme-miR-193-5p; +MIMAT0020850 dme-miR-956-5p; +MIMAT0020851 dme-miR-957-5p; +MIMAT0020852 dme-miR-958-5p; +MIMAT0020853 dme-miR-375-5p; +MIMAT0020854 dme-miR-959-5p; +MIMAT0020855 dme-miR-960-3p; +MIMAT0020856 dme-miR-961-3p; +MIMAT0020857 dme-miR-962-3p; +MIMAT0020858 dme-miR-963-3p; +MIMAT0020859 dme-miR-964-3p; +MIMAT0020860 dme-miR-932-3p; +MIMAT0020861 dme-miR-965-5p; +MIMAT0020862 dme-miR-966-3p; +MIMAT0020863 dme-miR-967-3p; +MIMAT0020864 dme-miR-1002-3p; +MIMAT0020865 dme-miR-968-3p; +MIMAT0020866 dme-miR-969-3p; +MIMAT0020867 dme-miR-970-5p; +MIMAT0020868 dme-miR-971-5p; +MIMAT0020869 dme-miR-972-5p; +MIMAT0020870 dme-miR-973-3p; +MIMAT0020871 dme-miR-974-3p; +MIMAT0020872 dme-miR-975-3p; +MIMAT0020873 dme-miR-976-5p; +MIMAT0020874 dme-miR-977-5p; +MIMAT0020875 dme-miR-978-5p; +MIMAT0020876 dme-miR-979-5p; +MIMAT0020877 dme-miR-980-5p; +MIMAT0020878 dme-miR-981-5p; +MIMAT0020879 dme-miR-982-3p; +MIMAT0020880 dme-miR-983-3p; +MIMAT0020881 dme-miR-984-3p; +MIMAT0020882 dme-miR-927-3p; +MIMAT0020883 dme-miR-985-5p; +MIMAT0020884 dme-miR-986-3p; +MIMAT0020885 dme-miR-987-3p; +MIMAT0020886 dme-miR-988-5p; +MIMAT0020887 dme-miR-989-5p; +MIMAT0020888 dme-miR-137-5p; +MIMAT0020889 dme-miR-990-3p; +MIMAT0020890 dme-miR-991-5p; +MIMAT0020891 dme-miR-992-5p; +MIMAT0020892 dme-miR-929-5p; +MIMAT0020893 dme-miR-993-5p; +MIMAT0020894 dme-miR-994-3p; +MIMAT0020895 dme-miR-996-5p; +MIMAT0020896 dme-miR-252-3p; +MIMAT0020897 dme-miR-997-3p; +MIMAT0020898 dme-miR-998-5p; +MIMAT0020899 dme-miR-999-5p; +MIMAT0020900 dme-miR-1000-3p; +MIMAT0020901 dme-miR-1001-3p; +MIMAT0020902 dme-miR-1003-5p; +MIMAT0020903 dme-miR-1006-5p; +MIMAT0020904 dme-miR-1007-5p; +MIMAT0020905 dme-miR-1010-5p; +MIMAT0020906 dme-miR-1012-5p; +MIMAT0020907 dme-miR-1014-5p; +MIMAT0020908 dme-miR-1016-5p; +MIMAT0020909 dme-miR-2283-3p; +MIMAT0020910 dme-miR-2489-5p; +MIMAT0020911 dme-miR-2490-3p; +MIMAT0020912 dme-miR-2491-3p; +MIMAT0020913 dme-miR-2492-5p; +MIMAT0020914 osa-miR319a-5p; +MIMAT0020915 osa-miR319a-3p; +MIMAT0020916 osa-miR169f.2; +MIMAT0020917 osa-miR169i.2;osa-miR169i-5p.2; +MIMAT0020918 osa-miR444a-5p; +MIMAT0020919 gma-miR159a-5p; +MIMAT0020920 gma-miR166a-5p; +MIMAT0020921 gma-miR172b-5p; +MIMAT0020922 gma-miR396a-3p; +MIMAT0020923 gma-miR396b-3p; +MIMAT0020924 hsa-miR-642a-3p; +MIMAT0020925 hsa-miR-550a-3-5p; +MIMAT0020926 osa-miR819a-3p; +MIMAT0020927 osa-miR819c-3p; +MIMAT0020928 osa-miR819d-3p; +MIMAT0020929 osa-miR819e-3p; +MIMAT0020930 osa-miR819h-3p; +MIMAT0020931 osa-miR819j-3p; +MIMAT0020932 osa-miR819k-3p; +MIMAT0020933 osa-miR1425-3p; +MIMAT0020934 gma-miR159b-5p; +MIMAT0020935 gma-miR390b*;gma-miR390b-3p; +MIMAT0020936 gma-miR1513*;gma-miR1513a-3p; +MIMAT0020937 gma-miR1516*;gma-miR1516a-5p; +MIMAT0020938 osa-miR1884b-3p; +MIMAT0020939 gma-miR1510b-5p; +MIMAT0020940 sbi-miR397-3p; +MIMAT0020941 mtr-miR2592d*;mtr-miR2592d-5p; +MIMAT0020942 mtr-miR2592e*;mtr-miR2592e-5p; +MIMAT0020943 mtr-miR2592o*;mtr-miR2592o-5p; +MIMAT0020944 mtr-miR2592q*;mtr-miR2592q-5p; +MIMAT0020945 mtr-miR2592a*;mtr-miR2592a-5p; +MIMAT0020946 mtr-miR2592a;mtr-miR2592a-3p; +MIMAT0020947 osa-miR2867-3p; +MIMAT0020948 osa-miR2871a-5p; +MIMAT0020949 osa-miR2876-5p; +MIMAT0020950 osa-miR1863b.2; +MIMAT0020951 gma-miR4376a-3p;gma-miR391a-3p; +MIMAT0020952 gma-miR482b-3p; +MIMAT0020953 gma-miR4397-5p; +MIMAT0020954 gma-miR4412-5p; +MIMAT0020955 gma-miR4415a-3p; +MIMAT0020956 hsa-miR-4433-5p;hsa-miR-4433a-5p; +MIMAT0020957 hsa-miR-548ah-3p; +MIMAT0020958 hsa-miR-4482-3p; +MIMAT0020959 hsa-miR-4536-3p; +MIMAT0020960 bgy-miR156; +MIMAT0020961 bgy-miR396a; +MIMAT0020962 bgy-miR396b; +MIMAT0020963 bgy-miR529; +MIMAT0020964 bcy-miR156; +MIMAT0020965 bcy-miR396a; +MIMAT0020966 bcy-miR396b; +MIMAT0020967 bcy-miR529; +MIMAT0020968 gma-miR156h; +MIMAT0020969 gma-miR156i; +MIMAT0020970 gma-miR160b; +MIMAT0020971 gma-miR160c; +MIMAT0020972 gma-miR160d; +MIMAT0020973 gma-miR160e; +MIMAT0020974 gma-miR162b; +MIMAT0020975 gma-miR164b; +MIMAT0020976 gma-miR164c; +MIMAT0020977 gma-miR164d; +MIMAT0020978 gma-miR166c;gma-miR166c-3p; +MIMAT0020979 gma-miR166d; +MIMAT0020980 gma-miR166e; +MIMAT0020981 gma-miR166f; +MIMAT0020982 gma-miR166g; +MIMAT0020983 gma-miR166h-5p; +MIMAT0020984 gma-miR166h-3p; +MIMAT0020985 gma-miR168b; +MIMAT0020986 gma-miR169f; +MIMAT0020987 gma-miR169g; +MIMAT0020988 gma-miR171d; +MIMAT0020989 gma-miR171e; +MIMAT0020990 gma-miR171f; +MIMAT0020991 gma-miR171g; +MIMAT0020992 gma-miR319d; +MIMAT0020993 gma-miR319e; +MIMAT0020994 gma-miR319f; +MIMAT0020995 gma-miR390c; +MIMAT0020996 gma-miR394c-5p; +MIMAT0020997 gma-miR398c; +MIMAT0020998 gma-miR408;gma-miR408d; +MIMAT0020999 gma-miR2118a;gma-miR2118a-3p; +MIMAT0021000 gma-miR2118b;gma-miR2118b-3p; +MIMAT0021001 gma-miR482c-5p; +MIMAT0021002 gma-miR482c-3p; +MIMAT0021003 gma-miR530;gma-miR530a; +MIMAT0021004 gma-miR862a; +MIMAT0021005 gma-miR1507c*;gma-miR1507c-5p; +MIMAT0021006 gma-miR1507c;gma-miR1507c-3p; +MIMAT0021007 gma-miR1508c; +MIMAT0021008 gma-miR1513b; +MIMAT0021009 gma-miR1535b; +MIMAT0021010 gma-miR4992; +MIMAT0021011 gma-miR4993; +MIMAT0021012 gma-miR4994;gma-miR4994-5p; +MIMAT0021013 gma-miR4995; +MIMAT0021014 gma-miR4996; +MIMAT0021015 gma-miR4997; +MIMAT0021016 gma-miR4998; +MIMAT0021017 hsa-miR-4999-5p; +MIMAT0021018 hsa-miR-4999-3p; +MIMAT0021019 hsa-miR-5000-5p; +MIMAT0021020 hsa-miR-5000-3p; +MIMAT0021021 hsa-miR-5001-5p; +MIMAT0021022 hsa-miR-5001-3p; +MIMAT0021023 hsa-miR-5002-5p; +MIMAT0021024 hsa-miR-5002-3p; +MIMAT0021025 hsa-miR-5003-5p; +MIMAT0021026 hsa-miR-5003-3p; +MIMAT0021027 hsa-miR-5004-5p; +MIMAT0021028 hsa-miR-5004-3p; +MIMAT0021029 hsa-miR-548ao-5p; +MIMAT0021030 hsa-miR-548ao-3p; +MIMAT0021033 hsa-miR-5006-5p; +MIMAT0021034 hsa-miR-5006-3p; +MIMAT0021035 hsa-miR-5007-5p; +MIMAT0021036 hsa-miR-5007-3p; +MIMAT0021037 hsa-miR-548ap-5p; +MIMAT0021038 hsa-miR-548ap-3p; +MIMAT0021039 hsa-miR-5008-5p; +MIMAT0021040 hsa-miR-5008-3p; +MIMAT0021041 hsa-miR-5009-5p; +MIMAT0021042 hsa-miR-5009-3p; +MIMAT0021043 hsa-miR-5010-5p; +MIMAT0021044 hsa-miR-5010-3p; +MIMAT0021045 hsa-miR-5011-5p; +MIMAT0021046 hsa-miR-5011-3p; +MIMAT0021047 ath-miR5014-5p;ath-miR5014a-5p; +MIMAT0021048 ath-miR5024-3p; +MIMAT0021049 gma-miR5030; +MIMAT0021050 gma-miR5031; +MIMAT0021051 gma-miR1523b; +MIMAT0021052 gma-miR5032; +MIMAT0021053 gma-miR5033; +MIMAT0021054 gma-miR171h; +MIMAT0021055 gma-miR5034; +MIMAT0021056 gma-miR171i-5p; +MIMAT0021057 gma-miR171i-3p; +MIMAT0021058 gma-miR5035;gma-miR5035-5p; +MIMAT0021059 gma-miR5036; +MIMAT0021060 gma-miR5037;gma-miR5037a; +MIMAT0021061 gma-miR1516b; +MIMAT0021062 gma-miR169h; +MIMAT0021063 gma-miR5038a; +MIMAT0021064 gma-miR167h; +MIMAT0021065 gma-miR1521b; +MIMAT0021066 gma-miR5039; +MIMAT0021067 gma-miR5040; +MIMAT0021068 gma-miR169i;gma-miR169i-3p; +MIMAT0021069 gma-miR396f; +MIMAT0021070 gma-miR5041;gma-miR5041-5p; +MIMAT0021071 gma-miR396g; +MIMAT0021072 gma-miR5042;gma-miR5042-5p; +MIMAT0021073 gma-miR4372b; +MIMAT0021074 gma-miR5043; +MIMAT0021075 gma-miR5044; +MIMAT0021076 gma-miR167i; +MIMAT0021077 gpy-miR-5045; +MIMAT0021078 tre-miR-5045; +MIMAT0021079 hsa-miR-5087; +MIMAT0021080 hsa-miR-5088;hsa-miR-5088-5p; +MIMAT0021081 hsa-miR-5089;hsa-miR-5089-5p; +MIMAT0021082 hsa-miR-5090; +MIMAT0021083 hsa-miR-5091; +MIMAT0021084 hsa-miR-5092; +MIMAT0021085 hsa-miR-5093; +MIMAT0021086 hsa-miR-5094; +MIMAT0021087 osa-miR5143;osa-miR5143a; +MIMAT0021088 osa-miR5144-5p; +MIMAT0021089 osa-miR5144-3p; +MIMAT0021090 osa-miR5145; +MIMAT0021091 osa-miR5146; +MIMAT0021092 osa-miR5147; +MIMAT0021093 osa-miR2863c; +MIMAT0021094 osa-miR5148a; +MIMAT0021095 osa-miR5148b; +MIMAT0021096 osa-miR5148c; +MIMAT0021097 osa-miR5149; +MIMAT0021098 osa-miR5150-5p; +MIMAT0021099 osa-miR5150-3p; +MIMAT0021100 osa-miR5151; +MIMAT0021101 osa-miR5152-5p; +MIMAT0021102 osa-miR5152-3p; +MIMAT0021103 osa-miR5153; +MIMAT0021104 osa-miR5154; +MIMAT0021105 osa-miR5155; +MIMAT0021106 osa-miR5156; +MIMAT0021107 osa-miR5157a-5p; +MIMAT0021108 osa-miR5157a-3p; +MIMAT0021109 osa-miR5157b-5p; +MIMAT0021110 osa-miR5157b-3p; +MIMAT0021111 osa-miR5158; +MIMAT0021112 osa-miR5159; +MIMAT0021113 osa-miR5160; +MIMAT0021114 osa-miR5161; +MIMAT0021115 osa-miR5162; +MIMAT0021116 hsa-miR-5186; +MIMAT0021117 hsa-miR-5187-5p; +MIMAT0021118 hsa-miR-5187-3p; +MIMAT0021119 hsa-miR-5188; +MIMAT0021120 hsa-miR-5189;hsa-miR-5189-5p; +MIMAT0021121 hsa-miR-5190; +MIMAT0021122 hsa-miR-5191; +MIMAT0021123 hsa-miR-5192; +MIMAT0021124 hsa-miR-5193; +MIMAT0021125 hsa-miR-5194; +MIMAT0021126 hsa-miR-5195-5p; +MIMAT0021127 hsa-miR-5195-3p; +MIMAT0021128 hsa-miR-5196-5p; +MIMAT0021129 hsa-miR-5196-3p; +MIMAT0021130 hsa-miR-5197-5p; +MIMAT0021131 hsa-miR-5197-3p; +MIMAT0021132 mtr-miR5204; +MIMAT0021133 mtr-miR5205a; +MIMAT0021134 mtr-miR5205b; +MIMAT0021135 mtr-miR5205c; +MIMAT0021136 mtr-miR5205d; +MIMAT0021137 mtr-miR5206;mtr-miR5206a; +MIMAT0021138 mtr-miR5207; +MIMAT0021139 mtr-miR5208a; +MIMAT0021140 mtr-miR5208b; +MIMAT0021141 mtr-miR5208c; +MIMAT0021142 mtr-miR5209; +MIMAT0021143 mtr-miR5210; +MIMAT0021144 mtr-miR5211; +MIMAT0021145 mtr-miR5212;mtr-miR5212-5p; +MIMAT0021146 mtr-miR5213;mtr-miR5213-5p; +MIMAT0021147 mtr-miR5213*;mtr-miR5213-3p; +MIMAT0021148 mtr-miR5214;mtr-miR5214-3p; +MIMAT0021149 mtr-miR2592t; +MIMAT0021150 mtr-miR5215; +MIMAT0021151 mtr-miR2592u; +MIMAT0021152 mtr-miR2592v; +MIMAT0021153 mtr-miR2592w; +MIMAT0021154 mtr-miR2592x; +MIMAT0021155 mtr-miR2592y; +MIMAT0021156 mtr-miR2592z; +MIMAT0021157 mtr-miR2592aa; +MIMAT0021158 mtr-miR2592ab; +MIMAT0021159 mtr-miR2592ac; +MIMAT0021160 mtr-miR2592ad; +MIMAT0021161 mtr-miR2592ae; +MIMAT0021162 mtr-miR2592af; +MIMAT0021163 mtr-miR2592ag; +MIMAT0021164 mtr-miR2592ah; +MIMAT0021165 mtr-miR2592ai; +MIMAT0021166 mtr-miR2592aj; +MIMAT0021167 mtr-miR2592ak; +MIMAT0021168 mtr-miR2592al; +MIMAT0021169 mtr-miR2592am; +MIMAT0021170 mtr-miR2592an; +MIMAT0021171 mtr-miR2592ao; +MIMAT0021172 mtr-miR2586b; +MIMAT0021173 mtr-miR5216a; +MIMAT0021174 mtr-miR5216b; +MIMAT0021175 mtr-miR5217; +MIMAT0021176 mtr-miR5218; +MIMAT0021177 mtr-miR5219a;mtr-miR5219; +MIMAT0021178 mtr-miR5221; +MIMAT0021179 mtr-miR5222; +MIMAT0021180 mtr-miR5223a;mtr-miR5223; +MIMAT0021181 mtr-miR5223b; +MIMAT0021182 mtr-miR5224a; +MIMAT0021183 mtr-miR5225;mtr-miR5225a; +MIMAT0021184 mtr-miR5226; +MIMAT0021185 mtr-miR5224b; +MIMAT0021186 mtr-miR5227; +MIMAT0021187 mtr-miR2592ap; +MIMAT0021188 mtr-miR2592aq; +MIMAT0021189 mtr-miR2592ar; +MIMAT0021190 mtr-miR2592as; +MIMAT0021191 mtr-miR2592at; +MIMAT0021192 mtr-miR2592au; +MIMAT0021193 mtr-miR2592av; +MIMAT0021194 mtr-miR2592aw; +MIMAT0021195 mtr-miR2592ax; +MIMAT0021196 mtr-miR2592ay; +MIMAT0021197 mtr-miR2592az; +MIMAT0021198 mtr-miR2592ba; +MIMAT0021199 mtr-miR2592bb; +MIMAT0021200 mtr-miR2592bc; +MIMAT0021201 mtr-miR2592bd; +MIMAT0021202 mtr-miR2592be; +MIMAT0021203 mtr-miR2592bf; +MIMAT0021204 mtr-miR2592bg; +MIMAT0021205 mtr-miR2592bh; +MIMAT0021206 mtr-miR4414a;mtr-miR4414a-5p; +MIMAT0021207 mtr-miR4414a*;mtr-miR4414a-3p; +MIMAT0021208 mtr-miR2670e; +MIMAT0021209 mtr-miR2670f; +MIMAT0021210 mtr-miR2670g; +MIMAT0021211 mtr-miR4414b; +MIMAT0021212 mtr-miR5228; +MIMAT0021213 mtr-miR5229a; +MIMAT0021214 mtr-miR5229b; +MIMAT0021215 mtr-miR5230; +MIMAT0021216 mtr-miR5231; +MIMAT0021217 mtr-miR5232; +MIMAT0021218 mtr-miR5233; +MIMAT0021219 mtr-miR5234; +MIMAT0021220 mtr-miR5235a; +MIMAT0021221 mtr-miR5235b; +MIMAT0021222 mtr-miR5236a; +MIMAT0021223 mtr-miR5236b; +MIMAT0021224 mtr-miR5236c; +MIMAT0021225 mtr-miR5236d; +MIMAT0021226 mtr-miR5236e; +MIMAT0021227 mtr-miR5237; +MIMAT0021228 mtr-miR5238; +MIMAT0021229 mtr-miR2592bi; +MIMAT0021230 mtr-miR2592bj; +MIMAT0021231 mtr-miR2592bk; +MIMAT0021232 mtr-miR482;mtr-miR482-5p; +MIMAT0021233 mtr-miR5239; +MIMAT0021234 mtr-miR5240; +MIMAT0021235 mtr-miR5241a; +MIMAT0021236 mtr-miR5241b; +MIMAT0021237 mtr-miR5241c; +MIMAT0021238 mtr-miR5242; +MIMAT0021239 mtr-miR5243; +MIMAT0021240 mtr-miR5244; +MIMAT0021241 mtr-miR5245; +MIMAT0021242 mtr-miR5246; +MIMAT0021243 mtr-miR5247; +MIMAT0021244 mtr-miR5248; +MIMAT0021245 mtr-miR5249; +MIMAT0021246 mtr-miR5250; +MIMAT0021247 mtr-miR5251; +MIMAT0021248 mtr-miR5252; +MIMAT0021249 mtr-miR2643b*;mtr-miR2643b-5p; +MIMAT0021250 mtr-miR2643b;mtr-miR2643b-3p; +MIMAT0021251 mtr-miR5253; +MIMAT0021252 mtr-miR5254; +MIMAT0021253 mtr-miR5255; +MIMAT0021254 mtr-miR5256; +MIMAT0021255 mtr-miR2111t;mtr-miR2111l; +MIMAT0021256 mtr-miR2111u;mtr-miR2111f; +MIMAT0021257 mtr-miR5257; +MIMAT0021258 mtr-miR5258; +MIMAT0021259 mtr-miR5259; +MIMAT0021260 mtr-miR5260; +MIMAT0021261 mtr-miR5261; +MIMAT0021262 mtr-miR5262; +MIMAT0021263 mtr-miR5263; +MIMAT0021264 mtr-miR172b; +MIMAT0021265 mtr-miR172c*;mtr-miR172c-5p; +MIMAT0021266 mtr-miR172c;mtr-miR172c-3p; +MIMAT0021267 mtr-miR159b; +MIMAT0021268 mtr-miR160f; +MIMAT0021269 mtr-miR171h; +MIMAT0021270 mtr-miR168b; +MIMAT0021271 mtr-miR399r; +MIMAT0021272 mtr-miR156j; +MIMAT0021273 mtr-miR5264; +MIMAT0021274 mtr-miR5265; +MIMAT0021275 mtr-miR5266; +MIMAT0021276 mtr-miR5267a; +MIMAT0021277 mtr-miR5267b; +MIMAT0021278 mtr-miR5267c; +MIMAT0021279 mtr-miR5267d; +MIMAT0021280 mtr-miR5267e; +MIMAT0021281 mtr-miR5267f; +MIMAT0021282 mtr-miR5267g; +MIMAT0021283 mtr-miR5267h; +MIMAT0021284 mtr-miR5267i; +MIMAT0021285 mtr-miR5267j; +MIMAT0021286 mtr-miR5267k; +MIMAT0021287 mtr-miR5267l; +MIMAT0021288 mtr-miR5267m; +MIMAT0021289 mtr-miR5267n; +MIMAT0021290 mtr-miR5267o; +MIMAT0021291 mtr-miR5268a; +MIMAT0021292 mtr-miR5268b; +MIMAT0021293 mtr-miR5269a; +MIMAT0021294 mtr-miR5269b; +MIMAT0021295 mtr-miR5270a; +MIMAT0021296 mtr-miR5270b; +MIMAT0021297 mtr-miR5271a; +MIMAT0021298 mtr-miR5271b; +MIMAT0021299 mtr-miR5271c; +MIMAT0021300 mtr-miR5271d; +MIMAT0021301 mtr-miR5271e; +MIMAT0021302 mtr-miR5272a; +MIMAT0021303 mtr-miR5272b; +MIMAT0021304 mtr-miR5272c; +MIMAT0021305 mtr-miR5272d; +MIMAT0021306 mtr-miR5272e; +MIMAT0021307 mtr-miR5272f; +MIMAT0021308 mtr-miR5273; +MIMAT0021309 mtr-miR2590g; +MIMAT0021310 mtr-miR2629h; +MIMAT0021311 mtr-miR5274;mtr-miR5274a; +MIMAT0021312 mtr-miR2606d;mtr-miR2606c; +MIMAT0021313 mtr-miR5275; +MIMAT0021314 mtr-miR5276; +MIMAT0021315 mtr-miR5208d; +MIMAT0021316 mtr-miR5277; +MIMAT0021317 mtr-miR5278; +MIMAT0021318 mtr-miR5279; +MIMAT0021319 mtr-miR5280; +MIMAT0021320 mtr-miR5281a; +MIMAT0021321 mtr-miR5281b; +MIMAT0021322 mtr-miR5281c; +MIMAT0021323 mtr-miR5281d; +MIMAT0021324 mtr-miR5281e; +MIMAT0021325 mtr-miR5281f; +MIMAT0021326 mtr-miR5282; +MIMAT0021327 mtr-miR5283; +MIMAT0021328 mtr-miR2600b; +MIMAT0021329 mtr-miR2600c; +MIMAT0021330 mtr-miR2600d; +MIMAT0021331 mtr-miR2600e; +MIMAT0021332 mtr-miR2590h; +MIMAT0021333 mtr-miR2590i; +MIMAT0021334 mtr-miR2590j; +MIMAT0021335 mtr-miR5284a; +MIMAT0021336 mtr-miR5284b; +MIMAT0021337 mtr-miR5284c; +MIMAT0021338 mtr-miR5284d; +MIMAT0021339 mtr-miR5284e; +MIMAT0021340 mtr-miR5284f; +MIMAT0021341 mtr-miR5284g; +MIMAT0021342 mtr-miR5284h; +MIMAT0021343 mtr-miR5285a; +MIMAT0021344 mtr-miR5285b; +MIMAT0021345 mtr-miR5285c; +MIMAT0021346 mtr-miR5286a; +MIMAT0021347 mtr-miR5287a; +MIMAT0021348 mtr-miR5287b; +MIMAT0021349 mtr-miR5288; +MIMAT0021350 mtr-miR5289a; +MIMAT0021351 mtr-miR5289b; +MIMAT0021352 mtr-miR5286b; +MIMAT0021353 mtr-miR5290; +MIMAT0021354 mtr-miR5291a; +MIMAT0021355 mtr-miR5291b; +MIMAT0021356 mtr-miR5291c; +MIMAT0021357 mtr-miR5292a; +MIMAT0021358 mtr-miR5292b; +MIMAT0021359 mtr-miR5293; +MIMAT0021360 mtr-miR5294a; +MIMAT0021361 mtr-miR5294b; +MIMAT0021362 mtr-miR5294c; +MIMAT0021363 mtr-miR5295a; +MIMAT0021364 mtr-miR5295b; +MIMAT0021365 mtr-miR5295c; +MIMAT0021366 mtr-miR5295d; +MIMAT0021367 mtr-miR5296; +MIMAT0021368 mtr-miR5297; +MIMAT0021369 mtr-miR5298a; +MIMAT0021370 mtr-miR5298b; +MIMAT0021371 mtr-miR5298c; +MIMAT0021372 mtr-miR5298d; +MIMAT0021373 mtr-miR5299; +MIMAT0021374 mtr-miR5219b; +MIMAT0021375 isc-miR-5305; +MIMAT0021376 isc-miR-5306; +MIMAT0021377 isc-miR-5307; +MIMAT0021378 isc-miR-5308; +MIMAT0021379 isc-miR-5309; +MIMAT0021380 isc-miR-3931; +MIMAT0021381 isc-miR-5310; +MIMAT0021382 isc-miR-5311; +MIMAT0021383 isc-miR-5312; +MIMAT0021384 isc-miR-5313; +MIMAT0021385 isc-miR-5314; +MIMAT0021386 isc-miR-5315; +MIMAT0021387 rmi-miR-5316a; +MIMAT0021388 rmi-miR-5316b; +MIMAT0021389 rmi-miR-5317a; +MIMAT0021390 rmi-miR-5318; +MIMAT0021391 rmi-miR-5317b; +MIMAT0021392 rmi-miR-5319; +MIMAT0021393 rmi-miR-5320; +MIMAT0021394 rmi-miR-5321; +MIMAT0021395 rmi-miR-5322; +MIMAT0021396 rmi-miR-5323; +MIMAT0021397 rmi-miR-5324; +MIMAT0021398 rmi-miR-5325; +MIMAT0021399 rmi-miR-5326; +MIMAT0021400 rmi-miR-5327; +MIMAT0021401 rmi-miR-5328; +MIMAT0021402 rmi-miR-5329; +MIMAT0021403 rmi-miR-5330; +MIMAT0021404 rmi-miR-5331; +MIMAT0021405 rmi-miR-5332; +MIMAT0021406 rmi-miR-5333; +MIMAT0021407 rmi-miR-5334; +MIMAT0021408 rmi-miR-5335; +MIMAT0021409 rmi-miR-5336; +MIMAT0021410 osa-miR5337;osa-miR5337a; +MIMAT0021411 osa-miR5338; +MIMAT0021412 osa-miR5339; +MIMAT0021413 osa-miR5340; +MIMAT0021414 rmi-miR-5341; +MIMAT0021415 asu-lin-4;asu-lin-4-5p; +MIMAT0021416 asu-lin-4*;asu-lin-4-3p; +MIMAT0021417 asu-let-7;asu-let-7-5p; +MIMAT0021418 asu-let-7*;asu-let-7-3p; +MIMAT0021419 asu-miR-81b*;asu-miR-81b-5p; +MIMAT0021420 asu-miR-81b;asu-miR-81b-3p; +MIMAT0021421 asu-miR-81c*;asu-miR-81c-5p; +MIMAT0021422 asu-miR-81c;asu-miR-81c-3p; +MIMAT0021423 asu-miR-1*;asu-miR-1-5p; +MIMAT0021424 asu-miR-1;asu-miR-1-3p; +MIMAT0021425 asu-miR-2a*;asu-miR-2a-5p; +MIMAT0021426 asu-miR-2a;asu-miR-2a-3p; +MIMAT0021427 asu-miR-2b*;asu-miR-2b-5p; +MIMAT0021428 asu-miR-2b;asu-miR-2b-3p; +MIMAT0021429 asu-miR-7;asu-miR-7-5p; +MIMAT0021430 asu-miR-7*;asu-miR-7-3p; +MIMAT0021431 asu-miR-9;asu-miR-9-5p; +MIMAT0021432 asu-miR-9*;asu-miR-9-3p; +MIMAT0021433 asu-miR-43d*;asu-miR-43d-5p; +MIMAT0021434 asu-miR-43d;asu-miR-43d-3p; +MIMAT0021435 asu-miR-43e*;asu-miR-43e-5p; +MIMAT0021436 asu-miR-43e;asu-miR-43e-3p; +MIMAT0021437 asu-miR-34;asu-miR-34-5p; +MIMAT0021438 asu-miR-34*;asu-miR-34-3p; +MIMAT0021439 asu-miR-36a*;asu-miR-36a-5p; +MIMAT0021440 asu-miR-36a;asu-miR-36a-3p; +MIMAT0021441 asu-miR-36b*;asu-miR-36b-5p; +MIMAT0021442 asu-miR-36b;asu-miR-36b-3p; +MIMAT0021443 asu-miR-36c*;asu-miR-36c-5p; +MIMAT0021444 asu-miR-36c;asu-miR-36c-3p; +MIMAT0021445 asu-miR-36d*;asu-miR-36d-5p; +MIMAT0021446 asu-miR-36d;asu-miR-36d-3p; +MIMAT0021447 asu-miR-36e*;asu-miR-36e-5p; +MIMAT0021448 asu-miR-36e;asu-miR-36e-3p; +MIMAT0021449 asu-miR-43a*;asu-miR-43a-5p; +MIMAT0021450 asu-miR-43a;asu-miR-43a-3p; +MIMAT0021451 asu-miR-43b*;asu-miR-43b-5p; +MIMAT0021452 asu-miR-43b;asu-miR-43b-3p; +MIMAT0021453 asu-miR-43c-1*;asu-miR-43c-1-5p; +MIMAT0021454 asu-miR-43c;asu-miR-43c-3p; +MIMAT0021455 asu-miR-44a*;asu-miR-44a-5p; +MIMAT0021456 asu-miR-44a;asu-miR-44a-3p; +MIMAT0021457 asu-miR-46*;asu-miR-46-5p; +MIMAT0021458 asu-miR-46;asu-miR-46-3p; +MIMAT0021459 asu-miR-49*;asu-miR-49-5p; +MIMAT0021460 asu-miR-49;asu-miR-49-3p; +MIMAT0021461 asu-miR-50;asu-miR-50-5p; +MIMAT0021462 asu-miR-50*;asu-miR-50-3p; +MIMAT0021463 asu-miR-56; +MIMAT0021464 asu-miR-57;asu-miR-57-5p; +MIMAT0021465 asu-miR-57*;asu-miR-57-3p; +MIMAT0021466 asu-miR-71;asu-miR-71-5p; +MIMAT0021467 asu-miR-71*;asu-miR-71-3p; +MIMAT0021468 asu-miR-72;asu-miR-72-5p; +MIMAT0021469 asu-miR-72*;asu-miR-72-3p; +MIMAT0021470 asu-miR-76*;asu-miR-76-5p; +MIMAT0021471 asu-miR-76;asu-miR-76-3p; +MIMAT0021472 asu-miR-79*;asu-miR-79-5p; +MIMAT0021473 asu-miR-79;asu-miR-79-3p; +MIMAT0021474 asu-miR-81a; +MIMAT0021475 asu-miR-83*;asu-miR-83-5p; +MIMAT0021476 asu-miR-83;asu-miR-83-3p; +MIMAT0021477 asu-miR-84;asu-miR-84-5p; +MIMAT0021478 asu-miR-84*;asu-miR-84-3p; +MIMAT0021479 asu-miR-86;asu-miR-86-5p; +MIMAT0021480 asu-miR-86*;asu-miR-86-3p; +MIMAT0021481 asu-miR-87a*;asu-miR-87a-5p; +MIMAT0021482 asu-miR-87a;asu-miR-87a-3p; +MIMAT0021483 asu-miR-87b*;asu-miR-87b-5p; +MIMAT0021484 asu-miR-87b;asu-miR-87b-3p; +MIMAT0021485 asu-miR-92*;asu-miR-92-5p; +MIMAT0021486 asu-miR-92;asu-miR-92-3p; +MIMAT0021487 asu-miR-100a;asu-miR-100a-5p; +MIMAT0021488 asu-miR-100a-1*;asu-miR-100a-1-3p; +MIMAT0021489 asu-miR-100b;asu-miR-100b-5p; +MIMAT0021490 asu-miR-100b*;asu-miR-100b-3p; +MIMAT0021491 asu-miR-100c;asu-miR-100c-5p; +MIMAT0021492 asu-miR-100c*;asu-miR-100c-3p; +MIMAT0021493 asu-miR-100d;asu-miR-100d-5p; +MIMAT0021494 asu-miR-100d*;asu-miR-100d-3p; +MIMAT0021495 asu-miR-124*;asu-miR-124-5p; +MIMAT0021496 asu-miR-124;asu-miR-124-3p; +MIMAT0021497 asu-miR-133*;asu-miR-133-5p; +MIMAT0021498 asu-miR-133;asu-miR-133-3p; +MIMAT0021499 asu-miR-137*;asu-miR-137-5p;asu-miR-234-5p; +MIMAT0021500 asu-miR-137;asu-miR-137-3p;asu-miR-234-3p; +MIMAT0021501 asu-miR-184*;asu-miR-184-5p; +MIMAT0021502 asu-miR-184;asu-miR-184-3p; +MIMAT0021503 asu-miR-228;asu-miR-228-5p; +MIMAT0021504 asu-miR-228*;asu-miR-228-3p; +MIMAT0021505 asu-miR-236*;asu-miR-236-5p; +MIMAT0021506 asu-miR-236;asu-miR-236-3p; +MIMAT0021507 asu-miR-250*;asu-miR-250-5p; +MIMAT0021508 asu-miR-250;asu-miR-250-3p; +MIMAT0021509 asu-miR-252;asu-miR-252-5p; +MIMAT0021510 asu-miR-252*;asu-miR-252-3p; +MIMAT0021511 asu-miR-279a*;asu-miR-279a-5p; +MIMAT0021512 asu-miR-279a;asu-miR-279a-3p; +MIMAT0021513 asu-miR-279b*;asu-miR-279b-5p; +MIMAT0021514 asu-miR-279b;asu-miR-279b-3p; +MIMAT0021515 asu-miR-279c*;asu-miR-279c-5p; +MIMAT0021516 asu-miR-279c;asu-miR-279c-3p; +MIMAT0021517 asu-miR-5342*;asu-miR-5342-5p; +MIMAT0021518 asu-miR-5342;asu-miR-5342-3p; +MIMAT0021519 asu-miR-5343;asu-miR-283-5p; +MIMAT0021520 asu-miR-5343*;asu-miR-283-3p; +MIMAT0021521 asu-miR-5344;asu-miR-239-5p; +MIMAT0021522 asu-miR-5344*;asu-miR-239-3p; +MIMAT0021523 asu-miR-67*;asu-miR-67-5p; +MIMAT0021524 asu-miR-67;asu-miR-67-3p; +MIMAT0021525 asu-miR-375*;asu-miR-375-5p; +MIMAT0021526 asu-miR-375;asu-miR-375-3p; +MIMAT0021527 asu-miR-750*;asu-miR-750-5p; +MIMAT0021528 asu-miR-750;asu-miR-750-3p; +MIMAT0021529 asu-miR-791*;asu-miR-791-5p; +MIMAT0021530 asu-miR-791;asu-miR-791-3p; +MIMAT0021531 asu-miR-993*;asu-miR-993-5p; +MIMAT0021532 asu-miR-993;asu-miR-993-3p; +MIMAT0021533 asu-miR-1175;asu-miR-1175-5p; +MIMAT0021534 asu-miR-1175*;asu-miR-1175-3p; +MIMAT0021535 asu-miR-1822*;asu-miR-1822-5p; +MIMAT0021536 asu-miR-1822;asu-miR-1822-3p; +MIMAT0021537 asu-miR-5345a;asu-miR-5345a-5p; +MIMAT0021538 asu-miR-5345a*;asu-miR-5345a-3p; +MIMAT0021539 asu-miR-5345b; +MIMAT0021540 asu-miR-5346*;asu-miR-5346-5p; +MIMAT0021541 asu-miR-5346;asu-miR-5346-3p; +MIMAT0021542 asu-miR-100e;asu-miR-100e-5p; +MIMAT0021543 asu-miR-100e*;asu-miR-100e-3p; +MIMAT0021544 asu-miR-5347*;asu-miR-5347-5p; +MIMAT0021545 asu-miR-5347;asu-miR-5347-3p; +MIMAT0021546 asu-miR-36f*;asu-miR-36f-5p; +MIMAT0021547 asu-miR-36f;asu-miR-36f-3p; +MIMAT0021548 asu-miR-5348*;asu-miR-5348-5p; +MIMAT0021549 asu-miR-5348;asu-miR-5348-3p; +MIMAT0021550 asu-miR-5349;asu-miR-5349-5p; +MIMAT0021551 asu-miR-5349*;asu-miR-5349-3p; +MIMAT0021552 asu-miR-5350a*;asu-miR-5350a-5p; +MIMAT0021553 asu-miR-5350a;asu-miR-5350a-3p; +MIMAT0021554 asu-miR-5350b*;asu-miR-5350b-5p; +MIMAT0021555 asu-miR-5350b;asu-miR-5350b-3p; +MIMAT0021556 asu-miR-5350c*;asu-miR-5350c-5p; +MIMAT0021557 asu-miR-5350c;asu-miR-5350c-3p; +MIMAT0021558 asu-miR-5350d*;asu-miR-5350d-5p; +MIMAT0021559 asu-miR-5350d;asu-miR-5350d-3p; +MIMAT0021560 asu-miR-5351*;asu-miR-5351-5p; +MIMAT0021561 asu-miR-5351;asu-miR-5351-3p; +MIMAT0021562 asu-miR-5352*;asu-miR-5352-5p; +MIMAT0021563 asu-miR-5352;asu-miR-5352-3p; +MIMAT0021564 asu-miR-44b;asu-miR-44b-5p; +MIMAT0021565 asu-miR-44b*;asu-miR-44b-3p; +MIMAT0021566 asu-miR-5353*;asu-miR-5353-5p; +MIMAT0021567 asu-miR-5353;asu-miR-5353-3p; +MIMAT0021568 asu-miR-5354;asu-miR-5354-5p; +MIMAT0021569 asu-miR-5354*;asu-miR-5354-3p; +MIMAT0021570 asu-miR-5355;asu-miR-5355-5p; +MIMAT0021571 asu-miR-5355*;asu-miR-5355-3p; +MIMAT0021572 asu-miR-5356a*;asu-miR-5356a-5p; +MIMAT0021573 asu-miR-5356a;asu-miR-5356a-3p; +MIMAT0021574 asu-miR-5356b;asu-miR-5356b-5p; +MIMAT0021575 asu-miR-5356b*;asu-miR-5356b-3p; +MIMAT0021576 asu-miR-5357*;asu-miR-5357-5p; +MIMAT0021577 asu-miR-5357;asu-miR-5357-3p; +MIMAT0021578 asu-miR-5358a*;asu-miR-5358a-5p; +MIMAT0021579 asu-miR-5358a;asu-miR-5358a-3p; +MIMAT0021580 asu-miR-5359;asu-miR-5359-5p; +MIMAT0021581 asu-miR-5359*;asu-miR-5359-3p; +MIMAT0021582 asu-miR-5360;asu-miR-5360-5p; +MIMAT0021583 asu-miR-5360*;asu-miR-5360-3p; +MIMAT0021584 asu-miR-5361;asu-miR-5361-5p; +MIMAT0021585 asu-miR-5361*;asu-miR-5361-3p; +MIMAT0021586 asu-miR-5362;asu-miR-5362-5p; +MIMAT0021587 asu-miR-5362*;asu-miR-5362-3p; +MIMAT0021588 asu-miR-5363;asu-miR-5363-5p; +MIMAT0021589 asu-miR-5363*;asu-miR-5363-3p; +MIMAT0021590 asu-miR-5364*;asu-miR-5364-5p; +MIMAT0021591 asu-miR-5364;asu-miR-5364-3p; +MIMAT0021592 asu-miR-5365a*;asu-miR-5365a-5p; +MIMAT0021593 asu-miR-5365a;asu-miR-5365a-3p; +MIMAT0021594 asu-miR-5366;asu-miR-5366-5p; +MIMAT0021595 asu-miR-5366*;asu-miR-5366-3p; +MIMAT0021596 asu-miR-5365b*;asu-miR-5365b-5p; +MIMAT0021597 asu-miR-5365b;asu-miR-5365b-3p; +MIMAT0021598 asu-miR-5358b*;asu-miR-5358b-5p; +MIMAT0021599 asu-miR-5358b;asu-miR-5358b-3p; +MIMAT0021600 asu-miR-5367*;asu-miR-5367-5p; +MIMAT0021601 asu-miR-5367;asu-miR-5367-3p; +MIMAT0021602 gma-miR5368; +MIMAT0021603 gma-miR5369; +MIMAT0021604 gma-miR862b; +MIMAT0021605 gma-miR5037b; +MIMAT0021606 gma-miR5037c; +MIMAT0021607 gma-miR5370; +MIMAT0021608 gma-miR5371-5p; +MIMAT0021609 gma-miR5371-3p; +MIMAT0021610 gma-miR5372; +MIMAT0021611 gma-miR5373; +MIMAT0021612 gma-miR5038b; +MIMAT0021613 gma-miR403a; +MIMAT0021614 gma-miR403b; +MIMAT0021615 gma-miR5374;gma-miR5374-5p; +MIMAT0021616 gma-miR5375; +MIMAT0021617 gma-miR5376; +MIMAT0021618 gma-miR5377; +MIMAT0021619 gma-miR5378; +MIMAT0021620 gma-miR5379; +MIMAT0021621 gma-miR5380a; +MIMAT0021622 gma-miR5380b; +MIMAT0021623 gma-miR171j;gma-miR171j-5p; +MIMAT0021624 gma-miR395a; +MIMAT0021625 gma-miR395b; +MIMAT0021626 gma-miR395c; +MIMAT0021627 gma-miR397a; +MIMAT0021628 gma-miR397b;gma-miR397b-5p; +MIMAT0021629 gma-miR408a;gma-miR408a-3p; +MIMAT0021630 gma-miR408b-5p; +MIMAT0021631 gma-miR408b-3p; +MIMAT0021632 gma-miR408c;gma-miR408c-3p; +MIMAT0021633 gma-miR3522; +MIMAT0021634 gma-miR156j; +MIMAT0021635 gma-miR156k; +MIMAT0021636 gma-miR156l; +MIMAT0021637 gma-miR156m; +MIMAT0021638 gma-miR156n; +MIMAT0021639 gma-miR156o; +MIMAT0021640 gma-miR159e-5p; +MIMAT0021641 gma-miR159e-3p; +MIMAT0021642 gma-miR159f-5p; +MIMAT0021643 gma-miR159f-3p; +MIMAT0021644 gma-miR162c; +MIMAT0021645 gma-miR166i-5p; +MIMAT0021646 gma-miR166i-3p; +MIMAT0021647 gma-miR166j-5p; +MIMAT0021648 gma-miR166j-3p; +MIMAT0021649 gma-miR169j-5p; +MIMAT0021650 gma-miR169j-3p; +MIMAT0021651 gma-miR169k; +MIMAT0021652 gma-miR169l;gma-miR169l-5p; +MIMAT0021653 gma-miR169m; +MIMAT0021654 gma-miR169n;gma-miR169n-5p; +MIMAT0021655 gma-miR171k;gma-miR171k-5p; +MIMAT0021656 gma-miR172g; +MIMAT0021657 gma-miR172h-5p; +MIMAT0021658 gma-miR172h-3p; +MIMAT0021659 gma-miR172i;gma-miR172i-5p; +MIMAT0021660 gma-miR172j; +MIMAT0021661 gma-miR319g; +MIMAT0021662 gma-miR319h; +MIMAT0021663 gma-miR319i; +MIMAT0021664 gma-miR319j; +MIMAT0021665 gma-miR319k; +MIMAT0021666 gma-miR319l; +MIMAT0021667 gma-miR319m; +MIMAT0021668 gma-miR396h; +MIMAT0021669 gma-miR396i-5p; +MIMAT0021670 gma-miR396i-3p; +MIMAT0021671 gma-miR482d-5p; +MIMAT0021672 gma-miR482d-3p; +MIMAT0021673 gma-miR1512b; +MIMAT0021674 gma-miR1513c; +MIMAT0021675 gma-miR4413b; +MIMAT0021676 gma-miR4415b;gma-miR4415b-3p; +MIMAT0021677 gma-miR167j; +MIMAT0021678 gma-miR171l; +MIMAT0021679 sbi-miR5381; +MIMAT0021680 sbi-miR5382; +MIMAT0021681 sbi-miR5383; +MIMAT0021682 sbi-miR5384; +MIMAT0021683 sbi-miR5385; +MIMAT0021684 sbi-miR5386; +MIMAT0021685 sbi-miR5387;sbi-miR5387a; +MIMAT0021686 sbi-miR5388; +MIMAT0021687 sbi-miR5389; +MIMAT0021688 aca-miR-5390; +MIMAT0021689 aca-miR-5391; +MIMAT0021690 aca-miR-5392; +MIMAT0021691 aca-miR-5393; +MIMAT0021692 aca-let-7a;aca-let-7a-5p; +MIMAT0021693 aca-let-7a*;aca-let-7a-3p; +MIMAT0021694 aca-let-7b;aca-let-7b-5p; +MIMAT0021695 aca-let-7b*;aca-let-7b-3p; +MIMAT0021696 aca-let-7c;aca-let-7c-5p; +MIMAT0021697 aca-let-7c-1*;aca-let-7c-1-3p; +MIMAT0021698 aca-let-7c-2*;aca-let-7c-2-3p; +MIMAT0021699 aca-let-7d;aca-let-7d-5p; +MIMAT0021700 aca-let-7d*;aca-let-7d-3p; +MIMAT0021701 aca-let-7e;aca-let-7e-5p; +MIMAT0021702 aca-let-7e*;aca-let-7e-3p; +MIMAT0021703 aca-let-7f;aca-let-7f-5p; +MIMAT0021704 aca-let-7f-1*;aca-let-7f-1-3p; +MIMAT0021705 aca-let-7f-2*;aca-let-7f-2-3p; +MIMAT0021706 aca-let-7g; +MIMAT0021707 aca-let-7i;aca-let-7i-5p; +MIMAT0021708 aca-let-7i*;aca-let-7i-3p; +MIMAT0021709 aca-miR-100; +MIMAT0021710 aca-miR-101-1*;aca-miR-101-1-5p; +MIMAT0021711 aca-miR-101;aca-miR-101-3p; +MIMAT0021712 aca-miR-101-2*;aca-miR-101-2-5p; +MIMAT0021713 aca-miR-107*;aca-miR-107-5p; +MIMAT0021714 aca-miR-107;aca-miR-107-3p; +MIMAT0021715 aca-miR-103*;aca-miR-103-5p; +MIMAT0021716 aca-miR-103;aca-miR-103-3p; +MIMAT0021717 aca-miR-10a;aca-miR-10a-5p; +MIMAT0021718 aca-miR-10a*;aca-miR-10a-3p; +MIMAT0021719 aca-miR-10b;aca-miR-10b-5p; +MIMAT0021720 aca-miR-10b*;aca-miR-10b-3p; +MIMAT0021721 aca-miR-10c;aca-miR-10c-5p; +MIMAT0021722 aca-miR-10c*;aca-miR-10c-3p; +MIMAT0021723 aca-miR-122;aca-miR-122-5p; +MIMAT0021724 aca-miR-122*;aca-miR-122-3p; +MIMAT0021725 aca-miR-124a; +MIMAT0021726 aca-miR-124b; +MIMAT0021727 aca-miR-125a;aca-miR-125a-5p; +MIMAT0021728 aca-miR-125a*;aca-miR-125a-3p; +MIMAT0021729 aca-miR-125b; +MIMAT0021730 aca-miR-126*;aca-miR-126-5p; +MIMAT0021731 aca-miR-126;aca-miR-126-3p; +MIMAT0021732 aca-miR-128*;aca-miR-128-5p; +MIMAT0021733 aca-miR-128;aca-miR-128-3p; +MIMAT0021734 aca-miR-129a;aca-miR-129a-5p; +MIMAT0021735 aca-miR-129a*;aca-miR-129a-3p; +MIMAT0021736 aca-miR-129b;aca-miR-129b-5p; +MIMAT0021737 aca-miR-129b*;aca-miR-129b-3p; +MIMAT0021738 aca-miR-1306; +MIMAT0021739 aca-miR-130a-1*;aca-miR-130a-1-5p; +MIMAT0021740 aca-miR-130a;aca-miR-130a-3p; +MIMAT0021741 aca-miR-130a-2*;aca-miR-130a-2-5p; +MIMAT0021742 aca-miR-130b*;aca-miR-130b-5p; +MIMAT0021743 aca-miR-130b;aca-miR-130b-3p; +MIMAT0021744 aca-miR-130c; +MIMAT0021745 aca-miR-132*;aca-miR-132-5p; +MIMAT0021746 aca-miR-132;aca-miR-132-3p; +MIMAT0021747 aca-miR-1329;aca-miR-1329-5p; +MIMAT0021748 aca-miR-1329*;aca-miR-1329-3p; +MIMAT0021749 aca-miR-133a; +MIMAT0021750 aca-miR-135;aca-miR-135-5p; +MIMAT0021751 aca-miR-135-1*;aca-miR-135-1-3p; +MIMAT0021752 aca-miR-135-2*;aca-miR-135-2-3p; +MIMAT0021753 aca-miR-135-3*;aca-miR-135-3-3p; +MIMAT0021754 aca-miR-137a; +MIMAT0021755 aca-miR-137b*;aca-miR-137b-5p; +MIMAT0021756 aca-miR-137b;aca-miR-137b-3p; +MIMAT0021757 aca-miR-138;aca-miR-138-5p; +MIMAT0021758 aca-miR-138-1*;aca-miR-138-1-3p; +MIMAT0021759 aca-miR-138-2*;aca-miR-138-2-3p; +MIMAT0021760 aca-miR-1388-5p; +MIMAT0021761 aca-miR-1388-3p; +MIMAT0021762 aca-miR-139-5p; +MIMAT0021763 aca-miR-139-3p; +MIMAT0021764 aca-miR-1397; +MIMAT0021765 aca-miR-140-5p; +MIMAT0021766 aca-miR-140-3p; +MIMAT0021767 aca-miR-142-5p; +MIMAT0021768 aca-miR-142-3p; +MIMAT0021769 aca-miR-143*;aca-miR-143-5p; +MIMAT0021770 aca-miR-143;aca-miR-143-3p; +MIMAT0021771 aca-miR-144*;aca-miR-144-5p; +MIMAT0021772 aca-miR-144;aca-miR-144-3p; +MIMAT0021773 aca-miR-145;aca-miR-145-5p; +MIMAT0021774 aca-miR-145*;aca-miR-145-3p; +MIMAT0021775 aca-miR-146a;aca-miR-146a-5p; +MIMAT0021776 aca-miR-146a*;aca-miR-146a-3p; +MIMAT0021777 aca-miR-146b;aca-miR-146b-5p; +MIMAT0021778 aca-miR-146b*;aca-miR-146b-3p; +MIMAT0021779 aca-miR-147; +MIMAT0021780 aca-miR-148a*;aca-miR-148a-5p; +MIMAT0021781 aca-miR-148a;aca-miR-148a-3p; +MIMAT0021782 aca-miR-148b*;aca-miR-148b-5p; +MIMAT0021783 aca-miR-148b;aca-miR-148b-3p; +MIMAT0021784 aca-miR-150;aca-miR-150-5p; +MIMAT0021785 aca-miR-150*;aca-miR-150-3p; +MIMAT0021786 aca-miR-153;aca-miR-153-3p; +MIMAT0021787 aca-miR-153*;aca-miR-153-5p; +MIMAT0021788 aca-miR-155;aca-miR-155-5p; +MIMAT0021789 aca-miR-155*;aca-miR-155-3p; +MIMAT0021790 aca-miR-15b;aca-miR-15b-5p; +MIMAT0021791 aca-miR-15b*;aca-miR-15b-3p; +MIMAT0021792 aca-miR-15a;aca-miR-15a-5p; +MIMAT0021793 aca-miR-15a*;aca-miR-15a-3p; +MIMAT0021794 aca-miR-1662;aca-miR-1662-5p; +MIMAT0021795 aca-miR-1662*;aca-miR-1662-3p; +MIMAT0021796 aca-miR-1677a; +MIMAT0021797 aca-miR-1677b*;aca-miR-1677b-5p; +MIMAT0021798 aca-miR-1677b;aca-miR-1677b-3p; +MIMAT0021799 aca-miR-16a;aca-miR-16a-5p; +MIMAT0021800 aca-miR-16a*;aca-miR-16a-3p; +MIMAT0021801 aca-miR-16b;aca-miR-16b-5p; +MIMAT0021802 aca-miR-16b*;aca-miR-16b-3p; +MIMAT0021803 aca-miR-17;aca-miR-17-5p; +MIMAT0021804 aca-miR-17*;aca-miR-17-3p; +MIMAT0021805 aca-miR-1788-5p; +MIMAT0021806 aca-miR-1788-3p; +MIMAT0021807 aca-miR-1805-5p; +MIMAT0021808 aca-miR-1805-3p; +MIMAT0021809 aca-miR-181a; +MIMAT0021810 aca-miR-181b; +MIMAT0021811 aca-miR-182;aca-miR-182-5p; +MIMAT0021812 aca-miR-182*;aca-miR-182-3p; +MIMAT0021813 aca-miR-184*;aca-miR-184-5p; +MIMAT0021814 aca-miR-184;aca-miR-184-3p; +MIMAT0021815 aca-miR-187*;aca-miR-187-5p; +MIMAT0021816 aca-miR-187;aca-miR-187-3p; +MIMAT0021817 aca-miR-18a;aca-miR-18a-5p; +MIMAT0021818 aca-miR-18a*;aca-miR-18a-3p; +MIMAT0021819 aca-miR-18b;aca-miR-18b-5p; +MIMAT0021820 aca-miR-18b*;aca-miR-18b-3p; +MIMAT0021821 aca-miR-190a;aca-miR-190a-5p; +MIMAT0021822 aca-miR-190a*;aca-miR-190a-3p; +MIMAT0021823 aca-miR-190b; +MIMAT0021824 aca-miR-191;aca-miR-191-5p; +MIMAT0021825 aca-miR-191*;aca-miR-191-3p; +MIMAT0021826 aca-miR-193*;aca-miR-193-5p; +MIMAT0021827 aca-miR-193;aca-miR-193-3p; +MIMAT0021828 aca-miR-194;aca-miR-194-5p; +MIMAT0021829 aca-miR-194-1*;aca-miR-194-1-3p; +MIMAT0021830 aca-miR-194-2*;aca-miR-194-2-3p; +MIMAT0021831 aca-miR-196a; +MIMAT0021832 aca-miR-196c;aca-miR-196c-5p; +MIMAT0021833 aca-miR-196c*;aca-miR-196c-3p; +MIMAT0021834 aca-miR-199a-5p; +MIMAT0021835 aca-miR-199b-5p; +MIMAT0021836 aca-miR-19a*;aca-miR-19a-5p; +MIMAT0021837 aca-miR-19a;aca-miR-19a-3p; +MIMAT0021838 aca-miR-19b; +MIMAT0021839 aca-miR-1a-1*;aca-miR-1a-1-5p; +MIMAT0021840 aca-miR-1a;aca-miR-1a-3p; +MIMAT0021841 aca-miR-1a-2*;aca-miR-1a-2-5p; +MIMAT0021842 aca-miR-1b*;aca-miR-1b-5p; +MIMAT0021843 aca-miR-1b;aca-miR-1b-3p; +MIMAT0021844 aca-miR-200a*;aca-miR-200a-5p; +MIMAT0021845 aca-miR-200a;aca-miR-200a-3p; +MIMAT0021846 aca-miR-200b*;aca-miR-200b-5p; +MIMAT0021847 aca-miR-200b;aca-miR-200b-3p; +MIMAT0021848 aca-miR-202-5p; +MIMAT0021849 aca-miR-202.2;aca-miR-202-5p.2; +MIMAT0021850 aca-miR-202.1;aca-miR-202-3p.1; +MIMAT0021851 aca-miR-203*;aca-miR-203-5p; +MIMAT0021852 aca-miR-203;aca-miR-203-3p; +MIMAT0021853 aca-miR-204a;aca-miR-204a-5p; +MIMAT0021854 aca-miR-204a*;aca-miR-204a-3p; +MIMAT0021855 aca-miR-205a; +MIMAT0021856 aca-miR-205b; +MIMAT0021857 aca-miR-206*;aca-miR-206-5p; +MIMAT0021858 aca-miR-206;aca-miR-206-3p; +MIMAT0021859 aca-miR-208*;aca-miR-208-5p; +MIMAT0021860 aca-miR-208;aca-miR-208-3p; +MIMAT0021861 aca-miR-20a;aca-miR-20a-5p; +MIMAT0021862 aca-miR-20a*;aca-miR-20a-3p; +MIMAT0021863 aca-miR-20b;aca-miR-20b-5p; +MIMAT0021864 aca-miR-20b*;aca-miR-20b-3p; +MIMAT0021865 aca-miR-21;aca-miR-21-5p; +MIMAT0021866 aca-miR-21*;aca-miR-21-3p; +MIMAT0021867 aca-miR-210*;aca-miR-210-5p; +MIMAT0021868 aca-miR-210;aca-miR-210-3p; +MIMAT0021869 aca-miR-212*;aca-miR-212-5p; +MIMAT0021870 aca-miR-212;aca-miR-212-3p; +MIMAT0021871 aca-miR-214*;aca-miR-214-5p; +MIMAT0021872 aca-miR-214;aca-miR-214-3p; +MIMAT0021873 aca-miR-215;aca-miR-215-5p; +MIMAT0021874 aca-miR-215*;aca-miR-215-3p; +MIMAT0021875 aca-miR-216a; +MIMAT0021876 aca-miR-216b;aca-miR-216b-5p; +MIMAT0021877 aca-miR-216b*;aca-miR-216b-3p; +MIMAT0021878 aca-miR-217;aca-miR-217-5p; +MIMAT0021879 aca-miR-217*;aca-miR-217-3p; +MIMAT0021880 aca-miR-218;aca-miR-218-5p; +MIMAT0021881 aca-miR-218*;aca-miR-218-3p; +MIMAT0021882 aca-miR-2188;aca-miR-2188-5p; +MIMAT0021883 aca-miR-2188*;aca-miR-2188-3p; +MIMAT0021884 aca-miR-219;aca-miR-219-5p; +MIMAT0021885 aca-miR-219-1*;aca-miR-219-1-3p; +MIMAT0021886 aca-miR-219-2*;aca-miR-219-2-3p; +MIMAT0021887 aca-miR-22*;aca-miR-22-5p; +MIMAT0021888 aca-miR-22;aca-miR-22-3p; +MIMAT0021889 aca-miR-221*;aca-miR-221-5p; +MIMAT0021890 aca-miR-221;aca-miR-221-3p; +MIMAT0021891 aca-miR-222*;aca-miR-222-5p;aca-miR-222a-5p; +MIMAT0021892 aca-miR-222;aca-miR-222-3p;aca-miR-222a-3p; +MIMAT0021893 aca-miR-223*;aca-miR-223-5p; +MIMAT0021894 aca-miR-223;aca-miR-223-3p; +MIMAT0021895 aca-miR-23a*;aca-miR-23a-5p; +MIMAT0021896 aca-miR-23a;aca-miR-23a-3p; +MIMAT0021897 aca-miR-23b*;aca-miR-23b-5p; +MIMAT0021898 aca-miR-23b;aca-miR-23b-3p; +MIMAT0021899 aca-miR-24-1*;aca-miR-24-1-5p; +MIMAT0021900 aca-miR-24;aca-miR-24-3p; +MIMAT0021901 aca-miR-24-2*;aca-miR-24-2-5p; +MIMAT0021902 aca-miR-26;aca-miR-26-5p; +MIMAT0021903 aca-miR-26-1*;aca-miR-26-1-3p; +MIMAT0021904 aca-miR-26-2*;aca-miR-26-2-3p; +MIMAT0021905 aca-miR-27a*;aca-miR-27a-5p; +MIMAT0021906 aca-miR-27a;aca-miR-27a-3p; +MIMAT0021907 aca-miR-27b*;aca-miR-27b-5p; +MIMAT0021908 aca-miR-27b;aca-miR-27b-3p; +MIMAT0021909 aca-miR-2970;aca-miR-2970-5p; +MIMAT0021910 aca-miR-2970*;aca-miR-2970-3p; +MIMAT0021911 aca-miR-29a-1*;aca-miR-29a-1-5p; +MIMAT0021912 aca-miR-29a;aca-miR-29a-3p; +MIMAT0021913 aca-miR-29a-2*;aca-miR-29a-2-5p; +MIMAT0021914 aca-miR-29b; +MIMAT0021915 aca-miR-301a*;aca-miR-301a-5p; +MIMAT0021916 aca-miR-301a;aca-miR-301a-3p; +MIMAT0021917 aca-miR-301b*;aca-miR-301b-5p; +MIMAT0021918 aca-miR-301b;aca-miR-301b-3p; +MIMAT0021919 aca-miR-302;aca-miR-302b; +MIMAT0021920 aca-miR-30a;aca-miR-30a-5p; +MIMAT0021921 aca-miR-30a*;aca-miR-30a-3p; +MIMAT0021922 aca-miR-30b;aca-miR-30b-5p; +MIMAT0021923 aca-miR-30b*;aca-miR-30b-3p; +MIMAT0021924 aca-miR-30c;aca-miR-30c-5p; +MIMAT0021925 aca-miR-30c*;aca-miR-30c-3p; +MIMAT0021926 aca-miR-30d;aca-miR-30d-5p; +MIMAT0021927 aca-miR-30d*;aca-miR-30d-3p; +MIMAT0021928 aca-miR-30e;aca-miR-30e-5p; +MIMAT0021929 aca-miR-30e*;aca-miR-30e-3p; +MIMAT0021930 aca-miR-31;aca-miR-31-5p; +MIMAT0021931 aca-miR-31*;aca-miR-31-3p; +MIMAT0021932 aca-miR-32;aca-miR-32-5p; +MIMAT0021933 aca-miR-32*;aca-miR-32-3p; +MIMAT0021934 aca-miR-33;aca-miR-33-5p; +MIMAT0021935 aca-miR-33-1*;aca-miR-33-1-3p; +MIMAT0021936 aca-miR-33-2*;aca-miR-33-2-3p; +MIMAT0021937 aca-miR-338-5p; +MIMAT0021938 aca-miR-338-3p; +MIMAT0021939 aca-miR-34a;aca-miR-34a-5p; +MIMAT0021940 aca-miR-34a*;aca-miR-34a-3p; +MIMAT0021941 aca-miR-34b;aca-miR-34b-5p; +MIMAT0021942 aca-miR-34b*;aca-miR-34b-3p; +MIMAT0021943 aca-miR-34c;aca-miR-34c-5p; +MIMAT0021944 aca-miR-34c*;aca-miR-34c-3p; +MIMAT0021945 aca-miR-363*;aca-miR-363-5p; +MIMAT0021946 aca-miR-363;aca-miR-363-3p; +MIMAT0021947 aca-miR-365*;aca-miR-365-5p; +MIMAT0021948 aca-miR-365;aca-miR-365-3p; +MIMAT0021949 aca-miR-367; +MIMAT0021950 aca-miR-375*;aca-miR-375-5p; +MIMAT0021951 aca-miR-375;aca-miR-375-3p; +MIMAT0021952 aca-miR-383;aca-miR-383-5p; +MIMAT0021953 aca-miR-383*;aca-miR-383-3p; +MIMAT0021954 aca-miR-425;aca-miR-425-5p; +MIMAT0021955 aca-miR-425*;aca-miR-425-3p; +MIMAT0021956 aca-miR-429*;aca-miR-429-5p; +MIMAT0021957 aca-miR-429;aca-miR-429-3p; +MIMAT0021958 aca-miR-449a; +MIMAT0021959 aca-miR-449b; +MIMAT0021960 aca-miR-451;aca-miR-451-5p; +MIMAT0021961 aca-miR-451*;aca-miR-451-3p; +MIMAT0021962 aca-miR-454*;aca-miR-454-5p; +MIMAT0021963 aca-miR-454;aca-miR-454-3p; +MIMAT0021964 aca-miR-455-5p; +MIMAT0021965 aca-miR-455-3p; +MIMAT0021966 aca-miR-456; +MIMAT0021967 aca-miR-457;aca-miR-457-5p; +MIMAT0021968 aca-miR-457*;aca-miR-457-3p; +MIMAT0021969 aca-miR-458; +MIMAT0021970 aca-miR-460a-5p; +MIMAT0021971 aca-miR-460a-3p; +MIMAT0021972 aca-miR-460b-5p; +MIMAT0021973 aca-miR-460b-3p; +MIMAT0021974 aca-miR-489-5p; +MIMAT0021975 aca-miR-489-3p; +MIMAT0021976 aca-miR-490-5p; +MIMAT0021977 aca-miR-490-3p; +MIMAT0021978 aca-miR-497;aca-miR-497-5p; +MIMAT0021979 aca-miR-497*;aca-miR-497-3p; +MIMAT0021980 aca-miR-499-5p; +MIMAT0021981 aca-miR-499-3p; +MIMAT0021982 aca-miR-551; +MIMAT0021983 aca-miR-7;aca-miR-7-5p; +MIMAT0021984 aca-miR-7-1*;aca-miR-7-1-3p; +MIMAT0021985 aca-miR-7-2*;aca-miR-7-2-3p; +MIMAT0021986 aca-miR-726; +MIMAT0021987 aca-miR-727*;aca-miR-727-5p; +MIMAT0021988 aca-miR-727;aca-miR-727-3p; +MIMAT0021989 aca-miR-875; +MIMAT0021990 aca-miR-9;aca-miR-9-5p; +MIMAT0021991 aca-miR-9-1*;aca-miR-9-1-3p; +MIMAT0021992 aca-miR-9-3*;aca-miR-9-3-3p; +MIMAT0021993 aca-miR-92a; +MIMAT0021994 aca-miR-98;aca-miR-98-5p; +MIMAT0021995 aca-miR-98*;aca-miR-98-3p; +MIMAT0021996 aca-miR-99a;aca-miR-99a-5p; +MIMAT0021997 aca-miR-99a*;aca-miR-99a-3p; +MIMAT0021998 aca-miR-99b;aca-miR-99b-5p; +MIMAT0021999 aca-miR-99b*;aca-miR-99b-3p; +MIMAT0022000 aca-miR-5394-5p; +MIMAT0022001 aca-miR-5394-3p; +MIMAT0022002 aca-miR-5395; +MIMAT0022003 aca-miR-5396;aca-miR-5396a; +MIMAT0022004 aca-miR-5397;aca-miR-5397-5p; +MIMAT0022005 aca-miR-5397*;aca-miR-5397-3p; +MIMAT0022006 aca-miR-5398-5p; +MIMAT0022007 aca-miR-5398-3p; +MIMAT0022008 aca-miR-5399*;aca-miR-5399-5p; +MIMAT0022009 aca-miR-5399;aca-miR-5399-3p; +MIMAT0022010 aca-miR-5400; +MIMAT0022011 aca-miR-5401; +MIMAT0022012 aca-miR-5402;aca-miR-5402-5p; +MIMAT0022013 aca-miR-5402*;aca-miR-5402-3p; +MIMAT0022014 aca-miR-449c;aca-miR-449c-5p; +MIMAT0022015 aca-miR-449c*;aca-miR-449c-3p; +MIMAT0022016 aca-miR-5403; +MIMAT0022017 aca-miR-5404; +MIMAT0022018 aca-miR-5405;aca-miR-5405-5p; +MIMAT0022019 aca-miR-5405*;aca-miR-5405-3p; +MIMAT0022020 aca-miR-5406-5p; +MIMAT0022021 aca-miR-5406-3p; +MIMAT0022022 aca-miR-5407;aca-miR-5407-5p; +MIMAT0022023 aca-miR-5407*;aca-miR-5407-3p; +MIMAT0022024 aca-miR-5408a;aca-miR-5408a-5p; +MIMAT0022025 aca-miR-5408a*;aca-miR-5408a-3p; +MIMAT0022026 aca-miR-5409; +MIMAT0022027 aca-miR-5410*;aca-miR-5410-5p; +MIMAT0022028 aca-miR-5410;aca-miR-5410-3p; +MIMAT0022029 aca-miR-5411; +MIMAT0022030 aca-miR-5412-5p; +MIMAT0022031 aca-miR-5412-3p; +MIMAT0022032 aca-miR-5413*;aca-miR-5413-5p; +MIMAT0022033 aca-miR-5413;aca-miR-5413-3p; +MIMAT0022034 aca-miR-5414; +MIMAT0022035 aca-miR-5415; +MIMAT0022036 aca-miR-5416; +MIMAT0022037 aca-miR-5417; +MIMAT0022038 aca-miR-5418; +MIMAT0022039 aca-miR-5419; +MIMAT0022040 aca-miR-5420; +MIMAT0022041 aca-miR-5421; +MIMAT0022042 aca-miR-5422; +MIMAT0022043 aca-miR-5423; +MIMAT0022044 aca-miR-5424; +MIMAT0022045 aca-miR-5425; +MIMAT0022046 aca-miR-5426-5p; +MIMAT0022047 aca-miR-5426-3p; +MIMAT0022048 aca-miR-5427; +MIMAT0022049 aca-miR-5428; +MIMAT0022050 aca-miR-5429; +MIMAT0022051 aca-miR-5430; +MIMAT0022052 aca-miR-5431; +MIMAT0022053 aca-miR-5432; +MIMAT0022054 aca-miR-5433; +MIMAT0022055 aca-miR-5434; +MIMAT0022056 aca-miR-5435a; +MIMAT0022057 aca-miR-5436-5p; +MIMAT0022058 aca-miR-5436-3p; +MIMAT0022059 aca-miR-5437; +MIMAT0022060 aca-miR-5438; +MIMAT0022061 aca-miR-5439; +MIMAT0022062 aca-miR-5440; +MIMAT0022063 aca-miR-5441; +MIMAT0022064 aca-miR-5442; +MIMAT0022065 aca-miR-5443; +MIMAT0022066 aca-miR-5444a; +MIMAT0022067 aca-miR-5445; +MIMAT0022068 aca-miR-5446; +MIMAT0022069 aca-miR-5447; +MIMAT0022070 aca-miR-5448; +MIMAT0022071 aca-miR-5449; +MIMAT0022072 aca-miR-5450; +MIMAT0022073 aca-miR-5408b; +MIMAT0022074 aca-miR-5451; +MIMAT0022075 aca-miR-5452;aca-miR-5452-5p; +MIMAT0022076 aca-miR-5452*;aca-miR-5452-3p; +MIMAT0022077 aca-miR-5408c-5p; +MIMAT0022078 aca-miR-5408c-3p; +MIMAT0022079 aca-miR-5453; +MIMAT0022080 aca-miR-5454; +MIMAT0022081 aca-miR-5455-5p; +MIMAT0022082 aca-miR-5455-3p; +MIMAT0022083 aca-miR-5456; +MIMAT0022084 aca-miR-5457; +MIMAT0022085 aca-miR-5458; +MIMAT0022086 aca-miR-5459; +MIMAT0022087 aca-miR-5444b; +MIMAT0022088 aca-miR-5460; +MIMAT0022089 aca-miR-5461; +MIMAT0022090 aca-miR-5435b-3p; +MIMAT0022091 aca-miR-5435b-5p; +MIMAT0022092 aca-miR-5435c-3p; +MIMAT0022093 aca-miR-5435c-5p; +MIMAT0022094 aca-miR-5462; +MIMAT0022095 aca-miR-5463; +MIMAT0022096 aca-miR-5464-5p; +MIMAT0022097 aca-miR-5464-3p; +MIMAT0022098 aca-miR-5465; +MIMAT0022099 aca-miR-5466; +MIMAT0022100 aca-miR-5467; +MIMAT0022101 aca-miR-5468; +MIMAT0022102 aca-miR-5469; +MIMAT0022103 aca-miR-5470; +MIMAT0022104 pti-miR5471; +MIMAT0022105 pti-miR5472; +MIMAT0022106 pti-miR5473; +MIMAT0022107 pti-miR5474; +MIMAT0022108 pti-miR5475; +MIMAT0022109 pti-miR5476; +MIMAT0022110 pti-miR5477; +MIMAT0022111 pti-miR5478; +MIMAT0022112 pti-miR5479; +MIMAT0022113 pti-miR5480; +MIMAT0022114 pti-miR5481; +MIMAT0022115 pti-miR5482; +MIMAT0022116 pti-miR5483; +MIMAT0022117 osa-miR5484; +MIMAT0022118 osa-miR5485; +MIMAT0022119 osa-miR5486; +MIMAT0022120 osa-miR5487; +MIMAT0022121 osa-miR5488; +MIMAT0022122 osa-miR5489; +MIMAT0022123 osa-miR5490; +MIMAT0022124 osa-miR5491; +MIMAT0022125 osa-miR5492; +MIMAT0022126 osa-miR5493; +MIMAT0022127 osa-miR5494; +MIMAT0022128 osa-miR5495; +MIMAT0022129 osa-miR5496; +MIMAT0022130 osa-miR5497; +MIMAT0022131 osa-miR5498; +MIMAT0022132 osa-miR5499; +MIMAT0022133 osa-miR5500; +MIMAT0022134 osa-miR5501; +MIMAT0022135 osa-miR5502; +MIMAT0022136 osa-miR5503; +MIMAT0022137 osa-miR5504; +MIMAT0022138 osa-miR5505; +MIMAT0022139 osa-miR5506; +MIMAT0022140 osa-miR5507; +MIMAT0022141 osa-miR5508; +MIMAT0022142 osa-miR5509; +MIMAT0022143 osa-miR5510; +MIMAT0022144 osa-miR5511; +MIMAT0022145 osa-miR5512;osa-miR5512a; +MIMAT0022146 osa-miR5513; +MIMAT0022147 osa-miR2275c; +MIMAT0022148 osa-miR5514; +MIMAT0022149 osa-miR5515; +MIMAT0022150 osa-miR5516;osa-miR5516a; +MIMAT0022151 osa-miR5517; +MIMAT0022152 osa-miR5518; +MIMAT0022153 osa-miR5519; +MIMAT0022154 osa-miR5520; +MIMAT0022155 osa-miR5521; +MIMAT0022156 osa-miR5522; +MIMAT0022157 osa-miR5523; +MIMAT0022158 osa-miR2275d; +MIMAT0022159 osa-miR5524; +MIMAT0022160 osa-miR5525; +MIMAT0022161 osa-miR5526; +MIMAT0022162 osa-miR5527; +MIMAT0022163 osa-miR5528; +MIMAT0022164 osa-miR5529; +MIMAT0022165 osa-miR5530; +MIMAT0022166 osa-miR5531; +MIMAT0022167 osa-miR5532; +MIMAT0022168 osa-miR5533; +MIMAT0022169 osa-miR5534a; +MIMAT0022170 osa-miR5534b; +MIMAT0022171 osa-miR5535; +MIMAT0022172 osa-miR5536; +MIMAT0022173 osa-miR5537; +MIMAT0022174 osa-miR5538; +MIMAT0022175 osa-miR5539;osa-miR5539a; +MIMAT0022176 osa-miR5540; +MIMAT0022177 osa-miR5541; +MIMAT0022178 osa-miR5542; +MIMAT0022179 osa-miR5543; +MIMAT0022180 osa-miR5544; +MIMAT0022181 cel-miR-5545-5p; +MIMAT0022182 cel-miR-5545-3p; +MIMAT0022183 cel-miR-5546-5p; +MIMAT0022184 cel-miR-5546-3p; +MIMAT0022185 cel-miR-5547-5p; +MIMAT0022186 cel-miR-5547-3p; +MIMAT0022187 cel-miR-5548-5p; +MIMAT0022188 cel-miR-5548-3p; +MIMAT0022189 cel-miR-5549-5p; +MIMAT0022190 cel-miR-5549-3p; +MIMAT0022191 cel-miR-5550-5p; +MIMAT0022192 cel-miR-5550-3p; +MIMAT0022193 cel-miR-5551-5p; +MIMAT0022194 cel-miR-5551-3p; +MIMAT0022195 cel-miR-5552-5p; +MIMAT0022196 cel-miR-5552-3p; +MIMAT0022197 cel-miR-5553-5p; +MIMAT0022198 cel-miR-5553-3p; +MIMAT0022199 mtr-miR5554a;mtr-miR5554a-5p; +MIMAT0022200 mtr-miR5554a*;mtr-miR5554a-3p; +MIMAT0022201 mtr-miR5555;mtr-miR5555-5p; +MIMAT0022202 mtr-miR5555*;mtr-miR5555-3p; +MIMAT0022203 mtr-miR2619b;mtr-miR2619b-5p; +MIMAT0022204 mtr-miR2619b*;mtr-miR2619b-3p; +MIMAT0022205 mtr-miR2592bl;mtr-miR2592bl-5p; +MIMAT0022206 mtr-miR2592bl*;mtr-miR2592bl-3p; +MIMAT0022207 mtr-miR5554b;mtr-miR5554b-5p; +MIMAT0022208 mtr-miR5554b*;mtr-miR5554b-3p; +MIMAT0022209 mtr-miR5274b;mtr-miR5274b-5p; +MIMAT0022210 mtr-miR5274b*;mtr-miR5274b-3p; +MIMAT0022211 mtr-miR5556*;mtr-miR5556-5p; +MIMAT0022212 mtr-miR5556;mtr-miR5556-3p; +MIMAT0022213 mtr-miR2592bm*;mtr-miR2592bm-5p; +MIMAT0022214 mtr-miR2592bm;mtr-miR2592bm-3p; +MIMAT0022215 mtr-miR5557*;mtr-miR5557-5p; +MIMAT0022216 mtr-miR5557;mtr-miR5557-3p; +MIMAT0022217 mtr-miR2592bn*;mtr-miR2592bn-5p; +MIMAT0022218 mtr-miR2592bn;mtr-miR2592bn-3p; +MIMAT0022219 mtr-miR5558;mtr-miR5558-5p; +MIMAT0022220 mtr-miR5558*;mtr-miR5558-3p; +MIMAT0022221 mtr-miR5559;mtr-miR5559-5p; +MIMAT0022222 mtr-miR5559*;mtr-miR5559-3p; +MIMAT0022223 mtr-miR5560*;mtr-miR5560-5p; +MIMAT0022224 mtr-miR5560;mtr-miR5560-3p; +MIMAT0022225 mtr-miR5554c;mtr-miR5554c-5p; +MIMAT0022226 mtr-miR5554c*;mtr-miR5554c-3p; +MIMAT0022227 mtr-miR5561;mtr-miR5561-5p; +MIMAT0022228 mtr-miR5561*;mtr-miR5561-3p; +MIMAT0022229 mtr-miR5562;mtr-miR5562-5p; +MIMAT0022230 mtr-miR5562*;mtr-miR5562-3p; +MIMAT0022231 mtr-miR5563;mtr-miR5563-5p; +MIMAT0022232 mtr-miR5563*;mtr-miR5563-3p; +MIMAT0022233 mtr-miR167b;mtr-miR167b-5p; +MIMAT0022234 mtr-miR167b*;mtr-miR167b-3p; +MIMAT0022235 mtr-miR168c;mtr-miR168c-5p; +MIMAT0022236 mtr-miR168c*;mtr-miR168c-3p; +MIMAT0022237 mtr-miR408*;mtr-miR408-5p; +MIMAT0022238 mtr-miR408;mtr-miR408-3p; +MIMAT0022239 mtr-miR2111v;mtr-miR2111v-5p;mtr-miR2111a-5p; +MIMAT0022240 mtr-miR2111v*;mtr-miR2111v-3p;mtr-miR2111a-3p; +MIMAT0022241 sbi-miR5564a; +MIMAT0022242 sbi-miR5564b; +MIMAT0022243 sbi-miR5565e; +MIMAT0022244 sbi-miR5565f; +MIMAT0022245 sbi-miR5566; +MIMAT0022246 sbi-miR5567; +MIMAT0022247 sbi-miR5565c; +MIMAT0022248 sbi-miR5568;sbi-miR5568a; +MIMAT0022249 sbi-miR5387b; +MIMAT0022250 sbi-miR5569; +MIMAT0022251 sbi-miR5570; +MIMAT0022252 sbi-miR5565a; +MIMAT0022253 sbi-miR5565b; +MIMAT0022254 sbi-miR5565d; +MIMAT0022255 hsa-miR-4524b-5p; +MIMAT0022256 hsa-miR-4524b-3p; +MIMAT0022257 hsa-miR-5571-5p; +MIMAT0022258 hsa-miR-5571-3p; +MIMAT0022259 hsa-miR-5100; +MIMAT0022260 hsa-miR-5572; +MIMAT0022261 zma-miR444a; +MIMAT0022262 zma-miR444b; +MIMAT0022263 hsa-miR-548aq-5p; +MIMAT0022264 hsa-miR-548aq-3p; +MIMAT0022265 hsa-miR-548ar-5p; +MIMAT0022266 hsa-miR-548ar-3p; +MIMAT0022267 hsa-miR-548as-5p; +MIMAT0022268 hsa-miR-548as-3p; +MIMAT0022269 hsa-miR-5579-5p; +MIMAT0022270 hsa-miR-5579-3p; +MIMAT0022271 hsa-miR-644b-5p;hsa-miR-664b-5p; +MIMAT0022272 hsa-miR-644b-3p;hsa-miR-664b-3p; +MIMAT0022273 hsa-miR-5580-5p; +MIMAT0022274 hsa-miR-5580-3p; +MIMAT0022275 hsa-miR-5581-5p; +MIMAT0022276 hsa-miR-5581-3p; +MIMAT0022277 hsa-miR-548at-5p; +MIMAT0022278 hsa-miR-548at-3p; +MIMAT0022279 hsa-miR-5582-5p; +MIMAT0022280 hsa-miR-5582-3p; +MIMAT0022281 hsa-miR-5583-5p; +MIMAT0022282 hsa-miR-5583-3p; +MIMAT0022283 hsa-miR-5584-5p; +MIMAT0022284 hsa-miR-5584-3p; +MIMAT0022285 hsa-miR-5585-5p; +MIMAT0022286 hsa-miR-5585-3p; +MIMAT0022287 hsa-miR-5586-5p; +MIMAT0022288 hsa-miR-5586-3p; +MIMAT0022289 hsa-miR-5587-5p; +MIMAT0022290 hsa-miR-5587-3p; +MIMAT0022291 hsa-miR-548au-5p; +MIMAT0022292 hsa-miR-548au-3p; +MIMAT0022293 hsa-miR-1295b-5p; +MIMAT0022294 hsa-miR-1295b-3p; +MIMAT0022295 hsa-miR-5588-5p; +MIMAT0022296 hsa-miR-5588-3p; +MIMAT0022297 hsa-miR-5589-5p; +MIMAT0022298 hsa-miR-5589-3p; +MIMAT0022299 hsa-miR-5590-5p; +MIMAT0022300 hsa-miR-5590-3p; +MIMAT0022301 hsa-miR-5591-5p; +MIMAT0022302 hsa-miR-5591-3p; +MIMAT0022303 hsa-miR-548av-5p; +MIMAT0022304 hsa-miR-548av-3p; +MIMAT0022305 cel-miR-5592-5p; +MIMAT0022306 cel-miR-5592-3p; +MIMAT0022307 cel-miR-5593-5p; +MIMAT0022308 cel-miR-5593-3p; +MIMAT0022309 cel-miR-5594-5p; +MIMAT0022310 cel-miR-5594-3p; +MIMAT0022311 cel-miR-356b-5p; +MIMAT0022312 cel-miR-356b-3p; +MIMAT0022313 cel-miR-5595-5p; +MIMAT0022314 cel-miR-5595-3p; +MIMAT0022315 cin-miR-5596a*;cin-miR-5596a-5p; +MIMAT0022316 cin-miR-5596a;cin-miR-5596a-3p; +MIMAT0022317 cin-miR-5597*;cin-miR-5597-5p; +MIMAT0022318 cin-miR-5597;cin-miR-5597-3p; +MIMAT0022319 cin-miR-5598*;cin-miR-5598-5p; +MIMAT0022320 cin-miR-5598;cin-miR-5598-3p; +MIMAT0022321 cin-miR-5599*;cin-miR-5599-5p; +MIMAT0022322 cin-miR-5599;cin-miR-5599-3p; +MIMAT0022323 cin-miR-5600*;cin-miR-5600-5p; +MIMAT0022324 cin-miR-5600;cin-miR-5600-3p; +MIMAT0022325 cin-miR-5601*;cin-miR-5601-5p; +MIMAT0022326 cin-miR-5601;cin-miR-5601-3p; +MIMAT0022327 cin-miR-5596b*;cin-miR-5596b-5p; +MIMAT0022328 cin-miR-5596b;cin-miR-5596b-3p; +MIMAT0022329 cin-miR-5602;cin-miR-5602-5p; +MIMAT0022330 cin-miR-5602*;cin-miR-5602-3p; +MIMAT0022331 cin-miR-5603*;cin-miR-5603-5p; +MIMAT0022332 cin-miR-5603;cin-miR-5603-3p; +MIMAT0022333 cin-miR-5604;cin-miR-5604-5p; +MIMAT0022334 cin-miR-5604*;cin-miR-5604-3p; +MIMAT0022335 cin-miR-4179b*;cin-miR-4179b-5p; +MIMAT0022336 cin-miR-4179b;cin-miR-4179b-3p; +MIMAT0022337 cin-miR-5605*;cin-miR-5605-5p; +MIMAT0022338 cin-miR-5605;cin-miR-5605-3p; +MIMAT0022339 cin-miR-5606;cin-miR-5606-5p; +MIMAT0022340 cin-miR-5606*;cin-miR-5606-3p; +MIMAT0022341 cin-miR-5607;cin-miR-5607-5p; +MIMAT0022342 cin-miR-5607*;cin-miR-5607-3p; +MIMAT0022343 cin-miR-5608;cin-miR-5608-5p; +MIMAT0022344 cin-miR-5608*;cin-miR-5608-3p; +MIMAT0022345 cin-miR-5609;cin-miR-5609-5p; +MIMAT0022346 cin-miR-5609*;cin-miR-5609-3p; +MIMAT0022347 cin-miR-5610*;cin-miR-5610-5p; +MIMAT0022348 cin-miR-5610;cin-miR-5610-3p; +MIMAT0022349 cin-miR-5611;cin-miR-5611-5p; +MIMAT0022350 cin-miR-5611*;cin-miR-5611-3p; +MIMAT0022351 cin-miR-5612*;cin-miR-5612-5p; +MIMAT0022352 cin-miR-5612;cin-miR-5612-3p; +MIMAT0022353 mmu-miR-3544-5p; +MIMAT0022354 mmu-miR-3544-3p; +MIMAT0022355 mmu-miR-5615-5p; +MIMAT0022356 mmu-miR-5615-3p; +MIMAT0022357 mmu-miR-1231-5p; +MIMAT0022358 mmu-miR-1231-3p; +MIMAT0022359 mmu-miR-5616-5p; +MIMAT0022360 mmu-miR-5616-3p; +MIMAT0022361 mmu-miR-5617-5p; +MIMAT0022362 mmu-miR-5617-3p; +MIMAT0022363 mmu-miR-5618-5p; +MIMAT0022364 mmu-miR-5618-3p; +MIMAT0022365 mmu-miR-5619-5p; +MIMAT0022366 mmu-miR-5619-3p; +MIMAT0022367 mmu-miR-5620-5p; +MIMAT0022368 mmu-miR-5620-3p; +MIMAT0022369 mmu-miR-5621-5p; +MIMAT0022370 mmu-miR-5621-3p; +MIMAT0022371 mmu-miR-5622-5p; +MIMAT0022372 mmu-miR-5622-3p; +MIMAT0022373 mmu-miR-5623-5p; +MIMAT0022374 mmu-miR-5623-3p; +MIMAT0022375 mmu-miR-3073b-5p; +MIMAT0022376 mmu-miR-3073b-3p; +MIMAT0022377 mmu-miR-5624-5p; +MIMAT0022378 mmu-miR-5624-3p; +MIMAT0022379 mmu-miR-5625-5p; +MIMAT0022380 mmu-miR-5625-3p; +MIMAT0022381 mmu-miR-5626-5p; +MIMAT0022382 mmu-miR-5626-3p; +MIMAT0022383 mmu-miR-344h-5p; +MIMAT0022384 mmu-miR-344h-3p; +MIMAT0022385 mmu-miR-5627-5p; +MIMAT0022386 mmu-miR-5627-3p; +MIMAT0022387 ath-miR5628; +MIMAT0022388 ath-miR5629; +MIMAT0022389 ath-miR5630a; +MIMAT0022390 ath-miR5631; +MIMAT0022391 ath-miR5020c; +MIMAT0022392 ath-miR5632;ath-miR5632-3p; +MIMAT0022393 ath-miR5633; +MIMAT0022394 ath-miR5634; +MIMAT0022395 ath-miR5635a; +MIMAT0022396 ath-miR5636; +MIMAT0022397 ath-miR5637; +MIMAT0022398 ath-miR5638a; +MIMAT0022399 ath-miR5630b; +MIMAT0022400 ath-miR5639;ath-miR5639-5p; +MIMAT0022401 ath-miR5640; +MIMAT0022402 ath-miR5641; +MIMAT0022403 ath-miR5642a; +MIMAT0022404 ath-miR5643a; +MIMAT0022405 ath-miR5635d; +MIMAT0022406 ath-miR5644; +MIMAT0022407 ath-miR5638b; +MIMAT0022408 ath-miR5645a; +MIMAT0022409 ath-miR5645b; +MIMAT0022410 ath-miR5646; +MIMAT0022411 ath-miR5647; +MIMAT0022412 ath-miR5648-5p; +MIMAT0022413 ath-miR5648-3p; +MIMAT0022414 ath-miR5645c; +MIMAT0022415 ath-miR5649a; +MIMAT0022416 ath-miR5650; +MIMAT0022417 ath-miR858b; +MIMAT0022418 ath-miR5635b; +MIMAT0022419 ath-miR833b; +MIMAT0022420 ath-miR781b; +MIMAT0022421 ath-miR156i; +MIMAT0022422 ath-miR5651; +MIMAT0022423 ath-miR156j; +MIMAT0022424 ath-miR5652; +MIMAT0022425 ath-miR5653; +MIMAT0022426 ath-miR5654;ath-miR5654-5p; +MIMAT0022427 ath-miR5655; +MIMAT0022428 ath-miR5635c; +MIMAT0022429 ath-miR5656; +MIMAT0022430 ath-miR5657; +MIMAT0022431 ath-miR5658; +MIMAT0022432 ath-miR5659; +MIMAT0022433 ath-miR5645d; +MIMAT0022434 ath-miR5660; +MIMAT0022435 ath-miR5642b; +MIMAT0022436 ath-miR1888b; +MIMAT0022437 ath-miR5649b; +MIMAT0022438 ath-miR5661; +MIMAT0022439 ath-miR5662; +MIMAT0022440 ath-miR5663;ath-miR5663-5p; +MIMAT0022441 ath-miR5645f; +MIMAT0022442 ath-miR5664; +MIMAT0022443 ath-miR5665; +MIMAT0022444 ath-miR5666; +MIMAT0022445 ath-miR5643b; +MIMAT0022446 ath-miR5645e; +MIMAT0022447 meu-miR-15c; +MIMAT0022448 meu-miR-16c; +MIMAT0022449 gma-miR5667;gma-miR5667-3p; +MIMAT0022450 gma-miR5668; +MIMAT0022451 gma-miR5669; +MIMAT0022452 gma-miR5670;gma-miR5670a; +MIMAT0022453 gma-miR5671;gma-miR5671a; +MIMAT0022454 gma-miR5672; +MIMAT0022455 gma-miR5037d; +MIMAT0022456 gma-miR5673; +MIMAT0022457 gma-miR2111;gma-miR2111a; +MIMAT0022458 gma-miR1512c; +MIMAT0022459 gma-miR5674;gma-miR5674a; +MIMAT0022460 gma-miR5675; +MIMAT0022461 gma-miR4401b; +MIMAT0022462 gma-miR5676; +MIMAT0022463 gma-miR530b; +MIMAT0022464 gma-miR4387e; +MIMAT0022465 gma-miR5677; +MIMAT0022466 gma-miR5678; +MIMAT0022467 gma-miR5679; +MIMAT0022468 hsa-miR-5680; +MIMAT0022469 hsa-miR-5681a; +MIMAT0022470 hsa-miR-5682; +MIMAT0022471 hsa-miR-548aw; +MIMAT0022472 hsa-miR-5683; +MIMAT0022473 hsa-miR-5684; +MIMAT0022474 hsa-miR-548ax; +MIMAT0022475 hsa-miR-5685; +MIMAT0022476 hsa-miR-5692c; +MIMAT0022477 hsa-miR-5686; +MIMAT0022478 hsa-miR-5687; +MIMAT0022479 hsa-miR-5688; +MIMAT0022480 hsa-miR-5681b; +MIMAT0022481 hsa-miR-5689; +MIMAT0022482 hsa-miR-5690; +MIMAT0022483 hsa-miR-5691; +MIMAT0022484 hsa-miR-5692a; +MIMAT0022485 hsa-miR-4666b; +MIMAT0022486 hsa-miR-5693; +MIMAT0022487 hsa-miR-5694; +MIMAT0022488 hsa-miR-5695; +MIMAT0022489 hsa-miR-5696; +MIMAT0022490 hsa-miR-5697; +MIMAT0022491 hsa-miR-5698; +MIMAT0022492 hsa-miR-5699;hsa-miR-5699-3p; +MIMAT0022493 hsa-miR-5700; +MIMAT0022494 hsa-miR-5701; +MIMAT0022495 hsa-miR-5702; +MIMAT0022496 hsa-miR-5703; +MIMAT0022497 hsa-miR-5692b; +MIMAT0022498 hsa-miR-5704; +MIMAT0022499 hsa-miR-5705; +MIMAT0022500 hsa-miR-5706; +MIMAT0022501 hsa-miR-5707; +MIMAT0022502 hsa-miR-5708; +MIMAT0022503 mmu-miR-344i; +MIMAT0022504 mmu-miR-5709;mmu-miR-5709-5p; +MIMAT0022505 mmu-miR-5710; +MIMAT0022506 ssl-miR156; +MIMAT0022507 ssl-miR164a; +MIMAT0022508 ssl-miR164b; +MIMAT0022509 ssl-miR166a; +MIMAT0022510 ssl-miR166b; +MIMAT0022511 ssl-miR169; +MIMAT0022512 ssl-miR171a; +MIMAT0022513 ssl-miR171b; +MIMAT0022514 ssl-miR172; +MIMAT0022515 ssl-miR394; +MIMAT0022516 ssl-miR395; +MIMAT0022517 ssl-miR396; +MIMAT0022518 ssl-miR397; +MIMAT0022519 ssl-miR398; +MIMAT0022520 ssl-miR399; +MIMAT0022521 ssl-miR828; +MIMAT0022522 ssl-miR948; +MIMAT0022523 ssl-miR1078; +MIMAT0022524 dme-miR-5613*; +MIMAT0022525 dme-miR-5613; +MIMAT0022526 dme-miR-5614*; +MIMAT0022527 dme-miR-5614; +MIMAT0022528 ola-miR-193a; +MIMAT0022529 ola-miR-218a; +MIMAT0022530 ola-miR-221; +MIMAT0022531 ola-miR-222; +MIMAT0022532 ola-miR-18; +MIMAT0022533 ola-miR-20a; +MIMAT0022534 ola-miR-92a; +MIMAT0022535 ola-miR-184-5p; +MIMAT0022536 ola-miR-184-3p; +MIMAT0022537 ola-miR-9a-3p; +MIMAT0022538 ola-miR-199a-5p; +MIMAT0022539 ola-miR-199a-3p; +MIMAT0022540 ola-miR-181b-5p; +MIMAT0022541 ola-miR-181b-3p; +MIMAT0022542 ola-miR-101a-5p; +MIMAT0022543 ola-miR-101a-3p; +MIMAT0022544 ola-miR-27b-5p; +MIMAT0022545 ola-miR-24a; +MIMAT0022546 ola-miR-9b-5p; +MIMAT0022547 ola-miR-135a; +MIMAT0022548 ola-miR-499; +MIMAT0022549 ola-let-7a-5p; +MIMAT0022550 ola-let-7a-3p; +MIMAT0022551 ola-let-7b; +MIMAT0022552 ola-miR-140-5p; +MIMAT0022553 ola-miR-140-3p; +MIMAT0022554 ola-miR-138; +MIMAT0022555 ola-miR-183-5p; +MIMAT0022556 ola-miR-183-3p; +MIMAT0022557 ola-miR-1-5p; +MIMAT0022558 ola-miR-1-3p; +MIMAT0022559 ola-miR-133-5p; +MIMAT0022560 ola-miR-133-3p; +MIMAT0022561 ola-miR-462; +MIMAT0022562 ola-miR-731; +MIMAT0022563 ola-let-7g; +MIMAT0022564 ola-miR-196a; +MIMAT0022565 ola-let-7e; +MIMAT0022566 ola-let-7a; +MIMAT0022567 ola-miR-1388-5p; +MIMAT0022568 ola-miR-1388-3p; +MIMAT0022569 ola-miR-29b; +MIMAT0022570 ola-miR-29a; +MIMAT0022571 ola-miR-200a; +MIMAT0022572 ola-miR-200b; +MIMAT0022573 ola-miR-124-3p; +MIMAT0022574 ola-miR-205; +MIMAT0022575 ola-miR-26; +MIMAT0022576 ola-miR-33; +MIMAT0022577 ola-miR-137; +MIMAT0022578 ola-miR-152; +MIMAT0022579 ola-miR-338-5p; +MIMAT0022580 ola-miR-338-3p; +MIMAT0022581 ola-miR-27c-5p; +MIMAT0022582 ola-miR-27c-3p; +MIMAT0022583 ola-miR-23a; +MIMAT0022584 ola-miR-150; +MIMAT0022585 ola-miR-24c; +MIMAT0022586 ola-miR-181a-5p; +MIMAT0022587 ola-miR-181a-3p; +MIMAT0022588 ola-miR-23b; +MIMAT0022589 ola-miR-204; +MIMAT0022590 ola-miR-1306; +MIMAT0022591 ola-miR-106a; +MIMAT0022592 ola-miR-19d; +MIMAT0022593 ola-miR-103; +MIMAT0022594 ola-miR-19b; +MIMAT0022595 ola-miR-458; +MIMAT0022596 ola-miR-187; +MIMAT0022597 ola-miR-30e; +MIMAT0022598 ola-miR-30c; +MIMAT0022599 ola-miR-30d-5p; +MIMAT0022600 ola-miR-30d-3p; +MIMAT0022601 ola-miR-128; +MIMAT0022602 ola-miR-126-5p; +MIMAT0022603 ola-miR-126-3p; +MIMAT0022604 ola-miR-122; +MIMAT0022605 ola-miR-101b-5p; +MIMAT0022606 ola-miR-101b-3p; +MIMAT0022607 ola-miR-455-5p; +MIMAT0022608 ola-miR-455-3p; +MIMAT0022609 ola-miR-218b; +MIMAT0022610 ola-miR-301b-5p; +MIMAT0022611 ola-miR-301b-3p; +MIMAT0022612 ola-miR-130c; +MIMAT0022613 ola-miR-16; +MIMAT0022614 ola-miR-100; +MIMAT0022615 ola-miR-125c; +MIMAT0022616 ola-miR-139; +MIMAT0022617 ola-miR-132; +MIMAT0022618 ola-miR-22; +MIMAT0022619 ola-miR-21; +MIMAT0022620 ola-miR-301a-5p; +MIMAT0022621 ola-miR-301a-3p; +MIMAT0022622 ola-miR-194-5p; +MIMAT0022623 ola-miR-194-3p; +MIMAT0022624 ola-miR-192-5p; +MIMAT0022625 ola-miR-192-3p; +MIMAT0022626 ola-miR-144; +MIMAT0022627 ola-miR-125b; +MIMAT0022628 ola-let-7c; +MIMAT0022629 ola-miR-99; +MIMAT0022630 ola-miR-223; +MIMAT0022631 ola-miR-142; +MIMAT0022632 ola-miR-107; +MIMAT0022633 ola-miR-10d; +MIMAT0022634 ola-miR-146a-3p; +MIMAT0022635 ola-miR-146a-5p; +MIMAT0022636 ola-miR-9a-5p; +MIMAT0022637 ola-miR-92b; +MIMAT0022638 ola-miR-125a-5p; +MIMAT0022639 ola-miR-125a-3p; +MIMAT0022640 ola-miR-214; +MIMAT0022641 ola-miR-7; +MIMAT0022642 ola-miR-460-5p; +MIMAT0022643 ola-miR-460-3p; +MIMAT0022644 ola-miR-24b-5p; +MIMAT0022645 ola-miR-24b-3p; +MIMAT0022646 ola-miR-27a; +MIMAT0022647 ola-miR-27d-3p; +MIMAT0022648 ola-miR-27d; +MIMAT0022649 ola-miR-31; +MIMAT0022650 ola-miR-15a; +MIMAT0022651 ola-miR-10b; +MIMAT0022652 ola-miR-148; +MIMAT0022653 ola-miR-19a; +MIMAT0022654 ola-miR-17; +MIMAT0022655 ola-miR-203; +MIMAT0022656 ola-miR-29c; +MIMAT0022657 ola-miR-135b; +MIMAT0022658 ola-miR-182; +MIMAT0022659 ola-miR-206; +MIMAT0022660 ola-miR-210-5p; +MIMAT0022661 ola-miR-210-3p; +MIMAT0022662 ola-miR-729; +MIMAT0022663 ola-miR-190b; +MIMAT0022664 ola-miR-459-5p; +MIMAT0022665 ola-miR-459-3p; +MIMAT0022666 ola-miR-30a-5p; +MIMAT0022667 ola-miR-30a-3p; +MIMAT0022668 ola-miR-143; +MIMAT0022669 ola-miR-145; +MIMAT0022670 ola-miR-1788; +MIMAT0022671 asu-miR-43c-2*;asu-miR-43c-2-5p; +MIMAT0022672 aau-miR160; +MIMAT0022673 aau-miR172; +MIMAT0022674 aau-miR396; +MIMAT0022675 aau-miR319; +MIMAT0022676 aau-miR2086; +MIMAT0022677 aau-miR162; +MIMAT0022678 aau-miR168; +MIMAT0022679 amg-miR319; +MIMAT0022680 amg-miR396; +MIMAT0022681 amg-miR2086; +MIMAT0022682 hvsa-miR-HSUR5-5p; +MIMAT0022683 hvsa-miR-HSUR5-3p; +MIMAT0022684 hvsa-miR-HSUR4-5p; +MIMAT0022685 hvsa-miR-HSUR4-3p; +MIMAT0022686 hvsa-miR-HSUR2-5p; +MIMAT0022687 hvsa-miR-HSUR2-3p; +MIMAT0022688 sly-miR4376;sly-miR391; +MIMAT0022689 ola-miR-124-5p; +MIMAT0022690 mmu-miR-184-5p; +MIMAT0022691 hsa-miR-197-5p; +MIMAT0022692 hsa-miR-181b-3p; +MIMAT0022693 hsa-miR-204-3p; +MIMAT0022694 hsa-miR-211-3p; +MIMAT0022695 hsa-miR-212-5p; +MIMAT0022696 hsa-miR-301a-5p; +MIMAT0022697 hsa-miR-382-3p; +MIMAT0022698 hsa-miR-345-3p; +MIMAT0022699 mmu-miR-468-5p; +MIMAT0022700 hsa-miR-450a-3p;hsa-miR-450a-1-3p; +MIMAT0022701 hsa-miR-506-5p; +MIMAT0022702 hsa-miR-514a-5p; +MIMAT0022704 mmu-miR-489-5p; +MIMAT0022705 hsa-miR-539-3p; +MIMAT0022706 hsa-miR-561-5p; +MIMAT0022707 hsa-miR-570-5p; +MIMAT0022708 hsa-miR-584-3p; +MIMAT0022709 hsa-miR-652-5p; +MIMAT0022710 hsa-miR-659-5p; +MIMAT0022711 hsa-miR-660-3p; +MIMAT0022712 hsa-miR-1271-3p; +MIMAT0022713 hsa-miR-1185-2-3p; +MIMAT0022714 hsa-miR-766-5p; +MIMAT0022715 mmu-miR-449c-3p; +MIMAT0022716 xtr-miR-449a-3p; +MIMAT0022717 hsa-miR-873-3p; +MIMAT0022718 mmu-miR-1196-3p; +MIMAT0022719 hsa-miR-1285-5p; +MIMAT0022720 hsa-miR-1304-3p; +MIMAT0022721 hsa-miR-1247-3p; +MIMAT0022722 hsa-miR-548g-5p; +MIMAT0022723 hsa-miR-548h-3p; +MIMAT0022724 hsa-miR-1277-5p; +MIMAT0022725 hsa-miR-1255b-2-3p; +MIMAT0022726 hsa-miR-1306-5p; +MIMAT0022727 hsa-miR-1307-5p; +MIMAT0022728 hsa-miR-513c-3p; +MIMAT0022729 mmu-miR-1929-3p; +MIMAT0022730 hsa-miR-548t-3p; +MIMAT0022731 hsa-miR-3184-3p; +MIMAT0022732 hsa-miR-3191-5p; +MIMAT0022733 hsa-miR-548x-5p; +MIMAT0022734 hsa-miR-3676-5p; +MIMAT0022735 hsa-miR-374c-3p; +MIMAT0022736 hsa-miR-642b-5p; +MIMAT0022737 hsa-miR-550b-2-5p; +MIMAT0022738 hsa-miR-548o-5p; +MIMAT0022739 hsa-miR-548aj-5p; +MIMAT0022740 hsa-miR-548am-5p; +MIMAT0022741 hsa-miR-3529-3p; +MIMAT0022742 hsa-miR-1273g-3p; +MIMAT0022743 mmu-miR-5111-5p; +MIMAT0022744 mmu-miR-5117-3p; +MIMAT0022745 xtr-miR-449b-5p; +MIMAT0022746 xtr-miR-449b-3p; +MIMAT0022747 xtr-miR-449c-5p; +MIMAT0022748 xtr-miR-449c-3p; +MIMAT0022749 cme-miR164;cme-miR164a; +MIMAT0022750 cme-miR390;cme-miR390b; +MIMAT0022751 cme-miR168; +MIMAT0022752 vun-miR156a; +MIMAT0022753 vun-miR156b; +MIMAT0022754 vun-miR319b; +MIMAT0022755 vun-miR160; +MIMAT0022756 vun-miR162; +MIMAT0022757 vun-miR164; +MIMAT0022758 vun-miR168; +MIMAT0022759 vun-miR169; +MIMAT0022760 vun-miR172; +MIMAT0022761 vun-miR319a; +MIMAT0022762 vun-miR395; +MIMAT0022763 vun-miR399a; +MIMAT0022764 vun-miR399b; +MIMAT0022765 vun-miR408; +MIMAT0022766 vun-miR482; +MIMAT0022767 vun-miR2118; +MIMAT0022768 sko-miR-219; +MIMAT0022769 sha-miR-190; +MIMAT0022770 sha-miR-181a-5p; +MIMAT0022771 sha-miR-138; +MIMAT0022772 sha-miR-352; +MIMAT0022773 sha-miR-1329; +MIMAT0022774 sha-miR-716a; +MIMAT0022775 sha-miR-340; +MIMAT0022776 sha-miR-216b; +MIMAT0022777 sha-miR-216a; +MIMAT0022778 sha-miR-140; +MIMAT0022779 sha-miR-126; +MIMAT0022780 sha-miR-202; +MIMAT0022781 sha-miR-1540; +MIMAT0022782 sha-miR-5105; +MIMAT0022783 sha-miR-9; +MIMAT0022784 sha-miR-133a; +MIMAT0022785 sha-miR-199a; +MIMAT0022786 sha-miR-23a; +MIMAT0022787 sha-miR-24; +MIMAT0022788 sha-miR-23b; +MIMAT0022789 sha-miR-27b; +MIMAT0022790 sha-miR-204; +MIMAT0022791 sha-miR-716b; +MIMAT0022792 sha-miR-193; +MIMAT0022793 sha-miR-7; +MIMAT0022794 sha-let-7g; +MIMAT0022795 sha-miR-1546; +MIMAT0022796 sha-miR-222; +MIMAT0022797 sha-miR-221; +MIMAT0022798 sha-miR-128; +MIMAT0022799 sha-miR-10b; +MIMAT0022800 sha-miR-100; +MIMAT0022801 sha-let-7a; +MIMAT0022802 sha-miR-125a; +MIMAT0022803 sha-miR-139; +MIMAT0022804 sha-miR-200b; +MIMAT0022805 sha-miR-200a; +MIMAT0022806 sha-miR-150; +MIMAT0022807 sha-miR-30e; +MIMAT0022808 sha-miR-30c; +MIMAT0022809 sha-miR-19b; +MIMAT0022810 sha-miR-125b; +MIMAT0022811 sha-miR-101; +MIMAT0022812 sha-miR-205; +MIMAT0022813 sha-miR-21; +MIMAT0022814 sha-miR-130b; +MIMAT0022815 sha-miR-454; +MIMAT0022816 sha-miR-142; +MIMAT0022817 sha-miR-10a; +MIMAT0022818 sha-miR-338; +MIMAT0022819 sha-miR-93; +MIMAT0022820 sha-miR-25; +MIMAT0022821 sha-miR-497; +MIMAT0022822 sha-let-7i; +MIMAT0022823 sha-miR-135a; +MIMAT0022824 sha-miR-1549; +MIMAT0022825 sha-miR-200c; +MIMAT0022826 sha-miR-141; +MIMAT0022827 sha-miR-129; +MIMAT0022828 sha-miR-26a; +MIMAT0022829 sha-miR-383; +MIMAT0022830 sha-miR-130a; +MIMAT0022831 sha-miR-363; +MIMAT0022832 sha-miR-92a; +MIMAT0022833 hsa-miR-365b-5p; +MIMAT0022834 hsa-miR-365b-3p; +MIMAT0022835 asu-miR-100a-2*;asu-miR-100a-2-3p; +MIMAT0022836 mmu-miR-299b-5p; +MIMAT0022837 mmu-miR-299b-3p; +MIMAT0022838 hsa-miR-1185-1-3p; +MIMAT0022839 hsa-miR-3190-3p; +MIMAT0022840 sha-miR-181a-3p; +MIMAT0022841 mmu-miR-219-2-3p;mmu-miR-219a-2-3p; +MIMAT0022842 hsa-miR-98-3p; +MIMAT0022843 ath-miR173-3p; +MIMAT0022844 hsa-miR-216a-3p; +MIMAT0022845 osa-miR156b-3p; +MIMAT0022846 osa-miR156c-3p; +MIMAT0022847 osa-miR156f-3p; +MIMAT0022848 osa-miR156g-3p; +MIMAT0022849 osa-miR156h-3p; +MIMAT0022850 osa-miR156j-3p; +MIMAT0022851 osa-miR160a-3p; +MIMAT0022852 osa-miR160b-3p; +MIMAT0022853 osa-miR160c-3p; +MIMAT0022854 osa-miR160d-3p; +MIMAT0022855 osa-miR166a-5p; +MIMAT0022856 osa-miR166b-5p; +MIMAT0022857 osa-miR166c-5p; +MIMAT0022858 osa-miR166d-5p; +MIMAT0022859 osa-miR166e-5p; +MIMAT0022860 osa-miR167c-3p; +MIMAT0022861 hsa-miR-376c-5p; +MIMAT0022862 hsa-miR-381-5p; +MIMAT0022863 osa-miR396a-3p; +MIMAT0022864 osa-miR396b-3p; +MIMAT0022865 osa-miR396c-3p; +MIMAT0022866 osa-miR156l-3p; +MIMAT0022867 osa-miR160e-3p; +MIMAT0022868 osa-miR160f-3p; +MIMAT0022869 osa-miR166j-5p; +MIMAT0022870 osa-miR166k-5p; +MIMAT0022871 osa-miR166l-5p; +MIMAT0022872 osa-miR167d-3p; +MIMAT0022873 osa-miR167e-3p; +MIMAT0022874 osa-miR167h-3p; +MIMAT0022875 osa-miR167i-3p; +MIMAT0022876 osa-miR169i-3p; +MIMAT0022877 osa-miR171c-5p; +MIMAT0022878 osa-miR171d-5p; +MIMAT0022879 osa-miR171e-5p; +MIMAT0022880 osa-miR171f-5p; +MIMAT0022881 osa-miR166g-5p; +MIMAT0022882 osa-miR166h-5p; +MIMAT0022883 osa-miR166i-5p; +MIMAT0022884 osa-miR408-5p; +MIMAT0022885 osa-miR172d-5p; +MIMAT0022886 osa-miR171i-5p; +MIMAT0022887 osa-miR166n-5p;osa-miR166j-5p; +MIMAT0022888 osa-miR390-3p; +MIMAT0022889 gma-miR160a-3p; +MIMAT0022890 ptc-miR160b-3p; +MIMAT0022891 ptc-miR160c-3p; +MIMAT0022892 ptc-miR160e-3p; +MIMAT0022893 ptc-miR167f-3p; +MIMAT0022894 ptc-miR167g-3p; +MIMAT0022895 ptc-miR167h-3p; +MIMAT0022896 ptc-miR168a-3p; +MIMAT0022897 ptc-miR168b-3p; +MIMAT0022898 ptc-miR169b-3p; +MIMAT0022899 ptc-miR169n-3p; +MIMAT0022900 ptc-miR169u-3p; +MIMAT0022901 ptc-miR171a-5p; +MIMAT0022902 ptc-miR171g-5p; +MIMAT0022903 ptc-miR171h-5p; +MIMAT0022904 ptc-miR172b-5p; +MIMAT0022905 ptc-miR172g-5p; +MIMAT0022906 ptc-miR172h-5p; +MIMAT0022907 ptc-miR390d-3p; +MIMAT0022908 ptc-miR393a-3p; +MIMAT0022909 ptc-miR393b-3p; +MIMAT0022910 ptc-miR396e-3p; +MIMAT0022911 ptc-miR396g-3p; +MIMAT0022912 ptc-miR398c-5p; +MIMAT0022913 ptc-miR408-5p; +MIMAT0022914 ptc-miR473a-3p;ptc-miR477e-3p; +MIMAT0022915 ptc-miR475a-5p; +MIMAT0022916 ptc-miR475b-5p; +MIMAT0022917 ptc-miR475d-5p; +MIMAT0022918 ptc-miR477a-3p; +MIMAT0022919 ssc-miR-145-3p; +MIMAT0022920 ssc-miR-148a-5p; +MIMAT0022921 ssc-miR-139-3p; +MIMAT0022922 ssc-miR-30c-3p; +MIMAT0022923 hsa-miR-376b-5p; +MIMAT0022924 hsa-miR-495-5p; +MIMAT0022925 hsa-miR-503-3p; +MIMAT0022926 osa-miR528-3p; +MIMAT0022927 osa-miR535-3p; +MIMAT0022928 hsa-miR-376a-2-5p; +MIMAT0022929 hsa-miR-758-5p; +MIMAT0022930 mmu-miR-698-5p; +MIMAT0022931 mmu-miR-702-5p; +MIMAT0022932 ptc-miR403c-5p; +MIMAT0022933 mtr-miR169d-3p; +MIMAT0022934 mtr-miR169e-3p; +MIMAT0022935 mtr-miR398a-5p; +MIMAT0022936 mtr-miR393b-3p; +MIMAT0022937 cgr-miR-21-3p; +MIMAT0022938 hsa-miR-937-5p; +MIMAT0022939 hsa-miR-939-3p; +MIMAT0022940 hsa-miR-1178-5p; +MIMAT0022941 hsa-miR-1227-5p; +MIMAT0022942 hsa-miR-1229-5p; +MIMAT0022943 hsa-miR-1233-1-5p;hsa-miR-1233-5p; +MIMAT0022944 hsa-miR-1234-5p; +MIMAT0022945 hsa-miR-1236-5p; +MIMAT0022946 hsa-miR-1237-5p; +MIMAT0022947 hsa-miR-1238-5p; +MIMAT0022948 hsa-miR-1292-3p; +MIMAT0022949 ssc-miR-221-5p; +MIMAT0022950 osa-miR1318-3p;osa-miR1432-3p; +MIMAT0022951 bta-miR-760-3p; +MIMAT0022952 mmu-miR-1966-3p; +MIMAT0022953 spu-miR-219-3p; +MIMAT0022954 ssc-miR-10a-3p; +MIMAT0022955 ssc-miR-148b-5p; +MIMAT0022956 ssc-miR-202-3p; +MIMAT0022957 ssc-miR-455-5p; +MIMAT0022958 ssc-miR-296-3p; +MIMAT0022959 ssc-miR-155-5p; +MIMAT0022960 ssc-miR-490-3p; +MIMAT0022961 ssc-miR-218-5p; +MIMAT0022962 ssc-miR-421-3p; +MIMAT0022963 ssc-miR-146a-5p; +MIMAT0022964 ssc-miR-1296-5p; +MIMAT0022965 hsa-miR-3606-3p; +MIMAT0022966 hsa-miR-3617-3p; +MIMAT0022967 hsa-miR-3620-5p; +MIMAT0022968 ame-miR-3049-5p; +MIMAT0022969 ame-miR-965-3p; +MIMAT0022970 hsa-miR-3927-5p; +MIMAT0022971 hvu-miR171-5p; +MIMAT0022972 gma-miR171c-3p; +MIMAT0022973 gma-miR394b-5p; +MIMAT0022974 gma-miR394a-5p; +MIMAT0022975 hsa-miR-3934-3p; +MIMAT0022976 ssc-miR-30c-1-3p; +MIMAT0022977 hsa-miR-4632-5p; +MIMAT0022978 hsa-miR-4743-3p; +MIMAT0022979 hsa-miR-4750-3p; +MIMAT0022980 gma-miR166c-5p; +MIMAT0022981 gma-miR2118a-5p; +MIMAT0022982 gma-miR2118b-5p; +MIMAT0022983 gma-miR169i-5p; +MIMAT0022984 hsa-miR-5089-3p; +MIMAT0022985 mmu-miR-5107-3p; +MIMAT0022986 mmu-miR-3572-5p; +MIMAT0022987 mmu-miR-5129-3p; +MIMAT0022988 mmu-miR-5132-3p; +MIMAT0022989 mmu-miR-5134-3p; +MIMAT0022990 gma-miR171j-3p; +MIMAT0022991 gma-miR397b-3p; +MIMAT0022992 gma-miR408a-5p; +MIMAT0022993 gma-miR408c-5p; +MIMAT0022994 gma-miR169l-3p; +MIMAT0022995 gma-miR171k-3p; +MIMAT0022996 gma-miR172i-3p; +MIMAT0022997 gma-miR4415b-5p; +MIMAT0022998 rgl-miR5573; +MIMAT0022999 rgl-miR5574; +MIMAT0023000 rgl-miR5575; +MIMAT0023001 rgl-miR5576; +MIMAT0023002 rgl-miR5577; +MIMAT0023003 rgl-miR5578; +MIMAT0023004 rgl-miR164; +MIMAT0023005 ath-miR5654-3p; +MIMAT0023006 bra-miR5711; +MIMAT0023007 bra-miR5654a; +MIMAT0023008 bra-miR5654b; +MIMAT0023009 bra-miR5712; +MIMAT0023010 bra-miR5713; +MIMAT0023011 bra-miR5714; +MIMAT0023012 bra-miR5715; +MIMAT0023013 bra-miR5716; +MIMAT0023014 bra-miR5717; +MIMAT0023015 bra-miR1885b; +MIMAT0023016 bra-miR5718; +MIMAT0023017 bra-miR5719; +MIMAT0023018 bra-miR5720; +MIMAT0023019 bra-miR5721; +MIMAT0023020 bra-miR5722; +MIMAT0023021 bra-miR1140; +MIMAT0023022 bra-miR5723; +MIMAT0023023 bra-miR5724; +MIMAT0023024 bra-miR5725; +MIMAT0023025 bra-miR5726; +MIMAT0023026 tur-miR-10-5p; +MIMAT0023027 tur-miR-10-3p; +MIMAT0023028 tur-miR-5727-5p; +MIMAT0023029 tur-miR-5727-3p; +MIMAT0023030 tur-miR-278-5p; +MIMAT0023031 tur-miR-278-3p; +MIMAT0023032 tur-miR-5728-1-5p; +MIMAT0023033 tur-miR-5728-3p; +MIMAT0023034 tur-miR-276-5p; +MIMAT0023035 tur-miR-276-3p; +MIMAT0023036 tur-miR-7-5p; +MIMAT0023037 tur-miR-7-3p; +MIMAT0023038 tur-miR-5729b-5p; +MIMAT0023039 tur-miR-5729b-3p; +MIMAT0023040 tur-miR-71-5p; +MIMAT0023041 tur-miR-71-3p; +MIMAT0023042 tur-miR-2-5p; +MIMAT0023043 tur-miR-2-3p; +MIMAT0023044 tur-miR-12b-5p; +MIMAT0023045 tur-miR-12b-3p; +MIMAT0023046 tur-miR-281-5p; +MIMAT0023047 tur-miR-281-3p; +MIMAT0023048 tur-miR-745-5p; +MIMAT0023049 tur-miR-745-3p; +MIMAT0023050 tur-miR-5730-5p; +MIMAT0023051 tur-miR-5730-3p; +MIMAT0023052 tur-miR-993b-5p; +MIMAT0023053 tur-miR-993b-3p; +MIMAT0023054 tur-miR-5729a-5p; +MIMAT0023055 tur-miR-5729a-3p; +MIMAT0023056 tur-miR-5731-5p; +MIMAT0023057 tur-miR-5731-3p; +MIMAT0023058 tur-miR-993a-5p; +MIMAT0023059 tur-miR-993a-3p; +MIMAT0023060 tur-miR-317-5p; +MIMAT0023061 tur-miR-317-3p; +MIMAT0023062 tur-miR-5732-5p; +MIMAT0023063 tur-miR-5732-3p; +MIMAT0023064 tur-miR-5733-5p; +MIMAT0023065 tur-miR-5733-3p; +MIMAT0023066 tur-miR-87-5p; +MIMAT0023067 tur-miR-87-3p; +MIMAT0023068 tur-miR-307-5p; +MIMAT0023069 tur-miR-307-3p; +MIMAT0023070 tur-miR-210-5p; +MIMAT0023071 tur-miR-210-3p; +MIMAT0023072 tur-miR-184-5p; +MIMAT0023073 tur-miR-184-3p; +MIMAT0023074 tur-miR-5734-5p; +MIMAT0023075 tur-miR-5734-3p; +MIMAT0023076 tur-miR-252-5p; +MIMAT0023077 tur-miR-252-3p; +MIMAT0023078 tur-miR-5736b-5p; +MIMAT0023079 tur-miR-5736b-3p; +MIMAT0023080 tur-miR-133-5p; +MIMAT0023081 tur-miR-133-3p; +MIMAT0023082 tur-miR-9-5p; +MIMAT0023083 tur-miR-9-3p; +MIMAT0023084 tur-miR-190-5p; +MIMAT0023085 tur-miR-190-3p; +MIMAT0023086 tur-miR-92-5p; +MIMAT0023087 tur-miR-92-3p; +MIMAT0023088 tur-miR-124-1-5p; +MIMAT0023089 tur-miR-124-3p; +MIMAT0023090 tur-miR-3931-5p; +MIMAT0023091 tur-miR-3931-3p; +MIMAT0023092 tur-miR-5735-5p; +MIMAT0023093 tur-miR-5735-3p; +MIMAT0023094 tur-miR-1-5p; +MIMAT0023095 tur-miR-1-3p; +MIMAT0023096 tur-miR-34-5p; +MIMAT0023097 tur-miR-34-3p; +MIMAT0023098 tur-miR-137-5p; +MIMAT0023099 tur-miR-137-3p; +MIMAT0023100 tur-miR-5736a-5p; +MIMAT0023101 tur-miR-5736a-3p; +MIMAT0023102 tur-miR-12a-5p; +MIMAT0023103 tur-miR-12a-3p; +MIMAT0023104 tur-miR-5737-5p; +MIMAT0023105 tur-miR-5737-3p; +MIMAT0023106 tur-miR-279-5p; +MIMAT0023107 tur-miR-279-3p; +MIMAT0023108 tur-miR-263b-5p; +MIMAT0023109 tur-miR-263b-3p; +MIMAT0023110 tur-miR-5738-5p; +MIMAT0023111 tur-miR-5738-3p; +MIMAT0023112 tur-miR-263a-5p; +MIMAT0023113 tur-miR-263a-3p; +MIMAT0023114 tur-miR-305-5p; +MIMAT0023115 tur-miR-305-3p; +MIMAT0023116 hsa-miR-5739; +MIMAT0023117 mtr-miR5740; +MIMAT0023118 mtr-miR5741a; +MIMAT0023119 mtr-miR396c; +MIMAT0023120 mtr-miR5742; +MIMAT0023121 mtr-miR5743a; +MIMAT0023122 mtr-miR5743b; +MIMAT0023123 mtr-miR5741b; +MIMAT0023124 mtr-miR5744; +MIMAT0023125 mtr-miR5745a; +MIMAT0023126 mtr-miR5746; +MIMAT0023127 mtr-miR5747; +MIMAT0023128 mtr-miR5748; +MIMAT0023129 mtr-miR5749; +MIMAT0023130 mtr-miR5750; +MIMAT0023131 mtr-miR5751; +MIMAT0023132 mtr-miR171i;mtr-miR171g; +MIMAT0023133 mtr-miR5752a; +MIMAT0023134 mtr-miR5752b; +MIMAT0023135 mtr-miR5753; +MIMAT0023136 mtr-miR5754; +MIMAT0023137 mtr-miR5755; +MIMAT0023138 mtr-miR169r; +MIMAT0023139 mtr-miR5741c; +MIMAT0023140 mtr-miR5756; +MIMAT0023141 mtr-miR5757; +MIMAT0023142 mtr-miR5225b; +MIMAT0023143 mtr-miR5225c; +MIMAT0023144 mtr-miR5758; +MIMAT0023145 mtr-miR5745b; +MIMAT0023146 mtr-miR5759; +MIMAT0023147 mtr-miR5741d; +MIMAT0023148 mtr-miR2593e; +MIMAT0023149 mtr-miR5760; +MIMAT0023150 mtr-miR5037a; +MIMAT0023151 mtr-miR5037b; +MIMAT0023152 mtr-miR5206b; +MIMAT0023153 mtr-miR5037c; +MIMAT0023154 mtr-miR2593d; +MIMAT0023155 mtr-miR5741e; +MIMAT0023156 mtr-miR530; +MIMAT0023157 gma-miR5761a; +MIMAT0023158 gma-miR5762; +MIMAT0023159 gma-miR5763a; +MIMAT0023160 gma-miR5763b; +MIMAT0023161 gma-miR5764; +MIMAT0023162 gma-miR5765; +MIMAT0023163 gma-miR5766; +MIMAT0023164 gma-miR5767; +MIMAT0023165 gma-miR5768; +MIMAT0023166 gma-miR5769; +MIMAT0023167 gma-miR5770a; +MIMAT0023168 gma-miR5559; +MIMAT0023169 gma-miR5225; +MIMAT0023170 gma-miR393b; +MIMAT0023171 gma-miR5771; +MIMAT0023172 gma-miR4416c;gma-miR4416c-5p; +MIMAT0023173 gma-miR5761b; +MIMAT0023174 gma-miR5772; +MIMAT0023175 gma-miR5773; +MIMAT0023176 gma-miR5774a; +MIMAT0023177 gma-miR4416b; +MIMAT0023178 gma-miR1516c; +MIMAT0023179 gma-miR5775; +MIMAT0023180 gma-miR1513d; +MIMAT0023181 gma-miR5776; +MIMAT0023182 gma-miR5777; +MIMAT0023183 gma-miR5778; +MIMAT0023184 gma-miR5779; +MIMAT0023185 gma-miR5780;gma-miR5780a; +MIMAT0023186 gma-miR5781; +MIMAT0023187 gma-miR5782; +MIMAT0023188 gma-miR5783; +MIMAT0023189 gma-miR5770b; +MIMAT0023190 gma-miR5784; +MIMAT0023191 gma-miR5785; +MIMAT0023192 gma-miR5763c; +MIMAT0023193 gma-miR5774b; +MIMAT0023194 gma-miR399a; +MIMAT0023195 gma-miR828a; +MIMAT0023196 gma-miR156p; +MIMAT0023197 gma-miR530c; +MIMAT0023198 gma-miR828b; +MIMAT0023199 gma-miR530d; +MIMAT0023200 gma-miR171m; +MIMAT0023201 gma-miR172k; +MIMAT0023202 gma-miR171n; +MIMAT0023203 gma-miR156q; +MIMAT0023204 gma-miR171o;gma-miR171o-3p; +MIMAT0023205 gma-miR172l; +MIMAT0023206 gma-miR169o; +MIMAT0023207 gma-miR319n; +MIMAT0023208 gma-miR171p; +MIMAT0023209 gma-miR530e; +MIMAT0023210 gma-miR394d; +MIMAT0023211 gma-miR169p; +MIMAT0023212 gma-miR156r; +MIMAT0023213 gma-miR399b; +MIMAT0023214 gma-miR396j; +MIMAT0023215 gma-miR171q; +MIMAT0023216 gma-miR156s; +MIMAT0023217 gma-miR169r; +MIMAT0023218 gma-miR169s;gma-miR169s-5p; +MIMAT0023219 gma-miR396k;gma-miR396k-3p; +MIMAT0023220 gma-miR2111b; +MIMAT0023221 gma-miR2111c; +MIMAT0023222 gma-miR5786; +MIMAT0023223 gma-miR166k; +MIMAT0023224 gma-miR2111d; +MIMAT0023225 gma-miR156t; +MIMAT0023226 gma-miR2606a; +MIMAT0023227 gma-miR482e; +MIMAT0023228 gma-miR399c; +MIMAT0023229 gma-miR171r; +MIMAT0023230 gma-miR394e; +MIMAT0023231 gma-miR399d; +MIMAT0023232 gma-miR399e; +MIMAT0023233 gma-miR169t; +MIMAT0023234 gma-miR171s; +MIMAT0023235 gma-miR166l; +MIMAT0023236 gma-miR171t; +MIMAT0023237 gma-miR2111e; +MIMAT0023238 gma-miR2111f; +MIMAT0023239 gma-miR394f; +MIMAT0023240 gma-miR171u; +MIMAT0023241 gma-miR399f; +MIMAT0023242 gma-miR399g; +MIMAT0023243 gma-miR395d; +MIMAT0023244 gma-miR395e; +MIMAT0023245 gma-miR395f; +MIMAT0023246 gma-miR395g; +MIMAT0023247 gma-miR166m; +MIMAT0023248 gma-miR5674b; +MIMAT0023249 gma-miR169u; +MIMAT0023250 gma-miR2606b; +MIMAT0023251 gma-miR399h; +MIMAT0023252 hsa-miR-5787; +MIMAT0023253 osa-miR5788; +MIMAT0023254 osa-miR812p; +MIMAT0023255 osa-miR812q; +MIMAT0023256 osa-miR5789; +MIMAT0023257 osa-miR5790; +MIMAT0023258 osa-miR5791; +MIMAT0023259 osa-miR5792; +MIMAT0023260 osa-miR5793; +MIMAT0023261 osa-miR5794; +MIMAT0023262 osa-miR812r; +MIMAT0023263 osa-miR5795; +MIMAT0023264 osa-miR5796; +MIMAT0023265 osa-miR5797; +MIMAT0023266 osa-miR5798; +MIMAT0023267 osa-miR812s; +MIMAT0023268 osa-miR5799; +MIMAT0023269 osa-miR5800; +MIMAT0023270 osa-miR5801;osa-miR5801a; +MIMAT0023271 osa-miR5802; +MIMAT0023272 osa-miR812t; +MIMAT0023273 osa-miR812u; +MIMAT0023274 osa-miR5803; +MIMAT0023275 osa-miR5804; +MIMAT0023276 osa-miR5805; +MIMAT0023277 osa-miR5806; +MIMAT0023278 osa-miR812v; +MIMAT0023279 osa-miR5807; +MIMAT0023280 osa-miR5808;osa-miR5801b; +MIMAT0023281 osa-miR5809; +MIMAT0023282 osa-miR5810; +MIMAT0023283 osa-miR5811; +MIMAT0023284 osa-miR5812; +MIMAT0023285 osa-miR5813; +MIMAT0023286 osa-miR5814; +MIMAT0023287 osa-miR5815; +MIMAT0023288 osa-miR5816; +MIMAT0023289 osa-miR5143b; +MIMAT0023290 osa-miR5817; +MIMAT0023291 osa-miR5818; +MIMAT0023292 osa-miR5819; +MIMAT0023293 osa-miR5820; +MIMAT0023294 osa-miR5821; +MIMAT0023295 osa-miR5822; +MIMAT0023296 osa-miR5823; +MIMAT0023297 osa-miR5824; +MIMAT0023298 osa-miR1319b; +MIMAT0023299 osa-miR5825; +MIMAT0023300 osa-miR5826; +MIMAT0023301 osa-miR5827; +MIMAT0023302 osa-miR5828; +MIMAT0023303 osa-miR5829; +MIMAT0023304 osa-miR5830; +MIMAT0023305 osa-miR5831; +MIMAT0023306 osa-miR5179; +MIMAT0023307 osa-miR5832; +MIMAT0023308 osa-miR5833; +MIMAT0023309 osa-miR5834; +MIMAT0023310 osa-miR5835; +MIMAT0023311 osa-miR2873c; +MIMAT0023312 osa-miR5836; +MIMAT0023313 osa-miR5837.2; +MIMAT0023314 osa-miR5837.1; +MIMAT0023315 osa-miR5516b; +MIMAT0023316 hco-miR-5884; +MIMAT0023317 hco-miR-133; +MIMAT0023318 hco-miR-63a; +MIMAT0023319 hco-miR-5885a; +MIMAT0023320 hco-miR-5886a; +MIMAT0023321 hco-miR-5887; +MIMAT0023322 hco-miR-5888; +MIMAT0023323 hco-miR-40b; +MIMAT0023324 hco-miR-5889; +MIMAT0023325 hco-miR-5890a; +MIMAT0023326 hco-miR-79; +MIMAT0023327 hco-miR-46; +MIMAT0023328 hco-miR-5891; +MIMAT0023329 hco-miR-50; +MIMAT0023330 hco-miR-250; +MIMAT0023331 hco-miR-5892a; +MIMAT0023332 hco-miR-5893; +MIMAT0023333 hco-miR-259; +MIMAT0023334 hco-miR-5894a; +MIMAT0023335 hco-miR-61; +MIMAT0023336 hco-miR-43; +MIMAT0023337 hco-miR-5895; +MIMAT0023338 hco-miR-124; +MIMAT0023339 hco-miR-45; +MIMAT0023340 hco-miR-5896; +MIMAT0023341 hco-miR-5897a; +MIMAT0023342 hco-miR-5898-5p; +MIMAT0023343 hco-miR-5898-3p; +MIMAT0023344 hco-miR-5899; +MIMAT0023345 hco-lin-4; +MIMAT0023346 hco-miR-5900; +MIMAT0023347 hco-miR-87a; +MIMAT0023348 hco-miR-9; +MIMAT0023349 hco-miR-87b; +MIMAT0023350 hco-miR-86; +MIMAT0023351 hco-miR-5901; +MIMAT0023352 hco-miR-5902-5p; +MIMAT0023353 hco-miR-5902-3p; +MIMAT0023354 hco-miR-5903; +MIMAT0023355 hco-miR-83; +MIMAT0023356 hco-miR-59; +MIMAT0023357 hco-miR-5904a; +MIMAT0023358 hco-miR-71; +MIMAT0023359 hco-miR-5905; +MIMAT0023360 hco-miR-5906; +MIMAT0023361 hco-miR-5907; +MIMAT0023362 hco-miR-5908-5p; +MIMAT0023363 hco-miR-5908-3p; +MIMAT0023364 hco-miR-5897b; +MIMAT0023365 hco-miR-5909; +MIMAT0023366 hco-miR-5910; +MIMAT0023367 hco-miR-5911a; +MIMAT0023368 hco-miR-84a; +MIMAT0023369 hco-miR-242; +MIMAT0023370 hco-miR-5890b-5p; +MIMAT0023371 hco-miR-5890b-3p; +MIMAT0023372 hco-miR-252; +MIMAT0023373 hco-miR-5904b; +MIMAT0023374 hco-miR-790; +MIMAT0023375 hco-miR-137;hco-miR-234; +MIMAT0023376 hco-miR-5912a; +MIMAT0023377 hco-miR-277; +MIMAT0023378 hco-miR-5890c; +MIMAT0023379 hco-miR-236; +MIMAT0023380 hco-miR-5897c; +MIMAT0023381 hco-miR-5352; +MIMAT0023382 hco-miR-5913; +MIMAT0023383 hco-miR-5914; +MIMAT0023384 hco-miR-5915; +MIMAT0023385 hco-miR-5916; +MIMAT0023386 hco-miR-5911b; +MIMAT0023387 hco-miR-7; +MIMAT0023388 hco-miR-235; +MIMAT0023389 hco-miR-228; +MIMAT0023390 hco-miR-5917; +MIMAT0023391 hco-miR-5918a; +MIMAT0023392 hco-miR-5919; +MIMAT0023393 hco-miR-5890d; +MIMAT0023394 hco-miR-5920; +MIMAT0023395 hco-miR-5921-5p; +MIMAT0023396 hco-miR-5921-3p; +MIMAT0023397 hco-miR-5911c; +MIMAT0023398 hco-miR-5922; +MIMAT0023399 hco-miR-5923; +MIMAT0023400 hco-miR-5894b; +MIMAT0023401 hco-miR-1; +MIMAT0023402 hco-miR-5890e; +MIMAT0023403 hco-miR-5924a-5p;hco-miR-5924-5p; +MIMAT0023404 hco-miR-5924a-3p;hco-miR-5924-3p; +MIMAT0023405 hco-miR-5925; +MIMAT0023406 hco-miR-5926; +MIMAT0023407 hco-miR-307; +MIMAT0023408 hco-miR-5927; +MIMAT0023409 hco-miR-5890f-5p; +MIMAT0023410 hco-miR-5890f-3p; +MIMAT0023411 hco-miR-255; +MIMAT0023412 hco-miR-5928a; +MIMAT0023413 hco-miR-993; +MIMAT0023414 hco-miR-5929; +MIMAT0023415 hco-miR-2; +MIMAT0023416 hco-miR-5930; +MIMAT0023417 hco-miR-5885b; +MIMAT0023418 hco-miR-5904c; +MIMAT0023419 hco-miR-5924b; +MIMAT0023420 hco-miR-5931; +MIMAT0023421 hco-miR-5918b; +MIMAT0023422 hco-miR-5918c; +MIMAT0023423 hco-miR-5912b; +MIMAT0023424 hco-miR-5932; +MIMAT0023425 hco-miR-5933; +MIMAT0023426 hco-miR-5934; +MIMAT0023427 hco-miR-5935; +MIMAT0023428 hco-miR-40e; +MIMAT0023429 hco-miR-40c; +MIMAT0023430 hco-miR-40d; +MIMAT0023431 hco-miR-5936; +MIMAT0023432 hco-miR-5937; +MIMAT0023433 hco-miR-5938; +MIMAT0023434 hco-miR-5939; +MIMAT0023435 hco-miR-5940; +MIMAT0023436 hco-miR-5941; +MIMAT0023437 hco-miR-5942; +MIMAT0023438 hco-miR-5928b; +MIMAT0023439 hco-miR-5943; +MIMAT0023440 hco-miR-63b; +MIMAT0023441 hco-miR-55; +MIMAT0023442 hco-miR-5918d; +MIMAT0023443 hco-miR-5944; +MIMAT0023444 hco-miR-40a; +MIMAT0023445 hco-miR-5928c; +MIMAT0023446 hco-miR-5945-5p; +MIMAT0023447 hco-miR-5945-3p; +MIMAT0023448 hco-miR-5946a; +MIMAT0023449 hco-miR-5947; +MIMAT0023450 hco-miR-5948; +MIMAT0023451 hco-miR-5949; +MIMAT0023452 hco-miR-5950; +MIMAT0023453 hco-miR-5951; +MIMAT0023454 hco-miR-5952; +MIMAT0023455 hco-miR-5953; +MIMAT0023456 hco-miR-5928d; +MIMAT0023457 hco-miR-5954; +MIMAT0023458 hco-miR-5955; +MIMAT0023459 hco-miR-5956; +MIMAT0023460 hco-miR-5957; +MIMAT0023461 hco-miR-5958; +MIMAT0023462 hco-miR-5886b; +MIMAT0023463 hco-miR-5959; +MIMAT0023464 hco-miR-5960; +MIMAT0023465 hco-miR-5961; +MIMAT0023466 hco-miR-5962; +MIMAT0023467 hco-miR-5963; +MIMAT0023468 hco-miR-60; +MIMAT0023469 hco-miR-5964; +MIMAT0023470 hco-miR-5946b; +MIMAT0023471 hco-miR-5946c; +MIMAT0023472 hco-miR-5965; +MIMAT0023473 hco-miR-5966; +MIMAT0023474 hco-miR-5967; +MIMAT0023475 hco-miR-5968; +MIMAT0023476 hco-miR-5969; +MIMAT0023477 hco-miR-5970; +MIMAT0023478 hco-miR-5971; +MIMAT0023479 hco-miR-5972; +MIMAT0023480 hco-miR-5973; +MIMAT0023481 hco-miR-5928e; +MIMAT0023482 hco-miR-5974; +MIMAT0023483 hco-miR-5975; +MIMAT0023484 hco-miR-5885c; +MIMAT0023485 hco-miR-5976; +MIMAT0023486 hco-miR-5892b; +MIMAT0023487 hco-miR-5977; +MIMAT0023488 hco-miR-5978; +MIMAT0023489 hco-miR-5979; +MIMAT0023490 hco-miR-5980; +MIMAT0023491 hco-miR-5981; +MIMAT0023492 hco-miR-5982; +MIMAT0023493 hco-miR-5983; +MIMAT0023494 hco-miR-5984a; +MIMAT0023495 hco-miR-5984b; +MIMAT0023496 hco-miR-76; +MIMAT0023497 hco-miR-5985; +MIMAT0023498 hco-miR-72; +MIMAT0023499 hco-miR-5986; +MIMAT0023500 hco-miR-5991; +MIMAT0023501 hco-miR-5987; +MIMAT0023502 hco-miR-190-5p; +MIMAT0023503 hco-miR-5988; +MIMAT0023504 hco-miR-87c; +MIMAT0023505 hco-miR-5989; +MIMAT0023506 hco-miR-5990-5p; +MIMAT0023507 hco-miR-84b; +MIMAT0023508 hco-miR-265; +MIMAT0023509 hco-miR-2159-3p; +MIMAT0023510 hhv6b-miR-Ro6-1-5p; +MIMAT0023511 hhv6b-miR-Ro6-1-3p; +MIMAT0023512 spu-miR-92d; +MIMAT0023513 spu-miR-92e; +MIMAT0023514 spu-miR-5992; +MIMAT0023515 spu-miR-5993; +MIMAT0023516 spu-miR-5994; +MIMAT0023517 ath-miR5595a; +MIMAT0023518 ath-miR5995b; +MIMAT0023519 ath-miR5996; +MIMAT0023520 ath-miR5997; +MIMAT0023521 ath-miR5998a; +MIMAT0023522 ath-miR5998b; +MIMAT0023523 ath-miR4245; +MIMAT0023524 ath-miR5014b; +MIMAT0023525 ath-miR5999; +MIMAT0023526 dpr-miR156a; +MIMAT0023527 dpr-miR156b; +MIMAT0023528 dpr-miR160; +MIMAT0023529 dpr-miR166a; +MIMAT0023530 dpr-miR166b; +MIMAT0023531 dpr-miR167a; +MIMAT0023532 dpr-miR167b; +MIMAT0023533 dpr-miR167c; +MIMAT0023534 dpr-miR172a; +MIMAT0023535 dpr-miR172b; +MIMAT0023536 dpr-miR396; +MIMAT0023537 dpr-miR397; +MIMAT0023538 dpr-miR408; +MIMAT0023539 ame-miR-6000a-5p; +MIMAT0023540 ame-miR-6000a-3p; +MIMAT0023541 ame-miR-6001-5p; +MIMAT0023542 ame-miR-6001-3p; +MIMAT0023543 ame-miR-6002-5p; +MIMAT0023544 ame-miR-6002-3p; +MIMAT0023545 ame-miR-6003-5p; +MIMAT0023546 ame-miR-6003-3p; +MIMAT0023547 ame-miR-6004-5p; +MIMAT0023548 ame-miR-6004-3p; +MIMAT0023549 ame-miR-6005-5p; +MIMAT0023550 ame-miR-6005-3p; +MIMAT0023551 ame-miR-2765-5p; +MIMAT0023552 ame-miR-2765-3p; +MIMAT0023553 ame-miR-6006-5p; +MIMAT0023554 ame-miR-6006-3p; +MIMAT0023555 tca-miR-6007-5p; +MIMAT0023556 tca-miR-6007-3p; +MIMAT0023557 tca-miR-6008-5p; +MIMAT0023558 tca-miR-6008-3p; +MIMAT0023559 tca-miR-6009-5p; +MIMAT0023560 tca-miR-6009-3p; +MIMAT0023561 tca-miR-6010-5p; +MIMAT0023562 tca-miR-6010-3p; +MIMAT0023563 tca-miR-6011-5p; +MIMAT0023564 tca-miR-6011-3p; +MIMAT0023565 tca-miR-6012-5p; +MIMAT0023566 tca-miR-6012-3p; +MIMAT0023567 tca-miR-6013-5p; +MIMAT0023568 tca-miR-6013-3p; +MIMAT0023569 tca-miR-6014-5p; +MIMAT0023570 tca-miR-6014-3p; +MIMAT0023571 tca-miR-6015-5p; +MIMAT0023572 tca-miR-6015-3p; +MIMAT0023573 tca-miR-6016-5p; +MIMAT0023574 tca-miR-6016-3p; +MIMAT0023575 tca-miR-6017-5p; +MIMAT0023576 tca-miR-6017-3p; +MIMAT0023577 tca-miR-6018-5p; +MIMAT0023578 tca-miR-6018-3p; +MIMAT0023579 tca-miR-927b-5p; +MIMAT0023580 tca-miR-927b-3p; +MIMAT0023581 tca-miR-9e-5p; +MIMAT0023582 tca-miR-9e-3p; +MIMAT0023583 nta-miR6019a; +MIMAT0023584 nta-miR6020a-5p; +MIMAT0023585 nta-miR6020a-3p; +MIMAT0023586 nta-miR6019b; +MIMAT0023587 nta-miR6020b; +MIMAT0023588 nta-miR6021; +MIMAT0023589 stu-miR6022; +MIMAT0023590 sly-miR6022; +MIMAT0023591 stu-miR6023; +MIMAT0023592 sly-miR6023; +MIMAT0023593 stu-miR6024;stu-miR6024-3p; +MIMAT0023594 sly-miR6024; +MIMAT0023595 nta-miR6024; +MIMAT0023596 stu-miR482c; +MIMAT0023597 stu-miR482b;stu-miR482b-3p; +MIMAT0023598 stu-miR482a;stu-miR482a-3p; +MIMAT0023599 nta-miR482a; +MIMAT0023600 stu-miR482d;stu-miR482d-3p; +MIMAT0023601 stu-miR482e;stu-miR482e-3p; +MIMAT0023602 sly-miR482b; +MIMAT0023603 sly-miR482c; +MIMAT0023604 nta-miR482b-5p; +MIMAT0023605 nta-miR482b-3p; +MIMAT0023606 nta-miR6025a; +MIMAT0023607 nta-miR6025b; +MIMAT0023608 stu-miR6025; +MIMAT0023609 stu-miR6026;stu-miR6026-3p; +MIMAT0023610 sly-miR6026; +MIMAT0023611 sly-miR6027;sly-miR6027-3p; +MIMAT0023612 stu-miR6027; +MIMAT0023613 bna-miR156d; +MIMAT0023614 bna-miR156e; +MIMAT0023615 bna-miR156f; +MIMAT0023616 bna-miR156g; +MIMAT0023617 bna-miR160a; +MIMAT0023618 bna-miR160b; +MIMAT0023619 bna-miR160c; +MIMAT0023620 bna-miR160d; +MIMAT0023621 bna-miR162a; +MIMAT0023622 bna-miR164b; +MIMAT0023623 bna-miR164c; +MIMAT0023624 bna-miR164d; +MIMAT0023625 bna-miR166f; +MIMAT0023626 bna-miR166e; +MIMAT0023627 bna-miR167d; +MIMAT0023628 bna-miR168b; +MIMAT0023629 bna-miR169n; +MIMAT0023630 bna-miR172d; +MIMAT0023631 bna-miR172b; +MIMAT0023632 bna-miR172c; +MIMAT0023633 bna-miR172a; +MIMAT0023634 bna-miR394a; +MIMAT0023635 bna-miR394b; +MIMAT0023636 bna-miR395a; +MIMAT0023637 bna-miR395b; +MIMAT0023638 bna-miR395c; +MIMAT0023639 bna-miR395d; +MIMAT0023640 bna-miR395e; +MIMAT0023641 bna-miR395f; +MIMAT0023642 bna-miR399b; +MIMAT0023643 bna-miR399c; +MIMAT0023644 bna-miR403; +MIMAT0023645 bna-miR860; +MIMAT0023646 bna-miR2111d; +MIMAT0023647 bna-miR2111c; +MIMAT0023648 bna-miR6028; +MIMAT0023649 bna-miR6029; +MIMAT0023650 bna-miR6030; +MIMAT0023651 bna-miR6031; +MIMAT0023652 bna-miR6032; +MIMAT0023653 bna-miR6033; +MIMAT0023654 bna-miR6034; +MIMAT0023655 bna-miR6035; +MIMAT0023656 bna-miR6036; +MIMAT0023657 ame-miR-6037;ame-miR-6037-3p; +MIMAT0023658 ame-miR-6038;ame-miR-6038-5p; +MIMAT0023659 ame-miR-6039;ame-miR-6039-5p; +MIMAT0023660 ame-miR-6040;ame-miR-6040-3p; +MIMAT0023661 ame-miR-6000b;ame-miR-6000b-3p; +MIMAT0023662 ame-miR-252b;ame-miR-252b-5p; +MIMAT0023663 ame-miR-6041;ame-miR-6041-3p; +MIMAT0023664 ame-miR-6042;ame-miR-6042-3p; +MIMAT0023665 ame-miR-6043;ame-miR-6043-3p; +MIMAT0023666 ame-miR-6044;ame-miR-6044-5p; +MIMAT0023667 ame-miR-6045;ame-miR-6045-5p; +MIMAT0023668 ame-miR-92c;ame-miR-92c-5p; +MIMAT0023669 ame-miR-6046;ame-miR-6046-3p; +MIMAT0023670 ame-miR-6012;ame-miR-6012-3p; +MIMAT0023671 ame-miR-6047a;ame-miR-6047a-3p; +MIMAT0023672 ame-miR-6048;ame-miR-6048-3p; +MIMAT0023673 ame-miR-6049;ame-miR-6049-5p; +MIMAT0023674 ame-miR-6050;ame-miR-6050-5p; +MIMAT0023675 ame-miR-6051;ame-miR-6051-3p; +MIMAT0023676 ame-miR-6052;ame-miR-6052-5p; +MIMAT0023677 ame-miR-6053;ame-miR-6053-5p; +MIMAT0023678 ame-miR-6054;ame-miR-6054-3p; +MIMAT0023679 ame-miR-6055;ame-miR-6055-5p; +MIMAT0023680 ame-miR-6056;ame-miR-6056-5p; +MIMAT0023681 ame-miR-6057;ame-miR-6057-5p; +MIMAT0023682 ame-miR-6058;ame-miR-6058-5p; +MIMAT0023683 ame-miR-6059;ame-miR-6059-3p; +MIMAT0023684 ame-miR-6060;ame-miR-6060-5p; +MIMAT0023685 ame-miR-6061;ame-miR-6061-3p; +MIMAT0023686 ame-miR-6062;ame-miR-6062-3p; +MIMAT0023687 ame-miR-6063;ame-miR-6063-3p; +MIMAT0023688 ame-miR-6047b;ame-miR-6047b-3p; +MIMAT0023689 ame-miR-6064;ame-miR-6064-5p; +MIMAT0023690 ame-miR-6065;ame-miR-6065-3p; +MIMAT0023691 ame-miR-6066;ame-miR-6066-5p; +MIMAT0023692 ame-miR-6067;ame-miR-6067-5p; +MIMAT0023693 hsa-miR-6068; +MIMAT0023694 hsa-miR-6069; +MIMAT0023695 hsa-miR-6070; +MIMAT0023696 hsa-miR-6071; +MIMAT0023697 hsa-miR-6072; +MIMAT0023698 hsa-miR-6073; +MIMAT0023699 hsa-miR-6074; +MIMAT0023700 hsa-miR-6075; +MIMAT0023701 hsa-miR-6076; +MIMAT0023702 hsa-miR-6077; +MIMAT0023703 hsa-miR-6078; +MIMAT0023704 hsa-miR-6079; +MIMAT0023705 hsa-miR-6080; +MIMAT0023706 hsa-miR-6081; +MIMAT0023707 hsa-miR-6082; +MIMAT0023708 hsa-miR-6083; +MIMAT0023709 hsa-miR-6084; +MIMAT0023710 hsa-miR-6085; +MIMAT0023711 hsa-miR-6086; +MIMAT0023712 hsa-miR-6087; +MIMAT0023713 hsa-miR-6088; +MIMAT0023714 hsa-miR-6089; +MIMAT0023715 hsa-miR-6090; +MIMAT0023716 cgr-let-7a; +MIMAT0023717 cgr-let-7b; +MIMAT0023718 cgr-let-7c; +MIMAT0023719 cgr-let-7d-5p; +MIMAT0023720 cgr-let-7d-3p; +MIMAT0023721 cgr-let-7f; +MIMAT0023722 cgr-let-7g-5p; +MIMAT0023723 cgr-let-7g-3p; +MIMAT0023724 cgr-let-7i; +MIMAT0023725 cgr-miR-1; +MIMAT0023726 cgr-miR-100-5p; +MIMAT0023727 cgr-miR-100-3p; +MIMAT0023728 cgr-miR-101b-5p; +MIMAT0023729 cgr-miR-101b-3p; +MIMAT0023730 cgr-miR-103-5p; +MIMAT0023731 cgr-miR-103-3p; +MIMAT0023732 cgr-miR-106b-5p; +MIMAT0023733 cgr-miR-106b-3p; +MIMAT0023734 cgr-miR-107; +MIMAT0023735 cgr-miR-10a-5p; +MIMAT0023736 cgr-miR-10a-3p; +MIMAT0023737 cgr-miR-10b-5p; +MIMAT0023738 cgr-miR-10b-3p; +MIMAT0023739 cgr-miR-122; +MIMAT0023740 cgr-miR-124; +MIMAT0023741 cgr-miR-125a-5p; +MIMAT0023742 cgr-miR-125a-3p; +MIMAT0023743 cgr-miR-125b-5p; +MIMAT0023744 cgr-miR-125b-3p; +MIMAT0023745 cgr-miR-126;cgr-miR-126a; +MIMAT0023746 cgr-miR-1260; +MIMAT0023747 cgr-miR-1271; +MIMAT0023748 cgr-miR-1285; +MIMAT0023749 cgr-miR-128-5p; +MIMAT0023750 cgr-miR-128-3p; +MIMAT0023751 cgr-miR-129; +MIMAT0023752 cgr-miR-1306-5p; +MIMAT0023753 cgr-miR-1306-3p; +MIMAT0023754 cgr-miR-130a-5p; +MIMAT0023755 cgr-miR-130a-3p; +MIMAT0023756 cgr-miR-130b-5p; +MIMAT0023757 cgr-miR-130b-3p; +MIMAT0023758 cgr-miR-132-5p; +MIMAT0023759 cgr-miR-132-3p; +MIMAT0023760 cgr-miR-134; +MIMAT0023761 cgr-miR-1343; +MIMAT0023762 cgr-miR-137-5p; +MIMAT0023763 cgr-miR-137-3p; +MIMAT0023764 cgr-miR-138; +MIMAT0023765 cgr-miR-139-5p; +MIMAT0023766 cgr-miR-139-3p; +MIMAT0023767 cgr-miR-140-5p; +MIMAT0023768 cgr-miR-140-3p; +MIMAT0023769 cgr-miR-141; +MIMAT0023770 cgr-miR-142-5p; +MIMAT0023771 cgr-miR-142-3p; +MIMAT0023772 cgr-miR-143; +MIMAT0023773 cgr-miR-144; +MIMAT0023774 cgr-miR-146a; +MIMAT0023775 cgr-miR-146b-5p; +MIMAT0023776 cgr-miR-146b-3p; +MIMAT0023777 cgr-miR-147; +MIMAT0023778 cgr-miR-148b-5p; +MIMAT0023779 cgr-miR-148b-3p; +MIMAT0023780 cgr-miR-149-5p; +MIMAT0023781 cgr-miR-149-3p; +MIMAT0023782 cgr-miR-151-5p; +MIMAT0023783 cgr-miR-151-3p; +MIMAT0023784 cgr-miR-152-5p; +MIMAT0023785 cgr-miR-152-3p; +MIMAT0023786 cgr-miR-154-5p; +MIMAT0023787 cgr-miR-154-3p; +MIMAT0023788 cgr-miR-155; +MIMAT0023789 cgr-miR-15a-5p; +MIMAT0023790 cgr-miR-15a-3p; +MIMAT0023791 cgr-miR-15b-5p; +MIMAT0023792 cgr-miR-15b-3p; +MIMAT0023793 cgr-miR-16-5p; +MIMAT0023794 cgr-miR-16-3p; +MIMAT0023795 cgr-miR-17-5p; +MIMAT0023796 cgr-miR-17-3p; +MIMAT0023797 cgr-miR-181a-5p; +MIMAT0023798 cgr-miR-181a-3p; +MIMAT0023799 cgr-miR-181b-5p; +MIMAT0023800 cgr-miR-181b-3p; +MIMAT0023801 cgr-miR-181c-5p; +MIMAT0023802 cgr-miR-181c-3p; +MIMAT0023803 cgr-miR-181d-5p; +MIMAT0023804 cgr-miR-181d-3p; +MIMAT0023805 cgr-miR-182; +MIMAT0023806 cgr-miR-183; +MIMAT0023807 cgr-miR-1839-5p; +MIMAT0023808 cgr-miR-1839-3p; +MIMAT0023809 cgr-miR-184; +MIMAT0023810 cgr-miR-1843; +MIMAT0023811 cgr-miR-185-5p; +MIMAT0023812 cgr-miR-185-3p; +MIMAT0023813 cgr-miR-186-5p; +MIMAT0023814 cgr-miR-186-3p; +MIMAT0023815 cgr-miR-187; +MIMAT0023816 cgr-miR-188; +MIMAT0023817 cgr-miR-18a-5p; +MIMAT0023818 cgr-miR-18a-3p; +MIMAT0023819 cgr-miR-190a; +MIMAT0023820 cgr-miR-1903; +MIMAT0023821 cgr-miR-190b; +MIMAT0023822 cgr-miR-191-5p; +MIMAT0023823 cgr-miR-191-3p; +MIMAT0023824 cgr-miR-192; +MIMAT0023825 cgr-miR-193b-5p; +MIMAT0023826 cgr-miR-193b-3p; +MIMAT0023827 cgr-miR-194; +MIMAT0023828 cgr-miR-1949; +MIMAT0023829 cgr-miR-195; +MIMAT0023830 cgr-miR-1956; +MIMAT0023831 cgr-miR-196a-5p; +MIMAT0023832 cgr-miR-196a-3p; +MIMAT0023833 cgr-miR-196b; +MIMAT0023834 cgr-miR-196c; +MIMAT0023835 cgr-miR-1973; +MIMAT0023836 cgr-miR-199a-5p; +MIMAT0023837 cgr-miR-199a-3p; +MIMAT0023838 cgr-miR-199b; +MIMAT0023839 cgr-miR-19a; +MIMAT0023840 cgr-miR-19b-5p; +MIMAT0023841 cgr-miR-19b-3p; +MIMAT0023842 cgr-miR-200b; +MIMAT0023843 cgr-miR-200c; +MIMAT0023844 cgr-miR-204; +MIMAT0023845 cgr-miR-205; +MIMAT0023846 cgr-miR-206; +MIMAT0023847 cgr-miR-20a; +MIMAT0023848 cgr-miR-210-5p; +MIMAT0023849 cgr-miR-210-3p; +MIMAT0023850 cgr-miR-212; +MIMAT0023851 cgr-miR-214-5p; +MIMAT0023852 cgr-miR-214-3p; +MIMAT0023853 cgr-miR-215-5p; +MIMAT0023854 cgr-miR-215-3p; +MIMAT0023855 cgr-miR-218a; +MIMAT0023856 cgr-miR-22-5p; +MIMAT0023857 cgr-miR-22-3p; +MIMAT0023858 cgr-miR-221-5p; +MIMAT0023859 cgr-miR-221-3p; +MIMAT0023860 cgr-miR-222-5p; +MIMAT0023861 cgr-miR-222-3p; +MIMAT0023862 cgr-miR-23a-5p; +MIMAT0023863 cgr-miR-23a-3p; +MIMAT0023864 cgr-miR-23b-5p; +MIMAT0023865 cgr-miR-23b-3p; +MIMAT0023866 cgr-miR-24-5p; +MIMAT0023867 cgr-miR-24-3p; +MIMAT0023868 cgr-miR-2424; +MIMAT0023869 cgr-miR-25-5p; +MIMAT0023870 cgr-miR-25-3p; +MIMAT0023871 cgr-miR-26a; +MIMAT0023872 cgr-miR-26b-5p; +MIMAT0023873 cgr-miR-26b-3p; +MIMAT0023874 cgr-miR-27a-5p; +MIMAT0023875 cgr-miR-27a-3p; +MIMAT0023876 cgr-miR-27b-5p; +MIMAT0023877 cgr-miR-27b-3p; +MIMAT0023878 cgr-miR-28-5p; +MIMAT0023879 cgr-miR-28-3p; +MIMAT0023880 cgr-miR-296; +MIMAT0023881 cgr-miR-298-5p; +MIMAT0023882 cgr-miR-298-3p; +MIMAT0023883 cgr-miR-29a-5p; +MIMAT0023884 cgr-miR-29a-3p; +MIMAT0023885 cgr-miR-29b-5p; +MIMAT0023886 cgr-miR-29b-3p; +MIMAT0023887 cgr-miR-29c-5p; +MIMAT0023888 cgr-miR-29c-3p; +MIMAT0023889 cgr-miR-300; +MIMAT0023890 cgr-miR-301a-5p; +MIMAT0023891 cgr-miR-301a-3p; +MIMAT0023892 cgr-miR-3072-5p; +MIMAT0023893 cgr-miR-3072-3p; +MIMAT0023894 cgr-miR-30a-5p; +MIMAT0023895 cgr-miR-30a-3p; +MIMAT0023896 cgr-miR-30b-5p; +MIMAT0023897 cgr-miR-30b-3p; +MIMAT0023898 cgr-miR-30c; +MIMAT0023899 cgr-miR-30d; +MIMAT0023900 cgr-miR-30e-5p; +MIMAT0023901 cgr-miR-30e-3p; +MIMAT0023902 cgr-miR-31-5p; +MIMAT0023903 cgr-miR-31-3p; +MIMAT0023904 cgr-miR-32-5p; +MIMAT0023905 cgr-miR-32-3p; +MIMAT0023906 cgr-miR-320a; +MIMAT0023907 cgr-miR-322-5p; +MIMAT0023908 cgr-miR-322-3p; +MIMAT0023909 cgr-miR-324-5p; +MIMAT0023910 cgr-miR-324-3p; +MIMAT0023911 cgr-miR-325-5p; +MIMAT0023912 cgr-miR-325-3p; +MIMAT0023913 cgr-miR-326; +MIMAT0023914 cgr-miR-328; +MIMAT0023915 cgr-miR-33; +MIMAT0023916 cgr-miR-331-5p; +MIMAT0023917 cgr-miR-331-3p; +MIMAT0023918 cgr-miR-338; +MIMAT0023919 cgr-miR-339; +MIMAT0023920 cgr-miR-340-5p; +MIMAT0023921 cgr-miR-340-3p; +MIMAT0023922 cgr-miR-342-5p; +MIMAT0023923 cgr-miR-342-3p; +MIMAT0023924 cgr-miR-344; +MIMAT0023925 cgr-miR-345; +MIMAT0023926 cgr-miR-34a; +MIMAT0023927 cgr-miR-34b-5p; +MIMAT0023928 cgr-miR-34b-3p; +MIMAT0023929 cgr-miR-34c-5p; +MIMAT0023930 cgr-miR-34c-3p; +MIMAT0023931 cgr-miR-350-5p; +MIMAT0023932 cgr-miR-350-3p; +MIMAT0023933 cgr-miR-361; +MIMAT0023934 cgr-miR-362; +MIMAT0023935 cgr-miR-365-5p; +MIMAT0023936 cgr-miR-365-3p; +MIMAT0023937 cgr-miR-369-5p; +MIMAT0023938 cgr-miR-369-3p; +MIMAT0023939 cgr-miR-374-5p; +MIMAT0023940 cgr-miR-374-3p; +MIMAT0023941 cgr-miR-377-5p; +MIMAT0023942 cgr-miR-377-3p; +MIMAT0023943 cgr-miR-378-5p; +MIMAT0023944 cgr-miR-378-3p; +MIMAT0023945 cgr-miR-379; +MIMAT0023946 cgr-miR-381; +MIMAT0023947 cgr-miR-382; +MIMAT0023948 cgr-miR-384-5p; +MIMAT0023949 cgr-miR-384-3p; +MIMAT0023950 cgr-miR-409-5p; +MIMAT0023951 cgr-miR-409-3p; +MIMAT0023952 cgr-miR-410-5p; +MIMAT0023953 cgr-miR-410-3p; +MIMAT0023954 cgr-miR-412-5p; +MIMAT0023955 cgr-miR-412-3p; +MIMAT0023956 cgr-miR-423-5p; +MIMAT0023957 cgr-miR-423-3p; +MIMAT0023958 cgr-miR-425-5p; +MIMAT0023959 cgr-miR-425-3p; +MIMAT0023960 cgr-miR-429; +MIMAT0023961 cgr-miR-450a; +MIMAT0023962 cgr-miR-450b-5p; +MIMAT0023963 cgr-miR-450b-3p; +MIMAT0023964 cgr-miR-455-5p; +MIMAT0023965 cgr-miR-455-3p; +MIMAT0023966 cgr-miR-484; +MIMAT0023967 cgr-miR-486-5p; +MIMAT0023968 cgr-miR-486-3p; +MIMAT0023969 cgr-miR-496; +MIMAT0023970 cgr-miR-497-5p; +MIMAT0023971 cgr-miR-497-3p; +MIMAT0023972 cgr-miR-499-5p; +MIMAT0023973 cgr-miR-499-3p; +MIMAT0023974 cgr-miR-500; +MIMAT0023975 cgr-miR-501-5p; +MIMAT0023976 cgr-miR-501-3p; +MIMAT0023977 cgr-miR-503; +MIMAT0023978 cgr-miR-504; +MIMAT0023979 cgr-miR-505-5p; +MIMAT0023980 cgr-miR-505-3p; +MIMAT0023981 cgr-miR-532-5p; +MIMAT0023982 cgr-miR-532-3p; +MIMAT0023983 cgr-miR-542-5p; +MIMAT0023984 cgr-miR-542-3p; +MIMAT0023985 cgr-miR-582; +MIMAT0023986 cgr-miR-598; +MIMAT0023987 cgr-miR-615-5p; +MIMAT0023988 cgr-miR-615-3p; +MIMAT0023989 cgr-miR-628; +MIMAT0023990 cgr-miR-632; +MIMAT0023991 cgr-miR-652-5p; +MIMAT0023992 cgr-miR-652-3p; +MIMAT0023993 cgr-miR-653; +MIMAT0023994 cgr-miR-664-5p; +MIMAT0023995 cgr-miR-664-3p; +MIMAT0023996 cgr-miR-671-5p; +MIMAT0023997 cgr-miR-671-3p; +MIMAT0023998 cgr-miR-672; +MIMAT0023999 cgr-miR-674; +MIMAT0024000 cgr-miR-702; +MIMAT0024001 cgr-miR-708; +MIMAT0024002 cgr-miR-744-5p; +MIMAT0024003 cgr-miR-744-3p; +MIMAT0024004 cgr-miR-7b; +MIMAT0024005 cgr-miR-872-5p; +MIMAT0024006 cgr-miR-872-3p; +MIMAT0024007 cgr-miR-874; +MIMAT0024008 cgr-miR-9; +MIMAT0024009 cgr-miR-92a-5p; +MIMAT0024010 cgr-miR-92a-3p; +MIMAT0024011 cgr-miR-92b-5p; +MIMAT0024012 cgr-miR-92b-3p; +MIMAT0024013 cgr-miR-93-5p; +MIMAT0024014 cgr-miR-93-3p; +MIMAT0024015 cgr-miR-98; +MIMAT0024016 cgr-miR-99a-5p; +MIMAT0024017 cgr-miR-99a-3p; +MIMAT0024018 cgr-miR-6091; +MIMAT0024019 cgr-miR-6092; +MIMAT0024020 egu-miR172a; +MIMAT0024021 egu-miR172b; +MIMAT0024022 egu-miR172c; +MIMAT0024023 egu-miR172d; +MIMAT0024024 egu-miR172e; +MIMAT0024025 egu-miR172f; +MIMAT0024026 ptr-miR-222; +MIMAT0024027 ptr-miR-4510; +MIMAT0024028 ptr-miR-92b; +MIMAT0024029 ptr-miR-4446; +MIMAT0024030 ptr-miR-320e; +MIMAT0024031 ptr-miR-3151; +MIMAT0024032 ptr-miR-767; +MIMAT0024033 ptr-miR-655; +MIMAT0024034 ptr-miR-3173; +MIMAT0024035 ptr-miR-4660; +MIMAT0024036 ptr-miR-3200; +MIMAT0024037 ptr-miR-2392; +MIMAT0024038 ptr-miR-3127; +MIMAT0024039 ptr-miR-1252; +MIMAT0024040 ptr-miR-3660; +MIMAT0024041 ptr-miR-3129; +MIMAT0024042 ptr-miR-3192; +MIMAT0024043 ptr-miR-4742; +MIMAT0024044 ptr-miR-378b; +MIMAT0024045 ptr-miR-4743; +MIMAT0024046 ptr-miR-3943; +MIMAT0024047 ptr-miR-3138; +MIMAT0024048 ptr-miR-23c; +MIMAT0024049 ptr-miR-676; +MIMAT0024050 ptr-miR-3117; +MIMAT0024051 ptr-miR-200c; +MIMAT0024052 ptr-miR-4536; +MIMAT0024053 ptr-miR-4654; +MIMAT0024054 ptr-miR-548o; +MIMAT0024055 ptr-miR-3937; +MIMAT0024056 ptr-miR-3149; +MIMAT0024057 ptr-miR-548e; +MIMAT0024058 ptr-miR-3132; +MIMAT0024059 ptr-miR-4524a; +MIMAT0024060 ptr-miR-4667; +MIMAT0024061 ptr-miR-3121; +MIMAT0024062 ptr-miR-3193; +MIMAT0024063 ptr-miR-3664; +MIMAT0024064 ptr-miR-3136; +MIMAT0024065 ptr-miR-4504; +MIMAT0024066 ptr-miR-1260b; +MIMAT0024067 ptr-miR-378e; +MIMAT0024068 ptr-miR-4423; +MIMAT0024069 ptr-miR-4428; +MIMAT0024070 ptr-miR-3165; +MIMAT0024071 ptr-miR-449c; +MIMAT0024072 ptr-miR-2114; +MIMAT0024073 ggo-let-7f; +MIMAT0024074 ggo-let-7a; +MIMAT0024075 ggo-let-7c; +MIMAT0024076 ggo-let-7g; +MIMAT0024077 ggo-let-7b; +MIMAT0024078 ggo-miR-1; +MIMAT0024079 ggo-let-7e; +MIMAT0024080 ggo-miR-320a; +MIMAT0024081 ggo-miR-140; +MIMAT0024082 ggo-miR-128; +MIMAT0024083 ggo-let-7i; +MIMAT0024084 ggo-miR-29c; +MIMAT0024085 ggo-miR-423; +MIMAT0024086 ggo-miR-185; +MIMAT0024087 ggo-miR-340; +MIMAT0024088 ggo-miR-330; +MIMAT0024089 ggo-miR-598; +MIMAT0024090 ggo-miR-129; +MIMAT0024091 ggo-miR-26b; +MIMAT0024092 ggo-miR-222; +MIMAT0024093 ggo-miR-191; +MIMAT0024094 ggo-miR-127; +MIMAT0024095 ggo-miR-23b; +MIMAT0024096 ggo-miR-146b; +MIMAT0024097 ggo-miR-22; +MIMAT0024098 ggo-miR-138; +MIMAT0024099 ggo-miR-152; +MIMAT0024100 ggo-miR-181d; +MIMAT0024101 ggo-miR-342; +MIMAT0024102 ggo-miR-485; +MIMAT0024103 ggo-miR-378a; +MIMAT0024104 ggo-miR-495; +MIMAT0024105 ggo-miR-487b; +MIMAT0024106 ggo-miR-139; +MIMAT0024107 ggo-miR-151a; +MIMAT0024108 ggo-miR-148b; +MIMAT0024109 ggo-miR-4510; +MIMAT0024110 ggo-miR-379; +MIMAT0024111 ggo-miR-30c; +MIMAT0024112 ggo-miR-27b; +MIMAT0024113 ggo-miR-433; +MIMAT0024114 ggo-miR-885; +MIMAT0024115 ggo-miR-889; +MIMAT0024116 ggo-miR-383; +MIMAT0024117 ggo-miR-432; +MIMAT0024118 ggo-miR-499a; +MIMAT0024119 ggo-miR-192; +MIMAT0024120 ggo-miR-92b; +MIMAT0024121 ggo-miR-410; +MIMAT0024122 ggo-miR-335; +MIMAT0024123 ggo-miR-34c; +MIMAT0024124 ggo-miR-30e; +MIMAT0024125 ggo-miR-338; +MIMAT0024126 ggo-miR-374b; +MIMAT0024127 ggo-miR-584; +MIMAT0024128 ggo-miR-331; +MIMAT0024129 ggo-miR-4446; +MIMAT0024130 ggo-miR-324; +MIMAT0024131 ggo-miR-532; +MIMAT0024132 ggo-miR-760; +MIMAT0024133 ggo-miR-125a; +MIMAT0024134 ggo-miR-323a; +MIMAT0024135 ggo-miR-146a; +MIMAT0024136 ggo-miR-361; +MIMAT0024137 ggo-miR-376c; +MIMAT0024138 ggo-miR-193b; +MIMAT0024139 ggo-miR-769; +MIMAT0024140 ggo-miR-874; +MIMAT0024141 ggo-miR-148a; +MIMAT0024142 ggo-miR-299; +MIMAT0024143 ggo-miR-497; +MIMAT0024144 ggo-miR-149; +MIMAT0024145 ggo-miR-487a; +MIMAT0024146 ggo-miR-210; +MIMAT0024147 ggo-miR-543; +MIMAT0024148 ggo-miR-411; +MIMAT0024149 ggo-miR-486; +MIMAT0024150 ggo-miR-365a; +MIMAT0024151 ggo-miR-424; +MIMAT0024152 ggo-miR-4488; +MIMAT0024153 ggo-miR-652; +MIMAT0024154 ggo-miR-655; +MIMAT0024155 ggo-miR-877; +MIMAT0024156 ggo-miR-130b; +MIMAT0024157 ggo-miR-363; +MIMAT0024158 ggo-miR-1301; +MIMAT0024159 ggo-miR-376a; +MIMAT0024160 ggo-miR-494; +MIMAT0024161 ggo-miR-339; +MIMAT0024162 ggo-miR-574; +MIMAT0024163 ggo-miR-504; +MIMAT0024164 ggo-miR-660; +MIMAT0024165 ggo-miR-577; +MIMAT0024166 ggo-miR-328; +MIMAT0024167 ggo-miR-873; +MIMAT0024168 ggo-miR-421; +MIMAT0024169 ggo-miR-374a; +MIMAT0024170 ggo-miR-409; +MIMAT0024171 ggo-miR-323b; +MIMAT0024172 ggo-miR-1296; +MIMAT0024173 ggo-miR-1185; +MIMAT0024174 ggo-miR-193a; +MIMAT0024175 ggo-miR-1277; +MIMAT0024176 ggo-miR-1255a; +MIMAT0024177 ggo-miR-142; +MIMAT0024178 ggo-miR-329b; +MIMAT0024179 ggo-miR-122; +MIMAT0024180 ggo-miR-197; +MIMAT0024181 ggo-miR-206; +MIMAT0024182 ggo-miR-370; +MIMAT0024183 ggo-miR-656; +MIMAT0024184 ggo-miR-431; +MIMAT0024185 ggo-miR-628; +MIMAT0024186 ggo-miR-551a; +MIMAT0024187 ggo-miR-502a; +MIMAT0024188 ggo-miR-551b; +MIMAT0024189 ggo-miR-375; +MIMAT0024190 ggo-miR-346; +MIMAT0024191 ggo-miR-483; +MIMAT0024192 ggo-miR-1271; +MIMAT0024193 ggo-miR-376b; +MIMAT0024194 ggo-miR-629; +MIMAT0024195 ggo-miR-380; +MIMAT0024196 ggo-miR-491; +MIMAT0024197 ggo-miR-4524a; +MIMAT0024198 ggo-miR-592; +MIMAT0024199 ggo-miR-4660; +MIMAT0024200 ggo-miR-484; +MIMAT0024201 ggo-miR-377; +MIMAT0024202 ggo-miR-582; +MIMAT0024203 ggo-miR-503; +MIMAT0024204 ggo-miR-887; +MIMAT0024205 ggo-miR-490; +MIMAT0024206 ggo-miR-590; +MIMAT0024207 ggo-miR-345; +MIMAT0024208 ggo-miR-1291; +MIMAT0024209 ggo-miR-448; +MIMAT0024210 ggo-miR-3943; +MIMAT0024211 ggo-miR-452; +MIMAT0024212 ggo-miR-767; +MIMAT0024213 ggo-miR-940; +MIMAT0024214 ggo-miR-1180; +MIMAT0024215 ggo-miR-326; +MIMAT0024216 ggo-miR-320b; +MIMAT0024217 ggo-miR-150; +MIMAT0024218 ggo-miR-1179; +MIMAT0024219 ggo-miR-144; +MIMAT0024220 ggo-miR-381; +MIMAT0024221 ggo-miR-155; +MIMAT0024222 ggo-miR-455; +MIMAT0024223 ggo-miR-496; +MIMAT0024224 ggo-miR-766; +MIMAT0024225 ggo-miR-1306; +MIMAT0024226 ggo-miR-34b; +MIMAT0024227 ggo-miR-20b; +MIMAT0024228 ggo-miR-505; +MIMAT0024229 ggo-miR-1228; +MIMAT0024230 ggo-miR-488; +MIMAT0024231 ggo-miR-542; +MIMAT0024232 ggo-miR-1298; +MIMAT0024233 ggo-miR-1287; +MIMAT0024234 ggo-miR-509; +MIMAT0024235 ggo-miR-1250; +MIMAT0024236 ggo-miR-3605; +MIMAT0024237 ggo-miR-450a; +MIMAT0024238 ggo-miR-654; +MIMAT0024239 ggo-miR-589; +MIMAT0024240 ggo-miR-1260b; +MIMAT0024241 ggo-miR-362; +MIMAT0024242 ggo-miR-378b; +MIMAT0024243 ggo-miR-337; +MIMAT0024244 ggo-miR-23c; +MIMAT0024245 ggo-miR-1197; +MIMAT0024246 ggo-miR-4520b; +MIMAT0024247 ggo-miR-1249; +MIMAT0024248 ggo-miR-4429; +MIMAT0024249 ggo-miR-493; +MIMAT0024250 ggo-miR-2110; +MIMAT0024251 ggo-miR-1252; +MIMAT0024252 ggo-miR-668; +MIMAT0024253 ggo-miR-135b; +MIMAT0024254 ggo-miR-517c; +MIMAT0024255 ggo-miR-4743; +MIMAT0024256 ggo-miR-1193; +MIMAT0024257 ggo-miR-1343; +MIMAT0024258 ggo-miR-3612; +MIMAT0024259 ggo-miR-3151; +MIMAT0024260 ggo-miR-548b; +MIMAT0024261 ggo-miR-3126; +MIMAT0024262 ggo-miR-641; +MIMAT0024263 ggo-miR-4529; +MIMAT0024264 ggo-miR-203b; +MIMAT0024265 ggo-miR-3129; +MIMAT0024266 ggo-miR-548c; +MIMAT0024267 ggo-miR-371b; +MIMAT0024268 ggo-miR-1266; +MIMAT0024269 ggo-miR-3127; +MIMAT0024270 ggo-miR-190b; +MIMAT0024271 ggo-miR-3138; +MIMAT0024272 ggo-miR-133b; +MIMAT0024273 ggo-miR-676; +MIMAT0024274 ggo-miR-651; +MIMAT0024275 ggo-miR-3173; +MIMAT0024276 ggo-miR-548e; +MIMAT0024277 ggo-miR-188; +MIMAT0024278 ggo-miR-548a; +MIMAT0024279 ggo-miR-671; +MIMAT0024280 ggo-miR-454; +MIMAT0024281 ggo-miR-3615; +MIMAT0024282 ggo-miR-1289; +MIMAT0024283 ggo-miR-1278; +MIMAT0024284 ggo-miR-4738; +MIMAT0024285 ggo-miR-508; +MIMAT0024286 ggo-miR-1264; +MIMAT0024287 ggo-miR-556; +MIMAT0024288 ggo-miR-548d; +MIMAT0024289 ggo-miR-1273c; +MIMAT0024290 ggo-miR-296; +MIMAT0024291 ggo-miR-1286; +MIMAT0024292 ggo-miR-516b; +MIMAT0024293 ggo-miR-4536; +MIMAT0024294 ggo-miR-548f; +MIMAT0024295 ggo-miR-3923; +MIMAT0024296 ggo-miR-450b; +MIMAT0024297 ggo-miR-202; +MIMAT0024298 ggo-miR-182; +MIMAT0024299 ggo-miR-200b; +MIMAT0024300 ggo-miR-200a; +MIMAT0024301 ggo-miR-609; +MIMAT0024302 ggo-miR-624; +MIMAT0024303 ggo-miR-378e; +MIMAT0024304 ggo-miR-429; +MIMAT0024305 ggo-miR-675b; +MIMAT0024306 ggo-miR-3927; +MIMAT0024307 ggo-miR-4484; +MIMAT0024308 ggo-miR-502b; +MIMAT0024309 ggo-miR-18b; +MIMAT0024310 mml-miR-4446;mml-miR-4446-3p; +MIMAT0024311 mml-miR-873;mml-miR-873-5p; +MIMAT0024312 mml-miR-320b; +MIMAT0024313 mml-miR-378d; +MIMAT0024314 mml-miR-1185;mml-miR-1185-5p; +MIMAT0024315 mml-miR-1271;mml-miR-1271-5p; +MIMAT0024316 mml-miR-1298;mml-miR-1298-5p; +MIMAT0024317 mml-miR-1277; +MIMAT0024318 mml-miR-3151; +MIMAT0024319 mml-miR-1260b; +MIMAT0024320 mml-miR-1255a;mml-miR-1255a-5p; +MIMAT0024321 mml-miR-1262;mml-miR-1262-3p; +MIMAT0024322 mml-miR-1258; +MIMAT0024323 mml-miR-3200;mml-miR-3200-3p; +MIMAT0024324 mml-miR-1249; +MIMAT0024325 mml-miR-676;mml-miR-676-3p; +MIMAT0024326 mml-miR-320c; +MIMAT0024327 mml-miR-4743; +MIMAT0024328 mml-miR-1296;mml-miR-1296-5p; +MIMAT0024329 mml-miR-1179; +MIMAT0024330 mml-miR-4803; +MIMAT0024331 mml-miR-3173; +MIMAT0024332 mml-miR-4536; +MIMAT0024333 mml-miR-4667; +MIMAT0024334 mml-miR-1250; +MIMAT0024335 mml-miR-891b;mml-miR-891b-5p; +MIMAT0024336 mml-miR-3146; +MIMAT0024337 mml-miR-4716; +MIMAT0024338 mml-miR-1243;mml-miR-1243-3p; +MIMAT0024339 mml-miR-1304; +MIMAT0024340 mml-miR-3122; +MIMAT0024341 mml-miR-4796;mml-miR-4796-3p; +MIMAT0024342 mml-miR-1255b; +MIMAT0024343 mml-miR-1284; +MIMAT0024344 mml-miR-4650; +MIMAT0024345 mml-miR-2114; +MIMAT0024346 mml-miR-1323;mml-miR-1323-5p; +MIMAT0024347 mml-miR-3140; +MIMAT0024348 mml-miR-514b;mml-miR-514b-3p; +MIMAT0024349 mml-miR-3145;mml-miR-3145-3p; +MIMAT0024350 mml-miR-3927; +MIMAT0024351 mml-miR-517c; +MIMAT0024352 mml-miR-1283; +MIMAT0024353 mml-miR-519e; +MIMAT0024354 mml-miR-217b; +MIMAT0024355 mml-miR-518d;mml-miR-518d-5p; +MIMAT0024356 ppy-miR-152; +MIMAT0024357 ppy-miR-4446; +MIMAT0024358 ppy-miR-320e; +MIMAT0024359 ppy-miR-202; +MIMAT0024360 ppy-miR-378d; +MIMAT0024361 ppy-miR-548e; +MIMAT0024362 ppy-miR-4451; +MIMAT0024363 ppy-miR-3943; +MIMAT0024364 ppy-miR-378b; +MIMAT0024365 ppy-miR-676; +MIMAT0024366 ppy-miR-4743; +MIMAT0024367 ppy-miR-454; +MIMAT0024368 ppy-miR-3155a; +MIMAT0024369 ppy-miR-1193; +MIMAT0024370 ppy-miR-1260b; +MIMAT0024371 ppy-miR-3660; +MIMAT0024372 ppy-miR-3617; +MIMAT0024373 ppy-miR-548a; +MIMAT0024374 ppy-miR-4798; +MIMAT0024375 ppy-miR-3934; +MIMAT0024376 ppy-miR-4782; +MIMAT0024377 ppy-miR-548h; +MIMAT0024378 ppy-miR-548f; +MIMAT0024379 ppy-miR-548c; +MIMAT0024380 ppy-miR-4791; +MIMAT0024381 ppy-miR-3940; +MIMAT0024382 ppy-miR-4774; +MIMAT0024383 ppy-miR-4484; +MIMAT0024384 ppy-miR-4515; +MIMAT0024385 ppy-miR-1273e; +MIMAT0024386 ppy-miR-4667; +MIMAT0024387 ppy-miR-3912; +MIMAT0024388 ppy-miR-3661; +MIMAT0024389 ppy-miR-4520a; +MIMAT0024390 ppy-miR-4637; +MIMAT0024391 ppy-miR-3938; +MIMAT0024392 ppy-miR-4529; +MIMAT0024393 ppy-miR-4526; +MIMAT0024394 ppy-miR-151b; +MIMAT0024395 ppy-miR-3173; +MIMAT0024396 ppy-miR-3121; +MIMAT0024397 ppy-miR-3170; +MIMAT0024398 ppy-miR-4672; +MIMAT0024399 ppy-miR-4796; +MIMAT0024400 ppy-miR-4427; +MIMAT0024401 ppy-miR-3188; +MIMAT0024402 ppy-miR-3154; +MIMAT0024403 ppy-miR-3145; +MIMAT0024404 ppy-miR-1976; +MIMAT0024405 ppy-miR-2861; +MIMAT0024406 ppy-miR-2278; +MIMAT0024407 ppy-miR-3174; +MIMAT0024408 ppy-miR-4788; +MIMAT0024409 ppy-miR-378e; +MIMAT0024410 mes-miR159;mes-miR159a;mes-miR159a-3p; +MIMAT0024411 mes-miR160; +MIMAT0024412 mes-miR166; +MIMAT0024413 mes-miR167;mes-miR167a; +MIMAT0024414 mes-miR168;mes-miR168a; +MIMAT0024415 mes-miR171;mes-miR171a; +MIMAT0024416 mes-miR172;mes-miR172a; +MIMAT0024417 mes-miR394;mes-miR394a; +MIMAT0024418 mes-miR399;mes-miR399a; +MIMAT0024419 mes-miR408; +MIMAT0024420 mse-miR-210; +MIMAT0024421 mse-miR-3286; +MIMAT0024422 mse-miR-11; +MIMAT0024423 mse-miR-998; +MIMAT0024424 mse-miR-190; +MIMAT0024425 mse-miR-2779; +MIMAT0024426 mse-miR-7; +MIMAT0024427 mse-miR-279b; +MIMAT0024428 mse-miR-965; +MIMAT0024429 mse-miR-33; +MIMAT0024430 mse-miR-275; +MIMAT0024431 mse-miR-989; +MIMAT0024432 mse-miR-3338; +MIMAT0024433 mse-miR-981; +MIMAT0024434 mse-miR-316; +MIMAT0024435 mse-miR-87; +MIMAT0024436 mse-miR-285; +MIMAT0024437 mse-let-7a; +MIMAT0024438 mse-miR-100; +MIMAT0024439 mse-miR-193; +MIMAT0024440 mse-miR-276; +MIMAT0024441 mse-miR-1000; +MIMAT0024442 mse-miR-2755; +MIMAT0024443 mse-miR-277; +MIMAT0024444 mse-miR-282; +MIMAT0024445 mse-miR-745; +MIMAT0024446 mse-miR-281; +MIMAT0024447 mse-miR-31; +MIMAT0024448 mse-miR-307; +MIMAT0024449 mse-miR-10a; +MIMAT0024450 mse-miR-279c; +MIMAT0024451 mse-miR-278; +MIMAT0024452 mse-bantam; +MIMAT0024453 mse-miR-970; +MIMAT0024454 mse-miR-932; +MIMAT0024455 mse-miR-279a; +MIMAT0024456 mse-miR-8; +MIMAT0024457 mse-miR-750; +MIMAT0024458 mse-miR-137; +MIMAT0024459 mse-miR-iab-4-5p; +MIMAT0024460 mse-miR-2768; +MIMAT0024461 mse-miR-2796; +MIMAT0024462 mse-miR-133; +MIMAT0024463 mse-miR-14; +MIMAT0024464 mse-miR-317; +MIMAT0024465 mse-miR-252; +MIMAT0024466 mse-miR-12; +MIMAT0024467 mse-miR-993; +MIMAT0024468 mse-miR-263a; +MIMAT0024469 mse-miR-283; +MIMAT0024470 mse-miR-2765; +MIMAT0024471 mse-miR-92a; +MIMAT0024472 mse-miR-79; +MIMAT0024473 mse-miR-9a; +MIMAT0024474 mse-miR-124; +MIMAT0024475 mse-miR-34; +MIMAT0024476 mse-miR-9b; +MIMAT0024477 mse-miR-184; +MIMAT0024478 mse-miR-308; +MIMAT0024479 mse-miR-2a; +MIMAT0024480 mse-miR-2b; +MIMAT0024481 mse-miR-71; +MIMAT0024482 mse-miR-2766; +MIMAT0024483 mse-miR-1a; +MIMAT0024484 mse-miR-263b; +MIMAT0024485 mse-miR-279d; +MIMAT0024486 mse-miR-306; +MIMAT0024487 mse-miR-92b; +MIMAT0024488 mse-miR-2767; +MIMAT0024489 mse-miR-2763; +MIMAT0024490 mse-miR-10b; +MIMAT0024491 mse-miR-10c; +MIMAT0024492 mse-miR-2788; +MIMAT0024493 mse-miR-1b; +MIMAT0024494 mse-miR-1926; +MIMAT0024495 mse-miR-2565; +MIMAT0024496 mse-miR-3389; +MIMAT0024497 mse-miR-450; +MIMAT0024498 mse-miR-929;mse-miR-929a; +MIMAT0024499 mse-miR-2797a; +MIMAT0024500 mse-miR-2797b; +MIMAT0024501 mse-miR-6093; +MIMAT0024502 mse-miR-6094; +MIMAT0024503 mse-miR-6095; +MIMAT0024504 mse-miR-6096; +MIMAT0024505 mse-miR-6097; +MIMAT0024506 mse-miR-6098; +MIMAT0024507 mse-miR-6099; +MIMAT0024508 mse-miR-6100; +MIMAT0024509 mse-miR-6101; +MIMAT0024510 cca-miR156a; +MIMAT0024511 cca-miR156b; +MIMAT0024512 cca-miR156c; +MIMAT0024513 cca-miR160a; +MIMAT0024514 cca-miR160b; +MIMAT0024515 cca-miR164; +MIMAT0024516 cca-miR167; +MIMAT0024517 cca-miR168a; +MIMAT0024518 cca-miR169a; +MIMAT0024519 cca-miR169b; +MIMAT0024520 cca-miR171; +MIMAT0024521 cca-miR172; +MIMAT0024522 cca-miR319; +MIMAT0024523 cca-miR390; +MIMAT0024524 cca-miR393; +MIMAT0024525 cca-miR394; +MIMAT0024526 cca-miR395a; +MIMAT0024527 cca-miR395b; +MIMAT0024528 cca-miR395c; +MIMAT0024529 cca-miR396a-5p; +MIMAT0024530 cca-miR396a-3p; +MIMAT0024531 cca-miR396b; +MIMAT0024532 cca-miR398; +MIMAT0024533 cca-miR399; +MIMAT0024534 cca-miR408; +MIMAT0024535 cca-miR6103-5p; +MIMAT0024536 cca-miR6103-3p; +MIMAT0024537 cca-miR6104; +MIMAT0024538 cca-miR6105a; +MIMAT0024539 cca-miR6106-5p; +MIMAT0024540 cca-miR6106-3p; +MIMAT0024541 cca-miR6107; +MIMAT0024542 cca-miR6105b; +MIMAT0024543 cca-miR6108a; +MIMAT0024544 cca-miR6108g; +MIMAT0024545 cca-miR6108b; +MIMAT0024546 cca-miR6109; +MIMAT0024547 cca-miR6110-5p; +MIMAT0024548 cca-miR6110-3p; +MIMAT0024549 cca-miR6111-5p; +MIMAT0024550 cca-miR6111-3p; +MIMAT0024551 cca-miR6112; +MIMAT0024552 cca-miR6113; +MIMAT0024553 cca-miR6114-5p; +MIMAT0024554 cca-miR6114-3p; +MIMAT0024555 cca-miR6108c; +MIMAT0024556 cca-miR6108d; +MIMAT0024557 cca-miR6108e-5p; +MIMAT0024558 cca-miR6108e-3p; +MIMAT0024559 cca-miR6108f; +MIMAT0024560 cca-miR6115; +MIMAT0024561 cca-miR396c; +MIMAT0024562 cca-miR6116-5p; +MIMAT0024563 cca-miR6116-3p; +MIMAT0024564 cca-miR6117; +MIMAT0024565 cca-miR6118-5p; +MIMAT0024566 cca-miR6118-3p; +MIMAT0024567 bta-miR-1246; +MIMAT0024568 bta-miR-1260b; +MIMAT0024569 bta-miR-1277; +MIMAT0024570 bta-miR-149-5p; +MIMAT0024571 bta-miR-149-3p; +MIMAT0024572 bta-miR-3120; +MIMAT0024573 bta-miR-3141; +MIMAT0024574 bta-miR-3613;bta-miR-3613a; +MIMAT0024575 bta-miR-4286; +MIMAT0024576 bta-miR-450b; +MIMAT0024577 bta-miR-574; +MIMAT0024578 bta-miR-652; +MIMAT0024579 bta-miR-2284y; +MIMAT0024580 bta-miR-2285e; +MIMAT0024581 bta-miR-2285f; +MIMAT0024582 bta-miR-2285g; +MIMAT0024583 bta-miR-2285h; +MIMAT0024584 bta-miR-2285i; +MIMAT0024585 bta-miR-2285j; +MIMAT0024586 bta-miR-2285k; +MIMAT0024587 bta-miR-2285l; +MIMAT0024588 bta-miR-6119-5p; +MIMAT0024589 bta-miR-6119-3p; +MIMAT0024590 bta-miR-6120-5p; +MIMAT0024591 bta-miR-6120-3p; +MIMAT0024592 bta-miR-6121-5p; +MIMAT0024593 bta-miR-6121-3p; +MIMAT0024594 bta-miR-6122-5p; +MIMAT0024595 bta-miR-6122-3p; +MIMAT0024596 bta-miR-6123; +MIMAT0024597 hsa-miR-6124; +MIMAT0024598 hsa-miR-6125; +MIMAT0024599 hsa-miR-6126; +MIMAT0024600 ptr-miR-6127; +MIMAT0024601 ptr-miR-6128; +MIMAT0024602 ptr-miR-378j; +MIMAT0024603 ptr-miR-6129; +MIMAT0024604 ptr-miR-6130; +MIMAT0024605 ptr-miR-6131; +MIMAT0024606 ptr-miR-6132; +MIMAT0024607 ptr-miR-6133; +MIMAT0024608 ptr-miR-3154; +MIMAT0024609 ptr-miR-6134; +MIMAT0024610 hsa-miR-6127; +MIMAT0024611 hsa-miR-6128; +MIMAT0024612 hsa-miR-378j; +MIMAT0024613 hsa-miR-6129; +MIMAT0024614 hsa-miR-6130; +MIMAT0024615 hsa-miR-6131; +MIMAT0024616 hsa-miR-6132; +MIMAT0024617 hsa-miR-6133; +MIMAT0024618 hsa-miR-6134; +MIMAT0024619 mml-miR-6127; +MIMAT0024620 mml-miR-6128; +MIMAT0024621 mml-miR-378j; +MIMAT0024622 mml-miR-6129; +MIMAT0024623 mml-miR-6130; +MIMAT0024624 mml-miR-6131; +MIMAT0024625 mml-miR-6132; +MIMAT0024626 mml-miR-6133; +MIMAT0024627 mml-miR-3154; +MIMAT0024628 mml-miR-6134; +MIMAT0024629 nta-miR156a; +MIMAT0024630 nta-miR156b; +MIMAT0024631 nta-miR156c; +MIMAT0024632 nta-miR156d; +MIMAT0024633 nta-miR156e; +MIMAT0024634 nta-miR156f; +MIMAT0024635 nta-miR156g; +MIMAT0024636 nta-miR156h; +MIMAT0024637 nta-miR156i; +MIMAT0024638 nta-miR156j; +MIMAT0024639 nta-miR159; +MIMAT0024640 nta-miR160a; +MIMAT0024641 nta-miR160b; +MIMAT0024642 nta-miR160c; +MIMAT0024643 nta-miR160d; +MIMAT0024644 nta-miR162a; +MIMAT0024645 nta-miR162b; +MIMAT0024646 nta-miR164a; +MIMAT0024647 nta-miR164b; +MIMAT0024648 nta-miR164c; +MIMAT0024649 nta-miR166a; +MIMAT0024650 nta-miR166b; +MIMAT0024651 nta-miR166c; +MIMAT0024652 nta-miR166d; +MIMAT0024653 nta-miR166e; +MIMAT0024654 nta-miR166f; +MIMAT0024655 nta-miR166g; +MIMAT0024656 nta-miR166h; +MIMAT0024657 nta-miR167a; +MIMAT0024658 nta-miR167b; +MIMAT0024659 nta-miR167c; +MIMAT0024660 nta-miR167d; +MIMAT0024661 nta-miR167e; +MIMAT0024662 nta-miR168a; +MIMAT0024663 nta-miR168b; +MIMAT0024664 nta-miR168c; +MIMAT0024665 nta-miR168d; +MIMAT0024666 nta-miR168e; +MIMAT0024667 nta-miR169a; +MIMAT0024668 nta-miR169b; +MIMAT0024669 nta-miR169c; +MIMAT0024670 nta-miR169d; +MIMAT0024671 nta-miR169e; +MIMAT0024672 nta-miR169f; +MIMAT0024673 nta-miR169g; +MIMAT0024674 nta-miR169h; +MIMAT0024675 nta-miR169i; +MIMAT0024676 nta-miR169j; +MIMAT0024677 nta-miR169k; +MIMAT0024678 nta-miR169l; +MIMAT0024679 nta-miR169m; +MIMAT0024680 nta-miR169o; +MIMAT0024681 nta-miR169p; +MIMAT0024682 nta-miR169q; +MIMAT0024683 nta-miR169r; +MIMAT0024684 nta-miR169s; +MIMAT0024685 nta-miR169t; +MIMAT0024686 nta-miR171a; +MIMAT0024687 nta-miR171b; +MIMAT0024688 nta-miR171c; +MIMAT0024689 nta-miR172a; +MIMAT0024690 nta-miR172b; +MIMAT0024691 nta-miR172c; +MIMAT0024692 nta-miR172d; +MIMAT0024693 nta-miR172e; +MIMAT0024694 nta-miR172f; +MIMAT0024695 nta-miR172g; +MIMAT0024696 nta-miR172h; +MIMAT0024697 nta-miR172i; +MIMAT0024698 nta-miR172j; +MIMAT0024699 nta-miR319a; +MIMAT0024700 nta-miR319b; +MIMAT0024701 nta-miR390a; +MIMAT0024702 nta-miR390b; +MIMAT0024703 nta-miR390c; +MIMAT0024704 nta-miR394; +MIMAT0024705 nta-miR395a; +MIMAT0024706 nta-miR395b; +MIMAT0024707 nta-miR395c; +MIMAT0024708 nta-miR396a; +MIMAT0024709 nta-miR396b; +MIMAT0024710 nta-miR396c; +MIMAT0024711 nta-miR397; +MIMAT0024712 nta-miR398; +MIMAT0024713 nta-miR399a; +MIMAT0024714 nta-miR399b; +MIMAT0024715 nta-miR399c; +MIMAT0024716 nta-miR399d; +MIMAT0024717 nta-miR399e; +MIMAT0024718 nta-miR399f; +MIMAT0024719 nta-miR399g; +MIMAT0024720 nta-miR408; +MIMAT0024721 nta-miR477a; +MIMAT0024722 nta-miR477b; +MIMAT0024723 nta-miR479a; +MIMAT0024724 nta-miR479b; +MIMAT0024725 nta-miR827; +MIMAT0024726 nta-miR1919; +MIMAT0024727 nta-miR482c; +MIMAT0024728 nta-miR2911; +MIMAT0024729 nta-miR6144; +MIMAT0024730 nta-miR6025c; +MIMAT0024731 nta-miR6145a; +MIMAT0024732 nta-miR6025d; +MIMAT0024733 nta-miR6025e; +MIMAT0024734 nta-miR6146a; +MIMAT0024735 nta-miR6146b; +MIMAT0024736 nta-miR6147; +MIMAT0024737 nta-miR6148a; +MIMAT0024738 nta-miR6148b; +MIMAT0024739 nta-miR6149a; +MIMAT0024740 nta-miR6149b; +MIMAT0024741 nta-miR6150; +MIMAT0024742 nta-miR6151a; +MIMAT0024743 nta-miR6151b; +MIMAT0024744 nta-miR6151c; +MIMAT0024745 nta-miR6151d; +MIMAT0024746 nta-miR6151e; +MIMAT0024747 nta-miR6151f; +MIMAT0024748 nta-miR6151g; +MIMAT0024749 nta-miR6151h; +MIMAT0024750 nta-miR6151i; +MIMAT0024751 nta-miR6152a; +MIMAT0024752 nta-miR6152b; +MIMAT0024753 nta-miR6145b; +MIMAT0024754 nta-miR6153; +MIMAT0024755 nta-miR6154a; +MIMAT0024756 nta-miR6154b; +MIMAT0024757 nta-miR6155; +MIMAT0024758 nta-miR6145c; +MIMAT0024759 nta-miR6156; +MIMAT0024760 nta-miR6157; +MIMAT0024761 nta-miR5303a; +MIMAT0024762 nta-miR5303b; +MIMAT0024763 nta-miR1446; +MIMAT0024764 nta-miR6145d; +MIMAT0024765 nta-miR6145e; +MIMAT0024766 nta-miR6158a; +MIMAT0024767 nta-miR6158b; +MIMAT0024768 nta-miR6158c; +MIMAT0024769 nta-miR6159; +MIMAT0024770 nta-miR5303c; +MIMAT0024771 nta-miR6145f; +MIMAT0024772 nta-miR6160; +MIMAT0024773 nta-miR6161d; +MIMAT0024774 nta-miR6161a; +MIMAT0024775 nta-miR6161b; +MIMAT0024776 nta-miR482d; +MIMAT0024777 nta-miR6162; +MIMAT0024778 nta-miR6161c; +MIMAT0024779 nta-miR6163; +MIMAT0024780 nta-miR6164a; +MIMAT0024781 nta-miR6164b; +MIMAT0024782 hsa-miR-6165; +MIMAT0024783 hbr-miR6166; +MIMAT0024784 hbr-miR2118; +MIMAT0024785 hbr-miR6167; +MIMAT0024786 hbr-miR6168; +MIMAT0024787 hbr-miR482;hbr-miR482a; +MIMAT0024788 hbr-miR6169; +MIMAT0024789 hbr-miR6170; +MIMAT0024790 hbr-miR6171; +MIMAT0024791 hbr-miR396a; +MIMAT0024792 hbr-miR6172; +MIMAT0024793 hbr-miR6173; +MIMAT0024794 hbr-miR398; +MIMAT0024795 hbr-miR6174; +MIMAT0024796 hbr-miR6175; +MIMAT0024797 hvu-miR5049b; +MIMAT0024798 hvu-miR1130; +MIMAT0024799 hvu-miR6176; +MIMAT0024800 hvu-miR6177; +MIMAT0024801 hvu-miR6178; +MIMAT0024802 hvu-miR6179; +MIMAT0024803 hvu-miR5049c; +MIMAT0024804 hvu-miR6180; +MIMAT0024805 hvu-miR6181; +MIMAT0024806 hvu-miR6182; +MIMAT0024807 hvu-miR6183; +MIMAT0024808 hvu-miR6184; +MIMAT0024809 hvu-miR6185; +MIMAT0024810 hvu-miR6186; +MIMAT0024811 hvu-miR6187; +MIMAT0024812 hvu-miR6188; +MIMAT0024813 hvu-miR5049d; +MIMAT0024814 hvu-miR6189; +MIMAT0024815 hvu-miR6190; +MIMAT0024816 hvu-miR6191; +MIMAT0024817 hvu-miR5048b; +MIMAT0024818 hvu-miR6192; +MIMAT0024819 hvu-miR6193; +MIMAT0024820 hvu-miR6194; +MIMAT0024821 hvu-miR6195; +MIMAT0024822 hvu-miR6196; +MIMAT0024823 hvu-miR6197; +MIMAT0024824 hvu-miR6198; +MIMAT0024825 hvu-miR6199; +MIMAT0024826 hvu-miR5049e; +MIMAT0024827 hvu-miR6200; +MIMAT0024828 hvu-miR6201; +MIMAT0024829 hvu-miR5049f; +MIMAT0024830 hvu-miR6202; +MIMAT0024831 hvu-miR6203; +MIMAT0024832 hvu-miR6204; +MIMAT0024833 hvu-miR6205; +MIMAT0024834 hvu-miR6206; +MIMAT0024835 hvu-miR6207; +MIMAT0024836 hvu-miR6208; +MIMAT0024837 hvu-miR6209; +MIMAT0024838 hvu-miR6210; +MIMAT0024839 hvu-miR6211; +MIMAT0024840 hvu-miR6212; +MIMAT0024841 hvu-miR6213; +MIMAT0024842 hvu-miR6214; +MIMAT0024843 rno-miR-1839-5p; +MIMAT0024844 rno-miR-1839-3p; +MIMAT0024845 rno-miR-3068-5p; +MIMAT0024846 rno-miR-3068-3p; +MIMAT0024847 rno-miR-1843-5p;rno-miR-1843a-5p; +MIMAT0024848 rno-miR-1843-3p;rno-miR-1843a-3p; +MIMAT0024849 rno-miR-509-5p; +MIMAT0024850 rno-miR-509-3p; +MIMAT0024851 rno-miR-1306-5p; +MIMAT0024852 rno-miR-1306-3p; +MIMAT0024853 rno-miR-3473; +MIMAT0024854 rno-miR-6215; +MIMAT0024855 rno-miR-378b; +MIMAT0024856 rno-miR-6216; +MIMAT0024857 mmu-miR-6236; +MIMAT0024858 mmu-miR-6237; +MIMAT0024859 mmu-miR-6238; +MIMAT0024860 mmu-miR-6239; +MIMAT0024861 mmu-miR-6240; +MIMAT0024862 mmu-miR-6241; +MIMAT0024863 mmu-miR-6243; +MIMAT0024864 mmu-miR-6244; +MIMAT0024865 osa-miR6245; +MIMAT0024866 osa-miR1440b; +MIMAT0024867 osa-miR6246; +MIMAT0024868 osa-miR6247; +MIMAT0024869 osa-miR6248; +MIMAT0024870 osa-miR5337b; +MIMAT0024871 osa-miR6249;osa-miR6249a; +MIMAT0024872 osa-miR5512b; +MIMAT0024873 osa-miR6250; +MIMAT0024874 osa-miR6251; +MIMAT0024875 osa-miR6252; +MIMAT0024876 osa-miR6253; +MIMAT0024877 osa-miR6254; +MIMAT0024878 osa-miR6255; +MIMAT0024879 osa-miR6256; +MIMAT0024880 gma-miR156u; +MIMAT0024881 gma-miR156v; +MIMAT0024882 gma-miR156w; +MIMAT0024883 gma-miR156x; +MIMAT0024884 gma-miR156y; +MIMAT0024885 gma-miR156z; +MIMAT0024886 gma-miR156aa; +MIMAT0024887 gma-miR156ab; +MIMAT0024888 gma-miR160f; +MIMAT0024889 gma-miR164e; +MIMAT0024890 gma-miR164f; +MIMAT0024891 gma-miR164g; +MIMAT0024892 gma-miR164h; +MIMAT0024893 gma-miR164i; +MIMAT0024894 gma-miR164j; +MIMAT0024895 gma-miR164k; +MIMAT0024896 gma-miR166n; +MIMAT0024897 gma-miR166o; +MIMAT0024898 gma-miR166p; +MIMAT0024899 gma-miR166q; +MIMAT0024900 gma-miR166r; +MIMAT0024901 gma-miR166s; +MIMAT0024902 gma-miR166t; +MIMAT0024903 gma-miR166u; +MIMAT0024905 gma-miR169v; +MIMAT0024906 gma-miR390d; +MIMAT0024907 gma-miR390e; +MIMAT0024908 gma-miR390f; +MIMAT0024909 gma-miR390g; +MIMAT0024910 gma-miR393c;gma-miR393c-5p; +MIMAT0024911 gma-miR393d; +MIMAT0024912 gma-miR393e; +MIMAT0024913 gma-miR393f; +MIMAT0024914 gma-miR393g; +MIMAT0024915 gma-miR393h; +MIMAT0024916 gma-miR393i; +MIMAT0024917 gma-miR393j; +MIMAT0024918 gma-miR393k; +MIMAT0024919 gma-miR394g; +MIMAT0024920 gma-miR395h; +MIMAT0024921 gma-miR395i; +MIMAT0024922 gma-miR395j; +MIMAT0024923 gma-miR395k; +MIMAT0024924 gma-miR395l; +MIMAT0024925 gma-miR395m; +MIMAT0024926 gma-miR1515b; +MIMAT0024927 gma-miR1516d; +MIMAT0024928 gma-miR6299; +MIMAT0024929 gma-miR6300; +MIMAT0024930 hme-bantam; +MIMAT0024931 hme-let-7; +MIMAT0024932 hme-miR-10; +MIMAT0024933 hme-miR-1000; +MIMAT0024934 hme-miR-11; +MIMAT0024935 hme-miR-1175; +MIMAT0024936 hme-miR-12; +MIMAT0024937 hme-miR-124; +MIMAT0024938 hme-miR-133; +MIMAT0024939 hme-miR-137; +MIMAT0024940 hme-miR-13a; +MIMAT0024941 hme-miR-13b; +MIMAT0024942 hme-miR-14; +MIMAT0024943 hme-miR-184; +MIMAT0024944 hme-miR-190; +MIMAT0024945 hme-miR-1b; +MIMAT0024946 hme-miR-1a; +MIMAT0024947 hme-miR-210; +MIMAT0024948 hme-miR-252; +MIMAT0024949 hme-miR-263a; +MIMAT0024950 hme-miR-263b; +MIMAT0024951 hme-miR-2733; +MIMAT0024952 hme-miR-2755; +MIMAT0024953 hme-miR-2756; +MIMAT0024954 hme-miR-276; +MIMAT0024955 hme-miR-2763; +MIMAT0024956 hme-miR-2765; +MIMAT0024957 hme-miR-2767; +MIMAT0024958 hme-miR-2768; +MIMAT0024959 hme-miR-277; +MIMAT0024960 hme-miR-278; +MIMAT0024961 hme-miR-279a; +MIMAT0024962 hme-miR-2796; +MIMAT0024963 hme-miR-2797; +MIMAT0024964 hme-miR-279b; +MIMAT0024965 hme-miR-279d; +MIMAT0024966 hme-miR-279c; +MIMAT0024967 hme-miR-281; +MIMAT0024968 hme-miR-282; +MIMAT0024969 hme-miR-283; +MIMAT0024970 hme-miR-285; +MIMAT0024971 hme-miR-2a; +MIMAT0024972 hme-miR-2b; +MIMAT0024973 hme-miR-2c; +MIMAT0024974 hme-miR-305; +MIMAT0024975 hme-miR-306; +MIMAT0024976 hme-miR-307; +MIMAT0024977 hme-miR-308; +MIMAT0024978 hme-miR-316; +MIMAT0024979 hme-miR-3286; +MIMAT0024980 hme-miR-33; +MIMAT0024981 hme-miR-3327; +MIMAT0024982 hme-miR-3338; +MIMAT0024983 hme-miR-34; +MIMAT0024984 hme-miR-7; +MIMAT0024985 hme-miR-71; +MIMAT0024986 hme-miR-745; +MIMAT0024987 hme-miR-79; +MIMAT0024988 hme-miR-8; +MIMAT0024989 hme-miR-87; +MIMAT0024990 hme-miR-927; +MIMAT0024991 hme-miR-928; +MIMAT0024992 hme-miR-929; +MIMAT0024993 hme-miR-92a; +MIMAT0024994 hme-miR-92b; +MIMAT0024995 hme-miR-932; +MIMAT0024996 hme-miR-965; +MIMAT0024997 hme-miR-970; +MIMAT0024998 hme-miR-971; +MIMAT0024999 hme-miR-981; +MIMAT0025000 hme-miR-993; +MIMAT0025001 hme-miR-998; +MIMAT0025002 hme-miR-9b; +MIMAT0025003 hme-miR-9a; +MIMAT0025004 hme-miR-6301-1-5p; +MIMAT0025005 hme-miR-6301-3p; +MIMAT0025006 hme-miR-6302-1-5p; +MIMAT0025007 hme-miR-6302-3p; +MIMAT0025008 hme-miR-6303-5p; +MIMAT0025009 hme-miR-6304-3p; +MIMAT0025010 hme-miR-6305-5p; +MIMAT0025011 hme-miR-6305-3p; +MIMAT0025012 hme-miR-6306-5p; +MIMAT0025013 hme-miR-6306-3p; +MIMAT0025014 hme-miR-6307-3p; +MIMAT0025015 hme-miR-6308-3p; +MIMAT0025016 hme-miR-6309-3p; +MIMAT0025017 hme-miR-6310-3p; +MIMAT0025018 hme-miR-6311-3p; +MIMAT0025019 hme-miR-6312-5p; +MIMAT0025020 hme-miR-6312-3p; +MIMAT0025021 meu-miR-6313; +MIMAT0025022 hsv1-miR-H26; +MIMAT0025023 sma-miR-10-5p; +MIMAT0025024 sma-miR-10-3p; +MIMAT0025025 sma-miR-124-5p;sma-miR-124a-5p; +MIMAT0025026 sma-miR-124-3p;sma-miR-124a-3p; +MIMAT0025027 sma-miR-190-5p; +MIMAT0025028 sma-miR-190-3p; +MIMAT0025029 sma-miR-2a-5p; +MIMAT0025030 sma-miR-2a-3p; +MIMAT0025031 sma-miR-2b-5p; +MIMAT0025032 sma-miR-2b-3p; +MIMAT0025033 sma-miR-2c-5p; +MIMAT0025034 sma-miR-2c-3p; +MIMAT0025035 sma-miR-2d-3p; +MIMAT0025036 sma-miR-2e-5p; +MIMAT0025037 sma-miR-2e-3p; +MIMAT0025038 sma-miR-31-5p; +MIMAT0025039 sma-miR-3479-3p; +MIMAT0025040 sma-miR-3492; +MIMAT0025041 sma-miR-36-3p;sma-miR-36a-3p; +MIMAT0025042 sma-miR-61;sma-miR-61-3p; +MIMAT0025043 sma-miR-71b-5p; +MIMAT0025044 sma-miR-71b-3p; +MIMAT0025045 sma-miR-8-5p; +MIMAT0025046 sma-miR-8-3p; +MIMAT0025047 rno-miR-6314; +MIMAT0025048 rno-miR-3099; +MIMAT0025049 rno-miR-344i; +MIMAT0025050 rno-miR-6315; +MIMAT0025051 rno-miR-3102; +MIMAT0025052 rno-miR-344g; +MIMAT0025053 rno-miR-6316; +MIMAT0025054 rno-miR-6317; +MIMAT0025055 rno-miR-6318; +MIMAT0025056 rno-miR-6319; +MIMAT0025057 rno-miR-3075; +MIMAT0025058 rno-miR-6320; +MIMAT0025059 rno-miR-6321; +MIMAT0025060 rno-miR-1298; +MIMAT0025061 rno-miR-6322; +MIMAT0025062 rno-miR-6323; +MIMAT0025063 rno-miR-6324; +MIMAT0025064 rno-miR-6325; +MIMAT0025065 rno-miR-6326; +MIMAT0025066 rno-miR-6327; +MIMAT0025067 rno-miR-6328; +MIMAT0025068 rno-miR-6329; +MIMAT0025069 rno-miR-6330; +MIMAT0025070 rno-miR-6331; +MIMAT0025071 rno-miR-3072; +MIMAT0025072 rno-miR-679; +MIMAT0025073 rno-miR-6332; +MIMAT0025074 rno-miR-6333; +MIMAT0025075 rno-miR-6334; +MIMAT0025076 mmu-miR-195b; +MIMAT0025077 mmu-miR-6335; +MIMAT0025078 mmu-miR-133c; +MIMAT0025079 mmu-miR-6336; +MIMAT0025080 mmu-miR-6337; +MIMAT0025081 mmu-miR-6338; +MIMAT0025082 mmu-miR-6339; +MIMAT0025083 mmu-miR-6340; +MIMAT0025084 mmu-miR-6341; +MIMAT0025085 mmu-miR-6342; +MIMAT0025086 mmu-miR-6343; +MIMAT0025087 mmu-miR-6344; +MIMAT0025088 mmu-miR-6345; +MIMAT0025089 mmu-miR-6346; +MIMAT0025090 mmu-miR-6347; +MIMAT0025091 mmu-miR-6348; +MIMAT0025092 mmu-miR-6349; +MIMAT0025093 mmu-miR-6350; +MIMAT0025094 mmu-miR-6351; +MIMAT0025095 mmu-miR-6352; +MIMAT0025096 mmu-miR-6353; +MIMAT0025097 mmu-miR-6354; +MIMAT0025098 mmu-miR-6355; +MIMAT0025099 mmu-miR-6356; +MIMAT0025100 mmu-miR-6357; +MIMAT0025101 mmu-miR-6358; +MIMAT0025102 mmu-miR-6359; +MIMAT0025103 mmu-miR-6360; +MIMAT0025104 mmu-miR-6361; +MIMAT0025105 mmu-miR-145b; +MIMAT0025106 mmu-miR-6362; +MIMAT0025107 mmu-miR-6363; +MIMAT0025108 mmu-miR-6364; +MIMAT0025109 mmu-miR-6365; +MIMAT0025110 mmu-miR-6366; +MIMAT0025111 mmu-miR-6367; +MIMAT0025112 mmu-miR-6368; +MIMAT0025113 mmu-miR-6369; +MIMAT0025114 mmu-miR-6370; +MIMAT0025115 mmu-miR-6371; +MIMAT0025116 mmu-miR-6372; +MIMAT0025117 mmu-miR-6373; +MIMAT0025118 mmu-miR-6374; +MIMAT0025119 mmu-miR-6375; +MIMAT0025120 mmu-miR-6376; +MIMAT0025121 mmu-miR-21b; +MIMAT0025122 mmu-miR-6377; +MIMAT0025123 mmu-let-7j; +MIMAT0025124 mmu-miR-6378; +MIMAT0025125 mmu-miR-6379; +MIMAT0025126 mmu-miR-6380; +MIMAT0025127 mmu-miR-6381; +MIMAT0025128 mmu-miR-6382; +MIMAT0025129 mmu-miR-6383; +MIMAT0025130 mmu-miR-6384; +MIMAT0025131 mmu-miR-6385; +MIMAT0025132 mmu-miR-130c; +MIMAT0025133 mmu-miR-6386; +MIMAT0025134 mmu-miR-6387; +MIMAT0025135 mmu-miR-6388; +MIMAT0025136 mmu-miR-5124b; +MIMAT0025137 mmu-miR-6389; +MIMAT0025138 mmu-miR-378c; +MIMAT0025139 mmu-miR-6390; +MIMAT0025140 mmu-miR-6391; +MIMAT0025141 mmu-miR-6392-5p; +MIMAT0025142 mmu-miR-6392-3p; +MIMAT0025143 mmu-miR-6393; +MIMAT0025144 mmu-miR-6394; +MIMAT0025145 mmu-miR-1957b; +MIMAT0025146 mmu-miR-6395; +MIMAT0025147 mmu-miR-6396; +MIMAT0025148 mmu-miR-21c; +MIMAT0025149 mmu-miR-6397; +MIMAT0025150 mmu-miR-6398; +MIMAT0025151 mmu-miR-6399; +MIMAT0025152 mmu-miR-6400; +MIMAT0025153 mmu-miR-6401; +MIMAT0025154 mmu-miR-6402; +MIMAT0025155 mmu-miR-6403; +MIMAT0025156 mmu-miR-6404; +MIMAT0025157 mmu-miR-6405; +MIMAT0025158 mmu-miR-496b; +MIMAT0025159 mmu-miR-6406; +MIMAT0025160 mmu-miR-6407; +MIMAT0025161 mmu-miR-6408; +MIMAT0025162 mmu-miR-6409; +MIMAT0025163 mmu-miR-6410; +MIMAT0025164 mmu-miR-6411; +MIMAT0025165 mmu-miR-6412; +MIMAT0025166 mmu-miR-6413; +MIMAT0025167 mmu-miR-378d; +MIMAT0025168 mmu-miR-6414; +MIMAT0025169 mmu-miR-6415; +MIMAT0025170 mmu-miR-6416-5p; +MIMAT0025171 mmu-miR-6416-3p; +MIMAT0025172 mmu-miR-6417; +MIMAT0025173 mmu-miR-6418-5p; +MIMAT0025174 mmu-miR-6418-3p; +MIMAT0025175 mmu-miR-6419; +MIMAT0025176 mmu-miR-6420; +MIMAT0025177 mmu-miR-873b; +MIMAT0025178 mmu-miR-451b; +MIMAT0025179 mmu-miR-30f; +MIMAT0025180 ptc-miR6421-5p; +MIMAT0025181 ptc-miR6421-3p; +MIMAT0025182 ptc-miR6458; +MIMAT0025183 ptc-miR6440b; +MIMAT0025184 ptc-miR6459-5p;ptc-miR6459a-5p; +MIMAT0025185 ptc-miR6459-3p;ptc-miR6459a-3p; +MIMAT0025186 ptc-miR6460; +MIMAT0025187 ptc-miR6461; +MIMAT0025188 ptc-miR6462a; +MIMAT0025189 ptc-miR6463; +MIMAT0025190 ptc-miR6425a-5p; +MIMAT0025191 ptc-miR6425a-3p; +MIMAT0025192 ptc-miR6464; +MIMAT0025193 ptc-miR6465; +MIMAT0025194 ptc-miR6466-5p; +MIMAT0025195 ptc-miR6466-3p; +MIMAT0025196 ptc-miR6467; +MIMAT0025197 ptc-miR6438b; +MIMAT0025198 ptc-miR6425b-5p; +MIMAT0025199 ptc-miR6425b-3p; +MIMAT0025200 ptc-miR6440c; +MIMAT0025201 ptc-miR6468;ptc-miR6468-3p; +MIMAT0025202 ptc-miR6469; +MIMAT0025203 ptc-miR6457b; +MIMAT0025204 ptc-miR6462b; +MIMAT0025205 ptc-miR6462c-5p; +MIMAT0025206 ptc-miR6462c-3p; +MIMAT0025207 ptc-miR6425c-5p; +MIMAT0025208 ptc-miR6425c-3p; +MIMAT0025209 ptc-miR6470; +MIMAT0025210 ptc-miR6471; +MIMAT0025211 ptc-miR6472; +MIMAT0025212 ptc-miR6473; +MIMAT0025213 ptc-miR6474; +MIMAT0025214 ptc-miR6425d-5p; +MIMAT0025215 ptc-miR6425d-3p; +MIMAT0025216 ptc-miR6475; +MIMAT0025217 ptc-miR6476;ptc-miR6476a; +MIMAT0025218 ptc-miR6477; +MIMAT0025219 ptc-miR6425e; +MIMAT0025220 ptc-miR6478; +MIMAT0025221 ptc-miR6426a; +MIMAT0025222 ptc-miR6479; +MIMAT0025223 ptc-miR6480; +MIMAT0025224 ptc-miR6462d; +MIMAT0025225 ptc-miR6437b; +MIMAT0025226 ptc-miR6440d; +MIMAT0025227 ptc-miR6427-5p; +MIMAT0025228 ptc-miR6427-3p; +MIMAT0025229 ptc-miR6428; +MIMAT0025230 ptc-miR6429; +MIMAT0025231 ptc-miR6430; +MIMAT0025232 ptc-miR6431; +MIMAT0025233 ptc-miR6432; +MIMAT0025234 ptc-miR6433-5p;ptc-miR482d-5p; +MIMAT0025235 ptc-miR6433-3p;ptc-miR482d-3p; +MIMAT0025236 ptc-miR6422; +MIMAT0025237 ptc-miR6434; +MIMAT0025238 ptc-miR6435; +MIMAT0025239 ptc-miR6436; +MIMAT0025240 ptc-miR6437a; +MIMAT0025241 ptc-miR6438a; +MIMAT0025242 ptc-miR6439a; +MIMAT0025243 ptc-miR6440a; +MIMAT0025244 ptc-miR6441; +MIMAT0025245 ptc-miR6442; +MIMAT0025246 ptc-miR6443; +MIMAT0025247 ptc-miR6444; +MIMAT0025248 ptc-miR6445a; +MIMAT0025249 ptc-miR6446; +MIMAT0025250 ptc-miR6447; +MIMAT0025251 ptc-miR6448; +MIMAT0025252 ptc-miR6423; +MIMAT0025253 ptc-miR6449; +MIMAT0025254 ptc-miR6450a; +MIMAT0025255 ptc-miR6451; +MIMAT0025256 ptc-miR6445b; +MIMAT0025257 ptc-miR477c; +MIMAT0025258 ptc-miR6439b; +MIMAT0025259 ptc-miR6426b; +MIMAT0025260 ptc-miR6424;ptc-miR536; +MIMAT0025261 ptc-miR6450b; +MIMAT0025262 ptc-miR6452; +MIMAT0025263 ptc-miR6453;ptc-miR3627a; +MIMAT0025264 ptc-miR6454; +MIMAT0025265 ptc-miR6455; +MIMAT0025266 ptc-miR6456; +MIMAT0025267 ptc-miR6457a; +MIMAT0025268 ptc-miR156l; +MIMAT0025269 ptc-miR169ag; +MIMAT0025270 ptc-miR2111a; +MIMAT0025271 ptc-miR482b;ptc-miR482b-3p; +MIMAT0025272 ptc-miR2111b; +MIMAT0025273 ptc-miR395k; +MIMAT0025274 ptc-miR403d-5p; +MIMAT0025275 ptc-miR477d-5p; +MIMAT0025276 ptc-miR477d-3p; +MIMAT0025277 ptc-miR482c-5p; +MIMAT0025278 ptc-miR482c-3p; +MIMAT0025279 ptc-miR828a; +MIMAT0025280 ptc-miR828b-5p; +MIMAT0025281 ptc-miR828b-3p; +MIMAT0025282 hbr-miR156; +MIMAT0025283 hbr-miR159a; +MIMAT0025284 hbr-miR166a; +MIMAT0025285 hbr-miR166b; +MIMAT0025286 hbr-miR319; +MIMAT0025287 hbr-miR396b; +MIMAT0025288 hbr-miR408a; +MIMAT0025289 hbr-miR408b; +MIMAT0025290 hbr-miR476; +MIMAT0025291 hbr-miR6482; +MIMAT0025292 hbr-miR6483; +MIMAT0025293 hbr-miR6484; +MIMAT0025294 hbr-miR159b; +MIMAT0025295 hbr-miR6485; +MIMAT0025296 mja-miR-6489-5p; +MIMAT0025297 mja-miR-6489-3p; +MIMAT0025298 mja-miR-6490; +MIMAT0025299 mja-miR-6491; +MIMAT0025300 mja-miR-6492; +MIMAT0025301 mja-miR-6493-5p; +MIMAT0025302 mja-miR-6493-3p; +MIMAT0025303 mja-miR-6494; +MIMAT0025304 prv-miR-LLT1; +MIMAT0025305 prv-miR-LLT2; +MIMAT0025306 prv-miR-LLT3; +MIMAT0025307 prv-miR-LLT4; +MIMAT0025308 prv-miR-LLT5; +MIMAT0025309 prv-miR-LLT6; +MIMAT0025310 prv-miR-LLT7;prv-miR-LLT7-5p; +MIMAT0025311 prv-miR-LLT8;prv-miR-LLT8-5p; +MIMAT0025312 prv-miR-LLT9; +MIMAT0025313 prv-miR-LLT10a; +MIMAT0025314 prv-miR-LLT10b; +MIMAT0025315 prv-miR-LLT11a;prv-miR-LLT11a-5p; +MIMAT0025316 prv-miR-LLT11b;prv-miR-LLT11b-5p; +MIMAT0025317 bmo-miR-6495-5p; +MIMAT0025318 bmo-miR-6495-3p; +MIMAT0025319 bmo-miR-6496-5p; +MIMAT0025320 bmo-miR-6496-3p; +MIMAT0025321 bmo-miR-6497-5p; +MIMAT0025322 bmo-miR-6497-3p; +MIMAT0025323 bmo-miR-6498-5p; +MIMAT0025324 bmo-miR-6498-3p; +MIMAT0025325 pde-miR159; +MIMAT0025326 pde-miR162; +MIMAT0025327 pde-miR166a; +MIMAT0025328 pde-miR166b; +MIMAT0025329 pde-miR169; +MIMAT0025330 pde-miR171; +MIMAT0025331 pde-miR390; +MIMAT0025332 pde-miR396; +MIMAT0025333 pde-miR482a; +MIMAT0025334 pde-miR482b; +MIMAT0025335 pde-miR482c; +MIMAT0025336 pde-miR482d; +MIMAT0025337 pde-miR783; +MIMAT0025338 pde-miR946; +MIMAT0025339 pde-miR947; +MIMAT0025340 pde-miR949a; +MIMAT0025341 pde-miR949b; +MIMAT0025342 pde-miR950; +MIMAT0025343 pde-miR951; +MIMAT0025344 pde-miR952a; +MIMAT0025345 pde-miR952b; +MIMAT0025346 pde-miR952c; +MIMAT0025347 pde-miR1310; +MIMAT0025348 pde-miR1311; +MIMAT0025349 pde-miR1312; +MIMAT0025350 pde-miR1313; +MIMAT0025351 pde-miR1314; +MIMAT0025352 pde-miR3701; +MIMAT0025353 pde-miR3704a; +MIMAT0025354 pde-miR3704b; +MIMAT0025355 pde-miR3712; +MIMAT0025356 ssc-let-7d-5p; +MIMAT0025357 ssc-let-7d-3p; +MIMAT0025358 ssc-miR-9; +MIMAT0025359 ssc-miR-20b; +MIMAT0025360 ssc-miR-31; +MIMAT0025361 ssc-miR-132; +MIMAT0025362 ssc-miR-137; +MIMAT0025363 ssc-miR-138; +MIMAT0025364 ssc-miR-144; +MIMAT0025365 ssc-miR-150; +MIMAT0025366 ssc-miR-182; +MIMAT0025367 ssc-miR-190a; +MIMAT0025368 ssc-miR-194a;ssc-miR-194a-5p; +MIMAT0025369 ssc-miR-196b; +MIMAT0025370 ssc-miR-212; +MIMAT0025371 ssc-miR-218; +MIMAT0025372 ssc-miR-339; +MIMAT0025373 ssc-miR-370; +MIMAT0025374 ssc-miR-452; +MIMAT0025375 ssc-miR-489; +MIMAT0025376 ssc-miR-490; +MIMAT0025377 ssc-miR-493-5p; +MIMAT0025378 ssc-miR-493-3p; +MIMAT0025379 ssc-miR-551a; +MIMAT0025380 ssc-miR-582;ssc-miR-582-3p; +MIMAT0025381 ssc-miR-671-5p; +MIMAT0025382 ssc-miR-671-3p; +MIMAT0025384 ssc-miR-874; +MIMAT0025385 ssc-miR-1249; +MIMAT0025386 ssc-miR-1468; +MIMAT0025387 ssc-miR-3613; +MIMAT0025388 ssc-miR-2366; +MIMAT0025389 ssc-miR-2411; +MIMAT0025390 ssc-miR-2483; +MIMAT0025391 bfl-miR-153; +MIMAT0025392 xtr-miR-190; +MIMAT0025393 tgu-miR-183; +MIMAT0025394 tgu-miR-196; +MIMAT0025395 tgu-miR-367; +MIMAT0025396 tgu-miR-499;tgu-miR-499-5p; +MIMAT0025397 tgu-miR-1397;tgu-miR-1397-5p; +MIMAT0025398 tgu-miR-1460; +MIMAT0025399 tgu-miR-1467;tgu-miR-1467-5p; +MIMAT0025400 tgu-miR-1641; +MIMAT0025401 tgu-miR-1669; +MIMAT0025402 tgu-miR-1743; +MIMAT0025403 tgu-miR-1744; +MIMAT0025404 tgu-mit-1756;tgu-miR-1756; +MIMAT0025405 tgu-miR-1759; +MIMAT0025406 tgu-miR-1781; +MIMAT0025407 tgu-miR-1788; +MIMAT0025408 tgu-miR-1789; +MIMAT0025409 tgu-miR-1791; +MIMAT0025410 tgu-miR-2131; +MIMAT0025411 tgu-miR-30e; +MIMAT0025412 pol-miR-1-5p; +MIMAT0025413 pol-miR-1-3p; +MIMAT0025414 pol-let-7b-5p; +MIMAT0025415 pol-let-7b-3p; +MIMAT0025416 pol-let-7a-5p; +MIMAT0025417 pol-let-7a-3p; +MIMAT0025418 pol-let-7d-5p; +MIMAT0025419 pol-let-7d-3p; +MIMAT0025420 pol-miR-9b-5p; +MIMAT0025421 pol-miR-9b-3p; +MIMAT0025422 pol-miR-10b-5p; +MIMAT0025423 pol-miR-10b-3p; +MIMAT0025424 pol-miR-21-5p; +MIMAT0025425 pol-miR-21-3p; +MIMAT0025426 pol-miR-22-5p; +MIMAT0025427 pol-miR-22-3p; +MIMAT0025428 pol-miR-122-5p; +MIMAT0025429 pol-miR-122-3p; +MIMAT0025430 pol-miR-124-5p; +MIMAT0025431 pol-miR-124-3p; +MIMAT0025432 pol-miR-133-5p; +MIMAT0025433 pol-miR-133-3p; +MIMAT0025434 pol-miR-140-5p; +MIMAT0025435 pol-miR-140-3p; +MIMAT0025436 pol-miR-144-5p; +MIMAT0025437 pol-miR-144-3p; +MIMAT0025438 pol-miR-182-5p; +MIMAT0025439 pol-miR-182-3p; +MIMAT0025440 pol-miR-199a-5p; +MIMAT0025441 pol-miR-199a-3p; +MIMAT0025442 pol-miR-203-5p; +MIMAT0025443 pol-miR-203-3p; +MIMAT0025444 pol-miR-206-5p; +MIMAT0025445 pol-miR-206-3p; +MIMAT0025446 pol-miR-219-5p; +MIMAT0025447 pol-miR-219-3p; +MIMAT0025448 pol-miR-221-5p; +MIMAT0025449 pol-miR-221-3p; +MIMAT0025450 hsa-miR-6499-5p; +MIMAT0025451 hsa-miR-6499-3p; +MIMAT0025452 hsa-miR-548ay-5p; +MIMAT0025453 hsa-miR-548ay-3p; +MIMAT0025454 hsa-miR-6500-5p; +MIMAT0025455 hsa-miR-6500-3p; +MIMAT0025456 hsa-miR-548az-5p; +MIMAT0025457 hsa-miR-548az-3p; +MIMAT0025458 hsa-miR-6501-5p; +MIMAT0025459 hsa-miR-6501-3p; +MIMAT0025460 hsa-miR-6502-5p; +MIMAT0025461 hsa-miR-6502-3p; +MIMAT0025462 hsa-miR-6503-5p; +MIMAT0025463 hsa-miR-6503-3p; +MIMAT0025464 hsa-miR-6504-5p; +MIMAT0025465 hsa-miR-6504-3p; +MIMAT0025466 hsa-miR-6505-5p; +MIMAT0025467 hsa-miR-6505-3p; +MIMAT0025468 hsa-miR-6506-5p; +MIMAT0025469 hsa-miR-6506-3p; +MIMAT0025470 hsa-miR-6507-5p; +MIMAT0025471 hsa-miR-6507-3p; +MIMAT0025472 hsa-miR-6508-5p; +MIMAT0025473 hsa-miR-6508-3p; +MIMAT0025474 hsa-miR-6509-5p; +MIMAT0025475 hsa-miR-6509-3p; +MIMAT0025476 hsa-miR-6510-5p; +MIMAT0025477 hsa-miR-6510-3p; +MIMAT0025478 hsa-miR-6511a-5p; +MIMAT0025479 hsa-miR-6511a-3p; +MIMAT0025480 hsa-miR-6512-5p; +MIMAT0025481 hsa-miR-6512-3p; +MIMAT0025482 hsa-miR-6513-5p; +MIMAT0025483 hsa-miR-6513-3p; +MIMAT0025484 hsa-miR-6514-5p; +MIMAT0025485 hsa-miR-6514-3p; +MIMAT0025486 hsa-miR-6515-5p; +MIMAT0025487 hsa-miR-6515-3p; +MIMAT0025488 han-miR156a; +MIMAT0025489 han-miR156b; +MIMAT0025490 hci-miR156a; +MIMAT0025491 hci-miR156b; +MIMAT0025492 htu-miR156a; +MIMAT0025493 har-miR156a; +MIMAT0025494 hpa-miR156a; +MIMAT0025495 har-miR156c; +MIMAT0025496 han-miR156c; +MIMAT0025497 htu-miR159a; +MIMAT0025498 han-miR160a; +MIMAT0025499 htu-miR160a; +MIMAT0025500 htu-miR162a; +MIMAT0025501 hpe-miR162a; +MIMAT0025502 hci-miR164a; +MIMAT0025503 hpa-miR166a; +MIMAT0025504 hpe-miR166a; +MIMAT0025505 hpa-miR171a; +MIMAT0025506 htu-miR171a; +MIMAT0025507 htu-miR171b; +MIMAT0025508 htu-miR171c; +MIMAT0025509 hex-miR390a; +MIMAT0025510 hex-miR390b; +MIMAT0025511 htu-miR393a; +MIMAT0025512 htu-miR393b; +MIMAT0025513 htu-miR393c; +MIMAT0025514 htu-miR403a; +MIMAT0025515 htu-miR403b; +MIMAT0025516 htu-miR403c; +MIMAT0025517 htu-miR403d; +MIMAT0025518 htu-miR403e; +MIMAT0025519 har-miR403a; +MIMAT0025520 hpe-miR403a; +MIMAT0025521 htu-miR530; +MIMAT0025522 han-miR1310; +MIMAT0025523 han-miR2911; +MIMAT0025524 han-miR3440; +MIMAT0025525 han-miR3630-5p; +MIMAT0025526 han-miR3630-3p; +MIMAT0025527 hhi-miR-147b; +MIMAT0025528 bta-miR-6517; +MIMAT0025529 bta-miR-3154; +MIMAT0025530 bta-miR-2285o; +MIMAT0025531 bta-miR-2285n; +MIMAT0025532 bta-miR-2285p; +MIMAT0025533 bta-miR-2285m; +MIMAT0025535 bta-miR-378b; +MIMAT0025536 bta-miR-6518; +MIMAT0025537 bta-miR-6519; +MIMAT0025538 bta-miR-6520; +MIMAT0025539 bta-miR-6521; +MIMAT0025540 bta-miR-6522; +MIMAT0025541 bta-miR-411b; +MIMAT0025542 bta-miR-154c; +MIMAT0025543 bta-miR-376e; +MIMAT0025544 bta-miR-3956; +MIMAT0025545 bta-miR-411c-5p; +MIMAT0025546 bta-miR-411c-3p; +MIMAT0025547 bta-miR-154b; +MIMAT0025548 bta-miR-3957; +MIMAT0025549 bta-miR-1247-5p; +MIMAT0025550 bta-miR-1247-3p; +MIMAT0025551 bta-miR-378c; +MIMAT0025552 bta-miR-6523;bta-miR-6523a; +MIMAT0025553 bta-miR-6524; +MIMAT0025554 bta-miR-6525; +MIMAT0025555 bta-miR-3660; +MIMAT0025556 bta-miR-6526; +MIMAT0025557 bta-miR-503-5p; +MIMAT0025558 bta-miR-503-3p; +MIMAT0025559 bta-miR-2284z; +MIMAT0025560 bta-miR-2284aa-1;bta-miR-2284aa; +MIMAT0025561 bta-miR-6527; +MIMAT0025562 bta-miR-6528; +MIMAT0025563 bta-miR-2284aa-2; +MIMAT0025564 bta-miR-2284aa-3; +MIMAT0025565 bta-miR-6529;bta-miR-6529a; +MIMAT0025566 bta-miR-6530; +MIMAT0025567 bta-miR-6531; +MIMAT0025568 bta-miR-6532; +MIMAT0025569 bta-miR-6533; +MIMAT0025570 bta-miR-6534; +MIMAT0025571 bta-miR-6535; +MIMAT0025572 bta-miR-6536; +MIMAT0025573 bta-miR-2284aa-4; +MIMAT0025574 bta-miR-2285q; +MIMAT0025575 bta-miR-2285r; +MIMAT0025576 bta-miR-2285s; +MIMAT0025577 bta-miR-2285t; +MIMAT0025578 bta-miR-2285u; +MIMAT0025579 bta-miR-2285v; +MIMAT0025580 mmu-let-7k; +MIMAT0025581 mmu-miR-6537-5p; +MIMAT0025582 mmu-miR-6537-3p; +MIMAT0025583 mmu-miR-6538; +MIMAT0025584 mmu-miR-6539; +MIMAT0025585 mmu-miR-6540-5p; +MIMAT0025586 mmu-miR-6540-3p; +MIMAT0025587 mmu-miR-3473e; +MIMAT0025588 mmu-miR-6541; +MIMAT0025589 gga-miR-6542-5p; +MIMAT0025590 gga-miR-6542-3p; +MIMAT0025591 gga-miR-6544-5p; +MIMAT0025592 gga-miR-6544-3p; +MIMAT0025593 gga-miR-6545-5p; +MIMAT0025594 gga-miR-6545-3p; +MIMAT0025595 gga-miR-6546-5p; +MIMAT0025596 gga-miR-6546-3p; +MIMAT0025597 gga-miR-6547-5p; +MIMAT0025598 gga-miR-6547-3p; +MIMAT0025599 gga-miR-124c-5p; +MIMAT0025600 gga-miR-124c-3p; +MIMAT0025601 gga-miR-6548-5p; +MIMAT0025602 gga-miR-6548-3p; +MIMAT0025603 gga-miR-6549-5p; +MIMAT0025604 gga-miR-6549-3p; +MIMAT0025605 gga-miR-6550-5p; +MIMAT0025606 gga-miR-6550-3p; +MIMAT0025607 gga-miR-3607-5p; +MIMAT0025608 gga-miR-3607-3p; +MIMAT0025609 gga-miR-6551-5p; +MIMAT0025610 gga-miR-6551-3p; +MIMAT0025611 gga-miR-6552-5p; +MIMAT0025612 gga-miR-6552-3p; +MIMAT0025613 gga-miR-6553-5p; +MIMAT0025614 gga-miR-6553-3p; +MIMAT0025615 gga-miR-6554-5p; +MIMAT0025616 gga-miR-6554-3p; +MIMAT0025617 gga-miR-222b-5p; +MIMAT0025618 gga-miR-222b-3p; +MIMAT0025619 gga-miR-6555-5p; +MIMAT0025620 gga-miR-6555-3p; +MIMAT0025621 gga-miR-6556-5p; +MIMAT0025622 gga-miR-6556-3p; +MIMAT0025623 gga-miR-6558-5p; +MIMAT0025624 gga-miR-6558-3p; +MIMAT0025625 gga-miR-6559-5p; +MIMAT0025626 gga-miR-6559-3p; +MIMAT0025627 gga-miR-6560-5p; +MIMAT0025628 gga-miR-6560-3p; +MIMAT0025629 gga-miR-6561-5p; +MIMAT0025630 gga-miR-6561-3p; +MIMAT0025631 gga-miR-3064-5p; +MIMAT0025632 gga-miR-3064-3p; +MIMAT0025633 gga-miR-6564-5p; +MIMAT0025634 gga-miR-6564-3p; +MIMAT0025635 gga-miR-6565-5p; +MIMAT0025636 gga-miR-6565-3p; +MIMAT0025637 gga-miR-6566-5p; +MIMAT0025638 gga-miR-6566-3p; +MIMAT0025639 gga-miR-6567-5p; +MIMAT0025640 gga-miR-6567-3p; +MIMAT0025641 gga-miR-3594-5p; +MIMAT0025642 gga-miR-3594-3p; +MIMAT0025643 gga-miR-6568-5p; +MIMAT0025644 gga-miR-6568-3p; +MIMAT0025645 gga-miR-6569-5p; +MIMAT0025646 gga-miR-6569-3p; +MIMAT0025647 gga-miR-6570-5p; +MIMAT0025648 gga-miR-6570-3p; +MIMAT0025649 gga-miR-6571-5p; +MIMAT0025650 gga-miR-6571-3p; +MIMAT0025651 gga-miR-6572-5p; +MIMAT0025652 gga-miR-6572-3p; +MIMAT0025653 gga-miR-6573-5p; +MIMAT0025654 gga-miR-6573-3p; +MIMAT0025655 gga-miR-6574-5p; +MIMAT0025656 gga-miR-6574-3p; +MIMAT0025657 gga-miR-6575-5p; +MIMAT0025658 gga-miR-6575-3p; +MIMAT0025659 gga-miR-6576-5p; +MIMAT0025660 gga-miR-6576-3p; +MIMAT0025661 gga-miR-6577-5p; +MIMAT0025662 gga-miR-6577-3p; +MIMAT0025663 gga-miR-6578-5p; +MIMAT0025664 gga-miR-6578-3p; +MIMAT0025665 gga-miR-6579-5p; +MIMAT0025666 gga-miR-6579-3p; +MIMAT0025667 gga-miR-6580-5p; +MIMAT0025668 gga-miR-6580-3p; +MIMAT0025669 gga-miR-6581-5p; +MIMAT0025670 gga-miR-6581-3p; +MIMAT0025671 gga-miR-6582-5p; +MIMAT0025672 gga-miR-6582-3p; +MIMAT0025673 gga-miR-6583-5p; +MIMAT0025674 gga-miR-365b-5p; +MIMAT0025675 gga-miR-6584-5p; +MIMAT0025676 gga-miR-6585-5p; +MIMAT0025677 gga-miR-6586-5p; +MIMAT0025678 gga-miR-6587-5p; +MIMAT0025679 gga-miR-6587-3p; +MIMAT0025680 gga-miR-6588-3p; +MIMAT0025681 gga-miR-6589-5p; +MIMAT0025682 gga-miR-6590-5p; +MIMAT0025683 gga-miR-6590-3p; +MIMAT0025684 gga-miR-6591-3p; +MIMAT0025685 gga-miR-6592-3p; +MIMAT0025686 gga-miR-6593-5p; +MIMAT0025687 gga-miR-6593-3p; +MIMAT0025688 gga-miR-6594-5p; +MIMAT0025689 gga-miR-6595-5p; +MIMAT0025690 gga-miR-6596-5p; +MIMAT0025691 gga-miR-6596-3p; +MIMAT0025692 gga-miR-6597-3p; +MIMAT0025693 gga-miR-6598-5p; +MIMAT0025694 gga-miR-6600-3p; +MIMAT0025695 gga-miR-6601-3p; +MIMAT0025696 gga-miR-6602-5p; +MIMAT0025697 gga-miR-6603-3p; +MIMAT0025698 gga-miR-6604-5p; +MIMAT0025699 gga-miR-6605-5p; +MIMAT0025700 gga-miR-6606-5p; +MIMAT0025701 gga-miR-6607-5p; +MIMAT0025702 gga-miR-6608-5p; +MIMAT0025703 gga-miR-6608-3p; +MIMAT0025704 gga-miR-6609-3p; +MIMAT0025705 gga-miR-6610-3p; +MIMAT0025706 gga-miR-6611-5p; +MIMAT0025707 gga-miR-6612-5p; +MIMAT0025708 gga-miR-6613-3p; +MIMAT0025709 gga-miR-6614-3p; +MIMAT0025710 gga-miR-6615-5p; +MIMAT0025711 gga-miR-6615-3p; +MIMAT0025712 gga-miR-6616-5p; +MIMAT0025713 gga-miR-6617-3p; +MIMAT0025714 gga-miR-6618-5p; +MIMAT0025715 gga-miR-6619-5p; +MIMAT0025716 gga-miR-6620-5p; +MIMAT0025717 gga-miR-4732-5p; +MIMAT0025718 gga-miR-6621-5p; +MIMAT0025719 gga-miR-6623-3p; +MIMAT0025720 gga-miR-6624-3p; +MIMAT0025721 gga-miR-6625-5p; +MIMAT0025722 gga-miR-6626-5p; +MIMAT0025723 gga-miR-6627-3p; +MIMAT0025724 gga-miR-6628-3p; +MIMAT0025725 gga-miR-6629-5p; +MIMAT0025726 gga-miR-6630-3p; +MIMAT0025727 gga-miR-6631-5p; +MIMAT0025728 gga-miR-6632-5p; +MIMAT0025729 gga-miR-6633-5p; +MIMAT0025730 gga-miR-6634-5p; +MIMAT0025731 gga-miR-6635-5p; +MIMAT0025733 gga-miR-6637-3p; +MIMAT0025735 gga-miR-6639-5p; +MIMAT0025736 gga-miR-6640-5p; +MIMAT0025737 gga-miR-6641-5p; +MIMAT0025738 gga-miR-6641-3p; +MIMAT0025739 gga-miR-6642-5p; +MIMAT0025740 gga-miR-6642-3p; +MIMAT0025741 gga-miR-6643-5p; +MIMAT0025742 gga-miR-6645-5p; +MIMAT0025743 gga-miR-6646-3p; +MIMAT0025744 gga-miR-6647-5p; +MIMAT0025745 gga-miR-6644-3p; +MIMAT0025746 gga-miR-6648-5p; +MIMAT0025747 gga-miR-6648-3p; +MIMAT0025748 gga-miR-6649-5p; +MIMAT0025749 gga-miR-6649-3p; +MIMAT0025750 gga-miR-6650-5p; +MIMAT0025751 gga-miR-6651-5p; +MIMAT0025752 gga-miR-6652-5p; +MIMAT0025753 gga-miR-3524b-3p; +MIMAT0025754 gga-miR-6653-3p; +MIMAT0025755 gga-miR-6654-3p; +MIMAT0025756 gga-miR-6655-5p; +MIMAT0025757 gga-miR-6656-5p; +MIMAT0025758 gga-miR-6657-3p; +MIMAT0025759 gga-miR-6658-3p; +MIMAT0025760 gga-miR-6659-3p; +MIMAT0025761 gga-miR-6660-3p; +MIMAT0025762 gga-miR-6661-5p; +MIMAT0025763 gga-miR-6662-3p; +MIMAT0025764 gga-miR-6663-5p; +MIMAT0025765 gga-miR-6664-3p; +MIMAT0025766 gga-miR-6665-5p; +MIMAT0025767 gga-miR-6666-3p; +MIMAT0025768 gga-miR-6667-5p; +MIMAT0025769 gga-miR-6668-3p; +MIMAT0025770 gga-miR-6669-5p; +MIMAT0025771 gga-miR-6669-3p; +MIMAT0025772 gga-miR-6670-5p; +MIMAT0025773 gga-miR-6671-5p; +MIMAT0025774 gga-miR-6672-3p; +MIMAT0025775 gga-miR-6673-3p; +MIMAT0025776 gga-miR-6674-3p; +MIMAT0025777 gga-miR-6675-5p; +MIMAT0025778 gga-miR-6675-3p; +MIMAT0025779 gga-miR-6676-3p; +MIMAT0025780 gga-miR-6677-5p; +MIMAT0025781 gga-miR-6677-3p; +MIMAT0025782 gga-miR-6678-3p; +MIMAT0025783 gga-miR-6679-5p; +MIMAT0025784 gga-miR-6680-3p; +MIMAT0025785 gga-miR-1684b-3p; +MIMAT0025786 gga-miR-6681-5p; +MIMAT0025787 gga-miR-6682-3p; +MIMAT0025788 gga-miR-6683-3p; +MIMAT0025789 gga-miR-6684-5p; +MIMAT0025790 gga-miR-6685-5p; +MIMAT0025791 gga-miR-6685-3p; +MIMAT0025792 gga-miR-6686-3p; +MIMAT0025793 gga-miR-6687-3p; +MIMAT0025794 gga-miR-6688-3p; +MIMAT0025795 gga-miR-6689-3p; +MIMAT0025796 gga-miR-6690-5p; +MIMAT0025797 gga-miR-6691-5p; +MIMAT0025798 gga-miR-6692-5p; +MIMAT0025799 gga-miR-6693-3p; +MIMAT0025800 gga-miR-6694-3p; +MIMAT0025801 gga-miR-6695-5p; +MIMAT0025802 gga-miR-6696-5p; +MIMAT0025803 gga-miR-6696-3p; +MIMAT0025804 gga-miR-6697-5p; +MIMAT0025805 gga-miR-6698-3p; +MIMAT0025806 gga-miR-6516-5p; +MIMAT0025807 gga-miR-6516-3p; +MIMAT0025808 gga-miR-6699-5p; +MIMAT0025809 gga-miR-6700-5p; +MIMAT0025810 gga-miR-6700-3p; +MIMAT0025811 gga-miR-6701-3p; +MIMAT0025812 gga-miR-6702-5p; +MIMAT0025813 gga-miR-6703-3p; +MIMAT0025814 gga-miR-6704-5p; +MIMAT0025815 gga-miR-6705-5p; +MIMAT0025816 gga-miR-6706-5p; +MIMAT0025817 gga-miR-6707-5p; +MIMAT0025818 gga-miR-6708-5p; +MIMAT0025819 gga-miR-6709-5p; +MIMAT0025820 gga-miR-6710-3p; +MIMAT0025821 gga-miR-6711-5p; +MIMAT0025822 gga-miR-6712-5p; +MIMAT0025823 gga-miR-6713-3p; +MIMAT0025824 gga-miR-6714-3p; +MIMAT0025825 gga-miR-6622-3p; +MIMAT0025826 gga-miR-6543-5p; +MIMAT0025827 gga-miR-6543-3p; +MIMAT0025828 gga-miR-6557-5p; +MIMAT0025829 gga-miR-6557-3p; +MIMAT0025830 gga-miR-458b-5p; +MIMAT0025831 gga-miR-458b-3p; +MIMAT0025832 gga-miR-6562-5p; +MIMAT0025833 gga-miR-6562-3p; +MIMAT0025834 gga-miR-6563-5p; +MIMAT0025835 gga-miR-6563-3p; +MIMAT0025836 gga-miR-6599-5p; +MIMAT0025837 gga-miR-6599-3p; +MIMAT0025838 ghr-miR167b; +MIMAT0025839 ghr-miR169;ghr-miR169a; +MIMAT0025840 ghr-miR399e; +MIMAT0025841 hsa-miR-6715a-3p; +MIMAT0025842 hsa-miR-6715b-5p; +MIMAT0025843 hsa-miR-6715b-3p; +MIMAT0025844 hsa-miR-6716-5p; +MIMAT0025845 hsa-miR-6716-3p; +MIMAT0025846 hsa-miR-6717-5p; +MIMAT0025847 hsa-miR-6511b-5p; +MIMAT0025848 hsa-miR-6511b-3p; +MIMAT0025849 hsa-miR-6718-5p; +MIMAT0025850 hsa-miR-6719-3p; +MIMAT0025851 hsa-miR-6720-3p; +MIMAT0025852 hsa-miR-6721-5p; +MIMAT0025853 hsa-miR-6722-5p; +MIMAT0025854 hsa-miR-6722-3p; +MIMAT0025855 hsa-miR-6723-5p; +MIMAT0025856 hsa-miR-6724-5p; +MIMAT0025857 hsa-miR-892c-5p; +MIMAT0025858 hsa-miR-892c-3p; +MIMAT0025859 blv-miR-B1-3p; +MIMAT0025860 blv-miR-B2-5p; +MIMAT0025861 blv-miR-B2-3p; +MIMAT0025862 blv-miR-B3-5p; +MIMAT0025863 blv-miR-B3-3p; +MIMAT0025864 blv-miR-B4-3p; +MIMAT0025865 blv-miR-B5-5p; +MIMAT0025866 blv-miR-B5-3p; +MIMAT0025867 mdm-miR156a; +MIMAT0025868 mdm-miR156b; +MIMAT0025869 mdm-miR156c; +MIMAT0025870 mdm-miR156d; +MIMAT0025871 mdm-miR156e; +MIMAT0025872 mdm-miR156f; +MIMAT0025873 mdm-miR156g; +MIMAT0025874 mdm-miR156h; +MIMAT0025875 mdm-miR156i; +MIMAT0025876 mdm-miR156j; +MIMAT0025877 mdm-miR156k; +MIMAT0025878 mdm-miR156l; +MIMAT0025879 mdm-miR156m; +MIMAT0025880 mdm-miR156n; +MIMAT0025881 mdm-miR156o; +MIMAT0025882 mdm-miR156p; +MIMAT0025883 mdm-miR156q; +MIMAT0025884 mdm-miR156r; +MIMAT0025885 mdm-miR156s; +MIMAT0025886 mdm-miR156t; +MIMAT0025887 mdm-miR156u; +MIMAT0025888 mdm-miR156v; +MIMAT0025889 mdm-miR156w; +MIMAT0025890 mdm-miR156x; +MIMAT0025891 mdm-miR156y; +MIMAT0025892 mdm-miR156z; +MIMAT0025893 mdm-miR156aa; +MIMAT0025894 mdm-miR156ab; +MIMAT0025895 mdm-miR156ac; +MIMAT0025896 mdm-miR156ad; +MIMAT0025897 mdm-miR156ae; +MIMAT0025898 mdm-miR159a; +MIMAT0025899 mdm-miR159b; +MIMAT0025900 mdm-miR160a; +MIMAT0025901 mdm-miR160b; +MIMAT0025902 mdm-miR160c; +MIMAT0025903 mdm-miR160d; +MIMAT0025904 mdm-miR160e; +MIMAT0025905 mdm-miR162a; +MIMAT0025906 mdm-miR162b; +MIMAT0025907 mdm-miR164a; +MIMAT0025908 mdm-miR164b; +MIMAT0025909 mdm-miR164c; +MIMAT0025910 mdm-miR164d; +MIMAT0025911 mdm-miR164e; +MIMAT0025912 mdm-miR164f; +MIMAT0025913 mdm-miR166a; +MIMAT0025914 mdm-miR166b; +MIMAT0025915 mdm-miR166c; +MIMAT0025916 mdm-miR166d; +MIMAT0025917 mdm-miR166e; +MIMAT0025918 mdm-miR166f; +MIMAT0025919 mdm-miR166g; +MIMAT0025920 mdm-miR166h; +MIMAT0025921 mdm-miR166i; +MIMAT0025922 mdm-miR167a; +MIMAT0025923 mdm-miR167b; +MIMAT0025924 mdm-miR167c; +MIMAT0025925 mdm-miR167d; +MIMAT0025926 mdm-miR167e; +MIMAT0025927 mdm-miR167f; +MIMAT0025928 mdm-miR167g; +MIMAT0025929 mdm-miR167h; +MIMAT0025930 mdm-miR167i; +MIMAT0025931 mdm-miR167j; +MIMAT0025932 mdm-miR168a; +MIMAT0025933 mdm-miR168b; +MIMAT0025934 mdm-miR169a; +MIMAT0025935 mdm-miR169b; +MIMAT0025936 mdm-miR169c; +MIMAT0025937 mdm-miR169d; +MIMAT0025938 mdm-miR171a; +MIMAT0025939 mdm-miR171b; +MIMAT0025940 mdm-miR171c; +MIMAT0025941 mdm-miR171d; +MIMAT0025942 mdm-miR171e; +MIMAT0025943 mdm-miR171f;mdm-miR171f-3p; +MIMAT0025944 mdm-miR171g; +MIMAT0025945 mdm-miR171h; +MIMAT0025946 mdm-miR171i; +MIMAT0025947 mdm-miR171j; +MIMAT0025948 mdm-miR171k; +MIMAT0025949 mdm-miR171l; +MIMAT0025950 mdm-miR171m; +MIMAT0025951 mdm-miR171n; +MIMAT0025952 mdm-miR172a; +MIMAT0025953 mdm-miR172b; +MIMAT0025954 mdm-miR172c; +MIMAT0025955 mdm-miR172d; +MIMAT0025956 mdm-miR172e; +MIMAT0025957 mdm-miR172f; +MIMAT0025958 mdm-miR172g; +MIMAT0025959 mdm-miR172h; +MIMAT0025960 mdm-miR172i; +MIMAT0025961 mdm-miR172j; +MIMAT0025962 mdm-miR172k; +MIMAT0025963 mdm-miR172l; +MIMAT0025964 mdm-miR172m; +MIMAT0025965 mdm-miR172n; +MIMAT0025966 mdm-miR172o; +MIMAT0025967 mdm-miR319a; +MIMAT0025968 mdm-miR319b;mdm-miR319b-3p; +MIMAT0025969 mdm-miR390a; +MIMAT0025970 mdm-miR390b; +MIMAT0025971 mdm-miR390c; +MIMAT0025972 mdm-miR390d; +MIMAT0025973 mdm-miR390e; +MIMAT0025974 mdm-miR390f; +MIMAT0025975 mdm-miR393a; +MIMAT0025976 mdm-miR393b; +MIMAT0025977 mdm-miR393c; +MIMAT0025978 mdm-miR394a; +MIMAT0025979 mdm-miR394b; +MIMAT0025980 mdm-miR395a; +MIMAT0025981 mdm-miR395b; +MIMAT0025982 mdm-miR395c; +MIMAT0025983 mdm-miR395d;mdm-miR395d-3p; +MIMAT0025984 mdm-miR395e; +MIMAT0025985 mdm-miR395f; +MIMAT0025986 mdm-miR395g;mdm-miR395g-3p; +MIMAT0025987 mdm-miR395h; +MIMAT0025988 mdm-miR395i;mdm-miR395i-3p; +MIMAT0025989 mdm-miR396a; +MIMAT0025990 mdm-miR396b; +MIMAT0025991 mdm-miR396c; +MIMAT0025992 mdm-miR396d; +MIMAT0025993 mdm-miR396e; +MIMAT0025994 mdm-miR396f; +MIMAT0025995 mdm-miR396g; +MIMAT0025996 mdm-miR397a; +MIMAT0025997 mdm-miR397b; +MIMAT0025998 mdm-miR398a; +MIMAT0025999 mdm-miR398b; +MIMAT0026000 mdm-miR398c; +MIMAT0026001 mdm-miR399a; +MIMAT0026002 mdm-miR399b; +MIMAT0026003 mdm-miR399c; +MIMAT0026004 mdm-miR399d; +MIMAT0026005 mdm-miR399e; +MIMAT0026006 mdm-miR399f; +MIMAT0026007 mdm-miR399g; +MIMAT0026008 mdm-miR399h; +MIMAT0026009 mdm-miR399i; +MIMAT0026010 mdm-miR399j; +MIMAT0026011 mdm-miR403a; +MIMAT0026012 mdm-miR403b; +MIMAT0026013 mdm-miR408a; +MIMAT0026014 mdm-miR2111a; +MIMAT0026015 mdm-miR2111b; +MIMAT0026016 mdm-miR3627a; +MIMAT0026017 mdm-miR3627b; +MIMAT0026018 mdm-miR3627c; +MIMAT0026019 mdm-miR391; +MIMAT0026020 mdm-miR447;mdm-miR477b; +MIMAT0026021 mdm-miR477;mdm-miR477a; +MIMAT0026022 mdm-miR482b; +MIMAT0026023 mdm-miR482c; +MIMAT0026024 mdm-miR535a; +MIMAT0026025 mdm-miR535b; +MIMAT0026026 mdm-miR535c; +MIMAT0026027 mdm-miR535d; +MIMAT0026028 mdm-miR827; +MIMAT0026029 mdm-miR828a; +MIMAT0026030 mdm-miR828b; +MIMAT0026031 mdm-miR408b; +MIMAT0026032 mdm-miR408c; +MIMAT0026033 mdm-miR408d; +MIMAT0026034 mdm-miR2118a; +MIMAT0026035 mdm-miR2118b; +MIMAT0026036 mdm-miR2118c; +MIMAT0026037 mdm-miR7120a;mdm-miR7120a-5p; +MIMAT0026038 mdm-miR7120b;mdm-miR7120b-5p; +MIMAT0026039 mdm-miR482d; +MIMAT0026040 mdm-miR7121a; +MIMAT0026041 mdm-miR7121b; +MIMAT0026042 mdm-miR7121c; +MIMAT0026043 mdm-miR7121d; +MIMAT0026044 mdm-miR7121e; +MIMAT0026045 mdm-miR7121f; +MIMAT0026046 mdm-miR7121g; +MIMAT0026047 mdm-miR7121h; +MIMAT0026048 mdm-miR7122a; +MIMAT0026049 mdm-miR7122b; +MIMAT0026050 mdm-miR7123a; +MIMAT0026051 mdm-miR7123b; +MIMAT0026052 mdm-miR5225c; +MIMAT0026053 mdm-miR159c; +MIMAT0026054 mdm-miR7124a; +MIMAT0026055 mdm-miR7124b; +MIMAT0026056 mdm-miR5225a; +MIMAT0026057 mdm-miR5225b; +MIMAT0026058 mdm-miR319c;mdm-miR319c-3p; +MIMAT0026059 mdm-miR7125; +MIMAT0026060 mdm-miR7126;mdm-miR7126-5p; +MIMAT0026061 mdm-miR393d; +MIMAT0026062 mdm-miR393e; +MIMAT0026063 mdm-miR393f; +MIMAT0026064 mdm-miR7127a; +MIMAT0026065 mdm-miR7127b; +MIMAT0026066 mdm-miR171o; +MIMAT0026067 mdm-miR169e; +MIMAT0026068 mdm-miR169f; +MIMAT0026069 mdm-miR7128; +MIMAT0026070 mdm-miR858; +MIMAT0026071 cme-miR156a; +MIMAT0026072 cme-miR160a; +MIMAT0026073 cme-miR169q; +MIMAT0026074 cme-miR169s; +MIMAT0026075 cme-miR169p; +MIMAT0026076 cme-miR169o; +MIMAT0026077 cme-miR169d; +MIMAT0026078 cme-miR399d; +MIMAT0026079 cme-miR169k; +MIMAT0026080 cme-miR162; +MIMAT0026081 cme-miR169c; +MIMAT0026082 cme-miR399e; +MIMAT0026083 cme-miR858; +MIMAT0026084 cme-miR845; +MIMAT0026085 cme-miR171i; +MIMAT0026086 cme-miR164c; +MIMAT0026087 cme-miR399f; +MIMAT0026088 cme-miR164b; +MIMAT0026089 cme-miR477a; +MIMAT0026090 cme-miR164d; +MIMAT0026091 cme-miR166i; +MIMAT0026092 cme-miR169m; +MIMAT0026093 cme-miR169j; +MIMAT0026094 cme-miR169b; +MIMAT0026095 cme-miR169a; +MIMAT0026096 cme-miR169i; +MIMAT0026097 cme-miR166c; +MIMAT0026098 cme-miR169l; +MIMAT0026099 cme-miR172f; +MIMAT0026100 cme-miR854; +MIMAT0026101 cme-miR1863; +MIMAT0026102 cme-miR477b; +MIMAT0026103 cme-miR166b; +MIMAT0026104 cme-miR530b; +MIMAT0026105 cme-miR156i; +MIMAT0026106 cme-miR396a; +MIMAT0026107 cme-miR166d; +MIMAT0026108 cme-miR166h; +MIMAT0026109 cme-miR166f; +MIMAT0026110 cme-miR166a; +MIMAT0026111 cme-miR156d; +MIMAT0026112 cme-miR167a; +MIMAT0026113 cme-miR167b; +MIMAT0026114 cme-miR169h; +MIMAT0026115 cme-miR169f; +MIMAT0026116 cme-miR169n; +MIMAT0026117 cme-miR169e; +MIMAT0026118 cme-miR171e; +MIMAT0026119 cme-miR171a; +MIMAT0026120 cme-miR171g; +MIMAT0026121 cme-miR156c; +MIMAT0026122 cme-miR171d; +MIMAT0026123 cme-miR171b; +MIMAT0026124 cme-miR172b; +MIMAT0026125 cme-miR172c; +MIMAT0026126 cme-miR172e; +MIMAT0026127 cme-miR172d; +MIMAT0026128 cme-miR319b; +MIMAT0026129 cme-miR319a; +MIMAT0026130 cme-miR319c; +MIMAT0026131 cme-miR156b; +MIMAT0026132 cme-miR319d; +MIMAT0026133 cme-miR390d; +MIMAT0026134 cme-miR390a; +MIMAT0026135 cme-miR390c; +MIMAT0026136 cme-miR393a; +MIMAT0026137 cme-miR393b; +MIMAT0026138 cme-miR393c; +MIMAT0026139 cme-miR394b; +MIMAT0026140 cme-miR394a; +MIMAT0026141 cme-miR395a; +MIMAT0026142 cme-miR395e; +MIMAT0026143 cme-miR395d; +MIMAT0026144 cme-miR395f; +MIMAT0026145 cme-miR396b; +MIMAT0026146 cme-miR396c; +MIMAT0026147 cme-miR396d; +MIMAT0026148 cme-miR397; +MIMAT0026149 cme-miR398b; +MIMAT0026150 cme-miR399a; +MIMAT0026151 cme-miR156f; +MIMAT0026152 cme-miR399c; +MIMAT0026153 cme-miR408; +MIMAT0026154 cme-miR171c; +MIMAT0026155 cme-miR2111a; +MIMAT0026156 cme-miR156e; +MIMAT0026157 cme-miR395b; +MIMAT0026158 cme-miR156h; +MIMAT0026159 cme-miR156g; +MIMAT0026160 cme-miR159a; +MIMAT0026161 cme-miR828; +MIMAT0026162 cme-miR396e; +MIMAT0026163 cme-miR167d; +MIMAT0026164 cme-miR167f; +MIMAT0026165 cme-miR166g; +MIMAT0026166 cme-miR171f; +MIMAT0026167 cme-miR399b; +MIMAT0026168 cme-miR159b; +MIMAT0026169 cme-miR2111b; +MIMAT0026170 cme-miR395c; +MIMAT0026171 cme-miR160b; +MIMAT0026172 cme-miR169g; +MIMAT0026173 cme-miR171h; +MIMAT0026174 cme-miR398a; +MIMAT0026175 cme-miR169r; +MIMAT0026176 cme-miR167c; +MIMAT0026177 cme-miR167e; +MIMAT0026178 cme-miR160d; +MIMAT0026179 cme-miR166e; +MIMAT0026180 cme-miR160c; +MIMAT0026181 cme-miR172a; +MIMAT0026182 cme-miR530a; +MIMAT0026183 cme-miR7129; +MIMAT0026184 cme-miR7130; +MIMAT0026185 cme-miR399g; +MIMAT0026186 cme-miR156j; +MIMAT0026187 cme-miR169t; +MIMAT0026188 mdm-miR1511; +MIMAT0026189 ccr-let-7a; +MIMAT0026190 ccr-let-7b; +MIMAT0026191 ccr-let-7g; +MIMAT0026192 ccr-let-7i; +MIMAT0026193 ccr-let-7j; +MIMAT0026194 ccr-miR-1; +MIMAT0026195 ccr-miR-100; +MIMAT0026196 ccr-miR-101a; +MIMAT0026197 ccr-miR-101b; +MIMAT0026198 ccr-miR-103; +MIMAT0026199 ccr-miR-107; +MIMAT0026200 ccr-miR-10b; +MIMAT0026201 ccr-miR-10c; +MIMAT0026202 ccr-miR-10d; +MIMAT0026203 ccr-miR-122; +MIMAT0026204 ccr-miR-125b; +MIMAT0026205 ccr-miR-125c; +MIMAT0026206 ccr-miR-126-5p; +MIMAT0026207 ccr-miR-126-3p; +MIMAT0026208 ccr-miR-128; +MIMAT0026209 ccr-miR-129; +MIMAT0026210 ccr-miR-130a; +MIMAT0026211 ccr-miR-130b; +MIMAT0026212 ccr-miR-130c; +MIMAT0026213 ccr-miR-132a; +MIMAT0026214 ccr-miR-133a-5p; +MIMAT0026215 ccr-miR-133a-3p; +MIMAT0026216 ccr-miR-135c; +MIMAT0026217 ccr-miR-137; +MIMAT0026218 ccr-miR-138; +MIMAT0026219 ccr-miR-139; +MIMAT0026220 ccr-miR-140-5p; +MIMAT0026221 ccr-miR-140-3p; +MIMAT0026222 ccr-miR-142-5p; +MIMAT0026223 ccr-miR-142-3p; +MIMAT0026224 ccr-miR-143; +MIMAT0026225 ccr-miR-144; +MIMAT0026226 ccr-miR-146a; +MIMAT0026227 ccr-miR-148; +MIMAT0026228 ccr-miR-15a; +MIMAT0026229 ccr-miR-153b; +MIMAT0026230 ccr-miR-153c; +MIMAT0026231 ccr-miR-155; +MIMAT0026232 ccr-miR-15b; +MIMAT0026233 ccr-miR-16a; +MIMAT0026234 ccr-miR-16b; +MIMAT0026235 ccr-miR-16c; +MIMAT0026236 ccr-miR-17-5p; +MIMAT0026237 ccr-miR-17-3p; +MIMAT0026238 ccr-miR-181a; +MIMAT0026239 ccr-miR-181b; +MIMAT0026240 ccr-miR-181c; +MIMAT0026241 ccr-miR-182-5p; +MIMAT0026242 ccr-miR-182-3p; +MIMAT0026243 ccr-miR-183; +MIMAT0026244 ccr-miR-184; +MIMAT0026245 ccr-miR-187; +MIMAT0026246 ccr-miR-18a; +MIMAT0026247 ccr-miR-18b; +MIMAT0026248 ccr-miR-18c; +MIMAT0026249 ccr-miR-190; +MIMAT0026250 ccr-miR-192; +MIMAT0026251 ccr-miR-193a; +MIMAT0026252 ccr-miR-194; +MIMAT0026253 ccr-miR-196a; +MIMAT0026254 ccr-miR-196b; +MIMAT0026255 ccr-miR-199-5p; +MIMAT0026256 ccr-miR-199-3p; +MIMAT0026257 ccr-miR-19d; +MIMAT0026258 ccr-miR-200a; +MIMAT0026259 ccr-miR-200b; +MIMAT0026260 ccr-miR-203a; +MIMAT0026261 ccr-miR-203b-5p; +MIMAT0026262 ccr-miR-203b-3p; +MIMAT0026263 ccr-miR-205; +MIMAT0026264 ccr-miR-206; +MIMAT0026265 ccr-miR-20a-5p; +MIMAT0026266 ccr-miR-20a-3p; +MIMAT0026267 ccr-miR-21; +MIMAT0026268 ccr-miR-210; +MIMAT0026269 ccr-miR-214; +MIMAT0026270 ccr-miR-217; +MIMAT0026271 ccr-miR-218a; +MIMAT0026272 ccr-miR-218b; +MIMAT0026273 ccr-miR-221; +MIMAT0026274 ccr-miR-222; +MIMAT0026275 ccr-miR-22a; +MIMAT0026276 ccr-miR-22b; +MIMAT0026277 ccr-miR-23a; +MIMAT0026278 ccr-miR-23b; +MIMAT0026279 ccr-miR-24; +MIMAT0026280 ccr-miR-25; +MIMAT0026281 ccr-miR-26a; +MIMAT0026282 ccr-miR-27a; +MIMAT0026283 ccr-miR-27c-5p; +MIMAT0026284 ccr-miR-27c-3p; +MIMAT0026285 ccr-miR-27d; +MIMAT0026286 ccr-miR-29a; +MIMAT0026287 ccr-miR-29b; +MIMAT0026288 ccr-miR-301a; +MIMAT0026289 ccr-miR-30b; +MIMAT0026290 ccr-miR-30d; +MIMAT0026291 ccr-miR-338; +MIMAT0026292 ccr-miR-34; +MIMAT0026293 ccr-miR-363; +MIMAT0026294 ccr-miR-365; +MIMAT0026295 ccr-miR-375; +MIMAT0026296 ccr-miR-738; +MIMAT0026297 ccr-miR-429; +MIMAT0026298 ccr-miR-430; +MIMAT0026299 ccr-miR-454a; +MIMAT0026300 ccr-miR-454b; +MIMAT0026301 ccr-miR-455; +MIMAT0026302 ccr-miR-457a; +MIMAT0026303 ccr-miR-457b; +MIMAT0026304 ccr-miR-459-5p; +MIMAT0026305 ccr-miR-459-3p; +MIMAT0026306 ccr-miR-460-5p; +MIMAT0026307 ccr-miR-460-3p; +MIMAT0026308 ccr-miR-489; +MIMAT0026309 ccr-miR-499; +MIMAT0026310 ccr-miR-722; +MIMAT0026311 ccr-miR-724; +MIMAT0026312 ccr-miR-725; +MIMAT0026313 ccr-miR-726; +MIMAT0026314 ccr-miR-727-5p; +MIMAT0026315 ccr-miR-727-3p; +MIMAT0026316 ccr-miR-729; +MIMAT0026317 ccr-miR-730; +MIMAT0026318 ccr-miR-734; +MIMAT0026319 ccr-miR-7a; +MIMAT0026320 ccr-miR-7b; +MIMAT0026321 ccr-miR-9-3p; +MIMAT0026322 ccr-miR-9-5p; +MIMAT0026323 ccr-miR-92a; +MIMAT0026324 ccr-miR-92b; +MIMAT0026325 ccr-miR-93; +MIMAT0026326 ccr-miR-96; +MIMAT0026327 ccr-miR-99; +MIMAT0026328 ccr-miR-2192; +MIMAT0026329 ccr-miR-551; +MIMAT0026330 ccr-miR-132b; +MIMAT0026331 ccr-miR-124a; +MIMAT0026332 ccr-miR-7132; +MIMAT0026333 ccr-miR-7133; +MIMAT0026334 ccr-miR-124b; +MIMAT0026335 osa-miR818f; +MIMAT0026336 bma-miR-5838;bma-miR-5838-3p; +MIMAT0026337 bma-miR-5839;bma-miR-5839-3p; +MIMAT0026338 bma-miR-5840; +MIMAT0026339 bma-miR-5841;bma-miR-5841-5p; +MIMAT0026340 bma-miR-5842;bma-miR-5842-3p; +MIMAT0026341 bma-miR-5843; +MIMAT0026342 bma-miR-5844; +MIMAT0026343 bma-miR-5845; +MIMAT0026344 bma-miR-5846; +MIMAT0026345 bma-miR-5847; +MIMAT0026346 bma-miR-5848; +MIMAT0026347 bma-miR-5849; +MIMAT0026348 bma-miR-5850;bma-miR-2i-5p; +MIMAT0026349 bma-miR-5851; +MIMAT0026350 bma-miR-5852; +MIMAT0026351 bma-miR-5853; +MIMAT0026352 bma-miR-5854; +MIMAT0026353 bma-miR-5855; +MIMAT0026354 bma-miR-5856a; +MIMAT0026355 bma-miR-5856b; +MIMAT0026356 bma-miR-5857; +MIMAT0026357 bma-miR-5858;bma-miR-5858-5p; +MIMAT0026358 bma-miR-5859; +MIMAT0026359 bma-miR-5860;bma-miR-2g-3p; +MIMAT0026360 bma-miR-5861; +MIMAT0026361 bma-miR-5862;bma-miR-5862-5p; +MIMAT0026362 bma-miR-5863; +MIMAT0026363 bma-miR-5864; +MIMAT0026364 bma-miR-5865; +MIMAT0026365 bma-miR-5866; +MIMAT0026366 bma-miR-5867; +MIMAT0026367 bma-miR-5868; +MIMAT0026368 bma-miR-5869; +MIMAT0026369 bma-miR-5870;bma-miR-2e; +MIMAT0026370 bma-miR-5871; +MIMAT0026371 bma-miR-5872; +MIMAT0026372 bma-miR-5873; +MIMAT0026373 bma-miR-5874; +MIMAT0026374 bma-miR-5875; +MIMAT0026375 bma-miR-5876; +MIMAT0026376 bma-miR-5877; +MIMAT0026377 bma-miR-5878; +MIMAT0026378 bma-miR-5879a; +MIMAT0026379 bma-miR-5879b; +MIMAT0026380 bma-miR-5880a; +MIMAT0026381 bma-miR-5880b; +MIMAT0026382 bma-miR-5881a; +MIMAT0026383 bma-miR-5881b; +MIMAT0026384 bma-miR-5881c-5p; +MIMAT0026385 bma-miR-5882a; +MIMAT0026386 bma-miR-5882b; +MIMAT0026387 bma-miR-5883; +MIMAT0026388 sbi-miR5568b-5p; +MIMAT0026389 sbi-miR5568b-3p; +MIMAT0026390 sbi-miR5564c-5p; +MIMAT0026391 sbi-miR5564c-3p; +MIMAT0026392 sbi-miR6217a-5p; +MIMAT0026393 sbi-miR6217a-3p; +MIMAT0026394 sbi-miR6217b-5p; +MIMAT0026395 sbi-miR6217b-3p; +MIMAT0026396 sbi-miR6218-5p; +MIMAT0026397 sbi-miR6218-3p; +MIMAT0026398 sbi-miR5565g-5p; +MIMAT0026399 sbi-miR5565g-3p; +MIMAT0026400 sbi-miR5568c-5p; +MIMAT0026401 sbi-miR5568c-3p; +MIMAT0026402 sbi-miR6219-5p; +MIMAT0026403 sbi-miR6219-3p; +MIMAT0026404 sbi-miR6220-5p; +MIMAT0026405 sbi-miR6220-3p; +MIMAT0026406 sbi-miR437x-5p; +MIMAT0026407 sbi-miR437x-3p; +MIMAT0026408 sbi-miR6221-5p; +MIMAT0026409 sbi-miR6221-3p; +MIMAT0026410 sbi-miR6222-5p; +MIMAT0026411 sbi-miR6222-3p; +MIMAT0026412 sbi-miR6223-5p; +MIMAT0026413 sbi-miR6223-3p; +MIMAT0026414 sbi-miR6224a-5p; +MIMAT0026415 sbi-miR6224a-3p; +MIMAT0026416 sbi-miR6224b-5p; +MIMAT0026417 sbi-miR6224b-3p; +MIMAT0026418 sbi-miR6224c-5p; +MIMAT0026419 sbi-miR6224c-3p; +MIMAT0026420 sbi-miR6225-5p; +MIMAT0026421 sbi-miR6225-3p; +MIMAT0026422 sbi-miR5568d-5p; +MIMAT0026423 sbi-miR5568d-3p; +MIMAT0026424 sbi-miR6226-5p; +MIMAT0026425 sbi-miR6226-3p; +MIMAT0026426 sbi-miR2118-5p; +MIMAT0026427 sbi-miR2118-3p; +MIMAT0026428 sbi-miR6227-5p; +MIMAT0026429 sbi-miR6227-3p; +MIMAT0026430 sbi-miR169r-5p; +MIMAT0026431 sbi-miR169r-3p;sbi-miR169d-3p; +MIMAT0026432 sbi-miR6228-5p; +MIMAT0026433 sbi-miR6228-3p; +MIMAT0026434 sbi-miR6229-5p; +MIMAT0026435 sbi-miR6229-3p; +MIMAT0026436 sbi-miR6230-5p; +MIMAT0026437 sbi-miR6230-3p; +MIMAT0026438 sbi-miR5568e-5p; +MIMAT0026439 sbi-miR5568e-3p; +MIMAT0026440 sbi-miR6231-5p; +MIMAT0026441 sbi-miR6231-3p; +MIMAT0026442 sbi-miR5568f-5p; +MIMAT0026443 sbi-miR5568f-3p; +MIMAT0026444 sbi-miR6232a-5p; +MIMAT0026445 sbi-miR6232a-3p; +MIMAT0026446 sbi-miR6232b-5p; +MIMAT0026447 sbi-miR6232b-3p; +MIMAT0026448 sbi-miR6233-5p; +MIMAT0026449 sbi-miR6233-3p; +MIMAT0026450 sbi-miR6234a-5p; +MIMAT0026451 sbi-miR6234a-3p; +MIMAT0026452 sbi-miR6234b-5p; +MIMAT0026453 sbi-miR6234b-3p; +MIMAT0026454 sbi-miR6235-5p; +MIMAT0026455 sbi-miR6235-3p; +MIMAT0026456 mtr-miR396a-3p; +MIMAT0026457 tur-miR-124-2-5p; +MIMAT0026458 hhv6b-miR-Ro6-2-5p; +MIMAT0026459 hhv6b-miR-Ro6-2-3p; +MIMAT0026460 hhv6b-miR-Ro6-3-5p; +MIMAT0026461 hhv6b-miR-Ro6-3-3p; +MIMAT0026462 hhv6b-miR-Ro6-4-5p; +MIMAT0026463 hhv6b-miR-Ro6-4-3p; +MIMAT0026464 hme-miR-6302-2-5p; +MIMAT0026465 sbi-miR5568g-5p; +MIMAT0026466 sbi-miR5568g-3p; +MIMAT0026467 rno-miR-125b-2-3p; +MIMAT0026468 ssc-miR-24-2-5p; +MIMAT0026469 tur-miR-5728-2-5p; +MIMAT0026470 hme-miR-6301-2-5p; +MIMAT0026471 cin-miR-4000a-2-3p; +MIMAT0026472 hsa-let-7c-3p; +MIMAT0026473 hsa-miR-95-5p; +MIMAT0026474 hsa-miR-208a-5p; +MIMAT0026475 hsa-miR-210-5p; +MIMAT0026476 hsa-miR-215-3p; +MIMAT0026477 hsa-miR-128-1-5p; +MIMAT0026478 hsa-miR-133a-5p; +MIMAT0026479 hsa-miR-152-5p; +MIMAT0026480 hsa-miR-153-5p; +MIMAT0026481 hsa-miR-134-3p; +MIMAT0026482 hsa-miR-190a-3p; +MIMAT0026483 hsa-miR-370-5p; +MIMAT0026484 hsa-miR-372-5p; +MIMAT0026485 hsa-miR-383-3p; +MIMAT0026486 hsa-miR-328-5p; +MIMAT0026487 gga-miR-29a-5p; +MIMAT0026488 gga-miR-29b-1-5p; +MIMAT0026489 gga-miR-135a-2-3p; +MIMAT0026490 gga-miR-33-3p; +MIMAT0026491 gga-let-7a-3p; +MIMAT0026492 gga-let-7c-3p; +MIMAT0026493 gga-miR-125b-3p; +MIMAT0026494 gga-miR-221-5p; +MIMAT0026495 gga-miR-92-5p; +MIMAT0026496 gga-miR-19b-5p; +MIMAT0026497 gga-miR-20a-3p; +MIMAT0026498 gga-miR-19a-5p; +MIMAT0026499 gga-miR-18a-3p; +MIMAT0026500 gga-miR-16-1-3p; +MIMAT0026501 gga-miR-26a-3p; +MIMAT0026502 gga-miR-153-5p; +MIMAT0026503 gga-miR-148a-5p; +MIMAT0026504 gga-miR-196-2-3p; +MIMAT0026505 gga-miR-138-1-3p; +MIMAT0026506 gga-miR-128-2-5p; +MIMAT0026507 gga-miR-187-5p; +MIMAT0026508 gga-miR-32-3p; +MIMAT0026509 gga-miR-133a-5p; +MIMAT0026510 gga-miR-1a-2-5p; +MIMAT0026511 gga-miR-124a-5p; +MIMAT0026512 gga-miR-30b-3p; +MIMAT0026513 gga-miR-217-3p; +MIMAT0026514 gga-miR-215-3p; +MIMAT0026515 gga-miR-30c-2-3p; +MIMAT0026516 gga-miR-18b-3p; +MIMAT0026517 gga-miR-106-3p; +MIMAT0026518 gga-miR-218-3p; +MIMAT0026519 gga-miR-103-2-5p; +MIMAT0026520 gga-miR-107-5p; +MIMAT0026521 gga-miR-10b-3p; +MIMAT0026522 gga-miR-181b-1-3p; +MIMAT0026523 gga-miR-137-5p; +MIMAT0026524 gga-miR-15b-3p; +MIMAT0026525 gga-miR-190-3p;gga-miR-190a-3p; +MIMAT0026526 gga-miR-184-5p; +MIMAT0026527 gga-let-7g-3p; +MIMAT0026528 gga-let-7f-3p; +MIMAT0026529 gga-miR-146a-3p; +MIMAT0026530 gga-miR-130b-5p; +MIMAT0026531 gga-miR-301a-5p; +MIMAT0026532 gga-miR-130a-5p; +MIMAT0026533 gga-miR-200a-5p; +MIMAT0026534 gga-miR-200b-5p; +MIMAT0026535 gga-miR-34a-3p; +MIMAT0026536 gga-miR-1b-5p; +MIMAT0026537 gga-miR-133c-5p; +MIMAT0026538 gga-miR-30e-3p; +MIMAT0026539 gga-miR-100-3p; +MIMAT0026540 gga-miR-34b-3p; +MIMAT0026541 gga-miR-34c-3p; +MIMAT0026542 gga-let-7j-3p; +MIMAT0026543 gga-let-7k-3p; +MIMAT0026544 gga-miR-29c-5p; +MIMAT0026545 gga-miR-101-1-5p; +MIMAT0026546 gga-miR-23b-5p; +MIMAT0026547 gga-miR-27b-5p; +MIMAT0026548 gga-miR-24-5p; +MIMAT0026549 gga-miR-31-3p; +MIMAT0026550 gga-miR-122-3p; +MIMAT0026551 gga-miR-20b-3p; +MIMAT0026552 hcmv-miR-UL112-5p; +MIMAT0026553 hcmv-miR-US5-2-5p; +MIMAT0026554 hsa-miR-433-5p; +MIMAT0026555 hsa-miR-329-5p; +MIMAT0026556 mtr-miR319a-5p; +MIMAT0026557 hsa-miR-412-5p; +MIMAT0026558 hsa-miR-410-5p; +MIMAT0026559 hsa-miR-487a-5p; +MIMAT0026560 mml-miR-200c-5p; +MIMAT0026561 mml-miR-141-5p; +MIMAT0026562 mml-miR-15b-3p; +MIMAT0026563 mml-miR-30b-3p; +MIMAT0026564 mml-miR-125b-1-3p; +MIMAT0026565 mml-miR-128a-5p; +MIMAT0026566 mml-miR-130a-5p; +MIMAT0026567 mml-miR-135a-2-3p; +MIMAT0026568 mml-miR-145-3p; +MIMAT0026569 mml-miR-153-1-5p; +MIMAT0026570 mml-miR-127-5p; +MIMAT0026571 mml-miR-188-3p; +MIMAT0026572 mml-miR-190a-3p; +MIMAT0026573 mml-miR-21-3p; +MIMAT0026574 mml-miR-26a-1-3p; +MIMAT0026575 mml-miR-28-3p; +MIMAT0026576 mml-miR-29a-5p; +MIMAT0026577 mml-miR-31-3p; +MIMAT0026578 mml-miR-32-3p; +MIMAT0026579 mml-miR-99a-3p; +MIMAT0026580 mml-miR-100-3p; +MIMAT0026581 mml-miR-101-1-5p; +MIMAT0026582 mml-miR-103-5p; +MIMAT0026583 mml-miR-105-3p; +MIMAT0026584 mml-miR-107-5p; +MIMAT0026585 mml-miR-124a-5p; +MIMAT0026586 mml-miR-34a-3p; +MIMAT0026587 mml-miR-181c-3p; +MIMAT0026588 mml-miR-214-5p; +MIMAT0026589 mml-miR-218-2-3p; +MIMAT0026590 mml-miR-221-5p; +MIMAT0026591 mml-miR-224-3p; +MIMAT0026592 mml-miR-181b-1-3p; +MIMAT0026593 mml-miR-15a-3p; +MIMAT0026594 mml-miR-16-1-3p; +MIMAT0026595 mml-miR-18a-3p; +MIMAT0026596 mml-miR-19a-5p; +MIMAT0026597 mml-miR-20a-3p; +MIMAT0026598 mml-miR-215-3p; +MIMAT0026599 mml-miR-23a-5p; +MIMAT0026600 mml-miR-27a-5p; +MIMAT0026601 mml-miR-106b-3p; +MIMAT0026602 mml-miR-93-3p; +MIMAT0026603 mml-miR-183-3p; +MIMAT0026604 mml-miR-106a-3p; +MIMAT0026605 hsa-miR-489-5p; +MIMAT0026606 hsa-miR-511-3p; +MIMAT0026607 hsa-miR-494-5p; +MIMAT0026608 hsa-miR-181d-3p; +MIMAT0026609 hsa-miR-520f-5p; +MIMAT0026610 hsa-miR-519d-5p; +MIMAT0026611 hsa-miR-520g-5p; +MIMAT0026612 hsa-miR-504-3p; +MIMAT0026613 hsa-miR-510-3p; +MIMAT0026614 hsa-miR-487b-5p; +MIMAT0026615 hsa-miR-552-5p; +MIMAT0026616 hsa-miR-579-5p; +MIMAT0026617 hsa-miR-580-5p; +MIMAT0026618 hsa-miR-585-5p; +MIMAT0026619 hsa-miR-597-3p; +MIMAT0026620 hsa-miR-598-5p; +MIMAT0026621 hsa-miR-605-3p; +MIMAT0026622 hsa-miR-619-5p; +MIMAT0026623 hsa-miR-627-3p; +MIMAT0026624 hsa-miR-651-3p; +MIMAT0026625 hsa-miR-653-3p; +MIMAT0026626 hsa-miR-655-5p; +MIMAT0026627 hsa-miR-656-5p; +MIMAT0026628 hcmv-miR-US4-3p; +MIMAT0026629 gga-miR-193b-5p; +MIMAT0026630 gga-miR-365-1-5p; +MIMAT0026631 gga-miR-383-3p; +MIMAT0026632 gga-miR-489-5p; +MIMAT0026633 gga-miR-490-5p; +MIMAT0026634 gga-miR-499-3p; +MIMAT0026635 gga-miR-429-5p; +MIMAT0026636 hsa-miR-668-5p; +MIMAT0026637 hsa-miR-1296-3p; +MIMAT0026638 hsa-miR-1468-3p; +MIMAT0026639 hsa-miR-1301-5p; +MIMAT0026640 hsa-miR-670-3p; +MIMAT0026641 hsa-miR-1298-3p; +MIMAT0026642 mmu-miR-3475-5p; +MIMAT0026643 gga-miR-21-3p; +MIMAT0026644 gga-miR-144-5p; +MIMAT0026645 gga-miR-456-5p; +MIMAT0026646 gga-miR-460a-3p; +MIMAT0026647 mdo-miR-1-1-5p; +MIMAT0026648 mdo-miR-10a-3p; +MIMAT0026649 mdo-miR-10b-3p; +MIMAT0026650 mdo-miR-21-3p; +MIMAT0026651 mdo-miR-22-5p; +MIMAT0026652 mdo-miR-30a-3p; +MIMAT0026653 mdo-miR-31-3p; +MIMAT0026654 mdo-miR-32-3p; +MIMAT0026655 mdo-miR-34a-3p; +MIMAT0026656 mdo-miR-100-3p; +MIMAT0026657 mdo-miR-101-2-5p; +MIMAT0026658 mdo-miR-103-1-5p; +MIMAT0026659 mdo-miR-122-3p; +MIMAT0026660 mdo-miR-124a-5p; +MIMAT0026661 mdo-miR-125b-1-3p; +MIMAT0026662 mdo-miR-128a-5p; +MIMAT0026663 mdo-miR-129-3p; +MIMAT0026664 mdo-miR-130a-5p; +MIMAT0026665 mdo-miR-133a-1-5p; +MIMAT0026666 mdo-miR-135a-3p; +MIMAT0026667 mdo-miR-135b-3p; +MIMAT0026668 mdo-miR-143-5p; +MIMAT0026669 mdo-miR-144-5p; +MIMAT0026670 mdo-miR-145-3p; +MIMAT0026671 mdo-miR-152-5p; +MIMAT0026672 mdo-miR-182-3p; +MIMAT0026673 mdo-miR-184-5p; +MIMAT0026674 mdo-miR-187-5p; +MIMAT0026676 mdo-miR-186-3p; +MIMAT0026677 mdo-miR-193a-5p; +MIMAT0026678 mdo-miR-199b-3p; +MIMAT0026679 mdo-miR-214-5p; +MIMAT0026680 mdo-miR-218-1-3p; +MIMAT0026681 mdo-miR-219-1-3p; +MIMAT0026682 mdo-miR-223-5p; +MIMAT0026683 mdo-miR-365-5p; +MIMAT0026684 mdo-miR-383-3p; +MIMAT0026685 mdo-miR-449a-3p; +MIMAT0026686 mdo-let-7a-3p; +MIMAT0026687 mdo-let-7g-3p; +MIMAT0026688 mdo-let-7i-3p; +MIMAT0026689 mdo-miR-15a-3p; +MIMAT0026690 mdo-miR-16-1-3p; +MIMAT0026691 mdo-miR-183-3p; +MIMAT0026692 mdo-miR-212-5p; +MIMAT0026693 mdo-miR-132-5p; +MIMAT0026694 mdo-miR-200c-5p; +MIMAT0026695 mdo-miR-141-5p; +MIMAT0026696 mdo-miR-191-3p; +MIMAT0026697 mdo-miR-425-5p; +MIMAT0026698 mdo-miR-181a-1-3p; +MIMAT0026699 mdo-miR-181b-1-3p; +MIMAT0026700 mdo-miR-200b-5p; +MIMAT0026701 mdo-miR-221-5p; +MIMAT0026702 mdo-let-7f-1-3p; +MIMAT0026703 mdo-miR-29b-1-5p; +MIMAT0026704 mdo-miR-29a-1-5p; +MIMAT0026705 mdo-miR-18a-3p; +MIMAT0026706 mdo-miR-19a-5p; +MIMAT0026707 mdo-miR-20a-3p; +MIMAT0026708 mdo-miR-19b-1-5p; +MIMAT0026709 mdo-miR-92a-1-5p; +MIMAT0026710 mdo-miR-23a-5p; +MIMAT0026711 mdo-miR-27a-5p; +MIMAT0026712 mdo-miR-24-5p; +MIMAT0026713 mdo-miR-23b-5p; +MIMAT0026714 mdo-miR-27b-5p; +MIMAT0026715 mdo-miR-93-3p; +MIMAT0026716 bta-miR-331-5p; +MIMAT0026717 hsa-miR-891a-3p; +MIMAT0026718 hsa-miR-874-5p; +MIMAT0026719 hsa-miR-889-5p; +MIMAT0026720 hsa-miR-887-5p; +MIMAT0026721 hsa-miR-216b-3p; +MIMAT0026722 hsa-miR-208b-5p; +MIMAT0026723 mtr-miR156b-3p; +MIMAT0026724 mtr-miR156c-3p; +MIMAT0026725 mtr-miR156d-3p; +MIMAT0026726 mtr-miR166e-5p; +MIMAT0026727 mtr-miR319b-5p; +MIMAT0026728 mtr-miR156g-3p; +MIMAT0026729 mtr-miR156h-3p; +MIMAT0026730 mtr-miR166g-5p; +MIMAT0026731 mtr-miR171e-5p; +MIMAT0026732 mtr-miR396b-3p; +MIMAT0026733 mtr-miR156i-3p; +MIMAT0026734 hsa-miR-942-3p; +MIMAT0026735 hsa-miR-1180-5p; +MIMAT0026736 hsa-miR-548e-5p; +MIMAT0026737 hsa-miR-548j-3p; +MIMAT0026738 hsa-miR-1287-3p; +MIMAT0026739 hsa-miR-548f-5p; +MIMAT0026740 hsa-miR-1250-3p; +MIMAT0026741 hsa-miR-1251-3p; +MIMAT0026742 hsa-miR-1266-3p; +MIMAT0026743 hsa-miR-1288-5p; +MIMAT0026744 hsa-miR-1252-3p; +MIMAT0026745 mml-miR-506-5p; +MIMAT0026746 mml-miR-508-5p; +MIMAT0026747 mml-miR-510-3p; +MIMAT0026748 mml-miR-514a-5p; +MIMAT0026749 hsa-miR-513b-3p; +MIMAT0026750 oan-miR-1327-3p; +MIMAT0026751 oan-miR-1332-5p; +MIMAT0026752 oan-miR-1a-5p; +MIMAT0026753 oan-miR-137b-5p; +MIMAT0026754 oan-miR-1420c-5p; +MIMAT0026755 oan-miR-1420e-5p; +MIMAT0026756 oan-miR-1351-3p; +MIMAT0026757 oan-miR-1421j-3p; +MIMAT0026758 oan-miR-1389-5p; +MIMAT0026759 oan-miR-1395-5p; +MIMAT0026760 oan-miR-1398-3p; +MIMAT0026761 oan-miR-1413-5p; +MIMAT0026762 osa-miR169r-5p; +MIMAT0026763 gga-miR-1306-5p; +MIMAT0026764 gga-miR-1462-3p; +MIMAT0026765 hsa-miR-1537-5p; +MIMAT0026766 mdo-miR-1542-1-5p; +MIMAT0026767 mdo-miR-340-3p; +MIMAT0026768 mdo-miR-1544a-3p; +MIMAT0026769 mdo-miR-1545a-5p; +MIMAT0026770 mdo-miR-1546-3p; +MIMAT0026771 mdo-miR-1547-3p; +MIMAT0026772 mdo-miR-1548-5p; +MIMAT0026773 mdo-miR-1549-5p; +MIMAT0026774 gga-miR-1555-5p; +MIMAT0026775 gga-miR-1559-3p; +MIMAT0026776 gga-miR-1618-5p; +MIMAT0026777 gga-miR-1655-3p; +MIMAT0026778 gga-miR-1667-5p; +MIMAT0026779 gga-miR-1703-3p; +MIMAT0026780 gga-miR-1731-3p; +MIMAT0026781 gga-miR-1747-3p; +MIMAT0026782 gga-miR-1754-3p; +MIMAT0026783 gga-miR-1759-3p; +MIMAT0026784 gga-miR-1775-5p; +MIMAT0026785 gga-miR-1812-3p; +MIMAT0026786 gga-miR-16c-3p; +MIMAT0026787 gga-miR-193a-5p; +MIMAT0026788 mml-miR-1-1-5p; +MIMAT0026789 mml-let-7a-3p; +MIMAT0026790 mml-let-7b-3p; +MIMAT0026791 mml-let-7c-3p; +MIMAT0026792 mml-let-7e-3p; +MIMAT0026793 mml-let-7f-3p; +MIMAT0026794 mml-let-7g-3p; +MIMAT0026795 mml-let-7i-3p; +MIMAT0026796 mml-miR-9-3p; +MIMAT0026797 mml-miR-10a-3p; +MIMAT0026798 mml-miR-10b-3p; +MIMAT0026799 mml-miR-20b-3p; +MIMAT0026800 mml-miR-23b-5p; +MIMAT0026801 mml-miR-26b-3p; +MIMAT0026802 mml-miR-27b-5p; +MIMAT0026803 mml-miR-29b-1-5p; +MIMAT0026804 mml-miR-29c-5p; +MIMAT0026805 mml-miR-30c-1-3p; +MIMAT0026806 mml-miR-30d-3p; +MIMAT0026807 mml-miR-30e-3p; +MIMAT0026808 mml-miR-33b-3p; +MIMAT0026809 mml-miR-92a-5p; +MIMAT0026810 mml-miR-92b-5p; +MIMAT0026811 mml-miR-95-5p; +MIMAT0026812 mml-miR-99b-3p; +MIMAT0026813 mml-miR-122a-3p; +MIMAT0026814 mml-miR-128b-5p; +MIMAT0026815 mml-miR-130b-5p; +MIMAT0026816 mml-miR-132-5p; +MIMAT0026817 mml-miR-133c-5p; +MIMAT0026818 mml-miR-133b-5p; +MIMAT0026819 mml-miR-134-3p; +MIMAT0026820 mml-miR-135b-3p; +MIMAT0026821 mml-miR-137-5p; +MIMAT0026822 mml-miR-138-3p; +MIMAT0026823 mml-miR-143-5p; +MIMAT0026824 mml-miR-146a-3p; +MIMAT0026825 mml-miR-148a-5p; +MIMAT0026826 mml-miR-148b-5p; +MIMAT0026827 mml-miR-149-3p; +MIMAT0026828 mml-miR-150-3p; +MIMAT0026829 mml-miR-152-5p; +MIMAT0026830 mml-miR-154-3p; +MIMAT0026831 mml-miR-185-3p; +MIMAT0026832 mml-miR-186-3p; +MIMAT0026833 mml-miR-187-5p; +MIMAT0026834 mml-miR-191-3p; +MIMAT0026835 mml-miR-192-3p; +MIMAT0026836 mml-miR-193b-5p; +MIMAT0026837 mml-miR-194-3p; +MIMAT0026838 mml-miR-195-3p; +MIMAT0026839 mml-miR-196a-3p; +MIMAT0026840 mml-miR-196b-3p; +MIMAT0026841 mml-miR-197-5p; +MIMAT0026842 mml-miR-200a-5p; +MIMAT0026843 mml-miR-204-3p; +MIMAT0026844 mml-miR-208a-5p; +MIMAT0026845 mml-miR-208b-5p; +MIMAT0026846 mml-miR-210-5p; +MIMAT0026847 mml-miR-212-5p; +MIMAT0026848 mml-miR-216a-3p; +MIMAT0026849 mml-miR-222-5p; +MIMAT0026850 mml-miR-301a-5p; +MIMAT0026851 mml-miR-302a-5p; +MIMAT0026852 mml-miR-329-1-5p; +MIMAT0026853 mml-miR-335-3p; +MIMAT0026854 mml-miR-340-3p; +MIMAT0026855 mml-miR-363-5p; +MIMAT0026856 mml-miR-365-1-5p; +MIMAT0026857 mml-miR-370-5p; +MIMAT0026858 mml-miR-372-5p; +MIMAT0026859 mml-miR-374a-3p; +MIMAT0026860 mml-miR-374b-3p; +MIMAT0026861 mml-miR-376a-1-5p; +MIMAT0026862 mml-miR-376b-5p; +MIMAT0026863 mml-miR-376c-5p; +MIMAT0026864 mml-miR-377-5p; +MIMAT0026865 mml-miR-379-3p; +MIMAT0026866 mml-miR-380-5p; +MIMAT0026867 mml-miR-381-5p; +MIMAT0026868 mml-miR-382-3p; +MIMAT0026869 mml-miR-410-5p; +MIMAT0026870 mml-miR-411-3p; +MIMAT0026871 mml-miR-412-5p; +MIMAT0026872 mml-miR-424-3p; +MIMAT0026873 mml-miR-429-5p; +MIMAT0026874 mml-miR-432-3p; +MIMAT0026875 mml-miR-433-5p; +MIMAT0026876 mml-miR-449a-3p; +MIMAT0026877 mml-miR-449b-3p; +MIMAT0026878 mml-miR-450a-1-3p; +MIMAT0026879 mml-miR-452-3p; +MIMAT0026880 mml-miR-454-5p; +MIMAT0026881 mml-miR-487b-5p; +MIMAT0026882 mml-miR-488-5p; +MIMAT0026883 mml-miR-489-5p; +MIMAT0026884 mml-miR-493-5p; +MIMAT0026885 mml-miR-494-5p; +MIMAT0026886 mml-miR-495-5p; +MIMAT0026887 mml-miR-497-3p; +MIMAT0026888 mml-miR-500a-3p; +MIMAT0026889 mml-miR-501-3p; +MIMAT0026890 mml-miR-503-3p; +MIMAT0026891 mml-miR-504-3p; +MIMAT0026892 mml-miR-505-5p; +MIMAT0026893 mml-miR-511-3p; +MIMAT0026894 mml-miR-518c-5p; +MIMAT0026895 mml-miR-519a-5p; +MIMAT0026896 mml-miR-520a-5p; +MIMAT0026897 mml-miR-550-3p; +MIMAT0026898 mml-miR-551b-5p; +MIMAT0026899 mml-miR-577-3p; +MIMAT0026900 mml-miR-584-3p; +MIMAT0026901 mml-miR-592-3p; +MIMAT0026902 mml-miR-598-5p; +MIMAT0026903 mml-miR-599-5p; +MIMAT0026904 mml-miR-627-5p; +MIMAT0026905 mml-miR-653-3p; +MIMAT0026906 mml-miR-656-5p; +MIMAT0026907 mml-miR-660-3p; +MIMAT0026908 mml-miR-675-3p; +MIMAT0026909 mml-miR-758-5p; +MIMAT0026910 mml-miR-874-5p; +MIMAT0026911 mml-miR-877-3p; +MIMAT0026912 mml-miR-889-5p; +MIMAT0026913 mml-miR-890-3p; +MIMAT0026914 mml-miR-934-3p; +MIMAT0026915 mml-miR-942-3p; +MIMAT0026916 hsa-miR-1908-3p; +MIMAT0026917 hsa-miR-1910-3p; +MIMAT0026918 bta-miR-296-5p; +MIMAT0026919 bta-miR-29d-5p; +MIMAT0026920 gga-miR-2131-3p; +MIMAT0026921 hsa-miR-2276-5p; +MIMAT0026922 bdi-miR166a-5p; +MIMAT0026923 bdi-miR171c-5p; +MIMAT0026924 mtr-miR2592b-5p; +MIMAT0026925 mtr-miR2592s-5p; +MIMAT0026926 mtr-miR2111d-3p; +MIMAT0026927 mtr-miR2111e-3p; +MIMAT0026928 mtr-miR2111m-3p; +MIMAT0026929 mdo-miR-26-2-3p; +MIMAT0026930 mdo-miR-148-5p; +MIMAT0026931 mdo-miR-153-2-5p; +MIMAT0026932 mdo-miR-301-5p; +MIMAT0026933 mdo-miR-190a-3p; +MIMAT0026934 mdo-miR-106-3p; +MIMAT0026935 mdo-miR-126-3p; +MIMAT0026936 mdo-miR-139-3p; +MIMAT0026937 mdo-miR-140-3p; +MIMAT0026938 mdo-miR-146a-3p; +MIMAT0026939 mdo-miR-146b-3p; +MIMAT0026940 mdo-miR-150-3p; +MIMAT0026941 mdo-miR-210-5p; +MIMAT0026942 mdo-miR-455-3p; +MIMAT0026943 mdo-miR-499-3p; +MIMAT0026944 mdo-miR-33-3p; +MIMAT0026945 mdo-miR-460-3p; +MIMAT0026946 mdo-miR-497-3p; +MIMAT0026947 mdo-miR-551b-5p; +MIMAT0026948 mdo-miR-599-5p; +MIMAT0026949 mdo-miR-875-3p; +MIMAT0026950 mml-miR-524-3p; +MIMAT0026951 mml-miR-541-3p; +MIMAT0026952 mml-miR-708-3p; +MIMAT0026953 mml-miR-543-5p; +MIMAT0026954 mml-miR-670-3p; +MIMAT0026955 oan-miR-182-3p; +MIMAT0026956 tgu-miR-1329-3p; +MIMAT0026957 tgu-miR-2955-5p; +MIMAT0026958 tgu-miR-1451-3p; +MIMAT0026959 tgu-miR-1677-3p; +MIMAT0026960 tgu-miR-1784-5p; +MIMAT0026961 tgu-miR-2963-5p; +MIMAT0026962 tgu-miR-458-5p; +MIMAT0026963 tgu-miR-1729-3p; +MIMAT0026964 tgu-miR-456-5p; +MIMAT0026965 tgu-miR-1803-5p; +MIMAT0026966 tgu-miR-2970-3p; +MIMAT0026967 tgu-miR-2188-3p; +MIMAT0026968 tgu-miR-2973-3p; +MIMAT0026969 tgu-miR-2979-3p; +MIMAT0026970 tgu-miR-2984-3p; +MIMAT0026971 tgu-miR-2987-5p; +MIMAT0026972 tgu-miR-363-5p; +MIMAT0026973 tgu-miR-148-5p;tgu-miR-148a-5p; +MIMAT0026974 tgu-let-7i-3p; +MIMAT0026975 tgu-let-7b-3p; +MIMAT0026976 tgu-miR-221-5p; +MIMAT0026977 tgu-miR-128-2-5p; +MIMAT0026978 tgu-miR-222-5p; +MIMAT0026979 tgu-miR-138-1-3p; +MIMAT0026980 tgu-miR-26-3p; +MIMAT0026981 tgu-miR-19b-1-5p; +MIMAT0026982 tgu-let-7e-3p; +MIMAT0026983 tgu-let-7c-3p; +MIMAT0026984 tgu-miR-218-3p; +MIMAT0026985 tgu-miR-103-5p; +MIMAT0026986 tgu-let-7g-3p; +MIMAT0026987 tgu-miR-122-3p; +MIMAT0026988 tgu-let-7f-3p; +MIMAT0026989 tgu-miR-383-3p; +MIMAT0026990 tgu-miR-29a-1-5p; +MIMAT0026991 tgu-miR-27-5p; +MIMAT0026992 tgu-let-7d-3p; +MIMAT0026993 tgu-miR-33-3p; +MIMAT0026994 tgu-miR-24-5p; +MIMAT0026995 tgu-miR-137-5p; +MIMAT0026996 tgu-miR-490-5p; +MIMAT0026997 tgu-miR-153-1-5p; +MIMAT0026998 tgu-miR-20a-3p; +MIMAT0026999 tgu-miR-142-3p; +MIMAT0027000 tgu-miR-15a-3p; +MIMAT0027001 tgu-miR-194-3p; +MIMAT0027002 tgu-miR-1-2-5p; +MIMAT0027003 tgu-miR-181b-1-3p; +MIMAT0027004 tgu-miR-187-5p; +MIMAT0027005 tgu-miR-133-5p; +MIMAT0027006 tgu-miR-130a-5p; +MIMAT0027007 tgu-miR-92-1-5p; +MIMAT0027008 tgu-miR-216a-3p; +MIMAT0027009 tgu-miR-215-3p; +MIMAT0027010 tgu-miR-217-3p; +MIMAT0027011 tgu-miR-454-5p; +MIMAT0027012 tgu-miR-130c-5p; +MIMAT0027013 tgu-miR-365-1-5p; +MIMAT0027014 tgu-miR-193a-5p; +MIMAT0027015 tgu-miR-190-3p; +MIMAT0027016 tgu-miR-106-3p; +MIMAT0027017 tgu-miR-20b-3p; +MIMAT0027018 tgu-miR-216b-3p; +MIMAT0027019 tgu-miR-1388-5p; +MIMAT0027020 tgu-miR-15b-3p; +MIMAT0027021 tgu-miR-214-5p; +MIMAT0027022 tgu-miR-203-5p; +MIMAT0027023 tgu-miR-19a-5p; +MIMAT0027024 tgu-miR-489-5p; +MIMAT0027025 tgu-miR-15c-3p; +MIMAT0027026 hsa-miR-3151-3p; +MIMAT0027027 hsa-miR-3192-3p; +MIMAT0027028 gga-miR-2188-3p; +MIMAT0027029 gga-miR-3530-5p; +MIMAT0027030 gga-miR-3531-3p; +MIMAT0027031 gga-miR-3532-5p; +MIMAT0027032 hsa-miR-500b-3p; +MIMAT0027033 tgu-miR-34c-3p; +MIMAT0027035 tgu-miR-10a-3p; +MIMAT0027036 hsa-miR-3912-5p; +MIMAT0027037 hsa-miR-3928-5p; +MIMAT0027038 hsa-miR-1343-5p; +MIMAT0027039 bdi-miR408-3p; +MIMAT0027040 bdi-miR1878-5p; +MIMAT0027041 hsa-miR-5088-3p; +MIMAT0027042 bdi-miR169j-3p; +MIMAT0027043 bdi-miR390a-3p; +MIMAT0027044 bdi-miR160a-3p; +MIMAT0027045 bdi-miR528-3p; +MIMAT0027046 bdi-miR166d-5p; +MIMAT0027047 bdi-miR171d-5p; +MIMAT0027048 bdi-miR166b-5p; +MIMAT0027049 bdi-miR160b-3p; +MIMAT0027050 bdi-miR167c-3p; +MIMAT0027051 bdi-miR396d-3p; +MIMAT0027052 bdi-miR169k-3p; +MIMAT0027053 bdi-miR168-3p; +MIMAT0027054 bdi-miR160c-3p; +MIMAT0027055 bdi-miR396c-3p; +MIMAT0027056 bdi-miR167d-3p; +MIMAT0027057 bdi-miR156b-3p; +MIMAT0027058 bdi-miR160d-3p; +MIMAT0027059 bdi-miR160e-3p; +MIMAT0027060 bdi-miR396e-3p; +MIMAT0027061 bdi-miR172a-5p; +MIMAT0027062 bdi-miR396a-3p; +MIMAT0027063 bdi-miR166e-5p; +MIMAT0027064 bdi-miR166c-5p; +MIMAT0027065 bdi-miR169e-3p; +MIMAT0027066 bdi-miR159-5p;bdi-miR159a-5p; +MIMAT0027067 bdi-miR164a-3p; +MIMAT0027068 bdi-miR169a-3p; +MIMAT0027069 bdi-miR156d-3p; +MIMAT0027070 bdi-miR393b-3p; +MIMAT0027071 bdi-miR169h-3p; +MIMAT0027072 bdi-miR396b-3p; +MIMAT0027073 bdi-miR169c-3p; +MIMAT0027074 bdi-miR395c-5p; +MIMAT0027075 bdi-miR827-5p; +MIMAT0027076 bdi-miR5163a-5p; +MIMAT0027077 bdi-miR5165-3p; +MIMAT0027078 bdi-miR5167-3p;bdi-miR5167a-3p; +MIMAT0027079 bdi-miR166g-5p; +MIMAT0027080 bdi-miR5172-5p; +MIMAT0027081 bdi-miR5173-3p; +MIMAT0027082 bdi-miR395d-5p; +MIMAT0027083 bdi-miR5178-5p; +MIMAT0027084 bdi-miR164c-3p; +MIMAT0027085 bdi-miR5181a-3p; +MIMAT0027086 bdi-miR5185a-3p; +MIMAT0027087 bdi-miR5185b-3p; +MIMAT0027088 hsa-miR-5189-3p; +MIMAT0027089 bdi-miR395e-5p; +MIMAT0027090 bdi-miR395f-5p; +MIMAT0027091 bdi-miR395g-5p; +MIMAT0027092 bdi-miR395h-5p; +MIMAT0027093 bdi-miR395j-5p; +MIMAT0027094 bdi-miR395k-5p; +MIMAT0027095 bdi-miR395l-5p; +MIMAT0027096 bdi-miR395n-5p; +MIMAT0027097 bdi-miR529-3p; +MIMAT0027098 bdi-miR5201-5p; +MIMAT0027099 bdi-miR319b-5p; +MIMAT0027100 mtr-miR5212-3p; +MIMAT0027101 mtr-miR5214-5p; +MIMAT0027102 mtr-miR482-3p; +MIMAT0027103 hsa-miR-5699-5p; +MIMAT0027104 mmu-miR-5709-3p; +MIMAT0027105 mml-miR-4446-5p; +MIMAT0027106 mml-miR-873-3p; +MIMAT0027107 mml-miR-1185-3p; +MIMAT0027108 mml-miR-1271-3p; +MIMAT0027109 mml-miR-1298-3p; +MIMAT0027110 mml-miR-1255a-3p; +MIMAT0027111 mml-miR-1262-5p; +MIMAT0027112 mml-miR-3200-5p; +MIMAT0027113 mml-miR-676-5p; +MIMAT0027114 mml-miR-1296-3p; +MIMAT0027115 mml-miR-891b-3p; +MIMAT0027116 mml-miR-1243-5p; +MIMAT0027117 mml-miR-4796-5p; +MIMAT0027118 mml-miR-1323-3p; +MIMAT0027119 mml-miR-514b-5p; +MIMAT0027120 mml-miR-3145-5p; +MIMAT0027121 mml-miR-518d-3p; +MIMAT0027122 lus-miR171a; +MIMAT0027123 lus-miR319a; +MIMAT0027124 lus-miR167a; +MIMAT0027125 lus-miR169a; +MIMAT0027126 lus-miR169b; +MIMAT0027127 lus-miR169c; +MIMAT0027128 lus-miR169d; +MIMAT0027129 lus-miR164a; +MIMAT0027130 lus-miR319b; +MIMAT0027131 lus-miR167b; +MIMAT0027132 lus-miR395a; +MIMAT0027133 lus-miR395b; +MIMAT0027134 lus-miR171b; +MIMAT0027135 lus-miR172a; +MIMAT0027136 lus-miR395c; +MIMAT0027137 lus-miR160a; +MIMAT0027138 lus-miR164b; +MIMAT0027139 lus-miR169e; +MIMAT0027140 lus-miR171c; +MIMAT0027141 lus-miR394a; +MIMAT0027142 lus-miR164c; +MIMAT0027143 lus-miR172b; +MIMAT0027144 lus-miR172c; +MIMAT0027145 lus-miR395d; +MIMAT0027146 lus-miR171d; +MIMAT0027147 lus-miR398a; +MIMAT0027148 lus-miR169f; +MIMAT0027149 lus-miR171e; +MIMAT0027150 lus-miR160b; +MIMAT0027151 lus-miR160c; +MIMAT0027152 lus-miR399a; +MIMAT0027153 lus-miR399b; +MIMAT0027154 lus-miR399c; +MIMAT0027155 lus-miR399d; +MIMAT0027156 lus-miR399e; +MIMAT0027157 lus-miR399f; +MIMAT0027158 lus-miR167c; +MIMAT0027159 lus-miR167d; +MIMAT0027160 lus-miR398b; +MIMAT0027161 lus-miR156b; +MIMAT0027162 lus-miR530a; +MIMAT0027163 lus-miR171f; +MIMAT0027164 lus-miR172d; +MIMAT0027165 lus-miR167e; +MIMAT0027166 lus-miR162a; +MIMAT0027167 lus-miR390a; +MIMAT0027168 lus-miR166a; +MIMAT0027169 lus-miR530b; +MIMAT0027170 lus-miR397a; +MIMAT0027171 lus-miR160d; +MIMAT0027172 lus-miR166b; +MIMAT0027173 lus-miR393a; +MIMAT0027174 lus-miR172e; +MIMAT0027175 lus-miR167f; +MIMAT0027176 lus-miR167g; +MIMAT0027177 lus-miR167h; +MIMAT0027178 lus-miR156i; +MIMAT0027179 lus-miR156c; +MIMAT0027180 lus-miR156d; +MIMAT0027181 lus-miR397b; +MIMAT0027182 lus-miR159a; +MIMAT0027183 lus-miR164d; +MIMAT0027184 lus-miR156e; +MIMAT0027185 lus-miR168a; +MIMAT0027186 lus-miR156f; +MIMAT0027187 lus-miR162b; +MIMAT0027188 lus-miR399g; +MIMAT0027189 lus-miR160e; +MIMAT0027190 lus-miR167i; +MIMAT0027191 lus-miR390b; +MIMAT0027192 lus-miR166c; +MIMAT0027193 lus-miR171g; +MIMAT0027194 lus-miR394b; +MIMAT0027195 lus-miR160f; +MIMAT0027196 lus-miR169g; +MIMAT0027197 lus-miR390c; +MIMAT0027198 lus-miR169h; +MIMAT0027199 lus-miR169i; +MIMAT0027200 lus-miR169j; +MIMAT0027201 lus-miR156g; +MIMAT0027202 lus-miR160g; +MIMAT0027203 lus-miR390d; +MIMAT0027204 lus-miR166d; +MIMAT0027205 lus-miR172f; +MIMAT0027206 lus-miR168b; +MIMAT0027207 lus-miR396a; +MIMAT0027208 lus-miR395e; +MIMAT0027209 lus-miR169k; +MIMAT0027210 lus-miR408a; +MIMAT0027211 lus-miR160h; +MIMAT0027212 lus-miR396b; +MIMAT0027213 lus-miR396c; +MIMAT0027214 lus-miR398c; +MIMAT0027215 lus-miR169l; +MIMAT0027216 lus-miR156a; +MIMAT0027217 lus-miR166e; +MIMAT0027218 lus-miR393b; +MIMAT0027219 lus-miR171h; +MIMAT0027220 lus-miR828a; +MIMAT0027221 lus-miR166f; +MIMAT0027222 lus-miR160i; +MIMAT0027223 lus-miR166g; +MIMAT0027224 lus-miR171i; +MIMAT0027225 lus-miR160j; +MIMAT0027226 lus-miR172g; +MIMAT0027227 lus-miR164e; +MIMAT0027228 lus-miR172h; +MIMAT0027229 lus-miR393c; +MIMAT0027230 lus-miR172i; +MIMAT0027231 lus-miR166h; +MIMAT0027232 lus-miR393d; +MIMAT0027233 lus-miR159b; +MIMAT0027234 lus-miR172j; +MIMAT0027235 lus-miR159c; +MIMAT0027236 lus-miR166i; +MIMAT0027237 lus-miR396d; +MIMAT0027238 pgi-miR482a; +MIMAT0027239 pgi-miR482b; +MIMAT0027240 pgi-miR2118; +MIMAT0027241 pgi-miR6135a; +MIMAT0027242 pgi-miR6135b; +MIMAT0027243 pgi-miR6135c; +MIMAT0027244 pgi-miR6135d; +MIMAT0027245 pgi-miR6135e-5p; +MIMAT0027246 pgi-miR6135e.2-5p; +MIMAT0027247 pgi-miR6135f; +MIMAT0027248 pgi-miR6135g; +MIMAT0027249 pgi-miR6135h; +MIMAT0027250 pgi-miR6135i; +MIMAT0027251 pgi-miR6135j; +MIMAT0027252 pgi-miR4376;pgi-miR391; +MIMAT0027253 pgi-miR6136a.1; +MIMAT0027254 pgi-miR6136a.2; +MIMAT0027255 pgi-miR6136b; +MIMAT0027256 pgi-miR6135k; +MIMAT0027257 pgi-miR6137a; +MIMAT0027258 pgi-miR6137b; +MIMAT0027259 pgi-miR6138; +MIMAT0027260 pgi-miR6139; +MIMAT0027261 pgi-miR6140a; +MIMAT0027262 pgi-miR6140b; +MIMAT0027263 pgi-miR6140c; +MIMAT0027264 pgi-miR6140d; +MIMAT0027265 pgi-miR6141; +MIMAT0027266 pgi-miR6142; +MIMAT0027267 pgi-miR6143a; +MIMAT0027268 pgi-miR6143b-5p; +MIMAT0027269 pgi-miR6143b-3p; +MIMAT0027270 ppe-miR6257; +MIMAT0027271 ppe-miR6258; +MIMAT0027272 ppe-miR482a-3p; +MIMAT0027273 ppe-miR482b-3p; +MIMAT0027274 ppe-miR171f; +MIMAT0027275 ppe-miR6259; +MIMAT0027276 ppe-miR6260; +MIMAT0027277 ppe-miR6261; +MIMAT0027278 ppe-miR6262; +MIMAT0027280 ppe-miR6263; +MIMAT0027281 ppe-miR6264; +MIMAT0027282 ppe-miR828-3p; +MIMAT0027283 ppe-miR482c-5p; +MIMAT0027284 ppe-miR6265; +MIMAT0027285 ppe-miR171h; +MIMAT0027286 ppe-miR171a; +MIMAT0027287 ppe-miR477a-3p; +MIMAT0027288 ppe-miR477b-3p; +MIMAT0027289 ppe-miR171e; +MIMAT0027290 ppe-miR6266a; +MIMAT0027291 ppe-miR6267a; +MIMAT0027293 ppe-miR6269; +MIMAT0027294 ppe-miR398a-3p; +MIMAT0027295 ppe-miR6270; +MIMAT0027296 ppe-miR6271; +MIMAT0027297 ppe-miR6267b; +MIMAT0027298 ppe-miR6272; +MIMAT0027299 ppe-miR6273; +MIMAT0027300 ppe-miR319a; +MIMAT0027301 ppe-miR6274;ppe-miR6274a; +MIMAT0027302 ppe-miR6275; +MIMAT0027303 ppe-miR319b; +MIMAT0027304 ppe-miR171g; +MIMAT0027305 ppe-miR6276; +MIMAT0027306 ppe-miR6277; +MIMAT0027307 ppe-miR6278; +MIMAT0027308 ppe-miR6279; +MIMAT0027309 ppe-miR171b; +MIMAT0027310 ppe-miR6280; +MIMAT0027311 ppe-miR6281; +MIMAT0027312 ppe-miR6282; +MIMAT0027313 ppe-miR6283; +MIMAT0027314 ppe-miR6284; +MIMAT0027315 ppe-miR482d-3p; +MIMAT0027316 ppe-miR6285; +MIMAT0027317 ppe-miR6286; +MIMAT0027318 ppe-miR482e; +MIMAT0027319 ppe-miR6287; +MIMAT0027320 ppe-miR6288;ppe-miR6288a; +MIMAT0027322 ppe-miR6289; +MIMAT0027323 ppe-miR171c; +MIMAT0027324 ppe-miR6266b; +MIMAT0027325 ppe-miR6290; +MIMAT0027326 ppe-miR6291a; +MIMAT0027327 ppe-miR6292; +MIMAT0027328 ppe-miR398b; +MIMAT0027329 ppe-miR6293; +MIMAT0027330 ppe-miR6294; +MIMAT0027331 ppe-miR6295; +MIMAT0027332 ppe-miR6296; +MIMAT0027333 ppe-miR6291b; +MIMAT0027334 ppe-miR6266c; +MIMAT0027335 ppe-miR6297a; +MIMAT0027336 ppe-miR6297b; +MIMAT0027337 ptc-miR6468-5p; +MIMAT0027338 ptc-miR482b-5p; +MIMAT0027339 mmu-miR-6481; +MIMAT0027340 tgu-miR-499-3p; +MIMAT0027341 tgu-miR-1397-3p; +MIMAT0027342 tgu-miR-1467-3p; +MIMAT0027343 mmu-miR-6516-5p; +MIMAT0027344 mmu-miR-6516-3p; +MIMAT0027345 hsa-miR-6720-5p; +MIMAT0027346 blv-miR-B1-5p; +MIMAT0027347 blv-miR-B4-5p; +MIMAT0027348 cln-miR162; +MIMAT0027349 cln-miR164; +MIMAT0027350 cln-miR166; +MIMAT0027351 cln-miR1310; +MIMAT0027352 cln-miR6725; +MIMAT0027353 hsa-miR-6726-5p; +MIMAT0027354 hsa-miR-6726-3p; +MIMAT0027355 hsa-miR-6727-5p; +MIMAT0027356 hsa-miR-6727-3p; +MIMAT0027357 hsa-miR-6728-5p; +MIMAT0027358 hsa-miR-6728-3p; +MIMAT0027359 hsa-miR-6729-5p; +MIMAT0027360 hsa-miR-6729-3p; +MIMAT0027361 hsa-miR-6730-5p; +MIMAT0027362 hsa-miR-6730-3p; +MIMAT0027363 hsa-miR-6731-5p; +MIMAT0027364 hsa-miR-6731-3p; +MIMAT0027365 hsa-miR-6732-5p; +MIMAT0027366 hsa-miR-6732-3p; +MIMAT0027367 hsa-miR-6733-5p; +MIMAT0027368 hsa-miR-6733-3p; +MIMAT0027369 hsa-miR-6734-5p; +MIMAT0027370 hsa-miR-6734-3p; +MIMAT0027371 hsa-miR-6735-5p; +MIMAT0027372 hsa-miR-6735-3p; +MIMAT0027373 hsa-miR-6736-5p; +MIMAT0027374 hsa-miR-6736-3p; +MIMAT0027375 hsa-miR-6737-5p; +MIMAT0027376 hsa-miR-6737-3p; +MIMAT0027377 hsa-miR-6738-5p; +MIMAT0027378 hsa-miR-6738-3p; +MIMAT0027379 hsa-miR-6739-5p; +MIMAT0027380 hsa-miR-6739-3p; +MIMAT0027381 hsa-miR-6740-5p; +MIMAT0027382 hsa-miR-6740-3p; +MIMAT0027383 hsa-miR-6741-5p; +MIMAT0027384 hsa-miR-6741-3p; +MIMAT0027385 hsa-miR-6742-5p; +MIMAT0027386 hsa-miR-6742-3p; +MIMAT0027387 hsa-miR-6743-5p; +MIMAT0027388 hsa-miR-6743-3p; +MIMAT0027389 hsa-miR-6744-5p; +MIMAT0027390 hsa-miR-6744-3p; +MIMAT0027391 hsa-miR-6745; +MIMAT0027392 hsa-miR-6746-5p; +MIMAT0027393 hsa-miR-6746-3p; +MIMAT0027394 hsa-miR-6747-5p; +MIMAT0027395 hsa-miR-6747-3p; +MIMAT0027396 hsa-miR-6748-5p; +MIMAT0027397 hsa-miR-6748-3p; +MIMAT0027398 hsa-miR-6749-5p; +MIMAT0027399 hsa-miR-6749-3p; +MIMAT0027400 hsa-miR-6750-5p; +MIMAT0027401 hsa-miR-6750-3p; +MIMAT0027402 hsa-miR-6751-5p; +MIMAT0027403 hsa-miR-6751-3p; +MIMAT0027404 hsa-miR-6752-5p; +MIMAT0027405 hsa-miR-6752-3p; +MIMAT0027406 hsa-miR-6753-5p; +MIMAT0027407 hsa-miR-6753-3p; +MIMAT0027408 hsa-miR-6754-5p; +MIMAT0027409 hsa-miR-6754-3p; +MIMAT0027410 hsa-miR-6755-5p; +MIMAT0027411 hsa-miR-6755-3p; +MIMAT0027412 hsa-miR-6756-5p; +MIMAT0027413 hsa-miR-6756-3p; +MIMAT0027414 hsa-miR-6757-5p; +MIMAT0027415 hsa-miR-6757-3p; +MIMAT0027416 hsa-miR-6758-5p; +MIMAT0027417 hsa-miR-6758-3p; +MIMAT0027418 hsa-miR-6759-5p; +MIMAT0027419 hsa-miR-6759-3p; +MIMAT0027420 hsa-miR-6760-5p; +MIMAT0027421 hsa-miR-6760-3p; +MIMAT0027422 hsa-miR-6761-5p; +MIMAT0027423 hsa-miR-6761-3p; +MIMAT0027424 hsa-miR-6762-5p; +MIMAT0027425 hsa-miR-6762-3p; +MIMAT0027426 hsa-miR-6763-5p; +MIMAT0027427 hsa-miR-6763-3p; +MIMAT0027428 hsa-miR-6764-5p; +MIMAT0027429 hsa-miR-6764-3p; +MIMAT0027430 hsa-miR-6765-5p; +MIMAT0027431 hsa-miR-6765-3p; +MIMAT0027432 hsa-miR-6766-5p; +MIMAT0027433 hsa-miR-6766-3p; +MIMAT0027434 hsa-miR-6767-5p; +MIMAT0027435 hsa-miR-6767-3p; +MIMAT0027436 hsa-miR-6768-5p; +MIMAT0027437 hsa-miR-6768-3p; +MIMAT0027438 hsa-miR-6769a-5p; +MIMAT0027439 hsa-miR-6769a-3p; +MIMAT0027440 hsa-miR-6770-5p; +MIMAT0027441 hsa-miR-6770-3p; +MIMAT0027442 hsa-miR-6771-5p; +MIMAT0027443 hsa-miR-6771-3p; +MIMAT0027444 hsa-miR-6772-5p; +MIMAT0027445 hsa-miR-6772-3p; +MIMAT0027446 hsa-miR-6773-5p; +MIMAT0027447 hsa-miR-6773-3p; +MIMAT0027448 hsa-miR-6774-5p; +MIMAT0027449 hsa-miR-6774-3p; +MIMAT0027450 hsa-miR-6775-5p; +MIMAT0027451 hsa-miR-6775-3p; +MIMAT0027452 hsa-miR-6776-5p; +MIMAT0027453 hsa-miR-6776-3p; +MIMAT0027454 hsa-miR-6777-5p; +MIMAT0027455 hsa-miR-6777-3p; +MIMAT0027456 hsa-miR-6778-5p; +MIMAT0027457 hsa-miR-6778-3p; +MIMAT0027458 hsa-miR-6779-5p; +MIMAT0027459 hsa-miR-6779-3p; +MIMAT0027460 hsa-miR-6780a-5p; +MIMAT0027461 hsa-miR-6780a-3p; +MIMAT0027462 hsa-miR-6781-5p; +MIMAT0027463 hsa-miR-6781-3p; +MIMAT0027464 hsa-miR-6782-5p; +MIMAT0027465 hsa-miR-6782-3p; +MIMAT0027466 hsa-miR-6783-5p; +MIMAT0027467 hsa-miR-6783-3p; +MIMAT0027468 hsa-miR-6784-5p; +MIMAT0027469 hsa-miR-6784-3p; +MIMAT0027470 hsa-miR-6785-5p; +MIMAT0027471 hsa-miR-6785-3p; +MIMAT0027472 hsa-miR-6786-5p; +MIMAT0027473 hsa-miR-6786-3p; +MIMAT0027474 hsa-miR-6787-5p; +MIMAT0027475 hsa-miR-6787-3p; +MIMAT0027476 hsa-miR-6788-5p; +MIMAT0027477 hsa-miR-6788-3p; +MIMAT0027478 hsa-miR-6789-5p; +MIMAT0027479 hsa-miR-6789-3p; +MIMAT0027480 hsa-miR-6790-5p; +MIMAT0027481 hsa-miR-6790-3p; +MIMAT0027482 hsa-miR-6791-5p; +MIMAT0027483 hsa-miR-6791-3p; +MIMAT0027484 hsa-miR-6792-5p; +MIMAT0027485 hsa-miR-6792-3p; +MIMAT0027486 hsa-miR-6793-5p; +MIMAT0027487 hsa-miR-6793-3p; +MIMAT0027488 hsa-miR-6794-5p; +MIMAT0027489 hsa-miR-6794-3p; +MIMAT0027490 hsa-miR-6795-5p; +MIMAT0027491 hsa-miR-6795-3p; +MIMAT0027492 hsa-miR-6796-5p; +MIMAT0027493 hsa-miR-6796-3p; +MIMAT0027494 hsa-miR-6797-5p; +MIMAT0027495 hsa-miR-6797-3p; +MIMAT0027496 hsa-miR-6798-5p; +MIMAT0027497 hsa-miR-6798-3p; +MIMAT0027498 hsa-miR-6799-5p; +MIMAT0027499 hsa-miR-6799-3p; +MIMAT0027500 hsa-miR-6800-5p; +MIMAT0027501 hsa-miR-6800-3p; +MIMAT0027502 hsa-miR-6801-5p; +MIMAT0027503 hsa-miR-6801-3p; +MIMAT0027504 hsa-miR-6802-5p; +MIMAT0027505 hsa-miR-6802-3p; +MIMAT0027506 hsa-miR-6803-5p; +MIMAT0027507 hsa-miR-6803-3p; +MIMAT0027508 hsa-miR-6804-5p; +MIMAT0027509 hsa-miR-6804-3p; +MIMAT0027510 hsa-miR-6805-5p; +MIMAT0027511 hsa-miR-6805-3p; +MIMAT0027512 hsa-miR-6806-5p; +MIMAT0027513 hsa-miR-6806-3p; +MIMAT0027514 hsa-miR-6807-5p; +MIMAT0027515 hsa-miR-6807-3p; +MIMAT0027516 hsa-miR-6808-5p; +MIMAT0027517 hsa-miR-6808-3p; +MIMAT0027518 hsa-miR-6809-5p; +MIMAT0027519 hsa-miR-6809-3p; +MIMAT0027520 hsa-miR-6810-5p; +MIMAT0027521 hsa-miR-6810-3p; +MIMAT0027522 hsa-miR-6811-5p; +MIMAT0027523 hsa-miR-6811-3p; +MIMAT0027524 hsa-miR-6812-5p; +MIMAT0027525 hsa-miR-6812-3p; +MIMAT0027526 hsa-miR-6813-5p; +MIMAT0027527 hsa-miR-6813-3p; +MIMAT0027528 hsa-miR-6814-5p; +MIMAT0027529 hsa-miR-6814-3p; +MIMAT0027530 hsa-miR-6815-5p; +MIMAT0027531 hsa-miR-6815-3p; +MIMAT0027532 hsa-miR-6816-5p; +MIMAT0027533 hsa-miR-6816-3p; +MIMAT0027534 hsa-miR-6817-5p; +MIMAT0027535 hsa-miR-6817-3p; +MIMAT0027536 hsa-miR-6818-5p; +MIMAT0027537 hsa-miR-6818-3p; +MIMAT0027538 hsa-miR-6819-5p; +MIMAT0027539 hsa-miR-6819-3p; +MIMAT0027540 hsa-miR-6820-5p; +MIMAT0027541 hsa-miR-6820-3p; +MIMAT0027542 hsa-miR-6821-5p; +MIMAT0027543 hsa-miR-6821-3p; +MIMAT0027544 hsa-miR-6822-5p; +MIMAT0027545 hsa-miR-6822-3p; +MIMAT0027546 hsa-miR-6823-5p; +MIMAT0027547 hsa-miR-6823-3p; +MIMAT0027548 hsa-miR-6824-5p; +MIMAT0027549 hsa-miR-6824-3p; +MIMAT0027550 hsa-miR-6825-5p; +MIMAT0027551 hsa-miR-6825-3p; +MIMAT0027552 hsa-miR-6826-5p; +MIMAT0027553 hsa-miR-6826-3p; +MIMAT0027554 hsa-miR-6827-5p; +MIMAT0027555 hsa-miR-6827-3p; +MIMAT0027556 hsa-miR-6828-5p; +MIMAT0027557 hsa-miR-6828-3p; +MIMAT0027558 hsa-miR-6829-5p; +MIMAT0027559 hsa-miR-6829-3p; +MIMAT0027560 hsa-miR-6830-5p; +MIMAT0027561 hsa-miR-6830-3p; +MIMAT0027562 hsa-miR-6831-5p; +MIMAT0027563 hsa-miR-6831-3p; +MIMAT0027564 hsa-miR-6832-5p; +MIMAT0027565 hsa-miR-6832-3p; +MIMAT0027566 hsa-miR-6833-5p; +MIMAT0027567 hsa-miR-6833-3p; +MIMAT0027568 hsa-miR-6834-5p; +MIMAT0027569 hsa-miR-6834-3p; +MIMAT0027570 hsa-miR-6835-5p; +MIMAT0027571 hsa-miR-6835-3p; +MIMAT0027572 hsa-miR-6780b-5p; +MIMAT0027573 hsa-miR-6780b-3p; +MIMAT0027574 hsa-miR-6836-5p; +MIMAT0027575 hsa-miR-6836-3p; +MIMAT0027576 hsa-miR-6837-5p; +MIMAT0027577 hsa-miR-6837-3p; +MIMAT0027578 hsa-miR-6838-5p; +MIMAT0027579 hsa-miR-6838-3p; +MIMAT0027580 hsa-miR-6839-5p; +MIMAT0027581 hsa-miR-6839-3p; +MIMAT0027582 hsa-miR-6840-5p; +MIMAT0027583 hsa-miR-6840-3p; +MIMAT0027584 hsa-miR-6841-5p; +MIMAT0027585 hsa-miR-6841-3p; +MIMAT0027586 hsa-miR-6842-5p; +MIMAT0027587 hsa-miR-6842-3p; +MIMAT0027588 hsa-miR-6843-3p; +MIMAT0027589 hsa-miR-6844; +MIMAT0027590 hsa-miR-6845-5p; +MIMAT0027591 hsa-miR-6845-3p; +MIMAT0027592 hsa-miR-6846-5p; +MIMAT0027593 hsa-miR-6846-3p; +MIMAT0027594 hsa-miR-6847-5p; +MIMAT0027595 hsa-miR-6847-3p; +MIMAT0027596 hsa-miR-6848-5p; +MIMAT0027597 hsa-miR-6848-3p; +MIMAT0027598 hsa-miR-6849-5p; +MIMAT0027599 hsa-miR-6849-3p; +MIMAT0027600 hsa-miR-6850-5p; +MIMAT0027601 hsa-miR-6850-3p; +MIMAT0027602 hsa-miR-6851-5p; +MIMAT0027603 hsa-miR-6851-3p; +MIMAT0027604 hsa-miR-6852-5p; +MIMAT0027605 hsa-miR-6852-3p; +MIMAT0027606 hsa-miR-6853-5p; +MIMAT0027607 hsa-miR-6853-3p; +MIMAT0027608 hsa-miR-6854-5p; +MIMAT0027609 hsa-miR-6854-3p; +MIMAT0027610 hsa-miR-6855-5p; +MIMAT0027611 hsa-miR-6855-3p; +MIMAT0027612 hsa-miR-6856-5p; +MIMAT0027613 hsa-miR-6856-3p; +MIMAT0027614 hsa-miR-6857-5p; +MIMAT0027615 hsa-miR-6857-3p; +MIMAT0027616 hsa-miR-6858-5p; +MIMAT0027617 hsa-miR-6858-3p; +MIMAT0027618 hsa-miR-6859-5p; +MIMAT0027619 hsa-miR-6859-3p; +MIMAT0027620 hsa-miR-6769b-5p; +MIMAT0027621 hsa-miR-6769b-3p; +MIMAT0027622 hsa-miR-6860; +MIMAT0027623 hsa-miR-6861-5p; +MIMAT0027624 hsa-miR-6861-3p; +MIMAT0027625 hsa-miR-6862-5p; +MIMAT0027626 hsa-miR-6862-3p; +MIMAT0027627 hsa-miR-6863; +MIMAT0027628 hsa-miR-6864-5p; +MIMAT0027629 hsa-miR-6864-3p; +MIMAT0027630 hsa-miR-6865-5p; +MIMAT0027631 hsa-miR-6865-3p; +MIMAT0027632 hsa-miR-6866-5p; +MIMAT0027633 hsa-miR-6866-3p; +MIMAT0027634 hsa-miR-6867-5p; +MIMAT0027635 hsa-miR-6867-3p; +MIMAT0027636 hsa-miR-6868-5p; +MIMAT0027637 hsa-miR-6868-3p; +MIMAT0027638 hsa-miR-6869-5p; +MIMAT0027639 hsa-miR-6869-3p; +MIMAT0027640 hsa-miR-6870-5p; +MIMAT0027641 hsa-miR-6870-3p; +MIMAT0027642 hsa-miR-6871-5p; +MIMAT0027643 hsa-miR-6871-3p; +MIMAT0027644 hsa-miR-6872-5p; +MIMAT0027645 hsa-miR-6872-3p; +MIMAT0027646 hsa-miR-6873-5p; +MIMAT0027647 hsa-miR-6873-3p; +MIMAT0027648 hsa-miR-6874-5p; +MIMAT0027649 hsa-miR-6874-3p; +MIMAT0027650 hsa-miR-6875-5p; +MIMAT0027651 hsa-miR-6875-3p; +MIMAT0027652 hsa-miR-6876-5p; +MIMAT0027653 hsa-miR-6876-3p; +MIMAT0027654 hsa-miR-6877-5p; +MIMAT0027655 hsa-miR-6877-3p; +MIMAT0027656 hsa-miR-6878-5p; +MIMAT0027657 hsa-miR-6878-3p; +MIMAT0027658 hsa-miR-6879-5p; +MIMAT0027659 hsa-miR-6879-3p; +MIMAT0027660 hsa-miR-6880-5p; +MIMAT0027661 hsa-miR-6880-3p; +MIMAT0027662 hsa-miR-6881-5p; +MIMAT0027663 hsa-miR-6881-3p; +MIMAT0027664 hsa-miR-6882-5p; +MIMAT0027665 hsa-miR-6882-3p; +MIMAT0027666 hsa-miR-6883-5p; +MIMAT0027667 hsa-miR-6883-3p; +MIMAT0027668 hsa-miR-6884-5p; +MIMAT0027669 hsa-miR-6884-3p; +MIMAT0027670 hsa-miR-6885-5p; +MIMAT0027671 hsa-miR-6885-3p; +MIMAT0027672 hsa-miR-6886-5p; +MIMAT0027673 hsa-miR-6886-3p; +MIMAT0027674 hsa-miR-6887-5p; +MIMAT0027675 hsa-miR-6887-3p; +MIMAT0027676 hsa-miR-6888-5p; +MIMAT0027677 hsa-miR-6888-3p; +MIMAT0027678 hsa-miR-6889-5p; +MIMAT0027679 hsa-miR-6889-3p; +MIMAT0027680 hsa-miR-6890-5p; +MIMAT0027681 hsa-miR-6890-3p; +MIMAT0027682 hsa-miR-6891-5p; +MIMAT0027683 hsa-miR-6891-3p; +MIMAT0027684 hsa-miR-6892-5p; +MIMAT0027685 hsa-miR-6892-3p; +MIMAT0027686 hsa-miR-6893-5p; +MIMAT0027687 hsa-miR-6893-3p; +MIMAT0027688 hsa-miR-6894-5p; +MIMAT0027689 hsa-miR-6894-3p; +MIMAT0027690 hsa-miR-6895-5p; +MIMAT0027691 hsa-miR-6895-3p; +MIMAT0027692 mmu-miR-6896-5p; +MIMAT0027693 mmu-miR-6896-3p; +MIMAT0027694 mmu-miR-6897-5p; +MIMAT0027695 mmu-miR-6897-3p; +MIMAT0027696 mmu-miR-6898-5p; +MIMAT0027697 mmu-miR-6898-3p; +MIMAT0027698 mmu-miR-6899-5p; +MIMAT0027699 mmu-miR-6899-3p; +MIMAT0027700 mmu-miR-6900-5p; +MIMAT0027701 mmu-miR-6900-3p; +MIMAT0027702 mmu-miR-6901-5p; +MIMAT0027703 mmu-miR-6901-3p; +MIMAT0027704 mmu-miR-6902-5p; +MIMAT0027705 mmu-miR-6902-3p; +MIMAT0027706 mmu-miR-6903-5p; +MIMAT0027707 mmu-miR-6903-3p; +MIMAT0027708 mmu-miR-6904-5p; +MIMAT0027709 mmu-miR-6904-3p; +MIMAT0027710 mmu-miR-6905-5p; +MIMAT0027711 mmu-miR-6905-3p; +MIMAT0027712 mmu-miR-6906-5p; +MIMAT0027713 mmu-miR-6906-3p; +MIMAT0027714 mmu-miR-6907-5p; +MIMAT0027715 mmu-miR-6907-3p; +MIMAT0027716 mmu-miR-6908-5p; +MIMAT0027717 mmu-miR-6908-3p; +MIMAT0027718 mmu-miR-6909-5p; +MIMAT0027719 mmu-miR-6909-3p; +MIMAT0027720 mmu-miR-6910-5p; +MIMAT0027721 mmu-miR-6910-3p; +MIMAT0027722 mmu-miR-6911-5p; +MIMAT0027723 mmu-miR-6911-3p; +MIMAT0027724 mmu-miR-6912-5p; +MIMAT0027725 mmu-miR-6912-3p; +MIMAT0027726 mmu-miR-6913-5p; +MIMAT0027727 mmu-miR-6913-3p; +MIMAT0027728 mmu-miR-6914-5p; +MIMAT0027729 mmu-miR-6914-3p; +MIMAT0027730 mmu-miR-6915-5p; +MIMAT0027731 mmu-miR-6915-3p; +MIMAT0027732 mmu-miR-6916-5p; +MIMAT0027733 mmu-miR-6916-3p; +MIMAT0027734 mmu-miR-6917-5p; +MIMAT0027735 mmu-miR-6917-3p; +MIMAT0027736 mmu-miR-6918-5p; +MIMAT0027737 mmu-miR-6918-3p; +MIMAT0027738 mmu-miR-6919-5p; +MIMAT0027739 mmu-miR-6919-3p; +MIMAT0027740 mmu-miR-6920-5p; +MIMAT0027741 mmu-miR-6920-3p; +MIMAT0027742 mmu-miR-6921-5p; +MIMAT0027743 mmu-miR-6921-3p; +MIMAT0027744 mmu-miR-6922-5p; +MIMAT0027745 mmu-miR-6922-3p; +MIMAT0027746 mmu-miR-6923-5p; +MIMAT0027747 mmu-miR-6923-3p; +MIMAT0027748 mmu-miR-6924-5p; +MIMAT0027749 mmu-miR-6924-3p; +MIMAT0027750 mmu-miR-6925-5p; +MIMAT0027751 mmu-miR-6925-3p; +MIMAT0027752 mmu-miR-6926-5p; +MIMAT0027753 mmu-miR-6926-3p; +MIMAT0027754 mmu-miR-6927-5p; +MIMAT0027755 mmu-miR-6927-3p; +MIMAT0027756 mmu-miR-6928-5p; +MIMAT0027757 mmu-miR-6928-3p; +MIMAT0027758 mmu-miR-6929-5p; +MIMAT0027759 mmu-miR-6929-3p; +MIMAT0027760 mmu-miR-6930-5p; +MIMAT0027761 mmu-miR-6930-3p; +MIMAT0027762 mmu-miR-6931-5p; +MIMAT0027763 mmu-miR-6931-3p; +MIMAT0027764 mmu-miR-6932-5p; +MIMAT0027765 mmu-miR-6932-3p; +MIMAT0027766 mmu-miR-6933-5p; +MIMAT0027767 mmu-miR-6933-3p; +MIMAT0027768 mmu-miR-6934-5p; +MIMAT0027769 mmu-miR-6934-3p; +MIMAT0027770 mmu-miR-6935-5p; +MIMAT0027771 mmu-miR-6935-3p; +MIMAT0027772 mmu-miR-6936-5p; +MIMAT0027773 mmu-miR-6936-3p; +MIMAT0027774 mmu-miR-6937-5p; +MIMAT0027775 mmu-miR-6937-3p; +MIMAT0027776 mmu-miR-6938-5p; +MIMAT0027777 mmu-miR-6938-3p; +MIMAT0027778 mmu-miR-6939-5p; +MIMAT0027779 mmu-miR-6939-3p; +MIMAT0027780 mmu-miR-6940-5p; +MIMAT0027781 mmu-miR-6940-3p; +MIMAT0027782 mmu-miR-6941-5p; +MIMAT0027783 mmu-miR-6941-3p; +MIMAT0027784 mmu-miR-6942-5p; +MIMAT0027785 mmu-miR-6942-3p; +MIMAT0027786 mmu-miR-6943-5p; +MIMAT0027787 mmu-miR-6943-3p; +MIMAT0027788 mmu-miR-6944-5p; +MIMAT0027789 mmu-miR-6944-3p; +MIMAT0027790 mmu-miR-6945-5p; +MIMAT0027791 mmu-miR-6945-3p; +MIMAT0027792 mmu-miR-6946-5p; +MIMAT0027793 mmu-miR-6946-3p; +MIMAT0027794 mmu-miR-6947-5p; +MIMAT0027795 mmu-miR-6947-3p; +MIMAT0027796 mmu-miR-6948-5p; +MIMAT0027797 mmu-miR-6948-3p; +MIMAT0027798 mmu-miR-6949-5p; +MIMAT0027799 mmu-miR-6949-3p; +MIMAT0027800 mmu-miR-6950-5p; +MIMAT0027801 mmu-miR-6950-3p; +MIMAT0027802 mmu-miR-6951-5p; +MIMAT0027803 mmu-miR-6951-3p; +MIMAT0027804 mmu-miR-6952-5p; +MIMAT0027805 mmu-miR-6952-3p; +MIMAT0027806 mmu-miR-6953-5p; +MIMAT0027807 mmu-miR-6953-3p; +MIMAT0027808 mmu-miR-6954-5p; +MIMAT0027809 mmu-miR-6954-3p; +MIMAT0027810 mmu-miR-6955-5p; +MIMAT0027811 mmu-miR-6955-3p; +MIMAT0027812 mmu-miR-6956-5p; +MIMAT0027813 mmu-miR-6956-3p; +MIMAT0027814 mmu-miR-6957-5p; +MIMAT0027815 mmu-miR-6957-3p; +MIMAT0027816 mmu-miR-6958-5p; +MIMAT0027817 mmu-miR-6958-3p; +MIMAT0027818 mmu-miR-6959-5p; +MIMAT0027819 mmu-miR-6959-3p; +MIMAT0027820 mmu-miR-6960-5p; +MIMAT0027821 mmu-miR-6960-3p; +MIMAT0027822 mmu-miR-6961-5p; +MIMAT0027823 mmu-miR-6961-3p; +MIMAT0027824 mmu-miR-6962-5p; +MIMAT0027825 mmu-miR-6962-3p; +MIMAT0027826 mmu-miR-6963-5p; +MIMAT0027827 mmu-miR-6963-3p; +MIMAT0027828 mmu-miR-6964-5p; +MIMAT0027829 mmu-miR-6964-3p; +MIMAT0027830 mmu-miR-6965-5p; +MIMAT0027831 mmu-miR-6965-3p; +MIMAT0027832 mmu-miR-3547-5p; +MIMAT0027833 mmu-miR-3547-3p; +MIMAT0027834 mmu-miR-6966-5p; +MIMAT0027835 mmu-miR-6966-3p; +MIMAT0027836 mmu-miR-6967-5p; +MIMAT0027837 mmu-miR-6967-3p; +MIMAT0027838 mmu-miR-6968-5p; +MIMAT0027839 mmu-miR-6968-3p; +MIMAT0027840 mmu-miR-6969-5p; +MIMAT0027841 mmu-miR-6969-3p; +MIMAT0027842 mmu-miR-6970-5p; +MIMAT0027843 mmu-miR-6970-3p; +MIMAT0027844 mmu-miR-6971-5p; +MIMAT0027845 mmu-miR-6971-3p; +MIMAT0027846 mmu-miR-6972-5p; +MIMAT0027847 mmu-miR-6972-3p; +MIMAT0027848 mmu-miR-6973a-5p; +MIMAT0027849 mmu-miR-6973a-3p; +MIMAT0027850 mmu-miR-6974-5p; +MIMAT0027851 mmu-miR-6974-3p; +MIMAT0027852 mmu-miR-6975-5p; +MIMAT0027853 mmu-miR-6975-3p; +MIMAT0027854 mmu-miR-6976-5p; +MIMAT0027855 mmu-miR-6976-3p; +MIMAT0027856 mmu-miR-6977-5p; +MIMAT0027857 mmu-miR-6977-3p; +MIMAT0027858 mmu-miR-6978-5p; +MIMAT0027859 mmu-miR-6978-3p; +MIMAT0027860 mmu-miR-6979-5p; +MIMAT0027861 mmu-miR-6979-3p; +MIMAT0027862 mmu-miR-6980-5p; +MIMAT0027863 mmu-miR-6980-3p; +MIMAT0027864 mmu-miR-6981-5p; +MIMAT0027865 mmu-miR-6981-3p; +MIMAT0027866 mmu-miR-6982-5p; +MIMAT0027867 mmu-miR-6982-3p; +MIMAT0027868 mmu-miR-6983-5p; +MIMAT0027869 mmu-miR-6983-3p; +MIMAT0027870 mmu-miR-6984-5p; +MIMAT0027871 mmu-miR-6984-3p; +MIMAT0027872 mmu-miR-6985-5p; +MIMAT0027873 mmu-miR-6985-3p; +MIMAT0027874 mmu-miR-6986-5p; +MIMAT0027875 mmu-miR-6986-3p; +MIMAT0027876 mmu-miR-6987-5p; +MIMAT0027877 mmu-miR-6987-3p; +MIMAT0027878 mmu-miR-6988-5p; +MIMAT0027879 mmu-miR-6988-3p; +MIMAT0027880 mmu-miR-6989-5p; +MIMAT0027881 mmu-miR-6989-3p; +MIMAT0027882 mmu-miR-6990-5p; +MIMAT0027883 mmu-miR-6990-3p; +MIMAT0027884 mmu-miR-6991-5p; +MIMAT0027885 mmu-miR-6991-3p; +MIMAT0027886 mmu-miR-6992-5p; +MIMAT0027887 mmu-miR-6992-3p; +MIMAT0027888 mmu-miR-6993-5p; +MIMAT0027889 mmu-miR-6993-3p; +MIMAT0027890 mmu-miR-6994-5p; +MIMAT0027891 mmu-miR-6994-3p; +MIMAT0027892 mmu-miR-6995-5p; +MIMAT0027893 mmu-miR-6995-3p; +MIMAT0027894 mmu-miR-6996-5p; +MIMAT0027895 mmu-miR-6996-3p; +MIMAT0027896 mmu-miR-6997-5p; +MIMAT0027897 mmu-miR-6997-3p; +MIMAT0027898 mmu-miR-6998-5p; +MIMAT0027899 mmu-miR-6998-3p; +MIMAT0027900 mmu-miR-6999-5p; +MIMAT0027901 mmu-miR-6999-3p; +MIMAT0027902 mmu-miR-7000-5p; +MIMAT0027903 mmu-miR-7000-3p; +MIMAT0027904 mmu-miR-7001-5p; +MIMAT0027905 mmu-miR-7001-3p; +MIMAT0027906 mmu-miR-7002-5p; +MIMAT0027907 mmu-miR-7002-3p; +MIMAT0027908 mmu-miR-6973b-5p; +MIMAT0027909 mmu-miR-6973b-3p; +MIMAT0027910 mmu-miR-7003-5p; +MIMAT0027911 mmu-miR-7003-3p; +MIMAT0027912 mmu-miR-7004-5p; +MIMAT0027913 mmu-miR-7004-3p; +MIMAT0027914 mmu-miR-7005-5p; +MIMAT0027915 mmu-miR-7005-3p; +MIMAT0027916 mmu-miR-7006-5p; +MIMAT0027917 mmu-miR-7006-3p; +MIMAT0027918 mmu-miR-7007-5p; +MIMAT0027919 mmu-miR-7007-3p; +MIMAT0027920 mmu-miR-7008-5p; +MIMAT0027921 mmu-miR-7008-3p; +MIMAT0027922 mmu-miR-7009-5p; +MIMAT0027923 mmu-miR-7009-3p; +MIMAT0027924 mmu-miR-7010-5p; +MIMAT0027925 mmu-miR-7010-3p; +MIMAT0027926 mmu-miR-7011-5p; +MIMAT0027927 mmu-miR-7011-3p; +MIMAT0027928 mmu-miR-7012-5p; +MIMAT0027929 mmu-miR-7012-3p; +MIMAT0027930 mmu-miR-7013-5p; +MIMAT0027931 mmu-miR-7013-3p; +MIMAT0027932 mmu-miR-7014-5p; +MIMAT0027933 mmu-miR-7014-3p; +MIMAT0027934 mmu-miR-7015-5p; +MIMAT0027935 mmu-miR-7015-3p; +MIMAT0027936 mmu-miR-7016-5p; +MIMAT0027937 mmu-miR-7016-3p; +MIMAT0027938 mmu-miR-7017-5p; +MIMAT0027939 mmu-miR-7017-3p; +MIMAT0027940 mmu-miR-7018-5p; +MIMAT0027941 mmu-miR-7018-3p; +MIMAT0027942 mmu-miR-7019-5p; +MIMAT0027943 mmu-miR-7019-3p; +MIMAT0027944 mmu-miR-7020-5p; +MIMAT0027945 mmu-miR-7020-3p; +MIMAT0027946 mmu-miR-7021-5p; +MIMAT0027947 mmu-miR-7021-3p; +MIMAT0027948 mmu-miR-7022-5p; +MIMAT0027949 mmu-miR-7022-3p; +MIMAT0027950 mmu-miR-7023-5p; +MIMAT0027951 mmu-miR-7023-3p; +MIMAT0027952 mmu-miR-7024-5p; +MIMAT0027953 mmu-miR-7024-3p; +MIMAT0027954 mmu-miR-7025-5p; +MIMAT0027955 mmu-miR-7025-3p; +MIMAT0027956 mmu-miR-7026-5p; +MIMAT0027957 mmu-miR-7026-3p; +MIMAT0027958 mmu-miR-7027-5p; +MIMAT0027959 mmu-miR-7027-3p; +MIMAT0027960 mmu-miR-7028-5p; +MIMAT0027961 mmu-miR-7028-3p; +MIMAT0027962 mmu-miR-7029-5p; +MIMAT0027963 mmu-miR-7029-3p; +MIMAT0027964 mmu-miR-7030-5p; +MIMAT0027965 mmu-miR-7030-3p; +MIMAT0027966 mmu-miR-7031-5p; +MIMAT0027967 mmu-miR-7031-3p; +MIMAT0027968 mmu-miR-7032-5p; +MIMAT0027969 mmu-miR-7032-3p; +MIMAT0027970 mmu-miR-7033-5p; +MIMAT0027971 mmu-miR-7033-3p; +MIMAT0027972 mmu-miR-7034-5p; +MIMAT0027973 mmu-miR-7034-3p; +MIMAT0027974 mmu-miR-7035-5p; +MIMAT0027975 mmu-miR-7035-3p; +MIMAT0027976 mmu-miR-7036-5p;mmu-miR-7036a-5p; +MIMAT0027977 mmu-miR-7036-3p;mmu-miR-7036a-3p; +MIMAT0027978 mmu-miR-7037-5p; +MIMAT0027979 mmu-miR-7037-3p; +MIMAT0027980 mmu-miR-7038-5p; +MIMAT0027981 mmu-miR-7038-3p; +MIMAT0027982 mmu-miR-7039-5p; +MIMAT0027983 mmu-miR-7039-3p; +MIMAT0027984 mmu-miR-7040-5p; +MIMAT0027985 mmu-miR-7040-3p; +MIMAT0027986 mmu-miR-7041-5p; +MIMAT0027987 mmu-miR-7041-3p; +MIMAT0027988 mmu-miR-7042-5p; +MIMAT0027989 mmu-miR-7042-3p; +MIMAT0027990 mmu-miR-7043-5p; +MIMAT0027991 mmu-miR-7043-3p; +MIMAT0027992 mmu-miR-7044-5p; +MIMAT0027993 mmu-miR-7044-3p; +MIMAT0027994 mmu-miR-7045-5p; +MIMAT0027995 mmu-miR-7045-3p; +MIMAT0027996 mmu-miR-7046-5p; +MIMAT0027997 mmu-miR-7046-3p; +MIMAT0027998 mmu-miR-7047-5p; +MIMAT0027999 mmu-miR-7047-3p; +MIMAT0028000 mmu-miR-7048-5p; +MIMAT0028001 mmu-miR-7048-3p; +MIMAT0028002 mmu-miR-7049-5p; +MIMAT0028003 mmu-miR-7049-3p; +MIMAT0028004 mmu-miR-7050-5p; +MIMAT0028005 mmu-miR-7050-3p; +MIMAT0028006 mmu-miR-7051-5p; +MIMAT0028007 mmu-miR-7051-3p; +MIMAT0028008 mmu-miR-7052-5p; +MIMAT0028009 mmu-miR-7052-3p; +MIMAT0028010 mmu-miR-7053-5p; +MIMAT0028011 mmu-miR-7053-3p; +MIMAT0028012 mmu-miR-7054-5p; +MIMAT0028013 mmu-miR-7054-3p; +MIMAT0028014 mmu-miR-7055-5p; +MIMAT0028015 mmu-miR-7055-3p; +MIMAT0028016 mmu-miR-7056-5p; +MIMAT0028017 mmu-miR-7056-3p; +MIMAT0028018 mmu-miR-7057-5p; +MIMAT0028019 mmu-miR-7057-3p; +MIMAT0028020 mmu-miR-7058-5p; +MIMAT0028021 mmu-miR-7058-3p; +MIMAT0028022 mmu-miR-7059-5p; +MIMAT0028023 mmu-miR-7059-3p; +MIMAT0028024 mmu-miR-7060-5p; +MIMAT0028025 mmu-miR-7060-3p; +MIMAT0028026 mmu-miR-7061-5p; +MIMAT0028027 mmu-miR-7061-3p; +MIMAT0028028 mmu-miR-7062-5p; +MIMAT0028029 mmu-miR-7062-3p; +MIMAT0028030 mmu-miR-7063-5p; +MIMAT0028031 mmu-miR-7063-3p; +MIMAT0028032 mmu-miR-7064-5p; +MIMAT0028033 mmu-miR-7064-3p; +MIMAT0028034 mmu-miR-7065-5p; +MIMAT0028035 mmu-miR-7065-3p; +MIMAT0028036 mmu-miR-7066-5p; +MIMAT0028037 mmu-miR-7066-3p; +MIMAT0028038 mmu-miR-7067-5p; +MIMAT0028039 mmu-miR-7067-3p; +MIMAT0028040 mmu-miR-6769b-5p; +MIMAT0028041 mmu-miR-6769b-3p; +MIMAT0028042 mmu-miR-7068-5p; +MIMAT0028043 mmu-miR-7068-3p; +MIMAT0028044 mmu-miR-7069-5p; +MIMAT0028045 mmu-miR-7069-3p; +MIMAT0028046 mmu-miR-7070-5p; +MIMAT0028047 mmu-miR-7070-3p; +MIMAT0028048 mmu-miR-7071-5p; +MIMAT0028049 mmu-miR-7071-3p; +MIMAT0028050 mmu-miR-7072-5p; +MIMAT0028051 mmu-miR-7072-3p; +MIMAT0028052 mmu-miR-7073-5p; +MIMAT0028053 mmu-miR-7073-3p; +MIMAT0028054 mmu-miR-7074-5p; +MIMAT0028055 mmu-miR-7074-3p; +MIMAT0028056 mmu-miR-7075-5p; +MIMAT0028057 mmu-miR-7075-3p; +MIMAT0028058 mmu-miR-7076-5p; +MIMAT0028059 mmu-miR-7076-3p; +MIMAT0028060 mmu-miR-7077-5p; +MIMAT0028061 mmu-miR-7077-3p; +MIMAT0028062 mmu-miR-7078-5p; +MIMAT0028063 mmu-miR-7078-3p; +MIMAT0028064 mmu-miR-7079-5p; +MIMAT0028065 mmu-miR-7079-3p; +MIMAT0028066 mmu-miR-7080-5p; +MIMAT0028067 mmu-miR-7080-3p; +MIMAT0028068 mmu-miR-7081-5p; +MIMAT0028069 mmu-miR-7081-3p; +MIMAT0028070 mmu-miR-7082-5p; +MIMAT0028071 mmu-miR-7082-3p; +MIMAT0028072 mmu-miR-7083-5p; +MIMAT0028073 mmu-miR-7083-3p; +MIMAT0028074 mmu-miR-7084-5p; +MIMAT0028075 mmu-miR-7084-3p; +MIMAT0028076 mmu-miR-7085-5p; +MIMAT0028077 mmu-miR-7085-3p; +MIMAT0028078 mmu-miR-7086-5p; +MIMAT0028079 mmu-miR-7086-3p; +MIMAT0028080 mmu-miR-7087-5p; +MIMAT0028081 mmu-miR-7087-3p; +MIMAT0028082 mmu-miR-7088-5p; +MIMAT0028083 mmu-miR-7088-3p; +MIMAT0028084 mmu-miR-7089-5p; +MIMAT0028085 mmu-miR-7089-3p; +MIMAT0028086 mmu-miR-7090-5p; +MIMAT0028087 mmu-miR-7090-3p; +MIMAT0028088 mmu-miR-7091-5p; +MIMAT0028089 mmu-miR-7091-3p; +MIMAT0028090 mmu-miR-7092-5p; +MIMAT0028091 mmu-miR-7092-3p; +MIMAT0028092 mmu-miR-7093-5p; +MIMAT0028093 mmu-miR-7093-3p; +MIMAT0028094 mmu-miR-7094-1-5p; +MIMAT0028095 mmu-miR-7094-3p; +MIMAT0028096 mmu-miR-7094b-2-5p; +MIMAT0028097 ddi-miR-7095-5p; +MIMAT0028098 ddi-miR-7095-3p; +MIMAT0028099 ddi-miR-7096; +MIMAT0028100 ddi-miR-7097; +MIMAT0028101 ddi-miR-7098; +MIMAT0028102 ddi-miR-7099; +MIMAT0028103 ddi-miR-7100; +MIMAT0028104 ddi-miR-7101; +MIMAT0028105 ddi-miR-7102; +MIMAT0028106 ddi-miR-7103; +MIMAT0028107 ddi-miR-7104; +MIMAT0028108 ddi-miR-7105; +MIMAT0028109 hsa-miR-7106-5p; +MIMAT0028110 hsa-miR-7106-3p; +MIMAT0028111 hsa-miR-7107-5p; +MIMAT0028112 hsa-miR-7107-3p; +MIMAT0028113 hsa-miR-7108-5p; +MIMAT0028114 hsa-miR-7108-3p; +MIMAT0028115 hsa-miR-7109-5p; +MIMAT0028116 hsa-miR-7109-3p; +MIMAT0028117 hsa-miR-7110-5p; +MIMAT0028118 hsa-miR-7110-3p; +MIMAT0028119 hsa-miR-7111-5p; +MIMAT0028120 hsa-miR-7111-3p; +MIMAT0028121 hsa-miR-7112-5p; +MIMAT0028122 hsa-miR-7112-3p; +MIMAT0028123 hsa-miR-7113-5p; +MIMAT0028124 hsa-miR-7113-3p; +MIMAT0028125 hsa-miR-7114-5p; +MIMAT0028126 hsa-miR-7114-3p; +MIMAT0028127 mmu-miR-7115-5p; +MIMAT0028128 mmu-miR-7115-3p; +MIMAT0028129 mmu-miR-7116-5p; +MIMAT0028130 mmu-miR-7116-3p; +MIMAT0028131 mmu-miR-7117-5p; +MIMAT0028132 mmu-miR-7117-3p; +MIMAT0028133 mmu-miR-7118-5p; +MIMAT0028134 mmu-miR-7118-3p; +MIMAT0028135 mmu-miR-7119-5p; +MIMAT0028136 mmu-miR-7119-3p; +MIMAT0028137 ddi-miR-7131a-5p; +MIMAT0028138 ddi-miR-7131a-3p; +MIMAT0028139 ddi-miR-7131d; +MIMAT0028140 ddi-miR-7131b; +MIMAT0028141 ddi-miR-7131c-5p; +MIMAT0028142 ddi-miR-7131c-3p; +MIMAT0028143 ssc-miR-7134-5p; +MIMAT0028144 ssc-miR-7134-3p; +MIMAT0028145 ssc-miR-7135-5p; +MIMAT0028146 ssc-miR-7135-3p; +MIMAT0028147 ssc-miR-7136-5p; +MIMAT0028148 ssc-miR-7136-3p; +MIMAT0028149 ssc-miR-7137-5p; +MIMAT0028150 ssc-miR-7137-3p; +MIMAT0028151 ssc-miR-7138-5p; +MIMAT0028152 ssc-miR-7138-3p; +MIMAT0028153 ssc-miR-7139-5p; +MIMAT0028154 ssc-miR-7139-3p; +MIMAT0028155 ssc-miR-7140-5p; +MIMAT0028156 ssc-miR-7140-3p; +MIMAT0028157 ssc-miR-7141-5p; +MIMAT0028158 ssc-miR-7141-3p; +MIMAT0028159 ssc-miR-7142-5p; +MIMAT0028160 ssc-miR-7142-3p; +MIMAT0028161 ssc-miR-7143-5p; +MIMAT0028162 ssc-miR-7143-3p; +MIMAT0028163 ssc-miR-7144-5p; +MIMAT0028164 ssc-miR-7144-3p; +MIMAT0028165 hcmv-miR-US22-5p; +MIMAT0028166 hcmv-miR-US22-3p; +MIMAT0028167 hcmv-miR-US29-5p; +MIMAT0028168 hcmv-miR-US29-3p; +MIMAT0028169 dev-miR-D1-5p; +MIMAT0028170 dev-miR-D1-3p; +MIMAT0028171 dev-miR-D2-3p; +MIMAT0028172 dev-miR-D3-3p; +MIMAT0028173 dev-miR-D4-3p; +MIMAT0028174 dev-miR-D5-5p; +MIMAT0028175 dev-miR-D6-5p; +MIMAT0028176 dev-miR-D6-3p; +MIMAT0028177 dev-miR-D7-5p; +MIMAT0028178 dev-miR-D8-5p; +MIMAT0028179 dev-miR-D8-3p; +MIMAT0028180 dev-miR-D9-5p; +MIMAT0028181 dev-miR-D9-3p; +MIMAT0028182 dev-miR-D10-3p; +MIMAT0028183 dev-miR-D11-3p; +MIMAT0028184 dev-miR-D12-5p; +MIMAT0028185 dev-miR-D12-3p; +MIMAT0028186 dev-miR-D13-5p; +MIMAT0028187 dev-miR-D14-3p; +MIMAT0028188 dev-miR-D15-3p; +MIMAT0028189 dev-miR-D16-3p; +MIMAT0028190 dev-miR-D17-5p; +MIMAT0028191 dev-miR-D17-3p; +MIMAT0028192 dev-miR-D18-5p; +MIMAT0028193 dev-miR-D18-3p; +MIMAT0028194 dev-miR-D19-5p; +MIMAT0028195 dev-miR-D20-5p; +MIMAT0028196 dev-miR-D21-5p; +MIMAT0028197 dev-miR-D21-3p; +MIMAT0028198 dev-miR-D22-5p; +MIMAT0028199 dev-miR-D22-3p; +MIMAT0028200 dev-miR-D23-3p; +MIMAT0028201 dev-miR-D24-3p; +MIMAT0028202 dre-miR-7145; +MIMAT0028203 dre-miR-7146-5p; +MIMAT0028204 dre-miR-7146-3p; +MIMAT0028205 dre-miR-7147; +MIMAT0028206 dre-miR-7148-5p; +MIMAT0028207 dre-miR-7148-3p; +MIMAT0028208 dre-miR-7149-5p; +MIMAT0028209 dre-miR-7149-3p; +MIMAT0028210 dre-miR-1306; +MIMAT0028211 hsa-miR-7150; +MIMAT0028212 hsa-miR-7151-5p; +MIMAT0028213 hsa-miR-7151-3p; +MIMAT0028214 hsa-miR-7152-5p; +MIMAT0028215 hsa-miR-7152-3p; +MIMAT0028216 hsa-miR-7153-5p; +MIMAT0028217 hsa-miR-7153-3p; +MIMAT0028218 hsa-miR-7154-5p; +MIMAT0028219 hsa-miR-7154-3p; +MIMAT0028220 hsa-miR-7155-5p; +MIMAT0028221 hsa-miR-7155-3p; +MIMAT0028222 hsa-miR-7156-5p; +MIMAT0028223 hsa-miR-7156-3p; +MIMAT0028224 hsa-miR-7157-5p; +MIMAT0028225 hsa-miR-7157-3p; +MIMAT0028226 hsa-miR-7158-5p; +MIMAT0028227 hsa-miR-7158-3p; +MIMAT0028228 hsa-miR-7159-5p; +MIMAT0028229 hsa-miR-7159-3p; +MIMAT0028230 hsa-miR-7160-5p; +MIMAT0028231 hsa-miR-7160-3p; +MIMAT0028232 hsa-miR-7161-5p; +MIMAT0028233 hsa-miR-7161-3p; +MIMAT0028234 hsa-miR-7162-5p; +MIMAT0028235 hsa-miR-7162-3p; +MIMAT0028236 mml-miR-500b-5p; +MIMAT0028237 mml-miR-500b-3p; +MIMAT0028238 mml-miR-4766-5p; +MIMAT0028239 mml-miR-4766-3p; +MIMAT0028240 mml-miR-1306-5p; +MIMAT0028241 mml-miR-1306-3p; +MIMAT0028242 mml-miR-1251-5p; +MIMAT0028243 mml-miR-1251-3p; +MIMAT0028244 mml-miR-7163-5p; +MIMAT0028245 mml-miR-7163-3p; +MIMAT0028246 mml-miR-3059-5p; +MIMAT0028247 mml-miR-3059-3p; +MIMAT0028248 mml-miR-6505-5p; +MIMAT0028249 mml-miR-6505-3p; +MIMAT0028250 mml-miR-1245-5p; +MIMAT0028251 mml-miR-1245-3p; +MIMAT0028252 mml-miR-7164-5p; +MIMAT0028253 mml-miR-7164-3p; +MIMAT0028254 mml-miR-548g-5p; +MIMAT0028255 mml-miR-548g-3p; +MIMAT0028256 mml-miR-548h-5p; +MIMAT0028257 mml-miR-548h-3p; +MIMAT0028258 mml-miR-3577-5p; +MIMAT0028259 mml-miR-3577-3p; +MIMAT0028260 mml-miR-3167-5p; +MIMAT0028261 mml-miR-3167-3p; +MIMAT0028262 mml-miR-7165-5p; +MIMAT0028263 mml-miR-7165-3p; +MIMAT0028264 mml-miR-1180-5p; +MIMAT0028265 mml-miR-1180-3p; +MIMAT0028266 mml-miR-7166-5p; +MIMAT0028267 mml-miR-7166-3p; +MIMAT0028268 mml-miR-7167-5p; +MIMAT0028269 mml-miR-7167-3p; +MIMAT0028270 mml-miR-7168-5p; +MIMAT0028271 mml-miR-7168-3p; +MIMAT0028272 mml-miR-7169-5p; +MIMAT0028273 mml-miR-7169-3p; +MIMAT0028274 mml-miR-7170-5p; +MIMAT0028275 mml-miR-7170-3p; +MIMAT0028276 mml-miR-7171-5p; +MIMAT0028277 mml-miR-7171-3p; +MIMAT0028278 mml-miR-4703-5p; +MIMAT0028279 mml-miR-4703-3p; +MIMAT0028280 mml-miR-133d-5p; +MIMAT0028281 mml-miR-133d-3p; +MIMAT0028282 mml-miR-7172-5p; +MIMAT0028283 mml-miR-7172-3p; +MIMAT0028284 mml-miR-7173-5p; +MIMAT0028285 mml-miR-7173-3p; +MIMAT0028286 mml-miR-7174-5p; +MIMAT0028287 mml-miR-7174-3p; +MIMAT0028288 mml-miR-6790-5p; +MIMAT0028289 mml-miR-6790-3p; +MIMAT0028290 mml-miR-7175-5p; +MIMAT0028291 mml-miR-7175-3p; +MIMAT0028292 mml-miR-7176-5p; +MIMAT0028293 mml-miR-7176-3p; +MIMAT0028294 mml-miR-6794-5p; +MIMAT0028295 mml-miR-6794-3p; +MIMAT0028296 mml-miR-518g-5p; +MIMAT0028297 mml-miR-518g-3p; +MIMAT0028298 mml-miR-7177-5p; +MIMAT0028299 mml-miR-7177-3p; +MIMAT0028300 mml-miR-7178-5p; +MIMAT0028301 mml-miR-7178-3p; +MIMAT0028302 mml-miR-7179-5p; +MIMAT0028303 mml-miR-7179-3p; +MIMAT0028304 mml-miR-7180-5p; +MIMAT0028305 mml-miR-7180-3p; +MIMAT0028306 mml-miR-4677-5p; +MIMAT0028307 mml-miR-4677-3p; +MIMAT0028308 mml-miR-7181-5p; +MIMAT0028309 mml-miR-7181-3p; +MIMAT0028310 mml-miR-7182-5p; +MIMAT0028311 mml-miR-7182-3p; +MIMAT0028312 mml-miR-6827-5p; +MIMAT0028313 mml-miR-6827-3p; +MIMAT0028314 mml-miR-6529-5p; +MIMAT0028315 mml-miR-6529-3p; +MIMAT0028316 mml-miR-3938-5p; +MIMAT0028317 mml-miR-3938-3p; +MIMAT0028318 mml-miR-7183-5p; +MIMAT0028319 mml-miR-7183-3p; +MIMAT0028320 mml-miR-7184-5p; +MIMAT0028321 mml-miR-7184-3p; +MIMAT0028322 mml-miR-548i-5p; +MIMAT0028323 mml-miR-548i-3p; +MIMAT0028324 mml-miR-7185-5p; +MIMAT0028325 mml-miR-7185-3p; +MIMAT0028326 mml-miR-7186-5p; +MIMAT0028327 mml-miR-7186-3p; +MIMAT0028328 mml-miR-7187-5p; +MIMAT0028329 mml-miR-7187-3p; +MIMAT0028330 mml-miR-7188-5p; +MIMAT0028331 mml-miR-7188-3p; +MIMAT0028332 mml-miR-548j-5p; +MIMAT0028333 mml-miR-548j-3p; +MIMAT0028334 mml-miR-769-5p; +MIMAT0028335 mml-miR-769-3p; +MIMAT0028336 mml-miR-7189-5p; +MIMAT0028337 mml-miR-7189-3p; +MIMAT0028338 mml-miR-7190-5p; +MIMAT0028339 mml-miR-7190-3p; +MIMAT0028340 mml-miR-7191-5p; +MIMAT0028341 mml-miR-7191-3p; +MIMAT0028342 mml-miR-7192-5p; +MIMAT0028343 mml-miR-7192-3p; +MIMAT0028344 mml-miR-549b-5p; +MIMAT0028345 mml-miR-549b-3p; +MIMAT0028346 mml-miR-7193-5p; +MIMAT0028347 mml-miR-7193-3p; +MIMAT0028348 mml-miR-7194-5p; +MIMAT0028349 mml-miR-7194-3p; +MIMAT0028350 mml-miR-7195-5p; +MIMAT0028351 mml-miR-7195-3p; +MIMAT0028352 mml-miR-7196-5p; +MIMAT0028353 mml-miR-7196-3p; +MIMAT0028354 mml-miR-323b-5p; +MIMAT0028355 mml-miR-323b-3p; +MIMAT0028356 mml-miR-7197-5p; +MIMAT0028357 mml-miR-7197-3p; +MIMAT0028358 mml-miR-1247-5p; +MIMAT0028359 mml-miR-1247-3p; +MIMAT0028360 mml-miR-7198-5p; +MIMAT0028361 mml-miR-7198-3p; +MIMAT0028362 mml-miR-7199-5p; +MIMAT0028363 mml-miR-7199-3p; +MIMAT0028364 mml-miR-7200-5p; +MIMAT0028365 mml-miR-7200-3p; +MIMAT0028366 mml-miR-7201-5p; +MIMAT0028367 mml-miR-7201-3p; +MIMAT0028368 mml-miR-7202-5p; +MIMAT0028369 mml-miR-7202-3p; +MIMAT0028370 mml-miR-7203-5p; +MIMAT0028371 mml-miR-7203-3p; +MIMAT0028372 mml-miR-7204-5p; +MIMAT0028373 mml-miR-7204-3p; +MIMAT0028374 mml-miR-1911-5p; +MIMAT0028375 mml-miR-1911-3p; +MIMAT0028376 mml-miR-7205-5p; +MIMAT0028377 mml-miR-7205-3p; +MIMAT0028378 mml-miR-7206-5p; +MIMAT0028379 mml-miR-7206-3p; +MIMAT0028380 mml-miR-7207-5p; +MIMAT0028381 mml-miR-7207-3p; +MIMAT0028382 mml-miR-7208-5p; +MIMAT0028383 mml-miR-7208-3p; +MIMAT0028384 mml-miR-892c-5p; +MIMAT0028385 mml-miR-892c-3p; +MIMAT0028388 mmu-miR-7210-5p; +MIMAT0028389 mmu-miR-7210-3p; +MIMAT0028390 mmu-miR-7211-5p; +MIMAT0028391 mmu-miR-7211-3p; +MIMAT0028392 mmu-miR-7212-5p; +MIMAT0028393 mmu-miR-7212-3p; +MIMAT0028394 mmu-miR-7213-5p; +MIMAT0028395 mmu-miR-7213-3p; +MIMAT0028396 mmu-miR-7214-5p; +MIMAT0028397 mmu-miR-7214-3p; +MIMAT0028398 mmu-miR-7215-5p; +MIMAT0028399 mmu-miR-7215-3p; +MIMAT0028400 mmu-miR-7216-5p; +MIMAT0028401 mmu-miR-7216-3p; +MIMAT0028402 mmu-miR-7217-5p; +MIMAT0028403 mmu-miR-7217-3p; +MIMAT0028404 mmu-miR-7218-5p; +MIMAT0028405 mmu-miR-7218-3p; +MIMAT0028406 mmu-miR-7219-5p; +MIMAT0028407 mmu-miR-7219-3p; +MIMAT0028408 mmu-miR-7220-5p; +MIMAT0028409 mmu-miR-7220-3p; +MIMAT0028410 mmu-miR-7221-5p; +MIMAT0028411 mmu-miR-7221-3p; +MIMAT0028412 mmu-miR-7222-5p; +MIMAT0028413 mmu-miR-7222-3p; +MIMAT0028414 mmu-miR-7223-5p; +MIMAT0028415 mmu-miR-7223-3p; +MIMAT0028416 mmu-miR-7224-5p; +MIMAT0028417 mmu-miR-7224-3p; +MIMAT0028418 mmu-miR-7225-5p; +MIMAT0028419 mmu-miR-7225-3p; +MIMAT0028420 mmu-miR-7226-5p; +MIMAT0028421 mmu-miR-7226-3p; +MIMAT0028422 mmu-miR-7227-5p; +MIMAT0028423 mmu-miR-7227-3p; +MIMAT0028424 mmu-miR-7228-5p; +MIMAT0028425 mmu-miR-7228-3p; +MIMAT0028426 mmu-miR-7229-5p; +MIMAT0028427 mmu-miR-7229-3p; +MIMAT0028428 mmu-miR-7230-5p; +MIMAT0028429 mmu-miR-7230-3p; +MIMAT0028430 mmu-miR-7231-5p; +MIMAT0028431 mmu-miR-7231-3p; +MIMAT0028432 mmu-miR-7232-5p; +MIMAT0028433 mmu-miR-7232-3p; +MIMAT0028434 mmu-miR-7233-5p; +MIMAT0028435 mmu-miR-7233-3p; +MIMAT0028436 mmu-miR-7234-5p; +MIMAT0028437 mmu-miR-7234-3p; +MIMAT0028438 mmu-miR-7235-5p; +MIMAT0028439 mmu-miR-7235-3p; +MIMAT0028440 mmu-miR-7236-5p; +MIMAT0028441 mmu-miR-7236-3p; +MIMAT0028442 mmu-miR-7237-5p; +MIMAT0028443 mmu-miR-7237-3p; +MIMAT0028444 mmu-miR-7238-5p; +MIMAT0028445 mmu-miR-7238-3p; +MIMAT0028446 mmu-miR-7239-5p; +MIMAT0028447 mmu-miR-7239-3p; +MIMAT0028448 mmu-miR-7240-5p; +MIMAT0028449 mmu-miR-7240-3p; +MIMAT0028450 mmu-miR-7241-5p; +MIMAT0028451 mmu-miR-7241-3p; +MIMAT0028452 mmu-miR-7242-5p; +MIMAT0028453 mmu-miR-7242-3p; +MIMAT0028454 mdo-miR-7244-5p; +MIMAT0028455 mdo-miR-7244-3p; +MIMAT0028456 mdo-miR-7245-5p; +MIMAT0028457 mdo-miR-7245-3p; +MIMAT0028458 mdo-miR-7246-5p; +MIMAT0028459 mdo-miR-7246-3p; +MIMAT0028460 mdo-miR-7247-5p; +MIMAT0028461 mdo-miR-7247-3p; +MIMAT0028462 mdo-miR-7248-5p; +MIMAT0028463 mdo-miR-7248-3p; +MIMAT0028464 mdo-miR-7249-5p; +MIMAT0028465 mdo-miR-7249-3p; +MIMAT0028466 mdo-miR-7250-5p; +MIMAT0028467 mdo-miR-7250-3p; +MIMAT0028468 mdo-miR-7251-5p; +MIMAT0028469 mdo-miR-7251-3p; +MIMAT0028470 mdo-miR-7252-5p; +MIMAT0028471 mdo-miR-7252-3p; +MIMAT0028472 mdo-miR-7253-5p; +MIMAT0028473 mdo-miR-7253-3p; +MIMAT0028474 mdo-miR-7254-5p; +MIMAT0028475 mdo-miR-7254-3p; +MIMAT0028476 mdo-miR-7255-5p; +MIMAT0028477 mdo-miR-7255-3p; +MIMAT0028478 mdo-miR-7256-5p; +MIMAT0028479 mdo-miR-7256-3p; +MIMAT0028480 mdo-miR-7257-5p; +MIMAT0028481 mdo-miR-7257-3p; +MIMAT0028482 mdo-miR-7258-5p; +MIMAT0028483 mdo-miR-7258-3p; +MIMAT0028484 mdo-miR-7259-5p; +MIMAT0028485 mdo-miR-7259-3p; +MIMAT0028486 mdo-miR-7260-5p; +MIMAT0028487 mdo-miR-7260-3p; +MIMAT0028488 mdo-miR-7261-5p; +MIMAT0028489 mdo-miR-7261-3p; +MIMAT0028490 mdo-miR-7262a-5p; +MIMAT0028491 mdo-miR-7262a-3p; +MIMAT0028492 mdo-miR-7263-5p; +MIMAT0028493 mdo-miR-7263-3p; +MIMAT0028494 mdo-miR-196a-5p; +MIMAT0028495 mdo-miR-196a-3p; +MIMAT0028496 mdo-miR-7264-5p; +MIMAT0028497 mdo-miR-7264-3p; +MIMAT0028498 mdo-miR-7265-5p; +MIMAT0028499 mdo-miR-7265-3p; +MIMAT0028500 mdo-miR-7266-5p; +MIMAT0028501 mdo-miR-7266-3p; +MIMAT0028502 mdo-miR-30c-5p; +MIMAT0028503 mdo-miR-30c-1-3p; +MIMAT0028504 mdo-miR-7267-5p; +MIMAT0028505 mdo-miR-7267-3p; +MIMAT0028506 mdo-miR-7268-5p; +MIMAT0028507 mdo-miR-7268-3p; +MIMAT0028508 mdo-miR-7269-5p; +MIMAT0028509 mdo-miR-7269-3p; +MIMAT0028510 mdo-miR-7270-5p; +MIMAT0028511 mdo-miR-7270-3p; +MIMAT0028512 mdo-miR-7271-5p; +MIMAT0028513 mdo-miR-7271-3p; +MIMAT0028514 mdo-miR-130c-1-5p; +MIMAT0028515 mdo-miR-130c-3p; +MIMAT0028516 mdo-miR-7272-5p; +MIMAT0028517 mdo-miR-7272-3p; +MIMAT0028518 mdo-miR-92b-5p; +MIMAT0028519 mdo-miR-92b-3p; +MIMAT0028520 mdo-miR-7273-5p; +MIMAT0028521 mdo-miR-7273-3p; +MIMAT0028522 mdo-miR-7274-5p; +MIMAT0028523 mdo-miR-7274-3p; +MIMAT0028524 mdo-miR-7275-5p; +MIMAT0028525 mdo-miR-7275-3p; +MIMAT0028526 mdo-miR-7276-5p; +MIMAT0028527 mdo-miR-7276-3p; +MIMAT0028528 mdo-miR-7277-5p; +MIMAT0028529 mdo-miR-7277-3p; +MIMAT0028530 mdo-miR-7278-5p; +MIMAT0028531 mdo-miR-7278-3p; +MIMAT0028532 mdo-miR-7279-5p; +MIMAT0028533 mdo-miR-7279-3p; +MIMAT0028534 mdo-miR-7280-5p; +MIMAT0028535 mdo-miR-7280-3p; +MIMAT0028536 mdo-miR-7281-5p; +MIMAT0028537 mdo-miR-7281-3p; +MIMAT0028538 mdo-miR-7282-5p; +MIMAT0028539 mdo-miR-7282-3p; +MIMAT0028540 mdo-miR-7283-5p; +MIMAT0028541 mdo-miR-7283-3p; +MIMAT0028542 mdo-miR-7284-5p; +MIMAT0028543 mdo-miR-7284-3p; +MIMAT0028544 mdo-miR-7262b-5p; +MIMAT0028545 mdo-miR-7262b-3p; +MIMAT0028546 mdo-miR-7285-5p; +MIMAT0028547 mdo-miR-7285-3p; +MIMAT0028548 mdo-miR-7286-5p; +MIMAT0028549 mdo-miR-7286-3p; +MIMAT0028550 mdo-miR-30b-5p; +MIMAT0028551 mdo-miR-30b-3p; +MIMAT0028552 mdo-miR-137b-5p; +MIMAT0028553 mdo-miR-137b-3p; +MIMAT0028554 mdo-miR-9b-5p; +MIMAT0028555 mdo-miR-9b-3p; +MIMAT0028556 mdo-miR-7287-5p; +MIMAT0028557 mdo-miR-7287-3p; +MIMAT0028558 mdo-miR-7288-5p; +MIMAT0028559 mdo-miR-7288-3p; +MIMAT0028560 mdo-miR-7289-5p; +MIMAT0028561 mdo-miR-7289-3p; +MIMAT0028562 mdo-miR-7290-5p; +MIMAT0028563 mdo-miR-7290-3p; +MIMAT0028564 mdo-miR-130b-5p; +MIMAT0028565 mdo-miR-130b-3p; +MIMAT0028566 mdo-miR-7291-5p; +MIMAT0028567 mdo-miR-7291-3p; +MIMAT0028568 mdo-miR-7292-5p; +MIMAT0028569 mdo-miR-7292-3p; +MIMAT0028570 mdo-miR-7293-5p; +MIMAT0028571 mdo-miR-7293-3p; +MIMAT0028572 mdo-miR-7294-5p; +MIMAT0028573 mdo-miR-7294-3p; +MIMAT0028574 mdo-miR-7295-5p; +MIMAT0028575 mdo-miR-7295-3p; +MIMAT0028576 mdo-miR-7296-5p; +MIMAT0028577 mdo-miR-7296-3p; +MIMAT0028578 mdo-miR-7297-5p; +MIMAT0028579 mdo-miR-7297-3p; +MIMAT0028580 mdo-miR-449c-5p; +MIMAT0028581 mdo-miR-449c-3p; +MIMAT0028582 mdo-miR-449b-5p; +MIMAT0028583 mdo-miR-449b-3p; +MIMAT0028584 mdo-miR-7298-5p; +MIMAT0028585 mdo-miR-7298-3p; +MIMAT0028586 mdo-miR-34c-5p; +MIMAT0028587 mdo-miR-34c-3p; +MIMAT0028588 mdo-miR-34b-5p; +MIMAT0028589 mdo-miR-34b-3p; +MIMAT0028590 mdo-miR-7299-5p; +MIMAT0028591 mdo-miR-7299-3p; +MIMAT0028592 mdo-miR-7300-5p; +MIMAT0028593 mdo-miR-7300-3p; +MIMAT0028594 mdo-miR-1643a-5p; +MIMAT0028595 mdo-miR-1643a-3p; +MIMAT0028596 mdo-miR-7302-5p; +MIMAT0028597 mdo-miR-7302-3p; +MIMAT0028598 mdo-miR-1643b-5p; +MIMAT0028599 mdo-miR-1643b-3p; +MIMAT0028600 mdo-miR-7303-5p; +MIMAT0028601 mdo-miR-7303-3p; +MIMAT0028602 mdo-miR-7304-5p; +MIMAT0028603 mdo-miR-7304-3p; +MIMAT0028604 mdo-miR-7305-5p; +MIMAT0028605 mdo-miR-7305-3p; +MIMAT0028606 mdo-miR-7306-5p; +MIMAT0028607 mdo-miR-7306-3p; +MIMAT0028608 mdo-miR-128b-5p; +MIMAT0028609 mdo-miR-128b-3p; +MIMAT0028610 mdo-miR-7307-5p; +MIMAT0028611 mdo-miR-7307-3p; +MIMAT0028612 mdo-miR-208b-5p; +MIMAT0028613 mdo-miR-208b-3p; +MIMAT0028614 mdo-miR-7308-5p; +MIMAT0028615 mdo-miR-7308-3p; +MIMAT0028616 mdo-miR-7309-5p; +MIMAT0028617 mdo-miR-7309-3p; +MIMAT0028618 mdo-miR-7310-5p; +MIMAT0028619 mdo-miR-7310-3p; +MIMAT0028620 mdo-miR-7311-5p; +MIMAT0028621 mdo-miR-7311-3p; +MIMAT0028622 mdo-miR-30d-5p; +MIMAT0028623 mdo-miR-30d-3p; +MIMAT0028624 mdo-miR-7312-5p; +MIMAT0028625 mdo-miR-7312-3p; +MIMAT0028626 mdo-miR-7313-5p; +MIMAT0028627 mdo-miR-7313-3p; +MIMAT0028628 mdo-miR-7314-5p; +MIMAT0028629 mdo-miR-7314-3p; +MIMAT0028630 mdo-miR-7315-5p; +MIMAT0028631 mdo-miR-7315-3p; +MIMAT0028632 mdo-miR-7316-5p; +MIMAT0028633 mdo-miR-7316-3p; +MIMAT0028634 mdo-miR-7317-5p; +MIMAT0028635 mdo-miR-7317-3p; +MIMAT0028636 mdo-miR-7318-5p; +MIMAT0028637 mdo-miR-7318-3p; +MIMAT0028638 mdo-miR-7319-5p; +MIMAT0028639 mdo-miR-7319-3p; +MIMAT0028640 mdo-miR-7320-5p; +MIMAT0028641 mdo-miR-7320-3p; +MIMAT0028642 mdo-miR-7321-5p; +MIMAT0028643 mdo-miR-7321-3p; +MIMAT0028644 mdo-miR-7322-5p; +MIMAT0028645 mdo-miR-7322-3p; +MIMAT0028646 mdo-miR-7323-5p; +MIMAT0028647 mdo-miR-7323-3p; +MIMAT0028648 mdo-miR-7324-5p; +MIMAT0028649 mdo-miR-7324-3p; +MIMAT0028650 mdo-miR-7325-5p; +MIMAT0028651 mdo-miR-7325-3p; +MIMAT0028652 mdo-miR-193b-5p; +MIMAT0028653 mdo-miR-193b-3p; +MIMAT0028654 mdo-miR-7326-5p; +MIMAT0028655 mdo-miR-7326-3p; +MIMAT0028656 mdo-miR-7327-5p; +MIMAT0028657 mdo-miR-7327-3p; +MIMAT0028658 mdo-miR-7328-5p; +MIMAT0028659 mdo-miR-7328-3p; +MIMAT0028660 mdo-miR-7329-5p; +MIMAT0028661 mdo-miR-7329-3p; +MIMAT0028662 mdo-miR-505-5p; +MIMAT0028663 mdo-miR-505-3p; +MIMAT0028664 mdo-miR-873-5p; +MIMAT0028665 mdo-miR-873-3p; +MIMAT0028666 mdo-miR-7330-5p; +MIMAT0028667 mdo-miR-7330-3p; +MIMAT0028668 mdo-miR-7331-5p; +MIMAT0028669 mdo-miR-7331-1-3p; +MIMAT0028670 mdo-miR-2970-5p; +MIMAT0028671 mdo-miR-2970-3p; +MIMAT0028672 mdo-miR-7332-5p; +MIMAT0028673 mdo-miR-7332-3p; +MIMAT0028674 mdo-miR-7333-5p; +MIMAT0028675 mdo-miR-7333-3p; +MIMAT0028676 mdo-miR-7334-5p; +MIMAT0028677 mdo-miR-7334-3p; +MIMAT0028678 mdo-miR-7335-5p; +MIMAT0028679 mdo-miR-7335-3p; +MIMAT0028680 mdo-miR-7336-5p; +MIMAT0028681 mdo-miR-7336-3p; +MIMAT0028682 mdo-miR-7337-5p; +MIMAT0028683 mdo-miR-7337-3p; +MIMAT0028684 mdo-miR-7338-5p; +MIMAT0028685 mdo-miR-7338-3p; +MIMAT0028686 mdo-miR-7339-5p; +MIMAT0028687 mdo-miR-7339-3p; +MIMAT0028688 mdo-miR-7340-5p; +MIMAT0028689 mdo-miR-7340-3p; +MIMAT0028690 mdo-miR-1805-5p; +MIMAT0028691 mdo-miR-1805-3p; +MIMAT0028692 mdo-miR-7341-5p; +MIMAT0028693 mdo-miR-7341-3p; +MIMAT0028694 mdo-miR-7342-5p; +MIMAT0028695 mdo-miR-7342-3p; +MIMAT0028696 mdo-miR-7343-5p; +MIMAT0028697 mdo-miR-7343-3p; +MIMAT0028698 mdo-miR-7344-5p; +MIMAT0028699 mdo-miR-7344-3p; +MIMAT0028700 mdo-miR-1251-5p; +MIMAT0028701 mdo-miR-1251-3p; +MIMAT0028702 mdo-miR-7345-5p; +MIMAT0028703 mdo-miR-7345-3p; +MIMAT0028704 mdo-miR-7346-5p; +MIMAT0028705 mdo-miR-7346-3p; +MIMAT0028706 mdo-miR-7347-5p; +MIMAT0028707 mdo-miR-7347-3p; +MIMAT0028708 mdo-miR-7348-5p; +MIMAT0028709 mdo-miR-7348-3p; +MIMAT0028710 mdo-miR-7349-5p; +MIMAT0028711 mdo-miR-7349-3p; +MIMAT0028712 mdo-miR-7350-5p; +MIMAT0028713 mdo-miR-7350-3p; +MIMAT0028714 mdo-miR-7351-5p; +MIMAT0028715 mdo-miR-7351-3p; +MIMAT0028716 mdo-miR-7352-5p; +MIMAT0028717 mdo-miR-7352-3p; +MIMAT0028718 mdo-miR-7353-5p; +MIMAT0028719 mdo-miR-7353-3p; +MIMAT0028720 mdo-miR-7354-5p; +MIMAT0028721 mdo-miR-7354-3p; +MIMAT0028722 mdo-miR-7355-5p; +MIMAT0028723 mdo-miR-7355-3p; +MIMAT0028724 mdo-miR-7356-5p; +MIMAT0028725 mdo-miR-7356-3p; +MIMAT0028726 mdo-miR-7357-5p; +MIMAT0028727 mdo-miR-7357-3p; +MIMAT0028728 mdo-miR-7358-5p; +MIMAT0028729 mdo-miR-7358-3p; +MIMAT0028730 mdo-miR-7359-5p; +MIMAT0028731 mdo-miR-7359a-3p; +MIMAT0028732 mdo-miR-7360-5p; +MIMAT0028733 mdo-miR-7360-3p; +MIMAT0028734 mdo-miR-7361-5p; +MIMAT0028735 mdo-miR-7361-3p; +MIMAT0028736 mdo-miR-7362-5p; +MIMAT0028737 mdo-miR-7362-3p; +MIMAT0028738 mdo-miR-7363-5p; +MIMAT0028739 mdo-miR-7363-3p; +MIMAT0028740 mdo-miR-7364-5p; +MIMAT0028741 mdo-miR-7364-3p; +MIMAT0028742 mdo-miR-7365-5p; +MIMAT0028743 mdo-miR-7365-3p; +MIMAT0028744 mdo-miR-1544b-5p; +MIMAT0028745 mdo-miR-1544b-3p; +MIMAT0028746 mdo-miR-1544c-5p; +MIMAT0028747 mdo-miR-1544c-3p; +MIMAT0028748 mdo-miR-7366-5p; +MIMAT0028749 mdo-miR-7366-3p; +MIMAT0028750 mdo-miR-1545b-5p; +MIMAT0028751 mdo-miR-1545b-3p; +MIMAT0028752 mdo-miR-1545c-5p; +MIMAT0028753 mdo-miR-1545c-3p; +MIMAT0028754 mdo-miR-1544d-5p; +MIMAT0028755 mdo-miR-1544d-3p; +MIMAT0028756 mdo-miR-7367-5p; +MIMAT0028757 mdo-miR-7367-3p; +MIMAT0028758 mdo-miR-7368-5p; +MIMAT0028759 mdo-miR-7368-3p; +MIMAT0028760 mdo-miR-7369-5p; +MIMAT0028761 mdo-miR-7369-3p; +MIMAT0028762 mdo-miR-7370-5p; +MIMAT0028763 mdo-miR-7370-3p; +MIMAT0028764 mdo-miR-20b-5p; +MIMAT0028765 mdo-miR-20b-3p; +MIMAT0028766 mdo-miR-18b-5p; +MIMAT0028767 mdo-miR-18b-3p; +MIMAT0028768 mdo-miR-15c-5p; +MIMAT0028769 mdo-miR-15c-3p; +MIMAT0028770 mdo-miR-7370i-5p; +MIMAT0028771 mdo-miR-7370i-3p; +MIMAT0028772 mdo-miR-7371a-5p; +MIMAT0028773 mdo-miR-7371a-3p; +MIMAT0028774 mdo-miR-7371b-5p; +MIMAT0028775 mdo-miR-7371b-3p; +MIMAT0028776 mdo-miR-7372-5p; +MIMAT0028777 mdo-miR-7372-3p; +MIMAT0028778 mdo-miR-7371c-5p; +MIMAT0028779 mdo-miR-7371c-3p; +MIMAT0028780 mdo-miR-7371d-5p; +MIMAT0028781 mdo-miR-7371d-3p; +MIMAT0028782 mdo-miR-7371e-5p; +MIMAT0028783 mdo-miR-7371e-3p; +MIMAT0028784 mdo-miR-7371f-5p; +MIMAT0028785 mdo-miR-7371f-3p; +MIMAT0028786 mdo-miR-7371g-5p; +MIMAT0028787 mdo-miR-7371g-3p; +MIMAT0028788 mdo-miR-7371h-5p; +MIMAT0028789 mdo-miR-7371h-3p; +MIMAT0028790 mdo-miR-7371j-5p; +MIMAT0028791 mdo-miR-7371j-3p; +MIMAT0028792 mdo-miR-7373a-5p; +MIMAT0028793 mdo-miR-7373a-3p; +MIMAT0028794 mdo-miR-7374a-5p; +MIMAT0028795 mdo-miR-7374a-3p; +MIMAT0028796 mdo-miR-7375-5p; +MIMAT0028797 mdo-miR-7375-3p; +MIMAT0028798 mdo-miR-7374c-5p; +MIMAT0028799 mdo-miR-7374c-3p; +MIMAT0028800 mdo-miR-7374b-5p; +MIMAT0028801 mdo-miR-7374b-3p; +MIMAT0028802 mdo-miR-7373b-5p; +MIMAT0028803 mdo-miR-7373b-3p; +MIMAT0028804 mdo-miR-7373c-5p; +MIMAT0028805 mdo-miR-7373c-3p; +MIMAT0028806 mdo-miR-7373d-5p; +MIMAT0028807 mdo-miR-7373d-3p; +MIMAT0028808 mdo-miR-7376-5p; +MIMAT0028809 mdo-miR-7376-3p; +MIMAT0028810 mdo-miR-7377-5p; +MIMAT0028811 mdo-miR-7377-3p; +MIMAT0028812 mdo-miR-7378-5p; +MIMAT0028813 mdo-miR-7378-3p; +MIMAT0028814 mdo-miR-7379-5p; +MIMAT0028815 mdo-miR-7379-3p; +MIMAT0028816 mdo-miR-7380-5p; +MIMAT0028817 mdo-miR-7380-3p; +MIMAT0028818 mdo-miR-7381-5p; +MIMAT0028819 mdo-miR-7381-3p; +MIMAT0028820 mdo-miR-7382-5p; +MIMAT0028821 mdo-miR-7382-3p; +MIMAT0028822 mdo-miR-7383-5p; +MIMAT0028823 mdo-miR-7383-3p; +MIMAT0028824 mdo-miR-7384-5p; +MIMAT0028825 mdo-miR-7384-3p; +MIMAT0028826 mdo-miR-7385a-5p; +MIMAT0028827 mdo-miR-7385a-3p; +MIMAT0028828 mdo-miR-7385b-5p; +MIMAT0028829 mdo-miR-7385b-3p; +MIMAT0028830 mdo-miR-7385c-5p; +MIMAT0028831 mdo-miR-7385c-3p; +MIMAT0028832 mdo-miR-7385d-5p; +MIMAT0028833 mdo-miR-7385d-3p; +MIMAT0028834 mdo-miR-7386a-5p; +MIMAT0028835 mdo-miR-7386a-3p; +MIMAT0028836 mdo-miR-7386b-5p; +MIMAT0028837 mdo-miR-7386b-3p; +MIMAT0028838 mdo-miR-7387-5p; +MIMAT0028839 mdo-miR-7387-3p; +MIMAT0028840 mdo-miR-7386h-5p; +MIMAT0028841 mdo-miR-7386h-3p; +MIMAT0028842 mdo-miR-7386c-5p; +MIMAT0028843 mdo-miR-7386c-3p; +MIMAT0028844 mdo-miR-7386i-5p; +MIMAT0028845 mdo-miR-7386i-3p; +MIMAT0028846 mdo-miR-7386j-5p; +MIMAT0028847 mdo-miR-7386j-3p; +MIMAT0028848 mdo-miR-7386k-5p; +MIMAT0028849 mdo-miR-7386k-3p; +MIMAT0028850 mdo-miR-7386d-5p; +MIMAT0028851 mdo-miR-7386d-3p; +MIMAT0028852 mdo-miR-7386e-5p; +MIMAT0028853 mdo-miR-7386e-3p; +MIMAT0028854 mdo-miR-7386l-5p; +MIMAT0028855 mdo-miR-7386l-3p; +MIMAT0028856 mdo-miR-7386f-5p; +MIMAT0028857 mdo-miR-7386f-3p; +MIMAT0028858 mdo-miR-7385e-5p; +MIMAT0028859 mdo-miR-7385e-3p; +MIMAT0028860 mdo-miR-7386g-5p; +MIMAT0028861 mdo-miR-7386g-3p; +MIMAT0028862 mdo-miR-7386m-5p; +MIMAT0028863 mdo-miR-7386m-3p; +MIMAT0028864 mdo-miR-7386n-5p; +MIMAT0028865 mdo-miR-7386n-3p; +MIMAT0028866 mdo-miR-7386o-5p; +MIMAT0028867 mdo-miR-7386o-3p; +MIMAT0028868 mdo-miR-7388a-5p; +MIMAT0028869 mdo-miR-7388a-3p; +MIMAT0028870 mdo-miR-7389-5p; +MIMAT0028871 mdo-miR-7389-3p; +MIMAT0028872 mdo-miR-7388b-5p; +MIMAT0028873 mdo-miR-7388b-3p; +MIMAT0028874 mdo-miR-7388c-5p; +MIMAT0028875 mdo-miR-7388c-3p; +MIMAT0028876 mdo-miR-7390-5p; +MIMAT0028877 mdo-miR-7390-3p; +MIMAT0028878 mdo-miR-7385f-5p; +MIMAT0028879 mdo-miR-7385f-3p; +MIMAT0028880 mdo-miR-7391-5p; +MIMAT0028881 mdo-miR-7391-3p; +MIMAT0028882 mdo-miR-7392-5p; +MIMAT0028883 mdo-miR-7392-3p; +MIMAT0028884 mdo-miR-7393-5p; +MIMAT0028885 mdo-miR-7393-3p; +MIMAT0028886 mdo-miR-7394a-5p; +MIMAT0028887 mdo-miR-7394a-3p; +MIMAT0028888 mdo-miR-7395-5p; +MIMAT0028889 mdo-miR-7395-3p; +MIMAT0028890 mdo-miR-7396-5p; +MIMAT0028891 mdo-miR-7396-3p; +MIMAT0028892 mdo-miR-7397-5p; +MIMAT0028893 mdo-miR-7397-3p; +MIMAT0028894 mdo-miR-7394b-5p; +MIMAT0028895 mdo-miR-7394b-3p; +MIMAT0028896 mdo-miR-7398e-5p; +MIMAT0028897 mdo-miR-7398e-3p; +MIMAT0028898 mdo-miR-7398f-5p; +MIMAT0028899 mdo-miR-7398f-3p; +MIMAT0028900 mdo-miR-7398a-5p; +MIMAT0028901 mdo-miR-7398a-3p; +MIMAT0028902 mdo-miR-7398r-5p; +MIMAT0028903 mdo-miR-7398r-3p; +MIMAT0028904 mdo-miR-7398n-5p; +MIMAT0028905 mdo-miR-7398n-3p; +MIMAT0028906 mdo-miR-7398k-5p; +MIMAT0028907 mdo-miR-7398k-1-3p; +MIMAT0028908 mdo-miR-7398o-5p; +MIMAT0028909 mdo-miR-7398o-3p; +MIMAT0028910 mdo-miR-7398l-5p; +MIMAT0028911 mdo-miR-7398l-3p; +MIMAT0028912 mdo-miR-7398m-5p; +MIMAT0028913 mdo-miR-7398m-3p; +MIMAT0028914 mdo-miR-7398c-5p; +MIMAT0028915 mdo-miR-7398c-3p; +MIMAT0028916 mdo-miR-7398b-5p; +MIMAT0028917 mdo-miR-7398b-3p; +MIMAT0028918 mdo-miR-7398p-5p; +MIMAT0028919 mdo-miR-7398p-3p; +MIMAT0028920 mdo-miR-7398q-5p; +MIMAT0028921 mdo-miR-7398q-3p; +MIMAT0028922 mdo-miR-7398d-5p; +MIMAT0028923 mdo-miR-7398d-3p; +MIMAT0028924 mdo-miR-7398s-5p; +MIMAT0028925 mdo-miR-7398s-3p; +MIMAT0028926 mdo-miR-7398u-5p; +MIMAT0028927 mdo-miR-7398u-3p; +MIMAT0028928 mdo-miR-7398j-5p; +MIMAT0028929 mdo-miR-7398j-3p; +MIMAT0028930 mdo-miR-7398g-5p; +MIMAT0028931 mdo-miR-7398g-3p; +MIMAT0028932 mdo-miR-7398h-5p; +MIMAT0028933 mdo-miR-7398h-3p; +MIMAT0028934 mdo-miR-7398t-5p; +MIMAT0028935 mdo-miR-7398t-3p; +MIMAT0028936 mdo-miR-7398i-5p; +MIMAT0028937 mdo-miR-7398i-3p; +MIMAT0028938 mdo-miR-1540b-5p; +MIMAT0028939 mdo-miR-1540b-3p; +MIMAT0028940 mdo-miR-7399-5p; +MIMAT0028941 mdo-miR-7399-3p; +MIMAT0028942 oan-miR-7400-5p; +MIMAT0028943 oan-miR-7400-3p; +MIMAT0028944 oan-miR-7401-5p; +MIMAT0028945 oan-miR-7401-3p; +MIMAT0028946 oan-miR-7402-5p; +MIMAT0028947 oan-miR-7402-3p; +MIMAT0028948 oan-miR-7403-5p; +MIMAT0028949 oan-miR-7403-3p; +MIMAT0028950 oan-miR-7404-5p; +MIMAT0028951 oan-miR-7404-3p; +MIMAT0028952 oan-miR-7405-5p; +MIMAT0028953 oan-miR-7405-3p; +MIMAT0028954 oan-miR-7406-5p; +MIMAT0028955 oan-miR-7406-3p; +MIMAT0028956 oan-miR-2985-5p; +MIMAT0028957 oan-miR-2985-3p; +MIMAT0028958 oan-let-7c-5p; +MIMAT0028959 oan-let-7c-3p; +MIMAT0028960 oan-miR-7407-5p; +MIMAT0028961 oan-miR-7407-3p; +MIMAT0028962 oan-miR-7408-5p; +MIMAT0028963 oan-miR-7408-3p; +MIMAT0028964 oan-miR-7409-5p; +MIMAT0028965 oan-miR-7409-3p; +MIMAT0028966 oan-miR-7410-5p; +MIMAT0028967 oan-miR-7410-3p; +MIMAT0028968 oan-miR-7411-5p; +MIMAT0028969 oan-miR-7411-3p; +MIMAT0028970 oan-miR-7412-5p; +MIMAT0028971 oan-miR-7412-3p; +MIMAT0028972 oan-miR-1421an-5p; +MIMAT0028973 oan-miR-1421an-3p; +MIMAT0028974 oan-miR-7413-5p; +MIMAT0028975 oan-miR-7413-3p; +MIMAT0028976 oan-miR-7414-5p; +MIMAT0028977 oan-miR-7414-3p; +MIMAT0028978 oan-miR-7415-5p; +MIMAT0028979 oan-miR-7415-3p; +MIMAT0028980 oan-miR-7416-5p; +MIMAT0028981 oan-miR-7416-3p; +MIMAT0028982 oan-miR-7417-5p; +MIMAT0028983 oan-miR-7417-3p; +MIMAT0028984 oan-miR-7418-5p; +MIMAT0028985 oan-miR-7418-3p; +MIMAT0028986 oan-miR-7419-5p; +MIMAT0028987 oan-miR-7419-3p; +MIMAT0028988 oan-miR-34b-5p; +MIMAT0028989 oan-miR-34b-3p; +MIMAT0028990 oan-miR-7420-5p; +MIMAT0028991 oan-miR-7420-3p; +MIMAT0028992 oan-miR-7421-5p; +MIMAT0028993 oan-miR-7421-3p; +MIMAT0028994 oan-miR-7422a-5p; +MIMAT0028995 oan-miR-7422a-3p; +MIMAT0028996 oan-miR-7423-5p; +MIMAT0028997 oan-miR-7423-3p; +MIMAT0028998 oan-miR-7424-5p; +MIMAT0028999 oan-miR-7424-3p; +MIMAT0029000 oan-miR-7425-5p; +MIMAT0029001 oan-miR-7425-3p; +MIMAT0029002 oan-miR-7426-5p; +MIMAT0029003 oan-miR-7426-3p; +MIMAT0029004 oan-miR-7427-5p; +MIMAT0029005 oan-miR-7427-3p; +MIMAT0029006 oan-miR-7428-5p; +MIMAT0029007 oan-miR-7428-3p; +MIMAT0029008 oan-miR-7429-5p; +MIMAT0029009 oan-miR-7429-3p; +MIMAT0029010 oan-miR-7430-5p; +MIMAT0029011 oan-miR-7430-3p; +MIMAT0029012 oan-miR-7431-5p; +MIMAT0029013 oan-miR-7431-3p; +MIMAT0029014 oan-miR-7432-5p; +MIMAT0029015 oan-miR-7432-3p; +MIMAT0029016 oan-miR-7433-5p; +MIMAT0029017 oan-miR-7433-3p; +MIMAT0029018 oan-miR-7434-5p; +MIMAT0029019 oan-miR-7434-3p; +MIMAT0029020 oan-miR-216b-5p; +MIMAT0029021 oan-miR-216b-3p; +MIMAT0029022 oan-miR-7422b-5p; +MIMAT0029023 oan-miR-7422b-3p; +MIMAT0029024 oan-miR-7435-5p; +MIMAT0029025 oan-miR-7435-3p; +MIMAT0029026 oan-miR-7436-5p; +MIMAT0029027 oan-miR-7436-3p; +MIMAT0029028 gga-miR-7437-5p; +MIMAT0029029 gga-miR-7437-3p; +MIMAT0029030 gga-miR-7438-5p; +MIMAT0029031 gga-miR-7438-3p; +MIMAT0029032 gga-miR-7439-5p; +MIMAT0029033 gga-miR-7439-3p; +MIMAT0029034 gga-miR-7440-5p; +MIMAT0029035 gga-miR-7440-3p; +MIMAT0029036 gga-miR-7441-5p; +MIMAT0029037 gga-miR-7441-3p; +MIMAT0029038 gga-miR-7442-5p; +MIMAT0029039 gga-miR-7442-3p; +MIMAT0029040 gga-miR-7443-5p; +MIMAT0029041 gga-miR-7443-3p; +MIMAT0029042 gga-miR-7444-5p; +MIMAT0029043 gga-miR-7444-3p; +MIMAT0029044 gga-miR-7445-5p; +MIMAT0029045 gga-miR-7445-3p; +MIMAT0029046 gga-miR-7446-5p; +MIMAT0029047 gga-miR-7446-3p; +MIMAT0029048 gga-miR-7447-5p; +MIMAT0029049 gga-miR-7447-3p; +MIMAT0029050 gga-miR-7448-5p; +MIMAT0029051 gga-miR-7448-3p; +MIMAT0029052 gga-miR-7449-5p; +MIMAT0029053 gga-miR-7449-3p; +MIMAT0029054 gga-miR-7450-5p; +MIMAT0029055 gga-miR-7450-3p; +MIMAT0029056 gga-miR-7451-5p; +MIMAT0029057 gga-miR-7451-3p; +MIMAT0029058 gga-miR-7452-5p; +MIMAT0029059 gga-miR-7452-3p; +MIMAT0029060 gga-miR-7453-5p; +MIMAT0029061 gga-miR-7453-3p; +MIMAT0029062 gga-miR-7454-5p; +MIMAT0029063 gga-miR-7454-3p; +MIMAT0029064 gga-miR-7455-5p; +MIMAT0029065 gga-miR-7455-3p; +MIMAT0029066 gga-miR-7456-5p; +MIMAT0029067 gga-miR-7456-3p; +MIMAT0029068 gga-miR-7457-5p; +MIMAT0029069 gga-miR-7457-3p; +MIMAT0029070 gga-miR-7458-5p; +MIMAT0029071 gga-miR-7458-3p; +MIMAT0029072 gga-miR-7459-5p; +MIMAT0029073 gga-miR-7459-3p; +MIMAT0029074 gga-miR-7460-5p; +MIMAT0029075 gga-miR-7460-3p; +MIMAT0029076 gga-miR-7461-5p; +MIMAT0029077 gga-miR-7461-3p; +MIMAT0029078 gga-miR-7462-5p; +MIMAT0029079 gga-miR-7462-3p; +MIMAT0029080 gga-miR-7463-5p; +MIMAT0029081 gga-miR-7463-3p; +MIMAT0029082 gga-miR-7464-5p; +MIMAT0029083 gga-miR-7464-3p; +MIMAT0029084 gga-miR-7465-5p; +MIMAT0029085 gga-miR-7465-3p; +MIMAT0029086 gga-miR-7466-5p; +MIMAT0029087 gga-miR-7466-3p; +MIMAT0029088 gga-miR-7467-5p; +MIMAT0029089 gga-miR-7467-3p; +MIMAT0029090 gga-miR-7468-5p; +MIMAT0029091 gga-miR-7468-3p; +MIMAT0029092 gga-miR-7469-5p; +MIMAT0029093 gga-miR-7469-3p; +MIMAT0029094 gga-miR-7470-5p; +MIMAT0029095 gga-miR-7470-3p; +MIMAT0029096 gga-miR-7471-5p; +MIMAT0029097 gga-miR-7471-3p; +MIMAT0029098 gga-miR-7472-5p; +MIMAT0029099 gga-miR-7472-3p; +MIMAT0029100 gga-miR-7473-5p; +MIMAT0029101 gga-miR-7473-3p; +MIMAT0029102 gga-miR-7474-5p; +MIMAT0029103 gga-miR-7474-3p; +MIMAT0029104 gga-miR-7475-5p; +MIMAT0029105 gga-miR-7475-3p; +MIMAT0029106 gga-miR-7476-5p; +MIMAT0029107 gga-miR-7476-3p; +MIMAT0029108 gga-miR-7477-5p; +MIMAT0029109 gga-miR-7477-3p; +MIMAT0029110 gga-miR-7478-5p; +MIMAT0029111 gga-miR-7478-3p; +MIMAT0029112 gga-miR-7479-5p; +MIMAT0029113 gga-miR-7479-3p; +MIMAT0029114 gga-miR-7480-5p; +MIMAT0029115 gga-miR-7480-3p; +MIMAT0029116 gga-miR-7481-5p; +MIMAT0029117 gga-miR-7481-3p; +MIMAT0029118 gga-miR-7482-5p; +MIMAT0029119 gga-miR-7482-3p; +MIMAT0029120 gga-miR-7483-5p; +MIMAT0029121 gga-miR-7483-3p; +MIMAT0029122 hcmv-miR-UL59; +MIMAT0029123 hcmv-miR-UL69; +MIMAT0029124 ghr-miR7484a; +MIMAT0029125 ghr-miR7484b; +MIMAT0029126 ghr-miR7485; +MIMAT0029127 ghr-miR7486a; +MIMAT0029128 ghr-miR7486b; +MIMAT0029129 ghr-miR7487; +MIMAT0029130 ghr-miR7488; +MIMAT0029131 ghr-miR7489; +MIMAT0029132 ghr-miR7490; +MIMAT0029133 ghr-miR7491; +MIMAT0029134 ghr-miR7492a; +MIMAT0029135 ghr-miR7492b; +MIMAT0029136 ghr-miR7492c; +MIMAT0029137 ghr-miR160; +MIMAT0029138 ghr-miR7493; +MIMAT0029139 ghr-miR7494; +MIMAT0029140 ghr-miR7495a; +MIMAT0029141 ghr-miR7495b; +MIMAT0029142 ghr-miR7496a; +MIMAT0029143 ghr-miR7496b; +MIMAT0029144 ghr-miR7497; +MIMAT0029145 ghr-miR7498; +MIMAT0029146 ghr-miR7499; +MIMAT0029147 ghr-miR7500; +MIMAT0029148 ghr-miR7501; +MIMAT0029149 ghr-miR7502; +MIMAT0029150 ghr-miR7503; +MIMAT0029151 ghr-miR7504a; +MIMAT0029152 ghr-miR7505; +MIMAT0029153 ghr-miR7506; +MIMAT0029154 ghr-miR7507; +MIMAT0029155 ghr-miR7508; +MIMAT0029156 ghr-miR7509; +MIMAT0029157 ghr-miR169b; +MIMAT0029158 ghr-miR7510a; +MIMAT0029159 ghr-miR7504b; +MIMAT0029160 ghr-miR7511; +MIMAT0029161 ghr-miR7512; +MIMAT0029162 ghr-miR7513; +MIMAT0029163 ghr-miR7510b; +MIMAT0029164 ghr-miR7514; +MIMAT0029165 mes-miR156a; +MIMAT0029166 mes-miR156b; +MIMAT0029167 mes-miR156c; +MIMAT0029168 mes-miR156d; +MIMAT0029169 mes-miR156e; +MIMAT0029170 mes-miR156f; +MIMAT0029171 mes-miR156g; +MIMAT0029172 mes-miR156h; +MIMAT0029173 mes-miR156i; +MIMAT0029174 mes-miR156j; +MIMAT0029175 mes-miR156k; +MIMAT0029176 mes-miR159b; +MIMAT0029177 mes-miR159c; +MIMAT0029178 mes-miR159d; +MIMAT0029179 mes-miR160a; +MIMAT0029180 mes-miR160b; +MIMAT0029181 mes-miR160c; +MIMAT0029182 mes-miR160d; +MIMAT0029183 mes-miR160e; +MIMAT0029184 mes-miR160f; +MIMAT0029185 mes-miR160g; +MIMAT0029186 mes-miR160h; +MIMAT0029187 mes-miR162; +MIMAT0029188 mes-miR164a; +MIMAT0029189 mes-miR164b; +MIMAT0029190 mes-miR164c; +MIMAT0029191 mes-miR164d; +MIMAT0029192 mes-miR166a; +MIMAT0029193 mes-miR166b; +MIMAT0029194 mes-miR166c; +MIMAT0029195 mes-miR166d; +MIMAT0029196 mes-miR166e; +MIMAT0029197 mes-miR166f; +MIMAT0029198 mes-miR166g; +MIMAT0029199 mes-miR166h; +MIMAT0029200 mes-miR166i; +MIMAT0029201 mes-miR166j; +MIMAT0029202 mes-miR167b; +MIMAT0029203 mes-miR167c; +MIMAT0029204 mes-miR167d; +MIMAT0029205 mes-miR167e; +MIMAT0029206 mes-miR167f; +MIMAT0029207 mes-miR167g; +MIMAT0029208 mes-miR167h; +MIMAT0029209 mes-miR169a; +MIMAT0029210 mes-miR169b; +MIMAT0029211 mes-miR169c; +MIMAT0029212 mes-miR169d; +MIMAT0029213 mes-miR169e; +MIMAT0029214 mes-miR169f; +MIMAT0029215 mes-miR169g; +MIMAT0029216 mes-miR169h; +MIMAT0029217 mes-miR169i; +MIMAT0029218 mes-miR169j; +MIMAT0029219 mes-miR169k; +MIMAT0029220 mes-miR169l; +MIMAT0029221 mes-miR169m; +MIMAT0029222 mes-miR169n; +MIMAT0029223 mes-miR169o; +MIMAT0029224 mes-miR169p; +MIMAT0029225 mes-miR169q; +MIMAT0029226 mes-miR169r; +MIMAT0029227 mes-miR169s; +MIMAT0029228 mes-miR169t; +MIMAT0029229 mes-miR169u; +MIMAT0029230 mes-miR169v; +MIMAT0029231 mes-miR169w; +MIMAT0029232 mes-miR169x; +MIMAT0029233 mes-miR169y; +MIMAT0029234 mes-miR169z; +MIMAT0029235 mes-miR169aa; +MIMAT0029236 mes-miR169ab; +MIMAT0029237 mes-miR169ac; +MIMAT0029238 mes-miR171b; +MIMAT0029239 mes-miR171c; +MIMAT0029240 mes-miR171d; +MIMAT0029241 mes-miR171e; +MIMAT0029242 mes-miR171f; +MIMAT0029243 mes-miR171g; +MIMAT0029244 mes-miR171h; +MIMAT0029245 mes-miR171i; +MIMAT0029246 mes-miR171j; +MIMAT0029247 mes-miR171k; +MIMAT0029248 mes-miR172b; +MIMAT0029249 mes-miR172c; +MIMAT0029250 mes-miR172d; +MIMAT0029251 mes-miR172e; +MIMAT0029252 mes-miR172f; +MIMAT0029253 mes-miR319a; +MIMAT0029254 mes-miR319b; +MIMAT0029255 mes-miR319c; +MIMAT0029256 mes-miR319d; +MIMAT0029257 mes-miR319e; +MIMAT0029258 mes-miR319f; +MIMAT0029259 mes-miR319g; +MIMAT0029260 mes-miR319h; +MIMAT0029261 mes-miR390; +MIMAT0029262 mes-miR393a; +MIMAT0029263 mes-miR393b; +MIMAT0029264 mes-miR393c; +MIMAT0029265 mes-miR393d; +MIMAT0029266 mes-miR394b; +MIMAT0029267 mes-miR394c; +MIMAT0029268 mes-miR395a; +MIMAT0029269 mes-miR395b; +MIMAT0029270 mes-miR395c; +MIMAT0029271 mes-miR395d; +MIMAT0029272 mes-miR395e; +MIMAT0029273 mes-miR396a; +MIMAT0029274 mes-miR396b; +MIMAT0029275 mes-miR396c; +MIMAT0029276 mes-miR396d; +MIMAT0029277 mes-miR396e; +MIMAT0029278 mes-miR396f; +MIMAT0029279 mes-miR397; +MIMAT0029280 mes-miR399b; +MIMAT0029281 mes-miR399c; +MIMAT0029282 mes-miR399d; +MIMAT0029283 mes-miR399e; +MIMAT0029284 mes-miR399f; +MIMAT0029285 mes-miR399g; +MIMAT0029286 mes-miR403a; +MIMAT0029287 mes-miR403b; +MIMAT0029288 mes-miR477h; +MIMAT0029289 mes-miR477i; +MIMAT0029290 mes-miR477a; +MIMAT0029291 mes-miR477b; +MIMAT0029292 mes-miR477c; +MIMAT0029293 mes-miR477d; +MIMAT0029294 mes-miR477e; +MIMAT0029295 mes-miR477f; +MIMAT0029296 mes-miR477g; +MIMAT0029297 mes-miR482; +MIMAT0029298 mes-miR530a; +MIMAT0029299 mes-miR530b; +MIMAT0029300 mes-miR535a; +MIMAT0029301 mes-miR535b; +MIMAT0029302 mes-miR827; +MIMAT0029303 mes-miR828a; +MIMAT0029304 mes-miR828b; +MIMAT0029305 mes-miR1446; +MIMAT0029306 mes-miR2111a; +MIMAT0029307 mes-miR2111b; +MIMAT0029308 mes-miR2275; +MIMAT0029309 mes-miR2950; +MIMAT0029310 hsa-miR-7515; +MIMAT0029311 lja-miR167a; +MIMAT0029312 lja-miR167b; +MIMAT0029313 lja-miR167c; +MIMAT0029314 lja-miR171a; +MIMAT0029315 lja-miR171b; +MIMAT0029316 lja-miR171c; +MIMAT0029317 lja-miR171d-3p; +MIMAT0029318 lja-miR171d-5p; +MIMAT0029319 lja-miR172a; +MIMAT0029320 lja-miR172b; +MIMAT0029321 lja-miR172c; +MIMAT0029322 lja-miR390a-5p; +MIMAT0029323 lja-miR390a-3p; +MIMAT0029324 lja-miR390b-5p; +MIMAT0029325 lja-miR390b-3p; +MIMAT0029326 lja-miR397; +MIMAT0029327 lja-miR408; +MIMAT0029328 lja-miR7516-5p; +MIMAT0029329 lja-miR7516-3p; +MIMAT0029330 lja-miR1507a; +MIMAT0029331 lja-miR1507b; +MIMAT0029332 lja-miR7517; +MIMAT0029333 lja-miR7518; +MIMAT0029334 lja-miR7519; +MIMAT0029335 lja-miR7520; +MIMAT0029336 lja-miR7521; +MIMAT0029337 lja-miR7522; +MIMAT0029338 lja-miR7523a; +MIMAT0029339 lja-miR7523b; +MIMAT0029340 lja-miR7524; +MIMAT0029341 lja-miR7525; +MIMAT0029342 lja-miR7526a; +MIMAT0029343 lja-miR7526b; +MIMAT0029344 lja-miR7526c; +MIMAT0029345 lja-miR7526d; +MIMAT0029346 lja-miR7526e; +MIMAT0029347 lja-miR7526f; +MIMAT0029348 lja-miR7526g; +MIMAT0029349 lja-miR7526h; +MIMAT0029350 lja-miR7527; +MIMAT0029351 lja-miR7528; +MIMAT0029352 lja-miR7529; +MIMAT0029353 lja-miR7530; +MIMAT0029354 lja-miR7531; +MIMAT0029355 lja-miR7532a; +MIMAT0029356 lja-miR7532b; +MIMAT0029357 lja-miR7533a; +MIMAT0029358 lja-miR7533b; +MIMAT0029359 lja-miR7534; +MIMAT0029360 lja-miR7535; +MIMAT0029361 lja-miR7536a; +MIMAT0029362 lja-miR7536b; +MIMAT0029363 lja-miR7537; +MIMAT0029364 lja-miR7538; +MIMAT0029365 lja-miR7539; +MIMAT0029366 lja-miR7540a; +MIMAT0029367 lja-miR7540b; +MIMAT0029368 lja-miR7541; +MIMAT0029369 lja-miR7542; +MIMAT0029370 lja-miR7543; +MIMAT0029371 lja-miR7544; +MIMAT0029372 lja-miR7545; +MIMAT0029373 lja-miR7546; +MIMAT0029374 ipu-let-7a; +MIMAT0029375 ipu-let-7b; +MIMAT0029376 ipu-let-7c; +MIMAT0029377 ipu-let-7d; +MIMAT0029378 ipu-let-7e; +MIMAT0029379 ipu-let-7f; +MIMAT0029380 ipu-let-7g; +MIMAT0029381 ipu-let-7h; +MIMAT0029382 ipu-let-7i; +MIMAT0029383 ipu-let-7j; +MIMAT0029384 ipu-miR-1; +MIMAT0029385 ipu-miR-100; +MIMAT0029386 ipu-miR-101a; +MIMAT0029387 ipu-miR-101b; +MIMAT0029388 ipu-miR-103; +MIMAT0029389 ipu-miR-107a; +MIMAT0029390 ipu-miR-107b; +MIMAT0029391 ipu-miR-10a; +MIMAT0029392 ipu-miR-10b; +MIMAT0029393 ipu-miR-10c; +MIMAT0029394 ipu-miR-10d; +MIMAT0029395 ipu-miR-122; +MIMAT0029396 ipu-miR-124a; +MIMAT0029397 ipu-miR-125a; +MIMAT0029398 ipu-miR-125b; +MIMAT0029399 ipu-miR-125c; +MIMAT0029400 ipu-miR-126a; +MIMAT0029401 ipu-miR-126b; +MIMAT0029402 ipu-miR-128; +MIMAT0029403 ipu-miR-129; +MIMAT0029404 ipu-miR-130c; +MIMAT0029405 ipu-miR-132a; +MIMAT0029406 ipu-miR-132b; +MIMAT0029407 ipu-miR-133a; +MIMAT0029408 ipu-miR-133b; +MIMAT0029409 ipu-miR-133c; +MIMAT0029410 ipu-miR-135a; +MIMAT0029411 ipu-miR-135b; +MIMAT0029412 ipu-miR-135c; +MIMAT0029413 ipu-miR-137; +MIMAT0029414 ipu-miR-138; +MIMAT0029415 ipu-miR-1388; +MIMAT0029416 ipu-miR-139; +MIMAT0029417 ipu-miR-140; +MIMAT0029418 ipu-miR-141; +MIMAT0029419 ipu-miR-142; +MIMAT0029420 ipu-miR-143; +MIMAT0029421 ipu-miR-144; +MIMAT0029422 ipu-miR-145; +MIMAT0029423 ipu-miR-146a; +MIMAT0029424 ipu-miR-146b; +MIMAT0029425 ipu-miR-148; +MIMAT0029426 ipu-miR-150; +MIMAT0029427 ipu-miR-152; +MIMAT0029428 ipu-miR-153b; +MIMAT0029429 ipu-miR-155; +MIMAT0029430 ipu-miR-15a; +MIMAT0029431 ipu-miR-15b; +MIMAT0029432 ipu-miR-16b; +MIMAT0029433 ipu-miR-1788; +MIMAT0029434 ipu-miR-17a; +MIMAT0029435 ipu-miR-17b; +MIMAT0029436 ipu-miR-181a; +MIMAT0029437 ipu-miR-181b; +MIMAT0029438 ipu-miR-181c; +MIMAT0029439 ipu-miR-182; +MIMAT0029440 ipu-miR-183; +MIMAT0029441 ipu-miR-184; +MIMAT0029442 ipu-miR-187; +MIMAT0029443 ipu-miR-18a; +MIMAT0029444 ipu-miR-190a; +MIMAT0029445 ipu-miR-190b; +MIMAT0029446 ipu-miR-192; +MIMAT0029447 ipu-miR-194a; +MIMAT0029448 ipu-miR-196a; +MIMAT0029449 ipu-miR-196d; +MIMAT0029450 ipu-miR-199a-5p; +MIMAT0029451 ipu-miR-19a; +MIMAT0029452 ipu-miR-19b; +MIMAT0029453 ipu-miR-200a; +MIMAT0029454 ipu-miR-200b; +MIMAT0029455 ipu-miR-200c; +MIMAT0029456 ipu-miR-202; +MIMAT0029457 ipu-miR-203a; +MIMAT0029458 ipu-miR-203b; +MIMAT0029459 ipu-miR-204; +MIMAT0029460 ipu-miR-205; +MIMAT0029461 ipu-miR-206; +MIMAT0029462 ipu-miR-20a; +MIMAT0029463 ipu-miR-21; +MIMAT0029464 ipu-miR-210; +MIMAT0029465 ipu-miR-212; +MIMAT0029466 ipu-miR-214; +MIMAT0029467 ipu-miR-216a; +MIMAT0029468 ipu-miR-216b; +MIMAT0029469 ipu-miR-217; +MIMAT0029470 ipu-miR-2187; +MIMAT0029471 ipu-miR-2188; +MIMAT0029472 ipu-miR-218a; +MIMAT0029473 ipu-miR-218b; +MIMAT0029474 ipu-miR-219a; +MIMAT0029475 ipu-miR-219b; +MIMAT0029476 ipu-miR-221; +MIMAT0029477 ipu-miR-222a; +MIMAT0029478 ipu-miR-223; +MIMAT0029479 ipu-miR-22a; +MIMAT0029480 ipu-miR-22b; +MIMAT0029481 ipu-miR-23a; +MIMAT0029482 ipu-miR-23b; +MIMAT0029483 ipu-miR-24; +MIMAT0029484 ipu-miR-25; +MIMAT0029485 ipu-miR-26a; +MIMAT0029486 ipu-miR-26b; +MIMAT0029487 ipu-miR-27a; +MIMAT0029488 ipu-miR-27b; +MIMAT0029489 ipu-miR-27c; +MIMAT0029490 ipu-miR-27d; +MIMAT0029491 ipu-miR-27e; +MIMAT0029492 ipu-miR-29c; +MIMAT0029493 ipu-miR-29b; +MIMAT0029494 ipu-miR-301a; +MIMAT0029495 ipu-miR-301c; +MIMAT0029496 ipu-miR-30a; +MIMAT0029497 ipu-miR-30b; +MIMAT0029498 ipu-miR-30c; +MIMAT0029499 ipu-miR-30d; +MIMAT0029500 ipu-miR-30e; +MIMAT0029501 ipu-miR-31; +MIMAT0029502 ipu-miR-338; +MIMAT0029503 ipu-miR-34a; +MIMAT0029504 ipu-miR-34b; +MIMAT0029505 ipu-miR-34c; +MIMAT0029506 ipu-miR-363; +MIMAT0029507 ipu-miR-365; +MIMAT0029508 ipu-miR-375; +MIMAT0029509 ipu-miR-429a; +MIMAT0029510 ipu-miR-429b; +MIMAT0029511 ipu-miR-454b; +MIMAT0029512 ipu-miR-455a; +MIMAT0029513 ipu-miR-455b; +MIMAT0029514 ipu-miR-456; +MIMAT0029515 ipu-miR-457a; +MIMAT0029516 ipu-miR-458; +MIMAT0029517 ipu-miR-459; +MIMAT0029518 ipu-miR-460; +MIMAT0029519 ipu-miR-462; +MIMAT0029520 ipu-miR-489; +MIMAT0029521 ipu-miR-499; +MIMAT0029522 ipu-miR-724; +MIMAT0029523 ipu-miR-728; +MIMAT0029524 ipu-miR-730; +MIMAT0029525 ipu-miR-737; +MIMAT0029526 ipu-miR-7a; +MIMAT0029527 ipu-miR-7b; +MIMAT0029528 ipu-miR-9; +MIMAT0029529 ipu-miR-92a; +MIMAT0029530 ipu-miR-92b; +MIMAT0029531 ipu-miR-96; +MIMAT0029532 ipu-miR-99a; +MIMAT0029533 ipu-miR-99b; +MIMAT0029534 ipu-miR-24b; +MIMAT0029535 ipu-miR-7547; +MIMAT0029536 ipu-miR-7147; +MIMAT0029537 ipu-miR-29a; +MIMAT0029538 ipu-miR-16c; +MIMAT0029539 ipu-miR-199b; +MIMAT0029540 ipu-miR-7548; +MIMAT0029541 ipu-miR-203c; +MIMAT0029542 ipu-miR-551; +MIMAT0029543 ipu-miR-7549; +MIMAT0029544 ipu-miR-129b; +MIMAT0029545 ipu-miR-7550; +MIMAT0029546 ipu-miR-3618; +MIMAT0029547 ipu-miR-7551; +MIMAT0029548 ipu-miR-7552; +MIMAT0029549 ipu-miR-7553; +MIMAT0029550 ipu-miR-7554; +MIMAT0029551 ipu-miR-7555; +MIMAT0029552 ipu-miR-7556; +MIMAT0029553 ipu-miR-7557; +MIMAT0029554 ipu-miR-7558a; +MIMAT0029555 ipu-miR-7559; +MIMAT0029556 ipu-miR-7560; +MIMAT0029557 ipu-miR-7558b; +MIMAT0029558 ipu-miR-7561; +MIMAT0029559 ipu-miR-7562; +MIMAT0029560 ipu-miR-7563a; +MIMAT0029561 ipu-miR-7563b; +MIMAT0029562 ipu-miR-7563c; +MIMAT0029563 ipu-miR-7564; +MIMAT0029564 ipu-miR-7565; +MIMAT0029565 ipu-miR-7566; +MIMAT0029566 ipu-miR-7567; +MIMAT0029567 ipu-miR-7568; +MIMAT0029568 ipu-miR-7569; +MIMAT0029569 ipu-miR-7570; +MIMAT0029570 ipu-miR-7571; +MIMAT0029571 ipu-miR-7572; +MIMAT0029572 ipu-miR-7573; +MIMAT0029573 ipu-miR-7574; +MIMAT0029574 ipu-miR-7575; +MIMAT0029575 ipu-miR-7576; +MIMAT0029576 ipu-miR-7577; +MIMAT0029577 ipu-miR-457b; +MIMAT0029578 mmu-miR-7578; +MIMAT0029579 rno-miR-7578; +MIMAT0029580 cbr-miR-7579; +MIMAT0029581 cbr-miR-7580; +MIMAT0029582 cbr-miR-7581; +MIMAT0029583 cbr-miR-7582; +MIMAT0029584 cbr-miR-7583a-5p; +MIMAT0029585 cbr-miR-7583a-3p; +MIMAT0029586 cbr-miR-7583b; +MIMAT0029587 cbr-miR-7584; +MIMAT0029588 cbr-miR-7585; +MIMAT0029589 cbr-miR-7586; +MIMAT0029590 cbr-miR-7587; +MIMAT0029591 cbr-miR-7583d; +MIMAT0029592 cbr-miR-7588; +MIMAT0029593 cbr-miR-7583c-5p; +MIMAT0029594 cbr-miR-7583c-3p; +MIMAT0029595 cbr-miR-7589; +MIMAT0029596 cbr-miR-7590; +MIMAT0029597 cbr-miR-7591; +MIMAT0029598 cbr-miR-7592; +MIMAT0029599 cbr-miR-7593; +MIMAT0029600 cbr-miR-7594a; +MIMAT0029601 cbr-miR-7594b; +MIMAT0029602 cbr-miR-7595; +MIMAT0029603 cbr-miR-64c; +MIMAT0029604 cbr-miR-7596; +MIMAT0029605 cbr-miR-247; +MIMAT0029606 cbr-miR-2; +MIMAT0029607 cbr-miR-124b; +MIMAT0029608 cbr-miR-124c; +MIMAT0029609 cbr-miR-785b; +MIMAT0029610 crm-miR-7579; +MIMAT0029611 crm-miR-1822; +MIMAT0029612 crm-miR-7597; +MIMAT0029613 crm-miR-1817b; +MIMAT0029614 crm-miR-358; +MIMAT0029615 crm-miR-7598; +MIMAT0029616 crm-miR-7599; +MIMAT0029617 crm-miR-7600; +MIMAT0029618 crm-miR-7601; +MIMAT0029619 crm-miR-7602; +MIMAT0029620 crm-miR-7603; +MIMAT0029621 crm-miR-7604; +MIMAT0029622 crm-miR-7605; +MIMAT0029623 crm-miR-54; +MIMAT0029624 crm-miR-7606; +MIMAT0029625 crm-miR-7607; +MIMAT0029626 crm-miR-7608; +MIMAT0029627 crm-miR-7609; +MIMAT0029628 crm-miR-7610; +MIMAT0029629 crm-miR-240; +MIMAT0029630 crm-miR-7611; +MIMAT0029631 crm-miR-7582; +MIMAT0029632 crm-miR-392; +MIMAT0029633 crm-miR-7594; +MIMAT0029634 crm-miR-7612; +MIMAT0029635 crm-miR-56; +MIMAT0029636 crm-miR-51; +MIMAT0029637 crm-miR-58c; +MIMAT0029638 crm-miR-58d; +MIMAT0029639 crm-miR-7613; +MIMAT0029640 crm-miR-2225; +MIMAT0029641 crm-miR-2254; +MIMAT0029642 crm-miR-1824; +MIMAT0029643 crm-miR-251; +MIMAT0029644 crm-miR-124b; +MIMAT0029645 crm-miR-234; +MIMAT0029646 crm-miR-254; +MIMAT0029647 crm-miR-359; +MIMAT0029648 crm-miR-2229a; +MIMAT0029649 crm-miR-2229b; +MIMAT0029650 cbn-miR-7579; +MIMAT0029651 cbn-miR-1822; +MIMAT0029652 cbn-miR-7614; +MIMAT0029653 cbn-miR-7597; +MIMAT0029654 cbn-miR-7615; +MIMAT0029655 cbn-miR-7616; +MIMAT0029656 cbn-miR-7617; +MIMAT0029657 cbn-miR-7618; +MIMAT0029658 cbn-miR-7619; +MIMAT0029659 cbn-miR-7620a; +MIMAT0029660 cbn-miR-7621a; +MIMAT0029661 cbn-miR-7621b; +MIMAT0029662 cbn-miR-7622; +MIMAT0029663 cbn-miR-789b; +MIMAT0029664 cbn-miR-789a; +MIMAT0029665 cbn-miR-7623; +MIMAT0029666 cbn-miR-7624; +MIMAT0029667 cbn-miR-7625; +MIMAT0029668 cbn-miR-7626; +MIMAT0029669 cbn-miR-7627; +MIMAT0029670 cbn-miR-7628; +MIMAT0029671 cbn-miR-7629; +MIMAT0029672 cbn-miR-7630; +MIMAT0029673 cbn-miR-7631; +MIMAT0029674 cbn-miR-230; +MIMAT0029675 cbn-miR-7632; +MIMAT0029676 cbn-miR-7633; +MIMAT0029677 cbn-miR-7634; +MIMAT0029678 cbn-miR-7635; +MIMAT0029679 cbn-miR-356; +MIMAT0029680 cbn-miR-7636; +MIMAT0029681 cbn-miR-84; +MIMAT0029682 cbn-let-7; +MIMAT0029683 cbn-miR-48; +MIMAT0029684 cbn-miR-7637; +MIMAT0029685 cbn-miR-241; +MIMAT0029686 cbn-miR-52; +MIMAT0029687 cbn-miR-54; +MIMAT0029688 cbn-miR-55; +MIMAT0029689 cbn-miR-56; +MIMAT0029690 cbn-miR-51; +MIMAT0029691 cbn-miR-80; +MIMAT0029692 cbn-miR-81; +MIMAT0029693 cbn-miR-58a; +MIMAT0029694 cbn-miR-82; +MIMAT0029695 cbn-miR-58b; +MIMAT0029696 cbn-miR-63; +MIMAT0029697 cbn-miR-64m; +MIMAT0029698 cbn-miR-64j; +MIMAT0029699 cbn-miR-64f; +MIMAT0029700 cbn-miR-64b; +MIMAT0029701 cbn-miR-64h; +MIMAT0029702 cbn-miR-64a; +MIMAT0029703 cbn-miR-64d; +MIMAT0029704 cbn-miR-64e; +MIMAT0029705 cbn-miR-64c; +MIMAT0029706 cbn-miR-64i; +MIMAT0029707 cbn-miR-64g; +MIMAT0029708 cbn-miR-64k; +MIMAT0029709 cbn-miR-64l; +MIMAT0029710 cbn-miR-1; +MIMAT0029711 cbn-miR-44; +MIMAT0029712 cbn-miR-61; +MIMAT0029713 cbn-miR-74c; +MIMAT0029714 cbn-miR-72a; +MIMAT0029715 cbn-miR-73a; +MIMAT0029716 cbn-miR-74b; +MIMAT0029717 cbn-miR-72b; +MIMAT0029718 cbn-miR-74a; +MIMAT0029719 cbn-miR-73b; +MIMAT0029720 cbn-miR-74d; +MIMAT0029721 cbn-miR-87; +MIMAT0029722 cbn-miR-233; +MIMAT0029723 cbn-miR-2; +MIMAT0029724 cbn-miR-43; +MIMAT0029725 cbn-miR-250; +MIMAT0029726 cbn-miR-238; +MIMAT0029727 cbn-miR-239b; +MIMAT0029728 cbn-miR-239a; +MIMAT0029729 cbn-miR-239c; +MIMAT0029730 cbn-miR-239d; +MIMAT0029731 cbn-miR-50; +MIMAT0029732 cbn-miR-90; +MIMAT0029733 cbn-miR-62; +MIMAT0029734 cbn-lin-4; +MIMAT0029735 cbn-miR-237; +MIMAT0029736 cbn-miR-1824a; +MIMAT0029737 cbn-miR-1824b; +MIMAT0029738 cbn-miR-7638; +MIMAT0029739 cbn-miR-231; +MIMAT0029740 cbn-miR-787; +MIMAT0029741 cbn-miR-251a; +MIMAT0029742 cbn-miR-357; +MIMAT0029743 cbn-miR-46; +MIMAT0029744 cbn-miR-47; +MIMAT0029745 cbn-miR-49; +MIMAT0029746 cbn-miR-83; +MIMAT0029747 cbn-miR-75; +MIMAT0029748 cbn-miR-79; +MIMAT0029749 cbn-miR-790; +MIMAT0029750 cbn-miR-86; +MIMAT0029751 cbn-miR-785; +MIMAT0029752 cbn-miR-124; +MIMAT0029753 cbn-miR-228; +MIMAT0029754 cbn-miR-7639; +MIMAT0029755 cbn-miR-232; +MIMAT0029756 cbn-miR-234; +MIMAT0029757 cbn-miR-235; +MIMAT0029758 cbn-miR-7620b; +MIMAT0029759 cbn-miR-236; +MIMAT0029760 cbn-miR-242; +MIMAT0029761 cbn-miR-244; +MIMAT0029762 cbn-miR-245; +MIMAT0029763 cbn-miR-7640; +MIMAT0029764 cbn-miR-246; +MIMAT0029765 cbn-miR-248; +MIMAT0029766 cbn-miR-249; +MIMAT0029767 cbn-miR-254; +MIMAT0029768 cbn-miR-255; +MIMAT0029769 cbn-miR-259; +MIMAT0029770 cbn-miR-34; +MIMAT0029771 cbn-miR-355; +MIMAT0029772 cbn-miR-359; +MIMAT0029773 cbn-miR-57; +MIMAT0029774 cbn-miR-60; +MIMAT0029775 cbn-miR-67; +MIMAT0029776 cbn-miR-70; +MIMAT0029777 cbn-miR-76; +MIMAT0029778 cbn-miR-77; +MIMAT0029779 cbn-miR-784; +MIMAT0029780 cbn-miR-85; +MIMAT0029781 cbn-miR-59; +MIMAT0029782 hsa-miR-7641; +MIMAT0029783 sci-miR-7642-5p; +MIMAT0029784 sci-miR-7642-3p; +MIMAT0029785 lco-miR-7642-3p; +MIMAT0029786 tgu-miR-7643-5p; +MIMAT0029787 tgu-miR-7643-3p; +MIMAT0029788 tgu-miR-7644-5p; +MIMAT0029789 tgu-miR-7644-3p; +MIMAT0029790 tgu-miR-7645-5p; +MIMAT0029791 tgu-miR-7645-3p; +MIMAT0029792 mmu-miR-6546-5p; +MIMAT0029793 mmu-miR-6546-3p; +MIMAT0029794 mmu-miR-7646-5p; +MIMAT0029795 mmu-miR-7646-3p; +MIMAT0029796 mmu-miR-7647-5p; +MIMAT0029797 mmu-miR-7647-3p; +MIMAT0029798 mmu-miR-7648-5p; +MIMAT0029799 mmu-miR-7648-3p; +MIMAT0029800 mmu-miR-7649-5p; +MIMAT0029801 mmu-miR-7649-3p; +MIMAT0029802 mmu-miR-7650-5p; +MIMAT0029803 mmu-miR-7650-3p; +MIMAT0029804 mmu-miR-7651-5p; +MIMAT0029805 mmu-miR-7651-3p; +MIMAT0029806 mmu-miR-219b-5p; +MIMAT0029807 mmu-miR-219b-3p; +MIMAT0029808 mmu-miR-7036b-5p; +MIMAT0029809 mmu-miR-7036b-3p; +MIMAT0029810 mmu-miR-7652-5p; +MIMAT0029811 mmu-miR-7652-3p; +MIMAT0029812 mmu-miR-7653-5p; +MIMAT0029813 mmu-miR-7653-3p; +MIMAT0029814 mmu-miR-7654-5p; +MIMAT0029815 mmu-miR-7654-3p; +MIMAT0029816 mmu-miR-7655-5p; +MIMAT0029817 mmu-miR-7655-3p; +MIMAT0029818 mmu-miR-7656-5p; +MIMAT0029819 mmu-miR-7656-3p; +MIMAT0029820 mmu-miR-7657-5p; +MIMAT0029821 mmu-miR-7657-3p; +MIMAT0029822 mmu-miR-7658-5p; +MIMAT0029823 mmu-miR-7658-3p; +MIMAT0029824 mmu-miR-7659-5p; +MIMAT0029825 mmu-miR-7659-3p; +MIMAT0029826 mmu-miR-7660-5p; +MIMAT0029827 mmu-miR-7660-3p; +MIMAT0029828 mmu-miR-7661-5p; +MIMAT0029829 mmu-miR-7661-3p; +MIMAT0029830 mmu-miR-7662-5p; +MIMAT0029831 mmu-miR-7662-3p; +MIMAT0029832 mmu-miR-7663-5p; +MIMAT0029833 mmu-miR-7663-3p; +MIMAT0029834 mmu-miR-7664-5p; +MIMAT0029835 mmu-miR-7664-3p; +MIMAT0029836 mmu-miR-7665-5p; +MIMAT0029837 mmu-miR-7665-3p; +MIMAT0029838 mmu-miR-7666-5p; +MIMAT0029839 mmu-miR-7666-3p; +MIMAT0029840 mmu-miR-7667-5p; +MIMAT0029841 mmu-miR-7667-3p; +MIMAT0029842 mmu-miR-7668-5p; +MIMAT0029843 mmu-miR-7668-3p; +MIMAT0029844 mmu-miR-7669-5p; +MIMAT0029845 mmu-miR-7669-3p; +MIMAT0029846 mmu-miR-7670-5p; +MIMAT0029847 mmu-miR-7670-3p; +MIMAT0029848 mmu-miR-7671-5p; +MIMAT0029849 mmu-miR-7671-3p; +MIMAT0029850 mmu-miR-7672-5p; +MIMAT0029851 mmu-miR-7672-3p; +MIMAT0029852 mmu-miR-7673-5p; +MIMAT0029853 mmu-miR-7673-3p; +MIMAT0029854 mmu-miR-3569-5p; +MIMAT0029855 mmu-miR-3569-3p; +MIMAT0029856 mmu-miR-7674-5p; +MIMAT0029857 mmu-miR-7674-3p; +MIMAT0029858 mmu-miR-7675-5p; +MIMAT0029859 mmu-miR-7675-3p; +MIMAT0029860 mmu-miR-7676-5p; +MIMAT0029861 mmu-miR-7676-3p; +MIMAT0029862 mmu-miR-129b-5p; +MIMAT0029863 mmu-miR-129b-3p; +MIMAT0029864 mmu-miR-292b-5p; +MIMAT0029865 mmu-miR-292b-3p; +MIMAT0029866 mmu-miR-1191b-5p; +MIMAT0029867 mmu-miR-1191b-3p; +MIMAT0029868 mmu-miR-7677-5p; +MIMAT0029869 mmu-miR-7677-3p; +MIMAT0029870 mmu-miR-7678-5p; +MIMAT0029871 mmu-miR-7678-3p; +MIMAT0029872 mmu-miR-7679-5p; +MIMAT0029873 mmu-miR-7679-3p; +MIMAT0029874 mmu-miR-7680-5p; +MIMAT0029875 mmu-miR-7680-3p; +MIMAT0029876 mmu-miR-6715-5p; +MIMAT0029877 mmu-miR-6715-3p; +MIMAT0029878 mmu-miR-3620-5p; +MIMAT0029879 mmu-miR-3620-3p; +MIMAT0029880 mmu-miR-465d-5p; +MIMAT0029881 mmu-miR-465d-3p; +MIMAT0029882 mmu-miR-7681-5p; +MIMAT0029883 mmu-miR-7681-3p; +MIMAT0029884 mmu-miR-7682-5p; +MIMAT0029885 mmu-miR-7682-3p; +MIMAT0029886 mmu-miR-7683-5p; +MIMAT0029887 mmu-miR-7683-3p; +MIMAT0029888 mmu-miR-216c-5p; +MIMAT0029889 mmu-miR-216c-3p; +MIMAT0029890 mmu-miR-7684-5p; +MIMAT0029891 mmu-miR-7684-3p; +MIMAT0029892 mmu-miR-219c-5p; +MIMAT0029893 mmu-miR-219c-3p; +MIMAT0029894 mmu-miR-126b-5p; +MIMAT0029895 mmu-miR-126b-3p; +MIMAT0029896 mmu-miR-7685-5p; +MIMAT0029897 mmu-miR-7685-3p; +MIMAT0029898 mmu-miR-7686-5p; +MIMAT0029899 mmu-miR-7686-3p; +MIMAT0029900 mmu-miR-290b-5p; +MIMAT0029901 mmu-miR-290b-3p; +MIMAT0029902 mmu-miR-7687-5p; +MIMAT0029903 mmu-miR-7687-3p; +MIMAT0029904 mmu-miR-1258-5p; +MIMAT0029905 mmu-miR-1258-3p; +MIMAT0029906 mmu-miR-7688-5p; +MIMAT0029907 mmu-miR-7688-3p; +MIMAT0029908 mmu-miR-7689-5p; +MIMAT0029909 mmu-miR-7689-3p; +MIMAT0029910 mmu-miR-7243-5p; +MIMAT0029911 mmu-miR-7243-3p; +MIMAT0029912 mml-miR-5697-5p; +MIMAT0029913 mml-miR-5697-3p; +MIMAT0029914 mdo-miR-7301-5p; +MIMAT0029915 mdo-miR-7301-3p; +MIMAT0029916 cbr-miR-4813; +MIMAT0029917 cbr-miR-2231; +MIMAT0029918 cbr-miR-35f; +MIMAT0029919 cbr-miR-35g; +MIMAT0029920 crm-miR-35h; +MIMAT0029921 crm-miR-36; +MIMAT0029922 crm-miR-255; +MIMAT0029923 crm-miR-360; +MIMAT0029924 crm-miR-35i; +MIMAT0029925 cbn-miR-39; +MIMAT0029926 cbn-miR-38; +MIMAT0029927 cbn-miR-36; +MIMAT0029928 cbn-miR-35a; +MIMAT0029929 cbn-miR-35b; +MIMAT0029930 cbn-miR-35c; +MIMAT0029931 cbn-miR-35d; +MIMAT0029932 cbn-miR-35e; +MIMAT0029933 cbn-miR-35f; +MIMAT0029934 cbn-miR-35g; +MIMAT0029935 cbn-miR-35h; +MIMAT0029936 cbn-miR-35i; +MIMAT0029937 cbn-miR-35j; +MIMAT0029938 cbn-miR-35k; +MIMAT0029939 cbn-miR-35l; +MIMAT0029940 cbn-miR-35m; +MIMAT0029941 cbn-miR-35n; +MIMAT0029942 cbn-miR-7690; +MIMAT0029943 cbn-miR-360; +MIMAT0029944 bta-miR-2285y; +MIMAT0029945 bta-miR-2285w; +MIMAT0029946 bta-miR-2285x; +MIMAT0029947 bta-miR-6529b; +MIMAT0029948 bta-miR-3613b; +MIMAT0029949 bta-miR-133c; +MIMAT0029950 bta-miR-2285z; +MIMAT0029951 bta-miR-6523b; +MIMAT0029952 bta-miR-7691; +MIMAT0029953 osa-miR1437b-5p; +MIMAT0029954 osa-miR1437b-3p; +MIMAT0029955 osa-miR7692-5p; +MIMAT0029956 osa-miR7692-3p; +MIMAT0029957 osa-miR7693-5p; +MIMAT0029958 osa-miR7693-3p; +MIMAT0029959 osa-miR7694-5p; +MIMAT0029960 osa-miR7694-3p; +MIMAT0029961 osa-miR7695-5p; +MIMAT0029962 osa-miR7695-3p; +MIMAT0029963 mtr-miR169i; +MIMAT0029964 mtr-miR2587g; +MIMAT0029965 mtr-miR2652m; +MIMAT0029966 mtr-miR2653d; +MIMAT0029967 mtr-miR2656c; +MIMAT0029968 mtr-miR2656d; +MIMAT0029969 mtr-miR2656e; +MIMAT0029970 mtr-miR2659g; +MIMAT0029971 mtr-miR2659h; +MIMAT0029972 mtr-miR2659i; +MIMAT0029973 mtr-miR2659j; +MIMAT0029974 mtr-miR2659k; +MIMAT0029975 mtr-miR2664b; +MIMAT0029976 mtr-miR2667b; +MIMAT0029977 mtr-miR2669b; +MIMAT0029978 mtr-miR172d-5p; +MIMAT0029979 mtr-miR172d-3p; +MIMAT0029980 mtr-miR319c-5p; +MIMAT0029981 mtr-miR319c-3p; +MIMAT0029982 mtr-miR319d-5p; +MIMAT0029983 mtr-miR319d-3p; +MIMAT0029984 mtr-miR397-5p; +MIMAT0029985 mtr-miR397-3p; +MIMAT0029986 mtr-miR7696a-5p; +MIMAT0029987 mtr-miR7696a-3p; +MIMAT0029988 mtr-miR7696b-5p; +MIMAT0029989 mtr-miR7696b-3p; +MIMAT0029990 mtr-miR7696c-5p; +MIMAT0029991 mtr-miR7696c-3p; +MIMAT0029992 mtr-miR7696d-5p; +MIMAT0029993 mtr-miR7696d-3p; +MIMAT0029994 mtr-miR7697-5p; +MIMAT0029995 mtr-miR7697-3p; +MIMAT0029996 mtr-miR7698-5p; +MIMAT0029997 mtr-miR7698-3p; +MIMAT0029998 mtr-miR7699-5p; +MIMAT0029999 mtr-miR7699-3p; +MIMAT0030000 mtr-miR7700-5p; +MIMAT0030001 mtr-miR169l-5p; +MIMAT0030002 mtr-miR169l-3p; +MIMAT0030003 mtr-miR399s-5p; +MIMAT0030004 mtr-miR399s-3p; +MIMAT0030005 mtr-miR399t-5p; +MIMAT0030006 mtr-miR399t-3p; +MIMAT0030007 mtr-miR2592bo-5p; +MIMAT0030008 mtr-miR2592bo-3p; +MIMAT0030009 mtr-miR2592bp-5p; +MIMAT0030010 mtr-miR2592bp-3p; +MIMAT0030011 mtr-miR2592bq-5p; +MIMAT0030012 mtr-miR2592bq-3p; +MIMAT0030013 mtr-miR2592br-5p; +MIMAT0030014 mtr-miR2592br-3p; +MIMAT0030015 mtr-miR7701-5p; +MIMAT0030016 mtr-miR7701-3p; +MIMAT0030017 hsa-miR-7702; +MIMAT0030018 hsa-miR-7703; +MIMAT0030019 hsa-miR-7704; +MIMAT0030020 hsa-miR-7705; +MIMAT0030021 hsa-miR-7706; +MIMAT0030022 oar-let-7a; +MIMAT0030023 oar-let-7d; +MIMAT0030024 oar-let-7f; +MIMAT0030025 oar-let-7g; +MIMAT0030026 oar-let-7i; +MIMAT0030027 oar-miR-103; +MIMAT0030028 oar-miR-106b; +MIMAT0030029 oar-miR-107; +MIMAT0030030 oar-miR-10a; +MIMAT0030031 oar-miR-10b; +MIMAT0030032 oar-miR-143; +MIMAT0030033 oar-miR-148a; +MIMAT0030034 oar-miR-150; +MIMAT0030035 oar-miR-152; +MIMAT0030036 oar-miR-16b; +MIMAT0030037 oar-miR-17-5p; +MIMAT0030038 oar-miR-191; +MIMAT0030039 oar-miR-194; +MIMAT0030040 oar-miR-199a-3p; +MIMAT0030041 oar-miR-19b; +MIMAT0030042 oar-miR-200a; +MIMAT0030043 oar-miR-200b; +MIMAT0030044 oar-miR-200c; +MIMAT0030045 oar-miR-218a; +MIMAT0030046 oar-miR-22-3p; +MIMAT0030047 oar-miR-221; +MIMAT0030048 oar-miR-23a; +MIMAT0030049 oar-miR-23b; +MIMAT0030050 oar-miR-25; +MIMAT0030051 oar-miR-26a; +MIMAT0030052 oar-miR-26b; +MIMAT0030053 oar-miR-27a; +MIMAT0030054 oar-miR-29b; +MIMAT0030055 oar-miR-30a-5p; +MIMAT0030056 oar-miR-30a-3p; +MIMAT0030057 oar-miR-30b; +MIMAT0030058 oar-miR-30c; +MIMAT0030059 oar-miR-30d; +MIMAT0030060 oar-miR-362; +MIMAT0030061 oar-miR-106a; +MIMAT0030062 oar-miR-374a; +MIMAT0030063 oar-miR-374b; +MIMAT0030064 oar-miR-99a; +MIMAT0030065 bdi-miR397b-5p; +MIMAT0030066 bdi-miR397b-3p; +MIMAT0030067 bdi-miR5174e-5p.2; +MIMAT0030068 bdi-miR5174e-5p.1; +MIMAT0030069 bdi-miR5174e-3p.1; +MIMAT0030070 bdi-miR5174e-3p.2; +MIMAT0030071 bdi-miR156e-5p; +MIMAT0030072 bdi-miR156e-3p; +MIMAT0030073 bdi-miR156f-5p; +MIMAT0030074 bdi-miR156f-3p; +MIMAT0030075 bdi-miR156g-5p; +MIMAT0030076 bdi-miR156g-3p; +MIMAT0030077 bdi-miR156h-5p; +MIMAT0030078 bdi-miR156h-3p; +MIMAT0030079 bdi-miR156i-5p; +MIMAT0030080 bdi-miR156i-3p; +MIMAT0030081 bdi-miR159b-5p.1; +MIMAT0030082 bdi-miR159b-5p.2; +MIMAT0030083 bdi-miR159b-5p.3; +MIMAT0030084 bdi-miR159b-3p.3; +MIMAT0030085 bdi-miR159b-3p.2; +MIMAT0030086 bdi-miR159b-3p.1; +MIMAT0030087 bdi-miR166h-5p; +MIMAT0030088 bdi-miR166h-3p; +MIMAT0030089 bdi-miR166i-5p; +MIMAT0030090 bdi-miR166i-3p; +MIMAT0030091 bdi-miR167e-5p; +MIMAT0030092 bdi-miR167e-3p; +MIMAT0030093 bdi-miR395o-5p; +MIMAT0030094 bdi-miR395o-3p; +MIMAT0030095 bdi-miR395p-5p; +MIMAT0030096 bdi-miR395p-3p; +MIMAT0030097 bdi-miR5163b-5p; +MIMAT0030098 bdi-miR5163b-3p; +MIMAT0030099 bdi-miR5167b-5p; +MIMAT0030100 bdi-miR5167b-3p; +MIMAT0030101 bdi-miR5174b-5p; +MIMAT0030102 bdi-miR5174b-3p; +MIMAT0030103 bdi-miR5174c-5p; +MIMAT0030104 bdi-miR5174c-3p; +MIMAT0030105 bdi-miR5174d-5p; +MIMAT0030106 bdi-miR5174d-3p; +MIMAT0030107 bdi-miR5181c-5p; +MIMAT0030108 bdi-miR5181c-3p; +MIMAT0030109 bdi-miR5185c-5p; +MIMAT0030110 bdi-miR5185c-3p; +MIMAT0030111 bdi-miR5185d-5p; +MIMAT0030112 bdi-miR5185d-3p; +MIMAT0030113 bdi-miR5185e-5p; +MIMAT0030114 bdi-miR5185e-3p; +MIMAT0030115 bdi-miR5185f-5p; +MIMAT0030116 bdi-miR5185f-3p; +MIMAT0030117 bdi-miR5185g-5p; +MIMAT0030118 bdi-miR5185g-3p; +MIMAT0030119 bdi-miR5185h-5p; +MIMAT0030120 bdi-miR5185h-3p; +MIMAT0030121 bdi-miR5185i-5p; +MIMAT0030122 bdi-miR5185i-3p; +MIMAT0030123 bdi-miR5185j-5p; +MIMAT0030124 bdi-miR5185j-3p; +MIMAT0030125 bdi-miR5185k-5p; +MIMAT0030126 bdi-miR5185k-3p; +MIMAT0030127 bdi-miR5185l-5p; +MIMAT0030128 bdi-miR5185l-3p; +MIMAT0030129 bdi-miR5185m-5p; +MIMAT0030130 bdi-miR5185m-3p; +MIMAT0030131 bdi-miR7707-5p; +MIMAT0030132 bdi-miR7707-3p; +MIMAT0030133 bdi-miR7708a-5p; +MIMAT0030134 bdi-miR7708a-3p; +MIMAT0030135 bdi-miR7709-5p; +MIMAT0030136 bdi-miR7709-3p; +MIMAT0030137 bdi-miR7710-5p; +MIMAT0030138 bdi-miR7710-3p; +MIMAT0030139 bdi-miR7711-5p.1; +MIMAT0030140 bdi-miR7711-5p.2; +MIMAT0030141 bdi-miR7711-5p.3; +MIMAT0030142 bdi-miR7711-5p.4; +MIMAT0030143 bdi-miR7711-3p.4; +MIMAT0030144 bdi-miR7711-3p.3; +MIMAT0030145 bdi-miR7711-3p.1; +MIMAT0030146 bdi-miR7712-5p; +MIMAT0030147 bdi-miR7712-3p; +MIMAT0030148 bdi-miR7713-5p; +MIMAT0030149 bdi-miR7713-3p; +MIMAT0030150 bdi-miR7714-5p; +MIMAT0030151 bdi-miR7714-3p; +MIMAT0030152 bdi-miR7715-5p; +MIMAT0030153 bdi-miR7715-3p; +MIMAT0030154 bdi-miR7716-5p; +MIMAT0030155 bdi-miR7716-3p; +MIMAT0030156 bdi-miR7717a-5p; +MIMAT0030157 bdi-miR7717a-3p; +MIMAT0030158 bdi-miR7718-5p; +MIMAT0030159 bdi-miR7718-3p; +MIMAT0030160 bdi-miR7719-5p; +MIMAT0030161 bdi-miR7719-3p; +MIMAT0030162 bdi-miR5049-5p; +MIMAT0030163 bdi-miR5049-3p; +MIMAT0030164 bdi-miR7720-5p; +MIMAT0030165 bdi-miR7720-3p; +MIMAT0030166 bdi-miR7721-5p; +MIMAT0030167 bdi-miR7721-3p; +MIMAT0030168 bdi-miR7717b-5p; +MIMAT0030169 bdi-miR7717b-3p; +MIMAT0030170 bdi-miR7722-5p; +MIMAT0030171 bdi-miR7722-3p; +MIMAT0030172 bdi-miR7723a-5p; +MIMAT0030173 bdi-miR7723a-3p; +MIMAT0030174 bdi-miR7724a-5p; +MIMAT0030175 bdi-miR7724a-3p; +MIMAT0030176 bdi-miR7724b-5p; +MIMAT0030177 bdi-miR7724b-3p; +MIMAT0030178 bdi-miR7725a-5p; +MIMAT0030179 bdi-miR7725a-3p; +MIMAT0030180 bdi-miR7725b-5p.1; +MIMAT0030181 bdi-miR7725b-5p.2; +MIMAT0030182 bdi-miR7725b-3p.2; +MIMAT0030183 bdi-miR7725b-3p.1; +MIMAT0030184 bdi-miR7726a-5p; +MIMAT0030185 bdi-miR7726a-3p; +MIMAT0030186 bdi-miR7727-5p; +MIMAT0030187 bdi-miR7727-3p; +MIMAT0030188 bdi-miR7728-5p; +MIMAT0030189 bdi-miR7728-3p; +MIMAT0030190 bdi-miR7729a-5p; +MIMAT0030191 bdi-miR7729a-3p; +MIMAT0030192 bdi-miR7729b-5p; +MIMAT0030193 bdi-miR7729b-3p; +MIMAT0030194 bdi-miR7730-5p; +MIMAT0030195 bdi-miR7730-3p; +MIMAT0030196 bdi-miR7731-5p; +MIMAT0030197 bdi-miR7731-3p; +MIMAT0030198 bdi-miR7732-5p; +MIMAT0030199 bdi-miR7732-3p; +MIMAT0030200 bdi-miR7733-5p; +MIMAT0030201 bdi-miR7733-3p; +MIMAT0030202 bdi-miR7734-5p; +MIMAT0030203 bdi-miR7734-3p; +MIMAT0030204 bdi-miR7717c-5p; +MIMAT0030205 bdi-miR7717c-3p; +MIMAT0030206 bdi-miR7735-5p; +MIMAT0030207 bdi-miR7735-3p; +MIMAT0030208 bdi-miR7736-5p; +MIMAT0030209 bdi-miR7736-3p; +MIMAT0030210 bdi-miR7737-5p; +MIMAT0030211 bdi-miR7737-3p; +MIMAT0030212 bdi-miR7738-5p; +MIMAT0030213 bdi-miR7738-3p; +MIMAT0030214 bdi-miR7739-5p; +MIMAT0030215 bdi-miR7739-3p; +MIMAT0030216 bdi-miR7740-5p; +MIMAT0030217 bdi-miR7740-3p; +MIMAT0030218 bdi-miR7726b-5p; +MIMAT0030219 bdi-miR7726b-3p; +MIMAT0030220 bdi-miR7741-5p.1; +MIMAT0030221 bdi-miR7741-5p.2; +MIMAT0030222 bdi-miR7741-3p.2; +MIMAT0030223 bdi-miR7741-3p.1; +MIMAT0030224 bdi-miR7742-5p; +MIMAT0030225 bdi-miR7742-3p; +MIMAT0030226 bdi-miR7743-5p; +MIMAT0030227 bdi-miR7743-3p; +MIMAT0030228 bdi-miR7744-5p; +MIMAT0030229 bdi-miR7744-3p; +MIMAT0030230 bdi-miR7745-5p; +MIMAT0030231 bdi-miR7745-3p; +MIMAT0030232 bdi-miR7746-5p; +MIMAT0030233 bdi-miR7746-3p; +MIMAT0030234 bdi-miR7747-5p; +MIMAT0030235 bdi-miR7747-3p; +MIMAT0030236 bdi-miR7748a-5p; +MIMAT0030237 bdi-miR7748a-3p; +MIMAT0030238 bdi-miR7749-5p; +MIMAT0030239 bdi-miR7749-3p; +MIMAT0030240 bdi-miR7750-5p; +MIMAT0030241 bdi-miR7750-3p; +MIMAT0030242 bdi-miR7751-5p; +MIMAT0030243 bdi-miR7751-3p; +MIMAT0030244 bdi-miR7752-5p; +MIMAT0030245 bdi-miR7752-3p; +MIMAT0030246 bdi-miR7753-5p; +MIMAT0030247 bdi-miR7753-3p; +MIMAT0030248 bdi-miR7748b-5p; +MIMAT0030249 bdi-miR7748b-3p; +MIMAT0030250 bdi-miR7754-5p; +MIMAT0030251 bdi-miR7754-3p; +MIMAT0030252 bdi-miR7755-5p; +MIMAT0030253 bdi-miR7755-3p; +MIMAT0030254 bdi-miR7723b-5p; +MIMAT0030255 bdi-miR7723b-3p; +MIMAT0030256 bdi-miR7756-5p; +MIMAT0030257 bdi-miR7756-3p; +MIMAT0030258 bdi-miR7757-5p.1; +MIMAT0030259 bdi-miR7757-5p.2; +MIMAT0030260 bdi-miR7757-3p.2; +MIMAT0030261 bdi-miR7757-3p.1; +MIMAT0030262 bdi-miR7758-5p; +MIMAT0030263 bdi-miR7758-3p; +MIMAT0030264 bdi-miR7759-5p; +MIMAT0030265 bdi-miR7759-3p; +MIMAT0030266 bdi-miR7760-5p; +MIMAT0030267 bdi-miR7760-3p; +MIMAT0030268 bdi-miR7761-5p; +MIMAT0030269 bdi-miR7761-3p; +MIMAT0030270 bdi-miR7762-5p; +MIMAT0030271 bdi-miR7762-3p; +MIMAT0030272 bdi-miR7763-5p; +MIMAT0030273 bdi-miR7763-3p; +MIMAT0030274 bdi-miR7764-5p; +MIMAT0030275 bdi-miR7764-3p; +MIMAT0030276 bdi-miR7708b-5p; +MIMAT0030277 bdi-miR7708b-3p; +MIMAT0030278 bdi-miR7765-5p; +MIMAT0030279 bdi-miR7765-3p; +MIMAT0030280 bdi-miR7766-5p; +MIMAT0030281 bdi-miR7766-3p; +MIMAT0030282 bdi-miR7767-5p; +MIMAT0030283 bdi-miR7767-3p; +MIMAT0030284 bdi-miR7768a-5p; +MIMAT0030285 bdi-miR7768a-3p; +MIMAT0030286 bdi-miR7768b-5p; +MIMAT0030287 bdi-miR7768b-3p; +MIMAT0030288 bdi-miR7769-5p; +MIMAT0030289 bdi-miR7769-3p; +MIMAT0030290 bdi-miR7770-5p; +MIMAT0030291 bdi-miR7770-3p; +MIMAT0030292 bdi-miR7771-5p; +MIMAT0030293 bdi-miR7771-3p; +MIMAT0030294 bdi-miR7772-5p; +MIMAT0030295 bdi-miR7772-3p; +MIMAT0030296 bdi-miR7773-5p; +MIMAT0030297 bdi-miR7773-3p; +MIMAT0030298 bdi-miR7774-5p; +MIMAT0030299 bdi-miR7774-3p; +MIMAT0030300 bdi-miR7775-5p; +MIMAT0030301 bdi-miR7775-3p; +MIMAT0030302 bdi-miR7776-5p.1; +MIMAT0030303 bdi-miR7776-5p.2; +MIMAT0030304 bdi-miR7776-3p.2; +MIMAT0030305 bdi-miR7776-3p.1; +MIMAT0030306 bdi-miR7777-5p.1; +MIMAT0030307 bdi-miR7777-5p.2; +MIMAT0030308 bdi-miR7777-3p.2; +MIMAT0030309 bdi-miR7777-3p.1; +MIMAT0030310 bdi-miR7778-5p; +MIMAT0030311 bdi-miR7778-3p; +MIMAT0030312 bdi-miR7779-5p; +MIMAT0030313 bdi-miR7779-3p; +MIMAT0030314 bdi-miR7780-5p; +MIMAT0030315 bdi-miR7780-3p; +MIMAT0030316 bdi-miR7781-5p; +MIMAT0030317 bdi-miR7781-3p; +MIMAT0030318 bdi-miR7782-5p; +MIMAT0030319 bdi-miR7782-3p; +MIMAT0030320 bdi-miR7783-5p; +MIMAT0030321 bdi-miR7783-3p; +MIMAT0030322 bdi-miR7784a-5p; +MIMAT0030323 bdi-miR7784a-3p; +MIMAT0030324 bdi-miR7784b-5p; +MIMAT0030325 bdi-miR7784b-3p; +MIMAT0030326 bdi-miR7785-5p; +MIMAT0030327 bdi-miR7785-3p; +MIMAT0030328 bdi-miR7786-5p; +MIMAT0030329 bdi-miR7786-3p; +MIMAT0030330 bdi-miR7787-5p; +MIMAT0030331 bdi-miR7787-3p; +MIMAT0030332 hhi-miR-7788; +MIMAT0030333 hhi-miR-7789; +MIMAT0030334 hhi-miR-7790; +MIMAT0030335 hhi-miR-723; +MIMAT0030336 hhi-miR-7791; +MIMAT0030337 hhi-miR-7792; +MIMAT0030338 hhi-miR-7793; +MIMAT0030339 hhi-miR-7794; +MIMAT0030340 hhi-miR-449; +MIMAT0030341 hhi-miR-430a; +MIMAT0030342 hhi-miR-7795; +MIMAT0030343 hhi-miR-7796; +MIMAT0030344 hhi-miR-7641; +MIMAT0030345 hhi-let-7c; +MIMAT0030346 hhi-let-7j; +MIMAT0030347 hhi-miR-1; +MIMAT0030348 hhi-miR-10d; +MIMAT0030349 hhi-miR-129b-5p; +MIMAT0030350 hhi-miR-129b-3p; +MIMAT0030351 hhi-miR-129a; +MIMAT0030352 hhi-miR-1788; +MIMAT0030353 hhi-miR-181b; +MIMAT0030354 hhi-miR-182; +MIMAT0030355 hhi-miR-183; +MIMAT0030356 hhi-miR-187; +MIMAT0030357 hhi-miR-196; +MIMAT0030358 hhi-miR-199a; +MIMAT0030359 hhi-miR-21; +MIMAT0030360 hhi-miR-23a; +MIMAT0030361 hhi-miR-26; +MIMAT0030362 hhi-miR-301; +MIMAT0030363 hhi-miR-430b; +MIMAT0030364 hhi-miR-728; +MIMAT0030365 hhi-miR-96; +MIMAT0030366 hhi-miR-15a; +MIMAT0030367 hhi-miR-737; +MIMAT0030368 ptc-miR6476b; +MIMAT0030369 ptc-miR6476c; +MIMAT0030370 ptc-miR403d; +MIMAT0030371 ptc-miR7812; +MIMAT0030372 ptc-miR7814; +MIMAT0030373 ptc-miR7815; +MIMAT0030374 ptc-miR7816; +MIMAT0030375 ptc-miR6462e; +MIMAT0030376 ptc-miR6462f; +MIMAT0030377 ptc-miR7817a; +MIMAT0030378 ptc-miR7818; +MIMAT0030379 ptc-miR7817b; +MIMAT0030380 ptc-miR7820; +MIMAT0030381 ptc-miR7822; +MIMAT0030382 ptc-miR7823; +MIMAT0030383 ptc-miR7824; +MIMAT0030384 ptc-miR7825; +MIMAT0030385 ptc-miR1444d; +MIMAT0030386 ptc-miR1444e; +MIMAT0030387 ptc-miR7826; +MIMAT0030388 ptc-miR7828; +MIMAT0030389 ptc-miR7830; +MIMAT0030390 ptc-miR7831; +MIMAT0030391 ptc-miR3627b; +MIMAT0030392 ptc-miR7833; +MIMAT0030393 ptc-miR7837; +MIMAT0030394 ptc-miR7838; +MIMAT0030395 ptc-miR7839; +MIMAT0030396 ptc-miR6459b; +MIMAT0030397 ptc-miR7840; +MIMAT0030398 ptc-miR7841; +MIMAT0030399 ptc-miR7842; +MIMAT0030400 ptc-miR7813; +MIMAT0030401 ptc-miR7819; +MIMAT0030402 ptc-miR7821; +MIMAT0030403 ptc-miR7827; +MIMAT0030404 ptc-miR7829; +MIMAT0030405 ptc-miR7832; +MIMAT0030406 ptc-miR7834; +MIMAT0030407 ptc-miR7835; +MIMAT0030408 ptc-miR7836; +MIMAT0030409 rno-miR-155-5p; +MIMAT0030410 rno-miR-155-3p; +MIMAT0030411 hsa-miR-7843-5p; +MIMAT0030412 hsa-miR-7843-3p; +MIMAT0030413 hsa-miR-4433b-5p; +MIMAT0030414 hsa-miR-4433b-3p; +MIMAT0030415 hsa-miR-1273h-5p; +MIMAT0030416 hsa-miR-1273h-3p; +MIMAT0030417 hsa-miR-6516-5p; +MIMAT0030418 hsa-miR-6516-3p; +MIMAT0030419 hsa-miR-7844-5p; +MIMAT0030420 hsa-miR-7845-5p; +MIMAT0030421 hsa-miR-7846-3p; +MIMAT0030422 hsa-miR-7847-3p; +MIMAT0030423 hsa-miR-7848-3p; +MIMAT0030424 hsa-miR-7849-3p; +MIMAT0030425 hsa-miR-7850-5p; +MIMAT0030426 hsa-miR-7851-3p; +MIMAT0030427 hsa-miR-7852-3p; +MIMAT0030428 hsa-miR-7853-5p; +MIMAT0030429 hsa-miR-7854-3p; +MIMAT0030430 hsa-miR-7855-5p; +MIMAT0030431 hsa-miR-7856-5p; +MIMAT0030432 bta-miR-7857;bta-miR-7857-5p; +MIMAT0030433 bta-miR-7858; +MIMAT0030434 bta-miR-7859; +MIMAT0030435 bta-miR-2285aa; +MIMAT0030436 bta-miR-2285ab; +MIMAT0030437 bta-miR-2284ab; +MIMAT0030438 bta-miR-664b; +MIMAT0030439 bta-miR-7860; +MIMAT0030440 bta-miR-2285ac; +MIMAT0030441 bta-miR-7861; +MIMAT0030442 bta-miR-7862; +MIMAT0030443 bta-miR-6516; +MIMAT0030444 bta-miR-219; +MIMAT0030445 bta-miR-7863; +MIMAT0030446 bta-miR-2285ad; +MIMAT0030447 bta-miR-2284ac; +MIMAT0030448 bta-miR-2285ae; +MIMAT0030449 bta-miR-7864; +MIMAT0030450 bta-miR-7865; +MIMAT0030451 ssp-miR166; +MIMAT0030452 prd-miR-7865-5p; +MIMAT0030453 prd-miR-7865-3p; +MIMAT0030454 prd-miR-100-5p; +MIMAT0030455 prd-miR-100-3p; +MIMAT0030456 prd-lin-4-5p; +MIMAT0030457 prd-lin-4-3p; +MIMAT0030458 prd-miR-7866-5p; +MIMAT0030459 prd-miR-7866-3p; +MIMAT0030460 prd-miR-71-5p; +MIMAT0030461 prd-miR-71-3p; +MIMAT0030462 prd-miR-239-5p; +MIMAT0030463 prd-miR-239-3p; +MIMAT0030464 prd-miR-5960-5p; +MIMAT0030465 prd-miR-5960-3p; +MIMAT0030466 prd-miR-86-5p; +MIMAT0030467 prd-miR-86-3p; +MIMAT0030468 prd-miR-5359-5p; +MIMAT0030469 prd-miR-5359-3p; +MIMAT0030470 prd-miR-84-5p; +MIMAT0030471 prd-miR-84-3p; +MIMAT0030472 prd-miR-7867-5p; +MIMAT0030473 prd-miR-7867-3p; +MIMAT0030474 prd-let-7-5p; +MIMAT0030475 prd-let-7-3p; +MIMAT0030476 prd-miR-7868-5p; +MIMAT0030477 prd-miR-7868-3p; +MIMAT0030478 prd-miR-72-5p; +MIMAT0030479 prd-miR-72-3p; +MIMAT0030480 prd-miR-7869-5p; +MIMAT0030481 prd-miR-7869-3p; +MIMAT0030482 prd-miR-50-5p; +MIMAT0030483 prd-miR-50-3p; +MIMAT0030484 prd-miR-7870-5p; +MIMAT0030485 prd-miR-7870-3p; +MIMAT0030486 prd-miR-7871-5p; +MIMAT0030487 prd-miR-7871-3p; +MIMAT0030488 prd-miR-7872-5p; +MIMAT0030489 prd-miR-7872-3p; +MIMAT0030490 prd-miR-7873a-5p; +MIMAT0030491 prd-miR-7873a-3p; +MIMAT0030492 prd-miR-7874-5p; +MIMAT0030493 prd-miR-7874-3p; +MIMAT0030494 prd-miR-34-5p; +MIMAT0030495 prd-miR-34-3p; +MIMAT0030496 prd-miR-7875-5p; +MIMAT0030497 prd-miR-7875-3p; +MIMAT0030498 prd-miR-5360-5p; +MIMAT0030499 prd-miR-5360-3p; +MIMAT0030500 prd-miR-9a-5p; +MIMAT0030501 prd-miR-9a-3p; +MIMAT0030502 prd-miR-1175-5p; +MIMAT0030503 prd-miR-1175-3p; +MIMAT0030504 prd-miR-7876-5p; +MIMAT0030505 prd-miR-7876-3p; +MIMAT0030506 prd-miR-7877-5p; +MIMAT0030507 prd-miR-7877-3p; +MIMAT0030508 prd-miR-46-5p; +MIMAT0030509 prd-miR-46-3p; +MIMAT0030510 prd-miR-35b-5p; +MIMAT0030511 prd-miR-35b-3p; +MIMAT0030512 prd-miR-7878-5p; +MIMAT0030513 prd-miR-7878-3p; +MIMAT0030514 prd-miR-7879-5p; +MIMAT0030515 prd-miR-7879-3p; +MIMAT0030516 prd-miR-242-5p; +MIMAT0030517 prd-miR-242-3p; +MIMAT0030518 prd-miR-7880-5p;prd-miR-7880a-5p; +MIMAT0030519 prd-miR-7880-3p;prd-miR-7880a-3p; +MIMAT0030520 prd-miR-7881-5p; +MIMAT0030521 prd-miR-7881-3p; +MIMAT0030522 prd-miR-7882-5p; +MIMAT0030523 prd-miR-7882-3p; +MIMAT0030524 prd-miR-252-5p; +MIMAT0030525 prd-miR-252-3p; +MIMAT0030526 prd-miR-7883a-5p; +MIMAT0030527 prd-miR-7883a-3p; +MIMAT0030528 prd-miR-7883b-5p; +MIMAT0030529 prd-miR-7883b-3p; +MIMAT0030530 prd-miR-36-5p; +MIMAT0030531 prd-miR-36-3p; +MIMAT0030532 prd-miR-7884-5p; +MIMAT0030533 prd-miR-7884-3p; +MIMAT0030534 prd-miR-5358a-5p; +MIMAT0030535 prd-miR-5358a-3p; +MIMAT0030536 prd-miR-7940c-5p; +MIMAT0030537 prd-miR-7940c-3p; +MIMAT0030538 prd-miR-7885-5p; +MIMAT0030539 prd-miR-7885-3p; +MIMAT0030540 prd-miR-360-5p; +MIMAT0030541 prd-miR-360-3p; +MIMAT0030542 prd-miR-7886-5p; +MIMAT0030543 prd-miR-7886-3p; +MIMAT0030544 prd-miR-7887-5p; +MIMAT0030545 prd-miR-7887-3p; +MIMAT0030546 prd-miR-7927a-5p; +MIMAT0030547 prd-miR-7927a-3p; +MIMAT0030548 prd-miR-7888-5p; +MIMAT0030549 prd-miR-7888-3p; +MIMAT0030550 prd-miR-7889-5p; +MIMAT0030551 prd-miR-7889-3p; +MIMAT0030552 prd-miR-7873b-5p; +MIMAT0030553 prd-miR-7873b-3p; +MIMAT0030554 prd-miR-7890-5p; +MIMAT0030555 prd-miR-7890-3p; +MIMAT0030556 prd-miR-7940b-5p; +MIMAT0030557 prd-miR-7940b-3p; +MIMAT0030558 prd-miR-2-5p; +MIMAT0030559 prd-miR-2-3p; +MIMAT0030560 prd-miR-58-5p; +MIMAT0030561 prd-miR-58-3p; +MIMAT0030562 prd-miR-7911c-5p; +MIMAT0030563 prd-miR-7911c-3p; +MIMAT0030564 prd-miR-7891-5p; +MIMAT0030565 prd-miR-7891-3p; +MIMAT0030566 prd-miR-37-5p; +MIMAT0030567 prd-miR-37-3p; +MIMAT0030568 prd-miR-7892-5p; +MIMAT0030569 prd-miR-7892-3p; +MIMAT0030570 prd-miR-7893-5p; +MIMAT0030571 prd-miR-7893-3p; +MIMAT0030572 prd-miR-5358b-5p; +MIMAT0030573 prd-miR-5358b-3p; +MIMAT0030574 prd-miR-7894-5p; +MIMAT0030575 prd-miR-7894-3p; +MIMAT0030576 prd-miR-9b-5p; +MIMAT0030577 prd-miR-9b-3p; +MIMAT0030578 prd-miR-61-5p; +MIMAT0030579 prd-miR-61-3p; +MIMAT0030580 prd-miR-7895-5p; +MIMAT0030581 prd-miR-7895-3p; +MIMAT0030582 prd-miR-7896-5p; +MIMAT0030583 prd-miR-7896-3p; +MIMAT0030584 prd-miR-5841-5p;prd-miR-7880b-5p; +MIMAT0030585 prd-miR-5841-3p;prd-miR-7880b-3p; +MIMAT0030586 prd-miR-7897-5p; +MIMAT0030587 prd-miR-7897-3p; +MIMAT0030588 prd-miR-60-5p; +MIMAT0030589 prd-miR-60-3p; +MIMAT0030590 prd-miR-7898-5p;prd-miR-7880c-5p; +MIMAT0030591 prd-miR-7898-3p;prd-miR-7880c-3p; +MIMAT0030592 prd-miR-240-5p; +MIMAT0030593 prd-miR-240-3p; +MIMAT0030594 prd-miR-7899-5p; +MIMAT0030595 prd-miR-7899-3p; +MIMAT0030596 prd-miR-7966a-5p; +MIMAT0030597 prd-miR-7966a-3p; +MIMAT0030598 prd-miR-7900-5p; +MIMAT0030599 prd-miR-7900-3p; +MIMAT0030600 prd-miR-7901-5p; +MIMAT0030601 prd-miR-7901-3p; +MIMAT0030602 prd-miR-235-5p; +MIMAT0030603 prd-miR-235-3p; +MIMAT0030604 prd-miR-4816-5p; +MIMAT0030605 prd-miR-4816-3p; +MIMAT0030606 prd-miR-7918a-5p; +MIMAT0030607 prd-miR-7918a-3p; +MIMAT0030608 prd-miR-7918b-5p; +MIMAT0030609 prd-miR-7918b-3p; +MIMAT0030610 prd-miR-7927c-5p; +MIMAT0030611 prd-miR-7927c-3p; +MIMAT0030612 prd-miR-7927d-5p; +MIMAT0030613 prd-miR-7927d-3p; +MIMAT0030614 prd-miR-7902-5p; +MIMAT0030615 prd-miR-7902-3p; +MIMAT0030616 prd-miR-993-5p; +MIMAT0030617 prd-miR-993-3p; +MIMAT0030618 prd-miR-7903-5p; +MIMAT0030619 prd-miR-7903-3p; +MIMAT0030620 prd-miR-7904-5p; +MIMAT0030621 prd-miR-7904-3p; +MIMAT0030622 prd-miR-7905-5p; +MIMAT0030623 prd-miR-7905-3p; +MIMAT0030624 prd-miR-7906-5p; +MIMAT0030625 prd-miR-7906-3p; +MIMAT0030626 prd-miR-7907a-5p; +MIMAT0030627 prd-miR-7907a-3p; +MIMAT0030628 prd-miR-7908-5p; +MIMAT0030629 prd-miR-7908-3p; +MIMAT0030630 prd-miR-7579-5p; +MIMAT0030631 prd-miR-7579-3p; +MIMAT0030632 prd-miR-7939c-5p; +MIMAT0030633 prd-miR-7939c-3p; +MIMAT0030634 prd-miR-7909-5p; +MIMAT0030635 prd-miR-7909-3p; +MIMAT0030636 prd-miR-7939i-5p; +MIMAT0030637 prd-miR-7939i-3p; +MIMAT0030638 prd-miR-7910a-5p; +MIMAT0030639 prd-miR-7910a-3p; +MIMAT0030640 prd-miR-7939f-5p; +MIMAT0030641 prd-miR-7939f-3p; +MIMAT0030642 prd-miR-7939d-5p; +MIMAT0030643 prd-miR-7939d-3p; +MIMAT0030644 prd-miR-7927b-5p; +MIMAT0030645 prd-miR-7927b-3p; +MIMAT0030646 prd-miR-7911a-5p; +MIMAT0030647 prd-miR-7911a-3p; +MIMAT0030648 prd-miR-7911b-5p; +MIMAT0030649 prd-miR-7911b-3p; +MIMAT0030650 prd-miR-7912-5p; +MIMAT0030651 prd-miR-7912-3p; +MIMAT0030652 prd-miR-7939e-5p; +MIMAT0030653 prd-miR-7939e-3p; +MIMAT0030654 prd-miR-7913-5p; +MIMAT0030655 prd-miR-7913-3p; +MIMAT0030656 prd-miR-87-5p; +MIMAT0030657 prd-miR-87-3p; +MIMAT0030658 prd-miR-7914-5p; +MIMAT0030659 prd-miR-7914-3p; +MIMAT0030660 prd-miR-7948c-5p; +MIMAT0030661 prd-miR-7948c-3p; +MIMAT0030662 prd-miR-7939h-5p; +MIMAT0030663 prd-miR-7939h-3p; +MIMAT0030664 prd-miR-7915-5p; +MIMAT0030665 prd-miR-7915-3p; +MIMAT0030666 prd-miR-7916-5p; +MIMAT0030667 prd-miR-7916-3p; +MIMAT0030668 prd-miR-7957b-5p; +MIMAT0030669 prd-miR-7957b-3p; +MIMAT0030670 prd-miR-7917-5p; +MIMAT0030671 prd-miR-7917-3p; +MIMAT0030672 prd-miR-7907b-5p; +MIMAT0030673 prd-miR-7907b-3p; +MIMAT0030674 prd-miR-7918e-5p; +MIMAT0030675 prd-miR-7918e-3p; +MIMAT0030676 prd-miR-7918f-5p; +MIMAT0030677 prd-miR-7918f-3p; +MIMAT0030678 prd-miR-7919-5p; +MIMAT0030679 prd-miR-7919-3p; +MIMAT0030680 prd-miR-40-5p; +MIMAT0030681 prd-miR-40-3p; +MIMAT0030682 prd-miR-7920-5p; +MIMAT0030683 prd-miR-7920-3p; +MIMAT0030684 prd-miR-7921-5p; +MIMAT0030685 prd-miR-7921-3p; +MIMAT0030686 prd-miR-7922-5p; +MIMAT0030687 prd-miR-7922-3p; +MIMAT0030688 prd-miR-81-5p; +MIMAT0030689 prd-miR-81-3p; +MIMAT0030690 prd-miR-7923-5p; +MIMAT0030691 prd-miR-7923-3p; +MIMAT0030692 prd-miR-7924-5p; +MIMAT0030693 prd-miR-7924-3p; +MIMAT0030694 prd-miR-7948b-5p; +MIMAT0030695 prd-miR-7948b-3p; +MIMAT0030696 prd-miR-7883c-5p; +MIMAT0030697 prd-miR-7883c-3p; +MIMAT0030698 prd-miR-7925-5p; +MIMAT0030699 prd-miR-7925-3p; +MIMAT0030700 prd-miR-7926-5p; +MIMAT0030701 prd-miR-7926-3p; +MIMAT0030702 prd-miR-7927e-5p; +MIMAT0030703 prd-miR-7927e-3p; +MIMAT0030704 prd-miR-7928-5p; +MIMAT0030705 prd-miR-7928-3p; +MIMAT0030706 prd-miR-7929-5p; +MIMAT0030707 prd-miR-7929-3p; +MIMAT0030708 prd-miR-7930-5p; +MIMAT0030709 prd-miR-7930-3p; +MIMAT0030710 prd-miR-7931-5p; +MIMAT0030711 prd-miR-7931-3p; +MIMAT0030712 prd-miR-7950c-5p; +MIMAT0030713 prd-miR-7950c-3p; +MIMAT0030714 prd-miR-35a-5p; +MIMAT0030715 prd-miR-35a-3p; +MIMAT0030716 prd-miR-7932-5p; +MIMAT0030717 prd-miR-7932-3p; +MIMAT0030718 prd-miR-7933-5p; +MIMAT0030719 prd-miR-7933-3p; +MIMAT0030720 prd-miR-1-5p; +MIMAT0030721 prd-miR-1-3p; +MIMAT0030722 prd-miR-7934-5p; +MIMAT0030723 prd-miR-7934-3p; +MIMAT0030724 prd-miR-7910b-5p; +MIMAT0030725 prd-miR-7910b-3p; +MIMAT0030726 prd-miR-7935-5p; +MIMAT0030727 prd-miR-7935-3p; +MIMAT0030728 prd-miR-7948a-5p; +MIMAT0030729 prd-miR-7948a-3p; +MIMAT0030730 prd-miR-7936-5p; +MIMAT0030731 prd-miR-7936-3p; +MIMAT0030732 prd-miR-7937-5p; +MIMAT0030733 prd-miR-7937-3p; +MIMAT0030734 prd-miR-7938-5p; +MIMAT0030735 prd-miR-7938-3p; +MIMAT0030736 prd-miR-7939j-5p; +MIMAT0030737 prd-miR-7939j-3p; +MIMAT0030738 prd-miR-7940a-5p; +MIMAT0030739 prd-miR-7940a-3p; +MIMAT0030740 prd-miR-49-5p; +MIMAT0030741 prd-miR-49-3p; +MIMAT0030742 prd-miR-7941-5p; +MIMAT0030743 prd-miR-7941-3p; +MIMAT0030744 prd-miR-7942-5p; +MIMAT0030745 prd-miR-7942-3p; +MIMAT0030746 prd-miR-7943-5p; +MIMAT0030747 prd-miR-7943-3p; +MIMAT0030748 prd-miR-7944-5p; +MIMAT0030749 prd-miR-7944-3p; +MIMAT0030750 prd-miR-7945-5p; +MIMAT0030751 prd-miR-7945-3p; +MIMAT0030752 prd-miR-7946-5p; +MIMAT0030753 prd-miR-7946-3p; +MIMAT0030754 prd-miR-67-5p; +MIMAT0030755 prd-miR-67-3p; +MIMAT0030756 prd-miR-236-5p; +MIMAT0030757 prd-miR-236-3p; +MIMAT0030758 prd-miR-7947-5p; +MIMAT0030759 prd-miR-7947-3p; +MIMAT0030760 prd-miR-255-5p; +MIMAT0030761 prd-miR-255-3p; +MIMAT0030762 prd-miR-7939b-5p; +MIMAT0030763 prd-miR-7939b-3p; +MIMAT0030764 prd-miR-5594-5p; +MIMAT0030765 prd-miR-5594-3p; +MIMAT0030766 prd-miR-7948d-5p; +MIMAT0030767 prd-miR-7948d-3p; +MIMAT0030768 prd-miR-7949-5p; +MIMAT0030769 prd-miR-7949-3p; +MIMAT0030770 prd-miR-7950a-5p; +MIMAT0030771 prd-miR-7950a-3p; +MIMAT0030772 prd-miR-7939g-5p; +MIMAT0030773 prd-miR-7939g-3p; +MIMAT0030774 prd-miR-7951-5p; +MIMAT0030775 prd-miR-7951-3p; +MIMAT0030776 prd-miR-7957a-5p; +MIMAT0030777 prd-miR-7957a-3p; +MIMAT0030778 prd-miR-7952-5p; +MIMAT0030779 prd-miR-7952-3p; +MIMAT0030780 prd-miR-7918d-5p; +MIMAT0030781 prd-miR-7918d-3p; +MIMAT0030782 prd-miR-7918c-5p; +MIMAT0030783 prd-miR-7918c-3p; +MIMAT0030784 prd-miR-44-5p; +MIMAT0030785 prd-miR-44-3p; +MIMAT0030786 prd-miR-124-5p; +MIMAT0030787 prd-miR-124-3p; +MIMAT0030788 prd-miR-184-5p; +MIMAT0030789 prd-miR-184-3p; +MIMAT0030790 prd-miR-7953-5p; +MIMAT0030791 prd-miR-7953-3p; +MIMAT0030792 prd-miR-234-5p; +MIMAT0030793 prd-miR-234-3p; +MIMAT0030794 prd-miR-7954-5p; +MIMAT0030795 prd-miR-7954-3p; +MIMAT0030796 prd-miR-7955-5p; +MIMAT0030797 prd-miR-7955-3p; +MIMAT0030798 prd-miR-7956-5p; +MIMAT0030799 prd-miR-7956-3p; +MIMAT0030800 prd-miR-7957d-5p; +MIMAT0030801 prd-miR-7957d-3p; +MIMAT0030802 prd-miR-7958-5p; +MIMAT0030803 prd-miR-7958-3p; +MIMAT0030804 prd-miR-7959b-5p; +MIMAT0030805 prd-miR-7959b-3p; +MIMAT0030806 prd-miR-7939a-5p; +MIMAT0030807 prd-miR-7939a-3p; +MIMAT0030808 prd-miR-7959a-5p; +MIMAT0030809 prd-miR-7959a-3p; +MIMAT0030810 prd-miR-277-5p; +MIMAT0030811 prd-miR-277-3p; +MIMAT0030812 prd-miR-39-5p; +MIMAT0030813 prd-miR-39-3p; +MIMAT0030814 prd-miR-7960-5p; +MIMAT0030815 prd-miR-7960-3p; +MIMAT0030816 prd-miR-7950b-5p; +MIMAT0030817 prd-miR-7950b-3p; +MIMAT0030818 prd-miR-76-5p; +MIMAT0030819 prd-miR-76-3p; +MIMAT0030820 prd-miR-7961-5p; +MIMAT0030821 prd-miR-7961-3p; +MIMAT0030822 prd-miR-7957c-5p; +MIMAT0030823 prd-miR-7957c-3p; +MIMAT0030824 prd-miR-7962-5p; +MIMAT0030825 prd-miR-7962-3p; +MIMAT0030826 prd-miR-7963-5p; +MIMAT0030827 prd-miR-7963-3p; +MIMAT0030828 prd-miR-7964a-5p; +MIMAT0030829 prd-miR-7964a-3p; +MIMAT0030830 prd-miR-7965-5p; +MIMAT0030831 prd-miR-7965-3p; +MIMAT0030832 prd-miR-7964b-5p; +MIMAT0030833 prd-miR-7964b-3p; +MIMAT0030834 prd-miR-7966b-5p; +MIMAT0030835 prd-miR-7966b-3p; +MIMAT0030836 prd-miR-7967-5p; +MIMAT0030837 prd-miR-7967-3p; +MIMAT0030838 prd-miR-7968-5p; +MIMAT0030839 prd-miR-7968-3p; +MIMAT0030840 prd-miR-7969-5p; +MIMAT0030841 prd-miR-7969-3p; +MIMAT0030842 prd-miR-7970-5p; +MIMAT0030843 prd-miR-7970-3p; +MIMAT0030844 prd-miR-7971-5p; +MIMAT0030845 prd-miR-7971-3p; +MIMAT0030846 stu-miR7979; +MIMAT0030847 stu-miR7980a; +MIMAT0030848 stu-miR7981-3p; +MIMAT0030849 stu-miR7982a; +MIMAT0030850 stu-miR7982b; +MIMAT0030851 stu-miR7983-3p; +MIMAT0030852 stu-miR7984a; +MIMAT0030853 stu-miR7984b-5p; +MIMAT0030854 stu-miR7985; +MIMAT0030855 stu-miR5303c; +MIMAT0030856 stu-miR5303a; +MIMAT0030857 stu-miR5303b; +MIMAT0030858 stu-miR5303d; +MIMAT0030859 stu-miR7986; +MIMAT0030860 stu-miR7987; +MIMAT0030861 stu-miR7984c-5p; +MIMAT0030862 stu-miR7988; +MIMAT0030863 stu-miR7989; +MIMAT0030864 stu-miR7990a; +MIMAT0030865 stu-miR7991a; +MIMAT0030866 stu-miR7991b; +MIMAT0030867 stu-miR7991c; +MIMAT0030868 stu-miR7992-5p; +MIMAT0030869 stu-miR1886a; +MIMAT0030870 stu-miR1886b; +MIMAT0030871 stu-miR1886c; +MIMAT0030872 stu-miR1886d; +MIMAT0030873 stu-miR1886e; +MIMAT0030874 stu-miR1886f; +MIMAT0030875 stu-miR7993a; +MIMAT0030876 stu-miR7993b-3p; +MIMAT0030877 stu-miR7993c; +MIMAT0030878 stu-miR7993d; +MIMAT0030879 stu-miR7994a; +MIMAT0030880 stu-miR7994b-3p; +MIMAT0030881 stu-miR7995; +MIMAT0030882 stu-miR7996a; +MIMAT0030883 stu-miR7996b; +MIMAT0030884 stu-miR7996c; +MIMAT0030885 stu-miR7997a; +MIMAT0030886 stu-miR7997b; +MIMAT0030887 stu-miR7997c; +MIMAT0030888 stu-miR7998; +MIMAT0030889 stu-miR7999-3p; +MIMAT0030890 stu-miR8000; +MIMAT0030891 stu-miR8001a; +MIMAT0030892 stu-miR8002-5p; +MIMAT0030893 stu-miR8003; +MIMAT0030894 stu-miR8004; +MIMAT0030895 stu-miR8005a; +MIMAT0030896 stu-miR8005b-3p; +MIMAT0030897 stu-miR8005c; +MIMAT0030898 stu-miR8006-5p; +MIMAT0030899 stu-miR8007a-5p; +MIMAT0030900 stu-miR1886g-5p; +MIMAT0030901 stu-miR8008a; +MIMAT0030902 stu-miR8009; +MIMAT0030903 stu-miR5303e; +MIMAT0030904 stu-miR5303f; +MIMAT0030905 stu-miR1886h; +MIMAT0030906 stu-miR8010; +MIMAT0030907 stu-miR8011a-3p; +MIMAT0030908 stu-miR8012; +MIMAT0030909 stu-miR8013; +MIMAT0030910 stu-miR8014-3p; +MIMAT0030911 stu-miR8007b-5p; +MIMAT0030912 stu-miR8015-5p; +MIMAT0030913 stu-miR8016; +MIMAT0030914 stu-miR8017; +MIMAT0030915 stu-miR8018; +MIMAT0030916 stu-miR8019-3p; +MIMAT0030917 stu-miR8001b-5p; +MIMAT0030918 stu-miR7990b; +MIMAT0030919 stu-miR8020; +MIMAT0030920 stu-miR8021; +MIMAT0030921 stu-miR8022; +MIMAT0030922 stu-miR8023; +MIMAT0030923 stu-miR8024a-3p; +MIMAT0030924 stu-miR8024b; +MIMAT0030925 stu-miR1886i-5p; +MIMAT0030926 stu-miR8025-5p; +MIMAT0030927 stu-miR8026; +MIMAT0030928 stu-miR7984d-5p; +MIMAT0030929 stu-miR8027; +MIMAT0030930 stu-miR7980b-3p; +MIMAT0030931 stu-miR8008b; +MIMAT0030932 stu-miR8028-3p; +MIMAT0030933 stu-miR8029; +MIMAT0030934 stu-miR8030-5p; +MIMAT0030935 stu-miR8031; +MIMAT0030936 stu-miR8032a-5p; +MIMAT0030937 stu-miR8032b-5p; +MIMAT0030938 stu-miR8032c; +MIMAT0030939 stu-miR8032d-5p; +MIMAT0030940 stu-miR8032e-5p; +MIMAT0030941 stu-miR8032f-5p; +MIMAT0030942 stu-miR8032g-5p; +MIMAT0030943 stu-miR8033-5p; +MIMAT0030944 stu-miR8034; +MIMAT0030945 stu-miR8035; +MIMAT0030946 stu-miR8036-3p; +MIMAT0030947 stu-miR8037; +MIMAT0030948 stu-miR8038a-5p; +MIMAT0030949 stu-miR8038b-5p; +MIMAT0030950 stu-miR8011b-3p; +MIMAT0030951 stu-miR8039; +MIMAT0030952 stu-miR319-3p; +MIMAT0030953 stu-miR8040-3p; +MIMAT0030954 stu-miR8041a-3p; +MIMAT0030955 stu-miR8041b-3p; +MIMAT0030956 stu-miR8042; +MIMAT0030957 stu-miR8043; +MIMAT0030958 stu-miR8044-3p; +MIMAT0030959 stu-miR8045; +MIMAT0030960 stu-miR7122-3p; +MIMAT0030961 stu-miR8046-5p; +MIMAT0030962 stu-miR8047; +MIMAT0030963 stu-miR6149-5p; +MIMAT0030964 stu-miR399a-5p; +MIMAT0030965 stu-miR399b-5p; +MIMAT0030966 stu-miR399c-5p; +MIMAT0030967 stu-miR399d-5p; +MIMAT0030968 stu-miR399e-5p; +MIMAT0030969 stu-miR399f-5p; +MIMAT0030970 stu-miR399g-5p; +MIMAT0030971 stu-miR399h; +MIMAT0030972 stu-miR8048-3p; +MIMAT0030973 stu-miR164-3p; +MIMAT0030974 stu-miR5304-5p; +MIMAT0030975 stu-miR8049-5p; +MIMAT0030976 stu-miR8050-3p; +MIMAT0030977 stu-miR1919-5p; +MIMAT0030978 stu-miR8051-5p; +MIMAT0030979 hsa-miR-8052; +MIMAT0030980 hsa-miR-8053; +MIMAT0030981 hsa-miR-8054; +MIMAT0030982 hsa-miR-8055; +MIMAT0030983 hsa-miR-8056; +MIMAT0030984 hsa-miR-8057; +MIMAT0030985 hsa-miR-8058; +MIMAT0030986 hsa-miR-8059; +MIMAT0030987 hsa-miR-8060; +MIMAT0030988 hsa-miR-8061; +MIMAT0030989 hsa-miR-8062; +MIMAT0030990 hsa-miR-8063; +MIMAT0030991 hsa-miR-8064; +MIMAT0030992 hsa-miR-8065; +MIMAT0030993 hsa-miR-8066; +MIMAT0030994 hsa-miR-8067; +MIMAT0030995 hsa-miR-8068; +MIMAT0030996 hsa-miR-8069; +MIMAT0030997 hsa-miR-8070; +MIMAT0030998 hsa-miR-8071; +MIMAT0030999 hsa-miR-8072; +MIMAT0031000 hsa-miR-8073; +MIMAT0031001 hsa-miR-8074; +MIMAT0031002 hsa-miR-8075; +MIMAT0031003 hsa-miR-8076; +MIMAT0031004 hsa-miR-8077; +MIMAT0031005 hsa-miR-8078; +MIMAT0031006 hsa-miR-8079; +MIMAT0031007 hsa-miR-8080; +MIMAT0031008 hsa-miR-8081; +MIMAT0031009 hsa-miR-8082; +MIMAT0031010 hsa-miR-8083; +MIMAT0031011 hsa-miR-8084; +MIMAT0031012 hsa-miR-8085; +MIMAT0031013 hsa-miR-8086; +MIMAT0031014 hsa-miR-8087; +MIMAT0031015 hsa-miR-8088; +MIMAT0031016 hsa-miR-8089; +MIMAT0031017 gga-miR-196-1-3p; +MIMAT0031018 mml-miR-16-2-3p; +MIMAT0031019 mml-miR-450a-2-3p; +MIMAT0031020 tgu-miR-7-4-3p; +MIMAT0031021 tgu-miR-138-2-3p; +MIMAT0031022 tgu-miR-153-2-5p; +MIMAT0031023 mdo-miR-29a-2-5p; +MIMAT0031024 mdo-miR-1545b-3-3p; +MIMAT0031025 mdo-miR-19b-2-5p; +MIMAT0031026 oan-miR-181a-2-3p; +MIMAT0031027 oan-miR-181a-3-3p; +MIMAT0031028 oan-miR-30c-1-3p; +MIMAT0031029 mml-miR-135a-1-3p; +MIMAT0031030 mdo-miR-26-3-3p; +MIMAT0031031 mdo-miR-26-1-3p; +MIMAT0031032 tgu-miR-92-2-5p; +MIMAT0031033 mdo-miR-1544e-5p; +MIMAT0031034 mdo-miR-1544e-3p; +MIMAT0031035 mdo-miR-1-2-5p; +MIMAT0031036 gga-miR-135a-1-3p; +MIMAT0031037 gga-let-7a-2-3p; +MIMAT0031038 gga-miR-135a-3-3p; +MIMAT0031039 mdo-miR-181a-3-3p; +MIMAT0031040 mdo-let-7f-2-3p; +MIMAT0031041 mml-let-7a-2-3p; +MIMAT0031042 mml-miR-181b-2-3p; +MIMAT0031043 tgu-miR-181a-2-3p; +MIMAT0031044 tgu-miR-181b-2-3p; +MIMAT0031045 mdo-miR-181a-2-3p; +MIMAT0031046 mdo-miR-181b-2-3p; +MIMAT0031047 mdo-miR-29b-2-5p; +MIMAT0031048 mdo-miR-181b-3-3p; +MIMAT0031049 mdo-miR-7359b-3p; +MIMAT0031050 mdo-miR-92a-2-5p; +MIMAT0031051 mdo-miR-7398a-1-5p; +MIMAT0031052 mdo-miR-7398k-2-3p; +MIMAT0031053 mdo-miR-7398a-4-5p; +MIMAT0031054 mdo-miR-7398a-5-5p; +MIMAT0031055 oan-miR-181b-2-3p; +MIMAT0031056 cbn-miR-251b; +MIMAT0031057 bta-miR-2285af; +MIMAT0031058 gga-miR-16-2-3p; +MIMAT0031059 gga-miR-181b-2-3p; +MIMAT0031060 mml-miR-153-2-5p; +MIMAT0031061 mdo-miR-1542-2-5p; +MIMAT0031062 mml-miR-26a-2-3p; +MIMAT0031063 tgu-miR-29a-2-5p; +MIMAT0031064 tgu-miR-29b-1-5p; +MIMAT0031065 mdo-miR-199b-2-5p; +MIMAT0031066 mdo-miR-199b-3-5p; +MIMAT0031067 oan-miR-365-2-5p; +MIMAT0031068 oan-miR-124a-2-3p; +MIMAT0031069 gga-miR-138-2-3p; +MIMAT0031070 gga-miR-103-1-5p; +MIMAT0031071 gga-miR-1a-1-5p; +MIMAT0031072 gga-miR-29b-2-5p; +MIMAT0031073 mml-miR-125b-2-3p; +MIMAT0031074 hsa-miR-450a-2-3p; +MIMAT0031075 gga-miR-365-2-5p; +MIMAT0031076 mdo-miR-101-1-5p; +MIMAT0031077 gga-miR-101-2-5p; +MIMAT0031078 mml-miR-9-3-3p; +MIMAT0031079 mml-miR-29b-2-5p; +MIMAT0031080 mml-miR-218-1-3p; +MIMAT0031081 mml-miR-365-2-5p; +MIMAT0031082 mml-miR-376a-2-5p; +MIMAT0031083 mml-miR-129-2-3p; +MIMAT0031084 tgu-miR-128-1-5p; +MIMAT0031085 tgu-let-7a-1-3p; +MIMAT0031086 tgu-let-7a-4-3p; +MIMAT0031087 tgu-miR-1-1-5p; +MIMAT0031088 tgu-miR-365-2-5p; +MIMAT0031089 tgu-miR-135a-2-3p; +MIMAT0031090 mdo-miR-30c-2-3p; +MIMAT0031091 mdo-miR-7331-2-3p; +MIMAT0031092 oan-miR-24-2-5p; +MIMAT0031093 ipu-miR-199a-3p; +MIMAT0031094 bta-miR-2285u; +MIMAT0031095 hsa-miR-128-2-5p; +MIMAT0031096 gga-miR-128-1-5p; +MIMAT0031097 mdo-miR-103-2-5p; +MIMAT0031098 oan-miR-103-1-5p; +MIMAT0031099 mml-miR-1-2-5p; +MIMAT0031100 mml-miR-101-2-5p; +MIMAT0031101 tgu-miR-101-1-5p; +MIMAT0031102 tgu-miR-19b-2-5p; +MIMAT0031103 mdo-miR-16-2-3p; +MIMAT0031104 oan-miR-19b-2-5p; +MIMAT0031105 gga-miR-30c-1-3p; +MIMAT0031106 mdo-miR-125b-2-3p; +MIMAT0031107 mml-miR-329-2-5p; +MIMAT0031108 mdo-miR-153-1-5p; +MIMAT0031109 mdo-miR-219-2-3p; +MIMAT0031110 mdo-miR-130c-2-5p; +MIMAT0031111 mdo-miR-218-2-3p; +MIMAT0031112 mdo-miR-7386a-3-3p; +MIMAT0031113 mdo-miR-133a-2-5p; +MIMAT0031114 oan-miR-135b-2-3p; +MIMAT0031115 oan-miR-26-2-3p; +MIMAT0031116 oan-miR-153-2-5p; +MIMAT0031117 mml-miR-30c-2-3p; +MIMAT0031118 mdo-miR-7360-9-5p; +MIMAT0031119 hsa-miR-1199-5p; +MIMAT0031120 hsa-miR-1199-3p; +MIMAT0031121 ppy-miR-1199-5p; +MIMAT0031122 ppy-miR-1199-3p; +MIMAT0031123 cfa-miR-1199-5p; +MIMAT0031124 cfa-miR-1199-3p; +MIMAT0031125 rno-miR-1199-5p; +MIMAT0031126 rno-miR-1199-3p; +MIMAT0031127 ptr-miR-1199-5p; +MIMAT0031128 ptr-miR-1199-3p; +MIMAT0031129 sly-miR168a-5p; +MIMAT0031130 sly-miR168a-3p; +MIMAT0031131 sly-miR168b-5p; +MIMAT0031132 sly-miR168b-3p; +MIMAT0031133 aja-miR-1893; +MIMAT0031134 aja-miR-3596; +MIMAT0031135 aja-miR-29b; +MIMAT0031136 aja-miR-142; +MIMAT0031137 aja-miR-144; +MIMAT0031138 aja-miR-145; +MIMAT0031139 aja-miR-671; +MIMAT0031140 aja-miR-21; +MIMAT0031141 aja-miR-22; +MIMAT0031142 aja-miR-25; +MIMAT0031143 aja-miR-7; +MIMAT0031144 aja-miR-214; +MIMAT0031145 aja-miR-3074; +MIMAT0031146 aja-miR-3120; +MIMAT0031147 aja-miR-143; +MIMAT0031148 aja-miR-3618; +MIMAT0031149 aja-miR-29c; +MIMAT0031150 aja-miR-331; +MIMAT0031151 aja-let-7i; +MIMAT0031152 hsv1-miR-H27; +MIMAT0031153 ama-miR156; +MIMAT0031154 ama-miR396-5p; +MIMAT0031155 ama-miR396-3p; +MIMAT0031156 osa-miR156h-5p; +MIMAT0031157 osa-miR156h-3p; +MIMAT0031158 hbv-miR-B20-3p; +MIMAT0031159 stu-miR6024-5p; +MIMAT0031160 stu-miR482b-5p; +MIMAT0031161 stu-miR482a-5p; +MIMAT0031162 stu-miR482d-5p; +MIMAT0031163 stu-miR482e-5p; +MIMAT0031164 stu-miR6026-5p; +MIMAT0031165 ppe-miR482a-5p; +MIMAT0031166 ppe-miR482b-5p; +MIMAT0031167 ppe-miR394a; +MIMAT0031168 ppe-miR828-5p; +MIMAT0031169 ppe-miR482c-3p; +MIMAT0031170 ppe-miR477a-5p; +MIMAT0031171 ppe-miR477b-5p; +MIMAT0031172 ppe-miR169e-5p; +MIMAT0031173 ppe-miR398a-5p; +MIMAT0031174 ppe-miR482d-5p; +MIMAT0031175 hsa-miR-548ba; +MIMAT0031176 hsa-miR-7973; +MIMAT0031177 hsa-miR-7974; +MIMAT0031178 hsa-miR-7975; +MIMAT0031179 hsa-miR-7976; +MIMAT0031180 hsa-miR-7977; +MIMAT0031181 hsa-miR-7978; +MIMAT0031182 stu-miR7981-5p; +MIMAT0031183 stu-miR7983-5p; +MIMAT0031184 stu-miR7984b-3p; +MIMAT0031185 stu-miR7984c-3p; +MIMAT0031186 stu-miR7992-3p; +MIMAT0031187 stu-miR7993b-5p; +MIMAT0031188 stu-miR7994b-5p; +MIMAT0031189 stu-miR7999-5p; +MIMAT0031190 stu-miR8002-3p; +MIMAT0031191 stu-miR8005b-5p; +MIMAT0031192 stu-miR8006-3p; +MIMAT0031193 stu-miR8007a-3p; +MIMAT0031194 stu-miR1886g-3p; +MIMAT0031195 stu-miR8011a-5p; +MIMAT0031196 stu-miR8014-5p; +MIMAT0031197 stu-miR8007b-3p; +MIMAT0031198 stu-miR8015-3p; +MIMAT0031199 stu-miR8019-5p; +MIMAT0031200 stu-miR8001b-3p; +MIMAT0031201 stu-miR8024a-5p; +MIMAT0031202 stu-miR1886i-3p; +MIMAT0031203 stu-miR8025-3p; +MIMAT0031204 stu-miR7984d-3p; +MIMAT0031205 stu-miR7980b-5p; +MIMAT0031206 stu-miR8028-5p; +MIMAT0031207 stu-miR8030-3p; +MIMAT0031208 stu-miR8032a-3p; +MIMAT0031209 stu-miR8032b-3p; +MIMAT0031210 stu-miR8032d-3p; +MIMAT0031211 stu-miR8032e-3p; +MIMAT0031212 stu-miR8032f-3p; +MIMAT0031213 stu-miR8032g-3p; +MIMAT0031214 stu-miR8033-3p; +MIMAT0031215 stu-miR8036-5p; +MIMAT0031216 stu-miR8038a-3p; +MIMAT0031217 stu-miR8038b-3p; +MIMAT0031218 stu-miR8011b-5p; +MIMAT0031219 stu-miR319-5p; +MIMAT0031220 stu-miR8040-5p; +MIMAT0031221 stu-miR8041a-5p; +MIMAT0031222 stu-miR8041b-5p; +MIMAT0031223 stu-miR8044-5p; +MIMAT0031224 stu-miR7122-5p; +MIMAT0031225 stu-miR8046-3p; +MIMAT0031226 stu-miR6149-3p; +MIMAT0031227 stu-miR399a-3p; +MIMAT0031228 stu-miR399b-3p; +MIMAT0031229 stu-miR399c-3p; +MIMAT0031230 stu-miR399d-3p; +MIMAT0031231 stu-miR399e-3p; +MIMAT0031232 stu-miR399f-3p; +MIMAT0031233 stu-miR399g-3p; +MIMAT0031234 stu-miR8048-5p; +MIMAT0031235 stu-miR164-5p; +MIMAT0031236 stu-miR5304-3p; +MIMAT0031237 stu-miR8049-3p; +MIMAT0031238 stu-miR8050-5p; +MIMAT0031239 stu-miR1919-3p; +MIMAT0031240 stu-miR8051-3p; +MIMAT0031241 stu-miR5303j; +MIMAT0031242 stu-miR5303g; +MIMAT0031243 stu-miR5303h; +MIMAT0031244 stu-miR5303i; +MIMAT0031245 stu-miR3627-5p; +MIMAT0031246 stu-miR3627-3p; +MIMAT0031247 stu-miR171b-5p; +MIMAT0031248 stu-miR171b-3p; +MIMAT0031249 stu-miR166a-5p; +MIMAT0031250 stu-miR166a-3p; +MIMAT0031251 stu-miR166b; +MIMAT0031252 stu-miR166c-5p; +MIMAT0031253 stu-miR166c-3p; +MIMAT0031254 stu-miR166d-5p; +MIMAT0031255 stu-miR166d-3p; +MIMAT0031256 stu-miR171a-5p; +MIMAT0031257 stu-miR171a-3p; +MIMAT0031258 stu-miR171c-5p; +MIMAT0031259 stu-miR171c-3p; +MIMAT0031260 stu-miR399i-5p; +MIMAT0031261 stu-miR399i-3p; +MIMAT0031262 stu-miR395a; +MIMAT0031263 stu-miR395b; +MIMAT0031264 stu-miR395c; +MIMAT0031265 stu-miR395d; +MIMAT0031266 stu-miR395e; +MIMAT0031267 stu-miR395f; +MIMAT0031268 stu-miR395g; +MIMAT0031269 stu-miR395h; +MIMAT0031270 stu-miR395i; +MIMAT0031271 stu-miR395j; +MIMAT0031272 stu-miR827-5p; +MIMAT0031273 stu-miR827-3p; +MIMAT0031274 stu-miR4376-5p;stu-miR391-5p; +MIMAT0031275 stu-miR4376-3p;stu-miR391-3p; +MIMAT0031276 stu-miR319b; +MIMAT0031277 stu-miR319a-5p; +MIMAT0031278 stu-miR319a-3p; +MIMAT0031279 stu-miR162a-5p; +MIMAT0031280 stu-miR162a-3p; +MIMAT0031281 stu-miR162b-5p; +MIMAT0031282 stu-miR162b-3p; +MIMAT0031283 stu-miR160a-5p; +MIMAT0031284 stu-miR160a-3p; +MIMAT0031285 stu-miR160b; +MIMAT0031286 stu-miR172b-5p; +MIMAT0031287 stu-miR172b-3p; +MIMAT0031288 stu-miR172c-5p; +MIMAT0031289 stu-miR172c-3p; +MIMAT0031290 stu-miR172a-5p; +MIMAT0031291 stu-miR172a-3p; +MIMAT0031292 stu-miR172d-5p; +MIMAT0031293 stu-miR172d-3p; +MIMAT0031294 stu-miR172e-5p; +MIMAT0031295 stu-miR172e-3p; +MIMAT0031296 stu-miR156a; +MIMAT0031297 stu-miR156b; +MIMAT0031298 stu-miR156c; +MIMAT0031299 stu-miR156d-5p; +MIMAT0031300 stu-miR156d-3p; +MIMAT0031301 stu-miR171d-5p; +MIMAT0031302 stu-miR171d-3p; +MIMAT0031303 stu-miR167c-5p; +MIMAT0031304 stu-miR167c-3p; +MIMAT0031305 stu-miR167b-5p; +MIMAT0031306 stu-miR167b-3p; +MIMAT0031307 stu-miR167a-5p; +MIMAT0031308 stu-miR167a-3p; +MIMAT0031309 stu-miR167d-5p; +MIMAT0031310 stu-miR167d-3p; +MIMAT0031311 stu-miR479; +MIMAT0031312 stu-miR399j-5p; +MIMAT0031313 stu-miR399j-3p; +MIMAT0031314 stu-miR399k-5p; +MIMAT0031315 stu-miR399k-3p; +MIMAT0031316 stu-miR399l-5p; +MIMAT0031317 stu-miR399l-3p; +MIMAT0031318 stu-miR399m-5p; +MIMAT0031319 stu-miR399m-3p; +MIMAT0031320 stu-miR399n-5p; +MIMAT0031321 stu-miR399n-3p; +MIMAT0031322 stu-miR399o-5p; +MIMAT0031323 stu-miR399o-3p; +MIMAT0031324 stu-miR393-5p; +MIMAT0031325 stu-miR393-3p; +MIMAT0031326 stu-miR477a-5p; +MIMAT0031327 stu-miR477a-3p; +MIMAT0031328 stu-miR477b-5p; +MIMAT0031329 stu-miR477b-3p; +MIMAT0031330 stu-miR530; +MIMAT0031331 stu-miR398a-5p; +MIMAT0031332 stu-miR398a-3p; +MIMAT0031333 stu-miR398b-5p; +MIMAT0031334 stu-miR398b-3p; +MIMAT0031335 stu-miR396-5p; +MIMAT0031336 stu-miR396-3p; +MIMAT0031337 stu-miR408a-5p; +MIMAT0031338 stu-miR408a-3p; +MIMAT0031339 stu-miR408b-5p; +MIMAT0031340 stu-miR408b-3p; +MIMAT0031341 stu-miR397-5p; +MIMAT0031342 stu-miR397-3p; +MIMAT0031343 stu-miR390-5p; +MIMAT0031344 stu-miR390-3p; +MIMAT0031345 stu-miR171e; +MIMAT0031346 stu-miR156e; +MIMAT0031347 stu-miR156f-5p; +MIMAT0031348 stu-miR156f-3p; +MIMAT0031349 stu-miR156g-5p; +MIMAT0031350 stu-miR156g-3p; +MIMAT0031351 stu-miR156h-5p; +MIMAT0031352 stu-miR156h-3p; +MIMAT0031353 stu-miR156i-5p; +MIMAT0031354 stu-miR156i-3p; +MIMAT0031355 stu-miR156j-5p; +MIMAT0031356 stu-miR156j-3p; +MIMAT0031357 stu-miR156k-5p; +MIMAT0031358 stu-miR156k-3p; +MIMAT0031359 stu-miR169a-5p; +MIMAT0031360 stu-miR169a-3p; +MIMAT0031361 stu-miR169b-5p; +MIMAT0031362 stu-miR169b-3p; +MIMAT0031363 stu-miR169c-5p; +MIMAT0031364 stu-miR169c-3p; +MIMAT0031365 stu-miR169d-5p; +MIMAT0031366 stu-miR169d-3p; +MIMAT0031367 stu-miR169e-5p; +MIMAT0031368 stu-miR169e-3p; +MIMAT0031369 stu-miR169f-5p; +MIMAT0031370 stu-miR169f-3p; +MIMAT0031371 stu-miR169g; +MIMAT0031372 stu-miR169h; +MIMAT0031373 stu-miR384-5p; +MIMAT0031374 stu-miR384-3p; +MIMAT0031375 osa-miR1861o; +MIMAT0031376 osa-miR5079b; +MIMAT0031377 osa-miR5539b; +MIMAT0031378 osa-miR6249b; +MIMAT0031379 osa-miR531c; +MIMAT0031380 aly-miR172f-5p; +MIMAT0031381 aly-miR172f-3p; +MIMAT0031382 aly-miR166h-5p; +MIMAT0031383 aly-miR166h-3p; +MIMAT0031384 aly-miR2111c-5p; +MIMAT0031385 aly-miR2111c-3p; +MIMAT0031386 aly-miR403b-5p; +MIMAT0031387 aly-miR403b-3p; +MIMAT0031388 aly-miR173b-5p; +MIMAT0031389 aly-miR173b-3p; +MIMAT0031390 mmu-miR-3473f; +MIMAT0031391 mmu-miR-8090; +MIMAT0031392 mmu-miR-8091; +MIMAT0031393 mmu-miR-8092; +MIMAT0031394 mmu-miR-8093; +MIMAT0031395 mmu-miR-8094; +MIMAT0031396 mmu-miR-8095; +MIMAT0031397 mmu-miR-1291; +MIMAT0031398 mmu-miR-8096; +MIMAT0031399 mmu-miR-8097; +MIMAT0031400 mmu-miR-8098; +MIMAT0031401 mmu-miR-8099; +MIMAT0031402 mmu-miR-142b; +MIMAT0031403 mmu-miR-8100; +MIMAT0031404 mmu-miR-497b; +MIMAT0031405 mmu-miR-8101; +MIMAT0031406 mmu-miR-8102; +MIMAT0031407 mmu-miR-8103; +MIMAT0031408 mmu-miR-8104; +MIMAT0031409 mmu-miR-8105; +MIMAT0031410 mmu-miR-3535; +MIMAT0031411 mmu-miR-8106; +MIMAT0031412 mmu-miR-8107; +MIMAT0031413 mmu-miR-8108; +MIMAT0031414 mmu-miR-1668; +MIMAT0031415 mmu-miR-8109; +MIMAT0031416 mmu-miR-8110; +MIMAT0031417 mmu-miR-8111; +MIMAT0031418 mmu-miR-8112; +MIMAT0031419 mmu-miR-8113; +MIMAT0031420 mmu-miR-8114; +MIMAT0031421 mmu-miR-8115; +MIMAT0031422 mmu-miR-8116; +MIMAT0031423 mmu-miR-8117; +MIMAT0031424 mmu-miR-8118; +MIMAT0031425 mmu-miR-8119; +MIMAT0031426 mmu-miR-8120; +MIMAT0031427 mmu-miR-3473g; +MIMAT0031428 ppe-miR156a; +MIMAT0031429 ppe-miR156b; +MIMAT0031430 ppe-miR156c; +MIMAT0031431 ppe-miR156d; +MIMAT0031432 ppe-miR156e; +MIMAT0031433 ppe-miR156f; +MIMAT0031434 ppe-miR156g; +MIMAT0031435 ppe-miR156h; +MIMAT0031436 ppe-miR156i; +MIMAT0031437 ppe-miR159; +MIMAT0031438 ppe-miR160a; +MIMAT0031439 ppe-miR160b; +MIMAT0031440 ppe-miR162; +MIMAT0031441 ppe-miR164a; +MIMAT0031442 ppe-miR164b; +MIMAT0031443 ppe-miR164c; +MIMAT0031444 ppe-miR164d; +MIMAT0031445 ppe-miR166a; +MIMAT0031446 ppe-miR166b; +MIMAT0031447 ppe-miR166c; +MIMAT0031448 ppe-miR166d; +MIMAT0031449 ppe-miR166e; +MIMAT0031450 ppe-miR167a; +MIMAT0031451 ppe-miR167b; +MIMAT0031452 ppe-miR167c; +MIMAT0031453 ppe-miR167d; +MIMAT0031454 ppe-miR168; +MIMAT0031455 ppe-miR169a; +MIMAT0031456 ppe-miR169b; +MIMAT0031457 ppe-miR169c; +MIMAT0031458 ppe-miR169d; +MIMAT0031459 ppe-miR169f; +MIMAT0031460 ppe-miR169g; +MIMAT0031461 ppe-miR169h; +MIMAT0031462 ppe-miR169i; +MIMAT0031463 ppe-miR169j; +MIMAT0031464 ppe-miR169k; +MIMAT0031465 ppe-miR169l; +MIMAT0031466 ppe-miR171d-5p; +MIMAT0031467 ppe-miR171d-3p; +MIMAT0031468 ppe-miR172a-5p; +MIMAT0031469 ppe-miR172a-3p; +MIMAT0031470 ppe-miR172b; +MIMAT0031471 ppe-miR172c; +MIMAT0031472 ppe-miR172d; +MIMAT0031473 ppe-miR390; +MIMAT0031474 ppe-miR393a; +MIMAT0031475 ppe-miR393b; +MIMAT0031476 ppe-miR394b; +MIMAT0031477 ppe-miR395a-5p; +MIMAT0031478 ppe-miR395a-3p; +MIMAT0031479 ppe-miR395b-5p; +MIMAT0031480 ppe-miR395b-3p; +MIMAT0031481 ppe-miR395c; +MIMAT0031482 ppe-miR395d; +MIMAT0031483 ppe-miR395e; +MIMAT0031484 ppe-miR395f; +MIMAT0031485 ppe-miR395g; +MIMAT0031486 ppe-miR395h; +MIMAT0031487 ppe-miR395i; +MIMAT0031488 ppe-miR395j; +MIMAT0031489 ppe-miR395k; +MIMAT0031490 ppe-miR395l; +MIMAT0031491 ppe-miR395m; +MIMAT0031492 ppe-miR395n; +MIMAT0031493 ppe-miR395o; +MIMAT0031494 ppe-miR396a; +MIMAT0031495 ppe-miR396b; +MIMAT0031496 ppe-miR397; +MIMAT0031497 ppe-miR399a; +MIMAT0031498 ppe-miR399b; +MIMAT0031499 ppe-miR399c; +MIMAT0031500 ppe-miR399d; +MIMAT0031501 ppe-miR399e; +MIMAT0031502 ppe-miR399f; +MIMAT0031503 ppe-miR399g; +MIMAT0031504 ppe-miR399h; +MIMAT0031505 ppe-miR399i; +MIMAT0031506 ppe-miR399j; +MIMAT0031507 ppe-miR399k; +MIMAT0031508 ppe-miR399l; +MIMAT0031509 ppe-miR399m; +MIMAT0031510 ppe-miR399n; +MIMAT0031511 ppe-miR403; +MIMAT0031512 ppe-miR482f; +MIMAT0031513 ppe-miR530; +MIMAT0031514 ppe-miR535a; +MIMAT0031515 ppe-miR535b; +MIMAT0031516 ppe-miR827; +MIMAT0031517 ppe-miR2111a; +MIMAT0031518 ppe-miR2111b; +MIMAT0031519 ppe-miR2111c; +MIMAT0031520 ppe-miR2111d; +MIMAT0031521 ppe-miR1511-5p; +MIMAT0031522 ppe-miR1511-3p; +MIMAT0031523 ppe-miR8122-5p; +MIMAT0031524 ppe-miR8122-3p; +MIMAT0031525 ppe-miR8123-5p; +MIMAT0031526 ppe-miR8123-3p; +MIMAT0031527 ppe-miR7122a-5p; +MIMAT0031528 ppe-miR7122a-3p; +MIMAT0031529 ppe-miR7122b-5p; +MIMAT0031530 ppe-miR7122b-3p; +MIMAT0031531 ppe-miR8124-5p; +MIMAT0031532 ppe-miR8124-3p; +MIMAT0031533 ppe-miR8125; +MIMAT0031534 ppe-miR3627-5p; +MIMAT0031535 ppe-miR3627-3p; +MIMAT0031536 ppe-miR7125-5p; +MIMAT0031537 ppe-miR7125-3p; +MIMAT0031538 ppe-miR8126-5p; +MIMAT0031539 ppe-miR8126-3p; +MIMAT0031540 ppe-miR477-5p; +MIMAT0031541 ppe-miR477-3p; +MIMAT0031542 ppe-miR6267c-5p; +MIMAT0031543 ppe-miR6267c-3p; +MIMAT0031544 ppe-miR6291c-5p; +MIMAT0031545 ppe-miR6291c-3p; +MIMAT0031546 ppe-miR8127-5p; +MIMAT0031547 ppe-miR8127-3p; +MIMAT0031548 ppe-miR5225-5p; +MIMAT0031549 ppe-miR5225-3p; +MIMAT0031550 ppe-miR8128-5p; +MIMAT0031551 ppe-miR8128-3p; +MIMAT0031552 ppe-miR6274b-5p; +MIMAT0031553 ppe-miR6274b-3p; +MIMAT0031554 ppe-miR8129-5p; +MIMAT0031555 ppe-miR8129-3p; +MIMAT0031556 ppe-miR8130-5p; +MIMAT0031557 ppe-miR8130-3p; +MIMAT0031558 ppe-miR8131-5p; +MIMAT0031559 ppe-miR8131-3p; +MIMAT0031560 ppe-miR6288b-5p; +MIMAT0031561 ppe-miR6288b-3p; +MIMAT0031562 ppe-miR8132; +MIMAT0031563 ppe-miR8133-5p; +MIMAT0031564 ppe-miR8133-3p; +MIMAT0031565 ppe-miR6288c-5p; +MIMAT0031566 ppe-miR6288c-3p; +MIMAT0031567 ppe-miR858; +MIMAT0031568 bbe-let-7a-5p; +MIMAT0031569 bbe-let-7a-3p; +MIMAT0031570 bbe-miR-100-5p; +MIMAT0031571 bbe-miR-100-3p; +MIMAT0031572 bbe-miR-10a-5p; +MIMAT0031573 bbe-miR-10a-3p; +MIMAT0031574 bbe-miR-10b-5p; +MIMAT0031575 bbe-miR-10b-3p; +MIMAT0031576 bbe-miR-10c-5p; +MIMAT0031577 bbe-miR-124-5p; +MIMAT0031578 bbe-miR-124-3p; +MIMAT0031579 bbe-miR-125a-5p; +MIMAT0031580 bbe-miR-125a-3p; +MIMAT0031581 bbe-miR-125b-3p; +MIMAT0031582 bbe-miR-129a-5p; +MIMAT0031583 bbe-miR-129a-3p; +MIMAT0031584 bbe-miR-129b-5p; +MIMAT0031585 bbe-miR-133-3p; +MIMAT0031586 bbe-miR-133-5p; +MIMAT0031587 bbe-miR-135a-5p; +MIMAT0031588 bbe-miR-135a-3p; +MIMAT0031589 bbe-miR-135b-5p; +MIMAT0031590 bbe-miR-137-3p; +MIMAT0031591 bbe-miR-1-3p; +MIMAT0031592 bbe-miR-1-5p; +MIMAT0031593 bbe-miR-153-3p; +MIMAT0031594 bbe-miR-182a-5p; +MIMAT0031595 bbe-miR-182a-3p; +MIMAT0031596 bbe-miR-182b-5p; +MIMAT0031597 bbe-miR-182b-3p; +MIMAT0031598 bbe-miR-182c-5p; +MIMAT0031599 bbe-miR-182d-3p; +MIMAT0031600 bbe-miR-183-5p; +MIMAT0031601 bbe-miR-184-5p; +MIMAT0031602 bbe-miR-184-3p; +MIMAT0031603 bbe-miR-190-5p; +MIMAT0031604 bbe-miR-190-3p; +MIMAT0031605 bbe-miR-193b-3p; +MIMAT0031606 bbe-miR-200a-3p; +MIMAT0031607 bbe-miR-200a-5p; +MIMAT0031608 bbe-miR-200b-3p; +MIMAT0031609 bbe-miR-200b-5p; +MIMAT0031610 bbe-miR-200c-3p; +MIMAT0031611 bbe-miR-2013-3p; +MIMAT0031612 bbe-miR-2056-3p; +MIMAT0031613 bbe-miR-2057-5p; +MIMAT0031614 bbe-miR-2057-3p; +MIMAT0031615 bbe-miR-2058-5p; +MIMAT0031616 bbe-miR-2058-3p; +MIMAT0031617 bbe-miR-2059-3p; +MIMAT0031618 bbe-miR-2059-5p; +MIMAT0031619 bbe-miR-2060a-3p; +MIMAT0031620 bbe-miR-2060b-3p; +MIMAT0031621 bbe-miR-2061-3p; +MIMAT0031622 bbe-miR-2061-5p; +MIMAT0031623 bbe-miR-2062-5p; +MIMAT0031624 bbe-miR-2062-3p; +MIMAT0031625 bbe-miR-2063-3p; +MIMAT0031626 bbe-miR-2063-5p; +MIMAT0031627 bbe-miR-2064-3p; +MIMAT0031628 bbe-miR-2064-5p; +MIMAT0031629 bbe-miR-2066-3p; +MIMAT0031630 bbe-miR-2066-5p; +MIMAT0031631 bbe-miR-2067-5p; +MIMAT0031632 bbe-miR-2067-3p; +MIMAT0031633 bbe-miR-2068-5p; +MIMAT0031634 bbe-miR-2068-3p; +MIMAT0031635 bbe-miR-2069-3p; +MIMAT0031636 bbe-miR-2070-5p; +MIMAT0031637 bbe-miR-2070-3p; +MIMAT0031638 bbe-miR-2071-3p; +MIMAT0031639 bbe-miR-2071-5p; +MIMAT0031640 bbe-miR-2072-5p; +MIMAT0031641 bbe-miR-2072-3p; +MIMAT0031642 bbe-miR-2076-5p; +MIMAT0031643 bbe-miR-2076-3p; +MIMAT0031644 bbe-miR-210-3p; +MIMAT0031645 bbe-miR-210-5p; +MIMAT0031646 bbe-miR-216-5p; +MIMAT0031647 bbe-miR-216-3p; +MIMAT0031648 bbe-miR-217-5p; +MIMAT0031649 bbe-miR-217-3p; +MIMAT0031650 bbe-miR-219-5p; +MIMAT0031651 bbe-miR-219-3p; +MIMAT0031652 bbe-miR-22-5p; +MIMAT0031653 bbe-miR-22-3p; +MIMAT0031654 bbe-miR-242-5p; +MIMAT0031655 bbe-miR-252a-5p; +MIMAT0031656 bbe-miR-252a-3p; +MIMAT0031657 bbe-miR-252b-5p; +MIMAT0031658 bbe-miR-252b-3p; +MIMAT0031659 bbe-miR-278-5p; +MIMAT0031660 bbe-miR-281-5p; +MIMAT0031661 bbe-miR-281-3p; +MIMAT0031662 bbe-miR-29a-5p; +MIMAT0031663 bbe-miR-29a-3p; +MIMAT0031664 bbe-miR-29b-5p; +MIMAT0031665 bbe-miR-29b-3p; +MIMAT0031666 bbe-miR-31-5p; +MIMAT0031667 bbe-miR-31-3p; +MIMAT0031668 bbe-miR-33-5p; +MIMAT0031669 bbe-miR-33-3p; +MIMAT0031670 bbe-miR-34a-5p; +MIMAT0031671 bbe-miR-34b-5p; +MIMAT0031672 bbe-miR-34b-3p; +MIMAT0031673 bbe-miR-34c-5p; +MIMAT0031674 bbe-miR-34d-5p; +MIMAT0031675 bbe-miR-34f-5p; +MIMAT0031676 bbe-miR-375-3p; +MIMAT0031677 bbe-miR-4057-3p; +MIMAT0031678 bbe-miR-4859-5p; +MIMAT0031679 bbe-miR-4859-3p; +MIMAT0031680 bbe-miR-4860-5p; +MIMAT0031681 bbe-miR-4860-3p; +MIMAT0031682 bbe-miR-4861-3p; +MIMAT0031683 bbe-miR-4863-5p; +MIMAT0031684 bbe-miR-4863-3p; +MIMAT0031685 bbe-miR-4864-5p; +MIMAT0031686 bbe-miR-4864-3p; +MIMAT0031687 bbe-miR-4865-5p; +MIMAT0031688 bbe-miR-4865-3p; +MIMAT0031689 bbe-miR-4866-5p; +MIMAT0031690 bbe-miR-4866-3p; +MIMAT0031691 bbe-miR-4867-3p; +MIMAT0031692 bbe-miR-4868a-3p; +MIMAT0031693 bbe-miR-4868b-3p; +MIMAT0031694 bbe-miR-4868c-3p; +MIMAT0031695 bbe-miR-4868c-5p; +MIMAT0031696 bbe-miR-4873-5p; +MIMAT0031697 bbe-miR-4874-5p; +MIMAT0031698 bbe-miR-4874-3p; +MIMAT0031699 bbe-miR-4876-3p; +MIMAT0031700 bbe-miR-4877-3p; +MIMAT0031701 bbe-miR-4878-5p; +MIMAT0031702 bbe-miR-4879-5p; +MIMAT0031703 bbe-miR-4880-5p; +MIMAT0031704 bbe-miR-4887-5p; +MIMAT0031705 bbe-miR-4888-5p; +MIMAT0031706 bbe-miR-4889b-3p; +MIMAT0031707 bbe-miR-4890-5p; +MIMAT0031708 bbe-miR-4891-5p; +MIMAT0031709 bbe-miR-4891-3p; +MIMAT0031710 bbe-miR-4899-5p; +MIMAT0031711 bbe-miR-4904-5p; +MIMAT0031712 bbe-miR-4904-3p; +MIMAT0031713 bbe-miR-4928-3p; +MIMAT0031714 bbe-miR-7-5p; +MIMAT0031715 bbe-miR-7-3p; +MIMAT0031716 bbe-miR-705-5p; +MIMAT0031717 bbe-miR-71-5p; +MIMAT0031718 bbe-miR-71-3p; +MIMAT0031719 bbe-miR-92a-5p; +MIMAT0031720 bbe-miR-92a-3p; +MIMAT0031721 bbe-miR-92b-5p; +MIMAT0031722 bbe-miR-92b-3p; +MIMAT0031723 bbe-miR-92c-3p; +MIMAT0031724 bbe-miR-92d-5p; +MIMAT0031725 bbe-miR-92d-3p; +MIMAT0031726 bbe-miR-9-5p; +MIMAT0031727 bbe-miR-9-3p; +MIMAT0031728 bbe-miR-96-5p; +MIMAT0031729 bbe-miR-96-3p; +MIMAT0031730 bbe-miR-34g-5p; +MIMAT0031731 bbe-miR-34h-5p; +MIMAT0031732 bbe-miR-2060c-3p; +MIMAT0031733 bbe-miR-4856a-5p; +MIMAT0031734 bbe-miR-4856a-3p; +MIMAT0031735 bbe-miR-4857-5p; +MIMAT0031736 bbe-miR-4857-3p; +MIMAT0031737 bbe-miR-4869-5p; +MIMAT0031738 bbe-miR-4869-3p; +MIMAT0031739 bma-miR-1175; +MIMAT0031740 bma-miR-1822; +MIMAT0031741 bma-miR-232; +MIMAT0031742 bma-miR-239;bma-miR-239-5p; +MIMAT0031743 bma-miR-250; +MIMAT0031744 bma-miR-252; +MIMAT0031745 bma-miR-268; +MIMAT0031746 bma-miR-283; +MIMAT0031747 bma-miR-2d; +MIMAT0031748 bma-miR-307; +MIMAT0031749 bma-miR-36;bma-miR-36a; +MIMAT0031750 bma-miR-45; +MIMAT0031751 bma-miR-49; +MIMAT0031752 bma-miR-5360; +MIMAT0031753 bma-miR-5361; +MIMAT0031754 bma-miR-5363;bma-miR-5363-5p; +MIMAT0031755 bma-miR-5364; +MIMAT0031756 bma-miR-5365a; +MIMAT0031757 bma-miR-5365b; +MIMAT0031758 bma-miR-5366;bma-miR-5366-3p; +MIMAT0031759 bma-miR-60; +MIMAT0031760 bma-miR-750; +MIMAT0031761 bma-miR-84-5p; +MIMAT0031762 bma-miR-86; +MIMAT0031763 hbv-miR-B2-3p; +MIMAT0031764 hbv-miR-B3RC-5p; +MIMAT0031765 hbv-miR-B3RC-3p; +MIMAT0031766 hbv-miR-B7-5p; +MIMAT0031767 hbv-miR-B8-5p; +MIMAT0031768 hbv-miR-B8-3p; +MIMAT0031769 hbv-miR-B19-5p; +MIMAT0031770 hbv-miR-B21RC-5p; +MIMAT0031771 hbv-miR-B26-5p; +MIMAT0031772 hbv-miR-B14RC-3p; +MIMAT0031773 hbv-miR-B22-3p; +MIMAT0031774 cpa-miR156a; +MIMAT0031775 cpa-miR156b; +MIMAT0031776 cpa-miR156c; +MIMAT0031777 cpa-miR156d; +MIMAT0031778 cpa-miR156e; +MIMAT0031779 cpa-miR156f; +MIMAT0031780 cpa-miR159a; +MIMAT0031781 cpa-miR159b; +MIMAT0031782 cpa-miR319; +MIMAT0031783 cpa-miR160a; +MIMAT0031784 cpa-miR160b; +MIMAT0031785 cpa-miR160c-5p; +MIMAT0031786 cpa-miR160c-3p; +MIMAT0031787 cpa-miR160d; +MIMAT0031788 cpa-miR160e; +MIMAT0031789 cpa-miR160f-5p; +MIMAT0031790 cpa-miR160f-3p; +MIMAT0031791 cpa-miR164a; +MIMAT0031792 cpa-miR164b; +MIMAT0031793 cpa-miR164c; +MIMAT0031794 cpa-miR164d; +MIMAT0031795 cpa-miR164e; +MIMAT0031796 cpa-miR166a; +MIMAT0031797 cpa-miR166b; +MIMAT0031798 cpa-miR166c; +MIMAT0031799 cpa-miR166d; +MIMAT0031800 cpa-miR166e; +MIMAT0031801 cpa-miR167a; +MIMAT0031802 cpa-miR167b; +MIMAT0031803 cpa-miR167c; +MIMAT0031804 cpa-miR167d; +MIMAT0031805 cpa-miR169; +MIMAT0031806 cpa-miR171a; +MIMAT0031807 cpa-miR171b; +MIMAT0031808 cpa-miR171c; +MIMAT0031809 cpa-miR171d; +MIMAT0031810 cpa-miR172a; +MIMAT0031811 cpa-miR172b; +MIMAT0031812 cpa-miR390a; +MIMAT0031813 cpa-miR390b; +MIMAT0031814 cpa-miR393; +MIMAT0031815 cpa-miR394a; +MIMAT0031816 cpa-miR394b; +MIMAT0031817 cpa-miR395a; +MIMAT0031818 cpa-miR395b; +MIMAT0031819 cpa-miR395c; +MIMAT0031820 cpa-miR395d; +MIMAT0031821 cpa-miR395e; +MIMAT0031822 cpa-miR396; +MIMAT0031823 cpa-miR408; +MIMAT0031824 cpa-miR535; +MIMAT0031825 cpa-miR8134; +MIMAT0031826 cpa-miR398; +MIMAT0031827 cpa-miR8135; +MIMAT0031828 cpa-miR477; +MIMAT0031829 cpa-miR8136; +MIMAT0031830 cpa-miR8137; +MIMAT0031831 cpa-miR8138; +MIMAT0031832 cpa-miR8139a; +MIMAT0031833 cpa-miR8139b; +MIMAT0031834 cpa-miR8139c; +MIMAT0031835 cpa-miR8139d; +MIMAT0031836 cpa-miR8139e; +MIMAT0031837 cpa-miR8140; +MIMAT0031838 cpa-miR8141; +MIMAT0031839 cpa-miR8142; +MIMAT0031840 cpa-miR8143; +MIMAT0031841 cpa-miR8144; +MIMAT0031842 cpa-miR8145; +MIMAT0031843 cpa-miR8146; +MIMAT0031844 cpa-miR8147; +MIMAT0031845 cpa-miR8148; +MIMAT0031846 cpa-miR8149; +MIMAT0031847 cpa-miR8150; +MIMAT0031848 cpa-miR8151; +MIMAT0031849 cpa-miR8152; +MIMAT0031850 cpa-miR8153; +MIMAT0031851 cpa-miR5211; +MIMAT0031852 cpa-miR8154; +MIMAT0031853 cpa-miR8155; +MIMAT0031854 lus-miR156h; +MIMAT0031855 lus-miR166j; +MIMAT0031856 lus-miR166k; +MIMAT0031857 lus-miR171j; +MIMAT0031858 lus-miR396e; +MIMAT0031859 lus-miR398d; +MIMAT0031860 lus-miR398e; +MIMAT0031861 lus-miR398f; +MIMAT0031862 bbe-let-7a-2-3p; +MIMAT0031863 bbe-miR-33-2-3p; +MIMAT0031864 bma-miR-84-3p; +MIMAT0031865 ath-miR156a-3p; +MIMAT0031866 ath-miR156b-3p; +MIMAT0031867 ath-miR156c-3p; +MIMAT0031868 ath-miR156d-3p; +MIMAT0031869 ath-miR156f-3p; +MIMAT0031870 ath-miR157a-3p; +MIMAT0031871 ath-miR157b-3p; +MIMAT0031872 ath-miR157c-3p; +MIMAT0031873 ath-miR158a-5p; +MIMAT0031874 ath-miR160a-3p; +MIMAT0031875 ath-miR160c-3p; +MIMAT0031876 ath-miR162a-5p; +MIMAT0031877 ath-miR162b-5p; +MIMAT0031878 ath-miR164b-3p; +MIMAT0031879 ath-miR165a-5p; +MIMAT0031880 ath-miR166a-5p; +MIMAT0031881 ath-miR166b-5p; +MIMAT0031882 ath-miR166e-5p; +MIMAT0031883 ath-miR167a-3p; +MIMAT0031884 ath-miR168a-3p; +MIMAT0031885 ath-miR168b-3p; +MIMAT0031886 ath-miR169a-3p; +MIMAT0031887 ath-miR170-5p; +MIMAT0031888 ath-miR171a-5p; +MIMAT0031889 ath-miR159b-5p; +MIMAT0031890 hsa-miR-203a-5p; +MIMAT0031891 cel-miR-254-5p; +MIMAT0031892 hsa-miR-1-5p; +MIMAT0031893 hsa-miR-181b-2-3p; +MIMAT0031894 cel-miR-354-5p; +MIMAT0031895 cel-miR-355-3p; +MIMAT0031896 cel-lsy-6-5p; +MIMAT0031897 ath-miR169b-3p; +MIMAT0031898 ath-miR169f-3p; +MIMAT0031899 ath-miR171b-5p; +MIMAT0031900 ath-miR171c-5p; +MIMAT0031901 ath-miR172d-5p; +MIMAT0031902 ath-miR390a-3p; +MIMAT0031903 ath-miR390b-3p; +MIMAT0031904 ath-miR391-3p; +MIMAT0031905 ath-miR393a-3p; +MIMAT0031906 ath-miR393b-3p; +MIMAT0031907 ath-miR394b-3p; +MIMAT0031908 ath-miR396a-3p; +MIMAT0031909 ath-miR396b-3p; +MIMAT0031910 ath-miR398a-5p; +MIMAT0031911 ath-miR398b-5p; +MIMAT0031912 ath-miR398c-5p; +MIMAT0031913 ath-miR399c-5p; +MIMAT0031914 ath-miR403-5p; +MIMAT0031915 ath-miR408-5p; +MIMAT0031916 ath-miR164c-3p; +MIMAT0031917 ath-miR167c-3p; +MIMAT0031918 ath-miR172e-5p; +MIMAT0031919 dre-miR-10b-3p; +MIMAT0031920 dre-miR-181b-3p; +MIMAT0031921 dre-miR-183-3p; +MIMAT0031922 dre-miR-199-3-3p; +MIMAT0031923 dre-miR-203a-5p; +MIMAT0031924 dre-miR-204-3p; +MIMAT0031925 dre-miR-205-3p; +MIMAT0031926 dre-miR-221-5p; +MIMAT0031927 dre-miR-222a-5p; +MIMAT0031928 dre-miR-430b-5p; +MIMAT0031929 dre-miR-430c-5p; +MIMAT0031930 dre-let-7c-3p; +MIMAT0031931 dre-let-7d-3p; +MIMAT0031932 dre-miR-9-4-3p; +MIMAT0031933 dre-miR-9-7-3p; +MIMAT0031934 dre-miR-10b-2-3p; +MIMAT0031935 dre-miR-10c-3p; +MIMAT0031936 dre-miR-15b-3p; +MIMAT0031937 dre-miR-16c-3p; +MIMAT0031938 dre-miR-17a-2-3p; +MIMAT0031939 dre-miR-20b-3p; +MIMAT0031940 dre-miR-19c-5p; +MIMAT0031941 dre-miR-19d-5p; +MIMAT0031942 dre-miR-22a-5p; +MIMAT0031943 dre-miR-22b-5p; +MIMAT0031944 dre-miR-23a-5p; +MIMAT0031945 dre-miR-23a-3-5p; +MIMAT0031946 dre-miR-25-5p; +MIMAT0031947 dre-miR-26a-3p; +MIMAT0031948 dre-miR-26a-2-3p; +MIMAT0031949 dre-miR-27a-5p; +MIMAT0031950 dre-miR-27b-5p; +MIMAT0031951 dre-miR-30a-3p; +MIMAT0031952 dre-miR-30c-3p; +MIMAT0031953 dre-miR-92a-5p; +MIMAT0031954 dre-miR-92a-2-5p; +MIMAT0031955 dre-miR-92b-5p; +MIMAT0031956 dre-miR-96-3p; +MIMAT0031957 dre-miR-100-3p; +MIMAT0031958 dre-miR-100-2-3p; +MIMAT0031959 dre-miR-107a-5p; +MIMAT0031960 dre-miR-124-5p; +MIMAT0031961 dre-miR-124-4-5p; +MIMAT0031962 dre-miR-124-6-5p; +MIMAT0031963 dre-miR-125b-1-3p; +MIMAT0031964 dre-miR-125b-2-3p; +MIMAT0031965 dre-miR-125b-3-3p; +MIMAT0031966 dre-miR-125c-3p; +MIMAT0031967 dre-miR-128-5p; +MIMAT0031968 dre-miR-129-1-3p; +MIMAT0031969 dre-miR-130c-5p; +MIMAT0031970 dre-miR-133a-2-5p; +MIMAT0031971 dre-miR-133c-5p; +MIMAT0031972 dre-miR-137-5p; +MIMAT0031973 dre-miR-138-3p; +MIMAT0031974 dre-miR-141-5p; +MIMAT0031975 dre-miR-144-5p; +MIMAT0031976 dre-miR-145-3p; +MIMAT0031977 dre-miR-153b-5p; +MIMAT0031978 dre-miR-153a-5p; +MIMAT0031979 dre-miR-153c-5p; +MIMAT0031980 dre-miR-181c-3p; +MIMAT0031981 dre-miR-193a-5p; +MIMAT0031982 dre-miR-193b-5p; +MIMAT0031983 dre-miR-196a-3p; +MIMAT0031984 dre-miR-200a-5p; +MIMAT0031985 dre-miR-200b-5p; +MIMAT0031986 dre-miR-200c-5p; +MIMAT0031987 dre-miR-204-2-3p; +MIMAT0031988 dre-miR-206-5p; +MIMAT0031989 dre-miR-219-3p; +MIMAT0031990 dre-miR-301b-5p; +MIMAT0031991 dre-miR-301c-5p; +MIMAT0031992 dre-miR-363-5p; +MIMAT0031993 dre-miR-455-3p; +MIMAT0031994 dre-miR-430a-5p; +MIMAT0031995 dre-miR-430a-4-5p; +MIMAT0031996 dre-miR-430a-11-5p; +MIMAT0031997 dre-miR-430a-12-5p; +MIMAT0031998 dre-miR-430a-13-5p; +MIMAT0031999 dre-miR-430a-14-5p; +MIMAT0032000 dre-miR-430a-15-5p; +MIMAT0032001 dre-miR-430a-16-5p; +MIMAT0032002 dre-miR-430a-17-5p; +MIMAT0032003 dre-miR-430i-5p; +MIMAT0032004 dre-miR-457b-3p; +MIMAT0032005 dre-miR-458-5p; +MIMAT0032006 dre-miR-135b-3p; +MIMAT0032007 dre-miR-181a-2-3p; +MIMAT0032008 dre-miR-139-3p; +MIMAT0032009 dre-miR-499-3p; +MIMAT0032010 dre-miR-725-5p; +MIMAT0032011 dre-miR-34c-3p; +MIMAT0032012 dre-miR-735-5p; +MIMAT0032013 dre-miR-737-5p; +MIMAT0032014 ath-miR472-5p; +MIMAT0032015 cel-miR-785-5p; +MIMAT0032016 cel-miR-789-5p; +MIMAT0032017 cel-miR-789-2-5p; +MIMAT0032018 ath-miR822-3p; +MIMAT0032019 ath-miR829-5p; +MIMAT0032020 ath-miR831-5p; +MIMAT0032021 ath-miR840-3p; +MIMAT0032022 ath-miR841a-3p; +MIMAT0032023 ath-miR846-5p; +MIMAT0032024 ath-miR824-3p; +MIMAT0032025 ath-miR870-5p; +MIMAT0032026 hsa-miR-301b-5p; +MIMAT0032027 dme-miR-1004-5p; +MIMAT0032028 dme-miR-1008-5p; +MIMAT0032029 hsa-miR-1249-5p; +MIMAT0032030 gma-miR1512a-3p; +MIMAT0032031 gma-miR1514a-3p; +MIMAT0032032 gma-miR1514b-3p; +MIMAT0032033 gma-miR1531-5p; +MIMAT0032034 cel-miR-1821-5p; +MIMAT0032035 cel-miR-1823-5p; +MIMAT0032036 cfa-miR-486-3p; +MIMAT0032037 cel-miR-1829b-3p; +MIMAT0032038 cel-miR-1829c-3p; +MIMAT0032039 cel-miR-1832a-5p; +MIMAT0032040 sly-miR1919c-5p; +MIMAT0032041 dvi-miR-314-5p; +MIMAT0032042 dvi-miR-2a-2-5p; +MIMAT0032043 dvi-miR-2a-5p; +MIMAT0032044 dvi-miR-2c-5p; +MIMAT0032045 dvi-miR-12-3p; +MIMAT0032046 dvi-miR-13a-5p; +MIMAT0032047 dvi-miR-279-5p; +MIMAT0032048 dvi-miR-11-5p; +MIMAT0032049 dvi-miR-125-3p; +MIMAT0032050 dvi-miR-313-5p; +MIMAT0032051 dvi-miR-263a-3p; +MIMAT0032052 dvi-miR-263b-3p; +MIMAT0032053 dvi-miR-6-2-5p; +MIMAT0032054 dvi-miR-9c-3p; +MIMAT0032055 dvi-miR-9b-3p; +MIMAT0032056 dvi-miR-210-5p; +MIMAT0032057 dvi-miR-9a-3p; +MIMAT0032058 dvi-miR-7-3p; +MIMAT0032059 dvi-miR-282-3p; +MIMAT0032060 dvi-miR-310-5p; +MIMAT0032061 dvi-miR-283-3p; +MIMAT0032062 dvi-miR-133-5p; +MIMAT0032063 dvi-miR-278-5p; +MIMAT0032064 dvi-miR-13b-5p; +MIMAT0032065 dvi-miR-124-5p; +MIMAT0032066 dvi-miR-305-3p; +MIMAT0032067 dvi-miR-33-3p; +MIMAT0032068 dvi-miR-276b-5p; +MIMAT0032069 dvi-miR-276a-5p; +MIMAT0032070 dvi-miR-6-3-5p; +MIMAT0032071 dvi-miR-316-3p; +MIMAT0032072 dvi-miR-277-5p; +MIMAT0032073 dvi-miR-317-5p; +MIMAT0032074 dvi-miR-286-5p; +MIMAT0032075 dvi-miR-2b-5p; +MIMAT0032076 dvi-miR-13b-2-5p; +MIMAT0032077 dvi-miR-8-5p; +MIMAT0032078 dvi-miR-34-3p; +MIMAT0032079 dvi-miR-4-5p; +MIMAT0032080 dvi-miR-3-5p; +MIMAT0032081 dvi-miR-309-5p; +MIMAT0032082 dvi-miR-1-5p; +MIMAT0032083 dvi-miR-10-3p; +MIMAT0032084 dvi-miR-5-3p; +MIMAT0032085 dvi-miR-92b-5p; +MIMAT0032086 dvi-bantam-5p; +MIMAT0032087 dvi-miR-31a-3p; +MIMAT0032088 dvi-miR-308-5p; +MIMAT0032089 dvi-miR-285-5p; +MIMAT0032090 dvi-miR-6-1-5p; +MIMAT0032091 dvi-miR-275-5p; +MIMAT0032092 dvi-miR-14-5p; +MIMAT0032093 dvi-miR-100-3p; +MIMAT0032094 dvi-miR-87-5p; +MIMAT0032095 dvi-miR-79-5p; +MIMAT0032096 dvi-miR-304-3p; +MIMAT0032097 dvi-miR-284-5p; +MIMAT0032098 dvi-miR-219-3p; +MIMAT0032099 dvi-miR-92a-5p; +MIMAT0032100 nve-miR-2022-5p; +MIMAT0032101 gma-miR2109-3p; +MIMAT0032102 sma-let-7-3p; +MIMAT0032103 sma-miR-71a-3p; +MIMAT0032104 sma-bantam-5p; +MIMAT0032105 sma-miR-125a-3p; +MIMAT0032107 ppc-miR-2235a-5p; +MIMAT0032108 ssc-miR-129a-5p; +MIMAT0032109 ath-miR4228-3p; +MIMAT0032110 hsa-miR-3653-5p; +MIMAT0032111 gma-miR1520f-5p; +MIMAT0032112 gma-miR4414-3p;gma-miR4414a-3p; +MIMAT0032113 ath-miR3932b-5p; +MIMAT0032114 hsa-miR-548ad-5p; +MIMAT0032115 hsa-miR-548ae-5p; +MIMAT0032116 hsa-miR-4485-5p; +MIMAT0032117 dme-miR-4919-3p; +MIMAT0032118 dme-miR-4968-3p; +MIMAT0032119 gma-miR4994-3p; +MIMAT0032120 ath-miR5017-5p; +MIMAT0032121 gma-miR5035-3p; +MIMAT0032122 gma-miR5041-3p; +MIMAT0032123 gma-miR5042-3p; +MIMAT0032124 sly-miR482e-3p; +MIMAT0032125 gma-miR5374-3p; +MIMAT0032126 gma-miR169n-3p; +MIMAT0032127 ath-miR5632-5p; +MIMAT0032128 ath-miR5639-3p; +MIMAT0032129 ath-miR5663-3p; +MIMAT0032130 gma-miR5667-5p; +MIMAT0032131 gma-miR171o-5p; +MIMAT0032132 gma-miR396k-5p; +MIMAT0032133 sly-miR6027-5p; +MIMAT0032134 gma-miR393c-3p; +MIMAT0032135 sma-miR-2d-5p; +MIMAT0032136 sma-miR-31-3p; +MIMAT0032137 sma-miR-36a-5p; +MIMAT0032138 sma-miR-61-5p; +MIMAT0032139 pmi-let-7-5p; +MIMAT0032140 pmi-miR-1-3p; +MIMAT0032141 pmi-miR-7-5p; +MIMAT0032142 pmi-miR-9-5p; +MIMAT0032143 pmi-miR-10-5p; +MIMAT0032144 pmi-miR-22-3p; +MIMAT0032145 pmi-miR-29a-3p; +MIMAT0032146 pmi-miR-29b-3p; +MIMAT0032147 pmi-miR-31-5p; +MIMAT0032148 pmi-miR-33-5p; +MIMAT0032149 pmi-miR-34-5p; +MIMAT0032150 pmi-miR-71-5p; +MIMAT0032151 pmi-miR-92a-3p; +MIMAT0032152 pmi-miR-92b-3p; +MIMAT0032153 pmi-miR-92c-3p; +MIMAT0032154 pmi-miR-92d-3p; +MIMAT0032155 pmi-miR-96-5p; +MIMAT0032156 pmi-miR-100-5p; +MIMAT0032157 pmi-miR-124-3p; +MIMAT0032158 pmi-miR-125-5p; +MIMAT0032159 pmi-miR-133-3p; +MIMAT0032160 pmi-miR-137-3p; +MIMAT0032161 pmi-miR-153-3p; +MIMAT0032162 pmi-miR-182-5p;pmi-miR-263-5p; +MIMAT0032163 pmi-miR-184-3p; +MIMAT0032164 pmi-miR-193-3p; +MIMAT0032165 pmi-miR-200-5p; +MIMAT0032166 pmi-miR-200-3p; +MIMAT0032167 pmi-miR-210-3p; +MIMAT0032168 pmi-miR-219-5p; +MIMAT0032169 pmi-miR-242-5p; +MIMAT0032170 pmi-miR-252a-5p; +MIMAT0032171 pmi-miR-252b-5p; +MIMAT0032172 pmi-miR-278-3p; +MIMAT0032173 pmi-miR-375-3p; +MIMAT0032174 pmi-miR-981-3p; +MIMAT0032175 pmi-miR-2001-5p; +MIMAT0032176 pmi-miR-2002-3p; +MIMAT0032177 pmi-miR-2004-3p; +MIMAT0032178 pmi-miR-2005-5p; +MIMAT0032179 pmi-miR-2006-5p; +MIMAT0032180 pmi-miR-2006-3p; +MIMAT0032181 pmi-miR-2007-5p; +MIMAT0032182 pmi-miR-2008-3p; +MIMAT0032183 pmi-miR-2009-3p; +MIMAT0032184 pmi-miR-2010-3p; +MIMAT0032185 pmi-miR-2011-5p; +MIMAT0032186 pmi-miR-2011-3p; +MIMAT0032187 pmi-miR-2012-5p; +MIMAT0032188 pmi-miR-2013-3p; +MIMAT0032189 lva-let-7-5p; +MIMAT0032190 lva-miR-1-3p; +MIMAT0032191 lva-miR-7-5p; +MIMAT0032192 lva-miR-9-5p; +MIMAT0032193 lva-miR-10-5p; +MIMAT0032194 lva-miR-22-3p; +MIMAT0032195 lva-miR-29a-3p; +MIMAT0032196 lva-miR-29b-3p; +MIMAT0032197 lva-miR-31-5p; +MIMAT0032198 lva-miR-33-5p; +MIMAT0032199 lva-miR-34-5p; +MIMAT0032200 lva-miR-71-5p; +MIMAT0032201 lva-miR-92a-3p; +MIMAT0032202 lva-miR-92b-3p; +MIMAT0032203 lva-miR-96-5p; +MIMAT0032204 lva-miR-124-3p; +MIMAT0032205 lva-miR-125-5p; +MIMAT0032206 lva-miR-133-3p; +MIMAT0032207 lva-miR-137-3p; +MIMAT0032208 lva-miR-153-3p; +MIMAT0032209 lva-miR-182-5p; +MIMAT0032210 lva-miR-183-5p; +MIMAT0032211 lva-miR-184-3p; +MIMAT0032212 lva-miR-193-3p; +MIMAT0032213 lva-miR-200-3p; +MIMAT0032214 lva-miR-210-3p; +MIMAT0032215 lva-miR-219-5p; +MIMAT0032216 lva-miR-242-5p; +MIMAT0032217 lva-miR-252a-5p; +MIMAT0032218 lva-miR-252b-5p; +MIMAT0032219 lva-miR-278-3p; +MIMAT0032220 lva-miR-375-3p; +MIMAT0032221 lva-miR-981-3p; +MIMAT0032222 lva-miR-2001-5p; +MIMAT0032223 lva-miR-2002-3p; +MIMAT0032224 lva-miR-2003-5p; +MIMAT0032225 lva-miR-2004-3p; +MIMAT0032226 lva-miR-2005-5p; +MIMAT0032227 lva-miR-2006-3p; +MIMAT0032228 lva-miR-2007-5p; +MIMAT0032229 lva-miR-2008-5p; +MIMAT0032230 lva-miR-2009-3p; +MIMAT0032231 lva-miR-2010-3p; +MIMAT0032232 lva-miR-2011-3p; +MIMAT0032233 lva-miR-2012-5p; +MIMAT0032234 lva-miR-2013-3p; +MIMAT0032235 lva-miR-4847-5p; +MIMAT0032236 lva-miR-4850-5p; +MIMAT0032237 lva-miR-4854-3p; +MIMAT0032238 rgl-miR7797a; +MIMAT0032239 rgl-miR7798; +MIMAT0032240 rgl-miR7799; +MIMAT0032241 rgl-miR7800; +MIMAT0032242 rgl-miR7801; +MIMAT0032243 rgl-miR7802; +MIMAT0032244 rgl-miR7803a; +MIMAT0032245 rgl-miR7804-5p; +MIMAT0032246 rgl-miR7804-3p; +MIMAT0032247 rgl-miR7805-5p; +MIMAT0032248 rgl-miR7805-3p; +MIMAT0032249 rgl-miR7806; +MIMAT0032250 rgl-miR7807a-5p; +MIMAT0032251 rgl-miR7807a-3p; +MIMAT0032252 rgl-miR7803b-5p; +MIMAT0032253 rgl-miR7803b-3p; +MIMAT0032254 rgl-miR7808; +MIMAT0032255 rgl-miR7809; +MIMAT0032256 rgl-miR7810; +MIMAT0032257 rgl-miR7811; +MIMAT0032258 rgl-miR7807b-5p; +MIMAT0032259 rgl-miR7807b-3p; +MIMAT0032260 rgl-miR7797b; +MIMAT0032261 rgl-miR7972; +MIMAT0032262 ath-miR8121; +MIMAT0032263 ssa-let-7j-5p; +MIMAT0032264 ssa-let-7j-3p; +MIMAT0032265 ssa-let-7c-5p; +MIMAT0032266 ssa-let-7c-3p; +MIMAT0032267 ssa-let-7c-2-3p; +MIMAT0032268 ssa-let-7f-5p; +MIMAT0032269 ssa-let-7f-3p; +MIMAT0032270 ssa-let-7g-5p; +MIMAT0032271 ssa-let-7g-3p; +MIMAT0032272 ssa-let-7h-5p; +MIMAT0032273 ssa-let-7h-3p; +MIMAT0032274 ssa-let-7i-5p; +MIMAT0032275 ssa-let-7i-3p; +MIMAT0032276 ssa-let-7i-2-3p; +MIMAT0032277 ssa-miR-100a-5p; +MIMAT0032278 ssa-miR-100a-3p; +MIMAT0032279 ssa-miR-100a-2-3p; +MIMAT0032280 ssa-miR-101a-5p; +MIMAT0032281 ssa-miR-101a-3p; +MIMAT0032282 ssa-miR-101b-5p; +MIMAT0032283 ssa-miR-101b-3p; +MIMAT0032284 ssa-miR-103-5p; +MIMAT0032285 ssa-miR-103-3p; +MIMAT0032286 ssa-miR-106a-5p; +MIMAT0032287 ssa-miR-106a-3p; +MIMAT0032288 ssa-miR-106b-5p; +MIMAT0032289 ssa-miR-106b-3p; +MIMAT0032290 ssa-miR-107-5p; +MIMAT0032291 ssa-miR-107-3p; +MIMAT0032292 ssa-miR-10a-5p; +MIMAT0032293 ssa-miR-10a-3p; +MIMAT0032294 ssa-miR-10a-2-3p; +MIMAT0032295 ssa-miR-10b-5p; +MIMAT0032296 ssa-miR-10b-3p; +MIMAT0032297 ssa-miR-10b-2-3p; +MIMAT0032298 ssa-miR-10b-3-3p; +MIMAT0032299 ssa-miR-10d-5p; +MIMAT0032300 ssa-miR-10d-3p; +MIMAT0032301 ssa-miR-122-5p; +MIMAT0032302 ssa-miR-122-3p; +MIMAT0032303 ssa-miR-122-2-3p; +MIMAT0032304 ssa-miR-125a-5p; +MIMAT0032305 ssa-miR-125a-3p; +MIMAT0032306 ssa-miR-125a-2-3p; +MIMAT0032307 ssa-miR-125b-5p; +MIMAT0032308 ssa-miR-125b-1-3p; +MIMAT0032309 ssa-miR-125b-2-3p; +MIMAT0032310 ssa-miR-125b-3-3p; +MIMAT0032311 ssa-miR-126-5p; +MIMAT0032312 ssa-miR-126-3p; +MIMAT0032313 ssa-miR-128-1-5p; +MIMAT0032314 ssa-miR-128-3p; +MIMAT0032315 ssa-miR-128-2-5p; +MIMAT0032316 ssa-miR-128-3-5p; +MIMAT0032317 ssa-miR-128-4-5p; +MIMAT0032318 ssa-miR-129-5p; +MIMAT0032319 ssa-miR-129-3p; +MIMAT0032320 ssa-miR-129-3-3p; +MIMAT0032321 ssa-miR-130a-5p; +MIMAT0032322 ssa-miR-130a-3p; +MIMAT0032323 ssa-miR-130a-2-3p; +MIMAT0032324 ssa-miR-130b-5p; +MIMAT0032325 ssa-miR-130b-3p; +MIMAT0032326 ssa-miR-130b-2-5p; +MIMAT0032327 ssa-miR-130d-1-5p; +MIMAT0032328 ssa-miR-130d-3p; +MIMAT0032329 ssa-miR-130d-2-5p; +MIMAT0032330 ssa-miR-130d-3-5p; +MIMAT0032331 ssa-miR-132-5p; +MIMAT0032332 ssa-miR-132-3p; +MIMAT0032333 ssa-miR-132-3-5p; +MIMAT0032334 ssa-miR-132-4-5p; +MIMAT0032335 ssa-miR-1338-5p; +MIMAT0032336 ssa-miR-1338-3p; +MIMAT0032337 ssa-miR-133a-5p; +MIMAT0032338 ssa-miR-133a-3p; +MIMAT0032339 ssa-miR-133b-5p; +MIMAT0032340 ssa-miR-133b-3p; +MIMAT0032341 ssa-miR-133a-3-5p; +MIMAT0032342 ssa-miR-135a-5p; +MIMAT0032343 ssa-miR-135a-3p; +MIMAT0032344 ssa-miR-135b-5p; +MIMAT0032345 ssa-miR-135b-1-3p; +MIMAT0032346 ssa-miR-135b-2-3p; +MIMAT0032347 ssa-miR-135b-3-3p; +MIMAT0032348 ssa-miR-135c-5p; +MIMAT0032349 ssa-miR-135c-3p; +MIMAT0032350 ssa-miR-137-5p; +MIMAT0032351 ssa-miR-137-3p; +MIMAT0032352 ssa-miR-138-5p; +MIMAT0032353 ssa-miR-138-3p; +MIMAT0032354 ssa-miR-138-3-3p; +MIMAT0032355 ssa-miR-138-4-3p; +MIMAT0032356 ssa-miR-139-5p; +MIMAT0032357 ssa-miR-139-3p; +MIMAT0032358 ssa-miR-139-2-3p; +MIMAT0032359 ssa-miR-140-5p; +MIMAT0032360 ssa-miR-140-3p; +MIMAT0032361 ssa-miR-142a-5p; +MIMAT0032362 ssa-miR-142a-3p; +MIMAT0032363 ssa-miR-142b-5p; +MIMAT0032364 ssa-miR-142b-3p; +MIMAT0032365 ssa-miR-143-5p; +MIMAT0032366 ssa-miR-143-3p; +MIMAT0032367 ssa-miR-144-5p; +MIMAT0032368 ssa-miR-144-3p; +MIMAT0032369 ssa-miR-145-5p; +MIMAT0032370 ssa-miR-145-3p; +MIMAT0032371 ssa-miR-146a-5p; +MIMAT0032372 ssa-miR-146a-3p; +MIMAT0032373 ssa-miR-146a-3-3p; +MIMAT0032374 ssa-miR-146b-5p; +MIMAT0032375 ssa-miR-146b-3p; +MIMAT0032376 ssa-miR-146d-5p; +MIMAT0032377 ssa-miR-146d-3p; +MIMAT0032378 ssa-miR-146d-2-3p; +MIMAT0032379 ssa-miR-148a-5p; +MIMAT0032380 ssa-miR-148a-3p; +MIMAT0032381 ssa-miR-148b-5p; +MIMAT0032382 ssa-miR-148b-3p; +MIMAT0032383 ssa-miR-150-5p; +MIMAT0032384 ssa-miR-150-3p; +MIMAT0032385 ssa-miR-152-5p; +MIMAT0032386 ssa-miR-152-3p; +MIMAT0032387 ssa-miR-153a-5p; +MIMAT0032388 ssa-miR-153a-3p; +MIMAT0032389 ssa-miR-153a-2-5p; +MIMAT0032390 ssa-miR-153b-5p; +MIMAT0032391 ssa-miR-153b-3p; +MIMAT0032392 ssa-miR-155-5p; +MIMAT0032393 ssa-miR-155-3p; +MIMAT0032394 ssa-miR-15a-5p; +MIMAT0032395 ssa-miR-15a-3p; +MIMAT0032396 ssa-miR-15b-5p; +MIMAT0032397 ssa-miR-15b-3p; +MIMAT0032398 ssa-miR-15c-5p; +MIMAT0032399 ssa-miR-15c-3p; +MIMAT0032400 ssa-miR-15c-2-3p; +MIMAT0032401 ssa-miR-15d-5p; +MIMAT0032402 ssa-miR-15d-3p; +MIMAT0032403 ssa-miR-15e-5p; +MIMAT0032404 ssa-miR-15e-3p; +MIMAT0032405 ssa-miR-16a-5p; +MIMAT0032406 ssa-miR-16a-3p; +MIMAT0032407 ssa-miR-16a-2-3p; +MIMAT0032408 ssa-miR-16b-5p; +MIMAT0032409 ssa-miR-16b-3p; +MIMAT0032410 ssa-miR-16c-5p; +MIMAT0032411 ssa-miR-16c-3p; +MIMAT0032412 ssa-miR-1788-5p; +MIMAT0032413 ssa-miR-1788-3p; +MIMAT0032414 ssa-miR-17-5p; +MIMAT0032415 ssa-miR-17-3-3p; +MIMAT0032416 ssa-miR-17-3p; +MIMAT0032417 ssa-miR-181a-5p; +MIMAT0032418 ssa-miR-181a-1-3p; +MIMAT0032419 ssa-miR-181a-2-3p; +MIMAT0032420 ssa-miR-181a-3-3p; +MIMAT0032421 ssa-miR-181a-4-3p; +MIMAT0032422 ssa-miR-181a-5-3p; +MIMAT0032423 ssa-miR-181b-5p; +MIMAT0032424 ssa-miR-181b-3p; +MIMAT0032425 ssa-miR-181c-5p; +MIMAT0032426 ssa-miR-181c-3p; +MIMAT0032427 ssa-miR-182-5p; +MIMAT0032428 ssa-miR-182-3p; +MIMAT0032429 ssa-miR-183-5p; +MIMAT0032430 ssa-miR-183-3p; +MIMAT0032431 ssa-miR-183-2-3p; +MIMAT0032432 ssa-miR-18a-5p; +MIMAT0032433 ssa-miR-18a-3p; +MIMAT0032434 ssa-miR-18b-5p; +MIMAT0032435 ssa-miR-18b-3p; +MIMAT0032436 ssa-miR-190a-5p; +MIMAT0032437 ssa-miR-190a-3p; +MIMAT0032438 ssa-miR-190b-5p; +MIMAT0032439 ssa-miR-190b-3p; +MIMAT0032440 ssa-miR-192a-5p; +MIMAT0032441 ssa-miR-192a-3p; +MIMAT0032442 ssa-miR-192a-2-3p; +MIMAT0032443 ssa-miR-192b-5p; +MIMAT0032444 ssa-miR-192b-3p; +MIMAT0032445 ssa-miR-193-5p; +MIMAT0032446 ssa-miR-193-3p; +MIMAT0032447 ssa-miR-194a-5p; +MIMAT0032448 ssa-miR-194a-3p; +MIMAT0032449 ssa-miR-194b-5p; +MIMAT0032450 ssa-miR-194b-3p; +MIMAT0032451 ssa-miR-194c-5p; +MIMAT0032452 ssa-miR-194c-3p; +MIMAT0032453 ssa-miR-196a-5p; +MIMAT0032454 ssa-miR-196a-1-3p; +MIMAT0032455 ssa-miR-196a-2-3p; +MIMAT0032456 ssa-miR-196a-3-3p; +MIMAT0032457 ssa-miR-196a-4-3p; +MIMAT0032458 ssa-miR-196b-5p; +MIMAT0032459 ssa-miR-196b-3p; +MIMAT0032460 ssa-miR-199a-5p; +MIMAT0032461 ssa-miR-199a-3p; +MIMAT0032462 ssa-miR-19a-5p; +MIMAT0032463 ssa-miR-19a-3p; +MIMAT0032464 ssa-miR-19a-3-5p; +MIMAT0032465 ssa-miR-19c-5p; +MIMAT0032466 ssa-miR-19c-3p; +MIMAT0032467 ssa-miR-19c-3-5p; +MIMAT0032468 ssa-miR-19c-4-5p; +MIMAT0032469 ssa-miR-19d-5p; +MIMAT0032470 ssa-miR-19d-3p; +MIMAT0032471 ssa-miR-1-3-5p; +MIMAT0032472 ssa-miR-1-3p; +MIMAT0032473 ssa-miR-1-5p; +MIMAT0032474 ssa-miR-1-4-5p; +MIMAT0032475 ssa-miR-200a-1-5p; +MIMAT0032476 ssa-miR-200a-3p; +MIMAT0032477 ssa-miR-200a-2-5p; +MIMAT0032478 ssa-miR-200a-3-5p; +MIMAT0032479 ssa-miR-200b-5p; +MIMAT0032480 ssa-miR-200b-3p; +MIMAT0032481 ssa-miR-202-3p; +MIMAT0032482 ssa-miR-202-5p; +MIMAT0032483 ssa-miR-203a-5p; +MIMAT0032484 ssa-miR-203a-3p; +MIMAT0032485 ssa-miR-203a-2-5p; +MIMAT0032486 ssa-miR-203b-5p; +MIMAT0032487 ssa-miR-203b-3p; +MIMAT0032488 ssa-miR-204-5p; +MIMAT0032489 ssa-miR-204-3p; +MIMAT0032490 ssa-miR-204-3-3p; +MIMAT0032491 ssa-miR-204-4-3p; +MIMAT0032492 ssa-miR-205a-5p; +MIMAT0032493 ssa-miR-205a-3p; +MIMAT0032494 ssa-miR-205a-2-3p; +MIMAT0032495 ssa-miR-205b-5p; +MIMAT0032496 ssa-miR-205b-1-3p; +MIMAT0032497 ssa-miR-205b-2-3p; +MIMAT0032498 ssa-miR-205b-3-3p; +MIMAT0032499 ssa-miR-205b-4-3p; +MIMAT0032500 ssa-miR-206-5p; +MIMAT0032501 ssa-miR-206-3p; +MIMAT0032502 ssa-miR-20a-5p; +MIMAT0032503 ssa-miR-20a-1-3p; +MIMAT0032504 ssa-miR-20a-2-3p; +MIMAT0032505 ssa-miR-20a-3-3p; +MIMAT0032506 ssa-miR-20b-5p; +MIMAT0032507 ssa-miR-20b-3p; +MIMAT0032508 ssa-miR-210-5p; +MIMAT0032509 ssa-miR-210-3p; +MIMAT0032510 ssa-miR-212a-5p; +MIMAT0032511 ssa-miR-212a-3p; +MIMAT0032512 ssa-miR-212b-5p; +MIMAT0032513 ssa-miR-212b-3p; +MIMAT0032514 ssa-miR-214-5p; +MIMAT0032515 ssa-miR-214-3p; +MIMAT0032516 ssa-miR-216a-5p; +MIMAT0032517 ssa-miR-216a-3p; +MIMAT0032518 ssa-miR-216b-5p; +MIMAT0032519 ssa-miR-216b-3p; +MIMAT0032520 ssa-miR-2187-5p; +MIMAT0032521 ssa-miR-2187-3p; +MIMAT0032522 ssa-miR-2188-5p; +MIMAT0032523 ssa-miR-2188-3p; +MIMAT0032524 ssa-miR-218-5p; +MIMAT0032525 ssa-miR-218-3p; +MIMAT0032526 ssa-miR-219a-5p; +MIMAT0032527 ssa-miR-219a-3p; +MIMAT0032528 ssa-miR-219b-5p; +MIMAT0032529 ssa-miR-219b-3p; +MIMAT0032530 ssa-miR-219c-5p; +MIMAT0032531 ssa-miR-219c-3p; +MIMAT0032532 ssa-miR-219c-2-3p; +MIMAT0032533 ssa-miR-21a-5p; +MIMAT0032534 ssa-miR-21a-3p; +MIMAT0032535 ssa-miR-21a-2-3p; +MIMAT0032536 ssa-miR-21b-5p; +MIMAT0032537 ssa-miR-21b-3p; +MIMAT0032538 ssa-miR-221-3p; +MIMAT0032539 ssa-miR-221-5p; +MIMAT0032540 ssa-miR-222a-5p; +MIMAT0032541 ssa-miR-222a-3p; +MIMAT0032542 ssa-miR-222b-5p; +MIMAT0032543 ssa-miR-222b-3p; +MIMAT0032544 ssa-miR-22a-5p; +MIMAT0032545 ssa-miR-22a-3p; +MIMAT0032546 ssa-miR-22b-5p; +MIMAT0032547 ssa-miR-22b-3p; +MIMAT0032548 ssa-miR-23a-3-5p; +MIMAT0032549 ssa-miR-23a-3p; +MIMAT0032550 ssa-miR-23a-4-5p; +MIMAT0032551 ssa-miR-23a-5p; +MIMAT0032552 ssa-miR-23b-5p; +MIMAT0032553 ssa-miR-23b-3p; +MIMAT0032554 ssa-miR-24a-4-5p; +MIMAT0032555 ssa-miR-24a-3p; +MIMAT0032556 ssa-miR-24a-5p; +MIMAT0032557 ssa-miR-24a-3-5p; +MIMAT0032558 ssa-miR-24b-5p; +MIMAT0032559 ssa-miR-24b-3p; +MIMAT0032560 ssa-miR-25-5p; +MIMAT0032561 ssa-miR-25-3p; +MIMAT0032562 ssa-miR-25-3-5p; +MIMAT0032563 ssa-miR-26a-5p; +MIMAT0032564 ssa-miR-26a-3p; +MIMAT0032565 ssa-miR-26a-3-3p; +MIMAT0032566 ssa-miR-26a-4-3p; +MIMAT0032567 ssa-miR-26a-5-3p; +MIMAT0032568 ssa-miR-26a-6-3p; +MIMAT0032569 ssa-miR-26b-5p; +MIMAT0032570 ssa-miR-26b-3p; +MIMAT0032571 ssa-miR-26d-5p; +MIMAT0032572 ssa-miR-26d-3p; +MIMAT0032573 ssa-miR-27a-5p; +MIMAT0032574 ssa-miR-27a-3p; +MIMAT0032575 ssa-miR-27a-2-5p; +MIMAT0032576 ssa-miR-27b-5p; +MIMAT0032577 ssa-miR-27b-3p; +MIMAT0032578 ssa-miR-27c-5p; +MIMAT0032579 ssa-miR-27c-3p; +MIMAT0032580 ssa-miR-27c-2-5p; +MIMAT0032581 ssa-miR-27d-5p; +MIMAT0032582 ssa-miR-27d-3p; +MIMAT0032583 ssa-miR-29a-5p; +MIMAT0032584 ssa-miR-29a-3p; +MIMAT0032585 ssa-miR-29b-1-5p; +MIMAT0032586 ssa-miR-29b-3p; +MIMAT0032587 ssa-miR-29b-2-5p; +MIMAT0032588 ssa-miR-29b-3-5p; +MIMAT0032589 ssa-miR-29b-4-5p; +MIMAT0032590 ssa-miR-29c-5p; +MIMAT0032591 ssa-miR-29c-3p; +MIMAT0032592 ssa-miR-301a-5p; +MIMAT0032593 ssa-miR-301a-3p; +MIMAT0032594 ssa-miR-301b-5p; +MIMAT0032595 ssa-miR-301b-3p; +MIMAT0032596 ssa-miR-301c-5p; +MIMAT0032597 ssa-miR-301c-3p; +MIMAT0032598 ssa-miR-301d-5p; +MIMAT0032599 ssa-miR-301d-3p; +MIMAT0032600 ssa-miR-30a-5p; +MIMAT0032601 ssa-miR-30a-3-3p; +MIMAT0032602 ssa-miR-30a-4-3p; +MIMAT0032603 ssa-miR-30a-3p; +MIMAT0032604 ssa-miR-30b-5p; +MIMAT0032605 ssa-miR-30b-3p; +MIMAT0032606 ssa-miR-30c-5p; +MIMAT0032607 ssa-miR-30c-3p; +MIMAT0032608 ssa-miR-30d-5p; +MIMAT0032609 ssa-miR-30d-3p; +MIMAT0032610 ssa-miR-30d-2-3p; +MIMAT0032611 ssa-miR-30e-5p; +MIMAT0032612 ssa-miR-30e-3p; +MIMAT0032613 ssa-miR-30e-3-3p; +MIMAT0032614 ssa-miR-338a-3-5p; +MIMAT0032615 ssa-miR-338a-3p; +MIMAT0032616 ssa-miR-338a-5p; +MIMAT0032617 ssa-miR-338a-4-5p; +MIMAT0032618 ssa-miR-33a-5p; +MIMAT0032619 ssa-miR-33a-3p; +MIMAT0032620 ssa-miR-33b-5p; +MIMAT0032621 ssa-miR-33b-3p; +MIMAT0032622 ssa-miR-365-5p; +MIMAT0032623 ssa-miR-365-3p; +MIMAT0032624 ssa-miR-365-2-5p; +MIMAT0032625 ssa-miR-375-5p; +MIMAT0032626 ssa-miR-375-3p; +MIMAT0032627 ssa-miR-375-2-5p; +MIMAT0032628 ssa-miR-375-3-5p; +MIMAT0032629 ssa-miR-429-5p; +MIMAT0032630 ssa-miR-429-3p; +MIMAT0032631 ssa-miR-430a-5p; +MIMAT0032632 ssa-miR-430a-3p; +MIMAT0032633 ssa-miR-430b-5p; +MIMAT0032634 ssa-miR-430b-3p; +MIMAT0032635 ssa-miR-430c-5p; +MIMAT0032636 ssa-miR-430c-3p; +MIMAT0032637 ssa-miR-449a-5p; +MIMAT0032638 ssa-miR-449a-3p; +MIMAT0032639 ssa-miR-449b-5p; +MIMAT0032640 ssa-miR-449b-3p; +MIMAT0032641 ssa-miR-454-5p; +MIMAT0032642 ssa-miR-454-3p; +MIMAT0032643 ssa-miR-455-5p; +MIMAT0032644 ssa-miR-455-3p; +MIMAT0032645 ssa-miR-456-5p; +MIMAT0032646 ssa-miR-456-3p; +MIMAT0032647 ssa-miR-458-5p; +MIMAT0032648 ssa-miR-458-3p; +MIMAT0032649 ssa-miR-459-5p; +MIMAT0032650 ssa-miR-459-3p; +MIMAT0032651 ssa-miR-460-5p; +MIMAT0032652 ssa-miR-460-3p; +MIMAT0032653 ssa-miR-462a-5p; +MIMAT0032654 ssa-miR-462a-3p; +MIMAT0032655 ssa-miR-462b-5p; +MIMAT0032656 ssa-miR-462b-3p; +MIMAT0032657 ssa-miR-489-5p; +MIMAT0032658 ssa-miR-489-3p; +MIMAT0032659 ssa-miR-499a-5p; +MIMAT0032660 ssa-miR-499a-3p; +MIMAT0032661 ssa-miR-499b-5p; +MIMAT0032662 ssa-miR-499b-3p; +MIMAT0032663 ssa-miR-551-5p; +MIMAT0032664 ssa-miR-551-3p; +MIMAT0032665 ssa-miR-7132a-5p; +MIMAT0032666 ssa-miR-7132a-3p; +MIMAT0032667 ssa-miR-722-5p; +MIMAT0032668 ssa-miR-722-3p; +MIMAT0032669 ssa-miR-723-5p; +MIMAT0032670 ssa-miR-723-3p; +MIMAT0032671 ssa-miR-724-5p; +MIMAT0032672 ssa-miR-724-3p; +MIMAT0032673 ssa-miR-725-5p; +MIMAT0032674 ssa-miR-725-3p; +MIMAT0032675 ssa-miR-727-5p; +MIMAT0032676 ssa-miR-727-3p; +MIMAT0032677 ssa-miR-729-5p; +MIMAT0032678 ssa-miR-729-3p; +MIMAT0032679 ssa-miR-730a-5p; +MIMAT0032680 ssa-miR-730a-3p; +MIMAT0032681 ssa-miR-730a-2-3p; +MIMAT0032682 ssa-miR-731-5p; +MIMAT0032683 ssa-miR-731-3p; +MIMAT0032684 ssa-miR-736-5p; +MIMAT0032685 ssa-miR-736-3p; +MIMAT0032686 ssa-miR-737-5p; +MIMAT0032687 ssa-miR-737-3p; +MIMAT0032688 ssa-let-7a-5p; +MIMAT0032689 ssa-let-7a-3p; +MIMAT0032690 ssa-let-7a-3-3p; +MIMAT0032691 ssa-let-7a-4-3p; +MIMAT0032692 ssa-let-7a-5-3p; +MIMAT0032693 ssa-miR-7a-5p; +MIMAT0032694 ssa-miR-7a-1-3p; +MIMAT0032695 ssa-miR-7a-2-3p; +MIMAT0032696 ssa-miR-7a-3-3p; +MIMAT0032697 ssa-miR-7a-4-3p; +MIMAT0032698 ssa-miR-7a-5-3p; +MIMAT0032699 ssa-miR-7a-6-3p; +MIMAT0032700 ssa-miR-7a-7-3p; +MIMAT0032701 ssa-let-7b-5p; +MIMAT0032702 ssa-let-7b-3p; +MIMAT0032703 ssa-let-7d-5p; +MIMAT0032704 ssa-let-7d-3p; +MIMAT0032705 ssa-let-7e-5p; +MIMAT0032706 ssa-let-7e-3p; +MIMAT0032707 ssa-miR-92a-5p; +MIMAT0032708 ssa-miR-92a-3p; +MIMAT0032709 ssa-miR-92a-3-5p; +MIMAT0032710 ssa-miR-92a-4-5p; +MIMAT0032711 ssa-miR-92b-5p; +MIMAT0032712 ssa-miR-92b-3p; +MIMAT0032713 ssa-miR-93a-5p; +MIMAT0032714 ssa-miR-93a-3p; +MIMAT0032715 ssa-miR-93a-2-3p; +MIMAT0032716 ssa-miR-96-5p; +MIMAT0032717 ssa-miR-96-3p; +MIMAT0032718 ssa-miR-99-5p; +MIMAT0032719 ssa-miR-99-3p; +MIMAT0032720 ssa-miR-99-2-3p; +MIMAT0032721 ssa-miR-9a-5p; +MIMAT0032722 ssa-miR-9a-1-3p; +MIMAT0032723 ssa-miR-9a-2-3p; +MIMAT0032724 ssa-miR-9a-3-3p; +MIMAT0032725 ssa-miR-9a-4-3p; +MIMAT0032726 ssa-miR-9a-5-3p; +MIMAT0032727 ssa-miR-9a-6-3p; +MIMAT0032728 ssa-miR-9a-7-3p; +MIMAT0032729 ssa-miR-9a-8-3p; +MIMAT0032730 ssa-miR-9b-5p; +MIMAT0032731 ssa-miR-9b-3p; +MIMAT0032732 ssa-miR-7132b-5p; +MIMAT0032733 ssa-miR-7132b-3p; +MIMAT0032734 ssa-miR-8156-5p; +MIMAT0032735 ssa-miR-8156-3p; +MIMAT0032736 ssa-miR-8157-5p; +MIMAT0032737 ssa-miR-8157-3p; +MIMAT0032738 ssa-miR-734-5p; +MIMAT0032739 ssa-miR-734-3p; +MIMAT0032740 ssa-miR-8158-5p; +MIMAT0032741 ssa-miR-8158-3p; +MIMAT0032742 ssa-miR-8159-5p; +MIMAT0032743 ssa-miR-8159-3p; +MIMAT0032744 ssa-miR-2184-5p; +MIMAT0032745 ssa-miR-2184-3p; +MIMAT0032746 ssa-miR-8160-5p; +MIMAT0032747 ssa-miR-8160-3p; +MIMAT0032748 ssa-miR-8161-5p; +MIMAT0032749 ssa-miR-8161-3p;ssa-miR-8160-2-3p; +MIMAT0032750 ssa-miR-7552b-5p; +MIMAT0032751 ssa-miR-7552b-3p; +MIMAT0032752 ssa-miR-7552a-5p; +MIMAT0032753 ssa-miR-7552a-3p; +MIMAT0032754 ssa-miR-7552a-2-3p; +MIMAT0032755 ssa-miR-8162-5p; +MIMAT0032756 ssa-miR-8162-3p; +MIMAT0032757 ssa-miR-8163-5p; +MIMAT0032758 ssa-miR-8163-3p; +MIMAT0032759 ssa-miR-8164-5p; +MIMAT0032760 ssa-miR-8164-3p; +MIMAT0032761 ath-miR8165; +MIMAT0032762 ath-miR8166; +MIMAT0032763 ath-miR8167a; +MIMAT0032764 ath-miR8167b; +MIMAT0032765 ath-miR8167c; +MIMAT0032766 ath-miR8168; +MIMAT0032767 ath-miR8169; +MIMAT0032768 ath-miR8170-5p; +MIMAT0032769 ath-miR8170-3p; +MIMAT0032770 ath-miR8171; +MIMAT0032771 ath-miR8172; +MIMAT0032772 ath-miR8173; +MIMAT0032773 ath-miR8174; +MIMAT0032774 ath-miR8175; +MIMAT0032775 ath-miR8176; +MIMAT0032776 ath-miR8177; +MIMAT0032777 ath-miR8178; +MIMAT0032778 ath-miR8179; +MIMAT0032779 ath-miR8180; +MIMAT0032780 ath-miR8181; +MIMAT0032781 ath-miR8182; +MIMAT0032782 ath-miR8183; +MIMAT0032783 ath-miR8184; +MIMAT0032784 sja-miR-8185; +MIMAT0032785 cel-miR-8186-5p; +MIMAT0032786 cel-miR-8186-3p; +MIMAT0032787 cel-miR-8187-5p; +MIMAT0032788 cel-miR-8187-3p; +MIMAT0032789 cel-miR-8188-5p; +MIMAT0032790 cel-miR-8188-3p; +MIMAT0032791 cel-miR-8189-5p; +MIMAT0032792 cel-miR-8189-3p; +MIMAT0032793 cel-miR-8190-5p; +MIMAT0032794 cel-miR-8190-3p; +MIMAT0032795 cel-miR-8191-5p; +MIMAT0032796 cel-miR-8191-3p; +MIMAT0032797 cel-miR-8192-5p; +MIMAT0032798 cel-miR-8192-3p; +MIMAT0032799 cel-miR-8193-5p; +MIMAT0032800 cel-miR-8193-3p; +MIMAT0032801 cel-miR-8194-5p; +MIMAT0032802 cel-miR-8194-3p; +MIMAT0032803 cel-miR-8195-5p; +MIMAT0032804 cel-miR-8195-3p; +MIMAT0032805 cel-miR-8196a-5p; +MIMAT0032806 cel-miR-8196a-3p; +MIMAT0032807 cel-miR-8197-5p; +MIMAT0032808 cel-miR-8197-3p; +MIMAT0032809 cel-miR-8198-5p; +MIMAT0032810 cel-miR-8198-3p; +MIMAT0032811 cel-miR-8199-5p; +MIMAT0032812 cel-miR-8199-3p; +MIMAT0032813 cel-miR-8200-5p; +MIMAT0032814 cel-miR-8200-3p; +MIMAT0032815 cel-miR-8201-5p; +MIMAT0032816 cel-miR-8201-3p; +MIMAT0032817 cel-miR-8202-5p; +MIMAT0032818 cel-miR-8202-3p; +MIMAT0032819 cel-miR-8203-5p; +MIMAT0032820 cel-miR-8203-3p; +MIMAT0032821 cel-miR-4810b-5p; +MIMAT0032822 cel-miR-4810b-3p; +MIMAT0032823 cel-miR-8204-5p; +MIMAT0032824 cel-miR-8204-3p; +MIMAT0032825 cel-miR-8196b-5p; +MIMAT0032826 cel-miR-8196b-3p; +MIMAT0032827 cel-miR-8205-5p; +MIMAT0032828 cel-miR-8205-3p; +MIMAT0032829 cel-miR-8206-5p; +MIMAT0032830 cel-miR-8206-3p; +MIMAT0032831 cel-miR-8207-5p; +MIMAT0032832 cel-miR-8207-3p; +MIMAT0032833 cel-miR-8208-5p; +MIMAT0032834 cel-miR-8208-3p; +MIMAT0032835 cel-miR-8209-5p; +MIMAT0032836 cel-miR-8209-3p; +MIMAT0032837 cel-miR-8210-5p; +MIMAT0032838 cel-miR-8210-3p; +MIMAT0032839 cel-miR-2217b-1-5p; +MIMAT0032840 cel-miR-2217b-3p; +MIMAT0032841 cel-miR-2217b-5p; +MIMAT0032842 cel-miR-8211-5p; +MIMAT0032843 cel-miR-8211-3p; +MIMAT0032844 cel-miR-8212-5p; +MIMAT0032845 cel-miR-8212-3p; +MIMAT0032846 ppc-miR-228-5p; +MIMAT0032847 ppc-miR-228-3p; +MIMAT0032848 ppc-miR-2251b-5p; +MIMAT0032849 ppc-miR-2251b-3p; +MIMAT0032850 ppc-miR-2235b-5p; +MIMAT0032851 ppc-miR-2235b-3p; +MIMAT0032852 ppc-miR-8213-5p; +MIMAT0032853 ppc-miR-8213-3p; +MIMAT0032854 ppc-miR-235-5p; +MIMAT0032855 ppc-miR-235-3p; +MIMAT0032856 ppc-miR-2238f-5p; +MIMAT0032857 ppc-miR-2238f-3p; +MIMAT0032858 ppc-miR-8214-5p; +MIMAT0032859 ppc-miR-8214-3p; +MIMAT0032860 ppc-miR-8215a-5p; +MIMAT0032861 ppc-miR-8215a-3p; +MIMAT0032862 ppc-miR-8216-5p; +MIMAT0032863 ppc-miR-8216-3p; +MIMAT0032864 ppc-miR-8217-5p; +MIMAT0032865 ppc-miR-8217-3p; +MIMAT0032866 ppc-miR-8218a-5p; +MIMAT0032867 ppc-miR-8218a-3p; +MIMAT0032868 ppc-miR-63i-5p; +MIMAT0032869 ppc-miR-63i-3p; +MIMAT0032870 ppc-miR-8219-5p; +MIMAT0032871 ppc-miR-8219-3p; +MIMAT0032872 ppc-miR-2a-5p; +MIMAT0032873 ppc-miR-2a-3p; +MIMAT0032874 ppc-miR-8220-5p; +MIMAT0032875 ppc-miR-8220-3p; +MIMAT0032876 ppc-miR-8221-5p; +MIMAT0032877 ppc-miR-8221-3p; +MIMAT0032878 ppc-miR-8222-5p; +MIMAT0032879 ppc-miR-8222-3p; +MIMAT0032880 ppc-miR-8215b-5p; +MIMAT0032881 ppc-miR-8215b-3p; +MIMAT0032882 ppc-miR-36-5p; +MIMAT0032883 ppc-miR-36-3p; +MIMAT0032884 ppc-miR-8223-5p; +MIMAT0032885 ppc-miR-8223-3p; +MIMAT0032886 ppc-miR-83-5p; +MIMAT0032887 ppc-miR-83-3p; +MIMAT0032888 ppc-miR-42c-5p; +MIMAT0032889 ppc-miR-42c-3p; +MIMAT0032890 ppc-miR-8224-5p; +MIMAT0032891 ppc-miR-8224-3p; +MIMAT0032892 ppc-miR-8225-5p; +MIMAT0032893 ppc-miR-8225-3p; +MIMAT0032894 ppc-miR-2238g-5p; +MIMAT0032895 ppc-miR-2238g-3p; +MIMAT0032896 ppc-miR-8226-5p; +MIMAT0032897 ppc-miR-8226-3p; +MIMAT0032898 ppc-miR-8227-5p; +MIMAT0032899 ppc-miR-8227-3p; +MIMAT0032900 ppc-miR-8228-5p; +MIMAT0032901 ppc-miR-8228-3p; +MIMAT0032902 ppc-miR-8229a-5p; +MIMAT0032903 ppc-miR-8229a-3p; +MIMAT0032904 ppc-miR-59-5p; +MIMAT0032905 ppc-miR-59-3p; +MIMAT0032906 ppc-miR-8230-5p; +MIMAT0032907 ppc-miR-8230-3p; +MIMAT0032908 ppc-miR-8231-5p; +MIMAT0032909 ppc-miR-8231-3p; +MIMAT0032910 ppc-miR-8364d-5p; +MIMAT0032911 ppc-miR-8364d-3p; +MIMAT0032912 ppc-miR-8232-5p; +MIMAT0032913 ppc-miR-8232-3p; +MIMAT0032914 ppc-miR-133-5p; +MIMAT0032915 ppc-miR-133-3p; +MIMAT0032916 ppc-miR-63j-5p; +MIMAT0032917 ppc-miR-63j-3p; +MIMAT0032918 ppc-miR-8233-5p; +MIMAT0032919 ppc-miR-8233-3p; +MIMAT0032920 ppc-miR-84d-5p; +MIMAT0032921 ppc-miR-84d-3p; +MIMAT0032922 ppc-miR-8234-5p; +MIMAT0032923 ppc-miR-8234-3p; +MIMAT0032924 ppc-miR-8235-5p; +MIMAT0032925 ppc-miR-8235-3p; +MIMAT0032926 ppc-miR-8236-5p; +MIMAT0032927 ppc-miR-8236-3p; +MIMAT0032928 ppc-miR-8237-5p; +MIMAT0032929 ppc-miR-8237-3p; +MIMAT0032930 ppc-miR-2238h-5p; +MIMAT0032931 ppc-miR-2238h-3p; +MIMAT0032932 ppc-miR-8238-5p; +MIMAT0032933 ppc-miR-8238-3p; +MIMAT0032934 ppc-miR-8239-5p; +MIMAT0032935 ppc-miR-8239-3p; +MIMAT0032936 ppc-miR-8240-5p; +MIMAT0032937 ppc-miR-8240-3p; +MIMAT0032938 ppc-miR-8241-5p; +MIMAT0032939 ppc-miR-8241-3p; +MIMAT0032940 ppc-miR-2238i-5p; +MIMAT0032941 ppc-miR-2238i-3p; +MIMAT0032942 ppc-miR-8242-5p; +MIMAT0032943 ppc-miR-8242-3p; +MIMAT0032944 ppc-miR-312b-5p; +MIMAT0032945 ppc-miR-312b-3p; +MIMAT0032946 ppc-miR-8243-5p; +MIMAT0032947 ppc-miR-8243-3p; +MIMAT0032948 ppc-miR-8244-5p; +MIMAT0032949 ppc-miR-8244-3p; +MIMAT0032950 ppc-miR-2235c-5p; +MIMAT0032951 ppc-miR-2235c-3p; +MIMAT0032952 ppc-miR-2235d-5p; +MIMAT0032953 ppc-miR-2235d-3p; +MIMAT0032954 ppc-miR-8245a-5p; +MIMAT0032955 ppc-miR-8245a-3p; +MIMAT0032956 ppc-miR-8246-5p; +MIMAT0032957 ppc-miR-8246-3p; +MIMAT0032958 ppc-miR-8247-5p; +MIMAT0032959 ppc-miR-8247-3p; +MIMAT0032960 ppc-miR-8248-5p; +MIMAT0032961 ppc-miR-8248-3p; +MIMAT0032962 ppc-miR-8249-5p; +MIMAT0032963 ppc-miR-8249-3p; +MIMAT0032964 ppc-miR-8250a-5p; +MIMAT0032965 ppc-miR-8250a-3p; +MIMAT0032966 ppc-miR-2238j-5p; +MIMAT0032967 ppc-miR-2238j-3p; +MIMAT0032968 ppc-miR-8251-5p; +MIMAT0032969 ppc-miR-8251-3p; +MIMAT0032970 ppc-miR-84c-5p; +MIMAT0032971 ppc-miR-84c-3p; +MIMAT0032972 ppc-miR-8252a-5p; +MIMAT0032973 ppc-miR-8252a-3p; +MIMAT0032974 ppc-miR-8253-5p; +MIMAT0032975 ppc-miR-8253-3p; +MIMAT0032976 ppc-miR-8254-5p; +MIMAT0032977 ppc-miR-8254-3p; +MIMAT0032978 ppc-miR-8255-5p; +MIMAT0032979 ppc-miR-8255-3p; +MIMAT0032980 ppc-miR-8256-5p; +MIMAT0032981 ppc-miR-8256-3p; +MIMAT0032982 ppc-miR-8257-5p; +MIMAT0032983 ppc-miR-8257-3p; +MIMAT0032984 ppc-miR-8258-5p; +MIMAT0032985 ppc-miR-8258-3p; +MIMAT0032986 ppc-miR-8259-5p; +MIMAT0032987 ppc-miR-8259-3p; +MIMAT0032988 ppc-miR-8250a-2-3p; +MIMAT0032989 ppc-miR-8260-5p; +MIMAT0032990 ppc-miR-8260-3p; +MIMAT0032991 ppc-miR-8250c-5p; +MIMAT0032992 ppc-miR-8250c-3p; +MIMAT0032993 ppc-miR-8250d-5p; +MIMAT0032994 ppc-miR-8250d-3p; +MIMAT0032995 ppc-miR-8261-5p; +MIMAT0032996 ppc-miR-8261-3p; +MIMAT0032997 ppc-miR-2237d-5p; +MIMAT0032998 ppc-miR-2237d-3p; +MIMAT0032999 ppc-miR-57-5p; +MIMAT0033000 ppc-miR-57-3p; +MIMAT0033001 ppc-miR-2253c-5p; +MIMAT0033002 ppc-miR-2253c-3p; +MIMAT0033003 ppc-miR-2253d-5p; +MIMAT0033004 ppc-miR-2253d-3p; +MIMAT0033005 ppc-miR-2235a-10-3p; +MIMAT0033006 ppc-miR-71b-5p; +MIMAT0033007 ppc-miR-71b-3p; +MIMAT0033008 ppc-miR-8262-5p; +MIMAT0033009 ppc-miR-8262-3p; +MIMAT0033010 ppc-miR-8263-5p; +MIMAT0033011 ppc-miR-8263-3p; +MIMAT0033012 ppc-miR-8264-5p; +MIMAT0033013 ppc-miR-8264-3p; +MIMAT0033014 ppc-miR-8265-5p; +MIMAT0033015 ppc-miR-8265-3p; +MIMAT0033016 ppc-miR-8266-5p; +MIMAT0033017 ppc-miR-8266-3p; +MIMAT0033018 ppc-miR-63k-5p; +MIMAT0033019 ppc-miR-63k-3p; +MIMAT0033020 ppc-miR-8267-5p; +MIMAT0033021 ppc-miR-8267-3p; +MIMAT0033022 ppc-miR-8268-5p; +MIMAT0033023 ppc-miR-8268-3p; +MIMAT0033024 ppc-miR-8269-5p; +MIMAT0033025 ppc-miR-8269-3p; +MIMAT0033026 ppc-miR-8364j-5p; +MIMAT0033027 ppc-miR-8364j-3p; +MIMAT0033028 ppc-miR-8364k-5p; +MIMAT0033029 ppc-miR-8364k-3p; +MIMAT0033030 ppc-miR-8364c-5p; +MIMAT0033031 ppc-miR-8364c-2-3p; +MIMAT0033032 ppc-miR-8270-5p; +MIMAT0033033 ppc-miR-8270-3p; +MIMAT0033034 ppc-miR-2235a-11-3p; +MIMAT0033035 ppc-miR-8271-5p; +MIMAT0033036 ppc-miR-8271-3p; +MIMAT0033037 ppc-miR-2238k-5p; +MIMAT0033038 ppc-miR-2238k-3p; +MIMAT0033039 ppc-miR-84e-5p; +MIMAT0033040 ppc-miR-84e-3p; +MIMAT0033041 ppc-miR-8272-5p; +MIMAT0033042 ppc-miR-8272-3p; +MIMAT0033043 ppc-miR-8273-5p; +MIMAT0033044 ppc-miR-8273-3p; +MIMAT0033045 ppc-miR-8364n-5p; +MIMAT0033046 ppc-miR-8364n-3p; +MIMAT0033047 ppc-miR-8274-5p; +MIMAT0033048 ppc-miR-8274-3p; +MIMAT0033049 ppc-miR-8275-5p; +MIMAT0033050 ppc-miR-8275-3p; +MIMAT0033051 ppc-miR-8276-5p; +MIMAT0033052 ppc-miR-8276-3p; +MIMAT0033053 ppc-miR-8277-5p; +MIMAT0033054 ppc-miR-8277-3p; +MIMAT0033055 ppc-miR-8278-5p; +MIMAT0033056 ppc-miR-8278-3p; +MIMAT0033057 ppc-miR-8279-5p; +MIMAT0033058 ppc-miR-8279-3p; +MIMAT0033059 ppc-miR-8364q-5p; +MIMAT0033060 ppc-miR-8364q-3p; +MIMAT0033061 ppc-miR-8280-5p; +MIMAT0033062 ppc-miR-8280-3p; +MIMAT0033063 ppc-miR-8364h-5p; +MIMAT0033064 ppc-miR-8364h-3p; +MIMAT0033065 ppc-miR-8281-5p; +MIMAT0033066 ppc-miR-8281-3p; +MIMAT0033067 ppc-miR-8282a-5p; +MIMAT0033068 ppc-miR-8282a-3p; +MIMAT0033069 ppc-miR-8283-5p; +MIMAT0033070 ppc-miR-8283-3p; +MIMAT0033071 ppc-miR-8284-5p; +MIMAT0033072 ppc-miR-8284-3p; +MIMAT0033073 ppc-miR-8304b-5p; +MIMAT0033074 ppc-miR-8304b-3p; +MIMAT0033075 ppc-miR-8285-5p; +MIMAT0033076 ppc-miR-8285-3p; +MIMAT0033077 ppc-miR-8286a-5p; +MIMAT0033078 ppc-miR-8286a-3p; +MIMAT0033079 ppc-miR-2238l-5p; +MIMAT0033080 ppc-miR-2238l-3p; +MIMAT0033081 ppc-miR-8364b-5p; +MIMAT0033082 ppc-miR-8364b-3p; +MIMAT0033083 ppc-miR-8287-5p; +MIMAT0033084 ppc-miR-8287-3p; +MIMAT0033085 ppc-miR-8288-5p; +MIMAT0033086 ppc-miR-8288-3p; +MIMAT0033087 ppc-miR-76-5p; +MIMAT0033088 ppc-miR-76-3p; +MIMAT0033089 ppc-miR-8317a-5p; +MIMAT0033090 ppc-miR-8317a-3p; +MIMAT0033091 ppc-miR-8289-5p; +MIMAT0033092 ppc-miR-8289-3p; +MIMAT0033093 ppc-miR-8290-5p; +MIMAT0033094 ppc-miR-8290-3p; +MIMAT0033095 ppc-miR-8291-5p; +MIMAT0033096 ppc-miR-8291-3p; +MIMAT0033097 ppc-miR-8292-5p; +MIMAT0033098 ppc-miR-8292-3p; +MIMAT0033099 ppc-miR-8293-5p; +MIMAT0033100 ppc-miR-8293-3p; +MIMAT0033101 ppc-miR-8294-5p; +MIMAT0033102 ppc-miR-8294-3p; +MIMAT0033103 ppc-miR-8295-5p; +MIMAT0033104 ppc-miR-8295-3p; +MIMAT0033105 ppc-miR-8296-5p; +MIMAT0033106 ppc-miR-8296-3p; +MIMAT0033107 ppc-miR-8364v-5p; +MIMAT0033108 ppc-miR-8364v-3p; +MIMAT0033109 ppc-miR-8364f-5p; +MIMAT0033110 ppc-miR-8364f-3p; +MIMAT0033111 ppc-miR-8297-5p; +MIMAT0033112 ppc-miR-8297-3p; +MIMAT0033113 ppc-miR-8298-5p; +MIMAT0033114 ppc-miR-8298-3p; +MIMAT0033115 ppc-miR-8299-5p; +MIMAT0033116 ppc-miR-8299-3p; +MIMAT0033117 ppc-miR-8300-5p; +MIMAT0033118 ppc-miR-8300-3p; +MIMAT0033119 ppc-miR-8364g-5p; +MIMAT0033120 ppc-miR-8364g-3p; +MIMAT0033121 ppc-miR-8301-5p; +MIMAT0033122 ppc-miR-8301-3p; +MIMAT0033123 ppc-miR-8364u-5p; +MIMAT0033124 ppc-miR-8364u-3p; +MIMAT0033125 ppc-miR-8302-5p; +MIMAT0033126 ppc-miR-8302-3p; +MIMAT0033127 ppc-miR-8303-5p; +MIMAT0033128 ppc-miR-8303-3p; +MIMAT0033129 ppc-miR-360-5p; +MIMAT0033130 ppc-miR-360-3p; +MIMAT0033131 ppc-miR-8303-2-3p; +MIMAT0033132 ppc-miR-8304a-5p; +MIMAT0033133 ppc-miR-8304a-3p; +MIMAT0033134 ppc-miR-8305-5p; +MIMAT0033135 ppc-miR-8305-3p; +MIMAT0033136 ppc-miR-8306-5p; +MIMAT0033137 ppc-miR-8306-3p; +MIMAT0033138 ppc-miR-8364o-5p; +MIMAT0033139 ppc-miR-8364o-3p; +MIMAT0033140 ppc-miR-8307-5p; +MIMAT0033141 ppc-miR-8307-3p; +MIMAT0033142 ppc-miR-8229b-5p; +MIMAT0033143 ppc-miR-8229b-3p; +MIMAT0033144 ppc-miR-8356b-5p; +MIMAT0033145 ppc-miR-8356b-3p; +MIMAT0033146 ppc-miR-8308-5p; +MIMAT0033147 ppc-miR-8308-3p; +MIMAT0033148 ppc-miR-8309-5p; +MIMAT0033149 ppc-miR-8309-3p; +MIMAT0033150 ppc-miR-8310-5p; +MIMAT0033151 ppc-miR-8310-3p; +MIMAT0033152 ppc-miR-8311-5p; +MIMAT0033153 ppc-miR-8311-3p; +MIMAT0033154 ppc-miR-8312-5p; +MIMAT0033155 ppc-miR-8312-3p; +MIMAT0033156 ppc-miR-8313-5p; +MIMAT0033157 ppc-miR-8313-3p; +MIMAT0033158 ppc-miR-8364c-3p; +MIMAT0033159 ppc-miR-8364p-5p; +MIMAT0033160 ppc-miR-8364p-3p; +MIMAT0033161 ppc-miR-8364w-5p; +MIMAT0033162 ppc-miR-8364w-3p; +MIMAT0033163 ppc-miR-8314-5p; +MIMAT0033164 ppc-miR-8314-3p; +MIMAT0033165 ppc-miR-8338-5p; +MIMAT0033166 ppc-miR-8338-3p; +MIMAT0033167 ppc-miR-8315-5p; +MIMAT0033168 ppc-miR-8315-3p; +MIMAT0033169 ppc-miR-8316-5p; +MIMAT0033170 ppc-miR-8316-3p; +MIMAT0033171 ppc-miR-8315-2-5p; +MIMAT0033172 ppc-miR-8317b-5p; +MIMAT0033173 ppc-miR-8317b-3p; +MIMAT0033174 ppc-miR-8318-5p; +MIMAT0033175 ppc-miR-8318-3p; +MIMAT0033176 ppc-miR-8364a-5p; +MIMAT0033177 ppc-miR-8364a-3p; +MIMAT0033178 ppc-miR-8319-5p; +MIMAT0033179 ppc-miR-8319-3p; +MIMAT0033180 ppc-miR-8320-5p; +MIMAT0033181 ppc-miR-8320-3p; +MIMAT0033182 ppc-miR-8321-5p; +MIMAT0033183 ppc-miR-8321-3p; +MIMAT0033184 ppc-miR-8322-5p; +MIMAT0033185 ppc-miR-8322-3p; +MIMAT0033186 ppc-miR-8245b-5p; +MIMAT0033187 ppc-miR-8245b-3p; +MIMAT0033188 ppc-miR-8364m-5p; +MIMAT0033189 ppc-miR-8364m-3p; +MIMAT0033190 ppc-miR-8323-5p; +MIMAT0033191 ppc-miR-8323-3p; +MIMAT0033192 ppc-miR-8324-5p; +MIMAT0033193 ppc-miR-8324-3p; +MIMAT0033194 ppc-miR-8325-5p; +MIMAT0033195 ppc-miR-8325-3p; +MIMAT0033196 ppc-miR-8326-5p; +MIMAT0033197 ppc-miR-8326-3p; +MIMAT0033198 ppc-miR-8327-5p; +MIMAT0033199 ppc-miR-8327-3p; +MIMAT0033200 ppc-miR-8328-5p; +MIMAT0033201 ppc-miR-8328-3p; +MIMAT0033202 ppc-miR-8329-5p; +MIMAT0033203 ppc-miR-8329-3p; +MIMAT0033204 ppc-miR-8330-5p; +MIMAT0033205 ppc-miR-8330-3p; +MIMAT0033206 ppc-miR-8331-5p; +MIMAT0033207 ppc-miR-8331-3p; +MIMAT0033208 ppc-miR-8332-5p; +MIMAT0033209 ppc-miR-8332-3p; +MIMAT0033210 ppc-miR-8333-5p; +MIMAT0033211 ppc-miR-8333-3p; +MIMAT0033212 ppc-miR-8334-5p; +MIMAT0033213 ppc-miR-8334-3p; +MIMAT0033214 ppc-miR-8335-5p; +MIMAT0033215 ppc-miR-8335-3p; +MIMAT0033216 ppc-miR-8364i-5p; +MIMAT0033217 ppc-miR-8364i-3p; +MIMAT0033218 ppc-miR-8336-5p; +MIMAT0033219 ppc-miR-8336-3p; +MIMAT0033220 ppc-miR-8337-5p; +MIMAT0033221 ppc-miR-8337-3p; +MIMAT0033222 ppc-miR-8338-2-3p; +MIMAT0033223 ppc-miR-8339-5p; +MIMAT0033224 ppc-miR-8339-3p; +MIMAT0033225 ppc-miR-8340-5p; +MIMAT0033226 ppc-miR-8340-3p; +MIMAT0033227 ppc-miR-8341-5p; +MIMAT0033228 ppc-miR-8341-3p; +MIMAT0033229 ppc-miR-8342-5p; +MIMAT0033230 ppc-miR-8342-3p; +MIMAT0033231 ppc-miR-8343-5p; +MIMAT0033232 ppc-miR-8343-3p; +MIMAT0033233 ppc-miR-2235a-9-3p; +MIMAT0033234 ppc-miR-8344-5p; +MIMAT0033235 ppc-miR-8344-3p; +MIMAT0033236 ppc-miR-8345-5p; +MIMAT0033237 ppc-miR-8345-3p; +MIMAT0033238 ppc-miR-8346-5p; +MIMAT0033239 ppc-miR-8346-3p; +MIMAT0033240 ppc-miR-8286b-5p; +MIMAT0033241 ppc-miR-8286b-3p; +MIMAT0033242 ppc-miR-8347-5p; +MIMAT0033243 ppc-miR-8347-3p; +MIMAT0033244 ppc-miR-8348-5p; +MIMAT0033245 ppc-miR-8348-3p; +MIMAT0033246 ppc-miR-8349-5p; +MIMAT0033247 ppc-miR-8349-3p; +MIMAT0033248 ppc-miR-8218b-5p; +MIMAT0033249 ppc-miR-8218b-3p; +MIMAT0033250 ppc-miR-8282b-5p; +MIMAT0033251 ppc-miR-8282b-3p; +MIMAT0033252 ppc-miR-8350-5p; +MIMAT0033253 ppc-miR-8350-3p; +MIMAT0033254 ppc-miR-8351-5p; +MIMAT0033255 ppc-miR-8351-3p; +MIMAT0033256 ppc-miR-8352-5p; +MIMAT0033257 ppc-miR-8352-3p; +MIMAT0033258 ppc-miR-8282c-5p; +MIMAT0033259 ppc-miR-8282c-3p; +MIMAT0033260 ppc-miR-8364e-5p; +MIMAT0033261 ppc-miR-8364e-3p; +MIMAT0033262 ppc-miR-8364r-5p; +MIMAT0033263 ppc-miR-8364r-3p; +MIMAT0033264 ppc-miR-8364l-5p; +MIMAT0033265 ppc-miR-8364l-3p; +MIMAT0033266 ppc-miR-8353-5p; +MIMAT0033267 ppc-miR-8353-3p; +MIMAT0033268 ppc-miR-8354-5p; +MIMAT0033269 ppc-miR-8354-3p; +MIMAT0033270 ppc-miR-8364s-5p; +MIMAT0033271 ppc-miR-8364s-3p; +MIMAT0033272 ppc-miR-8355-5p; +MIMAT0033273 ppc-miR-8355-3p; +MIMAT0033274 ppc-miR-8356a-5p; +MIMAT0033275 ppc-miR-8356a-3p; +MIMAT0033276 ppc-miR-8357-5p; +MIMAT0033277 ppc-miR-8357-3p; +MIMAT0033278 ppc-miR-8358-5p; +MIMAT0033279 ppc-miR-8358-3p; +MIMAT0033280 ppc-miR-8359-5p; +MIMAT0033281 ppc-miR-8359-3p; +MIMAT0033282 ppc-miR-8360-5p; +MIMAT0033283 ppc-miR-8360-3p; +MIMAT0033284 ppc-miR-8364t-5p; +MIMAT0033285 ppc-miR-8364t-3p; +MIMAT0033286 ppc-miR-84f-5p; +MIMAT0033287 ppc-miR-84f-3p; +MIMAT0033288 ppc-miR-8361-5p; +MIMAT0033289 ppc-miR-8361-3p; +MIMAT0033290 ppc-miR-8362-5p; +MIMAT0033291 ppc-miR-8362-3p; +MIMAT0033292 ppc-miR-8363-5p; +MIMAT0033293 ppc-miR-8363-3p; +MIMAT0033294 ppc-miR-8252b-5p; +MIMAT0033295 ppc-miR-8252b-3p; +MIMAT0033296 str-miR-1-5p; +MIMAT0033297 str-miR-1-3p; +MIMAT0033298 str-miR-7880a-5p; +MIMAT0033299 str-miR-7880a-3p; +MIMAT0033300 str-miR-50-5p; +MIMAT0033301 str-miR-50-3p; +MIMAT0033302 str-miR-8365-5p; +MIMAT0033303 str-miR-8365-3p; +MIMAT0033304 str-miR-7880b-1-5p; +MIMAT0033305 str-miR-7880b-3p; +MIMAT0033306 str-miR-8366a-5p; +MIMAT0033307 str-miR-8366a-3p; +MIMAT0033308 str-miR-7880b-2-5p; +MIMAT0033309 str-miR-7880b-3-5p; +MIMAT0033310 str-miR-7880b-4-5p; +MIMAT0033311 str-miR-7880c-5p; +MIMAT0033312 str-miR-7880c-3p; +MIMAT0033313 str-bantam-5p; +MIMAT0033314 str-bantam-3p; +MIMAT0033315 str-miR-7880d-5p; +MIMAT0033316 str-miR-7880d-3p; +MIMAT0033317 str-miR-71-5p; +MIMAT0033318 str-miR-71-3p; +MIMAT0033319 str-miR-7880e-5p; +MIMAT0033320 str-miR-7880e-3p; +MIMAT0033321 str-miR-7880f-5p; +MIMAT0033322 str-miR-7880f-3p; +MIMAT0033323 str-miR-7880g-5p; +MIMAT0033324 str-miR-7880g-3p; +MIMAT0033325 str-miR-252a-5p; +MIMAT0033326 str-miR-252a-3p; +MIMAT0033327 str-miR-7880h-5p; +MIMAT0033328 str-miR-7880h-3p; +MIMAT0033329 str-miR-7880i-5p; +MIMAT0033330 str-miR-7880i-3p; +MIMAT0033331 str-miR-81a-5p; +MIMAT0033332 str-miR-81a-3p; +MIMAT0033333 str-miR-8367-5p; +MIMAT0033334 str-miR-8367-3p; +MIMAT0033335 str-miR-7880e-2-5p; +MIMAT0033336 str-lin-4-5p; +MIMAT0033337 str-lin-4-3p; +MIMAT0033338 str-miR-8368-5p; +MIMAT0033339 str-miR-8368-3p; +MIMAT0033340 str-miR-236-5p; +MIMAT0033341 str-miR-236-3p; +MIMAT0033342 str-miR-81b-5p; +MIMAT0033343 str-miR-81b-3p; +MIMAT0033344 str-miR-81c-5p; +MIMAT0033345 str-miR-81c-3p; +MIMAT0033346 str-miR-72-5p; +MIMAT0033347 str-miR-72-3p; +MIMAT0033348 str-miR-8369-5p; +MIMAT0033349 str-miR-8369-3p; +MIMAT0033350 str-miR-7880j-5p; +MIMAT0033351 str-miR-7880j-3p; +MIMAT0033352 str-miR-5359-5p; +MIMAT0033353 str-miR-5359-3p; +MIMAT0033354 str-miR-86-5p; +MIMAT0033355 str-miR-86-3p; +MIMAT0033356 str-miR-92-5p; +MIMAT0033357 str-miR-92-3p; +MIMAT0033358 str-miR-7880k-5p; +MIMAT0033359 str-miR-7880k-3p; +MIMAT0033360 str-miR-8370-5p; +MIMAT0033361 str-miR-8370-3p; +MIMAT0033362 str-miR-7880l-5p; +MIMAT0033363 str-miR-7880l-3p; +MIMAT0033364 str-miR-7880m-5p; +MIMAT0033365 str-miR-7880m-3p; +MIMAT0033366 str-miR-8371-5p; +MIMAT0033367 str-miR-8371-3p; +MIMAT0033368 str-miR-7880n-5p; +MIMAT0033369 str-miR-7880n-3p; +MIMAT0033370 str-miR-252b-5p; +MIMAT0033371 str-miR-252b-3p; +MIMAT0033372 str-miR-7880o-5p; +MIMAT0033373 str-miR-7880o-3p; +MIMAT0033374 str-miR-7880p-5p; +MIMAT0033375 str-miR-7880p-3p; +MIMAT0033376 str-miR-1175-5p; +MIMAT0033377 str-miR-1175-3p; +MIMAT0033378 str-miR-7880q-5p; +MIMAT0033379 str-miR-7880q-3p; +MIMAT0033380 str-miR-8372-5p; +MIMAT0033381 str-miR-8372-3p; +MIMAT0033382 str-miR-8373-5p; +MIMAT0033383 str-miR-8373-3p; +MIMAT0033384 str-miR-8366b-5p; +MIMAT0033385 str-miR-8366b-3p; +MIMAT0033386 str-miR-7880r-5p; +MIMAT0033387 str-miR-7880r-3p; +MIMAT0033388 str-miR-7880s-5p; +MIMAT0033389 str-miR-7880s-3p; +MIMAT0033390 str-miR-8374-5p; +MIMAT0033391 str-miR-8374-3p; +MIMAT0033392 str-miR-8375-5p; +MIMAT0033393 str-miR-8375-3p; +MIMAT0033394 str-miR-8376-5p; +MIMAT0033395 str-miR-8376-3p; +MIMAT0033396 str-miR-7880t-5p; +MIMAT0033397 str-miR-7880t-3p; +MIMAT0033398 str-miR-9-5p; +MIMAT0033399 str-miR-9-3p; +MIMAT0033400 str-miR-8377-5p; +MIMAT0033401 str-miR-8377-3p; +MIMAT0033402 str-miR-87a-5p; +MIMAT0033403 str-miR-87a-3p; +MIMAT0033404 str-miR-47-5p; +MIMAT0033405 str-miR-47-3p; +MIMAT0033406 str-miR-7880u-5p; +MIMAT0033407 str-miR-7880u-3p; +MIMAT0033408 str-miR-8378-5p; +MIMAT0033409 str-miR-8378-3p; +MIMAT0033410 str-miR-84-5p; +MIMAT0033411 str-miR-84-3p; +MIMAT0033412 str-miR-8379a-5p; +MIMAT0033413 str-miR-8379a-3p; +MIMAT0033414 str-miR-76-5p; +MIMAT0033415 str-miR-76-3p; +MIMAT0033416 str-miR-8380-5p; +MIMAT0033417 str-miR-8380-3p; +MIMAT0033418 str-miR-8381-5p; +MIMAT0033419 str-miR-8381-3p; +MIMAT0033420 str-miR-8382-5p; +MIMAT0033421 str-miR-8382-3p; +MIMAT0033422 str-miR-7880v-5p; +MIMAT0033423 str-miR-7880v-3p; +MIMAT0033424 str-miR-8383-5p; +MIMAT0033425 str-miR-8383-3p; +MIMAT0033426 str-miR-7880w-5p; +MIMAT0033427 str-miR-7880w-3p; +MIMAT0033428 str-miR-8384-5p; +MIMAT0033429 str-miR-8384-3p; +MIMAT0033430 str-miR-8385-5p; +MIMAT0033431 str-miR-8385-3p; +MIMAT0033432 str-miR-8386-5p; +MIMAT0033433 str-miR-8386-3p; +MIMAT0033434 str-miR-8387-5p; +MIMAT0033435 str-miR-8387-3p; +MIMAT0033436 str-miR-40-5p; +MIMAT0033437 str-miR-40-3p; +MIMAT0033438 str-miR-124-5p; +MIMAT0033439 str-miR-124-3p; +MIMAT0033440 str-miR-184-5p; +MIMAT0033441 str-miR-184-3p; +MIMAT0033442 str-miR-8388-5p; +MIMAT0033443 str-miR-8388-3p; +MIMAT0033444 str-miR-8389-5p; +MIMAT0033445 str-miR-8389-3p; +MIMAT0033446 str-miR-240-5p; +MIMAT0033447 str-miR-240-3p; +MIMAT0033448 str-miR-8390-5p; +MIMAT0033449 str-miR-8390-3p; +MIMAT0033450 str-miR-8391-5p; +MIMAT0033451 str-miR-8391-3p; +MIMAT0033452 str-miR-8392-5p; +MIMAT0033453 str-miR-8392-3p; +MIMAT0033454 str-miR-37a-5p; +MIMAT0033455 str-miR-37a-3p; +MIMAT0033456 str-miR-255-5p; +MIMAT0033457 str-miR-255-3p; +MIMAT0033458 str-miR-8393-5p; +MIMAT0033459 str-miR-8393-3p; +MIMAT0033460 str-miR-360-5p; +MIMAT0033461 str-miR-360-3p; +MIMAT0033462 str-miR-8394-5p; +MIMAT0033463 str-miR-8394-3p; +MIMAT0033464 str-miR-58-5p; +MIMAT0033465 str-miR-58-3p; +MIMAT0033466 str-miR-37b-5p; +MIMAT0033467 str-miR-37b-3p; +MIMAT0033468 str-miR-8379b-3p; +MIMAT0033469 str-miR-8379b-5p; +MIMAT0033470 str-miR-279-5p; +MIMAT0033471 str-miR-279-3p; +MIMAT0033472 str-miR-87b-5p; +MIMAT0033473 str-miR-87b-3p; +MIMAT0033474 str-miR-2-5p; +MIMAT0033475 str-miR-2-3p; +MIMAT0033476 str-miR-234-5p; +MIMAT0033477 str-miR-234-3p; +MIMAT0033478 str-miR-7880x-5p; +MIMAT0033479 str-miR-7880x-3p; +MIMAT0033480 str-miR-8395-5p; +MIMAT0033481 str-miR-8395-3p; +MIMAT0033482 str-miR-8396-5p; +MIMAT0033483 str-miR-8396-3p; +MIMAT0033484 str-miR-34a-5p; +MIMAT0033485 str-miR-34a-3p; +MIMAT0033486 str-miR-34b-5p; +MIMAT0033487 str-miR-34b-3p; +MIMAT0033488 str-miR-8397-5p; +MIMAT0033489 str-miR-8397-3p; +MIMAT0033490 str-miR-8398-5p; +MIMAT0033491 str-miR-8398-3p; +MIMAT0033492 str-miR-8399-5p; +MIMAT0033493 str-miR-8399-3p; +MIMAT0033494 str-miR-8400-5p; +MIMAT0033495 str-miR-8400-3p; +MIMAT0033496 str-miR-8401-5p; +MIMAT0033497 str-miR-8401-3p; +MIMAT0033498 str-miR-7880y-5p; +MIMAT0033499 str-miR-7880y-3p; +MIMAT0033500 str-miR-8402-5p; +MIMAT0033501 str-miR-8402-3p; +MIMAT0033502 str-miR-34c-5p; +MIMAT0033503 str-miR-34c-3p; +MIMAT0033504 sma-miR-219-5p; +MIMAT0033505 sma-miR-219-3p; +MIMAT0033506 sma-miR-8403-5p; +MIMAT0033507 sma-miR-8403-3p; +MIMAT0033508 sma-miR-8404-5p; +MIMAT0033509 sma-miR-8404-3p; +MIMAT0033510 sma-miR-125c-5p; +MIMAT0033511 sma-miR-125c-3p; +MIMAT0033512 sma-miR-8405-5p; +MIMAT0033513 sma-miR-8405-3p; +MIMAT0033514 sma-miR-36b-5p; +MIMAT0033515 sma-miR-36b-3p; +MIMAT0033516 sma-miR-8406-5p; +MIMAT0033517 sma-miR-8406-3p; +MIMAT0033518 sma-miR-8407-5p; +MIMAT0033519 sma-miR-8407-3p; +MIMAT0033520 sma-miR-8408-5p; +MIMAT0033521 sma-miR-8408-3p; +MIMAT0033522 sma-miR-8409-5p; +MIMAT0033523 sma-miR-8409-3p; +MIMAT0033524 sma-miR-8410-5p; +MIMAT0033525 sma-miR-8410-3p; +MIMAT0033526 sma-miR-8411-5p; +MIMAT0033527 sma-miR-8411-3p; +MIMAT0033528 sma-miR-8412-5p; +MIMAT0033529 sma-miR-8412-3p; +MIMAT0033530 sma-miR-8413-5p; +MIMAT0033531 sma-miR-8413-3p; +MIMAT0033532 sma-miR-8414-5p; +MIMAT0033533 sma-miR-8414-3p; +MIMAT0033534 sma-miR-8415-5p; +MIMAT0033535 sma-miR-8415-3p; +MIMAT0033536 sma-miR-8416-5p; +MIMAT0033537 sma-miR-8416-3p; +MIMAT0033538 sma-miR-8417-5p; +MIMAT0033539 sma-miR-8417-3p; +MIMAT0033540 sma-miR-8418-5p; +MIMAT0033541 sma-miR-8418-3p; +MIMAT0033542 sma-miR-8419-5p; +MIMAT0033543 sma-miR-8419-3p; +MIMAT0033544 sma-miR-8420-5p; +MIMAT0033545 sma-miR-8420-3p; +MIMAT0033546 sma-miR-8421-5p; +MIMAT0033547 sma-miR-8421-3p; +MIMAT0033548 sma-miR-8422-5p; +MIMAT0033549 sma-miR-8422-3p; +MIMAT0033550 sma-miR-8423-5p; +MIMAT0033551 sma-miR-8423-3p; +MIMAT0033552 sma-miR-8424-5p; +MIMAT0033553 sma-miR-8424-3p; +MIMAT0033554 sma-miR-8425-5p; +MIMAT0033555 sma-miR-8425-3p; +MIMAT0033556 sma-miR-8426-5p; +MIMAT0033557 sma-miR-8426-3p; +MIMAT0033558 sma-miR-8427-5p; +MIMAT0033559 sma-miR-8427-3p; +MIMAT0033560 sma-miR-8428-5p; +MIMAT0033561 sma-miR-8428-3p; +MIMAT0033562 sma-miR-8429-5p; +MIMAT0033563 sma-miR-8429-3p; +MIMAT0033564 sma-miR-8430-5p; +MIMAT0033565 sma-miR-8430-3p; +MIMAT0033566 sma-miR-8431-5p; +MIMAT0033567 sma-miR-8431-3p; +MIMAT0033568 sma-miR-8432-5p; +MIMAT0033569 sma-miR-8432-3p; +MIMAT0033570 sma-miR-8433-5p; +MIMAT0033571 sma-miR-8433-3p; +MIMAT0033572 sma-miR-8434-5p; +MIMAT0033573 sma-miR-8434-3p; +MIMAT0033574 sma-miR-8435-5p; +MIMAT0033575 sma-miR-8435-3p; +MIMAT0033576 sma-miR-8436-5p; +MIMAT0033577 sma-miR-8436-3p; +MIMAT0033578 sma-miR-8437-5p; +MIMAT0033579 sma-miR-8437-3p; +MIMAT0033580 sma-miR-8438-5p; +MIMAT0033581 sma-miR-8438-3p; +MIMAT0033582 sma-miR-8439-5p; +MIMAT0033583 sma-miR-8439-3p; +MIMAT0033584 sma-miR-8440-5p; +MIMAT0033585 sma-miR-8440-3p; +MIMAT0033586 sma-miR-8441-5p; +MIMAT0033587 sma-miR-8441-3p; +MIMAT0033588 sma-miR-745-5p; +MIMAT0033589 sma-miR-745-3p; +MIMAT0033590 sma-miR-8442-5p; +MIMAT0033591 sma-miR-8442-3p; +MIMAT0033592 sma-miR-281-5p; +MIMAT0033593 sma-miR-281-3p; +MIMAT0033594 sma-miR-8443-5p; +MIMAT0033595 sma-miR-8443-3p; +MIMAT0033596 sma-miR-8444-5p; +MIMAT0033597 sma-miR-8444-3p; +MIMAT0033598 sma-miR-7-5p; +MIMAT0033599 sma-miR-7-3p; +MIMAT0033600 sma-miR-8445-5p; +MIMAT0033601 sma-miR-8445-3p; +MIMAT0033602 sma-miR-8446-5p; +MIMAT0033603 sma-miR-8446-3p; +MIMAT0033604 sma-miR-8447-5p; +MIMAT0033605 sma-miR-8447-3p; +MIMAT0033606 sma-miR-8448-5p; +MIMAT0033607 sma-miR-8448-3p; +MIMAT0033608 sma-miR-8449-5p; +MIMAT0033609 sma-miR-8449-3p; +MIMAT0033610 sma-miR-8450-5p; +MIMAT0033611 sma-miR-8450-3p; +MIMAT0033612 sma-miR-8451-5p; +MIMAT0033613 sma-miR-8451-3p; +MIMAT0033614 sma-miR-8452-5p; +MIMAT0033615 sma-miR-8452-3p; +MIMAT0033616 sma-miR-8453-5p; +MIMAT0033617 sma-miR-8453-3p; +MIMAT0033618 sma-miR-124b-5p; +MIMAT0033619 sma-miR-124b-3p; +MIMAT0033620 sma-miR-8454-5p; +MIMAT0033621 sma-miR-8454-3p; +MIMAT0033622 sma-miR-8455-5p; +MIMAT0033623 sma-miR-8455-3p; +MIMAT0033624 sma-miR-8456-5p; +MIMAT0033625 sma-miR-8456-3p; +MIMAT0033626 sma-miR-8457-5p; +MIMAT0033627 sma-miR-8457-3p; +MIMAT0033628 sma-miR-8458-5p; +MIMAT0033629 sma-miR-8458-3p; +MIMAT0033630 sma-miR-1a-5p; +MIMAT0033631 sma-miR-755-5p; +MIMAT0033632 sma-miR-755-3p; +MIMAT0033633 sma-miR-8459-5p; +MIMAT0033634 sma-miR-8459-3p; +MIMAT0033635 sma-miR-96-5p; +MIMAT0033636 sma-miR-96-3p; +MIMAT0033637 sma-miR-8460-5p; +MIMAT0033638 sma-miR-8460-3p; +MIMAT0033639 sma-miR-8461-5p; +MIMAT0033640 sma-miR-8461-3p; +MIMAT0033641 sma-miR-1b-5p; +MIMAT0033642 sma-miR-1b-3p; +MIMAT0033643 sma-miR-8462-5p; +MIMAT0033644 sma-miR-8462-3p; +MIMAT0033645 sma-miR-8463-5p; +MIMAT0033646 sma-miR-8463-3p; +MIMAT0033647 sma-miR-8464-5p; +MIMAT0033648 sma-miR-8464-3p; +MIMAT0033649 sma-miR-8465-5p; +MIMAT0033650 sma-miR-8465-3p; +MIMAT0033651 sma-miR-8466-5p; +MIMAT0033652 sma-miR-8466-3p; +MIMAT0033653 sma-miR-8467-5p; +MIMAT0033654 sma-miR-8467-3p; +MIMAT0033655 sma-miR-8468-5p; +MIMAT0033656 sma-miR-8468-3p; +MIMAT0033657 sma-miR-8469-5p; +MIMAT0033658 sma-miR-8469-3p; +MIMAT0033659 sma-miR-8470-5p; +MIMAT0033660 sma-miR-8470-3p; +MIMAT0033661 sma-miR-8471-5p; +MIMAT0033662 sma-miR-8471-3p; +MIMAT0033663 sma-miR-8472-5p; +MIMAT0033664 sma-miR-8472-3p; +MIMAT0033665 sma-miR-2162-5p; +MIMAT0033666 sma-miR-2162-3p; +MIMAT0033667 sma-miR-8473-5p; +MIMAT0033668 sma-miR-8473-3p; +MIMAT0033669 sma-miR-8474-5p; +MIMAT0033670 sma-miR-8474-3p; +MIMAT0033671 sma-miR-8475-5p; +MIMAT0033672 sma-miR-8475-3p; +MIMAT0033673 sma-miR-8476-5p; +MIMAT0033674 sma-miR-8476-3p; +MIMAT0033675 sma-miR-8477-5p; +MIMAT0033676 sma-miR-8477-3p; +MIMAT0033677 sma-miR-8478-5p; +MIMAT0033678 sma-miR-8478-3p; +MIMAT0033679 sma-miR-8479-5p; +MIMAT0033680 sma-miR-8479-3p; +MIMAT0033681 sma-miR-8480-5p; +MIMAT0033682 sma-miR-8480-3p; +MIMAT0033683 sma-miR-8481-5p; +MIMAT0033684 sma-miR-8481-3p; +MIMAT0033685 sma-miR-8482-5p; +MIMAT0033686 sma-miR-8482-3p; +MIMAT0033687 sma-miR-8483-5p; +MIMAT0033688 sma-miR-8483-3p; +MIMAT0033689 sma-miR-8484-5p; +MIMAT0033690 sma-miR-8484-3p; +MIMAT0033691 sma-miR-2f-3p; +MIMAT0033692 hsa-miR-8485; +MIMAT0033693 pxy-miR-8486; +MIMAT0033694 pxy-miR-8487; +MIMAT0033695 pxy-miR-8488; +MIMAT0033696 pxy-miR-8489a-5p; +MIMAT0033697 pxy-miR-8489a-3p; +MIMAT0033698 pxy-miR-8490; +MIMAT0033699 pxy-miR-8491; +MIMAT0033700 pxy-miR-8492; +MIMAT0033701 pxy-miR-8493; +MIMAT0033702 pxy-miR-8494-5p; +MIMAT0033703 pxy-miR-8494-3p; +MIMAT0033704 pxy-miR-8495-5p; +MIMAT0033705 pxy-miR-8495-3p; +MIMAT0033706 pxy-miR-8496; +MIMAT0033707 pxy-miR-8497; +MIMAT0033708 pxy-miR-8498; +MIMAT0033709 pxy-miR-8499a; +MIMAT0033710 pxy-miR-8499b; +MIMAT0033711 pxy-miR-8499c; +MIMAT0033712 pxy-miR-8501; +MIMAT0033713 pxy-miR-252; +MIMAT0033714 pxy-miR-8502; +MIMAT0033715 pxy-miR-8503; +MIMAT0033716 pxy-miR-8504; +MIMAT0033717 pxy-miR-2a-5p; +MIMAT0033718 pxy-miR-2a-3p; +MIMAT0033719 pxy-miR-965; +MIMAT0033720 pxy-miR-8505; +MIMAT0033721 pxy-miR-8537a;pxy-miR-8537-5p; +MIMAT0033722 pxy-miR-8506; +MIMAT0033723 pxy-miR-308; +MIMAT0033724 pxy-miR-8507-5p; +MIMAT0033725 pxy-miR-8507-3p; +MIMAT0033726 pxy-bantam; +MIMAT0033727 pxy-miR-184; +MIMAT0033728 pxy-miR-8508; +MIMAT0033729 pxy-miR-2733a; +MIMAT0033730 pxy-miR-7b; +MIMAT0033731 pxy-miR-8509; +MIMAT0033732 pxy-miR-8510a-5p; +MIMAT0033733 pxy-miR-8510a-3p; +MIMAT0033734 pxy-miR-8510b-5p; +MIMAT0033735 pxy-miR-8510b-3p; +MIMAT0033736 pxy-miR-750; +MIMAT0033737 pxy-miR-8512; +MIMAT0033738 pxy-miR-263; +MIMAT0033739 pxy-miR-8511; +MIMAT0033740 pxy-miR-2733b-5p; +MIMAT0033741 pxy-miR-2733b-3p; +MIMAT0033742 pxy-miR-8515; +MIMAT0033743 pxy-miR-8517a; +MIMAT0033744 pxy-miR-8513-5p; +MIMAT0033745 pxy-miR-8513-3p; +MIMAT0033746 pxy-miR-8514-5p; +MIMAT0033747 pxy-miR-8514-3p; +MIMAT0033748 pxy-miR-8528a; +MIMAT0033749 pxy-miR-2756; +MIMAT0033750 pxy-miR-929; +MIMAT0033751 pxy-miR-8521b; +MIMAT0033752 pxy-miR-8521a; +MIMAT0033753 pxy-miR-8516; +MIMAT0033754 pxy-miR-8517b; +MIMAT0033755 pxy-miR-279a; +MIMAT0033756 pxy-miR-8518; +MIMAT0033757 pxy-miR-8519; +MIMAT0033758 pxy-miR-8520-5p; +MIMAT0033759 pxy-miR-8520-3p; +MIMAT0033760 pxy-miR-8500; +MIMAT0033761 pxy-miR-6497; +MIMAT0033762 pxy-miR-7a; +MIMAT0033763 pxy-miR-8522; +MIMAT0033764 pxy-miR-8523; +MIMAT0033765 pxy-miR-8524-5p; +MIMAT0033766 pxy-miR-8524-3p; +MIMAT0033767 pxy-miR-8525; +MIMAT0033768 pxy-miR-8526; +MIMAT0033769 pxy-miR-8527; +MIMAT0033770 pxy-miR-8528b; +MIMAT0033771 pxy-miR-8529; +MIMAT0033772 pxy-miR-8530-5p; +MIMAT0033773 pxy-miR-8530-3p; +MIMAT0033774 pxy-miR-8531; +MIMAT0033775 pxy-miR-8489b; +MIMAT0033776 pxy-miR-9a; +MIMAT0033777 pxy-miR-8532-5p; +MIMAT0033778 pxy-miR-8532-3p; +MIMAT0033779 pxy-miR-8533; +MIMAT0033780 pxy-miR-8534-5p; +MIMAT0033781 pxy-miR-8534-3p; +MIMAT0033782 pxy-miR-193; +MIMAT0033783 pxy-miR-8535-5p; +MIMAT0033784 pxy-miR-8535-3p; +MIMAT0033785 pxy-miR-277; +MIMAT0033786 pxy-miR-283; +MIMAT0033787 pxy-miR-306; +MIMAT0033788 pxy-miR-3286; +MIMAT0033789 pxy-miR-8536b-5p; +MIMAT0033790 pxy-miR-8536b-3p; +MIMAT0033791 pxy-miR-8537b-5p; +MIMAT0033792 pxy-miR-8537b-3p;pxy-miR-8537-3p; +MIMAT0033793 pxy-miR-10-5p; +MIMAT0033794 pxy-miR-10-3p; +MIMAT0033795 pxy-miR-8538; +MIMAT0033796 pxy-miR-8539-5p; +MIMAT0033797 pxy-miR-8539-3p; +MIMAT0033798 pxy-miR-8540; +MIMAT0033799 pxy-miR-6307; +MIMAT0033800 pxy-miR-8541; +MIMAT0033801 pxy-miR-745; +MIMAT0033802 pxy-miR-8510a-8-3p; +MIMAT0033803 pxy-miR-2b; +MIMAT0033804 pxy-miR-281; +MIMAT0033805 pxy-miR-8542; +MIMAT0033806 pxy-miR-8543; +MIMAT0033807 pxy-miR-9b-5p; +MIMAT0033808 pxy-miR-9b-3p; +MIMAT0033809 pxy-miR-2525-5p; +MIMAT0033810 pxy-miR-2525-3p; +MIMAT0033811 pxy-miR-8544-5p; +MIMAT0033812 pxy-miR-8544-3p; +MIMAT0033813 pxy-miR-8545; +MIMAT0033814 pxy-miR-274; +MIMAT0033815 pxy-miR-8546; +MIMAT0033816 pxy-miR-8536a; +MIMAT0033817 pxy-miR-8547; +MIMAT0033818 pxy-miR-2767; +MIMAT0033819 pxy-miR-279b-5p; +MIMAT0033820 pxy-miR-279b-3p; +MIMAT0033821 bta-miR-8550; +MIMAT0033822 atr-miR8551; +MIMAT0033823 atr-miR8552a; +MIMAT0033824 atr-miR8553a; +MIMAT0033825 atr-miR8554; +MIMAT0033826 atr-miR8555; +MIMAT0033827 atr-miR8556; +MIMAT0033828 atr-miR8553b; +MIMAT0033829 atr-miR8557; +MIMAT0033830 atr-miR8558a; +MIMAT0033831 atr-miR8559; +MIMAT0033832 atr-miR8617; +MIMAT0033833 atr-miR8560; +MIMAT0033834 atr-miR8561.1; +MIMAT0033835 atr-miR8561.2; +MIMAT0033836 atr-miR8562a; +MIMAT0033837 atr-miR8562b; +MIMAT0033838 atr-miR8562c; +MIMAT0033839 atr-miR8563; +MIMAT0033840 atr-miR8564; +MIMAT0033841 atr-miR8565g; +MIMAT0033842 atr-miR8566; +MIMAT0033843 atr-miR8567; +MIMAT0033844 atr-miR8568; +MIMAT0033845 atr-miR8569; +MIMAT0033846 atr-miR8565a; +MIMAT0033847 atr-miR8565b; +MIMAT0033848 atr-miR8565c; +MIMAT0033849 atr-miR8565d; +MIMAT0033850 atr-miR8565e; +MIMAT0033851 atr-miR8565f; +MIMAT0033852 atr-miR8570; +MIMAT0033853 atr-miR8571; +MIMAT0033854 atr-miR8552b; +MIMAT0033855 atr-miR8572; +MIMAT0033856 atr-miR8573; +MIMAT0033857 atr-miR8574; +MIMAT0033858 atr-miR8575; +MIMAT0033859 atr-miR8576; +MIMAT0033860 atr-miR8577; +MIMAT0033861 atr-miR8578.1; +MIMAT0033862 atr-miR8578.2; +MIMAT0033863 atr-miR8579; +MIMAT0033864 atr-miR8580; +MIMAT0033865 atr-miR8581; +MIMAT0033866 atr-miR8552c; +MIMAT0033867 atr-miR8582; +MIMAT0033868 atr-miR8583; +MIMAT0033869 atr-miR8584; +MIMAT0033870 atr-miR8552d; +MIMAT0033871 atr-miR8585; +MIMAT0033872 atr-miR8586; +MIMAT0033873 atr-miR8616; +MIMAT0033874 atr-miR8587; +MIMAT0033875 atr-miR8588; +MIMAT0033876 atr-miR8589; +MIMAT0033877 atr-miR8590; +MIMAT0033878 atr-miR8591; +MIMAT0033879 atr-miR8592; +MIMAT0033880 atr-miR8593; +MIMAT0033881 atr-miR8565h; +MIMAT0033882 atr-miR8594.1; +MIMAT0033883 atr-miR8594.2; +MIMAT0033884 atr-miR8595; +MIMAT0033885 atr-miR8596; +MIMAT0033886 atr-miR8597; +MIMAT0033887 atr-miR8598; +MIMAT0033888 atr-miR8599; +MIMAT0033889 atr-miR8600; +MIMAT0033890 atr-miR8601; +MIMAT0033891 atr-miR8602; +MIMAT0033892 atr-miR8603; +MIMAT0033893 atr-miR8604; +MIMAT0033894 atr-miR8605; +MIMAT0033895 atr-miR8606; +MIMAT0033896 atr-miR8607; +MIMAT0033897 atr-miR2111; +MIMAT0033899 atr-miR8608; +MIMAT0033900 atr-miR8609; +MIMAT0033901 atr-miR8610.1; +MIMAT0033902 atr-miR8610.2; +MIMAT0033903 atr-miR8611; +MIMAT0033904 atr-miR8612; +MIMAT0033905 atr-miR8613; +MIMAT0033906 atr-miR8614; +MIMAT0033907 atr-miR156a; +MIMAT0033908 atr-miR156b; +MIMAT0033909 atr-miR156c; +MIMAT0033910 atr-miR156d; +MIMAT0033911 atr-miR159; +MIMAT0033912 atr-miR160; +MIMAT0033913 atr-miR164a; +MIMAT0033914 atr-miR164b; +MIMAT0033915 atr-miR166a; +MIMAT0033916 atr-miR166b; +MIMAT0033917 atr-miR166c; +MIMAT0033918 atr-miR166d; +MIMAT0033919 atr-miR167; +MIMAT0033920 atr-miR168; +MIMAT0033921 atr-miR169a; +MIMAT0033922 atr-miR169b; +MIMAT0033923 atr-miR169c; +MIMAT0033924 atr-miR171a; +MIMAT0033925 atr-miR171b; +MIMAT0033926 atr-miR171c; +MIMAT0033927 atr-miR172; +MIMAT0033928 atr-miR319a; +MIMAT0033929 atr-miR319b; +MIMAT0033930 atr-miR319c; +MIMAT0033931 atr-miR319d; +MIMAT0033932 atr-miR319e; +MIMAT0033933 atr-miR390.1; +MIMAT0033934 atr-miR390.2; +MIMAT0033935 atr-miR393; +MIMAT0033936 atr-miR394; +MIMAT0033937 atr-miR395; +MIMAT0033938 atr-miR396a; +MIMAT0033939 atr-miR396b; +MIMAT0033940 atr-miR396c; +MIMAT0033941 atr-miR396d; +MIMAT0033942 atr-miR396e; +MIMAT0033943 atr-miR397a; +MIMAT0033944 atr-miR397b; +MIMAT0033945 atr-miR398; +MIMAT0033946 atr-miR477; +MIMAT0033947 atr-miR535; +MIMAT0033948 atr-miR828; +MIMAT0033949 atr-miR8558b; +MIMAT0033950 atr-miR8615; +MIMAT0033951 atr-miR2950; +MIMAT0033952 esi-miR8618a; +MIMAT0033953 esi-miR8618b; +MIMAT0033954 esi-miR8619; +MIMAT0033955 esi-miR8620; +MIMAT0033956 esi-miR8621; +MIMAT0033957 esi-miR8622a; +MIMAT0033958 esi-miR8623c; +MIMAT0033959 esi-miR8622b; +MIMAT0033960 esi-miR8623a; +MIMAT0033961 esi-miR8624a; +MIMAT0033962 esi-miR8625; +MIMAT0033963 esi-miR8622c; +MIMAT0033964 esi-miR8626; +MIMAT0033965 esi-miR8627; +MIMAT0033966 esi-miR8628; +MIMAT0033967 esi-miR8629; +MIMAT0033968 esi-miR8623d; +MIMAT0033969 esi-miR8630; +MIMAT0033970 esi-miR8631; +MIMAT0033971 esi-miR8624b; +MIMAT0033972 esi-miR8623b; +MIMAT0033973 sly-miR164a-5p; +MIMAT0033974 sly-miR164a-3p; +MIMAT0033975 sly-miR164b-5p; +MIMAT0033976 sly-miR164b-3p; +MIMAT0033977 gra-miR7505b; +MIMAT0033978 gra-miR8632; +MIMAT0033979 gra-miR8633; +MIMAT0033980 gra-miR3267; +MIMAT0033981 gra-miR8634; +MIMAT0033982 gra-miR3476; +MIMAT0033983 gra-miR167a; +MIMAT0033984 gra-miR167b; +MIMAT0033985 gra-miR8635; +MIMAT0033986 gra-miR8636; +MIMAT0033987 gra-miR8637; +MIMAT0033988 gra-miR172a; +MIMAT0033989 gra-miR8639a; +MIMAT0033990 gra-miR8639b; +MIMAT0033991 gra-miR8639c; +MIMAT0033992 gra-miR8639f; +MIMAT0033993 gra-miR8639g; +MIMAT0033994 gra-miR8639h; +MIMAT0033995 gra-miR8639i; +MIMAT0033996 gra-miR8640; +MIMAT0033997 gra-miR7486e; +MIMAT0033998 gra-miR8642; +MIMAT0033999 gra-miR8643a; +MIMAT0034000 gra-miR8643b; +MIMAT0034001 gra-miR8663a; +MIMAT0034002 gra-miR8644; +MIMAT0034003 gra-miR8645; +MIMAT0034004 gra-miR8646; +MIMAT0034005 gra-miR8647; +MIMAT0034006 gra-miR8648; +MIMAT0034007 gra-miR8649; +MIMAT0034008 gra-miR8650; +MIMAT0034009 gra-miR5741; +MIMAT0034010 gra-miR8651; +MIMAT0034011 gra-miR8652; +MIMAT0034012 gra-miR8653a; +MIMAT0034013 gra-miR7502b; +MIMAT0034014 gra-miR7502c; +MIMAT0034015 gra-miR8709a; +MIMAT0034016 gra-miR7492d; +MIMAT0034017 gra-miR8654a; +MIMAT0034018 gra-miR8654b; +MIMAT0034019 gra-miR8654c; +MIMAT0034020 gra-miR8655; +MIMAT0034021 gra-miR8656; +MIMAT0034022 gra-miR8657a; +MIMAT0034023 gra-miR8657c; +MIMAT0034024 gra-miR8657d; +MIMAT0034025 gra-miR8657e; +MIMAT0034026 gra-miR8658; +MIMAT0034027 gra-miR7504c; +MIMAT0034028 gra-miR8659a; +MIMAT0034029 gra-miR8659b; +MIMAT0034030 gra-miR8660; +MIMAT0034031 gra-miR8661; +MIMAT0034032 gra-miR8662; +MIMAT0034033 gra-miR8663b; +MIMAT0034034 gra-miR8664; +MIMAT0034035 gra-miR7486d; +MIMAT0034036 gra-miR8665; +MIMAT0034037 gra-miR8666; +MIMAT0034038 gra-miR8667; +MIMAT0034039 gra-miR8668; +MIMAT0034040 gra-miR8669; +MIMAT0034041 gra-miR7503b; +MIMAT0034042 gra-miR1446; +MIMAT0034043 gra-miR8671; +MIMAT0034044 gra-miR8672; +MIMAT0034045 gra-miR8673; +MIMAT0034046 gra-miR8675a; +MIMAT0034047 gra-miR8676; +MIMAT0034048 gra-miR8677; +MIMAT0034049 gra-miR8678; +MIMAT0034050 gra-miR8679; +MIMAT0034051 gra-miR8680; +MIMAT0034052 gra-miR8681; +MIMAT0034053 gra-miR8682; +MIMAT0034054 gra-miR8683; +MIMAT0034055 gra-miR7484c; +MIMAT0034056 gra-miR7484d; +MIMAT0034057 gra-miR8684; +MIMAT0034058 gra-miR8685; +MIMAT0034059 gra-miR8686; +MIMAT0034060 gra-miR8687; +MIMAT0034061 gra-miR8688; +MIMAT0034062 gra-miR7494b; +MIMAT0034063 gra-miR8690; +MIMAT0034064 gra-miR8691; +MIMAT0034065 gra-miR8692; +MIMAT0034066 gra-miR7504d; +MIMAT0034067 gra-miR7504e; +MIMAT0034068 gra-miR7504f; +MIMAT0034069 gra-miR7504g; +MIMAT0034070 gra-miR7504h; +MIMAT0034071 gra-miR7584e; +MIMAT0034072 gra-miR7504n; +MIMAT0034073 gra-miR8693; +MIMAT0034074 gra-miR8694a; +MIMAT0034075 gra-miR8694b; +MIMAT0034076 gra-miR8695; +MIMAT0034077 gra-miR8696; +MIMAT0034078 gra-miR8697; +MIMAT0034079 gra-miR8698; +MIMAT0034080 gra-miR8699; +MIMAT0034081 gra-miR8700; +MIMAT0034082 gra-miR8701; +MIMAT0034083 gra-miR8702; +MIMAT0034084 gra-miR8675b; +MIMAT0034085 gra-miR8675c; +MIMAT0034086 gra-miR530a; +MIMAT0034087 gra-miR530b; +MIMAT0034088 gra-miR8703a; +MIMAT0034089 gra-miR8703b; +MIMAT0034090 gra-miR8703c; +MIMAT0034091 gra-miR8705; +MIMAT0034092 gra-miR8706a; +MIMAT0034093 gra-miR8706b; +MIMAT0034094 gra-miR8707; +MIMAT0034095 gra-miR8708; +MIMAT0034096 gra-miR8709c; +MIMAT0034097 gra-miR8710a; +MIMAT0034098 gra-miR8710b; +MIMAT0034099 gra-miR8711; +MIMAT0034100 gra-miR8712; +MIMAT0034101 gra-miR7504i; +MIMAT0034102 gra-miR8713; +MIMAT0034103 gra-miR8714; +MIMAT0034104 gra-miR7494c; +MIMAT0034105 gra-miR8715; +MIMAT0034106 gra-miR8716; +MIMAT0034107 gra-miR7484e; +MIMAT0034108 gra-miR8719; +MIMAT0034109 gra-miR8720; +MIMAT0034110 gra-miR7486j; +MIMAT0034111 gra-miR8721a; +MIMAT0034112 gra-miR8721b; +MIMAT0034113 gra-miR164a; +MIMAT0034114 gra-miR8722; +MIMAT0034115 gra-miR7492e; +MIMAT0034116 gra-miR8723b; +MIMAT0034117 gra-miR8724; +MIMAT0034118 gra-miR8725; +MIMAT0034119 gra-miR477; +MIMAT0034120 gra-miR8726; +MIMAT0034121 gra-miR7486f; +MIMAT0034122 gra-miR7486g; +MIMAT0034123 gra-miR8727; +MIMAT0034124 gra-miR7492g; +MIMAT0034125 gra-miR7492h; +MIMAT0034126 gra-miR7492i; +MIMAT0034127 gra-miR7492j; +MIMAT0034128 gra-miR7492k; +MIMAT0034129 gra-miR8729; +MIMAT0034130 gra-miR8730; +MIMAT0034131 gra-miR8731; +MIMAT0034132 gra-miR7492l; +MIMAT0034133 gra-miR7492m; +MIMAT0034134 gra-miR7506b; +MIMAT0034135 gra-miR5207; +MIMAT0034136 gra-miR7502d; +MIMAT0034137 gra-miR8732; +MIMAT0034138 gra-miR8733; +MIMAT0034139 gra-miR8734; +MIMAT0034140 gra-miR7484o; +MIMAT0034141 gra-miR172b; +MIMAT0034142 gra-miR7486i; +MIMAT0034143 gra-miR8771a; +MIMAT0034144 gra-miR8771b; +MIMAT0034145 gra-miR8771e; +MIMAT0034146 gra-miR399; +MIMAT0034147 gra-miR8735; +MIMAT0034148 gra-miR8736; +MIMAT0034149 gra-miR8737; +MIMAT0034150 gra-miR8738a; +MIMAT0034151 gra-miR8738b; +MIMAT0034152 gra-miR8740; +MIMAT0034153 gra-miR8741; +MIMAT0034154 gra-miR8771c; +MIMAT0034155 gra-miR7492n; +MIMAT0034156 gra-miR166c; +MIMAT0034157 gra-miR7484f; +MIMAT0034158 gra-miR8742a; +MIMAT0034159 gra-miR8742b; +MIMAT0034160 gra-miR8743c; +MIMAT0034161 gra-miR8743d; +MIMAT0034162 gra-miR8743e; +MIMAT0034163 gra-miR8743a; +MIMAT0034164 gra-miR8781a; +MIMAT0034165 gra-miR8744; +MIMAT0034166 gra-miR8745; +MIMAT0034167 gra-miR167c; +MIMAT0034168 gra-miR7494d; +MIMAT0034169 gra-miR8709b; +MIMAT0034170 gra-miR8746; +MIMAT0034171 gra-miR8747; +MIMAT0034172 gra-miR8748; +MIMAT0034173 gra-miR7494e; +MIMAT0034174 gra-miR7494f; +MIMAT0034175 gra-miR8749; +MIMAT0034176 gra-miR8750; +MIMAT0034177 gra-miR8751a; +MIMAT0034178 gra-miR8751b; +MIMAT0034179 gra-miR8752; +MIMAT0034180 gra-miR166d; +MIMAT0034181 gra-miR8753; +MIMAT0034182 gra-miR8771d; +MIMAT0034183 gra-miR8754; +MIMAT0034184 gra-miR8755; +MIMAT0034185 gra-miR8756; +MIMAT0034186 gra-miR8757a; +MIMAT0034187 gra-miR8758; +MIMAT0034188 gra-miR8757b; +MIMAT0034189 gra-miR8759; +MIMAT0034190 gra-miR8760; +MIMAT0034191 gra-miR8761; +MIMAT0034192 gra-miR8762a; +MIMAT0034193 gra-miR7502e; +MIMAT0034194 gra-miR8762b; +MIMAT0034195 gra-miR8763; +MIMAT0034196 gra-miR8674a; +MIMAT0034197 gra-miR8674b; +MIMAT0034198 gra-miR8764; +MIMAT0034199 gra-miR8765; +MIMAT0034200 gra-miR8766; +MIMAT0034201 gra-miR8653b; +MIMAT0034202 gra-miR8767a; +MIMAT0034203 gra-miR8767b; +MIMAT0034204 gra-miR8768; +MIMAT0034205 gra-miR482c; +MIMAT0034206 gra-miR7484g; +MIMAT0034207 gra-miR8769; +MIMAT0034208 gra-miR8770; +MIMAT0034209 gra-miR8771f; +MIMAT0034210 gra-miR8772; +MIMAT0034211 gra-miR8773; +MIMAT0034212 gra-miR8774; +MIMAT0034213 gra-miR8775; +MIMAT0034214 gra-miR8762d; +MIMAT0034215 gra-miR7484h; +MIMAT0034216 gra-miR7484i; +MIMAT0034217 gra-miR7484j; +MIMAT0034218 gra-miR7484k; +MIMAT0034219 gra-miR8776a; +MIMAT0034220 gra-miR8776b; +MIMAT0034221 gra-miR8776c; +MIMAT0034222 gra-miR8776d; +MIMAT0034223 gra-miR8777; +MIMAT0034224 gra-miR482d; +MIMAT0034225 gra-miR7504k; +MIMAT0034226 gra-miR7504l; +MIMAT0034227 gra-miR7504m; +MIMAT0034228 gra-miR8779; +MIMAT0034229 gra-miR7484l; +MIMAT0034230 gra-miR8780; +MIMAT0034231 gra-miR8743b; +MIMAT0034232 gra-miR8782; +MIMAT0034233 gra-miR8783; +MIMAT0034234 gra-miR7484m; +MIMAT0034235 gra-miR7486c; +MIMAT0034236 gra-miR8784; +MIMAT0034237 gra-miR8785; +MIMAT0034238 gra-miR8786a; +MIMAT0034239 gra-miR8786b; +MIMAT0034240 gra-miR8767c; +MIMAT0034241 gra-miR8787; +MIMAT0034242 gra-miR8762e; +MIMAT0034243 gra-miR8762c; +MIMAT0034244 gra-miR8670a; +MIMAT0034245 gra-miR8670b; +MIMAT0034246 gra-miR8657b; +MIMAT0034247 gra-miR7504j; +MIMAT0034248 gra-miR8717; +MIMAT0034249 gra-miR7492f; +MIMAT0034250 gra-miR8723a; +MIMAT0034251 gra-miR7492o; +MIMAT0034252 gra-miR8704; +MIMAT0034253 gra-miR8674c; +MIMAT0034254 gra-miR8781b; +MIMAT0034255 gra-miR7486h; +MIMAT0034256 gra-miR7493b; +MIMAT0034257 gra-miR8739; +MIMAT0034258 gra-miR7484n; +MIMAT0034259 gra-miR8728; +MIMAT0034260 gra-miR8778; +MIMAT0034261 gra-miR8718; +MIMAT0034262 gra-miR8641; +MIMAT0034263 gra-miR8639d; +MIMAT0034264 gra-miR8639e; +MIMAT0034265 gra-miR8689; +MIMAT0034266 gra-miR8638; +MIMAT0034267 gra-miR7502f; +MIMAT0034268 pin-miR8788-5p; +MIMAT0034269 pin-miR8788-3p; +MIMAT0034270 psj-miR8788a-5p; +MIMAT0034271 psj-miR8788a-3p; +MIMAT0034272 psj-miR8788b-5p; +MIMAT0034273 psj-miR8788b-3p; +MIMAT0034274 pra-miR8788a-5p; +MIMAT0034275 pra-miR8788a-3p; +MIMAT0034276 pra-miR8788b-5p; +MIMAT0034277 pra-miR8788b-3p; +MIMAT0034278 cfa-miR-6529; +MIMAT0034279 cfa-miR-8789; +MIMAT0034280 cfa-miR-8790; +MIMAT0034281 cfa-miR-8791a; +MIMAT0034282 cfa-miR-8792; +MIMAT0034283 cfa-miR-8793; +MIMAT0034284 cfa-miR-8794; +MIMAT0034285 cfa-miR-8795; +MIMAT0034286 cfa-miR-8796; +MIMAT0034287 cfa-miR-8797; +MIMAT0034288 cfa-miR-8798; +MIMAT0034289 cfa-miR-8799a; +MIMAT0034290 cfa-miR-8800; +MIMAT0034291 cfa-miR-8801; +MIMAT0034292 cfa-miR-8802; +MIMAT0034293 cfa-miR-8803; +MIMAT0034294 cfa-miR-8804; +MIMAT0034295 cfa-miR-8805; +MIMAT0034296 cfa-miR-8806; +MIMAT0034297 cfa-miR-8807; +MIMAT0034298 cfa-miR-8808; +MIMAT0034299 cfa-miR-8809; +MIMAT0034300 cfa-miR-8810; +MIMAT0034301 cfa-miR-8811; +MIMAT0034302 cfa-miR-8812; +MIMAT0034303 cfa-miR-8813; +MIMAT0034304 cfa-miR-8814; +MIMAT0034305 cfa-miR-8815; +MIMAT0034306 cfa-miR-8816; +MIMAT0034307 cfa-miR-8817; +MIMAT0034308 cfa-miR-8818; +MIMAT0034309 cfa-miR-8819; +MIMAT0034310 cfa-miR-8820; +MIMAT0034311 cfa-miR-8821; +MIMAT0034312 cfa-miR-8822; +MIMAT0034313 cfa-miR-8823; +MIMAT0034314 cfa-miR-8824; +MIMAT0034315 cfa-miR-8825; +MIMAT0034316 cfa-miR-8799b; +MIMAT0034317 cfa-miR-8826; +MIMAT0034318 cfa-miR-8799c; +MIMAT0034319 cfa-miR-8827; +MIMAT0034320 cfa-miR-8828; +MIMAT0034321 cfa-miR-1249; +MIMAT0034322 cfa-miR-8829; +MIMAT0034323 cfa-miR-8830; +MIMAT0034324 cfa-miR-8831; +MIMAT0034325 cfa-miR-8832; +MIMAT0034326 cfa-miR-8833; +MIMAT0034327 cfa-miR-8834a; +MIMAT0034328 cfa-miR-8835; +MIMAT0034329 cfa-miR-8836; +MIMAT0034330 cfa-miR-8837; +MIMAT0034331 cfa-miR-8838; +MIMAT0034332 cfa-miR-8839; +MIMAT0034333 cfa-miR-8840; +MIMAT0034334 cfa-miR-8841; +MIMAT0034335 cfa-miR-8842; +MIMAT0034336 cfa-miR-8843; +MIMAT0034337 cfa-miR-1301; +MIMAT0034338 cfa-miR-8844; +MIMAT0034339 cfa-miR-8845; +MIMAT0034340 cfa-miR-8846; +MIMAT0034341 cfa-miR-8799d; +MIMAT0034342 cfa-miR-8847; +MIMAT0034343 cfa-miR-8848; +MIMAT0034344 cfa-miR-8849; +MIMAT0034345 cfa-miR-8850; +MIMAT0034346 cfa-miR-8851; +MIMAT0034347 cfa-miR-8852; +MIMAT0034348 cfa-miR-8853; +MIMAT0034349 cfa-miR-8854; +MIMAT0034350 cfa-miR-8855; +MIMAT0034351 cfa-miR-8856; +MIMAT0034352 cfa-miR-8857; +MIMAT0034353 cfa-miR-8858; +MIMAT0034354 cfa-miR-8859a; +MIMAT0034355 cfa-miR-8860; +MIMAT0034356 cfa-miR-8861; +MIMAT0034357 cfa-miR-1343; +MIMAT0034358 cfa-miR-8859b; +MIMAT0034359 cfa-miR-8862; +MIMAT0034360 cfa-miR-8863; +MIMAT0034361 cfa-miR-8864; +MIMAT0034362 cfa-miR-8865; +MIMAT0034363 cfa-miR-8866; +MIMAT0034364 cfa-miR-8867; +MIMAT0034365 cfa-miR-8868; +MIMAT0034366 cfa-miR-8869; +MIMAT0034367 cfa-miR-8870; +MIMAT0034368 cfa-miR-8871; +MIMAT0034369 cfa-miR-8872; +MIMAT0034370 cfa-miR-2387; +MIMAT0034371 cfa-miR-8799e; +MIMAT0034372 cfa-miR-8799f; +MIMAT0034373 cfa-miR-8873a; +MIMAT0034374 cfa-miR-8874; +MIMAT0034375 cfa-miR-8875; +MIMAT0034376 cfa-miR-8876; +MIMAT0034377 cfa-miR-8877; +MIMAT0034378 cfa-miR-8878; +MIMAT0034379 cfa-miR-8879; +MIMAT0034380 cfa-miR-8880; +MIMAT0034381 cfa-miR-8881; +MIMAT0034382 cfa-miR-7180; +MIMAT0034383 cfa-miR-1185; +MIMAT0034384 cfa-miR-8882; +MIMAT0034385 cfa-miR-8883; +MIMAT0034386 cfa-miR-8884; +MIMAT0034387 cfa-miR-889; +MIMAT0034388 cfa-miR-3958; +MIMAT0034389 cfa-miR-8885; +MIMAT0034390 cfa-miR-8886; +MIMAT0034391 cfa-miR-8887; +MIMAT0034392 cfa-miR-8888; +MIMAT0034393 cfa-miR-6516; +MIMAT0034394 cfa-miR-8889; +MIMAT0034395 cfa-miR-8873b; +MIMAT0034396 cfa-let-7d; +MIMAT0034397 cfa-miR-8890; +MIMAT0034398 cfa-miR-8891; +MIMAT0034399 cfa-miR-8892; +MIMAT0034400 cfa-miR-769; +MIMAT0034401 cfa-miR-8893; +MIMAT0034402 cfa-miR-8894; +MIMAT0034403 cfa-miR-8895; +MIMAT0034404 cfa-miR-8896; +MIMAT0034405 cfa-miR-8897; +MIMAT0034406 cfa-miR-449b; +MIMAT0034407 cfa-miR-8799g; +MIMAT0034408 cfa-miR-8898; +MIMAT0034409 cfa-miR-8899; +MIMAT0034410 cfa-miR-8900; +MIMAT0034411 cfa-miR-8901; +MIMAT0034412 cfa-miR-8902; +MIMAT0034413 cfa-miR-1296; +MIMAT0034414 cfa-miR-8903; +MIMAT0034415 cfa-miR-8908b; +MIMAT0034416 cfa-miR-507b; +MIMAT0034417 cfa-miR-8904a; +MIMAT0034418 cfa-miR-8908f; +MIMAT0034419 cfa-miR-508a; +MIMAT0034420 cfa-miR-8908d; +MIMAT0034421 cfa-miR-2483; +MIMAT0034422 cfa-miR-506; +MIMAT0034423 cfa-miR-1468; +MIMAT0034424 cfa-miR-8904b; +MIMAT0034425 cfa-miR-508b; +MIMAT0034426 cfa-miR-8908e; +MIMAT0034427 cfa-miR-2114; +MIMAT0034428 cfa-miR-8908a-5p; +MIMAT0034429 cfa-miR-8908a-3p; +MIMAT0034430 cfa-miR-8791b; +MIMAT0034431 cfa-miR-8834b; +MIMAT0034432 cfa-miR-507a; +MIMAT0034433 cfa-miR-8908c; +MIMAT0034434 cfa-miR-8906; +MIMAT0034435 cfa-miR-8907; +MIMAT0034436 cfa-miR-8905; +MIMAT0034437 eca-miR-8909; +MIMAT0034438 eca-miR-8910; +MIMAT0034439 eca-miR-8911; +MIMAT0034440 eca-miR-8912; +MIMAT0034441 eca-miR-8913; +MIMAT0034442 eca-miR-8914; +MIMAT0034443 eca-miR-8915; +MIMAT0034444 eca-miR-8916; +MIMAT0034445 eca-miR-8917; +MIMAT0034446 eca-miR-8918; +MIMAT0034447 eca-miR-8919; +MIMAT0034448 eca-miR-8920; +MIMAT0034449 eca-miR-8921; +MIMAT0034450 eca-miR-8922; +MIMAT0034451 eca-miR-8923; +MIMAT0034452 eca-miR-8924; +MIMAT0034453 eca-miR-8925; +MIMAT0034454 eca-miR-8926; +MIMAT0034455 eca-miR-8927; +MIMAT0034456 eca-miR-8928; +MIMAT0034457 eca-miR-8929; +MIMAT0034458 eca-miR-8930; +MIMAT0034459 eca-miR-8931; +MIMAT0034460 eca-miR-8932; +MIMAT0034461 eca-miR-185; +MIMAT0034462 eca-miR-8933; +MIMAT0034463 eca-miR-8934; +MIMAT0034464 eca-miR-8935; +MIMAT0034465 eca-miR-8936; +MIMAT0034466 eca-miR-8937; +MIMAT0034467 eca-miR-8938; +MIMAT0034468 eca-miR-8939; +MIMAT0034469 eca-miR-8940; +MIMAT0034470 eca-miR-8941; +MIMAT0034471 eca-miR-8942; +MIMAT0034472 eca-miR-8943; +MIMAT0034473 eca-miR-8944; +MIMAT0034474 eca-miR-8945; +MIMAT0034475 eca-miR-8946; +MIMAT0034476 eca-miR-8947; +MIMAT0034477 eca-miR-8948; +MIMAT0034478 eca-miR-8949; +MIMAT0034479 eca-miR-8950; +MIMAT0034480 eca-miR-8951; +MIMAT0034481 eca-miR-8952; +MIMAT0034482 eca-miR-8953; +MIMAT0034483 eca-miR-8954; +MIMAT0034484 eca-miR-3959; +MIMAT0034485 eca-miR-8955; +MIMAT0034486 eca-miR-3958; +MIMAT0034487 eca-miR-329b; +MIMAT0034488 eca-miR-8956; +MIMAT0034489 eca-miR-154b; +MIMAT0034490 eca-miR-449b; +MIMAT0034491 eca-miR-8957; +MIMAT0034492 eca-miR-8958; +MIMAT0034493 eca-miR-8959; +MIMAT0034494 eca-miR-8960; +MIMAT0034495 eca-miR-8961; +MIMAT0034496 eca-miR-1388; +MIMAT0034497 eca-miR-8962; +MIMAT0034498 eca-miR-8963; +MIMAT0034499 eca-miR-8964; +MIMAT0034500 eca-miR-8965; +MIMAT0034501 eca-miR-8966; +MIMAT0034502 eca-miR-8967; +MIMAT0034503 eca-miR-8968; +MIMAT0034504 eca-miR-7177a; +MIMAT0034505 eca-miR-7045; +MIMAT0034506 eca-miR-8969; +MIMAT0034507 eca-miR-8970; +MIMAT0034508 eca-miR-8971; +MIMAT0034509 eca-miR-8972; +MIMAT0034510 eca-miR-8973; +MIMAT0034511 eca-miR-8974; +MIMAT0034512 eca-miR-8975; +MIMAT0034513 eca-miR-8976; +MIMAT0034514 eca-miR-8977; +MIMAT0034515 eca-miR-8978; +MIMAT0034516 eca-miR-8979; +MIMAT0034517 eca-miR-8980; +MIMAT0034518 eca-miR-8981; +MIMAT0034519 eca-miR-8982; +MIMAT0034520 eca-miR-8983; +MIMAT0034521 eca-miR-8984; +MIMAT0034522 eca-miR-8985; +MIMAT0034523 eca-miR-8986a; +MIMAT0034524 eca-miR-8987; +MIMAT0034525 eca-miR-8988; +MIMAT0034526 eca-miR-8989; +MIMAT0034527 eca-miR-8990; +MIMAT0034528 eca-miR-8991; +MIMAT0034529 eca-miR-8992; +MIMAT0034530 eca-miR-1271b; +MIMAT0034531 eca-miR-8993; +MIMAT0034532 eca-miR-8986b; +MIMAT0034533 eca-miR-8994; +MIMAT0034534 eca-miR-8995; +MIMAT0034535 eca-miR-8996; +MIMAT0034536 eca-miR-8997; +MIMAT0034537 eca-miR-7143; +MIMAT0034538 eca-miR-8998; +MIMAT0034539 eca-miR-8999; +MIMAT0034540 eca-miR-9000; +MIMAT0034541 eca-miR-9001; +MIMAT0034542 eca-miR-9002; +MIMAT0034543 eca-miR-9003; +MIMAT0034544 eca-miR-9004; +MIMAT0034545 eca-miR-9005; +MIMAT0034546 eca-miR-9006; +MIMAT0034547 eca-miR-9007; +MIMAT0034548 eca-miR-9008; +MIMAT0034549 eca-miR-9009; +MIMAT0034550 eca-miR-9010; +MIMAT0034551 eca-miR-3200; +MIMAT0034552 eca-miR-9011; +MIMAT0034553 eca-miR-9012; +MIMAT0034554 eca-miR-9013; +MIMAT0034555 eca-miR-9014; +MIMAT0034556 eca-miR-9015; +MIMAT0034557 eca-miR-9016; +MIMAT0034558 eca-miR-9017; +MIMAT0034559 eca-miR-9018; +MIMAT0034560 eca-miR-9019; +MIMAT0034561 eca-miR-9020; +MIMAT0034562 eca-miR-9021; +MIMAT0034563 eca-miR-1249; +MIMAT0034564 eca-miR-9022; +MIMAT0034565 eca-miR-9023; +MIMAT0034566 eca-miR-9024; +MIMAT0034567 eca-miR-9025; +MIMAT0034568 eca-miR-9026; +MIMAT0034569 eca-miR-9027; +MIMAT0034570 eca-miR-9028; +MIMAT0034571 eca-miR-9029; +MIMAT0034572 eca-miR-9030; +MIMAT0034573 eca-miR-9031; +MIMAT0034574 eca-miR-9032; +MIMAT0034575 eca-miR-9033; +MIMAT0034576 eca-miR-9034; +MIMAT0034577 eca-miR-9035; +MIMAT0034578 eca-miR-9036; +MIMAT0034579 eca-miR-9037; +MIMAT0034580 eca-miR-9038; +MIMAT0034581 eca-miR-9039; +MIMAT0034582 eca-miR-9040; +MIMAT0034583 eca-miR-9041; +MIMAT0034584 eca-miR-9042; +MIMAT0034585 eca-miR-7667; +MIMAT0034586 eca-miR-9043; +MIMAT0034587 eca-miR-9044; +MIMAT0034588 eca-miR-9045; +MIMAT0034589 eca-miR-1307; +MIMAT0034590 eca-miR-9046; +MIMAT0034591 eca-miR-9047; +MIMAT0034592 eca-miR-9048; +MIMAT0034593 eca-miR-9049; +MIMAT0034594 eca-miR-9050; +MIMAT0034595 eca-miR-9051; +MIMAT0034596 eca-miR-9052; +MIMAT0034597 eca-miR-9053; +MIMAT0034598 eca-miR-9054; +MIMAT0034599 eca-miR-9055; +MIMAT0034600 eca-miR-9056; +MIMAT0034601 eca-miR-9057; +MIMAT0034602 eca-miR-9058a; +MIMAT0034603 eca-miR-3548; +MIMAT0034604 eca-miR-9059; +MIMAT0034605 eca-miR-9060; +MIMAT0034606 eca-miR-9061; +MIMAT0034607 eca-miR-9062; +MIMAT0034608 eca-miR-9063; +MIMAT0034609 eca-miR-9064; +MIMAT0034610 eca-miR-9065; +MIMAT0034611 eca-miR-9066; +MIMAT0034612 eca-miR-9067; +MIMAT0034613 eca-miR-9068; +MIMAT0034614 eca-miR-9069; +MIMAT0034615 eca-miR-9070; +MIMAT0034616 eca-miR-9071; +MIMAT0034617 eca-miR-9072; +MIMAT0034618 eca-miR-9073; +MIMAT0034619 eca-miR-9074; +MIMAT0034620 eca-miR-9075; +MIMAT0034621 eca-miR-9076; +MIMAT0034622 eca-miR-9077; +MIMAT0034623 eca-miR-9078; +MIMAT0034624 eca-miR-9079; +MIMAT0034625 eca-miR-9080; +MIMAT0034626 eca-miR-9081; +MIMAT0034627 eca-miR-9082; +MIMAT0034628 eca-miR-9083; +MIMAT0034629 eca-miR-9084; +MIMAT0034630 eca-miR-9085; +MIMAT0034631 eca-miR-9086; +MIMAT0034632 eca-miR-9087; +MIMAT0034633 eca-miR-9088; +MIMAT0034634 eca-miR-9089; +MIMAT0034635 eca-miR-9090; +MIMAT0034636 eca-miR-9091; +MIMAT0034637 eca-miR-9092; +MIMAT0034638 eca-miR-9093; +MIMAT0034639 eca-miR-372; +MIMAT0034640 eca-miR-9094; +MIMAT0034641 eca-miR-9095; +MIMAT0034642 eca-miR-9096; +MIMAT0034643 eca-miR-9097; +MIMAT0034644 eca-miR-744; +MIMAT0034645 eca-miR-9098; +MIMAT0034646 eca-miR-9099; +MIMAT0034647 eca-miR-9100; +MIMAT0034648 eca-miR-9101; +MIMAT0034649 eca-miR-9102; +MIMAT0034650 eca-miR-9103; +MIMAT0034651 eca-miR-9104; +MIMAT0034652 eca-miR-9105; +MIMAT0034653 eca-miR-9106; +MIMAT0034654 eca-miR-7035; +MIMAT0034655 eca-miR-9107; +MIMAT0034656 eca-miR-9108; +MIMAT0034657 eca-miR-9109; +MIMAT0034658 eca-miR-3065; +MIMAT0034659 eca-miR-9110; +MIMAT0034660 eca-miR-9111; +MIMAT0034661 eca-miR-9112; +MIMAT0034662 eca-miR-9113; +MIMAT0034663 eca-miR-9114; +MIMAT0034664 eca-miR-9115; +MIMAT0034665 eca-miR-9116; +MIMAT0034666 eca-miR-9117; +MIMAT0034667 eca-miR-9118; +MIMAT0034668 eca-miR-9119; +MIMAT0034669 eca-miR-9120; +MIMAT0034670 eca-miR-483; +MIMAT0034671 eca-miR-9121; +MIMAT0034672 eca-miR-9122; +MIMAT0034673 eca-miR-9123; +MIMAT0034674 eca-miR-1379; +MIMAT0034675 eca-miR-9124; +MIMAT0034676 eca-miR-9125; +MIMAT0034677 eca-miR-9126; +MIMAT0034678 eca-miR-9127; +MIMAT0034679 eca-miR-9128; +MIMAT0034680 eca-miR-9129; +MIMAT0034681 eca-miR-9130; +MIMAT0034682 eca-miR-9131; +MIMAT0034683 eca-miR-9132; +MIMAT0034684 eca-miR-9133; +MIMAT0034685 eca-miR-9134; +MIMAT0034686 eca-miR-9135; +MIMAT0034687 eca-miR-9136; +MIMAT0034688 eca-miR-9137; +MIMAT0034689 eca-miR-9138; +MIMAT0034690 eca-miR-9139; +MIMAT0034691 eca-miR-7177b; +MIMAT0034692 eca-miR-9140; +MIMAT0034693 eca-miR-9141; +MIMAT0034694 eca-miR-8908k; +MIMAT0034695 eca-miR-9142; +MIMAT0034696 eca-miR-8908c; +MIMAT0034697 eca-miR-8908b; +MIMAT0034698 eca-miR-8908d; +MIMAT0034699 eca-miR-507b; +MIMAT0034700 eca-miR-2483; +MIMAT0034701 eca-miR-8908f; +MIMAT0034702 eca-miR-8908e; +MIMAT0034703 eca-miR-8908n; +MIMAT0034704 eca-miR-1911; +MIMAT0034705 eca-miR-676; +MIMAT0034706 eca-miR-514b; +MIMAT0034707 eca-miR-506a; +MIMAT0034708 eca-miR-8908g; +MIMAT0034709 eca-miR-509b; +MIMAT0034710 eca-miR-8908h; +MIMAT0034711 eca-miR-8908j; +MIMAT0034712 eca-miR-8908l; +MIMAT0034713 eca-miR-8908a; +MIMAT0034714 eca-miR-2114; +MIMAT0034715 eca-miR-514a; +MIMAT0034716 eca-miR-9143; +MIMAT0034717 eca-miR-8908m; +MIMAT0034718 eca-miR-9058b; +MIMAT0034719 eca-miR-8908i; +MIMAT0034720 eca-miR-9144; +MIMAT0034721 eca-miR-9145; +MIMAT0034722 eca-miR-9146; +MIMAT0034723 eca-miR-9147; +MIMAT0034724 eca-miR-9148; +MIMAT0034725 eca-miR-9149; +MIMAT0034726 eca-miR-9150; +MIMAT0034727 eca-miR-9151; +MIMAT0034728 eca-miR-9152; +MIMAT0034729 eca-miR-9153; +MIMAT0034730 eca-miR-9154; +MIMAT0034731 eca-miR-9155; +MIMAT0034732 eca-miR-9156; +MIMAT0034733 eca-miR-1543; +MIMAT0034734 eca-miR-9157; +MIMAT0034735 eca-miR-9158; +MIMAT0034736 eca-miR-9159; +MIMAT0034737 eca-miR-9160; +MIMAT0034738 eca-miR-9161; +MIMAT0034739 eca-miR-9162; +MIMAT0034740 eca-miR-9163; +MIMAT0034741 eca-miR-9164; +MIMAT0034742 eca-miR-3613; +MIMAT0034743 eca-miR-9165; +MIMAT0034744 eca-miR-9166; +MIMAT0034745 eca-miR-9167; +MIMAT0034746 eca-miR-9168; +MIMAT0034747 eca-miR-9169; +MIMAT0034748 eca-miR-9170; +MIMAT0034749 eca-miR-425; +MIMAT0034750 eca-miR-191b; +MIMAT0034751 eca-miR-9171; +MIMAT0034752 eca-miR-9172; +MIMAT0034753 eca-miR-9173; +MIMAT0034754 eca-miR-9174; +MIMAT0034755 eca-miR-9175; +MIMAT0034756 eca-miR-9176; +MIMAT0034757 eca-miR-9177; +MIMAT0034758 eca-miR-9178; +MIMAT0034759 eca-miR-9179; +MIMAT0034760 eca-miR-6529; +MIMAT0034761 eca-miR-9180; +MIMAT0034762 eca-miR-9181; +MIMAT0034763 eca-miR-9182; +MIMAT0034764 eca-miR-9183; +MIMAT0034765 eca-miR-9184; +MIMAT0034766 eca-miR-9185; +MIMAT0034767 efu-miR-9187; +MIMAT0034768 efu-miR-9188a; +MIMAT0034769 efu-miR-9189e; +MIMAT0034770 efu-miR-9190; +MIMAT0034771 efu-miR-9191; +MIMAT0034772 efu-miR-9192; +MIMAT0034773 efu-miR-9193; +MIMAT0034774 efu-miR-9194; +MIMAT0034775 efu-miR-9195; +MIMAT0034776 efu-miR-9196; +MIMAT0034777 efu-miR-9197; +MIMAT0034778 efu-miR-9203b; +MIMAT0034779 efu-miR-9198a; +MIMAT0034780 efu-miR-9198b; +MIMAT0034781 efu-miR-9198c; +MIMAT0034782 efu-miR-9198d; +MIMAT0034783 efu-miR-9198e; +MIMAT0034784 efu-miR-9199; +MIMAT0034785 efu-miR-9201a; +MIMAT0034786 efu-miR-9200b; +MIMAT0034787 efu-miR-9201b; +MIMAT0034788 efu-miR-9202; +MIMAT0034789 efu-miR-9203a; +MIMAT0034790 efu-miR-9188b; +MIMAT0034791 efu-miR-9204; +MIMAT0034792 efu-miR-9205; +MIMAT0034793 efu-miR-9243b; +MIMAT0034794 efu-miR-9206; +MIMAT0034795 efu-miR-9207; +MIMAT0034796 efu-miR-9209c; +MIMAT0034797 efu-miR-9209d; +MIMAT0034798 efu-miR-9208; +MIMAT0034799 efu-miR-9209a; +MIMAT0034800 efu-miR-9209b; +MIMAT0034801 efu-miR-9210; +MIMAT0034802 efu-miR-9211; +MIMAT0034803 efu-miR-9212; +MIMAT0034804 efu-miR-9213; +MIMAT0034805 efu-miR-9214; +MIMAT0034806 efu-miR-9215a; +MIMAT0034807 efu-miR-9215b; +MIMAT0034808 efu-miR-9216; +MIMAT0034809 efu-miR-9217; +MIMAT0034810 efu-miR-9218; +MIMAT0034811 efu-miR-9219; +MIMAT0034812 efu-miR-9220; +MIMAT0034813 efu-miR-378; +MIMAT0034814 efu-miR-9221; +MIMAT0034815 efu-miR-9222; +MIMAT0034816 efu-miR-9223a; +MIMAT0034817 efu-miR-9223f; +MIMAT0034818 efu-miR-9223c; +MIMAT0034819 efu-miR-9223e; +MIMAT0034820 efu-miR-9223b; +MIMAT0034821 efu-miR-9223g; +MIMAT0034822 efu-miR-9223d; +MIMAT0034823 efu-miR-9223h; +MIMAT0034824 efu-miR-9223i; +MIMAT0034825 efu-miR-9242; +MIMAT0034826 efu-miR-9224; +MIMAT0034827 efu-miR-9225; +MIMAT0034828 efu-miR-9226; +MIMAT0034829 efu-miR-9227; +MIMAT0034830 efu-miR-9228; +MIMAT0034831 efu-miR-9229a; +MIMAT0034832 efu-miR-9230a; +MIMAT0034833 efu-miR-9229b; +MIMAT0034834 efu-miR-9230b; +MIMAT0034835 efu-miR-9237b; +MIMAT0034836 efu-miR-9231; +MIMAT0034837 efu-miR-9230c; +MIMAT0034838 efu-miR-9232; +MIMAT0034839 efu-miR-9229d; +MIMAT0034840 efu-miR-9237c; +MIMAT0034841 efu-miR-9229c; +MIMAT0034842 efu-miR-9233; +MIMAT0034843 efu-miR-9234a; +MIMAT0034844 efu-miR-9235a; +MIMAT0034845 efu-miR-9236a; +MIMAT0034846 efu-miR-9229e; +MIMAT0034847 efu-miR-9229f; +MIMAT0034848 efu-miR-9234b; +MIMAT0034849 efu-miR-9236b; +MIMAT0034850 efu-miR-9235b; +MIMAT0034851 efu-miR-9236c; +MIMAT0034852 efu-miR-9234c;efu-miR-9234b; +MIMAT0034853 efu-miR-9237a; +MIMAT0034854 efu-miR-9238; +MIMAT0034855 efu-miR-9239; +MIMAT0034856 efu-miR-9240; +MIMAT0034857 efu-miR-9241; +MIMAT0034858 efu-miR-9243a; +MIMAT0034859 efu-miR-9244; +MIMAT0034860 efu-miR-9246a; +MIMAT0034861 efu-miR-9245; +MIMAT0034862 efu-miR-9246b; +MIMAT0034863 efu-miR-9246c; +MIMAT0034864 efu-miR-9247; +MIMAT0034865 efu-miR-9248; +MIMAT0034866 efu-miR-9249; +MIMAT0034867 efu-miR-9250; +MIMAT0034868 efu-miR-9251; +MIMAT0034869 efu-miR-9256a; +MIMAT0034870 efu-miR-9252; +MIMAT0034871 efu-miR-9253; +MIMAT0034872 efu-miR-9254; +MIMAT0034873 efu-miR-9255; +MIMAT0034874 efu-miR-9243c; +MIMAT0034875 efu-miR-9256b; +MIMAT0034876 efu-miR-9257; +MIMAT0034877 efu-miR-9258; +MIMAT0034878 efu-miR-544; +MIMAT0034879 efu-miR-9259; +MIMAT0034880 efu-miR-9260; +MIMAT0034881 efu-miR-9261; +MIMAT0034882 efu-miR-9262; +MIMAT0034883 efu-miR-9263; +MIMAT0034884 efu-miR-9189d; +MIMAT0034885 efu-miR-9189g; +MIMAT0034886 efu-miR-9189c; +MIMAT0034887 efu-miR-9189f; +MIMAT0034888 efu-miR-9189a; +MIMAT0034889 efu-miR-9189b; +MIMAT0034890 efu-miR-9189h; +MIMAT0034891 efu-miR-34b; +MIMAT0034892 efu-miR-9264; +MIMAT0034893 efu-miR-452; +MIMAT0034894 efu-miR-1249; +MIMAT0034895 efu-miR-9265; +MIMAT0034896 efu-miR-9266; +MIMAT0034897 efu-miR-9267; +MIMAT0034898 efu-miR-9268; +MIMAT0034899 efu-miR-23b; +MIMAT0034900 efu-miR-27b; +MIMAT0034901 efu-miR-9269; +MIMAT0034902 efu-miR-9270; +MIMAT0034903 efu-miR-9271; +MIMAT0034904 efu-miR-9186l; +MIMAT0034905 efu-miR-9272; +MIMAT0034906 efu-miR-191; +MIMAT0034907 efu-miR-9186p; +MIMAT0034908 efu-miR-9186f; +MIMAT0034909 efu-miR-490; +MIMAT0034910 efu-miR-9273; +MIMAT0034911 efu-miR-9274; +MIMAT0034912 efu-miR-9275; +MIMAT0034913 efu-miR-101; +MIMAT0034914 efu-miR-9276; +MIMAT0034915 efu-miR-9277; +MIMAT0034916 efu-miR-9278; +MIMAT0034917 efu-miR-9279a; +MIMAT0034918 efu-miR-9280; +MIMAT0034919 efu-miR-125b; +MIMAT0034920 efu-miR-10; +MIMAT0034921 efu-miR-33; +MIMAT0034922 efu-miR-128a; +MIMAT0034923 efu-miR-9281; +MIMAT0034924 efu-miR-194; +MIMAT0034925 efu-miR-215; +MIMAT0034926 efu-miR-9186g; +MIMAT0034927 efu-miR-330; +MIMAT0034928 efu-miR-337; +MIMAT0034929 efu-miR-493; +MIMAT0034930 efu-miR-9282; +MIMAT0034931 efu-miR-370; +MIMAT0034932 efu-miR-136; +MIMAT0034933 efu-miR-127; +MIMAT0034934 efu-miR-9283; +MIMAT0034935 efu-miR-9284; +MIMAT0034936 efu-miR-9285; +MIMAT0034937 efu-miR-9-5p; +MIMAT0034938 efu-miR-9-3p; +MIMAT0034939 efu-miR-26a; +MIMAT0034940 efu-miR-9286; +MIMAT0034941 efu-miR-29c; +MIMAT0034942 efu-miR-9287; +MIMAT0034943 efu-let-7c; +MIMAT0034944 efu-miR-99a; +MIMAT0034945 efu-miR-9288; +MIMAT0034946 efu-miR-199; +MIMAT0034947 efu-miR-9289; +MIMAT0034948 efu-miR-9290; +MIMAT0034949 efu-miR-28; +MIMAT0034950 efu-miR-9291; +MIMAT0034951 efu-miR-9186h; +MIMAT0034952 efu-miR-9292; +MIMAT0034953 efu-miR-9293; +MIMAT0034954 efu-miR-107; +MIMAT0034955 efu-miR-9294; +MIMAT0034956 efu-miR-9295; +MIMAT0034957 efu-miR-9296; +MIMAT0034958 efu-miR-9297; +MIMAT0034959 efu-miR-9186q; +MIMAT0034960 efu-miR-9186m; +MIMAT0034961 efu-miR-9298; +MIMAT0034962 efu-miR-9186n; +MIMAT0034963 efu-miR-9299; +MIMAT0034964 efu-miR-211; +MIMAT0034965 efu-miR-499; +MIMAT0034966 efu-miR-342; +MIMAT0034967 efu-miR-1307; +MIMAT0034968 efu-miR-9300; +MIMAT0034969 efu-miR-9301; +MIMAT0034970 efu-miR-135; +MIMAT0034971 efu-miR-513; +MIMAT0034972 efu-miR-148; +MIMAT0034973 efu-miR-30a; +MIMAT0034974 efu-miR-2683; +MIMAT0034975 efu-miR-9302; +MIMAT0034976 efu-miR-9303; +MIMAT0034977 efu-miR-9304; +MIMAT0034978 efu-miR-9305; +MIMAT0034979 efu-miR-9306; +MIMAT0034980 efu-miR-9307; +MIMAT0034981 efu-miR-9308; +MIMAT0034982 efu-miR-9309; +MIMAT0034983 efu-miR-9310; +MIMAT0034984 efu-miR-9311; +MIMAT0034985 efu-miR-4667; +MIMAT0034986 efu-miR-9312; +MIMAT0034987 efu-miR-497; +MIMAT0034988 efu-miR-9313; +MIMAT0034989 efu-miR-9314; +MIMAT0034990 efu-miR-1271; +MIMAT0034991 efu-miR-9315; +MIMAT0034992 efu-miR-130; +MIMAT0034993 efu-miR-9316; +MIMAT0034994 efu-miR-19; +MIMAT0034995 efu-miR-92a; +MIMAT0034996 efu-miR-20; +MIMAT0034997 efu-miR-18; +MIMAT0034998 efu-miR-92c; +MIMAT0034999 efu-miR-17; +MIMAT0035000 efu-miR-9317; +MIMAT0035001 efu-miR-129a; +MIMAT0035002 efu-miR-132; +MIMAT0035003 efu-miR-9318a; +MIMAT0035004 efu-miR-7b; +MIMAT0035005 efu-miR-128b; +MIMAT0035006 efu-miR-26c; +MIMAT0035007 efu-miR-181e; +MIMAT0035008 efu-miR-181f; +MIMAT0035009 efu-miR-9319; +MIMAT0035010 efu-miR-9320; +MIMAT0035011 efu-miR-103a; +MIMAT0035012 efu-miR-200b; +MIMAT0035013 efu-miR-200a; +MIMAT0035014 efu-miR-429; +MIMAT0035015 efu-miR-1388; +MIMAT0035016 efu-let-7d; +MIMAT0035017 efu-let-7f; +MIMAT0035018 efu-miR-9321; +MIMAT0035019 efu-miR-9279b; +MIMAT0035020 efu-miR-146; +MIMAT0035021 efu-miR-149; +MIMAT0035022 efu-miR-9186b; +MIMAT0035023 efu-miR-9318b; +MIMAT0035024 efu-miR-423; +MIMAT0035025 efu-miR-1193; +MIMAT0035026 efu-miR-376; +MIMAT0035027 efu-miR-299; +MIMAT0035028 efu-miR-494; +MIMAT0035029 efu-miR-411; +MIMAT0035030 efu-miR-323; +MIMAT0035031 efu-miR-495; +MIMAT0035032 efu-miR-379; +MIMAT0035033 efu-miR-3958; +MIMAT0035034 efu-miR-138b; +MIMAT0035035 efu-miR-383; +MIMAT0035036 efu-miR-218a; +MIMAT0035037 efu-miR-34a; +MIMAT0035038 efu-miR-485; +MIMAT0035039 efu-miR-154; +MIMAT0035040 efu-miR-382; +MIMAT0035041 efu-miR-409; +MIMAT0035042 efu-miR-487; +MIMAT0035043 efu-miR-412; +MIMAT0035044 efu-miR-133-5p; +MIMAT0035045 efu-miR-133-3p; +MIMAT0035046 efu-miR-34c; +MIMAT0035047 efu-miR-9186a; +MIMAT0035048 efu-miR-9186d; +MIMAT0035049 efu-miR-9322; +MIMAT0035050 efu-miR-9323; +MIMAT0035051 efu-miR-324; +MIMAT0035052 efu-miR-9324; +MIMAT0035053 efu-miR-125a; +MIMAT0035054 efu-miR-181a; +MIMAT0035055 efu-miR-181b; +MIMAT0035056 efu-miR-219; +MIMAT0035057 efu-miR-202; +MIMAT0035058 efu-miR-361; +MIMAT0035059 efu-miR-335; +MIMAT0035060 efu-miR-486; +MIMAT0035061 efu-miR-155; +MIMAT0035062 efu-miR-9325; +MIMAT0035063 efu-miR-138a; +MIMAT0035064 efu-miR-31; +MIMAT0035065 efu-miR-9326; +MIMAT0035066 efu-miR-9327; +MIMAT0035067 efu-miR-9186k; +MIMAT0035068 efu-miR-218b; +MIMAT0035069 efu-miR-9328; +MIMAT0035070 efu-miR-9329; +MIMAT0035071 efu-miR-30d; +MIMAT0035072 efu-miR-9330; +MIMAT0035073 efu-miR-185; +MIMAT0035074 efu-miR-507c; +MIMAT0035075 efu-miR-8908; +MIMAT0035076 efu-miR-26b; +MIMAT0035077 efu-miR-150; +MIMAT0035078 efu-miR-214; +MIMAT0035079 efu-miR-9331; +MIMAT0035080 efu-miR-9332; +MIMAT0035081 efu-miR-9333; +MIMAT0035082 efu-miR-9334; +MIMAT0035083 efu-miR-103b; +MIMAT0035084 efu-miR-9335; +MIMAT0035085 efu-miR-455; +MIMAT0035086 efu-miR-151; +MIMAT0035087 efu-miR-16; +MIMAT0035088 efu-miR-652; +MIMAT0035089 efu-miR-204; +MIMAT0035090 efu-miR-9336; +MIMAT0035091 efu-miR-9186o; +MIMAT0035092 efu-miR-9337; +MIMAT0035093 efu-miR-381; +MIMAT0035094 efu-miR-1185; +MIMAT0035095 efu-miR-9186c; +MIMAT0035096 efu-miR-200c; +MIMAT0035097 efu-miR-141; +MIMAT0035098 efu-miR-338; +MIMAT0035099 efu-miR-365; +MIMAT0035100 efu-miR-193b; +MIMAT0035101 efu-miR-9338; +MIMAT0035102 efu-miR-874; +MIMAT0035103 efu-miR-9339; +MIMAT0035104 efu-miR-9340; +MIMAT0035105 efu-miR-129b; +MIMAT0035106 efu-miR-153; +MIMAT0035107 efu-miR-182; +MIMAT0035108 efu-miR-449; +MIMAT0035109 efu-miR-9341; +MIMAT0035110 efu-miR-9342; +MIMAT0035111 efu-miR-9343; +MIMAT0035112 efu-miR-574; +MIMAT0035113 efu-miR-9344; +MIMAT0035114 efu-miR-9345; +MIMAT0035115 efu-miR-22; +MIMAT0035116 efu-miR-9346; +MIMAT0035117 efu-miR-9347; +MIMAT0035118 efu-miR-9348; +MIMAT0035119 efu-miR-582; +MIMAT0035120 efu-miR-507b; +MIMAT0035121 efu-miR-196; +MIMAT0035122 efu-miR-145; +MIMAT0035123 efu-miR-143; +MIMAT0035124 efu-miR-9349; +MIMAT0035125 efu-miR-9350; +MIMAT0035126 efu-miR-424; +MIMAT0035127 efu-miR-503; +MIMAT0035128 efu-miR-450; +MIMAT0035129 efu-miR-1; +MIMAT0035130 efu-miR-9351; +MIMAT0035131 efu-miR-124; +MIMAT0035132 efu-miR-181c; +MIMAT0035133 efu-miR-181d; +MIMAT0035134 efu-miR-152; +MIMAT0035135 efu-miR-30c; +MIMAT0035136 efu-miR-30e; +MIMAT0035137 efu-miR-1842; +MIMAT0035138 efu-miR-9352; +MIMAT0035139 efu-miR-628; +MIMAT0035140 efu-miR-9353; +MIMAT0035141 efu-miR-9354; +MIMAT0035142 efu-miR-193a; +MIMAT0035143 efu-miR-9186j; +MIMAT0035144 efu-miR-9186i; +MIMAT0035145 efu-miR-9355; +MIMAT0035146 efu-miR-21; +MIMAT0035147 efu-miR-210; +MIMAT0035148 efu-miR-331; +MIMAT0035149 efu-miR-9356; +MIMAT0035150 efu-miR-9357; +MIMAT0035151 efu-miR-188; +MIMAT0035152 efu-miR-500; +MIMAT0035153 efu-miR-532; +MIMAT0035154 efu-miR-660; +MIMAT0035155 efu-miR-502; +MIMAT0035156 efu-miR-205; +MIMAT0035157 efu-miR-7a; +MIMAT0035158 efu-miR-192; +MIMAT0035159 efu-miR-592; +MIMAT0035160 efu-miR-92b; +MIMAT0035161 efu-miR-23a; +MIMAT0035162 efu-miR-27a; +MIMAT0035163 efu-miR-139; +MIMAT0035164 efu-miR-106; +MIMAT0035165 efu-miR-93; +MIMAT0035166 efu-miR-25; +MIMAT0035167 efu-miR-9186e; +MIMAT0035168 efu-miR-9358; +MIMAT0035169 efu-miR-126; +MIMAT0035170 efu-miR-9359; +MIMAT0035171 efu-miR-9360; +MIMAT0035172 efu-miR-9361; +MIMAT0035173 efu-miR-9362; +MIMAT0035174 efu-miR-206; +MIMAT0035175 efu-miR-29b; +MIMAT0035176 efu-miR-29a; +MIMAT0035177 efu-miR-9363; +MIMAT0035178 efu-miR-1343; +MIMAT0035179 efu-miR-8915; +MIMAT0035180 efu-miR-375; +MIMAT0035181 efu-miR-9364; +MIMAT0035182 efu-miR-9365; +MIMAT0035183 efu-miR-506; +MIMAT0035184 efu-miR-507a; +MIMAT0035185 efu-miR-99b; +MIMAT0035186 efu-let-7e; +MIMAT0035187 efu-miR-7c; +MIMAT0035188 efu-miR-15; +MIMAT0035189 efu-miR-339; +MIMAT0035190 efu-miR-320; +MIMAT0035191 efu-miR-9366; +MIMAT0035192 efu-miR-30b; +MIMAT0035193 efu-miR-140; +MIMAT0035194 efu-miR-9367; +MIMAT0035195 efu-miR-9368; +MIMAT0035196 efu-miR-221; +MIMAT0035197 efu-miR-222; +MIMAT0035198 efu-miR-223; +MIMAT0035199 efu-miR-504; +MIMAT0035200 efu-miR-142; +MIMAT0035201 dme-miR-9369-5p; +MIMAT0035202 dme-miR-9369-3p; +MIMAT0035203 dme-miR-9370-5p; +MIMAT0035204 dme-miR-9370-3p; +MIMAT0035205 dme-miR-9371-5p; +MIMAT0035206 dme-miR-9371-3p; +MIMAT0035207 dme-miR-9372-5p; +MIMAT0035208 dme-miR-9372-3p; +MIMAT0035209 dme-miR-9373-5p; +MIMAT0035210 dme-miR-9373-3p; +MIMAT0035211 dme-miR-9374-5p; +MIMAT0035212 dme-miR-9374-3p; +MIMAT0035213 dme-miR-9375-5p; +MIMAT0035214 dme-miR-9375-3p; +MIMAT0035215 dme-miR-9376-5p; +MIMAT0035216 dme-miR-9376-3p; +MIMAT0035217 dme-miR-9377-5p; +MIMAT0035218 dme-miR-9377-3p; +MIMAT0035219 dme-miR-9378-5p; +MIMAT0035220 dme-miR-9378-3p; +MIMAT0035221 dme-miR-9379-5p; +MIMAT0035222 dme-miR-9379-3p; +MIMAT0035223 dme-miR-9380-5p; +MIMAT0035224 dme-miR-9380-3p; +MIMAT0035225 dme-miR-9381-5p; +MIMAT0035226 dme-miR-9381-3p; +MIMAT0035227 dme-miR-9382-5p; +MIMAT0035228 dme-miR-9382-3p; +MIMAT0035229 dme-miR-9383-5p; +MIMAT0035230 dme-miR-9383-3p; +MIMAT0035231 dme-miR-9384-5p; +MIMAT0035232 dme-miR-9384-3p; +MIMAT0035233 dme-miR-9385-5p; +MIMAT0035234 dme-miR-9385-3p; +MIMAT0035235 hbr-miR9386; +MIMAT0035236 hbr-miR9387; +MIMAT0035237 hbr-miR482b; +MIMAT0035238 dme-miR-9388-5p; +MIMAT0035239 dme-miR-9388-3p; +MIMAT0035240 gsa-miR-1-5p; +MIMAT0035241 gsa-miR-1-3p; +MIMAT0035242 gsa-miR-87-5p; +MIMAT0035243 gsa-miR-87-3p; +MIMAT0035244 gsa-miR-279-5p; +MIMAT0035245 gsa-miR-279-3p; +MIMAT0035246 gsa-miR-71a-5p; +MIMAT0035247 gsa-miR-71a-3p; +MIMAT0035248 gsa-miR-184a-5p; +MIMAT0035249 gsa-miR-184a-3p; +MIMAT0035250 gsa-miR-71b-5p; +MIMAT0035251 gsa-miR-71b-3p; +MIMAT0035252 gsa-miR-190-5p; +MIMAT0035253 gsa-miR-190-3p; +MIMAT0035254 gsa-miR-1175-5p; +MIMAT0035255 gsa-miR-1175-3p; +MIMAT0035256 gsa-miR-96a-5p; +MIMAT0035257 gsa-miR-96a-3p; +MIMAT0035258 gsa-miR-36-5p; +MIMAT0035259 gsa-miR-36-3p; +MIMAT0035260 gsa-let-7-5p; +MIMAT0035261 gsa-let-7-3p; +MIMAT0035262 gsa-miR-67-5p; +MIMAT0035263 gsa-miR-67-3p; +MIMAT0035264 gsa-miR-219-5p; +MIMAT0035265 gsa-miR-219-3p; +MIMAT0035266 gsa-miR-2a-5p; +MIMAT0035267 gsa-miR-2a-3p; +MIMAT0035268 gsa-miR-281-5p; +MIMAT0035269 gsa-miR-281-3p; +MIMAT0035270 gsa-miR-96b-5p; +MIMAT0035271 gsa-miR-96b-3p; +MIMAT0035272 gsa-miR-2b-5p; +MIMAT0035273 gsa-miR-2b-3p; +MIMAT0035274 gsa-miR-124a-5p; +MIMAT0035275 gsa-miR-124a-3p; +MIMAT0035276 gsa-miR-2c-5p; +MIMAT0035277 gsa-miR-2c-3p; +MIMAT0035278 gsa-miR-10a-5p; +MIMAT0035279 gsa-miR-10a-3p; +MIMAT0035280 gsa-miR-2001-5p; +MIMAT0035281 gsa-miR-2001-3p; +MIMAT0035282 gsa-miR-7-5p; +MIMAT0035283 gsa-miR-7-3p; +MIMAT0035284 gsa-miR-8-5p; +MIMAT0035285 gsa-miR-8-3p; +MIMAT0035286 gsa-miR-76a-5p; +MIMAT0035287 gsa-miR-76a-3p; +MIMAT0035288 gsa-miR-9-5p; +MIMAT0035289 gsa-miR-9-3p; +MIMAT0035290 gsa-bantam-5p; +MIMAT0035291 gsa-bantam-3p; +MIMAT0035292 gsa-miR-124b-5p; +MIMAT0035293 gsa-miR-124b-3p; +MIMAT0035294 gsa-miR-278-5p; +MIMAT0035295 gsa-miR-278-3p; +MIMAT0035296 gsa-miR-277a-5p; +MIMAT0035297 gsa-miR-277a-3p; +MIMAT0035298 gsa-miR-2d-5p; +MIMAT0035299 gsa-miR-2d-3p; +MIMAT0035300 gsa-miR-1993-5p; +MIMAT0035301 gsa-miR-1993-3p; +MIMAT0035302 gsa-miR-184b-5p; +MIMAT0035303 gsa-miR-184b-3p; +MIMAT0035304 gsa-miR-993-5p; +MIMAT0035305 gsa-miR-993-3p; +MIMAT0035306 gsa-lin-4-5p; +MIMAT0035307 gsa-lin-4-3p; +MIMAT0035308 gsa-miR-10b-5p; +MIMAT0035309 gsa-miR-10b-3p; +MIMAT0035310 gsa-miR-277b-5p; +MIMAT0035311 gsa-miR-277b-3p; +MIMAT0035312 gsa-miR-1992-5p; +MIMAT0035313 gsa-miR-1992-3p; +MIMAT0035314 gsa-miR-31-5p; +MIMAT0035315 gsa-miR-31-3p; +MIMAT0035316 gsa-miR-153-5p; +MIMAT0035317 gsa-miR-153-3p; +MIMAT0035318 gsa-miR-9389-5p; +MIMAT0035319 gsa-miR-9389-3p; +MIMAT0035320 gsa-miR-71c-5p; +MIMAT0035321 gsa-miR-71c-3p; +MIMAT0035322 gsa-miR-9390-5p; +MIMAT0035323 gsa-miR-9390-3p; +MIMAT0035324 gsa-miR-184c-5p; +MIMAT0035325 gsa-miR-184c-3p; +MIMAT0035326 gsa-miR-9391-5p; +MIMAT0035327 gsa-miR-9391-3p; +MIMAT0035328 gsa-miR-9392-5p; +MIMAT0035329 gsa-miR-9392-3p; +MIMAT0035330 gsa-miR-9393-5p; +MIMAT0035331 gsa-miR-9393-3p; +MIMAT0035332 gsa-miR-9394a-5p; +MIMAT0035333 gsa-miR-9394a-3p; +MIMAT0035334 gsa-miR-76b-5p; +MIMAT0035335 gsa-miR-76b-3p; +MIMAT0035336 gsa-miR-9395-5p; +MIMAT0035337 gsa-miR-9395-3p; +MIMAT0035338 gsa-miR-9396-5p; +MIMAT0035339 gsa-miR-9396-3p; +MIMAT0035340 gsa-miR-9397-5p; +MIMAT0035341 gsa-miR-9397-3p; +MIMAT0035342 gsa-miR-9398-5p; +MIMAT0035343 gsa-miR-9398-3p; +MIMAT0035344 gsa-miR-9399-5p; +MIMAT0035345 gsa-miR-9399-3p; +MIMAT0035346 gsa-miR-9400-5p; +MIMAT0035347 gsa-miR-9400-3p; +MIMAT0035348 gsa-miR-9394b-5p; +MIMAT0035349 gsa-miR-9394b-3p; +MIMAT0035350 gsa-miR-9401-5p; +MIMAT0035351 gsa-miR-9401-3p; +MIMAT0035352 gsa-miR-9402-5p; +MIMAT0035353 gsa-miR-9402-3p; +MIMAT0035354 gsa-miR-9403-5p; +MIMAT0035355 gsa-miR-9403-3p; +MIMAT0035356 gsa-miR-9404-5p; +MIMAT0035357 gsa-miR-9404-3p; +MIMAT0035358 gsa-miR-9405-5p; +MIMAT0035359 gsa-miR-9405-3p; +MIMAT0035360 xtr-miR-9406; +MIMAT0035361 xtr-miR-9407; +MIMAT0035362 xtr-miR-428b; +MIMAT0035363 bol-miR9408; +MIMAT0035364 bol-miR9409; +MIMAT0035365 bol-miR9410; +MIMAT0035366 bol-miR9411; +MIMAT0035367 nve-miR-9412; +MIMAT0035368 nve-miR-9413; +MIMAT0035369 nve-miR-9414-5p; +MIMAT0035370 nve-miR-9414-3p; +MIMAT0035371 nve-miR-9415; +MIMAT0035372 nve-miR-9416; +MIMAT0035373 nve-miR-9417; +MIMAT0035374 nve-miR-9418; +MIMAT0035375 nve-miR-9419; +MIMAT0035376 nve-miR-9420; +MIMAT0035377 nve-miR-9421; +MIMAT0035378 nve-miR-9422; +MIMAT0035379 nve-miR-9423; +MIMAT0035380 nve-miR-2041b; +MIMAT0035381 nve-miR-2041b-5p; +MIMAT0035382 nve-miR-2041b-3p; +MIMAT0035383 nve-miR-9424a; +MIMAT0035384 nve-miR-9425; +MIMAT0035385 nve-miR-9426; +MIMAT0035386 nve-miR-9427; +MIMAT0035387 nve-miR-9428; +MIMAT0035388 nve-miR-9429-5p; +MIMAT0035389 nve-miR-9429-3p; +MIMAT0035390 nve-miR-9430; +MIMAT0035391 nve-miR-9431; +MIMAT0035392 nve-miR-9424b; +MIMAT0035393 nve-miR-9432; +MIMAT0035394 nve-miR-9433; +MIMAT0035395 nve-miR-9434; +MIMAT0035396 nve-miR-9435; +MIMAT0035397 nve-miR-9436; +MIMAT0035398 nve-miR-9437; +MIMAT0035399 nve-miR-9438; +MIMAT0035400 nve-miR-9439; +MIMAT0035401 nve-miR-9440; +MIMAT0035402 nve-miR-9441; +MIMAT0035403 nve-miR-9442; +MIMAT0035404 nve-miR-9443; +MIMAT0035405 nve-miR-9444; +MIMAT0035406 nve-miR-9445; +MIMAT0035407 nve-miR-9446; +MIMAT0035408 nve-miR-9447; +MIMAT0035409 nve-miR-9448; +MIMAT0035410 nve-miR-9449; +MIMAT0035411 nve-miR-9450; +MIMAT0035412 nve-miR-9451; +MIMAT0035413 nve-miR-9452; +MIMAT0035414 nve-miR-9453; +MIMAT0035415 nve-miR-9454; +MIMAT0035416 nve-miR-9455; +MIMAT0035417 nve-miR-9456; +MIMAT0035418 nve-miR-9457; +MIMAT0035419 nve-miR-9458; +MIMAT0035420 nve-miR-9459; +MIMAT0035421 nve-miR-9460; +MIMAT0035422 nve-miR-9461; +MIMAT0035423 nve-miR-9462; +MIMAT0035424 nve-miR-9465; +MIMAT0035425 nve-miR-9466; +MIMAT0035426 nve-miR-9467; +MIMAT0035427 nve-miR-9468; +MIMAT0035428 nve-miR-9463; +MIMAT0035429 nve-miR-9464; +MIMAT0035430 sly-miR319b; +MIMAT0035431 sly-miR319c-5p; +MIMAT0035432 sly-miR319c-3p; +MIMAT0035433 sly-miR403-5p; +MIMAT0035434 sly-miR403-3p; +MIMAT0035435 sly-miR9469-5p; +MIMAT0035436 sly-miR9469-3p; +MIMAT0035437 sly-miR394-5p; +MIMAT0035438 sly-miR394-3p; +MIMAT0035439 sly-miR9470-5p; +MIMAT0035440 sly-miR9470-3p; +MIMAT0035441 sly-miR9471b-5p; +MIMAT0035442 sly-miR9471b-3p; +MIMAT0035443 sly-miR166c-5p; +MIMAT0035444 sly-miR166c-3p; +MIMAT0035445 sly-miR5302b-5p; +MIMAT0035446 sly-miR5302b-3p; +MIMAT0035447 sly-miR9471a-5p; +MIMAT0035448 sly-miR9471a-3p; +MIMAT0035449 sly-miR9472-5p; +MIMAT0035450 sly-miR9472-3p; +MIMAT0035451 sly-miR156d-5p; +MIMAT0035452 sly-miR156d-3p; +MIMAT0035453 sly-miR156e-5p; +MIMAT0035454 sly-miR156e-3p; +MIMAT0035455 sly-miR396a-5p; +MIMAT0035456 sly-miR396a-3p; +MIMAT0035457 sly-miR167b-5p; +MIMAT0035458 sly-miR167b-3p; +MIMAT0035459 sly-miR482d-5p; +MIMAT0035460 sly-miR482d-3p; +MIMAT0035461 sly-miR9473-5p; +MIMAT0035462 sly-miR9473-3p; +MIMAT0035463 sly-miR9474-5p; +MIMAT0035464 sly-miR9474-3p; +MIMAT0035465 sly-miR9475-5p; +MIMAT0035466 sly-miR9475-3p; +MIMAT0035467 sly-miR390a-5p; +MIMAT0035468 sly-miR390a-3p; +MIMAT0035469 sly-miR9476-5p; +MIMAT0035470 sly-miR9476-3p; +MIMAT0035471 sly-miR9477-5p; +MIMAT0035472 sly-miR9477-3p; +MIMAT0035473 sly-miR9478-5p; +MIMAT0035474 sly-miR9478-3p; +MIMAT0035475 sly-miR169e-5p; +MIMAT0035476 sly-miR169e-3p; +MIMAT0035477 sly-miR9479-5p; +MIMAT0035478 sly-miR9479-3p; +MIMAT0035479 sly-miR390b-5p; +MIMAT0035480 sly-miR390b-3p; +MIMAT0035481 sly-miR396b; +MIMAT0035482 sly-miR171e; +MIMAT0035483 sly-miR477-5p; +MIMAT0035484 sly-miR477-3p; +MIMAT0035485 bdi-miR9480a; +MIMAT0035486 bdi-miR9480b; +MIMAT0035487 bdi-miR9481a; +MIMAT0035488 bdi-miR9482; +MIMAT0035489 bdi-miR9483a; +MIMAT0035490 bdi-miR9483b; +MIMAT0035491 bdi-miR9484; +MIMAT0035492 bdi-miR9485; +MIMAT0035493 bdi-miR9486a; +MIMAT0035494 bdi-miR9487; +MIMAT0035495 bdi-miR9488; +MIMAT0035496 bdi-miR9489; +MIMAT0035497 bdi-miR9486b; +MIMAT0035498 bdi-miR9490; +MIMAT0035499 bdi-miR9481b; +MIMAT0035500 bdi-miR9491; +MIMAT0035501 bdi-miR9492; +MIMAT0035502 bdi-miR9493; +MIMAT0035503 bdi-miR9494; +MIMAT0035504 bdi-miR9495; +MIMAT0035505 bdi-miR9496; +MIMAT0035506 bdi-miR9497; +MIMAT0035507 bdi-miR9498; +MIMAT0035508 bdi-miR9499; +MIMAT0035509 bdi-miR156j; +MIMAT0035510 bdi-miR159c; +MIMAT0035511 bdi-miR160f; +MIMAT0035512 bdi-miR166j; +MIMAT0035513 bdi-miR167f; +MIMAT0035514 bdi-miR167g; +MIMAT0035515 bdi-miR169l; +MIMAT0035516 bdi-miR169m; +MIMAT0035517 bdi-miR169n; +MIMAT0035518 bdi-miR171e; +MIMAT0035519 bdi-miR171f; +MIMAT0035520 bdi-miR395q; +MIMAT0035521 bdi-miR399c; +MIMAT0035522 bdi-miR399d; +MIMAT0035523 bdi-miR444b; +MIMAT0035524 bdi-miR444c; +MIMAT0035525 bdi-miR444d; +MIMAT0035526 bdi-miR530a; +MIMAT0035527 bdi-miR530b; +MIMAT0035528 bdi-miR531; +MIMAT0035529 bdi-miR845; +MIMAT0035530 bdi-miR1432; +MIMAT0035531 bdi-miR2118a; +MIMAT0035532 bdi-miR2118b; +MIMAT0035533 bdi-miR2275a; +MIMAT0035534 bdi-miR2275b; +MIMAT0035535 bdi-miR2275c; +MIMAT0035536 bdi-miR5169b; +MIMAT0035537 bdi-miR5171b; +MIMAT0035538 bdi-miR5174f; +MIMAT0035539 bdi-miR5281b; +MIMAT0035540 bdi-miR5281a; +MIMAT0035541 bdi-miR5181e; +MIMAT0035542 hsa-miR-9500; +MIMAT0035543 ath-miR826b; +MIMAT0035544 bdi-miR5200a-5p; +MIMAT0035545 bdi-miR5200a-3p; +MIMAT0035546 bdi-miR5200b-5p; +MIMAT0035547 bdi-miR5200b-3p; +MIMAT0035548 dvi-miR-1000-5p; +MIMAT0035549 dvi-miR-1000-3p; +MIMAT0035550 dvi-miR-1002-5p; +MIMAT0035551 dvi-miR-1002-3p; +MIMAT0035552 dvi-miR-1003-3p; +MIMAT0035553 dvi-miR-1006-5p; +MIMAT0035554 dvi-miR-1006-3p; +MIMAT0035555 dvi-miR-1007-3p; +MIMAT0035556 dvi-miR-1010-5p; +MIMAT0035557 dvi-miR-1010-3p; +MIMAT0035558 dvi-miR-1017-3p; +MIMAT0035559 dvi-miR-137-3p; +MIMAT0035560 dvi-miR-190-5p; +MIMAT0035561 dvi-miR-190-3p; +MIMAT0035562 dvi-miR-193-5p; +MIMAT0035563 dvi-miR-193-3p; +MIMAT0035564 dvi-miR-252-5p; +MIMAT0035565 dvi-miR-252-3p; +MIMAT0035566 dvi-miR-311-5p; +MIMAT0035567 dvi-miR-311-3p; +MIMAT0035568 dvi-miR-375-5p; +MIMAT0035569 dvi-miR-375-3p; +MIMAT0035570 dvi-miR-927-5p; +MIMAT0035571 dvi-miR-927-3p; +MIMAT0035572 dvi-miR-929-5p; +MIMAT0035573 dvi-miR-932-5p; +MIMAT0035574 dvi-miR-932-3p; +MIMAT0035575 dvi-miR-955-3p; +MIMAT0035576 dvi-miR-956-5p; +MIMAT0035577 dvi-miR-956-3p; +MIMAT0035578 dvi-miR-957-3p; +MIMAT0035579 dvi-miR-958-5p; +MIMAT0035580 dvi-miR-958-3p; +MIMAT0035581 dvi-miR-962-5p; +MIMAT0035582 dvi-miR-963-5p; +MIMAT0035583 dvi-miR-964-5p; +MIMAT0035584 dvi-miR-965-5p; +MIMAT0035585 dvi-miR-965-3p; +MIMAT0035586 dvi-miR-968-5p; +MIMAT0035587 dvi-miR-968-3p; +MIMAT0035588 dvi-miR-969-5p; +MIMAT0035589 dvi-miR-969-3p; +MIMAT0035590 dvi-miR-970-5p; +MIMAT0035591 dvi-miR-970-3p; +MIMAT0035592 dvi-miR-971-3p; +MIMAT0035593 dvi-miR-973-3p; +MIMAT0035594 dvi-miR-976-3p; +MIMAT0035595 dvi-miR-980-5p; +MIMAT0035596 dvi-miR-980-3p; +MIMAT0035597 dvi-miR-981-5p; +MIMAT0035598 dvi-miR-981-3p; +MIMAT0035599 dvi-miR-987-5p; +MIMAT0035600 dvi-miR-988-5p; +MIMAT0035601 dvi-miR-988-3p; +MIMAT0035602 dvi-miR-989-5p; +MIMAT0035603 dvi-miR-989-3p; +MIMAT0035604 dvi-miR-993-5p; +MIMAT0035605 dvi-miR-993-3p; +MIMAT0035606 dvi-miR-994-5p; +MIMAT0035607 dvi-miR-994-3p; +MIMAT0035608 dvi-miR-995-5p; +MIMAT0035609 dvi-miR-995-3p; +MIMAT0035610 dvi-miR-996-5p; +MIMAT0035611 dvi-miR-996-3p; +MIMAT0035612 dvi-miR-998-5p; +MIMAT0035613 dvi-miR-998-3p; +MIMAT0035614 dvi-miR-999-5p; +MIMAT0035615 dvi-miR-999-3p; +MIMAT0035616 dvi-miR-iab-8-5p; +MIMAT0035617 dvi-miR-iab-8-3p; +MIMAT0035618 dvi-miR-9538-5p; +MIMAT0035619 dvi-miR-9538-3p; +MIMAT0035620 dvi-miR-9539-5p; +MIMAT0035621 dvi-miR-9539-3p; +MIMAT0035622 dvi-miR-9540-5p; +MIMAT0035623 dvi-miR-9540-3p; +MIMAT0035624 dvi-miR-9542a-5p; +MIMAT0035625 dvi-miR-9542a-3p; +MIMAT0035626 dvi-miR-9543a-5p; +MIMAT0035627 dvi-miR-9543a-3p; +MIMAT0035628 dvi-miR-9544a-5p; +MIMAT0035629 dvi-miR-9544a-3p; +MIMAT0035630 dvi-miR-9545-5p; +MIMAT0035631 dvi-miR-9545-3p; +MIMAT0035632 dvi-miR-9541-5p; +MIMAT0035633 dvi-miR-9541-3p; +MIMAT0035634 dvi-miR-9547-5p; +MIMAT0035635 dvi-miR-9547-3p; +MIMAT0035636 dvi-miR-9546-5p; +MIMAT0035637 dvi-miR-9546-3p; +MIMAT0035638 dvi-miR-9548-5p; +MIMAT0035639 dvi-miR-9548-3p; +MIMAT0035640 dvi-miR-9550-5p; +MIMAT0035641 dvi-miR-9550-3p; +MIMAT0035642 dvi-miR-9549-5p; +MIMAT0035643 dvi-miR-9549-3p; +MIMAT0035644 dvi-miR-974-1-5p; +MIMAT0035645 dvi-miR-974-2-5p; +MIMAT0035646 dvi-miR-974-3p; +MIMAT0035647 dvi-miR-975-5p; +MIMAT0035648 dvi-miR-975-3p; +MIMAT0035649 dvi-miR-977-3p; +MIMAT0035650 dvi-miR-986-5p; +MIMAT0035651 dvi-miR-986-3p; +MIMAT0035652 hco-miR-9551; +MIMAT0035653 bra-miR9552a-5p; +MIMAT0035654 bra-miR9552a-3p; +MIMAT0035655 bra-miR9552b-5p; +MIMAT0035656 bra-miR9552b-3p; +MIMAT0035657 bra-miR9408-5p; +MIMAT0035658 bra-miR9408-3p; +MIMAT0035659 bra-miR9553-5p; +MIMAT0035660 bra-miR9553-3p; +MIMAT0035661 bra-miR9554-5p; +MIMAT0035662 bra-miR9554-3p; +MIMAT0035663 bra-miR9555a-5p; +MIMAT0035664 bra-miR9555a-3p; +MIMAT0035665 bra-miR9556-5p; +MIMAT0035666 bra-miR9556-3p; +MIMAT0035667 bra-miR9557-5p; +MIMAT0035668 bra-miR9557-3p; +MIMAT0035669 bra-miR9558-5p; +MIMAT0035670 bra-miR9558-3p; +MIMAT0035671 bra-miR9559-5p; +MIMAT0035672 bra-miR9559-3p; +MIMAT0035673 bra-miR9560a-5p; +MIMAT0035674 bra-miR9560a-3p; +MIMAT0035675 bra-miR9560b-5p; +MIMAT0035676 bra-miR9560b-3p; +MIMAT0035677 bra-miR9561-5p; +MIMAT0035678 bra-miR9561-3p; +MIMAT0035679 bra-miR9555b-5p; +MIMAT0035680 bra-miR9555b-3p; +MIMAT0035681 bra-miR9562-5p; +MIMAT0035682 bra-miR9562-3p; +MIMAT0035683 bra-miR408-5p; +MIMAT0035684 bra-miR408-3p; +MIMAT0035685 bra-miR9563a-5p; +MIMAT0035686 bra-miR9563a-3p; +MIMAT0035687 bra-miR9564-5p; +MIMAT0035688 bra-miR9564-3p; +MIMAT0035689 bra-miR9565-5p; +MIMAT0035690 bra-miR9565-3p; +MIMAT0035691 bra-miR9566-5p; +MIMAT0035692 bra-miR9566-3p; +MIMAT0035693 bra-miR9567-5p; +MIMAT0035694 bra-miR9567-3p; +MIMAT0035695 bra-miR9563b-5p; +MIMAT0035696 bra-miR9563b-3p; +MIMAT0035697 bra-miR9568-5p; +MIMAT0035698 bra-miR9568-3p; +MIMAT0035699 bra-miR9569-5p; +MIMAT0035700 bra-miR9569-3p; +MIMAT0035701 bra-miR158-5p; +MIMAT0035702 bra-miR158-3p; +MIMAT0035703 hsa-miR-548bb-5p; +MIMAT0035704 hsa-miR-548bb-3p; +MIMAT0035705 mse-miR-929b; +MIMAT0035706 mse-miR-9570; +MIMAT0035707 mse-miR-9571a; +MIMAT0035708 mse-miR-9571b; +MIMAT0035709 bhv5-miR-B12; +MIMAT0035710 bhv5-miR-B13; +MIMAT0035711 bhv5-miR-B14; +MIMAT0035712 bhv5-miR-B8; +MIMAT0035713 bhv5-miR-B11; +MIMAT0035714 mmu-miR-3154; +MIMAT0035715 mmu-miR-3552; +MIMAT0035716 mmu-miR-3618-5p; +MIMAT0035717 mmu-miR-3618-3p; +MIMAT0035718 mmu-miR-935; +MIMAT0035719 rno-let-7g-5p; +MIMAT0035720 rno-let-7g-3p; +MIMAT0035721 rno-miR-1247-5p; +MIMAT0035722 rno-miR-1247-3p; +MIMAT0035723 rno-miR-1297; +MIMAT0035724 rno-miR-148a-5p; +MIMAT0035725 rno-miR-148a-3p; +MIMAT0035726 rno-miR-149-5p; +MIMAT0035727 rno-miR-149-3p; +MIMAT0035728 rno-miR-15a-5p; +MIMAT0035729 rno-miR-15a-3p; +MIMAT0035730 rno-miR-1843b-5p; +MIMAT0035731 rno-miR-1843b-3p; +MIMAT0035732 rno-miR-1896; +MIMAT0035733 rno-miR-193b-5p; +MIMAT0035734 rno-miR-193b-3p; +MIMAT0035735 rno-miR-1956-5p; +MIMAT0035736 rno-miR-1956-3p; +MIMAT0035737 rno-miR-3064-5p; +MIMAT0035738 rno-miR-3064-3p; +MIMAT0035739 rno-miR-3084a-5p;rno-miR-3084a-1-5p; +MIMAT0035740 rno-miR-3084a-3p; +MIMAT0035741 rno-miR-3084b-5p;rno-miR-3084a-5p; +MIMAT0035742 rno-miR-3084b-3p; +MIMAT0035743 rno-miR-3084c-5p;rno-miR-3084b-5p; +MIMAT0035744 rno-miR-3084c-3p;rno-miR-3084b-3p; +MIMAT0035745 rno-miR-3084d; +MIMAT0035746 rno-miR-450b-5p; +MIMAT0035747 rno-miR-450b-3p; +MIMAT0035748 rno-miR-452-5p; +MIMAT0035749 rno-miR-452-3p; +MIMAT0035750 rno-miR-5132-5p; +MIMAT0035751 rno-miR-5132-3p; +MIMAT0035752 rno-miR-762; +MIMAT0035753 bfv-miR-BF1-5p; +MIMAT0035754 bfv-miR-BF1-3p; +MIMAT0035755 bfv-miR-BF2-5p; +MIMAT0035756 bfv-miR-BF2-3p; +MIMAT0035757 tae-miR1122b-3p; +MIMAT0035758 tae-miR9652-5p; +MIMAT0035759 tae-miR9652-3p; +MIMAT0035760 tae-miR9653a-3p; +MIMAT0035761 tae-miR9654a-3p; +MIMAT0035762 tae-miR9655-3p; +MIMAT0035763 tae-miR9656-3p; +MIMAT0035764 tae-miR9654b-3p; +MIMAT0035765 tae-miR9657a-3p; +MIMAT0035766 tae-miR9658-3p; +MIMAT0035767 tae-miR9659-3p; +MIMAT0035768 tae-miR9660-5p; +MIMAT0035769 tae-miR1127b-3p; +MIMAT0035770 tae-miR9661-5p; +MIMAT0035771 tae-miR396-5p; +MIMAT0035772 tae-miR9662a-3p; +MIMAT0035773 tae-miR9663-5p; +MIMAT0035774 tae-miR1137b-5p; +MIMAT0035775 tae-miR9664-3p; +MIMAT0035776 tae-miR9665-3p; +MIMAT0035777 tae-miR2275-3p; +MIMAT0035778 tae-miR9666a-3p; +MIMAT0035779 tae-miR9667-5p; +MIMAT0035780 tae-miR9662b-3p; +MIMAT0035781 tae-miR5062-5p; +MIMAT0035782 tae-miR9668-5p; +MIMAT0035783 tae-miR9669-5p; +MIMAT0035784 tae-miR9666c-5p; +MIMAT0035785 tae-miR9670-3p; +MIMAT0035786 tae-miR1847-5p; +MIMAT0035787 tae-miR9671-5p; +MIMAT0035788 tae-miR1122c-3p; +MIMAT0035789 tae-miR167c-5p; +MIMAT0035790 tae-miR9672a-3p; +MIMAT0035791 tae-miR9673-5p; +MIMAT0035792 tae-miR5175-5p; +MIMAT0035793 tae-miR9674a-5p; +MIMAT0035794 tae-miR1120b-3p; +MIMAT0035795 tae-miR397-5p; +MIMAT0035796 tae-miR1130b-3p; +MIMAT0035797 tae-miR5384-3p; +MIMAT0035798 tae-miR9675-3p; +MIMAT0035799 tae-miR1120c-5p; +MIMAT0035800 tae-miR7757-5p; +MIMAT0035801 tae-miR9674b-5p; +MIMAT0035802 tae-miR9676-5p; +MIMAT0035803 tae-miR5048-5p; +MIMAT0035804 tae-miR9677a; +MIMAT0035805 tae-miR9678-3p; +MIMAT0035806 tae-miR6197-5p; +MIMAT0035807 tae-miR9657c-3p; +MIMAT0035808 tae-miR9679-5p; +MIMAT0035809 tae-miR5049-3p; +MIMAT0035810 tae-miR9657b-5p; +MIMAT0035811 tae-miR9657b-3p; +MIMAT0035812 tae-miR9666b-5p; +MIMAT0035813 tae-miR9666b-3p; +MIMAT0035814 hvu-miR397b-3p; +MIMAT0035815 hvu-miR156b; +MIMAT0035816 bra-miR156a-5p; +MIMAT0035817 bra-miR156a-3p; +MIMAT0035818 bra-miR156b-5p; +MIMAT0035819 bra-miR156b-3p; +MIMAT0035820 bra-miR156c-5p; +MIMAT0035821 bra-miR156c-3p; +MIMAT0035822 bra-miR156d-5p; +MIMAT0035823 bra-miR156d-3p; +MIMAT0035824 bra-miR156e-5p; +MIMAT0035825 bra-miR156e-3p; +MIMAT0035826 bra-miR156f-5p; +MIMAT0035827 bra-miR156f-3p; +MIMAT0035828 bra-miR156g-5p; +MIMAT0035829 bra-miR156g-3p; +MIMAT0035830 bra-miR162-5p; +MIMAT0035831 bra-miR162-3p; +MIMAT0035832 bra-miR168b-5p; +MIMAT0035833 bra-miR168b-3p; +MIMAT0035834 bra-miR168c-5p; +MIMAT0035835 bra-miR168c-3p; +MIMAT0035836 bra-miR168a-5p; +MIMAT0035837 bra-miR168a-3p; +MIMAT0035838 bra-miR319-5p; +MIMAT0035839 bra-miR319-3p; +MIMAT0035840 bra-miR390-5p; +MIMAT0035841 bra-miR390-3p; +MIMAT0035842 bra-miR391-5p; +MIMAT0035843 bra-miR391-3p; +MIMAT0035844 bra-miR395d-5p; +MIMAT0035845 bra-miR395d-3p; +MIMAT0035846 bra-miR395b-5p; +MIMAT0035847 bra-miR395b-3p; +MIMAT0035848 bra-miR395c-5p; +MIMAT0035849 bra-miR395c-3p; +MIMAT0035850 bra-miR395a-5p; +MIMAT0035851 bra-miR395a-3p; +MIMAT0035852 bra-miR396-5p; +MIMAT0035853 bra-miR396-3p; +MIMAT0035854 bra-miR398-5p; +MIMAT0035855 bra-miR398-3p; +MIMAT0035856 bra-miR400-5p; +MIMAT0035857 bra-miR400-3p; +MIMAT0035858 bra-miR403-5p; +MIMAT0035859 bra-miR403-3p; +MIMAT0035860 bra-miR860-5p; +MIMAT0035861 bra-miR860-3p; +MIMAT0035862 bra-miR6032-5p; +MIMAT0035863 bra-miR6032-3p; +MIMAT0035864 bra-miR164b-5p; +MIMAT0035865 bra-miR164b-3p; +MIMAT0035866 bra-miR164d-5p; +MIMAT0035867 bra-miR164d-3p; +MIMAT0035868 bra-miR164c-5p; +MIMAT0035869 bra-miR164c-3p; +MIMAT0035870 bra-miR164e-5p; +MIMAT0035871 bra-miR164e-3p; +MIMAT0035872 bra-miR172c-5p; +MIMAT0035873 bra-miR172c-3p; +MIMAT0035874 bra-miR2111-5p; +MIMAT0035875 bra-miR2111-3p; +MIMAT0035876 bra-miR172d-5p; +MIMAT0035877 bra-miR172d-3p; +MIMAT0035878 bra-miR161-5p; +MIMAT0035879 bra-miR161-3p; +MIMAT0035880 chi-let-7a-5p; +MIMAT0035881 chi-let-7a-3p; +MIMAT0035882 chi-let-7b-5p; +MIMAT0035883 chi-let-7b-3p; +MIMAT0035884 chi-let-7c-5p; +MIMAT0035885 chi-let-7c-3p; +MIMAT0035886 chi-let-7d-5p; +MIMAT0035887 chi-let-7d-3p; +MIMAT0035888 chi-let-7e-5p; +MIMAT0035889 chi-let-7e-3p; +MIMAT0035890 chi-let-7f-5p; +MIMAT0035891 chi-let-7f-3p; +MIMAT0035892 chi-let-7g-5p; +MIMAT0035893 chi-let-7g-3p; +MIMAT0035894 chi-let-7i-5p; +MIMAT0035895 chi-let-7i-3p; +MIMAT0035896 chi-miR-1; +MIMAT0035897 chi-miR-100-5p; +MIMAT0035898 chi-miR-100-3p; +MIMAT0035899 chi-miR-101-5p; +MIMAT0035900 chi-miR-101-3p; +MIMAT0035901 chi-miR-103-5p; +MIMAT0035902 chi-miR-103-3p; +MIMAT0035903 chi-miR-105a; +MIMAT0035904 chi-miR-105b-5p; +MIMAT0035905 chi-miR-105b-3p; +MIMAT0035906 chi-miR-106a-5p; +MIMAT0035907 chi-miR-106a-3p; +MIMAT0035908 chi-miR-106b-5p; +MIMAT0035909 chi-miR-106b-3p; +MIMAT0035910 chi-miR-107-3p; +MIMAT0035911 chi-miR-10a-5p; +MIMAT0035912 chi-miR-10a-3p; +MIMAT0035913 chi-miR-10b-5p; +MIMAT0035914 chi-miR-10b-3p; +MIMAT0035915 chi-miR-1185-5p; +MIMAT0035916 chi-miR-1185-3p; +MIMAT0035917 chi-miR-1197-3p; +MIMAT0035918 chi-miR-122; +MIMAT0035919 chi-miR-1224; +MIMAT0035920 chi-miR-1248-5p; +MIMAT0035921 chi-miR-1249; +MIMAT0035922 chi-miR-124a; +MIMAT0035923 chi-miR-125a-5p; +MIMAT0035924 chi-miR-125a-3p; +MIMAT0035925 chi-miR-125b-5p; +MIMAT0035926 chi-miR-125b-3p; +MIMAT0035927 chi-miR-126-5p; +MIMAT0035928 chi-miR-126-3p; +MIMAT0035929 chi-miR-127-5p; +MIMAT0035930 chi-miR-127-3p; +MIMAT0035931 chi-miR-1271-5p; +MIMAT0035932 chi-miR-1271-3p; +MIMAT0035933 chi-miR-128-5p; +MIMAT0035934 chi-miR-128-3p; +MIMAT0035935 chi-miR-1291; +MIMAT0035936 chi-miR-129-5p; +MIMAT0035937 chi-miR-129-3p; +MIMAT0035938 chi-miR-1296; +MIMAT0035939 chi-miR-1306-5p; +MIMAT0035940 chi-miR-1306-3p; +MIMAT0035941 chi-miR-1307-5p; +MIMAT0035942 chi-miR-1307-3p; +MIMAT0035943 chi-miR-130a-5p; +MIMAT0035944 chi-miR-130a-3p; +MIMAT0035945 chi-miR-130b-5p; +MIMAT0035946 chi-miR-130b-3p; +MIMAT0035947 chi-miR-133a-5p; +MIMAT0035948 chi-miR-133a-3p; +MIMAT0035949 chi-miR-133b; +MIMAT0035950 chi-miR-1343; +MIMAT0035951 chi-miR-134; +MIMAT0035952 chi-miR-135a; +MIMAT0035953 chi-miR-135b-5p; +MIMAT0035954 chi-miR-135b-3p; +MIMAT0035955 chi-miR-136-5p; +MIMAT0035956 chi-miR-136-3p; +MIMAT0035957 chi-miR-137; +MIMAT0035958 chi-miR-1388-5p; +MIMAT0035959 chi-miR-1388-3p; +MIMAT0035960 chi-miR-140-5p; +MIMAT0035961 chi-miR-140-3p; +MIMAT0035962 chi-miR-141; +MIMAT0035963 chi-miR-143-5p; +MIMAT0035964 chi-miR-143-3p; +MIMAT0035965 chi-miR-144-5p; +MIMAT0035966 chi-miR-144-3p; +MIMAT0035967 chi-miR-145-5p; +MIMAT0035968 chi-miR-145-3p; +MIMAT0035969 chi-miR-1468-5p; +MIMAT0035970 chi-miR-1468-3p; +MIMAT0035971 chi-miR-146a; +MIMAT0035972 chi-miR-146b-5p; +MIMAT0035973 chi-miR-146b-3p; +MIMAT0035974 chi-miR-147-5p; +MIMAT0035975 chi-miR-147-3p; +MIMAT0035976 chi-miR-148a-5p; +MIMAT0035977 chi-miR-148a-3p; +MIMAT0035978 chi-miR-148b-5p; +MIMAT0035979 chi-miR-148b-3p; +MIMAT0035980 chi-miR-150; +MIMAT0035981 chi-miR-151-5p; +MIMAT0035982 chi-miR-151-3p; +MIMAT0035983 chi-miR-153; +MIMAT0035984 chi-miR-154a-5p; +MIMAT0035985 chi-miR-154a-3p; +MIMAT0035986 chi-miR-154b-5p; +MIMAT0035987 chi-miR-154b-3p; +MIMAT0035988 chi-miR-155-5p; +MIMAT0035989 chi-miR-155-3p; +MIMAT0035990 chi-miR-15a-5p; +MIMAT0035991 chi-miR-15a-3p; +MIMAT0035992 chi-miR-15b-5p; +MIMAT0035993 chi-miR-15b-3p; +MIMAT0035994 chi-miR-16a-5p; +MIMAT0035995 chi-miR-16a-3p; +MIMAT0035996 chi-miR-16b-5p; +MIMAT0035997 chi-miR-16b-3p; +MIMAT0035998 chi-miR-17-5p; +MIMAT0035999 chi-miR-17-3p; +MIMAT0036000 chi-miR-1814; +MIMAT0036001 chi-miR-181b-5p; +MIMAT0036002 chi-miR-181b-3p; +MIMAT0036003 chi-miR-181c-5p; +MIMAT0036004 chi-miR-181c-3p; +MIMAT0036005 chi-miR-181d; +MIMAT0036006 chi-miR-182; +MIMAT0036007 chi-miR-183; +MIMAT0036008 chi-miR-1839; +MIMAT0036009 chi-miR-184; +MIMAT0036010 chi-miR-186-5p; +MIMAT0036011 chi-miR-186-3p; +MIMAT0036012 chi-miR-187; +MIMAT0036013 chi-miR-188-5p; +MIMAT0036014 chi-miR-188-3p; +MIMAT0036015 chi-miR-18a-5p; +MIMAT0036016 chi-miR-18a-3p; +MIMAT0036017 chi-miR-18b-5p; +MIMAT0036018 chi-miR-18b-3p; +MIMAT0036019 chi-miR-190a-5p; +MIMAT0036020 chi-miR-190a-3p; +MIMAT0036021 chi-miR-190b; +MIMAT0036022 chi-miR-191-5p; +MIMAT0036023 chi-miR-191-3p; +MIMAT0036024 chi-miR-192-5p; +MIMAT0036025 chi-miR-192-3p; +MIMAT0036026 chi-miR-193a; +MIMAT0036027 chi-miR-193b-5p; +MIMAT0036028 chi-miR-193b-3p; +MIMAT0036029 chi-miR-194; +MIMAT0036030 chi-miR-195-5p; +MIMAT0036031 chi-miR-195-3p; +MIMAT0036032 chi-miR-196a; +MIMAT0036033 chi-miR-196b; +MIMAT0036034 chi-miR-197-5p; +MIMAT0036035 chi-miR-197-3p; +MIMAT0036036 chi-miR-199a-5p; +MIMAT0036037 chi-miR-199a-3p; +MIMAT0036038 chi-miR-199b-5p; +MIMAT0036039 chi-miR-199b-3p; +MIMAT0036040 chi-miR-199c-5p; +MIMAT0036041 chi-miR-199c-3p; +MIMAT0036042 chi-miR-19a; +MIMAT0036043 chi-miR-19b-5p; +MIMAT0036044 chi-miR-19b-3p; +MIMAT0036045 chi-miR-200a; +MIMAT0036046 chi-miR-200b; +MIMAT0036047 chi-miR-200c; +MIMAT0036048 chi-miR-202-5p; +MIMAT0036049 chi-miR-202-3p; +MIMAT0036050 chi-miR-204-5p; +MIMAT0036051 chi-miR-204-3p; +MIMAT0036052 chi-miR-206; +MIMAT0036053 chi-miR-208b; +MIMAT0036054 chi-miR-20a-5p; +MIMAT0036055 chi-miR-20a-3p; +MIMAT0036056 chi-miR-20b; +MIMAT0036057 chi-miR-211; +MIMAT0036058 chi-miR-214-5p; +MIMAT0036059 chi-miR-214-3p; +MIMAT0036060 chi-miR-215-5p; +MIMAT0036061 chi-miR-21-5p; +MIMAT0036062 chi-miR-21-3p; +MIMAT0036063 chi-miR-216b; +MIMAT0036064 chi-miR-217-5p; +MIMAT0036065 chi-miR-217-3p; +MIMAT0036066 chi-miR-218; +MIMAT0036067 chi-miR-219; +MIMAT0036068 chi-miR-221-5p; +MIMAT0036069 chi-miR-221-3p; +MIMAT0036070 chi-miR-222-3p; +MIMAT0036071 chi-miR-223-5p; +MIMAT0036072 chi-miR-223-3p; +MIMAT0036073 chi-miR-224-5p; +MIMAT0036074 chi-miR-224-3p; +MIMAT0036075 chi-miR-22-5p; +MIMAT0036076 chi-miR-22-3p; +MIMAT0036077 chi-miR-2284a; +MIMAT0036078 chi-miR-2284b; +MIMAT0036079 chi-miR-2284c; +MIMAT0036080 chi-miR-2284d; +MIMAT0036081 chi-miR-2290; +MIMAT0036082 chi-miR-2318; +MIMAT0036083 chi-miR-2320; +MIMAT0036084 chi-miR-2331; +MIMAT0036085 chi-miR-2332; +MIMAT0036086 chi-miR-2335; +MIMAT0036087 chi-miR-23a; +MIMAT0036088 chi-miR-23b-5p; +MIMAT0036089 chi-miR-23b-3p; +MIMAT0036090 chi-miR-24-5p; +MIMAT0036091 chi-miR-24-3p; +MIMAT0036092 chi-miR-2404; +MIMAT0036093 chi-miR-2411-5p; +MIMAT0036094 chi-miR-2411-3p; +MIMAT0036095 chi-miR-2432; +MIMAT0036096 chi-miR-2284e; +MIMAT0036097 chi-miR-2483-5p; +MIMAT0036098 chi-miR-2483-3p; +MIMAT0036099 chi-miR-25-5p; +MIMAT0036100 chi-miR-25-3p; +MIMAT0036101 chi-miR-26a-5p; +MIMAT0036102 chi-miR-26a-3p; +MIMAT0036103 chi-miR-26b-5p; +MIMAT0036104 chi-miR-26b-3p; +MIMAT0036105 chi-miR-27a-5p; +MIMAT0036106 chi-miR-27a-3p; +MIMAT0036107 chi-miR-27b-5p; +MIMAT0036108 chi-miR-27b-3p; +MIMAT0036109 chi-miR-28-5p; +MIMAT0036110 chi-miR-28-3p; +MIMAT0036111 chi-miR-296-3p; +MIMAT0036112 chi-miR-29a-5p; +MIMAT0036113 chi-miR-29a-3p; +MIMAT0036114 chi-miR-29b-5p; +MIMAT0036115 chi-miR-29b-3p; +MIMAT0036116 chi-miR-29c-5p; +MIMAT0036117 chi-miR-29c-3p; +MIMAT0036118 chi-miR-301a-5p; +MIMAT0036119 chi-miR-301a-3p; +MIMAT0036120 chi-miR-301b; +MIMAT0036121 chi-miR-30a-5p; +MIMAT0036122 chi-miR-30a-3p; +MIMAT0036123 chi-miR-30b-5p; +MIMAT0036124 chi-miR-30b-3p; +MIMAT0036125 chi-miR-30c-5p; +MIMAT0036126 chi-miR-30c-3p; +MIMAT0036127 chi-miR-30d-3p; +MIMAT0036128 chi-miR-30e-5p; +MIMAT0036129 chi-miR-30e-3p; +MIMAT0036130 chi-miR-30f-5p; +MIMAT0036131 chi-miR-30f-3p; +MIMAT0036132 chi-miR-320-3p; +MIMAT0036133 chi-miR-323a-3p; +MIMAT0036134 chi-miR-323b; +MIMAT0036135 chi-miR-324-5p; +MIMAT0036136 chi-miR-324-3p; +MIMAT0036137 chi-miR-326-5p; +MIMAT0036138 chi-miR-326-3p; +MIMAT0036139 chi-miR-328-3p; +MIMAT0036140 chi-miR-329a-5p; +MIMAT0036141 chi-miR-329a-3p; +MIMAT0036142 chi-miR-329b-3p; +MIMAT0036143 chi-miR-330-5p; +MIMAT0036144 chi-miR-330-3p; +MIMAT0036145 chi-miR-331-5p; +MIMAT0036146 chi-miR-331-3p; +MIMAT0036147 chi-miR-335-5p; +MIMAT0036148 chi-miR-335-3p; +MIMAT0036149 chi-miR-338-5p; +MIMAT0036150 chi-miR-338-3p; +MIMAT0036151 chi-miR-33a-5p; +MIMAT0036152 chi-miR-33a-3p; +MIMAT0036153 chi-miR-33b-5p; +MIMAT0036154 chi-miR-33b-3p; +MIMAT0036155 chi-miR-340-5p; +MIMAT0036156 chi-miR-340-3p; +MIMAT0036157 chi-miR-342-5p; +MIMAT0036158 chi-miR-342-3p; +MIMAT0036159 chi-miR-3431-5p; +MIMAT0036160 chi-miR-3431-3p; +MIMAT0036161 chi-miR-3432-5p; +MIMAT0036162 chi-miR-3432-3p; +MIMAT0036163 chi-miR-345-5p; +MIMAT0036164 chi-miR-345-3p; +MIMAT0036165 chi-miR-346-5p; +MIMAT0036166 chi-miR-34a; +MIMAT0036167 chi-miR-34b-5p; +MIMAT0036168 chi-miR-34b-3p; +MIMAT0036169 chi-miR-34c-5p; +MIMAT0036170 chi-miR-34c-3p; +MIMAT0036171 chi-miR-361-5p; +MIMAT0036172 chi-miR-361-3p; +MIMAT0036173 chi-miR-362-5p; +MIMAT0036174 chi-miR-362-3p; +MIMAT0036175 chi-miR-363-5p; +MIMAT0036176 chi-miR-363-3p; +MIMAT0036177 chi-miR-365-3p; +MIMAT0036178 chi-miR-369-5p; +MIMAT0036179 chi-miR-369-3p; +MIMAT0036180 chi-miR-374a-5p; +MIMAT0036181 chi-miR-374a-3p; +MIMAT0036182 chi-miR-374b-5p; +MIMAT0036183 chi-miR-374b-3p; +MIMAT0036184 chi-miR-376a; +MIMAT0036185 chi-miR-376b-5p; +MIMAT0036186 chi-miR-376b-3p; +MIMAT0036187 chi-miR-376c-5p; +MIMAT0036188 chi-miR-376c-3p; +MIMAT0036189 chi-miR-376d; +MIMAT0036190 chi-miR-376e-5p; +MIMAT0036191 chi-miR-376e-3p; +MIMAT0036192 chi-miR-377; +MIMAT0036193 chi-miR-378-5p; +MIMAT0036194 chi-miR-378-3p; +MIMAT0036195 chi-miR-379-5p; +MIMAT0036196 chi-miR-379-3p; +MIMAT0036197 chi-miR-380-5p; +MIMAT0036198 chi-miR-380-3p; +MIMAT0036199 chi-miR-381; +MIMAT0036200 chi-miR-382-5p; +MIMAT0036201 chi-miR-382-3p; +MIMAT0036202 chi-miR-383; +MIMAT0036203 chi-miR-3955-5p; +MIMAT0036204 chi-miR-3955-3p; +MIMAT0036205 chi-miR-3958-5p; +MIMAT0036206 chi-miR-3958-3p; +MIMAT0036207 chi-miR-3959-5p; +MIMAT0036208 chi-miR-3959-3p; +MIMAT0036209 chi-miR-409-5p; +MIMAT0036210 chi-miR-409-3p; +MIMAT0036211 chi-miR-410-5p; +MIMAT0036212 chi-miR-410-3p; +MIMAT0036213 chi-miR-411a-5p; +MIMAT0036214 chi-miR-411a-3p; +MIMAT0036215 chi-miR-411b-5p; +MIMAT0036216 chi-miR-411b-3p; +MIMAT0036217 chi-miR-412-5p; +MIMAT0036218 chi-miR-412-3p; +MIMAT0036219 chi-miR-421-3p; +MIMAT0036220 chi-miR-423-5p; +MIMAT0036221 chi-miR-423-3p; +MIMAT0036222 chi-miR-424-5p; +MIMAT0036223 chi-miR-424-3p; +MIMAT0036224 chi-miR-425-5p; +MIMAT0036225 chi-miR-425-3p; +MIMAT0036226 chi-miR-429; +MIMAT0036227 chi-miR-432-5p; +MIMAT0036228 chi-miR-432-3p; +MIMAT0036229 chi-miR-433; +MIMAT0036230 chi-miR-449a-5p; +MIMAT0036231 chi-miR-449a-3p; +MIMAT0036232 chi-miR-449b-5p; +MIMAT0036233 chi-miR-449b-3p; +MIMAT0036234 chi-miR-449c; +MIMAT0036235 chi-miR-450-5p; +MIMAT0036236 chi-miR-450-3p; +MIMAT0036237 chi-miR-451-5p; +MIMAT0036238 chi-miR-451-3p; +MIMAT0036239 chi-miR-454-5p; +MIMAT0036240 chi-miR-454-3p; +MIMAT0036241 chi-miR-455-5p; +MIMAT0036242 chi-miR-455-3p; +MIMAT0036243 chi-miR-483; +MIMAT0036244 chi-miR-485-5p; +MIMAT0036245 chi-miR-485-3p; +MIMAT0036246 chi-miR-487a-5p; +MIMAT0036247 chi-miR-487a-3p; +MIMAT0036248 chi-miR-487b-5p; +MIMAT0036249 chi-miR-487b-3p; +MIMAT0036250 chi-miR-490; +MIMAT0036251 chi-miR-491-5p; +MIMAT0036252 chi-miR-491-3p; +MIMAT0036253 chi-miR-493-5p; +MIMAT0036254 chi-miR-493-3p; +MIMAT0036255 chi-miR-494; +MIMAT0036256 chi-miR-495-3p; +MIMAT0036257 chi-miR-496-5p; +MIMAT0036258 chi-miR-496-3p; +MIMAT0036259 chi-miR-497-5p; +MIMAT0036260 chi-miR-497-3p; +MIMAT0036261 chi-miR-499-5p; +MIMAT0036262 chi-miR-499-3p; +MIMAT0036263 chi-miR-500-5p; +MIMAT0036264 chi-miR-500-3p; +MIMAT0036265 chi-miR-502a; +MIMAT0036266 chi-miR-502b-5p; +MIMAT0036267 chi-miR-502b-3p; +MIMAT0036268 chi-miR-504; +MIMAT0036269 chi-miR-505-3p; +MIMAT0036270 chi-miR-532-5p; +MIMAT0036271 chi-miR-532-3p; +MIMAT0036272 chi-miR-542-5p; +MIMAT0036273 chi-miR-542-3p; +MIMAT0036274 chi-miR-543-5p; +MIMAT0036275 chi-miR-543-3p; +MIMAT0036276 chi-miR-544-5p; +MIMAT0036277 chi-miR-545-5p; +MIMAT0036278 chi-miR-545-3p; +MIMAT0036279 chi-miR-582-5p; +MIMAT0036280 chi-miR-592; +MIMAT0036281 chi-miR-628-5p; +MIMAT0036282 chi-miR-655; +MIMAT0036283 chi-miR-656; +MIMAT0036284 chi-miR-660; +MIMAT0036285 chi-miR-665; +MIMAT0036286 chi-miR-671-5p; +MIMAT0036287 chi-miR-671-3p; +MIMAT0036288 chi-miR-7-5p; +MIMAT0036289 chi-miR-7-3p; +MIMAT0036290 chi-miR-708-5p; +MIMAT0036291 chi-miR-708-3p; +MIMAT0036292 chi-miR-758; +MIMAT0036293 chi-miR-767; +MIMAT0036294 chi-miR-873-5p; +MIMAT0036295 chi-miR-873-3p; +MIMAT0036296 chi-miR-874-5p; +MIMAT0036297 chi-miR-874-3p; +MIMAT0036298 chi-miR-876-5p; +MIMAT0036299 chi-miR-876-3p; +MIMAT0036300 chi-miR-877-5p; +MIMAT0036301 chi-miR-877-3p; +MIMAT0036302 chi-miR-92a-5p; +MIMAT0036303 chi-miR-92a-3p; +MIMAT0036304 chi-miR-92b; +MIMAT0036305 chi-miR-93-5p; +MIMAT0036306 chi-miR-93-3p; +MIMAT0036307 chi-miR-9-5p; +MIMAT0036308 chi-miR-9-3p; +MIMAT0036309 chi-miR-96; +MIMAT0036310 chi-miR-98-5p; +MIMAT0036311 chi-miR-98-3p; +MIMAT0036312 chi-miR-99a-5p; +MIMAT0036313 chi-miR-99a-3p; +MIMAT0036314 chi-miR-99b-5p; +MIMAT0036315 chi-miR-99b-3p; +MIMAT0036316 ocu-miR-302b-5p; +MIMAT0036317 ocu-miR-302b-3p; +MIMAT0036318 ocu-miR-302c-5p; +MIMAT0036319 ocu-miR-302c-3p; +MIMAT0036320 ocu-miR-302a-5p; +MIMAT0036321 ocu-miR-302a-3p; +MIMAT0036322 ocu-miR-302d-5p; +MIMAT0036323 ocu-miR-302d-3p; +MIMAT0036324 ocu-miR-367-5p; +MIMAT0036325 ocu-miR-367-3p; +MIMAT0036326 ocu-miR-294-3p;ocu-miR-373-3p; +MIMAT0036327 ocu-miR-290-5p;ocu-miR-371-5p; +MIMAT0036328 ocu-miR-290-3p;ocu-miR-371-3p; +MIMAT0036329 ocu-miR-520e; +MIMAT0036330 ocu-miR-498; +MIMAT0036331 ocu-miR-512a-5p; +MIMAT0036332 ocu-miR-512a-3p; +MIMAT0036333 ocu-miR-512b-5p; +MIMAT0036334 ocu-miR-512b-3p; +MIMAT0036335 ocu-miR-191-5p; +MIMAT0036336 ocu-miR-191-3p; +MIMAT0036337 gma-miR9722; +MIMAT0036338 gma-miR9723; +MIMAT0036339 gma-miR9724; +MIMAT0036340 gma-miR9725; +MIMAT0036341 gma-miR5780b; +MIMAT0036342 gma-miR9726; +MIMAT0036343 gma-miR398d; +MIMAT0036344 gma-miR4348b; +MIMAT0036345 gma-miR9727; +MIMAT0036346 gma-miR9728; +MIMAT0036347 gma-miR9729; +MIMAT0036348 gma-miR5671b; +MIMAT0036349 gma-miR9730; +MIMAT0036350 gma-miR9731; +MIMAT0036351 gma-miR9732; +MIMAT0036352 gma-miR5780c; +MIMAT0036353 gma-miR9733; +MIMAT0036354 gma-miR9734; +MIMAT0036355 gma-miR9735; +MIMAT0036356 gma-miR9736; +MIMAT0036357 gma-miR9737; +MIMAT0036358 gma-miR9738; +MIMAT0036359 gma-miR9739; +MIMAT0036360 gma-miR9740; +MIMAT0036361 gma-miR9741; +MIMAT0036362 gma-miR9742; +MIMAT0036363 gma-miR9743; +MIMAT0036364 gma-miR9744; +MIMAT0036365 gma-miR9745; +MIMAT0036366 gma-miR9746a; +MIMAT0036367 gma-miR9746b; +MIMAT0036368 gma-miR9746c; +MIMAT0036369 gma-miR9746d; +MIMAT0036370 gma-miR9746e; +MIMAT0036371 gma-miR9746f; +MIMAT0036372 gma-miR9746g; +MIMAT0036373 gma-miR9746h; +MIMAT0036374 gma-miR9747; +MIMAT0036375 gma-miR9748; +MIMAT0036376 gma-miR9749; +MIMAT0036377 gma-miR319o; +MIMAT0036378 gma-miR9750;gma-miR9750-3p; +MIMAT0036379 gma-miR319p; +MIMAT0036380 gma-miR9751; +MIMAT0036381 gma-miR9752; +MIMAT0036382 gma-miR399i; +MIMAT0036383 gma-miR9746i; +MIMAT0036384 gma-miR9753; +MIMAT0036385 gma-miR9754; +MIMAT0036386 gma-miR9755; +MIMAT0036387 gma-miR9756; +MIMAT0036388 gma-miR167k; +MIMAT0036389 gma-miR4348c; +MIMAT0036390 gma-miR9757; +MIMAT0036391 gma-miR5380c; +MIMAT0036392 gma-miR9758; +MIMAT0036393 gma-miR5670b; +MIMAT0036394 gma-miR9759; +MIMAT0036395 gma-miR9760; +MIMAT0036396 gma-miR5780d; +MIMAT0036397 gma-miR9761; +MIMAT0036398 gma-miR319q; +MIMAT0036399 gma-miR9762; +MIMAT0036400 gma-miR9763; +MIMAT0036401 gma-miR9764; +MIMAT0036402 gma-miR9765; +MIMAT0036403 gma-miR9766; +MIMAT0036404 gma-miR9767; +MIMAT0036405 ggo-miR-515-5p; +MIMAT0036406 ggo-miR-515-3p; +MIMAT0036407 ggo-miR-519e-5p; +MIMAT0036408 ggo-miR-519e-3p; +MIMAT0036409 ggo-miR-520f; +MIMAT0036410 ggo-miR-519c-5p; +MIMAT0036411 ggo-miR-519c-3p; +MIMAT0036412 ggo-miR-525-5p; +MIMAT0036413 ggo-miR-525-3p; +MIMAT0036414 ggo-miR-523-5p; +MIMAT0036415 ggo-miR-523-3p; +MIMAT0036416 ggo-miR-518f-5p; +MIMAT0036417 ggo-miR-518f-3p; +MIMAT0036418 ggo-miR-519b; +MIMAT0036419 ggo-miR-518b; +MIMAT0036420 ggo-miR-520c; +MIMAT0036421 ggo-miR-518c-5p; +MIMAT0036422 ggo-miR-518c-3p; +MIMAT0036423 ggo-miR-524-5p; +MIMAT0036424 ggo-miR-524-3p; +MIMAT0036425 ggo-miR-519d; +MIMAT0036426 ggo-miR-526a; +MIMAT0036427 ggo-miR-518e-5p; +MIMAT0036428 ggo-miR-518e-3p; +MIMAT0036429 ggo-miR-518d-5p; +MIMAT0036430 ggo-miR-518d-3p; +MIMAT0036431 ggo-miR-1283; +MIMAT0036432 ggo-miR-517c-5p; +MIMAT0036433 ggo-miR-517c-3p; +MIMAT0036434 ggo-miR-520g; +MIMAT0036435 ggo-miR-519c; +MIMAT0036436 ggo-miR-521; +MIMAT0036437 ggo-miR-522-5p; +MIMAT0036438 ggo-miR-522-3p; +MIMAT0036439 ggo-miR-519a-5p; +MIMAT0036440 ggo-miR-519a-3p; +MIMAT0036441 ggo-miR-516a-5p; +MIMAT0036442 ggo-miR-516a-3p; +MIMAT0036443 ggo-miR-516a; +MIMAT0036444 ggo-miR-519a; +MIMAT0036445 mml-miR-519a; +MIMAT0036446 mml-miR-517b; +MIMAT0036447 ppy-miR-517c-5p; +MIMAT0036448 ppy-miR-517c-3p; +MIMAT0036449 ppy-miR-517c-??; +MIMAT0036450 ppy-miR-518g-5p;ppy-miR-518e-5p; +MIMAT0036451 ppy-miR-518g-3p;ppy-miR-518e-3p; +MIMAT0036452 ppy-miR-520i; +MIMAT0036453 ppy-miR-516a; +MIMAT0036454 ptr-miR-518g-5p; +MIMAT0036455 ptr-miR-518g-3p; +MIMAT0036456 ptr-miR-519f-5p; +MIMAT0036457 ptr-miR-519f-3p; +MIMAT0036458 ptr-miR-1283b; +MIMAT0036459 mmu-miR-9768-5p; +MIMAT0036460 mmu-miR-9768-3p; +MIMAT0036461 mmu-miR-9769-5p; +MIMAT0036462 mmu-miR-9769-3p; +MIMAT0036463 tch-miR-181a-5p; +MIMAT0036464 tch-miR-210; +MIMAT0036465 tch-miR-7-5p; +MIMAT0036466 tch-miR-200a-3p; +MIMAT0036467 tch-miR-1277-5p; +MIMAT0036468 tch-miR-33a-5p; +MIMAT0036469 tch-miR-9771a; +MIMAT0036470 tch-miR-142; +MIMAT0036471 tch-miR-10b-5p; +MIMAT0036472 tch-miR-155-5p; +MIMAT0036473 tch-miR-200c-3p; +MIMAT0036474 tch-miR-125a-5p; +MIMAT0036475 tch-miR-450a-5p; +MIMAT0036476 tch-miR-143-3p; +MIMAT0036477 tch-miR-9771b; +MIMAT0036478 tch-miR-592; +MIMAT0036479 tch-miR-199b-3p; +MIMAT0036480 tch-miR-103a-3p; +MIMAT0036481 tch-miR-6529; +MIMAT0036482 tch-miR-9771c; +MIMAT0036483 tch-let-7a-5p; +MIMAT0036484 tch-let-7a-3p; +MIMAT0036485 tch-miR-32-5p; +MIMAT0036486 tch-miR-95; +MIMAT0036487 tch-miR-342-3p; +MIMAT0036488 tch-miR-26a-5p; +MIMAT0036489 tch-miR-141-3p; +MIMAT0036490 tch-miR-411-5p; +MIMAT0036491 tch-miR-188-5p; +MIMAT0036492 tch-miR-188-3p; +MIMAT0036493 tch-miR-184; +MIMAT0036494 tch-miR-29b-3p; +MIMAT0036495 tch-miR-424-5p; +MIMAT0036496 tch-miR-1306-5p; +MIMAT0036497 tch-miR-1306-3p; +MIMAT0036498 tch-miR-365b-3p; +MIMAT0036499 tch-miR-505-3p; +MIMAT0036500 tch-miR-92a-3p; +MIMAT0036501 tch-miR-190b; +MIMAT0036502 tch-miR-409-3p; +MIMAT0036503 tch-miR-30b-5p; +MIMAT0036504 tch-miR-296-3p; +MIMAT0036505 tch-miR-539-3p; +MIMAT0036506 tch-miR-129-5p; +MIMAT0036507 tch-miR-101; +MIMAT0036508 tch-miR-107; +MIMAT0036509 tch-miR-499a-5p; +MIMAT0036510 tch-miR-34a-5p; +MIMAT0036511 tch-miR-29a-3p; +MIMAT0036512 tch-miR-147b; +MIMAT0036513 tch-miR-9771d; +MIMAT0036514 tch-miR-218-5p; +MIMAT0036515 tch-miR-376c-3p; +MIMAT0036516 tch-miR-17-5p; +MIMAT0036517 tch-miR-361-5p; +MIMAT0036518 tch-miR-135b-5p; +MIMAT0036519 tch-let-7g-5p; +MIMAT0036520 tch-miR-23b-3p; +MIMAT0036521 tch-miR-19b-3p; +MIMAT0036522 tch-miR-9771e; +MIMAT0036523 tch-miR-221-3p; +MIMAT0036524 tch-miR-9-5p; +MIMAT0036525 tch-miR-423-3p; +MIMAT0036526 tch-miR-181c-5p; +MIMAT0036527 tch-let-7f-5p; +MIMAT0036528 tch-miR-181d; +MIMAT0036529 tch-miR-199a-3p; +MIMAT0036530 tch-miR-122-5p; +MIMAT0036531 tch-miR-136-5p; +MIMAT0036532 tch-miR-193b-3p; +MIMAT0036533 tch-miR-378a-3p; +MIMAT0036534 tch-miR-148b-3p; +MIMAT0036535 tch-miR-27b-3p; +MIMAT0036536 tch-miR-432-5p; +MIMAT0036537 tch-miR-376a-3p; +MIMAT0036538 tch-miR-885-3p; +MIMAT0036539 tch-miR-9771f; +MIMAT0036540 tch-miR-139-5p; +MIMAT0036541 tch-miR-128; +MIMAT0036542 tch-miR-9771g; +MIMAT0036543 tch-miR-181b-5p; +MIMAT0036544 tch-miR-369-3p; +MIMAT0036545 tch-miR-152; +MIMAT0036546 tch-miR-29c-3p; +MIMAT0036547 tch-miR-9771h; +MIMAT0036548 tch-miR-365a-3p; +MIMAT0036549 tch-miR-195-5p; +MIMAT0036550 tch-miR-26b-5p; +MIMAT0036551 tch-miR-219-5p; +MIMAT0036552 tch-miR-15b-5p; +MIMAT0036553 tch-miR-486-3p; +MIMAT0036554 tch-miR-100-5p; +MIMAT0036555 tch-miR-9771i; +MIMAT0036556 tch-miR-656; +MIMAT0036557 tch-miR-9771j; +MIMAT0036558 tch-miR-497-5p; +MIMAT0036559 tch-miR-127-3p; +MIMAT0036560 tch-miR-140-5p; +MIMAT0036561 tch-miR-15a-5p; +MIMAT0036562 tch-miR-30a-5p; +MIMAT0036563 tch-miR-99a-5p; +MIMAT0036564 tch-miR-185-5p; +MIMAT0036565 tch-miR-28-5p; +MIMAT0036566 tch-miR-491-5p; +MIMAT0036567 tch-miR-146a-5p; +MIMAT0036568 tch-miR-381-3p; +MIMAT0036569 tch-miR-20a-5p; +MIMAT0036570 tch-miR-98-5p; +MIMAT0036571 tch-miR-191-5p; +MIMAT0036572 tch-miR-425-5p; +MIMAT0036573 tch-miR-183-5p; +MIMAT0036574 tch-miR-330-3p; +MIMAT0036575 tch-miR-34c-5p; +MIMAT0036576 tch-miR-652-3p; +MIMAT0036577 tch-miR-130a-3p; +MIMAT0036578 tch-miR-9771k; +MIMAT0036579 tch-miR-671-5p; +MIMAT0036580 tch-miR-190a; +MIMAT0036581 tch-miR-328; +MIMAT0036582 tch-miR-99b-5p; +MIMAT0036583 tch-miR-374b-5p; +MIMAT0036584 tch-miR-193a-3p; +MIMAT0036585 tch-miR-30c-5p; +MIMAT0036586 tch-miR-363-3p; +MIMAT0036587 tch-miR-708-5p; +MIMAT0036588 tch-miR-22-3p; +MIMAT0036589 tch-miR-374a-5p; +MIMAT0036590 tch-miR-25-3p; +MIMAT0036591 tch-miR-532-5p; +MIMAT0036592 tch-miR-21-5p; +MIMAT0036593 tch-miR-125b-5p; +MIMAT0036594 tch-miR-1247-5p; +MIMAT0036595 tch-miR-135a-5p; +MIMAT0036596 tch-miR-324-5p; +MIMAT0036597 tch-miR-9771l; +MIMAT0036598 tch-miR-1301; +MIMAT0036599 tch-miR-9771m; +MIMAT0036600 tch-miR-222-3p; +MIMAT0036601 tch-miR-326; +MIMAT0036602 tch-miR-26a-2-5p; +MIMAT0036603 tch-miR-19a-3p; +MIMAT0036604 tch-let-7i-5p; +MIMAT0036605 tch-miR-504; +MIMAT0036606 tch-miR-27a-3p; +MIMAT0036607 tch-miR-503; +MIMAT0036608 tch-miR-455-3p; +MIMAT0036609 tch-miR-376b-3p; +MIMAT0036610 tch-miR-9771n; +MIMAT0036611 tch-miR-148a-3p; +MIMAT0036612 tch-miR-200b-3p; +MIMAT0036613 tch-miR-542-3p; +MIMAT0036614 tch-miR-9771o; +MIMAT0036615 tch-miR-9770; +MIMAT0036616 tch-miR-192-5p; +MIMAT0036617 tch-miR-93-5p; +MIMAT0036618 tch-miR-335-5p; +MIMAT0036619 tch-miR-9771p; +MIMAT0036620 tch-let-7e-5p; +MIMAT0036621 tch-miR-628-5p; +MIMAT0036622 tch-miR-186-5p; +MIMAT0036623 tch-miR-196a-5p; +MIMAT0036624 tch-miR-194-5p; +MIMAT0036625 oha-let-7a; +MIMAT0036626 oha-let-7a-5p; +MIMAT0036627 oha-let-7a-2-3p; +MIMAT0036628 oha-let-7f-5p; +MIMAT0036629 oha-let-7f-1-3p; +MIMAT0036630 oha-let-7c-5p; +MIMAT0036631 oha-let-7c-1-3p; +MIMAT0036632 oha-let-7c-2-3p; +MIMAT0036633 oha-let-7c-3-3p; +MIMAT0036634 oha-let-7b-5p; +MIMAT0036635 oha-let-7b-3p; +MIMAT0036636 oha-let-7d-5p; +MIMAT0036637 oha-let-7d-3p; +MIMAT0036638 oha-let-7f-2-3p; +MIMAT0036639 oha-let-7a-3-3p; +MIMAT0036640 oha-let-7g-5p; +MIMAT0036641 oha-let-7g-3p; +MIMAT0036642 oha-let-7i-5p; +MIMAT0036643 oha-let-7i-3p; +MIMAT0036644 oha-let-7e-5p; +MIMAT0036645 oha-let-7e-3p; +MIMAT0036646 oha-miR-1a-5p; +MIMAT0036647 oha-miR-1a-3p; +MIMAT0036648 oha-miR-100-5p; +MIMAT0036649 oha-miR-100-3p; +MIMAT0036650 oha-miR-101a-5p; +MIMAT0036651 oha-miR-101a-3p; +MIMAT0036652 oha-miR-101b-5p; +MIMAT0036653 oha-miR-101b-3p; +MIMAT0036654 oha-miR-107-5p; +MIMAT0036655 oha-miR-107-3p; +MIMAT0036656 oha-miR-103a-5p; +MIMAT0036657 oha-miR-103a-3p; +MIMAT0036658 oha-miR-103b-5p; +MIMAT0036659 oha-miR-103b-3p; +MIMAT0036660 oha-miR-10a-5p; +MIMAT0036661 oha-miR-10a-3p; +MIMAT0036662 oha-miR-10b-5p; +MIMAT0036663 oha-miR-10b-3p; +MIMAT0036664 oha-miR-10c-5p; +MIMAT0036665 oha-miR-10c-3p; +MIMAT0036666 oha-miR-122-5p; +MIMAT0036667 oha-miR-122-3p; +MIMAT0036668 oha-miR-124; +MIMAT0036669 oha-miR-124-5p; +MIMAT0036670 oha-miR-124-3p; +MIMAT0036671 oha-miR-124-4-3p; +MIMAT0036672 oha-miR-125a-5p; +MIMAT0036673 oha-miR-125a-3p; +MIMAT0036674 oha-miR-125b-5p; +MIMAT0036675 oha-miR-125b-3p; +MIMAT0036676 oha-miR-126-5p; +MIMAT0036677 oha-miR-126-3p; +MIMAT0036678 oha-miR-128-5p; +MIMAT0036679 oha-miR-128-3p; +MIMAT0036680 oha-miR-129a-5p; +MIMAT0036681 oha-miR-129a-3p; +MIMAT0036682 oha-miR-129b; +MIMAT0036683 oha-miR-129b-5p; +MIMAT0036684 oha-miR-129b-3p; +MIMAT0036685 oha-miR-1306-5p; +MIMAT0036686 oha-miR-1306-3p; +MIMAT0036687 oha-miR-130a-5p; +MIMAT0036688 oha-miR-130a-3p; +MIMAT0036689 oha-miR-130b-5p; +MIMAT0036690 oha-miR-130b-3p; +MIMAT0036691 oha-miR-130c-5p; +MIMAT0036692 oha-miR-130c-3p; +MIMAT0036693 oha-miR-130d; +MIMAT0036694 oha-miR-132-5p; +MIMAT0036695 oha-miR-132-3p; +MIMAT0036696 oha-miR-1329-5p; +MIMAT0036697 oha-miR-1329-3p; +MIMAT0036698 oha-miR-133a-1-5p; +MIMAT0036699 oha-miR-133a-3p; +MIMAT0036700 oha-miR-133a-2-5p; +MIMAT0036701 oha-miR-133b-5p; +MIMAT0036702 oha-miR-133b-3p; +MIMAT0036703 oha-miR-133a-3-5p; +MIMAT0036704 oha-miR-135-5p; +MIMAT0036705 oha-miR-135-1-3p; +MIMAT0036706 oha-miR-135-2-3p; +MIMAT0036707 oha-miR-135-3-3p; +MIMAT0036708 oha-miR-137-5p; +MIMAT0036709 oha-miR-137-3p; +MIMAT0036710 oha-miR-138-5p; +MIMAT0036711 oha-miR-138-1-3p; +MIMAT0036712 oha-miR-138-2-3p; +MIMAT0036713 oha-miR-1388-5p; +MIMAT0036714 oha-miR-1388-3p; +MIMAT0036715 oha-miR-139-5p; +MIMAT0036716 oha-miR-139-3p; +MIMAT0036717 oha-miR-1397-5p; +MIMAT0036718 oha-miR-1397-3p; +MIMAT0036719 oha-miR-140-5p; +MIMAT0036720 oha-miR-140-3p; +MIMAT0036721 oha-miR-142-5p; +MIMAT0036722 oha-miR-142-3p; +MIMAT0036723 oha-miR-143-5p; +MIMAT0036724 oha-miR-143-3p; +MIMAT0036725 oha-miR-144-5p; +MIMAT0036726 oha-miR-144-3p; +MIMAT0036727 oha-miR-145-5p; +MIMAT0036728 oha-miR-145-3p; +MIMAT0036729 oha-miR-146b-5p; +MIMAT0036730 oha-miR-146b-3p; +MIMAT0036731 oha-miR-147-5p; +MIMAT0036732 oha-miR-147-3p; +MIMAT0036733 oha-miR-148a-5p; +MIMAT0036734 oha-miR-148a-3p; +MIMAT0036735 oha-miR-148b; +MIMAT0036736 oha-miR-150; +MIMAT0036737 oha-miR-153-1-5p; +MIMAT0036738 oha-miR-153-3p; +MIMAT0036739 oha-miR-153-2-5p; +MIMAT0036740 oha-miR-15a-5p; +MIMAT0036741 oha-miR-15a-3p; +MIMAT0036742 oha-miR-15b-5p; +MIMAT0036743 oha-miR-15b-3p; +MIMAT0036744 oha-miR-16a-5p; +MIMAT0036745 oha-miR-16a-3p; +MIMAT0036746 oha-miR-16b-5p; +MIMAT0036747 oha-miR-16b-3p; +MIMAT0036748 oha-miR-1641; +MIMAT0036749 oha-miR-1677b-5p; +MIMAT0036750 oha-miR-1677b-3p; +MIMAT0036751 oha-miR-17-5p; +MIMAT0036752 oha-miR-17-3p; +MIMAT0036753 oha-miR-1788-5p; +MIMAT0036754 oha-miR-1788-3p; +MIMAT0036755 oha-miR-1805-5p; +MIMAT0036756 oha-miR-1805-3p; +MIMAT0036757 oha-miR-181a-5p; +MIMAT0036758 oha-miR-181a-1-3p; +MIMAT0036759 oha-miR-181a-2-3p; +MIMAT0036760 oha-miR-181c-5p; +MIMAT0036761 oha-miR-181c-3p; +MIMAT0036762 oha-miR-181b-5p; +MIMAT0036763 oha-miR-181b-3p; +MIMAT0036764 oha-miR-182-5p; +MIMAT0036765 oha-miR-182-3p; +MIMAT0036766 oha-miR-183-5p; +MIMAT0036767 oha-miR-183-3p; +MIMAT0036768 oha-miR-18a-5p; +MIMAT0036769 oha-miR-18a-3p; +MIMAT0036770 oha-miR-18b-5p; +MIMAT0036771 oha-miR-18b-3p; +MIMAT0036772 oha-miR-190a-5p; +MIMAT0036773 oha-miR-190a-3p; +MIMAT0036774 oha-miR-1905; +MIMAT0036775 oha-miR-190b-5p; +MIMAT0036776 oha-miR-190b-3p; +MIMAT0036777 oha-miR-191-5p; +MIMAT0036778 oha-miR-191-3p; +MIMAT0036779 oha-miR-193-5p; +MIMAT0036780 oha-miR-193-3p; +MIMAT0036781 oha-miR-194-5p; +MIMAT0036782 oha-miR-194-3p; +MIMAT0036783 oha-miR-196a-5p; +MIMAT0036784 oha-miR-196a-3p; +MIMAT0036785 oha-miR-196b-5p; +MIMAT0036786 oha-miR-196b-3p; +MIMAT0036787 oha-miR-196c-5p; +MIMAT0036788 oha-miR-196c-3p; +MIMAT0036789 oha-miR-199a-5p; +MIMAT0036790 oha-miR-199a-3p; +MIMAT0036791 oha-miR-199b-5p; +MIMAT0036792 oha-miR-199b-3p; +MIMAT0036793 oha-miR-199c-5p; +MIMAT0036794 oha-miR-199c-3p; +MIMAT0036795 oha-miR-19a-5p; +MIMAT0036796 oha-miR-19a-3p; +MIMAT0036797 oha-miR-19b-5p; +MIMAT0036798 oha-miR-19b-3p; +MIMAT0036799 oha-miR-1b-5p; +MIMAT0036800 oha-miR-1b-3p; +MIMAT0036801 oha-miR-1c-5p; +MIMAT0036802 oha-miR-1c-3p; +MIMAT0036803 oha-miR-1d-5p; +MIMAT0036804 oha-miR-1d-3p; +MIMAT0036805 oha-miR-20b-5p; +MIMAT0036806 oha-miR-20b-3p; +MIMAT0036807 oha-miR-200a; +MIMAT0036808 oha-miR-202-5p; +MIMAT0036809 oha-miR-202-3p; +MIMAT0036810 oha-miR-203-5p; +MIMAT0036811 oha-miR-203-3p; +MIMAT0036812 oha-miR-204-5p; +MIMAT0036813 oha-miR-204-1-3p; +MIMAT0036814 oha-miR-204-2-3p; +MIMAT0036815 oha-miR-205a-5p; +MIMAT0036816 oha-miR-205a-3p; +MIMAT0036817 oha-miR-205b-5p; +MIMAT0036818 oha-miR-205b-3p; +MIMAT0036819 oha-miR-206; +MIMAT0036820 oha-miR-208-5p; +MIMAT0036821 oha-miR-208-3p; +MIMAT0036822 oha-miR-20a-5p; +MIMAT0036823 oha-miR-20a-3p; +MIMAT0036824 oha-miR-21-5p; +MIMAT0036825 oha-miR-21-3p; +MIMAT0036826 oha-miR-210-5p; +MIMAT0036827 oha-miR-210-3p; +MIMAT0036828 oha-miR-212-5p; +MIMAT0036829 oha-miR-212-3p; +MIMAT0036830 oha-miR-3120; +MIMAT0036831 oha-miR-215-5p; +MIMAT0036832 oha-miR-215-3p; +MIMAT0036833 oha-miR-216-5p; +MIMAT0036834 oha-miR-216-3p; +MIMAT0036835 oha-miR-217-5p; +MIMAT0036836 oha-miR-218-5p; +MIMAT0036837 oha-miR-218-1-3p; +MIMAT0036838 oha-miR-218-2-3p; +MIMAT0036839 oha-miR-2188-5p; +MIMAT0036840 oha-miR-2188-3p; +MIMAT0036841 oha-miR-219-5p; +MIMAT0036842 oha-miR-219-1-3p; +MIMAT0036843 oha-miR-219-2-3p; +MIMAT0036844 oha-miR-22b; +MIMAT0036845 oha-miR-22a; +MIMAT0036846 oha-miR-221-5p; +MIMAT0036847 oha-miR-221-3p; +MIMAT0036848 oha-miR-222a-5p; +MIMAT0036849 oha-miR-222a-3p; +MIMAT0036850 oha-miR-222b-5p; +MIMAT0036851 oha-miR-222b-3p; +MIMAT0036852 oha-miR-223-5p; +MIMAT0036853 oha-miR-223-3p; +MIMAT0036854 oha-miR-23a-5p; +MIMAT0036855 oha-miR-23a-3p; +MIMAT0036856 oha-miR-23b-5p; +MIMAT0036857 oha-miR-23b-3p; +MIMAT0036858 oha-miR-24-1-5p; +MIMAT0036859 oha-miR-24-3p; +MIMAT0036860 oha-miR-24-2-5p; +MIMAT0036861 oha-miR-26-5p; +MIMAT0036862 oha-miR-26-1-3p; +MIMAT0036863 oha-miR-26-2-3p; +MIMAT0036864 oha-miR-26-3-3p; +MIMAT0036865 oha-miR-27a-5p; +MIMAT0036866 oha-miR-27a-3p; +MIMAT0036867 oha-miR-27b-5p; +MIMAT0036868 oha-miR-27b-3p; +MIMAT0036869 oha-miR-2970-5p; +MIMAT0036870 oha-miR-2970-3p; +MIMAT0036871 oha-miR-2985a-5p; +MIMAT0036872 oha-miR-2985a-2-3p; +MIMAT0036873 oha-miR-2985a-3p; +MIMAT0036874 oha-miR-2985b-5p; +MIMAT0036875 oha-miR-2985b-3p; +MIMAT0036876 oha-miR-29a-1-5p; +MIMAT0036877 oha-miR-29a-3p; +MIMAT0036878 oha-miR-29b-1-5p; +MIMAT0036879 oha-miR-29b-3p; +MIMAT0036880 oha-miR-29b-2-5p; +MIMAT0036881 oha-miR-29a-2-5p; +MIMAT0036882 oha-miR-301b-5p; +MIMAT0036883 oha-miR-301b-3p; +MIMAT0036884 oha-miR-301a-5p; +MIMAT0036885 oha-miR-301a-3p; +MIMAT0036886 oha-miR-30e-5p; +MIMAT0036887 oha-miR-30e-3p; +MIMAT0036888 oha-miR-30a-5p; +MIMAT0036889 oha-miR-30a-3p; +MIMAT0036890 oha-miR-30b-5p; +MIMAT0036891 oha-miR-30b-3p; +MIMAT0036892 oha-miR-30c-5p; +MIMAT0036893 oha-miR-30c-2-3p; +MIMAT0036894 oha-miR-30c-1-3p; +MIMAT0036895 oha-miR-30d-5p; +MIMAT0036896 oha-miR-30d-3p; +MIMAT0036897 oha-miR-31-5p; +MIMAT0036898 oha-miR-31-3p; +MIMAT0036899 oha-miR-32-5p; +MIMAT0036900 oha-miR-32-3p; +MIMAT0036901 oha-miR-33-5p; +MIMAT0036902 oha-miR-33-3p; +MIMAT0036903 oha-miR-338-5p; +MIMAT0036904 oha-miR-338-3p; +MIMAT0036905 oha-miR-33a-5p; +MIMAT0036906 oha-miR-33a-3p; +MIMAT0036907 oha-miR-34a-5p; +MIMAT0036908 oha-miR-34a-3p; +MIMAT0036909 oha-miR-34c-5p; +MIMAT0036910 oha-miR-34c-3p; +MIMAT0036911 oha-miR-3618; +MIMAT0036912 oha-miR-363-5p; +MIMAT0036913 oha-miR-363-3p; +MIMAT0036914 oha-miR-365a-1-5p; +MIMAT0036915 oha-miR-365a-3p; +MIMAT0036916 oha-miR-365a-2-5p; +MIMAT0036917 oha-miR-375-5p; +MIMAT0036918 oha-miR-375-3p; +MIMAT0036919 oha-miR-383-5p; +MIMAT0036920 oha-miR-383-3p; +MIMAT0036921 oha-miR-425-5p; +MIMAT0036922 oha-miR-425-3p; +MIMAT0036923 oha-miR-429-5p; +MIMAT0036924 oha-miR-429-3p; +MIMAT0036925 oha-miR-449a-5p; +MIMAT0036926 oha-miR-449a-3p; +MIMAT0036927 oha-miR-449c-5p; +MIMAT0036928 oha-miR-449c-3p; +MIMAT0036929 oha-miR-451-??; +MIMAT0036930 oha-miR-451-3p; +MIMAT0036931 oha-miR-455-5p; +MIMAT0036932 oha-miR-455-3p; +MIMAT0036933 oha-miR-456; +MIMAT0036934 oha-miR-458-5p; +MIMAT0036935 oha-miR-458-3p; +MIMAT0036936 oha-miR-490-5p; +MIMAT0036937 oha-miR-490-3p; +MIMAT0036938 oha-miR-499-5p; +MIMAT0036939 oha-miR-499-3p; +MIMAT0036940 oha-miR-5391; +MIMAT0036941 oha-miR-5470; +MIMAT0036942 oha-miR-551b-5p; +MIMAT0036943 oha-miR-551b-3p; +MIMAT0036944 oha-miR-599; +MIMAT0036945 oha-miR-7-5p; +MIMAT0036946 oha-miR-7-1-3p; +MIMAT0036947 oha-miR-7-2-3p; +MIMAT0036948 oha-miR-7-3-3p; +MIMAT0036949 oha-miR-737-5p; +MIMAT0036950 oha-miR-737-3p; +MIMAT0036951 oha-miR-875-5p; +MIMAT0036952 oha-miR-875-3p; +MIMAT0036953 oha-miR-9-1-5p; +MIMAT0036954 oha-miR-9-3p; +MIMAT0036955 oha-miR-9-2-5p; +MIMAT0036956 oha-miR-9-3-5p; +MIMAT0036957 oha-miR-9-4-5p; +MIMAT0036958 oha-miR-92a-5p; +MIMAT0036959 oha-miR-92a-3p; +MIMAT0036960 oha-miR-92a; +MIMAT0036961 oha-miR-96; +MIMAT0036962 oha-miR-98-5p; +MIMAT0036963 oha-miR-98-3p; +MIMAT0036964 oha-miR-99a-5p; +MIMAT0036965 oha-miR-99a-3p; +MIMAT0036966 oha-miR-99b-5p; +MIMAT0036967 oha-miR-99b-3p; +MIMAT0036968 gra-miR827b; +MIMAT0036969 bta-miR-1842; +MIMAT0036970 bta-miR-4657; +MIMAT0036971 bta-miR-4523; +MIMAT0036972 bta-miR-378d; +MIMAT0036973 bta-miR-4449; +MIMAT0036974 bta-miR-3064; +MIMAT0036975 bta-miR-3533; +MIMAT0036976 bta-miR-3432b; +MIMAT0036977 bta-miR-2450d; +MIMAT0036978 bta-miR-4444; +MIMAT0036979 bta-miR-4680; +MIMAT0036980 efu-miR-9200a; +MIMAT0036981 tae-miR531; +MIMAT0036982 tae-miR9772; +MIMAT0036983 tae-miR9773; +MIMAT0036984 tae-miR9672b; +MIMAT0036985 tae-miR9774; +MIMAT0036986 tae-miR9775; +MIMAT0036987 tae-miR530; +MIMAT0036988 tae-miR9776; +MIMAT0036989 tae-miR5050; +MIMAT0036990 tae-miR9777; +MIMAT0036991 tae-miR9778; +MIMAT0036992 tae-miR6201; +MIMAT0036993 tae-miR9779; +MIMAT0036994 tae-miR9780; +MIMAT0036995 tae-miR9781; +MIMAT0036996 tae-miR9653b; +MIMAT0036997 tae-miR9782; +MIMAT0036998 tae-miR9677b; +MIMAT0036999 tae-miR9783; +MIMAT0037000 tae-miR5200; +MIMAT0037001 ssc-miR-9784-5p; +MIMAT0037002 ssc-miR-9785-5p; +MIMAT0037003 ssc-miR-9786-3p; +MIMAT0037004 ssc-miR-9787-3p; +MIMAT0037005 ssc-miR-9788-3p; +MIMAT0037006 ssc-miR-9789-3p; +MIMAT0037007 ssc-miR-7857-3p; +MIMAT0037008 ssc-miR-9790-3p; +MIMAT0037009 ssc-miR-9791-3p; +MIMAT0037010 ssc-miR-9792-5p; +MIMAT0037011 ssc-miR-9793-5p; +MIMAT0037012 ssc-miR-9794-3p; +MIMAT0037013 ssc-miR-9795-3p; +MIMAT0037014 ssc-miR-9796-3p; +MIMAT0037015 ssc-miR-9797-3p; +MIMAT0037016 ssc-miR-9798-3p; +MIMAT0037017 ssc-miR-9799-3p; +MIMAT0037018 ssc-miR-9800-3p; +MIMAT0037019 ssc-miR-9801-5p; +MIMAT0037020 ssc-miR-9802-3p; +MIMAT0037021 ssc-miR-9803-5p; +MIMAT0037022 ssc-miR-9804-5p; +MIMAT0037023 ssc-miR-9805-3p; +MIMAT0037024 ssc-miR-9806-5p; +MIMAT0037025 ssc-miR-9807-5p; +MIMAT0037026 ssc-miR-9808-3p; +MIMAT0037027 ssc-miR-9809-3p; +MIMAT0037028 ssc-miR-9810-3p; +MIMAT0037029 ssc-miR-9811-5p; +MIMAT0037030 ssc-miR-9812-3p; +MIMAT0037031 ssc-miR-9813-5p; +MIMAT0037032 ssc-miR-9814-3p; +MIMAT0037033 ssc-miR-9815-3p; +MIMAT0037034 ssc-miR-9816-3p; +MIMAT0037035 ssc-miR-9817-5p; +MIMAT0037036 ssc-miR-9818-3p; +MIMAT0037037 ssc-miR-9819-5p; +MIMAT0037038 ssc-miR-9820-5p; +MIMAT0037039 ssc-miR-9821-5p; +MIMAT0037040 ssc-miR-9822-3p; +MIMAT0037041 ssc-miR-9823-5p; +MIMAT0037042 ssc-miR-9824-5p; +MIMAT0037043 ssc-miR-9825-5p; +MIMAT0037044 ssc-miR-9826-5p; +MIMAT0037045 ssc-miR-9827-5p; +MIMAT0037046 ssc-miR-9828-3p; +MIMAT0037047 ssc-miR-9829-5p; +MIMAT0037048 ssc-miR-9830-5p; +MIMAT0037049 ssc-miR-9831-3p; +MIMAT0037050 ssc-miR-9832-3p; +MIMAT0037051 ssc-miR-9833-5p; +MIMAT0037052 ssc-miR-9834-5p; +MIMAT0037053 ssc-miR-9835-3p; +MIMAT0037054 ssc-miR-9836-3p; +MIMAT0037055 ssc-miR-9837-5p; +MIMAT0037056 ssc-miR-9838-5p; +MIMAT0037057 ssc-miR-9839-5p; +MIMAT0037058 ssc-miR-9840-3p; +MIMAT0037059 ssc-miR-9841-3p; +MIMAT0037060 ssc-miR-9842-5p; +MIMAT0037061 ssc-miR-9843-3p; +MIMAT0037062 ssc-miR-9844-3p; +MIMAT0037063 ssc-miR-9845-5p; +MIMAT0037064 ssc-miR-6782-3p; +MIMAT0037065 ssc-miR-9846-3p; +MIMAT0037066 ssc-miR-9847-3p; +MIMAT0037067 ssc-miR-9848-3p; +MIMAT0037068 ssc-miR-9849-5p; +MIMAT0037069 ssc-miR-9850-5p; +MIMAT0037070 ssc-miR-9851-3p; +MIMAT0037071 ssc-miR-9852-3p; +MIMAT0037072 ssc-miR-9853-5p; +MIMAT0037073 ssc-miR-9854-5p; +MIMAT0037074 ssc-miR-9855-5p; +MIMAT0037075 ssc-miR-9856-3p; +MIMAT0037076 ssc-miR-9857-5p; +MIMAT0037077 ssc-miR-9858-5p; +MIMAT0037078 ssc-miR-9859-3p; +MIMAT0037079 ssc-miR-9860-5p; +MIMAT0037080 ssc-miR-9861-5p; +MIMAT0037081 ssc-miR-371-5p; +MIMAT0037082 ssc-miR-378b-3p; +MIMAT0037083 ssc-miR-219b-3p; +MIMAT0037084 ssc-miR-9862-3p; +MIMAT0037085 ssc-miR-96-5p; +MIMAT0037086 ata-miR169g-5p; +MIMAT0037087 ata-miR169g-3p; +MIMAT0037088 ata-miR167c-5p; +MIMAT0037089 ata-miR167c-3p; +MIMAT0037090 ata-miR396a-5p; +MIMAT0037091 ata-miR396a-3p; +MIMAT0037092 ata-miR167a-5p; +MIMAT0037093 ata-miR167a-3p; +MIMAT0037094 ata-miR156d-5p; +MIMAT0037095 ata-miR156d-3p; +MIMAT0037096 ata-miR393-5p; +MIMAT0037097 ata-miR393-3p; +MIMAT0037098 ata-miR5070-5p; +MIMAT0037099 ata-miR5070-3p; +MIMAT0037100 ata-miR171c-5p; +MIMAT0037101 ata-miR171c-3p; +MIMAT0037102 ata-miR160b-5p; +MIMAT0037103 ata-miR160b-3p; +MIMAT0037104 ata-miR9863a-5p; +MIMAT0037105 ata-miR9863a-3p; +MIMAT0037106 ata-miR9772a-5p; +MIMAT0037107 ata-miR9772a-3p; +MIMAT0037108 ata-miR167e-5p; +MIMAT0037109 ata-miR167e-3p; +MIMAT0037110 ata-miR2275a-5p; +MIMAT0037111 ata-miR2275a-3p; +MIMAT0037112 ata-miR166a-5p; +MIMAT0037113 ata-miR166a-3p; +MIMAT0037114 ata-miR2118c-3p; +MIMAT0037115 ata-miR169e-5p; +MIMAT0037116 ata-miR395e-5p; +MIMAT0037117 ata-miR395e-3p; +MIMAT0037118 ata-miR156c-5p; +MIMAT0037119 ata-miR156c-3p; +MIMAT0037120 ata-miR166e-5p; +MIMAT0037121 ata-miR166e-3p; +MIMAT0037122 ata-miR156a-5p; +MIMAT0037123 ata-miR156a-3p; +MIMAT0037124 ata-miR2275b-5p; +MIMAT0037125 ata-miR2275b-3p; +MIMAT0037126 ata-miR166b-5p; +MIMAT0037127 ata-miR166b-3p; +MIMAT0037128 ata-miR9672-5p; +MIMAT0037129 ata-miR9672-3p; +MIMAT0037130 ata-miR5168-5p; +MIMAT0037131 ata-miR5168-3p; +MIMAT0037132 ata-miR156b-5p; +MIMAT0037133 ata-miR156b-3p; +MIMAT0037134 ata-miR172a-5p; +MIMAT0037135 ata-miR172a-3p; +MIMAT0037136 ata-miR169c-5p; +MIMAT0037137 ata-miR169c-3p; +MIMAT0037138 ata-miR5200-5p; +MIMAT0037139 ata-miR5200-3p; +MIMAT0037140 ata-miR390-5p; +MIMAT0037141 ata-miR390-3p; +MIMAT0037142 ata-miR169j-5p; +MIMAT0037143 ata-miR169j-3p; +MIMAT0037144 ata-miR5181-5p; +MIMAT0037145 ata-miR5181-3p; +MIMAT0037146 ata-miR169b-5p; +MIMAT0037147 ata-miR169b-3p; +MIMAT0037148 ata-miR172b-5p; +MIMAT0037149 ata-miR172b-3p; +MIMAT0037150 ata-miR395b-5p; +MIMAT0037151 ata-miR395b-3p; +MIMAT0037152 ata-miR168-5p; +MIMAT0037153 ata-miR168-3p; +MIMAT0037154 ata-miR9772b-5p; +MIMAT0037155 ata-miR9772b-3p; +MIMAT0037156 ata-miR160a-5p; +MIMAT0037157 ata-miR160a-3p; +MIMAT0037158 ata-miR166d-5p; +MIMAT0037159 ata-miR166d-3p; +MIMAT0037160 ata-miR396d-5p; +MIMAT0037161 ata-miR396d-3p; +MIMAT0037162 ata-miR395a-5p; +MIMAT0037163 ata-miR395a-3p; +MIMAT0037164 ata-miR395d-5p; +MIMAT0037165 ata-miR395d-3p; +MIMAT0037166 ata-miR169i-5p; +MIMAT0037167 ata-miR169i-3p; +MIMAT0037168 ata-miR396e-5p; +MIMAT0037169 ata-miR396e-3p; +MIMAT0037170 ata-miR396c-5p; +MIMAT0037171 ata-miR396c-3p; +MIMAT0037172 ata-miR6201-5p; +MIMAT0037173 ata-miR6201-3p; +MIMAT0037174 ata-miR167b-5p; +MIMAT0037175 ata-miR167b-3p; +MIMAT0037176 ata-miR398f-5p; +MIMAT0037177 ata-miR398f-3p; +MIMAT0037178 ata-miR169f-5p; +MIMAT0037179 ata-miR169f-3p; +MIMAT0037180 ata-miR2118a-5p; +MIMAT0037181 ata-miR2118a-3p; +MIMAT0037182 ata-miR396b-5p; +MIMAT0037183 ata-miR396b-3p; +MIMAT0037184 ata-miR395f-5p; +MIMAT0037185 ata-miR395f-3p; +MIMAT0037186 ata-miR5062a-5p; +MIMAT0037187 ata-miR5062a-3p; +MIMAT0037188 ata-miR408-5p; +MIMAT0037189 ata-miR408-3p; +MIMAT0037190 ata-miR171a-5p; +MIMAT0037191 ata-miR171a-3p; +MIMAT0037192 ata-miR528-5p; +MIMAT0037193 ata-miR528-3p; +MIMAT0037194 ata-miR9674c-5p; +MIMAT0037195 ata-miR9674c-3p; +MIMAT0037196 ata-miR167f-5p; +MIMAT0037197 ata-miR167f-3p; +MIMAT0037198 ata-miR399b-5p; +MIMAT0037199 ata-miR399b-3p; +MIMAT0037200 ata-miR160c-5p; +MIMAT0037201 ata-miR160c-3p; +MIMAT0037202 ata-miR5062b-5p; +MIMAT0037203 ata-miR5062b-3p; +MIMAT0037204 ata-miR9674a-5p; +MIMAT0037205 ata-miR9674a-3p; +MIMAT0037206 ata-miR169d-5p; +MIMAT0037207 ata-miR169d-3p; +MIMAT0037208 ata-miR169a-5p; +MIMAT0037209 ata-miR169a-3p; +MIMAT0037210 ata-miR395c-5p; +MIMAT0037211 ata-miR395c-3p; +MIMAT0037212 ata-miR164a-5p; +MIMAT0037213 ata-miR164a-3p; +MIMAT0037214 ata-miR1432-5p; +MIMAT0037215 ata-miR1432-3p; +MIMAT0037216 ata-miR9776-5p; +MIMAT0037217 ata-miR9776-3p; +MIMAT0037218 ata-miR164b-5p; +MIMAT0037219 ata-miR164b-3p; +MIMAT0037220 ata-miR2118b-5p; +MIMAT0037221 ata-miR2118b-3p; +MIMAT0037222 ata-miR172c-5p; +MIMAT0037223 ata-miR172c-3p; +MIMAT0037224 ata-miR9677-5p; +MIMAT0037225 ata-miR9677-3p; +MIMAT0037226 ata-miR2275c-5p; +MIMAT0037227 ata-miR2275c-3p; +MIMAT0037228 ata-miR171d-5p; +MIMAT0037229 ata-miR171d-3p; +MIMAT0037230 ata-miR398g-5p; +MIMAT0037231 ata-miR398g-3p; +MIMAT0037232 ata-miR167d-5p; +MIMAT0037233 ata-miR167d-3p; +MIMAT0037234 ata-miR394-5p; +MIMAT0037235 ata-miR394-3p; +MIMAT0037236 ata-miR9863b-5p; +MIMAT0037237 ata-miR9863b-3p; +MIMAT0037238 ata-miR156e-5p; +MIMAT0037239 ata-miR156e-3p; +MIMAT0037240 ata-miR399a-5p; +MIMAT0037241 ata-miR399a-3p; +MIMAT0037242 ata-miR164c-5p; +MIMAT0037243 ata-miR164c-3p; +MIMAT0037244 ata-miR319-5p; +MIMAT0037245 ata-miR319-3p; +MIMAT0037246 ata-miR9783-5p; +MIMAT0037247 ata-miR9783-3p; +MIMAT0037248 ata-miR166c-5p; +MIMAT0037249 ata-miR166c-3p; +MIMAT0037250 ata-miR171b-5p; +MIMAT0037251 ata-miR171b-3p; +MIMAT0037252 ata-miR169h-5p; +MIMAT0037253 ata-miR169h-3p; +MIMAT0037254 ata-miR5084-5p; +MIMAT0037255 ata-miR5084-3p; +MIMAT0037256 ata-miR9674b-5p; +MIMAT0037257 ata-miR9674b-3p; +MIMAT0037258 ata-miR2118d-3p; +MIMAT0037259 ath-miR8167d; +MIMAT0037260 ath-miR8167e; +MIMAT0037261 ath-miR8167f; +MIMAT0037262 rno-miR-466b-4-3p; +MIMAT0037263 rno-miR-1b; +MIMAT0037264 rno-miR-676; +MIMAT0037265 rno-miR-486; +MIMAT0037266 ame-miR-9864;ame-miR-9864-5p; +MIMAT0037267 ame-miR-279d;ame-miR-279d-3p; +MIMAT0037268 ame-miR-3718c;ame-miR-3718c-5p; +MIMAT0037269 ame-miR-9865;ame-miR-9865-5p; +MIMAT0037270 ame-miR-9866;ame-miR-9866-5p; +MIMAT0037271 ame-miR-9867;ame-miR-9867-5p; +MIMAT0037272 ame-miR-9868;ame-miR-9868-3p; +MIMAT0037273 ame-miR-9869;ame-miR-9869-5p; +MIMAT0037274 ame-miR-9870;ame-miR-9870-5p; +MIMAT0037275 ame-miR-9871;ame-miR-9871-3p; +MIMAT0037276 ame-miR-9872;ame-miR-9872-5p; +MIMAT0037277 ame-miR-9873;ame-miR-9873-3p; +MIMAT0037278 ame-miR-9874;ame-miR-9874-5p; +MIMAT0037279 ame-miR-9875;ame-miR-9875-3p; +MIMAT0037280 ame-miR-9876;ame-miR-9876-3p; +MIMAT0037281 ame-miR-9877;ame-miR-9877-3p; +MIMAT0037282 ame-miR-9878;ame-miR-9878-3p; +MIMAT0037283 ame-miR-9879;ame-miR-9879-3p; +MIMAT0037284 ame-miR-9880;ame-miR-9880-3p; +MIMAT0037285 ame-miR-9881;ame-miR-9881-5p; +MIMAT0037286 ame-miR-9882;ame-miR-9882-5p; +MIMAT0037287 ame-miR-9883;ame-miR-9883-5p; +MIMAT0037288 ame-miR-9884;ame-miR-9884-3p; +MIMAT0037289 ame-miR-9885;ame-miR-9885-5p; +MIMAT0037290 ame-miR-9886;ame-miR-9886-3p; +MIMAT0037291 ame-miR-9887;ame-miR-9887-5p; +MIMAT0037292 ame-miR-2b;ame-miR-2b-5p; +MIMAT0037293 ame-miR-9888;ame-miR-9888-5p; +MIMAT0037294 ame-miR-9889;ame-miR-9889-3p; +MIMAT0037295 ame-miR-9890;ame-miR-9890-5p; +MIMAT0037296 ame-miR-9891;ame-miR-9891-3p; +MIMAT0037297 ame-miR-9892;ame-miR-9892-3p; +MIMAT0037298 ame-miR-9893;ame-miR-9893-5p; +MIMAT0037299 ame-miR-9894;ame-miR-9894-3p; +MIMAT0037300 ame-miR-9895;ame-miR-9895-3p; +MIMAT0037301 ame-miR-9896;ame-miR-9896-5p; +MIMAT0037302 ame-miR-3478;ame-miR-3478-3p; +MIMAT0037303 cre-miR9897-5p; +MIMAT0037304 cre-miR9897-3p; +MIMAT0037305 vvi-miR171j; +MIMAT0037306 hsa-miR-103a-1-5p; +MIMAT0037307 hsa-miR-196a-1-3p; +MIMAT0037308 hsa-miR-217-3p; +MIMAT0037309 hsa-miR-135a-2-3p; +MIMAT0037310 hsa-miR-137-5p; +MIMAT0037311 hsa-miR-320a-5p; +MIMAT0037312 hsa-miR-101-2-5p; +MIMAT0037313 hsa-miR-375-5p; +MIMAT0037314 gma-miR398b-5p; +MIMAT0037315 ssc-miR-122-3p; +MIMAT0037316 ssc-miR-20a-3p; +MIMAT0037317 ssc-miR-7-3p; +MIMAT0037318 ssc-miR-214-5p; +MIMAT0037319 ssc-let-7i-3p; +MIMAT0037320 ssc-miR-136-3p; +MIMAT0037321 ssc-miR-186-3p; +MIMAT0037322 ssc-miR-21-3p; +MIMAT0037323 hsa-miR-498-3p; +MIMAT0037324 hsa-miR-520e-5p; +MIMAT0037325 hsa-miR-520b-5p; +MIMAT0037326 hsa-miR-526a-3p; +MIMAT0037327 hsa-miR-519a-2-5p; +MIMAT0037328 hsa-miR-549a-5p; +MIMAT0037329 rlcv-miR-rL1-3-5p; +MIMAT0037330 rlcv-miR-rL1-9-5p; +MIMAT0037331 hsa-miR-147b-5p; +MIMAT0037332 hsa-miR-190b-3p; +MIMAT0037333 hsa-miR-1912-5p; +MIMAT0037334 sly-miR171b-5p; +MIMAT0037335 sly-miR397-3p; +MIMAT0037336 der-miR-310b-5p; +MIMAT0037337 der-miR-311a-5p; +MIMAT0037338 der-miR-311b-5p; +MIMAT0037339 der-miR-311c-5p; +MIMAT0037340 der-miR-312-5p; +MIMAT0037341 der-miR-310a-5p; +MIMAT0037342 dse-miR-310-5p; +MIMAT0037343 dse-miR-311-5p; +MIMAT0037344 dse-miR-312-5p; +MIMAT0037345 dse-miR-313-5p; +MIMAT0037346 dsi-miR-310-5p; +MIMAT0037347 dsi-miR-311-5p; +MIMAT0037348 dsi-miR-313-5p; +MIMAT0037349 dya-miR-311a-5p; +MIMAT0037350 dya-miR-310-5p; +MIMAT0037351 dya-miR-312-5p; +MIMAT0037352 dya-miR-311b-5p; +MIMAT0037353 aga-miR-965-5p; +MIMAT0037354 dsi-miR-977-5p; +MIMAT0037355 dsi-miR-978a-5p; +MIMAT0037356 dsi-miR-975-3p; +MIMAT0037357 dsi-miR-976-5p; +MIMAT0037358 dsi-miR-978b-5p; +MIMAT0037359 dsi-miR-982c-5p; +MIMAT0037360 dsi-miR-982b-5p; +MIMAT0037361 dsi-miR-982a-3p; +MIMAT0037362 dsi-miR-303-3p; +MIMAT0037363 osa-miR2871b-5p; +MIMAT0037364 ssc-miR-29a-5p; +MIMAT0037365 ssc-miR-99a-3p; +MIMAT0037366 ssc-miR-130b-5p; +MIMAT0037367 ssc-miR-574-5p; +MIMAT0037368 ssc-miR-628-3p; +MIMAT0037369 ssc-miR-500-5p; +MIMAT0037370 csi-miR160a-3p; +MIMAT0037371 csi-miR164a-3p; +MIMAT0037372 csi-miR398a-5p; +MIMAT0037373 csi-miR166a-5p; +MIMAT0037374 csi-miR390a-3p; +MIMAT0037375 bma-miR-2b-5p; +MIMAT0037376 bma-miR-36c-5p; +MIMAT0037377 bma-miR-36b-5p; +MIMAT0037378 bma-miR-281-5p; +MIMAT0037379 ssc-miR-4331-5p; +MIMAT0037380 ssc-miR-381-3p; +MIMAT0037381 ssc-miR-1271-5p; +MIMAT0037382 pab-miR3695d-3p; +MIMAT0037383 pab-miR3701b-5p; +MIMAT0037384 pab-miR482d-3p; +MIMAT0037385 pab-miR396a-3p; +MIMAT0037386 pab-miR1311a-5p; +MIMAT0037387 ame-miR-3786-3p; +MIMAT0037388 tca-miR-3851d-5p; +MIMAT0037389 gma-miR4348a-3p; +MIMAT0037390 gma-miR4349-3p; +MIMAT0037391 csi-miR156a-3p; +MIMAT0037392 csi-miR159a-5p; +MIMAT0037393 csi-miR166c-5p; +MIMAT0037394 csi-miR167c-3p; +MIMAT0037395 csi-miR167b-3p; +MIMAT0037396 csi-miR171b-5p; +MIMAT0037397 csi-miR172c-5p; +MIMAT0037398 csi-miR396a-3p; +MIMAT0037399 csi-miR396b-3p; +MIMAT0037400 csi-miR397-3p; +MIMAT0037401 csi-miR399c-5p; +MIMAT0037402 csi-miR399d-5p; +MIMAT0037403 csi-miR399a-5p; +MIMAT0037404 csi-miR399b-5p; +MIMAT0037405 csi-miR403a-5p; +MIMAT0037406 csi-miR408-5p; +MIMAT0037407 csi-miR482f-5p; +MIMAT0037408 csi-miR477c-3p; +MIMAT0037409 csi-miR477a-3p; +MIMAT0037410 csi-miR477b-3p; +MIMAT0037411 csi-miR482b-5p; +MIMAT0037412 csi-miR530a-3p; +MIMAT0037413 csi-miR530b-3p; +MIMAT0037414 csi-miR3951a-3p; +MIMAT0037415 csi-miR3952-5p; +MIMAT0037416 csi-miR482c-5p; +MIMAT0037417 csi-miR167a-3p; +MIMAT0037418 egr-let-7-3p; +MIMAT0037419 egr-miR-2a-5p; +MIMAT0037420 egr-miR-2b-5p; +MIMAT0037421 egr-miR-7-3p; +MIMAT0037422 egr-miR-8-5p; +MIMAT0037423 egr-miR-9-3p; +MIMAT0037424 egr-miR-10a-3p; +MIMAT0037425 egr-miR-71-3p; +MIMAT0037426 egr-miR-124a-5p; +MIMAT0037427 egr-miR-125-3p; +MIMAT0037428 egr-miR-153-5p; +MIMAT0037429 egr-miR-190-3p; +MIMAT0037430 egr-miR-219-3p; +MIMAT0037431 egr-miR-745-5p; +MIMAT0037432 egr-miR-184-3p; +MIMAT0037433 egr-miR-4989-5p; +MIMAT0037434 emu-let-7-3p; +MIMAT0037435 emu-miR-2a-5p; +MIMAT0037436 emu-miR-2b-5p; +MIMAT0037437 emu-miR-2c-5p; +MIMAT0037438 emu-miR-7-3p; +MIMAT0037439 emu-miR-8-5p; +MIMAT0037440 emu-miR-9-3p; +MIMAT0037441 emu-miR-10-3p; +MIMAT0037442 emu-miR-71-3p; +MIMAT0037443 emu-miR-87-5p; +MIMAT0037444 emu-miR-124a-5p; +MIMAT0037445 emu-miR-124b-5p; +MIMAT0037446 emu-miR-125-3p; +MIMAT0037447 emu-miR-153-5p; +MIMAT0037448 emu-miR-190-3p; +MIMAT0037449 emu-miR-219-3p; +MIMAT0037450 emu-miR-745-5p; +MIMAT0037451 emu-miR-184-3p; +MIMAT0037452 emu-miR-4989-5p; +MIMAT0037453 gma-miR4416c-3p; +MIMAT0037454 gma-miR169s-3p; +MIMAT0037455 ame-miR-92c-3p; +MIMAT0037456 ame-miR-6047a-5p; +MIMAT0037457 cgr-miR-26a-2; +MIMAT0037458 cgr-miR-30c-2; +MIMAT0037459 mes-miR159a-5p; +MIMAT0037460 prv-miR-LLT7-3p; +MIMAT0037461 prv-miR-LLT8-3p; +MIMAT0037462 prv-miR-LLT11a-3p; +MIMAT0037463 prv-miR-LLT11b-3p; +MIMAT0037464 ssc-let-7f-3p; +MIMAT0037465 ssc-miR-194a-3p; +MIMAT0037466 ssc-miR-582-5p; +MIMAT0037467 mdm-miR171f-5p; +MIMAT0037468 mdm-miR319b-5p; +MIMAT0037469 mdm-miR395d-5p; +MIMAT0037470 mdm-miR395g-5p; +MIMAT0037471 mdm-miR395i-5p; +MIMAT0037472 mdm-miR7120a-3p; +MIMAT0037473 mdm-miR7120b-3p; +MIMAT0037474 mdm-miR319c-5p; +MIMAT0037475 mdm-miR7126-3p; +MIMAT0037476 bma-miR-5838-5p; +MIMAT0037477 bma-miR-5839-5p; +MIMAT0037478 bma-miR-5841-3p; +MIMAT0037479 bma-miR-5842-5p; +MIMAT0037480 bma-miR-2i-3p; +MIMAT0037481 bma-miR-5858-3p; +MIMAT0037482 bma-miR-2g-5p; +MIMAT0037483 bma-miR-5862-3p; +MIMAT0037484 bma-miR-239-3p; +MIMAT0037485 bma-miR-5363-3p; +MIMAT0037486 bma-miR-5366-5p; +MIMAT0037487 bta-miR-8548; +MIMAT0037488 bta-miR-8549; +MIMAT0037489 bma-miR-9501-3p; +MIMAT0037490 bma-miR-2f; +MIMAT0037491 bma-miR-36a-3; +MIMAT0037492 bma-miR-36d-5p; +MIMAT0037493 bma-miR-36d-3p; +MIMAT0037494 bma-miR-9502; +MIMAT0037495 bma-miR-9503; +MIMAT0037496 bma-miR-9504; +MIMAT0037497 bma-miR-9505-5p; +MIMAT0037498 bma-miR-9505-3p; +MIMAT0037499 bma-miR-9506-3p; +MIMAT0037500 bma-miR-9507; +MIMAT0037501 bma-miR-9508-5p; +MIMAT0037502 bma-miR-9509-3p; +MIMAT0037503 bma-miR-9510; +MIMAT0037504 bma-miR-9511-3p; +MIMAT0037505 bma-miR-9512; +MIMAT0037506 bma-miR-9513-5p; +MIMAT0037507 bma-miR-9514; +MIMAT0037508 bma-miR-9515; +MIMAT0037509 bma-miR-9516; +MIMAT0037510 bma-miR-9517-5p; +MIMAT0037511 bma-miR-9517-3p; +MIMAT0037512 bma-miR-9518; +MIMAT0037513 bma-miR-9519; +MIMAT0037514 bma-miR-9520; +MIMAT0037515 bma-miR-9521; +MIMAT0037516 bma-miR-9522; +MIMAT0037517 bma-miR-9523; +MIMAT0037519 bma-miR-9525; +MIMAT0037520 bma-miR-9526; +MIMAT0037521 bma-miR-9527; +MIMAT0037522 bma-miR-9528; +MIMAT0037523 bma-miR-9529; +MIMAT0037524 bma-miR-9530; +MIMAT0037525 bma-miR-9531; +MIMAT0037526 bma-miR-9532; +MIMAT0037527 bma-miR-9533; +MIMAT0037528 bma-miR-9534; +MIMAT0037529 bma-miR-2h-5p; +MIMAT0037530 bma-miR-2h-3p; +MIMAT0037531 bma-miR-9535; +MIMAT0037532 bma-miR-9536; +MIMAT0037533 bma-miR-9537; +MIMAT0037534 dvi-miR-973-5p; +MIMAT0037535 dvi-miR-976-5p; +MIMAT0037536 dvi-miR-974-1-3p; +MIMAT0037537 dvi-miR-977-5p; +MIMAT0037538 gga-miR-26a-2-5p; +MIMAT0037539 gga-miR-33-2-5p; +MIMAT0037540 gga-miR-96-5p; +MIMAT0037541 gga-miR-96-3p; +MIMAT0037542 gga-miR-145-5p; +MIMAT0037543 gga-miR-145-3p; +MIMAT0037544 gga-miR-182-5p; +MIMAT0037545 gga-miR-182-3p; +MIMAT0037546 gga-miR-190b-5p; +MIMAT0037547 gga-miR-190b-3p; +MIMAT0037548 gga-miR-203b-3p; +MIMAT0037549 gga-miR-210a-5p; +MIMAT0037550 gga-miR-210a-3p; +MIMAT0037551 gga-miR-338-5p; +MIMAT0037552 gga-miR-338-3p; +MIMAT0037553 gga-miR-363-5p; +MIMAT0037554 gga-miR-363-3p; +MIMAT0037555 gga-miR-1388a-5p; +MIMAT0037556 gga-miR-1388a-3p; +MIMAT0037557 aca-let-7c-3-3p; +MIMAT0037558 aca-let-7a-3-3p; +MIMAT0037559 aca-let-7a-2-3p; +MIMAT0037560 aca-miR-19c-3p; +MIMAT0037561 aca-miR-26-3-5p; +MIMAT0037562 aca-miR-26-3p; +MIMAT0037563 aca-miR-30c-2-3p; +MIMAT0037564 aca-miR-106-5p; +MIMAT0037565 aca-miR-106-3p; +MIMAT0037566 aca-miR-133a-3p; +MIMAT0037567 aca-miR-133b-5p; +MIMAT0037568 aca-miR-133b-3p; +MIMAT0037569 aca-miR-181c-5p; +MIMAT0037570 aca-miR-222b-5p; +MIMAT0037571 aca-miR-222b-3p; +MIMAT0037572 aca-miR-302a-3p; +MIMAT0037573 aca-miR-737-5p; +MIMAT0037574 aca-miR-737-3p; +MIMAT0037575 aca-miR-1641-5p; +MIMAT0037576 aca-miR-9572-5p; +MIMAT0037577 aca-miR-9572-3p; +MIMAT0037578 aca-miR-9573-5p; +MIMAT0037579 aca-miR-9573-3p; +MIMAT0037580 aca-miR-5396b-5p; +MIMAT0037581 aca-miR-5396b-3p; +MIMAT0037582 aca-miR-9574-5p; +MIMAT0037583 aca-miR-9574-3p; +MIMAT0037584 aca-miR-9575-5p; +MIMAT0037585 aca-miR-9575-3p; +MIMAT0037586 aca-miR-9576-5p; +MIMAT0037587 aca-miR-9576-3p; +MIMAT0037588 aca-miR-9577-5p; +MIMAT0037589 aca-miR-9577-3p; +MIMAT0037590 xtr-miR-454-3p; +MIMAT0037591 xtr-miR-460a-3p; +MIMAT0037592 xtr-miR-460b-3p; +MIMAT0037593 xtr-miR-551b-3p; +MIMAT0037594 cpi-let-7a-5p; +MIMAT0037595 cpi-let-7a-3p; +MIMAT0037596 cpi-let-7a-2-3p; +MIMAT0037597 cpi-let-7a-4-3p; +MIMAT0037598 cpi-let-7b-5p; +MIMAT0037599 cpi-let-7c-5p; +MIMAT0037600 cpi-let-7c-3p; +MIMAT0037601 cpi-let-7c-2-3p; +MIMAT0037602 cpi-let-7d-5p; +MIMAT0037603 cpi-let-7d-3p; +MIMAT0037604 cpi-let-7e-5p; +MIMAT0037605 cpi-let-7e-3p; +MIMAT0037606 cpi-let-7f-5p; +MIMAT0037607 cpi-let-7f-3p; +MIMAT0037608 cpi-let-7g-5p; +MIMAT0037609 cpi-let-7g-3p; +MIMAT0037610 cpi-let-7i-5p; +MIMAT0037611 cpi-let-7i-3p; +MIMAT0037612 cpi-miR-1a-5p; +MIMAT0037613 cpi-miR-1a-3p; +MIMAT0037614 cpi-miR-1a-2-5p; +MIMAT0037615 cpi-miR-1b-5p; +MIMAT0037616 cpi-miR-1b-3p; +MIMAT0037617 cpi-miR-7a-5p; +MIMAT0037618 cpi-miR-7a-3p; +MIMAT0037619 cpi-miR-7a-2-3p; +MIMAT0037620 cpi-miR-7a-3-3p; +MIMAT0037621 cpi-miR-7b-5p; +MIMAT0037622 cpi-miR-9-5p; +MIMAT0037623 cpi-miR-9-3p; +MIMAT0037624 cpi-miR-9-4-3p; +MIMAT0037625 cpi-miR-10a-5p; +MIMAT0037626 cpi-miR-10a-3p; +MIMAT0037627 cpi-miR-10b-5p; +MIMAT0037628 cpi-miR-10b-3p; +MIMAT0037629 cpi-miR-10c-5p; +MIMAT0037630 cpi-miR-10c-3p; +MIMAT0037631 cpi-miR-15a-5p; +MIMAT0037632 cpi-miR-15b-5p; +MIMAT0037633 cpi-miR-15b-3p; +MIMAT0037634 cpi-miR-16a-5p; +MIMAT0037635 cpi-miR-16a-3p; +MIMAT0037636 cpi-miR-16c-5p; +MIMAT0037637 cpi-miR-16c-3p; +MIMAT0037638 cpi-miR-18a-5p; +MIMAT0037639 cpi-miR-18a-3p; +MIMAT0037640 cpi-miR-18b-5p; +MIMAT0037641 cpi-miR-18b-3p; +MIMAT0037642 cpi-miR-19a-5p; +MIMAT0037643 cpi-miR-19a-3p; +MIMAT0037644 cpi-miR-19b-5p; +MIMAT0037645 cpi-miR-19b-3p; +MIMAT0037646 cpi-miR-19b-2-5p; +MIMAT0037647 cpi-miR-20a-5p; +MIMAT0037648 cpi-miR-20a-3p; +MIMAT0037649 cpi-miR-20b-5p; +MIMAT0037650 cpi-miR-20b-3p; +MIMAT0037651 cpi-miR-21-5p; +MIMAT0037652 cpi-miR-21-3p; +MIMAT0037653 cpi-miR-22-5p; +MIMAT0037654 cpi-miR-22-3p; +MIMAT0037655 cpi-miR-23a-3p; +MIMAT0037656 cpi-miR-23b-3p; +MIMAT0037657 cpi-miR-24-5p; +MIMAT0037658 cpi-miR-24-3p; +MIMAT0037659 cpi-miR-24-2-5p; +MIMAT0037660 cpi-miR-26-5p; +MIMAT0037661 cpi-miR-26-3p; +MIMAT0037662 cpi-miR-26-2-3p; +MIMAT0037663 cpi-miR-26-3-3p; +MIMAT0037664 cpi-miR-27a-5p; +MIMAT0037665 cpi-miR-27a-3p; +MIMAT0037666 cpi-miR-27b-5p; +MIMAT0037667 cpi-miR-27b-3p; +MIMAT0037668 cpi-miR-29a-5p; +MIMAT0037669 cpi-miR-29a-3p; +MIMAT0037670 cpi-miR-29a-2-5p; +MIMAT0037671 cpi-miR-29b-5p; +MIMAT0037672 cpi-miR-29b-3p; +MIMAT0037673 cpi-miR-29b-2-5p; +MIMAT0037674 cpi-miR-30a-5p; +MIMAT0037675 cpi-miR-30a-3p; +MIMAT0037676 cpi-miR-30b-5p; +MIMAT0037677 cpi-miR-30b-3p; +MIMAT0037678 cpi-miR-30c-5p; +MIMAT0037679 cpi-miR-30c-3p; +MIMAT0037680 cpi-miR-30c-2-3p; +MIMAT0037681 cpi-miR-30d-5p; +MIMAT0037682 cpi-miR-30d-3p; +MIMAT0037683 cpi-miR-30e-5p; +MIMAT0037684 cpi-miR-30e-3p; +MIMAT0037685 cpi-miR-31-5p; +MIMAT0037686 cpi-miR-31-3p; +MIMAT0037687 cpi-miR-32-5p; +MIMAT0037688 cpi-miR-32-3p; +MIMAT0037689 cpi-miR-33-5p; +MIMAT0037690 cpi-miR-33-3p; +MIMAT0037691 cpi-miR-33-2-3p; +MIMAT0037692 cpi-miR-34a-5p; +MIMAT0037693 cpi-miR-34a-3p; +MIMAT0037694 cpi-miR-34b-5p; +MIMAT0037695 cpi-miR-34b-3p; +MIMAT0037696 cpi-miR-34c-5p; +MIMAT0037697 cpi-miR-34c-3p; +MIMAT0037698 cpi-miR-92a-5p; +MIMAT0037699 cpi-miR-92a-3p; +MIMAT0037700 cpi-miR-92a-2-5p; +MIMAT0037701 cpi-miR-92b-5p; +MIMAT0037702 cpi-miR-92b-3p; +MIMAT0037703 cpi-miR-92c-5p; +MIMAT0037704 cpi-miR-92c-3p; +MIMAT0037705 cpi-miR-93-5p; +MIMAT0037706 cpi-miR-93-3p; +MIMAT0037707 cpi-miR-96-5p; +MIMAT0037708 cpi-miR-98-5p; +MIMAT0037709 cpi-miR-98-3p; +MIMAT0037710 cpi-miR-99a-5p; +MIMAT0037711 cpi-miR-99a-3p; +MIMAT0037712 cpi-miR-99b-5p; +MIMAT0037713 cpi-miR-99b-3p; +MIMAT0037714 cpi-miR-100-5p; +MIMAT0037715 cpi-miR-100-3p; +MIMAT0037716 cpi-miR-101-5p; +MIMAT0037717 cpi-miR-101-3p; +MIMAT0037718 cpi-miR-101-2-5p; +MIMAT0037719 cpi-miR-103-3p; +MIMAT0037720 cpi-miR-103-5p; +MIMAT0037721 cpi-miR-106a-5p; +MIMAT0037722 cpi-miR-106b-5p; +MIMAT0037723 cpi-miR-107-3p; +MIMAT0037724 cpi-miR-122-5p; +MIMAT0037725 cpi-miR-122-3p; +MIMAT0037726 cpi-miR-124-5p; +MIMAT0037727 cpi-miR-124-3p; +MIMAT0037728 cpi-miR-125a-5p; +MIMAT0037729 cpi-miR-125a-3p; +MIMAT0037730 cpi-miR-125b-5p; +MIMAT0037731 cpi-miR-125b-3p; +MIMAT0037732 cpi-miR-125b-2-3p; +MIMAT0037733 cpi-miR-126-5p; +MIMAT0037734 cpi-miR-126-3p; +MIMAT0037735 cpi-miR-128-5p; +MIMAT0037736 cpi-miR-128-3p; +MIMAT0037737 cpi-miR-128-2-5p; +MIMAT0037738 cpi-miR-129-5p; +MIMAT0037739 cpi-miR-129-3p; +MIMAT0037740 cpi-miR-129-2-3p; +MIMAT0037741 cpi-miR-130a-5p; +MIMAT0037742 cpi-miR-130a-3p; +MIMAT0037743 cpi-miR-130b-5p; +MIMAT0037744 cpi-miR-130b-3p; +MIMAT0037745 cpi-miR-130c-5p; +MIMAT0037746 cpi-miR-130c-3p; +MIMAT0037747 cpi-miR-130d-3p; +MIMAT0037748 cpi-miR-132-5p; +MIMAT0037749 cpi-miR-132-3p; +MIMAT0037750 cpi-miR-133a-5p; +MIMAT0037751 cpi-miR-133a-3p; +MIMAT0037752 cpi-miR-133b-3p; +MIMAT0037753 cpi-miR-133c-3p; +MIMAT0037754 cpi-miR-135-5p; +MIMAT0037755 cpi-miR-135-3p; +MIMAT0037756 cpi-miR-135-2-3p; +MIMAT0037757 cpi-miR-135-3-3p; +MIMAT0037758 cpi-miR-137a-3p; +MIMAT0037759 cpi-miR-137b-3p; +MIMAT0037760 cpi-miR-138-5p; +MIMAT0037761 cpi-miR-138-3p; +MIMAT0037762 cpi-miR-139-5p; +MIMAT0037763 cpi-miR-139-3p; +MIMAT0037764 cpi-miR-140-5p; +MIMAT0037765 cpi-miR-140-3p; +MIMAT0037766 cpi-miR-142-5p; +MIMAT0037767 cpi-miR-142-3p; +MIMAT0037768 cpi-miR-143-5p; +MIMAT0037769 cpi-miR-143-3p; +MIMAT0037770 cpi-miR-144-5p; +MIMAT0037771 cpi-miR-144-3p; +MIMAT0037772 cpi-miR-145-5p; +MIMAT0037773 cpi-miR-145-3p; +MIMAT0037774 cpi-miR-146a-5p; +MIMAT0037775 cpi-miR-146a-3p; +MIMAT0037776 cpi-miR-146b-5p; +MIMAT0037777 cpi-miR-146b-3p; +MIMAT0037778 cpi-miR-146c-5p; +MIMAT0037779 cpi-miR-146c-3p; +MIMAT0037780 cpi-miR-147-5p; +MIMAT0037781 cpi-miR-147-3p; +MIMAT0037782 cpi-miR-148a-5p; +MIMAT0037783 cpi-miR-148a-3p; +MIMAT0037784 cpi-miR-148b-3p; +MIMAT0037785 cpi-miR-152-5p; +MIMAT0037786 cpi-miR-152-3p; +MIMAT0037787 cpi-miR-153-5p; +MIMAT0037788 cpi-miR-153-3p; +MIMAT0037789 cpi-miR-155a-5p; +MIMAT0037790 cpi-miR-155b-5p; +MIMAT0037791 cpi-miR-181a-5p; +MIMAT0037792 cpi-miR-181a-3p; +MIMAT0037793 cpi-miR-181a-2-3p; +MIMAT0037794 cpi-miR-181a-3-3p; +MIMAT0037795 cpi-miR-181b-5p; +MIMAT0037796 cpi-miR-181b-1-3p; +MIMAT0037797 cpi-miR-181b-3p; +MIMAT0037798 cpi-miR-182-5p; +MIMAT0037799 cpi-miR-182-3p; +MIMAT0037800 cpi-miR-183-5p; +MIMAT0037801 cpi-miR-184-3p; +MIMAT0037802 cpi-miR-187-5p; +MIMAT0037803 cpi-miR-187-3p; +MIMAT0037804 cpi-miR-190a-5p; +MIMAT0037805 cpi-miR-190b-5p; +MIMAT0037806 cpi-miR-191-5p; +MIMAT0037807 cpi-miR-192-5p; +MIMAT0037808 cpi-miR-192-3p; +MIMAT0037809 cpi-miR-193a-5p; +MIMAT0037810 cpi-miR-193a-3p; +MIMAT0037811 cpi-miR-193b-3p; +MIMAT0037812 cpi-miR-194-5p; +MIMAT0037813 cpi-miR-194-3p; +MIMAT0037814 cpi-miR-194-2-3p; +MIMAT0037815 cpi-miR-196-5p; +MIMAT0037816 cpi-miR-196-3p; +MIMAT0037817 cpi-miR-196-2-3p; +MIMAT0037818 cpi-miR-199-5p; +MIMAT0037819 cpi-miR-199-3p; +MIMAT0037820 cpi-miR-200a-5p; +MIMAT0037821 cpi-miR-200a-3p; +MIMAT0037822 cpi-miR-200b-5p; +MIMAT0037823 cpi-miR-200b-3p; +MIMAT0037824 cpi-miR-202-5p; +MIMAT0037825 cpi-miR-203-5p; +MIMAT0037826 cpi-miR-203-3p; +MIMAT0037827 cpi-miR-204-5p; +MIMAT0037828 cpi-miR-204-3p; +MIMAT0037829 cpi-miR-204-3-3p; +MIMAT0037830 cpi-miR-205a-5p; +MIMAT0037831 cpi-miR-205a-3p; +MIMAT0037832 cpi-miR-205b-5p; +MIMAT0037833 cpi-miR-206-5p; +MIMAT0037834 cpi-miR-206-3p; +MIMAT0037835 cpi-miR-208-5p; +MIMAT0037836 cpi-miR-210-5p; +MIMAT0037837 cpi-miR-210-3p; +MIMAT0037838 cpi-miR-212-5p; +MIMAT0037839 cpi-miR-214-5p; +MIMAT0037840 cpi-miR-214-3p; +MIMAT0037841 cpi-miR-215-5p; +MIMAT0037842 cpi-miR-215-3p; +MIMAT0037843 cpi-miR-216a-5p; +MIMAT0037844 cpi-miR-216b-5p; +MIMAT0037845 cpi-miR-217-5p; +MIMAT0037846 cpi-miR-218-5p; +MIMAT0037847 cpi-miR-218-3p; +MIMAT0037848 cpi-miR-219-5p; +MIMAT0037849 cpi-miR-219-3p; +MIMAT0037850 cpi-miR-221-5p; +MIMAT0037851 cpi-miR-221-3p; +MIMAT0037852 cpi-miR-222a-5p; +MIMAT0037853 cpi-miR-222a-3p; +MIMAT0037854 cpi-miR-222b-5p; +MIMAT0037855 cpi-miR-222b-3p; +MIMAT0037856 cpi-miR-223-5p; +MIMAT0037857 cpi-miR-223-3p; +MIMAT0037858 cpi-miR-301a-3p; +MIMAT0037859 cpi-miR-301b-3p; +MIMAT0037860 cpi-miR-302a-3p; +MIMAT0037861 cpi-miR-302b-3p; +MIMAT0037862 cpi-miR-302c-3p; +MIMAT0037863 cpi-miR-302d-3p; +MIMAT0037864 cpi-miR-338a-5p; +MIMAT0037865 cpi-miR-338a-3p; +MIMAT0037866 cpi-miR-338b-5p; +MIMAT0037867 cpi-miR-338b-3p; +MIMAT0037868 cpi-miR-363-5p; +MIMAT0037869 cpi-miR-363-3p; +MIMAT0037870 cpi-miR-365-3p; +MIMAT0037871 cpi-miR-365-5p; +MIMAT0037872 cpi-miR-367-3p; +MIMAT0037873 cpi-miR-375-3p; +MIMAT0037874 cpi-miR-383-5p; +MIMAT0037875 cpi-miR-425-5p; +MIMAT0037876 cpi-miR-425-3p; +MIMAT0037877 cpi-miR-429-3p; +MIMAT0037878 cpi-miR-449a-5p; +MIMAT0037879 cpi-miR-449a-3p; +MIMAT0037880 cpi-miR-449b-5p; +MIMAT0037881 cpi-miR-449c-5p; +MIMAT0037882 cpi-miR-449d-5p; +MIMAT0037883 cpi-miR-451-5p; +MIMAT0037884 cpi-miR-451-3p; +MIMAT0037885 cpi-miR-454-5p; +MIMAT0037886 cpi-miR-454-3p; +MIMAT0037887 cpi-miR-455-5p; +MIMAT0037888 cpi-miR-455-3p; +MIMAT0037889 cpi-miR-456-3p; +MIMAT0037890 cpi-miR-458-5p; +MIMAT0037891 cpi-miR-458-3p; +MIMAT0037892 cpi-miR-459-5p; +MIMAT0037893 cpi-miR-459-3p; +MIMAT0037894 cpi-miR-460a-5p; +MIMAT0037895 cpi-miR-460a-3p; +MIMAT0037896 cpi-miR-460b-5p; +MIMAT0037897 cpi-miR-489-5p; +MIMAT0037898 cpi-miR-489-3p; +MIMAT0037899 cpi-miR-490-5p; +MIMAT0037900 cpi-miR-490-3p; +MIMAT0037901 cpi-miR-499-5p; +MIMAT0037902 cpi-miR-499-3p; +MIMAT0037903 cpi-miR-551-5p; +MIMAT0037904 cpi-miR-551-3p; +MIMAT0037905 cpi-miR-551-2-3p; +MIMAT0037906 cpi-miR-599-3p; +MIMAT0037907 cpi-miR-726-3p; +MIMAT0037908 cpi-miR-737-5p; +MIMAT0037909 cpi-miR-875-5p; +MIMAT0037910 cpi-miR-1306-5p; +MIMAT0037911 cpi-miR-1306-3p; +MIMAT0037912 cpi-miR-1329-5p; +MIMAT0037913 cpi-miR-1388-5p; +MIMAT0037914 cpi-miR-1388-3p; +MIMAT0037915 cpi-miR-1397-5p; +MIMAT0037916 cpi-miR-1416-5p; +MIMAT0037917 cpi-miR-1641-5p; +MIMAT0037918 cpi-miR-1662-5p; +MIMAT0037919 cpi-miR-1662-3p; +MIMAT0037920 cpi-miR-1677a-5p; +MIMAT0037921 cpi-miR-1677a-3p; +MIMAT0037922 cpi-miR-1677b-5p; +MIMAT0037923 cpi-miR-1677b-3p; +MIMAT0037924 cpi-miR-1677c-5p; +MIMAT0037925 cpi-miR-1677c-3p; +MIMAT0037926 cpi-miR-1677d-5p; +MIMAT0037927 cpi-miR-1677d-3p; +MIMAT0037928 cpi-miR-1677e-5p; +MIMAT0037929 cpi-miR-1677e-3p; +MIMAT0037930 cpi-miR-1677f-3p; +MIMAT0037931 cpi-miR-1677g-3p; +MIMAT0037932 cpi-miR-1677h-5p; +MIMAT0037933 cpi-miR-1677h-3p; +MIMAT0037934 cpi-miR-1720-3p; +MIMAT0037935 cpi-miR-1784-3p; +MIMAT0037936 cpi-miR-1788-5p; +MIMAT0037937 cpi-miR-1788-3p; +MIMAT0037938 cpi-miR-1791-5p; +MIMAT0037939 cpi-miR-1805-5p; +MIMAT0037940 cpi-miR-1805-3p; +MIMAT0037941 cpi-miR-2184-5p; +MIMAT0037942 cpi-miR-2184-3p; +MIMAT0037943 cpi-miR-2188-5p; +MIMAT0037944 cpi-miR-2188-3p; +MIMAT0037945 cpi-miR-2970-5p; +MIMAT0037946 cpi-miR-2970-3p; +MIMAT0037947 cpi-miR-2984-3p; +MIMAT0037948 cpi-miR-3064-3p; +MIMAT0037949 cpi-miR-3618-3p; +MIMAT0037950 cpi-miR-9578-5p; +MIMAT0037951 cpi-miR-9578-3p; +MIMAT0037952 cpi-miR-9579-5p; +MIMAT0037953 cpi-miR-9579-3p; +MIMAT0037954 cpi-miR-1729-5p; +MIMAT0037955 cpi-miR-1729-3p; +MIMAT0037956 cpi-miR-9580-5p; +MIMAT0037957 cpi-miR-9580-3p; +MIMAT0037958 cpi-miR-9581-5p; +MIMAT0037959 cpi-miR-9581-3p; +MIMAT0037960 cpi-miR-9582-5p; +MIMAT0037961 cpi-miR-9582-3p; +MIMAT0037962 cpi-miR-9583-5p; +MIMAT0037963 cpi-miR-9583-3p; +MIMAT0037964 cpi-miR-9584-5p; +MIMAT0037965 cpi-miR-9584-3p; +MIMAT0037966 cpi-miR-9585-5p; +MIMAT0037967 cpi-miR-9585-3p; +MIMAT0037968 cpi-miR-9586-5p; +MIMAT0037969 cpi-miR-9586-3p; +MIMAT0037970 cpi-miR-9587-5p; +MIMAT0037971 cpi-miR-9587-3p; +MIMAT0037972 cpi-miR-9588-5p; +MIMAT0037973 cpi-miR-9588-3p; +MIMAT0037974 cpi-miR-9589-5p; +MIMAT0037975 cpi-miR-9589-3p; +MIMAT0037976 cpi-miR-9590-5p; +MIMAT0037977 cpi-miR-9590-3p; +MIMAT0037978 cpi-miR-9591-5p; +MIMAT0037979 cpi-miR-9591-3p; +MIMAT0037980 cpi-miR-9592-5p; +MIMAT0037981 cpi-miR-9592-3p; +MIMAT0037982 cpi-miR-9593-5p; +MIMAT0037983 cpi-miR-9593-3p; +MIMAT0037984 cpi-miR-9594-5p; +MIMAT0037985 cpi-miR-9594-3p; +MIMAT0037986 cpi-miR-9595-5p; +MIMAT0037987 cpi-miR-9595-3p; +MIMAT0037988 cpi-miR-9596-5p; +MIMAT0037989 cpi-miR-9596-3p; +MIMAT0037990 cpi-miR-9597-5p; +MIMAT0037991 cpi-miR-9597-3p; +MIMAT0037992 cpi-miR-15c-5p; +MIMAT0037993 cpi-miR-15c-3p; +MIMAT0037994 cpi-miR-16b-5p; +MIMAT0037995 cpi-miR-16b-3p; +MIMAT0037996 cpi-miR-17-5p; +MIMAT0037997 cpi-miR-17-3p; +MIMAT0037998 cpi-miR-727-3p; +MIMAT0037999 ami-let-7a-5p; +MIMAT0038000 ami-let-7a-3p; +MIMAT0038001 ami-let-7a-2-3p; +MIMAT0038002 ami-let-7a-4-3p; +MIMAT0038003 ami-let-7b-5p; +MIMAT0038004 ami-let-7b-3p; +MIMAT0038005 ami-let-7c-5p; +MIMAT0038006 ami-let-7c-3p; +MIMAT0038007 ami-let-7c-2-3p; +MIMAT0038008 ami-let-7d-5p; +MIMAT0038009 ami-let-7d-3p; +MIMAT0038010 ami-let-7e-5p; +MIMAT0038011 ami-let-7e-3p; +MIMAT0038012 ami-let-7f-5p; +MIMAT0038013 ami-let-7f-3p; +MIMAT0038014 ami-let-7g-5p; +MIMAT0038015 ami-let-7g-3p; +MIMAT0038016 ami-let-7i-5p; +MIMAT0038017 ami-let-7i-3p; +MIMAT0038018 ami-miR-1a-5p; +MIMAT0038019 ami-miR-1a-3p; +MIMAT0038020 ami-miR-1a-2-5p; +MIMAT0038021 ami-miR-1b-5p; +MIMAT0038022 ami-miR-1b-3p; +MIMAT0038023 ami-miR-7a-5p; +MIMAT0038024 ami-miR-7a-3p; +MIMAT0038025 ami-miR-7a-2-3p; +MIMAT0038026 ami-miR-7b-5p; +MIMAT0038027 ami-miR-9-5p; +MIMAT0038028 ami-miR-9-3p; +MIMAT0038029 ami-miR-9-4-3p; +MIMAT0038030 ami-miR-10a-5p; +MIMAT0038031 ami-miR-10a-3p; +MIMAT0038032 ami-miR-10b-5p; +MIMAT0038033 ami-miR-10b-3p; +MIMAT0038034 ami-miR-10c-5p; +MIMAT0038035 ami-miR-10c-3p; +MIMAT0038036 ami-miR-15a-5p; +MIMAT0038037 ami-miR-15a-3p; +MIMAT0038038 ami-miR-15b-5p; +MIMAT0038039 ami-miR-15b-3p; +MIMAT0038040 ami-miR-15c-5p; +MIMAT0038041 ami-miR-15c-3p; +MIMAT0038042 ami-miR-16a-5p; +MIMAT0038043 ami-miR-16a-3p; +MIMAT0038044 ami-miR-16a-2-3p; +MIMAT0038045 ami-miR-16b-5p; +MIMAT0038046 ami-miR-16b-3p; +MIMAT0038047 ami-miR-17-5p; +MIMAT0038048 ami-miR-17-3p; +MIMAT0038049 ami-miR-18-5p; +MIMAT0038050 ami-miR-18-3p; +MIMAT0038051 ami-miR-19a-5p; +MIMAT0038052 ami-miR-19b-5p; +MIMAT0038053 ami-miR-19b-3p; +MIMAT0038054 ami-miR-20a-5p; +MIMAT0038055 ami-miR-20a-3p; +MIMAT0038056 ami-miR-21-5p; +MIMAT0038057 ami-miR-21-3p; +MIMAT0038058 ami-miR-23a-3p; +MIMAT0038059 ami-miR-23b-5p; +MIMAT0038060 ami-miR-23b-3p; +MIMAT0038061 ami-miR-24-5p; +MIMAT0038062 ami-miR-24-3p; +MIMAT0038063 ami-miR-24-2-5p; +MIMAT0038064 ami-miR-26-5p; +MIMAT0038065 ami-miR-26-3p; +MIMAT0038066 ami-miR-26-2-3p; +MIMAT0038067 ami-miR-27a-5p; +MIMAT0038068 ami-miR-27a-3p; +MIMAT0038069 ami-miR-27b-5p; +MIMAT0038070 ami-miR-27b-3p; +MIMAT0038071 ami-miR-29a-5p; +MIMAT0038072 ami-miR-29a-3p; +MIMAT0038073 ami-miR-29a-2-5p; +MIMAT0038074 ami-miR-29b-5p; +MIMAT0038075 ami-miR-29b-3p; +MIMAT0038076 ami-miR-29b-2-5p; +MIMAT0038077 ami-miR-30a-5p; +MIMAT0038078 ami-miR-30a-3p; +MIMAT0038079 ami-miR-30b-5p; +MIMAT0038080 ami-miR-30b-3p; +MIMAT0038081 ami-miR-30c-5p; +MIMAT0038082 ami-miR-30c-3p; +MIMAT0038083 ami-miR-30c-2-3p; +MIMAT0038084 ami-miR-30d-5p; +MIMAT0038085 ami-miR-30d-3p; +MIMAT0038086 ami-miR-30e-5p; +MIMAT0038087 ami-miR-30e-3p; +MIMAT0038088 ami-miR-31-5p; +MIMAT0038089 ami-miR-31-3p; +MIMAT0038090 ami-miR-32-5p; +MIMAT0038091 ami-miR-32-3p; +MIMAT0038092 ami-miR-33-5p; +MIMAT0038093 ami-miR-33-3p; +MIMAT0038094 ami-miR-33-2-3p; +MIMAT0038095 ami-miR-34a-5p; +MIMAT0038096 ami-miR-34a-3p; +MIMAT0038097 ami-miR-34b-5p; +MIMAT0038098 ami-miR-34b-3p; +MIMAT0038099 ami-miR-34c-5p; +MIMAT0038100 ami-miR-34c-3p; +MIMAT0038101 ami-miR-92a-5p; +MIMAT0038102 ami-miR-92a-3p; +MIMAT0038103 ami-miR-92b-3p; +MIMAT0038104 ami-miR-93-5p; +MIMAT0038105 ami-miR-93-3p; +MIMAT0038106 ami-miR-96-5p; +MIMAT0038107 ami-miR-96-3p; +MIMAT0038108 ami-miR-98-5p; +MIMAT0038109 ami-miR-98-3p; +MIMAT0038110 ami-miR-99a-5p; +MIMAT0038111 ami-miR-99a-3p; +MIMAT0038112 ami-miR-99b-5p; +MIMAT0038113 ami-miR-99b-3p; +MIMAT0038114 ami-miR-100-5p; +MIMAT0038115 ami-miR-100-3p; +MIMAT0038116 ami-miR-101-5p; +MIMAT0038117 ami-miR-101-3p; +MIMAT0038118 ami-miR-101-2-5p; +MIMAT0038119 ami-miR-103-3p; +MIMAT0038120 ami-miR-106-5p; +MIMAT0038121 ami-miR-107-5p; +MIMAT0038122 ami-miR-107-3p; +MIMAT0038123 ami-miR-122-5p; +MIMAT0038124 ami-miR-122-3p; +MIMAT0038125 ami-miR-124-5p; +MIMAT0038126 ami-miR-124-3p; +MIMAT0038127 ami-miR-125a-5p; +MIMAT0038128 ami-miR-125b-5p; +MIMAT0038129 ami-miR-125b-3p; +MIMAT0038130 ami-miR-125b-2-3p; +MIMAT0038131 ami-miR-126-5p; +MIMAT0038132 ami-miR-126-3p; +MIMAT0038133 ami-miR-128-5p; +MIMAT0038134 ami-miR-128-3p; +MIMAT0038135 ami-miR-128-2-5p; +MIMAT0038136 ami-miR-129a-5p; +MIMAT0038137 ami-miR-129a-3p; +MIMAT0038138 ami-miR-129b-5p; +MIMAT0038139 ami-miR-129b-3p; +MIMAT0038140 ami-miR-130a-3p; +MIMAT0038141 ami-miR-130b-5p; +MIMAT0038142 ami-miR-130b-3p; +MIMAT0038143 ami-miR-130c-3p; +MIMAT0038144 ami-miR-132-5p; +MIMAT0038145 ami-miR-132-3p; +MIMAT0038146 ami-miR-133a-5p; +MIMAT0038147 ami-miR-133a-3p; +MIMAT0038148 ami-miR-133b-3p; +MIMAT0038149 ami-miR-135-5p; +MIMAT0038150 ami-miR-135-3p; +MIMAT0038151 ami-miR-135-2-3p; +MIMAT0038152 ami-miR-135-3-3p; +MIMAT0038153 ami-miR-137a-3p; +MIMAT0038154 ami-miR-137b-3p; +MIMAT0038155 ami-miR-138-5p; +MIMAT0038156 ami-miR-138-3p; +MIMAT0038157 ami-miR-138-2-3p; +MIMAT0038158 ami-miR-139-5p; +MIMAT0038159 ami-miR-139-3p; +MIMAT0038160 ami-miR-140-5p; +MIMAT0038161 ami-miR-140-3p; +MIMAT0038162 ami-miR-142-5p; +MIMAT0038163 ami-miR-142-3p; +MIMAT0038164 ami-miR-142-2-5p; +MIMAT0038165 ami-miR-143-5p; +MIMAT0038166 ami-miR-143-3p; +MIMAT0038167 ami-miR-144-5p; +MIMAT0038168 ami-miR-144-3p; +MIMAT0038169 ami-miR-145-5p; +MIMAT0038170 ami-miR-145-3p; +MIMAT0038171 ami-miR-146a-5p; +MIMAT0038172 ami-miR-146b-5p; +MIMAT0038173 ami-miR-146b-3p; +MIMAT0038174 ami-miR-146c-5p; +MIMAT0038175 ami-miR-146c-3p; +MIMAT0038176 ami-miR-147-5p; +MIMAT0038177 ami-miR-147-3p; +MIMAT0038178 ami-miR-148b-5p; +MIMAT0038179 ami-miR-148b-3p; +MIMAT0038180 ami-miR-150-5p; +MIMAT0038181 ami-miR-150-3p; +MIMAT0038182 ami-miR-152-5p; +MIMAT0038183 ami-miR-152-3p; +MIMAT0038184 ami-miR-153-3p; +MIMAT0038185 ami-miR-155-5p; +MIMAT0038186 ami-miR-181a-5p; +MIMAT0038187 ami-miR-181a-3p; +MIMAT0038188 ami-miR-181a-2-3p; +MIMAT0038189 ami-miR-181a-3-3p; +MIMAT0038190 ami-miR-181b-5p; +MIMAT0038191 ami-miR-181b-3p; +MIMAT0038192 ami-miR-181b-2-3p; +MIMAT0038193 ami-miR-181b-3-3p; +MIMAT0038194 ami-miR-182-5p; +MIMAT0038195 ami-miR-182-3p; +MIMAT0038196 ami-miR-183-5p; +MIMAT0038197 ami-miR-183-3p; +MIMAT0038198 ami-miR-184-5p; +MIMAT0038199 ami-miR-184-3p; +MIMAT0038200 ami-miR-187-5p; +MIMAT0038201 ami-miR-187-3p; +MIMAT0038202 ami-miR-190a-5p; +MIMAT0038203 ami-miR-190a-3p; +MIMAT0038204 ami-miR-190b-5p; +MIMAT0038205 ami-miR-191-5p; +MIMAT0038206 ami-miR-192-5p; +MIMAT0038207 ami-miR-192-3p; +MIMAT0038208 ami-miR-193a-5p; +MIMAT0038209 ami-miR-193a-3p; +MIMAT0038210 ami-miR-193b-5p; +MIMAT0038211 ami-miR-193b-3p; +MIMAT0038212 ami-miR-194-5p; +MIMAT0038213 ami-miR-194-3p; +MIMAT0038214 ami-miR-194-2-3p; +MIMAT0038215 ami-miR-196-5p; +MIMAT0038216 ami-miR-199-5p; +MIMAT0038217 ami-miR-199-3p; +MIMAT0038218 ami-miR-200a-5p; +MIMAT0038219 ami-miR-200a-3p; +MIMAT0038220 ami-miR-200b-5p; +MIMAT0038221 ami-miR-200b-3p; +MIMAT0038222 ami-miR-202-5p; +MIMAT0038223 ami-miR-203-5p; +MIMAT0038224 ami-miR-203-3p; +MIMAT0038225 ami-miR-204-5p; +MIMAT0038226 ami-miR-204-3p; +MIMAT0038227 ami-miR-204-2-3p; +MIMAT0038228 ami-miR-205a-5p; +MIMAT0038229 ami-miR-205a-3p; +MIMAT0038230 ami-miR-205b-5p; +MIMAT0038231 ami-miR-206-5p; +MIMAT0038232 ami-miR-206-3p; +MIMAT0038233 ami-miR-208-3p; +MIMAT0038234 ami-miR-210-5p; +MIMAT0038235 ami-miR-210-3p; +MIMAT0038236 ami-miR-212-5p; +MIMAT0038237 ami-miR-212-3p; +MIMAT0038238 ami-miR-214-5p; +MIMAT0038239 ami-miR-214-3p; +MIMAT0038240 ami-miR-215-5p; +MIMAT0038241 ami-miR-215-3p; +MIMAT0038242 ami-miR-216a-5p; +MIMAT0038243 ami-miR-216b-5p; +MIMAT0038244 ami-miR-216b-3p; +MIMAT0038245 ami-miR-217-5p; +MIMAT0038246 ami-miR-217-3p; +MIMAT0038247 ami-miR-218-5p; +MIMAT0038248 ami-miR-219a-5p; +MIMAT0038249 ami-miR-219a-3p; +MIMAT0038250 ami-miR-219b-5p; +MIMAT0038251 ami-miR-219b-3p; +MIMAT0038252 ami-miR-221-5p; +MIMAT0038253 ami-miR-221-3p; +MIMAT0038254 ami-miR-222a-5p; +MIMAT0038255 ami-miR-222a-3p; +MIMAT0038256 ami-miR-222b-5p; +MIMAT0038257 ami-miR-222b-3p; +MIMAT0038258 ami-miR-223-5p; +MIMAT0038259 ami-miR-223-3p; +MIMAT0038260 ami-miR-301a-5p; +MIMAT0038261 ami-miR-301a-3p; +MIMAT0038262 ami-miR-301b-5p; +MIMAT0038263 ami-miR-301b-3p; +MIMAT0038264 ami-miR-302a-3p; +MIMAT0038265 ami-miR-302b-3p; +MIMAT0038266 ami-miR-302c-3p; +MIMAT0038267 ami-miR-302d-3p; +MIMAT0038268 ami-miR-338-5p; +MIMAT0038269 ami-miR-338-3p; +MIMAT0038270 ami-miR-338-2-5p; +MIMAT0038271 ami-miR-365-5p; +MIMAT0038272 ami-miR-365-3p; +MIMAT0038273 ami-miR-365-2-5p; +MIMAT0038274 ami-miR-367-3p; +MIMAT0038275 ami-miR-375-3p; +MIMAT0038276 ami-miR-383-5p; +MIMAT0038277 ami-miR-425-5p; +MIMAT0038278 ami-miR-425-3p; +MIMAT0038279 ami-miR-429-5p; +MIMAT0038280 ami-miR-429-3p; +MIMAT0038281 ami-miR-449a-5p; +MIMAT0038282 ami-miR-449b-5p; +MIMAT0038283 ami-miR-449c-5p; +MIMAT0038284 ami-miR-449d-5p; +MIMAT0038285 ami-miR-454-5p; +MIMAT0038286 ami-miR-454-3p; +MIMAT0038287 ami-miR-455-5p; +MIMAT0038288 ami-miR-455-3p; +MIMAT0038289 ami-miR-456-3p; +MIMAT0038290 ami-miR-458-3p; +MIMAT0038291 ami-miR-459-5p; +MIMAT0038292 ami-miR-460a-5p; +MIMAT0038293 ami-miR-460b-5p; +MIMAT0038294 ami-miR-460b-3p; +MIMAT0038295 ami-miR-489-5p; +MIMAT0038296 ami-miR-489-3p; +MIMAT0038297 ami-miR-490-5p; +MIMAT0038298 ami-miR-490-3p; +MIMAT0038299 ami-miR-497-5p; +MIMAT0038300 ami-miR-497-3p; +MIMAT0038301 ami-miR-499-5p; +MIMAT0038302 ami-miR-499-3p; +MIMAT0038303 ami-miR-551-5p; +MIMAT0038304 ami-miR-551-3p; +MIMAT0038305 ami-miR-599-5p; +MIMAT0038306 ami-miR-599-3p; +MIMAT0038307 ami-miR-737-5p; +MIMAT0038308 ami-miR-875-5p; +MIMAT0038309 ami-miR-1306-5p; +MIMAT0038310 ami-miR-1306-3p; +MIMAT0038311 ami-miR-1329-5p; +MIMAT0038312 ami-miR-1388-5p; +MIMAT0038313 ami-miR-1388-3p; +MIMAT0038314 ami-miR-1397-5p; +MIMAT0038315 ami-miR-1397-3p; +MIMAT0038316 ami-miR-1416-5p; +MIMAT0038317 ami-miR-1641-5p; +MIMAT0038318 ami-miR-1662-5p; +MIMAT0038319 ami-miR-1677a-3p; +MIMAT0038320 ami-miR-1677b-5p; +MIMAT0038321 ami-miR-1677b-3p; +MIMAT0038322 ami-miR-1677c-5p; +MIMAT0038323 ami-miR-1677c-3p; +MIMAT0038324 ami-miR-1720-3p; +MIMAT0038325 ami-miR-1788-5p; +MIMAT0038326 ami-miR-1788-3p; +MIMAT0038327 ami-miR-1791-5p; +MIMAT0038328 ami-miR-1791-3p; +MIMAT0038329 ami-miR-1805-5p; +MIMAT0038330 ami-miR-1805-3p; +MIMAT0038331 ami-miR-2184-5p; +MIMAT0038332 ami-miR-2184-3p; +MIMAT0038333 ami-miR-2188-5p; +MIMAT0038334 ami-miR-2188-3p; +MIMAT0038335 ami-miR-2970-5p; +MIMAT0038336 ami-miR-2970-3p; +MIMAT0038337 ami-miR-2984-3p; +MIMAT0038338 ami-miR-3064-3p; +MIMAT0038339 ami-miR-3618-3p; +MIMAT0038340 ami-miR-9598-5p; +MIMAT0038341 ami-miR-9598-3p; +MIMAT0038342 ami-miR-9599-5p; +MIMAT0038343 ami-miR-9599-3p; +MIMAT0038344 ami-miR-9600-5p; +MIMAT0038345 ami-miR-9600-3p; +MIMAT0038346 ami-miR-9601-5p; +MIMAT0038347 ami-miR-9601-3p; +MIMAT0038348 ami-miR-9602-5p; +MIMAT0038349 ami-miR-9602-3p; +MIMAT0038350 ami-miR-9603-5p; +MIMAT0038351 ami-miR-9603-3p; +MIMAT0038352 ami-miR-9604-5p; +MIMAT0038353 ami-miR-9604-3p; +MIMAT0038354 ami-miR-9605-5p; +MIMAT0038355 ami-miR-9605-3p; +MIMAT0038356 ami-miR-9606-5p; +MIMAT0038357 ami-miR-9606-3p; +MIMAT0038358 ami-miR-9607-5p; +MIMAT0038359 ami-miR-9607-3p; +MIMAT0038360 ami-miR-9608-5p; +MIMAT0038361 ami-miR-9608-3p; +MIMAT0038362 ami-miR-9609-5p; +MIMAT0038363 ami-miR-9609-3p; +MIMAT0038364 ami-miR-9610-5p; +MIMAT0038365 ami-miR-9610-3p; +MIMAT0038366 ami-miR-9611-5p; +MIMAT0038367 ami-miR-9611-3p; +MIMAT0038368 ami-miR-9612-5p; +MIMAT0038369 ami-miR-9612-3p; +MIMAT0038370 ami-miR-9613-5p; +MIMAT0038371 ami-miR-9613-3p; +MIMAT0038374 cli-let-7a-5p; +MIMAT0038375 cli-let-7a-3p; +MIMAT0038376 cli-let-7a-2-3p; +MIMAT0038377 cli-let-7a-4-3p; +MIMAT0038378 cli-let-7b-3p; +MIMAT0038379 cli-let-7c-5p; +MIMAT0038380 cli-let-7c-3p; +MIMAT0038381 cli-let-7d-5p; +MIMAT0038382 cli-let-7d-3p; +MIMAT0038383 cli-let-7e-5p; +MIMAT0038384 cli-let-7e-3p; +MIMAT0038385 cli-let-7f-5p; +MIMAT0038386 cli-let-7f-3p; +MIMAT0038387 cli-let-7g-5p; +MIMAT0038388 cli-let-7g-3p; +MIMAT0038389 cli-let-7i-5p; +MIMAT0038390 cli-let-7i-3p; +MIMAT0038391 cli-miR-1a-5p; +MIMAT0038392 cli-miR-1a-3p; +MIMAT0038393 cli-miR-1a-2-5p; +MIMAT0038394 cli-miR-1b-5p; +MIMAT0038395 cli-miR-1b-3p; +MIMAT0038396 cli-miR-7a-5p; +MIMAT0038397 cli-miR-7a-3p; +MIMAT0038398 cli-miR-7a-2-3p; +MIMAT0038399 cli-miR-7a-3-3p; +MIMAT0038400 cli-miR-7b-5p; +MIMAT0038401 cli-miR-9-5p; +MIMAT0038402 cli-miR-9-3p; +MIMAT0038403 cli-miR-9-3-3p; +MIMAT0038404 cli-miR-10a-5p; +MIMAT0038405 cli-miR-10a-3p; +MIMAT0038406 cli-miR-10b-5p; +MIMAT0038407 cli-miR-10b-3p; +MIMAT0038408 cli-miR-10c-5p; +MIMAT0038409 cli-miR-10c-3p; +MIMAT0038410 cli-miR-15a-5p; +MIMAT0038411 cli-miR-15a-3p; +MIMAT0038412 cli-miR-15b-5p; +MIMAT0038413 cli-miR-15b-3p; +MIMAT0038414 cli-miR-15c-5p; +MIMAT0038415 cli-miR-15c-3p; +MIMAT0038416 cli-miR-16a-5p; +MIMAT0038417 cli-miR-16a-3p; +MIMAT0038418 cli-miR-16a-2-3p; +MIMAT0038419 cli-miR-16b-5p; +MIMAT0038420 cli-miR-16b-3p; +MIMAT0038421 cli-miR-17-5p; +MIMAT0038422 cli-miR-17-3p; +MIMAT0038423 cli-miR-18a-5p; +MIMAT0038424 cli-miR-18a-3p; +MIMAT0038425 cli-miR-18b-5p; +MIMAT0038426 cli-miR-18b-3p; +MIMAT0038427 cli-miR-19a-5p; +MIMAT0038428 cli-miR-19a-3p; +MIMAT0038429 cli-miR-19b-5p; +MIMAT0038430 cli-miR-19b-3p; +MIMAT0038431 cli-miR-19b-2-5p; +MIMAT0038432 cli-miR-20a-5p; +MIMAT0038433 cli-miR-20a-3p; +MIMAT0038434 cli-miR-20b-5p; +MIMAT0038435 cli-miR-20b-3p; +MIMAT0038436 cli-miR-21-5p; +MIMAT0038437 cli-miR-21-3p; +MIMAT0038438 cli-miR-22-5p; +MIMAT0038439 cli-miR-22-3p; +MIMAT0038440 cli-miR-23b-5p; +MIMAT0038441 cli-miR-23b-3p; +MIMAT0038442 cli-miR-26-5p; +MIMAT0038443 cli-miR-26-3p; +MIMAT0038444 cli-miR-26-2-3p; +MIMAT0038445 cli-miR-27b-5p; +MIMAT0038446 cli-miR-27b-3p; +MIMAT0038447 cli-miR-29a-5p; +MIMAT0038448 cli-miR-29a-3p; +MIMAT0038449 cli-miR-29b-5p; +MIMAT0038450 cli-miR-29b-3p; +MIMAT0038451 cli-miR-30a-5p; +MIMAT0038452 cli-miR-30a-3p; +MIMAT0038453 cli-miR-30c-5p; +MIMAT0038454 cli-miR-30c-3p; +MIMAT0038455 cli-miR-30c-2-3p; +MIMAT0038456 cli-miR-30d-5p; +MIMAT0038457 cli-miR-30d-3p; +MIMAT0038458 cli-miR-30e-5p; +MIMAT0038459 cli-miR-30e-3p; +MIMAT0038460 cli-miR-31-5p; +MIMAT0038461 cli-miR-31-3p; +MIMAT0038462 cli-miR-32-5p; +MIMAT0038463 cli-miR-32-3p; +MIMAT0038464 cli-miR-33-5p; +MIMAT0038465 cli-miR-33-3p; +MIMAT0038466 cli-miR-33-2-3p; +MIMAT0038467 cli-miR-34a-5p; +MIMAT0038468 cli-miR-34a-3p; +MIMAT0038469 cli-miR-34b-5p; +MIMAT0038470 cli-miR-34b-3p; +MIMAT0038471 cli-miR-34c-5p; +MIMAT0038472 cli-miR-34c-3p; +MIMAT0038473 cli-miR-92-5p; +MIMAT0038474 cli-miR-92-3p; +MIMAT0038475 cli-miR-92-2-5p; +MIMAT0038476 cli-miR-96-5p; +MIMAT0038477 cli-miR-96-3p; +MIMAT0038478 cli-miR-99-5p; +MIMAT0038479 cli-miR-99-3p; +MIMAT0038480 cli-miR-100-5p; +MIMAT0038481 cli-miR-100-3p; +MIMAT0038482 cli-miR-101-5p; +MIMAT0038483 cli-miR-101-3p; +MIMAT0038484 cli-miR-101-2-5p; +MIMAT0038485 cli-miR-103-3p; +MIMAT0038486 cli-miR-103-5p; +MIMAT0038487 cli-miR-106-5p; +MIMAT0038488 cli-miR-106-3p; +MIMAT0038489 cli-miR-107-5p; +MIMAT0038490 cli-miR-107-3p; +MIMAT0038491 cli-miR-122-5p; +MIMAT0038492 cli-miR-122-3p; +MIMAT0038493 cli-miR-124-5p; +MIMAT0038494 cli-miR-124-3p; +MIMAT0038495 cli-miR-124-2-5p; +MIMAT0038496 cli-miR-125-5p; +MIMAT0038497 cli-miR-125-3p; +MIMAT0038498 cli-miR-125-2-3p; +MIMAT0038499 cli-miR-126-5p; +MIMAT0038500 cli-miR-126-3p; +MIMAT0038501 cli-miR-128-3p; +MIMAT0038502 cli-miR-128-5p; +MIMAT0038503 cli-miR-129-5p; +MIMAT0038504 cli-miR-129-3p; +MIMAT0038505 cli-miR-130a-5p; +MIMAT0038506 cli-miR-130a-3p; +MIMAT0038507 cli-miR-130c-5p; +MIMAT0038508 cli-miR-130c-3p; +MIMAT0038509 cli-miR-133a-5p; +MIMAT0038510 cli-miR-133a-3p; +MIMAT0038511 cli-miR-133b-5p; +MIMAT0038512 cli-miR-133b-3p; +MIMAT0038513 cli-miR-133c-3p; +MIMAT0038514 cli-miR-135-5p; +MIMAT0038515 cli-miR-135-3p; +MIMAT0038516 cli-miR-135-2-3p; +MIMAT0038517 cli-miR-135-3-3p; +MIMAT0038518 cli-miR-137a-5p; +MIMAT0038519 cli-miR-137a-3p; +MIMAT0038520 cli-miR-137b-5p; +MIMAT0038521 cli-miR-137b-3p; +MIMAT0038522 cli-miR-138-5p; +MIMAT0038523 cli-miR-138-3p; +MIMAT0038524 cli-miR-138-2-3p; +MIMAT0038525 cli-miR-139-5p; +MIMAT0038526 cli-miR-139-3p; +MIMAT0038527 cli-miR-140-5p; +MIMAT0038528 cli-miR-140-3p; +MIMAT0038529 cli-miR-142-5p; +MIMAT0038530 cli-miR-142-3p; +MIMAT0038531 cli-miR-143-5p; +MIMAT0038532 cli-miR-143-3p; +MIMAT0038533 cli-miR-145-5p; +MIMAT0038534 cli-miR-145-3p; +MIMAT0038535 cli-miR-146a-5p; +MIMAT0038536 cli-miR-146a-3p; +MIMAT0038537 cli-miR-146b-5p; +MIMAT0038538 cli-miR-146b-3p; +MIMAT0038539 cli-miR-146c-5p; +MIMAT0038540 cli-miR-146c-3p; +MIMAT0038541 cli-miR-147-3p; +MIMAT0038542 cli-miR-148a-5p; +MIMAT0038543 cli-miR-148a-3p; +MIMAT0038544 cli-miR-148b-3p; +MIMAT0038545 cli-miR-153a-5p; +MIMAT0038546 cli-miR-153a-3p; +MIMAT0038547 cli-miR-153b-5p; +MIMAT0038548 cli-miR-153b-3p; +MIMAT0038549 cli-miR-155-5p; +MIMAT0038550 cli-miR-181a-5p; +MIMAT0038551 cli-miR-181a-3p; +MIMAT0038552 cli-miR-181a-2-3p; +MIMAT0038553 cli-miR-181b-5p; +MIMAT0038554 cli-miR-181b-3p; +MIMAT0038555 cli-miR-181b-2-3p; +MIMAT0038556 cli-miR-182-5p; +MIMAT0038557 cli-miR-182-3p; +MIMAT0038558 cli-miR-183-5p; +MIMAT0038559 cli-miR-183-3p; +MIMAT0038560 cli-miR-184-5p; +MIMAT0038561 cli-miR-184-3p; +MIMAT0038562 cli-miR-187-5p; +MIMAT0038563 cli-miR-187-3p; +MIMAT0038564 cli-miR-190-5p; +MIMAT0038565 cli-miR-190-3p; +MIMAT0038566 cli-miR-193-5p; +MIMAT0038567 cli-miR-193-3p; +MIMAT0038568 cli-miR-194-5p; +MIMAT0038569 cli-miR-194-3p; +MIMAT0038570 cli-miR-196-5p; +MIMAT0038571 cli-miR-196-3p; +MIMAT0038572 cli-miR-196-3-3p; +MIMAT0038573 cli-miR-199-5p; +MIMAT0038574 cli-miR-199-3p; +MIMAT0038575 cli-miR-200a-5p; +MIMAT0038576 cli-miR-200a-3p; +MIMAT0038577 cli-miR-200b-5p; +MIMAT0038578 cli-miR-200b-3p; +MIMAT0038579 cli-miR-202-5p; +MIMAT0038580 cli-miR-204-5p; +MIMAT0038581 cli-miR-204-3p; +MIMAT0038582 cli-miR-204-2-3p; +MIMAT0038583 cli-miR-204-3-3p; +MIMAT0038584 cli-miR-205a-5p; +MIMAT0038585 cli-miR-205a-3p; +MIMAT0038586 cli-miR-205b-5p; +MIMAT0038587 cli-miR-205b-3p; +MIMAT0038588 cli-miR-206-5p; +MIMAT0038589 cli-miR-206-3p; +MIMAT0038590 cli-miR-210-5p; +MIMAT0038591 cli-miR-210-3p; +MIMAT0038592 cli-miR-214-5p; +MIMAT0038593 cli-miR-214-3p; +MIMAT0038594 cli-miR-215-5p; +MIMAT0038595 cli-miR-215-3p; +MIMAT0038596 cli-miR-216a-5p; +MIMAT0038597 cli-miR-216a-3p; +MIMAT0038598 cli-miR-216b-5p; +MIMAT0038599 cli-miR-216b-3p; +MIMAT0038600 cli-miR-217-5p; +MIMAT0038601 cli-miR-217-3p; +MIMAT0038602 cli-miR-218-5p; +MIMAT0038603 cli-miR-218-3p; +MIMAT0038604 cli-miR-221-5p; +MIMAT0038605 cli-miR-221-3p; +MIMAT0038606 cli-miR-222a-5p; +MIMAT0038607 cli-miR-222a-3p; +MIMAT0038608 cli-miR-222b-3p; +MIMAT0038609 cli-miR-223-5p; +MIMAT0038610 cli-miR-223-3p; +MIMAT0038611 cli-miR-301a-5p; +MIMAT0038612 cli-miR-301a-3p; +MIMAT0038613 cli-miR-301b-5p; +MIMAT0038614 cli-miR-301b-3p; +MIMAT0038615 cli-miR-302a-3p; +MIMAT0038616 cli-miR-302b-3p; +MIMAT0038617 cli-miR-302c-3p; +MIMAT0038618 cli-miR-338a-5p; +MIMAT0038619 cli-miR-338a-3p; +MIMAT0038620 cli-miR-338b-5p; +MIMAT0038621 cli-miR-338b-3p; +MIMAT0038622 cli-miR-363-5p; +MIMAT0038623 cli-miR-363-3p; +MIMAT0038624 cli-miR-365-5p; +MIMAT0038625 cli-miR-365-3p; +MIMAT0038626 cli-miR-365-2-5p; +MIMAT0038627 cli-miR-367-3p; +MIMAT0038628 cli-miR-375-5p; +MIMAT0038629 cli-miR-375-3p; +MIMAT0038630 cli-miR-383-5p; +MIMAT0038631 cli-miR-383-3p; +MIMAT0038632 cli-miR-425-5p; +MIMAT0038633 cli-miR-425-3p; +MIMAT0038634 cli-miR-429-5p; +MIMAT0038635 cli-miR-429-3p; +MIMAT0038636 cli-miR-449a-5p; +MIMAT0038637 cli-miR-449b-5p; +MIMAT0038638 cli-miR-449b-3p; +MIMAT0038639 cli-miR-449c-5p; +MIMAT0038640 cli-miR-449c-3p; +MIMAT0038641 cli-miR-449d-5p; +MIMAT0038642 cli-miR-449d-3p; +MIMAT0038643 cli-miR-451-5p; +MIMAT0038644 cli-miR-454-5p; +MIMAT0038645 cli-miR-454-3p; +MIMAT0038646 cli-miR-455-5p; +MIMAT0038647 cli-miR-455-3p; +MIMAT0038648 cli-miR-456-3p; +MIMAT0038649 cli-miR-458-5p; +MIMAT0038650 cli-miR-458-3p; +MIMAT0038651 cli-miR-459-5p; +MIMAT0038652 cli-miR-460a-5p; +MIMAT0038653 cli-miR-460a-3p; +MIMAT0038654 cli-miR-460b-5p; +MIMAT0038655 cli-miR-460b-3p; +MIMAT0038656 cli-miR-489-5p; +MIMAT0038657 cli-miR-489-3p; +MIMAT0038658 cli-miR-490-5p; +MIMAT0038659 cli-miR-490-3p; +MIMAT0038660 cli-miR-499-5p; +MIMAT0038661 cli-miR-499-3p; +MIMAT0038662 cli-miR-551a-5p; +MIMAT0038663 cli-miR-551a-3p; +MIMAT0038664 cli-miR-551b-5p; +MIMAT0038665 cli-miR-551b-3p; +MIMAT0038666 cli-miR-599-3p; +MIMAT0038667 cli-miR-737-5p; +MIMAT0038668 cli-miR-875-5p; +MIMAT0038669 cli-miR-875-3p; +MIMAT0038670 cli-miR-1306-5p; +MIMAT0038671 cli-miR-1306-3p; +MIMAT0038672 cli-miR-1329-5p; +MIMAT0038673 cli-miR-1329-3p; +MIMAT0038674 cli-miR-1388-5p; +MIMAT0038675 cli-miR-1388-3p; +MIMAT0038676 cli-miR-1416-5p; +MIMAT0038677 cli-miR-1416-3p; +MIMAT0038678 cli-miR-1451-5p; +MIMAT0038679 cli-miR-1451-3p; +MIMAT0038680 cli-miR-1467-5p; +MIMAT0038681 cli-miR-1467-3p; +MIMAT0038682 cli-miR-1550-5p; +MIMAT0038683 cli-miR-1552-5p; +MIMAT0038684 cli-miR-1552-3p; +MIMAT0038685 cli-miR-1559-5p; +MIMAT0038686 cli-miR-1559-3p; +MIMAT0038687 cli-miR-1641-5p; +MIMAT0038688 cli-miR-1655-3p; +MIMAT0038689 cli-miR-1662-5p; +MIMAT0038690 cli-miR-1662-3p; +MIMAT0038691 cli-miR-1677-5p; +MIMAT0038692 cli-miR-1677-3p; +MIMAT0038693 cli-miR-1720-5p; +MIMAT0038694 cli-miR-1720-3p; +MIMAT0038695 cli-miR-1729-5p; +MIMAT0038696 cli-miR-1729-3p; +MIMAT0038697 cli-miR-1781-3p; +MIMAT0038698 cli-miR-1782-3p; +MIMAT0038699 cli-miR-1784-5p; +MIMAT0038700 cli-miR-1788-5p; +MIMAT0038701 cli-miR-1788-3p; +MIMAT0038702 cli-miR-1791-3p; +MIMAT0038703 cli-miR-1803-5p; +MIMAT0038704 cli-miR-1803-3p; +MIMAT0038705 cli-miR-1805-5p; +MIMAT0038706 cli-miR-1805-3p; +MIMAT0038707 cli-miR-2131-5p; +MIMAT0038708 cli-miR-2131-3p; +MIMAT0038709 cli-miR-2188-5p; +MIMAT0038710 cli-miR-2188-3p; +MIMAT0038711 cli-miR-2954-5p; +MIMAT0038712 cli-miR-2954-3p; +MIMAT0038713 cli-miR-2970-5p; +MIMAT0038714 cli-miR-2970-3p; +MIMAT0038715 cli-miR-2984-5p; +MIMAT0038716 cli-miR-3064-3p; +MIMAT0038717 cli-miR-3618-5p; +MIMAT0038718 cli-miR-3618-3p; +MIMAT0038719 cli-miR-9615-5p; +MIMAT0038720 cli-miR-9615-3p; +MIMAT0038721 cli-miR-9616-5p; +MIMAT0038722 cli-miR-9616-3p; +MIMAT0038723 cli-miR-9617-5p; +MIMAT0038724 cli-miR-9617-3p; +MIMAT0038725 cli-miR-9618-5p; +MIMAT0038726 cli-miR-9618-3p; +MIMAT0038727 cli-miR-9619-5p; +MIMAT0038728 cli-miR-9619-3p; +MIMAT0038729 cli-miR-9620-5p; +MIMAT0038730 cli-miR-9620-3p; +MIMAT0038731 cli-miR-9621-5p; +MIMAT0038732 cli-miR-9621-3p; +MIMAT0038733 cli-miR-1756b-5p; +MIMAT0038734 cli-miR-1756b-3p; +MIMAT0038735 cli-miR-9622-5p; +MIMAT0038736 cli-miR-9622-3p; +MIMAT0038737 cli-miR-9623-5p; +MIMAT0038738 cli-miR-9623-3p; +MIMAT0038739 cli-miR-9624-5p; +MIMAT0038740 cli-miR-9624-3p; +MIMAT0038741 cli-miR-9625-5p; +MIMAT0038742 cli-miR-9625-3p; +MIMAT0038743 cli-miR-9626-5p; +MIMAT0038744 cli-miR-9626-3p; +MIMAT0038745 cli-miR-9627-5p; +MIMAT0038746 cli-miR-9627-3p; +MIMAT0038747 cli-miR-9628-5p; +MIMAT0038748 cli-miR-9628-3p; +MIMAT0038749 cli-miR-9629-5p; +MIMAT0038750 cli-miR-9629-3p; +MIMAT0038751 cli-miR-9630-5p; +MIMAT0038752 cli-miR-9630-3p; +MIMAT0038753 cli-miR-9631-5p; +MIMAT0038754 cli-miR-9631-3p; +MIMAT0038755 cli-miR-9632-5p; +MIMAT0038756 cli-miR-9632-3p; +MIMAT0038757 cli-miR-9633-5p; +MIMAT0038758 cli-miR-9633-3p; +MIMAT0038759 cli-miR-8993-5p; +MIMAT0038760 cli-miR-8993-3p; +MIMAT0038761 cli-miR-9634-5p; +MIMAT0038762 cli-miR-9634-3p; +MIMAT0038763 cli-miR-9635-5p; +MIMAT0038764 cli-miR-9635-3p; +MIMAT0038765 cli-miR-9636-5p; +MIMAT0038766 cli-miR-9636-3p; +MIMAT0038767 cli-miR-9637-5p; +MIMAT0038768 cli-miR-9637-3p; +MIMAT0038769 cli-miR-9638-5p; +MIMAT0038770 cli-miR-9638-3p; +MIMAT0038771 cli-miR-9639-5p; +MIMAT0038772 cli-miR-9639-3p; +MIMAT0038773 cli-miR-9640-5p; +MIMAT0038774 cli-miR-9640-3p; +MIMAT0038775 cli-miR-9641-5p; +MIMAT0038776 cli-miR-9641-3p; +MIMAT0038777 cli-miR-9642-5p; +MIMAT0038778 cli-miR-9642-3p; +MIMAT0038779 cli-miR-9643-5p; +MIMAT0038780 cli-miR-9643-3p; +MIMAT0038781 cli-miR-9644-5p; +MIMAT0038782 cli-miR-9644-3p; +MIMAT0038783 cli-miR-9645-5p; +MIMAT0038784 cli-miR-9645-3p; +MIMAT0038785 cli-miR-9646-5p; +MIMAT0038786 cli-miR-9646-3p; +MIMAT0038787 cli-miR-9647-5p; +MIMAT0038788 cli-miR-9647-3p; +MIMAT0038789 cli-miR-9648-5p; +MIMAT0038790 cli-miR-9648-3p; +MIMAT0038791 cli-miR-9649-5p; +MIMAT0038792 cli-miR-9649-3p; +MIMAT0038793 pbv-let-7a-5p; +MIMAT0038794 pbv-let-7a-3p; +MIMAT0038795 pbv-let-7a-2-3p; +MIMAT0038796 pbv-let-7b-5p; +MIMAT0038797 pbv-let-7b-3p; +MIMAT0038798 pbv-let-7c-5p; +MIMAT0038799 pbv-let-7c-3p; +MIMAT0038800 pbv-let-7c-2-3p; +MIMAT0038801 pbv-let-7d-5p; +MIMAT0038802 pbv-let-7d-3p; +MIMAT0038803 pbv-let-7e-5p; +MIMAT0038804 pbv-let-7e-3p; +MIMAT0038805 pbv-let-7f-5p; +MIMAT0038806 pbv-let-7f-3p; +MIMAT0038807 pbv-let-7f-2-3p; +MIMAT0038808 pbv-let-7g-5p; +MIMAT0038809 pbv-let-7g-3p; +MIMAT0038810 pbv-let-7i-5p; +MIMAT0038811 pbv-let-7i-3p; +MIMAT0038812 pbv-miR-1a-5p; +MIMAT0038813 pbv-miR-1a-3p; +MIMAT0038814 pbv-miR-1a-2-5p; +MIMAT0038815 pbv-miR-1b-5p; +MIMAT0038816 pbv-miR-1b-3p; +MIMAT0038817 pbv-miR-7-5p; +MIMAT0038818 pbv-miR-7-3p; +MIMAT0038819 pbv-miR-7-2-3p; +MIMAT0038820 pbv-miR-7-3-3p; +MIMAT0038821 pbv-miR-9-5p; +MIMAT0038822 pbv-miR-9-3p; +MIMAT0038823 pbv-miR-9-4-3p; +MIMAT0038824 pbv-miR-10a-5p; +MIMAT0038825 pbv-miR-10a-3p; +MIMAT0038826 pbv-miR-10b-5p; +MIMAT0038827 pbv-miR-10b-3p; +MIMAT0038828 pbv-miR-10b-2-3p; +MIMAT0038829 pbv-miR-15a-5p; +MIMAT0038830 pbv-miR-15a-3p; +MIMAT0038831 pbv-miR-15b-5p; +MIMAT0038832 pbv-miR-15b-3p; +MIMAT0038833 pbv-miR-16a-5p; +MIMAT0038834 pbv-miR-16b-5p; +MIMAT0038835 pbv-miR-16b-3p; +MIMAT0038836 pbv-miR-16c-5p; +MIMAT0038837 pbv-miR-16c-3p; +MIMAT0038838 pbv-miR-17-5p; +MIMAT0038839 pbv-miR-17-3p; +MIMAT0038840 pbv-miR-18a-5p; +MIMAT0038841 pbv-miR-18a-3p; +MIMAT0038842 pbv-miR-18b-5p; +MIMAT0038843 pbv-miR-19a-5p; +MIMAT0038844 pbv-miR-19a-3p; +MIMAT0038845 pbv-miR-19b-3p; +MIMAT0038846 pbv-miR-20a-5p; +MIMAT0038847 pbv-miR-20b-5p; +MIMAT0038848 pbv-miR-20b-3p; +MIMAT0038849 pbv-miR-21-5p; +MIMAT0038850 pbv-miR-21-3p; +MIMAT0038851 pbv-miR-22-5p; +MIMAT0038852 pbv-miR-22-3p; +MIMAT0038853 pbv-miR-23a-3p; +MIMAT0038854 pbv-miR-23b-5p; +MIMAT0038855 pbv-miR-23b-3p; +MIMAT0038856 pbv-miR-24-5p; +MIMAT0038857 pbv-miR-24-3p; +MIMAT0038858 pbv-miR-26-5p; +MIMAT0038859 pbv-miR-26-3p; +MIMAT0038860 pbv-miR-26-3-3p; +MIMAT0038861 pbv-miR-27a-5p; +MIMAT0038862 pbv-miR-27a-3p; +MIMAT0038863 pbv-miR-27b-5p; +MIMAT0038864 pbv-miR-27b-3p; +MIMAT0038865 pbv-miR-29a-5p; +MIMAT0038866 pbv-miR-29a-3p; +MIMAT0038867 pbv-miR-29a-2-5p; +MIMAT0038868 pbv-miR-29b-5p; +MIMAT0038869 pbv-miR-29b-3p; +MIMAT0038870 pbv-miR-30a-5p; +MIMAT0038871 pbv-miR-30a-3p; +MIMAT0038872 pbv-miR-30b-5p; +MIMAT0038873 pbv-miR-30c-5p; +MIMAT0038874 pbv-miR-30c-3p; +MIMAT0038875 pbv-miR-30c-2-3p; +MIMAT0038876 pbv-miR-30d-5p; +MIMAT0038877 pbv-miR-30d-3p; +MIMAT0038878 pbv-miR-30e-5p; +MIMAT0038879 pbv-miR-30e-3p; +MIMAT0038880 pbv-miR-31-5p; +MIMAT0038881 pbv-miR-32-5p; +MIMAT0038882 pbv-miR-33-5p; +MIMAT0038883 pbv-miR-33-3p; +MIMAT0038884 pbv-miR-34a-5p; +MIMAT0038885 pbv-miR-34b-5p; +MIMAT0038886 pbv-miR-34b-3p; +MIMAT0038887 pbv-miR-34c-5p; +MIMAT0038888 pbv-miR-34c-3p; +MIMAT0038889 pbv-miR-92a-3p; +MIMAT0038890 pbv-miR-92b-3p; +MIMAT0038891 pbv-miR-96-5p; +MIMAT0038892 pbv-miR-96-3p; +MIMAT0038893 pbv-miR-98-5p; +MIMAT0038894 pbv-miR-98-3p; +MIMAT0038895 pbv-miR-99a-5p; +MIMAT0038896 pbv-miR-99a-3p; +MIMAT0038897 pbv-miR-99b-5p; +MIMAT0038898 pbv-miR-99b-3p; +MIMAT0038899 pbv-miR-100-5p; +MIMAT0038900 pbv-miR-100-3p; +MIMAT0038901 pbv-miR-101-5p; +MIMAT0038902 pbv-miR-101-3p; +MIMAT0038903 pbv-miR-101-2-5p; +MIMAT0038904 pbv-miR-103-3p; +MIMAT0038905 pbv-miR-106-5p; +MIMAT0038906 pbv-miR-106-3p; +MIMAT0038907 pbv-miR-107-5p; +MIMAT0038908 pbv-miR-107-3p; +MIMAT0038909 pbv-miR-122-5p; +MIMAT0038910 pbv-miR-122-3p; +MIMAT0038911 pbv-miR-124b-5p; +MIMAT0038912 pbv-miR-124b-3p; +MIMAT0038913 pbv-miR-124a-5p; +MIMAT0038914 pbv-miR-124a-3p; +MIMAT0038915 pbv-miR-125a-5p; +MIMAT0038916 pbv-miR-125b-5p; +MIMAT0038917 pbv-miR-125b-3p; +MIMAT0038918 pbv-miR-126-5p; +MIMAT0038919 pbv-miR-126-3p; +MIMAT0038920 pbv-miR-128-5p; +MIMAT0038921 pbv-miR-128-3p; +MIMAT0038922 pbv-miR-129a-5p; +MIMAT0038923 pbv-miR-129a-3p; +MIMAT0038924 pbv-miR-129b-5p; +MIMAT0038925 pbv-miR-129b-3p; +MIMAT0038926 pbv-miR-130a-5p; +MIMAT0038927 pbv-miR-130a-3p; +MIMAT0038928 pbv-miR-130b-3p; +MIMAT0038929 pbv-miR-130c-5p; +MIMAT0038930 pbv-miR-130c-3p; +MIMAT0038931 pbv-miR-130d-5p; +MIMAT0038932 pbv-miR-130d-3p; +MIMAT0038933 pbv-miR-132-5p; +MIMAT0038934 pbv-miR-132-3p; +MIMAT0038935 pbv-miR-133a-5p; +MIMAT0038936 pbv-miR-133a-3p; +MIMAT0038937 pbv-miR-133a-2-5p; +MIMAT0038938 pbv-miR-133b-5p; +MIMAT0038939 pbv-miR-133b-3p; +MIMAT0038940 pbv-miR-133c-3p; +MIMAT0038941 pbv-miR-135-5p; +MIMAT0038942 pbv-miR-135-3p; +MIMAT0038943 pbv-miR-135-2-3p; +MIMAT0038944 pbv-miR-135-3-3p; +MIMAT0038945 pbv-miR-137a-5p; +MIMAT0038946 pbv-miR-137a-3p; +MIMAT0038947 pbv-miR-137b-5p; +MIMAT0038948 pbv-miR-137b-3p; +MIMAT0038949 pbv-miR-138-5p; +MIMAT0038950 pbv-miR-138-3p; +MIMAT0038951 pbv-miR-139-5p; +MIMAT0038952 pbv-miR-139-3p; +MIMAT0038953 pbv-miR-142-5p; +MIMAT0038954 pbv-miR-142-3p; +MIMAT0038955 pbv-miR-143-5p; +MIMAT0038956 pbv-miR-143-3p; +MIMAT0038957 pbv-miR-144-5p; +MIMAT0038958 pbv-miR-144-3p; +MIMAT0038959 pbv-miR-145-5p; +MIMAT0038960 pbv-miR-145-3p; +MIMAT0038961 pbv-miR-146a-5p; +MIMAT0038962 pbv-miR-146b-5p; +MIMAT0038963 pbv-miR-147-3p; +MIMAT0038964 pbv-miR-148a-5p; +MIMAT0038965 pbv-miR-148a-3p; +MIMAT0038966 pbv-miR-148b-5p; +MIMAT0038967 pbv-miR-148b-3p; +MIMAT0038968 pbv-miR-150-5p; +MIMAT0038969 pbv-miR-150-3p; +MIMAT0038970 pbv-miR-153-5p; +MIMAT0038971 pbv-miR-153-3p; +MIMAT0038972 pbv-miR-153-2-5p; +MIMAT0038973 pbv-miR-155a-5p; +MIMAT0038974 pbv-miR-155b-5p; +MIMAT0038975 pbv-miR-181a-5p; +MIMAT0038976 pbv-miR-181a-3p; +MIMAT0038977 pbv-miR-181b-5p; +MIMAT0038978 pbv-miR-181b-3p; +MIMAT0038979 pbv-miR-181c-5p; +MIMAT0038980 pbv-miR-182-5p; +MIMAT0038981 pbv-miR-182-3p; +MIMAT0038982 pbv-miR-183-5p; +MIMAT0038983 pbv-miR-184-3p; +MIMAT0038984 pbv-miR-190a-5p; +MIMAT0038985 pbv-miR-190a-3p; +MIMAT0038986 pbv-miR-190b-5p; +MIMAT0038987 pbv-miR-191-5p; +MIMAT0038988 pbv-miR-191-3p; +MIMAT0038989 pbv-miR-193a-5p; +MIMAT0038990 pbv-miR-193a-3p; +MIMAT0038991 pbv-miR-193b-3p; +MIMAT0038992 pbv-miR-194-5p; +MIMAT0038993 pbv-miR-196a-5p; +MIMAT0038994 pbv-miR-196a-3p; +MIMAT0038995 pbv-miR-196c-5p; +MIMAT0038996 pbv-miR-199-5p; +MIMAT0038997 pbv-miR-199-3p; +MIMAT0038998 pbv-miR-199-3-5p; +MIMAT0038999 pbv-miR-200a-5p; +MIMAT0039000 pbv-miR-200a-3p; +MIMAT0039001 pbv-miR-200b-5p; +MIMAT0039002 pbv-miR-200b-3p; +MIMAT0039003 pbv-miR-202-5p; +MIMAT0039004 pbv-miR-203-5p; +MIMAT0039005 pbv-miR-203-3p; +MIMAT0039006 pbv-miR-204-5p; +MIMAT0039007 pbv-miR-204-3p; +MIMAT0039008 pbv-miR-204-3-3p; +MIMAT0039009 pbv-miR-205a-5p; +MIMAT0039010 pbv-miR-205b-5p; +MIMAT0039011 pbv-miR-206-3p; +MIMAT0039012 pbv-miR-208-5p; +MIMAT0039013 pbv-miR-208-3p; +MIMAT0039014 pbv-miR-210-5p; +MIMAT0039015 pbv-miR-210-3p; +MIMAT0039016 pbv-miR-212-5p; +MIMAT0039017 pbv-miR-212-3p; +MIMAT0039018 pbv-miR-214-5p; +MIMAT0039019 pbv-miR-214-3p; +MIMAT0039020 pbv-miR-215-5p; +MIMAT0039021 pbv-miR-215-3p; +MIMAT0039022 pbv-miR-216a-5p; +MIMAT0039023 pbv-miR-216a-3p; +MIMAT0039024 pbv-miR-216b-5p; +MIMAT0039025 pbv-miR-216b-3p; +MIMAT0039026 pbv-miR-217-5p; +MIMAT0039027 pbv-miR-218-5p; +MIMAT0039028 pbv-miR-218-3p; +MIMAT0039029 pbv-miR-219-5p; +MIMAT0039030 pbv-miR-219-3p; +MIMAT0039031 pbv-miR-221-5p; +MIMAT0039032 pbv-miR-221-3p; +MIMAT0039033 pbv-miR-222a-5p; +MIMAT0039034 pbv-miR-222a-3p; +MIMAT0039035 pbv-miR-222b-5p; +MIMAT0039036 pbv-miR-222b-3p; +MIMAT0039037 pbv-miR-223-3p; +MIMAT0039038 pbv-miR-301a-5p; +MIMAT0039039 pbv-miR-301a-3p; +MIMAT0039040 pbv-miR-301b-3p; +MIMAT0039041 pbv-miR-338-5p; +MIMAT0039042 pbv-miR-338-3p; +MIMAT0039043 pbv-miR-363-3p; +MIMAT0039044 pbv-miR-365-3p; +MIMAT0039045 pbv-miR-375-3p; +MIMAT0039046 pbv-miR-383-5p; +MIMAT0039047 pbv-miR-383-3p; +MIMAT0039048 pbv-miR-425-5p; +MIMAT0039049 pbv-miR-425-3p; +MIMAT0039050 pbv-miR-429-3p; +MIMAT0039051 pbv-miR-449a-5p; +MIMAT0039052 pbv-miR-449b-5p; +MIMAT0039053 pbv-miR-449b-3p; +MIMAT0039054 pbv-miR-449c-5p; +MIMAT0039055 pbv-miR-449d-5p; +MIMAT0039056 pbv-miR-454-3p; +MIMAT0039057 pbv-miR-455-5p; +MIMAT0039058 pbv-miR-455-3p; +MIMAT0039059 pbv-miR-456-5p; +MIMAT0039060 pbv-miR-456-3p; +MIMAT0039061 pbv-miR-458-3p; +MIMAT0039062 pbv-miR-489-3p; +MIMAT0039063 pbv-miR-490-5p; +MIMAT0039064 pbv-miR-490-3p; +MIMAT0039065 pbv-miR-499-5p; +MIMAT0039066 pbv-miR-499-3p; +MIMAT0039067 pbv-miR-551a-3p; +MIMAT0039068 pbv-miR-551b-5p; +MIMAT0039069 pbv-miR-551b-3p; +MIMAT0039070 pbv-miR-599-3p; +MIMAT0039071 pbv-miR-737-5p; +MIMAT0039072 pbv-miR-737-3p; +MIMAT0039073 pbv-miR-875-5p; +MIMAT0039074 pbv-miR-1306-3p; +MIMAT0039075 pbv-miR-1329-5p; +MIMAT0039076 pbv-miR-1329-3p; +MIMAT0039077 pbv-miR-1388-5p; +MIMAT0039078 pbv-miR-1388-3p; +MIMAT0039079 pbv-miR-1397-5p; +MIMAT0039080 pbv-miR-1397-3p; +MIMAT0039081 pbv-miR-1641-5p; +MIMAT0039082 pbv-miR-1662-5p; +MIMAT0039083 pbv-miR-1677-5p; +MIMAT0039084 pbv-miR-1677-3p; +MIMAT0039085 pbv-miR-1788-5p; +MIMAT0039086 pbv-miR-1788-3p; +MIMAT0039087 pbv-miR-1805-5p; +MIMAT0039088 pbv-miR-1805-3p; +MIMAT0039089 pbv-miR-2188-5p; +MIMAT0039090 pbv-miR-2188-3p; +MIMAT0039091 pbv-miR-2970-5p; +MIMAT0039092 pbv-miR-2970-3p; +MIMAT0039093 pbv-miR-3064-3p; +MIMAT0039094 pbv-miR-3618-5p; +MIMAT0039095 pbv-miR-5420-3p; +MIMAT0039096 pbv-miR-9650-5p; +MIMAT0039097 pbv-miR-9650-3p; +MIMAT0039098 pbv-miR-9651-5p; +MIMAT0039099 pbv-miR-9651-3p; +MIMAT0039100 cli-miR-1756a-3p; +MIMAT0039101 dsi-miR-2498a-5p; +MIMAT0039102 dsi-miR-2498a-3p; +MIMAT0039103 dsi-miR-2498c-5p; +MIMAT0039104 dsi-miR-2498c-3p; +MIMAT0039105 dsi-miR-2498b-5p; +MIMAT0039106 dsi-miR-2498b-3p; +MIMAT0039107 dsi-miR-983b-5p; +MIMAT0039108 dsi-miR-983b-3p; +MIMAT0039109 dsi-miR-9680-5p; +MIMAT0039110 dsi-miR-9680-3p; +MIMAT0039111 dsi-miR-972-5p; +MIMAT0039112 dsi-miR-972-3p; +MIMAT0039113 dsi-miR-973-5p; +MIMAT0039114 dsi-miR-973-3p; +MIMAT0039115 dsi-miR-4966-5p; +MIMAT0039116 dsi-miR-4966-3p; +MIMAT0039117 dsi-miR-4966-3-3p; +MIMAT0039118 dsi-miR-9369-5p; +MIMAT0039119 dsi-miR-9369-3p; +MIMAT0039120 dsi-miR-974-5p; +MIMAT0039121 dsi-miR-974-3p; +MIMAT0039122 dsi-miR-2499-5p; +MIMAT0039123 dsi-miR-2499-3p; +MIMAT0039124 dse-miR-2498b-5p; +MIMAT0039125 dse-miR-2498b-3p; +MIMAT0039126 dse-miR-2498a-5p; +MIMAT0039127 dse-miR-2498a-3p; +MIMAT0039128 dse-miR-991-5p; +MIMAT0039129 dse-miR-991-3p; +MIMAT0039130 dse-miR-992-5p; +MIMAT0039131 dse-miR-992-3p; +MIMAT0039132 dse-miR-982c-5p; +MIMAT0039133 dse-miR-982c-3p; +MIMAT0039134 dse-miR-303-5p; +MIMAT0039135 dse-miR-303-3p; +MIMAT0039136 dse-miR-982b; +MIMAT0039137 dse-miR-2582-5p; +MIMAT0039138 dse-miR-2582-3p; +MIMAT0039139 dse-miR-983-5p; +MIMAT0039140 dse-miR-983-3p; +MIMAT0039141 dse-miR-973-5p; +MIMAT0039142 dse-miR-973-3p; +MIMAT0039143 dse-miR-976; +MIMAT0039144 dse-miR-4966-5p; +MIMAT0039145 dse-miR-4966-3p; +MIMAT0039146 dse-miR-4966-2-3p; +MIMAT0039147 dse-miR-975-5p; +MIMAT0039148 dse-miR-975-3p; +MIMAT0039149 dse-miR-974-5p; +MIMAT0039150 dse-miR-974-3p; +MIMAT0039151 dse-miR-2499-5p; +MIMAT0039152 dse-miR-2499-3p; +MIMAT0039153 dse-miR-978a-5p; +MIMAT0039154 dse-miR-978a-3p; +MIMAT0039155 dse-miR-978b; +MIMAT0039156 dse-miR-977-5p; +MIMAT0039157 dse-miR-977-3p; +MIMAT0039158 dse-miR-9680-5p; +MIMAT0039159 dse-miR-9680-3p; +MIMAT0039160 dse-miR-9369-5p; +MIMAT0039161 dse-miR-9369-3p; +MIMAT0039162 dse-miR-9685-5p; +MIMAT0039163 dse-miR-9685-3p; +MIMAT0039164 dya-miR-992-5p; +MIMAT0039165 dya-miR-992-3p; +MIMAT0039166 dya-miR-2498-5p; +MIMAT0039167 dya-miR-2498-3p; +MIMAT0039168 dya-miR-9681-5p; +MIMAT0039169 dya-miR-9681-3p; +MIMAT0039170 dya-miR-991-5p; +MIMAT0039171 dya-miR-991-3p; +MIMAT0039172 dya-miR-9682-5p; +MIMAT0039173 dya-miR-9682-3p; +MIMAT0039174 dya-miR-303; +MIMAT0039175 dya-miR-9683-5p; +MIMAT0039176 dya-miR-9683-3p; +MIMAT0039177 dya-miR-975-5p; +MIMAT0039178 dya-miR-975-3p; +MIMAT0039179 dya-miR-978-5p; +MIMAT0039180 dya-miR-978-3p; +MIMAT0039181 dya-miR-2499; +MIMAT0039182 dya-miR-976-5p; +MIMAT0039183 dya-miR-976-3p; +MIMAT0039184 dya-miR-9690-5p; +MIMAT0039185 dya-miR-9690-3p; +MIMAT0039186 dya-miR-977-5p; +MIMAT0039187 dya-miR-977-3p; +MIMAT0039188 der-miR-9681-5p; +MIMAT0039189 der-miR-9681-3p; +MIMAT0039190 der-miR-991-5p; +MIMAT0039191 der-miR-991-3p; +MIMAT0039192 der-miR-992-5p; +MIMAT0039193 der-miR-992-??; +MIMAT0039194 der-miR-2498a-5p; +MIMAT0039195 der-miR-2498a-3p; +MIMAT0039196 der-miR-2498b-5p; +MIMAT0039197 der-miR-2498b-3p; +MIMAT0039198 der-miR-992-2-5p; +MIMAT0039199 der-miR-9691-5p; +MIMAT0039200 der-miR-9691-3p; +MIMAT0039201 der-miR-983a-5p; +MIMAT0039202 der-miR-983a-3p; +MIMAT0039203 der-miR-983b-5p; +MIMAT0039204 der-miR-983b-3p; +MIMAT0039205 der-miR-9682-5p; +MIMAT0039206 der-miR-9682-3p; +MIMAT0039207 der-miR-2499; +MIMAT0039208 der-miR-975-5p; +MIMAT0039209 der-miR-975-3p; +MIMAT0039210 der-miR-977-5p; +MIMAT0039211 der-miR-977-3p; +MIMAT0039212 der-miR-978-5p; +MIMAT0039213 der-miR-978-3p; +MIMAT0039214 der-miR-974-5p; +MIMAT0039215 der-miR-974-3p; +MIMAT0039216 der-miR-976-5p; +MIMAT0039217 der-miR-976-3p; +MIMAT0039218 der-miR-973-5p; +MIMAT0039219 der-miR-973-3p; +MIMAT0039220 der-miR-9683-5p; +MIMAT0039221 der-miR-9683-3p; +MIMAT0039222 der-miR-9680-5p; +MIMAT0039223 der-miR-9680-3p; +MIMAT0039224 dvi-miR-9692-5p; +MIMAT0039225 dvi-miR-9692-3p; +MIMAT0039226 dvi-miR-9693-5p; +MIMAT0039227 dvi-miR-9693-3p; +MIMAT0039228 dvi-miR-9694-5p; +MIMAT0039229 dvi-miR-9694-3p; +MIMAT0039230 dvi-miR-9695-5p; +MIMAT0039231 dvi-miR-9695-3p; +MIMAT0039232 dvi-miR-9696a-5p; +MIMAT0039233 dvi-miR-9696a-3p; +MIMAT0039234 dvi-miR-9696b-5p; +MIMAT0039235 dvi-miR-9696b-3p; +MIMAT0039236 dvi-miR-9697-5p; +MIMAT0039237 dvi-miR-9697-3p; +MIMAT0039238 dvi-miR-9698-5p; +MIMAT0039239 dvi-miR-9698-3p; +MIMAT0039240 dvi-miR-9699-5p; +MIMAT0039241 dvi-miR-9699-3p; +MIMAT0039244 dvi-miR-9538b-5p; +MIMAT0039245 dvi-miR-9538b-3p; +MIMAT0039246 dvi-miR-9700a-5p; +MIMAT0039247 dvi-miR-9700a-3p; +MIMAT0039248 dvi-miR-9700b-5p; +MIMAT0039249 dvi-miR-9700b-3p; +MIMAT0039250 dvi-miR-9701a-5p; +MIMAT0039251 dvi-miR-9701a-3p; +MIMAT0039252 dvi-miR-9701b-5p; +MIMAT0039253 dvi-miR-9701b-3p; +MIMAT0039254 dvi-miR-9702-5p; +MIMAT0039255 dvi-miR-9702-3p; +MIMAT0039256 dvi-miR-9703-5p; +MIMAT0039257 dvi-miR-9703-3p; +MIMAT0039258 dvi-miR-9704-5p; +MIMAT0039259 dvi-miR-9704-3p; +MIMAT0039260 dvi-miR-9705-5p; +MIMAT0039261 dvi-miR-9705-3p; +MIMAT0039262 dvi-miR-9706a-5p; +MIMAT0039263 dvi-miR-9706a-3p; +MIMAT0039264 dvi-miR-9706b-5p; +MIMAT0039265 dvi-miR-9706b-3p; +MIMAT0039266 dvi-miR-9707-5p; +MIMAT0039267 dvi-miR-9707-3p; +MIMAT0039268 dvi-miR-9704-2-3p; +MIMAT0039269 dvi-miR-9708a-5p; +MIMAT0039270 dvi-miR-9708a-3p; +MIMAT0039271 dvi-miR-9708b-5p; +MIMAT0039272 dvi-miR-9708b-3p; +MIMAT0039273 dvi-miR-9708c-5p; +MIMAT0039274 dvi-miR-9708c-3p; +MIMAT0039275 dvi-miR-9708d-5p; +MIMAT0039276 dvi-miR-9708d-3p; +MIMAT0039277 dvi-miR-9544c-5p; +MIMAT0039278 dvi-miR-9544c-3p; +MIMAT0039279 dvi-miR-9544b-5p; +MIMAT0039280 dvi-miR-9544b-3p; +MIMAT0039281 dvi-miR-9709-5p; +MIMAT0039282 dvi-miR-9709-3p; +MIMAT0039283 dvi-miR-9541b-5p; +MIMAT0039284 dvi-miR-9541b-3p; +MIMAT0039285 dvi-miR-9541a-5p; +MIMAT0039286 dvi-miR-9541a-3p; +MIMAT0039287 dvi-miR-9710-5p; +MIMAT0039288 dvi-miR-9710-3p; +MIMAT0039289 dvi-miR-9711-5p; +MIMAT0039290 dvi-miR-9711-3p; +MIMAT0039291 dvi-miR-9712-5p; +MIMAT0039292 dvi-miR-9712-3p; +MIMAT0039293 dvi-miR-9713-5p; +MIMAT0039294 dvi-miR-9713-3p; +MIMAT0039295 dvi-miR-9714-5p; +MIMAT0039296 dvi-miR-9714-3p; +MIMAT0039297 dvi-miR-9542d-5p; +MIMAT0039298 dvi-miR-9542d-3p; +MIMAT0039299 dvi-miR-9542b-5p; +MIMAT0039300 dvi-miR-9542b-3p; +MIMAT0039301 dvi-miR-9542e-5p; +MIMAT0039302 dvi-miR-9542e-3p; +MIMAT0039303 dvi-miR-9542c-5p; +MIMAT0039304 dvi-miR-9542c-3p; +MIMAT0039305 dvi-miR-9716-5p; +MIMAT0039306 dvi-miR-9716-3p; +MIMAT0039307 dvi-miR-9717-5p; +MIMAT0039308 dvi-miR-9717-3p; +MIMAT0039309 mmu-miR-9718; +MIMAT0039310 hsa-miR-9718; +MIMAT0039311 dvi-miR-9719-5p; +MIMAT0039312 dvi-miR-9719-3p; +MIMAT0039313 dvi-miR-9720-5p; +MIMAT0039314 dvi-miR-9720-3p; +MIMAT0039315 dvi-miR-9721-5p; +MIMAT0039316 dvi-miR-9721-3p; +MIMAT0039317 gma-miR9750-5p; +MIMAT0039318 hsa-miR-9898; +MIMAT0039319 hsa-miR-9899; +MIMAT0039320 hsa-miR-9900; +MIMAT0039321 hsa-miR-9901; +MIMAT0039322 hsa-miR-9902; +MIMAT0039323 hsa-miR-9903; +MIMAT0039324 cja-let-7a; +MIMAT0039325 cja-let-7b; +MIMAT0039326 cja-let-7g; +MIMAT0039327 cja-miR-523; +MIMAT0039328 cja-miR-519a; +MIMAT0039329 cja-miR-372; +MIMAT0039330 cja-miR-371a; +MIMAT0039331 cja-miR-1323; +MIMAT0039332 cja-miR-513b-5p; +MIMAT0039333 cja-miR-513a-5p; +MIMAT0039334 cja-miR-513a-3p; +MIMAT0039335 cja-miR-513c-5p; +MIMAT0039336 cja-miR-320; +MIMAT0039337 cja-miR-548e; +MIMAT0039338 cja-miR-495; +MIMAT0039339 cja-miR-543; +MIMAT0039340 cja-miR-451; +MIMAT0039341 cja-miR-338; +MIMAT0039342 cja-miR-216b; +MIMAT0039343 cja-miR-329; +MIMAT0039344 cja-miR-181c; +MIMAT0039345 cja-miR-181a; +MIMAT0039346 cja-miR-181b; +MIMAT0039347 cja-miR-181d; +MIMAT0039348 cja-miR-99; +MIMAT0039349 cja-miR-193; +MIMAT0039350 cja-miR-452; +MIMAT0039351 cja-miR-708; +MIMAT0039352 cja-miR-369-5p; +MIMAT0039353 cja-miR-369-3p; +MIMAT0039354 cja-miR-410; +MIMAT0039355 cja-miR-656; +MIMAT0039356 cja-miR-487a; +MIMAT0039357 cja-miR-154; +MIMAT0039358 cja-miR-652a; +MIMAT0039359 cja-miR-363; +MIMAT0039360 cja-miR-214; +MIMAT0039361 cja-miR-199; +MIMAT0039362 cja-miR-665; +MIMAT0039363 cja-miR-1249; +MIMAT0039364 cja-miR-1251; +MIMAT0039365 cja-miR-9904; +MIMAT0039366 cja-miR-219; +MIMAT0039367 cja-miR-485; +MIMAT0039368 cja-miR-383a; +MIMAT0039369 cja-miR-103a; +MIMAT0039370 cja-miR-222; +MIMAT0039371 cja-miR-671; +MIMAT0039372 cja-miR-31; +MIMAT0039373 cja-miR-34c; +MIMAT0039374 cja-miR-296; +MIMAT0039375 cja-miR-491; +MIMAT0039376 cja-miR-655; +MIMAT0039377 cja-miR-374b; +MIMAT0039378 cja-miR-421; +MIMAT0039379 cja-miR-377; +MIMAT0039380 cja-miR-23b; +MIMAT0039381 cja-miR-539; +MIMAT0039382 cja-miR-376a-5p; +MIMAT0039383 cja-miR-376a-3p; +MIMAT0039384 cja-miR-376b; +MIMAT0039385 cja-miR-215; +MIMAT0039386 cja-miR-628; +MIMAT0039387 cja-miR-2355; +MIMAT0039388 cja-miR-186; +MIMAT0039389 cja-miR-20b; +MIMAT0039390 cja-miR-93; +MIMAT0039391 cja-miR-17; +MIMAT0039392 cja-miR-191; +MIMAT0039393 cja-miR-224; +MIMAT0039394 cja-miR-548m; +MIMAT0039395 cja-miR-3120; +MIMAT0039396 cja-miR-424; +MIMAT0039397 cja-miR-130b; +MIMAT0039398 cja-miR-1298; +MIMAT0039399 cja-miR-532; +MIMAT0039400 cja-miR-1306; +MIMAT0039401 cja-miR-323; +MIMAT0039402 cja-miR-324; +MIMAT0039403 cja-miR-1247; +MIMAT0039404 cja-miR-1468; +MIMAT0039405 cja-miR-328; +MIMAT0039406 cja-miR-675; +MIMAT0039407 cja-miR-374a; +MIMAT0039408 cja-miR-129; +MIMAT0039409 cja-miR-382; +MIMAT0039410 cja-miR-503; +MIMAT0039411 cja-miR-551; +MIMAT0039412 cja-miR-345; +MIMAT0039413 cja-miR-144; +MIMAT0039414 cja-miR-145; +MIMAT0039415 cja-miR-203; +MIMAT0039416 cja-miR-887-5p; +MIMAT0039417 cja-miR-887-3p; +MIMAT0039418 cja-miR-33; +MIMAT0039419 cja-miR-1327; +MIMAT0039420 cja-miR-548l; +MIMAT0039421 cja-miR-20a; +MIMAT0039422 cja-miR-141; +MIMAT0039423 cja-miR-132; +MIMAT0039424 cja-miR-582; +MIMAT0039425 cja-miR-124; +MIMAT0039426 cja-miR-200c; +MIMAT0039427 cja-miR-429; +MIMAT0039428 cja-miR-216a; +MIMAT0039429 cja-miR-365; +MIMAT0039430 cja-miR-101; +MIMAT0039431 cja-miR-140; +MIMAT0039432 cja-miR-660; +MIMAT0039433 cja-miR-10b; +MIMAT0039434 cja-miR-10a; +MIMAT0039435 cja-miR-598; +MIMAT0039436 cja-miR-217; +MIMAT0039437 cja-miR-29b; +MIMAT0039438 cja-miR-29c; +MIMAT0039439 cja-miR-15b; +MIMAT0039440 cja-miR-16; +MIMAT0039441 cja-miR-21; +MIMAT0039442 cja-miR-449c; +MIMAT0039443 cja-miR-196a; +MIMAT0039444 cja-miR-196b; +MIMAT0039445 cja-miR-411; +MIMAT0039446 cja-miR-381; +MIMAT0039447 cja-miR-3688; +MIMAT0039448 cja-miR-183; +MIMAT0039449 cja-miR-135; +MIMAT0039450 cja-miR-654; +MIMAT0039451 cja-miR-455; +MIMAT0039452 cja-miR-32; +MIMAT0039453 cja-miR-92b; +MIMAT0039454 cja-miR-92a; +MIMAT0039455 cja-miR-105; +MIMAT0039456 cja-miR-335-5p; +MIMAT0039457 cja-miR-335-3p; +MIMAT0039458 cja-miR-128; +MIMAT0039459 cja-miR-483; +MIMAT0039460 cja-miR-3065; +MIMAT0039461 cja-miR-148a; +MIMAT0039462 cja-miR-148b; +MIMAT0039463 cja-miR-152; +MIMAT0039464 cja-miR-885; +MIMAT0039465 cja-miR-125; +MIMAT0039466 cja-miR-615; +MIMAT0039467 cja-miR-205; +MIMAT0039468 cja-miR-151; +MIMAT0039469 cja-miR-127; +MIMAT0039470 cja-miR-126; +MIMAT0039471 cja-miR-187; +MIMAT0039472 cja-miR-139; +MIMAT0039473 cja-miR-342; +MIMAT0039474 cja-miR-150; +MIMAT0039475 cja-miR-9; +MIMAT0039476 cja-miR-494; +MIMAT0039477 cja-miR-146b; +MIMAT0039478 cja-miR-146a; +MIMAT0039479 cja-miR-769; +MIMAT0039480 cja-miR-143; +MIMAT0039481 cja-miR-2114; +MIMAT0039482 cja-miR-339; +MIMAT0039483 cja-miR-423-5p; +MIMAT0039484 cja-miR-423-3p; +MIMAT0039485 cja-miR-1911; +MIMAT0039486 cja-miR-190a; +MIMAT0039487 cja-miR-190b; +MIMAT0039488 cja-miR-767; +MIMAT0039489 cja-miR-7; +MIMAT0039490 cja-miR-1a; +MIMAT0039491 cja-miR-206; +MIMAT0039492 cja-miR-184; +MIMAT0039493 cja-miR-185; +MIMAT0039494 cja-miR-876; +MIMAT0039495 cja-miR-449a; +MIMAT0039496 cja-miR-34a; +MIMAT0039497 cja-miR-24; +MIMAT0039498 cja-miR-379; +MIMAT0039499 cja-miR-412; +MIMAT0039500 cja-miR-541; +MIMAT0039501 cja-miR-30d; +MIMAT0039502 cja-miR-30b; +MIMAT0039503 cja-miR-30a; +MIMAT0039504 cja-miR-30e; +MIMAT0039505 cja-miR-194; +MIMAT0039506 cja-miR-223; +MIMAT0039507 cja-miR-934; +MIMAT0039508 cja-miR-134; +MIMAT0039509 cja-miR-19b; +MIMAT0039510 cja-miR-499a; +MIMAT0039511 cja-miR-155; +MIMAT0039512 cja-miR-1296; +MIMAT0039513 cja-miR-361; +MIMAT0039514 cja-miR-137; +MIMAT0039515 cja-miR-95; +MIMAT0039516 cja-miR-26a; +MIMAT0039517 cja-miR-26b; +MIMAT0039518 cja-miR-27a; +MIMAT0039519 cja-miR-27b; +MIMAT0039520 cja-miR-197; +MIMAT0039521 cja-miR-204; +MIMAT0039522 cja-miR-211; +MIMAT0039523 cja-miR-202; +MIMAT0039524 cja-miR-488; +MIMAT0039525 cja-miR-9905; +MIMAT0039526 cja-miR-1301; +MIMAT0039527 cja-miR-153; +MIMAT0039528 cja-miR-448; +MIMAT0039529 cja-miR-133a; +MIMAT0039530 cja-miR-493; +MIMAT0039531 cja-miR-218; +MIMAT0039532 cja-miR-670; +MIMAT0039533 cja-miR-182; +MIMAT0039534 cja-miR-96; +MIMAT0039535 cja-miR-133b; +MIMAT0039536 cja-miR-450a; +MIMAT0039537 cja-miR-450b; +MIMAT0039538 cja-miR-497; +MIMAT0039539 cja-miR-373; +MIMAT0039540 cja-miR-383b; +MIMAT0039541 cja-miR-518a; +MIMAT0039542 cja-miR-510a; +MIMAT0039543 cja-miR-513d-5p; +MIMAT0039544 cja-miR-5191; +MIMAT0039545 cja-miR-1258a; +MIMAT0039546 cja-miR-3135; +MIMAT0039547 cja-miR-548a; +MIMAT0039548 cja-miR-34b; +MIMAT0039549 cja-miR-548b; +MIMAT0039550 cja-miR-548n; +MIMAT0039551 cja-miR-9906; +MIMAT0039552 cja-miR-9907; +MIMAT0039553 cja-miR-9908; +MIMAT0039554 cja-miR-330; +MIMAT0039555 cja-miR-676; +MIMAT0039556 cja-miR-504; +MIMAT0039557 cja-miR-9909; +MIMAT0039558 cja-miR-1258b; +MIMAT0039559 cja-miR-9910; +MIMAT0039560 cja-miR-142; +MIMAT0039561 cja-miR-505; +MIMAT0039562 cja-miR-299; +MIMAT0039563 cja-miR-616; +MIMAT0039564 cja-miR-337; +MIMAT0039565 cja-miR-891b; +MIMAT0039566 cja-miR-617; +MIMAT0039567 cja-miR-770; +MIMAT0039568 cja-miR-3074; +MIMAT0039569 cja-miR-542-5p; +MIMAT0039570 cja-miR-542-3p; +MIMAT0039571 cja-miR-371b-5p; +MIMAT0039572 cja-miR-371b-3p; +MIMAT0039573 cja-miR-514a; +MIMAT0039574 cja-miR-508; +MIMAT0039575 cja-miR-548q; +MIMAT0039576 cja-miR-548f; +MIMAT0039577 cja-miR-548x; +MIMAT0039578 cja-miR-548o; +MIMAT0039579 cja-miR-548d; +MIMAT0039580 cja-miR-561; +MIMAT0039581 cja-miR-499b; +MIMAT0039582 cja-miR-548s; +MIMAT0039583 cja-miR-622; +MIMAT0039584 cja-miR-466a; +MIMAT0039585 cja-miR-367; +MIMAT0039586 cja-miR-302a-5p; +MIMAT0039587 cja-miR-302a-3p; +MIMAT0039588 cja-miR-302b; +MIMAT0039589 cja-miR-302d-5p; +MIMAT0039590 cja-miR-302d-3p; +MIMAT0039591 cja-miR-631; +MIMAT0039592 cja-miR-138; +MIMAT0039593 cja-miR-1898; +MIMAT0039594 cja-miR-569; +MIMAT0039595 cja-miR-3546; +MIMAT0039596 cja-miR-208b; +MIMAT0039597 cja-miR-208a; +MIMAT0039598 cja-miR-4790; +MIMAT0039599 cja-miR-3152; +MIMAT0039600 cja-miR-548h; +MIMAT0039601 cja-miR-548p; +MIMAT0039602 cja-miR-548j; +MIMAT0039603 cja-miR-548c; +MIMAT0039604 cja-miR-1264; +MIMAT0039605 cja-miR-3940; +MIMAT0039606 cja-miR-763; +MIMAT0039607 cja-miR-875-5p; +MIMAT0039608 cja-miR-875-3p; +MIMAT0039609 cja-miR-4762; +MIMAT0039610 cja-miR-556; +MIMAT0039611 cja-miR-759; +MIMAT0039612 cja-miR-761; +MIMAT0039613 cja-miR-489; +MIMAT0039614 cja-miR-559; +MIMAT0039615 cja-miR-302c; +MIMAT0039616 cja-miR-1b-5p; +MIMAT0039617 cja-miR-1b-3p; +MIMAT0039618 cja-miR-466b; +MIMAT0039619 cja-miR-548v; +MIMAT0039620 cja-miR-1193; +MIMAT0039621 cja-miR-586; +MIMAT0039622 cja-miR-103b; +MIMAT0039623 cja-miR-1282; +MIMAT0039624 cja-miR-2968; +MIMAT0039625 cja-miR-581; +MIMAT0039626 cja-miR-548y; +MIMAT0039627 cja-miR-589; +MIMAT0039628 cja-miR-4745; +MIMAT0039629 cja-miR-4683; +MIMAT0039630 cja-miR-122; +MIMAT0039631 cja-miR-1294; +MIMAT0039632 cja-miR-651; +MIMAT0039633 cja-miR-2053; +MIMAT0039634 cja-miR-1302; +MIMAT0039635 cja-miR-544; +MIMAT0039636 cja-miR-2338; +MIMAT0039637 cja-miR-4460; +MIMAT0039638 cja-miR-4679; +MIMAT0039639 cja-miR-4780; +MIMAT0039640 cja-miR-1240; +MIMAT0039641 cja-miR-557; +MIMAT0039642 cja-miR-612; +MIMAT0039643 cja-miR-1305; +MIMAT0039644 cja-miR-545; +MIMAT0039645 cja-miR-548t; +MIMAT0039646 cja-miR-580; +MIMAT0039647 cja-miR-3118; +MIMAT0039648 cja-miR-3576; +MIMAT0039649 cja-miR-4503; +MIMAT0039650 cja-miR-4512; +MIMAT0039651 cja-miR-4772; +MIMAT0039652 cja-miR-548g; +MIMAT0039653 cja-miR-548r; +MIMAT0039654 cja-miR-548i; +MIMAT0039655 cja-miR-638; +MIMAT0039656 cja-miR-1253; +MIMAT0039657 cja-miR-1895; +MIMAT0039658 cja-miR-9911; +MIMAT0039659 cja-miR-9912; +MIMAT0039660 cja-miR-548u; +MIMAT0039661 cja-miR-548k; +MIMAT0039662 cja-miR-498; +MIMAT0039663 cja-miR-518b; +MIMAT0039664 cja-miR-519b; +MIMAT0039665 cja-miR-521; +MIMAT0039666 cja-miR-519c; +MIMAT0039667 cja-miR-513g-3p; +MIMAT0039668 cja-miR-514b; +MIMAT0039669 cja-miR-506; +MIMAT0039670 cja-miR-513f-3p; +MIMAT0039671 cja-miR-513f-5p; +MIMAT0039672 cja-miR-513h-3p; +MIMAT0039673 cja-miR-510b; +MIMAT0039674 cja-miR-509; +MIMAT0039675 cja-miR-513e-3p; +MIMAT0039676 cja-miR-9913; +MIMAT0039677 cja-miR-9914; +MIMAT0039678 cja-miR-9915; +MIMAT0039679 cja-miR-9916; +MIMAT0039680 cja-miR-9917; +MIMAT0039681 cja-miR-9918; +MIMAT0039682 cja-miR-9919; +MIMAT0039683 cja-miR-9921; +MIMAT0039684 cja-miR-652b; +MIMAT0039685 cja-miR-9922; +MIMAT0039686 cja-miR-9923; +MIMAT0039687 cja-miR-9924; +MIMAT0039688 cja-miR-9952b; +MIMAT0039689 cja-miR-9925; +MIMAT0039690 cja-miR-9926; +MIMAT0039691 cja-miR-9952c; +MIMAT0039692 cja-miR-3544; +MIMAT0039693 cja-miR-9927; +MIMAT0039694 cja-miR-9928; +MIMAT0039695 cja-miR-9929; +MIMAT0039696 cja-miR-9930; +MIMAT0039697 cja-miR-9931; +MIMAT0039698 cja-miR-9932; +MIMAT0039699 cja-miR-1185; +MIMAT0039700 cja-miR-9933; +MIMAT0039701 cja-miR-548w; +MIMAT0039702 cja-miR-9934; +MIMAT0039703 cja-miR-584; +MIMAT0039704 cja-miR-9935; +MIMAT0039705 cja-miR-507; +MIMAT0039706 cja-miR-9936; +MIMAT0039707 cja-miR-9937; +MIMAT0039708 cja-miR-9938; +MIMAT0039709 cja-miR-9939; +MIMAT0039710 cja-miR-9940; +MIMAT0039711 cja-miR-9941; +MIMAT0039712 cja-miR-9942; +MIMAT0039713 cja-miR-9943; +MIMAT0039714 cja-miR-9948a; +MIMAT0039715 cja-miR-9944; +MIMAT0039716 cja-miR-891c; +MIMAT0039717 cja-miR-9945; +MIMAT0039718 cja-miR-9946; +MIMAT0039719 cja-miR-6529; +MIMAT0039720 cja-miR-942; +MIMAT0039721 cja-miR-9947; +MIMAT0039722 cja-miR-9948b; +MIMAT0039723 cja-miR-9949; +MIMAT0039724 cja-miR-577; +MIMAT0039725 cja-miR-9950; +MIMAT0039726 cja-miR-9951; +MIMAT0039727 cja-miR-9952a; +MIMAT0039728 cja-miR-9953; +MIMAT0039729 cja-miR-9954; +MIMAT0039730 cja-miR-9955; +MIMAT0039731 cja-miR-9956; +MIMAT0039732 cja-miR-9957; +MIMAT0039733 cja-miR-9958; +MIMAT0039734 cja-miR-9959; +MIMAT0039735 cja-miR-9960; +MIMAT0039736 cja-miR-9961; +MIMAT0039737 cja-miR-9962; +MIMAT0039738 cja-miR-9963; +MIMAT0039739 cja-miR-9964; +MIMAT0039740 cja-miR-9965; +MIMAT0039741 cja-miR-9966; +MIMAT0039742 cja-miR-9967; +MIMAT0039743 cja-miR-9968; +MIMAT0039744 cja-miR-9969; +MIMAT0039745 cja-miR-891d; +MIMAT0039746 cja-miR-9970; +MIMAT0039747 cja-miR-9971; +MIMAT0039748 cja-miR-9972; +MIMAT0039749 cja-miR-9973; +MIMAT0039750 cja-miR-9974; +MIMAT0039751 cja-miR-9975; +MIMAT0039752 cja-miR-9976; +MIMAT0039753 cja-miR-9977; +MIMAT0039754 cja-miR-9978; +MIMAT0039755 cja-miR-653; +MIMAT0039756 cja-miR-9979; +MIMAT0039757 cja-miR-9980; +MIMAT0039758 cja-miR-9981; +MIMAT0039759 cja-miR-9982; +MIMAT0039760 cja-miR-9983; +MIMAT0039761 cja-miR-9984; +MIMAT0039762 cja-miR-487b; +MIMAT0039763 hsa-miR-9985; +MIMAT0039764 hsa-miR-1843; +MIMAT0039765 hsa-miR-548bc; +MIMAT0039766 hsa-miR-9986; +MIMAT0039767 pal-miR-1-5p; +MIMAT0039768 pal-miR-1-3p; +MIMAT0039769 pal-miR-1-2-5p; +MIMAT0039770 pal-let-7f-5p; +MIMAT0039771 pal-let-7f-3p; +MIMAT0039772 pal-let-7a-5p; +MIMAT0039773 pal-let-7a-3p; +MIMAT0039774 pal-let-7g-5p; +MIMAT0039775 pal-let-7g-3p; +MIMAT0039776 pal-miR-122-5p; +MIMAT0039777 pal-miR-122-3p; +MIMAT0039778 pal-miR-140-5p; +MIMAT0039779 pal-miR-140-3p; +MIMAT0039780 pal-miR-143-5p; +MIMAT0039781 pal-miR-143-3p; +MIMAT0039782 pal-miR-378-5p; +MIMAT0039783 pal-miR-378-3p; +MIMAT0039784 pal-let-7e-5p; +MIMAT0039785 pal-let-7e-3p; +MIMAT0039786 pal-let-7i-5p; +MIMAT0039787 pal-let-7i-3p; +MIMAT0039788 pal-miR-199-5p; +MIMAT0039789 pal-miR-199-3p; +MIMAT0039790 pal-miR-199-3-5p; +MIMAT0039791 pal-miR-34c-5p; +MIMAT0039792 pal-miR-34c-3p; +MIMAT0039793 pal-miR-128-5p; +MIMAT0039794 pal-miR-128-3p; +MIMAT0039795 pal-miR-21-5p; +MIMAT0039796 pal-miR-21-3p; +MIMAT0039797 pal-miR-206-5p; +MIMAT0039798 pal-miR-206-3p; +MIMAT0039799 pal-miR-30a-5p; +MIMAT0039800 pal-miR-30a-3p; +MIMAT0039801 pal-miR-29a-5p; +MIMAT0039802 pal-miR-29a-3p; +MIMAT0039803 pal-miR-26a-5p; +MIMAT0039804 pal-miR-26a-2-3p; +MIMAT0039805 pal-miR-192-5p; +MIMAT0039806 pal-miR-192-3p; +MIMAT0039807 pal-miR-3958-5p; +MIMAT0039808 pal-miR-3958-3p; +MIMAT0039809 pal-miR-27b-5p; +MIMAT0039810 pal-miR-27b-3p; +MIMAT0039811 pal-miR-191-5p; +MIMAT0039812 pal-miR-191-3p; +MIMAT0039813 pal-miR-672-5p; +MIMAT0039814 pal-miR-672-3p; +MIMAT0039815 pal-miR-181a-5p; +MIMAT0039816 pal-miR-181a-2-3p; +MIMAT0039817 pal-miR-181a-3p; +MIMAT0039818 pal-miR-148a-5p; +MIMAT0039819 pal-miR-148a-3p; +MIMAT0039820 pal-miR-499a-5p; +MIMAT0039821 pal-miR-499a-3p; +MIMAT0039822 pal-miR-25-5p; +MIMAT0039823 pal-miR-25-3p; +MIMAT0039824 pal-miR-30d-5p; +MIMAT0039825 pal-miR-30d-3p; +MIMAT0039826 pal-miR-10a-5p; +MIMAT0039827 pal-miR-10a-3p; +MIMAT0039828 pal-miR-215-5p; +MIMAT0039829 pal-miR-215-3p; +MIMAT0039830 pal-miR-423-5p; +MIMAT0039831 pal-miR-423-3p; +MIMAT0039832 pal-miR-30e-5p; +MIMAT0039833 pal-miR-30e-3p; +MIMAT0039834 pal-miR-99b-5p; +MIMAT0039835 pal-miR-99b-3p; +MIMAT0039836 pal-miR-124-5p; +MIMAT0039837 pal-miR-124-3p; +MIMAT0039838 pal-miR-92a-2-5p; +MIMAT0039839 pal-miR-92a-3p; +MIMAT0039840 pal-miR-185-5p; +MIMAT0039841 pal-miR-185-3p; +MIMAT0039842 pal-miR-221-5p; +MIMAT0039843 pal-miR-221-3p; +MIMAT0039844 pal-miR-181b-5p; +MIMAT0039845 pal-miR-181b-2-3p; +MIMAT0039846 pal-miR-486a-5p; +MIMAT0039847 pal-miR-486a-3p; +MIMAT0039848 pal-miR-99a-5p; +MIMAT0039849 pal-miR-99a-3p; +MIMAT0039850 pal-miR-125b-5p; +MIMAT0039851 pal-miR-125b-2-3p; +MIMAT0039852 pal-miR-181b-3p; +MIMAT0039853 pal-miR-125b-3p; +MIMAT0039854 pal-miR-129a-5p; +MIMAT0039855 pal-miR-129a-3p; +MIMAT0039856 pal-miR-23a-5p; +MIMAT0039857 pal-miR-23a-3p; +MIMAT0039858 pal-miR-27a-5p; +MIMAT0039859 pal-miR-27a-3p; +MIMAT0039860 pal-miR-22-5p; +MIMAT0039861 pal-miR-22-3p; +MIMAT0039862 pal-miR-202-5p; +MIMAT0039863 pal-miR-202-3p; +MIMAT0039864 pal-miR-200b-5p; +MIMAT0039865 pal-miR-200b-3p; +MIMAT0039866 pal-miR-200a-5p; +MIMAT0039867 pal-miR-200a-3p; +MIMAT0039868 pal-miR-148b-5p; +MIMAT0039869 pal-miR-148b-3p; +MIMAT0039870 pal-miR-23b-5p; +MIMAT0039871 pal-miR-23b-3p; +MIMAT0039872 pal-miR-129b-5p; +MIMAT0039873 pal-miR-129b-3p; +MIMAT0039874 pal-miR-133a-5p; +MIMAT0039875 pal-miR-133a-3p; +MIMAT0039876 pal-miR-363-5p; +MIMAT0039877 pal-miR-363-3p; +MIMAT0039878 pal-miR-485-5p; +MIMAT0039879 pal-miR-485-3p; +MIMAT0039880 pal-miR-30c-5p; +MIMAT0039881 pal-miR-30c-3p; +MIMAT0039882 pal-miR-98-5p; +MIMAT0039883 pal-miR-98-3p; +MIMAT0039884 pal-miR-9-5p; +MIMAT0039885 pal-miR-9-3p; +MIMAT0039886 pal-miR-379-5p; +MIMAT0039887 pal-miR-379-3p; +MIMAT0039888 pal-miR-34b-5p; +MIMAT0039889 pal-miR-34b-3p; +MIMAT0039890 pal-miR-28-5p; +MIMAT0039891 pal-miR-28-3p; +MIMAT0039892 pal-miR-16-5p; +MIMAT0039893 pal-miR-16-3p; +MIMAT0039894 pal-miR-16-2-3p; +MIMAT0039895 pal-miR-130-5p; +MIMAT0039896 pal-miR-130-3p; +MIMAT0039897 pal-miR-194b-5p; +MIMAT0039898 pal-miR-194b-3p; +MIMAT0039899 pal-miR-10b-5p; +MIMAT0039900 pal-miR-10b-3p; +MIMAT0039901 pal-miR-532-5p; +MIMAT0039902 pal-miR-532-3p; +MIMAT0039903 pal-miR-186-5p; +MIMAT0039904 pal-miR-186-3p; +MIMAT0039905 pal-miR-15b-5p; +MIMAT0039906 pal-miR-15b-3p; +MIMAT0039907 pal-miR-92b-5p; +MIMAT0039908 pal-miR-92b-3p; +MIMAT0039909 pal-miR-126-5p; +MIMAT0039910 pal-miR-126-3p; +MIMAT0039911 pal-miR-200c-5p; +MIMAT0039912 pal-miR-200c-3p; +MIMAT0039913 pal-miR-8908b-5p; +MIMAT0039914 pal-miR-8908b-3p; +MIMAT0039915 pal-miR-382-5p; +MIMAT0039916 pal-miR-382-3p; +MIMAT0039917 pal-miR-7b-5p; +MIMAT0039918 pal-miR-7b-3p; +MIMAT0039919 pal-miR-424-5p; +MIMAT0039920 pal-miR-424-3p; +MIMAT0039921 pal-miR-323-5p; +MIMAT0039922 pal-miR-323-3p; +MIMAT0039923 pal-miR-411-5p; +MIMAT0039924 pal-miR-411-3p; +MIMAT0039925 pal-miR-139-5p; +MIMAT0039926 pal-miR-139-3p; +MIMAT0039927 pal-miR-219a-5p; +MIMAT0039928 pal-miR-219a-2-3p; +MIMAT0039929 pal-miR-146b-5p; +MIMAT0039930 pal-miR-146b-3p; +MIMAT0039931 pal-miR-193a-5p; +MIMAT0039932 pal-miR-193a-3p; +MIMAT0039933 pal-miR-506-5p; +MIMAT0039934 pal-miR-506-3p; +MIMAT0039935 pal-miR-106b-5p; +MIMAT0039936 pal-miR-106b-3p; +MIMAT0039937 pal-miR-93-5p; +MIMAT0039938 pal-miR-93-3p; +MIMAT0039939 pal-miR-449a-5p; +MIMAT0039940 pal-miR-449a-3p; +MIMAT0039941 pal-miR-15a-5p; +MIMAT0039942 pal-miR-15a-3p; +MIMAT0039943 pal-miR-493-5p; +MIMAT0039944 pal-miR-493-3p; +MIMAT0039945 pal-miR-30b-5p; +MIMAT0039946 pal-miR-30b-3p; +MIMAT0039947 pal-miR-138-5p; +MIMAT0039948 pal-miR-138-3p; +MIMAT0039949 pal-miR-500-5p; +MIMAT0039950 pal-miR-500-3p; +MIMAT0039951 pal-miR-9987-5p; +MIMAT0039952 pal-miR-9987-3p; +MIMAT0039953 pal-miR-9988-5p; +MIMAT0039954 pal-miR-9988-3p; +MIMAT0039955 pal-miR-509b-5p; +MIMAT0039956 pal-miR-509b-3p; +MIMAT0039957 pal-miR-100-5p; +MIMAT0039958 pal-miR-100-3p; +MIMAT0039959 pal-miR-17-5p; +MIMAT0039960 pal-miR-17-3p; +MIMAT0039961 pal-miR-144-5p; +MIMAT0039962 pal-miR-144-3p; +MIMAT0039963 pal-miR-365b-5p; +MIMAT0039964 pal-miR-365b-3p; +MIMAT0039965 pal-miR-204-5p; +MIMAT0039966 pal-miR-204-3p; +MIMAT0039967 pal-miR-193b-5p; +MIMAT0039968 pal-miR-193b-3p; +MIMAT0039969 pal-miR-664a-5p; +MIMAT0039970 pal-miR-664a-3p; +MIMAT0039971 pal-miR-299a-5p; +MIMAT0039972 pal-miR-299a-3p; +MIMAT0039973 pal-miR-1185-5p; +MIMAT0039974 pal-miR-1185-3p; +MIMAT0039975 pal-miR-155-5p; +MIMAT0039976 pal-miR-155-3p; +MIMAT0039977 pal-miR-1388-5p; +MIMAT0039978 pal-miR-1388-3p; +MIMAT0039979 pal-miR-212-5p; +MIMAT0039980 pal-miR-212-3p; +MIMAT0039981 pal-miR-345-5p; +MIMAT0039982 pal-miR-345-3p; +MIMAT0039983 pal-miR-425-5p; +MIMAT0039984 pal-miR-425-3p; +MIMAT0039985 pal-miR-135-5p; +MIMAT0039986 pal-miR-135-3p; +MIMAT0039987 pal-miR-8908a-5p; +MIMAT0039988 pal-miR-8908a-2-3p; +MIMAT0039989 pal-miR-374b-5p; +MIMAT0039990 pal-miR-374b-3p; +MIMAT0039991 pal-miR-132-5p; +MIMAT0039992 pal-miR-132-3p; +MIMAT0039993 pal-miR-331-5p; +MIMAT0039994 pal-miR-331-3p; +MIMAT0039995 pal-miR-150-5p; +MIMAT0039996 pal-miR-150-3p; +MIMAT0039997 pal-miR-660-5p; +MIMAT0039998 pal-miR-660-3p; +MIMAT0039999 pal-miR-7140-5p; +MIMAT0040000 pal-miR-7140-3p; +MIMAT0040001 pal-miR-136-5p; +MIMAT0040002 pal-miR-136-3p; +MIMAT0040003 pal-miR-708-5p; +MIMAT0040004 pal-miR-708-3p; +MIMAT0040005 pal-miR-20b-5p; +MIMAT0040006 pal-miR-20b-3p; +MIMAT0040007 pal-miR-181c-5p; +MIMAT0040008 pal-miR-181c-3p; +MIMAT0040009 pal-miR-196b-5p; +MIMAT0040010 pal-miR-196b-3p; +MIMAT0040011 pal-miR-504-5p; +MIMAT0040012 pal-miR-504-3p; +MIMAT0040013 pal-miR-664b-5p; +MIMAT0040014 pal-miR-664b-3p; +MIMAT0040015 pal-miR-337-5p; +MIMAT0040016 pal-miR-337-3p; +MIMAT0040017 pal-miR-885-5p; +MIMAT0040018 pal-miR-885-3p; +MIMAT0040019 pal-miR-487b-5p; +MIMAT0040020 pal-miR-487b-3p; +MIMAT0040021 pal-miR-574-5p; +MIMAT0040022 pal-miR-574-3p; +MIMAT0040023 pal-miR-369-5p; +MIMAT0040024 pal-miR-369-3p; +MIMAT0040025 pal-miR-208a-5p; +MIMAT0040026 pal-miR-208a-3p; +MIMAT0040027 pal-miR-224-5p; +MIMAT0040028 pal-miR-224-3p; +MIMAT0040029 pal-miR-194a-5p; +MIMAT0040030 pal-miR-194a-3p; +MIMAT0040031 pal-miR-490-5p; +MIMAT0040032 pal-miR-490-3p; +MIMAT0040033 pal-miR-873-5p; +MIMAT0040034 pal-miR-873-3p; +MIMAT0040035 pal-miR-338-5p; +MIMAT0040036 pal-miR-338-3p; +MIMAT0040037 pal-miR-34a-5p; +MIMAT0040038 pal-miR-34a-3p; +MIMAT0040039 pal-miR-361-5p; +MIMAT0040040 pal-miR-361-3p; +MIMAT0040041 pal-miR-652-5p; +MIMAT0040042 pal-miR-652-3p; +MIMAT0040043 pal-miR-218-5p; +MIMAT0040044 pal-miR-218-2-3p; +MIMAT0040045 pal-miR-301a-5p; +MIMAT0040046 pal-miR-301a-3p; +MIMAT0040047 pal-miR-380-5p; +MIMAT0040048 pal-miR-380-3p; +MIMAT0040049 pal-miR-137-5p; +MIMAT0040050 pal-miR-137-3p; +MIMAT0040051 pal-miR-216b-5p; +MIMAT0040052 pal-miR-216b-3p; +MIMAT0040053 pal-miR-370-5p; +MIMAT0040054 pal-miR-370-3p; +MIMAT0040055 pal-miR-454-5p; +MIMAT0040056 pal-miR-454-3p; +MIMAT0040057 pal-miR-9989-5p; +MIMAT0040058 pal-miR-9989-3p; +MIMAT0040059 pal-miR-329b-5p; +MIMAT0040060 pal-miR-329b-3p; +MIMAT0040061 pal-miR-9990-5p; +MIMAT0040062 pal-miR-9990-3p; +MIMAT0040063 pal-miR-8908e-5p; +MIMAT0040064 pal-miR-8908e-3p; +MIMAT0040065 pal-miR-153-5p; +MIMAT0040066 pal-miR-153-3p; +MIMAT0040067 pal-miR-214-5p; +MIMAT0040068 pal-miR-214-3p; +MIMAT0040069 pal-miR-503-5p; +MIMAT0040070 pal-miR-503-3p; +MIMAT0040071 pal-miR-219a-3p; +MIMAT0040072 pal-miR-26a-3p; +MIMAT0040073 pal-miR-320-5p; +MIMAT0040074 pal-miR-320-3p; +MIMAT0040075 pal-miR-296-5p; +MIMAT0040076 pal-miR-296-3p; +MIMAT0040077 pal-miR-497-5p; +MIMAT0040078 pal-miR-497-3p; +MIMAT0040079 pal-miR-151-5p; +MIMAT0040080 pal-miR-151-3p; +MIMAT0040081 pal-miR-33a-5p; +MIMAT0040082 pal-miR-33a-3p; +MIMAT0040083 pal-miR-195-5p; +MIMAT0040084 pal-miR-195-3p; +MIMAT0040085 pal-miR-342-5p; +MIMAT0040086 pal-miR-342-3p; +MIMAT0040087 pal-miR-432-5p; +MIMAT0040088 pal-miR-432-3p; +MIMAT0040089 pal-miR-133b-5p; +MIMAT0040090 pal-miR-133b-3p; +MIMAT0040091 pal-miR-502-5p; +MIMAT0040092 pal-miR-502-3p; +MIMAT0040093 pal-miR-760-5p; +MIMAT0040094 pal-miR-760-3p; +MIMAT0040095 pal-miR-330-5p; +MIMAT0040096 pal-miR-330-3p; +MIMAT0040097 pal-miR-141-5p; +MIMAT0040098 pal-miR-141-3p; +MIMAT0040099 pal-miR-429-5p; +MIMAT0040100 pal-miR-429-3p; +MIMAT0040101 pal-miR-101-2-5p; +MIMAT0040102 pal-miR-101-3p; +MIMAT0040103 pal-miR-8908a-3p; +MIMAT0040104 pal-miR-196a-5p; +MIMAT0040105 pal-miR-196a-3p; +MIMAT0040106 pal-miR-152-5p; +MIMAT0040107 pal-miR-152-3p; +MIMAT0040108 pal-miR-125a-5p; +MIMAT0040109 pal-miR-125a-3p; +MIMAT0040110 pal-miR-205-5p; +MIMAT0040111 pal-miR-205-3p; +MIMAT0040112 pal-miR-7a-5p; +MIMAT0040113 pal-miR-7a-3p; +MIMAT0040114 pal-miR-412-5p; +MIMAT0040115 pal-miR-412-3p; +MIMAT0040116 pal-miR-26b-5p; +MIMAT0040117 pal-miR-26b-3p; +MIMAT0040118 pal-miR-1180-5p; +MIMAT0040119 pal-miR-1180-3p; +MIMAT0040120 pal-miR-375-5p; +MIMAT0040121 pal-miR-375-3p; +MIMAT0040122 pal-miR-450b-5p; +MIMAT0040123 pal-miR-450b-3p; +MIMAT0040124 pal-miR-222-5p; +MIMAT0040125 pal-miR-222-3p; +MIMAT0040126 pal-miR-409-5p; +MIMAT0040127 pal-miR-409-3p; +MIMAT0040128 pal-miR-323b-5p; +MIMAT0040129 pal-miR-323b-3p; +MIMAT0040130 pal-miR-142-5p; +MIMAT0040131 pal-miR-142-3p; +MIMAT0040132 pal-miR-1224-5p; +MIMAT0040133 pal-miR-1224-3p; +MIMAT0040134 pal-miR-96-5p; +MIMAT0040135 pal-miR-96-3p; +MIMAT0040136 pal-miR-31-5p; +MIMAT0040137 pal-miR-31-3p; +MIMAT0040138 pal-miR-20a-5p; +MIMAT0040139 pal-miR-20a-3p; +MIMAT0040140 pal-let-7c-5p; +MIMAT0040141 pal-let-7c-3p; +MIMAT0040142 pal-miR-181d-5p; +MIMAT0040143 pal-miR-181d-3p; +MIMAT0040144 pal-miR-183-5p; +MIMAT0040145 pal-miR-183-3p; +MIMAT0040146 pal-miR-127-5p; +MIMAT0040147 pal-miR-127-3p; +MIMAT0040148 pal-let-7a-2-3p; +MIMAT0040149 pal-miR-9991-5p; +MIMAT0040150 pal-miR-9991-3p; +MIMAT0040151 pal-miR-410-5p; +MIMAT0040152 pal-miR-410-3p; +MIMAT0040153 pal-miR-138-2-3p; +MIMAT0040154 pal-miR-381-5p; +MIMAT0040155 pal-miR-381-3p; +MIMAT0040156 pal-miR-9992-5p; +MIMAT0040157 pal-miR-9992-3p; +MIMAT0040158 pal-miR-145-5p; +MIMAT0040159 pal-miR-145-3p; +MIMAT0040160 pal-miR-92a-5p; +MIMAT0040161 pal-miR-335-5p; +MIMAT0040162 pal-miR-335-3p; +MIMAT0040163 pal-miR-7b-2-3p; +MIMAT0040164 pal-miR-184-5p; +MIMAT0040165 pal-miR-184-3p; +MIMAT0040166 pal-miR-19-5p; +MIMAT0040167 pal-miR-19-3p; +MIMAT0040168 pal-miR-19-2-5p; +MIMAT0040169 pal-miR-452-5p; +MIMAT0040170 pal-miR-452-3p; +MIMAT0040171 pal-miR-383-5p; +MIMAT0040172 pal-miR-383-3p; +MIMAT0040173 pal-miR-9993a-5p; +MIMAT0040174 pal-miR-9993a-3p; +MIMAT0040175 pal-miR-29b-5p; +MIMAT0040176 pal-miR-29b-3p; +MIMAT0040177 pal-miR-9994-5p; +MIMAT0040178 pal-miR-9994-3p; +MIMAT0040179 pal-miR-802-5p; +MIMAT0040180 pal-miR-802-3p; +MIMAT0040181 pal-miR-146a-5p; +MIMAT0040182 pal-miR-146a-3p; +MIMAT0040183 pal-miR-542-5p; +MIMAT0040184 pal-miR-542-3p; +MIMAT0040185 pal-miR-495-5p; +MIMAT0040186 pal-miR-495-3p; +MIMAT0040187 pal-miR-9995-5p; +MIMAT0040188 pal-miR-9995-3p; +MIMAT0040189 pal-miR-551b-5p; +MIMAT0040190 pal-miR-551b-3p; +MIMAT0040191 pal-miR-340-5p; +MIMAT0040192 pal-miR-340-3p; +MIMAT0040193 pal-miR-103a-5p; +MIMAT0040194 pal-miR-103a-3p; +MIMAT0040195 pal-miR-6529-5p; +MIMAT0040196 pal-miR-6529-3p; +MIMAT0040197 pal-miR-29c-5p; +MIMAT0040198 pal-miR-29c-3p; +MIMAT0040199 pal-miR-450a-5p; +MIMAT0040200 pal-miR-450a-3p; +MIMAT0040201 pal-miR-107a-5p; +MIMAT0040202 pal-miR-107a-3p; +MIMAT0040203 pal-miR-29b-2-5p; +MIMAT0040204 pal-miR-106a-5p; +MIMAT0040205 pal-miR-106a-3p; +MIMAT0040206 pal-miR-103b-5p; +MIMAT0040207 pal-miR-103b-3p; +MIMAT0040208 pal-miR-376d-5p; +MIMAT0040209 pal-miR-376d-3p; +MIMAT0040210 pal-miR-450a-2-3p; +MIMAT0040211 pal-miR-544-5p; +MIMAT0040212 pal-miR-544-3p; +MIMAT0040213 pal-miR-3959-5p; +MIMAT0040214 pal-miR-3959-3p; +MIMAT0040215 pal-miR-101-5p; +MIMAT0040216 pal-miR-1301-5p; +MIMAT0040217 pal-miR-1301-3p; +MIMAT0040218 pal-miR-543-5p; +MIMAT0040219 pal-miR-543-3p; +MIMAT0040220 pal-miR-9996-5p; +MIMAT0040221 pal-miR-9996-3p; +MIMAT0040222 pal-miR-18a-5p; +MIMAT0040223 pal-miR-18a-3p; +MIMAT0040224 pal-miR-196c-5p; +MIMAT0040225 pal-miR-196c-3p; +MIMAT0040226 pal-miR-889-5p; +MIMAT0040227 pal-miR-889-3p; +MIMAT0040228 pal-miR-8908g-5p; +MIMAT0040229 pal-miR-8908g-3p; +MIMAT0040230 pal-miR-376c-5p; +MIMAT0040231 pal-miR-376c-3p; +MIMAT0040232 pal-miR-105-5p; +MIMAT0040233 pal-miR-105-3p; +MIMAT0040234 pal-miR-9997-5p; +MIMAT0040235 pal-miR-9997-3p; +MIMAT0040236 pal-miR-376b-5p; +MIMAT0040237 pal-miR-376b-3p; +MIMAT0040238 pal-miR-8908f-5p; +MIMAT0040239 pal-miR-8908f-3p; +MIMAT0040240 pal-miR-6119-5p; +MIMAT0040241 pal-miR-6119-3p; +MIMAT0040242 pal-miR-628-5p; +MIMAT0040243 pal-miR-628-3p; +MIMAT0040244 pal-miR-9998-5p; +MIMAT0040245 pal-miR-9998-3p; +MIMAT0040246 pal-miR-218-3p; +MIMAT0040247 pal-miR-8908c-5p; +MIMAT0040248 pal-miR-8908c-3p; +MIMAT0040250 pal-miR-135-2-3p; +MIMAT0040251 pal-miR-758-5p; +MIMAT0040252 pal-miR-758-3p; +MIMAT0040253 pal-miR-458-5p; +MIMAT0040254 pal-miR-458-3p; +MIMAT0040255 pal-miR-4646-5p; +MIMAT0040256 pal-miR-4646-3p; +MIMAT0040257 pal-miR-3120-5p; +MIMAT0040258 pal-miR-3120-3p; +MIMAT0040259 pal-miR-208b-5p; +MIMAT0040260 pal-miR-208b-3p; +MIMAT0040261 pal-miR-9999-5p; +MIMAT0040262 pal-miR-9999-3p; +MIMAT0040263 pal-miR-665-5p; +MIMAT0040264 pal-miR-665-3p; +MIMAT0040265 pal-miR-10000-5p; +MIMAT0040266 pal-miR-10000-3p; +MIMAT0040267 pal-miR-1379-5p; +MIMAT0040268 pal-miR-1379-3p; +MIMAT0040269 pal-miR-10001-5p; +MIMAT0040270 pal-miR-10001-3p; +MIMAT0040271 pal-miR-10002-5p; +MIMAT0040272 pal-miR-10002-3p; +MIMAT0040273 pal-miR-541-5p; +MIMAT0040274 pal-miR-541-3p; +MIMAT0040275 pal-miR-154b-5p; +MIMAT0040276 pal-miR-154b-3p; +MIMAT0040277 pal-miR-9993b-5p; +MIMAT0040278 pal-miR-9993b-3p; +MIMAT0040279 pal-miR-9226-5p; +MIMAT0040280 pal-miR-9226-3p; +MIMAT0040281 pal-miR-486a-3-3p; +MIMAT0040282 pal-miR-282-5p; +MIMAT0040283 pal-miR-282-3p; +MIMAT0040284 pal-miR-339a-5p; +MIMAT0040285 pal-miR-339a-3p; +MIMAT0040286 pal-miR-10003-5p; +MIMAT0040287 pal-miR-10003-3p; +MIMAT0040288 pal-miR-421-5p; +MIMAT0040289 pal-miR-421-3p; +MIMAT0040290 pal-miR-10004-5p; +MIMAT0040291 pal-miR-10004-3p; +MIMAT0040292 pal-miR-10005-5p; +MIMAT0040293 pal-miR-10005-3p; +MIMAT0040294 pal-miR-9287-5p; +MIMAT0040295 pal-miR-9287-3p; +MIMAT0040296 pal-miR-10006-5p; +MIMAT0040297 pal-miR-10006-3p; +MIMAT0040298 pal-miR-433-5p; +MIMAT0040299 pal-miR-433-3p; +MIMAT0040300 pal-miR-33b-5p; +MIMAT0040301 pal-miR-33b-3p; +MIMAT0040302 pal-miR-182-5p; +MIMAT0040303 pal-miR-182-3p; +MIMAT0040304 pal-miR-10007-5p; +MIMAT0040305 pal-miR-10007-3p; +MIMAT0040306 pal-miR-874-5p; +MIMAT0040307 pal-miR-874-3p; +MIMAT0040308 pal-miR-10008-5p; +MIMAT0040309 pal-miR-10008-3p; +MIMAT0040310 pal-miR-8908d-5p; +MIMAT0040311 pal-miR-8908d-3p; +MIMAT0040312 pal-miR-10009-5p; +MIMAT0040313 pal-miR-10009-3p; +MIMAT0040314 pal-miR-219b-5p; +MIMAT0040315 pal-miR-219b-3p; +MIMAT0040316 pal-miR-1307-5p; +MIMAT0040317 pal-miR-1307-3p; +MIMAT0040318 pal-miR-10010-5p; +MIMAT0040319 pal-miR-10010-3p; +MIMAT0040320 pal-miR-10011-5p; +MIMAT0040321 pal-miR-10011-3p; +MIMAT0040322 pal-miR-324-5p; +MIMAT0040323 pal-miR-324-3p; +MIMAT0040324 pal-miR-10012-5p; +MIMAT0040325 pal-miR-10012-3p; +MIMAT0040326 pal-miR-153-2-5p; +MIMAT0040327 pal-miR-10013-5p; +MIMAT0040328 pal-miR-10013-3p; +MIMAT0040329 pal-miR-10014-5p; +MIMAT0040330 pal-miR-10014-3p; +MIMAT0040331 pal-miR-513-5p; +MIMAT0040332 pal-miR-513-3p; +MIMAT0040333 pal-miR-301b-5p; +MIMAT0040334 pal-miR-301b-3p; +MIMAT0040335 pal-miR-211-5p; +MIMAT0040336 pal-miR-211-3p; +MIMAT0040337 pal-miR-876-5p; +MIMAT0040338 pal-miR-876-3p; +MIMAT0040339 pal-miR-10015-5p; +MIMAT0040340 pal-miR-10015-3p; +MIMAT0040341 pal-miR-346-5p; +MIMAT0040342 pal-miR-346-3p; +MIMAT0040343 pal-miR-9298-5p; +MIMAT0040344 pal-miR-9298-3p; +MIMAT0040345 pal-miR-188-5p; +MIMAT0040346 pal-miR-188-3p; +MIMAT0040347 pal-miR-1296-5p; +MIMAT0040348 pal-miR-1296-3p; +MIMAT0040349 pal-miR-4657-5p; +MIMAT0040350 pal-miR-4657-3p; +MIMAT0040351 pal-miR-378d-5p; +MIMAT0040352 pal-miR-378d-3p; +MIMAT0040353 pal-miR-378e-5p; +MIMAT0040354 pal-miR-378e-3p; +MIMAT0040355 pal-miR-376a-5p; +MIMAT0040356 pal-miR-376a-3p; +MIMAT0040357 pal-miR-32-5p; +MIMAT0040358 pal-miR-32-3p; +MIMAT0040359 pal-miR-507-5p; +MIMAT0040360 pal-miR-507-3p; +MIMAT0040361 pal-miR-1249-5p; +MIMAT0040362 pal-miR-1249-3p; +MIMAT0040363 pal-miR-10016-5p; +MIMAT0040364 pal-miR-10016-3p; +MIMAT0040365 pal-miR-3085-5p; +MIMAT0040366 pal-miR-3085-3p; +MIMAT0040367 pal-miR-656-5p; +MIMAT0040368 pal-miR-656-3p; +MIMAT0040369 pal-miR-378c-5p; +MIMAT0040370 pal-miR-378c-3p; +MIMAT0040371 pal-miR-187-5p; +MIMAT0040372 pal-miR-187-3p; +MIMAT0040373 pal-miR-3059-5p; +MIMAT0040374 pal-miR-3059-3p; +MIMAT0040375 pal-miR-487a-5p; +MIMAT0040376 pal-miR-487a-3p; +MIMAT0040377 pal-miR-371-5p; +MIMAT0040378 pal-miR-371-3p; +MIMAT0040379 pal-miR-10017-5p; +MIMAT0040380 pal-miR-10017-3p; +MIMAT0040381 pal-miR-1306-5p; +MIMAT0040382 pal-miR-1306-3p; +MIMAT0040383 pal-miR-10018-5p; +MIMAT0040384 pal-miR-10018-3p; +MIMAT0040385 pal-miR-10017-2-5p; +MIMAT0040386 pal-miR-190b-5p; +MIMAT0040387 pal-miR-190b-3p; +MIMAT0040388 pal-miR-362-5p; +MIMAT0040389 pal-miR-362-3p; +MIMAT0040390 pal-miR-10019-5p; +MIMAT0040391 pal-miR-10019-3p; +MIMAT0040392 pal-miR-339b-5p; +MIMAT0040393 pal-miR-339b-3p; +MIMAT0040394 pal-miR-1911-5p; +MIMAT0040395 pal-miR-1911-3p; +MIMAT0040396 pal-miR-1839-5p; +MIMAT0040397 pal-miR-1839-3p; +MIMAT0040398 pal-miR-107b-5p; +MIMAT0040399 pal-miR-107b-3p; +MIMAT0040400 pal-miR-18b-5p; +MIMAT0040401 pal-miR-18b-3p; +MIMAT0040402 pal-miR-422c-5p; +MIMAT0040403 pal-miR-422c-3p; +MIMAT0040404 pal-miR-3064-5p; +MIMAT0040405 pal-miR-3064-3p; +MIMAT0040406 pal-miR-449c-5p; +MIMAT0040407 pal-miR-449c-3p; +MIMAT0040408 pal-miR-299b-5p; +MIMAT0040409 pal-miR-299b-3p; +MIMAT0040410 pal-miR-599-5p; +MIMAT0040411 pal-miR-599-3p; +MIMAT0040412 pal-miR-377-5p; +MIMAT0040413 pal-miR-377-3p; +MIMAT0040414 pal-miR-484-5p; +MIMAT0040415 pal-miR-484-3p; +MIMAT0040416 pal-miR-668-5p; +MIMAT0040417 pal-miR-668-3p; +MIMAT0040418 pal-miR-664a-2-5p; +MIMAT0040419 bta-miR-10020; +MIMAT0040420 hpo-miR-100-5p; +MIMAT0040421 hpo-miR-100-3p; +MIMAT0040422 hpo-miR-71-5p; +MIMAT0040423 hpo-miR-71-3p; +MIMAT0040424 hpo-miR-10021-5p; +MIMAT0040425 hpo-miR-10021-3p; +MIMAT0040426 hpo-miR-5885a-5p; +MIMAT0040427 hpo-miR-5885a-3p; +MIMAT0040428 hpo-miR-81-5p; +MIMAT0040429 hpo-miR-81-3p; +MIMAT0040430 hpo-miR-54a-5p; +MIMAT0040431 hpo-miR-54a-3p; +MIMAT0040432 hpo-miR-5899a-5p; +MIMAT0040433 hpo-miR-5899a-3p; +MIMAT0040434 hpo-miR-83-5p; +MIMAT0040435 hpo-miR-83-3p; +MIMAT0040436 hpo-miR-60a-5p; +MIMAT0040437 hpo-miR-60a-3p; +MIMAT0040438 hpo-miR-5885b-5p; +MIMAT0040439 hpo-miR-5885b-3p; +MIMAT0040440 hpo-miR-5885c-5p; +MIMAT0040441 hpo-miR-5885c-3p; +MIMAT0040442 hpo-let-7-5p; +MIMAT0040443 hpo-let-7-3p; +MIMAT0040444 hpo-miR-10022-5p; +MIMAT0040445 hpo-miR-10022-3p; +MIMAT0040446 hpo-miR-79-5p; +MIMAT0040447 hpo-miR-79-3p; +MIMAT0040448 hpo-miR-10023-5p; +MIMAT0040449 hpo-miR-10023-3p; +MIMAT0040450 hpo-miR-55-5p; +MIMAT0040451 hpo-miR-55-3p; +MIMAT0040452 hpo-miR-233-5p; +MIMAT0040453 hpo-miR-233-3p; +MIMAT0040454 hpo-miR-84a-5p; +MIMAT0040455 hpo-miR-84a-3p; +MIMAT0040456 hpo-miR-5908-5p; +MIMAT0040457 hpo-miR-5908-3p; +MIMAT0040458 hpo-miR-228-5p; +MIMAT0040459 hpo-miR-228-3p; +MIMAT0040460 hpo-miR-5899b-5p; +MIMAT0040461 hpo-miR-5899b-3p; +MIMAT0040462 hpo-lin-4-5p; +MIMAT0040463 hpo-lin-4-3p; +MIMAT0040464 hpo-miR-1-5p; +MIMAT0040465 hpo-miR-1-3p; +MIMAT0040466 hpo-miR-240-5p; +MIMAT0040467 hpo-miR-240-3p; +MIMAT0040468 hpo-miR-54b-5p; +MIMAT0040469 hpo-miR-54b-3p; +MIMAT0040470 hpo-miR-259-5p; +MIMAT0040471 hpo-miR-259-3p; +MIMAT0040472 hpo-miR-63a-5p; +MIMAT0040473 hpo-miR-63a-3p; +MIMAT0040474 hpo-miR-63b-5p; +MIMAT0040475 hpo-miR-63b-3p; +MIMAT0040476 hpo-miR-9-5p; +MIMAT0040477 hpo-miR-9-3p; +MIMAT0040478 hpo-miR-87b-5p; +MIMAT0040479 hpo-miR-87b-3p; +MIMAT0040480 hpo-miR-34-5p; +MIMAT0040481 hpo-miR-34-3p; +MIMAT0040482 hpo-miR-87a-5p; +MIMAT0040483 hpo-miR-87a-3p; +MIMAT0040484 hpo-miR-236-5p; +MIMAT0040485 hpo-miR-236-3p; +MIMAT0040486 hpo-miR-993-5p; +MIMAT0040487 hpo-miR-993-3p; +MIMAT0040488 hpo-miR-250-5p; +MIMAT0040489 hpo-miR-250-3p; +MIMAT0040490 hpo-miR-59-5p; +MIMAT0040491 hpo-miR-59-3p; +MIMAT0040492 hpo-miR-86-5p; +MIMAT0040493 hpo-miR-86-3p; +MIMAT0040494 hpo-miR-10024-5p; +MIMAT0040495 hpo-miR-10024-3p; +MIMAT0040496 hpo-miR-10025-5p; +MIMAT0040497 hpo-miR-10025-3p; +MIMAT0040498 hpo-miR-50-5p; +MIMAT0040499 hpo-miR-50-3p; +MIMAT0040500 hpo-miR-61a-5p; +MIMAT0040501 hpo-miR-61a-3p; +MIMAT0040502 hpo-miR-43a-5p; +MIMAT0040503 hpo-miR-43a-3p; +MIMAT0040504 hpo-miR-5884-5p; +MIMAT0040505 hpo-miR-5884-3p; +MIMAT0040506 hpo-miR-45-5p; +MIMAT0040507 hpo-miR-45-3p; +MIMAT0040508 hpo-miR-60b-5p; +MIMAT0040509 hpo-miR-60b-3p; +MIMAT0040510 hpo-miR-5895-5p; +MIMAT0040511 hpo-miR-5895-3p; +MIMAT0040512 hpo-miR-750-5p; +MIMAT0040513 hpo-miR-750-3p; +MIMAT0040514 hpo-miR-61b-5p; +MIMAT0040515 hpo-miR-61b-3p; +MIMAT0040516 hpo-miR-235-5p; +MIMAT0040517 hpo-miR-235-3p; +MIMAT0040518 hpo-miR-307-5p; +MIMAT0040519 hpo-miR-307-3p; +MIMAT0040520 hpo-miR-232a-5p; +MIMAT0040521 hpo-miR-232a-3p; +MIMAT0040522 hpo-miR-2-5p; +MIMAT0040523 hpo-miR-2-3p; +MIMAT0040524 hpo-miR-252-5p; +MIMAT0040525 hpo-miR-252-3p; +MIMAT0040526 hpo-miR-5976-5p; +MIMAT0040527 hpo-miR-5976-3p; +MIMAT0040528 hpo-miR-5896-5p; +MIMAT0040529 hpo-miR-5896-3p; +MIMAT0040530 hpo-miR-232b-5p; +MIMAT0040531 hpo-miR-232b-3p; +MIMAT0040532 hpo-miR-234-5p; +MIMAT0040533 hpo-miR-234-3p; +MIMAT0040534 hpo-miR-5948-5p; +MIMAT0040535 hpo-miR-5948-3p; +MIMAT0040536 hpo-miR-10026-5p; +MIMAT0040537 hpo-miR-10026-3p; +MIMAT0040538 hpo-miR-46-5p; +MIMAT0040539 hpo-miR-46-3p; +MIMAT0040540 hpo-miR-1175-5p; +MIMAT0040541 hpo-miR-1175-3p; +MIMAT0040542 hpo-miR-10027-5p; +MIMAT0040543 hpo-miR-10027-3p; +MIMAT0040544 hpo-miR-124-5p; +MIMAT0040545 hpo-miR-124-3p; +MIMAT0040546 hpo-miR-277-5p; +MIMAT0040547 hpo-miR-277-3p; +MIMAT0040548 hpo-miR-36a-5p; +MIMAT0040549 hpo-miR-36a-3p; +MIMAT0040550 hpo-miR-72-5p; +MIMAT0040551 hpo-miR-72-3p; +MIMAT0040552 hpo-miR-5352-5p; +MIMAT0040553 hpo-miR-5352-3p; +MIMAT0040554 hpo-miR-10028-5p; +MIMAT0040555 hpo-miR-10028-3p; +MIMAT0040556 hpo-miR-790-5p; +MIMAT0040557 hpo-miR-790-3p; +MIMAT0040558 hpo-miR-10029-5p; +MIMAT0040559 hpo-miR-10029-3p; +MIMAT0040560 hpo-miR-5983-5p; +MIMAT0040561 hpo-miR-5983-3p; +MIMAT0040562 hpo-miR-37-5p; +MIMAT0040563 hpo-miR-37-3p; +MIMAT0040564 hpo-miR-5906-5p; +MIMAT0040565 hpo-miR-5906-3p; +MIMAT0040566 hpo-miR-7-5p; +MIMAT0040567 hpo-miR-7-3p; +MIMAT0040568 hpo-miR-43b-5p; +MIMAT0040569 hpo-miR-43b-3p; +MIMAT0040570 hpo-miR-10030-5p; +MIMAT0040571 hpo-miR-10030-3p; +MIMAT0040572 hpo-miR-40a-5p; +MIMAT0040573 hpo-miR-40a-3p; +MIMAT0040574 hpo-miR-40b-5p; +MIMAT0040575 hpo-miR-40b-3p; +MIMAT0040576 hpo-miR-10031b-5p; +MIMAT0040577 hpo-miR-10031b-3p; +MIMAT0040578 hpo-miR-10032-5p; +MIMAT0040579 hpo-miR-10032-3p; +MIMAT0040580 hpo-miR-76-5p; +MIMAT0040581 hpo-miR-76-3p; +MIMAT0040582 hpo-miR-10033-5p; +MIMAT0040583 hpo-miR-10033-3p; +MIMAT0040584 hpo-miR-10034-5p; +MIMAT0040585 hpo-miR-10034-3p; +MIMAT0040587 hpo-miR-10035-5p; +MIMAT0040588 hpo-miR-10035-3p; +MIMAT0040589 hpo-miR-40c-5p; +MIMAT0040590 hpo-miR-40c-3p; +MIMAT0040591 hpo-miR-10036-5p; +MIMAT0040592 hpo-miR-10036-3p; +MIMAT0040593 hpo-miR-10036-2-5p; +MIMAT0040594 hpo-miR-10037-5p; +MIMAT0040595 hpo-miR-10037-3p; +MIMAT0040596 hpo-miR-10038-5p; +MIMAT0040597 hpo-miR-10038-3p; +MIMAT0040598 hpo-miR-40d-5p; +MIMAT0040599 hpo-miR-40d-3p; +MIMAT0040600 hpo-miR-10039-5p; +MIMAT0040601 hpo-miR-10039-3p; +MIMAT0040602 hpo-miR-10040-5p; +MIMAT0040603 hpo-miR-10040-3p; +MIMAT0040604 hpo-miR-10041-5p; +MIMAT0040605 hpo-miR-10041-3p; +MIMAT0040606 hpo-miR-10042-5p; +MIMAT0040607 hpo-miR-10042-3p; +MIMAT0040608 hpo-miR-10043a-5p; +MIMAT0040609 hpo-miR-10043a-3p; +MIMAT0040610 hpo-miR-10044-5p; +MIMAT0040611 hpo-miR-10044-3p; +MIMAT0040612 hpo-miR-10045-5p; +MIMAT0040613 hpo-miR-10045-3p; +MIMAT0040614 hpo-miR-10046-5p; +MIMAT0040615 hpo-miR-10046-3p; +MIMAT0040616 hpo-miR-10134-2-5p; +MIMAT0040617 hpo-miR-10134-3p; +MIMAT0040618 hpo-miR-10047-5p; +MIMAT0040619 hpo-miR-10047-3p; +MIMAT0040620 hpo-miR-10048-5p; +MIMAT0040621 hpo-miR-10048-3p; +MIMAT0040622 hpo-miR-40e-5p; +MIMAT0040623 hpo-miR-40e-3p; +MIMAT0040624 hpo-miR-10049-5p; +MIMAT0040625 hpo-miR-10049-3p; +MIMAT0040626 hpo-miR-10050-5p; +MIMAT0040627 hpo-miR-10050-3p; +MIMAT0040628 hpo-miR-10051-5p; +MIMAT0040629 hpo-miR-10051-3p; +MIMAT0040630 hpo-miR-10031a-2-5p; +MIMAT0040632 hpo-miR-10052-5p; +MIMAT0040633 hpo-miR-10052-3p; +MIMAT0040634 hpo-miR-10053-5p; +MIMAT0040635 hpo-miR-10053-3p; +MIMAT0040636 hpo-miR-10063a-5p; +MIMAT0040637 hpo-miR-10063a-3p; +MIMAT0040638 hpo-miR-10054-5p; +MIMAT0040639 hpo-miR-10054-3p; +MIMAT0040640 hpo-miR-5932-5p; +MIMAT0040641 hpo-miR-5932-3p; +MIMAT0040642 hpo-miR-10055-5p; +MIMAT0040643 hpo-miR-10055-3p; +MIMAT0040644 hpo-miR-5897-5p; +MIMAT0040645 hpo-miR-5897-3p; +MIMAT0040646 hpo-miR-10056-5p; +MIMAT0040647 hpo-miR-10056-3p; +MIMAT0040648 hpo-miR-10057-5p; +MIMAT0040649 hpo-miR-10057-3p; +MIMAT0040650 hpo-miR-10065b-5p; +MIMAT0040651 hpo-miR-10065b-2-3p; +MIMAT0040652 hpo-miR-10072b-5p; +MIMAT0040653 hpo-miR-10072b-3p; +MIMAT0040654 hpo-miR-10058-5p; +MIMAT0040655 hpo-miR-10058-3p; +MIMAT0040656 hpo-miR-10059-5p; +MIMAT0040657 hpo-miR-10059-3p; +MIMAT0040658 hpo-miR-10043b-5p; +MIMAT0040659 hpo-miR-10043b-3p; +MIMAT0040660 hpo-miR-10060-5p; +MIMAT0040661 hpo-miR-10060-3p; +MIMAT0040662 hpo-miR-10061-5p; +MIMAT0040663 hpo-miR-10061-3p; +MIMAT0040664 hpo-miR-10031c-5p; +MIMAT0040665 hpo-miR-10031c-3p; +MIMAT0040666 hpo-miR-10062-5p; +MIMAT0040667 hpo-miR-10062-3p; +MIMAT0040668 hpo-miR-40f-5p; +MIMAT0040669 hpo-miR-40f-3p; +MIMAT0040670 hpo-miR-1822-5p; +MIMAT0040671 hpo-miR-1822-3p; +MIMAT0040672 hpo-miR-10031a-5p; +MIMAT0040673 hpo-miR-10031a-3p; +MIMAT0040674 hpo-miR-10063b-5p; +MIMAT0040675 hpo-miR-10063b-3p; +MIMAT0040676 hpo-miR-10064-5p; +MIMAT0040677 hpo-miR-10064-3p; +MIMAT0040678 hpo-miR-10065a-5p; +MIMAT0040679 hpo-miR-10065a-3p; +MIMAT0040680 hpo-miR-10065b-3p; +MIMAT0040681 hpo-miR-10066-5p; +MIMAT0040682 hpo-miR-10066-3p; +MIMAT0040683 hpo-miR-10067-5p; +MIMAT0040684 hpo-miR-10067-3p; +MIMAT0040685 hpo-miR-10068-5p; +MIMAT0040686 hpo-miR-10068-3p; +MIMAT0040687 hpo-miR-10069-5p; +MIMAT0040688 hpo-miR-10069-3p; +MIMAT0040689 hpo-miR-10031d-5p; +MIMAT0040690 hpo-miR-10031d-3p; +MIMAT0040691 hpo-miR-10043c-5p; +MIMAT0040692 hpo-miR-10043c-3p; +MIMAT0040693 hpo-miR-10070-5p; +MIMAT0040694 hpo-miR-10070-3p; +MIMAT0040695 hpo-miR-10071-5p; +MIMAT0040696 hpo-miR-10071-3p; +MIMAT0040697 hpo-miR-10072a-5p; +MIMAT0040698 hpo-miR-10072a-3p; +MIMAT0040699 hpo-miR-10073-5p; +MIMAT0040700 hpo-miR-10073-3p; +MIMAT0040701 hpo-miR-10043d-5p; +MIMAT0040702 hpo-miR-10043d-3p; +MIMAT0040703 hpo-miR-10074-5p; +MIMAT0040704 hpo-miR-10074-3p; +MIMAT0040705 hpo-miR-10075a-5p; +MIMAT0040706 hpo-miR-10075a-3p; +MIMAT0040707 hpo-miR-10098a-5p; +MIMAT0040708 hpo-miR-10098a-3p; +MIMAT0040709 hpo-miR-10076-5p; +MIMAT0040710 hpo-miR-10076-3p; +MIMAT0040711 hpo-miR-10077-5p; +MIMAT0040712 hpo-miR-10077-3p; +MIMAT0040713 hpo-miR-36b-5p; +MIMAT0040714 hpo-miR-36b-3p; +MIMAT0040715 hpo-miR-10078-5p; +MIMAT0040716 hpo-miR-10078-3p; +MIMAT0040717 hpo-miR-10079-5p; +MIMAT0040718 hpo-miR-10079-3p; +MIMAT0040719 hpo-miR-10080-5p; +MIMAT0040720 hpo-miR-10080-3p; +MIMAT0040721 hpo-miR-10081-5p; +MIMAT0040722 hpo-miR-10081-3p; +MIMAT0040723 hpo-miR-10137a-5p; +MIMAT0040724 hpo-miR-10137a-3p; +MIMAT0040725 hpo-miR-10082-5p; +MIMAT0040726 hpo-miR-10082-3p; +MIMAT0040727 hpo-miR-10075b-5p; +MIMAT0040728 hpo-miR-10075b-3p; +MIMAT0040729 hpo-miR-10083-??; +MIMAT0040730 hpo-miR-10083-3p; +MIMAT0040731 hpo-miR-10084-5p; +MIMAT0040732 hpo-miR-10084-3p; +MIMAT0040733 hpo-miR-10085-5p; +MIMAT0040734 hpo-miR-10085-3p; +MIMAT0040735 hpo-miR-10086-5p; +MIMAT0040736 hpo-miR-10086-3p; +MIMAT0040737 hpo-miR-10087-5p; +MIMAT0040738 hpo-miR-10087-3p; +MIMAT0040739 hpo-miR-10088-5p; +MIMAT0040740 hpo-miR-10088-3p; +MIMAT0040741 hpo-miR-10089-5p; +MIMAT0040742 hpo-miR-10089-3p; +MIMAT0040743 hpo-miR-10090-5p; +MIMAT0040744 hpo-miR-10090-3p; +MIMAT0040745 hpo-miR-10091-5p; +MIMAT0040746 hpo-miR-10091-3p; +MIMAT0040747 hpo-miR-5898-5p; +MIMAT0040748 hpo-miR-5898-3p; +MIMAT0040749 hpo-miR-10092-5p; +MIMAT0040750 hpo-miR-10092-3p; +MIMAT0040751 hpo-miR-255-5p; +MIMAT0040752 hpo-miR-255-3p; +MIMAT0040753 hpo-miR-40g-5p; +MIMAT0040754 hpo-miR-40g-3p; +MIMAT0040755 hpo-miR-10156a-5p; +MIMAT0040756 hpo-miR-10156a-3p; +MIMAT0040757 hpo-miR-10093-5p; +MIMAT0040758 hpo-miR-10093-3p; +MIMAT0040759 hpo-miR-10094-5p; +MIMAT0040760 hpo-miR-10094-3p; +MIMAT0040761 hpo-miR-10095-5p; +MIMAT0040762 hpo-miR-10095-3p; +MIMAT0040763 hpo-miR-40h-5p; +MIMAT0040764 hpo-miR-40h-3p; +MIMAT0040765 hpo-miR-10096-5p; +MIMAT0040766 hpo-miR-10096-3p; +MIMAT0040767 hpo-miR-10097-5p; +MIMAT0040768 hpo-miR-10097-3p; +MIMAT0040769 hpo-miR-10098b-5p; +MIMAT0040770 hpo-miR-10098b-3p; +MIMAT0040771 hpo-miR-10099-5p; +MIMAT0040772 hpo-miR-10099-3p; +MIMAT0040773 hpo-miR-10100-5p; +MIMAT0040774 hpo-miR-10100-3p; +MIMAT0040775 hpo-miR-10101-5p; +MIMAT0040776 hpo-miR-10101-3p; +MIMAT0040777 hpo-miR-10102-5p; +MIMAT0040778 hpo-miR-10102-3p; +MIMAT0040779 hpo-miR-5902-5p; +MIMAT0040780 hpo-miR-5902-3p; +MIMAT0040781 hpo-miR-10103-5p; +MIMAT0040782 hpo-miR-10103-3p; +MIMAT0040783 hpo-miR-10043e-5p; +MIMAT0040784 hpo-miR-10043e-3p; +MIMAT0040785 hpo-miR-10104-5p; +MIMAT0040786 hpo-miR-10104-3p; +MIMAT0040787 hpo-miR-5915-5p; +MIMAT0040788 hpo-miR-5915-3p; +MIMAT0040789 hpo-miR-10105-5p; +MIMAT0040790 hpo-miR-10105-3p; +MIMAT0040791 hpo-miR-10106-5p; +MIMAT0040792 hpo-miR-10106-3p; +MIMAT0040793 hpo-miR-10107-5p; +MIMAT0040794 hpo-miR-10107-3p; +MIMAT0040795 hpo-miR-10108-5p; +MIMAT0040796 hpo-miR-10108-3p; +MIMAT0040797 hpo-miR-10109-5p; +MIMAT0040798 hpo-miR-10109-3p; +MIMAT0040799 hpo-miR-10110-5p; +MIMAT0040800 hpo-miR-10110-3p; +MIMAT0040801 hpo-miR-10111-5p; +MIMAT0040802 hpo-miR-10111-3p; +MIMAT0040803 hpo-miR-10112-5p; +MIMAT0040804 hpo-miR-10112-3p; +MIMAT0040805 hpo-miR-10113-5p; +MIMAT0040806 hpo-miR-10113-3p; +MIMAT0040807 hpo-miR-10114-5p; +MIMAT0040808 hpo-miR-10114-3p; +MIMAT0040809 hpo-miR-10115-5p; +MIMAT0040810 hpo-miR-10115-3p; +MIMAT0040811 hpo-miR-10116-5p; +MIMAT0040812 hpo-miR-10116-3p; +MIMAT0040813 hpo-miR-10117-5p; +MIMAT0040814 hpo-miR-10117-3p; +MIMAT0040815 hpo-miR-10118-5p; +MIMAT0040816 hpo-miR-10118-3p; +MIMAT0040817 hpo-miR-10119-5p; +MIMAT0040818 hpo-miR-10119-3p; +MIMAT0040819 hpo-miR-10120-5p; +MIMAT0040820 hpo-miR-10120-3p; +MIMAT0040821 hpo-miR-10121-5p; +MIMAT0040822 hpo-miR-10121-3p; +MIMAT0040823 hpo-miR-10122-5p; +MIMAT0040824 hpo-miR-10122-3p; +MIMAT0040825 hpo-miR-10123-5p; +MIMAT0040826 hpo-miR-10123-3p; +MIMAT0040827 hpo-miR-10124-5p; +MIMAT0040828 hpo-miR-10124-3p; +MIMAT0040829 hpo-miR-10125-5p; +MIMAT0040830 hpo-miR-10125-3p; +MIMAT0040831 hpo-miR-10126-5p; +MIMAT0040832 hpo-miR-10126-3p; +MIMAT0040833 hpo-miR-10127-5p; +MIMAT0040834 hpo-miR-10127-3p; +MIMAT0040835 hpo-miR-10128-5p; +MIMAT0040836 hpo-miR-10128-3p; +MIMAT0040837 hpo-miR-10129-5p; +MIMAT0040838 hpo-miR-10129-3p; +MIMAT0040839 hpo-miR-10130-5p; +MIMAT0040840 hpo-miR-10130-3p; +MIMAT0040841 hpo-miR-10131-5p; +MIMAT0040842 hpo-miR-10131-3p; +MIMAT0040843 hpo-miR-10132-5p; +MIMAT0040844 hpo-miR-10132-3p; +MIMAT0040845 hpo-miR-10133-5p; +MIMAT0040846 hpo-miR-10133-3p; +MIMAT0040847 hpo-miR-10134-5p; +MIMAT0040848 hpo-miR-10135-5p; +MIMAT0040849 hpo-miR-10135-3p; +MIMAT0040850 hpo-miR-10136-5p; +MIMAT0040851 hpo-miR-10136-3p; +MIMAT0040852 hpo-miR-10137b-5p; +MIMAT0040853 hpo-miR-10137b-3p; +MIMAT0040854 hpo-miR-10138-5p; +MIMAT0040855 hpo-miR-10138-3p; +MIMAT0040856 hpo-miR-10031e-5p; +MIMAT0040857 hpo-miR-10031e-3p; +MIMAT0040858 hpo-miR-10139-5p; +MIMAT0040859 hpo-miR-10139-3p; +MIMAT0040860 hpo-miR-10140-5p; +MIMAT0040861 hpo-miR-10140-3p; +MIMAT0040862 hpo-miR-10141-5p; +MIMAT0040863 hpo-miR-10141-3p; +MIMAT0040864 hpo-miR-10142-5p; +MIMAT0040865 hpo-miR-10142-3p; +MIMAT0040866 hpo-miR-10143-5p; +MIMAT0040867 hpo-miR-10143-3p; +MIMAT0040868 hpo-miR-10144-??; +MIMAT0040869 hpo-miR-10144-3p; +MIMAT0040870 hpo-miR-10145-5p; +MIMAT0040871 hpo-miR-10145-3p; +MIMAT0040872 hpo-miR-10146-5p; +MIMAT0040873 hpo-miR-10146-3p; +MIMAT0040874 hpo-miR-10157-5p; +MIMAT0040875 hpo-miR-10157-3p; +MIMAT0040876 hpo-miR-10147-5p; +MIMAT0040877 hpo-miR-10147-3p; +MIMAT0040878 hpo-miR-10148-5p; +MIMAT0040879 hpo-miR-10148-3p; +MIMAT0040880 hpo-miR-10149-5p; +MIMAT0040881 hpo-miR-10149-3p; +MIMAT0040882 hpo-miR-10150-5p; +MIMAT0040883 hpo-miR-10150-3p; +MIMAT0040884 hpo-miR-10151-5p; +MIMAT0040885 hpo-miR-10151-3p; +MIMAT0040886 hpo-miR-10152-5p; +MIMAT0040887 hpo-miR-10152-3p; +MIMAT0040888 hpo-miR-10153-5p; +MIMAT0040889 hpo-miR-10153-3p; +MIMAT0040890 hpo-miR-10154-5p; +MIMAT0040891 hpo-miR-10154-3p; +MIMAT0040892 hpo-miR-10043f-5p; +MIMAT0040893 hpo-miR-10043f-3p; +MIMAT0040894 hpo-miR-2709-5p; +MIMAT0040895 hpo-miR-2709-3p; +MIMAT0040896 hpo-miR-10155-5p; +MIMAT0040897 hpo-miR-10155-3p; +MIMAT0040898 hpo-miR-10156b-5p; +MIMAT0040899 hpo-miR-10156b-3p; +MIMAT0040900 hpo-miR-10158a-5p; +MIMAT0040901 hpo-miR-10158a-3p; +MIMAT0040902 hpo-miR-10158b-5p; +MIMAT0040903 hpo-miR-10158b-3p; +MIMAT0040904 hpo-miR-10159-5p; +MIMAT0040905 hpo-miR-10159-3p; +MIMAT0040906 hpo-miR-10160-5p; +MIMAT0040907 hpo-miR-10160-3p; +MIMAT0040908 bta-miR-10161-5p; +MIMAT0040909 bta-miR-10162-5p; +MIMAT0040910 bta-miR-10163-3p; +MIMAT0040911 bta-miR-10164-3p; +MIMAT0040912 bta-miR-10165-5p; +MIMAT0040913 bta-miR-10166-5p; +MIMAT0040914 bta-miR-10167-3p; +MIMAT0040915 bta-miR-507-3p; +MIMAT0040916 bta-miR-10168-5p; +MIMAT0040917 bta-miR-10169-3p; +MIMAT0040918 bta-miR-10170-5p; +MIMAT0040919 bta-miR-10171-3p; +MIMAT0040920 bta-miR-10172-5p; +MIMAT0040921 bta-miR-10172-3p; +MIMAT0040922 bta-miR-10173-5p; +MIMAT0040923 bta-miR-2285ag-3p; +MIMAT0040925 bta-miR-7857-3p; +MIMAT0040926 bta-miR-219b-3p; +MIMAT0040927 bta-miR-10174-5p; +MIMAT0040928 bta-miR-10174-3p; +MIMAT0040929 bta-miR-10175-5p; +MIMAT0040930 bta-miR-10175-3p; +MIMAT0040931 bta-miR-10176-5p; +MIMAT0040932 bta-miR-10177-5p; +MIMAT0040933 bta-miR-10178-5p; +MIMAT0040934 bta-miR-194b-3p; +MIMAT0040935 bta-miR-323b-3p; +MIMAT0040936 bta-miR-668-3p; +MIMAT0040937 bta-miR-10179-5p; +MIMAT0040938 bta-miR-10180-3p; +MIMAT0040939 bta-miR-10181-5p; +MIMAT0040940 bta-miR-10182-5p; +MIMAT0040941 bta-miR-10182-3p; +MIMAT0040942 bta-miR-10183-5p; +MIMAT0040943 bta-miR-10184-3p; +MIMAT0040944 bta-miR-10185-5p; +MIMAT0040945 bta-miR-2285ah-5p; +MIMAT0040946 bta-miR-2285ai-5p; +MIMAT0040947 bta-miR-2285aj-5p; +MIMAT0040948 bta-miR-2285ak-5p; +MIMAT0040949 bta-miR-2285al-5p; +MIMAT0040950 bta-miR-2285am-5p; +MIMAT0040951 gma-miR10186a; +MIMAT0040952 gma-miR10187; +MIMAT0040953 gma-miR10188; +MIMAT0040954 gma-miR10189; +MIMAT0040955 gma-miR10190; +MIMAT0040956 gma-miR10191; +MIMAT0040957 gma-miR5030b; +MIMAT0040958 gma-miR10192; +MIMAT0040959 gma-miR5770c; +MIMAT0040960 gma-miR10193a; +MIMAT0040961 gma-miR10194; +MIMAT0040962 gma-miR10195; +MIMAT0040963 gma-miR10196; +MIMAT0040964 gma-miR10197; +MIMAT0040965 gma-miR10198; +MIMAT0040966 gma-miR10199; +MIMAT0040967 gma-miR10200; +MIMAT0040968 gma-miR1446; +MIMAT0040969 gma-miR10201; +MIMAT0040970 gma-miR4392b; +MIMAT0040971 ttv-miR-T1-5p; +MIMAT0040972 ttv-miR-T1-3p; +MIMAT0040973 sfv-miR-S1-3p; +MIMAT0040974 sfv-miR-S2-5p; +MIMAT0040975 sfv-miR-S2-3p; +MIMAT0040976 sfv-miR-S3-5p; +MIMAT0040977 sfv-miR-S3-3p; +MIMAT0040978 sfv-miR-S4-5p; +MIMAT0040979 sfv-miR-S4-3p; +MIMAT0040980 sfv-miR-S5-5p; +MIMAT0040981 sfv-miR-S5-3p; +MIMAT0040982 sfv-miR-S6-5p; +MIMAT0040983 sfv-miR-S6-3p; +MIMAT0040984 sfv-miR-S7-5p; +MIMAT0040985 sfv-miR-S7-3p; +MIMAT0040986 vca-miR156a-5p; +MIMAT0040987 vca-miR156a-3p; +MIMAT0040988 vca-miR156b-5p; +MIMAT0040989 vca-miR156b-3p; +MIMAT0040990 vca-miR159-5p; +MIMAT0040991 vca-miR159-3p; +MIMAT0040992 vca-miR160-5p; +MIMAT0040993 vca-miR166a-5p; +MIMAT0040994 vca-miR166a-3p; +MIMAT0040995 vca-miR166b-5p; +MIMAT0040996 vca-miR166b-3p; +MIMAT0040997 vca-miR166c-5p; +MIMAT0040998 vca-miR166c-3p; +MIMAT0040999 vca-miR167a-5p; +MIMAT0041000 vca-miR167a-3p; +MIMAT0041001 vca-miR167b-5p; +MIMAT0041002 vca-miR167b-3p; +MIMAT0041003 vca-miR168a-5p; +MIMAT0041004 vca-miR168a-3p; +MIMAT0041005 vca-miR168b-5p; +MIMAT0041006 vca-miR168b-3p; +MIMAT0041007 vca-miR172a-5p; +MIMAT0041008 vca-miR172a-3p; +MIMAT0041009 vca-miR172b-5p; +MIMAT0041010 vca-miR172b-3p; +MIMAT0041011 vca-miR393-5p; +MIMAT0041012 vca-miR393-3p; +MIMAT0041013 vca-miR396-5p; +MIMAT0041014 vca-miR396-3p; +MIMAT0041015 vca-miR397-5p; +MIMAT0041016 vca-miR397-3p; +MIMAT0041017 vca-miR408-5p; +MIMAT0041018 vca-miR408-3p; +MIMAT0041019 vca-miR528-5p; +MIMAT0041020 vca-miR528-3p; +MIMAT0041021 vca-miR535-5p; +MIMAT0041022 vca-miR535-3p; +MIMAT0041023 vca-miR10202a-5p; +MIMAT0041024 vca-miR10202a-3p; +MIMAT0041025 vca-miR10202b-5p; +MIMAT0041026 vca-miR10202b-3p; +MIMAT0041027 vca-miR10203-5p; +MIMAT0041028 vca-miR10203-3p; +MIMAT0041029 vca-miR10204-5p; +MIMAT0041030 vca-miR10204-3p; +MIMAT0041031 vca-miR10205-5p; +MIMAT0041032 vca-miR10205-3p; +MIMAT0041033 vca-miR10206a-5p; +MIMAT0041034 vca-miR10206a-3p; +MIMAT0041035 vca-miR10206b-5p; +MIMAT0041036 vca-miR10206b-3p; +MIMAT0041037 vca-miR10207-5p; +MIMAT0041038 vca-miR10207-3p; +MIMAT0041039 vca-miR10208-3p; +MIMAT0041040 vca-miR10208-5p; +MIMAT0041041 vca-miR10209-5p; +MIMAT0041042 vca-miR10209-3p; +MIMAT0041043 vca-miR391-5p; +MIMAT0041044 vca-miR391-3p; +MIMAT0041045 vca-miR10210-5p; +MIMAT0041046 vca-miR10210-3p; +MIMAT0041047 vca-miR396b-5p; +MIMAT0041048 vca-miR396b-3p; +MIMAT0041049 vca-miR1432-5p; +MIMAT0041050 vca-miR1432-3p; +MIMAT0041051 eun-miR159-5p; +MIMAT0041052 eun-miR159-3p; +MIMAT0041053 eun-miR160-5p; +MIMAT0041054 eun-miR160-3p; +MIMAT0041055 eun-miR162-5p; +MIMAT0041056 eun-miR162-3p; +MIMAT0041057 eun-miR166-5p; +MIMAT0041058 eun-miR166-3p; +MIMAT0041059 eun-miR167a-5p; +MIMAT0041060 eun-miR167a-3p; +MIMAT0041061 eun-miR167b-5p; +MIMAT0041062 eun-miR167b-3p; +MIMAT0041063 eun-miR167c-5p; +MIMAT0041064 eun-miR167c-3p; +MIMAT0041065 eun-miR167d-5p; +MIMAT0041066 eun-miR172a-5p; +MIMAT0041067 eun-miR172a-3p; +MIMAT0041068 eun-miR172b-5p; +MIMAT0041069 eun-miR172b-3p; +MIMAT0041070 eun-miR172c-5p; +MIMAT0041071 eun-miR172c-3p; +MIMAT0041072 eun-miR395-5p; +MIMAT0041073 eun-miR395-3p; +MIMAT0041074 eun-miR396a-5p; +MIMAT0041075 eun-miR396a-3p; +MIMAT0041076 eun-miR396b-5p; +MIMAT0041077 eun-miR396b-3p; +MIMAT0041078 eun-miR397a-5p; +MIMAT0041079 eun-miR397a-3p; +MIMAT0041080 eun-miR397b-5p; +MIMAT0041081 eun-miR397b-3p; +MIMAT0041082 eun-miR482a-5p; +MIMAT0041083 eun-miR482a-3p; +MIMAT0041084 eun-miR482b-5p; +MIMAT0041085 eun-miR482b-3p; +MIMAT0041086 eun-miR482c-5p; +MIMAT0041087 eun-miR482c-3p; +MIMAT0041088 eun-miR530-5p; +MIMAT0041089 eun-miR530-3p; +MIMAT0041090 eun-miR535a-5p; +MIMAT0041091 eun-miR535a-3p; +MIMAT0041092 eun-miR535b-5p; +MIMAT0041093 eun-miR535b-3p; +MIMAT0041094 eun-miR827-5p; +MIMAT0041095 eun-miR827-3p; +MIMAT0041096 eun-miR10211a-5p; +MIMAT0041097 eun-miR10211a-3p; +MIMAT0041098 eun-miR10211b-5p; +MIMAT0041099 eun-miR10211b-3p; +MIMAT0041100 eun-miR10212-5p; +MIMAT0041101 eun-miR10212-3p; +MIMAT0041102 eun-miR10213-5p; +MIMAT0041103 eun-miR10213-3p; +MIMAT0041104 eun-miR10214a-5p; +MIMAT0041105 eun-miR10214a-3p; +MIMAT0041106 eun-miR10214b-3p; +MIMAT0041107 eun-miR10215-3p; +MIMAT0041108 eun-miR10216-5p; +MIMAT0041109 eun-miR10216-3p; +MIMAT0041110 eun-miR10217-5p; +MIMAT0041111 eun-miR10217-3p; +MIMAT0041112 eun-miR10218-5p; +MIMAT0041113 eun-miR10218-3p; +MIMAT0041114 eun-miR10219-5p; +MIMAT0041115 eun-miR10219-3p; +MIMAT0041116 eun-miR10220-5p; +MIMAT0041117 eun-miR10220-3p; +MIMAT0041118 eun-miR10221-5p; +MIMAT0041119 eun-miR10221-3p; +MIMAT0041120 eun-miR10222-5p; +MIMAT0041121 eun-miR10222-3p; +MIMAT0041122 eun-miR10223-5p; +MIMAT0041123 eun-miR10223-3p; +MIMAT0041124 eun-miR10224-3p; +MIMAT0041125 prv-miR-LLT12; +MIMAT0041126 bta-miR-10225a; +MIMAT0041127 bta-miR-10225b; +MIMAT0041128 hsa-miR-10226; +MIMAT0041129 cgr-miR-200a; +MIMAT0041130 cgr-let-7a-2; +MIMAT0041131 cgr-let-7c-2; +MIMAT0041132 cgr-let-7e; +MIMAT0041133 cgr-miR-148a; +MIMAT0041134 cgr-miR-194-2; +MIMAT0041135 cgr-miR-217; +MIMAT0041136 cgr-miR-219b; +MIMAT0041137 cgr-miR-26a; +MIMAT0041138 cgr-miR-301b; +MIMAT0041139 cgr-miR-3154; +MIMAT0041140 cgr-miR-449a; +MIMAT0041141 cgr-miR-451a; +MIMAT0041142 cgr-miR-574; +MIMAT0041143 cgr-miR-125b; +MIMAT0041144 cgr-miR-29b; +MIMAT0041145 cgr-miR-101a; +MIMAT0041146 cgr-miR-1224; +MIMAT0041147 cgr-miR-1249; +MIMAT0041148 cgr-miR-126b; +MIMAT0041149 cgr-miR-127; +MIMAT0041150 cgr-miR-150; +MIMAT0041151 cgr-miR-16; +MIMAT0041152 cgr-miR-193a; +MIMAT0041153 cgr-miR-199a; +MIMAT0041154 cgr-miR-1b; +MIMAT0041155 cgr-miR-202; +MIMAT0041156 cgr-miR-211; +MIMAT0041157 cgr-miR-216b; +MIMAT0041158 cgr-miR-24; +MIMAT0041159 cgr-miR-3068; +MIMAT0041160 cgr-miR-3074; +MIMAT0041161 cgr-miR-30c; +MIMAT0041162 cgr-miR-3102; +MIMAT0041163 cgr-miR-3535; +MIMAT0041164 cgr-miR-365; +MIMAT0041165 cgr-miR-497b; +MIMAT0041166 cgr-miR-760; +MIMAT0041167 cgr-miR-99b; +MIMAT0041168 cgr-miR-128; +MIMAT0041169 cgr-miR-330; +MIMAT0041170 cgr-miR-802; +MIMAT0041171 cgr-miR-18b; +MIMAT0041172 cgr-miR-20b; +MIMAT0041173 egr-bantam-5p; +MIMAT0041174 egr-bantam-3p; +MIMAT0041175 egr-miR-61-5p; +MIMAT0041176 egr-miR-61-3p; +MIMAT0041177 egr-miR-31-5p; +MIMAT0041178 egr-miR-31-3p; +MIMAT0041179 egr-miR-10227a-5p; +MIMAT0041180 egr-miR-10227a-3p; +MIMAT0041181 egr-miR-2162-5p; +MIMAT0041182 egr-miR-2162-3p; +MIMAT0041183 egr-miR-3479a-5p; +MIMAT0041184 egr-miR-3479a-3p; +MIMAT0041185 egr-miR-10228-5p; +MIMAT0041186 egr-miR-10228-3p; +MIMAT0041187 egr-miR-281-5p; +MIMAT0041188 egr-miR-281-3p; +MIMAT0041189 egr-miR-10229a-5p; +MIMAT0041190 egr-miR-10229a-3p; +MIMAT0041191 egr-miR-36a-5p; +MIMAT0041192 egr-miR-36a-3p; +MIMAT0041193 egr-miR-10227b-5p; +MIMAT0041194 egr-miR-10227b-3p; +MIMAT0041195 egr-miR-133-5p; +MIMAT0041196 egr-miR-133-3p; +MIMAT0041197 egr-miR-1992-5p; +MIMAT0041198 egr-miR-1992-3p; +MIMAT0041199 egr-miR-10229b-5p; +MIMAT0041200 egr-miR-10229b-3p; +MIMAT0041201 egr-miR-10227c-5p; +MIMAT0041202 egr-miR-10227c-3p; +MIMAT0041203 egr-miR-10230-5p; +MIMAT0041204 egr-miR-10230-3p; +MIMAT0041205 egr-miR-10231-5p; +MIMAT0041206 egr-miR-10231-3p; +MIMAT0041207 egr-miR-10232-5p; +MIMAT0041208 egr-miR-10232-3p; +MIMAT0041209 egr-miR-10233-5p; +MIMAT0041210 egr-miR-10233-3p; +MIMAT0041211 egr-miR-10234-5p; +MIMAT0041212 egr-miR-10234-3p; +MIMAT0041213 egr-miR-10235-5p; +MIMAT0041214 egr-miR-10235-3p; +MIMAT0041215 egr-miR-10236-5p; +MIMAT0041216 egr-miR-10236-3p; +MIMAT0041217 egr-miR-10237-5p; +MIMAT0041218 egr-miR-10237-3p; +MIMAT0041219 egr-miR-10238-5p; +MIMAT0041220 egr-miR-10238-3p; +MIMAT0041221 egr-miR-10239-5p; +MIMAT0041222 egr-miR-10239-3p; +MIMAT0041223 egr-miR-10240-5p; +MIMAT0041224 egr-miR-10240-3p; +MIMAT0041225 egr-miR-10241-5p; +MIMAT0041226 egr-miR-10241-3p; +MIMAT0041227 egr-miR-10227d-5p; +MIMAT0041228 egr-miR-10227d-3p; +MIMAT0041229 egr-miR-10242-5p; +MIMAT0041230 egr-miR-10242-3p; +MIMAT0041231 egr-miR-10243-5p; +MIMAT0041232 egr-miR-10243-3p; +MIMAT0041233 egr-miR-10244-5p; +MIMAT0041234 egr-miR-10244-3p; +MIMAT0041235 egr-miR-10245-5p; +MIMAT0041236 egr-miR-10245-3p; +MIMAT0041237 egr-miR-36b-5p; +MIMAT0041238 egr-miR-36b-3p; +MIMAT0041239 egr-miR-10247-5p; +MIMAT0041240 egr-miR-10247-3p; +MIMAT0041241 egr-miR-10248-5p; +MIMAT0041242 egr-miR-10248-3p; +MIMAT0041243 egr-miR-10249-5p; +MIMAT0041244 egr-miR-10249-3p; +MIMAT0041245 egr-miR-10227e-5p; +MIMAT0041246 egr-miR-10227e-3p; +MIMAT0041247 egr-miR-10250-5p; +MIMAT0041248 egr-miR-10250-3p; +MIMAT0041249 egr-miR-10251-5p; +MIMAT0041250 egr-miR-10251-3p; +MIMAT0041251 egr-miR-10252-5p; +MIMAT0041252 egr-miR-10252-3p; +MIMAT0041253 egr-miR-2d-5p; +MIMAT0041254 egr-miR-2d-3p; +MIMAT0041255 egr-miR-10253-5p; +MIMAT0041256 egr-miR-10253-3p; +MIMAT0041257 egr-miR-10254-5p; +MIMAT0041258 egr-miR-10254-3p; +MIMAT0041259 egr-miR-10255-5p; +MIMAT0041260 egr-miR-10255-3p; +MIMAT0041261 egr-miR-10256-5p; +MIMAT0041262 egr-miR-10256-3p; +MIMAT0041263 egr-miR-10257-5p; +MIMAT0041264 egr-miR-10257-3p; +MIMAT0041265 egr-miR-10258-5p; +MIMAT0041266 egr-miR-10258-3p; +MIMAT0041267 egr-miR-10259-5p; +MIMAT0041268 egr-miR-10259-3p; +MIMAT0041269 egr-miR-10260-5p; +MIMAT0041270 egr-miR-10260-3p; +MIMAT0041271 egr-miR-10261-5p; +MIMAT0041272 egr-miR-10261-3p; +MIMAT0041273 egr-miR-10262-5p; +MIMAT0041274 egr-miR-10262-3p; +MIMAT0041275 egr-miR-10263-5p; +MIMAT0041276 egr-miR-10263-3p; +MIMAT0041277 egr-miR-10264-5p; +MIMAT0041278 egr-miR-10264-3p; +MIMAT0041279 egr-miR-10265-5p; +MIMAT0041280 egr-miR-10265-3p; +MIMAT0041281 egr-miR-10266-5p; +MIMAT0041282 egr-miR-10266-3p; +MIMAT0041283 egr-miR-10267-5p; +MIMAT0041284 egr-miR-10267-3p; +MIMAT0041285 egr-miR-10268-5p; +MIMAT0041286 egr-miR-10268-3p; +MIMAT0041287 egr-miR-10269-5p; +MIMAT0041288 egr-miR-10269-3p; +MIMAT0041289 egr-miR-10270-5p; +MIMAT0041290 egr-miR-10270-3p; +MIMAT0041291 egr-miR-10271-5p; +MIMAT0041292 egr-miR-10271-3p; +MIMAT0041293 egr-miR-10272-5p; +MIMAT0041294 egr-miR-10272-3p; +MIMAT0041295 egr-miR-10273-5p; +MIMAT0041296 egr-miR-10273-3p; +MIMAT0041297 egr-miR-10274-5p; +MIMAT0041298 egr-miR-10274-3p; +MIMAT0041299 egr-miR-10275-5p; +MIMAT0041300 egr-miR-10275-3p; +MIMAT0041301 egr-miR-10276-5p; +MIMAT0041302 egr-miR-10276-3p; +MIMAT0041303 egr-miR-10277-5p; +MIMAT0041304 egr-miR-10277-3p; +MIMAT0041305 egr-miR-10278-5p; +MIMAT0041306 egr-miR-10278-3p; +MIMAT0041307 egr-miR-10279-5p; +MIMAT0041308 egr-miR-10279-3p; +MIMAT0041309 egr-miR-10280-5p; +MIMAT0041310 egr-miR-10280-3p; +MIMAT0041311 egr-miR-10281-5p; +MIMAT0041312 egr-miR-10281-3p; +MIMAT0041313 egr-miR-10282-5p; +MIMAT0041314 egr-miR-10282-3p; +MIMAT0041315 egr-miR-10283-5p; +MIMAT0041316 egr-miR-10283-3p; +MIMAT0041317 egr-miR-10284-5p; +MIMAT0041318 egr-miR-10284-3p; +MIMAT0041319 egr-miR-10285-5p; +MIMAT0041320 egr-miR-10285-3p; +MIMAT0041321 egr-miR-10286-5p; +MIMAT0041322 egr-miR-10286-3p; +MIMAT0041323 egr-miR-10287-5p; +MIMAT0041324 egr-miR-10287-3p; +MIMAT0041325 egr-miR-10288-5p; +MIMAT0041326 egr-miR-10288-3p; +MIMAT0041327 egr-miR-10289-5p; +MIMAT0041328 egr-miR-10289-3p; +MIMAT0041329 egr-miR-10290-5p; +MIMAT0041330 egr-miR-10290-3p; +MIMAT0041331 egr-miR-10291-5p; +MIMAT0041332 egr-miR-10291-3p; +MIMAT0041333 egr-miR-10292-5p; +MIMAT0041334 egr-miR-10292-3p; +MIMAT0041335 egr-miR-307-5p; +MIMAT0041336 egr-miR-307-3p; +MIMAT0041337 egr-miR-10293-5p; +MIMAT0041338 egr-miR-10293-3p; +MIMAT0041339 tcf-bantam; +MIMAT0041340 tcf-let-7-5p; +MIMAT0041341 tcf-let-7-3p; +MIMAT0041342 tcf-miR-1; +MIMAT0041343 tcf-miR-2a-5p; +MIMAT0041344 tcf-miR-2a-3p; +MIMAT0041345 tcf-miR-2b; +MIMAT0041346 tcf-miR-7; +MIMAT0041347 tcf-miR-8-5p; +MIMAT0041348 tcf-miR-8-3p; +MIMAT0041349 tcf-miR-9a-5p; +MIMAT0041350 tcf-miR-9a-3p; +MIMAT0041351 tcf-miR-9b-5p; +MIMAT0041352 tcf-miR-9b-3p; +MIMAT0041353 tcf-miR-10-5p; +MIMAT0041354 tcf-miR-10-3p; +MIMAT0041355 tcf-miR-12; +MIMAT0041356 tcf-miR-13; +MIMAT0041357 tcf-miR-31; +MIMAT0041358 tcf-miR-33; +MIMAT0041359 tcf-miR-34; +MIMAT0041360 tcf-miR-279f; +MIMAT0041361 tcf-miR-71-5p; +MIMAT0041362 tcf-miR-71-3p; +MIMAT0041363 tcf-miR-87; +MIMAT0041364 tcf-miR-92a; +MIMAT0041365 tcf-miR-92b; +MIMAT0041366 tcf-miR-96; +MIMAT0041367 tcf-miR-100; +MIMAT0041368 tcf-miR-124-5p; +MIMAT0041369 tcf-miR-124-3p; +MIMAT0041370 tcf-miR-125; +MIMAT0041371 tcf-miR-133; +MIMAT0041372 tcf-miR-137; +MIMAT0041373 tcf-miR-153-5p; +MIMAT0041374 tcf-miR-153-3p; +MIMAT0041375 tcf-miR-184-5p; +MIMAT0041376 tcf-miR-184-3p; +MIMAT0041377 tcf-miR-190; +MIMAT0041378 tcf-miR-193; +MIMAT0041379 tcf-miR-210-5p; +MIMAT0041380 tcf-miR-210-3p; +MIMAT0041381 tcf-miR-219; +MIMAT0041382 tcf-miR-252a-5p; +MIMAT0041383 tcf-miR-252a-3p; +MIMAT0041384 tcf-miR-252b; +MIMAT0041385 tcf-miR-263a; +MIMAT0041386 tcf-miR-263b; +MIMAT0041387 tcf-miR-275; +MIMAT0041388 tcf-miR-276-5p; +MIMAT0041389 tcf-miR-276-3p; +MIMAT0041390 tcf-miR-277; +MIMAT0041391 tcf-miR-278; +MIMAT0041392 tcf-miR-279a; +MIMAT0041393 tcf-miR-279b; +MIMAT0041394 tcf-miR-279c; +MIMAT0041395 tcf-miR-279d; +MIMAT0041396 tcf-miR-279e; +MIMAT0041397 tcf-miR-281-5p; +MIMAT0041398 tcf-miR-281-3p; +MIMAT0041399 tcf-miR-282; +MIMAT0041400 tcf-miR-283; +MIMAT0041401 tcf-miR-285; +MIMAT0041402 tcf-miR-305; +MIMAT0041403 tcf-miR-307; +MIMAT0041404 tcf-miR-315-5p; +MIMAT0041405 tcf-miR-315-3p; +MIMAT0041406 tcf-miR-317; +MIMAT0041407 tcf-miR-375; +MIMAT0041408 tcf-miR-745; +MIMAT0041409 tcf-miR-750; +MIMAT0041410 tcf-miR-965; +MIMAT0041411 tcf-miR-981; +MIMAT0041412 tcf-miR-993-5p; +MIMAT0041413 tcf-miR-993-3p; +MIMAT0041414 tcf-miR-995; +MIMAT0041415 tcf-miR-996; +MIMAT0041416 tcf-miR-998; +MIMAT0041417 tcf-miR-1175-5p; +MIMAT0041418 tcf-miR-1175-3p; +MIMAT0041419 tcf-miR-2788; +MIMAT0041420 tcf-miR-2944a; +MIMAT0041421 tcf-miR-3477; +MIMAT0041422 tcf-miR-3791; +MIMAT0041423 tcf-miR-iab-4; +MIMAT0041424 tcf-miR-iab-8; +MIMAT0041425 tcf-miR-10294; +MIMAT0041426 tcf-miR-10295; +MIMAT0041427 tcf-miR-10296; +MIMAT0041428 tcf-miR-10297; +MIMAT0041429 tcf-miR-10298a; +MIMAT0041430 tcf-miR-10299; +MIMAT0041431 tcf-miR-10300; +MIMAT0041432 tcf-miR-2944b; +MIMAT0041433 tcf-miR-10301; +MIMAT0041434 tcf-miR-10302; +MIMAT0041435 tcf-miR-10303a; +MIMAT0041436 tcf-miR-316; +MIMAT0041437 tcf-miR-10304; +MIMAT0041438 tcf-miR-10305; +MIMAT0041439 tcf-miR-79; +MIMAT0041440 tcf-miR-309; +MIMAT0041441 tcf-miR-318; +MIMAT0041442 tcf-miR-10306; +MIMAT0041443 tcf-miR-10307; +MIMAT0041444 tcf-miR-10402; +MIMAT0041445 tcf-miR-10403; +MIMAT0041446 tcf-miR-10308; +MIMAT0041447 tcf-miR-10309; +MIMAT0041448 tcf-miR-10310; +MIMAT0041449 tcf-miR-10311; +MIMAT0041450 tcf-miR-10312; +MIMAT0041451 tcf-miR-10313; +MIMAT0041452 tcf-miR-10314; +MIMAT0041453 tcf-miR-10303b; +MIMAT0041454 tcf-miR-10315a; +MIMAT0041455 tcf-miR-10316a; +MIMAT0041456 tcf-miR-10315b; +MIMAT0041457 tcf-miR-10317; +MIMAT0041458 tcf-miR-10318; +MIMAT0041459 tcf-miR-10319; +MIMAT0041460 tcf-miR-10320; +MIMAT0041461 tcf-miR-10321; +MIMAT0041462 tcf-miR-10322; +MIMAT0041463 tcf-miR-10323; +MIMAT0041464 tcf-miR-10324; +MIMAT0041465 tcf-miR-10325; +MIMAT0041466 tcf-miR-10326; +MIMAT0041467 tcf-miR-10327; +MIMAT0041468 tcf-miR-10328; +MIMAT0041469 tcf-miR-10329; +MIMAT0041470 tcf-miR-10330; +MIMAT0041471 tcf-miR-10331; +MIMAT0041472 tcf-miR-10332; +MIMAT0041473 tcf-miR-10333; +MIMAT0041474 tcf-miR-10334; +MIMAT0041475 tcf-miR-10335; +MIMAT0041476 tcf-miR-10336; +MIMAT0041477 tcf-miR-10337; +MIMAT0041478 tcf-miR-10338; +MIMAT0041479 tcf-miR-10339; +MIMAT0041480 tcf-miR-10340; +MIMAT0041481 tcf-miR-10316b; +MIMAT0041482 tcf-miR-10341; +MIMAT0041483 tcf-miR-10342; +MIMAT0041484 tcf-miR-10343; +MIMAT0041485 tcf-miR-10344; +MIMAT0041486 tcf-miR-10345; +MIMAT0041487 tcf-miR-10346; +MIMAT0041488 tcf-miR-10316c; +MIMAT0041489 tcf-miR-10347; +MIMAT0041490 tcf-miR-10348; +MIMAT0041491 tcf-miR-10349; +MIMAT0041492 tcf-miR-10350; +MIMAT0041493 tcf-miR-10351; +MIMAT0041494 tcf-miR-10352; +MIMAT0041495 tcf-miR-10298b; +MIMAT0041496 tcf-miR-10353; +MIMAT0041497 tcf-miR-10354; +MIMAT0041498 tcf-miR-87b; +MIMAT0041499 aga-miR-998-5p; +MIMAT0041500 aga-miR-998-3p; +MIMAT0041501 aga-miR-10355-5p; +MIMAT0041502 aga-miR-10355-3p; +MIMAT0041503 aga-miR-2944a-5p; +MIMAT0041504 aga-miR-2944a-3p; +MIMAT0041505 aga-miR-10361b-5p; +MIMAT0041506 aga-miR-10361b-3p; +MIMAT0041507 aga-miR-2944b-5p; +MIMAT0041508 aga-miR-2944b-3p; +MIMAT0041509 aga-miR-10356-5p; +MIMAT0041510 aga-miR-10356-3p; +MIMAT0041511 aga-miR-10357-5p; +MIMAT0041512 aga-miR-10357-3p; +MIMAT0041513 aga-miR-10358-5p; +MIMAT0041514 aga-miR-10358-3p; +MIMAT0041515 aga-miR-2945-5p; +MIMAT0041516 aga-miR-2945-3p; +MIMAT0041517 aga-miR-10359-5p; +MIMAT0041518 aga-miR-10359-3p; +MIMAT0041519 aga-miR-285-5p; +MIMAT0041520 aga-miR-285-3p; +MIMAT0041521 aga-miR-10360-5p; +MIMAT0041522 aga-miR-10360-3p; +MIMAT0041523 aga-miR-33-5p; +MIMAT0041524 aga-miR-33-3p; +MIMAT0041525 aga-miR-10361a-5p; +MIMAT0041526 aga-miR-10361a-3p; +MIMAT0041527 aga-miR-10362-5p; +MIMAT0041528 aga-miR-10362-3p; +MIMAT0041529 aga-miR-10363-5p; +MIMAT0041530 aga-miR-10363-3p; +MIMAT0041531 aga-miR-10364-5p; +MIMAT0041532 aga-miR-10364-3p; +MIMAT0041533 aga-miR-2796-5p; +MIMAT0041534 aga-miR-2796-3p; +MIMAT0041535 aga-miR-10365-5p; +MIMAT0041536 aga-miR-10365-3p; +MIMAT0041537 aga-miR-980-5p; +MIMAT0041538 aga-miR-980-3p; +MIMAT0041539 aga-miR-10366a-5p; +MIMAT0041540 aga-miR-10366a-3p; +MIMAT0041541 aga-miR-10367-5p; +MIMAT0041542 aga-miR-10367-3p; +MIMAT0041543 aga-miR-10366b-5p; +MIMAT0041544 aga-miR-10366b-3p; +MIMAT0041545 aga-miR-932-5p; +MIMAT0041546 aga-miR-932-3p; +MIMAT0041547 aga-miR-10366a-2-5p; +MIMAT0041548 aga-miR-10368-5p; +MIMAT0041549 aga-miR-10368-3p; +MIMAT0041550 aga-miR-10369-5p; +MIMAT0041551 aga-miR-10369-3p; +MIMAT0041552 aga-miR-10370-5p; +MIMAT0041553 aga-miR-10370-3p; +MIMAT0041554 aga-miR-10370-2-5p; +MIMAT0041555 aga-miR-10371-5p; +MIMAT0041556 aga-miR-10371-3p; +MIMAT0041557 aga-miR-10372a-5p; +MIMAT0041558 aga-miR-10372a-3p; +MIMAT0041559 aga-miR-10373-5p; +MIMAT0041560 aga-miR-10373-3p; +MIMAT0041561 aga-miR-10372b-5p; +MIMAT0041562 aga-miR-10372b-3p; +MIMAT0041563 aga-miR-10374-3p; +MIMAT0041564 aga-miR-2b-5p; +MIMAT0041565 aga-miR-2b-3p; +MIMAT0041566 aga-miR-286b-5p; +MIMAT0041567 aga-miR-286b-3p; +MIMAT0041568 aga-miR-31-5p; +MIMAT0041569 aga-miR-31-3p; +MIMAT0041570 aga-miR-10375a-5p; +MIMAT0041571 aga-miR-10375a-3p; +MIMAT0041572 aga-miR-10375b-5p; +MIMAT0041573 aga-miR-10375b-3p; +MIMAT0041574 aga-miR-10376-5p; +MIMAT0041575 aga-miR-10376-3p; +MIMAT0041576 aga-miR-10377a-5p; +MIMAT0041577 aga-miR-10377a-3p; +MIMAT0041578 aga-miR-2c-5p; +MIMAT0041579 aga-miR-2c-3p; +MIMAT0041580 aga-miR-10377b-5p; +MIMAT0041581 aga-miR-10377b-3p; +MIMAT0041582 aga-miR-10378-5p; +MIMAT0041583 aga-miR-10378-3p; +MIMAT0041584 aga-miR-10379-5p; +MIMAT0041585 aga-miR-10379-3p; +MIMAT0041586 aga-miR-10380-5p; +MIMAT0041587 aga-miR-10380-3p; +MIMAT0041588 aga-miR-10381-5p; +MIMAT0041589 ssc-miR-10382; +MIMAT0041590 ssc-miR-1388; +MIMAT0041591 ssc-miR-10383; +MIMAT0041592 ssc-miR-10384; +MIMAT0041594 ssc-miR-1842; +MIMAT0041595 ssc-miR-26b-5p; +MIMAT0041596 ssc-miR-26b-3p; +MIMAT0041597 ssc-miR-670; +MIMAT0041598 ssc-miR-10386; +MIMAT0041599 ssc-miR-10387; +MIMAT0041600 ssc-miR-10388; +MIMAT0041601 ssc-miR-330; +MIMAT0041602 ssc-miR-10389; +MIMAT0041603 ssc-miR-10390; +MIMAT0041604 ssc-miR-10391; +MIMAT0041605 ssc-miR-141; +MIMAT0041606 ssc-miR-200b; +MIMAT0041607 ssc-miR-223; +MIMAT0041608 ssc-miR-375; +MIMAT0041609 ssc-miR-454; +MIMAT0041610 ssc-miR-6516; +MIMAT0041611 ssc-miR-6529; +MIMAT0041612 ssc-miR-660; +MIMAT0041613 ssc-miR-802; +MIMAT0041615 hsa-miR-10392-5p; +MIMAT0041616 hsa-miR-10392-3p; +MIMAT0041617 hsa-miR-10393-5p; +MIMAT0041618 hsa-miR-10393-3p; +MIMAT0041619 hsa-miR-10394-5p; +MIMAT0041620 hsa-miR-10394-3p; +MIMAT0041621 hsa-miR-10395-5p; +MIMAT0041622 hsa-miR-10395-3p; +MIMAT0041623 hsa-miR-10396a-5p; +MIMAT0041624 hsa-miR-10396a-3p; +MIMAT0041625 hsa-miR-10397-5p; +MIMAT0041626 hsa-miR-10397-3p; +MIMAT0041627 hsa-miR-10398-5p; +MIMAT0041628 hsa-miR-10398-3p; +MIMAT0041629 hsa-miR-10399-5p; +MIMAT0041630 hsa-miR-10399-3p; +MIMAT0041631 hsa-miR-10400-5p; +MIMAT0041632 hsa-miR-10400-3p; +MIMAT0041633 hsa-miR-10401-5p; +MIMAT0041634 hsa-miR-10401-3p; +MIMAT0041635 hsa-miR-10396b-5p; +MIMAT0041636 hsa-miR-10396b-3p; +MIMAT0041637 dme-miR-10404-5p; +MIMAT0041638 dme-miR-10404-3p; +MIMAT0041639 gma-miR10405a; +MIMAT0041640 gma-miR4348d; +MIMAT0041641 gma-miR10406a; +MIMAT0041642 gma-miR10186b; +MIMAT0041643 gma-miR10407a; +MIMAT0041644 gma-miR10408; +MIMAT0041645 gma-miR10186c; +MIMAT0041646 gma-miR10409; +MIMAT0041647 gma-miR10410a; +MIMAT0041648 gma-miR10411; +MIMAT0041649 gma-miR10412; +MIMAT0041650 gma-miR10407c; +MIMAT0041651 gma-miR10413a; +MIMAT0041652 gma-miR10414; +MIMAT0041653 gma-miR10186d; +MIMAT0041654 gma-miR167l; +MIMAT0041655 gma-miR10407d; +MIMAT0041656 gma-miR10415; +MIMAT0041657 gma-miR10405e; +MIMAT0041658 gma-miR10416; +MIMAT0041659 gma-miR10413b; +MIMAT0041660 gma-miR10417; +MIMAT0041661 gma-miR10418; +MIMAT0041662 gma-miR4405b; +MIMAT0041663 gma-miR10193e; +MIMAT0041664 gma-miR399j; +MIMAT0041665 gma-miR10419; +MIMAT0041666 gma-miR10420; +MIMAT0041667 gma-miR10421; +MIMAT0041668 gma-miR10186e; +MIMAT0041669 gma-miR10422; +MIMAT0041670 gma-miR10423; +MIMAT0041671 gma-miR10424a; +MIMAT0041672 gma-miR399k; +MIMAT0041673 gma-miR10405b; +MIMAT0041674 gma-miR10405c; +MIMAT0041675 gma-miR10425; +MIMAT0041676 gma-miR169w; +MIMAT0041677 gma-miR10186f; +MIMAT0041678 gma-miR399l; +MIMAT0041679 gma-miR10410b; +MIMAT0041680 gma-miR4374c; +MIMAT0041681 gma-miR399m; +MIMAT0041682 gma-miR10426; +MIMAT0041683 gma-miR10193b; +MIMAT0041684 gma-miR10427a; +MIMAT0041685 gma-miR10406b; +MIMAT0041686 gma-miR10186g; +MIMAT0041687 gma-miR9724b; +MIMAT0041688 gma-miR4414b; +MIMAT0041689 gma-miR10424b; +MIMAT0041690 gma-miR10428; +MIMAT0041691 gma-miR4997b; +MIMAT0041692 gma-miR10429; +MIMAT0041693 gma-miR5377b; +MIMAT0041694 gma-miR10427b; +MIMAT0041695 gma-miR10430; +MIMAT0041696 gma-miR10186h; +MIMAT0041697 gma-miR10431; +MIMAT0041698 gma-miR10432; +MIMAT0041699 gma-miR10186i; +MIMAT0041700 gma-miR10433; +MIMAT0041701 gma-miR5764b; +MIMAT0041702 gma-miR10434; +MIMAT0041703 gma-miR10435; +MIMAT0041704 gma-miR10405d; +MIMAT0041705 gma-miR10410c; +MIMAT0041706 gma-miR10407b; +MIMAT0041707 gma-miR10436; +MIMAT0041708 gma-miR399n; +MIMAT0041709 gma-miR10437; +MIMAT0041710 gma-miR10438; +MIMAT0041711 gma-miR10439; +MIMAT0041712 gma-miR10424c; +MIMAT0041713 gma-miR10440; +MIMAT0041714 gma-miR10441; +MIMAT0041715 gma-miR10442; +MIMAT0041716 gma-miR10193c; +MIMAT0041717 gma-miR10193d; +MIMAT0041718 gma-miR10186j; +MIMAT0041719 gma-miR10186k; +MIMAT0041720 gma-miR10186l; +MIMAT0041721 gma-miR10443; +MIMAT0041722 gma-miR10424d; +MIMAT0041723 gma-miR10444; +MIMAT0041724 gma-miR10445; +MIMAT0041725 gma-miR10193f; +MIMAT0041726 gma-miR10446; +MIMAT0041727 gma-miR10447; +MIMAT0041728 gma-miR399o; +MIMAT0041729 gma-miR10448; +MIMAT0041730 egr-miR-3479b-5p; +MIMAT0041731 egr-miR-3479b-3p; +MIMAT0041732 egr-miR-10450-5p; +MIMAT0041733 egr-miR-10450-3p; +MIMAT0041734 egr-miR-277b-5p; +MIMAT0041735 egr-miR-277b-3p; +MIMAT0041736 emu-bantam-5p; +MIMAT0041737 emu-bantam-3p; +MIMAT0041738 emu-miR-31-5p; +MIMAT0041739 emu-miR-31-3p; +MIMAT0041740 emu-miR-36a-5p; +MIMAT0041741 emu-miR-36a-3p; +MIMAT0041742 emu-miR-36b-5p; +MIMAT0041743 emu-miR-36b-3p; +MIMAT0041744 emu-miR-61-5p; +MIMAT0041745 emu-miR-61-3p; +MIMAT0041746 emu-miR-133-5p; +MIMAT0041747 emu-miR-133-3p; +MIMAT0041748 emu-miR-281-5p; +MIMAT0041749 emu-miR-281-3p; +MIMAT0041750 emu-miR-307-5p; +MIMAT0041751 emu-miR-307-3p; +MIMAT0041752 emu-miR-1992-5p; +MIMAT0041753 emu-miR-1992-3p; +MIMAT0041754 emu-miR-2162-5p; +MIMAT0041755 emu-miR-2162-3p; +MIMAT0041756 emu-miR-3479a-5p; +MIMAT0041757 emu-miR-3479a-3p; +MIMAT0041758 emu-miR-3479b-5p; +MIMAT0041759 emu-miR-3479b-3p; +MIMAT0041760 emu-miR-10293-5p; +MIMAT0041761 emu-miR-10293-3p; +MIMAT0041762 emu-miR-277b-3p; +MIMAT0041763 sfr-miR-2c-5p; +MIMAT0041764 sfr-miR-2c-3p; +MIMAT0041765 sfr-miR-210-5p; +MIMAT0041766 sfr-miR-210-3p; +MIMAT0041767 sfr-miR-10451-5p; +MIMAT0041768 sfr-miR-10451-3p; +MIMAT0041769 sfr-miR-10452-5p; +MIMAT0041770 sfr-miR-10452-3p; +MIMAT0041771 sfr-miR-10453-5p; +MIMAT0041772 sfr-miR-10453-3p; +MIMAT0041773 sfr-miR-10454a-5p; +MIMAT0041774 sfr-miR-10454a-3p; +MIMAT0041775 sfr-miR-10454a-2-5p; +MIMAT0041776 sfr-miR-10455-5p; +MIMAT0041777 sfr-miR-10455-3p; +MIMAT0041778 sfr-miR-10456-5p; +MIMAT0041779 sfr-miR-10456-3p; +MIMAT0041780 sfr-miR-10457-5p; +MIMAT0041781 sfr-miR-10457-3p; +MIMAT0041782 sfr-miR-10458-5p; +MIMAT0041783 sfr-miR-10458-3p; +MIMAT0041784 sfr-miR-10459-5p; +MIMAT0041785 sfr-miR-10459-3p; +MIMAT0041786 sfr-miR-10460-5p; +MIMAT0041787 sfr-miR-10460-3p; +MIMAT0041788 sfr-miR-10461a-5p; +MIMAT0041789 sfr-miR-10461a-3p; +MIMAT0041790 sfr-miR-10454b-5p; +MIMAT0041791 sfr-miR-10454b-3p; +MIMAT0041792 sfr-miR-10454c-5p; +MIMAT0041793 sfr-miR-10454c-3p; +MIMAT0041794 sfr-miR-10462-5p; +MIMAT0041795 sfr-miR-10462-3p; +MIMAT0041796 sfr-miR-10463-5p; +MIMAT0041797 sfr-miR-10463-3p; +MIMAT0041798 sfr-miR-10464-5p; +MIMAT0041799 sfr-miR-10464-3p; +MIMAT0041800 sfr-miR-10465-5p; +MIMAT0041801 sfr-miR-10465-3p; +MIMAT0041802 sfr-miR-10466-5p; +MIMAT0041803 sfr-miR-10466-3p; +MIMAT0041804 sfr-miR-10467-5p; +MIMAT0041805 sfr-miR-10467-3p; +MIMAT0041806 sfr-miR-10468-5p; +MIMAT0041807 sfr-miR-10468-3p; +MIMAT0041808 sfr-miR-10454d-5p; +MIMAT0041809 sfr-miR-10454d-3p; +MIMAT0041810 sfr-miR-10454e-5p; +MIMAT0041811 sfr-miR-10454e-3p; +MIMAT0041812 sfr-miR-10454f-5p; +MIMAT0041813 sfr-miR-10454f-3p; +MIMAT0041814 sfr-miR-10469-5p; +MIMAT0041815 sfr-miR-10469-3p; +MIMAT0041816 sfr-miR-3286-5p; +MIMAT0041817 sfr-miR-3286-3p; +MIMAT0041818 sfr-miR-277-5p; +MIMAT0041819 sfr-miR-277-3p; +MIMAT0041820 sfr-miR-279c-5p; +MIMAT0041821 sfr-miR-279c-3p; +MIMAT0041822 sfr-miR-10470-5p; +MIMAT0041823 sfr-miR-10470-3p; +MIMAT0041824 sfr-miR-10471-5p; +MIMAT0041825 sfr-miR-10471-3p; +MIMAT0041826 sfr-miR-10472-5p; +MIMAT0041827 sfr-miR-10472-3p; +MIMAT0041828 sfr-miR-10473-5p; +MIMAT0041829 sfr-miR-10473-3p; +MIMAT0041830 sfr-miR-10454g-5p; +MIMAT0041831 sfr-miR-10454g-3p; +MIMAT0041832 sfr-miR-10474-5p; +MIMAT0041833 sfr-miR-10474-3p; +MIMAT0041834 sfr-miR-10475-5p; +MIMAT0041835 sfr-miR-10475-3p; +MIMAT0041836 sfr-miR-10476-5p; +MIMAT0041837 sfr-miR-10476-3p; +MIMAT0041838 sfr-miR-10477-5p; +MIMAT0041839 sfr-miR-10477-3p; +MIMAT0041840 sfr-miR-10465-2-3p; +MIMAT0041841 sfr-miR-10492c-5p; +MIMAT0041842 sfr-miR-10492c-3p; +MIMAT0041843 sfr-miR-10478-5p; +MIMAT0041844 sfr-miR-10478-3p; +MIMAT0041845 sfr-miR-10454h-5p; +MIMAT0041846 sfr-miR-10454h-3p; +MIMAT0041847 sfr-miR-10461b-5p; +MIMAT0041848 sfr-miR-10461b-3p; +MIMAT0041849 sfr-miR-10508b-5p; +MIMAT0041850 sfr-miR-10508b-3p; +MIMAT0041851 sfr-miR-10479-5p; +MIMAT0041852 sfr-miR-10479-3p; +MIMAT0041853 sfr-miR-10480-5p; +MIMAT0041854 sfr-miR-10480-3p; +MIMAT0041855 sfr-miR-10481-5p; +MIMAT0041856 sfr-miR-10481-3p; +MIMAT0041857 sfr-miR-10482-5p; +MIMAT0041858 sfr-miR-10482-3p; +MIMAT0041859 sfr-miR-10483-5p; +MIMAT0041860 sfr-miR-10483-3p; +MIMAT0041861 sfr-miR-10483-2-3p; +MIMAT0041862 sfr-miR-279a-5p; +MIMAT0041863 sfr-miR-279a-3p; +MIMAT0041864 sfr-miR-92a-5p; +MIMAT0041865 sfr-miR-92a-3p; +MIMAT0041866 sfr-miR-307-5p; +MIMAT0041867 sfr-miR-307-3p; +MIMAT0041868 sfr-miR-10484-??; +MIMAT0041869 sfr-miR-10484-3p; +MIMAT0041870 sfr-miR-2a-5p; +MIMAT0041871 sfr-miR-2a-3p; +MIMAT0041872 sfr-miR-10485-5p; +MIMAT0041873 sfr-miR-10485-3p; +MIMAT0041874 sfr-miR-10486-5p; +MIMAT0041875 sfr-miR-10486-3p; +MIMAT0041876 sfr-miR-2b-5p; +MIMAT0041877 sfr-miR-2b-3p; +MIMAT0041878 sfr-miR-34-5p; +MIMAT0041879 sfr-miR-34-3p; +MIMAT0041880 sfr-miR-11-5p; +MIMAT0041881 sfr-miR-11-3p; +MIMAT0041882 sfr-miR-375-5p; +MIMAT0041883 sfr-miR-375-3p; +MIMAT0041884 sfr-miR-317-5p; +MIMAT0041885 sfr-miR-317-3p; +MIMAT0041886 sfr-miR-10487-5p; +MIMAT0041887 sfr-miR-10487-3p; +MIMAT0041888 sfr-miR-10488-5p; +MIMAT0041889 sfr-miR-10488-3p; +MIMAT0041890 sfr-miR-316-5p; +MIMAT0041891 sfr-miR-316-3p; +MIMAT0041892 sfr-miR-13b-5p; +MIMAT0041893 sfr-miR-13b-3p; +MIMAT0041894 sfr-miR-6094-5p; +MIMAT0041895 sfr-miR-6094-3p; +MIMAT0041896 sfr-miR-10489-5p; +MIMAT0041897 sfr-miR-10489-3p; +MIMAT0041898 sfr-miR-281-5p; +MIMAT0041899 sfr-miR-281-3p; +MIMAT0041900 sfr-miR-10490-5p; +MIMAT0041901 sfr-miR-10490-3p; +MIMAT0041902 sfr-miR-2765-5p; +MIMAT0041903 sfr-miR-2765-3p; +MIMAT0041904 sfr-miR-10491-5p; +MIMAT0041905 sfr-miR-10491-3p; +MIMAT0041906 sfr-miR-13a-5p; +MIMAT0041907 sfr-miR-13a-3p; +MIMAT0041908 sfr-miR-2756-5p; +MIMAT0041909 sfr-miR-2756-3p; +MIMAT0041910 sfr-miR-10492a-5p; +MIMAT0041911 sfr-miR-10492a-3p; +MIMAT0041912 sfr-miR-932-5p; +MIMAT0041913 sfr-miR-932-3p; +MIMAT0041914 sfr-miR-10493-5p; +MIMAT0041915 sfr-miR-10493-3p; +MIMAT0041916 sfr-miR-2766-5p; +MIMAT0041917 sfr-miR-2766-3p; +MIMAT0041918 sfr-miR-10494-5p; +MIMAT0041919 sfr-miR-10494-3p; +MIMAT0041920 sfr-miR-10495-5p; +MIMAT0041921 sfr-miR-10495-3p; +MIMAT0041922 sfr-miR-10495-3-3p; +MIMAT0041923 sfr-miR-7-5p; +MIMAT0041924 sfr-miR-7-3p; +MIMAT0041925 sfr-miR-10496-5p; +MIMAT0041926 sfr-miR-10496-3p; +MIMAT0041927 sfr-miR-10497-5p; +MIMAT0041928 sfr-miR-10497-3p; +MIMAT0041929 sfr-miR-10498-5p; +MIMAT0041930 sfr-miR-10498-3p; +MIMAT0041931 sfr-miR-10499a-5p; +MIMAT0041932 sfr-miR-10499a-3p; +MIMAT0041933 sfr-miR-10-5p; +MIMAT0041934 sfr-miR-10-3p; +MIMAT0041935 sfr-miR-10499a-4-5p; +MIMAT0041936 sfr-miR-10500-5p; +MIMAT0041937 sfr-miR-10500-3p; +MIMAT0041938 sfr-miR-10501-5p; +MIMAT0041939 sfr-miR-10501-3p; +MIMAT0041940 sfr-miR-274-5p; +MIMAT0041941 sfr-miR-274-3p; +MIMAT0041942 sfr-miR-10502-5p; +MIMAT0041943 sfr-miR-10502-3p; +MIMAT0041944 sfr-miR-10503-5p; +MIMAT0041945 sfr-miR-10503-3p; +MIMAT0041946 sfr-miR-10504-5p; +MIMAT0041947 sfr-miR-10504-3p; +MIMAT0041948 sfr-miR-14-5p; +MIMAT0041949 sfr-miR-14-3p; +MIMAT0041950 sfr-miR-10505-5p; +MIMAT0041951 sfr-miR-10505-3p; +MIMAT0041952 sfr-miR-10506-5p; +MIMAT0041953 sfr-miR-10506-3p; +MIMAT0041954 sfr-miR-10507-5p; +MIMAT0041955 sfr-miR-10507-3p; +MIMAT0041956 sfr-miR-2755-5p; +MIMAT0041957 sfr-miR-2755-3p; +MIMAT0041958 sfr-miR-10508a-5p; +MIMAT0041959 sfr-miR-10508a-3p; +MIMAT0041960 sfr-miR-10508a-2-3p; +MIMAT0041961 sfr-miR-10509-5p; +MIMAT0041962 sfr-miR-10509-3p; +MIMAT0041963 sfr-miR-10492b-5p; +MIMAT0041964 sfr-miR-10492b-3p; +MIMAT0041965 sfr-miR-285-5p; +MIMAT0041966 sfr-miR-285-3p; +MIMAT0041967 sfr-miR-279b-5p; +MIMAT0041968 sfr-miR-279b-3p; +MIMAT0041969 sfr-miR-10510-5p; +MIMAT0041970 sfr-miR-10510-3p; +MIMAT0041971 sfr-miR-10499b-5p; +MIMAT0041972 sfr-miR-10499b-3p; +MIMAT0041973 sfr-miR-10499b-2-5p; +MIMAT0041974 sfr-miR-10511-5p; +MIMAT0041975 sfr-miR-10511-3p; +MIMAT0041976 sfr-miR-10512-5p; +MIMAT0041977 sfr-miR-10512-3p; +MIMAT0041978 sfr-miR-10513-5p; +MIMAT0041979 sfr-miR-10513-3p; +MIMAT0041980 sfr-miR-10514-5p; +MIMAT0041981 sfr-miR-10514-3p; +MIMAT0041982 sfr-miR-263b-5p; +MIMAT0041983 sfr-miR-263b-3p; +MIMAT0041984 ath-miR10515; +MIMAT0041985 tae-miR10516; +MIMAT0041986 tae-miR10517; +MIMAT0041987 tae-miR10518; +MIMAT0041988 tae-miR10519; +MIMAT0041989 tae-miR10520; +MIMAT0041990 tae-miR10521; +MIMAT0041991 hsa-miR-10522-5p; +MIMAT0041992 hsa-miR-10523-5p; +MIMAT0041993 hsa-miR-9983-3p; +MIMAT0041994 hsa-miR-10524-5p; +MIMAT0041995 hsa-miR-10525-3p; +MIMAT0041996 hsa-miR-10526-3p; +MIMAT0041997 hsa-miR-10527-5p; +MIMAT0041998 ptvpv2a-miR-P1-5p; +MIMAT0041999 ptvpv2a-miR-P1-3p; +MIMAT0042000 gggpv1-miR-P1-5p; +MIMAT0042001 gggpv1-miR-P1-3p; +MIMAT0042002 racpv-miR-P1-5p; +MIMAT0042003 racpv-miR-P1-3p; +MIMAT0042004 sly-miR172c; +MIMAT0042005 sly-miR408; +MIMAT0042006 sly-miR10528; +MIMAT0042007 sly-miR319d; +MIMAT0042008 sly-miR172d; +MIMAT0042009 sly-miR10529; +MIMAT0042010 sly-miR827; +MIMAT0042011 sly-miR530; +MIMAT0042012 sly-miR393; +MIMAT0042013 sly-miR10530; +MIMAT0042014 sly-miR398a; +MIMAT0042015 sly-miR7981e; +MIMAT0042016 sly-miR399b; +MIMAT0042017 sly-miR10531; +MIMAT0042018 sly-miR10532; +MIMAT0042019 sly-miR10533; +MIMAT0042020 sly-miR10534; +MIMAT0042021 sly-miR7981c; +MIMAT0042022 sly-miR10535a; +MIMAT0042023 sly-miR6025; +MIMAT0042024 sly-miR10536; +MIMAT0042025 sly-miR10537; +MIMAT0042026 sly-miR7981f; +MIMAT0042027 sly-miR10535b; +MIMAT0042028 sly-miR169f; +MIMAT0042029 sly-miR7981a; +MIMAT0042030 sly-miR7981b; +MIMAT0042031 sly-miR7981d; +MIMAT0042032 sly-miR10538; +MIMAT0042033 sly-miR10539; +MIMAT0042034 sly-miR10540; +MIMAT0042035 sly-miR10541; +MIMAT0042036 sly-miR159b; +MIMAT0042037 sly-miR10542; +MIMAT0042038 sly-miR171f; +MIMAT0042039 abu-miR-10a; +MIMAT0042040 abu-miR-183; +MIMAT0042041 abu-miR-100; +MIMAT0042042 abu-miR-192; +MIMAT0042043 abu-miR-10b; +MIMAT0042044 abu-miR-182; +MIMAT0042045 abu-miR-9-5p; +MIMAT0042046 abu-miR-204; +MIMAT0042047 abu-miR-143; +MIMAT0042048 abu-miR-21; +MIMAT0042049 abu-miR-9-3p; +MIMAT0042050 abu-miR-199-5p; +MIMAT0042051 abu-miR-199-3p; +MIMAT0042052 abu-miR-26a; +MIMAT0042053 abu-miR-92a; +MIMAT0042054 abu-miR-184a; +MIMAT0042055 abu-miR-133a; +MIMAT0042056 abu-let-7a; +MIMAT0042057 abu-miR-30a-5p; +MIMAT0042058 abu-miR-30a-3p; +MIMAT0042059 abu-miR-27b; +MIMAT0042060 abu-miR-203; +MIMAT0042061 abu-miR-140; +MIMAT0042062 abu-miR-205; +MIMAT0042063 abu-miR-22a; +MIMAT0042064 abu-miR-462; +MIMAT0042065 abu-miR-126-5p; +MIMAT0042066 abu-miR-126-3p; +MIMAT0042067 abu-miR-25; +MIMAT0042068 abu-miR-184b; +MIMAT0042069 abu-miR-2188; +MIMAT0042070 abu-let-7d; +MIMAT0042071 abu-miR-30b; +MIMAT0042072 abu-miR-99b; +MIMAT0042073 abu-miR-221; +MIMAT0042074 abu-miR-148a-5p; +MIMAT0042075 abu-miR-148a-3p; +MIMAT0042076 abu-miR-30c; +MIMAT0042077 abu-miR-135a-5p; +MIMAT0042078 abu-miR-135a-3p; +MIMAT0042079 abu-miR-222; +MIMAT0042080 abu-let-7g; +MIMAT0042081 abu-miR-153a; +MIMAT0042082 abu-let-7e; +MIMAT0042083 abu-miR-190b; +MIMAT0042084 abu-miR-30d; +MIMAT0042085 abu-miR-22b; +MIMAT0042086 abu-miR-1388; +MIMAT0042087 abu-let-7i; +MIMAT0042088 abu-miR-103; +MIMAT0042089 abu-miR-144; +MIMAT0042090 abu-miR-26b; +MIMAT0042091 abu-miR-125b; +MIMAT0042092 abu-miR-133b; +MIMAT0042093 abu-miR-214; +MIMAT0042094 abu-miR-206; +MIMAT0042095 abu-miR-125a; +MIMAT0042096 abu-miR-455; +MIMAT0042097 abu-miR-200b; +MIMAT0042098 abu-miR-724; +MIMAT0042099 abu-miR-27e; +MIMAT0042100 abu-miR-19b; +MIMAT0042101 abu-miR-218a; +MIMAT0042102 abu-miR-16b; +MIMAT0042103 abu-miR-142-5p; +MIMAT0042104 abu-miR-142-3p; +MIMAT0042105 abu-miR-96; +MIMAT0042106 abu-miR-92b; +MIMAT0042107 abu-miR-194a; +MIMAT0042108 abu-miR-200a; +MIMAT0042109 abu-miR-27a; +MIMAT0042110 abu-miR-456; +MIMAT0042111 abu-miR-301b; +MIMAT0042112 abu-miR-101a; +MIMAT0042113 abu-miR-17; +MIMAT0042114 abu-let-7c; +MIMAT0042115 abu-miR-1; +MIMAT0042116 abu-miR-338; +MIMAT0042117 abu-miR-122; +MIMAT0042118 abu-miR-128; +MIMAT0042119 abu-miR-19d; +MIMAT0042120 abu-miR-129; +MIMAT0042121 abu-miR-216b; +MIMAT0042122 abu-miR-23a; +MIMAT0042123 abu-miR-130; +MIMAT0042124 abu-miR-460; +MIMAT0042125 abu-miR-375; +MIMAT0042126 abu-miR-107; +MIMAT0042127 abu-let-7h; +MIMAT0042128 abu-miR-20a; +MIMAT0042129 abu-miR-19a; +MIMAT0042130 abu-miR-27d-5p; +MIMAT0042131 abu-miR-27d-3p; +MIMAT0042132 abu-miR-135b; +MIMAT0042133 abu-miR-138; +MIMAT0042134 abu-miR-23b; +MIMAT0042135 abu-miR-15a; +MIMAT0042136 abu-miR-499; +MIMAT0042137 abu-miR-18a; +MIMAT0042138 abu-let-7b; +MIMAT0042139 abu-miR-7; +MIMAT0042140 abu-miR-24a; +MIMAT0042141 abu-miR-93; +MIMAT0042142 abu-miR-132-3p; +MIMAT0042143 abu-miR-106; +MIMAT0042144 abu-miR-190a-5p; +MIMAT0042145 abu-miR-190a-3p; +MIMAT0042146 abu-miR-196a; +MIMAT0042147 abu-miR-34; +MIMAT0042148 abu-miR-139; +MIMAT0042149 abu-miR-489; +MIMAT0042150 abu-miR-22c; +MIMAT0042151 abu-miR-101b; +MIMAT0042152 abu-miR-219-5p; +MIMAT0042153 abu-miR-20b; +MIMAT0042154 abu-miR-365; +MIMAT0042155 abu-miR-155; +MIMAT0042156 abu-miR-135c-5p; +MIMAT0042157 abu-miR-135c-3p; +MIMAT0042158 abu-miR-187; +MIMAT0042159 abu-miR-730; +MIMAT0042160 abu-miR-193-5p; +MIMAT0042161 abu-miR-193-3p; +MIMAT0042162 abu-miR-153b; +MIMAT0042163 abu-miR-33-5p; +MIMAT0042164 abu-miR-2187a; +MIMAT0042165 abu-miR-29a; +MIMAT0042166 abu-miR-729; +MIMAT0042167 abu-miR-736; +MIMAT0042168 abu-miR-29b; +MIMAT0042169 abu-miR-16a; +MIMAT0042170 abu-miR-124; +MIMAT0042171 abu-miR-218b; +MIMAT0042172 abu-miR-429b; +MIMAT0042173 abu-miR-727a-5p; +MIMAT0042174 abu-miR-727b-3p; +MIMAT0042175 abu-miR-10c; +MIMAT0042176 abu-miR-458; +MIMAT0042177 abu-miR-731-5p; +MIMAT0042178 abu-miR-731-3p; +MIMAT0042179 abu-miR-132-5p; +MIMAT0042180 abu-miR-15b; +MIMAT0042181 abu-miR-24b-5p; +MIMAT0042182 abu-miR-24b-3p; +MIMAT0042183 abu-miR-301a; +MIMAT0042184 abu-miR-23c; +MIMAT0042185 abu-miR-734; +MIMAT0042186 abu-miR-194b; +MIMAT0042187 abu-miR-726; +MIMAT0042188 abu-miR-722; +MIMAT0042189 abu-let-7f; +MIMAT0042190 abu-miR-137; +MIMAT0042191 abu-miR-216a; +MIMAT0042192 abu-miR-135d; +MIMAT0042193 abu-miR-196b; +MIMAT0042194 abu-miR-457; +MIMAT0042195 abu-miR-153c; +MIMAT0042196 abu-miR-19c; +MIMAT0042197 abu-miR-31; +MIMAT0042198 abu-miR-15c-5p; +MIMAT0042199 abu-miR-15c-3p; +MIMAT0042200 abu-miR-2187b-5p; +MIMAT0042201 abu-miR-2187b-3p; +MIMAT0042202 abu-miR-723a; +MIMAT0042203 abu-miR-551; +MIMAT0042204 abu-miR-147; +MIMAT0042205 abu-miR-1788; +MIMAT0042206 abu-miR-728a; +MIMAT0042207 abu-miR-18b; +MIMAT0042208 abu-miR-10d; +MIMAT0042209 abu-miR-723b; +MIMAT0042210 abu-miR-181a; +MIMAT0042211 abu-miR-181b; +MIMAT0042212 abu-miR-430; +MIMAT0042213 abu-miR-212-3p; +MIMAT0042214 abu-miR-99a; +MIMAT0042215 abu-miR-7132a-5p; +MIMAT0042216 abu-miR-7132a-3p; +MIMAT0042217 abu-miR-7133-5p; +MIMAT0042218 abu-miR-7133-3p; +MIMAT0042219 abu-miR-7132b-5p; +MIMAT0042220 abu-miR-7132b-3p; +MIMAT0042221 abu-miR-29c-5p; +MIMAT0042222 abu-miR-29c-3p; +MIMAT0042223 abu-miR-725; +MIMAT0042224 abu-miR-449b-5p; +MIMAT0042225 abu-miR-449b-3p; +MIMAT0042226 abu-miR-449a; +MIMAT0042227 abu-miR-10543; +MIMAT0042228 abu-miR-8160b; +MIMAT0042229 abu-miR-10544; +MIMAT0042230 abu-miR-3120; +MIMAT0042231 abu-miR-10545-5p; +MIMAT0042232 abu-miR-10545-3p; +MIMAT0042233 abu-miR-8160a; +MIMAT0042235 abu-miR-10546; +MIMAT0042236 abu-miR-10547; +MIMAT0042237 abu-miR-7147; +MIMAT0042238 abu-miR-10548-5p; +MIMAT0042239 abu-miR-10548-3p; +MIMAT0042240 abu-miR-148b; +MIMAT0042241 abu-miR-10549; +MIMAT0042242 abu-miR-10550-5p; +MIMAT0042243 abu-miR-10550-3p; +MIMAT0042244 abu-miR-10551; +MIMAT0042245 abu-miR-10552; +MIMAT0042246 abu-miR-10553; +MIMAT0042247 abu-miR-454b; +MIMAT0042248 abu-miR-150; +MIMAT0042249 abu-miR-29d; +MIMAT0042250 abu-miR-146; +MIMAT0042251 abu-miR-451; +MIMAT0042252 abu-miR-145; +MIMAT0042253 abu-miR-181c; +MIMAT0042254 abu-miR-152; +MIMAT0042255 abu-miR-27c; +MIMAT0042256 abu-miR-210; +MIMAT0042257 abu-miR-728b; +MIMAT0042258 abu-miR-24c; +MIMAT0042259 abu-miR-737; +MIMAT0042260 abu-miR-202; +MIMAT0042261 abu-miR-10554; +MIMAT0042262 abu-miR-10555; +MIMAT0042263 abu-miR-16c; +MIMAT0042264 abu-miR-10556a; +MIMAT0042265 abu-miR-10557; +MIMAT0042266 abu-miR-10558; +MIMAT0042267 abu-miR-10559; +MIMAT0042268 abu-miR-10560; +MIMAT0042269 abu-miR-10561; +MIMAT0042270 abu-miR-10562; +MIMAT0042271 abu-miR-10563; +MIMAT0042272 abu-miR-10564; +MIMAT0042273 abu-miR-10556b; +MIMAT0042274 abu-miR-7552; +MIMAT0042275 abu-miR-10565; +MIMAT0042276 mze-miR-10a; +MIMAT0042277 mze-miR-10b; +MIMAT0042278 mze-miR-192; +MIMAT0042279 mze-miR-183; +MIMAT0042280 mze-miR-182; +MIMAT0042281 mze-miR-10c; +MIMAT0042282 mze-miR-21; +MIMAT0042283 mze-miR-92a; +MIMAT0042284 mze-miR-9; +MIMAT0042285 mze-miR-184a; +MIMAT0042286 mze-miR-146; +MIMAT0042287 mze-miR-199; +MIMAT0042288 mze-miR-100; +MIMAT0042289 mze-miR-26a; +MIMAT0042290 mze-miR-204; +MIMAT0042291 mze-let-7a; +MIMAT0042292 mze-miR-27b; +MIMAT0042293 mze-miR-462; +MIMAT0042294 mze-miR-140; +MIMAT0042295 mze-miR-30a; +MIMAT0042296 mze-miR-205; +MIMAT0042297 mze-miR-203; +MIMAT0042298 mze-miR-133a; +MIMAT0042299 mze-miR-22a; +MIMAT0042300 mze-miR-25; +MIMAT0042301 mze-let-7d; +MIMAT0042302 mze-miR-184b; +MIMAT0042303 mze-miR-126; +MIMAT0042304 mze-miR-2188; +MIMAT0042305 mze-miR-92b; +MIMAT0042306 mze-miR-30c; +MIMAT0042307 mze-miR-222; +MIMAT0042308 mze-let-7g; +MIMAT0042309 mze-miR-16a; +MIMAT0042310 mze-miR-125a; +MIMAT0042311 mze-miR-103; +MIMAT0042312 mze-let-7i; +MIMAT0042313 mze-miR-455; +MIMAT0042314 mze-miR-30b; +MIMAT0042315 mze-miR-153a; +MIMAT0042316 mze-miR-221; +MIMAT0042317 mze-miR-218a; +MIMAT0042318 mze-miR-26b; +MIMAT0042319 mze-let-7e; +MIMAT0042320 mze-miR-214; +MIMAT0042321 mze-miR-216b; +MIMAT0042322 mze-miR-135a; +MIMAT0042323 mze-miR-125b; +MIMAT0042324 mze-miR-301b; +MIMAT0042325 mze-miR-1388; +MIMAT0042326 mze-miR-27d-5p; +MIMAT0042327 mze-miR-27d-3p; +MIMAT0042328 mze-miR-99b; +MIMAT0042329 mze-miR-133b; +MIMAT0042330 mze-miR-128; +MIMAT0042331 mze-miR-724; +MIMAT0042332 mze-miR-206; +MIMAT0042333 mze-miR-130; +MIMAT0042334 mze-miR-194a; +MIMAT0042335 mze-miR-200b; +MIMAT0042336 mze-let-7c; +MIMAT0042337 mze-miR-27a; +MIMAT0042338 mze-miR-142; +MIMAT0042339 mze-miR-30d; +MIMAT0042340 mze-miR-17; +MIMAT0042341 mze-miR-190b; +MIMAT0042342 mze-miR-731; +MIMAT0042343 mze-miR-200a; +MIMAT0042344 mze-miR-16b; +MIMAT0042345 mze-miR-144; +MIMAT0042346 mze-miR-218b; +MIMAT0042347 mze-miR-429b; +MIMAT0042348 mze-miR-138; +MIMAT0042349 mze-miR-122; +MIMAT0042350 mze-miR-27e; +MIMAT0042351 mze-miR-107; +MIMAT0042352 mze-miR-460; +MIMAT0042353 mze-miR-101a; +MIMAT0042354 mze-miR-23b; +MIMAT0042355 mze-miR-19b; +MIMAT0042356 mze-miR-19d; +MIMAT0042357 mze-let-7h; +MIMAT0042358 mze-miR-20a; +MIMAT0042359 mze-miR-1; +MIMAT0042360 mze-miR-338; +MIMAT0042361 mze-miR-129; +MIMAT0042362 mze-miR-18a; +MIMAT0042363 mze-miR-15a; +MIMAT0042364 mze-miR-135b; +MIMAT0042365 mze-miR-96; +MIMAT0042366 mze-miR-106; +MIMAT0042367 mze-miR-93; +MIMAT0042368 mze-miR-19a; +MIMAT0042369 mze-miR-24a; +MIMAT0042370 mze-miR-7a; +MIMAT0042371 mze-miR-132a; +MIMAT0042372 mze-miR-22c; +MIMAT0042373 mze-miR-489; +MIMAT0042374 mze-miR-196a; +MIMAT0042375 mze-miR-499; +MIMAT0042376 mze-let-7b; +MIMAT0042377 mze-miR-7b; +MIMAT0042378 mze-miR-101b; +MIMAT0042379 mze-miR-190a; +MIMAT0042380 mze-miR-139; +MIMAT0042381 mze-miR-212a; +MIMAT0042382 mze-miR-20b; +MIMAT0042383 mze-miR-727; +MIMAT0042384 mze-miR-365; +MIMAT0042385 mze-miR-187; +MIMAT0042386 mze-miR-730; +MIMAT0042387 mze-miR-33b; +MIMAT0042388 mze-miR-135c; +MIMAT0042389 mze-miR-135c-3p; +MIMAT0042390 mze-miR-2187a; +MIMAT0042391 mze-miR-193; +MIMAT0042392 mze-miR-29a; +MIMAT0042393 mze-miR-219a; +MIMAT0042394 mze-miR-456; +MIMAT0042395 mze-miR-22b; +MIMAT0042396 mze-miR-23a; +MIMAT0042397 mze-miR-155; +MIMAT0042398 mze-miR-34; +MIMAT0042399 mze-miR-124; +MIMAT0042400 mze-miR-375; +MIMAT0042401 mze-miR-153b; +MIMAT0042402 mze-miR-29b; +MIMAT0042403 mze-miR-181b; +MIMAT0042404 mze-miR-458; +MIMAT0042405 mze-miR-132b; +MIMAT0042406 mze-miR-15b; +MIMAT0042407 mze-miR-23c; +MIMAT0042408 mze-miR-18b; +MIMAT0042409 mze-miR-24b; +MIMAT0042410 mze-miR-216a; +MIMAT0042411 mze-miR-734; +MIMAT0042412 mze-miR-137; +MIMAT0042413 mze-miR-722; +MIMAT0042414 mze-miR-196b; +MIMAT0042415 mze-miR-194b; +MIMAT0042416 mze-miR-150; +MIMAT0042417 mze-miR-135d; +MIMAT0042418 mze-miR-31; +MIMAT0042419 mze-miR-19c; +MIMAT0042420 mze-miR-726; +MIMAT0042421 mze-miR-153c; +MIMAT0042422 mze-miR-551; +MIMAT0042423 mze-miR-147; +MIMAT0042424 mze-miR-723a; +MIMAT0042425 mze-miR-728; +MIMAT0042426 mze-miR-457; +MIMAT0042427 mze-miR-301a; +MIMAT0042428 mze-miR-181a; +MIMAT0042429 mze-miR-10d; +MIMAT0042430 mze-miR-723b; +MIMAT0042431 mze-miR-2187b; +MIMAT0042432 mze-miR-125c; +MIMAT0042433 mze-miR-212b; +MIMAT0042434 mze-miR-219c; +MIMAT0042435 mze-miR-219b; +MIMAT0042436 mze-miR-33a; +MIMAT0042437 mze-miR-7132b-5p; +MIMAT0042438 mze-miR-7132b-3p; +MIMAT0042439 mze-miR-99a; +MIMAT0042440 mze-miR-148-5p; +MIMAT0042441 mze-miR-7132a-5p; +MIMAT0042442 mze-miR-7132a-3p; +MIMAT0042443 mze-miR-15c-5p; +MIMAT0042444 mze-miR-15c-3p; +MIMAT0042445 mze-miR-7133; +MIMAT0042446 mze-miR-725; +MIMAT0042447 mze-miR-449b; +MIMAT0042448 mze-miR-449a; +MIMAT0042449 mze-miR-8159; +MIMAT0042450 mze-miR-8160b; +MIMAT0042451 mze-miR-10566; +MIMAT0042452 mze-miR-7147; +MIMAT0042453 mze-miR-10544; +MIMAT0042454 mze-miR-10554; +MIMAT0042455 mze-miR-10567; +MIMAT0042456 mze-miR-3120; +MIMAT0042457 mze-miR-10552; +MIMAT0042458 mze-miR-10545; +MIMAT0042459 mze-miR-10553; +MIMAT0042460 nbr-miR-10568; +MIMAT0042461 nbr-miR-10569; +MIMAT0042462 nbr-miR-10570; +MIMAT0042463 nbr-miR-10571; +MIMAT0042464 nbr-miR-10572; +MIMAT0042465 nbr-miR-10a; +MIMAT0042466 nbr-miR-10b; +MIMAT0042467 nbr-miR-183; +MIMAT0042468 nbr-miR-192; +MIMAT0042469 nbr-miR-182; +MIMAT0042470 nbr-miR-9; +MIMAT0042471 nbr-miR-92a; +MIMAT0042472 nbr-miR-21; +MIMAT0042473 nbr-miR-204; +MIMAT0042474 nbr-miR-199; +MIMAT0042475 nbr-miR-100; +MIMAT0042476 nbr-miR-26a; +MIMAT0042477 nbr-miR-184a; +MIMAT0042478 nbr-miR-30a; +MIMAT0042479 nbr-miR-27b; +MIMAT0042480 nbr-miR-140; +MIMAT0042481 nbr-miR-203; +MIMAT0042482 nbr-miR-25; +MIMAT0042483 nbr-let-7a; +MIMAT0042484 nbr-miR-205; +MIMAT0042485 nbr-miR-22a; +MIMAT0042486 nbr-miR-133a; +MIMAT0042487 nbr-miR-462; +MIMAT0042488 nbr-miR-2188; +MIMAT0042489 nbr-miR-126; +MIMAT0042490 nbr-miR-222; +MIMAT0042491 nbr-miR-135a; +MIMAT0042492 nbr-miR-153a; +MIMAT0042493 nbr-miR-218b; +MIMAT0042494 nbr-miR-184b; +MIMAT0042495 nbr-miR-221; +MIMAT0042496 nbr-miR-30c; +MIMAT0042497 nbr-miR-92b; +MIMAT0042498 nbr-miR-125a; +MIMAT0042499 nbr-miR-125b; +MIMAT0042500 nbr-let-7d; +MIMAT0042501 nbr-let-7g; +MIMAT0042502 nbr-miR-103; +MIMAT0042503 nbr-miR-19b; +MIMAT0042504 nbr-miR-301b; +MIMAT0042505 nbr-miR-99b; +MIMAT0042506 nbr-miR-455; +MIMAT0042507 nbr-miR-30b; +MIMAT0042508 nbr-miR-206; +MIMAT0042509 nbr-miR-724; +MIMAT0042510 nbr-miR-214; +MIMAT0042511 nbr-miR-26b; +MIMAT0042512 nbr-miR-190b; +MIMAT0042513 nbr-miR-216b; +MIMAT0042514 nbr-miR-133b; +MIMAT0042515 nbr-let-7i; +MIMAT0042516 nbr-miR-731; +MIMAT0042517 nbr-miR-200b; +MIMAT0042518 nbr-let-7e; +MIMAT0042519 nbr-miR-19d; +MIMAT0042520 nbr-miR-1388; +MIMAT0042521 nbr-miR-130; +MIMAT0042522 nbr-miR-17; +MIMAT0042523 nbr-miR-16b; +MIMAT0042524 nbr-miR-200a; +MIMAT0042525 nbr-miR-144; +MIMAT0042526 nbr-miR-19a; +MIMAT0042527 nbr-miR-30d; +MIMAT0042528 nbr-miR-96; +MIMAT0042529 nbr-miR-138; +MIMAT0042530 nbr-miR-27a; +MIMAT0042531 nbr-miR-142; +MIMAT0042532 nbr-let-7c; +MIMAT0042533 nbr-miR-101a; +MIMAT0042534 nbr-miR-194a; +MIMAT0042535 nbr-miR-23b; +MIMAT0042536 nbr-miR-107; +MIMAT0042537 nbr-miR-18a; +MIMAT0042538 nbr-miR-135b; +MIMAT0042539 nbr-miR-20a; +MIMAT0042540 nbr-miR-27e; +MIMAT0042541 nbr-miR-460; +MIMAT0042542 nbr-miR-23a; +MIMAT0042543 nbr-miR-1; +MIMAT0042544 nbr-miR-338; +MIMAT0042545 nbr-miR-132a; +MIMAT0042546 nbr-miR-129; +MIMAT0042547 nbr-miR-27d-5p; +MIMAT0042548 nbr-miR-27d-3p; +MIMAT0042549 nbr-miR-7; +MIMAT0042550 nbr-miR-196a; +MIMAT0042551 nbr-miR-122; +MIMAT0042552 nbr-miR-93; +MIMAT0042553 nbr-miR-15a; +MIMAT0042554 nbr-miR-190a; +MIMAT0042555 nbr-miR-499; +MIMAT0042556 nbr-let-7h; +MIMAT0042557 nbr-miR-489; +MIMAT0042558 nbr-miR-20b; +MIMAT0042559 nbr-miR-24a; +MIMAT0042560 nbr-miR-139; +MIMAT0042561 nbr-miR-22c; +MIMAT0042562 nbr-miR-101b; +MIMAT0042563 nbr-miR-187; +MIMAT0042564 nbr-let-7b; +MIMAT0042565 nbr-miR-2187a; +MIMAT0042566 nbr-miR-727; +MIMAT0042567 nbr-miR-24c; +MIMAT0042568 nbr-miR-365; +MIMAT0042569 nbr-miR-219c; +MIMAT0042570 nbr-miR-730; +MIMAT0042571 nbr-miR-155; +MIMAT0042572 nbr-miR-33b; +MIMAT0042573 nbr-miR-193; +MIMAT0042574 nbr-miR-456; +MIMAT0042575 nbr-miR-218a; +MIMAT0042576 nbr-miR-22b; +MIMAT0042577 nbr-miR-124; +MIMAT0042578 nbr-miR-16a; +MIMAT0042579 nbr-miR-34; +MIMAT0042580 nbr-miR-429b; +MIMAT0042581 nbr-miR-375; +MIMAT0042582 nbr-miR-153b; +MIMAT0042583 nbr-miR-10c; +MIMAT0042584 nbr-miR-29a; +MIMAT0042585 nbr-miR-29b; +MIMAT0042586 nbr-miR-10d; +MIMAT0042587 nbr-miR-181b; +MIMAT0042588 nbr-miR-132b; +MIMAT0042589 nbr-miR-458; +MIMAT0042590 nbr-miR-301a; +MIMAT0042591 nbr-miR-734; +MIMAT0042592 nbr-miR-196b; +MIMAT0042593 nbr-miR-24b; +MIMAT0042594 nbr-miR-18b; +MIMAT0042595 nbr-miR-137; +MIMAT0042596 nbr-miR-216a; +MIMAT0042597 nbr-miR-23c; +MIMAT0042598 nbr-miR-150; +MIMAT0042599 nbr-miR-722; +MIMAT0042600 nbr-miR-135d; +MIMAT0042601 nbr-miR-723b; +MIMAT0042602 nbr-miR-19c; +MIMAT0042603 nbr-miR-194b; +MIMAT0042604 nbr-miR-31; +MIMAT0042605 nbr-miR-153c; +MIMAT0042606 nbr-miR-15c-5p; +MIMAT0042607 nbr-miR-15c-3p; +MIMAT0042608 nbr-miR-723a; +MIMAT0042609 nbr-miR-551; +MIMAT0042610 nbr-miR-726; +MIMAT0042611 nbr-miR-7133-5p; +MIMAT0042612 nbr-miR-7133-3p; +MIMAT0042613 nbr-miR-147; +MIMAT0042614 nbr-miR-728; +MIMAT0042615 nbr-miR-181a; +MIMAT0042616 nbr-miR-457; +MIMAT0042617 nbr-miR-15b; +MIMAT0042618 nbr-miR-2187b; +MIMAT0042619 nbr-miR-212a; +MIMAT0042620 nbr-miR-212b; +MIMAT0042621 nbr-miR-219a; +MIMAT0042622 nbr-miR-219b; +MIMAT0042623 nbr-miR-7132a-5p; +MIMAT0042624 nbr-miR-7132a; +MIMAT0042625 nbr-miR-33a; +MIMAT0042626 nbr-miR-99a; +MIMAT0042627 nbr-miR-148-5p; +MIMAT0042628 nbr-miR-148-3p; +MIMAT0042629 nbr-miR-135c-5p; +MIMAT0042630 nbr-miR-135c-3p; +MIMAT0042631 nbr-miR-29c; +MIMAT0042632 nbr-miR-7132b; +MIMAT0042633 nbr-miR-725; +MIMAT0042634 nbr-miR-449b; +MIMAT0042635 nbr-miR-449a; +MIMAT0042636 nbr-miR-7147; +MIMAT0042637 nbr-miR-10544; +MIMAT0042638 nbr-miR-3120; +MIMAT0042639 nbr-miR-10553; +MIMAT0042640 nbr-miR-8159; +MIMAT0042641 nbr-miR-8160; +MIMAT0042642 oni-miR-10a; +MIMAT0042643 oni-miR-10b; +MIMAT0042644 oni-miR-192; +MIMAT0042645 oni-miR-183; +MIMAT0042646 oni-miR-182; +MIMAT0042647 oni-miR-143; +MIMAT0042648 oni-miR-204a; +MIMAT0042649 oni-miR-21; +MIMAT0042650 oni-miR-199a; +MIMAT0042651 oni-miR-26a; +MIMAT0042652 oni-miR-92a; +MIMAT0042653 oni-miR-30a; +MIMAT0042654 oni-miR-100; +MIMAT0042655 oni-miR-9a-5p; +MIMAT0042656 oni-miR-9a-3p; +MIMAT0042657 oni-miR-27b; +MIMAT0042658 oni-miR-9a; +MIMAT0042659 oni-let-7a; +MIMAT0042660 oni-miR-140; +MIMAT0042661 oni-let-7d; +MIMAT0042662 oni-miR-462; +MIMAT0042663 oni-miR-133a; +MIMAT0042664 oni-miR-30c; +MIMAT0042665 oni-miR-184b; +MIMAT0042666 oni-miR-22a; +MIMAT0042667 oni-miR-2188; +MIMAT0042668 oni-miR-205; +MIMAT0042669 oni-miR-25; +MIMAT0042670 oni-miR-222; +MIMAT0042671 oni-let-7g; +MIMAT0042672 oni-miR-125b; +MIMAT0042673 oni-miR-126; +MIMAT0042674 oni-miR-30b; +MIMAT0042675 oni-miR-221; +MIMAT0042676 oni-miR-125a; +MIMAT0042677 oni-miR-103; +MIMAT0042678 oni-miR-144a; +MIMAT0042679 oni-miR-218a; +MIMAT0042680 oni-let-7e; +MIMAT0042681 oni-miR-22b; +MIMAT0042682 oni-let-7i; +MIMAT0042683 oni-miR-1388; +MIMAT0042684 oni-miR-19b; +MIMAT0042685 oni-miR-214; +MIMAT0042686 oni-miR-724; +MIMAT0042687 oni-miR-16a; +MIMAT0042688 oni-miR-190b; +MIMAT0042689 oni-miR-455; +MIMAT0042690 oni-miR-135a; +MIMAT0042691 oni-miR-26b; +MIMAT0042692 oni-miR-153a; +MIMAT0042693 oni-miR-133b; +MIMAT0042694 oni-miR-92b; +MIMAT0042695 oni-miR-99b; +MIMAT0042696 oni-miR-206; +MIMAT0042697 oni-let-7c; +MIMAT0042698 oni-miR-218b; +MIMAT0042699 oni-miR-301b; +MIMAT0042700 oni-miR-194a; +MIMAT0042701 oni-miR-142; +MIMAT0042702 oni-miR-128; +MIMAT0042703 oni-miR-17a; +MIMAT0042704 oni-miR-130a; +MIMAT0042705 oni-miR-19d; +MIMAT0042706 oni-miR-200b; +MIMAT0042707 oni-miR-30d; +MIMAT0042708 oni-miR-16b; +MIMAT0042709 oni-miR-27e; +MIMAT0042710 oni-miR-27a; +MIMAT0042711 oni-miR-19a; +MIMAT0042712 oni-miR-200a; +MIMAT0042713 oni-miR-23b; +MIMAT0042714 oni-miR-138; +MIMAT0042715 oni-miR-107; +MIMAT0042716 oni-miR-216b; +MIMAT0042717 oni-miR-460; +MIMAT0042718 oni-miR-217; +MIMAT0042719 oni-miR-20; +MIMAT0042720 oni-miR-101a; +MIMAT0042721 oni-miR-27d-5p; +MIMAT0042722 oni-miR-27d-3p; +MIMAT0042723 oni-miR-129; +MIMAT0042724 oni-miR-338; +MIMAT0042725 oni-miR-96; +MIMAT0042726 oni-miR-18a; +MIMAT0042727 oni-miR-122; +MIMAT0042728 oni-miR-1; +MIMAT0042729 oni-miR-196a; +MIMAT0042730 oni-let-7h; +MIMAT0042731 oni-miR-135b; +MIMAT0042732 oni-miR-489; +MIMAT0042733 oni-miR-24a; +MIMAT0042734 oni-miR-106; +MIMAT0042735 oni-miR-22c; +MIMAT0042736 oni-miR-93; +MIMAT0042737 oni-miR-7; +MIMAT0042738 oni-miR-15a; +MIMAT0042739 oni-miR-499; +MIMAT0042740 oni-miR-132a; +MIMAT0042741 oni-miR-190a; +MIMAT0042742 oni-miR-139; +MIMAT0042743 oni-let-7b; +MIMAT0042744 oni-miR-24a-3; +MIMAT0042745 oni-miR-34; +MIMAT0042746 oni-miR-212b; +MIMAT0042747 oni-miR-101b; +MIMAT0042748 oni-miR-153c; +MIMAT0042749 oni-miR-365; +MIMAT0042750 oni-miR-727a; +MIMAT0042751 oni-miR-155; +MIMAT0042752 oni-miR-2187a; +MIMAT0042753 oni-miR-33b-5p; +MIMAT0042754 oni-miR-33b-3p; +MIMAT0042755 oni-miR-730; +MIMAT0042756 oni-miR-135c; +MIMAT0042757 oni-miR-135c-3p; +MIMAT0042758 oni-miR-187; +MIMAT0042759 oni-miR-219b; +MIMAT0042760 oni-miR-729-5p; +MIMAT0042761 oni-miR-729-3p; +MIMAT0042762 oni-miR-153b; +MIMAT0042763 oni-miR-193; +MIMAT0042764 oni-miR-137a; +MIMAT0042765 oni-miR-29a; +MIMAT0042766 oni-miR-736; +MIMAT0042767 oni-miR-29b; +MIMAT0042768 oni-miR-456; +MIMAT0042769 oni-miR-23a; +MIMAT0042770 oni-miR-124a; +MIMAT0042771 oni-miR-24a-4; +MIMAT0042772 oni-miR-429b; +MIMAT0042773 oni-miR-184a; +MIMAT0042774 oni-miR-375; +MIMAT0042775 oni-miR-10c; +MIMAT0042776 oni-miR-10d; +MIMAT0042777 oni-miR-9a-7-3p; +MIMAT0042778 oni-miR-203a; +MIMAT0042779 oni-miR-181a; +MIMAT0042780 oni-miR-725; +MIMAT0042781 oni-miR-731; +MIMAT0042782 oni-miR-181b; +MIMAT0042783 oni-miR-132b-5p; +MIMAT0042784 oni-miR-132b-3p; +MIMAT0042785 oni-miR-15b; +MIMAT0042786 oni-miR-458; +MIMAT0042787 oni-miR-150; +MIMAT0042788 oni-miR-24b-5p; +MIMAT0042789 oni-miR-24b-3p; +MIMAT0042790 oni-miR-31; +MIMAT0042791 oni-miR-734; +MIMAT0042792 oni-miR-194b; +MIMAT0042793 oni-miR-23c; +MIMAT0042794 oni-miR-196b; +MIMAT0042795 oni-miR-137b; +MIMAT0042796 oni-miR-216a; +MIMAT0042797 oni-miR-722; +MIMAT0042798 oni-miR-135d; +MIMAT0042799 oni-miR-18b; +MIMAT0042800 oni-miR-723a; +MIMAT0042801 oni-miR-147; +MIMAT0042802 oni-miR-2187b; +MIMAT0042803 oni-miR-728a; +MIMAT0042804 oni-miR-457; +MIMAT0042805 oni-miR-301a; +MIMAT0042806 oni-miR-551; +MIMAT0042807 oni-miR-726; +MIMAT0042808 oni-miR-19c; +MIMAT0042809 oni-miR-723b; +MIMAT0042810 oni-miR-212a-5p; +MIMAT0042811 oni-miR-212a-3p; +MIMAT0042812 oni-miR-7132a-5p; +MIMAT0042813 oni-miR-7132a-3p; +MIMAT0042814 oni-miR-219a-5p; +MIMAT0042815 oni-miR-219a-3p; +MIMAT0042816 oni-miR-219c-5p; +MIMAT0042817 oni-miR-219c-3p; +MIMAT0042818 oni-miR-99a; +MIMAT0042819 oni-miR-33a-5p; +MIMAT0042820 oni-miR-33a-3p; +MIMAT0042821 oni-miR-7132b-5p; +MIMAT0042822 oni-miR-7132b-3p; +MIMAT0042823 oni-miR-148-5p; +MIMAT0042824 oni-miR-148-3p; +MIMAT0042825 oni-miR-130b-5p; +MIMAT0042826 oni-miR-130b-3p; +MIMAT0042827 oni-miR-7133; +MIMAT0042828 oni-miR-15c; +MIMAT0042829 oni-miR-29c; +MIMAT0042830 oni-miR-449b-5p; +MIMAT0042831 oni-miR-449b-3p; +MIMAT0042832 oni-miR-449a; +MIMAT0042833 oni-miR-8160a; +MIMAT0042834 oni-miR-10544; +MIMAT0042835 oni-miR-3120-5p; +MIMAT0042836 oni-miR-3120-3p; +MIMAT0042837 oni-miR-8159; +MIMAT0042838 oni-miR-10573a; +MIMAT0042839 oni-miR-10553; +MIMAT0042840 oni-miR-10574; +MIMAT0042841 oni-miR-10575; +MIMAT0042842 oni-miR-10573b; +MIMAT0042843 oni-miR-10576; +MIMAT0042844 oni-miR-10577; +MIMAT0042845 oni-miR-7147; +MIMAT0042846 oni-miR-10578; +MIMAT0042847 oni-miR-10579; +MIMAT0042848 oni-miR-10580; +MIMAT0042849 oni-miR-10551; +MIMAT0042850 oni-miR-10545; +MIMAT0042851 oni-miR-10555; +MIMAT0042852 pny-miR-10a; +MIMAT0042853 pny-miR-10b; +MIMAT0042854 pny-miR-192; +MIMAT0042855 pny-miR-183; +MIMAT0042856 pny-miR-182; +MIMAT0042857 pny-miR-92; +MIMAT0042858 pny-miR-21; +MIMAT0042859 pny-miR-184a; +MIMAT0042860 pny-miR-100; +MIMAT0042861 pny-miR-146; +MIMAT0042862 pny-miR-462; +MIMAT0042863 pny-miR-204; +MIMAT0042864 pny-miR-140; +MIMAT0042865 pny-miR-26a; +MIMAT0042866 pny-miR-199; +MIMAT0042867 pny-miR-27b; +MIMAT0042868 pny-miR-184b; +MIMAT0042869 pny-miR-30c; +MIMAT0042870 pny-miR-30a; +MIMAT0042871 pny-let-7a; +MIMAT0042872 pny-miR-25; +MIMAT0042873 pny-miR-205; +MIMAT0042874 pny-miR-222; +MIMAT0042875 pny-miR-22a; +MIMAT0042876 pny-miR-135a; +MIMAT0042877 pny-let-7d; +MIMAT0042878 pny-miR-30b; +MIMAT0042879 pny-miR-126; +MIMAT0042880 pny-miR-214; +MIMAT0042881 pny-miR-125a; +MIMAT0042882 pny-miR-2188; +MIMAT0042883 pny-let-7g; +MIMAT0042884 pny-miR-1388; +MIMAT0042885 pny-miR-103; +MIMAT0042886 pny-miR-724; +MIMAT0042887 pny-miR-19b; +MIMAT0042888 pny-miR-99b; +MIMAT0042889 pny-miR-221; +MIMAT0042890 pny-miR-125b; +MIMAT0042891 pny-miR-455; +MIMAT0042892 pny-miR-153a; +MIMAT0042893 pny-miR-17; +MIMAT0042894 pny-miR-122; +MIMAT0042895 pny-let-7e; +MIMAT0042896 pny-miR-124; +MIMAT0042897 pny-miR-206; +MIMAT0042898 pny-let-7i; +MIMAT0042899 pny-miR-130a; +MIMAT0042900 pny-miR-26b; +MIMAT0042901 pny-miR-133; +MIMAT0042902 pny-miR-19d; +MIMAT0042903 pny-miR-128; +MIMAT0042904 pny-miR-216b; +MIMAT0042905 pny-miR-30d; +MIMAT0042906 pny-miR-144; +MIMAT0042907 pny-miR-190b; +MIMAT0042908 pny-miR-20a; +MIMAT0042909 pny-miR-107; +MIMAT0042910 pny-miR-16b; +MIMAT0042911 pny-miR-301b-1; +MIMAT0042912 pny-let-7c; +MIMAT0042913 pny-miR-200a; +MIMAT0042914 pny-miR-27a; +MIMAT0042915 pny-miR-15a; +MIMAT0042916 pny-miR-138; +MIMAT0042917 pny-miR-142; +MIMAT0042918 pny-miR-19a; +MIMAT0042919 pny-miR-27e; +MIMAT0042920 pny-miR-106; +MIMAT0042921 pny-miR-200b; +MIMAT0042922 pny-miR-135b; +MIMAT0042923 pny-miR-18a; +MIMAT0042924 pny-miR-23b; +MIMAT0042925 pny-miR-375; +MIMAT0042926 pny-miR-101a; +MIMAT0042927 pny-miR-194a; +MIMAT0042928 pny-miR-93; +MIMAT0042929 pny-miR-218b; +MIMAT0042930 pny-miR-460; +MIMAT0042931 pny-miR-96; +MIMAT0042932 pny-let-7h; +MIMAT0042933 pny-miR-196a; +MIMAT0042934 pny-miR-499; +MIMAT0042935 pny-miR-24a; +MIMAT0042936 pny-miR-139; +MIMAT0042937 pny-miR-7; +MIMAT0042938 pny-miR-129; +MIMAT0042939 pny-miR-489; +MIMAT0042940 pny-miR-338; +MIMAT0042941 pny-miR-190a; +MIMAT0042942 pny-miR-22c; +MIMAT0042943 pny-miR-20b; +MIMAT0042944 pny-miR-132; +MIMAT0042945 pny-miR-24a-4; +MIMAT0042946 pny-let-7b; +MIMAT0042947 pny-miR-212; +MIMAT0042948 pny-miR-365; +MIMAT0042949 pny-miR-187; +MIMAT0042950 pny-miR-135c-5p; +MIMAT0042951 pny-miR-135c-3p; +MIMAT0042952 pny-miR-730; +MIMAT0042953 pny-miR-219b; +MIMAT0042954 pny-miR-29a; +MIMAT0042955 pny-miR-23a; +MIMAT0042956 pny-miR-22b; +MIMAT0042957 pny-miR-218a; +MIMAT0042958 pny-miR-456; +MIMAT0042959 pny-miR-301b; +MIMAT0042960 pny-miR-1; +MIMAT0042961 pny-miR-155; +MIMAT0042962 pny-miR-34; +MIMAT0042963 pny-miR-729; +MIMAT0042964 pny-miR-16a; +MIMAT0042965 pny-miR-429b; +MIMAT0042966 pny-miR-24a-3; +MIMAT0042967 pny-miR-153b; +MIMAT0042968 pny-miR-10c; +MIMAT0042969 pny-miR-29b; +MIMAT0042970 pny-miR-10d; +MIMAT0042971 pny-miR-203; +MIMAT0042972 pny-miR-731; +MIMAT0042973 pny-miR-181b; +MIMAT0042974 pny-miR-23c; +MIMAT0042975 pny-miR-15b; +MIMAT0042976 pny-miR-458; +MIMAT0042977 pny-miR-18b; +MIMAT0042978 pny-miR-24b; +MIMAT0042979 pny-miR-132-2; +MIMAT0042980 pny-miR-196b; +MIMAT0042981 pny-miR-734; +MIMAT0042982 pny-miR-216a; +MIMAT0042983 pny-miR-31; +MIMAT0042984 pny-miR-137; +MIMAT0042985 pny-miR-101b; +MIMAT0042986 pny-miR-135d; +MIMAT0042987 pny-miR-150; +MIMAT0042988 pny-miR-722; +MIMAT0042989 pny-miR-19c; +MIMAT0042990 pny-miR-194b; +MIMAT0042991 pny-miR-551; +MIMAT0042992 pny-miR-723a; +MIMAT0042993 pny-miR-147; +MIMAT0042994 pny-miR-2187a; +MIMAT0042995 pny-let-7f; +MIMAT0042996 pny-miR-301a; +MIMAT0042997 pny-miR-457; +MIMAT0042998 pny-miR-153c; +MIMAT0042999 pny-miR-726; +MIMAT0043000 pny-miR-728; +MIMAT0043001 pny-miR-723b; +MIMAT0043002 pny-miR-2187b; +MIMAT0043003 pny-miR-181a; +MIMAT0043004 pny-miR-430a; +MIMAT0043005 pny-miR-125c; +MIMAT0043006 pny-miR-212-2; +MIMAT0043007 pny-miR-219a; +MIMAT0043008 pny-miR-7132a-5p; +MIMAT0043009 pny-miR-7132a-3p; +MIMAT0043010 pny-miR-33; +MIMAT0043011 pny-miR-7132b; +MIMAT0043012 pny-miR-99a; +MIMAT0043013 pny-miR-27d-5p; +MIMAT0043014 pny-miR-27d-3p; +MIMAT0043015 pny-miR-148-5p; +MIMAT0043016 pny-miR-148-3p; +MIMAT0043017 pny-miR-130b-5p; +MIMAT0043018 pny-miR-130b-3p; +MIMAT0043019 pny-miR-15c-5p; +MIMAT0043020 pny-miR-15c-3p; +MIMAT0043021 pny-miR-7133; +MIMAT0043022 pny-miR-725; +MIMAT0043023 pny-miR-449a; +MIMAT0043024 pny-miR-8160b; +MIMAT0043025 pny-miR-10566; +MIMAT0043026 pny-miR-7147; +MIMAT0043027 pny-miR-3120; +MIMAT0043028 pny-miR-10553; +MIMAT0043029 pny-miR-8159; +MIMAT0043030 pny-miR-10549; +MIMAT0043031 pny-miR-10544; +MIMAT0043032 pny-miR-430b; +MIMAT0043033 pny-miR-10555; +MIMAT0043034 egr-miR-96-5p; +MIMAT0043035 egr-miR-96-3p; +MIMAT0043036 egr-miR-7b-5p; +MIMAT0043037 egr-miR-7b-3p; +MIMAT0043038 oni-miR-430a; +MIMAT0043039 oni-miR-454b; +MIMAT0043040 oni-miR-8160b; +MIMAT0043041 oni-let-7f; +MIMAT0043042 oni-miR-2184; +MIMAT0043043 oni-miR-430b; +MIMAT0043044 oni-miR-18a-2; +MIMAT0043045 oni-miR-10558; +MIMAT0043046 oni-miR-10547b; +MIMAT0043047 oni-miR-10581a; +MIMAT0043048 oni-miR-10582; +MIMAT0043049 oni-miR-10552; +MIMAT0043050 oni-miR-7552; +MIMAT0043051 oni-miR-10583; +MIMAT0043052 oni-miR-10584; +MIMAT0043053 oni-miR-10581c; +MIMAT0043054 oni-miR-10573d; +MIMAT0043055 oni-miR-10581d; +MIMAT0043056 oni-miR-10585; +MIMAT0043057 oni-miR-10586; +MIMAT0043058 oni-miR-10587; +MIMAT0043059 oni-miR-10588; +MIMAT0043060 oni-miR-10589; +MIMAT0043061 oni-miR-10590; +MIMAT0043062 oni-miR-10591; +MIMAT0043063 oni-miR-10581b; +MIMAT0043064 oni-miR-26c; +MIMAT0043065 oni-miR-10547d; +MIMAT0043066 oni-miR-10592; +MIMAT0043067 oni-miR-10593; +MIMAT0043068 oni-miR-10594a; +MIMAT0043069 oni-miR-10595; +MIMAT0043070 oni-miR-10596-5p; +MIMAT0043071 oni-miR-10596-3p; +MIMAT0043072 oni-miR-10548b; +MIMAT0043073 oni-miR-10597a; +MIMAT0043074 oni-miR-10598; +MIMAT0043075 oni-miR-10599; +MIMAT0043076 oni-miR-10600; +MIMAT0043077 oni-miR-10601; +MIMAT0043078 oni-miR-10602; +MIMAT0043079 oni-miR-199c; +MIMAT0043080 oni-miR-10603a; +MIMAT0043081 oni-miR-10604; +MIMAT0043082 oni-miR-10605; +MIMAT0043084 oni-miR-10606; +MIMAT0043085 oni-miR-9b; +MIMAT0043086 oni-miR-10607; +MIMAT0043087 oni-miR-10608a; +MIMAT0043088 oni-miR-10609; +MIMAT0043089 oni-miR-728b; +MIMAT0043090 oni-miR-10610a; +MIMAT0043091 oni-miR-10611; +MIMAT0043092 oni-miR-10612; +MIMAT0043093 oni-miR-10613; +MIMAT0043094 oni-miR-26d; +MIMAT0043095 oni-miR-10614; +MIMAT0043096 oni-miR-10615a; +MIMAT0043097 oni-miR-10616a; +MIMAT0043098 oni-miR-6960; +MIMAT0043099 oni-miR-10603b; +MIMAT0043100 oni-miR-202; +MIMAT0043101 oni-miR-10617; +MIMAT0043102 oni-miR-10618; +MIMAT0043103 oni-miR-451b; +MIMAT0043104 oni-miR-10619; +MIMAT0043105 oni-miR-10620; +MIMAT0043106 oni-miR-10610b; +MIMAT0043107 oni-miR-10621a; +MIMAT0043108 oni-miR-10622; +MIMAT0043109 oni-miR-10623; +MIMAT0043110 oni-miR-10624; +MIMAT0043111 oni-miR-10625; +MIMAT0043112 oni-miR-449c; +MIMAT0043113 oni-miR-10626; +MIMAT0043114 oni-miR-10627; +MIMAT0043115 oni-miR-10628; +MIMAT0043116 oni-miR-10629; +MIMAT0043117 oni-miR-10630; +MIMAT0043118 oni-miR-10631; +MIMAT0043119 oni-miR-10632; +MIMAT0043120 oni-miR-29d; +MIMAT0043121 oni-miR-10633; +MIMAT0043122 oni-miR-10634; +MIMAT0043123 oni-miR-10635; +MIMAT0043124 oni-miR-27f; +MIMAT0043125 oni-miR-10636; +MIMAT0043126 oni-miR-10637; +MIMAT0043127 oni-miR-10638; +MIMAT0043128 oni-miR-10639; +MIMAT0043129 oni-miR-10640; +MIMAT0043130 oni-miR-10641; +MIMAT0043131 oni-miR-10642; +MIMAT0043132 oni-miR-10643; +MIMAT0043133 oni-miR-10556a; +MIMAT0043134 oni-miR-10644; +MIMAT0043135 oni-miR-10645; +MIMAT0043136 oni-miR-10646a; +MIMAT0043137 oni-miR-10647; +MIMAT0043138 oni-miR-10646b; +MIMAT0043139 oni-miR-10648; +MIMAT0043140 oni-miR-10649; +MIMAT0043141 oni-miR-10650; +MIMAT0043142 oni-miR-199b; +MIMAT0043143 oni-miR-10651; +MIMAT0043144 oni-miR-10615b; +MIMAT0043145 oni-miR-204b; +MIMAT0043146 oni-miR-10652; +MIMAT0043147 oni-miR-10653; +MIMAT0043148 oni-miR-10654; +MIMAT0043149 oni-miR-10655; +MIMAT0043150 oni-miR-10656; +MIMAT0043151 oni-miR-10657; +MIMAT0043152 oni-miR-10658; +MIMAT0043153 oni-miR-10659; +MIMAT0043154 oni-miR-10660; +MIMAT0043155 oni-miR-10661; +MIMAT0043156 oni-miR-10662; +MIMAT0043157 oni-miR-10663; +MIMAT0043158 oni-miR-10664; +MIMAT0043159 oni-miR-7565; +MIMAT0043160 oni-miR-10665; +MIMAT0043161 oni-miR-10666; +MIMAT0043162 oni-miR-10667; +MIMAT0043163 oni-miR-10668; +MIMAT0043164 oni-miR-10669; +MIMAT0043165 oni-miR-10670; +MIMAT0043166 oni-miR-1788; +MIMAT0043167 oni-miR-10671; +MIMAT0043168 oni-miR-10672; +MIMAT0043169 oni-miR-726b; +MIMAT0043170 oni-miR-10673; +MIMAT0043171 oni-miR-10674; +MIMAT0043172 oni-miR-10675; +MIMAT0043173 oni-miR-10676; +MIMAT0043174 oni-miR-10677; +MIMAT0043175 oni-miR-10678; +MIMAT0043176 oni-miR-10679; +MIMAT0043177 oni-miR-132c; +MIMAT0043178 oni-miR-10548c; +MIMAT0043179 oni-miR-10680; +MIMAT0043180 oni-miR-10681; +MIMAT0043181 oni-miR-10682; +MIMAT0043182 oni-miR-10683; +MIMAT0043183 oni-miR-10684; +MIMAT0043184 oni-miR-10685; +MIMAT0043185 oni-miR-10686; +MIMAT0043186 oni-miR-10687; +MIMAT0043187 oni-miR-10688; +MIMAT0043188 oni-miR-34b; +MIMAT0043189 oni-miR-10689; +MIMAT0043190 oni-miR-10690; +MIMAT0043191 oni-miR-10691; +MIMAT0043192 oni-miR-10692; +MIMAT0043193 oni-miR-10693; +MIMAT0043194 oni-miR-10621b; +MIMAT0043195 oni-miR-10694; +MIMAT0043196 oni-miR-10695; +MIMAT0043197 oni-miR-10696; +MIMAT0043198 oni-miR-10697a; +MIMAT0043199 oni-miR-10698; +MIMAT0043200 oni-miR-10699; +MIMAT0043201 oni-miR-10700; +MIMAT0043202 oni-miR-10701; +MIMAT0043203 oni-miR-10702; +MIMAT0043204 oni-miR-10703; +MIMAT0043205 oni-miR-10704; +MIMAT0043206 oni-miR-10705; +MIMAT0043207 oni-miR-10706; +MIMAT0043208 oni-miR-10707; +MIMAT0043209 oni-miR-10708; +MIMAT0043210 oni-miR-10709; +MIMAT0043211 oni-miR-10710; +MIMAT0043212 oni-miR-10711; +MIMAT0043213 oni-miR-10712; +MIMAT0043214 oni-miR-10713; +MIMAT0043215 oni-miR-10714; +MIMAT0043216 oni-miR-10715; +MIMAT0043217 oni-miR-10716; +MIMAT0043218 oni-miR-10717; +MIMAT0043219 oni-miR-10718; +MIMAT0043220 oni-miR-10719; +MIMAT0043221 oni-miR-10720; +MIMAT0043222 oni-miR-10721; +MIMAT0043223 oni-miR-142b; +MIMAT0043224 oni-miR-10594c; +MIMAT0043225 oni-miR-10722; +MIMAT0043226 oni-miR-144b; +MIMAT0043227 oni-miR-10723; +MIMAT0043228 oni-miR-10724; +MIMAT0043229 oni-miR-10725; +MIMAT0043230 oni-miR-10726; +MIMAT0043231 oni-miR-10727; +MIMAT0043232 oni-miR-10728; +MIMAT0043233 oni-miR-10729; +MIMAT0043234 oni-miR-10730; +MIMAT0043235 oni-miR-10731; +MIMAT0043236 oni-miR-10732; +MIMAT0043237 oni-miR-10733; +MIMAT0043238 oni-miR-10734; +MIMAT0043239 oni-miR-10735; +MIMAT0043240 oni-miR-10610c; +MIMAT0043241 oni-miR-10736; +MIMAT0043242 oni-miR-10737; +MIMAT0043243 oni-miR-10738; +MIMAT0043244 oni-miR-10739; +MIMAT0043245 oni-miR-219d; +MIMAT0043246 oni-miR-10740; +MIMAT0043247 oni-miR-10741; +MIMAT0043248 oni-miR-10742; +MIMAT0043249 oni-miR-10743; +MIMAT0043250 oni-miR-10744; +MIMAT0043251 oni-miR-10745; +MIMAT0043252 oni-miR-10746; +MIMAT0043253 oni-miR-132d; +MIMAT0043254 oni-miR-10747; +MIMAT0043255 oni-miR-7144; +MIMAT0043256 oni-miR-10748; +MIMAT0043257 oni-miR-10749; +MIMAT0043258 oni-miR-10750; +MIMAT0043259 oni-miR-10751; +MIMAT0043260 oni-miR-10697b; +MIMAT0043261 oni-miR-10752; +MIMAT0043262 oni-miR-10753; +MIMAT0043263 oni-miR-10754; +MIMAT0043264 oni-miR-10755; +MIMAT0043265 oni-miR-10756; +MIMAT0043266 oni-miR-10757; +MIMAT0043267 oni-miR-10758; +MIMAT0043268 oni-miR-10759; +MIMAT0043269 oni-miR-10760; +MIMAT0043270 oni-miR-10761; +MIMAT0043271 oni-miR-10762; +MIMAT0043272 oni-miR-10763; +MIMAT0043273 oni-miR-10764; +MIMAT0043274 oni-miR-10765; +MIMAT0043275 oni-miR-10766; +MIMAT0043276 oni-miR-10767; +MIMAT0043277 oni-miR-10768; +MIMAT0043278 oni-miR-10769; +MIMAT0043279 oni-miR-10770; +MIMAT0043280 oni-miR-10771; +MIMAT0043281 oni-miR-10772; +MIMAT0043282 oni-miR-10773; +MIMAT0043283 oni-miR-10774; +MIMAT0043284 oni-miR-10775; +MIMAT0043285 oni-miR-10776; +MIMAT0043286 oni-miR-10777; +MIMAT0043287 oni-miR-10778; +MIMAT0043288 oni-miR-10779; +MIMAT0043289 oni-miR-10780; +MIMAT0043290 oni-miR-10781; +MIMAT0043291 oni-miR-10782; +MIMAT0043292 oni-miR-10783; +MIMAT0043293 oni-miR-10784; +MIMAT0043294 oni-miR-10785; +MIMAT0043295 oni-miR-10786; +MIMAT0043296 oni-miR-10787; +MIMAT0043297 oni-miR-10788; +MIMAT0043298 oni-miR-10789; +MIMAT0043299 oni-miR-10790; +MIMAT0043300 oni-miR-10791; +MIMAT0043301 oni-miR-10792; +MIMAT0043302 oni-miR-10793; +MIMAT0043303 oni-miR-10794; +MIMAT0043304 oni-miR-10795; +MIMAT0043305 oni-miR-10796; +MIMAT0043306 oni-miR-10797; +MIMAT0043307 oni-miR-10798; +MIMAT0043308 oni-miR-10799; +MIMAT0043309 oni-miR-10800; +MIMAT0043310 oni-miR-10801; +MIMAT0043311 oni-miR-10802; +MIMAT0043312 oni-miR-10803; +MIMAT0043313 oni-miR-10563; +MIMAT0043314 oni-miR-10804; +MIMAT0043315 oni-miR-10805; +MIMAT0043316 oni-miR-10806; +MIMAT0043317 oni-miR-10807; +MIMAT0043318 oni-miR-10808; +MIMAT0043319 oni-miR-10809; +MIMAT0043320 oni-miR-10810; +MIMAT0043321 oni-miR-10811; +MIMAT0043322 oni-miR-10812; +MIMAT0043323 oni-miR-10813; +MIMAT0043324 oni-miR-10814; +MIMAT0043325 oni-miR-10815; +MIMAT0043326 oni-miR-10559; +MIMAT0043327 oni-miR-10816; +MIMAT0043328 oni-miR-10817; +MIMAT0043329 oni-miR-10818; +MIMAT0043330 oni-miR-10819; +MIMAT0043331 oni-miR-10820; +MIMAT0043332 oni-miR-10821; +MIMAT0043333 oni-miR-10822; +MIMAT0043334 oni-miR-10823; +MIMAT0043335 oni-miR-10824; +MIMAT0043336 oni-miR-10825; +MIMAT0043337 oni-miR-9c-5p; +MIMAT0043338 oni-miR-124b; +MIMAT0043339 oni-miR-10826; +MIMAT0043340 oni-miR-10827; +MIMAT0043341 oni-miR-10828; +MIMAT0043342 oni-miR-10829; +MIMAT0043343 oni-miR-10830; +MIMAT0043344 oni-miR-10831a; +MIMAT0043345 oni-miR-10832; +MIMAT0043346 oni-miR-10573c; +MIMAT0043347 oni-miR-10833; +MIMAT0043348 oni-miR-10834; +MIMAT0043349 oni-miR-10835; +MIMAT0043350 oni-miR-10836; +MIMAT0043351 oni-miR-10837; +MIMAT0043352 oni-miR-10838; +MIMAT0043353 oni-miR-10839; +MIMAT0043354 oni-miR-10840; +MIMAT0043355 oni-miR-10841; +MIMAT0043356 oni-miR-10842; +MIMAT0043357 oni-miR-10556b; +MIMAT0043358 oni-miR-10843; +MIMAT0043359 oni-miR-10844; +MIMAT0043360 oni-miR-10616b; +MIMAT0043361 oni-miR-10845; +MIMAT0043362 oni-miR-10831b; +MIMAT0043363 oni-miR-10846; +MIMAT0043364 oni-miR-10847; +MIMAT0043366 oni-miR-10848; +MIMAT0043367 oni-miR-4585; +MIMAT0043368 oni-miR-10569; +MIMAT0043369 oni-miR-10849; +MIMAT0043370 oni-miR-10547c; +MIMAT0043371 oni-miR-10850; +MIMAT0043372 oni-miR-10851; +MIMAT0043373 oni-miR-10852; +MIMAT0043374 oni-miR-10853; +MIMAT0043375 oni-miR-10854; +MIMAT0043376 oni-miR-10855; +MIMAT0043377 oni-miR-10856; +MIMAT0043378 oni-miR-10857; +MIMAT0043379 oni-miR-10858; +MIMAT0043380 oni-miR-27c; +MIMAT0043381 oni-miR-10859; +MIMAT0043382 oni-miR-10860; +MIMAT0043383 oni-miR-10861; +MIMAT0043384 oni-miR-10862; +MIMAT0043385 oni-miR-10863; +MIMAT0043386 oni-miR-10864; +MIMAT0043387 oni-miR-10865; +MIMAT0043388 oni-miR-10866; +MIMAT0043389 oni-miR-10867; +MIMAT0043390 oni-miR-10868; +MIMAT0043391 oni-miR-10869; +MIMAT0043392 oni-miR-10870; +MIMAT0043393 oni-miR-10871; +MIMAT0043394 oni-miR-10548a; +MIMAT0043395 oni-miR-145; +MIMAT0043396 oni-miR-153d; +MIMAT0043397 oni-miR-10872; +MIMAT0043398 oni-miR-10608b; +MIMAT0043399 oni-miR-10873; +MIMAT0043400 oni-miR-10874; +MIMAT0043401 oni-miR-10875; +MIMAT0043402 oni-miR-10547a; +MIMAT0043403 oni-miR-10876; +MIMAT0043404 oni-miR-10877; +MIMAT0043405 oni-miR-10878; +MIMAT0043406 oni-miR-10594b; +MIMAT0043407 oni-miR-10879; +MIMAT0043408 oni-miR-10603c; +MIMAT0043409 oni-miR-10880; +MIMAT0043410 oni-miR-10881; +MIMAT0043411 oni-miR-10882; +MIMAT0043412 oni-miR-10883; +MIMAT0043413 oni-miR-10548d; +MIMAT0043414 oni-miR-10884; +MIMAT0043415 oni-miR-10885; +MIMAT0043416 oni-miR-10886; +MIMAT0043417 oni-miR-10887; +MIMAT0043418 oni-miR-10888; +MIMAT0043419 oni-miR-10889; +MIMAT0043420 oni-miR-10890; +MIMAT0043421 oni-miR-10891; +MIMAT0043422 oni-miR-10892; +MIMAT0043423 oni-miR-10549; +MIMAT0043424 oni-miR-10893; +MIMAT0043425 oni-miR-10894; +MIMAT0043426 oni-miR-10895; +MIMAT0043427 oni-miR-727b; +MIMAT0043428 oni-miR-181c; +MIMAT0043429 oni-miR-10896; +MIMAT0043430 oni-miR-10897; +MIMAT0043431 oni-miR-10898; +MIMAT0043432 oni-miR-10597b; +MIMAT0043433 oni-miR-10899; +MIMAT0043434 oni-miR-10900a; +MIMAT0043435 oni-miR-10901; +MIMAT0043436 oni-miR-10902; +MIMAT0043437 oni-miR-10903; +MIMAT0043438 oni-miR-34c; +MIMAT0043439 oni-miR-10904; +MIMAT0043440 oni-miR-10905; +MIMAT0043441 oni-miR-10597c; +MIMAT0043442 oni-miR-10906; +MIMAT0043443 oni-miR-10907; +MIMAT0043444 oni-miR-10562; +MIMAT0043445 oni-miR-184c; +MIMAT0043446 oni-miR-10597d; +MIMAT0043447 oni-miR-10908; +MIMAT0043448 oni-miR-10909; +MIMAT0043449 oni-miR-10910; +MIMAT0043450 oni-miR-3553; +MIMAT0043452 oni-miR-10912; +MIMAT0043453 oni-miR-10913; +MIMAT0043454 oni-miR-10914; +MIMAT0043455 oni-miR-10915; +MIMAT0043456 oni-miR-10916; +MIMAT0043457 oni-miR-10917; +MIMAT0043458 oni-miR-10918; +MIMAT0043459 oni-miR-10919; +MIMAT0043460 oni-miR-10920; +MIMAT0043461 oni-miR-10900b; +MIMAT0043462 oni-miR-10921; +MIMAT0043463 oni-miR-210; +MIMAT0043464 oni-miR-10922; +MIMAT0043465 oni-miR-10923; +MIMAT0043466 oni-miR-10924; +MIMAT0043467 oni-miR-301c; +MIMAT0043468 oni-miR-10925; +MIMAT0043469 oni-miR-10926; +MIMAT0043470 oni-miR-10927; +MIMAT0043471 oni-miR-10928; +MIMAT0043472 oni-miR-10929; +MIMAT0043473 oni-miR-10930; +MIMAT0043474 oni-miR-10931; +MIMAT0043475 oni-miR-10932; +MIMAT0043476 oni-miR-10933; +MIMAT0043477 oni-miR-10934; +MIMAT0043478 oni-miR-10935; +MIMAT0043479 oni-miR-10936; +MIMAT0043480 oni-miR-23d; +MIMAT0043481 oni-miR-10937; +MIMAT0043482 oni-miR-10938; +MIMAT0043483 oni-miR-10939; +MIMAT0043484 oni-miR-10940; +MIMAT0043485 oni-miR-10941; +MIMAT0043486 oni-miR-10942; +MIMAT0043487 oni-miR-10943; +MIMAT0043488 oni-miR-10944; +MIMAT0043490 oni-miR-10946; +MIMAT0043491 oni-miR-10947; +MIMAT0043492 oni-miR-10948; +MIMAT0043493 oni-miR-10949; +MIMAT0043494 oni-miR-10950; +MIMAT0043495 oni-miR-7550; +MIMAT0043496 oni-miR-10951; +MIMAT0043497 oni-miR-10952; +MIMAT0043498 oni-miR-10953; +MIMAT0043499 oni-miR-17b; +MIMAT0043500 oni-miR-10954; +MIMAT0043501 oni-miR-10955; +MIMAT0043502 oni-miR-10956; +MIMAT0043503 oni-miR-10957; +MIMAT0043504 oni-miR-10958; +MIMAT0043505 oni-miR-10959; +MIMAT0043506 oni-miR-10960; +MIMAT0043507 oni-miR-10961; +MIMAT0043508 oni-miR-10962; +MIMAT0043509 oni-miR-184d; +MIMAT0043510 oni-miR-10963; +MIMAT0043511 oni-miR-10964; +MIMAT0043512 oni-miR-10965; +MIMAT0043513 oni-miR-10966; +MIMAT0043514 oni-miR-10967; +MIMAT0043515 oni-miR-203b; +MIMAT0043516 oni-miR-10968; +MIMAT0043517 oni-miR-10969; +MIMAT0043518 oni-miR-10970; +MIMAT0043519 oni-miR-10971; +MIMAT0043520 oni-miR-10972; +MIMAT0043521 oni-miR-10973; +MIMAT0043522 oni-miR-10974; +MIMAT0043523 oni-miR-10975; +MIMAT0043524 oni-miR-10976; +MIMAT0043525 oni-miR-181d; +MIMAT0043526 oni-miR-10977; +MIMAT0043527 mdm-miR10978a; +MIMAT0043528 mdm-miR10978b; +MIMAT0043529 mdm-miR10979; +MIMAT0043530 mdm-miR10980a; +MIMAT0043531 mdm-miR10980b; +MIMAT0043532 mdm-miR10981a; +MIMAT0043533 mdm-miR10981b; +MIMAT0043534 mdm-miR3627d; +MIMAT0043535 mdm-miR10982a; +MIMAT0043536 mdm-miR10982b; +MIMAT0043537 mdm-miR10982c; +MIMAT0043538 mdm-miR10982d; +MIMAT0043539 mdm-miR159d; +MIMAT0043540 mdm-miR159e; +MIMAT0043541 mdm-miR159f; +MIMAT0043542 mdm-miR530a; +MIMAT0043543 mdm-miR530b; +MIMAT0043544 mdm-miR530c; +MIMAT0043545 mdm-miR166j; +MIMAT0043546 mdm-miR10983; +MIMAT0043547 mdm-miR10984a-5p; +MIMAT0043548 mdm-miR10984a-3p; +MIMAT0043549 mdm-miR10985; +MIMAT0043550 mdm-miR399k; +MIMAT0043551 mdm-miR10986; +MIMAT0043552 mdm-miR319d; +MIMAT0043553 mdm-miR10987; +MIMAT0043554 mdm-miR10988; +MIMAT0043555 mdm-miR10989a; +MIMAT0043556 mdm-miR10989b; +MIMAT0043557 mdm-miR10989c; +MIMAT0043558 mdm-miR10989d; +MIMAT0043559 mdm-miR10989e; +MIMAT0043560 mdm-miR10990; +MIMAT0043561 mdm-miR10991a; +MIMAT0043562 mdm-miR10991b; +MIMAT0043563 mdm-miR10991c; +MIMAT0043564 mdm-miR10991d; +MIMAT0043565 mdm-miR10991e; +MIMAT0043566 mdm-miR10992; +MIMAT0043567 mdm-miR319e; +MIMAT0043568 mdm-miR319f; +MIMAT0043569 mdm-miR319g; +MIMAT0043570 mdm-miR10993a; +MIMAT0043571 mdm-miR10993b; +MIMAT0043572 mdm-miR10994-5p; +MIMAT0043573 mdm-miR10994-3p; +MIMAT0043574 mdm-miR395j; +MIMAT0043575 mdm-miR169g; +MIMAT0043576 mdm-miR169h; +MIMAT0043577 mdm-miR169i; +MIMAT0043578 mdm-miR169j; +MIMAT0043579 mdm-miR10995; +MIMAT0043580 mdm-miR10996a; +MIMAT0043581 mdm-miR10997; +MIMAT0043582 mdm-miR171p; +MIMAT0043583 mdm-miR393g; +MIMAT0043584 mdm-miR393h; +MIMAT0043585 mdm-miR10998; +MIMAT0043586 mdm-miR395k; +MIMAT0043587 mdm-miR10993c; +MIMAT0043588 mdm-miR10993d; +MIMAT0043589 mdm-miR10993e; +MIMAT0043590 mdm-miR10993f; +MIMAT0043591 mdm-miR10999a; +MIMAT0043592 mdm-miR10999b; +MIMAT0043593 mdm-miR10981c; +MIMAT0043594 mdm-miR10981d; +MIMAT0043595 mdm-miR319h; +MIMAT0043596 mdm-miR11002c-5p; +MIMAT0043597 mdm-miR11002c-3p; +MIMAT0043598 mdm-miR11000; +MIMAT0043599 mdm-miR11001; +MIMAT0043600 mdm-miR11002a; +MIMAT0043601 mdm-miR11002b; +MIMAT0043602 mdm-miR11003; +MIMAT0043603 mdm-miR11004; +MIMAT0043604 mdm-miR11005; +MIMAT0043605 mdm-miR171q; +MIMAT0043606 mdm-miR11006; +MIMAT0043607 mdm-miR11007; +MIMAT0043608 mdm-miR11008; +MIMAT0043609 mdm-miR10984b-5p; +MIMAT0043610 mdm-miR10984b-3p; +MIMAT0043611 mdm-miR11009; +MIMAT0043612 mdm-miR11010; +MIMAT0043613 mdm-miR11011a; +MIMAT0043614 mdm-miR11012a; +MIMAT0043615 mdm-miR11012b; +MIMAT0043616 mdm-miR169k; +MIMAT0043617 mdm-miR169l; +MIMAT0043618 mdm-miR169m; +MIMAT0043619 mdm-miR169n; +MIMAT0043620 mdm-miR172p; +MIMAT0043621 mdm-miR11013; +MIMAT0043622 mdm-miR10996b; +MIMAT0043623 mdm-miR11014; +MIMAT0043624 mdm-miR11015; +MIMAT0043625 mdm-miR11016; +MIMAT0043626 mdm-miR395l; +MIMAT0043627 mdm-miR11017; +MIMAT0043628 mdm-miR11018; +MIMAT0043629 mdm-miR11019; +MIMAT0043630 mdm-miR11011b; +MIMAT0043631 mdm-miR11020; +MIMAT0043632 mdm-miR169o; +MIMAT0043633 seu-miR11021; +MIMAT0043634 seu-miR11022; +MIMAT0043635 seu-miR11023; +MIMAT0043636 seu-miR11024; +MIMAT0043637 seu-miR11025; +MIMAT0043638 seu-miR11026; +MIMAT0043639 seu-miR11027; +MIMAT0043640 seu-miR11028; +MIMAT0043641 seu-miR11029; +MIMAT0043642 seu-miR11030a; +MIMAT0043643 seu-miR11030b; +MIMAT0043644 seu-miR11031; +MIMAT0043645 seu-miR11032; +MIMAT0043646 seu-miR11033; +MIMAT0043647 seu-miR319; +MIMAT0043648 seu-miR11034; +MIMAT0043649 seu-miR11035; +MIMAT0043650 seu-miR11036; +MIMAT0043651 seu-miR11037; +MIMAT0043652 seu-miR11038; +MIMAT0043653 seu-miR11039; +MIMAT0043654 seu-miR11040; +MIMAT0043655 seu-miR11041; +MIMAT0043656 seu-miR11042; +MIMAT0043657 seu-miR11043; +MIMAT0043658 seu-miR11044; +MIMAT0043659 seu-miR11045; +MIMAT0043660 seu-miR11046; +MIMAT0043661 seu-miR11047; +MIMAT0043662 seu-miR11048; +MIMAT0043663 seu-miR11049; +MIMAT0043664 eel-miR-11050-5p; +MIMAT0043665 eel-miR-11050-3p; +MIMAT0043666 eel-miR-11051-5p; +MIMAT0043667 eel-miR-11052-3p; +MIMAT0043668 eel-miR-11053-5p; +MIMAT0043669 eel-miR-11053-3p; +MIMAT0043670 eel-miR-8160-5p; +MIMAT0043671 eel-miR-8160-3p; +MIMAT0043672 eel-miR-11054-5p; +MIMAT0043673 eel-miR-11054-3p; +MIMAT0043674 eel-miR-11055-5p; +MIMAT0043675 eel-miR-11055-3p; +MIMAT0043676 eel-miR-7132-5p; +MIMAT0043677 eel-miR-7132-3p; +MIMAT0043678 eel-miR-11056-5p; +MIMAT0043679 eel-miR-11056-3p; +MIMAT0043680 eel-miR-11057-5p; +MIMAT0043681 eel-miR-11057-3p; +MIMAT0043682 eel-miR-11058-5p; +MIMAT0043683 eel-miR-11059-5p; +MIMAT0043684 eel-miR-11059-3p; +MIMAT0043685 eel-miR-11060-5p; +MIMAT0043686 eel-miR-11060-3p; +MIMAT0043687 eel-miR-11061-3p; +MIMAT0043688 eel-miR-11062-5p; +MIMAT0043689 eel-miR-11062-3p; +MIMAT0043690 eel-miR-11063-5p; +MIMAT0043691 eel-miR-11063-3p; +MIMAT0043692 eel-miR-11064-3p; +MIMAT0043693 eel-miR-7552-5p; +MIMAT0043694 eel-miR-7552-3p; +MIMAT0043695 eel-miR-7552-2-3p; +MIMAT0043696 eel-miR-11065-5p; +MIMAT0043697 eel-miR-11065-3p; +MIMAT0043698 lja-miR11066-5p; +MIMAT0043699 lja-miR11066-3p; +MIMAT0043700 lja-miR7533c-5p; +MIMAT0043701 lja-miR11067-5p; +MIMAT0043702 lja-miR11067-3p; +MIMAT0043703 lja-miR11068a-5p; +MIMAT0043704 lja-miR11068a-3p; +MIMAT0043705 lja-miR11068b-3p; +MIMAT0043706 lja-miR11068c-5p; +MIMAT0043707 lja-miR11068c-3p; +MIMAT0043708 lja-miR11069-5p; +MIMAT0043709 lja-miR11070-5p; +MIMAT0043710 lja-miR11071-3p; +MIMAT0043711 lja-miR11072a-3p; +MIMAT0043712 lja-miR11073-5p; +MIMAT0043713 lja-miR11074-5p; +MIMAT0043714 lja-miR11075a-3p; +MIMAT0043715 lja-miR11076-5p; +MIMAT0043716 lja-miR11076-3p; +MIMAT0043717 lja-miR11077a-5p; +MIMAT0043718 lja-miR11077a-3p; +MIMAT0043719 lja-miR11078a-3p; +MIMAT0043720 lja-miR11078b-3p; +MIMAT0043721 lja-miR11078c-5p; +MIMAT0043722 lja-miR11078c-3p; +MIMAT0043723 lja-miR11078d-3p; +MIMAT0043724 lja-miR11079-5p; +MIMAT0043725 lja-miR11079-3p; +MIMAT0043726 lja-miR164-5p; +MIMAT0043727 lja-miR11080-3p; +MIMAT0043728 lja-miR11072c-3p; +MIMAT0043729 lja-miR11072d-3p; +MIMAT0043730 lja-miR11072e-3p; +MIMAT0043731 lja-miR11072h-3p; +MIMAT0043732 lja-miR11072f-3p; +MIMAT0043733 lja-miR11072g-3p; +MIMAT0043734 lja-miR11081-3p; +MIMAT0043735 lja-miR11082a-3p; +MIMAT0043736 lja-miR11082b-3p; +MIMAT0043737 lja-miR11082c-3p; +MIMAT0043738 lja-miR11082d-3p; +MIMAT0043739 lja-miR11082e-3p; +MIMAT0043740 lja-miR11082f-3p; +MIMAT0043741 lja-miR11082g-3p; +MIMAT0043742 lja-miR11082h-3p; +MIMAT0043743 lja-miR11082i-5p; +MIMAT0043744 lja-miR11082i-3p; +MIMAT0043745 lja-miR11082j-3p; +MIMAT0043746 lja-miR11082k-3p; +MIMAT0043747 lja-miR11083a-3p; +MIMAT0043748 lja-miR11083b-3p; +MIMAT0043749 lja-miR11083c-5p; +MIMAT0043750 lja-miR11083c-3p; +MIMAT0043751 lja-miR11078e-3p; +MIMAT0043752 lja-miR11072b-5p; +MIMAT0043753 lja-miR11072b-3p; +MIMAT0043754 lja-miR11068d-3p; +MIMAT0043755 lja-miR11072i-5p; +MIMAT0043756 lja-miR11072i-3p; +MIMAT0043757 lja-miR11075b-5p; +MIMAT0043758 lja-miR11075b-3p; +MIMAT0043759 lja-miR7526i-3p; +MIMAT0043760 lja-miR7526j-3p; +MIMAT0043761 lja-miR7526k-3p; +MIMAT0043762 lja-miR11084-5p; +MIMAT0043763 lja-miR11085-5p; +MIMAT0043764 lja-miR11085-3p; +MIMAT0043765 lja-miR11086-5p; +MIMAT0043766 lja-miR11086-3p; +MIMAT0043767 lja-miR11097c-3p; +MIMAT0043768 lja-miR11087-3p; +MIMAT0043769 lja-miR11088a-5p; +MIMAT0043770 lja-miR11088a-3p; +MIMAT0043771 lja-miR11089a-5p; +MIMAT0043772 lja-miR11068e-3p; +MIMAT0043773 lja-miR11108c-3p; +MIMAT0043774 lja-miR11090a-5p; +MIMAT0043775 lja-miR11090b-5p; +MIMAT0043776 lja-miR11090c-5p; +MIMAT0043777 lja-miR11090d-5p; +MIMAT0043778 lja-miR11090d-3p; +MIMAT0043779 lja-miR11091-3p; +MIMAT0043780 lja-miR11092-3p; +MIMAT0043781 lja-miR11093-3p; +MIMAT0043782 lja-miR11089b-3p; +MIMAT0043783 lja-miR11094-3p; +MIMAT0043784 lja-miR11095-5p; +MIMAT0043785 lja-miR11095-3p; +MIMAT0043786 lja-miR11096a-3p; +MIMAT0043787 lja-miR11096b-3p; +MIMAT0043788 lja-miR11097a-5p; +MIMAT0043789 lja-miR11097a-3p; +MIMAT0043790 lja-miR11108e-5p; +MIMAT0043791 lja-miR11108e-3p; +MIMAT0043792 lja-miR11098-3p; +MIMAT0043793 lja-miR11099-5p; +MIMAT0043794 lja-miR11100-5p; +MIMAT0043795 lja-miR11100-3p; +MIMAT0043796 lja-miR11101a-3p; +MIMAT0043797 lja-miR11101b-3p; +MIMAT0043798 lja-miR11077b-5p; +MIMAT0043799 lja-miR11102-3p; +MIMAT0043800 lja-miR11103a-3p; +MIMAT0043801 lja-miR7533d-3p; +MIMAT0043802 lja-miR11077c-5p; +MIMAT0043803 lja-miR11077d-5p; +MIMAT0043804 lja-miR11077d-3p; +MIMAT0043805 lja-miR11104-5p; +MIMAT0043806 lja-miR11104-3p; +MIMAT0043807 lja-miR11105a-5p; +MIMAT0043808 lja-miR11105b-5p; +MIMAT0043809 lja-miR11105c-5p; +MIMAT0043810 lja-miR11105d-5p; +MIMAT0043811 lja-miR11106-5p; +MIMAT0043812 lja-miR11106-3p; +MIMAT0043813 lja-miR11107a-5p; +MIMAT0043814 lja-miR11107a-3p; +MIMAT0043815 lja-miR11107b-3p; +MIMAT0043816 lja-miR11107c-5p; +MIMAT0043817 lja-miR11107c-3p; +MIMAT0043818 lja-miR7526l-5p; +MIMAT0043819 lja-miR7526l-3p; +MIMAT0043820 lja-miR11082l-3p; +MIMAT0043821 lja-miR11108a-5p; +MIMAT0043822 lja-miR11108a-3p; +MIMAT0043823 lja-miR11108b-3p; +MIMAT0043824 lja-miR11109-5p; +MIMAT0043825 lja-miR11110a-5p; +MIMAT0043826 lja-miR11110b-5p; +MIMAT0043827 lja-miR11110b-3p; +MIMAT0043828 lja-miR477-5p; +MIMAT0043829 lja-miR477-3p; +MIMAT0043830 lja-miR11111-3p; +MIMAT0043831 lja-miR11112-3p; +MIMAT0043832 lja-miR11097e-5p; +MIMAT0043833 lja-miR11113-5p; +MIMAT0043834 lja-miR11113-3p; +MIMAT0043835 lja-miR11078f-3p; +MIMAT0043836 lja-miR11114-5p; +MIMAT0043837 lja-miR11114-3p; +MIMAT0043838 lja-miR11108j-5p; +MIMAT0043839 lja-miR11108j-3p; +MIMAT0043840 lja-miR11115-5p; +MIMAT0043841 lja-miR11072j-5p; +MIMAT0043842 lja-miR11072j-3p; +MIMAT0043843 lja-miR11116-3p; +MIMAT0043844 lja-miR11097i-3p; +MIMAT0043845 lja-miR11097g-5p; +MIMAT0043846 lja-miR11097h-5p; +MIMAT0043847 lja-miR11117a-5p; +MIMAT0043848 lja-miR11117a-3p; +MIMAT0043849 lja-miR11117b-3p; +MIMAT0043850 lja-miR11118-5p; +MIMAT0043851 lja-miR11118-3p; +MIMAT0043852 lja-miR11119-5p; +MIMAT0043853 lja-miR11103b-5p; +MIMAT0043854 lja-miR11103c-5p; +MIMAT0043855 lja-miR11103c-3p; +MIMAT0043856 lja-miR11120-5p; +MIMAT0043857 lja-miR11120-3p; +MIMAT0043858 lja-miR398-5p; +MIMAT0043859 lja-miR398-3p; +MIMAT0043860 lja-miR11121-3p; +MIMAT0043861 lja-miR11122-3p; +MIMAT0043862 lja-miR5287a-3p; +MIMAT0043863 lja-miR11123-5p; +MIMAT0043864 lja-miR11123-3p; +MIMAT0043865 lja-miR11124-5p; +MIMAT0043866 lja-miR11124-3p; +MIMAT0043867 lja-miR11088b-5p; +MIMAT0043868 lja-miR11108g-5p; +MIMAT0043869 lja-miR11108h-5p; +MIMAT0043870 lja-miR11108k-5p; +MIMAT0043871 lja-miR11108k-3p; +MIMAT0043872 lja-miR11108l-5p; +MIMAT0043873 lja-miR11125-5p; +MIMAT0043874 lja-miR11097d-5p; +MIMAT0043875 lja-miR11108s-5p; +MIMAT0043876 lja-miR11108s-3p; +MIMAT0043877 lja-miR11126-5p; +MIMAT0043878 lja-miR11126-3p; +MIMAT0043879 lja-miR11097b-3p; +MIMAT0043880 lja-miR11127-5p; +MIMAT0043881 lja-miR11068f-3p; +MIMAT0043882 lja-miR11128-5p; +MIMAT0043883 lja-miR11128-3p; +MIMAT0043884 lja-miR11129-3p; +MIMAT0043885 lja-miR11108d-5p; +MIMAT0043886 lja-miR11108d-3p; +MIMAT0043887 lja-miR168-5p; +MIMAT0043888 lja-miR168-3p; +MIMAT0043889 lja-miR11130-5p; +MIMAT0043890 lja-miR11130-3p; +MIMAT0043891 lja-miR11131-5p; +MIMAT0043892 lja-miR11131-3p; +MIMAT0043893 lja-miR11108r-5p; +MIMAT0043894 lja-miR11108r-3p; +MIMAT0043895 lja-miR11132-5p; +MIMAT0043896 lja-miR11133-5p; +MIMAT0043897 lja-miR11134-5p; +MIMAT0043898 lja-miR11134-3p; +MIMAT0043899 lja-miR11108m-3p; +MIMAT0043900 lja-miR11108n-5p; +MIMAT0043901 lja-miR11108n-3p; +MIMAT0043902 lja-miR11108t-3p; +MIMAT0043903 lja-miR11108u-3p; +MIMAT0043904 lja-miR11135a-3p; +MIMAT0043905 lja-miR11135b-3p; +MIMAT0043906 lja-miR11135c-3p; +MIMAT0043907 lja-miR11136-5p; +MIMAT0043908 lja-miR11136-3p; +MIMAT0043909 lja-miR11137-5p; +MIMAT0043910 lja-miR11138-3p; +MIMAT0043911 lja-miR11139-3p; +MIMAT0043912 lja-miR11082m-3p; +MIMAT0043913 lja-miR11140-5p; +MIMAT0043914 lja-miR11140-3p; +MIMAT0043915 lja-miR11108x-5p; +MIMAT0043916 lja-miR11108q-5p; +MIMAT0043917 lja-miR11108q-3p; +MIMAT0043918 lja-miR11141-3p; +MIMAT0043919 lja-miR11142-3p; +MIMAT0043920 lja-miR11143-5p; +MIMAT0043921 lja-miR11143-3p; +MIMAT0043922 lja-miR11090e-5p; +MIMAT0043923 lja-miR11144-5p; +MIMAT0043924 lja-miR11144-3p; +MIMAT0043925 lja-miR11075c-3p; +MIMAT0043926 lja-miR11145a-3p; +MIMAT0043927 lja-miR11145b-3p; +MIMAT0043928 lja-miR11145c-3p; +MIMAT0043929 lja-miR11146-3p; +MIMAT0043930 lja-miR11147-5p; +MIMAT0043931 lja-miR11083d-3p; +MIMAT0043932 lja-miR11083e-3p; +MIMAT0043933 lja-miR11083f-3p; +MIMAT0043934 lja-miR11148-5p; +MIMAT0043935 lja-miR11108i-3p; +MIMAT0043936 lja-miR11149a-5p; +MIMAT0043937 lja-miR11149a-3p; +MIMAT0043938 lja-miR5287b-3p; +MIMAT0043939 lja-miR11108v-3p; +MIMAT0043940 lja-miR11108f-5p; +MIMAT0043941 lja-miR11108f-3p; +MIMAT0043942 lja-miR11103d-5p; +MIMAT0043943 lja-miR395-3p; +MIMAT0043944 lja-miR11150-3p; +MIMAT0043945 lja-miR11151-3p; +MIMAT0043946 lja-miR11152-5p; +MIMAT0043947 lja-miR11153-5p; +MIMAT0043948 lja-miR11154-5p; +MIMAT0043949 lja-miR11155a-5p; +MIMAT0043950 lja-miR1511-3p; +MIMAT0043951 lja-miR11156-5p; +MIMAT0043952 lja-miR11155b-5p; +MIMAT0043953 lja-miR11149b-3p; +MIMAT0043954 lja-miR11157-3p; +MIMAT0043955 lja-miR11158-3p; +MIMAT0043956 lja-miR11159-3p; +MIMAT0043957 lja-miR11103e-3p; +MIMAT0043958 lja-miR11160-5p; +MIMAT0043959 lja-miR11161-5p; +MIMAT0043960 lja-miR11162-3p; +MIMAT0043961 lja-miR11163-5p; +MIMAT0043962 lja-miR11145d-3p; +MIMAT0043963 lja-miR11155d-5p; +MIMAT0043964 lja-miR11089c-5p; +MIMAT0043965 lja-miR11164-5p; +MIMAT0043966 lja-miR11108w-5p; +MIMAT0043967 lja-miR166-3p; +MIMAT0043968 lja-miR11165-3p; +MIMAT0043969 lja-miR11166-3p; +MIMAT0043970 lja-miR11135d-3p; +MIMAT0043971 lja-miR11167-5p; +MIMAT0043972 lja-miR11168-5p; +MIMAT0043973 lja-miR1120-3p; +MIMAT0043974 lja-miR11169-5p; +MIMAT0043975 lja-miR11170-3p; +MIMAT0043976 lja-miR11108o-3p; +MIMAT0043977 lja-miR11108p-5p; +MIMAT0043978 lja-miR11108p-3p; +MIMAT0043979 lja-miR5287c-3p; +MIMAT0043980 lja-miR11171-5p; +MIMAT0043981 lja-miR11078g-3p; +MIMAT0043982 lja-miR11172-5p; +MIMAT0043983 lja-miR11155c-5p; +MIMAT0043984 lja-miR11155c-3p; +MIMAT0043985 lja-miR11173-3p; +MIMAT0043986 lja-miR11174-3p; +MIMAT0043987 lja-miR11175-5p; +MIMAT0043988 lja-miR11176-3p; +MIMAT0043989 lja-miR11177-5p; +MIMAT0043990 lja-miR11178-3p; +MIMAT0043991 lja-miR11179-3p; +MIMAT0043992 lja-miR11097f-5p; +MIMAT0043993 lja-miR5287d-3p; +MIMAT0043994 lja-miR11155e-5p; +MIMAT0043995 lja-miR11180-3p; +MIMAT0043996 hsa-miR-11181-5p; +MIMAT0043997 hsa-miR-11181-3p; +MIMAT0043998 dme-miR-11182; +MIMAT0043999 gmo-miR-29b-5p; +MIMAT0044000 gmo-miR-29b-3p; +MIMAT0044001 gmo-miR-722-3p; +MIMAT0044002 gmo-miR-187-5p; +MIMAT0044003 gmo-miR-187-3p; +MIMAT0044004 gmo-miR-23a-5p; +MIMAT0044005 gmo-miR-23a-3p; +MIMAT0044006 gmo-miR-723-5p; +MIMAT0044007 gmo-miR-723-3p; +MIMAT0044008 gmo-miR-27b-5p; +MIMAT0044009 gmo-miR-27b-3p; +MIMAT0044010 gmo-miR-458-5p; +MIMAT0044011 gmo-miR-458-3p; +MIMAT0044012 gmo-miR-301c-3p; +MIMAT0044013 gmo-miR-2188-5p; +MIMAT0044014 gmo-miR-2188-3p; +MIMAT0044015 gmo-miR-124-3-5p; +MIMAT0044016 gmo-miR-124-3p; +MIMAT0044017 gmo-miR-218a-5p; +MIMAT0044018 gmo-miR-152-5p; +MIMAT0044019 gmo-miR-152-3p; +MIMAT0044020 gmo-miR-23b-3p; +MIMAT0044021 gmo-miR-221-2-5p; +MIMAT0044022 gmo-miR-221-3p; +MIMAT0044023 gmo-miR-489-5p; +MIMAT0044024 gmo-miR-489-3p; +MIMAT0044025 gmo-miR-199-5p; +MIMAT0044026 gmo-miR-199-4-3p; +MIMAT0044027 gmo-miR-144-5p; +MIMAT0044028 gmo-miR-144-3p; +MIMAT0044029 gmo-miR-204-5p; +MIMAT0044030 gmo-miR-222-2-5p; +MIMAT0044031 gmo-miR-222-3p; +MIMAT0044032 gmo-miR-221-5p; +MIMAT0044033 gmo-miR-21-5p; +MIMAT0044034 gmo-miR-21-3p; +MIMAT0044035 gmo-miR-100a-5p; +MIMAT0044036 gmo-miR-100a-3p; +MIMAT0044037 gmo-miR-22b-5p; +MIMAT0044038 gmo-miR-22b-3p; +MIMAT0044039 gmo-miR-217-5p; +MIMAT0044040 gmo-miR-217-3p; +MIMAT0044041 gmo-miR-1-5p; +MIMAT0044042 gmo-miR-1-3p; +MIMAT0044043 gmo-miR-375-5p; +MIMAT0044044 gmo-miR-375-3p; +MIMAT0044045 gmo-miR-142-5p; +MIMAT0044046 gmo-miR-142-2-3p; +MIMAT0044047 gmo-miR-24a-4-5p; +MIMAT0044048 gmo-miR-24a-3p; +MIMAT0044049 gmo-miR-103-2-5p; +MIMAT0044050 gmo-miR-103-3p; +MIMAT0044051 gmo-miR-130a-5p; +MIMAT0044052 gmo-miR-130a-3p; +MIMAT0044053 gmo-miR-135b-5p; +MIMAT0044054 gmo-miR-135b-3p; +MIMAT0044055 gmo-miR-139-5p; +MIMAT0044056 gmo-miR-139-3p; +MIMAT0044057 gmo-miR-137-5p; +MIMAT0044058 gmo-miR-137-3p; +MIMAT0044059 gmo-miR-196b-5p; +MIMAT0044060 gmo-miR-155-5p; +MIMAT0044061 gmo-miR-430e-5p; +MIMAT0044062 gmo-miR-430b-5p; +MIMAT0044063 gmo-miR-122-5p; +MIMAT0044064 gmo-miR-122-3p; +MIMAT0044065 gmo-miR-223b-3p; +MIMAT0044066 gmo-miR-430c-5p; +MIMAT0044067 gmo-miR-8159-5p; +MIMAT0044068 gmo-miR-430f-3p; +MIMAT0044069 gmo-miR-128-5p; +MIMAT0044070 gmo-miR-128-3p; +MIMAT0044071 gmo-miR-29b-2-5p; +MIMAT0044072 gmo-miR-29a-2-5p; +MIMAT0044073 gmo-miR-29a-3p; +MIMAT0044074 gmo-miR-129-3-5p; +MIMAT0044075 gmo-miR-129-3p; +MIMAT0044076 gmo-miR-9-5p; +MIMAT0044077 gmo-miR-9-3p; +MIMAT0044078 gmo-miR-301b-3p; +MIMAT0044079 gmo-miR-430e-3p; +MIMAT0044080 gmo-miR-430d-5p; +MIMAT0044081 gmo-let-7a-5p; +MIMAT0044082 gmo-let-7a-3-3p; +MIMAT0044083 gmo-miR-202-3p; +MIMAT0044084 gmo-let-7a-4-3p; +MIMAT0044085 gmo-miR-128-2-5p; +MIMAT0044086 gmo-miR-148-5p; +MIMAT0044087 gmo-miR-148-3p; +MIMAT0044088 gmo-miR-10a-5p; +MIMAT0044089 gmo-miR-10a-3p; +MIMAT0044090 gmo-miR-181a-5p; +MIMAT0044091 gmo-miR-181c-5p; +MIMAT0044092 gmo-miR-181c-3p; +MIMAT0044093 gmo-miR-125b-5p; +MIMAT0044094 gmo-miR-30e-5p; +MIMAT0044095 gmo-miR-30e-3p; +MIMAT0044096 gmo-miR-30b-5p; +MIMAT0044097 gmo-miR-30b-3p; +MIMAT0044098 gmo-miR-30d-5p; +MIMAT0044099 gmo-miR-30d-3p; +MIMAT0044100 gmo-miR-31-5p; +MIMAT0044101 gmo-miR-27a-5p; +MIMAT0044102 gmo-miR-27a-3p; +MIMAT0044103 gmo-miR-200b-5p; +MIMAT0044104 gmo-miR-200b-3p; +MIMAT0044105 gmo-miR-200a-5p; +MIMAT0044106 gmo-miR-200a-3p; +MIMAT0044107 gmo-miR-429-5p; +MIMAT0044108 gmo-miR-429-3p; +MIMAT0044109 gmo-miR-728a-3p; +MIMAT0044110 gmo-miR-2187a-5p; +MIMAT0044111 gmo-miR-7133-3p; +MIMAT0044112 gmo-miR-462-5p; +MIMAT0044113 gmo-miR-462-3p; +MIMAT0044114 gmo-miR-731-5p; +MIMAT0044115 gmo-miR-219-5p; +MIMAT0044116 gmo-miR-24a-3-5p; +MIMAT0044117 gmo-miR-153b-5p; +MIMAT0044118 gmo-miR-153b-3p; +MIMAT0044119 gmo-miR-101a-5p; +MIMAT0044120 gmo-miR-101a-3p; +MIMAT0044121 gmo-miR-132-5p; +MIMAT0044122 gmo-miR-132-3p; +MIMAT0044123 gmo-miR-7a-5p; +MIMAT0044124 gmo-miR-1788-5p; +MIMAT0044125 gmo-miR-1788-3p; +MIMAT0044126 gmo-miR-137-2-5p; +MIMAT0044127 gmo-miR-205-5p; +MIMAT0044128 gmo-miR-205-3p; +MIMAT0044129 gmo-miR-29a-5p; +MIMAT0044130 gmo-miR-135c-5p; +MIMAT0044131 gmo-miR-22a-5p; +MIMAT0044132 gmo-miR-22a-3p; +MIMAT0044133 gmo-miR-181a-3p; +MIMAT0044134 gmo-miR-181b-5p; +MIMAT0044135 gmo-miR-181b-3p; +MIMAT0044136 gmo-miR-205-2-3p; +MIMAT0044137 gmo-let-7j-5p; +MIMAT0044138 gmo-let-7j-3p; +MIMAT0044139 gmo-miR-7132b-5p; +MIMAT0044140 gmo-miR-7132b-3p; +MIMAT0044141 gmo-miR-8825-5p; +MIMAT0044142 gmo-miR-30c-5p; +MIMAT0044143 gmo-miR-30c-3p; +MIMAT0044144 gmo-miR-30a-5p; +MIMAT0044145 gmo-miR-30a-3p; +MIMAT0044146 gmo-miR-196a-5p; +MIMAT0044147 gmo-miR-33b-5p; +MIMAT0044148 gmo-miR-33b-3p; +MIMAT0044149 gmo-miR-29d-5p; +MIMAT0044150 gmo-miR-29d-3p; +MIMAT0044151 gmo-miR-29a-3-5p; +MIMAT0044152 gmo-miR-338-2-5p; +MIMAT0044153 gmo-miR-338-3p; +MIMAT0044154 gmo-let-7f-5p; +MIMAT0044155 gmo-let-7f-3p; +MIMAT0044156 gmo-miR-16a-5p; +MIMAT0044157 gmo-miR-16a-3p; +MIMAT0044158 gmo-miR-15b-5p; +MIMAT0044159 gmo-miR-725-5p; +MIMAT0044160 gmo-miR-725-3p; +MIMAT0044161 gmo-miR-9-5-3p; +MIMAT0044162 gmo-miR-203b-5p; +MIMAT0044163 gmo-miR-203b-3p; +MIMAT0044164 gmo-miR-26a-5p; +MIMAT0044165 gmo-let-7h-5p; +MIMAT0044166 gmo-let-7h-2-3p; +MIMAT0044167 gmo-let-7g-5p; +MIMAT0044168 gmo-let-7g-3p; +MIMAT0044169 gmo-miR-11183-5p; +MIMAT0044170 gmo-miR-11183-3p; +MIMAT0044171 gmo-miR-11184a-3p; +MIMAT0044172 gmo-miR-737-5p; +MIMAT0044173 gmo-miR-737-3p; +MIMAT0044174 gmo-miR-24b-5p; +MIMAT0044175 gmo-miR-184-5p; +MIMAT0044176 gmo-miR-184-3p; +MIMAT0044177 gmo-miR-338-5p; +MIMAT0044178 gmo-miR-135c-3p; +MIMAT0044179 gmo-let-7e-5p; +MIMAT0044180 gmo-let-7e-3p; +MIMAT0044181 gmo-let-7a-5-3p; +MIMAT0044182 gmo-miR-210-5p; +MIMAT0044183 gmo-miR-210-3p; +MIMAT0044184 gmo-miR-734-3p; +MIMAT0044185 gmo-miR-19c-5p; +MIMAT0044186 gmo-miR-190b-5p; +MIMAT0044187 gmo-miR-190b-3p; +MIMAT0044188 gmo-miR-10b-5p; +MIMAT0044189 gmo-miR-103-5p; +MIMAT0044190 gmo-miR-199-3p; +MIMAT0044191 gmo-miR-129-4-5p; +MIMAT0044192 gmo-miR-430a-3p; +MIMAT0044193 gmo-miR-430g-3p; +MIMAT0044194 gmo-miR-125a-5p; +MIMAT0044195 gmo-let-7d-5p; +MIMAT0044196 gmo-miR-499-5p; +MIMAT0044197 gmo-miR-499-3p; +MIMAT0044198 gmo-miR-206-5p; +MIMAT0044199 gmo-miR-206-3p; +MIMAT0044200 gmo-miR-133b-5p; +MIMAT0044201 gmo-miR-133b-3p; +MIMAT0044202 gmo-let-7h-3p; +MIMAT0044203 gmo-miR-129-5p; +MIMAT0044204 gmo-miR-551-3p; +MIMAT0044205 gmo-miR-203a-5p; +MIMAT0044206 gmo-miR-203a-3p; +MIMAT0044207 gmo-miR-26b-5p; +MIMAT0044208 gmo-miR-214-5p; +MIMAT0044209 gmo-miR-214-3p; +MIMAT0044210 gmo-miR-153a-3p; +MIMAT0044211 gmo-miR-736-5p; +MIMAT0044212 gmo-miR-736-3p; +MIMAT0044213 gmo-miR-26a-2-3p; +MIMAT0044214 gmo-miR-455-5p; +MIMAT0044215 gmo-miR-455-3p; +MIMAT0044216 gmo-miR-126-5p; +MIMAT0044217 gmo-miR-126-3p; +MIMAT0044218 gmo-miR-9-3-3p; +MIMAT0044219 gmo-miR-7b-5p; +MIMAT0044220 gmo-miR-727-5p; +MIMAT0044221 gmo-miR-728b-3p; +MIMAT0044222 gmo-miR-218a-3p; +MIMAT0044223 gmo-miR-138-5p; +MIMAT0044224 gmo-miR-138-3-3p; +MIMAT0044225 gmo-miR-10c-5p; +MIMAT0044226 gmo-miR-10c-3p; +MIMAT0044227 gmo-miR-219-3p; +MIMAT0044228 gmo-miR-218b-5p; +MIMAT0044229 gmo-miR-130b-5p; +MIMAT0044230 gmo-miR-130b-3p; +MIMAT0044231 gmo-miR-101b-5p; +MIMAT0044232 gmo-miR-101b-3p; +MIMAT0044233 gmo-miR-194b-5p; +MIMAT0044234 gmo-miR-181d-5p; +MIMAT0044235 gmo-miR-9-6-3p; +MIMAT0044236 gmo-miR-7c-5p; +MIMAT0044237 gmo-miR-1338-5p; +MIMAT0044238 gmo-miR-1338-3p; +MIMAT0044239 gmo-miR-25-5p; +MIMAT0044240 gmo-miR-25-3p; +MIMAT0044241 gmo-miR-19d-5p; +MIMAT0044242 gmo-miR-19d-3p; +MIMAT0044243 gmo-miR-93-5p; +MIMAT0044244 gmo-miR-93-3p; +MIMAT0044245 gmo-miR-20a-5p; +MIMAT0044246 gmo-miR-20a-3-3p; +MIMAT0044247 gmo-miR-1-2-5p; +MIMAT0044248 gmo-miR-460-5p; +MIMAT0044249 gmo-miR-460-3p; +MIMAT0044250 gmo-miR-7132a-5p; +MIMAT0044251 gmo-miR-7132a-3p; +MIMAT0044252 gmo-miR-190a-5p; +MIMAT0044253 gmo-miR-190a-3p; +MIMAT0044256 gmo-miR-730-5p; +MIMAT0044257 gmo-miR-29c-5p; +MIMAT0044258 gmo-miR-29c-3p; +MIMAT0044259 gmo-miR-135d-5p; +MIMAT0044260 gmo-miR-135d-3p; +MIMAT0044261 gmo-miR-183-5p; +MIMAT0044262 gmo-miR-183-3p; +MIMAT0044263 gmo-miR-96-5p; +MIMAT0044264 gmo-miR-96-3p; +MIMAT0044265 gmo-miR-182-5p; +MIMAT0044266 gmo-miR-182-3p; +MIMAT0044267 gmo-miR-15a-5p; +MIMAT0044268 gmo-miR-16b-5p; +MIMAT0044269 gmo-miR-99-5p; +MIMAT0044270 gmo-miR-99-3p; +MIMAT0044271 gmo-let-7c-5p; +MIMAT0044272 gmo-let-7c-3p; +MIMAT0044273 gmo-miR-125b-3p; +MIMAT0044274 gmo-let-7a-3p; +MIMAT0044275 gmo-miR-100b-5p; +MIMAT0044276 gmo-miR-22a-2-5p; +MIMAT0044277 gmo-miR-192-5p; +MIMAT0044278 gmo-miR-194a-5p; +MIMAT0044279 gmo-miR-212-5p; +MIMAT0044280 gmo-miR-212-3p; +MIMAT0044281 gmo-miR-132-2-5p; +MIMAT0044282 gmo-miR-454-3p; +MIMAT0044283 gmo-miR-301a-5p; +MIMAT0044284 gmo-miR-301a-3p; +MIMAT0044285 gmo-miR-449a-5p; +MIMAT0044286 gmo-miR-449a-3p; +MIMAT0044287 gmo-miR-449b-5p; +MIMAT0044288 gmo-miR-193a-5p; +MIMAT0044289 gmo-miR-193a-3p; +MIMAT0044290 gmo-miR-365-5p; +MIMAT0044291 gmo-miR-365-3p; +MIMAT0044292 gmo-miR-24a-5p; +MIMAT0044293 gmo-let-7i-5p; +MIMAT0044294 gmo-let-7i-2-3p; +MIMAT0044295 gmo-miR-34-5p; +MIMAT0044296 gmo-miR-34-3p; +MIMAT0044297 gmo-miR-146-5p; +MIMAT0044298 gmo-miR-146-3p; +MIMAT0044299 gmo-miR-140-5p; +MIMAT0044300 gmo-miR-140-3p; +MIMAT0044301 gmo-miR-17-5p; +MIMAT0044302 gmo-miR-19a-5p; +MIMAT0044303 gmo-miR-19a-3p; +MIMAT0044304 gmo-miR-20a-3p; +MIMAT0044305 gmo-miR-19b-2-5p; +MIMAT0044306 gmo-miR-19b-3p; +MIMAT0044307 gmo-miR-10d-5p; +MIMAT0044308 gmo-miR-10d-3p; +MIMAT0044309 gmo-miR-338-3-5p; +MIMAT0044310 gmo-miR-150-5p; +MIMAT0044311 gmo-miR-456-5p; +MIMAT0044312 gmo-miR-456-3p; +MIMAT0044313 gmo-miR-219-3-3p; +MIMAT0044314 gmo-miR-125a-3p; +MIMAT0044315 gmo-let-7d-3p; +MIMAT0044316 gmo-miR-26a-3p; +MIMAT0044317 gmo-let-7i-3p; +MIMAT0044318 gmo-miR-724-5p; +MIMAT0044319 gmo-miR-724-3p; +MIMAT0044320 gmo-miR-138-3p; +MIMAT0044321 gmo-miR-18a-5p; +MIMAT0044322 gmo-miR-19a-2-5p; +MIMAT0044323 gmo-miR-20a-2-3p; +MIMAT0044324 gmo-miR-19b-5p; +MIMAT0044325 gmo-miR-92-5p; +MIMAT0044326 gmo-miR-222-5p; +MIMAT0044327 gmo-miR-124-5p; +MIMAT0044328 gmo-miR-135a-5p; +MIMAT0044329 gmo-miR-216a-5p; +MIMAT0044330 gmo-miR-216a-3p; +MIMAT0044331 gmo-miR-216b-5p; +MIMAT0044332 gmo-miR-27c-5p; +MIMAT0044333 gmo-miR-27c-3p; +MIMAT0044334 gmo-miR-145-5p; +MIMAT0044335 gmo-miR-145-3p; +MIMAT0044336 gmo-miR-143-5p; +MIMAT0044337 gmo-miR-143-3p; +MIMAT0044338 gmo-miR-92-2-5p; +MIMAT0044339 gmo-miR-92-3p; +MIMAT0044340 gmo-miR-363-3p; +MIMAT0044341 gmo-miR-20b-5p; +MIMAT0044342 gmo-miR-18b-5p; +MIMAT0044343 gmo-miR-11185-5p; +MIMAT0044344 gmo-miR-11186-5p; +MIMAT0044345 gmo-miR-11187-5p; +MIMAT0044346 gmo-miR-11187-3p; +MIMAT0044347 gmo-miR-11188-3p; +MIMAT0044348 gmo-miR-11189-5p; +MIMAT0044349 gmo-miR-11190-5p; +MIMAT0044350 gmo-miR-11191-3p; +MIMAT0044351 gmo-miR-11192-5p; +MIMAT0044352 gmo-miR-11193-5p; +MIMAT0044353 gmo-miR-10545-5p; +MIMAT0044354 gmo-miR-10545-3p; +MIMAT0044355 gmo-miR-11194-5p; +MIMAT0044356 gmo-miR-11195-5p; +MIMAT0044357 gmo-miR-8160a-5p; +MIMAT0044358 gmo-miR-8160a-3p; +MIMAT0044359 gmo-miR-11196-3p; +MIMAT0044360 gmo-miR-11197-3p; +MIMAT0044361 gmo-miR-11198-5p; +MIMAT0044362 gmo-miR-11199-5p; +MIMAT0044363 gmo-miR-11200-5p; +MIMAT0044364 gmo-miR-11201-3p; +MIMAT0044365 gmo-miR-11202-5p; +MIMAT0044366 gmo-miR-11203-5p; +MIMAT0044367 gmo-miR-11204a-3p; +MIMAT0044368 gmo-miR-11205-5p; +MIMAT0044369 gmo-miR-11205-3p; +MIMAT0044370 gmo-miR-11206-5p; +MIMAT0044371 gmo-miR-11207-3p; +MIMAT0044372 gmo-miR-10585-5p; +MIMAT0044373 gmo-miR-11208-5p; +MIMAT0044374 gmo-miR-11209-3p; +MIMAT0044375 gmo-miR-11210-5p; +MIMAT0044376 gmo-miR-11210-3p; +MIMAT0044377 gmo-miR-11211-3p; +MIMAT0044378 gmo-miR-11212-5p; +MIMAT0044379 gmo-miR-11213-5p; +MIMAT0044380 gmo-miR-11214-5p; +MIMAT0044381 gmo-miR-7552-5p; +MIMAT0044382 gmo-miR-11215-3p; +MIMAT0044383 gmo-miR-11204b-3p; +MIMAT0044384 gmo-miR-11216-5p; +MIMAT0044385 gmo-miR-11217-5p; +MIMAT0044386 gmo-miR-11218-5p; +MIMAT0044387 gmo-miR-11219-5p; +MIMAT0044388 gmo-miR-11220a-5p; +MIMAT0044389 gmo-miR-11221-5p; +MIMAT0044390 gmo-miR-11221-3p; +MIMAT0044391 gmo-miR-11222-5p; +MIMAT0044392 gmo-miR-11223-5p; +MIMAT0044393 gmo-miR-11223-3p; +MIMAT0044394 gmo-miR-11224a-5p; +MIMAT0044395 gmo-miR-11225-5p; +MIMAT0044396 gmo-miR-11226-3p; +MIMAT0044397 gmo-miR-11227-5p; +MIMAT0044398 gmo-miR-11228-3p; +MIMAT0044399 gmo-miR-11229-5p; +MIMAT0044400 gmo-miR-11230-5p; +MIMAT0044401 gmo-miR-11231-3p; +MIMAT0044402 gmo-miR-11220b-5p; +MIMAT0044403 gmo-miR-11232-3p; +MIMAT0044404 gmo-miR-11233-3p; +MIMAT0044405 gmo-miR-11234-3p; +MIMAT0044406 gmo-miR-11235-5p; +MIMAT0044407 gmo-miR-11184b-5p; +MIMAT0044408 gmo-miR-11236-5p; +MIMAT0044409 gmo-miR-11236-3p; +MIMAT0044410 gmo-miR-11237-5p; +MIMAT0044411 gmo-miR-8160b-5p; +MIMAT0044412 gmo-miR-8160b-3p; +MIMAT0044413 gmo-miR-11238-5p; +MIMAT0044414 gmo-miR-10544-5p; +MIMAT0044415 gmo-miR-10544-3p; +MIMAT0044416 gmo-miR-11239-3p; +MIMAT0044417 gmo-miR-11240-5p; +MIMAT0044418 gmo-miR-11241-3p; +MIMAT0044419 gmo-miR-11242-5p; +MIMAT0044420 gmo-miR-11243-3p; +MIMAT0044421 gmo-miR-11244-3p; +MIMAT0044422 gmo-miR-11245-5p; +MIMAT0044423 gmo-miR-11246-3p; +MIMAT0044424 gmo-miR-11247-5p; +MIMAT0044425 gmo-miR-7550-5p; +MIMAT0044426 gmo-miR-11248-5p; +MIMAT0044427 gmo-miR-11249-3p; +MIMAT0044428 gmo-miR-11250-3p; +MIMAT0044429 gmo-miR-11251-3p; +MIMAT0044430 gmo-miR-11252-5p; +MIMAT0044431 gmo-miR-11252-3p; +MIMAT0044432 gmo-miR-11204c-3p; +MIMAT0044433 gmo-miR-11253-3p; +MIMAT0044434 gmo-miR-11254-3p; +MIMAT0044435 gmo-miR-11255-5p; +MIMAT0044436 gmo-miR-11256-5p; +MIMAT0044437 gmo-miR-11257-3p; +MIMAT0044438 gmo-miR-11258-5p; +MIMAT0044439 gmo-miR-11259-5p; +MIMAT0044440 gmo-miR-11259-3p; +MIMAT0044441 gmo-miR-11260-5p; +MIMAT0044442 gmo-miR-11260-3p; +MIMAT0044443 gmo-miR-11261-3p; +MIMAT0044444 gmo-miR-11262-5p; +MIMAT0044445 gmo-miR-11262-3p; +MIMAT0044446 gmo-miR-11263-3p; +MIMAT0044447 gmo-miR-11264-5p; +MIMAT0044448 gmo-miR-11265-3p; +MIMAT0044449 gmo-miR-11266a-5p; +MIMAT0044450 gmo-miR-11266b-3p; +MIMAT0044451 gmo-miR-11267-5p; +MIMAT0044452 gmo-miR-11267-3p; +MIMAT0044453 gmo-miR-11268-5p; +MIMAT0044454 gmo-miR-11269-5p; +MIMAT0044455 gmo-miR-11270-3p; +MIMAT0044456 gmo-miR-11271-5p; +MIMAT0044457 gmo-miR-11272-5p; +MIMAT0044458 gmo-miR-11272-3p; +MIMAT0044459 gmo-miR-11273-5p; +MIMAT0044460 gmo-miR-11274-5p; +MIMAT0044461 gmo-miR-11275-5p; +MIMAT0044462 gmo-miR-11276-5p; +MIMAT0044463 gmo-miR-11277-3p; +MIMAT0044464 gmo-miR-11278-5p; +MIMAT0044465 gmo-miR-11279-5p; +MIMAT0044466 gmo-miR-11280-5p; +MIMAT0044467 gmo-miR-11280-3p; +MIMAT0044468 gmo-miR-11281-3p; +MIMAT0044469 gmo-miR-11204d-3p; +MIMAT0044470 gmo-miR-11282-5p; +MIMAT0044471 rno-miR-709; +MIMAT0044472 fve-miR11283; +MIMAT0044473 fve-miR11284; +MIMAT0044474 fve-miR11285; +MIMAT0044475 fve-miR1511; +MIMAT0044476 fve-miR156b; +MIMAT0044477 fve-miR156a; +MIMAT0044478 fve-miR156c; +MIMAT0044479 fve-miR156e; +MIMAT0044480 fve-miR156d; +MIMAT0044481 fve-miR156f; +MIMAT0044482 fve-miR156g-5p; +MIMAT0044483 fve-miR156g-3p; +MIMAT0044484 fve-miR156h; +MIMAT0044485 fve-miR156i; +MIMAT0044486 fve-miR156j; +MIMAT0044487 fve-miR159a-5p; +MIMAT0044488 fve-miR159a-3p; +MIMAT0044489 fve-miR159b; +MIMAT0044490 fve-miR159c; +MIMAT0044491 fve-miR160b; +MIMAT0044492 fve-miR160a; +MIMAT0044493 fve-miR162-5p; +MIMAT0044494 fve-miR162-3p; +MIMAT0044495 fve-miR164a-5p; +MIMAT0044496 fve-miR164a-3p; +MIMAT0044497 fve-miR164b; +MIMAT0044498 fve-miR164c; +MIMAT0044499 fve-miR166e; +MIMAT0044500 fve-miR166a; +MIMAT0044501 fve-miR166b; +MIMAT0044502 fve-miR166d-5p; +MIMAT0044503 fve-miR166d-3p; +MIMAT0044504 fve-miR166c; +MIMAT0044505 fve-miR166f; +MIMAT0044506 fve-miR167d; +MIMAT0044507 fve-miR167b; +MIMAT0044508 fve-miR167c; +MIMAT0044509 fve-miR167a; +MIMAT0044510 fve-miR168-5p; +MIMAT0044511 fve-miR168-3p; +MIMAT0044512 fve-miR169a; +MIMAT0044513 fve-miR169b; +MIMAT0044514 fve-miR169c; +MIMAT0044515 fve-miR169d; +MIMAT0044516 fve-miR169e; +MIMAT0044517 fve-miR169f; +MIMAT0044518 fve-miR171a; +MIMAT0044519 fve-miR171d; +MIMAT0044520 fve-miR171e; +MIMAT0044521 fve-miR171g; +MIMAT0044522 fve-miR171c-5p; +MIMAT0044523 fve-miR171c-3p; +MIMAT0044524 fve-miR171h; +MIMAT0044525 fve-miR171b; +MIMAT0044526 fve-miR171f-5p; +MIMAT0044527 fve-miR171f-3p; +MIMAT0044528 fve-miR172b; +MIMAT0044529 fve-miR172c; +MIMAT0044530 fve-miR172a; +MIMAT0044531 fve-miR2109; +MIMAT0044532 fve-miR2111c; +MIMAT0044533 fve-miR2111a; +MIMAT0044534 fve-miR2111b-5p; +MIMAT0044535 fve-miR2111b-3p; +MIMAT0044536 fve-miR319; +MIMAT0044537 fve-miR3627a; +MIMAT0044538 fve-miR3627b; +MIMAT0044539 fve-miR390a; +MIMAT0044540 fve-miR390b; +MIMAT0044541 fve-miR393b; +MIMAT0044542 fve-miR393a; +MIMAT0044543 fve-miR394; +MIMAT0044544 fve-miR396b-5p; +MIMAT0044545 fve-miR396b-3p; +MIMAT0044546 fve-miR396a-5p; +MIMAT0044547 fve-miR396a-3p; +MIMAT0044548 fve-miR396c-5p; +MIMAT0044549 fve-miR396c-3p; +MIMAT0044550 fve-miR396d; +MIMAT0044551 fve-miR396e; +MIMAT0044552 fve-miR397; +MIMAT0044553 fve-miR399a; +MIMAT0044554 fve-miR399b; +MIMAT0044555 fve-miR408; +MIMAT0044556 fve-miR477a; +MIMAT0044557 fve-miR482a; +MIMAT0044558 fve-miR482b; +MIMAT0044559 fve-miR482c; +MIMAT0044560 fve-miR482d; +MIMAT0044561 fve-miR5225; +MIMAT0044562 fve-miR530; +MIMAT0044563 fve-miR535a; +MIMAT0044564 fve-miR535b; +MIMAT0044565 fve-miR827; +MIMAT0044566 fve-miR845; +MIMAT0044567 fve-miR11286; +MIMAT0044568 fve-miR11287; +MIMAT0044569 fve-miR11288c-5p; +MIMAT0044570 fve-miR11288c-3p; +MIMAT0044571 fve-miR11289; +MIMAT0044572 fve-miR11290; +MIMAT0044573 fve-miR11288a; +MIMAT0044574 fve-miR11291; +MIMAT0044575 fve-miR11292; +MIMAT0044576 fve-miR11293; +MIMAT0044577 fve-miR11294; +MIMAT0044578 fve-miR11295; +MIMAT0044579 fve-miR11296; +MIMAT0044580 fve-miR11297; +MIMAT0044581 fve-miR11298; +MIMAT0044582 fve-miR11299; +MIMAT0044583 fve-miR11300; +MIMAT0044584 fve-miR11301; +MIMAT0044585 fve-miR11302; +MIMAT0044586 fve-miR11303; +MIMAT0044587 fve-miR11304; +MIMAT0044588 fve-miR11305; +MIMAT0044589 fve-miR11306; +MIMAT0044590 fve-miR11307; +MIMAT0044591 fve-miR11308; +MIMAT0044592 fve-miR11309; +MIMAT0044593 fve-miR11310; +MIMAT0044594 fve-miR11311; +MIMAT0044595 fve-miR11312; +MIMAT0044596 fve-miR477b; +MIMAT0044597 fve-miR11313; +MIMAT0044598 fve-miR11314; +MIMAT0044599 fve-miR11288b; +MIMAT0044600 fve-miR11288d; +MIMAT0044601 fve-miR11288e; +MIMAT0044602 fve-miR11315; +MIMAT0044603 ppt-miR11316; +MIMAT0044604 ppt-miR11317; +MIMAT0044605 ppt-miR11318; +MIMAT0044606 ppt-miR11319; +MIMAT0044607 ppt-miR11320; +MIMAT0044608 ppt-miR11321; +MIMAT0044609 ppt-miR11322; +MIMAT0044610 ppt-miR11323; +MIMAT0044611 ppt-miR11324; +MIMAT0044612 ppt-miR11325; +MIMAT0044613 ppt-miR11326; +MIMAT0044614 ppt-miR11327; +MIMAT0044615 ppt-miR11328; +MIMAT0044616 ppt-miR11329; +MIMAT0044617 ppt-miR11330; +MIMAT0044618 ppt-miR1027c; +MIMAT0044619 ppt-miR1034b; +MIMAT0044620 ppt-miR1049b; +MIMAT0044621 cst-miR11331; +MIMAT0044622 cst-miR11332; +MIMAT0044623 cst-miR11333; +MIMAT0044624 cst-miR11334; +MIMAT0044625 cst-miR11335; +MIMAT0044626 osa-miR11336-5p; +MIMAT0044627 osa-miR11336-3p; +MIMAT0044628 osa-miR11337-5p; +MIMAT0044629 osa-miR11337-3p; +MIMAT0044630 osa-miR11338-5p; +MIMAT0044631 osa-miR11338-3p; +MIMAT0044632 osa-miR11339-5p; +MIMAT0044633 osa-miR11339-3p; +MIMAT0044634 osa-miR11340-5p; +MIMAT0044635 osa-miR11340-3p; +MIMAT0044636 osa-miR11341-5p; +MIMAT0044637 osa-miR11341-3p; +MIMAT0044638 osa-miR11342-5p; +MIMAT0044639 osa-miR11342-3p; +MIMAT0044640 osa-miR11343-5p; +MIMAT0044641 osa-miR11343-3p; +MIMAT0044642 osa-miR11344-5p; +MIMAT0044643 osa-miR11344-3p; +MIMAT0044644 osa-miR2120b-5p; +MIMAT0044645 osa-miR2120b-3p; +MIMAT0044646 osa-miR5801c-5p; +MIMAT0044647 osa-miR5801c-3p; +MIMAT0044648 osa-miR6245b-5p; +MIMAT0044649 osa-miR6245b-3p; +MIMAT0044650 esi-miR3455b-5p; +MIMAT0044651 esi-miR3455b-3p; +MIMAT0044652 esi-miR3469b-5p; +MIMAT0044653 esi-miR3469b-3p; +MIMAT0044654 ssc-miR-33b-5p; +MIMAT0044655 ssc-miR-33b-3p; +MIMAT0044656 hsa-miR-11399; +MIMAT0044657 hsa-miR-11400; +MIMAT0044658 hsa-miR-11401; +MIMAT0044659 pab-miR156a; +MIMAT0044660 pab-miR156b; +MIMAT0044661 pab-miR156c; +MIMAT0044662 pab-miR156d; +MIMAT0044663 pab-miR156e; +MIMAT0044664 pab-miR156f; +MIMAT0044665 pab-miR156g; +MIMAT0044666 pab-miR156h; +MIMAT0044667 pab-miR156i; +MIMAT0044668 pab-miR156j; +MIMAT0044669 pab-miR156k; +MIMAT0044670 pab-miR156l; +MIMAT0044671 pab-miR156m; +MIMAT0044672 pab-miR156n; +MIMAT0044673 pab-miR156p; +MIMAT0044674 pab-miR156q; +MIMAT0044675 pab-miR156r; +MIMAT0044676 pab-miR156s; +MIMAT0044677 pab-miR156t; +MIMAT0044678 pab-miR156u; +MIMAT0044679 pab-miR156v; +MIMAT0044680 pab-miR156w; +MIMAT0044681 pab-miR156x; +MIMAT0044682 pab-miR156y; +MIMAT0044683 pab-miR156ab; +MIMAT0044684 pab-miR156aa; +MIMAT0044685 pab-miR159a; +MIMAT0044686 pab-miR159b; +MIMAT0044687 pab-miR159c; +MIMAT0044688 pab-miR159d; +MIMAT0044689 pab-miR159e; +MIMAT0044690 pab-miR160c; +MIMAT0044691 pab-miR160d; +MIMAT0044692 pab-miR160e; +MIMAT0044693 pab-miR160f; +MIMAT0044694 pab-miR162a; +MIMAT0044695 pab-miR162b; +MIMAT0044696 pab-miR162c; +MIMAT0044697 pab-miR164a; +MIMAT0044698 pab-miR164b; +MIMAT0044699 pab-miR166c; +MIMAT0044700 pab-miR166d; +MIMAT0044701 pab-miR166e; +MIMAT0044702 pab-miR166f; +MIMAT0044703 pab-miR166g; +MIMAT0044704 pab-miR166h; +MIMAT0044705 pab-miR166i; +MIMAT0044706 pab-miR166j; +MIMAT0044707 pab-miR167a; +MIMAT0044708 pab-miR167b; +MIMAT0044709 pab-miR168a; +MIMAT0044710 pab-miR168b; +MIMAT0044711 pab-miR169a; +MIMAT0044712 pab-miR169b; +MIMAT0044713 pab-miR169c; +MIMAT0044714 pab-miR169d; +MIMAT0044715 pab-miR169e; +MIMAT0044716 pab-miR171a; +MIMAT0044717 pab-miR171b; +MIMAT0044718 pab-miR171c; +MIMAT0044719 pab-miR171d; +MIMAT0044720 pab-miR171e; +MIMAT0044721 pab-miR319a; +MIMAT0044722 pab-miR319b; +MIMAT0044723 pab-miR319c; +MIMAT0044724 pab-miR319d; +MIMAT0044725 pab-miR319e; +MIMAT0044726 pab-miR319f; +MIMAT0044727 pab-miR319g; +MIMAT0044728 pab-miR319h; +MIMAT0044729 pab-miR319j; +MIMAT0044730 pab-miR390a; +MIMAT0044731 pab-miR390b; +MIMAT0044732 pab-miR393a; +MIMAT0044733 pab-miR393b; +MIMAT0044734 pab-miR393c; +MIMAT0044735 pab-miR393d; +MIMAT0044736 pab-miR394a; +MIMAT0044737 pab-miR394b; +MIMAT0044738 pab-miR394c; +MIMAT0044739 pab-miR395a; +MIMAT0044740 pab-miR395b; +MIMAT0044741 pab-miR395c; +MIMAT0044742 pab-miR395d; +MIMAT0044743 pab-miR395e; +MIMAT0044744 pab-miR395f; +MIMAT0044745 pab-miR395g; +MIMAT0044746 pab-miR395h; +MIMAT0044747 pab-miR395i; +MIMAT0044748 pab-miR396d; +MIMAT0044749 pab-miR396e; +MIMAT0044750 pab-miR396f; +MIMAT0044751 pab-miR396g; +MIMAT0044752 pab-miR396h; +MIMAT0044753 pab-miR396i; +MIMAT0044754 pab-miR396j; +MIMAT0044755 pab-miR396k; +MIMAT0044756 pab-miR396l; +MIMAT0044757 pab-miR396m; +MIMAT0044758 pab-miR396n; +MIMAT0044759 pab-miR396o; +MIMAT0044760 pab-miR396p; +MIMAT0044761 pab-miR396q; +MIMAT0044762 pab-miR396r; +MIMAT0044763 pab-miR396s; +MIMAT0044764 pab-miR396t; +MIMAT0044765 pab-miR396u; +MIMAT0044766 pab-miR397a; +MIMAT0044767 pab-miR397c; +MIMAT0044768 pab-miR397d; +MIMAT0044769 pab-miR397e; +MIMAT0044770 pab-miR397f; +MIMAT0044771 pab-miR397g; +MIMAT0044772 pab-miR397h; +MIMAT0044773 pab-miR397i; +MIMAT0044774 pab-miR397j; +MIMAT0044775 pab-miR397k; +MIMAT0044776 pab-miR397l; +MIMAT0044777 pab-miR397m; +MIMAT0044778 pab-miR397n; +MIMAT0044779 pab-miR397o; +MIMAT0044780 pab-miR397p; +MIMAT0044781 pab-miR397q; +MIMAT0044782 pab-miR397r; +MIMAT0044783 pab-miR397s; +MIMAT0044784 pab-miR397t; +MIMAT0044785 pab-miR397u; +MIMAT0044786 pab-miR398a; +MIMAT0044787 pab-miR398b; +MIMAT0044788 pab-miR399a; +MIMAT0044789 pab-miR399b; +MIMAT0044790 pab-miR399c; +MIMAT0044791 pab-miR399d; +MIMAT0044792 pab-miR399e; +MIMAT0044793 pab-miR399f; +MIMAT0044794 pab-miR399g; +MIMAT0044795 pab-miR399h; +MIMAT0044796 pab-miR472; +MIMAT0044797 pab-miR1083; +MIMAT0044798 pab-miR1311b; +MIMAT0044799 pab-miR1312a; +MIMAT0044800 pab-miR1312b; +MIMAT0044801 pab-miR1314; +MIMAT0044802 pab-miR1313a; +MIMAT0044803 pab-miR1313b; +MIMAT0044804 pab-miR1313c; +MIMAT0044805 pab-miR1313d; +MIMAT0044806 pab-miR11402; +MIMAT0044807 pab-miR11403; +MIMAT0044808 pab-miR2111; +MIMAT0044809 pab-miR2950a; +MIMAT0044810 pab-miR2950b; +MIMAT0044811 pab-miR3627a; +MIMAT0044812 pab-miR3627b; +MIMAT0044813 pab-miR3695a; +MIMAT0044814 pab-miR3695b; +MIMAT0044815 pab-miR3695c; +MIMAT0044816 pab-miR3697a; +MIMAT0044817 pab-miR3697c; +MIMAT0044818 pab-miR3701a; +MIMAT0044819 pab-miR3701c; +MIMAT0044820 pab-miR3701d; +MIMAT0044821 pab-miR3701e; +MIMAT0044822 pab-miR3701j; +MIMAT0044823 pab-miR3701f; +MIMAT0044824 pab-miR3701g; +MIMAT0044825 pab-miR3701h; +MIMAT0044826 pab-miR3701i; +MIMAT0044827 pab-miR3710b; +MIMAT0044828 pab-miR3710c; +MIMAT0044829 pab-miR3710d; +MIMAT0044830 pab-miR3710e; +MIMAT0044831 pab-miR3710f; +MIMAT0044832 pab-miR3710g; +MIMAT0044833 pab-miR3710h; +MIMAT0044834 pab-miR11404; +MIMAT0044835 pab-miR408; +MIMAT0044836 pab-miR391a; +MIMAT0044837 pab-miR391b; +MIMAT0044838 pab-miR391c; +MIMAT0044839 pab-miR391d; +MIMAT0044840 pab-miR391e; +MIMAT0044841 pab-miR391f; +MIMAT0044842 pab-miR391g; +MIMAT0044843 pab-miR391h; +MIMAT0044844 pab-miR391i; +MIMAT0044845 pab-miR4414; +MIMAT0044846 pab-miR482t; +MIMAT0044847 pab-miR482u; +MIMAT0044848 pab-miR482v; +MIMAT0044849 pab-miR482e; +MIMAT0044850 pab-miR482f; +MIMAT0044851 pab-miR482g; +MIMAT0044852 pab-miR482i; +MIMAT0044853 pab-miR482k; +MIMAT0044854 pab-miR482l; +MIMAT0044855 pab-miR482m; +MIMAT0044856 pab-miR482n; +MIMAT0044857 pab-miR482o; +MIMAT0044858 pab-miR482p; +MIMAT0044859 pab-miR482r; +MIMAT0044860 pab-miR482s; +MIMAT0044861 pab-miR11405; +MIMAT0044862 pab-miR11406; +MIMAT0044863 pab-miR529a; +MIMAT0044864 pab-miR529b; +MIMAT0044865 pab-miR529c; +MIMAT0044866 pab-miR529d; +MIMAT0044867 pab-miR529e; +MIMAT0044868 pab-miR529f; +MIMAT0044869 pab-miR529g; +MIMAT0044870 pab-miR529h; +MIMAT0044871 pab-miR529i; +MIMAT0044872 pab-miR529j; +MIMAT0044873 pab-miR529k; +MIMAT0044874 pab-miR529l; +MIMAT0044875 pab-miR529m; +MIMAT0044876 pab-miR529n; +MIMAT0044877 pab-miR529o; +MIMAT0044878 pab-miR529p; +MIMAT0044879 pab-miR535a; +MIMAT0044880 pab-miR535b; +MIMAT0044881 pab-miR535c; +MIMAT0044882 pab-miR535d; +MIMAT0044883 pab-miR536a; +MIMAT0044884 pab-miR536b; +MIMAT0044885 pab-miR946a; +MIMAT0044886 pab-miR946b; +MIMAT0044887 pab-miR946c; +MIMAT0044888 pab-miR946d; +MIMAT0044889 pab-miR946e; +MIMAT0044890 pab-miR946f; +MIMAT0044891 pab-miR946g; +MIMAT0044892 pab-miR946h; +MIMAT0044893 pab-miR949b; +MIMAT0044894 pab-miR949a; +MIMAT0044895 pab-miR950b; +MIMAT0044896 pab-miR950c; +MIMAT0044897 pab-miR950d; +MIMAT0044898 pab-miR950e; +MIMAT0044899 pab-miR950f; +MIMAT0044900 pab-miR950g; +MIMAT0044901 pab-miR950h; +MIMAT0044902 pab-miR950i; +MIMAT0044903 pab-miR11407a; +MIMAT0044904 pab-miR11408a; +MIMAT0044905 pab-miR11409a; +MIMAT0044906 pab-miR159f; +MIMAT0044907 pab-miR159g; +MIMAT0044908 pab-miR159h; +MIMAT0044909 pab-miR159i; +MIMAT0044910 pab-miR11410; +MIMAT0044911 pab-miR11411a; +MIMAT0044912 pab-miR11412; +MIMAT0044913 pab-miR11413a; +MIMAT0044914 pab-miR11413b; +MIMAT0044915 pab-miR482h; +MIMAT0044916 pab-miR11414; +MIMAT0044917 pab-miR11415; +MIMAT0044918 pab-miR11416; +MIMAT0044919 pab-miR11417; +MIMAT0044920 pab-miR11418; +MIMAT0044921 pab-miR11419; +MIMAT0044922 pab-miR3627c; +MIMAT0044923 pab-miR11420a; +MIMAT0044924 pab-miR11421; +MIMAT0044925 pab-miR11422a; +MIMAT0044926 pab-miR11422b; +MIMAT0044927 pab-miR11423a; +MIMAT0044928 pab-miR11424; +MIMAT0044929 pab-miR11425a; +MIMAT0044930 pab-miR11425b; +MIMAT0044931 pab-miR11425c; +MIMAT0044932 pab-miR11425d; +MIMAT0044933 pab-miR11425e; +MIMAT0044934 pab-miR11425f; +MIMAT0044935 pab-miR11426a; +MIMAT0044936 pab-miR11426b; +MIMAT0044937 pab-miR11427a; +MIMAT0044938 pab-miR11427b; +MIMAT0044939 pab-miR11428; +MIMAT0044940 pab-miR11429a; +MIMAT0044941 pab-miR11429b; +MIMAT0044942 pab-miR11429c; +MIMAT0044943 pab-miR11429d; +MIMAT0044944 pab-miR11430; +MIMAT0044945 pab-miR11431a; +MIMAT0044946 pab-miR11432; +MIMAT0044947 pab-miR11433; +MIMAT0044948 pab-miR3627d; +MIMAT0044949 pab-miR11434; +MIMAT0044950 pab-miR3693j; +MIMAT0044951 pab-miR3693k; +MIMAT0044952 pab-miR11409b; +MIMAT0044953 pab-miR11409c; +MIMAT0044954 pab-miR11435; +MIMAT0044955 pab-miR11436a; +MIMAT0044956 pab-miR11436b; +MIMAT0044957 pab-miR11436c; +MIMAT0044958 pab-miR11436d; +MIMAT0044959 pab-miR11437; +MIMAT0044960 pab-miR11438; +MIMAT0044961 pab-miR11439; +MIMAT0044962 pab-miR11440a; +MIMAT0044963 pab-miR11440b; +MIMAT0044964 pab-miR11441a; +MIMAT0044965 pab-miR11441b; +MIMAT0044966 pab-miR11442; +MIMAT0044967 pab-miR11443; +MIMAT0044968 pab-miR11444; +MIMAT0044969 pab-miR11445a; +MIMAT0044970 pab-miR11445b; +MIMAT0044971 pab-miR11445c; +MIMAT0044972 pab-miR11446; +MIMAT0044973 pab-miR11447; +MIMAT0044974 pab-miR11448; +MIMAT0044975 pab-miR11449; +MIMAT0044976 pab-miR11450; +MIMAT0044977 pab-miR11451; +MIMAT0044978 pab-miR11452; +MIMAT0044979 pab-miR11453; +MIMAT0044980 pab-miR11454a; +MIMAT0044981 pab-miR11454b; +MIMAT0044982 pab-miR3710i; +MIMAT0044983 pab-miR11455; +MIMAT0044984 pab-miR11456; +MIMAT0044985 pab-miR11457; +MIMAT0044986 pab-miR11408b; +MIMAT0044987 pab-miR11409d; +MIMAT0044988 pab-miR11458; +MIMAT0044989 pab-miR11459; +MIMAT0044990 pab-miR11423b; +MIMAT0044991 pab-miR11423c; +MIMAT0044992 pab-miR11460; +MIMAT0044993 pab-miR11461; +MIMAT0044994 pab-miR949c; +MIMAT0044995 pab-miR11462; +MIMAT0044996 pab-miR11423d; +MIMAT0044997 pab-miR11423e; +MIMAT0044998 pab-miR11423f; +MIMAT0044999 pab-miR11423g; +MIMAT0045000 pab-miR11423h; +MIMAT0045001 pab-miR11423i; +MIMAT0045002 pab-miR11423j; +MIMAT0045003 pab-miR11423k; +MIMAT0045004 pab-miR11463; +MIMAT0045005 pab-miR11464a; +MIMAT0045006 pab-miR11465; +MIMAT0045007 pab-miR11466a; +MIMAT0045008 pab-miR11467a; +MIMAT0045009 pab-miR11467b; +MIMAT0045010 pab-miR11468; +MIMAT0045011 pab-miR11469; +MIMAT0045012 pab-miR11470; +MIMAT0045013 pab-miR11471; +MIMAT0045014 pab-miR11472; +MIMAT0045015 pab-miR11473; +MIMAT0045016 pab-miR11474; +MIMAT0045017 pab-miR11475; +MIMAT0045018 pab-miR11476a; +MIMAT0045019 pab-miR11476b; +MIMAT0045020 pab-miR11477; +MIMAT0045021 pab-miR11478; +MIMAT0045022 pab-miR11479; +MIMAT0045023 pab-miR11480; +MIMAT0045024 pab-miR11420b; +MIMAT0045025 pab-miR11411b; +MIMAT0045026 pab-miR11481a; +MIMAT0045027 pab-miR3627g; +MIMAT0045028 pab-miR3627h; +MIMAT0045029 pab-miR3627i; +MIMAT0045030 pab-miR11482; +MIMAT0045031 pab-miR11483; +MIMAT0045032 pab-miR11431b; +MIMAT0045033 pab-miR11431c; +MIMAT0045034 pab-miR11408c; +MIMAT0045035 pab-miR11484; +MIMAT0045036 pab-miR3693h; +MIMAT0045037 pab-miR3693i; +MIMAT0045038 pab-miR1312c; +MIMAT0045039 pab-miR11485; +MIMAT0045040 pab-miR11486; +MIMAT0045041 pab-miR11487a; +MIMAT0045042 pab-miR11488; +MIMAT0045043 pab-miR11489; +MIMAT0045044 pab-miR11490a; +MIMAT0045045 pab-miR11490b; +MIMAT0045046 pab-miR11491; +MIMAT0045047 pab-miR11492; +MIMAT0045048 pab-miR11493a; +MIMAT0045049 pab-miR11493b; +MIMAT0045050 pab-miR11493c; +MIMAT0045051 pab-miR11494; +MIMAT0045052 pab-miR11495; +MIMAT0045053 pab-miR11496; +MIMAT0045054 pab-miR11497; +MIMAT0045055 pab-miR11498a; +MIMAT0045056 pab-miR11499a; +MIMAT0045057 pab-miR11499b; +MIMAT0045058 pab-miR11500; +MIMAT0045059 pab-miR11501; +MIMAT0045060 pab-miR11502; +MIMAT0045061 pab-miR11503; +MIMAT0045062 pab-miR11504; +MIMAT0045063 pab-miR11505; +MIMAT0045064 pab-miR11506; +MIMAT0045065 pab-miR11507; +MIMAT0045066 pab-miR11508; +MIMAT0045067 pab-miR3693b; +MIMAT0045068 pab-miR3693c; +MIMAT0045069 pab-miR11498b; +MIMAT0045070 pab-miR11498c; +MIMAT0045071 pab-miR11509; +MIMAT0045072 pab-miR11510; +MIMAT0045073 pab-miR11511; +MIMAT0045074 pab-miR11466b; +MIMAT0045075 pab-miR11512; +MIMAT0045076 pab-miR11513; +MIMAT0045077 pab-miR11481b; +MIMAT0045078 pab-miR11481c; +MIMAT0045079 pab-miR11514; +MIMAT0045080 pab-miR11407b; +MIMAT0045081 pab-miR11515a; +MIMAT0045082 pab-miR11516; +MIMAT0045083 pab-miR11423l; +MIMAT0045084 pab-miR11517; +MIMAT0045085 pab-miR11420c; +MIMAT0045086 pab-miR11518; +MIMAT0045087 pab-miR11519; +MIMAT0045088 pab-miR11520; +MIMAT0045089 pab-miR11466c; +MIMAT0045090 pab-miR11466d; +MIMAT0045091 pab-miR11521; +MIMAT0045092 pab-miR11522; +MIMAT0045093 pab-miR11523a; +MIMAT0045094 pab-miR11523b; +MIMAT0045095 pab-miR11523c; +MIMAT0045096 pab-miR11523d; +MIMAT0045097 pab-miR11524; +MIMAT0045098 pab-miR11525a; +MIMAT0045099 pab-miR11525b; +MIMAT0045100 pab-miR11526; +MIMAT0045101 pab-miR11527; +MIMAT0045102 pab-miR11528; +MIMAT0045103 pab-miR11529a; +MIMAT0045104 pab-miR11529b; +MIMAT0045105 pab-miR11529c; +MIMAT0045106 pab-miR11530; +MIMAT0045107 pab-miR11531; +MIMAT0045108 pab-miR11411c; +MIMAT0045109 pab-miR11411d; +MIMAT0045110 pab-miR11464b; +MIMAT0045111 pab-miR11532; +MIMAT0045112 pab-miR482w; +MIMAT0045113 pab-miR482x; +MIMAT0045114 pab-miR11487b; +MIMAT0045115 pab-miR11487c; +MIMAT0045116 pab-miR11533a; +MIMAT0045117 pab-miR11534; +MIMAT0045118 pab-miR11535; +MIMAT0045119 pab-miR11536; +MIMAT0045120 pab-miR11533b; +MIMAT0045121 pab-miR11537; +MIMAT0045122 pab-miR11538; +MIMAT0045123 pab-miR11539a; +MIMAT0045124 pab-miR11540; +MIMAT0045125 pab-miR11541; +MIMAT0045126 pab-miR3627f; +MIMAT0045127 pab-miR11542; +MIMAT0045128 pab-miR11539b; +MIMAT0045129 pab-miR3627e; +MIMAT0045130 pab-miR11543; +MIMAT0045131 pab-miR11544; +MIMAT0045132 pab-miR3627j; +MIMAT0045133 pab-miR11545; +MIMAT0045134 pab-miR11546a; +MIMAT0045135 pab-miR11546b; +MIMAT0045136 pab-miR11546c; +MIMAT0045137 pab-miR11546d; +MIMAT0045138 pab-miR11546e; +MIMAT0045139 pab-miR11547; +MIMAT0045140 pab-miR11548; +MIMAT0045141 pab-miR11549; +MIMAT0045142 pab-miR11550; +MIMAT0045143 pab-miR11551a; +MIMAT0045144 pab-miR11552; +MIMAT0045145 pab-miR11553; +MIMAT0045146 pab-miR11554; +MIMAT0045147 pab-miR11409e; +MIMAT0045148 pab-miR11555; +MIMAT0045149 pab-miR11556; +MIMAT0045150 pab-miR11557; +MIMAT0045151 pab-miR11558; +MIMAT0045152 pab-miR11559; +MIMAT0045153 pab-miR11466e; +MIMAT0045154 pab-miR11560; +MIMAT0045155 pab-miR11561; +MIMAT0045156 pab-miR11562a; +MIMAT0045157 pab-miR11562b; +MIMAT0045158 pab-miR11562c; +MIMAT0045159 pab-miR11563; +MIMAT0045160 pab-miR3693d; +MIMAT0045161 pab-miR3693e; +MIMAT0045162 pab-miR3693f; +MIMAT0045163 pab-miR3693g; +MIMAT0045164 pab-miR11546f; +MIMAT0045165 pab-miR11564a; +MIMAT0045166 pab-miR11564b; +MIMAT0045167 pab-miR11565; +MIMAT0045168 pab-miR11409f; +MIMAT0045169 pab-miR11566; +MIMAT0045170 pab-miR11409g; +MIMAT0045171 pab-miR11567; +MIMAT0045172 pab-miR11568; +MIMAT0045173 pab-miR11569; +MIMAT0045174 pab-miR11570a; +MIMAT0045175 pab-miR11570b; +MIMAT0045176 pab-miR11570c; +MIMAT0045177 pab-miR11571; +MIMAT0045178 pab-miR11572; +MIMAT0045179 pab-miR11573a; +MIMAT0045180 pab-miR11573b; +MIMAT0045181 pab-miR11420d; +MIMAT0045182 pab-miR11420e; +MIMAT0045183 pab-miR11420f; +MIMAT0045184 pab-miR11420g; +MIMAT0045185 pab-miR11574; +MIMAT0045186 pab-miR11515b; +MIMAT0045187 pab-miR11575; +MIMAT0045188 pab-miR11576; +MIMAT0045189 pab-miR11577; +MIMAT0045190 pab-miR11578; +MIMAT0045191 pab-miR11579; +MIMAT0045192 pab-miR11580; +MIMAT0045193 pab-miR11581; +MIMAT0045194 pab-miR11582; +MIMAT0045195 pab-miR11551b; +MIMAT0045196 pab-miR11583a; +MIMAT0045197 pab-miR11583b; +MIMAT0045198 fhe-bantam; +MIMAT0045199 fhe-miR-1; +MIMAT0045200 fhe-miR-61; +MIMAT0045201 fhe-miR-190; +MIMAT0045202 fhe-miR-219; +MIMAT0045203 fhe-miR-745a; +MIMAT0045204 fhe-miR-750; +MIMAT0045205 fhe-miR-2a; +MIMAT0045206 fhe-miR-2b; +MIMAT0045207 fhe-miR-2c; +MIMAT0045208 fhe-miR-2d; +MIMAT0045209 fhe-miR-2e; +MIMAT0045210 fhe-miR-2f; +MIMAT0045211 fhe-miR-8; +MIMAT0045212 fhe-miR-9; +MIMAT0045213 fhe-miR-10; +MIMAT0045214 fhe-miR-31; +MIMAT0045215 fhe-miR-36a; +MIMAT0045216 fhe-miR-46; +MIMAT0045217 fhe-miR-745b; +MIMAT0045218 fhe-miR-71a; +MIMAT0045219 fhe-miR-71b; +MIMAT0045220 fhe-miR-87; +MIMAT0045221 fhe-miR-96; +MIMAT0045222 fhe-miR-124; +MIMAT0045223 fhe-miR-125a; +MIMAT0045224 fhe-miR-125b; +MIMAT0045225 fhe-miR-277; +MIMAT0045226 fhe-miR-307; +MIMAT0045227 fhe-miR-3479; +MIMAT0045228 fhe-let-7; +MIMAT0045229 fhe-miR-7; +MIMAT0045230 fhe-miR-2162; +MIMAT0045231 fhe-miR-11584; +MIMAT0045232 fhe-miR-11585; +MIMAT0045233 fhe-miR-11586; +MIMAT0045234 fhe-miR-11587; +MIMAT0045235 fhe-miR-36b; +MIMAT0045236 apl-miR-11588-5p; +MIMAT0045237 apl-miR-11588-3p; +MIMAT0045238 apl-miR-11589-5p; +MIMAT0045239 apl-miR-11589-3p; +MIMAT0045240 apl-miR-11590-5p; +MIMAT0045241 apl-miR-11590-3p; +MIMAT0045242 apl-miR-11591-5p; +MIMAT0045243 apl-miR-11591-3p; +MIMAT0045244 pab-miR3698b; +MIMAT0045245 pab-miR482j; +MIMAT0045246 pab-miR828; +MIMAT0045247 pab-miR858a; +MIMAT0045248 pab-miR858b; +MIMAT0045249 pab-miR156z; +MIMAT0045250 pab-miR156o; +MIMAT0045251 pab-miR159j; +MIMAT0045252 pab-miR159k; +MIMAT0045253 pab-miR319i; +MIMAT0045254 pab-miR319k; +MIMAT0045255 pab-miR319l; +MIMAT0045256 pab-miR319m; +MIMAT0045257 pab-miR319n; +MIMAT0045258 pab-miR482q; +MIMAT0045259 bib-miR-2788; +MIMAT0045260 bib-miR-193; +MIMAT0045261 cas-miR158b; +MIMAT0045262 cas-miR827b; +MIMAT0045263 cas-miR159c-5; +MIMAT0045264 cas-miR159c-3p; +MIMAT0045265 cas-miR156a; +MIMAT0045266 cas-miR156b-5p; +MIMAT0045267 cas-miR156b-3p; +MIMAT0045268 cas-miR156c-5p; +MIMAT0045269 cas-miR156c-3p; +MIMAT0045270 cas-miR156d-5p; +MIMAT0045271 cas-miR156d-3p; +MIMAT0045272 cas-miR156e-5p; +MIMAT0045273 cas-miR156e-3p; +MIMAT0045274 cas-miR156f-5p; +MIMAT0045275 cas-miR156f-3p; +MIMAT0045276 cas-miR156g; +MIMAT0045277 cas-miR156h; +MIMAT0045278 cas-miR156i; +MIMAT0045279 cas-miR156j; +MIMAT0045280 cas-miR156k-5p; +MIMAT0045281 cas-miR156k-3p; +MIMAT0045282 cas-miR157a; +MIMAT0045283 cas-miR157b; +MIMAT0045284 cas-miR157c; +MIMAT0045285 cas-miR157d; +MIMAT0045286 cas-miR158a; +MIMAT0045287 cas-miR159b-5p; +MIMAT0045288 cas-miR159b-3p; +MIMAT0045289 cas-miR159a; +MIMAT0045290 cas-miR160a; +MIMAT0045291 cas-miR160b-5p; +MIMAT0045292 cas-miR160b-3p; +MIMAT0045293 cas-miR161; +MIMAT0045294 cas-miR162a; +MIMAT0045295 cas-miR164; +MIMAT0045296 cas-miR165a; +MIMAT0045297 cas-miR165b; +MIMAT0045298 cas-miR166a; +MIMAT0045299 cas-miR166b; +MIMAT0045300 cas-miR166c-5p; +MIMAT0045301 cas-miR166c-3p; +MIMAT0045302 cas-miR166d; +MIMAT0045303 cas-miR166e; +MIMAT0045304 cas-miR166f-5p; +MIMAT0045305 cas-miR166f-3p; +MIMAT0045306 cas-miR167a; +MIMAT0045307 cas-miR167b; +MIMAT0045308 cas-miR167c; +MIMAT0045309 cas-miR168; +MIMAT0045310 cas-miR169a; +MIMAT0045311 cas-miR169b; +MIMAT0045312 cas-miR169c; +MIMAT0045313 cas-miR169d; +MIMAT0045314 cas-miR169e-5p; +MIMAT0045315 cas-miR169e-3p; +MIMAT0045316 cas-miR169f; +MIMAT0045317 cas-miR169g-5p; +MIMAT0045318 cas-miR169g-3p; +MIMAT0045319 cas-miR170; +MIMAT0045320 cas-miR171a-5p; +MIMAT0045321 cas-miR171a-3p; +MIMAT0045322 cas-miR171b; +MIMAT0045323 cas-miR171c-5p; +MIMAT0045324 cas-miR171c-3p; +MIMAT0045325 cas-miR172a-5p; +MIMAT0045326 cas-miR172a-3p; +MIMAT0045327 cas-miR172b; +MIMAT0045328 cas-miR172c; +MIMAT0045329 cas-miR172d; +MIMAT0045330 cas-miR173; +MIMAT0045331 cas-miR319a; +MIMAT0045332 cas-miR319b; +MIMAT0045333 cas-miR319c; +MIMAT0045334 cas-miR390a-5p; +MIMAT0045335 cas-miR390a-3p; +MIMAT0045336 cas-miR390b; +MIMAT0045337 cas-miR393-5p; +MIMAT0045338 cas-miR393-3p; +MIMAT0045339 cas-miR394; +MIMAT0045340 cas-miR395a; +MIMAT0045341 cas-miR395b; +MIMAT0045342 cas-miR395c-5p; +MIMAT0045343 cas-miR395c-3p; +MIMAT0045344 cas-miR395d-5p; +MIMAT0045345 cas-miR395d-3p; +MIMAT0045346 cas-miR396a; +MIMAT0045347 cas-miR396b; +MIMAT0045348 cas-miR397; +MIMAT0045349 cas-miR398a-5p; +MIMAT0045350 cas-miR398a-3p; +MIMAT0045351 cas-miR398b; +MIMAT0045352 cas-miR399a; +MIMAT0045353 cas-miR399b; +MIMAT0045354 cas-miR400; +MIMAT0045355 cas-miR403; +MIMAT0045356 cas-miR408; +MIMAT0045357 cas-miR472; +MIMAT0045358 cas-miR825; +MIMAT0045359 cas-miR827a; +MIMAT0045360 cas-miR828; +MIMAT0045361 cas-miR845; +MIMAT0045362 cas-miR857; +MIMAT0045363 cas-miR858; +MIMAT0045364 cas-miR860; +MIMAT0045365 cas-miR2111a; +MIMAT0045366 cas-miR2111b; +MIMAT0045367 cas-miR3435; +MIMAT0045368 cas-miR5139; +MIMAT0045369 cas-miR8171; +MIMAT0045370 cas-miR9560; +MIMAT0045371 cas-miR11592; +MIMAT0045372 cas-miR162b; +MIMAT0045373 bdo-miR-2c; +MIMAT0045374 bdo-miR-307; +MIMAT0045375 bdo-miR-996; +MIMAT0045376 bdo-miR-929; +MIMAT0045377 bdo-miR-932; +MIMAT0045378 bdo-miR-998; +MIMAT0045379 bdo-miR-988; +MIMAT0045380 bdo-miR-971; +MIMAT0045381 bdo-miR-283; +MIMAT0045382 bdo-miR-263a; +MIMAT0045383 bdo-miR-193; +MIMAT0045384 bdo-miR-9b; +MIMAT0045385 bdo-miR-92b; +MIMAT0045386 bdo-miR-100; +MIMAT0045387 bdo-miR-8; +MIMAT0045388 bdo-miR-276b; +MIMAT0045389 bdo-miR-7; +MIMAT0045390 bdo-miR-315; +MIMAT0045391 bdo-miR-993; +MIMAT0045392 bdo-let-7; +MIMAT0045393 bdo-miR-276a; +MIMAT0045394 bdo-miR-275; +MIMAT0045395 bdo-miR-124; +MIMAT0045396 bdo-miR-iab-4; +MIMAT0045397 bdo-miR-9c; +MIMAT0045398 bdo-miR-999; +MIMAT0045399 bdo-miR-981; +MIMAT0045400 bdo-miR-970; +MIMAT0045401 bdo-miR-79; +MIMAT0045402 bdo-miR-305; +MIMAT0045403 bdo-miR-2a; +MIMAT0045404 bdo-miR-263b; +MIMAT0045405 bdo-miR-219; +MIMAT0045406 bdo-miR-190; +MIMAT0045407 bdo-miR-184; +MIMAT0045408 bdo-miR-137; +MIMAT0045409 bdo-miR-13b; +MIMAT0045410 bdo-miR-13a; +MIMAT0045411 bdo-miR-125; +MIMAT0045412 bdo-miR-1000; +MIMAT0045413 bdo-miR-10; +MIMAT0045414 bdo-miR-1; +MIMAT0045415 bdo-bantam; +MIMAT0045416 bdo-miR-2b; +MIMAT0045417 bdo-miR-2a-2; +MIMAT0045418 bdo-miR-281; +MIMAT0045419 bdo-miR-iab-8; +MIMAT0045420 bdo-miR-5b; +MIMAT0045421 bdo-miR-4; +MIMAT0045422 bdo-miR-5a; +MIMAT0045423 bdo-miR-12; +MIMAT0045424 bdo-miR-927; +MIMAT0045425 bdo-miR-87; +MIMAT0045426 bdo-miR-308; +MIMAT0045427 bdo-miR-994; +MIMAT0045428 bdo-miR-316; +MIMAT0045429 bdo-miR-284; +MIMAT0045430 bdo-miR-282; +MIMAT0045431 bdo-miR-210; +MIMAT0045432 bdo-miR-14; +MIMAT0045433 bdo-miR-286; +MIMAT0045434 bdo-miR-11; +MIMAT0045435 bdo-miR-252; +MIMAT0045436 bdo-miR-995; +MIMAT0045437 bdo-miR-318; +MIMAT0045438 bdo-miR-375; +MIMAT0045439 bdo-miR-306; +MIMAT0045440 bdo-miR-958; +MIMAT0045441 bdo-miR-11593; +MIMAT0045442 bdo-miR-304; +MIMAT0045443 bdo-miR-11594; +MIMAT0045444 bdo-miR-980; +MIMAT0045445 bdo-miR-11595; +MIMAT0045446 bdo-miR-6; +MIMAT0045447 bdo-miR-309b; +MIMAT0045448 bdo-miR-309a; +MIMAT0045449 bdo-miR-11596; +MIMAT0045450 bdo-miR-11597; +MIMAT0045451 pla-miR11598; +MIMAT0045452 pla-miR11599; +MIMAT0045453 pla-miR11600; +MIMAT0045454 pla-miR11601; +MIMAT0045455 pla-miR11602; +MIMAT0045456 pla-miR11603; +MIMAT0045457 pla-miR11604; +MIMAT0045458 pla-miR11605; +MIMAT0045459 pla-miR11606; +MIMAT0045460 pla-miR11607; +MIMAT0045461 pla-miR11608; +MIMAT0045462 pla-miR11609; +MIMAT0045463 pla-miR11610; +MIMAT0045464 pla-miR11611; +MIMAT0045465 pla-miR11612; +MIMAT0045466 tca-miR-3851m-5p; +MIMAT0045467 tca-miR-3851m-3p; +MIMAT0045468 tca-miR-11614-5p; +MIMAT0045469 tca-miR-11614-3p; +MIMAT0045470 tca-miR-11615-5p; +MIMAT0045471 tca-miR-11615-3p; +MIMAT0045472 tca-miR-3806b-5p; +MIMAT0045473 tca-miR-3806b-3p; +MIMAT0045474 tca-miR-11617b-5p; +MIMAT0045475 tca-miR-11617b-3p; +MIMAT0045476 tca-miR-3851l-5p; +MIMAT0045477 tca-miR-3851l-3p; +MIMAT0045478 tca-miR-11617c-5p; +MIMAT0045479 tca-miR-11617c-3p; +MIMAT0045480 tca-miR-3836c-5p; +MIMAT0045481 tca-miR-3836c-1-3p; +MIMAT0045482 tca-miR-3851n-5p; +MIMAT0045483 tca-miR-3851n-3p; +MIMAT0045484 tca-miR-11617a-5p; +MIMAT0045485 tca-miR-11617a-3p; +MIMAT0045486 tca-miR-3836d-5p; +MIMAT0045487 tca-miR-3836d-3p; +MIMAT0045488 tca-miR-3836c-2-3p; +MIMAT0045489 tca-miR-11618a-5p; +MIMAT0045490 tca-miR-11618a-3p; +MIMAT0045491 tca-miR-3851o-2-5p; +MIMAT0045492 tca-miR-3851o-3p; +MIMAT0045493 tca-miR-3851k-5p; +MIMAT0045494 tca-miR-3851k-3p; +MIMAT0045495 tca-miR-11618b-5p; +MIMAT0045496 tca-miR-11618b-3p; +MIMAT0045497 tca-miR-3836e-5p; +MIMAT0045498 tca-miR-3836e-3p; +MIMAT0045499 tca-miR-11619e-5p; +MIMAT0045500 tca-miR-11619e-3p; +MIMAT0045501 tca-miR-3836c-3-5p; +MIMAT0045502 tca-miR-3836c-3p; +MIMAT0045503 tca-miR-11618a-4-5p; +MIMAT0045504 tca-miR-3851o-5p; +MIMAT0045505 tca-miR-3851l-2-3p; +MIMAT0045506 tca-miR-3836f-5p; +MIMAT0045507 tca-miR-3836f-3p; +MIMAT0045508 tca-miR-11619f-5p; +MIMAT0045509 tca-miR-11619f-3p; +MIMAT0045510 tca-miR-11620-5p; +MIMAT0045511 tca-miR-11620-3p; +MIMAT0045512 tca-miR-11619b-3p; +MIMAT0045513 tca-miR-11621-5p; +MIMAT0045514 tca-miR-11621-3p; +MIMAT0045515 tca-miR-11619a-5p; +MIMAT0045516 tca-miR-11619a-3-3p; +MIMAT0045517 tca-miR-11622-5p; +MIMAT0045518 tca-miR-11622-3p; +MIMAT0045519 tca-miR-11623-5p; +MIMAT0045520 tca-miR-11623-3p; +MIMAT0045521 tca-miR-3851g-5p; +MIMAT0045522 tca-miR-3851g-3p; +MIMAT0045523 tca-miR-11624a-5p; +MIMAT0045524 tca-miR-11624a-3p; +MIMAT0045525 tca-miR-11624a-3-3p; +MIMAT0045526 tca-miR-309c-5p; +MIMAT0045527 tca-miR-309c-3p; +MIMAT0045528 tca-miR-11624b-5p; +MIMAT0045529 tca-miR-11624b-3p; +MIMAT0045530 tca-miR-3851h-5p; +MIMAT0045531 tca-miR-3851h-3p; +MIMAT0045532 tca-miR-11624d-5p; +MIMAT0045533 tca-miR-11624d-3p; +MIMAT0045534 tca-miR-3851i-5p; +MIMAT0045535 tca-miR-3851i-3p; +MIMAT0045536 tca-miR-3851j-5p; +MIMAT0045537 tca-miR-3851j-3p; +MIMAT0045538 tca-miR-11625a-5p; +MIMAT0045539 tca-miR-11625a-3p; +MIMAT0045540 tca-miR-11626a-5p; +MIMAT0045541 tca-miR-11626a-3p; +MIMAT0045542 tca-miR-11626b-5p; +MIMAT0045543 tca-miR-11626b-3p; +MIMAT0045544 tca-miR-11624c-5p; +MIMAT0045545 tca-miR-11624c-3p; +MIMAT0045546 tca-miR-11627-5p; +MIMAT0045547 tca-miR-11627-3p; +MIMAT0045548 tca-miR-11628-5p; +MIMAT0045549 tca-miR-11628-3p; +MIMAT0045550 tca-miR-11629-5p; +MIMAT0045551 tca-miR-11629-3p; +MIMAT0045552 tca-miR-11630-5p; +MIMAT0045553 tca-miR-11630-3p; +MIMAT0045554 tca-miR-3851l-3-5p; +MIMAT0045555 tca-miR-11618b-3-3p; +MIMAT0045556 tca-miR-11618a-3-3p; +MIMAT0045557 tca-miR-11617a-3-3p; +MIMAT0045558 tca-miR-11619a-3p; +MIMAT0045559 tca-miR-11618b-4-3p; +MIMAT0045560 tca-miR-11617a-4-3p; +MIMAT0045561 tca-miR-971b-5p; +MIMAT0045562 tca-miR-971b-3p; +MIMAT0045563 tca-miR-11619c-5p; +MIMAT0045564 tca-miR-11619c-3p; +MIMAT0045565 tca-miR-11619d-5p; +MIMAT0045566 tca-miR-11619d-3p; +MIMAT0045567 tca-miR-3851q-5p; +MIMAT0045568 tca-miR-3851q-3p; +MIMAT0045569 tca-miR-11625b-5p; +MIMAT0045570 tca-miR-11625b-3p; +MIMAT0045571 tca-miR-3851g-2-3p; +MIMAT0045572 tca-miR-11631-5p; +MIMAT0045573 tca-miR-11631-3p; +MIMAT0045574 tca-miR-3858a-5p; +MIMAT0045575 tca-miR-3858a-3p; +MIMAT0045576 tca-miR-3851d-2-5p; +MIMAT0045577 tca-miR-3858b-5p; +MIMAT0045578 tca-miR-3858b-3p; +MIMAT0045579 tca-miR-11632-5p; +MIMAT0045580 tca-miR-11632-3p; +MIMAT0045581 tca-miR-11633-5p; +MIMAT0045582 tca-miR-11633-3p; +MIMAT0045583 tca-miR-3836g-5p; +MIMAT0045584 tca-miR-3836g-3p; +MIMAT0045585 tca-miR-3851m-4-3p; +MIMAT0045586 tca-miR-3851r-5p; +MIMAT0045587 tca-miR-3851r-3p; +MIMAT0045588 tca-miR-11634-5p; +MIMAT0045589 tca-miR-11634-3p; +MIMAT0045590 tca-miR-11635-3p; +MIMAT0045591 tca-miR-11636-5p; +MIMAT0045592 tca-miR-11636-3p; +MIMAT0045593 tca-miR-3806c-3p; +MIMAT0045594 tca-miR-11637-5p; +MIMAT0045595 tca-miR-11638-3p; +MIMAT0045596 tca-miR-3836h-3p; +MIMAT0045597 tca-miR-11639-3p; +MIMAT0045598 tca-miR-11617d-5p; +MIMAT0045599 tca-miR-11617e-5p; +MIMAT0045600 tca-miR-11617f-5p; +MIMAT0045601 tca-miR-3836i-5p; +MIMAT0045602 tca-miR-3836i-3p; +MIMAT0045603 tca-miR-11641-5p; +MIMAT0045604 tca-miR-276b-5p; +MIMAT0045605 tca-miR-276b-3p; +MIMAT0045606 tca-miR-11642-5p; +MIMAT0045607 tca-miR-11642-3p; +MIMAT0045608 tca-miR-11643-5p; +MIMAT0045609 tca-miR-11643-3p; +MIMAT0045610 tca-miR-6016b-5p; +MIMAT0045611 tca-miR-6016b-3p; +MIMAT0045612 tca-miR-11644-5p; +MIMAT0045613 tca-miR-11644-3p; +MIMAT0045614 tca-miR-307b-5p; +MIMAT0045615 tca-miR-307b-3p; +MIMAT0045616 tca-miR-927c-5p; +MIMAT0045617 tca-miR-927c-3p; +MIMAT0045618 tca-miR-11645-5p; +MIMAT0045619 tca-miR-11646-5p; +MIMAT0045620 tca-miR-11646-3p; +MIMAT0045621 tca-miR-11647-3p; +MIMAT0045622 tca-miR-11648-5p; +MIMAT0045623 tca-miR-11648-3p; +MIMAT0045624 tca-miR-3851p-5p; +MIMAT0045625 tca-miR-3851p-3p; +MIMAT0045626 tca-miR-3836j-3p; +MIMAT0045627 tca-miR-11649-3p; +MIMAT0045628 tca-miR-11650-3p; +MIMAT0045629 dqu-bantam-5p; +MIMAT0045630 dqu-bantam-3p; +MIMAT0045631 dqu-let-7-5p; +MIMAT0045632 dqu-let-7-3p; +MIMAT0045633 dqu-iab-4-5p; +MIMAT0045634 dqu-iab-4-3p; +MIMAT0045635 dqu-miR-1a-5p; +MIMAT0045636 dqu-miR-1a-3p; +MIMAT0045637 dqu-miR-1b-5p; +MIMAT0045638 dqu-miR-1b-3p; +MIMAT0045639 dqu-miR-2a-5p; +MIMAT0045640 dqu-miR-2a-3p; +MIMAT0045641 dqu-miR-2b-5p; +MIMAT0045642 dqu-miR-2b-3p; +MIMAT0045643 dqu-miR-7-5p; +MIMAT0045644 dqu-miR-7-3p; +MIMAT0045645 dqu-miR-8-5p; +MIMAT0045646 dqu-miR-8-3p; +MIMAT0045647 dqu-miR-9-5p; +MIMAT0045648 dqu-miR-9-3p; +MIMAT0045649 dqu-miR-10-5p; +MIMAT0045650 dqu-miR-10-3p; +MIMAT0045651 dqu-miR-11-5p; +MIMAT0045652 dqu-miR-11-3p; +MIMAT0045653 dqu-miR-12-5p; +MIMAT0045654 dqu-miR-12-3p; +MIMAT0045655 dqu-miR-13a-5p; +MIMAT0045656 dqu-miR-13a-3p; +MIMAT0045657 dqu-miR-13b-5p; +MIMAT0045658 dqu-miR-13b-3p; +MIMAT0045659 dqu-miR-14-5p; +MIMAT0045660 dqu-miR-14-3p; +MIMAT0045661 dqu-miR-29-5p; +MIMAT0045662 dqu-miR-29-3p; +MIMAT0045663 dqu-miR-31-5p; +MIMAT0045664 dqu-miR-31-3p; +MIMAT0045665 dqu-miR-33-5p; +MIMAT0045666 dqu-miR-33-3p; +MIMAT0045667 dqu-miR-34-5p; +MIMAT0045668 dqu-miR-34-3p; +MIMAT0045669 dqu-miR-71-5p; +MIMAT0045670 dqu-miR-71-3p; +MIMAT0045671 dqu-miR-79-5p; +MIMAT0045672 dqu-miR-79-3p; +MIMAT0045673 dqu-miR-87-5p; +MIMAT0045674 dqu-miR-87-3p; +MIMAT0045675 dqu-miR-92a-5p; +MIMAT0045676 dqu-miR-92a-3p; +MIMAT0045677 dqu-miR-92b-5p; +MIMAT0045678 dqu-miR-92b-3p; +MIMAT0045679 dqu-miR-92c-5p; +MIMAT0045680 dqu-miR-92c-3p; +MIMAT0045681 dqu-miR-100-5p; +MIMAT0045682 dqu-miR-100-3p; +MIMAT0045683 dqu-miR-124-5p; +MIMAT0045684 dqu-miR-124-3p; +MIMAT0045685 dqu-miR-125-5p; +MIMAT0045686 dqu-miR-125-3p; +MIMAT0045687 dqu-miR-133-5p; +MIMAT0045688 dqu-miR-133-3p; +MIMAT0045689 dqu-miR-137-5p; +MIMAT0045690 dqu-miR-137-3p; +MIMAT0045691 dqu-miR-184-5p; +MIMAT0045692 dqu-miR-184-3p; +MIMAT0045693 dqu-miR-190-5p; +MIMAT0045694 dqu-miR-190-3p; +MIMAT0045695 dqu-miR-193-5p; +MIMAT0045696 dqu-miR-193-3p; +MIMAT0045697 dqu-miR-210-5p; +MIMAT0045698 dqu-miR-210-3p; +MIMAT0045699 dqu-miR-219-5p; +MIMAT0045700 dqu-miR-219-3p; +MIMAT0045701 dqu-miR-252a-5p; +MIMAT0045702 dqu-miR-252a-3p; +MIMAT0045703 dqu-miR-252b-5p; +MIMAT0045704 dqu-miR-252b-3p; +MIMAT0045705 dqu-miR-263a-5p; +MIMAT0045706 dqu-miR-263a-3p; +MIMAT0045707 dqu-miR-263b-5p; +MIMAT0045708 dqu-miR-263b-3p; +MIMAT0045709 dqu-miR-275-5p; +MIMAT0045710 dqu-miR-275-3p; +MIMAT0045711 dqu-miR-276-5p; +MIMAT0045712 dqu-miR-276-3p; +MIMAT0045713 dqu-miR-277-5p; +MIMAT0045714 dqu-miR-277-3p; +MIMAT0045715 dqu-miR-278-5p; +MIMAT0045716 dqu-miR-278-3p; +MIMAT0045717 dqu-miR-279a-5p; +MIMAT0045718 dqu-miR-279a-3p; +MIMAT0045719 dqu-miR-279b-5p; +MIMAT0045720 dqu-miR-279b-3p; +MIMAT0045721 dqu-miR-279c-5p; +MIMAT0045722 dqu-miR-279c-3p; +MIMAT0045723 dqu-miR-281-5p; +MIMAT0045724 dqu-miR-281-3p; +MIMAT0045725 dqu-miR-282-5p; +MIMAT0045726 dqu-miR-282-3p; +MIMAT0045727 dqu-miR-283-5p; +MIMAT0045728 dqu-miR-283-3p; +MIMAT0045729 dqu-miR-305-5p; +MIMAT0045730 dqu-miR-305-3p; +MIMAT0045731 dqu-miR-306-5p; +MIMAT0045732 dqu-miR-306-3p; +MIMAT0045733 dqu-miR-307-5p; +MIMAT0045734 dqu-miR-307-3p; +MIMAT0045735 dqu-miR-315-5p; +MIMAT0045736 dqu-miR-315-3p; +MIMAT0045737 dqu-miR-316-5p; +MIMAT0045738 dqu-miR-316-3p; +MIMAT0045739 dqu-miR-317-5p; +MIMAT0045740 dqu-miR-317-3p; +MIMAT0045741 dqu-miR-375-5p; +MIMAT0045742 dqu-miR-375-3p; +MIMAT0045743 dqu-miR-750-5p; +MIMAT0045744 dqu-miR-750-3p; +MIMAT0045745 dqu-miR-927a-5p; +MIMAT0045746 dqu-miR-927a-3p; +MIMAT0045747 dqu-miR-927b-5p; +MIMAT0045748 dqu-miR-927b-3p; +MIMAT0045749 dqu-miR-929-5p; +MIMAT0045750 dqu-miR-929-3p; +MIMAT0045751 dqu-miR-932-5p; +MIMAT0045752 dqu-miR-932-3p; +MIMAT0045753 dqu-miR-965-5p; +MIMAT0045754 dqu-miR-965-3p; +MIMAT0045755 dqu-miR-971-5p; +MIMAT0045756 dqu-miR-971-3p; +MIMAT0045757 dqu-miR-980-5p; +MIMAT0045758 dqu-miR-980-3p; +MIMAT0045759 dqu-miR-981-5p; +MIMAT0045760 dqu-miR-981-3p; +MIMAT0045761 dqu-miR-993-5p; +MIMAT0045762 dqu-miR-993-3p; +MIMAT0045763 dqu-miR-995-5p; +MIMAT0045764 dqu-miR-995-3p; +MIMAT0045765 dqu-miR-996-5p; +MIMAT0045766 dqu-miR-996-3p; +MIMAT0045767 dqu-miR-1000-5p; +MIMAT0045768 dqu-miR-1000-3p; +MIMAT0045769 dqu-miR-1175-5p; +MIMAT0045770 dqu-miR-1175-3p; +MIMAT0045771 dqu-miR-2765-5p; +MIMAT0045772 dqu-miR-2765-3p; +MIMAT0045773 dqu-miR-2788-5p; +MIMAT0045774 dqu-miR-2788-3p; +MIMAT0045775 dqu-miR-2796-5p; +MIMAT0045776 dqu-miR-2796-3p; +MIMAT0045777 dqu-miR-11651-5p; +MIMAT0045778 dqu-miR-11651-3p; +MIMAT0045779 dqu-miR-3477-5p; +MIMAT0045780 dqu-miR-3477-3p; +MIMAT0045781 dqu-miR-3715-5p; +MIMAT0045782 dqu-miR-3715-3p; +MIMAT0045783 dqu-miR-3759-3p; +MIMAT0045784 dqu-miR-3770-5p; +MIMAT0045785 dqu-miR-3770-3p; +MIMAT0045786 dqu-miR-3782-5p; +MIMAT0045787 dqu-miR-3783-5p; +MIMAT0045788 dqu-miR-3783-3p; +MIMAT0045789 dqu-miR-3785-5p; +MIMAT0045790 dqu-miR-3785-3p; +MIMAT0045791 dqu-miR-3786-5p; +MIMAT0045792 dqu-miR-3786-3p; +MIMAT0045793 dqu-miR-6001-5p; +MIMAT0045794 dqu-miR-6001-3p; +MIMAT0045795 dqu-miR-6037-5p; +MIMAT0045796 dqu-miR-6037-3p; +MIMAT0045797 dqu-miR-6038-5p; +MIMAT0045798 dqu-miR-6038-3p; +MIMAT0045799 dqu-miR-6039-5p; +MIMAT0045800 dqu-miR-6039-3p; +MIMAT0045801 dqu-miR-6060-5p; +MIMAT0045802 dqu-miR-6065-3p; +MIMAT0045803 dqu-miR-6067-5p; +MIMAT0045804 dqu-miR-11652-5p; +MIMAT0045805 dqu-miR-11652-3p; +MIMAT0045806 dqu-miR-11653-5p; +MIMAT0045807 dqu-miR-11653-3p; +MIMAT0045808 dqu-miR-11654-5p; +MIMAT0045809 dqu-miR-11654-3p; +MIMAT0045810 dqu-miR-11655-5p; +MIMAT0045811 dqu-miR-11655-3p; +MIMAT0045812 dqu-miR-11656-5p; +MIMAT0045813 dqu-miR-11656-3p; +MIMAT0045814 dqu-miR-11657-5p; +MIMAT0045815 dqu-miR-11657-3p; +MIMAT0045816 dqu-miR-11658-5p; +MIMAT0045817 dqu-miR-11658-3p; +MIMAT0045818 dqu-miR-11659-5p; +MIMAT0045819 dqu-miR-11659-3p; +MIMAT0045820 dqu-miR-11660-5p; +MIMAT0045821 dqu-miR-11660-3p; +MIMAT0045822 dqu-miR-11661-5p; +MIMAT0045823 dqu-miR-11661-3p; +MIMAT0045824 dqu-miR-11662-5p; +MIMAT0045825 dqu-miR-11662-3p; +MIMAT0045826 pca-bantam-5p; +MIMAT0045827 pca-bantam-3p; +MIMAT0045828 pca-let-7-5p; +MIMAT0045829 pca-let-7-3p; +MIMAT0045830 pca-iab-4-5p; +MIMAT0045831 pca-iab-4-3p; +MIMAT0045832 pca-miR-1-5p; +MIMAT0045833 pca-miR-1-3p; +MIMAT0045834 pca-miR-7-5p; +MIMAT0045835 pca-miR-7-3p; +MIMAT0045836 pca-miR-8-5p; +MIMAT0045837 pca-miR-8-3p; +MIMAT0045838 pca-miR-9-5p; +MIMAT0045839 pca-miR-9-3p; +MIMAT0045840 pca-miR-11-5p; +MIMAT0045841 pca-miR-11-3p; +MIMAT0045842 pca-miR-12-5p; +MIMAT0045843 pca-miR-12-3p; +MIMAT0045844 pca-miR-13a-5p; +MIMAT0045845 pca-miR-13a-3p; +MIMAT0045846 pca-miR-13b-5p; +MIMAT0045847 pca-miR-13b-3p; +MIMAT0045848 pca-miR-14-5p; +MIMAT0045849 pca-miR-14-3p; +MIMAT0045850 pca-miR-29-3p; +MIMAT0045851 pca-miR-31-5p; +MIMAT0045852 pca-miR-31-3p; +MIMAT0045853 pca-miR-33-5p; +MIMAT0045854 pca-miR-33-3p; +MIMAT0045855 pca-miR-34-5p; +MIMAT0045856 pca-miR-34-3p; +MIMAT0045857 pca-miR-71-5p; +MIMAT0045858 pca-miR-71-3p; +MIMAT0045859 pca-miR-92c-5p; +MIMAT0045860 pca-miR-92c-3p; +MIMAT0045861 pca-miR-100-5p; +MIMAT0045862 pca-miR-100-3p; +MIMAT0045863 pca-miR-124-5p; +MIMAT0045864 pca-miR-124-3p; +MIMAT0045865 pca-miR-133-5p; +MIMAT0045866 pca-miR-133-3p; +MIMAT0045867 pca-miR-137-5p; +MIMAT0045868 pca-miR-137-3p; +MIMAT0045869 pca-miR-184-5p; +MIMAT0045870 pca-miR-184-3p; +MIMAT0045871 pca-miR-190-5p; +MIMAT0045872 pca-miR-190-3p; +MIMAT0045873 pca-miR-210-5p; +MIMAT0045874 pca-miR-210-3p; +MIMAT0045875 pca-miR-219-5p; +MIMAT0045876 pca-miR-219-3p; +MIMAT0045877 pca-miR-252-5p; +MIMAT0045878 pca-miR-252-3p; +MIMAT0045879 pca-miR-263b-5p; +MIMAT0045880 pca-miR-263b-3p; +MIMAT0045881 pca-miR-275-5p; +MIMAT0045882 pca-miR-275-3p; +MIMAT0045883 pca-miR-276-5p; +MIMAT0045884 pca-miR-276-3p; +MIMAT0045885 pca-miR-277-5p; +MIMAT0045886 pca-miR-277-3p; +MIMAT0045887 pca-miR-278-5p; +MIMAT0045888 pca-miR-278-3p; +MIMAT0045889 pca-miR-279b-5p; +MIMAT0045890 pca-miR-279b-3p; +MIMAT0045891 pca-miR-279c-5p; +MIMAT0045892 pca-miR-279c-3p; +MIMAT0045893 pca-miR-281-5p; +MIMAT0045894 pca-miR-281-3p; +MIMAT0045895 pca-miR-282-5p; +MIMAT0045896 pca-miR-282-3p; +MIMAT0045897 pca-miR-283-5p; +MIMAT0045898 pca-miR-283-3p; +MIMAT0045899 pca-miR-305-5p; +MIMAT0045900 pca-miR-305-3p; +MIMAT0045901 pca-miR-306-5p; +MIMAT0045902 pca-miR-306-3p; +MIMAT0045903 pca-miR-315-5p; +MIMAT0045904 pca-miR-315-3p; +MIMAT0045905 pca-miR-316-5p; +MIMAT0045906 pca-miR-316-3p; +MIMAT0045907 pca-miR-317-5p; +MIMAT0045908 pca-miR-317-3p; +MIMAT0045909 pca-miR-750-5p; +MIMAT0045910 pca-miR-750-3p; +MIMAT0045911 pca-miR-927a-5p; +MIMAT0045912 pca-miR-927a-3p; +MIMAT0045913 pca-miR-927b-5p; +MIMAT0045914 pca-miR-927b-3p; +MIMAT0045915 pca-miR-929-5p; +MIMAT0045916 pca-miR-929-3p; +MIMAT0045917 pca-miR-932-5p; +MIMAT0045918 pca-miR-932-3p; +MIMAT0045919 pca-miR-965-5p; +MIMAT0045920 pca-miR-965-3p; +MIMAT0045921 pca-miR-971-5p; +MIMAT0045922 pca-miR-971-3p; +MIMAT0045923 pca-miR-980-5p; +MIMAT0045924 pca-miR-980-3p; +MIMAT0045925 pca-miR-981-5p; +MIMAT0045926 pca-miR-981-3p; +MIMAT0045927 pca-miR-995-5p; +MIMAT0045928 pca-miR-995-3p; +MIMAT0045929 pca-miR-1000-5p; +MIMAT0045930 pca-miR-1000-3p; +MIMAT0045931 pca-miR-1175-5p; +MIMAT0045932 pca-miR-1175-3p; +MIMAT0045933 pca-miR-2765-5p; +MIMAT0045934 pca-miR-2765-3p; +MIMAT0045935 pca-miR-2796-5p; +MIMAT0045936 pca-miR-2796-3p; +MIMAT0045937 pca-miR-3049-5p; +MIMAT0045938 pca-miR-3049-3p; +MIMAT0045939 pca-miR-3736-5p; +MIMAT0045940 pca-miR-3759-3p; +MIMAT0045941 pca-miR-3770-5p; +MIMAT0045942 pca-miR-3782-5p; +MIMAT0045943 pca-miR-3783-5p; +MIMAT0045944 pca-miR-3783-3p; +MIMAT0045945 pca-miR-3785-5p; +MIMAT0045946 pca-miR-3785-3p; +MIMAT0045947 pca-miR-3786-5p; +MIMAT0045948 pca-miR-3786-3p; +MIMAT0045949 pca-miR-6001-5p; +MIMAT0045950 pca-miR-6001-3p; +MIMAT0045951 pca-miR-6038-5p; +MIMAT0045952 pca-miR-6038-3p; +MIMAT0045953 pca-miR-6039-5p; +MIMAT0045954 pca-miR-6039-3p; +MIMAT0045955 pca-miR-6065-3p; +MIMAT0045956 pca-miR-6067-5p; +MIMAT0045957 pca-miR-6067-3p; +MIMAT0045958 pca-miR-11663-5p; +MIMAT0045959 pca-miR-11663-3p; +MIMAT0045960 pca-miR-11664a-5p; +MIMAT0045961 pca-miR-11664a-3p; +MIMAT0045962 pca-miR-11664b-5p; +MIMAT0045963 pca-miR-11664b-3p; +MIMAT0045964 pca-miR-11665-5p; +MIMAT0045965 pca-miR-11665-3p; +MIMAT0045966 tca-miR-11618a-5-3p; +MIMAT0045967 tca-miR-3851l-4-3p; +MIMAT0045968 mes-miR171l; +MIMAT0045969 mes-miR390b; +MIMAT0045970 mes-miR397b; +MIMAT0045971 mes-miR398; +MIMAT0045972 mes-miR399h; +MIMAT0045973 mes-miR477j; +MIMAT0045974 mes-miR477k; +MIMAT0045975 mes-miR2118; +MIMAT0045976 mes-miR482b; +MIMAT0045977 mes-miR482c; +MIMAT0045978 mes-miR482d; +MIMAT0045979 mes-miR482e; +MIMAT0045980 mes-miR535c; +MIMAT0045981 mes-miR535d; +MIMAT0045982 mes-miR1446b; +MIMAT0045983 mes-miR3627; +MIMAT0045984 mes-miR6445; +MIMAT0045985 mes-miR9386; +MIMAT0045986 mes-miR169ad; +MIMAT0045987 mes-miR11891; +MIMAT0045988 mes-miR11892; +MIMAT0045989 aae-miR-11893; +MIMAT0045990 aae-miR-11894a; +MIMAT0045991 aae-miR-11894b; +MIMAT0045992 aae-miR-11895; +MIMAT0045993 aae-miR-10365; +MIMAT0045994 aae-miR-11896; +MIMAT0045995 aae-miR-11897a; +MIMAT0045996 aae-miR-11898; +MIMAT0045997 aae-miR-11897b; +MIMAT0045998 aae-miR-11899; +MIMAT0045999 aae-miR-11900; +MIMAT0046000 aae-miR-11901; +MIMAT0046001 aae-miR-11902; +MIMAT0046002 aae-miR-11903a; +MIMAT0046003 aae-miR-11904; +MIMAT0046004 aae-miR-11905; +MIMAT0046005 aae-miR-11906; +MIMAT0046006 aae-miR-11907; +MIMAT0046007 aae-miR-11908; +MIMAT0046008 aae-miR-11909; +MIMAT0046009 aae-miR-11910; +MIMAT0046010 aae-miR-11911; +MIMAT0046011 aae-miR-11912; +MIMAT0046012 aae-miR-11913; +MIMAT0046013 aae-miR-11914; +MIMAT0046014 aae-miR-11903b; +MIMAT0046015 aae-miR-11915; +MIMAT0046016 aae-miR-11916; +MIMAT0046017 aae-miR-11917; +MIMAT0046018 aae-miR-11918; +MIMAT0046019 aae-miR-11919; +MIMAT0046020 aae-miR-11920; +MIMAT0046021 aae-miR-11921; +MIMAT0046022 aae-miR-11922; +MIMAT0046023 aae-miR-11923; +MIMAT0046024 aae-miR-11924; +MIMAT0046025 aae-miR-11925; +MIMAT0046026 aae-miR-11926; +MIMAT0046027 aae-miR-11927; +MIMAT0046028 aae-miR-11928; +MIMAT0046029 gmo-miR-133a-5p; +MIMAT0046030 gmo-miR-133a-3p; +MIMAT0046031 gmo-miR-18a-2-5p; +MIMAT0046032 gmo-miR-18a-3p; +MIMAT0046033 gmo-miR-190a-2-5p; +MIMAT0046034 gmo-miR-212-2-5p; +MIMAT0046035 gmo-miR-214-2-5p; +MIMAT0046036 gmo-miR-2184-5p; +MIMAT0046037 gmo-miR-2184-3p; +MIMAT0046038 gmo-miR-2187b-5p; +MIMAT0046039 gmo-miR-2187b-3p; +MIMAT0046040 gmo-miR-223a-5p; +MIMAT0046041 gmo-miR-223a-3p; +MIMAT0046042 gmo-miR-26a-4-3p; +MIMAT0046043 gmo-miR-27d-5p; +MIMAT0046044 gmo-miR-27d-3p; +MIMAT0046045 gmo-miR-33b-2-3p; +MIMAT0046046 gmo-miR-451-5p; +MIMAT0046047 gmo-miR-451-3p; +MIMAT0046048 gmo-miR-459-5p; +MIMAT0046049 gmo-miR-459-3p; +MIMAT0046050 gmo-miR-722-5p; +MIMAT0046051 gmo-miR-727b-5p; +MIMAT0046052 gmo-miR-727b-3p; +MIMAT0046053 gmo-miR-7552-3p; +MIMAT0046054 gmo-miR-11224b-5p; +MIMAT0046055 gmo-miR-11224b-3p; +MIMAT0046056 gmo-miR-11929-5p; +MIMAT0046057 gmo-miR-11929-3p; +MIMAT0046058 gmo-miR-11930-5p; +MIMAT0046059 gmo-miR-11930-3p; +MIMAT0046060 gmo-miR-11931-5p; +MIMAT0046061 gmo-miR-11931-3p; +MIMAT0046062 gmo-miR-11932-5p; +MIMAT0046063 gmo-miR-11932-3p; +MIMAT0046064 gmo-miR-11933-5p; +MIMAT0046065 gmo-miR-11933-3p; +MIMAT0046066 gmo-miR-11931-2-3p; +MIMAT0046067 gmo-miR-11934-5p; +MIMAT0046068 gmo-miR-11934-3p; +MIMAT0046069 gmo-miR-11935-5p; +MIMAT0046070 gmo-miR-11935-3p; +MIMAT0046071 gmo-miR-11936-5p; +MIMAT0046072 gmo-miR-11936-3p; +MIMAT0046073 gmo-miR-11937-5p; +MIMAT0046074 gmo-miR-11937-3p; +MIMAT0046075 pte-bantam-5p; +MIMAT0046076 pte-bantam-3p; +MIMAT0046077 pte-iab-4-5p; +MIMAT0046078 pte-iab-4-3p; +MIMAT0046079 pte-iab-4-2-3p; +MIMAT0046080 pte-iab-8-5p; +MIMAT0046081 pte-iab-8-3p; +MIMAT0046082 pte-let-7-5p; +MIMAT0046083 pte-let-7-3p; +MIMAT0046084 pte-miR-1-5p; +MIMAT0046085 pte-miR-1-3p; +MIMAT0046086 pte-miR-10-5p; +MIMAT0046087 pte-miR-10-3p; +MIMAT0046088 pte-miR-100a-5p; +MIMAT0046089 pte-miR-100a-3p; +MIMAT0046090 pte-miR-100b-5p; +MIMAT0046091 pte-miR-100b-3p; +MIMAT0046092 pte-miR-125a-5p; +MIMAT0046093 pte-miR-125a-3p; +MIMAT0046094 pte-miR-125b-5p; +MIMAT0046095 pte-miR-125b-3p; +MIMAT0046096 pte-miR-184-5p; +MIMAT0046097 pte-miR-184-3p; +MIMAT0046098 pte-miR-184-2-5p; +MIMAT0046099 pte-miR-190-5p; +MIMAT0046100 pte-miR-190-3p; +MIMAT0046101 pte-miR-193a-5p; +MIMAT0046102 pte-miR-193a-3p; +MIMAT0046103 pte-miR-193b-5p; +MIMAT0046104 pte-miR-193b-3p; +MIMAT0046105 pte-miR-210-5p; +MIMAT0046106 pte-miR-210-3p; +MIMAT0046107 pte-miR-263a-5p; +MIMAT0046108 pte-miR-263a-3p; +MIMAT0046109 pte-miR-263b-5p; +MIMAT0046110 pte-miR-263b-3p; +MIMAT0046111 pte-miR-275-5p; +MIMAT0046112 pte-miR-275-3p; +MIMAT0046113 pte-miR-276-5p; +MIMAT0046114 pte-miR-276-3p; +MIMAT0046115 pte-miR-276-2-5p; +MIMAT0046116 pte-miR-277a-5p; +MIMAT0046117 pte-miR-277a-3p; +MIMAT0046118 pte-miR-277b-5p; +MIMAT0046119 pte-miR-277b-3p; +MIMAT0046120 pte-miR-278a-5p; +MIMAT0046121 pte-miR-278a-3p; +MIMAT0046122 pte-miR-278b-5p; +MIMAT0046123 pte-miR-278b-3p; +MIMAT0046124 pte-miR-35a-5p; +MIMAT0046125 pte-miR-35a-3p; +MIMAT0046126 pte-miR-279-5p; +MIMAT0046127 pte-miR-279-3p; +MIMAT0046128 pte-miR-35b-5p; +MIMAT0046129 pte-miR-35b-3p; +MIMAT0046130 pte-miR-281-5p; +MIMAT0046131 pte-miR-281-3p; +MIMAT0046132 pte-miR-29a-5p; +MIMAT0046133 pte-miR-29a-3p; +MIMAT0046134 pte-miR-29b-5p; +MIMAT0046135 pte-miR-29b-3p; +MIMAT0046136 pte-miR-2a-5p; +MIMAT0046137 pte-miR-2a-3p; +MIMAT0046138 pte-miR-2b-5p; +MIMAT0046139 pte-miR-2b-3p; +MIMAT0046140 pte-miR-2b-2-5p; +MIMAT0046141 pte-miR-2c-5p; +MIMAT0046142 pte-miR-2c-3p; +MIMAT0046143 pte-miR-2d-5p; +MIMAT0046144 pte-miR-2d-3p; +MIMAT0046145 pte-miR-2e-5p; +MIMAT0046146 pte-miR-2e-3p; +MIMAT0046147 pte-miR-2f-5p; +MIMAT0046148 pte-miR-2f-3p; +MIMAT0046149 pte-miR-2g-5p; +MIMAT0046150 pte-miR-2g-3p; +MIMAT0046151 pte-miR-2g-2-5p; +MIMAT0046152 pte-miR-11938-5p; +MIMAT0046153 pte-miR-11938-3p; +MIMAT0046154 pte-miR-305-5p; +MIMAT0046155 pte-miR-305-3p; +MIMAT0046156 pte-miR-315-5p; +MIMAT0046157 pte-miR-315-3p; +MIMAT0046158 pte-miR-317-5p; +MIMAT0046159 pte-miR-317-3p; +MIMAT0046160 pte-miR-34-5p; +MIMAT0046161 pte-miR-34-3p; +MIMAT0046162 pte-miR-35c-5p; +MIMAT0046163 pte-miR-35c-3p; +MIMAT0046164 pte-miR-35o-5p; +MIMAT0046165 pte-miR-35o-3p; +MIMAT0046166 pte-miR-35q-1-5p; +MIMAT0046167 pte-miR-35q-3p; +MIMAT0046168 pte-miR-35t-5p; +MIMAT0046169 pte-miR-35t-3p; +MIMAT0046170 pte-miR-35n-5p; +MIMAT0046171 pte-miR-35n-3p; +MIMAT0046172 pte-miR-35k-5p; +MIMAT0046173 pte-miR-35k-3p; +MIMAT0046174 pte-miR-35d-5p; +MIMAT0046175 pte-miR-35d-3p; +MIMAT0046176 pte-miR-35j-5p; +MIMAT0046177 pte-miR-35j-3p; +MIMAT0046178 pte-miR-35e-5p; +MIMAT0046179 pte-miR-35e-3p; +MIMAT0046180 pte-miR-35f-5p; +MIMAT0046181 pte-miR-35f-3p; +MIMAT0046182 pte-miR-35g-5p; +MIMAT0046183 pte-miR-35g-3p; +MIMAT0046184 pte-miR-35h-5p; +MIMAT0046185 pte-miR-35h-3p; +MIMAT0046186 pte-miR-35i-5p; +MIMAT0046187 pte-miR-35i-3p; +MIMAT0046188 pte-miR-35s-5p; +MIMAT0046189 pte-miR-35s-3p; +MIMAT0046190 pte-miR-35m-5p; +MIMAT0046191 pte-miR-35m-3p; +MIMAT0046192 pte-miR-35z-5p; +MIMAT0046193 pte-miR-35z-3p; +MIMAT0046194 pte-miR-35u-5p; +MIMAT0046195 pte-miR-35u-3p; +MIMAT0046196 pte-miR-35p-5p; +MIMAT0046197 pte-miR-35p-3p; +MIMAT0046198 pte-miR-35w-5p; +MIMAT0046199 pte-miR-35w-3p; +MIMAT0046200 pte-miR-35l-5p; +MIMAT0046201 pte-miR-35l-3p; +MIMAT0046202 pte-miR-35x-5p; +MIMAT0046203 pte-miR-35x-3p; +MIMAT0046204 pte-miR-35y-5p; +MIMAT0046205 pte-miR-35y-3p; +MIMAT0046206 pte-miR-35v-5p; +MIMAT0046207 pte-miR-35v-3p; +MIMAT0046208 pte-miR-35r-5p; +MIMAT0046209 pte-miR-35r-3p; +MIMAT0046210 pte-miR-35q-5p; +MIMAT0046211 pte-miR-35o-2-5p; +MIMAT0046212 pte-miR-375-5p; +MIMAT0046213 pte-miR-375-3p; +MIMAT0046214 pte-miR-375-2-5p; +MIMAT0046215 pte-miR-3931-5p; +MIMAT0046216 pte-miR-3931-3p; +MIMAT0046217 pte-miR-7-5p; +MIMAT0046218 pte-miR-7-3p; +MIMAT0046219 pte-miR-71-5p; +MIMAT0046220 pte-miR-71-3p; +MIMAT0046221 pte-miR-745-5p; +MIMAT0046222 pte-miR-745-3p; +MIMAT0046223 pte-miR-8-5p; +MIMAT0046224 pte-miR-8-3p; +MIMAT0046225 pte-miR-87a-5p; +MIMAT0046226 pte-miR-87a-3p; +MIMAT0046227 pte-miR-87b-5p; +MIMAT0046228 pte-miR-87b-3p; +MIMAT0046229 pte-miR-87c-5p; +MIMAT0046230 pte-miR-87c-3p; +MIMAT0046231 pte-miR-9-5p; +MIMAT0046232 pte-miR-9-3p; +MIMAT0046233 pte-miR-92a-5p; +MIMAT0046234 pte-miR-92a-3p; +MIMAT0046235 pte-miR-92b-5p; +MIMAT0046236 pte-miR-92b-3p; +MIMAT0046237 pte-miR-92c-5p; +MIMAT0046238 pte-miR-92c-3p; +MIMAT0046239 pte-miR-96-5p; +MIMAT0046240 pte-miR-96-3p; +MIMAT0046241 pte-miR-981-5p; +MIMAT0046242 pte-miR-981-3p; +MIMAT0046243 pte-miR-993a-5p; +MIMAT0046244 pte-miR-993a-3p; +MIMAT0046245 pte-miR-993b-5p; +MIMAT0046246 pte-miR-993b-3p; +MIMAT0046247 pte-miR-993b-2-3p; +MIMAT0046248 pte-miR-11939-5p; +MIMAT0046249 pte-miR-11939-3p; +MIMAT0046250 pte-miR-11940-5p; +MIMAT0046251 pte-miR-11940-3p; +MIMAT0046252 pte-miR-11941-5p; +MIMAT0046253 pte-miR-11941-3p; +MIMAT0046254 pte-miR-11942a-5p; +MIMAT0046255 pte-miR-11942a-3p; +MIMAT0046256 pte-miR-11942b-5p; +MIMAT0046257 pte-miR-11942b-3p; +MIMAT0046258 pte-miR-11942c-5p; +MIMAT0046259 pte-miR-11942c-3p; +MIMAT0046260 pte-miR-11942d-5p; +MIMAT0046261 pte-miR-11942d-3p; +MIMAT0046262 pte-miR-11943-5p; +MIMAT0046263 pte-miR-11943-3p; +MIMAT0046264 pte-miR-14-5p; +MIMAT0046265 pte-miR-14-3p; +MIMAT0046266 pte-miR-11944-5p; +MIMAT0046267 pte-miR-11944-3p; +MIMAT0046268 pte-miR-11945-5p; +MIMAT0046269 pte-miR-11945-3p; +MIMAT0046270 pte-miR-11946-5p; +MIMAT0046271 pte-miR-11946-3p; +MIMAT0046272 pte-miR-11947a-5p; +MIMAT0046273 pte-miR-11947a-3p; +MIMAT0046274 pte-miR-11948-5p; +MIMAT0046275 pte-miR-11948-3p; +MIMAT0046276 pte-miR-11949-5p; +MIMAT0046277 pte-miR-11949-3p; +MIMAT0046278 pte-miR-11950-5p; +MIMAT0046279 pte-miR-11950-3p; +MIMAT0046280 pte-miR-11951a-5p; +MIMAT0046281 pte-miR-11951a-3p; +MIMAT0046282 pte-miR-11951b-5p; +MIMAT0046283 pte-miR-11951b-3p; +MIMAT0046284 pte-miR-11952-5p; +MIMAT0046285 pte-miR-11952-3p; +MIMAT0046286 pte-miR-3477-5p; +MIMAT0046287 pte-miR-3477-3p; +MIMAT0046288 pte-miR-11953-5p; +MIMAT0046289 pte-miR-11953-3p; +MIMAT0046290 pte-miR-11954-5p; +MIMAT0046291 pte-miR-11954-3p; +MIMAT0046292 pte-miR-11955-5p; +MIMAT0046293 pte-miR-11955-3p; +MIMAT0046294 pte-miR-11956-5p; +MIMAT0046295 pte-miR-11956-3p; +MIMAT0046296 pte-miR-11947b-5p; +MIMAT0046297 pte-miR-11947b-3p; +MIMAT0046298 pte-miR-11957-5p; +MIMAT0046299 pte-miR-11957-3p; +MIMAT0046300 pte-miR-11958-5p; +MIMAT0046301 pte-miR-11958-3p; +MIMAT0046302 pte-miR-11959-5p; +MIMAT0046303 pte-miR-11959-3p; +MIMAT0046304 pte-miR-11960-5p; +MIMAT0046305 pte-miR-11960-3p; +MIMAT0046306 pte-miR-11961a-5p; +MIMAT0046307 pte-miR-11961a-3p; +MIMAT0046308 pte-miR-11961b-5p; +MIMAT0046309 pte-miR-11961b-3p; +MIMAT0046310 pte-miR-11961c-5p; +MIMAT0046311 pte-miR-11961c-3p; +MIMAT0046312 pte-miR-11962a-5p; +MIMAT0046313 pte-miR-11962a-3p; +MIMAT0046314 pte-miR-11962b-5p; +MIMAT0046315 pte-miR-11962b-3p; +MIMAT0046316 pte-miR-11965-3-5p; +MIMAT0046317 pte-miR-11965-3p; +MIMAT0046318 pte-miR-11963a-5p; +MIMAT0046319 pte-miR-11963a-3p; +MIMAT0046320 pte-miR-11963b-5p; +MIMAT0046321 pte-miR-11963b-3p; +MIMAT0046322 pte-miR-11964-5p; +MIMAT0046323 pte-miR-11964-3p; +MIMAT0046324 pte-miR-11965-5p; +MIMAT0046325 pte-miR-11965-2-5p; +MIMAT0046326 pte-miR-11966-5p; +MIMAT0046327 pte-miR-11966-3p; +MIMAT0046328 pte-miR-11967-5p; +MIMAT0046329 pte-miR-11967-3p; +MIMAT0046330 pte-miR-11968-5p; +MIMAT0046331 pte-miR-11968-3p; +MIMAT0046332 zma-miR11969-5p; +MIMAT0046333 zma-miR11969-3p; +MIMAT0046334 zma-miR11970-5p; +MIMAT0046335 zma-miR11970-3p; +MIMAT0046336 bta-miR-11971; +MIMAT0046337 bta-miR-2285ar; +MIMAT0046338 bta-miR-2285as; +MIMAT0046341 bta-miR-11972; +MIMAT0046342 bta-miR-2285at; +MIMAT0046346 bta-miR-2285au; +MIMAT0046347 bta-miR-2285av; +MIMAT0046348 bta-miR-2285aw; +MIMAT0046349 bta-miR-11973; +MIMAT0046350 bta-miR-2285ax; +MIMAT0046353 bta-miR-11974; +MIMAT0046354 bta-miR-11975; +MIMAT0046355 bta-miR-2285ay; +MIMAT0046356 bta-miR-2285az; +MIMAT0046357 bta-miR-11976; +MIMAT0046358 bta-miR-2285an; +MIMAT0046359 bta-miR-11977; +MIMAT0046360 bta-miR-2285ao; +MIMAT0046362 bta-miR-2285ap; +MIMAT0046364 bta-miR-11978; +MIMAT0046365 bta-miR-2285aq; +MIMAT0046367 bta-miR-11979; +MIMAT0046368 bta-miR-11980; +MIMAT0046369 bta-miR-6715; +MIMAT0046370 bta-miR-11981; +MIMAT0046371 bta-miR-9851; +MIMAT0046372 bta-miR-11982; +MIMAT0046373 bta-miR-2285ba; +MIMAT0046375 bta-miR-2285bb; +MIMAT0046376 bta-miR-11983; +MIMAT0046377 bta-miR-2285bc; +MIMAT0046378 bta-miR-11984; +MIMAT0046379 bta-miR-2285bd; +MIMAT0046380 bta-miR-2285be; +MIMAT0046381 bta-miR-11985; +MIMAT0046382 bta-miR-2285bf; +MIMAT0046385 bta-miR-11986; +MIMAT0046386 bta-miR-2285bg; +MIMAT0046387 bta-miR-11987; +MIMAT0046388 bta-miR-2285bh; +MIMAT0046389 bta-miR-2285bi; +MIMAT0046391 bta-miR-2285bj; +MIMAT0046393 bta-miR-11988; +MIMAT0046394 bta-miR-374c; +MIMAT0046395 xla-let-7a-5p; +MIMAT0046396 xla-let-7a-3p; +MIMAT0046397 xla-let-7b-5p; +MIMAT0046398 xla-let-7b-3p; +MIMAT0046399 xla-let-7c-5p; +MIMAT0046400 xla-let-7c-3p; +MIMAT0046401 xla-let-7e-5p; +MIMAT0046402 xla-let-7e-3p; +MIMAT0046403 xla-let-7f-5p; +MIMAT0046404 xla-let-7f-3p; +MIMAT0046405 xla-let-7j-5p; +MIMAT0046406 xla-let-7j-3p; +MIMAT0046407 xla-let-7i-5p; +MIMAT0046408 xla-let-7i-3p; +MIMAT0046409 xla-miR-100-5p; +MIMAT0046410 xla-miR-100-2-3p; +MIMAT0046411 xla-miR-100-3p; +MIMAT0046412 xla-miR-101-5p; +MIMAT0046413 xla-miR-101-3p; +MIMAT0046414 xla-miR-103a-5p; +MIMAT0046415 xla-miR-103a-3p; +MIMAT0046416 xla-miR-103b-5p; +MIMAT0046417 xla-miR-103b-3p; +MIMAT0046418 xla-miR-106-5p; +MIMAT0046419 xla-miR-106-3p; +MIMAT0046420 xla-miR-107-5p; +MIMAT0046421 xla-miR-107-3p; +MIMAT0046422 xla-miR-10a-5p; +MIMAT0046423 xla-miR-10a-3p; +MIMAT0046424 xla-miR-10b-5p; +MIMAT0046425 xla-miR-10b-3p; +MIMAT0046426 xla-miR-122-5p; +MIMAT0046427 xla-miR-122-3p; +MIMAT0046428 xla-miR-124-2-5p; +MIMAT0046429 xla-miR-124-3p; +MIMAT0046430 xla-miR-124-5p; +MIMAT0046431 xla-miR-125a-5p; +MIMAT0046432 xla-miR-125a-3p; +MIMAT0046433 xla-miR-125b-5p; +MIMAT0046434 xla-miR-125b-3p; +MIMAT0046435 xla-miR-126-5p; +MIMAT0046436 xla-miR-126-3p; +MIMAT0046437 xla-miR-126-2-3p; +MIMAT0046438 xla-miR-128-2-5p; +MIMAT0046439 xla-miR-128-3p; +MIMAT0046440 xla-miR-128-5p; +MIMAT0046441 xla-miR-130a-5p; +MIMAT0046442 xla-miR-130a-3p; +MIMAT0046443 xla-miR-130b-5p; +MIMAT0046444 xla-miR-130b-3p; +MIMAT0046445 xla-miR-130c-5p; +MIMAT0046446 xla-miR-130c-3p; +MIMAT0046447 xla-miR-135-5p; +MIMAT0046448 xla-miR-135-3p; +MIMAT0046449 xla-miR-138-5p; +MIMAT0046450 xla-miR-138-2-3p; +MIMAT0046451 xla-miR-138-3p; +MIMAT0046452 xla-miR-140-5p; +MIMAT0046453 xla-miR-140-3p; +MIMAT0046454 xla-miR-142-5p; +MIMAT0046455 xla-miR-142-3p; +MIMAT0046456 xla-miR-143-5p; +MIMAT0046457 xla-miR-143-3p; +MIMAT0046458 xla-miR-144-5p; +MIMAT0046459 xla-miR-144-3p; +MIMAT0046460 xla-miR-145-5p; +MIMAT0046461 xla-miR-145-3p; +MIMAT0046462 xla-miR-146a-5p; +MIMAT0046463 xla-miR-146a-3p; +MIMAT0046464 xla-miR-146b-5p; +MIMAT0046465 xla-miR-146b-3p; +MIMAT0046466 xla-miR-148a-5p; +MIMAT0046467 xla-miR-148a-3p; +MIMAT0046468 xla-miR-148b-5p; +MIMAT0046469 xla-miR-148b-3p; +MIMAT0046470 xla-miR-15a-5p; +MIMAT0046471 xla-miR-15a-3p; +MIMAT0046472 xla-miR-15b-5p; +MIMAT0046473 xla-miR-15b-3p; +MIMAT0046474 xla-miR-15c-5p; +MIMAT0046475 xla-miR-15c-3p; +MIMAT0046476 xla-miR-16b-5p; +MIMAT0046477 xla-miR-16b-3p; +MIMAT0046478 xla-miR-16a-5p; +MIMAT0046479 xla-miR-16a-3p; +MIMAT0046480 xla-miR-16c-5p; +MIMAT0046481 xla-miR-16c-3p; +MIMAT0046482 xla-miR-17-5p; +MIMAT0046483 xla-miR-17-3p; +MIMAT0046484 xla-miR-17-2-3p; +MIMAT0046485 xla-miR-181a-5p; +MIMAT0046486 xla-miR-181a-3p; +MIMAT0046487 xla-miR-181b-5p; +MIMAT0046488 xla-miR-181b-3p; +MIMAT0046489 xla-miR-181b-2-3p; +MIMAT0046490 xla-miR-182-5p; +MIMAT0046491 xla-miR-182-3p; +MIMAT0046492 xla-miR-182-2-3p; +MIMAT0046493 xla-miR-183-5p; +MIMAT0046494 xla-miR-183-3p; +MIMAT0046495 xla-miR-184-5p; +MIMAT0046496 xla-miR-184-3p; +MIMAT0046497 xla-miR-18b-5p; +MIMAT0046498 xla-miR-18b-3p; +MIMAT0046499 xla-miR-18a-3p; +MIMAT0046500 xla-miR-190-5p; +MIMAT0046501 xla-miR-190-3p; +MIMAT0046502 xla-miR-191-5p; +MIMAT0046503 xla-miR-191-3p; +MIMAT0046504 xla-miR-192-5p; +MIMAT0046505 xla-miR-192-3p; +MIMAT0046506 xla-miR-193-5p; +MIMAT0046507 xla-miR-193-3p; +MIMAT0046508 xla-miR-194-5p; +MIMAT0046509 xla-miR-194-3p; +MIMAT0046510 xla-miR-199-5p; +MIMAT0046511 xla-miR-199-3p; +MIMAT0046512 xla-miR-19a-5p; +MIMAT0046513 xla-miR-19a-3p; +MIMAT0046514 xla-miR-19b-5p; +MIMAT0046515 xla-miR-19b-3p; +MIMAT0046516 xla-miR-1a-5p; +MIMAT0046517 xla-miR-1a-3p; +MIMAT0046518 xla-miR-200a-5p; +MIMAT0046519 xla-miR-200a-3p; +MIMAT0046520 xla-miR-200b-5p; +MIMAT0046521 xla-miR-200b-3p; +MIMAT0046522 xla-miR-202-5p; +MIMAT0046523 xla-miR-202-3p; +MIMAT0046524 xla-miR-203-5p; +MIMAT0046525 xla-miR-203-3p; +MIMAT0046526 xla-miR-206-5p; +MIMAT0046527 xla-miR-206-3p; +MIMAT0046528 xla-miR-20a-5p; +MIMAT0046529 xla-miR-20a-3p; +MIMAT0046530 xla-miR-210-5p; +MIMAT0046531 xla-miR-210-3p; +MIMAT0046532 xla-miR-212-5p; +MIMAT0046533 xla-miR-212-3p; +MIMAT0046534 xla-miR-214-5p; +MIMAT0046535 xla-miR-214-3p; +MIMAT0046536 xla-miR-216-5p; +MIMAT0046537 xla-miR-216-3p; +MIMAT0046538 xla-miR-217-5p; +MIMAT0046539 xla-miR-217-3p; +MIMAT0046540 xla-miR-22-5p; +MIMAT0046541 xla-miR-22-3p; +MIMAT0046542 xla-miR-221-5p; +MIMAT0046543 xla-miR-221-3p; +MIMAT0046544 xla-miR-222-5p; +MIMAT0046545 xla-miR-222-3p; +MIMAT0046546 xla-miR-23a-5p; +MIMAT0046547 xla-miR-23a-3p; +MIMAT0046548 xla-miR-23b-5p; +MIMAT0046549 xla-miR-23b-3p; +MIMAT0046550 xla-miR-24a-5p; +MIMAT0046551 xla-miR-24a-3p; +MIMAT0046552 xla-miR-24b-5p; +MIMAT0046553 xla-miR-25-5p; +MIMAT0046554 xla-miR-25-3p; +MIMAT0046555 xla-miR-26-5p; +MIMAT0046556 xla-miR-26-3p; +MIMAT0046557 xla-miR-26-2-3p; +MIMAT0046558 xla-miR-27a-5p; +MIMAT0046559 xla-miR-27a-3p; +MIMAT0046560 xla-miR-27b-5p; +MIMAT0046561 xla-miR-27b-3p; +MIMAT0046562 xla-miR-29b-5p; +MIMAT0046563 xla-miR-29b-3p; +MIMAT0046564 xla-miR-29c-5p; +MIMAT0046565 xla-miR-29c-3p; +MIMAT0046566 xla-miR-301-5p; +MIMAT0046567 xla-miR-301-3p; +MIMAT0046568 xla-miR-30a-5p; +MIMAT0046569 xla-miR-30a-3p; +MIMAT0046570 xla-miR-30b-5p; +MIMAT0046571 xla-miR-30b-3p; +MIMAT0046572 xla-miR-30c-5p; +MIMAT0046573 xla-miR-30c-3p; +MIMAT0046574 xla-miR-30d-5p; +MIMAT0046575 xla-miR-30d-3p; +MIMAT0046576 xla-miR-30e-5p; +MIMAT0046577 xla-miR-30e-3p; +MIMAT0046578 xla-miR-338-5p; +MIMAT0046579 xla-miR-338-3p; +MIMAT0046580 xla-miR-33a-5p; +MIMAT0046581 xla-miR-33a-3p; +MIMAT0046582 xla-miR-33b-5p; +MIMAT0046583 xla-miR-33b-3p; +MIMAT0046584 xla-miR-34a-5p; +MIMAT0046585 xla-miR-34a-3p; +MIMAT0046586 xla-miR-34b-5p; +MIMAT0046587 xla-miR-34b-3p; +MIMAT0046588 xla-miR-363-5p; +MIMAT0046589 xla-miR-363-3p; +MIMAT0046590 xla-miR-375-5p; +MIMAT0046591 xla-miR-375-3p; +MIMAT0046592 xla-miR-425-5p; +MIMAT0046593 xla-miR-425-3p; +MIMAT0046594 xla-miR-425-2-3p; +MIMAT0046595 xla-miR-427-5p; +MIMAT0046596 xla-miR-427-3p; +MIMAT0046597 xla-miR-428a-5p; +MIMAT0046598 xla-miR-428a-3p; +MIMAT0046599 xla-miR-428b-5p; +MIMAT0046600 xla-miR-428b-3p; +MIMAT0046601 xla-miR-429-5p; +MIMAT0046602 xla-miR-429-3p; +MIMAT0046603 xla-miR-449-5p; +MIMAT0046604 xla-miR-449-3p; +MIMAT0046605 xla-miR-455-5p; +MIMAT0046606 xla-miR-455-3p; +MIMAT0046607 xla-miR-499-5p; +MIMAT0046608 xla-miR-499-3p; +MIMAT0046609 xla-miR-92a-5p; +MIMAT0046610 xla-miR-92a-4-5p; +MIMAT0046611 xla-miR-92b-5p; +MIMAT0046612 xla-miR-92b-3p; +MIMAT0046613 xla-miR-93-5p; +MIMAT0046614 xla-miR-93-3p; +MIMAT0046615 xla-miR-96-5p; +MIMAT0046616 xla-miR-96-3p; +MIMAT0046617 xla-miR-98-5p; +MIMAT0046618 xla-miR-98-3p; +MIMAT0046619 xla-miR-99-5p; +MIMAT0046620 xla-miR-99-3p; +MIMAT0046621 bta-miR-11986b; +MIMAT0046622 bta-miR-2285bk; +MIMAT0046623 bta-miR-2285bl; +MIMAT0046624 bta-miR-2285bm; +MIMAT0046625 bta-miR-2285bn; +MIMAT0046626 bta-miR-7180; +MIMAT0046627 bta-miR-2285bo; +MIMAT0046628 bta-miR-11989; +MIMAT0046629 bta-miR-11990; +MIMAT0046630 bta-miR-1911; +MIMAT0046631 bta-miR-11991; +MIMAT0046632 bta-miR-11992; +MIMAT0046633 bta-miR-2285bp; +MIMAT0046634 bta-miR-11993; +MIMAT0046635 bta-miR-2285bq; +MIMAT0046636 bta-miR-2285br; +MIMAT0046637 bta-miR-2285bs; +MIMAT0046638 bta-miR-11986c; +MIMAT0046639 bta-miR-2285bt; +MIMAT0046640 bta-miR-2285bu; +MIMAT0046642 bta-miR-2285bv; +MIMAT0046643 bta-miR-2285bw; +MIMAT0046644 bta-miR-2285bx; +MIMAT0046645 bta-miR-2285by; +MIMAT0046646 bta-miR-2285bz; +MIMAT0046647 bta-miR-11994; +MIMAT0046648 bta-miR-11995; +MIMAT0046649 bta-miR-11996; +MIMAT0046650 bta-miR-2285ca; +MIMAT0046651 bta-miR-2285cb; +MIMAT0046652 bta-miR-2285cc; +MIMAT0046653 bta-miR-11997; +MIMAT0046654 bta-miR-11998; +MIMAT0046655 bta-miR-2285cd; +MIMAT0046656 bta-miR-1264; +MIMAT0046657 bta-miR-2285ce; +MIMAT0046658 bta-miR-11999; +MIMAT0046659 bta-miR-12000; +MIMAT0046660 bta-miR-12001; +MIMAT0046661 bta-miR-12002a; +MIMAT0046662 bta-miR-12003; +MIMAT0046663 bta-miR-2285cf; +MIMAT0046664 bta-miR-12004; +MIMAT0046665 bta-miR-2285cg; +MIMAT0046666 bta-miR-12005; +MIMAT0046667 bta-miR-12006; +MIMAT0046668 bta-miR-12007; +MIMAT0046669 bta-miR-299-2; +MIMAT0046670 bta-miR-148d; +MIMAT0046671 bta-miR-2285ch; +MIMAT0046672 bta-miR-2285ci; +MIMAT0046673 bta-miR-6775; +MIMAT0046674 bta-miR-2285cj; +MIMAT0046675 bta-miR-12008; +MIMAT0046676 bta-miR-2285ck; +MIMAT0046677 bta-miR-12009; +MIMAT0046678 bta-miR-12010; +MIMAT0046679 bta-miR-12011; +MIMAT0046680 bta-miR-12012; +MIMAT0046681 bta-miR-2285cl; +MIMAT0046682 bta-miR-2285cm; +MIMAT0046683 bta-miR-2285cn; +MIMAT0046684 bta-miR-12013; +MIMAT0046685 bta-miR-6501; +MIMAT0046686 bta-miR-2285co; +MIMAT0046687 bta-miR-2285cp; +MIMAT0046688 bta-miR-2285cq; +MIMAT0046689 bta-miR-12014; +MIMAT0046690 bta-miR-12015; +MIMAT0046691 bta-miR-2285cr; +MIMAT0046693 bta-miR-2285cs; +MIMAT0046694 bta-miR-12002b; +MIMAT0046695 bta-miR-2285ct; +MIMAT0046696 bta-miR-12016; +MIMAT0046697 bta-miR-12017; +MIMAT0046698 bta-miR-2285cu; +MIMAT0046699 bta-miR-2285cv; +MIMAT0046701 bta-miR-12018; +MIMAT0046702 bta-miR-2285cw; +MIMAT0046704 bta-miR-2285cx; +MIMAT0046705 bta-miR-2285cy; +MIMAT0046706 bta-miR-2285cz; +MIMAT0046707 bta-miR-2285da; +MIMAT0046708 bta-miR-12019; +MIMAT0046709 bta-miR-2285db; +MIMAT0046710 bta-miR-2285dc; +MIMAT0046711 bta-miR-12020; +MIMAT0046712 bta-miR-2285dd; +MIMAT0046713 bta-miR-2285de; +MIMAT0046714 bta-miR-12021; +MIMAT0046715 bta-miR-12022; +MIMAT0046716 bta-miR-12023; +MIMAT0046717 bta-miR-12024; +MIMAT0046718 bta-miR-12025; +MIMAT0046719 bta-miR-12026; +MIMAT0046720 bta-miR-12027; +MIMAT0046721 bta-miR-12028; +MIMAT0046722 bta-miR-12029; +MIMAT0046723 bta-miR-12030; +MIMAT0046724 bta-miR-12031; +MIMAT0046725 bta-miR-12032; +MIMAT0046726 bta-miR-12033; +MIMAT0046727 bta-miR-12034; +MIMAT0046728 bta-miR-12035; +MIMAT0046729 bta-miR-2285df; +MIMAT0046730 bta-miR-194b; +MIMAT0046731 bta-miR-12036; +MIMAT0046732 bta-miR-12037; +MIMAT0046733 bta-miR-12038; +MIMAT0046734 bta-miR-12039; +MIMAT0046735 bta-miR-12040; +MIMAT0046736 bta-miR-2285dg; +MIMAT0046737 bta-miR-12041; +MIMAT0046738 bta-miR-191b; +MIMAT0046739 bta-miR-12042; +MIMAT0046740 bta-miR-12043; +MIMAT0046741 bta-miR-3065; +MIMAT0046742 bta-miR-12044; +MIMAT0046743 bta-miR-12045; +MIMAT0046744 bta-miR-507b; +MIMAT0046745 bta-miR-2285dh; +MIMAT0046746 bta-miR-2285di; +MIMAT0046747 bta-miR-2285dj; +MIMAT0046748 bta-miR-12046; +MIMAT0046749 bta-miR-2285dk; +MIMAT0046750 bta-miR-12047; +MIMAT0046751 bta-miR-12048; +MIMAT0046752 bta-miR-12049; +MIMAT0046753 bta-miR-12050; +MIMAT0046754 bta-miR-12051; +MIMAT0046755 bta-miR-1949; +MIMAT0046756 bta-miR-2285dl-3p; +MIMAT0046758 bta-miR-2285dm; +MIMAT0046759 bta-miR-12052; +MIMAT0046760 bta-miR-12053; +MIMAT0046761 bta-miR-12054; +MIMAT0046762 bta-miR-12055; +MIMAT0046763 bta-miR-12056; +MIMAT0046764 bta-miR-12057; +MIMAT0046765 bta-miR-12058; +MIMAT0046766 bta-miR-12059; +MIMAT0046767 bta-miR-12060; +MIMAT0046768 bta-miR-12061; +MIMAT0046769 bta-miR-12062; +MIMAT0046770 bta-miR-12063; +MIMAT0046771 bta-miR-12064; +MIMAT0046772 mco-bantam-3p; +MIMAT0046773 mco-let-7-5p; +MIMAT0046774 mco-miR-1-3p; +MIMAT0046775 mco-miR-2a-3p; +MIMAT0046776 mco-miR-2b-3p; +MIMAT0046777 mco-miR-2c-3p; +MIMAT0046778 mco-miR-7a-5p; +MIMAT0046779 mco-miR-7b-3p; +MIMAT0046780 mco-miR-9-5p; +MIMAT0046781 mco-miR-10-5p; +MIMAT0046782 mco-miR-31-5p; +MIMAT0046783 mco-miR-36a-3p; +MIMAT0046784 mco-miR-36b-3p; +MIMAT0046785 mco-miR-61-3p; +MIMAT0046786 mco-miR-71-5p; +MIMAT0046787 mco-miR-87-3p; +MIMAT0046788 mco-miR-96-5p; +MIMAT0046789 mco-miR-124a-3p; +MIMAT0046790 mco-miR-124b-3p; +MIMAT0046791 mco-miR-125-5p; +MIMAT0046792 mco-miR-133-3p; +MIMAT0046793 mco-miR-153-3p; +MIMAT0046794 mco-miR-153-5p; +MIMAT0046795 mco-miR-184-3p; +MIMAT0046796 mco-miR-190-3p; +MIMAT0046797 mco-miR-190-5p; +MIMAT0046798 mco-miR-12065-3p; +MIMAT0046799 mco-miR-12066-3p; +MIMAT0046800 mco-miR-219-5p; +MIMAT0046801 mco-miR-277-3p; +MIMAT0046802 mco-miR-277b-3p; +MIMAT0046803 mco-miR-281-3p; +MIMAT0046804 mco-miR-307-3p; +MIMAT0046805 mco-miR-745-3p; +MIMAT0046806 mco-miR-2162-3p; +MIMAT0046807 mco-miR-3479a-3p; +MIMAT0046808 mco-miR-3479b-3p; +MIMAT0046809 mco-miR-4989-3p; +MIMAT0046810 mco-miR-10293-3p; +MIMAT0046811 mco-miR-12067-3p; +MIMAT0046812 mco-miR-12068-3p; +MIMAT0046813 mco-miR-12068-5p; +MIMAT0046814 mco-miR-12069-3p; +MIMAT0046815 mco-miR-12070-3p; +MIMAT0046816 mco-miR-12071-5p; +MIMAT0046817 cpo-let-7a-5p; +MIMAT0046818 cpo-let-7a-3p; +MIMAT0046819 cpo-let-7a-2-3p; +MIMAT0046820 cpo-let-7b-5p; +MIMAT0046821 cpo-let-7b-3p; +MIMAT0046822 cpo-let-7c-5p; +MIMAT0046823 cpo-let-7c-3p; +MIMAT0046824 cpo-let-7d-5p; +MIMAT0046825 cpo-let-7d-3p; +MIMAT0046826 cpo-let-7e-5p; +MIMAT0046827 cpo-let-7e-3p; +MIMAT0046828 cpo-let-7f-5p; +MIMAT0046829 cpo-let-7f-3p; +MIMAT0046830 cpo-let-7f-2-3p; +MIMAT0046831 cpo-let-7g-5p; +MIMAT0046832 cpo-let-7g-3p; +MIMAT0046833 cpo-let-7i-5p; +MIMAT0046834 cpo-let-7i-3p; +MIMAT0046835 cpo-miR-1b-5p; +MIMAT0046836 cpo-miR-1b-3p; +MIMAT0046837 cpo-miR-1a-5p; +MIMAT0046838 cpo-miR-1a-3p; +MIMAT0046839 cpo-miR-7-5p; +MIMAT0046840 cpo-miR-7-3p; +MIMAT0046841 cpo-miR-7-2-3p; +MIMAT0046842 cpo-miR-7-3-3p; +MIMAT0046843 cpo-miR-9-5p; +MIMAT0046844 cpo-miR-9-3p; +MIMAT0046845 cpo-miR-10a-5p; +MIMAT0046846 cpo-miR-10a-3p; +MIMAT0046847 cpo-miR-10b-5p; +MIMAT0046848 cpo-miR-10b-3p; +MIMAT0046849 cpo-miR-15a-5p; +MIMAT0046850 cpo-miR-15a-3p; +MIMAT0046851 cpo-miR-15b-5p; +MIMAT0046852 cpo-miR-15b-3p; +MIMAT0046853 cpo-miR-16a-5p; +MIMAT0046854 cpo-miR-16a-3p; +MIMAT0046855 cpo-miR-16b-5p; +MIMAT0046856 cpo-miR-16b-3p; +MIMAT0046857 cpo-miR-17-5p; +MIMAT0046858 cpo-miR-17-3p; +MIMAT0046859 cpo-miR-18a-5p; +MIMAT0046860 cpo-miR-18a-3p; +MIMAT0046861 cpo-miR-18b-5p; +MIMAT0046862 cpo-miR-18b-3p; +MIMAT0046863 cpo-miR-19a-5p; +MIMAT0046864 cpo-miR-19a-3p; +MIMAT0046865 cpo-miR-19b-5p; +MIMAT0046866 cpo-miR-19b-3p; +MIMAT0046867 cpo-miR-19b-2-5p; +MIMAT0046868 cpo-miR-20a-5p; +MIMAT0046869 cpo-miR-20a-3p; +MIMAT0046870 cpo-miR-20b-5p; +MIMAT0046871 cpo-miR-20b-3p; +MIMAT0046872 cpo-miR-21-5p; +MIMAT0046873 cpo-miR-21-3p; +MIMAT0046874 cpo-miR-22-5p; +MIMAT0046875 cpo-miR-22-3p; +MIMAT0046876 cpo-miR-23a-5p; +MIMAT0046877 cpo-miR-23a-3p; +MIMAT0046878 cpo-miR-23b-5p; +MIMAT0046879 cpo-miR-23b-3p; +MIMAT0046880 cpo-miR-24-5p; +MIMAT0046881 cpo-miR-24-3p; +MIMAT0046882 cpo-miR-24-2-5p; +MIMAT0046883 cpo-miR-25-5p; +MIMAT0046884 cpo-miR-25-3p; +MIMAT0046885 cpo-miR-26a-5p; +MIMAT0046886 cpo-miR-26a-3p; +MIMAT0046887 cpo-miR-26a-2-3p; +MIMAT0046888 cpo-miR-26b-5p; +MIMAT0046889 cpo-miR-26b-3p; +MIMAT0046890 cpo-miR-27a-5p; +MIMAT0046891 cpo-miR-27a-3p; +MIMAT0046892 cpo-miR-27b-5p; +MIMAT0046893 cpo-miR-27b-3p; +MIMAT0046894 cpo-miR-28-5p; +MIMAT0046895 cpo-miR-28-3p; +MIMAT0046896 cpo-miR-29a-5p; +MIMAT0046897 cpo-miR-29a-3p; +MIMAT0046898 cpo-miR-29b-5p; +MIMAT0046899 cpo-miR-29b-3p; +MIMAT0046900 cpo-miR-29b-2-5p; +MIMAT0046901 cpo-miR-29c-5p; +MIMAT0046902 cpo-miR-29c-3p; +MIMAT0046903 cpo-miR-30a-5p; +MIMAT0046904 cpo-miR-30a-3p; +MIMAT0046905 cpo-miR-30b-5p; +MIMAT0046906 cpo-miR-30b-3p; +MIMAT0046907 cpo-miR-30c-5p; +MIMAT0046908 cpo-miR-30c-3p; +MIMAT0046909 cpo-miR-30c-2-3p; +MIMAT0046910 cpo-miR-30d-5p; +MIMAT0046911 cpo-miR-30d-3p; +MIMAT0046912 cpo-miR-30e-5p; +MIMAT0046913 cpo-miR-30e-3p; +MIMAT0046914 cpo-miR-31-5p; +MIMAT0046915 cpo-miR-31-3p; +MIMAT0046916 cpo-miR-32-5p; +MIMAT0046917 cpo-miR-32-3p; +MIMAT0046918 cpo-miR-33a-5p; +MIMAT0046919 cpo-miR-33a-3p; +MIMAT0046920 cpo-miR-33b-5p; +MIMAT0046921 cpo-miR-33b-3p; +MIMAT0046922 cpo-miR-34a-5p; +MIMAT0046923 cpo-miR-34a-3p; +MIMAT0046924 cpo-miR-34b-5p; +MIMAT0046925 cpo-miR-34b-3p; +MIMAT0046926 cpo-miR-34c-5p; +MIMAT0046927 cpo-miR-34c-3p; +MIMAT0046928 cpo-miR-92a-5p; +MIMAT0046929 cpo-miR-92a-3p; +MIMAT0046930 cpo-miR-92a-2-5p; +MIMAT0046931 cpo-miR-92b-5p; +MIMAT0046932 cpo-miR-92b-3p; +MIMAT0046933 cpo-miR-93-5p; +MIMAT0046934 cpo-miR-93-3p; +MIMAT0046935 cpo-miR-95-5p; +MIMAT0046936 cpo-miR-95-3p; +MIMAT0046937 cpo-miR-96-5p; +MIMAT0046938 cpo-miR-96-3p; +MIMAT0046939 cpo-miR-98-5p; +MIMAT0046940 cpo-miR-98-3p; +MIMAT0046941 cpo-miR-99a-5p; +MIMAT0046942 cpo-miR-99a-3p; +MIMAT0046943 cpo-miR-99b-5p; +MIMAT0046944 cpo-miR-99b-3p; +MIMAT0046945 cpo-miR-100-5p; +MIMAT0046946 cpo-miR-100-3p; +MIMAT0046947 cpo-miR-101-5p; +MIMAT0046948 cpo-miR-101-3p; +MIMAT0046949 cpo-miR-101-2-5p; +MIMAT0046950 cpo-miR-103-5p; +MIMAT0046951 cpo-miR-103-3p; +MIMAT0046952 cpo-miR-103-2-5p; +MIMAT0046953 cpo-miR-105-5p; +MIMAT0046954 cpo-miR-105-3p; +MIMAT0046955 cpo-miR-106a-5p; +MIMAT0046956 cpo-miR-106a-3p; +MIMAT0046957 cpo-miR-106b-5p; +MIMAT0046958 cpo-miR-106b-3p; +MIMAT0046959 cpo-miR-107-5p; +MIMAT0046960 cpo-miR-107-3p; +MIMAT0046961 cpo-miR-122-5p; +MIMAT0046962 cpo-miR-122-3p; +MIMAT0046963 cpo-miR-124-5p; +MIMAT0046964 cpo-miR-124-3p; +MIMAT0046965 cpo-miR-125a-5p; +MIMAT0046966 cpo-miR-125a-3p; +MIMAT0046967 cpo-miR-125b-5p; +MIMAT0046968 cpo-miR-125b-3p; +MIMAT0046969 cpo-miR-125b-2-3p; +MIMAT0046970 cpo-miR-126-5p; +MIMAT0046971 cpo-miR-126-3p; +MIMAT0046972 cpo-miR-127-5p; +MIMAT0046973 cpo-miR-127-3p; +MIMAT0046974 cpo-miR-128-5p; +MIMAT0046975 cpo-miR-128-3p; +MIMAT0046976 cpo-miR-128-2-5p; +MIMAT0046977 cpo-miR-129-5p; +MIMAT0046978 cpo-miR-129-3p; +MIMAT0046979 cpo-miR-129-2-3p; +MIMAT0046980 cpo-miR-130a-5p; +MIMAT0046981 cpo-miR-130a-3p; +MIMAT0046982 cpo-miR-130b-5p; +MIMAT0046983 cpo-miR-130b-3p; +MIMAT0046984 cpo-miR-132-5p; +MIMAT0046985 cpo-miR-132-3p; +MIMAT0046986 cpo-miR-133a-5p; +MIMAT0046987 cpo-miR-133a-3p; +MIMAT0046988 cpo-miR-133b-5p; +MIMAT0046989 cpo-miR-133b-3p; +MIMAT0046990 cpo-miR-134-5p; +MIMAT0046991 cpo-miR-134-3p; +MIMAT0046992 cpo-miR-135a-5p; +MIMAT0046993 cpo-miR-135a-3p; +MIMAT0046994 cpo-miR-135a-2-3p; +MIMAT0046995 cpo-miR-135b-5p; +MIMAT0046996 cpo-miR-135b-3p; +MIMAT0046997 cpo-miR-136-5p; +MIMAT0046998 cpo-miR-136-3p; +MIMAT0046999 cpo-miR-138-5p; +MIMAT0047000 cpo-miR-138-3p; +MIMAT0047001 cpo-miR-138-2-3p; +MIMAT0047002 cpo-miR-139-5p; +MIMAT0047003 cpo-miR-139-3p; +MIMAT0047004 cpo-miR-140-5p; +MIMAT0047005 cpo-miR-140-3p; +MIMAT0047006 cpo-miR-141-5p; +MIMAT0047007 cpo-miR-141-3p; +MIMAT0047008 cpo-miR-142-5p; +MIMAT0047009 cpo-miR-142-3p; +MIMAT0047010 cpo-miR-143-5p; +MIMAT0047011 cpo-miR-143-3p; +MIMAT0047012 cpo-miR-144-5p; +MIMAT0047013 cpo-miR-144-3p; +MIMAT0047014 cpo-miR-145-5p; +MIMAT0047015 cpo-miR-145-3p; +MIMAT0047016 cpo-miR-146a-5p; +MIMAT0047017 cpo-miR-146a-3p; +MIMAT0047018 cpo-miR-146b-5p; +MIMAT0047019 cpo-miR-146b-3p; +MIMAT0047020 cpo-miR-147-5p; +MIMAT0047021 cpo-miR-147-3p; +MIMAT0047022 cpo-miR-148a-5p; +MIMAT0047023 cpo-miR-148a-3p; +MIMAT0047024 cpo-miR-148b-5p; +MIMAT0047025 cpo-miR-148b-3p; +MIMAT0047026 cpo-miR-149-5p; +MIMAT0047027 cpo-miR-149-3p; +MIMAT0047028 cpo-miR-150-5p; +MIMAT0047029 cpo-miR-150-3p; +MIMAT0047030 cpo-miR-151-5p; +MIMAT0047031 cpo-miR-151-3p; +MIMAT0047032 cpo-miR-152-5p; +MIMAT0047033 cpo-miR-152-3p; +MIMAT0047034 cpo-miR-153-5p; +MIMAT0047035 cpo-miR-153-3p; +MIMAT0047036 cpo-miR-154-5p; +MIMAT0047037 cpo-miR-154-3p; +MIMAT0047038 cpo-miR-155-5p; +MIMAT0047039 cpo-miR-155-3p; +MIMAT0047040 cpo-miR-181a-5p; +MIMAT0047041 cpo-miR-181a-3p; +MIMAT0047042 cpo-miR-181a-2-3p; +MIMAT0047043 cpo-miR-181b-5p; +MIMAT0047044 cpo-miR-181b-3p; +MIMAT0047045 cpo-miR-181b-2-3p; +MIMAT0047046 cpo-miR-181c-5p; +MIMAT0047047 cpo-miR-181c-3p; +MIMAT0047048 cpo-miR-182-5p; +MIMAT0047049 cpo-miR-182-3p; +MIMAT0047050 cpo-miR-183-5p; +MIMAT0047051 cpo-miR-183-3p; +MIMAT0047052 cpo-miR-184-5p; +MIMAT0047053 cpo-miR-184-3p; +MIMAT0047054 cpo-miR-185-5p; +MIMAT0047055 cpo-miR-185-3p; +MIMAT0047056 cpo-miR-186-5p; +MIMAT0047057 cpo-miR-186-3p; +MIMAT0047058 cpo-miR-187-5p; +MIMAT0047059 cpo-miR-187-3p; +MIMAT0047060 cpo-miR-188-5p; +MIMAT0047061 cpo-miR-188-3p; +MIMAT0047062 cpo-miR-190a-5p; +MIMAT0047063 cpo-miR-190a-3p; +MIMAT0047064 cpo-miR-190b-5p; +MIMAT0047065 cpo-miR-190b-3p; +MIMAT0047066 cpo-miR-191-5p; +MIMAT0047067 cpo-miR-191-3p; +MIMAT0047068 cpo-miR-192-5p; +MIMAT0047069 cpo-miR-192-3p; +MIMAT0047070 cpo-miR-193a-5p; +MIMAT0047071 cpo-miR-193a-3p; +MIMAT0047072 cpo-miR-193b-5p; +MIMAT0047073 cpo-miR-193b-3p; +MIMAT0047074 cpo-miR-194-5p; +MIMAT0047075 cpo-miR-194-3p; +MIMAT0047076 cpo-miR-195-5p; +MIMAT0047077 cpo-miR-195-3p; +MIMAT0047078 cpo-miR-196a-5p; +MIMAT0047079 cpo-miR-196a-3p; +MIMAT0047080 cpo-miR-196c-5p; +MIMAT0047081 cpo-miR-196c-3p; +MIMAT0047082 cpo-miR-196b-5p; +MIMAT0047083 cpo-miR-196b-3p; +MIMAT0047084 cpo-miR-197-5p; +MIMAT0047085 cpo-miR-197-3p; +MIMAT0047086 cpo-miR-199-5p; +MIMAT0047087 cpo-miR-199-3p; +MIMAT0047088 cpo-miR-199-3-5p; +MIMAT0047089 cpo-miR-200a-5p; +MIMAT0047090 cpo-miR-200a-3p; +MIMAT0047091 cpo-miR-200b-5p; +MIMAT0047092 cpo-miR-200b-3p; +MIMAT0047093 cpo-miR-200c-5p; +MIMAT0047094 cpo-miR-200c-3p; +MIMAT0047095 cpo-miR-202-5p; +MIMAT0047096 cpo-miR-202-3p; +MIMAT0047097 cpo-miR-203-5p; +MIMAT0047098 cpo-miR-203-3p; +MIMAT0047099 cpo-miR-204-5p; +MIMAT0047100 cpo-miR-204-3p; +MIMAT0047101 cpo-miR-205-5p; +MIMAT0047102 cpo-miR-205-3p; +MIMAT0047103 cpo-miR-206-5p; +MIMAT0047104 cpo-miR-206-3p; +MIMAT0047105 cpo-miR-208a-5p; +MIMAT0047106 cpo-miR-208a-3p; +MIMAT0047107 cpo-miR-208b-5p; +MIMAT0047108 cpo-miR-208b-3p; +MIMAT0047109 cpo-miR-210-5p; +MIMAT0047110 cpo-miR-210-3p; +MIMAT0047111 cpo-miR-211-5p; +MIMAT0047112 cpo-miR-211-3p; +MIMAT0047113 cpo-miR-212-5p; +MIMAT0047114 cpo-miR-212-3p; +MIMAT0047115 cpo-miR-214-5p; +MIMAT0047116 cpo-miR-214-3p; +MIMAT0047117 cpo-miR-215-5p; +MIMAT0047118 cpo-miR-215-3p; +MIMAT0047119 cpo-miR-216a-5p; +MIMAT0047120 cpo-miR-216a-3p; +MIMAT0047121 cpo-miR-216b-5p; +MIMAT0047122 cpo-miR-216b-3p; +MIMAT0047123 cpo-miR-217-5p; +MIMAT0047124 cpo-miR-217-3p; +MIMAT0047125 cpo-miR-218-5p; +MIMAT0047126 cpo-miR-218-3p; +MIMAT0047127 cpo-miR-218-2-3p; +MIMAT0047128 cpo-miR-219b-5p; +MIMAT0047129 cpo-miR-219b-3p; +MIMAT0047130 cpo-miR-221-5p; +MIMAT0047131 cpo-miR-221-3p; +MIMAT0047132 cpo-miR-222-5p; +MIMAT0047133 cpo-miR-222-3p; +MIMAT0047134 cpo-miR-223-5p; +MIMAT0047135 cpo-miR-223-3p; +MIMAT0047136 cpo-miR-224-5p; +MIMAT0047137 cpo-miR-224-3p; +MIMAT0047138 cpo-miR-296-5p; +MIMAT0047139 cpo-miR-296-3p; +MIMAT0047140 cpo-miR-299-5p; +MIMAT0047141 cpo-miR-299-3p; +MIMAT0047142 cpo-miR-301a-5p; +MIMAT0047143 cpo-miR-301a-3p; +MIMAT0047144 cpo-miR-301b-5p; +MIMAT0047145 cpo-miR-301b-3p; +MIMAT0047146 cpo-miR-302a-5p; +MIMAT0047147 cpo-miR-302a-3p; +MIMAT0047148 cpo-miR-302b-5p; +MIMAT0047149 cpo-miR-302b-3p; +MIMAT0047150 cpo-miR-302c-5p; +MIMAT0047151 cpo-miR-302c-3p; +MIMAT0047152 cpo-miR-302d-5p; +MIMAT0047153 cpo-miR-302d-3p; +MIMAT0047154 cpo-miR-323a-5p; +MIMAT0047155 cpo-miR-323a-3p; +MIMAT0047156 cpo-miR-323b-5p; +MIMAT0047157 cpo-miR-323b-3p; +MIMAT0047158 cpo-miR-324-5p; +MIMAT0047159 cpo-miR-324-3p; +MIMAT0047160 cpo-miR-326-5p; +MIMAT0047161 cpo-miR-326-3p; +MIMAT0047162 cpo-miR-328-5p; +MIMAT0047163 cpo-miR-328-3p; +MIMAT0047164 cpo-miR-329-5p; +MIMAT0047165 cpo-miR-329-3p; +MIMAT0047166 cpo-miR-330-5p; +MIMAT0047167 cpo-miR-330-3p; +MIMAT0047168 cpo-miR-331-5p; +MIMAT0047169 cpo-miR-331-3p; +MIMAT0047170 cpo-miR-335-5p; +MIMAT0047171 cpo-miR-335-3p; +MIMAT0047172 cpo-miR-337-5p; +MIMAT0047173 cpo-miR-337-3p; +MIMAT0047174 cpo-miR-338-5p; +MIMAT0047175 cpo-miR-338-3p; +MIMAT0047176 cpo-miR-339-5p; +MIMAT0047177 cpo-miR-339-3p; +MIMAT0047178 cpo-miR-340-5p; +MIMAT0047179 cpo-miR-340-3p; +MIMAT0047180 cpo-miR-342-5p; +MIMAT0047181 cpo-miR-342-3p; +MIMAT0047182 cpo-miR-345-5p; +MIMAT0047183 cpo-miR-345-3p; +MIMAT0047184 cpo-miR-346-5p; +MIMAT0047185 cpo-miR-346-3p; +MIMAT0047186 cpo-miR-350-5p; +MIMAT0047187 cpo-miR-350-3p; +MIMAT0047188 cpo-miR-361-5p; +MIMAT0047189 cpo-miR-361-3p; +MIMAT0047190 cpo-miR-362-5p; +MIMAT0047191 cpo-miR-362-3p; +MIMAT0047192 cpo-miR-363-5p; +MIMAT0047193 cpo-miR-363-3p; +MIMAT0047194 cpo-miR-365-5p; +MIMAT0047195 cpo-miR-365-3p; +MIMAT0047196 cpo-miR-365-2-5p; +MIMAT0047197 cpo-miR-367-5p; +MIMAT0047198 cpo-miR-367-3p; +MIMAT0047199 cpo-miR-369-5p; +MIMAT0047200 cpo-miR-369-3p; +MIMAT0047201 cpo-miR-370-5p; +MIMAT0047202 cpo-miR-370-3p; +MIMAT0047203 cpo-miR-290-5p; +MIMAT0047204 cpo-miR-290-3p; +MIMAT0047205 cpo-miR-374-5p; +MIMAT0047206 cpo-miR-374-3p; +MIMAT0047207 cpo-miR-375-5p; +MIMAT0047208 cpo-miR-375-3p; +MIMAT0047209 cpo-miR-376a-5p; +MIMAT0047210 cpo-miR-376a-3p; +MIMAT0047211 cpo-miR-376b-5p; +MIMAT0047212 cpo-miR-376b-3p; +MIMAT0047213 cpo-miR-376c-5p; +MIMAT0047214 cpo-miR-376c-3p; +MIMAT0047215 cpo-miR-376d-5p; +MIMAT0047216 cpo-miR-376d-3p; +MIMAT0047217 cpo-miR-377-5p; +MIMAT0047218 cpo-miR-377-3p; +MIMAT0047219 cpo-miR-378-5p; +MIMAT0047220 cpo-miR-378-3p; +MIMAT0047221 cpo-miR-379-5p; +MIMAT0047222 cpo-miR-379-3p; +MIMAT0047223 cpo-miR-380-5p; +MIMAT0047224 cpo-miR-380-3p; +MIMAT0047225 cpo-miR-381-5p; +MIMAT0047226 cpo-miR-381-3p; +MIMAT0047227 cpo-miR-382-5p; +MIMAT0047228 cpo-miR-382-3p; +MIMAT0047229 cpo-miR-383-5p; +MIMAT0047230 cpo-miR-383-3p; +MIMAT0047231 cpo-miR-892-5p; +MIMAT0047232 cpo-miR-892-3p; +MIMAT0047233 cpo-miR-409-5p; +MIMAT0047234 cpo-miR-409-3p; +MIMAT0047235 cpo-miR-410-5p; +MIMAT0047236 cpo-miR-410-3p; +MIMAT0047237 cpo-miR-411-5p; +MIMAT0047238 cpo-miR-411-3p; +MIMAT0047239 cpo-miR-412-5p; +MIMAT0047240 cpo-miR-412-3p; +MIMAT0047241 cpo-miR-423-5p; +MIMAT0047242 cpo-miR-423-3p; +MIMAT0047243 cpo-miR-424-5p; +MIMAT0047244 cpo-miR-424-3p; +MIMAT0047245 cpo-miR-425-5p; +MIMAT0047246 cpo-miR-425-3p; +MIMAT0047247 cpo-miR-429-5p; +MIMAT0047248 cpo-miR-429-3p; +MIMAT0047249 cpo-miR-431-5p; +MIMAT0047250 cpo-miR-431-3p; +MIMAT0047251 cpo-miR-432-5p; +MIMAT0047252 cpo-miR-432-3p; +MIMAT0047253 cpo-miR-433-5p; +MIMAT0047254 cpo-miR-433-3p; +MIMAT0047255 cpo-miR-448-5p; +MIMAT0047256 cpo-miR-448-3p; +MIMAT0047257 cpo-miR-449a-5p; +MIMAT0047258 cpo-miR-449a-3p; +MIMAT0047259 cpo-miR-449c-5p; +MIMAT0047260 cpo-miR-449c-3p; +MIMAT0047261 cpo-miR-450a-5p; +MIMAT0047262 cpo-miR-450a-3p; +MIMAT0047263 cpo-miR-450a-2-3p; +MIMAT0047264 cpo-miR-450b-5p; +MIMAT0047265 cpo-miR-450b-3p; +MIMAT0047266 cpo-miR-451-5p; +MIMAT0047267 cpo-miR-452-5p; +MIMAT0047268 cpo-miR-452-3p; +MIMAT0047269 cpo-miR-454-5p; +MIMAT0047270 cpo-miR-454-3p; +MIMAT0047271 cpo-miR-455-5p; +MIMAT0047272 cpo-miR-455-3p; +MIMAT0047273 cpo-miR-483-5p; +MIMAT0047274 cpo-miR-483-3p; +MIMAT0047275 cpo-miR-485-5p; +MIMAT0047276 cpo-miR-485-3p; +MIMAT0047277 cpo-miR-486-5p; +MIMAT0047278 cpo-miR-486-3p; +MIMAT0047279 cpo-miR-487a-5p; +MIMAT0047280 cpo-miR-487a-3p; +MIMAT0047281 cpo-miR-487b-5p; +MIMAT0047282 cpo-miR-487b-3p; +MIMAT0047283 cpo-miR-490-5p; +MIMAT0047284 cpo-miR-490-3p; +MIMAT0047285 cpo-miR-491-5p; +MIMAT0047286 cpo-miR-491-3p; +MIMAT0047287 cpo-miR-493-5p; +MIMAT0047288 cpo-miR-493-3p; +MIMAT0047289 cpo-miR-494-5p; +MIMAT0047290 cpo-miR-494-3p; +MIMAT0047291 cpo-miR-495-5p; +MIMAT0047292 cpo-miR-495-3p; +MIMAT0047293 cpo-miR-496-5p; +MIMAT0047294 cpo-miR-496-3p; +MIMAT0047295 cpo-miR-497-5p; +MIMAT0047296 cpo-miR-497-3p; +MIMAT0047297 cpo-miR-499-5p; +MIMAT0047298 cpo-miR-499-3p; +MIMAT0047299 cpo-miR-500a-5p; +MIMAT0047300 cpo-miR-500a-3p; +MIMAT0047301 cpo-miR-500b-5p; +MIMAT0047302 cpo-miR-500b-3p; +MIMAT0047303 cpo-miR-501-5p; +MIMAT0047304 cpo-miR-501-3p; +MIMAT0047305 cpo-miR-502a-5p; +MIMAT0047306 cpo-miR-502a-3p; +MIMAT0047307 cpo-miR-503-5p; +MIMAT0047308 cpo-miR-503-3p; +MIMAT0047309 cpo-miR-504-5p; +MIMAT0047310 cpo-miR-504-3p; +MIMAT0047311 cpo-miR-505-5p; +MIMAT0047312 cpo-miR-505-3p; +MIMAT0047313 cpo-miR-506-5p; +MIMAT0047314 cpo-miR-506-3p; +MIMAT0047315 cpo-miR-507a-5p; +MIMAT0047316 cpo-miR-507a-3p; +MIMAT0047317 cpo-miR-507b-5p; +MIMAT0047318 cpo-miR-507b-3p; +MIMAT0047319 cpo-miR-507c-5p; +MIMAT0047320 cpo-miR-507c-3p; +MIMAT0047321 cpo-miR-509a-5p; +MIMAT0047322 cpo-miR-509a-3p; +MIMAT0047323 cpo-miR-509b-5p; +MIMAT0047324 cpo-miR-509b-3p; +MIMAT0047325 cpo-miR-509c-5p; +MIMAT0047326 cpo-miR-509c-3p; +MIMAT0047327 cpo-miR-509d-5p; +MIMAT0047328 cpo-miR-509d-3p; +MIMAT0047329 cpo-miR-509e-5p; +MIMAT0047330 cpo-miR-509e-3p; +MIMAT0047331 cpo-miR-511-5p; +MIMAT0047332 cpo-miR-511-3p; +MIMAT0047333 cpo-miR-509f-5p; +MIMAT0047334 cpo-miR-509f-3p; +MIMAT0047335 cpo-miR-532-5p; +MIMAT0047336 cpo-miR-532-3p; +MIMAT0047337 cpo-miR-539-5p; +MIMAT0047338 cpo-miR-539-3p; +MIMAT0047339 cpo-miR-541-5p; +MIMAT0047340 cpo-miR-541-3p; +MIMAT0047341 cpo-miR-542-5p; +MIMAT0047342 cpo-miR-542-3p; +MIMAT0047343 cpo-miR-543-5p; +MIMAT0047344 cpo-miR-543-3p; +MIMAT0047345 cpo-miR-545-5p; +MIMAT0047346 cpo-miR-545-3p; +MIMAT0047347 cpo-miR-551-5p; +MIMAT0047348 cpo-miR-551-3p; +MIMAT0047349 cpo-miR-574-5p; +MIMAT0047350 cpo-miR-574-3p; +MIMAT0047351 cpo-miR-582-5p; +MIMAT0047352 cpo-miR-582-3p; +MIMAT0047353 cpo-miR-615-5p; +MIMAT0047354 cpo-miR-615-3p; +MIMAT0047355 cpo-miR-652-5p; +MIMAT0047356 cpo-miR-652-3p; +MIMAT0047357 cpo-miR-653-5p; +MIMAT0047358 cpo-miR-653-3p; +MIMAT0047359 cpo-miR-654-5p; +MIMAT0047360 cpo-miR-654-3p; +MIMAT0047361 cpo-miR-655-5p; +MIMAT0047362 cpo-miR-655-3p; +MIMAT0047363 cpo-miR-656-5p; +MIMAT0047364 cpo-miR-656-3p; +MIMAT0047365 cpo-miR-660-5p; +MIMAT0047366 cpo-miR-660-3p; +MIMAT0047367 cpo-miR-670-5p; +MIMAT0047368 cpo-miR-670-3p; +MIMAT0047369 cpo-miR-671-5p; +MIMAT0047370 cpo-miR-671-3p; +MIMAT0047371 cpo-miR-672-5p; +MIMAT0047372 cpo-miR-672-3p; +MIMAT0047373 cpo-miR-675-5p; +MIMAT0047374 cpo-miR-675-3p; +MIMAT0047375 cpo-miR-676-5p; +MIMAT0047376 cpo-miR-676-3p; +MIMAT0047377 cpo-miR-708-5p; +MIMAT0047378 cpo-miR-708-3p; +MIMAT0047379 cpo-miR-744-5p; +MIMAT0047380 cpo-miR-744-3p; +MIMAT0047381 cpo-miR-758-5p; +MIMAT0047382 cpo-miR-758-3p; +MIMAT0047383 cpo-miR-760-5p; +MIMAT0047384 cpo-miR-760-3p; +MIMAT0047385 cpo-miR-769-5p; +MIMAT0047386 cpo-miR-769-3p; +MIMAT0047387 cpo-miR-802-5p; +MIMAT0047388 cpo-miR-802-3p; +MIMAT0047389 cpo-miR-872-5p; +MIMAT0047390 cpo-miR-872-3p; +MIMAT0047391 cpo-miR-873-5p; +MIMAT0047392 cpo-miR-873-3p; +MIMAT0047393 cpo-miR-874-5p; +MIMAT0047394 cpo-miR-874-3p; +MIMAT0047395 cpo-miR-885-5p; +MIMAT0047396 cpo-miR-885-3p; +MIMAT0047397 cpo-miR-889-5p; +MIMAT0047398 cpo-miR-889-3p; +MIMAT0047399 cpo-miR-1185-5p; +MIMAT0047400 cpo-miR-1185-3p; +MIMAT0047401 cpo-miR-1193-5p; +MIMAT0047402 cpo-miR-1193-3p; +MIMAT0047403 cpo-miR-1197-5p; +MIMAT0047404 cpo-miR-1197-3p; +MIMAT0047405 cpo-miR-1247-5p; +MIMAT0047406 cpo-miR-1247-3p; +MIMAT0047407 cpo-miR-1251-5p; +MIMAT0047408 cpo-miR-1251-3p; +MIMAT0047409 cpo-miR-1264-5p; +MIMAT0047410 cpo-miR-1264-3p; +MIMAT0047411 cpo-miR-1271-5p; +MIMAT0047412 cpo-miR-1271-3p; +MIMAT0047413 cpo-miR-1277-5p; +MIMAT0047414 cpo-miR-1277-3p; +MIMAT0047415 cpo-miR-1296-5p; +MIMAT0047416 cpo-miR-1296-3p; +MIMAT0047417 cpo-miR-1298-5p; +MIMAT0047418 cpo-miR-1298-3p; +MIMAT0047419 cpo-miR-1301-5p; +MIMAT0047420 cpo-miR-1301-3p; +MIMAT0047421 cpo-miR-1343-5p; +MIMAT0047422 cpo-miR-1343-3p; +MIMAT0047423 cpo-miR-1379-5p; +MIMAT0047424 cpo-miR-1379-3p; +MIMAT0047425 cpo-miR-1388-5p; +MIMAT0047426 cpo-miR-1388-3p; +MIMAT0047427 cpo-miR-1842-5p; +MIMAT0047428 cpo-miR-1842-3p; +MIMAT0047429 cpo-miR-2355-5p; +MIMAT0047430 cpo-miR-2355-3p; +MIMAT0047431 cpo-miR-2387-5p; +MIMAT0047432 cpo-miR-2387-3p; +MIMAT0047433 cpo-miR-3059-5p; +MIMAT0047434 cpo-miR-3059-3p; +MIMAT0047435 cpo-miR-3085-5p; +MIMAT0047436 cpo-miR-3085-3p; +MIMAT0047437 cpo-miR-513-5p; +MIMAT0047438 cpo-miR-513-3p; +MIMAT0047439 cpo-miR-3613-5p; +MIMAT0047440 cpo-miR-3613-3p; +MIMAT0047441 cpo-miR-3959-5p; +MIMAT0047442 cpo-miR-3959-3p; +MIMAT0047443 cpo-miR-6529-5p; +MIMAT0047444 cpo-miR-6529-3p; +MIMAT0047445 cpo-miR-12072-5p; +MIMAT0047446 cpo-miR-12072-3p; +MIMAT0047447 cpo-miR-12073-5p; +MIMAT0047448 cpo-miR-12073-3p; +MIMAT0047449 cpo-miR-12074-5p; +MIMAT0047450 cpo-miR-12074-3p; +MIMAT0047451 cpo-miR-12075-5p; +MIMAT0047452 cpo-miR-12075-3p; +MIMAT0047453 cpo-miR-12076-5p; +MIMAT0047454 cpo-miR-12076-3p; +MIMAT0047455 cpo-miR-12077-5p; +MIMAT0047456 cpo-miR-12077-3p; +MIMAT0047457 cpo-miR-12078-5p; +MIMAT0047458 cpo-miR-12078-3p; +MIMAT0047459 cpo-miR-526-5p; +MIMAT0047460 cpo-miR-526-3p; +MIMAT0047461 cpo-miR-12079-5p; +MIMAT0047462 cpo-miR-12079-3p; +MIMAT0047463 cpo-miR-12080-5p; +MIMAT0047464 cpo-miR-12080-3p; +MIMAT0047465 cpo-miR-12081-5p; +MIMAT0047466 cpo-miR-12081-3p; +MIMAT0047467 cpo-miR-12082-5p; +MIMAT0047468 cpo-miR-12082-3p; +MIMAT0047469 cpo-miR-12083-5p; +MIMAT0047470 cpo-miR-12083-3p; +MIMAT0047471 cpo-miR-12084-5p; +MIMAT0047472 cpo-miR-12084-3p; +MIMAT0047473 dno-let-7a-5p; +MIMAT0047474 dno-let-7a-3p; +MIMAT0047475 dno-let-7c-5p; +MIMAT0047476 dno-let-7c-2-3p; +MIMAT0047477 dno-let-7b-5p; +MIMAT0047478 dno-let-7b-3p; +MIMAT0047479 dno-let-7c-3p; +MIMAT0047480 dno-let-7d-5p; +MIMAT0047481 dno-let-7d-3p; +MIMAT0047482 dno-let-7f-5p; +MIMAT0047483 dno-let-7f-3p; +MIMAT0047484 dno-let-7f-2-3p; +MIMAT0047485 dno-let-7g-5p; +MIMAT0047486 dno-let-7i-5p; +MIMAT0047487 dno-let-7i-3p; +MIMAT0047488 dno-miR-1-5p; +MIMAT0047489 dno-miR-1-3p; +MIMAT0047490 dno-miR-1-2-5p; +MIMAT0047491 dno-miR-7-5p; +MIMAT0047492 dno-miR-7-3p; +MIMAT0047493 dno-miR-7-2-3p; +MIMAT0047494 dno-miR-7-3-3p; +MIMAT0047495 dno-miR-9-5p; +MIMAT0047496 dno-miR-9-3p; +MIMAT0047497 dno-miR-10a-5p; +MIMAT0047498 dno-miR-10a-3p; +MIMAT0047499 dno-miR-10b-5p; +MIMAT0047500 dno-miR-10b-3p; +MIMAT0047501 dno-miR-15a-5p; +MIMAT0047502 dno-miR-15a-3p; +MIMAT0047503 dno-miR-15b-5p; +MIMAT0047504 dno-miR-15b-3p; +MIMAT0047505 dno-miR-16a-5p; +MIMAT0047506 dno-miR-16a-3p; +MIMAT0047507 dno-miR-16b-5p; +MIMAT0047508 dno-miR-16b-3p; +MIMAT0047509 dno-miR-17-5p; +MIMAT0047510 dno-miR-17-3p; +MIMAT0047511 dno-miR-18a-5p; +MIMAT0047512 dno-miR-18a-3p; +MIMAT0047513 dno-miR-18b-5p; +MIMAT0047514 dno-miR-18b-3p; +MIMAT0047515 dno-miR-19a-5p; +MIMAT0047516 dno-miR-19a-3p; +MIMAT0047517 dno-miR-19b-5p; +MIMAT0047518 dno-miR-19b-3p; +MIMAT0047519 dno-miR-19b-2-5p; +MIMAT0047520 dno-miR-20a-5p; +MIMAT0047521 dno-miR-20a-3p; +MIMAT0047522 dno-miR-20b-5p; +MIMAT0047523 dno-miR-20b-3p; +MIMAT0047524 dno-miR-21-5p; +MIMAT0047525 dno-miR-21-3p; +MIMAT0047526 dno-miR-22-5p; +MIMAT0047527 dno-miR-22-3p; +MIMAT0047528 dno-miR-23a-5p; +MIMAT0047529 dno-miR-23a-3p; +MIMAT0047530 dno-miR-23b-5p; +MIMAT0047531 dno-miR-23b-3p; +MIMAT0047532 dno-miR-24a-5p; +MIMAT0047533 dno-miR-24a-3p; +MIMAT0047534 dno-miR-24b-5p; +MIMAT0047535 dno-miR-24b-3p; +MIMAT0047536 dno-miR-25-5p; +MIMAT0047537 dno-miR-25-3p; +MIMAT0047538 dno-miR-26a-5p; +MIMAT0047539 dno-miR-26a-3p; +MIMAT0047540 dno-miR-26a-2-3p; +MIMAT0047541 dno-miR-26b-5p; +MIMAT0047542 dno-miR-26b-3p; +MIMAT0047543 dno-miR-27a-5p; +MIMAT0047544 dno-miR-27a-3p; +MIMAT0047545 dno-miR-27b-5p; +MIMAT0047546 dno-miR-27b-3p; +MIMAT0047547 dno-miR-28-5p; +MIMAT0047548 dno-miR-28-3p; +MIMAT0047549 dno-miR-29a-5p; +MIMAT0047550 dno-miR-29a-3p; +MIMAT0047551 dno-miR-29b-5p; +MIMAT0047552 dno-miR-29b-3p; +MIMAT0047553 dno-miR-29b-2-5p; +MIMAT0047554 dno-miR-29c-5p; +MIMAT0047555 dno-miR-29c-3p; +MIMAT0047556 dno-miR-30a-5p; +MIMAT0047557 dno-miR-30a-3p; +MIMAT0047558 dno-miR-30b-5p; +MIMAT0047559 dno-miR-30b-3p; +MIMAT0047560 dno-miR-30c-5p; +MIMAT0047561 dno-miR-30c-3p; +MIMAT0047562 dno-miR-30c-2-3p; +MIMAT0047563 dno-miR-30d-5p; +MIMAT0047564 dno-miR-30d-3p; +MIMAT0047565 dno-miR-30e-5p; +MIMAT0047566 dno-miR-30e-3p; +MIMAT0047567 dno-miR-31-5p; +MIMAT0047568 dno-miR-31-3p; +MIMAT0047569 dno-miR-32-5p; +MIMAT0047570 dno-miR-32-3p; +MIMAT0047571 dno-miR-33a-5p; +MIMAT0047572 dno-miR-33a-3p; +MIMAT0047573 dno-miR-33b-5p; +MIMAT0047574 dno-miR-33b-3p; +MIMAT0047575 dno-miR-34a-5p; +MIMAT0047576 dno-miR-34a-3p; +MIMAT0047577 dno-miR-34b-5p; +MIMAT0047578 dno-miR-34b-3p; +MIMAT0047579 dno-miR-34c-5p; +MIMAT0047580 dno-miR-34c-3p; +MIMAT0047581 dno-miR-92a-5p; +MIMAT0047582 dno-miR-92a-3p; +MIMAT0047583 dno-miR-92a-2-5p; +MIMAT0047584 dno-miR-92b-5p; +MIMAT0047585 dno-miR-92b-3p; +MIMAT0047586 dno-miR-93-5p; +MIMAT0047587 dno-miR-93-3p; +MIMAT0047588 dno-miR-95-5p; +MIMAT0047589 dno-miR-95-3p; +MIMAT0047590 dno-miR-96-5p; +MIMAT0047591 dno-miR-96-3p; +MIMAT0047592 dno-miR-98-5p; +MIMAT0047593 dno-miR-98-3p; +MIMAT0047594 dno-miR-99a-5p; +MIMAT0047595 dno-miR-99a-3p; +MIMAT0047596 dno-miR-100-5p; +MIMAT0047597 dno-miR-100-3p; +MIMAT0047598 dno-miR-101-5p; +MIMAT0047599 dno-miR-101-3p; +MIMAT0047600 dno-miR-101-2-5p; +MIMAT0047601 dno-miR-103a-5p; +MIMAT0047602 dno-miR-103a-3p; +MIMAT0047603 dno-miR-103a-2-5p; +MIMAT0047604 dno-miR-106a-5p; +MIMAT0047605 dno-miR-106a-3p; +MIMAT0047606 dno-miR-106b-5p; +MIMAT0047607 dno-miR-106b-3p; +MIMAT0047608 dno-miR-107-5p; +MIMAT0047609 dno-miR-107-3p; +MIMAT0047610 dno-miR-122-5p; +MIMAT0047611 dno-miR-122-3p; +MIMAT0047612 dno-miR-124-5p; +MIMAT0047613 dno-miR-124-3p; +MIMAT0047614 dno-miR-125b-5p; +MIMAT0047615 dno-miR-125b-3p; +MIMAT0047616 dno-miR-125b-2-3p; +MIMAT0047617 dno-miR-126-5p; +MIMAT0047618 dno-miR-126-3p; +MIMAT0047619 dno-miR-127-5p; +MIMAT0047620 dno-miR-127-3p; +MIMAT0047621 dno-miR-128-5p; +MIMAT0047622 dno-miR-128-3p; +MIMAT0047623 dno-miR-128-2-5p; +MIMAT0047624 dno-miR-129-5p; +MIMAT0047625 dno-miR-129-3p; +MIMAT0047626 dno-miR-129-2-3p; +MIMAT0047627 dno-miR-130a-5p; +MIMAT0047628 dno-miR-130a-3p; +MIMAT0047629 dno-miR-130b-5p; +MIMAT0047630 dno-miR-130b-3p; +MIMAT0047631 dno-miR-132-5p; +MIMAT0047632 dno-miR-132-3p; +MIMAT0047633 dno-miR-133a-5p; +MIMAT0047634 dno-miR-133a-3p; +MIMAT0047635 dno-miR-133b-5p; +MIMAT0047636 dno-miR-133b-3p; +MIMAT0047637 dno-miR-134-5p; +MIMAT0047638 dno-miR-134-3p; +MIMAT0047639 dno-miR-135a-5p; +MIMAT0047640 dno-miR-135a-3p; +MIMAT0047641 dno-miR-135a-2-3p; +MIMAT0047642 dno-miR-135b-5p; +MIMAT0047643 dno-miR-135b-3p; +MIMAT0047644 dno-miR-136-5p; +MIMAT0047645 dno-miR-136-3p; +MIMAT0047646 dno-miR-137-5p; +MIMAT0047647 dno-miR-137-3p; +MIMAT0047648 dno-miR-138-5p; +MIMAT0047649 dno-miR-138-3p; +MIMAT0047650 dno-miR-138-2-3p; +MIMAT0047651 dno-miR-139-5p; +MIMAT0047652 dno-miR-139-3p; +MIMAT0047653 dno-miR-140-5p; +MIMAT0047654 dno-miR-140-3p; +MIMAT0047655 dno-miR-141-5p; +MIMAT0047656 dno-miR-141-3p; +MIMAT0047657 dno-miR-142-5p; +MIMAT0047658 dno-miR-142-3p; +MIMAT0047659 dno-miR-143-5p; +MIMAT0047660 dno-miR-143-3p; +MIMAT0047661 dno-miR-144-5p; +MIMAT0047662 dno-miR-144-3p; +MIMAT0047663 dno-miR-146a-5p; +MIMAT0047664 dno-miR-146a-3p; +MIMAT0047665 dno-miR-146b-5p; +MIMAT0047666 dno-miR-146b-3p; +MIMAT0047667 dno-miR-147-5p; +MIMAT0047668 dno-miR-147-3p; +MIMAT0047669 dno-miR-148a-5p; +MIMAT0047670 dno-miR-148a-3p; +MIMAT0047671 dno-miR-148b-5p; +MIMAT0047672 dno-miR-148b-3p; +MIMAT0047673 dno-miR-149-5p; +MIMAT0047674 dno-miR-149-3p; +MIMAT0047675 dno-miR-150-5p; +MIMAT0047676 dno-miR-150-3p; +MIMAT0047677 dno-miR-151-5p; +MIMAT0047678 dno-miR-151-3p; +MIMAT0047679 dno-miR-153a-5p; +MIMAT0047680 dno-miR-153a-3p; +MIMAT0047681 dno-miR-153b-5p; +MIMAT0047682 dno-miR-153b-3p; +MIMAT0047683 dno-miR-154a-5p; +MIMAT0047684 dno-miR-154a-3p; +MIMAT0047685 dno-miR-154b-5p; +MIMAT0047686 dno-miR-154b-3p; +MIMAT0047687 dno-miR-155-5p; +MIMAT0047688 dno-miR-155-3p; +MIMAT0047689 dno-miR-181a-5p; +MIMAT0047690 dno-miR-181a-3p; +MIMAT0047691 dno-miR-181a-2-3p; +MIMAT0047692 dno-miR-181b-5p; +MIMAT0047693 dno-miR-181b-3p; +MIMAT0047694 dno-miR-181b-2-3p; +MIMAT0047695 dno-miR-181c-5p; +MIMAT0047696 dno-miR-181c-3p; +MIMAT0047697 dno-miR-181d-5p; +MIMAT0047698 dno-miR-181d-3p; +MIMAT0047699 dno-miR-182-5p; +MIMAT0047700 dno-miR-182-3p; +MIMAT0047701 dno-miR-183-5p; +MIMAT0047702 dno-miR-183-3p; +MIMAT0047703 dno-miR-184-5p; +MIMAT0047704 dno-miR-184-3p; +MIMAT0047705 dno-miR-185-5p; +MIMAT0047706 dno-miR-185-3p; +MIMAT0047707 dno-miR-186-5p; +MIMAT0047708 dno-miR-186-3p; +MIMAT0047709 dno-miR-187-5p; +MIMAT0047710 dno-miR-187-3p; +MIMAT0047711 dno-miR-188-5p; +MIMAT0047712 dno-miR-188-3p; +MIMAT0047713 dno-miR-190a-5p; +MIMAT0047714 dno-miR-190a-3p; +MIMAT0047715 dno-miR-190b-5p; +MIMAT0047716 dno-miR-190b-3p; +MIMAT0047717 dno-miR-191-5p; +MIMAT0047718 dno-miR-191-3p; +MIMAT0047719 dno-miR-192-5p; +MIMAT0047720 dno-miR-192-3p; +MIMAT0047721 dno-miR-193a-5p; +MIMAT0047722 dno-miR-193a-3p; +MIMAT0047723 dno-miR-193b-5p; +MIMAT0047724 dno-miR-193b-3p; +MIMAT0047725 dno-miR-194-5p; +MIMAT0047726 dno-miR-194-3p; +MIMAT0047727 dno-miR-195-5p; +MIMAT0047728 dno-miR-195-3p; +MIMAT0047729 dno-miR-196a-5p; +MIMAT0047730 dno-miR-196a-3p; +MIMAT0047731 dno-miR-196b-5p; +MIMAT0047732 dno-miR-196b-3p; +MIMAT0047733 dno-miR-196c-5p; +MIMAT0047734 dno-miR-196c-3p; +MIMAT0047735 dno-miR-197-5p; +MIMAT0047736 dno-miR-197-3p; +MIMAT0047737 dno-miR-199-5p; +MIMAT0047738 dno-miR-199-3p; +MIMAT0047739 dno-miR-199-2-5p; +MIMAT0047740 dno-miR-200b-5p; +MIMAT0047741 dno-miR-200b-3p; +MIMAT0047742 dno-miR-202-5p; +MIMAT0047743 dno-miR-202-3p; +MIMAT0047744 dno-miR-204-5p; +MIMAT0047745 dno-miR-204-3p; +MIMAT0047746 dno-miR-205-5p; +MIMAT0047747 dno-miR-205-3p; +MIMAT0047748 dno-miR-206-5p; +MIMAT0047749 dno-miR-206-3p; +MIMAT0047750 dno-miR-208a-5p; +MIMAT0047751 dno-miR-208a-3p; +MIMAT0047752 dno-miR-208b-5p; +MIMAT0047753 dno-miR-208b-3p; +MIMAT0047754 dno-miR-210-5p; +MIMAT0047755 dno-miR-210-3p; +MIMAT0047756 dno-miR-211-5p; +MIMAT0047757 dno-miR-211-3p; +MIMAT0047758 dno-miR-214-5p; +MIMAT0047759 dno-miR-214-3p; +MIMAT0047760 dno-miR-215-5p; +MIMAT0047761 dno-miR-215-3p; +MIMAT0047762 dno-miR-216a-5p; +MIMAT0047763 dno-miR-216a-3p; +MIMAT0047764 dno-miR-216b-5p; +MIMAT0047765 dno-miR-216b-3p; +MIMAT0047766 dno-miR-217-5p; +MIMAT0047767 dno-miR-217-3p; +MIMAT0047768 dno-miR-218-5p; +MIMAT0047769 dno-miR-218-3p; +MIMAT0047770 dno-miR-218-2-3p; +MIMAT0047771 dno-miR-219a-5p; +MIMAT0047772 dno-miR-219a-3p; +MIMAT0047773 dno-miR-219b-5p; +MIMAT0047774 dno-miR-219b-3p; +MIMAT0047775 dno-miR-221-5p; +MIMAT0047776 dno-miR-221-3p; +MIMAT0047777 dno-miR-222-5p; +MIMAT0047778 dno-miR-222-3p; +MIMAT0047779 dno-miR-223-5p; +MIMAT0047780 dno-miR-223-3p; +MIMAT0047781 dno-miR-224-5p; +MIMAT0047782 dno-miR-224-3p; +MIMAT0047783 dno-miR-296-5p; +MIMAT0047784 dno-miR-296-3p; +MIMAT0047785 dno-miR-299-5p; +MIMAT0047786 dno-miR-299-3p; +MIMAT0047787 dno-miR-301a-5p; +MIMAT0047788 dno-miR-301a-3p; +MIMAT0047789 dno-miR-301b-5p; +MIMAT0047790 dno-miR-301b-3p; +MIMAT0047791 dno-miR-302a-5p; +MIMAT0047792 dno-miR-302a-3p; +MIMAT0047793 dno-miR-302b-5p; +MIMAT0047794 dno-miR-302b-3p; +MIMAT0047795 dno-miR-302c-5p; +MIMAT0047796 dno-miR-302c-3p; +MIMAT0047797 dno-miR-302d-5p; +MIMAT0047798 dno-miR-302d-3p; +MIMAT0047799 dno-miR-323a-5p; +MIMAT0047800 dno-miR-323a-3p; +MIMAT0047801 dno-miR-323b-5p; +MIMAT0047802 dno-miR-323b-3p; +MIMAT0047803 dno-miR-324-5p; +MIMAT0047804 dno-miR-324-3p; +MIMAT0047805 dno-miR-326-5p; +MIMAT0047806 dno-miR-326-3p; +MIMAT0047807 dno-miR-328-5p; +MIMAT0047808 dno-miR-328-3p; +MIMAT0047809 dno-miR-329-5p; +MIMAT0047810 dno-miR-329-3p; +MIMAT0047811 dno-miR-330-5p; +MIMAT0047812 dno-miR-330-3p; +MIMAT0047813 dno-miR-331-5p; +MIMAT0047814 dno-miR-331-3p; +MIMAT0047815 dno-miR-335-5p; +MIMAT0047816 dno-miR-335-3p; +MIMAT0047817 dno-miR-337-5p; +MIMAT0047818 dno-miR-337-3p; +MIMAT0047819 dno-miR-338-5p; +MIMAT0047820 dno-miR-338-3p; +MIMAT0047821 dno-miR-339-5p; +MIMAT0047822 dno-miR-339-3p; +MIMAT0047823 dno-miR-340-5p; +MIMAT0047824 dno-miR-340-3p; +MIMAT0047825 dno-miR-342-5p; +MIMAT0047826 dno-miR-342-3p; +MIMAT0047827 dno-miR-345-5p; +MIMAT0047828 dno-miR-345-3p; +MIMAT0047829 dno-miR-361-5p; +MIMAT0047830 dno-miR-361-3p; +MIMAT0047831 dno-miR-362-5p; +MIMAT0047832 dno-miR-362-3p; +MIMAT0047833 dno-miR-363-5p; +MIMAT0047834 dno-miR-363-3p; +MIMAT0047835 dno-miR-365-5p; +MIMAT0047836 dno-miR-365-3p; +MIMAT0047837 dno-miR-365-2-5p; +MIMAT0047838 dno-miR-367-5p; +MIMAT0047839 dno-miR-367-3p; +MIMAT0047840 dno-miR-369-5p; +MIMAT0047841 dno-miR-369-3p; +MIMAT0047842 dno-miR-371-5p; +MIMAT0047843 dno-miR-371-3p; +MIMAT0047844 dno-miR-372-5p; +MIMAT0047845 dno-miR-372-3p; +MIMAT0047846 dno-miR-374a-5p; +MIMAT0047847 dno-miR-374a-3p; +MIMAT0047848 dno-miR-375-5p; +MIMAT0047849 dno-miR-375-3p; +MIMAT0047850 dno-miR-376a-5p; +MIMAT0047851 dno-miR-376a-3p; +MIMAT0047852 dno-miR-376b-5p; +MIMAT0047853 dno-miR-376b-3p; +MIMAT0047854 dno-miR-376d-5p; +MIMAT0047855 dno-miR-376d-3p; +MIMAT0047856 dno-miR-377-5p; +MIMAT0047857 dno-miR-377-3p; +MIMAT0047858 dno-miR-378-5p; +MIMAT0047859 dno-miR-378-3p; +MIMAT0047860 dno-miR-379-5p; +MIMAT0047861 dno-miR-379-3p; +MIMAT0047862 dno-miR-380-5p; +MIMAT0047863 dno-miR-380-3p; +MIMAT0047864 dno-miR-381-5p; +MIMAT0047865 dno-miR-381-3p; +MIMAT0047866 dno-miR-382-5p; +MIMAT0047867 dno-miR-382-3p; +MIMAT0047868 dno-miR-383-5p; +MIMAT0047869 dno-miR-383-3p; +MIMAT0047870 dno-miR-409-5p; +MIMAT0047871 dno-miR-409-3p; +MIMAT0047872 dno-miR-410-5p; +MIMAT0047873 dno-miR-410-3p; +MIMAT0047874 dno-miR-411-5p; +MIMAT0047875 dno-miR-411-3p; +MIMAT0047876 dno-miR-412-5p; +MIMAT0047877 dno-miR-412-3p; +MIMAT0047878 dno-miR-421-5p; +MIMAT0047879 dno-miR-421-3p; +MIMAT0047880 dno-miR-423-5p; +MIMAT0047881 dno-miR-423-3p; +MIMAT0047882 dno-miR-424-5p; +MIMAT0047883 dno-miR-424-3p; +MIMAT0047884 dno-miR-425-5p; +MIMAT0047885 dno-miR-425-3p; +MIMAT0047886 dno-miR-429-5p; +MIMAT0047887 dno-miR-429-3p; +MIMAT0047888 dno-miR-432-5p; +MIMAT0047889 dno-miR-432-3p; +MIMAT0047890 dno-miR-433-5p; +MIMAT0047891 dno-miR-433-3p; +MIMAT0047892 dno-miR-449a-5p; +MIMAT0047893 dno-miR-449a-3p; +MIMAT0047894 dno-miR-449b-3p; +MIMAT0047895 dno-miR-449c-5p; +MIMAT0047896 dno-miR-449c-3p; +MIMAT0047897 dno-miR-450a-5p; +MIMAT0047898 dno-miR-450a-3p; +MIMAT0047899 dno-miR-450b-5p; +MIMAT0047900 dno-miR-450b-3p; +MIMAT0047901 dno-miR-450c-5p; +MIMAT0047902 dno-miR-450c-3p; +MIMAT0047903 dno-miR-451-5p; +MIMAT0047904 dno-miR-454-5p; +MIMAT0047905 dno-miR-454-3p; +MIMAT0047906 dno-miR-455-5p; +MIMAT0047907 dno-miR-455-3p; +MIMAT0047908 dno-miR-483-5p; +MIMAT0047909 dno-miR-483-3p; +MIMAT0047910 dno-miR-485-5p; +MIMAT0047911 dno-miR-485-3p; +MIMAT0047912 dno-miR-486-5p; +MIMAT0047913 dno-miR-486-3p; +MIMAT0047914 dno-miR-487a-5p; +MIMAT0047915 dno-miR-487a-3p; +MIMAT0047916 dno-miR-487b-5p; +MIMAT0047917 dno-miR-487b-3p; +MIMAT0047918 dno-miR-488-5p; +MIMAT0047919 dno-miR-488-3p; +MIMAT0047920 dno-miR-489-5p; +MIMAT0047921 dno-miR-489-3p; +MIMAT0047922 dno-miR-490-5p; +MIMAT0047923 dno-miR-490-3p; +MIMAT0047924 dno-miR-491-5p; +MIMAT0047925 dno-miR-491-3p; +MIMAT0047926 dno-miR-493-5p; +MIMAT0047927 dno-miR-493-3p; +MIMAT0047928 dno-miR-494-5p; +MIMAT0047929 dno-miR-494-3p; +MIMAT0047930 dno-miR-495-5p; +MIMAT0047931 dno-miR-495-3p; +MIMAT0047932 dno-miR-496-5p; +MIMAT0047933 dno-miR-496-3p; +MIMAT0047934 dno-miR-497-5p; +MIMAT0047935 dno-miR-497-3p; +MIMAT0047936 dno-miR-499-5p; +MIMAT0047937 dno-miR-499-3p; +MIMAT0047938 dno-miR-500a-5p; +MIMAT0047939 dno-miR-500a-3p; +MIMAT0047940 dno-miR-500b-5p; +MIMAT0047941 dno-miR-500b-3p; +MIMAT0047942 dno-miR-502-5p; +MIMAT0047943 dno-miR-502-3p; +MIMAT0047944 dno-miR-503-5p; +MIMAT0047945 dno-miR-503-3p; +MIMAT0047946 dno-miR-504-5p; +MIMAT0047947 dno-miR-504-3p; +MIMAT0047948 dno-miR-505-5p; +MIMAT0047949 dno-miR-505-3p; +MIMAT0047950 dno-miR-506-5p; +MIMAT0047951 dno-miR-506-3p; +MIMAT0047952 dno-miR-507-5p; +MIMAT0047953 dno-miR-507-3p; +MIMAT0047954 dno-miR-508-5p; +MIMAT0047955 dno-miR-508-3p; +MIMAT0047956 dno-miR-509a-5p; +MIMAT0047957 dno-miR-509a-3p; +MIMAT0047958 dno-miR-509a-2-5p; +MIMAT0047959 dno-miR-509b-5p; +MIMAT0047960 dno-miR-509b-3p; +MIMAT0047961 dno-miR-512-5p; +MIMAT0047962 dno-miR-512-3p; +MIMAT0047963 dno-miR-532-5p; +MIMAT0047964 dno-miR-532-3p; +MIMAT0047965 dno-miR-539-5p; +MIMAT0047966 dno-miR-539-3p; +MIMAT0047967 dno-miR-541-5p; +MIMAT0047968 dno-miR-541-3p; +MIMAT0047969 dno-miR-542-5p; +MIMAT0047970 dno-miR-542-3p; +MIMAT0047971 dno-miR-543-5p; +MIMAT0047972 dno-miR-543-3p; +MIMAT0047973 dno-miR-545-5p; +MIMAT0047974 dno-miR-545-3p; +MIMAT0047975 dno-miR-551a-3p; +MIMAT0047976 dno-miR-551b-5p; +MIMAT0047977 dno-miR-551b-3p; +MIMAT0047978 dno-miR-574-5p; +MIMAT0047979 dno-miR-574-3p; +MIMAT0047980 dno-miR-582-5p; +MIMAT0047981 dno-miR-582-3p; +MIMAT0047982 dno-miR-590-5p; +MIMAT0047983 dno-miR-590-3p; +MIMAT0047984 dno-miR-628-5p; +MIMAT0047985 dno-miR-628-3p; +MIMAT0047986 dno-miR-652-5p; +MIMAT0047987 dno-miR-652-3p; +MIMAT0047988 dno-miR-653-5p; +MIMAT0047989 dno-miR-653-3p; +MIMAT0047990 dno-miR-654-5p; +MIMAT0047991 dno-miR-654-3p; +MIMAT0047992 dno-miR-656-5p; +MIMAT0047993 dno-miR-656-3p; +MIMAT0047994 dno-miR-660-5p; +MIMAT0047995 dno-miR-660-3p; +MIMAT0047996 dno-miR-670-5p; +MIMAT0047997 dno-miR-670-3p; +MIMAT0047998 dno-miR-671-5p; +MIMAT0047999 dno-miR-671-3p; +MIMAT0048000 dno-miR-672-5p; +MIMAT0048001 dno-miR-672-3p; +MIMAT0048002 dno-miR-675-5p; +MIMAT0048003 dno-miR-675-3p; +MIMAT0048004 dno-miR-676-5p; +MIMAT0048005 dno-miR-676-3p; +MIMAT0048006 dno-miR-708-5p; +MIMAT0048007 dno-miR-708-3p; +MIMAT0048008 dno-miR-744-5p; +MIMAT0048009 dno-miR-744-3p; +MIMAT0048010 dno-miR-758-5p; +MIMAT0048011 dno-miR-758-3p; +MIMAT0048012 dno-miR-760-5p; +MIMAT0048013 dno-miR-760-3p; +MIMAT0048014 dno-miR-802-5p; +MIMAT0048015 dno-miR-802-3p; +MIMAT0048016 dno-miR-873-5p; +MIMAT0048017 dno-miR-873-3p; +MIMAT0048018 dno-miR-874-5p; +MIMAT0048019 dno-miR-874-3p; +MIMAT0048020 dno-miR-885-5p; +MIMAT0048021 dno-miR-885-3p; +MIMAT0048022 dno-miR-889-5p; +MIMAT0048023 dno-miR-889-3p; +MIMAT0048024 dno-miR-1185-5p; +MIMAT0048025 dno-miR-1185-3p; +MIMAT0048026 dno-miR-1185-2-3p; +MIMAT0048027 dno-miR-1193-5p; +MIMAT0048028 dno-miR-1193-3p; +MIMAT0048029 dno-miR-1197-5p; +MIMAT0048030 dno-miR-1197-3p; +MIMAT0048031 dno-miR-1249-5p; +MIMAT0048032 dno-miR-1249-3p; +MIMAT0048033 dno-miR-1251-5p; +MIMAT0048034 dno-miR-1251-3p; +MIMAT0048035 dno-miR-1271-5p; +MIMAT0048036 dno-miR-1271-3p; +MIMAT0048037 dno-miR-1277-5p; +MIMAT0048038 dno-miR-1277-3p; +MIMAT0048039 dno-miR-1296-5p; +MIMAT0048040 dno-miR-1296-3p; +MIMAT0048041 dno-miR-1298-5p; +MIMAT0048042 dno-miR-1298-3p; +MIMAT0048043 dno-miR-1301-5p; +MIMAT0048044 dno-miR-1301-3p; +MIMAT0048045 dno-miR-1307-5p; +MIMAT0048046 dno-miR-1307-3p; +MIMAT0048047 dno-miR-1343-5p; +MIMAT0048048 dno-miR-1343-3p; +MIMAT0048049 dno-miR-1388-5p; +MIMAT0048050 dno-miR-1388-3p; +MIMAT0048051 dno-miR-1842-5p; +MIMAT0048052 dno-miR-1842-3p; +MIMAT0048053 dno-miR-2114-5p; +MIMAT0048054 dno-miR-2114-3p; +MIMAT0048055 dno-miR-2355-5p; +MIMAT0048056 dno-miR-2355-3p; +MIMAT0048057 dno-miR-2483-5p; +MIMAT0048058 dno-miR-2483-3p; +MIMAT0048059 dno-miR-3059-5p; +MIMAT0048060 dno-miR-3059-3p; +MIMAT0048061 dno-miR-3085-5p; +MIMAT0048062 dno-miR-3085-3p; +MIMAT0048063 dno-miR-3613-5p; +MIMAT0048064 dno-miR-3613-3p; +MIMAT0048065 dno-miR-3959-5p; +MIMAT0048066 dno-miR-3959-3p; +MIMAT0048067 dno-miR-6529-5p; +MIMAT0048068 dno-miR-6529-3p; +MIMAT0048069 dno-miR-12085-5p; +MIMAT0048070 dno-miR-12085-3p; +MIMAT0048071 dno-miR-12086-5p; +MIMAT0048072 dno-miR-12086-3p; +MIMAT0048073 dno-miR-12087-5p; +MIMAT0048074 dno-miR-12087-3p; +MIMAT0048075 ocu-let-7a-5p; +MIMAT0048076 ocu-let-7a-3p; +MIMAT0048077 ocu-let-7a-2-3p; +MIMAT0048078 ocu-let-7b-5p; +MIMAT0048079 ocu-let-7b-3p; +MIMAT0048080 ocu-let-7c-5p; +MIMAT0048081 ocu-let-7c-3p; +MIMAT0048082 ocu-let-7d-5p; +MIMAT0048083 ocu-let-7d-3p; +MIMAT0048084 ocu-let-7f-5p; +MIMAT0048085 ocu-let-7f-3p; +MIMAT0048086 ocu-let-7f-2-3p; +MIMAT0048087 ocu-let-7g-5p; +MIMAT0048088 ocu-let-7g-3p; +MIMAT0048089 ocu-let-7i-5p; +MIMAT0048090 ocu-let-7i-3p; +MIMAT0048091 ocu-miR-1-5p; +MIMAT0048092 ocu-miR-1-3p; +MIMAT0048093 ocu-miR-7a-5p; +MIMAT0048094 ocu-miR-7a-3p; +MIMAT0048095 ocu-miR-9-5p; +MIMAT0048096 ocu-miR-9-3p; +MIMAT0048097 ocu-miR-10a-5p; +MIMAT0048098 ocu-miR-10a-3p; +MIMAT0048099 ocu-miR-10b-5p; +MIMAT0048100 ocu-miR-10b-3p; +MIMAT0048101 ocu-miR-15a-5p; +MIMAT0048102 ocu-miR-15a-3p; +MIMAT0048103 ocu-miR-15b-5p; +MIMAT0048104 ocu-miR-15b-3p; +MIMAT0048105 ocu-miR-16a-5p; +MIMAT0048106 ocu-miR-16a-3p; +MIMAT0048107 ocu-miR-16b-5p; +MIMAT0048108 ocu-miR-16b-3p; +MIMAT0048109 ocu-miR-17-5p; +MIMAT0048110 ocu-miR-17-3p; +MIMAT0048111 ocu-miR-18a-5p; +MIMAT0048112 ocu-miR-18a-3p; +MIMAT0048113 ocu-miR-18b-5p; +MIMAT0048114 ocu-miR-18b-3p; +MIMAT0048115 ocu-miR-19a-5p; +MIMAT0048116 ocu-miR-19a-3p; +MIMAT0048117 ocu-miR-19b-5p; +MIMAT0048118 ocu-miR-19b-3p; +MIMAT0048119 ocu-miR-19b-2-5p; +MIMAT0048120 ocu-miR-20a-5p; +MIMAT0048121 ocu-miR-20a-3p; +MIMAT0048122 ocu-miR-20b-5p; +MIMAT0048123 ocu-miR-20b-3p; +MIMAT0048124 ocu-miR-21-5p; +MIMAT0048125 ocu-miR-21-3p; +MIMAT0048126 ocu-miR-22-5p; +MIMAT0048127 ocu-miR-22-3p; +MIMAT0048128 ocu-miR-23b-5p; +MIMAT0048129 ocu-miR-23b-3p; +MIMAT0048130 ocu-miR-24-5p; +MIMAT0048131 ocu-miR-24-3p; +MIMAT0048132 ocu-miR-24-2-5p; +MIMAT0048133 ocu-miR-25-5p; +MIMAT0048134 ocu-miR-25-3p; +MIMAT0048135 ocu-miR-26a-5p; +MIMAT0048136 ocu-miR-26a-3p; +MIMAT0048137 ocu-miR-26b-5p; +MIMAT0048138 ocu-miR-26b-3p; +MIMAT0048139 ocu-miR-27b-5p; +MIMAT0048140 ocu-miR-27b-3p; +MIMAT0048141 ocu-miR-28-5p; +MIMAT0048142 ocu-miR-28-3p; +MIMAT0048143 ocu-miR-29a-5p; +MIMAT0048144 ocu-miR-29a-3p; +MIMAT0048145 ocu-miR-29b-5p; +MIMAT0048146 ocu-miR-29b-3p; +MIMAT0048147 ocu-miR-29b-2-5p; +MIMAT0048148 ocu-miR-29c-5p; +MIMAT0048149 ocu-miR-29c-3p; +MIMAT0048150 ocu-miR-30a-5p; +MIMAT0048151 ocu-miR-30a-3p; +MIMAT0048152 ocu-miR-30b-5p; +MIMAT0048153 ocu-miR-30b-3p; +MIMAT0048154 ocu-miR-30c-5p; +MIMAT0048155 ocu-miR-30c-3p; +MIMAT0048156 ocu-miR-30c-2-3p; +MIMAT0048157 ocu-miR-30d-5p; +MIMAT0048158 ocu-miR-30d-3p; +MIMAT0048159 ocu-miR-30e-5p; +MIMAT0048160 ocu-miR-30e-3p; +MIMAT0048161 ocu-miR-31-5p; +MIMAT0048162 ocu-miR-31-3p; +MIMAT0048163 ocu-miR-32-5p; +MIMAT0048164 ocu-miR-32-3p; +MIMAT0048165 ocu-miR-33a-5p; +MIMAT0048166 ocu-miR-33a-3p; +MIMAT0048167 ocu-miR-34a-5p; +MIMAT0048168 ocu-miR-34a-3p; +MIMAT0048169 ocu-miR-34b-5p; +MIMAT0048170 ocu-miR-34b-3p; +MIMAT0048171 ocu-miR-34c-5p; +MIMAT0048172 ocu-miR-34c-3p; +MIMAT0048173 ocu-miR-92a-5p; +MIMAT0048174 ocu-miR-92a-3p; +MIMAT0048175 ocu-miR-92a-2-5p; +MIMAT0048176 ocu-miR-93-5p; +MIMAT0048177 ocu-miR-93-3p; +MIMAT0048178 ocu-miR-96-5p; +MIMAT0048179 ocu-miR-96-3p; +MIMAT0048180 ocu-miR-98-5p; +MIMAT0048181 ocu-miR-98-3p; +MIMAT0048182 ocu-miR-99a-5p; +MIMAT0048183 ocu-miR-99a-3p; +MIMAT0048184 ocu-miR-100-5p; +MIMAT0048185 ocu-miR-100-3p; +MIMAT0048186 ocu-miR-101-5p; +MIMAT0048187 ocu-miR-101-3p; +MIMAT0048188 ocu-miR-101-2-5p; +MIMAT0048189 ocu-miR-103a-5p; +MIMAT0048190 ocu-miR-103a-3p; +MIMAT0048191 ocu-miR-103a-2-5p; +MIMAT0048192 ocu-miR-105a-5p; +MIMAT0048193 ocu-miR-105a-3p; +MIMAT0048194 ocu-miR-105a-2-3p; +MIMAT0048195 ocu-miR-106a-5p; +MIMAT0048196 ocu-miR-106a-3p; +MIMAT0048197 ocu-miR-106b-5p; +MIMAT0048198 ocu-miR-106b-3p; +MIMAT0048199 ocu-miR-107-5p; +MIMAT0048200 ocu-miR-107-3p; +MIMAT0048201 ocu-miR-122-5p; +MIMAT0048202 ocu-miR-122-3p; +MIMAT0048203 ocu-miR-124-5p; +MIMAT0048204 ocu-miR-124-3p; +MIMAT0048205 ocu-miR-125b-5p; +MIMAT0048206 ocu-miR-125b-3p; +MIMAT0048207 ocu-miR-125b-2-3p; +MIMAT0048208 ocu-miR-127-5p; +MIMAT0048209 ocu-miR-127-3p; +MIMAT0048210 ocu-miR-128a-5p; +MIMAT0048211 ocu-miR-128a-3p; +MIMAT0048212 ocu-miR-128b-5p; +MIMAT0048213 ocu-miR-128b-3p; +MIMAT0048214 ocu-miR-129-5p; +MIMAT0048215 ocu-miR-129-3p; +MIMAT0048216 ocu-miR-129-2-3p; +MIMAT0048217 ocu-miR-130a-5p; +MIMAT0048218 ocu-miR-130a-3p; +MIMAT0048219 ocu-miR-130b-5p; +MIMAT0048220 ocu-miR-130b-3p; +MIMAT0048221 ocu-miR-133a-5p; +MIMAT0048222 ocu-miR-133a-3p; +MIMAT0048223 ocu-miR-133b-5p; +MIMAT0048224 ocu-miR-133b-3p; +MIMAT0048225 ocu-miR-134-5p; +MIMAT0048226 ocu-miR-134-3p; +MIMAT0048227 ocu-miR-135a-5p; +MIMAT0048228 ocu-miR-135a-3p; +MIMAT0048229 ocu-miR-135a-2-3p; +MIMAT0048230 ocu-miR-135b-5p; +MIMAT0048231 ocu-miR-135b-3p; +MIMAT0048232 ocu-miR-136-5p; +MIMAT0048233 ocu-miR-136-3p; +MIMAT0048234 ocu-miR-137-5p; +MIMAT0048235 ocu-miR-137-3p; +MIMAT0048236 ocu-miR-138-5p; +MIMAT0048237 ocu-miR-138-3p; +MIMAT0048238 ocu-miR-138-2-3p; +MIMAT0048239 ocu-miR-139-5p; +MIMAT0048240 ocu-miR-139-3p; +MIMAT0048241 ocu-miR-140-5p; +MIMAT0048242 ocu-miR-140-3p; +MIMAT0048243 ocu-miR-141-5p; +MIMAT0048244 ocu-miR-141-3p; +MIMAT0048245 ocu-miR-142-5p; +MIMAT0048246 ocu-miR-142-3p; +MIMAT0048247 ocu-miR-143-5p; +MIMAT0048248 ocu-miR-143-3p; +MIMAT0048249 ocu-miR-144-5p; +MIMAT0048250 ocu-miR-144-3p; +MIMAT0048251 ocu-miR-145-5p; +MIMAT0048252 ocu-miR-145-3p; +MIMAT0048253 ocu-miR-146a-5p; +MIMAT0048254 ocu-miR-146a-3p; +MIMAT0048255 ocu-miR-146b-5p; +MIMAT0048256 ocu-miR-146b-3p; +MIMAT0048257 ocu-miR-147-5p; +MIMAT0048258 ocu-miR-147-3p; +MIMAT0048259 ocu-miR-148a-5p; +MIMAT0048260 ocu-miR-148a-3p; +MIMAT0048261 ocu-miR-148b-5p; +MIMAT0048262 ocu-miR-148b-3p; +MIMAT0048263 ocu-miR-150-5p; +MIMAT0048264 ocu-miR-150-3p; +MIMAT0048265 ocu-miR-151-5p; +MIMAT0048266 ocu-miR-151-3p; +MIMAT0048267 ocu-miR-152-5p; +MIMAT0048268 ocu-miR-152-3p; +MIMAT0048269 ocu-miR-153-5p; +MIMAT0048270 ocu-miR-153-3p; +MIMAT0048271 ocu-miR-154-5p; +MIMAT0048272 ocu-miR-154-3p; +MIMAT0048273 ocu-miR-155-5p; +MIMAT0048274 ocu-miR-155-3p; +MIMAT0048275 ocu-miR-181a-5p; +MIMAT0048276 ocu-miR-181a-3p; +MIMAT0048277 ocu-miR-181a-2-3p; +MIMAT0048278 ocu-miR-181b-5p; +MIMAT0048279 ocu-miR-181b-3p; +MIMAT0048280 ocu-miR-181b-2-3p; +MIMAT0048281 ocu-miR-181c-5p; +MIMAT0048282 ocu-miR-181c-3p; +MIMAT0048283 ocu-miR-181d-5p; +MIMAT0048284 ocu-miR-181d-3p; +MIMAT0048285 ocu-miR-182-5p; +MIMAT0048286 ocu-miR-182-3p; +MIMAT0048287 ocu-miR-183-5p; +MIMAT0048288 ocu-miR-183-3p; +MIMAT0048289 ocu-miR-184-5p; +MIMAT0048290 ocu-miR-184-3p; +MIMAT0048291 ocu-miR-185-5p; +MIMAT0048292 ocu-miR-185-3p; +MIMAT0048293 ocu-miR-186-5p; +MIMAT0048294 ocu-miR-186-3p; +MIMAT0048295 ocu-miR-187-5p; +MIMAT0048296 ocu-miR-187-3p; +MIMAT0048297 ocu-miR-188-5p; +MIMAT0048298 ocu-miR-188-3p; +MIMAT0048299 ocu-miR-190a-5p; +MIMAT0048300 ocu-miR-190a-3p; +MIMAT0048301 ocu-miR-190b-5p; +MIMAT0048302 ocu-miR-190b-3p; +MIMAT0048303 ocu-miR-193a-5p; +MIMAT0048304 ocu-miR-193a-3p; +MIMAT0048305 ocu-miR-193b-5p; +MIMAT0048306 ocu-miR-193b-3p; +MIMAT0048307 ocu-miR-194-5p; +MIMAT0048308 ocu-miR-194-3p; +MIMAT0048309 ocu-miR-195-5p; +MIMAT0048310 ocu-miR-195-3p; +MIMAT0048311 ocu-miR-196a-5p; +MIMAT0048312 ocu-miR-196a-3p; +MIMAT0048313 ocu-miR-196a-2-5p; +MIMAT0048314 ocu-miR-196a-2-3p; +MIMAT0048315 ocu-miR-196b-5p; +MIMAT0048316 ocu-miR-196b-3p; +MIMAT0048317 ocu-miR-197-5p; +MIMAT0048318 ocu-miR-197-3p; +MIMAT0048319 ocu-miR-199a-5p; +MIMAT0048320 ocu-miR-199a-3p; +MIMAT0048321 ocu-miR-200c-5p; +MIMAT0048322 ocu-miR-200c-3p; +MIMAT0048323 ocu-miR-204-5p; +MIMAT0048324 ocu-miR-204-3p; +MIMAT0048325 ocu-miR-205-5p; +MIMAT0048326 ocu-miR-205-3p; +MIMAT0048327 ocu-miR-206-5p; +MIMAT0048328 ocu-miR-206-3p; +MIMAT0048329 ocu-miR-208a-5p; +MIMAT0048330 ocu-miR-208a-3p; +MIMAT0048331 ocu-miR-208b-5p; +MIMAT0048332 ocu-miR-208b-3p; +MIMAT0048333 ocu-miR-211-5p; +MIMAT0048334 ocu-miR-211-3p; +MIMAT0048335 ocu-miR-212-5p; +MIMAT0048336 ocu-miR-212-3p; +MIMAT0048337 ocu-miR-214-5p; +MIMAT0048338 ocu-miR-214-3p; +MIMAT0048339 ocu-miR-215-5p; +MIMAT0048340 ocu-miR-215-3p; +MIMAT0048341 ocu-miR-216a-5p; +MIMAT0048342 ocu-miR-216a-3p; +MIMAT0048343 ocu-miR-216b-5p; +MIMAT0048344 ocu-miR-216b-3p; +MIMAT0048345 ocu-miR-217-5p; +MIMAT0048346 ocu-miR-217-3p; +MIMAT0048347 ocu-miR-218-5p; +MIMAT0048348 ocu-miR-218-3p; +MIMAT0048349 ocu-miR-218-2-3p; +MIMAT0048350 ocu-miR-219a-5p; +MIMAT0048351 ocu-miR-219a-3p; +MIMAT0048352 ocu-miR-219b-5p; +MIMAT0048353 ocu-miR-219b-3p; +MIMAT0048354 ocu-miR-221-5p; +MIMAT0048355 ocu-miR-221-3p; +MIMAT0048356 ocu-miR-222-5p; +MIMAT0048357 ocu-miR-222-3p; +MIMAT0048358 ocu-miR-223-5p; +MIMAT0048359 ocu-miR-223-3p; +MIMAT0048360 ocu-miR-224-5p; +MIMAT0048361 ocu-miR-224-3p; +MIMAT0048362 ocu-miR-299-5p; +MIMAT0048363 ocu-miR-299-3p; +MIMAT0048364 ocu-miR-301a-5p; +MIMAT0048365 ocu-miR-301a-3p; +MIMAT0048366 ocu-miR-301b-5p; +MIMAT0048367 ocu-miR-301b-3p; +MIMAT0048368 ocu-miR-323a-5p; +MIMAT0048369 ocu-miR-323a-3p; +MIMAT0048370 ocu-miR-324-5p; +MIMAT0048371 ocu-miR-324-3p; +MIMAT0048372 ocu-miR-325-5p; +MIMAT0048373 ocu-miR-325-3p; +MIMAT0048374 ocu-miR-326-5p; +MIMAT0048375 ocu-miR-326-3p; +MIMAT0048376 ocu-miR-328-5p; +MIMAT0048377 ocu-miR-328-3p; +MIMAT0048378 ocu-miR-329-5p; +MIMAT0048379 ocu-miR-329-3p; +MIMAT0048380 ocu-miR-331-5p; +MIMAT0048381 ocu-miR-331-3p; +MIMAT0048382 ocu-miR-335-5p; +MIMAT0048383 ocu-miR-335-3p; +MIMAT0048384 ocu-miR-337-5p; +MIMAT0048385 ocu-miR-337-3p; +MIMAT0048386 ocu-miR-340-5p; +MIMAT0048387 ocu-miR-340-3p; +MIMAT0048388 ocu-miR-342-5p; +MIMAT0048389 ocu-miR-342-3p; +MIMAT0048390 ocu-miR-346-5p; +MIMAT0048391 ocu-miR-350-5p; +MIMAT0048392 ocu-miR-350-3p; +MIMAT0048393 ocu-miR-361-5p; +MIMAT0048394 ocu-miR-361-3p; +MIMAT0048395 ocu-miR-362-5p; +MIMAT0048396 ocu-miR-362-3p; +MIMAT0048397 ocu-miR-363-5p; +MIMAT0048398 ocu-miR-363-3p; +MIMAT0048399 ocu-miR-365-5p; +MIMAT0048400 ocu-miR-365-3p; +MIMAT0048401 ocu-miR-365-2-5p; +MIMAT0048402 ocu-miR-369-5p; +MIMAT0048403 ocu-miR-369-3p; +MIMAT0048404 ocu-miR-370-5p; +MIMAT0048405 ocu-miR-370-3p; +MIMAT0048406 ocu-miR-374a-5p; +MIMAT0048407 ocu-miR-374a-3p; +MIMAT0048408 ocu-miR-374b-5p; +MIMAT0048409 ocu-miR-374b-3p; +MIMAT0048410 ocu-miR-375-5p; +MIMAT0048411 ocu-miR-375-3p; +MIMAT0048412 ocu-miR-376a-5p; +MIMAT0048413 ocu-miR-376a-3p; +MIMAT0048414 ocu-miR-376b-5p; +MIMAT0048415 ocu-miR-376b-3p; +MIMAT0048416 ocu-miR-376c-5p; +MIMAT0048417 ocu-miR-376c-3p; +MIMAT0048418 ocu-miR-376c-2-3p; +MIMAT0048419 ocu-miR-377-5p; +MIMAT0048420 ocu-miR-377-3p; +MIMAT0048421 ocu-miR-378-5p; +MIMAT0048422 ocu-miR-378-3p; +MIMAT0048423 ocu-miR-379-5p; +MIMAT0048424 ocu-miR-379-3p; +MIMAT0048425 ocu-miR-381-5p; +MIMAT0048426 ocu-miR-381-3p; +MIMAT0048427 ocu-miR-382-5p; +MIMAT0048428 ocu-miR-382-3p; +MIMAT0048429 ocu-miR-383-5p; +MIMAT0048430 ocu-miR-383-3p; +MIMAT0048431 ocu-miR-384-5p; +MIMAT0048432 ocu-miR-384-3p; +MIMAT0048433 ocu-miR-409-5p; +MIMAT0048434 ocu-miR-409-3p; +MIMAT0048435 ocu-miR-410-5p; +MIMAT0048436 ocu-miR-410-3p; +MIMAT0048437 ocu-miR-411-5p; +MIMAT0048438 ocu-miR-411-3p; +MIMAT0048439 ocu-miR-421-5p; +MIMAT0048440 ocu-miR-421-3p; +MIMAT0048441 ocu-miR-423-5p; +MIMAT0048442 ocu-miR-423-3p; +MIMAT0048443 ocu-miR-424-5p; +MIMAT0048444 ocu-miR-424-3p; +MIMAT0048445 ocu-miR-425-5p; +MIMAT0048446 ocu-miR-425-3p; +MIMAT0048447 ocu-miR-432-5p; +MIMAT0048448 ocu-miR-432-3p; +MIMAT0048449 ocu-miR-433-5p; +MIMAT0048450 ocu-miR-433-3p; +MIMAT0048451 ocu-miR-448-5p; +MIMAT0048452 ocu-miR-448-3p; +MIMAT0048453 ocu-miR-449a-5p; +MIMAT0048454 ocu-miR-449a-3p; +MIMAT0048455 ocu-miR-449b-5p; +MIMAT0048456 ocu-miR-449b-3p; +MIMAT0048457 ocu-miR-450a-5p; +MIMAT0048458 ocu-miR-450a-3p; +MIMAT0048459 ocu-miR-450a-2-3p; +MIMAT0048460 ocu-miR-450b-5p; +MIMAT0048461 ocu-miR-450b-3p; +MIMAT0048462 ocu-miR-451-5p; +MIMAT0048463 ocu-miR-452-5p; +MIMAT0048464 ocu-miR-452-3p; +MIMAT0048465 ocu-miR-455-5p; +MIMAT0048466 ocu-miR-455-3p; +MIMAT0048467 ocu-miR-485-5p; +MIMAT0048468 ocu-miR-485-3p; +MIMAT0048469 ocu-miR-486-5p; +MIMAT0048470 ocu-miR-486-3p; +MIMAT0048471 ocu-miR-487a-5p; +MIMAT0048472 ocu-miR-487a-3p; +MIMAT0048473 ocu-miR-487b-5p; +MIMAT0048474 ocu-miR-487b-3p; +MIMAT0048475 ocu-miR-488-5p; +MIMAT0048476 ocu-miR-488-3p; +MIMAT0048477 ocu-miR-489-5p; +MIMAT0048478 ocu-miR-489-3p; +MIMAT0048479 ocu-miR-490-5p; +MIMAT0048480 ocu-miR-490-3p; +MIMAT0048481 ocu-miR-491-5p; +MIMAT0048482 ocu-miR-491-3p; +MIMAT0048483 ocu-miR-495-5p; +MIMAT0048484 ocu-miR-495-3p; +MIMAT0048485 ocu-miR-496-5p; +MIMAT0048486 ocu-miR-496-3p; +MIMAT0048487 ocu-miR-497-5p; +MIMAT0048488 ocu-miR-497-3p; +MIMAT0048489 ocu-miR-499-5p; +MIMAT0048490 ocu-miR-499-3p; +MIMAT0048491 ocu-miR-500-5p; +MIMAT0048492 ocu-miR-500-3p; +MIMAT0048493 ocu-miR-501-5p; +MIMAT0048494 ocu-miR-501-3p; +MIMAT0048495 ocu-miR-502a-5p; +MIMAT0048496 ocu-miR-502a-3p; +MIMAT0048497 ocu-miR-502b-5p; +MIMAT0048498 ocu-miR-502b-3p; +MIMAT0048499 ocu-miR-503-5p; +MIMAT0048500 ocu-miR-503-3p; +MIMAT0048501 ocu-miR-504-5p; +MIMAT0048502 ocu-miR-504-3p; +MIMAT0048503 ocu-miR-505-5p; +MIMAT0048504 ocu-miR-505-3p; +MIMAT0048505 ocu-miR-506-5p; +MIMAT0048506 ocu-miR-506-3p; +MIMAT0048507 ocu-miR-507-5p; +MIMAT0048508 ocu-miR-507-3p; +MIMAT0048509 ocu-miR-508-5p; +MIMAT0048510 ocu-miR-508-3p; +MIMAT0048511 ocu-miR-509a-5p; +MIMAT0048512 ocu-miR-509a-3p; +MIMAT0048513 ocu-miR-513-5p; +MIMAT0048514 ocu-miR-513-3p; +MIMAT0048515 ocu-miR-509b-5p; +MIMAT0048516 ocu-miR-509b-3p; +MIMAT0048517 ocu-miR-509c-5p; +MIMAT0048518 ocu-miR-509c-3p; +MIMAT0048519 ocu-miR-532-5p; +MIMAT0048520 ocu-miR-532-3p; +MIMAT0048521 ocu-miR-539-5p; +MIMAT0048522 ocu-miR-539-3p; +MIMAT0048523 ocu-miR-541-5p; +MIMAT0048524 ocu-miR-541-3p; +MIMAT0048525 ocu-miR-542-5p; +MIMAT0048526 ocu-miR-542-3p; +MIMAT0048527 ocu-miR-545-5p; +MIMAT0048528 ocu-miR-545-3p; +MIMAT0048529 ocu-miR-551b-5p; +MIMAT0048530 ocu-miR-551b-3p; +MIMAT0048531 ocu-miR-574-5p; +MIMAT0048532 ocu-miR-574-3p; +MIMAT0048533 ocu-miR-582-5p; +MIMAT0048534 ocu-miR-582-3p; +MIMAT0048535 ocu-miR-590-5p; +MIMAT0048536 ocu-miR-590-3p; +MIMAT0048537 ocu-miR-599-5p; +MIMAT0048538 ocu-miR-599-3p; +MIMAT0048539 ocu-miR-628-5p; +MIMAT0048540 ocu-miR-628-3p; +MIMAT0048541 ocu-miR-652-5p; +MIMAT0048542 ocu-miR-652-3p; +MIMAT0048543 ocu-miR-653-5p; +MIMAT0048544 ocu-miR-653-3p; +MIMAT0048545 ocu-miR-654-5p; +MIMAT0048546 ocu-miR-654-3p; +MIMAT0048547 ocu-miR-655-5p; +MIMAT0048548 ocu-miR-655-3p; +MIMAT0048549 ocu-miR-656-5p; +MIMAT0048550 ocu-miR-656-3p; +MIMAT0048551 ocu-miR-660-5p; +MIMAT0048552 ocu-miR-660-3p; +MIMAT0048553 ocu-miR-670-5p; +MIMAT0048554 ocu-miR-670-3p; +MIMAT0048555 ocu-miR-671-5p; +MIMAT0048556 ocu-miR-671-3p; +MIMAT0048557 ocu-miR-672-5p; +MIMAT0048558 ocu-miR-672-3p; +MIMAT0048559 ocu-miR-676-5p; +MIMAT0048560 ocu-miR-676-3p; +MIMAT0048561 ocu-miR-708-5p; +MIMAT0048562 ocu-miR-708-3p; +MIMAT0048563 ocu-miR-744-5p; +MIMAT0048564 ocu-miR-744-3p; +MIMAT0048565 ocu-miR-758-5p; +MIMAT0048566 ocu-miR-758-3p; +MIMAT0048567 ocu-miR-760-5p; +MIMAT0048568 ocu-miR-760-3p; +MIMAT0048569 ocu-miR-802-5p; +MIMAT0048570 ocu-miR-802-3p; +MIMAT0048571 ocu-miR-872-5p; +MIMAT0048572 ocu-miR-872-3p; +MIMAT0048573 ocu-miR-873-5p; +MIMAT0048574 ocu-miR-873-3p; +MIMAT0048575 ocu-miR-874-5p; +MIMAT0048576 ocu-miR-874-3p; +MIMAT0048577 ocu-miR-875-5p; +MIMAT0048578 ocu-miR-875-3p; +MIMAT0048579 ocu-miR-885-5p; +MIMAT0048580 ocu-miR-885-3p; +MIMAT0048581 ocu-miR-889-5p; +MIMAT0048582 ocu-miR-889-3p; +MIMAT0048583 ocu-miR-1197-5p; +MIMAT0048584 ocu-miR-1197-3p; +MIMAT0048585 ocu-miR-1249-5p; +MIMAT0048586 ocu-miR-1249-3p; +MIMAT0048587 ocu-miR-1251-5p; +MIMAT0048588 ocu-miR-1251-3p; +MIMAT0048589 ocu-miR-1264-5p; +MIMAT0048590 ocu-miR-1264-3p; +MIMAT0048591 ocu-miR-1277-5p; +MIMAT0048592 ocu-miR-1277-3p; +MIMAT0048593 ocu-miR-1296-5p; +MIMAT0048594 ocu-miR-1296-3p; +MIMAT0048595 ocu-miR-1298-5p; +MIMAT0048596 ocu-miR-1298-3p; +MIMAT0048597 ocu-miR-1307-5p; +MIMAT0048598 ocu-miR-1307-3p; +MIMAT0048599 ocu-miR-1343-5p; +MIMAT0048600 ocu-miR-1343-3p; +MIMAT0048601 ocu-miR-1911-5p; +MIMAT0048602 ocu-miR-1911-3p; +MIMAT0048603 ocu-miR-2355-5p; +MIMAT0048604 ocu-miR-2355-3p; +MIMAT0048605 ocu-miR-2387-5p; +MIMAT0048606 ocu-miR-2387-3p; +MIMAT0048607 ocu-miR-3059-5p; +MIMAT0048608 ocu-miR-3059-3p; +MIMAT0048609 ocu-miR-3085-5p; +MIMAT0048610 ocu-miR-3085-3p; +MIMAT0048611 ocu-miR-3613-5p; +MIMAT0048612 ocu-miR-3613-3p; +MIMAT0048613 ocu-miR-6529-5p; +MIMAT0048614 ocu-miR-6529-3p; +MIMAT0048615 ocu-miR-7180-5p; +MIMAT0048616 ocu-miR-7180-3p; +MIMAT0048617 ocu-miR-9851-5p; +MIMAT0048618 ocu-miR-9851-3p; +MIMAT0048619 ocu-miR-12090-5p; +MIMAT0048620 ocu-miR-12090-3p; +MIMAT0048621 ocu-miR-12091-5p; +MIMAT0048622 ocu-miR-12091-3p; +MIMAT0048623 ocu-miR-12092-5p; +MIMAT0048624 ocu-miR-12092-3p; +MIMAT0048625 ocu-miR-12093-5p; +MIMAT0048626 ocu-miR-12093-3p; +MIMAT0048627 ocu-miR-12094-5p; +MIMAT0048628 ocu-miR-12094-3p; +MIMAT0048629 ocu-miR-105b-5p; +MIMAT0048630 ocu-miR-105b-3p; +MIMAT0048631 ocu-miR-12095-5p; +MIMAT0048632 ocu-miR-12095-3p; +MIMAT0048633 hsa-miR-3059-5p; +MIMAT0048634 hsa-miR-3059-3p; +MIMAT0048635 hsa-miR-3085-5p; +MIMAT0048636 hsa-miR-3085-3p; +MIMAT0048637 hsa-miR-6529-5p; +MIMAT0048638 hsa-miR-6529-3p; +MIMAT0048639 hsa-miR-9851-5p; +MIMAT0048640 hsa-miR-9851-3p; +MIMAT0048641 mmu-miR-1271-5p; +MIMAT0048642 mmu-miR-1271-3p; +MIMAT0048643 mmu-miR-1911-5p; +MIMAT0048644 mmu-miR-1911-3p; +MIMAT0048645 gga-miR-143-5p; +MIMAT0048646 gga-miR-143-3p; +MIMAT0048647 gga-miR-449d-5p; +MIMAT0048648 gga-miR-449d-3p; +MIMAT0048649 dre-miR-129-3-3p; +MIMAT0048650 dre-miR-212-5p; +MIMAT0048651 dre-miR-212-3p; +MIMAT0048652 dre-miR-138-2-3p; +MIMAT0048653 dre-miR-181a-4-3p; +MIMAT0048654 dre-miR-181a-3-3p; +MIMAT0048655 dre-miR-181a-5-3p; +MIMAT0048656 dre-miR-181b-3-3p; +MIMAT0048657 dre-miR-181d-5p; +MIMAT0048658 dre-miR-181d-3p; +MIMAT0048659 dre-miR-204-3-3p; +MIMAT0048660 dre-miR-23b-5p; +MIMAT0048661 dre-miR-23b-3p; +MIMAT0048662 dre-miR-24b-5p; +MIMAT0048663 dre-miR-24b-3p; +MIMAT0048664 dre-miR-7133-5p; +MIMAT0048665 dre-miR-7133-3p; +MIMAT0048666 dre-miR-128-3-5p; +MIMAT0048667 dre-miR-29b3-5p; +MIMAT0048668 dre-miR-29b3-3p; +MIMAT0048669 dre-miR-7132-5p; +MIMAT0048670 dre-miR-7132-3p; +MIMAT0048671 gga-miR-9-4-3p; +MIMAT0048672 dre-miR-338-5p; +MIMAT0048673 dre-miR-338-3p; +MIMAT0048674 mle-bantam-5p; +MIMAT0048675 mle-bantam-3p; +MIMAT0048676 mle-let-7-5p; +MIMAT0048677 mle-let-7-3p; +MIMAT0048678 mle-miR-1-5p; +MIMAT0048679 mle-miR-1-3p; +MIMAT0048680 mle-miR-2a-5p; +MIMAT0048681 mle-miR-2a-3p; +MIMAT0048682 mle-miR-2b-5p; +MIMAT0048683 mle-miR-2b-3p; +MIMAT0048684 mle-miR-2c-5p; +MIMAT0048685 mle-miR-2c-3p; +MIMAT0048686 mle-miR-2d-5p; +MIMAT0048687 mle-miR-2d-3p; +MIMAT0048688 mle-miR-2e-5p; +MIMAT0048689 mle-miR-2e-3p; +MIMAT0048690 mle-miR-2f-5p; +MIMAT0048691 mle-miR-2f-3p; +MIMAT0048692 mle-miR-2g-5p; +MIMAT0048693 mle-miR-2g-3p; +MIMAT0048694 mle-miR-2h-5p; +MIMAT0048695 mle-miR-2h-3p; +MIMAT0048696 mle-miR-2i-5p; +MIMAT0048697 mle-miR-2i-3p; +MIMAT0048698 mle-miR-2j-5p; +MIMAT0048699 mle-miR-2j-3p; +MIMAT0048700 mle-miR-2k-5p; +MIMAT0048701 mle-miR-2k-3p; +MIMAT0048702 mle-miR-7-5p; +MIMAT0048703 mle-miR-7-3p; +MIMAT0048704 mle-miR-8-5p; +MIMAT0048705 mle-miR-8-3p; +MIMAT0048706 mle-miR-9-5p; +MIMAT0048707 mle-miR-9-3p; +MIMAT0048708 mle-miR-10a-5p; +MIMAT0048709 mle-miR-10a-3p; +MIMAT0048710 mle-miR-10b-5p; +MIMAT0048711 mle-miR-10b-3p; +MIMAT0048712 mle-miR-12-5p; +MIMAT0048713 mle-miR-12-3p; +MIMAT0048714 mle-miR-745a-5p; +MIMAT0048715 mle-miR-745a-3p; +MIMAT0048716 mle-miR-745b-5p; +MIMAT0048717 mle-miR-745b-3p; +MIMAT0048718 mle-miR-29a-5p; +MIMAT0048719 mle-miR-29a-3p; +MIMAT0048720 mle-miR-29b-5p; +MIMAT0048721 mle-miR-29b-3p; +MIMAT0048722 mle-miR-31-5p; +MIMAT0048723 mle-miR-31-3p; +MIMAT0048724 mle-miR-33-3p; +MIMAT0048725 mle-miR-34-5p; +MIMAT0048726 mle-miR-34-3p; +MIMAT0048727 mle-miR-67-5p; +MIMAT0048728 mle-miR-67-3p; +MIMAT0048729 mle-miR-71-5p; +MIMAT0048730 mle-miR-71-3p; +MIMAT0048731 mle-miR-981-5p; +MIMAT0048732 mle-miR-981-3p; +MIMAT0048733 mle-miR-87-5p; +MIMAT0048734 mle-miR-87-3p; +MIMAT0048735 mle-miR-92a-5p; +MIMAT0048736 mle-miR-92a-3p; +MIMAT0048737 mle-miR-92b-5p; +MIMAT0048738 mle-miR-92b-3p; +MIMAT0048739 mle-miR-92c-5p; +MIMAT0048740 mle-miR-92c-3p; +MIMAT0048741 mle-miR-96a-5p; +MIMAT0048742 mle-miR-96a-3p; +MIMAT0048743 mle-miR-96b-5p; +MIMAT0048744 mle-miR-96b-3p; +MIMAT0048745 mle-miR-100-5p; +MIMAT0048746 mle-miR-100-3p; +MIMAT0048747 mle-miR-124-5p; +MIMAT0048748 mle-miR-124-3p; +MIMAT0048749 mle-miR-125-5p; +MIMAT0048750 mle-miR-125-3p; +MIMAT0048751 mle-miR-133-5p; +MIMAT0048752 mle-miR-133-3p; +MIMAT0048753 mle-miR-137-5p; +MIMAT0048754 mle-miR-137-3p; +MIMAT0048755 mle-miR-153-5p; +MIMAT0048756 mle-miR-153-3p; +MIMAT0048757 mle-miR-263b-5p; +MIMAT0048758 mle-miR-263b-3p; +MIMAT0048759 mle-miR-263a-5p; +MIMAT0048760 mle-miR-263a-3p; +MIMAT0048761 mle-miR-184-5p; +MIMAT0048762 mle-miR-184-3p; +MIMAT0048763 mle-miR-190-5p; +MIMAT0048764 mle-miR-190-3p; +MIMAT0048765 mle-miR-193-5p; +MIMAT0048766 mle-miR-193-3p; +MIMAT0048767 mle-miR-210-5p; +MIMAT0048768 mle-miR-210-3p; +MIMAT0048769 mle-miR-216a-5p; +MIMAT0048770 mle-miR-216a-3p; +MIMAT0048771 mle-miR-216b-5p; +MIMAT0048772 mle-miR-216b-3p; +MIMAT0048773 mle-miR-219-5p; +MIMAT0048774 mle-miR-219-3p; +MIMAT0048775 mle-miR-242-5p; +MIMAT0048776 mle-miR-242-3p; +MIMAT0048777 mle-miR-252a-5p; +MIMAT0048778 mle-miR-252a-3p; +MIMAT0048779 mle-miR-252b-5p; +MIMAT0048780 mle-miR-252b-3p; +MIMAT0048781 mle-miR-277-5p; +MIMAT0048782 mle-miR-277-3p; +MIMAT0048783 mle-miR-279-5p; +MIMAT0048784 mle-miR-279-3p; +MIMAT0048785 mle-miR-281-5p; +MIMAT0048786 mle-miR-281-3p; +MIMAT0048787 mle-miR-315-5p; +MIMAT0048788 mle-miR-315-3p; +MIMAT0048789 mle-miR-317-5p; +MIMAT0048790 mle-miR-317-3p; +MIMAT0048791 mle-miR-365-5p; +MIMAT0048792 mle-miR-365-3p; +MIMAT0048793 mle-miR-375-5p; +MIMAT0048794 mle-miR-375-3p; +MIMAT0048795 mle-miR-750-5p; +MIMAT0048796 mle-miR-750-3p; +MIMAT0048797 mle-miR-1175-5p; +MIMAT0048798 mle-miR-1175-3p; +MIMAT0048799 mle-miR-1984-5p; +MIMAT0048800 mle-miR-1984-3p; +MIMAT0048801 mle-miR-1985-5p; +MIMAT0048802 mle-miR-1985-3p; +MIMAT0048803 mle-miR-1986-5p; +MIMAT0048804 mle-miR-1986-3p; +MIMAT0048805 mle-miR-1988a-5p; +MIMAT0048806 mle-miR-1988a-3p; +MIMAT0048807 mle-miR-1988b-5p; +MIMAT0048808 mle-miR-1988b-3p; +MIMAT0048809 mle-miR-1989a-5p; +MIMAT0048810 mle-miR-1989a-3p; +MIMAT0048811 mle-miR-1989b-5p; +MIMAT0048812 mle-miR-1989b-3p; +MIMAT0048813 mle-miR-1990-5p; +MIMAT0048814 mle-miR-1990-3p; +MIMAT0048815 mle-miR-1991-5p; +MIMAT0048816 mle-miR-1991-3p; +MIMAT0048817 mle-miR-1992-5p; +MIMAT0048818 mle-miR-1992-3p; +MIMAT0048819 mle-miR-1993-5p; +MIMAT0048820 mle-miR-1993-3p; +MIMAT0048821 mle-miR-1994a-5p; +MIMAT0048822 mle-miR-1994a-3p; +MIMAT0048823 mle-miR-1994b-5p; +MIMAT0048824 mle-miR-1994b-3p; +MIMAT0048825 mle-miR-2001-5p; +MIMAT0048826 mle-miR-2001-3p; +MIMAT0048827 mle-miR-2722-5p; +MIMAT0048828 mle-miR-2722-3p; +MIMAT0048829 mle-miR-12096a-5p; +MIMAT0048830 mle-miR-12096a-3p; +MIMAT0048831 mle-miR-12096b-5p; +MIMAT0048832 mle-miR-12096b-3p; +MIMAT0048833 mle-miR-12097-5p; +MIMAT0048834 mle-miR-12097-3p; +MIMAT0048835 mle-miR-12098-5p; +MIMAT0048836 mle-miR-12098-3p; +MIMAT0048837 mle-miR-12099-5p; +MIMAT0048838 mle-miR-12099-3p; +MIMAT0048839 mle-miR-12100-5p; +MIMAT0048840 mle-miR-12100-3p; +MIMAT0048841 mle-miR-29c-5p; +MIMAT0048842 mle-miR-29c-3p; +MIMAT0048843 mle-miR-12101-5p; +MIMAT0048844 mle-miR-12101-3p; +MIMAT0048845 mle-miR-12101-2-c5p; +MIMAT0048846 mle-miR-12102-5p; +MIMAT0048847 mle-miR-12102-3p; +MIMAT0048848 mle-miR-12103-3p; +MIMAT0048849 mle-miR-12104-3p; +MIMAT0048850 csi-miR156b-5p; +MIMAT0048851 csi-miR156b-3p; +MIMAT0048852 csi-miR156c-5p; +MIMAT0048853 csi-miR156c-3p; +MIMAT0048854 csi-miR156d-5p; +MIMAT0048855 csi-miR156e-5p; +MIMAT0048856 csi-miR156e-3p; +MIMAT0048857 csi-miR156f-5p; +MIMAT0048858 csi-miR156f-3p; +MIMAT0048859 csi-miR156g-5p; +MIMAT0048860 csi-miR156g-3p; +MIMAT0048861 csi-miR159b-5p; +MIMAT0048862 csi-miR159c-5p; +MIMAT0048863 csi-miR159c-3p; +MIMAT0048864 csi-miR160b-5p; +MIMAT0048865 csi-miR160b-3p; +MIMAT0048866 csi-miR160c-5p; +MIMAT0048867 csi-miR160c-3p; +MIMAT0048868 csi-miR164b-5p; +MIMAT0048869 csi-miR164b-3p; +MIMAT0048870 csi-miR164c-5p; +MIMAT0048871 csi-miR164c-3p; +MIMAT0048872 csi-miR166b-5p; +MIMAT0048873 csi-miR166b-3p; +MIMAT0048874 csi-miR166d-5p; +MIMAT0048875 csi-miR166d-3p; +MIMAT0048876 csi-miR166f-5p; +MIMAT0048877 csi-miR166f-3p; +MIMAT0048878 csi-miR166g-5p; +MIMAT0048879 csi-miR166g-3p; +MIMAT0048880 csi-miR166h-3p; +MIMAT0048881 csi-miR166i-3p; +MIMAT0048882 csi-miR166j-3p; +MIMAT0048883 csi-miR166k-3p; +MIMAT0048884 csi-miR167d-5p; +MIMAT0048885 csi-miR167d-3p; +MIMAT0048886 csi-miR167e-5p; +MIMAT0048887 csi-miR167e-3p; +MIMAT0048888 csi-miR169b-5p; +MIMAT0048889 csi-miR169c-5p; +MIMAT0048890 csi-miR169c-3p; +MIMAT0048891 csi-miR169d-5p; +MIMAT0048892 csi-miR169d-3p; +MIMAT0048893 csi-miR169e-5p; +MIMAT0048894 csi-miR169e-3p; +MIMAT0048895 csi-miR169f-5p; +MIMAT0048896 csi-miR169g-5p; +MIMAT0048897 csi-miR169h-5p; +MIMAT0048898 csi-miR169i-5p; +MIMAT0048899 csi-miR169j-5p; +MIMAT0048900 csi-miR169k-5p; +MIMAT0048901 csi-miR169l-5p; +MIMAT0048902 csi-miR169l-3p; +MIMAT0048903 csi-miR169m-5p; +MIMAT0048904 csi-miR169n-5p; +MIMAT0048905 csi-miR169n-3p; +MIMAT0048906 csi-miR171c-5p; +MIMAT0048907 csi-miR171c-3p; +MIMAT0048908 csi-miR171d-3p; +MIMAT0048909 csi-miR171e-3p; +MIMAT0048910 csi-miR171f-5p; +MIMAT0048911 csi-miR171f-3p; +MIMAT0048912 csi-miR171g-3p; +MIMAT0048913 csi-miR171h-3p; +MIMAT0048914 csi-miR171i-3p; +MIMAT0048915 csi-miR172b-5p; +MIMAT0048916 csi-miR172b-3p; +MIMAT0048917 csi-miR172d-5p; +MIMAT0048918 csi-miR390b-5p; +MIMAT0048919 csi-miR393b-5p; +MIMAT0048920 csi-miR393b-3p; +MIMAT0048921 csi-miR393c-5p; +MIMAT0048922 csi-miR393c-3p; +MIMAT0048923 csi-miR394b-5p; +MIMAT0048924 csi-miR395b-5p; +MIMAT0048925 csi-miR395b-3p; +MIMAT0048926 csi-miR395c-3p; +MIMAT0048927 csi-miR396d-3p; +MIMAT0048928 csi-miR396e-5p; +MIMAT0048929 csi-miR396e-3p; +MIMAT0048930 csi-miR396f-5p; +MIMAT0048931 csi-miR396f-3p; +MIMAT0048932 csi-miR398b-3p; +MIMAT0048933 csi-miR399e-5p; +MIMAT0048934 csi-miR399e-3p; +MIMAT0048935 csi-miR399f-5p; +MIMAT0048936 csi-miR399f-3p; +MIMAT0048937 csi-miR403b-5p; +MIMAT0048938 csi-miR403b-3p; +MIMAT0048939 csi-miR477d-5p; +MIMAT0048940 csi-miR477d-3p; +MIMAT0048941 csi-miR477e-5p; +MIMAT0048942 csi-miR477e-3p; +MIMAT0048943 csi-miR482d-5p; +MIMAT0048944 csi-miR482d-3p; +MIMAT0048945 csi-miR535b-5p; +MIMAT0048946 csi-miR535b-3p; +MIMAT0048947 csi-miR535c-5p; +MIMAT0048948 csi-miR535c-3p; +MIMAT0048949 csi-miR858-3p; +MIMAT0048950 csi-miR2275a-5p; +MIMAT0048951 csi-miR2275a-3p; +MIMAT0048952 csi-miR2275b-5p; +MIMAT0048953 csi-miR2275b-3p; +MIMAT0048954 csi-miR3627a-5p; +MIMAT0048955 csi-miR3627b-3p; +MIMAT0048956 csi-miR3627c-5p; +MIMAT0048957 csi-miR391-5p; +MIMAT0048958 csi-miR391-3p; +MIMAT0048959 csi-miR1515b-5p; +MIMAT0048960 csi-miR1515b-3p; +MIMAT0048961 csi-miR3952b-5p; +MIMAT0048962 csi-miR3952b-3p; +MIMAT0048963 csi-miR3954b-5p; +MIMAT0048964 csi-miR3954b-3p; +MIMAT0048965 csi-miR12105-5p; +MIMAT0048966 csi-miR12105-3p; +MIMAT0048967 csi-miR536-5p; +MIMAT0048968 csi-miR536-3p; +MIMAT0048969 csi-miR12106-5p; +MIMAT0048970 csi-miR12106-3p; +MIMAT0048971 csi-miR12107-5p; +MIMAT0048972 csi-miR12107-3p; +MIMAT0048973 csi-miR482e-5p; +MIMAT0048974 csi-miR482e-3p; +MIMAT0048975 csi-miR12108-5p; +MIMAT0048976 csi-miR12108-3p; +MIMAT0048977 csi-miR12109-5p; +MIMAT0048978 csi-miR12109-3p; +MIMAT0048979 csi-miR9560-5p; +MIMAT0048980 csi-miR9560-3p; +MIMAT0048981 csi-miR12110-5p; +MIMAT0048982 csi-miR12110-3p; +MIMAT0048983 csi-miR12111-5p; +MIMAT0048984 csi-miR12111-3p; +MIMAT0048985 csi-miR168-5p; +MIMAT0048986 csi-miR168-3p; +MIMAT0048987 csi-miR482g-5p; +MIMAT0048988 csi-miR482g-3p; +MIMAT0048989 csi-miR156h-5p; +MIMAT0048990 csi-miR156i-5p; +MIMAT0048991 csi-miR156j-5p; +MIMAT0048992 csi-miR156j-3p; +MIMAT0048993 csi-miR164d-5p; +MIMAT0048994 csi-miR164d-3p; +MIMAT0048995 csi-miR169o-5p; +MIMAT0048996 csi-miR169p-5p; +MIMAT0048997 csi-miR169q-5p; +MIMAT0048998 csi-miR535d-5p; +MIMAT0048999 csi-miR535d-3p; +MIMAT0049000 csi-miR535e-5p; +MIMAT0049001 csi-miR535f-5p; +MIMAT0049002 csi-miR2111-5p; +MIMAT0049003 csi-miR3951b-5p; +MIMAT0049004 csi-miR3951b-3p; +MIMAT0049005 csi-miR169r-5p; +MIMAT0049006 smi-miR12112; +MIMAT0049007 hsa-miR-12113; +MIMAT0049008 hsa-miR-12114; +MIMAT0049009 hsa-miR-12115; +MIMAT0049010 hsa-miR-12116; +MIMAT0049011 hsa-miR-12117; +MIMAT0049012 hsa-miR-12118; +MIMAT0049013 hsa-miR-12119; +MIMAT0049014 hsa-miR-12120; +MIMAT0049015 hsa-miR-12121; +MIMAT0049016 hsa-miR-12122; +MIMAT0049017 hsa-miR-12123; +MIMAT0049018 hsa-miR-12124; +MIMAT0049019 hsa-miR-12125; +MIMAT0049020 hsa-miR-12126; +MIMAT0049021 hsa-miR-12127; +MIMAT0049022 hsa-miR-12128; +MIMAT0049023 hsa-miR-12129; +MIMAT0049024 hsa-miR-12130; +MIMAT0049025 hsa-miR-12131; +MIMAT0049026 hsa-miR-12132; +MIMAT0049027 hsa-miR-12133; +MIMAT0049028 cel-miR-12134; +MIMAT0049029 cel-miR-55b; +MIMAT0049030 cel-miR-58c; +MIMAT0049031 hsa-miR-12135; +MIMAT0049032 hsa-miR-12136; +MIMAT0049033 ppa-miR-410; +MIMAT0049034 ppa-miR-369; +MIMAT0049035 ppa-miR-412; +MIMAT0049036 ppa-miR-409; +MIMAT0049037 ppa-miR-485; +MIMAT0049038 ppa-miR-382; +MIMAT0049039 ppa-miR-889; +MIMAT0049040 ppa-miR-381; +MIMAT0049041 ppa-miR-654; +MIMAT0049042 ppa-miR-376c; +MIMAT0049043 ppa-miR-494; +MIMAT0049044 ppa-miR-323; +MIMAT0049045 ppa-miR-299; +MIMAT0049046 ppa-miR-411a; +MIMAT0049047 ppa-miR-379; +MIMAT0049048 ppa-miR-370; +MIMAT0049049 ppa-miR-432; +MIMAT0049050 ppa-miR-127; +MIMAT0049051 ppa-miR-665; +MIMAT0049052 ppa-miR-493; +MIMAT0049053 ppa-miR-342; +MIMAT0049054 ppa-miR-193b; +MIMAT0049055 ppa-miR-574; +MIMAT0049056 ppa-miR-615; +MIMAT0049057 ppa-miR-145; +MIMAT0049058 ppa-miR-378a; +MIMAT0049059 ppa-miR-192; +MIMAT0049060 ppa-miR-152; +MIMAT0049061 ppa-miR-1307; +MIMAT0049062 ppa-miR-146b; +MIMAT0049063 ppa-let-7i; +MIMAT0049064 ppa-miR-421; +MIMAT0049065 ppa-miR-320a; +MIMAT0049066 ppa-miR-486-2; +MIMAT0049067 ppa-miR-486; +MIMAT0049068 ppa-miR-199b; +MIMAT0049069 ppa-miR-887; +MIMAT0049070 ppa-miR-2355; +MIMAT0049071 ppa-let-7a; +MIMAT0049072 ppa-miR-151; +MIMAT0049073 ppa-miR-155; +MIMAT0049074 ppa-let-7c; +MIMAT0049075 ppa-let-7g; +MIMAT0049076 ppa-miR-26b; +MIMAT0049077 ppa-miR-629; +MIMAT0049078 ppa-miR-191; +MIMAT0049079 ppa-miR-769; +MIMAT0049080 ppa-miR-92b; +MIMAT0049081 ppa-miR-30e; +MIMAT0049082 ppa-miR-320b; +MIMAT0049083 ppa-miR-181d; +MIMAT0049084 ppa-miR-140; +MIMAT0049085 ppa-miR-424; +MIMAT0049086 ppa-miR-542; +MIMAT0049087 ppa-miR-450a; +MIMAT0049088 ppa-miR-1304; +MIMAT0049089 ppa-miR-125a; +MIMAT0049090 ppa-let-7e; +MIMAT0049091 ppa-miR-423; +MIMAT0049092 ppa-let-7b; +MIMAT0049093 ppa-miR-328; +MIMAT0049094 ppa-miR-193a; +MIMAT0049095 ppa-miR-27b; +MIMAT0049096 ppa-miR-549; +MIMAT0049097 ppa-miR-222; +MIMAT0049098 ppa-miR-148a; +MIMAT0049099 ppa-let-7f; +MIMAT0049100 ppa-miR-148b; +MIMAT0049101 ppa-miR-210; +MIMAT0049102 ppa-miR-532; +MIMAT0049103 ppa-miR-660; +MIMAT0049104 ppa-miR-34c; +MIMAT0049105 ppa-miR-484; +MIMAT0049106 ppa-miR-340; +MIMAT0049107 ptr-miR-877; +MIMAT0049108 ptr-miR-2355; +MIMAT0049109 ptr-miR-4677; +MIMAT0049110 ggo-miR-196b; +MIMAT0049111 ggo-miR-301a; +MIMAT0049112 ggo-miR-2355; +MIMAT0049113 ggo-miR-561; +MIMAT0049114 ggo-miR-369; +MIMAT0049115 ggo-miR-541; +MIMAT0049116 ggo-miR-382; +MIMAT0049117 ggo-miR-539; +MIMAT0049118 ggo-miR-758; +MIMAT0049119 ggo-miR-615; +MIMAT0049120 ggo-miR-1304; +MIMAT0049121 ggo-miR-1307; +MIMAT0049122 ggo-miR-320a-2; +MIMAT0049123 mml-miR-574; +MIMAT0049124 mml-miR-328; +MIMAT0049125 mmr-miR-615; +MIMAT0049126 mmr-miR-204; +MIMAT0049127 mmr-miR-130a; +MIMAT0049128 mmr-miR-1839; +MIMAT0049129 mmr-miR-146a; +MIMAT0049130 mmr-miR-29b; +MIMAT0049131 mmr-miR-29a; +MIMAT0049132 mmr-miR-100; +MIMAT0049133 mmr-let-7a; +MIMAT0049134 mmr-miR-125a; +MIMAT0049135 mmr-miR-218b; +MIMAT0049136 mmr-miR-1307; +MIMAT0049137 mmr-miR-708; +MIMAT0049138 mmr-miR-15a; +MIMAT0049139 mmr-miR-126; +MIMAT0049140 mmr-miR-26a; +MIMAT0049141 mmr-miR-138; +MIMAT0049142 mmr-miR-29c; +MIMAT0049143 mmr-miR-103a; +MIMAT0049144 mmr-miR-221; +MIMAT0049145 mmr-miR-26b; +MIMAT0049146 mmr-miR-28; +MIMAT0049147 mmr-miR-152; +MIMAT0049148 mmr-miR-211; +MIMAT0049149 mmr-miR-455; +MIMAT0049150 mmr-miR-320a; +MIMAT0049151 mmr-let-7g; +MIMAT0049152 mmr-miR-872; +MIMAT0049153 mmr-miR-301a; +MIMAT0049154 mmr-miR-181a; +MIMAT0049155 mmr-miR-186; +MIMAT0049156 mmr-miR-136; +MIMAT0049157 mmr-miR-188; +MIMAT0049158 mmr-miR-532; +MIMAT0049159 mmr-miR-340; +MIMAT0049160 mmr-miR-107; +MIMAT0049161 mmr-miR-6313; +MIMAT0049162 mmr-miR-1388; +MIMAT0049163 mmr-miR-98; +MIMAT0049164 mmr-miR-374a; +MIMAT0049165 mmr-miR-101; +MIMAT0049166 mmr-miR-342; +MIMAT0049167 mmr-miR-365; +MIMAT0049168 mmr-miR-193; +MIMAT0049169 mmr-miR-103b; +MIMAT0049170 mmr-miR-486; +MIMAT0049171 mmr-let-7f; +MIMAT0049172 mmr-miR-361; +MIMAT0049173 mmr-miR-497; +MIMAT0049174 mmr-miR-590; +MIMAT0049175 mmr-miR-34c; +MIMAT0049176 mmr-miR-34b; +MIMAT0049177 mmr-miR-324; +MIMAT0049178 mmr-miR-34a; +MIMAT0049179 mmr-miR-199; +MIMAT0049180 mmr-miR-502a; +MIMAT0049181 mmr-miR-660; +MIMAT0049182 mmr-miR-500; +MIMAT0049183 mmr-miR-502b; +MIMAT0049184 mmr-miR-22; +MIMAT0049185 mmr-miR-19b; +MIMAT0049186 mmr-miR-92b; +MIMAT0049187 mmr-let-7b; +MIMAT0049188 mmr-miR-187; +MIMAT0049189 mmr-miR-410; +MIMAT0049190 mmr-miR-409; +MIMAT0049191 mmr-miR-3959; +MIMAT0049192 mmr-miR-381; +MIMAT0049193 mmr-miR-411b; +MIMAT0049194 mmr-miR-411a; +MIMAT0049195 mmr-miR-92a; +MIMAT0049196 mmr-miR-20; +MIMAT0049197 mmr-miR-18; +MIMAT0049198 mmr-miR-17; +MIMAT0049199 mmr-miR-21; +MIMAT0049200 mmr-miR-146b; +MIMAT0049201 mmr-let-7c; +MIMAT0049202 mmr-miR-99a; +MIMAT0049203 mmr-miR-140; +MIMAT0049204 mmr-miR-328; +MIMAT0049205 mmr-miR-212; +MIMAT0049206 mmr-miR-10; +MIMAT0049207 mmr-miR-222; +MIMAT0049208 mmr-miR-145; +MIMAT0049209 mmr-miR-148b; +MIMAT0049210 mmr-miR-214; +MIMAT0049211 mmr-miR-10a; +MIMAT0049212 mmr-miR-425; +MIMAT0049213 mmr-miR-191; +MIMAT0049214 mmr-miR-31; +MIMAT0049215 mmr-miR-218a; +MIMAT0049216 mmr-miR-182; +MIMAT0049217 mmr-miR-30a; +MIMAT0049218 mmr-miR-30c; +MIMAT0049219 mmr-miR-128; +MIMAT0049220 mmr-miR-30e; +MIMAT0049221 mmr-miR-151; +MIMAT0049222 mmr-miR-196b; +MIMAT0049223 mmr-miR-424; +MIMAT0049224 mmr-miR-542; +MIMAT0049225 mmr-miR-296; +MIMAT0049226 mmr-miR-24; +MIMAT0049227 mmr-miR-27b; +MIMAT0049228 mmr-miR-23b; +MIMAT0049229 mmr-miR-132; +MIMAT0049230 mmr-miR-484; +MIMAT0049231 mmr-miR-197; +MIMAT0049232 mmr-miR-345; +MIMAT0049233 mmr-miR-195; +MIMAT0049234 dma-miR-1388; +MIMAT0049235 dma-let-7a; +MIMAT0049236 dma-miR-140; +MIMAT0049237 dma-miR-193; +MIMAT0049238 dma-miR-26b; +MIMAT0049239 dma-miR-532; +MIMAT0049240 dma-miR-10a; +MIMAT0049241 dma-miR-30c; +MIMAT0049242 dma-miR-409; +MIMAT0049243 dma-miR-877; +MIMAT0049244 dma-miR-340; +MIMAT0049245 dma-miR-92a; +MIMAT0049246 dma-miR-19b; +MIMAT0049247 dma-miR-432; +MIMAT0049248 dma-miR-127; +MIMAT0049249 dma-miR-22; +MIMAT0049250 dma-miR-196; +MIMAT0049251 dma-let-7f; +MIMAT0049252 dma-miR-100; +MIMAT0049253 dma-miR-130a; +MIMAT0049254 dma-miR-125b; +MIMAT0049255 dma-miR-143; +MIMAT0049256 dma-miR-145; +MIMAT0049257 dma-miR-28; +MIMAT0049258 dma-let-7b; +MIMAT0049259 dma-miR-103a; +MIMAT0049260 dma-miR-1307; +MIMAT0049261 dma-miR-101; +MIMAT0049262 dma-miR-708; +MIMAT0049263 dma-miR-30a; +MIMAT0049264 dma-miR-26a; +MIMAT0049265 dma-miR-107; +MIMAT0049266 dma-miR-181a; +MIMAT0049267 dma-miR-181b; +MIMAT0049268 dma-miR-660; +MIMAT0049269 dma-miR-502b; +MIMAT0049270 dma-miR-31; +MIMAT0049271 dma-miR-186; +MIMAT0049272 dma-miR-214; +MIMAT0049273 dma-miR-199; +MIMAT0049274 dma-let-7c; +MIMAT0049275 dma-miR-103b; +MIMAT0049276 dma-miR-16; +MIMAT0049277 dma-miR-222; +MIMAT0049278 dma-miR-221; +MIMAT0049279 dma-miR-23b; +MIMAT0049280 dma-miR-27b; +MIMAT0049281 dma-miR-24; +MIMAT0049282 dma-miR-30e; +MIMAT0049283 dma-miR-381; +MIMAT0049284 dma-miR-25; +MIMAT0049285 dma-miR-93; +MIMAT0049286 dma-miR-106b; +MIMAT0049287 dma-miR-29a; +MIMAT0049288 dma-miR-296; +MIMAT0049289 dma-miR-6529; +MIMAT0049290 dma-let-7g; +MIMAT0049291 dma-miR-21; +MIMAT0049292 dma-miR-98; +MIMAT0049293 dma-miR-151; +MIMAT0049294 dma-miR-148b; +MIMAT0049295 dma-miR-191; +MIMAT0049296 dma-miR-181c; +MIMAT0049297 dma-miR-10; +MIMAT0049298 dma-miR-423; +MIMAT0049299 dma-miR-339; +MIMAT0049300 dma-miR-125a; +MIMAT0049301 cja-miR-450c; +MIMAT0049302 cja-miR-98; +MIMAT0049303 cja-miR-502b; +MIMAT0049304 cja-miR-331; +MIMAT0049305 cja-let-7i; +MIMAT0049306 cja-miR-29a; +MIMAT0049307 cja-miR-301a; +MIMAT0049308 cja-miR-22; +MIMAT0049309 cja-miR-30c; +MIMAT0049310 cja-miR-23a; +MIMAT0049311 cja-miR-125a; +MIMAT0049312 cja-let-7e; +MIMAT0049313 cja-miR-125b; +MIMAT0049314 cja-let-7c; +MIMAT0049315 cja-miR-340; +MIMAT0049316 cja-miR-378; +MIMAT0049317 cja-miR-25; +MIMAT0049318 cja-miR-106b; +MIMAT0049319 cja-miR-28; +MIMAT0049320 cja-miR-484; +MIMAT0049321 cja-miR-1307; +MIMAT0049322 cja-miR-100; +MIMAT0049323 cja-miR-130a; +MIMAT0049324 cja-miR-409; +MIMAT0049325 cja-miR-889; +MIMAT0049326 cja-miR-432; +MIMAT0049327 cja-let-7d; +MIMAT0049328 cja-let-7f; +MIMAT0049329 cja-miR-19a; +MIMAT0049330 cja-miR-873; +MIMAT0049331 cja-miR-101-2; +MIMAT0049332 ppy-miR-3136; +MIMAT0049333 ppy-miR-6529; +MIMAT0049334 ppy-miR-2355; +MIMAT0049335 ppy-miR-301a; +MIMAT0049336 nle-miR-324; +MIMAT0049337 nle-miR-153; +MIMAT0049338 nle-miR-484; +MIMAT0049339 nle-miR-210; +MIMAT0049340 nle-miR-5699; +MIMAT0049341 nle-miR-365; +MIMAT0049342 nle-miR-126; +MIMAT0049343 nle-miR-340; +MIMAT0049344 nle-miR-2467; +MIMAT0049345 nle-miR-149; +MIMAT0049346 nle-miR-10a; +MIMAT0049347 nle-miR-152; +MIMAT0049348 nle-let-7a; +MIMAT0049349 nle-miR-21; +MIMAT0049350 nle-miR-106b; +MIMAT0049351 nle-miR-93; +MIMAT0049352 nle-miR-25; +MIMAT0049353 nle-miR-212; +MIMAT0049354 nle-miR-132; +MIMAT0049355 nle-miR-22; +MIMAT0049356 nle-miR-769; +MIMAT0049357 nle-miR-4714; +MIMAT0049358 nle-miR-423; +MIMAT0049359 nle-miR-3925; +MIMAT0049360 nle-miR-502a; +MIMAT0049361 nle-miR-660; +MIMAT0049362 nle-miR-501; +MIMAT0049363 nle-miR-502b; +MIMAT0049364 nle-miR-532; +MIMAT0049365 nle-miR-151; +MIMAT0049366 nle-miR-98; +MIMAT0049367 nle-miR-30d; +MIMAT0049368 nle-miR-30b; +MIMAT0049369 nle-miR-410; +MIMAT0049370 nle-miR-409; +MIMAT0049371 nle-miR-381; +MIMAT0049372 nle-miR-136; +MIMAT0049373 nle-miR-127; +MIMAT0049374 nle-miR-24; +MIMAT0049375 nle-miR-199a; +MIMAT0049376 nle-miR-181c; +MIMAT0049377 nle-miR-549; +MIMAT0049378 nle-miR-345; +MIMAT0049379 nle-miR-130a; +MIMAT0049380 nle-miR-320b; +MIMAT0049381 nle-miR-497; +MIMAT0049382 nle-miR-195; +MIMAT0049383 nle-miR-34a; +MIMAT0049384 nle-miR-192; +MIMAT0049385 nle-miR-101; +MIMAT0049386 nle-miR-30e; +MIMAT0049387 nle-miR-29b; +MIMAT0049388 nle-miR-29c; +MIMAT0049389 nle-miR-320a; +MIMAT0049390 nle-miR-505; +MIMAT0049391 nle-miR-424; +MIMAT0049392 nle-miR-542; +MIMAT0049393 nle-miR-450a; +MIMAT0049394 nle-miR-450b; +MIMAT0049395 nle-miR-19b; +MIMAT0049396 nle-miR-92a; +MIMAT0049397 nle-miR-301a; +MIMAT0049398 nle-miR-454; +MIMAT0049399 nle-miR-877; +MIMAT0049400 nle-miR-224; +MIMAT0049401 nle-miR-30a; +MIMAT0049402 nle-miR-30c; +MIMAT0049403 nle-miR-222; +MIMAT0049404 nle-miR-221; +MIMAT0049405 nle-miR-671; +MIMAT0049406 nle-miR-196b; +MIMAT0049407 nle-miR-148a; +MIMAT0049408 nle-miR-15a; +MIMAT0049409 nle-miR-16; +MIMAT0049410 nle-miR-125a; +MIMAT0049411 nle-let-7e; +MIMAT0049412 nle-miR-193b; +MIMAT0049413 nle-miR-361; +MIMAT0049414 nle-miR-374a; +MIMAT0049415 nle-miR-421; +MIMAT0049416 nle-miR-218; +MIMAT0049417 nle-miR-103a; +MIMAT0049418 nle-miR-146a; +MIMAT0049419 nle-miR-378d; +MIMAT0049420 nle-miR-942; +MIMAT0049421 nle-miR-128; +MIMAT0049422 nle-miR-7180; +MIMAT0049423 nle-miR-190; +MIMAT0049424 nle-miR-628; +MIMAT0049425 nle-miR-378a; +MIMAT0049426 nle-miR-145; +MIMAT0049427 nle-miR-143; +MIMAT0049428 nle-miR-582; +MIMAT0049429 nle-miR-181a; +MIMAT0049430 nle-miR-181b; +MIMAT0049431 nle-miR-199b; +MIMAT0049432 nle-miR-455; +MIMAT0049433 nle-miR-155; +MIMAT0049434 nle-miR-125b; +MIMAT0049435 nle-let-7c; +MIMAT0049436 nle-miR-99a; +MIMAT0049437 nle-miR-887; +MIMAT0049438 nle-miR-140; +MIMAT0049439 nle-miR-138; +MIMAT0049440 nle-miR-320c; +MIMAT0049441 nle-miR-29a; +MIMAT0049442 nle-miR-182; +MIMAT0049443 nle-miR-4670; +MIMAT0049444 nle-miR-31; +MIMAT0049445 nle-miR-27b; +MIMAT0049446 nle-miR-23b; +MIMAT0049447 nle-let-7f; +MIMAT0049448 nle-miR-186; +MIMAT0049449 nle-miR-331; +MIMAT0049450 nle-miR-214; +MIMAT0049451 nle-miR-92b; +MIMAT0049452 nle-miR-1296; +MIMAT0049453 nle-miR-20; +MIMAT0049454 nle-miR-19a; +MIMAT0049455 nle-miR-17; +MIMAT0049456 nle-let-7g; +MIMAT0049457 nle-miR-191; +MIMAT0049458 nle-miR-26a; +MIMAT0049459 nle-miR-28; +MIMAT0049460 nle-miR-15b; +MIMAT0049461 nle-miR-1307; +MIMAT0049462 nle-miR-107; +MIMAT0049463 nle-miR-146b; +MIMAT0049464 nle-miR-561; +MIMAT0049465 nle-miR-10b; +MIMAT0049466 nle-miR-100; +MIMAT0049467 nle-miR-34c; +MIMAT0049468 nle-miR-1260b; +MIMAT0049469 nle-miR-148b; +MIMAT0049470 nle-let-7i; +MIMAT0049471 sbo-let-7e; +MIMAT0049472 sbo-miR-125a; +MIMAT0049473 sbo-miR-486b; +MIMAT0049474 sbo-miR-16; +MIMAT0049475 sbo-miR-151; +MIMAT0049476 sbo-miR-199; +MIMAT0049477 sbo-miR-24; +MIMAT0049478 sbo-miR-27a; +MIMAT0049479 sbo-miR-127; +MIMAT0049480 sbo-miR-181a; +MIMAT0049481 sbo-miR-221; +MIMAT0049482 sbo-let-7f; +MIMAT0049483 sbo-miR-27b; +MIMAT0049484 sbo-miR-191; +MIMAT0049485 sbo-miR-6529; +MIMAT0049486 sbo-miR-148a; +MIMAT0049487 sbo-miR-125b; +MIMAT0049488 sbo-miR-99a; +MIMAT0049489 sbo-miR-143; +MIMAT0049490 sbo-let-7b; +MIMAT0049491 sbo-miR-10a; +MIMAT0049492 sbo-miR-423; +MIMAT0049493 sbo-miR-424; +MIMAT0049494 sbo-miR-92a; +MIMAT0049495 sbo-miR-26a; +MIMAT0049496 sbo-miR-22; +MIMAT0049497 sbo-miR-21; +MIMAT0049498 sbo-miR-28; +MIMAT0049499 sbo-miR-214; +MIMAT0049500 sbo-let-7a; +MIMAT0049501 sbo-miR-100; +MIMAT0049502 sbo-miR-146b; +MIMAT0049503 sbo-miR-10b; +MIMAT0049504 sbo-miR-186; +MIMAT0049505 sbo-miR-29a; +MIMAT0049506 sbo-miR-486a; +MIMAT0049507 pha-let-7a; +MIMAT0049508 pha-let-7b; +MIMAT0049509 pha-miR-103b; +MIMAT0049510 pha-miR-769; +MIMAT0049511 pha-miR-361; +MIMAT0049512 pha-miR-423; +MIMAT0049513 pha-miR-145; +MIMAT0049514 pha-miR-143; +MIMAT0049515 pha-miR-186; +MIMAT0049516 pha-let-7e; +MIMAT0049517 pha-miR-125a; +MIMAT0049518 pha-miR-193a; +MIMAT0049519 pha-miR-181b; +MIMAT0049520 pha-miR-181a; +MIMAT0049521 pha-miR-125b; +MIMAT0049522 pha-miR-100; +MIMAT0049523 pha-miR-101; +MIMAT0049524 pha-miR-24; +MIMAT0049525 pha-miR-27b; +MIMAT0049526 pha-miR-23b; +MIMAT0049527 pha-miR-152; +MIMAT0049528 pha-miR-320b; +MIMAT0049529 pha-miR-199; +MIMAT0049530 pha-miR-130a; +MIMAT0049531 pha-miR-31; +MIMAT0049532 pha-miR-378; +MIMAT0049533 pha-miR-23a; +MIMAT0049534 pha-miR-27a; +MIMAT0049535 pha-miR-181c; +MIMAT0049536 pha-miR-29a; +MIMAT0049537 pha-miR-92a; +MIMAT0049538 pha-miR-19b; +MIMAT0049539 pha-miR-30d; +MIMAT0049540 pha-miR-10a; +MIMAT0049541 pha-miR-196a; +MIMAT0049542 pha-miR-148a; +MIMAT0049543 pha-miR-107; +MIMAT0049544 pha-miR-660; +MIMAT0049545 pha-miR-582; +MIMAT0049546 pha-miR-877; +MIMAT0049547 pha-miR-1307; +MIMAT0049548 pha-miR-26a; +MIMAT0049549 pha-miR-30e; +MIMAT0049550 pha-miR-130b; +MIMAT0049551 pha-miR-106b; +MIMAT0049552 pha-miR-93; +MIMAT0049553 pha-miR-25; +MIMAT0049554 pha-miR-26b; +MIMAT0049555 pha-miR-16; +MIMAT0049556 pha-miR-340; +MIMAT0049557 pha-miR-148b; +MIMAT0049558 pha-miR-155; +MIMAT0049559 pha-miR-221; +MIMAT0049560 pha-miR-222; +MIMAT0049561 pha-miR-151; +MIMAT0049562 pha-miR-132; +MIMAT0049563 pha-let-7f; +MIMAT0049564 pha-miR-502b; +MIMAT0049565 pha-miR-532; +MIMAT0049566 pha-miR-191; +MIMAT0049567 pha-miR-193b; +MIMAT0049568 pha-miR-21; +MIMAT0049569 pha-miR-98; +MIMAT0049570 pha-miR-146b; +MIMAT0049571 pha-let-7i; +MIMAT0049572 pha-miR-708; +MIMAT0049573 pha-miR-146a; +MIMAT0049574 pha-let-7g; +MIMAT0049575 pha-miR-210; +MIMAT0049576 pha-miR-409; +MIMAT0049577 pha-miR-381; +MIMAT0049578 pha-miR-299; +MIMAT0049579 pha-miR-411a; +MIMAT0049580 pha-miR-127; +MIMAT0049581 pha-miR-214; +MIMAT0049582 pha-miR-30a; +MIMAT0049583 pha-miR-30c; +MIMAT0049584 pha-miR-760; +MIMAT0049585 pha-miR-103a; +MIMAT0049586 pha-miR-22; +MIMAT0049587 pha-miR-320a; +MIMAT0049588 pha-miR-887; +MIMAT0049589 pha-let-7c; +MIMAT0049590 pha-miR-99a; +MIMAT0049591 pha-miR-140; +MIMAT0049592 pha-miR-10b; +MIMAT0049593 oga-miR-301a; +MIMAT0049594 oga-miR-21; +MIMAT0049595 oga-miR-760; +MIMAT0049596 oga-miR-197; +MIMAT0049597 oga-miR-101; +MIMAT0049598 oga-miR-186; +MIMAT0049599 oga-miR-6529; +MIMAT0049600 oga-let-7f; +MIMAT0049601 oga-miR-34c; +MIMAT0049602 oga-miR-34b; +MIMAT0049603 oga-miR-138; +MIMAT0049604 oga-miR-99a; +MIMAT0049605 oga-let-7c; +MIMAT0049606 oga-miR-125b; +MIMAT0049607 oga-miR-155; +MIMAT0049608 oga-miR-128; +MIMAT0049609 oga-miR-16; +MIMAT0049610 oga-miR-15b; +MIMAT0049611 oga-miR-320a; +MIMAT0049612 oga-miR-107; +MIMAT0049613 oga-miR-1296; +MIMAT0049614 oga-miR-218a; +MIMAT0049615 oga-miR-34a; +MIMAT0049616 oga-miR-30b; +MIMAT0049617 oga-miR-30d; +MIMAT0049618 oga-miR-151; +MIMAT0049619 oga-let-7a; +MIMAT0049620 oga-let-7b; +MIMAT0049621 oga-miR-28a; +MIMAT0049622 oga-miR-181b; +MIMAT0049623 oga-miR-181a; +MIMAT0049624 oga-miR-29b; +MIMAT0049625 oga-miR-23b; +MIMAT0049626 oga-miR-27b; +MIMAT0049627 oga-miR-24; +MIMAT0049628 oga-miR-872; +MIMAT0049629 oga-miR-31; +MIMAT0049630 oga-miR-29a; +MIMAT0049631 oga-miR-10; +MIMAT0049632 oga-miR-140; +MIMAT0049633 oga-miR-195; +MIMAT0049634 oga-miR-497; +MIMAT0049635 oga-miR-26a; +MIMAT0049636 oga-miR-148b; +MIMAT0049637 oga-miR-615; +MIMAT0049638 oga-miR-196; +MIMAT0049639 oga-miR-582; +MIMAT0049640 oga-miR-374a; +MIMAT0049641 oga-miR-421; +MIMAT0049642 oga-miR-30a; +MIMAT0049643 oga-miR-30c; +MIMAT0049644 oga-miR-92a; +MIMAT0049645 oga-miR-19b; +MIMAT0049646 oga-miR-19a; +MIMAT0049647 oga-miR-18; +MIMAT0049648 oga-miR-17; +MIMAT0049649 oga-let-7g; +MIMAT0049650 oga-miR-182; +MIMAT0049651 oga-miR-125a; +MIMAT0049652 oga-let-7e; +MIMAT0049653 oga-miR-99b; +MIMAT0049654 oga-miR-98; +MIMAT0049655 oga-miR-196b; +MIMAT0049656 oga-miR-148a; +MIMAT0049657 oga-miR-222; +MIMAT0049658 oga-miR-221; +MIMAT0049659 oga-miR-28b; +MIMAT0049660 oga-miR-210; +MIMAT0049661 oga-miR-365; +MIMAT0049662 oga-miR-193b; +MIMAT0049663 oga-miR-103b; +MIMAT0049664 oga-miR-1388; +MIMAT0049665 oga-miR-185; +MIMAT0049666 oga-miR-130a; +MIMAT0049667 oga-miR-143; +MIMAT0049668 oga-miR-145; +MIMAT0049669 oga-miR-378; +MIMAT0049670 oga-miR-103a; +MIMAT0049671 oga-miR-486; +MIMAT0049672 oga-miR-1247; +MIMAT0049673 oga-miR-410; +MIMAT0049674 oga-miR-409; +MIMAT0049675 oga-miR-381; +MIMAT0049676 oga-miR-411a; +MIMAT0049677 oga-miR-136; +MIMAT0049678 oga-miR-127; +MIMAT0049679 oga-miR-493; +MIMAT0049680 oga-miR-342; +MIMAT0049681 oga-miR-224; +MIMAT0049682 oga-miR-361; +MIMAT0049683 oga-miR-15a; +MIMAT0049684 oga-miR-574; +MIMAT0049685 oga-miR-191; +MIMAT0049686 oga-miR-196a; +MIMAT0049687 oga-miR-10a; +MIMAT0049688 oga-miR-152; +MIMAT0049689 oga-miR-660; +MIMAT0049690 oga-miR-500; +MIMAT0049691 oga-miR-502b; +MIMAT0049692 oga-miR-532; +MIMAT0049693 oga-miR-330; +MIMAT0049694 oga-miR-214; +MIMAT0049695 oga-miR-199; +MIMAT0049696 oga-miR-340; +MIMAT0049697 oga-miR-22; +MIMAT0049698 oga-miR-132; +MIMAT0049699 oga-miR-212; +MIMAT0049700 oga-miR-30e; +MIMAT0049701 oga-miR-25; +MIMAT0049702 oga-miR-93; +MIMAT0049703 oga-miR-106b; +MIMAT0049704 oga-miR-192; +MIMAT0049705 oga-let-7i; +MIMAT0049706 oga-miR-149; +MIMAT0049707 oga-miR-181e; +MIMAT0049708 oga-miR-455; +MIMAT0049709 oga-miR-181c; +MIMAT0049710 oga-miR-181d; +MIMAT0049711 oga-miR-27a; +MIMAT0049712 oga-miR-23a; +MIMAT0049713 oga-miR-26b; +MIMAT0049714 oga-miR-505; +MIMAT0049715 oga-miR-423; +MIMAT0049716 oga-miR-193a; +MIMAT0049717 oga-miR-100; +MIMAT0049718 oga-miR-184; +MIMAT0049719 oga-miR-190; +MIMAT0049720 aof-miR12137; +MIMAT0049721 aof-miR12138; +MIMAT0049722 aof-miR12139; +MIMAT0049723 aof-miR12140; +MIMAT0049724 aof-miR12141; +MIMAT0049725 aof-miR12142; +MIMAT0049726 aof-miR12143; +MIMAT0049727 aof-miR12144; +MIMAT0049728 aof-miR12145; +MIMAT0049729 aof-miR12146; +MIMAT0049730 aof-miR12147; +MIMAT0049731 aof-miR12148; +MIMAT0049732 aof-miR12149; +MIMAT0049733 aof-miR12150; +MIMAT0049734 aof-miR12151; +MIMAT0049735 aof-miR12152; +MIMAT0049736 aof-miR12153; +MIMAT0049737 aof-miR12154; +MIMAT0049738 aof-miR12155; +MIMAT0049739 aof-miR12156; +MIMAT0049740 aof-miR12157; +MIMAT0049741 aof-miR12158; +MIMAT0049742 aof-miR12159; +MIMAT0049743 aof-miR12160; +MIMAT0049744 aof-miR12161; +MIMAT0049745 aof-miR12162; +MIMAT0049746 aof-miR12163; +MIMAT0049747 aof-miR2275d; +MIMAT0049748 aof-miR482c; +MIMAT0049749 aof-miR12164; +MIMAT0049750 aof-miR12165; +MIMAT0049751 aof-miR12166; +MIMAT0049752 aof-miR12167; +MIMAT0049753 aof-miR12168; +MIMAT0049754 aof-miR12169; +MIMAT0049755 aof-miR12170; +MIMAT0049756 aof-miR12171; +MIMAT0049757 aof-miR12172; +MIMAT0049758 aof-miR477b; +MIMAT0049759 aof-miR12173; +MIMAT0049760 aof-miR399c; +MIMAT0049761 aof-miR12174; +MIMAT0049762 aof-miR12175; +MIMAT0049763 aof-miR12176; +MIMAT0049764 aof-miR12177; +MIMAT0049765 aof-miR156a; +MIMAT0049766 aof-miR156b; +MIMAT0049767 aof-miR156c; +MIMAT0049768 aof-miR159; +MIMAT0049769 aof-miR160a; +MIMAT0049770 aof-miR160b; +MIMAT0049771 aof-miR160c; +MIMAT0049772 aof-miR164; +MIMAT0049773 aof-miR166a; +MIMAT0049774 aof-miR166b; +MIMAT0049775 aof-miR166c; +MIMAT0049776 aof-miR166d; +MIMAT0049777 aof-miR167a; +MIMAT0049778 aof-miR167b; +MIMAT0049779 aof-miR167c; +MIMAT0049780 aof-miR168a; +MIMAT0049781 aof-miR168b; +MIMAT0049782 aof-miR169a; +MIMAT0049783 aof-miR169b; +MIMAT0049784 aof-miR169c; +MIMAT0049785 aof-miR171a; +MIMAT0049786 aof-miR171b; +MIMAT0049787 aof-miR171c; +MIMAT0049788 aof-miR172; +MIMAT0049789 aof-miR2118b; +MIMAT0049790 aof-miR2118c; +MIMAT0049791 aof-miR2118a; +MIMAT0049792 aof-miR2275a; +MIMAT0049793 aof-miR2275b; +MIMAT0049794 aof-miR2275c; +MIMAT0049795 aof-miR319a; +MIMAT0049796 aof-miR319b; +MIMAT0049797 aof-miR390; +MIMAT0049798 aof-miR393a; +MIMAT0049799 aof-miR393b; +MIMAT0049800 aof-miR394; +MIMAT0049801 aof-miR395a; +MIMAT0049802 aof-miR395b; +MIMAT0049803 aof-miR396a; +MIMAT0049804 aof-miR396b; +MIMAT0049805 aof-miR398; +MIMAT0049806 aof-miR399a; +MIMAT0049807 aof-miR399b; +MIMAT0049808 aof-miR408; +MIMAT0049809 aof-miR391; +MIMAT0049810 aof-miR477a; +MIMAT0049811 aof-miR479; +MIMAT0049812 aof-miR482a; +MIMAT0049813 aof-miR482b; +MIMAT0049814 aof-miR5139a; +MIMAT0049815 aof-miR535; +MIMAT0049816 aof-miR536; +MIMAT0049817 aof-miR8155; +MIMAT0049818 aof-miR5139b; +MIMAT0049819 aof-miR827; +MIMAT0049820 aof-miR828; +MIMAT0049821 mmu-miR-5104b-5p; +MIMAT0049822 mmu-miR-12178-5p; +MIMAT0049823 mmu-miR-12178-3p; +MIMAT0049824 mmu-miR-12179-5p; +MIMAT0049825 mmu-miR-12180-3p; +MIMAT0049826 mmu-miR-12181-5p; +MIMAT0049827 mmu-miR-12181-3p; +MIMAT0049828 mmu-miR-12182-5p; +MIMAT0049829 mmu-miR-12182-3p; +MIMAT0049830 mmu-miR-12183-5p; +MIMAT0049831 mmu-miR-203b-5p; +MIMAT0049832 mmu-miR-203b-3p; +MIMAT0049833 mmu-miR-12184-5p; +MIMAT0049834 mmu-miR-12184-3p; +MIMAT0049835 mmu-miR-9b-5p; +MIMAT0049836 mmu-miR-9b-3p; +MIMAT0049837 mmu-miR-12185-5p; +MIMAT0049838 mmu-miR-12185-3p; +MIMAT0049839 mmu-miR-12186-5p; +MIMAT0049840 mmu-miR-12186-3p; +MIMAT0049841 mmu-miR-12187-5p; +MIMAT0049842 mmu-miR-12187-3p; +MIMAT0049843 mmu-miR-1970b-5p; +MIMAT0049844 mmu-miR-12188-5p; +MIMAT0049845 mmu-miR-12188-3p; +MIMAT0049846 mmu-miR-3083b-5p; +MIMAT0049847 mmu-miR-3083b-3p; +MIMAT0049848 mmu-miR-12189-3p; +MIMAT0049849 mmu-miR-12190-3p; +MIMAT0049850 mmu-miR-12191-5p; +MIMAT0049851 mmu-miR-12191-3p; +MIMAT0049852 mmu-miR-122b-5p; +MIMAT0049853 mmu-miR-122b-3p; +MIMAT0049854 mmu-miR-12192-5p; +MIMAT0049855 mmu-miR-12193-5p; +MIMAT0049856 mmu-miR-12193-3p; +MIMAT0049857 mmu-miR-124b-3p; +MIMAT0049858 mmu-miR-12194-3p; +MIMAT0049859 mmu-miR-12195-5p; +MIMAT0049860 mmu-miR-12195-3p; +MIMAT0049861 mmu-miR-3473h-5p; +MIMAT0049862 mmu-miR-12196-5p; +MIMAT0049863 mmu-miR-12196-3p; +MIMAT0049864 mmu-miR-12197-3p; +MIMAT0049865 mmu-miR-12198-3p; +MIMAT0049866 mmu-miR-12199-3p; +MIMAT0049867 mmu-miR-12200-5p; +MIMAT0049868 mmu-miR-12200-3p; +MIMAT0049869 mmu-miR-12201-5p; +MIMAT0049870 mmu-miR-12201-3p; +MIMAT0049871 mmu-miR-12202-5p; +MIMAT0049872 mmu-miR-12202-3p; +MIMAT0049873 mmu-miR-12203-5p; +MIMAT0049874 mmu-miR-12203-3p; +MIMAT0049875 mmu-miR-12204-5p; +MIMAT0049876 mmu-miR-1970c-5p; +MIMAT0049877 mmu-miR-1970c-3p; +MIMAT0049878 mmu-miR-12205-5p; +MIMAT0049879 mmu-miR-12205-3p; +MIMAT0049880 mmu-miR-12206-5p; +MIMAT0049881 gga-miR-12207-5p; +MIMAT0049882 gga-miR-12207-3p; +MIMAT0049883 gga-miR-12208-5p; +MIMAT0049884 gga-miR-12208-3p; +MIMAT0049885 gga-miR-12209-5p; +MIMAT0049886 gga-miR-12209-3p; +MIMAT0049887 gga-miR-12210-5p; +MIMAT0049888 gga-miR-12210-3p; +MIMAT0049889 gga-miR-12211-5p; +MIMAT0049890 gga-miR-12211-3p; +MIMAT0049891 gga-miR-12212-5p; +MIMAT0049892 gga-miR-12213-5p; +MIMAT0049893 gga-miR-12213-3p; +MIMAT0049894 gga-miR-2984-5p; +MIMAT0049895 gga-miR-2984-3p; +MIMAT0049896 gga-miR-12214-5p; +MIMAT0049897 gga-miR-12214-3p; +MIMAT0049898 gga-miR-2985-5p; +MIMAT0049899 gga-miR-2985-3p; +MIMAT0049900 gga-miR-12215-5p; +MIMAT0049901 gga-miR-12216-5p; +MIMAT0049902 gga-miR-12216-3p; +MIMAT0049903 gga-miR-9b-5p; +MIMAT0049904 gga-miR-9b-3p; +MIMAT0049905 gga-miR-12217-3p; +MIMAT0049906 gga-miR-184b-5p; +MIMAT0049907 gga-miR-184b-3p; +MIMAT0049908 gga-miR-12218-5p; +MIMAT0049909 gga-miR-12218-3p; +MIMAT0049910 gga-miR-12219-5p; +MIMAT0049911 gga-miR-12219-3p; +MIMAT0049912 gga-miR-12220-5p; +MIMAT0049913 gga-miR-12220-3p; +MIMAT0049914 gga-miR-12221-5p; +MIMAT0049915 gga-miR-12221-3p; +MIMAT0049916 gga-miR-12221-2-3p; +MIMAT0049917 gga-miR-191-5p; +MIMAT0049918 gga-miR-191-3p; +MIMAT0049919 gga-miR-425-5p; +MIMAT0049920 gga-miR-425-3p; +MIMAT0049921 gga-miR-12222-5p; +MIMAT0049922 gga-miR-12222-3p; +MIMAT0049923 gga-miR-12223-5p; +MIMAT0049924 gga-miR-12223-3p; +MIMAT0049925 gga-miR-12224-5p; +MIMAT0049926 gga-miR-12224-3p; +MIMAT0049927 gga-miR-12225-5p; +MIMAT0049928 gga-miR-12225-3p; +MIMAT0049929 gga-miR-12226-5p; +MIMAT0049930 gga-miR-12226-3p; +MIMAT0049931 gga-miR-12227-5p; +MIMAT0049932 gga-miR-12227-3p; +MIMAT0049933 gga-miR-12228-5p; +MIMAT0049934 gga-miR-12228-3p; +MIMAT0049935 gga-miR-12229-5p; +MIMAT0049936 gga-miR-12229-3p; +MIMAT0049937 gga-miR-12230-5p; +MIMAT0049938 gga-miR-12231-5p; +MIMAT0049939 gga-miR-12231-3p; +MIMAT0049940 gga-miR-12232-5p; +MIMAT0049941 gga-miR-12232-3p; +MIMAT0049942 gga-miR-12233-5p; +MIMAT0049943 gga-miR-12233-3p; +MIMAT0049944 gga-miR-12234-5p; +MIMAT0049945 gga-miR-12234-3p; +MIMAT0049946 gga-miR-2184b-5p; +MIMAT0049947 gga-miR-2184b-3p; +MIMAT0049948 gga-miR-2184a-5p; +MIMAT0049949 gga-miR-2184a-3p; +MIMAT0049950 gga-miR-132a-5p; +MIMAT0049951 gga-miR-132a-3p; +MIMAT0049952 gga-miR-132b-5p; +MIMAT0049953 gga-miR-132b-3p; +MIMAT0049954 gga-miR-212-5p; +MIMAT0049955 gga-miR-212-3p; +MIMAT0049956 gga-miR-132c-5p; +MIMAT0049957 gga-miR-132c-3p; +MIMAT0049958 gga-miR-12235-5p; +MIMAT0049959 gga-miR-12235-3p; +MIMAT0049960 gga-miR-12236-5p; +MIMAT0049961 gga-miR-12236-3p; +MIMAT0049962 gga-miR-12237-5p; +MIMAT0049963 gga-miR-12237-3p; +MIMAT0049964 gga-miR-10585-5p; +MIMAT0049965 gga-miR-10585-3p; +MIMAT0049966 gga-miR-12238-3p; +MIMAT0049967 gga-miR-12239-5p; +MIMAT0049968 gga-miR-12239-3p; +MIMAT0049969 gga-miR-12240-5p; +MIMAT0049970 gga-miR-12240-3p; +MIMAT0049971 gga-miR-12241-3p; +MIMAT0049972 gga-miR-12242-5p; +MIMAT0049973 gga-miR-12242-3p; +MIMAT0049974 gga-miR-1388b-5p; +MIMAT0049975 gga-miR-1388b-3p; +MIMAT0049976 gga-miR-12243-5p; +MIMAT0049977 gga-miR-12243-3p; +MIMAT0049978 gga-miR-12244-5p; +MIMAT0049979 gga-miR-12245-5p; +MIMAT0049980 gga-miR-12245-3p; +MIMAT0049981 gga-miR-12246-5p; +MIMAT0049982 gga-miR-12246-3p; +MIMAT0049983 gga-miR-12247-5p; +MIMAT0049984 gga-miR-12247-3p; +MIMAT0049985 gga-miR-12248-5p; +MIMAT0049986 gga-miR-12248-3p; +MIMAT0049987 gga-miR-12249-5p; +MIMAT0049988 gga-miR-12249-3p; +MIMAT0049989 gga-miR-12250-5p; +MIMAT0049990 gga-miR-12250-3p; +MIMAT0049991 gga-miR-12251-5p; +MIMAT0049992 gga-miR-12251-3p; +MIMAT0049993 gga-miR-12252-5p; +MIMAT0049994 gga-miR-12252-3p; +MIMAT0049995 gga-miR-205c-5p; +MIMAT0049996 gga-miR-205c-3p; +MIMAT0049997 gga-miR-12253-5p; +MIMAT0049998 gga-miR-12253-3p; +MIMAT0049999 gga-miR-12254-5p; +MIMAT0050000 gga-miR-12254-3p; +MIMAT0050001 gga-miR-12255-5p; +MIMAT0050002 gga-miR-12255-3p; +MIMAT0050003 gga-miR-12256-5p; +MIMAT0050004 gga-miR-12256-3p; +MIMAT0050005 gga-miR-12257-5p; +MIMAT0050006 gga-miR-12257-3p; +MIMAT0050007 gga-miR-12258-5p; +MIMAT0050008 gga-miR-12258-3p; +MIMAT0050009 gga-miR-12259-5p; +MIMAT0050010 gga-miR-12259-3p; +MIMAT0050011 gga-miR-12260-5p; +MIMAT0050012 gga-miR-12260-3p; +MIMAT0050013 gga-miR-12261-5p; +MIMAT0050014 gga-miR-12261-3p; +MIMAT0050015 gga-miR-12262-5p; +MIMAT0050016 gga-miR-12263-5p; +MIMAT0050017 gga-miR-12263-3p; +MIMAT0050018 gga-miR-12264-5p; +MIMAT0050019 gga-miR-12264-3p; +MIMAT0050020 gga-miR-12265-5p; +MIMAT0050021 gga-miR-12265-3p; +MIMAT0050022 gga-miR-12266-5p; +MIMAT0050023 gga-miR-12266-3p; +MIMAT0050024 gga-miR-10c-5p; +MIMAT0050025 gga-miR-10c-3p; +MIMAT0050026 gga-miR-148b-5p; +MIMAT0050027 gga-miR-148b-3p; +MIMAT0050028 gga-miR-12267-5p; +MIMAT0050029 gga-miR-12267-3p; +MIMAT0050030 gga-miR-12268-5p; +MIMAT0050031 gga-miR-12269-5p; +MIMAT0050032 gga-miR-12269-3p; +MIMAT0050033 gga-miR-12270-5p; +MIMAT0050034 gga-miR-12270-3p; +MIMAT0050035 gga-miR-12271-5p; +MIMAT0050036 gga-miR-12271-3p; +MIMAT0050037 gga-miR-2985-2-3p; +MIMAT0050038 gga-miR-12272-5p; +MIMAT0050039 gga-miR-12272-3p; +MIMAT0050040 gga-miR-12273-5p; +MIMAT0050041 gga-miR-12273-3p; +MIMAT0050042 gga-miR-12274-5p; +MIMAT0050043 gga-miR-12274-3p; +MIMAT0050044 gga-miR-12275-5p; +MIMAT0050045 gga-miR-12275-3p; +MIMAT0050046 gga-miR-12276-5p; +MIMAT0050047 gga-miR-12276-3p; +MIMAT0050048 gga-miR-12277-5p; +MIMAT0050049 gga-miR-12277-3p; +MIMAT0050050 gga-miR-12278-5p; +MIMAT0050051 gga-miR-12278-3p; +MIMAT0050052 gga-miR-12279-5p; +MIMAT0050053 gga-miR-12279-3p; +MIMAT0050054 gga-miR-210b-5p; +MIMAT0050055 gga-miR-210b-3p; +MIMAT0050056 gga-miR-129-5p; +MIMAT0050057 gga-miR-129-1-3p; +MIMAT0050058 gga-miR-1763b-5p; +MIMAT0050059 gga-miR-1763b-3p; +MIMAT0050060 gga-miR-12280-5p; +MIMAT0050061 gga-miR-12280-3p; +MIMAT0050062 gga-miR-214b-5p; +MIMAT0050063 gga-miR-214b-3p; +MIMAT0050064 gga-miR-12281-3p; +MIMAT0050065 gga-miR-12282-5p; +MIMAT0050066 gga-miR-12282-3p; +MIMAT0050067 gga-miR-12283-5p; +MIMAT0050068 gga-miR-12283-3p; +MIMAT0050069 gga-miR-12284-5p; +MIMAT0050070 gga-miR-12284-3p; +MIMAT0050071 gga-miR-12285-5p; +MIMAT0050072 gga-miR-12285-3p; +MIMAT0050073 gga-miR-12286-5p; +MIMAT0050074 gga-miR-12286-3p; +MIMAT0050075 gga-miR-12287-5p; +MIMAT0050076 gga-miR-12288-5p; +MIMAT0050077 gga-miR-12288-3p; +MIMAT0050078 gga-miR-12289-5p; +MIMAT0050079 gga-miR-12289-3p; +MIMAT0050080 gga-let-7l-5p; +MIMAT0050081 gga-let-7l-3p; +MIMAT0050082 gga-miR-129-3p; +MIMAT0050083 gga-miR-12290-5p; +MIMAT0050084 gga-miR-12290-3p; +MIMAT0050085 gga-miR-726-5p; +MIMAT0050086 gga-miR-726-3p; +MIMAT0050087 gga-miR-12291-3p; +MIMAT0050088 gga-miR-12292-5p; +MIMAT0050089 gga-miR-12292-3p; +MIMAT0050090 gga-miR-12293-5p; +MIMAT0050091 gga-miR-12293-3p; +MIMAT0050092 gga-miR-122b-5p; +MIMAT0050093 gga-miR-122b-3p; +MIMAT0050094 gga-miR-12294-5p; +MIMAT0050095 gga-miR-12294-3p; +MIMAT0050096 gga-miR-12295-5p; +MIMAT0050097 gga-miR-12295-3p; +MIMAT0050098 mdo-miR-12296-5p; +MIMAT0050099 mdo-miR-12298-5p; +MIMAT0050100 mdo-miR-12298-3p; +MIMAT0050101 mdo-miR-9c-5p; +MIMAT0050102 mdo-miR-9c-3p; +MIMAT0050103 mdo-miR-12299-5p; +MIMAT0050104 mdo-miR-12299-3p; +MIMAT0050105 mdo-miR-12297g-5p; +MIMAT0050106 mdo-miR-12297g-3p; +MIMAT0050107 mdo-miR-12297d-5p; +MIMAT0050108 mdo-miR-12297j-5p; +MIMAT0050109 mdo-miR-12297j-3p; +MIMAT0050110 mdo-miR-12300-5p; +MIMAT0050111 mdo-miR-12300-3p; +MIMAT0050112 mdo-miR-325-5p; +MIMAT0050113 mdo-miR-325-3p; +MIMAT0050114 mdo-miR-12301-5p; +MIMAT0050115 mdo-miR-12301-3p; +MIMAT0050116 mdo-miR-12302-5p; +MIMAT0050117 mdo-miR-12302-3p; +MIMAT0050118 mdo-miR-12303-5p; +MIMAT0050119 mdo-miR-12303-3p; +MIMAT0050120 mdo-miR-12304-5p; +MIMAT0050121 mdo-miR-12304-3p; +MIMAT0050122 mdo-miR-12305-5p; +MIMAT0050123 mdo-miR-12305-3p; +MIMAT0050124 mdo-miR-7356b-5p; +MIMAT0050125 mdo-miR-7356b-3p; +MIMAT0050126 mdo-miR-12306-5p; +MIMAT0050127 mdo-miR-12306-3p; +MIMAT0050128 mdo-miR-12307-5p; +MIMAT0050129 mdo-miR-12307-3p; +MIMAT0050130 mdo-miR-12308a-5p; +MIMAT0050131 mdo-miR-12308a-3p; +MIMAT0050132 mdo-miR-1388-5p; +MIMAT0050133 mdo-miR-1388-3p; +MIMAT0050134 mdo-miR-352-5p; +MIMAT0050135 mdo-miR-352-3p; +MIMAT0050136 mdo-miR-12309-5p; +MIMAT0050137 mdo-miR-12309-3p; +MIMAT0050138 mdo-miR-12310-5p; +MIMAT0050139 mdo-miR-12310-3p; +MIMAT0050140 mdo-miR-12311-5p; +MIMAT0050141 mdo-miR-12311-3p; +MIMAT0050142 mdo-miR-12312-5p; +MIMAT0050143 mdo-miR-12312-3p; +MIMAT0050144 mdo-miR-1329-5p; +MIMAT0050145 mdo-miR-1329-3p; +MIMAT0050146 mdo-miR-12313-5p; +MIMAT0050147 mdo-miR-12313-3p; +MIMAT0050148 mdo-miR-7286b-5p; +MIMAT0050149 mdo-miR-7286b-3p; +MIMAT0050150 mdo-miR-12314-5p; +MIMAT0050151 mdo-miR-12315-3p; +MIMAT0050152 mdo-miR-12316-5p; +MIMAT0050153 mdo-miR-12316-3p; +MIMAT0050154 mdo-miR-12317-5p; +MIMAT0050155 mdo-miR-7284b-5p; +MIMAT0050156 mdo-miR-7284b-3p; +MIMAT0050157 mdo-miR-12318-5p; +MIMAT0050158 mdo-miR-12318-3p; +MIMAT0050159 mdo-miR-12319-5p; +MIMAT0050160 mdo-miR-12319-3p; +MIMAT0050161 mdo-miR-12320-5p; +MIMAT0050162 mdo-miR-12320-3p; +MIMAT0050163 mdo-miR-205b-5p; +MIMAT0050164 mdo-miR-205b-3p; +MIMAT0050165 mdo-miR-12321-5p; +MIMAT0050166 mdo-miR-12321-3p; +MIMAT0050167 mdo-miR-12322-3p; +MIMAT0050168 mdo-miR-12323-5p; +MIMAT0050169 mdo-miR-12323-3p; +MIMAT0050170 mdo-miR-12324a-5p; +MIMAT0050171 mdo-miR-12324a-3p; +MIMAT0050172 mdo-miR-12325-5p; +MIMAT0050173 mdo-miR-12325-3p; +MIMAT0050174 mdo-miR-12326-5p; +MIMAT0050175 mdo-miR-12326-3p; +MIMAT0050176 mdo-miR-12327-3p; +MIMAT0050177 mdo-miR-12328-5p; +MIMAT0050178 mdo-miR-12328-3p; +MIMAT0050179 mdo-miR-133b-5p; +MIMAT0050180 mdo-miR-133b-3p; +MIMAT0050181 mdo-miR-7262c-5p; +MIMAT0050182 mdo-miR-7262c-3p; +MIMAT0050183 mdo-miR-12329-5p; +MIMAT0050184 mdo-miR-12329-3p; +MIMAT0050185 mdo-miR-12330-5p; +MIMAT0050186 mdo-miR-12330-3p; +MIMAT0050187 mdo-miR-7262d-5p; +MIMAT0050188 mdo-miR-7262d-3p; +MIMAT0050189 mdo-miR-12331-5p; +MIMAT0050190 mdo-miR-12331-3p; +MIMAT0050191 mdo-miR-12332-5p; +MIMAT0050192 mdo-miR-12332-3p; +MIMAT0050193 mdo-miR-12324b-5p; +MIMAT0050194 mdo-miR-12324b-3p; +MIMAT0050195 mdo-miR-3600-3p; +MIMAT0050196 mdo-miR-12333-5p; +MIMAT0050197 mdo-miR-12333-3p; +MIMAT0050198 mdo-miR-12334-5p; +MIMAT0050199 mdo-miR-12334-3p; +MIMAT0050200 mdo-miR-12335-5p; +MIMAT0050201 mdo-miR-12335-3p; +MIMAT0050202 mdo-miR-12336-5p; +MIMAT0050203 mdo-miR-12336-3p; +MIMAT0050204 mdo-miR-7262e-5p; +MIMAT0050205 mdo-miR-7262e-3p; +MIMAT0050206 mdo-miR-12297c-5p; +MIMAT0050207 mdo-miR-12337-5p; +MIMAT0050208 mdo-miR-12337-3p; +MIMAT0050209 mdo-miR-12338-5p; +MIMAT0050210 mdo-miR-12338-3p; +MIMAT0050211 mdo-miR-7262k-5p; +MIMAT0050212 mdo-miR-7262k-3p; +MIMAT0050213 mdo-miR-12297e-3p; +MIMAT0050214 mdo-miR-122b-5p; +MIMAT0050215 mdo-miR-122b-3p; +MIMAT0050216 mdo-miR-12339-5p; +MIMAT0050217 mdo-miR-12339-3p; +MIMAT0050218 mdo-miR-30e-5p; +MIMAT0050219 mdo-miR-30e-3p; +MIMAT0050220 mdo-miR-12340-5p; +MIMAT0050221 mdo-miR-12340-3p; +MIMAT0050222 mdo-miR-12341-5p; +MIMAT0050223 mdo-miR-12341-3p; +MIMAT0050224 mdo-miR-12342-5p; +MIMAT0050225 mdo-miR-12342-3p; +MIMAT0050226 mdo-miR-12343-5p; +MIMAT0050227 mdo-miR-12343-3p; +MIMAT0050228 mdo-miR-12344-5p; +MIMAT0050229 mdo-miR-12344-3p; +MIMAT0050230 mdo-miR-12345-3p; +MIMAT0050231 mdo-miR-1306-5p; +MIMAT0050232 mdo-miR-1306-3p; +MIMAT0050233 mdo-miR-12346-5p; +MIMAT0050234 mdo-miR-12346-3p; +MIMAT0050235 mdo-miR-1546b-5p; +MIMAT0050236 mdo-miR-1546b-3p; +MIMAT0050237 mdo-miR-7312b-5p; +MIMAT0050238 mdo-miR-7312b-3p; +MIMAT0050239 mdo-miR-12297c-3p; +MIMAT0050240 mdo-miR-12308b-5p; +MIMAT0050241 mdo-miR-12308b-3p; +MIMAT0050242 mdo-miR-12347-5p; +MIMAT0050243 mdo-miR-12347-3p; +MIMAT0050244 mdo-miR-7262g-5p; +MIMAT0050245 mdo-miR-7262g-3p; +MIMAT0050246 mdo-miR-12348-5p; +MIMAT0050247 mdo-miR-12348-3p; +MIMAT0050248 mdo-miR-12349-3p; +MIMAT0050249 mdo-miR-12350-5p; +MIMAT0050250 mdo-miR-12351-5p; +MIMAT0050251 mdo-miR-12351-3p; +MIMAT0050252 mdo-miR-34d-5p; +MIMAT0050253 mdo-miR-34d-3p; +MIMAT0050254 mdo-miR-2985-5p; +MIMAT0050255 mdo-miR-2985-3p; +MIMAT0050256 mdo-miR-12352-5p; +MIMAT0050257 mdo-miR-12352-3p; +MIMAT0050258 mdo-miR-12353-5p; +MIMAT0050259 mdo-miR-12353-3p; +MIMAT0050260 mdo-miR-12354-5p; +MIMAT0050261 mdo-miR-12354-3p; +MIMAT0050262 mdo-miR-12297a-5p; +MIMAT0050263 mdo-miR-12297a-3p; +MIMAT0050264 mdo-miR-12355-5p; +MIMAT0050265 mdo-miR-12355-3p; +MIMAT0050266 mdo-miR-12356-5p; +MIMAT0050267 mdo-miR-12356-3p; +MIMAT0050268 mdo-miR-12357-5p; +MIMAT0050269 mdo-miR-12357-3p; +MIMAT0050270 mdo-miR-12297h-3p; +MIMAT0050271 mdo-miR-12358-5p; +MIMAT0050272 mdo-miR-12358-3p; +MIMAT0050273 mdo-miR-12359-5p; +MIMAT0050274 mdo-miR-12359-3p; +MIMAT0050275 mdo-miR-12360-5p; +MIMAT0050276 mdo-miR-12360-3p; +MIMAT0050277 mdo-miR-12361-5p; +MIMAT0050278 mdo-miR-12361-3p; +MIMAT0050279 mdo-miR-7323b-5p; +MIMAT0050280 mdo-miR-7323b-3p; +MIMAT0050281 mdo-miR-12362-5p; +MIMAT0050282 mdo-miR-12362-3p; +MIMAT0050283 mdo-miR-12363-5p; +MIMAT0050284 mdo-miR-12363-3p; +MIMAT0050285 mdo-miR-2985-2-3p; +MIMAT0050286 mdo-miR-7262j-5p; +MIMAT0050287 mdo-miR-7262j-3p; +MIMAT0050288 mdo-miR-12364-5p; +MIMAT0050289 mdo-miR-12364-3p; +MIMAT0050290 mdo-miR-12365-5p; +MIMAT0050291 mdo-miR-12365-3p; +MIMAT0050292 mdo-miR-7262l-5p; +MIMAT0050293 mdo-miR-7262l-3p; +MIMAT0050294 mdo-miR-12366a-5p; +MIMAT0050295 mdo-miR-12366a-3p; +MIMAT0050296 mdo-miR-12367-5p; +MIMAT0050297 mdo-miR-12367-3p; +MIMAT0050298 mdo-miR-7262m-3p; +MIMAT0050299 mdo-miR-12368-5p; +MIMAT0050300 mdo-miR-12368-3p; +MIMAT0050301 mdo-miR-12297i-5p; +MIMAT0050302 mdo-miR-12297i-3p; +MIMAT0050303 mdo-miR-7320b-5p; +MIMAT0050304 mdo-miR-12369-5p; +MIMAT0050305 mdo-miR-12369-3p; +MIMAT0050306 mdo-miR-12370-5p; +MIMAT0050307 mdo-miR-12370-3p; +MIMAT0050308 mdo-miR-12371-5p; +MIMAT0050309 mdo-miR-12371-3p; +MIMAT0050310 mdo-miR-12372-5p; +MIMAT0050311 mdo-miR-12372-3p; +MIMAT0050312 mdo-miR-12373-5p; +MIMAT0050313 mdo-miR-12374-5p; +MIMAT0050314 mdo-miR-12374-3p; +MIMAT0050315 mdo-miR-12375-5p; +MIMAT0050316 mdo-miR-12375-3p; +MIMAT0050317 mdo-miR-12376-5p; +MIMAT0050318 mdo-miR-12376-3p; +MIMAT0050319 mdo-miR-12377-3p; +MIMAT0050320 mdo-miR-12378-5p; +MIMAT0050321 mdo-miR-12378-3p; +MIMAT0050322 mdo-miR-12379-5p; +MIMAT0050323 mdo-miR-12380-5p; +MIMAT0050324 mdo-miR-12380-3p; +MIMAT0050325 mdo-miR-12381-5p; +MIMAT0050326 mdo-miR-12381-3p; +MIMAT0050327 mdo-miR-12382-5p; +MIMAT0050328 mdo-miR-12382-3p; +MIMAT0050329 mdo-miR-12383-5p; +MIMAT0050330 mdo-miR-12383-3p; +MIMAT0050331 mdo-miR-12384-5p; +MIMAT0050332 mdo-miR-12384-3p; +MIMAT0050333 mdo-miR-12297f-3p; +MIMAT0050334 mdo-miR-12385-5p; +MIMAT0050335 mdo-miR-12385-3p; +MIMAT0050336 mdo-miR-12386-5p; +MIMAT0050337 mdo-miR-12386-3p; +MIMAT0050338 mdo-miR-12387-5p; +MIMAT0050339 mdo-miR-12387-3p; +MIMAT0050340 mdo-miR-551c-5p; +MIMAT0050341 mdo-miR-551c-3p; +MIMAT0050342 mdo-miR-12388-5p; +MIMAT0050343 mdo-miR-12388-3p; +MIMAT0050344 mdo-miR-12389-5p; +MIMAT0050345 mdo-miR-12389-3p; +MIMAT0050346 mdo-miR-12297b-5p; +MIMAT0050347 mdo-miR-12390-5p; +MIMAT0050348 mdo-miR-12390-3p; +MIMAT0050349 mdo-miR-12391-5p; +MIMAT0050350 mdo-miR-12391-3p; +MIMAT0050351 mdo-miR-12392-5p; +MIMAT0050352 mdo-miR-12392-3p; +MIMAT0050353 mdo-miR-7262h-5p; +MIMAT0050354 mdo-miR-7262h-3p; +MIMAT0050355 mdo-miR-12393-5p; +MIMAT0050356 mdo-miR-12394-5p; +MIMAT0050357 mdo-miR-12394-3p; +MIMAT0050358 mdo-miR-12395-5p; +MIMAT0050359 mdo-miR-12395-3p; +MIMAT0050360 mdo-miR-12396-5p; +MIMAT0050361 mdo-miR-12396-3p; +MIMAT0050362 mdo-miR-12397-5p; +MIMAT0050363 mdo-miR-12397-3p; +MIMAT0050364 mdo-miR-12398-5p; +MIMAT0050365 mdo-miR-12398-3p; +MIMAT0050366 mdo-miR-210b-5p; +MIMAT0050367 mdo-miR-210b-3p; +MIMAT0050368 mdo-miR-1549b-5p; +MIMAT0050369 mdo-miR-1549b-3p; +MIMAT0050370 mdo-miR-7345b-5p; +MIMAT0050371 mdo-miR-7345b-3p; +MIMAT0050372 mdo-miR-12399-5p; +MIMAT0050373 mdo-miR-12399-3p; +MIMAT0050374 mdo-miR-12400-5p; +MIMAT0050375 mdo-miR-7385i-5p; +MIMAT0050376 mdo-miR-7385i-2-3p; +MIMAT0050377 mdo-miR-7385h-5p; +MIMAT0050378 mdo-miR-7385h-3p; +MIMAT0050379 mdo-miR-7385i-3p; +MIMAT0050380 mdo-miR-7385g-5p; +MIMAT0050381 mdo-miR-7385g-3-3p; +MIMAT0050382 mdo-miR-12401-5p; +MIMAT0050383 mdo-miR-12401-3p; +MIMAT0050384 mdo-miR-1544f-5p; +MIMAT0050385 mdo-miR-1544f-3p; +MIMAT0050386 mdo-miR-1545d-5p; +MIMAT0050387 mdo-miR-1545d-3p; +MIMAT0050388 mdo-miR-1545g-5p; +MIMAT0050389 mdo-miR-1545g-3p; +MIMAT0050390 mdo-miR-1545e-5p; +MIMAT0050391 mdo-miR-1545e-3p; +MIMAT0050392 mdo-miR-1545f-5p; +MIMAT0050393 mdo-miR-1545f-3p; +MIMAT0050394 mdo-miR-1545d-3-5p; +MIMAT0050395 mdo-miR-1545d-4-5p; +MIMAT0050396 mdo-miR-1545g-3-5p; +MIMAT0050397 mdo-miR-1544g-5p; +MIMAT0050398 mdo-miR-1544g-3p; +MIMAT0050399 mdo-miR-7262f-5p; +MIMAT0050400 mdo-miR-7262f-3p; +MIMAT0050401 mdo-miR-12402-5p; +MIMAT0050402 mdo-miR-12402-3p; +MIMAT0050403 mdo-miR-16b-5p; +MIMAT0050404 mdo-miR-16b-3p; +MIMAT0050405 mdo-miR-7386p-5p; +MIMAT0050406 mdo-miR-7386p-3p; +MIMAT0050407 mdo-miR-7371o-5p; +MIMAT0050408 mdo-miR-7371o-3p; +MIMAT0050409 mdo-miR-7371n-5p; +MIMAT0050410 mdo-miR-7371n-3p; +MIMAT0050411 mdo-miR-7371q-5p; +MIMAT0050412 mdo-miR-7371q-3p; +MIMAT0050413 mdo-miR-7371m-5p; +MIMAT0050414 mdo-miR-7371m-3p; +MIMAT0050415 mdo-miR-7371k-5p; +MIMAT0050416 mdo-miR-7371k-3p; +MIMAT0050417 mdo-miR-7386q-5p; +MIMAT0050418 mdo-miR-7386q-3p; +MIMAT0050419 mdo-miR-7371l-5p; +MIMAT0050420 mdo-miR-7371l-3p; +MIMAT0050421 mdo-miR-7371p-5p; +MIMAT0050422 mdo-miR-7371p-3p; +MIMAT0050423 mdo-miR-7373e-5p; +MIMAT0050424 mdo-miR-7373e-3p; +MIMAT0050425 mdo-miR-12403-5p; +MIMAT0050426 mdo-miR-12403-3p; +MIMAT0050427 mdo-miR-7375c-4-5p; +MIMAT0050428 mdo-miR-7375c-3p; +MIMAT0050429 mdo-miR-7375c-5p; +MIMAT0050430 mdo-miR-7375e-5p; +MIMAT0050431 mdo-miR-7375e-3p; +MIMAT0050432 mdo-miR-7375d-5p; +MIMAT0050433 mdo-miR-7375d-3p; +MIMAT0050434 mdo-miR-7374d-5p; +MIMAT0050435 mdo-miR-7374d-3p; +MIMAT0050436 mdo-miR-7373f-5p; +MIMAT0050437 mdo-miR-7373f-3p; +MIMAT0050438 mdo-miR-7262i-5p; +MIMAT0050439 mdo-miR-7262i-3p; +MIMAT0050440 mdo-miR-7394c-5p; +MIMAT0050441 mdo-miR-7394c-3p; +MIMAT0050442 mdo-miR-7398v-5p; +MIMAT0050443 mdo-miR-7398v-3p; +MIMAT0050444 mdo-miR-7398w-5p; +MIMAT0050445 mdo-miR-7398w-3p; +MIMAT0050446 mdo-miR-7398x-3p; +MIMAT0050447 mdo-miR-7398y-5p; +MIMAT0050448 mdo-miR-7398y-3p; +MIMAT0050449 mdo-miR-12404-5p; +MIMAT0050450 mdo-miR-12404-3p; +MIMAT0050451 mdo-miR-12405-5p; +MIMAT0050452 mdo-miR-12405-3p; +MIMAT0050453 mdo-miR-12406-5p; +MIMAT0050454 mdo-miR-12406-3p; +MIMAT0050455 mdo-miR-12407-5p; +MIMAT0050456 mdo-miR-12407-3p; +MIMAT0050457 mdo-miR-12408-5p; +MIMAT0050458 mdo-miR-12408-3p; +MIMAT0050459 mdo-miR-12409-5p; +MIMAT0050460 mdo-miR-12409-3p; +MIMAT0050461 mdo-miR-12366b-5p; +MIMAT0050462 mdo-miR-12366b-3p; +MIMAT0050463 mdo-miR-12410-5p; +MIMAT0050464 mdo-miR-12411-3p; +MIMAT0050465 mdo-miR-12412-5p; +MIMAT0050466 mdo-miR-12412-3p; +MIMAT0050467 aga-miR-12413-3p; +MIMAT0050468 aga-miR-12414-3p; +MIMAT0050469 aga-miR-12415-3p; +MIMAT0050470 aga-miR-12416-3p; +MIMAT0050471 aga-miR-12417-5p; +MIMAT0050472 aga-miR-12418-3p; +MIMAT0050473 aga-miR-12419-5p; +MIMAT0050474 smc-miR-12455-5p; +MIMAT0050475 smc-miR-12455-3p; +MIMAT0050476 smc-miR-12456-5p; +MIMAT0050477 smc-miR-12456-3p; +MIMAT0050478 smc-miR-12457-5p; +MIMAT0050479 smc-miR-12457-3p; +MIMAT0050480 smc-miR-12455-2-3p; +MIMAT0050481 smc-miR-12458-5p; +MIMAT0050482 smc-miR-12458-3p; +MIMAT0050483 smc-miR-12459-5p; +MIMAT0050484 smc-miR-12459-3p; +MIMAT0050485 smc-miR-12460-5p; +MIMAT0050486 smc-miR-12460-3p; +MIMAT0050487 smc-miR-12461-5p; +MIMAT0050488 smc-miR-12461-3p; +MIMAT0050489 gga-miR-1784b-5p; +MIMAT0050490 gga-miR-1784b-3p; +MIMAT0050491 mdo-miR-7385g-3p; +MIMAT0050492 mdo-miR-7385g-2-3p; diff --git a/modulector/files/disease.txt b/modulector/files/disease.txt new file mode 100644 index 0000000..a616d20 --- /dev/null +++ b/modulector/files/disease.txt @@ -0,0 +1,35548 @@ +category mir disease pmid description +circulation_biomarker_diagnosis_down hsa-mir-15a "Leukemia, Lymphocytic, Chronic, B-Cell" 15737576 Some human miRNAs are linked to leukemias: the miR-15a/miR-16 locus is frequently deleted or down-regulated in patients with B-cell chronic lymphocytic leukemia and miR-142 is at a translocation site found in a case of aggressive B-cell leukemia. +circulation_biomarker_diagnosis_down hsa-mir-16 "Leukemia, Lymphocytic, Chronic, B-Cell" 15737576 Some human miRNAs are linked to leukemias: the miR-15a/miR-16 locus is frequently deleted or down-regulated in patients with B-cell chronic lymphocytic leukemia and miR-142 is at a translocation site found in a case of aggressive B-cell leukemia. +circulation_biomarker_diagnosis_down hsa-mir-143 Colon Neoplasms 16195701 downregulation +circulation_biomarker_diagnosis_down hsa-mir-145 Colon Neoplasms 16195701 downregulation +circulation_biomarker_diagnosis_down hsa-mir-223 "Leukemia, Lymphocytic, Chronic, B-Cell" 16251535 downregulated +circulation_biomarker_diagnosis_down hsa-mir-29a "Leukemia, Lymphocytic, Chronic, B-Cell" 16251535 downregulated +circulation_biomarker_diagnosis_down hsa-mir-29c "Leukemia, Lymphocytic, Chronic, B-Cell" 16251535 downregulated +circulation_biomarker_diagnosis_down hsa-mir-10b Breast Neoplasms 16466964 down-regulated +circulation_biomarker_diagnosis_down hsa-mir-125b-1 Breast Neoplasms 16466964 down-regulated +circulation_biomarker_diagnosis_down hsa-mir-125b-2 Breast Neoplasms 16466964 down-regulated +circulation_biomarker_diagnosis_down hsa-mir-145 Breast Neoplasms 16466964 down-regulated +circulation_biomarker_diagnosis_down hsa-mir-106 Leukemia 16549775 "we performed microRNA expression profiling of in vitro-differentiated megakaryocytes derived from CD34(+) hematopoietic progenitors. The main finding was down-regulation of miR-10a, miR-126, miR-106, miR-10b, miR-17 and miR-20." +circulation_biomarker_diagnosis_down hsa-mir-10a Leukemia 16549775 "we performed microRNA expression profiling of in vitro-differentiated megakaryocytes derived from CD34(+) hematopoietic progenitors. The main finding was down-regulation of miR-10a, miR-126, miR-106, miR-10b, miR-17 and miR-20." +circulation_biomarker_diagnosis_down hsa-mir-10b Leukemia 16549775 "we performed microRNA expression profiling of in vitro-differentiated megakaryocytes derived from CD34(+) hematopoietic progenitors. The main finding was down-regulation of miR-10a, miR-126, miR-106, miR-10b, miR-17 and miR-20." +circulation_biomarker_diagnosis_down hsa-mir-126 Leukemia 16549775 "we performed microRNA expression profiling of in vitro-differentiated megakaryocytes derived from CD34(+) hematopoietic progenitors. The main finding was down-regulation of miR-10a, miR-126, miR-106, miR-10b, miR-17 and miR-20." +circulation_biomarker_diagnosis_down hsa-mir-17 Leukemia 16549775 "we performed microRNA expression profiling of in vitro-differentiated megakaryocytes derived from CD34(+) hematopoietic progenitors. The main finding was down-regulation of miR-10a, miR-126, miR-106, miR-10b, miR-17 and miR-20." +circulation_biomarker_diagnosis_down hsa-mir-20 Leukemia 16549775 "we performed microRNA expression profiling of in vitro-differentiated megakaryocytes derived from CD34(+) hematopoietic progenitors. The main finding was down-regulation of miR-10a, miR-126, miR-106, miR-10b, miR-17 and miR-20." +circulation_biomarker_diagnosis_down hsa-let-7a-1 Lung Neoplasms 16712479 downregulation +circulation_biomarker_diagnosis_down hsa-let-7a-2 Lung Neoplasms 16712479 downregulation +circulation_biomarker_diagnosis_down hsa-let-7a-3 Lung Neoplasms 16712479 downregulation +circulation_biomarker_diagnosis_down hsa-let-7b Lung Neoplasms 16712479 downregulation +circulation_biomarker_diagnosis_down hsa-let-7c Lung Neoplasms 16712479 downregulation +circulation_biomarker_diagnosis_down hsa-let-7d Lung Neoplasms 16712479 downregulation +circulation_biomarker_diagnosis_down hsa-let-7e Lung Neoplasms 16712479 downregulation +circulation_biomarker_diagnosis_down hsa-let-7f-1 Lung Neoplasms 16712479 downregulation +circulation_biomarker_diagnosis_down hsa-let-7f-2 Lung Neoplasms 16712479 downregulation +circulation_biomarker_diagnosis_down hsa-let-7g Lung Neoplasms 16712479 downregulation +circulation_biomarker_diagnosis_down hsa-let-7i Lung Neoplasms 16712479 downregulation +circulation_biomarker_diagnosis_down hsa-mir-143 Colorectal Carcinoma 16847880 reduced +circulation_biomarker_diagnosis_down hsa-mir-145 Colorectal Carcinoma 16847880 reduced +circulation_biomarker_diagnosis_down hsa-mir-181a-2 "Leukemia, Promyelocytic, Acute" 16847880 miR-181 expression is decreased inTPA-induced differentiation of human promyelocytic leukemia cells. +circulation_biomarker_diagnosis_down hsa-mir-181b-1 "Leukemia, Promyelocytic, Acute" 16847880 miR-181 expression is decreased inTPA-induced differentiation of human promyelocytic leukemia cells. +circulation_biomarker_diagnosis_down hsa-mir-181b-2 "Leukemia, Promyelocytic, Acute" 16847880 miR-181 expression is decreased inTPA-induced differentiation of human promyelocytic leukemia cells. +circulation_biomarker_diagnosis_down hsa-mir-181d "Leukemia, Promyelocytic, Acute" 16847880 miR-181 expression is decreased inTPA-induced differentiation of human promyelocytic leukemia cells. +circulation_biomarker_diagnosis_down hsa-mir-143 Colon Neoplasms 16885332 miR-143 and miR-145 expression is reduced. +circulation_biomarker_diagnosis_down hsa-mir-145 Breast Neoplasms 16885332 Reduced expression in breast cancers +circulation_biomarker_diagnosis_down hsa-mir-155 Neoplasms [unspecific] 16885332 "High expression of precursor miR-155/BIC in pediatric BL, but lack of BIC and miR-155 expression in adult BL" +circulation_biomarker_diagnosis_down hsa-mir-143 Colon Neoplasms 16940181 Downregulation of Mir-143 and Mir-145 has been observed in colorectal cancer. +circulation_biomarker_diagnosis_down hsa-mir-145 Colon Neoplasms 16940181 Downregulation of Mir-143 and Mir-145 has beenobserved in colorectal cancer. +circulation_biomarker_diagnosis_down hsa-mir-15a Pituitary Neoplasms 17028302 Downregulation of miR-15 and miR-16 miRNAs also appears to be a feature of pituitary adenomas. +circulation_biomarker_diagnosis_down hsa-mir-15b Pituitary Neoplasms 17028302 Downregulation of miR-15 and miR-16 miRNAs also appears to be a feature of pituitary adenomas. +circulation_biomarker_diagnosis_down hsa-mir-16-1 Pituitary Neoplasms 17028302 Downregulation of miR-15 and miR-16 miRNAs also appears to be a feature of pituitary adenomas. +circulation_biomarker_diagnosis_down hsa-mir-16-2 Pituitary Neoplasms 17028302 Downregulation of miR-15 and miR-16 miRNAs also appears to be a feature of pituitary adenomas. +circulation_biomarker_diagnosis_down hsa-let-7a-1 Lung Neoplasms 17096367 Recent study demonstrated that the expression of let-7 was significantly reduced while the expression of RAS was dramatically increased in lung tumor tissues. +circulation_biomarker_diagnosis_down hsa-let-7a-2 Lung Neoplasms 17096367 Recent study demonstrated that the expression of let-7 was significantly reduced while the expression of RAS was dramatically increased in lung tumor tissues. +circulation_biomarker_diagnosis_down hsa-let-7a-3 Lung Neoplasms 17096367 Recent study demonstrated that the expression of let-7 was significantly reduced while the expression of RAS was dramatically increased in lung tumor tissues. +circulation_biomarker_diagnosis_down hsa-let-7b Lung Neoplasms 17096367 Recent study demonstrated that the expression of let-7 was significantly reduced while the expression of RAS was dramatically increased in lung tumor tissues. +circulation_biomarker_diagnosis_down hsa-let-7c Lung Neoplasms 17096367 Recent study demonstrated that the expression of let-7 was significantly reduced while the expression of RAS was dramatically increased in lung tumor tissues. +circulation_biomarker_diagnosis_down hsa-let-7d Lung Neoplasms 17096367 Recent study demonstrated that the expression of let-7 was significantly reduced while the expression of RAS was dramatically increased in lung tumor tissues. +circulation_biomarker_diagnosis_down hsa-let-7e Lung Neoplasms 17096367 Recent study demonstrated that the expression of let-7 was significantly reduced while the expression of RAS was dramatically increased in lung tumor tissues. +circulation_biomarker_diagnosis_down hsa-let-7f-1 Lung Neoplasms 17096367 Recent study demonstrated that the expression of let-7 was significantly reduced while the expression of RAS was dramatically increased in lung tumor tissues. +circulation_biomarker_diagnosis_down hsa-let-7f-2 Lung Neoplasms 17096367 Recent study demonstrated that the expression of let-7 was significantly reduced while the expression of RAS was dramatically increased in lung tumor tissues. +circulation_biomarker_diagnosis_down hsa-let-7g Lung Neoplasms 17096367 Recent study demonstrated that the expression of let-7 was significantly reduced while the expression of RAS was dramatically increased in lung tumor tissues. +circulation_biomarker_diagnosis_down hsa-let-7i Lung Neoplasms 17096367 Recent study demonstrated that the expression of let-7 was significantly reduced while the expression of RAS was dramatically increased in lung tumor tissues. +circulation_biomarker_diagnosis_down hsa-let-7e "Carcinoma, Hepatocellular" 17188425 "Independent observations showed that the expression of miRNAs let-7e, 125a and 99b, located at 19q13.4, were considerably lower in HCC compared to nontumor liver [59] and [65]. Given that miRNA-125a targets expression of the mitochondrial tumor suppressor gene, MTSG1, and RAR|§Ú§Ó, chromosomal instability in and around FRA19A may extinguish expression of these tumor suppressor genes." +circulation_biomarker_diagnosis_down hsa-mir-125a "Carcinoma, Hepatocellular" 17188425 "Independent observations showed that the expression of miRNAs let-7e, 125a and 99b, located at 19q13.4, were considerably lower in HCC compared to nontumor liver [59] and [65]. Given that miRNA-125a targets expression of the mitochondrial tumor suppressor gene, MTSG1, and RAR|§Ú§Ó, chromosomal instability in and around FRA19A may extinguish expression of these tumor suppressor genes." +circulation_biomarker_diagnosis_down hsa-mir-99b "Carcinoma, Hepatocellular" 17188425 "Independent observations showed that the expression of miRNAs let-7e, 125a and 99b, located at 19q13.4, were considerably lower in HCC compared to nontumor liver [59] and [65]. Given that miRNA-125a targets expression of the mitochondrial tumor suppressor gene, MTSG1, and RAR|§Ú§Ó, chromosomal instability in and around FRA19A may extinguish expression of these tumor suppressor genes." +circulation_biomarker_diagnosis_down hsa-mir-1-1 "Cardiomyopathy, Hypertrophic" 17234972 "Significantly,the muscle-specific microRNA-1 (miR-1) was singularly downregulatedas early as day 1, persisting through day7, after aortic constriction Cinduced hypertrophy in a mouse model." +circulation_biomarker_diagnosis_down hsa-mir-1-2 "Cardiomyopathy, Hypertrophic" 17234972 "Significantly,the muscle-specific microRNA-1 (miR-1) was singularly downregulatedas early as day 1, persisting through day7, after aortic constriction Cinduced hypertrophy in a mouse model." +circulation_biomarker_diagnosis_down hsa-mir-15a "Leukemia, Lymphocytic, Chronic, B-Cell" 17327404 "Both approaches show that miR-21 and miR-155 are dramatically overexpressed in patients with CLL, although the corresponding genomic loci are not amplified. miR-150 and miR-92 are also significantly deregulated in patients with CLL. In addition, we detected a marked miR-15a and miR-16 decrease in about 11% of cases" +circulation_biomarker_diagnosis_down hsa-mir-16 "Leukemia, Lymphocytic, Chronic, B-Cell" 17327404 "Both approaches show that miR-21 and miR-155 are dramatically overexpressed in patients with CLL, although the corresponding genomic loci are not amplified. miR-150 and miR-92 are also significantly deregulated in patients with CLL. In addition, we detected a marked miR-15a and miR-16 decrease in about 11% of cases" +circulation_biomarker_diagnosis_down hsa-mir-127 Thyroid Neoplasms 17355635 "three miRNAs showed significantly more underexpression compared to the other downregulated miRNAs. These miRNAs are as follows mir-127, mir-130a and mir-144." +circulation_biomarker_diagnosis_down hsa-mir-130a Thyroid Neoplasms 17355635 "three miRNAs showed significantly more underexpression compared to the other downregulated miRNAs. These miRNAs are as follows mir-127, mir-130a and mir-144." +circulation_biomarker_diagnosis_down hsa-mir-144 Thyroid Neoplasms 17355635 "three miRNAs showed significantly more underexpression compared to the other downregulated miRNAs. These miRNAs are as follows mir-127, mir-130a and mir-144." +circulation_biomarker_diagnosis_down hsa-mir-17 Breast Neoplasms 17442096 "In breast cancer cells, mir-17-5p expression is decreased." +circulation_biomarker_diagnosis_down hsa-mir-1-1 "Cardiomyopathy, Hypertrophic" 17468766 downregulation +circulation_biomarker_diagnosis_down hsa-mir-1-2 "Cardiomyopathy, Hypertrophic" 17468766 downregulation +circulation_biomarker_diagnosis_down hsa-mir-133a-1 "Cardiomyopathy, Hypertrophic" 17468766 downregulation +circulation_biomarker_diagnosis_down hsa-mir-133a-2 "Cardiomyopathy, Hypertrophic" 17468766 downregulation +circulation_biomarker_diagnosis_down hsa-mir-1-1 "Cardiomyopathy, Hypertrophic" 17479098 "The researchers showed that expression of miR-1 and another muscle-specific miRNA, miR-133, is decreased in human and mouse hypertrophic heart tissue." +circulation_biomarker_diagnosis_down hsa-mir-1-2 "Cardiomyopathy, Hypertrophic" 17479098 "The researchers showed that expression of miR-1 and another muscle-specific miRNA, miR-133, is decreased in human and mouse hypertrophic heart tissue." +circulation_biomarker_diagnosis_down hsa-mir-133a-1 "Cardiomyopathy, Hypertrophic" 17479098 "The researchers showed that expression of miR-1 and another muscle-specific miRNA, miR-133, is decreased in human and mouse hypertrophic heart tissue." +circulation_biomarker_diagnosis_down hsa-mir-133a-2 "Cardiomyopathy, Hypertrophic" 17479098 "The researchers showed that expression of miR-1 and another muscle-specific miRNA, miR-133, is decreased in human and mouse hypertrophic heart tissue." +circulation_biomarker_diagnosis_down hsa-mir-148a Asthma 17847008 "Previously, we identified HLA-G as an asthma-susceptibility gene and discovered that the risk of asthma in a child was determined by both the child's HLA-G genotype and the mother's affection status. The activity of pluc-HLAG-G in the presence of each of the three miRNAs was significantly lower than those of pluc-HLAG-C and pluc-HLA-G-Del." +circulation_biomarker_diagnosis_down hsa-mir-148b Asthma 17847008 "Previously, we identified HLA-G as an asthma-susceptibility gene and discovered that the risk of asthma in a child was determined by both the child's HLA-G genotype and the mother's affection status. The activity of pluc-HLAG-G in the presence of each of the three miRNAs was significantly lower than those of pluc-HLAG-C and pluc-HLA-G-Del." +circulation_biomarker_diagnosis_down hsa-mir-152 Asthma 17847008 "Previously, we identified HLA-G as an asthma-susceptibility gene and discovered that the risk of asthma in a child was determined by both the child's HLA-G genotype and the mother's affection status. The activity of pluc-HLAG-G in the presence of each of the three miRNAs was significantly lower than those of pluc-HLAG-C and pluc-HLA-G-Del." +circulation_biomarker_diagnosis_down hsa-mir-143 "Lymphoma, B-Cell" 17892514 Downregulation of microRNAs-143 and -145 in B-cell malignancies. +circulation_biomarker_diagnosis_down hsa-mir-143 Breast Neoplasms 17940623 "Studies have implicated other miRNAs in tumorigenesis. MiR-143 and miR-145, for instance, have been shown to be constantly down-regulated in colorectal tumors, and recent studies by Croce et al. also have shown that the downregulation of these miRNAs is a common occurrence in breast carcinomas and breast cancer lines." +circulation_biomarker_diagnosis_down hsa-mir-143 Colon Neoplasms 17940623 "Studies have implicated other miRNAs in tumorigenesis. MiR-143 and miR-145, for instance, have been shown to be constantly down-regulated in colorectal tumors, and recent studies by Croce et al. also have shown that the downregulation of these miRNAs is a common occurrence in breast carcinomas and breast cancer lines." +circulation_biomarker_diagnosis_down hsa-mir-145 Breast Neoplasms 17940623 "Studies have implicated other miRNAs in tumorigenesis. MiR-143 and miR-145, for instance, have been shown to be constantly down-regulated in colorectal tumors, and recent studies by Croce et al. also have shown that the downregulation of these miRNAs is a common occurrence in breast carcinomas and breast cancer lines." +circulation_biomarker_diagnosis_down hsa-mir-145 Colon Neoplasms 17940623 "Studies have implicated other miRNAs in tumorigenesis. MiR-143 and miR-145, for instance, have been shown to be constantly down-regulated in colorectal tumors, and recent studies by Croce et al. also have shown that the downregulation of these miRNAs is a common occurrence in breast carcinomas and breast cancer lines." +circulation_biomarker_diagnosis_down hsa-mir-17 Breast Neoplasms 17965831 "miR-17-5p was down-regulated in breast cancer cells, and enhanced expression decreased tumour cell proliferation." +circulation_biomarker_diagnosis_down hsa-let-7a-3 Ovarian Neoplasms 17974952 decreased +circulation_biomarker_diagnosis_down hsa-mir-150 Polycythemia Vera 17976518 "Comparative analyses of control and PV EPs suggested increased levels of miR-451, miR-16, miR-21, and miR-26b and decreased levels of miR-150 and miR-221 in PV group, Expression of miR-150 progressively declined with erythroid differentiation, its expression decreased ninefold (p < 0.05) from days 7 to 11." +circulation_biomarker_diagnosis_down hsa-mir-155 Polycythemia Vera 17976518 "Comparative analyses of control and PV EPs suggested increased levels of miR-451, miR-16, miR-21, and miR-26b and decreased levels of miR-150 and miR-221 in PV group, Expression of miR-150 progressively declined with erythroid differentiation, its expression decreased ninefold (p < 0.05) from days 7 to 11." +circulation_biomarker_diagnosis_down hsa-mir-221 Polycythemia Vera 17976518 "Comparative analyses of control and PV EPs suggested increased levels of miR-451, miR-16, miR-21, and miR-26b and decreased levels of miR-150 and miR-221 in PV group, Expression of miR-150 progressively declined with erythroid differentiation, its expression decreased ninefold (p < 0.05) from days 7 to 11." +circulation_biomarker_diagnosis_down hsa-let-7b "Leukemia, Myeloid, Acute" 18056805 "Among them, miR-128a and -128b are significantly overexpressed, whereas let-7b and miR-223 are significantly down-regulated in ALL compared with AML." +circulation_biomarker_diagnosis_down hsa-mir-223 "Leukemia, Lymphoblastic" 18056805 "Among them, miR-128a and -128b are significantly overexpressed, whereas let-7b and miR-223 are significantly down-regulated in ALL compared with AML." +circulation_biomarker_diagnosis_down hsa-mir-128-1 "Lymphoma, Hodgkin" 18089852 down-regulated +circulation_biomarker_diagnosis_down hsa-mir-128-2 "Lymphoma, Hodgkin" 18089852 down-regulated +circulation_biomarker_diagnosis_down hsa-mir-96 "Lymphoma, Hodgkin" 18089852 down-regulated +circulation_biomarker_diagnosis_down hsa-mir-15a "Leukemia, Lymphocytic, Chronic, B-Cell" 18362358 lost or downregulated +circulation_biomarker_diagnosis_down hsa-mir-16-1 "Leukemia, Lymphocytic, Chronic, B-Cell" 18362358 lost or downregulated +circulation_biomarker_diagnosis_down hsa-mir-29c Nasopharyngeal Neoplasms 18390668 down-regulated +circulation_biomarker_diagnosis_down hsa-mir-199a-1 Neoplasms [unspecific] 18430245 decreased +circulation_biomarker_diagnosis_down hsa-let-7a Polycythemia Vera 18508790 "We observed down-regulation of let-7a and up-regulation of miR-182 in polycythemia vera granulocytes, up-regulation of miR-143, miR-145 and miR-223 in polycythemia vera mononuclear cells, up-regulation of miR-26b in polycythemia vera platelets, and down-regulation of miR-30b, miR-30c and miR-150 in polycythemia vera reticulocytes." +circulation_biomarker_diagnosis_down hsa-mir-150 Polycythemia Vera 18508790 "We observed down-regulation of let-7a and up-regulation of miR-182 in polycythemia vera granulocytes, up-regulation of miR-143, miR-145 and miR-223 in polycythemia vera mononuclear cells, up-regulation of miR-26b in polycythemia vera platelets, and down-regulation of miR-30b, miR-30c and miR-150 in polycythemia vera reticulocytes." +circulation_biomarker_diagnosis_down hsa-mir-30b Polycythemia Vera 18508790 "We observed down-regulation of let-7a and up-regulation of miR-182 in polycythemia vera granulocytes, up-regulation of miR-143, miR-145 and miR-223 in polycythemia vera mononuclear cells, up-regulation of miR-26b in polycythemia vera platelets, and down-regulation of miR-30b, miR-30c and miR-150 in polycythemia vera reticulocytes." +circulation_biomarker_diagnosis_down hsa-mir-30c Polycythemia Vera 18508790 "We observed down-regulation of let-7a and up-regulation of miR-182 in polycythemia vera granulocytes, up-regulation of miR-143, miR-145 and miR-223 in polycythemia vera mononuclear cells, up-regulation of miR-26b in polycythemia vera platelets, and down-regulation of miR-30b, miR-30c and miR-150 in polycythemia vera reticulocytes." +circulation_biomarker_diagnosis_down hsa-mir-222 Breast Neoplasms 18777135 miR-222: decreased expression in c-Myc induced mouse mammary tumors +circulation_biomarker_diagnosis_down hsa-let-7e Ovarian Neoplasms 18823650 let-7e: deregulated +circulation_biomarker_diagnosis_down hsa-mir-182 Retinal Degeneration 18834879 miR-182: decreased expression +circulation_biomarker_diagnosis_down hsa-mir-183 Retinal Degeneration 18834879 miR-183: decreased expression +circulation_biomarker_diagnosis_down hsa-mir-96 Retinal Degeneration 18834879 miR-96: decreased expression +circulation_biomarker_diagnosis_down hsa-mir-141 "Carcinoma, Renal Cell" 18925646 miR-141: down-regulation +circulation_biomarker_diagnosis_down hsa-mir-200c "Carcinoma, Renal Cell" 18925646 miR-200c: down-regulation +circulation_biomarker_diagnosis_down hsa-mir-125b-1 Myelodysplastic Syndromes 18936236 miR-125b-1: Myeloid cell differentiation arrest by miR-125b-1 +circulation_biomarker_diagnosis_down hsa-mir-17 "Lymphoma, B-Cell" 18941111 miR-17: down-regulates expression of distinct targets +circulation_biomarker_diagnosis_down hsa-mir-18a "Lymphoma, B-Cell" 18941111 miR-18a: down-regulates expression of distinct targets +circulation_biomarker_diagnosis_down hsa-mir-19a "Lymphoma, B-Cell" 18941111 miR-19a: down-regulates expression of distinct targets +circulation_biomarker_diagnosis_down hsa-mir-19b-1 "Lymphoma, B-Cell" 18941111 miR-19b: down-regulates expression of distinct targets +circulation_biomarker_diagnosis_down hsa-mir-19b-2 "Lymphoma, B-Cell" 18941111 miR-19b: down-regulates expression of distinct targets +circulation_biomarker_diagnosis_down hsa-mir-20a "Lymphoma, B-Cell" 18941111 miR-20a: down-regulates expression of distinct targets +circulation_biomarker_diagnosis_down hsa-mir-92a-1 "Lymphoma, B-Cell" 18941111 miR-92a: down-regulates expression of distinct targets +circulation_biomarker_diagnosis_down hsa-mir-92a-2 "Lymphoma, B-Cell" 18941111 miR-92a: down-regulates expression of distinct targets +circulation_biomarker_diagnosis_down hsa-mir-127 "Carcinoma, Hepatocellular" 18942116 miR-127: Down-regulation during hepatocarcinogenesis induced by a methyl-deficient diet +circulation_biomarker_diagnosis_down hsa-mir-200b "Carcinoma, Hepatocellular" 18942116 miR-200b: Down-regulation during hepatocarcinogenesis induced by a methyl-deficient diet +circulation_biomarker_diagnosis_down hsa-mir-34a "Carcinoma, Hepatocellular" 18942116 miR-34a: Down-regulation during hepatocarcinogenesis induced by a methyl-deficient diet +circulation_biomarker_diagnosis_down hsa-mir-337 Neurodegenerative Diseases [unspecific] 18987751 miR-337-3p: down-regulated +circulation_biomarker_diagnosis_down hsa-mir-338 Neurodegenerative Diseases [unspecific] 18987751 miR-338-3p: down-regulated +circulation_biomarker_diagnosis_down hsa-mir-150 Lupus Vulgaris 18998140 miR-150: downregulation +circulation_biomarker_diagnosis_down hsa-mir-210 Lupus Vulgaris 18998140 miR-210: downregulation +circulation_biomarker_diagnosis_down hsa-mir-223 Lupus Vulgaris 18998140 miR-223: downregulation +circulation_biomarker_diagnosis_down hsa-mir-296 Lupus Vulgaris 18998140 miR-296: downregulation +circulation_biomarker_diagnosis_down hsa-mir-30d Lupus Vulgaris 18998140 miR-30d: downregulation +circulation_biomarker_diagnosis_down hsa-mir-324 Lupus Vulgaris 18998140 miR-324-3p: downregulation +circulation_biomarker_diagnosis_down hsa-mir-346 Lupus Vulgaris 18998140 miR-346: downregulation +circulation_biomarker_diagnosis_down hsa-mir-365a Lupus Vulgaris 18998140 miR-365: downregulation +circulation_biomarker_diagnosis_down hsa-mir-365b Lupus Vulgaris 18998140 miR-365: downregulation +circulation_biomarker_diagnosis_down hsa-mir-423 Lupus Vulgaris 18998140 miR-423: downregulation +circulation_biomarker_diagnosis_down hsa-mir-484 Lupus Vulgaris 18998140 miR-484: downregulation +circulation_biomarker_diagnosis_down hsa-mir-486 Lupus Vulgaris 18998140 miR-486: downregulation +circulation_biomarker_diagnosis_down hsa-mir-500a Lupus Vulgaris 18998140 miR-500: downregulation +circulation_biomarker_diagnosis_down hsa-mir-518b Lupus Vulgaris 18998140 miR-518b: downregulation +circulation_biomarker_diagnosis_down hsa-mir-557 Lupus Vulgaris 18998140 miR-557: downregulation +circulation_biomarker_diagnosis_down hsa-mir-596 Lupus Vulgaris 18998140 miR-596: downregulation +circulation_biomarker_diagnosis_down hsa-mir-602 Lupus Vulgaris 18998140 miR-602: downregulation +circulation_biomarker_diagnosis_down hsa-mir-611 Lupus Vulgaris 18998140 miR-611: downregulation +circulation_biomarker_diagnosis_down hsa-mir-615 Lupus Vulgaris 18998140 miR-615: downregulation +circulation_biomarker_diagnosis_down hsa-mir-629 Lupus Vulgaris 18998140 miR-629: downregulation +circulation_biomarker_diagnosis_down hsa-mir-637 Lupus Vulgaris 18998140 miR-637: downregulation +circulation_biomarker_diagnosis_down hsa-mir-642a Lupus Vulgaris 18998140 miR-642: downregulation +circulation_biomarker_diagnosis_down hsa-mir-654 Lupus Vulgaris 18998140 miR-654: downregulation +circulation_biomarker_diagnosis_down hsa-mir-663a Lupus Vulgaris 18998140 miR-663: downregulation +circulation_biomarker_diagnosis_down hsa-mir-769 Lupus Vulgaris 18998140 miR-769-3p: downregulation +circulation_biomarker_diagnosis_down hsa-mir-99a Lupus Vulgaris 18998140 miR-99a: downregulation +circulation_biomarker_diagnosis_down hsa-mir-181a-2 Leukemia 19022373 miR-181a*: downregulated during human leukemic HL-60 cell differentiation induced by 4-hydroxynonenal +circulation_biomarker_diagnosis_down hsa-mir-199b Leukemia 19022373 miR-199b: downregulated during human leukemic HL-60 cell differentiation induced by 4-hydroxynonenal +circulation_biomarker_diagnosis_down hsa-mir-378a Leukemia 19022373 miR-378: downregulated during human leukemic HL-60 cell differentiation induced by 4-hydroxynonenal +circulation_biomarker_diagnosis_down hsa-mir-454 Leukemia 19022373 miR-454-3p: downregulated during human leukemic HL-60 cell differentiation induced by 4-hydroxynonenal +circulation_biomarker_diagnosis_down hsa-mir-575 Leukemia 19022373 miR-575: downregulated during human leukemic HL-60 cell differentiation induced by 4-hydroxynonenal +circulation_biomarker_diagnosis_down hsa-mir-10a "Leukemia, Myeloid, Chronic-Phase" 19074828 miR-10a: Down-regulation of hsa-miR-10a in chronic myeloid leukemia CD34+ cells increases USF2-mediated cell growth +circulation_biomarker_diagnosis_down hsa-mir-22 "Leukemia, Lymphocytic, Chronic, B-Cell" 19144983 miR-22: downregulation has in vivo significance in chronic lymphocytic leukemia and improves disease risk stratification +circulation_biomarker_diagnosis_down hsa-mir-29c "Leukemia, Lymphocytic, Chronic, B-Cell" 19144983 miR-29c: downregulation has in vivo significance in chronic lymphocytic leukemia and improves disease risk stratification +circulation_biomarker_diagnosis_down hsa-mir-373 "Leukemia-Lymphoma, Precursor B-Cell Lymphoblastic" 19206004 miR-373*: down-regulated +circulation_biomarker_diagnosis_down hsa-mir-451a "Leukemia-Lymphoma, Precursor B-Cell Lymphoblastic" 19206004 miR-451: down-regulated +circulation_biomarker_diagnosis_down hsa-mir-143 Colorectal Carcinoma 19242066 miR-143: only down-regulated in colon cancer but not in rectal cancer +circulation_biomarker_diagnosis_down hsa-mir-145 Colorectal Carcinoma 19242066 miR-145: down-regulated in both colon and rectal cancer +circulation_biomarker_diagnosis_down hsa-mir-346 Schizophrenia 19264453 miR-346: Expression of both miR-346 and GRID1 is lower in SZ patients than that in normal controls +circulation_biomarker_diagnosis_down hsa-mir-150 Marek Disease 19297609 miR-150: down-regulated +circulation_biomarker_diagnosis_down hsa-mir-223 Marek Disease 19297609 miR-223: down-regulated +circulation_biomarker_diagnosis_down hsa-mir-363 Autistic Disorder 19360674 miR-363: downregulated +circulation_biomarker_diagnosis_down hsa-mir-92a-1 Autistic Disorder 19360674 miR-92a-1: downregulated +circulation_biomarker_diagnosis_down hsa-mir-92a-2 Autistic Disorder 19360674 miR-92a-2: downregulated +circulation_biomarker_diagnosis_down hsa-mir-181b-1 "Leukemia, Lymphocytic, Chronic, B-Cell" 19717645 "low expression of the miR-223, miR-29c, miR-29b, and miR-181 family were strongly associated with disease progression in CLL cases harboring 17p deletion" +circulation_biomarker_diagnosis_down hsa-mir-181b-2 "Leukemia, Lymphocytic, Chronic, B-Cell" 19717645 "low expression of the miR-223, miR-29c, miR-29b, and miR-181 family were strongly associated with disease progression in CLL cases harboring 17p deletion" +circulation_biomarker_diagnosis_down hsa-mir-181c "Leukemia, Lymphocytic, Chronic, B-Cell" 19717645 "low expression of the miR-223, miR-29c, miR-29b, and miR-181 family were strongly associated with disease progression in CLL cases harboring 17p deletion" +circulation_biomarker_diagnosis_down hsa-mir-223 "Leukemia, Lymphocytic, Chronic, B-Cell" 19717645 "low expression of the miR-223, miR-29c, miR-29b, and miR-181 family were strongly associated with disease progression in CLL cases harboring 17p deletion" +circulation_biomarker_diagnosis_down hsa-mir-29b-2 "Leukemia, Lymphocytic, Chronic, B-Cell" 19717645 "low expression of the miR-223, miR-29c, miR-29b, and miR-181 family were strongly associated with disease progression in CLL cases harboring 17p deletion" +circulation_biomarker_diagnosis_down hsa-mir-145 Atherosclerosis 19744308 downregulated +circulation_biomarker_diagnosis_down hsa-mir-150 Sepsis 19823581 miR-150 as a plasma prognostic marker in patients with sepsis +circulation_biomarker_diagnosis_down hsa-mir-199b Choriocarcinoma 19900756 miR-199b:Decreased expression of microRNA-199b increases protein levels of SET (protein phosphatase 2A inhibitor) in human choriocarcinoma +circulation_biomarker_diagnosis_down hsa-mir-146a Sepsis 20188071 Serum miR-146a and miR-223 as potential new biomarkers for sepsis +circulation_biomarker_diagnosis_down hsa-mir-223 Sepsis 20188071 Serum miR-146a and miR-223 as potential new biomarkers for sepsis +circulation_biomarker_diagnosis_down hsa-mir-200a Glomerulonephritis 20364043 down-regulated +circulation_biomarker_diagnosis_down hsa-mir-200b Glomerulonephritis 20364043 down-regulated +circulation_biomarker_diagnosis_down hsa-mir-429 Glomerulonephritis 20364043 down-regulated +circulation_biomarker_diagnosis_down hsa-mir-106b "Child Development Disorders, Pervasive" 20374639 down-regulation +circulation_biomarker_diagnosis_down hsa-mir-181b-1 "Leukemia, Lymphocytic, Chronic, B-Cell" 20393129 "miR-181b:We found that miR-15a, miR-21, miR-34a, miR-155, and miR-181b were differentially expressed between CLLs with chromosome 17p deletion and CLLs with normal 17p and normal karyotype, and that miR-181b was down-regulated in therapy-refractory cases" +circulation_biomarker_diagnosis_down hsa-mir-181b-2 "Leukemia, Lymphocytic, Chronic, B-Cell" 20393129 "miR-181b:We found that miR-15a, miR-21, miR-34a, miR-155, and miR-181b were differentially expressed between CLLs with chromosome 17p deletion and CLLs with normal 17p and normal karyotype, and that miR-181b was down-regulated in therapy-refractory cases" +circulation_biomarker_diagnosis_down hsa-let-7i Melanoma 20529253 let-7i*:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients +circulation_biomarker_diagnosis_down hsa-mir-106b Melanoma 20529253 miR-106b:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients +circulation_biomarker_diagnosis_down hsa-mir-107 Melanoma 20529253 miR-107:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients +circulation_biomarker_diagnosis_down hsa-mir-17 Melanoma 20529253 miR-17:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients +circulation_biomarker_diagnosis_down hsa-mir-20a Melanoma 20529253 miR-20a:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients +circulation_biomarker_diagnosis_down hsa-mir-20b Melanoma 20529253 miR-20b:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients +circulation_biomarker_diagnosis_down hsa-mir-214 Melanoma 20529253 miR-214:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients +circulation_biomarker_diagnosis_down hsa-mir-216a Melanoma 20529253 miR-216a:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients +circulation_biomarker_diagnosis_down hsa-mir-217 Melanoma 20529253 miR-217:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients +circulation_biomarker_diagnosis_down hsa-mir-221 Melanoma 20529253 miR-221*:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients +circulation_biomarker_diagnosis_down hsa-mir-330 Melanoma 20529253 miR-330-3p:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients +circulation_biomarker_diagnosis_down hsa-mir-452 Melanoma 20529253 miR-452:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients +circulation_biomarker_diagnosis_down hsa-mir-509-3 Melanoma 20529253 miR-509-3-5p:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients +circulation_biomarker_diagnosis_down hsa-mir-517a Melanoma 20529253 miR-517*:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients +circulation_biomarker_diagnosis_down hsa-mir-518e Melanoma 20529253 miR-518e*:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients +circulation_biomarker_diagnosis_down hsa-mir-519b Melanoma 20529253 miR-519b-5p:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients +circulation_biomarker_diagnosis_down hsa-mir-593 Melanoma 20529253 miR-593*:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients +circulation_biomarker_diagnosis_down hsa-mir-621 Melanoma 20529253 miR-621:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients +circulation_biomarker_diagnosis_down hsa-mir-646 Melanoma 20529253 miR-646:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients +circulation_biomarker_diagnosis_down hsa-mir-767 Melanoma 20529253 miR-767-5p:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients +circulation_biomarker_diagnosis_down hsa-mir-126 "Diabetes Mellitus, Type 2" 20651284 decreased in plasma +circulation_biomarker_diagnosis_down hsa-mir-15a "Diabetes Mellitus, Type 2" 20651284 decreased in plasma +circulation_biomarker_diagnosis_down hsa-mir-191 "Diabetes Mellitus, Type 2" 20651284 decreased in plasma +circulation_biomarker_diagnosis_down hsa-mir-197 "Diabetes Mellitus, Type 2" 20651284 decreased in plasma +circulation_biomarker_diagnosis_down hsa-mir-20b "Diabetes Mellitus, Type 2" 20651284 decreased in plasma +circulation_biomarker_diagnosis_down hsa-mir-21 "Diabetes Mellitus, Type 2" 20651284 decreased in plasma +circulation_biomarker_diagnosis_down hsa-mir-223 "Diabetes Mellitus, Type 2" 20651284 decreased in plasma +circulation_biomarker_diagnosis_down hsa-mir-24-1 "Diabetes Mellitus, Type 2" 20651284 decreased in plasma +circulation_biomarker_diagnosis_down hsa-mir-24-2 "Diabetes Mellitus, Type 2" 20651284 decreased in plasma +circulation_biomarker_diagnosis_down hsa-mir-320a "Diabetes Mellitus, Type 2" 20651284 decreased in plasma +circulation_biomarker_diagnosis_down hsa-mir-486 "Diabetes Mellitus, Type 2" 20651284 decreased in plasma +circulation_biomarker_diagnosis_down hsa-mir-101-1 "Lymphoma, Large-Cell, Anaplastic" 20805506 miR-101:miR-101 was down-regulated in all ALCL model systems +circulation_biomarker_diagnosis_down hsa-mir-101-2 "Lymphoma, Large-Cell, Anaplastic" 20805506 miR-101:miR-101 was down-regulated in all ALCL model systems +circulation_biomarker_diagnosis_down hsa-mir-181b-1 Autistic Disorder 20868653 miR-181b:deregulated +circulation_biomarker_diagnosis_down hsa-mir-486 Autistic Disorder 20868653 miR-486:deregulated +circulation_biomarker_diagnosis_down hsa-mir-27a Leukemia 21070600 Down-regulated miR-331-5p and miR-27a are associated with chemotherapy resistance and relapse in leukaemia. +circulation_biomarker_diagnosis_down hsa-mir-331 Leukemia 21070600 Down-regulated miR-331-5p and miR-27a are associated with chemotherapy resistance and relapse in leukaemia. +circulation_biomarker_diagnosis_down hsa-mir-15a "Leukemia, Lymphocytic, Chronic, B-Cell" 21130495 Downregulation +circulation_biomarker_diagnosis_down hsa-mir-16-1 "Leukemia, Lymphocytic, Chronic, B-Cell" 21130495 Downregulation +circulation_biomarker_diagnosis_down hsa-mir-181a-2 "Leukemia, Lymphocytic, Chronic, B-Cell" 21130495 Downregulation +circulation_biomarker_diagnosis_down hsa-mir-181b-1 "Leukemia, Lymphocytic, Chronic, B-Cell" 21130495 Downregulation +circulation_biomarker_diagnosis_down hsa-mir-181b-2 "Leukemia, Lymphocytic, Chronic, B-Cell" 21130495 Downregulation +circulation_biomarker_diagnosis_down hsa-mir-29b-1 "Leukemia, Lymphocytic, Chronic, B-Cell" 21130495 Downregulation +circulation_biomarker_diagnosis_down hsa-mir-29b-2 "Leukemia, Lymphocytic, Chronic, B-Cell" 21130495 Downregulation +circulation_biomarker_diagnosis_down hsa-let-7d Pancreatic Neoplasms 21139804 downregulated +circulation_biomarker_diagnosis_down hsa-mir-146a Pancreatic Neoplasms 21139804 downregulated +circulation_biomarker_diagnosis_down hsa-mir-126 Heart Failure 21157109 "The plasma concentration of miR-126 was negatively correlated with age and NYHA class, and could be a useful biomarker for heart failure" +circulation_biomarker_diagnosis_down hsa-mir-424 Hemangioma 21179471 Down-Regulation of mir-424 Contributes to the Abnormal Angiogenesis via MEK1 and Cyclin E1 in Senile Hemangioma: Its Implications to Therapy. +circulation_biomarker_diagnosis_down hsa-mir-503 Diabetes Mellitus 21220732 Deregulation of microRNA-503 Contributes to Diabetes Mellitus-Induced Impairment of Endothelial Function and Reparative Angiogenesis After Limb Ischemia. +circulation_biomarker_diagnosis_down hsa-mir-125b-1 Human Immunodeficiency Virus Infection 21224041 "heroin-dependent subjects had significantly lower levels of anti-HIV miRNAs (miRNA-28, 125b, 150, and 382) in peripheral blood mononuclear cells than the healthy subjects" +circulation_biomarker_diagnosis_down hsa-mir-125b-2 Human Immunodeficiency Virus Infection 21224041 "heroin-dependent subjects had significantly lower levels of anti-HIV miRNAs (miRNA-28, 125b, 150, and 382) in peripheral blood mononuclear cells than the healthy subjects" +circulation_biomarker_diagnosis_down hsa-mir-150 Human Immunodeficiency Virus Infection 21224041 "heroin-dependent subjects had significantly lower levels of anti-HIV miRNAs (miRNA-28, 125b, 150, and 382) in peripheral blood mononuclear cells than the healthy subjects" +circulation_biomarker_diagnosis_down hsa-mir-28 Human Immunodeficiency Virus Infection 21224041 "heroin-dependent subjects had significantly lower levels of anti-HIV miRNAs (miRNA-28, 125b, 150, and 382) in peripheral blood mononuclear cells than the healthy subjects" +circulation_biomarker_diagnosis_down hsa-mir-382 Human Immunodeficiency Virus Infection 21224041 "heroin-dependent subjects had significantly lower levels of anti-HIV miRNAs (miRNA-28, 125b, 150, and 382) in peripheral blood mononuclear cells than the healthy subjects" +circulation_biomarker_diagnosis_down hsa-let-7a-1 "Carcinoma, Renal Cell" 21229250 "let-7 family, miR-30c, miR-26a are decreased in highly aggressive primary metastatic tumours." +circulation_biomarker_diagnosis_down hsa-let-7a-2 "Carcinoma, Renal Cell" 21229250 "let-7 family, miR-30c, miR-26a are decreased in highly aggressive primary metastatic tumours." +circulation_biomarker_diagnosis_down hsa-let-7a-3 "Carcinoma, Renal Cell" 21229250 "let-7 family, miR-30c, miR-26a are decreased in highly aggressive primary metastatic tumours." +circulation_biomarker_diagnosis_down hsa-let-7b "Carcinoma, Renal Cell" 21229250 "let-7 family, miR-30c, miR-26a are decreased in highly aggressive primary metastatic tumours." +circulation_biomarker_diagnosis_down hsa-let-7c "Carcinoma, Renal Cell" 21229250 "let-7 family, miR-30c, miR-26a are decreased in highly aggressive primary metastatic tumours." +circulation_biomarker_diagnosis_down hsa-let-7d "Carcinoma, Renal Cell" 21229250 "let-7 family, miR-30c, miR-26a are decreased in highly aggressive primary metastatic tumours." +circulation_biomarker_diagnosis_down hsa-let-7e "Carcinoma, Renal Cell" 21229250 "let-7 family, miR-30c, miR-26a are decreased in highly aggressive primary metastatic tumours." +circulation_biomarker_diagnosis_down hsa-let-7f-1 "Carcinoma, Renal Cell" 21229250 "let-7 family, miR-30c, miR-26a are decreased in highly aggressive primary metastatic tumours." +circulation_biomarker_diagnosis_down hsa-let-7f-2 "Carcinoma, Renal Cell" 21229250 "let-7 family, miR-30c, miR-26a are decreased in highly aggressive primary metastatic tumours." +circulation_biomarker_diagnosis_down hsa-let-7g "Carcinoma, Renal Cell" 21229250 "let-7 family, miR-30c, miR-26a are decreased in highly aggressive primary metastatic tumours." +circulation_biomarker_diagnosis_down hsa-let-7i "Carcinoma, Renal Cell" 21229250 "let-7 family, miR-30c, miR-26a are decreased in highly aggressive primary metastatic tumours." +circulation_biomarker_diagnosis_down hsa-mir-26a-1 "Carcinoma, Renal Cell" 21229250 "let-7 family, miR-30c, miR-26a are decreased in highly aggressive primary metastatic tumours." +circulation_biomarker_diagnosis_down hsa-mir-26a-2 "Carcinoma, Renal Cell" 21229250 "let-7 family, miR-30c, miR-26a are decreased in highly aggressive primary metastatic tumours." +circulation_biomarker_diagnosis_down hsa-mir-30c-1 "Carcinoma, Renal Cell" 21229250 "let-7 family, miR-30c, miR-26a are decreased in highly aggressive primary metastatic tumours." +circulation_biomarker_diagnosis_down hsa-mir-30c-2 "Carcinoma, Renal Cell" 21229250 "let-7 family, miR-30c, miR-26a are decreased in highly aggressive primary metastatic tumours." +circulation_biomarker_diagnosis_down hsa-let-7b "Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic" 21242186 "aberrant downregulation of let-7b (~70-fold) in MLL-rearranged acute lymphoblastic leukemia was linked to upregulation of oncoprotein c-Myc (P<0.0001). Resistance to vincristine and daunorubicin was characterized by ~20-fold upregulation of miR-125b, miR-99a and miR-100 (P<0.002)." +circulation_biomarker_diagnosis_down hsa-mir-16-1 "Carcinoma, Hepatocellular" 21278583 Serum levels of miR-16 and miR-199a were significantly lower in HCC than in CLD patients or control subjects (P<0.01). +circulation_biomarker_diagnosis_down hsa-mir-16-2 "Carcinoma, Hepatocellular" 21278583 Serum levels of miR-16 and miR-199a were significantly lower in HCC than in CLD patients or control subjects (P<0.01). +circulation_biomarker_diagnosis_down hsa-mir-199a-1 "Carcinoma, Hepatocellular" 21278583 Serum levels of miR-16 and miR-199a were significantly lower in HCC than in CLD patients or control subjects (P<0.01). +circulation_biomarker_diagnosis_down hsa-mir-199a-2 "Carcinoma, Hepatocellular" 21278583 Serum levels of miR-16 and miR-199a were significantly lower in HCC than in CLD patients or control subjects (P<0.01). +circulation_biomarker_diagnosis_down hsa-mir-1-1 Hypertrophy 21303526 "The downregulation of miR-1, miR-133a, and upregulation of miR-21 can be reversed by one single upstream regulator, SRF." +circulation_biomarker_diagnosis_down hsa-mir-1-2 Hypertrophy 21303526 "The downregulation of miR-1, miR-133a, and upregulation of miR-21 can be reversed by one single upstream regulator, SRF." +circulation_biomarker_diagnosis_down hsa-mir-133a-1 Hypertrophy 21303526 "The downregulation of miR-1, miR-133a, and upregulation of miR-21 can be reversed by one single upstream regulator, SRF." +circulation_biomarker_diagnosis_down hsa-mir-133a-2 Hypertrophy 21303526 "The downregulation of miR-1, miR-133a, and upregulation of miR-21 can be reversed by one single upstream regulator, SRF." +circulation_biomarker_diagnosis_down hsa-mir-101-1 Glioblastoma 21321380 "miR-101 is down-regulated in glioblastoma resulting in EZH2-induced proliferation, migration, and angiogenesis." +circulation_biomarker_diagnosis_down hsa-mir-101-2 Glioblastoma 21321380 "miR-101 is down-regulated in glioblastoma resulting in EZH2-induced proliferation, migration, and angiogenesis." +circulation_biomarker_diagnosis_down hsa-mir-141 Systemic Lupus Erythematosus 21372198 "The serum levels of miR-200a, miR-200b, miR-200c, miR-429, miR-205 and miR-192, and urinary miR-200a, miR-200c, miR-141, miR-429 and miR-192 of SLE patients were lower than those of controls." +circulation_biomarker_diagnosis_down hsa-mir-192 Systemic Lupus Erythematosus 21372198 "The serum levels of miR-200a, miR-200b, miR-200c, miR-429, miR-205 and miR-192, and urinary miR-200a, miR-200c, miR-141, miR-429 and miR-192 of SLE patients were lower than those of controls." +circulation_biomarker_diagnosis_down hsa-mir-200a Systemic Lupus Erythematosus 21372198 "The serum levels of miR-200a, miR-200b, miR-200c, miR-429, miR-205 and miR-192, and urinary miR-200a, miR-200c, miR-141, miR-429 and miR-192 of SLE patients were lower than those of controls." +circulation_biomarker_diagnosis_down hsa-mir-200b Systemic Lupus Erythematosus 21372198 "The serum levels of miR-200a, miR-200b, miR-200c, miR-429, miR-205 and miR-192, and urinary miR-200a, miR-200c, miR-141, miR-429 and miR-192 of SLE patients were lower than those of controls." +circulation_biomarker_diagnosis_down hsa-mir-200c Systemic Lupus Erythematosus 21372198 "The serum levels of miR-200a, miR-200b, miR-200c, miR-429, miR-205 and miR-192, and urinary miR-200a, miR-200c, miR-141, miR-429 and miR-192 of SLE patients were lower than those of controls." +circulation_biomarker_diagnosis_down hsa-mir-205 Systemic Lupus Erythematosus 21372198 "The serum levels of miR-200a, miR-200b, miR-200c, miR-429, miR-205 and miR-192, and urinary miR-200a, miR-200c, miR-141, miR-429 and miR-192 of SLE patients were lower than those of controls." +circulation_biomarker_diagnosis_down hsa-mir-429 Systemic Lupus Erythematosus 21372198 "The serum levels of miR-200a, miR-200b, miR-200c, miR-429, miR-205 and miR-192, and urinary miR-200a, miR-200c, miR-141, miR-429 and miR-192 of SLE patients were lower than those of controls." +circulation_biomarker_diagnosis_down hsa-mir-92a-1 Lymphoma 21383985 Down-Regulated Plasma miR-92a Levels in Non-Hodgkin's Lymphoma. +circulation_biomarker_diagnosis_down hsa-mir-92a-2 Lymphoma 21383985 Down-Regulated Plasma miR-92a Levels in Non-Hodgkin's Lymphoma. +circulation_biomarker_diagnosis_down hsa-mir-103a-1 "Leukemia, Lymphocytic, Chronic, B-Cell" 21408091 downregulation +circulation_biomarker_diagnosis_down hsa-mir-103a-2 "Leukemia, Lymphocytic, Chronic, B-Cell" 21408091 downregulation +circulation_biomarker_diagnosis_down hsa-mir-181a-2 "Leukemia, Lymphocytic, Chronic, B-Cell" 21408091 downregulation +circulation_biomarker_diagnosis_down hsa-mir-181b-1 "Leukemia, Lymphocytic, Chronic, B-Cell" 21408091 downregulation +circulation_biomarker_diagnosis_down hsa-mir-181b-2 "Leukemia, Lymphocytic, Chronic, B-Cell" 21408091 downregulation +circulation_biomarker_diagnosis_down hsa-mir-16-1 "Leukemia-Lymphoma, Adult T-Cell" 21441948 Triptolide inhibits the proliferation of cells from lymphocytic leukemic cell lines in association with downregulation of NF-kB activity and miR-16-1(*). +circulation_biomarker_diagnosis_down hsa-mir-100 "Carcinoma, Adrenocortical" 21472710 "miRs -100, -125b, and -195 were significantly down-regulated, whereas miR-483-5p was significantly up-regulated in malignant as compared with benign tumors." +circulation_biomarker_diagnosis_down hsa-mir-126 Mesothelioma 21483773 "Levels of miR-126 in serum, and its levels in patients' serum in association with a specific marker of MPM, SMRPs, correlate with subjects at high risk to develop malignant pleural mesothelioma (MPM)." +circulation_biomarker_diagnosis_down hsa-mir-451a "Leukemia, Myeloid, Chronic" 21511335 downregulated +circulation_biomarker_diagnosis_down hsa-mir-106a "Carcinoma, Lung, Non-Small-Cell" 21544802 "The expression of miR-146b, miR-221, let-7a, miR-155, miR-17-5p, miR-27a and miR-106a were significantly reduced in the serum of NSCLC cases while miR-29c was significantly increased." +circulation_biomarker_diagnosis_down hsa-mir-146b "Carcinoma, Lung, Non-Small-Cell" 21544802 "The expression of miR-146b, miR-221, let-7a, miR-155, miR-17-5p, miR-27a and miR-106a were significantly reduced in the serum of NSCLC cases while miR-29c was significantly increased." +circulation_biomarker_diagnosis_down hsa-mir-155 "Carcinoma, Lung, Non-Small-Cell" 21544802 "The expression of miR-146b, miR-221, let-7a, miR-155, miR-17-5p, miR-27a and miR-106a were significantly reduced in the serum of NSCLC cases while miR-29c was significantly increased." +circulation_biomarker_diagnosis_down hsa-mir-17 "Carcinoma, Lung, Non-Small-Cell" 21544802 "The expression of miR-146b, miR-221, let-7a, miR-155, miR-17-5p, miR-27a and miR-106a were significantly reduced in the serum of NSCLC cases while miR-29c was significantly increased." +circulation_biomarker_diagnosis_down hsa-mir-221 "Carcinoma, Lung, Non-Small-Cell" 21544802 "The expression of miR-146b, miR-221, let-7a, miR-155, miR-17-5p, miR-27a and miR-106a were significantly reduced in the serum of NSCLC cases while miR-29c was significantly increased." +circulation_biomarker_diagnosis_down hsa-mir-223 "Carcinoma, Lung, Non-Small-Cell" 21544802 Reduced plasma expression of let-7b was modestly associated with worse cancer-specific mortality in all patients and reduced serum expression of miR-223 was modestly associated with cancer-specific mortality in stage IA/B patients. +circulation_biomarker_diagnosis_down hsa-mir-27a "Carcinoma, Lung, Non-Small-Cell" 21544802 "The expression of miR-146b, miR-221, let-7a, miR-155, miR-17-5p, miR-27a and miR-106a were significantly reduced in the serum of NSCLC cases while miR-29c was significantly increased." +circulation_biomarker_diagnosis_down hsa-mir-590 Alzheimer Disease 21548758 "Decreased relative expression levels of hsa-miR-590-3p in blood cells was observed in patients with AD versus controls. hnRNP-A1 and its transcription regulatory factor miR-590-3p are disregulated in patients with AD, and the hnRNP-A1 rs7967622 C/C genotype is likely a risk factor for FTLD in male populations." +circulation_biomarker_diagnosis_down hsa-mir-342 Glioblastoma 21561454 miR-342-3p: downregulated in the peripheral blood of glioblastoma patients. +circulation_biomarker_diagnosis_down hsa-mir-181b-1 "Leukemia, Lymphocytic, Chronic, B-Cell" 21636858 MiR-181b is a biomarker of disease progression in chronic lymphocytic leukemia +circulation_biomarker_diagnosis_down hsa-mir-181b-2 "Leukemia, Lymphocytic, Chronic, B-Cell" 21636858 MiR-181b is a biomarker of disease progression in chronic lymphocytic leukemia +circulation_biomarker_diagnosis_down hsa-mir-671 Myelodysplastic Syndromes 21649547 miR-671-5p: down-regulation +circulation_biomarker_diagnosis_down hsa-mir-375 "Squamous Cell Carcinoma, Esophageal" 21673684 "the plasma level of miR-21 was significantly higher (P=0.0218) and that of miR-375 (P=0.0052) was significantly lower in ESCC patients than controls. (2) The high plasma miR-21 levels reflected tumour levels in all cases (100%). The plasma level of miR-21 was significantly reduced in postoperative samples (P=0.0058). (3) On validation analysis, the plasma level of miR-21 tended to be higher in ESCC patients (P=0.0649), while that of miR-375 was significantly lower (P<0.0001) and the miR-21/miR-375 ratio was significantly higher (P<0.0001) in ESCC patients than in controls. The value of the area under the receiver-operating characteristic curve (AUC) was 0.816 for the miR-21/miR-375 ratio assay. Patients with a high plasma level of miR-21 tended to have greater vascular invasion (P=0.1554) and to show a high correlation with recurrence (P=0.0164)." +circulation_biomarker_diagnosis_down hsa-mir-143 "Leukemia, Myeloid, Acute" 21678057 miR-29a and miR-142-3p show downregulation and diagnostic implication in human acute myeloid leukemia. +circulation_biomarker_diagnosis_down hsa-mir-29a "Leukemia, Myeloid, Acute" 21678057 miR-29a and miR-142-3p show downregulation and diagnostic implication in human acute myeloid leukemia. +circulation_biomarker_diagnosis_down hsa-mir-21 "Carcinoma, Hepatocellular" 21749846 "In the 10-patient group, plasma microRNA-21 levels significantly diminished after surgery compared with the pre-operative values (p=0.0125). Plasma microRNA-21 level in the 126 patients with hepatocellular carcinoma was significantly higher than in patients with chronic hepatitis and healthy volunteers (p<0.0001, p<0.0001, respectively). ROC analysis of plasma microRNA-21 yielded an AUC of 0.773 with 61.1% sensitivity and 83.3% specificity when differentiating hepatocellular carcinoma from chronic hepatitis, and an AUC of 0.953 with 87.3% sensitivity and 92.0% specificity when differentiating hepatocellular carcinoma from healthy volunteers." +circulation_biomarker_diagnosis_down hsa-mir-29a "Leukemia, Myeloid, Acute" 21818844 "Lower miR-29a expression was mainly observed in MLL-rearranged pediatric acute myeloid leukemia, specifically in cases carrying t(10;11)." +circulation_biomarker_diagnosis_down hsa-mir-17 Lymphoma 21910161 "miR-17-5p: Compared with normal canine peripheral blood mononuclear cells (PBMC) and normal lymph nodes (LN), the miRNA show an increased expression level." +circulation_biomarker_diagnosis_down hsa-mir-181a-2 Lymphoma 21910161 "Compared with normal canine peripheral blood mononuclear cells (PBMC) and normal lymph nodes (LN), the miRNA show a decreased expression level." +circulation_biomarker_diagnosis_down hsa-mir-19a Lymphoma 21910161 "Compared with normal canine peripheral blood mononuclear cells (PBMC) and normal lymph nodes (LN), the miRNA show an increased expression level." +circulation_biomarker_diagnosis_down hsa-mir-19b-1 Lymphoma 21910161 "Compared with normal canine peripheral blood mononuclear cells (PBMC) and normal lymph nodes (LN), the miRNA show an increased expression level." +circulation_biomarker_diagnosis_down hsa-mir-19b-2 Lymphoma 21910161 "Compared with normal cani ne peripheral blood mononuclear cells (PBMC) and normal lymph nodes (LN), the miRNA show an increased expression level." +circulation_biomarker_diagnosis_down hsa-mir-203 Lymphoma 21910161 "Compared with normal canine peripheral blood mononuclear cells (PBMC) and normal lymph nodes (LN), the miRNA show a decreased expression level." +circulation_biomarker_diagnosis_down hsa-mir-218-1 Lymphoma 21910161 "Compared with normal canine peripheral blood mononuclear cells (PBMC) and normal lymph nodes (LN), the miRNA show a decreased expression level." +circulation_biomarker_diagnosis_down hsa-mir-218-2 Lymphoma 21910161 "Compared with normal canine peripheral blood mononuclear cells (PBMC) and normal lymph nodes (LN), the miRNA show a decreased expression level." +circulation_biomarker_diagnosis_down hsa-mir-133b Hypertension 21924071 "MiR-296-5p (Fold change 0.47, P = 0.013) and miR-133b (Fold change 0.57, P = 0.033) were consistently down-regulated in the patient plasma, whereas let-7e (Fold change 1.62, P = 0.009) and hcmv-miR-UL112 (Fold change 2.72, P = 0.004), one human cytomegalovirus encoded microRNAs, were up-regulated in the patient samples." +circulation_biomarker_diagnosis_down hsa-mir-296 Hypertension 21924071 "MiR-296-5p (Fold change 0.47, P = 0.013) and miR-133b (Fold change 0.57, P = 0.033) were consistently down-regulated in the patient plasma, whereas let-7e (Fold change 1.62, P = 0.009) and hcmv-miR-UL112 (Fold change 2.72, P = 0.004), one human cytomegalovirus encoded microRNAs, were up-regulated in the patient samples." +circulation_biomarker_diagnosis_down hsa-mir-152 Preeclampsia 22095477 Serum expression level of mir-152 was down-regulated in preeclampsia patients. +circulation_biomarker_diagnosis_down hsa-mir-218-1 Urinary Bladder Cancer 22237456 Circulating microRNA-218 was reduced in cervical cancer and correlated with tumor invasion. +circulation_biomarker_diagnosis_down hsa-mir-218-2 Urinary Bladder Cancer 22237456 Circulating microRNA-218 was reduced in cervical cancer and correlated with tumor invasion. +circulation_biomarker_diagnosis_down hsa-mir-107 Breast Neoplasms 22242178 The miRNA is down-regulated in whole blood of breast cancer patients +circulation_biomarker_diagnosis_down hsa-mir-1469 Breast Neoplasms 22242178 The miRNA is down-regulated in whole blood of breast cancer patients +circulation_biomarker_diagnosis_down hsa-mir-1471 Breast Neoplasms 22242178 The miRNA is down-regulated in whole blood of breast cancer patients +circulation_biomarker_diagnosis_down hsa-mir-182 Breast Neoplasms 22242178 The miRNA is down-regulated in whole blood of breast cancer patients +circulation_biomarker_diagnosis_down hsa-mir-1915 Breast Neoplasms 22242178 The miRNA is down-regulated in whole blood of breast cancer patients +circulation_biomarker_diagnosis_down hsa-mir-193a Breast Neoplasms 22242178 miR-193a-3p is down-regulated in whole blood of breast cancer patients +circulation_biomarker_diagnosis_down hsa-mir-2355 Breast Neoplasms 22242178 The miRNA is down-regulated in whole blood of breast cancer patients +circulation_biomarker_diagnosis_down hsa-mir-24-1 Breast Neoplasms 22242178 The miRNA is down-regulated in whole blood of breast cancer patients +circulation_biomarker_diagnosis_down hsa-mir-24-2 Breast Neoplasms 22242178 The miRNA is down-regulated in whole blood of breast cancer patients +circulation_biomarker_diagnosis_down hsa-mir-3130-1 Breast Neoplasms 22242178 The miRNA is down-regulated in whole blood of breast cancer patients +circulation_biomarker_diagnosis_down hsa-mir-3130-2 Breast Neoplasms 22242178 The miRNA is down-regulated in whole blood of breast cancer patients +circulation_biomarker_diagnosis_down hsa-mir-3186 Breast Neoplasms 22242178 The miRNA is down-regulated in whole blood of breast cancer patients +circulation_biomarker_diagnosis_down hsa-mir-526a-1 Breast Neoplasms 22242178 The miRNA is down-regulated in whole blood of breast cancer patients +circulation_biomarker_diagnosis_down hsa-mir-526a-2 Breast Neoplasms 22242178 The miRNA is down-regulated in whole blood of breast cancer patients +circulation_biomarker_diagnosis_down hsa-mir-625 Breast Neoplasms 22242178 miR-625* is down-regulated in whole blood of breast cancer patients +circulation_biomarker_diagnosis_down hsa-mir-718 Breast Neoplasms 22242178 The miRNA is down-regulated in whole blood of breast cancer patients +circulation_biomarker_diagnosis_down hsa-mir-874 Breast Neoplasms 22242178 The miRNA is down-regulated in whole blood of breast cancer patients +circulation_biomarker_diagnosis_down hsa-mir-181a-2 "Leukemia, Myeloid, Acute" 22251480 Up-regulation of a HOXA-PBX3 homeobox-gene signature following down-regulation of miR-181 is associated with adverse prognosis in patients with cytogenetically abnormal AML. +circulation_biomarker_diagnosis_down hsa-mir-181b-1 "Leukemia, Myeloid, Acute" 22251480 Up-regulation of a HOXA-PBX3 homeobox-gene signature following down-regulation of miR-181 is associated with adverse prognosis in patients with cytogenetically abnormal AML. +circulation_biomarker_diagnosis_down hsa-mir-181b-2 "Leukemia, Myeloid, Acute" 22251480 Up-regulation of a HOXA-PBX3 homeobox-gene signature following down-regulation of miR-181 is associated with adverse prognosis in patients with cytogenetically abnormal AML. +circulation_biomarker_diagnosis_down hsa-mir-181c "Leukemia, Myeloid, Acute" 22251480 Up-regulation of a HOXA-PBX3 homeobox-gene signature following down-regulation of miR-181 is associated with adverse prognosis in patients with cytogenetically abnormal AML. +circulation_biomarker_diagnosis_down hsa-mir-181d "Leukemia, Myeloid, Acute" 22251480 Up-regulation of a HOXA-PBX3 homeobox-gene signature following down-regulation of miR-181 is associated with adverse prognosis in patients with cytogenetically abnormal AML. +circulation_biomarker_diagnosis_down hsa-mir-508 "Carcinoma, Renal Cell" 22369946 "Both miR-508-3p and miR-509-3p were down-regulated in renal cancer tissues. The level of miR-508-3p but not miR-509-3p in renal cell carcinoma (RCC) patient plasma demonstrated significant differences from that in control plasma. In addition, the overexpression of miR-508-3p and miR-509-3p suppressed the proliferation of RCC cells (786-0), induced cell apoptosis and inhibited cell migration in vitro." +circulation_biomarker_diagnosis_down hsa-mir-509-1 "Carcinoma, Renal Cell" 22369946 "Both miR-508-3p and miR-509-3p were down-regulated in renal cancer tissues. The level of miR-508-3p but not miR-509-3p in renal cell carcinoma (RCC) patient plasma demonstrated significant differences from that in control plasma. In addition, the overexpression of miR-508-3p and miR-509-3p suppressed the proliferation of RCC cells (786-0), induced cell apoptosis and inhibited cell migration in vitro." +circulation_biomarker_diagnosis_down hsa-mir-509-2 "Carcinoma, Renal Cell" 22369946 "Both miR-508-3p and miR-509-3p were down-regulated in renal cancer tissues. The level of miR-508-3p but not miR-509-3p in renal cell carcinoma (RCC) patient plasma demonstrated significant differences from that in control plasma. In addition, the overexpression of miR-508-3p and miR-509-3p suppressed the proliferation of RCC cells (786-0), induced cell apoptosis and inhibited cell migration in vitro." +circulation_biomarker_diagnosis_down hsa-mir-509-3 "Carcinoma, Renal Cell" 22369946 "Both miR-508-3p and miR-509-3p were down-regulated in renal cancer tissues. The level of miR-508-3p but not miR-509-3p in renal cell carcinoma (RCC) patient plasma demonstrated significant differences from that in control plasma. In addition, the overexpression of miR-508-3p and miR-509-3p suppressed the proliferation of RCC cells (786-0), induced cell apoptosis and inhibited cell migration in vitro." +circulation_biomarker_diagnosis_down hsa-mir-126 Mesothelioma 22374169 Kaplan-Meier analysis revealed that low level of circulating miR-126 in MM patients was strongly associated with worse prognosis. +circulation_biomarker_diagnosis_down hsa-let-7c Eosinophilic Esophagitis 22391115 downregulated +circulation_biomarker_diagnosis_down hsa-mir-144 Eosinophilic Esophagitis 22391115 miR-144*: downregulated +circulation_biomarker_diagnosis_down hsa-mir-193a Eosinophilic Esophagitis 22391115 miR-193a-5p and miR-193a-3p: downregulated +circulation_biomarker_diagnosis_down hsa-mir-193b Eosinophilic Esophagitis 22391115 downregulated +circulation_biomarker_diagnosis_down hsa-mir-203 Eosinophilic Esophagitis 22391115 downregulated +circulation_biomarker_diagnosis_down hsa-mir-210 Eosinophilic Esophagitis 22391115 downregulated +circulation_biomarker_diagnosis_down hsa-mir-211 Eosinophilic Esophagitis 22391115 downregulated +circulation_biomarker_diagnosis_down hsa-mir-30a Eosinophilic Esophagitis 22391115 miR-30a-3p: downregulated +circulation_biomarker_diagnosis_down hsa-mir-365a Eosinophilic Esophagitis 22391115 downregulated +circulation_biomarker_diagnosis_down hsa-mir-375 Eosinophilic Esophagitis 22391115 "The most downregulated miRNA, which strongly correlated with esophageal eosinophil levels." +circulation_biomarker_diagnosis_down hsa-mir-517a Ectopic Pregnancy 22395025 "Concentrations of serum hCG, progesterone, miR-517a, miR-519d, and miR-525-3p were significantly lower in EP and SA cases than in VIP cases. In contrast, the concentration of miR-323-3p was significantly increased in EP cases, compared with SA and VIP cases. As a single marker, miR-323-3p had the highest sensitivity of 37.0% (at a fixed specificity of 90%)." +circulation_biomarker_diagnosis_down hsa-mir-519d Ectopic Pregnancy 22395025 "Concentrations of serum hCG, progesterone, miR-517a, miR-519d, and miR-525-3p were significantly lower in EP and SA cases than in VIP cases. In contrast, the concentration of miR-323-3p was significantly increased in EP cases, compared with SA and VIP cases. As a single marker, miR-323-3p had the highest sensitivity of 37.0% (at a fixed specificity of 90%)." +circulation_biomarker_diagnosis_down hsa-mir-525 Ectopic Pregnancy 22395025 "Concentrations of serum hCG, progesterone, miR-517a, miR-519d, and miR-525-3p were significantly lower in EP and SA cases than in VIP cases. In contrast, the concentration of miR-323-3p was significantly increased in EP cases, compared with SA and VIP cases. As a single marker, miR-323-3p had the highest sensitivity of 37.0% (at a fixed specificity of 90%)." +circulation_biomarker_diagnosis_down hsa-let-7a-1 "Carcinoma, Renal Cell" 22440013 Down-regulated in the blook serum of patients with renal cell carcinoma compared to healthy controls. +circulation_biomarker_diagnosis_down hsa-let-7a-2 "Carcinoma, Renal Cell" 22440013 Down-regulated in the blook serum of patients with renal cell carcinoma compared to healthy controls. +circulation_biomarker_diagnosis_down hsa-let-7a-3 "Carcinoma, Renal Cell" 22440013 Down-regulated in the blook serum of patients with renal cell carcinoma compared to healthy controls. +circulation_biomarker_diagnosis_down hsa-let-7f-1 "Carcinoma, Renal Cell" 22440013 Down-regulated in the blook serum of patients with renal cell carcinoma compared to healthy controls. +circulation_biomarker_diagnosis_down hsa-let-7f-2 "Carcinoma, Renal Cell" 22440013 Down-regulated in the blook serum of patients with renal cell carcinoma compared to healthy controls. +circulation_biomarker_diagnosis_down hsa-mir-142 "Carcinoma, Renal Cell" 22440013 miR-142-5p: Down-regulated in the blook serum of patients with renal cell carcinoma compared to healthy controls. +circulation_biomarker_diagnosis_down hsa-mir-150 "Carcinoma, Renal Cell" 22440013 Down-regulated in the blook serum of patients with renal cell carcinoma compared to healthy controls. +circulation_biomarker_diagnosis_down hsa-mir-19a "Carcinoma, Renal Cell" 22440013 Down-regulated in the blook serum of patients with renal cell carcinoma compared to healthy controls. +circulation_biomarker_diagnosis_down hsa-mir-219 "Carcinoma, Renal Cell" 22440013 miR-219-5p: Down-regulated in the blook serum of patients with renal cell carcinoma compared to healthy controls. +circulation_biomarker_diagnosis_down hsa-mir-302b "Carcinoma, Renal Cell" 22440013 Down-regulated in the blook serum of patients with renal cell carcinoma compared to healthy controls. +circulation_biomarker_diagnosis_down hsa-mir-302c "Carcinoma, Renal Cell" 22440013 Down-regulated in the blook serum of patients with renal cell carcinoma compared to healthy controls. +circulation_biomarker_diagnosis_down hsa-mir-367 "Carcinoma, Renal Cell" 22440013 Down-regulated in the blook serum of patients with renal cell carcinoma compared to healthy controls. +circulation_biomarker_diagnosis_down hsa-mir-381 "Carcinoma, Renal Cell" 22440013 Down-regulated in the blook serum of patients with renal cell carcinoma compared to healthy controls. +circulation_biomarker_diagnosis_down hsa-mir-451a "Carcinoma, Renal Cell" 22440013 Down-regulated in the blook serum of patients with renal cell carcinoma compared to healthy controls. +circulation_biomarker_diagnosis_down hsa-mir-154 Graves Disease 22456620 "The expression of miR-154*, miR-376b, and miR-431* were suppressed in PBMC (peripheral blood mononuclear cells) from initial GD patients. In addition, their expression levels were recovered in GD patients in remission." +circulation_biomarker_diagnosis_down hsa-mir-376b Graves Disease 22456620 "The expression of miR-154*, miR-376b, and miR-431* were suppressed in PBMC (peripheral blood mononuclear cells) from initial GD patients. In addition, their expression levels were recovered in GD patients in remission." +circulation_biomarker_diagnosis_down hsa-mir-431 Graves Disease 22456620 "The expression of miR-154*, miR-376b, and miR-431* were suppressed in PBMC (peripheral blood mononuclear cells) from initial GD patients. In addition, their expression levels were recovered in GD patients in remission." +circulation_biomarker_diagnosis_down hsa-mir-34a Colorectal Carcinoma 22648208 Circulating miR-34a levels are reduced in colorectal cancer. +circulation_biomarker_diagnosis_down hsa-mir-361 "Carcinoma, Lung, Non-Small-Cell" 22675530 Low levels of cell-free circulating miR-361-3p and miR-625* could be blood-based markers for discriminating malignant from benign lung tumors. +circulation_biomarker_diagnosis_down hsa-mir-625 "Carcinoma, Lung, Non-Small-Cell" 22675530 Low levels of cell-free circulating miR-361-3p and miR-625* could be blood-based markers for discriminating malignant from benign lung tumors. +circulation_biomarker_diagnosis_down hsa-mir-181a-2 Breast Neoplasms 22692639 Decreased serum miR-181a is a potential new tool for breast cancer screening. +circulation_biomarker_diagnosis_down hsa-let-7b Prostate Neoplasms 22719071 downregulated in prostate cancer stem/progenitor cell. +circulation_biomarker_diagnosis_down hsa-mir-126 Myocardial Infarction 22719221 Increased miR-1 and decreased miR-126 in plasma from patients with AMI after the onset of symptoms compared with healthy subjects were found. +circulation_biomarker_diagnosis_down hsa-mir-21 Lung Neoplasms 22782668 "In addition, miR-21 and miR-24 serum levels were lower in post-operative samples than those in pre-operative samples, suggesting they can potentially be used as biomarkers for disease recurrence after surgery operation." +circulation_biomarker_diagnosis_down hsa-mir-24 Lung Neoplasms 22782668 "In addition, miR-21 and miR-24 serum levels were lower in post-operative samples than those in pre-operative samples, suggesting they can potentially be used as biomarkers for disease recurrence after surgery operation." +circulation_biomarker_diagnosis_down hsa-mir-92a-1 Multiple Myeloma 22829237 Downregulated plasma miR-92a levels have clinical impact on multiple myeloma and related disorders. +circulation_biomarker_diagnosis_down hsa-mir-155 Hepatitis C Virus Infection 22846613 Increased microRNA-155 expression in the serum and peripheral monocytes in chronic HCV infection. +circulation_biomarker_diagnosis_down hsa-mir-218-1 Gastric Neoplasms 22860003 "The plasma levels of miR-223 (P<0.001) and miR-21 (P<0.001) were significantly higher in GC patients than in healthy controls, while miR-218 (P<0.001) was significantly lower. The ROC analyses yielded the AUC values of 0.9089 for miR-223, 0.7944 for miR-21 and 0.7432 for miR-218, and combined ROC analysis revealed the highest AUC value of 0.9531 in discriminating GC patients from healthy controls." +circulation_biomarker_diagnosis_down hsa-mir-218-2 Gastric Neoplasms 22860003 "The plasma levels of miR-223 (P<0.001) and miR-21 (P<0.001) were significantly higher in GC patients than in healthy controls, while miR-218 (P<0.001) was significantly lower. The ROC analyses yielded the AUC values of 0.9089 for miR-223, 0.7944 for miR-21 and 0.7432 for miR-218, and combined ROC analysis revealed the highest AUC value of 0.9531 in discriminating GC patients from healthy controls." +circulation_biomarker_diagnosis_down hsa-let-7c Lung Neoplasms 22862169 "Some miRNAs as hsa-miR-126, hsa-miR-145, hsa-let-7g, hsa-let-7d, hsa-let-7c, hsa-let-7e and hsa-miR-98, which were lowly expressed in SPC-A1 cells, were not expressed in the pulmospheres." +circulation_biomarker_diagnosis_down hsa-let-7d Lung Neoplasms 22862169 "Some miRNAs as hsa-miR-126, hsa-miR-145, hsa-let-7g, hsa-let-7d, hsa-let-7c, hsa-let-7e and hsa-miR-98, which were lowly expressed in SPC-A1 cells, were not expressed in the pulmospheres." +circulation_biomarker_diagnosis_down hsa-let-7e Lung Neoplasms 22862169 "Some miRNAs as hsa-miR-126, hsa-miR-145, hsa-let-7g, hsa-let-7d, hsa-let-7c, hsa-let-7e and hsa-miR-98, which were lowly expressed in SPC-A1 cells, were not expressed in the pulmospheres." +circulation_biomarker_diagnosis_down hsa-let-7g Lung Neoplasms 22862169 "Some miRNAs as hsa-miR-126, hsa-miR-145, hsa-let-7g, hsa-let-7d, hsa-let-7c, hsa-let-7e and hsa-miR-98, which were lowly expressed in SPC-A1 cells, were not expressed in the pulmospheres." +circulation_biomarker_diagnosis_down hsa-mir-126 Lung Neoplasms 22862169 "Some miRNAs as hsa-miR-126, hsa-miR-145, hsa-let-7g, hsa-let-7d, hsa-let-7c, hsa-let-7e and hsa-miR-98, which were lowly expressed in SPC-A1 cells, were not expressed in the pulmospheres." +circulation_biomarker_diagnosis_down hsa-mir-145 Lung Neoplasms 22862169 "Some miRNAs as hsa-miR-126, hsa-miR-145, hsa-let-7g, hsa-let-7d, hsa-let-7c, hsa-let-7e and hsa-miR-98, which were lowly expressed in SPC-A1 cells, were not expressed in the pulmospheres." +circulation_biomarker_diagnosis_down hsa-mir-98 Lung Neoplasms 22862169 "Some miRNAs as hsa-miR-126, hsa-miR-145, hsa-let-7g, hsa-let-7d, hsa-let-7c, hsa-let-7e and hsa-miR-98, which were lowly expressed in SPC-A1 cells, were not expressed in the pulmospheres." +circulation_biomarker_diagnosis_down hsa-mir-409 Prostate Neoplasms 22887127 "MiR-375, miR-378*, and miR-141 were significantly over-expressed in serum from CRPC patients compared with serum from low-risk localized patients, while miR-409-3p was significantly under-expressed. In prostate primary tumor samples, miR-375 and miR-141 also had significantly higher expression levels compared with those in normal prostate tissue." +circulation_biomarker_diagnosis_down hsa-mir-125b Prostate Neoplasms 22892455 An increase in serum miR-223 and a decrease in miR-125b and miR-146a were observed in group B. +circulation_biomarker_diagnosis_down hsa-mir-146a Prostate Neoplasms 22892455 An increase in serum miR-223 and a decrease in miR-125b and miR-146a were observed in group B. +circulation_biomarker_diagnosis_down hsa-mir-421 Gastric Neoplasms 22926798 Gastric juice microRNA-421 is a new biomarker for screening gastric cancer. +circulation_biomarker_diagnosis_down hsa-mir-29a "Leukemia, Myeloid, Acute" 22981932 "Our data indicate for the first time that the down-regulation of miR-29a was associated with advanced clinical features and poor prognosis of pediatric AML patients, suggesting that miR-29a down-regulation may be used as an unfavorable prognostic marker in pediatric AML." +circulation_biomarker_diagnosis_down hsa-mir-21 Breast Neoplasms 23052693 Circulating microRNA-92a and microRNA-21 as novel minimally invasive biomarkers for primary breast cancer +circulation_biomarker_diagnosis_down hsa-mir-92a-1 Breast Neoplasms 23052693 Circulating microRNA-92a and microRNA-21 as novel minimally invasive biomarkers for primary breast cancer +circulation_biomarker_diagnosis_down hsa-mir-92a-2 Breast Neoplasms 23052693 Circulating microRNA-92a and microRNA-21 as novel minimally invasive biomarkers for primary breast cancer +circulation_biomarker_diagnosis_down hsa-mir-17 Systemic Lupus Erythematosus 23129428 Dual downregulation of microRNA 17-5p and E2F1 transcriptional factor in pediatric systemic lupus erythematosus patients +circulation_biomarker_diagnosis_down hsa-mir-145 Systemic Lupus Erythematosus 23199328 Decreased microRNA(miR)-145 and increased miR-224 expression in T cells from patients with systemic lupus erythematosus involved in lupus immunopathogenesis +circulation_biomarker_diagnosis_down hsa-mir-17 Endometriosis 23203215 "Plasma miR-17-5p, miR-20a and miR-22 are down-regulated in women with endometriosis" +circulation_biomarker_diagnosis_down hsa-mir-20a Endometriosis 23203215 "Plasma miR-17-5p, miR-20a and miR-22 are down-regulated in women with endometriosis" +circulation_biomarker_diagnosis_down hsa-mir-22 Endometriosis 23203215 "Plasma miR-17-5p, miR-20a and miR-22 are down-regulated in women with endometriosis" +circulation_biomarker_diagnosis_down hsa-mir-146b "Leukemia, Lymphocytic, Chronic, B-Cell" 23286334 "we found that malignant B-cells from patients with CLL subsequently developing AIHA present nine down-regulated (i.e. miR-19a, miR-20a, miR-29c, miR-146b-5p, miR-186, miR-223, miR-324-3p, miR-484 and miR-660) miRNAs." +circulation_biomarker_diagnosis_down hsa-mir-186 "Leukemia, Lymphocytic, Chronic, B-Cell" 23286334 "we found that malignant B-cells from patients with CLL subsequently developing AIHA present nine down-regulated (i.e. miR-19a, miR-20a, miR-29c, miR-146b-5p, miR-186, miR-223, miR-324-3p, miR-484 and miR-660) miRNAs." +circulation_biomarker_diagnosis_down hsa-mir-19a "Leukemia, Lymphocytic, Chronic, B-Cell" 23286334 "we found that malignant B-cells from patients with CLL subsequently developing AIHA present nine down-regulated (i.e. miR-19a, miR-20a, miR-29c, miR-146b-5p, miR-186, miR-223, miR-324-3p, miR-484 and miR-660) miRNAs." +circulation_biomarker_diagnosis_down hsa-mir-20a "Leukemia, Lymphocytic, Chronic, B-Cell" 23286334 "we found that malignant B-cells from patients with CLL subsequently developing AIHA present nine down-regulated (i.e. miR-19a, miR-20a, miR-29c, miR-146b-5p, miR-186, miR-223, miR-324-3p, miR-484 and miR-660) miRNAs." +circulation_biomarker_diagnosis_down hsa-mir-223 "Leukemia, Lymphocytic, Chronic, B-Cell" 23286334 "we found that malignant B-cells from patients with CLL subsequently developing AIHA present nine down-regulated (i.e. miR-19a, miR-20a, miR-29c, miR-146b-5p, miR-186, miR-223, miR-324-3p, miR-484 and miR-660) miRNAs." +circulation_biomarker_diagnosis_down hsa-mir-29c "Leukemia, Lymphocytic, Chronic, B-Cell" 23286334 "we found that malignant B-cells from patients with CLL subsequently developing AIHA present nine down-regulated (i.e. miR-19a, miR-20a, miR-29c, miR-146b-5p, miR-186, miR-223, miR-324-3p, miR-484 and miR-660) miRNAs." +circulation_biomarker_diagnosis_down hsa-mir-324 "Leukemia, Lymphocytic, Chronic, B-Cell" 23286334 "we found that malignant B-cells from patients with CLL subsequently developing AIHA present nine down-regulated (i.e. miR-19a, miR-20a, miR-29c, miR-146b-5p, miR-186, miR-223, miR-324-3p, miR-484 and miR-660) miRNAs." +circulation_biomarker_diagnosis_down hsa-mir-484 "Leukemia, Lymphocytic, Chronic, B-Cell" 23286334 "we found that malignant B-cells from patients with CLL subsequently developing AIHA present nine down-regulated (i.e. miR-19a, miR-20a, miR-29c, miR-146b-5p, miR-186, miR-223, miR-324-3p, miR-484 and miR-660) miRNAs." +circulation_biomarker_diagnosis_down hsa-mir-660 "Leukemia, Lymphocytic, Chronic, B-Cell" 23286334 "we found that malignant B-cells from patients with CLL subsequently developing AIHA present nine down-regulated (i.e. miR-19a, miR-20a, miR-29c, miR-146b-5p, miR-186, miR-223, miR-324-3p, miR-484 and miR-660) miRNAs." +circulation_biomarker_diagnosis_down hsa-mir-198 Lung Neoplasms 23354517 Circulating;Downregulation of cell-free miR-198 as a diagnostic biomarker for lung adenocarcinoma-associated malignant pleural effusion +circulation_biomarker_diagnosis_down hsa-mir-150 Sepsis 23372743 Circulating;Circulating MicroRNA-150 Serum Levels Predict Survival in Patients with Critical Illness and Sepsis +circulation_biomarker_diagnosis_down hsa-mir-30a Breast Neoplasms 23389917 plasma; plasma miRNA-30a decreased in patients with BC and has great potential to use as novel biomarkers for BC diagnosis +circulation_biomarker_diagnosis_down hsa-mir-106a Systemic Lupus Erythematosus 23401079 "Seven miRNAs were statistically significantly differentially expressed in plasma from patients with SLE. The expression of miRNA-142-3p (miR-142-3p) and miR-181a was increased, and the expression of miR-106a, miR-17, miR-20a, miR-203,and miR-92a was decreased" +circulation_biomarker_diagnosis_down hsa-mir-17 Systemic Lupus Erythematosus 23401079 "Seven miRNAs were statistically significantly differentially expressed in plasma from patients with SLE. The expression of miRNA-142-3p (miR-142-3p) and miR-181a was increased, and the expression of miR-106a, miR-17, miR-20a, miR-203,and miR-92a was decreased" +circulation_biomarker_diagnosis_down hsa-mir-203 Systemic Lupus Erythematosus 23401079 "Seven miRNAs were statistically significantly differentially expressed in plasma from patients with SLE. The expression of miRNA-142-3p (miR-142-3p) and miR-181a was increased, and the expression of miR-106a, miR-17, miR-20a, miR-203,and miR-92a was decreased" +circulation_biomarker_diagnosis_down hsa-mir-20a Systemic Lupus Erythematosus 23401079 "Seven miRNAs were statistically significantly differentially expressed in plasma from patients with SLE. The expression of miRNA-142-3p (miR-142-3p) and miR-181a was increased, and the expression of miR-106a, miR-17, miR-20a, miR-203,and miR-92a was decreased" +circulation_biomarker_diagnosis_down hsa-mir-92a Systemic Lupus Erythematosus 23401079 "Seven miRNAs were statistically significantly differentially expressed in plasma from patients with SLE. The expression of miRNA-142-3p (miR-142-3p) and miR-181a was increased, and the expression of miR-106a, miR-17, miR-20a, miR-203,and miR-92a was decreased" +circulation_biomarker_diagnosis_down hsa-mir-133 Heart Failure 23711953 "In surgical CAD patients, a decreased miR-133 expression is associated with variables characteristic of heart failure." +circulation_biomarker_diagnosis_down hsa-mir-197 Primary Biliary Cirrhosis 23776611 Our results indicate that sera from patients with PBC have a unique mirNA expression profile and that the down-regulated expression of mir-505-3p and mir-197-3p can serve as clinical biomarkers of PBC. +circulation_biomarker_diagnosis_down hsa-mir-505 Primary Biliary Cirrhosis 23776611 Our results indicate that sera from patients with PBC have a unique mirNA expression profile and that the down-regulated expression of mir-505-3p and mir-197-3p can serve as clinical biomarkers of PBC. +circulation_biomarker_diagnosis_down hsa-let-7f Alzheimer Disease 23895045 A blood based 12-miRNA signature of Alzheimer disease patients. +circulation_biomarker_diagnosis_down hsa-mir-103a Alzheimer Disease 23895045 A blood based 12-miRNA signature of Alzheimer disease patients. +circulation_biomarker_diagnosis_down hsa-mir-107 Alzheimer Disease 23895045 A blood based 12-miRNA signature of Alzheimer disease patients. +circulation_biomarker_diagnosis_down hsa-mir-1285 Alzheimer Disease 23895045 A blood based 12-miRNA signature of Alzheimer disease patients. +circulation_biomarker_diagnosis_down hsa-mir-26a Alzheimer Disease 23895045 A blood based 12-miRNA signature of Alzheimer disease patients. +circulation_biomarker_diagnosis_down hsa-mir-26b Alzheimer Disease 23895045 A blood based 12-miRNA signature of Alzheimer disease patients. +circulation_biomarker_diagnosis_down hsa-mir-532 Alzheimer Disease 23895045 A blood based 12-miRNA signature of Alzheimer disease patients. +circulation_biomarker_diagnosis_down hsa-mir-145 Myasthenia Gravis 24043548 Identification of novel MicroRNA signatures linked to experimental autoimmune myasthenia gravis pathogenesis: down-regulated miR-145 promotes pathogenetic Th17 cell response. +circulation_biomarker_diagnosis_down hsa-mir-21 Leukemia 24141112 "Moreover, the down-regulated expression of microRNA-21 in DF-1 chicken fibroblast cells infected with subgroup J avian leukemia virus (ALVs) was confirmed by the developed method, indicating that microRNA-21 might be a new biomarker for avian leukemia." +circulation_biomarker_diagnosis_down hsa-mir-15b Multiple Sclerosis 24277735 Decreased circulating miRNA levels in patients with primary progressive multiple sclerosis. +circulation_biomarker_diagnosis_down hsa-mir-223 Multiple Sclerosis 24277735 Decreased circulating miRNA levels in patients with primary progressive multiple sclerosis. +circulation_biomarker_diagnosis_down hsa-mir-23a Multiple Sclerosis 24277735 Decreased circulating miRNA levels in patients with primary progressive multiple sclerosis. +circulation_biomarker_diagnosis_down hsa-mir-1 Polycystic Kidney Disease 24489795 "We found that in ADPKD urine specimens, miRNA previously implicated as kidney tumor suppressors (miR-1 and miR-133), as well as miRNA of presumed inflammatory and fibroblast cell origin (miR-223/miR-199), are dysregulated when compared to other CKD patients. Concordant with findings in the primary tubule epithelial cell model, this suggests roles for dysregulated miRNA in ADPKD pathogenesis and potential use as biomarkers. We intend to assess prognostic potential of miRNA in a followup analysis." +circulation_biomarker_diagnosis_down hsa-mir-29a Parkinson Disease 24648008 "We found four statistically significant miRNAs that were downregulated in either LRRK2 or IPD (miR-29a, miR-29c, miR-19a, and miR-19b)." +circulation_biomarker_diagnosis_down hsa-mir-96 "Leukemia, Myeloid, Acute" 24678958 "Our data demonstrated that the expression of miR-96 was downregulated in newly diagnosed AML patients and associated with leukemic burden, as well as RFS and OS. This suggests that miR-96 detection might become a potential biomarker of prognosis and monitoring in AML." +circulation_biomarker_diagnosis_down hsa-mir-199b "Leukemia, Myeloid, Chronic" 24680705 Down-regulation of miR-199b associated with imatinib drug resistance in 9q34.1 deleted BCR/ABL positive CML patients. +circulation_biomarker_diagnosis_down hsa-let-7e Retinoblastoma 24748987 "Plasma miRNA (miR)-320, miR-let-7e and miR-21 levels were downregulated in the patient samples" +circulation_biomarker_diagnosis_down hsa-mir-146 "Diabetes Mellitus, Type 1" 24796653 Decreased miR-146 expression in peripheral blood mononuclear cells is correlated with ongoing islet autoimmunity in type 1 diabetes patients 1miR-146. +circulation_biomarker_diagnosis_down hsa-mir-125b Melanoma 24878024 "Exosomes can provide a suitable material to measure circulating miRNA in melanoma, and miR-16 can be used as an endogenous normalizer. Lower levels of miR-125b in exosomes obtained from serum are associated with advanced melanoma disease, probably reflecting the tumoral cell dysregulation." +circulation_biomarker_diagnosis_down hsa-mir-16 Melanoma 24878024 "Exosomes can provide a suitable material to measure circulating miRNA in melanoma, and miR-16 can be used as an endogenous normalizer. Lower levels of miR-125b in exosomes obtained from serum are associated with advanced melanoma disease, probably reflecting the tumoral cell dysregulation." +circulation_biomarker_diagnosis_down hsa-mir-107 Diabetes Mellitus 24908639 "Hyperglycemia may downregulate the expressions of miR-223 and miR-146a, leading to subsequent platelet activation in patients with diabetes mellitus. Low platelet and plasma miR-223 and miR-146a expression is a risk factor for ischemic stroke in Chinese diabetes mellitus patients." +circulation_biomarker_diagnosis_down hsa-mir-146a Diabetes Mellitus 24908639 "Hyperglycemia may downregulate the expressions of miR-223 and miR-146a, leading to subsequent platelet activation in patients with diabetes mellitus. Low platelet and plasma miR-223 and miR-146a expression is a risk factor for ischemic stroke in Chinese diabetes mellitus patients." +circulation_biomarker_diagnosis_down hsa-mir-223 Diabetes Mellitus 24908639 "Hyperglycemia may downregulate the expressions of miR-223 and miR-146a, leading to subsequent platelet activation in patients with diabetes mellitus. Low platelet and plasma miR-223 and miR-146a expression is a risk factor for ischemic stroke in Chinese diabetes mellitus patients." +circulation_biomarker_diagnosis_down hsa-mir-495 Diabetes Mellitus 24908639 "Hyperglycemia may downregulate the expressions of miR-223 and miR-146a, leading to subsequent platelet activation in patients with diabetes mellitus. Low platelet and plasma miR-223 and miR-146a expression is a risk factor for ischemic stroke in Chinese diabetes mellitus patients." +circulation_biomarker_diagnosis_down hsa-let-7b Crohn Disease 24910152 Both inflamed and non-inflamed terminal ileal mucosa in adult patients with active CD have their distinct miRNA expression patterns compared with healthy controls. Dysregulated miRNAs may be responsible for pathogenesis of CD. +circulation_biomarker_diagnosis_down hsa-mir-9-1 Methylmalonic Acidemia 24927441 "Plasma miR-9-1 is significantly down-regulated in MMA patients, but it is significantly up-regulated after vitamin B12 treatment, suggesting that miR-9-1 may act as a biomarker in monitoring the progression of MMA." +circulation_biomarker_diagnosis_down hsa-mir-155 Sjogren Syndrome 24931100 "Our results demonstrated miR-146a overexpression and miR-155 underexpression in the peripheral mononuclear blood cells of the patients with pSS. Furthermore, the expression levels of these miRNAs correlated with the patients' clinical features. Our data suggest that miR-146a and miR-155 might play important roles in the pathogenesis of pSS and that their expression levels may be useful for diagnosing pSS and for predicting disease activity and therapeutic responses." +circulation_biomarker_diagnosis_down hsa-mir-1 Bladder Neoplasms 25015192 Hsa-miR-1 downregulates long non-coding RNA urothelial cancer associated 1 in bladder cancer. +circulation_biomarker_diagnosis_down hsa-mir-16 Heart Failure 25033200 "We provide evidence that miR-16 decreases in the circulation of end-stage HF patients and increases with a LVAD. Modeling studies suggest that miR-16 binds to and decreases expression of VPS4a. Overexpression of VPS4a decreases cell number. Together, these experiments suggest that miR-16 and VPS4a expression are altered in end-stage HF and in response to unloading with a LVAD. This signaling pathway may lead to reduced circulating cell number in HF." +circulation_biomarker_diagnosis_down hsa-mir-195 Breast Neoplasms 25103018 Serum microRNA-195 is down-regulated in breast cancer: a potential marker for the diagnosis of breast cancer. +circulation_biomarker_diagnosis_down hsa-mir-181b Autism Spectrum Disorder 25126405 "MiR-151a-3p, miR-181b-5p, miR-320a, miR-328, miR-433, miR-489, miR-572, and miR-663a were downregulated, while miR-101-3p, miR-106b-5p, miR-130a-3p, miR-195-5p, and miR-19b-3p were upregulated." +circulation_biomarker_diagnosis_down hsa-mir-21 Rheumatoid Arthritis 25164131 Decreased expression of microRNA-21 correlates with the imbalance of Th17 and Treg cells in patients with rheumatoid arthritis. +circulation_biomarker_diagnosis_down hsa-mir-146b "Fatty Liver, Non-Alcoholic" 25232454 "Serum levels of miR-181d, miR-99a, miR-197 and miR-146b were significantly lower in biopsy-proven NAFLD patients than in the healthy controls." +circulation_biomarker_diagnosis_down hsa-mir-29a "Fatty Liver, Non-Alcoholic" 25232454 "Serum levels of miR-181d, miR-99a, miR-197 and miR-146b were significantly lower in biopsy-proven NAFLD patients than in the healthy controls." +circulation_biomarker_diagnosis_down hsa-mir-124 Stroke 25257664 serum miR-124 was significantly decreased within 24 hours after stroke onset and serum miR-9 was decreased in patients with larger stroke. +circulation_biomarker_diagnosis_down hsa-mir-9 Stroke 25257664 serum miR-124 was significantly decreased within 24 hours after stroke onset and serum miR-9 was decreased in patients with larger stroke. +circulation_biomarker_diagnosis_down hsa-mir-150 Sepsis 25394245 "The expression of two miRNAs, that is, let-7a (P < 0.001) and miR-150 (P < 0.001), were confirmed to be significantly downregulated in GNB urosepsis patients compared with healthy controls." +circulation_biomarker_diagnosis_down hsa-mir-320a Multiple Sclerosis 25468268 expression of miR-320a is decreased in B cells of MS patients and may contribute to increased blood-brain barrier permeability and neurological disability. +circulation_biomarker_diagnosis_down hsa-mir-210 Acute Cerebral Infarction 25476086 "The serum level of miR-210 in ACI was significantly lower than that in normal healthy persons, and it may be an important new serological marker in screening and diagnosis of ACI." +circulation_biomarker_diagnosis_down hsa-mir-146a "Diabetes Mellitus, Type 2" 25500583 "decreased serum anti-inflammatory miR-146a, increased pro-inflammatory IL-8 and increased HGF (a vascular/insular repair factor) as discriminating markers of failure of glucose control occurring on the background of obesity and dyslipidemia." +circulation_biomarker_diagnosis_down hsa-mir-155 "Diabetes Mellitus, Type 2" 25500583 "decreased serum anti-inflammatory miR-146a, increased pro-inflammatory IL-8 and increased HGF (a vascular/insular repair factor) as discriminating markers of failure of glucose control occurring on the background of obesity and dyslipidemia." +circulation_biomarker_diagnosis_down hsa-mir-22 Premature Ovarian Failure 25585503 Mir-22-3p showed a lower expression level in POF and was modestly effective in distinguishing POF from control subjects. The decreased expression of miR-22-3p in plasma of POF may reflect the diminished ovarian reserve and be a consequence of the pathologic process of POF. +circulation_biomarker_diagnosis_down hsa-mir-1 Arrhythmia 25625292 patients with SVT had lower miR-1 expression levels while those with VT had higher miR-133 expression levels. +circulation_biomarker_diagnosis_down hsa-mir-223 "Leukemia, Myeloid, Acute" 25793640 MIR233 is genetically or epigenetically silenced in a subset of acute myeloid leukemia (AML). +circulation_biomarker_diagnosis_down hsa-mir-218 "Carcinoma, Esophageal" 25812647 "The serum expression of miR-218 is downregulated in esophageal cancer patients and is correlated with tumor differentiation, stage, and lymph node metastasis. Serum miR-218 may be a potential biomarker for early detection and clinical evaluation in patient with esophageal cancer." +circulation_biomarker_diagnosis_down hsa-mir-181b Atherosclerosis 25896908 Hyperlipidemia reduced the expression of miR-181b and increased NT and N/M ratio. +circulation_biomarker_diagnosis_down hsa-mir-16 Plasmodium vivax Infection 25913668 Downregulation of plasma miR-451 and miR-16 in Plasmodium vivax infection. +circulation_biomarker_diagnosis_down hsa-mir-451 Plasmodium vivax Infection 25913668 Downregulation of plasma miR-451 and miR-16 in Plasmodium vivax infection. +circulation_biomarker_diagnosis_down hsa-mir-148a "Leukemia, Myeloid, Acute" 25924238 whilst anti-oncogenic microRNAsincluding miR-148a and miR-193a were down-regulated in MAPKBP1high patients with CN-AML +circulation_biomarker_diagnosis_down hsa-mir-214 Acute Myocardial Infarction 25931214 "The circulating level of miR-214 was significantly decreased in the AMI group, which might be correlated with the extent of the coronary lesion.Circulating miR-214 may be a promising biomarker for the diagnosis and prognosis of severe AMI." +circulation_biomarker_diagnosis_down hsa-mir-145 Coronary Artery Disease 25938589 "Lower plasma levels of miRNA-145 were significantly associated with the presence as well as severity of CAD. As a potential biomarker for CAD, plasma miRNA-145 may be useful in predicting CAD and its severity in patients presenting with chest pain." +circulation_biomarker_diagnosis_down hsa-mir-22 Rheumatoid Arthritis 25939484 "MiRNAs with a P-value <0.05 using three different normalizations were included in a multivariate model.After backwards elimination, the combination of low expression of miR-22 and high expression of miR-886.3p was associated with EULAR good response. Future studies to assess the utility of these miRNAs as predictive biomarkers are needed." +circulation_biomarker_diagnosis_down hsa-mir-181c Myasthenia Gravis 25962782 Decreased microRNA miR-181c expression in peripheral blood mononuclear cells correlates with elevated serum levels of IL-7 and IL-17 in patients with myasthenia gravis. +circulation_biomarker_diagnosis_down hsa-mir-130a Spinal Cord Injuries 25973054 Increased HDAC3 and decreased miRNA-130a expression in PBMCs through recruitment HDAC3 in patients with spinal cord injuries. +circulation_biomarker_diagnosis_down hsa-mir-126 Atherosclerosis 25975504 miR-126 and miR-223 platelets were reduced in the rabbit atherosclerotic plaque model group +circulation_biomarker_diagnosis_down hsa-mir-33b Multiple Myeloma 25975752 Downregulated miR-33b is a novel predictor associated with disease progression and poor prognosis in multiple myeloma. +circulation_biomarker_diagnosis_down hsa-mir-374a Hypoxic-Ischemic Encephalopathy 26001314 We have shown a significant step-wise downregulation of hsa-miR-374a expression in cord blood of infants with perinatal asphyxia and subsequent HIE. +circulation_biomarker_diagnosis_down hsa-mir-146a "Stroke, Ischemic" 26044809 miR-146a and miR-185 were present with quite low abundance in ISA compared with healthy individuals +circulation_biomarker_diagnosis_down hsa-mir-143 Alzheimer Disease 26078483 "The results showed that four miRNAs (miR-31, miR-93, miR-143, and miR-146a) were markedly decreased in AD patients'serum compared with controls." +circulation_biomarker_diagnosis_down hsa-mir-146a Alzheimer Disease 26078483 "The results showed that four miRNAs (miR-31, miR-93, miR-143, and miR-146a) were markedly decreased in AD patients'serum compared with controls." +circulation_biomarker_diagnosis_down hsa-mir-31 Alzheimer Disease 26078483 "The results showed that four miRNAs (miR-31, miR-93, miR-143, and miR-146a) were markedly decreased in AD patients'serum compared with controls." +circulation_biomarker_diagnosis_down hsa-mir-93 Alzheimer Disease 26078483 "The results showed that four miRNAs (miR-31, miR-93, miR-143, and miR-146a) were markedly decreased in AD patients'serum compared with controls." +circulation_biomarker_diagnosis_down hsa-mir-378 Dengue Virus Infection 26166761 "This study found that miR-27a*, miR-30e, and miR-378 were down-regulated in DENV-infected patients" +circulation_biomarker_diagnosis_down hsa-mir-155 Diabetes Mellitus 26188366 Downregulated microRNA-155 expression in peripheral blood mononuclear cells of type 2 diabetic patients is not correlated with increased inflammatory cytokine production. +circulation_biomarker_diagnosis_down hsa-mir-130b Heart Failure 26211628 MiR-130b levels were reduced in obese HF patients compared with HF lean (P=0.036) and controls (P=0.025). +circulation_biomarker_diagnosis_down hsa-mir-143 Obesity 26223376 "Circulating miR-335 (Pâ€?â€?.001), miR-143 (Pâ€?â€?.001) and miR-758 (Pâ€?â€?.006) in obese children were significantly lower than those of controls." +circulation_biomarker_diagnosis_down hsa-mir-335 Obesity 26223376 "Circulating miR-335 (Pâ€?â€?.001), miR-143 (Pâ€?â€?.001) and miR-758 (Pâ€?â€?.006) in obese children were significantly lower than those of controls." +circulation_biomarker_diagnosis_down hsa-mir-205 Glioma 26230475 Downregulation of serum microRNA-205 as a potential diagnostic and prognostic biomarker for human glioma. +circulation_biomarker_diagnosis_down hsa-mir-203 Gastric Neoplasms 26233325 serum miR-203 levels were significantly lower in stage IV than stage I-III GC patients. +circulation_biomarker_diagnosis_down hsa-mir-126 Diabetes Mellitus 26299579 Diabetes mellitus +circulation_biomarker_diagnosis_down hsa-mir-181b Atherosclerosis 26420120 The serum miR-181b level was significantly reduced in patients with atherosclerosis. miR-181b may function as an atherosclerosis suppressor by interupting the NF-¦ÊB pathway in endothelial cells and inhibiting the proliferation and migration of vascular smooth muscle cells. +circulation_biomarker_diagnosis_down hsa-mir-15a Diabetes Mellitus 26460159 "These results demonstrated that peripheral blood miR-15a expression levels were significantly lower in patients with T2D and IFG/IGT individuals, compared with healthy individuals. Thus, miR-15a in peripheral whole blood may serve as a potential biomarker for T2D and pre-diabetes." +circulation_biomarker_diagnosis_down hsa-mir-106a Cholangiocarcinoma 26534789 "Together, reduced expression of serum miR-106a is a powerful prognostic indicator for CCA patients. The dismal outcome of these CCA patients might correlate with a higher risk of lymph node metastasis." +circulation_biomarker_diagnosis_down hsa-mir-27a Acute Heart Failure 26569364 "The increase in creatinine during the first 3 days of hospitalization was significantly associated with lower levels of miR-199a-3p, miR-27a-3p, miR-652-3p, miR-423-5p, and miR-let-7i-5p" +circulation_biomarker_diagnosis_down hsa-mir-126 Acute Heart Failure 26580972 Levels of miR-126 and miR-423-5p were lower in AHF and in non-AHF patients compared to stable CHF patients (both p<0.001). +circulation_biomarker_diagnosis_down hsa-mir-122 Stroke 26661204 our recent studies have demonstrated that miR-122 decreased in whole blood of patients and in whole blood of rats following ischemic stroke +circulation_biomarker_diagnosis_down hsa-mir-150 Spondylarthritis 26689798 miR-150 was downregulated in all of the samples +circulation_biomarker_diagnosis_down hsa-mir-181a "Leukemia, Myeloid, Chronic" 26722250 The expression levels of miR-181a were significantly reduced in the patient with CML and in the CML K562 cell line. +circulation_biomarker_diagnosis_down hsa-mir-106b Human Immunodeficiency Virus Infection 26755399 we found that the miRNAs miR-106b and miR-20a that target p21 were specifically downregulated in HIV-1 infected CD4+ T cells. +circulation_biomarker_diagnosis_down hsa-mir-20a Human Immunodeficiency Virus Infection 26755399 we found that the miRNAs miR-106b and miR-20a that target p21 were specifically downregulated in HIV-1 infected CD4+ T cells. +circulation_biomarker_diagnosis_down hsa-mir-146a "Squamous Cell Carcinoma, Esophageal" 26794279 MicroRNA-146a is significantly reduced in cancerous tissue and serum samples of ESCC patients. It is an ideal biomarker for the prognosis and diagnosis of ESCC. +circulation_biomarker_diagnosis_down hsa-mir-221 Prostate Neoplasms 26831660 downregulation of hsa-miR-221* (now hsa-miR-221-5p) and hsa-miR-708* (now hsa-miR-708-3p) in PCa compared to BPH. +circulation_biomarker_diagnosis_down hsa-mir-708 Prostate Neoplasms 26831660 downregulation of hsa-miR-221* (now hsa-miR-221-5p) and hsa-miR-708* (now hsa-miR-708-3p) in PCa compared to BPH. +circulation_biomarker_diagnosis_down hsa-mir-199b "Leukemia, Myeloid, Acute" 26848406 Low miR-199b in AML patients correlates with worse overall survival and has prognostic significance for FAB-M5 subtype. +circulation_biomarker_diagnosis_down hsa-mir-199b Polycystic Ovarian Syndrome 26860517 whereas that of miR-199b-5p was down-regulated. +circulation_biomarker_diagnosis_down hsa-mir-34b "Leukemia, Myeloid, Acute, Pediatric" 26861642 miRâ€?4b levels in leukemia cell lines and primary leukemic cells were significantly lower than those in normal cells. +circulation_biomarker_diagnosis_down hsa-mir-194 Cholangiocarcinoma 26864161 miR-483-5p and miR-194 showed deregulated expression in CC compared with controls. +circulation_biomarker_diagnosis_down hsa-mir-483 Cholangiocarcinoma 26864161 whereas miR-483-5p and miR-194 showed deregulated expression in CC compared with controls +circulation_biomarker_diagnosis_down hsa-mir-15a "Leukemia, Lymphocytic, Chronic, B-Cell" 26908869 Downregulation of miR-15a and miR-16-1 at 13q14 in Chronic Lymphocytic Leukemia. +circulation_biomarker_diagnosis_down hsa-mir-16-1 "Leukemia, Lymphocytic, Chronic, B-Cell" 26908869 Downregulation of miR-15a and miR-16-1 at 13q14 in Chronic Lymphocytic Leukemia. +circulation_biomarker_diagnosis_down hsa-mir-126 Diabetes Mellitus 27005938 "Among those, miR-126 and miR-26a were significantly reduced in diabetic patients compared to non-diabetic patients." +circulation_biomarker_diagnosis_down hsa-mir-20a Endometriosis 27049094 "For recurred cases, miR-199 showed a remarkably high expression and miR-17-5p and miR-20a expressed significantly low." +circulation_biomarker_diagnosis_down hsa-mir-155 Chronic Hepatitis B 27110261 "In the HBV-infected patients, the miR-155 levels were significantly lower than in the healthy controls" +circulation_biomarker_diagnosis_down hsa-mir-106a Aortic Stenosis 27129184 "Levels of miR-30c were higher in the AS group than in the controls (P<0.01), whereas levels of miR-106a, miR-148a, miR-204, miR-211, miR-31 and miR-424 were lower in the AS group than in the controls (P<0.01)." +circulation_biomarker_diagnosis_down hsa-mir-148a Aortic Stenosis 27129184 "Levels of miR-30c were higher in the AS group than in the controls (P<0.01), whereas levels of miR-106a, miR-148a, miR-204, miR-211, miR-31 and miR-424 were lower in the AS group than in the controls (P<0.01)." +circulation_biomarker_diagnosis_down hsa-mir-204 Aortic Stenosis 27129184 "Levels of miR-30c were higher in the AS group than in the controls (P<0.01), whereas levels of miR-106a, miR-148a, miR-204, miR-211, miR-31 and miR-424 were lower in the AS group than in the controls (P<0.01)." +circulation_biomarker_diagnosis_down hsa-mir-211 Aortic Stenosis 27129184 "Levels of miR-30c were higher in the AS group than in the controls (P<0.01), whereas levels of miR-106a, miR-148a, miR-204, miR-211, miR-31 and miR-424 were lower in the AS group than in the controls (P<0.01)." +circulation_biomarker_diagnosis_down hsa-mir-30a Aortic Stenosis 27129184 "Levels of miR-30c were higher in the AS group than in the controls (P<0.01), whereas levels of miR-106a, miR-148a, miR-204, miR-211, miR-31 and miR-424 were lower in the AS group than in the controls (P<0.01)." +circulation_biomarker_diagnosis_down hsa-mir-31 Aortic Stenosis 27129184 "Levels of miR-30c were higher in the AS group than in the controls (P<0.01), whereas levels of miR-106a, miR-148a, miR-204, miR-211, miR-31 and miR-424 were lower in the AS group than in the controls (P<0.01)." +circulation_biomarker_diagnosis_down hsa-mir-424 Aortic Stenosis 27129184 "Levels of miR-30c were higher in the AS group than in the controls (P<0.01), whereas levels of miR-106a, miR-148a, miR-204, miR-211, miR-31 and miR-424 were lower in the AS group than in the controls (P<0.01)." +circulation_biomarker_diagnosis_down hsa-mir-1297 "Squamous Cell Carcinoma, Esophageal" 27152453 It was statistically decreased in ESCC patients compared with healthy controls. +circulation_biomarker_diagnosis_down hsa-mir-125b "Carcinoma, Hepatocellular, HBV-Related" 27152955 The levels of plasma miR-125b were remarkably decreased in HBV-HCC patients compared to healthy controls +circulation_biomarker_diagnosis_down hsa-mir-181a Human Immunodeficiency Virus Infection 27171002 "hsa-miR-155 and hsa-miR-181a were downregulated in VP whereas in the other groups, either an upregulation or no differences were observed after stimulation, respectively." +circulation_biomarker_diagnosis_down hsa-mir-200c Breast Neoplasms 27197674 "miR-21 (P < 0.001) and miR-146a (P = 0.001) were overexpressed, whereas miR-200c (P = 0.004) and miR-210 (P = 0.002) were underexpressed." +circulation_biomarker_diagnosis_down hsa-mir-210 Breast Neoplasms 27197674 "miR-21 (P < 0.001) and miR-146a (P = 0.001) were overexpressed, whereas miR-200c (P = 0.004) and miR-210 (P = 0.002) were underexpressed." +circulation_biomarker_diagnosis_down hsa-mir-182 Atherosclerosis 27199451 Atherosclerotic lesions from patients with high asymmetrical dimethylarginine plasma levels exhibited decreased miR-182-3p expression levels and elevated MYADM expression levels. +circulation_biomarker_diagnosis_down hsa-mir-181a Allergic Rhinitis 27199509 The OPN protein and miR-181a levels may serve as predictors of disease severity in childhood AR and appear to be promising targets for modulating AR. +circulation_biomarker_diagnosis_down hsa-mir-19a Lung Fibrosis 27312312 miR-19a in peripheral blood leukocyte could be used as an effective biomarker for silicosis +circulation_biomarker_diagnosis_down hsa-mir-126 Coronary Artery Disease 27321479 MiR-126 strongly associated with T2D and CAD +circulation_biomarker_diagnosis_down hsa-mir-126 "Diabetes Mellitus, Type 2" 27321479 "expression levels of circulating miR-126, determined by quantitative real time PCR, were decrease in peripheral blood of T2D patients and T2D with CAD compared with healthy controls." +circulation_biomarker_diagnosis_down hsa-mir-30 Atherosclerosis 27379414 circulating miR-30 might be used as a biomarker for atherosclerosis +circulation_biomarker_diagnosis_down hsa-mir-375 Diabetes Mellitus 27383196 lower circulating levels of miR-192 and miR-375 compared to CD period +circulation_biomarker_diagnosis_down hsa-mir-4505 Anxiety Disorders 27423364 "Results showed that the level of miR-4505 and miR-663 was negatively correlated with the total HAMA scores in GAD patients (r=0.2228, r=0.264 P<0.05)." +circulation_biomarker_diagnosis_down hsa-mir-663 Anxiety Disorders 27423364 "esults showed that the level of miR-4505 and miR-663 was negatively correlated with the total HAMA scores in GAD patients (r=0.2228, r=0.264 P<0.05)." +circulation_biomarker_diagnosis_down hsa-mir-320b Carotid Artery Diseases 27460454 Low serum miR-320b expression as a novel indicator of carotid atherosclerosis. +circulation_biomarker_diagnosis_down hsa-mir-335 Spinal Muscular Atrophy 27483257 The expression of miR-335-5p; already identified to control self-renewal or differentiation of mouse embryonic stem cells (mESCs); resulted to be reduced during the early steps of differentiation of SMA hiPSCs compared to wild type cells. +circulation_biomarker_diagnosis_down hsa-mir-31 Systemic Lupus Erythematosus 27510529 "The results revealed that miR-31 was lower expressed, while miR-21 was high expressed in SLE patients compared to their first-degree relatives and controls." +circulation_biomarker_diagnosis_down hsa-mir-200b Kideny Transplant Rejection 27521993 our findings indicated that the aberrant urinary miR-21 and miR-200b expression levels were accompanied with renal allograft dysfunction and IFTA. +circulation_biomarker_diagnosis_down hsa-mir-29a "Leukemia, Lymphoblastic" 27535859 "The expression of hsa-miR-29a , hsa-miR-126 and has-miR-181 family were significantly different in B-ALL." +circulation_biomarker_diagnosis_down hsa-mir-663 Leukemia 27535859 "The expression of hsa-miR-29a , hsa-miR-126 and has-miR-181 family were significantly different in B-ALL." +circulation_biomarker_diagnosis_down hsa-mir-150 Cholangiocarcinoma 27658773 Profiling of downregulated blood-circulating miR-150-5p as a novel tumor marker for cholangiocarcinoma. +circulation_biomarker_diagnosis_down hsa-mir-155 "Fatty Liver, Non-Alcoholic" 27832630 Decreased MiR-155 Level in the Peripheral Blood of Non-Alcoholic Fatty Liver Disease Patients may Serve as a Biomarker and may Influence LXR Activity. +circulation_biomarker_diagnosis_down hsa-mir-335 Acute Ischemic Stroke 27856935 Decreased plasma miR-335 expression in patients with acute ischemic stroke and its association with calmodulin expression. +circulation_biomarker_diagnosis_down hsa-mir-126 Cardiovascular Diseases [unspecific] 28065883 Down-regulation of proangiogenic microRNA-126 and microRNA-132 are early modulators of diabetic cardiac microangiopathy. +circulation_biomarker_diagnosis_down hsa-mir-132 Cardiovascular Diseases [unspecific] 28065883 Down-regulation of proangiogenic microRNA-126 and microRNA-132 are early modulators of diabetic cardiac microangiopathy. +circulation_biomarker_diagnosis_down hsa-mir-27a Heart Failure 28293796 Low circulating microRNA levels in heart failure patients are associated with atherosclerotic disease and cardiovascular-related rehospitalizations. +circulation_biomarker_diagnosis_down hsa-mir-204 Aortic Valve Disease 28377507 miR-486 inhibits Smurf2 expression to augment the miR-204 down-regulation +circulation_biomarker_diagnosis_down hsa-mir-150 "Leukemia, Lymphocytic, Chronic, B-Cell" 28407516 Quantitative miR analysis in chronic lymphocytic leukaemia/small lymphocytic lymphoma - proliferation centres are characterized by high miR-92a and miR-155 and low miR-150 expression. +circulation_biomarker_diagnosis_down hsa-mir-155 Myocardial Infarction 28618412 Failed Downregulation of Circulating MicroRNA-155 in the Early Phase after ST Elevation Myocardial Infarction Is Associated with Adverse Left Ventricular Remodeling. +circulation_biomarker_diagnosis_down hsa-mir-133a Vascular Hypertrophy 28772031 Local microRNA-133a downregulation is associated with hypertrophy in the dyssynchronous heart. +circulation_biomarker_diagnosis_down hsa-let-7f "Leukemia, Lymphoblastic, Acute, Childhood" 28910942 "The expression levels of let-7f-5p, miR-5100 and miR-25-3p in the cALL patients were significantly lower than those of the controls" +circulation_biomarker_diagnosis_down hsa-mir-25 "Leukemia, Lymphoblastic, Acute, Childhood" 28910942 "The expression levels of let-7f-5p, miR-5100 and miR-25-3p in the cALL patients were significantly lower than those of the controls" +circulation_biomarker_diagnosis_down hsa-mir-5100 "Leukemia, Lymphoblastic, Acute, Childhood" 28910942 "The expression levels of let-7f-5p, miR-5100 and miR-25-3p in the cALL patients were significantly lower than those of the controls" +circulation_biomarker_diagnosis_down hsa-mir-126 Coronary Artery Disease 29062343 miR-126 expression was significantly down-regulated in the circulation of CAD patients compared with control subjects +circulation_biomarker_diagnosis_down hsa-mir-18a "Leukemia, Lymphoblastic, Acute" 29068867 Low Expression of miR-18a as a Characteristic of Pediatric Acute Lymphoblastic Leukemia. +circulation_biomarker_diagnosis_down hsa-mir-21 "Diabetes Mellitus, Type 2" 29113498 Decreased serum microRNA-21 level is associated with obesity in healthy and type 2 diabetic subjects. +circulation_biomarker_diagnosis_down hsa-mir-638 "Carcinoma, Hepatocellular" 29278659 Decreased levels of serum exosomal miR-638 predict poor prognosis in hepatocellular carcinoma. +circulation_biomarker_diagnosis_down hsa-mir-133a Myocardial Infarction 29324314 Down-regulation of miR-133a/b in patients with myocardial infarction correlates with the presence of ventricular fibrillation +circulation_biomarker_diagnosis_down hsa-mir-133b Myocardial Infarction 29324314 Down-regulation of miR-133a/b in patients with myocardial infarction correlates with the presence of ventricular fibrillation +circulation_biomarker_diagnosis_down hsa-mir-222 Preeclampsia 29381395 serum miR-222 expression levels showed a significant decrease in PE compared to GH and normotensive groups +circulation_biomarker_diagnosis_down hsa-mir-34a Pulmonary Hypertension 29431643 Circulatory miR-34a-3p expression is decreased in both patients with PAH and preclinical models of PAH +circulation_biomarker_diagnosis_down hsa-mir-204 Frontotemporal Dementia 29434051 Downregulation of exosomal miR-204-5p and miR-632 as a biomarker for FTD: a GENFI study. +circulation_biomarker_diagnosis_down hsa-mir-632 Frontotemporal Dementia 29434051 Downregulation of exosomal miR-204-5p and miR-632 as a biomarker for FTD: a GENFI study. +circulation_biomarker_diagnosis_down hsa-mir-17 Myocardial Infarction 29536180 Downregulation of microRNA-17-5p improves cardiac function after myocardial infarction via attenuation of apoptosis in endothelial cells. +circulation_biomarker_diagnosis_down hsa-mir-20a "Diabetes Mellitus, Gestational" 29556924 Decreased Expression of Circulating miR-20a-5p in South African Women with Gestational Diabetes Mellitus. +circulation_biomarker_diagnosis_down hsa-mir-221 Colorectal Carcinoma 29630521 "Following the overexpression of GAS5, the GAS5expressions was up-regulated and miR-221 expression was down-regulated; the rate of cell proliferation, migration and invasion were decreased" +circulation_biomarker_diagnosis_down hsa-mir-29a Spinal Stenosis 29749498 Detection of miR?29a in plasma of patients with lumbar spinal stenosis and the clinical significance. +circulation_biomarker_diagnosis_down hsa-let-7d Familial Mediterranean Fever 29787577 "four miRNAs were upregulated (miR-144-3p, miR-21-5p, miR-4454, and miR-451a), and three were downregulated (miR-107, let-7d-5p, and miR-148b-3p)" +circulation_biomarker_diagnosis_down hsa-mir-107 Familial Mediterranean Fever 29787577 "four miRNAs were upregulated (miR-144-3p, miR-21-5p, miR-4454, and miR-451a), and three were downregulated (miR-107, let-7d-5p, and miR-148b-3p)" +circulation_biomarker_diagnosis_down hsa-mir-148b Familial Mediterranean Fever 29787577 "four miRNAs were upregulated (miR-144-3p, miR-21-5p, miR-4454, and miR-451a), and three were downregulated (miR-107, let-7d-5p, and miR-148b-3p)" +circulation_biomarker_diagnosis_down hsa-mir-122 Preeclampsia 29800045 "Circulating levels of miR-126-3p, -146a-5p, and -122-5p were significantly decreased in women with premature ACS who reported prior PE compared to those with prior normotensive pregnancy" +circulation_biomarker_diagnosis_down hsa-mir-126 Preeclampsia 29800045 "Circulating levels of miR-126-3p, -146a-5p, and -122-5p were significantly decreased in women with premature ACS who reported prior PE compared to those with prior normotensive pregnancy" +circulation_biomarker_diagnosis_down hsa-mir-146a Preeclampsia 29800045 "Circulating levels of miR-126-3p, -146a-5p, and -122-5p were significantly decreased in women with premature ACS who reported prior PE compared to those with prior normotensive pregnancy" +circulation_biomarker_diagnosis_down hsa-mir-1246 Systemic Lupus Erythematosus 29873187 "Although the levels of many miRNAs were unaffected after passage through the plasma adsorption membrane, expression of some miRNAs, including miR-1246, miR-4732-5p, and miR-6088 are declined" +circulation_biomarker_diagnosis_down hsa-mir-4732 Systemic Lupus Erythematosus 29873187 "Although the levels of many miRNAs were unaffected after passage through the plasma adsorption membrane, expression of some miRNAs, including miR-1246, miR-4732-5p, and miR-6088 are declined" +circulation_biomarker_diagnosis_down hsa-mir-6088 Systemic Lupus Erythematosus 29873187 "Although the levels of many miRNAs were unaffected after passage through the plasma adsorption membrane, expression of some miRNAs, including miR-1246, miR-4732-5p, and miR-6088 are declined" +circulation_biomarker_diagnosis_down hsa-mir-194 Traumatic Brain Injury 29873258 miR-300-3p and miR-598-3p increased while miR-450-3p and miR-194-5p significantly decreased following TBI +circulation_biomarker_diagnosis_down hsa-mir-450 Traumatic Brain Injury 29873258 miR-300-3p and miR-598-3p increased while miR-450-3p and miR-194-5p significantly decreased following TBI +circulation_biomarker_diagnosis_down hsa-mir-128 Systemic Lupus Erythematosus 29873766 "miR-361-5p, miR-128-3p and miR-181a-2-3p expression was lower in patients with a high IFN signature (false discovery rate <0.05) as compared with patients with a low IFN signature and HCs." +circulation_biomarker_diagnosis_down hsa-mir-181a Systemic Lupus Erythematosus 29873766 "miR-361-5p, miR-128-3p and miR-181a-2-3p expression was lower in patients with a high IFN signature (false discovery rate <0.05) as compared with patients with a low IFN signature and HCs." +circulation_biomarker_diagnosis_down hsa-mir-361 Systemic Lupus Erythematosus 29873766 "miR-361-5p, miR-128-3p and miR-181a-2-3p expression was lower in patients with a high IFN signature (false discovery rate <0.05) as compared with patients with a low IFN signature and HCs." +circulation_biomarker_diagnosis_down hsa-mir-142 Acute Lung Injury 29904430 "9 miRNAs were significantly upregulated (miR-1843-3p, miR-323-3p, miR-183-5p, miR-182 and miR-196b-3p) or downregulated (miR-547-3p, miR-301b-5p, miR-503-3p and miR-142-3p)" +circulation_biomarker_diagnosis_down hsa-mir-301b Acute Lung Injury 29904430 "9 miRNAs were significantly upregulated (miR-1843-3p, miR-323-3p, miR-183-5p, miR-182 and miR-196b-3p) or downregulated (miR-547-3p, miR-301b-5p, miR-503-3p and miR-142-3p)" +circulation_biomarker_diagnosis_down hsa-mir-503 Acute Lung Injury 29904430 "9 miRNAs were significantly upregulated (miR-1843-3p, miR-323-3p, miR-183-5p, miR-182 and miR-196b-3p) or downregulated (miR-547-3p, miR-301b-5p, miR-503-3p and miR-142-3p)" +circulation_biomarker_diagnosis_down hsa-mir-547 Acute Lung Injury 29904430 "9 miRNAs were significantly upregulated (miR-1843-3p, miR-323-3p, miR-183-5p, miR-182 and miR-196b-3p) or downregulated (miR-547-3p, miR-301b-5p, miR-503-3p and miR-142-3p)" +circulation_biomarker_diagnosis_down hsa-mir-141 Parkinson Disease 29935433 "We identified differential expression of 10 miRNA of which 5 were upregulated in PD (miR-9-5p, miR-135a-5p, miR-135b-5p, miR-449a, and miR-449b-5p) and 5 downregulated (miR-141-3p, miR-199a-5p, miR-299-5p, miR-518e-3p, and miR-519a-3p)" +circulation_biomarker_diagnosis_down hsa-mir-199a Parkinson Disease 29935433 "We identified differential expression of 10 miRNA of which 5 were upregulated in PD (miR-9-5p, miR-135a-5p, miR-135b-5p, miR-449a, and miR-449b-5p) and 5 downregulated (miR-141-3p, miR-199a-5p, miR-299-5p, miR-518e-3p, and miR-519a-3p)" +circulation_biomarker_diagnosis_down hsa-mir-299 Parkinson Disease 29935433 "We identified differential expression of 10 miRNA of which 5 were upregulated in PD (miR-9-5p, miR-135a-5p, miR-135b-5p, miR-449a, and miR-449b-5p) and 5 downregulated (miR-141-3p, miR-199a-5p, miR-299-5p, miR-518e-3p, and miR-519a-3p)" +circulation_biomarker_diagnosis_down hsa-mir-518e Parkinson Disease 29935433 "We identified differential expression of 10 miRNA of which 5 were upregulated in PD (miR-9-5p, miR-135a-5p, miR-135b-5p, miR-449a, and miR-449b-5p) and 5 downregulated (miR-141-3p, miR-199a-5p, miR-299-5p, miR-518e-3p, and miR-519a-3p)" +circulation_biomarker_diagnosis_down hsa-mir-519a Parkinson Disease 29935433 "We identified differential expression of 10 miRNA of which 5 were upregulated in PD (miR-9-5p, miR-135a-5p, miR-135b-5p, miR-449a, and miR-449b-5p) and 5 downregulated (miR-141-3p, miR-199a-5p, miR-299-5p, miR-518e-3p, and miR-519a-3p)" +circulation_biomarker_diagnosis_down hsa-mir-151a Lupus Nephritis 29998838 Down-regulation of serum miR-151a-3p is associated with renal tissue activity in class IV lupus nephritis. +circulation_biomarker_diagnosis_down hsa-mir-15b Systemic Lupus Erythematosus 30008716 "the downregulated expression of miR-19b, miR-25, miR-93, and miR-15b was associated with SLE disease activity (P?0.7, including miR-24, miR-134, miR-146a, miR-378, miR-484, miR-628-3p, and miR-1825." +circulation_biomarker_diagnosis_ns hsa-mir-146a Pancreatic Neoplasms 23697990 "Several other circulating miRNAs distinguished sera of patients with pancreatic cancer from those of healthy controls with AUCs >0.7, including miR-24, miR-134, miR-146a, miR-378, miR-484, miR-628-3p, and miR-1825." +circulation_biomarker_diagnosis_ns hsa-mir-1825 Pancreatic Neoplasms 23697990 "Several other circulating miRNAs distinguished sera of patients with pancreatic cancer from those of healthy controls with AUCs >0.7, including miR-24, miR-134, miR-146a, miR-378, miR-484, miR-628-3p, and miR-1825." +circulation_biomarker_diagnosis_ns hsa-mir-24 Pancreatic Neoplasms 23697990 "Several other circulating miRNAs distinguished sera of patients with pancreatic cancer from those of healthy controls with AUCs >0.7, including miR-24, miR-134, miR-146a, miR-378, miR-484, miR-628-3p, and miR-1825." +circulation_biomarker_diagnosis_ns hsa-mir-378 Pancreatic Neoplasms 23697990 "Several other circulating miRNAs distinguished sera of patients with pancreatic cancer from those of healthy controls with AUCs >0.7, including miR-24, miR-134, miR-146a, miR-378, miR-484, miR-628-3p, and miR-1825." +circulation_biomarker_diagnosis_ns hsa-mir-484 Pancreatic Neoplasms 23697990 "Several other circulating miRNAs distinguished sera of patients with pancreatic cancer from those of healthy controls with AUCs >0.7, including miR-24, miR-134, miR-146a, miR-378, miR-484, miR-628-3p, and miR-1825." +circulation_biomarker_diagnosis_ns hsa-mir-628 Pancreatic Neoplasms 23697990 "Several other circulating miRNAs distinguished sera of patients with pancreatic cancer from those of healthy controls with AUCs >0.7, including miR-24, miR-134, miR-146a, miR-378, miR-484, miR-628-3p, and miR-1825." +circulation_biomarker_diagnosis_ns hsa-mir-122 "Carcinoma, Hepatocellular" 23723713 Circulating microRNA-122a as a diagnostic marker for hepatocellular carcinoma. +circulation_biomarker_diagnosis_ns hsa-mir-199a-1 Gastric Neoplasms 23733518 MiRNA-199a-3p: A Potential Circulating Diagnostic Biomarker for Early Gastric Cancer. +circulation_biomarker_diagnosis_ns hsa-mir-199a-2 Gastric Neoplasms 23733518 MiRNA-199a-3p: A Potential Circulating Diagnostic Biomarker for Early Gastric Cancer. +circulation_biomarker_diagnosis_ns hsa-mir-145 Heart Failure 23736534 "Changed circulating miRNA-26b-5p, miRNA-145-5p, miRNA-92a-3p, miRNA-30e-5p, and miRNA-29a-3p" +circulation_biomarker_diagnosis_ns hsa-mir-26b Heart Failure 23736534 "Changed circulating miRNA-26b-5p, miRNA-145-5p, miRNA-92a-3p, miRNA-30e-5p, and miRNA-29a-3p" +circulation_biomarker_diagnosis_ns hsa-mir-29a Heart Failure 23736534 "Changed circulating miRNA-26b-5p, miRNA-145-5p, miRNA-92a-3p, miRNA-30e-5p, and miRNA-29a-3p" +circulation_biomarker_diagnosis_ns hsa-mir-30e Heart Failure 23736534 "Changed circulating miRNA-26b-5p, miRNA-145-5p, miRNA-92a-3p, miRNA-30e-5p, and miRNA-29a-3p" +circulation_biomarker_diagnosis_ns hsa-mir-92a-1 Heart Failure 23736534 "Changed circulating miRNA-26b-5p, miRNA-145-5p, miRNA-92a-3p, miRNA-30e-5p, and miRNA-29a-3p" +circulation_biomarker_diagnosis_ns hsa-mir-92a-2 Heart Failure 23736534 "Changed circulating miRNA-26b-5p, miRNA-145-5p, miRNA-92a-3p, miRNA-30e-5p, and miRNA-29a-3p" +circulation_biomarker_diagnosis_ns hsa-mir-1-1 Myocardial Infarction 23747779 "Circulating miR-1, miR-208a, and miR-133a continuously rose during the first 4 h after induction of AMI." +circulation_biomarker_diagnosis_ns hsa-mir-1-2 Myocardial Infarction 23747779 "Circulating miR-1, miR-208a, and miR-133a continuously rose during the first 4 h after induction of AMI." +circulation_biomarker_diagnosis_ns hsa-mir-133a-1 Myocardial Infarction 23747779 "Circulating miR-1, miR-208a, and miR-133a continuously rose during the first 4 h after induction of AMI." +circulation_biomarker_diagnosis_ns hsa-mir-133a-2 Myocardial Infarction 23747779 "Circulating miR-1, miR-208a, and miR-133a continuously rose during the first 4 h after induction of AMI." +circulation_biomarker_diagnosis_ns hsa-mir-208a Myocardial Infarction 23747779 "Circulating miR-1, miR-208a, and miR-133a continuously rose during the first 4 h after induction of AMI." +circulation_biomarker_diagnosis_ns hsa-mir-155 Breast Neoplasms 23748853 "Deregulated Serum Concentrations of Circulating Cell-Free MicroRNAs miR-17, miR-34a, miR-155, and miR-373 in Human Breast Cancer Development and Progression." +circulation_biomarker_diagnosis_ns hsa-mir-17 Breast Neoplasms 23748853 "Deregulated Serum Concentrations of Circulating Cell-Free MicroRNAs miR-17, miR-34a, miR-155, and miR-373 in Human Breast Cancer Development and Progression." +circulation_biomarker_diagnosis_ns hsa-mir-34a Breast Neoplasms 23748853 "Deregulated Serum Concentrations of Circulating Cell-Free MicroRNAs miR-17, miR-34a, miR-155, and miR-373 in Human Breast Cancer Development and Progression." +circulation_biomarker_diagnosis_ns hsa-mir-373 Breast Neoplasms 23748853 "Deregulated Serum Concentrations of Circulating Cell-Free MicroRNAs miR-17, miR-34a, miR-155, and miR-373 in Human Breast Cancer Development and Progression." +circulation_biomarker_diagnosis_ns hsa-mir-10a "Carcinoma, Lung, Non-Small-Cell" 23756108 "Plasma miR-21, miR-30d, miR-451, miR-10a, miR-30e-5p and miR-126*, miR-126, miR-145) were differentially expressed" +circulation_biomarker_diagnosis_ns hsa-mir-126 "Carcinoma, Lung, Non-Small-Cell" 23756108 "Plasma miR-21, miR-30d, miR-451, miR-10a, miR-30e-5p and miR-126*, miR-126, miR-145) were differentially expressed" +circulation_biomarker_diagnosis_ns hsa-mir-145 "Carcinoma, Lung, Non-Small-Cell" 23756108 "Plasma miR-21, miR-30d, miR-451, miR-10a, miR-30e-5p and miR-126*, miR-126, miR-145) were differentially expressed" +circulation_biomarker_diagnosis_ns hsa-mir-21 "Carcinoma, Lung, Non-Small-Cell" 23756108 "Plasma miR-21, miR-30d, miR-451, miR-10a, miR-30e-5p and miR-126*, miR-126, miR-145) were differentially expressed" +circulation_biomarker_diagnosis_ns hsa-mir-30d "Carcinoma, Lung, Non-Small-Cell" 23756108 "Plasma miR-21, miR-30d, miR-451, miR-10a, miR-30e-5p and miR-126*, miR-126, miR-145) were differentially expressed" +circulation_biomarker_diagnosis_ns hsa-mir-30e "Carcinoma, Lung, Non-Small-Cell" 23756108 "Plasma miR-21, miR-30d, miR-451, miR-10a, miR-30e-5p and miR-126*, miR-126, miR-145) were differentially expressed" +circulation_biomarker_diagnosis_ns hsa-mir-451a "Carcinoma, Lung, Non-Small-Cell" 23756108 "Plasma miR-21, miR-30d, miR-451, miR-10a, miR-30e-5p and miR-126*, miR-126, miR-145) were differentially expressed" +circulation_biomarker_diagnosis_ns hsa-mir-451b "Carcinoma, Lung, Non-Small-Cell" 23756108 "Plasma miR-21, miR-30d, miR-451, miR-10a, miR-30e-5p and miR-126*, miR-126, miR-145) were differentially expressed" +circulation_biomarker_diagnosis_ns hsa-mir-195 "Carcinoma, Adrenocortical" 23756429 Serum miR-483-5p and miR-195 are predictive of recurrence risk in adrenocortical cancer patients. +circulation_biomarker_diagnosis_ns hsa-mir-483 "Carcinoma, Adrenocortical" 23756429 Serum miR-483-5p and miR-195 are predictive of recurrence risk in adrenocortical cancer patients. +circulation_biomarker_diagnosis_ns hsa-mir-145 Multiple Sclerosis 23773985 "RRMS patients in remission had altered expression of mirNAs. We validated mir-145 as a potential diagnostic biomarker for the diagnosis of MS in blood, plasma and serum." +circulation_biomarker_diagnosis_ns hsa-mir-27a Pancreatic Neoplasms 23782250 Combined serum CA19-9 and miR-27a-3p in peripheral blood mononuclear cells to diagnose pancreatic cancer. +circulation_biomarker_diagnosis_ns hsa-mir-424 Fragile X Syndrome 23790110 MicroRNA expression profiling in blood from fragile X-associated tremor/ataxia syndrome patients. +circulation_biomarker_diagnosis_ns hsa-mir-574 Fragile X Syndrome 23790110 MicroRNA expression profiling in blood from fragile X-associated tremor/ataxia syndrome patients. +circulation_biomarker_diagnosis_ns hsa-mir-1246 Early-Stage Cervical Squamous Cell Carcinoma 23799609 Serum microRNA expression levels can predict lymph node metastasis in patients with early-stage cervical squamous cell carcinoma. +circulation_biomarker_diagnosis_ns hsa-mir-20a Early-Stage Cervical Squamous Cell Carcinoma 23799609 Serum microRNA expression levels can predict lymph node metastasis in patients with early-stage cervical squamous cell carcinoma. +circulation_biomarker_diagnosis_ns hsa-mir-2392 Early-Stage Cervical Squamous Cell Carcinoma 23799609 Serum microRNA expression levels can predict lymph node metastasis in patients with early-stage cervical squamous cell carcinoma. +circulation_biomarker_diagnosis_ns hsa-mir-3162 Early-Stage Cervical Squamous Cell Carcinoma 23799609 Serum microRNA expression levels can predict lymph node metastasis in patients with early-stage cervical squamous cell carcinoma. +circulation_biomarker_diagnosis_ns hsa-mir-4484 Early-Stage Cervical Squamous Cell Carcinoma 23799609 Serum microRNA expression levels can predict lymph node metastasis in patients with early-stage cervical squamous cell carcinoma. +circulation_biomarker_diagnosis_ns hsa-mir-106b Gastric Neoplasms 23806809 Validation of circulating miRNA biomarkers for predicting lymph node metastasis in gastric cancer. +circulation_biomarker_diagnosis_ns hsa-mir-146a Gastric Neoplasms 23806809 Validation of circulating miRNA biomarkers for predicting lymph node metastasis in gastric cancer. +circulation_biomarker_diagnosis_ns hsa-mir-148a Gastric Neoplasms 23806809 Validation of circulating miRNA biomarkers for predicting lymph node metastasis in gastric cancer. +circulation_biomarker_diagnosis_ns hsa-mir-21 Gastric Neoplasms 23806809 Validation of circulating miRNA biomarkers for predicting lymph node metastasis in gastric cancer. +circulation_biomarker_diagnosis_ns hsa-mir-223 Gastric Neoplasms 23806809 Validation of circulating miRNA biomarkers for predicting lymph node metastasis in gastric cancer. +circulation_biomarker_diagnosis_ns hsa-mir-27a Gastric Neoplasms 23806809 Validation of circulating miRNA biomarkers for predicting lymph node metastasis in gastric cancer. +circulation_biomarker_diagnosis_ns hsa-mir-433 Gastric Neoplasms 23806809 Validation of circulating miRNA biomarkers for predicting lymph node metastasis in gastric cancer. +circulation_biomarker_diagnosis_ns hsa-mir-1 "Carcinoma, Hepatocellular" 23810247 Our data indicate that serum miR-1 is a new independent parameter of OS in HCC patients and may therefore improve the predictive value of classical HCC staging scores. +circulation_biomarker_diagnosis_ns hsa-mir-122 "Carcinoma, Hepatocellular" 23810247 Our data indicate that serum miR-1 is a new independent parameter of OS in HCC patients and may therefore improve the predictive value of classical HCC staging scores. +circulation_biomarker_diagnosis_ns hsa-mir-122 Chronic Obstructive Pulmonary Disease 23814167 Plasma levels of individual myomiRs are altered in patients with COPD but alone do not predict muscle fibre size or proportion. Our findings are consistent with an increase in muscle wasting and turnover associated with the development of skeletal muscle dysfunction and fibre-type shift in patients with stable COPD. +circulation_biomarker_diagnosis_ns hsa-mir-16 Chronic Obstructive Pulmonary Disease 23814167 Plasma levels of individual myomiRs are altered in patients with COPD but alone do not predict muscle fibre size or proportion. Our findings are consistent with an increase in muscle wasting and turnover associated with the development of skeletal muscle dysfunction and fibre-type shift in patients with stable COPD. +circulation_biomarker_diagnosis_ns hsa-mir-107 Pancreatic Neoplasms 23834149 "At last, we have also explained the role of miRNAs in diagnostic marker (miR- 200, miR-21, miR-103, miR-107, and miR-155) and as a therapeutic modulator (miR-34, miR-21, miR-221, and miR-101) in pancreatic cancer." +circulation_biomarker_diagnosis_ns hsa-mir-29c Colorectal Carcinoma 23840538 "miRNA-29c shows anti-tumorigenesis activity, and preoperative circulating miRNA-29c levels can be used to predict postoperative early relapse of CRC." +circulation_biomarker_diagnosis_ns hsa-mir-145 Stroke 23860376 Serum miR-145 was not detected in over 50% of the patients and it may not be an ideal marker to predict stroke. MiR-21 and miR-221 are novel biomarkers for atherosclerosis and stroke. +circulation_biomarker_diagnosis_ns hsa-mir-221 Stroke 23860376 Serum miR-145 was not detected in over 50% of the patients and it may not be an ideal marker to predict stroke. MiR-21 and miR-221 are novel biomarkers for atherosclerosis and stroke. +circulation_biomarker_diagnosis_ns hsa-mir-145 Melanoma 23863473 Sensitive detection of melanoma metastasis using circulating microRNA expression profiles. +circulation_biomarker_diagnosis_ns hsa-mir-150 Melanoma 23863473 Sensitive detection of melanoma metastasis using circulating microRNA expression profiles. +circulation_biomarker_diagnosis_ns hsa-mir-155 Melanoma 23863473 Sensitive detection of melanoma metastasis using circulating microRNA expression profiles. +circulation_biomarker_diagnosis_ns hsa-mir-203 Melanoma 23863473 Sensitive detection of melanoma metastasis using circulating microRNA expression profiles. +circulation_biomarker_diagnosis_ns hsa-mir-205 Melanoma 23863473 Sensitive detection of melanoma metastasis using circulating microRNA expression profiles. +circulation_biomarker_diagnosis_ns hsa-mir-9 Melanoma 23863473 Sensitive detection of melanoma metastasis using circulating microRNA expression profiles. +circulation_biomarker_diagnosis_ns hsa-mir-130b Metabolic Syndrome 23868745 Circulating miR-130b reflects the degree of obesity and could serve as a potential biomarker for hypertriacylglycerolaemia and metabolic syndrome. Circulating miR-130b could function as a metabolic mediator for adipose muscle crosstalk and might be involved in the pathogenesis of obesity associated metabolic diseases. +circulation_biomarker_diagnosis_ns hsa-mir-106b Neoplasms [unspecific] 23874370 Principal component analysis based feature extraction approach to identify circulating microRNA biomarkers. +circulation_biomarker_diagnosis_ns hsa-mir-140 Neoplasms [unspecific] 23874370 Principal component analysis based feature extraction approach to identify circulating microRNA biomarkers. +circulation_biomarker_diagnosis_ns hsa-mir-15b Neoplasms [unspecific] 23874370 Principal component analysis based feature extraction approach to identify circulating microRNA biomarkers. +circulation_biomarker_diagnosis_ns hsa-mir-16 Neoplasms [unspecific] 23874370 Principal component analysis based feature extraction approach to identify circulating microRNA biomarkers. +circulation_biomarker_diagnosis_ns hsa-mir-185 Neoplasms [unspecific] 23874370 Principal component analysis based feature extraction approach to identify circulating microRNA biomarkers. +circulation_biomarker_diagnosis_ns hsa-mir-191 Neoplasms [unspecific] 23874370 Principal component analysis based feature extraction approach to identify circulating microRNA biomarkers. +circulation_biomarker_diagnosis_ns hsa-mir-19b Neoplasms [unspecific] 23874370 Principal component analysis based feature extraction approach to identify circulating microRNA biomarkers. +circulation_biomarker_diagnosis_ns hsa-mir-30d Neoplasms [unspecific] 23874370 Principal component analysis based feature extraction approach to identify circulating microRNA biomarkers. +circulation_biomarker_diagnosis_ns hsa-mir-320a Neoplasms [unspecific] 23874370 Principal component analysis based feature extraction approach to identify circulating microRNA biomarkers. +circulation_biomarker_diagnosis_ns hsa-mir-425 Neoplasms [unspecific] 23874370 Principal component analysis based feature extraction approach to identify circulating microRNA biomarkers. +circulation_biomarker_diagnosis_ns hsa-mir-486 Neoplasms [unspecific] 23874370 Principal component analysis based feature extraction approach to identify circulating microRNA biomarkers. +circulation_biomarker_diagnosis_ns hsa-mir-92a Neoplasms [unspecific] 23874370 Principal component analysis based feature extraction approach to identify circulating microRNA biomarkers. +circulation_biomarker_diagnosis_ns hsa-mir-125a Rheumatoid Arthritis 23874885 Comprehensive microRNA analysis identifies miR-24 and miR-125a-5p as plasma biomarkers for rheumatoid arthritis. +circulation_biomarker_diagnosis_ns hsa-mir-24 Rheumatoid Arthritis 23874885 Comprehensive microRNA analysis identifies miR-24 and miR-125a-5p as plasma biomarkers for rheumatoid arthritis. +circulation_biomarker_diagnosis_ns hsa-mir-125b Machado-Joseph Disease 23879331 MicroRNA profiling in the serums of SCA3/MJD patients. +circulation_biomarker_diagnosis_ns hsa-mir-25 Machado-Joseph Disease 23879331 MicroRNA profiling in the serums of SCA3/MJD patients. +circulation_biomarker_diagnosis_ns hsa-mir-29a Machado-Joseph Disease 23879331 MicroRNA profiling in the serums of SCA3/MJD patients. +circulation_biomarker_diagnosis_ns hsa-mir-34b Machado-Joseph Disease 23879331 MicroRNA profiling in the serums of SCA3/MJD patients. +circulation_biomarker_diagnosis_ns hsa-mir-205 "Carcinoma, Lung, Non-Small-Cell" 23881177 "Relative expressions of miR-205-5p, miR-205-3p, and miR-21 in tissues and serum of non-small cell lung cancer patients." +circulation_biomarker_diagnosis_ns hsa-mir-21 "Carcinoma, Lung, Non-Small-Cell" 23881177 "Relative expressions of miR-205-5p, miR-205-3p, and miR-21 in tissues and serum of non-small cell lung cancer patients." +circulation_biomarker_diagnosis_ns hsa-mir-16 Liver Diseases [unspecific] 23886700 Incubation of whole blood at room temperature does not alter the plasma concentrations of microRNA-16 and -223. +circulation_biomarker_diagnosis_ns hsa-mir-223 Liver Diseases [unspecific] 23886700 Incubation of whole blood at room temperature does not alter the plasma concentrations of microRNA-16 and -223. +circulation_biomarker_diagnosis_ns hsa-let-7d Alzheimer Disease 23922807 Circulating miRNA biomarkers for Alzheimer's disease. +circulation_biomarker_diagnosis_ns hsa-let-7g Alzheimer Disease 23922807 Circulating miRNA biomarkers for Alzheimer's disease. +circulation_biomarker_diagnosis_ns hsa-mir-142 Alzheimer Disease 23922807 Circulating miRNA biomarkers for Alzheimer's disease. +circulation_biomarker_diagnosis_ns hsa-mir-15b Alzheimer Disease 23922807 Circulating miRNA biomarkers for Alzheimer's disease. +circulation_biomarker_diagnosis_ns hsa-mir-191 Alzheimer Disease 23922807 Circulating miRNA biomarkers for Alzheimer's disease. +circulation_biomarker_diagnosis_ns hsa-mir-301a Alzheimer Disease 23922807 Circulating miRNA biomarkers for Alzheimer's disease. +circulation_biomarker_diagnosis_ns hsa-mir-545 Alzheimer Disease 23922807 Circulating miRNA biomarkers for Alzheimer's disease. +circulation_biomarker_diagnosis_ns hsa-mir-122 Metabolic Syndrome 23922812 These findings cast new light on the regulation of miR-33a and miR-122 in a dyslipidemic model of obese rats and the way these miRNAs are modulated by dietary components in the liver and in PBMCs. +circulation_biomarker_diagnosis_ns hsa-mir-33a Metabolic Syndrome 23922812 These findings cast new light on the regulation of miR-33a and miR-122 in a dyslipidemic model of obese rats and the way these miRNAs are modulated by dietary components in the liver and in PBMCs. +circulation_biomarker_diagnosis_ns hsa-mir-141 Prostate Neoplasms 23935962 Circulating microRNA profiling identifies a subset of metastatic prostate cancer patients with evidence of cancer-associated hypoxia. +circulation_biomarker_diagnosis_ns hsa-mir-200a Prostate Neoplasms 23935962 Circulating microRNA profiling identifies a subset of metastatic prostate cancer patients with evidence of cancer-associated hypoxia. +circulation_biomarker_diagnosis_ns hsa-mir-200c Prostate Neoplasms 23935962 Circulating microRNA profiling identifies a subset of metastatic prostate cancer patients with evidence of cancer-associated hypoxia. +circulation_biomarker_diagnosis_ns hsa-mir-210 Prostate Neoplasms 23935962 Circulating microRNA profiling identifies a subset of metastatic prostate cancer patients with evidence of cancer-associated hypoxia. +circulation_biomarker_diagnosis_ns hsa-mir-375 Prostate Neoplasms 23935962 Circulating microRNA profiling identifies a subset of metastatic prostate cancer patients with evidence of cancer-associated hypoxia. +circulation_biomarker_diagnosis_ns hsa-mir-124 Glioma 23936026 These results suggest that miR-124 may function as anti-migration and anti-invasion influence in glioma and provides a potential approach for developing miR-124-based therapeutic strategies for malignant glioma therapy. +circulation_biomarker_diagnosis_ns hsa-mir-133a Aortic Stenosis 23948643 "Preoperative plasma levels of miR-133a reflect their myocardial pression and predict the regression potential of LV hypertrophy after AVR. The value of this bedside information for the surgical timing, particularly in asymptomatic aortic stenosis patients, deserves confirmation in further clinical studies." +circulation_biomarker_diagnosis_ns hsa-mir-92 Ovary Mixed Epithelial Carcinoma 23963852 The detection of miR-92 levels in the serum might serve as a new tumour biomarker in the diagnosis and assessment of prognosis of EOC. +circulation_biomarker_diagnosis_ns hsa-mir-193b Leukemia 23998571 MicroRNA-193b expression in newly diagnosed leukemia patients and its significance. +circulation_biomarker_diagnosis_ns hsa-mir-139 Colorectal Carcinoma 24022433 "Plasma miRNAs are reliable, noninvasive, and inexpensive markers for CR adenomas. This miRNA panel warrants study in larger cohorts. Plasma-based assays could provide better screening compliance compared to fecal occult blood or endoscopic screening." +circulation_biomarker_diagnosis_ns hsa-mir-142 Colorectal Carcinoma 24022433 "Plasma miRNAs are reliable, noninvasive, and inexpensive markers for CR adenomas. This miRNA panel warrants study in larger cohorts. Plasma-based assays could provide better screening compliance compared to fecal occult blood or endoscopic screening." +circulation_biomarker_diagnosis_ns hsa-mir-15b Colorectal Carcinoma 24022433 "Plasma miRNAs are reliable, noninvasive, and inexpensive markers for CR adenomas. This miRNA panel warrants study in larger cohorts. Plasma-based assays could provide better screening compliance compared to fecal occult blood or endoscopic screening." +circulation_biomarker_diagnosis_ns hsa-mir-431 Colorectal Carcinoma 24022433 "Plasma miRNAs are reliable, noninvasive, and inexpensive markers for CR adenomas. This miRNA panel warrants study in larger cohorts. Plasma-based assays could provide better screening compliance compared to fecal occult blood or endoscopic screening." +circulation_biomarker_diagnosis_ns hsa-mir-532 Colorectal Carcinoma 24022433 "Plasma miRNAs are reliable, noninvasive, and inexpensive markers for CR adenomas. This miRNA panel warrants study in larger cohorts. Plasma-based assays could provide better screening compliance compared to fecal occult blood or endoscopic screening." +circulation_biomarker_diagnosis_ns hsa-mir-652 Colorectal Carcinoma 24022433 "Plasma miRNAs are reliable, noninvasive, and inexpensive markers for CR adenomas. This miRNA panel warrants study in larger cohorts. Plasma-based assays could provide better screening compliance compared to fecal occult blood or endoscopic screening." +circulation_biomarker_diagnosis_ns hsa-mir-16 "Carcinoma, Nasopharyngeal" 24025417 "plasma miRNA expression is a useful biomarker for NPC diagnosis but not for its prognosis. More importantly, it is simple, effective, and non-invasive. Combination of several plasma miRNAs can increase both NPC diagnostic sensitivity and specificity. miR-329,hsa-mir-487b,hsa-mir-494,hsa-mir-495" +circulation_biomarker_diagnosis_ns hsa-mir-210 Preeclampsia 24035613 "Hence, we conclude that aberrant expression of miR-210 may contribute to trophoblast function and that miR-210 is a novel predictive serum biomarker for preeclampsia that can help in identifying at-risk women for monitoring and treatment." +circulation_biomarker_diagnosis_ns hsa-mir-155 Graft-Versus-Host Disease 24041574 Plasma microRNA signature as a noninvasive biomarker for acute graft-versus-host disease. +circulation_biomarker_diagnosis_ns hsa-mir-199a Graft-Versus-Host Disease 24041574 Plasma microRNA signature as a noninvasive biomarker for acute graft-versus-host disease. +circulation_biomarker_diagnosis_ns hsa-mir-30a Graft-Versus-Host Disease 24041574 Plasma microRNA signature as a noninvasive biomarker for acute graft-versus-host disease. +circulation_biomarker_diagnosis_ns hsa-mir-377 Graft-Versus-Host Disease 24041574 Plasma microRNA signature as a noninvasive biomarker for acute graft-versus-host disease. +circulation_biomarker_diagnosis_ns hsa-mir-423 Graft-Versus-Host Disease 24041574 Plasma microRNA signature as a noninvasive biomarker for acute graft-versus-host disease. +circulation_biomarker_diagnosis_ns hsa-mir-93 Graft-Versus-Host Disease 24041574 Plasma microRNA signature as a noninvasive biomarker for acute graft-versus-host disease. +circulation_biomarker_diagnosis_ns hsa-mir-133a Acute Myocardial Infarction 24053180 Circulating miR-133a may be a new biomarker for AMI and as a potential diagnostic tool. And increased miR-133a level may be used to predict both the presence and severity of coronary lesions in CHD patients. +circulation_biomarker_diagnosis_ns hsa-mir-210 "Carcinoma, Lung, Non-Small-Cell" 24065453 These findings suggest that serum miR-210 levels might be a novel diagnostic and prognostic marker of NSCLC. +circulation_biomarker_diagnosis_ns hsa-mir-135a "Leukemia, Myeloid, Acute" 24072101 "miR-409-3p, miR-135a, miR-196b and mir-644 arose as prognostic markers for IR-AML, both overall and within specific molecular subgroups." +circulation_biomarker_diagnosis_ns hsa-mir-196b "Leukemia, Myeloid, Acute" 24072101 "miR-409-3p, miR-135a, miR-196b and mir-644 arose as prognostic markers for IR-AML, both overall and within specific molecular subgroups." +circulation_biomarker_diagnosis_ns hsa-mir-409 "Leukemia, Myeloid, Acute" 24072101 "miR-409-3p, miR-135a, miR-196b and mir-644 arose as prognostic markers for IR-AML, both overall and within specific molecular subgroups." +circulation_biomarker_diagnosis_ns hsa-mir-644 "Leukemia, Myeloid, Acute" 24072101 "miR-409-3p, miR-135a, miR-196b and mir-644 arose as prognostic markers for IR-AML, both overall and within specific molecular subgroups." +circulation_biomarker_diagnosis_ns hsa-mir-122 Liver Injury 24086271 "serum miR-122 has strong potential as a novel, specific and noninvasive biomarker for diagnosis of cholestasis-induced liver injury." +circulation_biomarker_diagnosis_ns hsa-mir-21 Biliary Tract Neoplasms 24118467 "Plasma miR-21 is a novel diagnostic biomarker for BTC, and may be useful in distinguishing between BTC and BBD patients." +circulation_biomarker_diagnosis_ns hsa-mir-15b Peripheral Vascular Disease 24129591 "A 12-miRNA PAD-specific signature, which includes let 7e, miR-15b, -16, -20b, -25, -26b,-27b, -28-5p, -126, -195, -335, and -363, was further investigated and validated in 2 additional sample sets. Each of these 12 miRNAs exhibited good diagnostic value as evidenced by receiver operating characteristic curve analyses.miR-16, miR-363, and miR-15b had the best predictive values" +circulation_biomarker_diagnosis_ns hsa-mir-16 Peripheral Vascular Disease 24129591 "A 12-miRNA PAD-specific signature, which includes let 7e, miR-15b, -16, -20b, -25, -26b,-27b, -28-5p, -126, -195, -335, and -363, was further investigated and validated in 2 additional sample sets. Each of these 12 miRNAs exhibited good diagnostic value as evidenced by receiver operating characteristic curve analyses.miR-16, miR-363, and miR-15b had the best predictive values" +circulation_biomarker_diagnosis_ns hsa-mir-363 Peripheral Vascular Disease 24129591 "A 12-miRNA PAD-specific signature, which includes let 7e, miR-15b, -16, -20b, -25, -26b,-27b, -28-5p, -126, -195, -335, and -363, was further investigated and validated in 2 additional sample sets. Each of these 12 miRNAs exhibited good diagnostic value as evidenced by receiver operating characteristic curve analyses.miR-16, miR-363, and miR-15b had the best predictive values" +circulation_biomarker_diagnosis_ns hsa-mir-126 Peripheral Vascular Disease 24129592 "A 12-miRNA PAD-specific signature, which includes let 7e, miR-15b, -16, -20b, -25, -26b,-27b, -28-5p, -126, -195, -335, and -363, was further investigated and validated in 2 additional sample sets. Each of these 12 miRNAs exhibited good diagnostic value as evidenced by receiver operating characteristic curve analyses." +circulation_biomarker_diagnosis_ns hsa-mir-15b Peripheral Vascular Disease 24129592 "A 12-miRNA PAD-specific signature, which includes let 7e, miR-15b, -16, -20b, -25, -26b,-27b, -28-5p, -126, -195, -335, and -363, was further investigated and validated in 2 additional sample sets. Each of these 12 miRNAs exhibited good diagnostic value as evidenced by receiver operating characteristic curve analyses." +circulation_biomarker_diagnosis_ns hsa-mir-16 Peripheral Vascular Disease 24129592 "A 12-miRNA PAD-specific signature, which includes let 7e, miR-15b, -16, -20b, -25, -26b,-27b, -28-5p, -126, -195, -335, and -363, was further investigated and validated in 2 additional sample sets. Each of these 12 miRNAs exhibited good diagnostic value as evidenced by receiver operating characteristic curve analyses." +circulation_biomarker_diagnosis_ns hsa-mir-181a-2 Peripheral Vascular Disease 24129592 "A 12-miRNA PAD-specific signature, which includes let 7e, miR-15b, -16, -20b, -25, -26b,-27b, -28-5p, -126, -195, -335, and -363, was further investigated and validated in 2 additional sample sets. Each of these 12 miRNAs exhibited good diagnostic value as evidenced by receiver operating characteristic curve analyses." +circulation_biomarker_diagnosis_ns hsa-mir-195 Peripheral Vascular Disease 24129592 "A 12-miRNA PAD-specific signature, which includes let 7e, miR-15b, -16, -20b, -25, -26b,-27b, -28-5p, -126, -195, -335, and -363, was further investigated and validated in 2 additional sample sets. Each of these 12 miRNAs exhibited good diagnostic value as evidenced by receiver operating characteristic curve analyses." +circulation_biomarker_diagnosis_ns hsa-mir-20b Peripheral Vascular Disease 24129592 "A 12-miRNA PAD-specific signature, which includes let 7e, miR-15b, -16, -20b, -25, -26b,-27b, -28-5p, -126, -195, -335, and -363, was further investigated and validated in 2 additional sample sets. Each of these 12 miRNAs exhibited good diagnostic value as evidenced by receiver operating characteristic curve analyses." +circulation_biomarker_diagnosis_ns hsa-mir-25 Peripheral Vascular Disease 24129592 "A 12-miRNA PAD-specific signature, which includes let 7e, miR-15b, -16, -20b, -25, -26b,-27b, -28-5p, -126, -195, -335, and -363, was further investigated and validated in 2 additional sample sets. Each of these 12 miRNAs exhibited good diagnostic value as evidenced by receiver operating characteristic curve analyses." +circulation_biomarker_diagnosis_ns hsa-mir-26b Peripheral Vascular Disease 24129592 "A 12-miRNA PAD-specific signature, which includes let 7e, miR-15b, -16, -20b, -25, -26b,-27b, -28-5p, -126, -195, -335, and -363, was further investigated and validated in 2 additional sample sets. Each of these 12 miRNAs exhibited good diagnostic value as evidenced by receiver operating characteristic curve analyses." +circulation_biomarker_diagnosis_ns hsa-mir-27b Peripheral Vascular Disease 24129592 "A 12-miRNA PAD-specific signature, which includes let 7e, miR-15b, -16, -20b, -25, -26b,-27b, -28-5p, -126, -195, -335, and -363, was further investigated and validated in 2 additional sample sets. Each of these 12 miRNAs exhibited good diagnostic value as evidenced by receiver operating characteristic curve analyses." +circulation_biomarker_diagnosis_ns hsa-mir-28 Peripheral Vascular Disease 24129592 "A 12-miRNA PAD-specific signature, which includes let 7e, miR-15b, -16, -20b, -25, -26b,-27b, -28-5p, -126, -195, -335, and -363, was further investigated and validated in 2 additional sample sets. Each of these 12 miRNAs exhibited good diagnostic value as evidenced by receiver operating characteristic curve analyses." +circulation_biomarker_diagnosis_ns hsa-mir-335 Peripheral Vascular Disease 24129592 "A 12-miRNA PAD-specific signature, which includes let 7e, miR-15b, -16, -20b, -25, -26b,-27b, -28-5p, -126, -195, -335, and -363, was further investigated and validated in 2 additional sample sets. Each of these 12 miRNAs exhibited good diagnostic value as evidenced by receiver operating characteristic curve analyses." +circulation_biomarker_diagnosis_ns hsa-mir-363 Peripheral Vascular Disease 24129592 "A 12-miRNA PAD-specific signature, which includes let 7e, miR-15b, -16, -20b, -25, -26b,-27b, -28-5p, -126, -195, -335, and -363, was further investigated and validated in 2 additional sample sets. Each of these 12 miRNAs exhibited good diagnostic value as evidenced by receiver operating characteristic curve analyses." +circulation_biomarker_diagnosis_ns hsa-mir-423 Hereditary Breast Carcinoma 24129975 miR-4417 and miR-423-3p expressions differentiated 70.1 % of hereditary and non-hereditary BCs. Array miR expression profiles can differentiate the four study groups using FFPE BC. +circulation_biomarker_diagnosis_ns hsa-mir-4417 Hereditary Breast Carcinoma 24129975 miR-4417 and miR-423-3p expressions differentiated 70.1 % of hereditary and non-hereditary BCs. Array miR expression profiles can differentiate the four study groups using FFPE BC. +circulation_biomarker_diagnosis_ns hsa-mir-19a "Squamous Cell Carcinoma, Lung" 24130905 "Tumor cells secrete miRNA-containing exosomes into circulation, and that miRNA profiling of the exosomal plasma fraction may reveal powerful cancer biomarkers." +circulation_biomarker_diagnosis_ns hsa-mir-19b "Squamous Cell Carcinoma, Lung" 24130905 "Tumor cells secrete miRNA-containing exosomes into circulation, and that miRNA profiling of the exosomal plasma fraction may reveal powerful cancer biomarkers." +circulation_biomarker_diagnosis_ns hsa-mir-205 "Squamous Cell Carcinoma, Lung" 24130905 "Tumor cells secrete miRNA-containing exosomes into circulation, and that miRNA profiling of the exosomal plasma fraction may reveal powerful cancer biomarkers." +circulation_biomarker_diagnosis_ns hsa-mir-20a "Squamous Cell Carcinoma, Lung" 24130905 "Tumor cells secrete miRNA-containing exosomes into circulation, and that miRNA profiling of the exosomal plasma fraction may reveal powerful cancer biomarkers." +circulation_biomarker_diagnosis_ns hsa-mir-30b "Squamous Cell Carcinoma, Lung" 24130905 "Tumor cells secrete miRNA-containing exosomes into circulation, and that miRNA profiling of the exosomal plasma fraction may reveal powerful cancer biomarkers." +circulation_biomarker_diagnosis_ns hsa-mir-125b Alzheimer Disease 24139697 Our results indicate that serum miR-125b may serve as a useful noninvasive biomarker for AD. +circulation_biomarker_diagnosis_ns hsa-mir-150 Sepsis 24146790 microRNA miR-150 and miR-4772-5p-iso were able to discriminate between patients who have systemic inflammatory response syndrome and patients with sepsis. +circulation_biomarker_diagnosis_ns hsa-mir-24 Leukemia 24153013 "Altered expression of miR-24, miR-126 and miR-365 does not affect viability of childhood TCF3-rearranged leukemia cells." +circulation_biomarker_diagnosis_ns hsa-mir-365 Leukemia 24153013 "Altered expression of miR-24, miR-126 and miR-365 does not affect viability of childhood TCF3-rearranged leukemia cells." +circulation_biomarker_diagnosis_ns hsa-mir-127 Breast Neoplasms 24194846 Plasma microRNA panel for minimally invasive detection of breast cancer. +circulation_biomarker_diagnosis_ns hsa-mir-148b Breast Neoplasms 24194846 Plasma microRNA panel for minimally invasive detection of breast cancer. +circulation_biomarker_diagnosis_ns hsa-mir-376a Breast Neoplasms 24194846 Plasma microRNA panel for minimally invasive detection of breast cancer. +circulation_biomarker_diagnosis_ns hsa-mir-376c Breast Neoplasms 24194846 Plasma microRNA panel for minimally invasive detection of breast cancer. +circulation_biomarker_diagnosis_ns hsa-mir-409 Breast Neoplasms 24194846 Plasma microRNA panel for minimally invasive detection of breast cancer. +circulation_biomarker_diagnosis_ns hsa-mir-652 Breast Neoplasms 24194846 Plasma microRNA panel for minimally invasive detection of breast cancer. +circulation_biomarker_diagnosis_ns hsa-mir-801 Breast Neoplasms 24194846 Plasma microRNA panel for minimally invasive detection of breast cancer. +circulation_biomarker_diagnosis_ns hsa-mir-138 "Diabetes Mellitus, Type 2" 24204780 "This study is the first to show a panel of serum miRNAs for obesity, and compare them with miRNAs identified in serum for diabetes and obesity with diabetes. Our results support the use of some miRNAs extracted from serum samples as potential predictive tools for obesity and type 2 diabetes." +circulation_biomarker_diagnosis_ns hsa-mir-15b "Diabetes Mellitus, Type 2" 24204780 "This study is the first to show a panel of serum miRNAs for obesity, and compare them with miRNAs identified in serum for diabetes and obesity with diabetes. Our results support the use of some miRNAs extracted from serum samples as potential predictive tools for obesity and type 2 diabetes." +circulation_biomarker_diagnosis_ns hsa-mir-376a "Diabetes Mellitus, Type 2" 24204780 "This study is the first to show a panel of serum miRNAs for obesity, and compare them with miRNAs identified in serum for diabetes and obesity with diabetes. Our results support the use of some miRNAs extracted from serum samples as potential predictive tools for obesity and type 2 diabetes." +circulation_biomarker_diagnosis_ns hsa-mir-503 "Diabetes Mellitus, Type 2" 24204780 "This study is the first to show a panel of serum miRNAs for obesity, and compare them with miRNAs identified in serum for diabetes and obesity with diabetes. Our results support the use of some miRNAs extracted from serum samples as potential predictive tools for obesity and type 2 diabetes." +circulation_biomarker_diagnosis_ns hsa-mir-210 "Carcinoma, Renal Cell, Clear-Cell" 24212760 Serum miR-210 as a potential biomarker of early clear cell renal cell carcinoma. +circulation_biomarker_diagnosis_ns hsa-let-7b "Stroke, Ischemic" 24237608 "These data suggest that miR-30a, miR-126 and let-7b might be useful biomarkers for ischemic stroke in humans." +circulation_biomarker_diagnosis_ns hsa-mir-126 "Stroke, Ischemic" 24237608 "These data suggest that miR-30a, miR-126 and let-7b might be useful biomarkers for ischemic stroke in humans." +circulation_biomarker_diagnosis_ns hsa-mir-30a "Stroke, Ischemic" 24237608 "These data suggest that miR-30a, miR-126 and let-7b might be useful biomarkers for ischemic stroke in humans." +circulation_biomarker_diagnosis_ns hsa-mir-34a "Carcinoma, Adrenocortical" 24238045 We show that dysregulated miRNAs in ACC are detectable in human serum samples. MiR-34a and miR-483-5p are candidate serum biomarkers for distinguishing between benign and malignant adrenocortical tumors. +circulation_biomarker_diagnosis_ns hsa-mir-483 "Carcinoma, Adrenocortical" 24238045 We show that dysregulated miRNAs in ACC are detectable in human serum samples. MiR-34a and miR-483-5p are candidate serum biomarkers for distinguishing between benign and malignant adrenocortical tumors. +circulation_biomarker_diagnosis_ns hsa-mir-1 Acute Myocardial Infarction 24253456 Early in acute myocardial infarction the expression of miR-423-5p in plasma is significantly increased with subsequent normalization within 6 hours.Potentially it is an early marker of myocardial necrosis. +circulation_biomarker_diagnosis_ns hsa-mir-195 "Adenocarcinoma, Lung" 24282590 "Plasma levels of miR-195 and miR-122 expression were also associated with overall survival in the patients, especially in those with advanced stage (HR=0.23, 95%CI:0.07-0.84; and HR=0.22, 95%CI:0.06-0.77) and EGFR mutation (HR=0.27, 95%CI:0.08-0.96; and HR=0.23, 95%CI=0.06-0.81)." +circulation_biomarker_diagnosis_ns hsa-let-7b Myocardial Infarction 24284400 "The circulating let-7b is suspected to be the biomarker of acute MI and let-7i, the biomarker of DCM." +circulation_biomarker_diagnosis_ns hsa-mir-122 Liver Injury 24287929 Plasma miR-122 expression is correlated with hepatectomy-induced liver injury in patients with HCC. Increase in miR-122 expression could be used as an index of such injury before and after hepatectomy in these patients. +circulation_biomarker_diagnosis_ns hsa-mir-146b "Carcinoma, Thyroid, Papillary" 24301304 This study demonstrated that tumor levels of miR-222 and miR-146b are associated with PTC recurrence and that miR-222 and miR-146b levels in the circulation correspond to the presence of PTC. The potential of these miRNAs as tumor biomarkers to improve patient stratification according to the risk of recurrence and as circulating biomarkers for PTC surveillance warrants further study. +circulation_biomarker_diagnosis_ns hsa-mir-222 "Carcinoma, Thyroid, Papillary" 24301304 This study demonstrated that tumor levels of miR-222 and miR-146b are associated with PTC recurrence and that miR-222 and miR-146b levels in the circulation correspond to the presence of PTC. The potential of these miRNAs as tumor biomarkers to improve patient stratification according to the risk of recurrence and as circulating biomarkers for PTC surveillance warrants further study. +circulation_biomarker_diagnosis_ns hsa-mir-122 HELLP Syndrome 24304191 "In our proof of principle study, we demonstrated that patients with HELLP syndrome showed alterations of serum miRNA expression patterns. Data analysis goes along with the hypothesis that HELLP syndrome is regarded to be a heterogeneous disease." +circulation_biomarker_diagnosis_ns hsa-mir-133a HELLP Syndrome 24304191 "In our proof of principle study, we demonstrated that patients with HELLP syndrome showed alterations of serum miRNA expression patterns. Data analysis goes along with the hypothesis that HELLP syndrome is regarded to be a heterogeneous disease." +circulation_biomarker_diagnosis_ns hsa-mir-758 HELLP Syndrome 24304191 "In our proof of principle study, we demonstrated that patients with HELLP syndrome showed alterations of serum miRNA expression patterns. Data analysis goes along with the hypothesis that HELLP syndrome is regarded to be a heterogeneous disease." +circulation_biomarker_diagnosis_ns hsa-mir-122 "Fatty Liver, Non-Alcoholic" 24313922 We found that the hepatic and serum miR-122 levels were associated with hepatic steatosis and fibrosis. The serum miR-122 level can be a useful predictive marker of liver fibrosis in patients with NAFLD. +circulation_biomarker_diagnosis_ns hsa-mir-9 "Carcinoma, Nasopharyngeal" 24327016 Our study reports that plasma miR-9 may serve as a useful biomarker to predict NPC metastasis and to monitor tumour dynamics. +circulation_biomarker_diagnosis_ns hsa-mir-100 Adrenal Cortex Neoplasms 24336071 "In contrast, of the selected eight miRNAs reported in the literature as differentially expressed in ACT tissues, five (hsa-miR-100, hsa-miR-181b, hsa-miR-184, hsa-miR-210 and hsa-miR-483-5p) showed a statistically significant overexpression in adrenocortical cancer vs adenoma when normalized on hsa-miR-16 as a reference gene." +circulation_biomarker_diagnosis_ns hsa-mir-210 Adrenal Cortex Neoplasms 24336071 "In contrast, of the selected eight miRNAs reported in the literature as differentially expressed in ACT tissues, five (hsa-miR-100, hsa-miR-181b, hsa-miR-184, hsa-miR-210 and hsa-miR-483-5p) showed a statistically significant overexpression in adrenocortical cancer vs adenoma when normalized on hsa-miR-16 as a reference gene." +circulation_biomarker_diagnosis_ns hsa-mir-128 Mild Cognitive Impairment 24368295 Plasma microRNA biomarkers for detection of mild cognitive impairment: biomarker validation study. +circulation_biomarker_diagnosis_ns hsa-mir-132 Mild Cognitive Impairment 24368295 Plasma microRNA biomarkers for detection of mild cognitive impairment: biomarker validation study. +circulation_biomarker_diagnosis_ns hsa-mir-134 Mild Cognitive Impairment 24368295 Plasma microRNA biomarkers for detection of mild cognitive impairment: biomarker validation study. +circulation_biomarker_diagnosis_ns hsa-mir-323 Mild Cognitive Impairment 24368295 Plasma microRNA biomarkers for detection of mild cognitive impairment: biomarker validation study. +circulation_biomarker_diagnosis_ns hsa-mir-370 Mild Cognitive Impairment 24368295 Plasma microRNA biomarkers for detection of mild cognitive impairment: biomarker validation study. +circulation_biomarker_diagnosis_ns hsa-mir-382 Mild Cognitive Impairment 24368295 Plasma microRNA biomarkers for detection of mild cognitive impairment: biomarker validation study. +circulation_biomarker_diagnosis_ns hsa-mir-491 Mild Cognitive Impairment 24368295 Plasma microRNA biomarkers for detection of mild cognitive impairment: biomarker validation study. +circulation_biomarker_diagnosis_ns hsa-mir-874 Mild Cognitive Impairment 24368295 Plasma microRNA biomarkers for detection of mild cognitive impairment: biomarker validation study. +circulation_biomarker_diagnosis_ns hsa-mir-125b Uveal Melanoma 24370793 The development of metastasis in uveal melanoma is associated with changes in immune effector and regulatory cells consistent with lessening tumor immune surveillance. These changes are associated with changes in plasma and cellular levels of immune regulatory miRs. The results may help guide uveal melanoma immunotherapy and biomarker development. +circulation_biomarker_diagnosis_ns hsa-mir-146a Uveal Melanoma 24370793 The development of metastasis in uveal melanoma is associated with changes in immune effector and regulatory cells consistent with lessening tumor immune surveillance. These changes are associated with changes in plasma and cellular levels of immune regulatory miRs. The results may help guide uveal melanoma immunotherapy and biomarker development. +circulation_biomarker_diagnosis_ns hsa-mir-155 Uveal Melanoma 24370793 The development of metastasis in uveal melanoma is associated with changes in immune effector and regulatory cells consistent with lessening tumor immune surveillance. These changes are associated with changes in plasma and cellular levels of immune regulatory miRs. The results may help guide uveal melanoma immunotherapy and biomarker development. +circulation_biomarker_diagnosis_ns hsa-mir-20a Uveal Melanoma 24370793 The development of metastasis in uveal melanoma is associated with changes in immune effector and regulatory cells consistent with lessening tumor immune surveillance. These changes are associated with changes in plasma and cellular levels of immune regulatory miRs. The results may help guide uveal melanoma immunotherapy and biomarker development. +circulation_biomarker_diagnosis_ns hsa-mir-223 Uveal Melanoma 24370793 The development of metastasis in uveal melanoma is associated with changes in immune effector and regulatory cells consistent with lessening tumor immune surveillance. These changes are associated with changes in plasma and cellular levels of immune regulatory miRs. The results may help guide uveal melanoma immunotherapy and biomarker development. +circulation_biomarker_diagnosis_ns hsa-mir-21 "Lymphoma, Large B-Cell, Diffuse" 24400911 Clinical significance and detection of microRNA-21 in serum of patients with diffuse large B-cell lymphoma in Chinese population. +circulation_biomarker_diagnosis_ns hsa-mir-133a Sepsis 24413579 Levels of circulating miR-133a are elevated in sepsis and predict mortality in critically ill patients. +circulation_biomarker_diagnosis_ns hsa-mir-223 Immune Thrombocytopenic Purpura 24418947 Plasma microRNA profiling of pediatric patients with immune thrombocytopenic purpura. +circulation_biomarker_diagnosis_ns hsa-mir-302a Immune Thrombocytopenic Purpura 24418947 Plasma microRNA profiling of pediatric patients with immune thrombocytopenic purpura. +circulation_biomarker_diagnosis_ns hsa-mir-302c Immune Thrombocytopenic Purpura 24418947 Plasma microRNA profiling of pediatric patients with immune thrombocytopenic purpura. +circulation_biomarker_diagnosis_ns hsa-mir-410 Immune Thrombocytopenic Purpura 24418947 Plasma microRNA profiling of pediatric patients with immune thrombocytopenic purpura. +circulation_biomarker_diagnosis_ns hsa-mir-483 Immune Thrombocytopenic Purpura 24418947 Plasma microRNA profiling of pediatric patients with immune thrombocytopenic purpura. +circulation_biomarker_diagnosis_ns hsa-mir-544a Immune Thrombocytopenic Purpura 24418947 Plasma microRNA profiling of pediatric patients with immune thrombocytopenic purpura. +circulation_biomarker_diagnosis_ns hsa-mir-597 Immune Thrombocytopenic Purpura 24418947 Plasma microRNA profiling of pediatric patients with immune thrombocytopenic purpura. +circulation_biomarker_diagnosis_ns hsa-mir-122 Sepsis 24421215 Serum miR-122 levels are related to coagulation disorders in sepsis patients. +circulation_biomarker_diagnosis_ns hsa-mir-378 Colorectal Carcinoma 24423916 "Plasma levels of miR-378 could be used to discriminate CRC patients from healthy individuals, irrespective of the level of haemoglobin of plasma samples." +circulation_biomarker_diagnosis_ns hsa-mir-122 Pancreatic Neoplasms 24449318 MicroRNA biomarkers in whole blood for detection of pancreatic cancer. +circulation_biomarker_diagnosis_ns hsa-mir-126 Pancreatic Neoplasms 24449318 MicroRNA biomarkers in whole blood for detection of pancreatic cancer. +circulation_biomarker_diagnosis_ns hsa-mir-145 Pancreatic Neoplasms 24449318 MicroRNA biomarkers in whole blood for detection of pancreatic cancer. +circulation_biomarker_diagnosis_ns hsa-mir-150 Pancreatic Neoplasms 24449318 MicroRNA biomarkers in whole blood for detection of pancreatic cancer. +circulation_biomarker_diagnosis_ns hsa-mir-223 Pancreatic Neoplasms 24449318 MicroRNA biomarkers in whole blood for detection of pancreatic cancer. +circulation_biomarker_diagnosis_ns hsa-mir-26b Pancreatic Neoplasms 24449318 MicroRNA biomarkers in whole blood for detection of pancreatic cancer. +circulation_biomarker_diagnosis_ns hsa-mir-34a Pancreatic Neoplasms 24449318 MicroRNA biomarkers in whole blood for detection of pancreatic cancer. +circulation_biomarker_diagnosis_ns hsa-mir-505 Pancreatic Neoplasms 24449318 MicroRNA biomarkers in whole blood for detection of pancreatic cancer. +circulation_biomarker_diagnosis_ns hsa-mir-636 Pancreatic Neoplasms 24449318 MicroRNA biomarkers in whole blood for detection of pancreatic cancer. +circulation_biomarker_diagnosis_ns hsa-mir-885 Pancreatic Neoplasms 24449318 MicroRNA biomarkers in whole blood for detection of pancreatic cancer. +circulation_biomarker_diagnosis_ns hsa-mir-186 "Squamous Cell Carcinoma, Oral" 24452363 "miR-186, miR-3651 and miR-494: potential biomarkers for oral squamous cell carcinoma extracted from whole blood." +circulation_biomarker_diagnosis_ns hsa-mir-3651 "Squamous Cell Carcinoma, Oral" 24452363 "miR-186, miR-3651 and miR-494: potential biomarkers for oral squamous cell carcinoma extracted from whole blood." +circulation_biomarker_diagnosis_ns hsa-mir-494 "Squamous Cell Carcinoma, Oral" 24452363 "miR-186, miR-3651 and miR-494: potential biomarkers for oral squamous cell carcinoma extracted from whole blood." +circulation_biomarker_diagnosis_ns hsa-mir-126 "Diabetes Mellitus, Type 2" 24455723 Plasma miR-126 is a potential biomarker for early prediction of type 2 diabetes mellitus in susceptible individuals. +circulation_biomarker_diagnosis_ns hsa-mir-1827 "Leukemia, Myeloid, Chronic" 24460325 Selective miRNA expression profile in chronic myeloid leukemia K562 cell-derived exosomes. +circulation_biomarker_diagnosis_ns hsa-mir-1973 "Leukemia, Myeloid, Chronic" 24460325 Selective miRNA expression profile in chronic myeloid leukemia K562 cell-derived exosomes. +circulation_biomarker_diagnosis_ns hsa-mir-298 "Leukemia, Myeloid, Chronic" 24460325 Selective miRNA expression profile in chronic myeloid leukemia K562 cell-derived exosomes. +circulation_biomarker_diagnosis_ns hsa-mir-299 "Leukemia, Myeloid, Chronic" 24460325 Selective miRNA expression profile in chronic myeloid leukemia K562 cell-derived exosomes. +circulation_biomarker_diagnosis_ns hsa-mir-3201 "Leukemia, Myeloid, Chronic" 24460325 Selective miRNA expression profile in chronic myeloid leukemia K562 cell-derived exosomes. +circulation_biomarker_diagnosis_ns hsa-mir-3611 "Leukemia, Myeloid, Chronic" 24460325 Selective miRNA expression profile in chronic myeloid leukemia K562 cell-derived exosomes. +circulation_biomarker_diagnosis_ns hsa-mir-3646 "Leukemia, Myeloid, Chronic" 24460325 Selective miRNA expression profile in chronic myeloid leukemia K562 cell-derived exosomes. +circulation_biomarker_diagnosis_ns hsa-mir-3686 "Leukemia, Myeloid, Chronic" 24460325 Selective miRNA expression profile in chronic myeloid leukemia K562 cell-derived exosomes. +circulation_biomarker_diagnosis_ns hsa-mir-3915 "Leukemia, Myeloid, Chronic" 24460325 Selective miRNA expression profile in chronic myeloid leukemia K562 cell-derived exosomes. +circulation_biomarker_diagnosis_ns hsa-mir-423 "Leukemia, Myeloid, Chronic" 24460325 Selective miRNA expression profile in chronic myeloid leukemia K562 cell-derived exosomes. +circulation_biomarker_diagnosis_ns hsa-mir-4268 "Leukemia, Myeloid, Chronic" 24460325 Selective miRNA expression profile in chronic myeloid leukemia K562 cell-derived exosomes. +circulation_biomarker_diagnosis_ns hsa-mir-4279 "Leukemia, Myeloid, Chronic" 24460325 Selective miRNA expression profile in chronic myeloid leukemia K562 cell-derived exosomes. +circulation_biomarker_diagnosis_ns hsa-mir-4290 "Leukemia, Myeloid, Chronic" 24460325 Selective miRNA expression profile in chronic myeloid leukemia K562 cell-derived exosomes. +circulation_biomarker_diagnosis_ns hsa-mir-483 "Leukemia, Myeloid, Chronic" 24460325 Selective miRNA expression profile in chronic myeloid leukemia K562 cell-derived exosomes. +circulation_biomarker_diagnosis_ns hsa-mir-498 "Leukemia, Myeloid, Chronic" 24460325 Selective miRNA expression profile in chronic myeloid leukemia K562 cell-derived exosomes. +circulation_biomarker_diagnosis_ns hsa-mir-518b "Leukemia, Myeloid, Chronic" 24460325 Selective miRNA expression profile in chronic myeloid leukemia K562 cell-derived exosomes. +circulation_biomarker_diagnosis_ns hsa-mir-525 "Leukemia, Myeloid, Chronic" 24460325 Selective miRNA expression profile in chronic myeloid leukemia K562 cell-derived exosomes. +circulation_biomarker_diagnosis_ns hsa-mir-612 "Leukemia, Myeloid, Chronic" 24460325 Selective miRNA expression profile in chronic myeloid leukemia K562 cell-derived exosomes. +circulation_biomarker_diagnosis_ns hsa-mir-665 "Leukemia, Myeloid, Chronic" 24460325 Selective miRNA expression profile in chronic myeloid leukemia K562 cell-derived exosomes. +circulation_biomarker_diagnosis_ns hsa-mir-711 "Leukemia, Myeloid, Chronic" 24460325 Selective miRNA expression profile in chronic myeloid leukemia K562 cell-derived exosomes. +circulation_biomarker_diagnosis_ns hsa-mir-943 "Leukemia, Myeloid, Chronic" 24460325 Selective miRNA expression profile in chronic myeloid leukemia K562 cell-derived exosomes. +circulation_biomarker_diagnosis_ns hsa-mir-1 "Muscular Dystrophy, Duchenne" 24460924 Serum miR-206 and other muscle-specific microRNAs as non-invasive biomarkers for Duchenne muscular dystrophy. +circulation_biomarker_diagnosis_ns hsa-mir-133 "Muscular Dystrophy, Duchenne" 24460924 Serum miR-206 and other muscle-specific microRNAs as non-invasive biomarkers for Duchenne muscular dystrophy. +circulation_biomarker_diagnosis_ns hsa-mir-206 "Muscular Dystrophy, Duchenne" 24460924 Serum miR-206 and other muscle-specific microRNAs as non-invasive biomarkers for Duchenne muscular dystrophy. +circulation_biomarker_diagnosis_ns hsa-mir-628 Prostate Neoplasms 24477576 "Our results demonstrate that the three miRNAs, particularly miR-628-5p, may be further developed as a biomarker, which can serve as novel noninvasive biomarker for PCa diagnosis and prognosis." +circulation_biomarker_diagnosis_ns hsa-mir-126 "Leukemia, Myeloid, Acute" 24477595 Attenuation of microRNA-126 expression that drives CD34+38- stem/progenitor cells in acute myeloid leukemia leads to tumor eradication. +circulation_biomarker_diagnosis_ns hsa-mir-122 Gastric Neoplasms 24481716 Plasma miR-122 and miR-192 as potential novel biomarkers for the early detection of distant metastasis of gastric cancer. +circulation_biomarker_diagnosis_ns hsa-mir-192 Gastric Neoplasms 24481716 Plasma miR-122 and miR-192 as potential novel biomarkers for the early detection of distant metastasis of gastric cancer. +circulation_biomarker_diagnosis_ns hsa-mir-182 Breast Neoplasms 24498016 "This study provides insight into the underlying molecular portrait of Luminal A-like breast cancer subtype. From an initial 76 miRNAs, 4 were validated with altered expression in the blood of women with Luminal A-like breast cancer. The expression profiles of these 3 miRNAs, in combination with mammography, has potential to facilitate accurate subtype-specific breast tumor detection." +circulation_biomarker_diagnosis_ns hsa-mir-19b Breast Neoplasms 24498016 "This study provides insight into the underlying molecular portrait of Luminal A-like breast cancer subtype. From an initial 76 miRNAs, 4 were validated with altered expression in the blood of women with Luminal A-like breast cancer. The expression profiles of these 3 miRNAs, in combination with mammography, has potential to facilitate accurate subtype-specific breast tumor detection." +circulation_biomarker_diagnosis_ns hsa-mir-223 Breast Neoplasms 24498016 "This study provides insight into the underlying molecular portrait of Luminal A-like breast cancer subtype. From an initial 76 miRNAs, 4 were validated with altered expression in the blood of women with Luminal A-like breast cancer. The expression profiles of these 3 miRNAs, in combination with mammography, has potential to facilitate accurate subtype-specific breast tumor detection." +circulation_biomarker_diagnosis_ns hsa-mir-29a Breast Neoplasms 24498016 "This study provides insight into the underlying molecular portrait of Luminal A-like breast cancer subtype. From an initial 76 miRNAs, 4 were validated with altered expression in the blood of women with Luminal A-like breast cancer. The expression profiles of these 3 miRNAs, in combination with mammography, has potential to facilitate accurate subtype-specific breast tumor detection." +circulation_biomarker_diagnosis_ns hsa-mir-301a Breast Neoplasms 24498016 "This study provides insight into the underlying molecular portrait of Luminal A-like breast cancer subtype. From an initial 76 miRNAs, 4 were validated with altered expression in the blood of women with Luminal A-like breast cancer. The expression profiles of these 3 miRNAs, in combination with mammography, has potential to facilitate accurate subtype-specific breast tumor detection." +circulation_biomarker_diagnosis_ns hsa-mir-423 Breast Neoplasms 24498016 "This study provides insight into the underlying molecular portrait of Luminal A-like breast cancer subtype. From an initial 76 miRNAs, 4 were validated with altered expression in the blood of women with Luminal A-like breast cancer. The expression profiles of these 3 miRNAs, in combination with mammography, has potential to facilitate accurate subtype-specific breast tumor detection." +circulation_biomarker_diagnosis_ns hsa-mir-486 Breast Neoplasms 24498016 "This study provides insight into the underlying molecular portrait of Luminal A-like breast cancer subtype. From an initial 76 miRNAs, 4 were validated with altered expression in the blood of women with Luminal A-like breast cancer. The expression profiles of these 3 miRNAs, in combination with mammography, has potential to facilitate accurate subtype-specific breast tumor detection." +circulation_biomarker_diagnosis_ns hsa-mir-652 Breast Neoplasms 24498016 "This study provides insight into the underlying molecular portrait of Luminal A-like breast cancer subtype. From an initial 76 miRNAs, 4 were validated with altered expression in the blood of women with Luminal A-like breast cancer. The expression profiles of these 3 miRNAs, in combination with mammography, has potential to facilitate accurate subtype-specific breast tumor detection." +circulation_biomarker_diagnosis_ns hsa-mir-93 Breast Neoplasms 24498016 "This study provides insight into the underlying molecular portrait of Luminal A-like breast cancer subtype. From an initial 76 miRNAs, 4 were validated with altered expression in the blood of women with Luminal A-like breast cancer. The expression profiles of these 3 miRNAs, in combination with mammography, has potential to facilitate accurate subtype-specific breast tumor detection." +circulation_biomarker_diagnosis_ns hsa-mir-21 Myelodysplastic Syndromes 24503739 Serum microRNA-21 as a potential biomarker for response to hypomethylating agents in myelodysplastic syndromes. +circulation_biomarker_diagnosis_ns hsa-mir-29c Early-Stage Non-Small-Cell Lung Carcinoma 24523873 "The results of the current study suggest that detection of serum miR-29c and miR-429 expression should be further evaluated as a novel,non-invasive biomarker for early stage NSCLC." +circulation_biomarker_diagnosis_ns hsa-mir-429 Early-Stage Non-Small-Cell Lung Carcinoma 24523873 "The results of the current study suggest that detection of serum miR-29c and miR-429 expression should be further evaluated as a novel,non-invasive biomarker for early stage NSCLC." +circulation_biomarker_diagnosis_ns hsa-mir-93 Early-Stage Non-Small-Cell Lung Carcinoma 24523873 "The results of the current study suggest that detection of serum miR-29c and miR-429 expression should be further evaluated as a novel,non-invasive biomarker for early stage NSCLC." +circulation_biomarker_diagnosis_ns hsa-mir-499 Myocardial Infarction 24533109 "MiRNAs, especially miR-499 and miR-133a, may be suitable for use as diagnostic biomarkers of myocardial infarction." +circulation_biomarker_diagnosis_ns hsa-mir-499 "Carcinoma, Lung, Non-Small-Cell" 24549225 Serum miR-499 as a novel diagnostic and prognostic biomarker in non-small cell lung cancer. +circulation_biomarker_diagnosis_ns hsa-mir-206 Early-Stage Lung Carcinoma 24553369 4-(Methylnitrosamino)-1-(3-pyridyl) -1-butanone induces circulating microRNA deregulation in early lung carcinogenesis. +circulation_biomarker_diagnosis_ns hsa-mir-210 Early-Stage Lung Carcinoma 24553369 4-(Methylnitrosamino)-1-(3-pyridyl) -1-butanone induces circulating microRNA deregulation in early lung carcinogenesis. +circulation_biomarker_diagnosis_ns hsa-mir-223 Cardiovascular Diseases [unspecific] 24573468 Smoking alters circulating plasma microvesicle pattern and microRNA signatures. +circulation_biomarker_diagnosis_ns hsa-mir-29b Cardiovascular Diseases [unspecific] 24573468 Smoking alters circulating plasma microvesicle pattern and microRNA signatures. +circulation_biomarker_diagnosis_ns hsa-mir-34a Colorectal Carcinoma 24573638 Detection of miR-34a and miR-34b/c in stool sample as potential screening biomarkers for noninvasive diagnosis of colorectal cancer. +circulation_biomarker_diagnosis_ns hsa-mir-34b Colorectal Carcinoma 24573638 Detection of miR-34a and miR-34b/c in stool sample as potential screening biomarkers for noninvasive diagnosis of colorectal cancer. +circulation_biomarker_diagnosis_ns hsa-mir-34c Colorectal Carcinoma 24573638 Detection of miR-34a and miR-34b/c in stool sample as potential screening biomarkers for noninvasive diagnosis of colorectal cancer. +circulation_biomarker_diagnosis_ns hsa-let-7d Alzheimer Disease 24577456 Genome-wide serum microRNA expression profiling identifies serum biomarkers for Alzheimer's disease. +circulation_biomarker_diagnosis_ns hsa-mir-191 Alzheimer Disease 24577456 Genome-wide serum microRNA expression profiling identifies serum biomarkers for Alzheimer's disease. +circulation_biomarker_diagnosis_ns hsa-mir-342 Alzheimer Disease 24577456 Genome-wide serum microRNA expression profiling identifies serum biomarkers for Alzheimer's disease. +circulation_biomarker_diagnosis_ns hsa-mir-483 Alzheimer Disease 24577456 Genome-wide serum microRNA expression profiling identifies serum biomarkers for Alzheimer's disease. +circulation_biomarker_diagnosis_ns hsa-mir-885 Alzheimer Disease 24577456 Genome-wide serum microRNA expression profiling identifies serum biomarkers for Alzheimer's disease. +circulation_biomarker_diagnosis_ns hsa-mir-98 Alzheimer Disease 24577456 Genome-wide serum microRNA expression profiling identifies serum biomarkers for Alzheimer's disease. +circulation_biomarker_diagnosis_ns hsa-let-7a Breast Neoplasms 24584717 "In summary, the data suggested that miRNAs in milk from milk stasis patients may contribute to breast carcinogenesis and that they are more sensitive biomarkers for breast cancer than miRNAs in the blood." +circulation_biomarker_diagnosis_ns hsa-mir-10 Breast Neoplasms 24584717 "In summary, the data suggested that miRNAs in milk from milk stasis patients may contribute to breast carcinogenesis and that they are more sensitive biomarkers for breast cancer than miRNAs in the blood." +circulation_biomarker_diagnosis_ns hsa-mir-107 Breast Neoplasms 24584717 "In summary, the data suggested that miRNAs in milk from milk stasis patients may contribute to breast carcinogenesis and that they are more sensitive biomarkers for breast cancer than miRNAs in the blood." +circulation_biomarker_diagnosis_ns hsa-mir-140 Breast Neoplasms 24584717 "In summary, the data suggested that miRNAs in milk from milk stasis patients may contribute to breast carcinogenesis and that they are more sensitive biomarkers for breast cancer than miRNAs in the blood." +circulation_biomarker_diagnosis_ns hsa-mir-146 Breast Neoplasms 24584717 "In summary, the data suggested that miRNAs in milk from milk stasis patients may contribute to breast carcinogenesis and that they are more sensitive biomarkers for breast cancer than miRNAs in the blood." +circulation_biomarker_diagnosis_ns hsa-mir-21 Breast Neoplasms 24584717 "In summary, the data suggested that miRNAs in milk from milk stasis patients may contribute to breast carcinogenesis and that they are more sensitive biomarkers for breast cancer than miRNAs in the blood." +circulation_biomarker_diagnosis_ns hsa-mir-223 Breast Neoplasms 24584717 "In summary, the data suggested that miRNAs in milk from milk stasis patients may contribute to breast carcinogenesis and that they are more sensitive biomarkers for breast cancer than miRNAs in the blood." +circulation_biomarker_diagnosis_ns hsa-mir-29a Breast Neoplasms 24584717 "In summary, the data suggested that miRNAs in milk from milk stasis patients may contribute to breast carcinogenesis and that they are more sensitive biomarkers for breast cancer than miRNAs in the blood." +circulation_biomarker_diagnosis_ns hsa-mir-451 Breast Neoplasms 24584717 "In summary, the data suggested that miRNAs in milk from milk stasis patients may contribute to breast carcinogenesis and that they are more sensitive biomarkers for breast cancer than miRNAs in the blood." +circulation_biomarker_diagnosis_ns hsa-mir-486 Breast Neoplasms 24584717 "In summary, the data suggested that miRNAs in milk from milk stasis patients may contribute to breast carcinogenesis and that they are more sensitive biomarkers for breast cancer than miRNAs in the blood." +circulation_biomarker_diagnosis_ns hsa-mir-92 Breast Neoplasms 24584717 "In summary, the data suggested that miRNAs in milk from milk stasis patients may contribute to breast carcinogenesis and that they are more sensitive biomarkers for breast cancer than miRNAs in the blood." +circulation_biomarker_diagnosis_ns hsa-mir-21 Colorectal Carcinoma 24586105 Re: Serum miR-21 as a diagnostic and prognostic biomarker in colorectal cancer. +circulation_biomarker_diagnosis_ns hsa-mir-206 Amyotrophic Lateral Sclerosis 24586506 MicroRNA-206: a potential circulating biomarker candidate for amyotrophic lateral sclerosis. +circulation_biomarker_diagnosis_ns hsa-mir-122 Non-Neoplastic Diseases 24586876 "Only a subset of reported blood-based microRNA biomarkers have specificity for a particular disease. The remainder of the reported non-neoplastic biomarkers are either biologically implausible, non-specific, or uninterpretable due to limitations of our current understanding of microRNA expression." +circulation_biomarker_diagnosis_ns hsa-mir-126 Non-Neoplastic Diseases 24586876 "Only a subset of reported blood-based microRNA biomarkers have specificity for a particular disease. The remainder of the reported non-neoplastic biomarkers are either biologically implausible, non-specific, or uninterpretable due to limitations of our current understanding of microRNA expression." +circulation_biomarker_diagnosis_ns hsa-mir-146a Non-Neoplastic Diseases 24586876 "Only a subset of reported blood-based microRNA biomarkers have specificity for a particular disease. The remainder of the reported non-neoplastic biomarkers are either biologically implausible, non-specific, or uninterpretable due to limitations of our current understanding of microRNA expression." +circulation_biomarker_diagnosis_ns hsa-mir-155 Non-Neoplastic Diseases 24586876 "Only a subset of reported blood-based microRNA biomarkers have specificity for a particular disease. The remainder of the reported non-neoplastic biomarkers are either biologically implausible, non-specific, or uninterpretable due to limitations of our current understanding of microRNA expression." +circulation_biomarker_diagnosis_ns hsa-mir-16 Non-Neoplastic Diseases 24586876 "Only a subset of reported blood-based microRNA biomarkers have specificity for a particular disease. The remainder of the reported non-neoplastic biomarkers are either biologically implausible, non-specific, or uninterpretable due to limitations of our current understanding of microRNA expression." +circulation_biomarker_diagnosis_ns hsa-mir-21 Non-Neoplastic Diseases 24586876 "Only a subset of reported blood-based microRNA biomarkers have specificity for a particular disease. The remainder of the reported non-neoplastic biomarkers are either biologically implausible, non-specific, or uninterpretable due to limitations of our current understanding of microRNA expression." +circulation_biomarker_diagnosis_ns hsa-mir-223 Non-Neoplastic Diseases 24586876 "Only a subset of reported blood-based microRNA biomarkers have specificity for a particular disease. The remainder of the reported non-neoplastic biomarkers are either biologically implausible, non-specific, or uninterpretable due to limitations of our current understanding of microRNA expression." +circulation_biomarker_diagnosis_ns hsa-mir-16 Early-Stage Gastric Carcinoma 24595006 A five-microRNA panel in plasma was identified as potential biomarker for early detection of gastric cancer. +circulation_biomarker_diagnosis_ns hsa-mir-25 Early-Stage Gastric Carcinoma 24595006 A five-microRNA panel in plasma was identified as potential biomarker for early detection of gastric cancer. +circulation_biomarker_diagnosis_ns hsa-mir-451 Early-Stage Gastric Carcinoma 24595006 A five-microRNA panel in plasma was identified as potential biomarker for early detection of gastric cancer. +circulation_biomarker_diagnosis_ns hsa-mir-486 Early-Stage Gastric Carcinoma 24595006 A five-microRNA panel in plasma was identified as potential biomarker for early detection of gastric cancer. +circulation_biomarker_diagnosis_ns hsa-mir-92a Early-Stage Gastric Carcinoma 24595006 A five-microRNA panel in plasma was identified as potential biomarker for early detection of gastric cancer. +circulation_biomarker_diagnosis_ns hsa-mir-125b Hepatitis B Virus Infection 24595450 Profiles of serum microRNAs; miR-125b-5p and miR223-3p serve as novel biomarkers for HBV-positive hepatocellular carcinoma. +circulation_biomarker_diagnosis_ns hsa-mir-223 Hepatitis B Virus Infection 24595450 Profiles of serum microRNAs; miR-125b-5p and miR223-3p serve as novel biomarkers for HBV-positive hepatocellular carcinoma. +circulation_biomarker_diagnosis_ns hsa-mir-16 "Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic" 24598659 Expression of miR-16 in patients with T lymphoblastic lymphoma/acute lymphoblastic leukemia. +circulation_biomarker_diagnosis_ns hsa-mir-425 Gastric Neoplasms 24603541 "Taken together, our results revealed the oncogenic roles of miR-191 and miR-425 in gastric carcinogenesis, and indicated the potential use of serum miR-191 as a novel and stable biomarker for GC diagnosis." +circulation_biomarker_diagnosis_ns hsa-mir-18a Gastric Neoplasms 24626859 Circulating miR-18a could be a useful biomarker for screening GC and monitoring tumor dynamics. +circulation_biomarker_diagnosis_ns hsa-mir-122 Myasthenia Gravis 24637658 Analysis of serum miRNA profiles of myasthenia gravis patients. +circulation_biomarker_diagnosis_ns hsa-mir-140 Myasthenia Gravis 24637658 Analysis of serum miRNA profiles of myasthenia gravis patients. +circulation_biomarker_diagnosis_ns hsa-mir-15b Myasthenia Gravis 24637658 Analysis of serum miRNA profiles of myasthenia gravis patients. +circulation_biomarker_diagnosis_ns hsa-mir-185 Myasthenia Gravis 24637658 Analysis of serum miRNA profiles of myasthenia gravis patients. +circulation_biomarker_diagnosis_ns hsa-mir-192 Myasthenia Gravis 24637658 Analysis of serum miRNA profiles of myasthenia gravis patients. +circulation_biomarker_diagnosis_ns hsa-mir-20b Myasthenia Gravis 24637658 Analysis of serum miRNA profiles of myasthenia gravis patients. +circulation_biomarker_diagnosis_ns hsa-mir-885 Myasthenia Gravis 24637658 Analysis of serum miRNA profiles of myasthenia gravis patients. +circulation_biomarker_diagnosis_ns hsa-mir-106b Ovarian Neoplasms 24641401 "This study shows that Solexa sequencing provides a promising method for cancer-related miRNA profiling, and selectively expressed miRNAs could be used as potential serum-based biomarkers for ovarian cancer diagnosis." +circulation_biomarker_diagnosis_ns hsa-mir-22 Ovarian Neoplasms 24641401 "This study shows that Solexa sequencing provides a promising method for cancer-related miRNA profiling, and selectively expressed miRNAs could be used as potential serum-based biomarkers for ovarian cancer diagnosis." +circulation_biomarker_diagnosis_ns hsa-mir-451 Ovarian Neoplasms 24641401 "This study shows that Solexa sequencing provides a promising method for cancer-related miRNA profiling, and selectively expressed miRNAs could be used as potential serum-based biomarkers for ovarian cancer diagnosis." +circulation_biomarker_diagnosis_ns hsa-mir-93 Ovarian Neoplasms 24641401 "This study shows that Solexa sequencing provides a promising method for cancer-related miRNA profiling, and selectively expressed miRNAs could be used as potential serum-based biomarkers for ovarian cancer diagnosis." +circulation_biomarker_diagnosis_ns hsa-mir-484 Early-Stage Breast Carcinoma 24641801 "In this study, we found that miR-484 is significantly differentially expressed in serum of early breast cancer patients compared to healthy volunteers. We did not however find any correlation between miR-484 levels with histopathological parameters of the breast cancers. With further studies, miR-484 may prove useful as an adjunct to mammography for detection of early breast cancer." +circulation_biomarker_diagnosis_ns hsa-mir-122 Chronic Hepatitis B 24643113 "Comparison of circulating, hepatocyte specific messenger RNA and microRNA as biomarkers for chronic hepatitis B and C." +circulation_biomarker_diagnosis_ns hsa-mir-122 Chronic Hepatitis C 24643113 "Comparison of circulating, hepatocyte specific messenger RNA and microRNA as biomarkers for chronic hepatitis B and C." +circulation_biomarker_diagnosis_ns hsa-mir-15b Colorectal Carcinoma 24646542 miR-15b and miR-17 Are Tumor-derived Plasma MicroRNAs Dysregulated in Colorectal Neoplasia. +circulation_biomarker_diagnosis_ns hsa-mir-17 Colorectal Carcinoma 24646542 miR-15b and miR-17 Are Tumor-derived Plasma MicroRNAs Dysregulated in Colorectal Neoplasia. +circulation_biomarker_diagnosis_ns hsa-mir-33 Psoriasis 24656994 In psoriasis patients plasma levels of lipid and glucose metabolism-related miRNA-33 are increased and correlated with insulin. The study of circulating miRNA-33 in psoriasis may provide new insights about the associated systemic inflammatory abnormalities. +circulation_biomarker_diagnosis_ns hsa-mir-223 "Lymphoma, Non-Hodgkin" 24675587 "Altered serum levels of miR-21, miR-122, and miR-223 are seen in HIV-infected individuals." +circulation_biomarker_diagnosis_ns hsa-mir-135b Colorectal Carcinoma 24691020 Stool-based miR-135b can be used as a noninvasive biomarker for the detection of CRC and advanced adenoma. +circulation_biomarker_diagnosis_ns hsa-mir-107 Early-Stage Breast Carcinoma 24694649 "We present herein a 9 miRNA signature capable of discriminating between ER-positive breast cancer and healthy controls. Using a specific algorithm based on the 9 miRNA signature, the risk for future individuals can be predicted. Since microRNAs are highly stable in blood components, this signature might be useful in the development of a blood-based multi-marker test to improve early detection of breast cancer. Such a test could potentially be used as a screening tool to identify individuals who would benefit from further diagnostic assessment." +circulation_biomarker_diagnosis_ns hsa-mir-133a Early-Stage Breast Carcinoma 24694649 "We present herein a 9 miRNA signature capable of discriminating between ER-positive breast cancer and healthy controls. Using a specific algorithm based on the 9 miRNA signature, the risk for future individuals can be predicted. Since microRNAs are highly stable in blood components, this signature might be useful in the development of a blood-based multi-marker test to improve early detection of breast cancer. Such a test could potentially be used as a screening tool to identify individuals who would benefit from further diagnostic assessment." +circulation_biomarker_diagnosis_ns hsa-mir-139 Early-Stage Breast Carcinoma 24694649 "We present herein a 9 miRNA signature capable of discriminating between ER-positive breast cancer and healthy controls. Using a specific algorithm based on the 9 miRNA signature, the risk for future individuals can be predicted. Since microRNAs are highly stable in blood components, this signature might be useful in the development of a blood-based multi-marker test to improve early detection of breast cancer. Such a test could potentially be used as a screening tool to identify individuals who would benefit from further diagnostic assessment." +circulation_biomarker_diagnosis_ns hsa-mir-143 Early-Stage Breast Carcinoma 24694649 "We present herein a 9 miRNA signature capable of discriminating between ER-positive breast cancer and healthy controls. Using a specific algorithm based on the 9 miRNA signature, the risk for future individuals can be predicted. Since microRNAs are highly stable in blood components, this signature might be useful in the development of a blood-based multi-marker test to improve early detection of breast cancer. Such a test could potentially be used as a screening tool to identify individuals who would benefit from further diagnostic assessment." +circulation_biomarker_diagnosis_ns hsa-mir-145 Early-Stage Breast Carcinoma 24694649 "We present herein a 9 miRNA signature capable of discriminating between ER-positive breast cancer and healthy controls. Using a specific algorithm based on the 9 miRNA signature, the risk for future individuals can be predicted. Since microRNAs are highly stable in blood components, this signature might be useful in the development of a blood-based multi-marker test to improve early detection of breast cancer. Such a test could potentially be used as a screening tool to identify individuals who would benefit from further diagnostic assessment." +circulation_biomarker_diagnosis_ns hsa-mir-15a Early-Stage Breast Carcinoma 24694649 "We present herein a 9 miRNA signature capable of discriminating between ER-positive breast cancer and healthy controls. Using a specific algorithm based on the 9 miRNA signature, the risk for future individuals can be predicted. Since microRNAs are highly stable in blood components, this signature might be useful in the development of a blood-based multi-marker test to improve early detection of breast cancer. Such a test could potentially be used as a screening tool to identify individuals who would benefit from further diagnostic assessment." +circulation_biomarker_diagnosis_ns hsa-mir-18a Early-Stage Breast Carcinoma 24694649 "We present herein a 9 miRNA signature capable of discriminating between ER-positive breast cancer and healthy controls. Using a specific algorithm based on the 9 miRNA signature, the risk for future individuals can be predicted. Since microRNAs are highly stable in blood components, this signature might be useful in the development of a blood-based multi-marker test to improve early detection of breast cancer. Such a test could potentially be used as a screening tool to identify individuals who would benefit from further diagnostic assessment." +circulation_biomarker_diagnosis_ns hsa-mir-365 Early-Stage Breast Carcinoma 24694649 "We present herein a 9 miRNA signature capable of discriminating between ER-positive breast cancer and healthy controls. Using a specific algorithm based on the 9 miRNA signature, the risk for future individuals can be predicted. Since microRNAs are highly stable in blood components, this signature might be useful in the development of a blood-based multi-marker test to improve early detection of breast cancer. Such a test could potentially be used as a screening tool to identify individuals who would benefit from further diagnostic assessment." +circulation_biomarker_diagnosis_ns hsa-mir-425 Early-Stage Breast Carcinoma 24694649 "We present herein a 9 miRNA signature capable of discriminating between ER-positive breast cancer and healthy controls. Using a specific algorithm based on the 9 miRNA signature, the risk for future individuals can be predicted. Since microRNAs are highly stable in blood components, this signature might be useful in the development of a blood-based multi-marker test to improve early detection of breast cancer. Such a test could potentially be used as a screening tool to identify individuals who would benefit from further diagnostic assessment." +circulation_biomarker_diagnosis_ns hsa-let-7f "Carcinoma, Hepatocellular" 24697119 "Serum miR-16, let-7f, and miR-21 are related with the biological behavior of HCC, which means that they could be considered as the potential indicators to estimate the tumor size or the recurrence of HCC." +circulation_biomarker_diagnosis_ns hsa-mir-16 "Carcinoma, Hepatocellular" 24697119 "Serum miR-16, let-7f, and miR-21 are related with the biological behavior of HCC, which means that they could be considered as the potential indicators to estimate the tumor size or the recurrence of HCC." +circulation_biomarker_diagnosis_ns hsa-mir-21 "Carcinoma, Hepatocellular" 24697119 "Serum miR-16, let-7f, and miR-21 are related with the biological behavior of HCC, which means that they could be considered as the potential indicators to estimate the tumor size or the recurrence of HCC." +circulation_biomarker_diagnosis_ns hsa-mir-17 Influenza 24699363 Comprehensive characterization of serum microRNA profile in response to the emerging avian influenza A (H7N9) virus infection in humans. +circulation_biomarker_diagnosis_ns hsa-mir-20a Influenza 24699363 Comprehensive characterization of serum microRNA profile in response to the emerging avian influenza A (H7N9) virus infection in humans. +circulation_biomarker_diagnosis_ns hsa-mir-376c Influenza 24699363 Comprehensive characterization of serum microRNA profile in response to the emerging avian influenza A (H7N9) virus infection in humans. +circulation_biomarker_diagnosis_ns hsa-let-7g Colorectal Carcinoma 24709885 Identification of a circulating microRNA signature for colorectal cancer detection. +circulation_biomarker_diagnosis_ns hsa-mir-181b Colorectal Carcinoma 24709885 Identification of a circulating microRNA signature for colorectal cancer detection. +circulation_biomarker_diagnosis_ns hsa-mir-203 Colorectal Carcinoma 24709885 Identification of a circulating microRNA signature for colorectal cancer detection. +circulation_biomarker_diagnosis_ns hsa-mir-21 Colorectal Carcinoma 24709885 Identification of a circulating microRNA signature for colorectal cancer detection. +circulation_biomarker_diagnosis_ns hsa-mir-31 Colorectal Carcinoma 24709885 Identification of a circulating microRNA signature for colorectal cancer detection. +circulation_biomarker_diagnosis_ns hsa-mir-92a Colorectal Carcinoma 24709885 Identification of a circulating microRNA signature for colorectal cancer detection. +circulation_biomarker_diagnosis_ns hsa-mir-186 Myocardial Infarction 24727883 "In a validation phase, a miRNA panel including miR-132, miR-150, and miR-186 showed the highest discriminatory power" +circulation_biomarker_diagnosis_ns hsa-mir-105 Breast Neoplasms 24735924 "miR-105 can be detected in the circulation at the premetastatic stage, and its levels in the blood and tumor are associated with ZO-1 expression and metastatic progression in early-stage breast cancer." +circulation_biomarker_diagnosis_ns hsa-mir-150 Irritable Bowel Syndrome 24768587 "This preliminary study reports the association of two miRNAs,detected in whole blood, with IBS. These miRNAs link to pain and inflammatory pathways both of which are thought to be dysregulated in IBS. Larger sample sizes are needed to confirm their importance and potential as biomarkers." +circulation_biomarker_diagnosis_ns hsa-mir-342 Irritable Bowel Syndrome 24768587 "This preliminary study reports the association of two miRNAs,detected in whole blood, with IBS. These miRNAs link to pain and inflammatory pathways both of which are thought to be dysregulated in IBS. Larger sample sizes are needed to confirm their importance and potential as biomarkers." +circulation_biomarker_diagnosis_ns hsa-mir-1207 Metabolic Syndrome 24784704 Blood microRNA profile associates with the levels of serum lipids and metabolites associated with glucose metabolism and insulin resistance and pinpoints pathways underlying metabolic syndrome: the cardiovascular risk in Young Finns Study. +circulation_biomarker_diagnosis_ns hsa-mir-1237 Metabolic Syndrome 24784704 Blood microRNA profile associates with the levels of serum lipids and metabolites associated with glucose metabolism and insulin resistance and pinpoints pathways underlying metabolic syndrome: the cardiovascular risk in Young Finns Study. +circulation_biomarker_diagnosis_ns hsa-mir-1288 Metabolic Syndrome 24784704 Blood microRNA profile associates with the levels of serum lipids and metabolites associated with glucose metabolism and insulin resistance and pinpoints pathways underlying metabolic syndrome: the cardiovascular risk in Young Finns Study. +circulation_biomarker_diagnosis_ns hsa-mir-129-1 Metabolic Syndrome 24784704 Blood microRNA profile associates with the levels of serum lipids and metabolites associated with glucose metabolism and insulin resistance and pinpoints pathways underlying metabolic syndrome: the cardiovascular risk in Young Finns Study. +circulation_biomarker_diagnosis_ns hsa-mir-129-2 Metabolic Syndrome 24784704 Blood microRNA profile associates with the levels of serum lipids and metabolites associated with glucose metabolism and insulin resistance and pinpoints pathways underlying metabolic syndrome: the cardiovascular risk in Young Finns Study. +circulation_biomarker_diagnosis_ns hsa-mir-144 Metabolic Syndrome 24784704 Blood microRNA profile associates with the levels of serum lipids and metabolites associated with glucose metabolism and insulin resistance and pinpoints pathways underlying metabolic syndrome: the cardiovascular risk in Young Finns Study. +circulation_biomarker_diagnosis_ns hsa-mir-331 Metabolic Syndrome 24784704 Blood microRNA profile associates with the levels of serum lipids and metabolites associated with glucose metabolism and insulin resistance and pinpoints pathways underlying metabolic syndrome: the cardiovascular risk in Young Finns Study. +circulation_biomarker_diagnosis_ns hsa-mir-484 Metabolic Syndrome 24784704 Blood microRNA profile associates with the levels of serum lipids and metabolites associated with glucose metabolism and insulin resistance and pinpoints pathways underlying metabolic syndrome: the cardiovascular risk in Young Finns Study. +circulation_biomarker_diagnosis_ns hsa-mir-625 Metabolic Syndrome 24784704 Blood microRNA profile associates with the levels of serum lipids and metabolites associated with glucose metabolism and insulin resistance and pinpoints pathways underlying metabolic syndrome: the cardiovascular risk in Young Finns Study. +circulation_biomarker_diagnosis_ns hsa-mir-18a Neoplasms [unspecific] 24815829 Circulating miR-18a: a sensitive cancer screening biomarker in human cancer. +circulation_biomarker_diagnosis_ns hsa-mir-21 Acute Cerebral Infarction 24841240 Identification of miRNA-21 and miRNA-24 in plasma as potential early stage markers of acute cerebral infarction. +circulation_biomarker_diagnosis_ns hsa-mir-24 Acute Cerebral Infarction 24841240 Identification of miRNA-21 and miRNA-24 in plasma as potential early stage markers of acute cerebral infarction. +circulation_biomarker_diagnosis_ns hsa-mir-3620 Immune Thrombocytopenic Purpura 24851893 The plasma differential miRNA profiles are identified in ITP patients. And miRNA is involved in calcium signaling pathway and T cell receptor signaling pathway may be associated with ITP pathogenesis. +circulation_biomarker_diagnosis_ns hsa-mir-378i Immune Thrombocytopenic Purpura 24851893 The plasma differential miRNA profiles are identified in ITP patients. And miRNA is involved in calcium signaling pathway and T cell receptor signaling pathway may be associated with ITP pathogenesis. +circulation_biomarker_diagnosis_ns hsa-mir-4721 Immune Thrombocytopenic Purpura 24851893 The plasma differential miRNA profiles are identified in ITP patients. And miRNA is involved in calcium signaling pathway and T cell receptor signaling pathway may be associated with ITP pathogenesis. +circulation_biomarker_diagnosis_ns hsa-let-7g Glioma 24858071 miRNA profile of the peripheral blood may serve as a new biomarker for glioma diagnosis with high specificity and sensitivity. +circulation_biomarker_diagnosis_ns hsa-mir-320 Glioma 24858071 miRNA profile of the peripheral blood may serve as a new biomarker for glioma diagnosis with high specificity and sensitivity. +circulation_biomarker_diagnosis_ns hsa-mir-340 Glioma 24858071 miRNA profile of the peripheral blood may serve as a new biomarker for glioma diagnosis with high specificity and sensitivity. +circulation_biomarker_diagnosis_ns hsa-mir-576 Glioma 24858071 miRNA profile of the peripheral blood may serve as a new biomarker for glioma diagnosis with high specificity and sensitivity. +circulation_biomarker_diagnosis_ns hsa-mir-626 Glioma 24858071 miRNA profile of the peripheral blood may serve as a new biomarker for glioma diagnosis with high specificity and sensitivity. +circulation_biomarker_diagnosis_ns hsa-mir-7 Glioma 24858071 miRNA profile of the peripheral blood may serve as a new biomarker for glioma diagnosis with high specificity and sensitivity. +circulation_biomarker_diagnosis_ns hsa-mir-21 "Carcinoma, Lung" 24865991 The current evidence suggests that serum miR-21 can be rapidly measured in lung carcinoma patients and has potential diagnostic value with moderate sensitivity and specificity. Further prospective studies to assess the early stage diagnostic value are needed in the future. +circulation_biomarker_diagnosis_ns hsa-mir-126 Cardiovascular Diseases [unspecific] 24874084 We have demonstrated that this panel of five serum miRNAs is expected to become potential non-invasive biomarkers for detection of MB. +circulation_biomarker_diagnosis_ns hsa-mir-151 Cardiovascular Diseases [unspecific] 24874084 We have demonstrated that this panel of five serum miRNAs is expected to become potential non-invasive biomarkers for detection of MB. +circulation_biomarker_diagnosis_ns hsa-mir-29b Cardiovascular Diseases [unspecific] 24874084 We have demonstrated that this panel of five serum miRNAs is expected to become potential non-invasive biomarkers for detection of MB. +circulation_biomarker_diagnosis_ns hsa-mir-503 Cardiovascular Diseases [unspecific] 24874084 We have demonstrated that this panel of five serum miRNAs is expected to become potential non-invasive biomarkers for detection of MB. +circulation_biomarker_diagnosis_ns hsa-mir-645 Cardiovascular Diseases [unspecific] 24874084 We have demonstrated that this panel of five serum miRNAs is expected to become potential non-invasive biomarkers for detection of MB. +circulation_biomarker_diagnosis_ns hsa-mir-483 "Carcinoma, Nasopharyngeal" 24874644 Plasma microRNA profiling in nasopharyngeal carcinoma patients reveals miR-548q and miR-483-5p as potential biomarkers. +circulation_biomarker_diagnosis_ns hsa-mir-548q "Carcinoma, Nasopharyngeal" 24874644 Plasma microRNA profiling in nasopharyngeal carcinoma patients reveals miR-548q and miR-483-5p as potential biomarkers. +circulation_biomarker_diagnosis_ns hsa-mir-19 Prostate Neoplasms 24893170 "miR-19, miR-345, miR-519c-5p serum levels predict adverse pathology in prostate cancer patients eligible for active surveillance." +circulation_biomarker_diagnosis_ns hsa-mir-345 Prostate Neoplasms 24893170 "miR-19, miR-345, miR-519c-5p serum levels predict adverse pathology in prostate cancer patients eligible for active surveillance." +circulation_biomarker_diagnosis_ns hsa-mir-519c Prostate Neoplasms 24893170 "miR-19, miR-345, miR-519c-5p serum levels predict adverse pathology in prostate cancer patients eligible for active surveillance." +circulation_biomarker_diagnosis_ns hsa-mir-143 Psoriasis 24909097 "We suggest that changes in the miR-223 and miR-143 expressions in PBMCs from patients with psoriasis may serve as novel biomarkers for disease activity in psoriasis; however, further investigations are warranted to clarify their specific roles." +circulation_biomarker_diagnosis_ns hsa-mir-223 Psoriasis 24909097 "We suggest that changes in the miR-223 and miR-143 expressions in PBMCs from patients with psoriasis may serve as novel biomarkers for disease activity in psoriasis; however, further investigations are warranted to clarify their specific roles." +circulation_biomarker_diagnosis_ns hsa-mir-138 Ovarian Neoplasms 24911418 our study suggests that detecting these ovarian cancer specific miRNAs in plasma might serve as novel non-invasive biomarkers for ovarian cancer. +circulation_biomarker_diagnosis_ns hsa-mir-126 Diabetes Mellitus 24927146 The role of circulating microRNA-126 (miR-126): a novel biomarker for screening prediabetes and newly diagnosed type 2 diabetes mellitus. +circulation_biomarker_diagnosis_ns hsa-mir-200c Gastric Neoplasms 24947260 "GDF15 and MMP7 serum levels have diagnostic value for GC. The combination marker formed by GDF15, MMP7 and miR-200c is indicative of adverse evolution in GC patients." +circulation_biomarker_diagnosis_ns hsa-mir-146a "Leukemia, Lymphoblastic, Acute" 24955371 these miRNAs not only may be used as biomarkers in diagnosis of ALL and monitoring the disease but also provide new insights into the potential roles of them in leukemogenesis. +circulation_biomarker_diagnosis_ns hsa-mir-155 "Leukemia, Lymphoblastic, Acute" 24955371 these miRNAs not only may be used as biomarkers in diagnosis of ALL and monitoring the disease but also provide new insights into the potential roles of them in leukemogenesis. +circulation_biomarker_diagnosis_ns hsa-mir-195 "Leukemia, Lymphoblastic, Acute" 24955371 these miRNAs not only may be used as biomarkers in diagnosis of ALL and monitoring the disease but also provide new insights into the potential roles of them in leukemogenesis. +circulation_biomarker_diagnosis_ns hsa-mir-152 Bladder Neoplasms 24961907 expression level of serum miR-152 could provide information on the recurrence risk of NMIBC. +circulation_biomarker_diagnosis_ns hsa-mir-21 "Carcinoma, Hepatocellular" 24963487 Expression of serum exosomal microRNA-21 in human hepatocellular carcinoma. +circulation_biomarker_diagnosis_ns hsa-mir-21 "Carcinoma, Esophageal" 24968850 "Both salivary and plasmatic miR-21 can be sensitive biomarkers for EC, and salivary miR-21 detection has the potential to replace plasma detection for EC diagnosis." +circulation_biomarker_diagnosis_ns hsa-mir-23a "Diabetes Mellitus, Type 2" 24981880 "Serum miR-23a, a potential biomarker for diagnosis of pre-diabetes and type 2 diabetes." +circulation_biomarker_diagnosis_ns hsa-mir-107 Breast Neoplasms 25004125 "A panel of 4 circulating miRNAs exhibited significantly altered levels following radical resection of primary ER+ breast cancers in post-menopausal women. These specific miRNAs may be involved in tumorigenesis and could potentially be used to monitor whether all cancer cells have been removed at surgery and/or, subsequently, whether the patients develop recurrence." +circulation_biomarker_diagnosis_ns hsa-mir-148a Breast Neoplasms 25004125 "A panel of 4 circulating miRNAs exhibited significantly altered levels following radical resection of primary ER+ breast cancers in post-menopausal women. These specific miRNAs may be involved in tumorigenesis and could potentially be used to monitor whether all cancer cells have been removed at surgery and/or, subsequently, whether the patients develop recurrence." +circulation_biomarker_diagnosis_ns hsa-mir-223 Breast Neoplasms 25004125 "A panel of 4 circulating miRNAs exhibited significantly altered levels following radical resection of primary ER+ breast cancers in post-menopausal women. These specific miRNAs may be involved in tumorigenesis and could potentially be used to monitor whether all cancer cells have been removed at surgery and/or, subsequently, whether the patients develop recurrence." +circulation_biomarker_diagnosis_ns hsa-mir-338 Breast Neoplasms 25004125 "A panel of 4 circulating miRNAs exhibited significantly altered levels following radical resection of primary ER+ breast cancers in post-menopausal women. These specific miRNAs may be involved in tumorigenesis and could potentially be used to monitor whether all cancer cells have been removed at surgery and/or, subsequently, whether the patients develop recurrence." +circulation_biomarker_diagnosis_ns hsa-mir-25 Pancreatic Neoplasms 25030590 "Plasma miR-21, miR-155, miR-25, miR-210 have diagnostic value for pancreatic cancer, and deserve further study." +circulation_biomarker_diagnosis_ns hsa-mir-1301 Preeclampsia 25064070 miR-1301 is dysregulated in early-onset preeclampsia and could possibly play a role in the regulation of leptin during pregnancy. +circulation_biomarker_diagnosis_ns hsa-mir-223 Preeclampsia 25064070 miR-1301 is dysregulated in early-onset preeclampsia and could possibly play a role in the regulation of leptin during pregnancy. +circulation_biomarker_diagnosis_ns hsa-mir-224 Preeclampsia 25064070 miR-1301 is dysregulated in early-onset preeclampsia and could possibly play a role in the regulation of leptin during pregnancy. +circulation_biomarker_diagnosis_ns hsa-mir-122 Hepatitis C Virus Infection 25065618 "miR-122, miR-126, miR-136 and miR-181a have been shown to be involved in HCV infection with different genotypes. Their expression has been associated with the gender, stage and grade of liver disease, mode of transmission, serum HCV load and the presence of steatosis." +circulation_biomarker_diagnosis_ns hsa-mir-126 Hepatitis C Virus Infection 25065618 "miR-122, miR-126, miR-136 and miR-181a have been shown to be involved in HCV infection with different genotypes. Their expression has been associated with the gender, stage and grade of liver disease, mode of transmission, serum HCV load and the presence of steatosis." +circulation_biomarker_diagnosis_ns hsa-mir-136 Hepatitis C Virus Infection 25065618 "miR-122, miR-126, miR-136 and miR-181a have been shown to be involved in HCV infection with different genotypes. Their expression has been associated with the gender, stage and grade of liver disease, mode of transmission, serum HCV load and the presence of steatosis." +circulation_biomarker_diagnosis_ns hsa-mir-181a Hepatitis C Virus Infection 25065618 "miR-122, miR-126, miR-136 and miR-181a have been shown to be involved in HCV infection with different genotypes. Their expression has been associated with the gender, stage and grade of liver disease, mode of transmission, serum HCV load and the presence of steatosis." +circulation_biomarker_diagnosis_ns hsa-mir-146a Sepsis 25086335 "So far, miR-223, miR-146a and miR-150 have been identified to have promising prognostic and diagnostic value to sepsis." +circulation_biomarker_diagnosis_ns hsa-mir-150 Sepsis 25086335 "So far, miR-223, miR-146a and miR-150 have been identified to have promising prognostic and diagnostic value to sepsis." +circulation_biomarker_diagnosis_ns hsa-mir-21 "Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal" 25099764 Combined detection of serum exosomal miR-21 and HOTAIR as diagnostic and prognostic biomarkers for laryngeal squamous cell carcinoma. +circulation_biomarker_diagnosis_ns hsa-mir-182 Colorectal Adenocarcinoma 25115394 Circulating miR-182 is a biomarker of colorectal adenocarcinoma progression. +circulation_biomarker_diagnosis_ns hsa-mir-25 "Squamous Cell Carcinoma, Esophageal" 25117812 Plasma miR-25 might be a clinically useful biomarker for cancer detection and the monitoring of tumour dynamics in ESCC patients. +circulation_biomarker_diagnosis_ns hsa-mir-193b Alzheimer Disease 25119742 MicroRNA-193b is a regulator of amyloid precursor protein in the blood and cerebrospinal fluid derived exosomal microRNA-193b is a biomarker of Alzheimer's disease. +circulation_biomarker_diagnosis_ns hsa-mir-375 Diabetes Mellitus 25120598 "Compared with the miR-375 levels in patients with normal glucose tolerance (NGT; n=53), the samples from patients with IGT (n=44) exhibited downregulation of miR-375, while those from patients with T2DM (n=54) exhibited upregulation of miR-375 in the plasma." +circulation_biomarker_diagnosis_ns hsa-mir-222 Gastric Neoplasms 25129310 Circulating miR-222 in plasma and its potential diagnostic and prognostic value in gastric cancer. +circulation_biomarker_diagnosis_ns hsa-mir-24 "Carcinoma, Hepatocellular" 25129312 Diagnostic and prognostic significance of serum miR-24-3p in HBV-related hepatocellular carcinoma. +circulation_biomarker_diagnosis_ns hsa-mir-124 Chronic Hepatitis B 25131617 Serum microRNA-124 is a novel biomarker for liver necroinflammation in patients with chronic hepatitis B virus infection. +circulation_biomarker_diagnosis_ns hsa-mir-29 Chronic Hepatitis B 25138057 Serum miR-29 levels are negatively correlated with liver fibrotic stages and necroinflammation grades in patients with chronic HBV infection. miR-29 appears to be a novel biomarkers for predicting disease progression in these patients. +circulation_biomarker_diagnosis_ns hsa-mir-1 Muscle Diseases [unspecific] 25146754 These miRNAs are potential biomarkers of muscle damage or adaptation to exercise. +circulation_biomarker_diagnosis_ns hsa-mir-1 "Muscular Dystrophy, Duchenne" 25150707 "Taken together, our data demonstrate that levels of miR-1, miR-133a, and miR-206 in serum of BMD and miR-1 in sera of LGMD and FSHD patients showed no significant differences compared with those of controls by Bonferroni correction. However, the results might need increase in sample sizes to evaluate these three miRNAs as variable biomarkers." +circulation_biomarker_diagnosis_ns hsa-mir-133a "Muscular Dystrophy, Duchenne" 25150707 "Taken together, our data demonstrate that levels of miR-1, miR-133a, and miR-206 in serum of BMD and miR-1 in sera of LGMD and FSHD patients showed no significant differences compared with those of controls by Bonferroni correction. However, the results might need increase in sample sizes to evaluate these three miRNAs as variable biomarkers." +circulation_biomarker_diagnosis_ns hsa-mir-206 "Muscular Dystrophy, Duchenne" 25150707 "Taken together, our data demonstrate that levels of miR-1, miR-133a, and miR-206 in serum of BMD and miR-1 in sera of LGMD and FSHD patients showed no significant differences compared with those of controls by Bonferroni correction. However, the results might need increase in sample sizes to evaluate these three miRNAs as variable biomarkers." +circulation_biomarker_diagnosis_ns hsa-mir-196a "Scleroderma, Localized" 25152444 Down-regulation of miR-196a and subsequent overexpression of type 1 collagen in dermal fibroblasts may play a key role in the pathogenesis of LSc. The serum levels of miR-196a may be useful as a diagnostic marker of LSc. +circulation_biomarker_diagnosis_ns hsa-mir-21 "Squamous Cell Carcinoma, Oral" 25174622 Circulating microRNA-21 (MIR-21) and phosphatase and tensin homolog (PTEN) are promising novel biomarkers for detection of oral squamous cell carcinoma. +circulation_biomarker_diagnosis_ns hsa-mir-148a Osteosarcoma 25185654 Circulating miR-148a is a significant diagnostic and prognostic biomarker for patients with osteosarcoma. +circulation_biomarker_diagnosis_ns hsa-mir-371a Germ Cell Tumor 25187505 MicroRNA miR-371a-3p in serum of patients with germ cell tumours: evaluations for establishing a serum biomarker. +circulation_biomarker_diagnosis_ns hsa-mir-192 Choriocarcinoma 25202432 "Normalization of miR-98 expression levels to those of U6 snRNA, miR-192 or a combination of these genes enabled the detection of a significant difference between BPE and LA-MPE samples." +circulation_biomarker_diagnosis_ns hsa-mir-708 "Leukemia, Lymphoblastic, Acute, Childhood" 25214155 MiR-708-5p is differentially expressed in childhood acute lymphoblastic leukemia but not strongly associated to clinical features. +circulation_biomarker_diagnosis_ns hsa-mir-483 Myeloma 25216866 Circulating microRNA 483-5p as a novel biomarker for diagnosis survival prediction in multiple myeloma. +circulation_biomarker_diagnosis_ns hsa-mir-106b Gastric Neoplasms 25218271 MicroRNA-106b~25 expressions in tumor tissues and plasma of patients with gastric cancers. +circulation_biomarker_diagnosis_ns hsa-mir-186 Focal Segmental Glomerulosclerosis 25218681 Plasma miR-186 may be a biomarker for FSGS with nephrotic proteinuria. +circulation_biomarker_diagnosis_ns hsa-mir-155 Systemic Lupus Erythematosus 25253569 Correcting the expression of miRNA-155 represses PP2Ac and enhances the release of IL-2 in PBMCs of juvenile SLE patients. +circulation_biomarker_diagnosis_ns hsa-mir-146a Sepsis 25265569 "miR-182, miR-143, miR-145, miR-146a, miR-150, and miR-155 were dysregulated in sepsis patients." +circulation_biomarker_diagnosis_ns hsa-mir-199a Colorectal Carcinoma 25269744 Circulating miR-199a-3p as a novel serum biomarker for colorectal cancer. +circulation_biomarker_diagnosis_ns hsa-mir-335 "Leukemia, Myeloid, Acute" 25301405 Our data offer the convincing evidence for the first time that serum miR-335 level may be markedly and consistently increased in pediatric AML patients. Serum miR-335 may serve as a promising marker for monitoring the progression and predicting the clinical outcome of patients with this disease. +circulation_biomarker_diagnosis_ns hsa-mir-182 Pancreatic Neoplasms 25326859 Circulating microRNA-182 in plasma and its potential diagnostic and prognostic value for pancreatic cancer. +circulation_biomarker_diagnosis_ns hsa-mir-126 Coronary Artery Disease 25327597 "Plasma miR-126 level is positively correlated to the CCC formation and is an independent predictor of CCC development in patients with severely narrowed coronary arteries, suggesting that plasma miR-126 might be a useful new, stable blood biomarker for predicting CCC formation in patients with severely narrowed coronary arteries." +circulation_biomarker_diagnosis_ns hsa-mir-126 Coronary Artery Disease 25349183 "In contrast, increased expression of miR-126 and miR-199a in circulating MVs was significantly associated with a lower major adverse CV event rate." +circulation_biomarker_diagnosis_ns hsa-mir-24 Heart Failure 25364765 miR-24 and miR-214 are bi-functional cardio-miRs. +circulation_biomarker_diagnosis_ns hsa-mir-29 Glioma 25367878 Identification and Evaluation of Serum MicroRNA-29 Family for Glioma Screening. +circulation_biomarker_diagnosis_ns hsa-mir-19a Acute Myocardial Infarction 25383678 Circulating microRNA-19a as a potential novel biomarker for diagnosis of acute myocardial infarction. +circulation_biomarker_diagnosis_ns hsa-mir-17 "Carcinoma, Hepatocellular" 25391771 "miR-30c-5p, miR-223-3p, miR-302c-3p and miR-17-8p could be used as novel non-invasive biomarkers of HCV-positive HCC in very early, even at cirrhosis stage of liver disease." +circulation_biomarker_diagnosis_ns hsa-mir-206 "Carcinoma, Hepatocellular" 25391771 "miR-30c-5p, miR-223-3p, miR-302c-3p and miR-17-9p could be used as novel non-invasive biomarkers of HCV-positive HCC in very early, even at cirrhosis stage of liver disease." +circulation_biomarker_diagnosis_ns hsa-mir-223 "Carcinoma, Hepatocellular" 25391771 "miR-30c-5p, miR-223-3p, miR-302c-3p and miR-17-6p could be used as novel non-invasive biomarkers of HCV-positive HCC in very early, even at cirrhosis stage of liver disease." +circulation_biomarker_diagnosis_ns hsa-mir-302c "Carcinoma, Hepatocellular" 25391771 "miR-30c-5p, miR-223-3p, miR-302c-3p and miR-17-7p could be used as novel non-invasive biomarkers of HCV-positive HCC in very early, even at cirrhosis stage of liver disease." +circulation_biomarker_diagnosis_ns hsa-mir-30c "Carcinoma, Hepatocellular" 25391771 "miR-30c-5p, miR-223-3p, miR-302c-3p and miR-17-5p could be used as novel non-invasive biomarkers of HCV-positive HCC in very early, even at cirrhosis stage of liver disease." +circulation_biomarker_diagnosis_ns hsa-mir-142 Systemic Lupus Erythematosus 25399392 "Circulating miRNA profiles are characteristic for SSc compared with both HC and SLE cases. Some of the predicted targets of the differentially regulated miRNA are of relevance for transforming growth factor-¦Â signaling andfibrosis, but need to be validated in independent studies." +circulation_biomarker_diagnosis_ns hsa-mir-150 Systemic Lupus Erythematosus 25399392 "Circulating miRNA profiles are characteristic for SSc compared with both HC and SLE cases. Some of the predicted targets of the differentially regulated miRNA are of relevance for transforming growth factor-¦Â signaling andfibrosis, but need to be validated in independent studies." +circulation_biomarker_diagnosis_ns hsa-mir-16 Systemic Lupus Erythematosus 25399392 "Circulating miRNA profiles are characteristic for SSc compared with both HC and SLE cases. Some of the predicted targets of the differentially regulated miRNA are of relevance for transforming growth factor-¦Â signaling andfibrosis, but need to be validated in independent studies." +circulation_biomarker_diagnosis_ns hsa-mir-223 Systemic Lupus Erythematosus 25399392 "Circulating miRNA profiles are characteristic for SSc compared with both HC and SLE cases. Some of the predicted targets of the differentially regulated miRNA are of relevance for transforming growth factor-¦Â signaling andfibrosis, but need to be validated in independent studies." +circulation_biomarker_diagnosis_ns hsa-mir-638 Systemic Lupus Erythematosus 25399392 "Circulating miRNA profiles are characteristic for SSc compared with both HC and SLE cases. Some of the predicted targets of the differentially regulated miRNA are of relevance for transforming growth factor-¦Â signaling andfibrosis, but need to be validated in independent studies." +circulation_biomarker_diagnosis_ns hsa-mir-125b Colorectal Carcinoma 25405754 "The measured levels of miRNAs in serum and plasma from same patients varied in the presence of hemolysis, and since hemolysis and other factors affected miRNA expression, it is important to consider these confounders while developing miRNA-based diagnostic assays." +circulation_biomarker_diagnosis_ns hsa-mir-16 Colorectal Carcinoma 25405754 "The measured levels of miRNAs in serum and plasma from same patients varied in the presence of hemolysis, and since hemolysis and other factors affected miRNA expression, it is important to consider these confounders while developing miRNA-based diagnostic assays." +circulation_biomarker_diagnosis_ns hsa-mir-21 Colorectal Carcinoma 25405754 "The measured levels of miRNAs in serum and plasma from same patients varied in the presence of hemolysis, and since hemolysis and other factors affected miRNA expression, it is important to consider these confounders while developing miRNA-based diagnostic assays." +circulation_biomarker_diagnosis_ns hsa-mir-29a Colorectal Carcinoma 25405754 "The measured levels of miRNAs in serum and plasma from same patients varied in the presence of hemolysis, and since hemolysis and other factors affected miRNA expression, it is important to consider these confounders while developing miRNA-based diagnostic assays." +circulation_biomarker_diagnosis_ns hsa-mir-124 Neoplasms [unspecific] 25416717 "This study describes a pipeline for robust diagnostic serum miRNA profiling in childhood solid tumors, and has identified candidate miRNA profiles for prospective testing." +circulation_biomarker_diagnosis_ns hsa-mir-1538 Neoplasms [unspecific] 25416717 "This study describes a pipeline for robust diagnostic serum miRNA profiling in childhood solid tumors, and has identified candidate miRNA profiles for prospective testing." +circulation_biomarker_diagnosis_ns hsa-mir-218 Neoplasms [unspecific] 25416717 "This study describes a pipeline for robust diagnostic serum miRNA profiling in childhood solid tumors, and has identified candidate miRNA profiles for prospective testing." +circulation_biomarker_diagnosis_ns hsa-mir-490 Neoplasms [unspecific] 25416717 "This study describes a pipeline for robust diagnostic serum miRNA profiling in childhood solid tumors, and has identified candidate miRNA profiles for prospective testing." +circulation_biomarker_diagnosis_ns hsa-mir-9 Neoplasms [unspecific] 25416717 "This study describes a pipeline for robust diagnostic serum miRNA profiling in childhood solid tumors, and has identified candidate miRNA profiles for prospective testing." +circulation_biomarker_diagnosis_ns hsa-mir-1179 Proliferative Diabetic Retinopathy 25427542 "serum miRNAs have the potential to be sensitive, cost-effective biomarkers for the early detection of PDR. These biomarkers could serve as a dynamic monitoring factor for detecting the progression of PDR from NPDR." +circulation_biomarker_diagnosis_ns hsa-mir-181c Proliferative Diabetic Retinopathy 25427542 "serum miRNAs have the potential to be sensitive, cost-effective biomarkers for the early detection of PDR. These biomarkers could serve as a dynamic monitoring factor for detecting the progression of PDR from NPDR." +circulation_biomarker_diagnosis_ns hsa-mir-21 Proliferative Diabetic Retinopathy 25427542 "serum miRNAs have the potential to be sensitive, cost-effective biomarkers for the early detection of PDR. These biomarkers could serve as a dynamic monitoring factor for detecting the progression of PDR from NPDR." +circulation_biomarker_diagnosis_ns hsa-mir-320a Macroglobulinemia 25428891 Combination of serum microRNA-320a and microRNA-320b as a marker for Waldenstr?m macroglobulinemia. +circulation_biomarker_diagnosis_ns hsa-mir-320b Macroglobulinemia 25428891 Combination of serum microRNA-320a and microRNA-321b as a marker for Waldenstr?m macroglobulinemia. +circulation_biomarker_diagnosis_ns hsa-mir-21 "Carcinoma, Breast" 25431259 "MiR-21 has a relatively high diagnostic value for detecting breast cancer, and miR-21 assays based on plasma, serum, and tissue achieved relatively higher accuracy" +circulation_biomarker_diagnosis_ns hsa-mir-21 Neoplasms [unspecific] 25431259 "MiR-21 has a relatively high diagnostic value for detecting breast cancer, and miR-21 assays based on plasma, serum, and tissue achieved relatively higher accuracy" +circulation_biomarker_diagnosis_ns hsa-mir-505 Hypertension 25449503 "hsa-mir-505 is a novel circulating signature of hypertension, which may play a role in angiogenesis. Our results provide mechanistic insights into hypertension-associated pathogenesis and point " +circulation_biomarker_diagnosis_ns hsa-mir-122 Hepatitis B Virus Infection 25452043 Serum microRNA levels reflect differences in the etiology and stage of viral hepatitis. +circulation_biomarker_diagnosis_ns hsa-mir-125b Hepatitis B Virus Infection 25452043 Serum microRNA levels reflect differences in the etiology and stage of viral hepatitis. +circulation_biomarker_diagnosis_ns hsa-mir-1275 Hepatitis B Virus Infection 25452043 Serum microRNA levels reflect differences in the etiology and stage of viral hepatitis. +circulation_biomarker_diagnosis_ns hsa-mir-22 Hepatitis B Virus Infection 25452043 Serum microRNA levels reflect differences in the etiology and stage of viral hepatitis. +circulation_biomarker_diagnosis_ns hsa-mir-720 Hepatitis B Virus Infection 25452043 Serum microRNA levels reflect differences in the etiology and stage of viral hepatitis. +circulation_biomarker_diagnosis_ns hsa-mir-99a Hepatitis B Virus Infection 25452043 Serum microRNA levels reflect differences in the etiology and stage of viral hepatitis. +circulation_biomarker_diagnosis_ns hsa-mir-146b Thyroid Neoplasms 25456009 miR-146b and miR-155 helped to discriminate between benign and malignant lesions. Circulating miRNA is likely a useful alternate serological marker for PTC. This preliminary study suggested that circulating miRNAs may be useful as follow-up tools as well as diagnostic tools. +circulation_biomarker_diagnosis_ns hsa-mir-155 Thyroid Neoplasms 25456009 miR-146b and miR-155 helped to discriminate between benign and malignant lesions. Circulating miRNA is likely a useful alternate serological marker for PTC. This preliminary study suggested that circulating miRNAs may be useful as follow-up tools as well as diagnostic tools. +circulation_biomarker_diagnosis_ns hsa-mir-29 Endomyocardial Fibrosis 25457410 "Reply: MicroRNA-29, a mysterious regulator in myocardial fibrosis and circulating miR-29a as a biomarker." +circulation_biomarker_diagnosis_ns hsa-mir-21 Glomerulonephritis 25468389 "Furthermore, the glomerular and serum levels of miR-21, a putative microRNA ligand of TLR8, were higher in BXSB-Yaa mice than in BXSB mice." +circulation_biomarker_diagnosis_ns hsa-mir-150 Intrahepatic Cholangiocarcinoma 25482320 "combination of these two markers improved the power of screening ICC. Moreover, on the basis of the plasma miR-150 level, 15 ICC patients were divided into a low or high expression group. We found that plasma miR-150 is a potential diagnostic biomarker for ICC." +circulation_biomarker_diagnosis_ns hsa-mir-196a Oral Neoplasms 25485932 Combined determination of circulating miR-196a and miR-196b levels may serve as panel plasma biomarkers for the early detection of oral cancer. +circulation_biomarker_diagnosis_ns hsa-mir-196b Oral Neoplasms 25485932 Combined determination of circulating miR-196a and miR-196b levels may serve as panel plasma biomarkers for the early detection of oral cancer. +circulation_biomarker_diagnosis_ns hsa-mir-132 Schizophrenia 25487174 "miRNA expression is more significant in plasma than in PBMC, and suggest that miR-30e in plasma may be a more sensitive biomarker for schizophrenia diagnosis, although its aberrant expression can be detected in both plasma and PBMC." +circulation_biomarker_diagnosis_ns hsa-mir-181b Schizophrenia 25487174 "miRNA expression is more significant in plasma than in PBMC, and suggest that miR-30e in plasma may be a more sensitive biomarker for schizophrenia diagnosis, although its aberrant expression can be detected in both plasma and PBMC." +circulation_biomarker_diagnosis_ns hsa-mir-195 Schizophrenia 25487174 "miRNA expression is more significant in plasma than in PBMC, and suggest that miR-30e in plasma may be a more sensitive biomarker for schizophrenia diagnosis, although its aberrant expression can be detected in both plasma and PBMC." +circulation_biomarker_diagnosis_ns hsa-mir-212 Schizophrenia 25487174 "miRNA expression is more significant in plasma than in PBMC, and suggest that miR-30e in plasma may be a more sensitive biomarker for schizophrenia diagnosis, although its aberrant expression can be detected in both plasma and PBMC." +circulation_biomarker_diagnosis_ns hsa-mir-30e Schizophrenia 25487174 "miRNA expression is more significant in plasma than in PBMC, and suggest that miR-30e in plasma may be a more sensitive biomarker for schizophrenia diagnosis, although its aberrant expression can be detected in both plasma and PBMC." +circulation_biomarker_diagnosis_ns hsa-mir-346 Schizophrenia 25487174 "miRNA expression is more significant in plasma than in PBMC, and suggest that miR-30e in plasma may be a more sensitive biomarker for schizophrenia diagnosis, although its aberrant expression can be detected in both plasma and PBMC." +circulation_biomarker_diagnosis_ns hsa-mir-34a Schizophrenia 25487174 "miRNA expression is more significant in plasma than in PBMC, and suggest that miR-30e in plasma may be a more sensitive biomarker for schizophrenia diagnosis, although its aberrant expression can be detected in both plasma and PBMC." +circulation_biomarker_diagnosis_ns hsa-mir-432 Schizophrenia 25487174 "miRNA expression is more significant in plasma than in PBMC, and suggest that miR-30e in plasma may be a more sensitive biomarker for schizophrenia diagnosis, although its aberrant expression can be detected in both plasma and PBMC." +circulation_biomarker_diagnosis_ns hsa-mir-7 Schizophrenia 25487174 "miRNA expression is more significant in plasma than in PBMC, and suggest that miR-30e in plasma may be a more sensitive biomarker for schizophrenia diagnosis, although its aberrant expression can be detected in both plasma and PBMC." +circulation_biomarker_diagnosis_ns hsa-mir-148a Lung Neoplasms 25501703 miRNAs have great potential to serve as promising novel biomarkers in NSCLC screening. Further large-scale studies are needed to validate our results. +circulation_biomarker_diagnosis_ns hsa-mir-148b Lung Neoplasms 25501703 miRNAs have great potential to serve as promising novel biomarkers in NSCLC screening. Further large-scale studies are needed to validate our results. +circulation_biomarker_diagnosis_ns hsa-mir-152 Lung Neoplasms 25501703 miRNAs have great potential to serve as promising novel biomarkers in NSCLC screening. Further large-scale studies are needed to validate our results. +circulation_biomarker_diagnosis_ns hsa-mir-21 Lung Neoplasms 25501703 miRNAs have great potential to serve as promising novel biomarkers in NSCLC screening. Further large-scale studies are needed to validate our results. +circulation_biomarker_diagnosis_ns hsa-mir-377 "Leukemia, Myeloid, Acute" 25502508 a miRNA signature in human cord blood stem and progenitor cells with a potential role in hematopoietic stemness properties and possibly in leukemogenesis of specific AML subtypes. +circulation_biomarker_diagnosis_ns hsa-mir-4739 "Leukemia, Myeloid, Acute" 25502508 a miRNA signature in human cord blood stem and progenitor cells with a potential role in hematopoietic stemness properties and possibly in leukemogenesis of specific AML subtypes. +circulation_biomarker_diagnosis_ns hsa-mir-142 "Lymphoma, T-Cell" 25503151 miR profiling in CTCL may be a key to improving both diagnosis and risk prediction. +circulation_biomarker_diagnosis_ns hsa-mir-146b "Lymphoma, T-Cell" 25503151 miR profiling in CTCL may be a key to improving both diagnosis and risk prediction. +circulation_biomarker_diagnosis_ns hsa-mir-155 "Lymphoma, T-Cell" 25503151 miR profiling in CTCL may be a key to improving both diagnosis and risk prediction. +circulation_biomarker_diagnosis_ns hsa-mir-16 "Lymphoma, T-Cell" 25503151 miR profiling in CTCL may be a key to improving both diagnosis and risk prediction. +circulation_biomarker_diagnosis_ns hsa-mir-21 "Lymphoma, T-Cell" 25503151 miR profiling in CTCL may be a key to improving both diagnosis and risk prediction. +circulation_biomarker_diagnosis_ns hsa-mir-342 "Lymphoma, T-Cell" 25503151 miR profiling in CTCL may be a key to improving both diagnosis and risk prediction. +circulation_biomarker_diagnosis_ns hsa-mir-92a "Lymphoma, T-Cell" 25503151 miR profiling in CTCL may be a key to improving both diagnosis and risk prediction. +circulation_biomarker_diagnosis_ns hsa-mir-93 "Lymphoma, T-Cell" 25503151 miR profiling in CTCL may be a key to improving both diagnosis and risk prediction. +circulation_biomarker_diagnosis_ns hsa-mir-16 Chronic Hepatitis C 25505813 "the expression levels of miR-16, miR-193b, miR-199a, miR-222, and miR-324 target miRNAs in PBMCs of CHC may act as significant risk biomarkers for the development of CHC." +circulation_biomarker_diagnosis_ns hsa-mir-193b Chronic Hepatitis C 25505813 "the expression levels of miR-16, miR-193b, miR-199a, miR-222, and miR-324 target miRNAs in PBMCs of CHC may act as significant risk biomarkers for the development of CHC." +circulation_biomarker_diagnosis_ns hsa-mir-199a Chronic Hepatitis C 25505813 "the expression levels of miR-16, miR-193b, miR-199a, miR-222, and miR-324 target miRNAs in PBMCs of CHC may act as significant risk biomarkers for the development of CHC." +circulation_biomarker_diagnosis_ns hsa-mir-222 Chronic Hepatitis C 25505813 "the expression levels of miR-16, miR-193b, miR-199a, miR-222, and miR-324 target miRNAs in PBMCs of CHC may act as significant risk biomarkers for the development of CHC." +circulation_biomarker_diagnosis_ns hsa-mir-324 Chronic Hepatitis C 25505813 "the expression levels of miR-16, miR-193b, miR-199a, miR-222, and miR-324 target miRNAs in PBMCs of CHC may act as significant risk biomarkers for the development of CHC." +circulation_biomarker_diagnosis_ns hsa-mir-21 Breast Neoplasms 25516467 "miR-21 is a potential biomarker for early diagnosis of breast cancer with high sensitivity and specificity, and its clinical application warrants further investigation" +circulation_biomarker_diagnosis_ns hsa-mir-200a "Carcinoma, Hepatocellular, HBV-Related" 25519019 "only in the HCC group, miR-18a, miR-100, miR-145 and miR-223 were up-regulated 3.48-, 2.95-, 2.12- and 3.91-fold, respectively, and miR-200a and miR-222 were down-regulated 2.56- and 2.00-fold, respectively." +circulation_biomarker_diagnosis_ns hsa-let-7c Prostate Neoplasms 25521481 the combination of the studied circulating plasma miRNAs and serum PSA has the potential to be used as a noninvasive diagnostic biomarker for PC screening outperforming the PSA testing alone. +circulation_biomarker_diagnosis_ns hsa-mir-141 Prostate Neoplasms 25521481 the combination of the studied circulating plasma miRNAs and serum PSA has the potential to be used as a noninvasive diagnostic biomarker for PC screening outperforming the PSA testing alone. +circulation_biomarker_diagnosis_ns hsa-mir-30c Prostate Neoplasms 25521481 the combination of the studied circulating plasma miRNAs and serum PSA has the potential to be used as a noninvasive diagnostic biomarker for PC screening outperforming the PSA testing alone. +circulation_biomarker_diagnosis_ns hsa-mir-375 Prostate Neoplasms 25521481 the combination of the studied circulating plasma miRNAs and serum PSA has the potential to be used as a noninvasive diagnostic biomarker for PC screening outperforming the PSA testing alone. +circulation_biomarker_diagnosis_ns hsa-mir-21 Colorectal Carcinoma 25524942 Circulating miR-21 may be a suitable diagnostic biomarker for CRC with moderate sensitivity and specificity. Further studies should evaluate the diagnostic value of miR-21 for CRC in the future. +circulation_biomarker_diagnosis_ns hsa-mir-21 Neoplasms [unspecific] 25527152 the circulating miR-21 may be a potential biomarker as diagnostic tool for early-stage cancer diagnosis. +circulation_biomarker_diagnosis_ns hsa-mir-182 "Diabetes Mellitus, Type 2" 25530976 miR-182 can be a biomarker in diagnosis of the potential T2D that has benefits for medical purpose. +circulation_biomarker_diagnosis_ns hsa-mir-192 Prediabetes 25532038 "the pattern of circulating miRNAs is modified by defects in glucose metabolism in a similar manner in mice and humans. This circulating miRNA signature for prediabetes could be used as a new diagnostic tool, as well as to monitor response to intervention." +circulation_biomarker_diagnosis_ns hsa-mir-193b Prediabetes 25532038 "the pattern of circulating miRNAs is modified by defects in glucose metabolism in a similar manner in mice and humans. This circulating miRNA signature for prediabetes could be used as a new diagnostic tool, as well as to monitor response to intervention." +circulation_biomarker_diagnosis_ns hsa-mir-16 Multiple Myeloma 25593199 A serum microRNA signature associated with complete remission and progression after autologous stem-cell transplantation in patients with multiple myeloma. +circulation_biomarker_diagnosis_ns hsa-mir-17 Multiple Myeloma 25593199 A serum microRNA signature associated with complete remission and progression after autologous stem-cell transplantation in patients with multiple myeloma. +circulation_biomarker_diagnosis_ns hsa-mir-19b Multiple Myeloma 25593199 A serum microRNA signature associated with complete remission and progression after autologous stem-cell transplantation in patients with multiple myeloma. +circulation_biomarker_diagnosis_ns hsa-mir-20a Multiple Myeloma 25593199 A serum microRNA signature associated with complete remission and progression after autologous stem-cell transplantation in patients with multiple myeloma. +circulation_biomarker_diagnosis_ns hsa-mir-25 Multiple Myeloma 25593199 A serum microRNA signature associated with complete remission and progression after autologous stem-cell transplantation in patients with multiple myeloma. +circulation_biomarker_diagnosis_ns hsa-mir-331 Multiple Myeloma 25593199 A serum microRNA signature associated with complete remission and progression after autologous stem-cell transplantation in patients with multiple myeloma. +circulation_biomarker_diagnosis_ns hsa-mir-660 Multiple Myeloma 25593199 A serum microRNA signature associated with complete remission and progression after autologous stem-cell transplantation in patients with multiple myeloma. +circulation_biomarker_diagnosis_ns hsa-mir-199a "Carcinoma, Hepatocellular" 25618599 "circulating miR-199a-3p showed better predictive value in patients with long-term drinking. Our data suggested that circulating miR-375 and miR-199a-3p could be a novel serum biomarker for HCC. Nevertheless, further validating and improving study with larger sample should be conducted to confirm our results." +circulation_biomarker_diagnosis_ns hsa-mir-375 "Carcinoma, Hepatocellular" 25618599 "circulating miR-199a-3p showed better predictive value in patients with long-term drinking. Our data suggested that circulating miR-375 and miR-199a-3p could be a novel serum biomarker for HCC. Nevertheless, further validating and improving study with larger sample should be conducted to confirm our results." +circulation_biomarker_diagnosis_ns hsa-mir-125a Heart Failure 25619197 "Of these, miR-1233, -183-3p, -190a, -193b-3p, -193b-5p, -211-5p, -494, and -671-5p distinguished HF from controls." +circulation_biomarker_diagnosis_ns hsa-mir-211 Heart Failure 25619197 "Of these, miR-1233, -183-3p, -190a, -193b-3p, -193b-5p, -211-5p, -494, and -671-5p distinguished HF from controls." +circulation_biomarker_diagnosis_ns hsa-let-7a "Carcinoma, Urothelial, Upper Tract" 25629698 MicroRNA expression is altered in UUTUC. The analysis of circulating miR-141 may be useful to identify patients with UUTUC. +circulation_biomarker_diagnosis_ns hsa-let-7b "Carcinoma, Urothelial, Upper Tract" 25629698 MicroRNA expression is altered in UUTUC. The analysis of circulating miR-141 may be useful to identify patients with UUTUC. +circulation_biomarker_diagnosis_ns hsa-let-7c "Carcinoma, Urothelial, Upper Tract" 25629698 MicroRNA expression is altered in UUTUC. The analysis of circulating miR-141 may be useful to identify patients with UUTUC. +circulation_biomarker_diagnosis_ns hsa-let-7f "Carcinoma, Urothelial, Upper Tract" 25629698 MicroRNA expression is altered in UUTUC. The analysis of circulating miR-141 may be useful to identify patients with UUTUC. +circulation_biomarker_diagnosis_ns hsa-mir-10a "Carcinoma, Urothelial, Upper Tract" 25629698 MicroRNA expression is altered in UUTUC. The analysis of circulating miR-141 may be useful to identify patients with UUTUC. +circulation_biomarker_diagnosis_ns hsa-mir-1244 "Carcinoma, Urothelial, Upper Tract" 25629698 MicroRNA expression is altered in UUTUC. The analysis of circulating miR-141 may be useful to identify patients with UUTUC. +circulation_biomarker_diagnosis_ns hsa-mir-135 "Carcinoma, Urothelial, Upper Tract" 25629698 MicroRNA expression is altered in UUTUC. The analysis of circulating miR-141 may be useful to identify patients with UUTUC. +circulation_biomarker_diagnosis_ns hsa-mir-141 "Carcinoma, Urothelial, Upper Tract" 25629698 MicroRNA expression is altered in UUTUC. The analysis of circulating miR-141 may be useful to identify patients with UUTUC. +circulation_biomarker_diagnosis_ns hsa-mir-16 "Carcinoma, Urothelial, Upper Tract" 25629698 MicroRNA expression is altered in UUTUC. The analysis of circulating miR-141 may be useful to identify patients with UUTUC. +circulation_biomarker_diagnosis_ns hsa-mir-182 "Carcinoma, Urothelial, Upper Tract" 25629698 MicroRNA expression is altered in UUTUC. The analysis of circulating miR-141 may be useful to identify patients with UUTUC. +circulation_biomarker_diagnosis_ns hsa-mir-200b "Carcinoma, Urothelial, Upper Tract" 25629698 MicroRNA expression is altered in UUTUC. The analysis of circulating miR-141 may be useful to identify patients with UUTUC. +circulation_biomarker_diagnosis_ns hsa-mir-205 "Carcinoma, Urothelial, Upper Tract" 25629698 MicroRNA expression is altered in UUTUC. The analysis of circulating miR-141 may be useful to identify patients with UUTUC. +circulation_biomarker_diagnosis_ns hsa-mir-21 "Carcinoma, Urothelial, Upper Tract" 25629698 MicroRNA expression is altered in UUTUC. The analysis of circulating miR-141 may be useful to identify patients with UUTUC. +circulation_biomarker_diagnosis_ns hsa-mir-429 "Carcinoma, Urothelial, Upper Tract" 25629698 MicroRNA expression is altered in UUTUC. The analysis of circulating miR-141 may be useful to identify patients with UUTUC. +circulation_biomarker_diagnosis_ns hsa-mir-520b "Carcinoma, Urothelial, Upper Tract" 25629698 MicroRNA expression is altered in UUTUC. The analysis of circulating miR-141 may be useful to identify patients with UUTUC. +circulation_biomarker_diagnosis_ns hsa-mir-96 "Carcinoma, Urothelial, Upper Tract" 25629698 MicroRNA expression is altered in UUTUC. The analysis of circulating miR-141 may be useful to identify patients with UUTUC. +circulation_biomarker_diagnosis_ns hsa-mir-143 Obesity 25637573 Obesity leads to alterations in miRNA expressions and miRNA-143 and -223s can be used as biomarkers for the metabolic changes in obesity. +circulation_biomarker_diagnosis_ns hsa-mir-223 Obesity 25637573 Obesity leads to alterations in miRNA expressions and miRNA-143 and -223s can be used as biomarkers for the metabolic changes in obesity. +circulation_biomarker_diagnosis_ns hsa-mir-125a Lung Neoplasms 25639977 the panel of miRNA biomarkers had the potential for the early detection of lung cancer. +circulation_biomarker_diagnosis_ns hsa-mir-126 Lung Neoplasms 25639977 the panel of miRNA biomarkers had the potential for the early detection of lung cancer. +circulation_biomarker_diagnosis_ns hsa-mir-25 Lung Neoplasms 25639977 the panel of miRNA biomarkers had the potential for the early detection of lung cancer. +circulation_biomarker_diagnosis_ns hsa-mir-132 Schizophrenia 25656957 A preliminary analysis of microRNA as potential clinical biomarker for schizophrenia. +circulation_biomarker_diagnosis_ns hsa-mir-181b Schizophrenia 25656957 A preliminary analysis of microRNA as potential clinical biomarker for schizophrenia. +circulation_biomarker_diagnosis_ns hsa-mir-212 Schizophrenia 25656957 A preliminary analysis of microRNA as potential clinical biomarker for schizophrenia. +circulation_biomarker_diagnosis_ns hsa-mir-30e Schizophrenia 25656957 A preliminary analysis of microRNA as potential clinical biomarker for schizophrenia. +circulation_biomarker_diagnosis_ns hsa-mir-346 Schizophrenia 25656957 A preliminary analysis of microRNA as potential clinical biomarker for schizophrenia. +circulation_biomarker_diagnosis_ns hsa-mir-432 Schizophrenia 25656957 A preliminary analysis of microRNA as potential clinical biomarker for schizophrenia. +circulation_biomarker_diagnosis_ns hsa-mir-149 Coronary Artery Disease 25664324 Circulating miR-765 and miR-149: potential noninvasive diagnostic biomarkers for geriatric coronary artery disease patients. +circulation_biomarker_diagnosis_ns hsa-mir-765 Coronary Artery Disease 25664324 Circulating miR-765 and miR-149: potential noninvasive diagnostic biomarkers for geriatric coronary artery disease patients. +circulation_biomarker_diagnosis_ns hsa-mir-223 Allergic Rhinitis 25675113 Serum hsa-miR-223 was significantly up-regulated in postseason compared with preseason samples. +circulation_biomarker_diagnosis_ns hsa-mir-103 "Diabetes Mellitus, Type 2" 25677225 "This meta-analysis confirms that 40 miRNAs are significantly dysregulated in type 2 diabetes. miR-29a, miR-34a, miR-375,miR-103, miR-107, miR-132, miR-142-3p and miR-144 are potential circulating biomarkers of type 2 diabetes. In addition, miR-199a-3p and miR-223 are potential tissue biomarkers of type 2 diabetes." +circulation_biomarker_diagnosis_ns hsa-mir-107 "Diabetes Mellitus, Type 2" 25677225 "This meta-analysis confirms that 40 miRNAs are significantly dysregulated in type 2 diabetes. miR-29a, miR-34a, miR-375,miR-103, miR-107, miR-132, miR-142-3p and miR-144 are potential circulating biomarkers of type 2 diabetes. In addition, miR-199a-3p and miR-223 are potential tissue biomarkers of type 2 diabetes." +circulation_biomarker_diagnosis_ns hsa-mir-132 "Diabetes Mellitus, Type 2" 25677225 "This meta-analysis confirms that 40 miRNAs are significantly dysregulated in type 2 diabetes. miR-29a, miR-34a, miR-375,miR-103, miR-107, miR-132, miR-142-3p and miR-144 are potential circulating biomarkers of type 2 diabetes. In addition, miR-199a-3p and miR-223 are potential tissue biomarkers of type 2 diabetes." +circulation_biomarker_diagnosis_ns hsa-mir-142 "Diabetes Mellitus, Type 2" 25677225 "This meta-analysis confirms that 40 miRNAs are significantly dysregulated in type 2 diabetes. miR-29a, miR-34a, miR-375,miR-103, miR-107, miR-132, miR-142-3p and miR-144 are potential circulating biomarkers of type 2 diabetes. In addition, miR-199a-3p and miR-223 are potential tissue biomarkers of type 2 diabetes." +circulation_biomarker_diagnosis_ns hsa-mir-144 "Diabetes Mellitus, Type 2" 25677225 "This meta-analysis confirms that 40 miRNAs are significantly dysregulated in type 2 diabetes. miR-29a, miR-34a, miR-375,miR-103, miR-107, miR-132, miR-142-3p and miR-144 are potential circulating biomarkers of type 2 diabetes. In addition, miR-199a-3p and miR-223 are potential tissue biomarkers of type 2 diabetes." +circulation_biomarker_diagnosis_ns hsa-mir-199a "Diabetes Mellitus, Type 2" 25677225 "This meta-analysis confirms that 40 miRNAs are significantly dysregulated in type 2 diabetes. miR-29a, miR-34a, miR-375,miR-103, miR-107, miR-132, miR-142-3p and miR-144 are potential circulating biomarkers of type 2 diabetes. In addition, miR-199a-3p and miR-223 are potential tissue biomarkers of type 2 diabetes." +circulation_biomarker_diagnosis_ns hsa-mir-223 "Diabetes Mellitus, Type 2" 25677225 "This meta-analysis confirms that 40 miRNAs are significantly dysregulated in type 2 diabetes. miR-29a, miR-34a, miR-375,miR-103, miR-107, miR-132, miR-142-3p and miR-144 are potential circulating biomarkers of type 2 diabetes. In addition, miR-199a-3p and miR-223 are potential tissue biomarkers of type 2 diabetes." +circulation_biomarker_diagnosis_ns hsa-mir-29a "Diabetes Mellitus, Type 2" 25677225 "This meta-analysis confirms that 40 miRNAs are significantly dysregulated in type 2 diabetes. miR-29a, miR-34a, miR-375,miR-103, miR-107, miR-132, miR-142-3p and miR-144 are potential circulating biomarkers of type 2 diabetes. In addition, miR-199a-3p and miR-223 are potential tissue biomarkers of type 2 diabetes." +circulation_biomarker_diagnosis_ns hsa-mir-30e "Diabetes Mellitus, Type 2" 25677225 "This meta-analysis confirms that 40 miRNAs are significantly dysregulated in type 2 diabetes. miR-29a, miR-34a, miR-375,miR-103, miR-107, miR-132, miR-142-3p and miR-144 are potential circulating biomarkers of type 2 diabetes. In addition, miR-199a-3p and miR-223 are potential tissue biomarkers of type 2 diabetes." +circulation_biomarker_diagnosis_ns hsa-mir-34a "Diabetes Mellitus, Type 2" 25677225 "This meta-analysis confirms that 40 miRNAs are significantly dysregulated in type 2 diabetes. miR-29a, miR-34a, miR-375,miR-103, miR-107, miR-132, miR-142-3p and miR-144 are potential circulating biomarkers of type 2 diabetes. In addition, miR-199a-3p and miR-223 are potential tissue biomarkers of type 2 diabetes." +circulation_biomarker_diagnosis_ns hsa-mir-375 "Diabetes Mellitus, Type 2" 25677225 "This meta-analysis confirms that 40 miRNAs are significantly dysregulated in type 2 diabetes. miR-29a, miR-34a, miR-375,miR-103, miR-107, miR-132, miR-142-3p and miR-144 are potential circulating biomarkers of type 2 diabetes. In addition, miR-199a-3p and miR-223 are potential tissue biomarkers of type 2 diabetes." +circulation_biomarker_diagnosis_ns hsa-mir-92a "Diabetes Mellitus, Type 2" 25677225 "This meta-analysis confirms that 40 miRNAs are significantly dysregulated in type 2 diabetes. miR-29a, miR-34a, miR-375,miR-103, miR-107, miR-132, miR-142-3p and miR-144 are potential circulating biomarkers of type 2 diabetes. In addition, miR-199a-3p and miR-223 are potential tissue biomarkers of type 2 diabetes." +circulation_biomarker_diagnosis_ns hsa-mir-1225 Focal Segmental Glomerulosclerosis 25682967 Patients with FSGS and minimal change disease (MCD) have a unique circulating and urinary miRNA profile. The diagnostic and prognostic potential of miRNAs in FSGS and minimal change disease (MCD) warrants further studies. +circulation_biomarker_diagnosis_ns hsa-mir-1915 Focal Segmental Glomerulosclerosis 25682967 Patients with FSGS and minimal change disease (MCD) have a unique circulating and urinary miRNA profile. The diagnostic and prognostic potential of miRNAs in FSGS and minimal change disease (MCD) warrants further studies. +circulation_biomarker_diagnosis_ns hsa-mir-30b Focal Segmental Glomerulosclerosis 25682967 Patients with FSGS and minimal change disease (MCD) have a unique circulating and urinary miRNA profile. The diagnostic and prognostic potential of miRNAs in FSGS and minimal change disease (MCD) warrants further studies. +circulation_biomarker_diagnosis_ns hsa-mir-30c Focal Segmental Glomerulosclerosis 25682967 Patients with FSGS and minimal change disease (MCD) have a unique circulating and urinary miRNA profile. The diagnostic and prognostic potential of miRNAs in FSGS and minimal change disease (MCD) warrants further studies. +circulation_biomarker_diagnosis_ns hsa-mir-342 Focal Segmental Glomerulosclerosis 25682967 Patients with FSGS and minimal change disease (MCD) have a unique circulating and urinary miRNA profile. The diagnostic and prognostic potential of miRNAs in FSGS and minimal change disease (MCD) warrants further studies. +circulation_biomarker_diagnosis_ns hsa-mir-34b Focal Segmental Glomerulosclerosis 25682967 Patients with FSGS and minimal change disease (MCD) have a unique circulating and urinary miRNA profile. The diagnostic and prognostic potential of miRNAs in FSGS and minimal change disease (MCD) warrants further studies. +circulation_biomarker_diagnosis_ns hsa-mir-34c Focal Segmental Glomerulosclerosis 25682967 Patients with FSGS and minimal change disease (MCD) have a unique circulating and urinary miRNA profile. The diagnostic and prognostic potential of miRNAs in FSGS and minimal change disease (MCD) warrants further studies. +circulation_biomarker_diagnosis_ns hsa-mir-663 Focal Segmental Glomerulosclerosis 25682967 Patients with FSGS and minimal change disease (MCD) have a unique circulating and urinary miRNA profile. The diagnostic and prognostic potential of miRNAs in FSGS and minimal change disease (MCD) warrants further studies. +circulation_biomarker_diagnosis_ns hsa-mir-21 Colorectal Carcinoma 25683351 The accuracy of circulating microRNA-21 in the diagnosis of colorectal cancer: a systematic review and meta-analysis. +circulation_biomarker_diagnosis_ns hsa-mir-127 "Carcinoma, Cervical" 25701838 Plasma miR-127 and miR-218 Might Serve as Potential Biomarkers for Cervical Cancer. +circulation_biomarker_diagnosis_ns hsa-mir-218 "Carcinoma, Cervical" 25701838 Plasma miR-127 and miR-218 Might Serve as Potential Biomarkers for Cervical Cancer. +circulation_biomarker_diagnosis_ns hsa-mir-28 Unstable Angina 25704294 "Our findings suggest that circulating miR-28-5p, involved in LXR¦Á-ABCA1 pathway, may be a potential biomarker for diagnosis and prognosis of unstable angina." +circulation_biomarker_diagnosis_ns hsa-mir-125a "Carcinoma, Biliary Tract" 25706130 Our results suggest that the assessment of these miRNA markers is clinically valuable to identify patients with pancreato-biliary cancers who could benefit from surgical intervention. +circulation_biomarker_diagnosis_ns hsa-mir-4294 "Carcinoma, Biliary Tract" 25706130 Our results suggest that the assessment of these miRNA markers is clinically valuable to identify patients with pancreato-biliary cancers who could benefit from surgical intervention. +circulation_biomarker_diagnosis_ns hsa-mir-4476 "Carcinoma, Biliary Tract" 25706130 Our results suggest that the assessment of these miRNA markers is clinically valuable to identify patients with pancreato-biliary cancers who could benefit from surgical intervention. +circulation_biomarker_diagnosis_ns hsa-mir-4530 "Carcinoma, Biliary Tract" 25706130 Our results suggest that the assessment of these miRNA markers is clinically valuable to identify patients with pancreato-biliary cancers who could benefit from surgical intervention. +circulation_biomarker_diagnosis_ns hsa-mir-6075 "Carcinoma, Biliary Tract" 25706130 Our results suggest that the assessment of these miRNA markers is clinically valuable to identify patients with pancreato-biliary cancers who could benefit from surgical intervention. +circulation_biomarker_diagnosis_ns hsa-mir-6799 "Carcinoma, Biliary Tract" 25706130 Our results suggest that the assessment of these miRNA markers is clinically valuable to identify patients with pancreato-biliary cancers who could benefit from surgical intervention. +circulation_biomarker_diagnosis_ns hsa-mir-6836 "Carcinoma, Biliary Tract" 25706130 Our results suggest that the assessment of these miRNA markers is clinically valuable to identify patients with pancreato-biliary cancers who could benefit from surgical intervention. +circulation_biomarker_diagnosis_ns hsa-mir-6880 "Carcinoma, Biliary Tract" 25706130 Our results suggest that the assessment of these miRNA markers is clinically valuable to identify patients with pancreato-biliary cancers who could benefit from surgical intervention. +circulation_biomarker_diagnosis_ns hsa-mir-21 Allergic Asthma 25707810 Serum MicroRNA-21 as a Biomarker for Allergic Inflammatory Disease in Children. +circulation_biomarker_diagnosis_ns hsa-mir-145 Ovarian Neoplasms 25722112 Serum microRNA-145 as a novel biomarker in human ovarian cancer. +circulation_biomarker_diagnosis_ns hsa-mir-100 Breast Neoplasms 25722304 These results point to using high levels of tRNA-derived small RNA fragments in combination with known miR signatures of tumors to distinguish tumor-derived EVs in circulation from EVs derived from other cell sources. Such biomarkers would be unique to the EVs where high abundances of tRNA fragments are amplified with respect to their cellular levels. +circulation_biomarker_diagnosis_ns hsa-let-7d Hyperactivity Disorder 25724585 Circulating MicroRNA Let-7d in Attention-Deficit/Hyperactivity Disorder. +circulation_biomarker_diagnosis_ns hsa-mir-92a Colorectal Carcinoma 25736690 All 3 miRNAs studied were positively inter-correlated. +circulation_biomarker_diagnosis_ns hsa-mir-196a Chronic Hepatitis C 25738504 Circulating microRNA-196a as a candidate diagnostic biomarker for chronic hepatitis C. +circulation_biomarker_diagnosis_ns hsa-mir-126 Preeclampsia 25738738 "the miRNAs identified in this study as being abnormally expressed in PE, may be useful as non-invasive diagnostic biomarkers. Co-regulated mRNAs and possible causal pathways involved in the pathogenesis of PE were also identified." +circulation_biomarker_diagnosis_ns hsa-mir-130a Preeclampsia 25738738 "the miRNAs identified in this study as being abnormally expressed in PE, may be useful as non-invasive diagnostic biomarkers. Co-regulated mRNAs and possible causal pathways involved in the pathogenesis of PE were also identified." +circulation_biomarker_diagnosis_ns hsa-mir-135b Preeclampsia 25738738 "the miRNAs identified in this study as being abnormally expressed in PE, may be useful as non-invasive diagnostic biomarkers. Co-regulated mRNAs and possible causal pathways involved in the pathogenesis of PE were also identified." +circulation_biomarker_diagnosis_ns hsa-mir-142 Preeclampsia 25738738 "the miRNAs identified in this study as being abnormally expressed in PE, may be useful as non-invasive diagnostic biomarkers. Co-regulated mRNAs and possible causal pathways involved in the pathogenesis of PE were also identified." +circulation_biomarker_diagnosis_ns hsa-mir-149 Preeclampsia 25738738 "the miRNAs identified in this study as being abnormally expressed in PE, may be useful as non-invasive diagnostic biomarkers. Co-regulated mRNAs and possible causal pathways involved in the pathogenesis of PE were also identified." +circulation_biomarker_diagnosis_ns hsa-mir-188 Preeclampsia 25738738 "the miRNAs identified in this study as being abnormally expressed in PE, may be useful as non-invasive diagnostic biomarkers. Co-regulated mRNAs and possible causal pathways involved in the pathogenesis of PE were also identified." +circulation_biomarker_diagnosis_ns hsa-mir-18a Preeclampsia 25738738 "the miRNAs identified in this study as being abnormally expressed in PE, may be useful as non-invasive diagnostic biomarkers. Co-regulated mRNAs and possible causal pathways involved in the pathogenesis of PE were also identified." +circulation_biomarker_diagnosis_ns hsa-mir-18b Preeclampsia 25738738 "the miRNAs identified in this study as being abnormally expressed in PE, may be useful as non-invasive diagnostic biomarkers. Co-regulated mRNAs and possible causal pathways involved in the pathogenesis of PE were also identified." +circulation_biomarker_diagnosis_ns hsa-mir-203 Preeclampsia 25738738 "the miRNAs identified in this study as being abnormally expressed in PE, may be useful as non-invasive diagnostic biomarkers. Co-regulated mRNAs and possible causal pathways involved in the pathogenesis of PE were also identified." +circulation_biomarker_diagnosis_ns hsa-mir-205 Preeclampsia 25738738 "the miRNAs identified in this study as being abnormally expressed in PE, may be useful as non-invasive diagnostic biomarkers. Co-regulated mRNAs and possible causal pathways involved in the pathogenesis of PE were also identified." +circulation_biomarker_diagnosis_ns hsa-mir-224 Preeclampsia 25738738 "the miRNAs identified in this study as being abnormally expressed in PE, may be useful as non-invasive diagnostic biomarkers. Co-regulated mRNAs and possible causal pathways involved in the pathogenesis of PE were also identified." +circulation_biomarker_diagnosis_ns hsa-mir-27a Preeclampsia 25738738 "the miRNAs identified in this study as being abnormally expressed in PE, may be useful as non-invasive diagnostic biomarkers. Co-regulated mRNAs and possible causal pathways involved in the pathogenesis of PE were also identified." +circulation_biomarker_diagnosis_ns hsa-mir-29a Preeclampsia 25738738 "the miRNAs identified in this study as being abnormally expressed in PE, may be useful as non-invasive diagnostic biomarkers. Co-regulated mRNAs and possible causal pathways involved in the pathogenesis of PE were also identified." +circulation_biomarker_diagnosis_ns hsa-mir-301a Preeclampsia 25738738 "the miRNAs identified in this study as being abnormally expressed in PE, may be useful as non-invasive diagnostic biomarkers. Co-regulated mRNAs and possible causal pathways involved in the pathogenesis of PE were also identified." +circulation_biomarker_diagnosis_ns hsa-mir-517c Preeclampsia 25738738 "the miRNAs identified in this study as being abnormally expressed in PE, may be useful as non-invasive diagnostic biomarkers. Co-regulated mRNAs and possible causal pathways involved in the pathogenesis of PE were also identified." +circulation_biomarker_diagnosis_ns hsa-mir-518 Preeclampsia 25738738 "the miRNAs identified in this study as being abnormally expressed in PE, may be useful as non-invasive diagnostic biomarkers. Co-regulated mRNAs and possible causal pathways involved in the pathogenesis of PE were also identified." +circulation_biomarker_diagnosis_ns hsa-mir-518e Preeclampsia 25738738 "the miRNAs identified in this study as being abnormally expressed in PE, may be useful as non-invasive diagnostic biomarkers. Co-regulated mRNAs and possible causal pathways involved in the pathogenesis of PE were also identified." +circulation_biomarker_diagnosis_ns hsa-mir-519d Preeclampsia 25738738 "the miRNAs identified in this study as being abnormally expressed in PE, may be useful as non-invasive diagnostic biomarkers. Co-regulated mRNAs and possible causal pathways involved in the pathogenesis of PE were also identified." +circulation_biomarker_diagnosis_ns hsa-mir-93 Preeclampsia 25738738 "the miRNAs identified in this study as being abnormally expressed in PE, may be useful as non-invasive diagnostic biomarkers. Co-regulated mRNAs and possible causal pathways involved in the pathogenesis of PE were also identified." +circulation_biomarker_diagnosis_ns hsa-mir-146a Heart Failure 25739750 "This study has shown for the first time that various miRNA combinations are useful biomarkers for HF, and also in the differentiation of HFpEF from HFrEF. The utility of these biomarker combinations can be altered by inclusion of natriuretic peptide. MiRNA biomarkers may support diagnostic strategies in subpopulations of patients with HF." +circulation_biomarker_diagnosis_ns hsa-mir-221 Heart Failure 25739750 "This study has shown for the first time that various miRNA combinations are useful biomarkers for HF, and also in the differentiation of HFpEF from HFrEF. The utility of these biomarker combinations can be altered by inclusion of natriuretic peptide. MiRNA biomarkers may support diagnostic strategies in subpopulations of patients with HF." +circulation_biomarker_diagnosis_ns hsa-mir-30c Heart Failure 25739750 "This study has shown for the first time that various miRNA combinations are useful biomarkers for HF, and also in the differentiation of HFpEF from HFrEF. The utility of these biomarker combinations can be altered by inclusion of natriuretic peptide. MiRNA biomarkers may support diagnostic strategies in subpopulations of patients with HF." +circulation_biomarker_diagnosis_ns hsa-mir-328 Heart Failure 25739750 "This study has shown for the first time that various miRNA combinations are useful biomarkers for HF, and also in the differentiation of HFpEF from HFrEF. The utility of these biomarker combinations can be altered by inclusion of natriuretic peptide. MiRNA biomarkers may support diagnostic strategies in subpopulations of patients with HF." +circulation_biomarker_diagnosis_ns hsa-mir-375 Heart Failure 25739750 "This study has shown for the first time that various miRNA combinations are useful biomarkers for HF, and also in the differentiation of HFpEF from HFrEF. The utility of these biomarker combinations can be altered by inclusion of natriuretic peptide. MiRNA biomarkers may support diagnostic strategies in subpopulations of patients with HF." +circulation_biomarker_diagnosis_ns hsa-mir-155 Male Infertility 25740880 Serum miR-155 as a potential biomarker of male fertility. +circulation_biomarker_diagnosis_ns hsa-mir-100 Acute Coronary Syndrome 25744750 Plasma microRNA-100 as a biomarker of coronary plaque vulnerability ¨C a new generation of biomarker for developing acute coronary syndrome. +circulation_biomarker_diagnosis_ns hsa-mir-93 Tuberculosis 25753045 Identification of miR-93 as a suitable miR for normalizing miRNA in plasma of tuberculosis patients. +circulation_biomarker_diagnosis_ns hsa-mir-375 Prostate Neoplasms 25754273 The combined serum levels of miR-375 and urokinase plasminogen activator receptor are suggested as diagnostic and prognostic biomarkers in prostate cancer. +circulation_biomarker_diagnosis_ns hsa-mir-125a "Carcinoma, Lung, Non-Small-Cell" 25755772 "These preliminary data suggest that serum miR-125a-5p, miR-145 and miR-146a may be useful noninvasive biomarkers for the clinical diagnosis of NSCLC." +circulation_biomarker_diagnosis_ns hsa-mir-145 "Carcinoma, Lung, Non-Small-Cell" 25755772 "These preliminary data suggest that serum miR-125a-5p, miR-145 and miR-146a may be useful noninvasive biomarkers for the clinical diagnosis of NSCLC." +circulation_biomarker_diagnosis_ns hsa-mir-146a "Carcinoma, Lung, Non-Small-Cell" 25755772 "These preliminary data suggest that serum miR-125a-5p, miR-145 and miR-146a may be useful noninvasive biomarkers for the clinical diagnosis of NSCLC." +circulation_biomarker_diagnosis_ns hsa-mir-210 Glioma 25756397 Serum miR-210 is a promising diagnostic and prognostic biomarker that can be detected in the peripheral blood of patients with glioma. +circulation_biomarker_diagnosis_ns hsa-let-7b Heart Failure 25763857 "Measured microRNA profiles did not separate the samples according to the clinical features of the patients. However, several previously identified heart failure marker microRNAs were detected. The pericardial fluid microRNA profile appeared to be a result of an active and selective secretory process indicating that microRNAs may act as paracrine signalling factors by mediating the local crosstalk between cardiac cells." +circulation_biomarker_diagnosis_ns hsa-mir-31 Lung Neoplasms 25765717 miRNA-31 may be a molecular marker for the diagnostic and prognostic evaluation of primary lung cancer. +circulation_biomarker_diagnosis_ns hsa-mir-195 Osteosarcoma 25775010 "Our data suggest that altered levels of circulating miRNAs might have great potential to serve as novel, non-invasive biomarkers for osteosarcoma." +circulation_biomarker_diagnosis_ns hsa-mir-199a Osteosarcoma 25775010 "Our data suggest that altered levels of circulating miRNAs might have great potential to serve as novel, non-invasive biomarkers for osteosarcoma." +circulation_biomarker_diagnosis_ns hsa-mir-320a Osteosarcoma 25775010 "Our data suggest that altered levels of circulating miRNAs might have great potential to serve as novel, non-invasive biomarkers for osteosarcoma." +circulation_biomarker_diagnosis_ns hsa-mir-374a Osteosarcoma 25775010 "Our data suggest that altered levels of circulating miRNAs might have great potential to serve as novel, non-invasive biomarkers for osteosarcoma." +circulation_biomarker_diagnosis_ns hsa-mir-21 Neoplasms [unspecific] 25777797 "Finally, the protocol was applied to monitor miRNA-21 expression in epithelial to mesenchymal transition (EMT)-induced MCF-7 cells, an epithelial tumor cell line. CK expression was lost in these cells,whereas miRNA-21 was still expressed, suggesting that miRNA-21 might be a good marker for detecting CTCs with an EMT phenotype." +circulation_biomarker_diagnosis_ns hsa-mir-1 Myocardial Ischemic-Reperfusion Injury 25791720 "A time-dependent change in miR-1/208a/499 levels occurred during open-heart surgery, and these were associated with levels of cTnI and CK-MB.These results reveal that miRNAs may be sensitive biomarkers for I/R injury during open-heart surgery." +circulation_biomarker_diagnosis_ns hsa-mir-208a Myocardial Ischemic-Reperfusion Injury 25791720 "A time-dependent change in miR-1/208a/499 levels occurred during open-heart surgery, and these were associated with levels of cTnI and CK-MB.These results reveal that miRNAs may be sensitive biomarkers for I/R injury during open-heart surgery." +circulation_biomarker_diagnosis_ns hsa-mir-21 Myocardial Ischemic-Reperfusion Injury 25791720 "A time-dependent change in miR-1/208a/499 levels occurred during open-heart surgery, and these were associated with levels of cTnI and CK-MB.These results reveal that miRNAs may be sensitive biomarkers for I/R injury during open-heart surgery." +circulation_biomarker_diagnosis_ns hsa-mir-499 Myocardial Ischemic-Reperfusion Injury 25791720 "A time-dependent change in miR-1/208a/499 levels occurred during open-heart surgery, and these were associated with levels of cTnI and CK-MB.These results reveal that miRNAs may be sensitive biomarkers for I/R injury during open-heart surgery." +circulation_biomarker_diagnosis_ns hsa-mir-423 Colorectal Carcinoma 25807655 The significance of detection of serum miR-423-5p and miR-484 for diagnosis of colorectal cancer. +circulation_biomarker_diagnosis_ns hsa-mir-484 Colorectal Carcinoma 25807655 The significance of detection of serum miR-423-5p and miR-484 for diagnosis of colorectal cancer. +circulation_biomarker_diagnosis_ns hsa-mir-223 Sepsis 25810564 "Recent reports on alterations in miR-223 serum levels during sepsis revealed contradictory results, preventing a potential use of this miRNA in clinical routine. We clearly show that miR-223 serum levels do not reflect the presence of sepsis neither in mouse models nor in a large cohort of ICU patients and do not indicate clinical outcome of critically ill patients. Thus miR-223 serum levels should not be used as a biomarker in this setting." +circulation_biomarker_diagnosis_ns hsa-let-7a "Carcinoma, Hepatocellular, HBV-Related" 25814782 "These findings highlight the importance of validating reference genes before quantifying target miRNAs.Furthermore, our findings will improve studies that monitor hepatitis progression and will aid in the discovery of noninvasive biomarkers to diagnose early stage HCC." +circulation_biomarker_diagnosis_ns hsa-mir-125a Liver Diseases [unspecific] 25815788 "Serum microRNA-125a-5p, a useful biomarker in liver diseases, correlates with disease progression." +circulation_biomarker_diagnosis_ns hsa-mir-223 Pancreatic Neoplasms 25819175 "Plasma miR-223 might be a clinically useful biomarker for screening PCa, and predicting malignant potential of IPMN and the invasiveness of PCa." +circulation_biomarker_diagnosis_ns hsa-let-7d Epilepsy 25825351 "Circulating miRNAs were differentially regulated in epilepsy patients as compared with controls. MiR-106b-5p may serve as a novel, noninvasive biomarker to improve the current diagnosis of epilepsy." +circulation_biomarker_diagnosis_ns hsa-mir-106b Epilepsy 25825351 "Circulating miRNAs were differentially regulated in epilepsy patients as compared with controls. MiR-106b-5p may serve as a novel, noninvasive biomarker to improve the current diagnosis of epilepsy." +circulation_biomarker_diagnosis_ns hsa-mir-130a Epilepsy 25825351 "Circulating miRNAs were differentially regulated in epilepsy patients as compared with controls. MiR-106b-5p may serve as a novel, noninvasive biomarker to improve the current diagnosis of epilepsy." +circulation_biomarker_diagnosis_ns hsa-mir-146a Epilepsy 25825351 "Circulating miRNAs were differentially regulated in epilepsy patients as compared with controls. MiR-106b-5p may serve as a novel, noninvasive biomarker to improve the current diagnosis of epilepsy." +circulation_biomarker_diagnosis_ns hsa-mir-15a Epilepsy 25825351 "Circulating miRNAs were differentially regulated in epilepsy patients as compared with controls. MiR-106b-5p may serve as a novel, noninvasive biomarker to improve the current diagnosis of epilepsy." +circulation_biomarker_diagnosis_ns hsa-mir-194 Epilepsy 25825351 "Circulating miRNAs were differentially regulated in epilepsy patients as compared with controls. MiR-106b-5p may serve as a novel, noninvasive biomarker to improve the current diagnosis of epilepsy." +circulation_biomarker_diagnosis_ns hsa-mir-155 "Cardiomyopathy, Dilated" 25840506 We identified specific miRNAs that are differentially regulated between children with DCM who need a transplant compared with children with DCM who recover. A unique biomarker signature of miRNAs that are specific to children with DCM who have the potential to recover would be valuable in risk stratification of this challenging patient population. +circulation_biomarker_diagnosis_ns hsa-mir-636 "Cardiomyopathy, Dilated" 25840506 We identified specific miRNAs that are differentially regulated between children with DCM who need a transplant compared with children with DCM who recover. A unique biomarker signature of miRNAs that are specific to children with DCM who have the potential to recover would be valuable in risk stratification of this challenging patient population. +circulation_biomarker_diagnosis_ns hsa-mir-639 "Cardiomyopathy, Dilated" 25840506 We identified specific miRNAs that are differentially regulated between children with DCM who need a transplant compared with children with DCM who recover. A unique biomarker signature of miRNAs that are specific to children with DCM who have the potential to recover would be valuable in risk stratification of this challenging patient population. +circulation_biomarker_diagnosis_ns hsa-mir-646 "Cardiomyopathy, Dilated" 25840506 We identified specific miRNAs that are differentially regulated between children with DCM who need a transplant compared with children with DCM who recover. A unique biomarker signature of miRNAs that are specific to children with DCM who have the potential to recover would be valuable in risk stratification of this challenging patient population. +circulation_biomarker_diagnosis_ns hsa-let-7 Neoplasms [unspecific] 25856466 "Let-7, mir-98 and mir-183 as biomarkers for cancer and schizophrenia [corrected]." +circulation_biomarker_diagnosis_ns hsa-mir-125b "Squamous Cell Carcinoma, Oral" 25858373 "Due to the satisfactory diagnostic performance, plasma miR-125b can be used as a promising biomarker in OSCC." +circulation_biomarker_diagnosis_ns hsa-let-7a "Carcinoma, Gallbladder" 25861754 "Our results suggest a possible pathological relationship between the differential expression of miRNA in peripheral blood and GBC, and these dysregulated miRNAs could be novel tumor biomarkers for early detection of GBC." +circulation_biomarker_diagnosis_ns hsa-mir-143 "Carcinoma, Gallbladder" 25861754 "Our results suggest a possible pathological relationship between the differential expression of miRNA in peripheral blood and GBC, and these dysregulated miRNAs could be novel tumor biomarkers for early detection of GBC." +circulation_biomarker_diagnosis_ns hsa-mir-187 "Carcinoma, Gallbladder" 25861754 "Our results suggest a possible pathological relationship between the differential expression of miRNA in peripheral blood and GBC, and these dysregulated miRNAs could be novel tumor biomarkers for early detection of GBC." +circulation_biomarker_diagnosis_ns hsa-mir-202 "Carcinoma, Gallbladder" 25861754 "Our results suggest a possible pathological relationship between the differential expression of miRNA in peripheral blood and GBC, and these dysregulated miRNAs could be novel tumor biomarkers for early detection of GBC." +circulation_biomarker_diagnosis_ns hsa-mir-21 "Carcinoma, Gallbladder" 25861754 "Our results suggest a possible pathological relationship between the differential expression of miRNA in peripheral blood and GBC, and these dysregulated miRNAs could be novel tumor biomarkers for early detection of GBC." +circulation_biomarker_diagnosis_ns hsa-mir-335 "Carcinoma, Gallbladder" 25861754 "Our results suggest a possible pathological relationship between the differential expression of miRNA in peripheral blood and GBC, and these dysregulated miRNAs could be novel tumor biomarkers for early detection of GBC." +circulation_biomarker_diagnosis_ns hsa-mir-146a Chronic Hepatitis C 25877355 Involvement of TLR2-MyD88 in abnormal expression of miR-146a in peripheral blood monocytes of patients with chronic hepatitis C. +circulation_biomarker_diagnosis_ns hsa-mir-10b Huntington Disease 25889241 "These results demonstrate that miRNA expression in cortical BA9 provides insight into striatal involvement and support a role for these miRNAs,particularly miR-10b-5p, in HD pathogenicity. The miRNAs identified in our studies of postmortem brain tissue may be detectable in peripheral fluids and thus warrant consideration as accessible biomarkers for disease stage, rate of progression, and other important clinical characteristics of HD." +circulation_biomarker_diagnosis_ns hsa-mir-106b "Carcinoma, Hepatocellular" 25894380 We found that plasma miR-106b has clinical value in the detection of HCC from healthy people and CLD patients. Further large-scale study may be needed to validate our findings. +circulation_biomarker_diagnosis_ns hsa-mir-34b "Carcinoma, Colon" 25894979 Increased microRNA-34b and -34c predominantly expressed in stromal tissues is associated with poor prognosis in human colon cancer. +circulation_biomarker_diagnosis_ns hsa-mir-34c "Carcinoma, Colon" 25894979 Increased microRNA-34b and -34c predominantly expressed in stromal tissues is associated with poor prognosis in human colon cancer. +circulation_biomarker_diagnosis_ns hsa-mir-1275 Intrahepatic Cholangiocarcinoma 25903557 "The association of unique miRNA profiles with different ICC subtypes suggests the involvement of specific miRNAs during ICC tumor progression. In plasma, an eight-miRNA signature associated with ICC could form the foundation of an accessible (plasma-based) miRNA-based biomarker for the early detection of ICC." +circulation_biomarker_diagnosis_ns hsa-mir-193a Intrahepatic Cholangiocarcinoma 25903557 "The association of unique miRNA profiles with different ICC subtypes suggests the involvement of specific miRNAs during ICC tumor progression. In plasma, an eight-miRNA signature associated with ICC could form the foundation of an accessible (plasma-based) miRNA-based biomarker for the early detection of ICC." +circulation_biomarker_diagnosis_ns hsa-mir-199b Intrahepatic Cholangiocarcinoma 25903557 "The association of unique miRNA profiles with different ICC subtypes suggests the involvement of specific miRNAs during ICC tumor progression. In plasma, an eight-miRNA signature associated with ICC could form the foundation of an accessible (plasma-based) miRNA-based biomarker for the early detection of ICC." +circulation_biomarker_diagnosis_ns hsa-mir-320a Intrahepatic Cholangiocarcinoma 25903557 "The association of unique miRNA profiles with different ICC subtypes suggests the involvement of specific miRNAs during ICC tumor progression. In plasma, an eight-miRNA signature associated with ICC could form the foundation of an accessible (plasma-based) miRNA-based biomarker for the early detection of ICC." +circulation_biomarker_diagnosis_ns hsa-mir-483 Intrahepatic Cholangiocarcinoma 25903557 "The association of unique miRNA profiles with different ICC subtypes suggests the involvement of specific miRNAs during ICC tumor progression. In plasma, an eight-miRNA signature associated with ICC could form the foundation of an accessible (plasma-based) miRNA-based biomarker for the early detection of ICC." +circulation_biomarker_diagnosis_ns hsa-mir-505 Intrahepatic Cholangiocarcinoma 25903557 "The association of unique miRNA profiles with different ICC subtypes suggests the involvement of specific miRNAs during ICC tumor progression. In plasma, an eight-miRNA signature associated with ICC could form the foundation of an accessible (plasma-based) miRNA-based biomarker for the early detection of ICC." +circulation_biomarker_diagnosis_ns hsa-mir-874 Intrahepatic Cholangiocarcinoma 25903557 "The association of unique miRNA profiles with different ICC subtypes suggests the involvement of specific miRNAs during ICC tumor progression. In plasma, an eight-miRNA signature associated with ICC could form the foundation of an accessible (plasma-based) miRNA-based biomarker for the early detection of ICC." +circulation_biomarker_diagnosis_ns hsa-mir-148 "Carcinoma, Lung, Non-Small-Cell" 25904302 The results of present study suggest that the expression levels of circulating miR-148/152 family may serve as biomarkers for NSCLC. +circulation_biomarker_diagnosis_ns hsa-mir-152 "Carcinoma, Lung, Non-Small-Cell" 25904302 The results of present study suggest that the expression levels of circulating miR-148/152 family may serve as biomarkers for NSCLC. +circulation_biomarker_diagnosis_ns hsa-mir-21 Neoplasms [unspecific] 25907045 "we selectively detected cancer cell-derived exosomal miRNA-21 among heterogeneous exosome mixtures and in human serum. The method developed in the article is simple, fast, and sensitive, so it will offer great opportunities for the high-throughput diagnosis and prognosis of diseases." +circulation_biomarker_diagnosis_ns hsa-mir-221 "Carcinoma, Renal Cell" 25909813 Combined Influence of EGF+61G>A and TGFB+869T>C Functional Polymorphisms in Renal Cell Carcinoma Progression and Overall Survival: The Link to Plasma Circulating MiR-7 and MiR-221/222 Expression. +circulation_biomarker_diagnosis_ns hsa-mir-222 "Carcinoma, Renal Cell" 25909813 Combined Influence of EGF+61G>A and TGFB+869T>C Functional Polymorphisms in Renal Cell Carcinoma Progression and Overall Survival: The Link to Plasma Circulating MiR-7 and MiR-221/222 Expression. +circulation_biomarker_diagnosis_ns hsa-mir-7 "Carcinoma, Renal Cell" 25909813 Combined Influence of EGF+61G>A and TGFB+869T>C Functional Polymorphisms in Renal Cell Carcinoma Progression and Overall Survival: The Link to Plasma Circulating MiR-7 and MiR-221/222 Expression. +circulation_biomarker_diagnosis_ns hsa-let-7a "Squamous Cell Carcinoma, Esophageal" 25914476 Plasma miR-20a and let-7a levels are significantly altered in patients with ESCC and can be used as potential biomarkers in the diagnosis of ESCC. +circulation_biomarker_diagnosis_ns hsa-mir-20a "Squamous Cell Carcinoma, Esophageal" 25914476 Plasma miR-20a and let-7a levels are significantly altered in patients with ESCC and can be used as potential biomarkers in the diagnosis of ESCC. +circulation_biomarker_diagnosis_ns hsa-mir-122 Acute Coronary Syndrome 25933289 "Plasma miR-122, -140-3p, -720, -2861, and -3149 were associated with and potentially novel biomarkers for ACS." +circulation_biomarker_diagnosis_ns hsa-mir-3149 Acute Coronary Syndrome 25933289 "Plasma miR-122, -140-3p, -720, -2861, and -3149 were associated with and potentially novel biomarkers for ACS." +circulation_biomarker_diagnosis_ns hsa-mir-572 Multiple Sclerosis 25947625 Evaluation of miR-572 may serve as a non-invasive biomarker for remyelination. +circulation_biomarker_diagnosis_ns hsa-mir-126 Brain Disease [unspecific] 25947950 MiRNAs are detectable in cerebral microdialysate; a large group of miRNAs consistently showed a high RR in cerebral microdialysate. Measurement of cerebral interstitial miRNA concentrations may aid in the investigation of secondary brain injury in neurocritical conditions. +circulation_biomarker_diagnosis_ns hsa-mir-142 Brain Disease [unspecific] 25947950 MiRNAs are detectable in cerebral microdialysate; a large group of miRNAs consistently showed a high RR in cerebral microdialysate. Measurement of cerebral interstitial miRNA concentrations may aid in the investigation of secondary brain injury in neurocritical conditions. +circulation_biomarker_diagnosis_ns hsa-mir-146b Brain Disease [unspecific] 25947950 MiRNAs are detectable in cerebral microdialysate; a large group of miRNAs consistently showed a high RR in cerebral microdialysate. Measurement of cerebral interstitial miRNA concentrations may aid in the investigation of secondary brain injury in neurocritical conditions. +circulation_biomarker_diagnosis_ns hsa-mir-150 Brain Disease [unspecific] 25947950 MiRNAs are detectable in cerebral microdialysate; a large group of miRNAs consistently showed a high RR in cerebral microdialysate. Measurement of cerebral interstitial miRNA concentrations may aid in the investigation of secondary brain injury in neurocritical conditions. +circulation_biomarker_diagnosis_ns hsa-mir-155 Brain Disease [unspecific] 25947950 MiRNAs are detectable in cerebral microdialysate; a large group of miRNAs consistently showed a high RR in cerebral microdialysate. Measurement of cerebral interstitial miRNA concentrations may aid in the investigation of secondary brain injury in neurocritical conditions. +circulation_biomarker_diagnosis_ns hsa-mir-15b Brain Disease [unspecific] 25947950 MiRNAs are detectable in cerebral microdialysate; a large group of miRNAs consistently showed a high RR in cerebral microdialysate. Measurement of cerebral interstitial miRNA concentrations may aid in the investigation of secondary brain injury in neurocritical conditions. +circulation_biomarker_diagnosis_ns hsa-mir-191 Brain Disease [unspecific] 25947950 MiRNAs are detectable in cerebral microdialysate; a large group of miRNAs consistently showed a high RR in cerebral microdialysate. Measurement of cerebral interstitial miRNA concentrations may aid in the investigation of secondary brain injury in neurocritical conditions. +circulation_biomarker_diagnosis_ns hsa-mir-193a Brain Disease [unspecific] 25947950 MiRNAs are detectable in cerebral microdialysate; a large group of miRNAs consistently showed a high RR in cerebral microdialysate. Measurement of cerebral interstitial miRNA concentrations may aid in the investigation of secondary brain injury in neurocritical conditions. +circulation_biomarker_diagnosis_ns hsa-mir-29b Brain Disease [unspecific] 25947950 MiRNAs are detectable in cerebral microdialysate; a large group of miRNAs consistently showed a high RR in cerebral microdialysate. Measurement of cerebral interstitial miRNA concentrations may aid in the investigation of secondary brain injury in neurocritical conditions. +circulation_biomarker_diagnosis_ns hsa-mir-30c Brain Disease [unspecific] 25947950 MiRNAs are detectable in cerebral microdialysate; a large group of miRNAs consistently showed a high RR in cerebral microdialysate. Measurement of cerebral interstitial miRNA concentrations may aid in the investigation of secondary brain injury in neurocritical conditions. +circulation_biomarker_diagnosis_ns hsa-mir-32 Brain Disease [unspecific] 25947950 MiRNAs are detectable in cerebral microdialysate; a large group of miRNAs consistently showed a high RR in cerebral microdialysate. Measurement of cerebral interstitial miRNA concentrations may aid in the investigation of secondary brain injury in neurocritical conditions. +circulation_biomarker_diagnosis_ns hsa-mir-34a Brain Disease [unspecific] 25947950 MiRNAs are detectable in cerebral microdialysate; a large group of miRNAs consistently showed a high RR in cerebral microdialysate. Measurement of cerebral interstitial miRNA concentrations may aid in the investigation of secondary brain injury in neurocritical conditions. +circulation_biomarker_diagnosis_ns hsa-mir-744 Brain Disease [unspecific] 25947950 MiRNAs are detectable in cerebral microdialysate; a large group of miRNAs consistently showed a high RR in cerebral microdialysate. Measurement of cerebral interstitial miRNA concentrations may aid in the investigation of secondary brain injury in neurocritical conditions. +circulation_biomarker_diagnosis_ns hsa-mir-886 Brain Disease [unspecific] 25947950 MiRNAs are detectable in cerebral microdialysate; a large group of miRNAs consistently showed a high RR in cerebral microdialysate. Measurement of cerebral interstitial miRNA concentrations may aid in the investigation of secondary brain injury in neurocritical conditions. +circulation_biomarker_diagnosis_ns hsa-mir-146a Uveal Melanoma 25951497 "Our findings suggest the possibility to detect in VH and serum of UM patients diagnostic miRNAs released by the affected eye: based on this,miR-146a could be considered a potential circulating marker of UM." +circulation_biomarker_diagnosis_ns hsa-mir-21 Uveal Melanoma 25951497 "Our findings suggest the possibility to detect in VH and serum of UM patients diagnostic miRNAs released by the affected eye: based on this,miR-146a could be considered a potential circulating marker of UM." +circulation_biomarker_diagnosis_ns hsa-mir-34a Uveal Melanoma 25951497 "Our findings suggest the possibility to detect in VH and serum of UM patients diagnostic miRNAs released by the affected eye: based on this,miR-146a could be considered a potential circulating marker of UM." +circulation_biomarker_diagnosis_ns hsa-mir-130b Diabetic Nephropathy 25952368 "Our findings suggest that serum miR-130b may be a new biomarker for the early diagnosis of DN in T2DM. Circulating miR-130b may possibly be involved in the pathological mechanism of DN, such as lipid metabolic disorders, oxidative stress, extracellular matrix deposition and renal fibrosis." +circulation_biomarker_diagnosis_ns hsa-mir-27a Osteosarcoma 25960240 miR-27a expression may be elevated in sera of osteosarcoma patients and in turn contributes to aggressive progression of this malignancy. Detection of serum miR-27a levels may have clinical potentials as a non-invasive diagnostic/prognostic biomarker for osteosarcoma patients. +circulation_biomarker_diagnosis_ns hsa-mir-21 "Carcinoma, Hepatocellular" 25973032 Significance of serum microRNA-21 in diagnosis of hepatocellular carcinoma (HCC):clinical analyses of patients and an HCC rat model. +circulation_biomarker_diagnosis_ns hsa-mir-194 Myelodysplastic Syndromes 25975751 MicroRNA-194-5p could serve as a diagnostic and prognostic biomarker in myelodysplastic syndromes. +circulation_biomarker_diagnosis_ns hsa-mir-181b Hepatitis B Virus Infection 25976622 Serum miR-181b is correlated with liver and serum HBV DNA levels as well as disease progression in CHB. +circulation_biomarker_diagnosis_ns hsa-mir-155 Preeclampsia 25981845 "The systemic effect of PE on maternal systems is evident in the circulating miRNAome with substantial alterations in miRNA expression in women who develop severe PE. In addition we provide novel evidence of disruption to miR-221 expression 1 year postpartum following a pregnancy complicated by PE compared to normotensive time-matched controls, which may allude to persistent inflammation in these women after delivery." +circulation_biomarker_diagnosis_ns hsa-mir-210 Preeclampsia 25981845 "The systemic effect of PE on maternal systems is evident in the circulating miRNAome with substantial alterations in miRNA expression in women who develop severe PE. In addition we provide novel evidence of disruption to miR-221 expression 1 year postpartum following a pregnancy complicated by PE compared to normotensive time-matched controls, which may allude to persistent inflammation in these women after delivery." +circulation_biomarker_diagnosis_ns hsa-mir-222 Preeclampsia 25981845 "The systemic effect of PE on maternal systems is evident in the circulating miRNAome with substantial alterations in miRNA expression in women who develop severe PE. In addition we provide novel evidence of disruption to miR-221 expression 1 year postpartum following a pregnancy complicated by PE compared to normotensive time-matched controls, which may allude to persistent inflammation in these women after delivery." +circulation_biomarker_diagnosis_ns hsa-mir-296 Preeclampsia 25981845 "The systemic effect of PE on maternal systems is evident in the circulating miRNAome with substantial alterations in miRNA expression in women who develop severe PE. In addition we provide novel evidence of disruption to miR-221 expression 1 year postpartum following a pregnancy complicated by PE compared to normotensive time-matched controls, which may allude to persistent inflammation in these women after delivery." +circulation_biomarker_diagnosis_ns hsa-mir-29b Preeclampsia 25981845 "The systemic effect of PE on maternal systems is evident in the circulating miRNAome with substantial alterations in miRNA expression in women who develop severe PE. In addition we provide novel evidence of disruption to miR-221 expression 1 year postpartum following a pregnancy complicated by PE compared to normotensive time-matched controls, which may allude to persistent inflammation in these women after delivery." +circulation_biomarker_diagnosis_ns hsa-mir-98 Preeclampsia 25981845 "The systemic effect of PE on maternal systems is evident in the circulating miRNAome with substantial alterations in miRNA expression in women who develop severe PE. In addition we provide novel evidence of disruption to miR-221 expression 1 year postpartum following a pregnancy complicated by PE compared to normotensive time-matched controls, which may allude to persistent inflammation in these women after delivery." +circulation_biomarker_diagnosis_ns hsa-mir-520h Breast Neoplasms 25982274 miR-520h is crucial for DAPK2 regulation and breast cancer progression. +circulation_biomarker_diagnosis_ns hsa-mir-19 Crohn Disease 25985247 These data identify miR-19-3p as a potential circulating marker of stricturing CD. Our data show that microRNAs have utility as noninvasive biomarkers of stricturing CD. Further longitudinal studies are required to determine the prognostic value of miR-19-3p at diagnosis. +circulation_biomarker_diagnosis_ns hsa-mir-182 Heart Failure 25985726 "miR-182 (p = 0.04), miR-200a* (p = 0.019), and miR-568 (p = 0.023) were found to be inversely correlated with LVM index (LVMI), while miR-155 (p = 0.019) and miR-595 (p = 0.04) were determined to be positively correlated with LVMI." +circulation_biomarker_diagnosis_ns hsa-mir-132 Schizophrenia 25985888 Alterations of miR-132 are novel diagnostic biomarkers in peripheral blood of schizophrenia patients. +circulation_biomarker_diagnosis_ns hsa-mir-18b Rectal Neoplasms 25990502 MicroRNA expression in patient plasma changes during preoperative CRT. The alteration is not continuous and the meaning requires additional analysis on a larger patient cohort. The co-occurrence of reduced miR-18b and miR-20a expression with lymph node negativity after preoperative CRT could help to stratify the surgical procedure with respect to total mesorectal excision and LR if validated prospectively. +circulation_biomarker_diagnosis_ns hsa-mir-20a Rectal Neoplasms 25990502 MicroRNA expression in patient plasma changes during preoperative CRT. The alteration is not continuous and the meaning requires additional analysis on a larger patient cohort. The co-occurrence of reduced miR-18b and miR-20a expression with lymph node negativity after preoperative CRT could help to stratify the surgical procedure with respect to total mesorectal excision and LR if validated prospectively. +circulation_biomarker_diagnosis_ns hsa-mir-30d Heart Failure 25995320 Baseline plasma miR-30d level is associated with response to CRT in HFDYS in this translational pilot study. MiR-30d increase in cardiomyocytes correlates with areas of increased wall stress in HFDYS and is protective against deleterious tumor necrosis factor signaling. +circulation_biomarker_diagnosis_ns hsa-mir-183 Human Immunodeficiency Virus Infection 25997625 "We show for the first time a joint miRNA and mRNA expression profile related to a HIV-1 latency phenotype, outline a dynamic network of potential regulators involving in HIV-1 latency or replication state, and gain new insights into the source messages for affecting HIV-1 latency." +circulation_biomarker_diagnosis_ns hsa-mir-125 Polycythemia Vera 26011312 "In conclusion, our data indicate that other factors such as aberrant miR-125 expression may influence on the disease phenotype in patients with PV and ET." +circulation_biomarker_diagnosis_ns hsa-mir-497 Bladder Neoplasms 26014226 Circulating miR-497 and miR-663b in plasma are potential novel biomarkers for bladder cancer. +circulation_biomarker_diagnosis_ns hsa-mir-663a Bladder Neoplasms 26014226 Circulating miR-497 and miR-663b in plasma are potential novel biomarkers for bladder cancer. +circulation_biomarker_diagnosis_ns hsa-mir-142 Vasculitis 26016752 "In this first study ever on circulating miRNA profiles in AAV, we find clear indication of their potential as biomarkers for diagnosis and classification, but more studies are needed to identify the best markers as well as the mechanisms responsible for variations." +circulation_biomarker_diagnosis_ns hsa-mir-20a Vasculitis 26016752 "In this first study ever on circulating miRNA profiles in AAV, we find clear indication of their potential as biomarkers for diagnosis and classification, but more studies are needed to identify the best markers as well as the mechanisms responsible for variations." +circulation_biomarker_diagnosis_ns hsa-mir-221 Vasculitis 26016752 "In this first study ever on circulating miRNA profiles in AAV, we find clear indication of their potential as biomarkers for diagnosis and classification, but more studies are needed to identify the best markers as well as the mechanisms responsible for variations." +circulation_biomarker_diagnosis_ns hsa-mir-29a Vasculitis 26016752 "In this first study ever on circulating miRNA profiles in AAV, we find clear indication of their potential as biomarkers for diagnosis and classification, but more studies are needed to identify the best markers as well as the mechanisms responsible for variations." +circulation_biomarker_diagnosis_ns hsa-mir-34a Vasculitis 26016752 "In this first study ever on circulating miRNA profiles in AAV, we find clear indication of their potential as biomarkers for diagnosis and classification, but more studies are needed to identify the best markers as well as the mechanisms responsible for variations." +circulation_biomarker_diagnosis_ns hsa-mir-383 Vasculitis 26016752 "In this first study ever on circulating miRNA profiles in AAV, we find clear indication of their potential as biomarkers for diagnosis and classification, but more studies are needed to identify the best markers as well as the mechanisms responsible for variations." +circulation_biomarker_diagnosis_ns hsa-mir-92a Vasculitis 26016752 "In this first study ever on circulating miRNA profiles in AAV, we find clear indication of their potential as biomarkers for diagnosis and classification, but more studies are needed to identify the best markers as well as the mechanisms responsible for variations." +circulation_biomarker_diagnosis_ns hsa-mir-24 "Carcinoma, Nasopharyngeal" 26018275 Plasma miR-24 may serve as a novel molecular biomarker for early diagnosis and prognosis of NPC. +circulation_biomarker_diagnosis_ns hsa-let-7g Osteoporosis 26026730 "In total 6 miRNAs, miR-10a-5p, miR-10b-5p, miR-133b, miR-22-3p, miR-328-3p, and let-7g-5p exhibited significantly different serum levels in response to fracture" +circulation_biomarker_diagnosis_ns hsa-mir-107 Breast Neoplasms 26033453 "Aberrant plasma levels of circulating miR-16, miR-107, miR-130a and miR-146a are associated with lymph node metastasis and receptor status of breast cancer patients." +circulation_biomarker_diagnosis_ns hsa-mir-130a Breast Neoplasms 26033453 "Aberrant plasma levels of circulating miR-16, miR-107, miR-130a and miR-146a are associated with lymph node metastasis and receptor status of breast cancer patients." +circulation_biomarker_diagnosis_ns hsa-mir-146a Breast Neoplasms 26033453 "Aberrant plasma levels of circulating miR-16, miR-107, miR-130a and miR-146a are associated with lymph node metastasis and receptor status of breast cancer patients." +circulation_biomarker_diagnosis_ns hsa-mir-16 Breast Neoplasms 26033453 "Aberrant plasma levels of circulating miR-16, miR-107, miR-130a and miR-146a are associated with lymph node metastasis and receptor status of breast cancer patients." +circulation_biomarker_diagnosis_ns hsa-mir-200c Neoplasms [unspecific] 26035744 "in clinicopathology analysis,miR-200c expression in blood was significantly associated with TNM stage, lymph node metastasis and distant metastasis. MiR-200c may have the potential to become a new blood biomarker to monitor cancer prognosis and progression." +circulation_biomarker_diagnosis_ns hsa-mir-125b Colorectal Carcinoma 26038573 "Because serum levels of miR-21, miR-29a, and miR-125b discriminated patients with early colorectal neoplasm from healthy controls, our data highlight the potential clinical use of these molecular signatures for noninvasive screening of patients with colorectal neoplasia." +circulation_biomarker_diagnosis_ns hsa-mir-21 Colorectal Carcinoma 26038573 "Because serum levels of miR-21, miR-29a, and miR-125b discriminated patients with early colorectal neoplasm from healthy controls, our data highlight the potential clinical use of these molecular signatures for noninvasive screening of patients with colorectal neoplasia." +circulation_biomarker_diagnosis_ns hsa-mir-29a Colorectal Carcinoma 26038573 "Because serum levels of miR-21, miR-29a, and miR-125b discriminated patients with early colorectal neoplasm from healthy controls, our data highlight the potential clinical use of these molecular signatures for noninvasive screening of patients with colorectal neoplasia." +circulation_biomarker_diagnosis_ns hsa-mir-1246 Melanoma 26039581 A profile of 2 miRNAs (miR-1246 and miR-185) significantly associated with metastatic melanoma with a sensitivity of 90.5% and a specificity of 89.1% was identified. This plasma miRNA profile may become an accurate non-invasive biomarker for melanoma. +circulation_biomarker_diagnosis_ns hsa-mir-185 Melanoma 26039581 A profile of 2 miRNAs (miR-1246 and miR-185) significantly associated with metastatic melanoma with a sensitivity of 90.5% and a specificity of 89.1% was identified. This plasma miRNA profile may become an accurate non-invasive biomarker for melanoma. +circulation_biomarker_diagnosis_ns hsa-mir-206 Melanoma 26045823 "Our results offer the convincing evidence that miR-206 may be implicated in aggressive progression of melanoma. More importantly, the serum level of miR-206 may be a noninvasive prognostic biomarker for the patients with melanoma." +circulation_biomarker_diagnosis_ns hsa-mir-586 Graft-Versus-Host Disease 26051902 Plasma microRNA-586 is a new biomarker for acute graft-versus-host disease. +circulation_biomarker_diagnosis_ns hsa-mir-101 Mycobacterium tuberculosis Infection 26053546 A unique signature of 11 microRNAs in human macrophages was identified to differentiate active MTB disease from LTBI and healthy controls. +circulation_biomarker_diagnosis_ns hsa-mir-140 Mycobacterium tuberculosis Infection 26053546 A unique signature of 11 microRNAs in human macrophages was identified to differentiate active MTB disease from LTBI and healthy controls. +circulation_biomarker_diagnosis_ns hsa-mir-146b Mycobacterium tuberculosis Infection 26053546 A unique signature of 11 microRNAs in human macrophages was identified to differentiate active MTB disease from LTBI and healthy controls. +circulation_biomarker_diagnosis_ns hsa-mir-150 Mycobacterium tuberculosis Infection 26053546 A unique signature of 11 microRNAs in human macrophages was identified to differentiate active MTB disease from LTBI and healthy controls. +circulation_biomarker_diagnosis_ns hsa-mir-193a Mycobacterium tuberculosis Infection 26053546 A unique signature of 11 microRNAs in human macrophages was identified to differentiate active MTB disease from LTBI and healthy controls. +circulation_biomarker_diagnosis_ns hsa-mir-21 Mycobacterium tuberculosis Infection 26053546 A unique signature of 11 microRNAs in human macrophages was identified to differentiate active MTB disease from LTBI and healthy controls. +circulation_biomarker_diagnosis_ns hsa-mir-296 Mycobacterium tuberculosis Infection 26053546 A unique signature of 11 microRNAs in human macrophages was identified to differentiate active MTB disease from LTBI and healthy controls. +circulation_biomarker_diagnosis_ns hsa-mir-485 Mycobacterium tuberculosis Infection 26053546 A unique signature of 11 microRNAs in human macrophages was identified to differentiate active MTB disease from LTBI and healthy controls. +circulation_biomarker_diagnosis_ns hsa-mir-125b Breast Neoplasms 26056355 Circulating miRNAs reflect the presence of breast tumors. The identification of deregulated miRNAs in plasma of patients with breast cancer supports the use of circulating miRNAs as a method for early breast cancer detection. +circulation_biomarker_diagnosis_ns hsa-mir-21 Breast Neoplasms 26056355 Circulating miRNAs reflect the presence of breast tumors. The identification of deregulated miRNAs in plasma of patients with breast cancer supports the use of circulating miRNAs as a method for early breast cancer detection. +circulation_biomarker_diagnosis_ns hsa-mir-505 Breast Neoplasms 26056355 Circulating miRNAs reflect the presence of breast tumors. The identification of deregulated miRNAs in plasma of patients with breast cancer supports the use of circulating miRNAs as a method for early breast cancer detection. +circulation_biomarker_diagnosis_ns hsa-mir-96 Breast Neoplasms 26056355 Circulating miRNAs reflect the presence of breast tumors. The identification of deregulated miRNAs in plasma of patients with breast cancer supports the use of circulating miRNAs as a method for early breast cancer detection. +circulation_biomarker_diagnosis_ns hsa-mir-185 Gastric Neoplasms 26059512 "In conclusion, we identified a five-miRNA signature in the peripheral plasma which could serve as a non-invasive biomarker in detection of GC." +circulation_biomarker_diagnosis_ns hsa-mir-20a Gastric Neoplasms 26059512 "In conclusion, we identified a five-miRNA signature in the peripheral plasma which could serve as a non-invasive biomarker in detection of GC." +circulation_biomarker_diagnosis_ns hsa-mir-210 Gastric Neoplasms 26059512 "In conclusion, we identified a five-miRNA signature in the peripheral plasma which could serve as a non-invasive biomarker in detection of GC." +circulation_biomarker_diagnosis_ns hsa-mir-92b Gastric Neoplasms 26059512 "In conclusion, we identified a five-miRNA signature in the peripheral plasma which could serve as a non-invasive biomarker in detection of GC." +circulation_biomarker_diagnosis_ns hsa-mir-103a Autism Spectrum Disorder 26061495 "this study provides the first global miRNA expression profile of ASD in China. The differentially expressed miR-34b may potentially explain the higher percentage of male ASD patients, and the aberrantly expressed miR-103a-3p may contribute to the abnormal ubiquitin-mediated proteolysis observed in ASD." +circulation_biomarker_diagnosis_ns hsa-mir-34b Autism Spectrum Disorder 26061495 "this study provides the first global miRNA expression profile of ASD in China. The differentially expressed miR-34b may potentially explain the higher percentage of male ASD patients, and the aberrantly expressed miR-103a-3p may contribute to the abnormal ubiquitin-mediated proteolysis observed in ASD." +circulation_biomarker_diagnosis_ns hsa-mir-21 Breast Neoplasms 26063582 "In conclusion, our findings demonstrate that serum miR-21 expression profile may serve as a potential non-invasive diagnostic and prognostic biomarker for breast cancer." +circulation_biomarker_diagnosis_ns hsa-mir-1246 "Leukemia, Myeloid, Acute" 26067326 "We propose development of serum exosome miRNA as a platform for a novel,sensitive compartment biomarker for prospective tracking and early detection of AML recurrence." +circulation_biomarker_diagnosis_ns hsa-mir-155 "Leukemia, Myeloid, Acute" 26067326 "We propose development of serum exosome miRNA as a platform for a novel,sensitive compartment biomarker for prospective tracking and early detection of AML recurrence." +circulation_biomarker_diagnosis_ns hsa-mir-199a Osteosarcoma 26069101 Identification of miR-199a-5p in serum as noninvasive biomarkers for detecting and monitoring osteosarcoma. +circulation_biomarker_diagnosis_ns hsa-mir-3662 Lung Neoplasms 26079400 Plasma circulating microRNA-944 and microRNA-3662 as potential histologic type-specific early lung cancer biomarkers. +circulation_biomarker_diagnosis_ns hsa-mir-944 Lung Neoplasms 26079400 Plasma circulating microRNA-944 and microRNA-3662 as potential histologic type-specific early lung cancer biomarkers. +circulation_biomarker_diagnosis_ns hsa-let-7a Liver Neoplasms 26082194 Assessment of endogenous reference gene suitability for serum exosomal microRNA expression analysis in liver carcinoma resection studies. +circulation_biomarker_diagnosis_ns hsa-mir-103 Liver Neoplasms 26082194 Assessment of endogenous reference gene suitability for serum exosomal microRNA expression analysis in liver carcinoma resection studies. +circulation_biomarker_diagnosis_ns hsa-mir-16 Liver Neoplasms 26082194 Assessment of endogenous reference gene suitability for serum exosomal microRNA expression analysis in liver carcinoma resection studies. +circulation_biomarker_diagnosis_ns hsa-mir-191 Liver Neoplasms 26082194 Assessment of endogenous reference gene suitability for serum exosomal microRNA expression analysis in liver carcinoma resection studies. +circulation_biomarker_diagnosis_ns hsa-mir-221 Liver Neoplasms 26082194 Assessment of endogenous reference gene suitability for serum exosomal microRNA expression analysis in liver carcinoma resection studies. +circulation_biomarker_diagnosis_ns hsa-mir-26a Liver Neoplasms 26082194 Assessment of endogenous reference gene suitability for serum exosomal microRNA expression analysis in liver carcinoma resection studies. +circulation_biomarker_diagnosis_ns hsa-mir-451 Liver Neoplasms 26082194 Assessment of endogenous reference gene suitability for serum exosomal microRNA expression analysis in liver carcinoma resection studies. +circulation_biomarker_diagnosis_ns hsa-mir-34c "Diabetes Mellitus, Type 2" 26083362 "The expression profile of microRNAs/mRNAs in monocytes of T2D patients indicates an altered adhesion, differentiation, and shape change potential. Monocyte inflammatory activation was only found in patients with normal serum lipids. Abnormal lipid values coincided with a reduced monocyte inflammatory state." +circulation_biomarker_diagnosis_ns hsa-mir-133a "Cardiomyopathy, Hypertrophic" 26086795 "We demonstrated that miR-29a and miR-29c show a specific signature to distinguish between aortic stenosis, hypertrophic non-obstructive and obstructive cardiomyopathies and thus could be developed into clinically useful biomarkers." +circulation_biomarker_diagnosis_ns hsa-mir-143 "Cardiomyopathy, Hypertrophic" 26086795 "We demonstrated that miR-29a and miR-29c show a specific signature to distinguish between aortic stenosis, hypertrophic non-obstructive and obstructive cardiomyopathies and thus could be developed into clinically useful biomarkers." +circulation_biomarker_diagnosis_ns hsa-mir-145 "Cardiomyopathy, Hypertrophic" 26086795 "We demonstrated that miR-29a and miR-29c show a specific signature to distinguish between aortic stenosis, hypertrophic non-obstructive and obstructive cardiomyopathies and thus could be developed into clinically useful biomarkers." +circulation_biomarker_diagnosis_ns hsa-mir-192 "Cardiomyopathy, Hypertrophic" 26086795 "We demonstrated that miR-29a and miR-29c show a specific signature to distinguish between aortic stenosis, hypertrophic non-obstructive and obstructive cardiomyopathies and thus could be developed into clinically useful biomarkers." +circulation_biomarker_diagnosis_ns hsa-mir-29a "Cardiomyopathy, Hypertrophic" 26086795 "We demonstrated that miR-29a and miR-29c show a specific signature to distinguish between aortic stenosis, hypertrophic non-obstructive and obstructive cardiomyopathies and thus could be developed into clinically useful biomarkers." +circulation_biomarker_diagnosis_ns hsa-mir-29c "Cardiomyopathy, Hypertrophic" 26086795 "We demonstrated that miR-29a and miR-29c show a specific signature to distinguish between aortic stenosis, hypertrophic non-obstructive and obstructive cardiomyopathies and thus could be developed into clinically useful biomarkers." +circulation_biomarker_diagnosis_ns hsa-mir-505 "Cardiomyopathy, Hypertrophic" 26086795 "We demonstrated that miR-29a and miR-29c show a specific signature to distinguish between aortic stenosis, hypertrophic non-obstructive and obstructive cardiomyopathies and thus could be developed into clinically useful biomarkers." +circulation_biomarker_diagnosis_ns hsa-mir-26a Cholangiocarcinoma 26087181 Serum miR-26a as a diagnostic and prognostic biomarker in cholangiocarcinoma. +circulation_biomarker_diagnosis_ns hsa-mir-143 "Carcinoma, Hepatocellular" 26088272 "A serum microRNA classifier for early detection of hepatocellular carcinoma: a multicentre, retrospective, longitudinal biomarker identification study with a nested case-control study." +circulation_biomarker_diagnosis_ns hsa-mir-145 "Carcinoma, Hepatocellular" 26088272 "A serum microRNA classifier for early detection of hepatocellular carcinoma: a multicentre, retrospective, longitudinal biomarker identification study with a nested case-control study." +circulation_biomarker_diagnosis_ns hsa-mir-192 "Carcinoma, Hepatocellular" 26088272 "A serum microRNA classifier for early detection of hepatocellular carcinoma: a multicentre, retrospective, longitudinal biomarker identification study with a nested case-control study." +circulation_biomarker_diagnosis_ns hsa-mir-29a "Carcinoma, Hepatocellular" 26088272 "A serum microRNA classifier for early detection of hepatocellular carcinoma: a multicentre, retrospective, longitudinal biomarker identification study with a nested case-control study." +circulation_biomarker_diagnosis_ns hsa-mir-29c "Carcinoma, Hepatocellular" 26088272 "A serum microRNA classifier for early detection of hepatocellular carcinoma: a multicentre, retrospective, longitudinal biomarker identification study with a nested case-control study." +circulation_biomarker_diagnosis_ns hsa-mir-505 "Carcinoma, Hepatocellular" 26088272 "A serum microRNA classifier for early detection of hepatocellular carcinoma: a multicentre, retrospective, longitudinal biomarker identification study with a nested case-control study." +circulation_biomarker_diagnosis_ns hsa-mir-126a Acute Pancreatitis 26094040 Serum levels of unique miR-551-5p and endothelial-specific miR-126a-5p allow discrimination of patients in the early phase of acute pancreatitis. +circulation_biomarker_diagnosis_ns hsa-mir-551 Acute Pancreatitis 26094040 Serum levels of unique miR-551-5p and endothelial-specific miR-126a-6p allow discrimination of patients in the early phase of acute pancreatitis. +circulation_biomarker_diagnosis_ns hsa-mir-520d Neoplasms [unspecific] 26094174 "Among HKGs that were expressed in all samples, we suggest that RNU6 and miR-520d-5p were the best candidates for HKGs for studies of plasma miRNA because of the consistent and high Ct in all samples and a very narrow,reproducible SD." +circulation_biomarker_diagnosis_ns hsa-mir-145 Acute Ischemic Stroke 26096228 Circulating miR-145 is associated with plasma high-sensitivity C-reactive protein in acute ischemic stroke patients. +circulation_biomarker_diagnosis_ns hsa-mir-145 Acute Kidney Failure 26106607 "miR-200a/b/c, miR-145, miR-192, miR-194, miR-216a/b, miR-217, and miR-449a expression profiles are useful as biomarkers for identification of various kidney injuries." +circulation_biomarker_diagnosis_ns hsa-mir-192 Acute Kidney Failure 26106607 "miR-200a/b/c, miR-145, miR-192, miR-194, miR-216a/b, miR-217, and miR-449a expression profiles are useful as biomarkers for identification of various kidney injuries." +circulation_biomarker_diagnosis_ns hsa-mir-194 Acute Kidney Failure 26106607 "miR-200a/b/c, miR-145, miR-192, miR-194, miR-216a/b, miR-217, and miR-449a expression profiles are useful as biomarkers for identification of various kidney injuries." +circulation_biomarker_diagnosis_ns hsa-mir-200a Acute Kidney Failure 26106607 "miR-200a/b/c, miR-145, miR-192, miR-194, miR-216a/b, miR-217, and miR-449a expression profiles are useful as biomarkers for identification of various kidney injuries." +circulation_biomarker_diagnosis_ns hsa-mir-200b Acute Kidney Failure 26106607 "miR-200a/b/c, miR-145, miR-192, miR-194, miR-216a/b, miR-217, and miR-449a expression profiles are useful as biomarkers for identification of various kidney injuries." +circulation_biomarker_diagnosis_ns hsa-mir-200c Acute Kidney Failure 26106607 "miR-200a/b/c, miR-145, miR-192, miR-194, miR-216a/b, miR-217, and miR-449a expression profiles are useful as biomarkers for identification of various kidney injuries." +circulation_biomarker_diagnosis_ns hsa-mir-216a Acute Kidney Failure 26106607 "miR-200a/b/c, miR-145, miR-192, miR-194, miR-216a/b, miR-217, and miR-449a expression profiles are useful as biomarkers for identification of various kidney injuries." +circulation_biomarker_diagnosis_ns hsa-mir-216b Acute Kidney Failure 26106607 "miR-200a/b/c, miR-145, miR-192, miR-194, miR-216a/b, miR-217, and miR-449a expression profiles are useful as biomarkers for identification of various kidney injuries." +circulation_biomarker_diagnosis_ns hsa-mir-217 Acute Kidney Failure 26106607 "miR-200a/b/c, miR-145, miR-192, miR-194, miR-216a/b, miR-217, and miR-449a expression profiles are useful as biomarkers for identification of various kidney injuries." +circulation_biomarker_diagnosis_ns hsa-mir-449a Acute Kidney Failure 26106607 "miR-200a/b/c, miR-145, miR-192, miR-194, miR-216a/b, miR-217, and miR-449a expression profiles are useful as biomarkers for identification of various kidney injuries." +circulation_biomarker_diagnosis_ns hsa-mir-21 Lung Neoplasms 26109362 "MiR-21 expression levels in whole blood and peripheral blood cells did not show significant differences between lung cancer patients and healthy controls, and it might be ineffective to measure miR-21 expression to achieve an early diagnosis of lung cancer." +circulation_biomarker_diagnosis_ns hsa-mir-21 Hypertension 26114349 "The decreased levels of NOx and eNOS found in this study indicate the co-existence of endothelial dysfunction and hypertension once more. In the absence of microalbuminuria, the increased miR-21 expression in patients with iCIMT made us conclude that this miRNA might be involved in the early stages of atherosclerotic process in hypertensive patients." +circulation_biomarker_diagnosis_ns hsa-mir-21 "Carcinoma, Hepatocellular" 26114756 Our current findings suggested that circulating miR-21 can serve as a potential co-biomarker for early-stage HCC diagnosis. Thorough large-scale studies are needed to confirm the generalizability of our findings. +circulation_biomarker_diagnosis_ns hsa-mir-15b "Carcinoma, Hepatocellular" 26119771 "Circulating miR-15b-5p, miR-338-5p, and miR-764 may be biomarkers for diagnosis of HCC." +circulation_biomarker_diagnosis_ns hsa-mir-338 "Carcinoma, Hepatocellular" 26119771 "Circulating miR-15b-5p, miR-338-5p, and miR-764 may be biomarkers for diagnosis of HCC." +circulation_biomarker_diagnosis_ns hsa-mir-764 "Carcinoma, Hepatocellular" 26119771 "Circulating miR-15b-5p, miR-338-5p, and miR-764 may be biomarkers for diagnosis of HCC." +circulation_biomarker_diagnosis_ns hsa-mir-144 Breast Neoplasms 26124344 Differentially expressed miRNAs from PBMCs may be potential non-invasive biomarkers for breast cancer prediction. Larger prospective studies are required to confirm whether our findings with specific miRNA loci were related to timing before diagnosis. +circulation_biomarker_diagnosis_ns hsa-mir-183 Breast Neoplasms 26124344 Differentially expressed miRNAs from PBMCs may be potential non-invasive biomarkers for breast cancer prediction. Larger prospective studies are required to confirm whether our findings with specific miRNA loci were related to timing before diagnosis. +circulation_biomarker_diagnosis_ns hsa-mir-451a Breast Neoplasms 26124344 Differentially expressed miRNAs from PBMCs may be potential non-invasive biomarkers for breast cancer prediction. Larger prospective studies are required to confirm whether our findings with specific miRNA loci were related to timing before diagnosis. +circulation_biomarker_diagnosis_ns hsa-mir-708 Breast Neoplasms 26124344 Differentially expressed miRNAs from PBMCs may be potential non-invasive biomarkers for breast cancer prediction. Larger prospective studies are required to confirm whether our findings with specific miRNA loci were related to timing before diagnosis. +circulation_biomarker_diagnosis_ns hsa-mir-146a Chronic Hepatitis B 26131144 Positive correlation was found between the levels of hsa- miR-146a and ALT +circulation_biomarker_diagnosis_ns hsa-mir-122 "Carcinoma, Hepatocellular" 26133725 The combination of serum miR-16 and serum AFP is a significant improvement on the current best practice of serum AFP for HCC in HCVpositive patients. Serum miR-199a and miR-16 could be used as potential indicators of the progress of HCC. +circulation_biomarker_diagnosis_ns hsa-mir-16 "Carcinoma, Hepatocellular" 26133725 The combination of serum miR-16 and serum AFP is a significant improvement on the current best practice of serum AFP for HCC in HCVpositive patients. Serum miR-199a and miR-18 could be used as potential indicators of the progress of HCC. +circulation_biomarker_diagnosis_ns hsa-mir-199a "Carcinoma, Hepatocellular" 26133725 The combination of serum miR-16 and serum AFP is a significant improvement on the current best practice of serum AFP for HCC in HCVpositive patients. Serum miR-199a and miR-17 could be used as potential indicators of the progress of HCC. +circulation_biomarker_diagnosis_ns hsa-mir-103 Colorectal Carcinoma 26134152 Circulating miR-103 and miR-720 as novel serum biomarkers for patients with colorectal cancer. +circulation_biomarker_diagnosis_ns hsa-mir-720 Colorectal Carcinoma 26134152 Circulating miR-103 and miR-720 as novel serum biomarkers for patients with colorectal cancer. +circulation_biomarker_diagnosis_ns hsa-mir-19b "Carcinoma, Lung" 26146958 The assessment of miRs-19b-3p and -29b-3p miRNAs may provide a new diagnostic approach for the early detection of non-small cell lung cancer +circulation_biomarker_diagnosis_ns hsa-mir-100 Coronary Atherosclerosis 26159918 "miR-221, miR-155, miR-100 and hsa-miR-1273,expression level can be used as potential markersfor early coronary atherosclerotic plaque formation." +circulation_biomarker_diagnosis_ns hsa-mir-1273 Coronary Atherosclerosis 26159918 "miR-221, miR-155, miR-100 and hsa-miR-1273,expression level can be used as potential markersfor early coronary atherosclerotic plaque formation." +circulation_biomarker_diagnosis_ns hsa-mir-155 Coronary Atherosclerosis 26159918 "miR-221, miR-155, miR-100 and hsa-miR-1273,expression level can be used as potential markersfor early coronary atherosclerotic plaque formation." +circulation_biomarker_diagnosis_ns hsa-mir-221 Coronary Atherosclerosis 26159918 "miR-221, miR-155, miR-100 and hsa-miR-1273,expression level can be used as potential markersfor early coronary atherosclerotic plaque formation." +circulation_biomarker_diagnosis_ns hsa-mir-103 Prediabetes 26164754 Dysregulated miR-103 and miR-143 expression in peripheral blood mononuclear cells from induced prediabetes and type 2 diabetes rats. +circulation_biomarker_diagnosis_ns hsa-mir-143 Prediabetes 26164754 Dysregulated miR-103 and miR-143 expression in peripheral blood mononuclear cells from induced prediabetes and type 2 diabetes rats. +circulation_biomarker_diagnosis_ns hsa-mir-25 "Carcinoma, Thyroid, Papillary" 26168287 Circulating miR-25-3p and miR-451a May Be Potential Biomarkers for the Diagnosis of Papillary Thyroid Carcinoma. +circulation_biomarker_diagnosis_ns hsa-mir-451a "Carcinoma, Thyroid, Papillary" 26168287 Circulating miR-25-3p and miR-451a May Be Potential Biomarkers for the Diagnosis of Papillary Thyroid Carcinoma. +circulation_biomarker_diagnosis_ns hsa-mir-141 "Carcinoma, Lung, Non-Small-Cell" 26202143 we identified a serum 4-miRNA signature that discriminated with high accuracy lung cancer patients from NC. Further prospective validation of this miRNA signature is warranted. +circulation_biomarker_diagnosis_ns hsa-mir-193b "Carcinoma, Lung, Non-Small-Cell" 26202143 we identified a serum 4-miRNA signature that discriminated with high accuracy lung cancer patients from NC. Further prospective validation of this miRNA signature is warranted. +circulation_biomarker_diagnosis_ns hsa-mir-200b "Carcinoma, Lung, Non-Small-Cell" 26202143 we identified a serum 4-miRNA signature that discriminated with high accuracy lung cancer patients from NC. Further prospective validation of this miRNA signature is warranted. +circulation_biomarker_diagnosis_ns hsa-mir-301 "Carcinoma, Lung, Non-Small-Cell" 26202143 we identified a serum 4-miRNA signature that discriminated with high accuracy lung cancer patients from NC. Further prospective validation of this miRNA signature is warranted. +circulation_biomarker_diagnosis_ns hsa-mir-200 Endometriosis 26206343 Circulating miR-200-family micro-RNAs have altered plasma levels in patients with endometriosis and vary with blood collection time. +circulation_biomarker_diagnosis_ns hsa-mir-10b Melanoma 26208390 "Evaluation of the expressions pattern of miR-10b, 21, 200c, 373 and 520c to find the correlation between epithelial-to-mesenchymal transition and melanoma stem cell potential in isolated cancer stem cells." +circulation_biomarker_diagnosis_ns hsa-mir-200c Melanoma 26208390 "Evaluation of the expressions pattern of miR-10b, 21, 200c, 373 and 520c to find the correlation between epithelial-to-mesenchymal transition and melanoma stem cell potential in isolated cancer stem cells." +circulation_biomarker_diagnosis_ns hsa-mir-21 Melanoma 26208390 "Evaluation of the expressions pattern of miR-10b, 21, 200c, 373 and 520c to find the correlation between epithelial-to-mesenchymal transition and melanoma stem cell potential in isolated cancer stem cells." +circulation_biomarker_diagnosis_ns hsa-mir-373 Melanoma 26208390 "Evaluation of the expressions pattern of miR-10b, 21, 200c, 373 and 520c to find the correlation between epithelial-to-mesenchymal transition and melanoma stem cell potential in isolated cancer stem cells." +circulation_biomarker_diagnosis_ns hsa-mir-520c Melanoma 26208390 "Evaluation of the expressions pattern of miR-10b, 21, 200c, 373 and 520c to find the correlation between epithelial-to-mesenchymal transition and melanoma stem cell potential in isolated cancer stem cells." +circulation_biomarker_diagnosis_ns hsa-mir-21 Heart Failure 26211628 MiR-21 levels were not different among the groups. +circulation_biomarker_diagnosis_ns hsa-let-7d Systemic Lupus Erythematosus 26225955 MicroRNA Profiling of B Cell Subsets from Systemic Lupus Erythematosus Patients Reveals Promising Novel Biomarkers. +circulation_biomarker_diagnosis_ns hsa-let-7e Systemic Lupus Erythematosus 26225955 MicroRNA Profiling of B Cell Subsets from Systemic Lupus Erythematosus Patients Reveals Promising Novel Biomarkers. +circulation_biomarker_diagnosis_ns hsa-mir-181c Systemic Lupus Erythematosus 26225955 MicroRNA Profiling of B Cell Subsets from Systemic Lupus Erythematosus Patients Reveals Promising Novel Biomarkers. +circulation_biomarker_diagnosis_ns hsa-mir-18b Systemic Lupus Erythematosus 26225955 MicroRNA Profiling of B Cell Subsets from Systemic Lupus Erythematosus Patients Reveals Promising Novel Biomarkers. +circulation_biomarker_diagnosis_ns hsa-mir-21 Systemic Lupus Erythematosus 26225955 MicroRNA Profiling of B Cell Subsets from Systemic Lupus Erythematosus Patients Reveals Promising Novel Biomarkers. +circulation_biomarker_diagnosis_ns hsa-mir-223 Systemic Lupus Erythematosus 26225955 MicroRNA Profiling of B Cell Subsets from Systemic Lupus Erythematosus Patients Reveals Promising Novel Biomarkers. +circulation_biomarker_diagnosis_ns hsa-mir-26a Systemic Lupus Erythematosus 26225955 MicroRNA Profiling of B Cell Subsets from Systemic Lupus Erythematosus Patients Reveals Promising Novel Biomarkers. +circulation_biomarker_diagnosis_ns hsa-mir-29b Systemic Lupus Erythematosus 26225955 MicroRNA Profiling of B Cell Subsets from Systemic Lupus Erythematosus Patients Reveals Promising Novel Biomarkers. +circulation_biomarker_diagnosis_ns hsa-mir-29c Systemic Lupus Erythematosus 26225955 MicroRNA Profiling of B Cell Subsets from Systemic Lupus Erythematosus Patients Reveals Promising Novel Biomarkers. +circulation_biomarker_diagnosis_ns hsa-mir-324 Systemic Lupus Erythematosus 26225955 MicroRNA Profiling of B Cell Subsets from Systemic Lupus Erythematosus Patients Reveals Promising Novel Biomarkers. +circulation_biomarker_diagnosis_ns hsa-mir-328 Systemic Lupus Erythematosus 26225955 MicroRNA Profiling of B Cell Subsets from Systemic Lupus Erythematosus Patients Reveals Promising Novel Biomarkers. +circulation_biomarker_diagnosis_ns hsa-mir-335 Systemic Lupus Erythematosus 26225955 MicroRNA Profiling of B Cell Subsets from Systemic Lupus Erythematosus Patients Reveals Promising Novel Biomarkers. +circulation_biomarker_diagnosis_ns hsa-mir-345 Systemic Lupus Erythematosus 26225955 MicroRNA Profiling of B Cell Subsets from Systemic Lupus Erythematosus Patients Reveals Promising Novel Biomarkers. +circulation_biomarker_diagnosis_ns hsa-mir-362 Systemic Lupus Erythematosus 26225955 MicroRNA Profiling of B Cell Subsets from Systemic Lupus Erythematosus Patients Reveals Promising Novel Biomarkers. +circulation_biomarker_diagnosis_ns hsa-mir-365 Systemic Lupus Erythematosus 26225955 MicroRNA Profiling of B Cell Subsets from Systemic Lupus Erythematosus Patients Reveals Promising Novel Biomarkers. +circulation_biomarker_diagnosis_ns hsa-mir-494 Systemic Lupus Erythematosus 26225955 MicroRNA Profiling of B Cell Subsets from Systemic Lupus Erythematosus Patients Reveals Promising Novel Biomarkers. +circulation_biomarker_diagnosis_ns hsa-mir-532 Systemic Lupus Erythematosus 26225955 MicroRNA Profiling of B Cell Subsets from Systemic Lupus Erythematosus Patients Reveals Promising Novel Biomarkers. +circulation_biomarker_diagnosis_ns hsa-mir-579 Systemic Lupus Erythematosus 26225955 MicroRNA Profiling of B Cell Subsets from Systemic Lupus Erythematosus Patients Reveals Promising Novel Biomarkers. +circulation_biomarker_diagnosis_ns hsa-mir-629 Systemic Lupus Erythematosus 26225955 MicroRNA Profiling of B Cell Subsets from Systemic Lupus Erythematosus Patients Reveals Promising Novel Biomarkers. +circulation_biomarker_diagnosis_ns hsa-mir-744 Systemic Lupus Erythematosus 26225955 MicroRNA Profiling of B Cell Subsets from Systemic Lupus Erythematosus Patients Reveals Promising Novel Biomarkers. +circulation_biomarker_diagnosis_ns hsa-mir-21 Intestinal Schistosomiasis 26230095 "The inconsistent levels of the host circulating miRNAs, miR-122, miR-21 and miR-34a in serum were confirmed in the two murine models during infection" +circulation_biomarker_diagnosis_ns hsa-mir-486 "Carcinoma, Lung, Non-Small-Cell" 26237047 The results suggest that miR-486 and miR-150 could be potential blood-based biomarkers for early diagnosis of NSCLC. Monitoring change of miR-486 expression in plasma might be an effective and non-invasive method for recurrence prediction of early-staged NSCLC patients. +circulation_biomarker_diagnosis_ns hsa-mir-146b Synovial Sarcoma 26250552 "Our results have identified a specific whole blood miRNA signature that may serve as an independent biomarker for the diagnosis of local recurrence or distant metastasis of synovial sarcoma. It even distinguishes synovial sarcoma from other sarcoma subtypes, thus potentially serving as a specific biomarker for synovial sarcoma." +circulation_biomarker_diagnosis_ns hsa-mir-148b Synovial Sarcoma 26250552 "Our results have identified a specific whole blood miRNA signature that may serve as an independent biomarker for the diagnosis of local recurrence or distant metastasis of synovial sarcoma. It even distinguishes synovial sarcoma from other sarcoma subtypes, thus potentially serving as a specific biomarker for synovial sarcoma." +circulation_biomarker_diagnosis_ns hsa-mir-195 Synovial Sarcoma 26250552 "Our results have identified a specific whole blood miRNA signature that may serve as an independent biomarker for the diagnosis of local recurrence or distant metastasis of synovial sarcoma. It even distinguishes synovial sarcoma from other sarcoma subtypes, thus potentially serving as a specific biomarker for synovial sarcoma." +circulation_biomarker_diagnosis_ns hsa-mir-223 Synovial Sarcoma 26250552 "Our results have identified a specific whole blood miRNA signature that may serve as an independent biomarker for the diagnosis of local recurrence or distant metastasis of synovial sarcoma. It even distinguishes synovial sarcoma from other sarcoma subtypes, thus potentially serving as a specific biomarker for synovial sarcoma." +circulation_biomarker_diagnosis_ns hsa-mir-500b Synovial Sarcoma 26250552 "Our results have identified a specific whole blood miRNA signature that may serve as an independent biomarker for the diagnosis of local recurrence or distant metastasis of synovial sarcoma. It even distinguishes synovial sarcoma from other sarcoma subtypes, thus potentially serving as a specific biomarker for synovial sarcoma." +circulation_biomarker_diagnosis_ns hsa-mir-505 Synovial Sarcoma 26250552 "Our results have identified a specific whole blood miRNA signature that may serve as an independent biomarker for the diagnosis of local recurrence or distant metastasis of synovial sarcoma. It even distinguishes synovial sarcoma from other sarcoma subtypes, thus potentially serving as a specific biomarker for synovial sarcoma." +circulation_biomarker_diagnosis_ns hsa-mir-99a Synovial Sarcoma 26250552 "Our results have identified a specific whole blood miRNA signature that may serve as an independent biomarker for the diagnosis of local recurrence or distant metastasis of synovial sarcoma. It even distinguishes synovial sarcoma from other sarcoma subtypes, thus potentially serving as a specific biomarker for synovial sarcoma." +circulation_biomarker_diagnosis_ns hsa-mir-210 Bladder Neoplasms 26252880 "Serum miR-210 Contributes to Tumor Detection, Stage Prediction and Dynamic Surveillance in Patients with Bladder Cancer." +circulation_biomarker_diagnosis_ns hsa-mir-192 Nephrotic Syndrome 26261628 Differential microRNA expression in the serum of patients with nephrotic syndrome and clinical correlation analysis. +circulation_biomarker_diagnosis_ns hsa-mir-210 Nephrotic Syndrome 26261628 Differential microRNA expression in the serum of patients with nephrotic syndrome and clinical correlation analysis. +circulation_biomarker_diagnosis_ns hsa-mir-30a Nephrotic Syndrome 26261628 Differential microRNA expression in the serum of patients with nephrotic syndrome and clinical correlation analysis. +circulation_biomarker_diagnosis_ns hsa-mir-586 Nephrotic Syndrome 26261628 Differential microRNA expression in the serum of patients with nephrotic syndrome and clinical correlation analysis. +circulation_biomarker_diagnosis_ns hsa-mir-942 Nephrotic Syndrome 26261628 Differential microRNA expression in the serum of patients with nephrotic syndrome and clinical correlation analysis. +circulation_biomarker_diagnosis_ns hsa-mir-21 "Adenocarcinoma, Pancreatic Ductal" 26262588 "Serum miR-21 and miR-34a are potentially useful diagnostic biomarkers of PDAC. In addition, our results suggest that these miRNAs are not differentially expressed in saliva, making them unsuitable for use as noninvasive biomarkers for diagnostic purposes." +circulation_biomarker_diagnosis_ns hsa-mir-34a "Adenocarcinoma, Pancreatic Ductal" 26262588 "Serum miR-21 and miR-34a are potentially useful diagnostic biomarkers of PDAC. In addition, our results suggest that these miRNAs are not differentially expressed in saliva, making them unsuitable for use as noninvasive biomarkers for diagnostic purposes." +circulation_biomarker_diagnosis_ns hsa-mir-143 "Carcinoma, Hepatocellular, HBV-Related" 26267843 "The miRNA expression profile of PBMCs is altered in patients with HBV-ACLF, and a signature of six miRNAs may be a promising biomarker for HBV-ACLF progression." +circulation_biomarker_diagnosis_ns hsa-mir-21 "Carcinoma, Hepatocellular, HBV-Related" 26267843 "The miRNA expression profile of PBMCs is altered in patients with HBV-ACLF, and a signature of six miRNAs may be a promising biomarker for HBV-ACLF progression." +circulation_biomarker_diagnosis_ns hsa-mir-34c "Carcinoma, Hepatocellular, HBV-Related" 26267843 "The miRNA expression profile of PBMCs is altered in patients with HBV-ACLF, and a signature of six miRNAs may be a promising biomarker for HBV-ACLF progression." +circulation_biomarker_diagnosis_ns hsa-mir-374a "Carcinoma, Hepatocellular, HBV-Related" 26267843 "The miRNA expression profile of PBMCs is altered in patients with HBV-ACLF, and a signature of six miRNAs may be a promising biomarker for HBV-ACLF progression." +circulation_biomarker_diagnosis_ns hsa-mir-542 "Carcinoma, Hepatocellular, HBV-Related" 26267843 "The miRNA expression profile of PBMCs is altered in patients with HBV-ACLF, and a signature of six miRNAs may be a promising biomarker for HBV-ACLF progression." +circulation_biomarker_diagnosis_ns hsa-mir-155 "Carcinoma, Hepatocellular, HCV-Related" 26272105 "This study shows that some microRNAs are differently expressed in peripheral blood mononuclear cells from hepatitis C virus patients who develop hepatocellular carcinoma or lymphoma, while others share a common behavior. Thus,analysis of the expression of microRNAs could be a noninvasive marker of hepatitis C virus-related carcinogenesis. This analysis could be a suitable tool for identifying the existence of a malignancy and also discriminating between these two hepatitis C virus-related cancers." +circulation_biomarker_diagnosis_ns hsa-mir-16 "Carcinoma, Hepatocellular, HCV-Related" 26272105 "This study shows that some microRNAs are differently expressed in peripheral blood mononuclear cells from hepatitis C virus patients who develop hepatocellular carcinoma or lymphoma, while others share a common behavior. Thus,analysis of the expression of microRNAs could be a noninvasive marker of hepatitis C virus-related carcinogenesis. This analysis could be a suitable tool for identifying the existence of a malignancy and also discriminating between these two hepatitis C virus-related cancers." +circulation_biomarker_diagnosis_ns hsa-mir-21 "Carcinoma, Hepatocellular, HCV-Related" 26272105 "This study shows that some microRNAs are differently expressed in peripheral blood mononuclear cells from hepatitis C virus patients who develop hepatocellular carcinoma or lymphoma, while others share a common behavior. Thus,analysis of the expression of microRNAs could be a noninvasive marker of hepatitis C virus-related carcinogenesis. This analysis could be a suitable tool for identifying the existence of a malignancy and also discriminating between these two hepatitis C virus-related cancers." +circulation_biomarker_diagnosis_ns hsa-mir-26b "Carcinoma, Hepatocellular, HCV-Related" 26272105 "This study shows that some microRNAs are differently expressed in peripheral blood mononuclear cells from hepatitis C virus patients who develop hepatocellular carcinoma or lymphoma, while others share a common behavior. Thus,analysis of the expression of microRNAs could be a noninvasive marker of hepatitis C virus-related carcinogenesis. This analysis could be a suitable tool for identifying the existence of a malignancy and also discriminating between these two hepatitis C virus-related cancers." +circulation_biomarker_diagnosis_ns hsa-mir-183 "Carcinoma, Hepatocellular" 26278140 "Sensitivity and specificity of miR-183 as a diagnostic marker of HCC were 57.9% and 76.2% in serum, and 78.9% and 81.0% in plasma" +circulation_biomarker_diagnosis_ns hsa-mir-122 Hepatitis C Virus Infection 26283876 Dysregulated Serum MicroRNA Expression Profile and Potential Biomarkers in Hepatitis C Virus-infected Patients. +circulation_biomarker_diagnosis_ns hsa-mir-134 Hepatitis C Virus Infection 26283876 Dysregulated Serum MicroRNA Expression Profile and Potential Biomarkers in Hepatitis C Virus-infected Patients. +circulation_biomarker_diagnosis_ns hsa-mir-424 Hepatitis C Virus Infection 26283876 Dysregulated Serum MicroRNA Expression Profile and Potential Biomarkers in Hepatitis C Virus-infected Patients. +circulation_biomarker_diagnosis_ns hsa-mir-629 Hepatitis C Virus Infection 26283876 Dysregulated Serum MicroRNA Expression Profile and Potential Biomarkers in Hepatitis C Virus-infected Patients. +circulation_biomarker_diagnosis_ns hsa-mir-21 Glioma 26284486 "Therefore, we concluded that the exosomal miR-21 levels could be demonstrated as a promising indicator for glioma diagnosis and prognosis, particularly with values to predict tumor recurrence or metastasis." +circulation_biomarker_diagnosis_ns hsa-mir-150 Melanoma 26288839 This panel was found to be superior to currently used serological markers for melanoma progression +circulation_biomarker_diagnosis_ns hsa-mir-15b Melanoma 26288839 This panel was found to be superior to currently used serological markers for melanoma progression +circulation_biomarker_diagnosis_ns hsa-mir-199a Melanoma 26288839 This panel was found to be superior to currently used serological markers for melanoma progression +circulation_biomarker_diagnosis_ns hsa-mir-211 Melanoma 26288839 This panel was found to be superior to currently used serological markers for melanoma progression +circulation_biomarker_diagnosis_ns hsa-mir-33a Melanoma 26288839 This panel was found to be superior to currently used serological markers for melanoma progression +circulation_biomarker_diagnosis_ns hsa-mir-424 Melanoma 26288839 This panel was found to be superior to currently used serological markers for melanoma progression +circulation_biomarker_diagnosis_ns hsa-mir-4487 Melanoma 26288839 This panel was found to be superior to currently used serological markers for melanoma progression +circulation_biomarker_diagnosis_ns hsa-mir-4706 Melanoma 26288839 This panel was found to be superior to currently used serological markers for melanoma progression +circulation_biomarker_diagnosis_ns hsa-mir-4731 Melanoma 26288839 This panel was found to be superior to currently used serological markers for melanoma progression +circulation_biomarker_diagnosis_ns hsa-mir-506 Melanoma 26288839 This panel was found to be superior to currently used serological markers for melanoma progression +circulation_biomarker_diagnosis_ns hsa-mir-509 Melanoma 26288839 This panel was found to be superior to currently used serological markers for melanoma progression +circulation_biomarker_diagnosis_ns hsa-mir-514 Melanoma 26288839 This panel was found to be superior to currently used serological markers for melanoma progression +circulation_biomarker_diagnosis_ns hsa-mir-514a Melanoma 26288839 This panel was found to be superior to currently used serological markers for melanoma progression +circulation_biomarker_diagnosis_ns hsa-mir-17 Bronchopulmonary Dysplasia 26291337 Our data are the first to demonstrate altered expression of the miR-17-92 cluster in bronchopulmonary dysplasia. The consistency between our autopsy and plasma findings further support our working hypothesis that the miR-17-92 cluster contributes to the molecular pathogenesis of bronchopulmonary dysplasia. +circulation_biomarker_diagnosis_ns hsa-mir-367 Neoplasms [unspecific] 26306513 Targeted miRNA-based blood tests for miR-371-3 and miR-367 clusters are currently under development and hold a great promise for the future. +circulation_biomarker_diagnosis_ns hsa-mir-185 "Squamous Cell Carcinoma, Esophageal" 26316588 "In conclusion, our findings shed novel light on the role of miR-185/RAGE in ESCC metastasis, and plasma miR-185 has potential as a novel diagnostic biomarker in ESCC." +circulation_biomarker_diagnosis_ns hsa-mir-196b "Leukemia, Myeloid, Acute" 26317787 "These results suggest that microRNA-155 is a potential diagnostic biomarker for all subgroups of paediatric AML, whereas microRNA-196b is specific for subgroups M4-M5." +circulation_biomarker_diagnosis_ns hsa-mir-210 Chronic Hepatitis B 26319884 "Serum miR-210 can be used as an indicator of HBV replication and translation, and a potential marker of necroinflammation in patients with CHB." +circulation_biomarker_diagnosis_ns hsa-mir-191 "Carcinoma, Urothelial, Upper Tract" 26323574 Identification of circulating microRNA signatures for upper tract urothelial carcinoma detection. +circulation_biomarker_diagnosis_ns hsa-mir-22 "Carcinoma, Urothelial, Upper Tract" 26323574 Identification of circulating microRNA signatures for upper tract urothelial carcinoma detection. +circulation_biomarker_diagnosis_ns hsa-mir-26a "Carcinoma, Urothelial, Upper Tract" 26323574 Identification of circulating microRNA signatures for upper tract urothelial carcinoma detection. +circulation_biomarker_diagnosis_ns hsa-mir-33b "Carcinoma, Urothelial, Upper Tract" 26323574 Identification of circulating microRNA signatures for upper tract urothelial carcinoma detection. +circulation_biomarker_diagnosis_ns hsa-mir-423 "Carcinoma, Urothelial, Upper Tract" 26323574 Identification of circulating microRNA signatures for upper tract urothelial carcinoma detection. +circulation_biomarker_diagnosis_ns hsa-mir-431 "Carcinoma, Urothelial, Upper Tract" 26323574 Identification of circulating microRNA signatures for upper tract urothelial carcinoma detection. +circulation_biomarker_diagnosis_ns hsa-mir-664a "Carcinoma, Urothelial, Upper Tract" 26323574 Identification of circulating microRNA signatures for upper tract urothelial carcinoma detection. +circulation_biomarker_diagnosis_ns hsa-mir-92a "Carcinoma, Urothelial, Upper Tract" 26323574 Identification of circulating microRNA signatures for upper tract urothelial carcinoma detection. +circulation_biomarker_diagnosis_ns hsa-let-7b Atherosclerosis 26333279 "A specific circulating miRNAs profile is associated with migraine without aura. Remarkably, the same miRNAs are known to be modulated in the setting of atherosclerosis and stroke in humans. This study represents a first step towards further characterization of MO diagnosis/pathophysiology, also in relation to its link with cardiovascular risk." +circulation_biomarker_diagnosis_ns hsa-let-7b Stroke 26333279 "A specific circulating miRNAs profile is associated with migraine without aura. Remarkably, the same miRNAs are known to be modulated in the setting of atherosclerosis and stroke in humans. This study represents a first step towards further characterization of MO diagnosis/pathophysiology, also in relation to its link with cardiovascular risk." +circulation_biomarker_diagnosis_ns hsa-mir-22 Atherosclerosis 26333279 "A specific circulating miRNAs profile is associated with migraine without aura. Remarkably, the same miRNAs are known to be modulated in the setting of atherosclerosis and stroke in humans. This study represents a first step towards further characterization of MO diagnosis/pathophysiology, also in relation to its link with cardiovascular risk." +circulation_biomarker_diagnosis_ns hsa-mir-22 Stroke 26333279 "A specific circulating miRNAs profile is associated with migraine without aura. Remarkably, the same miRNAs are known to be modulated in the setting of atherosclerosis and stroke in humans. This study represents a first step towards further characterization of MO diagnosis/pathophysiology, also in relation to its link with cardiovascular risk." +circulation_biomarker_diagnosis_ns hsa-mir-221 Atherosclerosis 26333279 "A specific circulating miRNAs profile is associated with migraine without aura. Remarkably, the same miRNAs are known to be modulated in the setting of atherosclerosis and stroke in humans. This study represents a first step towards further characterization of MO diagnosis/pathophysiology, also in relation to its link with cardiovascular risk." +circulation_biomarker_diagnosis_ns hsa-mir-221 Stroke 26333279 "A specific circulating miRNAs profile is associated with migraine without aura. Remarkably, the same miRNAs are known to be modulated in the setting of atherosclerosis and stroke in humans. This study represents a first step towards further characterization of MO diagnosis/pathophysiology, also in relation to its link with cardiovascular risk." +circulation_biomarker_diagnosis_ns hsa-mir-26a Atherosclerosis 26333279 "A specific circulating miRNAs profile is associated with migraine without aura. Remarkably, the same miRNAs are known to be modulated in the setting of atherosclerosis and stroke in humans. This study represents a first step towards further characterization of MO diagnosis/pathophysiology, also in relation to its link with cardiovascular risk." +circulation_biomarker_diagnosis_ns hsa-mir-26a Stroke 26333279 "A specific circulating miRNAs profile is associated with migraine without aura. Remarkably, the same miRNAs are known to be modulated in the setting of atherosclerosis and stroke in humans. This study represents a first step towards further characterization of MO diagnosis/pathophysiology, also in relation to its link with cardiovascular risk." +circulation_biomarker_diagnosis_ns hsa-mir-26b Atherosclerosis 26333279 "A specific circulating miRNAs profile is associated with migraine without aura. Remarkably, the same miRNAs are known to be modulated in the setting of atherosclerosis and stroke in humans. This study represents a first step towards further characterization of MO diagnosis/pathophysiology, also in relation to its link with cardiovascular risk." +circulation_biomarker_diagnosis_ns hsa-mir-26b Stroke 26333279 "A specific circulating miRNAs profile is associated with migraine without aura. Remarkably, the same miRNAs are known to be modulated in the setting of atherosclerosis and stroke in humans. This study represents a first step towards further characterization of MO diagnosis/pathophysiology, also in relation to its link with cardiovascular risk." +circulation_biomarker_diagnosis_ns hsa-mir-27b Atherosclerosis 26333279 "A specific circulating miRNAs profile is associated with migraine without aura. Remarkably, the same miRNAs are known to be modulated in the setting of atherosclerosis and stroke in humans. This study represents a first step towards further characterization of MO diagnosis/pathophysiology, also in relation to its link with cardiovascular risk." +circulation_biomarker_diagnosis_ns hsa-mir-27b Stroke 26333279 "A specific circulating miRNAs profile is associated with migraine without aura. Remarkably, the same miRNAs are known to be modulated in the setting of atherosclerosis and stroke in humans. This study represents a first step towards further characterization of MO diagnosis/pathophysiology, also in relation to its link with cardiovascular risk." +circulation_biomarker_diagnosis_ns hsa-mir-29b Atherosclerosis 26333279 "A specific circulating miRNAs profile is associated with migraine without aura. Remarkably, the same miRNAs are known to be modulated in the setting of atherosclerosis and stroke in humans. This study represents a first step towards further characterization of MO diagnosis/pathophysiology, also in relation to its link with cardiovascular risk." +circulation_biomarker_diagnosis_ns hsa-mir-29b Stroke 26333279 "A specific circulating miRNAs profile is associated with migraine without aura. Remarkably, the same miRNAs are known to be modulated in the setting of atherosclerosis and stroke in humans. This study represents a first step towards further characterization of MO diagnosis/pathophysiology, also in relation to its link with cardiovascular risk." +circulation_biomarker_diagnosis_ns hsa-mir-30b Atherosclerosis 26333279 "A specific circulating miRNAs profile is associated with migraine without aura. Remarkably, the same miRNAs are known to be modulated in the setting of atherosclerosis and stroke in humans. This study represents a first step towards further characterization of MO diagnosis/pathophysiology, also in relation to its link with cardiovascular risk." +circulation_biomarker_diagnosis_ns hsa-mir-30b Stroke 26333279 "A specific circulating miRNAs profile is associated with migraine without aura. Remarkably, the same miRNAs are known to be modulated in the setting of atherosclerosis and stroke in humans. This study represents a first step towards further characterization of MO diagnosis/pathophysiology, also in relation to its link with cardiovascular risk." +circulation_biomarker_diagnosis_ns hsa-mir-30e Atherosclerosis 26333279 "A specific circulating miRNAs profile is associated with migraine without aura. Remarkably, the same miRNAs are known to be modulated in the setting of atherosclerosis and stroke in humans. This study represents a first step towards further characterization of MO diagnosis/pathophysiology, also in relation to its link with cardiovascular risk." +circulation_biomarker_diagnosis_ns hsa-mir-30e Stroke 26333279 "A specific circulating miRNAs profile is associated with migraine without aura. Remarkably, the same miRNAs are known to be modulated in the setting of atherosclerosis and stroke in humans. This study represents a first step towards further characterization of MO diagnosis/pathophysiology, also in relation to its link with cardiovascular risk." +circulation_biomarker_diagnosis_ns hsa-mir-146a Myocardial Infarction 26337652 Circulating miR-146a and miR-21 may be novel biomarkers predictive of LVR after acute MI. Their combination may better predict LVR than either alone. +circulation_biomarker_diagnosis_ns hsa-mir-21 Myocardial Infarction 26337652 Circulating miR-146a and miR-21 may be novel biomarkers predictive of LVR after acute MI. Their combination may better predict LVR than either alone. +circulation_biomarker_diagnosis_ns hsa-let-7b "Carcinoma, Thyroid, Papillary" 26341226 MicroRNA is differentially expressed in the serum of patients with PTC. Serum miRNA has the potential to aid in thyroid cancer diagnosis. +circulation_biomarker_diagnosis_ns hsa-mir-10a "Carcinoma, Thyroid, Papillary" 26341226 MicroRNA is differentially expressed in the serum of patients with PTC. Serum miRNA has the potential to aid in thyroid cancer diagnosis. +circulation_biomarker_diagnosis_ns hsa-mir-146a "Carcinoma, Thyroid, Papillary" 26341226 MicroRNA is differentially expressed in the serum of patients with PTC. Serum miRNA has the potential to aid in thyroid cancer diagnosis. +circulation_biomarker_diagnosis_ns hsa-mir-199b "Carcinoma, Thyroid, Papillary" 26341226 MicroRNA is differentially expressed in the serum of patients with PTC. Serum miRNA has the potential to aid in thyroid cancer diagnosis. +circulation_biomarker_diagnosis_ns hsa-mir-27a Acute Heart Failure 26345695 Fifteen miRNAs found in the discovery phase to differ most significantly between healthy controls and patients with AHF +circulation_biomarker_diagnosis_ns hsa-mir-1 Essential Hypertension 26358152 Hypertrophic and antihypertrophic microRNA levels in peripheral blood mononuclear cells and their relationship to left ventricular hypertrophy in patients with essential hypertension. +circulation_biomarker_diagnosis_ns hsa-mir-133a Essential Hypertension 26358152 Hypertrophic and antihypertrophic microRNA levels in peripheral blood mononuclear cells and their relationship to left ventricular hypertrophy in patients with essential hypertension. +circulation_biomarker_diagnosis_ns hsa-mir-208b Essential Hypertension 26358152 Hypertrophic and antihypertrophic microRNA levels in peripheral blood mononuclear cells and their relationship to left ventricular hypertrophy in patients with essential hypertension. +circulation_biomarker_diagnosis_ns hsa-mir-21 Essential Hypertension 26358152 Hypertrophic and antihypertrophic microRNA levels in peripheral blood mononuclear cells and their relationship to left ventricular hypertrophy in patients with essential hypertension. +circulation_biomarker_diagnosis_ns hsa-mir-26b Essential Hypertension 26358152 Hypertrophic and antihypertrophic microRNA levels in peripheral blood mononuclear cells and their relationship to left ventricular hypertrophy in patients with essential hypertension. +circulation_biomarker_diagnosis_ns hsa-mir-499 Essential Hypertension 26358152 Hypertrophic and antihypertrophic microRNA levels in peripheral blood mononuclear cells and their relationship to left ventricular hypertrophy in patients with essential hypertension. +circulation_biomarker_diagnosis_ns hsa-mir-26a Osteosarcoma 26377680 "In conclusion, our findings suggested that expression level of miR-26a and miR-27a contributes to aggressive progression of this malignancy.Therefore, may have clinical potentials as a non-invasive diagnostic/prognostic biomarker for osteosarcoma patients." +circulation_biomarker_diagnosis_ns hsa-mir-27a Osteosarcoma 26377680 "In conclusion, our findings suggested that expression level of miR-26a and miR-27a contributes to aggressive progression of this malignancy.Therefore, may have clinical potentials as a non-invasive diagnostic/prognostic biomarker for osteosarcoma patients." +circulation_biomarker_diagnosis_ns hsa-mir-146a Epilepsy 26382856 "Those miRNAs that are altered in plasma before the first spontaneous seizure,like miR-9a-3p, may be proposed as putative biomarkers of epileptogenesis." +circulation_biomarker_diagnosis_ns hsa-mir-181c Epilepsy 26382856 "Those miRNAs that are altered in plasma before the first spontaneous seizure,like miR-9a-3p, may be proposed as putative biomarkers of epileptogenesis." +circulation_biomarker_diagnosis_ns hsa-mir-21 Epilepsy 26382856 "Those miRNAs that are altered in plasma before the first spontaneous seizure,like miR-9a-3p, may be proposed as putative biomarkers of epileptogenesis." +circulation_biomarker_diagnosis_ns hsa-mir-23a Epilepsy 26382856 "Those miRNAs that are altered in plasma before the first spontaneous seizure,like miR-9a-3p, may be proposed as putative biomarkers of epileptogenesis." +circulation_biomarker_diagnosis_ns hsa-mir-9a Epilepsy 26382856 "Those miRNAs that are altered in plasma before the first spontaneous seizure,like miR-9a-3p, may be proposed as putative biomarkers of epileptogenesis." +circulation_biomarker_diagnosis_ns hsa-mir-103 Obesity 26406295 This study provides the first identification of altered circulating miRNAs in maternal obesity and suggests a possible role of such miRNAS as markers for pre- and postnatal growth. +circulation_biomarker_diagnosis_ns hsa-mir-122 Obesity 26406295 This study provides the first identification of altered circulating miRNAs in maternal obesity and suggests a possible role of such miRNAS as markers for pre- and postnatal growth. +circulation_biomarker_diagnosis_ns hsa-mir-130a Obesity 26406295 This study provides the first identification of altered circulating miRNAs in maternal obesity and suggests a possible role of such miRNAS as markers for pre- and postnatal growth. +circulation_biomarker_diagnosis_ns hsa-mir-150 Obesity 26406295 This study provides the first identification of altered circulating miRNAs in maternal obesity and suggests a possible role of such miRNAS as markers for pre- and postnatal growth. +circulation_biomarker_diagnosis_ns hsa-mir-221 Obesity 26406295 This study provides the first identification of altered circulating miRNAs in maternal obesity and suggests a possible role of such miRNAS as markers for pre- and postnatal growth. +circulation_biomarker_diagnosis_ns hsa-mir-29c Obesity 26406295 This study provides the first identification of altered circulating miRNAs in maternal obesity and suggests a possible role of such miRNAS as markers for pre- and postnatal growth. +circulation_biomarker_diagnosis_ns hsa-mir-30a Obesity 26406295 This study provides the first identification of altered circulating miRNAs in maternal obesity and suggests a possible role of such miRNAS as markers for pre- and postnatal growth. +circulation_biomarker_diagnosis_ns hsa-mir-324 Obesity 26406295 This study provides the first identification of altered circulating miRNAs in maternal obesity and suggests a possible role of such miRNAS as markers for pre- and postnatal growth. +circulation_biomarker_diagnosis_ns hsa-mir-340 Obesity 26406295 This study provides the first identification of altered circulating miRNAs in maternal obesity and suggests a possible role of such miRNAS as markers for pre- and postnatal growth. +circulation_biomarker_diagnosis_ns hsa-mir-375 Obesity 26406295 This study provides the first identification of altered circulating miRNAs in maternal obesity and suggests a possible role of such miRNAS as markers for pre- and postnatal growth. +circulation_biomarker_diagnosis_ns hsa-mir-652 Obesity 26406295 This study provides the first identification of altered circulating miRNAs in maternal obesity and suggests a possible role of such miRNAS as markers for pre- and postnatal growth. +circulation_biomarker_diagnosis_ns hsa-mir-99b Obesity 26406295 This study provides the first identification of altered circulating miRNAs in maternal obesity and suggests a possible role of such miRNAS as markers for pre- and postnatal growth. +circulation_biomarker_diagnosis_ns hsa-let-7e "Stroke, Ischemic" 26415639 MicroRNA let-7e Is a Potential Circulating Biomarker of Acute Stage Ischemic Stroke. +circulation_biomarker_diagnosis_ns hsa-mir-210 "Carcinoma, Renal Cell" 26426010 Combination of MiR-378 and MiR-210 Serum Levels Enables Sensitive Detection of Renal Cell Carcinoma. +circulation_biomarker_diagnosis_ns hsa-mir-378 "Carcinoma, Renal Cell" 26426010 Combination of MiR-378 and MiR-210 Serum Levels Enables Sensitive Detection of Renal Cell Carcinoma. +circulation_biomarker_diagnosis_ns hsa-mir-3151 "Leukemia, Myeloid, Acute" 26430723 "In conclusion, the analysis of miR-3151 and BAALC expression may well contribute to an improved prognostic stratification of younger patients with IR-AML." +circulation_biomarker_diagnosis_ns hsa-let-7i Heart Failure 26430739 "Our data show a different miR expression pattern after LVAD support, suggesting that differentially expressed miRs are partially responsible for the cardiac morphological and functional changes observed after support. However, the miR expression patterns do not seem to significantly differ between pf- and cf-LVAD implying that most cardiac changes or clinical outcomes specific to each device do not relate to differences in miR expression levels." +circulation_biomarker_diagnosis_ns hsa-mir-129 Heart Failure 26430739 "Our data show a different miR expression pattern after LVAD support, suggesting that differentially expressed miRs are partially responsible for the cardiac morphological and functional changes observed after support. However, the miR expression patterns do not seem to significantly differ between pf- and cf-LVAD implying that most cardiac changes or clinical outcomes specific to each device do not relate to differences in miR expression levels." +circulation_biomarker_diagnosis_ns hsa-mir-146a Heart Failure 26430739 "Our data show a different miR expression pattern after LVAD support, suggesting that differentially expressed miRs are partially responsible for the cardiac morphological and functional changes observed after support. However, the miR expression patterns do not seem to significantly differ between pf- and cf-LVAD implying that most cardiac changes or clinical outcomes specific to each device do not relate to differences in miR expression levels." +circulation_biomarker_diagnosis_ns hsa-mir-155 Heart Failure 26430739 "Our data show a different miR expression pattern after LVAD support, suggesting that differentially expressed miRs are partially responsible for the cardiac morphological and functional changes observed after support. However, the miR expression patterns do not seem to significantly differ between pf- and cf-LVAD implying that most cardiac changes or clinical outcomes specific to each device do not relate to differences in miR expression levels." +circulation_biomarker_diagnosis_ns hsa-mir-21 Heart Failure 26430739 "Our data show a different miR expression pattern after LVAD support, suggesting that differentially expressed miRs are partially responsible for the cardiac morphological and functional changes observed after support. However, the miR expression patterns do not seem to significantly differ between pf- and cf-LVAD implying that most cardiac changes or clinical outcomes specific to each device do not relate to differences in miR expression levels." +circulation_biomarker_diagnosis_ns hsa-mir-221 Heart Failure 26430739 "Our data show a different miR expression pattern after LVAD support, suggesting that differentially expressed miRs are partially responsible for the cardiac morphological and functional changes observed after support. However, the miR expression patterns do not seem to significantly differ between pf- and cf-LVAD implying that most cardiac changes or clinical outcomes specific to each device do not relate to differences in miR expression levels." +circulation_biomarker_diagnosis_ns hsa-mir-222 Heart Failure 26430739 "Our data show a different miR expression pattern after LVAD support, suggesting that differentially expressed miRs are partially responsible for the cardiac morphological and functional changes observed after support. However, the miR expression patterns do not seem to significantly differ between pf- and cf-LVAD implying that most cardiac changes or clinical outcomes specific to each device do not relate to differences in miR expression levels." +circulation_biomarker_diagnosis_ns hsa-mir-378 Heart Failure 26430739 "Our data show a different miR expression pattern after LVAD support, suggesting that differentially expressed miRs are partially responsible for the cardiac morphological and functional changes observed after support. However, the miR expression patterns do not seem to significantly differ between pf- and cf-LVAD implying that most cardiac changes or clinical outcomes specific to each device do not relate to differences in miR expression levels." +circulation_biomarker_diagnosis_ns hsa-mir-200 "Carcinoma, Hepatocellular" 26447841 Circulating microRNA-200 family members are significantly deregulated in patients with HCC and liver cirrhosis. Further studies are necessary to confirm the diagnostic value of the microRNA-200 family as accurate serum marker for cirrhosis-associated HCC. +circulation_biomarker_diagnosis_ns hsa-mir-185 Glioma 26458593 These findings suggest that plasma miR-185 has become potential biomarkers for glioma and may be useful in clinical management for glioma patients. +circulation_biomarker_diagnosis_ns hsa-mir-126 Chronic Kidney Disease 26475583 Plasma levels of microRNA in chronic kidney disease: patterns in acute and chronic exercise. +circulation_biomarker_diagnosis_ns hsa-mir-146a Chronic Kidney Disease 26475583 Plasma levels of microRNA in chronic kidney disease: patterns in acute and chronic exercise. +circulation_biomarker_diagnosis_ns hsa-mir-150 Chronic Kidney Disease 26475583 Plasma levels of microRNA in chronic kidney disease: patterns in acute and chronic exercise. +circulation_biomarker_diagnosis_ns hsa-mir-21 Chronic Kidney Disease 26475583 Plasma levels of microRNA in chronic kidney disease: patterns in acute and chronic exercise. +circulation_biomarker_diagnosis_ns hsa-mir-210 Chronic Kidney Disease 26475583 Plasma levels of microRNA in chronic kidney disease: patterns in acute and chronic exercise. +circulation_biomarker_diagnosis_ns hsa-mir-199a Breast Neoplasms 26476723 "Our data demonstrate that the SdM-RT-PCR assay is an effective breast cancer profiling method that utilizes very small volumes and is compatible with Biobank.Furthermore, the identified 3-miRNA signature is a promising circulating biomarker for breast cancer diagnosis." +circulation_biomarker_diagnosis_ns hsa-mir-29c Breast Neoplasms 26476723 "Our data demonstrate that the SdM-RT-PCR assay is an effective breast cancer profiling method that utilizes very small volumes and is compatible with Biobank.Furthermore, the identified 3-miRNA signature is a promising circulating biomarker for breast cancer diagnosis." +circulation_biomarker_diagnosis_ns hsa-mir-424 Breast Neoplasms 26476723 "Our data demonstrate that the SdM-RT-PCR assay is an effective breast cancer profiling method that utilizes very small volumes and is compatible with Biobank.Furthermore, the identified 3-miRNA signature is a promising circulating biomarker for breast cancer diagnosis." +circulation_biomarker_diagnosis_ns hsa-mir-10a Chronic Hepatitis B 26483130 We constructed serum miRNA panels with considerable clinical value in diagnosing PNALT. +circulation_biomarker_diagnosis_ns hsa-mir-122 Chronic Hepatitis B 26483130 We constructed serum miRNA panels with considerable clinical value in diagnosing PNALT. +circulation_biomarker_diagnosis_ns hsa-mir-192 Chronic Hepatitis B 26483130 We constructed serum miRNA panels with considerable clinical value in diagnosing PNALT. +circulation_biomarker_diagnosis_ns hsa-mir-26a Chronic Hepatitis B 26483130 We constructed serum miRNA panels with considerable clinical value in diagnosing PNALT. +circulation_biomarker_diagnosis_ns hsa-mir-30b Chronic Hepatitis B 26483130 We constructed serum miRNA panels with considerable clinical value in diagnosing PNALT. +circulation_biomarker_diagnosis_ns hsa-mir-511 Chronic Hepatitis B 26483130 We constructed serum miRNA panels with considerable clinical value in diagnosing PNALT. +circulation_biomarker_diagnosis_ns hsa-mir-574 Chronic Hepatitis B 26483130 We constructed serum miRNA panels with considerable clinical value in diagnosing PNALT. +circulation_biomarker_diagnosis_ns hsa-mir-885 Chronic Hepatitis B 26483130 We constructed serum miRNA panels with considerable clinical value in diagnosing PNALT. +circulation_biomarker_diagnosis_ns hsa-mir-98 Chronic Hepatitis B 26483130 We constructed serum miRNA panels with considerable clinical value in diagnosing PNALT. +circulation_biomarker_diagnosis_ns hsa-mir-339 Ovarian Neoplasms 26485143 "10 miRNAs (miR-193a-5p, miR-375, miR-339-3p, miR-340-5p, miR-532-3p, miR-133a-3p, miR-25-3p, miR-10a-5p, miR-616-5p, and miR-148b-5p) displayed fold changes in concentration ranging from -2.9 to 4 (p<0.05), in recurrent platinum resistant ovarian cancer patients" +circulation_biomarker_diagnosis_ns hsa-mir-139 Behcet Disease 26486198 miR199-3p and miR720 deserve further confirmation as biomarkers of BD in larger studies. PBMCs from active BD displayed a unique signature of microRNAs which may be implicated in regulation of innate immunity activation and T-cell function. +circulation_biomarker_diagnosis_ns hsa-mir-720 Behcet Disease 26486198 miR199-3p and miR720 deserve further confirmation as biomarkers of BD in larger studies. PBMCs from active BD displayed a unique signature of microRNAs which may be implicated in regulation of innate immunity activation and T-cell function. +circulation_biomarker_diagnosis_ns hsa-mir-143 Bladder Neoplasms 26489968 MiRNAs detected in urine and serum/plasma will demonstrate their potentiality to describe the variegated scenario of BC and to become relevant clinical markers. +circulation_biomarker_diagnosis_ns hsa-mir-92a Bladder Neoplasms 26489968 MiRNAs detected in urine and serum/plasma will demonstrate their potentiality to describe the variegated scenario of BC and to become relevant clinical markers. +circulation_biomarker_diagnosis_ns hsa-mir-126 Diabetes Mellitus 26498351 MiR-21-5p and miR-126a-3p levels in plasma and circulating angiogenic cells:relationship with type 2 diabetes complications. +circulation_biomarker_diagnosis_ns hsa-mir-21 Diabetes Mellitus 26498351 MiR-21-5p and miR-126a-3p levels in plasma and circulating angiogenic cells:relationship with type 2 diabetes complications. +circulation_biomarker_diagnosis_ns hsa-mir-1 Heart Failure 26498537 Dysregulation of miR-1 and miR-21 expression may be essential for the development of HF; miR-1 might become a biomarker for predicting HF exacerbation. +circulation_biomarker_diagnosis_ns hsa-mir-208a Heart Failure 26498537 Dysregulation of miR-1 and miR-21 expression may be essential for the development of HF; miR-1 might become a biomarker for predicting HF exacerbation. +circulation_biomarker_diagnosis_ns hsa-mir-21 Heart Failure 26498537 Dysregulation of miR-1 and miR-21 expression may be essential for the development of HF; miR-1 might become a biomarker for predicting HF exacerbation. +circulation_biomarker_diagnosis_ns hsa-mir-744 Pancreatic Neoplasms 26505678 "Plasma miR-744 might be useful biomarker for screening PCa,monitoring, and predicting poor prognosis and chemoresistance in PCa patients." +circulation_biomarker_diagnosis_ns hsa-mir-494 "Carcinoma, Hepatocellular" 26509672 "Therefore, we show that circulating microRNAs deserve attention as non-invasive biomarkers in the diagnostic setting of HCC and that exosomal secretion contributes to discharging a subset of microRNAs into the extracellular compartment." +circulation_biomarker_diagnosis_ns hsa-mir-519d "Carcinoma, Hepatocellular" 26509672 "Therefore, we show that circulating microRNAs deserve attention as non-invasive biomarkers in the diagnostic setting of HCC and that exosomal secretion contributes to discharging a subset of microRNAs into the extracellular compartment." +circulation_biomarker_diagnosis_ns hsa-mir-595 "Carcinoma, Hepatocellular" 26509672 "Therefore, we show that circulating microRNAs deserve attention as non-invasive biomarkers in the diagnostic setting of HCC and that exosomal secretion contributes to discharging a subset of microRNAs into the extracellular compartment." +circulation_biomarker_diagnosis_ns hsa-mir-939 "Carcinoma, Hepatocellular" 26509672 "Therefore, we show that circulating microRNAs deserve attention as non-invasive biomarkers in the diagnostic setting of HCC and that exosomal secretion contributes to discharging a subset of microRNAs into the extracellular compartment." +circulation_biomarker_diagnosis_ns hsa-mir-21 Gastric Neoplasms 26509997 "In summary, we verified the diagnostic and prognostic value of tissue hsa-miR-21hsa-miR-21 and hsa-miR-29 in GC. Both of them can be potentially applied as novel and non-invasive biomarkers for GC." +circulation_biomarker_diagnosis_ns hsa-mir-29 Gastric Neoplasms 26509997 "In summary, we verified the diagnostic and prognostic value of tissue hsa-miR-21hsa-miR-21 and hsa-miR-29 in GC. Both of them can be potentially applied as novel and non-invasive biomarkers for GC." +circulation_biomarker_diagnosis_ns hsa-mir-126 Angiosarcoma 26512652 "Our findings suggest that these malignant endothelial proliferative diseases over-secreted miR-214 and miR-126, thus suggesting that these miRNAs have potential as diagnostic biomarkers for malignant endothelial proliferative diseases in canine and possible in human angiosarcoma." +circulation_biomarker_diagnosis_ns hsa-mir-214 Angiosarcoma 26512652 "Our findings suggest that these malignant endothelial proliferative diseases over-secreted miR-214 and miR-126, thus suggesting that these miRNAs have potential as diagnostic biomarkers for malignant endothelial proliferative diseases in canine and possible in human angiosarcoma." +circulation_biomarker_diagnosis_ns hsa-mir-15a Multiple Myeloma 26516702 "Therefore, our data suggest that the expression patterns of miR-15a/16-1 are different in MM patients, and miR-15a seems to be linked with disease progression and prognosis while miR-16-1 acts as a valuable diagnostic marker." +circulation_biomarker_diagnosis_ns hsa-mir-16-1 Multiple Myeloma 26516702 "Therefore, our data suggest that the expression patterns of miR-15a/16-1 are different in MM patients, and miR-15a seems to be linked with disease progression and prognosis while miR-16-1 acts as a valuable diagnostic marker." +circulation_biomarker_diagnosis_ns hsa-mir-10b Neoplasms [unspecific] 26522916 Heterogeneity of miR-10b expression in circulating tumor cells. +circulation_biomarker_diagnosis_ns hsa-mir-1 Acute Myocardial Infarction 26526403 "In summary, we confirmed the predictive values of plasma miR-1,miR-208 and miR-499 in AMI. In contrast to miR-1, the cardiac-specific miR-208 and miR-499 were supposed to be more reliable as biomarkers in AMI screening and prediction." +circulation_biomarker_diagnosis_ns hsa-mir-208 Acute Myocardial Infarction 26526403 "In summary, we confirmed the predictive values of plasma miR-1,miR-208 and miR-499 in AMI. In contrast to miR-1, the cardiac-specific miR-208 and miR-499 were supposed to be more reliable as biomarkers in AMI screening and prediction." +circulation_biomarker_diagnosis_ns hsa-mir-499 Acute Myocardial Infarction 26526403 "In summary, we confirmed the predictive values of plasma miR-1,miR-208 and miR-499 in AMI. In contrast to miR-1, the cardiac-specific miR-208 and miR-499 were supposed to be more reliable as biomarkers in AMI screening and prediction." +circulation_biomarker_diagnosis_ns hsa-mir-1183 Rheumatic Heart Diseases 26539505 Detection of Differentially Expressed MicroRNAs in Rheumatic Heart Disease:miR-1183 and miR-1299 as Potential Diagnostic Biomarkers. +circulation_biomarker_diagnosis_ns hsa-mir-1299 Rheumatic Heart Diseases 26539505 Detection of Differentially Expressed MicroRNAs in Rheumatic Heart Disease:miR-1183 and miR-1299 as Potential Diagnostic Biomarkers. +circulation_biomarker_diagnosis_ns hsa-mir-499 Acute Myocardial Infarction 26547429 "favorable sensitivity and selectivity,thus provides an alternative for the detection of miRNA. Most importantly, this effort may promote miRNA to work as an effective biomarker in the diagnosis of AMI." +circulation_biomarker_diagnosis_ns hsa-mir-10b "Squamous Cell Carcinoma, Esophageal" 26554762 "Predictive Value of Serum miR-10b, miR-29c, and miR-205 as Promising Biomarkers in Esophageal Squamous Cell Carcinoma Screening." +circulation_biomarker_diagnosis_ns hsa-mir-205 "Squamous Cell Carcinoma, Esophageal" 26554762 "Predictive Value of Serum miR-10b, miR-29c, and miR-205 as Promising Biomarkers in Esophageal Squamous Cell Carcinoma Screening." +circulation_biomarker_diagnosis_ns hsa-mir-29c "Squamous Cell Carcinoma, Esophageal" 26554762 "Predictive Value of Serum miR-10b, miR-29c, and miR-205 as Promising Biomarkers in Esophageal Squamous Cell Carcinoma Screening." +circulation_biomarker_diagnosis_ns hsa-mir-320d "Diabetes Mellitus, Type 2" 26554942 This study provided evidence that serum miRNAs had differential expressions between healthy controls and T2DM patients. These five differential expression miRNAs might be of help for subsequent study in T2DM. +circulation_biomarker_diagnosis_ns hsa-mir-3960 "Diabetes Mellitus, Type 2" 26554942 This study provided evidence that serum miRNAs had differential expressions between healthy controls and T2DM patients. These five differential expression miRNAs might be of help for subsequent study in T2DM. +circulation_biomarker_diagnosis_ns hsa-mir-451a "Diabetes Mellitus, Type 2" 26554942 This study provided evidence that serum miRNAs had differential expressions between healthy controls and T2DM patients. These five differential expression miRNAs might be of help for subsequent study in T2DM. +circulation_biomarker_diagnosis_ns hsa-mir-4534 "Diabetes Mellitus, Type 2" 26554942 This study provided evidence that serum miRNAs had differential expressions between healthy controls and T2DM patients. These five differential expression miRNAs might be of help for subsequent study in T2DM. +circulation_biomarker_diagnosis_ns hsa-mir-572 "Diabetes Mellitus, Type 2" 26554942 This study provided evidence that serum miRNAs had differential expressions between healthy controls and T2DM patients. These five differential expression miRNAs might be of help for subsequent study in T2DM. +circulation_biomarker_diagnosis_ns hsa-mir-146b "Colitis, Ulcerative" 26569605 "This is the first study to show the differential expression of miRNA involving different sites of colon in UC patients. Taking our data and previous reports into consideration, we propose that differential miRNA expression during UC perhaps contribute in the development of UC-associated CRC at the rectosigmoid area." +circulation_biomarker_diagnosis_ns hsa-mir-335 "Colitis, Ulcerative" 26569605 "This is the first study to show the differential expression of miRNA involving different sites of colon in UC patients. Taking our data and previous reports into consideration, we propose that differential miRNA expression during UC perhaps contribute in the development of UC-associated CRC at the rectosigmoid area." +circulation_biomarker_diagnosis_ns hsa-mir-342 "Colitis, Ulcerative" 26569605 "This is the first study to show the differential expression of miRNA involving different sites of colon in UC patients. Taking our data and previous reports into consideration, we propose that differential miRNA expression during UC perhaps contribute in the development of UC-associated CRC at the rectosigmoid area." +circulation_biomarker_diagnosis_ns hsa-mir-4732 "Colitis, Ulcerative" 26569605 "This is the first study to show the differential expression of miRNA involving different sites of colon in UC patients. Taking our data and previous reports into consideration, we propose that differential miRNA expression during UC perhaps contribute in the development of UC-associated CRC at the rectosigmoid area." +circulation_biomarker_diagnosis_ns hsa-mir-491 "Colitis, Ulcerative" 26569605 "This is the first study to show the differential expression of miRNA involving different sites of colon in UC patients. Taking our data and previous reports into consideration, we propose that differential miRNA expression during UC perhaps contribute in the development of UC-associated CRC at the rectosigmoid area." +circulation_biomarker_diagnosis_ns hsa-mir-644b "Colitis, Ulcerative" 26569605 "This is the first study to show the differential expression of miRNA involving different sites of colon in UC patients. Taking our data and previous reports into consideration, we propose that differential miRNA expression during UC perhaps contribute in the development of UC-associated CRC at the rectosigmoid area." +circulation_biomarker_diagnosis_ns hsa-mir-140 Gastric Neoplasms 26607322 "This study revealed a three-miRNA signature as a promising classifier for gastric cancer, and greatly enhances the feasibility of circulating miRNAs as non-invasive diagnostic marker for this disease." +circulation_biomarker_diagnosis_ns hsa-mir-18a Gastric Neoplasms 26607322 "This study revealed a three-miRNA signature as a promising classifier for gastric cancer, and greatly enhances the feasibility of circulating miRNAs as non-invasive diagnostic marker for this disease." +circulation_biomarker_diagnosis_ns hsa-mir-199a Gastric Neoplasms 26607322 "This study revealed a three-miRNA signature as a promising classifier for gastric cancer, and greatly enhances the feasibility of circulating miRNAs as non-invasive diagnostic marker for this disease." +circulation_biomarker_diagnosis_ns hsa-mir-627 Gastric Neoplasms 26607322 "This study revealed a three-miRNA signature as a promising classifier for gastric cancer, and greatly enhances the feasibility of circulating miRNAs as non-invasive diagnostic marker for this disease." +circulation_biomarker_diagnosis_ns hsa-mir-629 Gastric Neoplasms 26607322 "This study revealed a three-miRNA signature as a promising classifier for gastric cancer, and greatly enhances the feasibility of circulating miRNAs as non-invasive diagnostic marker for this disease." +circulation_biomarker_diagnosis_ns hsa-mir-652 Gastric Neoplasms 26607322 "This study revealed a three-miRNA signature as a promising classifier for gastric cancer, and greatly enhances the feasibility of circulating miRNAs as non-invasive diagnostic marker for this disease." +circulation_biomarker_diagnosis_ns hsa-mir-29b Glioma 26620922 miR-29b and VEGFA in blood were significantly different compared with the control group +circulation_biomarker_diagnosis_ns hsa-mir-193a "Carcinoma, Lung, Non-Small-Cell" 26629532 This serum miRNA panel holds the potential for diagnosing ethnically diverse NSCLC patients +circulation_biomarker_diagnosis_ns hsa-mir-214 "Carcinoma, Lung, Non-Small-Cell" 26629532 This serum miRNA panel holds the potential for diagnosing ethnically diverse NSCLC patients +circulation_biomarker_diagnosis_ns hsa-mir-25 "Carcinoma, Lung, Non-Small-Cell" 26629532 This serum miRNA panel holds the potential for diagnosing ethnically diverse NSCLC patients +circulation_biomarker_diagnosis_ns hsa-mir-483 "Carcinoma, Lung, Non-Small-Cell" 26629532 This serum miRNA panel holds the potential for diagnosing ethnically diverse NSCLC patients +circulation_biomarker_diagnosis_ns hsa-mir-7 "Carcinoma, Lung, Non-Small-Cell" 26629532 This serum miRNA panel holds the potential for diagnosing ethnically diverse NSCLC patients +circulation_biomarker_diagnosis_ns hsa-mir-125b "Carcinoma, Hepatocellular" 26637228 "A combination of serum miR-125b, miR-223, miR-27a, and miR-26a as a second-line tests could help detect HCC in AFP (-) subjects." +circulation_biomarker_diagnosis_ns hsa-mir-122 Rheumatoid Arthritis 26637811 "In conclusion, this study identified 9-plasma miRNAs signature in Chinese patients with RA which may serve as noninvasive biomarkers for the diagnosis of RA." +circulation_biomarker_diagnosis_ns hsa-mir-219-2 Rheumatoid Arthritis 26637811 "In conclusion, this study identified 9-plasma miRNAs signature in Chinese patients with RA which may serve as noninvasive biomarkers for the diagnosis of RA." +circulation_biomarker_diagnosis_ns hsa-mir-342 Rheumatoid Arthritis 26637811 "In conclusion, this study identified 9-plasma miRNAs signature in Chinese patients with RA which may serve as noninvasive biomarkers for the diagnosis of RA." +circulation_biomarker_diagnosis_ns hsa-mir-3925 Rheumatoid Arthritis 26637811 "In conclusion, this study identified 9-plasma miRNAs signature in Chinese patients with RA which may serve as noninvasive biomarkers for the diagnosis of RA." +circulation_biomarker_diagnosis_ns hsa-mir-3926 Rheumatoid Arthritis 26637811 "In conclusion, this study identified 9-plasma miRNAs signature in Chinese patients with RA which may serve as noninvasive biomarkers for the diagnosis of RA." +circulation_biomarker_diagnosis_ns hsa-mir-4634 Rheumatoid Arthritis 26637811 "In conclusion, this study identified 9-plasma miRNAs signature in Chinese patients with RA which may serve as noninvasive biomarkers for the diagnosis of RA." +circulation_biomarker_diagnosis_ns hsa-mir-4764 Rheumatoid Arthritis 26637811 "In conclusion, this study identified 9-plasma miRNAs signature in Chinese patients with RA which may serve as noninvasive biomarkers for the diagnosis of RA." +circulation_biomarker_diagnosis_ns hsa-mir-9 Rheumatoid Arthritis 26637811 "In conclusion, this study identified 9-plasma miRNAs signature in Chinese patients with RA which may serve as noninvasive biomarkers for the diagnosis of RA." +circulation_biomarker_diagnosis_ns hsa-mir-16-2 "Carcinoma, Cervical" 26656154 "Serum miRNAs panel (miR-16-2*, miR-195, miR-2861, miR-497) as novel non-invasive biomarkers for detection of cervical cancer." +circulation_biomarker_diagnosis_ns hsa-mir-195 "Carcinoma, Cervical" 26656154 "Serum miRNAs panel (miR-16-2*, miR-195, miR-2861, miR-497) as novel non-invasive biomarkers for detection of cervical cancer." +circulation_biomarker_diagnosis_ns hsa-mir-2861 "Carcinoma, Cervical" 26656154 "Serum miRNAs panel (miR-16-2*, miR-195, miR-2861, miR-497) as novel non-invasive biomarkers for detection of cervical cancer." +circulation_biomarker_diagnosis_ns hsa-mir-497 "Carcinoma, Cervical" 26656154 "Serum miRNAs panel (miR-16-2*, miR-195, miR-2861, miR-497) as novel non-invasive biomarkers for detection of cervical cancer." +circulation_biomarker_diagnosis_ns hsa-mir-34 Ewing Sarcoma 26659003 MicroRNA expression profiling may have some potential for prediction of disease progression and survival in Ewing sarcoma. +circulation_biomarker_diagnosis_ns hsa-mir-367 Germ Cell Tumor 26671749 A pipeline to quantify serum and cerebrospinal fluid microRNAs for diagnosis and detection of relapse in paediatric malignant germ-cell tumours. +circulation_biomarker_diagnosis_ns hsa-mir-371a Germ Cell Tumor 26671749 A pipeline to quantify serum and cerebrospinal fluid microRNAs for diagnosis and detection of relapse in paediatric malignant germ-cell tumours. +circulation_biomarker_diagnosis_ns hsa-mir-372 Germ Cell Tumor 26671749 A pipeline to quantify serum and cerebrospinal fluid microRNAs for diagnosis and detection of relapse in paediatric malignant germ-cell tumours. +circulation_biomarker_diagnosis_ns hsa-mir-373 Germ Cell Tumor 26671749 A pipeline to quantify serum and cerebrospinal fluid microRNAs for diagnosis and detection of relapse in paediatric malignant germ-cell tumours. +circulation_biomarker_diagnosis_ns hsa-mir-20a "Carcinoma, Lung, Non-Small-Cell" 26672767 "Among the top markers that were concordant between both studies we found hsa-miR-20b-5p, hsa-miR-20a-5p, hsa-miR-17-5p, and hsa-miR-106a-5p." +circulation_biomarker_diagnosis_ns hsa-mir-31 "Tuberculosis, Pulmonary" 26681217 "Therefore, miR-31 has the potential to be a diagnostic marker in pediatric TB patients." +circulation_biomarker_diagnosis_ns hsa-mir-21 Digestive System Neoplasms 26683919 Potential Role of Circulating MiR-21 in the Diagnosis and Prognosis of Digestive System Cancer: A Systematic Review and Meta-Analysis. +circulation_biomarker_diagnosis_ns hsa-mir-16 Spondylarthritis 26689798 The most repressed miRNA was miR-16 and is predicted to regulate the expression of activin A receptor +circulation_biomarker_diagnosis_ns hsa-mir-21 Gastric Neoplasms 26720919 Two-stage cyclic enzymatic amplification method for ultrasensitive electrochemical assay of microRNA-21 in the blood serum of gastric cancer patients. +circulation_biomarker_diagnosis_ns hsa-mir-1246 Breast Neoplasms 26749252 Novel combination of serum microRNA for detecting breast cancer in the early stage. +circulation_biomarker_diagnosis_ns hsa-mir-1307 Breast Neoplasms 26749252 Novel combination of serum microRNA for detecting breast cancer in the early stage. +circulation_biomarker_diagnosis_ns hsa-mir-4634 Breast Neoplasms 26749252 Novel combination of serum microRNA for detecting breast cancer in the early stage. +circulation_biomarker_diagnosis_ns hsa-mir-6861 Breast Neoplasms 26749252 Novel combination of serum microRNA for detecting breast cancer in the early stage. +circulation_biomarker_diagnosis_ns hsa-mir-6875 Breast Neoplasms 26749252 Novel combination of serum microRNA for detecting breast cancer in the early stage. +circulation_biomarker_diagnosis_ns hsa-mir-126 "Carcinoma, Hepatocellular" 26756996 Hepatic miR-126 is a potential plasma biomarker for detection of hepatitis B virus infected hepatocellular carcinoma. +circulation_biomarker_diagnosis_ns hsa-mir-155 Neoplasms [unspecific] 26765436 Appraising MicroRNA-155 as a Noninvasive Diagnostic Biomarker for Cancer Detection: A Meta-Analysis. +circulation_biomarker_diagnosis_ns hsa-mir-223 "Carcinoma, Hepatocellular" 26776075 Serum miR-30e and miR-224 as Novel Noninvasive Biomarkers for Hepatocellular Carcinoma. +circulation_biomarker_diagnosis_ns hsa-mir-30e "Carcinoma, Hepatocellular" 26776075 Serum miR-30e and miR-223 as Novel Noninvasive Biomarkers for Hepatocellular Carcinoma. +circulation_biomarker_diagnosis_ns hsa-mir-196a "Carcinoma, Cervical" 26782446 Clinical significance of serum miR-196a in cervical intraepithelial neoplasia and cervical cancer. +circulation_biomarker_diagnosis_ns hsa-mir-132 Stroke 26806865 "These results indicated that there was a substantial correlation between serum miR-132 expression and post-stroke cognitive functionality,suggesting that miR-132 may be a risk marker for PSCI. Because of the limitations of this study, the results should be treated with caution. cel-mir-39" +circulation_biomarker_diagnosis_ns hsa-mir-204 Pancreatic Adenocarcinoma 26807325 miR-223 and miR-204 were able to distinguish patients with early stage cancer from patients with CP +circulation_biomarker_diagnosis_ns hsa-mir-34b Major Depressive Disorder 26807671 "Differentially Notch-associated miRNAs expressions in peripheral blood might be involved in MDD, and the miR-34b-5p and miR-34c-5p levels in peripheral blood leukocytes are closely related to MDD, suicide idea and cognitive function, further studies with large sample size are warranted to test the feasibility of these miRNAs serving as biomarkers for MDD." +circulation_biomarker_diagnosis_ns hsa-mir-34c Major Depressive Disorder 26807671 "Differentially Notch-associated miRNAs expressions in peripheral blood might be involved in MDD, and the miR-34b-5p and miR-34c-5p levels in peripheral blood leukocytes are closely related to MDD, suicide idea and cognitive function, further studies with large sample size are warranted to test the feasibility of these miRNAs serving as biomarkers for MDD." +circulation_biomarker_diagnosis_ns hsa-mir-3663 Inherited Hemoglobin Disease 26837891 "Discussion Five of these microRNAs including U101, hsa-miR-4726-5p, hsa-miR7109 5p, hsa-miR3663, and hsa-miR940 had significant changes in expression and volume." +circulation_biomarker_diagnosis_ns hsa-mir-4726 Inherited Hemoglobin Disease 26837891 "Discussion Five of these microRNAs including U101, hsa-miR-4726-5p, hsa-miR7109 5p, hsa-miR3663, and hsa-miR940 had significant changes in expression and volume." +circulation_biomarker_diagnosis_ns hsa-mir-7109 Inherited Hemoglobin Disease 26837891 "Discussion Five of these microRNAs including U101, hsa-miR-4726-5p, hsa-miR7109 5p, hsa-miR3663, and hsa-miR940 had significant changes in expression and volume." +circulation_biomarker_diagnosis_ns hsa-mir-940 Inherited Hemoglobin Disease 26837891 "Discussion Five of these microRNAs including U101, hsa-miR-4726-5p, hsa-miR7109 5p, hsa-miR3663, and hsa-miR940 had significant changes in expression and volume." +circulation_biomarker_diagnosis_ns hsa-mir-200c Cholangiocarcinoma 26864161 miR-200c was found to be expressed differentially in PSC versus controls +circulation_biomarker_diagnosis_ns hsa-mir-222 Cholangiocarcinoma 26864161 a difference in the expression of miR-222 and miR-483-5p in CC versus PSC +circulation_biomarker_diagnosis_ns hsa-mir-21 Acute Myocardial Infarction 26875904 Plasma miR-21 may be a novel biomarker for the diagnosis of AMI. Our study may also provide implications for the development of new biomarkers. +circulation_biomarker_diagnosis_ns hsa-mir-132 Alzheimer Disease 26899870 Dysregulation of miRNA isoform level at 5' end in Alzheimer's disease. +circulation_biomarker_diagnosis_ns hsa-mir-136 Alzheimer Disease 26899870 Dysregulation of miRNA isoform level at 5' end in Alzheimer's disease. +circulation_biomarker_diagnosis_ns hsa-mir-137 Alzheimer Disease 26899870 Dysregulation of miRNA isoform level at 5' end in Alzheimer's disease. +circulation_biomarker_diagnosis_ns hsa-mir-103 Myotonic Dystrophy Type 1 26919350 "a selection of six candidate miRNAs, miR-103, miR-107, miR-21, miR-29a, miR-30c, and miR-652 all failed to show consistent differences in serum expression in subsequent validation experiments." +circulation_biomarker_diagnosis_ns hsa-mir-107 Myotonic Dystrophy Type 1 26919350 "a selection of six candidate miRNAs, miR-103, miR-107, miR-21, miR-29a, miR-30c, and miR-652 all failed to show consistent differences in serum expression in subsequent validation experiments." +circulation_biomarker_diagnosis_ns hsa-mir-107 Hirschsprung Disease 26933947 miRNA Profiling Reveals Dysregulation of RET and RET-Regulating Pathways in Hirschsprung's Disease. +circulation_biomarker_diagnosis_ns hsa-mir-142 Hirschsprung Disease 26933947 miRNA Profiling Reveals Dysregulation of RET and RET-Regulating Pathways in Hirschsprung's Disease. +circulation_biomarker_diagnosis_ns hsa-mir-146b Hirschsprung Disease 26933947 miRNA Profiling Reveals Dysregulation of RET and RET-Regulating Pathways in Hirschsprung's Disease. +circulation_biomarker_diagnosis_ns hsa-mir-369 Hirschsprung Disease 26933947 miRNA Profiling Reveals Dysregulation of RET and RET-Regulating Pathways in Hirschsprung's Disease. +circulation_biomarker_diagnosis_ns hsa-mir-429 Hirschsprung Disease 26933947 miRNA Profiling Reveals Dysregulation of RET and RET-Regulating Pathways in Hirschsprung's Disease. +circulation_biomarker_diagnosis_ns hsa-mir-638 Hirschsprung Disease 26933947 miRNA Profiling Reveals Dysregulation of RET and RET-Regulating Pathways in Hirschsprung's Disease. +circulation_biomarker_diagnosis_ns hsa-mir-885 Hirschsprung Disease 26933947 miRNA Profiling Reveals Dysregulation of RET and RET-Regulating Pathways in Hirschsprung's Disease. +circulation_biomarker_diagnosis_ns hsa-mir-938 Hirschsprung Disease 26933947 miRNA Profiling Reveals Dysregulation of RET and RET-Regulating Pathways in Hirschsprung's Disease. +circulation_biomarker_diagnosis_ns hsa-mir-133a Hypertension 26984682 miRNA-208b and miRNA-133a show distinct profiling in peripheral blood cells isolated from untreated patients +circulation_biomarker_diagnosis_ns hsa-mir-208b Hypertension 26984682 miRNA-208b and miRNA-133a show distinct profiling in peripheral blood cells isolated from untreated patients +circulation_biomarker_diagnosis_ns hsa-mir-26a Gastric Neoplasms 27010210 Circulating MicroRNA-26a in Plasma and Its Potential Diagnostic Value in Gastric Cancer. +circulation_biomarker_diagnosis_ns hsa-mir-146a Autoimmune Lymphoproliferative Syndrome 27060458 "miR-21-3p was over-expressed significantly (P = 0·0313) in the son, with no significant change in the expression of miR-146a, miR-146a-3p and miR-21." +circulation_biomarker_diagnosis_ns hsa-mir-130a "Carcinoma, Ovarian" 27062783 Expression of MiR-130a in Serum Samples of Patients with Epithelial Ovarian Cancer and Its Association with Platinum Resistance. +circulation_biomarker_diagnosis_ns hsa-mir-144 Glaucoma 27064390 "Our data illustrate the feasibility of miRNA analysis by NGS in small individual aqueous humor samples. Intraocular cells as well as blood plasma contribute to the extracellular aqueous humor miRNome. The data suggest possible roles of miRNA in intraocular cell adhesion and signaling by TGF-¦Â and Wnt, which are important in intraocular pressure regulation and glaucoma." +circulation_biomarker_diagnosis_ns hsa-mir-16 Glaucoma 27064390 "Our data illustrate the feasibility of miRNA analysis by NGS in small individual aqueous humor samples. Intraocular cells as well as blood plasma contribute to the extracellular aqueous humor miRNome. The data suggest possible roles of miRNA in intraocular cell adhesion and signaling by TGF-¦Â and Wnt, which are important in intraocular pressure regulation and glaucoma." +circulation_biomarker_diagnosis_ns hsa-mir-184 Glaucoma 27064390 "Our data illustrate the feasibility of miRNA analysis by NGS in small individual aqueous humor samples. Intraocular cells as well as blood plasma contribute to the extracellular aqueous humor miRNome. The data suggest possible roles of miRNA in intraocular cell adhesion and signaling by TGF-¦Â and Wnt, which are important in intraocular pressure regulation and glaucoma." +circulation_biomarker_diagnosis_ns hsa-mir-19a Glaucoma 27064390 "Our data illustrate the feasibility of miRNA analysis by NGS in small individual aqueous humor samples. Intraocular cells as well as blood plasma contribute to the extracellular aqueous humor miRNome. The data suggest possible roles of miRNA in intraocular cell adhesion and signaling by TGF-¦Â and Wnt, which are important in intraocular pressure regulation and glaucoma." +circulation_biomarker_diagnosis_ns hsa-mir-202 Glaucoma 27064390 "Our data illustrate the feasibility of miRNA analysis by NGS in small individual aqueous humor samples. Intraocular cells as well as blood plasma contribute to the extracellular aqueous humor miRNome. The data suggest possible roles of miRNA in intraocular cell adhesion and signaling by TGF-¦Â and Wnt, which are important in intraocular pressure regulation and glaucoma." +circulation_biomarker_diagnosis_ns hsa-mir-205 Glaucoma 27064390 "Our data illustrate the feasibility of miRNA analysis by NGS in small individual aqueous humor samples. Intraocular cells as well as blood plasma contribute to the extracellular aqueous humor miRNome. The data suggest possible roles of miRNA in intraocular cell adhesion and signaling by TGF-¦Â and Wnt, which are important in intraocular pressure regulation and glaucoma." +circulation_biomarker_diagnosis_ns hsa-mir-22 Glaucoma 27064390 "Our data illustrate the feasibility of miRNA analysis by NGS in small individual aqueous humor samples. Intraocular cells as well as blood plasma contribute to the extracellular aqueous humor miRNome. The data suggest possible roles of miRNA in intraocular cell adhesion and signaling by TGF-¦Â and Wnt, which are important in intraocular pressure regulation and glaucoma." +circulation_biomarker_diagnosis_ns hsa-mir-24 Glaucoma 27064390 "Our data illustrate the feasibility of miRNA analysis by NGS in small individual aqueous humor samples. Intraocular cells as well as blood plasma contribute to the extracellular aqueous humor miRNome. The data suggest possible roles of miRNA in intraocular cell adhesion and signaling by TGF-¦Â and Wnt, which are important in intraocular pressure regulation and glaucoma." +circulation_biomarker_diagnosis_ns hsa-mir-29a Glaucoma 27064390 "Our data illustrate the feasibility of miRNA analysis by NGS in small individual aqueous humor samples. Intraocular cells as well as blood plasma contribute to the extracellular aqueous humor miRNome. The data suggest possible roles of miRNA in intraocular cell adhesion and signaling by TGF-¦Â and Wnt, which are important in intraocular pressure regulation and glaucoma." +circulation_biomarker_diagnosis_ns hsa-mir-29c Glaucoma 27064390 "Our data illustrate the feasibility of miRNA analysis by NGS in small individual aqueous humor samples. Intraocular cells as well as blood plasma contribute to the extracellular aqueous humor miRNome. The data suggest possible roles of miRNA in intraocular cell adhesion and signaling by TGF-¦Â and Wnt, which are important in intraocular pressure regulation and glaucoma." +circulation_biomarker_diagnosis_ns hsa-mir-3074 Glaucoma 27064390 "Our data illustrate the feasibility of miRNA analysis by NGS in small individual aqueous humor samples. Intraocular cells as well as blood plasma contribute to the extracellular aqueous humor miRNome. The data suggest possible roles of miRNA in intraocular cell adhesion and signaling by TGF-¦Â and Wnt, which are important in intraocular pressure regulation and glaucoma." +circulation_biomarker_diagnosis_ns hsa-mir-30a Glaucoma 27064390 "Our data illustrate the feasibility of miRNA analysis by NGS in small individual aqueous humor samples. Intraocular cells as well as blood plasma contribute to the extracellular aqueous humor miRNome. The data suggest possible roles of miRNA in intraocular cell adhesion and signaling by TGF-¦Â and Wnt, which are important in intraocular pressure regulation and glaucoma." +circulation_biomarker_diagnosis_ns hsa-mir-30d Glaucoma 27064390 "Our data illustrate the feasibility of miRNA analysis by NGS in small individual aqueous humor samples. Intraocular cells as well as blood plasma contribute to the extracellular aqueous humor miRNome. The data suggest possible roles of miRNA in intraocular cell adhesion and signaling by TGF-¦Â and Wnt, which are important in intraocular pressure regulation and glaucoma." +circulation_biomarker_diagnosis_ns hsa-mir-4448 Glaucoma 27064390 "Our data illustrate the feasibility of miRNA analysis by NGS in small individual aqueous humor samples. Intraocular cells as well as blood plasma contribute to the extracellular aqueous humor miRNome. The data suggest possible roles of miRNA in intraocular cell adhesion and signaling by TGF-¦Â and Wnt, which are important in intraocular pressure regulation and glaucoma." +circulation_biomarker_diagnosis_ns hsa-mir-451a Glaucoma 27064390 "Our data illustrate the feasibility of miRNA analysis by NGS in small individual aqueous humor samples. Intraocular cells as well as blood plasma contribute to the extracellular aqueous humor miRNome. The data suggest possible roles of miRNA in intraocular cell adhesion and signaling by TGF-¦Â and Wnt, which are important in intraocular pressure regulation and glaucoma." +circulation_biomarker_diagnosis_ns hsa-mir-122 "Fatty Liver, Non-Alcoholic" 27077736 Association of Circulating Serum miR-34a and miR-122 with Dyslipidemia among Patients with Non-Alcoholic Fatty Liver Disease. +circulation_biomarker_diagnosis_ns hsa-mir-34a "Fatty Liver, Non-Alcoholic" 27077736 Association of Circulating Serum miR-34a and miR-122 with Dyslipidemia among Patients with Non-Alcoholic Fatty Liver Disease. +circulation_biomarker_diagnosis_ns hsa-mir-125b "Carcinoma, Ovarian" 27092777 Utility of Serum miR-125b as a Diagnostic and Prognostic Indicator and Its Alliance with a Panel of Tumor Suppressor Genes in Epithelial Ovarian Cancer. +circulation_biomarker_diagnosis_ns hsa-mir-126 Early-Stage Non-Small-Cell Lung Carcinoma 27093275 "Diagnostic Value of Serum miR-182, miR-183, miR-210, and miR-126 Levels in Patients with Early-Stage Non-Small Cell Lung Cancer." +circulation_biomarker_diagnosis_ns hsa-mir-182 Early-Stage Non-Small-Cell Lung Carcinoma 27093275 "Diagnostic Value of Serum miR-182, miR-183, miR-210, and miR-126 Levels in Patients with Early-Stage Non-Small Cell Lung Cancer." +circulation_biomarker_diagnosis_ns hsa-mir-183 Early-Stage Non-Small-Cell Lung Carcinoma 27093275 "Diagnostic Value of Serum miR-182, miR-183, miR-210, and miR-126 Levels in Patients with Early-Stage Non-Small Cell Lung Cancer." +circulation_biomarker_diagnosis_ns hsa-mir-210 Early-Stage Non-Small-Cell Lung Carcinoma 27093275 "Diagnostic Value of Serum miR-182, miR-183, miR-210, and miR-126 Levels in Patients with Early-Stage Non-Small Cell Lung Cancer." +circulation_biomarker_diagnosis_ns hsa-mir-372 "Carcinoma, Lung, Non-Small-Cell" 27122989 "A sputum mir-21, mir-210, and mir-372 expression profile might provide a sensitive and highly specific means for detecting nsclc." +circulation_biomarker_diagnosis_ns hsa-mir-122 "Stroke, Ischemic" 27151415 Two miRNAs (miR-145 and miR-122) may represent potential biomarkers in ischemic stroke +circulation_biomarker_diagnosis_ns hsa-let-7g Myocardial Infarction 27192016 we identified several miRs associated with future AMI +circulation_biomarker_diagnosis_ns hsa-mir-106a Myocardial Infarction 27192016 we identified several miRs associated with future AMI +circulation_biomarker_diagnosis_ns hsa-mir-144 Myocardial Infarction 27192016 we identified several miRs associated with future AMI +circulation_biomarker_diagnosis_ns hsa-mir-26a Myocardial Infarction 27192016 miR-424-5p and miR-26a-5p were associated exclusively with risk in men and women +circulation_biomarker_diagnosis_ns hsa-mir-424 Myocardial Infarction 27192016 we identified several miRs associated with future AMI +circulation_biomarker_diagnosis_ns hsa-mir-660 Myocardial Infarction 27192016 we identified several miRs associated with future AMI +circulation_biomarker_diagnosis_ns hsa-mir-122 Hepatitis C Virus Infection 27239848 Evaluation of miR-122 level in the plasma of chronically HCV infected patients. +circulation_biomarker_diagnosis_ns hsa-mir-122 Idiopathic Asthenospermia 27264812 Seminal plasma miR-122-3p and miR-141-5p stability and its diagnosis value for idiopathic asthenospermia. +circulation_biomarker_diagnosis_ns hsa-mir-141 Idiopathic Asthenospermia 27264812 Seminal plasma miR-122-3p and miR-141-5p stability and its diagnosis value for idiopathic asthenospermia. +circulation_biomarker_diagnosis_ns hsa-mir-122 "Carcinoma, Hepatocellular" 27271989 "Using miRNA panel of miR-122, miR-885-5p, and miR-29b with alpha fetoprotein (AFP) provided high diagnostic accuracy" +circulation_biomarker_diagnosis_ns hsa-mir-199a "Carcinoma, Hepatocellular" 27271989 using miRNA panel of miR-22 and miR-199a-3p with AFP provided high diagnostic accuracy +circulation_biomarker_diagnosis_ns hsa-mir-22 "Carcinoma, Hepatocellular" 27271989 using miRNA panel of miR-22 and miR-199a-3p with AFP provided high diagnostic accuracy +circulation_biomarker_diagnosis_ns hsa-mir-221 "Carcinoma, Hepatocellular" 27271989 "using miRNA panel of miR-122, miR-885-5p, miR-221, and miR-22 with AFP provided high diagnostic accuracy" +circulation_biomarker_diagnosis_ns hsa-mir-29b "Carcinoma, Hepatocellular" 27271989 "Using miRNA panel of miR-122, miR-885-5p, and miR-29b with alpha fetoprotein (AFP) provided high diagnostic accuracy" +circulation_biomarker_diagnosis_ns hsa-mir-885 "Carcinoma, Hepatocellular" 27271989 "Using miRNA panel of miR-122, miR-885-5p, and miR-29b with alpha fetoprotein (AFP) provided high diagnostic accuracy" +circulation_biomarker_diagnosis_ns hsa-mir-21 Breast Neoplasms 27311114 MicroRNA-21 (miR-21) is a promising diagnostic biomarker for breast cancer screening and disease progression +circulation_biomarker_diagnosis_ns hsa-mir-132 Spinal Muscular Atrophy 27377135 confirmed a significant alteration of miR-9 and miR-132 level in serum samples from SMA patients. +circulation_biomarker_diagnosis_ns hsa-mir-193b Pancreatic Neoplasms 27380024 "Patients with PDAC or IPMN showed significantly higher amounts of serum MAPK-associated miRNAs than those with AIP (p<0.009 for miR-7, p<0.002 for miR-34a, p<0.001 for miR-181d, p<0.002 for miR-193b)." +circulation_biomarker_diagnosis_ns hsa-mir-34a Pancreatic Neoplasms 27380024 "Patients with PDAC or IPMN showed significantly higher amounts of serum MAPK-associated miRNAs than those with AIP (p<0.009 for miR-7, p<0.002 for miR-34a, p<0.001 for miR-181d, p<0.002 for miR-193b)." +circulation_biomarker_diagnosis_ns hsa-mir-7 Pancreatic Neoplasms 27380024 "Patients with PDAC or IPMN showed significantly higher amounts of serum MAPK-associated miRNAs than those with AIP (p<0.009 for miR-7, p<0.002 for miR-34a, p<0.001 for miR-181d, p<0.002 for miR-193b)." +circulation_biomarker_diagnosis_ns hsa-mir-122 Sepsis 27434572 "The researches regarding circulating miRNA as biomarkers of sepsis were collected to analyze the characteristics of differential expression of miRNAs including miR-150, miR-133a, miR-122, miR-223, miR-4772, miR-297 and miR-574-5p etc." +circulation_biomarker_diagnosis_ns hsa-mir-133a Sepsis 27434572 "The researches regarding circulating miRNA as biomarkers of sepsis were collected to analyze the characteristics of differential expression of miRNAs including miR-150, miR-133a, miR-122, miR-223, miR-4772, miR-297 and miR-574-5p etc." +circulation_biomarker_diagnosis_ns hsa-mir-150 Sepsis 27434572 "The researches regarding circulating miRNA as biomarkers of sepsis were collected to analyze the characteristics of differential expression of miRNAs including miR-150, miR-133a, miR-122, miR-223, miR-4772, miR-297 and miR-574-5p etc." +circulation_biomarker_diagnosis_ns hsa-mir-223 Sepsis 27434572 "The researches regarding circulating miRNA as biomarkers of sepsis were collected to analyze the characteristics of differential expression of miRNAs including miR-150, miR-133a, miR-122, miR-223, miR-4772, miR-297 and miR-574-5p etc." +circulation_biomarker_diagnosis_ns hsa-mir-297 Sepsis 27434572 "The researches regarding circulating miRNA as biomarkers of sepsis were collected to analyze the characteristics of differential expression of miRNAs including miR-150, miR-133a, miR-122, miR-223, miR-4772, miR-297 and miR-574-5p etc." +circulation_biomarker_diagnosis_ns hsa-mir-4772 Sepsis 27434572 "The researches regarding circulating miRNA as biomarkers of sepsis were collected to analyze the characteristics of differential expression of miRNAs including miR-150, miR-133a, miR-122, miR-223, miR-4772, miR-297 and miR-574-5p etc." +circulation_biomarker_diagnosis_ns hsa-mir-574 Sepsis 27434572 "The researches regarding circulating miRNA as biomarkers of sepsis were collected to analyze the characteristics of differential expression of miRNAs including miR-150, miR-133a, miR-122, miR-223, miR-4772, miR-297 and miR-574-5p etc." +circulation_biomarker_diagnosis_ns hsa-mir-16 "Carcinoma, Pancreatic" 27464352 "We found that 34 miRNAs in serum from PC patients in the discovery cohort were expressed differently than in controls. These miRNAs were tested in the training cohort, and four diagnostic panels were constructed that included 5 or 12 miRNAs (miR-16, -18a, -20a, -24, -25, -27a, -29c, -30a.5p, -191, -323.3p, -345 and -483.5p)." +circulation_biomarker_diagnosis_ns hsa-mir-18a "Carcinoma, Pancreatic" 27464352 "We found that 34 miRNAs in serum from PC patients in the discovery cohort were expressed differently than in controls. These miRNAs were tested in the training cohort, and four diagnostic panels were constructed that included 5 or 12 miRNAs (miR-16, -18a, -20a, -24, -25, -27a, -29c, -30a.5p, -191, -323.3p, -345 and -483.5p)." +circulation_biomarker_diagnosis_ns hsa-mir-191 "Carcinoma, Pancreatic" 27464352 "We found that 34 miRNAs in serum from PC patients in the discovery cohort were expressed differently than in controls. These miRNAs were tested in the training cohort, and four diagnostic panels were constructed that included 5 or 12 miRNAs (miR-16, -18a, -20a, -24, -25, -27a, -29c, -30a.5p, -191, -323.3p, -345 and -483.5p)." +circulation_biomarker_diagnosis_ns hsa-mir-20a "Carcinoma, Pancreatic" 27464352 "We found that 34 miRNAs in serum from PC patients in the discovery cohort were expressed differently than in controls. These miRNAs were tested in the training cohort, and four diagnostic panels were constructed that included 5 or 12 miRNAs (miR-16, -18a, -20a, -24, -25, -27a, -29c, -30a.5p, -191, -323.3p, -345 and -483.5p)." +circulation_biomarker_diagnosis_ns hsa-mir-24 "Carcinoma, Pancreatic" 27464352 "We found that 34 miRNAs in serum from PC patients in the discovery cohort were expressed differently than in controls. These miRNAs were tested in the training cohort, and four diagnostic panels were constructed that included 5 or 12 miRNAs (miR-16, -18a, -20a, -24, -25, -27a, -29c, -30a.5p, -191, -323.3p, -345 and -483.5p)." +circulation_biomarker_diagnosis_ns hsa-mir-25 "Carcinoma, Pancreatic" 27464352 "We found that 34 miRNAs in serum from PC patients in the discovery cohort were expressed differently than in controls. These miRNAs were tested in the training cohort, and four diagnostic panels were constructed that included 5 or 12 miRNAs (miR-16, -18a, -20a, -24, -25, -27a, -29c, -30a.5p, -191, -323.3p, -345 and -483.5p)." +circulation_biomarker_diagnosis_ns hsa-mir-27a "Carcinoma, Pancreatic" 27464352 "We found that 34 miRNAs in serum from PC patients in the discovery cohort were expressed differently than in controls. These miRNAs were tested in the training cohort, and four diagnostic panels were constructed that included 5 or 12 miRNAs (miR-16, -18a, -20a, -24, -25, -27a, -29c, -30a.5p, -191, -323.3p, -345 and -483.5p)." +circulation_biomarker_diagnosis_ns hsa-mir-29c "Carcinoma, Pancreatic" 27464352 "We found that 34 miRNAs in serum from PC patients in the discovery cohort were expressed differently than in controls. These miRNAs were tested in the training cohort, and four diagnostic panels were constructed that included 5 or 12 miRNAs (miR-16, -18a, -20a, -24, -25, -27a, -29c, -30a.5p, -191, -323.3p, -345 and -483.5p)." +circulation_biomarker_diagnosis_ns hsa-mir-30a "Carcinoma, Pancreatic" 27464352 "We found that 34 miRNAs in serum from PC patients in the discovery cohort were expressed differently than in controls. These miRNAs were tested in the training cohort, and four diagnostic panels were constructed that included 5 or 12 miRNAs (miR-16, -18a, -20a, -24, -25, -27a, -29c, -30a.5p, -191, -323.3p, -345 and -483.5p)." +circulation_biomarker_diagnosis_ns hsa-mir-323 "Carcinoma, Pancreatic" 27464352 "We found that 34 miRNAs in serum from PC patients in the discovery cohort were expressed differently than in controls. These miRNAs were tested in the training cohort, and four diagnostic panels were constructed that included 5 or 12 miRNAs (miR-16, -18a, -20a, -24, -25, -27a, -29c, -30a.5p, -191, -323.3p, -345 and -483.5p)." +circulation_biomarker_diagnosis_ns hsa-mir-345 "Carcinoma, Pancreatic" 27464352 "We found that 34 miRNAs in serum from PC patients in the discovery cohort were expressed differently than in controls. These miRNAs were tested in the training cohort, and four diagnostic panels were constructed that included 5 or 12 miRNAs (miR-16, -18a, -20a, -24, -25, -27a, -29c, -30a.5p, -191, -323.3p, -345 and -483.5p)." +circulation_biomarker_diagnosis_ns hsa-mir-483 "Carcinoma, Pancreatic" 27464352 "We found that 34 miRNAs in serum from PC patients in the discovery cohort were expressed differently than in controls. These miRNAs were tested in the training cohort, and four diagnostic panels were constructed that included 5 or 12 miRNAs (miR-16, -18a, -20a, -24, -25, -27a, -29c, -30a.5p, -191, -323.3p, -345 and -483.5p)." +circulation_biomarker_diagnosis_ns hsa-mir-148b "Carcinoma, Thyroid, Follicular" 27473101 The best two-miRNA classifier (miR-484/miR-148b-3p) identified thyroid malignancy with a sensitivity of 89â€? and a specificity of 87â€?. +circulation_biomarker_diagnosis_ns hsa-mir-142 "Carcinoma, Colon" 27485599 "diagnostic four-microRNA signature consisting of miR-23a-3p, miR-27a-3p, miR-142-5p and miR-376c-3p was established (AUC = 0.917), distinguishing colon cancer patients from healthy donors." +circulation_biomarker_diagnosis_ns hsa-mir-23a "Carcinoma, Colon" 27485599 "A diagnostic four-microRNA signature consisting of miR-23a-3p, miR-27a-3p, miR-142-5p and miR-376c-3p was established (AUC = 0.917), distinguishing colon cancer patients from healthy donors with sensitivity of 89% and specificity of 81% (AUC = 0.922)." +circulation_biomarker_diagnosis_ns hsa-mir-27a "Carcinoma, Colon" 27485599 "A diagnostic four-microRNA signature consisting of miR-23a-3p, miR-27a-3p, miR-142-5p and miR-376c-3p was established (AUC = 0.917), distinguishing colon cancer patients from healthy donors with sensitivity of 89% and specificity of 81% (AUC = 0.922)." +circulation_biomarker_diagnosis_ns hsa-mir-376c "Carcinoma, Colon" 27485599 "A diagnostic four-microRNA signature consisting of miR-23a-3p, miR-27a-3p, miR-142-5p and miR-376c-3p was established (AUC = 0.917), distinguishing colon cancer patients from healthy donors with sensitivity of 89% and specificity of 81% (AUC = 0.922)." +circulation_biomarker_diagnosis_ns hsa-mir-206 Muscular Dystrophy 27529242 "miR-206 has potential as a ""liquid biopsy"" for carrier detection and genetic counseling in DMD." +circulation_biomarker_diagnosis_ns hsa-mir-221 Pancreatic Neoplasms 27539232 "Circulating microRNAs as Potential Diagnostic, Prognostic and Therapeutic Targets in Pancreatic Cancer." +circulation_biomarker_diagnosis_ns hsa-mir-96 Pancreatic Neoplasms 27539232 "Circulating microRNAs as Potential Diagnostic, Prognostic and Therapeutic Targets in Pancreatic Cancer." +circulation_biomarker_diagnosis_ns hsa-mir-26b Graft-Versus-Host Disease 27553380 The predictive value of selected serum microRNAs for acute GVHD by TaqMan MicroRNA arrays. +circulation_biomarker_diagnosis_ns hsa-mir-28 Graft-Versus-Host Disease 27553380 The predictive value of selected serum microRNAs for acute GVHD by TaqMan MicroRNA arrays. +circulation_biomarker_diagnosis_ns hsa-mir-374a Graft-Versus-Host Disease 27553380 The predictive value of selected serum microRNAs for acute GVHD by TaqMan MicroRNA arrays. +circulation_biomarker_diagnosis_ns hsa-mir-411 Graft-Versus-Host Disease 27553380 The predictive value of selected serum microRNAs for acute GVHD by TaqMan MicroRNA arrays. +circulation_biomarker_diagnosis_ns hsa-mir-489 Graft-Versus-Host Disease 27553380 The predictive value of selected serum microRNAs for acute GVHD by TaqMan MicroRNA arrays. +circulation_biomarker_diagnosis_ns hsa-mir-671 Graft-Versus-Host Disease 27553380 The predictive value of selected serum microRNAs for acute GVHD by TaqMan MicroRNA arrays. +circulation_biomarker_diagnosis_ns hsa-mir-23a "Squamous Cell Carcinoma, Esophageal" 27566562 Plasma microRNA profiles: identification of miR-23a as a novel biomarker for chemoresistance in esophageal squamous cell carcinoma. +circulation_biomarker_diagnosis_ns hsa-mir-21 Acute Coronary Syndrome 27590242 The role of serum levels of microRNA-21 and matrix metalloproteinase-9 in patients with acute coronary syndrome. +circulation_biomarker_diagnosis_ns hsa-mir-122 Acute Myocardial Infarction 27593229 Circulating miR-122-5p/miR-133b Ratio Is a Specific Early Prognostic Biomarker in Acute Myocardial Infarction. +circulation_biomarker_diagnosis_ns hsa-mir-133b Acute Myocardial Infarction 27593229 Circulating miR-122-5p/miR-133b Ratio Is a Specific Early Prognostic Biomarker in Acute Myocardial Infarction. +circulation_biomarker_diagnosis_ns hsa-mir-21 Hepatoblastoma 27601233 Diagnostic and prognostic values of serum exosomal microRNA-21 in children with hepatoblastoma: a Chinese population-based study. +circulation_biomarker_diagnosis_ns hsa-mir-208a Coronary Artery Disease 27602213 Analysis of plasma miR-208a and miR-370 expression levels for early diagnosis of coronary artery disease. +circulation_biomarker_diagnosis_ns hsa-mir-370 Coronary Artery Disease 27602213 Analysis of plasma miR-208a and miR-370 expression levels for early diagnosis of coronary artery disease. +circulation_biomarker_diagnosis_ns hsa-mir-27a Multiple Sclerosis 27606352 Comprehensive evaluation of serum microRNAs as biomarkers in multiple sclerosis. +circulation_biomarker_diagnosis_ns hsa-mir-206 "Carcinoma, Gastric" 27614739 Diagnostic and Prognostic Value of Serum MicroRNA-206 in Patients with Gastric Cancer. +circulation_biomarker_diagnosis_ns hsa-mir-22 "Carcinoma, Pancreatic" 27631726 "Plasma miR-22-3p, miR-642b-3p and miR-885-5p as diagnostic biomarkers for pancreatic cancer." +circulation_biomarker_diagnosis_ns hsa-mir-642b "Carcinoma, Pancreatic" 27631726 "Plasma miR-22-3p, miR-642b-3p and miR-885-5p as diagnostic biomarkers for pancreatic cancer." +circulation_biomarker_diagnosis_ns hsa-mir-885 "Carcinoma, Pancreatic" 27631726 "Plasma miR-22-3p, miR-642b-3p and miR-885-5p as diagnostic biomarkers for pancreatic cancer." +circulation_biomarker_diagnosis_ns hsa-mir-122 Colorectal Carcinoma 27632639 Plasma miR-122 and miR-200 family are prognostic markers in colorectal cancer. +circulation_biomarker_diagnosis_ns hsa-mir-200 Colorectal Carcinoma 27632639 Plasma miR-122 and miR-200 family are prognostic markers in colorectal cancer. +circulation_biomarker_diagnosis_ns hsa-mir-139 "Carcinoma, Hepatocellular" 27633066 Reanalysis of microRNA expression profiles identifies novel biomarkers for hepatocellular carcinoma prognosis. +circulation_biomarker_diagnosis_ns hsa-let-7f Liver Diseases [unspecific] 27639178 Extracellular vesicles released by hepatocytes from gastric infusion model of alcoholic liver disease contain a MicroRNA barcode that can be detected in blood. +circulation_biomarker_diagnosis_ns hsa-mir-29a Liver Diseases [unspecific] 27639178 Extracellular vesicles released by hepatocytes from gastric infusion model of alcoholic liver disease contain a MicroRNA barcode that can be detected in blood. +circulation_biomarker_diagnosis_ns hsa-mir-340 Liver Diseases [unspecific] 27639178 Extracellular vesicles released by hepatocytes from gastric infusion model of alcoholic liver disease contain a MicroRNA barcode that can be detected in blood. +circulation_biomarker_diagnosis_ns hsa-mir-25 "Carcinoma, Pancreatic" 27639768 Identification of Circulating MiR-25 as a Potential Biomarker for Pancreatic Cancer Diagnosis. +circulation_biomarker_diagnosis_ns hsa-mir-1 Aplastic Anemia 27658437 A plasma microRNA signature as a biomarker for acquired aplastic anemia. +circulation_biomarker_diagnosis_ns hsa-mir-146b Aplastic Anemia 27658437 A plasma microRNA signature as a biomarker for acquired aplastic anemia. +circulation_biomarker_diagnosis_ns hsa-mir-150 Aplastic Anemia 27658437 A plasma microRNA signature as a biomarker for acquired aplastic anemia. +circulation_biomarker_diagnosis_ns hsa-mir-125b Age-Related Macular Degeneration 27658786 "mir-17, miR-125b and miR-155 were dysregulated in multiple AMD mouse models as well as in human AMD plasma or retinae" +circulation_biomarker_diagnosis_ns hsa-mir-155 Age-Related Macular Degeneration 27658786 "mir-17, miR-125b and miR-155 were dysregulated in multiple AMD mouse models as well as in human AMD plasma or retinae" +circulation_biomarker_diagnosis_ns hsa-mir-17 Age-Related Macular Degeneration 27658786 "mir-17, miR-125b and miR-155 were dysregulated in multiple AMD mouse models as well as in human AMD plasma or retinae" +circulation_biomarker_diagnosis_ns hsa-mir-33a Atherosclerosis 27664032 Aberrant expression of plasma microRNA-33a in an atherosclerosis-risk group. +circulation_biomarker_diagnosis_ns hsa-let-7g "Tuberculosis, Pulmonary" 27682490 The expression of serum miRNAs in pneumoconiosis complicated with pulmonary tuberculosis patients. +circulation_biomarker_diagnosis_ns hsa-mir-155 "Tuberculosis, Pulmonary" 27682490 The expression of serum miRNAs in pneumoconiosis complicated with pulmonary tuberculosis patients. +circulation_biomarker_diagnosis_ns hsa-mir-16 "Tuberculosis, Pulmonary" 27682490 The expression of serum miRNAs in pneumoconiosis complicated with pulmonary tuberculosis patients. +circulation_biomarker_diagnosis_ns hsa-mir-192 "Tuberculosis, Pulmonary" 27682490 The expression of serum miRNAs in pneumoconiosis complicated with pulmonary tuberculosis patients. +circulation_biomarker_diagnosis_ns hsa-mir-200c "Tuberculosis, Pulmonary" 27682490 The expression of serum miRNAs in pneumoconiosis complicated with pulmonary tuberculosis patients. +circulation_biomarker_diagnosis_ns hsa-mir-204 "Tuberculosis, Pulmonary" 27682490 The expression of serum miRNAs in pneumoconiosis complicated with pulmonary tuberculosis patients. +circulation_biomarker_diagnosis_ns hsa-mir-206 "Tuberculosis, Pulmonary" 27682490 The expression of serum miRNAs in pneumoconiosis complicated with pulmonary tuberculosis patients. +circulation_biomarker_diagnosis_ns hsa-mir-21 "Tuberculosis, Pulmonary" 27682490 The expression of serum miRNAs in pneumoconiosis complicated with pulmonary tuberculosis patients. +circulation_biomarker_diagnosis_ns hsa-mir-29a "Tuberculosis, Pulmonary" 27682490 The expression of serum miRNAs in pneumoconiosis complicated with pulmonary tuberculosis patients. +circulation_biomarker_diagnosis_ns hsa-mir-30b "Tuberculosis, Pulmonary" 27682490 The expression of serum miRNAs in pneumoconiosis complicated with pulmonary tuberculosis patients. +circulation_biomarker_diagnosis_ns hsa-mir-21 Cholangiocarcinoma 27685844 Circulating Plasma Levels of MicroRNA-21 and MicroRNA-221 Are Potential Diagnostic Markers for Primary Intrahepatic Cholangiocarcinoma. +circulation_biomarker_diagnosis_ns hsa-mir-221 Cholangiocarcinoma 27685844 Circulating Plasma Levels of MicroRNA-21 and MicroRNA-221 Are Potential Diagnostic Markers for Primary Intrahepatic Cholangiocarcinoma. +circulation_biomarker_diagnosis_ns hsa-mir-23a Cardiovascular Diseases [unspecific] 27725938 Optimized Collection Protocol for Plasma MicroRNA Measurement in Patients with Cardiovascular Disease. +circulation_biomarker_diagnosis_ns hsa-mir-451a Cardiovascular Diseases [unspecific] 27725938 Optimized Collection Protocol for Plasma MicroRNA Measurement in Patients with Cardiovascular Disease. +circulation_biomarker_diagnosis_ns hsa-mir-150 "Leukemia, Lymphocytic, Chronic, B-Cell" 27730344 Expression of circulating miRNAs associated with lymphocyte differentiation and activation in CLL-another piece in the puzzle. +circulation_biomarker_diagnosis_ns hsa-mir-155 "Leukemia, Lymphocytic, Chronic, B-Cell" 27730344 Expression of circulating miRNAs associated with lymphocyte differentiation and activation in CLL-another piece in the puzzle. +circulation_biomarker_diagnosis_ns hsa-mir-15a "Leukemia, Lymphocytic, Chronic, B-Cell" 27730344 Expression of circulating miRNAs associated with lymphocyte differentiation and activation in CLL-another piece in the puzzle. +circulation_biomarker_diagnosis_ns hsa-mir-29a "Leukemia, Lymphocytic, Chronic, B-Cell" 27730344 Expression of circulating miRNAs associated with lymphocyte differentiation and activation in CLL-another piece in the puzzle. +circulation_biomarker_diagnosis_ns hsa-mir-31 "Leukemia, Lymphocytic, Chronic, B-Cell" 27730344 Expression of circulating miRNAs associated with lymphocyte differentiation and activation in CLL-another piece in the puzzle. +circulation_biomarker_diagnosis_ns hsa-mir-34a "Leukemia, Lymphocytic, Chronic, B-Cell" 27730344 Expression of circulating miRNAs associated with lymphocyte differentiation and activation in CLL-another piece in the puzzle. +circulation_biomarker_diagnosis_ns hsa-mir-195 "Carcinoma, Lung, Non-Small-Cell" 27733164 Diagnostic and prognostic value of plasma microRNA-195 in patients with non-small cell lung cancer. +circulation_biomarker_diagnosis_ns hsa-mir-497 Osteosarcoma 27735043 miR-497 as a potential serum biomarker for the diagnosis and prognosis of osteosarcoma. +circulation_biomarker_diagnosis_ns hsa-mir-221 Parkinson Disease 27748571 Serum miR-221 serves as a biomarker for Parkinson's disease. +circulation_biomarker_diagnosis_ns hsa-mir-155 "Carcinoma, Hepatocellular" 27751368 Relationship Between Serum microRNA155 and Telomerase Expression in Hepatocellular Carcinoma. +circulation_biomarker_diagnosis_ns hsa-mir-146a Ischemia-Reperfusion Injury 27760486 Micro RNA-320 as a novel potential biomarker in renal ischemia reperfusion. +circulation_biomarker_diagnosis_ns hsa-mir-155 Hematologic Neoplasms 27761889 "EV miR155 may serve as an attractive new, non-invasive diagnostic biomarker in human hematologic malignancies" +circulation_biomarker_diagnosis_ns hsa-mir-183 "Carcinoma, Lung" 27768748 Plasma miR-19b and miR-183 as Potential Biomarkers of Lung Cancer. +circulation_biomarker_diagnosis_ns hsa-mir-19b "Carcinoma, Lung" 27768748 Plasma miR-19b and miR-183 as Potential Biomarkers of Lung Cancer. +circulation_biomarker_diagnosis_ns hsa-let-7e "Stroke, Ischemic" 27776139 Identification of Blood Let-7e-5p as a Biomarker for Ischemic Stroke. +circulation_biomarker_diagnosis_ns hsa-mir-21 Atherosclerosis 27785570 "Association of serum microRNA-21 levels with Visfatin, inflammation, and acute coronary syndromes." +circulation_biomarker_diagnosis_ns hsa-mir-150 "Carcinoma, Colon" 27798914 "miR-21, miR-221 and miR-150 Are Deregulated in Peripheral Blood of Patients with Colorectal Cancer." +circulation_biomarker_diagnosis_ns hsa-mir-21 "Carcinoma, Colon" 27798914 "miR-21, miR-221 and miR-150 Are Deregulated in Peripheral Blood of Patients with Colorectal Cancer." +circulation_biomarker_diagnosis_ns hsa-mir-221 "Carcinoma, Colon" 27798914 "miR-21, miR-221 and miR-150 Are Deregulated in Peripheral Blood of Patients with Colorectal Cancer." +circulation_biomarker_diagnosis_ns hsa-mir-15a "Squamous Cell Carcinoma, Esophageal" 27802201 Serum microRNA-15a level acts as a potential diagnostic and prognostic biomarker for human esophageal squamous cell carcinoma. +circulation_biomarker_diagnosis_ns hsa-mir-106a "Carcinoma, Renal Cell" 27814278 Functional analysis of serum microRNAs miR-21 and miR-106a in renal cell carcinoma. +circulation_biomarker_diagnosis_ns hsa-mir-21 "Carcinoma, Renal Cell" 27814278 Functional analysis of serum microRNAs miR-21 and miR-106a in renal cell carcinoma. +circulation_biomarker_diagnosis_ns hsa-mir-181a Systemic Lupus Erythematosus 27816459 "MicroRNA-21, microRNA-181a and microRNA-196a as potential biomarkers in adult Egyptian patients with systemic lupus erythematosus." +circulation_biomarker_diagnosis_ns hsa-mir-196a Systemic Lupus Erythematosus 27816459 "MicroRNA-21, microRNA-181a and microRNA-196a as potential biomarkers in adult Egyptian patients with systemic lupus erythematosus." +circulation_biomarker_diagnosis_ns hsa-mir-21 Systemic Lupus Erythematosus 27816459 "MicroRNA-21, microRNA-181a and microRNA-196a as potential biomarkers in adult Egyptian patients with systemic lupus erythematosus." +circulation_biomarker_diagnosis_ns hsa-mir-143 Mesial Temporal Lobe Epilepsy 27833019 Changes in serum miRNAs following generalized convulsive seizures in human mesial temporal lobe epilepsy. +circulation_biomarker_diagnosis_ns hsa-mir-145 Mesial Temporal Lobe Epilepsy 27833019 Changes in serum miRNAs following generalized convulsive seizures in human mesial temporal lobe epilepsy. +circulation_biomarker_diagnosis_ns hsa-mir-365a Mesial Temporal Lobe Epilepsy 27833019 Changes in serum miRNAs following generalized convulsive seizures in human mesial temporal lobe epilepsy. +circulation_biomarker_diagnosis_ns hsa-mir-532 Mesial Temporal Lobe Epilepsy 27833019 Changes in serum miRNAs following generalized convulsive seizures in human mesial temporal lobe epilepsy. +circulation_biomarker_diagnosis_ns hsa-mir-663b Mesial Temporal Lobe Epilepsy 27833019 Changes in serum miRNAs following generalized convulsive seizures in human mesial temporal lobe epilepsy. +circulation_biomarker_diagnosis_ns hsa-mir-221 Systemic Lupus Erythematosus 27835701 High-Throughput Sequencing Reveals Circulating miRNAs as Potential Biomarkers of Kidney Damage in Patients with Systemic Lupus Erythematosus. +circulation_biomarker_diagnosis_ns hsa-mir-3074 Systemic Lupus Erythematosus 27835701 High-Throughput Sequencing Reveals Circulating miRNAs as Potential Biomarkers of Kidney Damage in Patients with Systemic Lupus Erythematosus. +circulation_biomarker_diagnosis_ns hsa-mir-380 Systemic Lupus Erythematosus 27835701 High-Throughput Sequencing Reveals Circulating miRNAs as Potential Biomarkers of Kidney Damage in Patients with Systemic Lupus Erythematosus. +circulation_biomarker_diagnosis_ns hsa-mir-556 Systemic Lupus Erythematosus 27835701 High-Throughput Sequencing Reveals Circulating miRNAs as Potential Biomarkers of Kidney Damage in Patients with Systemic Lupus Erythematosus. +circulation_biomarker_diagnosis_ns hsa-mir-758 Systemic Lupus Erythematosus 27835701 High-Throughput Sequencing Reveals Circulating miRNAs as Potential Biomarkers of Kidney Damage in Patients with Systemic Lupus Erythematosus. +circulation_biomarker_diagnosis_ns hsa-mir-106b Epilepsy 27840934 Identification of serum miRNAs differentially expressed in human epilepsy at seizure onset and post-seizure. +circulation_biomarker_diagnosis_ns hsa-mir-15a Epilepsy 27840934 Identification of serum miRNAs differentially expressed in human epilepsy at seizure onset and post-seizure. +circulation_biomarker_diagnosis_ns hsa-mir-30a Epilepsy 27840934 Identification of serum miRNAs differentially expressed in human epilepsy at seizure onset and post-seizure. +circulation_biomarker_diagnosis_ns hsa-mir-378 Epilepsy 27840934 Identification of serum miRNAs differentially expressed in human epilepsy at seizure onset and post-seizure. +circulation_biomarker_diagnosis_ns hsa-mir-16 Acute Cerebral Infarction 27846323 "Plasma MicroRNA-16 Is a Biomarker for Diagnosis, Stratification, and Prognosis of Hyperacute Cerebral Infarction." +circulation_biomarker_diagnosis_ns hsa-mir-1266 Atrial Fibrillation 27855199 The Values of Coronary Circulating miRNAs in Patients with Atrial Fibrillation. +circulation_biomarker_diagnosis_ns hsa-mir-3149 Atrial Fibrillation 27855199 The Values of Coronary Circulating miRNAs in Patients with Atrial Fibrillation. +circulation_biomarker_diagnosis_ns hsa-mir-3171 Atrial Fibrillation 27855199 The Values of Coronary Circulating miRNAs in Patients with Atrial Fibrillation. +circulation_biomarker_diagnosis_ns hsa-mir-4279 Atrial Fibrillation 27855199 The Values of Coronary Circulating miRNAs in Patients with Atrial Fibrillation. +circulation_biomarker_diagnosis_ns hsa-mir-4666a Atrial Fibrillation 27855199 The Values of Coronary Circulating miRNAs in Patients with Atrial Fibrillation. +circulation_biomarker_diagnosis_ns hsa-mir-892a Atrial Fibrillation 27855199 The Values of Coronary Circulating miRNAs in Patients with Atrial Fibrillation. +circulation_biomarker_diagnosis_ns hsa-mir-222 Neoplasms [unspecific] 27859748 Use of Serum MicroRNAs as Biomarker for Hepatobiliary Diseases in Dogs. +circulation_biomarker_diagnosis_ns hsa-mir-126 "Diabetes Mellitus, Type 2" 27869909 Altered levels of circulating cytokines and microRNAs in lean and obese individuals with prediabetes and type 2 diabetes. +circulation_biomarker_diagnosis_ns hsa-mir-146a "Diabetes Mellitus, Type 2" 27869909 Altered levels of circulating cytokines and microRNAs in lean and obese individuals with prediabetes and type 2 diabetes. +circulation_biomarker_diagnosis_ns hsa-mir-148 "Diabetes Mellitus, Type 2" 27869909 Altered levels of circulating cytokines and microRNAs in lean and obese individuals with prediabetes and type 2 diabetes. +circulation_biomarker_diagnosis_ns hsa-mir-150 "Diabetes Mellitus, Type 2" 27869909 Altered levels of circulating cytokines and microRNAs in lean and obese individuals with prediabetes and type 2 diabetes. +circulation_biomarker_diagnosis_ns hsa-mir-155 "Diabetes Mellitus, Type 2" 27869909 Altered levels of circulating cytokines and microRNAs in lean and obese individuals with prediabetes and type 2 diabetes. +circulation_biomarker_diagnosis_ns hsa-mir-21 "Diabetes Mellitus, Type 2" 27869909 Altered levels of circulating cytokines and microRNAs in lean and obese individuals with prediabetes and type 2 diabetes. +circulation_biomarker_diagnosis_ns hsa-mir-223 "Diabetes Mellitus, Type 2" 27869909 Altered levels of circulating cytokines and microRNAs in lean and obese individuals with prediabetes and type 2 diabetes. +circulation_biomarker_diagnosis_ns hsa-mir-24 "Diabetes Mellitus, Type 2" 27869909 Altered levels of circulating cytokines and microRNAs in lean and obese individuals with prediabetes and type 2 diabetes. +circulation_biomarker_diagnosis_ns hsa-mir-27a "Diabetes Mellitus, Type 2" 27869909 Altered levels of circulating cytokines and microRNAs in lean and obese individuals with prediabetes and type 2 diabetes. +circulation_biomarker_diagnosis_ns hsa-mir-28 "Diabetes Mellitus, Type 2" 27869909 Altered levels of circulating cytokines and microRNAs in lean and obese individuals with prediabetes and type 2 diabetes. +circulation_biomarker_diagnosis_ns hsa-mir-29b "Diabetes Mellitus, Type 2" 27869909 Altered levels of circulating cytokines and microRNAs in lean and obese individuals with prediabetes and type 2 diabetes. +circulation_biomarker_diagnosis_ns hsa-mir-30d "Diabetes Mellitus, Type 2" 27869909 Altered levels of circulating cytokines and microRNAs in lean and obese individuals with prediabetes and type 2 diabetes. +circulation_biomarker_diagnosis_ns hsa-mir-34a "Diabetes Mellitus, Type 2" 27869909 Altered levels of circulating cytokines and microRNAs in lean and obese individuals with prediabetes and type 2 diabetes. +circulation_biomarker_diagnosis_ns hsa-mir-93 "Diabetes Mellitus, Type 2" 27869909 Altered levels of circulating cytokines and microRNAs in lean and obese individuals with prediabetes and type 2 diabetes. +circulation_biomarker_diagnosis_ns hsa-mir-155 "Carcinoma, Colon" 27872469 Preoperative Serum MicroRNA-155 Expression Independently Predicts Postoperative Cognitive Dysfunction After Laparoscopic Surgery for Colon Cancer. +circulation_biomarker_diagnosis_ns hsa-mir-34a "Carcinoma, Hepatocellular" 27893432 MicroRNA-34a expression levels in serum and intratumoral tissue can predict bone metastasis in patients with hepatocellular carcinoma. +circulation_biomarker_diagnosis_ns hsa-mir-126 Arteriosclerosis Obliterans 27900989 Negative Association of Circulating MicroRNA-126 with High-sensitive C-reactive Protein and Vascular Cell Adhesion Molecule-1 in Patients with Coronary Artery Disease Following Percutaneous Coronary Intervention. +circulation_biomarker_diagnosis_ns hsa-mir-103 "Carcinoma, Gastric" 27909811 "Plasma microRNA-103, microRNA-107, and microRNA-194 levels are not biomarkers for human diffuse gastric cancer." +circulation_biomarker_diagnosis_ns hsa-mir-107 "Carcinoma, Gastric" 27909811 "Plasma microRNA-103, microRNA-107, and microRNA-194 levels are not biomarkers for human diffuse gastric cancer." +circulation_biomarker_diagnosis_ns hsa-mir-194 "Carcinoma, Gastric" 27909811 "Plasma microRNA-103, microRNA-107, and microRNA-194 levels are not biomarkers for human diffuse gastric cancer." +circulation_biomarker_diagnosis_ns hsa-mir-21 "Carcinoma, Colon" 27910062 Plasma and saliva miR-21 expression in colorectal cancer patients. +circulation_biomarker_diagnosis_ns hsa-mir-21 Osteosarcoma 27922432 miR-21 predicts poor prognosis in patients with osteosarcoma. +circulation_biomarker_diagnosis_ns hsa-mir-133 Cardiomyopathy 27922664 Expression of Bcl-2 and microRNAs in cardiac tissues of patients with dilated cardiomyopathy. +circulation_biomarker_diagnosis_ns hsa-mir-133a Cardiomyopathy 27922664 Expression of Bcl-2 and microRNAs in cardiac tissues of patients with dilated cardiomyopathy. +circulation_biomarker_diagnosis_ns hsa-mir-133b Cardiomyopathy 27922664 Expression of Bcl-2 and microRNAs in cardiac tissues of patients with dilated cardiomyopathy. +circulation_biomarker_diagnosis_ns hsa-mir-21 Cardiomyopathy 27922664 Expression of Bcl-2 and microRNAs in cardiac tissues of patients with dilated cardiomyopathy. +circulation_biomarker_diagnosis_ns hsa-mir-29 Cardiomyopathy 27922664 Expression of Bcl-2 and microRNAs in cardiac tissues of patients with dilated cardiomyopathy. +circulation_biomarker_diagnosis_ns hsa-mir-29a Cardiomyopathy 27922664 Expression of Bcl-2 and microRNAs in cardiac tissues of patients with dilated cardiomyopathy. +circulation_biomarker_diagnosis_ns hsa-mir-29b Cardiomyopathy 27922664 Expression of Bcl-2 and microRNAs in cardiac tissues of patients with dilated cardiomyopathy. +circulation_biomarker_diagnosis_ns hsa-mir-29c Cardiomyopathy 27922664 Expression of Bcl-2 and microRNAs in cardiac tissues of patients with dilated cardiomyopathy. +circulation_biomarker_diagnosis_ns hsa-mir-126 Cardiovascular Diseases [unspecific] 27924211 Circulating miR-126 and miR-499 reflect progression of cardiovascular disease; correlations with uric acid and ejection fraction. +circulation_biomarker_diagnosis_ns hsa-mir-122 "Fatty Liver, Non-Alcoholic" 27955628 Analysis of association between circulating miR-122 and histopathological features of nonalcoholic fatty liver disease in patients free of hepatocellular carcinoma. +circulation_biomarker_diagnosis_ns hsa-mir-34a "Fatty Liver, Non-Alcoholic" 27956809 Disease-specific miR-34a as diagnostic marker of non-alcoholic steatohepatitis in a Chinese population. +circulation_biomarker_diagnosis_ns hsa-mir-21 Ischemia-Reperfusion Injury 27979484 MicroRNA-125b as a new potential biomarker on diagnosis of renal ischemia-reperfusion injury. +circulation_biomarker_diagnosis_ns hsa-mir-199a Glioma 27981547 Circulating miR-199a-3p in plasma and its potential diagnostic and prognostic value in glioma. +circulation_biomarker_diagnosis_ns hsa-mir-125 "Carcinoma, Gastric" 27986464 Circular RNA profile identifies circPVT1 as a proliferative factor and prognostic marker in gastric cancer. +circulation_biomarker_diagnosis_ns hsa-mir-125b "Lymphoma, Burkitt" 27991481 "Circulating MicroRNA-21, MicroRNA-23a, and MicroRNA-125b as Biomarkers for Diagnosis and Prognosis of Burkitt Lymphoma in Children." +circulation_biomarker_diagnosis_ns hsa-mir-21 "Lymphoma, Burkitt" 27991481 "Circulating MicroRNA-21, MicroRNA-23a, and MicroRNA-125b as Biomarkers for Diagnosis and Prognosis of Burkitt Lymphoma in Children." +circulation_biomarker_diagnosis_ns hsa-mir-23a "Lymphoma, Burkitt" 27991481 "Circulating MicroRNA-21, MicroRNA-23a, and MicroRNA-125b as Biomarkers for Diagnosis and Prognosis of Burkitt Lymphoma in Children." +circulation_biomarker_diagnosis_ns hsa-mir-29a Atherosclerosis 27997904 The Relationship of Plasma miR-29a and Oxidized Low Density Lipoprotein with Atherosclerosis. +circulation_biomarker_diagnosis_ns hsa-mir-181a Acute Myocardial Infarction 27997916 Circulating miR-181a as a Potential Novel Biomarker for Diagnosis of Acute Myocardial Infarction. +circulation_biomarker_diagnosis_ns hsa-mir-135a Colorectal Carcinoma 27998467 Expression and significance of serum microRNA-135a-5p level in colorectal cancer. +circulation_biomarker_diagnosis_ns hsa-mir-155 "Carcinoma, Lung, Non-Small-Cell" 28002496 "a combination of miRs 21, 205, 155 and possibly other miRs as serum biomarkers for early detection of NSCLC" +circulation_biomarker_diagnosis_ns hsa-mir-205 "Carcinoma, Lung, Non-Small-Cell" 28002496 "a combination of miRs 21, 205, 155 and possibly other miRs as serum biomarkers for early detection of NSCLC" +circulation_biomarker_diagnosis_ns hsa-mir-21 "Carcinoma, Lung, Non-Small-Cell" 28002496 "a combination of miRs 21, 205, 155 and possibly other miRs as serum biomarkers for early detection of NSCLC" +circulation_biomarker_diagnosis_ns hsa-mir-1246 "Carcinoma, Ovarian, Serous" 28017893 Circulating miRNA landscape identifies miR-1246 as promising diagnostic biomarker in high-grade serous ovarian carcinoma: A validation across two independent cohorts. +circulation_biomarker_diagnosis_ns hsa-mir-375 "Squamous Cell Carcinoma, Oral" 28030794 Circulating miRNAs as biomarkers for oral squamous cell carcinoma recurrence in operated patients. +circulation_biomarker_diagnosis_ns hsa-mir-10b "Carcinoma, Hepatocellular" 28049231 An Explorative Analysis for the Role of Serum miR-10b-3p Levels in Predicting Response to Sorafenib in Patients with Advanced Hepatocellular Carcinoma. +circulation_biomarker_diagnosis_ns hsa-mir-1 Lofgren Syndrome 28050119 The Serum Expression of Selected miRNAs in Pulmonary Sarcoidosis with/without L?fgren's Syndrome. +circulation_biomarker_diagnosis_ns hsa-mir-146 Lofgren Syndrome 28050119 The Serum Expression of Selected miRNAs in Pulmonary Sarcoidosis with/without L?fgren's Syndrome. +circulation_biomarker_diagnosis_ns hsa-mir-150 Lofgren Syndrome 28050119 The Serum Expression of Selected miRNAs in Pulmonary Sarcoidosis with/without L?fgren's Syndrome. +circulation_biomarker_diagnosis_ns hsa-mir-16 Lofgren Syndrome 28050119 The Serum Expression of Selected miRNAs in Pulmonary Sarcoidosis with/without L?fgren's Syndrome. +circulation_biomarker_diagnosis_ns hsa-mir-21 Lofgren Syndrome 28050119 The Serum Expression of Selected miRNAs in Pulmonary Sarcoidosis with/without L?fgren's Syndrome. +circulation_biomarker_diagnosis_ns hsa-mir-212 Lofgren Syndrome 28050119 The Serum Expression of Selected miRNAs in Pulmonary Sarcoidosis with/without L?fgren's Syndrome. +circulation_biomarker_diagnosis_ns hsa-mir-340 Lofgren Syndrome 28050119 The Serum Expression of Selected miRNAs in Pulmonary Sarcoidosis with/without L?fgren's Syndrome. +circulation_biomarker_diagnosis_ns hsa-mir-425 Lofgren Syndrome 28050119 The Serum Expression of Selected miRNAs in Pulmonary Sarcoidosis with/without L?fgren's Syndrome. +circulation_biomarker_diagnosis_ns hsa-mir-93 Lofgren Syndrome 28050119 The Serum Expression of Selected miRNAs in Pulmonary Sarcoidosis with/without L?fgren's Syndrome. +circulation_biomarker_diagnosis_ns hsa-mir-145 Acute Myocardial Infarction 28051023 Circulating MicroRNA-145 is Associated with Acute Myocardial Infarction and Heart Failure. +circulation_biomarker_diagnosis_ns hsa-mir-99a Acute Myocardial Infarction 28051249 The clinical value of circulating miR-99a in plasma of patients with acute myocardial infarction. +circulation_biomarker_diagnosis_ns hsa-mir-378 "Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal" 28051256 Expression of serum microRNA-378 and its clinical significance in laryngeal squamous cell carcinoma. +circulation_biomarker_diagnosis_ns hsa-mir-1 Heart Failure 28052002 Circulating miR-1 as a potential biomarker of doxorubicin-induced cardiotoxicity in breast cancer patients. +circulation_biomarker_diagnosis_ns hsa-mir-10b "Carcinoma, Lung, Non-Small-Cell" 28055956 Circulating exosomal microRNAs as prognostic biomarkers for non-small-cell lung cancer. +circulation_biomarker_diagnosis_ns hsa-mir-21 "Carcinoma, Lung, Non-Small-Cell" 28055956 Circulating exosomal microRNAs as prognostic biomarkers for non-small-cell lung cancer. +circulation_biomarker_diagnosis_ns hsa-mir-23b "Carcinoma, Lung, Non-Small-Cell" 28055956 Circulating exosomal microRNAs as prognostic biomarkers for non-small-cell lung cancer. +circulation_biomarker_diagnosis_ns hsa-mir-192 Kidney Injury 28056546 Urinary MicroRNA-30c-5p and MicroRNA-192-5p as potential biomarkers of ischemia-reperfusion-induced kidney injury. +circulation_biomarker_diagnosis_ns hsa-mir-30c Kidney Injury 28056546 Urinary MicroRNA-30c-5p and MicroRNA-192-5p as potential biomarkers of ischemia-reperfusion-induced kidney injury. +circulation_biomarker_diagnosis_ns hsa-mir-132 "Carcinoma, Breast" 28058628 A pilot study on plasma levels of micro-RNAs involved in angiogenesis and vascular maturation in patients with breast cancer. +circulation_biomarker_diagnosis_ns hsa-mir-221 "Carcinoma, Breast" 28058628 A pilot study on plasma levels of micro-RNAs involved in angiogenesis and vascular maturation in patients with breast cancer. +circulation_biomarker_diagnosis_ns hsa-mir-27b "Carcinoma, Breast" 28058628 A pilot study on plasma levels of micro-RNAs involved in angiogenesis and vascular maturation in patients with breast cancer. +circulation_biomarker_diagnosis_ns hsa-mir-221 "Carcinoma, Thyroid, Papillary" 28061868 "MiR-221, a potential prognostic biomarker for recurrence in papillary thyroid cancer." +circulation_biomarker_diagnosis_ns hsa-mir-122 Liver Diseases [unspecific] 28070111 "circulating liver-specific miR-122 and miR-192 levels also increased 24 hr or later compared with ALT, suggesting that circulating miR-122 and miR-192 may serve as potential biomarkers to detect hepatotoxicity in cynomolgus monkeys" +circulation_biomarker_diagnosis_ns hsa-mir-192 Liver Diseases [unspecific] 28070111 "circulating liver-specific miR-122 and miR-192 levels also increased 24 hr or later compared with ALT, suggesting that circulating miR-122 and miR-192 may serve as potential biomarkers to detect hepatotoxicity in cynomolgus monkeys" +circulation_biomarker_diagnosis_ns hsa-let-7a Chronic Kidney Disease 28077372 "miRNA are associated with kidney fibrosis, and specific urinary and plasma miRNA profile may have diagnostic and prognostic utility in CKD" +circulation_biomarker_diagnosis_ns hsa-mir-1281 Chronic Kidney Disease 28077372 "miRNA are associated with kidney fibrosis, and specific urinary and plasma miRNA profile may have diagnostic and prognostic utility in CKD" +circulation_biomarker_diagnosis_ns hsa-mir-130a Chronic Kidney Disease 28077372 "miRNA are associated with kidney fibrosis, and specific urinary and plasma miRNA profile may have diagnostic and prognostic utility in CKD" +circulation_biomarker_diagnosis_ns hsa-mir-1825 Chronic Kidney Disease 28077372 "miRNA are associated with kidney fibrosis, and specific urinary and plasma miRNA profile may have diagnostic and prognostic utility in CKD" +circulation_biomarker_diagnosis_ns hsa-mir-423 Chronic Kidney Disease 28077372 "miRNA are associated with kidney fibrosis, and specific urinary and plasma miRNA profile may have diagnostic and prognostic utility in CKD" +circulation_biomarker_diagnosis_ns hsa-mir-21 "Carcinoma, Breast, Triple Negative" 28078851 Mechanism of serum miR-21 in the pathogenesis of familial and triple negative breast cancer. +circulation_biomarker_diagnosis_ns hsa-mir-107 "Carcinoma, Hepatocellular" 28079796 Serum microRNA panel for early diagnosis of the onset of hepatocellular carcinoma. +circulation_biomarker_diagnosis_ns hsa-mir-16 "Carcinoma, Hepatocellular" 28079796 Serum microRNA panel for early diagnosis of the onset of hepatocellular carcinoma. +circulation_biomarker_diagnosis_ns hsa-mir-3126 "Carcinoma, Hepatocellular" 28079796 Serum microRNA panel for early diagnosis of the onset of hepatocellular carcinoma. +circulation_biomarker_diagnosis_ns hsa-mir-92 "Carcinoma, Hepatocellular" 28079796 Serum microRNA panel for early diagnosis of the onset of hepatocellular carcinoma. +circulation_biomarker_diagnosis_ns hsa-mir-19b "Carcinoma, Prostate" 28091918 Changes in the Level of Circulating hsa-miR-297 and hsa-miR-19b-3p miRNA Are Associated with Generalization of Prostate Cancer. +circulation_biomarker_diagnosis_ns hsa-mir-297 "Carcinoma, Prostate" 28091918 Changes in the Level of Circulating hsa-miR-297 and hsa-miR-19b-3p miRNA Are Associated with Generalization of Prostate Cancer. +circulation_biomarker_diagnosis_ns hsa-mir-196a "Squamous Cell Carcinoma, Esophageal" 28095062 MicroRNA-196a as a Potential Diagnostic Biomarker for Esophageal Squamous Cell Carcinoma. +circulation_biomarker_diagnosis_ns hsa-mir-92a "Carcinoma, Lung, Small-Cell" 28106539 Plasma miR-92a-2 as a biomarker for small cell lung cancer. +circulation_biomarker_diagnosis_ns hsa-mir-142 Traumatic Brain Injury 28117263 Plasma micro-RNA biomarkers for diagnosis and prognosis after traumatic brain injury: A pilot study. +circulation_biomarker_diagnosis_ns hsa-mir-423 Traumatic Brain Injury 28117263 Plasma micro-RNA biomarkers for diagnosis and prognosis after traumatic brain injury: A pilot study. +circulation_biomarker_diagnosis_ns hsa-mir-21 "Carcinoma, Gastric" 28121346 miR-21 can be used for the diagnosis of gastric cancer and prognosis of lymph node metastasis in gastric cancer +circulation_biomarker_diagnosis_ns hsa-mir-222 "Adenocarcinoma, Lung" 28123597 Identification of A Panel of Serum microRNAs as Biomarkers for Early Detection of Lung Adenocarcinoma. +circulation_biomarker_diagnosis_ns hsa-mir-223 "Adenocarcinoma, Lung" 28123597 Identification of A Panel of Serum microRNAs as Biomarkers for Early Detection of Lung Adenocarcinoma. +circulation_biomarker_diagnosis_ns hsa-mir-208b Myocardial Infarction 28164501 Circulating miR-208b: A Potentially Sensitive and Reliable Biomarker for the Diagnosis and Prognosis of Acute Myocardial Infarction. +circulation_biomarker_diagnosis_ns hsa-mir-146a Sepsis 28164567 The Prognostic Value of Plasma MicroRNA-155 and MicroRNA-146a Level in Severe Sepsis and Sepsis-Induced Acute Lung Injury Patients. +circulation_biomarker_diagnosis_ns hsa-mir-155 Sepsis 28164567 The Prognostic Value of Plasma MicroRNA-155 and MicroRNA-146a Level in Severe Sepsis and Sepsis-Induced Acute Lung Injury Patients. +circulation_biomarker_diagnosis_ns hsa-mir-19a Colorectal Carcinoma 28177881 A panel of microRNA signature in serum for colorectal cancer diagnosis. +circulation_biomarker_diagnosis_ns hsa-mir-21 Colorectal Carcinoma 28177881 A panel of microRNA signature in serum for colorectal cancer diagnosis. +circulation_biomarker_diagnosis_ns hsa-mir-425 Colorectal Carcinoma 28177881 A panel of microRNA signature in serum for colorectal cancer diagnosis. +circulation_biomarker_diagnosis_ns hsa-mir-23a Polycystic Ovarian Syndrome 28193283 Circulatory microRNA 23a and microRNA 23b and polycystic ovary syndrome (PCOS): the effects of body mass index and sex hormones in an Eastern Han Chinese population. +circulation_biomarker_diagnosis_ns hsa-mir-23b Polycystic Ovarian Syndrome 28193283 Circulatory microRNA 23a and microRNA 23b and polycystic ovary syndrome (PCOS): the effects of body mass index and sex hormones in an Eastern Han Chinese population. +circulation_biomarker_diagnosis_ns hsa-mir-145 Coronary Artery Disease 28205634 "Circulating miR-155, miR-145 and let-7c as diagnostic biomarkers of the coronary artery disease." +circulation_biomarker_diagnosis_ns hsa-mir-122 Chronic Hepatitis C 28211229 Serum microRNAs as predictors for liver fibrosis staging in hepatitis C virus-associated chronic liver disease patients. +circulation_biomarker_diagnosis_ns hsa-mir-107 "Neuralgia, Postherpetic" 28225487 Comparing serum microRNA levels of acute herpes zoster patients with those of postherpetic neuralgia patients. +circulation_biomarker_diagnosis_ns hsa-mir-127 "Neuralgia, Postherpetic" 28225487 Comparing serum microRNA levels of acute herpes zoster patients with those of postherpetic neuralgia patients. +circulation_biomarker_diagnosis_ns hsa-mir-34c "Neuralgia, Postherpetic" 28225487 Comparing serum microRNA levels of acute herpes zoster patients with those of postherpetic neuralgia patients. +circulation_biomarker_diagnosis_ns hsa-mir-486 "Neuralgia, Postherpetic" 28225487 Comparing serum microRNA levels of acute herpes zoster patients with those of postherpetic neuralgia patients. +circulation_biomarker_diagnosis_ns hsa-mir-892b "Neuralgia, Postherpetic" 28225487 Comparing serum microRNA levels of acute herpes zoster patients with those of postherpetic neuralgia patients. +circulation_biomarker_diagnosis_ns hsa-let-7a "Carcinoma, Pancreatic" 28232049 A microRNA signature in circulating exosomes is superior to exosomal glypican-1 levels for diagnosing pancreatic cancer. +circulation_biomarker_diagnosis_ns hsa-mir-10b "Carcinoma, Pancreatic" 28232049 A microRNA signature in circulating exosomes is superior to exosomal glypican-1 levels for diagnosing pancreatic cancer. +circulation_biomarker_diagnosis_ns hsa-mir-181a "Carcinoma, Pancreatic" 28232049 A microRNA signature in circulating exosomes is superior to exosomal glypican-1 levels for diagnosing pancreatic cancer. +circulation_biomarker_diagnosis_ns hsa-mir-21 "Carcinoma, Pancreatic" 28232049 A microRNA signature in circulating exosomes is superior to exosomal glypican-1 levels for diagnosing pancreatic cancer. +circulation_biomarker_diagnosis_ns hsa-mir-30c "Carcinoma, Pancreatic" 28232049 A microRNA signature in circulating exosomes is superior to exosomal glypican-1 levels for diagnosing pancreatic cancer. +circulation_biomarker_diagnosis_ns hsa-mir-122 Hepatitis C Virus Infection 28232800 Circulating ECV-Associated miRNAs as Potential Clinical Biomarkers in Early Stage HBV and HCV Induced Liver Fibrosis. +circulation_biomarker_diagnosis_ns hsa-mir-200b Hepatitis C Virus Infection 28232800 Circulating ECV-Associated miRNAs as Potential Clinical Biomarkers in Early Stage HBV and HCV Induced Liver Fibrosis. +circulation_biomarker_diagnosis_ns hsa-mir-146b "Carcinoma, Bladder" 28239818 Identification of miR-146b-5p in tissues as a novel biomarker for prognosis of gallbladder carcinoma. +circulation_biomarker_diagnosis_ns hsa-mir-383 "Carcinoma, Gastric" 28243881 "The Value of MiR-383, an Intronic MiRNA, as a Diagnostic and Prognostic Biomarker in Intestinal-Type Gastric Cancer." +circulation_biomarker_diagnosis_ns hsa-mir-193a Focal Segmental Glomerulosclerosis 28246603 Urinary Exosomal miR-193a Can Be a Potential Biomarker for the Diagnosis of Primary Focal Segmental Glomerulosclerosis in Children. +circulation_biomarker_diagnosis_ns hsa-mir-126 "Carcinoma, Lung, Non-Small-Cell" 28253725 Predicative values of serum microRNA-22 and microRNA-126 levels for non-small cell lung cancer development and metastasis: a case-control study. +circulation_biomarker_diagnosis_ns hsa-mir-22 "Carcinoma, Lung, Non-Small-Cell" 28253725 Predicative values of serum microRNA-22 and microRNA-126 levels for non-small cell lung cancer development and metastasis: a case-control study. +circulation_biomarker_diagnosis_ns hsa-mir-144 "Diabetes Mellitus, Type 2" 28260062 Serum microRNA profiling and bioinformatics analysis of patients with type 2 diabetes mellitus in a Chinese population. +circulation_biomarker_diagnosis_ns hsa-mir-409 "Diabetes Mellitus, Type 2" 28260062 Serum microRNA profiling and bioinformatics analysis of patients with type 2 diabetes mellitus in a Chinese population. +circulation_biomarker_diagnosis_ns hsa-mir-454 "Diabetes Mellitus, Type 2" 28260062 Serum microRNA profiling and bioinformatics analysis of patients with type 2 diabetes mellitus in a Chinese population. +circulation_biomarker_diagnosis_ns hsa-mir-455 "Diabetes Mellitus, Type 2" 28260062 Serum microRNA profiling and bioinformatics analysis of patients with type 2 diabetes mellitus in a Chinese population. +circulation_biomarker_diagnosis_ns hsa-mir-665 "Diabetes Mellitus, Type 2" 28260062 Serum microRNA profiling and bioinformatics analysis of patients with type 2 diabetes mellitus in a Chinese population. +circulation_biomarker_diagnosis_ns hsa-mir-766 "Diabetes Mellitus, Type 2" 28260062 Serum microRNA profiling and bioinformatics analysis of patients with type 2 diabetes mellitus in a Chinese population. +circulation_biomarker_diagnosis_ns hsa-mir-96 "Diabetes Mellitus, Type 2" 28260062 Serum microRNA profiling and bioinformatics analysis of patients with type 2 diabetes mellitus in a Chinese population. +circulation_biomarker_diagnosis_ns hsa-mir-208b Acute Myocardial Infarction 28272696 A meta-analysis of the relations between blood microRNA-208b detection and acute myocardial infarction. +circulation_biomarker_diagnosis_ns hsa-mir-141 "Carcinoma, Thyroid, Papillary" 28288173 Microarray profiling of circular RNAs in human papillary thyroid carcinoma. +circulation_biomarker_diagnosis_ns hsa-mir-200a "Carcinoma, Thyroid, Papillary" 28288173 Microarray profiling of circular RNAs in human papillary thyroid carcinoma. +circulation_biomarker_diagnosis_ns hsa-mir-132 Mesothelioma 28321148 Circulating miR-132-3p as a Candidate Diagnostic Biomarker for Malignant Mesothelioma. +circulation_biomarker_diagnosis_ns hsa-mir-124 Acute Myocardial Infarction 28338188 Implication of peripheral blood miRNA-124 in predicting acute myocardial infarction. +circulation_biomarker_diagnosis_ns hsa-mir-182 "Carcinoma, Breast" 28359916 Identification of microRNA biomarkers in the blood of breast cancer patients based on microRNA profiling. +circulation_biomarker_diagnosis_ns hsa-mir-30b "Carcinoma, Breast" 28359916 Identification of microRNA biomarkers in the blood of breast cancer patients based on microRNA profiling. +circulation_biomarker_diagnosis_ns hsa-mir-374b "Carcinoma, Breast" 28359916 Identification of microRNA biomarkers in the blood of breast cancer patients based on microRNA profiling. +circulation_biomarker_diagnosis_ns hsa-mir-942 "Carcinoma, Breast" 28359916 Identification of microRNA biomarkers in the blood of breast cancer patients based on microRNA profiling. +circulation_biomarker_diagnosis_ns hsa-mir-96 "Carcinoma, Breast" 28359916 Identification of microRNA biomarkers in the blood of breast cancer patients based on microRNA profiling. +circulation_biomarker_diagnosis_ns hsa-mir-21 "Carcinoma, Colon" 28376502 Circulating Exosomal MicroRNA-21 as a Biomarker in Each Tumor Stage of Colorectal Cancer. +circulation_biomarker_diagnosis_ns hsa-mir-126 Cardiovascular Diseases [unspecific] 28379027 Regulatory RNAs and cardiovascular disease - with a special focus on circulating microRNAs. +circulation_biomarker_diagnosis_ns hsa-mir-143 Cardiovascular Diseases [unspecific] 28379027 Regulatory RNAs and cardiovascular disease - with a special focus on circulating microRNAs. +circulation_biomarker_diagnosis_ns hsa-mir-145 Cardiovascular Diseases [unspecific] 28379027 Regulatory RNAs and cardiovascular disease - with a special focus on circulating microRNAs. +circulation_biomarker_diagnosis_ns hsa-mir-221 Cardiovascular Diseases [unspecific] 28379027 Regulatory RNAs and cardiovascular disease - with a special focus on circulating microRNAs. +circulation_biomarker_diagnosis_ns hsa-mir-222 Cardiovascular Diseases [unspecific] 28379027 Regulatory RNAs and cardiovascular disease - with a special focus on circulating microRNAs. +circulation_biomarker_diagnosis_ns hsa-mir-26 Cardiovascular Diseases [unspecific] 28379027 Regulatory RNAs and cardiovascular disease - with a special focus on circulating microRNAs. +circulation_biomarker_diagnosis_ns hsa-mir-33 Cardiovascular Diseases [unspecific] 28379027 Regulatory RNAs and cardiovascular disease - with a special focus on circulating microRNAs. +circulation_biomarker_diagnosis_ns hsa-mir-758 Cardiovascular Diseases [unspecific] 28379027 Regulatory RNAs and cardiovascular disease - with a special focus on circulating microRNAs. +circulation_biomarker_diagnosis_ns hsa-mir-221 Glioblastoma 28381184 "microRNA expression levels was built, which has the potential to be used in clinics and thus to improve the survival status of glioblastoma multiforme patients" +circulation_biomarker_diagnosis_ns hsa-mir-222 Glioblastoma 28381184 "microRNA expression levels was built, which has the potential to be used in clinics and thus to improve the survival status of glioblastoma multiforme patients" +circulation_biomarker_diagnosis_ns hsa-mir-134 Mesial Temporal Lobe Epilepsy 28384161 MicroRNA hsa-miR-134 is a circulating biomarker for mesial temporal lobe epilepsy. +circulation_biomarker_diagnosis_ns hsa-mir-31 Foot-and-Mouth Disease 28388926 Proof-of-concept study: profile of circulating microRNAs in Bovine serum harvested during acute and persistent FMDV infection. +circulation_biomarker_diagnosis_ns hsa-mir-20a Gastric Neoplasms 28413641 Serum miR-20a is a promising biomarker for gastric cancer. +circulation_biomarker_diagnosis_ns hsa-let-7g Colon Neoplasms 28415718 Exosomal microRNAs isolated from plasma of mesenteric veins linked to liver metastases in resected patients with colon cancer. +circulation_biomarker_diagnosis_ns hsa-mir-155 Colon Neoplasms 28415718 Exosomal microRNAs isolated from plasma of mesenteric veins linked to liver metastases in resected patients with colon cancer. +circulation_biomarker_diagnosis_ns hsa-mir-126 "Aortic Aneurysm, Abdominal" 28425970 Aneurysm-Specific miR-221 and miR-146a Participates in Human Thoracic and Abdominal Aortic Aneurysms. +circulation_biomarker_diagnosis_ns hsa-mir-145 "Aortic Aneurysm, Abdominal" 28425970 Aneurysm-Specific miR-221 and miR-146a Participates in Human Thoracic and Abdominal Aortic Aneurysms. +circulation_biomarker_diagnosis_ns hsa-mir-361 Essential Hypertension 28445253 micro-RNA screening and prediction model construction for diagnosis of salt-sensitive essential hypertension. +circulation_biomarker_diagnosis_ns hsa-mir-362 Essential Hypertension 28445253 micro-RNA screening and prediction model construction for diagnosis of salt-sensitive essential hypertension. +circulation_biomarker_diagnosis_ns hsa-mir-16 Multiple Myeloma 28446295 Circulating Serum MicroRNA as Diagnostic Biomarkers for Multiple Myeloma. +circulation_biomarker_diagnosis_ns hsa-mir-375 "Adenocarcinoma, Lung" 28449331 miR-130A as a diagnostic marker to differentiate malignant mesothelioma from lung adenocarcinoma in pleural effusion cytology. +circulation_biomarker_diagnosis_ns hsa-mir-196a Pancreatic Adenocarcinoma 28466015 "Evaluation of Plasma MicroRNAs as Diagnostic and Prognostic Biomarkers in Pancreatic Adenocarcinoma: miR-196a and miR-210 Could Be Negative and Positive Prognostic Markers, Respectively." +circulation_biomarker_diagnosis_ns hsa-mir-210 Pancreatic Adenocarcinoma 28466015 "Evaluation of Plasma MicroRNAs as Diagnostic and Prognostic Biomarkers in Pancreatic Adenocarcinoma: miR-196a and miR-210 Could Be Negative and Positive Prognostic Markers, Respectively." +circulation_biomarker_diagnosis_ns hsa-mir-149 Cutaneous Melanoma 28466785 Identification of plasma microRNAs as new potential biomarkers with high diagnostic power in human cutaneous melanoma. +circulation_biomarker_diagnosis_ns hsa-mir-150 Cutaneous Melanoma 28466785 Identification of plasma microRNAs as new potential biomarkers with high diagnostic power in human cutaneous melanoma. +circulation_biomarker_diagnosis_ns hsa-mir-15b Cutaneous Melanoma 28466785 Identification of plasma microRNAs as new potential biomarkers with high diagnostic power in human cutaneous melanoma. +circulation_biomarker_diagnosis_ns hsa-mir-193a Cutaneous Melanoma 28466785 Identification of plasma microRNAs as new potential biomarkers with high diagnostic power in human cutaneous melanoma. +circulation_biomarker_diagnosis_ns hsa-mir-524 Cutaneous Melanoma 28466785 Identification of plasma microRNAs as new potential biomarkers with high diagnostic power in human cutaneous melanoma. +circulation_biomarker_diagnosis_ns hsa-mir-873 Ectopic Pregnancy 28472791 MicroRNA-873 is a Potential Serum Biomarker for the Detection of Ectopic Pregnancy. +circulation_biomarker_diagnosis_ns hsa-mir-1825 Glioma 28475008 A novel serum microRNA-based identification and classification biomarker of human glioma. +circulation_biomarker_diagnosis_ns hsa-mir-27a Heart Failure 28475616 Rodent heart failure models do not reflect the human circulating microRNA signature in heart failure. +circulation_biomarker_diagnosis_ns hsa-mir-125b Kidney Diseases [unspecific] 28522697 Circulating MicroRNA-125b Predicts the Presence and Progression of Uremic Vascular Calcification. +circulation_biomarker_diagnosis_ns hsa-mir-146a Sepsis 28552958 Characterization of basal and lipopolysaccharide-induced microRNA expression in equine peripheral blood mononuclear cells using Next-Generation Sequencing. +circulation_biomarker_diagnosis_ns hsa-mir-155 Sepsis 28552958 Characterization of basal and lipopolysaccharide-induced microRNA expression in equine peripheral blood mononuclear cells using Next-Generation Sequencing. +circulation_biomarker_diagnosis_ns hsa-mir-206 Pulmonary Hypertension 28554172 The Circulating MicroRNA-206 Level Predicts the Severity of Pulmonary Hypertension in Patients with Left Heart Diseases. +circulation_biomarker_diagnosis_ns hsa-mir-210 Rheumatoid Arthritis 28560518 miR-210 expression in PBMCs from patients with systemic lupus erythematosus and rheumatoid arthritis. +circulation_biomarker_diagnosis_ns hsa-mir-210 Systemic Lupus Erythematosus 28560518 miR-210 expression in PBMCs from patients with systemic lupus erythematosus and rheumatoid arthritis. +circulation_biomarker_diagnosis_ns hsa-mir-182 Chronic Hepatitis B 28562750 Circulating microRNA as a marker for predicting liver disease progression in patients with chronic hepatitis B. +circulation_biomarker_diagnosis_ns hsa-mir-125a Kideny Transplant Rejection 28577875 "Circulating miR-150, miR-192, miR-200b, and miR-423-3p as Non-invasive Biomarkers of Chronic Allograft Dysfunction." +circulation_biomarker_diagnosis_ns hsa-mir-150 Kideny Transplant Rejection 28577875 "Circulating miR-150, miR-192, miR-200b, and miR-423-3p as Non-invasive Biomarkers of Chronic Allograft Dysfunction." +circulation_biomarker_diagnosis_ns hsa-mir-192 Kideny Transplant Rejection 28577875 "Circulating miR-150, miR-192, miR-200b, and miR-423-3p as Non-invasive Biomarkers of Chronic Allograft Dysfunction." +circulation_biomarker_diagnosis_ns hsa-mir-200b Kideny Transplant Rejection 28577875 "Circulating miR-150, miR-192, miR-200b, and miR-423-3p as Non-invasive Biomarkers of Chronic Allograft Dysfunction." +circulation_biomarker_diagnosis_ns hsa-mir-423 Kideny Transplant Rejection 28577875 "Circulating miR-150, miR-192, miR-200b, and miR-423-3p as Non-invasive Biomarkers of Chronic Allograft Dysfunction." +circulation_biomarker_diagnosis_ns hsa-mir-499 Myocardial Infarction 28614255 miRNA-499 had better diagnostic accuracy over other miRNAs +circulation_biomarker_diagnosis_ns hsa-mir-130a Coronary Artery Disease 28628920 "Predictive Effects of Circulating miR-221, miR-130a and miR-155 for Coronary Heart Disease: A Multi-Ethnic Study in China." +circulation_biomarker_diagnosis_ns hsa-mir-155 Coronary Artery Disease 28628920 "Predictive Effects of Circulating miR-221, miR-130a and miR-155 for Coronary Heart Disease: A Multi-Ethnic Study in China." +circulation_biomarker_diagnosis_ns hsa-mir-221 Coronary Artery Disease 28628920 "Predictive Effects of Circulating miR-221, miR-130a and miR-155 for Coronary Heart Disease: A Multi-Ethnic Study in China." +circulation_biomarker_diagnosis_ns hsa-mir-143 Hyperhomocysteinemia 28633641 Expression levels of atherosclerosis-associated miR-143 and miR-145 in the plasma of patients with hyperhomocysteinaemia. +circulation_biomarker_diagnosis_ns hsa-mir-145 Hyperhomocysteinemia 28633641 Expression levels of atherosclerosis-associated miR-143 and miR-145 in the plasma of patients with hyperhomocysteinaemia. +circulation_biomarker_diagnosis_ns hsa-mir-16 "Carcinoma, Lung, Non-Small-Cell" 28634901 "Changes in plasma miR-9, miR-16, miR-205 and miR-486 levels after non-small cell lung cancer resection." +circulation_biomarker_diagnosis_ns hsa-mir-205 "Carcinoma, Lung, Non-Small-Cell" 28634901 "Changes in plasma miR-9, miR-16, miR-205 and miR-486 levels after non-small cell lung cancer resection." +circulation_biomarker_diagnosis_ns hsa-mir-375 Neoplasms [unspecific] 28638226 Validation of a serum microRNA panel as biomarkers for early diagnosis of hepatocellular carcinoma post-hepatitis C infection in Egyptian patients. +circulation_biomarker_diagnosis_ns hsa-mir-21 "Carcinoma, Gastric" 28641313 Evaluation of serum microRNA biomarkers for gastric cancer based on blood and tissue pools profiling: the importance of miR-21 and miR-331. +circulation_biomarker_diagnosis_ns hsa-mir-331 "Carcinoma, Gastric" 28641313 Evaluation of serum microRNA biomarkers for gastric cancer based on blood and tissue pools profiling: the importance of miR-21 and miR-331. +circulation_biomarker_diagnosis_ns hsa-mir-146a Osteoarthritis 28647559 "miRNA-146a, miRNA-155 and JNK expression levels in peripheral blood mononuclear cells according to grade of knee osteoarthritis." +circulation_biomarker_diagnosis_ns hsa-mir-155 Osteoarthritis 28647559 "miRNA-146a, miRNA-155 and JNK expression levels in peripheral blood mononuclear cells according to grade of knee osteoarthritis." +circulation_biomarker_diagnosis_ns hsa-mir-1 Myocardial Infarction 28663047 Diagnostic and prognostic value of miR-1 and miR-29b on adverse ventricular remodeling after acute myocardial infarction +circulation_biomarker_diagnosis_ns hsa-mir-29b Myocardial Infarction 28663047 Diagnostic and prognostic value of miR-1 and miR-29b on adverse ventricular remodeling after acute myocardial infarction +circulation_biomarker_diagnosis_ns hsa-mir-133a Heart Failure 28666417 Identifying differential miR and gene consensus patterns in peripheral blood of patients with cardiovascular diseases from literature data. +circulation_biomarker_diagnosis_ns hsa-mir-155 Preeclampsia 28700503 MiR-210 and miR-155 as potential diagnostic markers for pre-eclampsia pregnancies. +circulation_biomarker_diagnosis_ns hsa-mir-210 Preeclampsia 28700503 MiR-210 and miR-155 as potential diagnostic markers for pre-eclampsia pregnancies. +circulation_biomarker_diagnosis_ns hsa-mir-21 Osteosarcoma 28742209 The expression significance of serum MiR-21 in patients with osteosarcoma and its relationship with chemosensitivity. +circulation_biomarker_diagnosis_ns hsa-mir-122 "Carcinoma, Hepatocellular" 28750770 Circulating microRNAs panel as a diagnostic tool for discrimination of HCV-associated hepatocellular carcinoma +circulation_biomarker_diagnosis_ns hsa-mir-122 Ischemic Heart Disease 28768728 "six miRNA mimics (miR-34a, -122, -133a, -142, -146a, and -208a) induced cytokine production in a dose-dependent manner" +circulation_biomarker_diagnosis_ns hsa-mir-133a Ischemic Heart Disease 28768728 "six miRNA mimics (miR-34a, -122, -133a, -142, -146a, and -208a) induced cytokine production in a dose-dependent manner" +circulation_biomarker_diagnosis_ns hsa-mir-142 Ischemic Heart Disease 28768728 "six miRNA mimics (miR-34a, -122, -133a, -142, -146a, and -208a) induced cytokine production in a dose-dependent manner" +circulation_biomarker_diagnosis_ns hsa-mir-146a Ischemic Heart Disease 28768728 "six miRNA mimics (miR-34a, -122, -133a, -142, -146a, and -208a) induced cytokine production in a dose-dependent manner" +circulation_biomarker_diagnosis_ns hsa-mir-208a Ischemic Heart Disease 28768728 "six miRNA mimics (miR-34a, -122, -133a, -142, -146a, and -208a) induced cytokine production in a dose-dependent manner" +circulation_biomarker_diagnosis_ns hsa-mir-34a Ischemic Heart Disease 28768728 "six miRNA mimics (miR-34a, -122, -133a, -142, -146a, and -208a) induced cytokine production in a dose-dependent manner" +circulation_biomarker_diagnosis_ns hsa-mir-155 Rheumatoid Arthritis 28782994 Serum miR-210 and miR-155 expression levels as novel biomarkers for rheumatoid arthritis diagnosis. +circulation_biomarker_diagnosis_ns hsa-mir-210 Rheumatoid Arthritis 28782994 Serum miR-210 and miR-155 expression levels as novel biomarkers for rheumatoid arthritis diagnosis. +circulation_biomarker_diagnosis_ns hsa-mir-33a Hyperlipoproteinemia Type III 28811385 Circulating miR-200c is up-regulated in paediatric patients with familial hypercholesterolaemia and correlates with miR-33a/b levels: implication of a ZEB1-dependent mechanism. +circulation_biomarker_diagnosis_ns hsa-mir-33b Hyperlipoproteinemia Type III 28811385 Circulating miR-200c is up-regulated in paediatric patients with familial hypercholesterolaemia and correlates with miR-33a/b levels: implication of a ZEB1-dependent mechanism. +circulation_biomarker_diagnosis_ns hsa-mir-454 Glioma 28815332 "A signature composed of miR-93, miR-590-3p, and miR-454 enabled to nearly perfectly separate patients from controls" +circulation_biomarker_diagnosis_ns hsa-mir-590 Glioma 28815332 "A signature composed of miR-93, miR-590-3p, and miR-454 enabled to nearly perfectly separate patients from controls" +circulation_biomarker_diagnosis_ns hsa-mir-93 Glioma 28815332 "A signature composed of miR-93, miR-590-3p, and miR-454 enabled to nearly perfectly separate patients from controls" +circulation_biomarker_diagnosis_ns hsa-mir-181a "Leukemia, Lymphocytic, Chronic, B-Cell" 28830603 Comparison of microRNA expression in high-count monoclonal B-cell lymphocytosis and Binet A chronic lymphocytic leukemia +circulation_biomarker_diagnosis_ns hsa-mir-181a Acute Respiratory Distress Syndrome 28856588 "miR-181a and miR-92a are risk biomarkers for ARDS, whereas miR-424 is a protective biomarker" +circulation_biomarker_diagnosis_ns hsa-mir-424 Acute Respiratory Distress Syndrome 28856588 "miR-181a and miR-92a are risk biomarkers for ARDS, whereas miR-424 is a protective biomarker" +circulation_biomarker_diagnosis_ns hsa-mir-92a Acute Respiratory Distress Syndrome 28856588 "miR-181a and miR-92a are risk biomarkers for ARDS, whereas miR-424 is a protective biomarker" +circulation_biomarker_diagnosis_ns hsa-mir-146a Peripheral Nervous System Diseases 28870579 Aberrant microRNA expression in patients with painful peripheral neuropathies. +circulation_biomarker_diagnosis_ns hsa-mir-155 Peripheral Nervous System Diseases 28870579 Aberrant microRNA expression in patients with painful peripheral neuropathies. +circulation_biomarker_diagnosis_ns hsa-mir-21 Peripheral Nervous System Diseases 28870579 Aberrant microRNA expression in patients with painful peripheral neuropathies. +circulation_biomarker_diagnosis_ns hsa-mir-9 Schizophrenia 28877483 Dysregulation of miRNA-9 in a Subset of Schizophrenia Patient-Derived Neural Progenitor Cells. +circulation_biomarker_diagnosis_ns hsa-mir-449a Celiac Disease 28878141 Intestinal and Circulating MicroRNAs in Coeliac Disease. +circulation_biomarker_diagnosis_ns hsa-mir-23a "Carcinoma, Hepatocellular" 28878865 MicroRNA 23a can be used as a screening test for early detection of HCC +circulation_biomarker_diagnosis_ns hsa-mir-143 "Leukemia, Myeloid, Acute" 28890884 "Circulating miR-92a, miR-143 and miR-342 in Plasma are Novel Potential Biomarkers for Acute Myeloid Leukemia" +circulation_biomarker_diagnosis_ns hsa-mir-342 "Leukemia, Myeloid, Acute" 28890884 "Circulating miR-92a, miR-143 and miR-342 in Plasma are Novel Potential Biomarkers for Acute Myeloid Leukemia" +circulation_biomarker_diagnosis_ns hsa-mir-92a "Leukemia, Myeloid, Acute" 28890884 "Circulating miR-92a, miR-143 and miR-342 in Plasma are Novel Potential Biomarkers for Acute Myeloid Leukemia" +circulation_biomarker_diagnosis_ns hsa-mir-155 Cervical Neoplasms 28934937 "MiR-9, miR-21, and miR-155 as potential biomarkers for HPV positive and negative cervical cancer" +circulation_biomarker_diagnosis_ns hsa-mir-21 Cervical Neoplasms 28934937 "MiR-9, miR-21, and miR-155 as potential biomarkers for HPV positive and negative cervical cancer" +circulation_biomarker_diagnosis_ns hsa-mir-9 Cervical Neoplasms 28934937 "MiR-9, miR-21, and miR-155 as potential biomarkers for HPV positive and negative cervical cancer" +circulation_biomarker_diagnosis_ns hsa-mir-21 Human Immunodeficiency Virus Infection 28955339 Deregulated MicroRNA-21 Expression in Monocytes from HIV-Infected Patients Contributes to Elevated IP-10 Secretion in HIV Infection. +circulation_biomarker_diagnosis_ns hsa-mir-100 "Diabetes Mellitus, Type 1" 28986402 "Regarding circulating miRNAs, 11 were consistently dysregulated in T1DM patients compared to controls: miR-21-5p, miR-24-3p, miR-100-5p, miR-146a-5p, miR-148a-3p, miR-150-5p, miR-181a-5p, miR-210-5p, miR-342-3p, miR-375 and miR-1275" +circulation_biomarker_diagnosis_ns hsa-mir-1275 "Diabetes Mellitus, Type 1" 28986402 "Regarding circulating miRNAs, 11 were consistently dysregulated in T1DM patients compared to controls: miR-21-5p, miR-24-3p, miR-100-5p, miR-146a-5p, miR-148a-3p, miR-150-5p, miR-181a-5p, miR-210-5p, miR-342-3p, miR-375 and miR-1275" +circulation_biomarker_diagnosis_ns hsa-mir-146a "Diabetes Mellitus, Type 1" 28986402 "Regarding circulating miRNAs, 11 were consistently dysregulated in T1DM patients compared to controls: miR-21-5p, miR-24-3p, miR-100-5p, miR-146a-5p, miR-148a-3p, miR-150-5p, miR-181a-5p, miR-210-5p, miR-342-3p, miR-375 and miR-1275" +circulation_biomarker_diagnosis_ns hsa-mir-148a "Diabetes Mellitus, Type 1" 28986402 "Regarding circulating miRNAs, 11 were consistently dysregulated in T1DM patients compared to controls: miR-21-5p, miR-24-3p, miR-100-5p, miR-146a-5p, miR-148a-3p, miR-150-5p, miR-181a-5p, miR-210-5p, miR-342-3p, miR-375 and miR-1275" +circulation_biomarker_diagnosis_ns hsa-mir-150 "Diabetes Mellitus, Type 1" 28986402 "Regarding circulating miRNAs, 11 were consistently dysregulated in T1DM patients compared to controls: miR-21-5p, miR-24-3p, miR-100-5p, miR-146a-5p, miR-148a-3p, miR-150-5p, miR-181a-5p, miR-210-5p, miR-342-3p, miR-375 and miR-1275" +circulation_biomarker_diagnosis_ns hsa-mir-181a "Diabetes Mellitus, Type 1" 28986402 "Regarding circulating miRNAs, 11 were consistently dysregulated in T1DM patients compared to controls: miR-21-5p, miR-24-3p, miR-100-5p, miR-146a-5p, miR-148a-3p, miR-150-5p, miR-181a-5p, miR-210-5p, miR-342-3p, miR-375 and miR-1275" +circulation_biomarker_diagnosis_ns hsa-mir-21 "Diabetes Mellitus, Type 1" 28986402 "Regarding circulating miRNAs, 11 were consistently dysregulated in T1DM patients compared to controls: miR-21-5p, miR-24-3p, miR-100-5p, miR-146a-5p, miR-148a-3p, miR-150-5p, miR-181a-5p, miR-210-5p, miR-342-3p, miR-375 and miR-1275" +circulation_biomarker_diagnosis_ns hsa-mir-210 "Diabetes Mellitus, Type 1" 28986402 "Regarding circulating miRNAs, 11 were consistently dysregulated in T1DM patients compared to controls: miR-21-5p, miR-24-3p, miR-100-5p, miR-146a-5p, miR-148a-3p, miR-150-5p, miR-181a-5p, miR-210-5p, miR-342-3p, miR-375 and miR-1275" +circulation_biomarker_diagnosis_ns hsa-mir-24 "Diabetes Mellitus, Type 1" 28986402 "Regarding circulating miRNAs, 11 were consistently dysregulated in T1DM patients compared to controls: miR-21-5p, miR-24-3p, miR-100-5p, miR-146a-5p, miR-148a-3p, miR-150-5p, miR-181a-5p, miR-210-5p, miR-342-3p, miR-375 and miR-1275" +circulation_biomarker_diagnosis_ns hsa-mir-342 "Diabetes Mellitus, Type 1" 28986402 "Regarding circulating miRNAs, 11 were consistently dysregulated in T1DM patients compared to controls: miR-21-5p, miR-24-3p, miR-100-5p, miR-146a-5p, miR-148a-3p, miR-150-5p, miR-181a-5p, miR-210-5p, miR-342-3p, miR-375 and miR-1275" +circulation_biomarker_diagnosis_ns hsa-mir-375 "Diabetes Mellitus, Type 1" 28986402 "Regarding circulating miRNAs, 11 were consistently dysregulated in T1DM patients compared to controls: miR-21-5p, miR-24-3p, miR-100-5p, miR-146a-5p, miR-148a-3p, miR-150-5p, miR-181a-5p, miR-210-5p, miR-342-3p, miR-375 and miR-1275" +circulation_biomarker_diagnosis_ns hsa-mir-19b "Leukemia, Myeloid, Acute" 28987820 Transfer of multidrug resistance among acute myeloid leukemia cells via extracellular vesicles and their microRNA cargo. +circulation_biomarker_diagnosis_ns hsa-mir-483 Adrenal Cortex Neoplasms 29029450 "we demonstrated that miR483-5p absolute plasma levels in ACC patients are powerful molecular markers that may help in the follow-up of patients after surgery and chemotherapy, and contribute to more accurately classify and predict tumor progression." +circulation_biomarker_diagnosis_ns hsa-mir-1 Myocardial Infarction 29030746 Platelet microRNA for predicting acute myocardial infarction. +circulation_biomarker_diagnosis_ns hsa-mir-126 Myocardial Infarction 29030746 Platelet microRNA for predicting acute myocardial infarction. +circulation_biomarker_diagnosis_ns hsa-mir-150 Myocardial Infarction 29030746 Platelet microRNA for predicting acute myocardial infarction. +circulation_biomarker_diagnosis_ns hsa-mir-21 Myocardial Infarction 29030746 Platelet microRNA for predicting acute myocardial infarction. +circulation_biomarker_diagnosis_ns hsa-mir-181b Diabetic Cardiomyopathies 29044172 Circulating miR-19b and miR-181b are potential biomarkers for diabetic cardiomyopathy. +circulation_biomarker_diagnosis_ns hsa-mir-19b Diabetic Cardiomyopathies 29044172 Circulating miR-19b and miR-181b are potential biomarkers for diabetic cardiomyopathy. +circulation_biomarker_diagnosis_ns hsa-mir-155 Hypertension 29057982 Characterization of serum miRNAs as molecular biomarkers for acute Stanford type A aortic dissection diagnosis. +circulation_biomarker_diagnosis_ns hsa-mir-19b Acute Myocardial Infarction 29085838 The miRNA Expression Profile in Acute Myocardial Infarct Using Sheep Model with Left Ventricular Assist Device Unloading. +circulation_biomarker_diagnosis_ns hsa-mir-1246 Pancreatic Neoplasms 29100367 Plasma exosome miR-196a and miR-1246 are potential indicators of localized pancreatic cancer. +circulation_biomarker_diagnosis_ns hsa-mir-196a Pancreatic Neoplasms 29100367 Plasma exosome miR-196a and miR-1246 are potential indicators of localized pancreatic cancer. +circulation_biomarker_diagnosis_ns hsa-mir-21 "Adenocarcinoma, Lung" 29103767 Circulating microRNA-339-5p and -21 in plasma as an early detection predictors of lung adenocarcinoma. +circulation_biomarker_diagnosis_ns hsa-mir-339 "Adenocarcinoma, Lung" 29103767 Circulating microRNA-339-5p and -21 in plasma as an early detection predictors of lung adenocarcinoma. +circulation_biomarker_diagnosis_ns hsa-mir-346 Schizophrenia 29127368 Diagnostic value of blood-derived microRNAs for schizophrenia: results of a meta-analysis and validation. +circulation_biomarker_diagnosis_ns hsa-mir-16 Transitional Cell Carcinoma 29141625 MicroRNA profiling of dogs with transitional cell carcinoma of the bladder using blood and urine samples. +circulation_biomarker_diagnosis_ns hsa-mir-34a Transitional Cell Carcinoma 29141625 MicroRNA profiling of dogs with transitional cell carcinoma of the bladder using blood and urine samples. +circulation_biomarker_diagnosis_ns hsa-mir-126 Hypertension 29186297 "Cardiovascular morbidity is associated with differential expression of myriad miRNAs; miR-21, miR-155, miR-126, miR-146a/b, miR-143/145, miR-223, and miR-221 are the top 9 most reported miRNAs in hypertension and atherosclerotic disease" +circulation_biomarker_diagnosis_ns hsa-mir-143 Hypertension 29186297 "Cardiovascular morbidity is associated with differential expression of myriad miRNAs; miR-21, miR-155, miR-126, miR-146a/b, miR-143/145, miR-223, and miR-221 are the top 9 most reported miRNAs in hypertension and atherosclerotic disease" +circulation_biomarker_diagnosis_ns hsa-mir-145 Hypertension 29186297 "Cardiovascular morbidity is associated with differential expression of myriad miRNAs; miR-21, miR-155, miR-126, miR-146a/b, miR-143/145, miR-223, and miR-221 are the top 9 most reported miRNAs in hypertension and atherosclerotic disease" +circulation_biomarker_diagnosis_ns hsa-mir-146a Hypertension 29186297 "Cardiovascular morbidity is associated with differential expression of myriad miRNAs; miR-21, miR-155, miR-126, miR-146a/b, miR-143/145, miR-223, and miR-221 are the top 9 most reported miRNAs in hypertension and atherosclerotic disease" +circulation_biomarker_diagnosis_ns hsa-mir-146b Hypertension 29186297 "Cardiovascular morbidity is associated with differential expression of myriad miRNAs; miR-21, miR-155, miR-126, miR-146a/b, miR-143/145, miR-223, and miR-221 are the top 9 most reported miRNAs in hypertension and atherosclerotic disease" +circulation_biomarker_diagnosis_ns hsa-mir-155 Hypertension 29186297 "Cardiovascular morbidity is associated with differential expression of myriad miRNAs; miR-21, miR-155, miR-126, miR-146a/b, miR-143/145, miR-223, and miR-221 are the top 9 most reported miRNAs in hypertension and atherosclerotic disease" +circulation_biomarker_diagnosis_ns hsa-mir-21 Hypertension 29186297 "Cardiovascular morbidity is associated with differential expression of myriad miRNAs; miR-21, miR-155, miR-126, miR-146a/b, miR-143/145, miR-223, and miR-221 are the top 9 most reported miRNAs in hypertension and atherosclerotic disease" +circulation_biomarker_diagnosis_ns hsa-mir-221 Hypertension 29186297 "Cardiovascular morbidity is associated with differential expression of myriad miRNAs; miR-21, miR-155, miR-126, miR-146a/b, miR-143/145, miR-223, and miR-221 are the top 9 most reported miRNAs in hypertension and atherosclerotic disease" +circulation_biomarker_diagnosis_ns hsa-mir-223 Hypertension 29186297 "Cardiovascular morbidity is associated with differential expression of myriad miRNAs; miR-21, miR-155, miR-126, miR-146a/b, miR-143/145, miR-223, and miR-221 are the top 9 most reported miRNAs in hypertension and atherosclerotic disease" +circulation_biomarker_diagnosis_ns hsa-mir-21 Myocardial Infarction 29188800 Chip-based digital PCR as a novel detection method for quantifying microRNAs in acute myocardial infarction patients +circulation_biomarker_diagnosis_ns hsa-mir-499 Myocardial Infarction 29188800 Chip-based digital PCR as a novel detection method for quantifying microRNAs in acute myocardial infarction patients +circulation_biomarker_diagnosis_ns hsa-mir-21 "Carcinoma, Hepatocellular" 29215815 "Combination of plasma miRNA-21, -26a, and -29a-3p expression could predict early TACE refractoriness in patients with TACE-treated HCC" +circulation_biomarker_diagnosis_ns hsa-mir-26a "Carcinoma, Hepatocellular" 29215815 "Combination of plasma miRNA-21, -26a, and -29a-3p expression could predict early TACE refractoriness in patients with TACE-treated HCC" +circulation_biomarker_diagnosis_ns hsa-mir-29a "Carcinoma, Hepatocellular" 29215815 "Combination of plasma miRNA-21, -26a, and -29a-3p expression could predict early TACE refractoriness in patients with TACE-treated HCC" +circulation_biomarker_diagnosis_ns hsa-mir-145 Multiple Sclerosis 29246612 "miR-145, miR-223 and miR-326 expression profile is a promising diagnostic biomarker for MS and NPSLE, but not for NMOSD" +circulation_biomarker_diagnosis_ns hsa-mir-145 Systemic Lupus Erythematosus 29246612 "miR-145, miR-223 and miR-326 expression profile is a promising diagnostic biomarker for MS and NPSLE, but not for NMOSD" +circulation_biomarker_diagnosis_ns hsa-mir-223 Multiple Sclerosis 29246612 "miR-145, miR-223 and miR-326 expression profile is a promising diagnostic biomarker for MS and NPSLE, but not for NMOSD" +circulation_biomarker_diagnosis_ns hsa-mir-223 Systemic Lupus Erythematosus 29246612 "miR-145, miR-223 and miR-326 expression profile is a promising diagnostic biomarker for MS and NPSLE, but not for NMOSD" +circulation_biomarker_diagnosis_ns hsa-mir-326 Multiple Sclerosis 29246612 "miR-145, miR-223 and miR-326 expression profile is a promising diagnostic biomarker for MS and NPSLE, but not for NMOSD" +circulation_biomarker_diagnosis_ns hsa-mir-326 Systemic Lupus Erythematosus 29246612 "miR-145, miR-223 and miR-326 expression profile is a promising diagnostic biomarker for MS and NPSLE, but not for NMOSD" +circulation_biomarker_diagnosis_ns hsa-mir-223 Prostate Neoplasms 29246734 "A 3-miR (miRNA-223, miRNA-24 and miRNA-375) score was significant to predict patient reclassification" +circulation_biomarker_diagnosis_ns hsa-mir-24 Prostate Neoplasms 29246734 "A 3-miR (miRNA-223, miRNA-24 and miRNA-375) score was significant to predict patient reclassification" +circulation_biomarker_diagnosis_ns hsa-mir-375 Prostate Neoplasms 29246734 "A 3-miR (miRNA-223, miRNA-24 and miRNA-375) score was significant to predict patient reclassification" +circulation_biomarker_diagnosis_ns hsa-mir-146a Heart Failure 29258606 Inflammation-associated microRNA changes in circulating exosomes of heart failure patients +circulation_biomarker_diagnosis_ns hsa-mir-16 Heart Failure 29258606 Inflammation-associated microRNA changes in circulating exosomes of heart failure patients +circulation_biomarker_diagnosis_ns hsa-mir-1233 "Carcinoma, Renal Cell" 29262564 "Plasmatic miR-210, miR-221 and miR-1233 profile: potential liquid biopsies candidates for renal cell carcinoma" +circulation_biomarker_diagnosis_ns hsa-mir-210 "Carcinoma, Renal Cell" 29262564 "Plasmatic miR-210, miR-221 and miR-1233 profile: potential liquid biopsies candidates for renal cell carcinoma" +circulation_biomarker_diagnosis_ns hsa-mir-221 "Carcinoma, Renal Cell" 29262564 "Plasmatic miR-210, miR-221 and miR-1233 profile: potential liquid biopsies candidates for renal cell carcinoma" +circulation_biomarker_diagnosis_ns hsa-mir-598 Crohn Colitis 29272478 "Two miRNAs (miR-598, miR-642) were consistently different between the patient groups" +circulation_biomarker_diagnosis_ns hsa-mir-642 Crohn Colitis 29272478 "Two miRNAs (miR-598, miR-642) were consistently different between the patient groups" +circulation_biomarker_diagnosis_ns hsa-mir-145 Endometriosis 29308623 miR-31 and miR-145 as Potential Non-Invasive Regulatory Biomarkers in Patients with Endometriosis +circulation_biomarker_diagnosis_ns hsa-mir-31 Endometriosis 29308623 miR-31 and miR-145 as Potential Non-Invasive Regulatory Biomarkers in Patients with Endometriosis +circulation_biomarker_diagnosis_ns hsa-mir-106b "Carcinoma, Hepatocellular" 29312570 Serum microRNA signatures and metabolomics have high diagnostic value in hepatocellular carcinoma +circulation_biomarker_diagnosis_ns hsa-mir-182 "Carcinoma, Hepatocellular" 29312570 Serum microRNA signatures and metabolomics have high diagnostic value in hepatocellular carcinoma +circulation_biomarker_diagnosis_ns hsa-mir-126 Heart Failure 29314582 "A differential modulation of circulating levels of miR-423, -34a, -21-3p, -126, -199 and -30a was found across the aetiology groups" +circulation_biomarker_diagnosis_ns hsa-mir-199 Heart Failure 29314582 "A differential modulation of circulating levels of miR-423, -34a, -21-3p, -126, -199 and -30a was found across the aetiology groups" +circulation_biomarker_diagnosis_ns hsa-mir-21 Heart Failure 29314582 "A differential modulation of circulating levels of miR-423, -34a, -21-3p, -126, -199 and -30a was found across the aetiology groups" +circulation_biomarker_diagnosis_ns hsa-mir-30a Heart Failure 29314582 "A differential modulation of circulating levels of miR-423, -34a, -21-3p, -126, -199 and -30a was found across the aetiology groups" +circulation_biomarker_diagnosis_ns hsa-mir-34a Heart Failure 29314582 "A differential modulation of circulating levels of miR-423, -34a, -21-3p, -126, -199 and -30a was found across the aetiology groups" +circulation_biomarker_diagnosis_ns hsa-mir-423 Heart Failure 29314582 "A differential modulation of circulating levels of miR-423, -34a, -21-3p, -126, -199 and -30a was found across the aetiology groups" +circulation_biomarker_diagnosis_ns hsa-mir-125a "Carcinoma, Hepatocellular" 29333940 "the measurement of serum levels of miR-125a, miR-139, miR-145, and miR-199a can help to differentiate HCC from CHC and LC" +circulation_biomarker_diagnosis_ns hsa-mir-139 "Carcinoma, Hepatocellular" 29333940 "the measurement of serum levels of miR-125a, miR-139, miR-145, and miR-200a can help to differentiate HCC from CHC and LC" +circulation_biomarker_diagnosis_ns hsa-mir-145 "Carcinoma, Hepatocellular" 29333940 "the measurement of serum levels of miR-125a, miR-139, miR-145, and miR-201a can help to differentiate HCC from CHC and LC" +circulation_biomarker_diagnosis_ns hsa-mir-199a "Carcinoma, Hepatocellular" 29333940 "the measurement of serum levels of miR-125a, miR-139, miR-145, and miR-202a can help to differentiate HCC from CHC and LC" +circulation_biomarker_diagnosis_ns hsa-mir-1 Acute Coronary Syndrome 29350392 "although most investigated miRs levels differ significantly between patients with ACS and CIE, similar levels of circulating miR-1-3p, miR-133a-3p, miR-133b, and miR-375 were observed; furthermore, we identified several common miRs as possible risk factors for recurrent cardiovascular events" +circulation_biomarker_diagnosis_ns hsa-mir-133a Acute Coronary Syndrome 29350392 "although most investigated miRs levels differ significantly between patients with ACS and CIE, similar levels of circulating miR-1-3p, miR-133a-3p, miR-133b, and miR-375 were observed; furthermore, we identified several common miRs as possible risk factors for recurrent cardiovascular events" +circulation_biomarker_diagnosis_ns hsa-mir-133b Acute Coronary Syndrome 29350392 "although most investigated miRs levels differ significantly between patients with ACS and CIE, similar levels of circulating miR-1-3p, miR-133a-3p, miR-133b, and miR-375 were observed; furthermore, we identified several common miRs as possible risk factors for recurrent cardiovascular events" +circulation_biomarker_diagnosis_ns hsa-mir-375 Acute Coronary Syndrome 29350392 "although most investigated miRs levels differ significantly between patients with ACS and CIE, similar levels of circulating miR-1-3p, miR-133a-3p, miR-133b, and miR-375 were observed; furthermore, we identified several common miRs as possible risk factors for recurrent cardiovascular events" +circulation_biomarker_diagnosis_ns hsa-mir-146a Coronary Artery Disease 29357324 Circulating MiR-146a May be a Potential Biomarker of Coronary Heart Disease in Patients with Subclinical Hypothyroidism. +circulation_biomarker_diagnosis_ns hsa-mir-375 "Diabetes Mellitus, Type 2" 29373500 Evaluation of Two-Diabetes Related microRNAs Suitability as Earlier Blood Biomarkers for Detecting Prediabetes and type 2 Diabetes Mellitus +circulation_biomarker_diagnosis_ns hsa-mir-155 Coronary Artery Disease 29411649 serum miR-155 content may serve as a novel biomarker for evaluating severity of CHD +circulation_biomarker_diagnosis_ns hsa-mir-126 Diabetes Mellitus 29452547 Plasma miR-126 and miR-210 levels may be biomarkers for diabetes with or without CAD +circulation_biomarker_diagnosis_ns hsa-mir-106a Bicuspid Aortic Valve Disease 29462317 Expression of circulating miR-17 and miR-106a in the BAV root phenotype patients correlates with the severity of aortopathy and the risk of adverse aortic events +circulation_biomarker_diagnosis_ns hsa-mir-17 Bicuspid Aortic Valve Disease 29462317 Expression of circulating miR-17 and miR-106a in the BAV root phenotype patients correlates with the severity of aortopathy and the risk of adverse aortic events +circulation_biomarker_diagnosis_ns hsa-mir-136 Amyotrophic Lateral Sclerosis 29466830 "Changes in 4 miRNAs (miR-136-3p, miR-30b-5p, miR-331-3p, miR-496) correlated positively and change in 1 miRNA (miR-2110) correlated negatively with changes in clinical parameters in longitudinal analysis" +circulation_biomarker_diagnosis_ns hsa-mir-2110 Amyotrophic Lateral Sclerosis 29466830 "Changes in 4 miRNAs (miR-136-3p, miR-30b-5p, miR-331-3p, miR-496) correlated positively and change in 1 miRNA (miR-2110) correlated negatively with changes in clinical parameters in longitudinal analysis" +circulation_biomarker_diagnosis_ns hsa-mir-30b Amyotrophic Lateral Sclerosis 29466830 "Changes in 4 miRNAs (miR-136-3p, miR-30b-5p, miR-331-3p, miR-496) correlated positively and change in 1 miRNA (miR-2110) correlated negatively with changes in clinical parameters in longitudinal analysis" +circulation_biomarker_diagnosis_ns hsa-mir-331 Amyotrophic Lateral Sclerosis 29466830 "Changes in 4 miRNAs (miR-136-3p, miR-30b-5p, miR-331-3p, miR-496) correlated positively and change in 1 miRNA (miR-2110) correlated negatively with changes in clinical parameters in longitudinal analysis" +circulation_biomarker_diagnosis_ns hsa-mir-496 Amyotrophic Lateral Sclerosis 29466830 "Changes in 4 miRNAs (miR-136-3p, miR-30b-5p, miR-331-3p, miR-496) correlated positively and change in 1 miRNA (miR-2110) correlated negatively with changes in clinical parameters in longitudinal analysis" +circulation_biomarker_diagnosis_ns hsa-mir-208b Myocardial Infarction 29475914 plasma levels of circulating miR-208b and miR-499 could serve as potential AMI biomarkers +circulation_biomarker_diagnosis_ns hsa-mir-499 Myocardial Infarction 29475914 plasma levels of circulating miR-208b and miR-500 could serve as potential AMI biomarkers +circulation_biomarker_diagnosis_ns hsa-mir-25 Heart Failure 29499204 "miR-25 expression during different stages of heart disease, offers a new perspective for the role of miR-25 function in heart failure" +circulation_biomarker_diagnosis_ns hsa-mir-128 Friedreich Ataxia 29509186 "We found different expression profiles of miRNAs (hsa-miR-128-3p, hsa-miR-625-3p, hsa-miR-130b-5p, hsa-miR-151a-5p, hsa-miR-330-3p, hsa-miR-323a-3p, and hsa-miR-142-3p) between samples from patients and samples from healthy subjects" +circulation_biomarker_diagnosis_ns hsa-mir-130b Friedreich Ataxia 29509186 "We found different expression profiles of miRNAs (hsa-miR-128-3p, hsa-miR-625-3p, hsa-miR-130b-5p, hsa-miR-151a-5p, hsa-miR-330-3p, hsa-miR-323a-3p, and hsa-miR-142-3p) between samples from patients and samples from healthy subjects" +circulation_biomarker_diagnosis_ns hsa-mir-142 Friedreich Ataxia 29509186 "We found different expression profiles of miRNAs (hsa-miR-128-3p, hsa-miR-625-3p, hsa-miR-130b-5p, hsa-miR-151a-5p, hsa-miR-330-3p, hsa-miR-323a-3p, and hsa-miR-142-3p) between samples from patients and samples from healthy subjects" +circulation_biomarker_diagnosis_ns hsa-mir-151a Friedreich Ataxia 29509186 "We found different expression profiles of miRNAs (hsa-miR-128-3p, hsa-miR-625-3p, hsa-miR-130b-5p, hsa-miR-151a-5p, hsa-miR-330-3p, hsa-miR-323a-3p, and hsa-miR-142-3p) between samples from patients and samples from healthy subjects" +circulation_biomarker_diagnosis_ns hsa-mir-323a Friedreich Ataxia 29509186 "We found different expression profiles of miRNAs (hsa-miR-128-3p, hsa-miR-625-3p, hsa-miR-130b-5p, hsa-miR-151a-5p, hsa-miR-330-3p, hsa-miR-323a-3p, and hsa-miR-142-3p) between samples from patients and samples from healthy subjects" +circulation_biomarker_diagnosis_ns hsa-mir-330 Friedreich Ataxia 29509186 "We found different expression profiles of miRNAs (hsa-miR-128-3p, hsa-miR-625-3p, hsa-miR-130b-5p, hsa-miR-151a-5p, hsa-miR-330-3p, hsa-miR-323a-3p, and hsa-miR-142-3p) between samples from patients and samples from healthy subjects" +circulation_biomarker_diagnosis_ns hsa-mir-625 Friedreich Ataxia 29509186 "We found different expression profiles of miRNAs (hsa-miR-128-3p, hsa-miR-625-3p, hsa-miR-130b-5p, hsa-miR-151a-5p, hsa-miR-330-3p, hsa-miR-323a-3p, and hsa-miR-142-3p) between samples from patients and samples from healthy subjects" +circulation_biomarker_diagnosis_ns hsa-mir-146a Periodontitis 29517812 MicroRNA-146a and microRNA-155 as novel crevicular fluid biomarkers for periodontitis in non-diabetic and type 2 diabetic patients. +circulation_biomarker_diagnosis_ns hsa-mir-155 Periodontitis 29517812 MicroRNA-146a and microRNA-155 as novel crevicular fluid biomarkers for periodontitis in non-diabetic and type 2 diabetic patients. +circulation_biomarker_diagnosis_ns hsa-mir-191 "Aortic Aneurysm, Abdominal" 29518510 Expression in Whole Blood Samples of miRNA-191 and miRNA-455-3p in Patients with AAA and Their Relationship to Clinical Outcomes after Endovascular Repair. +circulation_biomarker_diagnosis_ns hsa-mir-455 "Aortic Aneurysm, Abdominal" 29518510 Expression in Whole Blood Samples of miRNA-191 and miRNA-455-3p in Patients with AAA and Their Relationship to Clinical Outcomes after Endovascular Repair. +circulation_biomarker_diagnosis_ns hsa-mir-128 Multiple Sclerosis 29527713 "Evaluation of serum miR-191-5p, miR-24-3p, miR-128-3p, and miR-376c-3 in multiple sclerosis patients." +circulation_biomarker_diagnosis_ns hsa-mir-191 Multiple Sclerosis 29527713 "Evaluation of serum miR-191-5p, miR-24-3p, miR-128-3p, and miR-376c-3 in multiple sclerosis patients." +circulation_biomarker_diagnosis_ns hsa-mir-24 Multiple Sclerosis 29527713 "Evaluation of serum miR-191-5p, miR-24-3p, miR-128-3p, and miR-376c-3 in multiple sclerosis patients." +circulation_biomarker_diagnosis_ns hsa-mir-376c Multiple Sclerosis 29527713 "Evaluation of serum miR-191-5p, miR-24-3p, miR-128-3p, and miR-376c-3 in multiple sclerosis patients." +circulation_biomarker_diagnosis_ns hsa-mir-126 Atherosclerosis 29531852 "A common microRNA profile to different atherosclerotic disease locations was identified, including deregulation of miR-21, miR-30, miR-126, and miR-221-4p" +circulation_biomarker_diagnosis_ns hsa-mir-21 Atherosclerosis 29531852 "A common microRNA profile to different atherosclerotic disease locations was identified, including deregulation of miR-21, miR-30, miR-126, and miR-221-3p" +circulation_biomarker_diagnosis_ns hsa-mir-221 Atherosclerosis 29531852 "A common microRNA profile to different atherosclerotic disease locations was identified, including deregulation of miR-21, miR-30, miR-126, and miR-221-5p" +circulation_biomarker_diagnosis_ns hsa-mir-30 Atherosclerosis 29531852 "A common microRNA profile to different atherosclerotic disease locations was identified, including deregulation of miR-21, miR-30, miR-126, and miR-221-3p" +circulation_biomarker_diagnosis_ns hsa-mir-196a Gastric Neoplasms 29535809 circulating miRNA-196a is a novel biomarker for detection of early gastric cancer and its precursor +circulation_biomarker_diagnosis_ns hsa-mir-204 Spinal Cord Injuries 29547407 "We identified 4 targeted miRNAs, including mir-204-5p, mir-519d-3p, mir-20b-5p, mir-6838-5p, which may be potential biomarkers for SCI patients" +circulation_biomarker_diagnosis_ns hsa-mir-20b Spinal Cord Injuries 29547407 "We identified 4 targeted miRNAs, including mir-204-5p, mir-519d-3p, mir-20b-5p, mir-6838-5p, which may be potential biomarkers for SCI patients" +circulation_biomarker_diagnosis_ns hsa-mir-519d Spinal Cord Injuries 29547407 "We identified 4 targeted miRNAs, including mir-204-5p, mir-519d-3p, mir-20b-5p, mir-6838-5p, which may be potential biomarkers for SCI patients" +circulation_biomarker_diagnosis_ns hsa-mir-6838 Spinal Cord Injuries 29547407 "We identified 4 targeted miRNAs, including mir-204-5p, mir-519d-3p, mir-20b-5p, mir-6838-5p, which may be potential biomarkers for SCI patients" +circulation_biomarker_diagnosis_ns hsa-mir-199a Multiple Sclerosis 29551498 "Analysis of the expression of mir-34a, mir-199a, mir-30c and mir-19a in peripheral blood CD4+T lymphocytes of relapsing-remitting multiple sclerosis patients." +circulation_biomarker_diagnosis_ns hsa-mir-19a Multiple Sclerosis 29551498 "Analysis of the expression of mir-34a, mir-199a, mir-30c and mir-19a in peripheral blood CD4+T lymphocytes of relapsing-remitting multiple sclerosis patients." +circulation_biomarker_diagnosis_ns hsa-mir-30c Multiple Sclerosis 29551498 "Analysis of the expression of mir-34a, mir-199a, mir-30c and mir-19a in peripheral blood CD4+T lymphocytes of relapsing-remitting multiple sclerosis patients." +circulation_biomarker_diagnosis_ns hsa-mir-34a Multiple Sclerosis 29551498 "Analysis of the expression of mir-34a, mir-199a, mir-30c and mir-19a in peripheral blood CD4+T lymphocytes of relapsing-remitting multiple sclerosis patients." +circulation_biomarker_diagnosis_ns hsa-mir-143 "Leukemia, Lymphoblastic, Acute, Childhood" 29556721 Clinical utility of miR-143/miR-182 levels in prognosis and risk stratification specificity of BFM-treated childhood acute lymphoblastic leukemia. +circulation_biomarker_diagnosis_ns hsa-mir-182 "Leukemia, Lymphoblastic, Acute, Childhood" 29556721 Clinical utility of miR-143/miR-182 levels in prognosis and risk stratification specificity of BFM-treated childhood acute lymphoblastic leukemia. +circulation_biomarker_diagnosis_ns hsa-mir-106a "Carcinoma, Breast" 29557526 Circulating microRNAs from the miR-106a-363 cluster on chromosome X as novel diagnostic biomarkers for breast cancer. +circulation_biomarker_diagnosis_ns hsa-mir-223 Dementia 29559383 Serum Exosomal miR-223 Serves as a Potential Diagnostic and Prognostic Biomarker for Dementia +circulation_biomarker_diagnosis_ns hsa-mir-208a Chagas Disease 29559958 Circulating Plasma MicroRNA-208a as Potential Biomarker of Chronic Indeterminate Phase of Chagas Disease +circulation_biomarker_diagnosis_ns hsa-let-7e Dengue Virus Infection 29566761 "six significantly differentially expressed miRNAs, including hsa-miR-184, hsa-let-7e-5p, hsa-miR-132-3p, hsa-miR-155-5p, and hsa-miR-1246, were chosen for RT-qPCR analysis" +circulation_biomarker_diagnosis_ns hsa-mir-1246 Dengue Virus Infection 29566761 "six significantly differentially expressed miRNAs, including hsa-miR-184, hsa-let-7e-5p, hsa-miR-132-3p, hsa-miR-155-5p, and hsa-miR-1246, were chosen for RT-qPCR analysis" +circulation_biomarker_diagnosis_ns hsa-mir-132 Dengue Virus Infection 29566761 "six significantly differentially expressed miRNAs, including hsa-miR-184, hsa-let-7e-5p, hsa-miR-132-3p, hsa-miR-155-5p, and hsa-miR-1246, were chosen for RT-qPCR analysis" +circulation_biomarker_diagnosis_ns hsa-mir-155 Dengue Virus Infection 29566761 "six significantly differentially expressed miRNAs, including hsa-miR-184, hsa-let-7e-5p, hsa-miR-132-3p, hsa-miR-155-5p, and hsa-miR-1246, were chosen for RT-qPCR analysis" +circulation_biomarker_diagnosis_ns hsa-mir-184 Dengue Virus Infection 29566761 "six significantly differentially expressed miRNAs, including hsa-miR-184, hsa-let-7e-5p, hsa-miR-132-3p, hsa-miR-155-5p, and hsa-miR-1246, were chosen for RT-qPCR analysis" +circulation_biomarker_diagnosis_ns hsa-mir-155 "Leukemia, Myeloid, Acute" 29601851 MicroRNA-155 expression and function in AML: An evolving paradigm. +circulation_biomarker_diagnosis_ns hsa-mir-33a "Diabetes Mellitus, Type 2" 29601916 B-RCA revealed circulating miR-33a/b associates with serum cholesterol in type 2 diabetes patients at high risk of ASCVD. +circulation_biomarker_diagnosis_ns hsa-mir-33b "Diabetes Mellitus, Type 2" 29601916 B-RCA revealed circulating miR-33a/b associates with serum cholesterol in type 2 diabetes patients at high risk of ASCVD. +circulation_biomarker_diagnosis_ns hsa-mir-126 Obesity 29607782 Dysregulation of circulating miRs may contribute mechanistically to the heightened inflammatory state associated with overweight and obesity +circulation_biomarker_diagnosis_ns hsa-mir-146a Obesity 29607782 Dysregulation of circulating miRs may contribute mechanistically to the heightened inflammatory state associated with overweight and obesity +circulation_biomarker_diagnosis_ns hsa-mir-150 Obesity 29607782 Dysregulation of circulating miRs may contribute mechanistically to the heightened inflammatory state associated with overweight and obesity +circulation_biomarker_diagnosis_ns hsa-mir-181b Obesity 29607782 Dysregulation of circulating miRs may contribute mechanistically to the heightened inflammatory state associated with overweight and obesity +circulation_biomarker_diagnosis_ns hsa-mir-34a Obesity 29607782 Dysregulation of circulating miRs may contribute mechanistically to the heightened inflammatory state associated with overweight and obesity +circulation_biomarker_diagnosis_ns hsa-mir-126 Hypertension 29615793 "Specifically, altered circulating expression of miR-17, miR-21, miR-34a, miR-92a, miR-126, miR-145, miR-146a, and miR-154 has been linked with the pathogenesis and progression of cardiovascular disease" +circulation_biomarker_diagnosis_ns hsa-mir-145 Hypertension 29615793 "Specifically, altered circulating expression of miR-17, miR-21, miR-34a, miR-92a, miR-126, miR-145, miR-146a, and miR-155 has been linked with the pathogenesis and progression of cardiovascular disease" +circulation_biomarker_diagnosis_ns hsa-mir-146a Hypertension 29615793 "Specifically, altered circulating expression of miR-17, miR-21, miR-34a, miR-92a, miR-126, miR-145, miR-146a, and miR-156 has been linked with the pathogenesis and progression of cardiovascular disease" +circulation_biomarker_diagnosis_ns hsa-mir-157 Hypertension 29615793 "Specifically, altered circulating expression of miR-17, miR-21, miR-34a, miR-92a, miR-126, miR-145, miR-146a, and miR-157 has been linked with the pathogenesis and progression of cardiovascular disease" +circulation_biomarker_diagnosis_ns hsa-mir-17 Hypertension 29615793 "Specifically, altered circulating expression of miR-17, miR-21, miR-34a, miR-92a, miR-126, miR-145, miR-146a, and miR-150 has been linked with the pathogenesis and progression of cardiovascular disease" +circulation_biomarker_diagnosis_ns hsa-mir-21 Hypertension 29615793 "Specifically, altered circulating expression of miR-17, miR-21, miR-34a, miR-92a, miR-126, miR-145, miR-146a, and miR-151 has been linked with the pathogenesis and progression of cardiovascular disease" +circulation_biomarker_diagnosis_ns hsa-mir-34a Hypertension 29615793 "Specifically, altered circulating expression of miR-17, miR-21, miR-34a, miR-92a, miR-126, miR-145, miR-146a, and miR-152 has been linked with the pathogenesis and progression of cardiovascular disease" +circulation_biomarker_diagnosis_ns hsa-mir-92a Hypertension 29615793 "Specifically, altered circulating expression of miR-17, miR-21, miR-34a, miR-92a, miR-126, miR-145, miR-146a, and miR-153 has been linked with the pathogenesis and progression of cardiovascular disease" +circulation_biomarker_diagnosis_ns hsa-mir-3162 Human Immunodeficiency Virus Infection 29627523 mircoRNA-3162-3p is a potential biomarker to identify new infections in HIV-1-infected patients. +circulation_biomarker_diagnosis_ns hsa-mir-200c "Leukemia, Lymphoblastic, Acute" 29630744 MicroRNA-326 and microRNA-200c: Two novel biomarkers for diagnosis and prognosis of pediatric acute lymphoblastic leukemia. +circulation_biomarker_diagnosis_ns hsa-mir-326 "Leukemia, Lymphoblastic, Acute" 29630744 MicroRNA-326 and microRNA-200c: Two novel biomarkers for diagnosis and prognosis of pediatric acute lymphoblastic leukemia. +circulation_biomarker_diagnosis_ns hsa-mir-141 Parkinson Disease 29631008 "Differential expression of miR-34a, miR-141, and miR-9 in MPP+-treated differentiated PC12 cells as a model of Parkinson's disease." +circulation_biomarker_diagnosis_ns hsa-mir-34a Parkinson Disease 29631008 "Differential expression of miR-34a, miR-141, and miR-9 in MPP+-treated differentiated PC12 cells as a model of Parkinson's disease." +circulation_biomarker_diagnosis_ns hsa-mir-9 Parkinson Disease 29631008 "Differential expression of miR-34a, miR-141, and miR-9 in MPP+-treated differentiated PC12 cells as a model of Parkinson's disease." +circulation_biomarker_diagnosis_ns hsa-mir-145 Endometriosis 29633787 miR-31 and miR-145 as Potential Non-Invasive Regulatory Biomarkers in Patients with Endometriosis +circulation_biomarker_diagnosis_ns hsa-mir-31 Endometriosis 29633787 miR-31 and miR-145 as Potential Non-Invasive Regulatory Biomarkers in Patients with Endometriosis +circulation_biomarker_diagnosis_ns hsa-mir-539 Azoospermia 29635626 a model that included miR-539-5p and miR-941 expression values is also described as being useful for predicting the presence of residual spermatogenesis in individuals with severe spermatogenic disorders with diagnostic accuracy +circulation_biomarker_diagnosis_ns hsa-mir-941 Azoospermia 29635626 a model that included miR-539-5p and miR-941 expression values is also described as being useful for predicting the presence of residual spermatogenesis in individuals with severe spermatogenic disorders with diagnostic accuracy +circulation_biomarker_diagnosis_ns hsa-mir-122 Liver Diseases [unspecific] 29636028 Comprehensive analysis of blood cells and plasma identifies tissue-specific miRNAs as potential novel circulating biomarkers +circulation_biomarker_diagnosis_ns hsa-mir-155 Inflammatory Bowel Diseases 29668922 "Target-based approach (miR-16, miR-21, miR-155, and miR-223) has been used to evaluate miRNA expression" +circulation_biomarker_diagnosis_ns hsa-mir-16 Inflammatory Bowel Diseases 29668922 "Target-based approach (miR-16, miR-21, miR-155, and miR-223) has been used to evaluate miRNA expression" +circulation_biomarker_diagnosis_ns hsa-mir-21 Inflammatory Bowel Diseases 29668922 "Target-based approach (miR-16, miR-21, miR-155, and miR-223) has been used to evaluate miRNA expression" +circulation_biomarker_diagnosis_ns hsa-mir-223 Inflammatory Bowel Diseases 29668922 "Target-based approach (miR-16, miR-21, miR-155, and miR-223) has been used to evaluate miRNA expression" +circulation_biomarker_diagnosis_ns hsa-let-7b Amyotrophic Lateral Sclerosis 29670510 "We observed significant aberrant dysregulation across our patient cohort for miR-124a, miR-206, miR-9, let-7b, and miR-638" +circulation_biomarker_diagnosis_ns hsa-mir-124a Amyotrophic Lateral Sclerosis 29670510 "We observed significant aberrant dysregulation across our patient cohort for miR-124a, miR-206, miR-9, let-7b, and miR-638" +circulation_biomarker_diagnosis_ns hsa-mir-206 Amyotrophic Lateral Sclerosis 29670510 "We observed significant aberrant dysregulation across our patient cohort for miR-124a, miR-206, miR-9, let-7b, and miR-638" +circulation_biomarker_diagnosis_ns hsa-mir-638 Amyotrophic Lateral Sclerosis 29670510 "We observed significant aberrant dysregulation across our patient cohort for miR-124a, miR-206, miR-9, let-7b, and miR-638" +circulation_biomarker_diagnosis_ns hsa-mir-9 Amyotrophic Lateral Sclerosis 29670510 "We observed significant aberrant dysregulation across our patient cohort for miR-124a, miR-206, miR-9, let-7b, and miR-638" +circulation_biomarker_diagnosis_ns hsa-mir-106a "Squamous Cell Carcinoma, Lung" 29673101 "a four-miRNA signature (miR-181a-5p, miR-21-5p, miR-106a-5p, and miR-93-5p) was identified for LSCC detection" +circulation_biomarker_diagnosis_ns hsa-mir-181a "Squamous Cell Carcinoma, Lung" 29673101 "a four-miRNA signature (miR-181a-5p, miR-21-5p, miR-106a-5p, and miR-93-5p) was identified for LSCC detection" +circulation_biomarker_diagnosis_ns hsa-mir-21 "Squamous Cell Carcinoma, Lung" 29673101 "a four-miRNA signature (miR-181a-5p, miR-21-5p, miR-106a-5p, and miR-93-5p) was identified for LSCC detection" +circulation_biomarker_diagnosis_ns hsa-mir-93 "Squamous Cell Carcinoma, Lung" 29673101 "a four-miRNA signature (miR-181a-5p, miR-21-5p, miR-106a-5p, and miR-93-5p) was identified for LSCC detection" +circulation_biomarker_diagnosis_ns hsa-let-7a Breast Neoplasms 29683112 "A panel of serum ncRNAs, including let-7a, miR-155, miR-574-5p, and MALAT1, was shown to be present in patients with breast cancer." +circulation_biomarker_diagnosis_ns hsa-mir-155 Breast Neoplasms 29683112 "A panel of serum ncRNAs, including let-7a, miR-155, miR-574-5p, and MALAT1, was shown to be present in patients with breast cancer." +circulation_biomarker_diagnosis_ns hsa-mir-574 Breast Neoplasms 29683112 "A panel of serum ncRNAs, including let-7a, miR-155, miR-574-5p, and MALAT1, was shown to be present in patients with breast cancer." +circulation_biomarker_diagnosis_ns hsa-mir-137 Schizophrenia 29684772 "Identification of miR-22-3p, miR-92a-3p, and miR-137 in peripheral blood as biomarker for schizophrenia" +circulation_biomarker_diagnosis_ns hsa-mir-22 Schizophrenia 29684772 "Identification of miR-22-3p, miR-92a-3p, and miR-137 in peripheral blood as biomarker for schizophrenia" +circulation_biomarker_diagnosis_ns hsa-mir-92a Schizophrenia 29684772 "Identification of miR-22-3p, miR-92a-3p, and miR-137 in peripheral blood as biomarker for schizophrenia" +circulation_biomarker_diagnosis_ns hsa-mir-3613 Liposarcoma 29689704 Whole blood miRNA expression analysis reveals miR-3613-3p as a potential biomarker for dedifferentiated liposarcoma. +circulation_biomarker_diagnosis_ns hsa-mir-1 Myocardial Infarction 29698386 "Following the identification of cardiac-specific microRNA miR-208a in circulation, more non-coding RNAs (miR-1, miR-499 and miR-133) have been identified as biomarkers not only for the diagnosis of AMI but also for prognosis post infarction" +circulation_biomarker_diagnosis_ns hsa-mir-133 Myocardial Infarction 29698386 "Following the identification of cardiac-specific microRNA miR-208a in circulation, more non-coding RNAs (miR-1, miR-499 and miR-133) have been identified as biomarkers not only for the diagnosis of AMI but also for prognosis post infarction" +circulation_biomarker_diagnosis_ns hsa-mir-208a Myocardial Infarction 29698386 "Following the identification of cardiac-specific microRNA miR-208a in circulation, more non-coding RNAs (miR-1, miR-499 and miR-133) have been identified as biomarkers not only for the diagnosis of AMI but also for prognosis post infarction" +circulation_biomarker_diagnosis_ns hsa-mir-499 Myocardial Infarction 29698386 "Following the identification of cardiac-specific microRNA miR-208a in circulation, more non-coding RNAs (miR-1, miR-499 and miR-133) have been identified as biomarkers not only for the diagnosis of AMI but also for prognosis post infarction" +circulation_biomarker_diagnosis_ns hsa-mir-21 "Leukemia, Lymphocytic, Chronic, B-Cell" 29730931 "specifically miR-21-5p and a 23 nucleotide long 5'-phosphorylated miRNA with 3'-uridylation (iso-miR-16-5p), were only detected in the CLL patients" +circulation_biomarker_diagnosis_ns hsa-let-7c Respiratory Syncytial Virus Pneumonia 29733865 "MicroRNA 146-5p, miR-let-7c-5p, miR-221 and miR-345-5p are differentially expressed in Respiratory Syncytial Virus (RSV) persistently infected HEp-2 cells." +circulation_biomarker_diagnosis_ns hsa-mir-146 Respiratory Syncytial Virus Pneumonia 29733865 "MicroRNA 146-5p, miR-let-7c-5p, miR-221 and miR-345-5p are differentially expressed in Respiratory Syncytial Virus (RSV) persistently infected HEp-2 cells." +circulation_biomarker_diagnosis_ns hsa-mir-221 Respiratory Syncytial Virus Pneumonia 29733865 "MicroRNA 146-5p, miR-let-7c-5p, miR-221 and miR-345-5p are differentially expressed in Respiratory Syncytial Virus (RSV) persistently infected HEp-2 cells." +circulation_biomarker_diagnosis_ns hsa-mir-345 Respiratory Syncytial Virus Pneumonia 29733865 "MicroRNA 146-5p, miR-let-7c-5p, miR-221 and miR-345-5p are differentially expressed in Respiratory Syncytial Virus (RSV) persistently infected HEp-2 cells." +circulation_biomarker_diagnosis_ns hsa-mir-146a Cerebral Malaria 29747626 "The differential expression profiles of these selected miRNA (miR-146a, miR-150, miR-193b, miR-205, miR-215, miR-467a, and miR-486) were analyzed in mouse MV" +circulation_biomarker_diagnosis_ns hsa-mir-150 Cerebral Malaria 29747626 "The differential expression profiles of these selected miRNA (miR-146a, miR-150, miR-193b, miR-205, miR-215, miR-467a, and miR-486) were analyzed in mouse MV" +circulation_biomarker_diagnosis_ns hsa-mir-193b Cerebral Malaria 29747626 "The differential expression profiles of these selected miRNA (miR-146a, miR-150, miR-193b, miR-205, miR-215, miR-467a, and miR-486) were analyzed in mouse MV" +circulation_biomarker_diagnosis_ns hsa-mir-205 Cerebral Malaria 29747626 "The differential expression profiles of these selected miRNA (miR-146a, miR-150, miR-193b, miR-205, miR-215, miR-467a, and miR-486) were analyzed in mouse MV" +circulation_biomarker_diagnosis_ns hsa-mir-215 Cerebral Malaria 29747626 "The differential expression profiles of these selected miRNA (miR-146a, miR-150, miR-193b, miR-205, miR-215, miR-467a, and miR-486) were analyzed in mouse MV" +circulation_biomarker_diagnosis_ns hsa-mir-467a Cerebral Malaria 29747626 "The differential expression profiles of these selected miRNA (miR-146a, miR-150, miR-193b, miR-205, miR-215, miR-467a, and miR-486) were analyzed in mouse MV" +circulation_biomarker_diagnosis_ns hsa-mir-486 Cerebral Malaria 29747626 "The differential expression profiles of these selected miRNA (miR-146a, miR-150, miR-193b, miR-205, miR-215, miR-467a, and miR-486) were analyzed in mouse MV" +circulation_biomarker_diagnosis_ns hsa-mir-106a Proliferative Glomerulonephritis 29748623 Plasma microRNA panel is a novel biomarker for focal segmental glomerulosclerosis and associated with podocyte apoptosis. +circulation_biomarker_diagnosis_ns hsa-mir-1229 Colorectal Carcinoma 29780253 "A 5-serum miRNA panel (miRNA-1246, miRNA-202-3p, miRNA-21-3p, miRNA-1229-3p, and miRNA-532-3p) effectively distinguished CRCs from HCs" +circulation_biomarker_diagnosis_ns hsa-mir-1246 Colorectal Carcinoma 29780253 "A 5-serum miRNA panel (miRNA-1246, miRNA-202-3p, miRNA-21-3p, miRNA-1229-3p, and miRNA-532-3p) effectively distinguished CRCs from HCs" +circulation_biomarker_diagnosis_ns hsa-mir-202 Colorectal Carcinoma 29780253 "A 5-serum miRNA panel (miRNA-1246, miRNA-202-3p, miRNA-21-3p, miRNA-1229-3p, and miRNA-532-3p) effectively distinguished CRCs from HCs" +circulation_biomarker_diagnosis_ns hsa-mir-21 Colorectal Carcinoma 29780253 "A 5-serum miRNA panel (miRNA-1246, miRNA-202-3p, miRNA-21-3p, miRNA-1229-3p, and miRNA-532-3p) effectively distinguished CRCs from HCs" +circulation_biomarker_diagnosis_ns hsa-mir-532 Colorectal Carcinoma 29780253 "A 5-serum miRNA panel (miRNA-1246, miRNA-202-3p, miRNA-21-3p, miRNA-1229-3p, and miRNA-532-3p) effectively distinguished CRCs from HCs" +circulation_biomarker_diagnosis_ns hsa-mir-451 Pulmonary Hypertension 29795360 Plasma miR-451 with echocardiography serves as a diagnostic reference for pulmonary hypertension. +circulation_biomarker_diagnosis_ns hsa-let-7a Diabetic Retinopathy 29812988 "a panel of three miRNAs (hsa-let-7a-5p, hsa-miR-novel-chr5_15976, and hsa-miR-28-3p) presented 0.92 sensitivity and 0.94 specificity for distinguishing T2DM-DR from T2DM-no-DR" +circulation_biomarker_diagnosis_ns hsa-mir-28 Diabetic Retinopathy 29812988 "a panel of three miRNAs (hsa-let-7a-5p, hsa-miR-novel-chr5_15976, and hsa-miR-28-3p) presented 0.92 sensitivity and 0.94 specificity for distinguishing T2DM-DR from T2DM-no-DR" +circulation_biomarker_diagnosis_ns hsa-mir-93 Uterine Cancer 29844841 Expression of serum Hsa-miR-93 in uterine cancer and its clinical significance. +circulation_biomarker_diagnosis_ns hsa-mir-192 Diabetic Nephropathy 29845236 Expression of microRNA?377 and microRNA?192 and their potential as blood?based biomarkers for early detection of type 2 diabetic nephropathy. +circulation_biomarker_diagnosis_ns hsa-mir-377 Diabetic Nephropathy 29845236 Expression of microRNA?377 and microRNA?192 and their potential as blood?based biomarkers for early detection of type 2 diabetic nephropathy. +circulation_biomarker_diagnosis_ns hsa-mir-29b Endometrial Neoplasms 29848072 Expression and prognostic value of miRNA-29b in peripheral blood for endometrial cancer. +circulation_biomarker_diagnosis_ns hsa-mir-21 Atrial Fibrillation 29848477 Circulating MicroRNA-21 Correlates With Left Atrial Low-Voltage Areas and Is Associated With Procedure Outcome in Patients Undergoing Atrial Fibrillation Ablation. +circulation_biomarker_diagnosis_ns hsa-mir-503 Coronary Artery Disease 29870767 The relationship of plasma miR-503 and coronary collateral circulation in patients with coronary artery disease. +circulation_biomarker_diagnosis_ns hsa-mir-122 Chronic Hepatitis B 29881991 Plasma miRNA-122-5p and miRNA-151a-3p identified as potential biomarkers for liver injury among CHB patients with PNALT. +circulation_biomarker_diagnosis_ns hsa-mir-151a Chronic Hepatitis B 29881991 Plasma miRNA-122-5p and miRNA-151a-3p identified as potential biomarkers for liver injury among CHB patients with PNALT. +circulation_biomarker_diagnosis_ns hsa-mir-107 Alzheimer Disease 29885309 "Only six of these were consistent in their direction of expression between studies (miR-107, miR-125b, miR-146a, miR-181c, miR-29b, and miR-342), and they were all shown to be down regulated in individuals with AD compared to controls" +circulation_biomarker_diagnosis_ns hsa-mir-125b Alzheimer Disease 29885309 "Only six of these were consistent in their direction of expression between studies (miR-107, miR-125b, miR-146a, miR-181c, miR-29b, and miR-342), and they were all shown to be down regulated in individuals with AD compared to controls" +circulation_biomarker_diagnosis_ns hsa-mir-146a Alzheimer Disease 29885309 "Only six of these were consistent in their direction of expression between studies (miR-107, miR-125b, miR-146a, miR-181c, miR-29b, and miR-342), and they were all shown to be down regulated in individuals with AD compared to controls" +circulation_biomarker_diagnosis_ns hsa-mir-181c Alzheimer Disease 29885309 "Only six of these were consistent in their direction of expression between studies (miR-107, miR-125b, miR-146a, miR-181c, miR-29b, and miR-342), and they were all shown to be down regulated in individuals with AD compared to controls" +circulation_biomarker_diagnosis_ns hsa-mir-29b Alzheimer Disease 29885309 "Only six of these were consistent in their direction of expression between studies (miR-107, miR-125b, miR-146a, miR-181c, miR-29b, and miR-342), and they were all shown to be down regulated in individuals with AD compared to controls" +circulation_biomarker_diagnosis_ns hsa-mir-342 Alzheimer Disease 29885309 "Only six of these were consistent in their direction of expression between studies (miR-107, miR-125b, miR-146a, miR-181c, miR-29b, and miR-342), and they were all shown to be down regulated in individuals with AD compared to controls" +circulation_biomarker_diagnosis_ns hsa-mir-509 Congenital Heart Diseases 29890280 Clinical diagnostic value of circulating serum miR-509-3p in pulmonary arterial hypertension with congenital heart disease. +circulation_biomarker_diagnosis_ns hsa-mir-16 Rheumatoid Arthritis 29892977 Circulating serum miR-223-3p and miR-16-5p as possible biomarkers of early rheumatoid arthritis. +circulation_biomarker_diagnosis_ns hsa-mir-223 Rheumatoid Arthritis 29892977 Circulating serum miR-223-3p and miR-16-5p as possible biomarkers of early rheumatoid arthritis. +circulation_biomarker_diagnosis_ns hsa-mir-17 Endometriosis 29901577 "the present study characterizes the role of miR-17, IL-4, and IL-6 in the pathogenesis of endometriosis, suggesting the feasibility of using miR-17 and selected cytokines as a noninvasive diagnostic test for the detection of endometriosis" +circulation_biomarker_diagnosis_ns hsa-mir-126 Diabetic Nephropathy 29902497 "6 miRNAs were consistently dysregulated in DKD patients compared to controls: miR-21-5p, miR-29a-3p, miR-126-3p, miR-192-5p, miR-214-3p, and miR-342-3p" +circulation_biomarker_diagnosis_ns hsa-mir-192 Diabetic Nephropathy 29902497 "6 miRNAs were consistently dysregulated in DKD patients compared to controls: miR-21-5p, miR-29a-3p, miR-126-3p, miR-192-5p, miR-214-3p, and miR-342-3p" +circulation_biomarker_diagnosis_ns hsa-mir-21 Diabetic Nephropathy 29902497 "6 miRNAs were consistently dysregulated in DKD patients compared to controls: miR-21-5p, miR-29a-3p, miR-126-3p, miR-192-5p, miR-214-3p, and miR-342-3p" +circulation_biomarker_diagnosis_ns hsa-mir-214 Diabetic Nephropathy 29902497 "6 miRNAs were consistently dysregulated in DKD patients compared to controls: miR-21-5p, miR-29a-3p, miR-126-3p, miR-192-5p, miR-214-3p, and miR-342-3p" +circulation_biomarker_diagnosis_ns hsa-mir-29a Diabetic Nephropathy 29902497 "6 miRNAs were consistently dysregulated in DKD patients compared to controls: miR-21-5p, miR-29a-3p, miR-126-3p, miR-192-5p, miR-214-3p, and miR-342-3p" +circulation_biomarker_diagnosis_ns hsa-mir-342 Diabetic Nephropathy 29902497 "6 miRNAs were consistently dysregulated in DKD patients compared to controls: miR-21-5p, miR-29a-3p, miR-126-3p, miR-192-5p, miR-214-3p, and miR-342-3p" +circulation_biomarker_diagnosis_ns hsa-mir-215 Osteosarcoma 29907935 Circulating miR-215-5p and miR-642a-5p as potential biomarker for diagnosis of osteosarcoma in Mexican population. +circulation_biomarker_diagnosis_ns hsa-mir-642a Osteosarcoma 29907935 Circulating miR-215-5p and miR-642a-5p as potential biomarker for diagnosis of osteosarcoma in Mexican population. +circulation_biomarker_diagnosis_ns hsa-mir-21 "Carcinoma, Pancreatic" 29922178 the diagnostic value of miR-21 in PA was also demonstrated by the pooled sensitivity +circulation_biomarker_diagnosis_ns hsa-mir-122 Primary Sclerosing Cholangitis 29922759 Serum miRNA-122 is an independent biomarker of survival in patients with primary sclerosing cholangitis. +circulation_biomarker_diagnosis_ns hsa-let-7a Gastric Neoplasms 29923196 "deregulation of several circulating miRNAs (i.e., let-7a, miR-21, miR-93, miR-192a, miR-18a, and miR-10b for gastric cancer, and miR-21, miR-375, miR-25-3p, miR-151a-3p, and miR-100-3p for esophageal cancer)" +circulation_biomarker_diagnosis_ns hsa-mir-100 Esophageal Neoplasms 29923196 "deregulation of several circulating miRNAs (i.e., let-7a, miR-21, miR-93, miR-192a, miR-18a, and miR-10b for gastric cancer, and miR-21, miR-375, miR-25-3p, miR-151a-3p, and miR-100-3p for esophageal cancer)" +circulation_biomarker_diagnosis_ns hsa-mir-10b Gastric Neoplasms 29923196 "deregulation of several circulating miRNAs (i.e., let-7a, miR-21, miR-93, miR-192a, miR-18a, and miR-10b for gastric cancer, and miR-21, miR-375, miR-25-3p, miR-151a-3p, and miR-100-3p for esophageal cancer)" +circulation_biomarker_diagnosis_ns hsa-mir-151a Esophageal Neoplasms 29923196 "deregulation of several circulating miRNAs (i.e., let-7a, miR-21, miR-93, miR-192a, miR-18a, and miR-10b for gastric cancer, and miR-21, miR-375, miR-25-3p, miR-151a-3p, and miR-100-3p for esophageal cancer)" +circulation_biomarker_diagnosis_ns hsa-mir-18a Gastric Neoplasms 29923196 "deregulation of several circulating miRNAs (i.e., let-7a, miR-21, miR-93, miR-192a, miR-18a, and miR-10b for gastric cancer, and miR-21, miR-375, miR-25-3p, miR-151a-3p, and miR-100-3p for esophageal cancer)" +circulation_biomarker_diagnosis_ns hsa-mir-192a Gastric Neoplasms 29923196 "deregulation of several circulating miRNAs (i.e., let-7a, miR-21, miR-93, miR-192a, miR-18a, and miR-10b for gastric cancer, and miR-21, miR-375, miR-25-3p, miR-151a-3p, and miR-100-3p for esophageal cancer)" +circulation_biomarker_diagnosis_ns hsa-mir-21 Esophageal Neoplasms 29923196 "deregulation of several circulating miRNAs (i.e., let-7a, miR-21, miR-93, miR-192a, miR-18a, and miR-10b for gastric cancer, and miR-21, miR-375, miR-25-3p, miR-151a-3p, and miR-100-3p for esophageal cancer)" +circulation_biomarker_diagnosis_ns hsa-mir-21 Gastric Neoplasms 29923196 "deregulation of several circulating miRNAs (i.e., let-7a, miR-21, miR-93, miR-192a, miR-18a, and miR-10b for gastric cancer, and miR-21, miR-375, miR-25-3p, miR-151a-3p, and miR-100-3p for esophageal cancer)" +circulation_biomarker_diagnosis_ns hsa-mir-25 Esophageal Neoplasms 29923196 "deregulation of several circulating miRNAs (i.e., let-7a, miR-21, miR-93, miR-192a, miR-18a, and miR-10b for gastric cancer, and miR-21, miR-375, miR-25-3p, miR-151a-3p, and miR-100-3p for esophageal cancer)" +circulation_biomarker_diagnosis_ns hsa-mir-375 Esophageal Neoplasms 29923196 "deregulation of several circulating miRNAs (i.e., let-7a, miR-21, miR-93, miR-192a, miR-18a, and miR-10b for gastric cancer, and miR-21, miR-375, miR-25-3p, miR-151a-3p, and miR-100-3p for esophageal cancer)" +circulation_biomarker_diagnosis_ns hsa-mir-93 Gastric Neoplasms 29923196 "deregulation of several circulating miRNAs (i.e., let-7a, miR-21, miR-93, miR-192a, miR-18a, and miR-10b for gastric cancer, and miR-21, miR-375, miR-25-3p, miR-151a-3p, and miR-100-3p for esophageal cancer)" +circulation_biomarker_diagnosis_ns hsa-mir-106a Gastric Neoplasms 29929476 "circulating miR-21, miR-93, miR-106a and miR-106b could be used as diagnostic plasma biomarkers in gastric cancer patients" +circulation_biomarker_diagnosis_ns hsa-mir-106b Gastric Neoplasms 29929476 "circulating miR-21, miR-93, miR-106a and miR-106b could be used as diagnostic plasma biomarkers in gastric cancer patients" +circulation_biomarker_diagnosis_ns hsa-mir-21 Gastric Neoplasms 29929476 "circulating miR-21, miR-93, miR-106a and miR-106b could be used as diagnostic plasma biomarkers in gastric cancer patients" +circulation_biomarker_diagnosis_ns hsa-mir-93 Gastric Neoplasms 29929476 "circulating miR-21, miR-93, miR-106a and miR-106b could be used as diagnostic plasma biomarkers in gastric cancer patients" +circulation_biomarker_diagnosis_ns hsa-mir-21 Gastric Neoplasms 29936770 Clinical application value of combined detection of serum miR-378 and miR-21 in gastric cancer +circulation_biomarker_diagnosis_ns hsa-mir-378 Gastric Neoplasms 29936770 Clinical application value of combined detection of serum miR-378 and miR-21 in gastric cancer +circulation_biomarker_diagnosis_ns hsa-mir-146b Asthma 29940952 "Stepwise logistic regression yielded a 3-microRNA model (miR-146b, miR-206 and miR-720) that, combined with the exacerbation clinical score, had excellent predictive power with a 0.81 AUROC" +circulation_biomarker_diagnosis_ns hsa-mir-206 Asthma 29940952 "Stepwise logistic regression yielded a 3-microRNA model (miR-146b, miR-206 and miR-720) that, combined with the exacerbation clinical score, had excellent predictive power with a 0.81 AUROC" +circulation_biomarker_diagnosis_ns hsa-mir-720 Asthma 29940952 "Stepwise logistic regression yielded a 3-microRNA model (miR-146b, miR-206 and miR-720) that, combined with the exacerbation clinical score, had excellent predictive power with a 0.81 AUROC" +circulation_biomarker_diagnosis_ns hsa-mir-338 Colorectal Carcinoma 29952077 Circulating miR-338-5p is a potential diagnostic biomarker in colorectal cancer. +circulation_biomarker_diagnosis_ns hsa-mir-146a Pulmonary Sarcoidosis 29956871 "Our data provide evidence that exosomes and microvesicles as extracellular vesicles are present in the bronchoalveolar space of sarcoidosis patients and they differentially express EV miRNA (miR-146a and miR-150), the expression of which correlates negatively with pulmonary function indices" +circulation_biomarker_diagnosis_ns hsa-mir-150 Pulmonary Sarcoidosis 29956871 "Our data provide evidence that exosomes and microvesicles as extracellular vesicles are present in the bronchoalveolar space of sarcoidosis patients and they differentially express EV miRNA (miR-146a and miR-150), the expression of which correlates negatively with pulmonary function indices" +circulation_biomarker_diagnosis_ns hsa-mir-10a "Carcinoma, Hepatocellular" 29962816 "The four serum miRNAs (miR-375, miR-10a, miR-122 and miR-423) could potentially serve as novel biomarkers for the diagnostic and prognostic of HCC" +circulation_biomarker_diagnosis_ns hsa-mir-122 "Carcinoma, Hepatocellular" 29962816 "The four serum miRNAs (miR-375, miR-10a, miR-122 and miR-423) could potentially serve as novel biomarkers for the diagnostic and prognostic of HCC" +circulation_biomarker_diagnosis_ns hsa-mir-375 "Carcinoma, Hepatocellular" 29962816 "The four serum miRNAs (miR-375, miR-10a, miR-122 and miR-423) could potentially serve as novel biomarkers for the diagnostic and prognostic of HCC" +circulation_biomarker_diagnosis_ns hsa-mir-423 "Carcinoma, Hepatocellular" 29962816 "The four serum miRNAs (miR-375, miR-10a, miR-122 and miR-423) could potentially serve as novel biomarkers for the diagnostic and prognostic of HCC" +circulation_biomarker_diagnosis_ns hsa-let-7i Traumatic Brain Injury 29963002 "Promising miRNAs such as miR-21, miR-16 or let-7i were identified as suitable candidate biomarkers for TBI" +circulation_biomarker_diagnosis_ns hsa-mir-16 Traumatic Brain Injury 29963002 "Promising miRNAs such as miR-21, miR-16 or let-7i were identified as suitable candidate biomarkers for TBI" +circulation_biomarker_diagnosis_ns hsa-mir-21 Traumatic Brain Injury 29963002 "Promising miRNAs such as miR-21, miR-16 or let-7i were identified as suitable candidate biomarkers for TBI" +circulation_biomarker_diagnosis_ns hsa-mir-125a Lupus Nephritis 29963250 "mir-125a-5p, miR-146a-5p, and mir-221-3p were found to be statistically significant not only in the screening study but also in the real-time qPCR verification studies" +circulation_biomarker_diagnosis_ns hsa-mir-146a Lupus Nephritis 29963250 "mir-125a-5p, miR-146a-5p, and mir-221-3p were found to be statistically significant not only in the screening study but also in the real-time qPCR verification studies" +circulation_biomarker_diagnosis_ns hsa-mir-221 Lupus Nephritis 29963250 "mir-125a-5p, miR-146a-5p, and mir-221-3p were found to be statistically significant not only in the screening study but also in the real-time qPCR verification studies" +circulation_biomarker_diagnosis_ns hsa-mir-652 "Leukemia, Lymphoblastic, Acute" 29967774 Expression of miR-652-3p and Effect on Apoptosis and Drug Sensitivity in Pediatric Acute Lymphoblastic Leukemia. +circulation_biomarker_diagnosis_ns hsa-mir-146a Rheumatoid Arthritis 29968332 MiR-146a levels in rheumatoid arthritis and their correlation with disease activity: a meta-analysis. +circulation_biomarker_diagnosis_ns hsa-mir-100 Recurrent Spontaneous Abortion 29973278 "Circulating miR-23a-3p, miR-27a-3p, miR-29a-3p, miR-100-5p, miR-127-3p and miR-486-5 might be involved in RM pathogenesis and present potential diagnostic biomarkers for RM" +circulation_biomarker_diagnosis_ns hsa-mir-127 Recurrent Spontaneous Abortion 29973278 "Circulating miR-23a-3p, miR-27a-3p, miR-29a-3p, miR-100-5p, miR-127-3p and miR-486-5 might be involved in RM pathogenesis and present potential diagnostic biomarkers for RM" +circulation_biomarker_diagnosis_ns hsa-mir-23a Recurrent Spontaneous Abortion 29973278 "Circulating miR-23a-3p, miR-27a-3p, miR-29a-3p, miR-100-5p, miR-127-3p and miR-486-5 might be involved in RM pathogenesis and present potential diagnostic biomarkers for RM" +circulation_biomarker_diagnosis_ns hsa-mir-27a Recurrent Spontaneous Abortion 29973278 "Circulating miR-23a-3p, miR-27a-3p, miR-29a-3p, miR-100-5p, miR-127-3p and miR-486-5 might be involved in RM pathogenesis and present potential diagnostic biomarkers for RM" +circulation_biomarker_diagnosis_ns hsa-mir-29a Recurrent Spontaneous Abortion 29973278 "Circulating miR-23a-3p, miR-27a-3p, miR-29a-3p, miR-100-5p, miR-127-3p and miR-486-5 might be involved in RM pathogenesis and present potential diagnostic biomarkers for RM" +circulation_biomarker_diagnosis_ns hsa-mir-486 Recurrent Spontaneous Abortion 29973278 "Circulating miR-23a-3p, miR-27a-3p, miR-29a-3p, miR-100-5p, miR-127-3p and miR-486-5 might be involved in RM pathogenesis and present potential diagnostic biomarkers for RM" +circulation_biomarker_diagnosis_ns hsa-let-7b Graves Disease 29976201 Serum and thyroid tissue level of let-7b and their correlation with TRAb in Graves' disease. +circulation_biomarker_diagnosis_ns hsa-mir-21 "Adenocarcinoma, Pancreatic Ductal" 29976637 Pre-operative Plasma miR-21-5p Is a Sensitive Biomarker and Independent Prognostic Factor in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Surgical Resection. +circulation_biomarker_diagnosis_ns hsa-mir-411 "Carcinoma, Lung, Non-Small-Cell" 29976955 "miR-411-5p edited in position 5 was significantly dysregulated in tissues as well as in exosomes of NSCLC patients, suggesting a potential targetome shift relevant to lung cancer biology" +circulation_biomarker_diagnosis_ns hsa-mir-19b "Lymphoma, Large B-Cell, Diffuse" 29977116 "miR-19b, miR-20a, and miR-451 could enable to differentiate, at the remission review, patients with residual tumor, from patients with complete remission." +circulation_biomarker_diagnosis_ns hsa-mir-20a "Lymphoma, Large B-Cell, Diffuse" 29977116 "miR-19b, miR-20a, and miR-451 could enable to differentiate, at the remission review, patients with residual tumor, from patients with complete remission." +circulation_biomarker_diagnosis_ns hsa-mir-451 "Lymphoma, Large B-Cell, Diffuse" 29977116 "miR-19b, miR-20a, and miR-451 could enable to differentiate, at the remission review, patients with residual tumor, from patients with complete remission." +circulation_biomarker_diagnosis_ns hsa-mir-155 "Carcinoma, Breast" 29981251 "the serum levels of c-miR16, c-miR21, c-miR155, and c-miR195 could be used as biomarkers to improve the early diagnosis of breast cancer" +circulation_biomarker_diagnosis_ns hsa-mir-16 "Carcinoma, Breast" 29981251 "the serum levels of c-miR16, c-miR21, c-miR155, and c-miR195 could be used as biomarkers to improve the early diagnosis of breast cancer" +circulation_biomarker_diagnosis_ns hsa-mir-195 "Carcinoma, Breast" 29981251 "the serum levels of c-miR16, c-miR21, c-miR155, and c-miR195 could be used as biomarkers to improve the early diagnosis of breast cancer" +circulation_biomarker_diagnosis_ns hsa-mir-21 "Carcinoma, Breast" 29981251 "the serum levels of c-miR16, c-miR21, c-miR155, and c-miR195 could be used as biomarkers to improve the early diagnosis of breast cancer" +circulation_biomarker_diagnosis_ns hsa-mir-190 "Carcinoma, Breast" 29996899 "A combination of of miR-21, miR-23b and miR-190 showe higher sensitivity and specificity in ROC analyses compared to each miRNA alone" +circulation_biomarker_diagnosis_ns hsa-mir-21 "Carcinoma, Breast" 29996899 "A combination of of miR-21, miR-23b and miR-190 showe higher sensitivity and specificity in ROC analyses compared to each miRNA alone" +circulation_biomarker_diagnosis_ns hsa-mir-23b "Carcinoma, Breast" 29996899 "A combination of of miR-21, miR-23b and miR-190 showe higher sensitivity and specificity in ROC analyses compared to each miRNA alone" +circulation_biomarker_diagnosis_ns hsa-mir-150 "Carcinoma, Hepatocellular" 30003924 Role of circulating miR-182 and miR-150 as biomarkers for cirrhosis and hepatocellular carcinoma post HCV infection in Egyptian patients. +circulation_biomarker_diagnosis_ns hsa-mir-182 "Carcinoma, Hepatocellular" 30003924 Role of circulating miR-182 and miR-150 as biomarkers for cirrhosis and hepatocellular carcinoma post HCV infection in Egyptian patients. +circulation_biomarker_diagnosis_ns hsa-mir-122 "Fatty Liver, Non-Alcoholic" 30006517 "we have re-examined the predictive value of these serum microRNAs and found that 9 of them (miR-34a, -192, -27b, -122, -22, -21, -197, -30c and -16) associated to NAFLD severity in our independent cohort" +circulation_biomarker_diagnosis_ns hsa-mir-16 "Fatty Liver, Non-Alcoholic" 30006517 "we have re-examined the predictive value of these serum microRNAs and found that 9 of them (miR-34a, -192, -27b, -122, -22, -21, -197, -30c and -16) associated to NAFLD severity in our independent cohort" +circulation_biomarker_diagnosis_ns hsa-mir-192 "Fatty Liver, Non-Alcoholic" 30006517 "we have re-examined the predictive value of these serum microRNAs and found that 9 of them (miR-34a, -192, -27b, -122, -22, -21, -197, -30c and -16) associated to NAFLD severity in our independent cohort" +circulation_biomarker_diagnosis_ns hsa-mir-197 "Fatty Liver, Non-Alcoholic" 30006517 "we have re-examined the predictive value of these serum microRNAs and found that 9 of them (miR-34a, -192, -27b, -122, -22, -21, -197, -30c and -16) associated to NAFLD severity in our independent cohort" +circulation_biomarker_diagnosis_ns hsa-mir-21 "Fatty Liver, Non-Alcoholic" 30006517 "we have re-examined the predictive value of these serum microRNAs and found that 9 of them (miR-34a, -192, -27b, -122, -22, -21, -197, -30c and -16) associated to NAFLD severity in our independent cohort" +circulation_biomarker_diagnosis_ns hsa-mir-22 "Fatty Liver, Non-Alcoholic" 30006517 "we have re-examined the predictive value of these serum microRNAs and found that 9 of them (miR-34a, -192, -27b, -122, -22, -21, -197, -30c and -16) associated to NAFLD severity in our independent cohort" +circulation_biomarker_diagnosis_ns hsa-mir-27b "Fatty Liver, Non-Alcoholic" 30006517 "we have re-examined the predictive value of these serum microRNAs and found that 9 of them (miR-34a, -192, -27b, -122, -22, -21, -197, -30c and -16) associated to NAFLD severity in our independent cohort" +circulation_biomarker_diagnosis_ns hsa-mir-30c "Fatty Liver, Non-Alcoholic" 30006517 "we have re-examined the predictive value of these serum microRNAs and found that 9 of them (miR-34a, -192, -27b, -122, -22, -21, -197, -30c and -16) associated to NAFLD severity in our independent cohort" +circulation_biomarker_diagnosis_ns hsa-mir-34a "Fatty Liver, Non-Alcoholic" 30006517 "we have re-examined the predictive value of these serum microRNAs and found that 9 of them (miR-34a, -192, -27b, -122, -22, -21, -197, -30c and -16) associated to NAFLD severity in our independent cohort" +circulation_biomarker_diagnosis_ns hsa-let-7a "Cardiomyopathy, Dilated" 30008018 "Among the candidates, let-7a-5p, miR-142-3p, miR-145-5p and miR-454-3p levels were significantly increased in LMNAMUT carriers compared to LMNAWT controls and iDCM patients" +circulation_biomarker_diagnosis_ns hsa-mir-142 "Cardiomyopathy, Dilated" 30008018 "Among the candidates, let-7a-5p, miR-142-3p, miR-145-5p and miR-454-3p levels were significantly increased in LMNAMUT carriers compared to LMNAWT controls and iDCM patients" +circulation_biomarker_diagnosis_ns hsa-mir-145 "Cardiomyopathy, Dilated" 30008018 "Among the candidates, let-7a-5p, miR-142-3p, miR-145-5p and miR-454-3p levels were significantly increased in LMNAMUT carriers compared to LMNAWT controls and iDCM patients" +circulation_biomarker_diagnosis_ns hsa-mir-454 "Cardiomyopathy, Dilated" 30008018 "Among the candidates, let-7a-5p, miR-142-3p, miR-145-5p and miR-454-3p levels were significantly increased in LMNAMUT carriers compared to LMNAWT controls and iDCM patients" +circulation_biomarker_diagnosis_ns hsa-mir-150 Diabetic Retinopathy 30008390 "Our data suggest a role for miR-150-5p, miR-21-3p and miR-30b-5p as potential biomarkers of the onset of diabetic retinopathy" +circulation_biomarker_diagnosis_ns hsa-mir-21 Diabetic Retinopathy 30008390 "Our data suggest a role for miR-150-5p, miR-21-3p and miR-30b-5p as potential biomarkers of the onset of diabetic retinopathy" +circulation_biomarker_diagnosis_ns hsa-mir-30b Diabetic Retinopathy 30008390 "Our data suggest a role for miR-150-5p, miR-21-3p and miR-30b-5p as potential biomarkers of the onset of diabetic retinopathy" +circulation_biomarker_diagnosis_ns hsa-let-7b Pulmonary Hypertension 30013141 "dysregulations in miRNAs let-7b-5p, -7c-5p, miR-1307-3p, -185-3p, -8084, -331-3p and -210-3p may be detrimental for the development and function of the lungs and pulmonary vasculature" +circulation_biomarker_diagnosis_ns hsa-let-7c Pulmonary Hypertension 30013141 "dysregulations in miRNAs let-7b-5p, -7c-5p, miR-1307-3p, -185-3p, -8084, -331-3p and -210-3p may be detrimental for the development and function of the lungs and pulmonary vasculature" +circulation_biomarker_diagnosis_ns hsa-mir-1307 Pulmonary Hypertension 30013141 "dysregulations in miRNAs let-7b-5p, -7c-5p, miR-1307-3p, -185-3p, -8084, -331-3p and -210-3p may be detrimental for the development and function of the lungs and pulmonary vasculature" +circulation_biomarker_diagnosis_ns hsa-mir-185 Pulmonary Hypertension 30013141 "dysregulations in miRNAs let-7b-5p, -7c-5p, miR-1307-3p, -185-3p, -8084, -331-3p and -210-3p may be detrimental for the development and function of the lungs and pulmonary vasculature" +circulation_biomarker_diagnosis_ns hsa-mir-210 Pulmonary Hypertension 30013141 "dysregulations in miRNAs let-7b-5p, -7c-5p, miR-1307-3p, -185-3p, -8084, -331-3p and -210-3p may be detrimental for the development and function of the lungs and pulmonary vasculature" +circulation_biomarker_diagnosis_ns hsa-mir-331 Pulmonary Hypertension 30013141 "dysregulations in miRNAs let-7b-5p, -7c-5p, miR-1307-3p, -185-3p, -8084, -331-3p and -210-3p may be detrimental for the development and function of the lungs and pulmonary vasculature" +circulation_biomarker_diagnosis_ns hsa-mir-8084 Pulmonary Hypertension 30013141 "dysregulations in miRNAs let-7b-5p, -7c-5p, miR-1307-3p, -185-3p, -8084, -331-3p and -210-3p may be detrimental for the development and function of the lungs and pulmonary vasculature" +circulation_biomarker_diagnosis_ns hsa-mir-18a Cystic Fibrosis 30014495 Expression levels of serum miR-18a-5p were correlated with increasing hepatic fibrosis stage in CFLD +circulation_biomarker_diagnosis_ns hsa-mir-1165 Allergic Asthma 30015513 A novel microRNA miR-1165-3p as a potential diagnostic biomarker for allergic asthma. +circulation_biomarker_diagnosis_ns hsa-mir-21 Hepatic Veno-Occlusive Disease 30019166 we found that LSEC-derived miR-21-5p and especially miR-511-3p in serum would serve as early phase biomarkers for SOS in response to LSEC damage +circulation_biomarker_diagnosis_ns hsa-mir-511 Hepatic Veno-Occlusive Disease 30019166 we found that LSEC-derived miR-21-5p and especially miR-511-3p in serum would serve as early phase biomarkers for SOS in response to LSEC damage +circulation_biomarker_diagnosis_ns hsa-mir-155 Lymphoma 30021904 Enhancer control of miR-155 expression in Epstein-Barr virus infected B cells. +circulation_biomarker_diagnosis_ns hsa-mir-122 "Fatty Liver, Non-Alcoholic" 30030064 "Plasma miR-17, miR-20a, miR-20b and miR-122 as potential biomarkers for diagnosis of NAFLD in type 2 diabetes mellitus patients." +circulation_biomarker_diagnosis_ns hsa-mir-17 "Fatty Liver, Non-Alcoholic" 30030064 "Plasma miR-17, miR-20a, miR-20b and miR-122 as potential biomarkers for diagnosis of NAFLD in type 2 diabetes mellitus patients." +circulation_biomarker_diagnosis_ns hsa-mir-20a "Fatty Liver, Non-Alcoholic" 30030064 "Plasma miR-17, miR-20a, miR-20b and miR-122 as potential biomarkers for diagnosis of NAFLD in type 2 diabetes mellitus patients." +circulation_biomarker_diagnosis_ns hsa-mir-20b "Fatty Liver, Non-Alcoholic" 30030064 "Plasma miR-17, miR-20a, miR-20b and miR-122 as potential biomarkers for diagnosis of NAFLD in type 2 diabetes mellitus patients." +circulation_biomarker_diagnosis_ns hsa-mir-126 Acute Ischemic Stroke 30030634 "Circulating miR-126 and miR-130a levels correlate with lower disease risk, disease severity, and reduced inflammatory cytokine levels in acute ischemic stroke patients." +circulation_biomarker_diagnosis_ns hsa-mir-130a Acute Ischemic Stroke 30030634 "Circulating miR-126 and miR-130a levels correlate with lower disease risk, disease severity, and reduced inflammatory cytokine levels in acute ischemic stroke patients." +circulation_biomarker_diagnosis_ns hsa-let-7c Graft-Versus-Host Disease 30042760 Differential MicroRNA Expression Levels in Cutaneous Acute Graft-Versus-Host Disease. +circulation_biomarker_diagnosis_ns hsa-mir-34a Graft-Versus-Host Disease 30042760 Differential MicroRNA Expression Levels in Cutaneous Acute Graft-Versus-Host Disease. +circulation_biomarker_diagnosis_ns hsa-mir-365a Graft-Versus-Host Disease 30042760 Differential MicroRNA Expression Levels in Cutaneous Acute Graft-Versus-Host Disease. +circulation_biomarker_diagnosis_ns hsa-mir-503 Graft-Versus-Host Disease 30042760 Differential MicroRNA Expression Levels in Cutaneous Acute Graft-Versus-Host Disease. +circulation_biomarker_diagnosis_ns hsa-mir-1915 "Carcinoma, Breast" 30048472 Identification of serum miR-1915-3p and miR-455-3p as biomarkers for breast cancer. +circulation_biomarker_diagnosis_ns hsa-mir-455 "Carcinoma, Breast" 30048472 Identification of serum miR-1915-3p and miR-455-3p as biomarkers for breast cancer. +circulation_biomarker_diagnosis_ns hsa-mir-142 Cerebral Malaria 30050092 "Differentially expressed microRNAs in experimental cerebral malaria and their involvement in endocytosis, adherens junctions, FoxO and TGF-¦Â signalling pathways." +circulation_biomarker_diagnosis_ns hsa-mir-19a Cerebral Malaria 30050092 "Differentially expressed microRNAs in experimental cerebral malaria and their involvement in endocytosis, adherens junctions, FoxO and TGF-¦Â signalling pathways." +circulation_biomarker_diagnosis_ns hsa-mir-19b Cerebral Malaria 30050092 "Differentially expressed microRNAs in experimental cerebral malaria and their involvement in endocytosis, adherens junctions, FoxO and TGF-¦Â signalling pathways." +circulation_biomarker_diagnosis_ns hsa-mir-223 Cerebral Malaria 30050092 "Differentially expressed microRNAs in experimental cerebral malaria and their involvement in endocytosis, adherens junctions, FoxO and TGF-¦Â signalling pathways." +circulation_biomarker_diagnosis_ns hsa-mir-126 Heart Failure 30054123 Serum microRNA-126 and -223 as new-generation biomarkers for sarcoidosis in patients with heart failure. +circulation_biomarker_diagnosis_ns hsa-mir-223 Heart Failure 30054123 Serum microRNA-126 and -223 as new-generation biomarkers for sarcoidosis in patients with heart failure. +circulation_biomarker_diagnosis_ns hsa-mir-488 "Carcinoma, Breast" 30061217 Circulating Pre-microRNA-488 in Peripheral Blood Is a Potential Biomarker for Predicting Recurrence in Breast Cancer. +circulation_biomarker_diagnosis_ns hsa-mir-144 "Carcinoma, Hepatocellular" 30065664 Extracellular Vesicle-Associated mir-21 and mir-144 Are Markedly Elevated in Serum of Patients With Hepatocellular Carcinoma. +circulation_biomarker_diagnosis_ns hsa-mir-21 "Carcinoma, Hepatocellular" 30065664 Extracellular Vesicle-Associated mir-21 and mir-144 Are Markedly Elevated in Serum of Patients With Hepatocellular Carcinoma. +circulation_biomarker_diagnosis_ns hsa-mir-106a Inflammatory Bowel Diseases 30069249 Micro-RNAs -106a and -362-3p in Peripheral Blood of Inflammatory Bowel Disease Patients. +circulation_biomarker_diagnosis_ns hsa-mir-362 Inflammatory Bowel Diseases 30069249 Micro-RNAs -106a and -362-3p in Peripheral Blood of Inflammatory Bowel Disease Patients. +circulation_biomarker_diagnosis_ns hsa-mir-183 Asthma 30074411 "Circulating miRs-183-5p, -206-3p and -381-3p may serve as novel biomarkers for 4,4'-methylene diphenyl diisocyanate exposure." +circulation_biomarker_diagnosis_ns hsa-mir-206 Asthma 30074411 "Circulating miRs-183-5p, -206-3p and -381-3p may serve as novel biomarkers for 4,4'-methylene diphenyl diisocyanate exposure." +circulation_biomarker_diagnosis_ns hsa-mir-381 Asthma 30074411 "Circulating miRs-183-5p, -206-3p and -381-3p may serve as novel biomarkers for 4,4'-methylene diphenyl diisocyanate exposure." +circulation_biomarker_diagnosis_ns hsa-mir-155 "Lymphoma, Large B-Cell, Diffuse" 30076183 "MicroRNA profiling of diffuse large B-cell lymphoma cells treated with OTX015 revealed changes in the expression levels of a limited number of microRNAs, including miR-92a-1-5p, miR-21-3p, miR-155-5p and miR-96-5p" +circulation_biomarker_diagnosis_ns hsa-mir-21 "Lymphoma, Large B-Cell, Diffuse" 30076183 "MicroRNA profiling of diffuse large B-cell lymphoma cells treated with OTX015 revealed changes in the expression levels of a limited number of microRNAs, including miR-92a-1-5p, miR-21-3p, miR-155-5p and miR-96-5p" +circulation_biomarker_diagnosis_ns hsa-mir-92a "Lymphoma, Large B-Cell, Diffuse" 30076183 "MicroRNA profiling of diffuse large B-cell lymphoma cells treated with OTX015 revealed changes in the expression levels of a limited number of microRNAs, including miR-92a-1-5p, miR-21-3p, miR-155-5p and miR-96-5p" +circulation_biomarker_diagnosis_ns hsa-mir-96 "Lymphoma, Large B-Cell, Diffuse" 30076183 "MicroRNA profiling of diffuse large B-cell lymphoma cells treated with OTX015 revealed changes in the expression levels of a limited number of microRNAs, including miR-92a-1-5p, miR-21-3p, miR-155-5p and miR-96-5p" +circulation_biomarker_diagnosis_ns hsa-mir-193b "Diabetes Mellitus, Type 2" 30083267 "Levels of miR-193b-3p, miR-199a-3p, miR-20a-3p, miR-26b-5p, miR-30b-5p, miR-30c-5p, miR-374a-5p, miR-409-3p, and miR-95-3p were significantly different between Ects obtained from patients with T2DM and those obtained from healthy controls" +circulation_biomarker_diagnosis_ns hsa-mir-199a "Diabetes Mellitus, Type 2" 30083267 "Levels of miR-193b-3p, miR-199a-3p, miR-20a-3p, miR-26b-5p, miR-30b-5p, miR-30c-5p, miR-374a-5p, miR-409-3p, and miR-95-3p were significantly different between Ects obtained from patients with T2DM and those obtained from healthy controls" +circulation_biomarker_diagnosis_ns hsa-mir-20a "Diabetes Mellitus, Type 2" 30083267 "Levels of miR-193b-3p, miR-199a-3p, miR-20a-3p, miR-26b-5p, miR-30b-5p, miR-30c-5p, miR-374a-5p, miR-409-3p, and miR-95-3p were significantly different between Ects obtained from patients with T2DM and those obtained from healthy controls" +circulation_biomarker_diagnosis_ns hsa-mir-26b "Diabetes Mellitus, Type 2" 30083267 "Levels of miR-193b-3p, miR-199a-3p, miR-20a-3p, miR-26b-5p, miR-30b-5p, miR-30c-5p, miR-374a-5p, miR-409-3p, and miR-95-3p were significantly different between Ects obtained from patients with T2DM and those obtained from healthy controls" +circulation_biomarker_diagnosis_ns hsa-mir-30b "Diabetes Mellitus, Type 2" 30083267 "Levels of miR-193b-3p, miR-199a-3p, miR-20a-3p, miR-26b-5p, miR-30b-5p, miR-30c-5p, miR-374a-5p, miR-409-3p, and miR-95-3p were significantly different between Ects obtained from patients with T2DM and those obtained from healthy controls" +circulation_biomarker_diagnosis_ns hsa-mir-30c "Diabetes Mellitus, Type 2" 30083267 "Levels of miR-193b-3p, miR-199a-3p, miR-20a-3p, miR-26b-5p, miR-30b-5p, miR-30c-5p, miR-374a-5p, miR-409-3p, and miR-95-3p were significantly different between Ects obtained from patients with T2DM and those obtained from healthy controls" +circulation_biomarker_diagnosis_ns hsa-mir-374a "Diabetes Mellitus, Type 2" 30083267 "Levels of miR-193b-3p, miR-199a-3p, miR-20a-3p, miR-26b-5p, miR-30b-5p, miR-30c-5p, miR-374a-5p, miR-409-3p, and miR-95-3p were significantly different between Ects obtained from patients with T2DM and those obtained from healthy controls" +circulation_biomarker_diagnosis_ns hsa-mir-409 "Diabetes Mellitus, Type 2" 30083267 "Levels of miR-193b-3p, miR-199a-3p, miR-20a-3p, miR-26b-5p, miR-30b-5p, miR-30c-5p, miR-374a-5p, miR-409-3p, and miR-95-3p were significantly different between Ects obtained from patients with T2DM and those obtained from healthy controls" +circulation_biomarker_diagnosis_ns hsa-mir-95 "Diabetes Mellitus, Type 2" 30083267 "Levels of miR-193b-3p, miR-199a-3p, miR-20a-3p, miR-26b-5p, miR-30b-5p, miR-30c-5p, miR-374a-5p, miR-409-3p, and miR-95-3p were significantly different between Ects obtained from patients with T2DM and those obtained from healthy controls" +circulation_biomarker_diagnosis_ns hsa-mir-134 Gastric Neoplasms 30083331 "We further validated the deregulation of miR-196a-5p in precursor lesions of gastric cancer and the deregulation of miR-134-5p, miR-144-3p and miR-451a in gastric cancer" +circulation_biomarker_diagnosis_ns hsa-mir-144 Gastric Neoplasms 30083331 "We further validated the deregulation of miR-196a-5p in precursor lesions of gastric cancer and the deregulation of miR-134-5p, miR-144-3p and miR-451a in gastric cancer" +circulation_biomarker_diagnosis_ns hsa-mir-196a Gastric Neoplasms 30083331 "We further validated the deregulation of miR-196a-5p in precursor lesions of gastric cancer and the deregulation of miR-134-5p, miR-144-3p and miR-451a in gastric cancer" +circulation_biomarker_diagnosis_ns hsa-mir-451a Gastric Neoplasms 30083331 "We further validated the deregulation of miR-196a-5p in precursor lesions of gastric cancer and the deregulation of miR-134-5p, miR-144-3p and miR-451a in gastric cancer" +circulation_biomarker_diagnosis_ns hsa-mir-19b Coronary Artery Disease 30088484 "Combination of peripheral blood mononuclear cell miR-19b-5p, miR- 221, miR-25-5p, and hypertension correlates with an increased heart failure risk in coronary heart disease patients." +circulation_biomarker_diagnosis_ns hsa-mir-221 Coronary Artery Disease 30088484 "Combination of peripheral blood mononuclear cell miR-19b-5p, miR- 221, miR-25-5p, and hypertension correlates with an increased heart failure risk in coronary heart disease patients." +circulation_biomarker_diagnosis_ns hsa-mir-25 Coronary Artery Disease 30088484 "Combination of peripheral blood mononuclear cell miR-19b-5p, miR- 221, miR-25-5p, and hypertension correlates with an increased heart failure risk in coronary heart disease patients." +circulation_biomarker_diagnosis_ns hsa-mir-22 Pulmonary Hypertension 30090067 Circulating MicroRNA Markers for Pulmonary Hypertension in Supervised Exercise Intervention and Nightly Oxygen Intervention. +circulation_biomarker_diagnosis_ns hsa-mir-451a Pulmonary Hypertension 30090067 Circulating MicroRNA Markers for Pulmonary Hypertension in Supervised Exercise Intervention and Nightly Oxygen Intervention. +circulation_biomarker_diagnosis_ns hsa-mir-126 "Diabetes Mellitus, Type 2" 30093963 "For instance, three miRNAs (miR-126-3p, miR-28-3p miR-486-5p) were dysregulated in prediabetes compared to screen-detected diabetes" +circulation_biomarker_diagnosis_ns hsa-mir-28 "Diabetes Mellitus, Type 2" 30093963 "For instance, three miRNAs (miR-126-3p, miR-28-3p miR-486-5p) were dysregulated in prediabetes compared to screen-detected diabetes" +circulation_biomarker_diagnosis_ns hsa-mir-486 "Diabetes Mellitus, Type 2" 30093963 "For instance, three miRNAs (miR-126-3p, miR-28-3p miR-486-5p) were dysregulated in prediabetes compared to screen-detected diabetes" +circulation_biomarker_diagnosis_ns hsa-mir-30a "Squamous Cell Carcinoma, Oral" 30098778 The proposed combination of miR-30a-5p and miR-769-5p in plasma from OSCC patients could serve as a minimal invasive biomarker for diagnosis and control of T-site recurrences +circulation_biomarker_diagnosis_ns hsa-mir-769 "Squamous Cell Carcinoma, Oral" 30098778 The proposed combination of miR-30a-5p and miR-769-5p in plasma from OSCC patients could serve as a minimal invasive biomarker for diagnosis and control of T-site recurrences +circulation_biomarker_diagnosis_ns hsa-mir-21 Systemic Lupus Erythematosus 30105262 "miR-22-3p¦¤CT and miR-21-5p¦¤CT, were negatively correlated with caspase-10 levels, which may repress extrinsic apoptosis and increase cell survival" +circulation_biomarker_diagnosis_ns hsa-mir-22 Systemic Lupus Erythematosus 30105262 "miR-22-3p¦¤CT and miR-21-5p¦¤CT, were negatively correlated with caspase-10 levels, which may repress extrinsic apoptosis and increase cell survival" +circulation_biomarker_diagnosis_ns hsa-mir-146a Hypertension 30107841 Urinary exosome miR-146a is a potential marker of albuminuria in essential hypertension. +circulation_biomarker_diagnosis_ns hsa-mir-221 Cardiovascular Diseases [unspecific] 30115076 The inverted pattern of circulating miR-221-3p and miR-222-3p associated with isolated low HDL-C phenotype. +circulation_biomarker_diagnosis_ns hsa-mir-222 Cardiovascular Diseases [unspecific] 30115076 The inverted pattern of circulating miR-221-3p and miR-222-3p associated with isolated low HDL-C phenotype. +circulation_biomarker_diagnosis_ns hsa-mir-21 Frailty 30116492 Positive correlations between miR-21 and AOPP and between miR-483 and IL-8 were detected +circulation_biomarker_diagnosis_ns hsa-mir-483 Frailty 30116492 Positive correlations between miR-21 and AOPP and between miR-483 and IL-8 were detected +circulation_biomarker_diagnosis_ns hsa-mir-103a Spinal Cord Injuries 30122113 "miR-125b-5p, miR-146a-5p, miR-328-3p, miR-191-5p, miR-103a-3p, and miR-30b-5p correlated with both oxLDL and cIMT, and showed distinct expression between the SCI-A and SCI-S groups" +circulation_biomarker_diagnosis_ns hsa-mir-125b Spinal Cord Injuries 30122113 "miR-125b-5p, miR-146a-5p, miR-328-3p, miR-191-5p, miR-103a-3p, and miR-30b-5p correlated with both oxLDL and cIMT, and showed distinct expression between the SCI-A and SCI-S groups" +circulation_biomarker_diagnosis_ns hsa-mir-146a Spinal Cord Injuries 30122113 "miR-125b-5p, miR-146a-5p, miR-328-3p, miR-191-5p, miR-103a-3p, and miR-30b-5p correlated with both oxLDL and cIMT, and showed distinct expression between the SCI-A and SCI-S groups" +circulation_biomarker_diagnosis_ns hsa-mir-191 Spinal Cord Injuries 30122113 "miR-125b-5p, miR-146a-5p, miR-328-3p, miR-191-5p, miR-103a-3p, and miR-30b-5p correlated with both oxLDL and cIMT, and showed distinct expression between the SCI-A and SCI-S groups" +circulation_biomarker_diagnosis_ns hsa-mir-30b Spinal Cord Injuries 30122113 "miR-125b-5p, miR-146a-5p, miR-328-3p, miR-191-5p, miR-103a-3p, and miR-30b-5p correlated with both oxLDL and cIMT, and showed distinct expression between the SCI-A and SCI-S groups" +circulation_biomarker_diagnosis_ns hsa-mir-328 Spinal Cord Injuries 30122113 "miR-125b-5p, miR-146a-5p, miR-328-3p, miR-191-5p, miR-103a-3p, and miR-30b-5p correlated with both oxLDL and cIMT, and showed distinct expression between the SCI-A and SCI-S groups" +circulation_biomarker_diagnosis_ns hsa-let-7b Liver Injury 30125006 "Identification of Specific MicroRNA Biomarkers in Early Stages of Hepatocellular Injury, Cholestasis, and Steatosis in Rats." +circulation_biomarker_diagnosis_ns hsa-mir-1 Liver Injury 30125006 "Identification of Specific MicroRNA Biomarkers in Early Stages of Hepatocellular Injury, Cholestasis, and Steatosis in Rats." +circulation_biomarker_diagnosis_ns hsa-mir-143 Liver Injury 30125006 "Identification of Specific MicroRNA Biomarkers in Early Stages of Hepatocellular Injury, Cholestasis, and Steatosis in Rats." +circulation_biomarker_diagnosis_ns hsa-mir-218a Liver Injury 30125006 "Identification of Specific MicroRNA Biomarkers in Early Stages of Hepatocellular Injury, Cholestasis, and Steatosis in Rats." +circulation_biomarker_diagnosis_ns hsa-mir-320 Liver Injury 30125006 "Identification of Specific MicroRNA Biomarkers in Early Stages of Hepatocellular Injury, Cholestasis, and Steatosis in Rats." +circulation_biomarker_diagnosis_ns hsa-mir-208a Coronary Artery Disease 30126654 "Droplet digital PCR of serum miR-499, miR-21 and miR-208a for the detection of functionally relevant coronary artery disease." +circulation_biomarker_diagnosis_ns hsa-mir-21 Coronary Artery Disease 30126654 "Droplet digital PCR of serum miR-499, miR-21 and miR-208a for the detection of functionally relevant coronary artery disease." +circulation_biomarker_diagnosis_ns hsa-mir-499 Coronary Artery Disease 30126654 "Droplet digital PCR of serum miR-499, miR-21 and miR-208a for the detection of functionally relevant coronary artery disease." +circulation_biomarker_diagnosis_ns hsa-mir-30d Multiple Myeloma 30132507 Serum miR-30d as a novel biomarker for multiple myeloma and its antitumor role in U266 cells through the targeting of the MTDH/PI3K/Akt signaling pathway. +circulation_biomarker_diagnosis_ns hsa-mir-1260a Melanoma 30132912 Differential expression of miR-150-5p and miR-1260a is present in plasma following surgical resection of metastatic melanoma in this small sample (n?=?6) of melanoma patients +circulation_biomarker_diagnosis_ns hsa-mir-150 Melanoma 30132912 Differential expression of miR-150-5p and miR-1260a is present in plasma following surgical resection of metastatic melanoma in this small sample (n?=?6) of melanoma patients +circulation_biomarker_diagnosis_ns hsa-mir-106 Hepatitis C Virus Infection 30133717 "miR-23b and miR-106 might be a useful biomarker for chronic hepatitis C (CHC). MiR-27a, miR-93, and miR-199 might have a potential role in the progression of liver diseases" +circulation_biomarker_diagnosis_ns hsa-mir-23b Hepatitis C Virus Infection 30133717 "miR-23b and miR-106 might be a useful biomarker for chronic hepatitis C (CHC). MiR-27a, miR-93, and miR-199 might have a potential role in the progression of liver diseases" +circulation_biomarker_diagnosis_ns hsa-let-7b "Leukemia, Lymphoblastic, Acute" 30139235 Expression of Micro-RNA 128 and Let-7b in Pediatric Acute Lymphoblastic Leukemia Cases +circulation_biomarker_diagnosis_ns hsa-mir-128 "Leukemia, Lymphoblastic, Acute" 30139235 Expression of Micro-RNA 128 and Let-7b in Pediatric Acute Lymphoblastic Leukemia Cases +circulation_biomarker_diagnosis_ns hsa-mir-125b Graft-Versus-Host Disease 30142940 "we selected the 10 miRNAs (miR-423-5p, miR-19a, miR-142-3p, miR-128, miR-193b, miR-30c, miR-193a, miR-191, miR-125b, and miR-574-3p) with the most significant differential expression" +circulation_biomarker_diagnosis_ns hsa-mir-128 Graft-Versus-Host Disease 30142940 "we selected the 10 miRNAs (miR-423-5p, miR-19a, miR-142-3p, miR-128, miR-193b, miR-30c, miR-193a, miR-191, miR-125b, and miR-574-3p) with the most significant differential expression" +circulation_biomarker_diagnosis_ns hsa-mir-142 Graft-Versus-Host Disease 30142940 "we selected the 10 miRNAs (miR-423-5p, miR-19a, miR-142-3p, miR-128, miR-193b, miR-30c, miR-193a, miR-191, miR-125b, and miR-574-3p) with the most significant differential expression" +circulation_biomarker_diagnosis_ns hsa-mir-191 Graft-Versus-Host Disease 30142940 "we selected the 10 miRNAs (miR-423-5p, miR-19a, miR-142-3p, miR-128, miR-193b, miR-30c, miR-193a, miR-191, miR-125b, and miR-574-3p) with the most significant differential expression" +circulation_biomarker_diagnosis_ns hsa-mir-193a Graft-Versus-Host Disease 30142940 "we selected the 10 miRNAs (miR-423-5p, miR-19a, miR-142-3p, miR-128, miR-193b, miR-30c, miR-193a, miR-191, miR-125b, and miR-574-3p) with the most significant differential expression" +circulation_biomarker_diagnosis_ns hsa-mir-193b Graft-Versus-Host Disease 30142940 "we selected the 10 miRNAs (miR-423-5p, miR-19a, miR-142-3p, miR-128, miR-193b, miR-30c, miR-193a, miR-191, miR-125b, and miR-574-3p) with the most significant differential expression" +circulation_biomarker_diagnosis_ns hsa-mir-19a Graft-Versus-Host Disease 30142940 "we selected the 10 miRNAs (miR-423-5p, miR-19a, miR-142-3p, miR-128, miR-193b, miR-30c, miR-193a, miR-191, miR-125b, and miR-574-3p) with the most significant differential expression" +circulation_biomarker_diagnosis_ns hsa-mir-30c Graft-Versus-Host Disease 30142940 "we selected the 10 miRNAs (miR-423-5p, miR-19a, miR-142-3p, miR-128, miR-193b, miR-30c, miR-193a, miR-191, miR-125b, and miR-574-3p) with the most significant differential expression" +circulation_biomarker_diagnosis_ns hsa-mir-423 Graft-Versus-Host Disease 30142940 "we selected the 10 miRNAs (miR-423-5p, miR-19a, miR-142-3p, miR-128, miR-193b, miR-30c, miR-193a, miR-191, miR-125b, and miR-574-3p) with the most significant differential expression" +circulation_biomarker_diagnosis_ns hsa-mir-574 Graft-Versus-Host Disease 30142940 "we selected the 10 miRNAs (miR-423-5p, miR-19a, miR-142-3p, miR-128, miR-193b, miR-30c, miR-193a, miR-191, miR-125b, and miR-574-3p) with the most significant differential expression" +circulation_biomarker_diagnosis_ns hsa-mir-144 Coronary Artery Disease 30143484 Altered Plasma miR-144 as a Novel Biomarker for Coronary Artery Disease. +circulation_biomarker_diagnosis_ns hsa-mir-12 Viral Infectious Disease 30146762 "To date, numerous biomarkers have been identified for thediagnostic or prognostic purpose; for instance, miR-182, miR-486, and miR15a in sepsis; miR-320 and miR505 in inflammatory bowel disease; miR-155 and miR-1260 in influenza; miR-12, miRVP-3p, and miR-184 in arboviruses; and miR-29b and miR-125 in hepatitis infection" +circulation_biomarker_diagnosis_ns hsa-mir-125 Hepatitis [unspecific] 30146762 "To date, numerous biomarkers have been identified for thediagnostic or prognostic purpose; for instance, miR-182, miR-486, and miR15a in sepsis; miR-320 and miR505 in inflammatory bowel disease; miR-155 and miR-1260 in influenza; miR-12, miRVP-3p, and miR-184 in arboviruses; and miR-29b and miR-125 in hepatitis infection" +circulation_biomarker_diagnosis_ns hsa-mir-1260 Influenza 30146762 "To date, numerous biomarkers have been identified for thediagnostic or prognostic purpose; for instance, miR-182, miR-486, and miR15a in sepsis; miR-320 and miR505 in inflammatory bowel disease; miR-155 and miR-1260 in influenza; miR-12, miRVP-3p, and miR-184 in arboviruses; and miR-29b and miR-125 in hepatitis infection" +circulation_biomarker_diagnosis_ns hsa-mir-155 Influenza 30146762 "To date, numerous biomarkers have been identified for thediagnostic or prognostic purpose; for instance, miR-182, miR-486, and miR15a in sepsis; miR-320 and miR505 in inflammatory bowel disease; miR-155 and miR-1260 in influenza; miR-12, miRVP-3p, and miR-184 in arboviruses; and miR-29b and miR-125 in hepatitis infection" +circulation_biomarker_diagnosis_ns hsa-mir-15a Sepsis 30146762 "To date, numerous biomarkers have been identified for thediagnostic or prognostic purpose; for instance, miR-182, miR-486, and miR15a in sepsis; miR-320 and miR505 in inflammatory bowel disease; miR-155 and miR-1260 in influenza; miR-12, miRVP-3p, and miR-184 in arboviruses; and miR-29b and miR-125 in hepatitis infection" +circulation_biomarker_diagnosis_ns hsa-mir-182 Sepsis 30146762 "To date, numerous biomarkers have been identified for thediagnostic or prognostic purpose; for instance, miR-182, miR-486, and miR15a in sepsis; miR-320 and miR505 in inflammatory bowel disease; miR-155 and miR-1260 in influenza; miR-12, miRVP-3p, and miR-184 in arboviruses; and miR-29b and miR-125 in hepatitis infection" +circulation_biomarker_diagnosis_ns hsa-mir-184 Viral Infectious Disease 30146762 "To date, numerous biomarkers have been identified for thediagnostic or prognostic purpose; for instance, miR-182, miR-486, and miR15a in sepsis; miR-320 and miR505 in inflammatory bowel disease; miR-155 and miR-1260 in influenza; miR-12, miRVP-3p, and miR-184 in arboviruses; and miR-29b and miR-125 in hepatitis infection" +circulation_biomarker_diagnosis_ns hsa-mir-29b Hepatitis [unspecific] 30146762 "To date, numerous biomarkers have been identified for thediagnostic or prognostic purpose; for instance, miR-182, miR-486, and miR15a in sepsis; miR-320 and miR505 in inflammatory bowel disease; miR-155 and miR-1260 in influenza; miR-12, miRVP-3p, and miR-184 in arboviruses; and miR-29b and miR-125 in hepatitis infection" +circulation_biomarker_diagnosis_ns hsa-mir-320 Inflammatory Bowel Diseases 30146762 "To date, numerous biomarkers have been identified for thediagnostic or prognostic purpose; for instance, miR-182, miR-486, and miR15a in sepsis; miR-320 and miR505 in inflammatory bowel disease; miR-155 and miR-1260 in influenza; miR-12, miRVP-3p, and miR-184 in arboviruses; and miR-29b and miR-125 in hepatitis infection" +circulation_biomarker_diagnosis_ns hsa-mir-486 Sepsis 30146762 "To date, numerous biomarkers have been identified for thediagnostic or prognostic purpose; for instance, miR-182, miR-486, and miR15a in sepsis; miR-320 and miR505 in inflammatory bowel disease; miR-155 and miR-1260 in influenza; miR-12, miRVP-3p, and miR-184 in arboviruses; and miR-29b and miR-125 in hepatitis infection" +circulation_biomarker_diagnosis_ns hsa-mir-505 Inflammatory Bowel Diseases 30146762 "To date, numerous biomarkers have been identified for thediagnostic or prognostic purpose; for instance, miR-182, miR-486, and miR15a in sepsis; miR-320 and miR505 in inflammatory bowel disease; miR-155 and miR-1260 in influenza; miR-12, miRVP-3p, and miR-184 in arboviruses; and miR-29b and miR-125 in hepatitis infection" +circulation_biomarker_diagnosis_ns hsa-mir-140 Osteoporosis 30171938 Serum miRNAs miR-140-3p and miR-23b-3p as potential biomarkers for osteoporosis and osteoporotic fracture in postmenopausal Mexican-Mestizo women. +circulation_biomarker_diagnosis_ns hsa-mir-23b Osteoporosis 30171938 Serum miRNAs miR-140-3p and miR-23b-3p as potential biomarkers for osteoporosis and osteoporotic fracture in postmenopausal Mexican-Mestizo women. +circulation_biomarker_diagnosis_ns hsa-let-7b Atherosclerosis 30178428 "miR-125b, miR-125a, let-7b, and let-7e could discriminate CARD patients from normal controls and other subtypes. Furthermore, ROC curves shown that miR-7-2-3p and miR-1908 showed significant area-under-the-curve values in both LAA and LAC patients" +circulation_biomarker_diagnosis_ns hsa-let-7e Atherosclerosis 30178428 "miR-125b, miR-125a, let-7b, and let-7e could discriminate CARD patients from normal controls and other subtypes. Furthermore, ROC curves shown that miR-7-2-3p and miR-1908 showed significant area-under-the-curve values in both LAA and LAC patients" +circulation_biomarker_diagnosis_ns hsa-mir-125a Atherosclerosis 30178428 "miR-125b, miR-125a, let-7b, and let-7e could discriminate CARD patients from normal controls and other subtypes. Furthermore, ROC curves shown that miR-7-2-3p and miR-1908 showed significant area-under-the-curve values in both LAA and LAC patients" +circulation_biomarker_diagnosis_ns hsa-mir-125b Atherosclerosis 30178428 "miR-125b, miR-125a, let-7b, and let-7e could discriminate CARD patients from normal controls and other subtypes. Furthermore, ROC curves shown that miR-7-2-3p and miR-1908 showed significant area-under-the-curve values in both LAA and LAC patients" +circulation_biomarker_diagnosis_ns hsa-mir-1908 Atherosclerosis 30178428 "miR-125b, miR-125a, let-7b, and let-7e could discriminate CARD patients from normal controls and other subtypes. Furthermore, ROC curves shown that miR-7-2-3p and miR-1908 showed significant area-under-the-curve values in both LAA and LAC patients" +circulation_biomarker_diagnosis_ns hsa-mir-7-2 Atherosclerosis 30178428 "miR-125b, miR-125a, let-7b, and let-7e could discriminate CARD patients from normal controls and other subtypes. Furthermore, ROC curves shown that miR-7-2-3p and miR-1908 showed significant area-under-the-curve values in both LAA and LAC patients" +circulation_biomarker_diagnosis_ns hsa-mir-376 Preeclampsia 30186390 Expression of miR-376 in blood of pregnant women with preeclampsia and its effect on 25-hydroxyvitamin D. +circulation_biomarker_diagnosis_ns hsa-mir-134 Kawasaki Syndrome 30186482 "Serum exosomal miR-328, miR-575, miR-134 and miR-671-5p as potential biomarkers for the diagnosis of Kawasaki disease and the prediction of therapeutic outcomes of intravenous immunoglobulin therapy." +circulation_biomarker_diagnosis_ns hsa-mir-328 Kawasaki Syndrome 30186482 "Serum exosomal miR-328, miR-575, miR-134 and miR-671-5p as potential biomarkers for the diagnosis of Kawasaki disease and the prediction of therapeutic outcomes of intravenous immunoglobulin therapy." +circulation_biomarker_diagnosis_ns hsa-mir-575 Kawasaki Syndrome 30186482 "Serum exosomal miR-328, miR-575, miR-134 and miR-671-5p as potential biomarkers for the diagnosis of Kawasaki disease and the prediction of therapeutic outcomes of intravenous immunoglobulin therapy." +circulation_biomarker_diagnosis_ns hsa-mir-671 Kawasaki Syndrome 30186482 "Serum exosomal miR-328, miR-575, miR-134 and miR-671-5p as potential biomarkers for the diagnosis of Kawasaki disease and the prediction of therapeutic outcomes of intravenous immunoglobulin therapy." +circulation_biomarker_diagnosis_ns hsa-mir-103a "Carcinoma, Breast" 30220214 miR-24 and miR-103a were valuable biomarkers for distinguishing AH and early-stage BC from healthy individuals/benign proliferative tumor patients +circulation_biomarker_diagnosis_ns hsa-mir-24 "Carcinoma, Breast" 30220214 miR-24 and miR-103a were valuable biomarkers for distinguishing AH and early-stage BC from healthy individuals/benign proliferative tumor patients +circulation_biomarker_diagnosis_ns hsa-mir-331 "Adenocarcinoma, Esophageal" 30228315 Serum miR-331-3p predicts tumor recurrence in esophageal adenocarcinoma. +circulation_biomarker_diagnosis_ns hsa-mir-126 Glioma 30233327 "Many microRNAs (miRNAs) such as miR-183, miR-9, miR-137 and miR-126 expression change may be involved in the cross talk between glioma prevalence and schizophrenia" +circulation_biomarker_diagnosis_ns hsa-mir-126 Schizophrenia 30233327 "Many microRNAs (miRNAs) such as miR-183, miR-9, miR-137 and miR-126 expression change may be involved in the cross talk between glioma prevalence and schizophrenia" +circulation_biomarker_diagnosis_ns hsa-mir-137 Glioma 30233327 "Many microRNAs (miRNAs) such as miR-183, miR-9, miR-137 and miR-126 expression change may be involved in the cross talk between glioma prevalence and schizophrenia" +circulation_biomarker_diagnosis_ns hsa-mir-137 Schizophrenia 30233327 "Many microRNAs (miRNAs) such as miR-183, miR-9, miR-137 and miR-126 expression change may be involved in the cross talk between glioma prevalence and schizophrenia" +circulation_biomarker_diagnosis_ns hsa-mir-183 Glioma 30233327 "Many microRNAs (miRNAs) such as miR-183, miR-9, miR-137 and miR-126 expression change may be involved in the cross talk between glioma prevalence and schizophrenia" +circulation_biomarker_diagnosis_ns hsa-mir-183 Schizophrenia 30233327 "Many microRNAs (miRNAs) such as miR-183, miR-9, miR-137 and miR-126 expression change may be involved in the cross talk between glioma prevalence and schizophrenia" +circulation_biomarker_diagnosis_ns hsa-mir-9 Glioma 30233327 "Many microRNAs (miRNAs) such as miR-183, miR-9, miR-137 and miR-126 expression change may be involved in the cross talk between glioma prevalence and schizophrenia" +circulation_biomarker_diagnosis_ns hsa-mir-9 Schizophrenia 30233327 "Many microRNAs (miRNAs) such as miR-183, miR-9, miR-137 and miR-126 expression change may be involved in the cross talk between glioma prevalence and schizophrenia" +circulation_biomarker_diagnosis_ns hsa-mir-138 Lung Neoplasms 30233883 "We validated a panel of miRNAs (hsa-miR-199a-3p, hsa-miR-148a-3p, hsa-miR-210-3p, hsa-miR-378d and hsa-miR-138-5p) to aid early diagnosis of lung adenocarcinoma by blood test in lung cancer" +circulation_biomarker_diagnosis_ns hsa-mir-148a Lung Neoplasms 30233883 "We validated a panel of miRNAs (hsa-miR-199a-3p, hsa-miR-148a-3p, hsa-miR-210-3p, hsa-miR-378d and hsa-miR-138-5p) to aid early diagnosis of lung adenocarcinoma by blood test in lung cancer" +circulation_biomarker_diagnosis_ns hsa-mir-199a Lung Neoplasms 30233883 "We validated a panel of miRNAs (hsa-miR-199a-3p, hsa-miR-148a-3p, hsa-miR-210-3p, hsa-miR-378d and hsa-miR-138-5p) to aid early diagnosis of lung adenocarcinoma by blood test in lung cancer" +circulation_biomarker_diagnosis_ns hsa-mir-210 Lung Neoplasms 30233883 "We validated a panel of miRNAs (hsa-miR-199a-3p, hsa-miR-148a-3p, hsa-miR-210-3p, hsa-miR-378d and hsa-miR-138-5p) to aid early diagnosis of lung adenocarcinoma by blood test in lung cancer" +circulation_biomarker_diagnosis_ns hsa-mir-378d Lung Neoplasms 30233883 "We validated a panel of miRNAs (hsa-miR-199a-3p, hsa-miR-148a-3p, hsa-miR-210-3p, hsa-miR-378d and hsa-miR-138-5p) to aid early diagnosis of lung adenocarcinoma by blood test in lung cancer" +circulation_biomarker_diagnosis_ns hsa-mir-192 Diabetes Mellitus 30250222 Circulating microRNAs -192 and -194 are associated with the presence and incidence of diabetes mellitus. +circulation_biomarker_diagnosis_ns hsa-mir-194 Diabetes Mellitus 30250222 Circulating microRNAs -192 and -194 are associated with the presence and incidence of diabetes mellitus. +circulation_biomarker_diagnosis_ns hsa-mir-223 Prostate Neoplasms 30250541 Monitoring of platelet function parameters and microRNA expression levels in patients with prostate cancer treated with volumetric modulated arc radiotherapy. +circulation_biomarker_diagnosis_ns hsa-mir-122 "Fatty Liver, Non-Alcoholic" 30252499 "The liver-specific microRNAs including miR-122, miR-130,miR-183, miR-196, miR-209 and miR-96 are potential indicators of liver injury" +circulation_biomarker_diagnosis_ns hsa-mir-130 "Fatty Liver, Non-Alcoholic" 30252499 "The liver-specific microRNAs including miR-122, miR-130,miR-183, miR-196, miR-209 and miR-96 are potential indicators of liver injury" +circulation_biomarker_diagnosis_ns hsa-mir-183 "Fatty Liver, Non-Alcoholic" 30252499 "The liver-specific microRNAs including miR-122, miR-130,miR-183, miR-196, miR-209 and miR-96 are potential indicators of liver injury" +circulation_biomarker_diagnosis_ns hsa-mir-196 "Fatty Liver, Non-Alcoholic" 30252499 "The liver-specific microRNAs including miR-122, miR-130,miR-183, miR-196, miR-209 and miR-96 are potential indicators of liver injury" +circulation_biomarker_diagnosis_ns hsa-mir-209 "Fatty Liver, Non-Alcoholic" 30252499 "The liver-specific microRNAs including miR-122, miR-130,miR-183, miR-196, miR-209 and miR-96 are potential indicators of liver injury" +circulation_biomarker_diagnosis_ns hsa-mir-96 "Fatty Liver, Non-Alcoholic" 30252499 "The liver-specific microRNAs including miR-122, miR-130,miR-183, miR-196, miR-209 and miR-96 are potential indicators of liver injury" +circulation_biomarker_diagnosis_ns hsa-mir-183 "Carcinoma, Hepatocellular" 30256056 Expression Analysis of Serum microRNA-34a and microRNA-183 in Hepatocellular Carcinoma +circulation_biomarker_diagnosis_ns hsa-mir-34a "Carcinoma, Hepatocellular" 30256056 Expression Analysis of Serum microRNA-34a and microRNA-183 in Hepatocellular Carcinoma +circulation_biomarker_diagnosis_ns hsa-mir-22 Myocardial Infarction 30256407 Circulating miR-22-5p and miR-122-5p are promising novel biomarkers for diagnosis of acute myocardial infarction. +circulation_biomarker_diagnosis_ns hsa-mir-22 Myocardial Infarction 30256407 Circulating miR-22-5p and miR-122-5p are promising novel biomarkers for diagnosis of acute myocardial infarction. +circulation_biomarker_diagnosis_ns hsa-mir-199a Diabetes Mellitus 30258406 "Diabetes Modulates MicroRNAs 29b-3p, 29c-3p, 199a-5p and 532-3p Expression in Muscle: Possible Role in GLUT4 and HK2 Repression." +circulation_biomarker_diagnosis_ns hsa-mir-29b Diabetes Mellitus 30258406 "Diabetes Modulates MicroRNAs 29b-3p, 29c-3p, 199a-5p and 532-3p Expression in Muscle: Possible Role in GLUT4 and HK2 Repression." +circulation_biomarker_diagnosis_ns hsa-mir-29c Diabetes Mellitus 30258406 "Diabetes Modulates MicroRNAs 29b-3p, 29c-3p, 199a-5p and 532-3p Expression in Muscle: Possible Role in GLUT4 and HK2 Repression." +circulation_biomarker_diagnosis_ns hsa-mir-532 Diabetes Mellitus 30258406 "Diabetes Modulates MicroRNAs 29b-3p, 29c-3p, 199a-5p and 532-3p Expression in Muscle: Possible Role in GLUT4 and HK2 Repression." +circulation_biomarker_diagnosis_ns hsa-let-7g "Diabetes Mellitus, Type 1" 30259606 Temporal dynamics of serum let-7g expression mirror the decline of residual beta-cell function in longitudinal observation of children with type 1 diabetes. +circulation_biomarker_diagnosis_ns hsa-mir-136 Preeclampsia 30261165 "Role of mesenchymal stem cells exosomes derived microRNAs; miR-136, miR-494 and miR-495 in pre-eclampsia diagnosis and evaluation." +circulation_biomarker_diagnosis_ns hsa-mir-494 Preeclampsia 30261165 "Role of mesenchymal stem cells exosomes derived microRNAs; miR-136, miR-494 and miR-495 in pre-eclampsia diagnosis and evaluation." +circulation_biomarker_diagnosis_ns hsa-mir-495 Preeclampsia 30261165 "Role of mesenchymal stem cells exosomes derived microRNAs; miR-136, miR-494 and miR-495 in pre-eclampsia diagnosis and evaluation." +circulation_biomarker_diagnosis_ns hsa-mir-200 Ovarian Neoplasms 30275195 Increased Soluble PD-L1 Levels in the Plasma of Patients with Epithelial Ovarian Cancer Correlate with Plasma Levels of miR34a and miR200. +circulation_biomarker_diagnosis_ns hsa-mir-34a Ovarian Neoplasms 30275195 Increased Soluble PD-L1 Levels in the Plasma of Patients with Epithelial Ovarian Cancer Correlate with Plasma Levels of miR34a and miR200. +circulation_biomarker_diagnosis_ns hsa-mir-142a Myocardial Infarction 30279543 A novel system-level approach using RNA-sequencing data identifies miR-30-5p and miR-142a-5p as key regulators of apoptosis in myocardial infarction. +circulation_biomarker_diagnosis_ns hsa-mir-30 Myocardial Infarction 30279543 A novel system-level approach using RNA-sequencing data identifies miR-30-5p and miR-142a-5p as key regulators of apoptosis in myocardial infarction. +circulation_biomarker_diagnosis_ns hsa-mir-210 "Carcinoma, Renal Cell, Clear-Cell" 30304555 Serum exosomal miR-210 as a potential biomarker for clear cell renal cell carcinoma. +circulation_biomarker_diagnosis_ns hsa-mir-371b Systemic Lupus Erythematosus 30304699 Serum miRNA-371b-5p and miRNA-5100 act as biomarkers for systemic lupus erythematosus. +circulation_biomarker_diagnosis_ns hsa-mir-5100 Systemic Lupus Erythematosus 30304699 Serum miRNA-371b-5p and miRNA-5100 act as biomarkers for systemic lupus erythematosus. +circulation_biomarker_diagnosis_ns hsa-mir-146a Lupus Nephritis 30306067 "miR-3135b, miR-654-5p and miR-146a-5p in urinary exosomes could be used as novel non-invasive diagnostic markers for LNIV-CC" +circulation_biomarker_diagnosis_ns hsa-mir-3135b Lupus Nephritis 30306067 "miR-3135b, miR-654-5p and miR-146a-5p in urinary exosomes could be used as novel non-invasive diagnostic markers for LNIV-CC" +circulation_biomarker_diagnosis_ns hsa-mir-654 Lupus Nephritis 30306067 "miR-3135b, miR-654-5p and miR-146a-5p in urinary exosomes could be used as novel non-invasive diagnostic markers for LNIV-CC" +circulation_biomarker_diagnosis_ns hsa-mir-29c Atherosclerosis 30308507 Plasma MicroRNA-29c Levels Are Associated with Carotid Intima-Media Thickness and is a Potential Biomarker for the Early Detection of Atherosclerosis. +circulation_biomarker_diagnosis_ns hsa-mir-1254 Myocardial Infarction 30310086 Circulating miR-1254 predicts ventricular remodeling in patients with ST-Segment-Elevation Myocardial Infarction: A cardiovascular magnetic resonance study. +circulation_biomarker_diagnosis_ns hsa-mir-142a Alzheimer Disease 30314521 "four of these (miR-142a-5p, miR-146a-5p, miR-155-5p and miR-455-5p) are altered in AD patients" +circulation_biomarker_diagnosis_ns hsa-mir-146a Alzheimer Disease 30314521 "four of these (miR-142a-5p, miR-146a-5p, miR-155-5p and miR-455-5p) are altered in AD patients" +circulation_biomarker_diagnosis_ns hsa-mir-155 Alzheimer Disease 30314521 "four of these (miR-142a-5p, miR-146a-5p, miR-155-5p and miR-455-5p) are altered in AD patients" +circulation_biomarker_diagnosis_ns hsa-mir-455 Alzheimer Disease 30314521 "four of these (miR-142a-5p, miR-146a-5p, miR-155-5p and miR-455-5p) are altered in AD patients" +circulation_biomarker_diagnosis_ns hsa-mir-2166 "Stroke, Ischemic" 30316639 "Ten of these miRNA had not previously been associated with ischemic stroke (miR-664a-3p, -2116-5pp, -4531, -4765-5p, -647, -4709-3p, -4742-3p, -5584-3p, -4756-3p, and -5187-3p)" +circulation_biomarker_diagnosis_ns hsa-mir-4531 "Stroke, Ischemic" 30316639 "Ten of these miRNA had not previously been associated with ischemic stroke (miR-664a-3p, -2116-5pp, -4531, -4765-5p, -647, -4709-3p, -4742-3p, -5584-3p, -4756-3p, and -5187-3p)" +circulation_biomarker_diagnosis_ns hsa-mir-4709 "Stroke, Ischemic" 30316639 "Ten of these miRNA had not previously been associated with ischemic stroke (miR-664a-3p, -2116-5pp, -4531, -4765-5p, -647, -4709-3p, -4742-3p, -5584-3p, -4756-3p, and -5187-3p)" +circulation_biomarker_diagnosis_ns hsa-mir-4742 "Stroke, Ischemic" 30316639 "Ten of these miRNA had not previously been associated with ischemic stroke (miR-664a-3p, -2116-5pp, -4531, -4765-5p, -647, -4709-3p, -4742-3p, -5584-3p, -4756-3p, and -5187-3p)" +circulation_biomarker_diagnosis_ns hsa-mir-4756 "Stroke, Ischemic" 30316639 "Ten of these miRNA had not previously been associated with ischemic stroke (miR-664a-3p, -2116-5pp, -4531, -4765-5p, -647, -4709-3p, -4742-3p, -5584-3p, -4756-3p, and -5187-3p)" +circulation_biomarker_diagnosis_ns hsa-mir-4765 "Stroke, Ischemic" 30316639 "Ten of these miRNA had not previously been associated with ischemic stroke (miR-664a-3p, -2116-5pp, -4531, -4765-5p, -647, -4709-3p, -4742-3p, -5584-3p, -4756-3p, and -5187-3p)" +circulation_biomarker_diagnosis_ns hsa-mir-5187 "Stroke, Ischemic" 30316639 "Ten of these miRNA had not previously been associated with ischemic stroke (miR-664a-3p, -2116-5pp, -4531, -4765-5p, -647, -4709-3p, -4742-3p, -5584-3p, -4756-3p, and -5187-3p)" +circulation_biomarker_diagnosis_ns hsa-mir-5584 "Stroke, Ischemic" 30316639 "Ten of these miRNA had not previously been associated with ischemic stroke (miR-664a-3p, -2116-5pp, -4531, -4765-5p, -647, -4709-3p, -4742-3p, -5584-3p, -4756-3p, and -5187-3p)" +circulation_biomarker_diagnosis_ns hsa-mir-647 "Stroke, Ischemic" 30316639 "Ten of these miRNA had not previously been associated with ischemic stroke (miR-664a-3p, -2116-5pp, -4531, -4765-5p, -647, -4709-3p, -4742-3p, -5584-3p, -4756-3p, and -5187-3p)" +circulation_biomarker_diagnosis_ns hsa-mir-664a "Stroke, Ischemic" 30316639 "Ten of these miRNA had not previously been associated with ischemic stroke (miR-664a-3p, -2116-5pp, -4531, -4765-5p, -647, -4709-3p, -4742-3p, -5584-3p, -4756-3p, and -5187-3p)" +circulation_biomarker_diagnosis_ns hsa-mir-371a Testicular Germ Cell Tumor 30321995 MiR-371a-3p Serum Levels Are Increased in Recurrence of Testicular Germ Cell Tumor Patients. +circulation_biomarker_diagnosis_ns hsa-mir-210 Preeclampsia 30324123 miR-210 could serve as a novel biomarker to predict PE pathophysiology +circulation_biomarker_diagnosis_ns hsa-let-7b Prostate Neoplasms 30324582 "miR-1825, miR-484, miR-205, miR-141, and let-7b were shown to be highly specific for PCa" +circulation_biomarker_diagnosis_ns hsa-mir-141 Prostate Neoplasms 30324582 "miR-1825, miR-484, miR-205, miR-141, and let-7b were shown to be highly specific for PCa" +circulation_biomarker_diagnosis_ns hsa-mir-1825 Prostate Neoplasms 30324582 "miR-1825, miR-484, miR-205, miR-141, and let-7b were shown to be highly specific for PCa" +circulation_biomarker_diagnosis_ns hsa-mir-205 Prostate Neoplasms 30324582 "miR-1825, miR-484, miR-205, miR-141, and let-7b were shown to be highly specific for PCa" +circulation_biomarker_diagnosis_ns hsa-mir-484 Prostate Neoplasms 30324582 "miR-1825, miR-484, miR-205, miR-141, and let-7b were shown to be highly specific for PCa" +circulation_biomarker_diagnosis_ns hsa-mir-143 Sepsis 30332984 MicroRNAs 143 and 150 in whole blood enable detection of T-cell immunoparalysis in sepsis. +circulation_biomarker_diagnosis_ns hsa-mir-150 Sepsis 30332984 MicroRNAs 143 and 150 in whole blood enable detection of T-cell immunoparalysis in sepsis. +circulation_biomarker_diagnosis_ns hsa-mir-10a Vascular Myelopathy 30352301 "MicroRNA-10a, -210 and -563 as circulating biomarkers for Ossification of the Posterior Longitudinal Ligament." +circulation_biomarker_diagnosis_ns hsa-mir-210 Vascular Myelopathy 30352301 "MicroRNA-10a, -210 and -563 as circulating biomarkers for Ossification of the Posterior Longitudinal Ligament." +circulation_biomarker_diagnosis_ns hsa-mir-563 Vascular Myelopathy 30352301 "MicroRNA-10a, -210 and -563 as circulating biomarkers for Ossification of the Posterior Longitudinal Ligament." +circulation_biomarker_diagnosis_ns hsa-mir-3177 Aneurysmal Subarachnoid Hemorrhage 30354977 whole-blood miRNA levels of hsa-miR-3177-3p could serve as a biomarker for vasospasm +circulation_biomarker_diagnosis_ns hsa-mir-126 Colorectal Carcinoma 30357530 "Role of miRNA-210, miRNA-21 and miRNA-126 as diagnostic biomarkers in colorectal carcinoma: impact of HIF-1¦Á-VEGF signaling pathway." +circulation_biomarker_diagnosis_ns hsa-mir-21 Colorectal Carcinoma 30357530 "Role of miRNA-210, miRNA-21 and miRNA-126 as diagnostic biomarkers in colorectal carcinoma: impact of HIF-1¦Á-VEGF signaling pathway." +circulation_biomarker_diagnosis_ns hsa-mir-210 Colorectal Carcinoma 30357530 "Role of miRNA-210, miRNA-21 and miRNA-126 as diagnostic biomarkers in colorectal carcinoma: impact of HIF-1¦Á-VEGF signaling pathway." +circulation_biomarker_diagnosis_ns hsa-mir-128 Huntington Disease 30359470 "hsa-miR-338-3p, hsa-miR-128-3p, hsa-miR-23a-3p and hsa-miR-24-3p are potential HD-biomarkers" +circulation_biomarker_diagnosis_ns hsa-mir-23a Huntington Disease 30359470 "hsa-miR-338-3p, hsa-miR-128-3p, hsa-miR-23a-3p and hsa-miR-24-3p are potential HD-biomarkers" +circulation_biomarker_diagnosis_ns hsa-mir-24 Huntington Disease 30359470 "hsa-miR-338-3p, hsa-miR-128-3p, hsa-miR-23a-3p and hsa-miR-24-3p are potential HD-biomarkers" +circulation_biomarker_diagnosis_ns hsa-mir-338 Huntington Disease 30359470 "hsa-miR-338-3p, hsa-miR-128-3p, hsa-miR-23a-3p and hsa-miR-24-3p are potential HD-biomarkers" +circulation_biomarker_diagnosis_ns hsa-mir-122 Gastric Neoplasms 30364858 miR-122-5p as a novel biomarker for alpha-fetoprotein-producing gastric cancer. +circulation_biomarker_diagnosis_ns hsa-mir-142 Gastric Neoplasms 30373600 miR-338-3p and miR-142-3p may be promising predictive biomarkers for such patients +circulation_biomarker_diagnosis_ns hsa-mir-338 Gastric Neoplasms 30373600 miR-338-3p and miR-142-3p may be promising predictive biomarkers for such patients +circulation_biomarker_diagnosis_ns hsa-mir-1185-1 "Carcinoma, Bladder" 30382619 Circulating miRNA Panels for Specific and Early Detection in Bladder Cancer. +circulation_biomarker_diagnosis_ns hsa-mir-1343 "Carcinoma, Bladder" 30382619 Circulating miRNA Panels for Specific and Early Detection in Bladder Cancer. +circulation_biomarker_diagnosis_ns hsa-mir-3960 "Carcinoma, Bladder" 30382619 Circulating miRNA Panels for Specific and Early Detection in Bladder Cancer. +circulation_biomarker_diagnosis_ns hsa-mir-4695 "Carcinoma, Bladder" 30382619 Circulating miRNA Panels for Specific and Early Detection in Bladder Cancer. +circulation_biomarker_diagnosis_ns hsa-mir-6087 "Carcinoma, Bladder" 30382619 Circulating miRNA Panels for Specific and Early Detection in Bladder Cancer. +circulation_biomarker_diagnosis_ns hsa-mir-6724 "Carcinoma, Bladder" 30382619 Circulating miRNA Panels for Specific and Early Detection in Bladder Cancer. +circulation_biomarker_diagnosis_ns hsa-mir-6831 "Carcinoma, Bladder" 30382619 Circulating miRNA Panels for Specific and Early Detection in Bladder Cancer. +circulation_biomarker_diagnosis_up hsa-mir-155 "Lymphoma, Burkitt" 14695998 upregulated +circulation_biomarker_diagnosis_up hsa-mir-155 "Lymphoma, B-Cell" 15738415 upregulated +circulation_biomarker_diagnosis_up hsa-mir-155 "Lymphoma, Burkitt" 16195701 overexpression +circulation_biomarker_diagnosis_up hsa-mir-17 "Leukemia, B-Cell" 16224045 Overexpression +circulation_biomarker_diagnosis_up hsa-mir-18a "Leukemia, B-Cell" 16224045 Overexpression +circulation_biomarker_diagnosis_up hsa-mir-19a "Leukemia, B-Cell" 16224045 Overexpression +circulation_biomarker_diagnosis_up hsa-mir-19b-1 "Leukemia, B-Cell" 16224045 Overexpression +circulation_biomarker_diagnosis_up hsa-mir-20a "Leukemia, B-Cell" 16224045 Overexpression +circulation_biomarker_diagnosis_up hsa-mir-92a-1 "Leukemia, B-Cell" 16224045 Overexpression +circulation_biomarker_diagnosis_up hsa-mir-146a "Leukemia, Lymphocytic, Chronic, B-Cell" 16251535 overexpression +circulation_biomarker_diagnosis_up hsa-mir-146b "Leukemia, Lymphocytic, Chronic, B-Cell" 16251535 overexpression +circulation_biomarker_diagnosis_up hsa-mir-155 "Leukemia, Lymphocytic, Chronic, B-Cell" 16251535 overexpression +circulation_biomarker_diagnosis_up hsa-mir-15a "Leukemia, Lymphocytic, Chronic, B-Cell" 16251535 overexpression +circulation_biomarker_diagnosis_up hsa-mir-195 "Leukemia, Lymphocytic, Chronic, B-Cell" 16251535 overexpression +circulation_biomarker_diagnosis_up hsa-mir-221 "Leukemia, Lymphocytic, Chronic, B-Cell" 16251535 overexpression +circulation_biomarker_diagnosis_up hsa-mir-23b "Leukemia, Lymphocytic, Chronic, B-Cell" 16251535 overexpression +circulation_biomarker_diagnosis_up hsa-mir-24-1 "Leukemia, Lymphocytic, Chronic, B-Cell" 16251535 overexpression +circulation_biomarker_diagnosis_up hsa-mir-17 Lung Neoplasms 16266980 overexpressed +circulation_biomarker_diagnosis_up hsa-mir-18a Lung Neoplasms 16266980 overexpressed +circulation_biomarker_diagnosis_up hsa-mir-19a Lung Neoplasms 16266980 overexpressed +circulation_biomarker_diagnosis_up hsa-mir-19b-1 Lung Neoplasms 16266980 overexpressed +circulation_biomarker_diagnosis_up hsa-mir-20a Lung Neoplasms 16266980 overexpressed +circulation_biomarker_diagnosis_up hsa-mir-92a-1 Lung Neoplasms 16266980 overexpressed +circulation_biomarker_diagnosis_up hsa-mir-155 Breast Neoplasms 16466964 overexpressed +circulation_biomarker_diagnosis_up hsa-mir-155 "Leukemia, B-Cell" 16466964 overexpressed +circulation_biomarker_diagnosis_up hsa-mir-155 "Lymphoma, Burkitt" 16466964 overexpressed +circulation_biomarker_diagnosis_up hsa-mir-155 "Lymphoma, Hodgkin" 16466964 overexpressed +circulation_biomarker_diagnosis_up hsa-mir-21 Brain Neoplasms 16466964 overexpressed +circulation_biomarker_diagnosis_up hsa-mir-21 Glioblastoma 16466964 overexpressed +circulation_biomarker_diagnosis_up hsa-mir-155 "Leukemia, B-Cell" 16736018 upregulation of miR-155 and the miR-17-92 cluster +circulation_biomarker_diagnosis_up hsa-mir-17 "Leukemia, B-Cell" 16736018 upregulation of miR-155 and the miR-17-92 cluster +circulation_biomarker_diagnosis_up hsa-mir-18a "Leukemia, B-Cell" 16736018 upregulation of miR-155 and the miR-17-92 cluster +circulation_biomarker_diagnosis_up hsa-mir-19a "Leukemia, B-Cell" 16736018 upregulation of miR-155 and the miR-17-92 cluster +circulation_biomarker_diagnosis_up hsa-mir-19b-1 "Leukemia, B-Cell" 16736018 upregulation of miR-155 and the miR-17-92 cluster +circulation_biomarker_diagnosis_up hsa-mir-20a "Leukemia, B-Cell" 16736018 upregulation of miR-155 and the miR-17-92 cluster +circulation_biomarker_diagnosis_up hsa-mir-92a-1 "Leukemia, B-Cell" 16736018 upregulation of miR-155 and the miR-17-92 cluster +circulation_biomarker_diagnosis_up hsa-mir-127 Breast Neoplasms 16766263 upregulation +circulation_biomarker_diagnosis_up hsa-mir-145 Colon Neoplasms 16885332 Reduced accumulation in colon adenomas and carcinomas +circulation_biomarker_diagnosis_up hsa-mir-146a Thyroid Neoplasms 16885332 up-regulation +circulation_biomarker_diagnosis_up hsa-mir-146b Thyroid Neoplasms 16885332 up-regulation +circulation_biomarker_diagnosis_up hsa-mir-155 Breast Neoplasms 16885332 Overexpression in breast cancers +circulation_biomarker_diagnosis_up hsa-mir-17 Lung Neoplasms 16885332 Overexpressed in lung cancers +circulation_biomarker_diagnosis_up hsa-mir-17 Lymphoma 16885332 Primary transcripts overexpressed in lymphomas +circulation_biomarker_diagnosis_up hsa-mir-18a Lung Neoplasms 16885332 Overexpressed in lung cancers +circulation_biomarker_diagnosis_up hsa-mir-18a Lymphoma 16885332 Primary transcripts overexpressed in lymphomas +circulation_biomarker_diagnosis_up hsa-mir-19a Lung Neoplasms 16885332 Overexpressed in lung cancers +circulation_biomarker_diagnosis_up hsa-mir-19a Lymphoma 16885332 Primary transcripts overexpressed in lymphomas +circulation_biomarker_diagnosis_up hsa-mir-19b-1 Lung Neoplasms 16885332 Overexpressed in lung cancers +circulation_biomarker_diagnosis_up hsa-mir-19b-1 Lymphoma 16885332 Primary transcripts overexpressed in lymphomas +circulation_biomarker_diagnosis_up hsa-mir-20a Lung Neoplasms 16885332 Overexpressed in lung cancers +circulation_biomarker_diagnosis_up hsa-mir-20a Lymphoma 16885332 Primary transcripts overexpressed in lymphomas +circulation_biomarker_diagnosis_up hsa-mir-21 Breast Neoplasms 16885332 Overexpression in breast cancers +circulation_biomarker_diagnosis_up hsa-mir-21 Glioblastoma 16885332 Elevated levels in glioblastoma primary tumors and cell lines +circulation_biomarker_diagnosis_up hsa-mir-221 Thyroid Neoplasms 16885332 "It was shown that miR-221, highly overexpressed in papillary thyroid tumors, is also overexpressed in normal thyroid tissue adjacent to tumors but not in normal thyroid tissues from individuals without clinical thyroid disease." +circulation_biomarker_diagnosis_up hsa-mir-222 Thyroid Neoplasms 16885332 up-regulation +circulation_biomarker_diagnosis_up hsa-mir-92a-1 Lung Neoplasms 16885332 Overexpressed in lung cancers +circulation_biomarker_diagnosis_up hsa-mir-92a-1 Lymphoma 16885332 Primary transcripts overexpressed in lymphomas +circulation_biomarker_diagnosis_up hsa-mir-155 "Lymphoma, Burkitt" 16940181 Increased expression of the precursor of Mir-155has been detected in pediatric Burkitt lymphoma. +circulation_biomarker_diagnosis_up hsa-mir-21 Glioblastoma 17028302 "miR-21 is strongly overexpressed in this highly malignant brain tumor type, while knockdown of miR-21 in glioblastoma cells by an antisense-oligonucleotide triggered activation of caspases and led to increased apoptotic cell death, suggesting that miR-21 overexpression may contribute to the malignant phenotype by suppressing critical apoptosis-related genes." +circulation_biomarker_diagnosis_up hsa-mir-17 Neoplasms [unspecific] 17060945 overexpressed +circulation_biomarker_diagnosis_up hsa-mir-191 Neoplasms [unspecific] 17060945 overexpressed +circulation_biomarker_diagnosis_up hsa-mir-17 Neoplasms [unspecific] 17189674 "Co-expression of a cluster of miRNAs derived from one genomic locus (miR-17, -18, -19, and -20) caused a significant acceleration of tumorigenesis in a c-Myc driven mouse model of lymphomagenesis. The miR-17 cluster for instance was found to be highly expressed in follicular lymphoma, low grade B cell malignancy , several types of lymphoma and solid tumors and small cell lung cancer." +circulation_biomarker_diagnosis_up hsa-mir-18a Neoplasms [unspecific] 17189674 "Co-expression of a cluster of miRNAs derived from one genomic locus (miR-17, -18, -19, and -20) caused a significant acceleration of tumorigenesis in a c-Myc driven mouse model of lymphomagenesis. The miR-17§Ò§ÙC19 cluster for instance was found to be highly expressed in follicular lymphoma, low grade B cell malignancy , several types of lymphoma and solid tumors and small cell lung cancer." +circulation_biomarker_diagnosis_up hsa-mir-18b Neoplasms [unspecific] 17189674 "Co-expression of a cluster of miRNAs derived from one genomic locus (miR-17, -18, -19, and -20) caused a significant acceleration of tumorigenesis in a c-Myc driven mouse model of lymphomagenesis. The miR-17§Ò§ÙC19 cluster for instance was found to be highly expressed in follicular lymphoma, low grade B cell malignancy , several types of lymphoma and solid tumors and small cell lung cancer." +circulation_biomarker_diagnosis_up hsa-mir-19a Neoplasms [unspecific] 17189674 "Co-expression of a cluster of miRNAs derived from one genomic locus (miR-17, -18, -19, and -20) caused a significant acceleration of tumorigenesis in a c-Myc driven mouse model of lymphomagenesis. The miR-17§Ò§ÙC19 cluster for instance was found to be highly expressed in follicular lymphoma, low grade B cell malignancy , several types of lymphoma and solid tumors and small cell lung cancer." +circulation_biomarker_diagnosis_up hsa-mir-19b-1 Neoplasms [unspecific] 17189674 "Co-expression of a cluster of miRNAs derived from one genomic locus (miR-17, -18, -19, and -20) caused a significant acceleration of tumorigenesis in a c-Myc driven mouse model of lymphomagenesis. The miR-17§Ò§ÙC19 cluster for instance was found to be highly expressed in follicular lymphoma, low grade B cell malignancy , several types of lymphoma and solid tumors and small cell lung cancer." +circulation_biomarker_diagnosis_up hsa-mir-19b-2 Neoplasms [unspecific] 17189674 "Co-expression of a cluster of miRNAs derived from one genomic locus (miR-17, -18, -19, and -20) caused a significant acceleration of tumorigenesis in a c-Myc driven mouse model of lymphomagenesis. The miR-17§Ò§ÙC19 cluster for instance was found to be highly expressed in follicular lymphoma, low grade B cell malignancy , several types of lymphoma and solid tumors and small cell lung cancer." +circulation_biomarker_diagnosis_up hsa-mir-20a Neoplasms [unspecific] 17189674 "Co-expression of a cluster of miRNAs derived from one genomic locus (miR-17, -18, -19, and -20) caused a significant acceleration of tumorigenesis in a c-Myc driven mouse model of lymphomagenesis. The miR-17§Ò§ÙC19 cluster for instance was found to be highly expressed in follicular lymphoma, low grade B cell malignancy , several types of lymphoma and solid tumors and small cell lung cancer." +circulation_biomarker_diagnosis_up hsa-mir-20b Neoplasms [unspecific] 17189674 "Co-expression of a cluster of miRNAs derived from one genomic locus (miR-17, -18, -19, and -20) caused a significant acceleration of tumorigenesis in a c-Myc driven mouse model of lymphomagenesis. The miR-17§Ò§ÙC19 cluster for instance was found to be highly expressed in follicular lymphoma, low grade B cell malignancy , several types of lymphoma and solid tumors and small cell lung cancer." +circulation_biomarker_diagnosis_up hsa-mir-372 Testicular Neoplasms 17189674 "The relevance to human tumorigenesis was shown when it was found that these miRNAs are hyper-expressed in Testicular Germ Cell Tumors, a tumor type characterized by its prevalence of wild type p53." +circulation_biomarker_diagnosis_up hsa-mir-373 Testicular Neoplasms 17189674 "The relevance to human tumorigenesis was shown when it was found that these miRNAs are hyper-expressed in Testicular Germ Cell Tumors, a tumor type characterized by its prevalence of wild type p53." +circulation_biomarker_diagnosis_up hsa-let-7a-3 "Leukemia, Promyelocytic, Acute" 17260024 "We found upregulation of miR-15a, miR-15b, miR-16-1, let-7a-3, let-7c, let-7d, miR-223, miR-342 and miR-107, whereas miR-181b was downregulated. Among the upregulated miRNAs, miR-107 is predicted to target NFI-A, a gene that has been involved in a regulatory loop involving miR-223 and C/EBPa during granulocytic differentiation." +circulation_biomarker_diagnosis_up hsa-let-7c "Leukemia, Promyelocytic, Acute" 17260024 "We found upregulation of miR-15a, miR-15b, miR-16-1, let-7a-3, let-7c, let-7d, miR-223, miR-342 and miR-107, whereas miR-181b was downregulated. Among the upregulated miRNAs, miR-107 is predicted to target NFI-A, a gene that has been involved in a regulatory loop involving miR-223 and C/EBPa during granulocytic differentiation." +circulation_biomarker_diagnosis_up hsa-let-7d "Leukemia, Promyelocytic, Acute" 17260024 "We found upregulation of miR-15a, miR-15b, miR-16-1, let-7a-3, let-7c, let-7d, miR-223, miR-342 and miR-107, whereas miR-181b was downregulated. Among the upregulated miRNAs, miR-107 is predicted to target NFI-A, a gene that has been involved in a regulatory loop involving miR-223 and C/EBPa during granulocytic differentiation." +circulation_biomarker_diagnosis_up hsa-mir-107 "Leukemia, Promyelocytic, Acute" 17260024 "We found upregulation of miR-15a, miR-15b, miR-16-1, let-7a-3, let-7c, let-7d, miR-223, miR-342 and miR-107, whereas miR-181b was downregulated. Among the upregulated miRNAs, miR-107 is predicted to target NFI-A, a gene that has been involved in a regulatory loop involving miR-223 and C/EBPa during granulocytic differentiation." +circulation_biomarker_diagnosis_up hsa-mir-15a "Leukemia, Promyelocytic, Acute" 17260024 "We found upregulation of miR-15a, miR-15b, miR-16-1, let-7a-3, let-7c, let-7d, miR-223, miR-342 and miR-107, whereas miR-181b was downregulated. Among the upregulated miRNAs, miR-107 is predicted to target NFI-A, a gene that has been involved in a regulatory loop involving miR-223 and C/EBPa during granulocytic differentiation." +circulation_biomarker_diagnosis_up hsa-mir-15b "Leukemia, Promyelocytic, Acute" 17260024 "We found upregulation of miR-15a, miR-15b, miR-16-1, let-7a-3, let-7c, let-7d, miR-223, miR-342 and miR-107, whereas miR-181b was downregulated. Among the upregulated miRNAs, miR-107 is predicted to target NFI-A, a gene that has been involved in a regulatory loop involving miR-223 and C/EBPa during granulocytic differentiation." +circulation_biomarker_diagnosis_up hsa-mir-16-1 "Leukemia, Promyelocytic, Acute" 17260024 "We found upregulation of miR-15a, miR-15b, miR-16-1, let-7a-3, let-7c, let-7d, miR-223, miR-342 and miR-107, whereas miR-181b was downregulated. Among the upregulated miRNAs, miR-107 is predicted to target NFI-A, a gene that has been involved in a regulatory loop involving miR-223 and C/EBPa during granulocytic differentiation." +circulation_biomarker_diagnosis_up hsa-mir-223 "Leukemia, Promyelocytic, Acute" 17260024 "We found upregulation of miR-15a, miR-15b, miR-16-1, let-7a-3, let-7c, let-7d, miR-223, miR-342 and miR-107, whereas miR-181b was downregulated. Among the upregulated miRNAs, miR-107 is predicted to target NFI-A, a gene that has been involved in a regulatory loop involving miR-223 and C/EBPa during granulocytic differentiation." +circulation_biomarker_diagnosis_up hsa-mir-342 "Leukemia, Promyelocytic, Acute" 17260024 "We found upregulation of miR-15a, miR-15b, miR-16-1, let-7a-3, let-7c, let-7d, miR-223, miR-342 and miR-107, whereas miR-181b was downregulated. Among the upregulated miRNAs, miR-107 is predicted to target NFI-A, a gene that has been involved in a regulatory loop involving miR-223 and C/EBPa during granulocytic differentiation." +circulation_biomarker_diagnosis_up hsa-mir-155 "Leukemia, Lymphocytic, Chronic, B-Cell" 17327404 "Both approaches show that miR-21 and miR-155 are dramatically overexpressed in patients with CLL, although the corresponding genomic loci are not amplified. miR-150 and miR-92 are also significantly deregulated in patients with CLL. In addition, we detected a marked miR-15a and miR-16 decrease in about 11% of cases" +circulation_biomarker_diagnosis_up hsa-mir-21 "Leukemia, Lymphocytic, Chronic, B-Cell" 17327404 "Both approaches show that miR-21 and miR-155 are dramatically overexpressed in patients with CLL, although the corresponding genomic loci are not amplified. miR-150 and miR-92 are also significantly deregulated in patients with CLL. In addition, we detected a marked miR-15a and miR-16 decrease in about 11% of cases" +circulation_biomarker_diagnosis_up hsa-mir-141 Cholangiocarcinoma 17355635 These include miR-200b and miR-141 which have been shown to be highly overexpressed in malignant cholangiocytes and in colon carcinoma. +circulation_biomarker_diagnosis_up hsa-mir-141 Colon Neoplasms 17355635 These include miR-200b and miR-141 which have been shown to be highly overexpressed in malignant cholangiocytes and in colon carcinoma. +circulation_biomarker_diagnosis_up hsa-mir-146a Thyroid Neoplasms 17355635 "Recent studies in miRNA deregulation PTC found an aberrant miRNA expression profile in PTCs compared to normal thyroid tissues. In particular, a significant increase in mir-222, mir-221, mir-146." +circulation_biomarker_diagnosis_up hsa-mir-146b Thyroid Neoplasms 17355635 "Recent studies in miRNA deregulation PTC found an aberrant miRNA expression profile in PTCs compared to normal thyroid tissues. In particular, a significant increase in mir-222, mir-221, mir-146." +circulation_biomarker_diagnosis_up hsa-mir-200a Thyroid Neoplasms 17355635 "Three of these upregulated miRNAs showed significantly higher fold change than the other upregulated miRNAs, these are mir-200a, mir-200b and mir-141." +circulation_biomarker_diagnosis_up hsa-mir-200b Cholangiocarcinoma 17355635 These include miR-200b and miR-141 which have been shown to be highly overexpressed in malignant cholangiocytes and in colon carcinoma. +circulation_biomarker_diagnosis_up hsa-mir-200b Colon Neoplasms 17355635 These include miR-200b and miR-141 which have been shown to be highly overexpressed in malignant cholangiocytes and in colon carcinoma. +circulation_biomarker_diagnosis_up hsa-mir-200b Thyroid Neoplasms 17355635 "Three of these upregulated miRNAs showed significantly higher fold change than the other upregulated miRNAs, these are mir-200a, mir-200b and mir-141." +circulation_biomarker_diagnosis_up hsa-mir-221 Thyroid Neoplasms 17355635 "Recent studies in miRNA deregulation PTC found an aberrant miRNA expression profile in PTCs compared to normal thyroid tissues. In particular, a significant increase in mir-222, mir-221, mir-146." +circulation_biomarker_diagnosis_up hsa-mir-222 Thyroid Neoplasms 17355635 "Recent studies in miRNA deregulation PTC found an aberrant miRNA expression profile in PTCs compared to normal thyroid tissues. In particular, a significant increase in mir-222, mir-221, mir-146." +circulation_biomarker_diagnosis_up hsa-mir-208a Heart Failure 17379774 upregulation +circulation_biomarker_diagnosis_up hsa-mir-106a Colon Neoplasms 17442096 "Indeed, in human solid tumors, mir-106a expression is increased in colon, pancreas, and prostate tumors." +circulation_biomarker_diagnosis_up hsa-mir-106a Pancreatic Neoplasms 17442096 "Indeed, in human solid tumors, mir-106a expression is increased in colon, pancreas, and prostate tumors." +circulation_biomarker_diagnosis_up hsa-mir-106a Prostate Neoplasms 17442096 "Indeed, in human solid tumors, mir-106a expression is increased in colon, pancreas, and prostate tumors." +circulation_biomarker_diagnosis_up hsa-mir-17 Lung Neoplasms 17442096 The mir-17 cluster is also overexpressed in human lung cancer. +circulation_biomarker_diagnosis_up hsa-mir-132 Breast Neoplasms 17447837 "miR-132, previously shown to be differentially upregulated in six solid cancer types (breast, colon, lung, pancreas, prostate, and stomach carcinomas)" +circulation_biomarker_diagnosis_up hsa-mir-132 Colon Neoplasms 17447837 "miR-132, previously shown to be differentially upregulated in six solid cancer types (breast, colon, lung, pancreas, prostate, and stomach carcinomas)" +circulation_biomarker_diagnosis_up hsa-mir-132 Gastric Neoplasms 17447837 "miR-132, previously shown to be differentially upregulated in six solid cancer types (breast, colon, lung, pancreas, prostate, and stomach carcinomas)" +circulation_biomarker_diagnosis_up hsa-mir-132 Lung Neoplasms 17447837 "miR-132, previously shown to be differentially upregulated in six solid cancer types (breast, colon, lung, pancreas, prostate, and stomach carcinomas)" +circulation_biomarker_diagnosis_up hsa-mir-132 Pancreatic Neoplasms 17447837 "miR-132, previously shown to be differentially upregulated in six solid cancer types (breast, colon, lung, pancreas, prostate, and stomach carcinomas)" +circulation_biomarker_diagnosis_up hsa-mir-132 Prostate Neoplasms 17447837 "miR-132, previously shown to be differentially upregulated in six solid cancer types (breast, colon, lung, pancreas, prostate, and stomach carcinomas)" +circulation_biomarker_diagnosis_up hsa-mir-21 Focal Epithelial Hyperplasia 17478730 We found that miR-21 was one of the most upregulated miRNAs in the vascular wall after balloon injury. Our results strongly indicate that miR-21 is an important regulator for neointimal hyperplasia. +circulation_biomarker_diagnosis_up hsa-mir-155 "Lymphoma, Large B-Cell, Diffuse" 17487835 "DLBCL cases over-expressed miR-21, miR-155 and miR-221 by an average of 9.3, 4.6 and 2.3-fold respectively compared to normal peripheral blood B cells." +circulation_biomarker_diagnosis_up hsa-mir-21 "Lymphoma, Large B-Cell, Diffuse" 17487835 "DLBCL cases over-expressed miR-21, miR-155 and miR-221 by an average of 9.3, 4.6 and 2.3-fold respectively compared to normal peripheral blood B cells." +circulation_biomarker_diagnosis_up hsa-mir-221 "Lymphoma, Large B-Cell, Diffuse" 17487835 "DLBCL cases over-expressed miR-21, miR-155 and miR-221 by an average of 9.3, 4.6 and 2.3-fold respectively compared to normal peripheral blood B cells." +circulation_biomarker_diagnosis_up hsa-mir-195 "Cardiomyopathy, Hypertrophic" 17786230 "Cardiac-specific overexpression of miRNA-195 (miR-195), which is consistently upregulated in rodent and human hypertrophic hearts, for example, results in dilated cardiomyopathy and heart failure in mice as early as two weeks of age, implying that upregulation of miR-195 during cardiac hypertrophy actively contributes to the disease process." +circulation_biomarker_diagnosis_up hsa-mir-1-1 Coronary Artery Disease 17919180 elevated expression +circulation_biomarker_diagnosis_up hsa-mir-1-2 Coronary Artery Disease 17919180 elevated expression +circulation_biomarker_diagnosis_up hsa-mir-128b "Leukemia, Lymphoblastic, Acute" 17934639 "The five most highly expressed miRNAs were miR-128b, miR-204, miR-218, miR-331, and miR-181b-1 in ALL, and miR-331, miR-29a, miR-195, miR-34a, and miR-29c in CLL." +circulation_biomarker_diagnosis_up hsa-mir-17 "Leukemia, Lymphoblastic, Acute" 17934639 "The miR-17-92 cluster was also found to be up-regulated in ALL, as previously reported for some types of lymphomas." +circulation_biomarker_diagnosis_up hsa-mir-18 "Leukemia, Lymphoblastic, Acute" 17934639 "The miR-17-92 cluster was also found to be up-regulated in ALL, as previously reported for some types of lymphomas." +circulation_biomarker_diagnosis_up hsa-mir-181b-1 "Leukemia, Lymphoblastic, Acute" 17934639 "The five most highly expressed miRNAs were miR-128b, miR-204, miR-218, miR-331, and miR-181b-1 in ALL, and miR-331, miR-29a, miR-195, miR-34a, and miR-29c in CLL." +circulation_biomarker_diagnosis_up hsa-mir-195 "Leukemia, Lymphocytic, Chronic, B-Cell" 17934639 "The five most highly expressed miRNAs were miR-128b, miR-204, miR-218, miR-331, and miR-181b-1 in ALL, and miR-331, miR-29a, miR-195, miR-34a, and miR-29c in CLL." +circulation_biomarker_diagnosis_up hsa-mir-19a "Leukemia, Lymphoblastic, Acute" 17934639 "The miR-17-92 cluster was also found to be up-regulated in ALL, as previously reported for some types of lymphomas." +circulation_biomarker_diagnosis_up hsa-mir-19b-1 "Leukemia, Lymphoblastic, Acute" 17934639 "The miR-17-92 cluster was also found to be up-regulated in ALL, as previously reported for some types of lymphomas." +circulation_biomarker_diagnosis_up hsa-mir-204 "Leukemia, Lymphoblastic, Acute" 17934639 "The five most highly expressed miRNAs were miR-128b, miR-204, miR-218, miR-331, and miR-181b-1 in ALL, and miR-331, miR-29a, miR-195, miR-34a, and miR-29c in CLL." +circulation_biomarker_diagnosis_up hsa-mir-20a "Leukemia, Lymphoblastic, Acute" 17934639 "The miR-17-92 cluster was also found to be up-regulated in ALL, as previously reported for some types of lymphomas." +circulation_biomarker_diagnosis_up hsa-mir-218 "Leukemia, Lymphoblastic, Acute" 17934639 "The five most highly expressed miRNAs were miR-128b, miR-204, miR-218, miR-331, and miR-181b-1 in ALL, and miR-331, miR-29a, miR-195, miR-34a, and miR-29c in CLL." +circulation_biomarker_diagnosis_up hsa-mir-29a "Leukemia, Lymphocytic, Chronic, B-Cell" 17934639 "The five most highly expressed miRNAs were miR-128b, miR-204, miR-218, miR-331, and miR-181b-1 in ALL, and miR-331, miR-29a, miR-195, miR-34a, and miR-29c in CLL." +circulation_biomarker_diagnosis_up hsa-mir-29c "Leukemia, Lymphocytic, Chronic, B-Cell" 17934639 "The five most highly expressed miRNAs were miR-128b, miR-204, miR-218, miR-331, and miR-181b-1 in ALL, and miR-331, miR-29a, miR-195, miR-34a, and miR-29c in CLL." +circulation_biomarker_diagnosis_up hsa-mir-331 "Leukemia, Lymphoblastic, Acute" 17934639 "The five most highly expressed miRNAs were miR-128b, miR-204, miR-218, miR-331, and miR-181b-1 in ALL, and miR-331, miR-29a, miR-195, miR-34a, and miR-29c in CLL." +circulation_biomarker_diagnosis_up hsa-mir-331 "Leukemia, Lymphocytic, Chronic, B-Cell" 17934639 "The five most highly expressed miRNAs were miR-128b, miR-204, miR-218, miR-331, and miR-181b-1 in ALL, and miR-331, miR-29a, miR-195, miR-34a, and miR-29c in CLL." +circulation_biomarker_diagnosis_up hsa-mir-34a "Leukemia, Lymphocytic, Chronic, B-Cell" 17934639 "The five most highly expressed miRNAs were miR-128b, miR-204, miR-218, miR-331, and miR-181b-1 in ALL, and miR-331, miR-29a, miR-195, miR-34a, and miR-29c in CLL." +circulation_biomarker_diagnosis_up hsa-mir-92-1 "Leukemia, Lymphoblastic, Acute" 17934639 "The miR-17-92 cluster was also found to be up-regulated in ALL, as previously reported for some types of lymphomas." +circulation_biomarker_diagnosis_up hsa-mir-155 "Leukemia, B-Cell" 17940623 "miR-155 is encoded by nucleotides 241-262 of BIC, which was originally identified as a transcript derived from an integration site for the avian leucosis virus and found to be overexpressed in B-cell lymphomas. The role of miR-155 is not restricted to B cell lymphomas, however. Recent studies have reported that miR-155 is upregulated in breast, lung, colon, and thyroid cancers." +circulation_biomarker_diagnosis_up hsa-mir-1-1 "Cardiomyopathy, Hypertrophic" 17965831 "miR-1 is overexpressed in patients with coronary artery disease and that overexpression of miR-1 in a rat model of cardiac infarction exacerbated arrhythmogenesis. Cardiac hypertrophy may also be regulated by miR-1, which is significantly down-regulated in hypertrophic tissue." +circulation_biomarker_diagnosis_up hsa-mir-1-1 Coronary Artery Disease 17965831 "miR-1 is overexpressed in patients with coronary artery disease and that overexpression of miR-1 in a rat model of cardiac infarction exacerbated arrhythmogenesis. Cardiac hypertrophy may also be regulated by miR-1, which is significantly down-regulated in hypertrophic tissue." +circulation_biomarker_diagnosis_up hsa-mir-1-2 "Cardiomyopathy, Hypertrophic" 17965831 "miR-1 is overexpressed in patients with coronary artery disease and that overexpression of miR-1 in a rat model of cardiac infarction exacerbated arrhythmogenesis. Cardiac hypertrophy may also be regulated by miR-1, which is significantly down-regulated in hypertrophic tissue." +circulation_biomarker_diagnosis_up hsa-mir-1-2 Coronary Artery Disease 17965831 "miR-1 is overexpressed in patients with coronary artery disease and that overexpression of miR-1 in a rat model of cardiac infarction exacerbated arrhythmogenesis. Cardiac hypertrophy may also be regulated by miR-1, which is significantly down-regulated in hypertrophic tissue." +circulation_biomarker_diagnosis_up hsa-mir-146a Psoriasis 17965831 miR-146 is also expressed highly in the skin of psoriasis patients. +circulation_biomarker_diagnosis_up hsa-mir-146a Thyroid Neoplasms 17965831 "Numerous miRNAs are also up-regulated in papillary thyroid carcinoma, including miR-221, miR-22 and miR-146. This up-regulation was associated with a downregulation in the expression of the oncogene KIT, a tyrosine kinase important for the control of cell proliferation." +circulation_biomarker_diagnosis_up hsa-mir-146b Psoriasis 17965831 miR-146 is also expressed highly in the skin of psoriasis patients. +circulation_biomarker_diagnosis_up hsa-mir-146b Thyroid Neoplasms 17965831 "Numerous miRNAs are also up-regulated in papillary thyroid carcinoma, including miR-221, miR-22 and miR-146. This up-regulation was associated with a downregulation in the expression of the oncogene KIT, a tyrosine kinase important for the control of cell proliferation." +circulation_biomarker_diagnosis_up hsa-mir-22 Thyroid Neoplasms 17965831 "Numerous miRNAs are also up-regulated in papillary thyroid carcinoma, including miR-221, miR-22 and miR-146. This up-regulation was associated with a downregulation in the expression of the oncogene KIT, a tyrosine kinase important for the control of cell proliferation." +circulation_biomarker_diagnosis_up hsa-mir-221 Thyroid Neoplasms 17965831 "Numerous miRNAs are also up-regulated in papillary thyroid carcinoma, including miR-221, miR-22 and miR-146. This up-regulation was associated with a downregulation in the expression of the oncogene KIT, a tyrosine kinase important for the control of cell proliferation." +circulation_biomarker_diagnosis_up hsa-mir-16-1 Polycythemia Vera 17976518 "Comparative analyses of control and PV EPs suggested increased levels of miR-451, miR-16, miR-21, and miR-26b and decreased levels of miR-150 and miR-221 in PV group, Expression of miR-150 progressively declined with erythroid differentiation, its expression decreased ninefold (p < 0.05) from days 7 to 11." +circulation_biomarker_diagnosis_up hsa-mir-16-2 Polycythemia Vera 17976518 "Comparative analyses of control and PV EPs suggested increased levels of miR-451, miR-16, miR-21, and miR-26b and decreased levels of miR-150 and miR-221 in PV group, Expression of miR-150 progressively declined with erythroid differentiation, its expression decreased ninefold (p < 0.05) from days 7 to 11." +circulation_biomarker_diagnosis_up hsa-mir-21 Polycythemia Vera 17976518 "Comparative analyses of control and PV EPs suggested increased levels of miR-451, miR-16, miR-21, and miR-26b and decreased levels of miR-150 and miR-221 in PV group, Expression of miR-150 progressively declined with erythroid differentiation, its expression decreased ninefold (p < 0.05) from days 7 to 11." +circulation_biomarker_diagnosis_up hsa-mir-26b Polycythemia Vera 17976518 "Comparative analyses of control and PV EPs suggested increased levels of miR-451, miR-16, miR-21, and miR-26b and decreased levels of miR-150 and miR-221 in PV group, Expression of miR-150 progressively declined with erythroid differentiation, its expression decreased ninefold (p < 0.05) from days 7 to 11." +circulation_biomarker_diagnosis_up hsa-mir-451a Polycythemia Vera 17976518 "Comparative analyses of control and PV EPs suggested increased levels of miR-451, miR-16, miR-21, and miR-26b and decreased levels of miR-150 and miR-221 in PV group, Expression of miR-150 progressively declined with erythroid differentiation, its expression decreased ninefold (p < 0.05) from days 7 to 11." +circulation_biomarker_diagnosis_up hsa-mir-128a "Leukemia, Lymphoblastic" 18056805 "Among them, miR-128a and -128b are significantly overexpressed, whereas let-7b and miR-223 are significantly down-regulated in ALL compared with AML." +circulation_biomarker_diagnosis_up hsa-mir-128b "Leukemia, Lymphoblastic" 18056805 "Among them, miR-128a and -128b are significantly overexpressed, whereas let-7b and miR-223 are significantly down-regulated in ALL compared with AML." +circulation_biomarker_diagnosis_up hsa-mir-212 Liver Diseases [unspecific] 18162065 increased +circulation_biomarker_diagnosis_up hsa-mir-21 "Carcinoma, Hepatocellular" 18223217 increased +circulation_biomarker_diagnosis_up hsa-mir-128-2 Lung Neoplasms 18304967 increased +circulation_biomarker_diagnosis_up hsa-mir-150 Lymphoma 18348159 "Three of 15 miRNAs (miR-16, miR-21, and miR-150) showed a high expression level in both blood and lymph node samples. " +circulation_biomarker_diagnosis_up hsa-mir-16 Lymphoma 18348159 "Three of 15 miRNAs (miR-16, miR-21, and miR-150) showed a high expression level in both blood and lymph node samples. " +circulation_biomarker_diagnosis_up hsa-mir-21 Lymphoma 18348159 "Three of 15 miRNAs (miR-16, miR-21, and miR-150) showed a high expression level in both blood and lymph node samples. " +circulation_biomarker_diagnosis_up hsa-mir-146a Eczema Herpeticum 18419608 upregulation +circulation_biomarker_diagnosis_up hsa-mir-143 Polycythemia Vera 18508790 "We observed down-regulation of let-7a and up-regulation of miR-182 in polycythemia vera granulocytes, up-regulation of miR-143, miR-145 and miR-223 in polycythemia vera mononuclear cells, up-regulation of miR-26b in polycythemia vera platelets, and down-regulation of miR-30b, miR-30c and miR-150 in polycythemia vera reticulocytes." +circulation_biomarker_diagnosis_up hsa-mir-145 Polycythemia Vera 18508790 "We observed down-regulation of let-7a and up-regulation of miR-182 in polycythemia vera granulocytes, up-regulation of miR-143, miR-145 and miR-223 in polycythemia vera mononuclear cells, up-regulation of miR-26b in polycythemia vera platelets, and down-regulation of miR-30b, miR-30c and miR-150 in polycythemia vera reticulocytes." +circulation_biomarker_diagnosis_up hsa-mir-182 Polycythemia Vera 18508790 "We observed down-regulation of let-7a and up-regulation of miR-182 in polycythemia vera granulocytes, up-regulation of miR-143, miR-145 and miR-223 in polycythemia vera mononuclear cells, up-regulation of miR-26b in polycythemia vera platelets, and down-regulation of miR-30b, miR-30c and miR-150 in polycythemia vera reticulocytes." +circulation_biomarker_diagnosis_up hsa-mir-223 Polycythemia Vera 18508790 "We observed down-regulation of let-7a and up-regulation of miR-182 in polycythemia vera granulocytes, up-regulation of miR-143, miR-145 and miR-223 in polycythemia vera mononuclear cells, up-regulation of miR-26b in polycythemia vera platelets, and down-regulation of miR-30b, miR-30c and miR-150 in polycythemia vera reticulocytes." +circulation_biomarker_diagnosis_up hsa-mir-26b Polycythemia Vera 18508790 "We observed down-regulation of let-7a and up-regulation of miR-182 in polycythemia vera granulocytes, up-regulation of miR-143, miR-145 and miR-223 in polycythemia vera mononuclear cells, up-regulation of miR-26b in polycythemia vera platelets, and down-regulation of miR-30b, miR-30c and miR-150 in polycythemia vera reticulocytes." +circulation_biomarker_diagnosis_up hsa-let-7a-1 "Lymphoma, Hodgkin" 18583325 "let-7a: overexpressed, down-regulation of PRDM1/Blimp-1" +circulation_biomarker_diagnosis_up hsa-let-7a-2 "Lymphoma, Hodgkin" 18583325 "let-7a: overexpressed, down-regulation of PRDM1/Blimp-1" +circulation_biomarker_diagnosis_up hsa-let-7a-3 "Lymphoma, Hodgkin" 18583325 "let-7a: overexpressed, down-regulation of PRDM1/Blimp-1" +circulation_biomarker_diagnosis_up hsa-mir-9-1 "Lymphoma, Hodgkin" 18583325 "miR-9: overexpressed, down-regulation of PRDM1/Blimp-1" +circulation_biomarker_diagnosis_up hsa-mir-9-2 "Lymphoma, Hodgkin" 18583325 "miR-9: overexpressed, down-regulation of PRDM1/Blimp-1" +circulation_biomarker_diagnosis_up hsa-mir-9-3 "Lymphoma, Hodgkin" 18583325 "miR-9: overexpressed, down-regulation of PRDM1/Blimp-1" +circulation_biomarker_diagnosis_up hsa-mir-17 "Carcinoma, Hepatocellular" 18688024 miR-17: Elevated expression of the miR-17-92 polycistron and miR-21 contributes to the malignant phenotype +circulation_biomarker_diagnosis_up hsa-mir-18a "Carcinoma, Hepatocellular" 18688024 miR-18a: Elevated expression of the miR-17-92 polycistron and miR-21 contributes to the malignant phenotype +circulation_biomarker_diagnosis_up hsa-mir-19a "Carcinoma, Hepatocellular" 18688024 miR-19a: Elevated expression of the miR-17-92 polycistron and miR-21 contributes to the malignant phenotype +circulation_biomarker_diagnosis_up hsa-mir-19b-1 "Carcinoma, Hepatocellular" 18688024 miR-19b: Elevated expression of the miR-17-92 polycistron and miR-21 contributes to the malignant phenotype +circulation_biomarker_diagnosis_up hsa-mir-19b-2 "Carcinoma, Hepatocellular" 18688024 miR-19b: Elevated expression of the miR-17-92 polycistron and miR-21 contributes to the malignant phenotype +circulation_biomarker_diagnosis_up hsa-mir-20a "Carcinoma, Hepatocellular" 18688024 miR-20a: Elevated expression of the miR-17-92 polycistron and miR-21 contributes to the malignant phenotype +circulation_biomarker_diagnosis_up hsa-mir-21 "Carcinoma, Hepatocellular" 18688024 miR-21: Elevated expression of the miR-17-92 polycistron and miR-21 contributes to the malignant phenotype +circulation_biomarker_diagnosis_up hsa-mir-92a-1 "Carcinoma, Hepatocellular" 18688024 miR-92a: Elevated expression of the miR-17-92 polycistron and miR-21 contributes to the malignant phenotype +circulation_biomarker_diagnosis_up hsa-mir-92a-2 "Carcinoma, Hepatocellular" 18688024 miR-92a: Elevated expression of the miR-17-92 polycistron and miR-21 contributes to the malignant phenotype +circulation_biomarker_diagnosis_up hsa-mir-377 Diabetic Nephropathy 18716028 miR-377: MicroRNA-377 is up-regulated and can lead to increased fibronectin production in diabetic nephropathy +circulation_biomarker_diagnosis_up hsa-mir-20a Breast Neoplasms 18777135 miR-20a: increased expression in c-Myc induced mouse mammary tumors +circulation_biomarker_diagnosis_up hsa-mir-20b Breast Neoplasms 18777135 miR-20b: increased expression in c-Myc induced mouse mammary tumors +circulation_biomarker_diagnosis_up hsa-mir-9-1 Breast Neoplasms 18777135 miR-9: increased expression in c-Myc induced mouse mammary tumors +circulation_biomarker_diagnosis_up hsa-mir-9-2 Breast Neoplasms 18777135 miR-9: increased expression in c-Myc induced mouse mammary tumors +circulation_biomarker_diagnosis_up hsa-mir-9-3 Breast Neoplasms 18777135 miR-9: increased expression in c-Myc induced mouse mammary tumors +circulation_biomarker_diagnosis_up hsa-mir-206 Muscular Dystrophy 18827405 miR-206: miR-206 high expression for muscle regeneration and maturation +circulation_biomarker_diagnosis_up hsa-mir-1-1 Retinal Degeneration 18834879 miR-1: upregulation +circulation_biomarker_diagnosis_up hsa-mir-1-2 Retinal Degeneration 18834879 miR-1: upregulation +circulation_biomarker_diagnosis_up hsa-mir-133b Retinal Degeneration 18834879 miR-133: upregulation +circulation_biomarker_diagnosis_up hsa-mir-142 Retinal Degeneration 18834879 miR-142: upregulation +circulation_biomarker_diagnosis_up hsa-mir-196b Leukemia 18923441 the expression of miR-196b was 500-fold higher in MLL-rearranged and 800-fold higher in 5 of 15 T-ALL cases as compared with the expression level in the remaining precursor B-ALL cases (P<0.001). +circulation_biomarker_diagnosis_up hsa-let-7b Neurodegenerative Diseases [unspecific] 18987751 let-7b: up-regulated +circulation_biomarker_diagnosis_up hsa-mir-139 Neurodegenerative Diseases [unspecific] 18987751 miR-139-5p: up-regulated +circulation_biomarker_diagnosis_up hsa-mir-146a Neurodegenerative Diseases [unspecific] 18987751 miR-146a: up-regulated +circulation_biomarker_diagnosis_up hsa-mir-328 Neurodegenerative Diseases [unspecific] 18987751 miR-328: up-regulated +circulation_biomarker_diagnosis_up hsa-mir-342 Neurodegenerative Diseases [unspecific] 18987751 miR-342-3p: up-regulated +circulation_biomarker_diagnosis_up hsa-let-7a-1 Lupus Vulgaris 18998140 let-7a: upregulation +circulation_biomarker_diagnosis_up hsa-let-7a-2 Lupus Vulgaris 18998140 let-7a: upregulation +circulation_biomarker_diagnosis_up hsa-let-7a-3 Lupus Vulgaris 18998140 let-7a: upregulation +circulation_biomarker_diagnosis_up hsa-let-7e Lupus Vulgaris 18998140 let-7e: upregulation +circulation_biomarker_diagnosis_up hsa-mir-130b Lupus Vulgaris 18998140 miR-130b: upregulation +circulation_biomarker_diagnosis_up hsa-mir-134 Lupus Vulgaris 18998140 miR-134: upregulation +circulation_biomarker_diagnosis_up hsa-mir-142 Lupus Vulgaris 18998140 miR-142-5p: upregulation +circulation_biomarker_diagnosis_up hsa-mir-184 Lupus Vulgaris 18998140 miR-184: upregulation +circulation_biomarker_diagnosis_up hsa-mir-185 Lupus Vulgaris 18998140 miR-185: upregulation +circulation_biomarker_diagnosis_up hsa-mir-195 Lupus Vulgaris 18998140 miR-195: upregulation +circulation_biomarker_diagnosis_up hsa-mir-197 Lupus Vulgaris 18998140 miR-197: upregulation +circulation_biomarker_diagnosis_up hsa-mir-198 Lupus Vulgaris 18998140 miR-198: upregulation +circulation_biomarker_diagnosis_up hsa-mir-200c Lupus Vulgaris 18998140 miR-200c: upregulation +circulation_biomarker_diagnosis_up hsa-mir-208b Lupus Vulgaris 18998140 miR-208: upregulation +circulation_biomarker_diagnosis_up hsa-mir-23a Lupus Vulgaris 18998140 miR-23a: upregulation +circulation_biomarker_diagnosis_up hsa-mir-30a Lupus Vulgaris 18998140 miR-30a-5p: upregulation +circulation_biomarker_diagnosis_up hsa-mir-433 Lupus Vulgaris 18998140 miR-433: upregulation +circulation_biomarker_diagnosis_up hsa-mir-494 Lupus Vulgaris 18998140 miR-494: upregulation +circulation_biomarker_diagnosis_up hsa-mir-516a-1 Lupus Vulgaris 18998140 miR-516-5p: upregulation +circulation_biomarker_diagnosis_up hsa-mir-516a-2 Lupus Vulgaris 18998140 miR-516-5p: upregulation +circulation_biomarker_diagnosis_up hsa-mir-516b-1 Lupus Vulgaris 18998140 miR-516-5p: upregulation +circulation_biomarker_diagnosis_up hsa-mir-516b-2 Lupus Vulgaris 18998140 miR-516-5p: upregulation +circulation_biomarker_diagnosis_up hsa-mir-518c Lupus Vulgaris 18998140 miR-518c*: upregulation +circulation_biomarker_diagnosis_up hsa-mir-575 Lupus Vulgaris 18998140 miR-575: upregulation +circulation_biomarker_diagnosis_up hsa-mir-583 Lupus Vulgaris 18998140 miR-583: upregulation +circulation_biomarker_diagnosis_up hsa-mir-600 Lupus Vulgaris 18998140 miR-600: upregulation +circulation_biomarker_diagnosis_up hsa-mir-601 Lupus Vulgaris 18998140 miR-601: upregulation +circulation_biomarker_diagnosis_up hsa-mir-608 Lupus Vulgaris 18998140 miR-608: upregulation +circulation_biomarker_diagnosis_up hsa-mir-612 Lupus Vulgaris 18998140 miR-612: upregulation +circulation_biomarker_diagnosis_up hsa-mir-622 Lupus Vulgaris 18998140 miR-622: upregulation +circulation_biomarker_diagnosis_up hsa-mir-638 Lupus Vulgaris 18998140 miR-638: upregulation +circulation_biomarker_diagnosis_up hsa-mir-657 Lupus Vulgaris 18998140 miR-657: upregulation +circulation_biomarker_diagnosis_up hsa-mir-658 Lupus Vulgaris 18998140 miR-658: upregulation +circulation_biomarker_diagnosis_up hsa-mir-662 Lupus Vulgaris 18998140 miR-662: upregulation +circulation_biomarker_diagnosis_up hsa-mir-125a Leukemia 19022373 miR-125a: upregulated during human leukemic HL-60 cell differentiation induced by 4-hydroxynonenal +circulation_biomarker_diagnosis_up hsa-mir-339 Leukemia 19022373 miR-339: upregulated during human leukemic HL-60 cell differentiation induced by 4-hydroxynonenal +circulation_biomarker_diagnosis_up hsa-mir-660 Leukemia 19022373 miR-660: upregulated during human leukemic HL-60 cell differentiation induced by 4-hydroxynonenal +circulation_biomarker_diagnosis_up hsa-mir-663a Leukemia 19022373 miR-663: upregulated during human leukemic HL-60 cell differentiation induced by 4-hydroxynonenal +circulation_biomarker_diagnosis_up hsa-mir-145 Colorectal Carcinoma 19047896 miR-145: increased expression +circulation_biomarker_diagnosis_up hsa-mir-181b-1 Colorectal Carcinoma 19047896 miR-181b: increased expression +circulation_biomarker_diagnosis_up hsa-mir-203 Colorectal Carcinoma 19047896 miR-203: increased expression +circulation_biomarker_diagnosis_up hsa-mir-20a Colorectal Carcinoma 19047896 miR-20a: increased expression +circulation_biomarker_diagnosis_up hsa-mir-21 Colorectal Carcinoma 19047896 miR-21: increased expression +circulation_biomarker_diagnosis_up hsa-mir-372 "Carcinoma, Embryonal" 19057917 miR-372: highly up-regulated +circulation_biomarker_diagnosis_up hsa-mir-372 Cerebellum Cancer 19057917 miR-372: highly up-regulated +circulation_biomarker_diagnosis_up hsa-mir-373 "Carcinoma, Embryonal" 19057917 miR-373: highly up-regulated +circulation_biomarker_diagnosis_up hsa-mir-373 Cerebellum Cancer 19057917 miR-373: highly up-regulated +circulation_biomarker_diagnosis_up hsa-mir-17 "Leukemia, Myeloid" 19155294 miR-17: overexpressed +circulation_biomarker_diagnosis_up hsa-mir-18a "Leukemia, Myeloid" 19155294 miR-18a: overexpressed +circulation_biomarker_diagnosis_up hsa-mir-19a "Leukemia, Myeloid" 19155294 miR-19a: overexpressed +circulation_biomarker_diagnosis_up hsa-mir-19b-1 "Leukemia, Myeloid" 19155294 miR-19b: overexpressed +circulation_biomarker_diagnosis_up hsa-mir-19b-2 "Leukemia, Myeloid" 19155294 miR-19b: overexpressed +circulation_biomarker_diagnosis_up hsa-mir-20a "Leukemia, Myeloid" 19155294 miR-20a: overexpressed +circulation_biomarker_diagnosis_up hsa-mir-92a-1 "Leukemia, Myeloid" 19155294 miR-92a: overexpressed +circulation_biomarker_diagnosis_up hsa-mir-92a-2 "Leukemia, Myeloid" 19155294 miR-92a: overexpressed +circulation_biomarker_diagnosis_up hsa-mir-155 "Lymphoma, Hodgkin" 19177201 miR-155: overexpressed +circulation_biomarker_diagnosis_up hsa-mir-16-1 "Lymphoma, Hodgkin" 19177201 miR-16: overexpressed +circulation_biomarker_diagnosis_up hsa-mir-16-2 "Lymphoma, Hodgkin" 19177201 miR-16: overexpressed +circulation_biomarker_diagnosis_up hsa-mir-17 "Lymphoma, Hodgkin" 19177201 miR-17: overexpressed +circulation_biomarker_diagnosis_up hsa-mir-18a "Lymphoma, Hodgkin" 19177201 miR-18a: overexpressed +circulation_biomarker_diagnosis_up hsa-mir-19a "Lymphoma, Hodgkin" 19177201 miR-19a: overexpressed +circulation_biomarker_diagnosis_up hsa-mir-19b-1 "Lymphoma, Hodgkin" 19177201 miR-19b: overexpressed +circulation_biomarker_diagnosis_up hsa-mir-19b-2 "Lymphoma, Hodgkin" 19177201 miR-19b: overexpressed +circulation_biomarker_diagnosis_up hsa-mir-20a "Lymphoma, Hodgkin" 19177201 miR-20a: overexpressed +circulation_biomarker_diagnosis_up hsa-mir-21 "Lymphoma, Hodgkin" 19177201 miR-21: overexpressed +circulation_biomarker_diagnosis_up hsa-mir-24-1 "Lymphoma, Hodgkin" 19177201 miR-24: overexpressed +circulation_biomarker_diagnosis_up hsa-mir-24-2 "Lymphoma, Hodgkin" 19177201 miR-24: overexpressed +circulation_biomarker_diagnosis_up hsa-mir-92a-1 "Lymphoma, Hodgkin" 19177201 miR-92a: overexpressed +circulation_biomarker_diagnosis_up hsa-mir-92a-2 "Lymphoma, Hodgkin" 19177201 miR-92a: overexpressed +circulation_biomarker_diagnosis_up hsa-mir-142 "Leukemia-Lymphoma, Precursor B-Cell Lymphoblastic" 19206004 miR-142-3p: up-regulated +circulation_biomarker_diagnosis_up hsa-mir-222 "Leukemia-Lymphoma, Precursor B-Cell Lymphoblastic" 19206004 miR-222: up-regulated +circulation_biomarker_diagnosis_up hsa-mir-339 "Leukemia-Lymphoma, Precursor B-Cell Lymphoblastic" 19206004 miR-339: up-regulated +circulation_biomarker_diagnosis_up hsa-mir-184 Tongue Neoplasms 19219377 miR-184: overexpressed +circulation_biomarker_diagnosis_up hsa-mir-31 Colorectal Carcinoma 19242066 miR-31: up-regulated compared with normal control +circulation_biomarker_diagnosis_up hsa-mir-1-1 Myocardial Infarction 19245789 miR-1: Upregulated expression in a rat model +circulation_biomarker_diagnosis_up hsa-mir-1-2 Myocardial Infarction 19245789 miR-1: Upregulated expression in a rat model +circulation_biomarker_diagnosis_up hsa-mir-206 Myocardial Infarction 19245789 miR-206: Upregulated expression in a rat model +circulation_biomarker_diagnosis_up hsa-mir-132 Autistic Disorder 19360674 miR-132: upregulated +circulation_biomarker_diagnosis_up hsa-mir-146a Autistic Disorder 19360674 miR-146a: upregulated +circulation_biomarker_diagnosis_up hsa-mir-146b Autistic Disorder 19360674 mir-146b: upregulated +circulation_biomarker_diagnosis_up hsa-mir-23a Autistic Disorder 19360674 miR-23a: upregulated +circulation_biomarker_diagnosis_up hsa-mir-23b Autistic Disorder 19360674 miR-23b: upregulated +circulation_biomarker_diagnosis_up hsa-mir-663a Autistic Disorder 19360674 miR-663: upregulated +circulation_biomarker_diagnosis_up hsa-mir-342 Prion Diseases 19712440 upregulated +circulation_biomarker_diagnosis_up hsa-mir-494 Prion Diseases 19712440 upregulated +circulation_biomarker_diagnosis_up hsa-mir-181a-2 "Leukemia, Lymphocytic, Chronic, B-Cell" 19717645 high expression +circulation_biomarker_diagnosis_up hsa-mir-15a Schizophrenia 19721432 upregulated +circulation_biomarker_diagnosis_up hsa-mir-15b Schizophrenia 19721432 upregulated +circulation_biomarker_diagnosis_up hsa-mir-196a-1 Pancreatic Adenocarcinoma 19723895 uperegulated +circulation_biomarker_diagnosis_up hsa-mir-196a-2 Pancreatic Adenocarcinoma 19723895 uperegulated +circulation_biomarker_diagnosis_up hsa-mir-122 Stroke 19745058 diagnostical sensitivity: illustrated liver and muscle toxicity +circulation_biomarker_diagnosis_up hsa-mir-124-1 Stroke 19745058 "diagnostical sensitivity:illustrated injuries in liver, muscle, and brain" +circulation_biomarker_diagnosis_up hsa-mir-124-2 Stroke 19745058 "diagnostical sensitivity:illustrated injuries in liver, muscle, and brain" +circulation_biomarker_diagnosis_up hsa-mir-124-3 Stroke 19745058 "diagnostical sensitivity:illustrated injuries in liver, muscle, and brain" +circulation_biomarker_diagnosis_up hsa-mir-133a-1 Stroke 19745058 diagnostical sensitivity: illustrated liver and muscle toxicity +circulation_biomarker_diagnosis_up hsa-mir-133a-2 Stroke 19745058 diagnostical sensitivity: illustrated liver and muscle toxicity +circulation_biomarker_diagnosis_up hsa-mir-208a Myocardial Infarction 20159880 Elevated cardiac-specific miR-208a in plasma may be a novel biomarker for early detection of myocardial injury in humans +circulation_biomarker_diagnosis_up hsa-mir-423 Heart Failure 20185794 MiR423-5p as a circulating biomarker for heart failure +circulation_biomarker_diagnosis_up hsa-mir-210 "Squamous Cell Carcinoma, Head and Neck" 20187102 Expression of hsa-miR-210 in head and neck cancer correlates with other approaches for assessing hypoxia and is associated with prognosis +circulation_biomarker_diagnosis_up hsa-mir-106a Neoplasms [unspecific] 20234369 "the plasma concentrations of miRNAs (miR-17-5p, miR-21, miR-106a, miR-106b) were significantly higher in GC patients than controls" +circulation_biomarker_diagnosis_up hsa-mir-17 Neoplasms [unspecific] 20234369 "the plasma concentrations of miRNAs (miR-17-5p, miR-21, miR-106a, miR-106b) were significantly higher in GC patients than controls" +circulation_biomarker_diagnosis_up hsa-mir-21 Neoplasms [unspecific] 20234369 "the plasma concentrations of miRNAs (miR-17-5p, miR-21, miR-106a, miR-106b) were significantly higher in GC patients than controls" +circulation_biomarker_diagnosis_up hsa-mir-210 Pancreatic Neoplasms 20360935 Circulating miR-210 as a Novel Hypoxia Marker in Pancreatic Cancer +circulation_biomarker_diagnosis_up hsa-mir-23a "Child Development Disorders, Pervasive" 20374639 up-regulation +circulation_biomarker_diagnosis_up hsa-mir-21 "Leukemia, Lymphocytic, Chronic, B-Cell" 20393129 microRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival +circulation_biomarker_diagnosis_up hsa-mir-499a Myocardial Infarction 20395621 Plasma microRNA 499 as a biomarker of acute myocardial infarction +circulation_biomarker_diagnosis_up hsa-mir-223 "Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic" 20418243 miR-223:over-expression of miR-223 +circulation_biomarker_diagnosis_up hsa-mir-126 Atherosclerosis 20489169 miR-126:found high levels of expression for all of them in quiescent endothelial cells +circulation_biomarker_diagnosis_up hsa-mir-17 Atherosclerosis 20489169 miR-17-5p:found high levels of expression for all of them in quiescent endothelial cells +circulation_biomarker_diagnosis_up hsa-mir-21 Atherosclerosis 20489169 miR-21:found high levels of expression for all of them in quiescent endothelial cells +circulation_biomarker_diagnosis_up hsa-mir-210 Atherosclerosis 20489169 miR-210:found high levels of expression for all of them in quiescent endothelial cells +circulation_biomarker_diagnosis_up hsa-mir-221 Atherosclerosis 20489169 miR-221:found high levels of expression for all of them in quiescent endothelial cells +circulation_biomarker_diagnosis_up hsa-mir-222 Atherosclerosis 20489169 miR-222:found high levels of expression for all of them in quiescent endothelial cells +circulation_biomarker_diagnosis_up hsa-mir-296 Atherosclerosis 20489169 miR-296:found high levels of expression for all of them in quiescent endothelial cells +circulation_biomarker_diagnosis_up hsa-mir-148a "Leukemia, Lymphocytic, Chronic, B-Cell" 20504344 "miR-148a:miR-148a, miR-222 and miR-21 exhibited a significantly higher expression in non-responder patients" +circulation_biomarker_diagnosis_up hsa-mir-21 "Leukemia, Lymphocytic, Chronic, B-Cell" 20504344 "miR-21:miR-148a, miR-222 and miR-21 exhibited a significantly higher expression in non-responder patients" +circulation_biomarker_diagnosis_up hsa-mir-222 "Leukemia, Lymphocytic, Chronic, B-Cell" 20504344 "miR-222:miR-148a, miR-222 and miR-21 exhibited a significantly higher expression in non-responder patients" +circulation_biomarker_diagnosis_up hsa-let-7d Melanoma 20529253 let-7d:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients +circulation_biomarker_diagnosis_up hsa-mir-1249 Melanoma 20529253 miR-1249:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients +circulation_biomarker_diagnosis_up hsa-mir-125a Melanoma 20529253 miR-125a-5p:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients +circulation_biomarker_diagnosis_up hsa-mir-1280 Melanoma 20529253 miR-1280:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients +circulation_biomarker_diagnosis_up hsa-mir-142 Melanoma 20529253 miR-142-3p:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients +circulation_biomarker_diagnosis_up hsa-mir-145 Melanoma 20529253 miR-145:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients +circulation_biomarker_diagnosis_up hsa-mir-146a Melanoma 20529253 miR-146a:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients +circulation_biomarker_diagnosis_up hsa-mir-151a Melanoma 20529253 miR-151-3p:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients +circulation_biomarker_diagnosis_up hsa-mir-181a-2 Melanoma 20529253 miR-181a-2*:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients +circulation_biomarker_diagnosis_up hsa-mir-183 Melanoma 20529253 miR-183*:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients +circulation_biomarker_diagnosis_up hsa-mir-186 Melanoma 20529253 miR-186:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients +circulation_biomarker_diagnosis_up hsa-mir-18a Melanoma 20529253 miR-18a:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients +circulation_biomarker_diagnosis_up hsa-mir-199a-1 Melanoma 20529253 miR-199a-5p:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients +circulation_biomarker_diagnosis_up hsa-mir-199a-2 Melanoma 20529253 miR-199a-5p:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients +circulation_biomarker_diagnosis_up hsa-mir-22 Melanoma 20529253 miR-22*:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients +circulation_biomarker_diagnosis_up hsa-mir-30a Melanoma 20529253 miR-30a:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients +circulation_biomarker_diagnosis_up hsa-mir-30e Melanoma 20529253 miR-30e*:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients +circulation_biomarker_diagnosis_up hsa-mir-328 Melanoma 20529253 miR-328:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients +circulation_biomarker_diagnosis_up hsa-mir-342 Melanoma 20529253 miR-342-5p:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients +circulation_biomarker_diagnosis_up hsa-mir-361 Melanoma 20529253 miR-361-3p:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients +circulation_biomarker_diagnosis_up hsa-mir-362 Melanoma 20529253 miR-362-3p:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients +circulation_biomarker_diagnosis_up hsa-mir-365a Melanoma 20529253 miR-365:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients +circulation_biomarker_diagnosis_up hsa-mir-365b Melanoma 20529253 miR-365:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients +circulation_biomarker_diagnosis_up hsa-mir-378a Melanoma 20529253 miR-378*:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients +circulation_biomarker_diagnosis_up hsa-mir-422a Melanoma 20529253 miR-422a:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients +circulation_biomarker_diagnosis_up hsa-mir-501 Melanoma 20529253 miR-501-5p:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients +circulation_biomarker_diagnosis_up hsa-mir-550a-1 Melanoma 20529253 miR-550*:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients +circulation_biomarker_diagnosis_up hsa-mir-550a-2 Melanoma 20529253 miR-550*:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients +circulation_biomarker_diagnosis_up hsa-mir-584 Melanoma 20529253 miR-584:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients +circulation_biomarker_diagnosis_up hsa-mir-625 Melanoma 20529253 miR-625:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients +circulation_biomarker_diagnosis_up hsa-mir-664 Melanoma 20529253 miR-664:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients +circulation_biomarker_diagnosis_up hsa-mir-99a Melanoma 20529253 miR-99a:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients +circulation_biomarker_diagnosis_up hsa-mir-125b-1 "Leukemia, Myeloid" 20660734 "miR-125b:Overexpression of the most advantageous miRNA, miR-125b, caused a dose-dependent myeloproliferative disorder that progressed to a lethal myeloid leukemia in mice" +circulation_biomarker_diagnosis_up hsa-mir-125b-2 "Leukemia, Myeloid" 20660734 "miR-125b:Overexpression of the most advantageous miRNA, miR-125b, caused a dose-dependent myeloproliferative disorder that progressed to a lethal myeloid leukemia in mice" +circulation_biomarker_diagnosis_up hsa-mir-206 Rhabdomyosarcoma 20696132 "miR-206:miR-206, as landmark biomarkers for RMS" +circulation_biomarker_diagnosis_up hsa-mir-155 "Lymphoma, Large-Cell, Anaplastic" 20805506 "miR-155:Five members of the miR-17-92 cluster were expressed more highly in ALK(+) ALCL, whereas miR-155 was expressed more than 10-fold higher in ALK(-) ALCL" +circulation_biomarker_diagnosis_up hsa-mir-17 "Lymphoma, Large-Cell, Anaplastic" 20805506 "miR-17:Five members of the miR-17-92 cluster were expressed more highly in ALK(+) ALCL, whereas miR-155 was expressed more than 10-fold higher in ALK(-) ALCL" +circulation_biomarker_diagnosis_up hsa-mir-18a "Lymphoma, Large-Cell, Anaplastic" 20805506 "miR-18a:Five members of the miR-17-92 cluster were expressed more highly in ALK(+) ALCL, whereas miR-155 was expressed more than 10-fold higher in ALK(-) ALCL" +circulation_biomarker_diagnosis_up hsa-mir-19a "Lymphoma, Large-Cell, Anaplastic" 20805506 "miR-19a:Five members of the miR-17-92 cluster were expressed more highly in ALK(+) ALCL, whereas miR-155 was expressed more than 10-fold higher in ALK(-) ALCL" +circulation_biomarker_diagnosis_up hsa-mir-19b-1 "Lymphoma, Large-Cell, Anaplastic" 20805506 "miR-19b:Five members of the miR-17-92 cluster were expressed more highly in ALK(+) ALCL, whereas miR-155 was expressed more than 10-fold higher in ALK(-) ALCL" +circulation_biomarker_diagnosis_up hsa-mir-19b-2 "Lymphoma, Large-Cell, Anaplastic" 20805506 "miR-19b:Five members of the miR-17-92 cluster were expressed more highly in ALK(+) ALCL, whereas miR-155 was expressed more than 10-fold higher in ALK(-) ALCL" +circulation_biomarker_diagnosis_up hsa-mir-20a "Lymphoma, Large-Cell, Anaplastic" 20805506 "miR-20a:Five members of the miR-17-92 cluster were expressed more highly in ALK(+) ALCL, whereas miR-155 was expressed more than 10-fold higher in ALK(-) ALCL" +circulation_biomarker_diagnosis_up hsa-mir-92a-1 "Lymphoma, Large-Cell, Anaplastic" 20805506 "miR-92a:Five members of the miR-17-92 cluster were expressed more highly in ALK(+) ALCL, whereas miR-155 was expressed more than 10-fold higher in ALK(-) ALCL" +circulation_biomarker_diagnosis_up hsa-mir-92a-2 "Lymphoma, Large-Cell, Anaplastic" 20805506 "miR-92a:Five members of the miR-17-92 cluster were expressed more highly in ALK(+) ALCL, whereas miR-155 was expressed more than 10-fold higher in ALK(-) ALCL" +circulation_biomarker_diagnosis_up hsa-mir-208b Myocardial Infarction 20921333 miRs-208b and -499 were highly elevated in acute myocardial infarction plasma +circulation_biomarker_diagnosis_up hsa-mir-208b Viral Myocarditis 20921333 a milder but significant elevation of miRs-208b and -499 were highly elevated in Viral Myocarditis plasma +circulation_biomarker_diagnosis_up hsa-mir-499a Heart Failure 20921333 miR-499 was significantly elevated +circulation_biomarker_diagnosis_up hsa-mir-499a Myocardial Infarction 20921333 miRs-208b and -499 were highly elevated in acute myocardial infarction plasma +circulation_biomarker_diagnosis_up hsa-mir-499a Viral Myocarditis 20921333 a milder but significant elevation of miRs-208b and -499 were highly elevated in Viral Myocarditis plasma +circulation_biomarker_diagnosis_up hsa-let-7e Synovial Sarcoma 21140508 upregulated +circulation_biomarker_diagnosis_up hsa-mir-125a Synovial Sarcoma 21140508 miR-125a-3p: upregulated +circulation_biomarker_diagnosis_up hsa-mir-99b Synovial Sarcoma 21140508 upregulated +circulation_biomarker_diagnosis_up hsa-mir-326 Multiple Sclerosis 21151203 The expression of miRNA-326 in blood cells has been reported to increase during relapses. +circulation_biomarker_diagnosis_up hsa-mir-122 Liver Neoplasms 21154767 "in serum, miR-21, miR-122, and miR-223 were significantly higher in patients with HCC than those in healthy controls" +circulation_biomarker_diagnosis_up hsa-mir-223 Liver Neoplasms 21154767 "in serum, miR-21, miR-122, and miR-223 were significantly higher in patients with HCC than those in healthy controls" +circulation_biomarker_diagnosis_up hsa-mir-183 Urinary Bladder Cancer 21166959 "MiR-96 and miR-183 detection in urine serve as potential tumor markers of urothelial carcinoma: correlation with stage and grade, and comparison with urinary cytology." +circulation_biomarker_diagnosis_up hsa-mir-96 Urinary Bladder Cancer 21166959 "MiR-96 and miR-183 detection in urine serve as potential tumor markers of urothelial carcinoma: correlation with stage and grade, and comparison with urinary cytology." +circulation_biomarker_diagnosis_up hsa-mir-122 "Carcinoma, Hepatocellular" 21229610 "Our results indicate that serum miR-21, miR-122 and miR-223 are elevated in patients with HCC or chronic hepatitis and these miRNAs have strong potential to serve as novel biomarkers for liver injury but not specifically for HCC." +circulation_biomarker_diagnosis_up hsa-mir-21 "Carcinoma, Hepatocellular" 21229610 "Our results indicate that serum miR-21, miR-122 and miR-223 are elevated in patients with HCC or chronic hepatitis and these miRNAs have strong potential to serve as novel biomarkers for liver injury but not specifically for HCC." +circulation_biomarker_diagnosis_up hsa-mir-223 "Carcinoma, Hepatocellular" 21229610 "Our results indicate that serum miR-21, miR-122 and miR-223 are elevated in patients with HCC or chronic hepatitis and these miRNAs have strong potential to serve as novel biomarkers for liver injury but not specifically for HCC." +circulation_biomarker_diagnosis_up hsa-mir-100 "Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic" 21242186 "aberrant downregulation of let-7b (~70-fold) in MLL-rearranged acute lymphoblastic leukemia was linked to upregulation of oncoprotein c-Myc (P<0.0001). Resistance to vincristine and daunorubicin was characterized by ~20-fold upregulation of miR-125b, miR-99a and miR-100 (P<0.002)." +circulation_biomarker_diagnosis_up hsa-mir-125b-1 "Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic" 21242186 "aberrant downregulation of let-7b (~70-fold) in MLL-rearranged acute lymphoblastic leukemia was linked to upregulation of oncoprotein c-Myc (P<0.0001). Resistance to vincristine and daunorubicin was characterized by ~20-fold upregulation of miR-125b, miR-99a and miR-100 (P<0.002)." +circulation_biomarker_diagnosis_up hsa-mir-125b-2 "Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic" 21242186 "aberrant downregulation of let-7b (~70-fold) in MLL-rearranged acute lymphoblastic leukemia was linked to upregulation of oncoprotein c-Myc (P<0.0001). Resistance to vincristine and daunorubicin was characterized by ~20-fold upregulation of miR-125b, miR-99a and miR-100 (P<0.002)." +circulation_biomarker_diagnosis_up hsa-mir-99a "Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic" 21242186 "aberrant downregulation of let-7b (~70-fold) in MLL-rearranged acute lymphoblastic leukemia was linked to upregulation of oncoprotein c-Myc (P<0.0001). Resistance to vincristine and daunorubicin was characterized by ~20-fold upregulation of miR-125b, miR-99a and miR-100 (P<0.002)." +circulation_biomarker_diagnosis_up hsa-mir-181a-1 "Squamous Cell Carcinoma, Oral" 21244495 "miR-181 as a putative biomarker for lymph-node metastasis of oral squamous cell carcinoma.miR-181 may enhance lymph-node metastasis through regulating migration, which could potentially be exploited as a putative biomarker for patients with OSCC." +circulation_biomarker_diagnosis_up hsa-mir-181a-2 "Squamous Cell Carcinoma, Oral" 21244495 "miR-181 as a putative biomarker for lymph-node metastasis of oral squamous cell carcinoma.miR-181 may enhance lymph-node metastasis through regulating migration, which could potentially be exploited as a putative biomarker for patients with OSCC." +circulation_biomarker_diagnosis_up hsa-mir-181b-1 "Squamous Cell Carcinoma, Oral" 21244495 "miR-181 as a putative biomarker for lymph-node metastasis of oral squamous cell carcinoma.miR-181 may enhance lymph-node metastasis through regulating migration, which could potentially be exploited as a putative biomarker for patients with OSCC." +circulation_biomarker_diagnosis_up hsa-mir-181b-2 "Squamous Cell Carcinoma, Oral" 21244495 "miR-181 as a putative biomarker for lymph-node metastasis of oral squamous cell carcinoma.miR-181 may enhance lymph-node metastasis through regulating migration, which could potentially be exploited as a putative biomarker for patients with OSCC." +circulation_biomarker_diagnosis_up hsa-mir-181c "Squamous Cell Carcinoma, Oral" 21244495 "miR-181 as a putative biomarker for lymph-node metastasis of oral squamous cell carcinoma.miR-181 may enhance lymph-node metastasis through regulating migration, which could potentially be exploited as a putative biomarker for patients with OSCC." +circulation_biomarker_diagnosis_up hsa-mir-181d "Squamous Cell Carcinoma, Oral" 21244495 "miR-181 as a putative biomarker for lymph-node metastasis of oral squamous cell carcinoma.miR-181 may enhance lymph-node metastasis through regulating migration, which could potentially be exploited as a putative biomarker for patients with OSCC." +circulation_biomarker_diagnosis_up hsa-mir-1254-1 "Carcinoma, Lung, Non-Small-Cell" 21258252 miR-1254 and miR-574-5p: Serum-Based microRNA Biomarkers for Early-Stage Non-small Cell Lung Cancer. The expression of hsa-miR-1254 and hsa-miR-574-5p was significantly increased in the early-stage NSCLC samples with respect to the controls. The utility of miR-1254 and miR-574-5p serum-based biomarkers as minimally invasive screening and triage tools for subsequent diagnostic evaluation warrants additional validation. +circulation_biomarker_diagnosis_up hsa-mir-574 "Carcinoma, Lung, Non-Small-Cell" 21258252 miR-1254 and miR-574-5p: Serum-Based microRNA Biomarkers for Early-Stage Non-small Cell Lung Cancer. The expression of hsa-miR-1254 and hsa-miR-574-5p was significantly increased in the early-stage NSCLC samples with respect to the controls. The utility of miR-1254 and miR-574-5p serum-based biomarkers as minimally invasive screening and triage tools for subsequent diagnostic evaluation warrants additional validation. +circulation_biomarker_diagnosis_up hsa-mir-221 Melanoma 21273047 Malignant melanoma patients had significantly higher miR-221 levels than healthy controls in serum. +circulation_biomarker_diagnosis_up hsa-mir-141 Prostate Neoplasms 21274675 the miRNA levels in patient blood were higher than that of the controls +circulation_biomarker_diagnosis_up hsa-mir-21 Prostate Neoplasms 21274675 the miRNA levels in patient blood were higher than that of the controls +circulation_biomarker_diagnosis_up hsa-mir-221 Prostate Neoplasms 21274675 the miRNA levels in patient blood were higher than that of the controls +circulation_biomarker_diagnosis_up hsa-mir-21 Hypertrophy 21303526 "The downregulation of miR-1, miR-133a, and upregulation of miR-21 can be reversed by one single upstream regulator, SRF." +circulation_biomarker_diagnosis_up hsa-mir-148a Medulloblastoma 21358093 "A number of miRNAs like miR-193a, miR-224/miR-452 cluster, miR-182/miR-183/miR-96 cluster, and miR-148a having potential tumor/metastasis suppressive activity were found to be overexpressed in the WNT signaling associated medulloblastomas." +circulation_biomarker_diagnosis_up hsa-mir-182 Medulloblastoma 21358093 "A number of miRNAs like miR-193a, miR-224/miR-452 cluster, miR-182/miR-183/miR-96 cluster, and miR-148a having potential tumor/metastasis suppressive activity were found to be overexpressed in the WNT signaling associated medulloblastomas." +circulation_biomarker_diagnosis_up hsa-mir-183 Medulloblastoma 21358093 "A number of miRNAs like miR-193a, miR-224/miR-452 cluster, miR-182/miR-183/miR-96 cluster, and miR-148a having potential tumor/metastasis suppressive activity were found to be overexpressed in the WNT signaling associated medulloblastomas." +circulation_biomarker_diagnosis_up hsa-mir-193a Medulloblastoma 21358093 "A number of miRNAs like miR-193a, miR-224/miR-452 cluster, miR-182/miR-183/miR-96 cluster, and miR-148a having potential tumor/metastasis suppressive activity were found to be overexpressed in the WNT signaling associated medulloblastomas." +circulation_biomarker_diagnosis_up hsa-mir-193b Medulloblastoma 21358093 "A number of miRNAs like miR-193a, miR-224/miR-452 cluster, miR-182/miR-183/miR-96 cluster, and miR-148a having potential tumor/metastasis suppressive activity were found to be overexpressed in the WNT signaling associated medulloblastomas." +circulation_biomarker_diagnosis_up hsa-mir-224 Medulloblastoma 21358093 "A number of miRNAs like miR-193a, miR-224/miR-452 cluster, miR-182/miR-183/miR-96 cluster, and miR-148a having potential tumor/metastasis suppressive activity were found to be overexpressed in the WNT signaling associated medulloblastomas." +circulation_biomarker_diagnosis_up hsa-mir-452 Medulloblastoma 21358093 "A number of miRNAs like miR-193a, miR-224/miR-452 cluster, miR-182/miR-183/miR-96 cluster, and miR-148a having potential tumor/metastasis suppressive activity were found to be overexpressed in the WNT signaling associated medulloblastomas." +circulation_biomarker_diagnosis_up hsa-mir-96 Medulloblastoma 21358093 "A number of miRNAs like miR-193a, miR-224/miR-452 cluster, miR-182/miR-183/miR-96 cluster, and miR-148a having potential tumor/metastasis suppressive activity were found to be overexpressed in the WNT signaling associated medulloblastomas." +circulation_biomarker_diagnosis_up hsa-mir-210 Ischemic Diseases [unspecific] 21360638 "High levels of miR-210 have been linked to an in vivo hypoxic signature and associated with adverse prognosis in cancer patients. A wide spectrum of miR-210 targets have been identified, with roles in mitochondrial metabolism, angiogenesis, DNA repair, and cell survival." +circulation_biomarker_diagnosis_up hsa-mir-155 "Leukemia, Lymphocytic, Chronic, B-Cell" 21408091 upregulation +circulation_biomarker_diagnosis_up hsa-mir-342 "Leukemia, Lymphocytic, Chronic, B-Cell" 21408091 miR-342-3p upregulation +circulation_biomarker_diagnosis_up hsa-mir-34a "Leukemia, Lymphocytic, Chronic, B-Cell" 21408091 upregulation +circulation_biomarker_diagnosis_up hsa-mir-34b Huntington Disease 21421997 Hsa-miR-34b is a plasma-stable microRNA that is elevated in pre-manifest Huntington's disease. +circulation_biomarker_diagnosis_up hsa-mir-1-1 "Muscular Dystrophy, Duchenne" 21479190 "the serum levels of several muscle-specific miRNAs (miR-1, miR-133a and miR-206) are increased" +circulation_biomarker_diagnosis_up hsa-mir-1-2 "Muscular Dystrophy, Duchenne" 21479190 "the serum levels of several muscle-specific miRNAs (miR-1, miR-133a and miR-206) are increased" +circulation_biomarker_diagnosis_up hsa-mir-133a-1 "Muscular Dystrophy, Duchenne" 21479190 "the serum levels of several muscle-specific miRNAs (miR-1, miR-133a and miR-206) are increased" +circulation_biomarker_diagnosis_up hsa-mir-133a-2 "Muscular Dystrophy, Duchenne" 21479190 "the serum levels of several muscle-specific miRNAs (miR-1, miR-133a and miR-206) are increased" +circulation_biomarker_diagnosis_up hsa-mir-206 "Muscular Dystrophy, Duchenne" 21479190 "the serum levels of several muscle-specific miRNAs (miR-1, miR-133a and miR-206) are increased" +circulation_biomarker_diagnosis_up hsa-mir-146a Systemic Lupus Erythematosus 21529448 Increased Expression in Peripheral Blood Mononuclear Cells in Patients with Systemic Lupus Erythematosus. +circulation_biomarker_diagnosis_up hsa-mir-9-1 Wounds and Injuries [unspecific] 21538484 Upregulated in in serum +circulation_biomarker_diagnosis_up hsa-mir-9-2 Wounds and Injuries [unspecific] 21538484 Upregulated in in serum +circulation_biomarker_diagnosis_up hsa-mir-9-3 Wounds and Injuries [unspecific] 21538484 Upregulated in in serum +circulation_biomarker_diagnosis_up hsa-mir-29c "Carcinoma, Lung, Non-Small-Cell" 21544802 "The expression of miR-146b, miR-221, let-7a, miR-155, miR-17-5p, miR-27a and miR-106a were significantly reduced in the serum of NSCLC cases while miR-29c was significantly increased." +circulation_biomarker_diagnosis_up hsa-mir-124-1 Acute Cerebral Infarction 21551949 "Plasma concentrations of miR-124 were significantly elevated at 6 h, and remained elevated at 48 h after middle cerebral artery occlusion introduction." +circulation_biomarker_diagnosis_up hsa-mir-124-2 Acute Cerebral Infarction 21551949 "Plasma concentrations of miR-124 were significantly elevated at 6 h, and remained elevated at 48 h after middle cerebral artery occlusion introduction." +circulation_biomarker_diagnosis_up hsa-mir-124-3 Acute Cerebral Infarction 21551949 "Plasma concentrations of miR-124 were significantly elevated at 6 h, and remained elevated at 48 h after middle cerebral artery occlusion introduction." +circulation_biomarker_diagnosis_up hsa-mir-128-1 Glioblastoma 21561454 upregulated in the peripheral blood of glioblastoma patients. +circulation_biomarker_diagnosis_up hsa-mir-128-2 Glioblastoma 21561454 upregulated in the peripheral blood of glioblastoma patients. +circulation_biomarker_diagnosis_up hsa-mir-21 "Carcinoma, Lung, Non-Small-Cell" 21627863 "Plasma miR-21 was significantly higher in NSCLC patients than in age- and sex-matched controls (P < 0.001). miR-21 was related to TNM stage (P < 0.001), but not related to age, sex, smoking status, histological classification, lymph node status, and metastasis (all P > 0.05)." +circulation_biomarker_diagnosis_up hsa-mir-1-1 Myocardial Infarction 21642241 Increased MicroRNA-1 and MicroRNA-133a Levels in Serum of Patients With Cardiovascular Disease Indicate Myocardial Damage. +circulation_biomarker_diagnosis_up hsa-mir-1-2 Myocardial Infarction 21642241 Increased MicroRNA-1 and MicroRNA-133a Levels in Serum of Patients With Cardiovascular Disease Indicate Myocardial Damage. +circulation_biomarker_diagnosis_up hsa-mir-133a-1 Myocardial Infarction 21642241 Increased MicroRNA-1 and MicroRNA-133a Levels in Serum of Patients With Cardiovascular Disease Indicate Myocardial Damage. +circulation_biomarker_diagnosis_up hsa-mir-133a-2 Myocardial Infarction 21642241 Increased MicroRNA-1 and MicroRNA-133a Levels in Serum of Patients With Cardiovascular Disease Indicate Myocardial Damage. +circulation_biomarker_diagnosis_up hsa-mir-21 Myelodysplastic Syndromes 21649547 up-regulation +circulation_biomarker_diagnosis_up hsa-mir-720 Myelodysplastic Syndromes 21649547 up-regulation +circulation_biomarker_diagnosis_up hsa-mir-21 "Squamous Cell Carcinoma, Esophageal" 21673684 "the plasma level of miR-21 was significantly higher (P=0.0218) and that of miR-375 (P=0.0052) was significantly lower in ESCC patients than controls. (2) The high plasma miR-21 levels reflected tumour levels in all cases (100%). The plasma level of miR-21 was significantly reduced in postoperative samples (P=0.0058). (3) On validation analysis, the plasma level of miR-21 tended to be higher in ESCC patients (P=0.0649), while that of miR-375 was significantly lower (P<0.0001) and the miR-21/miR-375 ratio was significantly higher (P<0.0001) in ESCC patients than in controls. The value of the area under the receiver-operating characteristic curve (AUC) was 0.816 for the miR-21/miR-375 ratio assay. Patients with a high plasma level of miR-21 tended to have greater vascular invasion (P=0.1554) and to show a high correlation with recurrence (P=0.0164)." +circulation_biomarker_diagnosis_up hsa-mir-146a Glomerulonephritis 21694443 The expression levels of miR-146a and miR-155 in kidney biopsy and urine from patients with IgA nephropathy were elevated. +circulation_biomarker_diagnosis_up hsa-mir-155 Glomerulonephritis 21694443 The expression levels of miR-146a and miR-155 in kidney biopsy and urine from patients with IgA nephropathy were elevated. +circulation_biomarker_diagnosis_up hsa-mir-21 "Carcinoma, Lung, Non-Small-Cell" 21721011 serum miR-21 expression was an independent prognostic factor for NSCLC patients. +circulation_biomarker_diagnosis_up hsa-mir-10a "Leukemia, Myeloid, Acute" 21784052 miR-10a overexpression is associated with NPM1 mutations and MDM4 downregulation in intermediate-risk acute myeloid leukemia. +circulation_biomarker_diagnosis_up hsa-mir-196a-1 "Leukemia, Myeloid, Acute" 21818844 "High miR-196a and -b expression was observed in patients carrying MLL gene rearrangements, NPM1 mutations, or FLT3-ITD in a cytogenetically normal background, compared to all other patients. In contrast, CEBPA mutated cases had a low expression of miR-196a and -b. Expression of miR-196a and -b was correlated with expression of neighboring HOXA and HOXB genes." +circulation_biomarker_diagnosis_up hsa-mir-196a-2 "Leukemia, Myeloid, Acute" 21818844 "High miR-196a and -b expression was observed in patients carrying MLL gene rearrangements, NPM1 mutations, or FLT3-ITD in a cytogenetically normal background, compared to all other patients. In contrast, CEBPA mutated cases had a low expression of miR-196a and -b. Expression of miR-196a and -b was correlated with expression of neighboring HOXA and HOXB genes." +circulation_biomarker_diagnosis_up hsa-mir-196b "Leukemia, Myeloid, Acute" 21818844 "High miR-196a and -b expression was observed in patients carrying MLL gene rearrangements, NPM1 mutations, or FLT3-ITD in a cytogenetically normal background, compared to all other patients. In contrast, CEBPA mutated cases had a low expression of miR-196a and -b. Expression of miR-196a and -b was correlated with expression of neighboring HOXA and HOXB genes." +circulation_biomarker_diagnosis_up hsa-mir-146a Atherosclerosis 21820659 "miR-21, miR-210, miR-34a, and miR-146a/b are up-regulated in human atherosclerotic plaques (compared to non-atherosclerotic left internal thoracic arteries (LITA)) in the Tampere Vascular Study." +circulation_biomarker_diagnosis_up hsa-mir-146b Atherosclerosis 21820659 "miR-21, miR-210, miR-34a, and miR-146a/b are up-regulated in human atherosclerotic plaques (compared to non-atherosclerotic left internal thoracic arteries (LITA)) in the Tampere Vascular Study." +circulation_biomarker_diagnosis_up hsa-mir-21 Atherosclerosis 21820659 "miR-21, miR-210, miR-34a, and miR-146a/b are up-regulated in human atherosclerotic plaques (compared to non-atherosclerotic left internal thoracic arteries (LITA)) in the Tampere Vascular Study." +circulation_biomarker_diagnosis_up hsa-mir-210 Atherosclerosis 21820659 "miR-21, miR-210, miR-34a, and miR-146a/b are up-regulated in human atherosclerotic plaques (compared to non-atherosclerotic left internal thoracic arteries (LITA)) in the Tampere Vascular Study." +circulation_biomarker_diagnosis_up hsa-mir-34a Atherosclerosis 21820659 "miR-21, miR-210, miR-34a, and miR-146a/b are up-regulated in human atherosclerotic plaques (compared to non-atherosclerotic left internal thoracic arteries (LITA)) in the Tampere Vascular Study." +circulation_biomarker_diagnosis_up hsa-mir-146a Multiple Sclerosis 21875645 "In peripheral mononuclear cells, a statistically significant increased expression of miR-21, miR-146a and -b was observed in relapsing remitting (RR)MS patients as compared with controls." +circulation_biomarker_diagnosis_up hsa-mir-146b Multiple Sclerosis 21875645 "In peripheral mononuclear cells, a statistically significant increased expression of miR-21, miR-146a and -b was observed in relapsing remitting (RR)MS patients as compared with controls." +circulation_biomarker_diagnosis_up hsa-mir-21 Multiple Sclerosis 21875645 "In peripheral mononuclear cells, a statistically significant increased expression of miR-21, miR-146a and -b was observed in relapsing remitting (RR)MS patients as compared with controls." +circulation_biomarker_diagnosis_up hsa-mir-133a-1 Myocardial Infarction 21881276 "The miR-133 levels in plasma from AMI patients exhibited a 4.4-fold increase compared with control subjects (p=0.006). Moreover, the increased miR-133 levels in whole blood were comparable with those in plasma samples." +circulation_biomarker_diagnosis_up hsa-mir-133a-2 Myocardial Infarction 21881276 "The miR-133 levels in plasma from AMI patients exhibited a 4.4-fold increase compared with control subjects (p=0.006). Moreover, the increased miR-133 levels in whole blood were comparable with those in plasma samples." +circulation_biomarker_diagnosis_up hsa-mir-133b Myocardial Infarction 21881276 "The miR-133 levels in plasma from AMI patients exhibited a 4.4-fold increase compared with control subjects (p=0.006). Moreover, the increased miR-133 levels in whole blood were comparable with those in plasma samples." +circulation_biomarker_diagnosis_up hsa-mir-328 Myocardial Infarction 21881276 "miR-328 levels in plasma and whole blood of AMI patients were markedly increased by 10.9-fold and 16.1-fold, respectively, compared to those in control subjects (p=0.033 and p<0.001)." +circulation_biomarker_diagnosis_up hsa-mir-142 "Scleroderma, Systemic" 21883400 "Serum miR-142-3p levels in patients with SSc (systemic sclerosis) were significantly higher than in patients with SSD (scleroderma spectrum disorder), SLE (systemic lupus erythematosus) or DM (dermatomyositis), and healthy control groups. Patients with increased miR-142-3p levels tended to have a short sublingual frenulum." +circulation_biomarker_diagnosis_up hsa-mir-122 "Fatty Liver, Alcoholic" 21886843 "Serum levels of miR-122, miR-34a and miR-16 were significantly higher in NAFLD patients than in controls. miR-122 and miR-34a levels positively correlated with disease severity from simple steatosis to steatohepatitis." +circulation_biomarker_diagnosis_up hsa-mir-122 Hepatitis C Virus Infection 21886843 "Extracellular levels of circulating miRNAs, miR-122, miR-34a and to a lesser extent miR-16, steadily increased during the course of HCV infection." +circulation_biomarker_diagnosis_up hsa-mir-16-1 "Fatty Liver, Alcoholic" 21886843 "Serum levels of miR-122, miR-34a and miR-16 were significantly higher in NAFLD patients than in controls. miR-122 and miR-34a levels positively correlated with disease severity from simple steatosis to steatohepatitis." +circulation_biomarker_diagnosis_up hsa-mir-16-1 Hepatitis C Virus Infection 21886843 "Extracellular levels of circulating miRNAs, miR-122, miR-34a and to a lesser extent miR-16, steadily increased during the course of HCV infection." +circulation_biomarker_diagnosis_up hsa-mir-16-2 "Fatty Liver, Alcoholic" 21886843 "Serum levels of miR-122, miR-34a and miR-16 were significantly higher in NAFLD patients than in controls. miR-122 and miR-34a levels positively correlated with disease severity from simple steatosis to steatohepatitis." +circulation_biomarker_diagnosis_up hsa-mir-16-2 Hepatitis C Virus Infection 21886843 "Extracellular levels of circulating miRNAs, miR-122, miR-34a and to a lesser extent miR-16, steadily increased during the course of HCV infection." +circulation_biomarker_diagnosis_up hsa-mir-34a "Fatty Liver, Alcoholic" 21886843 "Serum levels of miR-122, miR-34a and miR-16 were significantly higher in NAFLD patients than in controls. miR-122 and miR-34a levels positively correlated with disease severity from simple steatosis to steatohepatitis." +circulation_biomarker_diagnosis_up hsa-mir-34a Hepatitis C Virus Infection 21886843 "Extracellular levels of circulating miRNAs, miR-122, miR-34a and to a lesser extent miR-16, steadily increased during the course of HCV infection." +circulation_biomarker_diagnosis_up hsa-mir-155 Lung Neoplasms 21904633 "The levels of miR-155, miR-197, and miR-182 in the plasma of lung cancer including stage I patients were significantly elevated compared with controls (P<0.001). The combination of these 3 miRNAs yielded 81.33% sensitivity and 86.76% specificity in discriminating lung cancer patients from controls. The levels of miR-155 and miR-197 were higher in the plasma from lung cancer patients with metastasis than in those without metastasis (P<0.05) and were significantly decreased in responsive patients during chemotherapy (P<0.001)." +circulation_biomarker_diagnosis_up hsa-mir-182 Lung Neoplasms 21904633 "The levels of miR-155, miR-197, and miR-182 in the plasma of lung cancer including stage I patients were significantly elevated compared with controls (P<0.001). The combination of these 3 miRNAs yielded 81.33% sensitivity and 86.76% specificity in discriminating lung cancer patients from controls. The levels of miR-155 and miR-197 were higher in the plasma from lung cancer patients with metastasis than in those without metastasis (P<0.05) and were significantly decreased in responsive patients during chemotherapy (P<0.001)." +circulation_biomarker_diagnosis_up hsa-mir-197 Lung Neoplasms 21904633 "The levels of miR-155, miR-197, and miR-182 in the plasma of lung cancer including stage I patients were significantly elevated compared with controls (P<0.001). The combination of these 3 miRNAs yielded 81.33% sensitivity and 86.76% specificity in discriminating lung cancer patients from controls. The levels of miR-155 and miR-197 were higher in the plasma from lung cancer patients with metastasis than in those without metastasis (P<0.05) and were significantly decreased in responsive patients during chemotherapy (P<0.001)." +circulation_biomarker_diagnosis_up hsa-let-7e Hypertension 21924071 "MiR-296-5p (Fold change 0.47, P = 0.013) and miR-133b (Fold change 0.57, P = 0.033) were consistently down-regulated in the patient plasma, whereas let-7e (Fold change 1.62, P = 0.009) and hcmv-miR-UL112 (Fold change 2.72, P = 0.004), one human cytomegalovirus encoded microRNAs, were up-regulated in the patient samples." +circulation_biomarker_diagnosis_up hsa-mir-134 Pulmonary Embolism 21943159 "Plasma miRNA-134 (miR-134) level was significantly higher in the APE patients than in the healthy controls or non-APE patients. The ROC curve showed that plasma miR-134 was a specific diagnostic predictor of APE with an area under the curve of 0.833 (95% confidence interval, 0.737 to 0.929; P<0.001). The findings indicated that plasma miR-134 could be an important biomarker for the diagnosis of APE." +circulation_biomarker_diagnosis_up hsa-mir-29a Liver Cirrhosis 21946200 MiR-29 directly suppresses the expression of a variety of extracellular matrix components and regulates signaling pathways associated with fibrosis. The serum level of miR-29 in patients with liver disease is consistent with the degree of liver cirrhosis. +circulation_biomarker_diagnosis_up hsa-mir-29b-1 Liver Cirrhosis 21946200 MiR-29 directly suppresses the expression of a variety of extracellular matrix components and regulates signaling pathways associated with fibrosis. The serum level of miR-29 in patients with liver disease is consistent with the degree of liver cirrhosis. +circulation_biomarker_diagnosis_up hsa-mir-29b-2 Liver Cirrhosis 21946200 MiR-29 directly suppresses the expression of a variety of extracellular matrix components and regulates signaling pathways associated with fibrosis. The serum level of miR-29 in patients with liver disease is consistent with the degree of liver cirrhosis. +circulation_biomarker_diagnosis_up hsa-mir-29c Liver Cirrhosis 21946200 MiR-29 directly suppresses the expression of a variety of extracellular matrix components and regulates signaling pathways associated with fibrosis. The serum level of miR-29 in patients with liver disease is consistent with the degree of liver cirrhosis. +circulation_biomarker_diagnosis_up hsa-mir-106b "Carcinoma, Renal Cell" 21984948 "Up-regulation in serum and tissue of RCC patients: miR-7-1*, miR-93, miR-106b*, miR-210, miR-320b, miR-1233 and miR-1290" +circulation_biomarker_diagnosis_up hsa-mir-1233-1 "Carcinoma, Renal Cell" 21984948 "Up-regulation in serum and tissue of RCC patients: miR-7-1*, miR-93, miR-106b*, miR-210, miR-320b, miR-1233 and miR-1290" +circulation_biomarker_diagnosis_up hsa-mir-1233-2 "Carcinoma, Renal Cell" 21984948 "Up-regulation in serum and tissue of RCC patients: miR-7-1*, miR-93, miR-106b*, miR-210, miR-320b, miR-1233 and miR-1290" +circulation_biomarker_diagnosis_up hsa-mir-1290 "Carcinoma, Renal Cell" 21984948 "Up-regulation in serum and tissue of RCC patients: miR-7-1*, miR-93, miR-106b*, miR-210, miR-320b, miR-1233 and miR-1290" +circulation_biomarker_diagnosis_up hsa-mir-210 "Carcinoma, Renal Cell" 21984948 "Up-regulation in serum and tissue of RCC patients: miR-7-1*, miR-93, miR-106b*, miR-210, miR-320b, miR-1233 and miR-1290" +circulation_biomarker_diagnosis_up hsa-mir-320b-1 "Carcinoma, Renal Cell" 21984948 "Up-regulation in serum and tissue of RCC patients: miR-7-1*, miR-93, miR-106b*, miR-210, miR-320b, miR-1233 and miR-1290" +circulation_biomarker_diagnosis_up hsa-mir-320b-2 "Carcinoma, Renal Cell" 21984948 "Up-regulation in serum and tissue of RCC patients: miR-7-1*, miR-93, miR-106b*, miR-210, miR-320b, miR-1233 and miR-1290" +circulation_biomarker_diagnosis_up hsa-mir-7-1 "Carcinoma, Renal Cell" 21984948 "Up-regulation in serum and tissue of RCC patients: miR-7-1*, miR-93, miR-106b*, miR-210, miR-320b, miR-1233 and miR-1290" +circulation_biomarker_diagnosis_up hsa-mir-93 "Carcinoma, Renal Cell" 21984948 "Up-regulation in serum and tissue of RCC patients: miR-7-1*, miR-93, miR-106b*, miR-210, miR-320b, miR-1233 and miR-1290" +circulation_biomarker_diagnosis_up hsa-mir-155 "Tuberculosis, Pulmonary" 22037148 Analysis of microRNA expression profiling identifies miR-155 and miR-155* as potential diagnostic markers for active tuberculosis. +circulation_biomarker_diagnosis_up hsa-mir-18a Pancreatic Neoplasms 22045190 The expression of miR-18a was significantly higher in pancreatic cancer tissues (P=0.012) and pancreatic cancer cell lines (P=0.015) than in normal tissues and fibroblasts. Plasma concentrations of miR-18a were significantly higher in pancreatic cancer patients than in controls (P<0.0001). The value of the area under the receiver-operating characteristic curve (AUC) was 0.9369. Plasma levels of miR-18a were significantly lower in postoperative samples than in preoperative samples (P=0.0077). +circulation_biomarker_diagnosis_up hsa-mir-192 Liver Injury 22045675 Serum miR-122 and miR-192 were substantially higher in APAP-ALI patients. +circulation_biomarker_diagnosis_up hsa-mir-223 "Leukemia, Promyelocytic, Acute" 22053279 overexpression +circulation_biomarker_diagnosis_up hsa-mir-326 "Diabetes Mellitus, Type 1" 22069274 Increased expression of microRNA miR-326 in type 1 diabetic patients with ongoing islet autoimmunity. +circulation_biomarker_diagnosis_up hsa-mir-210 Preeclampsia 22095477 Serum expression level of miR-210 was up-regulated in preeclampsia patients. +circulation_biomarker_diagnosis_up hsa-mir-100 "Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic" 22099053 "A significant association was observed between higher expression levels of miR-196b and T-ALL, miR-100 and patients with low white blood cell count at diagnosis and t(12;21) positive ALL." +circulation_biomarker_diagnosis_up hsa-mir-196b "Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic" 22099053 "A significant association was observed between higher expression levels of miR-196b and T-ALL, miR-100 and patients with low white blood cell count at diagnosis and t(12;21) positive ALL." +circulation_biomarker_diagnosis_up hsa-mir-22 Heart Failure 22120965 significantly increased serum level +circulation_biomarker_diagnosis_up hsa-mir-320a Heart Failure 22120965 significantly increased serum level +circulation_biomarker_diagnosis_up hsa-mir-423 Heart Failure 22120965 miR-423-5p: significantly increased serum level +circulation_biomarker_diagnosis_up hsa-mir-92b Heart Failure 22120965 significantly increased serum level +circulation_biomarker_diagnosis_up hsa-mir-1266 Psoriasis 22133505 Increased serum levels of miR-1266 in patients with psoriasis vulgaris. +circulation_biomarker_diagnosis_up hsa-mir-1 Cardiovascular Diseases [unspecific] 22135162 miR-1 and miR-133 are highly expressed in cardiomyocytes and their precursors and regulate cardiomyogenesis. +circulation_biomarker_diagnosis_up hsa-mir-133 Cardiovascular Diseases [unspecific] 22135162 miR-1 and miR-133 are highly expressed in cardiomyocytes and their precursors and regulate cardiomyogenesis. +circulation_biomarker_diagnosis_up hsa-mir-140 Osteoarthritis 22143896 the expression of both miR-140-5p and miR-455-3p was increased in OA cartilage. +circulation_biomarker_diagnosis_up hsa-mir-455 Osteoarthritis 22143896 the expression of both miR-140-5p and miR-455-3p was increased in OA cartilage. +circulation_biomarker_diagnosis_up hsa-mir-92a-1 Myocardial Infarction 22153007 "In STEMI (ST-segment elevation myocardial infarction) patients, the expression of circulating miR-92a is up-regulated. PCI therapy may suppress such up-regulation. Survival rate is higher in patients showing down-regulation of miR-92a. Our data suggest that miR-92a might have potential for diagnosis and therapeutic application in the prevention and treatment of STEMI." +circulation_biomarker_diagnosis_up hsa-mir-92a-2 Myocardial Infarction 22153007 "In STEMI (ST-segment elevation myocardial infarction) patients, the expression of circulating miR-92a is up-regulated. PCI therapy may suppress such up-regulation. Survival rate is higher in patients showing down-regulation of miR-92a. Our data suggest that miR-92a might have potential for diagnosis and therapeutic application in the prevention and treatment of STEMI." +circulation_biomarker_diagnosis_up hsa-mir-103a-1 Preeclampsia 22187671 "Seven microRNAs, namely miR-24, miR-26a, miR-103, miR-130b, miR-181a, miR-342-3p, and miR-574-5p, were validated to be elevated in plasma from severe pre-eclamptic pregnancies by using real-time quantitative stem-loop reverse-transcription polymerase chain reaction analysis." +circulation_biomarker_diagnosis_up hsa-mir-103a-2 Preeclampsia 22187671 "Seven microRNAs, namely miR-24, miR-26a, miR-103, miR-130b, miR-181a, miR-342-3p, and miR-574-5p, were validated to be elevated in plasma from severe pre-eclamptic pregnancies by using real-time quantitative stem-loop reverse-transcription polymerase chain reaction analysis." +circulation_biomarker_diagnosis_up hsa-mir-103b-1 Preeclampsia 22187671 "Seven microRNAs, namely miR-24, miR-26a, miR-103, miR-130b, miR-181a, miR-342-3p, and miR-574-5p, were validated to be elevated in plasma from severe pre-eclamptic pregnancies by using real-time quantitative stem-loop reverse-transcription polymerase chain reaction analysis." +circulation_biomarker_diagnosis_up hsa-mir-103b-2 Preeclampsia 22187671 "Seven microRNAs, namely miR-24, miR-26a, miR-103, miR-130b, miR-181a, miR-342-3p, and miR-574-5p, were validated to be elevated in plasma from severe pre-eclamptic pregnancies by using real-time quantitative stem-loop reverse-transcription polymerase chain reaction analysis." +circulation_biomarker_diagnosis_up hsa-mir-130b Preeclampsia 22187671 "Seven microRNAs, namely miR-24, miR-26a, miR-103, miR-130b, miR-181a, miR-342-3p, and miR-574-5p, were validated to be elevated in plasma from severe pre-eclamptic pregnancies by using real-time quantitative stem-loop reverse-transcription polymerase chain reaction analysis." +circulation_biomarker_diagnosis_up hsa-mir-181a-1 Preeclampsia 22187671 "Seven microRNAs, namely miR-24, miR-26a, miR-103, miR-130b, miR-181a, miR-342-3p, and miR-574-5p, were validated to be elevated in plasma from severe pre-eclamptic pregnancies by using real-time quantitative stem-loop reverse-transcription polymerase chain reaction analysis." +circulation_biomarker_diagnosis_up hsa-mir-181a-2 Preeclampsia 22187671 "Seven microRNAs, namely miR-24, miR-26a, miR-103, miR-130b, miR-181a, miR-342-3p, and miR-574-5p, were validated to be elevated in plasma from severe pre-eclamptic pregnancies by using real-time quantitative stem-loop reverse-transcription polymerase chain reaction analysis." +circulation_biomarker_diagnosis_up hsa-mir-24-1 Preeclampsia 22187671 "Seven microRNAs, namely miR-24, miR-26a, miR-103, miR-130b, miR-181a, miR-342-3p, and miR-574-5p, were validated to be elevated in plasma from severe pre-eclamptic pregnancies by using real-time quantitative stem-loop reverse-transcription polymerase chain reaction analysis." +circulation_biomarker_diagnosis_up hsa-mir-24-2 Preeclampsia 22187671 "Seven microRNAs, namely miR-24, miR-26a, miR-103, miR-130b, miR-181a, miR-342-3p, and miR-574-5p, were validated to be elevated in plasma from severe pre-eclamptic pregnancies by using real-time quantitative stem-loop reverse-transcription polymerase chain reaction analysis." +circulation_biomarker_diagnosis_up hsa-mir-26a-1 Preeclampsia 22187671 "Seven microRNAs, namely miR-24, miR-26a, miR-103, miR-130b, miR-181a, miR-342-3p, and miR-574-5p, were validated to be elevated in plasma from severe pre-eclamptic pregnancies by using real-time quantitative stem-loop reverse-transcription polymerase chain reaction analysis." +circulation_biomarker_diagnosis_up hsa-mir-26a-2 Preeclampsia 22187671 "Seven microRNAs, namely miR-24, miR-26a, miR-103, miR-130b, miR-181a, miR-342-3p, and miR-574-5p, were validated to be elevated in plasma from severe pre-eclamptic pregnancies by using real-time quantitative stem-loop reverse-transcription polymerase chain reaction analysis." +circulation_biomarker_diagnosis_up hsa-mir-342 Preeclampsia 22187671 "Seven microRNAs, namely miR-24, miR-26a, miR-103, miR-130b, miR-181a, miR-342-3p, and miR-574-5p, were validated to be elevated in plasma from severe pre-eclamptic pregnancies by using real-time quantitative stem-loop reverse-transcription polymerase chain reaction analysis." +circulation_biomarker_diagnosis_up hsa-mir-574 Preeclampsia 22187671 "Seven microRNAs, namely miR-24, miR-26a, miR-103, miR-130b, miR-181a, miR-342-3p, and miR-574-5p, were validated to be elevated in plasma from severe pre-eclamptic pregnancies by using real-time quantitative stem-loop reverse-transcription polymerase chain reaction analysis." +circulation_biomarker_diagnosis_up hsa-mir-22 Multiple Sclerosis 22231906 "Six plasma miRNA (miR-614, miR-572, miR-648, miR-1826, miR-422a and miR-22) that were significantly up-regulated and one plasma miRNA (miR-1979) that was significantly down-regulated in MS individuals." +circulation_biomarker_diagnosis_up hsa-mir-422a Multiple Sclerosis 22231906 "Six plasma miRNA (miR-614, miR-572, miR-648, miR-1826, miR-422a and miR-22) that were significantly up-regulated and one plasma miRNA (miR-1979) that was significantly down-regulated in MS individuals." +circulation_biomarker_diagnosis_up hsa-mir-572 Multiple Sclerosis 22231906 "Six plasma miRNA (miR-614, miR-572, miR-648, miR-1826, miR-422a and miR-22) that were significantly up-regulated and one plasma miRNA (miR-1979) that was significantly down-regulated in MS individuals." +circulation_biomarker_diagnosis_up hsa-mir-614 Multiple Sclerosis 22231906 "Six plasma miRNA (miR-614, miR-572, miR-648, miR-1826, miR-422a and miR-22) that were significantly up-regulated and one plasma miRNA (miR-1979) that was significantly down-regulated in MS individuals." +circulation_biomarker_diagnosis_up hsa-mir-648 Multiple Sclerosis 22231906 "Six plasma miRNA (miR-614, miR-572, miR-648, miR-1826, miR-422a and miR-22) that were significantly up-regulated and one plasma miRNA (miR-1979) that was significantly down-regulated in MS individuals." +circulation_biomarker_diagnosis_up hsa-let-7a-1 Breast Neoplasms 22242178 let-7a* is up-regulated in whole blood of breast cancer patients +circulation_biomarker_diagnosis_up hsa-let-7a-2 Breast Neoplasms 22242178 let-7a* is up-regulated in whole blood of breast cancer patients +circulation_biomarker_diagnosis_up hsa-let-7a-3 Breast Neoplasms 22242178 let-7a* is up-regulated in whole blood of breast cancer patients +circulation_biomarker_diagnosis_up hsa-mir-106b Breast Neoplasms 22242178 The miRNA is up-regulated in whole blood of breast cancer patients +circulation_biomarker_diagnosis_up hsa-mir-1323 Breast Neoplasms 22242178 The miRNA is up-regulated in whole blood of breast cancer patients +circulation_biomarker_diagnosis_up hsa-mir-202 Breast Neoplasms 22242178 The miRNA is up-regulated in whole blood of breast cancer patients +circulation_biomarker_diagnosis_up hsa-mir-335 Breast Neoplasms 22242178 The miRNA is up-regulated in whole blood of breast cancer patients +circulation_biomarker_diagnosis_up hsa-mir-4257 Breast Neoplasms 22242178 The miRNA is up-regulated in whole blood of breast cancer patients +circulation_biomarker_diagnosis_up hsa-mir-4306 Breast Neoplasms 22242178 The miRNA is up-regulated in whole blood of breast cancer patients +circulation_biomarker_diagnosis_up hsa-mir-497 Breast Neoplasms 22242178 The miRNA is up-regulated in whole blood of breast cancer patients +circulation_biomarker_diagnosis_up hsa-mir-516b-1 Breast Neoplasms 22242178 The miRNA is up-regulated in whole blood of breast cancer patients +circulation_biomarker_diagnosis_up hsa-mir-516b-2 Breast Neoplasms 22242178 The miRNA is up-regulated in whole blood of breast cancer patients +circulation_biomarker_diagnosis_up hsa-mir-922 Breast Neoplasms 22242178 The miRNA is up-regulated in whole blood of breast cancer patients +circulation_biomarker_diagnosis_up hsa-mir-103a-1 Mesothelioma 22253921 miR-103 was identified as a potential biomarker for malignant mesothelioma +circulation_biomarker_diagnosis_up hsa-mir-103a-2 Mesothelioma 22253921 miR-103 was identified as a potential biomarker for malignant mesothelioma +circulation_biomarker_diagnosis_up hsa-mir-125b "Leukemia, Lymphoblastic" 22335948 "These three subtypes of leukemia could be identified by unsupervised hierarchical cluster analysis of microRNA expression and had specific up-regulation of miR-335, miR-126 and miR-125b, respectively." +circulation_biomarker_diagnosis_up hsa-mir-126 "Leukemia, Lymphoblastic" 22335948 "These three subtypes of leukemia could be identified by unsupervised hierarchical cluster analysis of microRNA expression and had specific up-regulation of miR-335, miR-126 and miR-125b, respectively." +circulation_biomarker_diagnosis_up hsa-mir-335 "Leukemia, Lymphoblastic" 22335948 "These three subtypes of leukemia could be identified by unsupervised hierarchical cluster analysis of microRNA expression and had specific up-regulation of miR-335, miR-126 and miR-125b, respectively." +circulation_biomarker_diagnosis_up hsa-mir-20a Breast Neoplasms 22350790 "Levels of preoperative serum miR-20a and miR-21 were significantly higher in patients with breast cancer and benign disease than in healthy women (p = 0.0001), but only serum miR-214 could discriminate malignant from benign tumors and healthy controls (p = 0.0001) with an area under the curve of 0.878 and 0.883 in ROC analysis, respectively." +circulation_biomarker_diagnosis_up hsa-mir-21 Breast Neoplasms 22350790 "Levels of preoperative serum miR-20a and miR-21 were significantly higher in patients with breast cancer and benign disease than in healthy women (p = 0.0001), but only serum miR-214 could discriminate malignant from benign tumors and healthy controls (p = 0.0001) with an area under the curve of 0.878 and 0.883 in ROC analysis, respectively." +circulation_biomarker_diagnosis_up hsa-mir-214 Breast Neoplasms 22350790 "Levels of preoperative serum miR-20a and miR-21 were significantly higher in patients with breast cancer and benign disease than in healthy women (p = 0.0001), but only serum miR-214 could discriminate malignant from benign tumors and healthy controls (p = 0.0001) with an area under the curve of 0.878 and 0.883 in ROC analysis, respectively." +circulation_biomarker_diagnosis_up hsa-mir-21 Esophageal Neoplasms 22354855 "Serum concentration of miRNA-21 in ESCC patients was significantly higher than that in healthy controls (P<0.001). A significant reduction in the serum miR-21 levels was observed in the postoperative samples versus the preoperative samples (P=0.003). Furthermore, miRNA-21 levels were significantly reduced in ESCC patients who responded to chemotherapy (P=0.003), whereas no significant change was observed in the non-responders." +circulation_biomarker_diagnosis_up hsa-mir-145 Cerebral Ischemia 22370881 Circulatory microRNA-145 expression is increased in cerebral ischemia. +circulation_biomarker_diagnosis_up hsa-mir-106a Crohn Disease 22386737 The miRNA showed significantly higher levels in the blood from patients with CD compared with the healthy controls. +circulation_biomarker_diagnosis_up hsa-mir-107 Crohn Disease 22386737 The miRNA showed significantly higher levels in the blood from patients with CD compared with the healthy controls. +circulation_biomarker_diagnosis_up hsa-mir-126 Crohn Disease 22386737 The miRNA showed significantly higher levels in the blood from patients with CD compared with the healthy controls. +circulation_biomarker_diagnosis_up hsa-mir-16-1 Crohn Disease 22386737 The miRNA showed significantly higher levels in the blood from patients with CD compared with the healthy controls. +circulation_biomarker_diagnosis_up hsa-mir-16-2 Crohn Disease 22386737 The miRNA showed significantly higher levels in the blood from patients with CD compared with the healthy controls. +circulation_biomarker_diagnosis_up hsa-mir-191 Crohn Disease 22386737 The miRNA showed significantly higher levels in the blood from patients with CD compared with the healthy controls. +circulation_biomarker_diagnosis_up hsa-mir-199a-1 Crohn Disease 22386737 The miRNA showed significantly higher levels in the blood from patients with CD compared with the healthy controls. +circulation_biomarker_diagnosis_up hsa-mir-199a-2 Crohn Disease 22386737 The miRNA showed significantly higher levels in the blood from patients with CD compared with the healthy controls. +circulation_biomarker_diagnosis_up hsa-mir-200c Crohn Disease 22386737 The miRNA showed significantly higher levels in the blood from patients with CD compared with the healthy controls. +circulation_biomarker_diagnosis_up hsa-mir-23a Crohn Disease 22386737 The miRNA showed significantly higher levels in the blood from patients with CD compared with the healthy controls. +circulation_biomarker_diagnosis_up hsa-mir-29a Crohn Disease 22386737 The miRNA showed significantly higher levels in the blood from patients with CD compared with the healthy controls. +circulation_biomarker_diagnosis_up hsa-mir-362 Crohn Disease 22386737 The miRNA showed significantly higher levels in the blood from patients with CD compared with the healthy controls. +circulation_biomarker_diagnosis_up hsa-mir-532 Crohn Disease 22386737 The miRNA showed significantly higher levels in the blood from patients with CD compared with the healthy controls. +circulation_biomarker_diagnosis_up hsa-mir-103a-1 Breast Neoplasms 22387599 significantly increased in serum of breast cancer patients. +circulation_biomarker_diagnosis_up hsa-mir-222 Breast Neoplasms 22387599 significantly increased in serum of breast cancer patients. +circulation_biomarker_diagnosis_up hsa-mir-23a Breast Neoplasms 22387599 significantly increased in serum of breast cancer patients. +circulation_biomarker_diagnosis_up hsa-mir-23b Breast Neoplasms 22387599 significantly increased in serum of breast cancer patients. +circulation_biomarker_diagnosis_up hsa-mir-24-1 Breast Neoplasms 22387599 significantly increased in serum of breast cancer patients. +circulation_biomarker_diagnosis_up hsa-mir-25 Breast Neoplasms 22387599 significantly increased in serum of breast cancer patients. +circulation_biomarker_diagnosis_up hsa-mir-29a Breast Neoplasms 22387599 significantly increased in serum of breast cancer patients. +circulation_biomarker_diagnosis_up hsa-mir-210 "Carcinoma, Hepatocellular" 22387901 "Downregulation of miR-210 expression inhibits proliferation, induces apoptosis and enhances radiosensitivity in hypoxic human hepatoma cells in vitro." +circulation_biomarker_diagnosis_up hsa-mir-106b Eosinophilic Esophagitis 22391115 miR-106b*: upregulated +circulation_biomarker_diagnosis_up hsa-mir-132 Eosinophilic Esophagitis 22391115 upregulated +circulation_biomarker_diagnosis_up hsa-mir-142 Eosinophilic Esophagitis 22391115 upregulated +circulation_biomarker_diagnosis_up hsa-mir-146a Eosinophilic Esophagitis 22391115 "Plasma analysis of the most upregulated esophageal miRNAs identified miR-146a, miR-146b, and miR-223 as the most differentially expressed miRNAs in the plasma." +circulation_biomarker_diagnosis_up hsa-mir-146b Eosinophilic Esophagitis 22391115 "Plasma analysis of the most upregulated esophageal miRNAs identified miR-146a, miR-146b, and miR-223 as the most differentially expressed miRNAs in the plasma." +circulation_biomarker_diagnosis_up hsa-mir-21 Eosinophilic Esophagitis 22391115 "One of the most upregulated miRNA, which strongly correlated with esophageal eosinophil levels." +circulation_biomarker_diagnosis_up hsa-mir-212 Eosinophilic Esophagitis 22391115 upregulated +circulation_biomarker_diagnosis_up hsa-mir-222 Eosinophilic Esophagitis 22391115 miR-222*: upregulated +circulation_biomarker_diagnosis_up hsa-mir-223 Eosinophilic Esophagitis 22391115 "One of the most upregulated miRNA, which strongly correlated with esophageal eosinophil levels. And miR-223 is one of the most differentially expressed miRNAs in the plasma." +circulation_biomarker_diagnosis_up hsa-mir-29b-1 Eosinophilic Esophagitis 22391115 upregulated +circulation_biomarker_diagnosis_up hsa-mir-29b-2 Eosinophilic Esophagitis 22391115 upregulated +circulation_biomarker_diagnosis_up hsa-mir-339 Eosinophilic Esophagitis 22391115 miR-339-5p: upregulated +circulation_biomarker_diagnosis_up hsa-mir-592 Eosinophilic Esophagitis 22391115 upregulated +circulation_biomarker_diagnosis_up hsa-mir-7-1 Eosinophilic Esophagitis 22391115 upregulated +circulation_biomarker_diagnosis_up hsa-mir-7-2 Eosinophilic Esophagitis 22391115 upregulated +circulation_biomarker_diagnosis_up hsa-mir-7-3 Eosinophilic Esophagitis 22391115 upregulated +circulation_biomarker_diagnosis_up hsa-mir-92a-1 Eosinophilic Esophagitis 22391115 miR-92a-1*: upregulated +circulation_biomarker_diagnosis_up hsa-mir-323a Ectopic Pregnancy 22395025 "Concentrations of serum hCG, progesterone, miR-517a, miR-519d, and miR-525-3p were significantly lower in EP and SA cases than in VIP cases. In contrast, the concentration of miR-323-3p was significantly increased in EP cases, compared with SA and VIP cases. As a single marker, miR-323-3p had the highest sensitivity of 37.0% (at a fixed specificity of 90%)." +circulation_biomarker_diagnosis_up hsa-mir-130b "Carcinoma, Hepatocellular" 22403344 "Serum miR-15b, miR-21, miR-130b and miR-183 highly expressed in tumours. Combined miR-15b and miR-130b demonstrated as a classifier for HCC detection, yielding a receiver operating characteristic curve area of 0.98 (98.2% sensitivity and 91.5% specificity)." +circulation_biomarker_diagnosis_up hsa-mir-15b "Carcinoma, Hepatocellular" 22403344 "Serum miR-15b, miR-21, miR-130b and miR-183 highly expressed in tumours. Combined miR-15b and miR-130b demonstrated as a classifier for HCC detection, yielding a receiver operating characteristic curve area of 0.98 (98.2% sensitivity and 91.5% specificity)." +circulation_biomarker_diagnosis_up hsa-mir-183 "Carcinoma, Hepatocellular" 22403344 "Serum miR-15b, miR-21, miR-130b and miR-183 highly expressed in tumours. Combined miR-15b and miR-130b demonstrated as a classifier for HCC detection, yielding a receiver operating characteristic curve area of 0.98 (98.2% sensitivity and 91.5% specificity)." +circulation_biomarker_diagnosis_up hsa-mir-21 "Carcinoma, Hepatocellular" 22403344 "Serum miR-15b, miR-21, miR-130b and miR-183 highly expressed in tumours. Combined miR-15b and miR-130b demonstrated as a classifier for HCC detection, yielding a receiver operating characteristic curve area of 0.98 (98.2% sensitivity and 91.5% specificity)." +circulation_biomarker_diagnosis_up hsa-mir-126 "Carcinoma, Renal Cell" 22440013 miR-126*: Up-regulated in the blook serum of patients with renal cell carcinoma compared to healthy controls. +circulation_biomarker_diagnosis_up hsa-mir-134 "Carcinoma, Renal Cell" 22440013 Up-regulated in the blook serum of patients with renal cell carcinoma compared to healthy controls. +circulation_biomarker_diagnosis_up hsa-mir-144 "Carcinoma, Renal Cell" 22440013 miR-144*: Up-regulated in the blook serum of patients with renal cell carcinoma compared to healthy controls. +circulation_biomarker_diagnosis_up hsa-mir-151a "Carcinoma, Renal Cell" 22440013 miR-151-30: Up-regulated in the blook serum of patients with renal cell carcinoma compared to healthy controls. +circulation_biomarker_diagnosis_up hsa-mir-151b "Carcinoma, Renal Cell" 22440013 miR-151-30: Up-regulated in the blook serum of patients with renal cell carcinoma compared to healthy controls. +circulation_biomarker_diagnosis_up hsa-mir-203 "Carcinoma, Renal Cell" 22440013 Up-regulated in the blook serum of patients with renal cell carcinoma compared to healthy controls. +circulation_biomarker_diagnosis_up hsa-mir-26b "Carcinoma, Renal Cell" 22440013 miR-26b*: Up-regulated in the blook serum of patients with renal cell carcinoma compared to healthy controls. +circulation_biomarker_diagnosis_up hsa-mir-29c "Carcinoma, Renal Cell" 22440013 miR-29c*: Up-regulated in the blook serum of patients with renal cell carcinoma compared to healthy controls. +circulation_biomarker_diagnosis_up hsa-mir-320a "Carcinoma, Renal Cell" 22440013 Up-regulated in the blook serum of patients with renal cell carcinoma compared to healthy controls. +circulation_biomarker_diagnosis_up hsa-mir-339 "Carcinoma, Renal Cell" 22440013 miR-339-3p: Up-regulated in the blook serum of patients with renal cell carcinoma compared to healthy controls. +circulation_biomarker_diagnosis_up hsa-mir-365a "Carcinoma, Renal Cell" 22440013 Up-regulated in the blook serum of patients with renal cell carcinoma compared to healthy controls. +circulation_biomarker_diagnosis_up hsa-mir-365b "Carcinoma, Renal Cell" 22440013 Up-regulated in the blook serum of patients with renal cell carcinoma compared to healthy controls. +circulation_biomarker_diagnosis_up hsa-mir-378a "Carcinoma, Renal Cell" 22440013 Up-regulated in the blook serum of patients with renal cell carcinoma compared to healthy controls. +circulation_biomarker_diagnosis_up hsa-mir-425 "Carcinoma, Renal Cell" 22440013 miR-425*: Up-regulated in the blook serum of patients with renal cell carcinoma compared to healthy controls. +circulation_biomarker_diagnosis_up hsa-mir-454 "Carcinoma, Renal Cell" 22440013 miR-454*: Up-regulated in the blook serum of patients with renal cell carcinoma compared to healthy controls. +circulation_biomarker_diagnosis_up hsa-mir-571 "Carcinoma, Renal Cell" 22440013 Up-regulated in the blook serum of patients with renal cell carcinoma compared to healthy controls. +circulation_biomarker_diagnosis_up hsa-mir-625 "Carcinoma, Renal Cell" 22440013 miR-625*: Up-regulated in the blook serum of patients with renal cell carcinoma compared to healthy controls. +circulation_biomarker_diagnosis_up hsa-mir-629 "Carcinoma, Renal Cell" 22440013 Up-regulated in the blook serum of patients with renal cell carcinoma compared to healthy controls. +circulation_biomarker_diagnosis_up hsa-mir-655 "Carcinoma, Renal Cell" 22440013 Up-regulated in the blook serum of patients with renal cell carcinoma compared to healthy controls. +circulation_biomarker_diagnosis_up hsa-mir-760 "Carcinoma, Renal Cell" 22440013 Up-regulated in the blook serum of patients with renal cell carcinoma compared to healthy controls. +circulation_biomarker_diagnosis_up hsa-mir-148a Multiple Myeloma 22447484 Plasma level was significantly upregulated in MM.High levels of miR-20a and miR-148a were related to shorter relapse-free survival. +circulation_biomarker_diagnosis_up hsa-mir-181a-1 Multiple Myeloma 22447484 Plasma level was significantly upregulated in MM. +circulation_biomarker_diagnosis_up hsa-mir-181a-2 Multiple Myeloma 22447484 Plasma level was significantly upregulated in MM. +circulation_biomarker_diagnosis_up hsa-mir-20a Multiple Myeloma 22447484 Plasma level was significantly upregulated in MM. +circulation_biomarker_diagnosis_up hsa-mir-221 Multiple Myeloma 22447484 Plasma level was significantly upregulated in MM.High levels of miR-20a and miR-148a were related to shorter relapse-free survival. +circulation_biomarker_diagnosis_up hsa-mir-625 Multiple Myeloma 22447484 Plasma level was significantly upregulated in MM. +circulation_biomarker_diagnosis_up hsa-mir-99b Multiple Myeloma 22447484 Plasma level was significantly upregulated in MM. +circulation_biomarker_diagnosis_up hsa-mir-29b "Leukemia, Lymphoblastic, Acute" 22456238 "BCR-ABL1 positive cases, in contrast to negative ones, were characterized by slightly, but still significantly, higher expression levels of miR-29b." +circulation_biomarker_diagnosis_up hsa-let-7e Thyroid Neoplasms 22472564 "The expression of serum let-7e, miR-151-5p, and miR-222 was significantly increased in PTC (papillary thyroid carcinomas ) cases relative to benign cases and healthy controls. Serum let-7e, miR-151-5p, and miR-222 levels were found to be well correlated with certain clinicopathological variables, such as nodal status, tumor size, multifocal lesion status, and Tumor-Node-Metastasis stage." +circulation_biomarker_diagnosis_up hsa-mir-151a Thyroid Neoplasms 22472564 "The expression of serum let-7e, miR-151-5p, and miR-222 was significantly increased in PTC (papillary thyroid carcinomas ) cases relative to benign cases and healthy controls. Serum let-7e, miR-151-5p, and miR-222 levels were found to be well correlated with certain clinicopathological variables, such as nodal status, tumor size, multifocal lesion status, and Tumor-Node-Metastasis stage." +circulation_biomarker_diagnosis_up hsa-mir-151b Thyroid Neoplasms 22472564 "The expression of serum let-7e, miR-151-5p, and miR-222 was significantly increased in PTC (papillary thyroid carcinomas ) cases relative to benign cases and healthy controls. Serum let-7e, miR-151-5p, and miR-222 levels were found to be well correlated with certain clinicopathological variables, such as nodal status, tumor size, multifocal lesion status, and Tumor-Node-Metastasis stage." +circulation_biomarker_diagnosis_up hsa-mir-222 Thyroid Neoplasms 22472564 "The expression of serum let-7e, miR-151-5p, and miR-222 was significantly increased in PTC (papillary thyroid carcinomas ) cases relative to benign cases and healthy controls. Serum let-7e, miR-151-5p, and miR-222 levels were found to be well correlated with certain clinicopathological variables, such as nodal status, tumor size, multifocal lesion status, and Tumor-Node-Metastasis stage." +circulation_biomarker_diagnosis_up hsa-mir-21 "Lymphoma, Non-Hodgkin" 22487708 B-cell activation induced microRNA-21 is elevated in circulating B cells preceding the diagnosis of AIDS-related non-Hodgkin lymphomas. +circulation_biomarker_diagnosis_up hsa-mir-155 "Adenocarcinoma, Pancreatic Ductal" 22513294 "Quantification by real-time quantitative polymerase chain reaction revealed that miR-155, miR-21, and miR-210 were higher in serum of PDAC rats,similar to plasma of patients with PDAC" +circulation_biomarker_diagnosis_up hsa-mir-21 "Adenocarcinoma, Pancreatic Ductal" 22513294 "Quantification by real-time quantitative polymerase chain reaction revealed that miR-155, miR-21, and miR-210 were higher in serum of PDAC rats,similar to plasma of patients with PDAC" +circulation_biomarker_diagnosis_up hsa-mir-210 "Adenocarcinoma, Pancreatic Ductal" 22513294 "Quantification by real-time quantitative polymerase chain reaction revealed that miR-155, miR-21, and miR-210 were higher in serum of PDAC rats,similar to plasma of patients with PDAC" +circulation_biomarker_diagnosis_up hsa-mir-378a "Carcinoma, Renal Cell" 22542158 The level of miR-378 was significantly increased in serum of ccRCC patients. +circulation_biomarker_diagnosis_up hsa-mir-378b "Carcinoma, Renal Cell" 22542158 The level of miR-378 was significantly increased in serum of ccRCC patients. +circulation_biomarker_diagnosis_up hsa-mir-378c "Carcinoma, Renal Cell" 22542158 The level of miR-378 was significantly increased in serum of ccRCC patients. +circulation_biomarker_diagnosis_up hsa-mir-378d-1 "Carcinoma, Renal Cell" 22542158 The level of miR-378 was significantly increased in serum of ccRCC patients. +circulation_biomarker_diagnosis_up hsa-mir-378d-2 "Carcinoma, Renal Cell" 22542158 The level of miR-378 was significantly increased in serum of ccRCC patients. +circulation_biomarker_diagnosis_up hsa-mir-378e "Carcinoma, Renal Cell" 22542158 The level of miR-378 was significantly increased in serum of ccRCC patients. +circulation_biomarker_diagnosis_up hsa-mir-378f "Carcinoma, Renal Cell" 22542158 The level of miR-378 was significantly increased in serum of ccRCC patients. +circulation_biomarker_diagnosis_up hsa-mir-378g "Carcinoma, Renal Cell" 22542158 The level of miR-378 was significantly increased in serum of ccRCC patients. +circulation_biomarker_diagnosis_up hsa-mir-378h "Carcinoma, Renal Cell" 22542158 The level of miR-378 was significantly increased in serum of ccRCC patients. +circulation_biomarker_diagnosis_up hsa-mir-378i "Carcinoma, Renal Cell" 22542158 The level of miR-378 was significantly increased in serum of ccRCC patients. +circulation_biomarker_diagnosis_up hsa-mir-122 Coronary Artery Disease 22587332 Plasma levels of lipometabolism-related miR-122 and miR-370 are increased in patients with hyperlipidemia and associated with coronary artery disease. +circulation_biomarker_diagnosis_up hsa-mir-122 Hyperlipidemia 22587332 Plasma levels of lipometabolism-related miR-122 and miR-370 are increased in patients with hyperlipidemia and associated with coronary artery disease. +circulation_biomarker_diagnosis_up hsa-mir-370 Coronary Artery Disease 22587332 Plasma levels of lipometabolism-related miR-122 and miR-370 are increased in patients with hyperlipidemia and associated with coronary artery disease. +circulation_biomarker_diagnosis_up hsa-mir-370 Hyperlipidemia 22587332 Plasma levels of lipometabolism-related miR-122 and miR-370 are increased in patients with hyperlipidemia and associated with coronary artery disease. +circulation_biomarker_diagnosis_up hsa-mir-103a-1 Breast Neoplasms 22588912 "The serum levels of miR-103 expression were significantly higher in the cancer patients than in the healthy control group (P<0.01). In the cancer patients, high miR-103 expression was significantly correlated to advanced clinical stage (P<0.05) and lymph node metastasis (P<0.05)." +circulation_biomarker_diagnosis_up hsa-mir-103a-2 Breast Neoplasms 22588912 "The serum levels of miR-103 expression were significantly higher in the cancer patients than in the healthy control group (P<0.01). In the cancer patients, high miR-103 expression was significantly correlated to advanced clinical stage (P<0.05) and lymph node metastasis (P<0.05)." +circulation_biomarker_diagnosis_up hsa-mir-103b-1 Breast Neoplasms 22588912 "The serum levels of miR-103 expression were significantly higher in the cancer patients than in the healthy control group (P<0.01). In the cancer patients, high miR-103 expression was significantly correlated to advanced clinical stage (P<0.05) and lymph node metastasis (P<0.05)." +circulation_biomarker_diagnosis_up hsa-mir-103b-2 Breast Neoplasms 22588912 "The serum levels of miR-103 expression were significantly higher in the cancer patients than in the healthy control group (P<0.01). In the cancer patients, high miR-103 expression was significantly correlated to advanced clinical stage (P<0.05) and lymph node metastasis (P<0.05)." +circulation_biomarker_diagnosis_up hsa-mir-625 Mesothelioma 22617246 Increased circulating miR-625-3p is a potential biomarker for patients with malignant pleural mesothelioma. +circulation_biomarker_diagnosis_up hsa-mir-126 Systemic Lupus Erythematosus 22683424 miR-126 was specifically enriched only in the blood of the SLE patients +circulation_biomarker_diagnosis_up hsa-mir-1-1 Myocardial Infarction 22719221 Increased miR-1 and decreased miR-126 in plasma from patients with AMI after the onset of symptoms compared with healthy subjects were found. +circulation_biomarker_diagnosis_up hsa-mir-1-2 Myocardial Infarction 22719221 Increased miR-1 and decreased miR-126 in plasma from patients with AMI after the onset of symptoms compared with healthy subjects were found. +circulation_biomarker_diagnosis_up hsa-mir-21 Esophageal Neoplasms 22799367 "Serum miR-21 expression in ESCC samples was significantly higher than in paired cancer-free samples (P <0.05). Metastasis was associated with mir-21 expression in serum (P <0.05), ESCC patients with metastasis having 8.4-fold higher serum miR-21 concentrations than healthy controls." +circulation_biomarker_diagnosis_up hsa-let-7b Breast Neoplasms 22821209 "Potential biomarker microRNAs were identified, including let-7b, let-7g and miR-18b, with higher circulating levels associated with tumours." +circulation_biomarker_diagnosis_up hsa-let-7g Breast Neoplasms 22821209 "Potential biomarker microRNAs were identified, including let-7b, let-7g and miR-18b, with higher circulating levels associated with tumours." +circulation_biomarker_diagnosis_up hsa-mir-18b Breast Neoplasms 22821209 "Potential biomarker microRNAs were identified, including let-7b, let-7g and miR-18b, with higher circulating levels associated with tumours." +circulation_biomarker_diagnosis_up hsa-mir-21 Gastric Neoplasms 22860003 "The plasma levels of miR-223 (P<0.001) and miR-21 (P<0.001) were significantly higher in GC patients than in healthy controls, while miR-218 (P<0.001) was significantly lower. The ROC analyses yielded the AUC values of 0.9089 for miR-223, 0.7944 for miR-21 and 0.7432 for miR-218, and combined ROC analysis revealed the highest AUC value of 0.9531 in discriminating GC patients from healthy controls." +circulation_biomarker_diagnosis_up hsa-mir-223 Gastric Neoplasms 22860003 "The plasma levels of miR-223 (P<0.001) and miR-21 (P<0.001) were significantly higher in GC patients than in healthy controls, while miR-218 (P<0.001) was significantly lower. The ROC analyses yielded the AUC values of 0.9089 for miR-223, 0.7944 for miR-21 and 0.7432 for miR-218, and combined ROC analysis revealed the highest AUC value of 0.9531 in discriminating GC patients from healthy controls." +circulation_biomarker_diagnosis_up hsa-mir-18a "Carcinoma, Hepatocellular" 22865399 Serum miR-18a was significantly higher in HBV patients with HCC than healthy controls (p < 0.01). +circulation_biomarker_diagnosis_up hsa-mir-21 Colorectal Carcinoma 22868372 "In the plasma group, miR-21 differentiated CRC patients from controls with 90% specificity and sensitivity." +circulation_biomarker_diagnosis_up hsa-mir-21 Aortic Stenosis 22882958 The myocardial and plasma levels of miR-21 were significantly higher in the AS patients compared with the controls and correlated directly with the echocardiographic mean transvalvular gradients. +circulation_biomarker_diagnosis_up hsa-mir-155 "Leukemia-Lymphoma, Adult T-Cell" 22884882 The high and low plasma levels of miR-155 and miR-126 changed with ATL stage. +circulation_biomarker_diagnosis_up hsa-mir-141 Prostate Neoplasms 22887127 "MiR-375, miR-378*, and miR-141 were significantly over-expressed in serum from CRPC patients compared with serum from low-risk localized patients, while miR-409-3p was significantly under-expressed. In prostate primary tumor samples, miR-375 and miR-141 also had significantly higher expression levels compared with those in normal prostate tissue." +circulation_biomarker_diagnosis_up hsa-mir-375 Prostate Neoplasms 22887127 "MiR-375, miR-378*, and miR-141 were significantly over-expressed in serum from CRPC patients compared with serum from low-risk localized patients, while miR-409-3p was significantly under-expressed. In prostate primary tumor samples, miR-375 and miR-141 also had significantly higher expression levels compared with those in normal prostate tissue." +circulation_biomarker_diagnosis_up hsa-mir-378a Prostate Neoplasms 22887127 "MiR-375, miR-378*, and miR-141 were significantly over-expressed in serum from CRPC patients compared with serum from low-risk localized patients, while miR-409-3p was significantly under-expressed. In prostate primary tumor samples, miR-375 and miR-141 also had significantly higher expression levels compared with those in normal prostate tissue." +circulation_biomarker_diagnosis_up hsa-mir-378b Prostate Neoplasms 22887127 "MiR-375, miR-378*, and miR-141 were significantly over-expressed in serum from CRPC patients compared with serum from low-risk localized patients, while miR-409-3p was significantly under-expressed. In prostate primary tumor samples, miR-375 and miR-141 also had significantly higher expression levels compared with those in normal prostate tissue." +circulation_biomarker_diagnosis_up hsa-mir-378c Prostate Neoplasms 22887127 "MiR-375, miR-378*, and miR-141 were significantly over-expressed in serum from CRPC patients compared with serum from low-risk localized patients, while miR-409-3p was significantly under-expressed. In prostate primary tumor samples, miR-375 and miR-141 also had significantly higher expression levels compared with those in normal prostate tissue." +circulation_biomarker_diagnosis_up hsa-mir-378d-1 Prostate Neoplasms 22887127 "MiR-375, miR-378*, and miR-141 were significantly over-expressed in serum from CRPC patients compared with serum from low-risk localized patients, while miR-409-3p was significantly under-expressed. In prostate primary tumor samples, miR-375 and miR-141 also had significantly higher expression levels compared with those in normal prostate tissue." +circulation_biomarker_diagnosis_up hsa-mir-378d-2 Prostate Neoplasms 22887127 "MiR-375, miR-378*, and miR-141 were significantly over-expressed in serum from CRPC patients compared with serum from low-risk localized patients, while miR-409-3p was significantly under-expressed. In prostate primary tumor samples, miR-375 and miR-141 also had significantly higher expression levels compared with those in normal prostate tissue." +circulation_biomarker_diagnosis_up hsa-mir-378e Prostate Neoplasms 22887127 "MiR-375, miR-378*, and miR-141 were significantly over-expressed in serum from CRPC patients compared with serum from low-risk localized patients, while miR-409-3p was significantly under-expressed. In prostate primary tumor samples, miR-375 and miR-141 also had significantly higher expression levels compared with those in normal prostate tissue." +circulation_biomarker_diagnosis_up hsa-mir-378f Prostate Neoplasms 22887127 "MiR-375, miR-378*, and miR-141 were significantly over-expressed in serum from CRPC patients compared with serum from low-risk localized patients, while miR-409-3p was significantly under-expressed. In prostate primary tumor samples, miR-375 and miR-141 also had significantly higher expression levels compared with those in normal prostate tissue." +circulation_biomarker_diagnosis_up hsa-mir-378g Prostate Neoplasms 22887127 "MiR-375, miR-378*, and miR-141 were significantly over-expressed in serum from CRPC patients compared with serum from low-risk localized patients, while miR-409-3p was significantly under-expressed. In prostate primary tumor samples, miR-375 and miR-141 also had significantly higher expression levels compared with those in normal prostate tissue." +circulation_biomarker_diagnosis_up hsa-mir-378h Prostate Neoplasms 22887127 "MiR-375, miR-378*, and miR-141 were significantly over-expressed in serum from CRPC patients compared with serum from low-risk localized patients, while miR-409-3p was significantly under-expressed. In prostate primary tumor samples, miR-375 and miR-141 also had significantly higher expression levels compared with those in normal prostate tissue." +circulation_biomarker_diagnosis_up hsa-mir-378i Prostate Neoplasms 22887127 "MiR-375, miR-378*, and miR-141 were significantly over-expressed in serum from CRPC patients compared with serum from low-risk localized patients, while miR-409-3p was significantly under-expressed. In prostate primary tumor samples, miR-375 and miR-141 also had significantly higher expression levels compared with those in normal prostate tissue." +circulation_biomarker_diagnosis_up hsa-mir-21 Glioblastoma 22891879 Plasma MicroRNA-21 in glioblastoma was significantly higher than controls (p = .02) and decreased significantly in 9 patients (p = .05). One patient with increasing microRNA-21 developed a histopathologically proven recurrence after the second sample collection. +circulation_biomarker_diagnosis_up hsa-mir-223 Prostate Neoplasms 22892455 An increase in serum miR-223 and a decrease in miR-125b and miR-146a were observed in group B. +circulation_biomarker_diagnosis_up hsa-mir-10b Breast Neoplasms 22906258 Serum Overexpression of MicroRNA-10b in Patients with Bone Metastatic Primary Breast Cancer. +circulation_biomarker_diagnosis_up hsa-mir-148b Breast Neoplasms 22927033 "Four miRNAs (miR-148b, miR-376c, miR-409-3p and miR-801) were shown to be significantly upregulated in the plasma of breast cancer patients." +circulation_biomarker_diagnosis_up hsa-mir-376c Breast Neoplasms 22927033 "Four miRNAs (miR-148b, miR-376c, miR-409-3p and miR-801) were shown to be significantly upregulated in the plasma of breast cancer patients." +circulation_biomarker_diagnosis_up hsa-mir-409 Breast Neoplasms 22927033 "Four miRNAs (miR-148b, miR-376c, miR-409-3p and miR-801) were shown to be significantly upregulated in the plasma of breast cancer patients." +circulation_biomarker_diagnosis_up hsa-mir-100 "Carcinoma, Lung, Non-Small-Cell" 22937028 "High expression of miR-100 and low expression of miRNA-93, miRNA-134, miRNA-151 and miRNA-345 were associated with poor survival in both the training and validation cohort." +circulation_biomarker_diagnosis_up hsa-mir-141 Breast Neoplasms 22952344 "CTC (circulating tumour cells)-positive had significantly higher levels of miR-141, miR-200a, miR-200b, miR-200c, miR-203, miR-210, miR-375 and miR-801 than CTC-negative MBC and controls (P < 0.00001), while miR-768-3p was present in lower amounts in MBC (metastatic breast cancer) cases (P < 0.05)." +circulation_biomarker_diagnosis_up hsa-mir-200a Breast Neoplasms 22952344 "CTC (circulating tumour cells)-positive had significantly higher levels of miR-141, miR-200a, miR-200b, miR-200c, miR-203, miR-210, miR-375 and miR-801 than CTC-negative MBC and controls (P < 0.00001), while miR-768-3p was present in lower amounts in MBC (metastatic breast cancer) cases (P < 0.05)." +circulation_biomarker_diagnosis_up hsa-mir-200b Breast Neoplasms 22952344 "CTC (circulating tumour cells)-positive had significantly higher levels of miR-141, miR-200a, miR-200b, miR-200c, miR-203, miR-210, miR-375 and miR-801 than CTC-negative MBC and controls (P < 0.00001), while miR-768-3p was present in lower amounts in MBC (metastatic breast cancer) cases (P < 0.05)." +circulation_biomarker_diagnosis_up hsa-mir-200c Breast Neoplasms 22952344 "CTC (circulating tumour cells)-positive had significantly higher levels of miR-141, miR-200a, miR-200b, miR-200c, miR-203, miR-210, miR-375 and miR-801 than CTC-negative MBC and controls (P < 0.00001), while miR-768-3p was present in lower amounts in MBC (metastatic breast cancer) cases (P < 0.05)." +circulation_biomarker_diagnosis_up hsa-mir-203 Breast Neoplasms 22952344 "CTC (circulating tumour cells)-positive had significantly higher levels of miR-141, miR-200a, miR-200b, miR-200c, miR-203, miR-210, miR-375 and miR-801 than CTC-negative MBC and controls (P < 0.00001), while miR-768-3p was present in lower amounts in MBC (metastatic breast cancer) cases (P < 0.05)." +circulation_biomarker_diagnosis_up hsa-mir-210 Breast Neoplasms 22952344 "CTC (circulating tumour cells)-positive had significantly higher levels of miR-141, miR-200a, miR-200b, miR-200c, miR-203, miR-210, miR-375 and miR-801 than CTC-negative MBC and controls (P < 0.00001), while miR-768-3p was present in lower amounts in MBC (metastatic breast cancer) cases (P < 0.05)." +circulation_biomarker_diagnosis_up hsa-mir-375 Breast Neoplasms 22952344 "CTC (circulating tumour cells)-positive had significantly higher levels of miR-141, miR-200a, miR-200b, miR-200c, miR-203, miR-210, miR-375 and miR-801 than CTC-negative MBC and controls (P < 0.00001), while miR-768-3p was present in lower amounts in MBC (metastatic breast cancer) cases (P < 0.05)." +circulation_biomarker_diagnosis_up hsa-mir-200c Gastric Neoplasms 22954417 The miR-200c blood expression levels in GC patients were significantly higher than in normal controls (p = 0.018). increased miR-200c levels are detected in the blood of gastric cancer patients. MiR-200c has the potential to be a predictor of progression and survival. +circulation_biomarker_diagnosis_up hsa-mir-151a Gastric Neoplasms 22956063 Plasma miRNA-199a-3p and miRNA-151-5p were significantly elevated (p < 0.05) and were significantly reduced after surgery (p < 0.05) in gastric cancer patients. +circulation_biomarker_diagnosis_up hsa-mir-151b Gastric Neoplasms 22956063 Plasma miRNA-199a-3p and miRNA-151-5p were significantly elevated (p < 0.05) and were significantly reduced after surgery (p < 0.05) in gastric cancer patients. +circulation_biomarker_diagnosis_up hsa-mir-199a-1 Gastric Neoplasms 22956063 Plasma miRNA-199a-3p and miRNA-151-5p were significantly elevated (p < 0.05) and were significantly reduced after surgery (p < 0.05) in gastric cancer patients. +circulation_biomarker_diagnosis_up hsa-mir-199a-2 Gastric Neoplasms 22956063 Plasma miRNA-199a-3p and miRNA-151-5p were significantly elevated (p < 0.05) and were significantly reduced after surgery (p < 0.05) in gastric cancer patients. +circulation_biomarker_diagnosis_up hsa-mir-126 Kidney Diseases [unspecific] 23070235 Circulating levels of inflammation-associated miR-155 and endothelial-enriched miR-126 in patients with end-stage renal disease +circulation_biomarker_diagnosis_up hsa-mir-224 Systemic Lupus Erythematosus 23199328 Decreased microRNA(miR)-145 and increased miR-224 expression in T cells from patients with systemic lupus erythematosus involved in lupus immunopathogenesis +circulation_biomarker_diagnosis_up hsa-mir-21 Esophageal Neoplasms 23224754 Clinical impact of serum exosomal microRNA-21 as a clinical biomarker in human esophageal squamous cell carcinoma +circulation_biomarker_diagnosis_up hsa-mir-132 Inflammation 23264652 "In peptidoglycan (PGN)/TLR2-stimulated THP-1 monocytes, PBMCs, and primary macrophages showed rapid and dramatic miR-132 and miR-212 (miR-132/-212) upregulation." +circulation_biomarker_diagnosis_up hsa-mir-212 Inflammation 23264652 "In peptidoglycan (PGN)/TLR2-stimulated THP-1 monocytes, PBMCs, and primary macrophages showed rapid and dramatic miR-132 and miR-212 (miR-132/-212) upregulation." +circulation_biomarker_diagnosis_up hsa-mir-200a Ovarian Neoplasms 23272653 Elevated levels of circulating microRNA-200 family members correlate with serous epithelial ovarian cancer +circulation_biomarker_diagnosis_up hsa-mir-200b Ovarian Neoplasms 23272653 Elevated levels of circulating microRNA-200 family members correlate with serous epithelial ovarian cancer +circulation_biomarker_diagnosis_up hsa-mir-200c Ovarian Neoplasms 23272653 Elevated levels of circulating microRNA-200 family members correlate with serous epithelial ovarian cancer +circulation_biomarker_diagnosis_up hsa-mir-15b Fatty Liver [unspecific] 23287814 Upregulation of miR-15b in NAFLD models and in the serum of patients with fatty liver disease +circulation_biomarker_diagnosis_up hsa-mir-145 Hypertension 23339529 Overexpression of microRNA-145 in atherosclerotic plaques from hypertensive patients +circulation_biomarker_diagnosis_up hsa-mir-155 Breast Neoplasms 23372341 serum;miR-205 was down-regulated and miR-155 was up-regulated in BC patient serum +circulation_biomarker_diagnosis_up hsa-mir-205 Breast Neoplasms 23372341 serum;miR-205 was down-regulated and miR-155 was up-regulated in BC patient serum +circulation_biomarker_diagnosis_up hsa-mir-141 Prostate Neoplasms 23377530 serum;An elevated serum miR-141 level in patients with bone-metastatic prostate cancer is correlated with more bone lesions +circulation_biomarker_diagnosis_up hsa-mir-106b Heart Failure 23388090 "Quantitative real-time polymerase chain reaction (PCR) analysis for a selected panel of miRNAs indicated that circulating levels of miR-16, miR-20b, miR-93, miR-106b, miR-223, and miR-423-5p were significantly increased in response to hypertension-induced heart failure" +circulation_biomarker_diagnosis_up hsa-mir-16 Heart Failure 23388090 "Quantitative real-time polymerase chain reaction (PCR) analysis for a selected panel of miRNAs indicated that circulating levels of miR-16, miR-20b, miR-93, miR-106b, miR-223, and miR-423-5p were significantly increased in response to hypertension-induced heart failure" +circulation_biomarker_diagnosis_up hsa-mir-20b Heart Failure 23388090 "Quantitative real-time polymerase chain reaction (PCR) analysis for a selected panel of miRNAs indicated that circulating levels of miR-16, miR-20b, miR-93, miR-106b, miR-223, and miR-423-5p were significantly increased in response to hypertension-induced heart failure" +circulation_biomarker_diagnosis_up hsa-mir-223 Heart Failure 23388090 "Quantitative real-time polymerase chain reaction (PCR) analysis for a selected panel of miRNAs indicated that circulating levels of miR-16, miR-20b, miR-93, miR-106b, miR-223, and miR-423-5p were significantly increased in response to hypertension-induced heart failure" +circulation_biomarker_diagnosis_up hsa-mir-423 Heart Failure 23388090 "Quantitative real-time polymerase chain reaction (PCR) analysis for a selected panel of miRNAs indicated that circulating levels of miR-16, miR-20b, miR-93, miR-106b, miR-223, and miR-423-5p were significantly increased in response to hypertension-induced heart failure" +circulation_biomarker_diagnosis_up hsa-mir-93 Heart Failure 23388090 "Quantitative real-time polymerase chain reaction (PCR) analysis for a selected panel of miRNAs indicated that circulating levels of miR-16, miR-20b, miR-93, miR-106b, miR-223, and miR-423-5p were significantly increased in response to hypertension-induced heart failure" +circulation_biomarker_diagnosis_up hsa-mir-142 Systemic Lupus Erythematosus 23401079 "Seven miRNAs were statistically significantly differentially expressed in plasma from patients with SLE. The expression of miRNA-142-3p (miR-142-3p) and miR-181a was increased, and the expression of miR-106a, miR-17, miR-20a, miR-203,and miR-92a was decreased" +circulation_biomarker_diagnosis_up hsa-mir-181 Systemic Lupus Erythematosus 23401079 "Seven miRNAs were statistically significantly differentially expressed in plasma from patients with SLE. The expression of miRNA-142-3p (miR-142-3p) and miR-181a was increased, and the expression of miR-106a, miR-17, miR-20a, miR-203,and miR-92a was decreased" +circulation_biomarker_diagnosis_up hsa-mir-423-5p Heart Failure 23438607 Patients with DCM have elevated plasma miR-423-5p levels. The plasma concentration of miR-423-5p was positively correlated with the level of NT-proBNP. Circulating levels of miR-423-5p could be served as a diagnostic biomarker for heart failure caused by DCM. +circulation_biomarker_diagnosis_up hsa-mir-132 Hypertension 23712358 "The miR-132 and miR-212 are highly increased in the heart, aortic wall and kidney of rats with hypertension (159 ¡À 12 mm Hg) and cardiac hypertrophy following chronic AngII infusion." +circulation_biomarker_diagnosis_up hsa-mir-212 Hypertension 23712358 "The miR-132 and miR-212 are highly increased in the heart, aortic wall and kidney of rats with hypertension (159 ¡À 12 mm Hg) and cardiac hypertrophy following chronic AngII infusion." +circulation_biomarker_diagnosis_up hsa-mir-122 "Fatty Liver, Non-Alcoholic" 23727030 "Serum levels of miRNAs, miR-21, miR-34a, miR-122, and miR-451 were higher in participants with NAFLD. The serum level of miR-122 was correlated with the severity of liver steatosis." +circulation_biomarker_diagnosis_up hsa-mir-21 "Fatty Liver, Non-Alcoholic" 23727030 "Serum levels of miRNAs, miR-21, miR-34a, miR-122, and miR-451 were higher in participants with NAFLD. The serum level of miR-122 was correlated with the severity of liver steatosis." +circulation_biomarker_diagnosis_up hsa-mir-34a "Fatty Liver, Non-Alcoholic" 23727030 "Serum levels of miRNAs, miR-21, miR-34a, miR-122, and miR-451 were higher in participants with NAFLD. The serum level of miR-122 was correlated with the severity of liver steatosis." +circulation_biomarker_diagnosis_up hsa-mir-451 "Fatty Liver, Non-Alcoholic" 23727030 "Serum levels of miRNAs, miR-21, miR-34a, miR-122, and miR-451 were higher in participants with NAFLD. The serum level of miR-122 was correlated with the severity of liver steatosis." +circulation_biomarker_diagnosis_up hsa-mir-192 Heart Failure 23743335 "Among the 377 examined microRNAs, the serum level of only miR-192 was significantly upregulated in AMI patients with development of ischemic HF" +circulation_biomarker_diagnosis_up hsa-let-7d Alzheimer Disease 23895045 A blood based 12-miRNA signature of Alzheimer disease patients. +circulation_biomarker_diagnosis_up hsa-mir-112 Alzheimer Disease 23895045 A blood based 12-miRNA signature of Alzheimer disease patients. +circulation_biomarker_diagnosis_up hsa-mir-151a Alzheimer Disease 23895045 A blood based 12-miRNA signature of Alzheimer disease patients. +circulation_biomarker_diagnosis_up hsa-mir-161 Alzheimer Disease 23895045 A blood based 12-miRNA signature of Alzheimer disease patients. +circulation_biomarker_diagnosis_up hsa-mir-5010 Alzheimer Disease 23895045 A blood based 12-miRNA signature of Alzheimer disease patients. +circulation_biomarker_diagnosis_up hsa-mir-221 "Leukemia, Myeloid, Acute" 23895238 Overexpression of primary microRNA 221/222 in acute myeloid leukemia. +circulation_biomarker_diagnosis_up hsa-mir-222 "Leukemia, Myeloid, Acute" 23895238 Overexpression of primary microRNA 221/222 in acute myeloid leukemia. +circulation_biomarker_diagnosis_up hsa-mir-146a Breast Neoplasms 23898484 Overexpression of circulating miRNA-21 and miRNA-146a in plasma samples of breast cancer patients. +circulation_biomarker_diagnosis_up hsa-mir-21 Breast Neoplasms 23898484 Overexpression of circulating miRNA-21 and miRNA-146a in plasma samples of breast cancer patients. +circulation_biomarker_diagnosis_up hsa-mir-10b Choriocarcinoma 23933230 "we observed that miR-21 was significantly overexpressed in PDAC, and miR-10b was highly expressed in PanIN II-III." +circulation_biomarker_diagnosis_up hsa-mir-146a "Diabetes Mellitus, Type 2" 24023848 circulating miRNA-146a levels were significantly elevated in new-T2DM patients compared with healthy controls. Whether expression of circulating miRNA-146a holds predictive value for T2DM warrants further investigations. +circulation_biomarker_diagnosis_up hsa-mir-375 "Adenocarcinoma, Pancreatic Ductal" 24048453 "In the plasma-miRNA population, we find miRNA-375, which is selectively expressed in the endocrine pancreas under normal conditions, increased in PDAC cases compared with patients with other pancreatic or gastrointestinal diseases. The miRNA-375 does not outperform CA-19-9 diagnostically in the present cohort." +circulation_biomarker_diagnosis_up hsa-mir-202 Multiple Myeloma 24048721 "The relative expression of serum miR-202 in MM patients was significantly higher than that in healthy controls, and therefore it may prove to be useful in the auxiliary diagnosis of MM." +circulation_biomarker_diagnosis_up hsa-mir-146a Rheumatoid Arthritis 24120842 "Elevated expression of specific microRNAs (miRNA) in peripheral blood-derived mononuclear cells (PBMC), particularly miR-146a and miR-155, is associated with rheumatoid arthritis (RA)." +circulation_biomarker_diagnosis_up hsa-mir-155 Rheumatoid Arthritis 24120842 "Elevated expression of specific microRNAs (miRNA) in peripheral blood-derived mononuclear cells (PBMC), particularly miR-146a and miR-155, is associated with rheumatoid arthritis (RA)." +circulation_biomarker_diagnosis_up hsa-mir-369 Psoriasis 24135466 "The expression of miR-369-3p is increased in both serum samples and skin tissues from psoriasis patients, and its level in the skin positively correlates with disease severity. Further studies are needed to clarify the role of miR-369-3p in the pathogenesis of psoriasis." +circulation_biomarker_diagnosis_up hsa-mir-29a "Cardiomyopathy, Hypertrophic" 24161319 "cardiac remodeling associated with HCM determines a significant release of miRNAs into the bloodstream: the circulating levels of both cardiac- and non-cardiac-specific miRNAs are significantly increased in the plasma of HCM patients. However, correlation with left ventricular hypertrophy parameters holds true for only a few miRNAs (i.e.,miR-199a-5p, -27a, and -29a), whereas only miR-29a is significantly associated with both hypertrophy and fibrosis, identifying it as a potential biomarker for myocardial remodeling assessment in HCM." +circulation_biomarker_diagnosis_up hsa-mir-155 "Adenocarcinoma, Lung" 24190459 endogenous miR-155 stably existed in patient serum and could be sensitively and specifically measured. Overexpression of miR-155 in serum specimens could constitute a diagnostic marker for the early detection of lung adenocarcinoma. +circulation_biomarker_diagnosis_up hsa-mir-208a Acute Myocardial Infarction 24253456 Early in acute myocardial infarction the expression of miR-423-5p in plasma is significantly increased with subsequent normalization within 6 hours.Potentially it is an early marker of myocardial necrosis. +circulation_biomarker_diagnosis_up hsa-mir-423 Acute Myocardial Infarction 24253456 Early in acute myocardial infarction the expression of miR-423-5p in plasma is significantly increased with subsequent normalization within 6 hours.Potentially it is an early marker of myocardial necrosis. +circulation_biomarker_diagnosis_up hsa-mir-200c Kawasaki Syndrome 24259014 Elevated serum level of microRNA (miRNA)-200c and miRNA-371-5p in children with Kawasaki disease. +circulation_biomarker_diagnosis_up hsa-mir-371 Kawasaki Syndrome 24259014 Elevated serum level of microRNA (miRNA)-200c and miRNA-371-5p in children with Kawasaki disease. +circulation_biomarker_diagnosis_up hsa-mir-1 Essential Hypertension 24284386 "Hypertensive patients showed lower miR-143, miR-145 and miR-133 and higher miR-21 and miR-1 expression levels compared with controls" +circulation_biomarker_diagnosis_up hsa-mir-185 Idiopathic Short Stature 24342208 plasma miR-185 expression was significantly up-regulated +circulation_biomarker_diagnosis_up hsa-mir-208a Myocardial Infarction 24482699 Serum miR-208a was increased by 36-fold and 51-fold while miR-499 was elevated by 103-fold and 95-fold at 4 h and 24 h after AMI. +circulation_biomarker_diagnosis_up hsa-mir-499 Myocardial Infarction 24482699 Serum miR-208a was increased by 36-fold and 51-fold while miR-499 was elevated by 103-fold and 95-fold at 4 h and 24 h after AMI. +circulation_biomarker_diagnosis_up hsa-mir-22 Graves Disease 24533739 "Further analysis consistently showed that serum levels of miR-22, miR-375 and miR-451 were increased in patients with HT. On the other hand, the serum levels of miR-16, miR-22, miR-375 and miR-451 were increased in patients with GD compared with healthy subjects." +circulation_biomarker_diagnosis_up hsa-mir-192 Ischemia-Reperfusion Injury 24553149 "However, miR-10a, miR-192, and miR-194 were significantly increased in plasma of rats with renal ischemia-reperfusion injury, among which miR-10a was elevated within 1 h after reperfusion, whereas miR-192 and miR-194 were elevated at 6 h after injury." +circulation_biomarker_diagnosis_up hsa-mir-194 Ischemia-Reperfusion Injury 24553149 "However, miR-10a, miR-192, and miR-194 were significantly increased in plasma of rats with renal ischemia-reperfusion injury, among which miR-10a was elevated within 1 h after reperfusion, whereas miR-192 and miR-194 were elevated at 6 h after injury." +circulation_biomarker_diagnosis_up hsa-mir-21 Chronic Obstructive Pulmonary Disease 24556821 An increased ratio of serum miR-21 to miR-181a levels is associated with the early pathogenic process of chronic obstructive pulmonary disease in asymptomatic heavy smokers. +circulation_biomarker_diagnosis_up hsa-mir-29a Ankylosing Spondylitis 24593209 "We report for the first time elevated miR-29a expression in PBMCs of patients with ankylosing spondylitis, and miR-29a might be used as a useful diagnostic marker in new bone formation but cannot reflect disease activity." +circulation_biomarker_diagnosis_up hsa-mir-204 Kidney Injury 24641951 Our findings indicate that miR-204/miR-211 downregulation accounts at least partially for the Hmx1 upregulation and the miR-204/miR-211-Hmx1 signaling axis may contribute to immune-suppression in the host thereby the Candidemia-induced kidney dysfunction. +circulation_biomarker_diagnosis_up hsa-mir-211 Kidney Injury 24641951 Our findings indicate that miR-204/miR-211 downregulation accounts at least partially for the Hmx1 upregulation and the miR-204/miR-211-Hmx1 signaling axis may contribute to immune-suppression in the host thereby the Candidemia-induced kidney dysfunction. +circulation_biomarker_diagnosis_up hsa-mir-100 "Squamous Cell Carcinoma, Esophageal" 24651474 "Seven serum miRNAs were found to be significantly higher in ESCC than in controls; namely, miR-25, miR-100, miR-193-3p, miR-194, miR-223, miR-337-5p and miR-483-5p" +circulation_biomarker_diagnosis_up hsa-mir-193 "Squamous Cell Carcinoma, Esophageal" 24651474 "Seven serum miRNAs were found to be significantly higher in ESCC than in controls; namely, miR-25, miR-100, miR-193-3p, miR-194, miR-223, miR-337-5p and miR-483-5p" +circulation_biomarker_diagnosis_up hsa-mir-194 "Squamous Cell Carcinoma, Esophageal" 24651474 "Seven serum miRNAs were found to be significantly higher in ESCC than in controls; namely, miR-25, miR-100, miR-193-3p, miR-194, miR-223, miR-337-5p and miR-483-5p" +circulation_biomarker_diagnosis_up hsa-mir-223 "Squamous Cell Carcinoma, Esophageal" 24651474 "Seven serum miRNAs were found to be significantly higher in ESCC than in controls; namely, miR-25, miR-100, miR-193-3p, miR-194, miR-223, miR-337-5p and miR-483-5p" +circulation_biomarker_diagnosis_up hsa-mir-25 "Squamous Cell Carcinoma, Esophageal" 24651474 "Seven serum miRNAs were found to be significantly higher in ESCC than in controls; namely, miR-25, miR-100, miR-193-3p, miR-194, miR-223, miR-337-5p and miR-483-5p" +circulation_biomarker_diagnosis_up hsa-mir-337 "Squamous Cell Carcinoma, Esophageal" 24651474 "Seven serum miRNAs were found to be significantly higher in ESCC than in controls; namely, miR-25, miR-100, miR-193-3p, miR-194, miR-223, miR-337-5p and miR-483-5p" +circulation_biomarker_diagnosis_up hsa-mir-483 "Squamous Cell Carcinoma, Esophageal" 24651474 "Seven serum miRNAs were found to be significantly higher in ESCC than in controls; namely, miR-25, miR-100, miR-193-3p, miR-194, miR-223, miR-337-5p and miR-483-5p" +circulation_biomarker_diagnosis_up hsa-mir-21 Systemic Lupus Erythematosus 24659142 "Plasma miR-21 in SLE patients from Central China is overexpressed.Since circulating miR-21 is aberrantly expressed in many diseases, the applying of it as a disease biomarker should be considered carefully." +circulation_biomarker_diagnosis_up hsa-mir-146a Sepsis 24680405 "The expression levels of miR-146a and miR-223 in plasma in pediatric patients with sepsis was significantly upregulated, and had a positive correlation with IL-10 and IL-10/TNF-¦Á, which may be used as early diagnostic markers and can reflect the severity of condition to a certain degree." +circulation_biomarker_diagnosis_up hsa-mir-223 Sepsis 24680405 "The expression levels of miR-146a and miR-223 in plasma in pediatric patients with sepsis was significantly upregulated, and had a positive correlation with IL-10 and IL-10/TNF-¦Á, which may be used as early diagnostic markers and can reflect the severity of condition to a certain degree." +circulation_biomarker_diagnosis_up hsa-mir-516a "Systemic Lupus Erythematosus, With Pericarditis" 24687380 "High expression levels of microRNA-629, microRNA-525-5p and microRNA-516a-3p in paediatric systemic lupus erythematosus." +circulation_biomarker_diagnosis_up hsa-mir-525 "Systemic Lupus Erythematosus, With Pericarditis" 24687380 "High expression levels of microRNA-629, microRNA-525-5p and microRNA-516a-3p in paediatric systemic lupus erythematosus." +circulation_biomarker_diagnosis_up hsa-mir-629 "Systemic Lupus Erythematosus, With Pericarditis" 24687380 "High expression levels of microRNA-629, microRNA-525-5p and microRNA-516a-3p in paediatric systemic lupus erythematosus." +circulation_biomarker_diagnosis_up hsa-mir-193b Pancreatic Endocrine Carcinoma 24778027 "Evaluation of microRNAs appears to be promising in the assessment of pNEN. In particular, miR-193b, which is also increased in serum, may be a potential new biomarker of pNEN." +circulation_biomarker_diagnosis_up hsa-mir-21 Ankylosing Spondylitis 24786924 Higher expression of whole blood microRNA-21 in patients with ankylosing spondylitis associated with programmed cell death 4 mRNA expression and collagen cross-linked C-telopeptide concentration. +circulation_biomarker_diagnosis_up hsa-mir-21 Atherosclerosis 24848278 "In atherosclerosis, miR-21, 122, 130a, and 211 were significantly increased whereas miR-92a, 126, and 222 were markedly decreased." +circulation_biomarker_diagnosis_up hsa-mir-143 "Diabetes Mellitus, Type 2" 24927876 Elevated expression levels of miR-143/5 in saphenous vein smooth muscle cells from patients with Type 2 diabetes drive persistent changes in phenotype and function. +circulation_biomarker_diagnosis_up hsa-mir-145 "Diabetes Mellitus, Type 2" 24927876 Elevated expression levels of miR-143/5 in saphenous vein smooth muscle cells from patients with Type 2 diabetes drive persistent changes in phenotype and function. +circulation_biomarker_diagnosis_up hsa-mir-146a Sjogren Syndrome 24931100 "Our results demonstrated miR-146a overexpression and miR-155 underexpression in the peripheral mononuclear blood cells of the patients with pSS. Furthermore, the expression levels of these miRNAs correlated with the patients' clinical features. Our data suggest that miR-146a and miR-155 might play important roles in the pathogenesis of pSS and that their expression levels may be useful for diagnosing pSS and for predicting disease activity and therapeutic responses." +circulation_biomarker_diagnosis_up hsa-mir-196a Pancreatic Neoplasms 24956938 Serum levels of miR-196a and -196b were significantly higher in mice with PanIN2/3 lesions (n = 10) or PC (n = 8) as compared to control mice (n = 10) or mice with PanIN1 lesions (n = 10; P = .01). +circulation_biomarker_diagnosis_up hsa-mir-130a Moyamoya Disease 25093848 "In an independent MMD cohort, real-time PCR confirmed that miR-106b, miR-130a and miR-126 were significantly upregulated while miR-125a-3p was significantly downregulated in serum." +circulation_biomarker_diagnosis_up hsa-mir-21 Neoplasms [unspecific] 25098165 "Over-expression of mir-21, especially in cancerous tissue, was effectively predictive of worse prognosis in various carcinomas. Non-invasive circulating mir-21, however, exhibited modest ability to discriminate outcomes.Major concerns about mir-21 assay standardization and selection of specimen need to be fully addressed before its practical implementation in management of cancer." +circulation_biomarker_diagnosis_up hsa-mir-323 Acute Coronary Syndrome 25124998 Our study identifies miR-652 as a novel candidate biomarker for post-ACS prognosis beyond existing biomarkers of LVEF and NT-proBNP. Moreover circulating miR-323-3p was markedly elevated in patients for at least a year post-ACS and may be a stable biomarker for ACS. +circulation_biomarker_diagnosis_up hsa-mir-652 Acute Coronary Syndrome 25124998 Our study identifies miR-652 as a novel candidate biomarker for post-ACS prognosis beyond existing biomarkers of LVEF and NT-proBNP. Moreover circulating miR-323-3p was markedly elevated in patients for at least a year post-ACS and may be a stable biomarker for ACS. +circulation_biomarker_diagnosis_up hsa-mir-181a Sjogren Syndrome 25128511 "Together, these observations suggested that an elevated miRNA-181a level is a general phenomenon in Chinese patients with pSS." +circulation_biomarker_diagnosis_up hsa-mir-338 Amyotrophic Lateral Sclerosis 25130371 "miR-338-3p is over-expressed in blood, CFS, serum and spinal cord from sporadic amyotrophic lateral sclerosis patients." +circulation_biomarker_diagnosis_up hsa-mir-21 Colorectal Carcinoma 25178939 Elevated level of microRNA-21 in the serum of patients with colorectal cancer. +circulation_biomarker_diagnosis_up hsa-mir-1 Myocardial Infarction 25225581 the expression of plasma miR-1 was significantly increased in the AMI patients compared with the healthy controls +circulation_biomarker_diagnosis_up hsa-mir-92a "Lymphoma, Non-Hodgkin" 25236768 "MiR-92a was decreased exclusively in HBV-/HCV- B-NHLs, while miR-30b was increased in HBV+ and HCV+ samples, though only the HCV+ achieved full statistical significance." +circulation_biomarker_diagnosis_up hsa-mir-205 Pancreatic Neoplasms 25258651 "A marked difference in the profiles of four circulating miRNAs (miR-205, miR-210, miR-492, and miR-1427) was observed in pancreatic juice collected from patients with PDAC and those without pancreatic disease." +circulation_biomarker_diagnosis_up hsa-mir-210 Pancreatic Neoplasms 25258651 "A marked difference in the profiles of four circulating miRNAs (miR-205, miR-210, miR-492, and miR-1427) was observed in pancreatic juice collected from patients with PDAC and those without pancreatic disease." +circulation_biomarker_diagnosis_up hsa-mir-373 Breast Neoplasms 25333260 Increased serum levels of circulating exosomal microRNA-373 in receptor-negative breast cancer patients. +circulation_biomarker_diagnosis_up hsa-mir-195 Heart Failure 25364765 "Circulating miR-195 is elevated in acute myocardial infarction, breast cancer, prostate cancer and colorectal adenoma." +circulation_biomarker_diagnosis_up hsa-mir-21 Pancreatic Neoplasms 25384963 Circulating miR-483-3p and miR-21 is highly expressed in plasma of pancreatic cancer. +circulation_biomarker_diagnosis_up hsa-mir-483 Pancreatic Neoplasms 25384963 Circulating miR-483-3p and miR-21 is highly expressed in plasma of pancreatic cancer. +circulation_biomarker_diagnosis_up hsa-mir-221 Hepatitis C Virus Infection 25433287 HCVcc infection could upregulate the expression of miR-221 in NF-¦ÊB dependent manner. +circulation_biomarker_diagnosis_up hsa-mir-122 Chronic Hepatitis C 25461662 "serum microRNA-122 was elevated in acute and chronic hepatitis patients. However, this biomarker for acute liver injury did not reflect the liver inflammation activity in CHC patients." +circulation_biomarker_diagnosis_up hsa-mir-421 Gastric Neoplasms 25510566 miR-421 increased significantly in GC patients than in controls. miR-421 in either serum or PBMCs had higher sensitivity and specificity than CEA and CA-125 in GC diagnosis. +circulation_biomarker_diagnosis_up hsa-mir-203 Atopic Dermatitis 25531302 miR-203 and miR-483-5p were significantly up-regulated in serum of children with AD compared with healthy children. +circulation_biomarker_diagnosis_up hsa-mir-132 Mild Cognitive Impairment 25589731 circulating miR-206 and miR-132 as novel miRNAs upregulated in MCI patient were potential biomarkers for diagnosis of MCI. +circulation_biomarker_diagnosis_up hsa-mir-206 Mild Cognitive Impairment 25589731 circulating miR-206 and miR-132 as novel miRNAs upregulated in MCI patient were potential biomarkers for diagnosis of MCI. +circulation_biomarker_diagnosis_up hsa-mir-133 Arrhythmia 25625292 patients with SVT had lower miR-1 expression levels while those with VT had higher miR-133 expression levels. +circulation_biomarker_diagnosis_up hsa-mir-182 Heart Failure 25643195 "Microarray profiling revealed an increase in the expression of miR-21, miR-650, miR-744, miR-516-5p, miR-1292, miR-182, miR-1228, miR-595, miR-663b, miR-1296, miR-1825, miR-299-3p, miR-662 miR-122, miR-3148 and miR-518e and a decrease in the expression of miR-129-3p, miR-3155, miR-3175, miR-583, miR-568, miR-30d, miR-200a-star, miR-1979, miR-371-3p, miR-155-star and miR-502-5p in sera of CHF patients." +circulation_biomarker_diagnosis_up hsa-mir-299 Heart Failure 25643195 "Microarray profiling revealed an increase in the expression of miR-21, miR-650, miR-744, miR-516-5p, miR-1292, miR-182, miR-1228, miR-595, miR-663b, miR-1296, miR-1825, miR-299-3p, miR-662 miR-122, miR-3148 and miR-518e and a decrease in the expression of miR-129-3p, miR-3155, miR-3175, miR-583, miR-568, miR-30d, miR-200a-star, miR-1979, miR-371-3p, miR-155-star and miR-502-5p in sera of CHF patients." +circulation_biomarker_diagnosis_up hsa-mir-197 Breast Neoplasms 25644077 "The expression level of miR-29b-2, -155, -197 and -205 was significantly increased in the serum of breast cancer patients." +circulation_biomarker_diagnosis_up hsa-mir-10a "Leukemia, Myeloid, Acute" 25687041 "The high expression of miR-10a may be closely related to over-proliferation of promyelocyte and drug resistance of acute myeloid leukemia cells, except M3." +circulation_biomarker_diagnosis_up hsa-mir-126 Atherosclerosis 25697638 and the levels of miR-126 had positive correlation with cerebral atherosclerosis +circulation_biomarker_diagnosis_up hsa-mir-17 Atherosclerosis 25697638 he levels of miR-17 were significantly increased in acute stroke patients +circulation_biomarker_diagnosis_up hsa-mir-101 "Diabetes Mellitus, Type 2" 25726255 "The present findings demonstrated that the circulating miR-101, miR-375 and miR-802 levels are significantly increased in T2D patients versus NGT subjects and they may become the new biomarkers for type 2 diabetes." +circulation_biomarker_diagnosis_up hsa-mir-375 "Diabetes Mellitus, Type 2" 25726255 "The present findings demonstrated that the circulating miR-101, miR-375 and miR-802 levels are significantly increased in T2D patients versus NGT subjects and they may become the new biomarkers for type 2 diabetes." +circulation_biomarker_diagnosis_up hsa-mir-802 "Diabetes Mellitus, Type 2" 25726255 "The present findings demonstrated that the circulating miR-101, miR-375 and miR-802 levels are significantly increased in T2D patients versus NGT subjects and they may become the new biomarkers for type 2 diabetes." +circulation_biomarker_diagnosis_up hsa-mir-29a Colorectal Carcinoma 25736690 Significant upregulation of miR-29a in CRC was reported when compared to normal +circulation_biomarker_diagnosis_up hsa-mir-146a Oral Lichen Planus 25779071 The expressions of PBMC and plasma miRNA-155 and miRNA-146a are higher in OLP patients. The expressions of plasma miRNA-155 and miRNA-146a are associated with OLP severity. The over expression of miRNA-155 and miRNA-146a in OLP may play a role in the pathogenesis of OLP. +circulation_biomarker_diagnosis_up hsa-mir-155 Oral Lichen Planus 25779071 The expressions of PBMC and plasma miRNA-155 and miRNA-146a are higher in OLP patients. The expressions of plasma miRNA-155 and miRNA-146a are associated with OLP severity. The over expression of miRNA-155 and miRNA-146a in OLP may play a role in the pathogenesis of OLP. +circulation_biomarker_diagnosis_up hsa-mir-184 Oral Neoplasms 25784212 There was a highly significant increase in salivary miRNA-21 and miRNA-184 in OSCC and PMD +circulation_biomarker_diagnosis_up hsa-mir-296 Chronic Hepatitis C 25790297 "Serum miR-34a, miR-130a, miR-19a, miR-192, miR-195, and miR-296 were upregulated, whereas serum miR-146a was downregulated in CHC compared to controls." +circulation_biomarker_diagnosis_up hsa-mir-122 Hypertension 25837765 MiR-122 and miR-637 expressions were also significantly upregulated in the WCH group compared with the NT group +circulation_biomarker_diagnosis_up hsa-mir-10b "Carcinoma, Lung, Non-Small-Cell" 25869877 Prognostic value of microRNA-10b overexpression in peripheral blood mononuclear cells of nonsmall-cell lung cancer patients. +circulation_biomarker_diagnosis_up hsa-mir-192 Pancreatic Neoplasms 25894267 "Our data shows that miR-21, miR-192 and miR-200 could be used as new diagnostic markers for pancreatic cancer." +circulation_biomarker_diagnosis_up hsa-mir-200 Pancreatic Neoplasms 25894267 "Our data shows that miR-21, miR-192 and miR-200 could be used as new diagnostic markers for pancreatic cancer." +circulation_biomarker_diagnosis_up hsa-mir-21 Pancreatic Neoplasms 25894267 "Our data shows that miR-21, miR-192 and miR-200 could be used as new diagnostic markers for pancreatic cancer." +circulation_biomarker_diagnosis_up hsa-mir-182 "Carcinoma, Hepatocellular" 25903466 "our present study indicates that serum miR-182 and miR-331-3p, upregulated in HCC, can provide positive diagnostic and prognostic values for HCC" +circulation_biomarker_diagnosis_up hsa-mir-331 "Carcinoma, Hepatocellular" 25903466 Serum miR-182 and miR-331-3p as diagnostic and prognostic markers in patients with hepatocellular carcinoma. +circulation_biomarker_diagnosis_up hsa-mir-499 Myocardial Infarction 25922707 miR-499 was shown to substantially increase the diagnostic accuracy of CK-MB and cTnI in the diagnosis of AMI +circulation_biomarker_diagnosis_up hsa-mir-451 Mountain Sickness 25948209 "There is a certain level of microRNA-451 in healthy people, the expression of microRNA-451 in CMS patients is significantly higher than that in healthy people. MicroRNA-451 may play an important role in the process of chronic mountain sickness." +circulation_biomarker_diagnosis_up hsa-mir-499 Myocardial Infarction 25966174 the expression of microRNA-499 in serum of patients with AMI was significantly higher than in controls +circulation_biomarker_diagnosis_up hsa-mir-25 Pancreatic Neoplasms 25991015 "A combination of six serum miRNAs (miR-483-5p, miR-19a, miR-29a, miR-20a, miR-24, miR-25) was selected by qRT-PCR as a biomarker for PaC-DM." +circulation_biomarker_diagnosis_up hsa-mir-499 Acute Myocardial Infarction 26101645 miR-499 expression levels were significantly higher in the 53 AMI patients +circulation_biomarker_diagnosis_up hsa-mir-122 Hepatitis C Virus Infection 26157120 "During acute HCV infection, increases in miR-122 (P < 0.01) and miR-885-5p (Pcorrected < 0.05) and a decrease in miR-494 (Pcorrected < 0.05) were observed at the earliest time points after virus detection." +circulation_biomarker_diagnosis_up hsa-mir-223 Rheumatoid Arthritis 26164649 "MiR-16, miR-146a/b, miR-150, miR-155, and miR-223 described here were shown to be overexpressed at the systemic level: in both the periphery and RA joints." +circulation_biomarker_diagnosis_up hsa-mir-200a Cervical Neoplasms 26171195 The Solexa sequencing results revealed 12 markedly upregulated serum miRNAs in cervical cancer patients compared with controls +circulation_biomarker_diagnosis_up hsa-mir-146b Schizophrenia 26173148 "a nominally significant increase in the expression of several miRNAs was found in the 22q11.2 neurons that were previously found to be differentially expressed in autopsy samples and peripheral blood in SZ and autism spectrum disorders (e.g.,miR-34, miR-4449, miR-146b-3p, and miR-23a-5p)." +circulation_biomarker_diagnosis_up hsa-mir-23a Schizophrenia 26173148 "a nominally significant increase in the expression of several miRNAs was found in the 22q11.2 neurons that were previously found to be differentially expressed in autopsy samples and peripheral blood in SZ and autism spectrum disorders (e.g.,miR-34, miR-4449, miR-146b-3p, and miR-23a-5p)." +circulation_biomarker_diagnosis_up hsa-mir-34 Schizophrenia 26173148 "a nominally significant increase in the expression of several miRNAs was found in the 22q11.2 neurons that were previously found to be differentially expressed in autopsy samples and peripheral blood in SZ and autism spectrum disorders (e.g.,miR-34, miR-4449, miR-146b-3p, and miR-23a-5p)." +circulation_biomarker_diagnosis_up hsa-mir-4449 Schizophrenia 26173148 "a nominally significant increase in the expression of several miRNAs was found in the 22q11.2 neurons that were previously found to be differentially expressed in autopsy samples and peripheral blood in SZ and autism spectrum disorders (e.g.,miR-34, miR-4449, miR-146b-3p, and miR-23a-5p)." +circulation_biomarker_diagnosis_up hsa-mir-144 "Stroke, Ischemic" 26175178 "In conclusion, hyperglycemia may activate platelets through miR-144 and miR-223 to downregulate IRS-1 and upregulate P2Y12 expression in the platelets of T2DM patients through an IRS-1-PI3K-Akt signaling." +circulation_biomarker_diagnosis_up hsa-mir-223 "Stroke, Ischemic" 26175178 "In conclusion, hyperglycemia may activate platelets through miR-144 and miR-223 to downregulate IRS-1 and upregulate P2Y12 expression in the platelets of T2DM patients through an IRS-1-PI3K-Akt signaling." +circulation_biomarker_diagnosis_up hsa-mir-130b Schizophrenia 26183697 "The up-regulation of miR-130b and miR-193a-3p is a state-independent biomarker for schizophrenia, and these two miRNAs could be used to develop a diagnostic tool for schizophrenia." +circulation_biomarker_diagnosis_up hsa-mir-193a Schizophrenia 26183697 "The up-regulation of miR-130b and miR-193a-3p is a state-independent biomarker for schizophrenia, and these two miRNAs could be used to develop a diagnostic tool for schizophrenia." +circulation_biomarker_diagnosis_up hsa-mir-92a-2 Cardiac Allograft Vasculopathy 26198441 "Median plasma levels of miR-210-5p, miR-92a-3p, miR-126-3p, and miR-126-5p were higher in patients with CAV than in patients without CAV." +circulation_biomarker_diagnosis_up hsa-mir-133b Myocardial Infarction 26198874 "The level of miR-133a, miR-133b and miR-499-5p were significantly higher in both STEMI and NSTEMI patients compared to healthy volunteers" +circulation_biomarker_diagnosis_up hsa-mir-16 "Squamous Cell Carcinoma, Esophageal" 26221263 "Levels of four of the selected miRNAs were found to be significantly higher in ESCC patients than in controls; namely, miR-16, miR-21, miR-185, and miR-375 (P < 0.050)." +circulation_biomarker_diagnosis_up hsa-mir-370 Obesity 26223376 "circulating miR-27 (Pâ€?â€?.032), miR-378 (Pâ€?â€?.001) and miR-370 (Pâ€?â€?.045) in obese children were significantly higher" +circulation_biomarker_diagnosis_up hsa-mir-378 Obesity 26223376 "circulating miR-27 (Pâ€?â€?.032), miR-378 (Pâ€?â€?.001) and miR-370 (Pâ€?â€?.045) in obese children were significantly higher" +circulation_biomarker_diagnosis_up hsa-mir-33a Hypercholesterolaemia 26229086 Circulating miR-33a and miR-33b are up-regulated in familial hypercholesterolaemia in paediatric age. +circulation_biomarker_diagnosis_up hsa-mir-33b Hypercholesterolaemia 26229086 Circulating miR-33a and miR-33b are up-regulated in familial hypercholesterolaemia in paediatric age. +circulation_biomarker_diagnosis_up hsa-mir-21 Coronary Artery Disease 26248417 "miRNA-21 was significantly elevated in acute myocardial infarction subgroup than the control group. The level of miRNA-21 associates with the degree of coronary artery stenosis, and might be a potential marker for the diagnosis of acute myocardial infarction. miRNA-21 may play an important role in protecting myocardium from ischemia/reperfusion injury." +circulation_biomarker_diagnosis_up hsa-mir-223 Tuberculosis 26316141 "Leukocyte recruitment, measured as the expression of microRNA-223 was increased in pulmonary TB patients compared to LTBI" +circulation_biomarker_diagnosis_up hsa-mir-301a Autoimmune Diseases [unspecific] 26338824 Our data reveal a novel mechanism in which the elevated miR-301a in PBMC and inflamed mucosa of IBD promotes Th17 cell differentiation through downregulation of SNIP1. +circulation_biomarker_diagnosis_up hsa-mir-222 "Carcinoma, Hepatocellular" 26380927 "The serum levels of exosomal miR-18a, miR-221, miR-222 and miR-224 were significantly higher in patients with HCC" +circulation_biomarker_diagnosis_up hsa-mir-27b Diabetic Retinopathy 26395742 "miR-27b and miR-320a, were associated with incidence and with progression of retinopathy" +circulation_biomarker_diagnosis_up hsa-mir-107 Gastric Neoplasms 26406411 The overexpression of miR-107 in tumors and serum of gastric cancer patients and its correlation with HIF-1¦Á expression in tumor tissues was indicated that miR-107 may have a potential to use as a biomarker for detection of gastric cancer patients and hypoxia in gastric cancer tumor. +circulation_biomarker_diagnosis_up hsa-mir-191 Osteosarcoma 26406942 "Our data provide new insights for the involvement of miR-191 in osteosarcoma and suggest that the increased expression of miR-191 may be associated with aggressive tumor progression and adverse outcome. Of note, serum miR-191 quantification may be a promising biomarker for the diagnosis and prognosis in osteosarcoma." +circulation_biomarker_diagnosis_up hsa-mir-200b "Carcinoma, Ovarian" 26416421 Plasma miR-200b proved to have a greater average concentration in OvCa samples +circulation_biomarker_diagnosis_up hsa-mir-15a "Leukemia, Lymphoblastic, Acute" 26434860 "The results of our study indicate that resveratrol induces apoptosis in a time and dose-dependent manner in CCRF-CEM cells. Also, increased expression level of miR 16-1 and miR 15a by means of resveratrol in CCRF-CEM" +circulation_biomarker_diagnosis_up hsa-mir-16-1 "Leukemia, Lymphoblastic, Acute" 26434860 "The results of our study indicate that resveratrol induces apoptosis in a time and dose- dependent manner in CCRF-CEM cells. Also, increased expression level of miR 16-1 and miR 15a by means of resveratrol in CCRF-CEM" +circulation_biomarker_diagnosis_up hsa-mir-192 Cholangiocarcinoma 26456596 "We found that miR-192 was significantly higher in O. viverrini infected, PDF and also CCA groups (p<0.05) than in healthy controls." +circulation_biomarker_diagnosis_up hsa-mir-21 Cholangiocarcinoma 26456596 MiR-21 was significantly higher in PDF and CCA groups (p<0.05) than in healthy controls. +circulation_biomarker_diagnosis_up hsa-mir-18a "Leukemia, Myeloid, Chronic" 26458312 "up-regulated expression of oncogenic miRNAs (miR-17, miR-18a, miR-20a, miR-21, miR-27a and miR-155)" +circulation_biomarker_diagnosis_up hsa-mir-184 Neoplasms [unspecific] 26525105 "The increase of plasma miR-146a, miR-184 and miR-372 was detectable early in the induction, and it was particularly eminent at the most advanced lesion state." +circulation_biomarker_diagnosis_up hsa-mir-31 Neoplasms [unspecific] 26525105 "A progressive increase of miR-21, miR-31 and miR-146a in both saliva and plasma samples was also noted." +circulation_biomarker_diagnosis_up hsa-mir-372 Neoplasms [unspecific] 26525105 "The increase of plasma miR-146a, miR-184 and miR-372 was detectable early in the induction" +circulation_biomarker_diagnosis_up hsa-mir-208a Myocardial Infarction 26528525 miRNA-208a was increased in STEMI patients at the time of admission and nearly undetectable in CAD patients and controls. +circulation_biomarker_diagnosis_up hsa-mir-210 "Leukemia, Myeloid, Acute" 26549593 MiR-210 up-regulation was associated with poor prognosis in AML and it might be useful as a marker for predicting the clinical outcome of AML patients. +circulation_biomarker_diagnosis_up hsa-mir-423 Cardiovascular Diseases [unspecific] 26562412 "Our results suggested that miR-423-5p is enriched in PF, and serum miR-423-5p may be associate with uAP. Its expression pattern was different to that of muscle- and vascular-enriched miRNAs, miR-133a, miR-126, and miR-92a." +circulation_biomarker_diagnosis_up hsa-mir-223 Polycystic Ovarian Syndrome 26582398 "In conclusion, circulating miRNA-93 and miRNA-223 were higher in women with PCOS compared to age and weight matched controls independent of insulin resistance and testosterone levels, and miR-93 may represent a novel diagnostic biomarker for PCOS." +circulation_biomarker_diagnosis_up hsa-mir-93 Polycystic Ovarian Syndrome 26582398 "In conclusion, circulating miRNA-93 and miRNA-223 were higher in women with PCOS compared to age and weight matched controls independent of insulin resistance and testosterone levels, and miR-93 may represent a novel diagnostic biomarker for PCOS." +circulation_biomarker_diagnosis_up hsa-mir-208 Cardiomegaly 26622415 miR-208 expression levels are increased in the peripheral blood of patients with cardiac hypertrophy. +circulation_biomarker_diagnosis_up hsa-mir-195 Parkinson Disease 26631952 "miR-195 was up-regulated, and miR-185, miR-15b, miR-221 and miR-181a were down-regulated." +circulation_biomarker_diagnosis_up hsa-mir-206 Coronary Artery Disease 26685009 miRNA 206 and miRNA 574-5p are highly expression in coronary artery disease. +circulation_biomarker_diagnosis_up hsa-mir-574 Coronary Artery Disease 26685009 miRNA 206 and miRNA 574-5p are highly expression in coronary artery disease. +circulation_biomarker_diagnosis_up hsa-mir-196b "Leukemia, Myeloid, Acute" 26744876 The expression level of miR-155 was significantly higher in AML patients than in controls. +circulation_biomarker_diagnosis_up hsa-mir-191 Traumatic Brain Injury 26756543 "Elevated serum miR-93, miR-191, and miR-499 are noninvasive biomarkers for the presence and progression of traumatic brain injury." +circulation_biomarker_diagnosis_up hsa-mir-499 Traumatic Brain Injury 26756543 "Elevated serum miR-93, miR-191, and miR-499 are noninvasive biomarkers for the presence and progression of traumatic brain injury." +circulation_biomarker_diagnosis_up hsa-mir-93 Traumatic Brain Injury 26756543 "Elevated serum miR-93, miR-191, and miR-499 are noninvasive biomarkers for the presence and progression of traumatic brain injury." +circulation_biomarker_diagnosis_up hsa-mir-96 "Carcinoma, Hepatocellular" 26770453 Serum miR-96 levels in the HCC patients were remarkably higher than in the other groups +circulation_biomarker_diagnosis_up hsa-mir-92a Gastric Neoplasms 26790436 High expression of miR-92a compared with adjacent normal tissues was associated with shorter OS. +circulation_biomarker_diagnosis_up hsa-mir-125b Chronic Hepatitis B 26802212 serum miRNA-125b was positively correlated with the serum HBV DNA level. +circulation_biomarker_diagnosis_up hsa-mir-143 Pancreatic Adenocarcinoma 26807325 "Three miRNAs (miR-143, miR-223, and miR-30e) were significantly over-expressed in patients with Stage I cancer when compared with age-matched healthy individuals" +circulation_biomarker_diagnosis_up hsa-mir-223 Choriocarcinoma 26807325 "Three miRNAs (miR-143, miR-223, and miR-30e) were significantly over-expressed in patients with Stage I cancer when compared with age-matched healthy individuals" +circulation_biomarker_diagnosis_up hsa-mir-122 Chronic Hepatitis C 26812693 serum levels of miR-122 and miR-222 were significantly elevated in HCV patients +circulation_biomarker_diagnosis_up hsa-mir-222 Chronic Hepatitis C 26812693 the serum levels of miR-122 and miR-222 were significantly elevated in HCV patients +circulation_biomarker_diagnosis_up hsa-mir-21 Breast Neoplasms 26827795 the serum levels of miR-21 and miR-221 were significantly overexpressed in breast cancer patients +circulation_biomarker_diagnosis_up hsa-mir-221 Breast Neoplasms 26827795 the serum levels of miR-21 and miR-221 were significantly overexpressed in breast cancer patients +circulation_biomarker_diagnosis_up hsa-mir-885 Preeclampsia 26853698 "miR-885-5p is increased in plasma from pre-eclampsia compared with healthy pregnant women, and it is released into circulation mainly inside exosomes." +circulation_biomarker_diagnosis_up hsa-mir-122 Polycystic Ovarian Syndrome 26860517 "relative expression of miR-122, miR-193b, and miR-194 was up-regulated in PCOS patients" +circulation_biomarker_diagnosis_up hsa-mir-193b Polycystic Ovarian Syndrome 26860517 "relative expression of miR-122, miR-193b, and miR-194 was up-regulated in PCOS patients" +circulation_biomarker_diagnosis_up hsa-mir-194 Polycystic Ovarian Syndrome 26860517 "relative expression of miR-122, miR-193b, and miR-194 was up-regulated in PCOS patients" +circulation_biomarker_diagnosis_up hsa-mir-155 Lung Neoplasms 26867772 "Two miRNAs, miR-21 and miR-155, were found to be significantly upregulated in recurrent tumors compared to primary tumors." +circulation_biomarker_diagnosis_up hsa-mir-21 Lung Neoplasms 26867772 "Two miRNAs, miR-21 and miR-155, were found to be significantly upregulated in recurrent tumors compared to primary tumors." +circulation_biomarker_diagnosis_up hsa-mir-21 Multiple Myeloma 26909911 We found that the expression level of serum mir-21 in the MM group was significantly higher than the MGUS group and the NC group +circulation_biomarker_diagnosis_up hsa-let-7 Myasthenia Gravis 26943954 Disease specific enrichment of circulating let-7 family microRNA in MuSK+ myasthenia gravis. +circulation_biomarker_diagnosis_up hsa-mir-99b Chronic Fatigue Syndrome 26967895 "Microarray analysis identified differential expression of 34 miRNA, all of which were up-regulated." +circulation_biomarker_diagnosis_up hsa-mir-182 Glioma 26978735 Our findings showed that the level of circulating miR-182 in glioma patients was higher than that in healthy controls +circulation_biomarker_diagnosis_up hsa-mir-328 Atrial Fibrillation 26987792 Plasma levels of miR-328 were higher in patients with AF than in control subjects. +circulation_biomarker_diagnosis_up hsa-mir-96 Colorectal Adenocarcinoma 27044381 miR-96 is significantly upregulated in colorectal adenocarcinoma specimens compared to their non-cancerous counterparts +circulation_biomarker_diagnosis_up hsa-mir-15b Glioma 27047250 "we identified significantly increased levels of two candidate biomarkers, miR-15b and miR-21, in blood of patients affected by gliomas" +circulation_biomarker_diagnosis_up hsa-mir-16 Glioma 27047250 "we identified significantly increased levels of two candidate biomarkers, miR-15b and miR-21, in blood of patients affected by gliomas" +circulation_biomarker_diagnosis_up hsa-mir-21 Glioblastoma 27047250 "we identified significantly increased levels of two candidate biomarkers, miR-15b and miR-21, in blood of patients affected by gliomas" +circulation_biomarker_diagnosis_up hsa-mir-21 Glioma 27047250 "we identified significantly increased levels of two candidate biomarkers, miR-15b and miR-21, in blood of patients affected by gliomas" +circulation_biomarker_diagnosis_up hsa-mir-21 Autoimmune Lymphoproliferative Syndrome 27060458 "miR-21-3p was over-expressed significantly (P = 0·0313) in the son, with no significant change in the expression of miR-146a, miR-146a-3p and miR-21." +circulation_biomarker_diagnosis_up hsa-mir-21 "Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal" 27067271 "Compared with controls, miR-21 levels in tissue and plasma were significantly higher for both PLL and LSCC groups" +circulation_biomarker_diagnosis_up hsa-mir-124 Depression Disorder 27078210 expression levels of miR-124 from PBMCs in MDD patients were significantly higher than those in healthy controls +circulation_biomarker_diagnosis_up hsa-mir-133a Acute Myocardial Infarction 27124025 "circulating miR-133a is upregulated in AMI patients," +circulation_biomarker_diagnosis_up hsa-mir-135a Colorectal Carcinoma 27126269 Serum miR-135a-5p expression in colorectal cancer patients was higher than that in patients with colorectal polyps and healthy controls +circulation_biomarker_diagnosis_up hsa-mir-30c Aortic Stenosis 27129184 "Levels of miR-30c were higher in the AS group than in the controls (P<0.01), whereas levels of miR-106a, miR-148a, miR-204, miR-211, miR-31 and miR-424 were lower in the AS group than in the controls (P<0.01)." +circulation_biomarker_diagnosis_up hsa-mir-4449 Multiple Myeloma 27155004 The expression levels of serum miR-4449 in MM patients were significantly higher than in healthy controls +circulation_biomarker_diagnosis_up hsa-mir-499 Acute Myocardial Infarction 27162785 the circulating levels of miRNA-499 was increased in AMI patients. +circulation_biomarker_diagnosis_up hsa-mir-499 Heart Failure 27162785 the circulating levels of miRNA-499 was increased in AMI patients. +circulation_biomarker_diagnosis_up hsa-mir-21 Glioma 27166186 CSF-based miR-21 might serve as a potential biomarker for diagnosing brain cancer +circulation_biomarker_diagnosis_up hsa-mir-125b Myocardial Infarction 27176713 "miR-125b-5p and miR-30d-5p presented a diagnostic value for early diagnosis of AMI, and miRâ€?0dâ€?p may have a higher diagnostic value than cTnI." +circulation_biomarker_diagnosis_up hsa-mir-30d Acute Myocardial Infarction 27176713 "miR-125b-5p and miR-30d-5p presented a diagnostic value for early diagnosis of AMI, and miRâ€?0dâ€?p may have a higher diagnostic value than cTnI." +circulation_biomarker_diagnosis_up hsa-mir-146a Breast Neoplasms 27197674 "miR-21 (P < 0.001) and miR-146a (P = 0.001) were overexpressed, whereas miR-200c (P = 0.004) and miR-210 (P = 0.002) were underexpressed." +circulation_biomarker_diagnosis_up hsa-mir-21 Breast Neoplasms 27197674 "miR-21 (P < 0.001) and miR-146a (P = 0.001) were overexpressed, whereas miR-200c (P = 0.004) and miR-210 (P = 0.002) were underexpressed." +circulation_biomarker_diagnosis_up hsa-mir-125a Lupus Nephritis 27215082 "Elevated Serum Inflammatory Cytokines in Lupus Nephritis Patients, in Association with Promoted hsa-miR-125a." +circulation_biomarker_diagnosis_up hsa-mir-143 Sepsis 27225861 Serum miR-143 levels were significantly higher in patients with sepsis +circulation_biomarker_diagnosis_up hsa-mir-223 Viral Infectious Disease 27226534 vesicular stomatitis virus (VSV) infection induced significant up-regulation of miR-223 in murine macrophages. +circulation_biomarker_diagnosis_up hsa-mir-21 Stroke 27288814 The stroke with SAI group had significantly higher miRNA-21 expression +circulation_biomarker_diagnosis_up hsa-mir-16 Ischemia-Reperfusion Injury 27297958 urinary miR-16 was 100-fold higher in AKI patients. +circulation_biomarker_diagnosis_up hsa-mir-126 "Leukemia, B-Cell" 27300437 miRNA-126 is highly expressed in a subset of human B-ALL +circulation_biomarker_diagnosis_up hsa-mir-33b "Diabetes Mellitus, Type 2" 27301461 plasma miRNA33b may be useful as a new metabolic biomarker of dyslipidemia in patients with T2DM +circulation_biomarker_diagnosis_up hsa-let-7c Down Syndrome 27323694 "Seven miRNAs were verified as upregulated in DS placentas (miR-99a, miR-542-5p, miR-10b, miR-125b, miR-615, let-7c and miR-654)" +circulation_biomarker_diagnosis_up hsa-mir-199a Graft-Versus-Host Disease 27342518 "The expression of miR-423, miR-199a-3p, miR-93* are upregulated in aGVHD group, which can be used as biomarkes to monitor and to diagnose aGVHD." +circulation_biomarker_diagnosis_up hsa-mir-423 Graft-Versus-Host Disease 27342518 "The expression of miR-423, miR-199a-3p, miR-93* are upregulated in aGVHD group, which can be used as biomarkes to monitor and to diagnose aGVHD." +circulation_biomarker_diagnosis_up hsa-mir-93 Graft-Versus-Host Disease 27342518 "The expression of miR-423, miR-199a-3p, miR-93* are upregulated in aGVHD group, which can be used as biomarkes to monitor and to diagnose aGVHD." +circulation_biomarker_diagnosis_up hsa-mir-210 Myocardial Infarction 27346801 miRNA-499 and miRNA-210 expression levels were significantly increased +circulation_biomarker_diagnosis_up hsa-mir-499 Acute Coronary Syndrome 27346801 miRNA-499 and miRNA-210 expression levels were significantly increased +circulation_biomarker_diagnosis_up hsa-mir-499 Myocardial Infarction 27346801 miRNA-499 and miRNA-210 expression levels were significantly increased +circulation_biomarker_diagnosis_up hsa-mir-1266 Psoriasis 27371164 Increased MicroRNA-1266 levels as a biomarker for disease activity in psoriasis vulgaris. +circulation_biomarker_diagnosis_up hsa-mir-221 Acute Myocardial Infarction 27374153 Circulating miR-221-3p as a novel marker for early prediction of acute myocardial infarction. +circulation_biomarker_diagnosis_up hsa-mir-146b Acute Kidney Failure 27400799 "The results showed that in acute kidney injury induced by cisplatin, miR-146b in serum increased more quickly than did the usual indexes of kidney injury and decreased with restoration of MSCs." +circulation_biomarker_diagnosis_up hsa-mir-21 Prostate Neoplasms 27434290 The expression levels of miR-21 in PCa group were increased compared to BPH and control group +circulation_biomarker_diagnosis_up hsa-mir-133a Sepsis 27434558 The mRNA expressions of serum miR-155-5p and miR-133a-3p were gradually increased with the aggravation of sepsis. +circulation_biomarker_diagnosis_up hsa-mir-155 Sepsis 27434558 The mRNA expressions of serum miR-155-5p and miR-133a-3p were gradually increased with the aggravation of sepsis. +circulation_biomarker_diagnosis_up hsa-mir-223 Oral Neoplasms 27441818 "circulating miR-223 levels were significantly higher (~2-fold, P< 0.05) in patients with oral cancer (n = 31) than in those without cancer (n = 31)." +circulation_biomarker_diagnosis_up hsa-mir-30 Diabetic Nephropathy 27470555 "We found urinary exosomalmiR-133b, miR-342, and miR-30a were expressed at significantly elevated levels in T2DN patients (P<0.001) compared to normal." +circulation_biomarker_diagnosis_up hsa-mir-342 Diabetic Nephropathy 27470555 "We found urinary exosomalmiR-133b, miR-342, and miR-30a were expressed at significantly elevated levels in T2DN patients (P<0.001) compared to normal." +circulation_biomarker_diagnosis_up hsa-mir-122 Acute Pancreatitis 27477940 "In mice, we found that LPS-induced inflammation increases blood levels of MIR122, which reduces expression of Epo in the kidney;" +circulation_biomarker_diagnosis_up hsa-mir-22 Myocardial Infarction 27484208 Subsequent validation in an independent patient group confirmed that miRâ€?33b and miRâ€?2â€?p were significantly up‑regulated in the serum of patients with AMI. +circulation_biomarker_diagnosis_up hsa-mir-106b Schizophrenia 27489379 "Schizophrenia patients showed statistically significant upregulation of five microRNAs: miR9-5p (p=0.002), miR29a-3p (pï¼?.001), miR106b-5p (p=0.002), miR125a-3p (pï¼?.001), and miR125b-3p (p=0.018)." +circulation_biomarker_diagnosis_up hsa-mir-29a Schizophrenia 27489379 "Schizophrenia patients showed statistically significant upregulation of five microRNAs: miR9-5p (p=0.002), miR29a-3p (pï¼?.001), miR106b-5p (p=0.002), miR125a-3p (pï¼?.001), and miR125b-3p (p=0.018)." +circulation_biomarker_diagnosis_up hsa-mir-19a Allergic Rhinitis 27491928 "The results showed that the levels of miR-19a, but not the rest of the 5 members (miR-17, miR-18a, miR-19b, miR-20a, and miR-92a), were significantly higher in peripheral B cells from AR patients as than in B cells from healthy participants." +circulation_biomarker_diagnosis_up hsa-mir-146a Atherosclerosis 27502756 "In monocytes, miR124a and -125a were low, while miR-146a and miR-155 appeared elevated." +circulation_biomarker_diagnosis_up hsa-mir-21 Systemic Lupus Erythematosus 27510529 miR-21 was high expressed in SLE patients compared to their first-degree relatives and controls. +circulation_biomarker_diagnosis_up hsa-mir-147 Diabetes Mellitus 27518498 Analysis for serum microRNAs expression showed the distinctive and synergistic upregulation of miR-147 with periodontitis-induced effects in rats +circulation_biomarker_diagnosis_up hsa-mir-122 Acute Coronary Syndrome 27519051 "MiR-223, miR-92a, miR-486, miR-122, miR-125a and miR-146a levels were higher in the hyperglycemic ACS compared to normoglycemic sera." +circulation_biomarker_diagnosis_up hsa-mir-125a Acute Coronary Syndrome 27519051 "MiR-223, miR-92a, miR-486, miR-122, miR-125a and miR-146a levels were higher in the hyperglycemic ACS compared to normoglycemic sera." +circulation_biomarker_diagnosis_up hsa-mir-146a Acute Coronary Syndrome 27519051 "MiR-223, miR-92a, miR-486, miR-122, miR-125a and miR-146a levels were higher in the hyperglycemic ACS compared to normoglycemic sera." +circulation_biomarker_diagnosis_up hsa-mir-223 Acute Coronary Syndrome 27519051 "MiR-223, miR-92a, miR-486, miR-122, miR-125a and miR-146a levels were higher in the hyperglycemic ACS compared to normoglycemic sera." +circulation_biomarker_diagnosis_up hsa-mir-486 Acute Coronary Syndrome 27519051 "MiR-223, miR-92a, miR-486, miR-122, miR-125a and miR-146a levels were higher in the hyperglycemic ACS compared to normoglycemic sera." +circulation_biomarker_diagnosis_up hsa-mir-92a Acute Coronary Syndrome 27519051 "MiR-223, miR-92a, miR-486, miR-122, miR-125a and miR-146a levels were higher in the hyperglycemic ACS compared to normoglycemic sera." +circulation_biomarker_diagnosis_up hsa-mir-21 Kideny Transplant Rejection 27521993 our findings indicated that the aberrant urinary miR-21 and miR-200b expression levels were accompanied with renal allograft dysfunction and IFTA. +circulation_biomarker_diagnosis_up hsa-mir-217 "Diabetes Mellitus, Type 2" 27522360 "Compared with control, serum microRNA-217 levels were significantly increased in type 2 diabetes patients" +circulation_biomarker_diagnosis_up hsa-mir-146a Psoriasis 27535005 "Psoriasis patients presented, at baseline, increased expression of miRNA-155, let-7i, miRNA-146a, miRNA-21 and miRNA-223 in PBMCs, plus miRNA-21, miRNA-146a and miRNA-223 in plasma." +circulation_biomarker_diagnosis_up hsa-mir-155 Psoriasis 27535005 "Psoriasis patients presented, at baseline, increased expression of miRNA-155, let-7i, miRNA-146a, miRNA-21 and miRNA-223 in PBMCs, plus miRNA-21, miRNA-146a and miRNA-223 in plasma." +circulation_biomarker_diagnosis_up hsa-mir-21 Psoriasis 27535005 "Psoriasis patients presented, at baseline, increased expression of miRNA-155, let-7i, miRNA-146a, miRNA-21 and miRNA-223 in PBMCs, plus miRNA-21, miRNA-146a and miRNA-223 in plasma." +circulation_biomarker_diagnosis_up hsa-mir-223 Psoriasis 27535005 "Psoriasis patients presented, at baseline, increased expression of miRNA-155, let-7i, miRNA-146a, miRNA-21 and miRNA-223 in PBMCs, plus miRNA-21, miRNA-146a and miRNA-223 in plasma." +circulation_biomarker_diagnosis_up hsa-mir-181a "Lymphoma, B-Cell" 27535859 "The expression of hsa-miR-29a , hsa-miR-126 and has-miR-181 family were significantly different in B-ALL." +circulation_biomarker_diagnosis_up hsa-mir-181c "Leukemia, Lymphoblastic" 27535859 "The expression of hsa-miR-29a , hsa-miR-126 and has-miR-181 family were significantly different in B-ALL." +circulation_biomarker_diagnosis_up hsa-mir-155 Leukemia 27619068 MicroRNA-155 is upregulated in MLL-rearranged AML but its absence does not affect leukemia development. +circulation_biomarker_diagnosis_up hsa-mir-126 Arteriosclerosis Obliterans 27766047 "In smokers who completely attained smoking cessation, both RH-PAT index and plasma miR-126 values were increased" +circulation_biomarker_diagnosis_up hsa-mir-146a Melanoma 27895580 Increased Levels of miRNA-146a in Serum and Histologic Samples of Patients with Uveal Melanoma. +circulation_biomarker_diagnosis_up hsa-mir-127 "Carcinoma, Breast" 27983524 Combined detection of plasma miR-127-3p and HE4 improves the diagnostic efficacy of breast cancer. +circulation_biomarker_diagnosis_up hsa-mir-140 "Leukemia, Myeloid, Chronic" 28197964 Up-regulated exosomal miRNA-140-3p in CML patients with musculoskeletal pain associated with discontinuation of tyrosine kinase inhibitors. +circulation_biomarker_diagnosis_up hsa-mir-16 Hearing Loss 28224282 "The plasma levels of miR-24-3p, miR-16-5p,miR-185-5p, and miR-451a were upregulated during noise exposures, and increased levels of miR-21 have been found in vestibular schwannomas and human cholesteatoma" +circulation_biomarker_diagnosis_up hsa-mir-185 Hearing Loss 28224282 "The plasma levels of miR-24-3p, miR-16-5p,miR-185-5p, and miR-451a were upregulated during noise exposures, and increased levels of miR-21 have been found in vestibular schwannomas and human cholesteatoma" +circulation_biomarker_diagnosis_up hsa-mir-21 Cholesteatoma 28224282 "The plasma levels of miR-24-3p, miR-16-5p,miR-185-5p, and miR-451a were upregulated during noise exposures, and increased levels of miR-21 have been found in vestibular schwannomas and human cholesteatoma" +circulation_biomarker_diagnosis_up hsa-mir-21 Neurilemmoma 28224282 "The plasma levels of miR-24-3p, miR-16-5p,miR-185-5p, and miR-451a were upregulated during noise exposures, and increased levels of miR-21 have been found in vestibular schwannomas and human cholesteatoma" +circulation_biomarker_diagnosis_up hsa-mir-24 Hearing Loss 28224282 "The plasma levels of miR-24-3p, miR-16-5p,miR-185-5p, and miR-451a were upregulated during noise exposures, and increased levels of miR-21 have been found in vestibular schwannomas and human cholesteatoma" +circulation_biomarker_diagnosis_up hsa-mir-451a Hearing Loss 28224282 "The plasma levels of miR-24-3p, miR-16-5p,miR-185-5p, and miR-451a were upregulated during noise exposures, and increased levels of miR-21 have been found in vestibular schwannomas and human cholesteatoma" +circulation_biomarker_diagnosis_up hsa-mir-29a Atherosclerosis 28250354 Elevated Plasma miR-29a Levels Are Associated with Increased Carotid Intima-Media Thickness in Atherosclerosis Patients. +circulation_biomarker_diagnosis_up hsa-mir-155 Heart Failure 28319523 Plasma Levels of MicroRNA-155 Are Upregulated with Long-Term Left Ventricular Assist Device Support. +circulation_biomarker_diagnosis_up hsa-mir-142 Kideny Transplant Rejection 28380212 Upregulation of microRNA 142-3p in the peripheral blood and urinary cells of kidney transplant recipients with post-transplant graft dysfunction. +circulation_biomarker_diagnosis_up hsa-mir-155 "Leukemia, Lymphocytic, Chronic, B-Cell" 28407516 Quantitative miR analysis in chronic lymphocytic leukaemia/small lymphocytic lymphoma - proliferation centres are characterized by high miR-92a and miR-155 and low miR-150 expression. +circulation_biomarker_diagnosis_up hsa-mir-92a "Leukemia, Lymphocytic, Chronic, B-Cell" 28407516 Quantitative miR analysis in chronic lymphocytic leukaemia/small lymphocytic lymphoma - proliferation centres are characterized by high miR-92a and miR-155 and low miR-150 expression. +circulation_biomarker_diagnosis_up hsa-mir-125b "Leukemia-Lymphoma, Precursor B-Cell Lymphoblastic" 28415578 High expression of miR-125b-2 and SNORD116 noncoding RNA clusters characterize ERG-related B cell precursor acute lymphoblastic leukemia. +circulation_biomarker_diagnosis_up hsa-mir-21 Vascular Disease [unspecific] 28464406 "miR-21 and miR-92 levels increased, but did not reach the level of significance" +circulation_biomarker_diagnosis_up hsa-mir-92 Vascular Disease [unspecific] 28464406 "miR-21 and miR-92 levels increased, but did not reach the level of significance" +circulation_biomarker_diagnosis_up hsa-mir-196b "Leukemia, Myeloid, Acute" 28507466 High level of miR-196b at newly diagnosed pediatric acute myeloid leukemia predicts a poor outcome. +circulation_biomarker_diagnosis_up hsa-mir-155 Human Immunodeficiency Virus Infection 28627655 Elevated expression of miR-155 is associated with the differentiation of CD8+ T cells in patients with HIV-1. +circulation_biomarker_diagnosis_up hsa-mir-125b Rheumatoid Arthritis 28738524 Elevated microRNA-125b promotes inflammation in rheumatoid arthritis by activation of NF-¦ÊB pathway. +circulation_biomarker_diagnosis_up hsa-mir-126 Coronary Artery Disease 28751542 "patients with stenosis showed an increase of circulating miRNA-21, miRNA-126-3p, and miRNA-222 in response to cardiac stress" +circulation_biomarker_diagnosis_up hsa-mir-21 Coronary Artery Disease 28751542 "patients with stenosis showed an increase of circulating miRNA-21, miRNA-126-3p, and miRNA-222 in response to cardiac stress" +circulation_biomarker_diagnosis_up hsa-mir-222 Coronary Artery Disease 28751542 "patients with stenosis showed an increase of circulating miRNA-21, miRNA-126-3p, and miRNA-222 in response to cardiac stress" +circulation_biomarker_diagnosis_up hsa-mir-146a Osteoarthritis 28785809 "MBT can modify the expression of miR-155, miR-181a, miR-146a, and miR-223, which are upregulated in OA" +circulation_biomarker_diagnosis_up hsa-mir-155 Osteoarthritis 28785809 "MBT can modify the expression of miR-155, miR-181a, miR-146a, and miR-223, which are upregulated in OA" +circulation_biomarker_diagnosis_up hsa-mir-181a Osteoarthritis 28785809 "MBT can modify the expression of miR-155, miR-181a, miR-146a, and miR-223, which are upregulated in OA" +circulation_biomarker_diagnosis_up hsa-mir-223 Osteoarthritis 28785809 "MBT can modify the expression of miR-155, miR-181a, miR-146a, and miR-223, which are upregulated in OA" +circulation_biomarker_diagnosis_up hsa-mir-21 Human Immunodeficiency Virus Infection 28968466 upregulation of hsa-miR-21 and hsa-miR-222 by Tat may contribute to protect against apoptosis and to anergy observed in HIV-infected CD4+ T cells +circulation_biomarker_diagnosis_up hsa-mir-222 Human Immunodeficiency Virus Infection 28968466 upregulation of hsa-miR-21 and hsa-miR-222 by Tat may contribute to protect against apoptosis and to anergy observed in HIV-infected CD4+ T cells +circulation_biomarker_diagnosis_up hsa-mir-19b "Leukemia, Myeloid, Acute" 29032147 High bone marrow miR-19b level predicts poor prognosis and disease recurrence in de novo acute myeloid leukemia. +circulation_biomarker_diagnosis_up hsa-mir-144 Arrhythmia 29036525 "Plasma levels of miR-144-3p, 145-5p, 185-5p, and 494 were significantly elevated in definite ARVC patients with VA" +circulation_biomarker_diagnosis_up hsa-mir-145 Arrhythmia 29036525 "Plasma levels of miR-144-3p, 145-5p, 185-5p, and 494 were significantly elevated in definite ARVC patients with VA" +circulation_biomarker_diagnosis_up hsa-mir-185 Arrhythmia 29036525 "Plasma levels of miR-144-3p, 145-5p, 185-5p, and 494 were significantly elevated in definite ARVC patients with VA" +circulation_biomarker_diagnosis_up hsa-mir-494 Arrhythmia 29036525 "Plasma levels of miR-144-3p, 145-5p, 185-5p, and 494 were significantly elevated in definite ARVC patients with VA" +circulation_biomarker_diagnosis_up hsa-mir-146b Intrahepatic Cholangiocarcinoma 29095255 Both plasma and tumor tissue miR-146a high expression correlates with prolonged overall survival of surgical patients with intrahepatic cholangiocarcinoma. +circulation_biomarker_diagnosis_up hsa-let-7g Migraine 29126355 " migraine patients had upregulated expression of miR-155 (6.17-fold, p?=?0.018), miR-126 (6.17-fold, p?=?0.013), and let-7g (7.37-fold, p?=?0.005)" +circulation_biomarker_diagnosis_up hsa-mir-126 Migraine 29126355 " migraine patients had upregulated expression of miR-155 (6.17-fold, p?=?0.018), miR-126 (6.17-fold, p?=?0.013), and let-7g (7.37-fold, p?=?0.005)" +circulation_biomarker_diagnosis_up hsa-mir-155 Migraine 29126355 " migraine patients had upregulated expression of miR-155 (6.17-fold, p?=?0.018), miR-126 (6.17-fold, p?=?0.013), and let-7g (7.37-fold, p?=?0.005)" +circulation_biomarker_diagnosis_up hsa-mir-1 Myocardial Infarction 29150941 significantly elevated levels of miRNA-1 in post-MI old heart could be predictive of cardiac injury in older mice as the high risk biomarker for MI in older individuals +circulation_biomarker_diagnosis_up hsa-mir-210 Neoplasms [unspecific] 29187235 miR-210 was >?sixfold higher in the TCC group compared to the control group +circulation_biomarker_diagnosis_up hsa-mir-139 Rheumatoid Arthritis 29191214 "The expression levels of miR-139-3p, miR-204, miR-214, and miR-760 increased in RA patients receiving biologic agents" +circulation_biomarker_diagnosis_up hsa-mir-204 Rheumatoid Arthritis 29191214 "The expression levels of miR-139-3p, miR-204, miR-214, and miR-760 increased in RA patients receiving biologic agents" +circulation_biomarker_diagnosis_up hsa-mir-214 Rheumatoid Arthritis 29191214 "The expression levels of miR-139-3p, miR-204, miR-214, and miR-760 increased in RA patients receiving biologic agents" +circulation_biomarker_diagnosis_up hsa-mir-760 Rheumatoid Arthritis 29191214 "The expression levels of miR-139-3p, miR-204, miR-214, and miR-760 increased in RA patients receiving biologic agents" +circulation_biomarker_diagnosis_up hsa-mir-21 Myocardial Infarction 29197221 "Expression of miRNA-21 was upregulated in the serum of elderly patients with AMI, which inhibited TNF-a induced apoptosis in HCM by activating the JNK/p38/caspase-3 signaling pathway" +circulation_biomarker_diagnosis_up hsa-mir-126 Multiple Sclerosis 29325906 "The upregulation of miR-126-3p, miR-146b-5p, miR-155, miR-196a-5p, miR-21-5p, miR-223-3p, miR-326 and miR-379-5p in remission compared to relapse was observed" +circulation_biomarker_diagnosis_up hsa-mir-146b Multiple Sclerosis 29325906 "The upregulation of miR-126-3p, miR-146b-5p, miR-155, miR-196a-5p, miR-21-5p, miR-223-3p, miR-326 and miR-379-5p in remission compared to relapse was observed" +circulation_biomarker_diagnosis_up hsa-mir-155 Multiple Sclerosis 29325906 "The upregulation of miR-126-3p, miR-146b-5p, miR-155, miR-196a-5p, miR-21-5p, miR-223-3p, miR-326 and miR-379-5p in remission compared to relapse was observed" +circulation_biomarker_diagnosis_up hsa-mir-196a Multiple Sclerosis 29325906 "The upregulation of miR-126-3p, miR-146b-5p, miR-155, miR-196a-5p, miR-21-5p, miR-223-3p, miR-326 and miR-379-5p in remission compared to relapse was observed" +circulation_biomarker_diagnosis_up hsa-mir-21 Multiple Sclerosis 29325906 "The upregulation of miR-126-3p, miR-146b-5p, miR-155, miR-196a-5p, miR-21-5p, miR-223-3p, miR-326 and miR-379-5p in remission compared to relapse was observed" +circulation_biomarker_diagnosis_up hsa-mir-223 Multiple Sclerosis 29325906 "The upregulation of miR-126-3p, miR-146b-5p, miR-155, miR-196a-5p, miR-21-5p, miR-223-3p, miR-326 and miR-379-5p in remission compared to relapse was observed" +circulation_biomarker_diagnosis_up hsa-mir-326 Multiple Sclerosis 29325906 "The upregulation of miR-126-3p, miR-146b-5p, miR-155, miR-196a-5p, miR-21-5p, miR-223-3p, miR-326 and miR-379-5p in remission compared to relapse was observed" +circulation_biomarker_diagnosis_up hsa-mir-379 Multiple Sclerosis 29325906 "The upregulation of miR-126-3p, miR-146b-5p, miR-155, miR-196a-5p, miR-21-5p, miR-223-3p, miR-326 and miR-379-5p in remission compared to relapse was observed" +circulation_biomarker_diagnosis_up hsa-mir-21 Ovarian Neoplasms 29373877 miR-21 may be used as a diagnostic biomarker for human ovarian cancer +circulation_biomarker_diagnosis_up hsa-mir-191 Pancreatic Neoplasms 29385987 "An elevated expression of serum exosomal microRNA-191, -21, -451a of pancreatic neoplasm is considered to be efficient diagnostic marker" +circulation_biomarker_diagnosis_up hsa-mir-21 Pancreatic Neoplasms 29385987 "An elevated expression of serum exosomal microRNA-191, -21, -451a of pancreatic neoplasm is considered to be efficient diagnostic marker" +circulation_biomarker_diagnosis_up hsa-mir-451a Pancreatic Neoplasms 29385987 "An elevated expression of serum exosomal microRNA-191, -21, -451a of pancreatic neoplasm is considered to be efficient diagnostic marker" +circulation_biomarker_diagnosis_up hsa-mir-146b Stroke 29402769 upregulated serum miR-146b in acute ischemic stroke might be a potential biomarker for AIS evaluation +circulation_biomarker_diagnosis_up hsa-mir-210 Acute Cerebral Infarction 29434712 "miR-210 is upregulated in the serum of patients with ACI, and miR-210 may be involved in the pathogenesis of ACI through regulating the proliferation and apoptosis of endothelial cells" +circulation_biomarker_diagnosis_up hsa-mir-1 Cardiovascular Diseases [unspecific] 29506853 Plasma microRNAs reflecting cardiac and inflammatory injury in coronary artery bypass grafting surgery +circulation_biomarker_diagnosis_up hsa-mir-133a Cardiovascular Diseases [unspecific] 29506853 Plasma microRNAs reflecting cardiac and inflammatory injury in coronary artery bypass grafting surgery +circulation_biomarker_diagnosis_up hsa-mir-208a Cardiovascular Diseases [unspecific] 29506853 Plasma microRNAs reflecting cardiac and inflammatory injury in coronary artery bypass grafting surgery +circulation_biomarker_diagnosis_up hsa-mir-21 Cholangiocarcinoma 29516989 serum miR-21 was a promising biomarker for diagnosing the late stage CCA and would have potential to be a useful prognostic biomarker of CCA +circulation_biomarker_diagnosis_up hsa-mir-155 Hepatitis C Virus Infection 29528577 MicroRNA-155 is a relatively reliable marker for HCC detection +circulation_biomarker_diagnosis_up hsa-mir-208a Heart Failure 29559958 "miR-208a, a microRNA that is a key factor in promoting cardiovascular dysfunction during cardiac hypertrophy processes of heart failure, has its circulating levels increased during chronic indeterminate phase when compared to cardiac (CARD) clinical forms in patients with Chagas disease" +circulation_biomarker_diagnosis_up hsa-mir-21 Breast Neoplasms 29679553 "Assessment of miRNAs in serum samples can be applied as minimally non-invasive markers for early detection of breast cancer, and as discriminator between different clinicopathological characters" +circulation_biomarker_diagnosis_up hsa-mir-222 Breast Neoplasms 29679553 "Assessment of miRNAs in serum samples can be applied as minimally non-invasive markers for early detection of breast cancer, and as discriminator between different clinicopathological characters" +circulation_biomarker_diagnosis_up hsa-mir-373 Breast Neoplasms 29679553 "Assessment of miRNAs in serum samples can be applied as minimally non-invasive markers for early detection of breast cancer, and as discriminator between different clinicopathological characters" +circulation_biomarker_diagnosis_up hsa-mir-144 Familial Mediterranean Fever 29787577 "four miRNAs were upregulated (miR-144-3p, miR-21-5p, miR-4454, and miR-451a), and three were downregulated (miR-107, let-7d-5p, and miR-148b-3p)" +circulation_biomarker_diagnosis_up hsa-mir-21 Familial Mediterranean Fever 29787577 "four miRNAs were upregulated (miR-144-3p, miR-21-5p, miR-4454, and miR-451a), and three were downregulated (miR-107, let-7d-5p, and miR-148b-3p)" +circulation_biomarker_diagnosis_up hsa-mir-4454 Familial Mediterranean Fever 29787577 "four miRNAs were upregulated (miR-144-3p, miR-21-5p, miR-4454, and miR-451a), and three were downregulated (miR-107, let-7d-5p, and miR-148b-3p)" +circulation_biomarker_diagnosis_up hsa-mir-451a Familial Mediterranean Fever 29787577 "four miRNAs were upregulated (miR-144-3p, miR-21-5p, miR-4454, and miR-451a), and three were downregulated (miR-107, let-7d-5p, and miR-148b-3p)" +circulation_biomarker_diagnosis_up hsa-mir-21 "Leukemia, Myeloid" 29795410 MiR-21 was found to be normally upregulated in all types of ML +circulation_biomarker_diagnosis_up hsa-mir-300 Traumatic Brain Injury 29873258 miR-300-3p and miR-598-3p increased while miR-450-3p and miR-194-5p significantly decreased following TBI +circulation_biomarker_diagnosis_up hsa-mir-598 Traumatic Brain Injury 29873258 miR-300-3p and miR-598-3p increased while miR-450-3p and miR-194-5p significantly decreased following TBI +circulation_biomarker_diagnosis_up hsa-mir-195 "Diabetes Mellitus, Gestational" 29879500 "increased miRNA expression, especially miR-195-5p, in plasma is characteristic of and causally related to the development of GDM" +circulation_biomarker_diagnosis_up hsa-mir-144 "Carcinoma, Thyroid" 29885402 Evaluation of miRNAs expression in medullary thyroid carcinoma tissue samples: miR-34a and miR-144 as promising overexpressed markers in MTC. +circulation_biomarker_diagnosis_up hsa-mir-34a "Carcinoma, Thyroid" 29885402 Evaluation of miRNAs expression in medullary thyroid carcinoma tissue samples: miR-34a and miR-144 as promising overexpressed markers in MTC. +circulation_biomarker_diagnosis_up hsa-mir-223 Coronary Artery Disease 29888618 Association between elevated plasma microRNA-223 content and severity of coronary heart disease. +circulation_biomarker_diagnosis_up hsa-mir-4649 Chronic Brucellosis 29897958 The microRNA expression signature of CD4+ T cells in the transition of brucellosis into chronicity. +circulation_biomarker_diagnosis_up hsa-mir-182 Acute Lung Injury 29904430 "9 miRNAs were significantly upregulated (miR-1843-3p, miR-323-3p, miR-183-5p, miR-182 and miR-196b-3p) or downregulated (miR-547-3p, miR-301b-5p, miR-503-3p and miR-142-3p)" +circulation_biomarker_diagnosis_up hsa-mir-183 Acute Lung Injury 29904430 "9 miRNAs were significantly upregulated (miR-1843-3p, miR-323-3p, miR-183-5p, miR-182 and miR-196b-3p) or downregulated (miR-547-3p, miR-301b-5p, miR-503-3p and miR-142-3p)" +circulation_biomarker_diagnosis_up hsa-mir-1843 Acute Lung Injury 29904430 "9 miRNAs were significantly upregulated (miR-1843-3p, miR-323-3p, miR-183-5p, miR-182 and miR-196b-3p) or downregulated (miR-547-3p, miR-301b-5p, miR-503-3p and miR-142-3p)" +circulation_biomarker_diagnosis_up hsa-mir-196b Acute Lung Injury 29904430 "9 miRNAs were significantly upregulated (miR-1843-3p, miR-323-3p, miR-183-5p, miR-182 and miR-196b-3p) or downregulated (miR-547-3p, miR-301b-5p, miR-503-3p and miR-142-3p)" +circulation_biomarker_diagnosis_up hsa-mir-323 Acute Lung Injury 29904430 "9 miRNAs were significantly upregulated (miR-1843-3p, miR-323-3p, miR-183-5p, miR-182 and miR-196b-3p) or downregulated (miR-547-3p, miR-301b-5p, miR-503-3p and miR-142-3p)" +circulation_biomarker_diagnosis_up hsa-mir-135a Parkinson Disease 29935433 "We identified differential expression of 10 miRNA of which 5 were upregulated in PD (miR-9-5p, miR-135a-5p, miR-135b-5p, miR-449a, and miR-449b-5p) and 5 downregulated (miR-141-3p, miR-199a-5p, miR-299-5p, miR-518e-3p, and miR-519a-3p)" +circulation_biomarker_diagnosis_up hsa-mir-135b Parkinson Disease 29935433 "We identified differential expression of 10 miRNA of which 5 were upregulated in PD (miR-9-5p, miR-135a-5p, miR-135b-5p, miR-449a, and miR-449b-5p) and 5 downregulated (miR-141-3p, miR-199a-5p, miR-299-5p, miR-518e-3p, and miR-519a-3p)" +circulation_biomarker_diagnosis_up hsa-mir-449a Parkinson Disease 29935433 "We identified differential expression of 10 miRNA of which 5 were upregulated in PD (miR-9-5p, miR-135a-5p, miR-135b-5p, miR-449a, and miR-449b-5p) and 5 downregulated (miR-141-3p, miR-199a-5p, miR-299-5p, miR-518e-3p, and miR-519a-3p)" +circulation_biomarker_diagnosis_up hsa-mir-449b Parkinson Disease 29935433 "We identified differential expression of 10 miRNA of which 5 were upregulated in PD (miR-9-5p, miR-135a-5p, miR-135b-5p, miR-449a, and miR-449b-5p) and 5 downregulated (miR-141-3p, miR-199a-5p, miR-299-5p, miR-518e-3p, and miR-519a-3p)" +circulation_biomarker_diagnosis_up hsa-mir-9 Parkinson Disease 29935433 "We identified differential expression of 10 miRNA of which 5 were upregulated in PD (miR-9-5p, miR-135a-5p, miR-135b-5p, miR-449a, and miR-449b-5p) and 5 downregulated (miR-141-3p, miR-199a-5p, miR-299-5p, miR-518e-3p, and miR-519a-3p)" +circulation_biomarker_diagnosis_up hsa-mir-101a Peripheral Nerve Injury 29960630 "4 miRs (miR-101a, miR-138, miR-338, and miR-142) levels were finally validated for over-expression by quantitative (PCR) reaction" +circulation_biomarker_diagnosis_up hsa-mir-138 Peripheral Nerve Injury 29960630 "4 miRs (miR-101a, miR-138, miR-338, and miR-142) levels were finally validated for over-expression by quantitative (PCR) reaction" +circulation_biomarker_diagnosis_up hsa-mir-142 Peripheral Nerve Injury 29960630 "4 miRs (miR-101a, miR-138, miR-338, and miR-142) levels were finally validated for over-expression by quantitative (PCR) reaction" +circulation_biomarker_diagnosis_up hsa-mir-338 Peripheral Nerve Injury 29960630 "4 miRs (miR-101a, miR-138, miR-338, and miR-142) levels were finally validated for over-expression by quantitative (PCR) reaction" +circulation_biomarker_diagnosis_up hsa-mir-551b Acute Pancreatitis 29989302 Elevated Level of miR-551b-5p is Associated With Inflammation and Disease Progression in Patients With Severe Acute Pancreatitis. +circulation_biomarker_diagnosis_up hsa-mir-133a Glycogen Storage Disease II 29997386 miR-133a levels were significantly higher in Pompe disease patients than in controls and correlated with phenotype severity +circulation_biomarker_diagnosis_up hsa-mir-221 Hypertrophy 30009269 an elevated miR-221 level is potentially associated with an increased risk of SCD in subjects with cardiac hypertrophy +circulation_biomarker_diagnosis_up hsa-mir-10a Diabetic Nephropathy 30019103 "three up-regulated (miR-21-5p, miR-146a-5p, miR-10a-5p) and two down-regulated (miR-25-3p and miR-26a-5p) miRNAs" +circulation_biomarker_diagnosis_up hsa-mir-146a Diabetic Nephropathy 30019103 "three up-regulated (miR-21-5p, miR-146a-5p, miR-10a-5p) and two down-regulated (miR-25-3p and miR-26a-5p) miRNAs" +circulation_biomarker_diagnosis_up hsa-mir-21 Diabetic Nephropathy 30019103 "three up-regulated (miR-21-5p, miR-146a-5p, miR-10a-5p) and two down-regulated (miR-25-3p and miR-26a-5p) miRNAs" +circulation_biomarker_diagnosis_up hsa-mir-462a Anemia 30041004 "two miRNAs, miR-462a-5p and miR-125b-5p, showed increased and decreased expression, respectively, during ISAV infection" +circulation_biomarker_diagnosis_up hsa-mir-103 Colorectal Carcinoma 30058684 Upregulation of serum miR-103 predicts unfavorable prognosis in patients with colorectal cancer. +circulation_biomarker_diagnosis_up hsa-mir-100 "Squamous Cell Carcinoma, Esophageal" 30127929 "Among the 5 miRNAs considered (miR-21, miR-223, miR-375, miR-25 and miR-100), miR-21 and miR-223 were significantly overexpressed whereas miR-375 expression was reduced in patients with ESCC compared with healthy individuals" +circulation_biomarker_diagnosis_up hsa-mir-21 "Squamous Cell Carcinoma, Esophageal" 30127929 "Among the 5 miRNAs considered (miR-21, miR-223, miR-375, miR-25 and miR-100), miR-21 and miR-223 were significantly overexpressed whereas miR-375 expression was reduced in patients with ESCC compared with healthy individuals" +circulation_biomarker_diagnosis_up hsa-mir-223 "Squamous Cell Carcinoma, Esophageal" 30127929 "Among the 5 miRNAs considered (miR-21, miR-223, miR-375, miR-25 and miR-100), miR-21 and miR-223 were significantly overexpressed whereas miR-375 expression was reduced in patients with ESCC compared with healthy individuals" +circulation_biomarker_diagnosis_up hsa-mir-25 "Squamous Cell Carcinoma, Esophageal" 30127929 "Among the 5 miRNAs considered (miR-21, miR-223, miR-375, miR-25 and miR-100), miR-21 and miR-223 were significantly overexpressed whereas miR-375 expression was reduced in patients with ESCC compared with healthy individuals" +circulation_biomarker_diagnosis_up hsa-mir-125b Multiple Myeloma 30128020 The diagnostic and prognostic value of plasma microRNA-125b-5p in patients with multiple myeloma. +circulation_biomarker_diagnosis_up hsa-mir-221 Rheumatoid Arthritis 30132091 Upregulation of miR-221/222 expression in rheumatoid arthritis (RA) patients: correlation with disease activity. +circulation_biomarker_diagnosis_up hsa-mir-222 Rheumatoid Arthritis 30132091 Upregulation of miR-221/222 expression in rheumatoid arthritis (RA) patients: correlation with disease activity. +circulation_biomarker_diagnosis_up hsa-mir-1255a Stroke 30135469 "six microRNAs showed significantly increased expression - miR-371-3p, miR-524, miR-520g, miR-1255A, miR-453, and miR-583, while 3 showed significantly decreased expression - miR-941, miR-449b, and miR-581" +circulation_biomarker_diagnosis_up hsa-mir-371 Stroke 30135469 "six microRNAs showed significantly increased expression - miR-371-3p, miR-524, miR-520g, miR-1255A, miR-453, and miR-583, while 3 showed significantly decreased expression - miR-941, miR-449b, and miR-581" +circulation_biomarker_diagnosis_up hsa-mir-453 Stroke 30135469 "six microRNAs showed significantly increased expression - miR-371-3p, miR-524, miR-520g, miR-1255A, miR-453, and miR-583, while 3 showed significantly decreased expression - miR-941, miR-449b, and miR-581" +circulation_biomarker_diagnosis_up hsa-mir-520g Stroke 30135469 "six microRNAs showed significantly increased expression - miR-371-3p, miR-524, miR-520g, miR-1255A, miR-453, and miR-583, while 3 showed significantly decreased expression - miR-941, miR-449b, and miR-581" +circulation_biomarker_diagnosis_up hsa-mir-524 Stroke 30135469 "six microRNAs showed significantly increased expression - miR-371-3p, miR-524, miR-520g, miR-1255A, miR-453, and miR-583, while 3 showed significantly decreased expression - miR-941, miR-449b, and miR-581" +circulation_biomarker_diagnosis_up hsa-mir-583 Stroke 30135469 "six microRNAs showed significantly increased expression - miR-371-3p, miR-524, miR-520g, miR-1255A, miR-453, and miR-583, while 3 showed significantly decreased expression - miR-941, miR-449b, and miR-581" +circulation_biomarker_diagnosis_up hsa-mir-125a "Diabetes Mellitus, Type 2" 30150203 Up regulation of miR-125a in WAT of type 2 Diabetes mellitus have been observed +circulation_biomarker_diagnosis_up hsa-mir-148a Prostate Neoplasms 30160020 Increased levels of serum miR-148a-3p are associated with prostate cancer. +circulation_biomarker_diagnosis_up hsa-mir-122 Obesity 30160046 Pilot study on circulating miRNA signature in children with obesity born small for gestational age and appropriate for gestational age. +circulation_biomarker_diagnosis_up hsa-mir-423 Obesity 30160046 Pilot study on circulating miRNA signature in children with obesity born small for gestational age and appropriate for gestational age. +circulation_biomarker_diagnosis_up hsa-mir-484 Obesity 30160046 Pilot study on circulating miRNA signature in children with obesity born small for gestational age and appropriate for gestational age. +circulation_biomarker_diagnosis_up hsa-mir-486 Obesity 30160046 Pilot study on circulating miRNA signature in children with obesity born small for gestational age and appropriate for gestational age. +circulation_biomarker_diagnosis_up hsa-mir-532 Obesity 30160046 Pilot study on circulating miRNA signature in children with obesity born small for gestational age and appropriate for gestational age. +circulation_biomarker_diagnosis_up hsa-mir-92a Obesity 30160046 Pilot study on circulating miRNA signature in children with obesity born small for gestational age and appropriate for gestational age. +circulation_biomarker_diagnosis_up hsa-let-7i Diabetic Nephropathy 30165157 "a urinary EV miRNA signature was found to comprise increased levels of let-7i-3p, miR-24-3p and miR-27b-3p, and decreased levels of miR-15b-5p, to identify patients with MIC" +circulation_biomarker_diagnosis_up hsa-mir-24 Diabetic Nephropathy 30165157 "a urinary EV miRNA signature was found to comprise increased levels of let-7i-3p, miR-24-3p and miR-27b-3p, and decreased levels of miR-15b-5p, to identify patients with MIC" +circulation_biomarker_diagnosis_up hsa-mir-27b Diabetic Nephropathy 30165157 "a urinary EV miRNA signature was found to comprise increased levels of let-7i-3p, miR-24-3p and miR-27b-3p, and decreased levels of miR-15b-5p, to identify patients with MIC" +circulation_biomarker_diagnosis_up hsa-mir-21 Diabetic Nephropathy 30167868 "In the validation sample, miR-21-3p and miR-378-3p were confirmed to be upregulated in patients with severe DKD, while miR-16-5p and miR-29a-3p were downregulated in this group compared to T1DM controls and patients with moderate DKD" +circulation_biomarker_diagnosis_up hsa-mir-378 Diabetic Nephropathy 30167868 "In the validation sample, miR-21-3p and miR-378-3p were confirmed to be upregulated in patients with severe DKD, while miR-16-5p and miR-29a-3p were downregulated in this group compared to T1DM controls and patients with moderate DKD" +circulation_biomarker_diagnosis_up hsa-mir-203 "Carcinoma, Cervical" 30191988 "The upregulation of some circulating miRNAs, for example, miRNA-20a, miRNA-203, miRNA-21, miRNA-205, miRNA-218, and miR-485-5, as well as tissue-specific miRNAs, for example, miR-7, miR-10a, miR-17-5p, miR-135b, miR-149, and miR-203 have been found in patients with CC" +circulation_biomarker_diagnosis_up hsa-mir-205 "Carcinoma, Cervical" 30191988 "The upregulation of some circulating miRNAs, for example, miRNA-20a, miRNA-203, miRNA-21, miRNA-205, miRNA-218, and miR-485-5, as well as tissue-specific miRNAs, for example, miR-7, miR-10a, miR-17-5p, miR-135b, miR-149, and miR-203 have been found in patients with CC" +circulation_biomarker_diagnosis_up hsa-mir-20a "Carcinoma, Cervical" 30191988 "The upregulation of some circulating miRNAs, for example, miRNA-20a, miRNA-203, miRNA-21, miRNA-205, miRNA-218, and miR-485-5, as well as tissue-specific miRNAs, for example, miR-7, miR-10a, miR-17-5p, miR-135b, miR-149, and miR-203 have been found in patients with CC" +circulation_biomarker_diagnosis_up hsa-mir-21 "Carcinoma, Cervical" 30191988 "The upregulation of some circulating miRNAs, for example, miRNA-20a, miRNA-203, miRNA-21, miRNA-205, miRNA-218, and miR-485-5, as well as tissue-specific miRNAs, for example, miR-7, miR-10a, miR-17-5p, miR-135b, miR-149, and miR-203 have been found in patients with CC" +circulation_biomarker_diagnosis_up hsa-mir-218 "Carcinoma, Cervical" 30191988 "The upregulation of some circulating miRNAs, for example, miRNA-20a, miRNA-203, miRNA-21, miRNA-205, miRNA-218, and miR-485-5, as well as tissue-specific miRNAs, for example, miR-7, miR-10a, miR-17-5p, miR-135b, miR-149, and miR-203 have been found in patients with CC" +circulation_biomarker_diagnosis_up hsa-mir-485 "Carcinoma, Cervical" 30191988 "The upregulation of some circulating miRNAs, for example, miRNA-20a, miRNA-203, miRNA-21, miRNA-205, miRNA-218, and miR-485-5, as well as tissue-specific miRNAs, for example, miR-7, miR-10a, miR-17-5p, miR-135b, miR-149, and miR-203 have been found in patients with CC" +circulation_biomarker_diagnosis_up hsa-mir-20a "Diabetes Mellitus, Type 1" 30194557 "Increased expression of microRNAs, miR-20a and miR-326 in PBMCs of patients with type 1 diabetes." +circulation_biomarker_diagnosis_up hsa-mir-326 "Diabetes Mellitus, Type 1" 30194557 "Increased expression of microRNAs, miR-20a and miR-326 in PBMCs of patients with type 1 diabetes." +circulation_biomarker_diagnosis_up hsa-mir-150 "Diabetes Mellitus, Type 2" 30195754 "Cox regression analyses showed that patients with low miR-103, miR-28-3p, miR-29a, and miR-9 and high miR-30a-5p and miR-150 circulating levels have a higher risk of disease" +circulation_biomarker_diagnosis_up hsa-mir-30a "Diabetes Mellitus, Type 2" 30195754 "Cox regression analyses showed that patients with low miR-103, miR-28-3p, miR-29a, and miR-9 and high miR-30a-5p and miR-150 circulating levels have a higher risk of disease" +circulation_biomarker_diagnosis_up hsa-mir-126 Obesity 30248300 Circulating microRNAs are upregulated following acute aerobic exercise in obese individuals. +circulation_biomarker_diagnosis_up hsa-mir-130b Obesity 30248300 Circulating microRNAs are upregulated following acute aerobic exercise in obese individuals. +circulation_biomarker_diagnosis_up hsa-mir-21 Obesity 30248300 Circulating microRNAs are upregulated following acute aerobic exercise in obese individuals. +circulation_biomarker_diagnosis_up hsa-mir-221 Obesity 30248300 Circulating microRNAs are upregulated following acute aerobic exercise in obese individuals. +circulation_biomarker_diagnosis_up hsa-mir-222 Obesity 30248300 Circulating microRNAs are upregulated following acute aerobic exercise in obese individuals. +circulation_biomarker_diagnosis_up hsa-mir-26a Parkinson Disease 30267378 "Parkinsonian rats presented a significant increase in miR-26a and miR-34a, while miR-7 and Let7a were downregulated" +circulation_biomarker_diagnosis_up hsa-mir-34a Parkinson Disease 30267378 "Parkinsonian rats presented a significant increase in miR-26a and miR-34a, while miR-7 and Let7a were downregulated" +circulation_biomarker_diagnosis_up hsa-mir-1 Hyperactivity Disorder 30270454 "three miRNAs (miR-1-b, miR-741-3p, and miR-206-3p) were upregulated and four (miR-182, miR-471-5p, miR-183-5p, and miR-211-5p) were downregulated in the SHR group compared with the WKY group" +circulation_biomarker_diagnosis_up hsa-mir-206 Hyperactivity Disorder 30270454 "three miRNAs (miR-1-b, miR-741-3p, and miR-206-3p) were upregulated and four (miR-182, miR-471-5p, miR-183-5p, and miR-211-5p) were downregulated in the SHR group compared with the WKY group" +circulation_biomarker_diagnosis_up hsa-mir-741 Hyperactivity Disorder 30270454 "three miRNAs (miR-1-b, miR-741-3p, and miR-206-3p) were upregulated and four (miR-182, miR-471-5p, miR-183-5p, and miR-211-5p) were downregulated in the SHR group compared with the WKY group" +circulation_biomarker_diagnosis_up hsa-mir-106b Preeclampsia 30277561 "There was significant upregulation of miR-106b and miR-326 ( p?=?0.0048 and 0.028, respectively) in PE patients in comparison with the control group" +circulation_biomarker_diagnosis_up hsa-mir-326 Preeclampsia 30277561 "There was significant upregulation of miR-106b and miR-326 ( p?=?0.0048 and 0.028, respectively) in PE patients in comparison with the control group" +circulation_biomarker_diagnosis_up hsa-mir-1260b Aplastic Anemia 30298490 expression of miR-155-5p and miR-1260b were increased in both CAA and SAA patients compared with the normal controls +circulation_biomarker_diagnosis_up hsa-mir-155 Aplastic Anemia 30298490 expression of miR-155-5p and miR-1260b were increased in both CAA and SAA patients compared with the normal controls +circulation_biomarker_diagnosis_up hsa-mir-30a Heart Diseases [unspecific] 30308506 "Five miRNAs were upregulated (hsa-miR-4508, hsa-miR-novel-chr8_87373, hsa-miR-30a-3p, hsa-miR-novel-chr16_26099, hsa-miR-4306) and seven miRNAs (hsa-miR-744-5p, hsa-miR-320a, hsa-miR-novel-chr9_90035, hsa-miR-101-3p, hsa-miR-150-5p, hsa-miR-342-3p, and hsa-miR-140-3p) were downregulated" +circulation_biomarker_diagnosis_up hsa-mir-4306 Heart Diseases [unspecific] 30308506 "Five miRNAs were upregulated (hsa-miR-4508, hsa-miR-novel-chr8_87373, hsa-miR-30a-3p, hsa-miR-novel-chr16_26099, hsa-miR-4306) and seven miRNAs (hsa-miR-744-5p, hsa-miR-320a, hsa-miR-novel-chr9_90035, hsa-miR-101-3p, hsa-miR-150-5p, hsa-miR-342-3p, and hsa-miR-140-3p) were downregulated" +circulation_biomarker_diagnosis_up hsa-mir-4508 Heart Diseases [unspecific] 30308506 "Five miRNAs were upregulated (hsa-miR-4508, hsa-miR-novel-chr8_87373, hsa-miR-30a-3p, hsa-miR-novel-chr16_26099, hsa-miR-4306) and seven miRNAs (hsa-miR-744-5p, hsa-miR-320a, hsa-miR-novel-chr9_90035, hsa-miR-101-3p, hsa-miR-150-5p, hsa-miR-342-3p, and hsa-miR-140-3p) were downregulated" +circulation_biomarker_diagnosis_up hsa-mir-130 Metabolic Syndrome 30309709 "increased concentrations of miRNAS; miR-142-3p, miR-140-5p, miR-222 miR-143, miR-130, and decreased concentrations of miR-532-5p, miR-423-5p,miR-520c-3p, miR-146a, and miR-15a" +circulation_biomarker_diagnosis_up hsa-mir-140 Metabolic Syndrome 30309709 "increased concentrations of miRNAS; miR-142-3p, miR-140-5p, miR-222 miR-143, miR-130, and decreased concentrations of miR-532-5p, miR-423-5p,miR-520c-3p, miR-146a, and miR-15a" +circulation_biomarker_diagnosis_up hsa-mir-142 Metabolic Syndrome 30309709 "increased concentrations of miRNAS; miR-142-3p, miR-140-5p, miR-222 miR-143, miR-130, and decreased concentrations of miR-532-5p, miR-423-5p,miR-520c-3p, miR-146a, and miR-15a" +circulation_biomarker_diagnosis_up hsa-mir-143 Metabolic Syndrome 30309709 "increased concentrations of miRNAS; miR-142-3p, miR-140-5p, miR-222 miR-143, miR-130, and decreased concentrations of miR-532-5p, miR-423-5p,miR-520c-3p, miR-146a, and miR-15a" +circulation_biomarker_diagnosis_up hsa-mir-222 Metabolic Syndrome 30309709 "increased concentrations of miRNAS; miR-142-3p, miR-140-5p, miR-222 miR-143, miR-130, and decreased concentrations of miR-532-5p, miR-423-5p,miR-520c-3p, miR-146a, and miR-15a" +circulation_biomarker_diagnosis_up hsa-mir-135b Colon Neoplasms 30311185 "the expression of the miR-135b, miR-155, and KRAS was increased in the AOM group compared to the control group in both the plasma and the colon tissue samples" +circulation_biomarker_diagnosis_up hsa-mir-155 Colon Neoplasms 30311185 "the expression of the miR-135b, miR-155, and KRAS was increased in the AOM group compared to the control group in both the plasma and the colon tissue samples" +circulation_biomarker_diagnosis_up hsa-mir-144 Atopic Dermatitis 30312706 Hsa-mir-144-3p is increased in umbilical cord serum of infants developing atopic dermatitis. +circulation_biomarker_diagnosis_up hsa-mir-106b Behcet Disease 30317557 "T-cell-associated miRNA expression levels, miR-25, miR-106b, miR-326, and miR-93 were significantly upregulated, while miR-146a and miR-155 levels were lower in PBMCs of patients with BD" +circulation_biomarker_diagnosis_up hsa-mir-25 Behcet Disease 30317557 "T-cell-associated miRNA expression levels, miR-25, miR-106b, miR-326, and miR-93 were significantly upregulated, while miR-146a and miR-155 levels were lower in PBMCs of patients with BD" +circulation_biomarker_diagnosis_up hsa-mir-326 Behcet Disease 30317557 "T-cell-associated miRNA expression levels, miR-25, miR-106b, miR-326, and miR-93 were significantly upregulated, while miR-146a and miR-155 levels were lower in PBMCs of patients with BD" +circulation_biomarker_diagnosis_up hsa-mir-93 Behcet Disease 30317557 "T-cell-associated miRNA expression levels, miR-25, miR-106b, miR-326, and miR-93 were significantly upregulated, while miR-146a and miR-155 levels were lower in PBMCs of patients with BD" +circulation_biomarker_diagnosis_up hsa-mir-339 Amyloidosis 30332417 MiR-339-3p was increased in blood of patients with senile cardiac amyloidosis +circulation_biomarker_diagnosis-down hsa-mir-181b Obesity 30160046 Pilot study on circulating miRNA signature in children with obesity born small for gestational age and appropriate for gestational age. +circulation_biomarker_prognosis_down hsa-mir-326 Multiple Sclerosis 25642434 "Our longitudinal analysis revealed that miR-18a, miR-20b, miR-29a, and miR-103 were upregulated and predominantly expressed by CD4(+) T cells, whereas miR-326 was downregulated upon natalizumab treatment." +circulation_biomarker_prognosis_down hsa-let-7a-1 Lung Neoplasms 17940623 Studies by Takamizawa et al. and Yanaihara et al. have presented evidence that transcripts of certain let-7 homologs are significantly downregulated in human lung cancer and that low levels of let-7 correlate with poor prognosis. +circulation_biomarker_prognosis_down hsa-let-7a-2 Lung Neoplasms 17940623 Studies by Takamizawa et al. and Yanaihara et al. have presented evidence that transcripts of certain let-7 homologs are significantly downregulated in human lung cancer and that low levels of let-7 correlate with poor prognosis. +circulation_biomarker_prognosis_down hsa-let-7a-3 Lung Neoplasms 17940623 Studies by Takamizawa et al. and Yanaihara et al. have presented evidence that transcripts of certain let-7 homologs are significantly downregulated in human lung cancer and that low levels of let-7 correlate with poor prognosis. +circulation_biomarker_prognosis_down hsa-let-7b Lung Neoplasms 17940623 Studies by Takamizawa et al. and Yanaihara et al. have presented evidence that transcripts of certain let-7 homologs are significantly downregulated in human lung cancer and that low levels of let-7 correlate with poor prognosis. +circulation_biomarker_prognosis_down hsa-let-7c Lung Neoplasms 17940623 Studies by Takamizawa et al. and Yanaihara et al. have presented evidence that transcripts of certain let-7 homologs are significantly downregulated in human lung cancer and that low levels of let-7 correlate with poor prognosis. +circulation_biomarker_prognosis_down hsa-let-7d Lung Neoplasms 17940623 Studies by Takamizawa et al. and Yanaihara et al. have presented evidence that transcripts of certain let-7 homologs are significantly downregulated in human lung cancer and that low levels of let-7 correlate with poor prognosis. +circulation_biomarker_prognosis_down hsa-let-7e Lung Neoplasms 17940623 Studies by Takamizawa et al. and Yanaihara et al. have presented evidence that transcripts of certain let-7 homologs are significantly downregulated in human lung cancer and that low levels of let-7 correlate with poor prognosis. +circulation_biomarker_prognosis_down hsa-let-7f-1 Lung Neoplasms 17940623 Studies by Takamizawa et al. and Yanaihara et al. have presented evidence that transcripts of certain let-7 homologs are significantly downregulated in human lung cancer and that low levels of let-7 correlate with poor prognosis. +circulation_biomarker_prognosis_down hsa-let-7f-2 Lung Neoplasms 17940623 Studies by Takamizawa et al. and Yanaihara et al. have presented evidence that transcripts of certain let-7 homologs are significantly downregulated in human lung cancer and that low levels of let-7 correlate with poor prognosis. +circulation_biomarker_prognosis_down hsa-let-7g Lung Neoplasms 17940623 Studies by Takamizawa et al. and Yanaihara et al. have presented evidence that transcripts of certain let-7 homologs are significantly downregulated in human lung cancer and that low levels of let-7 correlate with poor prognosis. +circulation_biomarker_prognosis_down hsa-let-7i Lung Neoplasms 17940623 Studies by Takamizawa et al. and Yanaihara et al. have presented evidence that transcripts of certain let-7 homologs are significantly downregulated in human lung cancer and that low levels of let-7 correlate with poor prognosis. +circulation_biomarker_prognosis_down hsa-mir-9-1 Waldenstrom Macroglobulinemia 19074725 miR-9*: decreased expression +circulation_biomarker_prognosis_down hsa-mir-9-2 Waldenstrom Macroglobulinemia 19074725 miR-9*: decreased expression +circulation_biomarker_prognosis_down hsa-mir-9-3 Waldenstrom Macroglobulinemia 19074725 miR-9*: decreased expression +circulation_biomarker_prognosis_down hsa-mir-195 Breast Neoplasms 20134314 circulating levels of miR-195 and let-7a decreased in cancer patients postoperatively +circulation_biomarker_prognosis_down hsa-mir-296 Colon Neoplasms 22892953 Decrease in blood miR-296 predicts chemotherapy resistance and poor clinical outcome in patients receiving systemic chemotherapy for metastatic colon cancer. +circulation_biomarker_prognosis_down hsa-mir-100 Urinary Bladder Cancer 23173870 Reduced expression of microRNA-100 confers unfavorable prognosis in patients with bladder cancer +circulation_biomarker_prognosis_down hsa-mir-150 Hypertension 23220912 Reduced miR-150 is Associated with Poor Survival in Pulmonary Arterial Hypertension +circulation_biomarker_prognosis_down hsa-mir-129-1 "Lymphoma, Large B-Cell, Diffuse" 23463124 Low expression of microRNA-129-5p predicts poor clinical outcome in diffuse large B cell lymphoma (DLBCL) +circulation_biomarker_prognosis_down hsa-mir-129-2 "Lymphoma, Large B-Cell, Diffuse" 23463124 Low expression of microRNA-129-5p predicts poor clinical outcome in diffuse large B cell lymphoma (DLBCL) +circulation_biomarker_prognosis_down hsa-mir-100 "Carcinoma, Hepatocellular" 23842624 Downregulation of microRNA-100 correlates with tumor progression and poor prognosis in hepatocellular carcinoma. +circulation_biomarker_prognosis_down hsa-mir-150 Myocardial Infarction 23967079 "We enrolled 150 patients after AMI. Blood samples were obtained at discharge for determination of N-terminal pro-brain natriuretic peptide (Nt-proBNP) and levels of miR-16, miR-27a, miR-101 and miR-150." +circulation_biomarker_prognosis_down hsa-mir-124-1 "Leukemia, Myeloid, Acute" 24135052 These findings suggest that miR-124-1 underexpression is a common event and might have a favorable impact on prognosis in AML. +circulation_biomarker_prognosis_down hsa-mir-34a Gastric Neoplasms 24232982 "Decreased miR-34a expression and increased FOXP1, p53, and BCL2 coexpression to predict a poor OS for MALT lymphoma and DLBCL patients could become very important prognostic markers in daily clinical work. Further investigation of these changes may be of prognostic significance in clinical practice." +circulation_biomarker_prognosis_down hsa-mir-146b "Lymphoma, Large B-Cell, Diffuse" 24931464 "Low expression of microRNA-146b-5p and microRNA-320d predicts poor outcome of large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine,and prednisone." +circulation_biomarker_prognosis_down hsa-mir-320d "Lymphoma, Large B-Cell, Diffuse" 24931464 "Low expression of microRNA-146b-5p and microRNA-320d predicts poor outcome of large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine,and prednisone." +circulation_biomarker_prognosis_down hsa-mir-19a Myeloma 25220540 Low serum miR-19a expression as a novel poor prognostic indicator in multiple myeloma. +circulation_biomarker_prognosis_down hsa-let-7g "Squamous Cell Carcinoma, Head and Neck" 25677760 "decreased expressions of miR-153, miR-200c, miR-363, miR-203, miR-17, miR-205, miR-Let-7d, Let-7g, miR-34a, miR-126a, miR-375, miR-491-p5, miR 218, miR-451 and miR-125b were associated with poor prognosis." +circulation_biomarker_prognosis_down hsa-mir-204 "Leukemia, Myeloid, Acute" 26126974 We showed low miR-204 expression in AML and found it to be an independent prognostic factor in this patient population. +circulation_biomarker_prognosis_down hsa-mir-328 "Leukemia, Myeloid, Acute" 26185105 Low expression of circulating microRNA-328 is associated with poor prognosis in patients with acute myeloid leukemia. +circulation_biomarker_prognosis_down hsa-mir-128 Prostate Neoplasms 26339409 "Our data suggest that the decreased expression of miR-128 in both tissue and serum samples of PCa patients may be associated with tumor malignant progression and BCR-free survival. Particularly, serum miR-128 may be developed as a novel noninvasive biomarker for PCa diagnosis and prognosis." +circulation_biomarker_prognosis_down hsa-mir-153 "Carcinoma, Lung, Non-Small-Cell" 26339455 "Decreased expression of miR-153 might be a potential unfavorable prognostic factor for patients with NSCLC, and further studies would be needed to prove our findings." +circulation_biomarker_prognosis_down hsa-mir-17 Preeclampsia 26339600 "ur data indicate that short-term exposure of 3A villous first trimester trophoblasts to H2O2 significantly alters miRNA profile and mRNA expression of genes implicated in defective placental development. Our data, which indicate that oxidative stress alters miRNAs and RNAs expression, could partially explain some of the early changes in gene expression profiles and miRNA observed in PE." +circulation_biomarker_prognosis_down hsa-mir-204 "Carcinoma, Lung, Non-Small-Cell" 26497897 Decreased expression of miR-204 in plasma is associated with a poor prognosis in patients with non-small cell lung cancer. +circulation_biomarker_prognosis_down hsa-mir-1 "Carcinoma, Hepatocellular" 26554254 Low miR-1 expression is associated with shortened survival time.MiR-1 may act as a potential prognostic biomarker for HCC patients. +circulation_biomarker_prognosis_down hsa-mir-1 Acute Heart Failure 26580972 admission levels of miR-1 were lower in AHF and stable CHF patients compared to non-AHF patients +circulation_biomarker_prognosis_down hsa-mir-218 "Carcinoma, Hepatocellular" 26586116 "Consequently, our findings revealed that serum miR-218 levels were remarkably underexpressed in HCC patients as compared to BLD patients and healthy controls." +circulation_biomarker_prognosis_down hsa-mir-100 Bladder Neoplasms 26662386 "The present study demonstrated that the downregulation of miR-100 was associated with advanced clinical features and poor prognosis for bladder cancer patients, suggesting that miR-100 downregulation may be used as an unfavorable prognostic biomarker in bladder cancer." +circulation_biomarker_prognosis_down hsa-mir-215 "Leukemia, Myeloid, Acute" 26802165 Our study demonstrates that reduced microRNA-215 expression is a common event and is associated with poor clinical outcome in acute myeloid leukemia. +circulation_biomarker_prognosis_down hsa-mir-16 Colorectal Carcinoma 26934556 Serum miR-16 levels were significantly lower in the high blood glucose patients +circulation_biomarker_prognosis_down hsa-mir-199a Ovarian Neoplasms 26951510 Expression of miR-199a was found to be significantly downregulated in comparison with matched normal controls. +circulation_biomarker_prognosis_down hsa-mir-200a Choriocarcinoma 27081702 "Eleven miRNAs were significantly different between R and NR (miR-154, miR-409-3p, miR-127-3p, miR-214*, miR-299-5p and miR-125b overexpressed in NR; miR-33a, miR-30e, miR-338-3p, miR-200a and miR-378 decreased)." +circulation_biomarker_prognosis_down hsa-mir-34a "Adenocarcinoma, Pancreatic Ductal" 27458977 "A loss of expression of miR-34a, but not of miR-150, is associated with disease progression and poor prognosis in PDAC patients, and may be involved in the chemoresistance of PDAC cells." +circulation_biomarker_prognosis_down hsa-mir-145 "Carcinoma, Gastric" 27460730 "MiR-145-5p is down-expressed in GC, and can be used as a marker of poor prognosis in GC patients." +circulation_biomarker_prognosis_down hsa-mir-1300 "Carcinoma, Colon" 27485175 Low expression of miR-1300 and miR-939 was significantly correlated with shorter distant metastasis-free survival (DMFS) in Cox univariate analysis (p.adjusted = 0.049). +circulation_biomarker_prognosis_down hsa-mir-939 "Carcinoma, Colon" 27485175 Low expression of miR-1300 and miR-939 was significantly correlated with shorter distant metastasis-free survival (DMFS) in Cox univariate analysis (p.adjusted = 0.049). +circulation_biomarker_prognosis_down hsa-mir-126 Arteriosclerosis Obliterans 27497911 "Furthermore, plasma miR-126-5p levels were significantly down-regulated in CAD patients with multi-vessel disease, higher SYNTAX score, rather than isolated LMCA and low SYNTAX score." +circulation_biomarker_prognosis_down hsa-mir-126 Coronary Artery Disease 27497911 "Furthermore, plasma miR-126-5p levels were significantly down-regulated in CAD patients with multi-vessel disease, higher SYNTAX score, rather than isolated LMCA and low SYNTAX score." +circulation_biomarker_prognosis_down hsa-mir-126 Myocardial Infarction 27497911 "Furthermore, plasma miR-126-5p levels were significantly down-regulated in CAD patients with multi-vessel disease, higher SYNTAX score, rather than isolated LMCA and low SYNTAX score." +circulation_biomarker_prognosis_down hsa-mir-30c "Carcinoma, Lung, Non-Small-Cell" 27506865 MiR-30c-2* negative regulated MTA-1 expression involved in metastasis and drug resistance of HPV-infected non-small cell lung cancer. +circulation_biomarker_prognosis_down hsa-mir-30c Human Papilloma Virus Infection 27506865 MiR-30c-2* negative regulated MTA-1 expression involved in metastasis and drug resistance of HPV-infected non-small cell lung cancer. +circulation_biomarker_prognosis_down hsa-mir-29c "Carcinoma, Hepatocellular" 27525839 Our findings demonstrate that miR-29c expression is significantly downregulated in HCC patients and that miR-29c can act as an independent predictor of unfavorable clinical outcome. +circulation_biomarker_prognosis_down hsa-mir-135a "Carcinoma, Lung, Non-Small-Cell" 27525941 "the serum miR-135a level was downregulated in NSCLC patients, and was associated with poor prognosis." +circulation_biomarker_prognosis_down hsa-mir-148a Gastric Neoplasms 27529338 Down-regulation of miR-26a and miR-148a was significantly associated with shorter OS of GC patients +circulation_biomarker_prognosis_down hsa-mir-26a Gastric Neoplasms 27529338 Down-regulation of miR-26a and miR-148a was significantly associated with shorter OS of GC patients +circulation_biomarker_prognosis_down hsa-mir-218 Neoplasms [unspecific] 27631228 Prognostic significance of low microRNA-218 expression in patients with different types of cancer: Evidence from published studies. +circulation_biomarker_prognosis_down hsa-mir-99a "Carcinoma, Breast" 27706621 Low levels of serum miR-99a is a predictor of poor prognosis in breast cancer. +circulation_biomarker_prognosis_down hsa-mir-146a Coronary Artery Disease 28050558 Reduced Plasma miR-146a Is a Predictor of Poor Coronary Collateral Circulation in Patients with Coronary Artery Disease. +circulation_biomarker_prognosis_down hsa-let-7i "Leukemia, Myeloid, Chronic" 28512058 Downregulation of miR-224 and let-7i contribute to cell survival and chemoresistance in chronic myeloid leukemia cells by regulating ST3GAL IV expression. +circulation_biomarker_prognosis_down hsa-mir-224 "Leukemia, Myeloid, Chronic" 28512058 Downregulation of miR-224 and let-7i contribute to cell survival and chemoresistance in chronic myeloid leukemia cells by regulating ST3GAL IV expression. +circulation_biomarker_prognosis_down hsa-mir-19a Breast Neoplasms 29189128 "up-regulation of miR181b, miR-34a, miR-16, miR-15a and miR-146b-5p, and down-regulation of miR-19a and miR-19b have been shown following the treatment of several breast cancer cell lines with curcumin" +circulation_biomarker_prognosis_down hsa-mir-19b Breast Neoplasms 29189128 "up-regulation of miR181b, miR-34a, miR-16, miR-15a and miR-146b-5p, and down-regulation of miR-19a and miR-19b have been shown following the treatment of several breast cancer cell lines with curcumin" +circulation_biomarker_prognosis_down hsa-mir-122 "Leukemia, Myeloid, Acute" 29627222 Lower expression of bone marrow miR-122 is an independent risk factor for overall survival in cytogenetically normal acute myeloid leukemia. +circulation_biomarker_prognosis_down hsa-mir-21 Atrial Fibrillation 29676832 "The miRNAs had different expression profiles dependent on the AF condition, with higher expression in the acute new-onset AF than well-controlled AF" +circulation_biomarker_prognosis_down hsa-mir-451 "Carcinoma, Breast" 30099860 "baseline miR-222 overexpression, C2 miR-20a up-regulation and C2 miR-451 down-regulation were predictive markers of response to NCT in HR+/HER2- breast cancer" +circulation_biomarker_prognosis_down hsa-mir-146a Osteoarthritis 30105874 "Circulating miRNA expression profiles act as important roles in knee OA patients underwent celecoxib treatment, and miR-126-5p, miR-320a as well as miR-146a-5p might correlate with treatment response to celecoxib" +circulation_biomarker_prognosis_down hsa-mir-130b "Carcinoma, Breast" 30109140 "postoperatively downregulated circulating miR-130b-5p, miR-151a-5p, miR-206, and miR-222-3p may be potential biomarkers for breast cancer diagnosis and prognosis" +circulation_biomarker_prognosis_down hsa-mir-151a "Carcinoma, Breast" 30109140 "postoperatively downregulated circulating miR-130b-5p, miR-151a-5p, miR-206, and miR-222-3p may be potential biomarkers for breast cancer diagnosis and prognosis" +circulation_biomarker_prognosis_down hsa-mir-206 "Carcinoma, Breast" 30109140 "postoperatively downregulated circulating miR-130b-5p, miR-151a-5p, miR-206, and miR-222-3p may be potential biomarkers for breast cancer diagnosis and prognosis" +circulation_biomarker_prognosis_down hsa-mir-222 "Carcinoma, Breast" 30109140 "postoperatively downregulated circulating miR-130b-5p, miR-151a-5p, miR-206, and miR-222-3p may be potential biomarkers for breast cancer diagnosis and prognosis" +circulation_biomarker_prognosis_down hsa-mir-146a "Leukemia, Myeloid, Acute" 30242879 "the high expression of hsa-miR-509 and hsa-miR-542 were independent poor prognostic factors, whereas that of hsa-miR-146a and hsa-miR-3667 had a trend to be favorable factors" +circulation_biomarker_prognosis_down hsa-mir-3667 "Leukemia, Myeloid, Acute" 30242879 "the high expression of hsa-miR-509 and hsa-miR-542 were independent poor prognostic factors, whereas that of hsa-miR-146a and hsa-miR-3667 had a trend to be favorable factors" +circulation_biomarker_prognosis_ns hsa-mir-1 Chronic Hepatitis C 21070682 "The main aim of this study was to evaluate the expression of several miRNAs (miR-1, miR-30, miR-128, miR-196, miR-296) in peripheral blood mononuclear cells (PBMCs) from healthy individuals after in vitro IFN-treatment and in PBMCs from patients with chronic hepatitis C (CHC) before and 12 hours after the first injection of pegylated IFN alpha" +circulation_biomarker_prognosis_ns hsa-mir-128 Chronic Hepatitis C 21070682 "The main aim of this study was to evaluate the expression of several miRNAs (miR-1, miR-30, miR-128, miR-196, miR-296) in peripheral blood mononuclear cells (PBMCs) from healthy individuals after in vitro IFN-treatment and in PBMCs from patients with chronic hepatitis C (CHC) before and 12 hours after the first injection of pegylated IFN alpha" +circulation_biomarker_prognosis_ns hsa-mir-196 Chronic Hepatitis C 21070682 "The main aim of this study was to evaluate the expression of several miRNAs (miR-1, miR-30, miR-128, miR-196, miR-296) in peripheral blood mononuclear cells (PBMCs) from healthy individuals after in vitro IFN-treatment and in PBMCs from patients with chronic hepatitis C (CHC) before and 12 hours after the first injection of pegylated IFN alpha" +circulation_biomarker_prognosis_ns hsa-mir-296 Chronic Hepatitis C 21070682 "The main aim of this study was to evaluate the expression of several miRNAs (miR-1, miR-30, miR-128, miR-196, miR-296) in peripheral blood mononuclear cells (PBMCs) from healthy individuals after in vitro IFN-treatment and in PBMCs from patients with chronic hepatitis C (CHC) before and 12 hours after the first injection of pegylated IFN alpha" +circulation_biomarker_prognosis_ns hsa-mir-30 Chronic Hepatitis C 21070682 "The main aim of this study was to evaluate the expression of several miRNAs (miR-1, miR-30, miR-128, miR-196, miR-296) in peripheral blood mononuclear cells (PBMCs) from healthy individuals after in vitro IFN-treatment and in PBMCs from patients with chronic hepatitis C (CHC) before and 12 hours after the first injection of pegylated IFN alpha" +circulation_biomarker_prognosis_ns hsa-mir-126 Vascular Disease [unspecific] 23386708 plasma;Aspirin treatment hampers the use of plasma microRNA-126 as a biomarker for the progression of vascular disease +circulation_biomarker_prognosis_ns hsa-mir-103 Prostate Neoplasms 24583788 Serum microRNA expression patterns that predict early treatment failure in prostate cancer patients. +circulation_biomarker_prognosis_ns hsa-mir-125b Prostate Neoplasms 24583788 Serum microRNA expression patterns that predict early treatment failure in prostate cancer patients. +circulation_biomarker_prognosis_ns hsa-mir-222 Prostate Neoplasms 24583788 Serum microRNA expression patterns that predict early treatment failure in prostate cancer patients. +circulation_biomarker_prognosis_ns hsa-mir-103 Colorectal Carcinoma 26271186 Variability in microRNA recovery from plasma: Comparison of five commercial kits. +circulation_biomarker_prognosis_ns hsa-mir-18a Colorectal Carcinoma 26271186 Variability in microRNA recovery from plasma: Comparison of five commercial kits. +circulation_biomarker_prognosis_ns hsa-mir-191 Colorectal Carcinoma 26271186 Variability in microRNA recovery from plasma: Comparison of five commercial kits. +circulation_biomarker_prognosis_ns hsa-mir-21 Colorectal Carcinoma 26271186 Variability in microRNA recovery from plasma: Comparison of five commercial kits. +circulation_biomarker_prognosis_ns hsa-mir-23a Colorectal Carcinoma 26271186 Variability in microRNA recovery from plasma: Comparison of five commercial kits. +circulation_biomarker_prognosis_ns hsa-mir-29a Colorectal Carcinoma 26271186 Variability in microRNA recovery from plasma: Comparison of five commercial kits. +circulation_biomarker_prognosis_ns hsa-mir-451 Colorectal Carcinoma 26271186 Variability in microRNA recovery from plasma: Comparison of five commercial kits. +circulation_biomarker_prognosis_ns hsa-mir-34a "Carcinoma, Breast" 28178621 Changes of serum miR34a expression during neoadjuvant chemotherapy predict the treatment response and prognosis in stage II/III breast cancer. +circulation_biomarker_prognosis_ns hsa-mir-22 Atherosclerosis 28301500 Circulating progenitor cells in hypertensive subjects: Effectiveness of a treatment with olmesartan in improving cell number and miR profile in addition to expected pharmacological effects. +circulation_biomarker_prognosis_ns hsa-mir-221 Atherosclerosis 28301500 Circulating progenitor cells in hypertensive subjects: Effectiveness of a treatment with olmesartan in improving cell number and miR profile in addition to expected pharmacological effects. +circulation_biomarker_prognosis_ns hsa-mir-222 Atherosclerosis 28301500 Circulating progenitor cells in hypertensive subjects: Effectiveness of a treatment with olmesartan in improving cell number and miR profile in addition to expected pharmacological effects. +circulation_biomarker_prognosis_ns hsa-mir-145 Chronic Hepatitis 28368488 Plasma MicroRNA Levels Are Associated With Hepatitis B e Antigen Status and Treatment Response in Chronic Hepatitis B Patients. +circulation_biomarker_prognosis_ns hsa-mir-126 Atherosclerosis 28785651 Circulating level of microRNA-126 may be a potential biomarker for recovery from smoking-related vascular damage in middle-aged habitual smokers. +circulation_biomarker_prognosis_ns hsa-mir-208 Viral Myocarditis 29916103 "Circulating MicroRNAs: a Potential Biomarker for Cardiac Damage, Inflammatory Response, and Left Ventricular Function Recovery in Pediatric Viral Myocarditis." +circulation_biomarker_prognosis_ns hsa-mir-21 Viral Myocarditis 29916103 "Circulating MicroRNAs: a Potential Biomarker for Cardiac Damage, Inflammatory Response, and Left Ventricular Function Recovery in Pediatric Viral Myocarditis." +circulation_biomarker_prognosis_ns hsa-mir-125b Chronic Hepatitis B 30344656 Baseline serum miR-125b levels predict virologic response to nucleos(t)ide analogue treatment in patients with HBeAg-positive chronic hepatitis B. +circulation_biomarker_prognosis_ns hsa-let-7a-1 Lung Neoplasms 16885332 let-7a-1 expression correlates with poor survival of lung cancer patients +circulation_biomarker_prognosis_ns hsa-let-7a-2 Lung Neoplasms 16885332 let-7a-1 expression correlates with poor survival of lung cancer patients +circulation_biomarker_prognosis_ns hsa-let-7a-3 Lung Neoplasms 16885332 let-7a-1 expression correlates with poor survival of lung cancer patients +circulation_biomarker_prognosis_ns hsa-let-7b Lung Neoplasms 16885332 let-7a-1 expression correlates with poor survival of lung cancer patients +circulation_biomarker_prognosis_ns hsa-let-7c Lung Neoplasms 16885332 let-7a-1 expression correlates with poor survival of lung cancer patients +circulation_biomarker_prognosis_ns hsa-let-7d Lung Neoplasms 16885332 let-7a-1 expression correlates with poor survival of lung cancer patients +circulation_biomarker_prognosis_ns hsa-let-7e Lung Neoplasms 16885332 let-7a-1 expression correlates with poor survival of lung cancer patients +circulation_biomarker_prognosis_ns hsa-let-7f-1 Lung Neoplasms 16885332 let-7a-1 expression correlates with poor survival of lung cancer patients +circulation_biomarker_prognosis_ns hsa-let-7f-2 Lung Neoplasms 16885332 let-7a-1 expression correlates with poor survival of lung cancer patients +circulation_biomarker_prognosis_ns hsa-let-7g Lung Neoplasms 16885332 let-7a-1 expression correlates with poor survival of lung cancer patients +circulation_biomarker_prognosis_ns hsa-let-7i Lung Neoplasms 16885332 let-7a-1 expression correlates with poor survival of lung cancer patients +circulation_biomarker_prognosis_ns hsa-mir-16 Leukemia 19195700 Prognostic value of miR-16 expression in childhood acute lymphoblastic leukemia relationships to normal and malignant lymphocyte proliferation. +circulation_biomarker_prognosis_ns hsa-mir-181a-2 "Leukemia, Lymphocytic, Chronic, B-Cell" 20487546 "miR-181a:Differential expression of the sulfatase SULF2 and of miR-29a, -181a, and -221 was also observed between resistant and sensitive patients before treatment" +circulation_biomarker_prognosis_ns hsa-mir-221 "Leukemia, Lymphocytic, Chronic, B-Cell" 20487546 "miR-221:Differential expression of the sulfatase SULF2 and of miR-29a, -181a, and -221 was also observed between resistant and sensitive patients before treatment" +circulation_biomarker_prognosis_ns hsa-mir-29a "Leukemia, Lymphocytic, Chronic, B-Cell" 20487546 "miR-29a:Differential expression of the sulfatase SULF2 and of miR-29a, -181a, and -221 was also observed between resistant and sensitive patients before treatment" +circulation_biomarker_prognosis_ns hsa-mir-92a-1 Leukemia 21182798 The miR-92a expression in leukemia cells could be a prognostic factor in ALL patients +circulation_biomarker_prognosis_ns hsa-mir-92a-2 Leukemia 21182798 The miR-92a expression in leukemia cells could be a prognostic factor in ALL patients +circulation_biomarker_prognosis_ns hsa-let-7a-1 Myelodysplastic Syndromes 21332710 dysregulated +circulation_biomarker_prognosis_ns hsa-let-7a-2 Myelodysplastic Syndromes 21332710 dysregulated +circulation_biomarker_prognosis_ns hsa-let-7a-3 Myelodysplastic Syndromes 21332710 dysregulated +circulation_biomarker_prognosis_ns hsa-let-7b Myelodysplastic Syndromes 21332710 dysregulated +circulation_biomarker_prognosis_ns hsa-let-7c Myelodysplastic Syndromes 21332710 dysregulated +circulation_biomarker_prognosis_ns hsa-let-7d Myelodysplastic Syndromes 21332710 dysregulated +circulation_biomarker_prognosis_ns hsa-let-7e Myelodysplastic Syndromes 21332710 dysregulated +circulation_biomarker_prognosis_ns hsa-let-7f-1 Myelodysplastic Syndromes 21332710 dysregulated +circulation_biomarker_prognosis_ns hsa-let-7f-2 Myelodysplastic Syndromes 21332710 dysregulated +circulation_biomarker_prognosis_ns hsa-let-7g Myelodysplastic Syndromes 21332710 dysregulated +circulation_biomarker_prognosis_ns hsa-let-7i Myelodysplastic Syndromes 21332710 dysregulated +circulation_biomarker_prognosis_ns hsa-mir-181a-1 Myelodysplastic Syndromes 21332710 dysregulated +circulation_biomarker_prognosis_ns hsa-mir-181a-2 Myelodysplastic Syndromes 21332710 dysregulated +circulation_biomarker_prognosis_ns hsa-mir-181b-2 Myelodysplastic Syndromes 21332710 dysregulated +circulation_biomarker_prognosis_ns hsa-mir-181c Myelodysplastic Syndromes 21332710 dysregulated +circulation_biomarker_prognosis_ns hsa-mir-181d Myelodysplastic Syndromes 21332710 dysregulated +circulation_biomarker_prognosis_ns hsa-let-7a-1 Ovarian Neoplasms 21571355 let-7a is a potential marker for selection of paclitaxel in ovarian cancer management. +circulation_biomarker_prognosis_ns hsa-mir-155 Leukemia 22209839 "These results support that miR-128, let-7b, miR-223 and miR181a have a diagnosis value in AL, while miR-181a and miR-155 are of great prognostic significance in AML." +circulation_biomarker_prognosis_ns hsa-mir-181a Leukemia 22209839 "These results support that miR-128, let-7b, miR-223 and miR181a have a diagnosis value in AL, while miR-181a and miR-155 are of great prognostic significance in AML." +circulation_biomarker_prognosis_ns hsa-mir-17 Gastric Neoplasms 22406928 The concentrations of plasma miR-17-5p/20a were significantly associated with the differentiation status and TNM stages of gastric cancer. Kaplan-Meier curve analysis revealed that high expression levels of miR-17-5p/20a were significantly correlated with poor overall survival. Cox regression analysis demonstrated that the level of plasma miR-20a was an independent risk predictor for prognosis. +circulation_biomarker_prognosis_ns hsa-mir-20a Gastric Neoplasms 22406928 The concentrations of plasma miR-17-5p/20a were significantly associated with the differentiation status and TNM stages of gastric cancer. Kaplan-Meier curve analysis revealed that high expression levels of miR-17-5p/20a were significantly correlated with poor overall survival. Cox regression analysis demonstrated that the level of plasma miR-20a was an independent risk predictor for prognosis. +circulation_biomarker_prognosis_ns hsa-mir-21 Esophageal Neoplasms 22519435 Circulating miR-21 and miR-375 could be reliable prognostic markers for ESCC. +circulation_biomarker_prognosis_ns hsa-mir-375 Esophageal Neoplasms 22519435 Circulating miR-21 and miR-375 could be reliable prognostic markers for ESCC. +circulation_biomarker_prognosis_ns hsa-mir-125b-1 "Carcinoma, Lung, Non-Small-Cell" 22806310 Circulating miR-125b is a novel biomarker for screening non-small-cell lung cancer and predicts poor prognosis. +circulation_biomarker_prognosis_ns hsa-mir-125b-2 "Carcinoma, Lung, Non-Small-Cell" 22806310 Circulating miR-125b is a novel biomarker for screening non-small-cell lung cancer and predicts poor prognosis. +circulation_biomarker_prognosis_ns hsa-mir-223 "Lymphoma, Large B-Cell, Diffuse" 22932402 "As a potential prognostic biomarker, overexpression of miR-223 correlates with a longer OS of patients with DLBCL (diffuse large B cell lymphoma)." +circulation_biomarker_prognosis_ns hsa-mir-150 "Lymphoma, B-Cell" 22936066 miR-155 and miR-150 expression levels were associated with progression-free survival . +circulation_biomarker_prognosis_ns hsa-mir-155 "Lymphoma, B-Cell" 22936066 miR-155 and miR-150 expression levels were associated with progression-free survival . +circulation_biomarker_prognosis_ns hsa-mir-133a-1 Myocardial Infarction 23137501 Relation of circulating MicroRNA-133a concentrations with myocardial damage and clinical prognosis in ST-elevation myocardial infarction +circulation_biomarker_prognosis_ns hsa-mir-133a-2 Myocardial Infarction 23137501 Relation of circulating MicroRNA-133a concentrations with myocardial damage and clinical prognosis in ST-elevation myocardial infarction +circulation_biomarker_prognosis_ns hsa-mir-15a Ischemia 23233752 MicroRNA-15a and MicroRNA-16 Impair Human Circulating Proangiogenic Cell Functions and Are Increased in the Proangiogenic Cells and Serum of Patients With Critical Limb Ischemia +circulation_biomarker_prognosis_ns hsa-mir-16-1 "Leukemia-Lymphoma, Adult T-Cell" 23260326 Micro-RNA-16 expression in paraffin-embedded specimen correlates with overall survival of T-lymphoblastic lymphoma/leukemia +circulation_biomarker_prognosis_ns hsa-mir-16-2 "Leukemia-Lymphoma, Adult T-Cell" 23260326 Micro-RNA-16 expression in paraffin-embedded specimen correlates with overall survival of T-lymphoblastic lymphoma/leukemia +circulation_biomarker_prognosis_ns hsa-mir-21 Osteosarcoma 23321165 Identification of Serum MicroRNA-21 as a Biomarker for Chemosensitivity and Prognosis in Human Osteosarcoma +circulation_biomarker_prognosis_ns hsa-mir-126 Cardiovascular Diseases [unspecific] 23391580 "Platelets, endothelium, and circulating microRNA-126 as a prognostic biomarker in cardiovascular diseases: per aspirin ad astra." +circulation_biomarker_prognosis_ns hsa-mir-16-1 "Carcinoma, Lung, Non-Small-Cell" 23774211 MiR-16 exhibited the most statistically significant association: high expression of miR-16 was associated with a significantly better survival +circulation_biomarker_prognosis_ns hsa-mir-22 "Carcinoma, Lung, Non-Small-Cell" 23794259 "Circulating miR-22, miR-24 and miR-34a as novel predictive biomarkers to pemetrexed-based chemotherapy in advanced non-small cell lung cancer." +circulation_biomarker_prognosis_ns hsa-mir-24 "Carcinoma, Lung, Non-Small-Cell" 23794259 "Circulating miR-22, miR-24 and miR-34a as novel predictive biomarkers to pemetrexed-based chemotherapy in advanced non-small cell lung cancer." +circulation_biomarker_prognosis_ns hsa-mir-34a "Carcinoma, Lung, Non-Small-Cell" 23794259 "Circulating miR-22, miR-24 and miR-34a as novel predictive biomarkers to pemetrexed-based chemotherapy in advanced non-small cell lung cancer." +circulation_biomarker_prognosis_ns hsa-let-7 Prostate Neoplasms 23798998 Distinct microRNA expression profile in prostate cancer patients with early clinical failure and the impact of let-7 as prognostic marker in high-risk prostate cancer. +circulation_biomarker_prognosis_ns hsa-mir-155 Idiopathic Pulmonary Fibrosis 23822889 "These findings suggest that serum miR-21 is associated with IPF and the degree of damage indicated by FVC and radiologic examinations could correlate with miR-21 and miR-155 expression in serum. From another perspective, our study confirmed serum miRNA can be stable and detectable in serum of patients with IPF,which could prove useful as it could be considered as a new biomarker in serum for diagnosis and assessment of prognosis of IPF in the future." +circulation_biomarker_prognosis_ns hsa-mir-21 Idiopathic Pulmonary Fibrosis 23822889 "These findings suggest that serum miR-21 is associated with IPF and the degree of damage indicated by FVC and radiologic examinations could correlate with miR-21 and miR-155 expression in serum. From another perspective, our study confirmed serum miRNA can be stable and detectable in serum of patients with IPF,which could prove useful as it could be considered as a new biomarker in serum for diagnosis and assessment of prognosis of IPF in the future." +circulation_biomarker_prognosis_ns hsa-mir-21 Central Nervous System Embryonal Tumor 23832112 Serum miR-21 is a diagnostic and prognostic marker of primary central nervous system lymphoma. +circulation_biomarker_prognosis_ns hsa-mir-200c "Carcinoma, Esophageal" 23838916 The serum level of miR-200c can be useful for predicting the response to chemotherapy and the prognosis of patients with esophageal cancer who receive neoadjuvant chemotherapy. +circulation_biomarker_prognosis_ns hsa-mir-21 Colorectal Carcinoma 23970420 "Our results suggest that circulating serum miR-21 is a promising prognostic tumour marker, and they highlight the potential clinical utility of miR-21 expression as a prognostic marker for CRC prognosis." +circulation_biomarker_prognosis_ns hsa-mir-100 Gastric Neoplasms 23975664 Prognostic role of microRNA polymorphisms in advanced gastric cancer: a translational study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). +circulation_biomarker_prognosis_ns hsa-mir-200c Colorectal Carcinoma 23982750 Serum miR-200c is a novel prognostic and metastasis-predictive biomarker in patients with colorectal cancer. +circulation_biomarker_prognosis_ns hsa-mir-21 Neoplasms [unspecific] 24076132 "Our findings suggest that circulating miR-21 may not suitable to be a diagnostic biomarker, but it has a prognostic value in patients with cancer." +circulation_biomarker_prognosis_ns hsa-mir-149 Neoplasms [unspecific] 24180461 The regression analysis identified tumour stage and miR-31 and miR-149 expression as independently associated with tumour progression and tumour stage and miR-149 expression as independently associated with cancer-specific survival. +circulation_biomarker_prognosis_ns hsa-let-7f Ovarian Neoplasms 24223734 Our findings indicate that plasma miR-205 and let-7f are biomarkers for ovarian cancer detection that complement CA-125; let-7f may be predictive of ovarian cancer prognosis. +circulation_biomarker_prognosis_ns hsa-mir-31 "Adenocarcinoma, Pancreatic Ductal" 24289824 "In a cohort of 70 patients, the high expression of miR-21 (p=0.018, HR=2.610; 95% CI=1.179-5.777) and miR-31 (p=0.039, HR=2.735; 95% CI=1.317-6.426), the low expression of miR-375 (p=0.022, HR=2.337; 95% CI=1.431-5.066) were associated with poor overall survival following resection, independent of clinical covariates." +circulation_biomarker_prognosis_ns hsa-mir-130 Colorectal Carcinoma 24304648 Circulating microRNA expressions in colorectal cancer as predictors of response to chemotherapy. +circulation_biomarker_prognosis_ns hsa-mir-145 Colorectal Carcinoma 24304648 Circulating microRNA expressions in colorectal cancer as predictors of response to chemotherapy. +circulation_biomarker_prognosis_ns hsa-mir-20a Colorectal Carcinoma 24304648 Circulating microRNA expressions in colorectal cancer as predictors of response to chemotherapy. +circulation_biomarker_prognosis_ns hsa-mir-216 Colorectal Carcinoma 24304648 Circulating microRNA expressions in colorectal cancer as predictors of response to chemotherapy. +circulation_biomarker_prognosis_ns hsa-mir-372 Colorectal Carcinoma 24304648 Circulating microRNA expressions in colorectal cancer as predictors of response to chemotherapy. +circulation_biomarker_prognosis_ns hsa-mir-221 Neoplasms [unspecific] 24319365 Lack of significant association between plasma/serum miR-221 expression and poor survival of carcinoma: a meta analysis. +circulation_biomarker_prognosis_ns hsa-mir-223 Intestinal Schistosomiasis 24330517 This study suggested that the circulating miR-223 could serve as a potential new biomarker for the detection of schistosome infection and the assessment of the response to chemotherapy. +circulation_biomarker_prognosis_ns hsa-mir-223 "Squamous Cell Carcinoma, Esophageal" 24390317 "miR-25, miR-223, and miR-375 were abnormally expressed in ESCC tissues and sera. Serum miR-223 and miR-375 are potential prognostic biomarkers for ESCC." +circulation_biomarker_prognosis_ns hsa-mir-25 "Squamous Cell Carcinoma, Esophageal" 24390317 "miR-25, miR-223, and miR-375 were abnormally expressed in ESCC tissues and sera. Serum miR-223 and miR-375 are potential prognostic biomarkers for ESCC." +circulation_biomarker_prognosis_ns hsa-mir-375 "Squamous Cell Carcinoma, Esophageal" 24390317 "miR-25, miR-223, and miR-375 were abnormally expressed in ESCC tissues and sera. Serum miR-223 and miR-375 are potential prognostic biomarkers for ESCC." +circulation_biomarker_prognosis_ns hsa-mir-16 Lymphoma 24447552 Significance of microRNA-16 and bcl-2 expression in T lymphoblastic lymphoma/leukemia and its relation with prognosis. +circulation_biomarker_prognosis_ns hsa-mir-19a Colorectal Carcinoma 24460313 Serum miR-19a predicts resistance to FOLFOX chemotherapy in advanced colorectal cancer cases. +circulation_biomarker_prognosis_ns hsa-mir-21 Gastric Neoplasms 24460332 Plasma post-operative miR-21 expression in the prognosis of gastric cancers. +circulation_biomarker_prognosis_ns hsa-mir-499 Myocardial Infarction 24461971 Admission levels of circulating miR-499-5p and risk of death in elderly patients after acute non-ST elevation myocardial infarction. +circulation_biomarker_prognosis_ns hsa-mir-146a "Carcinoma, Lung, Non-Small-Cell" 24531034 Serum levels of miR-19b and miR-146a as prognostic biomarkers for non-small cell lung cancer. +circulation_biomarker_prognosis_ns hsa-mir-19b "Carcinoma, Lung, Non-Small-Cell" 24531034 Serum levels of miR-19b and miR-146a as prognostic biomarkers for non-small cell lung cancer. +circulation_biomarker_prognosis_ns hsa-mir-103 "Carcinoma, Nasopharyngeal" 24563490 Differentially expressed plasma miRNAs as identified by next-generation sequencing can be helpful for predicting survival in NPC patients. +circulation_biomarker_prognosis_ns hsa-mir-29a "Carcinoma, Nasopharyngeal" 24563490 Differentially expressed plasma miRNAs as identified by next-generation sequencing can be helpful for predicting survival in NPC patients. +circulation_biomarker_prognosis_ns hsa-mir-483 "Carcinoma, Nasopharyngeal" 24563490 Differentially expressed plasma miRNAs as identified by next-generation sequencing can be helpful for predicting survival in NPC patients. +circulation_biomarker_prognosis_ns hsa-mir-21 Neoplasms [unspecific] 24664585 The present meta-analysis suggests that circulating miR-21 expression is associated with poor survival in patients with cancer and could be a prognostic biomarker for those patients. +circulation_biomarker_prognosis_ns hsa-mir-1236 "Lymphoma, Large B-Cell, Diffuse" 24858372 novel prognostic biomarkers to predict the clinical outcome of DLBCL patients treated with R-CHOP regimen. +circulation_biomarker_prognosis_ns hsa-mir-224 "Lymphoma, Large B-Cell, Diffuse" 24858372 novel prognostic biomarkers to predict the clinical outcome of DLBCL patients treated with R-CHOP regimen. +circulation_biomarker_prognosis_ns hsa-mir-33a "Lymphoma, Large B-Cell, Diffuse" 24858372 novel prognostic biomarkers to predict the clinical outcome of DLBCL patients treated with R-CHOP regimen. +circulation_biomarker_prognosis_ns hsa-mir-455 "Lymphoma, Large B-Cell, Diffuse" 24858372 novel prognostic biomarkers to predict the clinical outcome of DLBCL patients treated with R-CHOP regimen. +circulation_biomarker_prognosis_ns hsa-mir-520d "Lymphoma, Large B-Cell, Diffuse" 24858372 novel prognostic biomarkers to predict the clinical outcome of DLBCL patients treated with R-CHOP regimen. +circulation_biomarker_prognosis_ns hsa-let-7c Breast Neoplasms 24866763 "Our identified mRNAs and microRNAs were validated as prognostic factors of BC disease progression, and could potentially facilitate the implementation of assays for laboratory validation, due to their reduced number." +circulation_biomarker_prognosis_ns hsa-mir-139 Breast Neoplasms 24866763 "Our identified mRNAs and microRNAs were validated as prognostic factors of BC disease progression, and could potentially facilitate the implementation of assays for laboratory validation, due to their reduced number." +circulation_biomarker_prognosis_ns hsa-mir-320d Breast Neoplasms 24866763 "Our identified mRNAs and microRNAs were validated as prognostic factors of BC disease progression, and could potentially facilitate the implementation of assays for laboratory validation, due to their reduced number." +circulation_biomarker_prognosis_ns hsa-mir-567 Breast Neoplasms 24866763 "Our identified mRNAs and microRNAs were validated as prognostic factors of BC disease progression, and could potentially facilitate the implementation of assays for laboratory validation, due to their reduced number." +circulation_biomarker_prognosis_ns hsa-mir-29a "Carcinoma, Lung, Non-Small-Cell" 24928469 "Ten miRNA's were significantly associated with OS, with hsa-miR-29a being the strongest prognostic marker (HR=6.44, 95%-CI 2.39-17.33)." +circulation_biomarker_prognosis_ns hsa-mir-376a "Carcinoma, Lung, Non-Small-Cell" 24928469 "Six out of the 10 miRNA's (hsa-miRN-29a, hsa-miR-542-5p, hsa-miR-502-3p, hsa-miR-376a, hsa-miR-500a, hsa-miR-424) were insensitive to perturbations according to jackknife cross-validation on their HR for OS." +circulation_biomarker_prognosis_ns hsa-mir-424 "Carcinoma, Lung, Non-Small-Cell" 24928469 "Six out of the 10 miRNA's (hsa-miRN-29a, hsa-miR-542-5p, hsa-miR-502-3p, hsa-miR-376a, hsa-miR-500a, hsa-miR-424) were insensitive to perturbations according to jackknife cross-validation on their HR for OS." +circulation_biomarker_prognosis_ns hsa-mir-500a "Carcinoma, Lung, Non-Small-Cell" 24928469 "Six out of the 10 miRNA's (hsa-miRN-29a, hsa-miR-542-5p, hsa-miR-502-3p, hsa-miR-376a, hsa-miR-500a, hsa-miR-424) were insensitive to perturbations according to jackknife cross-validation on their HR for OS." +circulation_biomarker_prognosis_ns hsa-mir-502 "Carcinoma, Lung, Non-Small-Cell" 24928469 "Six out of the 10 miRNA's (hsa-miRN-29a, hsa-miR-542-5p, hsa-miR-502-3p, hsa-miR-376a, hsa-miR-500a, hsa-miR-424) were insensitive to perturbations according to jackknife cross-validation on their HR for OS." +circulation_biomarker_prognosis_ns hsa-mir-542 "Carcinoma, Lung, Non-Small-Cell" 24928469 "Six out of the 10 miRNA's (hsa-miRN-29a, hsa-miR-542-5p, hsa-miR-502-3p, hsa-miR-376a, hsa-miR-500a, hsa-miR-424) were insensitive to perturbations according to jackknife cross-validation on their HR for OS." +circulation_biomarker_prognosis_ns hsa-mir-210 "Carcinoma, Hepatocellular" 24935355 Serum miR-210 may represent a novel biomarker for predicting efficacy of transarterial chemoembolization and overall survival for patients with HCC. +circulation_biomarker_prognosis_ns hsa-let-7a Diabetes Mellitus 24937531 "Treatment-na?ve, poorly controlled diabetic patients show a significant dysregulation of miRNAs involved in the regulation of the adiponectin pathway, a phenomenon that may be reversed, at least in part, by improved glycemic control." +circulation_biomarker_prognosis_ns hsa-mir-143 Colorectal Carcinoma 24940606 We identified miR-345 in whole blood as a potential biomarker for clinical outcome. MiR-345 was a single prognostic biomarker for both OS and PFS in all patients and also in the non-KRAS mutant population. +circulation_biomarker_prognosis_ns hsa-mir-324 Colorectal Carcinoma 24940606 We identified miR-345 in whole blood as a potential biomarker for clinical outcome. MiR-345 was a single prognostic biomarker for both OS and PFS in all patients and also in the non-KRAS mutant population. +circulation_biomarker_prognosis_ns hsa-mir-345 Colorectal Carcinoma 24940606 We identified miR-345 in whole blood as a potential biomarker for clinical outcome. MiR-345 was a single prognostic biomarker for both OS and PFS in all patients and also in the non-KRAS mutant population. +circulation_biomarker_prognosis_ns hsa-mir-34a Colorectal Carcinoma 24940606 We identified miR-345 in whole blood as a potential biomarker for clinical outcome. MiR-345 was a single prognostic biomarker for both OS and PFS in all patients and also in the non-KRAS mutant population. +circulation_biomarker_prognosis_ns hsa-mir-628 Colorectal Carcinoma 24940606 We identified miR-345 in whole blood as a potential biomarker for clinical outcome. MiR-345 was a single prognostic biomarker for both OS and PFS in all patients and also in the non-KRAS mutant population. +circulation_biomarker_prognosis_ns hsa-mir-886 Colorectal Carcinoma 24940606 We identified miR-345 in whole blood as a potential biomarker for clinical outcome. MiR-345 was a single prognostic biomarker for both OS and PFS in all patients and also in the non-KRAS mutant population. +circulation_biomarker_prognosis_ns hsa-mir-218 Gastric Neoplasms 24944481 "miR-218 is deregulated in gastric cancer patients and is strongly correlated with tumor stage, grade and metastasis. Serum expression of miR-218 may be a prognostic marker." +circulation_biomarker_prognosis_ns hsa-mir-105 Pelvic Inflammatory Disease 24961692 Early microRNA expression profile as a prognostic biomarker for the development of pelvic inflammatory disease in a mouse model of chlamydial genital infection. +circulation_biomarker_prognosis_ns hsa-mir-132 Pelvic Inflammatory Disease 24961692 Early microRNA expression profile as a prognostic biomarker for the development of pelvic inflammatory disease in a mouse model of chlamydial genital infection. +circulation_biomarker_prognosis_ns hsa-mir-135a Pelvic Inflammatory Disease 24961692 Early microRNA expression profile as a prognostic biomarker for the development of pelvic inflammatory disease in a mouse model of chlamydial genital infection. +circulation_biomarker_prognosis_ns hsa-mir-142 Pelvic Inflammatory Disease 24961692 Early microRNA expression profile as a prognostic biomarker for the development of pelvic inflammatory disease in a mouse model of chlamydial genital infection. +circulation_biomarker_prognosis_ns hsa-mir-147 Pelvic Inflammatory Disease 24961692 Early microRNA expression profile as a prognostic biomarker for the development of pelvic inflammatory disease in a mouse model of chlamydial genital infection. +circulation_biomarker_prognosis_ns hsa-mir-155 Pelvic Inflammatory Disease 24961692 Early microRNA expression profile as a prognostic biomarker for the development of pelvic inflammatory disease in a mouse model of chlamydial genital infection. +circulation_biomarker_prognosis_ns hsa-mir-223 Pelvic Inflammatory Disease 24961692 Early microRNA expression profile as a prognostic biomarker for the development of pelvic inflammatory disease in a mouse model of chlamydial genital infection. +circulation_biomarker_prognosis_ns hsa-mir-298 Pelvic Inflammatory Disease 24961692 Early microRNA expression profile as a prognostic biomarker for the development of pelvic inflammatory disease in a mouse model of chlamydial genital infection. +circulation_biomarker_prognosis_ns hsa-mir-299a Pelvic Inflammatory Disease 24961692 Early microRNA expression profile as a prognostic biomarker for the development of pelvic inflammatory disease in a mouse model of chlamydial genital infection. +circulation_biomarker_prognosis_ns hsa-mir-325 Pelvic Inflammatory Disease 24961692 Early microRNA expression profile as a prognostic biomarker for the development of pelvic inflammatory disease in a mouse model of chlamydial genital infection. +circulation_biomarker_prognosis_ns hsa-mir-410 Pelvic Inflammatory Disease 24961692 Early microRNA expression profile as a prognostic biomarker for the development of pelvic inflammatory disease in a mouse model of chlamydial genital infection. +circulation_biomarker_prognosis_ns hsa-mir-202 Breast Neoplasms 24983365 "Based on their cancer-specific increase in breast cancer patients,circulating MAGE-A and BORIS mRNAs may be further explored for early detection of breast cancer and monitoring of MAGE-directed immunotherapies. Moreover, serum miR-202 is associated with prognosis." +circulation_biomarker_prognosis_ns hsa-mir-224 "Lymphoma, Large B-Cell, Diffuse" 25052605 miR-224 expression may play an important role in the development and progression of DLBCL and could be prognostic significance. +circulation_biomarker_prognosis_ns hsa-mir-21 Breast Neoplasms 25086636 "Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy" +circulation_biomarker_prognosis_ns hsa-mir-210 Breast Neoplasms 25086636 "Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy" +circulation_biomarker_prognosis_ns hsa-mir-373 Breast Neoplasms 25086636 "Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy" +circulation_biomarker_prognosis_ns hsa-mir-133b Osteosarcoma 25120799 Serum levels of microRNA-133b and microRNA-206 expression predict prognosis in patients with osteosarcoma. +circulation_biomarker_prognosis_ns hsa-mir-206 Osteosarcoma 25120799 Serum levels of microRNA-133b and microRNA-206 expression predict prognosis in patients with osteosarcoma. +circulation_biomarker_prognosis_ns hsa-mir-19a Breast Neoplasms 25137071 The combination of miR-19a and miR-205 in the serum may predict the chemosensitivity of luminal A subtype of breast cancer to epirubicin plus paclitaxel neoadjuvant chemotherapy. +circulation_biomarker_prognosis_ns hsa-mir-205 Breast Neoplasms 25137071 The combination of miR-19a and miR-205 in the serum may predict the chemosensitivity of luminal A subtype of breast cancer to epirubicin plus paclitaxel neoadjuvant chemotherapy. +circulation_biomarker_prognosis_ns hsa-mir-146a "Leukemia, Promyelocytic, Acute" 25161335 These findings indicated that miR-146a played an important role in the development of APL in part through the repression on Smad4 protein expression. miR-146a functioned as an oncogene and may be a novel prognostic biomarker in APL. +circulation_biomarker_prognosis_ns hsa-mir-454 Glioma 25190548 Plasma miR-454-3p as a potential prognostic indicator in human glioma. +circulation_biomarker_prognosis_ns hsa-mir-145 "Adenocarcinoma, Lung" 25192889 miRNA-145 is strongly associated with overall survival +circulation_biomarker_prognosis_ns hsa-mir-21 Glioma 25279461 "Moreover, in the GBM dataset miR-21 and miR-210 were predictors of worse prognosis in both univariable and multivariable Cox regression analyses" +circulation_biomarker_prognosis_ns hsa-mir-10b Breast Neoplasms 25369070 "Moreover, miR-10b, miR-21 and miR-182 were significantly associated to lymph node metastases occurrence in triple negative breast carcinoma while only miR-10b was associated with grade III in non triple negative breast cancer cases." +circulation_biomarker_prognosis_ns hsa-mir-182 Breast Neoplasms 25369070 "Moreover, miR-10b, miR-21 and miR-182 were significantly associated to lymph node metastases occurrence in triple negative breast carcinoma" +circulation_biomarker_prognosis_ns hsa-mir-221 Lymphoma 25430553 serum miR-221 expression level has prognostic value in patients with CMM. +circulation_biomarker_prognosis_ns hsa-mir-155 Colorectal Carcinoma 25528214 the detection of miR-155 levels in the serum might serve as a new tumor biomarker in the diagnosis and assessment of prognosis of CRC. +circulation_biomarker_prognosis_ns hsa-mir-15a Glioma 25575767 "the expression of miR-15a is significantly correlated with prognosis in glioma patients, suggesting that the miR-15a may serve as independent prognostic marker." +circulation_biomarker_prognosis_ns hsa-mir-718 "Carcinoma, Hepatocellular" 25584485 Circulating miRs in serum exosomes have potential as novel biomarkers for predicting HCC recurrence. +circulation_biomarker_prognosis_ns hsa-mir-150 "Leukemia, Lymphocytic, Chronic, B-Cell" 25584781 Cellular and serum levels of miR-150 are associated with opposite clinical prognoses and could be used to molecularly monitor disease evolution as a new prognostic factor in CLL. +circulation_biomarker_prognosis_ns hsa-mir-224 Graves Ophthalmopathy 25588771 baseline serum miR-224-5p was associated with GC sensitivity in GO and in vitro overexpression of miR-224-5p restored GC sensitivity in a resistant cell model. A parameter combined serum miR-224-5p and TRAb could effectively predict GC ensitivity in GO patients. +circulation_biomarker_prognosis_ns hsa-mir-106b Breast Neoplasms 25619461 "MiR-106b was found to be associated with a high risk of recurrence of breast cancer, and miR-106b is a putative plasma marker for risk assessment in patients with breast cancer." +circulation_biomarker_prognosis_ns hsa-mir-141 Ovarian Neoplasms 25636451 miR-200c and miR-141 may be predictive biomarkers for ovarian cancer prognosis. Further large-scale studies are still needed to confirm our findings. +circulation_biomarker_prognosis_ns hsa-mir-200c Ovarian Neoplasms 25636451 miR-200c and miR-141 may be predictive biomarkers for ovarian cancer prognosis. Further large-scale studies are still needed to confirm our findings. +circulation_biomarker_prognosis_ns hsa-mir-128-2 "Carcinoma, Hepatocellular" 25642945 Serum miR-128-2 serves as a prognostic marker for patients with hepatocellular carcinoma. +circulation_biomarker_prognosis_ns hsa-let-7i Colorectal Carcinoma 25663689 We discovered a metastasis-specific miRNA signature in pCRCs and discovered novel tissue- and serum-based CRC metastasis-specific miRNA biomarkers through intensive validation. These unique miRNAs may be clinically applicable to predict prognosis and distant metastasis in CRC. +circulation_biomarker_prognosis_ns hsa-mir-10b Colorectal Carcinoma 25663689 We discovered a metastasis-specific miRNA signature in pCRCs and discovered novel tissue- and serum-based CRC metastasis-specific miRNA biomarkers through intensive validation. These unique miRNAs may be clinically applicable to predict prognosis and distant metastasis in CRC. +circulation_biomarker_prognosis_ns hsa-mir-221 Colorectal Carcinoma 25663689 We discovered a metastasis-specific miRNA signature in pCRCs and discovered novel tissue- and serum-based CRC metastasis-specific miRNA biomarkers through intensive validation. These unique miRNAs may be clinically applicable to predict prognosis and distant metastasis in CRC. +circulation_biomarker_prognosis_ns hsa-mir-320a Colorectal Carcinoma 25663689 We discovered a metastasis-specific miRNA signature in pCRCs and discovered novel tissue- and serum-based CRC metastasis-specific miRNA biomarkers through intensive validation. These unique miRNAs may be clinically applicable to predict prognosis and distant metastasis in CRC. +circulation_biomarker_prognosis_ns hsa-mir-885 Colorectal Carcinoma 25663689 We discovered a metastasis-specific miRNA signature in pCRCs and discovered novel tissue- and serum-based CRC metastasis-specific miRNA biomarkers through intensive validation. These unique miRNAs may be clinically applicable to predict prognosis and distant metastasis in CRC. +circulation_biomarker_prognosis_ns hsa-mir-122 Sepsis 25672224 Serum miR-122 correlates with short-term mortality in sepsis patients. +circulation_biomarker_prognosis_ns hsa-mir-224 "Carcinoma, Hepatocellular" 25688365 Serum miR-224 might be BCLC stage dependent. It can reflect the status of tumor and liver damage. It was an independent predictor for the survival of HCC patients. +circulation_biomarker_prognosis_ns hsa-mir-214 "Lymphoma, Large B-Cell, Diffuse" 25723320 Comprehensive miRNA sequence analysis reveals survival differences in diffuse large B-cell lymphoma patients +circulation_biomarker_prognosis_ns hsa-mir-28 "Lymphoma, Large B-Cell, Diffuse" 25723320 Comprehensive miRNA sequence analysis reveals survival differences in diffuse large B-cell lymphoma patients +circulation_biomarker_prognosis_ns hsa-mir-339 "Lymphoma, Large B-Cell, Diffuse" 25723320 Comprehensive miRNA sequence analysis reveals survival differences in diffuse large B-cell lymphoma patients +circulation_biomarker_prognosis_ns hsa-mir-5586 "Lymphoma, Large B-Cell, Diffuse" 25723320 Comprehensive miRNA sequence analysis reveals survival differences in diffuse large B-cell lymphoma patients +circulation_biomarker_prognosis_ns hsa-mir-210 "Adenocarcinoma, Lung" 25733977 "Significant correlations were found between miR-210 expression and lymph node metastasis, late disease stages, and poor prognosis in patients with adenocarcinoma." +circulation_biomarker_prognosis_ns hsa-mir-210 Melanoma 25749524 A direct plasma assay of circulating microRNA-210 of hypoxia can identify early systemic metastasis recurrence in melanoma patients. +circulation_biomarker_prognosis_ns hsa-mir-122 Hepatitis C Virus Infection 25811198 The expression levels of miR-21 and miR-122 were significantly different between the SVR and NR groups. +circulation_biomarker_prognosis_ns hsa-mir-141 Breast Neoplasms 25885099 "Circulating miR-200c and miR-141 were deregulated in BC comparing with controls. Furthermore, miR-200c and miR-141 were independent prognostic factors and associated with distinct outcomes of BC patients." +circulation_biomarker_prognosis_ns hsa-mir-200c Breast Neoplasms 25885099 "Circulating miR-200c and miR-141 were deregulated in BC comparing with controls. Furthermore, miR-200c and miR-141 were independent prognostic factors and associated with distinct outcomes of BC patients." +circulation_biomarker_prognosis_ns hsa-mir-208a Breast Neoplasms 26046768 Circulating mir-208a fails as a biomarker of doxorubicin-induced cardiotoxicity in breast cancer patients. +circulation_biomarker_prognosis_ns hsa-mir-200a Ovarian Neoplasms 26063644 "Our findings suggest that miR-200a, miR-200b, and miR-200c overexpressions are associated with the aggressive tumor progression and be recognized as reliable markers to predict the prognosis and survival in EOC patients." +circulation_biomarker_prognosis_ns hsa-mir-200b Ovarian Neoplasms 26063644 "Our findings suggest that miR-200a, miR-200b, and miR-200c overexpressions are associated with the aggressive tumor progression and be recognized as reliable markers to predict the prognosis and survival in EOC patients." +circulation_biomarker_prognosis_ns hsa-mir-200c Ovarian Neoplasms 26063644 "Our findings suggest that miR-200a, miR-200b, and miR-200c overexpressions are associated with the aggressive tumor progression and be recognized as reliable markers to predict the prognosis and survival in EOC patients." +circulation_biomarker_prognosis_ns hsa-mir-21 Gastric Neoplasms 26063956 Circulating MicroRNA-21 Is a Potential Diagnostic Biomarker in Gastric Cancer. +circulation_biomarker_prognosis_ns hsa-mir-197 Lung Neoplasms 26078336 Especially hsa-miR-197 could be validated by qRT-PCR as prognostic marker. +circulation_biomarker_prognosis_ns hsa-mir-126 Intermittent Claudication 26116711 "Whole blood expression of pro-angiogenic microRNA-126 increased after maximal exercise in the PLA session, but treatment with NAC prevented this response." +circulation_biomarker_prognosis_ns hsa-mir-10 "Leukemia, Myeloid, Acute" 26134365 Serum level of miR-10-5p as a prognostic biomarker for acute myeloid leukemia. +circulation_biomarker_prognosis_ns hsa-mir-106a Colorectal Carcinoma 26250939 The present study reveals novel serum-miRNA-based biomarkers for monitoring tumor dynamics as well as for predicting disease recurrence in patients with stage II/III CRC. +circulation_biomarker_prognosis_ns hsa-mir-145 Colorectal Carcinoma 26250939 The present study reveals novel serum-miRNA-based biomarkers for monitoring tumor dynamics as well as for predicting disease recurrence in patients with stage II/III CRC. +circulation_biomarker_prognosis_ns hsa-mir-17 Colorectal Carcinoma 26250939 The present study reveals novel serum-miRNA-based biomarkers for monitoring tumor dynamics as well as for predicting disease recurrence in patients with stage II/III CRC. +circulation_biomarker_prognosis_ns hsa-mir-101 Pleural Mesothelioma 26262875 "In conclusion, we suggest that miRNA signature A is predictive of sarcomatoid histotype and of worse prognosis in MPM." +circulation_biomarker_prognosis_ns hsa-mir-191 Pleural Mesothelioma 26262875 "In conclusion, we suggest that miRNA signature A is predictive of sarcomatoid histotype and of worse prognosis in MPM." +circulation_biomarker_prognosis_ns hsa-mir-223 Pleural Mesothelioma 26262875 "In conclusion, we suggest that miRNA signature A is predictive of sarcomatoid histotype and of worse prognosis in MPM." +circulation_biomarker_prognosis_ns hsa-mir-25 Pleural Mesothelioma 26262875 "In conclusion, we suggest that miRNA signature A is predictive of sarcomatoid histotype and of worse prognosis in MPM." +circulation_biomarker_prognosis_ns hsa-mir-26b Pleural Mesothelioma 26262875 "In conclusion, we suggest that miRNA signature A is predictive of sarcomatoid histotype and of worse prognosis in MPM." +circulation_biomarker_prognosis_ns hsa-mir-29a Pleural Mesothelioma 26262875 "In conclusion, we suggest that miRNA signature A is predictive of sarcomatoid histotype and of worse prognosis in MPM." +circulation_biomarker_prognosis_ns hsa-mir-335 Pleural Mesothelioma 26262875 "In conclusion, we suggest that miRNA signature A is predictive of sarcomatoid histotype and of worse prognosis in MPM." +circulation_biomarker_prognosis_ns hsa-mir-433 Pleural Mesothelioma 26262875 "In conclusion, we suggest that miRNA signature A is predictive of sarcomatoid histotype and of worse prognosis in MPM." +circulation_biomarker_prognosis_ns hsa-mir-516 Pleural Mesothelioma 26262875 "In conclusion, we suggest that miRNA signature A is predictive of sarcomatoid histotype and of worse prognosis in MPM." +circulation_biomarker_prognosis_ns hsa-mir-224 Lymphoma 26301883 MiR-224 expression level is implicated as a prognostic marker for DLBCL patients treated with R-CHOP. +circulation_biomarker_prognosis_ns hsa-mir-124 Toxic Epidermal Necrolysis 26394757 "The serum miR-124 concentration can be used as a disease activity marker for severe drug eruptions, reflecting the severity of keratinocyte apoptosis." +circulation_biomarker_prognosis_ns hsa-mir-4728 Breast Neoplasms 26406406 MiR-4728-3p had better ability in distinguishing patients with different status of HER2 than miR-4728-5p. And plasma miR-4728-3p might act as a non-invasive biomarker in predicting HER2 status. +circulation_biomarker_prognosis_ns hsa-mir-200c Malignant Neoplasms [unspecific] 26556949 "Our findings indicated that, compared to their tissue counterparts, the expression level of miR-200c and miR-141 in peripheral blood may be more effective for monitoring cancer prognosis. High miR-141 expression was better at predicting tumor progression than survival for malignant tumors." +circulation_biomarker_prognosis_ns hsa-mir-122 Autoimmune Hepatitis 26575387 Alternations of miR-21 and miR-122 serum levels could reflect their putative roles in the mediation of inflammatory processes in AIH. +circulation_biomarker_prognosis_ns hsa-mir-21 Autoimmune Hepatitis 26575387 Alternations of miR-21 and miR-122 serum levels could reflect their putative roles in the mediation of inflammatory processes in AIH. +circulation_biomarker_prognosis_ns hsa-mir-200c Gastric Neoplasms 26662382 Serum miR-200c expression level as a prognostic biomarker for gastric cancer. +circulation_biomarker_prognosis_ns hsa-mir-15a Sepsis 26683209 The plasma levels of miRNA are altered in patients with severe sepsis complicated by shock and may offer prognostic value as well as insights into the mechanisms of endothelial dysfunction in sepsis. +circulation_biomarker_prognosis_ns hsa-mir-27a Sepsis 26683209 The plasma levels of miRNA are altered in patients with severe sepsis complicated by shock and may offer prognostic value as well as insights into the mechanisms of endothelial dysfunction in sepsis. +circulation_biomarker_prognosis_ns hsa-mir-16 "Squamous Cell Carcinoma, Esophageal" 26692950 the level of miR-16 in the patients with good outcome was significantly higher than that in the patients with poor outcome +circulation_biomarker_prognosis_ns hsa-mir-197 Coronary Artery Disease 26720041 Serum-derived circulating miRNA-197 and miRNA-223 were identified as predictors for cardiovascular death in a large patient cohort with CAD. These results reinforce the assumption that circulating miRNAs are promising biomarkers with prognostic value with respect to future cardiovascular events. +circulation_biomarker_prognosis_ns hsa-mir-223 Coronary Artery Disease 26720041 Serum-derived circulating miRNA-197 and miRNA-223 were identified as predictors for cardiovascular death in a large patient cohort with CAD. These results reinforce the assumption that circulating miRNAs are promising biomarkers with prognostic value with respect to future cardiovascular events. +circulation_biomarker_prognosis_ns hsa-mir-122 "Carcinoma, Hepatocellular" 27074850 "HCC and/or histological components of NASH affected serum miR-122 levels, independently." +circulation_biomarker_prognosis_ns hsa-mir-455 "Squamous Cell Carcinoma, Head and Neck" 27109697 "miR-193b-3p and miR-455-5p were positively associated with survival, and miR-92a-3p and miR-497-5p were negatively associated with survival in OPSCC." +circulation_biomarker_prognosis_ns hsa-let-7 Lung Neoplasms 27133539 Patients with a high level of baseline serum let-7 expression level had significantly better overall survival +circulation_biomarker_prognosis_ns hsa-let-7 Chronic Hepatitis C 27227815 reduced levels of let-7a/7c/7d-5p (let-7s) in plasma were correlated with advanced histological hepatic fibrosis stage +circulation_biomarker_prognosis_ns hsa-mir-29a Acquired Immunodeficiency Syndrome 27232693 the expression level of miR-29a was found to be inversely correlated with HIV viral load +circulation_biomarker_prognosis_ns hsa-mir-29a Human Immunodeficiency Virus Infection 27232693 the expression level of miR-29a was found to be inversely correlated with HIV viral load +circulation_biomarker_prognosis_ns hsa-mir-125b "Carcinoma, Hepatocellular" 27267832 serum miR-125b can serve as a biomarker to reliably predict microvascular invasion +circulation_biomarker_prognosis_ns hsa-mir-181d Pancreatic Neoplasms 27380024 serum miR-181d was significantly associated with the presence of metastasis in patients with PDA +circulation_biomarker_prognosis_ns hsa-mir-106b Ependymoma 27390862 "Three miRNAs were shown to efficiently differentiate between grade II and III ependymomas: miR-17-5p, miR-19a-3p, and miR-106b-5p." +circulation_biomarker_prognosis_ns hsa-mir-196a Gastric Neoplasms 27420607 "Taken together, we propose that circulating miR-196a/b serve as a more sensitive and specific novel biomarker than carbohydrate antigen 19-9 for GC monitor, diagnosis and prognosis." +circulation_biomarker_prognosis_ns hsa-mir-196b Gastric Neoplasms 27420607 "Taken together, we propose that circulating miR-196a/b serve as a more sensitive and specific novel biomarker than carbohydrate antigen 19-9 for GC monitor, diagnosis and prognosis." +circulation_biomarker_prognosis_ns hsa-mir-484 "Carcinoma, Thyroid, Follicular" 27473101 The best two-miRNA classifier (miR-484/miR-148b-3p) identified thyroid malignancy with a sensitivity of 89â€? and a specificity of 87â€?. +circulation_biomarker_prognosis_ns hsa-mir-1296 "Carcinoma, Colon" 27485175 "The expression signature of five miRNAs (miR-1296, miR-135b, miR-539, miR-572 and miR-185) was found to be prognostic [p = 1.28E-07, HR 8.4 (95 % CI: 3.81-18.52)] for DMFS" +circulation_biomarker_prognosis_ns hsa-mir-135b "Carcinoma, Colon" 27485175 "The expression signature of five miRNAs (miR-1296, miR-135b, miR-539, miR-572 and miR-185) was found to be prognostic [p = 1.28E-07, HR 8.4 (95 % CI: 3.81-18.52)] for DMFS." +circulation_biomarker_prognosis_ns hsa-mir-185 "Carcinoma, Colon" 27485175 "The expression signature of five miRNAs (miR-1296, miR-135b, miR-539, miR-572 and miR-185) was found to be prognostic [p = 1.28E-07, HR 8.4 (95 % CI: 3.81-18.52)] for DMFS." +circulation_biomarker_prognosis_ns hsa-mir-539 "Carcinoma, Colon" 27485175 "The expression signature of five miRNAs (miR-1296, miR-135b, miR-539, miR-572 and miR-185) was found to be prognostic [p = 1.28E-07, HR 8.4 (95 % CI: 3.81-18.52)] for DMFS." +circulation_biomarker_prognosis_ns hsa-mir-572 "Carcinoma, Colon" 27485175 "The expression signature of five miRNAs (miR-1296, miR-135b, miR-539, miR-572 and miR-185) was found to be prognostic [p = 1.28E-07, HR 8.4 (95 % CI: 3.81-18.52)] for DMFS." +circulation_biomarker_prognosis_ns hsa-mir-592 "Carcinoma, Colon" 27485175 The expression of miR-592 was significantly associated with the MMR status (p.adjusted <0.01). +circulation_biomarker_prognosis_ns hsa-mir-516a Breast Neoplasms 27528030 "Finally, we show that a combination of 2 miRNAs (miR-190b and miR-516a-5p) exhibiting altered expression in TamR cell lines were predictive of treatment outcome in a cohort of ER+ breast cancer patients receiving adjuvant tamoxifen mono-therapy." +circulation_biomarker_prognosis_ns hsa-mir-34a "Carcinoma, Breast" 27561942 Human serum miR-34a as an indicator of exposure to ionizing radiation. +circulation_biomarker_prognosis_ns hsa-mir-18a Retinoblastoma 27574784 "Downregulation of inhibitor of apoptosis proteins, tumor miRNA-18a, altered serum cytokines, and serum miRNA-18a levels were observed upon NCL-APT treatment" +circulation_biomarker_prognosis_ns hsa-mir-21 "Carcinoma, Breast" 27696295 Serum microRNA-21 expression as a prognostic and therapeutic biomarker for breast cancer patients. +circulation_biomarker_prognosis_ns hsa-mir-15b Multiple Sclerosis 27725128 "Effect of fingolimod treatment on circulating miR-15b, miR23a and miR-223 levels in patients with multiple sclerosis." +circulation_biomarker_prognosis_ns hsa-mir-223 Multiple Sclerosis 27725128 "Effect of fingolimod treatment on circulating miR-15b, miR23a and miR-223 levels in patients with multiple sclerosis." +circulation_biomarker_prognosis_ns hsa-mir-23a Multiple Sclerosis 27725128 "Effect of fingolimod treatment on circulating miR-15b, miR23a and miR-223 levels in patients with multiple sclerosis." +circulation_biomarker_prognosis_ns hsa-mir-6826 "Carcinoma, Colon" 27878288 MicroRNA-6826 and -6875 in plasma are valuable non?invasive biomarkers that predict the efficacy of vaccine treatment against metastatic colorectal cancer. +circulation_biomarker_prognosis_ns hsa-mir-6875 "Carcinoma, Colon" 27878288 MicroRNA-6826 and -6875 in plasma are valuable non?invasive biomarkers that predict the efficacy of vaccine treatment against metastatic colorectal cancer. +circulation_biomarker_prognosis_ns hsa-let-7i "Carcinoma, Breast" 27959953 Identification of MicroRNAs as Breast Cancer Prognosis Markers through the Cancer Genome Atlas. +circulation_biomarker_prognosis_ns hsa-mir-103a "Carcinoma, Breast" 27959953 Identification of MicroRNAs as Breast Cancer Prognosis Markers through the Cancer Genome Atlas. +circulation_biomarker_prognosis_ns hsa-mir-140 "Carcinoma, Breast" 27959953 Identification of MicroRNAs as Breast Cancer Prognosis Markers through the Cancer Genome Atlas. +circulation_biomarker_prognosis_ns hsa-mir-200c "Carcinoma, Breast" 27959953 Identification of MicroRNAs as Breast Cancer Prognosis Markers through the Cancer Genome Atlas. +circulation_biomarker_prognosis_ns hsa-mir-21 "Carcinoma, Breast" 27959953 Identification of MicroRNAs as Breast Cancer Prognosis Markers through the Cancer Genome Atlas. +circulation_biomarker_prognosis_ns hsa-mir-25 "Carcinoma, Breast" 27959953 Identification of MicroRNAs as Breast Cancer Prognosis Markers through the Cancer Genome Atlas. +circulation_biomarker_prognosis_ns hsa-mir-30a "Carcinoma, Breast" 27959953 Identification of MicroRNAs as Breast Cancer Prognosis Markers through the Cancer Genome Atlas. +circulation_biomarker_prognosis_ns hsa-mir-30c "Carcinoma, Breast" 27959953 Identification of MicroRNAs as Breast Cancer Prognosis Markers through the Cancer Genome Atlas. +circulation_biomarker_prognosis_ns hsa-mir-320a "Carcinoma, Breast" 27959953 Identification of MicroRNAs as Breast Cancer Prognosis Markers through the Cancer Genome Atlas. +circulation_biomarker_prognosis_ns hsa-mir-361 "Carcinoma, Breast" 27959953 Identification of MicroRNAs as Breast Cancer Prognosis Markers through the Cancer Genome Atlas. +circulation_biomarker_prognosis_ns hsa-mir-374b "Carcinoma, Breast" 27959953 Identification of MicroRNAs as Breast Cancer Prognosis Markers through the Cancer Genome Atlas. +circulation_biomarker_prognosis_ns hsa-mir-651 "Carcinoma, Breast" 27959953 Identification of MicroRNAs as Breast Cancer Prognosis Markers through the Cancer Genome Atlas. +circulation_biomarker_prognosis_ns hsa-mir-101 Heart Transplant Rejection 28125729 Association of Serum MiR-142-3p and MiR-101-3p Levels with Acute Cellular Rejection after Heart Transplantation. +circulation_biomarker_prognosis_ns hsa-mir-142 Heart Transplant Rejection 28125729 Association of Serum MiR-142-3p and MiR-101-3p Levels with Acute Cellular Rejection after Heart Transplantation. +circulation_biomarker_prognosis_ns hsa-mir-33a "Carcinoma, Lung, Non-Small-Cell" 28141816 Association of microRNA-33a Molecular Signature with Non-Small Cell Lung Cancer Diagnosis and Prognosis after Chemotherapy. +circulation_biomarker_prognosis_ns hsa-let-7b Multiple Myeloma 28213378 Prognostic role of circulating exosomal miRNAs in multiple myeloma. +circulation_biomarker_prognosis_ns hsa-mir-18a Multiple Myeloma 28213378 Prognostic role of circulating exosomal miRNAs in multiple myeloma. +circulation_biomarker_prognosis_ns hsa-mir-30d Heart Failure 28214846 Circulating miR-30d Predicts Survival in Patients with Acute Heart Failure. +circulation_biomarker_prognosis_ns hsa-mir-106a Glioblastoma 28284220 Serum microRNA profiling in patients with glioblastoma: a survival analysis. +circulation_biomarker_prognosis_ns hsa-mir-145 Glioblastoma 28284220 Serum microRNA profiling in patients with glioblastoma: a survival analysis. +circulation_biomarker_prognosis_ns hsa-mir-182 Glioblastoma 28284220 Serum microRNA profiling in patients with glioblastoma: a survival analysis. +circulation_biomarker_prognosis_ns hsa-mir-20a Glioblastoma 28284220 Serum microRNA profiling in patients with glioblastoma: a survival analysis. +circulation_biomarker_prognosis_ns hsa-mir-222 Glioblastoma 28284220 Serum microRNA profiling in patients with glioblastoma: a survival analysis. +circulation_biomarker_prognosis_ns hsa-mir-1274a "Carcinoma, Ovarian" 28293063 Evaluation of Prognostic and Predictive Significance of Circulating MicroRNAs in Ovarian Cancer Patients. +circulation_biomarker_prognosis_ns hsa-mir-141 "Carcinoma, Ovarian" 28293063 Evaluation of Prognostic and Predictive Significance of Circulating MicroRNAs in Ovarian Cancer Patients. +circulation_biomarker_prognosis_ns hsa-mir-200b "Carcinoma, Ovarian" 28293063 Evaluation of Prognostic and Predictive Significance of Circulating MicroRNAs in Ovarian Cancer Patients. +circulation_biomarker_prognosis_ns hsa-mir-200c "Carcinoma, Ovarian" 28293063 Evaluation of Prognostic and Predictive Significance of Circulating MicroRNAs in Ovarian Cancer Patients. +circulation_biomarker_prognosis_ns hsa-mir-200 Neoplasms [unspecific] 28321402 Prognostic Role of the MicroRNA-200 Family in Various Carcinomas: A Systematic Review and Meta-Analysis. +circulation_biomarker_prognosis_ns hsa-mir-192 "Carcinoma, Periampullary" 28351309 Plasma microRNA192 in combination with serum CA19-9 as non-invasive prognostic biomarker in periampullary carcinoma. +circulation_biomarker_prognosis_ns hsa-mir-122 "Lymphoma, Hodgkin" 28377796 Redox Regulating Enzymes and Connected MicroRNA Regulators Have Prognostic Value in Classical Hodgkin Lymphomas. +circulation_biomarker_prognosis_ns hsa-mir-144 "Lymphoma, Hodgkin" 28377796 Redox Regulating Enzymes and Connected MicroRNA Regulators Have Prognostic Value in Classical Hodgkin Lymphomas. +circulation_biomarker_prognosis_ns hsa-mir-212 "Lymphoma, Hodgkin" 28377796 Redox Regulating Enzymes and Connected MicroRNA Regulators Have Prognostic Value in Classical Hodgkin Lymphomas. +circulation_biomarker_prognosis_ns hsa-mir-23b "Lymphoma, Hodgkin" 28377796 Redox Regulating Enzymes and Connected MicroRNA Regulators Have Prognostic Value in Classical Hodgkin Lymphomas. +circulation_biomarker_prognosis_ns hsa-mir-510 "Lymphoma, Hodgkin" 28377796 Redox Regulating Enzymes and Connected MicroRNA Regulators Have Prognostic Value in Classical Hodgkin Lymphomas. +circulation_biomarker_prognosis_ns hsa-mir-122 Chronic Hepatitis C 28401565 Serum and exosomal miR-122 and miR-199a as a biomarker to predict therapeutic efficacy of hepatitis C patients. +circulation_biomarker_prognosis_ns hsa-mir-199a Chronic Hepatitis C 28401565 Serum and exosomal miR-122 and miR-199a as a biomarker to predict therapeutic efficacy of hepatitis C patients. +circulation_biomarker_prognosis_ns hsa-mir-1 Atrial Fibrillation 28422282 "Analysis of Circulating miR-1, miR-23a, and miR-26a in Atrial Fibrillation Patients Undergoing Coronary Bypass Artery Grafting Surgery." +circulation_biomarker_prognosis_ns hsa-mir-23a Atrial Fibrillation 28422282 "Analysis of Circulating miR-1, miR-23a, and miR-26a in Atrial Fibrillation Patients Undergoing Coronary Bypass Artery Grafting Surgery." +circulation_biomarker_prognosis_ns hsa-mir-26a Atrial Fibrillation 28422282 "Analysis of Circulating miR-1, miR-23a, and miR-26a in Atrial Fibrillation Patients Undergoing Coronary Bypass Artery Grafting Surgery." +circulation_biomarker_prognosis_ns hsa-mir-15a "Leukemia, Lymphocytic, Chronic, B-Cell" 28599250 Evaluation of MiR-15a and MiR-16-1 as prognostic biomarkers in chronic lymphocytic leukemia. +circulation_biomarker_prognosis_ns hsa-mir-16-1 "Leukemia, Lymphocytic, Chronic, B-Cell" 28599250 Evaluation of MiR-15a and MiR-16-1 as prognostic biomarkers in chronic lymphocytic leukemia. +circulation_biomarker_prognosis_ns hsa-mir-21 Preeclampsia 28694210 Circulating microRNA expression as predictor of preeclampsia and its severity. +circulation_biomarker_prognosis_ns hsa-mir-125b "Carcinoma, Hepatocellular" 28814883 Serum exosomal miR-125b is a novel prognostic marker for hepatocellular carcinoma +circulation_biomarker_prognosis_ns hsa-mir-34a "Fatty Liver, Non-Alcoholic" 28853202 Potentially pro-apoptotic miR-34a was reduced in the vesicle-free fraction in serum but not in liver after UDCA treatment +circulation_biomarker_prognosis_ns hsa-mir-192 "Carcinoma, Urothelial" 28928837 "hsa-mir-7705, hsa-mir-192 and hsa-mir-518b can be applied as independent prognostic markers for bladder urothelial carcinoma" +circulation_biomarker_prognosis_ns hsa-mir-518b "Carcinoma, Urothelial" 28928837 "hsa-mir-7705, hsa-mir-192 and hsa-mir-518b can be applied as independent prognostic markers for bladder urothelial carcinoma" +circulation_biomarker_prognosis_ns hsa-mir-7705 "Carcinoma, Urothelial" 28928837 "hsa-mir-7705, hsa-mir-192 and hsa-mir-518b can be applied as independent prognostic markers for bladder urothelial carcinoma" +circulation_biomarker_prognosis_ns hsa-mir-181a "Leukemia, Myeloid, Acute" 29166738 Expression characteristics and prognosis significance of miRNA-181a in acute myeloid leukemia with normal karyotype +circulation_biomarker_prognosis_ns hsa-mir-122 "Carcinoma, Breast" 29243807 "some exosomal miRNAs including miR-126, miR-122, miR-92-1, miR-19a, and miR-29c together with circular miRNAs, such as miR-21-5p, miR-96-5p, and miR-125b-5p can provide a promising evaluation route in breast cancer prognosis" +circulation_biomarker_prognosis_ns hsa-mir-125b "Carcinoma, Breast" 29243807 "some exosomal miRNAs including miR-126, miR-122, miR-92-1, miR-19a, and miR-29c together with circular miRNAs, such as miR-21-5p, miR-96-5p, and miR-125b-5p can provide a promising evaluation route in breast cancer prognosis" +circulation_biomarker_prognosis_ns hsa-mir-126 "Carcinoma, Breast" 29243807 "some exosomal miRNAs including miR-126, miR-122, miR-92-1, miR-19a, and miR-29c together with circular miRNAs, such as miR-21-5p, miR-96-5p, and miR-125b-5p can provide a promising evaluation route in breast cancer prognosis" +circulation_biomarker_prognosis_ns hsa-mir-19a "Carcinoma, Breast" 29243807 "some exosomal miRNAs including miR-126, miR-122, miR-92-1, miR-19a, and miR-29c together with circular miRNAs, such as miR-21-5p, miR-96-5p, and miR-125b-5p can provide a promising evaluation route in breast cancer prognosis" +circulation_biomarker_prognosis_ns hsa-mir-21 "Carcinoma, Breast" 29243807 "some exosomal miRNAs including miR-126, miR-122, miR-92-1, miR-19a, and miR-29c together with circular miRNAs, such as miR-21-5p, miR-96-5p, and miR-125b-5p can provide a promising evaluation route in breast cancer prognosis" +circulation_biomarker_prognosis_ns hsa-mir-29c "Carcinoma, Breast" 29243807 "some exosomal miRNAs including miR-126, miR-122, miR-92-1, miR-19a, and miR-29c together with circular miRNAs, such as miR-21-5p, miR-96-5p, and miR-125b-5p can provide a promising evaluation route in breast cancer prognosis" +circulation_biomarker_prognosis_ns hsa-mir-92-1 "Carcinoma, Breast" 29243807 "some exosomal miRNAs including miR-126, miR-122, miR-92-1, miR-19a, and miR-29c together with circular miRNAs, such as miR-21-5p, miR-96-5p, and miR-125b-5p can provide a promising evaluation route in breast cancer prognosis" +circulation_biomarker_prognosis_ns hsa-mir-96 "Carcinoma, Breast" 29243807 "some exosomal miRNAs including miR-126, miR-122, miR-92-1, miR-19a, and miR-29c together with circular miRNAs, such as miR-21-5p, miR-96-5p, and miR-125b-5p can provide a promising evaluation route in breast cancer prognosis" +circulation_biomarker_prognosis_ns hsa-mir-148a "Carcinoma, Hepatocellular" 29291025 "tissue miR-9, miR-21, miR-22, miR-29c, miR-34a, miR-34c, miR-155, miR-199a, miR-200a, miR-203, miR-221 and blood miR-21, miR-148a, miR-192, miR-224 demonstrate significantly prognostic value" +circulation_biomarker_prognosis_ns hsa-mir-192 "Carcinoma, Hepatocellular" 29291025 "tissue miR-9, miR-21, miR-22, miR-29c, miR-34a, miR-34c, miR-155, miR-199a, miR-200a, miR-203, miR-221 and blood miR-21, miR-148a, miR-192, miR-224 demonstrate significantly prognostic value" +circulation_biomarker_prognosis_ns hsa-mir-21 "Carcinoma, Hepatocellular" 29291025 "tissue miR-9, miR-21, miR-22, miR-29c, miR-34a, miR-34c, miR-155, miR-199a, miR-200a, miR-203, miR-221 and blood miR-21, miR-148a, miR-192, miR-224 demonstrate significantly prognostic value" +circulation_biomarker_prognosis_ns hsa-mir-224 "Carcinoma, Hepatocellular" 29291025 "tissue miR-9, miR-21, miR-22, miR-29c, miR-34a, miR-34c, miR-155, miR-199a, miR-200a, miR-203, miR-221 and blood miR-21, miR-148a, miR-192, miR-224 demonstrate significantly prognostic value" +circulation_biomarker_prognosis_ns hsa-mir-16 "Carcinoma, Hepatocellular" 29333940 "Also, miR-16, miR-34a, and miR-221 serum levels would have a prognostic value" +circulation_biomarker_prognosis_ns hsa-mir-221 "Carcinoma, Hepatocellular" 29333940 "Also, miR-16, miR-34a, and miR-221 serum levels would have a prognostic value" +circulation_biomarker_prognosis_ns hsa-mir-34a "Carcinoma, Hepatocellular" 29333940 "Also, miR-16, miR-34a, and miR-221 serum levels would have a prognostic value" +circulation_biomarker_prognosis_ns hsa-mir-155 Leukemia 29654787 miR-155 might be a promising prognostic biomarker for this patient population +circulation_biomarker_prognosis_ns hsa-mir-126 Aplastic Anemia 29674506 "mir-126-5p, was negatively correlated with a response to therapy in aplastic anemia" +circulation_biomarker_prognosis_ns hsa-mir-215 Lung Neoplasms 29683761 "we identified a signature of seven microRNAs (miR-215-5p, miR-411-3p, miR-493-5p, miR-494-3p, miR-495-3p, miR-548j-5p and miR-93-3p) significantly associated with overall survival" +circulation_biomarker_prognosis_ns hsa-mir-411 Lung Neoplasms 29683761 "we identified a signature of seven microRNAs (miR-215-5p, miR-411-3p, miR-493-5p, miR-494-3p, miR-495-3p, miR-548j-5p and miR-93-3p) significantly associated with overall survival" +circulation_biomarker_prognosis_ns hsa-mir-493 Lung Neoplasms 29683761 "we identified a signature of seven microRNAs (miR-215-5p, miR-411-3p, miR-493-5p, miR-494-3p, miR-495-3p, miR-548j-5p and miR-93-3p) significantly associated with overall survival" +circulation_biomarker_prognosis_ns hsa-mir-494 Lung Neoplasms 29683761 "we identified a signature of seven microRNAs (miR-215-5p, miR-411-3p, miR-493-5p, miR-494-3p, miR-495-3p, miR-548j-5p and miR-93-3p) significantly associated with overall survival" +circulation_biomarker_prognosis_ns hsa-mir-495 Lung Neoplasms 29683761 "we identified a signature of seven microRNAs (miR-215-5p, miR-411-3p, miR-493-5p, miR-494-3p, miR-495-3p, miR-548j-5p and miR-93-3p) significantly associated with overall survival" +circulation_biomarker_prognosis_ns hsa-mir-548j Lung Neoplasms 29683761 "we identified a signature of seven microRNAs (miR-215-5p, miR-411-3p, miR-493-5p, miR-494-3p, miR-495-3p, miR-548j-5p and miR-93-3p) significantly associated with overall survival" +circulation_biomarker_prognosis_ns hsa-mir-93 Lung Neoplasms 29683761 "we identified a signature of seven microRNAs (miR-215-5p, miR-411-3p, miR-493-5p, miR-494-3p, miR-495-3p, miR-548j-5p and miR-93-3p) significantly associated with overall survival" +circulation_biomarker_prognosis_ns hsa-mir-3662 "Leukemia-Lymphoma, Adult T-Cell" 29684346 MicroRNA-3662 expression correlates with antiviral drug resistance in adult T-cell leukemia/lymphoma cells. +circulation_biomarker_prognosis_ns hsa-mir-142 Coronary Artery Disease 29891858 Plasma miR-142 predicts major adverse cardiovascular events as an intermediate biomarker of dual antiplatelet therapy. +circulation_biomarker_prognosis_ns hsa-mir-125b "Carcinoma, Pancreatic" 29913239 Plasma miR-125b-5p might act as an independent biomarker in predicting OS of PC patients +circulation_biomarker_prognosis_ns hsa-mir-21 Liver Cirrhosis 29935272 MicroRNA profiles in serum samples from patients with stable cirrhosis and miRNA-21 as a predictor of transplant-free survival. +circulation_biomarker_prognosis_ns hsa-mir-30a Myocardial Infarction 29959359 Circulating miR-30a-5p as a prognostic biomarker of left ventricular dysfunction after acute myocardial infarction. +circulation_biomarker_prognosis_ns hsa-mir-122 "Carcinoma, Hepatocellular" 30127924 Serum exosomal microRNA-122 and microRNA-21 as predictive biomarkers in transarterial chemoembolization-treated hepatocellular carcinoma patients. +circulation_biomarker_prognosis_ns hsa-mir-21 "Carcinoma, Hepatocellular" 30127924 Serum exosomal microRNA-122 and microRNA-21 as predictive biomarkers in transarterial chemoembolization-treated hepatocellular carcinoma patients. +circulation_biomarker_prognosis_ns hsa-mir-141 Colon Neoplasms 30138915 Prognostic Impact of miR-200 Family Members in Plasma and Exosomes from Tumor-Draining versus Peripheral Veins of Colon Cancer Patients. +circulation_biomarker_prognosis_ns hsa-mir-200a Colon Neoplasms 30138915 Prognostic Impact of miR-200 Family Members in Plasma and Exosomes from Tumor-Draining versus Peripheral Veins of Colon Cancer Patients. +circulation_biomarker_prognosis_ns hsa-mir-200b Colon Neoplasms 30138915 Prognostic Impact of miR-200 Family Members in Plasma and Exosomes from Tumor-Draining versus Peripheral Veins of Colon Cancer Patients. +circulation_biomarker_prognosis_ns hsa-mir-200c Colon Neoplasms 30138915 Prognostic Impact of miR-200 Family Members in Plasma and Exosomes from Tumor-Draining versus Peripheral Veins of Colon Cancer Patients. +circulation_biomarker_prognosis_ns hsa-mir-429 Colon Neoplasms 30138915 Prognostic Impact of miR-200 Family Members in Plasma and Exosomes from Tumor-Draining versus Peripheral Veins of Colon Cancer Patients. +circulation_biomarker_prognosis_ns hsa-mir-328 Colorectal Carcinoma 30166271 Serum-based microRNA signature predicts relapse and therapeutic outcome of adjuvant chemotherapy in colorectal cancer patients. +circulation_biomarker_prognosis_ns hsa-mir-342 Colorectal Carcinoma 30166271 Serum-based microRNA signature predicts relapse and therapeutic outcome of adjuvant chemotherapy in colorectal cancer patients. +circulation_biomarker_prognosis_ns hsa-mir-501 Colorectal Carcinoma 30166271 Serum-based microRNA signature predicts relapse and therapeutic outcome of adjuvant chemotherapy in colorectal cancer patients. +circulation_biomarker_prognosis_ns hsa-mir-652 Colorectal Carcinoma 30166271 Serum-based microRNA signature predicts relapse and therapeutic outcome of adjuvant chemotherapy in colorectal cancer patients. +circulation_biomarker_prognosis_ns hsa-mir-1202 Depression Disorder 30181751 "Serum-based microRNA biomarkers for major depression: MiR-16, miR-135a, and miR-1202." +circulation_biomarker_prognosis_ns hsa-mir-135a Depression Disorder 30181751 "Serum-based microRNA biomarkers for major depression: MiR-16, miR-135a, and miR-1202." +circulation_biomarker_prognosis_ns hsa-mir-16 Depression Disorder 30181751 "Serum-based microRNA biomarkers for major depression: MiR-16, miR-135a, and miR-1202." +circulation_biomarker_prognosis_ns hsa-mir-21 "Carcinoma, Lung, Non-Small-Cell" 30190521 "combination of miR-1290, miR-196b and miR-135a in tumor tissue, and miR-21, miR-25, miR27b, and miR-326 in plasma were predictive for response to platinum-based chemotherapy in advanced NSCLC" +circulation_biomarker_prognosis_ns hsa-mir-25 "Carcinoma, Lung, Non-Small-Cell" 30190521 "combination of miR-1290, miR-196b and miR-135a in tumor tissue, and miR-21, miR-25, miR27b, and miR-326 in plasma were predictive for response to platinum-based chemotherapy in advanced NSCLC" +circulation_biomarker_prognosis_ns hsa-mir-27b "Carcinoma, Lung, Non-Small-Cell" 30190521 "combination of miR-1290, miR-196b and miR-135a in tumor tissue, and miR-21, miR-25, miR27b, and miR-326 in plasma were predictive for response to platinum-based chemotherapy in advanced NSCLC" +circulation_biomarker_prognosis_ns hsa-mir-326 "Carcinoma, Lung, Non-Small-Cell" 30190521 "combination of miR-1290, miR-196b and miR-135a in tumor tissue, and miR-21, miR-25, miR27b, and miR-326 in plasma were predictive for response to platinum-based chemotherapy in advanced NSCLC" +circulation_biomarker_prognosis_ns hsa-mir-125a "Leukemia, Lymphocytic, Chronic, B-Cell" 30242085 MiR-125a and MiR-34a expression predicts Richter syndrome in chronic lymphocytic leukemia patients. +circulation_biomarker_prognosis_ns hsa-mir-34a "Leukemia, Lymphocytic, Chronic, B-Cell" 30242085 MiR-125a and MiR-34a expression predicts Richter syndrome in chronic lymphocytic leukemia patients. +circulation_biomarker_prognosis_ns hsa-mir-21 "Adenocarcinoma, Pancreatic Ductal" 30336280 "Prognostic significance of circulating microRNA-21 expression in esophageal, pancreatic and colorectal cancers; a systematic review and meta-analysis." +circulation_biomarker_prognosis_ns hsa-mir-21 Colorectal Carcinoma 30336280 "Prognostic significance of circulating microRNA-21 expression in esophageal, pancreatic and colorectal cancers; a systematic review and meta-analysis." +circulation_biomarker_prognosis_ns hsa-mir-21 "Squamous Cell Carcinoma, Esophageal" 30336280 "Prognostic significance of circulating microRNA-21 expression in esophageal, pancreatic and colorectal cancers; a systematic review and meta-analysis." +circulation_biomarker_prognosis_ns hsa-mir-155 "Leukemia, Lymphoblastic, Acute" 30362157 miRNA-155 and miRNA-181a as prognostic biomarkers for pediatric acute lymphoblastic leukemia. +circulation_biomarker_prognosis_ns hsa-mir-181a "Leukemia, Lymphoblastic, Acute" 30362157 miRNA-155 and miRNA-181a as prognostic biomarkers for pediatric acute lymphoblastic leukemia. +circulation_biomarker_prognosis_up hsa-mir-29b Encephalitis 30196835 Increased serum microRNA-29b expression and bad recovery in Japanese encephalitis virus infected patients; A new component to improve the disease recovery. +circulation_biomarker_prognosis_up hsa-mir-155 Lung Neoplasms 17028302 A high expression of miR-155 has been suggested to be significantly associated with unfavorable prognosis in lung adenocarcinoma patients. +circulation_biomarker_prognosis_up hsa-mir-155 Lung Neoplasms 17028596 "High mir-155 associated with poor prognosis in lung cancer (Yanaihara et al., 2006)." +circulation_biomarker_prognosis_up hsa-mir-125b-1 Rectal Neoplasms 18695884 miR-125b: frequently upregulated in response to capecitabine chemoradiotherapy of rectal cancer +circulation_biomarker_prognosis_up hsa-mir-125b-2 Rectal Neoplasms 18695884 miR-125b: frequently upregulated in response to capecitabine chemoradiotherapy of rectal cancer +circulation_biomarker_prognosis_up hsa-mir-137 Rectal Neoplasms 18695884 miR-137: frequently upregulated in response to capecitabine chemoradiotherapy of rectal cancer +circulation_biomarker_prognosis_up hsa-mir-21 Breast Neoplasms 18812439 "miR-21: miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis" +circulation_biomarker_prognosis_up hsa-mir-211 "Carcinoma, Oral" 18946016 miR-211: Association between high miR-211 microRNA expression and the poor prognosis +circulation_biomarker_prognosis_up hsa-mir-155 Waldenstrom Macroglobulinemia 19074725 miR-155: increased expression +circulation_biomarker_prognosis_up hsa-mir-184 Waldenstrom Macroglobulinemia 19074725 miR-184: increased expression +circulation_biomarker_prognosis_up hsa-mir-206 Waldenstrom Macroglobulinemia 19074725 miR-206: increased expression +circulation_biomarker_prognosis_up hsa-mir-363 Waldenstrom Macroglobulinemia 19074725 miR-363*: increased expression +circulation_biomarker_prognosis_up hsa-mir-494 Waldenstrom Macroglobulinemia 19074725 miR-494: increased expression +circulation_biomarker_prognosis_up hsa-mir-542 Waldenstrom Macroglobulinemia 19074725 miR-542-3p: increased expression +circulation_biomarker_prognosis_up hsa-mir-21 Pancreatic Neoplasms 21139804 upregulated and correlated with worse survival +circulation_biomarker_prognosis_up hsa-mir-221 "Carcinoma, Hepatocellular" 21295551 "Serum miR-221, upregulated in HCC, can provide predictive significance for prognosis of HCC patients." +circulation_biomarker_prognosis_up hsa-mir-141 Colorectal Carcinoma 21445232 High levels of plasma miR-141 predicted poor survival in both cohorts and that miR-141 was an independent prognostic factor for advanced colon cancer. +circulation_biomarker_prognosis_up hsa-mir-200c Lung Neoplasms 21516486 High expression of serum miR-21 and tumor miR-200c associated with poor prognosis in patients with lung cancer +circulation_biomarker_prognosis_up hsa-mir-21 Lung Neoplasms 21516486 High expression of serum miR-21 and tumor miR-200c associated with poor prognosis in patients with lung cancer +circulation_biomarker_prognosis_up hsa-mir-663a "Leukemia, Myeloid, Acute" 21518431 Retinoic acid induces HL-60 cell differentiation via the upregulation of miR-663 +circulation_biomarker_prognosis_up hsa-mir-183 Lung Neoplasms 21920043 Expression levels of members of the miR-183 family in lung cancer tumor and sera were higher than that of their normal counterparts. The miR-96 expression in tumors was positively associated with its expression in sera. Log-rank and Cox regression analyses demonstrated that high expression of tumor and serum miRNAs of the miR-183 family were associated with overall poor survival in patients with lung cancer. +circulation_biomarker_prognosis_up hsa-mir-96 Lung Neoplasms 21920043 Expression levels of members of the miR-183 family in lung cancer tumor and sera were higher than that of their normal counterparts. The miR-96 expression in tumors was positively associated with its expression in sera. Log-rank and Cox regression analyses demonstrated that high expression of tumor and serum miRNAs of the miR-183 family were associated with overall poor survival in patients with lung cancer. +circulation_biomarker_prognosis_up hsa-mir-21 Lymphoma 22541087 The expression of miR-21 in plasma of lymphoma patient group significantly correlated with their serum LDH level. The expressions of miR-21 and miR-210 in plasma of previously untreated lymphoma patient group were higher than those of the patients treated for 6 or more courses +circulation_biomarker_prognosis_up hsa-mir-210 Lymphoma 22541087 The expression of miR-21 in plasma of lymphoma patient group significantly correlated with their serum LDH level. The expressions of miR-21 and miR-210 in plasma of previously untreated lymphoma patient group were higher than those of the patients treated for 6 or more courses +circulation_biomarker_prognosis_up hsa-let-7d Glioblastoma 22722712 "miR-181b, miR-153, miR-145, miR-137, and let-7d were significantly upregulated after treatment with both TMZ (temozolomide ) and OLE (Olea europaea leaf extract)." +circulation_biomarker_prognosis_up hsa-mir-155 Acute Myocardial Infarction 22995291 "Real-time RT-PCR confirmed that the serum levels of miR-155 and miR-380* were approximately 4- and 3-fold higher, respectively, in patients who experienced cardiac death within 1 year after discharge." +circulation_biomarker_prognosis_up hsa-mir-380 Acute Myocardial Infarction 22995291 "Real-time RT-PCR confirmed that the serum levels of miR-155 and miR-380* were approximately 4- and 3-fold higher, respectively, in patients who experienced cardiac death within 1 year after discharge." +circulation_biomarker_prognosis_up hsa-mir-100 "Leukemia, Myeloid, Acute" 23055746 Upregulation of microRNA-100 predicts poor prognosis in patients with pediatric acute myeloid leukemia +circulation_biomarker_prognosis_up hsa-mir-1 Heart Failure 23079087 Elevated plasma microRNA-1 predicts heart failure after acute myocardial infarction. +circulation_biomarker_prognosis_up hsa-mir-17 "Carcinoma, Hepatocellular" 23108086 High expression of serum miR-17-5p associated with poor prognosis in patients with hepatocellular carcinoma +circulation_biomarker_prognosis_up hsa-mir-200c "Lymphoma, Large B-Cell, Diffuse" 23232598 High expression of microRNA-200c predicts poor clinical outcome in diffuse large B-cell lymphoma +circulation_biomarker_prognosis_up hsa-mir-221 "Leukemia, Lymphoblastic, Acute" 23566596 Increased expression of miR-221 is associated with shorter overall survival in T-cell acute lymphoid leukemia +circulation_biomarker_prognosis_up hsa-mir-146b Prostate Neoplasms 23846169 Multivariate analysis revealed that miR-146b-3p possessed prognostic information beyond standard clinicopathological parameters. +circulation_biomarker_prognosis_up hsa-mir-194 Prostate Neoplasms 23846169 "Analysis of tissue cohorts revealed that miR-194 was robustly expressed in the prostate, elevated in metastases, and its expression in primary tumours was associated with a poor prognosis." +circulation_biomarker_prognosis_up hsa-mir-375 "Leukemia, Myeloid, Acute" 23864342 Upregulation of microRNA-375 is associated with poor prognosis in pediatric acute myeloid leukemia. +circulation_biomarker_prognosis_up hsa-mir-27a Neoplasms [unspecific] 24122958 miRNA27a is a biomarker for predicting chemosensitivity and prognosis in metastatic or recurrent gastric cancer. +circulation_biomarker_prognosis_up hsa-mir-221 "Carcinoma, Renal Cell" 24379138 Higher circulating expression levels of miR-221 associated with poor overall survival in renal cell carcinoma patients. +circulation_biomarker_prognosis_up hsa-mir-10b Breast Neoplasms 24416156 "High levels of miR-21 and miR-10b were present in the serum of patients with non-metastatic and metastatic HER2(+) breast cancer, respectively. High levels of serum miR-19a may represent a biomarker for IBC that is predictive for favorable clinical outcome in patients with metastatic HER2(+) IBC." +circulation_biomarker_prognosis_up hsa-mir-19a Breast Neoplasms 24416156 "High levels of miR-21 and miR-10b were present in the serum of patients with non-metastatic and metastatic HER2(+) breast cancer, respectively. High levels of serum miR-19a may represent a biomarker for IBC that is predictive for favorable clinical outcome in patients with metastatic HER2(+) IBC." +circulation_biomarker_prognosis_up hsa-mir-21 Breast Neoplasms 24416156 "High levels of miR-21 and miR-10b were present in the serum of patients with non-metastatic and metastatic HER2(+) breast cancer, respectively. High levels of serum miR-19a may represent a biomarker for IBC that is predictive for favorable clinical outcome in patients with metastatic HER2(+) IBC." +circulation_biomarker_prognosis_up hsa-mir-210 Aortic Stenosis 24626394 Circulating miR-210 levels are increased in patients with AS and provide independent prognostic information to established risk indices.Analytical characteristics were also excellent supporting the potential of micro-RNAs as novel CV biomarkers. +circulation_biomarker_prognosis_up hsa-mir-221 Prostate Neoplasms 24760272 Influence of peripheral whole-blood microRNA-7 and microRNA-221 high expression levels on the acquisition of castration-resistant prostate cancer: evidences from in vitro and in vivo studies. +circulation_biomarker_prognosis_up hsa-mir-7 Prostate Neoplasms 24760272 Influence of peripheral whole-blood microRNA-7 and microRNA-221 high expression levels on the acquisition of castration-resistant prostate cancer: evidences from in vitro and in vivo studies. +circulation_biomarker_prognosis_up hsa-mir-200c Neoplasms [unspecific] 24870778 Low expression of microRNA 200c in tumor tissue and high expression of microRNA 200c in serum are associated with worse survival in solid tumors. Further study is needed to elucidate this contradiction. +circulation_biomarker_prognosis_up hsa-mir-15b Melanoma 25155861 Serum miR-15b levels significantly increased over time in recurrent patients +circulation_biomarker_prognosis_up hsa-mir-21 Breast Neoplasms 25277099 "Women with metastatic breast cancer, especially CSII, presented up-regulated levels of miR-183, miR-494 and miR-21, which were associated with a poor prognosis." +circulation_biomarker_prognosis_up hsa-mir-221 "Carcinoma, Lung, Non-Small-Cell" 25466375 High serum miR-155 and miR-221 during the first 2 weeks of CRT were associated with the development of severe RIET +circulation_biomarker_prognosis_up hsa-mir-155 Breast Neoplasms 25503185 a possible involvement of miR-155 in surgery-induced angiogenesis and potential prognostic significance of high postoperative levels of circulating miR-195 in patients with breast cancer. +circulation_biomarker_prognosis_up hsa-mir-195 Breast Neoplasms 25503185 a possible involvement of miR-155 in surgery-induced angiogenesis and potential prognostic significance of high postoperative levels of circulating miR-195 in patients with breast cancer. +circulation_biomarker_prognosis_up hsa-mir-21 Breast Neoplasms 25503185 a possible involvement of miR-155 in surgery-induced angiogenesis and potential prognostic significance of high postoperative levels of circulating miR-195 in patients with breast cancer. +circulation_biomarker_prognosis_up hsa-mir-183 Colorectal Carcinoma 25629978 the elevated miR-183 in the plasma could be a promising biomarker for predicting the risk of tumor recurrence and poor survival in CRC patients. +circulation_biomarker_prognosis_up hsa-mir-122 "Carcinoma, Hepatocellular" 25636448 "high serum miR-122 level is independently associated with higher overall survival rate in hepatocellular carcinoma patients, and it is a good biomarker of better prognosis in patients with hepatocellular carcinoma." +circulation_biomarker_prognosis_up hsa-mir-24 "Leukemia, Acute" 25672522 High miR-24 expression is associated with risk of relapse and poor survival in acute leukemia. +circulation_biomarker_prognosis_up hsa-mir-18a "Squamous Cell Carcinoma, Head and Neck" 25677760 "significant elevated expressions of miR-21, miR-18a, miR-134a, miR-210, miR-181a, miR-19a, and miR-155 were associated with poor survival in human HNSCC." +circulation_biomarker_prognosis_up hsa-mir-18b Lymphoma 25736311 miR-18b overexpression identifies mantle cell lymphoma patients with poor outcome and improves the MIPI-B prognosticator. +circulation_biomarker_prognosis_up hsa-mir-183 Tuberculosis 25755759 High serum miR-183 level is associated with the bioactivity of macrophage derived from tuberculosis patients. +circulation_biomarker_prognosis_up hsa-mir-126 "Leukemia, Myeloid, Acute" 25759982 "The results of the present study demonstrated that higher expression levels of miR-126-5p/3p in patients with AML resulted in a poorer prognosis. Furthermore, miR-126-5p elevated the phosphorylation of Akt." +circulation_biomarker_prognosis_up hsa-mir-21 Brain Neoplasms 25790954 "microRNA-21 is associated with the prognosis of patients with brain tumors, and high expression of microRNA-21 can predict poor prognosis in patients with brain tumors." +circulation_biomarker_prognosis_up hsa-mir-206 Myotonic Muscular Dystrophy 25915631 "Specifically, miR-1, miR-133a, miR133b and miR-206 serum levels were found elevated in DM1 patients with progressive muscle wasting compared to disease stable DM1 patients." +circulation_biomarker_prognosis_up hsa-mir-155 Bladder Neoplasms 25918190 We found that elevated expression of miR-155 is correlated with a poor outcome for patients with bladder cancer; this suggests that miR-155 is a potential biomarker for bladder cancer prognosis. +circulation_biomarker_prognosis_up hsa-mir-17 Colorectal Carcinoma 26057451 Abundant expression of exosomal miR-19a in serum was identified as a prognostic biomarker for recurrence in CRC patients. +circulation_biomarker_prognosis_up hsa-mir-18 Colorectal Carcinoma 26057451 Abundant expression of exosomal miR-19a in serum was identified as a prognostic biomarker for recurrence in CRC patients. +circulation_biomarker_prognosis_up hsa-mir-19a Colorectal Carcinoma 26057451 Abundant expression of exosomal miR-19a in serum was identified as a prognostic biomarker for recurrence in CRC patients. +circulation_biomarker_prognosis_up hsa-mir-19b-1 Colorectal Carcinoma 26057451 Abundant expression of exosomal miR-19a in serum was identified as a prognostic biomarker for recurrence in CRC patients. +circulation_biomarker_prognosis_up hsa-mir-20a Colorectal Carcinoma 26057451 Abundant expression of exosomal miR-19a in serum was identified as a prognostic biomarker for recurrence in CRC patients. +circulation_biomarker_prognosis_up hsa-mir-92-1 Colorectal Carcinoma 26057451 Abundant expression of exosomal miR-19a in serum was identified as a prognostic biomarker for recurrence in CRC patients. +circulation_biomarker_prognosis_up hsa-mir-183 Kidney Neoplasms 26091793 High serum miR-183 level is associated with poor responsiveness of renal cancer to natural killer cells. +circulation_biomarker_prognosis_up hsa-mir-551b "Leukemia, Myeloid, Acute" 26108690 MicroRNA-551b is highly expressed in hematopoietic stem cells and a biomarker for relapse and poor prognosis in acute myeloid leukemia. +circulation_biomarker_prognosis_up hsa-mir-483 "Adenocarcinoma, Pancreatic Ductal" 26124009 Elevated miR-483-3p expression is an early event and indicates poor prognosis in pancreatic ductal adenocarcinoma. +circulation_biomarker_prognosis_up hsa-mir-122 "Carcinoma, Hepatocellular" 26129878 High plasma microRNA-122 expression was associated with poor OS in patients with HBV-related hepatocellular carcinoma who underwent RFA. +circulation_biomarker_prognosis_up hsa-mir-21 Prostate Neoplasms 26247873 "Our study demonstrates that high miR-21 expression levels in PBMCs were correlated with the presence, recurrence, and metastasis of PCa and that this may be a useful biomarker for screening PCa and monitoring the risk of Pca recurrence and metastasis." +circulation_biomarker_prognosis_up hsa-mir-141 Malignant Neoplasms [unspecific] 26556949 "Our findings indicated that, compared to their tissue counterparts, the expression level of miR-200c and miR-141 in peripheral blood may be more effective for monitoring cancer prognosis. High miR-141 expression was better at predicting tumor progression than survival for malignant tumors." +circulation_biomarker_prognosis_up hsa-mir-203 Colorectal Carcinoma 26701878 "Serum miR-203 levels were significantly upregulated in a stage-dependent manner, and high miR-203 expression was associated with poor survival in patients with CRC in both patient cohorts." +circulation_biomarker_prognosis_up hsa-mir-21 "Adenocarcinoma, Pancreatic Ductal" 26705427 Upregulation of these microRNAs was associated with a significantly shorter overall survival and recurrence-free survival +circulation_biomarker_prognosis_up hsa-mir-210 "Adenocarcinoma, Pancreatic Ductal" 26705427 Upregulation of these microRNAs was associated with a significantly shorter overall survival and recurrence-free survival +circulation_biomarker_prognosis_up hsa-mir-34a "Lymphoma, B-Cell" 26854484 High miR-34a expression improves response to doxorubicin in diffuse large B-cell lymphoma. +circulation_biomarker_prognosis_up hsa-mir-125b "Lymphoma, Large B-Cell" 26870228 high miR-125b indicated poor prognosis +circulation_biomarker_prognosis_up hsa-mir-21 "Adenocarcinoma, Pancreatic Ductal" 26969625 Our meta-analysis indicated that elevated miR-21 expression level can predict poor prognosis in patients with PDAC. +circulation_biomarker_prognosis_up hsa-mir-17 "Lymphoma, Burkitt" 27044389 miR-17-92 cluster components analysis in Burkitt lymphoma: overexpression of miR-17 is associated with poor prognosis. +circulation_biomarker_prognosis_up hsa-mir-20a "Lymphoma, Burkitt" 27044389 We found that upregulated expression of miR-17 and miR-20a correlates with lack of pro-apoptotic Bim expression. +circulation_biomarker_prognosis_up hsa-mir-125b Rectum Adenocarcinoma 27081702 High miR-125b expression in tissue and serum were associated with a poor treatment response in LARC patients +circulation_biomarker_prognosis_up hsa-mir-21 Cervical Neoplasms 27101583 Increased circulating miR-21 expression in serum is associated with lymph node metastasis in patients with cervical cancer. +circulation_biomarker_prognosis_up hsa-mir-29c Diabetic Nephropathy 27279796 "miR-21, miR-29a/b/c and miR-192 could reflect DN pathogenesis" +circulation_biomarker_prognosis_up hsa-mir-21 "Carcinoma, Urothelial" 27383043 miR-21 may be a prognostic marker for cancer progression. +circulation_biomarker_prognosis_up hsa-mir-1260b Colorectal Carcinoma 27399918 The high expression level of miR-1260b is an independent prognostic biomarker that indicates a worse prognosis for patients with CRC. +circulation_biomarker_prognosis_up hsa-mir-10b Pancreatic Adenocarcinoma 27456015 We conclude that elevated miRNA-10b levels in station 8 lymph nodes could be utilized to assess risk for early disease progression in patients with periampullary tumors. +circulation_biomarker_prognosis_up hsa-mir-522 "Carcinoma, Hepatocellular" 27466991 Upregulation of miR-522 is associated with poor outcome of hepatocellular carcinoma. +circulation_biomarker_prognosis_up hsa-mir-18b "Carcinoma, Colon" 27485175 "The expression of several novel miRNAs were found to be tumour specific, e.g. miR-888, miR-523, miR-18b, miR-302a, miR-423-5p, miR-582-3p (p < 0.05)." +circulation_biomarker_prognosis_up hsa-mir-302a "Carcinoma, Colon" 27485175 "The expression of several novel miRNAs were found to be tumour specific, e.g. miR-888, miR-523, miR-18b, miR-302a, miR-423-5p, miR-582-3p (p < 0.05)." +circulation_biomarker_prognosis_up hsa-mir-423 "Carcinoma, Colon" 27485175 "The expression of several novel miRNAs were found to be tumour specific, e.g. miR-888, miR-523, miR-18b, miR-302a, miR-423-5p, miR-582-3p (p < 0.05)." +circulation_biomarker_prognosis_up hsa-mir-523 "Carcinoma, Colon" 27485175 "The expression of several novel miRNAs were found to be tumour specific, e.g. miR-888, miR-523, miR-18b, miR-302a, miR-423-5p, miR-582-3p (p < 0.05)." +circulation_biomarker_prognosis_up hsa-mir-582 "Carcinoma, Colon" 27485175 "The expression of several novel miRNAs were found to be tumour specific, e.g. miR-888, miR-523, miR-18b, miR-302a, miR-423-5p, miR-582-3p (p < 0.05)." +circulation_biomarker_prognosis_up hsa-mir-888 "Carcinoma, Colon" 27485175 "The expression of several novel miRNAs were found to be tumour specific, e.g. miR-888, miR-523, miR-18b, miR-302a, miR-423-5p, miR-582-3p (p < 0.05)." +circulation_biomarker_prognosis_up hsa-mir-101 "Carcinoma, Hepatocellular" 27498785 "High miR-101 expression, vascular invasion, tumor size â‰? cm and late pathological stage were the risk factors of recurrence-free survival rate." +circulation_biomarker_prognosis_up hsa-mir-155 "Leukemia, Myeloid, Acute" 27511899 High miR-155 expression is an adverse prognostic factor in pediatric NK-AML patients. +circulation_biomarker_prognosis_up hsa-mir-133a Hypertension 27514547 The hypertensive ocean seamen had significantly higher expression levels of microRNA21 and MicroRNA133a than the healthy ocean seamen. +circulation_biomarker_prognosis_up hsa-mir-21 Hypertension 27514547 The hypertensive ocean seamen had significantly higher expression levels of microRNA21 and MicroRNA133a than the healthy ocean seamen. +circulation_biomarker_prognosis_up hsa-mir-21 Glioblastoma 27531352 Further subgroup analysis indicated that increased expression of miRNA-21 was also associated with OS in GBM patients. +circulation_biomarker_prognosis_up hsa-mir-21 Glioma 27531352 Our analysis revealed that the high expression of miRNA-21 is associated with the worse OS in gliomas. +circulation_biomarker_prognosis_up hsa-mir-155 "Leukemia, Myeloid, Acute" 27531760 The high expression of miR-155 is an poor prognostic factor for patients with AML. +circulation_biomarker_prognosis_up hsa-mir-181c Cholangiocarcinoma 27533020 Down-regulation of NDRG2 and overexpression of miR-181c or LIF are significantly associated with a poorer overall survival (OS) in CCA patients. +circulation_biomarker_prognosis_up hsa-mir-126 Diabetic Foot 27623390 Increasing the miR-126 expression in the peripheral blood of patients with diabetic foot ulcers treated with maggot debridement therapy. +circulation_biomarker_prognosis_up hsa-mir-21 B-cell Childhood Acute Lymphoblastic Leukemia 28253825 Upregulation of microRNA-21 is a poor prognostic marker in patients with childhood B cell acute lymphoblastic leukemia. +circulation_biomarker_prognosis_up hsa-mir-203 Breast Neoplasms 28351024 the upregulation of circulating miR-203 in blood was associated with poor prognosis in colorectal cancer and breast cancer +circulation_biomarker_prognosis_up hsa-mir-203 Colorectal Carcinoma 28351024 the upregulation of circulating miR-203 in blood was associated with poor prognosis in colorectal cancer and breast cancer +circulation_biomarker_prognosis_up hsa-mir-146b "Leukemia, Myeloid, Acute" 28473658 high expression of hsa-miR-146b was independent poor prognostic factor +circulation_biomarker_prognosis_up hsa-mir-181c "Leukemia, Myeloid, Acute" 28473658 high expression of hsa-miR-181c and hsa-miR-4786 appeared to be favorable factors +circulation_biomarker_prognosis_up hsa-mir-206 Rhabdomyosarcoma 28834127 "Serum microRNA-206 levels were elevated and remained high after three cycles of vincristine, dactinomycin, and cyclophosphamide (VAC)" +circulation_biomarker_prognosis_up hsa-mir-146b Breast Neoplasms 29189128 "up-regulation of miR181b, miR-34a, miR-16, miR-15a and miR-146b-5p, and down-regulation of miR-19a and miR-19b have been shown following the treatment of several breast cancer cell lines with curcumin" +circulation_biomarker_prognosis_up hsa-mir-15a Breast Neoplasms 29189128 "up-regulation of miR181b, miR-34a, miR-16, miR-15a and miR-146b-5p, and down-regulation of miR-19a and miR-19b have been shown following the treatment of several breast cancer cell lines with curcumin" +circulation_biomarker_prognosis_up hsa-mir-16 Breast Neoplasms 29189128 "up-regulation of miR181b, miR-34a, miR-16, miR-15a and miR-146b-5p, and down-regulation of miR-19a and miR-19b have been shown following the treatment of several breast cancer cell lines with curcumin" +circulation_biomarker_prognosis_up hsa-mir-181b Breast Neoplasms 29189128 "up-regulation of miR181b, miR-34a, miR-16, miR-15a and miR-146b-5p, and down-regulation of miR-19a and miR-19b have been shown following the treatment of several breast cancer cell lines with curcumin" +circulation_biomarker_prognosis_up hsa-mir-34a Breast Neoplasms 29189128 "up-regulation of miR181b, miR-34a, miR-16, miR-15a and miR-146b-5p, and down-regulation of miR-19a and miR-19b have been shown following the treatment of several breast cancer cell lines with curcumin" +circulation_biomarker_prognosis_up hsa-mir-155 Stevens-Johnson Syndrome 29644860 "MiR-155 up-regulation wasdetected in PBMCs from all hypersensitive patients 24 h after drug treatment, while miR-18a and miR-21 expression was up-regulated after 48 h" +circulation_biomarker_prognosis_up hsa-mir-133b Atrial Fibrillation 29676832 "The miRNAs had different expression profiles dependent on the AF condition, with higher expression in the acute new-onset AF than well-controlled AF" +circulation_biomarker_prognosis_up hsa-mir-328 Atrial Fibrillation 29676832 "The miRNAs had different expression profiles dependent on the AF condition, with higher expression in the acute new-onset AF than well-controlled AF" +circulation_biomarker_prognosis_up hsa-mir-499 Atrial Fibrillation 29676832 "The miRNAs had different expression profiles dependent on the AF condition, with higher expression in the acute new-onset AF than well-controlled AF" +circulation_biomarker_prognosis_up hsa-mir-103a "Diabetes Mellitus, Type 1" 29679626 "miR-103a-3p, miR-155-5p, miR-200a-3p, and miR-210-3p were confirmed as being upregulated in recently-diagnosed T1DM patients compared with controls or patients with ¡Ý5?years of diagnosis" +circulation_biomarker_prognosis_up hsa-mir-155 "Diabetes Mellitus, Type 1" 29679626 "miR-103a-3p, miR-155-5p, miR-200a-3p, and miR-210-3p were confirmed as being upregulated in recently-diagnosed T1DM patients compared with controls or patients with ¡Ý5?years of diagnosis" +circulation_biomarker_prognosis_up hsa-mir-200a "Diabetes Mellitus, Type 1" 29679626 "miR-103a-3p, miR-155-5p, miR-200a-3p, and miR-210-3p were confirmed as being upregulated in recently-diagnosed T1DM patients compared with controls or patients with ¡Ý5?years of diagnosis" +circulation_biomarker_prognosis_up hsa-mir-210 "Diabetes Mellitus, Type 1" 29679626 "miR-103a-3p, miR-155-5p, miR-200a-3p, and miR-210-3p were confirmed as being upregulated in recently-diagnosed T1DM patients compared with controls or patients with ¡Ý5?years of diagnosis" +circulation_biomarker_prognosis_up hsa-mir-502 Aneurysmal Subarachnoid Hemorrhage 29689401 Persistent High Levels of miR-502-5p Are Associated with Poor Neurologic Outcome in Patients with Aneurysmal Subarachnoid Hemorrhage. +circulation_biomarker_prognosis_up hsa-mir-20a "Carcinoma, Breast" 30099860 "baseline miR-222 overexpression, C2 miR-20a up-regulation and C2 miR-451 down-regulation were predictive markers of response to NCT in HR+/HER2- breast cancer" +circulation_biomarker_prognosis_up hsa-mir-222 "Carcinoma, Breast" 30099860 "baseline miR-222 overexpression, C2 miR-20a up-regulation and C2 miR-451 down-regulation were predictive markers of response to NCT in HR+/HER2- breast cancer" +circulation_biomarker_prognosis_up hsa-mir-126 Osteoarthritis 30105874 "Circulating miRNA expression profiles act as important roles in knee OA patients underwent celecoxib treatment, and miR-126-5p, miR-320a as well as miR-146a-5p might correlate with treatment response to celecoxib" +circulation_biomarker_prognosis_up hsa-mir-320a Osteoarthritis 30105874 "Circulating miRNA expression profiles act as important roles in knee OA patients underwent celecoxib treatment, and miR-126-5p, miR-320a as well as miR-146a-5p might correlate with treatment response to celecoxib" +circulation_biomarker_prognosis_up hsa-mir-509 "Leukemia, Myeloid, Acute" 30242879 "the high expression of hsa-miR-509 and hsa-miR-542 were independent poor prognostic factors, whereas that of hsa-miR-146a and hsa-miR-3667 had a trend to be favorable factors" +circulation_biomarker_prognosis_up hsa-mir-542 "Leukemia, Myeloid, Acute" 30242879 "the high expression of hsa-miR-509 and hsa-miR-542 were independent poor prognostic factors, whereas that of hsa-miR-146a and hsa-miR-3667 had a trend to be favorable factors" +circulation_biomarker_prognosis_up hsa-mir-1273g Ovarian Neoplasms 30264202 hsa-miR-1273g-3p may be used as a prognostic marker for recurrent EOC after chemotherapy +circulation_biomarker_prognosis_up hsa-mir-183 Major Depressive Disorder 30269040 Antidepressant treatment increased serum miR-183 and miR-212 levels in patients with major depressive disorder. +circulation_biomarker_prognosis_up hsa-mir-212 Major Depressive Disorder 30269040 Antidepressant treatment increased serum miR-183 and miR-212 levels in patients with major depressive disorder. +circulation_biomarker_prognosis_up hsa-mir-1246 Plasmodium Falciparum Malaria 30352683 "we identified five enriched upregulated miRNA sets (miR-3135b, miR-6780b-5p, miR-1246, miR-6126, and miR-3613-5p) as potential blood biomarkers of immunopathological status and prediction of early host responses, disease prognosis, and severe outcomes in AIFM" +circulation_biomarker_prognosis_up hsa-mir-3135b Plasmodium Falciparum Malaria 30352683 "we identified five enriched upregulated miRNA sets (miR-3135b, miR-6780b-5p, miR-1246, miR-6126, and miR-3613-5p) as potential blood biomarkers of immunopathological status and prediction of early host responses, disease prognosis, and severe outcomes in AIFM" +circulation_biomarker_prognosis_up hsa-mir-3613 Plasmodium Falciparum Malaria 30352683 "we identified five enriched upregulated miRNA sets (miR-3135b, miR-6780b-5p, miR-1246, miR-6126, and miR-3613-5p) as potential blood biomarkers of immunopathological status and prediction of early host responses, disease prognosis, and severe outcomes in AIFM" +circulation_biomarker_prognosis_up hsa-mir-6126 Plasmodium Falciparum Malaria 30352683 "we identified five enriched upregulated miRNA sets (miR-3135b, miR-6780b-5p, miR-1246, miR-6126, and miR-3613-5p) as potential blood biomarkers of immunopathological status and prediction of early host responses, disease prognosis, and severe outcomes in AIFM" +circulation_biomarker_prognosis_up hsa-mir-6780b Plasmodium Falciparum Malaria 30352683 "we identified five enriched upregulated miRNA sets (miR-3135b, miR-6780b-5p, miR-1246, miR-6126, and miR-3613-5p) as potential blood biomarkers of immunopathological status and prediction of early host responses, disease prognosis, and severe outcomes in AIFM" +circulation_biomarker_prognosis_up hsa-mir-200c Colorectal Carcinoma 30381824 Detection of Circulating MicroRNAs with Ago2 Complexes to Monitor the Tumor Dynamics of Colorectal Cancer Patients during Chemotherapy. +epigenetics hsa-mir-195 "Carcinoma, Hepatocellular" 17188425 "miRNA-195 expression is decreased in HCC compared to nontumor liver [59], and is also deleted in lung cancer [65], suggesting it is tumor related. miRNA-195 alters the expression of methyl-CpG binding protein 2 (which alters DNA methylation), the SKI oncogene, and a Bcl-2 like protein [59], suggesting miRNA-195 may act as a tumor suppressor in HCC." +epigenetics hsa-mir-127 Colon Neoplasms 17355635 "Human miR-127 is embedded in a CpG island and is silenced in several human cancers including bladder, prostate and colon cancer and has been suggested to play a role as a possible tumour suppressor gene." +epigenetics hsa-mir-127 Prostate Neoplasms 17355635 "Human miR-127 is embedded in a CpG island and is silenced in several human cancers including bladder, prostate and colon cancer and has been suggested to play a role as a possible tumour suppressor gene." +epigenetics hsa-mir-127 Urinary Bladder Cancer 17355635 "Human miR-127 is embedded in a CpG island and is silenced in several human cancers including bladder, prostate and colon cancer and has been suggested to play a role as a possible tumour suppressor gene." +epigenetics hsa-mir-29a Lung Neoplasms 17890317 "mir-29 family (29a,b,c) reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B." +epigenetics hsa-mir-29b Lung Neoplasms 17890317 MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. +epigenetics hsa-mir-29b-1 Lung Neoplasms 17890317 "mir-29 family (29a,b,c) reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B." +epigenetics hsa-mir-29c Lung Neoplasms 17890317 "mir-29 family (29a,b,c) reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B." +epigenetics hsa-mir-34b Colorectal Carcinoma 18519671 "Our results suggest that miR-34b/c and BTG4 are novel tumor suppressors in CRC and that the miR-34b/c CpG island, which bidirectionally regulates miR-34b/c and BTG4, is a frequent target of epigenetic silencing in CRC." +epigenetics hsa-mir-34c Colorectal Carcinoma 18519671 "Our results suggest that miR-34b/c and BTG4 are novel tumor suppressors in CRC and that the miR-34b/c CpG island, which bidirectionally regulates miR-34b/c and BTG4, is a frequent target of epigenetic silencing in CRC." +epigenetics hsa-mir-1 Cardiomegaly 18539123 "Microinjecting fragments of either the coding region or the related microRNA miR-1 led to high levels of expression of homologous RNA, resulting in an epigenetic defect, cardiac hypertrophy, whose efficient hereditary transmission correlated with the presence of miR-1 in the sperm nucleus." +epigenetics hsa-mir-34a Neoplasms [unspecific] 18719384 "miR-34a: inactivation, Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer" +epigenetics hsa-mir-34b Neoplasms [unspecific] 18768788 miR-34b: were found to undergo specific hypermethylation-associated silencing in cancer cells compared with normal tissues +epigenetics hsa-mir-34c Neoplasms [unspecific] 18768788 miR-34c: were found to undergo specific hypermethylation-associated silencing in cancer cells compared with normal tissues +epigenetics hsa-mir-9-1 Neoplasms [unspecific] 18768788 miR-9: were found to undergo specific hypermethylation-associated silencing in cancer cells compared with normal tissues +epigenetics hsa-mir-9-2 Neoplasms [unspecific] 18768788 miR-9: were found to undergo specific hypermethylation-associated silencing in cancer cells compared with normal tissues +epigenetics hsa-mir-9-3 Neoplasms [unspecific] 18768788 miR-9: were found to undergo specific hypermethylation-associated silencing in cancer cells compared with normal tissues +epigenetics hsa-mir-126 Neoplasms [unspecific] 19116145 miR-126: a tumor supressor: Epigenetic therapy upregulates the tumor suppressor microRNA-126 and its host gene EGFL7 +epigenetics hsa-mir-29b-1 "Leukemia, Myeloid, Acute" 19211935 miR-29b: induces global DNA hypomethylation and tumor suppressor gene re-expression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1 +epigenetics hsa-mir-29b-2 "Leukemia, Myeloid, Acute" 19211935 miR-29b: induces global DNA hypomethylation and tumor suppressor gene re-expression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1 +epigenetics hsa-mir-107 Pancreatic Neoplasms 19407485 Epigenetic silencing of MicroRNA miR-107 regulates cyclin-dependent kinase 6 expression in pancreatic cancer. +epigenetics hsa-mir-512 Gastric Neoplasms 19503096 Chromatin remodeling at Alu repeats by epigenetic treatment activates silenced microRNA-512-5p with downregulation of Mcl-1 in human gastric cancer cells. +epigenetics hsa-mir-22 "Leukemia, Lymphoblastic, Acute" 19807731 "Thus, accumulation of H3K27triM independent of promoter DNA methylation may be a novel epigenetic mechanism for MIR22 silencing in ALL." +epigenetics hsa-mir-124-1 "Carcinoma, Hepatocellular" 19843643 miR-124:miR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepatocellular carcinoma. +epigenetics hsa-mir-124-2 "Carcinoma, Hepatocellular" 19843643 miR-124:miR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepatocellular carcinoma. +epigenetics hsa-mir-124-3 "Carcinoma, Hepatocellular" 19843643 miR-124:miR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepatocellular carcinoma. +epigenetics hsa-mir-203 "Carcinoma, Hepatocellular" 19843643 miR-203:miR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepatocellular carcinoma. +epigenetics hsa-mir-212 Gastric Neoplasms 20020497 miR-212:miR-212 is downregulated and suppresses methyl-CpG-binding protein MeCP2 in human gastric cancer +epigenetics hsa-mir-193b Prostate Neoplasms 20073067 miR-193b:miR-193b is an epigenetically regulated putative tumor suppressor in prostate cancer +epigenetics hsa-mir-181c Gastric Neoplasms 20080834 miR-181c:Involvement of epigenetically silenced microRNA-181c in gastric carcinogenesis. +epigenetics hsa-mir-137 "Squamous Cell Carcinoma, Oral" 20197299 miR-137:MicroRNA-137 promoter methylation in oral rinses from patients with squamous cell carcinoma of the head and neck is associated with gender and body mass index +epigenetics hsa-mir-148a Lung Neoplasms 20431052 miR-148a:The silencing of microRNA 148a production by DNA hypermethylation is an early event in pancreatic carcinogenesis +epigenetics hsa-mir-124-1 Myelodysplastic Syndromes 20448201 miRNA-124:Methylation and silencing of miRNA-124 by EVI1 and self-renewal exhaustion of hematopoietic stem cells in murine myelodysplastic syndrome +epigenetics hsa-mir-124-2 Myelodysplastic Syndromes 20448201 miRNA-124:Methylation and silencing of miRNA-124 by EVI1 and self-renewal exhaustion of hematopoietic stem cells in murine myelodysplastic syndrome +epigenetics hsa-mir-124-3 Myelodysplastic Syndromes 20448201 miRNA-124:Methylation and silencing of miRNA-124 by EVI1 and self-renewal exhaustion of hematopoietic stem cells in murine myelodysplastic syndrome +epigenetics hsa-mir-27a Pancreatic Neoplasms 20488920 "microRNA-27a:Methyl 2-cyano-3,12-dioxooleana-1,9-dien-28-oate decreases specificity protein transcription factors and inhibits pancreatic tumor growth: role of microRNA-27a" +epigenetics hsa-mir-206 Waldenstrom Macroglobulinemia 20519629 miR-206:Waldenstr?m macroglobulinemia (WM) cells present with increased expression of microRNA-206 (miRNA-206) and reduced expression of miRNA-9 +epigenetics hsa-mir-9-1 Waldenstrom Macroglobulinemia 20519629 miR-9:Waldenstr?m macroglobulinemia (WM) cells present with increased expression of microRNA-206 (miRNA-206) and reduced expression of miRNA-9 +epigenetics hsa-mir-9-2 Waldenstrom Macroglobulinemia 20519629 miR-9:Waldenstr?m macroglobulinemia (WM) cells present with increased expression of microRNA-206 (miRNA-206) and reduced expression of miRNA-9 +epigenetics hsa-mir-152 "Carcinoma, Hepatocellular" 20578129 microRNA-152:a tumor-suppressive role of miR-152 in the epigenetic aberration of HBV-related HCC +epigenetics hsa-mir-181b-1 Inflammation 20797623 miR-181b-1:STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer +epigenetics hsa-mir-181b-1 Neoplasms [unspecific] 20797623 miR-181b-1:STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer +epigenetics hsa-mir-21 Inflammation 20797623 miR-21:STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer +epigenetics hsa-mir-21 Neoplasms [unspecific] 20797623 miR-21:STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer +epigenetics hsa-mir-34b Gastric Neoplasms 20924086 "These results suggest that miR-34b and miR-34c are novel tumor suppressors frequently silenced by DNA methylation in GC, that methylation of miR-34b/c is involved in an epigenetic field defect and that the methylation might be a predictive marker of GC risk." +epigenetics hsa-mir-34c Gastrointestinal Neoplasms 20924086 "These results suggest that miR-34b and miR-34c are novel tumor suppressors frequently silenced by DNA methylation in GC, that methylation of miR-34b/c is involved in an epigenetic field defect and that the methylation might be a predictive marker of GC risk." +epigenetics hsa-mir-375 Breast Neoplasms 20978187 Epigenetically deregulated microRNA-375 is involved in a positive feedback loop with estrogen receptor alpha in breast cancer cells. +epigenetics hsa-mir-212 Gastrointestinal Neoplasms 21053104 "The conclusion could be deduced from the study that decreased expression of miR-212 may be due to hypermethylation of CPI in gastric cancer cells, and miR-212 might act on the progression of gastric cancer through the potential target gene Myc." +epigenetics hsa-mir-1224 Urinary Bladder Cancer 21138856 hypermethylation was more frequent and dense in CpG shores than islands +epigenetics hsa-mir-1227 Urinary Bladder Cancer 21138856 hypermethylation was more frequent and dense in CpG shores than islands +epigenetics hsa-mir-1229 Urinary Bladder Cancer 21138856 hypermethylation was more frequent and dense in CpG shores than islands +epigenetics hsa-mir-149 Urinary Bladder Cancer 21138856 hypermethylation was more frequent and dense in CpG shores than islands +epigenetics hsa-mir-210 Urinary Bladder Cancer 21138856 hypermethylation was more frequent and dense in CpG shores than islands +epigenetics hsa-mir-212 Urinary Bladder Cancer 21138856 hypermethylation was more frequent and dense in CpG shores than islands +epigenetics hsa-mir-328 Urinary Bladder Cancer 21138856 hypermethylation was more frequent and dense in CpG shores than islands +epigenetics hsa-mir-503 Urinary Bladder Cancer 21138856 hypermethylation was more frequent and dense in CpG shores than islands +epigenetics hsa-mir-9-1 Urinary Bladder Cancer 21138856 hypermethylation was more frequent and dense in CpG shores than islands +epigenetics hsa-mir-9-2 Urinary Bladder Cancer 21138856 hypermethylation was more frequent and dense in CpG shores than islands +epigenetics hsa-mir-9-3 Urinary Bladder Cancer 21138856 hypermethylation was more frequent and dense in CpG shores than islands +epigenetics hsa-mir-373 Cholangiocarcinoma 21165562 Methyl-CpG binding protein MBD2 is implicated in methylation-mediated suppression of miR-373 in hilar Cholangiocarcinoma. +epigenetics hsa-mir-126 Systemic Lupus Erythematosus 21165896 MicroRNA-126 regulates DNA methylation in CD4(+) T cells and contributes to systemic lupus erythematosus by targeting DNA methyltransferase 1. +epigenetics hsa-mir-129-2 Gastric Neoplasms 21213213 "upstream CpG-rich regions of mir-34b and mir-129-2 are frequently methylated in gastric cancer tissues compared with adjacent normal tissues, and their methylation status correlated inversely with their expression patterns." +epigenetics hsa-mir-34b Gastric Neoplasms 21213213 "upstream CpG-rich regions of mir-34b and mir-129-2 are frequently methylated in gastric cancer tissues compared with adjacent normal tissues, and their methylation status correlated inversely with their expression patterns." +epigenetics hsa-mir-34a Breast Neoplasms 21225432 "Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas." +epigenetics hsa-mir-34a "Carcinoma, Renal Cell" 21225432 "Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas." +epigenetics hsa-mir-34a Colorectal Carcinoma 21225432 "Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas." +epigenetics hsa-mir-34a Ovarian Neoplasms 21225432 "Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas." +epigenetics hsa-mir-34a Pancreatic Neoplasms 21225432 "Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas." +epigenetics hsa-mir-34a Sarcoma [unspecific] 21225432 "Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas." +epigenetics hsa-mir-34a Urinary Bladder Cancer 21225432 "Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas." +epigenetics hsa-mir-34b Breast Neoplasms 21225432 "Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas." +epigenetics hsa-mir-34b "Carcinoma, Renal Cell" 21225432 "Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas." +epigenetics hsa-mir-34b Colorectal Carcinoma 21225432 "Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas." +epigenetics hsa-mir-34b Ovarian Neoplasms 21225432 "Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas." +epigenetics hsa-mir-34b Pancreatic Neoplasms 21225432 "Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas." +epigenetics hsa-mir-34b Sarcoma [unspecific] 21225432 "Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas." +epigenetics hsa-mir-34b Urinary Bladder Cancer 21225432 "Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas." +epigenetics hsa-mir-34c Breast Neoplasms 21225432 "Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas." +epigenetics hsa-mir-34c "Carcinoma, Renal Cell" 21225432 "Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas." +epigenetics hsa-mir-34c Colorectal Carcinoma 21225432 "Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas." +epigenetics hsa-mir-34c Ovarian Neoplasms 21225432 "Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas." +epigenetics hsa-mir-34c Pancreatic Neoplasms 21225432 "Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas." +epigenetics hsa-mir-34c Sarcoma [unspecific] 21225432 "Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas." +epigenetics hsa-mir-34c Urinary Bladder Cancer 21225432 "Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas." +epigenetics hsa-mir-196b Prostate Neoplasms 21255435 "We find miR-205, miR-21, and miR-196b to be epigenetically repressed, and miR-615 epigenetically activated in prostate cancer cells." +epigenetics hsa-mir-205 Prostate Neoplasms 21255435 "We find miR-205, miR-21, and miR-196b to be epigenetically repressed, and miR-615 epigenetically activated in prostate cancer cells." +epigenetics hsa-mir-21 Prostate Neoplasms 21255435 "We find miR-205, miR-21, and miR-196b to be epigenetically repressed, and miR-615 epigenetically activated in prostate cancer cells." +epigenetics hsa-mir-29b-1 Atherosclerosis 21266537 "OxLDL up-regulates microRNA-29b, leading to epigenetic modifications of MMP-2/MMP-9 genes: a novel mechanism for cardiovascular diseases." +epigenetics hsa-mir-29b-2 Atherosclerosis 21266537 "OxLDL up-regulates microRNA-29b, leading to epigenetic modifications of MMP-2/MMP-9 genes: a novel mechanism for cardiovascular diseases." +epigenetics hsa-mir-335 Breast Neoplasms 21289068 MicroRNA-335 inhibits tumor reinitiation and is silenced through genetic and epigenetic mechanisms in human breast cancer. +epigenetics hsa-mir-200b Neoplasms [unspecific] 21292642 Depletion of miR-200 in arsenite-transformed cells involved induction of the EMT-inducing transcription factors ZEB1 (zinc-finger E-box-binding homeobox factor 1) and ZEB2 and increased methylation of miR-200 promoters. +epigenetics hsa-mir-199a-1 Breast Neoplasms 21317930 "Axl receptor expression can be regulated by miR-34a and miR-199a/b, which are suppressed by promoter methylation in solid cancer cells" +epigenetics hsa-mir-199a-1 "Carcinoma, Lung, Non-Small-Cell" 21317930 "Axl receptor expression can be regulated by miR-34a and miR-199a/b, which are suppressed by promoter methylation in solid cancer cells" +epigenetics hsa-mir-199a-1 Colorectal Carcinoma 21317930 "Axl receptor expression can be regulated by miR-34a and miR-199a/b, which are suppressed by promoter methylation in solid cancer cells" +epigenetics hsa-mir-199a-2 Breast Neoplasms 21317930 "Axl receptor expression can be regulated by miR-34a and miR-199a/b, which are suppressed by promoter methylation in solid cancer cells" +epigenetics hsa-mir-199a-2 "Carcinoma, Lung, Non-Small-Cell" 21317930 "Axl receptor expression can be regulated by miR-34a and miR-199a/b, which are suppressed by promoter methylation in solid cancer cells" +epigenetics hsa-mir-199a-2 Colorectal Carcinoma 21317930 "Axl receptor expression can be regulated by miR-34a and miR-199a/b, which are suppressed by promoter methylation in solid cancer cells" +epigenetics hsa-mir-199b Breast Neoplasms 21317930 "Axl receptor expression can be regulated by miR-34a and miR-199a/b, which are suppressed by promoter methylation in solid cancer cells" +epigenetics hsa-mir-199b "Carcinoma, Lung, Non-Small-Cell" 21317930 "Axl receptor expression can be regulated by miR-34a and miR-199a/b, which are suppressed by promoter methylation in solid cancer cells" +epigenetics hsa-mir-199b Colorectal Carcinoma 21317930 "Axl receptor expression can be regulated by miR-34a and miR-199a/b, which are suppressed by promoter methylation in solid cancer cells" +epigenetics hsa-mir-34a Breast Neoplasms 21317930 "Axl receptor expression can be regulated by miR-34a and miR-199a/b, which are suppressed by promoter methylation in solid cancer cells" +epigenetics hsa-mir-34a "Carcinoma, Lung, Non-Small-Cell" 21317930 "Axl receptor expression can be regulated by miR-34a and miR-199a/b, which are suppressed by promoter methylation in solid cancer cells" +epigenetics hsa-mir-34a Colorectal Carcinoma 21317930 "Axl receptor expression can be regulated by miR-34a and miR-199a/b, which are suppressed by promoter methylation in solid cancer cells" +epigenetics hsa-mir-203 "Leukemia, Myeloid, Acute" 21323860 The frequent hsa-miR-203 methylation in lymphoid malignancies suggested a pathogenetic role of hsa-miR-203 methylation. +epigenetics hsa-mir-1-1 Colorectal Carcinoma 21327300 "Compared with the respective normal tissues, the predominant alteration in tumor tissues was increased methylation for the miRNAs 1-1, 124a-1, 124a-2, 124a-3, 148a, 152, and 18b; decreased methylation for 200a and 208a;" +epigenetics hsa-mir-1-1 Endometrial Neoplasms 21327300 "Compared with the respective normal tissues, the predominant alteration in tumor tissues was increased methylation for the miRNAs 1-1, 124a-1, 124a-2, 124a-3, 148a, 152, and 18b; decreased methylation for 200a and 208a;" +epigenetics hsa-mir-1-1 Gastrointestinal Neoplasms 21327300 "Compared with the respective normal tissues, the predominant alteration in tumor tissues was increased methylation for the miRNAs 1-1, 124a-1, 124a-2, 124a-3, 148a, 152, and 18b; decreased methylation for 200a and 208a;" +epigenetics hsa-mir-124-1 Colorectal Carcinoma 21327300 "Compared with the respective normal tissues, the predominant alteration in tumor tissues was increased methylation for the miRNAs 1-1, 124a-1, 124a-2, 124a-3, 148a, 152, and 18b; decreased methylation for 200a and 208a;" +epigenetics hsa-mir-124-1 Endometrial Neoplasms 21327300 "Compared with the respective normal tissues, the predominant alteration in tumor tissues was increased methylation for the miRNAs 1-1, 124a-1, 124a-2, 124a-3, 148a, 152, and 18b; decreased methylation for 200a and 208a;" +epigenetics hsa-mir-124-1 Gastrointestinal Neoplasms 21327300 "Compared with the respective normal tissues, the predominant alteration in tumor tissues was increased methylation for the miRNAs 1-1, 124a-1, 124a-2, 124a-3, 148a, 152, and 18b; decreased methylation for 200a and 208a;" +epigenetics hsa-mir-124-2 Colorectal Carcinoma 21327300 "Compared with the respective normal tissues, the predominant alteration in tumor tissues was increased methylation for the miRNAs 1-1, 124a-1, 124a-2, 124a-3, 148a, 152, and 18b; decreased methylation for 200a and 208a;" +epigenetics hsa-mir-124-2 Endometrial Neoplasms 21327300 "Compared with the respective normal tissues, the predominant alteration in tumor tissues was increased methylation for the miRNAs 1-1, 124a-1, 124a-2, 124a-3, 148a, 152, and 18b; decreased methylation for 200a and 208a;" +epigenetics hsa-mir-124-2 Gastrointestinal Neoplasms 21327300 "Compared with the respective normal tissues, the predominant alteration in tumor tissues was increased methylation for the miRNAs 1-1, 124a-1, 124a-2, 124a-3, 148a, 152, and 18b; decreased methylation for 200a and 208a;" +epigenetics hsa-mir-124-3 Colorectal Carcinoma 21327300 "Compared with the respective normal tissues, the predominant alteration in tumor tissues was increased methylation for the miRNAs 1-1, 124a-1, 124a-2, 124a-3, 148a, 152, and 18b; decreased methylation for 200a and 208a;" +epigenetics hsa-mir-124-3 Endometrial Neoplasms 21327300 "Compared with the respective normal tissues, the predominant alteration in tumor tissues was increased methylation for the miRNAs 1-1, 124a-1, 124a-2, 124a-3, 148a, 152, and 18b; decreased methylation for 200a and 208a;" +epigenetics hsa-mir-124-3 Gastrointestinal Neoplasms 21327300 "Compared with the respective normal tissues, the predominant alteration in tumor tissues was increased methylation for the miRNAs 1-1, 124a-1, 124a-2, 124a-3, 148a, 152, and 18b; decreased methylation for 200a and 208a;" +epigenetics hsa-mir-148a Colorectal Carcinoma 21327300 "Compared with the respective normal tissues, the predominant alteration in tumor tissues was increased methylation for the miRNAs 1-1, 124a-1, 124a-2, 124a-3, 148a, 152, and 18b; decreased methylation for 200a and 208a;" +epigenetics hsa-mir-148a Endometrial Neoplasms 21327300 "Compared with the respective normal tissues, the predominant alteration in tumor tissues was increased methylation for the miRNAs 1-1, 124a-1, 124a-2, 124a-3, 148a, 152, and 18b; decreased methylation for 200a and 208a;" +epigenetics hsa-mir-148a Gastrointestinal Neoplasms 21327300 "Compared with the respective normal tissues, the predominant alteration in tumor tissues was increased methylation for the miRNAs 1-1, 124a-1, 124a-2, 124a-3, 148a, 152, and 18b; decreased methylation for 200a and 208a;" +epigenetics hsa-mir-152 Colorectal Carcinoma 21327300 "Compared with the respective normal tissues, the predominant alteration in tumor tissues was increased methylation for the miRNAs 1-1, 124a-1, 124a-2, 124a-3, 148a, 152, and 18b; decreased methylation for 200a and 208a;" +epigenetics hsa-mir-152 Endometrial Neoplasms 21327300 "Compared with the respective normal tissues, the predominant alteration in tumor tissues was increased methylation for the miRNAs 1-1, 124a-1, 124a-2, 124a-3, 148a, 152, and 18b; decreased methylation for 200a and 208a;" +epigenetics hsa-mir-152 Gastrointestinal Neoplasms 21327300 "Compared with the respective normal tissues, the predominant alteration in tumor tissues was increased methylation for the miRNAs 1-1, 124a-1, 124a-2, 124a-3, 148a, 152, and 18b; decreased methylation for 200a and 208a;" +epigenetics hsa-mir-18b Colorectal Carcinoma 21327300 "Compared with the respective normal tissues, the predominant alteration in tumor tissues was increased methylation for the miRNAs 1-1, 124a-1, 124a-2, 124a-3, 148a, 152, and 18b; decreased methylation for 200a and 208a;" +epigenetics hsa-mir-18b Endometrial Neoplasms 21327300 "Compared with the respective normal tissues, the predominant alteration in tumor tissues was increased methylation for the miRNAs 1-1, 124a-1, 124a-2, 124a-3, 148a, 152, and 18b; decreased methylation for 200a and 208a;" +epigenetics hsa-mir-18b Gastrointestinal Neoplasms 21327300 "Compared with the respective normal tissues, the predominant alteration in tumor tissues was increased methylation for the miRNAs 1-1, 124a-1, 124a-2, 124a-3, 148a, 152, and 18b; decreased methylation for 200a and 208a;" +epigenetics hsa-mir-200a Colorectal Carcinoma 21327300 "Compared with the respective normal tissues, the predominant alteration in tumor tissues was increased methylation for the miRNAs 1-1, 124a-1, 124a-2, 124a-3, 148a, 152, and 18b; decreased methylation for 200a and 208a;" +epigenetics hsa-mir-200a Endometrial Neoplasms 21327300 "Compared with the respective normal tissues, the predominant alteration in tumor tissues was increased methylation for the miRNAs 1-1, 124a-1, 124a-2, 124a-3, 148a, 152, and 18b; decreased methylation for 200a and 208a;" +epigenetics hsa-mir-200a Gastrointestinal Neoplasms 21327300 "Compared with the respective normal tissues, the predominant alteration in tumor tissues was increased methylation for the miRNAs 1-1, 124a-1, 124a-2, 124a-3, 148a, 152, and 18b; decreased methylation for 200a and 208a;" +epigenetics hsa-mir-208a Colorectal Carcinoma 21327300 "Compared with the respective normal tissues, the predominant alteration in tumor tissues was increased methylation for the miRNAs 1-1, 124a-1, 124a-2, 124a-3, 148a, 152, and 18b; decreased methylation for 200a and 208a;" +epigenetics hsa-mir-208a Endometrial Neoplasms 21327300 "Compared with the respective normal tissues, the predominant alteration in tumor tissues was increased methylation for the miRNAs 1-1, 124a-1, 124a-2, 124a-3, 148a, 152, and 18b; decreased methylation for 200a and 208a;" +epigenetics hsa-mir-208a Gastrointestinal Neoplasms 21327300 "Compared with the respective normal tissues, the predominant alteration in tumor tissues was increased methylation for the miRNAs 1-1, 124a-1, 124a-2, 124a-3, 148a, 152, and 18b; decreased methylation for 200a and 208a;" +epigenetics hsa-mir-145 Prostate Neoplasms 21349819 this is the first report documenting that downregulation of miR-145 is through DNA methylation and p53 mutation pathways in prostate cancer. +epigenetics hsa-mir-124-1 Gastric Neoplasms 21365509 "Significant associations were found between hypermethylation of hsa-miR-124a and tumor size, differentiation, lymphatic metastasis, and invasion depth(P<0.01)." +epigenetics hsa-mir-124-2 Gastric Neoplasms 21365509 "Significant associations were found between hypermethylation of hsa-miR-124a and tumor size, differentiation, lymphatic metastasis, and invasion depth(P<0.01)." +epigenetics hsa-mir-124-3 Gastric Neoplasms 21365509 "Significant associations were found between hypermethylation of hsa-miR-124a and tumor size, differentiation, lymphatic metastasis, and invasion depth(P<0.01)." +epigenetics hsa-mir-34b "Carcinoma, Lung, Non-Small-Cell" 21383543 DNA hypermethylation of microRNA-34b/c has prognostic value for stage ¢ñ non-small cell lung cancer. +epigenetics hsa-mir-34c "Carcinoma, Lung, Non-Small-Cell" 21383543 DNA hypermethylation of microRNA-34b/c has prognostic value for stage ¢ñ non-small cell lung cancer. +epigenetics hsa-mir-199a-1 Testicular Neoplasms 21383689 "PODXL is a downstream effector mediating the action of miR199a-5p. This report identifies DNA methylation, miR-199a dysregulation and PODXL as critical factors in tumor malignancy." +epigenetics hsa-mir-199a-2 Testicular Neoplasms 21383689 "PODXL is a downstream effector mediating the action of miR199a-5p. This report identifies DNA methylation, miR-199a dysregulation and PODXL as critical factors in tumor malignancy." +epigenetics hsa-mir-193a "Leukemia, Myeloid, Acute" 21399664 MicroRNA-193a represses c-kit expression and functions as a methylation-silenced tumor suppressor in acute myeloid leukemia. +epigenetics hsa-mir-137 "Squamous Cell Carcinoma, Head and Neck" 21425146 MicroRNA-137 promoter methylation is associated with poorer overall survival in patients with squamous cell carcinoma of the head and neck. +epigenetics hsa-mir-203 Lymphoma 21454413 Epigenetic silencing of microRNA-203 dysregulates ABL1 expression and drives Helicobacter-associated gastric lymphomagenesis. +epigenetics hsa-mir-203 Urinary Bladder Cancer 21461574 hypermethylation of miR-124a and miR-203 in the precursor lesions compared to the control samples +epigenetics hsa-mir-181a-2 "Carcinoma, Hepatocellular" 21464043 "HBx promotes stemness by activating {beta}-catenin and epigenetic up-regulation of miR-181, both of which target EpCAM." +epigenetics hsa-mir-181b-1 "Carcinoma, Hepatocellular" 21464043 "HBx promotes stemness by activating {beta}-catenin and epigenetic up-regulation of miR-181, both of which target EpCAM." +epigenetics hsa-mir-181b-2 "Carcinoma, Hepatocellular" 21464043 "HBx promotes stemness by activating {beta}-catenin and epigenetic up-regulation of miR-181, both of which target EpCAM." +epigenetics hsa-mir-181c "Carcinoma, Hepatocellular" 21464043 "HBx promotes stemness by activating {beta}-catenin and epigenetic up-regulation of miR-181, both of which target EpCAM." +epigenetics hsa-mir-181d "Carcinoma, Hepatocellular" 21464043 "HBx promotes stemness by activating {beta}-catenin and epigenetic up-regulation of miR-181, both of which target EpCAM." +epigenetics hsa-mir-375 Esophageal Neoplasms 21533613 Epigenetic Silencing of MicroRNA-375 Regulates PDK1 Expression in Esophageal Cancer +epigenetics hsa-mir-126 Systemic Lupus Erythematosus 21538319 MicroRNA-126 regulates DNA methylation in CD4+ T cells and contributes to systemic lupus erythematosus by targeting DNA methyltransferase 1. +epigenetics hsa-mir-24-1 "Leukemia, Myeloid, Acute" 21544199 miR-124-1 is epigenetically inactivated in Haematological Malignancies. +epigenetics hsa-mir-24-1 Lymphoma 21544199 miR-124-1 is epigenetically inactivated in Haematological Malignancies. +epigenetics hsa-mir-24-1 Multiple Myeloma 21544199 miR-124-1 is epigenetically inactivated in Haematological Malignancies. +epigenetics hsa-mir-129-2 Esophageal Neoplasms 21547903 "The methylation ratio of miR-34a, miR-34b/c and miR-129-2 is 66.7%(36/54), 40.7%(22/54), and 96.3%(52/54) respectively in ESCC, which are significantly higher than that in corresponding non-tumor tissues(p<0.01)." +epigenetics hsa-mir-129-2 "Squamous Cell Carcinoma, Esophageal" 21547903 "The methylation ratio of miR-34a, miR-34b/c and miR-129-2 is 66.7%(36/54), 40.7%(22/54), and 96.3%(52/54) respectively in ESCC, which are significantly higher than that in corresponding non-tumor tissues(p<0.01)." +epigenetics hsa-mir-34a Esophageal Neoplasms 21547903 "The methylation ratio of miR-34a, miR-34b/c and miR-129-2 is 66.7%(36/54), 40.7%(22/54), and 96.3%(52/54) respectively in ESCC, which are significantly higher than that in corresponding non-tumor tissues(p<0.01)." +epigenetics hsa-mir-34a "Squamous Cell Carcinoma, Esophageal" 21547903 "The methylation ratio of miR-34a, miR-34b/c and miR-129-2 is 66.7%(36/54), 40.7%(22/54), and 96.3%(52/54) respectively in ESCC, which are significantly higher than that in corresponding non-tumor tissues(p<0.01)." +epigenetics hsa-mir-34b Esophageal Neoplasms 21547903 "The methylation ratio of miR-34a, miR-34b/c and miR-129-2 is 66.7%(36/54), 40.7%(22/54), and 96.3%(52/54) respectively in ESCC, which are significantly higher than that in corresponding non-tumor tissues(p<0.01)." +epigenetics hsa-mir-34b "Squamous Cell Carcinoma, Esophageal" 21547903 "The methylation ratio of miR-34a, miR-34b/c and miR-129-2 is 66.7%(36/54), 40.7%(22/54), and 96.3%(52/54) respectively in ESCC, which are significantly higher than that in corresponding non-tumor tissues(p<0.01)." +epigenetics hsa-mir-34c Esophageal Neoplasms 21547903 "The methylation ratio of miR-34a, miR-34b/c and miR-129-2 is 66.7%(36/54), 40.7%(22/54), and 96.3%(52/54) respectively in ESCC, which are significantly higher than that in corresponding non-tumor tissues(p<0.01)." +epigenetics hsa-mir-34c "Squamous Cell Carcinoma, Esophageal" 21547903 "The methylation ratio of miR-34a, miR-34b/c and miR-129-2 is 66.7%(36/54), 40.7%(22/54), and 96.3%(52/54) respectively in ESCC, which are significantly higher than that in corresponding non-tumor tissues(p<0.01)." +epigenetics hsa-mir-10b Gastric Neoplasms 21562367 "miR-10b methylation may be a useful molecular biomarker for assessing the risk of gastric cancer development, and modulation of miR-10b may represent a therapeutic approach for treating gastric cancer." +epigenetics hsa-mir-34b Colorectal Carcinoma 21610744 Epigenetically silenced miR-34b/c as a novel faecal-based screening marker for colorectal cancer. +epigenetics hsa-mir-34c Colorectal Carcinoma 21610744 Epigenetically silenced miR-34b/c as a novel faecal-based screening marker for colorectal cancer. +epigenetics hsa-mir-132 Pancreatic Neoplasms 21665894 Downregulation of miR-132 by promoter methylation contributes to pancreatic cancer development. +epigenetics hsa-mir-345 Colorectal Carcinoma 21665895 "MicroRNA 345, a methylation-sensitive microRNA is involved in cell proliferation and invasion in human colorectal cancer." +epigenetics hsa-mir-34b Mesothelioma 21673066 Epigenetic Silencing of MicroRNA-34b/c Plays an Important Role in the Pathogenesis of Malignant Pleural Mesothelioma. +epigenetics hsa-mir-34c Mesothelioma 21673066 Epigenetic Silencing of MicroRNA-34b/c Plays an Important Role in the Pathogenesis of Malignant Pleural Mesothelioma. +epigenetics hsa-mir-221 Breast Neoplasms 21673316 TRPS1 targeting by miR-221/222 promotes the epithelial-to-mesenchymal transition in breast cancer. +epigenetics hsa-mir-196a-2 "Carcinoma, Hepatocellular" 21692953 The CC genotype of the miR-196a-2 rs11614913 polymorphism is associated with increased risk of HCC development in this Turkish population. +epigenetics hsa-mir-126 "Carcinoma, Lung, Non-Small-Cell" 21702040 mir-34b and mir-126 were silenced by DNA methylation. +epigenetics hsa-mir-34b "Carcinoma, Lung, Non-Small-Cell" 21702040 mir-34b and mir-126 were silenced by DNA methylation. +epigenetics hsa-mir-143 "Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic" 21706045 Methylation-mediated repression of microRNA-143 enhances MLL-AF4 oncogene expression. +epigenetics hsa-mir-373 Liver Neoplasms 21706058 "Thus, histone deacetylation of CDH1 and downregulation of miR-373, together with the previously demonstrated hypermethylation of CDH1 by HBx, may be important for the understanding of HBV-related carcinogenesis." +epigenetics hsa-mir-203 Multiple Myeloma 21707582 MIR203 is epigeneticlly silenced in multiple myeloma. +epigenetics hsa-mir-373 Colorectal Carcinoma 21785829 Epigenetic silencing of microRNA-373 plays an important role in regulating cell proliferation in colon cancer. +epigenetics hsa-mir-200a "Carcinoma, Hepatocellular" 21837748 The histone deacetylase 4/Sp1/miR-200a regulatory network contributes to aberrant histone acetylation in hepatocellular carcinoma. +epigenetics hsa-mir-152 Endometrial Neoplasms 21868754 miR-152 is a tumor suppressor microRNA that is silenced by DNA hypermethylation in endometrial cancer. +epigenetics hsa-mir-17 "Leukemia, Myeloid, Acute" 21897363 We propose that upon macrophage differentiation PU.1 represses the miR-17-92 cluster promoter by an Egr-2/Jarid1b-mediated H3K4 demethylation mechanism whose deregulation may contribute to leukaemic states. +epigenetics hsa-mir-18 "Leukemia, Myeloid, Acute" 21897363 We propose that upon macrophage differentiation PU.1 represses the miR-17-92 cluster promoter by an Egr-2/Jarid1b-mediated H3K4 demethylation mechanism whose deregulation may contribute to leukaemic states. +epigenetics hsa-mir-19a "Leukemia, Myeloid, Acute" 21897363 We propose that upon macrophage differentiation PU.1 represses the miR-17-92 cluster promoter by an Egr-2/Jarid1b-mediated H3K4 demethylation mechanism whose deregulation may contribute to leukaemic states. +epigenetics hsa-mir-19b-1 "Leukemia, Myeloid, Acute" 21897363 We propose that upon macrophage differentiation PU.1 represses the miR-17-92 cluster promoter by an Egr-2/Jarid1b-mediated H3K4 demethylation mechanism whose deregulation may contribute to leukaemic states. +epigenetics hsa-mir-20a "Leukemia, Myeloid, Acute" 21897363 We propose that upon macrophage differentiation PU.1 represses the miR-17-92 cluster promoter by an Egr-2/Jarid1b-mediated H3K4 demethylation mechanism whose deregulation may contribute to leukaemic states. +epigenetics hsa-mir-92-1 "Leukemia, Myeloid, Acute" 21897363 We propose that upon macrophage differentiation PU.1 represses the miR-17-92 cluster promoter by an Egr-2/Jarid1b-mediated H3K4 demethylation mechanism whose deregulation may contribute to leukaemic states. +epigenetics hsa-mir-124-1 Gastric Neoplasms 21914401 The hypermethylation of miRNA-34b/c and miRNA-124a gene promoters may play a crucial role in the occurrence and development of gastric carcinoma. +epigenetics hsa-mir-34b Gastric Neoplasms 21914401 The hypermethylation of miRNA-34b/c and miRNA-124a gene promoters may play a crucial role in the occurrence and development of gastric carcinoma. +epigenetics hsa-mir-34c Gastric Neoplasms 21914401 The hypermethylation of miRNA-34b/c and miRNA-124a gene promoters may play a crucial role in the occurrence and development of gastric carcinoma. +epigenetics hsa-mir-124-2 "Carcinoma, Lung, Non-Small-Cell" 21917081 "The methylation of mir-9-3, -124-2, and -124-3 was individually associated with an advanced T factor independently of age, sex, and smoking habit." +epigenetics hsa-mir-124-3 "Carcinoma, Lung, Non-Small-Cell" 21917081 "The methylation of mir-9-3, -124-2, and -124-3 was individually associated with an advanced T factor independently of age, sex, and smoking habit." +epigenetics hsa-mir-9-3 "Carcinoma, Lung, Non-Small-Cell" 21917081 "The methylation of mir-9-3, -124-2, and -124-3 was individually associated with an advanced T factor independently of age, sex, and smoking habit." +epigenetics hsa-mir-139 Gastric Neoplasms 21925125 HER2 Interacts with CD44 to Upregulate CXCR4 via Epigenetic Silencing of microRNA-139 in Gastric Cancer Cells. +epigenetics hsa-mir-9-1 Gastric Neoplasms 21931274 "In this study, we demonstrate that three independent genetic loci encoding for miR-9 (miR-9-1, miR-9-2 and miR-9-3) are simultaneously modified by DNA methylation in gastric cancer cells. Methylation-mediated silencing of these three miR-9 genes can be reactivated in gastric cancer cells through 5-Aza-dC treatment." +epigenetics hsa-mir-9-2 Gastric Neoplasms 21931274 "In this study, we demonstrate that three independent genetic loci encoding for miR-9 (miR-9-1, miR-9-2 and miR-9-3) are simultaneously modified by DNA methylation in gastric cancer cells. Methylation-mediated silencing of these three miR-9 genes can be reactivated in gastric cancer cells through 5-Aza-dC treatment." +epigenetics hsa-mir-9-3 Gastric Neoplasms 21931274 "In this study, we demonstrate that three independent genetic loci encoding for miR-9 (miR-9-1, miR-9-2 and miR-9-3) are simultaneously modified by DNA methylation in gastric cancer cells. Methylation-mediated silencing of these three miR-9 genes can be reactivated in gastric cancer cells through 5-Aza-dC treatment." +epigenetics hsa-mir-129-1 Thyroid Neoplasms 21946411 "Two HDACi, Trichostatin A and vorinostat, induced miR-129-5p overexpression, histone acetylation and cell death. In addition, miR-129-5p alone was sufficient to induce cell death and knockdown experiments showed that expression of this miRNA was required for HDACi-induced cell death. Moreover, miR-129-5p was also able to improve the anti-proliferative effects of other cancer drugs such as etoposide or HAMLET (human alpha lactalbumin made letal for tumor cells). Taken together, the data show that miR-129-5p is involved in the antitumor activity of HDACi and highlight that miRNA-driven cell death may be an efficient approach to cancer treatment." +epigenetics hsa-mir-129-2 Thyroid Neoplasms 21946411 "Two HDACi, Trichostatin A and vorinostat, induced miR-129-5p overexpression, histone acetylation and cell death. In addition, miR-129-5p alone was sufficient to induce cell death and knockdown experiments showed that expression of this miRNA was required for HDACi-induced cell death. Moreover, miR-129-5p was also able to improve the anti-proliferative effects of other cancer drugs such as etoposide or HAMLET (human alpha lactalbumin made letal for tumor cells). Taken together, the data show that miR-129-5p is involved in the antitumor activity of HDACi and highlight that miRNA-driven cell death may be an efficient approach to cancer treatment." +epigenetics hsa-mir-129-2 Gastric Neoplasms 21960261 "The methylation-silenced expression of the miRNA could be reactivated in gastric cancer cells by treatment with demethylating drugs in a time-dependent manner.Analysis of the methylation status of these miRNAs showed that the upstream CpG-rich regions of mir-34b and mir-129-2 are frequently methylated in gastric cancer tissues compared to adjacent normal tissues, and their methylation status correlated inversely with their expression patterns. The expression of miR-34b and miR-129-3p was downregulated by DNA hypermethylation in primary gastric cancers, and the low expression was associated with poor clinicopathological features." +epigenetics hsa-mir-34b Gastric Neoplasms 21960261 "The methylation-silenced expression of the miRNA could be reactivated in gastric cancer cells by treatment with demethylating drugs in a time-dependent manner.Analysis of the methylation status of these miRNAs showed that the upstream CpG-rich regions of mir-34b and mir-129-2 are frequently methylated in gastric cancer tissues compared to adjacent normal tissues, and their methylation status correlated inversely with their expression patterns. The expression of miR-34b and miR-129-3p was downregulated by DNA hypermethylation in primary gastric cancers, and the low expression was associated with poor clinicopathological features." +epigenetics hsa-mir-185 Glioma 21962230 MiR-185 Targets the DNA Methyltransferases 1 and Regulates Global DNA Methylation in human glioma. +epigenetics hsa-let-7e Breast Neoplasms 21969366 Jumonji/Arid1 B (JARID1B) promotes breast tumor cell cycle progression through epigenetic repression of micro RNA let-7e. +epigenetics hsa-mir-191 "Carcinoma, Hepatocellular" 21969817 Hypomethylation of the hsa-miR-191 Locus Causes High Expression of hsa-miR-191 and Promotes the Epithelial-to-Mesenchymal Transition in Hepatocellular Carcinoma. +epigenetics hsa-mir-34b "Carcinoma, Lung, Small-Cell" 22047961 Frequent methylation and oncogenic role of microRNA-34b/c in small-cell lung cancer. +epigenetics hsa-mir-34c "Carcinoma, Lung, Small-Cell" 22047961 Frequent methylation and oncogenic role of microRNA-34b/c in small-cell lung cancer. +epigenetics hsa-mir-29a Influenza 22072783 Epigenetic Changes Mediated by miR29 Activate Cyclooxygenase-2 and Interferon Production during Viral Infection. +epigenetics hsa-mir-34c Breast Neoplasms 22074923 MiR-34c down-regulation via DNA methylation promotes self-renewal and epithelial-mesenchymal transition in breast tumor-initiating cells. +epigenetics hsa-mir-34b Neoplasms [unspecific] 22082000 "miR-34b/c were homozygously methylated in HEL cells but heterozygously in MEG-01. In HEL cells, homozygous miR-34b/c methylation was associated with miR silencing, and 5-aza-2'-deoxycytidine treatment led to re-expression of both miR-34b and miR-34c, consistent with that both miRs are under the regulation of the same promoter CpG island. miR-34a was heterozygously methylated in MEG-01 and K-562. miR-203 was completely unmethylated in K-562 and SET-2 but no MSP amplification was found in both HEL and MEG-01, suggestive of miR deletion. In primary samples, four each had miR-34b/c and -203 methylation, in which two had concomitant methylation of miR-34b/c and -203. miR-34a was methylated in one patient and none had methylation of miR-124-1." +epigenetics hsa-mir-34c Neoplasms [unspecific] 22082000 "miR-34b/c were homozygously methylated in HEL cells but heterozygously in MEG-01. In HEL cells, homozygous miR-34b/c methylation was associated with miR silencing, and 5-aza-2'-deoxycytidine treatment led to re-expression of both miR-34b and miR-34c, consistent with that both miRs are under the regulation of the same promoter CpG island. miR-34a was heterozygously methylated in MEG-01 and K-562. miR-203 was completely unmethylated in K-562 and SET-2 but no MSP amplification was found in both HEL and MEG-01, suggestive of miR deletion. In primary samples, four each had miR-34b/c and -203 methylation, in which two had concomitant methylation of miR-34b/c and -203. miR-34a was methylated in one patient and none had methylation of miR-124-1." +epigenetics hsa-mir-369 "Leukemia, Myeloid, Chronic" 22089542 "The CpG islands in the upstream regions of miR-663, miR-369, miR-615, and miR-410, and promoter activity was detected in the upstream region of pre-miR-663. We found that a decrease in methylation of a CpG island could up-regulate the expression of miR-663, suggesting that miR-663 could be regulated by DNA methylation." +epigenetics hsa-mir-410 "Leukemia, Myeloid, Chronic" 22089542 "The CpG islands in the upstream regions of miR-663, miR-369, miR-615, and miR-410, and promoter activity was detected in the upstream region of pre-miR-663. We found that a decrease in methylation of a CpG island could up-regulate the expression of miR-663, suggesting that miR-663 could be regulated by DNA methylation." +epigenetics hsa-mir-615 "Leukemia, Myeloid, Chronic" 22089542 "The CpG islands in the upstream regions of miR-663, miR-369, miR-615, and miR-410, and promoter activity was detected in the upstream region of pre-miR-663. We found that a decrease in methylation of a CpG island could up-regulate the expression of miR-663, suggesting that miR-663 could be regulated by DNA methylation." +epigenetics hsa-mir-663a "Leukemia, Myeloid, Chronic" 22089542 "The CpG islands in the upstream regions of miR-663, miR-369, miR-615, and miR-410, and promoter activity was detected in the upstream region of pre-miR-663. We found that a decrease in methylation of a CpG island could up-regulate the expression of miR-663, suggesting that miR-663 could be regulated by DNA methylation." +epigenetics hsa-mir-15a "Leukemia, Lymphocytic, Chronic, B-Cell" 22096249 "Histone deacetylases mediate the silencing of miR-15a, miR-16 and miR-29b in chronic lymphocytic leukemia." +epigenetics hsa-mir-16-1 "Leukemia, Lymphocytic, Chronic, B-Cell" 22096249 "Histone deacetylases mediate the silencing of miR-15a, miR-16 and miR-29b in chronic lymphocytic leukemia." +epigenetics hsa-mir-16-2 "Leukemia, Lymphocytic, Chronic, B-Cell" 22096249 "Histone deacetylases mediate the silencing of miR-15a, miR-16 and miR-29b in chronic lymphocytic leukemia." +epigenetics hsa-mir-29b-1 "Leukemia, Lymphocytic, Chronic, B-Cell" 22096249 "Histone deacetylases mediate the silencing of miR-15a, miR-16 and miR-29b in chronic lymphocytic leukemia." +epigenetics hsa-mir-29b-2 "Leukemia, Lymphocytic, Chronic, B-Cell" 22096249 "Histone deacetylases mediate the silencing of miR-15a, miR-16 and miR-29b in chronic lymphocytic leukemia." +epigenetics hsa-mir-212 "Carcinoma, Lung, Non-Small-Cell" 22110741 "We identified histone modifications rather than DNA hypermethylation as epigenetic events that regulate miR-212 levels in NSCLC. Moreover, we found that miR-212 silencing in vivo is closely associated with the severity of the disease." +epigenetics hsa-mir-193a "Carcinoma, Hepatocellular" 22117060 DNA methylation regulated miR-193a-3p dictates resistance of hepatocellular carcinoma to 5-fluorouracil via SRSF2. +epigenetics hsa-mir-127 "Carcinoma, Oral" 22132151 "MiR-375 is repressed and miR-127 activated in OSCC, and we confirm previous reports of miR-137 hypermethylation in oral cancer. The miR-200 s/miR-205 were epigenetically activated in tumors vs normal tissues, but repressed in the absence of DNA hypermethylation specifically in CD44(high) oral CSCs. Aberrant miR-375 and miR-200a expression and miR-200c-141 methylation could be detected in and distinguish OSCC patient oral rinse and saliva from healthy volunteers." +epigenetics hsa-mir-137 "Carcinoma, Oral" 22132151 "MiR-375 is repressed and miR-127 activated in OSCC, and we confirm previous reports of miR-137 hypermethylation in oral cancer. The miR-200 s/miR-205 were epigenetically activated in tumors vs normal tissues, but repressed in the absence of DNA hypermethylation specifically in CD44(high) oral CSCs. Aberrant miR-375 and miR-200a expression and miR-200c-141 methylation could be detected in and distinguish OSCC patient oral rinse and saliva from healthy volunteers." +epigenetics hsa-mir-141 "Carcinoma, Oral" 22132151 "MiR-375 is repressed and miR-127 activated in OSCC, and we confirm previous reports of miR-137 hypermethylation in oral cancer. The miR-200 s/miR-205 were epigenetically activated in tumors vs normal tissues, but repressed in the absence of DNA hypermethylation specifically in CD44(high) oral CSCs. Aberrant miR-375 and miR-200a expression and miR-200c-141 methylation could be detected in and distinguish OSCC patient oral rinse and saliva from healthy volunteers." +epigenetics hsa-mir-200a "Carcinoma, Oral" 22132151 "MiR-375 is repressed and miR-127 activated in OSCC, and we confirm previous reports of miR-137 hypermethylation in oral cancer. The miR-200 s/miR-205 were epigenetically activated in tumors vs normal tissues, but repressed in the absence of DNA hypermethylation specifically in CD44(high) oral CSCs. Aberrant miR-375 and miR-200a expression and miR-200c-141 methylation could be detected in and distinguish OSCC patient oral rinse and saliva from healthy volunteers." +epigenetics hsa-mir-200c "Carcinoma, Oral" 22132151 "MiR-375 is repressed and miR-127 activated in OSCC, and we confirm previous reports of miR-137 hypermethylation in oral cancer. The miR-200 s/miR-205 were epigenetically activated in tumors vs normal tissues, but repressed in the absence of DNA hypermethylation specifically in CD44(high) oral CSCs. Aberrant miR-375 and miR-200a expression and miR-200c-141 methylation could be detected in and distinguish OSCC patient oral rinse and saliva from healthy volunteers." +epigenetics hsa-mir-375 "Carcinoma, Oral" 22132151 "MiR-375 is repressed and miR-127 activated in OSCC, and we confirm previous reports of miR-137 hypermethylation in oral cancer. The miR-200 s/miR-205 were epigenetically activated in tumors vs normal tissues, but repressed in the absence of DNA hypermethylation specifically in CD44(high) oral CSCs. Aberrant miR-375 and miR-200a expression and miR-200c-141 methylation could be detected in and distinguish OSCC patient oral rinse and saliva from healthy volunteers." +epigenetics hsa-mir-9-1 "Squamous Cell Carcinoma, Oral" 22133638 Methylation of microRNA-9 is a specific and sensitive biomarker for oral and oropharyngeal squamous cell carcinomas. +epigenetics hsa-mir-9-3 "Squamous Cell Carcinoma, Oral" 22133638 Methylation of microRNA-9 is a specific and sensitive biomarker for oral and oropharyngeal squamous cell carcinomas. +epigenetics hsa-mir-148a Gastric Neoplasms 22167392 MicroRNA-148a is silenced by hypermethylation and interacts with DNA methyltransferase 1 in gastric cancer. +epigenetics hsa-mir-29b Cardiovascular Diseases [unspecific] 22226905 This article is part of a Special Issue entitled OxLDL causes both epigenetic modification and signaling regulation on the microRNA-29b gene: Novel mechanisms for cardiovascular diseases. +epigenetics hsa-mir-200b Breast Neoplasms 22231446 Methylation of functional promoters of the Hsa-mir-200b is associated with metastasis or hormone receptor status in advanced breast cancer. +epigenetics hsa-mir-519d "Carcinoma, Hepatocellular" 22262409 "In hepatocellular carcinoma miR-519d is upregulated by p53 and DNA hypomethylation and targets CDKN1A/p21, PTEN, AKT3 and TIMP2." +epigenetics hsa-mir-125b-1 Breast Neoplasms 22277129 "We observed a significant reduction on the expression of miR-125b1 in cancer cells in comparison with controls, suggesting that DNA methylation at the CpG island might reduce miR-125b1 expression." +epigenetics hsa-mir-193a "Carcinoma, Lung, Non-Small-Cell" 22282464 Genome-Wide miRNA Expression Profiling Identifies miR-9-3 and miR-193a as Targets for DNA Methylation in Non-Small Cell Lung Cancers. +epigenetics hsa-mir-9-3 "Carcinoma, Lung, Non-Small-Cell" 22282464 Genome-Wide miRNA Expression Profiling Identifies miR-9-3 and miR-193a as Targets for DNA Methylation in Non-Small Cell Lung Cancers. +epigenetics hsa-mir-31 Breast Neoplasms 22289355 miR-31 and its host gene lncRNA LOC554202 are regulated by promoter hypermethylation in triple-negative breast cancer. +epigenetics hsa-mir-152 Atherosclerosis 22295098 MicroRNA-152 mediates DNMT1-regulated DNA methylation in the estrogen receptor ¦Á gene. +epigenetics hsa-mir-17 Colorectal Carcinoma 22308110 Histone deacetylase inhibition in colorectal cancer cells reveals competing roles for members of the oncogenic miR-17-92 cluster. +epigenetics hsa-mir-18a Colorectal Carcinoma 22308110 Histone deacetylase inhibition in colorectal cancer cells reveals competing roles for members of the oncogenic miR-17-92 cluster. +epigenetics hsa-mir-19a Colorectal Carcinoma 22308110 Histone deacetylase inhibition in colorectal cancer cells reveals competing roles for members of the oncogenic miR-17-92 cluster. +epigenetics hsa-mir-19b-1 Colorectal Carcinoma 22308110 Histone deacetylase inhibition in colorectal cancer cells reveals competing roles for members of the oncogenic miR-17-92 cluster. +epigenetics hsa-mir-20a Colorectal Carcinoma 22308110 Histone deacetylase inhibition in colorectal cancer cells reveals competing roles for members of the oncogenic miR-17-92 cluster. +epigenetics hsa-mir-92a-1 Colorectal Carcinoma 22308110 Histone deacetylase inhibition in colorectal cancer cells reveals competing roles for members of the oncogenic miR-17-92 cluster. +epigenetics hsa-mir-132 Prostate Neoplasms 22310291 DNA methylation silences miR-132 in prostate cancer. +epigenetics hsa-mir-34a Prostate Neoplasms 22347519 Epigenetic silencing of miR-34a in human prostate cancer cells and tumor tissue specimens can be reversed by BR-DIM treatment. +epigenetics hsa-let-7c "Carcinoma, Hepatocellular" 22370893 "Enhancer of zeste homolog 2 (EZH2) epigenetically silences multiple tumor suppressor miRNAs (miR-139-5p, miR-125b, miR-101, let-7c, and miR-200b) to promote liver cancer metastasis." +epigenetics hsa-mir-101-1 "Carcinoma, Hepatocellular" 22370893 "Enhancer of zeste homolog 2 (EZH2) epigenetically silences multiple tumor suppressor miRNAs (miR-139-5p, miR-125b, miR-101, let-7c, and miR-200b) to promote liver cancer metastasis." +epigenetics hsa-mir-125b-1 "Carcinoma, Hepatocellular" 22370893 "Enhancer of zeste homolog 2 (EZH2) epigenetically silences multiple tumor suppressor miRNAs (miR-139-5p, miR-125b, miR-101, let-7c, and miR-200b) to promote liver cancer metastasis." +epigenetics hsa-mir-125b-2 "Carcinoma, Hepatocellular" 22370893 "Enhancer of zeste homolog 2 (EZH2) epigenetically silences multiple tumor suppressor miRNAs (miR-139-5p, miR-125b, miR-101, let-7c, and miR-200b) to promote liver cancer metastasis." +epigenetics hsa-mir-139 "Carcinoma, Hepatocellular" 22370893 "Enhancer of zeste homolog 2 (EZH2) epigenetically silences multiple tumor suppressor miRNAs (miR-139-5p, miR-125b, miR-101, let-7c, and miR-200b) to promote liver cancer metastasis." +epigenetics hsa-mir-200b "Carcinoma, Hepatocellular" 22370893 "Enhancer of zeste homolog 2 (EZH2) epigenetically silences multiple tumor suppressor miRNAs (miR-139-5p, miR-125b, miR-101, let-7c, and miR-200b) to promote liver cancer metastasis." +epigenetics hsa-mir-675 Eosinophilic Esophagitis 22391115 EoE remission induced a single miRNA (miR-675) likely to be involved in DNA methylation. +epigenetics hsa-mir-203 Breast Neoplasms 22393463 Epigenetic Silencing of miR-203 Upregulates SNAI2 and Contributes to the Invasiveness of Malignant Breast Cancer Cells. +epigenetics hsa-mir-199b Medulloblastoma 22411914 "The micro-RNA 199b-5p regulatory circuit involves Hes1, CD15, and epigenetic modifications in medulloblastoma." +epigenetics hsa-mir-224 "Carcinoma, Hepatocellular" 22459148 MicroRNA-224 is up-regulated in hepatocellular carcinoma through epigenetic mechanisms. +epigenetics hsa-let-7b Liver Neoplasms 22683924 Downregulation of HMGA2 by the pan-deacetylase inhibitor panobinostat is dependent on hsa-let-7b expression in liver cancer cell lines. +epigenetics hsa-mir-137 Gastric Neoplasms 22703336 "Methylation frequency of 5 miR CpG islands (miR-9-1, miR-9-3, miR-137, miR-34b, and miR-210) gradually increased while the proportion of methylated miR-200b gradually decreased during gastric carcinogenesis" +epigenetics hsa-mir-210 Gastric Neoplasms 22703336 "Methylation frequency of 5 miR CpG islands (miR-9-1, miR-9-3, miR-137, miR-34b, and miR-210) gradually increased while the proportion of methylated miR-200b gradually decreased during gastric carcinogenesis" +epigenetics hsa-mir-34b Gastric Neoplasms 22703336 "Methylation frequency of 5 miR CpG islands (miR-9-1, miR-9-3, miR-137, miR-34b, and miR-210) gradually increased while the proportion of methylated miR-200b gradually decreased during gastric carcinogenesis" +epigenetics hsa-mir-9-1 Gastric Neoplasms 22703336 "Methylation frequency of 5 miR CpG islands (miR-9-1, miR-9-3, miR-137, miR-34b, and miR-210) gradually increased while the proportion of methylated miR-200b gradually decreased during gastric carcinogenesis" +epigenetics hsa-mir-9-3 Gastric Neoplasms 22703336 "Methylation frequency of 5 miR CpG islands (miR-9-1, miR-9-3, miR-137, miR-34b, and miR-210) gradually increased while the proportion of methylated miR-200b gradually decreased during gastric carcinogenesis" +epigenetics hsa-mir-218-1 Breast Neoplasms 22705304 miR-7 and miR-218 epigenetically control tumor suppressor genes RASSF1A and Claudin-6 by targeting HoxB3 in breast cancer. +epigenetics hsa-mir-218-2 Breast Neoplasms 22705304 miR-7 and miR-218 epigenetically control tumor suppressor genes RASSF1A and Claudin-6 by targeting HoxB3 in breast cancer. +epigenetics hsa-mir-7-1 Breast Neoplasms 22705304 miR-7 and miR-218 epigenetically control tumor suppressor genes RASSF1A and Claudin-6 by targeting HoxB3 in breast cancer. +epigenetics hsa-mir-7-2 Breast Neoplasms 22705304 miR-7 and miR-218 epigenetically control tumor suppressor genes RASSF1A and Claudin-6 by targeting HoxB3 in breast cancer. +epigenetics hsa-mir-7-3 Breast Neoplasms 22705304 miR-7 and miR-218 epigenetically control tumor suppressor genes RASSF1A and Claudin-6 by targeting HoxB3 in breast cancer. +epigenetics hsa-mir-1-1 Colorectal Carcinoma 22766685 Silencing of miR-1-1 and miR-133a-2 cluster expression by DNA hypermethylation in colorectal cancer. +epigenetics hsa-mir-133a-1 Colorectal Carcinoma 22766685 Silencing of miR-1-1 and miR-133a-2 cluster expression by DNA hypermethylation in colorectal cancer. +epigenetics hsa-mir-133a-2 Colorectal Carcinoma 22766685 Silencing of miR-1-1 and miR-133a-2 cluster expression by DNA hypermethylation in colorectal cancer. +epigenetics hsa-mir-340 Neuroblastoma 22797059 miR-340 is upregulated by demethylation of an upstream genomic region that occurs during the process of neuroblastoma cell differentiation induced by all-trans retinoic acid (ATRA). +epigenetics hsa-mir-1256 Prostate Neoplasms 22805767 Epigenetic deregulation of miR-29a and miR-1256 by isoflavone contributes to the inhibition of prostate cancer cell growth and invasion. +epigenetics hsa-mir-29a Prostate Neoplasms 22805767 Epigenetic deregulation of miR-29a and miR-1256 by isoflavone contributes to the inhibition of prostate cancer cell growth and invasion. +epigenetics hsa-mir-124-1 Cholangiocarcinoma 22819820 Epigenetic regulation of miR-124 by Hepatitis C Virus core protein promotes migration and invasion of intrahepatic cholangiocarcinoma cells by targeting SMYD3. +epigenetics hsa-mir-124-2 Cholangiocarcinoma 22819820 Epigenetic regulation of miR-124 by Hepatitis C Virus core protein promotes migration and invasion of intrahepatic cholangiocarcinoma cells by targeting SMYD3. +epigenetics hsa-mir-149 Colorectal Carcinoma 22821729 SP1 mediates the link between methylation of the tumour suppressor miR-149 and outcome in colorectal cancer. +epigenetics hsa-mir-205 Prostate Neoplasms 22869146 Epigenetic-induced repression of microRNA-205 is associated with MED1 activation and a poorer prognosis in localized prostate cancer. +epigenetics hsa-mir-124a Colorectal Carcinoma 22870149 The results showed that the methylation of miR-124a and miR-34b/c occured early in colorectal carcinogenesis and certain CRCs may arise from a field defect defined by the epigenetic inactivation of miRs. +epigenetics hsa-mir-34b Colorectal Carcinoma 22870149 The results showed that the methylation of miR-124a and miR-34b/c occured early in colorectal carcinogenesis and certain CRCs may arise from a field defect defined by the epigenetic inactivation of miRs. +epigenetics hsa-mir-34c Colorectal Carcinoma 22870149 The results showed that the methylation of miR-124a and miR-34b/c occured early in colorectal carcinogenesis and certain CRCs may arise from a field defect defined by the epigenetic inactivation of miRs. +epigenetics hsa-mir-141 Esophageal Neoplasms 22921431 Inhibition of SOX17 by MicroRNA-141 and Methylation Activates the WNT Signaling Pathway in Esophageal Cancer. +epigenetics hsa-mir-31 Melanoma 22948084 Genetic and epigenetic loss of microRNA-31 leads to feed-forward expression of EZH2 in melanoma. +epigenetics hsa-mir-127 Osteosarcoma 22957032 "Treatment with 4-phenylbutyrate increased acetylation of histones associated with 14q32 miRNAs, but interestingly, robust restoration of 14q32 miRNA expression, attenuation of cMYC expression, and induction of apoptosis required concomitant treatment with 5-Azacytidine, an inhibitor of DNA methylation. combination of these chromatin-modifying drugs may be a useful adjuvant in the treatment of rapidly progressive osteosarcoma." +epigenetics hsa-mir-411 Osteosarcoma 22957032 "Treatment with 4-phenylbutyrate increased acetylation of histones associated with 14q32 miRNAs, but interestingly, robust restoration of 14q32 miRNA expression, attenuation of cMYC expression, and induction of apoptosis required concomitant treatment with 5-Azacytidine, an inhibitor of DNA methylation. combination of these chromatin-modifying drugs may be a useful adjuvant in the treatment of rapidly progressive osteosarcoma." +epigenetics hsa-mir-431 Osteosarcoma 22957032 "Treatment with 4-phenylbutyrate increased acetylation of histones associated with 14q32 miRNAs, but interestingly, robust restoration of 14q32 miRNA expression, attenuation of cMYC expression, and induction of apoptosis required concomitant treatment with 5-Azacytidine, an inhibitor of DNA methylation. combination of these chromatin-modifying drugs may be a useful adjuvant in the treatment of rapidly progressive osteosarcoma." +epigenetics hsa-mir-432 Osteosarcoma 22957032 "Treatment with 4-phenylbutyrate increased acetylation of histones associated with 14q32 miRNAs, but interestingly, robust restoration of 14q32 miRNA expression, attenuation of cMYC expression, and induction of apoptosis required concomitant treatment with 5-Azacytidine, an inhibitor of DNA methylation. combination of these chromatin-modifying drugs may be a useful adjuvant in the treatment of rapidly progressive osteosarcoma." +epigenetics hsa-mir-23b Prostate Neoplasms 23074286 miR-23b Represses Proto-oncogene Src Kinase and Functions as Methylation-Silenced Tumor Suppressor with Diagnostic and Prognostic Significance in Prostate Cancer +epigenetics hsa-mir-29b-1 Multiple Myeloma 23100393 DNA-demethylating and anti-tumor activity of synthetic miR-29b mimics in multiple myeloma +epigenetics hsa-mir-29b-2 Multiple Myeloma 23100393 DNA-demethylating and anti-tumor activity of synthetic miR-29b mimics in multiple myeloma +epigenetics hsa-mir-200a Breast Neoplasms 23112837 the expression and methylation status of miR-200f could be used as hypothetical biomarkers to assess the occurrence of EMT in breast cancer +epigenetics hsa-mir-200b Breast Neoplasms 23112837 the expression and methylation status of miR-200f could be used as hypothetical biomarkers to assess the occurrence of EMT in breast cancer +epigenetics hsa-mir-200c Breast Neoplasms 23112837 the expression and methylation status of miR-200f could be used as hypothetical biomarkers to assess the occurrence of EMT in breast cancer +epigenetics hsa-mir-149 Colorectal Carcinoma 23115050 Non-CpG island promoter hypomethylation and miR-149 regulate the expression of SRPX2 in colorectal cancer +epigenetics hsa-mir-137 "Squamous Cell Carcinoma, Oral" 23121285 MicroRNA-137 promoter methylation in oral lichen planus and oral squamous cell carcinoma +epigenetics hsa-mir-101-1 Hepatitis B Virus Infection 23124077 miR-101 is down-regulated by the hepatitis B virus x protein and induces aberrant DNA methylation by targeting DNA methyltransferase 3A +epigenetics hsa-mir-101-2 Hepatitis B Virus Infection 23124077 miR-101 is down-regulated by the hepatitis B virus x protein and induces aberrant DNA methylation by targeting DNA methyltransferase 3A +epigenetics hsa-mir-29b-1 Systemic Lupus Erythematosus 23142053 MicroRNA-29b contributes to DNA hypomethylation of CD4+ T cells in systemic lupus erythematosus by indirectly targeting DNA methyltransferase 1 +epigenetics hsa-mir-29b-2 Systemic Lupus Erythematosus 23142053 MicroRNA-29b contributes to DNA hypomethylation of CD4+ T cells in systemic lupus erythematosus by indirectly targeting DNA methyltransferase 1 +epigenetics hsa-mir-34b Prostate Neoplasms 23147995 "miRNA-34b Inhibits Prostate Cancer through Demethylation, Active Chromatin Modifications, and AKT Pathways" +epigenetics hsa-mir-29b-1 "Leukemia, Myeloid, Acute" 23178755 Increased anti-leukemic activity of decitabine via AR-42-induced upregulation of miR-29b: a novel epigenetic-targeting approach in acute myeloid leukemia +epigenetics hsa-mir-29b-2 "Leukemia, Myeloid, Acute" 23178755 Increased anti-leukemic activity of decitabine via AR-42-induced upregulation of miR-29b: a novel epigenetic-targeting approach in acute myeloid leukemia +epigenetics hsa-mir-29b-1 Ovarian Neoplasms 23179556 Anticancer role of MUC1 aptamer-miR-29b chimera in epithelial ovarian carcinoma cells through regulation of PTEN methylation +epigenetics hsa-mir-29b-2 Ovarian Neoplasms 23179556 Anticancer role of MUC1 aptamer-miR-29b chimera in epithelial ovarian carcinoma cells through regulation of PTEN methylation +epigenetics hsa-mir-211 Glioma 23183822 "Epigenetic Regulation of miRNA-211 by MMP-9 Governs Glioma Cell Apoptosis,Chemosensitivity and Radiosensitivity" +epigenetics hsa-mir-124 Bladder Neoplasms 23200812 "Among them, miR-137,miR-124-2, miR-124-3, and miR-9-3 were frequently and tumor-specifically methylated in primary cancers" +epigenetics hsa-mir-137 Bladder Neoplasms 23200812 "Among them, miR-137,miR-124-2, miR-124-3, and miR-9-3 were frequently and tumor-specifically methylated in primary cancers" +epigenetics hsa-mir-9 Bladder Neoplasms 23200812 "Among them, miR-137,miR-124-2, miR-124-3, and miR-9-3 were frequently and tumor-specifically methylated in primary cancers" +epigenetics hsa-mir-200a "Carcinoma, Hepatocellular" 23222811 Epigenetic activation of the MiR-200 family contributes to H19-mediated metastasis suppression in hepatocellular carcinoma +epigenetics hsa-mir-200b "Carcinoma, Hepatocellular" 23222811 Epigenetic activation of the MiR-200 family contributes to H19-mediated metastasis suppression in hepatocellular carcinoma +epigenetics hsa-mir-200c "Carcinoma, Hepatocellular" 23222811 Epigenetic activation of the MiR-200 family contributes to H19-mediated metastasis suppression in hepatocellular carcinoma +epigenetics hsa-mir-193a "Leukemia, Myeloid, Acute" 23223432 Epigenetic silencing of microRNA-193a contributes to leukemogenesis in t(8;21)acute myeloid leukemia by activating the PTEN/PI3K signal pathway +epigenetics hsa-mir-335 "Carcinoma, Hepatocellular" 23229728 Epigenetic silencing of miR-335 and its host gene MEST in hepatocellular carcinoma +epigenetics hsa-mir-31 Prostate Neoplasms 23233736 Epigenetic repression of miR-31 disrupts androgen receptor homeostasis and contributes to prostate cancer progression +epigenetics hsa-mir-34a Colon Neoplasms 23243217 Detection of miR-34a Promoter Methylation in Combination with Elevated Expression of c-Met and beta-Catenin Predicts Distant Metastasis of Colon Cancer +epigenetics hsa-mir-34a Breast Neoplasms 23292869 Downregulation of miR-34a in breast tumors is not associated with either p53 mutations or promoter hypermethylation while it correlates with metastasis +epigenetics hsa-mir-124-1 "Carcinoma, Renal Cell" 23321515 Hsa-mir-124-3 CpG island methylation is associated with advanced tumours and disease recurrence of patients with clear cell renal cell carcinoma +epigenetics hsa-mir-124-2 "Carcinoma, Renal Cell" 23321515 Hsa-mir-124-3 CpG island methylation is associated with advanced tumours and disease recurrence of patients with clear cell renal cell carcinoma +epigenetics hsa-mir-124-3 "Carcinoma, Renal Cell" 23321515 Hsa-mir-124-3 CpG island methylation is associated with advanced tumours and disease recurrence of patients with clear cell renal cell carcinoma +epigenetics hsa-mir-195 Gastric Neoplasms 23333942 MicroRNA-195 and microRNA-378 mediate tumor growth suppression by epigenetical regulation in gastric cancer +epigenetics hsa-mir-378a Gastric Neoplasms 23333942 MicroRNA-195 and microRNA-378 mediate tumor growth suppression by epigenetical regulation in gastric cancer +epigenetics hsa-mir-124-1 Pancreatic Neoplasms 23334332 Methylation-mediated silencing of the miR-124 genes facilitates pancreatic cancer progression and metastasis by targeting Rac1 +epigenetics hsa-mir-124-2 Pancreatic Neoplasms 23334332 Methylation-mediated silencing of the miR-124 genes facilitates pancreatic cancer progression and metastasis by targeting Rac1 +epigenetics hsa-mir-124-3 Pancreatic Neoplasms 23334332 Methylation-mediated silencing of the miR-124 genes facilitates pancreatic cancer progression and metastasis by targeting Rac1 +epigenetics hsa-mir-129-2 "Carcinoma, Hepatocellular" 23402613 Methylation-mediated repression of microRNA 129-2 enhances oncogenic SOX4 expression in HCC +epigenetics hsa-mir-200 Breast Neoplasms 23525011 Epigenetic modulation of the miR-200 family is associated with transition to a breast cancer stem cell-like state +epigenetics hsa-mir-146a "Lymphoma, Burkitt" 23528241 "We concluded that similarly to the promoters of protein coding genes, both DNA methylation and histone modifications contribute to the host cell dependent expression of miR-146a." +epigenetics hsa-mir-129-1 "Carcinoma, Hepatocellular" 23580407 Frequent DNA methylation of MiR-129-2 and its potential clinical implication in hepatocellular carcinoma +epigenetics hsa-mir-129-2 "Carcinoma, Hepatocellular" 23580407 Frequent DNA methylation of MiR-129-2 and its potential clinical implication in hepatocellular carcinoma +epigenetics hsa-mir-1286 Human Papilloma Virus Infection 23732000 "We found hypermethylation of miR-432, miR-1286, miR-641, miR-1290, miR-1287 and miR-95 may have some relationship with HPV infection in cervical cell lines." +epigenetics hsa-mir-1287 Human Papilloma Virus Infection 23732000 "We found hypermethylation of miR-432, miR-1286, miR-641, miR-1290, miR-1287 and miR-95 may have some relationship with HPV infection in cervical cell lines." +epigenetics hsa-mir-1290 Human Papilloma Virus Infection 23732000 "We found hypermethylation of miR-432, miR-1286, miR-641, miR-1290, miR-1287 and miR-95 may have some relationship with HPV infection in cervical cell lines." +epigenetics hsa-mir-432 Human Papilloma Virus Infection 23732000 "We found hypermethylation of miR-432, miR-1286, miR-641, miR-1290, miR-1287 and miR-95 may have some relationship with HPV infection in cervical cell lines." +epigenetics hsa-mir-641 Human Papilloma Virus Infection 23732000 "We found hypermethylation of miR-432, miR-1286, miR-641, miR-1290, miR-1287 and miR-95 may have some relationship with HPV infection in cervical cell lines." +epigenetics hsa-mir-95 Human Papilloma Virus Infection 23732000 "We found hypermethylation of miR-432, miR-1286, miR-641, miR-1290, miR-1287 and miR-95 may have some relationship with HPV infection in cervical cell lines." +epigenetics hsa-mir-124a-2 "Carcinoma, Renal Cell" 23755536 "The frequency of methylation of six genes (miR-124a-2, -124a-3, -9-1, -9-3, -34b/c and -129-2) was significantly higher in tumor samples than in samples of histologically normal tissue" +epigenetics hsa-mir-124a-3 "Carcinoma, Renal Cell" 23755536 "The frequency of methylation of six genes (miR-124a-2, -124a-3, -9-1, -9-3, -34b/c and -129-2) was significantly higher in tumor samples than in samples of histologically normal tissue" +epigenetics hsa-mir-129-2 "Carcinoma, Renal Cell" 23755536 "The frequency of methylation of six genes (miR-124a-2, -124a-3, -9-1, -9-3, -34b/c and -129-2) was significantly higher in tumor samples than in samples of histologically normal tissue" +epigenetics hsa-mir-34b "Carcinoma, Renal Cell" 23755536 "The frequency of methylation of six genes (miR-124a-2, -124a-3, -9-1, -9-3, -34b/c and -129-2) was significantly higher in tumor samples than in samples of histologically normal tissue" +epigenetics hsa-mir-34c "Carcinoma, Renal Cell" 23755536 "The frequency of methylation of six genes (miR-124a-2, -124a-3, -9-1, -9-3, -34b/c and -129-2) was significantly higher in tumor samples than in samples of histologically normal tissue" +epigenetics hsa-mir-9-1 "Carcinoma, Renal Cell" 23755536 "The frequency of methylation of six genes (miR-124a-2, -124a-3, -9-1, -9-3, -34b/c and -129-2) was significantly higher in tumor samples than in samples of histologically normal tissue" +epigenetics hsa-mir-9-3 "Carcinoma, Renal Cell" 23755536 "The frequency of methylation of six genes (miR-124a-2, -124a-3, -9-1, -9-3, -34b/c and -129-2) was significantly higher in tumor samples than in samples of histologically normal tissue" +epigenetics hsa-mir-29a "Carcinoma, Hepatocellular" 23789939 miR-29a could regulate TGF-¦Â-induced EMT by affecting DNA methylation via the suppression of DNMT. +epigenetics hsa-mir-219 Breast Neoplasms 23813567 Aberrant DNA methylation of miR-219 promoter in long-term night shiftworkers. +epigenetics hsa-mir-10a Bladder Neoplasms 23867826 "Analyses in human urothelial cells identify methylation of miR-152, miR-200b and miR-10a genes as candidate bladder cancer biomarkers." +epigenetics hsa-mir-152 Bladder Neoplasms 23867826 "Analyses in human urothelial cells identify methylation of miR-152, miR-200b and miR-10a genes as candidate bladder cancer biomarkers." +epigenetics hsa-mir-200b Bladder Neoplasms 23867826 "Analyses in human urothelial cells identify methylation of miR-152, miR-200b and miR-10a genes as candidate bladder cancer biomarkers." +epigenetics hsa-mir-15a "Carcinoma, Lung, Non-Small-Cell" 23867991 Histone deacetylases inhibitor trichostatin A increases the expression of Dleu2/miR-15a/16-1 via HDAC3 in non-small cell lung cancer. +epigenetics hsa-mir-16-1 "Carcinoma, Lung, Non-Small-Cell" 23867991 Histone deacetylases inhibitor trichostatin A increases the expression of Dleu2/miR-15a/16-1 via HDAC3 in non-small cell lung cancer. +epigenetics hsa-mir-663 "Leukemia, Myeloid, Acute" 23870168 "Expression of miR-663 was significantly lower in pediatric AML cells compared to NBM controls; furthermore, a high frequency of miR-663 promoter hypermethylation was observed in both AML cell lines and pediatric AML samples.Inactivation of miR-663 by promoter hypermethylation could be affected by 5-Aza demethylation. These findings suggest that hypermethylation of the miR-663 promoter may be an early event in the development of pediatric AML." +epigenetics hsa-mir-126 Colorectal Carcinoma 23900443 Epigenetic silencing of miR-126 contributes to tumor invasion and angiogenesis in colorectal cancer. +epigenetics hsa-mir-29 "Carcinoma, Lung, Non-Small-Cell" 23939044 Suppression of Wnt signaling by the miR-29 family is mediated by demethylation of WIF-1 in non-small-cell lung cancer. +epigenetics hsa-mir-34b Gastric Neoplasms 23942619 Our results suggest that methylation of miR-34b/c in the mucosa of the noncancerous gastric body may be a useful biomarker for predicting the risk of metachronous GC. +epigenetics hsa-mir-34c Gastric Neoplasms 23942619 Our results suggest that methylation of miR-34b/c in the mucosa of the noncancerous gastric body may be a useful biomarker for predicting the risk of metachronous GC. +epigenetics hsa-mir-199a Testicular Neoplasms 23959088 "microRNA-199a-3p, DNMT3A, and aberrant DNA methylation in testicular cancer." +epigenetics hsa-mir-126 Systemic Lupus Erythematosus 23981988 The upregulation of miR-126 and its host gene EGFL7 expression in CD4+ T cells from SLE is associated with the hypomethylation of the EGFL7 promoter. +epigenetics hsa-mir-328 Breast Neoplasms 23991164 Methylation patterns in the miR-328 5'-flanking region are involved in the inter-individual difference in BCRP levels in human placenta +epigenetics hsa-mir-122 "Carcinoma, Hepatocellular" 24085423 The expression of miRNA-122 is regulated by DNA methylation and correlated with apoptosis of liver cancer cells. Methylation regulation of miRNA-122 expression might be involved in the development of hepatocellular carcinoma. +epigenetics hsa-mir-29 Neoplasms [unspecific] 24096364 The miR-29 family recurrently regulates active DNA demethylation pathway members TET1 and TDG. +epigenetics hsa-mir-203 "Leukemia, Myeloid, Acute, Pediatric" 24103876 miR-203 may not be regulated with methylation mechanism in pediatric acute leukemia. miR- 203 may be a protooncogene involved in the formation of pediatric acute leukemia and ALL. Further analyses indicated that high expression of miR-203 may be associated with poor prognosis of pediatric ALL and acute leukemia. +epigenetics hsa-mir-125b Melanoma 24118912 "the reduction in miR-125b expression in pigmented cells was at least partially due to the hypermethylation of the MIR125B-1 promoter, and miR-125b expression was regulated by intracellular cAMP levels." +epigenetics hsa-mir-200 Hepatoblastoma 24122292 The strong correlation between expression and DNA methylation suggests a major role for this epigenetic mark in the regulation of the miR-141-200c locus. +epigenetics hsa-mir-205 Hepatoblastoma 24122292 The strong correlation between expression and DNA methylation suggests a major role for this epigenetic mark in the regulation of the miR-141-200c locus. +epigenetics hsa-mir-214 Lung Fibrosis 24122720 "Stable decreases in miR-124 expression contribute to an epigenetically reprogrammed, highly proliferative, migratory, and inflammatory phenotype of hypertensive pulmonary adventitial fibroblasts. Thus, therapies directed at restoring miR-124 function, including histone deacetylase inhibitors,should be investigated." +epigenetics hsa-mir-34b Early-Stage Lung Adenocarcinoma 24130071 Epigenetic inactivation of microRNA-34b/c predicts poor disease-free survival in early-stage lung adenocarcinoma. +epigenetics hsa-mir-34c Early-Stage Lung Adenocarcinoma 24130071 Epigenetic inactivation of microRNA-34b/c predicts poor disease-free survival in early-stage lung adenocarcinoma. +epigenetics hsa-mir-29b Liver Fibrosis 24138392 Curcumin up-regulates phosphatase and tensin homologue deleted on chromosome 10 through microRNA-mediated control of DNA methylation--a novel mechanism suppressing liver fibrosis. +epigenetics hsa-mir-34b Pleural Mesothelioma 24168922 "Our digital MSP assay can quantify miR-34b/c methylation in serum-circulating DNA. The degree of miR-34b/c methylation in serum-circulating DNA is associated with MPM, suggesting that this approach might be useful for the establishment of a new detection system for MPM." +epigenetics hsa-mir-34c Pleural Mesothelioma 24168922 "Our digital MSP assay can quantify miR-34b/c methylation in serum-circulating DNA. The degree of miR-34b/c methylation in serum-circulating DNA is associated with MPM, suggesting that this approach might be useful for the establishment of a new detection system for MPM." +epigenetics hsa-mir-375 Prostate Neoplasms 24173286 Androgen receptor is negatively correlated with the methylation-mediated transcriptional repression of miR-375 in human prostate cancer cells. +epigenetics hsa-mir-143 Breast Neoplasms 24218337 MicroRNA-143 is downregulated in breast cancer and regulates DNA methyltransferases 3A in breast cancer cells. +epigenetics hsa-mir-124a Rheumatoid Arthritis 24223605 "The methylation status of miR-124a seen in this study concurs with that reported in tumor cells, indicating epigenetic dysregulation constituents, a mechanism in the development of rheumatoid arthritis." +epigenetics hsa-mir-203 Rhabdomyosarcoma 24247238 "miR-203, a tumor suppressor frequently down-regulated by promoter hypermethylation in rhabdomyosarcoma." +epigenetics hsa-mir-148b Breast Neoplasms 24257477 "Our data provide novel evidence of the mechanisms behind miRNA dysregulation in breast cancer. The study contributes to the understanding of how methylation and copy number alterations influence miRNA expression, emphasizing miRNA functionality through redundant encoding, and suggests novel miRNAs important in breast cancer." +epigenetics hsa-mir-151a Breast Neoplasms 24257477 "Our data provide novel evidence of the mechanisms behind miRNA dysregulation in breast cancer. The study contributes to the understanding of how methylation and copy number alterations influence miRNA expression, emphasizing miRNA functionality through redundant encoding, and suggests novel miRNAs important in breast cancer." +epigenetics hsa-mir-21 Breast Neoplasms 24257477 "Our data provide novel evidence of the mechanisms behind miRNA dysregulation in breast cancer. The study contributes to the understanding of how methylation and copy number alterations influence miRNA expression, emphasizing miRNA functionality through redundant encoding, and suggests novel miRNAs important in breast cancer." +epigenetics hsa-mir-29c Breast Neoplasms 24297604 Dysregulation of microRNA expression drives aberrant DNA hypermethylation in basal-like breast cancer. +epigenetics hsa-mir-199a Chronic Obstructive Pulmonary Disease 24299514 "miR-199a-5p is a key regulator of the unfolded protein response in AAT-deficient monocytes, and epigenetic silencing of its expression regulates this process in chronic obstructive pulmonary disease." +epigenetics hsa-mir-124a Melanoma 24303550 Epigenetic regulation of melanoma tumor suppressor miRNA-124a. +epigenetics hsa-mir-128a "Leukemia, T-Cell" 24316133 Epigenetic regulation of microRNA-128a expression contributes to the apoptosis-resistance of human T-cell leukaemia jurkat cells by modulating expression of fas-associated protein with death domain (FADD). +epigenetics hsa-mir-223 "Carcinoma, Hepatocellular" 24333181 Downregulation of miR-223 in HCC is associated with the epigenetic regulation by highly expressed sulfatide and involved in tumor metastasis. +epigenetics hsa-mir-205 Hepatitis B Virus Infection 24339740 Hepatitis B virus X protein inhibits tumor suppressor miR-205 through inducing hypermethylation of miR-205 promoter to enhance carcinogenesis. +epigenetics hsa-mir-9 Medulloblastoma 24346283 microRNA-9 is a methylation-silenced tumour suppressor that could be a potential candidate predictive marker for poor prognosis of medulloblastoma. +epigenetics hsa-mir-22 Ewing Sarcoma 24362521 The histone demethylase KDM3A is a microRNA-22-regulated tumor promoter in Ewing Sarcoma. +epigenetics hsa-let-7c Cardiomyopathy 24365598 Cardiomyogenesis is controlled by the miR-99a/let-7c cluster and epigenetic modifications. +epigenetics hsa-mir-99a Cardiomyopathy 24365598 Cardiomyogenesis is controlled by the miR-99a/let-7c cluster and epigenetic modifications. +epigenetics hsa-mir-375 "Diabetes Mellitus, Type 2" 24366165 Expression and DNA methylation status of microRNA-375 in patients with type 2 diabetes mellitus. +epigenetics hsa-mir-9 "Leukemia, Lymphocytic, Chronic, B-Cell" 24373626 "Of the miR-9 family, miR-9-3 is a tumor suppressor miRNA relatively frequently methylated, and hence silenced in CLL; whereas miR-9-1 methylation is rare in CLL. The role of miR-9-3 methylation in the constitutive activation of NF¦ÊB signaling pathway in CLL warrants further study." +epigenetics hsa-mir-124a-1 Breast Neoplasms 24375250 "Methylation of miR-124a-1, miR-124a-2, and miR-124a-3 genes correlates with aggressive and advanced breast cancer disease." +epigenetics hsa-mir-124a-2 Breast Neoplasms 24375250 "Methylation of miR-124a-1, miR-124a-2, and miR-124a-3 genes correlates with aggressive and advanced breast cancer disease." +epigenetics hsa-mir-124a-3 Breast Neoplasms 24375250 "Methylation of miR-124a-1, miR-124a-2, and miR-124a-3 genes correlates with aggressive and advanced breast cancer disease." +epigenetics hsa-mir-124 Pulmonary Hypertension 24385500 Deacetylation of MicroRNA-124 in fibroblasts: role in pulmonary hypertension. +epigenetics hsa-mir-297 Squamous Cell Carcinoma 24394434 Phospho-¦¤Np63¦Á/microRNA network modulates epigenetic regulatory enzymes in squamous cell carcinomas. +epigenetics hsa-mir-485 Squamous Cell Carcinoma 24394434 Phospho-¦¤Np63¦Á/microRNA network modulates epigenetic regulatory enzymes in squamous cell carcinomas. +epigenetics hsa-mir-92b Squamous Cell Carcinoma 24394434 Phospho-¦¤Np63¦Á/microRNA network modulates epigenetic regulatory enzymes in squamous cell carcinomas. +epigenetics hsa-mir-34a Bladder Neoplasms 24423412 "Cisplatin-based chemotherapy induced demethylation of miR-34a promoter and increased miR-34a expression, which in turn sensitized MIBC cells to cisplatin and decreased the tumorigenicity and proliferation of cancer cells that by reducing the production of CD44." +epigenetics hsa-let-7a-3 Neoplasms [unspecific] 24423609 Reduction of let-7a3/let-7b miRNA may be one of mechanisms leading to overexpression of HMGA2 in AT/RT tissues. +epigenetics hsa-mir-1258 Lung Neoplasms 24450160 Novel miRNA genes methylated in lung tumors. +epigenetics hsa-mir-137 Lung Neoplasms 24450160 Novel miRNA genes methylated in lung tumors. +epigenetics hsa-mir-375 Lung Neoplasms 24450160 Novel miRNA genes methylated in lung tumors. +epigenetics hsa-mir-21 Pancreatic Neoplasms 24460329 MiR-21 upregulation induced by histone acetylation in the promoter zone is associated with chemoresistance to gemcitabine and enhanced malignant potential in pancreatic cancer cells. +epigenetics hsa-mir-10b Gastric Neoplasms 24481854 "Taken together, these findings suggest that miR-10b may function as a novel tumor suppressor and is partially silenced by DNA hypermethylation in GC." +epigenetics hsa-mir-1260b Prostate Neoplasms 24504368 Our data suggest that genistein exerts its anti-tumour effect via downregulation of miR-1260b that targeted sRRP1 and Smad4 genes in prostate cancer cells. The expression of sFRP1 and Smad4 was also modulated by genistein via DNA methylation or histone modifications in PC cell lines. +epigenetics hsa-mir-203 "Carcinoma, Endometrial" 24530564 "Hypermethylation of miR-203 is a frequent event in endometrial carcinomas and is strongly associated with microsatellite instability and MLH1 methylation status. Thus, miR-203 methylation level might represent a marker for patients with endometrioid and clear endometrial sub-cancers." +epigenetics hsa-mir-34a "Leukemia, Lymphocytic, Chronic, B-Cell" 24559316 "Taken together, miR-34b/c is a tumor suppressor miRNA frequently methylated, and hence silenced in CLL. Together with DAPK1 methylation, miR-34b/c methylation is implicated in the disruption of the TP53-centered tumor suppressor network. Moreover, the association of miRNA methylation warrants further study." +epigenetics hsa-mir-34b "Leukemia, Lymphocytic, Chronic, B-Cell" 24559316 "Taken together, miR-34b/c is a tumor suppressor miRNA frequently methylated, and hence silenced in CLL. Together with DAPK1 methylation, miR-34b/c methylation is implicated in the disruption of the TP53-centered tumor suppressor network. Moreover, the association of miRNA methylation warrants further study." +epigenetics hsa-mir-34c "Leukemia, Lymphocytic, Chronic, B-Cell" 24559316 "Taken together, miR-34b/c is a tumor suppressor miRNA frequently methylated, and hence silenced in CLL. Together with DAPK1 methylation, miR-34b/c methylation is implicated in the disruption of the TP53-centered tumor suppressor network. Moreover, the association of miRNA methylation warrants further study." +epigenetics hsa-mir-375 "Carcinoma, Breast" 24571711 "Epigenetic silencing of miR-375 causes the upregulation of IGF1R,which at least partially underlies trastuzumab resistance of breast cancer cells.Our study has implications for miR-375 as a potential target in combination with trastuzumab for treating HER2-positive breast cancers." +epigenetics hsa-mir-429 "Carcinoma, Hepatocellular" 24572141 "Epigenetic modification of miR-429 can manipulate liver T-ICs by targeting the RBBP4/E2F1/OCT4 axis. This miRNA might be targeted to inactivate T-ICs, thus providing a novel strategy for HCC prevention and treatment." +epigenetics hsa-mir-199b Ovarian Neoplasms 24659709 Epigenetic silencing of microRNA-199b-5p is associated with acquired chemoresistance via activation of JAG1-Notch1 signaling in ovarian cancer. +epigenetics hsa-mir-127 Lung Neoplasms 24665010 Epigenetic analysis of microRNA genes in tumors from surgically resected lung cancer patients and association with survival. +epigenetics hsa-mir-491 Liver Neoplasms 24680928 Arsenic trioxide attenuates the invasion potential of human liver cancer cells through the demethylation-activated microRNA-491. +epigenetics hsa-mir-34 "Leukemia, Lymphocytic, Chronic, B-Cell" 24686393 microRNA-34b/c on chromosome 11q23 is aberrantly methylated in chronic lymphocytic leukemia. +epigenetics hsa-mir-34b "Leukemia, Lymphocytic, Chronic, B-Cell" 24686393 microRNA-34b/c on chromosome 11q23 is aberrantly methylated in chronic lymphocytic leukemia. +epigenetics hsa-mir-34c "Leukemia, Lymphocytic, Chronic, B-Cell" 24686393 microRNA-34b/c on chromosome 11q23 is aberrantly methylated in chronic lymphocytic leukemia. +epigenetics hsa-let-7a-3 "Leukemia, Myeloid, Acute" 24703161 "MicroRNA let-7a-3 gene methylation is associated with karyotyping, CEBPA promoter methylation, and survival in acute myeloid leukemia." +epigenetics hsa-mir-34b "Carcinoma, Hepatocellular" 24704024 Methylation-associated silencing of microRNA-34b in hepatocellular carcinoma cancer. +epigenetics hsa-mir-148a "Carcinoma, Hepatocellular" 24714841 MicroRNA-148a is silenced by hypermethylation and interacts with DNA methyltransferase 1 in hepatocellular carcinogenesis. +epigenetics hsa-mir-200c Breast Neoplasms 24729530 Induction of the mesenchymal to epithelial transition by demethylation- activated microRNA-200c is involved in the anti-migration/invasion effects of arsenic trioxide on human breast cancer cells. +epigenetics hsa-mir-224 Prostate Neoplasms 24737792 "The GABRE-miR-452-miR-224 locus is downregulated and hypermethylated in prostate cancer and is a new promising epigenetic candidate biomarker for prostate cancer diagnosis and prognosis. Tumor-suppressive functions of the intronic miR-224 and miR-452 were demonstrated in two prostate cancer cell lines,suggesting that epigenetic silencing of GABRE/miR-452/miR-224 may be selected for in prostate cancer." +epigenetics hsa-mir-452 Prostate Neoplasms 24737792 "The GABRE-miR-452-miR-224 locus is downregulated and hypermethylated in prostate cancer and is a new promising epigenetic candidate biomarker for prostate cancer diagnosis and prognosis. Tumor-suppressive functions of the intronic miR-224 and miR-452 were demonstrated in two prostate cancer cell lines,suggesting that epigenetic silencing of GABRE/miR-452/miR-224 may be selected for in prostate cancer." +epigenetics hsa-mir-302 "Carcinoma, Hepatocellular" 24740829 "miR-302-mediated iPSC technology reprogrammed HCC cells and improved drug sensitivity through AOF2 down-regulation, which caused H3K4 methylation and c-Myc repression." +epigenetics hsa-mir-375 "Diabetes Mellitus, Type 2" 24741571 Ethnic differences in microRNA-375 expression level and DNA methylation status in type 2 diabetes of Han and Kazak populations. +epigenetics hsa-mir-31 "Adenocarcinoma, Colon" 24752710 "MicroRNA-31 expression in relation to BRAF mutation, CpG island methylation and colorectal continuum in serrated lesions." +epigenetics hsa-mir-615 "Adenocarcinoma, Pancreatic Ductal" 24769899 miR-615-5p is epigenetically inactivated and functions as a tumor suppressor in pancreatic ductal adenocarcinoma. +epigenetics hsa-mir-449a Gastric Neoplasms 24810364 Long noncoding RNA ANRIL indicates a poor prognosis of gastric cancer and promotes tumor growth by epigenetically silencing of miR-99a/miR-449a. +epigenetics hsa-mir-99a Gastric Neoplasms 24810364 Long noncoding RNA ANRIL indicates a poor prognosis of gastric cancer and promotes tumor growth by epigenetically silencing of miR-99a/miR-449a. +epigenetics hsa-mir-214 Rhabdomyosarcoma 24811402 MiR-214 and N-ras regulatory loop suppresses rhabdomyosarcoma cell growth and xenograft tumorigenesis. +epigenetics hsa-mir-34a "Leukemia, Promyelocytic, Acute" 24811488 "Epigenetic inactivation of DAPK1, p14ARF, mir-34a and -34b/c in acute promyelocytic leukaemia." +epigenetics hsa-mir-34b "Leukemia, Promyelocytic, Acute" 24811488 "Epigenetic inactivation of DAPK1, p14ARF, mir-34a and -34b/c in acute promyelocytic leukaemia." +epigenetics hsa-mir-34c "Leukemia, Promyelocytic, Acute" 24811488 "Epigenetic inactivation of DAPK1, p14ARF, mir-34a and -34b/c in acute promyelocytic leukaemia." +epigenetics hsa-mir-126 Myeloma 24875904 "TNF¦Á in the marrow microenvironment led to RANKL demethylation and re-expression in myeloma cells through DNMT1 repression and upregulation of miR-126-3p and miR-140, both known to repress DNMT1 translation." +epigenetics hsa-mir-140 Myeloma 24875904 "TNF¦Á in the marrow microenvironment led to RANKL demethylation and re-expression in myeloma cells through DNMT1 repression and upregulation of miR-126-3p and miR-140, both known to repress DNMT1 translation." +epigenetics hsa-mir-146a Prostate Neoplasms 24885368 "Up-regulating miR-146a expression via the hypomethylation of the miR-146a promoter by 5-Aza-CdR was correlated with delayed progression of castration-resistant prostate cancers. Moreover, site-specific DNA methylation may play an important role in miR-146a expression in androgen-dependent prostate cancer progression to androgen-independent prostate cancer and therefore provides a potentially useful biomarker for assessing drug efficacy in prostate cancer." +epigenetics hsa-mir-15a "Leukemia, Myeloid, Acute" 24885794 "The DLEU2 locus and embedded miRNA cluster miR-15a/16-1 is commonly deleted in adult cancers and shown to induce leukaemogenesis, however in paediatric AML we found the region to be transcriptionally repressed. In combination, our data highlights the utility of interrogating DNA methylation and microRNA in combination with underlying genetic status to provide novel insights into AML biology." +epigenetics hsa-mir-16-1 "Leukemia, Myeloid, Acute" 24885794 "The DLEU2 locus and embedded miRNA cluster miR-15a/16-1 is commonly deleted in adult cancers and shown to induce leukaemogenesis, however in paediatric AML we found the region to be transcriptionally repressed. In combination, our data highlights the utility of interrogating DNA methylation and microRNA in combination with underlying genetic status to provide novel insights into AML biology." +epigenetics hsa-mir-30b Gastric Neoplasms 24913034 Decreased miR-30b-5p expression by DNMT1 methylation regulation involved in gastric cancer metastasis. +epigenetics hsa-mir-200 Breast Neoplasms 24918286 SUMOylation of FOXM1B alters its transcriptional activity on regulation of MiR-200 family and JNK1 in MCF7 human breast cancer cells. +epigenetics hsa-mir-219 Chronic Inflammatory Pain 25031391 methylation-mediated epigenetic modification of spinal miR-219 expression regulates chronic inflammatory pain by targeting CaMKII¦Ã. +epigenetics hsa-mir-105 Neoplasms [unspecific] 25089631 A novel cancer-germline transcript carrying pro-metastatic miR-105 and TET-targeting miR-767 induced by DNA hypomethylation in tumors. +epigenetics hsa-mir-767 Neoplasms [unspecific] 25089631 A novel cancer-germline transcript carrying pro-metastatic miR-105 and TET-targeting miR-767 induced by DNA hypomethylation in tumors. +epigenetics hsa-mir-145 Chondrosarcoma 25145279 The epigenetic regulation of SOX9 by miR-145 in human chondrosarcoma. +epigenetics hsa-mir-149 Breast Neoplasms 25156775 Methylation-regulated miR-149 modulates chemoresistance by targeting GlcNAc N-deacetylase/N-sulfotransferase-1 in human breast cancer. +epigenetics hsa-mir-320a Breast Neoplasms 25159093 A methylation-based regulatory network for microRNA 320a in chemoresistant breast cancer. +epigenetics hsa-mir-200 Neoplasms [unspecific] 25178837 Zeb1 and Snail1 engage miR-200f transcriptional and epigenetic regulation during EMT. +epigenetics hsa-mir-210 Helicobacter pylori Infection 25187177 Epigenetic silencing of miR-210 increases the proliferation of gastric epithelium during chronic Helicobacter pylori infection. +epigenetics hsa-mir-193a Bladder Neoplasms 25188512 The DNA methylation-regulated miR-193a-3p dictates the multi-chemoresistance of bladder cancer via repression of SRSF2/PLAU/HIC2 expression. +epigenetics hsa-mir-101 Lung Neoplasms 25210796 Restoration of miR-101 suppresses lung tumorigenesis through inhibition of DNMT3a-dependent DNA methylation. +epigenetics hsa-mir-155 "Lymphoma, Non-Hodgkin" 25211095 Methylation of miR-155-3p in mantle cell lymphoma and other non-Hodgkin's lymphomas. +epigenetics hsa-mir-106b Polycystic Ovarian Syndrome 25243570 "Our data suggest that the expression of MCM7 and miR-93/25 is PCOSand IR related, whereas that of miR-106b is related to IR only. In 3T3-L1 adipocytes, neither hyperglycemia nor hyperinsulinemia altered the expression of miR-93 or miR-25, although increasing glucose levels down-regulated MCM7 and paradoxically increased that of miR-106b expression. The expression of the miR-25/93/106b family may be regulated through mechanisms distinct from its host gene, MCM7. Finally, our studies suggest potential epigenetic mechanisms for both IR and PCOS." +epigenetics hsa-mir-25 Polycystic Ovarian Syndrome 25243570 "Our data suggest that the expression of MCM7 and miR-93/25 is PCOSand IR related, whereas that of miR-106b is related to IR only. In 3T3-L1 adipocytes, neither hyperglycemia nor hyperinsulinemia altered the expression of miR-93 or miR-25, although increasing glucose levels down-regulated MCM7 and paradoxically increased that of miR-106b expression. The expression of the miR-25/93/106b family may be regulated through mechanisms distinct from its host gene, MCM7. Finally, our studies suggest potential epigenetic mechanisms for both IR and PCOS." +epigenetics hsa-mir-93 Polycystic Ovarian Syndrome 25243570 "Our data suggest that the expression of MCM7 and miR-93/25 is PCOSand IR related, whereas that of miR-106b is related to IR only. In 3T3-L1 adipocytes, neither hyperglycemia nor hyperinsulinemia altered the expression of miR-93 or miR-25, although increasing glucose levels down-regulated MCM7 and paradoxically increased that of miR-106b expression. The expression of the miR-25/93/106b family may be regulated through mechanisms distinct from its host gene, MCM7. Finally, our studies suggest potential epigenetic mechanisms for both IR and PCOS." +epigenetics hsa-mir-9 Gastric Neoplasms 25270964 Epigenetic silencing of miRNA-9 is correlated with promoter-proximal CpG island hypermethylation in gastric cancer in vitro and in vivo. +epigenetics hsa-mir-148a "Carcinoma, Nasopharyngeal" 25277193 Silencing of miRNA-148a by hypermethylation activates the integrin-mediated signaling pathway in nasopharyngeal carcinoma. +epigenetics hsa-mir-10b Squamous Cell Carcinoma 25312779 Reduction of TIP30 in esophageal squamous cell carcinoma cells involves promoter methylation and microRNA-10b. +epigenetics hsa-mir-24 "Carcinoma, Nasopharyngeal" 25319395 Involvement of microRNA-24 and DNA methylation in resistance of nasopharyngeal carcinoma to ionizing radiation. +epigenetics hsa-mir-129 Gastric Neoplasms 25344911 Methylation of miR-129-5p CpG island modulates multi-drug resistance in gastric cancer by targeting ABC transporters. +epigenetics hsa-mir-214 "Leukemia, Lymphocytic, Chronic, B-Cell" 25361012 "miR-26a and miR-214 down-regulate expression of the PTEN gene in chronic lymphocytic leukemia, but not PTEN mutation or promoter methylation." +epigenetics hsa-mir-26a "Leukemia, Lymphocytic, Chronic, B-Cell" 25361012 "miR-26a and miR-214 down-regulate expression of the PTEN gene in chronic lymphocytic leukemia, but not PTEN mutation or promoter methylation." +epigenetics hsa-mir-34b Breast Neoplasms 25398683 long-term shiftwork may increase the risk of breast cancer via methylation-based suppression of miR-34b and a consequent reduction in immunomediated anti-tumor capacity and support our previous findings that LAN may induce epigenetic alteration of cancer-relevant microRNAs. +epigenetics hsa-mir-142 "Lymphoma, T-Cell" 25405321 These results reveal a subgroup-specific epigenetically regulated microRNA signatures for MFt and CD30+ cALCL patients. +epigenetics hsa-mir-146a "Lymphoma, T-Cell" 25405321 These results reveal a subgroup-specific epigenetically regulated microRNA signatures for MFt and CD30+ cALCL patients. +epigenetics hsa-mir-155 "Lymphoma, T-Cell" 25405321 These results reveal a subgroup-specific epigenetically regulated microRNA signatures for MFt and CD30+ cALCL patients. +epigenetics hsa-mir-181b "Lymphoma, T-Cell" 25405321 These results reveal a subgroup-specific epigenetically regulated microRNA signatures for MFt and CD30+ cALCL patients. +epigenetics hsa-mir-21 "Lymphoma, T-Cell" 25405321 These results reveal a subgroup-specific epigenetically regulated microRNA signatures for MFt and CD30+ cALCL patients. +epigenetics hsa-mir-720 "Leukemia, Myeloid, Acute" 25417880 "The expression of miR-720 in AML patients reduced significantly, and DNA methylation-mediated epigenetic silencing of miR-720 contributed to maintain the malignant characteristics of AML." +epigenetics hsa-mir-34a Colorectal Carcinoma 25422210 "miRNA-34a-5p may play a role as a tumor suppressor gene in colorectal cancer, with involvement of DNA methylation." +epigenetics hsa-mir-106b "Carcinoma, Hepatocellular" 25424171 "DNA methylation plays an important and complex role in the regulation of miRNA expression in HCC, which may provide insights into the pathogenesis of HCC and thus may be used for diagnosis and intervention." +epigenetics hsa-mir-148a "Carcinoma, Hepatocellular" 25424171 "DNA methylation plays an important and complex role in the regulation of miRNA expression in HCC, which may provide insights into the pathogenesis of HCC and thus may be used for diagnosis and intervention." +epigenetics hsa-mir-195 "Carcinoma, Hepatocellular" 25424171 "DNA methylation plays an important and complex role in the regulation of miRNA expression in HCC, which may provide insights into the pathogenesis of HCC and thus may be used for diagnosis and intervention." +epigenetics hsa-mir-23a "Carcinoma, Hepatocellular" 25424171 "DNA methylation plays an important and complex role in the regulation of miRNA expression in HCC, which may provide insights into the pathogenesis of HCC and thus may be used for diagnosis and intervention." +epigenetics hsa-mir-25 "Carcinoma, Hepatocellular" 25424171 "DNA methylation plays an important and complex role in the regulation of miRNA expression in HCC, which may provide insights into the pathogenesis of HCC and thus may be used for diagnosis and intervention." +epigenetics hsa-mir-27a "Carcinoma, Hepatocellular" 25424171 "DNA methylation plays an important and complex role in the regulation of miRNA expression in HCC, which may provide insights into the pathogenesis of HCC and thus may be used for diagnosis and intervention." +epigenetics hsa-mir-375 "Carcinoma, Hepatocellular" 25424171 "DNA methylation plays an important and complex role in the regulation of miRNA expression in HCC, which may provide insights into the pathogenesis of HCC and thus may be used for diagnosis and intervention." +epigenetics hsa-mir-378 "Carcinoma, Hepatocellular" 25424171 "DNA methylation plays an important and complex role in the regulation of miRNA expression in HCC, which may provide insights into the pathogenesis of HCC and thus may be used for diagnosis and intervention." +epigenetics hsa-mir-497 "Carcinoma, Hepatocellular" 25424171 "DNA methylation plays an important and complex role in the regulation of miRNA expression in HCC, which may provide insights into the pathogenesis of HCC and thus may be used for diagnosis and intervention." +epigenetics hsa-mir-93 "Carcinoma, Hepatocellular" 25424171 "DNA methylation plays an important and complex role in the regulation of miRNA expression in HCC, which may provide insights into the pathogenesis of HCC and thus may be used for diagnosis and intervention." +epigenetics hsa-mir-155 Multiple Myeloma 25497370 "DNA methylation contributes to miR-155 expression in myeloma cells. Interestingly, the survival data showed an association between miR-155 expression and outcome of MM." +epigenetics hsa-mir-141 Gastric Neoplasms 25502084 "sion of miR-200c/141 induced by TGF-¦Â in SGC-7901 cells. Our study revealed that miR-200c/141 was downregulated by CpG island methylation and TGF-¦Â signaling, which decreased ZEB1/2 expression and increased E-cadherin expression to inhibit migration and invasion of gastric cancer cells and provides powerful evidence for the application of decitabine in gastric cancer treatment." +epigenetics hsa-mir-155 "Carcinoma, Colon" 25502084 "miR-200c/141 was downregulated by CpG island methylation and TGF-¦Â signaling, which decreased ZEB1/2 expression and increased E-cadherin expression to inhibit migration and invasion of gastric cancer cells and provides powerful evidence for the application of decitabine in gastric cancer treatment." +epigenetics hsa-mir-200 Gastric Neoplasms 25502084 "sion of miR-200c/141 induced by TGF-¦Â in SGC-7901 cells. Our study revealed that miR-200c/141 was downregulated by CpG island methylation and TGF-¦Â signaling, which decreased ZEB1/2 expression and increased E-cadherin expression to inhibit migration and invasion of gastric cancer cells and provides powerful evidence for the application of decitabine in gastric cancer treatment." +epigenetics hsa-mir-490 "Carcinoma, Gastric" 25503559 "hypermethylation-mediated silencing of miR-490-3p reactivates SMARCD1 to confer malignant phenotypes, mechanistically linking H. pylori, chromatin remodeling, and gastric carcinogenesis." +epigenetics hsa-mir-137 Neuroblastoma 25505154 "an epigenetic mechanism involving miR-137-mediated EZH2 repression in RSV-induced apoptosis and tumor suppression of neuroblastoma, which would provide a key potential therapeutic target in neuroblastoma treatment." +epigenetics hsa-mir-21 "Leukemia, Myeloid, Chronic" 25575817 RBP2 epigenetically downregulated miR-21 in blast transformation of CML. +epigenetics hsa-mir-34b Leukemia 25582471 "The hypermethylation of promoter leads to decrease in the expression levels of miR-34b in leukemia cell lines, which attenuate mechanism of proliferative inhibition may be one of the reasons of occurrence or development of childhood leukemia." +epigenetics hsa-mir-328 Osteosarcoma 25605016 the role of RESV-induced molecular and epigenetic regulation in suppressing tumor metastasis. +epigenetics hsa-mir-34b Wilms Tumor 25625843 Epigenetic analysis of sporadic and Lynch-associated ovarian cancers reveals histology-specific patterns of DNA methylation. +epigenetics hsa-mir-142 Systemic Lupus Erythematosus 25661834 "Data from this study suggest that MPA activates miR-142 and miR-146a expression through histone modification at the promoter region, which may partially explain the pharmacological mechanisms of MPA for SLE." +epigenetics hsa-mir-146a Systemic Lupus Erythematosus 25661834 "Data from this study suggest that MPA activates miR-142 and miR-146a expression through histone modification at the promoter region, which may partially explain the pharmacological mechanisms of MPA for SLE." +epigenetics hsa-mir-375 Myeloproliferative Neoplasms 25666256 Epigenetic deregulated miR-375 contributes to the constitutive activation of JAK2/STAT signaling in myeloproliferative neoplasm. +epigenetics hsa-mir-484 Colorectal Carcinoma 25727216 Methylation-induced loss of miR-484 in microsatellite-unstable colorectal cancer promotes both viability and IL-8 production via CD137L. +epigenetics hsa-mir-125b-2 Prostate Neoplasms 25728837 Our work underlined the importance of histone demethylation and DNA oxidation/repairing machinery in androgen-dependent transcription. The present finds have implications for research into new druggable targets for prostate cancer relying on the cascade of AR activity regulation. +epigenetics hsa-mir-133b Prostate Neoplasms 25728837 Our work underlined the importance of histone demethylation and DNA oxidation/repairing machinery in androgen-dependent transcription. The present finds have implications for research into new druggable targets for prostate cancer relying on the cascade of AR activity regulation. +epigenetics hsa-mir-145 Prostate Neoplasms 25749421 A feedback regulation between miR-145 and DNA methyltransferase 3b in prostate cancer cell and their responses to irradiation. +epigenetics hsa-mir-129-2 Glioma 25772485 MiR-129-2 functions as a tumor suppressor in glioma cells by targeting HMGB1 and is down-regulated by DNA methylation. +epigenetics hsa-mir-34b Soft Tissue Sarcoma 25773680 Hypermethylation of potential tumor suppressor miR-34b/c is correlated with late clinical stage in patients with soft tissue sarcomas. +epigenetics hsa-mir-34c Soft Tissue Sarcoma 25773680 Hypermethylation of potential tumor suppressor miR-34b/c is correlated with late clinical stage in patients with soft tissue sarcomas. +epigenetics hsa-mir-101 Glioma 25829251 MiR-101 reverses the hypomethylation of the LMO3 promoter in glioma cells. +epigenetics hsa-mir-9-1 Multiple Myeloma 25855800 "Hypermethylation of miR-9-3 and miR-9-1 is tumour-specific in MM,leading to reversible miRNA silencing. Frequent methylation of miR-9-3 and miR-9-1 in cell lines, but not in primary samples, may be acquired during in vitro culture, and indicates an unimportant role of miR-9 methylation in myelomagenesis." +epigenetics hsa-mir-9-3 Multiple Myeloma 25855800 "Hypermethylation of miR-9-3 and miR-9-1 is tumour-specific in MM,leading to reversible miRNA silencing. Frequent methylation of miR-9-3 and miR-9-1 in cell lines, but not in primary samples, may be acquired during in vitro culture, and indicates an unimportant role of miR-9 methylation in myelomagenesis." +epigenetics hsa-mir-34a Gastric Neoplasms 25860861 Sirt7 promotes gastric cancer growth and inhibits apoptosis by epigenetically inhibiting miR-34a. +epigenetics hsa-mir-124 Prostate Neoplasms 25860954 Regulation and methylation of tumor suppressor miR-124 by androgen receptor in prostate cancer cells. +epigenetics hsa-mir-29b Gastric Neoplasms 25874772 "Deregulation between miR-29b/c and DNMT3A is associated with epigenetic silencing of the CDH1 gene, affecting cell migration and invasion in gastric cancer." +epigenetics hsa-mir-29c Gastric Neoplasms 25874772 "Deregulation between miR-29b/c and DNMT3A is associated with epigenetic silencing of the CDH1 gene, affecting cell migration and invasion in gastric cancer." +epigenetics hsa-mir-24-2 Neoplasms [unspecific] 25943634 The conclusion drawn of hsa-miR-24-2 targeting the genes of cell survival correlated with the methylation profile and resultant transcription factor binding site gain or loss in support of absence of cell survival. +epigenetics hsa-mir-182 Lung Neoplasms 25975295 DNA methylation occurs in the miR-182 promoter region in lung cancer cell lines. This methylation can regulate the expression level of miR-182.Further study must be conducted to explore the function of miR-182 promoter methylation in lung cancer occurrence and development. +epigenetics hsa-mir-34b Neoplasms [unspecific] 25979762 "although results obtained by the different DNA methylation analysis techniques are largely comparable, an appropriate correction may be necessary for stringent comparison." +epigenetics hsa-mir-34c Neoplasms [unspecific] 25979762 "although results obtained by the different DNA methylation analysis techniques are largely comparable, an appropriate correction may be necessary for stringent comparison." +epigenetics hsa-mir-148a Breast Neoplasms 25980823 Glabridin inhibits cancer stem cell-like properties of human breast cancer cells:An epigenetic regulation of miR-148a/SMAd2 signaling. +epigenetics hsa-mir-137 Neoplasms [unspecific] 26066330 We also found that miR-137 and its host gene are epigenetically silenced in human cancer specimens and cell lines.These results support the development and testing of microRNA-based therapies (in particular based on restoring miR-137 levels) for targeting the oncogenic family of p160 SRCs in cancer. +epigenetics hsa-mir-129-2 Lung Neoplasms 26081366 Epigenetic regulation of miR-129-2 and its effects on the proliferation and invasion in lung cancer cells. +epigenetics hsa-mir-302c Chondrosarcoma 26094604 Epigenetic regulation of embryonic stem cell marker miR302C in human chondrosarcoma as determinant of antiproliferative activity of proline-rich polypeptide 1. +epigenetics hsa-mir-10a Atherosclerosis 26148682 "Methylation-specific PCR (MSP) confirmed differential CpG methylation of HOXA genes, the ER stress gene ATF4, inflammatory regulator microRNA-10a and ARHGAP25 that encodes a negative regulator of Rho GTPases involved in cytoskeleton remodeling." +epigenetics hsa-mir-137 Glioblastoma 26187071 Direct transfection of miR-137 mimics is more effective than DNA demethylation of miR-137 promoter to augment anti-tumor mechanisms of delphinidin in human glioblastoma U87MG and LN18 cells. +epigenetics hsa-mir-203 Melanoma 26225581 DNA methylation contributes toward silencing of antioncogenic microRNA-203 in human and canine melanoma cells. +epigenetics hsa-mir-210 Cardiovascular Diseases [unspecific] 26254226 Oxidized low-density lipoprotein is a common risk factor for cardiovascular diseases and gastroenterological cancers via epigenomical regulation of microRNA-210. +epigenetics hsa-mir-145 "Squamous Cell Carcinoma, Esophageal" 26254350 Suppressor microRNA-145 Is Epigenetically Regulated by Promoter Hypermethylation in Esophageal Squamous Cell Carcinoma. +epigenetics hsa-mir-139 "Carcinoma, Lung, Non-Small-Cell" 26256448 Histone methylation-mediated silencing of miR-139 enhances invasion of non-small-cell lung cancer. +epigenetics hsa-let-7 Neoplasms [unspecific] 26303212 Impact of Histone Deacetylase Inhibitors on microRNA Expression and Cancer Therapy: A Review. +epigenetics hsa-mir-106a Neoplasms [unspecific] 26303212 Impact of Histone Deacetylase Inhibitors on microRNA Expression and Cancer Therapy: A Review. +epigenetics hsa-mir-106b Neoplasms [unspecific] 26303212 Impact of Histone Deacetylase Inhibitors on microRNA Expression and Cancer Therapy: A Review. +epigenetics hsa-mir-15a Neoplasms [unspecific] 26303212 Impact of Histone Deacetylase Inhibitors on microRNA Expression and Cancer Therapy: A Review. +epigenetics hsa-mir-16 Neoplasms [unspecific] 26303212 Impact of Histone Deacetylase Inhibitors on microRNA Expression and Cancer Therapy: A Review. +epigenetics hsa-mir-17 Neoplasms [unspecific] 26303212 Impact of Histone Deacetylase Inhibitors on microRNA Expression and Cancer Therapy: A Review. +epigenetics hsa-mir-19b Neoplasms [unspecific] 26303212 Impact of Histone Deacetylase Inhibitors on microRNA Expression and Cancer Therapy: A Review. +epigenetics hsa-mir-148 Hematologic Neoplasms 26314468 "This article summarizes the expression of miR-148/152 family in hematological malignancies, aiming at expounding the signicance of relationship between DNA methylation modification and microRNA." +epigenetics hsa-mir-152 Hematologic Neoplasms 26314468 "This article summarizes the expression of miR-148/152 family in hematological malignancies, aiming at expounding the signicance of relationship between DNA methylation modification and microRNA." +epigenetics hsa-mir-20a Glioma 26337869 "In summary, DNMT1 mediated chemosensitivity by reducing methylation of the microRNA-20a promoter in glioma cells." +epigenetics hsa-mir-125b Neoplasms [unspecific] 26354435 "Taken together, our results demonstrated that miR-125b mediates PAR2-induced cancer cell migration by targeting Gab2 and that NSun2-dependent RNA methylation contributes to the down-regulation of miR-125b by PAR2 signaling. " +epigenetics hsa-let-7 Glioma 26463235 epigenetic modification is a crucial mechanism for controlling the expression of miR-126 in glioma. +epigenetics hsa-mir-126 Rheumatoid Arthritis 26464634 Correlation between miR-126 expression and DNA hypomethylation of CD4+ T cells in rheumatoid arthritis patients. +epigenetics hsa-mir-122 Germ Cell Tumor 26497383 "Cross platform analysis of methylation, miRNA and stem cell gene expression data in germ cell tumors highlights characteristic differences by tumor histology." +epigenetics hsa-mir-302a Germ Cell Tumor 26497383 "Cross platform analysis of methylation, miRNA and stem cell gene expression data in germ cell tumors highlights characteristic differences by tumor histology." +epigenetics hsa-mir-302d Germ Cell Tumor 26497383 "Cross platform analysis of methylation, miRNA and stem cell gene expression data in germ cell tumors highlights characteristic differences by tumor histology." +epigenetics hsa-mir-371 Germ Cell Tumor 26497383 "Cross platform analysis of methylation, miRNA and stem cell gene expression data in germ cell tumors highlights characteristic differences by tumor histology." +epigenetics hsa-mir-373 Germ Cell Tumor 26497383 "Cross platform analysis of methylation, miRNA and stem cell gene expression data in germ cell tumors highlights characteristic differences by tumor histology." +epigenetics hsa-mir-129-2 Breast Neoplasms 26519551 "In summary, the obtained data indicate the involvement of methylation in the down-regulation of the studied coding and miRNA genes and suggest the involvement of miR-129-2 in the deregulation of RASSF1(A) via a direct interaction or/and mediators in common pathways (according to KEGG, Gene Ontology (FDR < 0.01), and GeneCards data) in the examined gynecological tumors." +epigenetics hsa-mir-129-2 Ovarian Neoplasms 26519551 "In summary, the obtained data indicate the involvement of methylation in the down-regulation of the studied coding and miRNA genes and suggest the involvement of miR-129-2 in the deregulation of RASSF1(A) via a direct interaction or/and mediators in common pathways (according to KEGG, Gene Ontology (FDR < 0.01), and GeneCards data) in the examined gynecological tumors." +epigenetics hsa-mir-9-1 Breast Neoplasms 26519551 "In summary, the obtained data indicate the involvement of methylation in the down-regulation of the studied coding and miRNA genes and suggest the involvement of miR-129-2 in the deregulation of RASSF1(A) via a direct interaction or/and mediators in common pathways (according to KEGG, Gene Ontology (FDR < 0.01), and GeneCards data) in the examined gynecological tumors." +epigenetics hsa-mir-9-1 Ovarian Neoplasms 26519551 "In summary, the obtained data indicate the involvement of methylation in the down-regulation of the studied coding and miRNA genes and suggest the involvement of miR-129-2 in the deregulation of RASSF1(A) via a direct interaction or/and mediators in common pathways (according to KEGG, Gene Ontology (FDR < 0.01), and GeneCards data) in the examined gynecological tumors." +epigenetics hsa-mir-34b Leukemia 26524015 "CpG island methylation of miR-34b promoter region in leukemia cell lines can decrease the expression levels of miR-34b, which is also the reason why miR-34b can reduce the inhibition of cell proliferation, thus miR-34b might be a tumor suppressor gene involved in the regulation of leukemia." +epigenetics hsa-mir-29c Breast Neoplasms 26539832 Molecular Subtype-Specific Expression of MicroRNA-29c in Breast Cancer Is Associated with CpG Dinucleotide Methylation of the Promoter. +epigenetics hsa-mir-24 Colon Adenoma 26559563 "Butyrate and partial TSA reduced the expression of miR-135a, miR-135b, miR-24 and miR-let-7a (~0.5-fold, 24 h) and miR-24, miR-106b and miR-let-7a (~0.5-0.7-fold, 48 h) in LT97 cells." +epigenetics hsa-mir-143 Vascular Disease [unspecific] 26573388 "Taken together, these findings suggest that DNMT3a is a direct target of miR-143, and that the upregulation of DNMT3 is responsible for the hypermethylation of miR-143 in Hcy-induced VSMC proliferation." +epigenetics hsa-mir-145 "Adenocarcinoma, Lung" 26582602 "Taken together, DNA hyper-methylation in the miR-145 promoter region reduced its expression in LAC and miR-145 expression level might serve as a novel prognostic biomarker." +epigenetics hsa-mir-218 "Carcinoma, Esophageal" 26610476 "In conclusion, our results support that aberrant CpG hypermethylation at least partly accounts for miR-218 silencing in ESCC, which impairs its tumor-suppressive function." +epigenetics hsa-mir-148a Skin Neoplasms 26638007 "Taken together, the expression of miR-148a was regulated by DNA methylation and targeted by TGIF2.Its methylation may be a potential prognostic indicator in skin cancer." +epigenetics hsa-mir-125a Colorectal Carcinoma 26693202 "Our results suggest that DNA hypermethylation may be involved in the inactivation of miR-125a and miR-125b in CRC, and hypermethylation of miR-125 is a potential biomarker for clinical outcome." +epigenetics hsa-mir-125b Colorectal Carcinoma 26693202 "Our results suggest that DNA hypermethylation may be involved in the inactivation of miR-125a and miR-125b in CRC, and hypermethylation of miR-125 is a potential biomarker for clinical outcome." +epigenetics hsa-mir-34c Colorectal Carcinoma 26704889 "In conclusion, our results suggested the existence of E2F1-miR-34c-SCF negative feedback loop which was interrupted by the hyper-methylation of miR-34c promoter in CRC cells and increased cell proliferation." +epigenetics hsa-mir-140 Osteoarthritis 26723856 "Some miRNA have also been identified and more extensively characterized, such as delineation of the role played by miR-140 in chondrogenesis, followed by the discovery of numerous miRNA potentially involved in the epigenetic regulation of osteoarthritic disease." +epigenetics hsa-mir-21 Colorectal Carcinoma 26787105 This study suggests a high frequency of miR-21 overexpression and aberrant promoter methylation in down-regulation of PTEN expression in colorectal carcinoma. Loss of PTEN may be a prognostic factor for patients with CRC. +epigenetics hsa-mir-133a Cardiomegaly 26830171 Phe exposure led to methylation of CpG sites within the miR-133a locus and reduced miR-133a expression in H9C2 cells +epigenetics hsa-mir-34b Sarcomatoid Mesothelioma 26870271 miR-34b/c was heavily methylated in 2/4 established MPM cell lines +epigenetics hsa-mir-34c Sarcomatoid Mesothelioma 26870271 miR-34b/c was heavily methylated in 2/4 established MPM cell lines +epigenetics hsa-mir-34a Ovarian Neoplasms 26879132 "We demonstrated a clinical independent role of miR-34a in epithelial ovarian cancers. Moreover, we corroborated the correlation between miR-34a expression and its promoter methylation in a large set of ovarian cancers. The inverse association between miR-34a expression and grading, p53 mutation status and dualistic tumor type classification, together with its prognostic relevance may underline the tumor-suppressive character of miR-34a in ovarian cancer." +epigenetics hsa-mir-296 Glioblastoma 26898758 We show that miR-296-5p expression is repressed in a DNA methylation-dependent manner under conditions that promote GBM cell stemness +epigenetics hsa-mir-378 "Leukemia, Myeloid, Chronic" 26913395 Methylation of miR-378 in Chronic Myeloid Leukemia. +epigenetics hsa-mir-181c Glioblastoma 26983574 Epigenetic silencing of miR-181c by DNA methylation in glioblastoma cell lines. +epigenetics hsa-mir-10b "Squamous Cell Carcinoma, Head and Neck" 27002147 DOT1L-associated epigenetic changes induced by HA play pivotal roles in miR-10 production leading to up-regulation of RhoGTPase and survival proteins. +epigenetics hsa-mir-497 Hematologic Neoplasms 27075177 "Strikingly, low-dose decitabine was able to augment chemosensitivity in cancer stem cells, likely by the upregulation of miRNA-497" +epigenetics hsa-mir-155 Lymphoma 27110708 DNA methylation regulates miR-155 expression. +epigenetics hsa-mir-30d Ovarian Neoplasms 27141829 TET3 inhibits TGF-β1-induced epithelial-mesenchymal transition by demethylating miR-30d precursor gene in ovarian cancer cells +epigenetics hsa-mir-193b "Adenocarcinoma, Esophageal" 27176876 Aberrant methylation of microRNA-193b in human Barrett's esophagus and esophageal adenocarcinoma +epigenetics hsa-mir-141 Prostate Neoplasms 27198154 miR-200c and miR-141 are under epigenetic regulation in PCa cells. +epigenetics hsa-mir-200c Prostate Neoplasms 27198154 miR-200c and miR-141 are under epigenetic regulation in PCa cells. +epigenetics hsa-mir-153 Glioblastoma 27215075 MiR-153 as a Tumor Suppressor in Glioblastoma Multiforme is Downregulated by DNA Methylation. +epigenetics hsa-mir-211 Melanoma 27237979 DNMT1 mediated promoter methylation is a mechanism of miRNA suppression in melanoma +epigenetics hsa-mir-200b Cervical Neoplasms 27272214 Long noncoding RNA PVT1 promotes cervical cancer progression through epigenetically silencing miR-200b +epigenetics hsa-mir-27b Breast Neoplasms 27363334 MiR-27b is epigenetically downregulated in tamoxifen resistant breast cancer cells +epigenetics hsa-mir-19a Breast Neoplasms 27445062 "CAP treatment of MCF-7 induced hypermethylation at the promoter CpG sites and downregulation of miR-19a, which was known as an oncomiR." +epigenetics hsa-mir-34a "Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal" 27450916 "Our study revealed that miR-34a promoter hypermethylation was a risk factor for LSCC, played a critical role in the disease progression and metastasis, and could serve as a poor prognostic factor for LSCC." +epigenetics hsa-mir-375 "Carcinoma, Breast" 27466996 "MiR-375 is downregulated in MCF-7/ADM and MCF-7/PTX cells, and its downregulation is a result of promoter methylation." +epigenetics hsa-mir-152 "Carcinoma, Breast" 27475839 DNA methylation and not H3K4 trimethylation dictates the expression status of miR-152 gene which inhibits migration of breast cancer cells via DNMT1/CDH1 loop. +epigenetics hsa-mir-615 "Carcinoma, Hepatocellular" 27487123 "In conclusion, our findings characterize miR-615-5p as an important epigenetically silenced miRNA involved in the Rab-Ras pathway in hepatocellular carcinoma and expand our understanding of the molecular mechanism underlying hepatocarcinogenesis and metastasis." +epigenetics hsa-let-7b "Carcinoma, Colon" 27525719 "G9a binds with and stabilizes RelB, thereby recruiting DNA methyltransferase 3 on the Let-7b promoter and repressing its expression." +epigenetics hsa-mir-34a "Carcinoma, Bladder" 27557899 MicroRNA epigenetic signatures in human disease. +epigenetics hsa-mir-34b Bladder Neoplasms 27557899 MicroRNA epigenetic signatures in human disease. +epigenetics hsa-mir-34c "Carcinoma, Bladder" 27557899 MicroRNA epigenetic signatures in human disease. +epigenetics hsa-mir-125b Chondrosarcoma 27576314 Induction of the mesenchymal to epithelial transition by demethylation-activated microRNA-125b is involved in the anti-migration/invasion effects of arsenic trioxide on human chondrosarcoma. +epigenetics hsa-mir-429 Cholangiocarcinoma 27593557 Cadherin-6 is a putative tumor suppressor and target of epigenetically dysregulated miR-429 in cholangiocarcinoma. +epigenetics hsa-mir-17 Bronchopulmonary Dysplasia 27694474 our data support a plausible role for epigenetically altered miR-17/92 cluster in the pathogenesis of severe BPD +epigenetics hsa-mir-18 Bronchopulmonary Dysplasia 27694474 our data support a plausible role for epigenetically altered miR-17/92 cluster in the pathogenesis of severe BPD +epigenetics hsa-mir-19a Bronchopulmonary Dysplasia 27694474 our data support a plausible role for epigenetically altered miR-17/92 cluster in the pathogenesis of severe BPD +epigenetics hsa-mir-19b-1 Bronchopulmonary Dysplasia 27694474 our data support a plausible role for epigenetically altered miR-17/92 cluster in the pathogenesis of severe BPD +epigenetics hsa-mir-20a Bronchopulmonary Dysplasia 27694474 our data support a plausible role for epigenetically altered miR-17/92 cluster in the pathogenesis of severe BPD +epigenetics hsa-mir-92-1 Bronchopulmonary Dysplasia 27694474 our data support a plausible role for epigenetically altered miR-17/92 cluster in the pathogenesis of severe BPD +epigenetics hsa-mir-200c "Carcinoma, Breast" 27717206 Epigenetic silencing of miR-200c in breast cancer is associated with aggressiveness and is modulated by ZEB1. +epigenetics hsa-mir-200 Ovarian Serous Cystadenocarcinoma 27746113 DNA methylation-regulated microRNA pathways in ovarian serous cystadenocarcinoma: A meta-analysis. +epigenetics hsa-mir-200 "Leukemia, Myeloid, Acute" 27756750 epigenetic silencing of the miR-200 family microRNAs affects ZEB2 expression +epigenetics hsa-mir-124 Cervical Neoplasms 27765948 Suppression of iASPP-dependent aggressiveness in cervical cancer through reversal of methylation silencing of microRNA-124. +epigenetics hsa-mir-126 "Carcinoma, Hepatocellular" 27774652 METTL14 suppresses the metastatic potential of hepatocellular carcinoma by modulating N6 -methyladenosine-dependent primary MicroRNA processing. +epigenetics hsa-mir-149 Glioblastoma 27783537 "MicroRNA-149 is epigenetically silenced tumor-suppressive microRNA, involved in cell proliferation and downregulation of AKT1 and cyclin?D1 in human glioblastoma multiforme." +epigenetics hsa-mir-181a Neurodegenerative Diseases [unspecific] 27789312 PPAR¦Â/¦Ä activation protects against corticosterone-induced ER?stress?in astrocytes by inhibiting the CpG hypermethylation of?microRNA-181a. +epigenetics hsa-mir-124a Rheumatoid Arthritis 27824863 Demethylation of MicroRNA-124a Genes Attenuated Proliferation of Rheumatoid Arthritis Derived Fibroblast-Like Synoviocytes and Synthesis of Tumor Necrosis Factor-¦Á. +epigenetics hsa-mir-107 "Carcinoma, Breast" 27830681 Novel miRNA genes hypermethylated in breast cancer. +epigenetics hsa-mir-1258 "Carcinoma, Breast" 27830681 Novel miRNA genes hypermethylated in breast cancer. +epigenetics hsa-mir-130b "Carcinoma, Breast" 27830681 Novel miRNA genes hypermethylated in breast cancer. +epigenetics hsa-mir-132 "Carcinoma, Breast" 27830681 Novel miRNA genes hypermethylated in breast cancer. +epigenetics hsa-mir-137 "Carcinoma, Breast" 27830681 Novel miRNA genes hypermethylated in breast cancer. +epigenetics hsa-mir-378a Liver Cirrhosis 27855367 The Epigenetically-Regulated microRNA-378a Targets TGF-¦Â2 in TGF-¦Â1-Treated Hepatic Stellate Cells. +epigenetics hsa-mir-148a Osteoporosis 27900532 MiR-148a the epigenetic regulator of bone homeostasis is increased in plasma of osteoporotic postmenopausal women. +epigenetics hsa-mir-124 "Carcinoma, Breast" 27998789 DNA methylation contributes to deregulation of 12 cancer-associated microRNAs and breast cancer progression. +epigenetics hsa-mir-125b "Carcinoma, Breast" 27998789 DNA methylation contributes to deregulation of 12 cancer-associated microRNAs and breast cancer progression. +epigenetics hsa-mir-127 "Carcinoma, Breast" 27998789 DNA methylation contributes to deregulation of 12 cancer-associated microRNAs and breast cancer progression. +epigenetics hsa-mir-132 "Carcinoma, Breast" 27998789 DNA methylation contributes to deregulation of 12 cancer-associated microRNAs and breast cancer progression. +epigenetics hsa-mir-137 "Carcinoma, Breast" 27998789 DNA methylation contributes to deregulation of 12 cancer-associated microRNAs and breast cancer progression. +epigenetics hsa-mir-148a "Carcinoma, Breast" 27998789 DNA methylation contributes to deregulation of 12 cancer-associated microRNAs and breast cancer progression. +epigenetics hsa-mir-191 "Carcinoma, Breast" 27998789 DNA methylation contributes to deregulation of 12 cancer-associated microRNAs and breast cancer progression. +epigenetics hsa-mir-193a "Carcinoma, Breast" 27998789 DNA methylation contributes to deregulation of 12 cancer-associated microRNAs and breast cancer progression. +epigenetics hsa-mir-203 "Carcinoma, Breast" 27998789 DNA methylation contributes to deregulation of 12 cancer-associated microRNAs and breast cancer progression. +epigenetics hsa-mir-212 "Carcinoma, Breast" 27998789 DNA methylation contributes to deregulation of 12 cancer-associated microRNAs and breast cancer progression. +epigenetics hsa-mir-34b "Carcinoma, Breast" 27998789 DNA methylation contributes to deregulation of 12 cancer-associated microRNAs and breast cancer progression. +epigenetics hsa-mir-375 "Carcinoma, Breast" 27998789 DNA methylation contributes to deregulation of 12 cancer-associated microRNAs and breast cancer progression. +epigenetics hsa-mir-9 "Carcinoma, Breast" 27998789 DNA methylation contributes to deregulation of 12 cancer-associated microRNAs and breast cancer progression. +epigenetics hsa-mir-149 Hematologic Neoplasms 28035377 Histone deacetylases meet microRNA-associated MMP-9 expression regulation in glucocorticoid-sensitive and -resistant cell lines. +epigenetics hsa-mir-520c Hematologic Neoplasms 28035377 Histone deacetylases meet microRNA-associated MMP-9 expression regulation in glucocorticoid-sensitive and -resistant cell lines. +epigenetics hsa-mir-106b "Adenocarcinoma, Esophageal" 28049580 Epigenetic regulation on the gene expression signature in esophagus adenocarcinoma. +epigenetics hsa-mir-129 "Carcinoma, Urothelial" 28081549 MicroRNA promoter methylation: a new tool for accurate detection of urothelial carcinoma. +epigenetics hsa-mir-663a "Carcinoma, Urothelial" 28081549 MicroRNA promoter methylation: a new tool for accurate detection of urothelial carcinoma. +epigenetics hsa-mir-200 "Carcinoma, Endometrioid Endometrial" 28088687 Whole-Genome DNA Methylation Profiling Identifies Epigenetic Signatures of Uterine Carcinosarcoma. +epigenetics hsa-mir-193b Prostate Neoplasms 28143614 MiR-193b promoter methylation accurately detects prostate cancer in urine sediments and miR-34b/c or miR-129-2 promoter methylation define subsets of clinically aggressive tumors. +epigenetics hsa-mir-371 Testicular Germ Cell Tumor 28199193 Epigenetic and risk factors of testicular germ cell tumors: a brief review. +epigenetics hsa-mir-373 Testicular Germ Cell Tumor 28199193 Epigenetic and risk factors of testicular germ cell tumors: a brief review. +epigenetics hsa-mir-1 Heart Diseases [unspecific] 28209718 Demethylation of H3K27 Is Essential for the Induction of Direct Cardiac Reprogramming by miR Combo. +epigenetics hsa-mir-133 Heart Diseases [unspecific] 28209718 Demethylation of H3K27 Is Essential for the Induction of Direct Cardiac Reprogramming by miR Combo. +epigenetics hsa-mir-208 Heart Diseases [unspecific] 28209718 Demethylation of H3K27 Is Essential for the Induction of Direct Cardiac Reprogramming by miR Combo. +epigenetics hsa-mir-499 Heart Diseases [unspecific] 28209718 Demethylation of H3K27 Is Essential for the Induction of Direct Cardiac Reprogramming by miR Combo. +epigenetics hsa-mir-137 "Carcinoma, Lung, Non-Small-Cell" 28223039 Oncogene LSD1 is epigenetically suppressed by miR-137 overexpression in human non-small cell lung cancer. +epigenetics hsa-mir-183 "Carcinoma, Hepatocellular" 28321157 hsa-mir-183 is frequently methylated and related to poor survival in human hepatocellular carcinoma. +epigenetics hsa-mir-210 Colorectal Carcinoma 28364795 The significance of DNA methylation profile in metastasis-related genes for the progression of colorectal cancer. +epigenetics hsa-mir-34 Colorectal Carcinoma 28364795 The significance of DNA methylation profile in metastasis-related genes for the progression of colorectal cancer. +epigenetics hsa-mir-9 Colorectal Carcinoma 28364795 The significance of DNA methylation profile in metastasis-related genes for the progression of colorectal cancer. +epigenetics hsa-mir-370 Cholangiocarcinoma 28545228 Aberrant DNA Methylation as a Biomarker and a Therapeutic Target of Cholangiocarcinoma. +epigenetics hsa-mir-10b Atherosclerosis 28601079 Variability of Methylation Profiles of CpG Sites in microrNA Genes in Leukocytes and Vascular Tissues of Patients with Atherosclerosis. +epigenetics hsa-mir-200 Lung Neoplasms 28698146 Epigenetic regulation of epithelial-mesenchymal transition by KDM6A histone demethylase in lung cancer cells. +epigenetics hsa-mir-200c Breast Neoplasms 28724364 Tamoxifen reverses epithelial-mesenchymal transition by demethylating miR-200c in triple-negative breast cancer cells. +epigenetics hsa-mir-21 Multiple Sclerosis 28766461 Hypermethylation of MIR21 in CD4+ T cells from patients with relapsing-remitting multiple sclerosis associates with lower miRNA-21 levels and concomitant up-regulation of its target genes. +epigenetics hsa-mir-21 Nervous System Diseases [unspecific] 28903050 Changes in the Coding and Non-coding Transcriptome and DNA Methylome that Define the Schwann Cell Repair Phenotype after Nerve Injury. +epigenetics hsa-mir-34a Cholangiocarcinoma 28923203 Epigenetic Silencing of miRNA-34a in Human Cholangiocarcinoma via EZH2 and DNA Methylation: Impact on Regulation of Notch Pathway. +epigenetics hsa-mir-142 "Carcinoma, Hepatocellular" 28963738 Loss-of-function of miR-142 by hypermethylation promotes TGF-¦Â-mediated tumour growth and metastasis in hepatocellular carcinoma. +epigenetics hsa-mir-200b Cervical Neoplasms 29077234 DNA methylation regulated microRNAs in human cervical cancer. +epigenetics hsa-mir-342 Multiple Myeloma 29242101 Epigenetic silencing of EVL/miR-342 in multiple myeloma +epigenetics hsa-mir-101 Glioblastoma 29251856 Studies of intragenic and distant intergenic alterations in DNA methylation will help elucidate the nature of epigenetic deregulation in glioblastoma +epigenetics hsa-mir-29a "Lymphoma, Burkitt" 29318382 methylation-mediated miR-29 epigenetic silencing may occur during BL development +epigenetics hsa-mir-22 Cholangiocarcinoma 29406621 MicroRNA (miR)-433 and miR-22 dysregulations induce histone-deacetylase-6 overexpression and ciliary loss in cholangiocarcinoma. +epigenetics hsa-mir-433 Cholangiocarcinoma 29406621 MicroRNA (miR)-433 and miR-22 dysregulations induce histone-deacetylase-6 overexpression and ciliary loss in cholangiocarcinoma. +epigenetics hsa-mir-196b Prostate Neoplasms 29536528 "CLCA2 epigenetic regulation by CTBP1, HDACs, ZEB1, EP300 and miR-196b-5p impacts prostate cancer cell adhesion and EMT in metabolic syndrome disease." +epigenetics hsa-mir-34a Preeclampsia 29557690 Hypomethylation of the miRNA-34a gene promoter is associated with Severe Preeclampsia +epigenetics hsa-mir-1179 "Carcinoma, Lung, Non-Small-Cell" 29570800 DNA methylation of microRNA-coding genes in non-small-cell lung cancer patients. +epigenetics hsa-mir-148a Prostate Neoplasms 29596883 miR-148a is silenced by DNA methylation and ectopic expression of miR-148a suppresses DNMT1 expression and induced apoptotic genes expression in hormone-refractory prostate cancer cells +epigenetics hsa-mir-375 "Carcinoma, Ovarian" 29631007 Novel miRNA genes deregulated by aberrant methylation in ovarian carcinoma are involved in metastasis +epigenetics hsa-mir-449a "Carcinoma, Pancreatic" 29684857 MicroRNA-449a functions as a tumor suppressor in pancreatic cancer by the epigenetic regulation of ATDC expression. +epigenetics hsa-mir-34c Colorectal Carcinoma 29701273 SATB2 targeted by methylated miR-34c-5p suppresses proliferation and metastasis attenuating the epithelial-mesenchymal transition in colorectal cancer. +epigenetics hsa-mir-483 "Carcinoma, Lung, Non-Small-Cell" 29717264 Epigenetic silencing of miR-483-3p promotes acquired gefitinib resistance and EMT in EGFR-mutant NSCLC by targeting integrin ¦Â3. +epigenetics hsa-mir-570 Osteosarcoma 29795113 Inhibition of LCMR1 and ATG12 by demethylation-activated miR-570-3p is involved in the anti-metastasis effects of metformin on human osteosarcoma. +epigenetics hsa-mir-1271 Gastric Neoplasms 29862663 Epigenetic silencing of miR-1271 enhances MEK1 and TEAD4 expression in gastric cancer. +epigenetics hsa-mir-155 Glioma 29885519 Methylation-mediated miR-155-FAM133A axis contributes to the attenuated invasion and migration of IDH mutant gliomas. +epigenetics hsa-mir-34b Neoplasms [unspecific] 29893976 Regulation of miR-34b/c-targeted gene expression program by SUMOylation. +epigenetics hsa-mir-34c Neoplasms [unspecific] 29893976 Regulation of miR-34b/c-targeted gene expression program by SUMOylation. +epigenetics hsa-mir-34 "Carcinoma, Breast" 29916548 Methylation profiles of miR34 gene family in Vietnamese patients suffering from breast and lung cancers. +epigenetics hsa-mir-137 Endometrial Neoplasms 29955087 miR-137 is a tumor suppressor in endometrial cancer and is repressed by DNA hypermethylation. +epigenetics hsa-mir-124 "Carcinoma, Cervical" 29960712 "Methylation of the hsa-miR-124, SOX1, TERT, and LMX1A genes as biomarkers for precursor lesions in cervical cancer." +epigenetics hsa-mir-145 Ovarian Neoplasms 29993160 Double-negative feedback interaction between DNA methyltransferase 3A and microRNA-145 in the Warburg effect of ovarian cancer cells. +epigenetics hsa-mir-125a Gastric Neoplasms 30117667 Epigenetic silenced miR-125a-5p could be self-activated through targeting Suv39H1 in gastric cancer. +epigenetics hsa-mir-122 "Carcinoma, Hepatocellular" 30195653 LncRNA HOTAIR epigenetically suppresses miR-122 expression in hepatocellular carcinoma via DNA methylation. +epigenetics hsa-mir-4532 "Carcinoma, Breast" 30202238 Downregulation of hypermethylated in cancer-1 by miR-4532 promotes adriamycin resistance in breast cancer cells. +epigenetics hsa-mir-873 Liver Cirrhosis 30237481 MiR-873-5p acts as an epigenetic regulator in early stages of liver fibrosis and cirrhosis. +epigenetics hsa-mir-486 Colorectal Carcinoma 30305607 DNA-methylation-mediated silencing of miR-486-5p promotes colorectal cancer proliferation and migration through activation of PLAGL2/IGF2/¦Â-catenin signal pathways. +epigenetics hsa-mir-388 Gastric Neoplasms 30308487 Hypermethylation of miR-338-3p and Impact of its Suppression on Cell Metastasis Through N-Cadherin Accumulation at the Cell -Cell Junction and Degradation of MMP in Gastric Cancer. +epigenetics hsa-mir-107 Ovarian Neoplasms 30363055 "Hypermethylation of miR-107, miR-130b, miR-203a, miR-1258 Genes Associated with Ovarian Cancer Development and Metastasis" +epigenetics hsa-mir-1258 Ovarian Neoplasms 30363055 "Hypermethylation of miR-107, miR-130b, miR-203a, miR-1258 Genes Associated with Ovarian Cancer Development and Metastasis" +epigenetics hsa-mir-130b Ovarian Neoplasms 30363055 "Hypermethylation of miR-107, miR-130b, miR-203a, miR-1258 Genes Associated with Ovarian Cancer Development and Metastasis" +epigenetics hsa-mir-203a Ovarian Neoplasms 30363055 "Hypermethylation of miR-107, miR-130b, miR-203a, miR-1258 Genes Associated with Ovarian Cancer Development and Metastasis" +epigenetics hsa-mir-132 "Carcinoma, Pancreatic" 30387838 Dexamethasone-induced inhibition of miR-132 via methylation promotes TGF-¦Â-driven progression of pancreatic cancer. +genetics_GWAS hsa-mir-142 Leukemia 15737576 Some human miRNAs are linked to leukemias: the miR-15a/miR-16 locus is frequently deleted or down-regulated in patients with B-cell chronic lymphocytic leukemia and miR-142 is at a translocation site found in a case of aggressive B-cell leukemia. +genetics_GWAS hsa-mir-189 Tourette Syndrome 16224024 we identified a frameshift mutation and two independent occurrences of the identical variant in the binding site for microRNA hsa-miR-189 +genetics_GWAS hsa-mir-16-1 "Leukemia, Lymphocytic, Chronic, B-Cell" 16251535 mutation +genetics_GWAS hsa-mir-187 "Leukemia, Lymphocytic, Chronic, B-Cell" 16251535 mutation +genetics_GWAS hsa-mir-206 "Leukemia, Lymphocytic, Chronic, B-Cell" 16251535 mutation +genetics_GWAS hsa-mir-27b "Leukemia, Lymphocytic, Chronic, B-Cell" 16251535 mutation +genetics_GWAS hsa-mir-29b-1 "Leukemia, Lymphocytic, Chronic, B-Cell" 16251535 mutation +genetics_GWAS hsa-mir-103a-2 Breast Neoplasms 16754881 copy number gain +genetics_GWAS hsa-mir-103a-2 Melanoma 16754881 copy number gain +genetics_GWAS hsa-mir-103a-2 Ovarian Neoplasms 16754881 copy number gain +genetics_GWAS hsa-mir-106b Breast Neoplasms 16754881 copy number gain +genetics_GWAS hsa-mir-106b Melanoma 16754881 copy number gain +genetics_GWAS hsa-mir-106b Ovarian Neoplasms 16754881 copy number gain +genetics_GWAS hsa-mir-1-1 Breast Neoplasms 16754881 copy number gain +genetics_GWAS hsa-mir-1-1 Melanoma 16754881 copy number gain +genetics_GWAS hsa-mir-1-1 Ovarian Neoplasms 16754881 copy number gain +genetics_GWAS hsa-mir-133a-2 Breast Neoplasms 16754881 copy number gain +genetics_GWAS hsa-mir-133a-2 Melanoma 16754881 copy number gain +genetics_GWAS hsa-mir-133a-2 Ovarian Neoplasms 16754881 copy number gain +genetics_GWAS hsa-mir-135b Breast Neoplasms 16754881 copy number gain +genetics_GWAS hsa-mir-135b Melanoma 16754881 copy number gain +genetics_GWAS hsa-mir-135b Ovarian Neoplasms 16754881 copy number gain +genetics_GWAS hsa-mir-151a Breast Neoplasms 16754881 copy number gain +genetics_GWAS hsa-mir-151a Melanoma 16754881 copy number gain +genetics_GWAS hsa-mir-151a Ovarian Neoplasms 16754881 copy number gain +genetics_GWAS hsa-mir-153-2 Breast Neoplasms 16754881 copy number gain +genetics_GWAS hsa-mir-153-2 Melanoma 16754881 copy number gain +genetics_GWAS hsa-mir-153-2 Ovarian Neoplasms 16754881 copy number gain +genetics_GWAS hsa-mir-17 Breast Neoplasms 16754881 copy number loss +genetics_GWAS hsa-mir-17 Melanoma 16754881 copy number loss +genetics_GWAS hsa-mir-17 Ovarian Neoplasms 16754881 copy number loss +genetics_GWAS hsa-mir-18a Breast Neoplasms 16754881 copy number loss +genetics_GWAS hsa-mir-18a Melanoma 16754881 copy number loss +genetics_GWAS hsa-mir-18a Ovarian Neoplasms 16754881 copy number loss +genetics_GWAS hsa-mir-194-1 Breast Neoplasms 16754881 copy number gain +genetics_GWAS hsa-mir-194-1 Melanoma 16754881 copy number gain +genetics_GWAS hsa-mir-194-1 Ovarian Neoplasms 16754881 copy number gain +genetics_GWAS hsa-mir-199a-2 Breast Neoplasms 16754881 copy number gain +genetics_GWAS hsa-mir-199a-2 Melanoma 16754881 copy number gain +genetics_GWAS hsa-mir-199a-2 Ovarian Neoplasms 16754881 copy number gain +genetics_GWAS hsa-mir-19a Breast Neoplasms 16754881 copy number loss +genetics_GWAS hsa-mir-19a Melanoma 16754881 copy number loss +genetics_GWAS hsa-mir-19a Ovarian Neoplasms 16754881 copy number loss +genetics_GWAS hsa-mir-19b-1 Breast Neoplasms 16754881 copy number loss +genetics_GWAS hsa-mir-19b-1 Melanoma 16754881 copy number loss +genetics_GWAS hsa-mir-19b-1 Ovarian Neoplasms 16754881 copy number loss +genetics_GWAS hsa-mir-200a Breast Neoplasms 16754881 copy number gain +genetics_GWAS hsa-mir-200a Melanoma 16754881 copy number gain +genetics_GWAS hsa-mir-200a Ovarian Neoplasms 16754881 copy number gain +genetics_GWAS hsa-mir-200b Breast Neoplasms 16754881 copy number gain +genetics_GWAS hsa-mir-200b Melanoma 16754881 copy number gain +genetics_GWAS hsa-mir-200b Ovarian Neoplasms 16754881 copy number gain +genetics_GWAS hsa-mir-20a Breast Neoplasms 16754881 copy number loss +genetics_GWAS hsa-mir-20a Melanoma 16754881 copy number loss +genetics_GWAS hsa-mir-20a Ovarian Neoplasms 16754881 copy number loss +genetics_GWAS hsa-mir-214 Breast Neoplasms 16754881 copy number gain +genetics_GWAS hsa-mir-214 Melanoma 16754881 copy number gain +genetics_GWAS hsa-mir-214 Ovarian Neoplasms 16754881 copy number gain +genetics_GWAS hsa-mir-215 Breast Neoplasms 16754881 copy number gain +genetics_GWAS hsa-mir-215 Melanoma 16754881 copy number gain +genetics_GWAS hsa-mir-215 Ovarian Neoplasms 16754881 copy number gain +genetics_GWAS hsa-mir-218-1 Breast Neoplasms 16754881 copy number loss +genetics_GWAS hsa-mir-218-1 Melanoma 16754881 copy number loss +genetics_GWAS hsa-mir-218-1 Ovarian Neoplasms 16754881 copy number loss +genetics_GWAS hsa-mir-219-1 Breast Neoplasms 16754881 copy number gain +genetics_GWAS hsa-mir-219-1 Melanoma 16754881 copy number gain +genetics_GWAS hsa-mir-219-1 Ovarian Neoplasms 16754881 copy number gain +genetics_GWAS hsa-mir-25 Breast Neoplasms 16754881 copy number gain +genetics_GWAS hsa-mir-25 Melanoma 16754881 copy number gain +genetics_GWAS hsa-mir-25 Ovarian Neoplasms 16754881 copy number gain +genetics_GWAS hsa-mir-296 Breast Neoplasms 16754881 copy number gain +genetics_GWAS hsa-mir-296 Melanoma 16754881 copy number gain +genetics_GWAS hsa-mir-296 Ovarian Neoplasms 16754881 copy number gain +genetics_GWAS hsa-mir-302a Breast Neoplasms 16754881 copy number loss +genetics_GWAS hsa-mir-302a Melanoma 16754881 copy number loss +genetics_GWAS hsa-mir-302a Ovarian Neoplasms 16754881 copy number loss +genetics_GWAS hsa-mir-302b Breast Neoplasms 16754881 copy number loss +genetics_GWAS hsa-mir-302b Melanoma 16754881 copy number loss +genetics_GWAS hsa-mir-302b Ovarian Neoplasms 16754881 copy number loss +genetics_GWAS hsa-mir-302c Breast Neoplasms 16754881 copy number loss +genetics_GWAS hsa-mir-302c Melanoma 16754881 copy number loss +genetics_GWAS hsa-mir-302c Ovarian Neoplasms 16754881 copy number loss +genetics_GWAS hsa-mir-302d Breast Neoplasms 16754881 copy number loss +genetics_GWAS hsa-mir-302d Melanoma 16754881 copy number loss +genetics_GWAS hsa-mir-302d Ovarian Neoplasms 16754881 copy number loss +genetics_GWAS hsa-mir-30b Breast Neoplasms 16754881 copy number gain +genetics_GWAS hsa-mir-30b Melanoma 16754881 copy number gain +genetics_GWAS hsa-mir-30b Ovarian Neoplasms 16754881 copy number gain +genetics_GWAS hsa-mir-30d Breast Neoplasms 16754881 copy number gain +genetics_GWAS hsa-mir-30d Melanoma 16754881 copy number gain +genetics_GWAS hsa-mir-30d Ovarian Neoplasms 16754881 copy number gain +genetics_GWAS hsa-mir-320a Breast Neoplasms 16754881 copy number loss +genetics_GWAS hsa-mir-320a Melanoma 16754881 copy number loss +genetics_GWAS hsa-mir-320a Ovarian Neoplasms 16754881 copy number loss +genetics_GWAS hsa-mir-338 Breast Neoplasms 16754881 copy number gain +genetics_GWAS hsa-mir-338 Melanoma 16754881 copy number gain +genetics_GWAS hsa-mir-338 Ovarian Neoplasms 16754881 copy number gain +genetics_GWAS hsa-mir-339 Breast Neoplasms 16754881 copy number gain +genetics_GWAS hsa-mir-339 Melanoma 16754881 copy number gain +genetics_GWAS hsa-mir-339 Ovarian Neoplasms 16754881 copy number gain +genetics_GWAS hsa-mir-367 Breast Neoplasms 16754881 copy number loss +genetics_GWAS hsa-mir-367 Melanoma 16754881 copy number loss +genetics_GWAS hsa-mir-367 Ovarian Neoplasms 16754881 copy number loss +genetics_GWAS hsa-mir-383 Breast Neoplasms 16754881 copy number loss +genetics_GWAS hsa-mir-383 Melanoma 16754881 copy number loss +genetics_GWAS hsa-mir-383 Ovarian Neoplasms 16754881 copy number loss +genetics_GWAS hsa-mir-429 Breast Neoplasms 16754881 copy number gain +genetics_GWAS hsa-mir-429 Melanoma 16754881 copy number gain +genetics_GWAS hsa-mir-429 Ovarian Neoplasms 16754881 copy number gain +genetics_GWAS hsa-mir-488 Breast Neoplasms 16754881 copy number gain +genetics_GWAS hsa-mir-488 Melanoma 16754881 copy number gain +genetics_GWAS hsa-mir-488 Ovarian Neoplasms 16754881 copy number gain +genetics_GWAS hsa-mir-9-1 Breast Neoplasms 16754881 copy number gain +genetics_GWAS hsa-mir-9-1 Melanoma 16754881 copy number gain +genetics_GWAS hsa-mir-9-1 Ovarian Neoplasms 16754881 copy number gain +genetics_GWAS hsa-mir-93 Breast Neoplasms 16754881 copy number gain +genetics_GWAS hsa-mir-93 Melanoma 16754881 copy number gain +genetics_GWAS hsa-mir-93 Ovarian Neoplasms 16754881 copy number gain +genetics_GWAS hsa-mir-1 Vascular Hypertrophy 17381315 we have identified an A-to-G transition in the 3'UTR of the GDF8 gene that reveals an illegitimate target site for microRNAs miR-1 and miR-206 that are highly expressed in skeletal muscle. +genetics_GWAS hsa-mir-206 Vascular Hypertrophy 17381315 we have identified an A-to-G transition in the 3'UTR of the GDF8 gene that reveals an illegitimate target site for microRNAs miR-1 and miR-206 that are highly expressed in skeletal muscle. +genetics_GWAS hsa-mir-146a Thyroid Neoplasms 17468766 "somatic mutations altering binding sites for miR-221, miR-222 and miR-146 have been observed in the 3'UTR of the KIT oncogene in papillary thyroid carcinoma." +genetics_GWAS hsa-mir-146b Thyroid Neoplasms 17468766 "somatic mutations altering binding sites for miR-221, miR-222 and miR-146 have been observed in the 3'UTR of the KIT oncogene in papillary thyroid carcinoma." +genetics_GWAS hsa-mir-221 Thyroid Neoplasms 17468766 "somatic mutations altering binding sites for miR-221, miR-222 and miR-146 have been observed in the 3'UTR of the KIT oncogene in papillary thyroid carcinoma." +genetics_GWAS hsa-mir-222 Thyroid Neoplasms 17468766 "somatic mutations altering binding sites for miR-221, miR-222 and miR-146 have been observed in the 3'UTR of the KIT oncogene in papillary thyroid carcinoma." +genetics_GWAS hsa-mir-198 Schizophrenia 17849003 SNP (rs1700) disease susceptibility +genetics_GWAS hsa-mir-206 Schizophrenia 17849003 SNP (rs17578796) disease susceptibility +genetics_GWAS hsa-mir-146a Thyroid Neoplasms 18474871 "Thus, our data suggest that a common polymorphism in pre-miR-146a affects the miR expression, contributes to the genetic predisposition to PTC, and plays a role in the tumorigenesis through somatic mutation." +genetics_GWAS hsa-mir-196a-2 Lung Neoplasms 18521189 "Therefore, the rs11614913 SNP in hsa-mir-196a2 may be a prognostic biomarker for NSCLC." +genetics_GWAS hsa-mir-510 Irritable Bowel Syndrome 18614545 First evidence for an association of a functional variant in the microRNA-510 target site of the serotonin receptor type 3E gene with diarrhea predominant irritable bowel syndrome. +genetics_GWAS hsa-mir-146a Breast Neoplasms 18634034 miR-146: rs2910164 were associated with increased risk of breast cancer in Chinese women +genetics_GWAS hsa-mir-146b Breast Neoplasms 18634034 miR-146: rs2910164 were associated with increased risk of breast cancer in Chinese women +genetics_GWAS hsa-mir-149 Breast Neoplasms 18634034 miR-149: rs2292832 were associated with increased risk of breast cancer in Chinese women +genetics_GWAS hsa-mir-196a-2 Breast Neoplasms 18634034 miR-196a-2: rs11614913 were associated with increased risk of breast cancer in Chinese women +genetics_GWAS hsa-mir-499a Breast Neoplasms 18634034 miR-499: rs3746444 were associated with increased risk of breast cancer in Chinese women +genetics_GWAS hsa-mir-146a Breast Neoplasms 18660546 miR-146a: A functional polymorphism (rs2910164) in the miR-146a gene and age of familial breast/ovarian cancer diagnosis +genetics_GWAS hsa-mir-146a Ovarian Neoplasms 18660546 miR-146a: A functional polymorphism (rs2910164) in the miR-146a gene and age of familial breast/ovarian cancer diagnosis +genetics_GWAS hsa-mir-146a "Carcinoma, Hepatocellular" 18711148 miR-146a: A functional polymorphism (rs2910164) in the miR-146a gene is associated with the risk for hepatocellular carcinoma +genetics_GWAS hsa-mir-659 Dementia 18723524 miR-659: Common variation in the miR-659 binding-site of GRN is a major risk factor for TDP43-positive frontotemporal dementia +genetics_GWAS hsa-let-7a "Carcinoma, Lung, Non-Small-Cell" 18922928 A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk. +genetics_GWAS hsa-let-7a-1 "Carcinoma, Lung, Non-Small-Cell" 18922928 A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk. +genetics_GWAS hsa-let-7a-1 Lung Neoplasms 18922928 let-7a: A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk +genetics_GWAS hsa-let-7a-2 "Carcinoma, Lung, Non-Small-Cell" 18922928 A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk. +genetics_GWAS hsa-let-7a-2 Lung Neoplasms 18922928 let-7a: A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk +genetics_GWAS hsa-let-7a-3 "Carcinoma, Lung, Non-Small-Cell" 18922928 A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk. +genetics_GWAS hsa-let-7a-3 Lung Neoplasms 18922928 let-7a: A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk +genetics_GWAS hsa-let-7b "Carcinoma, Lung, Non-Small-Cell" 18922928 A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk. +genetics_GWAS hsa-let-7b Lung Neoplasms 18922928 let-7b: A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk +genetics_GWAS hsa-let-7c Lung Neoplasms 18922928 let-7c: A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk +genetics_GWAS hsa-let-7d "Carcinoma, Lung, Non-Small-Cell" 18922928 A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk. +genetics_GWAS hsa-let-7d Lung Neoplasms 18922928 let-7d: A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk +genetics_GWAS hsa-let-7e Lung Neoplasms 18922928 let-7e: A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk +genetics_GWAS hsa-let-7f-1 Lung Neoplasms 18922928 let-7f: A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk +genetics_GWAS hsa-let-7f-2 Lung Neoplasms 18922928 let-7f: A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk +genetics_GWAS hsa-let-7g "Carcinoma, Lung, Non-Small-Cell" 18922928 A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk. +genetics_GWAS hsa-let-7g Lung Neoplasms 18922928 let-7g: A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk +genetics_GWAS hsa-let-7i Lung Neoplasms 18922928 let-7i: A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk +genetics_GWAS hsa-mir-17 Breast Neoplasms 19048628 miR-17: mutations +genetics_GWAS hsa-mir-30c-1 Breast Neoplasms 19048628 miR-30c-1: mutations +genetics_GWAS hsa-mir-122 Hypertension 19067360 a polymorphism of the 3'UTR of the SLC7A1 gene affects the binding with miR-122 +genetics_GWAS hsa-mir-146a Thyroid Neoplasms 19164563 miR-146a: SNP rs2910164 contribute to thyroid cancer +genetics_GWAS hsa-mir-96 Sensorineural Hearing Loss 19363478 miR-96: An ENU-induced mutation +genetics_GWAS hsa-mir-96 Sensorineural Hearing Loss 19363479 miR-96: Mutations in the seed region +genetics_GWAS hsa-mir-128 Anxiety Disorders 19370765 Allele variants in functional MicroRNA target sites of the neurotrophin-3 receptor gene (NTRK3) as susceptibility factors for anxiety disorders. +genetics_GWAS hsa-mir-148a Anxiety Disorders 19370765 Allele variants in functional MicroRNA target sites of the neurotrophin-3 receptor gene (NTRK3) as susceptibility factors for anxiety disorders. +genetics_GWAS hsa-mir-148b Anxiety Disorders 19370765 Allele variants in functional MicroRNA target sites of the neurotrophin-3 receptor gene (NTRK3) as susceptibility factors for anxiety disorders. +genetics_GWAS hsa-mir-152 Anxiety Disorders 19370765 Allele variants in functional MicroRNA target sites of the neurotrophin-3 receptor gene (NTRK3) as susceptibility factors for anxiety disorders. +genetics_GWAS hsa-mir-485 Anxiety Disorders 19370765 Allele variants in functional MicroRNA target sites of the neurotrophin-3 receptor gene (NTRK3) as susceptibility factors for anxiety disorders. +genetics_GWAS hsa-mir-509 Anxiety Disorders 19370765 Allele variants in functional MicroRNA target sites of the neurotrophin-3 receptor gene (NTRK3) as susceptibility factors for anxiety disorders. +genetics_GWAS hsa-mir-765 Anxiety Disorders 19370765 Allele variants in functional MicroRNA target sites of the neurotrophin-3 receptor gene (NTRK3) as susceptibility factors for anxiety disorders. +genetics_GWAS hsa-mir-125b Breast Neoplasms 19738052 A risk variant in an miR-125b binding site in BMPR1B is associated with breast cancer pathogenesis. +genetics_GWAS hsa-mir-196a-2 Gastric Neoplasms 19834808 miR-196a-2:Association of microRNA-196a-2 gene polymorphism with gastric cancer risk +genetics_GWAS hsa-mir-499 Breast Neoplasms 19847796 "Recently, the SNPs rs11614913 in hsa-mir-196a2 and rs3746444 in hsa-mir-499 were reported to be associated with increased breast cancer risk, and the SNP rs2910164 in hsa-mir-146a was shown to have an effect on age of breast cancer diagnosis." +genetics_GWAS hsa-mir-146a Prostate Neoplasms 19902466 "The natural genetic variation in pre-miR-146a affects the amount of mature miR-146a, contributes to the genetic predisposition to CaP." +genetics_GWAS hsa-mir-15a Multiple Myeloma 20031211 miR-15a:Micro-RNA-15a and micro-RNA-16 expression and chromosome 13 deletions in multiple myeloma +genetics_GWAS hsa-mir-16-1 Multiple Myeloma 20031211 miR-16:Micro-RNA-15a and micro-RNA-16 expression and chromosome 13 deletions in multiple myeloma +genetics_GWAS hsa-mir-16-2 Multiple Myeloma 20031211 miR-16:Micro-RNA-15a and micro-RNA-16 expression and chromosome 13 deletions in multiple myeloma +genetics_GWAS hsa-mir-492 Colorectal Carcinoma 20044760 "mir-492:In a univariate analysis, the progression-free survival of the patients with the combined mir492 C/G and G/G genotype was significantly worse than that of the patients with the mir492 C/C genotype (rs2289030) (P value = 0.0426)" +genetics_GWAS hsa-mir-218-1 Urinary Bladder Cancer 20163849 miR-218:Polymorphisms involved in the miR-218-LAMB3 pathway and susceptibility of cervical cancer +genetics_GWAS hsa-mir-218-2 Urinary Bladder Cancer 20163849 miR-218:Polymorphisms involved in the miR-218-LAMB3 pathway and susceptibility of cervical cancer +genetics_GWAS hsa-mir-191 Ovarian Neoplasms 20167074 Novel genetic variants in miR-191 gene and familial ovarian cancer +genetics_GWAS hsa-mir-196a-2 "Carcinoma, Hepatocellular" 20188135 miR-196a2:MIR196A2 polymorphism was associated with susceptibility to HBV-related HCC in a maleChinese population. +genetics_GWAS hsa-mir-196a-1 Glioma 20229273 A polymorphism of microRNA196a genome region was associated with decreased risk of glioma in Chinese population +genetics_GWAS hsa-mir-196a-2 Glioma 20229273 A polymorphism of microRNA196a genome region was associated with decreased risk of glioma in Chinese population +genetics_GWAS hsa-mir-128-2 "Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic" 20237425 A novel mutation in the miR-128b gene reduces miRNA processing and leads to glucocorticoid resistance of MLL-AF4 acute lymphocytic leukemia cells. +genetics_GWAS hsa-mir-30e Schizophrenia 20347265 miR-30e:mir-30e ss178077483 plays a role in schizophrenia susceptibility +genetics_GWAS hsa-mir-204 Neoplasms [unspecific] 20439436 "miR-204:hsa-miR-30 and hsa-miR-204, were found to be physically altered at the DNA copy number level as well" +genetics_GWAS hsa-mir-20a Neoplasms [unspecific] 20439436 mir-20a:We correctly identified hsa-miR-17/92 family as amplified and the hsa-miR-143/145 cluster as deleted +genetics_GWAS hsa-mir-30a Neoplasms [unspecific] 20439436 "miR-30:hsa-miR-103/106 were downgraded in cancer, whereas hsa-miR-30 became most prominent" +genetics_GWAS hsa-mir-125b-1 "Leukemia, Biphenotypic, Acute" 20485370 miR-125b-1:A new recurrent translocation t(11;14)(q24;q32) involving IGH@ and miR-125b-1 in B-cell progenitor acute lymphoblastic leukemia +genetics_GWAS hsa-mir-196a-2 "Cardiomyopathy, Dilated" 20488170 mir-196a2:Common genetic polymorphisms in pre-microRNAs were associated with increased risk of dilated cardiomyopathy +genetics_GWAS hsa-mir-499a "Cardiomyopathy, Dilated" 20488170 mir-499:Common genetic polymorphisms in pre-microRNAs were associated with increased risk of dilated cardiomyopathy +genetics_GWAS hsa-mir-499 "Squamous Cell Carcinoma, Head and Neck" 20549817 "Of the 4 SNPs that were studied, the hsa-mir-499 AG and GG genotypes were associated with a reduced risk of SCCHN" +genetics_GWAS hsa-mir-30e Schizophrenia 20579744 Our previous study revealed a strong association between the polymorphism ss178077483 in the miRNA-30e precursor (pre-miR-30e) and the risk of SCZ. +genetics_GWAS hsa-mir-126 "Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic" 20621067 miR-126:Alteration of processing induced by a single nucleotide polymorphism in pri-miR-126 +genetics_GWAS hsa-mir-146a Gastrointestinal Neoplasms 20653068 Pre-miR-146a C/G polymorphism might be associated with an elevatedrisk of gastric cancer in Chinese population. +genetics_GWAS hsa-mir-27a Gastric Neoplasms 20666778 mir-27a:mir-27a genetic variant contributes to gastric cancer susceptibility +genetics_GWAS hsa-mir-146a Gastrointestinal Neoplasms 20721625 This study revealed the combined effect of miR-146a rs2910164 G/G and TLR4 +3725 C allele on the increased risk of severe gastric atrophy among the H. pylori-infected Japanese subjects. +genetics_GWAS hsa-mir-155 Hypertension 20966899 "The interplay between miR-155 expression, +1166C polymorphism, and AT1R protein expression may have a role in the regulation of blood pressure." +genetics_GWAS hsa-mir-146a Gastrointestinal Neoplasms 21073609 The rs2910164 (G>C) SNP in the miR-146a is associated with susceptibility to GC. +genetics_GWAS hsa-mir-221 Melanoma 21119596 This KIT variant results in a mismatch in the seed region of a miR-221 complementary site and reporter data suggests that this mismatch can result in increased expression ofthe KIT oncogene. +genetics_GWAS hsa-mir-491 Colorectal Carcinoma 21128281 deleted +genetics_GWAS hsa-mir-646 Colorectal Carcinoma 21128281 deleted +genetics_GWAS hsa-mir-17 Breast Neoplasms 21140207 SNP (rs3739008) located at 3'UTR of NPAS2 and the C to T changing of the SNP may disrupt the binding of microRNA- (miR-)17-5p and miR-519e to the 3'UTR of NPAS2 +genetics_GWAS hsa-mir-519e Breast Neoplasms 21140207 SNP (rs3739008) located at 3'UTR of NPAS2 and the C to T changing of the SNP may disrupt the binding of microRNA- (miR-)17-5p and miR-519e to the 3'UTR of NPAS2 +genetics_GWAS hsa-mir-569 Systemic Lupus Erythematosus 21162035 Association of a functional polymorphism in the 3' untranslated region of SPI1 with systemic lupus erythematosus. +genetics_GWAS hsa-mir-196a-2 Colorectal Carcinoma 21241442 A variant ( rs11614913 ) in microRNA-196a2 is not associated with susceptibility to and progression of colorectal cancer in Chinese. +genetics_GWAS hsa-mir-196a-1 Crohn Disease 21278745 The common exonic synonymous SNP (c.313C>T) in IRGM alters a binding site for miR-196 and causes deregulation of IRGM-dependent xenophagy in Crohn's disease. +genetics_GWAS hsa-mir-196a-2 Crohn Disease 21278745 The common exonic synonymous SNP (c.313C>T) in IRGM alters a binding site for miR-196 and causes deregulation of IRGM-dependent xenophagy in Crohn's disease. +genetics_GWAS hsa-mir-196b Crohn Disease 21278745 The common exonic synonymous SNP (c.313C>T) in IRGM alters a binding site for miR-196 and causes deregulation of IRGM-dependent xenophagy in Crohn's disease. +genetics_GWAS hsa-mir-124-1 Breast Neoplasms 21318219 Genetic variants (SNP rs1042538 A/T) at the miR-124 binding site on the cytoskeleton-organizing IQGAP1 gene confer differential predisposition to breast cancer. +genetics_GWAS hsa-mir-124-2 Breast Neoplasms 21318219 Genetic variants (SNP rs1042538 A/T) at the miR-124 binding site on the cytoskeleton-organizing IQGAP1 gene confer differential predisposition to breast cancer. +genetics_GWAS hsa-mir-124-3 Breast Neoplasms 21318219 Genetic variants (SNP rs1042538 A/T) at the miR-124 binding site on the cytoskeleton-organizing IQGAP1 gene confer differential predisposition to breast cancer. +genetics_GWAS hsa-mir-146a Esophageal Neoplasms 21319225 SNP (rs2910164 G/C): Significantly increased CSCC risks were found to be associated with G allele of rs2910164 +genetics_GWAS hsa-mir-146a "Squamous Cell Carcinoma, Cerevial" 21319225 SNP (rs2910164 G/C): Significantly increased CSCC risks were found to be associated with G allele of rs2910164 +genetics_GWAS hsa-mir-499a Esophageal Neoplasms 21319225 SNP (rs3746444 A/G): Significantly increased CSCC risks were found to be associated with G allele of rs3746444 +genetics_GWAS hsa-mir-499a "Squamous Cell Carcinoma, Cerevial" 21319225 SNP (rs3746444 A/G): Significantly increased CSCC risks were found to be associated with G allele of rs3746444 +genetics_GWAS hsa-mir-196a-2 Urinary Bladder Cancer 21345130 "Our results showed that the heterozygous genotype of rs11614913 (hsa-mir-196a2 C>T rs11614913) was higher in cases than controls but the results were marginally significant (p=0.055; odds ratio, 1.44)." +genetics_GWAS hsa-mir-196b Urinary Bladder Cancer 21345130 "Our results showed that the heterozygous genotype of rs11614913 (hsa-mir-196a2 C>T rs11614913) was higher in cases than controls but the results were marginally significant (p=0.055; odds ratio, 1.44)." +genetics_GWAS hsa-mir-569 Systemic Lupus Erythematosus 21360505 rs1057233 alters a target sequence for microRNA hsa-miR-569 (miR-569). +genetics_GWAS hsa-mir-328 Myopia 21421876 "SNPs rs644242 and rs662702 had marginal significance (p=0.063) and further analyses showed that these SNPs were associated with extreme myopia. The OR for extreme myopia was 2.1 (empirical p=0.007) for the CC genotype at SNP rs662702 at 3' UTR. The functional assay for SNP rs662702 demonstrated that the C allele had a significantly lower expression level than the T allele (P=0.0001). SNP rs662702 was predicted to be located in the microRNA-328 binding site, which may explain the differential allelic effect on gene expression." +genetics_GWAS hsa-let-7a-1 Ovarian Neoplasms 21482675 "rs12194974 (G>A), a SNP in a putative transcription factor binding site in the LIN28B promoter region (summary OR=0.90, 95% CI: 0.82-0.98; P=0.015). LIN28B LIN28B over-expression in epithelial ovarian cancer (EOC) contributes to tumorigenesis by repressing tumor suppressor let-7 expression." +genetics_GWAS hsa-let-7a-2 Ovarian Neoplasms 21482675 "rs12194974 (G>A), a SNP in a putative transcription factor binding site in the LIN28B promoter region (summary OR=0.90, 95% CI: 0.82-0.98; P=0.015). LIN28B LIN28B over-expression in epithelial ovarian cancer (EOC) contributes to tumorigenesis by repressing tumor suppressor let-7 expression." +genetics_GWAS hsa-let-7a-3 Ovarian Neoplasms 21482675 "rs12194974 (G>A), a SNP in a putative transcription factor binding site in the LIN28B promoter region (summary OR=0.90, 95% CI: 0.82-0.98; P=0.015). LIN28B LIN28B over-expression in epithelial ovarian cancer (EOC) contributes to tumorigenesis by repressing tumor suppressor let-7 expression." +genetics_GWAS hsa-mir-196a-2 Breast Neoplasms 21483822 "rs11614913 polymorphism:Overall, individuals with the TC/CC genotypes were associated with higher cancer risk than those with the TT genotype (OR=1.18, 95% CI=1.03-1.34, P<0.001 for heterogeneity test). In the stratified analyses, we observed that the CC genotype might modulate breast cancer risk (OR=1.11, 95%CI=1.01-1.23, P(heterogeneity)=0.210) and lung cancer risk (OR=1.25, 95%CI=1.06-1.46, P(heterogeneity)=0.958), comparing with the TC/TT genotype. Moreover, a significantly increased risk was found among Asian populations in a dominant model (TC/CC versus TT, OR=1.24, 95% CI=1.07-1.43, P(heterogeneity)=0.006)." +genetics_GWAS hsa-mir-196a-2 Lung Neoplasms 21483822 "rs11614913 polymorphism:Overall, individuals with the TC/CC genotypes were associated with higher cancer risk than those with the TT genotype (OR=1.18, 95% CI=1.03-1.34, P<0.001 for heterogeneity test). In the stratified analyses, we observed that the CC genotype might modulate breast cancer risk (OR=1.11, 95%CI=1.01-1.23, P(heterogeneity)=0.210) and lung cancer risk (OR=1.25, 95%CI=1.06-1.46, P(heterogeneity)=0.958), comparing with the TC/TT genotype. Moreover, a significantly increased risk was found among Asian populations in a dominant model (TC/CC versus TT, OR=1.24, 95% CI=1.07-1.43, P(heterogeneity)=0.006)." +genetics_GWAS hsa-mir-146a "Tuberculosis, Pulmonary" 21524676 "A polymorphism (rs2910164 G>C, in miR-146a) indicated an association with PTB risk in both Tibetan (p = 0.031) and Han (p = 0.000) populations. However, the role of the G allele of rs2910164, like the C allele in rs3746444, differed in the Tibetan (OR = 1.509, p < 0.05) and Han (OR = 0.575, p < 0.05) groups." +genetics_GWAS hsa-mir-499a "Tuberculosis, Pulmonary" 21524676 "There was no association between rs3746444 (in hsa-mir-499) and PTB risk (p = 0.118) in the Han population, but subjects carrying the C allele exhibited decreased PTB risk (odds ratio [OR] = 0.403 [95% confidence interval (95% CI) 0.278-0.583]). There was an association between rs3746444 and PTB in the Tibetan population, and individuals carrying the C allele exhibited increased PTB risk (OR = 1.870 [95% CI 1.218-2.871])." +genetics_GWAS hsa-mir-146a Urinary Bladder Cancer 21529907 Polymorphism (rs2910164) of the pre-miR-146a is associated with risk of cervical cancer in a Chinese population. The subjects carrying GG homozygote had a 1.496-foldincreased risk than those carrying CG/CC genotypes. The carriers of GG genotype had obviously more reduced miR-146a expression level compared with the carriers of CC genotype. +genetics_GWAS hsa-mir-137 Melanoma 21543894 miR-137 under expression was significantly associated with melanomas with the KRAS-variant. +genetics_GWAS hsa-mir-125b-1 Prostate Neoplasms 21556765 rs1434536 in the 3'UTR of BMPR1B gene affects the binding ability of miR-125b to BMPR1B mRNA and contributes to the genetic hspredisposition to localized prostate cancer and patients aged >70years. +genetics_GWAS hsa-mir-125b-2 Prostate Neoplasms 21556765 rs1434536 in the 3'UTR of BMPR1B gene affects the binding ability of miR-125b to BMPR1B mRNA and contributes to the genetic hspredisposition to localized prostate cancer and patients aged >70years. +genetics_GWAS hsa-mir-637 Hypertension 21558123 A common genetic variant (rs938671) in the 3'-UTR of Vacuolar H+-ATPase ATP6V0A1 creates a micro-RNA (hsa-miR-637) motif to alter Chromogranin A (CHGA) processing and hypertension risk. +genetics_GWAS hsa-mir-519a-1 Gout 21558165 There was a clear link between the rs1333049 genotypic and allelic frequencies between gout cases and controls. There was a significantly increased risk of gout in carriers of the CC genotype.This SNP is homologous to miR-519 and miR-520. +genetics_GWAS hsa-mir-519a-2 Gout 21558165 There was a clear link between the rs1333049 genotypic and allelic frequencies between gout cases and controls. There was a significantly increased risk of gout in carriers of the CC genotype.This SNP is homologous to miR-519 and miR-520. +genetics_GWAS hsa-mir-519b Gout 21558165 There was a clear link between the rs1333049 genotypic and allelic frequencies between gout cases and controls. There was a significantly increased risk of gout in carriers of the CC genotype.This SNP is homologous to miR-519 and miR-520. +genetics_GWAS hsa-mir-519c Gout 21558165 There was a clear link between the rs1333049 genotypic and allelic frequencies between gout cases and controls. There was a significantly increased risk of gout in carriers of the CC genotype.This SNP is homologous to miR-519 and miR-520. +genetics_GWAS hsa-mir-519d Gout 21558165 There was a clear link between the rs1333049 genotypic and allelic frequencies between gout cases and controls. There was a significantly increased risk of gout in carriers of the CC genotype.This SNP is homologous to miR-519 and miR-520. +genetics_GWAS hsa-mir-519e Gout 21558165 There was a clear link between the rs1333049 genotypic and allelic frequencies between gout cases and controls. There was a significantly increased risk of gout in carriers of the CC genotype.This SNP is homologous to miR-519 and miR-520. +genetics_GWAS hsa-mir-520a Gout 21558165 There was a clear link between the rs1333049 genotypic and allelic frequencies between gout cases and controls. There was a significantly increased risk of gout in carriers of the CC genotype.This SNP is homologous to miR-519 and miR-520. +genetics_GWAS hsa-mir-520b Gout 21558165 There was a clear link between the rs1333049 genotypic and allelic frequencies between gout cases and controls. There was a significantly increased risk of gout in carriers of the CC genotype.This SNP is homologous to miR-519 and miR-520. +genetics_GWAS hsa-mir-520d Gout 21558165 There was a clear link between the rs1333049 genotypic and allelic frequencies between gout cases and controls. There was a significantly increased risk of gout in carriers of the CC genotype.This SNP is homologous to miR-519 and miR-520. +genetics_GWAS hsa-mir-520e Gout 21558165 There was a clear link between the rs1333049 genotypic and allelic frequencies between gout cases and controls. There was a significantly increased risk of gout in carriers of the CC genotype.This SNP is homologous to miR-519 and miR-520. +genetics_GWAS hsa-mir-520f Gout 21558165 There was a clear link between the rs1333049 genotypic and allelic frequencies between gout cases and controls. There was a significantly increased risk of gout in carriers of the CC genotype.This SNP is homologous to miR-519 and miR-520. +genetics_GWAS hsa-mir-520g Gout 21558165 There was a clear link between the rs1333049 genotypic and allelic frequencies between gout cases and controls. There was a significantly increased risk of gout in carriers of the CC genotype.This SNP is homologous to miR-519 and miR-520. +genetics_GWAS hsa-mir-520h Gout 21558165 There was a clear link between the rs1333049 genotypic and allelic frequencies between gout cases and controls. There was a significantly increased risk of gout in carriers of the CC genotype.This SNP is homologous to miR-519 and miR-520. +genetics_GWAS hsa-mir-196a-2 Chronic Obstructive Pulmonary Disease 21565178 "The TT genotype and T allele of miR-196a2 rs11614913 were significantly associated with a decreased risk for COPD (Chronic obstructive pulmonary disease), compared with the CC genotype and C allele. Similarly, the GG genotype and G allele of miR-499 rs3746444 were associated with a decreased risk for COPD, compared with the AA genotype and A allele." +genetics_GWAS hsa-mir-499a Chronic Obstructive Pulmonary Disease 21565178 "The TT genotype and T allele of miR-196a2 rs11614913 were significantly associated with a decreased risk for COPD (Chronic obstructive pulmonary disease), compared with the CC genotype and C allele. Similarly, the GG genotype and G allele of miR-499 rs3746444 were associated with a decreased risk for COPD, compared with the AA genotype and A allele." +genetics_GWAS hsa-mir-196a-2 Colorectal Carcinoma 21565628 A Functional Variant in MicroRNA-196a2 (rs11614913 SNP) Is Associated with Susceptibility of Colorectal Cancer in a Chinese Population. +genetics_GWAS hsa-mir-1302-1 Male Infertility 21601192 "Two SNPs from two genes (rs6631 of CGA and rs2303846 of CPEB1)(binding sites of miR-1302) were found to be associated with idiopathic male infertility. Functionally, the substitution of A by T in rs6631 results in decreased binding affinity of miR-1302 and overexpression of CGA in vitro." +genetics_GWAS hsa-mir-1302-2 Male Infertility 21601192 "Two SNPs from two genes (rs6631 of CGA and rs2303846 of CPEB1)(binding sites of miR-1302) were found to be associated with idiopathic male infertility. Functionally, the substitution of A by T in rs6631 results in decreased binding affinity of miR-1302 and overexpression of CGA in vitro." +genetics_GWAS hsa-mir-1302-3 Male Infertility 21601192 "Two SNPs from two genes (rs6631 of CGA and rs2303846 of CPEB1)(binding sites of miR-1302) were found to be associated with idiopathic male infertility. Functionally, the substitution of A by T in rs6631 results in decreased binding affinity of miR-1302 and overexpression of CGA in vitro." +genetics_GWAS hsa-mir-1302-4 Male Infertility 21601192 "Two SNPs from two genes (rs6631 of CGA and rs2303846 of CPEB1)(binding sites of miR-1302) were found to be associated with idiopathic male infertility. Functionally, the substitution of A by T in rs6631 results in decreased binding affinity of miR-1302 and overexpression of CGA in vitro." +genetics_GWAS hsa-mir-1302-5 Male Infertility 21601192 "Two SNPs from two genes (rs6631 of CGA and rs2303846 of CPEB1)(binding sites of miR-1302) were found to be associated with idiopathic male infertility. Functionally, the substitution of A by T in rs6631 results in decreased binding affinity of miR-1302 and overexpression of CGA in vitro." +genetics_GWAS hsa-mir-1302-6 Male Infertility 21601192 "Two SNPs from two genes (rs6631 of CGA and rs2303846 of CPEB1)(binding sites of miR-1302) were found to be associated with idiopathic male infertility. Functionally, the substitution of A by T in rs6631 results in decreased binding affinity of miR-1302 and overexpression of CGA in vitro." +genetics_GWAS hsa-mir-1302-7 Male Infertility 21601192 "Two SNPs from two genes (rs6631 of CGA and rs2303846 of CPEB1)(binding sites of miR-1302) were found to be associated with idiopathic male infertility. Functionally, the substitution of A by T in rs6631 results in decreased binding affinity of miR-1302 and overexpression of CGA in vitro." +genetics_GWAS hsa-mir-1302-8 Male Infertility 21601192 "Two SNPs from two genes (rs6631 of CGA and rs2303846 of CPEB1)(binding sites of miR-1302) were found to be associated with idiopathic male infertility. Functionally, the substitution of A by T in rs6631 results in decreased binding affinity of miR-1302 and overexpression of CGA in vitro." +genetics_GWAS hsa-mir-196a-2 Hepatitis C Virus Infection 21604580 SNP rs11614913 on miR196a-2 gene is associated with the antiviral therapy efficacy of hepatitis C patients.The TT genotype or T alleles be associated with the SVR while the CC genotype or C allele could be related to the NVR or recurrence. +genetics_GWAS hsa-mir-196a-2 "Carcinoma, Lung, Non-Small-Cell" 21617338 MicroRNA196a2 rs11614913 Genotypes are associated with the Risk of Non-Small Cell Lung Cancer in Korean Population. +genetics_GWAS hsa-mir-146a Gastric Neoplasms 21632853 "miR-146a levels in cancer tissues were significantly lower than those in the corresponding noncancerous tissue. Lower levels of miR-146a were associated with lymph node metastasis and venous invasion. Moreover, a lower level of miR-146a was an independent prognostic factor for overall survival.Ectopic expression of miR-146a inhibited migration and invasion and downregulated EGFR and IRAK1 expression in gastric cancer cells. In addition, G/C SNP within the pre-miR-146a seed sequence significantly reduced miR-146a levels in the GG genotype compared with the CC genotype." +genetics_GWAS hsa-mir-492 Psoriasis 21655935 "The rs8259 T allele was associated with significantly decreased psoriasis susceptibility (OR=0.758, 95% CI 0.638-0.901, p=0.002) compared to A allele. the rs8259 polymorphism was located in a seed region for miR-492 binding." +genetics_GWAS hsa-mir-1827 "Carcinoma, Lung, Small-Cell" 21676885 "Genetic Variation in an miRNA-1827 Binding Site in MYCL1 Alters Susceptibility to Small-Cell Lung Cancer. The rs3134615T allele was associated with a significantly increased risk of SCLC, with the OR for carrying the GT or TT genotype being 2.08 (95% confidence interval, 1.39-3.21; P = 0.0004) compared with the GG genotype." +genetics_GWAS hsa-mir-146a Systemic Lupus Erythematosus 21738483 A functional variant in microRNA-146a promoter modulates its expression and confers disease risk for systemic lupus erythematosus. +genetics_GWAS hsa-mir-146a Glioblastoma 21744077 "A functional polymorphism in the pre-miR-146a gene is associated with risk and prognosis in adult glioma. An increased glioma risk was observed among rs2910164 minor allele (C) carriers (per allele OR (95%CI)=1.22 (1.01-1.46, p (trend)=0.039)). The association was stronger among older subjects carrying at least one copy of the C allele (OR (95% CI)=1.38 (1.04-1.83, P=0.026). Mortality was increased among minor allele carriers (HR(95% CI)=1.33 (1.03-1.72, P=0.029)), with the association largely restricted to females (HR (95% CI)=2.02 (1.28-3.17, P=0.002))." +genetics_GWAS hsa-mir-101 "Carcinoma, Ovarian" 21765906 "a few of which have been found in the genomic fragile regions that are associated with abnormal deletion or amplification in cancer, such as miR-21, miR-101-1, miR-210 and miR-301a." +genetics_GWAS hsa-mir-21 "Carcinoma, Ovarian" 21765906 "a few of which have been found in the genomic fragile regions that are associated with abnormal deletion or amplification in cancer, such as miR-21, miR-101-1, miR-210 and miR-301a." +genetics_GWAS hsa-mir-210 "Carcinoma, Ovarian" 21765906 "a few of which have been found in the genomic fragile regions that are associated with abnormal deletion or amplification in cancer, such as miR-21, miR-101-1, miR-210 and miR-301a." +genetics_GWAS hsa-mir-301a "Carcinoma, Ovarian" 21765906 "a few of which have been found in the genomic fragile regions that are associated with abnormal deletion or amplification in cancer, such as miR-21, miR-101-1, miR-210 and miR-301a." +genetics_GWAS hsa-mir-155 Hypertrophy 21771600 the C allele of rs5186 was associated with a significant increase in SWT (p=0.003) and LVM (p=0.001). This functional polymorphism increases expression of AGTR1 by altering the binding site for miR-155 +genetics_GWAS hsa-mir-125a Habitual Abortion 21788734 "Two common SNPs (rs41275794, rs12976445) in pri-miR-125a alter the mature miRNA expression and associate with Abortion, Habitual in a Han-Chinese population." +genetics_GWAS hsa-mir-367 Breast Neoplasms 21810988 "Functional SNP (rs1044129, is present in binding region) in the microRNA-367 binding site in the 3'UTR of the calcium channel ryanodine receptor gene 3 (RYR3) affects breast cancer risk and calcification." +genetics_GWAS hsa-mir-196a-2 Colorectal Carcinoma 21815818 A Functional Polymorphism (rs11614913 (T>C)) in miRNA-196a2 Is Associated with Colorectal Cancer Risk in a Chinese Population. +genetics_GWAS hsa-mir-542 Colorectal Carcinoma 21822307 A common single-nucleotide polymorphism (T8473CA) in cyclooxygenase-2 disrupts microRNA (miR-542-3p)-mediated regulation. +genetics_GWAS hsa-mir-637 Hypertension 21846868 ATP6V0A1 Polymorphism and MicroRNA-637 may have A Pathogenetic Role for MicroRNAs in Essential Hypertension. +genetics_GWAS hsa-mir-146a "Carcinoma, Lung, Non-Small-Cell" 21902575 CG genotype of miR-146a(rs2910164 C-G) appeared associated to an increased risk for NSCLC (p=0.042 and 1.77 OR). +genetics_GWAS hsa-mir-146b "Carcinoma, Lung, Non-Small-Cell" 21902575 CG genotype of miR-146a(rs2910164 C-G) appeared associated to an increased risk for NSCLC (p=0.042 and 1.77 OR). +genetics_GWAS hsa-mir-196a-2 "Carcinoma, Lung, Non-Small-Cell" 21902575 "The authors clearly detected a significant increase (p<0.001) of miR-196a2 expression in NSCLC. In particular the authors found a significant association between miR-196a2 (rs11614913 C-T) CC genotype and high expression, whereas TT genotype showed a very low expression in comparison to both CT (p<0.005) and CC patients (p<0.01)." +genetics_GWAS hsa-mir-137 Schizophrenia 21926974 "GWAS analysis revealed that rs1625579 within an intron of a putative primary transcript for MIR137 (microRNA 137), a known regulator of neuronal development was associated with schizophrenia." +genetics_GWAS hsa-mir-184 "Squamous Cell Carcinoma, Head and Neck" 21934093 "The authors found that, compared with the rs8126 TT (a SNP of miR-184 Binding Site in TNFAIP2) genotype, the variant C allele were associated with increased SCCHN risk in an allele-dose response manner (adjusted odds ratio=1.48 and 95% confidence interval=1.06-2.05 for CC, respectively; P(trend)=0.009)." +genetics_GWAS hsa-mir-149 Gastric Neoplasms 21976437 "Marginally significant associations were found both for hsa-miR-149 rs2292832 with gastric cancer risk (TC+CC vs. TT, OR=0.68, 95% CI: 0.44-1.04) and for hsa-miR-605 rs2043556 with colorectal cancer risk (AG+GG vs. AA, OR=0.70, 95% CI: 0.48-1.02) in males." +genetics_GWAS hsa-mir-605 Gastric Neoplasms 21976437 "Marginally significant associations were found both for hsa-miR-149 rs2292832 with gastric cancer risk (TC+CC vs. TT, OR=0.68, 95% CI: 0.44-1.04) and for hsa-miR-605 rs2043556 with colorectal cancer risk (AG+GG vs. AA, OR=0.70, 95% CI: 0.48-1.02) in males." +genetics_GWAS hsa-mir-146a Thyroid Neoplasms 21978540 "Despite some limitations, this meta-analysis suggests that the miR-146a G allele is a low-penetrant risk factor for papillary thyroid carcinoma development." +genetics_GWAS hsa-mir-218-1 "Carcinoma, Hepatocellular" 22011248 "The AG genotype of pri-miR-218 rs11134527 A/G was associated with family history (p=0.018, odds ratio [OR]=2.96, 95% confidence interval [CI]: 1.16-7.56) and elevated serum alpha-fetoprotein (serum alpha-fetoprotein [AFP]) levels (¡Ý20 ng/mL; p=0.009, OR=1.92, 95% CI: 1.17-3.14) in HCC patients. These findings suggested that the AG genotype of pri-miR-218 rs11134527 might relate to genetic predisposition and be involved in regulating the expression of AFP in Chinese HCC patients." +genetics_GWAS hsa-mir-218-2 "Carcinoma, Hepatocellular" 22011248 "The AG genotype of pri-miR-218 rs11134527 A/G was associated with family history (p=0.018, odds ratio [OR]=2.96, 95% confidence interval [CI]: 1.16-7.56) and elevated serum alpha-fetoprotein (serum alpha-fetoprotein [AFP]) levels (¡Ý20 ng/mL; p=0.009, OR=1.92, 95% CI: 1.17-3.14) in HCC patients. These findings suggested that the AG genotype of pri-miR-218 rs11134527 might relate to genetic predisposition and be involved in regulating the expression of AFP in Chinese HCC patients." +genetics_GWAS hsa-mir-499a Rheumatoid Arthritis 22019503 "There was a significant difference in the levels of CRP and ESR among different genotypes in rs3746444 (hsa-mir-499) (p = 0.031 and p = 0.047, respectively) in Chinese Han people. The heterozygote CT had significantly higher levels of CRP and ESR compared with homozygotes CC and TT." +genetics_GWAS hsa-mir-423 Colorectal Carcinoma 22028396 "Two SNPs were identified to be significantly associated with recurrence-free survival and overall survival of the patients. The most significant SNP was rs6505162 in pre-miR-423. Compared to the homozygous wild-type genotype, the variant-containing genotypes of this SNP were significantly associated with both the overall survival (HR=2.12, 95% CI1.34--3.34, P=0.001) and the recurrence-free survival (HR=1.59, 95% CI1.08--2.36, P=0.019). Another SNP, rs4919510 in pre-miR-608, was also associated with altered recurrence-free survival (HR=0.61, 95% CI 0.41-0.92, P=0.017). These effects were evident only in patients receiving chemotherapy but not in those without chemotherapy. In addition, the combined analysis of the two SNPs conferred a 2.84-fold (95% CI 1.50-5.37, P=0.001) increased risk of recurrence and/or death. Similarly, this effect was only prominent in those receiving chemotherapy (P<0.001) but not in those without chemotherapy (P=0.999)." +genetics_GWAS hsa-mir-608 Colorectal Carcinoma 22028396 "Two SNPs were identified to be significantly associated with recurrence-free survival and overall survival of the patients. The most significant SNP was rs6505162 in pre-miR-423. Compared to the homozygous wild-type genotype, the variant-containing genotypes of this SNP were significantly associated with both the overall survival (HR=2.12, 95% CI1.34--3.34, P=0.001) and the recurrence-free survival (HR=1.59, 95% CI1.08--2.36, P=0.019). Another SNP, rs4919510 in pre-miR-608, was also associated with altered recurrence-free survival (HR=0.61, 95% CI 0.41-0.92, P=0.017). These effects were evident only in patients receiving chemotherapy but not in those without chemotherapy. In addition, the combined analysis of the two SNPs conferred a 2.84-fold (95% CI 1.50-5.37, P=0.001) increased risk of recurrence and/or death. Similarly, this effect was only prominent in those receiving chemotherapy (P<0.001) but not in those without chemotherapy (P=0.999)." +genetics_GWAS hsa-mir-196a-2 Breast Neoplasms 22074121 "The Chinese women with menarche age less than 16 years had increased breast cancer risk (OR = 2.10, 95% CI: 1.23-3.60). Marginally significant association between rs11614913 (hsa-miR-196a-2) CT/CC genotypes and reduced breast cancer risk was observed (OR = 0.65, 95% CI: 0.40-1.06)," +genetics_GWAS hsa-mir-502 "Carcinoma, Hepatocellular" 22095217 "We analysed a single nucleotide polymorphism (rs16917496) within the miR-502 microRNA seed region for the 3' UTR of SET8 in Chinese hepatocellular carcinoma (HCC) patients. The SET8 CC genotype was independently associated with longer post-operative survival in HCC patients by multivariate analysis (relative risk, 0.175; 95% CI, 0.053 - 0.577; p = 0.004). The SET8 CC genotype was associated with reduced SET8 protein levels based on the immunostaining of 51 HCC tissue samples. We also found the low SET8 levels was associated with longer HCC survival. Our data suggest that SET8 modifies HCC outcome by altering its expression, which depends, at least in part, on its binding affinity with miR502." +genetics_GWAS hsa-mir-30c-1 Gastric Neoplasms 22108846 "The genotype frequencies of pre-miR-30c A/G (Polymorphism rs928508 in pre-miR-30c) in gastric cancer patients were obviously different from those in the controls (P = 0.022). AA genotype carriers were associated with an increased risk of gastric cancer compared with GG genotype (adjusted odds ratio (OR) = 1.83, 95% confidence interval (CI): 1.07-3.15, P = 0.029). Moreover, the gastric cancer risk especially elevated in older individuals (aged >60 years), males, nonsmokers, and Helicobacter pylori (H. pylori)-infected individuals (adjusted OR = 2.66, 95% CI: 1.38-5.13, P = 0.004; adjusted OR = 1.90, 95% CI: 1.10-3.27, P = 0.022; adjusted OR = 1.94, 95% CI: 1.12-3.35, P = 0.018; adjusted OR = 1.83, 95% CI: 1.08-3.10, P = 0.024, respectively). Further stratified analysis indicated that AA genotype facilitated developing of gastric cancer with lymph node metastasis (adjusted OR = 2.23, 95% CI: 1.07-4.64, P = 0.032). Expression analysis detected that rs928508 AA showed a significantly increased level of mature miR-30c compared with GG or AG/GG genotype (P = 0.011 or P = 0.013). Patients with AA genotype were associated with unfavorable outcome in overall survival compared with AG/GG genotype (Log rank 5.848, P = 0.016). This study demonstrates that pre-miR-30c A/G polymorphism may be associated with an increased risk of gastric cancer in a Chinese population through altering mature miR-30c expression." +genetics_GWAS hsa-mir-30c-2 Gastric Neoplasms 22108846 "The genotype frequencies of pre-miR-30c A/G (Polymorphism rs928508 in pre-miR-30c) in gastric cancer patients were obviously different from those in the controls (P = 0.022). AA genotype carriers were associated with an increased risk of gastric cancer compared with GG genotype (adjusted odds ratio (OR) = 1.83, 95% confidence interval (CI): 1.07-3.15, P = 0.029). Moreover, the gastric cancer risk especially elevated in older individuals (aged >60 years), males, nonsmokers, and Helicobacter pylori (H. pylori)-infected individuals (adjusted OR = 2.66, 95% CI: 1.38-5.13, P = 0.004; adjusted OR = 1.90, 95% CI: 1.10-3.27, P = 0.022; adjusted OR = 1.94, 95% CI: 1.12-3.35, P = 0.018; adjusted OR = 1.83, 95% CI: 1.08-3.10, P = 0.024, respectively). Further stratified analysis indicated that AA genotype facilitated developing of gastric cancer with lymph node metastasis (adjusted OR = 2.23, 95% CI: 1.07-4.64, P = 0.032). Expression analysis detected that rs928508 AA showed a significantly increased level of mature miR-30c compared with GG or AG/GG genotype (P = 0.011 or P = 0.013). Patients with AA genotype were associated with unfavorable outcome in overall survival compared with AG/GG genotype (Log rank 5.848, P = 0.016). This study demonstrates that pre-miR-30c A/G polymorphism may be associated with an increased risk of gastric cancer in a Chinese population through altering mature miR-30c expression." +genetics_GWAS hsa-mir-629 Lung Neoplasms 22114071 "The rs2735383CC (NBS1 gene) genotype had a significantly increased risk of lung cancer under a recessive genetic model in the total 1559 cases versus 1679 controls (OR = 1.40, 95% C.I. = 1.18-1.66, P = 0.0001) when compared with GG or GC genotypes; the rs2735383CC genotype carriers had lower mRNA and protein expression levels in tumor tissues than those of other genotypes as qPCR and western blot shown. Luciferase assay revealed that the rs2735383C allele had a lower transcription activity than G allele; and the hsa-miR-629 but not hsa-miR-499-5P had effect on modulation of NBS1 gene in vitro. We further observed that the X-ray radiation induced more chromatid breaks in lymphocyte cells from the carriers of rs2735383CC homozygote than those from the subjects with other genotypes (P = 0.0008). Our data suggested that the rs2735383G>C variation contributes to an increased risk of lung cancer by diminishing gene's expression through binding of microRNA-629 to the polymorphic site in the 3'-UTR of NBS1 gene." +genetics_GWAS hsa-mir-196a-2 Coronary Artery Disease 22159951 "The variant genotypes CC/CT of hsa-mir-196a2 rs11614913 T ¡ú C were not associated with a significantly increased risk of CAD (adjusted OR = 1.02, 95% CI = 0.76-1.38), compared with wide genotype TT, but CC and CC/CT genotypes were associated with 34 and 35% increased risks of serious prognosis of CAD (adjusted HR = 1.34, 95% CI = 1.02-1.75 for CC; adjusted HR = 1.35, 95% CI = 1.03-1.75 for CC/CT). In the variant of hsa-mir-499 rs3746444A ¡ú G, GG was associated with the 223% increased risk of CAD (adjusted OR = 3.23, 95% CI = 1.56-6.67). Cox regression analysis showed that age, smoking status, numbers of pathological changes in coronary arteries, rs11614913 T ¡ú C, and diabetes mellitus were associated with serious prognosis of CAD." +genetics_GWAS hsa-mir-499a Coronary Artery Disease 22159951 "The variant genotypes CC/CT of hsa-mir-196a2 rs11614913 T ¡ú C were not associated with a significantly increased risk of CAD (adjusted OR = 1.02, 95% CI = 0.76-1.38), compared with wide genotype TT, but CC and CC/CT genotypes were associated with 34 and 35% increased risks of serious prognosis of CAD (adjusted HR = 1.34, 95% CI = 1.02-1.75 for CC; adjusted HR = 1.35, 95% CI = 1.03-1.75 for CC/CT). In the variant of hsa-mir-499 rs3746444A ¡ú G, GG was associated with the 223% increased risk of CAD (adjusted OR = 3.23, 95% CI = 1.56-6.67). Cox regression analysis showed that age, smoking status, numbers of pathological changes in coronary arteries, rs11614913 T ¡ú C, and diabetes mellitus were associated with serious prognosis of CAD." +genetics_GWAS hsa-mir-196a-2 Colorectal Carcinoma 22161766 The authors found a significantly increased colorectal cancer risk with the miR-196a2CC (rs11614913) genotype compared with the TT/CT genotype (AOR=1.50; 95% CI=1.11-2.04; P=0.01; FDR-P=0.04) in Korean population. +genetics_GWAS hsa-mir-146a "Squamous Cell Carcinoma, Oral" 22182931 "This study identifies that areca nut extract, TNFalpha and TGFbeta up-regulates miR-146a in OSCC cells. The increased expression of miR-146a enhanced the oncogenicity of OSCC cells. In addition, a G to C polymorphism (rs2910164), which is located in the pre-miR-146a and has been associated with functional alterations in miR-146a, was significantly more prevalent among OSCC patients having more advanced nodal involvement. Our analysis also suggested a higher miR-146a expression in OSCC tissues of patients carrying C polymorphism. The present study concluded a higher prevalence of the pre-mir-146a C-variant was associated with OSCC progression in patients with this disease." +genetics_GWAS hsa-mir-570 Gastric Neoplasms 22190470 A guanine-to-cytosine mutation at the 3'-UTR of CD274 mRNA led to CD274 over-expression by disrupting the miR-570 binding. A frequent somatic mutation in CD274 3'-UTR leads to protein over-expression in gastric cancer by disrupting miR-570 binding. +genetics_GWAS hsa-mir-200b Endometrial Neoplasms 22194984 Luciferase assays and Western blot analysis demonstrated that the miR-200b/200c/429 family recognized the MRE in the 3' UTR of AP-2alpha gene and negatively regulated the expression of endogenous AP-2alpha proteins. SNP rs1045385 A>C variation enhanced AP-2alpha. +genetics_GWAS hsa-mir-200c Endometrial Neoplasms 22194984 Luciferase assays and Western blot analysis demonstrated that the miR-200b/200c/429 family recognized the MRE in the 3' UTR of AP-2 alpha gene and negatively regulated the expression of endogenous AP-2 alpha proteins. SNP rs1045385 A>C variation enhanced AP-2 alpha expression. +genetics_GWAS hsa-mir-429 Endometrial Neoplasms 22194984 Luciferase assays and Western blot analysis demonstrated that the miR-200b/200c/429 family recognized the MRE in the 3' UTR of AP-2 alpha gene and negatively regulated the expression of endogenous AP-2 alpha proteins. SNP rs1045385 A>C variation enhanced AP-2 alpha expression. +genetics_GWAS hsa-mir-146a Systemic Lupus Erythematosus 22218224 "The SNP (rs2431697) was associated with the microRNA-146a, where the risk allele correlates with lower expression of the miRNA." +genetics_GWAS hsa-mir-196a-2 Habitual Abortion 22222140 "RSA(recurrent spontaneous abortion) patients exhibited significantly different frequencies of the miR-196a2CC (TT+TC vs. CC; adjusted odds ratio [AOR], 1.587; 95% confidence interval [CI], 1.042-2.417) and miR-499AG+GG genotypes (AOR, 1.671; 95% CI, 1.054-2.651) compared with the control group." +genetics_GWAS hsa-mir-499a Habitual Abortion 22222140 "RSA(recurrent spontaneous abortion) patients exhibited significantly different frequencies of the miR-196a2CC (TT+TC vs. CC; adjusted odds ratio [AOR], 1.587; 95% confidence interval [CI], 1.042-2.417) and miR-499AG+GG genotypes (AOR, 1.671; 95% CI, 1.054-2.651) compared with the control group." +genetics_GWAS hsa-mir-17 Ovarian Neoplasms 22235027 "The most notable cluster is the tumorigenic miR-17-92 cluster with five microRNAs, all of which are significantly associated with rs3814113" +genetics_GWAS hsa-mir-18a Ovarian Neoplasms 22235027 "The most notable cluster is the tumorigenic miR-17-92 cluster with five microRNAs, all of which are significantly associated with rs3814113" +genetics_GWAS hsa-mir-19a Ovarian Neoplasms 22235027 "The most notable cluster is the tumorigenic miR-17-92 cluster with five microRNAs, all of which are significantly associated with rs3814113" +genetics_GWAS hsa-mir-19b-1 Ovarian Neoplasms 22235027 "The most notable cluster is the tumorigenic miR-17-92 cluster with five microRNAs, all of which are significantly associated with rs3814113" +genetics_GWAS hsa-mir-20a Ovarian Neoplasms 22235027 "The most notable cluster is the tumorigenic miR-17-92 cluster with five microRNAs, all of which are significantly associated with rs3814113" +genetics_GWAS hsa-mir-92a-1 Ovarian Neoplasms 22235027 "The most notable cluster is the tumorigenic miR-17-92 cluster with five microRNAs, all of which are significantly associated with rs3814113" +genetics_GWAS hsa-let-7e Crohn Disease 22262659 The rs10889677 variant in the 3'-untranslated region of the IL-23R gene displays enhanced levels of both mRNA and protein production of IL-23R. This can be attributed to a loss of binding capacity for the microRNAs (miRNAs) Let-7e and Let-7f by the variant allele. +genetics_GWAS hsa-let-7f-1 Crohn Disease 22262659 The rs10889677 variant in the 3'-untranslated region of the IL-23R gene displays enhanced levels of both mRNA and protein production of IL-23R. This can be attributed to a loss of binding capacity for the microRNAs (miRNAs) Let-7e and Let-7f by the variant allele. +genetics_GWAS hsa-let-7f-2 Crohn Disease 22262659 The rs10889677 variant in the 3'-untranslated region of the IL-23R gene displays enhanced levels of both mRNA and protein production of IL-23R. This can be attributed to a loss of binding capacity for the microRNAs (miRNAs) Let-7e and Let-7f by the variant allele. +genetics_GWAS hsa-let-7a-1 Endometriosis 22307873 The authors detected a KRAS variant allele in 31% of women with endometriosis as opposed to 5% of a large diverse control population. +genetics_GWAS hsa-let-7a-2 Endometriosis 22307873 The authors detected a KRAS variant allele in 31% of women with endometriosis as opposed to 5% of a large diverse control population. +genetics_GWAS hsa-let-7a-3 Endometriosis 22307873 The authors detected a KRAS variant allele in 31% of women with endometriosis as opposed to 5% of a large diverse control population. +genetics_GWAS hsa-let-7b Endometriosis 22307873 The authors detected a KRAS variant allele in 31% of women with endometriosis as opposed to 5% of a large diverse control population. +genetics_GWAS hsa-let-7c Endometriosis 22307873 The authors detected a KRAS variant allele in 31% of women with endometriosis as opposed to 5% of a large diverse control population. +genetics_GWAS hsa-let-7d Endometriosis 22307873 The authors detected a KRAS variant allele in 31% of women with endometriosis as opposed to 5% of a large diverse control population. +genetics_GWAS hsa-let-7e Endometriosis 22307873 The authors detected a KRAS variant allele in 31% of women with endometriosis as opposed to 5% of a large diverse control population. +genetics_GWAS hsa-let-7f-1 Endometriosis 22307873 The authors detected a KRAS variant allele in 31% of women with endometriosis as opposed to 5% of a large diverse control population. +genetics_GWAS hsa-let-7f-2 Endometriosis 22307873 The authors detected a KRAS variant allele in 31% of women with endometriosis as opposed to 5% of a large diverse control population. +genetics_GWAS hsa-let-7g Endometriosis 22307873 The authors detected a KRAS variant allele in 31% of women with endometriosis as opposed to 5% of a large diverse control population. +genetics_GWAS hsa-let-7i Endometriosis 22307873 The authors detected a KRAS variant allele in 31% of women with endometriosis as opposed to 5% of a large diverse control population. +genetics_GWAS hsa-mir-1207 Glomerulonephritis 22319602 "A miR-1207-5p binding site polymorphism (C1936T, rs13385) abolishes regulation of HBEGF and is associated with disease severity in CFHR5 nephropathy." +genetics_GWAS hsa-mir-155 "Lymphoma, Non-Hodgkin" 22347493 "Variant rs928883, near miR-155, showed an association (OR per A-allele: 2.80 [95% CI: 1.63-4.82]; p(F)=0.027) with marginal zone lymphoma that is significant after correction for multiple testing." +genetics_GWAS hsa-mir-1273c Colorectal Carcinoma 22348132 "hsa-mir-1273c, hsa-mir-1303 and hsa-mir-567, with frequent and sometimes bi-allelic mutations in MSI tumors." +genetics_GWAS hsa-mir-1303 Colorectal Carcinoma 22348132 "hsa-mir-1273c, hsa-mir-1303 and hsa-mir-567, with frequent and sometimes bi-allelic mutations in MSI tumors." +genetics_GWAS hsa-mir-567 Colorectal Carcinoma 22348132 "hsa-mir-1273c, hsa-mir-1303 and hsa-mir-567, with frequent and sometimes bi-allelic mutations in MSI tumors." +genetics_GWAS hsa-mir-25 Lung Neoplasms 22349819 REV3L 3'UTR 460 T>C polymorphism in microRNA(miR-25/32) target sites contributes to lung cancer susceptibility. +genetics_GWAS hsa-mir-32 Lung Neoplasms 22349819 REV3L 3'UTR 460 T>C polymorphism in microRNA(miR-25/32) target sites contributes to lung cancer susceptibility. +genetics_GWAS hsa-mir-27a Gastric Neoplasms 22350505 The SNP rs895819 in the miR-27a gene with the minor allele C presented significantly reduced risk to gastric cancer in Chinese population. +genetics_GWAS hsa-mir-146a Breast Neoplasms 22363415 "The authors found that hs-miR-196a2 in premenopausal patients, and hs-miR-499, hs-miR-146a and hs-miR-196a2 in postmenopausal patients, may discriminate breast cancer patients from healthy individuals. In addition, we found a significant association between two microRNA polymorphisms (hs-miR-196a2 and hs-miR-499) and breast cancer risk." +genetics_GWAS hsa-mir-196a-2 Breast Neoplasms 22363415 "The authors found that hs-miR-196a2 in premenopausal patients, and hs-miR-499, hs-miR-146a and hs-miR-196a2 in postmenopausal patients, may discriminate breast cancer patients from healthy individuals. In addition, we found a significant association between two microRNA polymorphisms (hs-miR-196a2 and hs-miR-499) and breast cancer risk." +genetics_GWAS hsa-mir-499a Breast Neoplasms 22363415 "The authors found that hs-miR-196a2 in premenopausal patients, and hs-miR-499, hs-miR-146a and hs-miR-196a2 in postmenopausal patients, may discriminate breast cancer patients from healthy individuals. In addition, we found a significant association between two microRNA polymorphisms (hs-miR-196a2 and hs-miR-499) and breast cancer risk." +genetics_GWAS hsa-mir-146a Breast Neoplasms 22363684 Increased Risk of Breast Cancer Associated with CC Genotype of Has-miR-146a Rs2910164 Polymorphism in Europeans. +genetics_GWAS hsa-mir-499a Heart Failure 22374132 A naturally occurring miR-499 mutation(u17c in the 3' end) outside the critical seed sequence modifies mRNA targeting and end-organ function. +genetics_GWAS hsa-mir-106b "Carcinoma, Hepatocellular" 22393390 "A Genetic Variant (rs999885) in the Promoter Region of miR-106b-25 Cluster and Risk of HBV Infection and Hepatocellular Carcinoma.Compared with the HBV natural clearance subjects carrying rs999885 AA genotype, those with AG/GG genotypes had a decreased risk of chronic HBV infection with an adjusted odds ratio (OR) of 0.79 [95% confidence intervals (CIs)=0.67-0.93]. However, the AG/GG genotypes were significantly associated with an increased HCC risk in HBV persistent carriers (adjusted OR=1.25, 95% CIs=1.06-1.47). Expression analysis revealed that the expression level of miR-106b-25 cluster was significantly higher in AG/GG carriers than those in AA carriers in non-tumor liver tissues." +genetics_GWAS hsa-mir-106b Hepatitis B Virus Infection 22393390 "A Genetic Variant (rs999885) in the Promoter Region of miR-106b-25 Cluster and Risk of HBV Infection and Hepatocellular Carcinoma.Compared with the HBV natural clearance subjects carrying rs999885 AA genotype, those with AG/GG genotypes had a decreased risk of chronic HBV infection with an adjusted odds ratio (OR) of 0.79 [95% confidence intervals (CIs)=0.67-0.93]. However, the AG/GG genotypes were significantly associated with an increased HCC risk in HBV persistent carriers (adjusted OR=1.25, 95% CIs=1.06-1.47). Expression analysis revealed that the expression level of miR-106b-25 cluster was significantly higher in AG/GG carriers than those in AA carriers in non-tumor liver tissues." +genetics_GWAS hsa-mir-25 "Carcinoma, Hepatocellular" 22393390 "A Genetic Variant (rs999885) in the Promoter Region of miR-106b-25 Cluster and Risk of HBV Infection and Hepatocellular Carcinoma.Compared with the HBV natural clearance subjects carrying rs999885 AA genotype, those with AG/GG genotypes had a decreased risk of chronic HBV infection with an adjusted odds ratio (OR) of 0.79 [95% confidence intervals (CIs)=0.67-0.93]. However, the AG/GG genotypes were significantly associated with an increased HCC risk in HBV persistent carriers (adjusted OR=1.25, 95% CIs=1.06-1.47). Expression analysis revealed that the expression level of miR-106b-25 cluster was significantly higher in AG/GG carriers than those in AA carriers in non-tumor liver tissues." +genetics_GWAS hsa-mir-25 Hepatitis B Virus Infection 22393390 "A Genetic Variant (rs999885) in the Promoter Region of miR-106b-25 Cluster and Risk of HBV Infection and Hepatocellular Carcinoma.Compared with the HBV natural clearance subjects carrying rs999885 AA genotype, those with AG/GG genotypes had a decreased risk of chronic HBV infection with an adjusted odds ratio (OR) of 0.79 [95% confidence intervals (CIs)=0.67-0.93]. However, the AG/GG genotypes were significantly associated with an increased HCC risk in HBV persistent carriers (adjusted OR=1.25, 95% CIs=1.06-1.47). Expression analysis revealed that the expression level of miR-106b-25 cluster was significantly higher in AG/GG carriers than those in AA carriers in non-tumor liver tissues." +genetics_GWAS hsa-mir-325 Dyspepsia 22438098 "Genetic polymorphism ( rs5981521 (C>T)) of pri-microRNA 325, targeting SLC6A4 3'-UTR, is closely associated with the risk of functional dyspepsia in Japan." +genetics_GWAS hsa-mir-146a Gastric Neoplasms 22455393 A Functional Polymorphism (rs2910164) in Pre-miR-146a Is Associated with Susceptibility to Gastric Cancer in a Chinese Population. +genetics_GWAS hsa-mir-938 Gastric Neoplasms 22537748 "Genetic polymorphisms of IL17A ((rs2275913 (-197 G > A), rs3748067 (*1249 C > T)) and pri-microRNA-938 (pri-miR-938, rs2505901 (T > C).), targeting IL17A 3'-UTR, influence susceptibility to gastric cancer." +genetics_GWAS hsa-mir-520a Colorectal Carcinoma 22553375 A 3' untranslated region (UTR) mutation was also shown to be associated with increased sensitivity to saracatinib and have a reduced affinity for miR-520a and miR-525a. +genetics_GWAS hsa-mir-608 Breast Neoplasms 22586447 Polymorphism rs4919510:C>G in mature sequence of human microRNA-608 contributes to the risk of HER2-positive breast cancer but not other subtypes. +genetics_GWAS hsa-mir-423 Breast Neoplasms 22593246 A genetic variant (rs6505162:A>C) located in miR-423 is associated with reduced breast cancer risk. +genetics_GWAS hsa-mir-608 Colorectal Carcinoma 22606253 rs4919510 in hsa-mir-608 is associated with outcome but not risk of colorectal cancer. +genetics_GWAS hsa-mir-146a Moyamoya Disease 22659075 "Association of the miR-146aC>G, miR-196a2C>T, and miR-499A>G polymorphisms with moyamoya disease in the Korean population." +genetics_GWAS hsa-mir-196a-2 Moyamoya Disease 22659075 "Association of the miR-146aC>G, miR-196a2C>T, and miR-499A>G polymorphisms with moyamoya disease in the Korean population." +genetics_GWAS hsa-mir-219-1 Colorectal Carcinoma 22661538 "The mir219-1:rs213210 showed consistent association with death in the training set, the replication set, and combined data set" +genetics_GWAS hsa-mir-608 Colorectal Carcinoma 22661538 "In patients with stage III disease, mir608: rs4919510 was associated with increased risk for both recurrence and death." +genetics_GWAS hsa-mir-146a Nasopharyngeal Neoplasms 22711332 A single nucleotide polymorphism (rs2910164) in microRNA-146a is associated with the risk for nasopharyngeal carcinoma. +genetics_GWAS hsa-mir-182 Melanoma 22752337 Up-regulation of miR-182 expression after epigenetic modulation of human melanoma cells. +genetics_GWAS hsa-mir-499a "Squamous Cell Carcinoma, Oral" 22761899 "This study determined that a significant association of miRNA499 with CC genotype, as compared to the subjects with TT genotype, had a higher risk of oral squamous cell carcinoma." +genetics_GWAS hsa-mir-499b "Squamous Cell Carcinoma, Oral" 22761899 "This study determined that a significant association of miRNA499 with CC genotype, as compared to the subjects with TT genotype, had a higher risk of oral squamous cell carcinoma." +genetics_GWAS hsa-mir-7-1 Urinary Bladder Cancer 22768238 A microRNA-7 binding site polymorphism (1010A/G) in HOXB5 leads to differential gene expression in bladder cancer. +genetics_GWAS hsa-mir-7-2 Urinary Bladder Cancer 22768238 A microRNA-7 binding site polymorphism (1010A/G) in HOXB5 leads to differential gene expression in bladder cancer. +genetics_GWAS hsa-mir-7-3 Urinary Bladder Cancer 22768238 A microRNA-7 binding site polymorphism (1010A/G) in HOXB5 leads to differential gene expression in bladder cancer. +genetics_GWAS hsa-mir-146a Lung Neoplasms 22818121 Our findings suggest that polymorphisms in the rs2910164 of miR-146a and the rs11614913 of miR-196a2 are associated with prognosis in patients with completely resected NSCLC. +genetics_GWAS hsa-mir-196a Lung Neoplasms 22818121 Our findings suggest that polymorphisms in the rs2910164 of miR-146a and the rs11614913 of miR-196a2 are associated with prognosis in patients with completely resected NSCLC. +genetics_GWAS hsa-mir-146a Asthma 22823586 MiR-146a polymorphism is associated with asthma but not with systemic lupus erythematosus and juvenile rheumatoid arthritis in Mexican patients. +genetics_GWAS hsa-mir-1231 "Carcinoma, Hepatocellular" 22824466 A miR-1231 binding site polymorphism (rs17875871) in the 3'UTR of IFNAR1 is associated with hepatocellular carcinoma susceptibility. +genetics_GWAS hsa-mir-125b-1 "Leukemia, Myeloid, Acute" 22843432 MicroRNA-125b-1 accelerates a C-terminal mutant of C/EBP¦Á (C/EBP¦Á-C(m))-induced myeloid leukemia. +genetics_GWAS hsa-mir-34b Intracranial Aneurysm 22844323 "The CC genotype of miR-34b/c rs4938723 was significantly associated with a decreased risk of IA compared with the TT genotype. Moreover, a significant gene interaction of the carriers with the combined genotypes of miR-34b/c rs4938723CC and TP53 Arg72Pro CG/CC/GG had a decreased risk of IA, compared with those carrying miR-34b/c rs4938723CT/TT+TP53 Arg72Pro GG/CG/CC combined genotypes." +genetics_GWAS hsa-mir-34c Intracranial Aneurysm 22844323 "The CC genotype of miR-34b/c rs4938723 was significantly associated with a decreased risk of IA compared with the TT genotype. Moreover, a significant gene interaction of the carriers with the combined genotypes of miR-34b/c rs4938723CC and TP53 Arg72Pro CG/CC/GG had a decreased risk of IA, compared with those carrying miR-34b/c rs4938723CT/TT+TP53 Arg72Pro GG/CG/CC combined genotypes." +genetics_GWAS hsa-mir-146a Urinary Bladder Cancer 22846912 miR-146a rs2910164 C allele inhibited cell proliferation and significantly downregulates expression of IRAK1 and TRAF6 in bladder cancer cells. +genetics_GWAS hsa-mir-196a-1 Esophageal Neoplasms 22859270 MiR-196a binding-site SNP (rs6573) regulates RAP1A expression contributing to esophageal squamous cell carcinoma risk and metastasis. +genetics_GWAS hsa-mir-196a-2 Esophageal Neoplasms 22859270 MiR-196a binding-site SNP (rs6573) regulates RAP1A expression contributing to esophageal squamous cell carcinoma risk and metastasis. +genetics_GWAS hsa-mir-502 Ovarian Neoplasms 22867998 A polymorphism (rs16917496) at the miR-502 binding site in the 3' untranslated region of the SET8 gene is associated with the risk of epithelial ovarian cancer. +genetics_GWAS hsa-let-7a-2 Ovarian Neoplasms 22970210 "We found that there was a reduction in the copy number of let-7 genes in a cancer-type specific manner. Importantly, focal deletion of four let-7 family members was found in three cancer types: medulloblastoma (let-7a-2 and let-7e), breast cancer (let-7a-2), and ovarian cancer (let-7a-3/let-7b)." +genetics_GWAS hsa-let-7e Ovarian Neoplasms 22970210 "We found that there was a reduction in the copy number of let-7 genes in a cancer-type specific manner. Importantly, focal deletion of four let-7 family members was found in three cancer types: medulloblastoma (let-7a-2 and let-7e), breast cancer (let-7a-2), and ovarian cancer (let-7a-3/let-7b)." +genetics_GWAS hsa-mir-499 Breast Neoplasms 23053947 "In conclusion, this meta-analysis suggests that the miR-499 rs3746444 polymorphism (A>G) is a low-penetrant risk factor for cancer development among Asians and may contribute to breast cancer susceptibility." +genetics_GWAS hsa-mir-337 "Leukemia, Myeloid, Acute" 23065518 A polymorphism in the 3'-untranslated region of the NPM1 gene causes illegitimate regulation by microRNA-337-5p and correlates with adverse outcome in acute myeloid leukemia +genetics_GWAS hsa-mir-200c Gastric Neoplasms 23065816 G-A variant in miR-200c binding site of EFNA1 alters susceptibility to gastric cancer +genetics_GWAS hsa-mir-370 "Leukemia, Myeloid, Acute" 23077663 Integration of SNP and mRNA arrays with microRNA profiling reveals that MiR-370 is upregulated and targets NF1 in acute myeloid leukemia +genetics_GWAS hsa-mir-27a "Carcinoma, Renal Cell" 23118855 A genetic variant in pre-miR-27a is associated with a reduced renal cell cancer risk in a Chinese population +genetics_GWAS hsa-mir-196a-1 Lung Neoplasms 23143626 Hsa-miR-196a2 functional SNP is associated with severe toxicity after platinum-based chemotherapy of advanced nonsmall cell lung cancer patients in a Chinese population +genetics_GWAS hsa-mir-196a-2 Lung Neoplasms 23143626 Hsa-miR-196a2 functional SNP is associated with severe toxicity after platinum-based chemotherapy of advanced nonsmall cell lung cancer patients in a Chinese population +genetics_GWAS hsa-mir-30c-1 Lung Neoplasms 23159078 Single nucleotide polymorphism in flanking region of miR-30c influences the maturing process of miR-30c in lung carcinoma +genetics_GWAS hsa-mir-30c-2 Lung Neoplasms 23159078 Single nucleotide polymorphism in flanking region of miR-30c influences the maturing process of miR-30c in lung carcinoma +genetics_GWAS hsa-mir-146a Acute Cerebral Infarction 23202363 "Association of the miR-146a, miR-149, miR-196a2, and miR-499 Polymorphisms With Ischemic Stroke and Silent Brain Infarction Risk" +genetics_GWAS hsa-mir-149 Acute Cerebral Infarction 23202363 "Association of the miR-146a, miR-149, miR-196a2, and miR-499 Polymorphisms With Ischemic Stroke and Silent Brain Infarction Risk" +genetics_GWAS hsa-mir-196a-1 Acute Cerebral Infarction 23202363 "Association of the miR-146a, miR-149, miR-196a2, and miR-499 Polymorphisms With Ischemic Stroke and Silent Brain Infarction Risk" +genetics_GWAS hsa-mir-196a-2 Acute Cerebral Infarction 23202363 "Association of the miR-146a, miR-149, miR-196a2, and miR-499 Polymorphisms With Ischemic Stroke and Silent Brain Infarction Risk" +genetics_GWAS hsa-mir-146a Melanoma 23222547 The rs2910164 G>C polymorphism in microRNA-146a is associated with the incidence of malignant melanoma +genetics_GWAS hsa-mir-196a-1 Breast Neoplasms 23228090 Evaluation of single nucleotide polymorphisms in microRNAs (hsa-miR-196a2 rs11614913 C/T) from Brazilian women with breast cancer +genetics_GWAS hsa-mir-196a-2 Breast Neoplasms 23228090 Evaluation of single nucleotide polymorphisms in microRNAs (hsa-miR-196a2 rs11614913 C/T) from Brazilian women with breast cancer +genetics_GWAS hsa-mir-27a Gastric Neoplasms 23246964 Genetic variations in miR-27a gene decrease mature miR-27a level and reduce gastric cancer susceptibility +genetics_GWAS hsa-mir-146a Behcet Disease 23268366 MicroRNA-146a and Ets-1 gene polymorphisms in ocular Behcet's disease and Vogt-Koyanagi-Harada syndrome +genetics_GWAS hsa-mir-885 Head And Neck Neoplasms 23271051 A functional variant at the miR-885-5p binding site of CASP3 confers risk of both index and second primary malignancies in patients with head and neck cancer +genetics_GWAS hsa-mir-149 "Squamous Cell Carcinoma, Head and Neck" 23272122 The Association between Genetic Polymorphism and the Processing Efficiency of miR-149 Affects the Prognosis of Patients with Head and Neck Squamous Cell Carcinoma +genetics_GWAS hsa-mir-146a Hepatitis B Virus Infection 23292505 Association of a single-nucleotide polymorphism within the miR-146a gene with susceptibility for acute-on-chronic hepatitis B liver failure +genetics_GWAS hsa-mir-146a Colorectal Carcinoma 23306950 A genetic variant in miR-146a modifies colorectal cancer susceptibility in a chinese population +genetics_GWAS hsa-mir-218-1 Urinary Bladder Cancer 23320911 The pri-miR-218 rs11134527 SNP was significantly associated with the risk of cervical carcinoma in Eastern Chinese women +genetics_GWAS hsa-mir-218-2 Urinary Bladder Cancer 23320911 The pri-miR-218 rs11134527 SNP was significantly associated with the risk of cervical carcinoma in Eastern Chinese women +genetics_GWAS hsa-mir-520a Endometriosis 23364396 A microRNA-520 mirSNP at the MMP2 gene influences susceptibility to endometriosis in Chinese women +genetics_GWAS hsa-mir-520b Endometriosis 23364396 A microRNA-520 mirSNP at the MMP2 gene influences susceptibility to endometriosis in Chinese women +genetics_GWAS hsa-mir-520c Endometriosis 23364396 A microRNA-520 mirSNP at the MMP2 gene influences susceptibility to endometriosis in Chinese women +genetics_GWAS hsa-mir-520d Endometriosis 23364396 A microRNA-520 mirSNP at the MMP2 gene influences susceptibility to endometriosis in Chinese women +genetics_GWAS hsa-mir-520e Endometriosis 23364396 A microRNA-520 mirSNP at the MMP2 gene influences susceptibility to endometriosis in Chinese women +genetics_GWAS hsa-mir-520f Endometriosis 23364396 A microRNA-520 mirSNP at the MMP2 gene influences susceptibility to endometriosis in Chinese women +genetics_GWAS hsa-mir-520g Endometriosis 23364396 A microRNA-520 mirSNP at the MMP2 gene influences susceptibility to endometriosis in Chinese women +genetics_GWAS hsa-mir-520h Endometriosis 23364396 A microRNA-520 mirSNP at the MMP2 gene influences susceptibility to endometriosis in Chinese women +genetics_GWAS hsa-mir-22 Heart Failure 23372812 Common variation neighbouring micro-RNA 22 is associated with increased left ventricular mass. +genetics_GWAS hsa-mir-367 Colorectal Carcinoma 23393343 the functional variant (rs1044129) in the miR-367 binding site of RYR3 may be a potential marker for prognosis in patients following curative surgery for CRC +genetics_GWAS hsa-mir-151a Nasopharyngeal Neoplasms 23416081 A miR-151 binding site polymorphism in the 3'-untranslated region of the cyclin E1 gene associated with nasopharyngeal carcinoma +genetics_GWAS hsa-mir-151b Nasopharyngeal Neoplasms 23416081 A miR-151 binding site polymorphism in the 3'-untranslated region of the cyclin E1 gene associated with nasopharyngeal carcinoma +genetics_GWAS hsa-mir-125a Breast Neoplasms 23420759 rs12976445 variant in the pri-miR-125a correlates with a lower level of hsa-miR-125a and ERBB2 overexpression in breast cancer patients +genetics_GWAS hsa-mir-196a-2 Vitiligo 23433405 A Single Nucleotide Polymorphism of miR-196a-2 and Vitiligo: An Association Study and Functional Analysis in a Han Chinese Population +genetics_GWAS hsa-mir-146a Thyroid Neoplasms 23451063 Association between the rs2910164 Polymorphism in Pre-Mir-146a Sequence and Thyroid Carcinogenesis +genetics_GWAS hsa-mir-34b Nasopharyngeal Neoplasms 23504554 Interactions of miR-34b/c and TP-53 polymorphisms on the risk of nasopharyngeal carcinoma +genetics_GWAS hsa-mir-34c Nasopharyngeal Neoplasms 23504554 Interactions of miR-34b/c and TP-53 polymorphisms on the risk of nasopharyngeal carcinoma +genetics_GWAS hsa-mir-196a-1 Hepatitis B Virus Infection 23516510 Associations of pri-miR-34b/c and pre-miR-196a2 Polymorphisms and Their Multiplicative Interactions with Hepatitis B Virus Mutations with Hepatocellular Carcinoma Risk +genetics_GWAS hsa-mir-196a-2 Hepatitis B Virus Infection 23516510 Associations of pri-miR-34b/c and pre-miR-196a2 Polymorphisms and Their Multiplicative Interactions with Hepatitis B Virus Mutations with Hepatocellular Carcinoma Risk +genetics_GWAS hsa-mir-34b Hepatitis B Virus Infection 23516510 Associations of pri-miR-34b/c and pre-miR-196a2 Polymorphisms and Their Multiplicative Interactions with Hepatitis B Virus Mutations with Hepatocellular Carcinoma Risk +genetics_GWAS hsa-mir-34c Hepatitis B Virus Infection 23516510 Associations of pri-miR-34b/c and pre-miR-196a2 Polymorphisms and Their Multiplicative Interactions with Hepatitis B Virus Mutations with Hepatocellular Carcinoma Risk +genetics_GWAS hsa-mir-196a Neoplasms [unspecific] 23691458 "The meta-analysis demonstrated that the miR-196a-2 polymorphism is associated with cancer susceptibility, especially lung cancer, colorectal cancer, and breast cancer among Asian populations." +genetics_GWAS hsa-mir-184 Gastric Neoplasms 23724109 The miR-184 Binding-Site rs8126 T>C Polymorphism in TNFAIP2 Is Associated with Risk of Gastric Cancer. +genetics_GWAS hsa-mir-137 Psychiatric Disorders 23786914 Analysis of miR-137 expression and rs1625579 in dorsolateral prefrontal cortex. +genetics_GWAS hsa-mir-196a-2 "Carcinoma, Hepatocellular" 23791656 Three common functional polymorphisms in microRNA encoding genes in the susceptibility to hepatocellular carcinoma: a systematic review and meta-analysis. +genetics_GWAS hsa-mir-499 "Carcinoma, Hepatocellular" 23791656 Three common functional polymorphisms in microRNA encoding genes in the susceptibility to hepatocellular carcinoma: a systematic review and meta-analysis. +genetics_GWAS hsa-mir-146a "Squamous Cell Carcinoma, Esophageal" 23792053 "These findings indicated that functional polymorphism miR-196a2 rs11614913 T > C might contribute to decreased ESCC risk among women patients and patients who never smoking or drinking. However, our results were obtained with a limited sample size. Future larger studies with other ethnic populations and tissue-specific biological characterization are required to confirm current findings." +genetics_GWAS hsa-mir-196a-2 "Squamous Cell Carcinoma, Esophageal" 23792053 "These findings indicated that functional polymorphism miR-196a2 rs11614913 T > C might contribute to decreased ESCC risk among women patients and patients who never smoking or drinking. However, our results were obtained with a limited sample size. Future larger studies with other ethnic populations and tissue-specific biological characterization are required to confirm current findings." +genetics_GWAS hsa-mir-26a-1 "Squamous Cell Carcinoma, Esophageal" 23792053 "These findings indicated that functional polymorphism miR-196a2 rs11614913 T > C might contribute to decreased ESCC risk among women patients and patients who never smoking or drinking. However, our results were obtained with a limited sample size. Future larger studies with other ethnic populations and tissue-specific biological characterization are required to confirm current findings." +genetics_GWAS hsa-mir-27a "Squamous Cell Carcinoma, Esophageal" 23792053 "These findings indicated that functional polymorphism miR-196a2 rs11614913 T > C might contribute to decreased ESCC risk among women patients and patients who never smoking or drinking. However, our results were obtained with a limited sample size. Future larger studies with other ethnic populations and tissue-specific biological characterization are required to confirm current findings." +genetics_GWAS hsa-mir-499 "Squamous Cell Carcinoma, Esophageal" 23792053 "These findings indicated that functional polymorphism miR-196a2 rs11614913 T > C might contribute to decreased ESCC risk among women patients and patients who never smoking or drinking. However, our results were obtained with a limited sample size. Future larger studies with other ethnic populations and tissue-specific biological characterization are required to confirm current findings." +genetics_GWAS hsa-mir-146a Coronary Artery Disease 23794009 "miR-146a polymorphism influences levels of miR-146a, IRAK-1, and TRAF-6 in young patients with coronary artery disease." +genetics_GWAS hsa-mir-608 "Carcinoma, Nasopharyngeal" 23796562 A sequence polymorphism in miR-608 predicts recurrence after radiotherapy for nasopharyngeal carcinoma. +genetics_GWAS hsa-mir-124 Hepatitis B Virus Infection 23807362 Association between microRNA polymorphisms and humoral immunity to hepatitis B vaccine. +genetics_GWAS hsa-mir-146a Hepatitis B Virus Infection 23807362 Association between microRNA polymorphisms and humoral immunity to hepatitis B vaccine. +genetics_GWAS hsa-mir-149 Hepatitis B Virus Infection 23807362 Association between microRNA polymorphisms and humoral immunity to hepatitis B vaccine. +genetics_GWAS hsa-mir-196a-2 Hepatitis B Virus Infection 23807362 Association between microRNA polymorphisms and humoral immunity to hepatitis B vaccine. +genetics_GWAS hsa-mir-26a-1 Hepatitis B Virus Infection 23807362 Association between microRNA polymorphisms and humoral immunity to hepatitis B vaccine. +genetics_GWAS hsa-mir-27a Hepatitis B Virus Infection 23807362 Association between microRNA polymorphisms and humoral immunity to hepatitis B vaccine. +genetics_GWAS hsa-mir-146 Colorectal Carcinoma 23898084 "The current study provides evidence that the miR-146a rs2690164 polymorphism, as the dominant model of the G allele, is associated with the susceptibility and prognosis of CRC." +genetics_GWAS hsa-mir-182 Hyperactivity Disorder 23906647 Evaluation of single nucleotide polymorphisms in the miR-183-96-182 cluster in adulthood attention-deficit and hyperactivity disorder (ADHD) and substance use disorders (SUDs). +genetics_GWAS hsa-mir-183 Hyperactivity Disorder 23906647 Evaluation of single nucleotide polymorphisms in the miR-183-96-182 cluster in adulthood attention-deficit and hyperactivity disorder (ADHD) and substance use disorders (SUDs). +genetics_GWAS hsa-mir-96 Hyperactivity Disorder 23906647 Evaluation of single nucleotide polymorphisms in the miR-183-96-182 cluster in adulthood attention-deficit and hyperactivity disorder (ADHD) and substance use disorders (SUDs). +genetics_GWAS hsa-mir-34b "Carcinoma, Hepatocellular" 23935875 Lack of association of MiR-34b/c polymorphism (rs4938723) with hepatocellular carcinoma: a meta-analysis. +genetics_GWAS hsa-mir-31 Hypertension 23943853 Human angiotensinogen +11525 C/A polymorphism modulates its gene expression through microRNA binding. +genetics_GWAS hsa-mir-584 Hypertension 23943853 Human angiotensinogen +11525 C/A polymorphism modulates its gene expression through microRNA binding. +genetics_GWAS hsa-mir-27a Breast Neoplasms 23954879 A genetic variant in pre-miR-27a is associated with a reduced breast cancer risk in younger Chinese population. +genetics_GWAS hsa-mir-146a Gastric Neoplasms 23975664 Prognostic role of microRNA polymorphisms in advanced gastric cancer: a translational study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). +genetics_GWAS hsa-mir-196a-2 Gastric Neoplasms 23975664 Prognostic role of microRNA polymorphisms in advanced gastric cancer: a translational study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). +genetics_GWAS hsa-mir-219-1 Gastric Neoplasms 23975664 Prognostic role of microRNA polymorphisms in advanced gastric cancer: a translational study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). +genetics_GWAS hsa-mir-26a-1 Gastric Neoplasms 23975664 Prognostic role of microRNA polymorphisms in advanced gastric cancer: a translational study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). +genetics_GWAS hsa-mir-27a Gastric Neoplasms 23975664 Prognostic role of microRNA polymorphisms in advanced gastric cancer: a translational study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). +genetics_GWAS hsa-mir-423 Gastric Neoplasms 23975664 Prognostic role of microRNA polymorphisms in advanced gastric cancer: a translational study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). +genetics_GWAS hsa-mir-196a-2 Breast Neoplasms 23982873 "the current meta-analysis supports that the miR-196a-2 rs11614913*T, miR-499 rs3746444*T, miR-605 rs2043556*A, and miR-27a rs895919*C alleles might be protective factors for breast cancer" +genetics_GWAS hsa-mir-27a Breast Neoplasms 23982873 "the current meta-analysis supports that the miR-196a-2 rs11614913*T, miR-499 rs3746444*T, miR-605 rs2043556*A, and miR-27a rs895919*C alleles might be protective factors for breast cancer" +genetics_GWAS hsa-mir-499 Breast Neoplasms 23982873 "the current meta-analysis supports that the miR-196a-2 rs11614913*T, miR-499 rs3746444*T, miR-605 rs2043556*A, and miR-27a rs895919*C alleles might be protective factors for breast cancer" +genetics_GWAS hsa-mir-605 Breast Neoplasms 23982873 "the current meta-analysis supports that the miR-196a-2 rs11614913*T, miR-499 rs3746444*T, miR-605 rs2043556*A, and miR-27a rs895919*C alleles might be protective factors for breast cancer" +genetics_GWAS hsa-mir-146a Breast Neoplasms 24039706 "This meta-analysis demonstrates the compelling evidence that the rs11614913 CC genotype in miR-196a2 increases breast cancer risk, which provides useful information for the early diagnosis and prevention of breast cancer." +genetics_GWAS hsa-mir-196a Breast Neoplasms 24039706 "This meta-analysis demonstrates the compelling evidence that the rs11614913 CC genotype in miR-196a2 increases breast cancer risk, which provides useful information for the early diagnosis and prevention of breast cancer." +genetics_GWAS hsa-mir-499 Breast Neoplasms 24039706 "This meta-analysis demonstrates the compelling evidence that the rs11614913 CC genotype in miR-196a2 increases breast cancer risk, which provides useful information for the early diagnosis and prevention of breast cancer." +genetics_GWAS hsa-mir-149 "Carcinoma, Hepatocellular" 24040059 Results of this meta-analysis suggest that the hsa-miR-149 rs2292832 polymorphism is not associated with cancer risk in spite of the potentially protective role of C allele in hepatocellular carcinoma and male gastric cancer. +genetics_GWAS hsa-mir-21 Bladder Neoplasms 24078506 "In accordance to the observed similarity between TGF-¦Â variants and miR-21 gene expression alterations in bladder tumors, treating 5637 bladder cancer cell line with TGF-¦Â recombinant protein caused a significant upregulation of miR-21. The later finding further confirmed a correlated expression of TGF-¦Âand miR-21 in bladder tumors." +genetics_GWAS hsa-mir-499 Neoplasms [unspecific] 24085457 The miR-499 rs3746444 polymorphism is associated with an increased cancer risk. +genetics_GWAS hsa-mir-499 Gastric Neoplasms 24107911 The rs3746444 (A>G) SNP is not associated with susceptibility to GC in the Chinese population. +genetics_GWAS hsa-mir-218 "Carcinoma, Hepatocellular" 24118778 "rs11134527 may be a novel genetic risk factor of HCC in HBV-exposed subjects, can facilitate HBV preS deletion generation and predispose the host to the effect of T1674C/G and preS1 start codon mutation in hepatocarcinogenesis." +genetics_GWAS hsa-mir-137 Schizophrenia 24132022 Impact of the genome-wide schizophrenia risk single nucleotide polymorphism (rs1625579) in miR-137 on brain structures in healthy individuals. +genetics_GWAS hsa-mir-146a Colorectal Carcinoma 24136745 Association between microRNA genetic variants and susceptibility to colorectal cancer in Chinese population. +genetics_GWAS hsa-mir-184 Cataract 24138095 "C.57 C > T Mutation in MIR 184 is Responsible for Congenital Cataracts and Corneal Abnormalities in a Five-generation Family from Galicia, Spain." +genetics_GWAS hsa-mir-146a Lung Neoplasms 24144839 "These findings suggest that the rs2910164C>G in pre-miR-146a may contribute to genetic susceptibility to lung cancer, and that miR-146a might be involved in lung cancer development." +genetics_GWAS hsa-mir-502 "Carcinoma, Lung, Non-Small-Cell" 24146953 Our data suggested that the rs16917496 T>C located at miR-502 binding site contributes to NSCLC survival by altering SET8 expression through modulating miRNA-target interaction. +genetics_GWAS hsa-mir-561 "Carcinoma, Breast" 24166930 Genetic variant rs16430 6bp > 0bp at the microRNA-binding site in TYMS and risk of sporadic breast cancer risk in non-Hispanic white women aged ¡Ü 55 years. +genetics_GWAS hsa-mir-423 "Squamous Cell Carcinoma, Esophageal" 24205249 MicroRNA polymorphisms and environmental smoke exposure as risk factors for oesophageal squamous cell carcinoma. +genetics_GWAS hsa-mir-27a "Carcinoma, Lung, Non-Small-Cell" 24223174 Our results suggest that the pre-miR-27a rs895819 polymorphism may influence NSCLC patients' clinical outcome. Further large sample studies should be used to validate our findings. +genetics_GWAS hsa-mir-146a "Carcinoma, Lung" 24246082 The rs2910164 C allele in pre-miR-146a and rs11614913 C allele in pre-miR-196a2 were associated with increased genetic damage levels in coke oven workers +genetics_GWAS hsa-mir-196a-2 "Carcinoma, Lung" 24246082 The rs2910164 C allele in pre-miR-146a and rs11614913 C allele in pre-miR-196a2 were associated with increased genetic damage levels in coke oven workers +genetics_GWAS hsa-mir-146a Digestive System Neoplasms 24247819 miR-146a gene polymorphism rs2910164 and the risk of digestive tumors: A meta-analysis of 21 case-control studies. +genetics_GWAS hsa-mir-196a-2 Chronic Hepatitis B 24248733 MicroRNA-196A-2 polymorphisms and hepatocellular carcinoma in patients with chronic hepatitis B. +genetics_GWAS hsa-mir-499 Neoplasms [unspecific] 24258110 Quantitative assessment of the association between microRNA-499 rs3746444 A/G polymorphism and cancer risk. +genetics_GWAS hsa-mir-34b "Carcinoma, Esophageal" 24260422 Hsa-miR-34b/c rs4938723 T>C and hsa-miR-423 rs6505162 C>A polymorphisms are associated with the risk of esophageal cancer in a Chinese population. +genetics_GWAS hsa-mir-34c "Carcinoma, Esophageal" 24260422 Hsa-miR-34b/c rs4938723 T>C and hsa-miR-423 rs6505162 C>A polymorphisms are associated with the risk of esophageal cancer in a Chinese population. +genetics_GWAS hsa-mir-423 "Carcinoma, Esophageal" 24260422 Hsa-miR-34b/c rs4938723 T>C and hsa-miR-423 rs6505162 C>A polymorphisms are associated with the risk of esophageal cancer in a Chinese population. +genetics_GWAS hsa-mir-146a Neoplasms [unspecific] 24278149 Association between microRNA polymorphisms and cancer risk based on the findings of 66 case-control studies. +genetics_GWAS hsa-mir-149 Neoplasms [unspecific] 24278149 Association between microRNA polymorphisms and cancer risk based on the findings of 66 case-control studies. +genetics_GWAS hsa-mir-196a-2 Neoplasms [unspecific] 24278149 Association between microRNA polymorphisms and cancer risk based on the findings of 66 case-control studies. +genetics_GWAS hsa-mir-499 Neoplasms [unspecific] 24278149 Association between microRNA polymorphisms and cancer risk based on the findings of 66 case-control studies. +genetics_GWAS hsa-mir-100 "Squamous Cell Carcinoma, Esophageal" 24288122 "Taken together, these findings indicate that miRNA polymorphisms may predict prognosis in advanced ESCC patients receiving platinum-based chemotherapy." +genetics_GWAS hsa-mir-125a "Squamous Cell Carcinoma, Esophageal" 24288122 "Taken together, these findings indicate that miRNA polymorphisms may predict prognosis in advanced ESCC patients receiving platinum-based chemotherapy." +genetics_GWAS hsa-mir-146a "Squamous Cell Carcinoma, Esophageal" 24288122 "Taken together, these findings indicate that miRNA polymorphisms may predict prognosis in advanced ESCC patients receiving platinum-based chemotherapy." +genetics_GWAS hsa-mir-196a-2 "Squamous Cell Carcinoma, Esophageal" 24288122 "Taken together, these findings indicate that miRNA polymorphisms may predict prognosis in advanced ESCC patients receiving platinum-based chemotherapy." +genetics_GWAS hsa-mir-26a-1 "Squamous Cell Carcinoma, Esophageal" 24288122 "Taken together, these findings indicate that miRNA polymorphisms may predict prognosis in advanced ESCC patients receiving platinum-based chemotherapy." +genetics_GWAS hsa-mir-34b Oral Neoplasms 24297336 Genetic variations at microRNA and processing genes and risk of oral cancer. +genetics_GWAS hsa-mir-499 "Carcinoma, Hepatocellular" 24301908 miR-499A>G rs3746444 and miR-146aG>C expression and hepatocellular carcinoma risk in the Chinese population. +genetics_GWAS hsa-mir-27b Bladder Neoplasms 24312312 "Taken together, these findings suggested that DROSHA rs10719T>C polymorphism may be associated with bladder cancer risk in a Chinese population, and hsa-miR-27b can influence the expression of DROSHA protein by binding with 3'UTR." +genetics_GWAS hsa-mir-196a-2 "Squamous Cell Carcinoma, Esophageal" 24320161 These results suggest that the miRNA-196a2 functional polymorphism rs11614913 might be an effective genetic marker for ESCC risk assessment in individuals younger than 60 years of age from a region of high ESCC incidence in northern China. +genetics_GWAS hsa-mir-499 Rheumatoid Arthritis 24327058 This study suggested that miR-499 polymorphisms were associated with a significantly increased risk of RA in Mediterranean populations. +genetics_GWAS hsa-mir-21 "Squamous Cell Carcinoma, Head and Neck" 24327270 "CLU is a specific, functional target of oncogenic miRNA-21 in HNSCCs. CLU-1 isoform is the predominant growth-suppressive variant targeted by miRNA-21." +genetics_GWAS hsa-mir-34b Colorectal Carcinoma 24337371 Polymorphisms of the pri-miR-34b/c promoter and TP53 codon 72 are associated with risk of colorectal cancer. +genetics_GWAS hsa-mir-34c Colorectal Carcinoma 24337371 Polymorphisms of the pri-miR-34b/c promoter and TP53 codon 72 are associated with risk of colorectal cancer. +genetics_GWAS hsa-mir-125b Endometriosis 24339876 Genetic variation at the miR-125b binding site may play functional roles to protect against endometriosis progression. +genetics_GWAS hsa-mir-502 "Carcinoma, Lung, Non-Small-Cell" 24374662 Association of miR-502-binding site single nucleotide polymorphism in the 3'-untranslated region of SET8 and TP53 codon 72 polymorphism with non-small cell lung cancer in Chinese population. +genetics_GWAS hsa-mir-146a "Carcinoma, Hepatocellular" 24377574 "Our results demonstrate that miR-196a4 CC genotype and C allele have an important role in HCC risk in Chinese, especially in patients with HBV infection." +genetics_GWAS hsa-mir-196a "Carcinoma, Hepatocellular" 24377574 "Our results demonstrate that miR-196a2 CC genotype and C allele have an important role in HCC risk in Chinese, especially in patients with HBV infection." +genetics_GWAS hsa-mir-499 "Carcinoma, Hepatocellular" 24377574 "Our results demonstrate that miR-196a3 CC genotype and C allele have an important role in HCC risk in Chinese, especially in patients with HBV infection." +genetics_GWAS hsa-mir-146a Gastric Neoplasms 24379078 "Association of the miR-146aC>G, miR-149T>C, and miR-196a2T>C polymorphisms with gastric cancer risk and survival in the Greek population." +genetics_GWAS hsa-mir-149 Gastric Neoplasms 24379078 "Association of the miR-146aC>G, miR-149T>C, and miR-196a2T>C polymorphisms with gastric cancer risk and survival in the Greek population." +genetics_GWAS hsa-mir-196a-2 Gastric Neoplasms 24379078 "Association of the miR-146aC>G, miR-149T>C, and miR-196a2T>C polymorphisms with gastric cancer risk and survival in the Greek population." +genetics_GWAS hsa-mir-27a "Carcinoma, Cervical" 24380734 A genetic variant in pre-miR-27a is associated with a reduced cervical cancer risk in southern Chinese women. +genetics_GWAS hsa-mir-485 Hyperglycemia 24387992 An APOA5 3' UTR variant associated with plasma triglycerides triggers APOA5 downregulation by creating a functional miR-485-5p binding site. +genetics_GWAS hsa-mir-146a Colorectal Carcinoma 24399071 Effects of common polymorphisms rs2910164 in miR-146a and rs11614913 in miR-196a2 on susceptibility to colorectal cancer: a systematic review meta-analysis. +genetics_GWAS hsa-mir-196a-2 Colorectal Carcinoma 24399071 Effects of common polymorphisms rs2910164 in miR-146a and rs11614913 in miR-196a2 on susceptibility to colorectal cancer: a systematic review meta-analysis. +genetics_GWAS hsa-mir-106b "Carcinoma, Hepatocellular" 24416400 A genetic variant in the promoter region of miR-106b-25 cluster predict clinical outcome of HBV-related hepatocellular carcinoma in Chinese. +genetics_GWAS hsa-mir-330 Psychiatric Disorders 24436253 The effects of a MAP2K5 microRNA target site SNP on risk for anxiety and depressive disorders. +genetics_GWAS hsa-mir-146 Coronary Artery Disease 24447667 A common variant in pre-miR-146 is associated with coronary artery disease risk and its mature miRNA expression. +genetics_GWAS hsa-mir-135b "Carcinoma, Cervical" 24465869 Genetic variants in microRNA target sites of 37 selected cancer-related genes and the risk of cervical cancer. +genetics_GWAS hsa-mir-101-1 Breast Neoplasms 24475105 Genetic variations in the flanking regions of miR-101-2 are associated with increased risk of breast cancer. +genetics_GWAS hsa-mir-101-2 Breast Neoplasms 24475105 Genetic variations in the flanking regions of miR-101-2 are associated with increased risk of breast cancer. +genetics_GWAS hsa-mir-146a Immune Thrombocytopenic Purpura 24502829 hsa-mir-146a rs2910164 polymorphism and risk of immune thrombocytopenia. +genetics_GWAS hsa-mir-34b "Carcinoma, Renal Cell" 24503183 A potentially functional polymorphism in the promoter region of miR-34b/c is associated with renal cell cancer risk in a Chinese population. +genetics_GWAS hsa-mir-34c "Carcinoma, Renal Cell" 24503183 A potentially functional polymorphism in the promoter region of miR-34b/c is associated with renal cell cancer risk in a Chinese population. +genetics_GWAS hsa-mir-499 Breast Neoplasms 24521023 Our findings demonstrated that the hsa-mir-499 rs3746444 polymorphism is associated with higher risk of developing breast cancer in our population. +genetics_GWAS hsa-mir-146a Gastric Neoplasms 24528016 A genetic variant in MiR-146a modifies digestive system cancer risk: a meta-analysis. +genetics_GWAS hsa-mir-146a Colorectal Carcinoma 24568449 These findings supported that the miR-196a2 rs11614913 and miR-149 rs2292832 polymorphisms may contribute to susceptibility to CRC. +genetics_GWAS hsa-mir-149 Colorectal Carcinoma 24568449 These findings supported that the miR-196a2 rs11614913 and miR-149 rs2292832 polymorphisms may contribute to susceptibility to CRC. +genetics_GWAS hsa-mir-196a Colorectal Carcinoma 24568449 These findings supported that the miR-196a2 rs11614913 and miR-149 rs2292832 polymorphisms may contribute to susceptibility to CRC. +genetics_GWAS hsa-mir-499 Colorectal Carcinoma 24568449 These findings supported that the miR-196a2 rs11614913 and miR-149 rs2292832 polymorphisms may contribute to susceptibility to CRC. +genetics_GWAS hsa-mir-624 Gastric Neoplasms 24568522 Bioinformatic prediction of SNPs within miRNA binding sites of inflammatory genes associated with gastric cancer. +genetics_GWAS hsa-mir-146a Alzheimer Disease 24586483 A functional polymorphism in the promoter region of microRNA-146a is associated with the risk of Alzheimer disease and the rate of cognitive decline in patients. +genetics_GWAS hsa-mir-146a "Carcinoma, Hepatocellular" 24587132 "These results suggest that a significant association exists between miRNA499 SNPs and hepatocellular carcinoma. Gene-environment interactions of miRNA499 polymorphisms, smoking, and alcohol consumption might alter hepatocellular carcinoma susceptibility." +genetics_GWAS hsa-mir-149 "Carcinoma, Hepatocellular" 24587132 "These results suggest that a significant association exists between miRNA499 SNPs and hepatocellular carcinoma. Gene-environment interactions of miRNA499 polymorphisms, smoking, and alcohol consumption might alter hepatocellular carcinoma susceptibility." +genetics_GWAS hsa-mir-196 "Carcinoma, Hepatocellular" 24587132 "These results suggest that a significant association exists between miRNA499 SNPs and hepatocellular carcinoma. Gene-environment interactions of miRNA499 polymorphisms, smoking, and alcohol consumption might alter hepatocellular carcinoma susceptibility." +genetics_GWAS hsa-mir-499 "Carcinoma, Hepatocellular" 24587132 "These results suggest that a significant association exists between miRNA499 SNPs and hepatocellular carcinoma. Gene-environment interactions of miRNA499 polymorphisms, smoking, and alcohol consumption might alter hepatocellular carcinoma susceptibility." +genetics_GWAS hsa-mir-124 "Carcinoma, Cervical" 24589598 "miR-124 rs531564 polymorphism may play a role in cervical cancer susceptibility in Chinese Han women, and G allele is associated with a reduced risk of cervical cancer." +genetics_GWAS hsa-mir-526b "Carcinoma, Gastric" 24595048 The has-miR-526b binding-site rs8506G>a polymorphism in the lincRNA-NR_024015 exon identified by GWASs predispose to non-cardia gastric cancer risk. +genetics_GWAS hsa-mir-3649 Non-Syndromic Orofacial Clefts 24603642 "Taken together, these findings indicate that SNPs in the miRNA-binding sites might play an important role in the development of NSOCs. Furthermore, if confirmed in subsequent studies, the polymorphisms may be considered as additional markers for the evaluation of infants' risk of NSOCs." +genetics_GWAS hsa-mir-146a "Carcinoma, Hepatocellular" 24615520 miR-146a G>C polymorphisms and risk of hepatocellular carcinoma in a Chinese population. +genetics_GWAS hsa-mir-499 "Leukemia, Lymphoblastic, Acute" 24618566 "We found 11 SNPs significantly associated with ALL susceptibility. These included three SNPs present in miRNA genes (miR-612, miR-499, and miR-449b) and eight SNPs present in six miRNA biogenesis pathway genes (TNRC6B, DROSHA, DGCR8, EIF2C1, CNOT1, and CNOT6)." +genetics_GWAS hsa-mir-146a Alcohol Use Disorder 24630744 This is the first genetic association study to explore the relationship of miRNA polymorphisms with AUDs and to show an association of the miR-146a C>G rs2910164 allelic variant with this disease. +genetics_GWAS hsa-mir-196a-2 Liver Neoplasms 24633889 "Quantitative assessment of the association between miR-196a2 rs11614913 polymorphism and cancer risk: evidence based on 45,816 subjects." +genetics_GWAS hsa-mir-2278 Multiple Sclerosis 24638856 Assessment of microRNA-related SNP effects in the 3' untranslated region of the IL22RA2 risk locus in multiple sclerosis. +genetics_GWAS hsa-mir-411 Multiple Sclerosis 24638856 Assessment of microRNA-related SNP effects in the 3' untranslated region of the IL22RA2 risk locus in multiple sclerosis. +genetics_GWAS hsa-mir-146a Uveitis 24658012 This study shows that miR-146a and Ets-1 are both associated with pediatric uveitis in Han Chinese. SNP rs10893872 may affect the genetic predisposition to pediatric uveitis by modulating expression of Ets-1. +genetics_GWAS hsa-mir-4436b-1 Autism Spectrum Disorder 24667286 Assessing the impact of copy number variants on miRNA genes in autism by Monte Carlo simulation. +genetics_GWAS hsa-mir-4436b-2 Autism Spectrum Disorder 24667286 Assessing the impact of copy number variants on miRNA genes in autism by Monte Carlo simulation. +genetics_GWAS hsa-mir-424 Myelodysplastic Syndromes 24674452 Detection of an activated JAK3 variant and a Xq26.3 microdeletion causing loss of PHF6 and miR-424 expression in myelodysplastic syndromes by combined targeted next generation sequencing and SNP array analysis. +genetics_GWAS hsa-mir-224 Coronary Artery Disease 24676100 Coronary heart disease-associated variation in TCF21 disrupts a miR-224 binding site and miRNA-mediated regulation. +genetics_GWAS hsa-mir-149 "Carcinoma, Renal Cell" 24681820 "We genotyped four common miRNA SNPs (i.e. miR-146a rs2910164, miR-149 rs2292832, miR-196a2 rs11614913 and miR-499 rs3746444) to assess their associations with RCC risk in a two-stage case-control study (355 cases and 362 controls in discovery set, meanwhile 647 cases and 660 controls in validation set), as well as RCC survival in 311 patients." +genetics_GWAS hsa-mir-518 Hypertension 24687999 Our results suggest that TGFBR2 and miR-518 harbor variants that increase the risk of EH and affect blood pressure homeostasis as well as efficacy of antihypertensive agents. +genetics_GWAS hsa-mir-146a Skin Neoplasms 24699816 "we investigated the impact of MIR146A SNP rs2910164 on cancer risk, and interaction with a SNP in one of its putative targets (RNASEL, rs486907)." +genetics_GWAS hsa-mir-146a Sepsis 24701036 The functional polymorphisms of miR-146a are associated with susceptibility to severe sepsis in the Chinese population. +genetics_GWAS hsa-mir-146a Dermatomyositis 24716199 MIRSNP rs2910164 of miR-146a is associated with the muscle involvement in polymyositis/dermatomyositis. +genetics_GWAS hsa-mir-146a Neoplasms [unspecific] 24716941 Association analysis of single nucleotide polymorphisms in miR-146a and miR-196a2 on the prevalence of cancer in elderly Japanese: a case-control study. +genetics_GWAS hsa-mir-196a-2 Neoplasms [unspecific] 24716941 Association analysis of single nucleotide polymorphisms in miR-146a and miR-196a2 on the prevalence of cancer in elderly Japanese: a case-control study. +genetics_GWAS hsa-mir-142 "Leukemia, Myeloid, Acute" 24724784 Absence of miR-142 mutation in Chinese patients with acute myeloid leukemia. +genetics_GWAS hsa-let-7 "Carcinoma, Colon" 24727325 "In the largest association study investigating the LCS6 polymorphism in colon cancers, the germline LCS6 genotype was not associated with KRAS mutation status or with clinical outcome in patients with stage III tumors." +genetics_GWAS hsa-let-7 Hepatitis B Virus Infection 24729511 Association of a functional RAD52 genetic variant locating in a miRNA binding site with risk of HBV-related hepatocellular carcinoma. +genetics_GWAS hsa-mir-146a Colorectal Carcinoma 24740563 Association of a genetic variant in microRNA-146a with risk of colorectal cancer: a population-based case-control study. +genetics_GWAS hsa-mir-378 "Carcinoma, Hepatocellular" 24751683 These findings indicate that rs1076064 may be a biomarker for HCC susceptibility and prognosis through altering pri-miR-378 transcription. +genetics_GWAS hsa-mir-143 Congenital Heart Diseases 24752771 No association of pri-miR-143 rs41291957 polymorphism with the risk of congenital heart disease in a Chinese population. +genetics_GWAS hsa-let-7a Gastric Neoplasms 24760009 "pri-let-7a-2 rs629367 CC genotype could increase the risks of gastric cancer as well as atrophic gastritis and was also associated with poor survival of gastric cancer, which possibly by affecting the mature let-7a expression, and could serve as a predicting biomarker for high-risk and poor prognosis of gastric cancer." +genetics_GWAS hsa-mir-218 Neoplasms [unspecific] 24761857 "The findings suggest that pre-miR-218 rs11134527 polymorphism may have some relation to cancer development in Chinese. However, well-designed studies with larger sample size and more detailed data are needed to confirm these conclusions." +genetics_GWAS hsa-mir-608 "Squamous Cell Carcinoma, Esophageal" 24770678 "The hereditary genetic polymorphisms of mir-608, RAN, and GEMIN4 can serve as predictors for clinical outcome in ESCC patients treated with concurrent chemoradiotherapy." +genetics_GWAS hsa-mir-146a IgA Nephropathy 24781267 These results indicated that rs2910164 may affect the susceptibility and severity of pediatric IgAN. Further studies are needed to validate these findings. +genetics_GWAS hsa-mir-182 Behcet Disease 24801147 Predisposition to Behcet's disease and VKH syndrome by genetic variants of miR-182. +genetics_GWAS hsa-mir-146a Systemic Lupus Erythematosus 24803388 Association of miR-146a polymorphisms with systemic lupus erythematosus: a meta-analysis. +genetics_GWAS hsa-mir-26b Obesity 24807789 "Expression of microRNA-26b, an obesity-related microRNA, is regulated by free fatty acids, glucose, dexamethasone and growth hormone in human adipocytes." +genetics_GWAS hsa-mir-146a "Carcinoma, Hepatocellular" 24816919 Association between miR-146aG>C and miR-196a2C>T polymorphisms and the risk of hepatocellular carcinoma in a Chinese population. +genetics_GWAS hsa-mir-196a-2 "Carcinoma, Hepatocellular" 24816919 Association between miR-146aG>C and miR-196a2C>T polymorphisms and the risk of hepatocellular carcinoma in a Chinese population. +genetics_GWAS hsa-mir-499 "Carcinoma, Hepatocellular" 24816919 Association between miR-146aG>C and miR-196a2C>T polymorphisms and the risk of hepatocellular carcinoma in a Chinese population. +genetics_GWAS hsa-mir-146a Rheumatoid Arthritis 24824381 Association of two polymorphisms rs2910164 in miRNA-146a and rs3746444 in miRNA-499 with rheumatoid arthritis: a meta-analysis. +genetics_GWAS hsa-mir-499 Rheumatoid Arthritis 24824381 Association of two polymorphisms rs2910164 in miRNA-146a and rs3746444 in miRNA-499 with rheumatoid arthritis: a meta-analysis. +genetics_GWAS hsa-mir-33b Hyperglycemia 24825092 Association of rs8066560 variant in the sterol regulatory element-binding protein 1 (SREBP-1) and miR-33b genes with hyperglycemia and insulin resistance. +genetics_GWAS hsa-mir-146a Myocardial Infarction 24850191 Association of microRNA polymorphisms with the risk of myocardial infarction in a Chinese population. +genetics_GWAS hsa-mir-149 Myocardial Infarction 24850191 Association of microRNA polymorphisms with the risk of myocardial infarction in a Chinese population. +genetics_GWAS hsa-mir-196a-2 Myocardial Infarction 24850191 Association of microRNA polymorphisms with the risk of myocardial infarction in a Chinese population. +genetics_GWAS hsa-mir-218 Myocardial Infarction 24850191 Association of microRNA polymorphisms with the risk of myocardial infarction in a Chinese population. +genetics_GWAS hsa-mir-499 Myocardial Infarction 24850191 Association of microRNA polymorphisms with the risk of myocardial infarction in a Chinese population. +genetics_GWAS hsa-mir-196a-2 "Carcinoma, Lung, Non-Small-Cell" 24853117 "Importantly, this method can be further applied to analyze the point mutation of mir-196a2 in the lung tissues of non small-cell lung cancer patients." +genetics_GWAS hsa-mir-499 "Carcinoma, Hepatocellular" 24854593 "miR-499 rs3746444 may contribute to the risk and prognosis of HCC, indicating that this SNP could be developed as a biomarker for HCC prediction." +genetics_GWAS hsa-mir-29a Oral Neoplasms 24885463 Variations in microRNAs and their processing genes modulated risk of precancer but further in-depth study is needed to understand mechanism of disease process. +genetics_GWAS hsa-mir-34b Oral Neoplasms 24885463 Variations in microRNAs and their processing genes modulated risk of precancer but further in-depth study is needed to understand mechanism of disease process. +genetics_GWAS hsa-mir-423 Oral Neoplasms 24885463 Variations in microRNAs and their processing genes modulated risk of precancer but further in-depth study is needed to understand mechanism of disease process. +genetics_GWAS hsa-mir-34c "Leukemia, Myeloid" 24886876 Our study implicates that microRNA-binding site polymorphisms modulate leukemia risk by interfering with the miRNA-mediated regulation. Our findings underscore the significance of variability in 3' untranslated regions in leukemia. +genetics_GWAS hsa-mir-449b "Leukemia, Myeloid" 24886876 Our study implicates that microRNA-binding site polymorphisms modulate leukemia risk by interfering with the miRNA-mediated regulation. Our findings underscore the significance of variability in 3' untranslated regions in leukemia. +genetics_GWAS hsa-let-7 Colorectal Carcinoma 24890702 Let-7 microRNA-binding-site polymorphism in the 3'UTR of KRAS and colorectal cancer outcome: a systematic review and meta-analysis. +genetics_GWAS hsa-mir-196a Breast Neoplasms 24922658 The current study provides evidence that the miR-196a rs11614913T>C polymorphisms are possible prognostic biomarker for patients with hormone receptor-expressing early breast cancer. +genetics_GWAS hsa-mir-603 Colorectal Carcinoma 24934365 "Our data suggest that hsa-miR-603 may be involved in colorectal tumorigenesis, and the genetic polymorphism in hsa-miR-603 is associated with CRC susceptibility." +genetics_GWAS hsa-mir-124 "Squamous Cell Carcinoma, Esophageal" 24945256 Pri-miR-124 rs531564 and pri-miR-34b/c rs4938723 polymorphisms are associated with decreased risk of esophageal squamous cell carcinoma in Chinese populations. +genetics_GWAS hsa-mir-34b "Squamous Cell Carcinoma, Esophageal" 24945256 Pri-miR-124 rs531564 and pri-miR-34b/c rs4938723 polymorphisms are associated with decreased risk of esophageal squamous cell carcinoma in Chinese populations. +genetics_GWAS hsa-mir-34c "Squamous Cell Carcinoma, Esophageal" 24945256 Pri-miR-124 rs531564 and pri-miR-34b/c rs4938723 polymorphisms are associated with decreased risk of esophageal squamous cell carcinoma in Chinese populations. +genetics_GWAS hsa-mir-146a "Stroke, Ischemic" 24952884 miR-146a and miR-196a2 polymorphisms in patients with ischemic stroke in the northern Chinese Han population. +genetics_GWAS hsa-mir-196a-2 "Stroke, Ischemic" 24952884 miR-146a and miR-196a2 polymorphisms in patients with ischemic stroke in the northern Chinese Han population. +genetics_GWAS hsa-mir-196a-2 "Diabetes Mellitus, Type 2" 24972764 Our findings suggest that miRNA-196a2 T/C polymorphism (rs11614913) is associated with an increased risk of CVD in type 2 diabetes patients. This provides further insights on pathogenesis of cardiovascular disease in type 2 diabetes patients. +genetics_GWAS hsa-mir-132 Gastric Neoplasms 24981235 "A functional variant at miR-132-3p, miR-212-3p, and miR-361-5p binding site in CD80 gene alters susceptibility to gastric cancer in a Chinese Han population." +genetics_GWAS hsa-mir-212 Gastric Neoplasms 24981235 "A functional variant at miR-132-3p, miR-212-3p, and miR-361-5p binding site in CD80 gene alters susceptibility to gastric cancer in a Chinese Han population." +genetics_GWAS hsa-mir-361 Gastric Neoplasms 24981235 "A functional variant at miR-132-3p, miR-212-3p, and miR-361-5p binding site in CD80 gene alters susceptibility to gastric cancer in a Chinese Han population." +genetics_GWAS hsa-mir-410 Stroke 24990426 "We report a novel association between a microRNA target site variant and stroke incidence, which is modulated by diet in terms of decreasing triglycerides and possibly stroke risk in rs13702 C allele carriers after a high-unsaturated fat MedDiet intervention." +genetics_GWAS hsa-mir-125a Autoimmune Thyroiditis 24990808 Associations of single nucleotide polymorphisms in precursor-microRNA (miR)-125a and the expression of mature miR-125a with the development and prognosis of autoimmune thyroid diseases. +genetics_GWAS hsa-mir-122 "Carcinoma, Hepatocellular" 24995424 A genetic variant in microRNA-122 regulatory region confers risk for chronic hepatitis B virus infection and hepatocellular carcinoma in Han Chinese. +genetics_GWAS hsa-mir-485 Breast Neoplasms 25003827 miR-485-5p binding site SNP rs8752 in HPGD gene is associated with breast cancer risk. +genetics_GWAS hsa-mir-137 Schizophrenia 25044277 The miR-137 schizophrenia susceptibility variant rs1625579 does not predict variability in brain volume in a sample of schizophrenic patients and healthy individuals. +genetics_GWAS hsa-mir-146a Coronary Restenosis 25053223 we found a negative association for the G/C (P = 0.007) and a positive association for the C/C genotype with the risk of restenosis +genetics_GWAS hsa-mir-149 "Carcinoma, Hepatocellular" 25061729 Association of miR-149C>T and miR-500A>G polymorphisms with the risk of hepatocellular carcinoma in the Chinese population. +genetics_GWAS hsa-mir-499a "Carcinoma, Hepatocellular" 25061729 Association of miR-149C>T and miR-499A>G polymorphisms with the risk of hepatocellular carcinoma in the Chinese population. +genetics_GWAS hsa-mir-26a Neurodegenerative Diseases [unspecific] 25074322 A functional SNP catalog of overlapping miRNA-binding sites in genes implicated in prion disease and other neurodegenerative disorders. +genetics_GWAS hsa-mir-146a Lung Neoplasms 25077922 Effects of four single nucleotide polymorphisms in microRNA-coding genes on lung cancer risk. +genetics_GWAS hsa-mir-149 Lung Neoplasms 25077922 Effects of four single nucleotide polymorphisms in microRNA-coding genes on lung cancer risk. +genetics_GWAS hsa-mir-196a-2 Lung Neoplasms 25077922 Effects of four single nucleotide polymorphisms in microRNA-coding genes on lung cancer risk. +genetics_GWAS hsa-mir-499b Lung Neoplasms 25077922 Effects of four single nucleotide polymorphisms in microRNA-coding genes on lung cancer risk. +genetics_GWAS hsa-mir-27a Colorectal Carcinoma 25078482 Association between miR-27a genetic variants and susceptibility to colorectal cancer. +genetics_GWAS hsa-mir-146a Prostate Neoplasms 25084752 Association between genetic variant in hsa-miR-146a gene and prostate cancer progression +genetics_GWAS hsa-mir-146a Colorectal Carcinoma 25103961 "Lack of association between miR-27a, miR-146a, miR-196a-2, miR-492 and miR-608 gene polymorphisms and colorectal cancer." +genetics_GWAS hsa-mir-196a-2 Colorectal Carcinoma 25103961 "Lack of association between miR-27a, miR-146a, miR-196a-2, miR-492 and miR-608 gene polymorphisms and colorectal cancer." +genetics_GWAS hsa-mir-27a Colorectal Carcinoma 25103961 "Lack of association between miR-27a, miR-146a, miR-196a-2, miR-492 and miR-608 gene polymorphisms and colorectal cancer." +genetics_GWAS hsa-mir-125a Gastric Neoplasms 25109760 "In this study, we found that a germline mutation in the miR-125a coding region is associated with human gastric cancer." +genetics_GWAS hsa-mir-146a Lung Neoplasms 25154761 MicroRNA-146a rs2910164 polymorphism is associated with susceptibility to non-small cell lung cancer in the Chinese population. +genetics_GWAS hsa-mir-502 "Carcinoma, Cervical" 25169478 "These data suggest that there are significant associations between the miR-502-binding site SNP in the 3'-UTR of SET8 and the TP53 codon 72 polymorphism with cervical cancer in Chinese, and there is a gene-gene interaction." +genetics_GWAS hsa-mir-646 "Carcinoma, Hepatocellular" 25177719 Our findings support the view that the miR-646 SNP rs6513497 may contribute to the susceptibility of HCC. +genetics_GWAS hsa-mir-34a "Carcinoma, Hepatocellular" 25179842 A functional variant at miR-34a binding site in toll-like receptor 4 gene alters susceptibility to hepatocellular carcinoma in a Chinese Han population. +genetics_GWAS hsa-mir-146a Leprosy 25187983 Pre-miR-146a (rs2910164 G>C) single nucleotide polymorphism is genetically and functionally associated with leprosy. +genetics_GWAS hsa-mir-34b Neoplasms [unspecific] 25190019 The genetic association between pri-miR-34b/c polymorphism (rs4938723 T>C) and susceptibility to cancers: evidence from published studies. +genetics_GWAS hsa-mir-34c Neoplasms [unspecific] 25190019 The genetic association between pri-miR-34b/c polymorphism (rs4938723 T>C) and susceptibility to cancers: evidence from published studies. +genetics_GWAS hsa-mir-34b Gastric Neoplasms 25190020 Promoter polymorphisms of miR-34b/c are associated with risk of gastric cancer in a Chinese population. +genetics_GWAS hsa-mir-34c Gastric Neoplasms 25190020 Promoter polymorphisms of miR-34b/c are associated with risk of gastric cancer in a Chinese population. +genetics_GWAS hsa-mir-1 Coronary Artery Disease 25197382 Polymorphism in miRNA-1 target site and circulating miRNA-1 phenotype are associated with the decreased risk and prognosis of coronary artery disease. +genetics_GWAS hsa-mir-146a Psoriasis 25209759 A single-nucleotide polymorphism of miR-146a and psoriasis: an association and functional study. +genetics_GWAS hsa-mir-146a Systemic Lupus Erythematosus 25218914 "The present meta-analysis suggests important roles for the mir-499 rs3746444 polymorphism in RA, especially in the Caucasian population and for miR-146a rs57095329 polymorphism in SLE." +genetics_GWAS hsa-mir-149 "Carcinoma, Hepatocellular" 25222224 Role of miR-149C>T polymorphisms on the risk of hepatocellular carcinoma in a Chinese population. +genetics_GWAS hsa-mir-27a Colorectal Carcinoma 25222241 Association between a functional variant in microRNA-27a and susceptibility to colorectal cancer in a Chinese Han population. +genetics_GWAS hsa-mir-137 Schizophrenia 25241074 Lack of association between microRNA-137 SNP rs1625579 and schizophrenia in a replication study of Han Chinese. +genetics_GWAS hsa-mir-4513 Coronary Artery Disease 25256095 "A genetic variant in the seed region of miR-4513 shows pleiotropic effects on lipid and glucose homeostasis, blood pressure, and coronary artery disease." +genetics_GWAS hsa-mir-146a Arthritis 25269878 This meta-analysis suggests that the miR-499 rs374644 and IRAKI rs3027898 polymorphisms are associated with susceptibility to inflammatory arthritis. +genetics_GWAS hsa-mir-499 Arthritis 25269878 This meta-analysis suggests that the miR-499 rs374644 and IRAKI rs3027898 polymorphisms are associated with susceptibility to inflammatory arthritis. +genetics_GWAS hsa-mir-146a Colorectal Carcinoma 25283877 Effect of a common genetic variant microRNA-146a rs2910164 on colorectal cancer: a meta-analysis. +genetics_GWAS hsa-mir-146a Generalized Epilepsy with Febrile Seizures Plus 25319229 Association of genetic polymorphism of pre-microRNA-146a rs2910164 and serum high-mobility group box 1 with febrile seizures in Egyptian children. +genetics_GWAS hsa-mir-146a Gastric Neoplasms 25326754 The present meta-analysis suggests an increased risk between miR-146a rs2910164 GG genotype and gastric cancer susceptibility in Chinese based on published literatures. +genetics_GWAS hsa-mir-218 "Squamous Cell Carcinoma, Esophageal" 25337271 The impact of pri-miR-218 rs11134527 on the risk and prognosis of patients with esophageal squamous cell carcinoma. +genetics_GWAS hsa-mir-502 "Lymphoma, Non-Hodgkin" 25343552 the SNP in the miRNA binding site of the SET8 3'-untranslated region seems to influence survival of NHL. It may have possible prognostic and survival value in the clinic. +genetics_GWAS hsa-mir-143 Prostate Neoplasms 25354797 there is the significant association between the functional promoter variant rs4705342T>C in miR-143 and PCa risk +genetics_GWAS hsa-mir-518 Premature Ovarian Failure 25365407 "Association study of TGFBR2 and miR-518 gene polymorphisms with age at natural menopause, premature ovarian failure, and early menopause among Chinese Hanwomen." +genetics_GWAS hsa-mir-146a "Lymphoma, B-Cell" 25370733 MicroRNA-146a rs2910164 polymorphism and the risk of diffuse large B cell lymphoma in the Chinese Han population. +genetics_GWAS hsa-mir-184 "Squamous Cell Carcinoma, Esophageal" 25383966 Our data demonstrate that functional TNFAIP2 rs8126 genetic variant is a ESCC susceptibility SNP. +genetics_GWAS hsa-mir-146a Gastric Neoplasms 25386093 "The miR-146a rs2910164 polymorphism is associated with increased gastric cancer risk, particularly evident in high quality studies with small sample sized Caucasian populations." +genetics_GWAS hsa-mir-27a Gastric Neoplasms 25399405 rs895819 and rs11671784 inversely affect gastric cancer risk and the influence was closely related to their effects on miR-27a expression. +genetics_GWAS hsa-mir-148a Gastric Neoplasms 25399950 the SCRN1 rs6976789 polymorphism may play an important role in the GC development and progression. +genetics_GWAS hsa-mir-149 Thyroid Neoplasms 25405731 "Rs2292832 was possibly involved in the susceptibility and local progression of PTC in Chinese patients, by altering the expression level of mir-149-5p and its target genes." +genetics_GWAS hsa-mir-604 "Carcinoma, Hepatocellular" 25408584 "The T allele at miR-604 rs2368392 may be a risk allele for the chronicity of HBV infection, but may be a protective allele for the progression to HCC in chronic HBV carriers." +genetics_GWAS hsa-mir-499 Neoplasms [unspecific] 25433484 "hsa-mir-499 rs3746444 T > C polymorphism is associated with the risk of cancer in Asians, mainly in Iranian and Chinese population. However, rs3746444 T > C polymorphism is negatively associated with the risk of esophageal cancer." +genetics_GWAS hsa-mir-137 Schizophrenia 25434007 "rare noncoding risk variants are associated with SZ and BP at MIR137/MIR2682 locus, with risk alleles decreasing MIR137/MIR2682 expression." +genetics_GWAS hsa-mir-2682 Schizophrenia 25434007 "rare noncoding risk variants are associated with SZ and BP at MIR137/MIR2682 locus, with risk alleles decreasing MIR137/MIR2682 expression." +genetics_GWAS hsa-mir-611 Pleural Mesothelioma 25436799 MRP performance as diagnostic biomarker improved by considering the genotype rs1057147. This polymorphism most likely affects a binding site for miR-611. +genetics_GWAS hsa-mir-146a Hirschsprung Disease 25445498 "the polymorphism rs2910164 in pre-miR-146a might alter the production of mature miR-146a and then down-regulate the target gene ROBO1, which plays an important role in pathogenesis of HSCR." +genetics_GWAS hsa-mir-146a Gastric Neoplasms 25455160 "miR-146a rs2910164 polymorphism was associated with the susceptibility to gastric cancer, especially in Asian population." +genetics_GWAS hsa-mir-34b Colorectal Carcinoma 25475831 rs4938723 was a susceptible locus only for hepatocellular cancer and colorectal cancer. +genetics_GWAS hsa-mir-34c Colorectal Carcinoma 25475831 rs4938723 was a susceptible locus only for hepatocellular cancer and colorectal cancer. +genetics_GWAS hsa-mir-196a "Lymphoma, Non-Hodgkin" 25501512 the miR-196a2 polymorphism may increase the risk of NHL by altering the expression of mature miR-196a. +genetics_GWAS hsa-mir-146a Lung Neoplasms 25524943 mir-196a2 SNP influences the susceptibility of lung cancer. Mir-146a and mir-149 SNP do not play a role in lung cancer risk. These findings need more validation by larger studies. +genetics_GWAS hsa-mir-149 Lung Neoplasms 25524943 mir-196a2 SNP influences the susceptibility of lung cancer. Mir-146a and mir-149 SNP do not play a role in lung cancer risk. These findings need more validation by larger studies. +genetics_GWAS hsa-mir-196a-2 Lung Neoplasms 25524943 mir-196a2 SNP influences the susceptibility of lung cancer. Mir-146a and mir-149 SNP do not play a role in lung cancer risk. These findings need more validation by larger studies. +genetics_GWAS hsa-mir-34a Parkinson Disease 25541488 "down-regulation of miR-34b and miR-34c in the brain, as well as an SNP in the 3'-UTR of ¦Á-syn can increase ¦Á-syn expression, possibly contributing to PD pathogenesis." +genetics_GWAS hsa-mir-146a "Carcinoma, Hepatocellular" 25546664 "the miR-146a rs2910164 polymorphism contributes to increased HCC susceptibility, especially in Asian populations. Further large and well-designed studies are required to validate this association." +genetics_GWAS hsa-mir-196a-2 "Carcinoma, Hepatocellular" 25546664 "the miR-146a rs2910165 polymorphism contributes to increased HCC susceptibility, especially in Asian populations. Further large and well-designed studies are required to validate this association." +genetics_GWAS hsa-mir-146a Digestive System Neoplasms 25555557 "digestive tract neoplasms might associate with miR-146a variants, but not miR-196a2 variants" +genetics_GWAS hsa-mir-196a Digestive System Neoplasms 25555557 "digestive tract neoplasms might associate with miR-146a variants, but not miR-196a2 variants" +genetics_GWAS hsa-mir-27a Breast Neoplasms 25556434 an association between pre-miR-27a polymorphism rs895819 and cancer risk in Caucasians. The protective effect of rs895819 [G] allele in younger breast cancer and in the group of unilateral breast cancer patients await further confirmation since the included studies in this meta-analysis were limited. +genetics_GWAS hsa-mir-320b Coronary Artery Disease 25573129 "The common SNP (rs10916581) in the promoter region of pre-miR-320b-2 might have little contribution to the CHD predisposition in Chinese Han population, and it might not affect circulating miR-320b level. Conventional CHD risk factors (BMI, TC/HDL-C, hypertension and diabetes) might have effects on its circulating level." +genetics_GWAS hsa-mir-146a Multiple Sclerosis 25591770 rs2910164 may play a role in MS susceptibility in females. The rs2910164 G>C variation may affect the expression of miR-146a and the release of proinflammatory cytokines. +genetics_GWAS hsa-mir-499 Lung Neoplasms 25614447 "the rs3746444T>C polymorphism in mature miR-499 sequence could contribute to poor prognosis by modulating cancer-related genes' expression and thus involve tumorigenesis and anti-chemotherapy, which may be a useful biomarker to predict lung cancer patients' prognosis." +genetics_GWAS hsa-mir-208b "Cardiomyopathy, Hypertrophic" 25633875 Sequence variants in miRNAs of patients with HCM are not frequent and the contribution of these variants to the development of this disease was not demonstrated. +genetics_GWAS hsa-mir-367 "Cardiomyopathy, Hypertrophic" 25633875 Sequence variants in miRNAs of patients with HCM are not frequent and the contribution of these variants to the development of this disease was not demonstrated. +genetics_GWAS hsa-mir-499 Neoplasms [unspecific] 25640376 hsa-mir-499 rs3746444 A>G polymorphism is not associated with risk of cancer based on current evidence. +genetics_GWAS hsa-mir-146a "Tuberculosis, Pulmonary" 25650003 "Association of the miR-146a, miR-149, miR-196a2 and miR-499 polymorphisms with susceptibility to pulmonary tuberculosis in the Chinese Uygur, Kazak and Southern Han populations." +genetics_GWAS hsa-mir-149 "Tuberculosis, Pulmonary" 25650003 "Association of the miR-146a, miR-149, miR-196a2 and miR-499 polymorphisms with susceptibility to pulmonary tuberculosis in the Chinese Uygur, Kazak and Southern Han populations." +genetics_GWAS hsa-mir-196a-2 "Tuberculosis, Pulmonary" 25650003 "Association of the miR-146a, miR-149, miR-196a2 and miR-499 polymorphisms with susceptibility to pulmonary tuberculosis in the Chinese Uygur, Kazak and Southern Han populations." +genetics_GWAS hsa-mir-499 "Tuberculosis, Pulmonary" 25650003 "Association of the miR-146a, miR-149, miR-196a2 and miR-499 polymorphisms with susceptibility to pulmonary tuberculosis in the Chinese Uygur, Kazak and Southern Han populations." +genetics_GWAS hsa-mir-34b Gastric Neoplasms 25658980 rs4938723 polymorphism is associated with a decreased risk of gastric cancer. +genetics_GWAS hsa-mir-34c Gastric Neoplasms 25658980 rs4938723 polymorphism is associated with a decreased risk of gastric cancer. +genetics_GWAS hsa-mir-29c Gastric Neoplasms 25661340 A miR-29c binding site genetic variant in the 3'-untranslated region of LAMTOR3 gene is associated with gastric cancer risk. +genetics_GWAS hsa-mir-17 Osteosarcoma 25663449 "This study suggests that SNPs in RISC complex genes may be involved in osteosarcoma susceptibility, especially rs11866002 in CNOT1." +genetics_GWAS hsa-mir-18 Osteosarcoma 25663449 "This study suggests that SNPs in RISC complex genes may be involved in osteosarcoma susceptibility, especially rs11866002 in CNOT1." +genetics_GWAS hsa-mir-19a Osteosarcoma 25663449 "This study suggests that SNPs in RISC complex genes may be involved in osteosarcoma susceptibility, especially rs11866002 in CNOT1." +genetics_GWAS hsa-mir-19b-1 Osteosarcoma 25663449 "This study suggests that SNPs in RISC complex genes may be involved in osteosarcoma susceptibility, especially rs11866002 in CNOT1." +genetics_GWAS hsa-mir-20a Osteosarcoma 25663449 "This study suggests that SNPs in RISC complex genes may be involved in osteosarcoma susceptibility, especially rs11866002 in CNOT1." +genetics_GWAS hsa-mir-92-1 Osteosarcoma 25663449 "This study suggests that SNPs in RISC complex genes may be involved in osteosarcoma susceptibility, especially rs11866002 in CNOT1." +genetics_GWAS hsa-mir-124a "Diabetes Mellitus, Type 2" 25673459 "Affection of single-nucleotide polymorphisms in miR-27a, miR-124a, and miR-146a on susceptibility to type 2 diabetes mellitus in Chinese Han people." +genetics_GWAS hsa-mir-146a "Diabetes Mellitus, Type 2" 25673459 "Affection of single-nucleotide polymorphisms in miR-27a, miR-124a, and miR-146a on susceptibility to type 2 diabetes mellitus in Chinese Han people." +genetics_GWAS hsa-mir-27a "Diabetes Mellitus, Type 2" 25673459 "Affection of single-nucleotide polymorphisms in miR-27a, miR-124a, and miR-146a on susceptibility to type 2 diabetes mellitus in Chinese Han people." +genetics_GWAS hsa-mir-155 "Lymphoma, Large B-Cell, Diffuse" 25677902 "the miRs expression in B-NHLs[11q] provides a new suggestion, in addition to pathomorphological and clinical similarities between classical, i.e.,MYC translocation-positive BL, and B-NHLs[11q], to recognize the B-NHLs[11q] subgroup of DLBCL/BL category as a MYC translocation-negative variant of BL in most cases, and points to the potential utility of miR-155/BIC/miR-21/miR-26a for the differential diagnosis of a heterogeneous category of DLBCL/BL." +genetics_GWAS hsa-mir-21 "Lymphoma, Large B-Cell, Diffuse" 25677902 "the miRs expression in B-NHLs[11q] provides a new suggestion, in addition to pathomorphological and clinical similarities between classical, i.e.,MYC translocation-positive BL, and B-NHLs[11q], to recognize the B-NHLs[11q] subgroup of DLBCL/BL category as a MYC translocation-negative variant of BL in most cases, and points to the potential utility of miR-155/BIC/miR-21/miR-26a for the differential diagnosis of a heterogeneous category of DLBCL/BL." +genetics_GWAS hsa-mir-26a "Lymphoma, Large B-Cell, Diffuse" 25677902 "the miRs expression in B-NHLs[11q] provides a new suggestion, in addition to pathomorphological and clinical similarities between classical, i.e.,MYC translocation-positive BL, and B-NHLs[11q], to recognize the B-NHLs[11q] subgroup of DLBCL/BL category as a MYC translocation-negative variant of BL in most cases, and points to the potential utility of miR-155/BIC/miR-21/miR-26a for the differential diagnosis of a heterogeneous category of DLBCL/BL." +genetics_GWAS hsa-mir-17 Breast Neoplasms 25680407 Association of microRNA 17-92 cluster host gene (MIR17HG) polymorphisms with breast cancer. +genetics_GWAS hsa-mir-18 Breast Neoplasms 25680407 Association of microRNA 17-92 cluster host gene (MIR17HG) polymorphisms with breast cancer. +genetics_GWAS hsa-mir-19a Breast Neoplasms 25680407 Association of microRNA 17-92 cluster host gene (MIR17HG) polymorphisms with breast cancer. +genetics_GWAS hsa-mir-19b-1 Breast Neoplasms 25680407 Association of microRNA 17-92 cluster host gene (MIR17HG) polymorphisms with breast cancer. +genetics_GWAS hsa-mir-20a Breast Neoplasms 25680407 Association of microRNA 17-92 cluster host gene (MIR17HG) polymorphisms with breast cancer. +genetics_GWAS hsa-mir-92-1 Breast Neoplasms 25680407 Association of microRNA 17-92 cluster host gene (MIR17HG) polymorphisms with breast cancer. +genetics_GWAS hsa-mir-605 Li-Fraumeni Syndrome 25683625 A functional variant in miR-605 modifies the age of onset in Li-Fraumeni syndrome. +genetics_GWAS hsa-mir-3162 Prostate Neoplasms 25691096 "Findings from this large association study suggest that a focus on miRSNPs, including functional evaluation, can identify candidate risk loci below currently accepted statistical levels of genome-wide significance. Studies of miRNAs and their interactions with SNPs could provide further insights into the mechanisms of prostate cancer risk." +genetics_GWAS hsa-mir-370 Prostate Neoplasms 25691096 "Findings from this large association study suggest that a focus on miRSNPs, including functional evaluation, can identify candidate risk loci below currently accepted statistical levels of genome-wide significance. Studies of miRNAs and their interactions with SNPs could provide further insights into the mechanisms of prostate cancer risk." +genetics_GWAS hsa-mir-146a Gastrointestinal Neoplasms 25693929 "No significant association between miR-146a rs2910164G/C polymorphism and gastrointestinal cancer susceptibility was found in this meta-analysis. But for homozygous model, people with GG genotype may have increased risk of developing colorectal cancer." +genetics_GWAS hsa-mir-17 "Carcinoma, Lung, Non-Small-Cell" 25716425 The rs3660G>C affects KRT81 expression and thus influences survival in early-stage NSCLC. The analysis of the rs3660G>C polymorphism may be useful to identify patients at high risk of a poor disease outcome. +genetics_GWAS hsa-mir-20b "Carcinoma, Lung, Non-Small-Cell" 25716425 The rs3660G>C affects KRT81 expression and thus influences survival in early-stage NSCLC. The analysis of the rs3660G>C polymorphism may be useful to identify patients at high risk of a poor disease outcome. +genetics_GWAS hsa-mir-146a Chronic Obstructive Pulmonary Disease 25767384 "the rs2910164 CC and GC genotype was found to be associated with an improved lung function and milder disease stages, at least partially, mediated by its ability to increase in COX2 expression and PGE2 production." +genetics_GWAS hsa-mir-146b Psychiatric Disorders 25771167 Our findings highlight trans effects of common variants on microRNA-mediated gene expression as an integral part of the genetic architecture of complex disorders and traits. +genetics_GWAS hsa-mir-107 "Adenocarcinoma, Gastric" 25771723 miR-107 is dysregulated in GAC pathogenesis and the SNP rs2296616 may play a role in the process. +genetics_GWAS hsa-mir-1206 "Leukemia, Lymphocytic, Chronic, B-Cell" 25793711 These findings suggest that polymorphisms in genes involved in miRNAs biogenesis pathway as well as in pre-miRNAs contribute to the risk of CLL. Large-scale studies are needed to validate the current findings. +genetics_GWAS hsa-mir-196a-2 "Leukemia, Lymphocytic, Chronic, B-Cell" 25793711 These findings suggest that polymorphisms in genes involved in miRNAs biogenesis pathway as well as in pre-miRNAs contribute to the risk of CLL. Large-scale studies are needed to validate the current findings. +genetics_GWAS hsa-mir-146a Gastric Neoplasms 25795117 miR-27a rs895819 and miR-149 rs2292832 are of potential forewarning ability for gastric cancer risk. +genetics_GWAS hsa-mir-149 Gastric Neoplasms 25795117 miR-27a rs895819 and miR-149 rs2292832 are of potential forewarning ability for gastric cancer risk. +genetics_GWAS hsa-mir-196a-2 Gastric Neoplasms 25795117 miR-27a rs895819 and miR-149 rs2292832 are of potential forewarning ability for gastric cancer risk. +genetics_GWAS hsa-mir-27a Gastric Neoplasms 25795117 miR-27a rs895819 and miR-149 rs2292832 are of potential forewarning ability for gastric cancer risk. +genetics_GWAS hsa-mir-499 Gastric Neoplasms 25795117 miR-27a rs895819 and miR-149 rs2292832 are of potential forewarning ability for gastric cancer risk. +genetics_GWAS hsa-mir-548ac Multiple Sclerosis 25795118 Susceptibility variants in the CD58 gene locus point to a role of microRNA-548ac in the pathogenesis of multiple sclerosis. +genetics_GWAS hsa-mir-5481 Glaucoma 25809640 These data support the role of hsa-miR-548l as a regulator of FOXC1 translation and provide evidence for the c.*734A>T variant as a modifier factor for the activity of coding glaucoma-associated FOXC1 mutations. +genetics_GWAS hsa-mir-320e Cardiometabolic Disorders 25814643 We provide evidence for a model in which polymorphisms in miRNA-binding sites can both positively and negatively affect miRNA-mediated regulation of cardiometabolic genes. +genetics_GWAS hsa-mir-146a Autoimmune Diseases [unspecific] 25830862 MiR-146a rs2910164 G>C polymorphism was associated with the susceptibility of ADs. +genetics_GWAS hsa-mir-520a Colorectal Carcinoma 25834816 A functional variant at miR-520a binding site in PIK3CA alters susceptibility to colorectal cancer in a Chinese Han population. +genetics_GWAS hsa-mir-146a Ankylosing Spondylitis 25836258 Association between ankylosing spondylitis and the miR-146a and miR-499 polymorphisms. +genetics_GWAS hsa-mir-499 Ankylosing Spondylitis 25836258 Association between ankylosing spondylitis and the miR-146a and miR-499 polymorphisms. +genetics_GWAS hsa-mir-124-1 Neuropsychiatric Disorders [unspecific] 25841663 We showed for the first time the association of a functional polymorphism in MIR124-1 and aggressiveness. Known targets of miR-124 (such as BDNF and DRD4 genes) could explain the effect of this miRNA on behavior. A future analysis of additional novel functional polymorphisms in other brain expressed miRNAs could be useful for a deeper understanding of aggression in humans. +genetics_GWAS hsa-mir-608 "Carcinoma, Nasopharyngeal" 25861865 Polymorphism in mature microRNA-608 sequence is associated with an increased risk of nasopharyngeal carcinoma. +genetics_GWAS hsa-mir-146a Cardiovascular Diseases [unspecific] 25865299 Association of miR-146a rs2910164 polymorphism with cardio-cerebrovascular diseases: A systematic review and meta-analysis. +genetics_GWAS hsa-mir-499 "Carcinoma, Hepatocellular" 25867338 "subjects carrying the miR-499 A allele showed a greatly increased risk of HCC in subjects infected with HBV compared with subjects carrying the miR-499 A allele, with an adjusted odds ratio (95% confidence interval) of 1.53 (1.34-2.41). In conclusion, the miR-146aG>C and miR-499A>G polymorphisms do not have a role in the genetic susceptibility to HCC." +genetics_GWAS hsa-mir-146a Epilepsy 25891929 Our data indicate that the rs57095329 polymorphism in the promoter region of miR-146a is involved in the genetic susceptibility to DRE and the seizures frequency. +genetics_GWAS hsa-mir-196a-2 Vitiligo 25896941 miR-196a-2 rs11614913 polymorphism is associated with vitiligo by affecting heterodimeric molecular complexes of Tyr and Tyrp1. +genetics_GWAS hsa-mir-137 Schizophrenia 25921703 "The impact of genome wide supported microRNA-137 (MIR137) risk variants on frontal and striatal white matter integrity, neurocognitive functioning, and negative symptoms in schizophrenia." +genetics_GWAS hsa-mir-122 "Squamous Cell Carcinoma, Cerevial" 25955681 These findings indicate that the IL1A rs3783553 polymorphism may be associated with the etiology of CSCC. +genetics_GWAS hsa-mir-146a Metabolic Syndrome 25958310 The C allele of miRNA-146a rs2910164 showed positive association with increased susceptibility to metabolic syndrome and its phenotypes in the study population. +genetics_GWAS hsa-let-7c Hepatitis B Virus Infection 25966251 "The meta-analysis results indicated that the miR-196a-2*T,miR-122*del, miR-106b-25*A, and miR-let-7c*del alleles/carriers increase the risk of hepatitis B among the Asian population. However, the miR-146a, miR- 499,miR-149, miR-218, and miR-34b/c polymorphisms may not be linked with the risk of hepatitis B. Further investigations are warranted to determine the exact associations between microRNA mutations and hepatitis B susceptibility." +genetics_GWAS hsa-mir-106b Hepatitis B Virus Infection 25966251 "The meta-analysis results indicated that the miR-196a-2*T,miR-122*del, miR-106b-25*A, and miR-let-7c*del alleles/carriers increase the risk of hepatitis B among the Asian population. However, the miR-146a, miR- 499,miR-149, miR-218, and miR-34b/c polymorphisms may not be linked with the risk of hepatitis B. Further investigations are warranted to determine the exact associations between microRNA mutations and hepatitis B susceptibility." +genetics_GWAS hsa-mir-122 Hepatitis B Virus Infection 25966251 "The meta-analysis results indicated that the miR-196a-2*T,miR-122*del, miR-106b-25*A, and miR-let-7c*del alleles/carriers increase the risk of hepatitis B among the Asian population. However, the miR-146a, miR- 499,miR-149, miR-218, and miR-34b/c polymorphisms may not be linked with the risk of hepatitis B. Further investigations are warranted to determine the exact associations between microRNA mutations and hepatitis B susceptibility." +genetics_GWAS hsa-mir-146a Hepatitis B Virus Infection 25966251 "The meta-analysis results indicated that the miR-196a-2*T,miR-122*del, miR-106b-25*A, and miR-let-7c*del alleles/carriers increase the risk of hepatitis B among the Asian population. However, the miR-146a, miR- 499,miR-149, miR-218, and miR-34b/c polymorphisms may not be linked with the risk of hepatitis B. Further investigations are warranted to determine the exact associations between microRNA mutations and hepatitis B susceptibility." +genetics_GWAS hsa-mir-149 Hepatitis B Virus Infection 25966251 "The meta-analysis results indicated that the miR-196a-2*T,miR-122*del, miR-106b-25*A, and miR-let-7c*del alleles/carriers increase the risk of hepatitis B among the Asian population. However, the miR-146a, miR- 499,miR-149, miR-218, and miR-34b/c polymorphisms may not be linked with the risk of hepatitis B. Further investigations are warranted to determine the exact associations between microRNA mutations and hepatitis B susceptibility." +genetics_GWAS hsa-mir-196a-2 Hepatitis B Virus Infection 25966251 "The meta-analysis results indicated that the miR-196a-2*T,miR-122*del, miR-106b-25*A, and miR-let-7c*del alleles/carriers increase the risk of hepatitis B among the Asian population. However, the miR-146a, miR- 499,miR-149, miR-218, and miR-34b/c polymorphisms may not be linked with the risk of hepatitis B. Further investigations are warranted to determine the exact associations between microRNA mutations and hepatitis B susceptibility." +genetics_GWAS hsa-mir-218 Hepatitis B Virus Infection 25966251 "The meta-analysis results indicated that the miR-196a-2*T,miR-122*del, miR-106b-25*A, and miR-let-7c*del alleles/carriers increase the risk of hepatitis B among the Asian population. However, the miR-146a, miR- 499,miR-149, miR-218, and miR-34b/c polymorphisms may not be linked with the risk of hepatitis B. Further investigations are warranted to determine the exact associations between microRNA mutations and hepatitis B susceptibility." +genetics_GWAS hsa-mir-34b Hepatitis B Virus Infection 25966251 "The meta-analysis results indicated that the miR-196a-2*T,miR-122*del, miR-106b-25*A, and miR-let-7c*del alleles/carriers increase the risk of hepatitis B among the Asian population. However, the miR-146a, miR- 499,miR-149, miR-218, and miR-34b/c polymorphisms may not be linked with the risk of hepatitis B. Further investigations are warranted to determine the exact associations between microRNA mutations and hepatitis B susceptibility." +genetics_GWAS hsa-mir-34c Hepatitis B Virus Infection 25966251 "The meta-analysis results indicated that the miR-196a-2*T,miR-122*del, miR-106b-25*A, and miR-let-7c*del alleles/carriers increase the risk of hepatitis B among the Asian population. However, the miR-146a, miR- 499,miR-149, miR-218, and miR-34b/c polymorphisms may not be linked with the risk of hepatitis B. Further investigations are warranted to determine the exact associations between microRNA mutations and hepatitis B susceptibility." +genetics_GWAS hsa-mir-499 Hepatitis B Virus Infection 25966251 "The meta-analysis results indicated that the miR-196a-2*T,miR-122*del, miR-106b-25*A, and miR-let-7c*del alleles/carriers increase the risk of hepatitis B among the Asian population. However, the miR-146a, miR- 499,miR-149, miR-218, and miR-34b/c polymorphisms may not be linked with the risk of hepatitis B. Further investigations are warranted to determine the exact associations between microRNA mutations and hepatitis B susceptibility." +genetics_GWAS hsa-mir-27a Colorectal Carcinoma 25976406 miR-27a rs895819 polymorphism was associated with increased risk of colorectal cancer in Chinese population. +genetics_GWAS hsa-mir-122 Oral Neoplasms 25981582 "These results suggest that IL-1¦Á 3' UTR rs3783553 polymorphism may be functional and influence susceptibility to HPV16-associated OSCC, particularly for SCCOP. Validation of our findings is warranted." +genetics_GWAS hsa-mir-21 "Carcinoma, Cervical" 25987069 E6D25E of the HPV16As variant differed from the E6 prototype in its activities on epigenetic modulation and immune surveillance and this might be a key factor for the important role of this variant in cervical cancer progression. +genetics_GWAS hsa-mir-214 Gastric Neoplasms 25998065 "Our data suggested that rs114673809, which is located at the miR-214 binding site in the 3'-UTR of MTHFR, may play an important role in the development of gastric cancer in a Chinese Han population." +genetics_GWAS hsa-mir-146a Endometrial Neoplasms 26008204 "Association of SNPs in miR-146a, miR-196a2, and miR-499 with the risk of endometrial/ovarian cancer." +genetics_GWAS hsa-mir-196a-2 Endometrial Neoplasms 26008204 "Association of SNPs in miR-146a, miR-196a2, and miR-499 with the risk of endometrial/ovarian cancer." +genetics_GWAS hsa-mir-499 Endometrial Neoplasms 26008204 "Association of SNPs in miR-146a, miR-196a2, and miR-499 with the risk of endometrial/ovarian cancer." +genetics_GWAS hsa-mir-509 Colorectal Carcinoma 26010608 These findings suggest that the rs13347C/T in microRNA binding site may be potential biomarkers for genetic susceptibility to CRC. +genetics_GWAS hsa-mir-149 Rheumatoid Arthritis 26032077 "SNP rs22928323 in miR-149 is correlated with RA in the east of Chinese Han population, whereas there is no correlation between miR-149 polymorphism and clinical characteristics in patients with RA." +genetics_GWAS hsa-mir-146a Behcet Disease 26053525 Association of Pre-miRNA-499 rs3746444 and Pre-miRNA-146a rs2910164 Polymorphisms and Susceptibility to Behcet's Disease. +genetics_GWAS hsa-mir-499 Behcet Disease 26053525 Association of Pre-miRNA-499 rs3746444 and Pre-miRNA-146a rs2910164 Polymorphisms and Susceptibility to Behcet's Disease. +genetics_GWAS hsa-mir-4293 "Squamous Cell Carcinoma, Esophageal" 26055141 miR-449b rs10061133 and miR-4293 rs12220909 polymorphisms are associated with decreased esophageal squamous cell carcinoma in a Chinese population. +genetics_GWAS hsa-mir-449b "Squamous Cell Carcinoma, Esophageal" 26055141 miR-449b rs10061133 and miR-4293 rs12220909 polymorphisms are associated with decreased esophageal squamous cell carcinoma in a Chinese population. +genetics_GWAS hsa-mir-155 Melanoma 26068396 Polymorphisms in 3'UTR of TYRP1 mRNA can affect TYRP1 mRNA regulation by miR-155 and its subsequent translation into protein. These SNPs can render TYRP1 mRNA and protein expression nonsusceptible to miR-155 activity and disclose a prognostic value for TYRP1 protein in a subgroup of melanoma patients. These data support the interest in the prognostic value of melanogenic markers and propose TYRP1 to refine prognosis in patients with advanced disease. +genetics_GWAS hsa-mir-146a Lung Neoplasms 26083623 The interactions between miRNA SNPs and cooking oil fume exposure suggested by ORs of different combination were not statistically significant. +genetics_GWAS hsa-mir-196a-2 Lung Neoplasms 26083623 The interactions between miRNA SNPs and cooking oil fume exposure suggested by ORs of different combination were not statistically significant. +genetics_GWAS hsa-mir-27a Lung Neoplasms 26083623 The interactions between miRNA SNPs and cooking oil fume exposure suggested by ORs of different combination were not statistically significant. +genetics_GWAS hsa-mir-423 Lung Neoplasms 26083623 The interactions between miRNA SNPs and cooking oil fume exposure suggested by ORs of different combination were not statistically significant. +genetics_GWAS hsa-mir-608 Lung Neoplasms 26083623 The interactions between miRNA SNPs and cooking oil fume exposure suggested by ORs of different combination were not statistically significant. +genetics_GWAS hsa-mir-146a Alzheimer Disease 26095531 A single nucleotide polymorphism in primary-microRNA-146a reduces the expression of mature microRNA-146a in patients with Alzheimer's disease and is associated with the pathogenesis of Alzheimer's disease. +genetics_GWAS hsa-mir-196a-2 Prostate Neoplasms 26112096 "Assessment of association between genetic variants in microRNA genes hsa-miR-499,hsa-miR-196a2 and hsa-miR-27a and prostate cancer risk in Serbian population." +genetics_GWAS hsa-mir-27a Prostate Neoplasms 26112096 "Assessment of association between genetic variants in microRNA genes hsa-miR-499,hsa-miR-196a2 and hsa-miR-27a and prostate cancer risk in Serbian population." +genetics_GWAS hsa-mir-499 Prostate Neoplasms 26112096 "Assessment of association between genetic variants in microRNA genes hsa-miR-499,hsa-miR-196a2 and hsa-miR-27a and prostate cancer risk in Serbian population." +genetics_GWAS hsa-mir-146a Melanoma 26122011 Association of microRNA 146a polymorphism rs2910164 and the risk of melanoma in an Italian population. +genetics_GWAS hsa-mir-196a-2 Breast Neoplasms 26125831 Our results suggested that miR-146a rs2910164 G>C and miR-196a2 rs11614913 T>C may be biomarkers for predicting breast cancer risk in the Chinese population. +genetics_GWAS hsa-mir-3622a Colorectal Carcinoma 26147304 "Our results indicate variations in RAN rs14035, DICER1 rs3742330, XPO5 rs11077, and DROSHA rs10719 of Korean patients are significantly associated with their risk of CRC." +genetics_GWAS hsa-mir-5582 Colorectal Carcinoma 26147304 "Our results indicate variations in RAN rs14035, DICER1 rs3742330, XPO5 rs11077, and DROSHA rs10719 of Korean patients are significantly associated with their risk of CRC." +genetics_GWAS hsa-mir-125b Breast Neoplasms 26190157 Evaluation the susceptibility of five polymorphisms in microRNA-binding sites to female breast cancer risk in Chinese population. +genetics_GWAS hsa-mir-320 Breast Neoplasms 26190157 Evaluation the susceptibility of five polymorphisms in microRNA-binding sites to female breast cancer risk in Chinese population. +genetics_GWAS hsa-mir-367 Breast Neoplasms 26190157 Evaluation the susceptibility of five polymorphisms in microRNA-binding sites to female breast cancer risk in Chinese population. +genetics_GWAS hsa-mir-570 Viral Infectious Disease 26199425 it was demonstrated that human CYP2E1 was regulated by miR-570 in a genotype-dependent manner. This report describes the first proof that SNP in 3'-UTR of human P450 affects binding of miRNA to modulate the expression in the liver. +genetics_GWAS hsa-mir-146a Pulmonary Hypertension 26202355 "the results of this study demonstrate that the rs2910164 CC and GC genotype is associated with a decreased risk of pulmonary hypertension, which could be attributed to defective miRNA processing and compromised ability to inhibit production of COX-2 and PGI2." +genetics_GWAS hsa-mir-146a Intracranial Aneurysm 26214448 Association between the hsa-miR-146a rs2910164 functional polymorphism with susceptibility to intracranial aneurysm. +genetics_GWAS hsa-mir-146a "Squamous Cell Carcinoma, Oral" 26214637 "The miR-146a rs2910164 polymorphism is associated with increased risk for cervical and skin SCC. In contrast, rs2910164 in miR-146a is related to decreased risk for nasopharyngeal and oral SCC." +genetics_GWAS hsa-mir-483 Colorectal Carcinoma 26235181 Both the single nucleotide polymorphism variants showed a positive association toward risk of lung cancer. +genetics_GWAS hsa-mir-551a Colorectal Carcinoma 26235181 Both the single nucleotide polymorphism variants showed a positive association toward risk of lung cancer. +genetics_GWAS hsa-mir-219 Schizophrenia 26257337 "These findings suggest that GRIN2B may be associated with schizophrenia and interaction effects of the polymorphisms in hsa-miR-219, CAKM2G, GRIN2B and GRIN3A may confer susceptibility to schizophrenia in the Chinese Han population." +genetics_GWAS hsa-mir-100 "Squamous Cell Carcinoma, Esophageal" 26261633 Genetic variation in miR-100 rs1834306 is associated with decreased risk for esophageal squamous cell carcinoma in Kazakh patients in northwest China. +genetics_GWAS hsa-let-7c Essential Hypertension 26274321 "In conclusion, our experimental results provide evidence that the T allele of rs17168525 in the 3'-UTR of myotrophin might influence the level of myotrophin protein by interfering with let-7/miR-98 binding." +genetics_GWAS hsa-mir-503 Essential Hypertension 26274321 "In conclusion, our experimental results provide evidence that the T allele of rs17168525 in the 3'-UTR of myotrophin might influence the level of myotrophin protein by interfering with let-7/miR-98 binding." +genetics_GWAS hsa-mir-98 Essential Hypertension 26274321 "In conclusion, our experimental results provide evidence that the T allele of rs17168525 in the 3'-UTR of myotrophin might influence the level of myotrophin protein by interfering with let-7/miR-98 binding." +genetics_GWAS hsa-mir-146a Head And Neck Neoplasms 26277865 Significant association between functional microRNA polymorphisms and head and neck cancer susceptibility: a comprehensive meta-analysis. +genetics_GWAS hsa-mir-149 Head And Neck Neoplasms 26277865 Significant association between functional microRNA polymorphisms and head and neck cancer susceptibility: a comprehensive meta-analysis. +genetics_GWAS hsa-mir-196a-2 Head And Neck Neoplasms 26277865 Significant association between functional microRNA polymorphisms and head and neck cancer susceptibility: a comprehensive meta-analysis. +genetics_GWAS hsa-mir-499 Head And Neck Neoplasms 26277865 Significant association between functional microRNA polymorphisms and head and neck cancer susceptibility: a comprehensive meta-analysis. +genetics_GWAS hsa-mir-27a Colorectal Carcinoma 26302683 Genotype GG of rs895819 Functional Polymorphism Within miR-27a Might Increase Genetic Susceptibility to Colorectal Cancer in Han Chinese Population +genetics_GWAS hsa-mir-34b Digestive System Neoplasms 26320502 The current evidence supports the conclusion that the miR-34b/c rs4938723 polymorphism decreases an individual's susceptibility to digestive cancers. +genetics_GWAS hsa-mir-146a "Carcinoma, Renal Cell" 26323945 the observed association between the GG and GC genotype and poorer survival rate of RCC was at least partially mediated by the decreased expression of miR-146a. +genetics_GWAS hsa-mir-214 Diabetes Mellitus 26329304 "We have detected the interactions of hsa-miR-214-5p/hsa-miR-550a-5p and the 3'UTR SNP of the HNF1B gene by in vitro luciferase reporter assays, and propose that the binding of such miRNAs regulates the expression of the HNF1B gene and the susceptibility of T2DM." +genetics_GWAS hsa-mir-550a Diabetes Mellitus 26329304 "We have detected the interactions of hsa-miR-214-5p/hsa-miR-550a-5p and the 3'UTR SNP of the HNF1B gene by in vitro luciferase reporter assays, and propose that the binding of such miRNAs regulates the expression of the HNF1B gene and the susceptibility of T2DM." +genetics_GWAS hsa-mir-146a Neoplasms [unspecific] 26337564 We conclude that rs2910164 may represent a valuable biomarker associated with the risk of developing specific types of cancer. +genetics_GWAS hsa-mir-146a Gastric Neoplasms 26345764 "Overall, this meta-analysis failed to detect an association between five common miR-146a gene polymorphisms and GC susceptibility. However, this does not necessarily completely rule out a correlation between miRNA polymorphisms and GC susceptibility." +genetics_GWAS hsa-mir-149 Gastric Neoplasms 26345764 "Overall, this meta-analysis failed to detect an association between five common miR-146a gene polymorphisms and GC susceptibility. However, this does not necessarily completely rule out a correlation between miRNA polymorphisms and GC susceptibility." +genetics_GWAS hsa-mir-196a-2 Gastric Neoplasms 26345764 "Overall, this meta-analysis failed to detect an association between five common miR-146a gene polymorphisms and GC susceptibility. However, this does not necessarily completely rule out a correlation between miRNA polymorphisms and GC susceptibility." +genetics_GWAS hsa-mir-27a Gastric Neoplasms 26345764 "Overall, this meta-analysis failed to detect an association between five common miR-146a gene polymorphisms and GC susceptibility. However, this does not necessarily completely rule out a correlation between miRNA polymorphisms and GC susceptibility." +genetics_GWAS hsa-mir-499 Gastric Neoplasms 26345764 "Overall, this meta-analysis failed to detect an association between five common miR-146a gene polymorphisms and GC susceptibility. However, this does not necessarily completely rule out a correlation between miRNA polymorphisms and GC susceptibility." +genetics_GWAS hsa-mir-146a Gastric Neoplasms 26345790 "In summary, the results suggested that the miR-146a rs2910164 polymorphism was related to gastric cancer risk in Asians but not in Caucasians, and no distinct correlation seemed to exist between the miR-196a-2 rs11614913 polymorphism and the risk of gastric cancer." +genetics_GWAS hsa-mir-196a-2 Gastric Neoplasms 26345790 "In summary, the results suggested that the miR-146a rs2910164 polymorphism was related to gastric cancer risk in Asians but not in Caucasians, and no distinct correlation seemed to exist between the miR-196a-2 rs11614913 polymorphism and the risk of gastric cancer." +genetics_GWAS hsa-mir-196a-2 "Carcinoma, Hepatocellular" 26365437 "In conclusion,the donor miR-196a-2 rs11614913 polymorphism is associated with HCC recurrence after LT and improves the predictive value of clinical models. The overexpression of miR-196a in the liver might provide a tumor-favorable environment for the development of HCC." +genetics_GWAS hsa-mir-219-1 "Squamous Cell Carcinoma, Esophageal" 26379361 These findings indicated that functional polymorphisms miR-219-1 rs107822G > A might change individual susceptibility to Kazakh ESCC. +genetics_GWAS hsa-mir-505 Gastric Neoplasms 26394032 "The PSMD10 rs111638916 SNP is highly associated with an increased risk of GC in Chinese patients, and could serve as a novel biomarker for this disease." +genetics_GWAS hsa-mir-34b "Carcinoma, Thyroid, Papillary" 26402809 These findings indicate that the miR-34b/c rs4938723 and TP-53 Arg72Pro polymorphisms may contribute to the susceptibility of PTC. +genetics_GWAS hsa-mir-34c "Carcinoma, Thyroid, Papillary" 26402809 These findings indicate that the miR-34b/c rs4938723 and TP-53 Arg72Pro polymorphisms may contribute to the susceptibility of PTC. +genetics_GWAS hsa-mir-196a-2 Gastric Neoplasms 26406571 "Our studies suggested that the miR-146a rs2910164 polymorphism might marginally contribute to a decreased risk of gastric cancer, especially in Caucasians, whereas the miR-196a2 rs11614913 polymorphism might not be associated with susceptibility to GC." +genetics_GWAS hsa-mir-155 Epilepsy 26425555 "This study first demonstrates the association of MIR155HG/miR-155 tag SNPs with epilepsy and shows that rare CNVs were found exclusively in epileptic patients, clarifying the genetic role of miR-155 in epilepsy." +genetics_GWAS hsa-mir-146a Kidney Diseases [unspecific] 26426696 "There was no association of rs2910164 with susceptibility to IgAN in adults from a Chinese Han population. However, rs2910164 was correlated with the age of onset of IgAN in adult patients." +genetics_GWAS hsa-mir-137 Schizophrenia 26429811 A GWAS SNP for Schizophrenia Is Linked to the Internal MIR137 Promoter and Supports Differential Allele-Specific Expression. +genetics_GWAS hsa-mir-101-1 "Carcinoma, Hepatocellular" 26434859 "Our results revealed no significant association between miR-149 (rs2292832) and miR-101-1 (rs7536540) and the risk of HCC in our Thai population.However, this research is the first study of miR-149 (rs2292832) and miR-101-1 (rs7536541) in HCC in Thai populations and the results need to be confirmed with a larger population." +genetics_GWAS hsa-mir-149 "Carcinoma, Hepatocellular" 26434859 "Our results revealed no significant association between miR-149 (rs2292832) and miR-101-1 (rs7536540) and the risk of HCC in our Thai population.However, this research is the first study of miR-149 (rs2292832) and miR-101-1 (rs7536540) in HCC in Thai populations and the results need to be confirmed with a larger population." +genetics_GWAS hsa-mir-146a "Carcinoma, Cervical" 26464690 "The miR-146a (rs2910164) polymorphism is significantly correlated to ethnic factor and tumor diameters. miR-146a has differential expression in cervical tissues. Allele G of miR-146a (rs2910164) is related to the high expression of miR-146a, and the progression of cervical cancer." +genetics_GWAS hsa-mir-196a-2 "Carcinoma, Hepatocellular" 26464719 "In conclusion, miR-196a2 rs11614913 polymorphism may contribute to identifying individuals, especially in HBV-infected subjects, who are at high risk for HCC." +genetics_GWAS hsa-mir-92a Breast Neoplasms 26471763 "MDM4 SNP34091 status to be associated with reduced risk of breast cancer, in particular in individuals carrying the MDM2 SNP309GG genotype, but not to be associated with either lung-, colon- or prostate cancer." +genetics_GWAS hsa-mir-146a Breast Neoplasms 26476291 The microRNA miR146a has a potential role in the development of breast cancer and the effects of its SNPs require further inquiry to determine the nature of their influence on breast tissue and cancer. +genetics_GWAS hsa-mir-34b Male Infertility 26505368 Our results indicated that the MTHFR 3'-UTR rs55763075 polymorphism might modify the susceptibility to male infertility with idiopathic azoospermia. +genetics_GWAS hsa-mir-146a Carotid Atherosclerosis 26505665 "The miR-146a rs2910164 polymorphism might be associated with carotid vulnerable plaque risk in Chinese type 2 diabetes mellitus patients, particularly in older patients, females, those with diabetes duration of more than 10 years and those with hypertension. The transcriptional coactivator p300 rs20551 polymorphism may not be a risk factor for the development or progression of atherosclerosis in type 2 diabetes mellitus." +genetics_GWAS hsa-mir-423 "Squamous Cell Carcinoma, Esophageal" 26518769 "Four SNPs including miR-196a2 rs11614913, miR-146a rs2910164, miR-499 rs3746444, and miR-423 rs6505162 were selected with comprehensive collection strategy and genotyped using the SNaPshot Multiplex System." +genetics_GWAS hsa-let-7 Hematologic Neoplasms 26520014 our compiled results will be valuable for researchers interested in determining the role of target-SNPs in the development of hematological malignancies. +genetics_GWAS hsa-mir-146 Hematologic Neoplasms 26520014 our compiled results will be valuable for researchers interested in determining the role of target-SNPs in the development of hematological malignancies. +genetics_GWAS hsa-mir-150 Hematologic Neoplasms 26520014 our compiled results will be valuable for researchers interested in determining the role of target-SNPs in the development of hematological malignancies. +genetics_GWAS hsa-mir-155 Hematologic Neoplasms 26520014 our compiled results will be valuable for researchers interested in determining the role of target-SNPs in the development of hematological malignancies. +genetics_GWAS hsa-mir-15a Hematologic Neoplasms 26520014 our compiled results will be valuable for researchers interested in determining the role of target-SNPs in the development of hematological malignancies. +genetics_GWAS hsa-mir-16-1 Hematologic Neoplasms 26520014 our compiled results will be valuable for researchers interested in determining the role of target-SNPs in the development of hematological malignancies. +genetics_GWAS hsa-mir-21 Hematologic Neoplasms 26520014 our compiled results will be valuable for researchers interested in determining the role of target-SNPs in the development of hematological malignancies. +genetics_GWAS hsa-mir-221 Hematologic Neoplasms 26520014 our compiled results will be valuable for researchers interested in determining the role of target-SNPs in the development of hematological malignancies. +genetics_GWAS hsa-mir-222 Hematologic Neoplasms 26520014 our compiled results will be valuable for researchers interested in determining the role of target-SNPs in the development of hematological malignancies. +genetics_GWAS hsa-mir-29 Hematologic Neoplasms 26520014 our compiled results will be valuable for researchers interested in determining the role of target-SNPs in the development of hematological malignancies. +genetics_GWAS hsa-mir-34 Hematologic Neoplasms 26520014 our compiled results will be valuable for researchers interested in determining the role of target-SNPs in the development of hematological malignancies. +genetics_GWAS hsa-mir-372 Hematologic Neoplasms 26520014 our compiled results will be valuable for researchers interested in determining the role of target-SNPs in the development of hematological malignancies. +genetics_GWAS hsa-mir-373 Hematologic Neoplasms 26520014 our compiled results will be valuable for researchers interested in determining the role of target-SNPs in the development of hematological malignancies. +genetics_GWAS hsa-mir-708 Hematologic Neoplasms 26520014 our compiled results will be valuable for researchers interested in determining the role of target-SNPs in the development of hematological malignancies. +genetics_GWAS hsa-mir-196a-2 Liver Cirrhosis 26529280 "In summary, rs12304647 is associated with a reduced risk of progression to HCC in patients with chronic HBV infection." +genetics_GWAS hsa-mir-146a Acute Coronary Syndrome 26537765 These findings indicate that miR-146a rs2910164 may act as a novel molecular marker for ACS susceptibility. +genetics_GWAS hsa-mir-196a-2 Atrial Fibrillation 26554236 "Our data support that the pre-miR-196a2 polymorphism is associated with AF, and the C allele is a risk factor for AF." +genetics_GWAS hsa-mir-125 Diabetic Nephropathy 26563755 "We identified miR-125a as a direct regulator of IL-6R, and the genotype of rs12976445 might be a novel predictor of the development of DN in DM." +genetics_GWAS hsa-mir-145 Breast Neoplasms 26577090 Our study is the first to report an association between a miR-SNP in MIR145 and breast cancer risk in individuals of Caucasian background. This finding requires further validation through genotyping of larger cohorts or in individuals of different ethnicities to determine the potential significance of this finding as well as studies aimed to determine functional significance. +genetics_GWAS hsa-mir-499 Gastric Neoplasms 26597478 The present study indicated that miR-499 rs3746444 might contribute to GC risk and this SNP could be developed as a biomarker for GC prediction. +genetics_GWAS hsa-mir-146a "Stroke, Ischemic" 26608782 "Although the 3 SNPs might be associated with IS, the association varied significantly in different countries." +genetics_GWAS hsa-mir-196a-2 "Stroke, Ischemic" 26608782 "Although the 3 SNPs might be associated with IS, the association varied significantly in different countries." +genetics_GWAS hsa-mir-499 "Stroke, Ischemic" 26608782 "Although the 3 SNPs might be associated with IS, the association varied significantly in different countries." +genetics_GWAS hsa-mir-149 "Squamous Cell Carcinoma, Oral" 26625766 Our study suggests that miR-196a2C>T and miR-149C>T polymorphisms may play crucial roles in the development of OSCC in South Indian subjects. +genetics_GWAS hsa-mir-124 Neoplasms [unspecific] 26625819 This meta-analysis suggests that the miR-124 rs531564 C > G polymorphism is an important risk factor for cancers among the Chinese population. +genetics_GWAS hsa-let-7a "Carcinoma, Colon" 26630397 "Of the 327 SNPs identified in the literature as being important because of their potential regulation of miRNA expression levels, 12.5% had statistically significantly associations with miRNA expression. However, only two of these SNPs were significantly associated with colon cancer." +genetics_GWAS hsa-mir-143 "Carcinoma, Colon" 26630397 "Of the 327 SNPs identified in the literature as being important because of their potential regulation of miRNA expression levels, 12.5% had statistically significantly associations with miRNA expression. However, only two of these SNPs were significantly associated with colon cancer." +genetics_GWAS hsa-mir-145 "Carcinoma, Colon" 26630397 "Of the 327 SNPs identified in the literature as being important because of their potential regulation of miRNA expression levels, 12.5% had statistically significantly associations with miRNA expression. However, only two of these SNPs were significantly associated with colon cancer." +genetics_GWAS hsa-mir-146a "Carcinoma, Colon" 26630397 "Of the 327 SNPs identified in the literature as being important because of their potential regulation of miRNA expression levels, 12.5% had statistically significantly associations with miRNA expression. However, only two of these SNPs were significantly associated with colon cancer." +genetics_GWAS hsa-mir-19a "Carcinoma, Colon" 26630397 "Of the 327 SNPs identified in the literature as being important because of their potential regulation of miRNA expression levels, 12.5% had statistically significantly associations with miRNA expression. However, only two of these SNPs were significantly associated with colon cancer." +genetics_GWAS hsa-mir-19b "Carcinoma, Colon" 26630397 "Of the 327 SNPs identified in the literature as being important because of their potential regulation of miRNA expression levels, 12.5% had statistically significantly associations with miRNA expression. However, only two of these SNPs were significantly associated with colon cancer." +genetics_GWAS hsa-mir-214 "Carcinoma, Colon" 26630397 "Of the 327 SNPs identified in the literature as being important because of their potential regulation of miRNA expression levels, 12.5% had statistically significantly associations with miRNA expression. However, only two of these SNPs were significantly associated with colon cancer." +genetics_GWAS hsa-mir-25 "Carcinoma, Colon" 26630397 "Of the 327 SNPs identified in the literature as being important because of their potential regulation of miRNA expression levels, 12.5% had statistically significantly associations with miRNA expression. However, only two of these SNPs were significantly associated with colon cancer." +genetics_GWAS hsa-mir-525 "Carcinoma, Colon" 26630397 "Of the 327 SNPs identified in the literature as being important because of their potential regulation of miRNA expression levels, 12.5% had statistically significantly associations with miRNA expression. However, only two of these SNPs were significantly associated with colon cancer." +genetics_GWAS hsa-mir-140 Bladder Neoplasms 26695686 "Together, these results suggest that rs35592567 in TP63 may be a novel causal variant contributing to the susceptibility to bladder cancer, which provides additional insight into the pathogenesis of bladder carcinogenesis." +genetics_GWAS hsa-mir-196a-2 Breast Neoplasms 26710106 Somatic Mutation of the SNP rs11614913 and Its Association with Increased MIR 196A2 Expression in Breast Cancer. +genetics_GWAS hsa-mir-603 Breast Neoplasms 26718432 "In conclusion,the findings indicated that Mir603 rs11014002 T allele might contribute to decrease the risk of BC in a sample of Iranian population. Further studies with larger sample sizes and different ethnicities are warranted to confirm our findings." +genetics_GWAS hsa-mir-449a Gastric Neoplasms 26722545 "In conclusion, our findings suggest that miR-449a rs112310158 is a genetic risk factor for GC." +genetics_GWAS hsa-mir-146a "Carcinoma, Thyroid, Papillary" 26722556 "Our study indicated that the miR-146a polymorphism was significantly associated with PTC risk. In contrast, meta-analysis revealed no evidence of association between miR-146a variants and PTC risk. Further studies are required to elucidate the role of miR-146a in the etiology of PTC." +genetics_GWAS hsa-mir-492 "Carcinoma, Hepatocellular" 26753964 miR-492G>C polymorphism (rs2289030) is associated with overall survival of hepatocellular carcinoma patients. +genetics_GWAS hsa-mir-146a Breast Neoplasms 26785832 "e identified one rare variant in MIR146A, four in MIR146B, five in BRCA1 3'-UTR and one in BRCA2 3'-UTR in 716 index cases and 619 controls." +genetics_GWAS hsa-mir-146a Ovarian Neoplasms 26785832 "e identified one rare variant in MIR146A, four in MIR146B, five in BRCA1 3'-UTR and one in BRCA2 3'-UTR in 716 index cases and 619 controls." +genetics_GWAS hsa-mir-146b Breast Neoplasms 26785832 "we identified one rare variant in MIR146A, four in MIR146B, five in BRCA1 3'-UTR and one in BRCA2 3'-UTR in 716 index cases and 619 controls." +genetics_GWAS hsa-mir-146b Ovarian Neoplasms 26785832 "we identified one rare variant in MIR146A, four in MIR146B, five in BRCA1 3'-UTR and one in BRCA2 3'-UTR in 716 index cases and 619 controls." +genetics_GWAS hsa-mir-146a Colorectal Carcinoma 26813595 "SNPs in the miRNA genes are important for tumorigenesis. The changes by hsa-mir-146a rs1052918 C>G may result in loss of Wnt, constant activation of the Wnt signaling pathway, and uncontrolled cell proliferation and tumor progression." +genetics_GWAS hsa-mir-608 "Carcinoma, Hepatocellular" 26815502 MiR-608 rs4919510 is associated with prognosis of hepatocellular carcinoma. +genetics_GWAS hsa-mir-149 "Carcinoma, Hepatocellular" 26823863 "Predictive role of miR-146a rs2910164 (C>G), miR-149 rs2292832 (T>C), miR-196a2 rs11614913 (T>C) and miR-499 rs3746444 (T>C) in the development of hepatocellular carcinoma." +genetics_GWAS hsa-mir-137 Schizophrenia 26836412 Polymorphisms in MIR137HG and microRNA-137-regulated genes influence gray matter structure in schizophrenia. +genetics_GWAS hsa-mir-199a "Adenocarcinoma, Pancreatic Ductal" 26872370 our study demonstrates that host genetic variants could disturb the regulation of the miR-199a/HIF1A regulatory loop and alter PDAC risk and poor prognosis. +genetics_GWAS hsa-mir-146a Atherosclerosis 26875519 Apolipoprotein E Epsilon 4 Enhances the Association between the rs2910164 Polymorphism of miR-146a and Risk of Atherosclerotic Cerebral Infarction. +genetics_GWAS hsa-mir-146a Coronary Artery Disease 26909569 "Our data provide the first evidence for the association of miR-146a rs2910164 and TCF21 rs12190287 with CAD in an Iranian population, encouraging further research to elucidate the disease-related effects of miR-146a rs2910164." +genetics_GWAS hsa-mir-146a Lung Neoplasms 26926727 "Rs11614913, rs12894467 and rs2910164 polymorphism were potentially associated with primary lung cancer in Fujian Han population." +genetics_GWAS hsa-mir-196a-2 Lung Neoplasms 26926727 "Rs11614913, rs12894467 and rs2910164 polymorphism were potentially associated with primary lung cancer in Fujian Han population." +genetics_GWAS hsa-mir-26a-1 Lung Neoplasms 26926727 "Rs11614913, rs12894467 and rs2910164 polymorphism were potentially associated with primary lung cancer in Fujian Han population." +genetics_GWAS hsa-mir-27a Lung Neoplasms 26926727 "Rs11614913, rs12894467 and rs2910164 polymorphism were potentially associated with primary lung cancer in Fujian Han population." +genetics_GWAS hsa-mir-300 Lung Neoplasms 26926727 "Rs11614913, rs12894467 and rs2910164 polymorphism were potentially associated with primary lung cancer in Fujian Han population." +genetics_GWAS hsa-mir-15a "Leukemia, Lymphocytic, Chronic, B-Cell" 26959643 mutations in the mir-15a/16-1 loci are responsible for decreased expression +genetics_GWAS hsa-mir-423 Lung Neoplasms 26973201 These findings suggest that miR-146a rs2910164C>G and miR-423 rs6505162C>A polymorphisms may contribute to genetic susceptibility to lung cancer and lung adenocarcinoma in Chinese non-smoking females. +genetics_GWAS hsa-mir-146a Diabetic Nephropathy 26997512 Rs2910164 is significantly associated with microvascular complications DN in patients with T1DM and DME in patients with T2DM. +genetics_GWAS hsa-mir-146a Diabetic Retinopathy 26997512 Rs2910164 is significantly associated with microvascular complications DN in patients with T1DM and DME in patients with T2DM. +genetics_GWAS hsa-mir-618 "Stroke, Ischemic" 27011381 Our findings suggest that miR-618 SNP rs2682818 may play an important role in the recurrence of ischemic stroke. +genetics_GWAS hsa-mir-149 Squamous Cell Carcinoma 27050146 hsa-mir-149 rs2292832 and hsa-mir-499 rs3746444 polymorphisms play a significant role in the prognosis of SCCNOP +genetics_GWAS hsa-mir-365 Neuropsychiatric Disorders [unspecific] 27074815 single nucleotide polymorphism (SNP) rs2235749 (in high linkage disequilibrium with rs910080) modifies striatal PDYN expression via impaired binding of miR-365 +genetics_GWAS hsa-mir-137 Schizophrenia 27096222 A single nucleotide polymorphism rs1625579 in the miR-137 gene has recently been reported to confer risk of schizophrenia +genetics_GWAS hsa-mir-146a Psoriasis 27098222 "The miR-146a SNPs rs2910164, rs57095329, rs2431697 are associated with susceptibility to certain autoimmune diseases." +genetics_GWAS hsa-mir-149 "Carcinoma, Hepatocellular" 27141902 "A meta-analysis of microRNA-149, microRNA-499 gene polymorphism and susceptibility to hepatocellular carcinoma" +genetics_GWAS hsa-mir-146a Graft-Versus-Host Disease 27156151 "expression levels of miR-146aC>G, miR-196a2T>C and putative gene-gene interaction between miR-146a, miR-196a2, miR-149 may be involved in RIF development in Korean women." +genetics_GWAS hsa-mir-149 Graft-Versus-Host Disease 27156151 "expression levels of miR-146aC>G, miR-196a2T>C and putative gene-gene interaction between miR-146a, miR-196a2, miR-149 may be involved in RIF development in Korean women." +genetics_GWAS hsa-mir-196a-2 Graft-Versus-Host Disease 27156151 "expression levels of miR-146aC>G, miR-196a2T>C and putative gene-gene interaction between miR-146a, miR-196a2, miR-149 may be involved in RIF development in Korean women." +genetics_GWAS hsa-mir-499a Graft-Versus-Host Disease 27156151 "expression levels of miR-146aC>G, miR-196a2T>C and putative gene-gene interaction between miR-146a, miR-196a2, miR-149 may be involved in RIF development in Korean women." +genetics_GWAS hsa-mir-124 Mesial Temporal Lobe Epilepsy 27188998 "In this study, the effect of the SNP of one neuronal miRNA, miR-124, on susceptibility to MTLE was investigated using a case control study." +genetics_GWAS hsa-mir-34b Osteoporosis 27227383 The present findings indicate that pri-miR-34b/c rs4938723 and TP53 Arg72Pro polymorphisms may contribute to the risk of OP. +genetics_GWAS hsa-mir-34c Osteoporosis 27227383 The present findings indicate that pri-miR-34b/c rs4938723 and TP53 Arg72Pro polymorphisms may contribute to the risk of OP. +genetics_GWAS hsa-let-7 Colorectal Carcinoma 27234654 rs868 is associated with lower TGFBR1 expression thereby increasing CRC risk. +genetics_GWAS hsa-mir-130a "Stroke, Ischemic" 27246008 "Association of miR-34a, miR-130a, miR-150 and miR-155 polymorphisms with the risk of ischemic stroke" +genetics_GWAS hsa-mir-150 "Stroke, Ischemic" 27246008 "Association of miR-34a, miR-130a, miR-150 and miR-155 polymorphisms with the risk of ischemic stroke" +genetics_GWAS hsa-mir-155 "Stroke, Ischemic" 27246008 "Association of miR-34a, miR-130a, miR-150 and miR-155 polymorphisms with the risk of ischemic stroke" +genetics_GWAS hsa-mir-34a "Stroke, Ischemic" 27246008 "Association of miR-34a, miR-130a, miR-150 and miR-155 polymorphisms with the risk of ischemic stroke" +genetics_GWAS hsa-mir-146a Gastric Neoplasms 27267319 rs2910164 of miR-146a is associated with GC +genetics_GWAS hsa-mir-27a "Diabetes Mellitus, Type 2" 27300034 The pre-mir-27a variant rs895819 may contribute to type 2 diabetes mellitus susceptibility +genetics_GWAS hsa-mir-501 "Carcinoma, Hepatocellular" 27310251 We identified a novel SNP located in miR-501 acting as an important factor of the HCC susceptibility +genetics_GWAS hsa-mir-214 "Squamous Cell Carcinoma, Esophageal" 27323028 esophageal squamous cell carcinoma +genetics_GWAS hsa-mir-146a Rheumatoid Arthritis 27342690 12 single nucleotide polymorphisms +genetics_GWAS hsa-mir-502 "Carcinoma, Renal Cell, Clear-Cell" 27346408 Polymorphism at the miR-502 binding site in the 3' untranslated region of SET8 gene is associated with the risk of clear cell renal cell carcinoma +genetics_GWAS hsa-mir-149 "Carcinoma, Hepatocellular" 27348444 MIR-149 gene rs2292832 polymorphism contributed to the risk of HCC +genetics_GWAS hsa-mir-370 Colorectal Carcinoma 27354594 "rs2279398G>A may affect the expression of DOK3 by altering the miRNA binding efficiency at the miRNA-binding sites of the 3'-UTR in DOK3, thereby impacting CRC tumorigenesis." +genetics_GWAS hsa-mir-1273d Tooth Agenesis 27362534 our findings indicate that rs15705 and rs317250 are associated with the susceptibility of non-syndromic tooth agenesis by possibly affecting miRNAs and mRNA interaction. +genetics_GWAS hsa-mir-4639 Tooth Agenesis 27362534 rs15705 and rs317250 are associated with the susceptibility of non-syndromic tooth agenesis by possibly affecting miRNAs and mRNA interaction. +genetics_GWAS hsa-mir-429 "Carcinoma, Lung, Non-Small-Cell" 27374108 rs9660710 in miR-200b/200a/429 cluster and rs763354 in miR-30a might modify the susceptibility to NSCLC. +genetics_GWAS hsa-mir-146a Hypertension 27379568 "This study suggests that the variant of miR-146aC>G polymorphism and allelic combinations, at least in Koreans, affect susceptibility to hypertension." +genetics_GWAS hsa-mir-6826 Breast Neoplasms 27380242 "We systematically put together a list of 822 and 10,468 genetic variants among primary miRNA sequences and 38 genes in the miRNA biogenesis pathway" +genetics_GWAS hsa-mir-608 Rectal Neoplasms 27381831 Sequence variation in mature microRNA-608 and benefit from neo-adjuvant treatment in locally advanced rectal cancer patients. +genetics_GWAS hsa-mir-152 Asthma 27383317 Single nucleotide polymorphisms in the promoter region of mir-133a-1 and in pre-mir-152 rs1707 may contribute to the risk of asthma in a Chinese Han population. +genetics_GWAS hsa-mir-142 "Lymphoma, Follicular" 27389057 "We found recurrent mutations of miR-142, which has not been previously been reported to be mutated in FL/tFL." +genetics_GWAS hsa-mir-142 "Lymphoma, Large B-Cell, Diffuse" 27390358 "Additionally, we detected recurrent mutations of hsa-miR-142 in diffuse large B-cell lymphomas and follicular lymphomas, and editing of the hsa-miR-376 cluster, providing evidence for microRNA editing in lymphomagenesis." +genetics_GWAS hsa-mir-376 "Lymphoma, Large B-Cell, Diffuse" 27390358 "we detected recurrent mutations of hsa-miR-142 in diffuse large B-cell lymphomas and follicular lymphomas, and editing of the hsa-miR-376 cluster, providing evidence for microRNA editing in lymphomagenesis." +genetics_GWAS hsa-mir-483 "Squamous Cell Carcinoma, Esophageal" 27420938 SNP at miR-483-5p-binding site in the 3'-untranslated region of the BSG gene is associated with susceptibility to esophageal cancer in a Chinese population. +genetics_GWAS hsa-mir-584 Pemphigus 27424220 "Collectively, these results suggest that a disease-associated SNP located within the 3'UTR of KLRG1 directly interferes with miR-584-5p binding, allowing for KLRG1 mRNA differential accumulation, which in turn may contribute to pathogenesis of autoimmune diseases, such as pemphigus." +genetics_GWAS hsa-mir-206 Schizophrenia 27424800 Our study therefore suggests that miR-206 may contribute to schizophrenia risk through allele-dependent regulation of the genome-wide significant gene NT5C2. +genetics_GWAS hsa-let-7a Osteosarcoma 27430246 "Taken together, the findings of the present study demonstrated that the KRAS 3'-UTR rs61764370 polymorphism interfered with miRNA/mRNA interaction, and showed that the minor allele was associated with an elevated risk of developing metastatic disease in OS." +genetics_GWAS hsa-mir-146a Coronary Artery Disease 27430349 "miRNA polymorphisms (miRâ€?46a, miRâ€?49, miRâ€?96a2 and miRâ€?99) are associated with the risk of coronary artery disease." +genetics_GWAS hsa-mir-149 Coronary Artery Disease 27430349 "miRNA polymorphisms (miRâ€?46a, miRâ€?49, miRâ€?96a2 and miRâ€?99) are associated with the risk of coronary artery disease." +genetics_GWAS hsa-mir-196a-2 Coronary Artery Disease 27430349 "miRNA polymorphisms (miRâ€?46a, miRâ€?49, miRâ€?96a2 and miRâ€?99) are associated with the risk of coronary artery disease." +genetics_GWAS hsa-mir-499 Coronary Artery Disease 27430349 "miRNA polymorphisms (miRâ€?46a, miRâ€?49, miRâ€?96a2 and miRâ€?99) are associated with the risk of coronary artery disease." +genetics_GWAS hsa-mir-146a Asthma 27431205 "The miRâ€?46a rs2910164 polymorphism CC genotype was identified to be significantly associated with a decreased risk of BHR in response to intubation when compared with the GG or GC genotype (odds ratio, 0.38; confidence interval, 0.18â€?.78)." +genetics_GWAS hsa-mir-125b Cataract 27431420 rs78378222 polymorphism in the 3'-untranslated region of TP53 contributes to development of age-associated cataracts by modifying microRNA-125b-induced apoptosis of lens epithelial cells. +genetics_GWAS hsa-mir-146a Breast Neoplasms 27434289 "Logistic regression data represented the C allele of rs2910164 (OR = 4.00, p= 0.0037) as the risk allele and associated with Her2-positive phenotype." +genetics_GWAS hsa-mir-143 Bladder Neoplasms 27438131 These findings suggest that the functional rs353293 polymorphism may be a useful biomarker to predict the risk of bladder cancer. +genetics_GWAS hsa-mir-145 Bladder Neoplasms 27438131 These findings suggest that the functional rs353293 polymorphism may be a useful biomarker to predict the risk of bladder cancer. +genetics_GWAS hsa-mir-145 Colorectal Carcinoma 27444415 These findings indicate that the rs353292 polymorphism is functional and may be a risk factor for the development of CRC. +genetics_GWAS hsa-mir-499 "Carcinoma, Hepatocellular" 27453271 miR-499 rs3746444 was significantly associated with an increased the risk of HCC. +genetics_GWAS hsa-mir-146a Ossification of Posterior Longitudinal Ligament 27454313 The miR-146a/-149/-196a2/-499 allele combinations may be a genetic risk factor for cervical OPLL in the Korean population. +genetics_GWAS hsa-mir-149 Ossification of Posterior Longitudinal Ligament 27454313 The miR-146a/-149/-196a2/-499 allele combinations may be a genetic risk factor for cervical OPLL in the Korean population. +genetics_GWAS hsa-mir-196a-2 Ossification of Posterior Longitudinal Ligament 27454313 The miR-146a/-149/-196a2/-499 allele combinations may be a genetic risk factor for cervical OPLL in the Korean population. +genetics_GWAS hsa-mir-499 Ossification of Posterior Longitudinal Ligament 27454313 The results indicate that GG genotype of miR-499 is associated with significantly higher risks of OPLL in the segmental OPLL group. +genetics_GWAS hsa-mir-196a-2 Asthma 27487239 microRNA-196a2 rs11614913 polymorphism might be associated with asthma severity in our sample of the Egyptian population. +genetics_GWAS hsa-mir-149 "Squamous Cell Carcinoma, Head and Neck" 27515039 "However, no significant association was detected between the other three SNPs (miR-149 rs2292832, miR-146a rs2910164, and miR-608 rs4919510) and HNSCC risk." +genetics_GWAS hsa-mir-1269b "Carcinoma, Oral" 27525378 "Genetic variants in microRNA-146a (C>G) and microRNA-1269b (G>C) are associated with the decreased risk of oral premalignant lesions, oral cancer, and pharyngeal cancer." +genetics_GWAS hsa-mir-146a "Carcinoma, Oral" 27525378 "Genetic variants in microRNA-146a (C>G) and microRNA-1269b (G>C) are associated with the decreased risk of oral premalignant lesions, oral cancer, and pharyngeal cancer." +genetics_GWAS hsa-mir-137 Schizophrenia 27525637 "Genome-wide association studies (GWAS) have identified a region at chromosome 1p21.3, containing the microRNA MIR137, to be among the most significant associations for schizophrenia." +genetics_GWAS hsa-let-7 "Stroke, Ischemic" 27530126 An rs13293512 polymorphism in the promoter of let-7 is associated with a reduced risk of ischemic stroke. +genetics_GWAS hsa-mir-155 Neoplasms [unspecific] 27531892 Our findings suggested that miR-155 and its functional variant rs767649 might contribute to the increased risk and poor prognosis of HCC +genetics_GWAS hsa-mir-182 Glaucoma 27537254 A Common Variant in MIR182 Is Associated With Primary Open-Angle Glaucoma in the NEIGHBORHOOD Consortium. +genetics_GWAS hsa-mir-27a Obesity 27537871 MicroRNAs and Drinking: Association between the Pre-miR-27a rs895819 Polymorphism and Alcohol Consumption in a Mediterranean Population. +genetics_GWAS hsa-mir-124a Osteosarcoma 27540978 Single nucleotide polymorphism of hsa-miR-124a affects risk and prognosis of osteosarcoma. +genetics_GWAS hsa-mir-526b "Squamous Cell Carcinoma, Esophageal" 27583835 A genetic polymorphism at miR-526b binding-site in the lincRNA-NR_024015 exon confers risk of esophageal squamous cell carcinoma in a population of North China. +genetics_GWAS hsa-mir-130b "Stroke, Ischemic" 27603512 "Association of the Single Nucleotide Polymorphisms in microRNAs 130b, 200b, and 495 with Ischemic Stroke Susceptibility and Post-Stroke Mortality." +genetics_GWAS hsa-mir-200b "Stroke, Ischemic" 27603512 "Association of the Single Nucleotide Polymorphisms in microRNAs 130b, 200b, and 495 with Ischemic Stroke Susceptibility and Post-Stroke Mortality." +genetics_GWAS hsa-mir-495 "Stroke, Ischemic" 27603512 "Association of the Single Nucleotide Polymorphisms in microRNAs 130b, 200b, and 495 with Ischemic Stroke Susceptibility and Post-Stroke Mortality." +genetics_GWAS hsa-mir-200b "Carcinoma, Breast" 27609814 "Mutation of putative miRNA-binding sites (miR-374a/b, miR-200b/c, miR-29a/b/c, miR-488) in these regions did not have significant impact on 3'UTR activity" +genetics_GWAS hsa-mir-200c "Carcinoma, Breast" 27609814 "Mutation of putative miRNA-binding sites (miR-374a/b, miR-200b/c, miR-29a/b/c, miR-488) in these regions did not have significant impact on 3'UTR activity" +genetics_GWAS hsa-mir-29a "Carcinoma, Breast" 27609814 "Mutation of putative miRNA-binding sites (miR-374a/b, miR-200b/c, miR-29a/b/c, miR-488) in these regions did not have significant impact on 4'UTR activity" +genetics_GWAS hsa-mir-29b "Carcinoma, Breast" 27609814 "Mutation of putative miRNA-binding sites (miR-374a/b, miR-200b/c, miR-29a/b/c, miR-488) in these regions did not have significant impact on 5'UTR activity" +genetics_GWAS hsa-mir-374a "Carcinoma, Breast" 27609814 "Mutation of putative miRNA-binding sites (miR-374a/b, miR-200b/c, miR-29a/b/c, miR-488) in these regions did not have significant impact on 6'UTR activity" +genetics_GWAS hsa-mir-374b "Carcinoma, Breast" 27609814 "Mutation of putative miRNA-binding sites (miR-374a/b, miR-200b/c, miR-29a/b/c, miR-488) in these regions did not have significant impact on 7'UTR activity" +genetics_GWAS hsa-mir-488 "Carcinoma, Breast" 27609814 "Mutation of putative miRNA-binding sites (miR-374a/b, miR-200b/c, miR-29a/b/c, miR-488) in these regions did not have significant impact on 8'UTR activity" +genetics_GWAS hsa-mir-214 "Carcinoma, Hepatocellular" 27619679 U/G SNP rs111904020 in 3'UTR of STAT3 regulated by miR-214 promotes hepatocellular carcinoma development in Chinese population. +genetics_GWAS hsa-mir-149 Lung Neoplasms 27685326 MicroRNA-149 rs2292832 polymorphism may not be associated with lung cancer risk in Chinese non-smoking female +genetics_GWAS hsa-mir-146a "Carcinoma, Ovarian" 27706635 miR-146a and miR-196a2 polymorphisms in ovarian cancer risk. +genetics_GWAS hsa-mir-196a-2 "Carcinoma, Ovarian" 27706635 miR-146a and miR-196a2 polymorphisms in ovarian cancer risk. +genetics_GWAS hsa-mir-146a "Carcinoma, Colon" 27706637 MicroRNA variants and colorectal cancer risk: a meta-analysis. +genetics_GWAS hsa-mir-149 "Carcinoma, Colon" 27706637 MicroRNA variants and colorectal cancer risk: a meta-analysis. +genetics_GWAS hsa-mir-196a "Carcinoma, Colon" 27706637 MicroRNA variants and colorectal cancer risk: a meta-analysis. +genetics_GWAS hsa-mir-27a "Carcinoma, Colon" 27706637 MicroRNA variants and colorectal cancer risk: a meta-analysis. +genetics_GWAS hsa-mir-499 "Carcinoma, Colon" 27706637 MicroRNA variants and colorectal cancer risk: a meta-analysis. +genetics_GWAS hsa-mir-146a "Carcinoma, Hepatocellular" 27706712 "Contributions of polymorphisms in miR146a, miR196a, and miR499 to the development of hepatocellular carcinoma." +genetics_GWAS hsa-mir-196a "Carcinoma, Hepatocellular" 27706712 "Contributions of polymorphisms in miR146a, miR196a, and miR499 to the development of hepatocellular carcinoma." +genetics_GWAS hsa-mir-499 "Carcinoma, Hepatocellular" 27706712 "Contributions of polymorphisms in miR146a, miR196a, and miR499 to the development of hepatocellular carcinoma." +genetics_GWAS hsa-mir-27a "Carcinoma, Colon" 27751356 Association between microRNA-27a rs895819 polymorphism and risk of colorectal cancer: A meta-analysis. +genetics_GWAS hsa-mir-196a-2 Glioma 27796868 Effect of rs11614913 Polymorphism on Mature miR196a2 Expression and its Target Gene HOXC8 Expression in Human Glioma. +genetics_GWAS hsa-mir-34a Neuroblastoma 27805929 Genetic variant rs3750625 in the 3'UTR of ADRA2A affects stress-dependent acute pain severity after trauma and alters a microRNA-34a regulatory site. +genetics_GWAS hsa-mir-627 "Carcinoma, Breast" 27807724 rs15869 at miRNA binding site in BRCA2 is associated with breast cancer susceptibility. +genetics_GWAS hsa-mir-34b "Carcinoma, Hepatocellular" 27808368 Association between polymorphisms in the promoter region of pri-miR-34b/c and risk of hepatocellular carcinoma. +genetics_GWAS hsa-mir-34c "Carcinoma, Hepatocellular" 27808368 Association between polymorphisms in the promoter region of pri-miR-34b/c and risk of hepatocellular carcinoma. +genetics_GWAS hsa-mir-196a-2 Congenital Heart Diseases 27813602 "Association of miR-196a2, miR-27a, and miR-499 polymorphisms with isolated congenital heart disease in a Chinese population." +genetics_GWAS hsa-mir-27a Congenital Heart Diseases 27813602 "Association of miR-196a2, miR-27a, and miR-499 polymorphisms with isolated congenital heart disease in a Chinese population." +genetics_GWAS hsa-mir-499 Congenital Heart Diseases 27813602 "Association of miR-196a2, miR-27a, and miR-499 polymorphisms with isolated congenital heart disease in a Chinese population." +genetics_GWAS hsa-mir-125a "Carcinoma, Hepatocellular" 27814341 Association Between microRNA-125a rs12976445 C>T Polymorphism and 18F-Fluorodeoxyglucose (18FDG) Uptake: Clinical and Metabolic Response in Patients with Non-Small Cell Lung Cancer. +genetics_GWAS hsa-mir-146a Kaposi Sarcoma 27819716 Association of genetic variations in miR-146a rs2910164 and miR-149 rs11614913 with the development of classic Kaposi sarcoma. +genetics_GWAS hsa-mir-149 Kaposi Sarcoma 27819716 Association of genetic variations in miR-146a rs2910164 and miR-149 rs11614913 with the development of classic Kaposi sarcoma. +genetics_GWAS hsa-mir-146a "Carcinoma, Colon" 27824903 miR-146a Polymorphism (rs2910164) Predicts Colorectal Cancer Patients' Susceptibility to Liver Metastasis. +genetics_GWAS hsa-mir-205 "Carcinoma, Breast" 27885248 Rs3842530 Polymorphism in MicroRNA-205 Host Gene in Lung and Breast Cancer Patients. +genetics_GWAS hsa-mir-146a "Carcinoma, Hepatocellular" 27886162 miR-146a rs2910164 and hepatocellular carcinoma: a meta-analysis. +genetics_GWAS hsa-mir-34b "Leukemia, Lymphoblastic, Acute, Childhood" 27886674 Pri-miR-34b/c rs4938723 polymorphism is associated with the risk of childhood acute lymphoblastic leukemia. +genetics_GWAS hsa-mir-34c "Leukemia, Lymphoblastic, Acute, Childhood" 27886674 Pri-miR-34b/c rs4938723 polymorphism is associated with the risk of childhood acute lymphoblastic leukemia. +genetics_GWAS hsa-mir-27a Human Immunodeficiency Virus Infection 27919232 microRNA-27a rs895819 is associated with obesity in HIV infected preeclamptic Black South African women on HAART. +genetics_GWAS hsa-mir-34b "Carcinoma, Prostate" 27983526 Pri-miR-34b/c rs4938723 polymorphism increased the risk of prostate cancer. +genetics_GWAS hsa-mir-34c "Carcinoma, Prostate" 27983526 Pri-miR-34b/c rs4938723 polymorphism increased the risk of prostate cancer. +genetics_GWAS hsa-let-7 Liver Cirrhosis 27992614 A Single Nucleotide Polymorphism in the RASGRF2 Gene Is Associated with Alcoholic Liver Cirrhosis in Men. +genetics_GWAS hsa-mir-3131 "Carcinoma, Hepatocellular" 28034876 An indel polymorphism within pre-miR3131 confers risk for hepatocellular carcinoma. +genetics_GWAS hsa-mir-1269a "Carcinoma, Hepatocellular" 28081866 A single nucleotide variant in microRNA-1269a promotes the occurrence and process of hepatocellular carcinoma by targeting to oncogenes SPATS2L and LRP6. +genetics_GWAS hsa-mir-122 Chronic Hepatitis C 28082397 Differential hepatitis C virus RNA target site selection and host factor activities of naturally occurring miR-122 3? variants. +genetics_GWAS hsa-mir-146a Rheumatoid Arthritis 28083614 Significance of Polymorphism and Expression of miR-146a and NFkB1 Genetic Variants in Patients with Rheumatoid Arthritis. +genetics_GWAS hsa-mir-146a "Diabetes Mellitus, Type 2" 28101643 Polymorphisms in genes encoding miR-155 and miR-146a are associated with protection to type 1 diabetes mellitus. +genetics_GWAS hsa-mir-155 "Diabetes Mellitus, Type 2" 28101643 Polymorphisms in genes encoding miR-155 and miR-146a are associated with protection to type 1 diabetes mellitus. +genetics_GWAS hsa-mir-34b Retinoblastoma 28106538 A polymorphism in mir-34b/c as a potential biomarker for early onset of hereditary retinoblastoma. +genetics_GWAS hsa-mir-34c Retinoblastoma 28106538 A polymorphism in mir-34b/c as a potential biomarker for early onset of hereditary retinoblastoma. +genetics_GWAS hsa-mir-1203 "Stroke, Ischemic" 28171870 Methylene Tetrahydrofolate Reductase (MTHFR) rs868014 Polymorphism Regulated by miR-1203 Associates with Risk and Short Term Outcome of Ischemic Stroke. +genetics_GWAS hsa-mir-149 Allergic Rhinitis 28181414 A functional variant of miRNA-149 confers risk for allergic rhinitis and comorbid asthma in Chinese children. +genetics_GWAS hsa-mir-146a "Carcinoma, Hepatocellular" 28188097 "Our findings supported the proposition that the polymorphisms of miR-146a rs2910164, miR-196a2 rs11614913, and miR-196a2 rs11614913 may contribute to the susceptibility of HCC" +genetics_GWAS hsa-mir-196a "Carcinoma, Hepatocellular" 28188097 "Our findings supported the proposition that the polymorphisms of miR-146a rs2910164, miR-196a2 rs11614913, and miR-196a2 rs11614913 may contribute to the susceptibility of HCC" +genetics_GWAS hsa-mir-27b "Carcinoma, Gastric" 28214904 rs10719 Polymorphism Located within DROSHA 3'-Untranslated Region is Responsible for Development of Primary Hypertension by Disrupting Binding with microRNA-27b. +genetics_GWAS hsa-mir-199a "Stroke, Ischemic" 28234972 the +936C/T variants significantly increased the risk of poorer stroke outcome by affecting the bindings of miR-199a and miR-199b to VEGF mRNA at the rs30250340 polymorphic site +genetics_GWAS hsa-mir-199b "Stroke, Ischemic" 28234972 the +936C/T variants significantly increased the risk of poorer stroke outcome by affecting the bindings of miR-199a and miR-199b to VEGF mRNA at the rs30250340 polymorphic site +genetics_GWAS hsa-mir-126 Endometriosis 28277133 mir-126 rs4636297 and TGF¦ÂRI rs334348 functional gene variants are associated with susceptibility to endometriosis and its severity. +genetics_GWAS hsa-mir-218 "Carcinoma, Gastric" 28298809 "Predictive Value of MiR-219-1, MiR-938, MiR-34b/c, and MiR-218 Polymorphisms for Gastric Cancer Susceptibility and Prognosis." +genetics_GWAS hsa-mir-219 "Carcinoma, Gastric" 28298809 "Predictive Value of MiR-219-1, MiR-938, MiR-34b/c, and MiR-218 Polymorphisms for Gastric Cancer Susceptibility and Prognosis." +genetics_GWAS hsa-mir-34b "Carcinoma, Gastric" 28298809 "Predictive Value of MiR-219-1, MiR-938, MiR-34b/c, and MiR-218 Polymorphisms for Gastric Cancer Susceptibility and Prognosis." +genetics_GWAS hsa-mir-34c "Carcinoma, Gastric" 28298809 "Predictive Value of MiR-219-1, MiR-938, MiR-34b/c, and MiR-218 Polymorphisms for Gastric Cancer Susceptibility and Prognosis." +genetics_GWAS hsa-mir-938 "Carcinoma, Gastric" 28298809 "Predictive Value of MiR-219-1, MiR-938, MiR-34b/c, and MiR-218 Polymorphisms for Gastric Cancer Susceptibility and Prognosis." +genetics_GWAS hsa-mir-196a "Colitis, Ulcerative" 28301487 Association of miR-196a-2 and miR-499 variants with ulcerative colitis and their correlation with expression of respective miRNAs. +genetics_GWAS hsa-mir-499 "Colitis, Ulcerative" 28301487 Association of miR-196a-2 and miR-499 variants with ulcerative colitis and their correlation with expression of respective miRNAs. +genetics_GWAS hsa-let-7 Macular Degeneration 28343170 "miRNAs, single nucleotide polymorphisms (SNPs) and age-related macular degeneration (AMD)." +genetics_GWAS hsa-let-7a Macular Degeneration 28343170 "miRNAs, single nucleotide polymorphisms (SNPs) and age-related macular degeneration (AMD)." +genetics_GWAS hsa-let-7b Macular Degeneration 28343170 "miRNAs, single nucleotide polymorphisms (SNPs) and age-related macular degeneration (AMD)." +genetics_GWAS hsa-let-7d Macular Degeneration 28343170 "miRNAs, single nucleotide polymorphisms (SNPs) and age-related macular degeneration (AMD)." +genetics_GWAS hsa-mir-146a Macular Degeneration 28343170 "miRNAs, single nucleotide polymorphisms (SNPs) and age-related macular degeneration (AMD)." +genetics_GWAS hsa-mir-155 Macular Degeneration 28343170 "miRNAs, single nucleotide polymorphisms (SNPs) and age-related macular degeneration (AMD)." +genetics_GWAS hsa-mir-101 "Carcinoma, Hepatocellular" 28366737 miRNA-101-1 and miRNA-221 expressions and their polymorphisms as biomarkers for early diagnosis of hepatocellular carcinoma. +genetics_GWAS hsa-mir-221 "Carcinoma, Hepatocellular" 28366737 miRNA-101-1 and miRNA-221 expressions and their polymorphisms as biomarkers for early diagnosis of hepatocellular carcinoma. +genetics_GWAS hsa-mir-4293 "Carcinoma, Lung, Non-Small-Cell" 28410417 Genetic variant of miR-4293 rs12220909 is associated with susceptibility to non-small cell lung cancer in a Chinese Han population. +genetics_GWAS hsa-mir-423 Neoplasms [unspecific] 28430524 miRNA-Related Polymorphisms in miR-423 (rs6505162) and PEX6 (rs1129186) and Risk of Esophageal Squamous Cell Carcinoma in an Iranian Cohort. +genetics_GWAS hsa-mir-122 "Carcinoma, Hepatocellular" 28512857 Interest of variations in microRNA-152 and -122 in a series of hepatocellular carcinomas related to hepatitis C virus infection. +genetics_GWAS hsa-mir-149 Gastric Neoplasms 28523307 miR-149 rs2292832 C>T polymorphism and risk of gastric cancer. +genetics_GWAS hsa-mir-608 "Carcinoma, Colon" 28653886 The miR-608 rs4919510 polymorphism may modify cancer susceptibility based on type. +genetics_GWAS hsa-mir-146a Melanoma 28654546 Sex-specific effect of RNASEL rs486907 and miR-146a rs2910164 polymorphisms' interaction as a susceptibility factor for melanoma skin cancer. +genetics_GWAS hsa-mir-146a Atherosclerosis 28674224 Association of NFKB1A and microRNAs variations and the susceptibility to atherosclerosis. +genetics_GWAS hsa-mir-181a Neuroinflammation 28769921 MicroRNA-181 Variants Regulate T Cell Phenotype in the Context of Autoimmune Neuroinflammation +genetics_GWAS hsa-mir-181b Neuroinflammation 28769921 MicroRNA-181 Variants Regulate T Cell Phenotype in the Context of Autoimmune Neuroinflammation. +genetics_GWAS hsa-mir-146a Thyroid Neoplasms 28899898 The rs2910164 variant in MIR146A is significantly associated with DTC +genetics_GWAS hsa-mir-149 "Squamous Cell Carcinoma, Oral" 29103762 miRNA genetic variants: As potential diagnostic biomarkers for oral cancer. +genetics_GWAS hsa-mir-146a Lung Neoplasms 29127520 MiR-146a rs2910164 polymorphism might be associated with the susceptibility to lung cancer and nasopharyngeal carcinoma +genetics_GWAS hsa-mir-146a Nasopharyngeal Neoplasms 29127520 MiR-146a rs2910164 polymorphism might be associated with the susceptibility to lung cancer and nasopharyngeal carcinoma +genetics_GWAS hsa-mir-122 Stroke 29145255 Functional polymorphism rs3783553 in the 3'-untranslated region of IL-1A increased the risk of ischemic stroke +genetics_GWAS hsa-mir-196a Crohn Disease 29152405 "Association of miR-146 rs2910164, miR-196a rs11614913, miR-221 rs113054794 and miR-224 rs188519172 polymorphisms with anti-TNF treatment response in a Greek population with Crohn's disease" +genetics_GWAS hsa-let-7i "Squamous Cell Carcinoma, Cerevial" 29154871 Association between genetic polymorphisms in the promoters of let-7 and risk of cervical squamous cell carcinoma +genetics_GWAS hsa-mir-146a Creutzfeldt-Jakob Disease 29216791 The associations of two SNPs in miRNA-146a and one SNP in ZBTB38-RASA2 with the disease susceptibility and the clinical features of the Chinese patients of sCJD and FFI. +genetics_GWAS hsa-mir-126 Myocardial Infarction 29304813 The association between pre-miR-27a rs895819 polymorphism and myocardial infarction risk in a Chinese Han population +genetics_GWAS hsa-mir-98 Osteoporosis 29307778 Computational and functional characterization of four SNPs in the SOST locus associated with osteoporosis +genetics_GWAS hsa-mir-423 Colorectal Carcinoma 29419695 Association of microRNA-423 rs6505162 C>A polymorphism with susceptibility and metastasis of colorectal carcinoma. +genetics_GWAS hsa-mir-146a Bladder Neoplasms 29491365 "miR-146a rs2910164 polymorphism is a risk factor for urological neoplasms, particularly for bladder cancer" +genetics_GWAS hsa-mir-6720 Lymphedema 29511529 "rs121909106 and rs121909107 were predicted to have the most harmful effects, while hsa-miR-6886-5p, hsa-miR-6886-5p and hsa-miR-6720-3p were predicted to be the most important miRNAs affected" +genetics_GWAS hsa-mir-6886 Lymphedema 29511529 "rs121909106 and rs121909107 were predicted to have the most harmful effects, while hsa-miR-6886-5p, hsa-miR-6886-5p and hsa-miR-6720-3p were predicted to be the most important miRNAs affected" +genetics_GWAS hsa-mir-146a Breast Neoplasms 29521182 "Effects of miR-27a, miR-196a2 and miR-146a polymorphisms on the risk of breast cancer" +genetics_GWAS hsa-mir-196a-2 Breast Neoplasms 29521182 "Effects of miR-27a, miR-196a2 and miR-148a polymorphisms on the risk of breast cancer" +genetics_GWAS hsa-mir-27a Breast Neoplasms 29521182 "Effects of miR-27a, miR-196a2 and miR-147a polymorphisms on the risk of breast cancer" +genetics_GWAS hsa-mir-556 "Carcinoma, Renal Cell, Clear-Cell" 29569387 A novel functional polymorphism of GSTM3 reduces clear cell renal cell carcinoma risk through enhancing its expression by interfering miR-556 binding. +genetics_GWAS hsa-mir-146a Psoriasis 29587639 "A single nucleotide polymorphism in the miR-146a gene (rs2910164), aberrantly alters its gene expression and linked with the pathogenesis of several disorders, including psoriasis and PsA" +genetics_GWAS hsa-mir-146a Psoriatic Arthritis 29587639 "A single nucleotide polymorphism in the miR-146a gene (rs2910164), aberrantly alters its gene expression and linked with the pathogenesis of several disorders, including psoriasis and PsA" +genetics_GWAS hsa-mir-1302 Infertility 29627965 Association of T/A polymorphism in miR-1302 binding site in CGA gene with male infertility in Isfahan population. +genetics_GWAS hsa-mir-146a Polycystic Ovarian Syndrome 29637801 "women with miR-146a variation are at a higher risk for developing PCOS, which can be due to up-regulation of miR-146a" +genetics_GWAS hsa-mir-196a-2 "Squamous Cell Carcinoma, Head and Neck" 29705927 "Single nucleotide polymorphism rs11614913 associated with CC genotype in miR-196a2 is overrepresented in laryngeal squamous cell carcinoma, but not salivary gland tumors in Polish population." +genetics_GWAS hsa-mir-146a Colorectal Carcinoma 29715515 Hsa-mir-149C/T rs2292832 and hsa-mir-146a G/C rs2910164 may influence CRC risk in an ethnicity-dependent manner by interfering with CRC progression parameters in Tunisian cohort +genetics_GWAS hsa-mir-149 Colorectal Carcinoma 29715515 Hsa-mir-149C/T rs2292832 and hsa-mir-146a G/C rs2910164 may influence CRC risk in an ethnicity-dependent manner by interfering with CRC progression parameters in Tunisian cohort +genetics_GWAS hsa-mir-149 Charcot-Marie-Tooth Disease Type 1A 29729827 Association of miR-149 polymorphism with onset age and severity in Charcot-Marie-Tooth disease type 1A. +genetics_GWAS hsa-mir-218 Neuroblastoma 29858046 the miR-34b/c rs4938723?T > C and miR-218 rs11134527 A > G polymorphisms displayed a protective role from neuroblastoma +genetics_GWAS hsa-mir-34b Neuroblastoma 29858046 the miR-34b/c rs4938723?T > C and miR-218 rs11134527 A > G polymorphisms displayed a protective role from neuroblastoma +genetics_GWAS hsa-mir-34c Neuroblastoma 29858046 the miR-34b/c rs4938723?T > C and miR-218 rs11134527 A > G polymorphisms displayed a protective role from neuroblastoma +genetics_GWAS hsa-mir-124-1 Gastric Neoplasms 29938592 Influence of single nucleotide polymorphisms in pri-miR-124-1 and STAT3 genes on gastric cancer susceptibility. +genetics_GWAS hsa-mir-499 "Carcinoma, Hepatocellular" 29946268 "miR-499 rs3746444 is associated with susceptibility of cervical squamous cell carcinoma, lung cancer, prostate cancer, and hepatocellular carcinoma" +genetics_GWAS hsa-mir-499 Lung Neoplasms 29946268 "miR-499 rs3746444 is associated with susceptibility of cervical squamous cell carcinoma, lung cancer, prostate cancer, and hepatocellular carcinoma" +genetics_GWAS hsa-mir-499 Prostate Neoplasms 29946268 "miR-499 rs3746444 is associated with susceptibility of cervical squamous cell carcinoma, lung cancer, prostate cancer, and hepatocellular carcinoma" +genetics_GWAS hsa-mir-499 "Squamous Cell Carcinoma, Cerevial" 29946268 "miR-499 rs3746444 is associated with susceptibility of cervical squamous cell carcinoma, lung cancer, prostate cancer, and hepatocellular carcinoma" +genetics_GWAS hsa-mir-499 "Carcinoma, Hepatocellular" 29970712 MiR-499 rs3746444 polymorphism and hepatocellular carcinoma risk: A meta-analysis. +genetics_GWAS hsa-mir-146a Prostate Neoplasms 30001553 "Polymorphisms of miR-196a2 rs11614913, miR-146a rs2910164, and miR-499 rs3746444 may contribute to the risk for developing prostate cancer in Asian descendants" +genetics_GWAS hsa-mir-196a Prostate Neoplasms 30001553 "Polymorphisms of miR-196a2 rs11614913, miR-146a rs2910164, and miR-499 rs3746444 may contribute to the risk for developing prostate cancer in Asian descendants" +genetics_GWAS hsa-mir-499 Prostate Neoplasms 30001553 "Polymorphisms of miR-196a2 rs11614913, miR-146a rs2910164, and miR-499 rs3746444 may contribute to the risk for developing prostate cancer in Asian descendants" +genetics_GWAS hsa-mir-122 Hepatitis C Virus Infection 30053137 "miR-122, small RNA annealing and sequence mutations alter the predicted structure of the Hepatitis C virus 5' UTR RNA to stabilize and promote viral RNA accumulation." +genetics_GWAS hsa-mir-146a Lung Neoplasms 30069329 "We found that an allele carriers of miR-146a rs2910164 (P=0.022, OR=1.315) and C allele carriers of miR-149 rs71428439 (P=0.042, OR=1.372) performance a high risk of lung cancer" +genetics_GWAS hsa-mir-149 Lung Neoplasms 30069329 "We found that an allele carriers of miR-146a rs2910164 (P=0.022, OR=1.315) and C allele carriers of miR-149 rs71428439 (P=0.042, OR=1.372) performance a high risk of lung cancer" +genetics_GWAS hsa-mir-499 Congenital Heart Diseases 30084801 Association of a MiR-499 SNP and risk of congenital heart disease in a Chinese population. +genetics_GWAS hsa-mir-499 Cardiovascular Diseases [unspecific] 30102014 A polymorphism rs3746444 within the pre-miR-499 alters the maturation of miR-499-5p and its antiapoptotic function. +genetics_GWAS hsa-mir-218 "Squamous Cell Carcinoma, Esophageal" 30120974 Association between miR-218 rs11134527 polymorphism and risk of selected types of cancer in Asian population: An updated meta-analysis of case-control studies. +genetics_GWAS hsa-mir-125a "Carcinoma, Breast" 30135399 "Genetic Variants in pre-miR-146a, pre-miR-499, pre-miR-125a, pre-miR-605, and pri-miR-182 Are Associated with Breast Cancer Susceptibility in a South American Population." +genetics_GWAS hsa-mir-146a "Carcinoma, Breast" 30135399 "Genetic Variants in pre-miR-146a, pre-miR-499, pre-miR-125a, pre-miR-605, and pri-miR-182 Are Associated with Breast Cancer Susceptibility in a South American Population." +genetics_GWAS hsa-mir-182 "Carcinoma, Breast" 30135399 "Genetic Variants in pre-miR-146a, pre-miR-499, pre-miR-125a, pre-miR-605, and pri-miR-182 Are Associated with Breast Cancer Susceptibility in a South American Population." +genetics_GWAS hsa-mir-499 "Carcinoma, Breast" 30135399 "Genetic Variants in pre-miR-146a, pre-miR-499, pre-miR-125a, pre-miR-605, and pri-miR-182 Are Associated with Breast Cancer Susceptibility in a South American Population." +genetics_GWAS hsa-mir-605 "Carcinoma, Breast" 30135399 "Genetic Variants in pre-miR-146a, pre-miR-499, pre-miR-125a, pre-miR-605, and pri-miR-182 Are Associated with Breast Cancer Susceptibility in a South American Population." +genetics_GWAS hsa-mir-3161 Glaucoma 30148417 "MicroRNA-related polymorphisms in pseudoexfoliation syndrome, pseudoexfoliative glaucoma, and primary open-angle glaucoma." +genetics_GWAS hsa-mir-21 Atherosclerosis 30205366 rs145204276 was associated with the risk of atherosclerosis by affecting the proliferation and apoptosis of endothelial cells via regulating the GAS5/miR-21/PDCD4 signaling pathway +genetics_GWAS hsa-mir-499 "Stroke, Ischemic" 30229913 hsa-mir-499 rs3746444 A/G polymorphism may be associated with a significantly increased risk of IS in an Iranian population +genetics_GWAS hsa-mir-34a Gastric Neoplasms 30242897 Minor allele of rs1057317 polymorphism in TLR4 is associated with increased risk of Helicobacter pylori -induced gastric cancer. +genetics_GWAS hsa-mir-146a "Stroke, Ischemic" 30254431 the GG genotype of miR-146a (rs2910164) and CC genotype of miR-149 (rs2292832) may confer increased susceptibility to IS +genetics_GWAS hsa-mir-149 "Stroke, Ischemic" 30254431 the GG genotype of miR-146a (rs2910164) and CC genotype of miR-149 (rs2292832) may confer increased susceptibility to IS +genetics_GWAS hsa-mir-300 Lung Neoplasms 30271206 miR-300 rs12894467 polymorphism may be associated with susceptibility to primary lung cancer in the Chinese Han population. +genetics_GWAS hsa-mir-149 Gastric Neoplasms 30274913 Association Between miR-149 Gene rs2292832 Polymorphism and Risk of Gastric Cancer: A Case-control Study. +genetics_GWAS hsa-mir-146a "Colitis, Ulcerative" 30278502 Association of miRNA-146a rs2910164 and miRNA-196 rs11614913 polymorphisms in patients with ulcerative colitis: A meta-analysis and review. +genetics_GWAS hsa-mir-196a "Colitis, Ulcerative" 30278502 Association of miRNA-146a rs2910164 and miRNA-196 rs11614913 polymorphisms in patients with ulcerative colitis: A meta-analysis and review. +genetics_GWAS hsa-mir-423 Coronary Artery Disease 30289085 Potential impact of microRNA-423 gene variability in coronary artery disease. +genetics_GWAS hsa-mir-125a "Carcinoma, Lung" 30302847 Regulation of miR-125a expression by rs12976445 single-nucleotide polymorphism?is associated with radiotherapy-induced pneumonitis in lung carcinoma patients. +genetics_GWAS hsa-mir-589 Cataract 30315181 luciferase reporter gene expression can be down regulated by hsa-miR-589-5p in cells transfected with rs2229090 C allele compared to G allele +genetics_GWAS hsa-mir-579 Anxiety Disorders 30341278 A functional genetic variation of SLC6A2 repressor hsa-miR-579-3p upregulates sympathetic noradrenergic processes of fear and anxiety. +genetics_GWAS hsa-mir-21 Inflammation 30375257 Cigarette smoking affects microRNAs and inflammatory biomarkers in healthy individuals and an association to single nucleotide polymorphisms is indicated. +genetics_knock down_promote hsa-mir-15a Leukemia 12434020 deletion or downregulation +genetics_knock down_promote hsa-mir-15a "Leukemia, Lymphocytic, Chronic, B-Cell" 12434020 deletion or downregulation +genetics_knock down_promote hsa-mir-16-1 Leukemia 12434020 deletion or downregulation +genetics_knock down_promote hsa-mir-16-1 "Leukemia, Lymphocytic, Chronic, B-Cell" 12434020 deletion or downregulation +genetics_knock down_promote hsa-mir-125b-1 Breast Neoplasms 14973191 deletion +genetics_knock down_promote hsa-mir-125b-1 Lung Neoplasms 14973191 deletion +genetics_knock down_promote hsa-mir-125b-1 Ovarian Neoplasms 14973191 deletion +genetics_knock down_promote hsa-mir-125b-1 Urinary Bladder Cancer 14973191 deletion +genetics_knock down_promote hsa-mir-17 "Carcinoma, Hepatocellular" 15944709 loss of heterozygosity of this cluster +genetics_knock down_promote hsa-mir-18a "Carcinoma, Hepatocellular" 15944709 loss of heterozygosity of this cluster +genetics_knock down_promote hsa-mir-19a "Carcinoma, Hepatocellular" 15944709 loss of heterozygosity of this cluster +genetics_knock down_promote hsa-mir-19b-1 "Carcinoma, Hepatocellular" 15944709 loss of heterozygosity of this cluster +genetics_knock down_promote hsa-mir-20a "Carcinoma, Hepatocellular" 15944709 loss of heterozygosity of this cluster +genetics_knock down_promote hsa-mir-125b-1 "Leukemia-Lymphoma, Precursor B-Cell Lymphoblastic" 16151463 an insertion of pre-miRNA into the immunoglobulin heavy-chain locus +genetics_knock down_promote hsa-mir-15a Leukemia 16166262 the deletion or downregulation of mir-15a results in increased expression of BCL2. +genetics_knock down_promote hsa-mir-15a Lymphoma 16166262 the deletion or downregulation of mir-15a results in increased expression of BCL2. +genetics_knock down_promote hsa-mir-16-1 Leukemia 16166262 the deletion or downregulation of mir-15a results in increased expression of BCL2. +genetics_knock down_promote hsa-mir-16-1 Lymphoma 16166262 the deletion or downregulation of mir-15a results in increased expression of BCL2. +genetics_knock down_promote hsa-mir-125b-1 "Leukemia, B-Cell" 16885332 "In a precursor B-cell acute lymphoblastic leukemia, an insertion of miR-125b-1 into a rearranged immunoglobulin heavy chain locus was described." +genetics_knock down_promote hsa-mir-142 "Leukemia, B-Cell" 16885332 It was shown later that miR-142 is located at the chromosome 17 breakpoint and that c-Myc was rearranged under the control of the promoter of miR-142 with consequent overexpression. +genetics_knock down_promote hsa-mir-15a "Leukemia, B-Cell" 16885332 Deleted and down-regulated in the majority of B-CLLs +genetics_knock down_promote hsa-mir-15a Pituitary Neoplasms 16885332 a type of benign tumors displaying deletions at 13q14.3 and reduced expression of miR-16-1 and miR-15a +genetics_knock down_promote hsa-mir-16-1 "Leukemia, B-Cell" 16885332 Deleted and down-regulated in the majority of B-CLLs +genetics_knock down_promote hsa-mir-16-1 Pituitary Neoplasms 16885332 a type of benign tumors displaying deletions at 13q14.3 and reduced expression of miR-16-1 and miR-15a +genetics_knock down_promote hsa-mir-17 Breast Neoplasms 16940181 "The genomic location of Mir-17-5p also undergoesloss of heterozygosity in different types of cancer, including breast cancer." +genetics_knock down_promote hsa-mir-92a-1 Hematologic Neoplasms 17011485 The miR-17-92 cluster is amplified in hematopoietic malignancies. +genetics_knock down_promote hsa-mir-15a Breast Neoplasms 17012848 "Later on, deletion of mir-16-1 and mir-15a deletion were also identified in epithelial tumors, such as pituitary adenomas, ovarian and breast cancer." +genetics_knock down_promote hsa-mir-15a "Leukemia, Lymphocytic, Chronic, B-Cell" 17012848 "It was found that mir-16-1 and mir-15a at 13q14 are deleted in more than 50% patients, with concurrent reduced expression in ~65% patients. Further studies demonstrated that these two miRNAs suppress BCL2 expression and may serve as tumor suppressor genes in this disease." +genetics_knock down_promote hsa-mir-16-1 "Leukemia, Lymphocytic, Chronic, B-Cell" 17012848 "It was found that mir-16-1 and mir-15a at 13q14 are deleted in more than 50% patients, with concurrent reduced expression in ~65% patients. Further studies demonstrated that these two miRNAs suppress BCL2 expression and may serve as tumor suppressor genes in this disease." +genetics_knock down_promote hsa-mir-16-1 Ovarian Neoplasms 17012848 "Later on, deletion of mir-16-1 and mir-15a deletion were also identified in epithelial tumors, such as pituitary adenomas, ovarian and breast cancer." +genetics_knock down_promote hsa-mir-16-1 Pituitary Neoplasms 17012848 "Later on, deletion of mir-16-1 and mir-15a deletion were also identified in epithelial tumors, such as pituitary adenomas, ovarian and breast cancer." +genetics_knock down_promote hsa-mir-125b-1 "Leukemia, B-Cell" 17028302 "It is of note that insertion of miR-125b-1 into a rearranged immunoglobulin heavy chain gene locus was recently reported in a patient with precursor B-cell acute lymphoblastic leukemia, though the expression miR-125b-1 was not investigated." +genetics_knock down_promote hsa-mir-15a "Leukemia, Lymphocytic, Chronic, B-Cell" 17028302 "Detailed analyses of deletion and expression status revealed these two miRNAs to be located within a 30 kb minimally deleted region in chronic lymphocytic leukemia (CLL) patients, both of which were deleted or downregulated in most CLL cases, suggesting that miR-15a and miR-16-1 may function as tumor suppressor genes." +genetics_knock down_promote hsa-mir-16-1 "Leukemia, Lymphocytic, Chronic, B-Cell" 17028302 "Detailed analyses of deletion and expression status revealed these two miRNAs to be located within a 30 kb minimally deleted region in chronic lymphocytic leukemia (CLL) patients, both of which were deleted or downregulated in most CLL cases, suggesting that miR-15a and miR-16-1 may function as tumor suppressor genes." +genetics_knock down_promote hsa-mir-199a-1 "Carcinoma, Hepatocellular" 17188425 "This region encodes miRNA-199a-1 (19p13.2), whose expression levels are lower in HCC compared to nontumor liver [59] and is deleted in several other tumor types." +genetics_knock down_promote hsa-mir-15a "Leukemia, Lymphocytic, Chronic, B-Cell" 17234972 "After years of futile attemptsto identify the gene(s) in the deleted 13q14 region that participatein the pathogenesis of chronic lymphocytic leukemia, Calin etal discovered that miR-15 and miR-16 are located within thissequence and that both are downregulated in 68% of cases." +genetics_knock down_promote hsa-mir-15b "Leukemia, Lymphocytic, Chronic, B-Cell" 17234972 "After years of futile attemptsto identify the gene(s) in the deleted 13q14 region that participatein the pathogenesis of chronic lymphocytic leukemia, Calin etal discovered that miR-15 and miR-16 are located within thissequence and that both are downregulated in 68% of cases." +genetics_knock down_promote hsa-mir-16-1 "Leukemia, Lymphocytic, Chronic, B-Cell" 17234972 "After years of futile attemptsto identify the gene(s) in the deleted 13q14 region that participatein the pathogenesis of chronic lymphocytic leukemia, Calin etal discovered that miR-15 and miR-16 are located within thissequence and that both are downregulated in 68% of cases." +genetics_knock down_promote hsa-mir-16-2 "Leukemia, Lymphocytic, Chronic, B-Cell" 17234972 "After years of futile attemptsto identify the gene(s) in the deleted 13q14 region that participatein the pathogenesis of chronic lymphocytic leukemia, Calin etal discovered that miR-15 and miR-16 are located within thissequence and that both are downregulated in 68% of cases." +genetics_knock down_promote hsa-mir-181b-2 Urinary Bladder Cancer 17470785 "mir-181b-2 and mir-199b are 3.3 Mb from the peak of the colon Scc2 locus on Chr 2; homologous human miRNAs are located inside a cancer-associated genomic region, which is a region commonly deleted in bladder cancer." +genetics_knock down_promote hsa-mir-199b Urinary Bladder Cancer 17470785 "mir-181b-2 and mir-199b are 3.3 Mb from the peak of the colon Scc2 locus on Chr 2; homologous human miRNAs are located inside a cancer-associated genomic region, which is a region commonly deleted in bladder cancer." +genetics_knock down_promote hsa-mir-15a "Leukemia, Lymphocytic, Chronic, B-Cell" 17531469 "The loss-of-function of miR-15a and miR-16-1 in CLL, and perhaps other cancers as well, may contribute to malignant transformation by upregulating Bcl2 thereby preventing apoptosis." +genetics_knock down_promote hsa-mir-16-1 "Leukemia, Lymphocytic, Chronic, B-Cell" 17531469 "the loss-of-function of miR-15a and miR-16-1 in CLL, and perhaps other cancers as well, may contribute to malignant transformation by upregulating Bcl2 thereby preventing apoptosis." +genetics_knock down_promote hsa-mir-15a "Leukemia, Lymphocytic, Chronic, B-Cell" 17940623 "The common loss of miR-15a and miR-16-1 in CLL, as well as the loss of 13q14 in mantle cell lymphoma (50 percent of cases), multiple myeloma (16 to 40 percent) and prostate cancer (60 percent), strongly suggests that these two miRNAs act as tumor suppressor genes. While their full target complement is unknown, they appear to mediate their effects largely by down-regulating the anti-apoptotic protein BCL2. This protein is often found expressed at high levels in CLL and is thought to be important for the survival of the malignant cells." +genetics_knock down_promote hsa-mir-15a "Lymphoma, Mantle-Cell" 17940623 "The common loss of miR-15a and miR-16-1 in CLL, as well as the loss of 13q14 in mantle cell lymphoma (50 percent of cases), multiple myeloma (16 to 40 percent) and prostate cancer (60 percent), strongly suggests that these two miRNAs act as tumor suppressor genes. While their full target complement is unknown, they appear to mediate their effects largely by down-regulating the anti-apoptotic protein BCL2. This protein is often found expressed at high levels in CLL and is thought to be important for the survival of the malignant cells." +genetics_knock down_promote hsa-mir-15a Multiple Myeloma 17940623 "The common loss of miR-15a and miR-16-1 in CLL, as well as the loss of 13q14 in mantle cell lymphoma (50 percent of cases), multiple myeloma (16 to 40 percent) and prostate cancer (60 percent), strongly suggests that these two miRNAs act as tumor suppressor genes. While their full target complement is unknown, they appear to mediate their effects largely by down-regulating the anti-apoptotic protein BCL2. This protein is often found expressed at high levels in CLL and is thought to be important for the survival of the malignant cells." +genetics_knock down_promote hsa-mir-15a Prostate Neoplasms 17940623 "The common loss of miR-15a and miR-16-1 in CLL, as well as the loss of 13q14 in mantle cell lymphoma (50 percent of cases), multiple myeloma (16 to 40 percent) and prostate cancer (60 percent), strongly suggests that these two miRNAs act as tumor suppressor genes. While their full target complement is unknown, they appear to mediate their effects largely by down-regulating the anti-apoptotic protein BCL2. This protein is often found expressed at high levels in CLL and is thought to be important for the survival of the malignant cells." +genetics_knock down_promote hsa-mir-16-1 "Leukemia, Lymphocytic, Chronic, B-Cell" 17940623 "The common loss of miR-15a and miR-16-1 in CLL, as well as the loss of 13q14 in mantle cell lymphoma (50 percent of cases), multiple myeloma (16 to 40 percent) and prostate cancer (60 percent), strongly suggests that these two miRNAs act as tumor suppressor genes. While their full target complement is unknown, they appear to mediate their effects largely by down-regulating the anti-apoptotic protein BCL2. This protein is often found expressed at high levels in CLL and is thought to be important for the survival of the malignant cells." +genetics_knock down_promote hsa-mir-16-1 "Lymphoma, Mantle-Cell" 17940623 "The common loss of miR-15a and miR-16-1 in CLL, as well as the loss of 13q14 in mantle cell lymphoma (50 percent of cases), multiple myeloma (16 to 40 percent) and prostate cancer (60 percent), strongly suggests that these two miRNAs act as tumor suppressor genes. While their full target complement is unknown, they appear to mediate their effects largely by down-regulating the anti-apoptotic protein BCL2. This protein is often found expressed at high levels in CLL and is thought to be important for the survival of the malignant cells." +genetics_knock down_promote hsa-mir-16-1 Multiple Myeloma 17940623 "The common loss of miR-15a and miR-16-1 in CLL, as well as the loss of 13q14 in mantle cell lymphoma (50 percent of cases), multiple myeloma (16 to 40 percent) and prostate cancer (60 percent), strongly suggests that these two miRNAs act as tumor suppressor genes. While their full target complement is unknown, they appear to mediate their effects largely by down-regulating the anti-apoptotic protein BCL2. This protein is often found expressed at high levels in CLL and is thought to be important for the survival of the malignant cells." +genetics_knock down_promote hsa-mir-16-1 Prostate Neoplasms 17940623 "The common loss of miR-15a and miR-16-1 in CLL, as well as the loss of 13q14 in mantle cell lymphoma (50 percent of cases), multiple myeloma (16 to 40 percent) and prostate cancer (60 percent), strongly suggests that these two miRNAs act as tumor suppressor genes. While their full target complement is unknown, they appear to mediate their effects largely by down-regulating the anti-apoptotic protein BCL2. This protein is often found expressed at high levels in CLL and is thought to be important for the survival of the malignant cells." +genetics_knock down_promote hsa-mir-15a "Leukemia, Lymphocytic, Chronic, B-Cell" 17965831 "miR-15a and miR-16 are often deleted from chromosome 13q14.2 in patients with B cell CLL, suggesting that these miRNAs may be involved in tumour suppression. Additionally, introduction of exogenous miR-16 into a malignant B-1 cell line resulted in increased apoptosis." +genetics_knock down_promote hsa-mir-16-1 "Leukemia, Lymphocytic, Chronic, B-Cell" 17965831 "miR-15a and miR-16 are often deleted from chromosome 13q14.2 in patients with B cell CLL, suggesting that these miRNAs may be involved in tumour suppression. Additionally, introduction of exogenous miR-16 into a malignant B-1 cell line resulted in increased apoptosis." +genetics_knock down_promote hsa-mir-16-2 "Leukemia, Lymphocytic, Chronic, B-Cell" 17965831 "miR-15a and miR-16 are often deleted from chromosome 13q14.2 in patients with B cell CLL, suggesting that these miRNAs may be involved in tumour suppression. Additionally, introduction of exogenous miR-16 into a malignant B-1 cell line resulted in increased apoptosis." +genetics_knock down_promote hsa-mir-29a Alzheimer Disease 18434550 loss +genetics_knock down_promote hsa-mir-29b-1 Alzheimer Disease 18434550 loss +genetics_knock down_promote hsa-mir-1-1 "Carcinoma, Hepatocellular" 18593903 miR-1: silenced +genetics_knock down_promote hsa-mir-1-2 "Carcinoma, Hepatocellular" 18593903 miR-1: silenced +genetics_knock down_promote hsa-mir-34a Neoplasms [unspecific] 18834855 miR-34a: reduced or lost +genetics_knock down_promote hsa-mir-101-1 Neoplasms [unspecific] 19008416 miR-101: Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer +genetics_knock down_promote hsa-mir-101-2 Neoplasms [unspecific] 19008416 miR-101: Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer +genetics_knock down_promote hsa-mir-31 Neoplasms [unspecific] 20179198 miR-31 is associated with defects in the p53 pathway and functions in serous ovarian cancer and other cancers +genetics_knock down_promote hsa-mir-31 Ovarian Neoplasms 20179198 miR-31 is associated with defects in the p53 pathway and functions in serous ovarian cancer and other cancers +genetics_knock down_promote hsa-mir-143 Neoplasms [unspecific] 20439436 miR-143:We correctly identified hsa-miR-17/92 family as amplified and the hsa-miR-143/145 cluster as deleted +genetics_knock down_promote hsa-mir-145 Neoplasms [unspecific] 20439436 miR-145:We correctly identified hsa-miR-17/92 family as amplified and the hsa-miR-143/145 cluster as deleted +genetics_knock down_promote hsa-mir-31 Mesothelioma 20463022 miR-31:Pro-tumorigenic effects of miR-31 loss in mesothelioma +genetics_knock down_promote hsa-mir-301a Lung Neoplasms 20470754 "miR-301:blocking of miR-301 in A549 cells leads to a decrease in the expression of the host gene, ska2" +genetics_knock down_promote hsa-mir-29a "Leukemia, Myeloid, Acute" 20628397 miR-29a:The tumour-suppressive miR-29a/b1 cluster is regulated by CEBPA and blocked in human AML +genetics_knock down_promote hsa-mir-29b-1 "Leukemia, Myeloid, Acute" 20628397 miR-29b1:The tumour-suppressive miR-29a/b1 cluster is regulated by CEBPA and blocked in human AML +genetics_knock down_promote hsa-mir-15a "Leukemia, Lymphocytic, Chronic, B-Cell" 21156224 often absent +genetics_knock down_promote hsa-mir-16-1 "Leukemia, Lymphocytic, Chronic, B-Cell" 21156224 often absent +genetics_knock down_promote hsa-mir-107 Urinary Bladder Cancer 21388952 Specific deletion of p53 in urothelial cells is associated with specific overexpression of miR-18a and miR-19a and down-regulation of miR-107. +genetics_knock down_promote hsa-mir-486 Gastric Neoplasms 21415212 Genomic Loss of miR-486 Regulates Tumor Progression and the OLFM4 Anti-apoptotic Factor in Gastric Cancer. +genetics_knock down_promote hsa-mir-15a Prostate Neoplasms 21472816 The miR-15a-miR-16-1 locus is homozygously deleted in a subset of prostate cancers. +genetics_knock down_promote hsa-mir-16-1 Prostate Neoplasms 21472816 The miR-15a-miR-16-1 locus is homozygously deleted in a subset of prostate cancers. +genetics_knock down_promote hsa-mir-218-1 Urinary Bladder Cancer 21519788 miR-218 on the genomic loss region of chromosome 4p15.31 functions as a tumor suppressor in bladder cancer. +genetics_knock down_promote hsa-mir-218-2 Urinary Bladder Cancer 21519788 miR-218 on the genomic loss region of chromosome 4p15.31 functions as a tumor suppressor in bladder cancer. +genetics_knock down_promote hsa-mir-1-1 Myotonic Muscular Dystrophy 21685920 "As a consequence of miR-1 loss, expression of GJA1 (connexin 43) and CACNA1C (Cav1.2), which are targets of miR-1, is increased in both DM1- and DM2-affected hearts." +genetics_knock down_promote hsa-mir-1-2 Myotonic Muscular Dystrophy 21685920 "As a consequence of miR-1 loss, expression of GJA1 (connexin 43) and CACNA1C (Cav1.2), which are targets of miR-1, is increased in both DM1- and DM2-affected hearts." +genetics_knock down_promote hsa-mir-135a-1 Medulloblastoma 21793975 deletion +genetics_knock down_promote hsa-mir-135a-2 Medulloblastoma 21793975 deletion or amplification +genetics_knock down_promote hsa-mir-135b Medulloblastoma 21793975 deletion or amplification +genetics_knock down_promote hsa-mir-186 Medulloblastoma 21793975 deletion +genetics_knock down_promote hsa-mir-33b Medulloblastoma 21793975 "deletion, amplification or a mutation at the precursor miRNA" +genetics_knock down_promote hsa-mir-512-2 Medulloblastoma 21793975 "deletion. Antisense-based knockdown of miR-512-5p (mature sequence of miR-512-2) resulted in significant upregulation of MYCC expression in HeLa and A549 cells, while forced overexpression of miR-512-2 in medulloblastoma/PNET cell lines DAOY, UW-228-2, PFSK resulted in downregulation of MYCC protein." +genetics_knock down_promote hsa-mir-548d-1 Medulloblastoma 21793975 deletion +genetics_knock down_promote hsa-mir-548d-2 Medulloblastoma 21793975 deletion +genetics_knock down_promote hsa-mir-132 Progressive Supranuclear Palsy 21807765 "MicroRNA-132 loss is associated with tau exon 10 inclusion in Supranuclear Palsy, Progressive." +genetics_knock down_promote hsa-mir-101-1 Lung Neoplasms 21849855 miR-101 DNA Copy Loss is a Prominent Subtype Specific Event in Lung Cancer. +genetics_knock down_promote hsa-mir-101-2 Lung Neoplasms 21849855 miR-101 DNA Copy Loss is a Prominent Subtype Specific Event in Lung Cancer. +genetics_knock down_promote hsa-mir-145 Myelodysplastic Syndromes 21873545 miR-145 affects megakaryocyte and erythroid differentiation.Patients with del(5q) MDS have decreased expression of miR-145 and increased expression of Fli-1. Combined loss of miR-145 and RPS14 cooperate to alter erythroid-megakaryocytic differentiation in a manner similar to the 5q- syndrome. +genetics_knock down_promote hsa-mir-17 Musculoskeletal Abnormalities [unspecific] 21892160 Germline deletion of the miR-17-92 cluster causes skeletal and growth defects in humans. +genetics_knock down_promote hsa-mir-18a Musculoskeletal Abnormalities [unspecific] 21892160 Germline deletion of the miR-17-92 cluster causes skeletal and growth defects in humans. +genetics_knock down_promote hsa-mir-19a Musculoskeletal Abnormalities [unspecific] 21892160 Germline deletion of the miR-17-92 cluster causes skeletal and growth defects in humans. +genetics_knock down_promote hsa-mir-19b-1 Musculoskeletal Abnormalities [unspecific] 21892160 Germline deletion of the miR-17-92 cluster causes skeletal and growth defects in humans. +genetics_knock down_promote hsa-mir-20a Musculoskeletal Abnormalities [unspecific] 21892160 Germline deletion of the miR-17-92 cluster causes skeletal and growth defects in humans. +genetics_knock down_promote hsa-mir-92a-1 Musculoskeletal Abnormalities [unspecific] 21892160 Germline deletion of the miR-17-92 cluster causes skeletal and growth defects in humans. +genetics_knock down_promote hsa-mir-21 Hypertension 21920918 "Induction of miR-21 and miR-27a may be a critical component of BMP-induced growth suppression, loss of which likely contributes to vascular cell proliferation in HPAH (Heritable pulmonary arterial hypertension)." +genetics_knock down_promote hsa-mir-101-1 Pancreatic Neoplasms 21932133 Loss of MicroRNA-101 Promotes Overexpression of Histone Methyltransferase EZH2. +genetics_knock down_promote hsa-mir-101-2 Pancreatic Neoplasms 21932133 Loss of MicroRNA-101 Promotes Overexpression of Histone Methyltransferase EZH2. +genetics_knock down_promote hsa-mir-101-1 "Carcinoma, Lung, Non-Small-Cell" 21993632 "Down-regulation of miR-101 was associated with overexpression of Mcl-1 mRNA in NSCLC tissue when compared with corresponding normal tissue, with a negative correlation (r = -0.724, P < 0.01). MiR-101 expression was significantly associated with pathological stage (P = 0.004) and lymph node involvement (P = 0.012). Overexpression of Mcl-1 was associated with pathological grade (P = 0.022) and lymph node involvement (P = 0.017). A comparison of survival curves of low versus high expressers of miR-101 and Mcl-1 revealed a highly significant difference in NSCLC (P < 0.05), which suggests that reduced expression of miR-101 versus overexpression of Mcl-1 is associated with a poorer prognosis." +genetics_knock down_promote hsa-mir-101-2 "Carcinoma, Lung, Non-Small-Cell" 21993632 "Down-regulation of miR-101 was associated with overexpression of Mcl-1 mRNA in NSCLC tissue when compared with corresponding normal tissue, with a negative correlation (r = -0.724, P < 0.01). MiR-101 expression was significantly associated with pathological stage (P = 0.004) and lymph node involvement (P = 0.012). Overexpression of Mcl-1 was associated with pathological grade (P = 0.022) and lymph node involvement (P = 0.017). A comparison of survival curves of low versus high expressers of miR-101 and Mcl-1 revealed a highly significant difference in NSCLC (P < 0.05), which suggests that reduced expression of miR-101 versus overexpression of Mcl-1 is associated with a poorer prognosis." +genetics_knock down_promote hsa-mir-144 Thyroid Neoplasms 22049245 miR-199b-5p and miR-144 which were essentially lost in the carcinomas. +genetics_knock down_promote hsa-mir-199b Thyroid Neoplasms 22049245 miR-199b-5p and miR-144 which were essentially lost in the carcinomas. +genetics_knock down_promote hsa-mir-29a Kidney Diseases [unspecific] 22095944 Suppression of microRNA-29 Expression by TGF-beta1 Promotes Collagen Expression and Renal Fibrosis. +genetics_knock down_promote hsa-mir-29b-1 Kidney Diseases [unspecific] 22095944 Suppression of microRNA-29 Expression by TGF-beta1 Promotes Collagen Expression and Renal Fibrosis. +genetics_knock down_promote hsa-mir-29b-2 Kidney Diseases [unspecific] 22095944 Suppression of microRNA-29 Expression by TGF-beta1 Promotes Collagen Expression and Renal Fibrosis. +genetics_knock down_promote hsa-mir-29c Kidney Diseases [unspecific] 22095944 Suppression of microRNA-29 Expression by TGF-beta1 Promotes Collagen Expression and Renal Fibrosis. +genetics_knock down_promote hsa-mir-122 Hepatitis B Virus Infection 22105316 Loss of MiR-122 expression in patients with hepatitis B enhances hepatitis B virus replication through cyclin G1 modulated P53 activity. +genetics_knock down_promote hsa-mir-34a Rheumatoid Arthritis 22161761 Downregulation of microRNA-34a* in rheumatoid arthritis synovial fibroblasts promotes apoptosis resistance. +genetics_knock down_promote hsa-mir-124-1 Glioma 22253443 Loss of brain-enriched miR-124 enhances the stem-like traits and invasiveness of glioma cells. +genetics_knock down_promote hsa-mir-124-2 Glioma 22253443 Loss of brain-enriched miR-124 enhances the stem-like traits and invasiveness of glioma cells. +genetics_knock down_promote hsa-mir-124-3 Glioma 22253443 Loss of brain-enriched miR-124 enhances the stem-like traits and invasiveness of glioma cells. +genetics_knock down_promote hsa-mir-145 Ovarian Neoplasms 22285623 The loss of miR-145 can result in the activation of factors that promote oncogenesis and cellular pluripotency which in turn could lead to the development of ovarian cancer. +genetics_knock down_promote hsa-mir-133a-1 Breast Neoplasms 22292984 Loss of miR-133a expression associated with poor survival of breast cancer and restoration of miR-133a expression inhibited breast cancer cell growth and invasion. +genetics_knock down_promote hsa-mir-133a-2 Breast Neoplasms 22292984 Loss of miR-133a expression associated with poor survival of breast cancer and restoration of miR-133a expression inhibited breast cancer cell growth and invasion. +genetics_knock down_promote hsa-mir-29a "Muscular Dystrophy, Duchenne" 22434133 Loss of miR-29 in Myoblasts Contributes to Dystrophic Muscle Pathogenesis. +genetics_knock down_promote hsa-mir-29b-1 "Muscular Dystrophy, Duchenne" 22434133 Loss of miR-29 in Myoblasts Contributes to Dystrophic Muscle Pathogenesis. +genetics_knock down_promote hsa-mir-29b-2 "Muscular Dystrophy, Duchenne" 22434133 Loss of miR-29 in Myoblasts Contributes to Dystrophic Muscle Pathogenesis. +genetics_knock down_promote hsa-mir-29c "Muscular Dystrophy, Duchenne" 22434133 Loss of miR-29 in Myoblasts Contributes to Dystrophic Muscle Pathogenesis. +genetics_knock down_promote hsa-mir-101-1 Gastric Neoplasms 22450781 Lack of microRNA-101 causes E-cadherin functional deregulation through EZH2 upregulation in intestinal gastric cancer. +genetics_knock down_promote hsa-let-7c Prostate Neoplasms 22479342 MicroRNA let-7c Is Downregulated in Prostate Cancer and Suppresses Prostate Cancer Growth. +genetics_knock down_promote hsa-mir-205 Melanoma 22525428 Loss of microRNA-205 expression is associated with melanoma progression. +genetics_knock down_promote hsa-let-7g Melanoma 22551973 The downregulation of this miRNA was associated with selective genomic loss in SSM cell lines and primary tumors. +genetics_knock down_promote hsa-mir-126 Pancreatic Neoplasms 22845403 Loss of miR-126 is crucial to pancreatic cancer progression. +genetics_knock down_promote hsa-mir-148a Endometrial Neoplasms 22890324 Silencing of miR-148a in cancer-associated fibroblasts results in WNT10B-mediated stimulation of tumor cell motility. +genetics_knock down_promote hsa-mir-218-1 Breast Neoplasms 22898079 Silencing of miRNA-218 promotes migration and invasion of breast cancer via Slit2-Robo1 pathway. +genetics_knock down_promote hsa-mir-218-2 Breast Neoplasms 22898079 Silencing of miRNA-218 promotes migration and invasion of breast cancer via Slit2-Robo1 pathway. +genetics_knock down_promote hsa-mir-101-1 Colon Neoplasms 22930392 Loss of miR-101 Expression Promotes Wnt/beta-Catenin Signalling Pathway Activation and Malignancy in Colon Cancer Cells. +genetics_knock down_promote hsa-mir-200a Melanoma 22956368 "Loss of microRNA-200a and c, and microRNA-203 expression at the invasive front of primary cutaneous melanoma is associated with increased thickness and disease progression." +genetics_knock down_promote hsa-mir-200c Melanoma 22956368 "Loss of microRNA-200a and c, and microRNA-203 expression at the invasive front of primary cutaneous melanoma is associated with increased thickness and disease progression." +genetics_knock down_promote hsa-mir-203 Melanoma 22956368 "Loss of microRNA-200a and c, and microRNA-203 expression at the invasive front of primary cutaneous melanoma is associated with increased thickness and disease progression." +genetics_knock down_promote hsa-mir-370 Cholangiocarcinoma 23110045 Silencing of miR-370 in human cholangiocarcinoma by allelic loss and interleukin-6 induced maternal to paternal epigenotype switch +genetics_knock down_promote hsa-mir-126 Heart Failure 23136161 Loss of AngiomiR-126 and 130a in Angiogenic Early Outgrowth Cells From Patients With Chronic Heart Failure: Role for Impaired In Vivo Neovascularization and Cardiac Repair Capacity +genetics_knock down_promote hsa-mir-130a Heart Failure 23136161 Loss of AngiomiR-126 and 130a in Angiogenic Early Outgrowth Cells From Patients With Chronic Heart Failure: Role for Impaired In Vivo Neovascularization and Cardiac Repair Capacity +genetics_knock down_promote hsa-mir-204 Glioma 23204229 Loss of miR-204 Expression Enhances Glioma Migration and Stem Cell-like Phenotype +genetics_knock down_promote hsa-mir-132 Osteosarcoma 23801049 Loss of microRNA-132 predicts poor prognosis in patients with primary osteosarcoma. +genetics_knock down_promote hsa-let-7 Prostate Neoplasms 23977098 "MSCs co-evolve with prostate cancer cells in the tumor microenvironment, and the downregulation of let-7 by cancer-associated MSCs upregulates IL-6 expression." +genetics_knock down_promote hsa-mir-15a "Leukemia, Lymphocytic, Chronic, B-Cell" 24026141 "There was a significantly decreased expression of both miRNAs in patients with biallelic deletion of the 13q14 region but only when deletions were present in 77% or more of cells, as detected by fluorescent in situ hybridization (FISH)." +genetics_knock down_promote hsa-mir-16-1 "Leukemia, Lymphocytic, Chronic, B-Cell" 24026141 "There was a significantly decreased expression of both miRNAs in patients with biallelic deletion of the 13q14 region but only when deletions were present in 77% or more of cells, as detected by fluorescent in situ hybridization (FISH)." +genetics_knock down_promote hsa-mir-21 Ischemia-Reperfusion Injury 24098402 Our data clearly demonstrate that miR-21 is involved in IPost-mediated cardiac protection against I/R injury and dysfunction through the PTEN/Akt signaling pathway in vivo. +genetics_knock down_promote hsa-mir-10a Neoplasms [unspecific] 24204315 Loss of miR-10a activates lpo and collaborates with activated Wnt signaling in inducing intestinal neoplasia in female mice. +genetics_knock down_promote hsa-mir-200a Breast Neoplasms 24280074 Loss of microRNA-200a expression correlates with tumor progression in breast cancer. +genetics_knock down_promote hsa-mir-126 Prostate Neoplasms 24350576 These findings suggest for the first time that the loss of miR-126 expression may play a positive role in the malignant progression of PCa. +genetics_knock down_promote hsa-mir-214 "Carcinoma, Nasopharyngeal" 24465927 Knockdown of miR-214 promotes apoptosis and inhibits cell proliferation in nasopharyngeal carcinoma. +genetics_knock down_promote hsa-mir-223 Sepsis 24486439 "Taken together, these data indicate that loss of miR-223/-223* causes an aggravation of sepsis-induced inflammation, myocardial dysfunction and mortality." +genetics_knock down_promote hsa-mir-206 Amyotrophic Lateral Sclerosis 24664281 "in mutant mice lacking miR-206, reinnervation is impaired following nerve injury and loss of NMJs is accelerated in a mouse model of amyotrophic lateral sclerosis (ALS)." +genetics_knock down_promote hsa-mir-145 "Carcinoma, Hepatocellular" 24690171 "Our results demonstrated that miR-145 could inhibit HCC through targeting IRS1 and its downstream signaling, implicating the loss of miR-145 regulation may be a potential molecular mechanism causing aberrant oncogenic signaling in HCC." +genetics_knock down_promote hsa-mir-15a "Leukemia, Lymphocytic, Chronic, B-Cell" 24732594 Allele-specific loss and transcription of the miR-15a/16-1 cluster in chronic lymphocytic leukemia. +genetics_knock down_promote hsa-mir-16-1 "Leukemia, Lymphocytic, Chronic, B-Cell" 24732594 Allele-specific loss and transcription of the miR-15a/16-1 cluster in chronic lymphocytic leukemia. +genetics_knock down_promote hsa-mir-21 Pulmonary Hypertension 24732886 "In vivo, genetic deletion of microRNA-21 in mice (miR-21(-/-) mice) resulted in functional activation of the PDCD4/caspase-3 axis in the pulmonary tissues, leading to the onset of progressive PH." +genetics_knock down_promote hsa-mir-424 Hepatoblastoma 24796297 "Furthermore, miR-424 or miR-503 depletion enhanced extravasation to the lungs of hepatocarcinoma cells injected in the tail vein of mice." +genetics_knock down_promote hsa-mir-100 Prostate Neoplasms 24805183 "Loss of miR-100 enhances migration, invasion, epithelial-mesenchymal transition and stemness properties in prostate cancer cells through targeting Argonaute 2." +genetics_knock down_promote hsa-mir-451a "Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal" 24918822 Loss of tumour suppressive miR-451a enhanced cancer cell migration and invasion in HSCC through direct regulation of ESDN. Our miRNA signature and functional analysis of targets regulated by tumour suppressive miR-451a provide new insights into the potential mechanisms of HSCC oncogenesis and metastasis. +genetics_knock down_promote hsa-mir-17 Atrial Fibrillation 24927531 "miR-17-92 and miR-106b-25 directly repress genes, such as Shox2 and Tbx3, that are required for sinoatrial node development.Together, to our knowledge, these findings provide the first genetic evidence for an miR loss-of-function that increases atrial fibrillation susceptibility." +genetics_knock down_promote hsa-mir-18 Atrial Fibrillation 24927531 "miR-17-92 and miR-106b-25 directly repress genes, such as Shox2 and Tbx3, that are required for sinoatrial node development.Together, to our knowledge, these findings provide the first genetic evidence for an miR loss-of-function that increases atrial fibrillation susceptibility." +genetics_knock down_promote hsa-mir-19a Atrial Fibrillation 24927531 "miR-17-92 and miR-106b-25 directly repress genes, such as Shox2 and Tbx3, that are required for sinoatrial node development.Together, to our knowledge, these findings provide the first genetic evidence for an miR loss-of-function that increases atrial fibrillation susceptibility." +genetics_knock down_promote hsa-mir-19b-1 Atrial Fibrillation 24927531 "miR-17-92 and miR-106b-25 directly repress genes, such as Shox2 and Tbx3, that are required for sinoatrial node development.Together, to our knowledge, these findings provide the first genetic evidence for an miR loss-of-function that increases atrial fibrillation susceptibility." +genetics_knock down_promote hsa-mir-20a Atrial Fibrillation 24927531 "miR-17-92 and miR-106b-25 directly repress genes, such as Shox2 and Tbx3, that are required for sinoatrial node development.Together, to our knowledge, these findings provide the first genetic evidence for an miR loss-of-function that increases atrial fibrillation susceptibility." +genetics_knock down_promote hsa-mir-92-1 Atrial Fibrillation 24927531 "miR-17-92 and miR-106b-25 directly repress genes, such as Shox2 and Tbx3, that are required for sinoatrial node development.Together, to our knowledge, these findings provide the first genetic evidence for an miR loss-of-function that increases atrial fibrillation susceptibility." +genetics_knock down_promote hsa-mir-203 Prostate Neoplasms 24980827 Loss of tumor suppressor mir-203 mediates overexpression of LIM and SH3 Protein 1 (LASP1) in high-risk prostate cancer thereby increasing cell proliferation and migration. +genetics_knock down_promote hsa-mir-155 Melanoma 25143000 Our current study showed that both B16-F10 melanoma and Lewis lung carcinoma tumors grew much faster in bic/miR-155 knockout (miR-155(-/-) ) mice +genetics_knock down_promote hsa-mir-378 Prostate Neoplasms 25153390 "Loss of miR-378 in prostate cancer, a common regulator of KLK2 and KLK4, correlates with aggressive disease phenotype and predicts the short-term relapse of the patients." +genetics_knock down_promote hsa-mir-100 "Carcinoma, Hepatocellular" 25361001 Downregulation of microRNA-100 enhances the ICMT-Rac1 signaling and promotes metastasis of hepatocellular carcinoma cells. +genetics_knock down_promote hsa-mir-101 "Carcinoma, Esophageal" 25400732 decreased expression of miR-101 might promote metastasis of human ESCC by inducing accumulation of EZH2 protein. +genetics_knock down_promote hsa-mir-101 Lung Neoplasms 25428391 "particle can induce the secretion of interleukin-1¦Â. Interleukin-1¦Â subsequently induces the downregulation of mir-101, which may result in the upregulated level of EZH2, and occurrence of lung cancer. We for the first time proposed the role interleukin-1¦Â-mir-101-EZH2 axes in the particle-induced lung cancer. Further study may be needed to decipher the detailed mechanism involved." +genetics_knock down_promote hsa-mir-34a Prostate Neoplasms 25436980 "the bone metastasis and anti-apoptotic effects found in Ras signaling-activated prostate cancer cells require miR-34a deficiency, which in turn aids in cell survival by activating the WNT and anti-apoptotic signaling pathways thereby inducing TCF7 and BIRC5 expressions." +genetics_knock down_promote hsa-mir-34a Diabetes Mellitus 25483877 "Knockdown of miR-34a slightly decreased proliferation, but as apoptosis and NO synthesis were highly reduced, miR-34a may be further investigated as a therapeutic target to reduce β-cell death and dysfunction." +genetics_knock down_promote hsa-mir-7 Breast Neoplasms 25532106 Suppression of miR-7 in the MCF-7 cell line resulted in enhanced colony formation activity but not cell migration +genetics_knock down_promote hsa-mir-204 Prostate Neoplasms 25630658 "not only tumor suppressor micro-RNA loss, but also significant genome rearrangement-driven regulatory loop perturbations play a role in the advanced cancer progression, conferring better pro-survival and metastatic potential." +genetics_knock down_promote hsa-mir-26a Neoplasms [unspecific] 25668004 Loss of tumour-suppressive miR-26a/b enhanced cancer cell migration and invasion in OSCC through direct regulation of TMEM184B. Our data describing pathways regulated by tumour-suppressive miR-26a/b provide new insights into the potential mechanisms of OSCC oncogenesis and metastasis. +genetics_knock down_promote hsa-mir-26b Neoplasms [unspecific] 25668004 Loss of tumour-suppressive miR-26a/b enhanced cancer cell migration and invasion in OSCC through direct regulation of TMEM184B. Our data describing pathways regulated by tumour-suppressive miR-26a/b provide new insights into the potential mechanisms of OSCC oncogenesis and metastasis. +genetics_knock down_promote hsa-mir-1 Prostate Neoplasms 25802280 Our data support the existence of an AR-miR-1-SRC regulatory network.We propose that loss of miR-1 is one mechanistic link between low canonical Androgen receptor (AR) output and SRC-promoted metastatic phenotypes. +genetics_knock down_promote hsa-mir-23a Idiopathic Pulmonary Hypertension 25815108 "Finally we found that silencing of miR23a resulted in an increase of the expression of PGC1¦Á, as well as in its well-known regulated genes CYC, SOD, NRF2,and HO1. The results point to the utility of circulating miRNA expression as a biomarker of disease progression." +genetics_knock down_promote hsa-mir-146b "Carcinoma, Thyroid, Papillary" 25819770 "The results showed that PTC cells overexpress miR-146b and miR-222 in exosomes; and that factors released by both normal thyroid and PTC cells alter proliferation of other cells in a complex manner. The intercellular interactions were likely conferred in part by exosomal miRNA, which can potentially be developed as biomarkers of PTC recurrence." +genetics_knock down_promote hsa-mir-222 "Carcinoma, Thyroid, Papillary" 25819770 "The results showed that PTC cells overexpress miR-146b and miR-222 in exosomes; and that factors released by both normal thyroid and PTC cells alter proliferation of other cells in a complex manner. The intercellular interactions were likely conferred in part by exosomal miRNA, which can potentially be developed as biomarkers of PTC recurrence." +genetics_knock down_promote hsa-mir-150 Heart Failure 25824147 we show that genetic deletion of miR-150 in mice causes abnormalities in cardiac structural and functional remodelling after MI. +genetics_knock down_promote hsa-mir-150 Myocardial Infarction 25824147 we show that genetic deletion of miR-150 in mice causes abnormalities in cardiac structural and functional remodelling after MI. +genetics_knock down_promote hsa-mir-155 "Lymphoma, B-Cell" 25829072 "A deficiency of miR-155 in the immune system causes attenuated immune functions. Clinically, several types of malignancy including diffuse large B-cell lymphoma have high miR-155 expression levels." +genetics_knock down_promote hsa-mir-21 Acute Kidney Failure 25844699 "Knockdown of miR-21 upregulated its target effectors programmed cell death protein 4 and phosphatase and tensin homolog deleted on chromosome 10 expression, resulted in an increase in apoptosis, and exacerbated lipopolysaccharide-induced acute kidney injury." +genetics_knock down_promote hsa-mir-155 Mycobacterium tuberculosis Infection 25846955 "Following infection, miR-155-deficient C57BL/6 mice died significantly earlier and had significantly higher numbers of CFU in lungs than wild-type mice." +genetics_knock down_promote hsa-mir-377 Lymphoma 25889255 Our results suggest that miR-377 is an important negative regulator of E2F and MAP3K7/NF-kB signaling pathway in melanoma cells; it is tempting to speculate that its silencing in melanoma promotes the tumorigenic and metastatic potential of the cells through activation of these pathways. +genetics_knock down_promote hsa-mir-142 Primary Immunodeficiency Disease 25931583 "miR-142 as an essential regulator of lymphopoiesis, and suggest that lesions in this miRNA gene may lead to primary immunodeficiency." +genetics_knock down_promote hsa-mir-132 Inflammation 26052826 Blockage of miR-132 using miR-132 inhibitor reversed the Ach action upon LPS-induced release of inflammatory mediators and reduction in AchE protein/activity. +genetics_knock down_promote hsa-mir-205 Prostate Neoplasms 26059417 Loss of tumor-suppressive microRNA-205 seems to enhance cancer cell migration and invasion in prostate cancer through direct regulation of centromere protein F. Our data describing pathways regulated by tumor-suppressive microRNA-205 provide new insights into the potential mechanisms of prostate cancer oncogenesis and metastasis. +genetics_knock down_promote hsa-mir-133a Heart Failure 26064437 attenuation of miR-133a contributes to the exacerbation of diabetes mediated cardiac autophagy and hypertrophy in heart failure +genetics_knock down_promote hsa-mir-133a Hypertrophy 26064437 attenuation of miR-133a contributes to the exacerbation of diabetes mediated cardiac autophagy and hypertrophy in heart failure +genetics_knock down_promote hsa-mir-21 "Carcinoma, Hepatocellular" 26282675 "microRNA-21 knockdown led to increased HBP1 and p53 and subsequently reduced lipogenesis and delayed G1/S transition, and the additional treatment of HBP1-siRNA antagonised the effect of microRNA-21-ASO, suggesting that HBP1 mediated the inhibitory effects of microRNA-21-ASO on both hepatic lipid accumulation and hepatocarcinogenesis." +genetics_knock down_promote hsa-mir-622 Colorectal Carcinoma 26333174 miR-622 inhibited tumor proliferation and migration in vitro. +genetics_knock down_promote hsa-mir-214 Parkinson Disease 26349993 "The loss of miR-214 in PD resulted in the increase of ¦Á-synuclein expression, which was the potential mechanism underlying the neuroprotective effects of Resveratrol." +genetics_knock down_promote hsa-mir-195 Cervical Neoplasms 26511972 reducing the endogenous miR-195 level by miR-195 inhibitor promoted the proliferation of cervical cancer cells. +genetics_knock down_promote hsa-mir-377 Ischemia-Reperfusion Injury 26564600 "These findings indicate that HF increased miR-377 expression in the myocardium, which is detrimental to stem cell function, and transplantation of miR-377 knockdown hCD34(+) cells into ischemic myocardium promoted their angiogenic ability, attenuating left ventricular remodeling and cardiac fibrosis." +genetics_knock down_promote hsa-mir-150 Sepsis 26743170 miR-150(-/-) mice died rapidly after sepsis. +genetics_knock down_promote hsa-mir-29b "Carcinoma, Renal Cell" 26823729 "Inhibition of miR-29b expression could promote apoptosis, and inhibit proliferation and invasion ability in SN12-PM6 cells." +genetics_knock down_promote hsa-mir-150 Obesity 26833392 miR-150KO mice displayed exacerbated obesity-associated tissue inflammation and systemic insulin resistance +genetics_knock down_promote hsa-mir-29c "Carcinoma, Embryonal" 26848028 "Inhibition of miRâ€?9c promoted proliferation, and suppressed the apoptosis and differentiation of P19 cells." +genetics_knock down_promote hsa-mir-196a Renal Fibrosis 26940097 depletion of renal miR-196a/b by miR-196a/b antagomirs substantially aggravated UUO-induced renal fibrosis. +genetics_knock down_promote hsa-mir-196b Renal Fibrosis 26940097 depletion of renal miR-196a/b by miR-196a/b antagomirs substantially aggravated UUO-induced renal fibrosis. +genetics_knock down_promote hsa-mir-126a Sepsis 26968021 "The down-regulation of miR-126a-3p in endothelial cells resulted in the increased apoptosis, and decreased proliferation and migration," +genetics_knock down_promote hsa-mir-124 Glioblastoma 26993295 inhibitor of miR-124 promoted the expression of STAT3 and cell proliferation. +genetics_knock down_promote hsa-mir-181 Autism Spectrum Disorder 27017280 this loss-of miR-181c function resulted in enhanced neurite sprouting and reduced synaptogenesis +genetics_knock down_promote hsa-mir-4282 Colorectal Carcinoma 27120047 "It was found that miR-4282 inhibition promoted cell growth, migration and invasion (P<0.05) of HT29 and HCT116 colorectal carcinoma cells while miR-4282 overexpression suppressed cell growth and mobility (P<0.05)." +genetics_knock down_promote hsa-mir-146a Ischemia-Reperfusion Injury 27250735 miR146a exerts a kidney protective effect through negative regulation of acute inflammatory response +genetics_knock down_promote hsa-mir-505 "Carcinoma, Hepatocellular" 27259809 "the up-regulation of miR-505 suppressed, whereas the down-regulation of miR-505 promoted proliferation, invasion and epithelial-mesenchymal transition in MHCC97." +genetics_knock down_promote hsa-mir-206 Rhabdomyosarcoma 27277678 Genetic deletion of miR-206 in a mouse model of FN-RMS accelerated and exacerbated tumor development +genetics_knock down_promote hsa-mir-150 Diabetic Retinopathy 27304911 deletion of miR-150 significantly increased the retinal pathological angiogenesis +genetics_knock down_promote hsa-mir-34a Obesity 27377585 miR-34a(-/-) mice are susceptible to diet-induced obesity. +genetics_knock down_promote hsa-mir-122 Pterygium 27415790 "Decreased expression of miR-122 in pterygium might result in abnormal cell apoptosis via its regulation of the expression of Bcl-w, and subsequently contribute to the development of pterygium." +genetics_knock down_promote hsa-mir-146a Ischemia-Reperfusion Injury 27444565 "After unilateral IRI, miR-146a-/- mice exhibited more extensive tubular injury, inflammatory infiltrates, and fibrosis than wild-type mice." +genetics_knock down_promote hsa-mir-145 Prostate Neoplasms 27465939 "ASC-derived conditioned medium (CM) significantly inhibited PC3M-luc2 cell proliferation, inducing apoptosis, but the effect was canceled by miR-145 knockdown in ASCs." +genetics_knock down_promote hsa-mir-200b "Squamous Cell Carcinoma, Esophageal" 27496804 "Correlating with the frequent loss of miR-200b in ESCC, both CDK2 and PAF levels are significantly increased in ESCC tumors compared to case-matched normal tissues." +genetics_knock down_promote hsa-mir-27a Rheumatoid Arthritis 27498552 "However, miR-27a inhibition promoted the migration and invasion of FLS." +genetics_knock down_promote hsa-mir-424 "Carcinoma, Lung, Non-Small-Cell" 27500472 It was found that down-regulation of miR-424-3p was pronouncedly associated with NSCLC progression and overall prognosis; +genetics_knock down_promote hsa-let-7 Kaposi Sarcoma 27531260 "Let-7 silencing may activate the replication of KSHV, possibly through up-regulating MAP4K4 and its downstream molecules COX-2, MMP-13, and phosphorylation of ERK1/2, finally results in the progression of Kaposi sarcoma." +genetics_knock down_promote hsa-mir-15a Leukemia 27533467 both miR-15a deficient HSC and B1P cells are capable of repopulating irradiated recipients and produce higher numbers of B1 cells than sources with normal miR-15a/16 levels. +genetics_knock down_promote hsa-mir-142 "Carcinoma, Hepatocellular" 28177895 Over-expression of Thrombospondin 4 correlates with loss of miR-142 and contributes to migration and vascular invasion of advanced hepatocellular carcinoma. +genetics_knock down_promote hsa-mir-7 Hypogonadotropic Hypogonadism 28218624 Loss of microRNA-7a2 induces hypogonadotropic hypogonadism and infertility. +genetics_knock down_promote hsa-mir-320a "Carcinoma, Hepatocellular" 28288874 Loss of exosomal miR-320a from cancer-associated fibroblasts contributes to HCC proliferation and metastasis. +genetics_knock down_promote hsa-mir-423 Glioma 28381178 miR-423-5p knockdown enhances the sensitivity of glioma stem cells to apigenin through the mitochondrial pathway. +genetics_knock down_promote hsa-mir-126 "Carcinoma, Hepatocellular" 28639884 Loss of tumor suppressor miR-126 contributes to the development of hepatitis B virus-related hepatocellular carcinoma metastasis through the upregulation of ADAM9. +genetics_knock down_promote hsa-mir-200a "Squamous Cell Carcinoma, Oral" 29480379 lack of significant alterations in miR-31 and miR-200a levels in saliva of OLP patients may be indicative for absence of malignant transformation +genetics_knock down_promote hsa-mir-31 "Squamous Cell Carcinoma, Oral" 29480379 lack of significant alterations in miR-31 and miR-200a levels in saliva of OLP patients may be indicative for absence of malignant transformation +genetics_knock down_promote hsa-mir-146a Gout 29544526 "miR-146a provides negative feedback regulation of gouty arthritis development and lack of miR-146a enhances gouty arthritis via upregulation of TRAK6, IRAK-1, and the NALP3 inflammasome function" +genetics_knock down_promote hsa-mir-15a "Carcinoma, Lung, Non-Small-Cell" 29551936 Knocking down MiR-15a expression promotes the occurrence and development and induces the EMT of NSCLC cells in vitro +genetics_knock down_promote hsa-mir-125b "Leukemia, B-Cell" 29555645 physiological silencing of miR-125b is required for normal B-cell development and also acts as a mechanism of cancer suppression +genetics_knock down_promote hsa-mir-21 Spinal Cord Injuries 29934690 Knockdown of MicroRNA-21 Promotes Neurological Recovery After Acute Spinal Cord Injury. +genetics_knock down_promote hsa-mir-148b Endometrial Neoplasms 30146796 Loss of exosomal miR-148b from cancer-associated fibroblasts promotes endometrial cancer cell invasion and cancer metastasis. +genetics_knock down_promote hsa-mir-146b "Leukemia, Lymphoblastic, Acute, T-Cell" 30362152 Loss of miR-146b-5p promotes T cell acute lymphoblastic leukemia migration and invasion via the IL-17A pathway. +genetics_knock down_suppress hsa-mir-223 "Leukemia, Promyelocytic, Acute" 16325577 "In line with this, both RNAi against NFI-A and ectopic expression of miR-223 in acute promyelocytic leukemia (APL) cells enhance differentiation, whereas miR-223 knockdown inhibits the differentiation response to RA." +genetics_knock down_suppress hsa-mir-1-2 Chronic Heart Failure 17397913 deletion +genetics_knock down_suppress hsa-mir-24-1 Tourette Syndrome 17462786 "A mutation in the 3'UTR of the SLITRK1 gene which is associated with Tourette's syndrome was found to enhance repression of the SLITRK mRNA by miR-189, presumably preventing SLITRK1's promotion of dendritic growth." +genetics_knock down_suppress hsa-let-7a-1 Colon Neoplasms 17965831 "Furthermore, a reduction in the expression of let-7 was associated with lung cancers and in particular with reduced survival./ Mayr et al. demonstrated that a chromosomal translocation at 12q5 disrupts let-7 expression and consequently curtails inhibition of the oncogene High Mobility Group A2 (Hmga2). Let-7 has also been implicated in the development of colon cancers and the progression of colorectal cancers." +genetics_knock down_suppress hsa-let-7a-1 Lung Neoplasms 17965831 "Furthermore, a reduction in the expression of let-7 was associated with lung cancers and in particular with reduced survival./ Mayr et al. demonstrated that a chromosomal translocation at 12q5 disrupts let-7 expression and consequently curtails inhibition of the oncogene High Mobility Group A2 (Hmga2). Let-7 has also been implicated in the development of colon cancers and the progression of colorectal cancers." +genetics_knock down_suppress hsa-let-7a-2 Colon Neoplasms 17965831 "Furthermore, a reduction in the expression of let-7 was associated with lung cancers and in particular with reduced survival./ Mayr et al. demonstrated that a chromosomal translocation at 12q5 disrupts let-7 expression and consequently curtails inhibition of the oncogene High Mobility Group A2 (Hmga2). Let-7 has also been implicated in the development of colon cancers and the progression of colorectal cancers." +genetics_knock down_suppress hsa-let-7a-2 Lung Neoplasms 17965831 "Furthermore, a reduction in the expression of let-7 was associated with lung cancers and in particular with reduced survival./ Mayr et al. demonstrated that a chromosomal translocation at 12q5 disrupts let-7 expression and consequently curtails inhibition of the oncogene High Mobility Group A2 (Hmga2). Let-7 has also been implicated in the development of colon cancers and the progression of colorectal cancers." +genetics_knock down_suppress hsa-let-7a-3 Colon Neoplasms 17965831 "Furthermore, a reduction in the expression of let-7 was associated with lung cancers and in particular with reduced survival./ Mayr et al. demonstrated that a chromosomal translocation at 12q5 disrupts let-7 expression and consequently curtails inhibition of the oncogene High Mobility Group A2 (Hmga2). Let-7 has also been implicated in the development of colon cancers and the progression of colorectal cancers." +genetics_knock down_suppress hsa-let-7a-3 Lung Neoplasms 17965831 "Furthermore, a reduction in the expression of let-7 was associated with lung cancers and in particular with reduced survival./ Mayr et al. demonstrated that a chromosomal translocation at 12q5 disrupts let-7 expression and consequently curtails inhibition of the oncogene High Mobility Group A2 (Hmga2). Let-7 has also been implicated in the development of colon cancers and the progression of colorectal cancers." +genetics_knock down_suppress hsa-let-7b Colon Neoplasms 17965831 "Furthermore, a reduction in the expression of let-7 was associated with lung cancers and in particular with reduced survival./ Mayr et al. demonstrated that a chromosomal translocation at 12q5 disrupts let-7 expression and consequently curtails inhibition of the oncogene High Mobility Group A2 (Hmga2). Let-7 has also been implicated in the development of colon cancers and the progression of colorectal cancers." +genetics_knock down_suppress hsa-let-7b Lung Neoplasms 17965831 "Furthermore, a reduction in the expression of let-7 was associated with lung cancers and in particular with reduced survival./ Mayr et al. demonstrated that a chromosomal translocation at 12q5 disrupts let-7 expression and consequently curtails inhibition of the oncogene High Mobility Group A2 (Hmga2). Let-7 has also been implicated in the development of colon cancers and the progression of colorectal cancers." +genetics_knock down_suppress hsa-let-7c Colon Neoplasms 17965831 "Furthermore, a reduction in the expression of let-7 was associated with lung cancers and in particular with reduced survival./ Mayr et al. demonstrated that a chromosomal translocation at 12q5 disrupts let-7 expression and consequently curtails inhibition of the oncogene High Mobility Group A2 (Hmga2). Let-7 has also been implicated in the development of colon cancers and the progression of colorectal cancers." +genetics_knock down_suppress hsa-let-7c Lung Neoplasms 17965831 "Furthermore, a reduction in the expression of let-7 was associated with lung cancers and in particular with reduced survival./ Mayr et al. demonstrated that a chromosomal translocation at 12q5 disrupts let-7 expression and consequently curtails inhibition of the oncogene High Mobility Group A2 (Hmga2). Let-7 has also been implicated in the development of colon cancers and the progression of colorectal cancers." +genetics_knock down_suppress hsa-let-7d Colon Neoplasms 17965831 "Furthermore, a reduction in the expression of let-7 was associated with lung cancers and in particular with reduced survival./ Mayr et al. demonstrated that a chromosomal translocation at 12q5 disrupts let-7 expression and consequently curtails inhibition of the oncogene High Mobility Group A2 (Hmga2). Let-7 has also been implicated in the development of colon cancers and the progression of colorectal cancers." +genetics_knock down_suppress hsa-let-7d Lung Neoplasms 17965831 "Furthermore, a reduction in the expression of let-7 was associated with lung cancers and in particular with reduced survival./ Mayr et al. demonstrated that a chromosomal translocation at 12q5 disrupts let-7 expression and consequently curtails inhibition of the oncogene High Mobility Group A2 (Hmga2). Let-7 has also been implicated in the development of colon cancers and the progression of colorectal cancers." +genetics_knock down_suppress hsa-let-7e Colon Neoplasms 17965831 "Furthermore, a reduction in the expression of let-7 was associated with lung cancers and in particular with reduced survival./ Mayr et al. demonstrated that a chromosomal translocation at 12q5 disrupts let-7 expression and consequently curtails inhibition of the oncogene High Mobility Group A2 (Hmga2). Let-7 has also been implicated in the development of colon cancers and the progression of colorectal cancers." +genetics_knock down_suppress hsa-let-7e Lung Neoplasms 17965831 "Furthermore, a reduction in the expression of let-7 was associated with lung cancers and in particular with reduced survival./ Mayr et al. demonstrated that a chromosomal translocation at 12q5 disrupts let-7 expression and consequently curtails inhibition of the oncogene High Mobility Group A2 (Hmga2). Let-7 has also been implicated in the development of colon cancers and the progression of colorectal cancers." +genetics_knock down_suppress hsa-let-7f-1 Colon Neoplasms 17965831 "Furthermore, a reduction in the expression of let-7 was associated with lung cancers and in particular with reduced survival./ Mayr et al. demonstrated that a chromosomal translocation at 12q5 disrupts let-7 expression and consequently curtails inhibition of the oncogene High Mobility Group A2 (Hmga2). Let-7 has also been implicated in the development of colon cancers and the progression of colorectal cancers." +genetics_knock down_suppress hsa-let-7f-1 Lung Neoplasms 17965831 "Furthermore, a reduction in the expression of let-7 was associated with lung cancers and in particular with reduced survival./ Mayr et al. demonstrated that a chromosomal translocation at 12q5 disrupts let-7 expression and consequently curtails inhibition of the oncogene High Mobility Group A2 (Hmga2). Let-7 has also been implicated in the development of colon cancers and the progression of colorectal cancers." +genetics_knock down_suppress hsa-let-7f-2 Colon Neoplasms 17965831 "Furthermore, a reduction in the expression of let-7 was associated with lung cancers and in particular with reduced survival./ Mayr et al. demonstrated that a chromosomal translocation at 12q5 disrupts let-7 expression and consequently curtails inhibition of the oncogene High Mobility Group A2 (Hmga2). Let-7 has also been implicated in the development of colon cancers and the progression of colorectal cancers." +genetics_knock down_suppress hsa-let-7f-2 Lung Neoplasms 17965831 "Furthermore, a reduction in the expression of let-7 was associated with lung cancers and in particular with reduced survival./ Mayr et al. demonstrated that a chromosomal translocation at 12q5 disrupts let-7 expression and consequently curtails inhibition of the oncogene High Mobility Group A2 (Hmga2). Let-7 has also been implicated in the development of colon cancers and the progression of colorectal cancers." +genetics_knock down_suppress hsa-let-7g Colon Neoplasms 17965831 "Furthermore, a reduction in the expression of let-7 was associated with lung cancers and in particular with reduced survival./ Mayr et al. demonstrated that a chromosomal translocation at 12q5 disrupts let-7 expression and consequently curtails inhibition of the oncogene High Mobility Group A2 (Hmga2). Let-7 has also been implicated in the development of colon cancers and the progression of colorectal cancers." +genetics_knock down_suppress hsa-let-7g Lung Neoplasms 17965831 "Furthermore, a reduction in the expression of let-7 was associated with lung cancers and in particular with reduced survival./ Mayr et al. demonstrated that a chromosomal translocation at 12q5 disrupts let-7 expression and consequently curtails inhibition of the oncogene High Mobility Group A2 (Hmga2). Let-7 has also been implicated in the development of colon cancers and the progression of colorectal cancers." +genetics_knock down_suppress hsa-let-7i Colon Neoplasms 17965831 "Furthermore, a reduction in the expression of let-7 was associated with lung cancers and in particular with reduced survival./ Mayr et al. demonstrated that a chromosomal translocation at 12q5 disrupts let-7 expression and consequently curtails inhibition of the oncogene High Mobility Group A2 (Hmga2). Let-7 has also been implicated in the development of colon cancers and the progression of colorectal cancers." +genetics_knock down_suppress hsa-let-7i Lung Neoplasms 17965831 "Furthermore, a reduction in the expression of let-7 was associated with lung cancers and in particular with reduced survival./ Mayr et al. demonstrated that a chromosomal translocation at 12q5 disrupts let-7 expression and consequently curtails inhibition of the oncogene High Mobility Group A2 (Hmga2). Let-7 has also been implicated in the development of colon cancers and the progression of colorectal cancers." +genetics_knock down_suppress hsa-mir-221 Carotid Artery Diseases 19150885 miR-221: knockdown of miR-221 and miR-222 in rat carotid arteries suppressed VSMC proliferation in vivo and neointimal lesion formation after angioplasty. The results indicate that miR-221 and miR-222 are novel regulators for VSMC proliferation and neointimal hype +genetics_knock down_suppress hsa-mir-222 Carotid Artery Diseases 19150885 miR-222: knockdown of miR-221 and miR-222 in rat carotid arteries suppressed VSMC proliferation in vivo and neointimal lesion formation after angioplasty. The results indicate that miR-221 and miR-222 are novel regulators for VSMC proliferation and neointimal hype +genetics_knock down_suppress hsa-mir-10b Myocardial Infarction 19595696 Knockdown of microRNA-181 by lentivirus decreases the arrhythmogenic effect of skeletal myoblast transplantation in rat with myocardial infarction. +genetics_knock down_suppress hsa-mir-150 "Carcinoma, Hepatocellular" 19617899 repressed in a subset of primary tumorscharacterized by poor prognosis; loss of miR-122 expression correlates with suppression of the hepatic phenotype and gain of metastatic properties; a diagnostic and prognostic marker +genetics_knock down_suppress hsa-mir-15a "Leukemia, Lymphocytic, Chronic, B-Cell" 19744129 "Their aberrant expression has been associated with solid tumors and hematopoietic malignancies as suggested by the frequent deletion of mir-15a and mir-16-1 in chronic lymphocytic leukemia, the increased levels of mir-155 in diffuse large B-cell lymphomas and the increased levels of mir-181 in acute myeloid leukemia M1 and M2. " +genetics_knock down_suppress hsa-mir-16-1 "Leukemia, Lymphocytic, Chronic, B-Cell" 19744129 "Their aberrant expression has been associated with solid tumors and hematopoietic malignancies as suggested by the frequent deletion of mir-15a and mir-16-1 in chronic lymphocytic leukemia, the increased levels of mir-155 in diffuse large B-cell lymphomas and the increased levels of mir-181 in acute myeloid leukemia M1 and M2. " +genetics_knock down_suppress hsa-mir-126 Asthma 19843690 Selective blockade of microRNA (miR)-126 suppressed the asthmatic phenotype +genetics_knock down_suppress hsa-mir-15a "Leukemia, Lymphocytic, Chronic, B-Cell" 20129242 miR-15a and miR-16-1 were the first microRNAs linked to cancer because their genes are commonly deleted in human chronic lymphocytic leukemia (CLL) +genetics_knock down_suppress hsa-let-7a-1 Neoplasms [unspecific] 20614490 let-7a:Gastric carcinoma has relatively lower expression of let-7a +genetics_knock down_suppress hsa-let-7a-2 Neoplasms [unspecific] 20614490 let-7a:Gastric carcinoma has relatively lower expression of let-7a +genetics_knock down_suppress hsa-let-7a-3 Neoplasms [unspecific] 20614490 let-7a:Gastric carcinoma has relatively lower expression of let-7a +genetics_knock down_suppress hsa-mir-200a Neoplasms [unspecific] 20832727 miR-200a:Loss of miR-200 inhibition of Suz12 leads to polycomb-mediated repression required for the formation and maintenance of cancer stem cells +genetics_knock down_suppress hsa-mir-200b Neoplasms [unspecific] 20832727 miR-200b:Loss of miR-200 inhibition of Suz12 leads to polycomb-mediated repression required for the formation and maintenance of cancer stem cells +genetics_knock down_suppress hsa-mir-200c Neoplasms [unspecific] 20832727 miR-200c:Loss of miR-200 inhibition of Suz12 leads to polycomb-mediated repression required for the formation and maintenance of cancer stem cells +genetics_knock down_suppress hsa-mir-21 Breast Neoplasms 21219636 "In vitro assays showed that ERBB2 is a direct target of miR-125a-5p, which potently suppressed the proliferation of gastric cancer cells" +genetics_knock down_suppress hsa-mir-221 "Carcinoma, Hepatocellular" 22009537 miR-221 silencing blocks hepatocellular carcinoma and promotes survival. +genetics_knock down_suppress hsa-mir-124-1 Neuroblastoma 22024478 "Silencing of miR-124 induces neuroblastoma SK-N-SH cell differentiation, cell cycle arrest and apoptosis through promoting AHR." +genetics_knock down_suppress hsa-mir-124-2 Neuroblastoma 22024478 "Silencing of miR-124 induces neuroblastoma SK-N-SH cell differentiation, cell cycle arrest and apoptosis through promoting AHR." +genetics_knock down_suppress hsa-mir-124-3 Neuroblastoma 22024478 "Silencing of miR-124 induces neuroblastoma SK-N-SH cell differentiation, cell cycle arrest and apoptosis through promoting AHR." +genetics_knock down_suppress hsa-mir-183 "Carcinoma, Thyroid, Medullary" 22024754 MiR-183 knockdown in an MTC cell line (TT cells) reduced cellular proliferation in association with elevated LC3B expression. +genetics_knock down_suppress hsa-mir-143 Neoplasms [unspecific] 22330136 Loss of microRNA-143/145 disturbs cellular growth and apoptosis of human epithelial cancers by impairing the MDM2-p53 feedback loop. +genetics_knock down_suppress hsa-mir-145 Neoplasms [unspecific] 22330136 Loss of microRNA-143/145 disturbs cellular growth and apoptosis of human epithelial cancers by impairing the MDM2-p53 feedback loop. +genetics_knock down_suppress hsa-mir-122 Hepatitis C Virus Infection 22898980 The use of an HSP90 inhibitor or knockdown of HSP90 decreased GW182 and miR-122 expression and significantly reduced HCV replication. +genetics_knock down_suppress hsa-mir-181b-1 "Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic" 22916024 Deletion of mir-181a-1/b-1 expression inhibits the development of Notch1 oncogene-induced T cell acute lymphoblastic leukemia (T-ALL). mir-181a-1/b-1 controls the strength and threshold of Notch activity in tumorigenesis in part by dampening multiple negative feedback regulators downstream of NOTCH and pre-T cell receptor (TCR) signaling pathways. +genetics_knock down_suppress hsa-mir-21 Heart Failure 22923342 "Atrial miR-21 knockdown suppresses atrial fibrosis and AF promotion, implicating miR-21 as an important signaling molecule for the AF substrate and pointing to miR-21 as a potential target for molecular interventions designed to prevent AF" +genetics_knock down_suppress hsa-let-7i "Carcinoma, Renal Cell" 22926558 "We also validated the prognostic value of miRNA let-7i in RCC. miR-138, located in chromosome 3p deletion, was also found to have suppressive effects on tumor proliferation and migration abilities." +genetics_knock down_suppress hsa-mir-138-1 "Carcinoma, Renal Cell" 22926558 "We also validated the prognostic value of miRNA let-7i in RCC. miR-138, located in chromosome 3p deletion, was also found to have suppressive effects on tumor proliferation and migration abilities." +genetics_knock down_suppress hsa-mir-138-2 "Carcinoma, Renal Cell" 22926558 "We also validated the prognostic value of miRNA let-7i in RCC. miR-138, located in chromosome 3p deletion, was also found to have suppressive effects on tumor proliferation and migration abilities." +genetics_knock down_suppress hsa-mir-21 Glioma 23077620 Silencing of microRNA-21 confers radio-sensitivity through inhibition of the PI3K/AKT pathway and enhancing autophagy in malignant glioma cell lines +genetics_knock down_suppress hsa-mir-150 Leukemia 23079661 Blockade of miR-150 maturation by MLL-fusion/MYC/LIN-28 is required for MLL-associated leukemia +genetics_knock down_suppress hsa-mir-204 Neoplasms [unspecific] 23285024 Genomic Loss of Tumor Suppressor miRNA-204 Promotes Cancer Cell Migration and Invasion by Activating AKT/mTOR/Rac1 Signaling and Actin Reorganization +genetics_knock down_suppress hsa-mir-21 Ischemia-Reperfusion Injury 23681145 "Knockdown of miR-21 induced significant up-regulation of programmed cell death protein 4 and phosphatase and tensin homolog deleted on chromosome 10, two proapoptotic target effectors of miR-21, and resulted in significant down-regulation of phosphorylated protein kinase B and increased tubular cell apoptosis." +genetics_knock down_suppress hsa-mir-21 Glioblastoma 23732394 Silencing of miR-21 by locked nucleic acid-lipid nanocapsule complexes sensitize human glioblastoma cells to radiation-induced cell death. +genetics_knock down_suppress hsa-mir-18a Immune System Disease [unspecific] 24131405 Treatment of cells with a microRNA-18a mimic in PCPS (PCPS/miR-18) knocked down 90% expression of the microRNA-18a target gene ATM. +genetics_knock down_suppress hsa-mir-17 Medulloblastoma 24145352 Silencing of the miR-17~92 cluster family inhibits medulloblastoma progression. +genetics_knock down_suppress hsa-mir-19a Medulloblastoma 24145352 Silencing of the miR-17~92 cluster family inhibits medulloblastoma progression. +genetics_knock down_suppress hsa-mir-23a "Squamous Cell Carcinoma, Head and Neck" 24317043 Transfection with anti-miR-23a inhibited the proliferation of HN4 cells and induced cell apoptosis. +genetics_knock down_suppress hsa-mir-196b "Leukemia, Myeloid, Acute" 24334453 "Therapeutic inhibition of microRNA-21 and microRNA-196b inhibited in vitro leukemic colony forming activity and depleted in vivo leukemia-initiating cell activity of HOX-based leukemias, which led to leukemia-free survival in a murine AML model and delayed disease onset in xenograft models." +genetics_knock down_suppress hsa-mir-21 "Leukemia, Myeloid, Acute" 24334453 "Therapeutic inhibition of microRNA-21 and microRNA-196b inhibited in vitro leukemic colony forming activity and depleted in vivo leukemia-initiating cell activity of HOX-based leukemias, which led to leukemia-free survival in a murine AML model and delayed disease onset in xenograft models." +genetics_knock down_suppress hsa-mir-92a "Leukemia, Promyelocytic, Acute" 24385779 Down-regulation of miR-92a in APL cell line (HL-60) by LNA antagomir extensively decreased cell viability in APL. +genetics_knock down_suppress hsa-let-7b Neoplasms [unspecific] 24423609 Reduction of let-7a3/let-7b miRNA may be one of mechanisms leading to overexpression of HMGA2 in AT/RT tissues. +genetics_knock down_suppress hsa-mir-21 Heart Failure 24551276 "After injection of miR-21 antagonist, the the cardiac atrophy and cardiac fibrosis were conspicuously ameliorated." +genetics_knock down_suppress hsa-mir-92a "Leukemia, Promyelocytic, Acute" 24627869 The assessment of the apoptosis and necrosis indicates that miR-92a inhibition can decrease the viable HL-60 cells and this is at least partially due to induction of apoptosis. +genetics_knock down_suppress hsa-mir-17 Multiple Sclerosis 24644282 T cell-specific miR-17-92 deficiency reduced TH17 differentiation and ameliorated experimental autoimmune encephalomyelitis (EAE) symptoms. +genetics_knock down_suppress hsa-mir-155 Encephalomyelitis 24648472 MiR-155 (-/-) mice are highly resistant to experimental autoimmune encephalomyelitis (EAE) +genetics_knock down_suppress hsa-mir-18a Prostate Neoplasms 24752237 "Interestingly, miR-18a knockdown decreased cell growth in prostate cancer cells and significantly decreased prostate tumor growth in in vivo nude mice experiments through STK4-mediated dephosphorylation of AKT and thereby inducing apoptosis." +genetics_knock down_suppress hsa-mir-21 "Carcinoma, Lung, Non-Small-Cell" 24804226 Silencing miR-21 sensitizes non-small cell lung cancer A549 cells to ionizing radiation through inhibition of PI3K/Akt. +genetics_knock down_suppress hsa-mir-182 Ovarian Neoplasms 24825857 "we found that anti-miR182 treatment can significantly reduce tumor burden (size), local invasion, and distant metastasis compared with its control in both models." +genetics_knock down_suppress hsa-mir-17 Medulloblastoma 24928431 "Remarkably, deletion of the miR-17âˆ?2 cluster abolished the development of SHH-MB in Ptch1(+/-) mice." +genetics_knock down_suppress hsa-mir-92a Myocardial Ischemic-Reperfusion Injury 24941323 Inhibiting miR-92a can attenuate myocardiocyte apoptosis induced by hypoxia/reoxygenation by targeting Smad7. +genetics_knock down_suppress hsa-mir-221 "Carcinoma, Hepatocellular" 24993451 Bioinformatics analysis identifies miR-221 as a core regulator in hepatocellular carcinoma and its silencing suppresses tumor properties. +genetics_knock down_suppress hsa-mir-145 Atherosclerosis 25008143 Absence of miR-143/145 significantly reduced atherosclerotic plaque size and macrophage infiltration. +genetics_knock down_suppress hsa-mir-21 Lung Neoplasms 25065740 "PHF8 promotes miR-21 expression in human lung cancer, and miR-21 knockdown blocks the effects of PHF8 on proliferation and apoptosis of lung cancer cells." +genetics_knock down_suppress hsa-mir-21 Obesity 25141837 "MiR-21 inhibition reduced body weight, as well as adipocyte size and serum triglycerides were significantly decreased." +genetics_knock down_suppress hsa-mir-17 "Leukemia, Lymphocytic, Chronic, B-Cell" 25339346 In-vitro administration of antagomiR17 effectively reduced miR-17 expression and the proliferation of CLL-like MEC-1 cells. +genetics_knock down_suppress hsa-mir-21 Vascular Disease [unspecific] 25360215 "Low expression of miR-21 significantly inhibited VSMC proliferation, invasion and migration." +genetics_knock down_suppress hsa-mir-21 "Leukemia, Lymphoblastic, Acute" 25451263 "Transient inhibition of miR-21 resulted in increased apoptosis, PTEN upregulation and AKT dephosphorylation, whereas ectopic overexpression of miR-21 further conferred imatinib resistance." +genetics_knock down_suppress hsa-mir-19b "Carcinoma, Embryonal" 25483911 The results demonstrated that miR-19b knockdown inhibited the proliferation and apoptosis of P19 cells. +genetics_knock down_suppress hsa-let-7c Heart Failure 25505600 "Let-7c inhibitor prevented the deterioration of cardiac function postinfarction, as demonstrated by preserved LV ejection fraction and elevated cardiac output." +genetics_knock down_suppress hsa-mir-155 Neoplasms [unspecific] 25598954 the proper increase of miR-155 inhibitor concentration can inhibit miR-155 and consequently increase caspase-3 activity and induce apoptosis in the Jurkat cells leading to cell death ultimately. +genetics_knock down_suppress hsa-mir-17 "Leukemia, Myeloid, Chronic" 25647305 "Furthermore, overexpression of c-Myc or miR-17/20a alleviated NC induced differentiation and apoptosis in K562 cells." +genetics_knock down_suppress hsa-mir-20a "Leukemia, Myeloid, Chronic" 25647305 "Furthermore, overexpression of c-Myc or miR-17/20a alleviated NC induced differentiation and apoptosis in K562 cells." +genetics_knock down_suppress hsa-mir-155 Spinal Cord Injuries 25651871 Mir-155 deficiency suppresses Th17 cell differentiation and improves locomotor recovery after SCI. +genetics_knock down_suppress hsa-let-7b Neoplasms [unspecific] 25682900 "our findings suggest that let-7b contributes to the fidelity of cell division via regulation of Aurora B. Moreover, the loss of let-7b in aggressive tumors may drive tumorigenesis by up-regulation of Aurora B and other targets of the miRNA, which further supports the role of let-7b in tumor suppression." +genetics_knock down_suppress hsa-mir-21 Cholangiocarcinoma 25769721 anti-miR-21 treatment reduced liver tumor growth and prevented tumor development. +genetics_knock down_suppress hsa-mir-122 Hepatitis C Virus Infection 25848473 "miR-122 promotes HCV accumulation, inhibition of miR-122 has been shown as an effective therapy for the treatment of HCV infection in both chimpanzees and humans." +genetics_knock down_suppress hsa-mir-221 Rheumatoid Arthritis 25891943 Downregulation of miR-221 significantly suppressed the expression of pro-inflammatory cytokines and the chemokine +genetics_knock down_suppress hsa-mir-31 Myocardial Infarction 25925791 miR-31 downregulation alleviated myocardial infarct size in vivo. +genetics_knock down_suppress hsa-mir-208a Myocardial Infarction 25936493 Overexpression of antagomir-208a and pretreatment with atorvastatin and valsartan in the AMI group significantly decreased the area of myocardial fibrosis induced by infarction. +genetics_knock down_suppress hsa-mir-21 Glioblastoma 25991676 Both MPS1 and miR-21 depletion suppressed GBM cell proliferation +genetics_knock down_suppress hsa-mir-195 Diabetic Cardiomyopathies 25994075 Therapeutic silencing of miR-195 reduces myocardial hypertrophy and improves coronary blood flow and myocardial function in diabetes +genetics_knock down_suppress hsa-mir-21 Colorectal Carcinoma 25994220 "miR-21-knockout mice showed reduced expression of proinflammatory and procarcinogenic cytokines (interleukin (IL) 6, IL-23, IL-17A and IL-21) and a decrease in the size and number of tumours compared with the control mouse group." +genetics_knock down_suppress hsa-let-7 Neoplasms [unspecific] 26033159 "we found that expression of DICER1 hotspot mutants promoted cell proliferation, whereas wild-type (WT) DICER1 inhibited cell proliferation. Furthermore, targets of let-7 family miRNAs are enriched among the up-regulated genes, suggesting that loss of let-7 may be impacting downstream pathways. Our results reveal that DICER1 hotspot mutations are implicated in common malignancies and may constitute a unique oncogenic pathway." +genetics_knock down_suppress hsa-mir-34a Myocardial Infarction 26082557 locked nucleic acid-based anti-miR-34a treatment diminished post-MI miR-34a upregulation in adult hearts and significantly improved post-MI remodeling. +genetics_knock down_suppress hsa-mir-150 Myocardial Infarction 26109086 MicroRNA-150 deletion in mice protects kidney from myocardial infarction-induced acute kidney injury. +genetics_knock down_suppress hsa-mir-214 Liver Fibrosis 26122702 Pdgf-c Tg mice treated with LNA-antimiR-214 showed a marked reduction in fibrosis and tumor incidence compared with saline or LNA-miR-control-injected control mice. +genetics_knock down_suppress hsa-mir-17 Graft-Versus-Host Disease 26138686 "Furthermore, we evaluated a translational approach and found that systemic administration of antagomir to block miR-17 or miR-19b in this cluster significantly inhibited alloreactive T-cell expansion and interferon-γ (IFNγ) production, and prolonged" +genetics_knock down_suppress hsa-mir-19b Graft-Versus-Host Disease 26138686 systemic administration of antagomir to block miR-17 or miR-19b in this cluster significantly inhibited alloreactive T-cell expansion and interferon-γ (IFNγ) production +genetics_knock down_suppress hsa-mir-372 "Adenocarcinoma, Gastric" 26151747 "Subcutaneously delivered LNAs reduce tumor growth of AGS xenografts in mice, upon formation of a stable, specific heteroduplex with the targeted miR-372 and -373 and LATS2 upregulation." +genetics_knock down_suppress hsa-mir-150 Liver Injury 26196694 miR-150 deficiency prevents Fas-induced hepatocyte apoptosis and liver injury through regulation of the Akt pathway. +genetics_knock down_suppress hsa-mir-181a Ischemic Diseases [unspecific] 26283227 "Delivery of anti-miR-181a, which neutralizes endogenous miR-181a, significantly attenuated H2O2-induced decrease of HKII expression and disruption of mitochondrial membrane potential, improving the survival of MSCs exposed to H2O2." +genetics_knock down_suppress hsa-mir-31 "Squamous Cell Carcinoma, Esophageal" 26286729 anti-miR-31 reduced miR-31 overexpression (P = .002) and suppressed the esophageal preneoplasia in Zn-deficient rats. +genetics_knock down_suppress hsa-mir-214 "Adenocarcinoma, Lung" 26299367 "downregulation of miR-214 expression in CSLCs resulted in a significant decrease in spheroid formation and the expression of the stem-cell markers Nanog, Oct-4, and Sox-2." +genetics_knock down_suppress hsa-mir-21 "Fatty Liver, Non-Alcoholic" 26338827 "MicroRNA-21 inhibition or suppression decreases liver injury, inflammation and fibrosis" +genetics_knock down_suppress hsa-mir-155 Stroke 26354913 In Vivo Inhibition of miR-155 Promotes Recovery after Experimental Mouse Stroke. +genetics_knock down_suppress hsa-mir-20a "Carcinoma, Lung, Non-Small-Cell" 26356817 Stable knock down of miR-20a increases TβRII expression and inhibits tumorigenicity of lung cancer cells in vivo. +genetics_knock down_suppress hsa-mir-205 Neoplasms [unspecific] 26446417 "When HEC-50B cells and HEC-1-A cells were treated with anti-miR-205 inhibitor, the migration and invasion were decreased as compared with the negative control." +genetics_knock down_suppress hsa-mir-222 Pancreatic Neoplasms 26535064 "we co-transfected miR-222 inhibitor and p57 si-RNA into Capan-2 cells, and found that proliferation-suppressing effects of miR-222 inhibitor on Capan-2 cells could be partially reversed by silencing p57." +genetics_knock down_suppress hsa-mir-192 "Adenocarcinoma, Lung" 26550150 MiR-192 inhibitor treated tumor exhibits sensitivity to cisplatin and gemcitabine therapy. +genetics_knock down_suppress hsa-mir-503 "Carcinoma, Esophageal" 26580839 The specific inhibition of miR-503 expression remarkably suppressed proliferation and invasion of tumor cells. +genetics_knock down_suppress hsa-mir-96 Bladder Neoplasms 26582573 the inhibition of miR-96 expression remarkably decreased cell proliferation and promoted cell apoptosis of BC cell lines +genetics_knock down_suppress hsa-mir-155 Acute Myocardial Infarction 26589288 "We reveal that in vivo, miR-155 knockout improves left ventricular function, reduces infarct size, and attenuates collagen deposition, whereas overexpression of miR-155 produces the opposite effects." +genetics_knock down_suppress hsa-mir-106b "Carcinoma, Renal Cell" 26648244 Downregulation of miR-106b with a synthesized inhibitor suppressed cell migration and proliferation and induced renal cancer cell apoptosis +genetics_knock down_suppress hsa-mir-208a Myocardial Infarction 26688617 "Therapeutic inhibition of miR-208a decreased cardiac fibrosis, hypertrophy, and apoptosis and significantly improved cardiac function 28 days after MI." +genetics_knock down_suppress hsa-mir-210 Nervous System Diseases [unspecific] 26708520 "Application of miR-210 inhibitor efficiently downregulated endogenous miR-210, protected apoptosis and neurite retraction in bupivacaine damaged DRG neurons." +genetics_knock down_suppress hsa-mir-184 "Adenocarcinoma, Pancreatic Ductal" 26722418 "The transfection of inhibitor effectively suppressed the expression of miR-184, and further inhibited both cell proliferation and invasion abilities, in addition to the up-regulation of pro-apoptotic protein caspase 3 expression." +genetics_knock down_suppress hsa-mir-630 Ovarian Neoplasms 26725326 Treatment with the combination of anti-miR-630 and anti-vascular endothelial growth factor antibody in mice resulted in rescue of Dicer expression and significantly decreased tumor growth and metastasis. +genetics_knock down_suppress hsa-mir-15b Colorectal Carcinoma 26743779 "Inhibition of miR-15b activity by adenovirus carrying antimiR-15b sequence significantly increased MTSS1 and Klotho protein expression and subsequently decreased colony formation ability, invasion, and migration of HCT116 cells in vitro and liver metastasis of HCT116 tumors in vivo." +genetics_knock down_suppress hsa-mir-193 Gastric Neoplasms 26753960 "In AGS and MKN-45 cells, miR-193-3p downregulation reduced cancer proliferation, migration and 5-FU chemoresistance in vitro, and tumorigenicity in vivo." +genetics_knock down_suppress hsa-mir-126 Myocardial Infarction 26782549 miR-126 is down-regulated in myocardial ischemia-reperfusion injury and that the inhibition of miR-126 may protect against myocardial cell apoptosis caused by ischemia-reperfusion. +genetics_knock down_suppress hsa-mir-223 Encephalomyelitis 26783338 We demonstrate that miR-223-knockout mice display significantly reduced active and adoptive-transfer experimental autoimmune encephalomyelitis +genetics_knock down_suppress hsa-mir-125b Amyotrophic Lateral Sclerosis 26794445 "by restoring A20 levels, miR-125b inhibition then sustains motor neuron survival." +genetics_knock down_suppress hsa-mir-210 Myocardial Infarction 26807177 Inhibition of miR-210 expression improved the survival and cardiac function of MI mice. +genetics_knock down_suppress hsa-mir-130b "Carcinoma, Hepatocellular" 26861561 knockdown or overexpression of miR-130b inhibited and promoted proliferation and metastasis of HCC cells +genetics_knock down_suppress hsa-mir-21 Myocardial Ischemic-Reperfusion Injury 26862785 recombinant HMGB1-box treatment protects against I/R injury and the mechanisms may involve inhibition of miR-21 expression. +genetics_knock down_suppress hsa-mir-183 Pancreatic Adenocarcinoma 26870180 miR-183 knockdown decreased cell growth and motility in pancreatic cancer cells and significantly increased the expression of SOCS-6. +genetics_knock down_suppress hsa-mir-146b "Carcinoma, Thyroid, Papillary" 26883911 miR-146b-5p positively regulates migration and invasion of thyroid normal and tumor follicular cells +genetics_knock down_suppress hsa-mir-222 Neoplasms [unspecific] 26909602 "Anti-miR-222 inhibitor treatment decreased cell proliferation, migration, tube formation, and induced apoptosis." +genetics_knock down_suppress hsa-mir-199a Pancreatic Neoplasms 26918939 "Inhibition of miR-199a/-214 using hairpin inhibitors significantly inhibited TGFβ-induced differentiation markers (e.g. α-SMA, collagen, PDGFβR), migration and proliferation." +genetics_knock down_suppress hsa-mir-34a Cholangiocarcinoma 26923637 "The inhibition of miR-34a decreased proliferation, migration and invasion in cholangiocarcinoma cells." +genetics_knock down_suppress hsa-mir-125b Melanoma 26968260 inhibition of miR-125b reduces migratory and invasive potentials without affecting cell proliferation in vitro. +genetics_knock down_suppress hsa-mir-21 Ischemia-Reperfusion Injury 27030384 "With downregulation of miR-21, the protection of delayed IPC was attenuated and PHD2 protein was increased." +genetics_knock down_suppress hsa-mir-223 Multiple Sclerosis 27083389 "miR223 promotes EAE, probably through enhancing DC activation and subsequently the differentiation of naive T cells toward Th1 and Th17 effector cells." +genetics_knock down_suppress hsa-mir-25 Choriocarcinoma 27120728 Inhibition of miR-25 by its sponge in AGS cells resulted in suppressed cell viability (P<0.01) and promoted cell apoptosis (P<0.01) +genetics_knock down_suppress hsa-mir-192 Liver Injury 27129188 "Functional experiments confirmed a protective effect of down-regulation of miR-192-5p in hepatocytes, suggesting a role of miR-192-5p in limiting liver injury." +genetics_knock down_suppress hsa-mir-23b "Carcinoma, Nasopharyngeal" 27150436 "inhibition of miRâ€?3b could significantly suppress NPC cell proliferation, migration and invasion." +genetics_knock down_suppress hsa-mir-128 Myocardial Ischemic-Reperfusion Injury 27150726 miRâ€?28 antagomirs significantly reduced apoptosis in hearts subjected to I/R injury +genetics_knock down_suppress hsa-mir-125b "Leukemia, Myeloid, Chronic" 27158338 inhibition of miR-125b decreased the proliferation rates and promoted apoptosis with cell cycle arrest at the G0/G1 phase in both K562 and NB-4 cells +genetics_knock down_suppress hsa-mir-451 "Leukemia, Myeloid, Chronic" 27158338 inhibition of miR-125b decreased the proliferation rates and promoted apoptosis with cell cycle arrest at the G0/G1 phase in both K562 and NB-4 cells +genetics_knock down_suppress hsa-mir-224 Cerebral Ischemia 27165196 miR-224 inhibitor reduced neuronal cell apoptosis +genetics_knock down_suppress hsa-mir-544a Colorectal Carcinoma 27165435 miR-544a inhibitor and/or HOXA10 overexpression reduced lung metastases in HCT116 xenografts. +genetics_knock down_suppress hsa-mir-592 Colorectal Carcinoma 27167185 "miR-592 inhibitor exhibited a significant reduction of migration, proliferation, and clonogenicity in CRC cells." +genetics_knock down_suppress hsa-mir-21 Esophageal Neoplasms 27188433 "the proliferation, migration, and invasion of TE11 cells were less active in Inhibition-miR21 group." +genetics_knock down_suppress hsa-mir-138 Intervertebral Disc Degeneration 27207584 "inhibition of miR-138-5p downregulated PTEN protein expression and promoted activation of PI3K/AKT, and knockdown of either SIRT1 or the PI3K/Akt inhibitor (LY294002) abolished the effect of miR-138-5p on NP cell apoptosis." +genetics_knock down_suppress hsa-mir-27b "Carcinoma, Lung, Non-Small-Cell" 27221512 introduction of miRâ€?7b inhibitors significantly induced apoptosis and inhibited the proliferation of A549 cells. +genetics_knock down_suppress hsa-mir-21 Liver Cirrhosis 27226339 Ad-TuD-21 administered to liver fibrosis rats could remarkably suppress profibrotic gene expression +genetics_knock down_suppress hsa-mir-455 "Squamous Cell Carcinoma, Oral" 27235675 MiR-455-5p knockdown reduced both the anchorage-independent growth and the proliferative ability of oral cancer cells +genetics_knock down_suppress hsa-mir-454 "Carcinoma, Lung, Non-Small-Cell" 27261580 "Down-regulation of miR-454 could significantly reduce NSCLC cell proliferation, enhance cell apoptosis, and impair cell invasion and migration in vitro, while up-regulation of miR-454 showed opposite effects." +genetics_knock down_suppress hsa-mir-93 Cervical Neoplasms 27279231 Enforced miR-93 knockdown or RAB11FIP1 overexpression suppressed proliferation and promoted apoptosis +genetics_knock down_suppress hsa-mir-206 Mycobacterium tuberculosis Infection 27291149 Inhibition of miR-206 markedly suppressed inflammatory cytokine secretion +genetics_knock down_suppress hsa-mir-155 Graft-Versus-Host Disease 27296836 miR-155-/- mice showed resistance to cardiac rejection along with weakened T-cell-mediated inflammation +genetics_knock down_suppress hsa-mir-224 Gastric Neoplasms 27315344 "inhibition of miR-224 significantly reduced the expression of mTOR and improved caspase-9/3 expression while decreased cyclin D1/2 levels, attenuating gastric cancer cell proliferation." +genetics_knock down_suppress hsa-mir-214 Breast Neoplasms 27328731 "Depleting miR-214 or elevating miR-148b blocked the dissemination of melanoma or breast cancer cells, an effect that could be accentuated by dual alteration." +genetics_knock down_suppress hsa-mir-214 Melanoma 27328731 "Depleting miR-214 or elevating miR-148b blocked the dissemination of melanoma or breast cancer cells, an effect that could be accentuated by dual alteration." +genetics_knock down_suppress hsa-mir-154 Glioblastoma 27338789 Knockdown of miR-154 remarkably suppressed proliferation and migration of CD133(+) GBM cells. +genetics_knock down_suppress hsa-mir-24 "Squamous Cell Carcinoma, Tongue" 27350307 "Inhibition of miR-24 significantly suppressed the proliferation, migration and invasion of TSCC cells in vitro." +genetics_knock down_suppress hsa-mir-21 Colorectal Adenocarcinoma 27364574 Locked nucleic acid anti-miR-21 inhibits cell growth and invasive behaviors of a colorectal adenocarcinoma cell line +genetics_knock down_suppress hsa-mir-155 Acute Lung Injury 27371731 miR-155 gene inactivation protected mice from LPS-induced ALI +genetics_knock down_suppress hsa-mir-181a "Carcinoma, Hepatocellular" 27384977 "Exogenous miR-181a expression in HepG2 cells reduced apoptosis, whereas inhibition of miR-181a in Hpe3B cells increased apoptosis." +genetics_knock down_suppress hsa-mir-9 "Carcinoma, Breast, Triple Negative" 27402080 "miR-9 and miR-200 promoted and inhibited, respectively, the formation of vascular-like structures in vitro" +genetics_knock down_suppress hsa-mir-23a Macular Degeneration 27411920 Inhibition of the H2O2-induced miR-23a by antagomiR protected the RPE cells from the oxidative stress-induced cell death. +genetics_knock down_suppress hsa-mir-18a "Adenocarcinoma, Lung" 27412935 Downregulation of miR-18a or miR-328 can inhibit the invasion and migration abilities of A549 cells effectively. +genetics_knock down_suppress hsa-mir-328 "Adenocarcinoma, Lung" 27412935 Downregulation of miR-18a or miR-328 can inhibit the invasion and migration abilities of A549 cells effectively. +genetics_knock down_suppress hsa-mir-200a Breast Neoplasms 27433802 "We further showed that inhibition of miR-200a function, mimicking the effect of calorie restriction on this microRNA, inhibited proliferation in both rat (LA7) and human (MCF7) luminal mammary cancer cell lines." +genetics_knock down_suppress hsa-mir-942 Kaposi Sarcoma 27440900 "Suppression of miR-942-5p relieved I¦ÊB¦Á expression and reduced Vpr inhibition of KSHV replication, while overexpression of miR-942-5p enhanced Vpr inhibition of KSHV replication." +genetics_knock down_suppress hsa-mir-10b Endometrial Neoplasms 27447302 "The silence of miR-10b resulted in significantly enhanced cell apoptosis, and remarkably reduced cell proliferation, migration, and invasion (pâ€?â€?.05)." +genetics_knock down_suppress hsa-mir-9 Prostate Neoplasms 27447934 "Inhibition of miR-9 resulted in reduced migratory and invasive potential of the M12 cell line, and reduced tumour growth and metastases in male athymic nude mice." +genetics_knock down_suppress hsa-mir-21 Asthma 27448447 "Treatment with Ant-21, or the pan-PI3K inhibitor LY294002, reduced PI3K activity and restored HDAC2 levels. This led to suppression of airway hyperresponsiveness and restored steroid sensitivity to allergic airway disease." +genetics_knock down_suppress hsa-mir-106b Pituitary Neoplasms 27465551 "Down-regulation of miR-106b or up-regulation of PTEN could suppress cell proliferation and invasion of AtT-20 cells, and PTEN expression plasmid could partially simulate the function of miR-106b." +genetics_knock down_suppress hsa-mir-155 "Carcinoma, Cervical" 27470551 "Moreover, knockdown of miR-155 was demonstrated to inhibit cell proliferation, migration, and invasion in vitro." +genetics_knock down_suppress hsa-mir-210 Epilepsy 27471387 Our data showed that morphological changes of hippocampal neurons and apoptosis triggered by epilepsy were mitigated by miR-210 inhibition. +genetics_knock down_suppress hsa-mir-182 "Carcinoma, Breast, Triple Negative" 27476169 Knockdown of miR-182 promotes apoptosis via regulating RIP1 deubiquitination in TNF-α-treated triple-negative breast cancer cells. +genetics_knock down_suppress hsa-mir-137 Vascular Injuries 27497953 "Down-regulation of miR-137 ameliorates HG-induced injury in HUVECs by overexpression of AMPKα1, leading to increasing cellular reductive reactions and decreasing oxidative stress." +genetics_knock down_suppress hsa-mir-17 Lymphoma 27498867 "Loss of miR-17/92 in Myc(+) tumor cells leads to a global decrease in tumor cell metabolism, affecting both glycolytic and mitochondrial metabolism, whereas increased miR-17/92 expression is sufficient to drive increased nutrient usage by tumor cells." +genetics_knock down_suppress hsa-mir-126 "Carcinoma, Hepatocellular" 27499630 Inhibition of miR-126 expression increased Spred1 expression and decreased vascular endothelial growth factor expression (P<0.01). +genetics_knock down_suppress hsa-mir-346 "Carcinoma, Nasopharyngeal" 27501413 Inhibition of miR-346 significantly attenuated the migration and invasion of NPC cells. +genetics_knock down_suppress hsa-mir-106a "Carcinoma, Ovarian" 27510094 Downregulation of the expression of miR-106a inhibited cell growth and metastasis of ovarian cancer cells. +genetics_knock down_suppress hsa-mir-24 "Squamous Cell Carcinoma, Head and Neck" 27513190 "Inhibition of miR-24-3p reduced cell proliferation, colony formation efficiency and reversed chemoresistance in HNSCC cells." +genetics_knock down_suppress hsa-mir-21 Osteosarcoma 27513462 microRNA-21 inhibition slowed proliferation and exogenously expressed microRNA-21 promoted this process. +genetics_knock down_suppress hsa-mir-106b "Carcinoma, Breast" 27519168 "down-regulation of miR-106b increased the expression of FUT6 and resulted in an obvious decrease of cell migration, invasion, and proliferation in MDA-MB-231 cells." +genetics_knock down_suppress hsa-mir-127 Obesity 27532680 "On the other hand, locked nucleic acid inhibitor synthesized to target miR-127-5p significantly increased b-F1-ATPase translation efficiency in myotubes." +genetics_knock down_suppress hsa-mir-21 Melanoma 27533779 "MiR-21 can promote the proliferation, migration, and inhibit the apoptosis of human melanoma A375 cells by inhibiting SPRY1, PDCD4, and PTEN via ERK/NF-kB signaling pathway." +genetics_knock down_suppress hsa-mir-181a "Carcinoma, Cervical" 27534652 Inhibition of microRNA-181a may suppress proliferation and invasion and promote apoptosis of cervical cancer cells through the PTEN/Akt/FOXO1 pathway. +genetics_knock down_suppress hsa-mir-21 Liver Cirrhosis 27775690 Knockout of microRNA-21 reduces biliary hyperplasia and liver fibrosis in cholestatic bile duct ligated mice. +genetics_knock down_suppress hsa-mir-322 "Carcinoma, Breast" 28404630 miR-424(322)/503 is a breast cancer tumor suppressor whose loss promotes resistance to chemotherapy. +genetics_knock down_suppress hsa-mir-424 "Carcinoma, Breast" 28404630 miR-424(322)/503 is a breast cancer tumor suppressor whose loss promotes resistance to chemotherapy. +genetics_knock down_suppress hsa-mir-503 "Carcinoma, Breast" 28404630 miR-424(322)/503 is a breast cancer tumor suppressor whose loss promotes resistance to chemotherapy. +genetics_knock down_suppress hsa-mir-27a Colorectal Carcinoma 28423356 Knockdown of miR-27a sensitizes colorectal cancer stem cells to TRAIL by promoting the formation of Apaf-1-caspase-9 complex. +genetics_knock down_suppress hsa-mir-155 Infection [unspecific] 28804270 Knockdown of miR-155 protects microglia against LPS-induced inflammatory injury via targeting RACK1: a novel research for intracranial infection +genetics_knock down_suppress hsa-mir-29a "Carcinoma, Breast" 29021023 Knockdown of microRNA-29a Changes the Expression of Heat Shock Proteins in Breast Carcinoma MCF-7 Cells. +genetics_knock down_suppress hsa-mir-29a "Carcinoma, Breast" 29435304 Knockdown of microRNA-29a regulates the expression of apoptosis-related genes in MCF-7 breast carcinoma cells +genetics_knock down_suppress hsa-mir-21 Neoplasms [unspecific] 29540832 miR-21 depletion in macrophages promotes tumoricidal polarization and enhances PD-1 immunotherapy +genetics_knock down_suppress hsa-mir-146a Listeriosis 29587465 MicroRNA-146a Deficiency Protects against Listeria monocytogenes Infection by Modulating the Gut Microbiota +genetics_knock down_suppress hsa-mir-21 Colitis 29608690 Loss of microRNA-21 Influences the Gut Microbiota Causing Reduced Susceptibility in a Murine Model of Colitis +genetics_knock down_suppress hsa-mir-21 Alcoholic Hepatitis 29848019 Knockout of microRNA-21 attenuates alcoholic hepatitis through the VHL/NF-¦ÊB signaling pathway in hepatic stellate cells. +genetics_knock down_suppress hsa-mir-1246 "Carcinoma, Cervical" 30078258 Lentivirus media miR-1246 knockdown inhibits tumor growth and promotes apoptosis of SiHa cells +genetics_knock down_suppress hsa-mir-299 "Carcinoma, Hepatocellular" 30266288 Knockdown of miR-299-5p inhibits the progression of hepatocellular carcinoma by targeting SIAH1. +genetics_overexpression_promote hsa-mir-17 Lymphoma 16940181 "Mir-17-5p, also known as Mir-91,is located on chromosome 13q31; this gene is amplified in childhoodlymphoma." +genetics_overexpression_promote hsa-mir-17 Hematologic Neoplasms 17011485 The miR-17-92 cluster is amplified in hematopoietic malignancies. +genetics_overexpression_promote hsa-mir-18a Hematologic Neoplasms 17011485 The miR-17-92 cluster is amplified in hematopoietic malignancies. +genetics_overexpression_promote hsa-mir-19a Hematologic Neoplasms 17011485 The miR-17-92 cluster is amplified in hematopoietic malignancies. +genetics_overexpression_promote hsa-mir-19b-1 Hematologic Neoplasms 17011485 The miR-17-92 cluster is amplified in hematopoietic malignancies. +genetics_overexpression_promote hsa-mir-20a Hematologic Neoplasms 17011485 The miR-17-92 cluster is amplified in hematopoietic malignancies. +genetics_overexpression_promote hsa-mir-17 Colon Neoplasms 17965831 "The miRNA cluster miR-17-92 is located at 13q31.3 and has been associated with several types of cancer, including colorectal cancer and lung cancer, and is thought to be a potential oncogene [86, 87] that enhances cell proliferation." +genetics_overexpression_promote hsa-mir-17 Lung Neoplasms 17965831 "The miRNA cluster miR-17-92 is located at 13q31.3 and has been associated with several types of cancer, including colorectal cancer and lung cancer, and is thought to be a potential oncogene [86, 87] that enhances cell proliferation." +genetics_overexpression_promote hsa-mir-18a Colon Neoplasms 17965831 "The miRNA cluster miR-17-92 is located at 13q31.3 and has been associated with several types of cancer, including colorectal cancer and lung cancer, and is thought to be a potential oncogene [86, 87] that enhances cell proliferation." +genetics_overexpression_promote hsa-mir-18a Lung Neoplasms 17965831 "The miRNA cluster miR-17-92 is located at 13q31.3 and has been associated with several types of cancer, including colorectal cancer and lung cancer, and is thought to be a potential oncogene [86, 87] that enhances cell proliferation." +genetics_overexpression_promote hsa-mir-19a Colon Neoplasms 17965831 "The miRNA cluster miR-17-92 is located at 13q31.3 and has been associated with several types of cancer, including colorectal cancer and lung cancer, and is thought to be a potential oncogene [86, 87] that enhances cell proliferation." +genetics_overexpression_promote hsa-mir-19a Lung Neoplasms 17965831 "The miRNA cluster miR-17-92 is located at 13q31.3 and has been associated with several types of cancer, including colorectal cancer and lung cancer, and is thought to be a potential oncogene [86, 87] that enhances cell proliferation." +genetics_overexpression_promote hsa-mir-19b-1 Colon Neoplasms 17965831 "The miRNA cluster miR-17-92 is located at 13q31.3 and has been associated with several types of cancer, including colorectal cancer and lung cancer, and is thought to be a potential oncogene [86, 87] that enhances cell proliferation." +genetics_overexpression_promote hsa-mir-19b-1 Lung Neoplasms 17965831 "The miRNA cluster miR-17-92 is located at 13q31.3 and has been associated with several types of cancer, including colorectal cancer and lung cancer, and is thought to be a potential oncogene [86, 87] that enhances cell proliferation." +genetics_overexpression_promote hsa-mir-20a Colon Neoplasms 17965831 "The miRNA cluster miR-17-92 is located at 13q31.3 and has been associated with several types of cancer, including colorectal cancer and lung cancer, and is thought to be a potential oncogene [86, 87] that enhances cell proliferation." +genetics_overexpression_promote hsa-mir-20a Lung Neoplasms 17965831 "The miRNA cluster miR-17-92 is located at 13q31.3 and has been associated with several types of cancer, including colorectal cancer and lung cancer, and is thought to be a potential oncogene [86, 87] that enhances cell proliferation." +genetics_overexpression_promote hsa-mir-92a-1 Colon Neoplasms 17965831 "The miRNA cluster miR-17-92 is located at 13q31.3 and has been associated with several types of cancer, including colorectal cancer and lung cancer, and is thought to be a potential oncogene [86, 87] that enhances cell proliferation." +genetics_overexpression_promote hsa-mir-92a-1 Lung Neoplasms 17965831 "The miRNA cluster miR-17-92 is located at 13q31.3 and has been associated with several types of cancer, including colorectal cancer and lung cancer, and is thought to be a potential oncogene [86, 87] that enhances cell proliferation." +genetics_overexpression_promote hsa-let-7g "Carcinoma, Lung, Non-Small-Cell" 18308936 we observed significant growth reduction of both murine and human non-small cell lung tumors when overexpression of let-7g was induced from lentiviral vectors +genetics_overexpression_promote hsa-mir-184 Squamous Cell Carcinoma 18451220 "Overexpression of miR-184 might play an oncogenic role in the antiapoptotic and proliferative processes of tongue SCC. In addition, plasma miR-184 levels were associated with the presence of primary tumor. " +genetics_overexpression_promote hsa-mir-221 Prostate Neoplasms 19107213 miR-221: The inhibition of the highly expressed miR-221 and miR-222 impairs the growth of prostate carcinoma xenografts in mice +genetics_overexpression_promote hsa-mir-222 Prostate Neoplasms 19107213 miR-222: The inhibition of the highly expressed miR-221 and miR-222 impairs the growth of prostate carcinoma xenografts in mice +genetics_overexpression_promote hsa-mir-31 Leiomyosarcoma 19602040 overexpression; leads to HMGA2 overexpression; Disrupting the control of HMGA2 and let-7 pairs promotes ULMS cell growth in vitro. +genetics_overexpression_promote hsa-mir-125a Ovarian Neoplasms 19881956 Overexpression of miR-125a induces conversion of highly invasive ovarian cancer cells +genetics_overexpression_promote hsa-mir-26a Glioblastoma 20080666 "Overexpression of miR-26a in PTEN-competent and PTEN-deficient glioblastoma cells promoted tumor growth in vivo, and it further increased growth in cells overexpressing CDK4 or CENTG1." +genetics_overexpression_promote hsa-mir-17 Neoplasms [unspecific] 20439436 mir-17:We correctly identified hsa-miR-17/92 family as amplified and the hsa-miR-143/145 cluster as deleted +genetics_overexpression_promote hsa-mir-18a Neoplasms [unspecific] 20439436 mir-18a:We correctly identified hsa-miR-17/92 family as amplified and the hsa-miR-143/145 cluster as deleted +genetics_overexpression_promote hsa-mir-19a Neoplasms [unspecific] 20439436 mir-19a:We correctly identified hsa-miR-17/92 family as amplified and the hsa-miR-143/145 cluster as deleted +genetics_overexpression_promote hsa-mir-19b-1 Neoplasms [unspecific] 20439436 mir-19b:We correctly identified hsa-miR-17/92 family as amplified and the hsa-miR-143/145 cluster as deleted +genetics_overexpression_promote hsa-mir-19b-2 Neoplasms [unspecific] 20439436 mir-19b:We correctly identified hsa-miR-17/92 family as amplified and the hsa-miR-143/145 cluster as deleted +genetics_overexpression_promote hsa-mir-92a-1 Neoplasms [unspecific] 20439436 mir-92a:We correctly identified hsa-miR-17/92 family as amplified and the hsa-miR-143/145 cluster as deleted +genetics_overexpression_promote hsa-mir-92a-2 Neoplasms [unspecific] 20439436 mir-92a:We correctly identified hsa-miR-17/92 family as amplified and the hsa-miR-143/145 cluster as deleted +genetics_overexpression_promote hsa-mir-125b Leukemia 21118985 "Thus, we show that overexpression of miR-125b is sufficient both to shorten the latency of BCR-ABL-induced leukemia and to independently induce leukemia in a mouse model." +genetics_overexpression_promote hsa-mir-18a Urinary Bladder Cancer 21388952 Specific deletion of p53 in urothelial cells is associated with specific overexpression of miR-18a and miR-19a and down-regulation of miR-107. +genetics_overexpression_promote hsa-mir-19a Urinary Bladder Cancer 21388952 Specific deletion of p53 in urothelial cells is associated with specific overexpression of miR-18a and miR-19a and down-regulation of miR-107. +genetics_overexpression_promote hsa-mir-155 Hepatitis C Virus Infection 21750860 Coordinated increase of miRNA-155 and miRNA-196b expression correlates with the detection of the antigenomic strand of hepatitis C virus in peripheral blood mononuclear cells. +genetics_overexpression_promote hsa-mir-196b Hepatitis C Virus Infection 21750860 Coordinated increase of miRNA-155 and miRNA-196b expression correlates with the detection of the antigenomic strand of hepatitis C virus in peripheral blood mononuclear cells. +genetics_overexpression_promote hsa-mir-125b-2 Glioblastoma 21879257 miR-125b-2 overexpression might confer glioblastoma stem cells resistance to TMZ. +genetics_overexpression_promote hsa-mir-21 Breast Neoplasms 21917003 High expression of miR-21 in tumor stroma correlates with increased cancer cell proliferation in human breast cancer. +genetics_overexpression_promote hsa-mir-17 "Lymphoma, Burkitt" 21981616 The minimum common amplified region on 13q was at 13q31 and included the MIR17HG (MIR17-92) locus. Samples with this gain had higher levels of MIR17 RNA and showed a tendency for early relapse. +genetics_overexpression_promote hsa-mir-18a "Lymphoma, Burkitt" 21981616 The minimum common amplified region on 13q was at 13q31 and included the MIR17HG (MIR17-92) locus. Samples with this gain had higher levels of MIR17 RNA and showed a tendency for early relapse. +genetics_overexpression_promote hsa-mir-19a "Lymphoma, Burkitt" 21981616 The minimum common amplified region on 13q was at 13q31 and included the MIR17HG (MIR17-92) locus. Samples with this gain had higher levels of MIR17 RNA and showed a tendency for early relapse. +genetics_overexpression_promote hsa-mir-19b-1 "Lymphoma, Burkitt" 21981616 The minimum common amplified region on 13q was at 13q31 and included the MIR17HG (MIR17-92) locus. Samples with this gain had higher levels of MIR17 RNA and showed a tendency for early relapse. +genetics_overexpression_promote hsa-mir-20a "Lymphoma, Burkitt" 21981616 The minimum common amplified region on 13q was at 13q31 and included the MIR17HG (MIR17-92) locus. Samples with this gain had higher levels of MIR17 RNA and showed a tendency for early relapse. +genetics_overexpression_promote hsa-mir-92a-1 "Lymphoma, Burkitt" 21981616 The minimum common amplified region on 13q was at 13q31 and included the MIR17HG (MIR17-92) locus. Samples with this gain had higher levels of MIR17 RNA and showed a tendency for early relapse. +genetics_overexpression_promote hsa-mir-10b Pancreatic Neoplasms 22018284 "MicroRNA-10b is overexpressed in pancreatic cancer, promotes its invasiveness, and correlates with a poor prognosis." +genetics_overexpression_promote hsa-mir-17 Colon Neoplasms 22065543 "MiR-17-92 cluster and its paralogs were significantly overexpressed in colon tumor. No significant associations were found between the deregulation of certain miRNAs and the clinical and pathologic characteristics observed in patients. Kaplan-Meier curves demonstrated significantly reduced overall survival in patients expressing high levels of miR-17. In multivariate Cox models, miR-17 overexpression (HR 2.67; P=0.007) and TNM staging (HR 8.87; P=0.002) were significantly associated with a risk of death." +genetics_overexpression_promote hsa-mir-18a Colon Neoplasms 22065543 "MiR-17-92 cluster and its paralogs were significantly overexpressed in colon tumor. No significant associations were found between the deregulation of certain miRNAs and the clinical and pathologic characteristics observed in patients. Kaplan-Meier curves demonstrated significantly reduced overall survival in patients expressing high levels of miR-17. In multivariate Cox models, miR-17 overexpression (HR 2.67; P=0.007) and TNM staging (HR 8.87; P=0.002) were significantly associated with a risk of death." +genetics_overexpression_promote hsa-mir-19a Colon Neoplasms 22065543 "MiR-17-92 cluster and its paralogs were significantly overexpressed in colon tumor. No significant associations were found between the deregulation of certain miRNAs and the clinical and pathologic characteristics observed in patients. Kaplan-Meier curves demonstrated significantly reduced overall survival in patients expressing high levels of miR-17. In multivariate Cox models, miR-17 overexpression (HR 2.67; P=0.007) and TNM staging (HR 8.87; P=0.002) were significantly associated with a risk of death." +genetics_overexpression_promote hsa-mir-19b-1 Colon Neoplasms 22065543 "MiR-17-92 cluster and its paralogs were significantly overexpressed in colon tumor. No significant associations were found between the deregulation of certain miRNAs and the clinical and pathologic characteristics observed in patients. Kaplan-Meier curves demonstrated significantly reduced overall survival in patients expressing high levels of miR-17. In multivariate Cox models, miR-17 overexpression (HR 2.67; P=0.007) and TNM staging (HR 8.87; P=0.002) were significantly associated with a risk of death." +genetics_overexpression_promote hsa-mir-20a Colon Neoplasms 22065543 "MiR-17-92 cluster and its paralogs were significantly overexpressed in colon tumor. No significant associations were found between the deregulation of certain miRNAs and the clinical and pathologic characteristics observed in patients. Kaplan-Meier curves demonstrated significantly reduced overall survival in patients expressing high levels of miR-17. In multivariate Cox models, miR-17 overexpression (HR 2.67; P=0.007) and TNM staging (HR 8.87; P=0.002) were significantly associated with a risk of death." +genetics_overexpression_promote hsa-mir-92a-1 Colon Neoplasms 22065543 "MiR-17-92 cluster and its paralogs were significantly overexpressed in colon tumor. No significant associations were found between the deregulation of certain miRNAs and the clinical and pathologic characteristics observed in patients. Kaplan-Meier curves demonstrated significantly reduced overall survival in patients expressing high levels of miR-17. In multivariate Cox models, miR-17 overexpression (HR 2.67; P=0.007) and TNM staging (HR 8.87; P=0.002) were significantly associated with a risk of death." +genetics_overexpression_promote hsa-mir-125b-1 Rhinosinusitis 22071331 "Overexpression of miR-125b, a Novel Regulator of Innate Immunity, in Eosinophilic Chronic Rhinosinusitis with Nasal Polyps." +genetics_overexpression_promote hsa-mir-125b-2 Rhinosinusitis 22071331 "Overexpression of miR-125b, a Novel Regulator of Innate Immunity, in Eosinophilic Chronic Rhinosinusitis with Nasal Polyps." +genetics_overexpression_promote hsa-mir-155 "Carcinoma, Hepatocellular" 22071603 Up-regulation of microRNA-155 promotes cancer cell invasion and predicts poor survival of hepatocellular carcinoma following liver transplantation. +genetics_overexpression_promote hsa-mir-223 "Squamous Cell Carcinoma, Esophageal" 22108521 Overexpression of microRNA-223 regulates the ubiquitin ligase FBXW7 in oesophageal squamous cell carcinoma. +genetics_overexpression_promote hsa-mir-124-1 Neuroblastoma 22123030 "Ectopic overexpression of miR-124 resulted in the downregulation of CDK6, decreased cellular proliferation, and induced cellular morphological changes." +genetics_overexpression_promote hsa-mir-124-2 Neuroblastoma 22123030 "Ectopic overexpression of miR-124 resulted in the downregulation of CDK6, decreased cellular proliferation, and induced cellular morphological changes." +genetics_overexpression_promote hsa-mir-124-3 Neuroblastoma 22123030 "Ectopic overexpression of miR-124 resulted in the downregulation of CDK6, decreased cellular proliferation, and induced cellular morphological changes." +genetics_overexpression_promote hsa-mir-122 "Carcinoma, Hepatocellular" 22140464 "miR-122 expression is highly elevated in quiescent human primary hepatocytes (hPHs) but lost or attenuated in hESCs and HCCs, while an opposing expression pattern is observed for Pkm2. Depleting hESCs and HCCs of Pkm2, or overexpressing miR-122, leads to a common deficiency in self-renewal and proliferation." +genetics_overexpression_promote hsa-mir-223 "Leukemia, Lymphocytic, Chronic, B-Cell" 22145958 microRNA-223 expression is uniformly down-regulated in B cell lymphoproliferative disorders and is associated with poor survival in chronic lymphocytic leukemia patients. +genetics_overexpression_promote hsa-mir-200a Prostate Neoplasms 22161972 "miR-200a overexpression reduced prostate cancer cell growth and may have potential, in combination with other markers, in stratifying prostate cancer patients for more intensive monitoring and therapy." +genetics_overexpression_promote hsa-mir-28 Colorectal Carcinoma 22240480 "miR-28-5p altered expression of CCND1 and HOXB3, whereas miR-28-3p bound NM23-H1. Overexpression of miR-28-5p reduced CRC cell proliferation, migration, and invasion in vitro, whereas miR-28-3p increased CRC cell migration and invasion in vitro." +genetics_overexpression_promote hsa-mir-182 Ovarian Neoplasms 22322863 "miR-182 overexpression resulted in increased tumor transformation in vitro, and enhanced tumor invasiveness in vitro and metastasis in vivo. The oncogenic properties of miR-182 in ovarian cancer were mediated in part by its impaired repair of DNA double-strand breaks and negative regulation of breast cancer 1 (BRCA1) and metastasis suppressor 1 (MTSS1) expressions as well as its positive regulation of oncogene high-mobility group AT-hook 2 (HMGA2)." +genetics_overexpression_promote hsa-mir-21 "Carcinoma, Lung, Non-Small-Cell" 22335905 Overexpression of miR-21 promotes proliferation and reduces apoptosis in non-small cell lung cancer]. +genetics_overexpression_promote hsa-mir-34a Myocardial Infarction 22403243 "IGF-1 significantly inhibited H(2)O(2)-induced miR-34a expression, and miR-34a overexpression abolished the anti-apoptotic effect of IGF-1." +genetics_overexpression_promote hsa-mir-17 Leukemia 22451425 "In both murine and human leukemias, p53 inactivation contributed to the selective overexpression of oncogenic miR-92a and miR-19a, and down-regulation of tumor-suppressive miR-17." +genetics_overexpression_promote hsa-mir-19a Acute Erythroid Leukemia 22451425 "overexpression of individual miRNAs from this locus, miR-19a or miR-92a, results in B-cell hyperplasia and erythroleukemia, respectively." +genetics_overexpression_promote hsa-mir-92a Acute Erythroid Leukemia 22451425 "overexpression of individual miRNAs from this locus, miR-19a or miR-92a, results in B-cell hyperplasia and erythroleukemia, respectively." +genetics_overexpression_promote hsa-mir-130a Ovarian Neoplasms 22455133 The over expression of miR-130a is associated with cisplatin resistance of ovarian cancer. Inhibiting miR-130a expression may help reverse the cisplatin resistance of ovarian cancer. +genetics_overexpression_promote hsa-mir-21 Breast Neoplasms 22547075 DNA damage induces NF-kB-dependent microRNA-21 upregulation and promotes breast cancer cell invasion. +genetics_overexpression_promote hsa-mir-125b "Leukemia, Myeloid, Acute" 22689670 "We previously described a t(2;11)(p21;q23) chromosomal translocation found in patients with myelodysplasia or acute myeloid leukemia that leads to over-expression of the microRNA miR-125b, and we showed that transplantation of mice with murine stem/progenitor cells overexpressing miR-125b is able to induce leukemia." +genetics_overexpression_promote hsa-mir-615 "Carcinoma, Hepatocellular" 22819824 miR-615-5p is restrictedly expressed in cirrhotic and cancerous liver tissues and its overexpression alleviates the tumorigenic effects in hepatocellular carcinoma. +genetics_overexpression_promote hsa-mir-221 Thyroid Neoplasms 22855362 Overexpression of miR-221 is associated with aggressive clinicopathologic characteristics and the BRAF mutation in papillary thyroid carcinomas. +genetics_overexpression_promote hsa-mir-132 Heart Failure 23011132 "MiR-212/132 null mice are protected from pressure-overload-induced heart failure, whereas cardiomyocyte-specific overexpression of the miR-212/132 family leads to pathological cardiac hypertrophy, heart failure and death in mice." +genetics_overexpression_promote hsa-mir-212 Heart Failure 23011132 "MiR-212/132 null mice are protected from pressure-overload-induced heart failure, whereas cardiomyocyte-specific overexpression of the miR-212/132 family leads to pathological cardiac hypertrophy, heart failure and death in mice." +genetics_overexpression_promote hsa-mir-221 Inflammation 23023232 "The overexpression of oncogenic miR-221 and miR-222 caused by HMGB1 is associated with an increase in malignancy scores, namely cell growth and motility." +genetics_overexpression_promote hsa-mir-222 "Carcinoma, Thyroid, Papillary" 23023232 "The overexpression of oncogenic miR-221 and miR-222 caused by HMGB1 is associated with an increase in malignancy scores, namely cell growth and motility." +genetics_overexpression_promote hsa-mir-17 Gastric Neoplasms 23333058 "Overexpression of miR-17-5p/20a promoted gastric cancer cell cycle progression and inhibited cell apoptosis, whereas knockdown of miR-17-5p/20a resulted in cell cycle arrest and increased apoptosis." +genetics_overexpression_promote hsa-mir-20a Gastric Neoplasms 23333058 "Overexpression of miR-17-5p/20a promoted gastric cancer cell cycle progression and inhibited cell apoptosis, whereas knockdown of miR-17-5p/20a resulted in cell cycle arrest and increased apoptosis." +genetics_overexpression_promote hsa-mir-100 "Carcinoma, Renal Cell" 23378187 miR-100 overexpression strongly associates with advanced tumor progression and unfavorable clinical outcome of patients with RCC +genetics_overexpression_promote hsa-mir-106b "Carcinoma, Hepatocellular" 23483935 Over-Expression of miR-106b Promotes Cell Migration and Metastasis in Hepatocellular Carcinoma by Activating Epithelial-Mesenchymal Transition Process +genetics_overexpression_promote hsa-mir-449a "Adenocarcinoma, Lung" 23614048 "Overexpression of miR-449a in CL1-0 cells effectively increased irradiation-induced DNA damage and apoptosis,altered the cell cycle distribution and eventually led to sensitization of CL1-0 to irradiation." +genetics_overexpression_promote hsa-mir-1 Myocardial Infarction 23615185 Overexpression of MicroRNA-1 improves the efficacy of mesenchymal stem cell transplantation after myocardial infarction. +genetics_overexpression_promote hsa-mir-146a Sepsis 23638011 Overexpression of miR-146a induces a state analogous to tolerance in BLP-stimulated cells and therefore may represent a future target for exogenous modulation of tolerance during microbial infection and sepsis. +genetics_overexpression_promote hsa-mir-9 Leukemia 23798388 miR-9 is an essential oncogenic microRNA specifically overexpressed in mixed lineage leukemia-rearranged leukemia. +genetics_overexpression_promote hsa-mir-146b Inflammation 23813877 MicroRNA-146b improves intestinal injury in mouse colitis by activating nuclear factor-¦ÊB and improving epithelial barrier function. +genetics_overexpression_promote hsa-mir-22 Heart Failure 24086656 microRNA-22 promotes heart failure through coordinate suppression of PPAR/ERR-nuclear hormone receptor transcription. +genetics_overexpression_promote hsa-mir-449a Retinoblastoma 24120948 We are the first to confirm an inhibitory effect of miR-449a and -449b in retinoblastoma by demonstrating significantly impaired proliferation and increased apoptosis of tumor cells when these miRNAs are overexpressed. +genetics_overexpression_promote hsa-mir-32 Colorectal Carcinoma 24123284 "MiR-32 overexpression was correlated with specific CRC clinicopathological features and may be a marker of poor prognosis in CRC patients. MiR-32 and PTEN expression were inversely correlated, and miR-32 may be associated with the development of CRC." +genetics_overexpression_promote hsa-mir-17 Leukemia 24145403 "The miR-17?92 overexpression was driven by the E?-enhancer and Ig heavy-chain promoter, and a 3' GFP tag was added to the transgene to track the miR expression." +genetics_overexpression_promote hsa-mir-18a "Leukemia, B-Cell" 24145403 "The miR-17?92 overexpression was driven by the E?-enhancer and Ig heavy-chain promoter, and a 3' GFP tag was added to the transgene to track the miR expression." +genetics_overexpression_promote hsa-mir-19a "Leukemia, B-Cell" 24145403 "The miR-17?92 overexpression was driven by the E?-enhancer and Ig heavy-chain promoter, and a 3' GFP tag was added to the transgene to track the miR expression." +genetics_overexpression_promote hsa-mir-19b "Leukemia, B-Cell" 24145403 "The miR-17?92 overexpression was driven by the E?-enhancer and Ig heavy-chain promoter, and a 3' GFP tag was added to the transgene to track the miR expression." +genetics_overexpression_promote hsa-mir-92a "Leukemia, B-Cell" 24145403 "The miR-17?92 overexpression was driven by the E?-enhancer and Ig heavy-chain promoter, and a 3' GFP tag was added to the transgene to track the miR expression." +genetics_overexpression_promote hsa-mir-21 Colorectal Carcinoma 24149370 "miR-21 is a key player in oncogenic EMT, its overexpression is controlled by the cooperation of genetic and epigenetic alterations, and its levels, along with ITG¦Â4 and PDCD4 expression, could be exploited as a prognostic tool for CRC metastasis." +genetics_overexpression_promote hsa-mir-18a Toxic Epidermal Necrolysis 24184144 Our results indicated that downregulated BCL2L10 caused by miR-18a-5p overexpression mediates intrinsic keratinocyte apoptosis in patients with TEN. Serum miR-18a-5p levels can be a useful disease marker for drug eruptions. +genetics_overexpression_promote hsa-let-7a Systemic Lupus Erythematosus 24240124 our results suggest that overexpression of let-7a may contribute to hyperplasia and the proinflammatory response in SLE. +genetics_overexpression_promote hsa-mir-296 Prostate Neoplasms 24263102 "Interestingly, ectopic expression of miR-296-3p in P69 increases the tolerance to NK cells whereas knockdown of miR-296-3p in M12 reduces the resistance to NK cells, which both phenotypes can be rescued by re-expression or silencing of ICAM-1 in P69 and M12, respectively." +genetics_overexpression_promote hsa-mir-9 Pulmonary Hypertension 24615545 "Knockdown of miR-9 followed by hypoxia exposure attenuated PASMCs proliferation and enhanced the expression of contractile genes in vascular smooth muscle cells (VSMCs), while overexpression of miR-9 in normoxia promoted a proliferative phenotype in PASMCs." +genetics_overexpression_promote hsa-mir-210 Gastrointestinal Stromal Tumor 24623741 "Overexpression of miR-210 is associated with SDH-related pheochromocytomas, paragangliomas, and gastrointestinal stromal tumours." +genetics_overexpression_promote hsa-mir-125a Myelodysplastic Syndromes 24690917 Overexpression of miR-125a in myelodysplastic syndrome CD34+ cells modulates NF-¦ÊB activation and enhances erythroid differentiation arrest. +genetics_overexpression_promote hsa-mir-30c Heart Failure 24789369 Taken together these data indicate impaired mitochondrial function due to OXPHOS protein depletion as a potential cause for the observed dilated cardiomyopathic phenotype in miRNA-30c transgenic mice. +genetics_overexpression_promote hsa-mir-429 Ovarian Neoplasms 24802724 Ectopic over-expression of miR-429 induces mesenchymal-to-epithelial transition (MET) and increased drug sensitivity in metastasizing ovarian cancer cells. +genetics_overexpression_promote hsa-mir-30a Nasopharyngeal Neoplasms 24812123 "Furthermore, over-expression of miR-30a transfected with precursor increased the ability of metastasis and invasion of NPC tumor cells in vivo and in vitro." +genetics_overexpression_promote hsa-mir-222 "Carcinoma, Hepatocellular" 24955159 "MiR-222 overexpression induced an enhancement of HepG2 cell proliferation in vitro, paralleling with an altered cell cycle progression via increased cell population in S phase." +genetics_overexpression_promote hsa-mir-23b Breast Neoplasms 24966325 Ectopic expression of the miRNAs in the weakly metastatic mouse 4TO7 mammary tumor cell line had no effect on proliferation or morphology of tumor cells in vitro but was found to increase lung metastasis in a mouse model of breast cancer metastasis. +genetics_overexpression_promote hsa-mir-24 Breast Neoplasms 24966325 Ectopic expression of the miRNAs in the weakly metastatic mouse 4TO7 mammary tumor cell line had no effect on proliferation or morphology of tumor cells in vitro but was found to increase lung metastasis in a mouse model of breast cancer metastasis. +genetics_overexpression_promote hsa-mir-27b Breast Neoplasms 24966325 Ectopic expression of the miRNAs in the weakly metastatic mouse 4TO7 mammary tumor cell line had no effect on proliferation or morphology of tumor cells in vitro but was found to increase lung metastasis in a mouse model of breast cancer metastasis. +genetics_overexpression_promote hsa-mir-9 Osteosarcoma 24969351 "The findings of our study suggest that increased miR-9 expression has a strong correlation with the aggressive progression of osteosarcoma and its overexpression is a statistically significant risk factor affecting overall survival, suggesting that increased miR-9 expression could be a valuable marker of tumor progression and for prognosis of osteosarcoma." +genetics_overexpression_promote hsa-mir-17 Gastric Neoplasms 25047501 Overexpression of miR-17 in gastric cancer is correlated with proliferation-associated oncogene amplification. +genetics_overexpression_promote hsa-mir-214 Cardiomegaly 25085702 Cardiac hypertrophy and dysfunction induced by overexpression of miR-214 in vivo. +genetics_overexpression_promote hsa-mir-195 Heart Failure 25100012 Cardiac overexpression of miR-195 results in pathological cardiac growth and heart failure in transgenic mice. +genetics_overexpression_promote hsa-mir-146a Breast Neoplasms 25123132 Overexpression of miR-146a in basal-like breast cancer cells confers enhanced tumorigenic potential in association with altered p53 status. +genetics_overexpression_promote hsa-mir-21 Gastric Neoplasms 25230738 "This meta-analysis indicates that miR-21 detection has a prognostic value in patients with gastric cancer. In addition, overexpression of miR-21 is associated with worse tumor differentiation, lymph node metastasis, and TNM stage." +genetics_overexpression_promote hsa-mir-196a Oral Neoplasms 25233933 "Functionally, miR-196 actively promoted cell migration and invasion without affecting cell growth." +genetics_overexpression_promote hsa-mir-21 Neoplasms [unspecific] 25241894 Ectopic expression of miR-21 and miR-29a promotes angiogenesis and tumor cell proliferation +genetics_overexpression_promote hsa-mir-223 Colorectal Carcinoma 25270282 Overexpression of miR-223 correlates with tumor metastasis and poor prognosis in patients with colorectal cancer. +genetics_overexpression_promote hsa-mir-410 Colorectal Carcinoma 25272045 MiR-410 is overexpressed in liver and colorectal tumors and enhances tumor cell growth by silencing FHL1 via a direct/indirect mechanism. +genetics_overexpression_promote hsa-mir-374a Neoplasms [unspecific] 25299640 The miR-545/374a cluster encoded in the Ftx lncRNA is overexpressed in HBV-related hepatocellular carcinoma and promotes tumorigenesis and tumor progression. +genetics_overexpression_promote hsa-mir-545 Neoplasms [unspecific] 25299640 The miR-545/374a cluster encoded in the Ftx lncRNA is overexpressed in HBV-related hepatocellular carcinoma and promotes tumorigenesis and tumor progression. +genetics_overexpression_promote hsa-mir-200c Breast Neoplasms 25329395 Overexpression of microRNA-200c predicts poor outcome in patients with PR-negative breast cancer. +genetics_overexpression_promote hsa-mir-184 "Squamous Cell Carcinoma, Head and Neck" 25351569 Treatment with the precursors of these miRNAs increases the proliferation and migration of HNSCC cells. +genetics_overexpression_promote hsa-mir-1269 "Carcinoma, Hepatocellular" 25472505 "overexpression of miR-1269 promotes cell proliferation in HCC through directly suppressing FOXO1, and functions as an oncomiR in HCC." +genetics_overexpression_promote hsa-mir-17 Hematologic Neoplasms 25597017 overexpression of miR-17-92 in a limited number of hematopoietic cells is sufficient to cause B cell malignancies. +genetics_overexpression_promote hsa-mir-34a Sensorineural Hearing Loss 25638533 "In the inner ear HEI-OC1 cell line, miR-34a overexpression inhibited SIRT1, leading to an increase in p53 acetylation and apoptosis." +genetics_overexpression_promote hsa-mir-29c Brain Disease [unspecific] 25678279 "over-expression of miR-29c effectively reduced Birc2 (also Bak1) mRNA and protein levels, increased infarct volume and apoptosis, and deteriorated neurological outcomes, whereas down-regulation played a neuroprotective role." +genetics_overexpression_promote hsa-mir-433 Ovarian Neoplasms 25684390 Overexpression of the microRNA miR-433 promotes resistance to paclitaxel through the induction of cellular senescence in ovarian cancer cells. +genetics_overexpression_promote hsa-mir-221 Neoplasms [unspecific] 25686829 Over-expression of miR-221 stimulated stem-like cells in luminal type of cancer and the miR-221 level was correlated with clinical outcome in breast cancer patients. +genetics_overexpression_promote hsa-mir-153 "Carcinoma, Hepatocellular" 25714700 Over-expression of miR-153 down-regulated the activity of Etoposide and Paclitaxel on cell cycle arrest of HepG2 cells and the effect of Sorafenib on the invasion and migration of HepG2 cells. +genetics_overexpression_promote hsa-mir-196a "Squamous Cell Carcinoma, Head and Neck" 25860510 "These results show that miR-196a and HOXB9 are overexpressed,perhaps co-ordinately, as HNSCC develops and exert a pro-tumourigenic phenotype in HNSCC and OPM cells." +genetics_overexpression_promote hsa-mir-21 "Carcinoma, Cervical" 25963606 Overexpression of miR-21 promotes the proliferation and migration of cervical cancer cells via the inhibition of PTEN. +genetics_overexpression_promote hsa-mir-125a Chronic Hepatitis B 25993287 "Conversely, the overexpression of miR-125a or knockdown of A20 mimicked HBx to enhance TRAIL susceptibility in hepatocytes." +genetics_overexpression_promote hsa-mir-196a Osteosarcoma 26045752 "Taken together, miR-196a should be an oncogene in osteosarcoma. The possible mechanism was that overexpression of miR-196a promoted proliferation of MG63 and U2OS cells by modulating the PTEN/PI3K/Akt signaling pathway." +genetics_overexpression_promote hsa-mir-221 "Carcinoma, Lung, Non-Small-Cell" 26131134 We found that miR-222 overexpression increased cell viability and proliferative rate in H460 cells while opposite effects were obtained by down-regulation of miR-222. +genetics_overexpression_promote hsa-mir-144 Diabetic Cardiomyopathies 26164195 The miR-144 mimics aggravated high glucose-induced ROS formation and apoptosis in cardiomyocytes +genetics_overexpression_promote hsa-mir-23a "Carcinoma, Laryngeal" 26171041 "Ectopic expression of miR-23a and knockdown of APAF-1 significantly promoted cell proliferation and colony formation, and inhibited early apoptosis in Hep2 cells." +genetics_overexpression_promote hsa-mir-132 "Diabetes Mellitus, Type 2" 26218441 Overexpression of miR-132 or miR-212 enhances glucose and GLP-1-stimulated insulin secretion. +genetics_overexpression_promote hsa-mir-212 "Diabetes Mellitus, Type 2" 26218441 Overexpression of miR-132 or miR-212 enhances glucose and GLP-1-stimulated insulin secretion. +genetics_overexpression_promote hsa-mir-331 Prostate Neoplasms 26259043 "Overexpression of miR-331-3p upregulated mesenchymal markers such as vimentin, N-cadherin, and snail and downregulated epithelial markers such as E-cadherin and desmoplakin in the prostate cancer cell line PC3." +genetics_overexpression_promote hsa-mir-93 "Squamous Cell Carcinoma, Esophageal" 26273410 "The introduction of miR-93 significantly promotes cell proliferation,cell cycle progression, and the metastatic capability of EC109 cells. " +genetics_overexpression_promote hsa-mir-20a Gastric Neoplasms 26286834 "ectopic expression of miR-20a dramatically decreased the expression of NFKBIB; increased the expression of p65, livin, and survivin" +genetics_overexpression_promote hsa-mir-215 Glioma 26317904 "In summary, miR-215 is overexpressed in human glioma, is involved in TGF-¦Â1-induced oncogenesis, and can be used as a marker of poor prognosis in glioma patients." +genetics_overexpression_promote hsa-mir-206 Cardiomegaly 26333362 Cardiac-specific overexpression of miR-206 in mice induced hypertrophy and protected the heart from ischemia/reperfusion injury +genetics_overexpression_promote hsa-mir-1207 Ovarian Neoplasms 26337084 MiR-1207 overexpression promotes cancer stem cell-like traits in ovarian cancer by activating the Wnt/¦Â-catenin signaling pathway. +genetics_overexpression_promote hsa-mir-302 Fanconi Anemia 26343459 "Taken together, our results suggest that overexpression of miR-302 plays a critical role in the regulation of FANCD2 monoubiquitination, resulting in characteristic defects in DNA repair within cells." +genetics_overexpression_promote hsa-mir-92a "Carcinoma, Lung, Non-Small-Cell" 26432332 "upregulation of miR-92a in NSCLC cells promoted cell proliferation, migration, and invasion, decreased apoptosis and caspase-3 activity, and enhanced chemoresistance of NSCLC cells, whereas downregulation of miR-92a showed the opposite effects." +genetics_overexpression_promote hsa-mir-451 "Squamous Cell Carcinoma, Head and Neck" 26506880 And overexpression of miRNA-451 in cells with low endogenous expression of miRNA-451 accelerated proliferation. +genetics_overexpression_promote hsa-mir-664 Osteosarcoma 26515813 Overexpression of miR-664 was associated with increased migration and invasive abilities of OS cells in vitro +genetics_overexpression_promote hsa-mir-221 Inflammation 26549234 Enforced expression of miR-221 significantly increased the production of proinflammatory cytokines +genetics_overexpression_promote hsa-mir-21 Asthma 26651881 "This study provides the first in vitro evidence that overexpression of miR-21 in HASM cells can trigger cell proliferation and migration, and the effects of miR-21 depend on the level of PTEN." +genetics_overexpression_promote hsa-mir-27b Cervical Neoplasms 26706910 "Upregulation of miR-27b significantly accelerated the proliferation, cell cycle transition from G1 to S phase, migration and invasion of C33A cells" +genetics_overexpression_promote hsa-mir-183 Colorectal Carcinoma 26717041 "over-expression of miR-183 resulted in the attenuation of rapamycin- or starvation-induced autophagy in cancer cells, whereas inhibition of endogenous miR-183 stimulated autophagy and apoptosis." +genetics_overexpression_promote hsa-mir-200a "Carcinoma, Nasopharyngeal" 26718506 Overexpression of miR-200a resulted in the proliferation of CNE2 cells. +genetics_overexpression_promote hsa-mir-203 Pancreatic Neoplasms 26719072 "miR-203 promotes proliferation, migration and invasion in pancreatic cancer cells" +genetics_overexpression_promote hsa-mir-421 Osteosarcoma 26758431 "overexpression of miR-421 promoted osteosarcoma cell line MG-63 proliferation, migration, and invasion." +genetics_overexpression_promote hsa-mir-21 Osteosarcoma 26779632 miR-21 overexpression in MG63 caused a significant raise in cell proliferation and invasion and a significant reduction in cell apoptosis. +genetics_overexpression_promote hsa-mir-222 Bladder Neoplasms 26800397 Overexpression of miR-222 attenuated cisplatin-induced cell death in bladder cancer cells. +genetics_overexpression_promote hsa-mir-96 Glioma 26846266 "In vivo, microRNA-96 overexpression inhibits the apoptosis and increases tumor growth." +genetics_overexpression_promote hsa-mir-21 Heart Failure 26865549 Overexpression of miR-21 in this monocyte cell line activated a fibrotic gene programme and promoted monocyte-to-fibrocyte transition +genetics_overexpression_promote hsa-mir-183 Glioma 26879754 "Introduction of miR-183 mimics into U251 cells could promoted, while its antisense oligos inhibited cell proliferation and invasion." +genetics_overexpression_promote hsa-mir-205 "Carcinoma, Nasopharyngeal" 26880795 "Overexpression of miR-205 increased the proliferation, migration and invasion of CNE2 cells" +genetics_overexpression_promote hsa-mir-21 "Carcinoma, Cervical" 26884851 "The overexpression of HPV E7 protein facilitated the expression of miR-21, which potentiated Hela cell proliferation and invasion." +genetics_overexpression_promote hsa-mir-138 Glioblastoma 26887050 Transient transfection of miR-138 mimics in glioma cells with low basal miR-138 expression increased glioma cell proliferation. +genetics_overexpression_promote hsa-mir-27b Cervical Neoplasms 26910911 "MiR-27b, up-regulated by E7, promoted CaSki and SiHa cell proliferation and invasion, inhibit paclitaxel-induced apoptosis." +genetics_overexpression_promote hsa-mir-195 Spinal Cord Injuries 26927342 "In addition, Ad-miR-195 also obviously increased the number of apoptotic cells and decreased the neurological recovery in the animals injected with Ad-miR-195." +genetics_overexpression_promote hsa-mir-449a Breast Neoplasms 26934316 "In vitro, miR-449a promoted breast cancer cell proliferation, clonogenic survival, migration, and invasion." +genetics_overexpression_promote hsa-mir-214 Breast Neoplasms 26951965 the overexpression of miRâ€?14 markedly increased cell viability and abrogated the apoptosis triggered by serum starvation +genetics_overexpression_promote hsa-mir-522 "Carcinoma, Hepatocellular" 26960688 "miR-522 overexpression promoted cell proliferation, colony formation, and cell cycle progression, whereas knockdown of miR-522 reduced these effects." +genetics_overexpression_promote hsa-mir-210 Kidney Neoplasms 26985942 ACHN cell proliferation and invasion were significantly increased and apoptosis was significantly decreased (P < 0.05) when miR-210 was overexpressed. +genetics_overexpression_promote hsa-mir-146a Chronic Hepatitis B 26996068 Overexpression of miR-146a reduced NK cell-mediated cytotoxicity +genetics_overexpression_promote hsa-mir-141 "Carcinoma, Nasopharyngeal" 27010857 ectopic expression of miR-141 can significantly promote cell proliferation and inhibit apoptosis in NPC +genetics_overexpression_promote hsa-mir-125a Juvenile Rheumatoid Arthritis 27014994 miR-125a-5p overexpression enhanced M2b polarization and altered other polarized populations +genetics_overexpression_promote hsa-mir-195 Myocardial Ischemic-Reperfusion Injury 27019437 "miR-195 expression was upregulated in myocardial I/R injury, and miR-195 overexpression may promote cardiomyocyte apoptosis by targeting Bcl-2 and inducing mitochondrial apoptotic pathway." +genetics_overexpression_promote hsa-mir-93 "Carcinoma, Gastric" 27021515 miR-93 promoted the development of gastric tumor growth in xenograft mice +genetics_overexpression_promote hsa-mir-9 Glioblastoma 27036038 "hsa-miR-9 overexpression leads to MAPKAP signaling inhibition, partially by interfering with the MAPK14/MAPKAP3 complex. Further, hsa-miR-9 overexpression initiates re-arrangement of actin filament" +genetics_overexpression_promote hsa-mir-221 Breast Neoplasms 27044817 "Enforced expression of miR-221/222 promoted breast cancer cell proliferation, migration and invasion via targeting PTEN/Akt pathway." +genetics_overexpression_promote hsa-mir-222 Breast Neoplasms 27044817 "Enforced expression of miR-221/222 promoted breast cancer cell proliferation, migration and invasion via targeting PTEN/Akt pathway." +genetics_overexpression_promote hsa-mir-373 "Squamous Cell Carcinoma, Esophageal" 27073718 "Overexpression of miR-373 in ECA109 cells enhanced proliferation, G1-phase cell proportion, migration, and invasion." +genetics_overexpression_promote hsa-mir-141 Breast Neoplasms 27075851 "Ectopic expression of miR-141 in nonexpressing MDA-MB-231 enhanced brain metastatic colonization (5/9 mice vs 0/10 mice,P= .02)." +genetics_overexpression_promote hsa-mir-92b "Carcinoma, Hepatocellular" 27100897 miR-92b could promote cell proliferation and metastasis of HCC in vitro and in vivo. +genetics_overexpression_promote hsa-mir-146a Multiple Myeloma 27102001 "overexpressing miR-146a in MSC, secretion of several cytokines and chemokines including CXCL1, IL6, IL-8, IP-10, MCP-1, and CCL-5 was elevated, resulting in the enhancement of MM cell viability and migration." +genetics_overexpression_promote hsa-mir-196a "Carcinoma, Hepatocellular" 27108614 "HCV core protein increased the expression of miRâ€?96a, and that overexpression of miRâ€?96a in the HepG2 and Huhâ€? HCC cell lines promoted cell proliferation by inducing the G1‑S transition." +genetics_overexpression_promote hsa-mir-449a Hepatitis B Virus Infection 27138288 "Ectopic miR-449a expression in HCC cells strongly enhanced HBV replication, transcription, progeny virions secretion, and antigen expression in a dose-dependent manner." +genetics_overexpression_promote hsa-mir-106a Gastric Neoplasms 27142596 "Abnormal over-expression of miR-106a significantly promoted gastric cancer cell proliferation, metastasis, inhibited the cell apoptosis." +genetics_overexpression_promote hsa-mir-96 "Carcinoma, Prostate" 27164937 Overexpressing miR-96 led to increased proliferation and colony formation of normal prostate epithelial cells. +genetics_overexpression_promote hsa-mir-410 Colorectal Carcinoma 27177325 overexpression of miRâ€?10 resulted in an increase in growth activity and decrease in the extent of apoptosis +genetics_overexpression_promote hsa-mir-937 Lung Neoplasms 27179609 Overexpression of miR-937 in A549 promoted anchorage -dependent and -independent growth +genetics_overexpression_promote hsa-mir-200b "Cytotoxicity Tests, Immunologic" 27183614 Cells overexpressing miR-200b/c or miR-217 showed reduced sensitivity to CDC +genetics_overexpression_promote hsa-mir-200c "Cytotoxicity Tests, Immunologic" 27183614 Cells overexpressing miR-200b/c or miR-217 showed reduced sensitivity to CDC +genetics_overexpression_promote hsa-mir-217 "Cytotoxicity Tests, Immunologic" 27183614 Cells overexpressing miR-200b/c or miR-217 showed reduced sensitivity to CDC +genetics_overexpression_promote hsa-mir-182 Liver Injury 27196584 "miR-182, which is associated with disease severity and liver injury." +genetics_overexpression_promote hsa-mir-126 "Neovascularization, Pathologic" 27203443 "silencing of miR-126-3p repressed angiogenesis, while overexpression of miR-126-5p enhanced angiogenesis." +genetics_overexpression_promote hsa-mir-21 Hypertrophic Scar 27207585 overexpression of miR-21 promoted fibroproliferative expression in fibroblasts. +genetics_overexpression_promote hsa-mir-125b "Carcinoma, Gastric" 27220320 Overexpression of miR-125b promoted gastric cancer cell migration and invasion in vitro and metastasis in vivo. +genetics_overexpression_promote hsa-mir-211 "Squamous Cell Carcinoma, Oral" 27221705 Induction of oral carcinogenesis in transgenic mice using 4-nitroquinoline 1-oxide (4NQO) resulted in more extensive and severe tongue tumorigenesis compared with control animals. +genetics_overexpression_promote hsa-mir-221 "Adenocarcinoma, Pancreatic Ductal" 27230035 Overexpressing miR-221 significantly increased cell vitality and promoted cell proliferation and G1-to-S phase transition of the cell cycle in Capan-2 cells +genetics_overexpression_promote hsa-mir-146a Alzheimer Disease 27241555 "Overexpression of miRNA-146a in SH-SY5Y cells significantly decreased Lrp2 expression, resulting in a reduction of Akt activation and induction of proapoptotic caspase-3, thereby increasing cell apoptosis." +genetics_overexpression_promote hsa-mir-182 Cerebral Ischemia 27242323 miR-182 plays an aggressive role in the cerebral ischemia injury +genetics_overexpression_promote hsa-mir-34a Osteoarthritis 27247228 Overexpression of miR-34a promoted apoptosis and inhibited cell proliferation in human chondrocytes +genetics_overexpression_promote hsa-mir-1908 Wound Healing 27256397 miR-1908 had a positive role in scar formation +genetics_overexpression_promote hsa-mir-1301 Prostate Neoplasms 27261573 miR-1301 promoted cell proliferation of prostate cancer. +genetics_overexpression_promote hsa-mir-205 Colorectal Carcinoma 27271572 miR-205 and miR-373 may differentially contribute to the aggressive phenotype of MAC in CRC. +genetics_overexpression_promote hsa-mir-373 Colorectal Carcinoma 27271572 miR-205 and miR-373 may differentially contribute to the aggressive phenotype of MAC in CRC. +genetics_overexpression_promote hsa-mir-206 Alzheimer Disease 27277332 miRâ€?06 upregulation enhanced LPS‑induced inflammation and Aβ release in microglia +genetics_overexpression_promote hsa-mir-21 Neuroblastoma 27285119 "Forced overexpression of miR-21 significantly increased NB cell proliferation, migration, and invasion." +genetics_overexpression_promote hsa-mir-18a "Squamous Cell Carcinoma, Esophageal" 27291152 upregulation of miR-18a promoted cell proliferation by increasing cylin D1 +genetics_overexpression_promote hsa-mir-429 Diabetes Mellitus 27299781 "increased miR-429 could down-regulate the expression of Ocln by targeting the Ocln 3'-UTR, which impaired intestinal barrier function in DM mice." +genetics_overexpression_promote hsa-mir-9 Influenza 27322373 Overexpression of miR-9 enhanced viral gene expression and production of infectious progeny +genetics_overexpression_promote hsa-mir-222 Gastric Neoplasms 27323780 "Gastrin-induced miR-222 overexpression resulted in reduced expression and cytoplasmic mislocalisation of p27kip1, which in turn caused actin remodelling and increased migration in AGSGR cells." +genetics_overexpression_promote hsa-mir-19a Glioma 27329239 Overexpression of miR-19a by a miR-19a mimic promoted glioma cell proliferation and invasion. +genetics_overexpression_promote hsa-mir-548a "Carcinoma, Hepatocellular" 27340352 "overexpression of miR-548a-5p in HCC cell lines promoted cell proliferation, increased colony forming ability and hampered cell apoptosis." +genetics_overexpression_promote hsa-mir-29a Atrial Fibrillation 27341015 miR-29a-3p transfection in cardiomyocytes produced the effects on the ICa +genetics_overexpression_promote hsa-mir-301b Lung Neoplasms 27352910 "ectopic expression of miR-301b enhanced cell population growth, reduced apoptosis and reduced sensitivity of cells to chemotherapy." +genetics_overexpression_promote hsa-mir-20a Uveal Melanoma 27356499 "miRâ€?0a mimics were transfected into UM cells, which led to increases in cell growth, migration and invasion activities." +genetics_overexpression_promote hsa-mir-92a "Carcinoma, Nasopharyngeal" 27366095 miR-92a overexpression potentiated the migration and invasion of 6-10B cells +genetics_overexpression_promote hsa-mir-340 Gastric Neoplasms 27374211 "Functionally, forced expression of miR-340 promoted cell viability, proliferation, colony formation and cell cycle progression in the SGC-7901 cells" +genetics_overexpression_promote hsa-mir-21 Cholesteatoma 27376830 miR-21 promotes the proliferation and invasion of cholesteatoma keratinocytes. +genetics_overexpression_promote hsa-mir-488 Osteosarcoma 27376839 "We also found that exogenous over-expression of microRNA-488 promotes the proliferation, reduces the apoptosis and decreases the sensitivity to chemotherapy (doxorubicin) of osteosarcoma cells" +genetics_overexpression_promote hsa-mir-205 Myelodysplastic Syndromes 27379838 Our findings suggest that miR-205-5p upregulation contributes to MDS by suppressing PTEN and that miR-205-5p thus acts as an oncogene in hematopoietic cells. +genetics_overexpression_promote hsa-mir-181b Gastric Neoplasms 27383203 Overexpression of miR-181b mimic induced an in vitro EMT-like change to a phenotype similar to that following TGF-β treatment alone and was reversed by miRNA-181b inhibitor. +genetics_overexpression_promote hsa-mir-27a Gastric Neoplasms 27409164 "And overexpression of miR-27a-3p, but not miR-27a-5p, markedly promoted gastric cancer cell proliferation in vitro as well as tumor growth in vivo." +genetics_overexpression_promote hsa-mir-92a Acute Myocardial Infarction 27411964 "Further, it could be observed in cellular experiments that treatment of miR-92a mimics can further upregulate endothelial injury markers." +genetics_overexpression_promote hsa-mir-92b Bladder Neoplasms 27430302 "In this study, we demonstrated that miR-92b could uniquely promote cell migration and invasion of BCa cells, but had no effect on cell proliferation." +genetics_overexpression_promote hsa-mir-1303 Neuroblastoma 27434867 "miR-1303 overexpression promoted the proliferation of SH-SY5Y NB cell investigated by MTT assay, colony formation assay and anchorage-independent growth ability assay, while miR-1303 knockdown reduced this effect." +genetics_overexpression_promote hsa-mir-146a Cerebral Ischemia 27449900 "In conclusion, our study revealed that miR-146a contributes to OGD/R injury in vitro." +genetics_overexpression_promote hsa-mir-940 "Carcinoma, Pancreatic" 27459115 Over-expression of microRNA-940 promotes cell proliferation by targeting GSK3β and sFRP1 in human pancreatic carcinoma. +genetics_overexpression_promote hsa-mir-181a Atherosclerosis 27460740 The exogenous overexpression of miR-181a accelerates the apoptosis rates of HUVECs in response to H2O2. +genetics_overexpression_promote hsa-mir-769 Melanoma 27470346 "Overexpression of miR-769 promoted cell proliferation in human melanoma cell line A375, whereas miR-769-in reverses the function." +genetics_overexpression_promote hsa-mir-183 "Carcinoma, Breast" 27476679 Overexpression of miR-183-5p significantly enhanced the cell proliferation and inhibited cell apoptosis in MCF-7 and MDA-MB-231 cells. +genetics_overexpression_promote hsa-mir-194 "Carcinoma, Ovarian" 27486333 "Overexpression of miR-194 in ovarian cancer cells promotes cell proliferation, migration, and invasion; in contrast, inhibition of the expression of miR-194 has the opposite effects." +genetics_overexpression_promote hsa-mir-195 Myocardial Ischemic-Reperfusion Injury 27489501 Up-regulation of miR-195 in ischemic cardiomyocytes promotes ischemic apoptosis by targeting Bcl-2. +genetics_overexpression_promote hsa-mir-363 Glioma 27495233 "Transfection of miR-363 induced cell survival, while inhibition of miR-363 significantly reduced glioma cell viability." +genetics_overexpression_promote hsa-mir-200c "Carcinoma, Gastric" 27498672 "Finally, ectopic expression of miR-200c or knockdown of DNMT3a expression impeded GC cell growth, migration and invasion." +genetics_overexpression_promote hsa-mir-15b "Carcinoma, Hepatocellular" 27499071 "It was observed that high expression of miR-15b promoted cell proliferation of the HCC cells, while low expression of miR-15b suppressed cell growth and induced the apoptosis of HepG2 cells." +genetics_overexpression_promote hsa-mir-17 Macular Degeneration 27505139 Transfection of miR-17-3p mimic in ARPE-19 induced cell death and exacerbated oxidative lethality that was alleviated by miR-17-3p inhibitor. +genetics_overexpression_promote hsa-mir-19b Lung Fibrosis 27508324 "Overexpression of miR-19b in small-airway epithelial cells promoted the mechanical stretch-induced EMT phenotypes, whereas inhibition of miR-19b attenuated it." +genetics_overexpression_promote hsa-mir-1 "Carcinoma, Colon" 27511117 overexpression of PIK3CA-premir1 in HCT116 and SW480 cells resulted in significant reduction of the sub-G1 cell distribution and apoptotic cell rate and resulted in increased cell proliferation. +genetics_overexpression_promote hsa-mir-483 "Carcinoma, Gastric" 27511210 overexpression of miRâ€?83â€?p by transfection with miRâ€?83â€?p mimics significantly increased cell proliferation and Annexin V‑propidium iodide staining indicated the suppression of cell apoptosis. +genetics_overexpression_promote hsa-mir-125b Retinoblastoma 27518550 overexpression of miR-125b apparently promotes RB cell proliferation and migration in vitro. +genetics_overexpression_promote hsa-mir-31 "Squamous Cell Carcinoma, Head and Neck" 27528032 miR-31 associated oncogenicities were rescued by ARID1A expression in HNSCC cells. +genetics_overexpression_promote hsa-mir-15b Neoplasms [unspecific] 27530410 increased miR-15b and decreased RECK expression may contribute to the pathobiology of LYO. +genetics_overexpression_promote hsa-mir-15b Uterine Leiomyoma 27530410 "Our findings suggest that miR-15b negatively regulates RECK expression in LYO, and increased miR-15b and decreased RECK expression may contribute to the pathobiology of LYO." +genetics_overexpression_promote hsa-mir-375 Liver Failure 27531059 "Thus miR-375 is identified as a novel repressor of UGT1A-mediated hepatic acetaminophen glucuronidation through reduced AhR expression, which could predispose some individuals to increased risk for acetaminophen-induced ALF" +genetics_overexpression_promote hsa-mir-181a "Leukemia, Myeloid, Acute" 27531761 Overexpression of miR-181a can promote AML cell proliferation. +genetics_overexpression_promote hsa-mir-29b Hearing Loss 27635430 miR-29b overexpression induces cochlear hair cell apoptosis through the regulation of SIRT1/PGC-1¦Á signaling: Implications for age-related hearing loss. +genetics_overexpression_promote hsa-mir-1288 "Squamous Cell Carcinoma, Esophageal" 27658568 Overexpression of miR-1288 play a key role in thepathogenesis of ESCCs and its modulation may have potential therapeutic value in patients with ESCC +genetics_overexpression_promote hsa-mir-9 Osteosarcoma 27724924 MiR-9 is overexpressed in spontaneous canine osteosarcoma and promotes a metastatic phenotype including invasion and migration in osteoblasts and osteosarcoma cell lines. +genetics_overexpression_promote hsa-mir-760 "Carcinoma, Ovarian" 27726922 MiR-760 overexpression promotes proliferation in ovarian cancer by downregulation of PHLPP2 expression. +genetics_overexpression_promote hsa-mir-182 "Squamous Cell Carcinoma, Head and Neck" 27744260 Overexpression of TP53 mutation-associated microRNA-182 promotes tumor cell proliferation and migration in head and neck squamous cell carcinoma. +genetics_overexpression_promote hsa-mir-138 Obesity 27762728 miR-138/miR-222 Overexpression Characterizes the miRNome of Amniotic Mesenchymal Stem Cells in Obesity. +genetics_overexpression_promote hsa-mir-222 Obesity 27762728 miR-138/miR-222 Overexpression Characterizes the miRNome of Amniotic Mesenchymal Stem Cells in Obesity. +genetics_overexpression_promote hsa-mir-212 "Adenocarcinoma, Pancreatic Ductal" 27814273 Overexpressions of miR-212 are associated with poor prognosis of patients with pancreatic ductal adenocarcinoma. +genetics_overexpression_promote hsa-mir-21 Choriocarcinoma 27922982 "miR-21 Is Overexpressed in Hydatidiform Mole Tissues and Promotes Proliferation, Migration, and Invasion in Choriocarcinoma Cells." +genetics_overexpression_promote hsa-mir-675 "Squamous Cell Carcinoma, Head and Neck" 27994496 Overexpression of lncRNA H19/miR-675 promotes tumorigenesis in head and neck squamous cell carcinoma. +genetics_overexpression_promote hsa-mir-375 Diabetes Mellitus 28017506 Insulin producing cells generation by overexpression of miR-375 in adipose-derived mesenchymal stem cells from diabetic patients. +genetics_overexpression_promote hsa-mir-223 Glioblastoma 28035389 "overexpression of miR-223 increases TMZ chemoresistance, while inhibition of miR-223 with antagomir markedly decreases TMZ chemoresistance in GBM cells" +genetics_overexpression_promote hsa-mir-92a Osteosarcoma 28069547 Overexpression of miR-92a promotes the tumor growth of osteosarcoma by suppressing F-box and WD repeat-containing protein 7. +genetics_overexpression_promote hsa-mir-205 Endometrial Neoplasms 28105153 Overexpression of microRNA-205 predicts lymph node metastasis and indicates an unfavorable prognosis in endometrial cancer. +genetics_overexpression_promote hsa-mir-196b Myelodysplastic Syndromes 28224273 Over-expression of miR-196b-5p is significantly associated with the progression of myelodysplastic syndrome. +genetics_overexpression_promote hsa-mir-214 Osteosarcoma 28260089 Overexpression of miR?214 promotes the progression of human osteosarcoma by regulating the Wnt/¦Â?catenin signaling pathway. +genetics_overexpression_promote hsa-mir-320 Ovarian Neoplasms 28338235 Overexpression of Hsa-miR-320 Is Associated With Invasion and Metastasis of Ovarian Cancer. +genetics_overexpression_promote hsa-mir-10b Colorectal Carcinoma 28345456 Overexpression of miR-10b in colorectal cancer patients: Correlation with TWIST-1 and E-cadherin expression. +genetics_overexpression_promote hsa-mir-221 Ovarian Neoplasms 28350128 Overexpression of miRNA-221 promotes cell proliferation by targeting the apoptotic protease activating factor-1 and indicates a poor prognosis in ovarian cancer. +genetics_overexpression_promote hsa-mir-196b "Carcinoma, Ovarian" 28387653 Overexpression of microRNA-196b Accelerates Invasiveness of Cancer Cells in Recurrent Epithelial Ovarian Cancer Through Regulation of Homeobox A9. +genetics_overexpression_promote hsa-mir-1 Myocardial Infarction 28397788 Over-expression of microRNA-1 causes arrhythmia by disturbing intracellular trafficking system. +genetics_overexpression_promote hsa-mir-34a Colorectal Adenocarcinoma 28624481 "miR-34a overexpression predicts poor prognostic outcome in colorectal adenocarcinoma, independently of clinicopathological factors with established prognostic value." +genetics_overexpression_promote hsa-let-7 "Carcinoma, Hepatocellular" 28796071 Overexpression of microRNA let-7 correlates with disease progression and poor prognosis in hepatocellular carcinoma +genetics_overexpression_promote hsa-let-7a "Carcinoma, Hepatocellular" 28796071 Overexpression of microRNA let-7 correlates with disease progression and poor prognosis in hepatocellular carcinoma +genetics_overexpression_promote hsa-let-7e "Carcinoma, Hepatocellular" 28796071 Overexpression of microRNA let-7 correlates with disease progression and poor prognosis in hepatocellular carcinoma +genetics_overexpression_promote hsa-mir-194 Colorectal Carcinoma 29109785 Overexpression of miR-194 Reverses HMGA2-driven Signatures in Colorectal Cancer. +genetics_overexpression_promote hsa-mir-10b Neoplasms [unspecific] 29262659 "the overexpression of miR-10b was significantly correlated with metastasis status, and indicated the potential clinical use of miR-10b as a molecular biomarker, particularly in assessing prognosis for patients with cancers" +genetics_overexpression_promote hsa-mir-130a "Leukemia, Myeloid, Acute" 29493383 MiR-130a is aberrantly overexpressed in adult acute myeloid leukemia with t(8;21) and its suppression induces AML cell death. +genetics_overexpression_promote hsa-mir-155 "Leukemia, Myeloid, Acute" 29657293 miR-155 overexpression plays a key pathogenic role in some lymphomas and acute myeloid leukemias has led to the development of an antagomir-based approach as a new promising therapeutic strategy +genetics_overexpression_promote hsa-mir-19a Multiple Myeloma 29665917 "miR-19a is overexpressed significantly in Lp-1 and U266 multiple myeloma cells, and promots the proliferation and invasion of the myeloma cells, but inhibits their apoptosis" +genetics_overexpression_promote hsa-mir-34a Pituitary Adenoma 30109259 Overexpression of microRNA-34a Attenuates Proliferation and Induces Apoptosis in Pituitary Adenoma Cells via SOX7. +genetics_overexpression_promote hsa-mir-221 "Carcinoma, Breast" 30110679 Our findings provide strong evidence that miR-9 and miR-221 can enhance the generation of cancer stem cells to yield an invasive phenotype and that overexpression of these miRNAs predicts a poor outcome for breast cancer patients +genetics_overexpression_promote hsa-mir-9 "Carcinoma, Breast" 30110679 Our findings provide strong evidence that miR-9 and miR-221 can enhance the generation of cancer stem cells to yield an invasive phenotype and that overexpression of these miRNAs predicts a poor outcome for breast cancer patients +genetics_overexpression_promote hsa-mir-214 Myeloma 30357841 "Bone marrow fibroblasts overexpress miR-27b and miR-214 in step with multiple myeloma progression, dependent on tumour cell-derived exosomes." +genetics_overexpression_promote hsa-mir-27b Myeloma 30357841 "Bone marrow fibroblasts overexpress miR-27b and miR-214 in step with multiple myeloma progression, dependent on tumour cell-derived exosomes." +genetics_overexpression_promote hsa-mir-301a Colorectal Carcinoma 30362160 Overexpression of miR-301a-3p promotes colorectal cancer cell proliferation and metastasis by targeting deleted in liver cancer-1 and runt-related transcription factor 3. +genetics_overexpression_promote hsa-mir-361 "Adenocarcinoma, Lung" 30365047 Overexpression of miR?361?5p plays an oncogenic role in human lung adenocarcinoma through the regulation of SMAD2. +genetics_overexpression_suppress hsa-mir-125b-1 "Carcinoma, Hepatocellular" 18649363 miR-125b: overexpression of miR-125b in HCC cell line could obviously suppress the cell growth and phosporylation of Akt +genetics_overexpression_suppress hsa-mir-125b-2 "Carcinoma, Hepatocellular" 18649363 miR-125b: overexpression of miR-125b in HCC cell line could obviously suppress the cell growth and phosporylation of Akt +genetics_overexpression_suppress hsa-mir-142 Lung Neoplasms 19228723 "miR-142-5p: were repressed, overexpression can inhibitu lung cancer growth" +genetics_overexpression_suppress hsa-mir-145 Lung Neoplasms 19228723 "miR-145: were repressed, overexpression can inhibitu lung cancer growth" +genetics_overexpression_suppress hsa-mir-34c Lung Neoplasms 19228723 "miR-34c: were repressed, overexpression can inhibitu lung cancer growth" +genetics_overexpression_suppress hsa-mir-100 Ovarian Neoplasms 20081105 "Overexpression of mir-100 inhibited mTOR signaling and enhanced sensitivity to the rapamycin analog RAD001 (everolimus), confirming the key relationship between mir-100 and the mTOR pathway." +genetics_overexpression_suppress hsa-mir-22 Ovarian Neoplasms 20081105 "overexpression of the putative tumor suppressor mir-22 repressed the EVI1 oncogene, which is known to suppress apoptosis by stimulating phosphatidylinositol 3-kinase/v-akt murine thymoma viral oncogene homolog 1 signaling." +genetics_overexpression_suppress hsa-mir-194 Liver Neoplasms 20979124 The overexpression of miR-194 in liver mesenchymal-like cancer cells reduced the expression of the mesenchymal cell marker N-cadherin and suppressed invasion and migration of the mesenchymal-like cancer cells both in vitro and in vivo +genetics_overexpression_suppress hsa-let-7a-1 Hypertrophy 21183740 Thioredoxin 1 Negatively Regulates Angiotensin II-Induced Cardiac Hypertrophy Through Upregulation of miR-98/let-7. +genetics_overexpression_suppress hsa-let-7a-2 Hypertrophy 21183740 Thioredoxin 1 Negatively Regulates Angiotensin II-Induced Cardiac Hypertrophy Through Upregulation of miR-98/let-7. +genetics_overexpression_suppress hsa-let-7a-3 Hypertrophy 21183740 Thioredoxin 1 Negatively Regulates Angiotensin II-Induced Cardiac Hypertrophy Through Upregulation of miR-98/let-7. +genetics_overexpression_suppress hsa-let-7b Hypertrophy 21183740 Thioredoxin 1 Negatively Regulates Angiotensin II-Induced Cardiac Hypertrophy Through Upregulation of miR-98/let-7. +genetics_overexpression_suppress hsa-let-7c Hypertrophy 21183740 Thioredoxin 1 Negatively Regulates Angiotensin II-Induced Cardiac Hypertrophy Through Upregulation of miR-98/let-7. +genetics_overexpression_suppress hsa-let-7d Hypertrophy 21183740 Thioredoxin 1 Negatively Regulates Angiotensin II-Induced Cardiac Hypertrophy Through Upregulation of miR-98/let-7. +genetics_overexpression_suppress hsa-let-7e Hypertrophy 21183740 Thioredoxin 1 Negatively Regulates Angiotensin II-Induced Cardiac Hypertrophy Through Upregulation of miR-98/let-7. +genetics_overexpression_suppress hsa-let-7f-1 Hypertrophy 21183740 Thioredoxin 1 Negatively Regulates Angiotensin II-Induced Cardiac Hypertrophy Through Upregulation of miR-98/let-7. +genetics_overexpression_suppress hsa-let-7f-2 Hypertrophy 21183740 Thioredoxin 1 Negatively Regulates Angiotensin II-Induced Cardiac Hypertrophy Through Upregulation of miR-98/let-7. +genetics_overexpression_suppress hsa-let-7g Hypertrophy 21183740 Thioredoxin 1 Negatively Regulates Angiotensin II-Induced Cardiac Hypertrophy Through Upregulation of miR-98/let-7. +genetics_overexpression_suppress hsa-let-7i Hypertrophy 21183740 Thioredoxin 1 Negatively Regulates Angiotensin II-Induced Cardiac Hypertrophy Through Upregulation of miR-98/let-7. +genetics_overexpression_suppress hsa-mir-98 Hypertrophy 21183740 Thioredoxin 1 Negatively Regulates Angiotensin II-Induced Cardiac Hypertrophy Through Upregulation of miR-98/let-7. +genetics_overexpression_suppress hsa-mir-146a Atherosclerosis 21329689 Over-expression of miR-146a may be useful in the prevention and treatment of atherosclerosis. +genetics_overexpression_suppress hsa-mir-128 Glioblastoma 21358821 "Our analysis predicted a significant association between miR-128 and the protein kinase WEE1, which we subsequently validated experimentally by showing that the over-expression of the naturally under-expressed miR-128 in glioma cells resulted in the inhibition of WEE1 in glioblastoma cells." +genetics_overexpression_suppress hsa-mir-663 Leukemia 21518471 "miRNA-663 in K562 cells is up-regulated after 5-aza treatment. Over-expression of miR-663 can suppress the proliferation of K562 cells, which suggests that miR-663 may possesses suppressive effect for leukaemia." +genetics_overexpression_suppress hsa-mir-146b Lung Neoplasms 21789255 Overexpression of the Lung Cancer-Prognostic miR-146b MicroRNAs Has a Minimal and Negative Effect on the Malignant Phenotype of A549 Lung Cancer Cells. +genetics_overexpression_suppress hsa-mir-199a-1 "Carcinoma, Hepatocellular" 21847633 Lentivirus-Mediated Overexpression of MicroRNA-199a Inhibits Cell Proliferation of Human Hepatocellular Carcinoma. +genetics_overexpression_suppress hsa-mir-199a-2 "Carcinoma, Hepatocellular" 21847633 Lentivirus-Mediated Overexpression of MicroRNA-199a Inhibits Cell Proliferation of Human Hepatocellular Carcinoma. +genetics_overexpression_suppress hsa-mir-16 Acute Lung Injury 22185353 "Accordingly, over-expression of miR-16 could significantly suppress the luciferase activity of reporter fusion with the binding sites of TNF¦Á in its 3'UTR region, suggesting that miR-16 played its role in LPS-induced lung inflammation by a direct manner." +genetics_overexpression_suppress hsa-mir-10a "Leukemia, Myeloid, Acute" 22348345 miR-10a is aberrantly overexpressed in Nucleophosmin1 mutated Acute Myeloid Leukaemia and its suppression induces cell death. +genetics_overexpression_suppress hsa-mir-143 Colon Neoplasms 22362069 "Overexpression of three miRNA (miR200c*, miR143*, and miR424*) significantly abrogated invasive potential." +genetics_overexpression_suppress hsa-mir-200c Colon Neoplasms 22362069 "Overexpression of three miRNA (miR200c*, miR143*, and miR424*) significantly abrogated invasive potential." +genetics_overexpression_suppress hsa-mir-424 Colon Neoplasms 22362069 "Overexpression of three miRNA (miR200c*, miR143*, and miR424*) significantly abrogated invasive potential." +genetics_overexpression_suppress hsa-let-7a-1 Esophageal Neoplasms 22363450 "Curcumin treatment down-regulate the expressions of Notch-1 specific microRNAs miR-21 and miR-34a, and upregulated tumor suppressor let-7a miRNA." +genetics_overexpression_suppress hsa-let-7a-2 Esophageal Neoplasms 22363450 "Curcumin treatment down-regulate the expressions of Notch-1 specific microRNAs miR-21 and miR-34a, and upregulated tumor suppressor let-7a miRNA." +genetics_overexpression_suppress hsa-let-7a-3 Esophageal Neoplasms 22363450 "Curcumin treatment down-regulate the expressions of Notch-1 specific microRNAs miR-21 and miR-34a, and upregulated tumor suppressor let-7a miRNA." +genetics_overexpression_suppress hsa-mir-29a Ovarian Neoplasms 22479643 over-expression of miR-29a in vitro repressed several anti-correlated genes (including DNMT3A and DNMT3B) and substantially decreased ovarian cancer cell viability. +genetics_overexpression_suppress hsa-let-7a-1 Colorectal Carcinoma 22584434 High let-7a microRNA levels in KRAS-mutated colorectal carcinomas may rescue anti-EGFR therapy effects in patients with chemotherapy-refractory metastatic disease. +genetics_overexpression_suppress hsa-let-7a-2 Colorectal Carcinoma 22584434 High let-7a microRNA levels in KRAS-mutated colorectal carcinomas may rescue anti-EGFR therapy effects in patients with chemotherapy-refractory metastatic disease. +genetics_overexpression_suppress hsa-let-7a-3 Colorectal Carcinoma 22584434 High let-7a microRNA levels in KRAS-mutated colorectal carcinomas may rescue anti-EGFR therapy effects in patients with chemotherapy-refractory metastatic disease. +genetics_overexpression_suppress hsa-mir-92a-1 "Carcinoma, Hepatocellular" 22587342 Oxidative DNA damage correlates with cell immortalization and mir-92 expression in hepatocellular carcinoma. +genetics_overexpression_suppress hsa-mir-34b "Carcinoma, Lung, Non-Small-Cell" 22593438 Overexpression of miR-34b significantly reduced cell survival at lower than 4 Gy radiation doses. +genetics_overexpression_suppress hsa-mir-223 Rheumatoid Arthritis 22903258 Overexpression of microRNA-223 in rheumatoid arthritis synovium controls osteoclast differentiation. +genetics_overexpression_suppress hsa-let-7b "Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic" 22918121 The enforced expression of let-7b in ALL cell lines with an MLL fusion gene inhibited their growth. +genetics_overexpression_suppress hsa-mir-34a Melanoma 22969970 "These results suggest that overexpression of miR-34a and c suppresses invasive and generative potentials, respectively, in human malignant melanoma." +genetics_overexpression_suppress hsa-mir-34c Melanoma 22969970 "All four melanoma cell lines showed significant expression of miR-34s - A375: miR-34a 0.6176, miR-34b 0.7625, miR-34c 0.7877; " +genetics_overexpression_suppress hsa-mir-124 Medulloblastoma 23172372 "MiR-124 overexpression inhibits the proliferation of medulloblastoma cells, and this effect is mediated mostly through the action of miR-124 upon CDK6." +genetics_overexpression_suppress hsa-mir-142 Gastric Neoplasms 23209550 Overexpression of miR-142-5p and miR-155 in Gastric Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma Resistant to Helicobacter pylori Eradication +genetics_overexpression_suppress hsa-mir-155 Gastric Neoplasms 23209550 Overexpression of miR-142-5p and miR-155 in Gastric Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma Resistant to Helicobacter pylori Eradication +genetics_overexpression_suppress hsa-mir-19b Cardiovascular Diseases [unspecific] 23443808 "Overexpression of miR-19b inhibited activation of the Wnt/¦Â-catenin signaling pathway in P19 cells, which may regulate cardiomyocyte differentiation." +genetics_overexpression_suppress hsa-mir-133a Hypertension 23460283 "In vitro overexpression of miR-27a,-29a, and -133a inhibited cardiomyocyte hypertrophy and reduced collagen expression. " +genetics_overexpression_suppress hsa-mir-27a Hypertension 23460283 "In vitro overexpression of miR-27a,-29a, and -133a inhibited cardiomyocyte hypertrophy and reduced collagen expression. " +genetics_overexpression_suppress hsa-mir-29a Hypertension 23460283 "In vitro overexpression of miR-27a,-29a, and -133a inhibited cardiomyocyte hypertrophy and reduced collagen expression. " +genetics_overexpression_suppress hsa-mir-155 Ovarian Neoplasms 23523916 overexpression of miR-155 may prevent tumorigenesis in human ovarian cancer through downregulation of CLDN1. +genetics_overexpression_suppress hsa-mir-138-1 Neuroblastoma 23562653 miR-138 Overexpression is more powerful than hTERT knockdown to potentiate apigenin for apoptosis in neuroblastoma in vitro and in vivo +genetics_overexpression_suppress hsa-mir-138-2 Neuroblastoma 23562653 miR-138 Overexpression is more powerful than hTERT knockdown to potentiate apigenin for apoptosis in neuroblastoma in vitro and in vivo +genetics_overexpression_suppress hsa-mir-34a Gastric Neoplasms 24068565 "miR-34a over-expression could improve the sensitivity of gastric cancer cells against cisplatin-based chemotherapies, with PI3K/AKT/survivin signaling pathway possibly involved in the mechanism." +genetics_overexpression_suppress hsa-mir-181b Atherosclerosis 24084690 overexpression of miR-181b in the aortic intima of apolipoprotein E-deficient mice and suppressed NF-¦ÊB signaling revealed by bioluminescence imaging and reduced target gene expression in the aortic arch in apolipoprotein E-deficient/NF-¦ÊB-luciferase transgenic mice. +genetics_overexpression_suppress hsa-mir-129 Medulloblastoma 24093088 Overexpression of miR-129-5p using mimics decreased DAOY proliferation +genetics_overexpression_suppress hsa-let-7a Neoplasms [unspecific] 24100239 Human Argonaute-3 specifically enhances the passenger strand expression and activity of the tumor suppressor microRNA let-7a. +genetics_overexpression_suppress hsa-mir-486 Breast Neoplasms 24104550 "in vitro functional screening of the downregulated miRNAs in non-malignant and breast cancer cell lines identified several possible tumor suppressor miRNAs, including miR-193b, miR-193a-3p, miR-126, miR-134, miR-132, miR-486-5p, miR-886-3p, miR-195 and miR-497, showing reduced growth when re-expressed in cancer cells" +genetics_overexpression_suppress hsa-let-7a "Diabetes Mellitus, Type 2" 24105413 "Expression of microRNA let-7a and let-7d, which are direct translational repressors of the IL-13 gene, was increased in skeletal muscle from T2DM patients. " +genetics_overexpression_suppress hsa-mir-200c Melanoma 24120113 Overexpression of microRna-200c in CD44+CD133+ CSCS inhibits the cellular migratory and invasion as well as tumorigenicity in mice. +genetics_overexpression_suppress hsa-mir-145 Melanoma 24248543 Overexpression of miR-145 increases the sensitivity of vemurafenib in drug-resistant colo205 cell line. +genetics_overexpression_suppress hsa-mir-449a "Adenocarcinoma, Gastric" 24260067 The overexpression of miR-449a inhibited gastric adenocarcinoma cell growth and promoted cell apoptosis in the MGC-803 and SGC-7901 gastric adenocarcinoma cell lines. +genetics_overexpression_suppress hsa-let-7a Ewing Sarcoma 24383407 "Restored let-7a expression inhibited cell proliferation, migration, as well as invasion; arrested cell cycle progression; and induced cell apoptosis of both cell lines." +genetics_overexpression_suppress hsa-mir-133b Gastric Neoplasms 24443799 MiR-133b is frequently decreased in gastric cancer and its overexpression reduces the metastatic potential of gastric cancer cells. +genetics_overexpression_suppress hsa-mir-24 Heart Failure 24454859 "In vivo delivery of miR-24 into a mouse MI model suppressed cardiac cell death, attenuated infarct size, and rescued cardiac dysfunction." +genetics_overexpression_suppress hsa-mir-34a "Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal" 24482044 Ectopic expression of miR-34a and miR-34c in Hep-2 cells significantly induced the cell proliferation and migration ability in vitro. +genetics_overexpression_suppress hsa-mir-34c "Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal" 24482044 Ectopic expression of miR-34a and miR-34c in Hep-2 cells significantly induced the cell proliferation and migration ability in vitro. +genetics_overexpression_suppress hsa-mir-107 Breast Neoplasms 24482686 "Overexpression of miR-107 suppressed MDA-MB-231 cell proliferation and migration, meanwhile the cells were arrested at G0/G1 phase." +genetics_overexpression_suppress hsa-mir-7 Liver Neoplasms 24491049 "Over-expression of miR-7 could significantly inhibit the growth of human lung cancer cells in vivo and in vitro, which might be related to the down-regulated expression of tumor growth-associated protein CGGBP1." +genetics_overexpression_suppress hsa-mir-21 Atherosclerosis 24502419 "Further analysis confirmed that overexpression of miR-21 by transfection with miR-21 mimics notably attenuated lipid accumulation and lipid-laden foam cell formation in LPS-stimulated macrophages, which was reversely up-regulated when silencing miR-21 expression via anti-miR-21 inhibitor transfection, indicating a reverse regulator of miR-21 in LPS-induced foam cell formation." +genetics_overexpression_suppress hsa-let-7c Ovarian Neoplasms 24507678 "After application of let-7c, number of T29A2+ cell clones was decreased significantly, however, after the application of Anti-let-7, the number of clones restored, and there was no significant difference compared with the negative control group." +genetics_overexpression_suppress hsa-mir-29a Diabetes Mellitus 24578127 "Diabetic miR-29a transgenic mice had better nephrin levels, podocyte viability, and renal function and less glomerular fibrosis and inflammation reaction compared with diabetic wild-type mice." +genetics_overexpression_suppress hsa-mir-206 Ovarian Neoplasms 24604205 microRNA-206 overexpression inhibits cellular proliferation and invasion of estrogen receptor ¦Á-positive ovarian cancer cells. +genetics_overexpression_suppress hsa-mir-183 Neuropathic Pain 24612023 "Intrathecal administration of lentivirions expressing miR-183 downregulated SNL-induced increases in the expression of Nav1.3 and brain-derived neurotrophic factor (BDNF), which correlated with the significant attenuation of SNL-induced mechanical allodynia." +genetics_overexpression_suppress hsa-mir-143 Leukemia 24626955 Overexpression of microRNA-143 inhibits growth and induces apoptosis in human leukemia cells. +genetics_overexpression_suppress hsa-mir-499 Heart Failure 24646523 "We report that cardiac-abundant miR-499 could protect neonatal rat cardiomyocytes against H 2O 2-induced apoptosis. Increased miR-499 level favored survival, while decreased miR-499 level favored apoptosis." +genetics_overexpression_suppress hsa-mir-499 Myocardial Infarction 24646523 "We report that cardiac-abundant miR-499 could protect neonatal rat cardiomyocytes against H 2O 2-induced apoptosis. Increased miR-499 level favored survival, while decreased miR-499 level favored apoptosis." +genetics_overexpression_suppress hsa-mir-155 Glioblastoma 24705102 "Over-expression of miR-136 and miR-634 miRNAs negatively affected proliferation, but not migration, while expression of miR-155 reduced migration but did not affect the proliferation of LN229 cells." +genetics_overexpression_suppress hsa-mir-155 Arthritis 24708712 Overexpression of miR-155 in the gouty SFMC leads to suppress SHIP-1 levels and enhance proinflammatory cytokines. +genetics_overexpression_suppress hsa-mir-34a "Carcinoma, Renal Cell" 24765202 "The Cell Counting Kit-8 identified that transient forced expression of miR-34a inhibited cell growth and resulted in cell cycle arrest, which was evaluated by flow cytometry." +genetics_overexpression_suppress hsa-mir-206 "Carcinoma, Hepatocellular" 24919811 "MicroRNA-206 overexpression promotes apoptosis, induces cell cycle arrest and inhibits the migration of human hepatocellular carcinoma HepG2 cells." +genetics_overexpression_suppress hsa-mir-99a Bladder Neoplasms 24944696 "It was found that miRNA-99a inhibits cell proliferation, migration and invasion in T24 and EJ cells." +genetics_overexpression_suppress hsa-mir-34a Glioma 24944883 "Ectopic expression of miR-34a in glioma stem cell-lines HNGC-2 and NSG-K16 decreased the proliferative and migratory potential of these cells, induced cell cycle arrest and caused apoptosis." +genetics_overexpression_suppress hsa-mir-146a Ischemia-Reperfusion Injury 24987958 "Overexpression of miR-146a directly decreased IRAK1 and TRAF6 expression and attenuated the release of proinflammatory cytokines through the inactivation of NF-κB P65 in hypoxia/reoxygenation (H/R)-induced macrophages, RAW264.7 cells." +genetics_overexpression_suppress hsa-let-7 Pancreatic Neoplasms 25017900 "Sulforaphane, quercetin and catechins complement each other in elimination of advanced pancreatic cancer by miR-let-7 induction and K-ras inhibition." +genetics_overexpression_suppress hsa-mir-7 Neurodegenerative Diseases [unspecific] 25071443 "Overexpression of miR-7 or miR-153 by adenoviral transduction protected cortical neurons from MPP(+)-induced toxicity, restored neuronal viability and anti-apoptotic BCL-2 protein levels while attenuated activation of caspase-3." +genetics_overexpression_suppress hsa-mir-155 Cerebral Malaria 25189739 AAV8-mediated in vivo overexpression of miR-155 enhances the protective capacity of genetically attenuated malarial parasites. +genetics_overexpression_suppress hsa-let-7d "Carcinoma, Renal Cell" 25193015 "Functional studies indicated that ectopic expression of let-7d significantly inhibited RCC cell proliferation, migration, and peripheral blood monocyte (PBMC) recruitment in vitro, as well as tumor growth, metastasis, and tumor macrophage infiltration in vivo." +genetics_overexpression_suppress hsa-let-7g Osteosarcoma 25197332 "Functional investigation revealed both restoration of let-7g and silencing Aurora-B induce cell apoptosis and suppressed cell viability, migratory and invasive ability in OS cells." +genetics_overexpression_suppress hsa-mir-449a "Carcinoma, Gastric" 25202363 The level of MGC-803 cell proliferation was decreased and the apoptosis level was increased by the upregulation of miR-449a expression +genetics_overexpression_suppress hsa-mir-200b Hypertrophic Scar 25228082 Overexpression of miR-200b inhibits the cell proliferation and promotes apoptosis of human hypertrophic scar fibroblasts in vitro. +genetics_overexpression_suppress hsa-mir-206 "Squamous Cell Carcinoma, Oral" 25246801 "upregulation of miR-206 in Tca8113 cells was able to reduce cell proliferation, invasion, and migration and promote cell apoptosis in vitro." +genetics_overexpression_suppress hsa-mir-200c Lung Neoplasms 25277203 miR-200c overexpression is associated with better efficacy of EGFR-TKIs in non-small cell lung cancer patients with EGFR wild-type. +genetics_overexpression_suppress hsa-mir-21 Ischemia-Reperfusion Injury 25322693 miR-21 is endowed with anti-apoptotic properties by suppressing the expression of PDCD4 gene and active caspase 3/8 fragments in the condition of renal IRI. +genetics_overexpression_suppress hsa-mir-7 Lung Neoplasms 25334070 "Restoration of miR-7 inhibited 3LL cell proliferation, induced cell apoptosis in vitro and reduced tumorigenicity in vivo." +genetics_overexpression_suppress hsa-mir-30b "Carcinoma, Laryngeal" 25356506 Overexpression of microRNA-30b improves adenovirus-mediated p53 cancer gene therapy for laryngeal carcinoma. +genetics_overexpression_suppress hsa-mir-218 "Carcinoma, Hepatocellular" 25374061 Overexpression of miR-218 inhibits hepatocellular carcinoma cell growth through RET. +genetics_overexpression_suppress hsa-let-7g "Carcinoma, Hepatocellular" 25435961 "the overexpression of let-7g/i significantly suppressed DNA replication, inhibited cell proliferation and promoted apoptosis of BEL-7402 hepatoma cells." +genetics_overexpression_suppress hsa-let-7i "Carcinoma, Hepatocellular" 25435961 "the overexpression of let-7g/i significantly suppressed DNA replication, inhibited cell proliferation and promoted apoptosis of BEL-7402 hepatoma cells." +genetics_overexpression_suppress hsa-mir-133a Myocardial Infarction 25465869 "miR-133a overexpression protected CPCs against cell death, targeting, among others, the proapoptotic genes Bim and Bmf." +genetics_overexpression_suppress hsa-mir-150 Myocardial Infarction 25466411 "In vivo studies showed that overexpression of miR-150 in mice resulted in improved cardiac function, reduced myocardial infarction size, inhibition of apoptosis, and reduced inflammatory Ly-6C(high) monocyte invasion levels after AMI." +genetics_overexpression_suppress hsa-let-7b Gastric Neoplasms 25510669 "Ectopic expression of let-7b suppressed the growth, migration, invasion, and tumorigenicity of GC cells, whereas let-7b knockdown promoted these phenotypes." +genetics_overexpression_suppress hsa-mir-16 Glioma 25511497 miR-16 can significantly inhibit the in vivo growth of U87MG glioma. +genetics_overexpression_suppress hsa-let-7 Gastric Neoplasms 25549793 There were significant negative correlations between serum let-7c and its target gene PGC expression +genetics_overexpression_suppress hsa-mir-10a Congenital Diaphragmatic Hernia 25563880 Human fetal hypoplastic CDH lungs have a specific miR-200/miR-10a signature. Survival after FETO is associated with increased miR-200 family expression. miR-200b overexpression in CDH lungs results in decreased TGF-¦Â/SMAD signaling. +genetics_overexpression_suppress hsa-mir-200 Congenital Diaphragmatic Hernia 25563880 Human fetal hypoplastic CDH lungs have a specific miR-200/miR-10a signature. Survival after FETO is associated with increased miR-200 family expression. miR-200b overexpression in CDH lungs results in decreased TGF-¦Â/SMAD signaling. +genetics_overexpression_suppress hsa-mir-200b Congenital Diaphragmatic Hernia 25563880 Human fetal hypoplastic CDH lungs have a specific miR-200/miR-10a signature. Survival after FETO is associated with increased miR-200 family expression. miR-200b overexpression in CDH lungs results in decreased TGF-¦Â/SMAD signaling. +genetics_overexpression_suppress hsa-mir-146b Cervical Neoplasms 25572123 "miRâ€?46bâ€?p was able to inhibit the proliferative, invasive and adhesive potential and block the cell cycle progression of Caski human cervical cancer cells" +genetics_overexpression_suppress hsa-mir-143 Osteosarcoma 25576341 Forced miR-143 expression significantly inhibited tumor growth in xenograft SAOS-2-Dox and U2OS-Dox animal models. +genetics_overexpression_suppress hsa-let-7b Uveal Melanoma 25588203 We then confirmed that let-7b mimics could inhibit UM growth both in vitro and in vivo. +genetics_overexpression_suppress hsa-mir-214 Ischemia-Reperfusion Injury 25593579 Transfection of miR-214 mimic showed protective effects on OGD-induced injury to H9c2 cells by reducing apoptosis +genetics_overexpression_suppress hsa-mir-17 Melanoma 25594054 "The melanoma tumors formed in mice overexpressing miR-17 were less than that in wild type mice. In addition, the miR-17 tumors were less invasive and less angiogenic." +genetics_overexpression_suppress hsa-let-7 Neoplasms [unspecific] 25597880 let-7 microRNA would be involved in over-expression of cofilin-1 mediated tumor suppression in vitro and in vivo. +genetics_overexpression_suppress hsa-mir-30a Hepatitis B Virus Infection 25620738 "HBx induces autophagosome formation via beclin-1 expression, whereas miRNA-30a overexpression could successfully inhibit the beclin-1 expression induced by HBx, thereby modulating autophagosome formation in hepatic cells." +genetics_overexpression_suppress hsa-mir-29a Glioblastoma 25625222 "Exogenous miR-29s substantially inhibited the proliferation, migration and invasion of U87MG cells, and promoted their apoptosis." +genetics_overexpression_suppress hsa-mir-135a Medulloblastoma 25639612 "Remarkably, enforced expression of miR-135a in HT CSCs strongly inhibited tumorigenesis by repressing the miR-135a direct target gene Arhgef6." +genetics_overexpression_suppress hsa-mir-133a Heart Failure 25658461 transfecting MSCs with miR-133a mimic improves survival of MSCs as determined by the MTT assay. +genetics_overexpression_suppress hsa-mir-124 Osteosarcoma 25667613 "transfection of miR-124 mimic into MG63 cells was able to reduce cell proliferation, invasion and migration, and promote cell apoptosis." +genetics_overexpression_suppress hsa-mir-184 "Carcinoma, Renal Cell" 25667660 "Our studies revealed that miR-184 mimic significantly inhibits cell migration, suppresses cell proliferation and induces renal cancer cell apoptosis in vitro when compared with the negative control (P<0.05)." +genetics_overexpression_suppress hsa-mir-16 Breast Neoplasms 25672252 "Overexpression of microRNA-16 declines cellular growth, proliferation and induces apoptosis in human breast cancer cells." +genetics_overexpression_suppress hsa-mir-1 "Squamous Cell Carcinoma, Esophageal" 25672418 Downregulation of microRNA-1 in esophageal squamous cell carcinoma correlates with an advanced clinical stage and its overexpression inhibits cell migration and invasion. +genetics_overexpression_suppress hsa-mir-150 "Leukemia, Lymphoblastic, Acute" 25687053 "miR-150 may be a putative oncoprotein in T-ALL cells. Overexpression of miR-150 has noticeable effects on the proliferation inhibition and apoptosis induction of Jurkat cells, which may be mediated by the negative regulation of PI3K/Akt /NF-¦ÊB signaling pathway." +genetics_overexpression_suppress hsa-mir-21 Immune System Disease [unspecific] 25688245 miR-21 has emerged as a key mediator of the anti-inflammatory response in macrophages. +genetics_overexpression_suppress hsa-mir-203 Brain Disease [unspecific] 25723469 enforced expression of miR-203 or MyD88 siRNA silencing inhibits downstream NF-¦Ê¦Â signaling and microglia activation +genetics_overexpression_suppress hsa-mir-126 Spinal Cord Injuries 25724143 "increased levels of miR-126 promoted angiogenesis, and inhibited leukocyte extravasation into the injured spinal cord" +genetics_overexpression_suppress hsa-let-7f Glioma 25735962 "The enhanced expression of Let-7f suppressed glioma cells proliferation, migration, and invasion via direct targeting perisotin oncogenic activity." +genetics_overexpression_suppress hsa-mir-122 Liver Neoplasms 25762642 "miR-107, mir-122, miR-29, miR-365 and miR-802 exhibited weak to moderate tumor suppressor potential." +genetics_overexpression_suppress hsa-mir-210 Cerebral Ischemia 25783636 Rats treated with VNS showed increased miR-210 expression as well as decreased apoptosis and antioxidant stress responses compared with the I/R group +genetics_overexpression_suppress hsa-mir-29b Prostate Neoplasms 25784815 forced expression of miR-29b inhibited cell proliferation and cell invasion and induced cell apoptosis in PCa. +genetics_overexpression_suppress hsa-mir-184 Retinal Neovascularization 25796186 miR-184 mimic inhibits Wnt signaling in the OIR retina +genetics_overexpression_suppress hsa-mir-26a Nervous System Diseases [unspecific] 25808510 We found that miR-26a up-regulation promoted neurite outgrowth and reduced apoptosis in bupivacaine-injured DRG neurons. +genetics_overexpression_suppress hsa-mir-21 Myocardial Infarction 25809568 "In miR-21 group, myocardial infarct size reduced by 36.9% in comparison with LV-GFP group." +genetics_overexpression_suppress hsa-let-7a Breast Neoplasms 25846193 "Cell proliferation, colony formation, migration and invasion were decreased after overexpression of let-7a in breast cancer cells and vice versa." +genetics_overexpression_suppress hsa-mir-193b Adenovirus Infection 25854561 The over-expression of miR-193b may suppress the proliferation of K562 cells. +genetics_overexpression_suppress hsa-mir-206 Medulloblastoma 25859932 "MiR-206, a Cerebellum Enriched miRNA Is Downregulated in All Medulloblastoma Subgroups and Its Overexpression Is Necessary for Growth Inhibition of Medulloblastoma Cells." +genetics_overexpression_suppress hsa-mir-26a Graft-Versus-Host Disease 25865461 The prolonged allograft survival induced by LV-Mir-26a was also completely abrogated by IL-6 overexpression. +genetics_overexpression_suppress hsa-let-7a "Carcinoma, Nasopharyngeal" 25884389 "synthetic let-7a mimics suppressed NPC cells migration, invasion and EMT process and knockdown of HMGA2 was consistent with the effects of let-7a in NPC cells." +genetics_overexpression_suppress hsa-mir-146a Atherosclerosis 25904598 cellular enrichment of miR-146a through the systemic delivery of miR-146a mimetics in Apoe(-/-)Ldlr(-/-) and Ldlr(-/-) mice attenuated monocyte/macrophage activation and atherosclerosis in the absence of plasma lipid reduction. +genetics_overexpression_suppress hsa-mir-145 Malignant Neoplasms [unspecific] 25926306 "cell proliferation level of OS-732 with microRNA-145 overexpression was significantly decreased, and OS-732 cell invasion capacity was also significantly decreased" +genetics_overexpression_suppress hsa-mir-145 Prostate Neoplasms 25951106 Overexpression of miR-145-5p inhibits proliferation of prostate cancer cells and reduces SOX2 expression. +genetics_overexpression_suppress hsa-mir-133a Heart Failure 25960234 The miR-133a mimic and miR-133a overexpression significantly caused a decrease in the fibrosis of heart in chronic heart failure rats. +genetics_overexpression_suppress hsa-mir-138 "Carcinoma, Gallbladder" 25962180 Expression of miR-138 is frequently reduced in gallbladder carcinoma when compared to normal cells. Overexpression of miR-138 inhibited cell proliferation by directly suppressing the expression of Bag-1. These results suggest that miR-138 plays an important role in inhibiting the growth of gallbladder carcinoma. +genetics_overexpression_suppress hsa-mir-95 "Adenocarcinoma, Lung" 25971210 Overexpression of microRNA-95-3p suppresses brain metastasis of lung adenocarcinoma through downregulation of cyclin D1. +genetics_overexpression_suppress hsa-mir-202 Multiple Myeloma 25971527 The growth rate of miR-202 mimics transfection cells was significantly lower than that of non-transfected cells. +genetics_overexpression_suppress hsa-mir-133a Vascular Hypertrophy 25995211 delivery of miR-1 and miR-133a suppressed inducible cAMP early repressor expression and prevented both electrical remodeling and hypertrophy. +genetics_overexpression_suppress hsa-mir-100 Osteosarcoma 26018508 Overexpression of miR-100 inhibits growth of osteosarcoma through FGFR3. +genetics_overexpression_suppress hsa-mir-214 Ischemia-Reperfusion Injury 26025394 214 may participate in the protective function of ischemic post conditioning by down regulating HIF1AN. +genetics_overexpression_suppress hsa-mir-16 Sarcoma [unspecific] 26044957 "miR-16, but not other downregulated miRNAs, was able to significantly suppress both migration and invasion in vitro" +genetics_overexpression_suppress hsa-mir-146a Sepsis 26048146 In vivo transfection of LmiR-146a attenuated sepsis-induced cardiac dysfunction. +genetics_overexpression_suppress hsa-mir-506 Breast Neoplasms 26059632 "MiR-506 over-expression significantly inhibits the proliferation,colony formation, and migration of breast cancer cells. miR-506 over-expression may thus be able to improve the malignant phenotype of breast cancer cells." +genetics_overexpression_suppress hsa-mir-16 "Adenocarcinoma, Lung" 26064212 enforced expression of mir-16 lead to reduced A549 cell proliferation and promote apoptosis. +genetics_overexpression_suppress hsa-mir-195 Colorectal Carcinoma 26064276 has-miR-195 can promote cell apoptosis and inhibit the invasion and metastasis by inhibiting the expression of Bcl-2. +genetics_overexpression_suppress hsa-mir-98 Neuroinflammation 26126865 "Overexpression of let-7 and miR-98 in vitro and in vivo resulted in reduced leukocyte adhesion to and migration across endothelium, diminished expression of pro-inflammatory cytokines, and increased BBB tightness, attenuating barrier 'leakiness' in neuroinflammation conditions." +genetics_overexpression_suppress hsa-mir-138 Cardiovascular Diseases [unspecific] 26129883 over-expression of miR-138 significantly enhanced the cell growth and significantly attenuated the cell apoptosis in hypoxic conditions. +genetics_overexpression_suppress hsa-mir-29a Prostate Neoplasms 26131109 "enforced expression of miR-29a in PC-3 and LNCaP cells inhibited proliferation, and induced apoptosis by repressing the expression of KDM5B." +genetics_overexpression_suppress hsa-mir-146a Sepsis 26138422 "Up-regulation of miR-146a inhibit the release of the inflammatory cytokine TNF-α stimulated by sepsis, and alleviate inflammatory reaction and lung tissue injury in mice with sepsis-induced ALI." +genetics_overexpression_suppress hsa-mir-27b Cardiovascular Diseases [unspecific] 26161255 miR-27b mimic had overall beneficial effects +genetics_overexpression_suppress hsa-mir-573 Rheumatoid Arthritis 26166764 miR-573 overexpression suppressed the expression of interleukin 6 (IL-6) and cyclooxygenase 2 in RASFs +genetics_overexpression_suppress hsa-mir-137 Melanoma 26186482 overexpression of miR-137 inhibited the proliferation of melanoma cells +genetics_overexpression_suppress hsa-mir-34c Diabetic Nephropathy 26191142 miR-34c was downregulated and that overexpression of miR-34c inhibited HG-induced podocyte apoptosis. +genetics_overexpression_suppress hsa-mir-221 Astrocytoma 26191177 Overexpression of miR-221 inhibits proliferation and promotes apoptosis of human astrocytoma cells. +genetics_overexpression_suppress hsa-mir-23b Neoplasms [unspecific] 26198058 "miR-23b, miR-199a, and miR-15a displayed increased expression during early AVC development whereas others such as miR-130a and miR-200a display decreased expression levels" +genetics_overexpression_suppress hsa-mir-26a "Diabetes Mellitus, Type 2" 26208605 Mir-26a suppresses autoimmune diabetes in NOD mice in part through promoted regulatory T cells (Tregs) expression. +genetics_overexpression_suppress hsa-mir-140 Osteosarcoma 26219893 "relative miR-140 expression was increased, cell proliferation was inhibited, cell population in G0/G1 phase was increased, cell population in G2/M phase and S phases and proliferation index (PI), and cell migration distance were decreased in the miR-140 mimic group" +genetics_overexpression_suppress hsa-mir-210 Osteoarthritis 26244598 "Transfection with miR-210 mimic inhibited LPS-induced pro-inflammatory cytokines production, cell viability reduction and cell apoptosis." +genetics_overexpression_suppress hsa-mir-1 Vascular Hypertrophy 26253469 the administration of a miR-1 mimic attenuated cardiac hypertrophy by suppressing the transverse aortic constriction-induced increase in myocardin expression +genetics_overexpression_suppress hsa-mir-302b "Carcinoma, Hepatocellular" 26254095 Overexpression of miR-302b suppressed HCC cell invasion and metastasis. +genetics_overexpression_suppress hsa-mir-143 Prostate Neoplasms 26269764 "miR-143 has an inhibitory effect on cell proliferation as evidenced by decreased cell viability, increased cell apoptosis and cell cycle arrest at the G1/S transition." +genetics_overexpression_suppress hsa-mir-125a Colon Neoplasms 26297542 overexpression of miR-125a-5p inhibited cell proliferation and induced cell apoptosis in colon cancer cells. +genetics_overexpression_suppress hsa-mir-31 "Adenocarcinoma, Lung" 26299665 overexpression of miR-31 led to the inhibition of adenocarcinoma cell proliferation. +genetics_overexpression_suppress hsa-mir-206 "Carcinoma, Lung, Non-Small-Cell" 26309565 "Forced overexpression of miR-206 significantly inhibited cell proliferation, migration and invasion of NSCLC cells." +genetics_overexpression_suppress hsa-mir-26a Ischemia-Reperfusion Injury 26320674 Mir-26a overexpression results in attenuated cardiac IR injury and inhibited HMGB1 expression. +genetics_overexpression_suppress hsa-mir-33b Colorectal Carcinoma 26329295 miR-33b inhibited tumor cell growth and induced cell cycle arrest. +genetics_overexpression_suppress hsa-mir-9 Inflammation 26354749 "miR-9 overexpression significantly repressed NF-κB expression and, thereby, suppressed inflammation but promoted LEC tube formation" +genetics_overexpression_suppress hsa-mir-9 Spinal Cord Injuries 26359086 miR-9 overexpression promoted osteoblast differentiation and angiogenesis +genetics_overexpression_suppress hsa-mir-634 Cervical Neoplasms 26367112 "miR-634 inhibited cell proliferation, migration and invasiveness in cervical cancer cells and the block of miR-634 enhances the mTOR expression at both the mRNA and protein levels which regulated the expression of mTOR negatively." +genetics_overexpression_suppress hsa-mir-16 Glioblastoma 26373393 "Overexpression of microRNA- 16 in the A172 and U87 GBM cell lines inhibited the activities of co-cultured endothelial cells, including proliferation, migration, extension and tubule formation." +genetics_overexpression_suppress hsa-mir-145 Glioblastoma 26374689 "CSCs expressed low levels of miR-145, and its introduction decreased self-renewal through reductions in AKT signaling and stem cell marker (SOX2, OCT4, and NANOG) expression" +genetics_overexpression_suppress hsa-mir-449a Liver Neoplasms 26375440 "Overexpression of miR-449a inhibited cell proliferation, induced G1 phase arrest and cell apoptosis in liver cancer." +genetics_overexpression_suppress hsa-mir-1 Myocardial Infarction 26380976 miR-1 and -21 jointly blocked hypoxia-induced cardiomyocytes apoptosis. +genetics_overexpression_suppress hsa-mir-21 Myocardial Infarction 26380976 miR-1 and -21 jointly blocked hypoxia-induced cardiomyocytes apoptosis. +genetics_overexpression_suppress hsa-mir-16 "Carcinoma, Nasopharyngeal" 26383521 "we identified upregulation of tumor suppressor miR-16a, which inhibited cell cycle progression and sensitized NPC cells to chemotherapy." +genetics_overexpression_suppress hsa-mir-221 Ischemia-Reperfusion Injury 26396139 "Mimics of miRNA-221, -150, and -206 were protective in both H9c2 and NRVM." +genetics_overexpression_suppress hsa-mir-133a "Cardiomyopathy, Hypertrophic" 26403739 miR-133a is an important regulator of phenylephrine-induced cardiomyocyte hypertrophy and negatively regulates this process. +genetics_overexpression_suppress hsa-mir-7 Adrenal Cortex Neoplasms 26452132 microRNA-7-5p (miR-7) reduces cell proliferation in vitro and induces G1 cell cycle arrest. +genetics_overexpression_suppress hsa-mir-125b Cholangiocarcinoma 26455324 "We also found that enforced expression of let-7c, miR-99a or miR-125b could reduce the activity of STAT3 and further suppress CCA tumorigenicity in vivo and inhibit the migration and invasion of CCA cells in vitro." +genetics_overexpression_suppress hsa-mir-34a Alzheimer Disease 26459758 "Importantly, the overexpression of TAp73α and miR-34a reversed cell cycle-related neuronal apoptosis (CRNA)." +genetics_overexpression_suppress hsa-mir-140 Rheumatoid Arthritis 26473405 "Overexpression of miRNAs 140-3p and 140-5p caused a reduction in expression, with correlated kinetic patterns, of their corresponding target molecules sirtuin 1 and stromal cell-derived factor 1 in the SFs and joints of mice." +genetics_overexpression_suppress hsa-mir-29a "Carcinoma, Thyroid, Papillary" 26482618 "overexpression of miR-29a markedly suppressed PTC cell proliferation, migration, and invasion and promoted PTC apoptosis and cell cycle arrest at G0/G1 phase." +genetics_overexpression_suppress hsa-mir-29c "Carcinoma, Embryonal" 26484393 MicroRNA-29c overexpression inhibits proliferation and promotes apoptosis and differentiation in P19 embryonal carcinoma cells. +genetics_overexpression_suppress hsa-mir-26a "Carcinoma, Lung, Non-Small-Cell" 26492332 "Overexpression of miR-26a in A549 cells inhibited G1-S transition, increased cell death in response to CDDP treatment, and decreased the colony formation of A549 cells." +genetics_overexpression_suppress hsa-mir-214 "Carcinoma, Hepatocellular" 26498144 Overexpression of miR-214 in HCC cells inhibited proliferation by inducing G1-S checkpoint arrest. +genetics_overexpression_suppress hsa-mir-138 Laryngeal Neoplasms 26499780 "miR-138 overexpression inhibited ZEB2-mediated cell invasiveness, while miR-138 depletion increased ZEB2-mediated cell invasiveness in LC cells." +genetics_overexpression_suppress hsa-mir-16 "Carcinoma, Hepatocellular" 26499886 "The results of this study suggest that the overexpression of miR-16 inhibits the proliferation, invasion and metastasis of HepG2 HCC cells, and that these effects are associated with the PI3K/Akt signaling pathway." +genetics_overexpression_suppress hsa-mir-152 Cervical Neoplasms 26515145 Overexpression of miR-152 repressed WNT1 and ERBB3 expression and decreased proliferation of HeLa cells. +genetics_overexpression_suppress hsa-mir-222 "Squamous Cell Carcinoma, Tongue" 26517090 "Moreover, miR-222 mimics and ABCG2 siRNA inhibited tumor growth and lung metastasis in vivo." +genetics_overexpression_suppress hsa-mir-449a Prostate Neoplasms 26520443 "Overexpression of miR-449a induces cell cycle arrest, apoptosis, and senescence" +genetics_overexpression_suppress hsa-mir-205 "Carcinoma, Skin" 26527515 "Ectopic expression of miR-205-5p in spindle cancer cells reduces Rap1a, mitigates cell invasiveness, decreases proliferation, and delays tumor onset." +genetics_overexpression_suppress hsa-mir-195 Thyroid Neoplasms 26527888 exogenous overexpression of miR-195 significantly inhibits the protein expression of Raf1 and blocks the thyroid cancer cell proliferation. +genetics_overexpression_suppress hsa-let-7b Myocardial Ischemic-Reperfusion Injury 26542107 intramyocardial injection of let-7b-modified MSCs significantly enhanced ventricular function and facilitated myocardial repair by protecting transplanted cells from apoptosis and autophagy in the rat cardiac ischemia-reperfusion model. +genetics_overexpression_suppress hsa-mir-363 Head And Neck Neoplasms 26545583 "These findings demonstrate that the overexpression of miR-363 reduces cellular migration in head and neck cancer and reveal the biological relationship between miR-363, myosin 1b, and HPV-positive SCCHN." +genetics_overexpression_suppress hsa-mir-150 Osteosarcoma 26561465 "restoration of miR-150 expression in OS cells could inhibit cell proliferation, migration, and invasion and induced apoptosis in vitro as well as suppressed tumor growth of OS in vivo." +genetics_overexpression_suppress hsa-mir-7-1 Glioblastoma 26573275 "In conclusion, our results clearly demonstrated that overexpression of miR-7-1-3p augmented the anti-tumor activities of LUT and SIL to inhibit autophagy and induce apoptosis for controlling growth of different human glioblastomas in vivo." +genetics_overexpression_suppress hsa-mir-15a "Carcinoma, Hepatocellular" 26581909 "Ectopic overexpression of miR-15a-5p suppressed cancer proliferation, induced cell cycle arrest in HepG2 or SNU-182 cells in vitro, and inhibited HCC tumor growth in vivo." +genetics_overexpression_suppress hsa-mir-16 Alzheimer Disease 26592823 Overexpression and inhibition of miR-16 in the cellular AD model with primary hippocampal neurons decreased and increased apoptosis +genetics_overexpression_suppress hsa-mir-125b Melanoma 26596831 Restored expression of miR-125b in melanoma suppressed cell proliferation and invasion both in vitro and in vivo. +genetics_overexpression_suppress hsa-mir-100 Ovarian Neoplasms 26607088 The expression of miR-100 is downregulated in SKOV3/DDP cells.Overexpressing miR-100 may effectively increase the sensitivity to cisplatin of human ovarian epithelial cancer SKOV3/DDP cells and may reverse cisplatin-resistance of EOC (epithelial ovarian cancer). +genetics_overexpression_suppress hsa-mir-145 "Carcinoma, Hepatocellular" 26615424 "Overexpression of miR-145 in HCC cell lines significantly inhibited cell proliferation, migration, and invasion in vitro." +genetics_overexpression_suppress hsa-mir-143 Breast Neoplasms 26618772 "Up-regulating miR-143 enhanced E-cadherin-mediated cell-cell adhesion ability, reduced mesenchymal markers, and decreased cell proliferation, migration, and invasion in vitro." +genetics_overexpression_suppress hsa-mir-18a "Carcinoma, Gastric" 26622381 The results showed that miR-18a overexpression was able to promote cell apoptosis and inhibit cell invasion. +genetics_overexpression_suppress hsa-mir-182 Glioma 26622652 "overexpression of miR-182 affected cell cycle regulation and cell migration capacity in vitro, which may have been associated with the promotion of apoptosis by this molecule." +genetics_overexpression_suppress hsa-mir-195 Cervical Neoplasms 26622903 "The expression of miR-195 mimics in the cervical cancer HeLa cell line significantly decreased the cell proliferation, migration and invasion capacities in vitro." +genetics_overexpression_suppress hsa-mir-302b Breast Neoplasms 26623722 "miR-302b overexpression enhances sensitivity to cisplatin in breast cancer cell lines, reducing cell viability and proliferation in response to the treatment." +genetics_overexpression_suppress hsa-mir-195 Cervical Neoplasms 26631043 overexpression of miR-195 played a suppressor role in the proliferation of HeLa and SiHa cells and promoted cell apoptosis. +genetics_overexpression_suppress hsa-mir-195 Breast Neoplasms 26632252 "ectopic expression of hsa-miR-195 in MCF-7 and MDA-MB-231 cells not only altered cellular cholesterol and triglyceride levels significantly but also resulted in reduced proliferation, invasion and migration." +genetics_overexpression_suppress hsa-mir-1 Cardiomegaly 26638879 miRNA-1 overexpression prevented cardiomyocyte hypertrophy. +genetics_overexpression_suppress hsa-mir-16 "Lymphoma, Non-Hodgkin" 26640145 The miR-16 transfection significantly decreased senescent cells and increased apoptotic cells +genetics_overexpression_suppress hsa-mir-16 "Lymphoma, T-Cell, Cutaneous" 26640145 The miR-16 transfection significantly decreased senescent cells and increased apoptotic cells +genetics_overexpression_suppress hsa-mir-16 "Carcinoma, Nasopharyngeal" 26655091 "Ectopic expression of miR-16 suppressed NPC cell proliferation, migration, and invasion in vitro and inhibited tumor growth and metastatic colonization in the lung in vivo." +genetics_overexpression_suppress hsa-mir-372 "Carcinoma, Endometrial" 26673619 miR-372 overexpression suppressed tumor growth +genetics_overexpression_suppress hsa-mir-222 Osteoarthritis 26673737 Over-expression of miR-222 significantly suppressed apoptotic death by down-regulating HDAC-4 and MMP-13 level. +genetics_overexpression_suppress hsa-mir-30a "Carcinoma, Ovarian" 26675258 "Overexpression of miR-30a decreased Akt and mitogen activated protein kinase signaling pathway activation, cell proliferation, invasion, plasticity, EMT marker levels, and vascular endothelial growth factor release." +genetics_overexpression_suppress hsa-mir-215 Ovarian Neoplasms 26676658 "Upregulation of miR-215 inhibited cell proliferation, promoted apoptosis and increased sensitivity to chemotherapy drugs in EOC cells." +genetics_overexpression_suppress hsa-mir-192 "Carcinoma, Hepatocellular" 26684241 miR-192 significantly suppressed metastasis of HCC cells in vitro and in vivo. +genetics_overexpression_suppress hsa-mir-181d "Squamous Cell Carcinoma, Oral" 26693182 Ectopic expression of miR-181a/d decreased anchorage independent growth and CSC phenotype of HPV16-transfected OSCC. +genetics_overexpression_suppress hsa-mir-494 "Carcinoma, Ovarian" 26695144 "overexpression of miR-494 in EOC cells could remarkably inhibit proliferation, colony formation, migration, and invasion and induce cell apoptosis, G0/G1 phase arrest." +genetics_overexpression_suppress hsa-mir-1 "Cardiomyopathy, Hypertrophic" 26699910 "miR-1 mimic, in parallel to CDK6 siRNA, could inhibit PE-induced hypertrophy of NRVCs, with decreases in cell size" +genetics_overexpression_suppress hsa-mir-148a Breast Neoplasms 26707142 The ectopic miR-148a expression inhibited the migration and invasion of MCF-7 and MDA-MB-231 breast cancer cells. +genetics_overexpression_suppress hsa-mir-145 Breast Neoplasms 26715279 "Overexpression of miR-145 in MCF-7 and BT-549 cell lines significantly inhibited cell proliferation, migration, and invasion in vitro." +genetics_overexpression_suppress hsa-mir-206 "Carcinoma, Renal Cell, Clear-Cell" 26718123 "upregulation of miR-206 inhibited renal cancer cell proliferation, invasion and migration" +genetics_overexpression_suppress hsa-mir-452 "Carcinoma, Lung, Non-Small-Cell" 26718215 "xpression of miR-452 via adenoviral (Ad) vector inhibits the proliferation, invasion, and migration of NSCLC cells A549 or H460." +genetics_overexpression_suppress hsa-mir-143 Prostate Neoplasms 26721309 miR-143 restoration decreased secreted MMP-2 and MMP-9 enzyme activities compared with scramble controls +genetics_overexpression_suppress hsa-mir-34c "Carcinoma, Hepatocellular, HBV-Related" 26722295 "The restoration of miR-34c in HepG2.2.15 cells suppressed TGIF2 expression, HBV replication and viral antigen synthesis; inhibited cell proliferation; and induced apoptosis." +genetics_overexpression_suppress hsa-mir-34a Prostate Neoplasms 26722316 The over-expression of miR-34a inhibited PC-3 cells growth and resulted in increased cell cycle arrest compared with the negative control (P<0.05). +genetics_overexpression_suppress hsa-mir-145 "Carcinoma, Breast, Triple Negative" 26733177 tumor necrosis factor-alpha (TNF-α)-induced apoptosis was expanded by the transfection of miR-145 in MDA-MB-231 which belongs to the TNBC cell lines. +genetics_overexpression_suppress hsa-mir-488 Gastric Neoplasms 26738864 "The ectopic expression of miR-488 suppressed the GC cell proliferation, cell cycle, colony information, and migration." +genetics_overexpression_suppress hsa-mir-125b Osteosarcoma 26744308 "stable overexpression of miR-125b in osteosarcoma cell lines U2OS and MG-63 inhibited cell proliferation, migration, and invasion." +genetics_overexpression_suppress hsa-let-7 Gastric Neoplasms 26745603 "overexpression of miR-let-7a markedly suppressed the proliferation, migration, and invasion of GC cells by down-regulating the expression of PKM2." +genetics_overexpression_suppress hsa-mir-23b Asthma 26748386 Overexpression of miR-23b significantly inhibited TGF-β1-induced ASMCs proliferation and promoted apoptosis. +genetics_overexpression_suppress hsa-mir-378 Breast Neoplasms 26749280 "ectopic expression of miR-378 in MDA-MB-231 cells inhibited Runx1 and suppressed migration and invasion, while inhibition of miR-378 in MCF7 cells increased Runx1 levels and cell migration." +genetics_overexpression_suppress hsa-let-7f Glioma 26750768 inhibiting the pro-migratory function of POSTN by the overexpression of miR-Let-7f significantly reduced the formation of VM. +genetics_overexpression_suppress hsa-mir-320 Cervical Neoplasms 26753959 "miR-320 induces apoptosis via down-regulation of Mcl-1 and activation of caspase-3 but inhibits cell proliferation, migration, invasion, and tumorigenesis in cervical cancer cells." +genetics_overexpression_suppress hsa-mir-340 Breast Neoplasms 26758430 miR-340 could dramatically down-regulate metastasis by targeting Wnt signaling in breast cancer cells. +genetics_overexpression_suppress hsa-mir-143 "Squamous Cell Carcinoma, Esophageal" 26758433 "miR-143 exerted a tumor-suppressing effect by inhibiting the proliferation, migration, and invasion and inducing G1/G0 phase arrest of ESCC cells via the negative regulation of FAM83F expression." +genetics_overexpression_suppress hsa-mir-381 Ovarian Neoplasms 26768613 "Overexpression of miR-381 significantly inhibited EOC cell proliferation, migration, and invasion." +genetics_overexpression_suppress hsa-mir-503 Osteosarcoma 26768615 miR-503 overexpression suppressed cell invasion and migration and inhibited epithelial-to-mesenchymal transition (EMT) of MG-63. +genetics_overexpression_suppress hsa-mir-29a Multiple Myeloma 26771839 "In addition, ectopic expression of miRNA-29a or exposure to PRIMA-1Met reduced cell proliferation and induced apoptosis in MM cells." +genetics_overexpression_suppress hsa-mir-30a "Carcinoma, Urothelial" 26775686 Both miR-30a and small interfering RNA Notch1 negatively regulated cell proliferation +genetics_overexpression_suppress hsa-mir-210 Hypoxia 26780211 miR-210 upregulation exerted amelioration on the hypoxia-induced apoptosis +genetics_overexpression_suppress hsa-mir-27b Gastric Neoplasms 26780940 miR-27b overexpression significantly inhibited H. pylori infection-induced cell proliferation and WNT signaling pathway activation in gastric cancer cells. +genetics_overexpression_suppress hsa-mir-20a "Squamous Cell Carcinoma, Oral" 26781875 "Upregulation of miR-20a by transfected plasmid HPV-16 E7 can significantly inhibit Cal27 cell proliferation, invasion, and migration." +genetics_overexpression_suppress hsa-mir-214 "Carcinoma, Hepatocellular" 26788207 enhanced expression of miR-214 or silencing of E2F3 inhibited the proliferation of HCC SMMC-7721 cells. +genetics_overexpression_suppress hsa-mir-382 Colorectal Carcinoma 26800338 "Transfection with miR-382 mimics impeded the growth, migration, and invasion of CRC cells." +genetics_overexpression_suppress hsa-mir-125b Bladder Neoplasms 26807182 "Overexpression of miR-125b inhibited cellular growth, suppressed cellular migration and caused an accumulation of cells in the G1 phase of the cell cycle" +genetics_overexpression_suppress hsa-mir-152 Colorectal Carcinoma 26820128 restoring the expression of miR-152 in CRC cells dramatically reduced the cell proliferation and cell migration and invasion and promoted apoptosis +genetics_overexpression_suppress hsa-mir-451 Rheumatoid Arthritis 26823778 miR-451 treatment significantly decreased cell proliferation ability +genetics_overexpression_suppress hsa-mir-30a "Adenocarcinoma, Lung" 26837415 overexpression of miR-30a in A549 cells inhibited migration and invasion but not cell proliferation and cell cycle progression +genetics_overexpression_suppress hsa-mir-137 Gastric Neoplasms 26840256 Overexpression of miR-9 and miR-137 downregulated the CUL4A-LATS1-Hippo signaling pathway and suppressed GC cell proliferation and invasion in vitro. +genetics_overexpression_suppress hsa-mir-9 Gastric Neoplasms 26840256 Overexpression of miR-9 and miR-137 downregulated the CUL4A-LATS1-Hippo signaling pathway and suppressed GC cell proliferation and invasion in vitro. +genetics_overexpression_suppress hsa-mir-21 Ischemia 26841045 over-expressing miR-21 in UCBMSCs could improve neovascularization in CLI +genetics_overexpression_suppress hsa-mir-448 Gastric Neoplasms 26852749 "Ectopic expression of miR-448 suppressed GC cell proliferation, colony formation, and invasion." +genetics_overexpression_suppress hsa-mir-200b Endometriosis 26854065 "up-regulation of miR-200b reverts EMT, emerging as a potential therapeutic approach to inhibit endometriotic cell motility and invasiveness." +genetics_overexpression_suppress hsa-mir-373 Glioma 26858153 "although miR-373 does not affect cell growth of U251, it inhibits migration and invasion of U251." +genetics_overexpression_suppress hsa-mir-144 "Lymphoma, Large B-Cell" 26865454 "forced expression of miR-144 significantly attenuated cell proliferation and invasion of OCI-Ly3 cells in vitro, and the tumor-suppressor effect of miR-144 was also confirmed using a xenograft mouse model in vivo Taken together" +genetics_overexpression_suppress hsa-mir-150 "Carcinoma, Hepatocellular" 26871477 "miR-150 overexpression inhibited cell proliferation, migration and invasion in vitro and tumor growth and metastasis in vivo." +genetics_overexpression_suppress hsa-mir-19a Lung Fibrosis 26873752 "intratracheal application of miR-19a, -19b, and 26b reduced the pulmonary fibrotic severity induced by bleomycin" +genetics_overexpression_suppress hsa-mir-19b Lung Fibrosis 26873752 "intratracheal application of miR-19a, -19b, and 26b reduced the pulmonary fibrotic severity induced by bleomycin" +genetics_overexpression_suppress hsa-mir-26b Lung Fibrosis 26873752 "intratracheal application of miR-19a, -19b, and 26b reduced the pulmonary fibrotic severity induced by bleomycin" +genetics_overexpression_suppress hsa-mir-223 Breast Neoplasms 26876200 both RT-induced miR-223 and peri-operative inhibition of EGFR efficiently prevented BC cell growth and reduced recurrence formation in mouse models of BC. +genetics_overexpression_suppress hsa-mir-203 "Squamous Cell Carcinoma, Head and Neck" 26882562 "oreover, ectopic overexpression of miR-203 suppressed the invasion and induced mesenchymal-epithelial transition (MET) in HNSCC cells." +genetics_overexpression_suppress hsa-mir-451 "Carcinoma, Renal Cell" 26884830 "microRNA-451 inhibited proliferation, migration and invasion of renal cell carcinomas cells." +genetics_overexpression_suppress hsa-mir-15b Liver Neoplasms 26884837 MiR-15b mimic transfection promoted miR-15b overexpression and inhibited HepG2 cell proliferation significantly +genetics_overexpression_suppress hsa-mir-26b "Carcinoma, Hepatocellular" 26891666 miR-26b-5p inhibited HCC cell growth and impaired the tube formation ability of the HCC cells +genetics_overexpression_suppress hsa-mir-15a Gastric Neoplasms 26894855 ectopic expression of miR-15a decreased Bmi-1 in gastric cancer cell lines with reduced proliferation and tumor invasion. +genetics_overexpression_suppress hsa-mir-23b Prostate Neoplasms 26898757 miR-23b/-27b expression in prostate cancer cells decreased seminal vesicle invasion and distant metastases +genetics_overexpression_suppress hsa-mir-27b Prostate Neoplasms 26898757 miR-23b/-27b expression in prostate cancer cells decreased seminal vesicle invasion and distant metastases +genetics_overexpression_suppress hsa-mir-99a Cardiovascular Diseases [unspecific] 26914935 Overexpression of microRNA-99a Attenuates Cardiac Hypertrophy. +genetics_overexpression_suppress hsa-mir-146a Glioblastoma 26916895 The upregulation of miR-146a in glioma cells through miR-146a mimic transfection led to reduction of cell viability and to an increase in the percentage of apoptosis. +genetics_overexpression_suppress hsa-mir-19b Myocardial Ischemic-Reperfusion Injury 26918829 we found that overexpression of miR-19b decreased H2O2-induced apoptosis and improved cell survival +genetics_overexpression_suppress hsa-mir-200b "Carcinoma, Hepatocellular" 26919246 "Forced expression of microRNA-200b in HCC cells dramatically repressed proliferation, colony formation, cell cycle progression, and invasion." +genetics_overexpression_suppress hsa-mir-24 "Carcinoma, Nasopharyngeal" 26922862 cell proliferation was suppressed and radiosensitivity increased when miR-24 was ectopically expressed in NPC cells. +genetics_overexpression_suppress hsa-mir-34b Osteosarcoma 26924291 Upregulation of miR-34b also induced apoptosis and increased the sensitivity of the cells to the anticancer drugs +genetics_overexpression_suppress hsa-mir-372 Gastric Neoplasms 26928593 inhibit proliferations of adenocarcinoma gastric cancer (AGS) cells overexpressing these miRNAs +genetics_overexpression_suppress hsa-mir-27a Endometrial Neoplasms 26934121 Enforced expression of miR-124 suppresses EC cell invasion and proliferation. +genetics_overexpression_suppress hsa-mir-204 "Carcinoma, Lung, Non-Small-Cell" 26935060 "Transient over-expression of miR-204 by transfecting with miR-204 mimics suppressed NSCLC cell proliferation, migration, and induced apoptosis and G1 arrest" +genetics_overexpression_suppress hsa-mir-200b "Carcinoma, Cervical" 26935156 miRâ€?00b suppressed the migratory potential of cervical carcinoma cells +genetics_overexpression_suppress hsa-mir-200c "Carcinoma, Lung, Non-Small-Cell" 26935975 Overexpression of miRâ€?00c significantly suppressed cell migration and invasion of A549 NSCLC cells. +genetics_overexpression_suppress hsa-mir-141 Neuroblastoma 26936280 "lentivirus-induced miR-141 upregulation inhibited cancer proliferation, cell cycle progression, migration and increased cisplatin chemosensitivity in vitro." +genetics_overexpression_suppress hsa-mir-181a "Lymphoma, Large B-Cell" 26941399 "miR-181a decreases DLBCL tumor cell proliferation and survival, and anti-miR-181a abrogates these effects." +genetics_overexpression_suppress hsa-mir-21 Acute Myocardial Infarction 26978580 combination of miR-21 and miR-146a has a greater protective effect against cardiac ischemia/hypoxia-induced apoptosis +genetics_overexpression_suppress hsa-mir-1 Colorectal Carcinoma 26980745 The ectopic expression of these miRs induced growth suppression and autophagic cell death +genetics_overexpression_suppress hsa-mir-200b "Carcinoma, Hepatocellular" 26986232 "Upregulated miRâ€?00b expression in HepG2 cells led to a decrease in DNMT3a expression levels, and an inhibition of cell proliferation." +genetics_overexpression_suppress hsa-mir-508 Glioma 27003587 over-expression of miR-508-5p was found to decrease glioma cell growth. +genetics_overexpression_suppress hsa-mir-7 Parkinson Disease 27003614 The upregulation of miR-7 promoted cell viability and suppressed cell apoptosis in MPP(+)-treated SH-SY5Y cells. +genetics_overexpression_suppress hsa-mir-182 Ischemic Diseases [unspecific] 27008992 Both exogenous miR-182 and Kenpaullone significantly suppressed hypoxia-induced cardiomyocyte death in vitro. +genetics_overexpression_suppress hsa-mir-134 Glioma 27012554 upregulated miR-134 expression restrained the proliferation and invasion of U251 cells in vitro. +genetics_overexpression_suppress hsa-mir-154 Glioblastoma 27013470 overexpression of miR-154 suppressed cell migration and invasion of U87 and U251 cells. +genetics_overexpression_suppress hsa-mir-20a Liver Diseases [unspecific] 27019188 miR-20a-5p mimic could reverse high glucose-induced impaired glycogenesis and AKT/GSK activation in NCTC1469 and Hep1-6 cells. +genetics_overexpression_suppress hsa-mir-490 Colorectal Carcinoma 27037061 miR-490-3p suppresses cancer cell proliferation by inducing apoptosis +genetics_overexpression_suppress hsa-let-7 "Carcinoma, Salivary Adenoid Cystic" 27042128 "the overexpression of miR-98 in ACC-M cells inhibited cell proliferation, invasion, and migration in vitro." +genetics_overexpression_suppress hsa-mir-130b Ovarian Neoplasms 27048832 overexpression of miR-130b reduced the expression of RUNX3 and inhibited cancer cell migration and invasion of EOC cells +genetics_overexpression_suppress hsa-mir-206 Muscle Atrophy 27054781 Injection of miR-206 (30 μg/rat) attenuated morphological and physiological deterioration of muscle characteristics +genetics_overexpression_suppress hsa-mir-429 Bladder Neoplasms 27058893 Exogenous mimic of miR-429 treatment dramatically inhibited the migratory ability of T24 cells. +genetics_overexpression_suppress hsa-mir-221 Neuropathic Pain 27059231 "Intrathecal injection of a miR-221 inhibitor attenuated CCI-induced mechanical allodynia and thermal hyperalgesia, and reduced proinflammatory cytokine expression" +genetics_overexpression_suppress hsa-mir-29a Endomyocardial Fibrosis 27060017 over-expression of miRNA-29a suppresses cardiac fibroblasts proliferation. +genetics_overexpression_suppress hsa-mir-506 Pancreatic Neoplasms 27065335 "miR-506 inhibited cell proliferation, induced cell cycle arrest at the G1/S transition and enhanced apoptosis and chemosensitivity of pancreatic cancer cells." +genetics_overexpression_suppress hsa-mir-101 Osteosarcoma 27073439 "Independent inhibition of c-FOS and overexpression of miR-101 expression levels significantly suppressed U2OS cell proliferation, migration and invasion (P<0.01)." +genetics_overexpression_suppress hsa-mir-124 "Carcinoma, Lung, Non-Small-Cell" 27073840 Overexpression of miR-124 apparently suppressed the proliferation and invasion of NSCLC cell lines in vitro. +genetics_overexpression_suppress hsa-mir-154 Prostate Neoplasms 27074041 "The forced expression of miR-154-5p or E2F5 knockdown significantly restrained cell growth, as well as the migratory and invasive capabilities." +genetics_overexpression_suppress hsa-mir-502 Breast Neoplasms 27080302 "Treatment with miR-502 or downregulation of SET8 suppressed cell proliferation and cell cycle, and reduced cell migration, invasion and EMT." +genetics_overexpression_suppress hsa-mir-15b Glioma 27082313 "Furthermore, miRâ€?5b inhibited proliferation and invasion, and promoted apoptosis of glioma cells while downregulating the expression of MMPâ€? and MMPâ€?." +genetics_overexpression_suppress hsa-mir-199a Breast Neoplasms 27094578 "Overexpression of miR-199a-5p reduced the mRNA and protein levels of Ets-1 in MCF-7 and MDA-MB-231 cells, whereas anti-miR-199a-5p elevated Ets-1." +genetics_overexpression_suppress hsa-mir-125a Retinoblastoma 27094723 The overexpression of miR-125a-5p significantly suppressed cell proliferation and tumor formation in retinoblastoma. +genetics_overexpression_suppress hsa-mir-138 Osteosarcoma 27095063 "miR-138 inhibited cell proliferation and invasion, and promoted cell apoptosis of human osteosarcoma cells." +genetics_overexpression_suppress hsa-mir-542 Melanoma 27107696 "Exogenous expression of miR-542-3p resulted in marked inhibition of melanoma cell migration, invasion and epithelial-mesenchymal transition (EMT) in vitro and lung metastasis in vivo." +genetics_overexpression_suppress hsa-mir-34a Lung Neoplasms 27109632 Systemic and local injection of ghR-form miR-34a (ghR-34a) suppressed tumor growth in a mouse model of RAS-induced lung cancer. +genetics_overexpression_suppress hsa-mir-130b Lupus Nephritis 27111096 overexpressing miR-130b suppressed signaling downstream from the type I IFN pathway in RMCs by targeting IFN regulatory factor 1 (IRF-1). +genetics_overexpression_suppress hsa-mir-1180 Bladder Neoplasms 27112784 miR-1180-5p also suppressed the tumor growth in vivo significantly +genetics_overexpression_suppress hsa-mir-9 Schizophrenia 27117414 "Overexpression of miR-9 was sufficient to ameliorate a previously reported neural migration deficit in SZ NPCs, whereas knockdown partially phenocopied aberrant migration in control NPCs." +genetics_overexpression_suppress hsa-mir-182 Osteosarcoma 27123060 "upregulation of miRNA-182 promotes cell apoptosis and inhibits cell viability, proliferation, invasion and migration." +genetics_overexpression_suppress hsa-let-7i "Carcinoma, Hepatocellular" 27126374 "Let-7i was downregulated in HCC tissues, and transfection of HuH-7 with let-7i inhibited malignant cell behaviors and decreased IGF2BPs transcripts." +genetics_overexpression_suppress hsa-mir-214 "Carcinoma, Hepatocellular" 27129291 Overexpression of miR-214 significantly attenuated cell proliferation. +genetics_overexpression_suppress hsa-mir-429 Cervical Neoplasms 27133071 "miR-429 over-expression and inhibition on cell elongation, migration, stress fiber formation, and invasion." +genetics_overexpression_suppress hsa-mir-370 Glioma 27138069 Overexpression of miR-370-3p showed a significant inhibitory effect on cell proliferation and accompanied cell cycle G0/G1 arrest in U251 and U87-MG cells. +genetics_overexpression_suppress hsa-mir-199b Colorectal Carcinoma 27145368 restoration of miR-199b considerably reduced cell invasion and migration in vitro and in vivo +genetics_overexpression_suppress hsa-mir-223 Inflammation 27148749 The overexpression of miR-223 in both J774A.1 and peritoneal macrophages induced a phenotypic change from M1 to M2 state +genetics_overexpression_suppress hsa-mir-133a Glioma 27154818 "Transfection of miR-150-5p or miR-133a mimics into glioma cell lines reduced MT1-MMP expression and MMP-2 activation by these cells, and cell proliferation and invasion/migration were also suppressed by it." +genetics_overexpression_suppress hsa-mir-150 Glioma 27154818 "Transfection of miR-150-5p or miR-133a mimics into glioma cell lines reduced MT1-MMP expression and MMP-2 activation by these cells, and cell proliferation and invasion/migration were also suppressed by it." +genetics_overexpression_suppress hsa-mir-140 Biliary Tract Neoplasms 27155525 Ectopic expression of miR-140-5p markedly decreased SEPT2 protein concentration in BTC cells and suppressed cell proliferation and colony formation in vitro. +genetics_overexpression_suppress hsa-mir-130a "Leukemia, Myeloid, Chronic" 27158382 over-expression of miR-130a in A562 CML cells dramatically suppresses cell proliferation and induces cell apoptosis both in vitro and in vivo. +genetics_overexpression_suppress hsa-mir-26a Ovarian Neoplasms 27158389 over-expression could significantly inhibit the proliferation of ovarian cancer cells and induce their apoptosis. +genetics_overexpression_suppress hsa-mir-1 "Squamous Cell Carcinoma, Head and Neck" 27169691 miR-1 and miR-206 significantly inhibited HNSCC cells' aggressiveness. +genetics_overexpression_suppress hsa-mir-206 "Squamous Cell Carcinoma, Head and Neck" 27169691 restoration of miR-1 and miR-206 significantly inhibited HNSCC cells' aggressiveness. +genetics_overexpression_suppress hsa-mir-196a "Carcinoma, Renal Cell" 27175581 "miRâ€?96a suppressed cell proliferation, apoptosis and migration of the 786‑O and ACHN RCC cell lines." +genetics_overexpression_suppress hsa-mir-195 Prostate Neoplasms 27175617 "miR-195 overexpression inhibited cell proliferation, cell cycle progression and tumorigenesis via directly targeting HMGA1." +genetics_overexpression_suppress hsa-mir-126 Thyroid Neoplasms 27175968 "upregulation of miRâ€?26 inhibited cell proliferation, migration and invasion in thyroid cancer cells." +genetics_overexpression_suppress hsa-mir-34a Glioma 27176117 "Overexpression of miRâ€?4a inhibited proliferation, and induced apoptosis of U87 cells." +genetics_overexpression_suppress hsa-mir-497 Osteosarcoma 27176490 "upregulation of miRâ€?97 inhibited cell proliferation, migration and invasion in osteosarcoma cell lines" +genetics_overexpression_suppress hsa-mir-223 "Carcinoma, Lung, Non-Small-Cell" 27177336 "The overexpression of miRâ€?23 may partially reverse the acquired resistance to epidermal growth factor receptor-TKIs, thus, providing a potential therapeutic strategy for TKI-resistant NSCLC." +genetics_overexpression_suppress hsa-mir-191 "Carcinoma, Lung, Non-Small-Cell" 27178817 cell proliferation was notably reduced by the miR-1908 mimic transfection +genetics_overexpression_suppress hsa-mir-126 Atherosclerosis 27180261 miR-126 up-regulation activates EPCs and ECs and contributes to vascular healing and neovessel formation +genetics_overexpression_suppress hsa-mir-328 Cervical Neoplasms 27181358 Enforced expression of miR-328 led to a decline in the expression of endogenous TCF7L2 in cervical cancer cells. +genetics_overexpression_suppress hsa-mir-448 "Squamous Cell Carcinoma, Oral" 27184799 Knockdown of N4BP2L1 and upregulation of miR-448 significantly reduced the invasive potential of oral squamous cell carcinoma cells. +genetics_overexpression_suppress hsa-mir-544 "Carcinoma, Breast, Triple Negative" 27186677 "overexpression of miR-544 in triple negative breast cancer cells significantly down-regulated expressions of Bcl6 and Stat3, which in turn severely inhibited cancer cell proliferation, migration and invasion in vitro." +genetics_overexpression_suppress hsa-mir-145 Ovarian Neoplasms 27191261 Activating miR-145 suppresses ovarian tumor growth and metastasis +genetics_overexpression_suppress hsa-let-7c Kidney Injury 27203438 miR-let7c-MSC therapy attenuated kidney injury +genetics_overexpression_suppress hsa-mir-30a Gastric Neoplasms 27208176 forced miR-30a over-expression in cancer cells can be a potential way to inhibit tumour development. +genetics_overexpression_suppress hsa-mir-320a Prostate Neoplasms 27212625 Restoration of mature miRâ€?20a in PCa cell lines showed that miRâ€?20a significantly inhibited cancer cell migration and invasion. +genetics_overexpression_suppress hsa-mir-320 Prostate Neoplasms 27216188 An miR-320a mimic suppressed AR protein expression together with growth suppression +genetics_overexpression_suppress hsa-mir-192 "Adenocarcinoma, Pancreatic Ductal" 27216198 overexpression of miR-192 was sufficient to reduce cell proliferation and invasion. +genetics_overexpression_suppress hsa-mir-150 Atherosclerosis 27216461 The suppressive effects of miR-150 on macrophage foam cell formation are mediated through targeting of AdipoR2. +genetics_overexpression_suppress hsa-mir-19a Hypoxia 27220268 miR-19a overexpression clearly ameliorated hypoxia-induced cell death (necrosis and apoptosis) +genetics_overexpression_suppress hsa-mir-34a "Carcinoma, Laryngeal" 27220728 expression of miR-34a inhibited cell proliferation and migration in laryngeal carcinoma cells. +genetics_overexpression_suppress hsa-mir-495 Glioma 27220777 restoration of hsa-miR-495 inhibited glioma cell proliferation and invasion in vitro. +genetics_overexpression_suppress hsa-mir-18b Melanoma 27220837 Ectopic expression of miR-18b decreased the proliferation of A375 and B16 cells +genetics_overexpression_suppress hsa-mir-874 Colorectal Carcinoma 27221209 expression of miR-874 was downregulated in CRC tissues and cell lines +genetics_overexpression_suppress hsa-mir-410 Breast Neoplasms 27221455 "miR-410-3p overexpression reduced cell growth, colony formation and the number of EdU-positive cells in the MDA-MB-231 cells." +genetics_overexpression_suppress hsa-mir-181a Cardiomegaly 27221738 "Over-expression of miR-30c or miR-181a decreased expression of p53, p21, ANP, cardiomyocyte cell size, and apoptosis in HG-treated cardiomyocytes." +genetics_overexpression_suppress hsa-mir-375 Colorectal Carcinoma 27222350 "miR-375 inhibited proliferation, invasion and migration in DLD1 and HCT8 cells." +genetics_overexpression_suppress hsa-mir-224 Osteosarcoma 27222381 "overexpression of miR-224 suppressed osteosarcoma cell proliferation, migration and invasion" +genetics_overexpression_suppress hsa-mir-214 Kidney Neoplasms 27226530 miR-214 significantly blocked IGF-1R-forced renal cancer cell proliferation +genetics_overexpression_suppress hsa-mir-137 Melanoma 27233613 Overexpression of miR-137 decreased cell proliferation and colony formation in vitro. +genetics_overexpression_suppress hsa-mir-126 "Carcinoma, Lung, Non-Small-Cell" 27236384 "Upregulation of miR-126 resulted in the decrease of the proliferation, migration, and invasive abilities of A549 cells" +genetics_overexpression_suppress hsa-mir-208b Myocardial Infarction 27236543 Overexpressing miR-208b improved myocardial functions +genetics_overexpression_suppress hsa-mir-134 "Carcinoma, Lung, Non-Small-Cell" 27241841 miR-134 suppressed tumour growth of A549 xenograft in nude mice. +genetics_overexpression_suppress hsa-mir-17 Mesothelioma 27245839 Transfection of MPM cells with a miR-17-5p mimic or KCNMA1-specific siRNAs reduced mRNA expression of KCa1.1 and inhibited MPM cell migration. +genetics_overexpression_suppress hsa-mir-450 Lung Neoplasms 27246609 transfection with lentivirus carrying miRâ€?50 upregulated miRâ€?50 expression and significantly attenuated lung cancer cell proliferation and invasion +genetics_overexpression_suppress hsa-mir-1 "Squamous Cell Carcinoma, Esophageal" 27247259 miRâ€? suppressed ESCC cell proliferation and increased apoptosis +genetics_overexpression_suppress hsa-mir-124 "Carcinoma, Lung" 27251409 overexpression of miR-124 in A549 cells suppressed cell migration and invasion activity +genetics_overexpression_suppress hsa-mir-218 "Cardiomyopathy, Hypertrophic" 27258257 Overexpression of miR-218 is sufficient to reduce hypertrophy +genetics_overexpression_suppress hsa-mir-497 Ischemia-Reperfusion Injury 27261611 miR-497 could inhibit inflammation and apoptosis of spinal cord IR through its targets +genetics_overexpression_suppress hsa-mir-744 Cervical Neoplasms 27261616 "up-regulation of miR-744 and down-regulation of Bcl-2 could stimulate Caspase-3 expression, promoting apoptosis of cervical cancer cells." +genetics_overexpression_suppress hsa-mir-663a "Carcinoma, Hepatocellular" 27261623 "miR-663a distinctly inhibited cell proliferation, migration and invasion." +genetics_overexpression_suppress hsa-mir-411 Breast Neoplasms 27264952 Ectopic expression of miR-411-5p suppressed the breast cancer cell proliferation +genetics_overexpression_suppress hsa-mir-26a Osteosarcoma 27270422 miR-26a overexpression inhibits the tumor cell growth both in vitro and in vivo. +genetics_overexpression_suppress hsa-mir-106b Atherosclerosis 27270534 Overexpression of miR-106b-5p with miR-106b-5p mimic inhibited PTEN expression and TNF-α-induced apoptosis in HUVEC. +genetics_overexpression_suppress hsa-mir-29b Liver Cirrhosis 27273381 miR-29b overexpression inhibited proliferation of LX-2 cells 24 h after transfection. +genetics_overexpression_suppress hsa-mir-320 "Carcinoma, Lung, Non-Small-Cell" 27277534 "miRâ€?20 inhibited cell growth, migration and invasion in NSCLC cells." +genetics_overexpression_suppress hsa-mir-375 "Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal" 27279635 "Overexpression of miR-375 led to a decreased protein level of Krüppel-like factor 4 (KLF4) and marked suppression of the proliferation and invasion, and induced apoptosis of LSCC cell line" +genetics_overexpression_suppress hsa-mir-24 "Carcinoma, Endometrial" 27279639 Up-regulation of miR-24 inhibited the cell proliferation +genetics_overexpression_suppress hsa-mir-205 Colon Neoplasms 27283988 miR-205 decreases cell proliferation and decreases migratory and invasive potential of colon cancer cells +genetics_overexpression_suppress hsa-mir-486 Colorectal Carcinoma 27284245 overexpression of miR-486-5p inhibited the tumor growth and lymphangiogenesis in nude mice +genetics_overexpression_suppress hsa-mir-210 Intervertebral Disc Degeneration 27284319 downregulation of miR-210 may promote Fas-mediated apoptosis in human IDD by regulating the expression of HOXA9. +genetics_overexpression_suppress hsa-mir-214 Ischemia-Reperfusion Injury 27288437 Overexpression of the two miRs in cardiomyocytes mimics the effects of carvedilol +genetics_overexpression_suppress hsa-mir-145 Liver Fibrosis 27289031 over-expression of miR-145 inhibited TGF-β1-induced the activation and proliferation of HSC-T6 cells in vitro. +genetics_overexpression_suppress hsa-mir-210 Colorectal Carcinoma 27293381 miR-210 mediated the induction of apoptosis +genetics_overexpression_suppress hsa-mir-153 Glioma 27295037 "Exogenous overexpression of miR-153 downregulated Rictor (mRNA and protein) and decreased p-Akt Ser473 in U87MG cells, leading to significant growth inhibition and apoptosis activation." +genetics_overexpression_suppress hsa-let-7 Neoplasms [unspecific] 27295554 genetic rescue of Let-7 miRNA activity in Dicer1-deficient TAMs partly restored their M2-like phenotype and decreased tumour-infiltrating CTLs. +genetics_overexpression_suppress hsa-mir-10b Cervical Neoplasms 27296950 overexpression of miR-10b in cervical cancer cells could inhibit the cell proliferation and invasion +genetics_overexpression_suppress hsa-mir-34b "Leukemia, Myeloid, Acute" 27296951 the miR-34b mimicked transfection-mediated restoration of miR-34b inhibited cell viability and promoted cell apoptosis of HL-60 and OCI-AML3 cell lines. +genetics_overexpression_suppress hsa-mir-149 "Carcinoma, Hepatocellular" 27300349 Overexpression of miR-149 or inhibition of PARP-2 expression could inhibit tumor growth but was more effective in sensitizing chemotherapy and radiotherapy in xenograft HCC animal models +genetics_overexpression_suppress hsa-mir-196b Lung Neoplasms 27302168 miR-196b reexpression also significantly reduced the growth of tumor xenografts. +genetics_overexpression_suppress hsa-mir-34 Pulmonary Hypertension 27302634 "miR-34a overexpression down-regulated platelet-derived growth factor receptor alpha (PDGFRA) expression, which is a key factor in PAH development." +genetics_overexpression_suppress hsa-mir-497 Breast Neoplasms 27303812 "Enforced miR-497 expression, accompanied with SMAD7 reduction, suppressed MDA-MB-231 and MCF-7 breast cancer cell growth" +genetics_overexpression_suppress hsa-mir-26b Bladder Neoplasms 27310702 Restoration of these miRNAs inhibited cell migration and invasion in BC. +genetics_overexpression_suppress hsa-mir-674 Liver Injury 27313091 miR-674-5p might be a negative regulator in 5-LO mediated autoimmune liver injury +genetics_overexpression_suppress hsa-mir-20a "Carcinoma, Hepatocellular" 27313460 growth of HepG2 cells in the miR-20a mimics group was significantly inhibited +genetics_overexpression_suppress hsa-mir-27a "Carcinoma, Renal Cell" 27313769 upregulated miR-27a attenuated RCC tumor growth in the tumor xenograft animal model +genetics_overexpression_suppress hsa-mir-494 Ovarian Neoplasms 27313773 Overexpression of miR-494 inhibited ovarian cancer cell proliferation by inducing apoptosis. +genetics_overexpression_suppress hsa-mir-218 "Carcinoma, Renal Cell" 27314976 cell proliferation was suppressed in miRâ€?18 mimic‑transfected RCC cells compared with control cells +genetics_overexpression_suppress hsa-mir-23a Osteoarthritis 27318087 miR-23a-3p overexpression suppresses type II collagen and aggrecan expression +genetics_overexpression_suppress hsa-mir-206 "Carcinoma, Breast, Triple Negative" 27318091 The miR-206 mimics inhibited TNBC breast cell invasion and angiogenesis. +genetics_overexpression_suppress hsa-let-7 Endometriosis 27320036 increased let-7f expression effectively reduced the migration of endometrial cells. +genetics_overexpression_suppress hsa-let-7f Endometriosis 27320036 increased let-7f expression effectively reduced the migration of endometrial cells. +genetics_overexpression_suppress hsa-mir-137 Glioblastoma 27328425 "overexpression of miR-137 in GBM cells also inhibited cell proliferation, migration, and invasion." +genetics_overexpression_suppress hsa-mir-148b Breast Neoplasms 27328731 "Depleting miR-214 or elevating miR-148b blocked the dissemination of melanoma or breast cancer cells, an effect that could be accentuated by dual alteration." +genetics_overexpression_suppress hsa-mir-148b Melanoma 27328731 "Depleting miR-214 or elevating miR-148b blocked the dissemination of melanoma or breast cancer cells, an effect that could be accentuated by dual alteration." +genetics_overexpression_suppress hsa-mir-30b "Carcinoma, Hepatocellular" 27333771 Gain- and loss-of-function studies revealed that miR-30b could dramatically inhibit in vitro HCC cell migration and invasion. +genetics_overexpression_suppress hsa-mir-141 "Carcinoma, Renal Cell, Clear-Cell" 27336447 a tumor suppressive effect of miR-141-3p and miR-145-5p by decreasing migration and invasion of RCC cells could be shown. +genetics_overexpression_suppress hsa-mir-145 "Carcinoma, Renal Cell, Clear-Cell" 27336447 a tumor suppressive effect of miR-141-3p and miR-145-5p by decreasing migration and invasion of RCC cells could be shown. +genetics_overexpression_suppress hsa-mir-18a "Carcinoma, Breast, Triple Negative" 27338042 Enforced miR-18a overexpression directly led to increased autophagy in MDA-MB-231 cells +genetics_overexpression_suppress hsa-mir-126 Age-Related Macular Degeneration 27338342 overexpression effects of miR-126 were also proven on human microvascular endothelial cells +genetics_overexpression_suppress hsa-mir-156a "Carcinoma, Nasopharyngeal" 27341697 synthetic miR156a mimic inhibited the EMT of NPC cells in vitro. +genetics_overexpression_suppress hsa-mir-376c Cervical Neoplasms 27345009 "Upregulation of miR-376c impaired cell proliferation, blocked G1/S checkpoint of cell cycle and suppressed cell invasion in vitro." +genetics_overexpression_suppress hsa-mir-195 Colon Neoplasms 27347317 "Overexpression of miR-195-5p inhibited cellular growth, suppressed cellular migration and invasion, and led to cell cycle arrest at G1 phase in vitro." +genetics_overexpression_suppress hsa-mir-132 Chronic Pain 27349406 Spinal administration of miR-132-3p antagonists via intrathecal (i.t.) catheters dose dependently reversed mechanical allodyina (p<0.001) and eliminated pain behavior +genetics_overexpression_suppress hsa-mir-24 Cerebral Ischemia 27349868 miR-24 overexpression or silencing of neurocan shows an antihypoxic effect in SH-SY5Y cells. +genetics_overexpression_suppress hsa-mir-24 Lacrimal Adenoid Cystic Carcinoma 27351203 overexpression of miR-24-3p decreased its malignant phenotype. +genetics_overexpression_suppress hsa-mir-449a Lung Fibrosis 27351886 miR-449a significantly reduced both the distribution and severity of lung lesions induced by silica. +genetics_overexpression_suppress hsa-mir-410 Systemic Lupus Erythematosus 27351906 overexpression of miR-410 significantly reduced the expression levels of IL-10. +genetics_overexpression_suppress hsa-mir-548an Pancreatic Neoplasms 27353169 overexpression of miR-548an significantly inhibited the proliferation and invasion of pancreatic cancer cell +genetics_overexpression_suppress hsa-mir-140 Gastric Neoplasms 27353653 miR-140 overexpression inhibited HGC-27 cell viability and colony formation and resulted in G0/G1 arrest. +genetics_overexpression_suppress hsa-mir-139 Bladder Neoplasms 27355528 Gain-of-function studies showed that miR-139-5p and miR-139-3p significantly inhibited cell migration and invasion by BC cells. +genetics_overexpression_suppress hsa-mir-335 Bladder Neoplasms 27356628 Overexpression of miRâ€?35 in T24 cells inhibited cell proliferation and induced apoptosis +genetics_overexpression_suppress hsa-mir-200b "Carcinoma, Lung, Non-Small-Cell" 27356635 Overexpression of miRâ€?00b significantly inhibited NSCLC cell migration and invasion. +genetics_overexpression_suppress hsa-mir-143 "Squamous Cell Carcinoma, Esophageal" 27358073 Ectopic expression of miR-143-3p also reduced the metastatic potential of cells by selectively regulating epithelial-mesenchymal transition regulatory proteins. +genetics_overexpression_suppress hsa-mir-330 Cutaneous Melanoma 27363653 Enforced expression of miR-330-5p inhibits malignant CMM cells proliferation and migration and led to downregulation of the TYR and PDIA3 protein. +genetics_overexpression_suppress hsa-mir-145 "Carcinoma, Breast, Triple Negative" 27364572 Upregulating miR-145 in HCC1937 cells dramatically suppressed cell proliferation and induced G1-phase arrest +genetics_overexpression_suppress hsa-mir-124 "Carcinoma, Lung, Non-Small-Cell" 27376157 "Overexpression of miR-124 significantly suppresses tumor cell proliferation, colony formation, migration, and induction of apoptosis in H322 and A549 cells." +genetics_overexpression_suppress hsa-mir-26a "Fatty Liver, Non-Alcoholic" 27377869 LV-26a-infected mice were protected from glucose dysmetabolism and showed markedly decreased total liver weight +genetics_overexpression_suppress hsa-mir-125b Ovarian Neoplasms 27383536 Ectopic expression of miR-125b in EOC cells significantly inhibited tumor invasion. +genetics_overexpression_suppress hsa-mir-106a Osteosarcoma 27383537 "Downregulation of miR-106a-5p was found in OS tissues, and upregulation of miR-106a-5p can inhibit the proliferation, migration, and invasion by targeting HMGA2 in OS cells." +genetics_overexpression_suppress hsa-mir-210 Acute Ischemic Stroke 27390218 Lentivirus-mediated miR-210 overexpression enhanced the microvessel density and the number of neural progenitor cells in the ischemic mouse brain (P < 0.05) and improved neurobehavioral outcomes in the ischemic mouse (P < 0.05). +genetics_overexpression_suppress hsa-mir-7 "Carcinoma, Hepatocellular" 27391479 Overexpression of miR-7 inhibited the HCC cell proliferation and invasion. Overexpression of miR-7 could suppress the direct target gene CCNE1 and PIK3CD expression. +genetics_overexpression_suppress hsa-mir-185 Idiopathic Pulmonary Fibrosis 27392970 "Furthermore, mimics of miR-185 and miR-186 blocked transforming growth factor-β-induced collagen V overexpression and alleviated transforming growth factor-β-induced epithelial-mesenchymal transition in A549 cells and HCC827 cells." +genetics_overexpression_suppress hsa-mir-186 Idiopathic Pulmonary Fibrosis 27392970 "Our findings suggest that attenuated expression of miR-185 and miR-186 may be responsible for collagen V overexpression during idiopathic pulmonary fibrosis, and these miRNAs may serve as pathogenesis-related biomarkers and treatment targets." +genetics_overexpression_suppress hsa-mir-449a "Carcinoma, Hepatocellular" 27398144 "Ectopic expression of miR-449a suppressed HCC cell proliferation, colony formation, migration and invasion." +genetics_overexpression_suppress hsa-mir-146a Liver Cirrhosis 27399683 "Overexpression of miR-146a-5p inhibited LPS induced pro-inflammatory cytokines secretion through down-regulating the expression levels of TLR-4, IL-1 receptor-associated kinase 1 (IRAK1), TNF receptor associated factor-6 (TRAF6) and phosphorylation of nuclear factor-kappa B (NF-κB)." +genetics_overexpression_suppress hsa-mir-200 "Carcinoma, Breast, Triple Negative" 27402080 "miR-9 and miR-200 promoted and inhibited, respectively, the formation of vascular-like structures in vitro" +genetics_overexpression_suppress hsa-mir-149 "Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal" 27403438 In vitro studies revealed that the exogenous expression of miRNA-149 inhibits the proliferation of human Hep-2 cells and induces cell apoptosis. +genetics_overexpression_suppress hsa-mir-218 Chronic Obstructive Pulmonary Disease 27409149 Perturbation experiments with a miR-218-5p mimic or inhibitor demonstrated a protective role of miR-218-5p in cigarette smoke-induced inflammation and COPD. +genetics_overexpression_suppress hsa-mir-133a Heart Diseases [unspecific] 27411382 "Our results revealed that miR-133a mimic treatment improved the contractility of the diabetic rat's heart concomitant with upregulation of TH, cardiac NE, β-AR, and downregulation of TAT and plasma levels of NE." +genetics_overexpression_suppress hsa-mir-141 "Carcinoma, Hepatocellular" 27412940 "Over-expression of miR-141 inhibits the proliferation, invasion and migration of hepatocellular carcinoma MHCC-97H cells" +genetics_overexpression_suppress hsa-mir-149 Colorectal Carcinoma 27415661 "Re-expression of miR-149 could enhance the 5-FU sensitivity of 5-FU-resistant CRC cells by increasing 5-FU-inducing apoptosis, while downregulation of miR-149 could decrease the 5-FU sensitivity of parental CRC cells by decreasing 5-FU-inducing apoptosis" +genetics_overexpression_suppress hsa-mir-18a "Carcinoma, Hepatocellular" 27421245 "We transfected HepG2.2.15 with miR-18a mimics and CTGF siRNA, finding that upregulated miR-18a and downregulated CTGF suppress the viability and cause cell cycle arrest." +genetics_overexpression_suppress hsa-mir-34a Leukemia 27424989 "Induced expression of miR-34a in TIM3 positive leukemia stem cells (LSC), inhibits the clonogenic expansion, tumor progression and metastasis of leukemia." +genetics_overexpression_suppress hsa-mir-320b "Carcinoma, Nasopharyngeal" 27428374 "Further studies showed that overexpression of miR-320b suppressed NPC cell proliferation and enhanced mitochondrial fragmentation and apoptosis both in vitro and in vivo, while silencing of miR-320b promoted tumor growth and suppressed apoptosis." +genetics_overexpression_suppress hsa-mir-497 Invasive Bladder Transitional Cell Carcinoma 27430325 "We also found that overexpression of miR-497 inhibited the proliferation, migration and invasion of bladder cancer cells by downregulating E2F3 (an miR-497 target gene) mRNA and protein and that siRNA against E2F3 inhibited cell proliferation, migration and invasion, which was similar to the effect of miR-497 overexpression in the BTCC cells." +genetics_overexpression_suppress hsa-mir-338 Lung Neoplasms 27431198 "Regaining the expression of miR-338 in lung cancer cell lines significantly impaired cellular adhesion, migration, invasion and lung tumor formation in nude mice." +genetics_overexpression_suppress hsa-mir-184 "Carcinoma, Renal Cell" 27431728 "Overexpression of pre-miR-184 changed the metabolic and proliferation features of ccRCC cells by reducing cell glucose consumption, lactate production and cell proliferation." +genetics_overexpression_suppress hsa-mir-183 "Carcinoma, Nasopharyngeal" 27431799 "Using transient or stable transfection, we showed that ectopic expression of miR-96 and miR-183 suppressed cell growth and tumor sphere formation in NPC." +genetics_overexpression_suppress hsa-mir-96 "Carcinoma, Nasopharyngeal" 27431799 "Using transient or stable transfection, we showed that ectopic expression of miR-96 and miR-183 suppressed cell growth and tumor sphere formation in NPC." +genetics_overexpression_suppress hsa-mir-30a Prostate Neoplasms 27431942 "miRâ€?0a overexpression resulted in a significant suppression of cell growth in vitro, and reduced tumorigenicity in vivo." +genetics_overexpression_suppress hsa-mir-200c Lung Neoplasms 27432063 "Over expression of miR-200c could significantly inhibit cell proliferation, induce G0/G1 cell cycle arrest and induce cell apoptosis." +genetics_overexpression_suppress hsa-mir-27a "Squamous Cell Carcinoma, Oral" 27432214 "Intriguingly, increased expression of miR-27a-3p could significantly decrease the expression level of YAP1 as well as several epithelial to mesenchymal transition (EMT)-related molecules in OSCC cell lines, including Twist and Snail." +genetics_overexpression_suppress hsa-mir-199a Testicular Neoplasms 27432288 it was determined that overexpression of miRâ€?99aâ€?p in Nteraâ€? cells caused suppression of cell growth and migration. +genetics_overexpression_suppress hsa-mir-541 "Carcinoma, Lung, Non-Small-Cell" 27448300 We found that expression of miR-541-3p was decreased obviously in NSCLC tissues and plasma. Down-regulation of miR-541-3p was associated with TNM stage and postoperative survival. +genetics_overexpression_suppress hsa-mir-26a Prostate Neoplasms 27449037 It was confirmed that miR-26a-5p was markedly downregulated in PC tissues compared with normal controls whose reduced expression was significantly associated with metastasis and poor overall prognosis and found that miR-26a-5p was able to prevent proliferation and motility of PC cells in vitro. +genetics_overexpression_suppress hsa-mir-613 Breast Neoplasms 27449609 "miR-613 mimics significantly inhibited the migration and invasion of breast cancer cells, whereas miR-613 inhibitors significantly increased cell migration and invasion." +genetics_overexpression_suppress hsa-mir-455 Gastric Neoplasms 27451075 "re-expression of miR-455-5p could inhibit human GC cell proliferation and invasion, overexpression of miR-455-5p could also promote GC cell apoptosis." +genetics_overexpression_suppress hsa-mir-338 "Carcinoma, Lung, Non-Small-Cell" 27453416 Forced expression of miR-338-3p in A549 cells led to the suppression of migration/invasion capacity and inhibition of epithelial markers. +genetics_overexpression_suppress hsa-mir-34a "Carcinoma, Cervical" 27456356 "While forced expression of miR-34a in CaCx and CRC cells inhibited HMGB1 mRNA and protein levels, proliferation, migration and invasion, inhibition of endogenous miR-34a enhanced these tumourigenic properties." +genetics_overexpression_suppress hsa-mir-34a Colorectal Carcinoma 27456356 "While forced expression of miR-34a in CaCx and CRC cells inhibited HMGB1 mRNA and protein levels, proliferation, migration and invasion, inhibition of endogenous miR-34a enhanced these tumourigenic properties." +genetics_overexpression_suppress hsa-mir-497 Breast Neoplasms 27456360 "Further, overexpression of miR-497 not only inhibited ERRα expression but also reduced MIF level and MMP9 activity, which led to significant decreases in cell proliferation, migration, and invasion of ERα negative breast cancer." +genetics_overexpression_suppress hsa-mir-15a "Carcinoma, Nasopharyngeal" 27458095 "As a result, miR-15a overexpression significantly reduced cell proliferation (pâ€?â€?.01 or pâ€?â€?.001) and induced cell apoptosis (pâ€?â€?.001), while miR-15a suppression got the opposite result for cell proliferation and apoptosis." +genetics_overexpression_suppress hsa-mir-451 "Carcinoma, Hepatocellular" 27461244 "In this study, overexpression of miR-451 clearly attenuated the promoting effects of HCC cells on cell proliferation, migration and tube formation of human umbilical vein endothelial cells (HUVECs)." +genetics_overexpression_suppress hsa-mir-1207 "Carcinoma, Hepatocellular" 27461404 Overexpression of miR-1207-5p significantly suppressed the cell growth and invasion of HCC cells. +genetics_overexpression_suppress hsa-mir-34c Prostate Neoplasms 27461446 "In this study, we identified that miR-34C was under-expressed in the purified CD133+ PCSCs and enforced introduction of miR-34C attenuated the stemness of CD133+ PCSCs." +genetics_overexpression_suppress hsa-mir-520a Lymphoma 27461820 "Our data indicated that the mimics of miRâ€?20a inhibited growth, proliferation of Raji cells and promoted its apoptosis, which was related to downregulation of AKT1, NF‑κB and ER stress response mediated by PERK/eIF2α pathway." +genetics_overexpression_suppress hsa-mir-520a "Lymphoma, Burkitt" 27461820 "Our data indicated that the mimics of miRâ€?20a inhibited growth, proliferation of Raji cells and promoted its apoptosis, which was related to downregulation of AKT1, NF‑κB and ER stress response mediated by PERK/eIF2α pathway." +genetics_overexpression_suppress hsa-mir-520a "Lymphoma, Hodgkin" 27461820 "Our data indicated that the mimics of miRâ€?20a inhibited growth, proliferation of Raji cells and promoted its apoptosis, which was related to downregulation of AKT1, NF‑κB and ER stress response mediated by PERK/eIF2α pathway." +genetics_overexpression_suppress hsa-mir-520a "Lymphoma, Non-Hodgkin" 27461820 "Our data indicated that the mimics of miRâ€?20a inhibited growth, proliferation of Raji cells and promoted its apoptosis, which was related to downregulation of AKT1, NF‑κB and ER stress response mediated by PERK/eIF2α pathway." +genetics_overexpression_suppress hsa-mir-132 "Carcinoma, Hepatocellular" 27467251 The tumor-suppressive role of miR-132 in HCC has been further confirmed by in vitro experiments. +genetics_overexpression_suppress hsa-mir-203 Glioblastoma 27467502 Conversely reconstitution of miR-203 expression induced apoptosis and inhibited migratory property of glioma cells. +genetics_overexpression_suppress hsa-mir-26a Osteosarcoma 27468358 "Using in vitro and in vivo assays, we confirmed that miR-26a could inhibit the abilities of in vitro proliferation and suppress in vivo tumor growth in mouse model." +genetics_overexpression_suppress hsa-mir-205 "Carcinoma, Breast" 27468619 Knock-up of miR-205 expression by transfection with its mimics promoted MDA-MB-468 cells apoptosis (P=0.006 1). +genetics_overexpression_suppress hsa-mir-137 "Carcinoma, Gastric" 27468717 "Over expression of miR-137 could inhibit the cell migration, proliferation, and promote cell cycle arrest in G0/G1 stage in BGC-823 and SGC-7901 cell lines." +genetics_overexpression_suppress hsa-mir-182 "Carcinoma, Renal Cell, Clear-Cell" 27468875 "Compared to the control group, cell viability, colony-forming ability, and numbers of migrated and invaded cells were significantly decreased by transfection with miR-182 mimic but were markedly increased by miR-182 inhibitor (all P < 0.05)." +genetics_overexpression_suppress hsa-mir-148a "Carcinoma, Ovarian" 27470550 "Moreover, cell experiments confirmed that miR-148a could inhibit proliferation, migration and invasion of ovarian cancer cells." +genetics_overexpression_suppress hsa-mir-122 Cholangiocarcinoma 27472451 "MiR-122 overexpression reduced cell invasion and migration ability, and inhibited cell apoptosis and p53 expression. Inhibiting miR-122 caused the opposite results." +genetics_overexpression_suppress hsa-mir-451 Glioma 27476171 "By targeting CAB 39, miRNA-451 likely triggers the LKB1/AMPK/PI3K/AKT pathway, which regulates GLUT1, to inhibit the glucose metabolism of, reduce the energy supply to, and inhibit the proliferation and invasion of glioma cells." +genetics_overexpression_suppress hsa-mir-29b Wound Healing 27477081 "Importantly, local delivery of miR-29b lentiviral particles inhibited HSP47 expression and collagen biosynthesis as well as suppressed angiogenesis, thus reducing scar formation in an excisional wound splinting model." +genetics_overexpression_suppress hsa-mir-194 "Squamous Cell Carcinoma, Esophageal" 27480251 miR-194 was found to inhibit proliferation and invasion and promote apoptosis of esophageal squamous cell carcinoma cells. +genetics_overexpression_suppress hsa-mir-203 Glioblastoma 27484906 MicroRNA-203 transfected GBM-SCs had reduced capacity for self-renewal in the cell sphere assay and increased expression of glial and neuronal differentiation markers. +genetics_overexpression_suppress hsa-mir-26a Vascular Hypertrophy 27485101 "Taken together, the present study suggested an anti‑hypertrophic role of miRâ€?6a in cardiac hypertrophy, possibly via inhibition of GATA4." +genetics_overexpression_suppress hsa-mir-101 "Carcinoma, Bladder" 27485165 "In addition, plasmid‑mediated overexpression of miRâ€?01 and small hairpin RNA‑mediated inhibition of c‑FOS significantly inhibited the proliferation and invasive capacity of T24 cells." +genetics_overexpression_suppress hsa-mir-610 Glioma 27485527 "Furthermore, the present study revealed that miRâ€?10 inhibited cell growth, migration and invasion in glioma cells." +genetics_overexpression_suppress hsa-mir-329 Osteosarcoma 27487475 "MiR-329 is able to inhibit osteosarcoma cell proliferation, promote apoptosis, and induce G0/G1 cell cycle arrest." +genetics_overexpression_suppress hsa-mir-29a "Carcinoma, Lung" 27488440 Restoration of miR-29a suppressed cancer cell aggressiveness and fibroblast migration. +genetics_overexpression_suppress hsa-mir-29a Idiopathic Pulmonary Fibrosis 27488440 Restoration of miR-29a suppressed cancer cell aggressiveness and fibroblast migration. +genetics_overexpression_suppress hsa-mir-29b Granular Corneal Dystrophy 27490049 Overexpression of miR-29b decreased ECM protein production in human corneal endothelial cells. +genetics_overexpression_suppress hsa-mir-1299 "Carcinoma, Hepatocellular" 27490780 "miR-1299 overexpression inhibited cell proliferation and arrested cell cycle in G0/G1 phase analyzed by MTT assay, soft agar assay, BrdU cell proliferation assay and cell cycle assay, while miR-1299 knockdown promoted cell proliferation and accelerated G1/S transition." +genetics_overexpression_suppress hsa-mir-15a Melanoma 27492455 miR-15a displayed inhibitory effects on proliferation and invasiveness of several malignant melanoma cell lines. +genetics_overexpression_suppress hsa-mir-137 "Carcinoma, Hepatocellular" 27492460 "Overexpression of miR-137 via adenoviral vector inhibited the proliferation and anchorage-independent growth of HCC cells, HepG2 and MHCC-97H." +genetics_overexpression_suppress hsa-mir-143 Leukemia 27492780 miRNA143 transfection inhibited K562 cell growth and induced its apoptosis. +genetics_overexpression_suppress hsa-mir-3178 "Carcinoma, Gastric" 27493095 "The condition medium from miR-3178 mimic transfected GES-1 cells could inhibit proliferation and induce apoptosis of inflammation-related gastric cancer cells SGC7901 and MGC803 by decreasing the production of inflammatory cytokines TNF-α and IL-6, which were secreted by GES-1 cells." +genetics_overexpression_suppress hsa-mir-187 "Carcinoma, Lung, Non-Small-Cell" 27495872 Overexpression of miR-187-5p inhibited the growth and metastasis of NSCLC cells. +genetics_overexpression_suppress hsa-mir-155 Allergy 27497617 miR-155 overexpression significantly suppressed IL-13-induced secretion of CCL11 and CCL26. +genetics_overexpression_suppress hsa-mir-509 "Carcinoma, Lung" 27498003 "In addition, over-expression of miR-509-3-5p markedly blocked A549 cell proliferation and sensitized the cells to CIS and ADR treatment." +genetics_overexpression_suppress hsa-let-7a "Carcinoma, Colon" 27498032 Further studies demonstrated that over-expressed let-7a could remarkably inhibit HCT-116 and SW620 cell growth and metastasis by directly down-regulating Rhotekin (RTKN). +genetics_overexpression_suppress hsa-mir-140 Glioma 27498787 "Restoration of miR-140 obviously suppressed glioma cell proliferation, migration and invasion." +genetics_overexpression_suppress hsa-mir-205 "Carcinoma, Renal Cell" 27498834 "It was revealed that miRâ€?05 promoted the apoptosis of RCC cells and suppressed their proliferation, metastasis and invasion compared with the negative control." +genetics_overexpression_suppress hsa-mir-124 Retinoblastoma 27498908 "The ectopic expression of miR-124 in the RB cell lines (Y79 and SO-RB50) suppresses cell proliferation, migration and invasion, induced cell apoptosis in vitro." +genetics_overexpression_suppress hsa-mir-186 "Carcinoma, Lung, Non-Small-Cell" 27498924 "Furthermore, overexpression of miR-186 suppressed lung cancer cell proliferation, migration and invasion, and induced cell apoptosis." +genetics_overexpression_suppress hsa-mir-107 "Carcinoma, Lung" 27498977 "Function assays showed that overexpression of miR-107 suppressed cell proliferation, migration and invasion in A549 cells in vitro, and inhibited NSCLC tumor growth in vivo." +genetics_overexpression_suppress hsa-mir-17 "Carcinoma, Ovarian" 27499367 "Forced expression of miR-17 led to markedly diminished adhesion and invasion of ovarian cancer cells in vitro, and notably reduced metastatic nodules inside the peritoneal cavity in in vivo SKOV3 xenografts model." +genetics_overexpression_suppress hsa-mir-370 "Carcinoma, Gastric" 27499479 Upregulation of microRNA-370 promotes cell apoptosis and inhibits proliferation by targeting PTEN in human gastric cancer. +genetics_overexpression_suppress hsa-mir-622 "Squamous Cell Carcinoma, Esophageal" 27501502 "Up-regulation of miR-622 could significantly reduce ESCC cell proliferation, enhance cell apoptosis, and impair cell invasion and migration in vitro, while down-regulation of miR-622 showed opposite effects." +genetics_overexpression_suppress hsa-mir-223 Ischemia-Reperfusion Injury 27502281 Precursor miR-223 (pre-miR-223) transgenic mouse hearts exhibited better recovery of contractile performance over reperfusion period and lesser degree of myocardial necrosis than wild type hearts upon ex vivo and in vivo myocardial ischemia. +genetics_overexpression_suppress hsa-mir-148b "Carcinoma, Cervical" 27505047 "miR-148b mimics significantly decreased the cell proliferation ability and invasion ability, and statistically induced apoptosis." +genetics_overexpression_suppress hsa-mir-139 "Carcinoma, Cervical" 27505862 "Overexpression of miR-139-3p significantly suppressed HeLa cell proliferation, migration and invasion and induced cell apoptosis." +genetics_overexpression_suppress hsa-mir-490 "Carcinoma, Breast, Triple Negative" 27506313 Gain-of-function studies revealed that miR-490-3p-3p overexpression inhibited cell growth and invasion in both MDA-MB-231 and MDA-MB-436 TNBC cells and impaired tumorigenesis of MDA-MB-231 cells in nude mice. +genetics_overexpression_suppress hsa-mir-122 Bladder Neoplasms 27508026 "Furthermore, miR-122 over-expression decreases bladder cancer cell migration, invasion, colony formation in vitro and slow bladder cancer growth and angiogenesis in vivo." +genetics_overexpression_suppress hsa-mir-145 Breast Neoplasms 27508031 Wound healing assay and transwell migration assay showed that ectopic expression of miR-145 significantly inhibited breast cancer cell migration. +genetics_overexpression_suppress hsa-mir-338 Ovarian Neoplasms 27508048 "Restoration of miR-338-3p expression in ovarian cancer cells could inhibit cell proliferation, lactate production and lactate production of ovarian cancer cells." +genetics_overexpression_suppress hsa-mir-20a "Squamous Cell Carcinoma, Esophageal" 27508097 "Together, our findings demonstrate that miR-17/20a suppresses cell migration and invasion of ESCC by modulating TGF-β/ITGB6 pathway." +genetics_overexpression_suppress hsa-mir-497 "Carcinoma, Ovarian" 27513319 Overexpression of microRNA-497 suppresses cell proliferation and induces apoptosis through targeting paired box 2 in human ovarian cancer. +genetics_overexpression_suppress hsa-mir-221 Lung Fibrosis 27513632 miRâ€?21 targets HMGA2 to inhibit bleomycin‑induced pulmonary fibrosis by regulating TGF‑Î?/Smad3-induced EMT. +genetics_overexpression_suppress hsa-mir-106a "Carcinoma, Bladder" 27513725 Overexpression of mir-106a suppressed the proliferation of bladder cancer cell in EJ. +genetics_overexpression_suppress hsa-mir-34a "Carcinoma, Gastric" 27513895 Upregulation of miR-34a enhanced the DDP sensitivity of SGC7901/DDP cells to DDP through the inhibition of cell proliferation and induction of cell apoptosis. +genetics_overexpression_suppress hsa-mir-101 "Leukemia, Myeloid, Chronic" 27517565 These findings suggest that miR-101 acts as a tumor suppressor by downregulating Jak2 expression and sensitizing K562 cells to imatinib. +genetics_overexpression_suppress hsa-mir-181a Leukemia 27517749 "NP-mediated upregulation of miR-181a led to reduced proliferation, impaired colony formation and increased sensitivity to chemotherapy." +genetics_overexpression_suppress hsa-mir-26a "Carcinoma, Breast" 27517917 MiR-26a overexpression resulted in a reduction in cell viability that was partially recovered by inhibiting it. +genetics_overexpression_suppress hsa-mir-148a "Carcinoma, Gastric" 27518872 "Ectopic expression of miR-148a inhibited tumor cell proliferation and migration in vitro, and inhibited tumor formation in vivo." +genetics_overexpression_suppress hsa-let-7b Glioma 27520092 "upregulation of Let-7b, a member of the Let-7 microRNA family, inhibited proliferation, migration, and invasion in glioma cell lines." +genetics_overexpression_suppress hsa-mir-34a "Carcinoma, Breast" 27524218 MiR-34a expression was remarkably down-regulated in BC tissues and cell lines compared with normal tissues and cell lines. +genetics_overexpression_suppress hsa-mir-132 "Carcinoma, Prostate" 27527117 "Notably, overexpression of miR-132/212 could inhibit TGF-¦Â (transforming growth factor-¦Â)-induced EMT in Vcap and Lncap cells at both the mRNA and protein expression levels." +genetics_overexpression_suppress hsa-mir-132 Prostate Neoplasms 27527117 "Notably, overexpression of miR-132/212 could inhibit TGF-¦Â (transforming growth factor-¦Â)-induced EMT in Vcap and Lncap cells at both the mRNA and protein expression levels." +genetics_overexpression_suppress hsa-mir-212 "Carcinoma, Prostate" 27527117 "Notably, overexpression of miR-132/212 could inhibit TGF-¦Â (transforming growth factor-¦Â)-induced EMT in Vcap and Lncap cells at both the mRNA and protein expression levels." +genetics_overexpression_suppress hsa-mir-210 Ischemic Diseases [unspecific] 27530798 "Neonatal rats show down-regulated expression of miRNA-210 after HI, suggesting that miRNA-210 may be involved in the development and progression of hypoxic-ischemic brain edema in neonatal rats." +genetics_overexpression_suppress hsa-mir-15a Diabetes Mellitus 27531575 "miR-15a overexpression led to modulation toward nondiabetic levels, rather than complete inhibition of ASM and VEGF-A providing therapeutic effect without detrimental consequences of ASM and VEGF-A deficiencies" +genetics_overexpression_suppress hsa-mir-15a Diabetic Retinopathy 27531575 "Over-expression of miR-15a downregulated, and inhibition of miR-15a upregulated ASM and VEGF-A expression in retinal cells." +genetics_overexpression_suppress hsa-mir-1 Heart Diseases [unspecific] 27531746 We also found that microRNAs (miRNAs) 1 and 21 bind PLN strongly and relieve PLN inhibition of SERCA to a greater extent than a similar length random sequence RNA mixture. +genetics_overexpression_suppress hsa-mir-21 Heart Diseases [unspecific] 27531746 We also found that microRNAs (miRNAs) 1 and 21 bind PLN strongly and relieve PLN inhibition of SERCA to a greater extent than a similar length random sequence RNA mixture. +genetics_overexpression_suppress hsa-mir-613 Ischemia-Reperfusion Injury 27534371 miR-613 inhibits I/R-induced cardiomyocyte apoptosis by targeting PDCD10 by regulating the PI3K/AKT signaling pathway +genetics_overexpression_suppress hsa-mir-613 Myocardial Ischemic-Reperfusion Injury 27534371 miR-613 inhibits I/R-induced cardiomyocyte apoptosis by targeting PDCD10 by regulating the PI3K/AKT signaling pathway. +genetics_overexpression_suppress hsa-mir-17 Rheumatoid Arthritis 27534557 MicroRNA-17 Suppresses TNF-B Signaling by Interfering with TRAF2 and cIAP2 Association in Rheumatoid Arthritis Synovial Fibroblasts. +genetics_overexpression_suppress hsa-mir-200a "Cardiomyopathy, Ischemic" 27573160 Overexpression of miR-200a protects cardiomyocytes against hypoxia-induced apoptosis by modulating the kelch-like ECH-associated protein 1-nuclear factor erythroid 2-related factor 2 signaling axis. +genetics_overexpression_suppress hsa-mir-21 Ischemia-Reperfusion Injury 27593550 Overexpression of microRNA-21 protects spinal cords against transient ischemia. +genetics_overexpression_suppress hsa-mir-140 Osteosarcoma 27624383 Overexpression of miR-140 Inhibits Proliferation of Osteosarcoma Cells via Suppression of Histone Deacetylase 4. +genetics_overexpression_suppress hsa-mir-422a Osteosarcoma 27779704 "Overexpression of miR-422a inhibits cell proliferation and invasion, and enhances chemosensitivity in osteosarcoma cells." +genetics_overexpression_suppress hsa-mir-21 "Carcinoma, Hepatocellular" 27793160 Overexpression of microRNA-21 strengthens stem cell-like characteristics in a hepatocellular carcinoma cell line. +genetics_overexpression_suppress hsa-mir-126 Atherosclerosis 27827458 MicroRNA-126 overexpression rescues diabetes-induced impairment in efferocytosis of apoptotic cardiomyocytes. +genetics_overexpression_suppress hsa-mir-93 Glaucoma 27878244 MicroRNA?93 is overexpressed and induces apoptosis in glaucoma trabecular meshwork cells. +genetics_overexpression_suppress hsa-mir-365 "Carcinoma, Breast" 27906431 Overexpression of microRNA-365 inhibits breast cancer cell growth and chemo-resistance through GALNT4. +genetics_overexpression_suppress hsa-mir-210 "Carcinoma, Pancreatic" 27940128 microRNA-210 overexpression inhibits tumor growth and potentially reverses gemcitabine resistance in pancreatic cancer. +genetics_overexpression_suppress hsa-mir-34a "Carcinoma, Colon" 28035390 "overexpression of miR-34a may inhibit the proliferation, invasion and metastasis of HCT116 cells" +genetics_overexpression_suppress hsa-mir-1 Heart Failure 28063219 MicroRNA-1 overexpression blunts cardiomyocyte hypertrophy elicited by thyroid hormone. +genetics_overexpression_suppress hsa-mir-142 "Carcinoma, Hepatocellular" 28081734 MicroRNA-142-5p Overexpression Inhibits Cell Growth and Induces Apoptosis by Regulating FOXO in Hepatocellular Carcinoma Cells. +genetics_overexpression_suppress hsa-mir-27b "Carcinoma, Lung, Non-Small-Cell" 28081743 "Overexpression of MicroRNA-27b Inhibits Proliferation, Migration, and Invasion via Suppression of MET Expression." +genetics_overexpression_suppress hsa-mir-29a Glioblastoma 28212562 Overexpression of miR-29a reduces the oncogenic properties of glioblastoma stem cells by downregulating Quaking gene isoform 6. +genetics_overexpression_suppress hsa-mir-519d "Adenocarcinoma, Lung" 28351305 Overexpression of miR-519d in lung adenocarcinoma inhibits cell proliferation and invasion via the association of eIF4H. +genetics_overexpression_suppress hsa-mir-138 Coronary Artery Disease 28371277 Overexpression of microRNA-138 alleviates human coronary artery endothelial cell injury and inflammatory response by inhibiting the PI3K/Akt/eNOS pathway. +genetics_overexpression_suppress hsa-mir-24 "Lymphoma, Hodgkin" 28432871 miR-24-3p Is Overexpressed in Hodgkin Lymphoma and Protects Hodgkin and Reed-Sternberg Cells from Apoptosis. +genetics_overexpression_suppress hsa-mir-125b "Leukemia, Myeloid, Acute" 28478034 "Overexpression of microRNA-125b inhibits human acute myeloid leukemia cells invasion, proliferation and promotes cells apoptosis by targeting NF-¦ÊB signaling pathway." +genetics_overexpression_suppress hsa-mir-194 Adenovirus Infection 28618953 Overexpression of microRNA-194 suppresses the epithelial-mesenchymal transition in targeting stem cell transcription factor Sox3 in endometrial carcinoma stem cells. +genetics_overexpression_suppress hsa-mir-183 "Carcinoma, Nasopharyngeal" 28631568 MiR-183 overexpression inhibits tumorigenesis and enhances DDP-induced cytotoxicity by targeting MTA1 in nasopharyngeal carcinoma. +genetics_overexpression_suppress hsa-mir-211 Thyroid Neoplasms 28703321 "Overexpression miR-211-5p hinders the proliferation, migration, and invasion of thyroid tumor cells by downregulating SOX11." +genetics_overexpression_suppress hsa-mir-124 Cardiovascular Diseases [unspecific] 28849090 Overexpressed microRNA-506 and microRNA-124 alleviate H2O2-induced human cardiomyocyte dysfunction by targeting kr¨¹ppel-like factor 4/5. +genetics_overexpression_suppress hsa-mir-506 Cardiovascular Diseases [unspecific] 28849090 Overexpressed microRNA-506 and microRNA-124 alleviate H2O2-induced human cardiomyocyte dysfunction by targeting kr¨¹ppel-like factor 4/5. +genetics_overexpression_suppress hsa-mir-34a "Carcinoma, Cervical" 28893346 Overexpression of MicroRNA-34a-5p Inhibits Proliferation and Promotes Apoptosis of Human Cervical Cancer Cells by Downregulation of Bcl-2. +genetics_overexpression_suppress hsa-mir-19a Colorectal Carcinoma 29207158 Overexpression of miR-19a inhibits colorectal cancer angiogenesis by suppressing KRAS expression +genetics_overexpression_suppress hsa-mir-150 Ischemia-Reperfusion Injury 29328381 Overexpressing microRNA-150 attenuates hypoxia-induced human cardiomyocyte cell apoptosis by targeting glucose-regulated protein-94 +genetics_overexpression_suppress hsa-mir-204 Ischemia-Reperfusion Injury 29421577 overexpression of miR-204 has a protective effect against myocardial I/R injury +genetics_overexpression_suppress hsa-mir-145 Breast Neoplasms 29425746 miR-145 overexpression triggers alteration of the whole transcriptome and inhibits breast cancer development +genetics_overexpression_suppress hsa-mir-143 "Carcinoma, Lung, Non-Small-Cell" 29630116 "overexpression of miR-143 downregulated cell proliferation, promoted the apoptosis, and suppressed the phosphorylation of EGFR, AKT and ERK1/2; thus, miR-143 may play a role in treatment of NSCLC to enhance therapeutic efficacy" +genetics_overexpression_suppress hsa-mir-203 "Fatty Liver, Alcoholic" 29670525 over-expression of miR-203 inhibited the liver lipids accumulation and the progression of AFL by targeting Lipin1 +genetics_overexpression_suppress hsa-mir-27b Atrial Fibrillation 29671258 Atrial overexpression of microRNA-27b attenuates angiotensin II-induced atrial fibrosis and fibrillation by targeting ALK5. +genetics_overexpression_suppress hsa-mir-132 Heart Failure 29682535 Overexpression of microRNA-132 dramatically increased the antioxidant stress and antiapoptotic ability of H9C2 cells and decreased the expression of TGF-¦Â1 and smad3 +genetics_overexpression_suppress hsa-mir-140 Intervertebral Disc Degeneration 29901170 Overexpression of miR-140-5p inhibits lipopolysaccharide-induced human intervertebral disc inflammation and degeneration by downregulating toll-like receptor 4. +genetics_overexpression_suppress hsa-mir-7 "Carcinoma, Hepatocellular" 29936764 Overexpression of miR-7 can inhibit the proliferation and invasion ability of hepatocellular carcinoma cells HepG2 by downregulating Raf1 in vitro +genetics_overexpression_suppress hsa-mir-410 "Carcinoma, Hepatocellular" 30086463 overexpression of miR-133a suppressed biological behaviour of HCC through TGF-¦Â/Smad3 signaling pathway +other hsa-mir-142 "Leukemia, B-Cell" 12007417 A translocation that make MYC overexpression +other hsa-mir-143 Colon Neoplasms 14573789 reduced miRNA levels +other hsa-mir-145 Colon Neoplasms 14573789 reduced miRNA levels +other hsa-mir-17 Lymphoma 16096373 "Herein, we propose a model in which the mir-17 cluster prevents excessive E2F1 activity, and thereby apoptosis, in response to activation of c-Myc." +other hsa-mir-122 Hepatitis C Virus Infection 16141076 interaction with non-coding regions of Hepatitis C help its replication +other hsa-mir-375 Diabetes Mellitus 16195701 mir-375 was found to modulate glucose-stimulated insulin secretion and exocytosis. +other hsa-mir-29a Acquired Immunodeficiency Syndrome 16236258 miRNAs expressed in T-cells can repress nef function and thus influence disease progression. +other hsa-mir-29b-1 Acquired Immunodeficiency Syndrome 16236258 miRNAs expressed in T-cells can repress nef function and thus influence disease progression. +other hsa-mir-181a Hematologic Neoplasms 16249029 "The stress-induced modulation of hematopoietic miR-181a levels through AChE, PKC and PKA cascade(s) suggests using miRNA mimics for diverting the fate of hematopoietic tumor cells towards differentiation and/or apoptosis." +other hsa-mir-15a "Leukemia, Lymphocytic, Chronic, B-Cell" 16885332 The finding that essentially all indolent CLLs have lost miR-15a/miR-16-1 expression suggests that this event is the initiating event in the pathogenesis of the indolent form of CLL. +other hsa-mir-16-1 "Leukemia, Lymphocytic, Chronic, B-Cell" 16885332 The finding that essentially all indolent CLLs have lost miR-15a/miR-16-1 expression suggests that this event is the initiating event in the pathogenesis of the indolent form of CLL. +other hsa-mir-372 Neoplasms [unspecific] 17028596 "mir-372/373 shown to be oncogenes cooperating with Ras (Voorhoeve et al., 2006)" +other hsa-mir-373 Neoplasms [unspecific] 17028596 "mir-372/373 shown to be oncogenes cooperating with Ras (Voorhoeve et al., 2006)" +other hsa-mir-17 Lymphoma 17093929 These data demonstrate that OncomiR-1 accelerates lymphoma and promotes a more disseminated disease. +other hsa-mir-18a Lymphoma 17093929 These data demonstrate that OncomiR-1 accelerates lymphoma and promotes a more disseminated disease. +other hsa-mir-18b Lymphoma 17093929 These data demonstrate that OncomiR-1 accelerates lymphoma and promotes a more disseminated disease. +other hsa-mir-19a Lymphoma 17093929 These data demonstrate that OncomiR-1 accelerates lymphoma and promotes a more disseminated disease. +other hsa-mir-19b-1 Lymphoma 17093929 These data demonstrate that OncomiR-1 accelerates lymphoma and promotes a more disseminated disease. +other hsa-mir-19b-2 Lymphoma 17093929 These data demonstrate that OncomiR-1 accelerates lymphoma and promotes a more disseminated disease. +other hsa-mir-20a Lymphoma 17093929 These data demonstrate that OncomiR-1 accelerates lymphoma and promotes a more disseminated disease. +other hsa-mir-20b Lymphoma 17093929 These data demonstrate that OncomiR-1 accelerates lymphoma and promotes a more disseminated disease. +other hsa-mir-92a-1 Lymphoma 17093929 These data demonstrate that OncomiR-1 accelerates lymphoma and promotes a more disseminated disease. +other hsa-mir-92a-2 Lymphoma 17093929 These data demonstrate that OncomiR-1 accelerates lymphoma and promotes a more disseminated disease. +other hsa-mir-92b Lymphoma 17093929 These data demonstrate that OncomiR-1 accelerates lymphoma and promotes a more disseminated disease. +other hsa-mir-32 Viral Infectious Disease 17096367 "The authors found that a cellular miRNA, miR-32, mediated antiviral defense in human cells, and regulated primate foamy virus type I (PFV-1) proliferation." +other hsa-mir-17 "Lymphoma, Burkitt" 17135268 "We recently demonstrated that a polycistronic cluster of miRNAs, miR-17-92, is oncogenic in a mouse model for Burkitt's lymphoma." +other hsa-mir-18 "Lymphoma, Burkitt" 17135268 "We recently demonstrated that a polycistronic cluster of miRNAs, miR-17-92, is oncogenic in a mouse model for Burkitt's lymphoma." +other hsa-mir-19a "Lymphoma, Burkitt" 17135268 "We recently demonstrated that a polycistronic cluster of miRNAs, miR-17-92, is oncogenic in a mouse model for Burkitt's lymphoma." +other hsa-mir-19b-1 "Lymphoma, Burkitt" 17135268 "We recently demonstrated that a polycistronic cluster of miRNAs, miR-17-92, is oncogenic in a mouse model for Burkitt's lymphoma." +other hsa-mir-20a "Lymphoma, Burkitt" 17135268 "We recently demonstrated that a polycistronic cluster of miRNAs, miR-17-92, is oncogenic in a mouse model for Burkitt's lymphoma." +other hsa-mir-92-1 "Lymphoma, Burkitt" 17135268 "We recently demonstrated that a polycistronic cluster of miRNAs, miR-17-92, is oncogenic in a mouse model for Burkitt's lymphoma." +other hsa-mir-155 "Lymphoma, Burkitt" 17173072 "Our data provide evidence for two levels of regulation for mature miR-155 expression: one at the transcriptional level involving PKC and NF-kappaB, and one at the processing level. Burkitt lymphoma cells not only express low levels of BIC, but also prevent processing of BIC via an, as yet, unknown mechanism." +other hsa-mir-143 Hepatitis C Virus Infection 17188425 "miRNA-143 and -145 levels increase as disease progresses from chronic hepatitis to cirrhosis, suggesting that they may turn on inflammatory or fibrosis related genes and/or turn off tumor suppressor genes." +other hsa-mir-145 Hepatitis C Virus Infection 17188425 "miRNA-143 and -145 levels increase as disease progresses from chronic hepatitis to cirrhosis, suggesting that they may turn on inflammatory or fibrosis related genes and/or turn off tumor suppressor genes." +other hsa-mir-223 "Leukemia, Promyelocytic, Acute" 17217039 "The activation of both pathways of transcriptional regulation by the myeloid lineage-specific transcription factor C/EBPalpha (CCAAT/enhancer-binding protein-alpha), and posttranscriptional regulation by miR-223 appears essential for granulocytic differentiation and clinical response of acute promyelocytic leukemia (APL) blasts to all-trans retinoic acid (ATRA)." +other hsa-mir-155 Vascular Disease [unspecific] 17293455 "As predicted, miRNA-155 transduction greatly reduced both myeloid and erythroid colony formation of normal human HSPCs." +other hsa-mir-34a Neuroblastoma 17297439 MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells. +other hsa-mir-17 Lung Neoplasms 17384677 "In marked contrast, antisense ONs against miR-18a and miR-19a did not exhibit such inhibitory effects, whereas inhibition of miR-92-1 resulted in only modest reduction of cell growth, showing significant distinctions among miRNAs of the miR-17-92 cluster in terms of their roles in cancer cell growth." +other hsa-mir-18 Lung Neoplasms 17384677 "In marked contrast, antisense ONs against miR-18a and miR-19a did not exhibit such inhibitory effects, whereas inhibition of miR-92-1 resulted in only modest reduction of cell growth, showing significant distinctions among miRNAs of the miR-17-92 cluster in terms of their roles in cancer cell growth." +other hsa-mir-18a Lung Neoplasms 17384677 "In marked contrast, antisense ONs against miR-18a and miR-19a did not exhibit such inhibitory effects, whereas inhibition of miR-92-1 resulted in only modest reduction of cell growth, showing significant distinctions among miRNAs of the miR-17-92 cluster in terms of their roles in cancer cell growth." +other hsa-mir-19a Lung Neoplasms 17384677 "In marked contrast, antisense ONs against miR-18a and miR-19a did not exhibit such inhibitory effects, whereas inhibition of miR-92-1 resulted in only modest reduction of cell growth, showing significant distinctions among miRNAs of the miR-17-92 cluster in terms of their roles in cancer cell growth." +other hsa-mir-19b-1 Lung Neoplasms 17384677 "In marked contrast, antisense ONs against miR-18a and miR-19a did not exhibit such inhibitory effects, whereas inhibition of miR-92-1 resulted in only modest reduction of cell growth, showing significant distinctions among miRNAs of the miR-17-92 cluster in terms of their roles in cancer cell growth." +other hsa-mir-20a Lung Neoplasms 17384677 "In marked contrast, antisense ONs against miR-18a and miR-19a did not exhibit such inhibitory effects, whereas inhibition of miR-92-1 resulted in only modest reduction of cell growth, showing significant distinctions among miRNAs of the miR-17-92 cluster in terms of their roles in cancer cell growth." +other hsa-mir-92-1 Lung Neoplasms 17384677 "In marked contrast, antisense ONs against miR-18a and miR-19a did not exhibit such inhibitory effects, whereas inhibition of miR-92-1 resulted in only modest reduction of cell growth, showing significant distinctions among miRNAs of the miR-17-92 cluster in terms of their roles in cancer cell growth." +other hsa-mir-1-1 Arrhythmia 17401374 These data strongly indicate that miR-1 is an arrhythmogenic or proarrhythmic factor that is detrimental to the ischemic heart. Delivery of miR-1 into healthy hearts was also arrhythmogenic. +other hsa-mir-1-2 Arrhythmia 17401374 These data strongly indicate that miR-1 is an arrhythmogenic or proarrhythmic factor that is detrimental to the ischemic heart. Delivery of miR-1 into healthy hearts was also arrhythmogenic. +other hsa-mir-155 Down Syndrome 17468766 "Because miR-155 maps to chromosome 21, Setupathy et al. speculate that miR-155 overexpression in trisomics'a which they confirmed experimentally a accounts for the lower levels of diastolic and systolic blood pressure associated with Down syndrome." +other hsa-mir-194-1 Urinary Bladder Cancer 17470785 "The list of miRNAs at or near sites commonly altered in human cancers includes mir-215 and mir-194-1, which are <0.17 kb from D1Mit208, a marker that defines the peak of the colon Scc3 locus on Chr 1. Homologous human miRNAs are located inside the FRA1H at Chr 1q42.1; this fragile site is an HPV16 integration site involved in cervical cancer." +other hsa-mir-215 Urinary Bladder Cancer 17470785 "The list of miRNAs at or near sites commonly altered in human cancers includes mir-215 and mir-194-1, which are <0.17 kb from D1Mit208, a marker that defines the peak of the colon Scc3 locus on Chr 1. Homologous human miRNAs are located inside the FRA1H at Chr 1q42.1; this fragile site is an HPV16 integration site involved in cervical cancer." +other hsa-mir-21 "Cardiomyopathy, Hypertrophic" 17525252 Modulating miR-21 expression via antisense-mediated depletion (knockdown) had a significant negative effect on cardiomyocyte hypertrophy. +other hsa-mir-34a Pancreatic Neoplasms 17540599 "Therefore, it is likely that an important function of miR-34a is the modulation and fine-tuning of the gene expression program initiated by p53." +other hsa-let-7a Vascular Disease [unspecific] 17540974 The let-7 family and mir-27b appear to be attractive targets for modulating angiogenesis. +other hsa-let-7b Vascular Disease [unspecific] 17540974 The let-7 family and mir-27b appear to be attractive targets for modulating angiogenesis. +other hsa-let-7c Vascular Disease [unspecific] 17540974 The let-7 family and mir-27b appear to be attractive targets for modulating angiogenesis. +other hsa-let-7d Vascular Disease [unspecific] 17540974 The let-7 family and mir-27b appear to be attractive targets for modulating angiogenesis. +other hsa-let-7e Vascular Disease [unspecific] 17540974 The let-7 family and mir-27b appear to be attractive targets for modulating angiogenesis. +other hsa-let-7f Vascular Disease [unspecific] 17540974 The let-7 family and mir-27b appear to be attractive targets for modulating angiogenesis. +other hsa-let-7g Vascular Disease [unspecific] 17540974 The let-7 family and mir-27b appear to be attractive targets for modulating angiogenesis. +other hsa-let-7i Vascular Disease [unspecific] 17540974 The let-7 family and mir-27b appear to be attractive targets for modulating angiogenesis. +other hsa-let-7a Neoplasms [unspecific] 17554199 Other p53-induced miRNAs identified here may also have tumor suppressive potential as they are known to suppress the anti-apoptotic factor Bcl2 (miR-15a/16) and the oncogenes RAS and HMGA2 (let-7a). +other hsa-mir-17 Lymphoma 17608773 "The c13orf25/miR-17 cluster, which is responsible for 13q31-q32 amplification in malignant lymphoma, contains the microRNA-17-18-19-20-92 polycistron." +other hsa-mir-18 Lymphoma 17608773 "The c13orf25/miR-17 cluster, which is responsible for 13q31-q32 amplification in malignant lymphoma, contains the microRNA-17-18-19-20-92 polycistron." +other hsa-mir-19a Lymphoma 17608773 "The c13orf25/miR-17 cluster, which is responsible for 13q31-q32 amplification in malignant lymphoma, contains the microRNA-17-18-19-20-92 polycistron." +other hsa-mir-19b-1 Lymphoma 17608773 "The c13orf25/miR-17 cluster, which is responsible for 13q31-q32 amplification in malignant lymphoma, contains the microRNA-17-18-19-20-92 polycistron." +other hsa-mir-20a Lymphoma 17608773 "The c13orf25/miR-17 cluster, which is responsible for 13q31-q32 amplification in malignant lymphoma, contains the microRNA-17-18-19-20-92 polycistron." +other hsa-mir-92-1 Lymphoma 17608773 "The c13orf25/miR-17 cluster, which is responsible for 13q31-q32 amplification in malignant lymphoma, contains the microRNA-17-18-19-20-92 polycistron." +other hsa-mir-370 Neoplasms [unspecific] 17621267 "Thus, IL-6 may contribute to tumor growth by modulation of expression of selected miRNAs, such as miR-370. These studies define a mechanism by which inflammation-associated cytokines can epigenetically modulate gene expression and directly contribute to tumor biology." +other hsa-mir-16 Leukemia 17683260 "several confirmed miRNA targets appear in our high-confidence set, such as the interactions between miR-92 and the signal transduction gene MAP2K4, as well as the relationship between miR-16 and BCL2, an anti-apoptotic gene which has been implicated in chronic lymphocytic leukemia." +other hsa-mir-92 Leukemia 17683260 "several confirmed miRNA targets appear in our high-confidence set, such as the interactions between miR-92 and the signal transduction gene MAP2K4, as well as the relationship between miR-16 and BCL2, an anti-apoptotic gene which has been implicated in chronic lymphocytic leukemia." +other hsa-mir-372 Germ Cell And Embryonal Neoplasms 17695719 "we identified miR-372 and miR-373, each permitting proliferation and tumorigenesis of primary human cells that harbor both oncogenic RAS and active wild-type p53." +other hsa-mir-373 Germ Cell And Embryonal Neoplasms 17695719 "we identified miR-372 and miR-373, each permitting proliferation and tumorigenesis of primary human cells that harbor both oncogenic RAS and active wild-type p53." +other hsa-mir-21 Colon Neoplasms 17702597 "In colon cancer cells, at a clinically relevant concentration,the drug up-regulates or down-regulates in vitro the expression of 19 and 3 miR genes, respectively, by a factor of not less than two-fold. In some instances, 5-FU up-regulates miR genes that are already over-expressed in neoplastic tissues, including, for example, miR-21 that is associated with anti-apoptotic functions characterizing malignant cells. " +other hsa-mir-124a Teratocarcinoma 17716626 "Based on these observations, it is suggested that the miR-302 cluster and miR-124a may be useful molecular indicators in the assessmentof degree of undifferentiation and/or differentiation in the course of neuronal differentiation." +other hsa-mir-155 Lymphoma 17727326 "Cancer-associated microRNAs can act as both tumour suppressor molecules (e.g., miR-15a and miR-16-1) and have oncogenic properties (e.g., miR-155 and miR-17-92 cluster)." +other hsa-mir-15a Lymphoma 17727326 "Cancer-associated microRNAs can act as both tumour suppressor molecules (e.g., miR-15a and miR-16-1) and have oncogenic properties (e.g., miR-155 and miR-17-92 cluster)." +other hsa-mir-16-1 Lymphoma 17727326 "Cancer-associated microRNAs can act as both tumour suppressor molecules (e.g., miR-15a and miR-16-1) and have oncogenic properties (e.g., miR-155 and miR-17-92 cluster)." +other hsa-mir-17 Lymphoma 17727326 "Cancer-associated microRNAs can act as both tumour suppressor molecules (e.g., miR-15a and miR-16-1) and have oncogenic properties (e.g., miR-155 and miR-17-92 cluster)." +other hsa-mir-18 Lymphoma 17727326 "Cancer-associated microRNAs can act as both tumour suppressor molecules (e.g., miR-15a and miR-16-1) and have oncogenic properties (e.g., miR-155 and miR-17-92 cluster)." +other hsa-mir-19a Lymphoma 17727326 "Cancer-associated microRNAs can act as both tumour suppressor molecules (e.g., miR-15a and miR-16-1) and have oncogenic properties (e.g., miR-155 and miR-17-92 cluster)." +other hsa-mir-19b-1 Lymphoma 17727326 "Cancer-associated microRNAs can act as both tumour suppressor molecules (e.g., miR-15a and miR-16-1) and have oncogenic properties (e.g., miR-155 and miR-17-92 cluster)." +other hsa-mir-20a Lymphoma 17727326 "Cancer-associated microRNAs can act as both tumour suppressor molecules (e.g., miR-15a and miR-16-1) and have oncogenic properties (e.g., miR-155 and miR-17-92 cluster)." +other hsa-mir-92-1 Lymphoma 17727326 "Cancer-associated microRNAs can act as both tumour suppressor molecules (e.g., miR-15a and miR-16-1) and have oncogenic properties (e.g., miR-155 and miR-17-92 cluster)." +other hsa-mir-133b Parkinson Disease 17761882 "Expression of one of these precursor miRNAs, miR-133b, was specifically enriched in the midbrain and deficient in the context of Parkinson's disease patient samples, as determined by ribonuclease (RNase) protection assays, qPCR, and Northern blotting for mature miR-133b." +other hsa-mir-1-1 Arrhythmia 17786230 the finding that increasing or decreasing miR-1 expression causes lethal cardiac arrhythmias highlights not only the exquisite sensitivity of the heart to the levels of expression of this miRNA but also poses significant hurdles to the possible therapeutic manipulation of miR-1 levels in the settings of cardiac conduction abnormalities or myocardial repair. +other hsa-mir-1-2 Arrhythmia 17786230 the finding that increasing or decreasing miR-1 expression causes lethal cardiac arrhythmias highlights not only the exquisite sensitivity of the heart to the levels of expression of this miRNA but also poses significant hurdles to the possible therapeutic manipulation of miR-1 levels in the settings of cardiac conduction abnormalities or myocardial repair. +other hsa-mir-133a-1 Arrhythmia 17786230 "These results suggest an active role for miR-133 in the inhibition of cardiac hypertrophy. Xiao et al. reported miR-133 to play a role in cardiac conductance abnormalities during diabetes by lowering the protein levels of ether-a-go-go§Ò§ÙCrelated gene (ERG), which encodes a key K+ channel (IKr) responsible for rapid delayed rectifier K+ current in cardiac cells." +other hsa-mir-133a-1 "Cardiomyopathy, Hypertrophic" 17786230 "These results suggest an active role for miR-133 in the inhibition of cardiac hypertrophy. Xiao et al. reported miR-133 to play a role in cardiac conductance abnormalities during diabetes by lowering the protein levels of ether-a-go-go§Ò§ÙCrelated gene (ERG), which encodes a key K+ channel (IKr) responsible for rapid delayed rectifier K+ current in cardiac cells." +other hsa-mir-133a-2 Arrhythmia 17786230 "These results suggest an active role for miR-133 in the inhibition of cardiac hypertrophy. Xiao et al. reported miR-133 to play a role in cardiac conductance abnormalities during diabetes by lowering the protein levels of ether-a-go-go§Ò§ÙCrelated gene (ERG), which encodes a key K+ channel (IKr) responsible for rapid delayed rectifier K+ current in cardiac cells." +other hsa-mir-133a-2 "Cardiomyopathy, Hypertrophic" 17786230 "These results suggest an active role for miR-133 in the inhibition of cardiac hypertrophy. Xiao et al. reported miR-133 to play a role in cardiac conductance abnormalities during diabetes by lowering the protein levels of ether-a-go-go§Ò§ÙCrelated gene (ERG), which encodes a key K+ channel (IKr) responsible for rapid delayed rectifier K+ current in cardiac cells." +other hsa-mir-208a Endomyocardial Fibrosis 17786230 "Clearly, miR-208 is also essential for expression of the genes involved in cardiac fibrosis and hypertrophic growth." +other hsa-mir-208a Hypertrophy 17786230 "Clearly, miR-208 is also essential for expression of the genes involved in cardiac fibrosis and hypertrophic growth." +other hsa-mir-21 Heart Diseases [unspecific] 17786230 "Another miRNA consistently induced by cardiac stress, miR-21, appears to function as a regulator of cardiac growth and fetal gene activation in primary cardiomyocytes in vitro although some confusion remains regarding its exact role." +other hsa-mir-155 Kaposi Sarcoma 17881434 "Together, these findings indicate that KSHV miR-K12-11 is an ortholog of miR-155." +other hsa-mir-150 Leukemia 17923094 "Combining loss- and gain-of-function gene targeting approaches for miR-150 with conditional and partial ablation of c-Myb, we show that miR-150 indeed controls c-Myb expression in vivo in a dose-dependent manner over a narrow range of miRNA and c-Myb concentrations and that this dramatically affects lymphocyte development and response." +other hsa-mir-17 "Leukemia, B-Cell" 17940623 "These data suggested a direct involvement of this miRNA cluster in tumorigenesis. The miR-17-92 cluster encompassing six miRNAs: miR-17, miR-18a, miR-19a, miR-20a, miR-19b-1 and miR-92-1." +other hsa-mir-18a "Leukemia, B-Cell" 17940623 "These data suggested a direct involvement of this miRNA cluster in tumorigenesis. The miR-17-92 cluster encompassing six miRNAs: miR-17, miR-18a, miR-19a, miR-20a, miR-19b-1 and miR-92-1." +other hsa-mir-19a "Leukemia, B-Cell" 17940623 "These data suggested a direct involvement of this miRNA cluster in tumorigenesis. The miR-17-92 cluster encompassing six miRNAs: miR-17, miR-18a, miR-19a, miR-20a, miR-19b-1 and miR-92-1." +other hsa-mir-19b-1 "Leukemia, B-Cell" 17940623 "These data suggested a direct involvement of this miRNA cluster in tumorigenesis. The miR-17-92 cluster encompassing six miRNAs: miR-17, miR-18a, miR-19a, miR-20a, miR-19b-1 and miR-92-1." +other hsa-mir-20a "Leukemia, B-Cell" 17940623 "These data suggested a direct involvement of this miRNA cluster in tumorigenesis. The miR-17-92 cluster encompassing six miRNAs: miR-17, miR-18a, miR-19a, miR-20a, miR-19b-1 and miR-92-1." +other hsa-mir-92a-1 "Leukemia, B-Cell" 17940623 "These data suggested a direct involvement of this miRNA cluster in tumorigenesis. The miR-17-92 cluster encompassing six miRNAs: miR-17, miR-18a, miR-19a, miR-20a, miR-19b-1 and miR-92-1." +other hsa-mir-122 Lipid Metabolism Disorder 17965831 Inhibition of miR-122 resulted in decreased levels of cholesterol in the plasma and improved liver function in obese mice. +other hsa-mir-155 Kidney Diseases [unspecific] 17965831 miR-155 was shown to decrease the expression of angiotensin II type 1 receptor in human primary fibroblasts [175]. This suggests that miR-155 may regulate a diverse set of physiological functions including fluid homeostasis and renal function. +other hsa-mir-155 Lung Neoplasms 17965831 "miR-155 has also been implicated in a number of cancers including Burkitt_s lymphoma, Hodgkin lymphoma and lung cancer." +other hsa-mir-155 "Lymphoma, Burkitt" 17965831 "miR-155 has also been implicated in a number of cancers including Burkitt_s lymphoma, Hodgkin lymphoma and lung cancer." +other hsa-mir-155 "Lymphoma, Hodgkin" 17965831 "miR-155 has also been implicated in a number of cancers including Burkitt_s lymphoma, Hodgkin lymphoma and lung cancer." +other hsa-mir-208a "Cardiomyopathy, Hypertrophic" 17965831 "miR-208 was recently shown to enhance stress-related cardiac muscle growth by up-regulating a contractile protein, bMHC, possibly by repressing translation of thyroid hormone receptor-associated protein 1 (THRAP1)." +other hsa-mir-372 Testicular Neoplasms 17965831 miR-372 and miR-373 have been implicated in testicular germ cell tumours. +other hsa-mir-373 Testicular Neoplasms 17965831 miR-372 and miR-373 have been implicated in testicular germ cell tumours. +other hsa-mir-375 Diabetes Mellitus 17965831 "For instance, miR-375 was shown to directly regulate insulin secretion from pancreatic islet cells. Overexpression of miR-375 led to an enhanced inhibition of insulin exocytosis, whereas anti-sense to miR-375 enhanced insulin secretion by blocking the effects of the miRNA." +other hsa-mir-222 Polycythemia Vera 17976518 "Comparative analyses of control and PV EPs suggested increased levels of miR-451, miR-16, miR-21, and miR-26b and decreased levels of miR-150 and miR-221 in PV group, Expression of miR-150 progressively declined with erythroid differentiation, its expression decreased ninefold (p < 0.05) from days 7 to 11." +other hsa-mir-339 Polycythemia Vera 17976518 biphasic regulation +other hsa-mir-378a Polycythemia Vera 17976518 "Comparative analyses of control and PV EPs suggested increased levels of miR-451, miR-16, miR-21, and miR-26b and decreased levels of miR-150 and miR-221 in PV group, Expression of miR-150 progressively declined with erythroid differentiation, its expression decreased ninefold (p < 0.05) from days 7 to 11." +other hsa-mir-17 "Leukemia, B-Cell" 17989227 "the miR-17 cluster (8, 9) synergizes with MYC to induce B cell lymphoma." +other hsa-mir-132 Neoplasms [unspecific] 18075311 "In this review, we will discuss the specific roles of miRNA-(miR-)132 and miR-219 in the SCN, as well as a more general outlook on this newly elucidated layer of circadian clock regulation: inducible translation control via miRNAs." +other hsa-mir-219 Neoplasms [unspecific] 18075311 "In this review, we will discuss the specific roles of miRNA-(miR-)132 and miR-219 in the SCN, as well as a more general outlook on this newly elucidated layer of circadian clock regulation: inducible translation control via miRNAs." +other hsa-let-7g Colon Neoplasms 18172508 Non-coding MicroRNAs hsa-let-7g and hsa-miR-181b are Associated with Chemoresponse to S-1 in Colon Cancer. +other hsa-mir-181b Colon Neoplasms 18172508 Non-coding MicroRNAs hsa-let-7g and hsa-miR-181b are Associated with Chemoresponse to S-1 in Colon Cancer. +other hsa-let-7c Colon Neoplasms 18188765 "Let-7C was clearly present in lung, prostate, and colon cancers but undetectable in ovary and thyroid cancer samples" +other hsa-mir-155 Kaposi Sarcoma 18191785 "Two new papers provide strong evidence that a KSHV-encoded microRNA and mir-155 share a common set of mRNA targets and binding sites, implying a possible link between viral- and non-viral-mediated tumorigenesis." +other hsa-mir-373 Prostate Neoplasms 18193036 "Taken together, our findings indicate that miRNAs are involved in tumour migration and invasion, and implicate miR-373 and miR-520c as metastasis-promoting miRNAs." +other hsa-mir-214 Ovarian Neoplasms 18199536 These findings indicate that deregulation of miRNAs is a recurrent event in human ovarian cancer and that miR-214 induces cell survival and cisplatin resistance primarily through targeting the PTEN/Akt pathway. +other hsa-mir-10b Neoplasms [unspecific] 18256538 pro-metastatic +other hsa-mir-181a Inflammation 18291670 "MiRNAs are implicated in establishing and maintaining the cell fate of immune cells (e.g. miR-181a and miR-223), and they are involved in innate immunity by regulating Toll-like receptor signaling and ensuing cytokine response (e.g. miR-146)." +other hsa-mir-203 Inflammation 18291670 "MiRNAs are implicated in establishing and maintaining the cell fate of immune cells (e.g. miR-181a and miR-223), and they are involved in innate immunity by regulating Toll-like receptor signaling and ensuing cytokine response (e.g. miR-146)." +other hsa-mir-137 Melanoma 18316599 MicroRNA-137 targets microphthalmia-associated transcription factor in melanoma cell lines. +other hsa-mir-17 Lymphoma 18329372 These results provide key insights into the physiologic functions of this family of microRNAs and suggest a link between the oncogenic properties of miR-17 approximately 92 and its functionsduring B lymphopoiesis and lung development. +other hsa-mir-18 Lymphoma 18329372 These results provide key insights into the physiologic functions of this family of microRNAs and suggest a link between the oncogenic properties of miR-17 approximately 92 and its functionsduring B lymphopoiesis and lung development. +other hsa-mir-19a Lymphoma 18329372 These results provide key insights into the physiologic functions of this family of microRNAs and suggest a link between the oncogenic properties of miR-17 approximately 92 and its functionsduring B lymphopoiesis and lung development. +other hsa-mir-19b-1 Lymphoma 18329372 These results provide key insights into the physiologic functions of this family of microRNAs and suggest a link between the oncogenic properties of miR-17 approximately 92 and its functionsduring B lymphopoiesis and lung development. +other hsa-mir-20a Lymphoma 18329372 These results provide key insights into the physiologic functions of this family of microRNAs and suggest a link between the oncogenic properties of miR-17 approximately 92 and its functionsduring B lymphopoiesis and lung development. +other hsa-mir-92-1 Lymphoma 18329372 These results provide key insights into the physiologic functions of this family of microRNAs and suggest a link between the oncogenic properties of miR-17 approximately 92 and its functionsduring B lymphopoiesis and lung development. +other hsa-mir-146a "Lymphoma, Burkitt" 18347435 induced by EBV-encoded latent membrane protein 1 (LMP1) +other hsa-mir-155 "Lymphoma, Burkitt" 18347435 induced by EBV-encoded latent membrane protein 1 (LMP1) +other hsa-mir-155 "Lymphoma, Burkitt" 18354490 process BIC +other hsa-mir-206 Vascular Hypertrophy 18381085 The review is also intended to serve as a comprehensive resource for miR-206 with the hope of encouraging further research on the role of miR-206 in skeletal muscle. +other hsa-mir-200a Neoplasms [unspecific] 18381893 the epithelial-to-mesenchymal transition +other hsa-mir-200b Neoplasms [unspecific] 18381893 the epithelial-to-mesenchymal transition +other hsa-mir-200c Neoplasms [unspecific] 18381893 the epithelial-to-mesenchymal transition +other hsa-mir-146b Inflammation 18390754 "Overall, these studies indicate that rapid increase in miRNA-146a expression provides a novel mechanism for the negative regulation of severe inflammation during the innate immune response." +other hsa-mir-146a Osteoarthritis 18438844 This study shows that miR-146 is expressed in RA synovial tissue and that its expression is induced by stimulation with TNFalpha and IL-1beta. Further studies are required to elucidate the function of miR-146 in these tissues. +other hsa-mir-100 Ovarian Neoplasms 18451233 normal +other hsa-mir-125a Ovarian Neoplasms 18451233 normal +other hsa-mir-145 Ovarian Neoplasms 18451233 normal +other hsa-mir-21 Ovarian Neoplasms 18451233 normal +other hsa-mir-99a Ovarian Neoplasms 18451233 normal +other hsa-mir-7 Glioblastoma 18483236 microRNA-7 inhibits the epidermal growth factor receptor and the Akt pathway and is down-regulated in glioblastoma. +other hsa-mir-141 "Carcinoma, Rectal" 18483486 "Here, we report that ZEB1 directly suppresses transcription of microRNA-200 family members miR-141 and miR-200c, which strongly activate epithelial differentiation in pancreatic, colorectal and breast cancer cells." +other hsa-mir-200c "Carcinoma, Rectal" 18483486 "Here, we report that ZEB1 directly suppresses transcription of microRNA-200 family members miR-141 and miR-200c, which strongly activate epithelial differentiation in pancreatic, colorectal and breast cancer cells." +other hsa-mir-150 Leukemia 18536574 "Using animal models engineered to overexpress miR-150, miR-17 approximately 92 and miR-155 or to be deficient for miR-223, miR-155 and miR-17 approximately 92 expression, several groups have now shown that miRNAs are critical for B-lymphocyte development (miR-150 and miR-17 approximately 92), granulopoiesis (miR-223), immune function (miR-155) and B-lymphoproliferative disorders (miR-155 and miR-17 approximately 92)." +other hsa-mir-155 Leukemia 18536574 "Using animal models engineered to overexpress miR-150, miR-17 approximately 92 and miR-155 or to be deficient for miR-223, miR-155 and miR-17 approximately 92 expression, several groups have now shown that miRNAs are critical for B-lymphocyte development (miR-150 and miR-17 approximately 92), granulopoiesis (miR-223), immune function (miR-155) and B-lymphoproliferative disorders (miR-155 and miR-17 approximately 92)." +other hsa-mir-17 Leukemia 18536574 "Using animal models engineered to overexpress miR-150, miR-17 approximately 92 and miR-155 or to be deficient for miR-223, miR-155 and miR-17 approximately 92 expression, several groups have now shown that miRNAs are critical for B-lymphocyte development (miR-150 and miR-17 approximately 92), granulopoiesis (miR-223), immune function (miR-155) and B-lymphoproliferative disorders (miR-155 and miR-17 approximately 92)." +other hsa-mir-18 Leukemia 18536574 "Using animal models engineered to overexpress miR-150, miR-17 approximately 92 and miR-155 or to be deficient for miR-223, miR-155 and miR-17 approximately 92 expression, several groups have now shown that miRNAs are critical for B-lymphocyte development (miR-150 and miR-17 approximately 92), granulopoiesis (miR-223), immune function (miR-155) and B-lymphoproliferative disorders (miR-155 and miR-17 approximately 92)." +other hsa-mir-19a Leukemia 18536574 "Using animal models engineered to overexpress miR-150, miR-17 approximately 92 and miR-155 or to be deficient for miR-223, miR-155 and miR-17 approximately 92 expression, several groups have now shown that miRNAs are critical for B-lymphocyte development (miR-150 and miR-17 approximately 92), granulopoiesis (miR-223), immune function (miR-155) and B-lymphoproliferative disorders (miR-155 and miR-17 approximately 92)." +other hsa-mir-19b-1 Leukemia 18536574 "Using animal models engineered to overexpress miR-150, miR-17 approximately 92 and miR-155 or to be deficient for miR-223, miR-155 and miR-17 approximately 92 expression, several groups have now shown that miRNAs are critical for B-lymphocyte development (miR-150 and miR-17 approximately 92), granulopoiesis (miR-223), immune function (miR-155) and B-lymphoproliferative disorders (miR-155 and miR-17 approximately 92)." +other hsa-mir-20a Leukemia 18536574 "Using animal models engineered to overexpress miR-150, miR-17 approximately 92 and miR-155 or to be deficient for miR-223, miR-155 and miR-17 approximately 92 expression, several groups have now shown that miRNAs are critical for B-lymphocyte development (miR-150 and miR-17 approximately 92), granulopoiesis (miR-223), immune function (miR-155) and B-lymphoproliferative disorders (miR-155 and miR-17 approximately 92)." +other hsa-mir-223 Leukemia 18536574 "Using animal models engineered to overexpress miR-150, miR-17 approximately 92 and miR-155 or to be deficient for miR-223, miR-155 and miR-17 approximately 92 expression, several groups have now shown that miRNAs are critical for B-lymphocyte development (miR-150 and miR-17 approximately 92), granulopoiesis (miR-223), immune function (miR-155) and B-lymphoproliferative disorders (miR-155 and miR-17 approximately 92)." +other hsa-mir-92-1 Leukemia 18536574 "Using animal models engineered to overexpress miR-150, miR-17 approximately 92 and miR-155 or to be deficient for miR-223, miR-155 and miR-17 approximately 92 expression, several groups have now shown that miRNAs are critical for B-lymphocyte development (miR-150 and miR-17 approximately 92), granulopoiesis (miR-223), immune function (miR-155) and B-lymphoproliferative disorders (miR-155 and miR-17 approximately 92)." +other hsa-let-7f Vascular Disease [unspecific] 18550634 "Meanwhile, a few specific miRNAs that regulate endothelial cell functions and angiogenesis have been described. Let7-f, miR-27b, and mir-130a were identified as pro-angiogenic miRNAs" +other hsa-mir-130a Vascular Disease [unspecific] 18550634 "Meanwhile, a few specific miRNAs that regulate endothelial cell functions and angiogenesis have been described. Let7-f, miR-27b, and mir-130a were identified as pro-angiogenic miRNAs" +other hsa-mir-27b Vascular Disease [unspecific] 18550634 "Meanwhile, a few specific miRNAs that regulate endothelial cell functions and angiogenesis have been described. Let7-f, miR-27b, and mir-130a were identified as pro-angiogenic miRNAs" +other hsa-mir-122 Hepatitis C Virus Infection 18550664 miR-122: Liver-specific microRNA miR-122 enhances the replication of hepatitis C virus in nonhepatic cells +other hsa-mir-198 Schizophrenia 18552348 "Human microRNAs (Hsa-mir-198 and Hsa-mir-206) are predicted to bind to influenza, rubella, or poliovirus genes. Certain genes associated with schizophrenia, including those also concerned with neurophysiology, are intimately related to the life cycles of the pathogens implicated in the disease." +other hsa-mir-206 Schizophrenia 18552348 "Human microRNAs (Hsa-mir-198 and Hsa-mir-206) are predicted to bind to influenza, rubella, or poliovirus genes. Certain genes associated with schizophrenia, including those also concerned with neurophysiology, are intimately related to the life cycles of the pathogens implicated in the disease." +other hsa-mir-223 "Carcinoma, Hepatocellular" 18555017 miR-223: MicroRNA-223 is commonly reproessed in hepatocellular carcinoma and potentiates expression of Stathmin1 +other hsa-let-7a-1 Neoplasms [unspecific] 18560417 let-7a: A let-7 MicroRNA-sensitive vesicular stomatitis virus demonstrates tumor-specific replication +other hsa-let-7a-2 Neoplasms [unspecific] 18560417 let-7a: A let-7 MicroRNA-sensitive vesicular stomatitis virus demonstrates tumor-specific replication +other hsa-let-7a-3 Neoplasms [unspecific] 18560417 let-7a: A let-7 MicroRNA-sensitive vesicular stomatitis virus demonstrates tumor-specific replication +other hsa-let-7b Neoplasms [unspecific] 18560417 let-7b: A let-7 MicroRNA-sensitive vesicular stomatitis virus demonstrates tumor-specific replication +other hsa-let-7c Neoplasms [unspecific] 18560417 let-7c: A let-7 MicroRNA-sensitive vesicular stomatitis virus demonstrates tumor-specific replication +other hsa-let-7d Neoplasms [unspecific] 18560417 let-7d: A let-7 MicroRNA-sensitive vesicular stomatitis virus demonstrates tumor-specific replication +other hsa-let-7e Neoplasms [unspecific] 18560417 let-7e: A let-7 MicroRNA-sensitive vesicular stomatitis virus demonstrates tumor-specific replication +other hsa-let-7f-1 Neoplasms [unspecific] 18560417 let-7f: A let-7 MicroRNA-sensitive vesicular stomatitis virus demonstrates tumor-specific replication +other hsa-let-7f-2 Neoplasms [unspecific] 18560417 let-7f: A let-7 MicroRNA-sensitive vesicular stomatitis virus demonstrates tumor-specific replication +other hsa-let-7g Neoplasms [unspecific] 18560417 let-7g: A let-7 MicroRNA-sensitive vesicular stomatitis virus demonstrates tumor-specific replication +other hsa-let-7i Neoplasms [unspecific] 18560417 let-7i: A let-7 MicroRNA-sensitive vesicular stomatitis virus demonstrates tumor-specific replication +other hsa-mir-124-1 Glioblastoma 18577219 miR-124: miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells +other hsa-mir-124-2 Glioblastoma 18577219 miR-124: miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells +other hsa-mir-124-3 Glioblastoma 18577219 miR-124: miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells +other hsa-mir-137 Glioblastoma 18577219 miR-137: miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells +other hsa-mir-100 Heart Failure 18582896 "To pursue the observation that changes in expression levels of individual miRNAs are functionally relevant, microRNA mimics and inhibitors to miR-92, miR-100 and miR-133b were expressed in primary cultures of neonatal rat cardiac myocytes." +other hsa-mir-133b Heart Failure 18582896 "To pursue the observation that changes in expression levels of individual miRNAs are functionally relevant, microRNA mimics and inhibitors to miR-92, miR-100 and miR-133b were expressed in primary cultures of neonatal rat cardiac myocytes." +other hsa-mir-92 Heart Failure 18582896 "To pursue the observation that changes in expression levels of individual miRNAs are functionally relevant, microRNA mimics and inhibitors to miR-92, miR-100 and miR-133b were expressed in primary cultures of neonatal rat cardiac myocytes." +other hsa-mir-126 Lung Neoplasms 18602365 miR-126: MicroRNA-126 inhibits invasion in non-small cell lung carcinoma cell lines +other hsa-mir-451a Breast Neoplasms 18645025 miR-451: Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin +other hsa-mir-126 Colon Neoplasms 18663744 miR-126: miR-126 suppresses the growth of neoplastic cells +other hsa-mir-150 Leukemia 18667440 Our findings suggest that c-Myb is an evolutionally conserved target of miR-150 and miR-150/c-Myb interaction is important for embryonic development and possibly oncogenesis. +other hsa-mir-145 Colon Neoplasms 18676867 miR-145: miR-145 potently suppressed growth of three different colon carcinoma cell lines +other hsa-mir-498 Colon Neoplasms 18676867 miR-498: correlated with the probability of recurrence-free survival +other hsa-mir-126 Myocardial Infarction 18694565 We show that an endothelial cell-restricted microRNA (miR-126) mediates developmental angiogenesis in vivo. +other hsa-mir-17 Neoplasms [unspecific] 18700987 miR-17-5p: The miR-17-5p microRNA is able to act as both an oncogene and a tumor suppressor in different cellular contexts +other hsa-mir-181a-2 Glioma 18710654 miR-181a: mir suppressor +other hsa-mir-181b-1 Glioma 18710654 miR-181b: mir suppressor +other hsa-mir-181b-2 Glioma 18710654 miR-181b: mir suppressor +other hsa-mir-302a Skin Neoplasms 18755840 miR-302: Mir-302 reprograms human skin cancer cells into a pluripotent ES-cell-like state +other hsa-mir-302b Skin Neoplasms 18755840 miR-302: Mir-302 reprograms human skin cancer cells into a pluripotent ES-cell-like state +other hsa-mir-302c Skin Neoplasms 18755840 miR-302: Mir-302 reprograms human skin cancer cells into a pluripotent ES-cell-like state +other hsa-mir-302d Skin Neoplasms 18755840 miR-302: Mir-302 reprograms human skin cancer cells into a pluripotent ES-cell-like state +other hsa-mir-210 Breast Neoplasms 18755890 "miR-210: associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer" +other hsa-mir-516a-1 Breast Neoplasms 18755890 "miR-516-3p: associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer" +other hsa-mir-516a-2 Breast Neoplasms 18755890 "miR-516-3p: associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer" +other hsa-mir-516b-1 Breast Neoplasms 18755890 "miR-516-3p: associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer" +other hsa-mir-516b-2 Breast Neoplasms 18755890 "miR-516-3p: associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer" +other hsa-mir-7-1 Breast Neoplasms 18755890 "miR-7: associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer" +other hsa-mir-7-2 Breast Neoplasms 18755890 "miR-7: associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer" +other hsa-mir-7-3 Breast Neoplasms 18755890 "miR-7: associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer" +other hsa-mir-221 Glioblastoma 18759060 Up-regulation of micro-RNA-221 (miRNA-221; chr Xp11.3) and caspase-3 accompanies down-regulation of the survivin-1 homolog BIRC1 (NAIP) in glioblastoma multiforme (GBM). +other hsa-mir-27a Gastric Neoplasms 18789835 miR-27a: MicroRNA-27a functions as an oncogene in gastric adenocarcinoma by targeting prohibitin +other hsa-mir-221 Breast Neoplasms 18790736 miR-221: MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer +other hsa-mir-222 Breast Neoplasms 18790736 miR-222: MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer +other hsa-mir-21 Gastric Neoplasms 18794849 miR-21: miR-21 plays a pivotal role in gastric cancer pathogenesis and progression +other hsa-mir-34b "Lymphoma, Burkitt" 18802929 These results indicate for the first time that hsa-mir-34b may influence c-Myc expression in Burkitt lymphoma as the more common aberrant control exercised by the immunoglobulin enhancer locus. +other hsa-mir-34a Gastric Neoplasms 18803879 miR-34: tumor suppressor miR-34 inhibits human p53-mutant gastric cancer tumorspheres +other hsa-mir-34b Gastric Neoplasms 18803879 miR-34: tumor suppressor miR-34 inhibits human p53-mutant gastric cancer tumorspheres +other hsa-mir-34c Gastric Neoplasms 18803879 miR-34: tumor suppressor miR-34 inhibits human p53-mutant gastric cancer tumorspheres +other hsa-mir-21 Glioblastoma 18829576 miR-21: MicroRNA-21 targets a network of key tumor-suppressive pathways in glioblastoma +other hsa-mir-126 "Leukemia, Myeloid, Acute" 18832181 "miR-126: discriminate CBF, t(15;17), and MLL-rearrangement AMLs" +other hsa-mir-17 "Leukemia, Myeloid, Acute" 18832181 "miR-17-5p: discriminate CBF, t(15;17), and MLL-rearrangement AMLs" +other hsa-mir-20a "Leukemia, Myeloid, Acute" 18832181 "miR-20a: discriminate CBF, t(15;17), and MLL-rearrangement AMLs" +other hsa-mir-224 "Leukemia, Myeloid, Acute" 18832181 "miR-224: discriminate CBF, t(15;17), and MLL-rearrangement AMLs" +other hsa-mir-382 "Leukemia, Myeloid, Acute" 18832181 "miR-382: discriminate CBF, t(15;17), and MLL-rearrangement AMLs" +other hsa-mir-183 Lung Neoplasms 18840437 miR-183: a potential metastasis-inhibitor +other hsa-mir-125b Psoriasis 18853072 "Recent findings report their involvement in hair follicle morphogenesis (ablation of miRNAs from keratinocytes causes several defects, such as evagination instead of invagination), in psoriasis (skin-specific expression of miR-203 and psoriasisspecific expression of miR-146a, miR-21 and miR-125b in the skin)" +other hsa-mir-146a Psoriasis 18853072 "Recent findings report their involvement in hair follicle morphogenesis (ablation of miRNAs from keratinocytes causes several defects, such as evagination instead of invagination), in psoriasis (skin-specific expression of miR-203 and psoriasisspecific expression of miR-146a, miR-21 and miR-125b in the skin)" +other hsa-mir-203 Psoriasis 18853072 "Recent findings report their involvement in hair follicle morphogenesis (ablation of miRNAs from keratinocytes causes several defects, such as evagination instead of invagination), in psoriasis (skin-specific expression of miR-203 and psoriasisspecific expression of miR-146a, miR-21 and miR-125b in the skin)" +other hsa-mir-21 Psoriasis 18853072 "Recent findings report their involvement in hair follicle morphogenesis (ablation of miRNAs from keratinocytes causes several defects, such as evagination instead of invagination), in psoriasis (skin-specific expression of miR-203 and psoriasisspecific expression of miR-146a, miR-21 and miR-125b in the skin)" +other hsa-mir-106b Neoplasms [unspecific] 18922889 miR-106b: key modulators of TGFbeta signaling +other hsa-mir-17 Neoplasms [unspecific] 18922889 miR-17: key modulators of TGFbeta signaling +other hsa-mir-18a Neoplasms [unspecific] 18922889 miR-18a: key modulators of TGFbeta signaling +other hsa-mir-19a Neoplasms [unspecific] 18922889 miR-19a: key modulators of TGFbeta signaling +other hsa-mir-19b-1 Neoplasms [unspecific] 18922889 miR-19b: key modulators of TGFbeta signaling +other hsa-mir-19b-2 Neoplasms [unspecific] 18922889 miR-19b: key modulators of TGFbeta signaling +other hsa-mir-20a Neoplasms [unspecific] 18922889 miR-20a: key modulators of TGFbeta signaling +other hsa-mir-25 Neoplasms [unspecific] 18922889 miR-25: key modulators of TGFbeta signaling +other hsa-mir-92a-1 Neoplasms [unspecific] 18922889 miR-92a: key modulators of TGFbeta signaling +other hsa-mir-92a-2 Neoplasms [unspecific] 18922889 miR-92a: key modulators of TGFbeta signaling +other hsa-mir-93 Neoplasms [unspecific] 18922889 miR-93: key modulators of TGFbeta signaling +other hsa-mir-141 Neoplasms [unspecific] 18927505 Several recent studies have identified the miR-200 family and miR-205 as key regulators of EMT and enforcers of the epithelial phenotype. +other hsa-mir-200a Neoplasms [unspecific] 18927505 Several recent studies have identified the miR-200 family and miR-205 as key regulators of EMT and enforcers of the epithelial phenotype. +other hsa-mir-200b Neoplasms [unspecific] 18927505 Several recent studies have identified the miR-200 family and miR-205 as key regulators of EMT and enforcers of the epithelial phenotype. +other hsa-mir-200c Neoplasms [unspecific] 18927505 Several recent studies have identified the miR-200 family and miR-205 as key regulators of EMT and enforcers of the epithelial phenotype. +other hsa-mir-205 Neoplasms [unspecific] 18927505 Several recent studies have identified the miR-200 family and miR-205 as key regulators of EMT and enforcers of the epithelial phenotype. +other hsa-mir-429 Neoplasms [unspecific] 18927505 Several recent studies have identified the miR-200 family and miR-205 as key regulators of EMT and enforcers of the epithelial phenotype. +other hsa-mir-21 Breast Neoplasms 18932017 miR-21: High miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGF-beta1 +other hsa-mir-125b-1 "Leukemia, Myeloid, Acute" 18936236 miR-125b-1: Myeloid cell differentiation arrest by miR-125b-1 +other hsa-mir-21 Kaposi Sarcoma 18971265 "Therefore, K15M may contribute to KSHV-mediated tumor metastasis and angiogenesis via regulation of miR-21 and miR-31, which we show here for the first time to be a specific regulator of cell migration." +other hsa-mir-31 Kaposi Sarcoma 18971265 "Therefore, K15M may contribute to KSHV-mediated tumor metastasis and angiogenesis via regulation of miR-21 and miR-31, which we show here for the first time to be a specific regulator of cell migration." +other hsa-mir-125a Medulloblastoma 18973228 miR-125a: promote growth arrest and apoptosis of MB cells +other hsa-mir-9-1 Medulloblastoma 18973228 miR-9: promote growth arrest and apoptosis of MB cells +other hsa-mir-9-2 Medulloblastoma 18973228 miR-9: promote growth arrest and apoptosis of MB cells +other hsa-mir-9-3 Medulloblastoma 18973228 miR-9: promote growth arrest and apoptosis of MB cells +other hsa-mir-106a Gastric Neoplasms 18996190 miR-106a: oncogenic activity +other hsa-mir-34a "Carcinoma, Hepatocellular" 19006648 miR-34a: miR-34a inhibits migration and invasion by down-regulation of c-Met expression in human hepatocellular carcinoma cells +other hsa-mir-133a-1 Chronic Heart Failure 19015276 microRNA-133a regulates cardiomyocyte proliferation and suppresses smooth muscle gene expression in the heart +other hsa-mir-133a-2 Chronic Heart Failure 19015276 microRNA-133a regulates cardiomyocyte proliferation and suppresses smooth muscle gene expression in the heart +other hsa-mir-122 Hepatitis C Virus Infection 19020517 miR-122: microRNA-122 stimulates translation of hepatitis C virus RNA +other hsa-mir-18a "Carcinoma, Hepatocellular" 19027010 "miR-18a: prevents estrogen receptor-alpha expression, promoting proliferation" +other hsa-mir-453 Breast Neoplasms 19028706 "In contrast, the T allele attenuates the binding of miR-453, which might lead to a reduced miRNA-mediated ESR1 repression, in consequence higher ESR1 protein levels and an increased breast cancer risk." +other hsa-mir-21 Cardiomyopathy 19043405 miR-21: MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts +other hsa-mir-21 Cardiovascular Diseases [unspecific] 19043405 MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts +other hsa-mir-133a Heart Failure 19056878 "It will be interesting to see, if miR-133a is also involved in human heart diseases, especially VSD and dilated cardiomyopathy." +other hsa-mir-21 Neoplasms [unspecific] 19073608 miR-21: coordinately regulate EGFR signaling in multiple human cancer cell types +other hsa-mir-7-1 Neoplasms [unspecific] 19073608 miR-7: coordinately regulate EGFR signaling in multiple human cancer cell types +other hsa-mir-7-2 Neoplasms [unspecific] 19073608 miR-7: coordinately regulate EGFR signaling in multiple human cancer cell types +other hsa-mir-7-3 Neoplasms [unspecific] 19073608 miR-7: coordinately regulate EGFR signaling in multiple human cancer cell types +other hsa-mir-122 Chronic Hepatitis C 19085952 "Moreover, CD56(+) T SN treatment inhibited the expression of HCV-supportive micro RNA (miRNA)-122 and enhanced the levels of anti-HCV miRNA-196a in human hepatocytes." +other hsa-mir-196a Chronic Hepatitis C 19085952 "Moreover, CD56(+) T SN treatment inhibited the expression of HCV-supportive micro RNA (miRNA)-122 and enhanced the levels of anti-HCV miRNA-196a in human hepatocytes." +other hsa-mir-133a-1 Cardiomegaly 19096030 miR-133 and miR-30 regulate connective tissue growth factor: implications for a role of microRNAs in myocardial matrix remodeling +other hsa-mir-133a-1 Heart Failure 19096030 miR-133 and miR-30 regulate connective tissue growth factor: implications for a role of microRNAs in myocardial matrix remodeling +other hsa-mir-133a-2 Cardiomegaly 19096030 miR-133 and miR-30 regulate connective tissue growth factor: implications for a role of microRNAs in myocardial matrix remodeling +other hsa-mir-133a-2 Heart Failure 19096030 miR-133 and miR-30 regulate connective tissue growth factor: implications for a role of microRNAs in myocardial matrix remodeling +other hsa-mir-133b Cardiomegaly 19096030 miR-133 and miR-30 regulate connective tissue growth factor: implications for a role of microRNAs in myocardial matrix remodeling +other hsa-mir-133b Heart Failure 19096030 miR-133 and miR-30 regulate connective tissue growth factor: implications for a role of microRNAs in myocardial matrix remodeling +other hsa-mir-30a Cardiomegaly 19096030 miR-133 and miR-30 regulate connective tissue growth factor: implications for a role of microRNAs in myocardial matrix remodeling +other hsa-mir-30a Heart Failure 19096030 miR-133 and miR-30 regulate connective tissue growth factor: implications for a role of microRNAs in myocardial matrix remodeling +other hsa-mir-30b Cardiomegaly 19096030 miR-133 and miR-30 regulate connective tissue growth factor: implications for a role of microRNAs in myocardial matrix remodeling +other hsa-mir-30b Heart Failure 19096030 miR-133 and miR-30 regulate connective tissue growth factor: implications for a role of microRNAs in myocardial matrix remodeling +other hsa-mir-29a Acquired Immunodeficiency Syndrome 19102781 miR-29a: Human cellular microRNA hsa-miR-29a interferes with viral nef protein expression and HIV-1 replication +other hsa-mir-520b Neoplasms [unspecific] 19109132 "miR-520b: miR-520b was induced by IFN-gamma, leading to a reduction in MICA surface protein levels" +other hsa-mir-106b Alzheimer Disease 19110058 miR-106b: endogenous regulators of APP expression +other hsa-mir-17 Alzheimer Disease 19110058 miR-17-5p: endogenous regulators of APP expression +other hsa-mir-20a Alzheimer Disease 19110058 miR-20a: endogenous regulators of APP expression +other hsa-mir-200c Pancreatic Neoplasms 19112422 Expression of microRNA was determined with microRNA array. Expression of miR-200c and miR-21 was detected by Northern blotting. +other hsa-mir-195 Schizophrenia 19121517 "Using a postmortem case-control design, the association between BDNF protein, NPY/SST/PV mRNAs, and two BDNF-regulating microRNAs (miR-195 and miR-30a-5p) was determined in samples from the PFC of 20 schizophrenia and 20 control subjects." +other hsa-mir-30a Schizophrenia 19121517 "Using a postmortem case-control design, the association between BDNF protein, NPY/SST/PV mRNAs, and two BDNF-regulating microRNAs (miR-195 and miR-30a-5p) was determined in samples from the PFC of 20 schizophrenia and 20 control subjects." +other hsa-mir-122 Hepatitis C Virus Infection 19122656 miR-122: Decreased levels of microRNA miR-122 in individuals with hepatitis C responding poorly to interferon therapy +other hsa-mir-101-1 Colon Neoplasms 19133256 miR-101: MiR-101 downregulation is involved in cyclooxygenase-2 overexpression +other hsa-mir-101-2 Colon Neoplasms 19133256 miR-101: MiR-101 downregulation is involved in cyclooxygenase-2 overexpression +other hsa-let-7a-1 Pituitary Neoplasms 19136928 let-7a: Overexpression of HMGA2 relates to reduction of the let-7 +other hsa-let-7a-2 Pituitary Neoplasms 19136928 let-7a: Overexpression of HMGA2 relates to reduction of the let-7 +other hsa-let-7a-3 Pituitary Neoplasms 19136928 let-7a: Overexpression of HMGA2 relates to reduction of the let-7 +other hsa-let-7b Pituitary Neoplasms 19136928 let-7b: Overexpression of HMGA2 relates to reduction of the let-7 +other hsa-let-7c Pituitary Neoplasms 19136928 let-7c: Overexpression of HMGA2 relates to reduction of the let-7 +other hsa-let-7d Pituitary Neoplasms 19136928 let-7d: Overexpression of HMGA2 relates to reduction of the let-7 +other hsa-let-7e Pituitary Neoplasms 19136928 let-7e: Overexpression of HMGA2 relates to reduction of the let-7 +other hsa-let-7f-1 Pituitary Neoplasms 19136928 let-7f: Overexpression of HMGA2 relates to reduction of the let-7 +other hsa-let-7f-2 Pituitary Neoplasms 19136928 let-7f: Overexpression of HMGA2 relates to reduction of the let-7 +other hsa-let-7g Pituitary Neoplasms 19136928 let-7g: Overexpression of HMGA2 relates to reduction of the let-7 +other hsa-let-7i Pituitary Neoplasms 19136928 let-7i: Overexpression of HMGA2 relates to reduction of the let-7 +other hsa-mir-199a-1 Hepatitis C Virus Infection 19144437 miR-199a: Regulation of the hepatitis C virus genome replication +other hsa-mir-199a-2 Hepatitis C Virus Infection 19144437 miR-199a: Regulation of the hepatitis C virus genome replication +other hsa-mir-21 Myocardial Infarction 19147588 miR-21: miR-21 regulates fibroblast metalloprotease-2 via phosphatase and tensin homologue +other hsa-mir-223 "Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic" 19148136 miR-223: regulated by Glucocorticoids (GCs) +other hsa-mir-198 Acquired Immunodeficiency Syndrome 19148268 miR-198: miR-198 inhibits HIV-1 gene expression and replication in monocytes +other hsa-mir-27a Gastric Neoplasms 19148490 miR-27a: There was a correlation between mir-27a and lymph node metastasis +other hsa-mir-1 Heart Failure 19149547 "miR-133 and miR-1 are specifically expressed in cardiac and skeletal muscle and control myogenesis, cardiac development, cardiac performance and cardiomyocyte hypertrophy (mainly by tuning transcription factors and other growth-related targets)." +other hsa-mir-133 Heart Failure 19149547 "miR-133 and miR-1 are specifically expressed in cardiac and skeletal muscle and control myogenesis, cardiac development, cardiac performance and cardiomyocyte hypertrophy (mainly by tuning transcription factors and other growth-related targets)." +other hsa-mir-34a "Leukemia, Promyelocytic, Acute" 19151778 miR-34: that enforced expression of miR-342 in APL cells stimulated ATRA-induced differentiation +other hsa-mir-34b "Leukemia, Promyelocytic, Acute" 19151778 miR-34: that enforced expression of miR-342 in APL cells stimulated ATRA-induced differentiation +other hsa-mir-34c "Leukemia, Promyelocytic, Acute" 19151778 miR-34: that enforced expression of miR-342 in APL cells stimulated ATRA-induced differentiation +other hsa-mir-101-1 "Carcinoma, Hepatocellular" 19155302 miR-101: a tumor suppressor +other hsa-mir-101-2 "Carcinoma, Hepatocellular" 19155302 miR-101: a tumor suppressor +other hsa-mir-143 Urinary Bladder Cancer 19157460 miR-143: a tumor suppressor +other hsa-mir-21 Brain Neoplasms 19175699 "Since its identification 3 years ago as the miRNA most commonly and strongly up-regulated in human brain tumour glioblastoma [1], miR-21 has attracted the attention of researchers in various fields" +other hsa-mir-143 Obesity 19188425 Our results provide the first experimental evidence for miR-103 function in adipose biology. +other hsa-mir-196b Leukemia 19188669 miR-196b: MLL normally regulates expression of mir-196b +other hsa-mir-143 Barrett Esophagus 19190970 miR-143: significantly higher +other hsa-mir-219 Nervous System Diseases [unspecific] 19196972 miR-219: MicroRNA-219 modulates NMDA receptor-mediated neurobehavioral dysfunction +other hsa-mir-17 Medulloblastoma 19196975 miR-17: collaborates with the Sonic Hedgehog pathway +other hsa-mir-18a Medulloblastoma 19196975 miR-18a: collaborates with the Sonic Hedgehog pathway +other hsa-mir-19a Medulloblastoma 19196975 miR-19a: collaborates with the Sonic Hedgehog pathway +other hsa-mir-19b-1 Medulloblastoma 19196975 miR-19b: collaborates with the Sonic Hedgehog pathway +other hsa-mir-19b-2 Medulloblastoma 19196975 miR-19b: collaborates with the Sonic Hedgehog pathway +other hsa-mir-20a Medulloblastoma 19196975 miR-20a: collaborates with the Sonic Hedgehog pathway +other hsa-mir-92a-1 Medulloblastoma 19196975 miR-92a: collaborates with the Sonic Hedgehog pathway +other hsa-mir-92a-2 Medulloblastoma 19196975 miR-92a: collaborates with the Sonic Hedgehog pathway +other hsa-mir-21 Liver Cirrhosis 19203462 miR-21: n/a +other hsa-mir-106a Lung Neoplasms 19209007 "High levels of miR-106a were associated with small-cell lung cancer (p = 0.031), and high levels of miR-19a with advanced NSCLC (p = 0.008)." +other hsa-let-7a-1 Neoplasms [unspecific] 19221491 let-7a: guardians against pluripotency and cancer progression +other hsa-let-7a-2 Neoplasms [unspecific] 19221491 let-7a: guardians against pluripotency and cancer progression +other hsa-let-7a-3 Neoplasms [unspecific] 19221491 let-7a: guardians against pluripotency and cancer progression +other hsa-let-7b Neoplasms [unspecific] 19221491 let-7b: guardians against pluripotency and cancer progression +other hsa-let-7c Neoplasms [unspecific] 19221491 let-7c: guardians against pluripotency and cancer progression +other hsa-let-7d Neoplasms [unspecific] 19221491 let-7d: guardians against pluripotency and cancer progression +other hsa-let-7e Neoplasms [unspecific] 19221491 let-7e: guardians against pluripotency and cancer progression +other hsa-let-7f-1 Neoplasms [unspecific] 19221491 let-7f: guardians against pluripotency and cancer progression +other hsa-let-7f-2 Neoplasms [unspecific] 19221491 let-7f: guardians against pluripotency and cancer progression +other hsa-let-7g Neoplasms [unspecific] 19221491 let-7g: guardians against pluripotency and cancer progression +other hsa-let-7i Neoplasms [unspecific] 19221491 let-7i: guardians against pluripotency and cancer progression +other hsa-mir-200a Neoplasms [unspecific] 19221491 miR-200: guardians against pluripotency and cancer progression +other hsa-mir-200b Neoplasms [unspecific] 19221491 miR-200: guardians against pluripotency and cancer progression +other hsa-mir-200c Neoplasms [unspecific] 19221491 miR-200: guardians against pluripotency and cancer progression +other hsa-mir-126 Lung Neoplasms 19223090 miR-126: inhibit the growth +other hsa-mir-205 Prostate Neoplasms 19244118 miR-205: miR-205 Exerts tumor-suppressive functions in human prostate through down-regulation of protein kinase Cepsilon +other hsa-mir-29a Breast Neoplasms 19247375 "miR-29a: miR-29a suppresses tristetraprolin, which is a regulator of epithelial polarity and metastasis. Therefore, miRNAs can act as either oncogenes or tumour suppressors, depending on the context" +other hsa-mir-34a Urinary Bladder Cancer 19258450 miR-34a: Oncogenic HPV infection interrupts the expression of tumor-suppressive miR-34a through viral oncoprotein E6 +other hsa-mir-182 Prostate Neoplasms 19267923 miR-182: with high analytical sensitivity and specificity +other hsa-mir-21 Prostate Neoplasms 19267923 miR-21: with high analytical sensitivity and specificity +other hsa-mir-221 Prostate Neoplasms 19267923 miR-221: with high analytical sensitivity and specificity +other hsa-mir-222 Prostate Neoplasms 19267923 miR-222: with high analytical sensitivity and specificity +other hsa-mir-16-1 Neoplasms [unspecific] 19269153 miR-16: can be upregulated by Epigallocatechin gallate +other hsa-mir-16-2 Neoplasms [unspecific] 19269153 miR-16: can be upregulated by Epigallocatechin gallate +other hsa-mir-205 Lung Neoplasms 19273703 miR-205: hsa-miR-205 as a highly specific marker for squamous cell lung carcinoma +other hsa-mir-196b Neutropenia 19278956 miR-196b: regulated by Gfi1 +other hsa-mir-21 Neutropenia 19278956 miR-21: regulated by Gfi1 +other hsa-mir-101-1 Prostate Neoplasms 19285253 miR-101: decrease of miR-101 leads to the overexpression of EZH2 +other hsa-mir-101-2 Prostate Neoplasms 19285253 miR-101: decrease of miR-101 leads to the overexpression of EZH2 +other hsa-mir-196a-2 Lung Neoplasms 19293314 miR-196a-2: Susceptibility of Lung Cancer in Chinese +other hsa-mir-122 "Carcinoma, Hepatocellular" 19296470 miR-122: a tumor suppressor microRNA that regulates intrahepatic metastasis of hepatocellular carcinoma +other hsa-mir-199b Medulloblastoma 19308264 miR-199b-5p: MicroRNA-199b-5p impairs cancer stem cells through negative regulation of HES1 in medulloblastoma +other hsa-mir-451a Gastrointestinal Neoplasms 19318487 miR-451: microRNA-451 Regulates Macrophage Migration Inhibitory Factor Proliferation of Gastrointestinal Cancer Cells Production +other hsa-mir-1 Heart Failure 19320780 "The implication of several miRNAs in cardiovascular diseases has been well documented such as miRNA-1 in arrhythmia,miRNA-29 in cardiac fibrosis, miRNA-126 in angiogenesis and miRNA-133 in cardiac hypertrophy." +other hsa-mir-126 Heart Failure 19320780 "The implication of several miRNAs in cardiovascular diseases has been well documented such as miRNA-1 in arrhythmia,miRNA-29 in cardiac fibrosis, miRNA-126 in angiogenesis and miRNA-133 in cardiac hypertrophy." +other hsa-mir-133 Heart Failure 19320780 "The implication of several miRNAs in cardiovascular diseases has been well documented such as miRNA-1 in arrhythmia,miRNA-29 in cardiac fibrosis, miRNA-126 in angiogenesis and miRNA-133 in cardiac hypertrophy." +other hsa-mir-29 Heart Failure 19320780 "The implication of several miRNAs in cardiovascular diseases has been well documented such as miRNA-1 in arrhythmia,miRNA-29 in cardiac fibrosis, miRNA-126 in angiogenesis and miRNA-133 in cardiac hypertrophy." +other hsa-let-7a-1 Pancreatic Neoplasms 19323605 Let-7a: inhibits in vitro cell proliferation but fails to alter tumor progression +other hsa-let-7a-2 Pancreatic Neoplasms 19323605 Let-7a: inhibits in vitro cell proliferation but fails to alter tumor progression +other hsa-let-7a-3 Pancreatic Neoplasms 19323605 Let-7a: inhibits in vitro cell proliferation but fails to alter tumor progression +other hsa-let-7b Pancreatic Neoplasms 19323605 Let-7b: inhibits in vitro cell proliferation but fails to alter tumor progression +other hsa-let-7c Pancreatic Neoplasms 19323605 Let-7c: inhibits in vitro cell proliferation but fails to alter tumor progression +other hsa-let-7d Pancreatic Neoplasms 19323605 Let-7d: inhibits in vitro cell proliferation but fails to alter tumor progression +other hsa-let-7e Pancreatic Neoplasms 19323605 Let-7e: inhibits in vitro cell proliferation but fails to alter tumor progression +other hsa-let-7f-1 Pancreatic Neoplasms 19323605 Let-7f: inhibits in vitro cell proliferation but fails to alter tumor progression +other hsa-let-7f-2 Pancreatic Neoplasms 19323605 Let-7f: inhibits in vitro cell proliferation but fails to alter tumor progression +other hsa-let-7g Pancreatic Neoplasms 19323605 Let-7g: inhibits in vitro cell proliferation but fails to alter tumor progression +other hsa-let-7i Pancreatic Neoplasms 19323605 Let-7i: inhibits in vitro cell proliferation but fails to alter tumor progression +other hsa-mir-146a Lupus Vulgaris 19333922 miR-146a: miR-146a contributes to abnormal activation of the type i interferon pathway in human lupus by targeting the key signaling proteins +other hsa-mir-221 Hyperglycemia 19351599 miR-221: induced expression +other hsa-mir-221 Vascular Disease [unspecific] 19351599 MicroRNA-221 regulates high glucose-induced endothelial dysfunction +other hsa-let-7c Prostate Neoplasms 19372056 "We hypothesize that miR-let7c, miR-100, and miR-218 may be involved in the process of metastasization of PC, and their role as controllers of the expression of RAS, c-myc, Laminin 5 ¦Â3, THAP2, SMARCA5, and BAZ2A should be matter of additional studies." +other hsa-mir-100 Prostate Neoplasms 19372056 "We hypothesize that miR-let7c, miR-100, and miR-218 may be involved in the process of metastasization of PC, and their role as controllers of the expression of RAS, c-myc, Laminin 5 ¦Â3, THAP2, SMARCA5, and BAZ2A should be matter of additional studies." +other hsa-mir-218 Prostate Neoplasms 19372056 "We hypothesize that miR-let7c, miR-100, and miR-218 may be involved in the process of metastasization of PC, and their role as controllers of the expression of RAS, c-myc, Laminin 5 ¦Â3, THAP2, SMARCA5, and BAZ2A should be matter of additional studies." +other hsa-mir-34a Neuroblastoma 19373781 "Neuroblastoma (NB) is the most common extracranial solid tumor in children below the age of 5 years. miR-34a, located in chromosome band 1p36, has been recently implicated as a tumor suppressor gene in NB." +other hsa-mir-124a Rheumatoid Arthritis 19404929 The results of this study suggest that miR-124a is a key miRNA in the posttranscriptional regulatory mechanisms of RA synoviocytes. +other hsa-mir-196a "Carcinoma, Rectal" 19418581 miR-196a exerts a pro-oncogenic influence in colorectal cancer. +other hsa-mir-143 Gastrointestinal Neoplasms 19439999 "Taken together, these findings suggest that miR-143 and miR-145 act as anti-oncomirs common to gastrointestinal tumors." +other hsa-mir-145 Gastrointestinal Neoplasms 19439999 "Taken together, these findings suggest that miR-143 and miR-145 act as anti-oncomirs common to gastrointestinal tumors." +other hsa-mir-34a Neuroblastoma 19461653 "In this review, the evidence for a role of miR-34a and miR-34b/c in the apoptotic response of normal and tumor cells is surveyed." +other hsa-mir-224 Pancreatic Neoplasms 19475450 miR-224 and miR-486 are associated with the progression of pancreatic ductal adenocarcinomas +other hsa-mir-486 Pancreatic Neoplasms 19475450 miR-224 and miR-486 are associated with the progression of pancreatic ductal adenocarcinomas +other hsa-let-7a Ovarian Neoplasms 19477633 Our study also suggests that lin-28B may promote ovarian cancer progression and serve as an unfavourable prognostic marker for the disease. +other hsa-mir-129 Bladder Neoplasms 19487295 "We identified several miRNAs with prognostic potential for predicting disease progression (e.g., miR-129, miR-133b, and miR-518c*)." +other hsa-mir-133b Bladder Neoplasms 19487295 "We identified several miRNAs with prognostic potential for predicting disease progression (e.g., miR-129, miR-133b, and miR-518c*)." +other hsa-mir-26a Glioma 19487573 The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo. +other hsa-mir-106a Mesothelioma 19502386 "The expression of miR-17-5p, miR-21, miR-29a, miR-30c, miR-30e-5p, miR-106a, and miR-143 was significantly associated with the histopathological subtype" +other hsa-mir-143 Mesothelioma 19502386 "The expression of miR-17-5p, miR-21, miR-29a, miR-30c, miR-30e-5p, miR-106a, and miR-143 was significantly associated with the histopathological subtype" +other hsa-mir-17 Mesothelioma 19502386 "The expression of miR-17-5p, miR-21, miR-29a, miR-30c, miR-30e-5p, miR-106a, and miR-143 was significantly associated with the histopathological subtype" +other hsa-mir-21 Mesothelioma 19502386 "The expression of miR-17-5p, miR-21, miR-29a, miR-30c, miR-30e-5p, miR-106a, and miR-143 was significantly associated with the histopathological subtype" +other hsa-mir-29a Mesothelioma 19502386 "The expression of miR-17-5p, miR-21, miR-29a, miR-30c, miR-30e-5p, miR-106a, and miR-143 was significantly associated with the histopathological subtype" +other hsa-mir-30c-1 Mesothelioma 19502386 "The expression of miR-17-5p, miR-21, miR-29a, miR-30c, miR-30e-5p, miR-106a, and miR-143 was significantly associated with the histopathological subtype" +other hsa-mir-30c-2 Mesothelioma 19502386 "The expression of miR-17-5p, miR-21, miR-29a, miR-30c, miR-30e-5p, miR-106a, and miR-143 was significantly associated with the histopathological subtype" +other hsa-mir-30e Mesothelioma 19502386 "The expression of miR-17-5p, miR-21, miR-29a, miR-30c, miR-30e-5p, miR-106a, and miR-143 was significantly associated with the histopathological subtype" +other hsa-mir-1 Heart Failure 19519553 MiR-1 influences susceptibility to cardiac arrhythmias after myocardial infarction. +other hsa-mir-208 Heart Failure 19519553 MiR-208 is involved in the shift toward a fetal gene expression pattern in contractile proteins in heart failure. +other hsa-mir-21 Heart Failure 19519553 MiR-29 is involved in fibrotic reaction after myocardial infarction while miR-21 may exert a fundamental role in post-angioplasty restenosis. +other hsa-mir-222 Glioblastoma 19520829 "Immunohistochemical and in situ hybridization analyses of 30 primary glioblastoma tissues demonstrated that expression of Dicer, miR-222, or miR-339 was inversely associated with ICAM-1 expression." +other hsa-mir-339 Glioblastoma 19520829 "Immunohistochemical and in situ hybridization analyses of 30 primary glioblastoma tissues demonstrated that expression of Dicer, miR-222, or miR-339 was inversely associated with ICAM-1 expression." +other hsa-mir-184 Neoplasms [unspecific] 19546886 "laryngeal carcinoma, upregulated; control of the G1-S phase transition;regulate BTG2, a cell cycle gene" +other hsa-mir-15a "Carcinoma, Lung, Non-Small-Cell" 19549910 miR-15a and miR-16 are implicated in cell cycle regulation in a Rb-dependent manner and are frequently deleted or down-regulated in non-small cell lung cancer. +other hsa-mir-16 "Carcinoma, Lung, Non-Small-Cell" 19549910 miR-15a and miR-16 are implicated in cell cycle regulation in a Rb-dependent manner and are frequently deleted or down-regulated in non-small cell lung cancer. +other hsa-mir-29a Breast Neoplasms 19567675 "potentially oncogenic role in breast tumorigenesis; significantly associated with decreased breast cancer risk; mutant precursors of miR-196a-2 into breast cancer cells led to less efficient processing of the miRNA precursor to its mature form as well as diminished capacity to regulate target genes, further showed that cell cycle response to mutagen challenge was significantly enhanced;" +other hsa-mir-23a Hepatitis C Virus Infection 19578061 "virus specific, miR-122-sensitive double-helical switch element in the 5' region--a new mechanism of action of micro-RNAs" +other hsa-mir-661 "Squamous Cell Carcinoma, Lung" 19584273 miR-146b alone have the strongest prediction accuracy for stratifying prognostic groups; +other hsa-let-7 Infection [unspecific] 19592657 "Our data suggest that miR-98 and let-7 confer cholangiocyte expression of CIS in response to microbial challenge, a process that may be relevant to the regulation of TLR-mediated epithelial innate immune response." +other hsa-mir-98 Infection [unspecific] 19592657 "Our data suggest that miR-98 and let-7 confer cholangiocyte expression of CIS in response to microbial challenge, a process that may be relevant to the regulation of TLR-mediated epithelial innate immune response." +other hsa-mir-141 Neoplasms [unspecific] 19593777 association with cancer progression +other hsa-mir-200b Neoplasms [unspecific] 19593777 association with cancer progression +other hsa-mir-200c Neoplasms [unspecific] 19593777 association with cancer progression +other hsa-mir-205 Neoplasms [unspecific] 19593777 association with cancer progression +other hsa-mir-21 Neoplasms [unspecific] 19593777 association with cancer progression +other hsa-mir-30a Neoplasms [unspecific] 19593777 association with cancer progression +other hsa-mir-30e Neoplasms [unspecific] 19593777 association with cancer progression +other hsa-mir-21 Prostate Neoplasms 19597470 acts as tumor suppressor and induces apoptosis of tumor cells through E2F1-mediated suppression of Akt phosphorylation +other hsa-mir-330 Prostate Neoplasms 19597470 MicroRNA-330 acts as tumor suppressor and induces apoptosis of prostate cancer cells through E2F1-mediated suppression of Akt phosphorylation +other hsa-mir-122 Gastrointestinal Neoplasms 19607815 The down-regulation of miR-122a mediated by aberrant APC/beta-catenin signaling is important to the pathogenesis of gastrointestinal cancers. +other hsa-mir-125a Myelodysplastic Syndromes 19615744 Significant inverse correlation of microRNA-150/MYB and microRNA-222/p27 in myelodysplastic syndrome +other hsa-mir-221 Myelodysplastic Syndromes 19615744 Significant inverse correlation of microRNA-150/MYB and microRNA-222/p27 in myelodysplastic syndrome +other hsa-mir-222 Myelodysplastic Syndromes 19615744 Significant inverse correlation of microRNA-150/MYB and microRNA-222/p27 in myelodysplastic syndrome +other hsa-mir-599 Multiple Sclerosis 19617918 relevant at the time of relapse +other hsa-mir-96 Multiple Sclerosis 19617918 relevant at the time of relapse +other hsa-mir-206 Rhabdomyosarcoma 19620785 miR-1 was barely detectable in primary RMS +other hsa-mir-34c Rhabdomyosarcoma 19620785 "The muscle-specific microRNA miR-206, blocks human rhabdomyosarcoma growth in xenotransplanted mice by promoting myogenic differentiation" +other hsa-mir-188 Cardiovascular Diseases [unspecific] 19669742 These findings suggest that dicer and miRNAs especially miR-188 are involved in Hcy-induced cardiac remodeling +other hsa-mir-93 Urinary Bladder Cancer 19671845 control the EMT process and sensitivity to EGFR therapy +other hsa-mir-18b Breast Neoplasms 19684618 inhibit Eralpha signaling +other hsa-mir-193b Breast Neoplasms 19684618 inhibit Eralpha signaling +other hsa-mir-206 Breast Neoplasms 19684618 inhibit Eralpha signaling +other hsa-mir-302c Breast Neoplasms 19684618 inhibit Eralpha signaling +other hsa-mir-185 Lung Neoplasms 19688090 cell cycle arrest +other hsa-mir-18a Lung Neoplasms 19688090 cell cycle arrest +other hsa-mir-125a Muscular Dystrophy 19690046 regulation of §Ø©ãmyosin heavy chain gene +other hsa-mir-208b Muscular Dystrophy 19690046 regulation of §Ø©ãmyosin heavy chain gene +other hsa-mir-107 "Leukemia, Lymphocytic, Chronic, B-Cell" 19692702 "regulation of PLAG1 by miR-181a, miR-181b, miR-107, and miR-424" +other hsa-mir-182 Pain 19699278 "association with chronic neuropathic pain, mechanical hypersensitivity" +other hsa-mir-183 Pain 19699278 "association with chronic neuropathic pain, mechanical hypersensitivity" +other hsa-mir-34a Pain 19699278 "association with chronic neuropathic pain, mechanical hypersensitivity" +other hsa-mir-96 Pain 19699278 "association with chronic neuropathic pain, mechanical hypersensitivity" +other hsa-mir-155 Gastric Neoplasms 19702585 possible role in the intimate relationship +other hsa-mir-15a Myelodysplastic Syndromes 19702585 differentially expressed between low-risk and high-risk +other hsa-mir-21 Gastric Neoplasms 19702585 possible role in the intimate relationship +other hsa-mir-221 Gastric Neoplasms 19702585 possible role in the intimate relationship +other hsa-mir-222 Gastric Neoplasms 19702585 possible role in the intimate relationship +other hsa-mir-27a Gastric Neoplasms 19702585 possible role in the intimate relationship +other hsa-mir-125a Lung Neoplasms 19702827 "Taken together, our results provide compelling evidence that miR-125a-5p, an epidermal growth factor-signaling-regulated miRNA, may function as a metastatic suppressor." +other hsa-mir-200a Meningioma 19703647 Down-regulation Promotes Tumor Growth by reducing E-cadherin and Activating the Wnt/{beta} catenin Signaling Pathway +other hsa-mir-200a Meningioma 19703993 "This reveals a previously unrecognized signaling cascade involved in meningioma tumor development and highlights a novel molecular interaction between miR-200a and Wnt signaling, thereby providing insights into novel therapies for meningiomas." +other hsa-mir-128-1 Neuroblastoma 19713529 reduce cell motility and invasiveness +other hsa-mir-128-2 Neuroblastoma 19713529 reduce cell motility and invasiveness +other hsa-mir-34a Pancreatic Neoplasms 19714243 inhibits tumor-initiating cells. +other hsa-mir-34b Pancreatic Neoplasms 19714243 inhibits tumor-initiating cells. +other hsa-mir-34c Pancreatic Neoplasms 19714243 inhibits tumor-initiating cells. +other hsa-mir-146a "Leukemia, Lymphocytic, Chronic, B-Cell" 19717645 correlated with assessment of biological impact on Chronic Lymphocytic Leukemia +other hsa-mir-146b "Leukemia, Lymphocytic, Chronic, B-Cell" 19717645 correlated with assessment of biological impact on Chronic Lymphocytic Leukemia +other hsa-mir-148a "Leukemia, Lymphocytic, Chronic, B-Cell" 19717645 correlated with assessment of biological impact on Chronic Lymphocytic Leukemia +other hsa-mir-151a "Leukemia, Lymphocytic, Chronic, B-Cell" 19717645 correlated with assessment of biological impact on Chronic Lymphocytic Leukemia +other hsa-mir-155 "Leukemia, Lymphocytic, Chronic, B-Cell" 19717645 correlated with assessment of biological impact on Chronic Lymphocytic Leukemia +other hsa-mir-29b-1 "Leukemia, Lymphocytic, Chronic, B-Cell" 19717645 correlated with assessment of biological impact on Chronic Lymphocytic Leukemia +other hsa-mir-29c "Leukemia, Lymphocytic, Chronic, B-Cell" 19717645 correlated with assessment of biological impact on Chronic Lymphocytic Leukemia +other hsa-mir-34a "Leukemia, Lymphocytic, Chronic, B-Cell" 19717645 correlated with assessment of biological impact on Chronic Lymphocytic Leukemia +other hsa-mir-640 "Leukemia, Lymphocytic, Chronic, B-Cell" 19717645 correlated with assessment of biological impact on Chronic Lymphocytic Leukemia +other hsa-mir-155 Intracerebral Hemorrhage 19724284 correlate +other hsa-mir-298 Intracerebral Hemorrhage 19724284 correlate +other hsa-mir-362 Intracerebral Hemorrhage 19724284 correlate +other hsa-mir-21 Pancreatic Adenocarcinoma 19730150 "Antisense Inhibition of microRNA-21 or -221 Arrests Cell Cycle, Induces Apoptosis, and Sensitizes the Effects of Gemcitabine in Pancreatic Adenocarcinoma." +other hsa-mir-221 Pancreatic Adenocarcinoma 19730150 "Antisense Inhibition of microRNA-21 or -221 Arrests Cell Cycle, Induces Apoptosis, and Sensitizes the Effects of Gemcitabine in Pancreatic Adenocarcinoma." +other hsa-mir-145 Breast Neoplasms 19730444 miR-145 participates with TP53 in a death-promoting regulatory loop and targets estrogen receptor-alpha in human breast cancer cells. +other hsa-mir-140 Colon Neoplasms 19734943 high-throughput microRNA (miRNA) expression analysis revealed that the expression of miR-140 was associated with chemosensitivity in osteosarcoma tumor xenografts +other hsa-mir-140 Osteosarcoma 19734943 high-throughput microRNA (miRNA) expression analysis revealed that the expression of miR-140 was associated with chemosensitivity in osteosarcoma tumor xenografts +other hsa-mir-34a Lung Neoplasms 19736307 relevant to the diagnosis +other hsa-mir-500a "Carcinoma, Hepatocellular" 19737067 oncofetal miRNA relevant to the diagnosis +other hsa-mir-21 "Adenocarcinoma, Colon" 19737943 predictors of prognosis +other hsa-mir-10a Pancreatic Neoplasms 19747919 Inhibition of miR-10a expression (with retinoic acid receptor antagonists) or function (with specific inhibitors) is a promising starting point for antimetastatic therapies. +other hsa-mir-126 "Leukemia, Lymphoblastic" 19760605 "ANOVA highlighted a set of six miRNAs-namely miR-425-5p, miR-191, miR-146b, miR-128, miR-629, and miR-126-that can discriminate B-lineage ALL subgroups harboring specific molecular lesions." +other hsa-mir-128 "Leukemia, Lymphoblastic" 19760605 "ANOVA highlighted a set of six miRNAs-namely miR-425-5p, miR-191, miR-146b, miR-128, miR-629, and miR-126-that can discriminate B-lineage ALL subgroups harboring specific molecular lesions." +other hsa-mir-146b "Leukemia, Lymphoblastic" 19760605 "ANOVA highlighted a set of six miRNAs-namely miR-425-5p, miR-191, miR-146b, miR-128, miR-629, and miR-126-that can discriminate B-lineage ALL subgroups harboring specific molecular lesions." +other hsa-mir-191 "Leukemia, Lymphoblastic" 19760605 "ANOVA highlighted a set of six miRNAs-namely miR-425-5p, miR-191, miR-146b, miR-128, miR-629, and miR-126-that can discriminate B-lineage ALL subgroups harboring specific molecular lesions." +other hsa-mir-425 "Leukemia, Lymphoblastic" 19760605 "ANOVA highlighted a set of six miRNAs-namely miR-425-5p, miR-191, miR-146b, miR-128, miR-629, and miR-126-that can discriminate B-lineage ALL subgroups harboring specific molecular lesions." +other hsa-mir-629 "Leukemia, Lymphoblastic" 19760605 "ANOVA highlighted a set of six miRNAs-namely miR-425-5p, miR-191, miR-146b, miR-128, miR-629, and miR-126-that can discriminate B-lineage ALL subgroups harboring specific molecular lesions." +other hsa-mir-17 Prostate Neoplasms 19771525 "MicroRNA-17-3p is a prostate tumor suppressor in vitro and in vivo, and is decreased in high grade prostate tumors analyzed by laser capture microdissection." +other hsa-mir-210 Pancreatic Neoplasms 19782034 "When human head and neck or pancreatic tumor cells ectopically expressing mir-210 were implanted into immunodeficient mice, mir-210 repressed initiation of tumor growth." +other hsa-let-7a Laryngeal Neoplasms 19787239 "Thus, we propose that let-7a may be a tumor suppressor in laryngeal cancer by inhibiting cell growth, inducing cell apoptosis and downregulating the oncogenes expression." +other hsa-mir-375 Diabetes Mellitus 19800254 "Recent studies, for example, implicate miR-375 in pancreatic islet cell viability and function, and removal or overexpression of miR-375 profoundly affects glucose metabolism. " +other hsa-mir-421 Gastrointestinal Neoplasms 19802518 miR-421 may involve in the early stage of stomach carcinogenesis and could be used as an efficient diagnostic biomarker. +other hsa-mir-106b Alopecia 19821055 "mir-106b:four microRNAs (miR-221, miR-125b, miR-106b and miR-410) that could participate in pathogenesis of MPB" +other hsa-mir-125b-1 Alopecia 19821055 "miR-125b:four microRNAs (miR-221, miR-125b, miR-106b and miR-410) that could participate in pathogenesis of MPB" +other hsa-mir-125b-2 Alopecia 19821055 "miR-125b:four microRNAs (miR-221, miR-125b, miR-106b and miR-410) that could participate in pathogenesis of MPB" +other hsa-mir-221 Alopecia 19821055 "miR-221:four microRNAs (miR-221, miR-125b, miR-106b and miR-410) that could participate in pathogenesis of MPB" +other hsa-mir-410 Alopecia 19821055 "miR-410:four microRNAs (miR-221, miR-125b, miR-106b and miR-410) that could participate in pathogenesis of MPB" +other hsa-mir-141 Colorectal Carcinoma 19830559 miR-141:miR-141 regulates SIP1 to inhibit migration and invasion of CRC cells +other hsa-mir-326 Multiple Sclerosis 19838199 miR-326 regulates TH-17 differentiation and is associated with the pathogenesis of multiple sclerosis +other hsa-mir-200a Breast Neoplasms 19839049 miR-200a:microRNA-200 family alterations is related to mesenchymal and drug-resistant phenotypes in human breast cancer cells +other hsa-mir-200b Breast Neoplasms 19839049 miR-200b:microRNA-200 family alterations is related to mesenchymal and drug-resistant phenotypes in human breast cancer cells +other hsa-mir-200c Breast Neoplasms 19839049 miR-200c:microRNA-200 family alterations is related to mesenchymal and drug-resistant phenotypes in human breast cancer cells +other hsa-mir-143 Colorectal Carcinoma 19843160 "Collectively, the data obtained in the present study suggest anti-proliferative, chemosensitizer and putative pro-apoptotic roles for miR-143 in colon cancer." +other hsa-mir-143 Colorectal Carcinoma 19843336 In vitro functional studies indicated that miR-143 and miR-145 appear to function in opposing manners to either inhibit or augment cell proliferation in a metastatic CRC model. +other hsa-mir-145 Colorectal Carcinoma 19843336 In vitro functional studies indicated that miR-143 and miR-145 appear to function in opposing manners to either inhibit or augment cell proliferation in a metastatic CRC model. +other hsa-mir-130a Adrenal Cortex Neoplasms 19849700 miR-130a:miR-130a and miR-382 as putative diagnostic MMAD markers +other hsa-mir-382 Adrenal Cortex Neoplasms 19849700 miR-382:miR-130a and miR-382 as putative diagnostic MMAD markers +other hsa-mir-144 Schizophrenia 19849891 "The most promising miRNAs so far identified include miR-181, miR-346 and miR-195 in schizophrenia and miR-34a and miR-144 in bipolar disorder." +other hsa-mir-181 Schizophrenia 19849891 "The most promising miRNAs so far identified include miR-181, miR-346 and miR-195 in schizophrenia and miR-34a and miR-144 in bipolar disorder." +other hsa-mir-195 Schizophrenia 19849891 "The most promising miRNAs so far identified include miR-181, miR-346 and miR-195 in schizophrenia and miR-34a and miR-144 in bipolar disorder." +other hsa-mir-346 Schizophrenia 19849891 "The most promising miRNAs so far identified include miR-181, miR-346 and miR-195 in schizophrenia and miR-34a and miR-144 in bipolar disorder." +other hsa-mir-34a Schizophrenia 19849891 "The most promising miRNAs so far identified include miR-181, miR-346 and miR-195 in schizophrenia and miR-34a and miR-144 in bipolar disorder." +other hsa-mir-500 "Carcinoma, Hepatocellular" 19863192 "Our findings reveal that diverse changes of miRNAs occur during liver development and, one of these, miR-500 is an oncofetal miRNA relevant to the diagnosis of human HCC." +other hsa-mir-15a "Leukemia, Myeloid, Acute" 19883312 miR-15a in BM ( p = 0.034) and miR-16 in PB ( p = 0.005) were differentially expressed between low-risk and high-risk groups +other hsa-mir-222 "Leukemia, Myeloid, Acute" 19883312 miR-222 ( p = 0.0023) and miR-181a ( p = 0.014) expression was higher in AML than in MDS +other hsa-mir-326 Breast Neoplasms 19883630 Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1 +other hsa-mir-17 Neoplasms [unspecific] 19887902 miR-17-5p has initially been linked to tumorigenesis +other hsa-mir-18a Neoplasms [unspecific] 19887902 has initially been linked to tumorigenesis +other hsa-mir-19a Neoplasms [unspecific] 19887902 has initially been linked to tumorigenesis +other hsa-mir-20a Neoplasms [unspecific] 19887902 has initially been linked to tumorigenesis +other hsa-mir-138-1 Leukemia 19896708 miR-138:miR-138 might reverse multidrug resistance of leukemia cells +other hsa-mir-138-2 Leukemia 19896708 miR-138:miR-138 might reverse multidrug resistance of leukemia cells +other hsa-mir-145 Myelodysplastic Syndromes 19898489 "5q- syndrome deleted,Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype" +other hsa-mir-146a Myelodysplastic Syndromes 19898489 "5q- syndrome deleted,Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype" +other hsa-mir-17 Severe Acute Respiratory Syndrome Virus Infection 19915717 "Upregulated BASC miRNAs-17*, -574-5p, and -214 are co-opted by SARS-CoV to suppress its own replication and evade immune elimination" +other hsa-mir-214 Severe Acute Respiratory Syndrome Virus Infection 19915717 "Upregulated BASC miRNAs-17*, -574-5p, and -214 are co-opted by SARS-CoV to suppress its own replication and evade immune elimination" +other hsa-mir-574 Severe Acute Respiratory Syndrome Virus Infection 19915717 "Upregulated BASC miRNAs-17*, -574-5p, and -214 are co-opted by SARS-CoV to suppress its own replication and evade immune elimination" +other hsa-mir-126 Vascular Disease [unspecific] 19917099 "miR-126, miR-24 and miR-23a are selectively expressed in microvascular endothelial cells in vivo" +other hsa-mir-145 Vascular Disease [unspecific] 19917099 elevated levels of miR-145 reduced migration of microvascular cells in response to growth factor gradients in vitro +other hsa-mir-23a Vascular Disease [unspecific] 19917099 "miR-126, miR-24 and miR-23a are selectively expressed in microvascular endothelial cells in vivo" +other hsa-mir-25 Endomyocardial Fibrosis 19919989 both miR-25 and miR-29a were sufficient to decrease collagen gene expression +other hsa-mir-29a Endomyocardial Fibrosis 19919989 both miR-25 and miR-29a were sufficient to decrease collagen gene expression +other hsa-mir-27a Breast Neoplasms 19921425 "We hypothesize that the G-variant of rs895819 might impair the maturation of the oncogenic miR-27a and thus, is associated with familial breast cancer risk." +other hsa-mir-34a Lung Neoplasms 19921694 miR-34a:MicroRNA-34a is an important component of PRIMA-1-induced apoptotic network in human lung cancer cells +other hsa-mir-17 Lymphoma 19933089 "miR-17-5p can induce tumorigenesis, such as lymphoma and vascularized tumor as an oncogene" +other hsa-mir-18a Lymphoma 19933089 "it can induce tumorigenesis, such as lymphoma and vascularized tumor as an oncogene" +other hsa-mir-19a Lymphoma 19933089 "it can induce tumorigenesis, such as lymphoma and vascularized tumor as an oncogene" +other hsa-mir-20a Lymphoma 19933089 "it can induce tumorigenesis, such as lymphoma and vascularized tumor as an oncogene" +other hsa-mir-21 Glioma 19934272 the results of our study show that the downregulation of miR-21 contributes to the antitumor effects of IFN-beta and that miR-21 expression is negatively regulated by STAT3 activation. These results highlight the importance of understanding the transcriptional regulation of the miRNAs involved in oncogenesis. +other hsa-mir-140 Osteoarthritis 19948051 "We investigated whether two highly predicted microRNAs (miRNAs), miR-140 and miR-27a, regulate these two genes in human OA chondrocytes." +other hsa-mir-27a Osteoarthritis 19948051 "We investigated whether two highly predicted microRNAs (miRNAs), miR-140 and miR-27a, regulate these two genes in human OA chondrocytes." +other hsa-let-7g Gastric Neoplasms 19948396 "different miRNAs have been found to predict sensitivity to anticancer treatment: miR-30c, miR-130a and miR-335 are downregulated in various chemoresistant cell lines, hsa-Let-7g and hsa-miR-181b are strongly associated with response to 5-fluorouracil-based antimetabolite S-1" +other hsa-mir-181b Gastric Neoplasms 19948396 "different miRNAs have been found to predict sensitivity to anticancer treatment: miR-30c, miR-130a and miR-335 are downregulated in various chemoresistant cell lines, hsa-Let-7g and hsa-miR-181b are strongly associated with response to 5-fluorouracil-based antimetabolite S-1" +other hsa-mir-126 Gastrointestinal Neoplasms 19951901 "We have identified a seven-miRNA signature (miR-10b, miR-21, miR-223, miR-338, let-7a, miR-30a-5p, miR-126) for overall survival (p=0.0009) and relapse-free survival (p=0.0005) of gastric cancer patients. " +other hsa-mir-29a Irritable Bowel Syndrome 19951903 miR-29a:MicroRNA-29a regulates intestinal membrane permeability in patients with irritable bowel syndrome +other hsa-mir-27a "Squamous Cell Carcinoma, Esophageal" 19960259 miR-27a:Down-regulation of miR-27a might reverse multidrug resistance of esophageal squamous cell carcinoma +other hsa-mir-146a Immune System Disease [unspecific] 19965651 "Our results demonstrate that several signaling pathways, other than inflammation, are influenced by miR-146a. In particular, we provide experimental evidence that miR-146a modulates activation-induced cell death (AICD), acting as an antiapoptotic factor, and that Fas-associated death domain (FADD) is a target of miR-146a." +other hsa-mir-122 Hepatitis C Virus Infection 19965718 a locked nucleic acid (LNA)-modified oligonucleotide (SPC3649) complementary to miR-122 leads to long-lasting suppression of HCV viremia +other hsa-mir-145 Breast Neoplasms 19996288 "Taken together, these results suggest that as a tumor suppressor, miR-145 inhibits not only tumor growth but also cell invasion and metastasis." +other hsa-mir-145 Prostate Neoplasms 19996289 miR-145 and miR-331-3p are predicted to target 3 of the 20 hub genes +other hsa-mir-331 Prostate Neoplasms 19996289 miR-145 and miR-331-3p are predicted to target 3 of the 20 hub genes +other hsa-mir-126 Atherosclerosis 19996457 Administration of apoptotic bodies or miR-126 limited atherosclerosis +other hsa-mir-21 Cystic Fibrosis 19997496 "mir-125b-1, mir-21, mir-30b, and mir-23b-27b-24-1 cluster genes were transactivated through promoter binding of the NF-kappaB p65 subunit following C. parvum infection" +other hsa-mir-23b Cystic Fibrosis 19997496 "mir-125b-1, mir-21, mir-30b, and mir-23b-27b-24-1 cluster genes were transactivated through promoter binding of the NF-kappaB p65 subunit following C. parvum infection" +other hsa-mir-27b Cystic Fibrosis 19997496 "mir-125b-1, mir-21, mir-30b, and mir-23b-27b-24-1 cluster genes were transactivated through promoter binding of the NF-kappaB p65 subunit following C. parvum infection" +other hsa-mir-30b Cystic Fibrosis 19997496 "mir-125b-1, mir-21, mir-30b, and mir-23b-27b-24-1 cluster genes were transactivated through promoter binding of the NF-kappaB p65 subunit following C. parvum infection" +other hsa-mir-31 Intestinal Schistosomiasis 19997615 "some nucleotides at many positions of Schistosoma miRNAs, such as miR-8, let-7, miR-10, miR-31, miR-92, miR-124, and miR-125, are indeed significantly distinct from other bilaterian orthologs" +other hsa-let-7a-1 Retinoblastoma 20004941 "Correlation of overexpression of HMGA1 and HMGA2 with poor tumor differentiation,invasion, and proliferation associated with let-7 down-regulation in retinoblastomas." +other hsa-let-7a-2 Retinoblastoma 20004941 "Correlation of overexpression of HMGA1 and HMGA2 with poor tumor differentiation,invasion, and proliferation associated with let-7 down-regulation in retinoblastomas." +other hsa-let-7a-3 Retinoblastoma 20004941 "Correlation of overexpression of HMGA1 and HMGA2 with poor tumor differentiation,invasion, and proliferation associated with let-7 down-regulation in retinoblastomas." +other hsa-let-7b Retinoblastoma 20004941 "Correlation of overexpression of HMGA1 and HMGA2 with poor tumor differentiation,invasion, and proliferation associated with let-7 down-regulation in retinoblastomas." +other hsa-let-7c Retinoblastoma 20004941 "Correlation of overexpression of HMGA1 and HMGA2 with poor tumor differentiation,invasion, and proliferation associated with let-7 down-regulation in retinoblastomas." +other hsa-let-7d Retinoblastoma 20004941 "Correlation of overexpression of HMGA1 and HMGA2 with poor tumor differentiation,invasion, and proliferation associated with let-7 down-regulation in retinoblastomas." +other hsa-let-7e Retinoblastoma 20004941 "Correlation of overexpression of HMGA1 and HMGA2 with poor tumor differentiation,invasion, and proliferation associated with let-7 down-regulation in retinoblastomas." +other hsa-let-7f-1 Retinoblastoma 20004941 "Correlation of overexpression of HMGA1 and HMGA2 with poor tumor differentiation,invasion, and proliferation associated with let-7 down-regulation in retinoblastomas." +other hsa-let-7f-2 Retinoblastoma 20004941 "Correlation of overexpression of HMGA1 and HMGA2 with poor tumor differentiation,invasion, and proliferation associated with let-7 down-regulation in retinoblastomas." +other hsa-let-7g Retinoblastoma 20004941 "Correlation of overexpression of HMGA1 and HMGA2 with poor tumor differentiation,invasion, and proliferation associated with let-7 down-regulation in retinoblastomas." +other hsa-let-7i Retinoblastoma 20004941 "Correlation of overexpression of HMGA1 and HMGA2 with poor tumor differentiation,invasion, and proliferation associated with let-7 down-regulation in retinoblastomas." +other hsa-mir-132 Inflammation 20005135 MicroRNA-132 potentiates cholinergic anti-inflammatory signaling by targeting acetylcholinesterase +other hsa-mir-1181 Hepatitis C Virus Infection 20006370 "miR-24, miR-149, miR-638 and miR-1181 were identified to be involved in HCV entry, replication and propagation" +other hsa-mir-149 Hepatitis C Virus Infection 20006370 "miR-24, miR-149, miR-638 and miR-1181 were identified to be involved in HCV entry, replication and propagation" +other hsa-mir-24-1 Hepatitis C Virus Infection 20006370 "miR-24, miR-149, miR-638 and miR-1181 were identified to be involved in HCV entry, replication and propagation" +other hsa-mir-24-2 Hepatitis C Virus Infection 20006370 "miR-24, miR-149, miR-638 and miR-1181 were identified to be involved in HCV entry, replication and propagation" +other hsa-mir-638 Hepatitis C Virus Infection 20006370 "miR-24, miR-149, miR-638 and miR-1181 were identified to be involved in HCV entry, replication and propagation" +other hsa-mir-206 Amyotrophic Lateral Sclerosis 20007902 MicroRNA-206 delays ALS progression and promotes regeneration of neuromuscular synapses in mice +other hsa-mir-19a Neoplasms [unspecific] 20008935 miR-19 is a key oncogenic component of mir-17-92 +other hsa-mir-19b-1 Neoplasms [unspecific] 20008935 miR-19 is a key oncogenic component of mir-17-92 +other hsa-mir-19b-2 Neoplasms [unspecific] 20008935 miR-19 is a key oncogenic component of mir-17-92 +other hsa-mir-146a Chlamydial Infection 20011700 microRNA-146a is a negative regulator of Tolllike receptor (TLR) signaling +other hsa-mir-133a-1 "Cardiomyopathy, Hypertrophic" 20013939 miR133a regulates cardiomyocyte hypertrophy in diabetes +other hsa-mir-133a-2 "Cardiomyopathy, Hypertrophic" 20013939 miR133a regulates cardiomyocyte hypertrophy in diabetes +other hsa-let-7c "Carcinoma, Hepatocellular" 20018759 "A set of 12 miRNAs (including miR-21, miR-221/222, miR-34a, miR-519a, miR-93, miR-96, and let-7c) was linked to disease progression from normal liver through cirrhosis to full-blown HCC" +other hsa-mir-21 "Carcinoma, Hepatocellular" 20018759 "A set of 12 miRNAs (including miR-21, miR-221/222, miR-34a, miR-519a, miR-93, miR-96, and let-7c) was linked to disease progression from normal liver through cirrhosis to full-blown HCC" +other hsa-mir-222 "Carcinoma, Hepatocellular" 20018759 "A set of 12 miRNAs (including miR-21, miR-221/222, miR-34a, miR-519a, miR-93, miR-96, and let-7c) was linked to disease progression from normal liver through cirrhosis to full-blown HCC" +other hsa-mir-34a "Carcinoma, Hepatocellular" 20018759 "A set of 12 miRNAs (including miR-21, miR-221/222, miR-34a, miR-519a, miR-93, miR-96, and let-7c) was linked to disease progression from normal liver through cirrhosis to full-blown HCC" +other hsa-mir-93 "Carcinoma, Hepatocellular" 20018759 "A set of 12 miRNAs (including miR-21, miR-221/222, miR-34a, miR-519a, miR-93, miR-96, and let-7c) was linked to disease progression from normal liver through cirrhosis to full-blown HCC" +other hsa-mir-96 "Carcinoma, Hepatocellular" 20018759 "A set of 12 miRNAs (including miR-21, miR-221/222, miR-34a, miR-519a, miR-93, miR-96, and let-7c) was linked to disease progression from normal liver through cirrhosis to full-blown HCC" +other hsa-let-7a Retinoblastoma 20019750 "miRNA profiling of these tumors identified members of the let-7 and miR-34(34b,34c) families as candidate tumor suppressors in retinoblastoma." +other hsa-let-7b Retinoblastoma 20019750 "miRNA profiling of these tumors identified members of the let-7 and miR-34(34b,34c) families as candidate tumor suppressors in retinoblastoma." +other hsa-let-7c Retinoblastoma 20019750 "miRNA profiling of these tumors identified members of the let-7 and miR-34(34b,34c) families as candidate tumor suppressors in retinoblastoma." +other hsa-let-7d Retinoblastoma 20019750 "miRNA profiling of these tumors identified members of the let-7 and miR-34(34b,34c) families as candidate tumor suppressors in retinoblastoma." +other hsa-let-7e Retinoblastoma 20019750 "miRNA profiling of these tumors identified members of the let-7 and miR-34(34b,34c) families as candidate tumor suppressors in retinoblastoma." +other hsa-let-7f Retinoblastoma 20019750 "miRNA profiling of these tumors identified members of the let-7 and miR-34(34b,34c) families as candidate tumor suppressors in retinoblastoma." +other hsa-let-7g Retinoblastoma 20019750 "miRNA profiling of these tumors identified members of the let-7 and miR-34(34b,34c) families as candidate tumor suppressors in retinoblastoma." +other hsa-let-7i Retinoblastoma 20019750 "miRNA profiling of these tumors identified members of the let-7 and miR-34(34b,34c) families as candidate tumor suppressors in retinoblastoma." +other hsa-mir-202 Retinoblastoma 20019750 "miRNA profiling of these tumors identified members of the let-7 and miR-34(34b,34c) families as candidate tumor suppressors in retinoblastoma." +other hsa-mir-34b Retinoblastoma 20019750 "miRNA profiling of these tumors identified members of the let-7 and miR-34(34b,34c) families as candidate tumor suppressors in retinoblastoma." +other hsa-mir-34c Retinoblastoma 20019750 "miRNA profiling of these tumors identified members of the let-7 and miR-34(34b,34c) families as candidate tumor suppressors in retinoblastoma." +other hsa-mir-98 Retinoblastoma 20019750 "miRNA profiling of these tumors identified members of the let-7 and miR-34(34b,34c) families as candidate tumor suppressors in retinoblastoma." +other hsa-mir-20a "Carcinoma, Renal Cell" 20022054 Transfection of miR-20a inhibitor significantly decreased cell proliferation in a dose dependent manner. +other hsa-mir-100 Gastric Neoplasms 20022810 "progression-related signature, miR-125b, miR-199a, and miR-100 were the most important microRNAs involved" +other hsa-mir-146a Kaposi Sarcoma 20023696 Our results show that K13-induced NF-kappaB activity suppresses CXCR4 through upregulation of miR-146a. +other hsa-mir-200a Ovarian Neoplasms 20035894 miR-200a:involved in epithelial-to-mesenchymal transition (EMT) +other hsa-mir-200b Ovarian Neoplasms 20035894 miR-200b:involved in epithelial-to-mesenchymal transition (EMT) +other hsa-mir-200c Ovarian Neoplasms 20035894 miR-200c:involved in epithelial-to-mesenchymal transition (EMT) +other hsa-mir-1-1 Chordoma 20041488 miR-1:miRNA-1 may have a functional effect on chordoma tumor pathogenesis +other hsa-mir-1-2 Chordoma 20041488 miR-1:miRNA-1 may have a functional effect on chordoma tumor pathogenesis +other hsa-mir-128a Breast Neoplasms 20054641 These data suggest that the hormone-responsive miR-128a can modulate TGF¦Â signaling and survival of the letrozole-resistant cell lines. +other hsa-mir-132 Inflammation 20064444 Boosting the brain's ability to block inflammation via microRNA-132. +other hsa-mir-10b Esophageal Neoplasms 20075075 MicroRNA-10b promotes migration and invasion through KLF4 in human esophageal cancer cell lines. +other hsa-mir-21 Breast Neoplasms 20082533 Downregulation of miR-21 enhances chemotherapeutic effect of taxol in breast carcinoma cells +other hsa-mir-130a Ovarian Neoplasms 20083225 "we discuss several other microRNAs that have been associated with chemotherapy resistance, such as miR-214, miR-130a, miR-27a and miR-451. In the final section, we speculate on the possibilities of microRNA-based therapies and the use of microRNAs as diagnostic tools." +other hsa-mir-214 Ovarian Neoplasms 20083225 "we discuss several other microRNAs that have been associated with chemotherapy resistance, such as miR-214, miR-130a, miR-27a and miR-451. In the final section, we speculate on the possibilities of microRNA-based therapies and the use of microRNAs as diagnostic tools." +other hsa-mir-27a Ovarian Neoplasms 20083225 "we discuss several other microRNAs that have been associated with chemotherapy resistance, such as miR-214, miR-130a, miR-27a and miR-451. In the final section, we speculate on the possibilities of microRNA-based therapies and the use of microRNAs as diagnostic tools." +other hsa-mir-451 Ovarian Neoplasms 20083225 "we discuss several other microRNAs that have been associated with chemotherapy resistance, such as miR-214, miR-130a, miR-27a and miR-451. In the final section, we speculate on the possibilities of microRNA-based therapies and the use of microRNAs as diagnostic tools." +other hsa-mir-23a Neoplasms [unspecific] 20086171 "In addition to its known function in regulating the cell cycle and glucose metabolism, recent studies document a role for Myc in stimulating glutamine catabolism, in part through the repression of miRNAs miR-23a and miR-23b." +other hsa-mir-23b Neoplasms [unspecific] 20086171 "In addition to its known function in regulating the cell cycle and glucose metabolism, recent studies document a role for Myc in stimulating glutamine catabolism, in part through the repression of miRNAs miR-23a and miR-23b." +other hsa-mir-146a Diabetes Mellitus 20086228 "Our data identify miR-21, miR-34a, and miR-146a as novel players in beta-cell failure elicited in vitro and in vivo by proinflammatory cytokines,notably during the development of peri-insulitis that precedes overt diabetes in NOD mice." +other hsa-mir-21 Diabetes Mellitus 20086228 "Our data identify miR-21, miR-34a, and miR-146a as novel players in beta-cell failure elicited in vitro and in vivo by proinflammatory cytokines,notably during the development of peri-insulitis that precedes overt diabetes in NOD mice." +other hsa-mir-34a Diabetes Mellitus 20086228 "Our data identify miR-21, miR-34a, and miR-146a as novel players in beta-cell failure elicited in vitro and in vivo by proinflammatory cytokines,notably during the development of peri-insulitis that precedes overt diabetes in NOD mice." +other hsa-mir-29a "Lymphoma, B-Cell" 20086245 "our results in primary MCL cells indicate that down-regulation of miR-29 could cooperate with cyclin D1 in MCL pathogenesis. Thus, our findings provide not only miRNA expression signature but also a novel prognostic marker and pathogenetic factor for this malignancy." +other hsa-mir-106b Toxoplasma gondii Infection 20090903 play crucial roles in mammalian cell regulation and have been implicated in numerous hyperproliferative diseases +other hsa-mir-17 Toxoplasma gondii Infection 20090903 play crucial roles in mammalian cell regulation and have been implicated in numerous hyperproliferative diseases +other hsa-mir-18a Toxoplasma gondii Infection 20090903 play crucial roles in mammalian cell regulation and have been implicated in numerous hyperproliferative diseases +other hsa-mir-19a Toxoplasma gondii Infection 20090903 play crucial roles in mammalian cell regulation and have been implicated in numerous hyperproliferative diseases +other hsa-mir-19b-1 Toxoplasma gondii Infection 20090903 play crucial roles in mammalian cell regulation and have been implicated in numerous hyperproliferative diseases +other hsa-mir-19b-2 Toxoplasma gondii Infection 20090903 play crucial roles in mammalian cell regulation and have been implicated in numerous hyperproliferative diseases +other hsa-mir-20a Toxoplasma gondii Infection 20090903 play crucial roles in mammalian cell regulation and have been implicated in numerous hyperproliferative diseases +other hsa-mir-21 Prostate Neoplasms 20092645 oncogenic properties of miR-21 could be cell and tissue dependent +other hsa-mir-143 Colorectal Carcinoma 20094072 anti-oncomirs +other hsa-let-7a-1 Lung Neoplasms 20097187 inhibition of proliferation in non-small cell lung cancer +other hsa-let-7a-2 Lung Neoplasms 20097187 inhibition of proliferation in non-small cell lung cancer +other hsa-let-7a-3 Lung Neoplasms 20097187 inhibition of proliferation in non-small cell lung cancer +other hsa-mir-126 Lung Neoplasms 20097187 inhibition of proliferation in non-small cell lung cancer +other hsa-mir-145 Lung Neoplasms 20097187 inhibition of proliferation in non-small cell lung cancer +other hsa-mir-146a "Leukemia, Myeloid, Acute" 20110180 "Of them, three (i.e., miR-146a, miR-181a/c, and miR-221), five (i.e., miR-25, miR-26a, miR-29b, miR-146a, and miR-196b), and three (i.e.,miR-26a, miR-29b, and miR-146a) miRNAs are significantly associated with overall survival (P<0.05) of the 32 ALL, 53 AML, and 40 non-M3 AML patients," +other hsa-mir-146a "Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic" 20110180 "Of them, three (i.e., miR-146a, miR-181a/c, and miR-221), five (i.e., miR-25, miR-26a, miR-29b, miR-146a, and miR-196b), and three (i.e.,miR-26a, miR-29b, and miR-146a) miRNAs are significantly associated with overall survival (P<0.05) of the 32 ALL, 53 AML, and 40 non-M3 AML patients," +other hsa-mir-181a-2 "Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic" 20110180 "Of them, three (i.e., miR-146a, miR-181a/c, and miR-221), five (i.e., miR-25, miR-26a, miR-29b, miR-146a, and miR-196b), and three (i.e.,miR-26a, miR-29b, and miR-146a) miRNAs are significantly associated with overall survival (P<0.05) of the 32 ALL, 53 AML, and 40 non-M3 AML patients," +other hsa-mir-181c "Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic" 20110180 "Of them, three (i.e., miR-146a, miR-181a/c, and miR-221), five (i.e., miR-25, miR-26a, miR-29b, miR-146a, and miR-196b), and three (i.e.,miR-26a, miR-29b, and miR-146a) miRNAs are significantly associated with overall survival (P<0.05) of the 32 ALL, 53 AML, and 40 non-M3 AML patients," +other hsa-mir-196b "Leukemia, Myeloid, Acute" 20110180 "Of them, three (i.e., miR-146a, miR-181a/c, and miR-221), five (i.e., miR-25, miR-26a, miR-29b, miR-146a, and miR-196b), and three (i.e.,miR-26a, miR-29b, and miR-146a) miRNAs are significantly associated with overall survival (P<0.05) of the 32 ALL, 53 AML, and 40 non-M3 AML patients," +other hsa-mir-221 "Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic" 20110180 "Of them, three (i.e., miR-146a, miR-181a/c, and miR-221), five (i.e., miR-25, miR-26a, miR-29b, miR-146a, and miR-196b), and three (i.e.,miR-26a, miR-29b, and miR-146a) miRNAs are significantly associated with overall survival (P<0.05) of the 32 ALL, 53 AML, and 40 non-M3 AML patients," +other hsa-mir-25 "Leukemia, Myeloid, Acute" 20110180 "Of them, three (i.e., miR-146a, miR-181a/c, and miR-221), five (i.e., miR-25, miR-26a, miR-29b, miR-146a, and miR-196b), and three (i.e.,miR-26a, miR-29b, and miR-146a) miRNAs are significantly associated with overall survival (P<0.05) of the 32 ALL, 53 AML, and 40 non-M3 AML patients," +other hsa-mir-26a-1 "Leukemia, Myeloid, Acute" 20110180 "Of them, three (i.e., miR-146a, miR-181a/c, and miR-221), five (i.e., miR-25, miR-26a, miR-29b, miR-146a, and miR-196b), and three (i.e.,miR-26a, miR-29b, and miR-146a) miRNAs are significantly associated with overall survival (P<0.05) of the 32 ALL, 53 AML, and 40 non-M3 AML patients," +other hsa-mir-26a-2 "Leukemia, Myeloid, Acute" 20110180 "Of them, three (i.e., miR-146a, miR-181a/c, and miR-221), five (i.e., miR-25, miR-26a, miR-29b, miR-146a, and miR-196b), and three (i.e.,miR-26a, miR-29b, and miR-146a) miRNAs are significantly associated with overall survival (P<0.05) of the 32 ALL, 53 AML, and 40 non-M3 AML patients," +other hsa-mir-29b-1 "Leukemia, Myeloid, Acute" 20110180 "Of them, three (i.e., miR-146a, miR-181a/c, and miR-221), five (i.e., miR-25, miR-26a, miR-29b, miR-146a, and miR-196b), and three (i.e.,miR-26a, miR-29b, and miR-146a) miRNAs are significantly associated with overall survival (P<0.05) of the 32 ALL, 53 AML, and 40 non-M3 AML patients," +other hsa-mir-29b-2 "Leukemia, Myeloid, Acute" 20110180 "Of them, three (i.e., miR-146a, miR-181a/c, and miR-221), five (i.e., miR-25, miR-26a, miR-29b, miR-146a, and miR-196b), and three (i.e.,miR-26a, miR-29b, and miR-146a) miRNAs are significantly associated with overall survival (P<0.05) of the 32 ALL, 53 AML, and 40 non-M3 AML patients," +other hsa-mir-221 Inflammation 20110463 "Functional inhibition of miR-221 with anti-miR-221 induced ICAM-1 protein expression. Moreover, IFN-gamma stimulation decreased miR-221 expression in cholangiocytes in a signal transducer and activator of transcription 1-dependent manner." +other hsa-mir-146a Pancreatic Neoplasms 20124483 miR-146a suppresses invasion of pancreatic cancer cells. +other hsa-mir-200a Urinary Bladder Cancer 20124485 play important regulatory roles in cervical cancer control +other hsa-mir-196a-1 "Carcinoma, Hepatocellular" 20127796 miR-196:MicroRNA-196 represses Bach1 protein and hepatitis C virus gene expression +other hsa-mir-196a-2 "Carcinoma, Hepatocellular" 20127796 miR-196:MicroRNA-196 represses Bach1 protein and hepatitis C virus gene expression +other hsa-mir-27b Osteoarthritis 20131257 miR-27b:MicroRNA-27b regulates the expression of matrix metalloproteinase 13 in human osteoarthritis chondrocytes +other hsa-mir-155 Lymphoma 20133617 "Together, our data helped explain miR-155 function, highlighted a hitherto unappreciated role of SMAD5 in lymphoma biology, and defined a unique mechanism used by cancer cells to escape TGF-beta's growth-inhibitory effects." +other hsa-mir-125b-1 Neoplasms [unspecific] 20144731 "miR-125b:in macrophages, miR-125b, miR-146, and miR-155 act as Pathogen Associated Molecular Pattern Molecule-associated microRNAs" +other hsa-mir-125b-2 Neoplasms [unspecific] 20144731 "miR-125b:in macrophages, miR-125b, miR-146, and miR-155 act as Pathogen Associated Molecular Pattern Molecule-associated microRNAs" +other hsa-mir-146a Neoplasms [unspecific] 20144731 "miR-146:in macrophages, miR-125b, miR-146, and miR-155 act as Pathogen Associated Molecular Pattern Molecule-associated microRNAs" +other hsa-mir-155 Neoplasms [unspecific] 20144731 "miR-155:in macrophages, miR-125b, miR-146, and miR-155 act as Pathogen Associated Molecular Pattern Molecule-associated microRNAs" +other hsa-mir-17 Neoplasms [unspecific] 20144731 "miR-17:Targets identified already in T cells include microRNAs, miR-17-92 family, miR-155, and miR-181a" +other hsa-mir-181a-1 Neoplasms [unspecific] 20144731 "miR-181a:Targets identified already in T cells include microRNAs, miR-17-92 family, miR-155, and miR-181a" +other hsa-mir-181a-2 Neoplasms [unspecific] 20144731 "miR-181a:Targets identified already in T cells include microRNAs, miR-17-92 family, miR-155, and miR-181a" +other hsa-mir-18a Neoplasms [unspecific] 20144731 "miR-18a:Targets identified already in T cells include microRNAs, miR-17-92 family, miR-155, and miR-181a" +other hsa-mir-19a Neoplasms [unspecific] 20144731 "miR-19a:Targets identified already in T cells include microRNAs, miR-17-92 family, miR-155, and miR-181a" +other hsa-mir-19b-1 Neoplasms [unspecific] 20144731 "miR-19b:Targets identified already in T cells include microRNAs, miR-17-92 family, miR-155, and miR-181a" +other hsa-mir-19b-2 Neoplasms [unspecific] 20144731 "miR-19b:Targets identified already in T cells include microRNAs, miR-17-92 family, miR-155, and miR-181a" +other hsa-mir-20a Neoplasms [unspecific] 20144731 "miR-20a:Targets identified already in T cells include microRNAs, miR-17-92 family, miR-155, and miR-181a" +other hsa-mir-214 Neoplasms [unspecific] 20144731 miR-214:miR-34C and miR-214 as Damage Associated Molecular Pattern Molecules-associated miRs +other hsa-mir-34c Neoplasms [unspecific] 20144731 miR-34c:miR-34C and miR-214 as Damage Associated Molecular Pattern Molecules-associated miRs +other hsa-mir-92a-1 Neoplasms [unspecific] 20144731 "miR-92a:Targets identified already in T cells include microRNAs, miR-17-92 family, miR-155, and miR-181a" +other hsa-mir-92a-2 Neoplasms [unspecific] 20144731 "miR-92a:Targets identified already in T cells include microRNAs, miR-17-92 family, miR-155, and miR-181a" +other hsa-mir-31 Neoplasms [unspecific] 20145132 miR-31 ablates expression of the HIF regulatory factor FIH to activate the HIF pathway in head and neck carcinoma +other hsa-mir-125b-1 Melanoma 20153427 "miR-125b:miRNA125b may be involved in the regulation of VDR expression and in the resistance against 1,25(OH)(2)D(3) in melanoma cells" +other hsa-mir-125b-2 Melanoma 20153427 "miR-125b:miRNA125b may be involved in the regulation of VDR expression and in the resistance against 1,25(OH)(2)D(3) in melanoma cells" +other hsa-mir-21 Prostate Neoplasms 20160498 "The transcriptional regulation of miR-21, its multiple transcripts, and their implication in prostate cancer" +other hsa-mir-1 Myocardial Infarction 20163779 We conclude that miR-1 and miR-133 seem to be important regulators of heart adaptation after ischaemic stress. +other hsa-mir-133b Myocardial Infarction 20163779 We conclude that miR-1 and miR-133 seem to be important regulators of heart adaptation after ischaemic stress. +other hsa-mir-27b Inflammation 20164187 We provide evidence that LPS-induced miR-27b contributes to destabilization of PPARgamma1 mRNA. Understanding molecular mechanisms decreasing PPARgamma might help to better appreciate inflammatory diseases. +other hsa-mir-9-1 "Cardiomyopathy, Hypertrophic" 20177053 miR-9 and NFATc3 regulate myocardin in cardiac hypertrophy +other hsa-mir-9-2 "Cardiomyopathy, Hypertrophic" 20177053 miR-9 and NFATc3 regulate myocardin in cardiac hypertrophy +other hsa-mir-9-3 "Cardiomyopathy, Hypertrophic" 20177053 miR-9 and NFATc3 regulate myocardin in cardiac hypertrophy +other hsa-let-7f "Carcinoma, Renal Cell" 20180642 Transfection of miR-224 into HEK-293 cells resulted in decreased KLK1 protein levels. A luciferase assay demonstrated that hsa-let-7f can target KLK10 in the RCC cell line ACHN. +other hsa-mir-224 "Carcinoma, Renal Cell" 20180642 Transfection of miR-224 into HEK-293 cells resulted in decreased KLK1 protein levels. A luciferase assay demonstrated that hsa-let-7f can target KLK10 in the RCC cell line ACHN. +other hsa-mir-34a Brain Neoplasms 20190569 microRNA-34a is tumor suppressive in brain tumors and glioma stem cells +other hsa-mir-34a Glioma 20190569 microRNA-34a is tumor suppressive in brain tumors and glioma stem cells +other hsa-mir-125b-2 Acute Megakaryoblastic Leukemia 20194440 we propose miR-125b-2 as a positive regulator of megakaryopoiesis and an oncomiR involved in the pathogenesis of trisomy 21-associated megakaryoblastic leukemia. +other hsa-mir-1-1 "Carcinoma, Lung, Non-Small-Cell" 20194856 significantly associated with overal survival +other hsa-mir-1-2 "Carcinoma, Lung, Non-Small-Cell" 20194856 significantly associated with overal survival +other hsa-mir-30d "Carcinoma, Lung, Non-Small-Cell" 20194856 significantly associated with overal survival +other hsa-mir-30d Lung Neoplasms 20194856 "levels of four miRNAs (ie, miR-486, miR-30d, miR-1 and miR-499) were significantly associated with overall survival" +other hsa-mir-486 "Carcinoma, Lung, Non-Small-Cell" 20194856 significantly associated with overal survival +other hsa-mir-486 Lung Neoplasms 20194856 "levels of four miRNAs (ie, miR-486, miR-30d, miR-1 and miR-499) were significantly associated with overall survival" +other hsa-mir-499a "Carcinoma, Lung, Non-Small-Cell" 20194856 significantly associated with overal survival +other hsa-mir-499a Lung Neoplasms 20194856 "levels of four miRNAs (ie, miR-486, miR-30d, miR-1 and miR-499) were significantly associated with overall survival" +other hsa-mir-146a Acute Coronary Syndrome 20195282 miR-146a in PBMCs modulates Th1 function in patients with acute coronary syndrome +other hsa-mir-146a Atherosclerosis 20195282 "this study also provided evidence that miR-146a treatment in vitro could induce the protein expression of TNF-alpha, MCP-1, NF-kappaB p65, which are key pro-inflammatory cytokines and critical transcription factor in AS" +other hsa-mir-17 Multiple Sclerosis 20201009 "Specifically, miR-17-5p, which is involved in autoimmunity, is upregulated in CD4(+) cells from MS patients" +other hsa-mir-216 "Carcinoma, Hepatocellular" 20206398 We also found an inverse correlation between IGF activation and miR-100/miR-216 levels (FDR<0.05). +other hsa-mir-146a Inflammation 20214679 miR-146a in reactive astrocytes supports the possible involvement of miRNAs in the modulation of the astroglial inflammatory response +other hsa-mir-21 Neoplasms [unspecific] 20219416 "miR-21 serves as a chemosensitive miRNA, while miR-214 and -23a serve as chemoresistant miRNAs in the tongue squamous cell carcinoma lines" +other hsa-mir-214 Neoplasms [unspecific] 20219416 "miR-21 serves as a chemosensitive miRNA, while miR-214 and -23a serve as chemoresistant miRNAs in the tongue squamous cell carcinoma lines" +other hsa-mir-23a Neoplasms [unspecific] 20219416 "miR-21 serves as a chemosensitive miRNA, while miR-214 and -23a serve as chemoresistant miRNAs in the tongue squamous cell carcinoma lines" +other hsa-mir-451a Glioma 20227367 MicroRNA-451 regulates LKB1/AMPK signaling and allows adaptation to metabolic stress in glioma cells +other hsa-mir-17 Neoplasms [unspecific] 20227518 "mir-17-92, a cluster of miRNAs in the midst of the cancer network" +other hsa-mir-18a Neoplasms [unspecific] 20227518 "mir-17-92, a cluster of miRNAs in the midst of the cancer network" +other hsa-mir-19a Neoplasms [unspecific] 20227518 "mir-17-92, a cluster of miRNAs in the midst of the cancer network" +other hsa-mir-19b-1 Neoplasms [unspecific] 20227518 "mir-17-92, a cluster of miRNAs in the midst of the cancer network" +other hsa-mir-19b-2 Neoplasms [unspecific] 20227518 "mir-17-92, a cluster of miRNAs in the midst of the cancer network" +other hsa-mir-20a Neoplasms [unspecific] 20227518 "mir-17-92, a cluster of miRNAs in the midst of the cancer network" +other hsa-mir-92a-1 Neoplasms [unspecific] 20227518 "miR-92a:mir-17-92, a cluster of miRNAs in the midst of the cancer network" +other hsa-mir-92a-2 Neoplasms [unspecific] 20227518 "miR-92a:mir-17-92, a cluster of miRNAs in the midst of the cancer network" +other hsa-mir-134 Coronary Artery Disease 20230787 "a cluster of three microRNAs including miR-134, miR-198, and miR-370, suggesting that the microRNA signatures can be used to identify patients at risk for acute coronary syndromes" +other hsa-mir-198 Coronary Artery Disease 20230787 "a cluster of three microRNAs including miR-134, miR-198, and miR-370, suggesting that the microRNA signatures can be used to identify patients at risk for acute coronary syndromes" +other hsa-mir-370 Coronary Artery Disease 20230787 "a cluster of three microRNAs including miR-134, miR-198, and miR-370, suggesting that the microRNA signatures can be used to identify patients at risk for acute coronary syndromes" +other hsa-mir-210 Inflammation 20237418 miR-210 appears to function as a master microRNA relevant for the control of diverse functions in the hypoxic state +other hsa-mir-210 Ischemia 20237418 miR-210 appears to function as a master microRNA relevant for the control of diverse functions in the hypoxic state +other hsa-mir-210 Neoplasms [unspecific] 20237418 miR-210 appears to function as a master microRNA relevant for the control of diverse functions in the hypoxic state +other hsa-mir-21 Multiple Myeloma 20302778 miR-21 acts as an oncogene and miR-30b a tumor suppressor gene in MM +other hsa-mir-30b Multiple Myeloma 20302778 miR-21 acts as an oncogene and miR-30b a tumor suppressor gene in MM +other hsa-mir-151a Glioblastoma 20305651 "significantly increases HCC cell migration and invasion in vitro and in vivo, mainly through miR-151-5p, but not through miR-151-3p" +other hsa-mir-17 Glioblastoma 20305691 De-repression of CTGF via the miR-17-92 cluster upon differentiation of human glioblastoma spheroid cultures +other hsa-mir-18a Glioblastoma 20305691 De-repression of CTGF via the miR-17-92 cluster upon differentiation of human glioblastoma spheroid cultures +other hsa-mir-19a Glioblastoma 20305691 De-repression of CTGF via the miR-17-92 cluster upon differentiation of human glioblastoma spheroid cultures +other hsa-mir-19b-1 Glioblastoma 20305691 De-repression of CTGF via the miR-17-92 cluster upon differentiation of human glioblastoma spheroid cultures +other hsa-mir-19b-2 Glioblastoma 20305691 De-repression of CTGF via the miR-17-92 cluster upon differentiation of human glioblastoma spheroid cultures +other hsa-mir-20a Glioblastoma 20305691 De-repression of CTGF via the miR-17-92 cluster upon differentiation of human glioblastoma spheroid cultures +other hsa-mir-126 "Adenocarcinoma, Esophageal" 20309880 "we found that miR-126 expression was associated with tumor cell de-differentiation and lymph node metastasis," +other hsa-mir-16-2 "Adenocarcinoma, Esophageal" 20309880 miR-16-2 was associated with lymph node metastasis +other hsa-mir-195 "Adenocarcinoma, Esophageal" 20309880 miR-195p was associated with higher pathologic disease stages in patients with esophageal adenocarcinoma +other hsa-mir-129-2 Gastric Neoplasms 20331975 We also found that inactivation of SOX4 by siRNA and restoration of miR-129-2 induced apoptosis in gastric cancer cells. +other hsa-mir-1296 Prostate Neoplasms 20332239 Regulation of minichromosome maintenance gene family by microRNA-1296 and genistein in prostate cancer +other hsa-mir-155 Pancreatic Adenocarcinoma 20332664 Aberrant MicroRNA-155 expression is an early event in the multistep progression of pancreatic adenocarcinoma +other hsa-mir-21 Neoplasms [unspecific] 20335152 Expression of microRNA-21 in ovarian epithelial carcinoma and its clinical significance +other hsa-mir-107 Breast Neoplasms 20348243 "MicroRNAs are also integral components of this gene regulation network because miR-107, miR-424, miR-570, miR-618, and miR-760 are regulated by 17beta-estradiol along with other microRNAs that can target a significant number of transcripts belonging to one or more estrogen-responsive gene clusters." +other hsa-mir-424 Breast Neoplasms 20348243 "MicroRNAs are also integral components of this gene regulation network because miR-107, miR-424, miR-570, miR-618, and miR-760 are regulated by 17beta-estradiol along with other microRNAs that can target a significant number of transcripts belonging to one or more estrogen-responsive gene clusters." +other hsa-mir-570 Breast Neoplasms 20348243 "MicroRNAs are also integral components of this gene regulation network because miR-107, miR-424, miR-570, miR-618, and miR-760 are regulated by 17beta-estradiol along with other microRNAs that can target a significant number of transcripts belonging to one or more estrogen-responsive gene clusters." +other hsa-mir-618 Breast Neoplasms 20348243 "MicroRNAs are also integral components of this gene regulation network because miR-107, miR-424, miR-570, miR-618, and miR-760 are regulated by 17beta-estradiol along with other microRNAs that can target a significant number of transcripts belonging to one or more estrogen-responsive gene clusters." +other hsa-mir-760 Breast Neoplasms 20348243 "MicroRNAs are also integral components of this gene regulation network because miR-107, miR-424, miR-570, miR-618, and miR-760 are regulated by 17beta-estradiol along with other microRNAs that can target a significant number of transcripts belonging to one or more estrogen-responsive gene clusters." +other hsa-mir-155 Colorectal Carcinoma 20351277 Modulation of mismatch repair and genomic stability by miR-155 +other hsa-mir-10b Neoplasms [unspecific] 20351690 Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model +other hsa-mir-181a-2 Glioblastoma 20353279 MicroRNA-181 family predicts response to concomitant chemoradiotherapy with temozolomide in glioblastoma patients +other hsa-mir-181b-1 Glioblastoma 20353279 MicroRNA-181 family predicts response to concomitant chemoradiotherapy with temozolomide in glioblastoma patients +other hsa-mir-181b-2 Glioblastoma 20353279 MicroRNA-181 family predicts response to concomitant chemoradiotherapy with temozolomide in glioblastoma patients +other hsa-mir-181c Glioblastoma 20353279 MicroRNA-181 family predicts response to concomitant chemoradiotherapy with temozolomide in glioblastoma patients +other hsa-mir-181d Glioblastoma 20353279 MicroRNA-181 family predicts response to concomitant chemoradiotherapy with temozolomide in glioblastoma patients +other hsa-mir-21 Granulosa Cell Tumor 20357270 MicroRNA 21 Blocks Apoptosis in Mouse Periovulatory Granulosa Cells +other hsa-mir-9 Brain Disease [unspecific] 20362537 These results identify miR-9 as a novel regulator that coordinates the proliferation and migration of hNPCs. +other hsa-mir-204 Head And Neck Neoplasms 20369013 Network modeling identifies molecular functions targeted by miR-204 to suppress head and neck tumor metastasis +other hsa-mir-122 Hepatitis C Virus Infection 20371461 "miR-122, a major regulatory RNA in liver that fine-tunes the expression of over 100 cellular genes and enhances HCV replication" +other hsa-mir-122 Liver Neoplasms 20371461 "miR-122, a major regulatory RNA in liver that fine-tunes the expression of over 100 cellular genes and enhances HCV replication" +other hsa-mir-650 Gastric Neoplasms 20381459 we show that miR-650 is involved in lymphatic and distant metastasis in human gastric cancer +other hsa-mir-27a Breast Neoplasms 20382698 miR-27a:MicroRNA-27a Indirectly Regulates Estrogen Receptor {alpha} Expression and Hormone Responsiveness in MCF-7 Breast Cancer Cells +other hsa-mir-145 Ewing Sarcoma 20382729 EWS-FLI-1 modulates miRNA145 and SOX2 expression to initiate mesenchymal stem cell reprogramming toward Ewing sarcoma cancer stem cells. +other hsa-mir-146a Inflammation 20384865 "functional role of miR-146a in innate immune, inflammatory response, virus infection and human diseases" +other hsa-mir-200a Pancreatic Neoplasms 20388782 miR-200:Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF +other hsa-mir-21 Pancreatic Neoplasms 20388782 miR-21:Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF +other hsa-mir-199a-1 Ovarian Neoplasms 20400975 "miR-199a:TWISTing stemness, inflammation and proliferation of epithelial ovarian cancer cells through MIR199A2/214" +other hsa-mir-199a-2 Ovarian Neoplasms 20400975 "miR-199a:TWISTing stemness, inflammation and proliferation of epithelial ovarian cancer cells through MIR199A2/214" +other hsa-mir-214 Ovarian Neoplasms 20400975 "miR-214:TWISTing stemness, inflammation and proliferation of epithelial ovarian cancer cells through MIR199A2/214" +other hsa-mir-21 Cardiovascular Diseases [unspecific] 20404348 MicroRNA-21 is a downstream effector of AKT that mediates its antiapoptotic effects via suppression of Fas ligand +other hsa-mir-21 Neoplasms [unspecific] 20404348 miR-21:function of AKT by which it inhibits apoptosis through miR-21-dependent suppression of FasL +other hsa-mir-146b Neoplasms [unspecific] 20406109 "miR-146b:potential importance of miR-221, miR-222, and miR-146b in determining the aggressive properties of PTCs" +other hsa-mir-221 Neoplasms [unspecific] 20406109 "miR-221:potential importance of miR-221, miR-222, and miR-146b in determining the aggressive properties of PTCs" +other hsa-mir-222 Neoplasms [unspecific] 20406109 "miR-222:potential importance of miR-221, miR-222, and miR-146b in determining the aggressive properties of PTCs" +other hsa-mir-17 Breast Neoplasms 20406904 microRNA 17/20 inhibits cellular invasion and tumor metastasis in breast cancer by heterotypic signaling +other hsa-mir-20a Breast Neoplasms 20406904 microRNA 17/20 inhibits cellular invasion and tumor metastasis in breast cancer by heterotypic signaling +other hsa-mir-20b Breast Neoplasms 20406904 microRNA 17/20 inhibits cellular invasion and tumor metastasis in breast cancer by heterotypic signaling +other hsa-mir-107 Alzheimer Disease 20413881 MiR-107 is reduced in Alzheimer's disease brain neocortex: validation study. +other hsa-mir-296 Atherosclerosis 20415654 Tumor angiogenesis is additionally controlled by miR-296 and miR-378. +other hsa-let-7b Neurodegenerative Diseases [unspecific] 20423455 "Interestingly, both miRNAs are capable of binding directly to TDP-43 in different positions: within the miRNA sequence itself (let-7b) or in the hairpin precursor (miR-663)." +other hsa-mir-663 Neurodegenerative Diseases [unspecific] 20423455 "Interestingly, both miRNAs are capable of binding directly to TDP-43 in different positions: within the miRNA sequence itself (let-7b) or in the hairpin precursor (miR-663)." +other hsa-let-7a-1 "Leukemia, Myeloid, Acute" 20425795 "hsa-let-7a:miR-155, miR-221, let-7, miR-126 and miR-196b appear to be associated with particular subtypes." +other hsa-let-7a-2 "Leukemia, Myeloid, Acute" 20425795 "hsa-let-7a:miR-155, miR-221, let-7, miR-126 and miR-196b appear to be associated with particular subtypes." +other hsa-let-7a-3 "Leukemia, Myeloid, Acute" 20425795 "hsa-let-7a:miR-155, miR-221, let-7, miR-126 and miR-196b appear to be associated with particular subtypes." +other hsa-let-7b "Leukemia, Myeloid, Acute" 20425795 "hsa-let-7b:miR-155, miR-221, let-7, miR-126 and miR-196b appear to be associated with particular subtypes." +other hsa-let-7c "Leukemia, Myeloid, Acute" 20425795 "hsa-let-7c:miR-155, miR-221, let-7, miR-126 and miR-196b appear to be associated with particular subtypes." +other hsa-let-7d "Leukemia, Myeloid, Acute" 20425795 "hsa-let-7d:miR-155, miR-221, let-7, miR-126 and miR-196b appear to be associated with particular subtypes." +other hsa-let-7e "Leukemia, Myeloid, Acute" 20425795 "hsa-let-7e:miR-155, miR-221, let-7, miR-126 and miR-196b appear to be associated with particular subtypes." +other hsa-let-7f-1 "Leukemia, Myeloid, Acute" 20425795 "hsa-let-7f:miR-155, miR-221, let-7, miR-126 and miR-196b appear to be associated with particular subtypes." +other hsa-let-7f-2 "Leukemia, Myeloid, Acute" 20425795 "hsa-let-7f:miR-155, miR-221, let-7, miR-126 and miR-196b appear to be associated with particular subtypes." +other hsa-let-7g "Leukemia, Myeloid, Acute" 20425795 "hsa-let-7g:miR-155, miR-221, let-7, miR-126 and miR-196b appear to be associated with particular subtypes." +other hsa-let-7i "Leukemia, Myeloid, Acute" 20425795 "hsa-let-7i:miR-155, miR-221, let-7, miR-126 and miR-196b appear to be associated with particular subtypes." +other hsa-mir-126 "Leukemia, Myeloid, Acute" 20425795 "miR-126:miR-155, miR-221, let-7, miR-126 and miR-196b appear to be associated with particular subtypes." +other hsa-mir-155 "Leukemia, Myeloid, Acute" 20425795 "miR-155:miR-155, miR-221, let-7, miR-126 and miR-196b appear to be associated with particular subtypes." +other hsa-mir-196b "Leukemia, Myeloid, Acute" 20425795 "miR-196b:miR-155, miR-221, let-7, miR-126 and miR-196b appear to be associated with particular subtypes." +other hsa-mir-221 "Leukemia, Myeloid, Acute" 20425795 "miR-221:miR-155, miR-221, let-7, miR-126 and miR-196b appear to be associated with particular subtypes." +other hsa-mir-98 "Leukemia, Myeloid, Acute" 20425795 "hsa-mir-98:miR-155, miR-221, let-7, miR-126 and miR-196b appear to be associated with particular subtypes." +other hsa-mir-34a Colon Neoplasms 20433755 "For instance, miR-34a up-regulation corresponded with a down-regulation of BCL2 protein. Treating Par-4-overexpressing HT29 cells with a miR-34a antagomir functionally reversed both BCL2 down-regulation and apoptosis by 5-FU." +other hsa-mir-125b Inflammation 20435889 "The process required to disrupt protein synthesis followed Toll-like receptor 4 (TLR4)-dependent induction of microRNA (miR)-221, miR-579, and miR-125b, which coupled with RNA-binding proteins TTP, AUF1, and TIAR at the 3'-untranslated region to arrest protein synthesis." +other hsa-mir-221 Inflammation 20435889 "The process required to disrupt protein synthesis followed Toll-like receptor 4 (TLR4)-dependent induction of microRNA (miR)-221, miR-579, and miR-125b, which coupled with RNA-binding proteins TTP, AUF1, and TIAR at the 3'-untranslated region to arrest protein synthesis." +other hsa-mir-579 Inflammation 20435889 "The process required to disrupt protein synthesis followed Toll-like receptor 4 (TLR4)-dependent induction of microRNA (miR)-221, miR-579, and miR-125b, which coupled with RNA-binding proteins TTP, AUF1, and TIAR at the 3'-untranslated region to arrest protein synthesis." +other hsa-mir-101-1 "Carcinoma, Hepatocellular" 20444294 miR-101:PKCalpha mediated induction of miR-101 in human hepatoma HepG2 cells +other hsa-mir-101-2 "Carcinoma, Hepatocellular" 20444294 miR-101:PKCalpha mediated induction of miR-101 in human hepatoma HepG2 cells +other hsa-mir-10a Glioblastoma 20444541 "miR-10a:miR-195, miR-455-3p and miR-10a( *) are implicated in acquired temozolomide resistance in glioblastoma multiforme cells" +other hsa-mir-195 Glioblastoma 20444541 "miR-195:miR-195, miR-455-3p and miR-10a( *) are implicated in acquired temozolomide resistance in glioblastoma multiforme cells" +other hsa-mir-455 Glioblastoma 20444541 "miR-455-3p:miR-195, miR-455-3p and miR-10a( *) are implicated in acquired temozolomide resistance in glioblastoma multiforme cells" +other hsa-mir-10b Neoplasms [unspecific] 20444703 miR-10b:miR-10b targets Tiam1: implications for Rac activation and carcinoma migration +other hsa-mir-21 "Carcinoma, Hepatocellular" 20447717 microRNA-21:MicroRNA-21 acts as an oncomir through multiple targets in human hepatocellular carcinoma +other hsa-mir-199a-1 Cardiomegaly 20458739 miR-199a:miR-199a is essential for the maintenance of cell size in cardiomyocytes +other hsa-mir-199a-1 Cardiovascular Diseases [unspecific] 20458739 miR-199a is essential for the maintenance of cell size in cardiomyocytes +other hsa-mir-199a-2 Cardiomegaly 20458739 miR-199a:miR-199a is essential for the maintenance of cell size in cardiomyocytes +other hsa-mir-199a-2 Cardiovascular Diseases [unspecific] 20458739 miR-199a is essential for the maintenance of cell size in cardiomyocytes +other hsa-mir-21 "Adenocarcinoma, Pancreatic Ductal" 20460539 miR-21:miR-21 expression correlated with outcome in PDAC patients treated with gemcitabine +other hsa-mir-221 Neoplasms [unspecific] 20461750 MiR-221:MiR-221 and MiR-222 alterations in sporadic ovarian carcinoma +other hsa-mir-222 Neoplasms [unspecific] 20461750 MiR-222:MiR-221 and MiR-222 alterations in sporadic ovarian carcinoma +other hsa-mir-542 Neuroblastoma 20466808 "miR-542-5p:the putative tumor suppressive microRNAs, miR-542-5p and miR-628, were expressed in favorable NBs and virtually absent in unfavorable NBs" +other hsa-mir-628 Neuroblastoma 20466808 "miR-628:the putative tumor suppressive microRNAs, miR-542-5p and miR-628, were expressed in favorable NBs and virtually absent in unfavorable NBs" +other hsa-mir-140 Osteoarthritis 20466812 "We show that miR-140 regulates cartilage development and homeostasis, and its loss contributes to the development of age-related OA-like changes." +other hsa-mir-125b-1 "Cardiomyopathy, Hypertrophic" 20470752 "miR-125b:miR-23a, miR-27b, miR-125b and miR-195 were induced during early hypertrophic growth" +other hsa-mir-125b-2 "Cardiomyopathy, Hypertrophic" 20470752 "miR-125b:miR-23a, miR-27b, miR-125b and miR-195 were induced during early hypertrophic growth" +other hsa-mir-195 "Cardiomyopathy, Hypertrophic" 20470752 "miR-195:miR-23a, miR-27b, miR-125b and miR-195 were induced during early hypertrophic growth" +other hsa-mir-23a "Cardiomyopathy, Hypertrophic" 20470752 "miR-23a:miR-23a, miR-27b, miR-125b and miR-195 were induced during early hypertrophic growth" +other hsa-mir-27b "Cardiomyopathy, Hypertrophic" 20470752 "miR-27b:miR-23a, miR-27b, miR-125b and miR-195 were induced during early hypertrophic growth" +other hsa-mir-196a-1 Melanoma 20480203 miR-196a:MicroRNA miR-196a is a central regulator of HOX-B7 and BMP4 expression in malignant melanoma +other hsa-mir-196a-2 Melanoma 20480203 miR-196a:MicroRNA miR-196a is a central regulator of HOX-B7 and BMP4 expression in malignant melanoma +other hsa-mir-100 Adrenal Cortex Neoplasms 20484036 "miR-100:differentially regulated in childhood adrenocortical tumors (ACT), including miR-99a and miR-100" +other hsa-mir-99a Adrenal Cortex Neoplasms 20484036 "miR-99a:differentially regulated in childhood adrenocortical tumors (ACT), including miR-99a and miR-100" +other hsa-mir-20b "Lymphoma, Mantle-Cell" 20485376 "miR-20b:miR-20b, whose lack of expression distinguished cases with a survival probability of 56% at 60 months" +other hsa-mir-26a-1 "Lymphoma, Mantle-Cell" 20485376 miR-26a:NF-kappaB subunit nuclear translocation to be regulated by the expression of miR-26a +other hsa-mir-26a-2 "Lymphoma, Mantle-Cell" 20485376 miR-26a:NF-kappaB subunit nuclear translocation to be regulated by the expression of miR-26a +other hsa-mir-21 Coronary Artery Disease 20489163 miR-21:We identified a novel miR-21-dependent mechanism of ADMA-mediated APC dysfunction +other hsa-mir-196b "Leukemia, Lymphoblastic, Acute, Childhood" 20494936 Expression of miR-196b is not exclusively MLL-driven but is especially linked to activation of HOXA genes in pediatric acute lymphoblastic leukemia. +other hsa-mir-27b Melanoma 20495621 "we identified miRNAs that are up- and down-regulated in melanoma cells exposed to a hESC microenvironment, such as miR-302a and miR-27b, respectively." +other hsa-mir-302a Melanoma 20495621 "we identified miRNAs that are up- and down-regulated in melanoma cells exposed to a hESC microenvironment, such as miR-302a and miR-27b, respectively." +other hsa-mir-30a Breast Neoplasms 20498642 Mir-30:Mir-30 reduction maintains self-renewal and inhibits apoptosis in breast tumor-initiating cells +other hsa-mir-21 Pancreatic Neoplasms 20498843 microRNA-21:Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer +other hsa-mir-520h Neoplasms [unspecific] 20501832 miR-520h:Downregulation of microRNA miR-520h by E1A contributes to anticancer activity +other hsa-mir-206 Rhabdomyosarcoma 20502458 MicroRNA-206:MicroRNA-206 expression levels correlate with clinical behaviour of rhabdomyosarcomas +other hsa-mir-21 Glioma 20514462 miR-21:Reduction of miR-21 induces glioma cell apoptosis via activating caspase 9 and 3 +other hsa-mir-140 Osteoarthritis 20516192 miR-140:miR-140 has a critical and nonredundant role in cartilage development and homeostasis +other hsa-mir-26a-1 Hypertrophy 20525681 MiR-26a:stretch or enforced expression of miR-26a induces HASMC hypertrophy +other hsa-mir-26a-2 Hypertrophy 20525681 MiR-26a:stretch or enforced expression of miR-26a induces HASMC hypertrophy +other hsa-mir-222 Neoplasms [unspecific] 20525881 "miR-222:five miRNAs that negatively control cell proliferation, including miRNA-34a" +other hsa-mir-224 Neoplasms [unspecific] 20525881 "miR-224:five miRNAs that negatively control cell proliferation, including miRNA-34a" +other hsa-mir-29b-1 Neoplasms [unspecific] 20525881 "miR-29b:five miRNAs that negatively control cell proliferation, including miRNA-34a" +other hsa-mir-29b-2 Neoplasms [unspecific] 20525881 "miR-29b:five miRNAs that negatively control cell proliferation, including miRNA-34a" +other hsa-mir-34a Neoplasms [unspecific] 20525881 "miR-34a:five miRNAs that negatively control cell proliferation, including miRNA-34a" +other hsa-mir-532 Neoplasms [unspecific] 20525881 "miR-532:five miRNAs that negatively control cell proliferation, including miRNA-34a" +other hsa-mir-122 "Carcinoma, Hepatocellular" 20527935 miR-122:Small molecule modifiers of microRNA miR-122 function for the treatment of hepatitis C virus infection and hepatocellular carcinoma +other hsa-mir-122 Hepatitis C Virus Infection 20527935 miR-122:Small molecule modifiers of microRNA miR-122 function for the treatment of hepatitis C virus infection and hepatocellular carcinoma +other hsa-mir-140 Arteriosclerosis Obliterans 20528768 "Global analysis of predicted miRNA targets found significantly reduced expression of genes with target regions compared with those without: hsa-miR-140-3p (P=0.002), hsa-miR-182 (P=0.001), hsa-miR-92a and hsa-miR-92b (P=2.2x10-16)." +other hsa-mir-182 Arteriosclerosis Obliterans 20528768 "Global analysis of predicted miRNA targets found significantly reduced expression of genes with target regions compared with those without: hsa-miR-140-3p (P=0.002), hsa-miR-182 (P=0.001), hsa-miR-92a and hsa-miR-92b (P=2.2x10-16)." +other hsa-mir-92a Arteriosclerosis Obliterans 20528768 "Global analysis of predicted miRNA targets found significantly reduced expression of genes with target regions compared with those without: hsa-miR-140-3p (P=0.002), hsa-miR-182 (P=0.001), hsa-miR-92a and hsa-miR-92b (P=2.2x10-16)." +other hsa-mir-92b Arteriosclerosis Obliterans 20528768 "Global analysis of predicted miRNA targets found significantly reduced expression of genes with target regions compared with those without: hsa-miR-140-3p (P=0.002), hsa-miR-182 (P=0.001), hsa-miR-92a and hsa-miR-92b (P=2.2x10-16)." +other hsa-mir-31 Neoplasms [unspecific] 20530680 "miR-31:Concurrent suppression of integrin alpha5, radixin, and RhoA phenocopies the effects of miR-31 on metastasis" +other hsa-mir-221 Melanoma 20547861 microRNA-221:Human polynucleotide phosphorylase selectively and preferentially degrades microRNA-221 in human melanoma cells +other hsa-mir-196b "Leukemia, Lymphocytic, Chronic, B-Cell" 20549547 miR-196b:Potential tumor suppressive function of miR-196b in B-cell lineage acute lymphoblastic leukemia +other hsa-mir-125b Bladder Neoplasms 20549700 "Taken together, miR-125b may act as a tumor suppressor in bladder urothelium, and downregulation of miR-125b may contribute to the tumorigenesis of bladder cancer." +other hsa-mir-29a "Leukemia, Lymphocytic, Chronic, B-Cell" 20566844 miR-29:dysregulation of miR-29 can contribute to the pathogenesis of indolent B-CLL +other hsa-mir-196a Leukemia 20570349 our results identify miR-196a and miR-196b as ERG regulators and implicate a potential role for these miRNAs in acute leukemia. +other hsa-mir-196b Leukemia 20570349 our results identify miR-196a and miR-196b as ERG regulators and implicate a potential role for these miRNAs in acute leukemia. +other hsa-mir-181a-2 "Carcinoma, Hepatocellular" 20576283 miRNA-181a:Micro-RNA-181a regulates osteopontin-dependent metastatic function in hepatocellular cancer cell lines +other hsa-mir-196a Glioma 20601442 Our results suggest that miR-196 may play a role in the malignant progression of gliomas and may be a prognostic predictor in glioblastomas. +other hsa-mir-212 Cocaine Abuse 20613834 miR-212:miR-212 signalling has a key role in determining vulnerability to cocaine addiction +other hsa-mir-101 Neoplasms [unspecific] 20617180 "Up-regulating miR-101 efficiently reduced the protein levels of DNA-PKcs and ATM in these tumor cells and most importantly, sensitized the tumor cells to radiation in vitro and in vivo." +other hsa-mir-1-1 Distal Myopathy 20619221 miR-1:have a profound influence on multiple myopathies +other hsa-mir-1-1 Hypertrophy 20619221 miR-1:have a profound influence on multiple myopathies +other hsa-mir-1-2 Distal Myopathy 20619221 miR-1:have a profound influence on multiple myopathies +other hsa-mir-1-2 Hypertrophy 20619221 miR-1:have a profound influence on multiple myopathies +other hsa-mir-133a-1 Distal Myopathy 20619221 miR-133:have a profound influence on multiple myopathies +other hsa-mir-133a-1 Hypertrophy 20619221 miR-133:have a profound influence on multiple myopathies +other hsa-mir-133a-2 Distal Myopathy 20619221 miR-133:have a profound influence on multiple myopathies +other hsa-mir-133a-2 Hypertrophy 20619221 miR-133:have a profound influence on multiple myopathies +other hsa-mir-206 Distal Myopathy 20619221 miR-206:have a profound influence on multiple myopathies +other hsa-mir-206 Hypertrophy 20619221 miR-206:have a profound influence on multiple myopathies +other hsa-mir-141 "Carcinoma, Hepatocellular" 20619223 "miR-141:Hsa-miR-141 and hsa-miR-200c, microRNAs that promote epithelial phenotypes, had significantly higher levels in non-hepatic epithelial tumors" +other hsa-mir-200c "Carcinoma, Hepatocellular" 20619223 "miR-200c:Hsa-miR-141 and hsa-miR-200c, microRNAs that promote epithelial phenotypes, had significantly higher levels in non-hepatic epithelial tumors" +other hsa-mir-126 Gastric Neoplasms 20619534 miR-126:miR-126 functions as a tumour suppressor in human gastric cancer +other hsa-let-7i "Squamous Cell Carcinoma, Lung" 20620595 "let-7i:Seven human miRNAs (miR-126, miR-193a-3p, miR-30d, miR-30a, miR-101, let-7i, and miR-15a) were found to be significantly downregulated in lung SCC" +other hsa-mir-143 Colorectal Carcinoma 20620599 miR-143:MiR-21 and miR-143 expressions were quantified by using the quantitative reverse transcription polymerase chain reaction method +other hsa-mir-21 Colorectal Carcinoma 20620599 miR-21:Our results support the hypothesis about oncogenic function of miR-21 +other hsa-mir-134 Central Nervous System Embryonal Tumor 20622856 miR-134:A novel pathway regulates memory and plasticity via SIRT1 and miR-134 +other hsa-mir-34a Atherosclerosis 20627091 MiR-34a:MicroRNA-34a regulation of endothelial senescence +other hsa-mir-34a Cardiovascular Diseases [unspecific] 20627091 MiR-34a:MicroRNA-34a regulation of endothelial senescence +other hsa-let-7a-1 Asthma 20630862 let-7a:Proinflammatory role for let-7 microRNAS in experimental asthma +other hsa-let-7a-2 Asthma 20630862 let-7a:Proinflammatory role for let-7 microRNAS in experimental asthma +other hsa-let-7a-3 Asthma 20630862 let-7a:Proinflammatory role for let-7 microRNAS in experimental asthma +other hsa-let-7b Asthma 20630862 let-7b:Proinflammatory role for let-7 microRNAS in experimental asthma +other hsa-let-7c Asthma 20630862 let-7c:Proinflammatory role for let-7 microRNAS in experimental asthma +other hsa-let-7d Asthma 20630862 let-7d:Proinflammatory role for let-7 microRNAS in experimental asthma +other hsa-let-7e Asthma 20630862 let-7e:Proinflammatory role for let-7 microRNAS in experimental asthma +other hsa-let-7f-1 Asthma 20630862 let-7f:Proinflammatory role for let-7 microRNAS in experimental asthma +other hsa-let-7f-2 Asthma 20630862 let-7f:Proinflammatory role for let-7 microRNAS in experimental asthma +other hsa-let-7g Asthma 20630862 let-7g:Proinflammatory role for let-7 microRNAS in experimental asthma +other hsa-let-7i Asthma 20630862 let-7i:Proinflammatory role for let-7 microRNAS in experimental asthma +other hsa-mir-21 Lung Fibrosis 20643828 miR-21:These experiments demonstrate an important role for miR-21 in fibrotic lung diseases +other hsa-mir-16-1 Neoplasms [unspecific] 20668064 miR-16:miR-16 in the regulation of Wip1 phosphatase in the DNA damage response and mammary tumorigenesis +other hsa-mir-16-2 Neoplasms [unspecific] 20668064 miR-16:miR-16 in the regulation of Wip1 phosphatase in the DNA damage response and mammary tumorigenesis +other hsa-mir-132 Neoplasms [unspecific] 20676106 miR-132:miR-132 was highly expressed in the endothelium of human tumors and hemangiomas +other hsa-mir-146a "Carcinoma, Basal Cell" 20680470 These findings suggest that this functional SNP in pre-miR-146a could contribute to ESCC susceptibility and clinical outcome. +other hsa-mir-34a Prostate Neoplasms 20687223 MiR-34a:MiR-34a attenuates paclitaxel-resistance of hormone-refractory prostate cancer PC3 cells through direct and indirect mechanisms +other hsa-mir-21 "Lymphoma, B-Cell" 20693987 miR-21:OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma +other hsa-mir-212 Cocaine Abuse 20711185 miR-212:miR-212 in dorsal striatum may be important in regulating vulnerability to cocaine addiction +other hsa-mir-335 Neoplasms [unspecific] 20713524 miR-335:miR-335 activates the p53 tumor suppressor pathway to limit cell proliferation and neoplastic cell transformation +other hsa-mir-382 Renal Fibrosis 20716515 The study provided experimental evidence in the form of reciprocal expression at the protein level for a large number of predicted miRNA-target pairs and discovered a novel role of miR-382 and SOD2 in the loss of epithelial characteristics induced by TGF¦Â1. +other hsa-mir-125a "Carcinoma, Lung, Non-Small-Cell" 20719190 hsa-miR-125a-5p was poorly-expressed in lung cancer cells and it could enhance lung cancer cell invasion by up-regulating hsa-miR-125a-5p. +other hsa-mir-195 Colorectal Carcinoma 20727858 miR-195:microRNA-195 promotes apoptosis and suppresses tumorigenicity of human colorectal cancer cells +other hsa-mir-30b Schizophrenia 20732949 These preliminary findings point to the possibility that disease-related changes in the expression of small noncoding RNAs such as miR-30b in schizophrenia could be influenced by gender and potentially regulated by estrogen signaling. +other hsa-mir-145 Myelodysplastic Syndromes 20733155 "Other mouse modeling data suggest that haploinsufficiency of the microRNA genes miR-145 and miR-146a may contribute to the thrombocytosis seen in the 5q- syndrome. Lenalidomide has become an established therapy for the 5q- syndrome, although its precise mode of action remains uncertain." +other hsa-mir-146a Myelodysplastic Syndromes 20733155 "Other mouse modeling data suggest that haploinsufficiency of the microRNA genes miR-145 and miR-146a may contribute to the thrombocytosis seen in the 5q- syndrome. Lenalidomide has become an established therapy for the 5q- syndrome, although its precise mode of action remains uncertain." +other hsa-mir-34a "Carcinoma, Rectal" 20734047 Satraplatin treatment induces p53-related genes and its direct microRNA target of miR-34a independently. +other hsa-mir-205 Prostate Neoplasms 20737563 MicroRNA-205-directed transcriptional activation of tumor suppressor genes in prostate cancer. +other hsa-mir-320a Childhood Leukemia 20807887 "In summary our data suggest that TEL-AML1 might exert its antiapoptotic action at least in part by suppressing miRNA-494 and miRNA-320a, lowering their expression causing enhanced survivin expression." +other hsa-mir-494 Childhood Leukemia 20807887 "In summary our data suggest that TEL-AML1 might exert its antiapoptotic action at least in part by suppressing miRNA-494 and miRNA-320a, lowering their expression causing enhanced survivin expression." +other hsa-let-7a "Carcinoma, Gastric" 20809749 Lentiviral vector-mediated upregulation of let-7a inhibits gastric carcinoma cell growth in vitro and in vivo. +other hsa-mir-146a Ovarian Neoplasms 20810544 Association between hsa-mir-146a genotype and tumor age-of-onset in BRCA1/BRCA2-negative familial breast and ovarian cancer patients. +other hsa-mir-151 "Carcinoma, Hepatocellular" 20812359 MicroRNA-151 and its hosting gene FAK (focal adhesion kinase) regulate tumor cell migration and spreading of hepatocellular carcinoma. +other hsa-mir-451 Glioblastoma 20816946 MiRNA-451 plays a role as tumor suppressor in human glioma cells. +other hsa-mir-145 Breast Neoplasms 20818426 miR-145-dependent targeting of junctional adhesion molecule A and modulation of fascin expression are associated with reduced breast cancer cell motility and invasiveness. +other hsa-mir-200a "Carcinoma, Nasopharyngeal" 20826811 Our findings reveal for the first time the function of miR-200a in shifting nasopharyngeal carcinoma cell states via a reversible process coined as epithelial-mesenchymal to stem-like transition through differential and specific mechanisms. +other hsa-mir-21 "Carcinoma, Lung, Non-Small-Cell" 20832755 miR-21:Modulation of K-Ras-dependent lung tumorigenesis by MicroRNA-21 +other hsa-mir-210 Myocardial Infarction 20837903 "miR-210:MicroRNA-210 can improve angiogenesis, inhibit apoptosis, and improve cardiac function in a murine model of myocardial infarction." +other hsa-mir-16 Leukemia 20839343 "The murine disease is linked to a genetic abnormality in microRNA mir-15a/16-1 locus, resulting in decreased mature miR-15a/16." +other hsa-mir-146a Rheumatoid Arthritis 20840794 These results indicated that miR-146a was associated with IL-17 expression in the PBMC and synovium in RA patients. There is the possibility that miR-146a participates in the IL-17 expression. +other hsa-mir-17 "Leukemia, Lymphoblastic" 20855495 "NKX3.1 is necessary for T-ALL proliferation, can partially restore proliferation in TAL1 knockdown cells, and directly regulates miR-17-92." +other hsa-mir-18 "Leukemia, Lymphoblastic" 20855495 "NKX3.1 is necessary for T-ALL proliferation, can partially restore proliferation in TAL1 knockdown cells, and directly regulates miR-17-92." +other hsa-mir-19a "Leukemia, Lymphoblastic" 20855495 "NKX3.1 is necessary for T-ALL proliferation, can partially restore proliferation in TAL1 knockdown cells, and directly regulates miR-17-92." +other hsa-mir-19b-1 "Leukemia, Lymphoblastic" 20855495 "NKX3.1 is necessary for T-ALL proliferation, can partially restore proliferation in TAL1 knockdown cells, and directly regulates miR-17-92." +other hsa-mir-20a "Leukemia, Lymphoblastic" 20855495 "NKX3.1 is necessary for T-ALL proliferation, can partially restore proliferation in TAL1 knockdown cells, and directly regulates miR-17-92." +other hsa-mir-92-1 "Leukemia, Lymphoblastic" 20855495 "NKX3.1 is necessary for T-ALL proliferation, can partially restore proliferation in TAL1 knockdown cells, and directly regulates miR-17-92." +other hsa-mir-223 "Leukemia, Lymphocytic, Chronic, B-Cell" 20862275 "miR-223:ZAP70, LPL, CLLU1, microRNA-29c and microRNA-223 were measured by real time PCR in a cohort of 170 patients" +other hsa-mir-29c "Leukemia, Lymphocytic, Chronic, B-Cell" 20862275 "miR-29c:ZAP70, LPL, CLLU1, microRNA-29c and microRNA-223 were measured by real time PCR in a cohort of 170 patients" +other hsa-mir-22 Ovarian Neoplasms 20869762 miR-22:miR-22 might be involved in inhibiting ovarian cancer metastasis +other hsa-mir-380 Neuroblastoma 20871609 In vivo delivery of a miR-380-5p antagonist decreases tumor size in an orthotopic mouse model of neuroblastoma. +other hsa-mir-130b Prostate Neoplasms 20875868 miR-130b:The hsa-miR-130b also shows a high variance between samples. +other hsa-mir-122 Lipid Metabolism Disorder 20880716 "In addition to miR-33, miR-122 and miR-370 have been shown to play important roles in regulating cholesterol and fatty acid metabolism." +other hsa-mir-33 Lipid Metabolism Disorder 20880716 "In addition to miR-33, miR-122 and miR-370 have been shown to play important roles in regulating cholesterol and fatty acid metabolism." +other hsa-mir-370 Lipid Metabolism Disorder 20880716 "In addition to miR-33, miR-122 and miR-370 have been shown to play important roles in regulating cholesterol and fatty acid metabolism." +other hsa-mir-146b Colorectal Carcinoma 20881268 miR-146b-3p and miR-486-5p are more abundant in KRAS mutated samples after cetuximab treatment respect to wild-type ones +other hsa-mir-486 Colorectal Carcinoma 20881268 miR-146b-3p and miR-486-5p are more abundant in KRAS mutated samples after cetuximab treatment respect to wild-type ones +other hsa-mir-103 Metabolic Syndrome 20886002 "Interestingly, a strong correlation was observed between miR-103 and -107 expression, as well as miR-221 and -222 in both experiments." +other hsa-mir-143 Metabolic Syndrome 20886002 "Interestingly, a strong correlation was observed between miR-103 and -107 expression, as well as miR-221 and -222 in both experiments." +other hsa-mir-221 Metabolic Syndrome 20886002 "Interestingly, a strong correlation was observed between miR-103 and -107 expression, as well as miR-221 and -222 in both experiments." +other hsa-mir-222 Metabolic Syndrome 20886002 "Interestingly, a strong correlation was observed between miR-103 and -107 expression, as well as miR-221 and -222 in both experiments." +other hsa-mir-130b Prostate Neoplasms 20890088 We recommend using hsa-miR-130b or the geometric mean of hsa-miR-130b and small RNA RNU6-2 for normalization in miRNA expression studies of prostate cancer. +other hsa-mir-339 Breast Neoplasms 20932331 MiR-339-5p inhibits breast cancer cell migration and invasion in vitro and may be a potential biomarker for breast cancer prognosis. +other hsa-mir-17 Glioblastoma 20940405 "Together, our results define a pathway in which c-Myc activation of miR-17?92 attenuates the TGF¦Â signaling pathway to shut down clusterin expression, thereby stimulating angiogenesis and tumor cell growth." +other hsa-mir-18 Glioblastoma 20940405 "Together, our results define a pathway in which c-Myc activation of miR-17?92 attenuates the TGF¦Â signaling pathway to shut down clusterin expression, thereby stimulating angiogenesis and tumor cell growth." +other hsa-mir-19a Glioblastoma 20940405 "Together, our results define a pathway in which c-Myc activation of miR-17?92 attenuates the TGF¦Â signaling pathway to shut down clusterin expression, thereby stimulating angiogenesis and tumor cell growth." +other hsa-mir-19b-1 Glioblastoma 20940405 "Together, our results define a pathway in which c-Myc activation of miR-17?92 attenuates the TGF¦Â signaling pathway to shut down clusterin expression, thereby stimulating angiogenesis and tumor cell growth." +other hsa-mir-20a Glioblastoma 20940405 "Together, our results define a pathway in which c-Myc activation of miR-17?92 attenuates the TGF¦Â signaling pathway to shut down clusterin expression, thereby stimulating angiogenesis and tumor cell growth." +other hsa-mir-92-1 Glioblastoma 20940405 "Together, our results define a pathway in which c-Myc activation of miR-17?92 attenuates the TGF¦Â signaling pathway to shut down clusterin expression, thereby stimulating angiogenesis and tumor cell growth." +other hsa-mir-192 Multiple Myeloma 20951946 "Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development" +other hsa-mir-194-1 Multiple Myeloma 20951946 "Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development" +other hsa-mir-194-2 Multiple Myeloma 20951946 "Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development" +other hsa-mir-215 Multiple Myeloma 20951946 "Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development" +other hsa-mir-141 Melanoma 20957176 "Overall our findings call into question the general role of miR-200 in suppressing invasion and metastasis, and highlight novel distinguishing characteristics of individual miR-200 family members." +other hsa-mir-200a Melanoma 20957176 "Overall our findings call into question the general role of miR-200 in suppressing invasion and metastasis, and highlight novel distinguishing characteristics of individual miR-200 family members." +other hsa-mir-200b Melanoma 20957176 "Overall our findings call into question the general role of miR-200 in suppressing invasion and metastasis, and highlight novel distinguishing characteristics of individual miR-200 family members." +other hsa-mir-200c Melanoma 20957176 "Overall our findings call into question the general role of miR-200 in suppressing invasion and metastasis, and highlight novel distinguishing characteristics of individual miR-200 family members." +other hsa-mir-429 Melanoma 20957176 "Overall our findings call into question the general role of miR-200 in suppressing invasion and metastasis, and highlight novel distinguishing characteristics of individual miR-200 family members." +other hsa-mir-1 Myocardial Infarction 20959496 "Studies using various in vivo, ex vivo, and in vitro models have suggested the possible involvement of miR-1, miR-21, miR-29, miR-92a,miR-133, miR-199a, and miR-320 in ischemia-reperfusion injury and/or remodeling after myocardial infarction." +other hsa-mir-133 Myocardial Infarction 20959496 "Studies using various in vivo, ex vivo, and in vitro models have suggested the possible involvement of miR-1, miR-21, miR-29, miR-92a,miR-133, miR-199a, and miR-320 in ischemia-reperfusion injury and/or remodeling after myocardial infarction." +other hsa-mir-199a Myocardial Infarction 20959496 "Studies using various in vivo, ex vivo, and in vitro models have suggested the possible involvement of miR-1, miR-21, miR-29, miR-92a,miR-133, miR-199a, and miR-320 in ischemia-reperfusion injury and/or remodeling after myocardial infarction." +other hsa-mir-21 Myocardial Infarction 20959496 "Studies using various in vivo, ex vivo, and in vitro models have suggested the possible involvement of miR-1, miR-21, miR-29, miR-92a,miR-133, miR-199a, and miR-320 in ischemia-reperfusion injury and/or remodeling after myocardial infarction." +other hsa-mir-29 Myocardial Infarction 20959496 "Studies using various in vivo, ex vivo, and in vitro models have suggested the possible involvement of miR-1, miR-21, miR-29, miR-92a,miR-133, miR-199a, and miR-320 in ischemia-reperfusion injury and/or remodeling after myocardial infarction." +other hsa-mir-320 Myocardial Infarction 20959496 "Studies using various in vivo, ex vivo, and in vitro models have suggested the possible involvement of miR-1, miR-21, miR-29, miR-92a,miR-133, miR-199a, and miR-320 in ischemia-reperfusion injury and/or remodeling after myocardial infarction." +other hsa-mir-92a Myocardial Infarction 20959496 "Studies using various in vivo, ex vivo, and in vitro models have suggested the possible involvement of miR-1, miR-21, miR-29, miR-92a,miR-133, miR-199a, and miR-320 in ischemia-reperfusion injury and/or remodeling after myocardial infarction." +other hsa-mir-145 Leukemia 20962326 "As evidence that this subset of miRNAs is relevant to leukemia, we show that loss of 2 miRNAs identified in our analysis, miR-145 and miR-146a, results in leukemia in a mouse model." +other hsa-mir-146a Leukemia 20962326 "As evidence that this subset of miRNAs is relevant to leukemia, we show that loss of 2 miRNAs identified in our analysis, miR-145 and miR-146a, results in leukemia in a mouse model." +other hsa-let-7i "Carcinoma, Renal Cell" 20964835 "This pattern of regulation was also seen in renal cancer tissue for several of these miRNAs (miR-210, miR-155, let-7i and members of the miR-17-92 cluster) when compared with normal tissue." +other hsa-mir-155 "Carcinoma, Renal Cell" 20964835 "This pattern of regulation was also seen in renal cancer tissue for several of these miRNAs (miR-210, miR-155, let-7i and members of the miR-17-92 cluster) when compared with normal tissue." +other hsa-mir-17 "Carcinoma, Renal Cell" 20964835 "This pattern of regulation was also seen in renal cancer tissue for several of these miRNAs (miR-210, miR-155, let-7i and members of the miR-17-92 cluster) when compared with normal tissue." +other hsa-mir-18 "Carcinoma, Renal Cell" 20964835 "This pattern of regulation was also seen in renal cancer tissue for several of these miRNAs (miR-210, miR-155, let-7i and members of the miR-17-92 cluster) when compared with normal tissue." +other hsa-mir-19a "Carcinoma, Renal Cell" 20964835 "This pattern of regulation was also seen in renal cancer tissue for several of these miRNAs (miR-210, miR-155, let-7i and members of the miR-17-92 cluster) when compared with normal tissue." +other hsa-mir-19b-1 "Carcinoma, Renal Cell" 20964835 "This pattern of regulation was also seen in renal cancer tissue for several of these miRNAs (miR-210, miR-155, let-7i and members of the miR-17-92 cluster) when compared with normal tissue." +other hsa-mir-20a "Carcinoma, Renal Cell" 20964835 "This pattern of regulation was also seen in renal cancer tissue for several of these miRNAs (miR-210, miR-155, let-7i and members of the miR-17-92 cluster) when compared with normal tissue." +other hsa-mir-210 "Carcinoma, Renal Cell" 20964835 "This pattern of regulation was also seen in renal cancer tissue for several of these miRNAs (miR-210, miR-155, let-7i and members of the miR-17-92 cluster) when compared with normal tissue." +other hsa-mir-92-1 "Carcinoma, Renal Cell" 20964835 "This pattern of regulation was also seen in renal cancer tissue for several of these miRNAs (miR-210, miR-155, let-7i and members of the miR-17-92 cluster) when compared with normal tissue." +other hsa-mir-199a-1 Heart Failure 20965886 Signal transducer and activator of transcription 3-mediated regulation of miR-199a-5p links cardiomyocyte and endothelial cell function in the heart +other hsa-mir-199a-2 Heart Failure 20965886 Signal transducer and activator of transcription 3-mediated regulation of miR-199a-5p links cardiomyocyte and endothelial cell function in the heart +other hsa-mir-17 Neuroblastoma 20980091 "Mir-21, an established oncomir in a variety of cancer types, became strongly up-regulated upon MYCN knockdown and the subsequent differentiation." +other hsa-mir-210 "Squamous Cell Carcinoma, Esophageal" 21044961 "Taken together, our findings show an important role for miR-210 as a tumor-suppressive microRNA with effects on cancer cell proliferation." +other hsa-mir-141 Ovarian Neoplasms 21051560 "In conclusion, miR-200 family members(200a,200b,200c,141,429) affect the final ¦Â-tubulin III protein content of ovarian carcinomas. Furthermore, these microRNAs might constitute the biomarkers of response to paclitaxel-based treatments and relapse/progression of advanced stage ovarian carcinoma patients." +other hsa-mir-200a Ovarian Neoplasms 21051560 "In conclusion, miR-200 family members(200a,200b,200c,141,429) affect the final ¦Â-tubulin III protein content of ovarian carcinomas. Furthermore, these microRNAs might constitute the biomarkers of response to paclitaxel-based treatments and relapse/progression of advanced stage ovarian carcinoma patients." +other hsa-mir-200b Ovarian Neoplasms 21051560 "In conclusion, miR-200 family members(200a,200b,200c,141,429) affect the final ¦Â-tubulin III protein content of ovarian carcinomas. Furthermore, these microRNAs might constitute the biomarkers of response to paclitaxel-based treatments and relapse/progression of advanced stage ovarian carcinoma patients." +other hsa-mir-200c Ovarian Neoplasms 21051560 "In conclusion, miR-200 family members(200a,200b,200c,141,429) affect the final ¦Â-tubulin III protein content of ovarian carcinomas. Furthermore, these microRNAs might constitute the biomarkers of response to paclitaxel-based treatments and relapse/progression of advanced stage ovarian carcinoma patients." +other hsa-mir-429 Ovarian Neoplasms 21051560 "In conclusion, miR-200 family members(200a,200b,200c,141,429) affect the final ¦Â-tubulin III protein content of ovarian carcinomas. Furthermore, these microRNAs might constitute the biomarkers of response to paclitaxel-based treatments and relapse/progression of advanced stage ovarian carcinoma patients." +other hsa-mir-34a Melanoma 21051724 The authors' previous studies on miR-34a showed that miRNA can influence the growth of uveal melanoma cells. +other hsa-mir-31 Colon Neoplasms 21062447 "Suppression of microRNA-31 increases sensitivity to 5-FU at an early stage, and affects cell migration and invasion in HCT-116 colon cancer cells." +other hsa-mir-203 "Carcinoma, Rectal" 21063914 miR-203 may be related to the proliferation and invasion of gastric and colorectal cancers. +other hsa-let-7b Melanoma 21087605 "Taken together, the present study identifies let-7b as a tumor suppressor that represses cancer cell proliferation and migration as well as tumor metastasis in mouse melanoma cells." +other hsa-let-7a Lung Neoplasms 21097396 Construction of let-7a expression plasmid and its inhibitory effect on k-Ras protein in A549 lung cancer cells +other hsa-mir-20a Lymphoma 21114763 The pro-senescence role of miR-20a and miR-290 in MEF is apparently in contrast with their proliferative role in tumour and ES cells. +other hsa-mir-584 "Carcinoma, Renal Cell, Clear-Cell" 21119662 Tumour suppressor microRNA-584 directly targets oncogene Rock-1 and decreases invasion ability in human clear cell renal cell carcinoma. +other hsa-let-7a Ovarian Neoplasms 21122376 "Bioinformatic analysis indicated that let-7a, let-7e, let-7f, miR-22 and miR-886-5p may be involved in cancer invasion and metastasis." +other hsa-let-7e Ovarian Neoplasms 21122376 "Bioinformatic analysis indicated that let-7a, let-7e, let-7f, miR-22 and miR-886-5p may be involved in cancer invasion and metastasis." +other hsa-let-7f Ovarian Neoplasms 21122376 "Bioinformatic analysis indicated that let-7a, let-7e, let-7f, miR-22 and miR-886-5p may be involved in cancer invasion and metastasis." +other hsa-mir-22 Ovarian Neoplasms 21122376 "Bioinformatic analysis indicated that let-7a, let-7e, let-7f, miR-22 and miR-886-5p may be involved in cancer invasion and metastasis." +other hsa-mir-886 Ovarian Neoplasms 21122376 "Bioinformatic analysis indicated that let-7a, let-7e, let-7f, miR-22 and miR-886-5p may be involved in cancer invasion and metastasis." +other hsa-mir-203 "Carcinoma, Endometrial" 21125666 "In addition, miR-23b and miR-29c, which are involved in the inhibition of mesenchymal markers, and miR-203, which is involved in the inhibition of cell stemness" +other hsa-mir-23b "Carcinoma, Endometrial" 21125666 "In addition, miR-23b and miR-29c, which are involved in the inhibition of mesenchymal markers, and miR-203, which is involved in the inhibition of cell stemness" +other hsa-mir-29c "Carcinoma, Endometrial" 21125666 "In addition, miR-23b and miR-29c, which are involved in the inhibition of mesenchymal markers, and miR-203, which is involved in the inhibition of cell stemness" +other hsa-mir-192 Neoplasms [unspecific] 21128228 "The meta-analysis also revealed some novel tumor-related miRNAs such as hsa-miR-144, hsa-miR-130b, hsa-miR-132, hsa-miR-154, hsa-miR-192 and hsa-miR-345" +other hsa-mir-34a Cervical Neoplasms 21128241 "In summary, our study demonstrates an intimate connection among oncogenic HPV E6,p53, miR-34a and p18Ink4c and identifies p18Ink4c as a possible biomarker for cervical cancer." +other hsa-mir-21 Breast Neoplasms 21131358 Induction of MIR-21 by retinoic acid in estrogen-receptor-positive breast carcinoma cells: biological correlates and molecular targets +other hsa-mir-373 Prostate Neoplasms 21139802 "The oncogenic mi-croRNAs, miR-373 and miR-520c interact with CD44 in Prostate Cancer" +other hsa-mir-520c Prostate Neoplasms 21139802 "The oncogenic mi-croRNAs, miR-373 and miR-520c interact with CD44 in Prostate Cancer" +other hsa-let-7a-1 Prostate Neoplasms 21148031 RPS2 control let-7a expression in human prostate cancer. +other hsa-mir-92a-1 Esophageal Neoplasms 21148309 microRNA-92a promotes lymph node metastasis of human esophageal squamous cell carcinoma via E-cadherin. +other hsa-mir-92a-2 Esophageal Neoplasms 21148309 microRNA-92a promotes lymph node metastasis of human esophageal squamous cell carcinoma via E-cadherin. +other hsa-mir-206 Lung Neoplasms 21157919 MicroRNA-206 Is Associated With Invasion and Metastasis of Lung Cancer. +other hsa-mir-143 Pancreatic Neoplasms 21159815 Repression of the miR-143/145 cluster by oncogenic Ras initiates a tumor-promoting feed-forward pathway. +other hsa-mir-145 Pancreatic Neoplasms 21159815 Repression of the miR-143/145 cluster by oncogenic Ras initiates a tumor-promoting feed-forward pathway. +other hsa-mir-203 Prostate Neoplasms 21159887 miR-203 expression is specifically attenuated in bone metastatic prostate cancer suggesting a fundamental anti-metastatic role for this miRNA +other hsa-mir-138-2 Panic Disorder 21168126 "Human microRNAs miR-22, miR-138-2, miR-148a, and miR-488 Are Associated with Panic Disorder and Regulate Several Anxiety Candidate Genes and Related Pathways." +other hsa-mir-148a Panic Disorder 21168126 "Human microRNAs miR-22, miR-138-2, miR-148a, and miR-488 Are Associated with Panic Disorder and Regulate Several Anxiety Candidate Genes and Related Pathways." +other hsa-mir-22 Panic Disorder 21168126 "Human microRNAs miR-22, miR-138-2, miR-148a, and miR-488 Are Associated with Panic Disorder and Regulate Several Anxiety Candidate Genes and Related Pathways." +other hsa-mir-488 Panic Disorder 21168126 "Human microRNAs miR-22, miR-138-2, miR-148a, and miR-488 Are Associated with Panic Disorder and Regulate Several Anxiety Candidate Genes and Related Pathways." +other hsa-mir-101-1 Alzheimer Disease 21172309 MicroRNA-101 downregulates Alzheimer's amyloid-beta precursor protein levels in human cell cultures and is differentially expressed. +other hsa-let-7i Liver Neoplasms 21176238 let-7i* is overexpressed in side population of HCC cells compared to fetal liver cells +other hsa-mir-155 Endometrial Neoplasms 21176560 "Hsa-miR-155 may play an important role in the proliferation, and metastasis of endometrial cancer, which may be a indicator in the diagnosis and prognosis of endometrial cancer and may be used as a predictive biomarker." +other hsa-mir-30a Medulloblastoma 21177782 miR-34a confers chemosensitivity through modulation of MAGE-A and p53 in medulloblastoma. +other hsa-mir-30a Glioblastoma 21178384 the transcriptional BDNF inhibitor miR-30a-5p was also overexpressed at 6 and 12 h of paroxetine incubation +other hsa-mir-135a Heart Failure 21185128 Possible involvement of microRNAs (miR-135a?) in heart failure associated with 25bp deletion in MYBPC3 (cardiac myosin binding protein C) gene. +other hsa-mir-126 Coronary Artery Disease 21195052 Coronary Artery Disease +other hsa-mir-130a Coronary Artery Disease 21195052 Coronary Artery Disease +other hsa-mir-221 Coronary Artery Disease 21195052 Coronary Artery Disease +other hsa-mir-222 Coronary Artery Disease 21195052 Coronary Artery Disease +other hsa-mir-92a-1 Coronary Artery Disease 21195052 Coronary Artery Disease +other hsa-mir-92a-2 Coronary Artery Disease 21195052 Coronary Artery Disease +other hsa-mir-19a "Lymphoma, B-Cell" 21200023 diffuse large B-cell lymphoma +other hsa-mir-19b-1 "Lymphoma, B-Cell" 21200023 diffuse large B-cell lymphoma +other hsa-mir-19b-2 "Lymphoma, B-Cell" 21200023 diffuse large B-cell lymphoma +other hsa-mir-21 "Lymphoma, B-Cell" 21200023 diffuse large B-cell lymphoma +other hsa-mir-92a-1 "Lymphoma, B-Cell" 21200023 diffuse large B-cell lymphoma +other hsa-mir-92a-2 "Lymphoma, B-Cell" 21200023 diffuse large B-cell lymphoma +other hsa-mir-17 Prostate Neoplasms 21203553 miR-17* Suppresses Tumorigenicity of Prostate Cancer by Inhibiting Mitochondrial Antioxidant Enzymes. +other hsa-mir-100 Prostate Neoplasms 21212412 miR-99 family of microRNAs suppresses the expression of prostate specific antigen and prostate cancer cell proliferation. +other hsa-mir-99a Prostate Neoplasms 21212412 miR-99 family of microRNAs suppresses the expression of prostate specific antigen and prostate cancer cell proliferation. +other hsa-mir-99b Prostate Neoplasms 21212412 miR-99 family of microRNAs suppresses the expression of prostate specific antigen and prostate cancer cell proliferation. +other hsa-mir-153-1 Glioblastoma 21213215 Chromatin-modifying drugs induce miRNA-153 expression to suppress Irs-2 in glioblastoma cell lines +other hsa-mir-145 Ewing Sarcoma 21217773 Hsa-mir-145 is the top EWS-FLI1-repressed microRNA involved in a positive feedback loop in Ewing's sarcoma. +other hsa-mir-143 Gastrointestinal Neoplasms 21219233 "The review focuses on the role of specific miRNAs (miR-192/194/215 and miR-7) in the differentiation of gastrointestinal epithelium and on the role of tumor-suppressive (miR-34, miR-143, miR-145) and oncogenic miRNAs (miR-21,miR-17-92 cluster) in gastrointestinal tumors." +other hsa-mir-145 Gastrointestinal Neoplasms 21219233 "The review focuses on the role of specific miRNAs (miR-192/194/215 and miR-7) in the differentiation of gastrointestinal epithelium and on the role of tumor-suppressive (miR-34, miR-143, miR-145) and oncogenic miRNAs (miR-21,miR-17-92 cluster) in gastrointestinal tumors." +other hsa-mir-17 Gastrointestinal Neoplasms 21219233 "The review focuses on the role of specific miRNAs (miR-192/194/215 and miR-7) in the differentiation of gastrointestinal epithelium and on the role of tumor-suppressive (miR-34, miR-143, miR-145) and oncogenic miRNAs (miR-21,miR-17-92 cluster) in gastrointestinal tumors." +other hsa-mir-18 Gastrointestinal Neoplasms 21219233 "The review focuses on the role of specific miRNAs (miR-192/194/215 and miR-7) in the differentiation of gastrointestinal epithelium and on the role of tumor-suppressive (miR-34, miR-143, miR-145) and oncogenic miRNAs (miR-21,miR-17-92 cluster) in gastrointestinal tumors." +other hsa-mir-192 Gastrointestinal Neoplasms 21219233 "The review focuses on the role of specific miRNAs (miR-192/194/215 and miR-7) in the differentiation of gastrointestinal epithelium and on the role of tumor-suppressive (miR-34, miR-143, miR-145) and oncogenic miRNAs (miR-21,miR-17-92 cluster) in gastrointestinal tumors." +other hsa-mir-194 Gastrointestinal Neoplasms 21219233 "The review focuses on the role of specific miRNAs (miR-192/194/215 and miR-7) in the differentiation of gastrointestinal epithelium and on the role of tumor-suppressive (miR-34, miR-143, miR-145) and oncogenic miRNAs (miR-21,miR-17-92 cluster) in gastrointestinal tumors." +other hsa-mir-19a Gastrointestinal Neoplasms 21219233 "The review focuses on the role of specific miRNAs (miR-192/194/215 and miR-7) in the differentiation of gastrointestinal epithelium and on the role of tumor-suppressive (miR-34, miR-143, miR-145) and oncogenic miRNAs (miR-21,miR-17-92 cluster) in gastrointestinal tumors." +other hsa-mir-19b-1 Gastrointestinal Neoplasms 21219233 "The review focuses on the role of specific miRNAs (miR-192/194/215 and miR-7) in the differentiation of gastrointestinal epithelium and on the role of tumor-suppressive (miR-34, miR-143, miR-145) and oncogenic miRNAs (miR-21,miR-17-92 cluster) in gastrointestinal tumors." +other hsa-mir-20a Gastrointestinal Neoplasms 21219233 "The review focuses on the role of specific miRNAs (miR-192/194/215 and miR-7) in the differentiation of gastrointestinal epithelium and on the role of tumor-suppressive (miR-34, miR-143, miR-145) and oncogenic miRNAs (miR-21,miR-17-92 cluster) in gastrointestinal tumors." +other hsa-mir-21 Gastrointestinal Neoplasms 21219233 "The review focuses on the role of specific miRNAs (miR-192/194/215 and miR-7) in the differentiation of gastrointestinal epithelium and on the role of tumor-suppressive (miR-34, miR-143, miR-145) and oncogenic miRNAs (miR-21,miR-17-92 cluster) in gastrointestinal tumors." +other hsa-mir-215 Gastrointestinal Neoplasms 21219233 "The review focuses on the role of specific miRNAs (miR-192/194/215 and miR-7) in the differentiation of gastrointestinal epithelium and on the role of tumor-suppressive (miR-34, miR-143, miR-145) and oncogenic miRNAs (miR-21,miR-17-92 cluster) in gastrointestinal tumors." +other hsa-mir-34 Gastrointestinal Neoplasms 21219233 "The review focuses on the role of specific miRNAs (miR-192/194/215 and miR-7) in the differentiation of gastrointestinal epithelium and on the role of tumor-suppressive (miR-34, miR-143, miR-145) and oncogenic miRNAs (miR-21,miR-17-92 cluster) in gastrointestinal tumors." +other hsa-mir-7 Gastrointestinal Neoplasms 21219233 "The review focuses on the role of specific miRNAs (miR-192/194/215 and miR-7) in the differentiation of gastrointestinal epithelium and on the role of tumor-suppressive (miR-34, miR-143, miR-145) and oncogenic miRNAs (miR-21,miR-17-92 cluster) in gastrointestinal tumors." +other hsa-mir-92-1 Gastrointestinal Neoplasms 21219233 "The review focuses on the role of specific miRNAs (miR-192/194/215 and miR-7) in the differentiation of gastrointestinal epithelium and on the role of tumor-suppressive (miR-34, miR-143, miR-145) and oncogenic miRNAs (miR-21,miR-17-92 cluster) in gastrointestinal tumors." +other hsa-mir-155 "Carcinoma, Lung, Non-Small-Cell" 21219656 The prognostic impact of miR-155 depends on histological subtype and nodal status in NSCLC. +other hsa-mir-221 "Squamous Cell Carcinoma, Oral" 21226887 miR-221 and miR-222 expression increased the growth and tumorigenesis of oral carcinoma cells. +other hsa-mir-222 "Squamous Cell Carcinoma, Oral" 21226887 miR-221 and miR-222 expression increased the growth and tumorigenesis of oral carcinoma cells. +other hsa-mir-200a Neoplasms [unspecific] 21237487 "Down-regulation of microRNAs of the miR-200 family and miR-205, and an altered expression of classic and desmosomal cadherins in spindle cell carcinoma of the head and neck-hallmark of epithelial-mesenchymal transition." +other hsa-mir-200b Neoplasms [unspecific] 21237487 "Down-regulation of microRNAs of the miR-200 family and miR-205, and an altered expression of classic and desmosomal cadherins in spindle cell carcinoma of the head and neck-hallmark of epithelial-mesenchymal transition." +other hsa-mir-200c Neoplasms [unspecific] 21237487 "Down-regulation of microRNAs of the miR-200 family and miR-205, and an altered expression of classic and desmosomal cadherins in spindle cell carcinoma of the head and neck-hallmark of epithelial-mesenchymal transition." +other hsa-mir-205 Neoplasms [unspecific] 21237487 "Down-regulation of microRNAs of the miR-200 family and miR-205, and an altered expression of classic and desmosomal cadherins in spindle cell carcinoma of the head and neck-hallmark of epithelial-mesenchymal transition." +other hsa-mir-378a Neoplasms [unspecific] 21242960 Myc/miR-378/TOB2/cyclin D1 functional module regulates oncogenic transformation. +other hsa-mir-23b Urinary Bladder Cancer 21242962 Human papillomavirus type 16 E6 induces cervical cancer cell migration through the p53/microRNA-23b/urokinase-type plasminogen activator pathway. +other hsa-mir-148a Esophageal Neoplasms 21246413 Mir-148a Improves Response to Chemotherapy in Sensitive and Resistant Oesophageal Adenocarcinoma and Squamous Cell Carcinoma Cells. +other hsa-mir-148a "Squamous Cell Carcinoma, Esophageal" 21246413 Mir-148a Improves Response to Chemotherapy in Sensitive and Resistant Oesophageal Adenocarcinoma and Squamous Cell Carcinoma Cells. +other hsa-let-7a Retinoblastoma 21247883 "E2F4 binding sites also occurred near regulatory elements for miRNAs such as let-7a and mir-17, suggestive of regulation of miRNAs by E2F4. Taken together, our genome-wide analysis provided evidence of versatile roles of E2F4 and insights into its functions." +other hsa-mir-17 Retinoblastoma 21247883 "E2F4 binding sites also occurred near regulatory elements for miRNAs such as let-7a and mir-17, suggestive of regulation of miRNAs by E2F4. Taken together, our genome-wide analysis provided evidence of versatile roles of E2F4 and insights into its functions." +other hsa-mir-200c Esophageal Neoplasms 21248297 Overexpression of miR-200c induces chemoresistance in esophageal cancers mediated through activation of the Akt signaling pathway. +other hsa-mir-146a "Diabetes Mellitus, Type 2" 21249428 Impaired miR-146a expression links subclinical inflammation and insulin resistance in Type 2 diabetes. +other hsa-mir-184 "Carcinoma, Renal Cell" 21253009 "miR-210, miR-184 and miR-206) play pivotal roles in ccRCC development" +other hsa-mir-206 "Carcinoma, Renal Cell" 21253009 "miR-210, miR-184 and miR-206) play pivotal roles in ccRCC development" +other hsa-mir-210 "Carcinoma, Renal Cell" 21253009 "miR-210, miR-184 and miR-206) play pivotal roles in ccRCC development" +other hsa-mir-146a Periodontal Diseases 21263019 Polymicrobial Infection with Periodontal Pathogens Specifically enhances miR-146a in ApoE-/- Mice during Experimental Periodontal Disease. +other hsa-mir-205 "Carcinoma, Lung, Non-Small-Cell" 21263248 "In conclusion, the relative quantification of miR-205 and miR-21 seems to be a promising diagnostic tool" +other hsa-mir-21 "Carcinoma, Lung, Non-Small-Cell" 21263248 "In conclusion, the relative quantification of miR-205 and miR-21 seems to be a promising diagnostic tool" +other hsa-mir-34a Neuroblastoma 21266077 This microRNA is a potent tumor suppressor molecule in vivo in neuroblastoma. +other hsa-mir-1258 Breast Neoplasms 21266359 Suppresses Breast Cancer Brain Metastasis by Targeting Heparanase. +other hsa-mir-146b Glioblastoma 21266476 Induction of miR-146b by PDGF-BB is modulated via MAPK-dependent induction of c-fos. +other hsa-mir-146b Ovarian Neoplasms 21266476 Induction of miR-146b by PDGF-BB is modulated via MAPK-dependent induction of c-fos. +other hsa-mir-143 Colon Neoplasms 21276449 The ecotropic viral integration site 1 oncoprotein (Evi1) is a transcriptional suppressor of the miRNA-143 gene. +other hsa-mir-429 Ovarian Neoplasms 21277012 Overexpression of miR-429 induces mesenchymal-to-epithelial transition (MET) in metastatic ovarian cancer cells. +other hsa-mir-21 Colon Neoplasms 21279518 PDCD4 nuclear loss inversely correlates with miR-21 levels in colon carcinogenesis. +other hsa-mir-203 Rheumatoid Arthritis 21279994 elevated levels of miR-203 lead to increased secretion of MMP-1 and IL-6 via the NF-kB pathway and thereby contribute to the activated phenotype of synovial fibroblasts in RA. +other hsa-mir-155 Cystic Fibrosis 21282106 Elevated miR-155 promotes inflammation in cystic fibrosis by driving hyper-expression of interleukin-8. +other hsa-mir-155 Inflammation 21282106 Elevated miR-155 promotes inflammation in cystic fibrosis by driving hyper-expression of interleukin-8. +other hsa-mir-24-1 Inflammation 21282569 "Role of miR-204 in the regulation of apoptosis, ER stress response, and inflammation in human trabecular meshwork cells." +other hsa-mir-24-2 Inflammation 21282569 "Role of miR-204 in the regulation of apoptosis, ER stress response, and inflammation in human trabecular meshwork cells." +other hsa-mir-199a-1 Liver Cirrhosis 21283674 "In both the mouse and human studies, the expression levels of miR-199a, 199a*, 200a, and 200b were positively and significantly correlated to the progressed liver fibrosis." +other hsa-mir-199a-2 Liver Cirrhosis 21283674 "In both the mouse and human studies, the expression levels of miR-199a, 199a*, 200a, and 200b were positively and significantly correlated to the progressed liver fibrosis." +other hsa-mir-200a Liver Cirrhosis 21283674 "In both the mouse and human studies, the expression levels of miR-199a, 199a*, 200a, and 200b were positively and significantly correlated to the progressed liver fibrosis." +other hsa-mir-200b Liver Cirrhosis 21283674 "In both the mouse and human studies, the expression levels of miR-199a, 199a*, 200a, and 200b were positively and significantly correlated to the progressed liver fibrosis." +other hsa-mir-106b Colon Neoplasms 21283757 Butyrate-induced p21 protein expression was dampened by treatment with a miR-106b mimic. +other hsa-mir-200a Pancreatic Neoplasms 21285251 DCAMKL-1 regulates epithelial-mesenchymal transition in human pancreatic cells through a miR-200a-dependent mechanism. +other hsa-mir-33a Inflammation 21285396 "miR-33 reduces RIP140 coactivator activity for NF-kB, which is supported by the reduction in NF-kB reporter activity and the inflammatory potential in macrophages." +other hsa-mir-33b Inflammation 21285396 "miR-33 reduces RIP140 coactivator activity for NF-kB, which is supported by the reduction in NF-kB reporter activity and the inflammatory potential in macrophages." +other hsa-mir-375 Obesity 21291493 "Taken together, these data suggest that miR-375 promotes 3T3-L1 adipocyte differentiation, possibly through modulating the ERK-PPAR¦Ã2-aP2 pathway." +other hsa-let-7a-1 Head And Neck Neoplasms 21292542 MicroRNA let-7a represses chemoresistance and tumourigenicity in head and neck cancer via stem-like properties ablation. +other hsa-let-7a-2 Head And Neck Neoplasms 21292542 MicroRNA let-7a represses chemoresistance and tumourigenicity in head and neck cancer via stem-like properties ablation. +other hsa-let-7a-3 Head And Neck Neoplasms 21292542 MicroRNA let-7a represses chemoresistance and tumourigenicity in head and neck cancer via stem-like properties ablation. +other hsa-mir-193a "Squamous Cell Carcinoma, Head and Neck" 21293058 "miR-193a-5p, expression of which was repressed by p63, was activated by proapoptotic p73 isoforms in both normal cells and tumor cells in vivo." +other hsa-mir-200c Head And Neck Neoplasms 21294122 MicroRNA-200c attenuates tumour growth and metastasis of presumptive head and neck squamous cell carcinoma stem cells. +other hsa-mir-200c "Squamous Cell Carcinoma, Head and Neck" 21294122 MicroRNA-200c attenuates tumour growth and metastasis of presumptive head and neck squamous cell carcinoma stem cells. +other hsa-let-7e "Carcinoma, Hepatocellular" 21298008 recurence related +other hsa-let-7f-1 "Carcinoma, Hepatocellular" 21298008 recurence related +other hsa-let-7f-2 "Carcinoma, Hepatocellular" 21298008 recurence related +other hsa-mir-100 "Carcinoma, Hepatocellular" 21298008 recurence related +other hsa-mir-103a-1 "Carcinoma, Hepatocellular" 21298008 recurence related +other hsa-mir-103a-2 "Carcinoma, Hepatocellular" 21298008 recurence related +other hsa-mir-107 "Carcinoma, Hepatocellular" 21298008 recurence related +other hsa-mir-1202 "Carcinoma, Hepatocellular" 21298008 recurence related +other hsa-mir-125a "Carcinoma, Hepatocellular" 21298008 miR-125a-5p recurence related +other hsa-mir-125b-1 "Carcinoma, Hepatocellular" 21298008 recurence related +other hsa-mir-125b-2 "Carcinoma, Hepatocellular" 21298008 recurence related +other hsa-mir-126 "Carcinoma, Hepatocellular" 21298008 miR-126* recurence related +other hsa-mir-129-1 "Carcinoma, Hepatocellular" 21298008 miR-129-5p recurence related +other hsa-mir-129-2 "Carcinoma, Hepatocellular" 21298008 miR-129-5p recurence related +other hsa-mir-140 "Carcinoma, Hepatocellular" 21298008 miR-140-3p recurence related +other hsa-mir-142 "Carcinoma, Hepatocellular" 21298008 miR-142-3p recurence related +other hsa-mir-145 "Carcinoma, Hepatocellular" 21298008 recurence related +other hsa-mir-148a "Carcinoma, Hepatocellular" 21298008 recurence related +other hsa-mir-18a "Carcinoma, Hepatocellular" 21298008 recurence related +other hsa-mir-18b "Carcinoma, Hepatocellular" 21298008 recurence related +other hsa-mir-191 "Carcinoma, Hepatocellular" 21298008 recurence related +other hsa-mir-195 "Carcinoma, Hepatocellular" 21298008 recurence related +other hsa-mir-21 "Carcinoma, Hepatocellular" 21298008 recurence related +other hsa-mir-22 "Carcinoma, Hepatocellular" 21298008 recurence related +other hsa-mir-221 "Carcinoma, Hepatocellular" 21298008 recurence related +other hsa-mir-222 "Carcinoma, Hepatocellular" 21298008 recurence related +other hsa-mir-23a "Carcinoma, Hepatocellular" 21298008 recurence related +other hsa-mir-24-1 "Carcinoma, Hepatocellular" 21298008 recurence related +other hsa-mir-24-2 "Carcinoma, Hepatocellular" 21298008 recurence related +other hsa-mir-27a "Carcinoma, Hepatocellular" 21298008 recurence related +other hsa-mir-362 "Carcinoma, Hepatocellular" 21298008 miR-362-3p recurence related +other hsa-mir-378a "Carcinoma, Hepatocellular" 21298008 recurence related +other hsa-mir-425 "Carcinoma, Hepatocellular" 21298008 recurence related +other hsa-mir-497 "Carcinoma, Hepatocellular" 21298008 recurence related +other hsa-mir-96 "Carcinoma, Hepatocellular" 21298008 recurence related +other hsa-mir-99a "Carcinoma, Hepatocellular" 21298008 recurence related +other hsa-mir-99b "Carcinoma, Hepatocellular" 21298008 recurence related +other hsa-mir-206 Breast Neoplasms 21302623 miR-206 may suppress invasion and migration of MDA-MB-231 cells in vitro partly via regulating actin cytoskeleton remodelling such as filopodia formation +other hsa-mir-146b Asthma 21305051 "Inverse correlation with the expression of potential mRNA targets identified mmu-miR-146b, -223, -29b, -29c, -483, -574-5p, -672 and -690 as the best candidates for an active implication in asthma pathogenesis. " +other hsa-mir-223 Asthma 21305051 "Inverse correlation with the expression of potential mRNA targets identified mmu-miR-146b, -223, -29b, -29c, -483, -574-5p, -672 and -690 as the best candidates for an active implication in asthma pathogenesis. " +other hsa-mir-29b Asthma 21305051 "Inverse correlation with the expression of potential mRNA targets identified mmu-miR-146b, -223, -29b, -29c, -483, -574-5p, -672 and -690 as the best candidates for an active implication in asthma pathogenesis. " +other hsa-mir-29c Asthma 21305051 "Inverse correlation with the expression of potential mRNA targets identified mmu-miR-146b, -223, -29b, -29c, -483, -574-5p, -672 and -690 as the best candidates for an active implication in asthma pathogenesis. " +other hsa-mir-483 Asthma 21305051 "Inverse correlation with the expression of potential mRNA targets identified mmu-miR-146b, -223, -29b, -29c, -483, -574-5p, -672 and -690 as the best candidates for an active implication in asthma pathogenesis. " +other hsa-mir-574 Asthma 21305051 "Inverse correlation with the expression of potential mRNA targets identified mmu-miR-146b, -223, -29b, -29c, -483, -574-5p, -672 and -690 as the best candidates for an active implication in asthma pathogenesis. " +other hsa-mir-672 Asthma 21305051 "Inverse correlation with the expression of potential mRNA targets identified mmu-miR-146b, -223, -29b, -29c, -483, -574-5p, -672 and -690 as the best candidates for an active implication in asthma pathogenesis. " +other hsa-mir-690 Asthma 21305051 "Inverse correlation with the expression of potential mRNA targets identified mmu-miR-146b, -223, -29b, -29c, -483, -574-5p, -672 and -690 as the best candidates for an active implication in asthma pathogenesis. " +other hsa-mir-542 Neuroblastoma 21310526 MicroRNA-542-5p as a novel tumor suppressor in neuroblastoma. +other hsa-mir-125a Hepatitis B Virus Infection 21317190 "hsa-mir-125a-5p, was found to interact with the viral sequence and to suppress the reporter activity markedly." +other hsa-mir-1224 Neoplasms [unspecific] 21320120 Lipopolysaccharide-induced miR-1224 negatively regulates tumour necrosis factor-alpha gene expression by modulating Sp1. +other hsa-mir-451a "Carcinoma, Lung, Non-Small-Cell" 21329503 Upregulation of microRNA-451 increases cisplatin sensitivity of non-small cell lung cancer cell line (A549). +other hsa-mir-205 "Carcinoma, Renal Cell" 21330408 MicroRNA-205 inhibits Src-mediated oncogenic pathways in renal cancer. +other hsa-mir-16-1 "Carcinoma, Hepatocellular" 21336967 P-glycoprotein enhances radiation-induced apoptotic cell death through the regulation of miR-16 and Bcl-2 expressions in hepatocellular carcinoma cells. +other hsa-mir-16-2 "Carcinoma, Hepatocellular" 21336967 P-glycoprotein enhances radiation-induced apoptotic cell death through the regulation of miR-16 and Bcl-2 expressions in hepatocellular carcinoma cells. +other hsa-mir-155 "Carcinoma, Lung, Non-Small-Cell" 21350005 "Elevated miR-21 (HR 2.06, 1.13-3.75), miR-17 (HR 2.00, 1.10-3.61), and miR-155 (HR 2.37, 1.27-4.42) was associated with worse cancer-specific mortality in the Maryland cohort." +other hsa-mir-17 "Carcinoma, Lung, Non-Small-Cell" 21350005 "Elevated miR-21 (HR 2.06, 1.13-3.75), miR-17 (HR 2.00, 1.10-3.61), and miR-155 (HR 2.37, 1.27-4.42) was associated with worse cancer-specific mortality in the Maryland cohort." +other hsa-mir-21 "Carcinoma, Lung, Non-Small-Cell" 21350005 "Elevated miR-21 (HR 2.06, 1.13-3.75), miR-17 (HR 2.00, 1.10-3.61), and miR-155 (HR 2.37, 1.27-4.42) was associated with worse cancer-specific mortality in the Maryland cohort." +other hsa-mir-200b Diabetic Retinopathy 21357793 MicroRNA-200b Regulates Vascular Endothelial Growth Factor-Mediated Alterations in Diabetic Retinopathy. +other hsa-mir-29b-1 Breast Neoplasms 21359530 miR-29b regulates migration of human breast cancer cells. +other hsa-mir-29b-2 Breast Neoplasms 21359530 miR-29b regulates migration of human breast cancer cells. +other hsa-mir-145 Prostate Neoplasms 21360565 "SWAP70, actin-binding protein, function as an oncogene targeting tumor-suppressive miR-145 in prostate cancer." +other hsa-mir-144 "Tuberculosis, Pulmonary" 21367459 Modulation of T cell cytokine production by miR-144* with elevated expression in patients with pulmonary tuberculosis. +other hsa-mir-203 Prostate Neoplasms 21368580 "MiR-203 controls proliferation, migration and invasive potential of prostate cancer cell lines." +other hsa-let-7a-1 Breast Neoplasms 21368581 Micro(mi)RNA expression profile of breast cancer epithelial cells treated with the anti-diabetic drug metformin: Induction of the tumor suppressor miRNA let-7a and suppression of the TGFbeta-induced oncomiR miRNA-181a. +other hsa-let-7a-2 Breast Neoplasms 21368581 Micro(mi)RNA expression profile of breast cancer epithelial cells treated with the anti-diabetic drug metformin: Induction of the tumor suppressor miRNA let-7a and suppression of the TGFbe-induced oncomiR miRNA-181a. +other hsa-let-7a-3 Breast Neoplasms 21368581 Micro(mi)RNA expression profile of breast cancer epithelial cells treated with the anti-diabetic drug metformin: Induction of the tumor suppressor miRNA let-7a and suppression of the TGFbeta-induced oncomiR miRNA-181a. +other hsa-mir-181a-2 Breast Neoplasms 21368581 Micro(mi)RNA expression profile of breast cancer epithelial cells treated with the anti-diabetic drug metformin: Induction of the tumor suppressor miRNA let-7a and suppression of the TGFbeta-induced oncomiR miRNA-181a. +other hsa-mir-205 Prostate Neoplasms 21368878 Downregulation of miR-205 and miR-31 confers resistance to chemotherapy-induced apoptosis in prostate cancer cells. +other hsa-mir-31 Prostate Neoplasms 21368878 Downregulation of miR-205 and miR-31 confers resistance to chemotherapy-induced apoptosis in prostate cancer cells. +other hsa-mir-1 Inflammation 21385380 "Acute noxious stimulation with capsaicin also increased the expression of miR-1 and -16 in DRG cells but, on the other hand, in the spinal dorsal horn only a high dose of capsaicin was able to downregulate miR-206 expression." +other hsa-mir-16 Inflammation 21385380 "Acute noxious stimulation with capsaicin also increased the expression of miR-1 and -16 in DRG cells but, on the other hand, in the spinal dorsal horn only a high dose of capsaicin was able to downregulate miR-206 expression." +other hsa-mir-206 Inflammation 21385380 "Acute noxious stimulation with capsaicin also increased the expression of miR-1 and -16 in DRG cells but, on the other hand, in the spinal dorsal horn only a high dose of capsaicin was able to downregulate miR-206 expression." +other hsa-mir-210 Preeclampsia 21388516 Elevated levels of hypoxia-inducible microRNA-210 in preeclampsia. +other hsa-mir-301a Breast Neoplasms 21393507 miR-301 as a crucial oncogene in human breast cancer that acts through multiple pathways and mechanisms to promote nodal or distant relapses. +other hsa-mir-301b Breast Neoplasms 21393507 miR-301 as a crucial oncogene in human breast cancer that acts through multiple pathways and mechanisms to promote nodal or distant relapses. +other hsa-mir-125b-1 Colorectal Carcinoma 21399871 miR-125b is directly involved in cancer progression and is associated with poor prognosis in human colorectal cancer. Our findings suggest that miR-125b could be an important prognostic indicator for colorectal cancer patients. +other hsa-mir-125b-2 Colorectal Carcinoma 21399871 miR-125b is directly involved in cancer progression and is associated with poor prognosis in human colorectal cancer. Our findings suggest that miR-125b could be an important prognostic indicator for colorectal cancer patients. +other hsa-mir-34a Breast Neoplasms 21399894 increased expression of miR-34a in an acquired model of docetaxel resistance in breast cancer. +other hsa-mir-223 Multiple Myeloma 21401705 Expression of CD19 and lack of miR-223 distinguish extramedullary plasmacytoma from multiple myeloma. +other hsa-mir-31 Breast Neoplasms 21406558 Activation of miR-31 function in already-established metastases elicits metastatic regression. +other hsa-mir-16-1 Colorectal Carcinoma 21406606 "Diet and carcinogen exposure modulated a number of microRNAs (miR-16, miR-19b, miR-21, miR26b, miR27b, miR-93 and miR-203) linked to canonical oncogenic signaling pathways." +other hsa-mir-16-2 Colorectal Carcinoma 21406606 "Diet and carcinogen exposure modulated a number of microRNAs (miR-16, miR-19b, miR-21, miR26b, miR27b, miR-93 and miR-203) linked to canonical oncogenic signaling pathways." +other hsa-mir-19b-1 Colorectal Carcinoma 21406606 "Diet and carcinogen exposure modulated a number of microRNAs (miR-16, miR-19b, miR-21, miR26b, miR27b, miR-93 and miR-203) linked to canonical oncogenic signaling pathways." +other hsa-mir-19b-2 Colorectal Carcinoma 21406606 "Diet and carcinogen exposure modulated a number of microRNAs (miR-16, miR-19b, miR-21, miR26b, miR27b, miR-93 and miR-203) linked to canonical oncogenic signaling pathways." +other hsa-mir-203 Colorectal Carcinoma 21406606 "Diet and carcinogen exposure modulated a number of microRNAs (miR-16, miR-19b, miR-21, miR26b, miR27b, miR-93 and miR-203) linked to canonical oncogenic signaling pathways." +other hsa-mir-21 Colorectal Carcinoma 21406606 "Diet and carcinogen exposure modulated a number of microRNAs (miR-16, miR-19b, miR-21, miR26b, miR27b, miR-93 and miR-203) linked to canonical oncogenic signaling pathways." +other hsa-mir-26b Colorectal Carcinoma 21406606 "Diet and carcinogen exposure modulated a number of microRNAs (miR-16, miR-19b, miR-21, miR26b, miR27b, miR-93 and miR-203) linked to canonical oncogenic signaling pathways." +other hsa-mir-27b Colorectal Carcinoma 21406606 "Diet and carcinogen exposure modulated a number of microRNAs (miR-16, miR-19b, miR-21, miR26b, miR27b, miR-93 and miR-203) linked to canonical oncogenic signaling pathways." +other hsa-mir-93 Colorectal Carcinoma 21406606 "Diet and carcinogen exposure modulated a number of microRNAs (miR-16, miR-19b, miR-21, miR26b, miR27b, miR-93 and miR-203) linked to canonical oncogenic signaling pathways." +other hsa-mir-200a Pancreatic Neoplasms 21408027 "Anti-Tumor Activity of a Novel Compound-CDF Is Mediated by Regulating miR-21, miR-200, and PTEN in Pancreatic Cancer." +other hsa-mir-200b Pancreatic Neoplasms 21408027 in gemcitabine-resistant (MIAPaCa-2) PC cells containing high proportion of CSCs consistent with increased miR-21 and decreased miR-200. +other hsa-mir-200c Pancreatic Neoplasms 21408027 in gemcitabine-resistant (MIAPaCa-2) PC cells containing high proportion of CSCs consistent with increased miR-21 and decreased miR-200. +other hsa-mir-21 Pancreatic Neoplasms 21408027 "Anti-Tumor Activity of a Novel Compound-CDF Is Mediated by Regulating miR-21, miR-200, and PTEN in Pancreatic Cancer." +other hsa-let-7c Breast Neoplasms 21409395 "let7c, miR-125b, miR-126, miR-127-3p, miR-143, miR-145, miR-146b-5p, and miR-199a-3p), preferentially expressed in normal basal cells" +other hsa-let-7b Liposarcoma 21412931 Let-7 MicroRNA and HMGA2 levels of expression are not inversely linked in adipocytic tumors: Analysis of 56 lipomas and liposarcomas with molecular cytogenetic data. +other hsa-let-7g Liposarcoma 21412931 Let-7 MicroRNA and HMGA2 levels of expression are not inversely linked in adipocytic tumors: Analysis of 56 lipomas and liposarcomas with molecular cytogenetic data. +other hsa-mir-146a Lymphoma 21416002 "In addition, LMP1 can also modulate cellular gene expression programs by affecting, via the NF-¦ÊB pathway, levels of cellular microRNAs miR-146a and miR-155" +other hsa-mir-155 Lymphoma 21416002 "In addition, LMP1 can also modulate cellular gene expression programs by affecting, via the NF-¦ÊB pathway, levels of cellular microRNAs miR-146a and miR-155" +other hsa-mir-193a Esophageal Neoplasms 21420070 The expression of three miRNAs (miR-99b and miR-199a_3p and _5p) was associated with the presence of lymph node metastasis. +other hsa-mir-99b Esophageal Neoplasms 21420070 The expression of three miRNAs (miR-99b and miR-199a_3p and _5p) was associated with the presence of lymph node metastasis. +other hsa-mir-34a Ovarian Neoplasms 21423204 We propose that elevated TRP53 and miR-34a-c may exert negatively regulatory effects that reduce the proliferative potential of OSE cells leading to the low-grade serous adenocarcinoma phenotype. +other hsa-mir-21 "Squamous Cell Carcinoma, Tongue" 21426775 Anti-sense miRNA-21 oligonucleotide inhibits Tb 3.1 human tongue squamous cell carcinoma growth in vitro.] +other hsa-mir-143 Osteosarcoma 21427707 MicroRNA-143 Regulates Human Osteosarcoma Metastasis by Regulating Matrix Metalloprotease-13 Expression. +other hsa-mir-101-1 Prostate Neoplasms 21430074 Enforced Expression of miR-101 inhibits prostate cancer cell growth by modulating cyclooxygenase-2 pathway in vivo. +other hsa-mir-101-2 Prostate Neoplasms 21430074 Enforced Expression of miR-101 inhibits prostate cancer cell growth by modulating cyclooxygenase-2 pathway in vivo. +other hsa-mir-200c Prostate Neoplasms 21431706 Differentially expressed between androgen-dependent and androgen-independent metastatic prostate cancer cells +other hsa-mir-205 Prostate Neoplasms 21431706 Differentially expressed between androgen-dependent and androgen-independent metastatic prostate cancer cells +other hsa-mir-211 Melanoma 21435193 Melanoma cell invasiveness is regulated by miR-211 suppression of the BRN2 transcription factor. +other hsa-mir-381 Glioblastoma 21435336 Interaction of hsa-miR-381 and glioma suppressor LRRC4 is involved in glioma growth. +other hsa-let-7a Human Papilloma Virus Infection 21442230 "HPV-38 was predicted to express an miRNA conserved to human let-7a and the expression of let-7a, in HPV-38-positive non-melanoma skin cancer (NMSC) biopsies was 10-fold higher than those with HPV-positive (for other types except HPV-38) and HPV-negative NMSCs, suggesting that let-7a expression might be related to HPV-38 infection." +other hsa-mir-328 "Carcinoma, Lung, Non-Small-Cell" 21448905 MicroRNA-328 is associated with (non-small) cell lung cancer (NSCLC) brain metastasis and mediates NSCLC migration. +other hsa-mir-10 "Leukemia, Myeloid" 21455993 Our analysis identified a strong positive correlation between HOX-related genes and miR-10 and miR-20a. +other hsa-mir-128a Leukemia 21455993 "we observed a negative correlation between miR-181a and miR-181b, miR-155, and miR-146 expression with that of genes involved in immunity and inflammation (eg, IRF7 and TLR4) and a positive correlation between miR-23a, miR-26a, miR-128a, and miR-145 expression with that of proapoptotic genes (eg, BIM and PTEN)" +other hsa-mir-145 Leukemia 21455993 "we observed a negative correlation between miR-181a and miR-181b, miR-155, and miR-146 expression with that of genes involved in immunity and inflammation (eg, IRF7 and TLR4) and a positive correlation between miR-23a, miR-26a, miR-128a, and miR-145 expression with that of proapoptotic genes (eg, BIM and PTEN)" +other hsa-mir-146 Leukemia 21455993 "we observed a negative correlation between miR-181a and miR-181b, miR-155, and miR-146 expression with that of genes involved in immunity and inflammation (eg, IRF7 and TLR4) and a positive correlation between miR-23a, miR-26a, miR-128a, and miR-145 expression with that of proapoptotic genes (eg, BIM and PTEN)" +other hsa-mir-155 Leukemia 21455993 "we observed a negative correlation between miR-181a and miR-181b, miR-155, and miR-146 expression with that of genes involved in immunity and inflammation (eg, IRF7 and TLR4) and a positive correlation between miR-23a, miR-26a, miR-128a, and miR-145 expression with that of proapoptotic genes (eg, BIM and PTEN)" +other hsa-mir-181a Leukemia 21455993 "we observed a negative correlation between miR-181a and miR-181b, miR-155, and miR-146 expression with that of genes involved in immunity and inflammation (eg, IRF7 and TLR4) and a positive correlation between miR-23a, miR-26a, miR-128a, and miR-145 expression with that of proapoptotic genes (eg, BIM and PTEN)" +other hsa-mir-181b Leukemia 21455993 "we observed a negative correlation between miR-181a and miR-181b, miR-155, and miR-146 expression with that of genes involved in immunity and inflammation (eg, IRF7 and TLR4) and a positive correlation between miR-23a, miR-26a, miR-128a, and miR-145 expression with that of proapoptotic genes (eg, BIM and PTEN)" +other hsa-mir-20a "Leukemia, Myeloid" 21455993 Our analysis identified a strong positive correlation between HOX-related genes and miR-10 and miR-20a. +other hsa-mir-23a Leukemia 21455993 "we observed a negative correlation between miR-181a and miR-181b, miR-155, and miR-146 expression with that of genes involved in immunity and inflammation (eg, IRF7 and TLR4) and a positive correlation between miR-23a, miR-26a, miR-128a, and miR-145 expression with that of proapoptotic genes (eg, BIM and PTEN)" +other hsa-mir-26a Leukemia 21455993 "we observed a negative correlation between miR-181a and miR-181b, miR-155, and miR-146 expression with that of genes involved in immunity and inflammation (eg, IRF7 and TLR4) and a positive correlation between miR-23a, miR-26a, miR-128a, and miR-145 expression with that of proapoptotic genes (eg, BIM and PTEN)" +other hsa-mir-155 Breast Neoplasms 21460854 miR-155 promotes macroscopic tumor formation yet inhibits tumor dissemination from mammary fat pads to the lung by preventing EMT. +other hsa-mir-1 "Cardiomyopathy, Hypertrophic" 21464712 "The cardiac-enriched miRNAs, including miR-1, miR-133, and miR-208, as well as the ubiquitous miR-23a and miR-199b, play major roles in the development of cardiac hypertrophy." +other hsa-mir-133 "Cardiomyopathy, Hypertrophic" 21464712 "The cardiac-enriched miRNAs, including miR-1, miR-133, and miR-208, as well as the ubiquitous miR-23a and miR-199b, play major roles in the development of cardiac hypertrophy." +other hsa-mir-199a Ischemic Diseases [unspecific] 21464712 "On the other hand, miR-21, miR-199a, miR-210, and miR-494 have been proven critical for the myocytes' adaptation and survival during hypoxia/ischemia." +other hsa-mir-199b "Cardiomyopathy, Hypertrophic" 21464712 "The cardiac-enriched miRNAs, including miR-1, miR-133, and miR-208, as well as the ubiquitous miR-23a and miR-199b, play major roles in the development of cardiac hypertrophy." +other hsa-mir-208 "Cardiomyopathy, Hypertrophic" 21464712 "The cardiac-enriched miRNAs, including miR-1, miR-133, and miR-208, as well as the ubiquitous miR-23a and miR-199b, play major roles in the development of cardiac hypertrophy." +other hsa-mir-21 Ischemic Diseases [unspecific] 21464712 "On the other hand, miR-21, miR-199a, miR-210, and miR-494 have been proven critical for the myocytes' adaptation and survival during hypoxia/ischemia." +other hsa-mir-210 Ischemic Diseases [unspecific] 21464712 "On the other hand, miR-21, miR-199a, miR-210, and miR-494 have been proven critical for the myocytes' adaptation and survival during hypoxia/ischemia." +other hsa-mir-23a "Cardiomyopathy, Hypertrophic" 21464712 "The cardiac-enriched miRNAs, including miR-1, miR-133, and miR-208, as well as the ubiquitous miR-23a and miR-199b, play major roles in the development of cardiac hypertrophy." +other hsa-mir-494 Ischemic Diseases [unspecific] 21464712 "On the other hand, miR-21, miR-199a, miR-210, and miR-494 have been proven critical for the myocytes' adaptation and survival during hypoxia/ischemia." +other hsa-mir-210 Inflammation 21467158 miRNA-210 is a good example in this category that impairs wound closure. +other hsa-mir-21 Urinary Bladder Cancer 21468550 microRNA-21 modulates cell proliferation and sensitivity to doxorubicin in bladder cancer cells +other hsa-mir-21 Breast Neoplasms 21471222 Upregulation of MIR-21 mediates resistance to trastuzumab therapy for breast cancer. +other hsa-mir-10b Glioblastoma 21471404 Human glioma growth is controlled by microRNA-10b +other hsa-mir-146a "Carcinoma, Renal Cell" 21472233 "Carbamylated albumin stimulates microRNA-146, which is increased in human renal cell carcinoma." +other hsa-mir-146b "Carcinoma, Renal Cell" 21472233 "Carbamylated albumin stimulates microRNA-146, which is increased in human renal cell carcinoma." +other hsa-let-7g Lung Neoplasms 21472347 Precursor let-7g microRNA can supress A549 lung cancer cell migration. +other hsa-mir-146a Breast Neoplasms 21472990 Down-regulation of BRCA1 expression by miR-146a and miR-146b-5p in triple negative sporadic breast cancers. +other hsa-mir-146b Breast Neoplasms 21472990 Down-regulation of BRCA1 expression by miR-146a and miR-146b-5p in triple negative sporadic breast cancers. +other hsa-mir-517a Urinary Bladder Cancer 21479368 Restoration of miR-517a expression induces cell apoptosis in bladder cancer cell lines. +other hsa-mir-221 Neoplasms [unspecific] 21481725 miRNA-221/-222 control radiation sensitivity by regulating the PTEN/AKT pathway and can be explored as novel targets for radiosensitization. +other hsa-mir-222 Neoplasms [unspecific] 21481725 miRNA-221/-222 control radiation sensitivity by regulating the PTEN/AKT pathway and can be explored as novel targets for radiosensitization. +other hsa-mir-503 "Carcinoma, Hepatocellular" 21495032 microRNA-503 regulates metastatic function in hepatocellular cancer cell. +other hsa-mir-22 Neoplasms [unspecific] 21502362 miR-22 represses cancer progression by inducing cellular senescence. +other hsa-mir-150 Lymphoma 21502955 microRNA-150 is a tumor suppressor in malignant lymphoma +other hsa-mir-183 Lung Neoplasms 21503569 microRNA-182 inhibits the proliferation and invasion of human lung adenocarcinoma cells through its effect on human cortical actin-associated protein. +other hsa-mir-192 Retinoblastoma 21511813 MicroRNA-192 targeting retinoblastoma 1 inhibits cell proliferation and induces cell apoptosis in lung cancer cells. +other hsa-mir-193b Breast Neoplasms 21512034 "we present here a proteomic screen to identify targets of miR-193b, and a systems biological approach to mimic its effects at the level of cellular phenotypes." +other hsa-mir-1-1 Hepatitis B Virus Infection 21520166 "MiR-1 regulates the expression of several host genes to enhance HBV replication and reverse cancer cell phenotype, which is apparently beneficial for HBV replication." +other hsa-mir-1-2 Hepatitis B Virus Infection 21520166 "MiR-1 regulates the expression of several host genes to enhance HBV replication and reverse cancer cell phenotype, which is apparently beneficial for HBV replication." +other hsa-mir-181a Lymphoma 21525173 "A multivariate Cox regression analysis including the IPI, the 6-gene model-derived mortality predictor score and expression of the miR-18a, miR-181a, and miR-222, revealed that all variables were independent predictors of survival except the expression of miR-222 for OS and the expression of miR-18a for PFS." +other hsa-mir-18a Lymphoma 21525173 "A multivariate Cox regression analysis including the IPI, the 6-gene model-derived mortality predictor score and expression of the miR-18a, miR-181a, and miR-222, revealed that all variables were independent predictors of survival except the expression of miR-222 for OS and the expression of miR-18a for PFS." +other hsa-mir-222 Lymphoma 21525173 "A multivariate Cox regression analysis including the IPI, the 6-gene model-derived mortality predictor score and expression of the miR-18a, miR-181a, and miR-222, revealed that all variables were independent predictors of survival except the expression of miR-222 for OS and the expression of miR-18a for PFS." +other hsa-mir-15a Multiple Myeloma 21534877 Bone marrow stromal cells protect myeloma cells from bortezomib induced apoptosis by suppressing microRNA-15a expression. +other hsa-mir-16-1 Prostate Neoplasms 21539977 "We observed correlations with clinical-pathologic parameters: miR-16, miR-195, and miR-26a were significantly correlated with surgical margin positivity; miR-195 and miR-let7i were significantly correlated with the Gleason score." +other hsa-mir-16-2 Prostate Neoplasms 21539977 "We observed correlations with clinical-pathologic parameters: miR-16, miR-195, and miR-26a were significantly correlated with surgical margin positivity; miR-195 and miR-let7i were significantly correlated with the Gleason score." +other hsa-mir-195 Prostate Neoplasms 21539977 "We observed correlations with clinical-pathologic parameters: miR-16, miR-195, and miR-26a were significantly correlated with surgical margin positivity; miR-195 and miR-let7i were significantly correlated with the Gleason score." +other hsa-mir-26a-1 Prostate Neoplasms 21539977 "We observed correlations with clinical-pathologic parameters: miR-16, miR-195, and miR-26a were significantly correlated with surgical margin positivity; miR-195 and miR-let7i were significantly correlated with the Gleason score." +other hsa-mir-26a-2 Prostate Neoplasms 21539977 "We observed correlations with clinical-pathologic parameters: miR-16, miR-195, and miR-26a were significantly correlated with surgical margin positivity; miR-195 and miR-let7i were significantly correlated with the Gleason score." +other hsa-mir-155 Nasopharyngeal Neoplasms 21541331 Upregulation of MiR-155 in Nasopharyngeal Carcinoma is Partly Driven by LMP1 and LMP2A and Downregulates a Negative Prognostic Marker JMJD1A. +other hsa-mir-34a Melanoma 21541354 miR-34a and miR-185 were further shown to inhibit the growth of melanoma xenografts when implanted in SCID-NOD mice. +other hsa-mir-142 Melanoma 21543894 "miR-142-3p, miR-486, miR-214, miR-218, miR-362, miR-650 and miR-31, were significantly correlated with acral as compared to non-acral melanomas (p < 0.04)." +other hsa-mir-214 Melanoma 21543894 "miR-142-3p, miR-486, miR-214, miR-218, miR-362, miR-650 and miR-31, were significantly correlated with acral as compared to non-acral melanomas (p < 0.04)." +other hsa-mir-218-1 Melanoma 21543894 "miR-142-3p, miR-486, miR-214, miR-218, miR-362, miR-650 and miR-31, were significantly correlated with acral as compared to non-acral melanomas (p < 0.04)." +other hsa-mir-218-2 Melanoma 21543894 "miR-142-3p, miR-486, miR-214, miR-218, miR-362, miR-650 and miR-31, were significantly correlated with acral as compared to non-acral melanomas (p < 0.04)." +other hsa-mir-31 Melanoma 21543894 "miR-142-3p, miR-486, miR-214, miR-218, miR-362, miR-650 and miR-31, were significantly correlated with acral as compared to non-acral melanomas (p < 0.04)." +other hsa-mir-362 Melanoma 21543894 "miR-142-3p, miR-486, miR-214, miR-218, miR-362, miR-650 and miR-31, were significantly correlated with acral as compared to non-acral melanomas (p < 0.04)." +other hsa-mir-486 Melanoma 21543894 "miR-142-3p, miR-486, miR-214, miR-218, miR-362, miR-650 and miR-31, were significantly correlated with acral as compared to non-acral melanomas (p < 0.04)." +other hsa-mir-650 Melanoma 21543894 "miR-142-3p, miR-486, miR-214, miR-218, miR-362, miR-650 and miR-31, were significantly correlated with acral as compared to non-acral melanomas (p < 0.04)." +other hsa-let-7d Prostate Neoplasms 21548940 PBX3 is up-regulated in prostate cancer and post- transcriptionally regulated by androgen through Let-7d. +other hsa-mir-143 Urinary Bladder Cancer 21550168 MicroRNA-143 functions as a tumor suppressor in human bladder cancer T24 cells +other hsa-mir-135a-1 "Carcinoma, Lung, Non-Small-Cell" 21552288 miR-135a contributes to paclitaxel resistance in tumor cells both in vitro and in vivo. +other hsa-mir-135a-2 "Carcinoma, Lung, Non-Small-Cell" 21552288 miR-135a contributes to paclitaxel resistance in tumor cells both in vitro and in vivo. +other hsa-mir-200c Breast Neoplasms 21553120 "Suppression of miR-200c, miR-203, and miR-205 and increases in miR-222 and miR-221 are involved in the inducement of EMT and repression of the estrogen receptor." +other hsa-mir-203 Breast Neoplasms 21553120 "Suppression of miR-200c, miR-203, and miR-205 and increases in miR-222 and miR-221 are involved in the inducement of EMT and repression of the estrogen receptor." +other hsa-mir-205 Breast Neoplasms 21553120 "Suppression of miR-200c, miR-203, and miR-205 and increases in miR-222 and miR-221 are involved in the inducement of EMT and repression of the estrogen receptor." +other hsa-mir-221 Breast Neoplasms 21553120 "Suppression of miR-200c, miR-203, and miR-205 and increases in miR-222 and miR-221 are involved in the inducement of EMT and repression of the estrogen receptor." +other hsa-mir-222 Breast Neoplasms 21553120 "Suppression of miR-200c, miR-203, and miR-205 and increases in miR-222 and miR-221 are involved in the inducement of EMT and repression of the estrogen receptor." +other hsa-mir-146a Neoplasms [unspecific] 21555486 "miR-146a is a significant brake on autoimmunity, myeloproliferation, and cancer in mice." +other hsa-mir-143 Rectal Neoplasms 21567082 Altered levels of the onco-microRNA 21 and the tumor-supressor microRNAs 143 and 145 in advanced rectal cancer indicate successful neoadjuvant chemoradiotherapy. +other hsa-mir-145 Rectal Neoplasms 21567082 Altered levels of the onco-microRNA 21 and the tumor-supressor microRNAs 143 and 145 in advanced rectal cancer indicate successful neoadjuvant chemoradiotherapy. +other hsa-mir-21 Rectal Neoplasms 21567082 Altered levels of the onco-microRNA 21 and the tumor-supressor microRNAs 143 and 145 in advanced rectal cancer indicate successful neoadjuvant chemoradiotherapy. +other hsa-mir-27a Gastric Neoplasms 21569481 Down-regulation of miR-27a might inhibit proliferation and drug resistance of gastric cancer cells. +other hsa-mir-92a-1 Neuroblastoma 21572098 MYCN-regulated miRNA-92 Inhibits Secretion of the Tumor Suppressor DICKKOPF-3 (DKK3) in Neuroblastoma. +other hsa-mir-92a-2 Neuroblastoma 21572098 MYCN-regulated miRNA-92 Inhibits Secretion of the Tumor Suppressor DICKKOPF-3 (DKK3) in Neuroblastoma. +other hsa-mir-92b Neuroblastoma 21572098 MYCN-regulated miRNA-92 Inhibits Secretion of the Tumor Suppressor DICKKOPF-3 (DKK3) in Neuroblastoma. +other hsa-mir-15a "Carcinoma, Lung, Non-Small-Cell" 21575235 miR-34a and miR-15a/16 are co-regulated in non-small cell lung cancer and control cell cycle progression in a synergistic and Rb-dependent manner. +other hsa-mir-16-1 "Carcinoma, Lung, Non-Small-Cell" 21575235 miR-34a and miR-15a/16 are co-regulated in non-small cell lung cancer and control cell cycle progression in a synergistic and Rb-dependent manner. +other hsa-mir-16-2 "Carcinoma, Lung, Non-Small-Cell" 21575235 miR-34a and miR-15a/16 are co-regulated in non-small cell lung cancer and control cell cycle progression in a synergistic and Rb-dependent manner. +other hsa-mir-34a "Carcinoma, Lung, Non-Small-Cell" 21575235 miR-34a and miR-15a/16 are co-regulated in non-small cell lung cancer and control cell cycle progression in a synergistic and Rb-dependent manner. +other hsa-mir-133a "Cardiomyopathy, Hypertrophic" 21586423 "Logistic regression analysis identified microRNA-133a as a significant positive predictor of LVM normalisation, whereas ¦Â-myosin heavy chain and BMI constituted negative predictors." +other hsa-mir-146a Ovarian Neoplasms 21591024 "In conclusion, the polymorphism in the miR-146a gene is unlikely to be of substantial significance regarding breast cancer risk." +other hsa-mir-335 Astrocytoma 21592405 Targeting oncogenic miR-335 inhibits growth and invasion of malignant astrocytoma cells. +other hsa-mir-7-1 Neoplasms [unspecific] 21592959 USP18 regulates EGF receptor expression and cancer cell survival via microrna-7. +other hsa-mir-7-2 Neoplasms [unspecific] 21592959 USP18 regulates EGF receptor expression and cancer cell survival via microrna-7. +other hsa-mir-7-3 Neoplasms [unspecific] 21592959 USP18 regulates EGF receptor expression and cancer cell survival via microrna-7. +other hsa-mir-214 Melanoma 21593728 miR-214 drives melanoma metastasis. +other hsa-mir-29a Hepatitis C Virus Infection 21606534 Hepatitis C Virus Infection and Hepatic Stellate Cell Activation Downregulate miR-29: miR-29 Overexpression Reduces Hepatitis C Viral Abundance in Culture. +other hsa-mir-29b-1 Hepatitis C Virus Infection 21606534 Hepatitis C Virus Infection and Hepatic Stellate Cell Activation Downregulate miR-29: miR-29 Overexpression Reduces Hepatitis C Viral Abundance in Culture. +other hsa-mir-29b-2 Hepatitis C Virus Infection 21606534 Hepatitis C Virus Infection and Hepatic Stellate Cell Activation Downregulate miR-29: miR-29 Overexpression Reduces Hepatitis C Viral Abundance in Culture. +other hsa-mir-29c Hepatitis C Virus Infection 21606534 Hepatitis C Virus Infection and Hepatic Stellate Cell Activation Downregulate miR-29: miR-29 Overexpression Reduces Hepatitis C Viral Abundance in Culture. +other hsa-mir-26a-1 "Carcinoma, Hepatocellular" 21610700 Tumor-specific Expression of MicroRNA-26a Suppresses Human Hepatocellular Carcinoma Growth via Cyclin-dependent and -independent Pathways. +other hsa-mir-26a-2 "Carcinoma, Hepatocellular" 21610700 Tumor-specific Expression of MicroRNA-26a Suppresses Human Hepatocellular Carcinoma Growth via Cyclin-dependent and -independent Pathways. +other hsa-mir-346 Rheumatoid Arthritis 21611196 miR-346 Controls Release of TNF-a Protein and Stability of Its mRNA in Rheumatoid Arthritis via Tristetraprolin Stabilization. +other hsa-mir-21 Diabetes Mellitus 21613227 microRNA-21 orchestrates high glucose-induced signals to TORC1 for renal cell pathology in diabetes. +other hsa-mir-21 Glioblastoma 21618027 A miR-21 inhibitor enhances apoptosis and reduces G(2)-M accumulation induced by ionizing radiation in human glioblastoma U251 cells. +other hsa-let-7 Ovarian Neoplasms 21618519 Let-7 modulates acquired resistance of ovarian cancer to Taxanes via IMP-1-mediated stabilization of multidrug resistance 1. +other hsa-mir-183 Congenital Deafness 21621863 The quantitative real-time polymerase chain reaction result demonstrated that the miR-183 family exhibits cell-specific expression in cochlear progenitor cells compared with neural stem cells. +other hsa-mir-34a Pancreatic Neoplasms 21622730 "Two miRNA candidates known to be downregulated in the majority of pancreatic cancers were selected for nanovector delivery: miR-34a, which is a component of the p53 transcriptional network and regulates cancer stem cell survival, and the miR-143/145 cluster, which together repress the expression of KRAS2 and its downstream effector Ras-responsive element binding protein-1 (RREB1)." +other hsa-mir-22 Colorectal Carcinoma 21629773 MicroRNA-22 regulates hypoxia signaling in colon cancer cells. +other hsa-mir-1246 Down Syndrome 21637297 p53 downregulates Down syndrome-associated DYRK1A through miR-1246. +other hsa-mir-130a "Leukemia, Myeloid" 21638198 MicroRNAs 130a/b are regulated by BCR-ABL and downregulate expression of CCN3 in CML (Chronic Myeloid Leukaemia). +other hsa-mir-130b "Leukemia, Myeloid" 21638198 MicroRNAs 130a/b are regulated by BCR-ABL and downregulate expression of CCN3 in CML (Chronic Myeloid Leukaemia). +other hsa-mir-21 Wounds and Injuries [unspecific] 21647251 miR-21 promotes keratinocyte migration and re-epithelialization during wound healing. +other hsa-mir-143 Prostate Neoplasms 21647377 miRs-143 and -145 are associated with bone metastasis of prostate cancer and involved in the regulation of EMT. +other hsa-mir-145 Prostate Neoplasms 21647377 miRs-143 and -145 are associated with bone metastasis of prostate cancer and involved in the regulation of EMT. +other hsa-mir-10b Pancreatic Neoplasms 21652542 microRNA-10b Expression Correlates with Response to Neoadjuvant Therapy and Survival in Pancreatic Ductal Adenocarcinoma. +other hsa-mir-122 Hepatitis C Virus Infection 21653556 miR-122 activates hepatitis C virus translation by a specialized mechanism requiring particular RNA components. +other hsa-mir-143 Colon Neoplasms 21653642 "EGFR suppresses miR-143 and miR-145 in murine models of colon cancer. Furthermore, Western diet unmasks the tumor suppressor roles of these EGFR-regulated miRNAs." +other hsa-mir-145 Colon Neoplasms 21653642 "EGFR suppresses miR-143 and miR-145 in murine models of colon cancer. Furthermore, Western diet unmasks the tumor suppressor roles of these EGFR-regulated miRNAs." +other hsa-mir-103a-1 "Diabetes Mellitus, Type 2" 21654750 MicroRNAs 103 and 107 regulate insulin sensitivity. +other hsa-mir-103a-2 "Diabetes Mellitus, Type 2" 21654750 MicroRNAs 103 and 107 regulate insulin sensitivity. +other hsa-mir-17 Multiple Myeloma 21664042 miR-17-92 cluster microRNAs confers tumorigenicity in multiple myeloma. +other hsa-mir-18a Multiple Myeloma 21664042 miR-17-92 cluster microRNAs confers tumorigenicity in multiple myeloma. +other hsa-mir-19a Multiple Myeloma 21664042 miR-17-92 cluster microRNAs confers tumorigenicity in multiple myeloma. +other hsa-mir-19b-1 Multiple Myeloma 21664042 miR-17-92 cluster microRNAs confers tumorigenicity in multiple myeloma. +other hsa-mir-20a Multiple Myeloma 21664042 miR-17-92 cluster microRNAs confers tumorigenicity in multiple myeloma. +other hsa-mir-92a-1 Multiple Myeloma 21664042 miR-17-92 cluster microRNAs confers tumorigenicity in multiple myeloma. +other hsa-mir-483 Wounds and Injuries [unspecific] 21676945 miR-483-3p controls proliferation in wounded epithelial cells. +other hsa-mir-429 Gastric Neoplasms 21684154 miR-429 Modulates the expression of c-myc in human gastric carcinoma cells. +other hsa-mir-21 "Squamous Cell Carcinoma, Head and Neck" 21685938 Stem cell marker (Nanog) and Stat-3 signaling promote MicroRNA-21 expression and chemoresistance in hyaluronan/CD44-activated head and neck squamous cell carcinoma cells. +other hsa-mir-143 Liposarcoma 21693658 microRNA-143 is a tumor suppressor activity in liposarcoma +other hsa-mir-34a Urinary Bladder Cancer 21702042 MiR-34a chemo-sensitizes bladder cancer cells to cisplatin treatment regardless of P53-Rb pathway status. +other hsa-mir-125b-1 "Carcinoma, Hepatocellular" 21703189 microRNA-125b regulates of placenta growth factor in hepatocellular cancer +other hsa-mir-125b-2 "Carcinoma, Hepatocellular" 21703189 microRNA-125b regulates of placenta growth factor in hepatocellular cancer +other hsa-mir-519d Prostate Neoplasms 21703393 "miR-519d,and miR-647 could be used to separate patients with and without biochemical recurrence" +other hsa-mir-647 Prostate Neoplasms 21703393 "miR-519d,and miR-647 could be used to separate patients with and without biochemical recurrence" +other hsa-mir-378a Myelodysplastic Syndromes 21703983 "hsa-mir-378, hsa-miR-632, and hsa-miR-636 demonstrated particularly high discrimination between MDS and normal controls." +other hsa-mir-632 Myelodysplastic Syndromes 21703983 "hsa-mir-378, hsa-miR-632, and hsa-miR-636 demonstrated particularly high discrimination between MDS and normal controls." +other hsa-mir-636 Myelodysplastic Syndromes 21703983 "hsa-mir-378, hsa-miR-632, and hsa-miR-636 demonstrated particularly high discrimination between MDS and normal controls." +other hsa-mir-130a "Carcinoma, Hepatocellular" 21712254 The hepatitis B virus-associated estrogen receptor alpha (ER{alpha}) was regulated by microRNA-130a in HepG2.2.15 human hepatocellular carcinoma cells. +other hsa-mir-21 Cardiovascular Diseases [unspecific] 21712654 "The small regulatory RNA microRNA-21 (miR-21) plays a crucial role in a plethora of biological functions and diseases including development, cancer, cardiovascular diseases and inflammation." +other hsa-mir-21 Multiple Myeloma 21718132 Myeloma cell adhesion to bone marrow stromal cells confers drug resistance by microRNA-21 up-regulation. +other hsa-let-7b Colorectal Carcinoma 21722265 The miRNA has a role in colorectal liver metastases. +other hsa-mir-1275 Colorectal Carcinoma 21722265 The miRNA has a role in colorectal liver metastases. +other hsa-mir-143 Colorectal Carcinoma 21722265 The miRNA has a role in colorectal liver metastases. +other hsa-mir-145 Colorectal Carcinoma 21722265 The miRNA has a role in colorectal liver metastases. +other hsa-mir-194-1 Colorectal Carcinoma 21722265 The miRNA has a role in colorectal liver metastases. +other hsa-mir-194-2 Colorectal Carcinoma 21722265 The miRNA has a role in colorectal liver metastases. +other hsa-mir-19b-1 Colorectal Carcinoma 21722265 The miRNA has a role in colorectal liver metastases. +other hsa-mir-19b-2 Colorectal Carcinoma 21722265 The miRNA has a role in colorectal liver metastases. +other hsa-mir-638 Colorectal Carcinoma 21722265 The miRNA has a role in colorectal liver metastases. +other hsa-mir-375 Melanoma 21723283 "Ectopic expression of miR-375 inhibited melanoma cell proliferation, invasion, and cell motility, and induced cell shape changes, strongly suggesting that miR-375 may have an important function in the development and progression of human melanomas." +other hsa-mir-141 Prostate Neoplasms 21723797 miR-141 demonstrated high correlation with changes of the other biomarkers. +other hsa-let-7d "Squamous Cell Carcinoma, Oral" 21725603 Let-7d functions as novel regulator of epithelial-mesenchymal transition and chemoresistant property in oral cancer. +other hsa-mir-141 Choriocarcinoma 21726338 Reduction in miR-141 is induced by leukemia inhibitory factor and inhibits proliferation in choriocarcinoma cell line JEG-3. +other hsa-mir-125b "Leukemia-Lymphoma, Precursor B-Cell Lymphoblastic" 21738213 Our results provide direct evidence that miR-125b has important roles in the tumorigenesis of precursor B cells. +other hsa-mir-210 Breast Neoplasms 21738599 "MiR-210 associated with tumor proliferation, invasion and poor clinical outcome in breast cancer." +other hsa-let-7i Immune System Disease [unspecific] 21742974 Dynamic regulation of let-7i may fine-tune immune responses by inducing Ag-specific immune tolerance. +other hsa-mir-1286 Esophageal Neoplasms 21743970 "Thirteen miRNAs (miR-199a-5p, miR-302f, miR-320a, miR-342-3p, miR-425, miR-455-3p, miR-486-3p, miR-519c-5p, miR-548d-5p, miR-617, miR-758, miR-766, miR-1286) were deregulated after 24- and/or 72-h treatment by Chemotherapy." +other hsa-mir-199a-1 Esophageal Neoplasms 21743970 "Thirteen miRNAs (miR-199a-5p, miR-302f, miR-320a, miR-342-3p, miR-425, miR-455-3p, miR-486-3p, miR-519c-5p, miR-548d-5p, miR-617, miR-758, miR-766, miR-1286) were deregulated after 24- and/or 72-h treatment by Chemotherapy." +other hsa-mir-199a-2 Esophageal Neoplasms 21743970 "Thirteen miRNAs (miR-199a-5p, miR-302f, miR-320a, miR-342-3p, miR-425, miR-455-3p, miR-486-3p, miR-519c-5p, miR-548d-5p, miR-617, miR-758, miR-766, miR-1286) were deregulated after 24- and/or 72-h treatment by Chemotherapy." +other hsa-mir-302a Esophageal Neoplasms 21743970 "Thirteen miRNAs (miR-199a-5p, miR-302f, miR-320a, miR-342-3p, miR-425, miR-455-3p, miR-486-3p, miR-519c-5p, miR-548d-5p, miR-617, miR-758, miR-766, miR-1286) were deregulated after 24- and/or 72-h treatment by Chemotherapy." +other hsa-mir-302f Esophageal Neoplasms 21743970 "Thirteen miRNAs (miR-199a-5p, miR-302f, miR-320a, miR-342-3p, miR-425, miR-455-3p, miR-486-3p, miR-519c-5p, miR-548d-5p, miR-617, miR-758, miR-766, miR-1286) were deregulated after 24- and/or 72-h treatment by Chemotherapy." +other hsa-mir-342 Esophageal Neoplasms 21743970 "Thirteen miRNAs (miR-199a-5p, miR-302f, miR-320a, miR-342-3p, miR-425, miR-455-3p, miR-486-3p, miR-519c-5p, miR-548d-5p, miR-617, miR-758, miR-766, miR-1286) were deregulated after 24- and/or 72-h treatment by Chemotherapy." +other hsa-mir-425 Esophageal Neoplasms 21743970 "Thirteen miRNAs (miR-199a-5p, miR-302f, miR-320a, miR-342-3p, miR-425, miR-455-3p, miR-486-3p, miR-519c-5p, miR-548d-5p, miR-617, miR-758, miR-766, miR-1286) were deregulated after 24- and/or 72-h treatment by Chemotherapy." +other hsa-mir-455 Esophageal Neoplasms 21743970 "Thirteen miRNAs (miR-199a-5p, miR-302f, miR-320a, miR-342-3p, miR-425, miR-455-3p, miR-486-3p, miR-519c-5p, miR-548d-5p, miR-617, miR-758, miR-766, miR-1286) were deregulated after 24- and/or 72-h treatment by Chemotherapy." +other hsa-mir-486 Esophageal Neoplasms 21743970 "Thirteen miRNAs (miR-199a-5p, miR-302f, miR-320a, miR-342-3p, miR-425, miR-455-3p, miR-486-3p, miR-519c-5p, miR-548d-5p, miR-617, miR-758, miR-766, miR-1286) were deregulated after 24- and/or 72-h treatment by Chemotherapy." +other hsa-mir-519c Esophageal Neoplasms 21743970 "Thirteen miRNAs (miR-199a-5p, miR-302f, miR-320a, miR-342-3p, miR-425, miR-455-3p, miR-486-3p, miR-519c-5p, miR-548d-5p, miR-617, miR-758, miR-766, miR-1286) were deregulated after 24- and/or 72-h treatment by Chemotherapy." +other hsa-mir-548d-1 Esophageal Neoplasms 21743970 "Thirteen miRNAs (miR-199a-5p, miR-302f, miR-320a, miR-342-3p, miR-425, miR-455-3p, miR-486-3p, miR-519c-5p, miR-548d-5p, miR-617, miR-758, miR-766, miR-1286) were deregulated after 24- and/or 72-h treatment by Chemotherapy." +other hsa-mir-548d-2 Esophageal Neoplasms 21743970 "Thirteen miRNAs (miR-199a-5p, miR-302f, miR-320a, miR-342-3p, miR-425, miR-455-3p, miR-486-3p, miR-519c-5p, miR-548d-5p, miR-617, miR-758, miR-766, miR-1286) were deregulated after 24- and/or 72-h treatment by Chemotherapy." +other hsa-mir-617 Esophageal Neoplasms 21743970 "Thirteen miRNAs (miR-199a-5p, miR-302f, miR-320a, miR-342-3p, miR-425, miR-455-3p, miR-486-3p, miR-519c-5p, miR-548d-5p, miR-617, miR-758, miR-766, miR-1286) were deregulated after 24- and/or 72-h treatment by Chemotherapy." +other hsa-mir-758 Esophageal Neoplasms 21743970 "Thirteen miRNAs (miR-199a-5p, miR-302f, miR-320a, miR-342-3p, miR-425, miR-455-3p, miR-486-3p, miR-519c-5p, miR-548d-5p, miR-617, miR-758, miR-766, miR-1286) were deregulated after 24- and/or 72-h treatment by Chemotherapy." +other hsa-mir-766 Esophageal Neoplasms 21743970 "Thirteen miRNAs (miR-199a-5p, miR-302f, miR-320a, miR-342-3p, miR-425, miR-455-3p, miR-486-3p, miR-519c-5p, miR-548d-5p, miR-617, miR-758, miR-766, miR-1286) were deregulated after 24- and/or 72-h treatment by Chemotherapy." +other hsa-mir-22 "Carcinoma, Hepatocellular" 21750200 miR-22 promotes HBV related hepatocellular carcinoma development in males. +other hsa-mir-103a-1 Hypertension 21753805 MicroRNA-130a Mediates Proliferation of Vascular Smooth Muscle Cells in Hypertension. +other hsa-mir-103a-2 Hypertension 21753805 MicroRNA-130a Mediates Proliferation of Vascular Smooth Muscle Cells in Hypertension. +other hsa-mir-18a Breast Neoplasms 21755340 "miR-18a expression was much higher in ERa-negative than in ERa-positive tumors (P < 0.0001), with the expression levels of miR-18a not differing in ERa-positive breast cancer as a function of ERa protein level." +other hsa-mir-18b Breast Neoplasms 21755340 "Low miR-18b expression was significantly associated with improved survival in HER2-negative breast cancer, although miR-18b expression was not correlated with ERa protein expression." +other hsa-mir-193b Breast Neoplasms 21755340 "The expression levels of miR-193b and miR-221 were significantly lower in ERa-negative than in ERa-positive tumors (P = 0.0015 and P = 0.0045, respectively), and the levels of these miRNAs gradually increased as ERa protein expression increased." +other hsa-mir-221 Breast Neoplasms 21755340 "The expression levels of miR-193b and miR-221 were significantly lower in ERa-negative than in ERa-positive tumors (P = 0.0015 and P = 0.0045, respectively), and the levels of these miRNAs gradually increased as ERa protein expression increased." +other hsa-mir-542 Neoplasms [unspecific] 21756784 "miR-542-3p affects carcinogenesis induced by anti-benzo(a) pyrene-7,8-diol-9,10-epoxide" +other hsa-mir-130b Multiple Myeloma 21761344 "miR-130b, miR-181a, and miR-636 to be differentially expressed between GC-sensitive and GC-resistant MM.1 cell lines." +other hsa-mir-181a-1 Multiple Myeloma 21761344 "miR-130b, miR-181a, and miR-636 to be differentially expressed between GC-sensitive and GC-resistant MM.1 cell lines." +other hsa-mir-181a-2 Multiple Myeloma 21761344 "miR-130b, miR-181a, and miR-636 to be differentially expressed between GC-sensitive and GC-resistant MM.1 cell lines." +other hsa-mir-636 Multiple Myeloma 21761344 "miR-130b, miR-181a, and miR-636 to be differentially expressed between GC-sensitive and GC-resistant MM.1 cell lines." +other hsa-mir-155 Lung Neoplasms 21762626 "miR-155 could significantly inhibit the growth of human lung cancer 95D cells in vitro, which might be closely related to miR-155 induced G0/G1 phase arrest." +other hsa-mir-138-1 "Squamous Cell Carcinoma, Head and Neck" 21770894 MicroRNA-138 suppresses epithelial-mesenchymal transition in squamous cell carcinoma cell lines. +other hsa-mir-138-2 "Squamous Cell Carcinoma, Head and Neck" 21770894 MicroRNA-138 suppresses epithelial-mesenchymal transition in squamous cell carcinoma cell lines. +other hsa-mir-21 Medulloblastoma 21775132 MicroRNA-21 suppression impedes medulloblastoma cell migration. +other hsa-mir-221 Pancreatic Neoplasms 21779484 The miRNA is Potentially Associated with Antiproliferative Activity of Benzyl Isothiocyanate in Pancreatic Cancer +other hsa-mir-375 Pancreatic Neoplasms 21779484 The miRNA is Potentially Associated with Antiproliferative Activity of Benzyl Isothiocyanate in Pancreatic Cancer +other hsa-mir-29a Renal Fibrosis 21784902 TGF-{beta}/Smad3 Signaling Promotes Renal Fibrosis by Inhibiting miR-29. +other hsa-mir-29b-1 Renal Fibrosis 21784902 TGF-{beta}/Smad3 Signaling Promotes Renal Fibrosis by Inhibiting miR-29. +other hsa-mir-29b-2 Renal Fibrosis 21784902 TGF-{beta}/Smad3 Signaling Promotes Renal Fibrosis by Inhibiting miR-29. +other hsa-mir-29c Renal Fibrosis 21784902 TGF-{beta}/Smad3 Signaling Promotes Renal Fibrosis by Inhibiting miR-29. +other hsa-mir-203 "Carcinoma, Hepatocellular" 21786180 miR-203 expression predicts outcome after liver transplantation for hepatocellular carcinoma in cirrhotic liver. +other hsa-mir-138-1 "Carcinoma, Lung, Non-Small-Cell" 21787234 miR-138 could play an important role in the development of cisplatin resistance in non-small cell lung cancer (NSCLC) +other hsa-mir-138-2 "Carcinoma, Lung, Non-Small-Cell" 21787234 miR-138 could play an important role in the development of cisplatin resistance in non-small cell lung cancer (NSCLC) +other hsa-mir-205 Breast Neoplasms 21787752 ErbB2 down-regulates microRNA-205 in breast cancer. +other hsa-mir-155 Encephalomyelitis 21788439 Silencing MicroRNA-155 Ameliorates Experimental Autoimmune Encephalomyelitis. +other hsa-mir-24-1 Myocardial Infarction 21788589 MicroRNA-24 Regulates Vascularity After Myocardial Infarction +other hsa-mir-24-2 Myocardial Infarction 21788589 MicroRNA-24 Regulates Vascularity After Myocardial Infarction +other hsa-mir-19b-1 Antiphospholipid Syndrome 21794077 Down-regulation of miR-19b and miR-20a observed in patients with SLE and SAF could contribute to increase TF expression and thus provoke the hypercoagulable state characteristic of these patients. +other hsa-mir-19b-1 Systemic Lupus Erythematosus 21794077 Down-regulation of miR-19b and miR-20a observed in patients with SLE and SAF could contribute to increase TF expression and thus provoke the hypercoagulable state characteristic of these patients. +other hsa-mir-20a Antiphospholipid Syndrome 21794077 Down-regulation of miR-19b and miR-20a observed in patients with SLE and SAF could contribute to increase TF expression and thus provoke the hypercoagulable state characteristic of these patients. +other hsa-mir-20a Systemic Lupus Erythematosus 21794077 Down-regulation of miR-19b and miR-20a observed in patients with SLE and SAF could contribute to increase TF expression and thus provoke the hypercoagulable state characteristic of these patients. +other hsa-mir-155 Acute Coronary Syndrome 21804579 The altered expression of inflammation-related microRNAs with microRNA-155 expression correlates with Th17 differentiation in patients with acute coronary syndrome. +other hsa-mir-155 Colorectal Carcinoma 21806946 "Neurotensin Signaling Activates MicroRNAs -21 and -155 and Akt, Promotes Tumor Growth in Mice, and is Increased in Human Colon Tumors." +other hsa-mir-21 Colorectal Carcinoma 21806946 "Neurotensin Signaling Activates MicroRNAs -21 and -155 and Akt, Promotes Tumor Growth in Mice, and is Increased in Human Colon Tumors." +other hsa-mir-1-1 Acute Coronary Syndrome 21806992 The miRNA was independently associated with hsTnT levels. +other hsa-mir-1-2 Acute Coronary Syndrome 21806992 The miRNA was independently associated with hsTnT levels. +other hsa-mir-133a-1 Acute Coronary Syndrome 21806992 The miRNA was independently associated with hsTnT levels. Its level was significantly associated with the risk of death in univariate and age- and gender-adjusted analyses. +other hsa-mir-133a-2 Acute Coronary Syndrome 21806992 The miRNA was independently associated with hsTnT levels. Its level was significantly associated with the risk of death in univariate and age- and gender-adjusted analyses. +other hsa-mir-133b Acute Coronary Syndrome 21806992 The miRNA was independently associated with hsTnT levels. +other hsa-mir-208b Acute Coronary Syndrome 21806992 The miRNA was independently associated with hsTnT levels. Its level was significantly associated with the risk of death in univariate and age- and gender-adjusted analyses. +other hsa-mir-637 "Carcinoma, Hepatocellular" 21809363 Primate-specific miRNA-637 inhibits tumorigenesis in hepatocellular carcinoma by disrupting stat3 signaling. +other hsa-mir-17 Retinoblastoma 21816922 miR-17~92 cooperates with RB pathway mutations to promote retinoblastoma. +other hsa-mir-18a Retinoblastoma 21816922 miR-17~92 cooperates with RB pathway mutations to promote retinoblastoma. +other hsa-mir-19a Retinoblastoma 21816922 miR-17~92 cooperates with RB pathway mutations to promote retinoblastoma. +other hsa-mir-19b-1 Retinoblastoma 21816922 miR-17~92 cooperates with RB pathway mutations to promote retinoblastoma. +other hsa-mir-20a Retinoblastoma 21816922 miR-17~92 cooperates with RB pathway mutations to promote retinoblastoma. +other hsa-mir-92a-1 Retinoblastoma 21816922 miR-17~92 cooperates with RB pathway mutations to promote retinoblastoma. +other hsa-mir-21 Atherosclerosis 21817107 MicroRNA-21 Regulates Vascular Smooth Muscle Cell Function via Targeting Tropomyosin 1 in Arteriosclerosis Obliterans of Lower Extremities. +other hsa-mir-101-1 Ovarian Neoplasms 21818714 MicroRNA-101 Inhibits Growth of Epithelial Ovarian Cancer by Relieving Chromatin-Mediated Transcriptional Repression of p21(waf1/cip1). +other hsa-mir-101-2 Ovarian Neoplasms 21818714 MicroRNA-101 Inhibits Growth of Epithelial Ovarian Cancer by Relieving Chromatin-Mediated Transcriptional Repression of p21(waf1/cip1). +other hsa-mir-155 Pancreatic Neoplasms 21826251 preferential expression in holoclones +other hsa-mir-21 Pancreatic Neoplasms 21826251 preferential expression in holoclones +other hsa-mir-214 Pancreatic Neoplasms 21826251 preferential expression in holoclones +other hsa-mir-221 Pancreatic Neoplasms 21826251 preferential expression in holoclones +other hsa-mir-222 Pancreatic Neoplasms 21826251 preferential expression in holoclones +other hsa-mir-155 "Lymphoma, Burkitt" 21831295 miR-93 repressed human activation induced cytidine deaminase. +other hsa-mir-93 "Lymphoma, Burkitt" 21831295 miR-93 repressed human activation induced cytidine deaminase. +other hsa-mir-203 Urinary Bladder Cancer 21836020 Curcumin modulates microRNA-203 mediated regulation of the Src-Akt axis in bladder cancer. +other hsa-mir-15a Leukemia 21838537 These data indicate that miR-15a/16-1 plays an important role in the ATRA-induced differentiation of leukemic and primary AML cells. +other hsa-mir-184 "Carcinoma, Renal Cell" 21844955 miR-184 show abnormal expression in human renal carcinoma. +other hsa-mir-194-1 Gastric Neoplasms 21845495 There is an inverse Association between miR-194 Expression and Tumor Invasion in Gastric Cancer. +other hsa-mir-194-2 Gastric Neoplasms 21845495 There is an inverse Association between miR-194 Expression and Tumor Invasion in Gastric Cancer. +other hsa-mir-874 "Squamous Cell Carcinoma, Maxillary Sinus" 21847129 Tumour suppressive microRNA-874 regulates novel cancer networks in maxillary sinus squamous cell carcinoma. +other hsa-mir-708 "Carcinoma, Renal Cell" 21852381 MicroRNA-708 induces apoptosis and suppresses tumorigenicity in renal cancer cells. +other hsa-mir-21 Renal Fibrosis 21852586 Smad3-Mediated Upregulation of miR-21 Promotes Renal Fibrosis. +other hsa-mir-126 Ischemia 21856785 MicroRNA-126 modulates endothelial SDF-1 expression and mobilization of Sca-1+/Lin- progenitor cells in ischemia. +other hsa-mir-203 "Leukemia-Lymphoma, Adult T-Cell" 21865341 repressed +other hsa-mir-205 "Leukemia-Lymphoma, Adult T-Cell" 21865341 repressed +other hsa-mir-326 "Leukemia-Lymphoma, Adult T-Cell" 21865341 induced +other hsa-mir-663a "Leukemia-Lymphoma, Adult T-Cell" 21865341 induced +other hsa-mir-711 "Leukemia-Lymphoma, Adult T-Cell" 21865341 induced +other hsa-mir-15b Influenza 21872652 Ginsenoside metabolite protopanaxatriol showed significant suppression effect on IP-10 production upon H9N2/G1 infection through up-regulation of miR-15b expression. +other hsa-mir-200c Colorectal Carcinoma 21873159 Oncogenic KRAS Regulates miR-200c and miR-221/222 in a 3D-Specific Manner in Colorectal Cancer Cells. +other hsa-mir-221 Colorectal Carcinoma 21873159 Oncogenic KRAS Regulates miR-200c and miR-221/222 in a 3D-Specific Manner in Colorectal Cancer Cells. +other hsa-mir-222 Colorectal Carcinoma 21873159 Oncogenic KRAS Regulates miR-200c and miR-221/222 in a 3D-Specific Manner in Colorectal Cancer Cells. +other hsa-mir-149 Nasopharyngeal Neoplasms 21873783 miR-149 promotes epithelial-mesenchymal transition and invasion in nasopharyngeal carcinoma cells. +other hsa-mir-128-1 Glioblastoma 21874051 Pro-neural miR-128 is a glioma tumor suppressor that targets mitogenic kinases. +other hsa-mir-128-2 Glioblastoma 21874051 Pro-neural miR-128 is a glioma tumor suppressor that targets mitogenic kinases. +other hsa-mir-138-1 "Carcinoma, Renal Cell" 21875287 MiR-138 Suppresses Expression of Hypoxia-inducible factor 1a (HIF-1a) in Clear Cell Renal Cell Carcinoma 786-O Cells. +other hsa-mir-138-2 "Carcinoma, Renal Cell" 21875287 MiR-138 Suppresses Expression of Hypoxia-inducible factor 1a (HIF-1a) in Clear Cell Renal Cell Carcinoma 786-O Cells. +other hsa-mir-31 Neoplasms [unspecific] 21875932 miR-31 is a master regulator of integrins. The expression of miR-31 in cancer cells resulted in a significant repression of these integrin subunits both at the mRNA and protein levels. +other hsa-mir-101-1 "Carcinoma, Hepatocellular" 21876625 potential associated miRNA +other hsa-mir-101-1 Hepatitis B Virus Infection 21876625 potential associated miRNA +other hsa-mir-101-2 "Carcinoma, Hepatocellular" 21876625 potential associated miRNA +other hsa-mir-101-2 Hepatitis B Virus Infection 21876625 potential associated miRNA +other hsa-mir-106a "Carcinoma, Hepatocellular" 21876625 potential associated miRNA +other hsa-mir-106a Hepatitis B Virus Infection 21876625 potential associated miRNA +other hsa-mir-106b "Carcinoma, Hepatocellular" 21876625 potential associated miRNA +other hsa-mir-106b Hepatitis B Virus Infection 21876625 potential associated miRNA +other hsa-mir-18a "Carcinoma, Hepatocellular" 21876625 potential associated miRNA +other hsa-mir-18a Hepatitis B Virus Infection 21876625 potential associated miRNA +other hsa-mir-18b "Carcinoma, Hepatocellular" 21876625 potential associated miRNA +other hsa-mir-18b Hepatitis B Virus Infection 21876625 potential associated miRNA +other hsa-mir-125b-1 "Leukemia, Promyelocytic, Acute" 21880154 Upregulation of microRNA-125b contributes to leukemogenesis and increases drug resistance in pediatric acute promyelocytic leukemia. +other hsa-mir-29a "Leukemia, Myeloid, Acute" 21880628 miR-29a and miR-30c might contribute to the sensitivity to cytarabine +other hsa-mir-30c-1 "Leukemia, Myeloid, Acute" 21880628 miR-29a and miR-30c might contribute to the sensitivity to cytarabine +other hsa-mir-30c-2 "Leukemia, Myeloid, Acute" 21880628 miR-29a and miR-30c might contribute to the sensitivity to cytarabine +other hsa-mir-637 Osteoporosis 21880893 "miR-637 suppressed the growth of hMSCs and induced S-phase arrest. Expression of miR-637 was increased during adipocyte differentiation (AD) whereas it was decreased during osteoblast differentiation (OS), which suggests that miR-637 could act as a mediator of adipo-osteogenic differentiation. Disruption of this differentiation balance leads to various bone-related metabolic diseases, including osteoporosis. Therefore, miR-637 could contributes to osteoporosis." +other hsa-mir-155 Atrophic Gastritis 21880981 MicroRNA-155 Is Essential for the T Cell-Mediated Control of Helicobacter pylori Infection and for the Induction of Chronic Gastritis and Colitis. +other hsa-mir-155 Colitis 21880981 MicroRNA-155 Is Essential for the T Cell-Mediated Control of Helicobacter pylori Infection and for the Induction of Chronic Gastritis and Colitis. +other hsa-mir-15a "Leukemia, Lymphocytic, Chronic, B-Cell" 21881595 Systemic in vivo lentiviral delivery of miR-15a/16 reduces malignancy in the NZB de novo mouse model of chronic lymphocytic leukemia. +other hsa-mir-16 "Leukemia, Lymphocytic, Chronic, B-Cell" 21881595 Systemic in vivo lentiviral delivery of miR-15a/16 reduces malignancy in the NZB de novo mouse model of chronic lymphocytic leukemia. +other hsa-mir-92a-1 Colon Neoplasms 21883694 miR-92 is a key oncogenic component of the miR-17-92 cluster in colon cancer +other hsa-mir-204 Hypertension 21890685 "These effects were associated with the inhibition of Src, STAT3, Pim1, NFATc2, and Survivin and the upregulation of BMPR2 and miR-204." +other hsa-mir-181c Glioblastoma 21895872 Evaluation of the miR-181c in combination with miR-21 predicted time to progression within six months from diagnosis with 92% sensitivity and 81% specificity (p < 0.0001). The combination of miR-181c and miR-21 could be a very sensitive and specific test to identify patients at high risk of early progression after surgery. +other hsa-mir-195 Glioblastoma 21895872 miR-195 (P=0.0124; log-rank test) has positively correlated with overall survival. +other hsa-mir-196b Glioblastoma 21895872 miR-196b (P=0.0492; log-rank test) has positively correlated with overall survival. +other hsa-mir-21 Glioblastoma 21895872 Evaluation of the miR-181c in combination with miR-21 predicted time to progression within six months from diagnosis with 92% sensitivity and 81% specificity (p < 0.0001). The combination of miR-181c and miR-21 could be a very sensitive and specific test to identify patients at high risk of early progression after surgery. +other hsa-mir-149 Melanoma 21896753 "p53 directly up-regulates microRNA-149* (miR-149*) that in turn targets glycogen synthase kinase-3§Ø©ã resulting in increased expression of Mcl-1 and resistance to apoptosis in melanoma cells. Although deficiency in miR-149* undermined survival of melanoma cells and inhibited melanoma growth in a mouse xenograft model, elevated expression of miR-149* was found in fresh human metastatic melanoma isolates, which was associated with decreased glycogen synthase kinase-3§Ø©ãand increased Mcl-1." +other hsa-mir-17 Periodontitis 21898695 MiR-17 Modulates Osteogenic Differentiation Through a Coherent Feed-Forward Loop in Mesenchymal Stem Cells Isolated from Periodontal Ligaments of Patients With Periodontitis. +other hsa-mir-26a-1 "Leukemia, Myeloid, Acute" 21901171 Critical Role of c-Myc in Acute Myeloid Leukemia Involving Direct Regulation of miR-26a and Histone Methyltransferase EZH2. +other hsa-mir-26a-2 "Leukemia, Myeloid, Acute" 21901171 Critical Role of c-Myc in Acute Myeloid Leukemia Involving Direct Regulation of miR-26a and Histone Methyltransferase EZH2. +other hsa-mir-122 Hepatitis B Virus Infection 21902631 "Hybridization between the host-encoded, liver-specific microRNA (miR-122) and the 5'-untranslated region of HCV genome was shown to be required for effective viral RNA replication." +other hsa-mir-122 Hepatitis B Virus Infection 21903935 "miR-122 may down-regulate HBV replication by binding to the viral target sequence, contributing to the persistent/chronic infection of HBV, and that HBV-induced modulation of miR-122 expression may represent a mechanism to facilitate viral pathogenesis." +other hsa-mir-155 Multiple Sclerosis 21908875 "Expression of three neurosteroid synthesis enzyme-specific micro-RNAs (miR-338, miR-155 and miR-491) showed a bias towards induction in patients with multiple sclerosis (P < 0.05)." +other hsa-mir-338 Multiple Sclerosis 21908875 "Expression of three neurosteroid synthesis enzyme-specific micro-RNAs (miR-338, miR-155 and miR-491) showed a bias towards induction in patients with multiple sclerosis (P < 0.05)." +other hsa-mir-491 Multiple Sclerosis 21908875 "Expression of three neurosteroid synthesis enzyme-specific micro-RNAs (miR-338, miR-155 and miR-491) showed a bias towards induction in patients with multiple sclerosis (P < 0.05)." +other hsa-mir-21 Cardiovascular Diseases [unspecific] 21909994 This review highlights the complex roles that miRNA-21 plays in cancer and cardiovascular diseases and its potential clinical applications. +other hsa-mir-16-1 Pancreatic Neoplasms 21913185 miR-16 and miR-196a possessed an independent role in discriminating PCa (pancreatic cancer) from normal and CP. +other hsa-mir-16-2 Pancreatic Neoplasms 21913185 miR-16 and miR-196a possessed an independent role in discriminating PCa (pancreatic cancer) from normal and CP. +other hsa-mir-196a-1 Pancreatic Neoplasms 21913185 miR-16 and miR-196a possessed an independent role in discriminating PCa (pancreatic cancer) from normal and CP. +other hsa-mir-196a-2 Pancreatic Neoplasms 21913185 miR-16 and miR-196a possessed an independent role in discriminating PCa (pancreatic cancer) from normal and CP. +other hsa-mir-125b-1 Hailey-Hailey Disease 21913998 Oxidative stress activation of miR-125b is part of the molecular switch for Hailey-Hailey disease manifestation. +other hsa-mir-122 "Carcinoma, Hepatocellular" 21917968 HepG2 cells expressing miR-122 support the entire hepatitis C virus life cycle. +other hsa-mir-151a Anemia 21921042 Expression of miR-26b and miR-151-3p were both associated with HbF levels at MTD (maximum tolerated dose). +other hsa-mir-26b Anemia 21921042 Expression of miR-26b and miR-151-3p were both associated with HbF levels at MTD (maximum tolerated dose). +other hsa-mir-375 "Squamous Cell Carcinoma, Maxillary Sinus" 21922130 Tumor suppressive microRNA-375 regulates lactate dehydrogenase B in maxillary sinus squamous cell carcinoma. +other hsa-mir-708 "Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic" 21926415 miR-708 was also found to be associated with the in vivo glucocorticoid therapy response and with disease risk stratification. +other hsa-mir-144 Colorectal Carcinoma 21929751 Nanoparticle-based delivery of siDCAMKL-1 increases microRNA-144 and inhibits colorectal cancer tumor growth via a Notch-1 dependent mechanism. +other hsa-mir-150 Lung Neoplasms 21935578 Anti-miR-150 vector can regress A549 lung cancer tumors. +other hsa-mir-15a Multiple Myeloma 21936961 Suppressing miRNA-15a/-16 expression by interleukin-6 enhances drug-resistance in myeloma cells. +other hsa-mir-16-1 Multiple Myeloma 21936961 Suppressing miRNA-15a/-16 expression by interleukin-6 enhances drug-resistance in myeloma cells. +other hsa-mir-15b Glioma 21937590 "MiR-15b and miR-21 were differentially expressed in CSF (cerebrospinal fluid) samples from patients with gliomas, compared to control subjects with various neurologic disorders, including patients with primary CNS lymphoma and carcinomatous brain metastases.In conclusion, the results of this pilot study demonstrate that miR-15b and miR-21 are markers for gliomas, which can be assessed in the CSF by means of qRT-PCR." +other hsa-mir-21 Glioma 21937590 "MiR-15b and miR-21 were differentially expressed in CSF (cerebrospinal fluid) samples from patients with gliomas, compared to control subjects with various neurologic disorders, including patients with primary CNS lymphoma and carcinomatous brain metastases.In conclusion, the results of this pilot study demonstrate that miR-15b and miR-21 are markers for gliomas, which can be assessed in the CSF by means of qRT-PCR." +other hsa-mir-21 Melanoma 21940630 MicroRNA-21 regulates the metastatic behavior of B16 melanoma cells. +other hsa-mir-451a "Leukemia, Myeloid, Chronic" 21944890 miRNA-451 is a putative predictor marker of Imatinib therapy response in chronic myeloid leukemia. +other hsa-mir-126 Atherosclerosis 21946298 "Other known miRNAs,including miR-31, miR17-3p, miR-155, miR-221, miR-222, and miR-126, are important factors in the regulation of vascular inflammation." +other hsa-mir-126 Cardiomegaly 21946298 "Other known miRNAs,including miR-31, miR17-3p, miR-155, miR-221, miR-222, and miR-126, are important factors in the regulation of vascular inflammation." +other hsa-mir-126 Coronary Artery Disease 21946298 "Other known miRNAs,including miR-31, miR17-3p, miR-155, miR-221, miR-222, and miR-126, are important factors in the regulation of vascular inflammation." +other hsa-mir-126 Diabetes Mellitus 21946298 "Other known miRNAs,including miR-31, miR17-3p, miR-155, miR-221, miR-222, and miR-126, are important factors in the regulation of vascular inflammation." +other hsa-mir-126 Hypertension 21946298 "Other known miRNAs,including miR-31, miR17-3p, miR-155, miR-221, miR-222, and miR-126, are important factors in the regulation of vascular inflammation." +other hsa-mir-155 Atherosclerosis 21946298 "Other known miRNAs,including miR-31, miR17-3p, miR-155, miR-221, miR-222, and miR-126, are important factors in the regulation of vascular inflammation." +other hsa-mir-155 Cardiomegaly 21946298 "Other known miRNAs,including miR-31, miR17-3p, miR-155, miR-221, miR-222, and miR-126, are important factors in the regulation of vascular inflammation." +other hsa-mir-155 Coronary Artery Disease 21946298 "Other known miRNAs,including miR-31, miR17-3p, miR-155, miR-221, miR-222, and miR-126, are important factors in the regulation of vascular inflammation." +other hsa-mir-155 Diabetes Mellitus 21946298 "Other known miRNAs,including miR-31, miR17-3p, miR-155, miR-221, miR-222, and miR-126, are important factors in the regulation of vascular inflammation." +other hsa-mir-155 Hypertension 21946298 "Other known miRNAs,including miR-31, miR17-3p, miR-155, miR-221, miR-222, and miR-126, are important factors in the regulation of vascular inflammation." +other hsa-mir-17 Atherosclerosis 21946298 "Other known miRNAs,including miR-31, miR17-3p, miR-155, miR-221, miR-222, and miR-126, are important factors in the regulation of vascular inflammation." +other hsa-mir-17 Cardiomegaly 21946298 "Other known miRNAs,including miR-31, miR17-3p, miR-155, miR-221, miR-222, and miR-126, are important factors in the regulation of vascular inflammation." +other hsa-mir-17 Coronary Artery Disease 21946298 "Other known miRNAs,including miR-31, miR17-3p, miR-155, miR-221, miR-222, and miR-126, are important factors in the regulation of vascular inflammation." +other hsa-mir-17 Diabetes Mellitus 21946298 "Other known miRNAs,including miR-31, miR17-3p, miR-155, miR-221, miR-222, and miR-126, are important factors in the regulation of vascular inflammation." +other hsa-mir-17 Hypertension 21946298 "Other known miRNAs,including miR-31, miR17-3p, miR-155, miR-221, miR-222, and miR-126, are important factors in the regulation of vascular inflammation." +other hsa-mir-221 Atherosclerosis 21946298 "Other known miRNAs,including miR-31, miR17-3p, miR-155, miR-221, miR-222, and miR-126, are important factors in the regulation of vascular inflammation." +other hsa-mir-221 Cardiomegaly 21946298 "Other known miRNAs,including miR-31, miR17-3p, miR-155, miR-221, miR-222, and miR-126, are important factors in the regulation of vascular inflammation." +other hsa-mir-221 Coronary Artery Disease 21946298 "Other known miRNAs,including miR-31, miR17-3p, miR-155, miR-221, miR-222, and miR-126, are important factors in the regulation of vascular inflammation." +other hsa-mir-221 Diabetes Mellitus 21946298 "Other known miRNAs,including miR-31, miR17-3p, miR-155, miR-221, miR-222, and miR-126, are important factors in the regulation of vascular inflammation." +other hsa-mir-221 Hypertension 21946298 "Other known miRNAs,including miR-31, miR17-3p, miR-155, miR-221, miR-222, and miR-126, are important factors in the regulation of vascular inflammation." +other hsa-mir-222 Atherosclerosis 21946298 "Other known miRNAs,including miR-31, miR17-3p, miR-155, miR-221, miR-222, and miR-126, are important factors in the regulation of vascular inflammation." +other hsa-mir-222 Cardiomegaly 21946298 "Other known miRNAs,including miR-31, miR17-3p, miR-155, miR-221, miR-222, and miR-126, are important factors in the regulation of vascular inflammation." +other hsa-mir-222 Coronary Artery Disease 21946298 "Other known miRNAs,including miR-31, miR17-3p, miR-155, miR-221, miR-222, and miR-126, are important factors in the regulation of vascular inflammation." +other hsa-mir-222 Diabetes Mellitus 21946298 "Other known miRNAs,including miR-31, miR17-3p, miR-155, miR-221, miR-222, and miR-126, are important factors in the regulation of vascular inflammation." +other hsa-mir-222 Hypertension 21946298 "Other known miRNAs,including miR-31, miR17-3p, miR-155, miR-221, miR-222, and miR-126, are important factors in the regulation of vascular inflammation." +other hsa-mir-31 Atherosclerosis 21946298 "Other known miRNAs,including miR-31, miR17-3p, miR-155, miR-221, miR-222, and miR-126, are important factors in the regulation of vascular inflammation." +other hsa-mir-31 Cardiomegaly 21946298 "Other known miRNAs,including miR-31, miR17-3p, miR-155, miR-221, miR-222, and miR-126, are important factors in the regulation of vascular inflammation." +other hsa-mir-31 Coronary Artery Disease 21946298 "Other known miRNAs,including miR-31, miR17-3p, miR-155, miR-221, miR-222, and miR-126, are important factors in the regulation of vascular inflammation." +other hsa-mir-31 Diabetes Mellitus 21946298 "Other known miRNAs,including miR-31, miR17-3p, miR-155, miR-221, miR-222, and miR-126, are important factors in the regulation of vascular inflammation." +other hsa-mir-31 Hypertension 21946298 "Other known miRNAs,including miR-31, miR17-3p, miR-155, miR-221, miR-222, and miR-126, are important factors in the regulation of vascular inflammation." +other hsa-mir-548d-1 Pancreatic Neoplasms 21946813 MicroRNA miR-548d Is a Superior Regulator in Pancreatic Cancer. +other hsa-mir-548d-2 Pancreatic Neoplasms 21946813 MicroRNA miR-548d Is a Superior Regulator in Pancreatic Cancer. +other hsa-mir-146a Gastric Neoplasms 21947847 H. pylori related proinflammatory cytokines contribute to the induction of miR-146a in human gastric epithelial cells. +other hsa-mir-451a Colorectal Carcinoma 21948564 "Microrna-451 is Involved in the Self-Renewal, Tumorigenicity and Chemoresistance of Colorectal Cancer Stem Cells." +other hsa-mir-126 Myocardial Infarction 21949332 "miR-223 and miR-197 showed positive associations (multivariable HR 2.19 [95% CI 1.26 to 3.83], p=0.006, and 1.79 [95% CI 1.00 to 3.20], p=0.049) while miR-126 was inversely correlated with disease risk (multivariable HR 0.40 [95% CI 0.22 to 0.73], p=0.003)." +other hsa-mir-197 Myocardial Infarction 21949332 "miR-223 and miR-197 showed positive associations (multivariable HR 2.19 [95% CI 1.26 to 3.83], p=0.006, and 1.79 [95% CI 1.00 to 3.20], p=0.049) while miR-126 was inversely correlated with disease risk (multivariable HR 0.40 [95% CI 0.22 to 0.73], p=0.003)." +other hsa-mir-223 Myocardial Infarction 21949332 "miR-223 and miR-197 showed positive associations (multivariable HR 2.19 [95% CI 1.26 to 3.83], p=0.006, and 1.79 [95% CI 1.00 to 3.20], p=0.049) while miR-126 was inversely correlated with disease risk (multivariable HR 0.40 [95% CI 0.22 to 0.73], p=0.003)." +other hsa-mir-34b Melanoma 21949788 "Expression of miR-34b reduced cell invasion and motility rates of both WM1552C and A375, suggesting that the enhanced cell invasiveness and motility observed in metastatic melanoma cells may be related to their reduced expression of miR-34b." +other hsa-mir-10a Atherosclerosis 21952822 Endothelial inflammation is critically regulated by miRNAs such as miR-126 and miR-10a in vitro and in vivo. +other hsa-mir-126 Atherosclerosis 21952822 Endothelial inflammation is critically regulated by miRNAs such as miR-126 and miR-10a in vitro and in vivo. +other hsa-mir-146a Systemic Lupus Erythematosus 21952984 miR-146a has a role in the pathogenesis of systemic lupus erythematosus with atherosclerosis. +other hsa-mir-135b Pancreatic Neoplasms 21953293 "Using relative qRT-PCR to measure miR-135b normalized to miR-24 in 75 FFPE specimens (42 PDAC and 33 CP) covering a broad range of tumor content, the authors discriminated CP from PDAC with a sensitivity and specificity of 92.9% [95%CI=(80.5,98.5)] and 93.4% [95%CI=(79.8,99.3)], respectively. Therefore, miR-135b could be a novel biomarker for pancreatic ductal adenocarcinoma." +other hsa-mir-200b Lung Neoplasms 21954225 "Stably expressing microRNA-200b in As-p53lowHBECs (human bronchial epithelial cell) abolished Akt and Erk1/2 activation, and completely suppressed cell migration and invasion." +other hsa-mir-34a Dementia 21956116 miR-34a was among the most highly induced miRNAs in HIV-1 Tat-treated neurons. +other hsa-mir-34a Ewing Sarcoma 21960059 "miR-34a and miR490-3p achieved sufficient statistical power to predict prognosis.Patients with the highest expression of miR-34a did not experience adverse events in 5 years; in contrast, patients with the lowest expression recurred within two years." +other hsa-mir-490 Ewing Sarcoma 21960059 miR-34a and miR490-3p achieved sufficient statistical power to predict prognosis. +other hsa-mir-125b-1 Glioblastoma 21961478 altered expression after Polyunsaturated fatty acids (PUFAs) treatment +other hsa-mir-125b-2 Glioblastoma 21961478 altered expression after Polyunsaturated fatty acids (PUFAs) treatment +other hsa-mir-143 Glioblastoma 21961478 altered expression after Polyunsaturated fatty acids (PUFAs) treatment +other hsa-mir-145 Glioblastoma 21961478 altered expression after Polyunsaturated fatty acids (PUFAs) treatment +other hsa-mir-149 Glioblastoma 21961478 altered expression after Polyunsaturated fatty acids (PUFAs) treatment +other hsa-mir-16-1 Glioblastoma 21961478 altered expression after Polyunsaturated fatty acids (PUFAs) treatment +other hsa-mir-16-2 Glioblastoma 21961478 altered expression after Polyunsaturated fatty acids (PUFAs) treatment +other hsa-mir-17 Glioblastoma 21961478 altered expression after Polyunsaturated fatty acids (PUFAs) treatment +other hsa-mir-181a-2 Glioblastoma 21961478 altered expression after Polyunsaturated fatty acids (PUFAs) treatment +other hsa-mir-183 Glioblastoma 21961478 altered expression after Polyunsaturated fatty acids (PUFAs) treatment +other hsa-mir-206 Glioblastoma 21961478 altered expression after Polyunsaturated fatty acids (PUFAs) treatment +other hsa-mir-208a Glioblastoma 21961478 altered expression after Polyunsaturated fatty acids (PUFAs) treatment +other hsa-mir-208b Glioblastoma 21961478 altered expression after Polyunsaturated fatty acids (PUFAs) treatment +other hsa-mir-20a Glioblastoma 21961478 altered expression after Polyunsaturated fatty acids (PUFAs) treatment +other hsa-mir-20b Glioblastoma 21961478 altered expression after Polyunsaturated fatty acids (PUFAs) treatment +other hsa-mir-22 Glioblastoma 21961478 altered expression after Polyunsaturated fatty acids (PUFAs) treatment +other hsa-mir-224 Glioblastoma 21961478 altered expression after Polyunsaturated fatty acids (PUFAs) treatment +other hsa-mir-25 Glioblastoma 21961478 altered expression after Polyunsaturated fatty acids (PUFAs) treatment +other hsa-mir-26a-1 Glioblastoma 21961478 altered expression after Polyunsaturated fatty acids (PUFAs) treatment +other hsa-mir-26a-2 Glioblastoma 21961478 altered expression after Polyunsaturated fatty acids (PUFAs) treatment +other hsa-mir-29a Glioblastoma 21961478 altered expression after Polyunsaturated fatty acids (PUFAs) treatment +other hsa-mir-29c Glioblastoma 21961478 altered expression after Polyunsaturated fatty acids (PUFAs) treatment +other hsa-mir-30c-1 Glioblastoma 21961478 altered expression after Polyunsaturated fatty acids (PUFAs) treatment +other hsa-mir-30c-2 Glioblastoma 21961478 altered expression after Polyunsaturated fatty acids (PUFAs) treatment +other hsa-mir-126 Arteriosclerosis Obliterans 21969012 "Muscle-enriched miR-499 and miR-133a are released from the heart into the coronary circulation on myocardial injury, whereas the vascular miR-126 is consumed during transcoronary passage. " +other hsa-mir-133a Arteriosclerosis Obliterans 21969012 "Muscle-enriched miR-499 and miR-133a are released from the heart into the coronary circulation on myocardial injury, whereas the vascular miR-126 is consumed during transcoronary passage. " +other hsa-mir-499 Arteriosclerosis Obliterans 21969012 "Muscle-enriched miR-499 and miR-133a are released from the heart into the coronary circulation on myocardial injury, whereas the vascular miR-126 is consumed during transcoronary passage. " +other hsa-mir-142 Hepatitis C Virus Infection 21970718 "miR-128a, miR-196a and miR-142-3p were modulated in a concerted fashion in all three HCV clones" +other hsa-mir-196a-1 Hepatitis C Virus Infection 21970718 "miR-128a, miR-196a and miR-142-3p were modulated in a concerted fashion in all three HCV clones" +other hsa-mir-331 Prostate Neoplasms 21971048 The RNA-binding protein HuR opposes the repression of ERBB-2 expression by miR-331-3p in prostate cancer cells. +other hsa-mir-148a Ovarian Neoplasms 21971665 Ovarian Altered expression of miR-152 and miR-148a in ovarian cancer is related to cell proliferation. +other hsa-mir-152 Ovarian Neoplasms 21971665 Ovarian Altered expression of miR-152 and miR-148a in ovarian cancer is related to cell proliferation. +other hsa-mir-212 Heart Failure 21977024 "Conversely, alcohol-mediated inhibition of mTOR/S6K1, down-regulation of INS receptor and growth-inhibitory mir-200 family, and upregulation of mir-212 that promotes fetal gene program may exacerbate CRS-related cardiomyopathy." +other hsa-mir-146a Prostate Neoplasms 21980038 "Microdissected epithelial structures with CgA-positive cell clusters exhibited a more than 5- and 7-fold lower expression of miR-146a and miR-146b-5p than their CgA-negative counterparts. As focal basal cell layer disruptions and the reduction or loss of miR-146a and miR-146b-5p has been documented to correlate with prostate tumor invasion and hormone refractoriness, our findings suggest that aberrant CgA expression in epithelial structures with FBCLD may represent an early sign of these events." +other hsa-mir-126 Prostate Neoplasms 21980368 "miR-16, miR-34a, miR-126*, miR-145, miR-205 have been linked to prostate cancer metastasis" +other hsa-mir-145 Prostate Neoplasms 21980368 "miR-16, miR-34a, miR-126*, miR-145, miR-205 have been linked to prostate cancer metastasis" +other hsa-mir-16-1 Prostate Neoplasms 21980368 "miR-16, miR-34a, miR-126*, miR-145, miR-205 have been linked to prostate cancer metastasis" +other hsa-mir-16-2 Prostate Neoplasms 21980368 "miR-16, miR-34a, miR-126*, miR-145, miR-205 have been linked to prostate cancer metastasis" +other hsa-mir-205 Prostate Neoplasms 21980368 "miR-16, miR-34a, miR-126*, miR-145, miR-205 have been linked to prostate cancer metastasis" +other hsa-mir-34a Prostate Neoplasms 21980368 "miR-16, miR-34a, miR-126*, miR-145, miR-205 have been linked to prostate cancer metastasis" +other hsa-mir-146a "Carcinoma, Hepatocellular" 21982769 miR-146a suppresses the sensitivity to interferon-a in hepatocellular carcinoma cells. +other hsa-mir-206 "Carcinoma, Endometrioid Endometrial" 21983130 Expression of the tumor suppressor miR-206 is associated with cellular proliferative inhibition and impairs invasion in ER§Ø©ãpositive endometrioid adenocarcinoma. +other hsa-mir-205 Mesothelioma 21983934 "our findings indicate that epithelial-mesenchymal transition has a significant part in the morphological features of malignant mesothelioma. In particular, miR-205 down-regulation correlated ignificantly with both a mesenchymal phenotype and a more aggressive behavior." +other hsa-mir-15a "Lymphoma, Mantle-Cell" 22002311 Myc represses miR-15a/miR-16-1 expression through recruitment of HDAC3 in mantle cell and other non-Hodgkin B-cell lymphomas. +other hsa-mir-16-1 "Lymphoma, Mantle-Cell" 22002311 Myc represses miR-15a/miR-16-1 expression through recruitment of HDAC3 in mantle cell and other non-Hodgkin B-cell lymphomas. +other hsa-mir-181b Breast Neoplasms 22009755 "In conclusion, miR-221/222 and -181b facilitate growth factor signaling in tamoxifen-resistant breast cancer by down-regulating TIMP3, and corresponding anti-miRs can be used to render these tumors responsive to tamoxifen." +other hsa-mir-221 Breast Neoplasms 22009755 "In conclusion, miR-221/222 and -181b facilitate growth factor signaling in tamoxifen-resistant breast cancer by down-regulating TIMP3, and corresponding anti-miRs can be used to render these tumors responsive to tamoxifen." +other hsa-mir-222 Breast Neoplasms 22009755 "In conclusion, miR-221/222 and -181b facilitate growth factor signaling in tamoxifen-resistant breast cancer by down-regulating TIMP3, and corresponding anti-miRs can be used to render these tumors responsive to tamoxifen." +other hsa-mir-101-1 "Carcinoma, Lung, Non-Small-Cell" 22014955 "The endogenous miR-101 level was similar or lower in 13 NSCLC cell lines but was 11-fold higher in one cell line (H157) than in NL20 cells. Although ectopic miR-101 efficiently decreased the ATM and DNA-PKcs levels and increased the radiosensitization level in H1299, H1975, and A549 cells, it did not change the levels of the miR-101 targets or radiosensitivity in H157 cells." +other hsa-mir-101-2 "Carcinoma, Lung, Non-Small-Cell" 22014955 "The endogenous miR-101 level was similar or lower in 13 NSCLC cell lines but was 11-fold higher in one cell line (H157) than in NL20 cells. Although ectopic miR-101 efficiently decreased the ATM and DNA-PKcs levels and increased the radiosensitization level in H1299, H1975, and A549 cells, it did not change the levels of the miR-101 targets or radiosensitivity in H157 cells." +other hsa-mir-15b "Leukemia, Myeloid, Acute" 22015065 "miR-590-5p, miR-219-5p, miR-15b and miR-628-5p are commonly regulated by IL-3, GM-CSF and G-CSF in acute myeloid leukemia." +other hsa-mir-219 "Leukemia, Myeloid, Acute" 22015065 "miR-590-5p, miR-219-5p, miR-15b and miR-628-5p are commonly regulated by IL-3, GM-CSF and G-CSF in acute myeloid leukemia." +other hsa-mir-219-1 "Leukemia, Myeloid, Acute" 22015065 "miR-590-5p, miR-219-5p, miR-15b and miR-628-5p are commonly regulated by IL-3, GM-CSF and G-CSF in acute myeloid leukemia." +other hsa-mir-590 "Leukemia, Myeloid, Acute" 22015065 "miR-590-5p, miR-219-5p, miR-15b and miR-628-5p are commonly regulated by IL-3, GM-CSF and G-CSF in acute myeloid leukemia." +other hsa-mir-628 "Leukemia, Myeloid, Acute" 22015065 "miR-590-5p, miR-219-5p, miR-15b and miR-628-5p are commonly regulated by IL-3, GM-CSF and G-CSF in acute myeloid leukemia." +other hsa-mir-27a Gastric Neoplasms 22018270 miR-27 promotes human gastric cancer cell metastasis by inducing epithelial-to-mesenchymal transition. +other hsa-mir-27b Gastric Neoplasms 22018270 miR-27 promotes human gastric cancer cell metastasis by inducing epithelial-to-mesenchymal transition. +other hsa-mir-10b Breast Neoplasms 22020939 Cysteine rich 61-connective tissue growth factor-nephroblastoma-overexpressed 5 (CCN5)/Wnt-1-induced signaling protein-2(WISP-2) regulates microRNA-10b via hypoxia-inducible factor-1{alpha}-TWIST signaling networks in human breast cancer cells. +other hsa-mir-340 Coronary Artery Disease 22022480 Platelets in Patients with Premature Coronary Artery Disease Exhibit Upregulation of miRNA340* and miRNA624*. +other hsa-mir-624 Coronary Artery Disease 22022480 Platelets in Patients with Premature Coronary Artery Disease Exhibit Upregulation of miRNA340* and miRNA624*. +other hsa-mir-335 Breast Neoplasms 22034498 Aryl Hydrocarbon Receptor (AHR) Agonists Induce MicroRNA-335 Expression and Inhibit Lung Metastasis of Estrogen Receptor Negative Breast Cancer Cells. +other hsa-mir-101-1 "Carcinoma, Hepatocellular" 22035408 "Benzothiazole based compounds exhibited effective cytotoxicity at 4 M concentration and have shown G1 cell cycle arrest with decrease in levels of G1 cell cycle proteins such as cyclin D1 and Skp2. Involvement of tumour suppressor proteins such as PTEN and p53 was studied. Interestingly these compounds displayed decrease in the phosphorylated forms of AKT, p38 MAPK and ERK1/2 which play a vital role in cell proliferation. Compounds have exhibited strong and significant effect on the expression of micro RNAs such as miR-195a & miR-101-1 which regulate hepatic cell proliferation." +other hsa-mir-15b Anus Neoplasm 22045185 "The expression of miR-15b was shown to be highly correlated with that of five selected E2F-induced genes (CCNA2, CCNB1, CCNB2, MSH6 and MCM7). A knockdown of HPV16 E7 resulted in decreased levels of miR-15b in Ca Ski cells.Conclusion:MiR-15b expression correlates with E2F-regulated genes in anal carcinoma and appears to be part of the E2F-regulatory network." +other hsa-mir-200c "Carcinoma, Lung, Non-Small-Cell" 22045191 "Ectopic expression of mir-200c alters expression of EMT proteins, sensitivity to erlotinib, and migration in lung cells." +other hsa-mir-505 Breast Neoplasms 22051041 "miR-505 is a novel tumor suppressive miRNA and inhibits cell proliferation by inducing apoptosis. We also find that Akt3, correlate inversely with miR-505, modulates drug sensitivity in MCF7-ADR." +other hsa-mir-150 Colorectal Carcinoma 22052060 "Only one miR-150 was found to show a decrease in expression levels in the three tissue groups (normal, adenoma and cancer tissue) in parallel with increasing carcinogenesis of the colorectal tissue. In both ISH and qRT-PCR analysis, tumour tissue had reduced levels of miR-150 expression compared with paired non-cancerous tissue, which indicated that the levels of miR-150 expression were associated with CRC. Moreover, patients whose tumours had low miR-150 expression had shorter survival and a worse response to adjuvant chemotherapy than patients whose tumours had high miRNA expression." +other hsa-mir-378a "Carcinoma, Lung, Non-Small-Cell" 22052152 "MicroRNA-378 is associated with non-small cell lung cancer brain metastasis by promoting cell migration, invasion and tumor angiogenesis." +other hsa-mir-34b "Adenocarcinoma, Endometrial" 22052540 MicroRNA-34b functions as a potential tumor suppressor in endometrial serous adenocarcinoma. +other hsa-mir-155 Ischemia 22052914 Inhibition of miR-15 Protects Against Cardiac Ischemic Injury. +other hsa-let-7d Ependymoma 22053178 "Three miRNAs (let-7d, miR-596 and miR-367) strongly correlate to overall survival." +other hsa-mir-203 Ependymoma 22053178 miR-203 is an independent marker for relapse compared to the parameters that are currently used. +other hsa-mir-367 Ependymoma 22053178 "Three miRNAs (let-7d, miR-596 and miR-367) strongly correlate to overall survival." +other hsa-mir-596 Ependymoma 22053178 "Three miRNAs (let-7d, miR-596 and miR-367) strongly correlate to overall survival." +other hsa-mir-30d Ovarian Neoplasms 22058146 A combined array-based comparative genomic hybridization (aCGH) and functional library screening approach identifies mir-30d as an oncomir in cancer. +other hsa-mir-200a "Carcinoma, Renal Cell" 22082152 MiRNA-9 and MiRNA-200a distinguish hemangioblastomas from metastatic clear cell renal cell carcinomas in the CNS. +other hsa-mir-9-1 "Carcinoma, Renal Cell" 22082152 MiRNA-9 and MiRNA-200a distinguish hemangioblastomas from metastatic clear cell renal cell carcinomas in the CNS. +other hsa-mir-9-2 "Carcinoma, Renal Cell" 22082152 MiRNA-9 and MiRNA-200a distinguish hemangioblastomas from metastatic clear cell renal cell carcinomas in the CNS. +other hsa-mir-9-3 "Carcinoma, Renal Cell" 22082152 MiRNA-9 and MiRNA-200a distinguish hemangioblastomas from metastatic clear cell renal cell carcinomas in the CNS. +other hsa-mir-23a Hypertrophy 22084234 Cardiac hypertrophy is positively regulated by miR-23a. +other hsa-let-7a-1 Pancreatic Neoplasms 22086681 "We found that metformin significantly decreased cell survival, clonogenicity, wound healing capacity, sphere-forming capacity (pancreatospheres), and increased disintegration of pancreatospheres in both gemcitabine-sensitive and gemcitabine-resistant PC cells. Metformin also decreased the expression of CSC markers, CD44, EpCAM, EZH2, Notch-1, Nanog and Oct4, and caused re-expression of miRNAs (let-7a, b, miR-26a, miR-101, and miR-200b, c) that are typically lost in PC and especially in pancreatospheres. We also found that re-expression of miR-26a by transfection led to decreased expression of EZH2 and EpCAM in PC cells." +other hsa-let-7a-2 Pancreatic Neoplasms 22086681 "We found that metformin significantly decreased cell survival, clonogenicity, wound healing capacity, sphere-forming capacity (pancreatospheres), and increased disintegration of pancreatospheres in both gemcitabine-sensitive and gemcitabine-resistant PC cells. Metformin also decreased the expression of CSC markers, CD44, EpCAM, EZH2, Notch-1, Nanog and Oct4, and caused re-expression of miRNAs (let-7a, b, miR-26a, miR-101, and miR-200b, c) that are typically lost in PC and especially in pancreatospheres. We also found that re-expression of miR-26a by transfection led to decreased expression of EZH2 and EpCAM in PC cells." +other hsa-let-7a-3 Pancreatic Neoplasms 22086681 "We found that metformin significantly decreased cell survival, clonogenicity, wound healing capacity, sphere-forming capacity (pancreatospheres), and increased disintegration of pancreatospheres in both gemcitabine-sensitive and gemcitabine-resistant PC cells. Metformin also decreased the expression of CSC markers, CD44, EpCAM, EZH2, Notch-1, Nanog and Oct4, and caused re-expression of miRNAs (let-7a, b, miR-26a, miR-101, and miR-200b, c) that are typically lost in PC and especially in pancreatospheres. We also found that re-expression of miR-26a by transfection led to decreased expression of EZH2 and EpCAM in PC cells." +other hsa-let-7b Pancreatic Neoplasms 22086681 "We found that metformin significantly decreased cell survival, clonogenicity, wound healing capacity, sphere-forming capacity (pancreatospheres), and increased disintegration of pancreatospheres in both gemcitabine-sensitive and gemcitabine-resistant PC cells. Metformin also decreased the expression of CSC markers, CD44, EpCAM, EZH2, Notch-1, Nanog and Oct4, and caused re-expression of miRNAs (let-7a, b, miR-26a, miR-101, and miR-200b, c) that are typically lost in PC and especially in pancreatospheres. We also found that re-expression of miR-26a by transfection led to decreased expression of EZH2 and EpCAM in PC cells." +other hsa-mir-101-1 Pancreatic Neoplasms 22086681 "We found that metformin significantly decreased cell survival, clonogenicity, wound healing capacity, sphere-forming capacity (pancreatospheres), and increased disintegration of pancreatospheres in both gemcitabine-sensitive and gemcitabine-resistant PC cells. Metformin also decreased the expression of CSC markers, CD44, EpCAM, EZH2, Notch-1, Nanog and Oct4, and caused re-expression of miRNAs (let-7a, b, miR-26a, miR-101, and miR-200b, c) that are typically lost in PC and especially in pancreatospheres. We also found that re-expression of miR-26a by transfection led to decreased expression of EZH2 and EpCAM in PC cells." +other hsa-mir-101-2 Pancreatic Neoplasms 22086681 "We found that metformin significantly decreased cell survival, clonogenicity, wound healing capacity, sphere-forming capacity (pancreatospheres), and increased disintegration of pancreatospheres in both gemcitabine-sensitive and gemcitabine-resistant PC cells. Metformin also decreased the expression of CSC markers, CD44, EpCAM, EZH2, Notch-1, Nanog and Oct4, and caused re-expression of miRNAs (let-7a, b, miR-26a, miR-101, and miR-200b, c) that are typically lost in PC and especially in pancreatospheres. We also found that re-expression of miR-26a by transfection led to decreased expression of EZH2 and EpCAM in PC cells." +other hsa-mir-200b Pancreatic Neoplasms 22086681 "We found that metformin significantly decreased cell survival, clonogenicity, wound healing capacity, sphere-forming capacity (pancreatospheres), and increased disintegration of pancreatospheres in both gemcitabine-sensitive and gemcitabine-resistant PC cells. Metformin also decreased the expression of CSC markers, CD44, EpCAM, EZH2, Notch-1, Nanog and Oct4, and caused re-expression of miRNAs (let-7a, b, miR-26a, miR-101, and miR-200b, c) that are typically lost in PC and especially in pancreatospheres. We also found that re-expression of miR-26a by transfection led to decreased expression of EZH2 and EpCAM in PC cells." +other hsa-mir-200c Pancreatic Neoplasms 22086681 "We found that metformin significantly decreased cell survival, clonogenicity, wound healing capacity, sphere-forming capacity (pancreatospheres), and increased disintegration of pancreatospheres in both gemcitabine-sensitive and gemcitabine-resistant PC cells. Metformin also decreased the expression of CSC markers, CD44, EpCAM, EZH2, Notch-1, Nanog and Oct4, and caused re-expression of miRNAs (let-7a, b, miR-26a, miR-101, and miR-200b, c) that are typically lost in PC and especially in pancreatospheres. We also found that re-expression of miR-26a by transfection led to decreased expression of EZH2 and EpCAM in PC cells." +other hsa-mir-26a-1 Pancreatic Neoplasms 22086681 "We found that metformin significantly decreased cell survival, clonogenicity, wound healing capacity, sphere-forming capacity (pancreatospheres), and increased disintegration of pancreatospheres in both gemcitabine-sensitive and gemcitabine-resistant PC cells. Metformin also decreased the expression of CSC markers, CD44, EpCAM, EZH2, Notch-1, Nanog and Oct4, and caused re-expression of miRNAs (let-7a, b, miR-26a, miR-101, and miR-200b, c) that are typically lost in PC and especially in pancreatospheres. We also found that re-expression of miR-26a by transfection led to decreased expression of EZH2 and EpCAM in PC cells." +other hsa-mir-26a-2 Pancreatic Neoplasms 22086681 "We found that metformin significantly decreased cell survival, clonogenicity, wound healing capacity, sphere-forming capacity (pancreatospheres), and increased disintegration of pancreatospheres in both gemcitabine-sensitive and gemcitabine-resistant PC cells. Metformin also decreased the expression of CSC markers, CD44, EpCAM, EZH2, Notch-1, Nanog and Oct4, and caused re-expression of miRNAs (let-7a, b, miR-26a, miR-101, and miR-200b, c) that are typically lost in PC and especially in pancreatospheres. We also found that re-expression of miR-26a by transfection led to decreased expression of EZH2 and EpCAM in PC cells." +other hsa-mir-140 "Hand, Foot And Mouth Disease" 22087245 "A receiver operating characteristic (ROC) curve analysis revealed that six serum miRNAs (miR-148a, miR-143, miR-324-3p, miR-628-3p, miR-140-5p, and miR-362-3p) were able to discriminate patients with enterovirus infections from healthy controls with area under curve (AUC) values ranged from 0.828 to 0.934. The combined six miRNA using multiple logistic regression analysis provided not only a sensitivity of 97.1% and a specificity of 92.7% but also a unique profile that differentiated enterovirial infections from other microbial infections. Expression levels of five miRNAs (miR-148a, miR-143, miR-324-3p, miR-545, and miR-140-5p) were significantly increased in patients with CVA16 versus those with EV71 (p<0.05). Combination of miR-545, miR-324-3p, and miR-143 possessed a moderate ability to discrimination between CVA16 and EV71 with an AUC value of 0.761." +other hsa-mir-143 "Hand, Foot And Mouth Disease" 22087245 "A receiver operating characteristic (ROC) curve analysis revealed that six serum miRNAs (miR-148a, miR-143, miR-324-3p, miR-628-3p, miR-140-5p, and miR-362-3p) were able to discriminate patients with enterovirus infections from healthy controls with area under curve (AUC) values ranged from 0.828 to 0.934. The combined six miRNA using multiple logistic regression analysis provided not only a sensitivity of 97.1% and a specificity of 92.7% but also a unique profile that differentiated enterovirial infections from other microbial infections. Expression levels of five miRNAs (miR-148a, miR-143, miR-324-3p, miR-545, and miR-140-5p) were significantly increased in patients with CVA16 versus those with EV71 (p<0.05). Combination of miR-545, miR-324-3p, and miR-143 possessed a moderate ability to discrimination between CVA16 and EV71 with an AUC value of 0.761." +other hsa-mir-148a "Hand, Foot And Mouth Disease" 22087245 "A receiver operating characteristic (ROC) curve analysis revealed that six serum miRNAs (miR-148a, miR-143, miR-324-3p, miR-628-3p, miR-140-5p, and miR-362-3p) were able to discriminate patients with enterovirus infections from healthy controls with area under curve (AUC) values ranged from 0.828 to 0.934. The combined six miRNA using multiple logistic regression analysis provided not only a sensitivity of 97.1% and a specificity of 92.7% but also a unique profile that differentiated enterovirial infections from other microbial infections. Expression levels of five miRNAs (miR-148a, miR-143, miR-324-3p, miR-545, and miR-140-5p) were significantly increased in patients with CVA16 versus those with EV71 (p<0.05). Combination of miR-545, miR-324-3p, and miR-143 possessed a moderate ability to discrimination between CVA16 and EV71 with an AUC value of 0.761." +other hsa-mir-324 "Hand, Foot And Mouth Disease" 22087245 "A receiver operating characteristic (ROC) curve analysis revealed that six serum miRNAs (miR-148a, miR-143, miR-324-3p, miR-628-3p, miR-140-5p, and miR-362-3p) were able to discriminate patients with enterovirus infections from healthy controls with area under curve (AUC) values ranged from 0.828 to 0.934. The combined six miRNA using multiple logistic regression analysis provided not only a sensitivity of 97.1% and a specificity of 92.7% but also a unique profile that differentiated enterovirial infections from other microbial infections. Expression levels of five miRNAs (miR-148a, miR-143, miR-324-3p, miR-545, and miR-140-5p) were significantly increased in patients with CVA16 versus those with EV71 (p<0.05). Combination of miR-545, miR-324-3p, and miR-143 possessed a moderate ability to discrimination between CVA16 and EV71 with an AUC value of 0.761." +other hsa-mir-362 "Hand, Foot And Mouth Disease" 22087245 "A receiver operating characteristic (ROC) curve analysis revealed that six serum miRNAs (miR-148a, miR-143, miR-324-3p, miR-628-3p, miR-140-5p, and miR-362-3p) were able to discriminate patients with enterovirus infections from healthy controls with area under curve (AUC) values ranged from 0.828 to 0.934. The combined six miRNA using multiple logistic regression analysis provided not only a sensitivity of 97.1% and a specificity of 92.7% but also a unique profile that differentiated enterovirial infections from other microbial infections. Expression levels of five miRNAs (miR-148a, miR-143, miR-324-3p, miR-545, and miR-140-5p) were significantly increased in patients with CVA16 versus those with EV71 (p<0.05). Combination of miR-545, miR-324-3p, and miR-143 possessed a moderate ability to discrimination between CVA16 and EV71 with an AUC value of 0.761." +other hsa-mir-545 "Hand, Foot And Mouth Disease" 22087245 "A receiver operating characteristic (ROC) curve analysis revealed that six serum miRNAs (miR-148a, miR-143, miR-324-3p, miR-628-3p, miR-140-5p, and miR-362-3p) were able to discriminate patients with enterovirus infections from healthy controls with area under curve (AUC) values ranged from 0.828 to 0.934. The combined six miRNA using multiple logistic regression analysis provided not only a sensitivity of 97.1% and a specificity of 92.7% but also a unique profile that differentiated enterovirial infections from other microbial infections. Expression levels of five miRNAs (miR-148a, miR-143, miR-324-3p, miR-545, and miR-140-5p) were significantly increased in patients with CVA16 versus those with EV71 (p<0.05). Combination of miR-545, miR-324-3p, and miR-143 possessed a moderate ability to discrimination between CVA16 and EV71 with an AUC value of 0.761." +other hsa-mir-628 "Hand, Foot And Mouth Disease" 22087245 "A receiver operating characteristic (ROC) curve analysis revealed that six serum miRNAs (miR-148a, miR-143, miR-324-3p, miR-628-3p, miR-140-5p, and miR-362-3p) were able to discriminate patients with enterovirus infections from healthy controls with area under curve (AUC) values ranged from 0.828 to 0.934. The combined six miRNA using multiple logistic regression analysis provided not only a sensitivity of 97.1% and a specificity of 92.7% but also a unique profile that differentiated enterovirial infections from other microbial infections. Expression levels of five miRNAs (miR-148a, miR-143, miR-324-3p, miR-545, and miR-140-5p) were significantly increased in patients with CVA16 versus those with EV71 (p<0.05). Combination of miR-545, miR-324-3p, and miR-143 possessed a moderate ability to discrimination between CVA16 and EV71 with an AUC value of 0.761." +other hsa-mir-133a-1 Lung Neoplasms 22089643 Tumor suppressive microRNA-133a regulates novel molecular networks in lung squamous cell carcinoma. +other hsa-mir-15b Heart Failure 22093502 "The real-time PCR confirmed lower expression in LV recovery patients for 4 miRs (15b, -1.5-fold; 23a, -2.2-fold; 26a, -1.4-fold; and 195, -1.8-fold; all p < 0.04 vs. VAD dependent). The validation cohort similarly showed lower miRs expression in LV recovery patients (23a, -1.8-fold; and 195, -1.5-fold; both p < 0.03). Furthermore, miR 23a and 195 expression in nonfailing hearts was similar to LV recovery patients (both p < 0.04 vs. VAD dependent)." +other hsa-mir-195 Heart Failure 22093502 "The real-time PCR confirmed lower expression in LV recovery patients for 4 miRs (15b, -1.5-fold; 23a, -2.2-fold; 26a, -1.4-fold; and 195, -1.8-fold; all p < 0.04 vs. VAD dependent). The validation cohort similarly showed lower miRs expression in LV recovery patients (23a, -1.8-fold; and 195, -1.5-fold; both p < 0.03). Furthermore, miR 23a and 195 expression in nonfailing hearts was similar to LV recovery patients (both p < 0.04 vs. VAD dependent)." +other hsa-mir-23a Heart Failure 22093502 "The real-time PCR confirmed lower expression in LV recovery patients for 4 miRs (15b, -1.5-fold; 23a, -2.2-fold; 26a, -1.4-fold; and 195, -1.8-fold; all p < 0.04 vs. VAD dependent). The validation cohort similarly showed lower miRs expression in LV recovery patients (23a, -1.8-fold; and 195, -1.5-fold; both p < 0.03). Furthermore, miR 23a and 195 expression in nonfailing hearts was similar to LV recovery patients (both p < 0.04 vs. VAD dependent)." +other hsa-mir-26a-1 Heart Failure 22093502 "The real-time PCR confirmed lower expression in LV recovery patients for 4 miRs (15b, -1.5-fold; 23a, -2.2-fold; 26a, -1.4-fold; and 195, -1.8-fold; all p < 0.04 vs. VAD dependent). The validation cohort similarly showed lower miRs expression in LV recovery patients (23a, -1.8-fold; and 195, -1.5-fold; both p < 0.03). Furthermore, miR 23a and 195 expression in nonfailing hearts was similar to LV recovery patients (both p < 0.04 vs. VAD dependent)." +other hsa-mir-26a-2 Heart Failure 22093502 "The real-time PCR confirmed lower expression in LV recovery patients for 4 miRs (15b, -1.5-fold; 23a, -2.2-fold; 26a, -1.4-fold; and 195, -1.8-fold; all p < 0.04 vs. VAD dependent). The validation cohort similarly showed lower miRs expression in LV recovery patients (23a, -1.8-fold; and 195, -1.5-fold; both p < 0.03). Furthermore, miR 23a and 195 expression in nonfailing hearts was similar to LV recovery patients (both p < 0.04 vs. VAD dependent)." +other hsa-mir-26a-1 Breast Neoplasms 22094936 High miR-26a and low CDC2 levels associate with decreased EZH2 expression and with favorable outcome on tamoxifen in metastatic breast cancer. +other hsa-mir-26a-2 Breast Neoplasms 22094936 High miR-26a and low CDC2 levels associate with decreased EZH2 expression and with favorable outcome on tamoxifen in metastatic breast cancer. +other hsa-mir-155 Lymphoma 22096245 miR-155 regulates HGAL expression and increases lymphoma cell motility. +other hsa-mir-141 Ovarian Neoplasms 22101765 miR-141 and miR-200a act on ovarian tumorigenesis by controlling oxidative stress response. +other hsa-mir-200a Ovarian Neoplasms 22101765 miR-141 and miR-200a act on ovarian tumorigenesis by controlling oxidative stress response. +other hsa-mir-34a Melanoma 22102694 "Tumor suppressive microRNAs miR-34a/c control cancer cell expression of ULBP2, a stress induced ligand of the natural killer cell receptor NKG2D." +other hsa-mir-34c Melanoma 22102694 "Tumor suppressive microRNAs miR-34a/c control cancer cell expression of ULBP2, a stress induced ligand of the natural killer cell receptor NKG2D." +other hsa-mir-34a Breast Neoplasms 22102859 MiR-34a Expression Has an Effect for Lower Risk of Metastasis and Associates with Expression Patterns Predicting Clinical Outcome in Breast Cancer. +other hsa-mir-23b Colon Neoplasms 22109528 Genome-wide functional screening of miR-23b as a pleiotropic modulator suppressing cancer metastasis. +other hsa-mir-1 Heart Failure 22110643 "We conclude that miR-1 and -499 play differential roles in cardiac differentiation of hESCs in a context-dependent fashion. While miR-499 promotes ventricular specification of hESCs, miR-1 serves to facilitate electrophysiological maturation." +other hsa-mir-499 Heart Failure 22110643 "We conclude that miR-1 and -499 play differential roles in cardiac differentiation of hESCs in a context-dependent fashion. While miR-499 promotes ventricular specification of hESCs, miR-1 serves to facilitate electrophysiological maturation." +other hsa-mir-126 Myocardial Infarction 22113756 "Transplantation of MSCs transfected with miR-126 can improve angiogenesis and cardiac function in the infarcted area of the hearts of mice, which may be due to stimulation of the AKT/ERK-related pathway." +other hsa-mir-155 Waldenstrom Macroglobulinemia 22122052 "Among deregulated miRNAs, miR-155 and miR-9* play a pivotal role in the pathogenesis of this disease." +other hsa-mir-9 Waldenstrom Macroglobulinemia 22122052 "Among deregulated miRNAs, miR-155 and miR-9* play a pivotal role in the pathogenesis of this disease." +other hsa-mir-210 Ischemic Diseases [unspecific] 22123256 Upregulation of microRNA-210 regulates renal angiogenesis mediated by activation of VEGF signaling pathway under ischemia/perfusion injury in vivo and in vitro. +other hsa-let-7a Neoplasms [unspecific] 22129484 "The let-7 family of microRNAs has cancer suppressor activity, and recent evidence suggests that markedly reduced levels of let-7 are not only a typical feature of cancer stem cells, but may be largely responsible for cancer stemness." +other hsa-let-7b Neoplasms [unspecific] 22129484 "The let-7 family of microRNAs has cancer suppressor activity, and recent evidence suggests that markedly reduced levels of let-7 are not only a typical feature of cancer stem cells, but may be largely responsible for cancer stemness." +other hsa-let-7c Neoplasms [unspecific] 22129484 "The let-7 family of microRNAs has cancer suppressor activity, and recent evidence suggests that markedly reduced levels of let-7 are not only a typical feature of cancer stem cells, but may be largely responsible for cancer stemness." +other hsa-let-7d Neoplasms [unspecific] 22129484 "The let-7 family of microRNAs has cancer suppressor activity, and recent evidence suggests that markedly reduced levels of let-7 are not only a typical feature of cancer stem cells, but may be largely responsible for cancer stemness." +other hsa-let-7e Neoplasms [unspecific] 22129484 "The let-7 family of microRNAs has cancer suppressor activity, and recent evidence suggests that markedly reduced levels of let-7 are not only a typical feature of cancer stem cells, but may be largely responsible for cancer stemness." +other hsa-let-7f Neoplasms [unspecific] 22129484 "The let-7 family of microRNAs has cancer suppressor activity, and recent evidence suggests that markedly reduced levels of let-7 are not only a typical feature of cancer stem cells, but may be largely responsible for cancer stemness." +other hsa-let-7g Neoplasms [unspecific] 22129484 "The let-7 family of microRNAs has cancer suppressor activity, and recent evidence suggests that markedly reduced levels of let-7 are not only a typical feature of cancer stem cells, but may be largely responsible for cancer stemness." +other hsa-let-7i Neoplasms [unspecific] 22129484 "The let-7 family of microRNAs has cancer suppressor activity, and recent evidence suggests that markedly reduced levels of let-7 are not only a typical feature of cancer stem cells, but may be largely responsible for cancer stemness." +other hsa-mir-202 Neoplasms [unspecific] 22129484 "The let-7 family of microRNAs has cancer suppressor activity, and recent evidence suggests that markedly reduced levels of let-7 are not only a typical feature of cancer stem cells, but may be largely responsible for cancer stemness." +other hsa-mir-98 Neoplasms [unspecific] 22129484 "The let-7 family of microRNAs has cancer suppressor activity, and recent evidence suggests that markedly reduced levels of let-7 are not only a typical feature of cancer stem cells, but may be largely responsible for cancer stemness." +other hsa-mir-182 Medulloblastoma 22134538 MicroRNA-182 promotes leptomeningeal spread of non-sonic hedgehog-medulloblastoma. +other hsa-mir-143 Cardiovascular Diseases [unspecific] 22135162 "MicroRNAs are critical for vascular smooth muscle cell differentiation and phenotype regulation, and miR-143 and miR-145 play a particularly important role in this respect." +other hsa-mir-145 Cardiovascular Diseases [unspecific] 22135162 "MicroRNAs are critical for vascular smooth muscle cell differentiation and phenotype regulation, and miR-143 and miR-145 play a particularly important role in this respect." +other hsa-mir-135a-1 Glioma 22139076 MiR-135a functions as a selective killer of malignant glioma. +other hsa-mir-135a-2 Glioma 22139076 MiR-135a functions as a selective killer of malignant glioma. +other hsa-mir-7-1 Gastric Neoplasms 22139078 Inflammation-induced repression of tumor suppressor miR-7 in gastric tumor cells. +other hsa-mir-7-2 Gastric Neoplasms 22139078 Inflammation-induced repression of tumor suppressor miR-7 in gastric tumor cells. +other hsa-mir-7-3 Gastric Neoplasms 22139078 Inflammation-induced repression of tumor suppressor miR-7 in gastric tumor cells. +other hsa-mir-30c-1 Endometrial Neoplasms 22139444 Endometrial Neoplasms +other hsa-mir-30c-2 Endometrial Neoplasms 22139444 Endometrial Neoplasms +other hsa-mir-494 Lung Neoplasms 22151897 MicroRNA-494 suppresses cell proliferation and induces senescence in A549 lung cancer cells. +other hsa-mir-30e Glioma 22156201 MicroRNA-30e* promotes human glioma cell invasiveness in an orthotopic xenotransplantation model by disrupting the NF-§Ø¨mB/I§Ø¨mB§Ø©ãnegative feedback loop. +other hsa-mir-1301 "Carcinoma, Hepatocellular" 22159405 microRNA-1301-mediated inhibition of tumorigenesis. +other hsa-mir-96 "Carcinoma, Hepatocellular" 22160187 Suppression of microRNA-96 expression inhibits the invasion of hepatocellular carcinoma cells. +other hsa-mir-17 Hypertension 22161164 Inhibition of microRNA-17 Improves Lung and Heart Function in Experimental Pulmonary Hypertension. +other hsa-mir-1-1 Heart Failure 22163007 MicroRNA-1 and -133 Increase Arrhythmogenesis in Heart Failure by Dissociating Phosphatase Activity from RyR2 Complex. +other hsa-mir-1-2 Heart Failure 22163007 MicroRNA-1 and -133 Increase Arrhythmogenesis in Heart Failure by Dissociating Phosphatase Activity from RyR2 Complex. +other hsa-mir-133a-1 Heart Failure 22163007 MicroRNA-1 and -133 Increase Arrhythmogenesis in Heart Failure by Dissociating Phosphatase Activity from RyR2 Complex. +other hsa-mir-133a-2 Heart Failure 22163007 MicroRNA-1 and -133 Increase Arrhythmogenesis in Heart Failure by Dissociating Phosphatase Activity from RyR2 Complex. +other hsa-mir-133b Heart Failure 22163007 MicroRNA-1 and -133 Increase Arrhythmogenesis in Heart Failure by Dissociating Phosphatase Activity from RyR2 Complex. +other hsa-mir-29a Biliary Atresia 22167021 MicroRNA Profiling Identifies miR-29 as a Regulator of Disease-Associated Pathways in Experimental Biliary Atresia. +other hsa-mir-29b-1 Biliary Atresia 22167021 MicroRNA Profiling Identifies miR-29 as a Regulator of Disease-Associated Pathways in Experimental Biliary Atresia. +other hsa-let-7a Gastrointestinal Neoplasms 22168593 "The aim of the present review was to describe the mechanisms of several known miR, summarize recent studies on oncogenic miR (e.g. miR-21, miR-106a and miR-17), tumor suppressor miR (e.g. miR-101, miR-181, miR-449, miR-486, let-7a) and controversial roles of miR (e.g. miR-107, miR-126) for gastric cancer." +other hsa-mir-101 Gastrointestinal Neoplasms 22168593 "The aim of the present review was to describe the mechanisms of several known miR, summarize recent studies on oncogenic miR (e.g. miR-21, miR-106a and miR-17), tumor suppressor miR (e.g. miR-101, miR-181, miR-449, miR-486, let-7a) and controversial roles of miR (e.g. miR-107, miR-126) for gastric cancer." +other hsa-mir-106a Gastrointestinal Neoplasms 22168593 "The aim of the present review was to describe the mechanisms of several known miR, summarize recent studies on oncogenic miR (e.g. miR-21, miR-106a and miR-17), tumor suppressor miR (e.g. miR-101, miR-181, miR-449, miR-486, let-7a) and controversial roles of miR (e.g. miR-107, miR-126) for gastric cancer." +other hsa-mir-107 Gastrointestinal Neoplasms 22168593 "The aim of the present review was to describe the mechanisms of several known miR, summarize recent studies on oncogenic miR (e.g. miR-21, miR-106a and miR-17), tumor suppressor miR (e.g. miR-101, miR-181, miR-449, miR-486, let-7a) and controversial roles of miR (e.g. miR-107, miR-126) for gastric cancer." +other hsa-mir-126 Gastrointestinal Neoplasms 22168593 "The aim of the present review was to describe the mechanisms of several known miR, summarize recent studies on oncogenic miR (e.g. miR-21, miR-106a and miR-17), tumor suppressor miR (e.g. miR-101, miR-181, miR-449, miR-486, let-7a) and controversial roles of miR (e.g. miR-107, miR-126) for gastric cancer." +other hsa-mir-17 Gastrointestinal Neoplasms 22168593 "The aim of the present review was to describe the mechanisms of several known miR, summarize recent studies on oncogenic miR (e.g. miR-21, miR-106a and miR-17), tumor suppressor miR (e.g. miR-101, miR-181, miR-449, miR-486, let-7a) and controversial roles of miR (e.g. miR-107, miR-126) for gastric cancer." +other hsa-mir-181 Gastrointestinal Neoplasms 22168593 "The aim of the present review was to describe the mechanisms of several known miR, summarize recent studies on oncogenic miR (e.g. miR-21, miR-106a and miR-17), tumor suppressor miR (e.g. miR-101, miR-181, miR-449, miR-486, let-7a) and controversial roles of miR (e.g. miR-107, miR-126) for gastric cancer." +other hsa-mir-21 Gastrointestinal Neoplasms 22168593 "The aim of the present review was to describe the mechanisms of several known miR, summarize recent studies on oncogenic miR (e.g. miR-21, miR-106a and miR-17), tumor suppressor miR (e.g. miR-101, miR-181, miR-449, miR-486, let-7a) and controversial roles of miR (e.g. miR-107, miR-126) for gastric cancer." +other hsa-mir-449 Gastrointestinal Neoplasms 22168593 "The aim of the present review was to describe the mechanisms of several known miR, summarize recent studies on oncogenic miR (e.g. miR-21, miR-106a and miR-17), tumor suppressor miR (e.g. miR-101, miR-181, miR-449, miR-486, let-7a) and controversial roles of miR (e.g. miR-107, miR-126) for gastric cancer." +other hsa-mir-486 Gastrointestinal Neoplasms 22168593 "The aim of the present review was to describe the mechanisms of several known miR, summarize recent studies on oncogenic miR (e.g. miR-21, miR-106a and miR-17), tumor suppressor miR (e.g. miR-101, miR-181, miR-449, miR-486, let-7a) and controversial roles of miR (e.g. miR-107, miR-126) for gastric cancer." +other hsa-mir-335 Glioma 22172575 MiR-335 is Required for Differentiation of Malignant Glioma Cells Induced by Activation of cAMP/PKA Pathway. +other hsa-mir-574 Urinary Bladder Cancer 22179486 Novel oncogenic function of mesoderm development candidate 1 and its regulation by MiR-574-3p in bladder cancer cell lines. +other hsa-mir-1-1 Colon Neoplasms 22179665 MIR-1 DOWNREGULATION COOPERATES WITH MACC1 IN PROMOTING MET OVEREXPRESSION IN HUMAN COLON CANCER. +other hsa-mir-133b Urinary Bladder Cancer 22179829 MicroRNA-133b is a key promoter of cervical carcinoma development through the activation of the ERK and AKT1 pathways. +other hsa-mir-21 Breast Neoplasms 22187223 Re-expression of miR-21 contributes to migration and invasion by inducing epithelial-mesenchymal transition consistent with cancer stem cell characteristics in MCF-7 cells. +other hsa-mir-610 Gastric Neoplasms 22189055 MicroRNA-610 inhibits the migration and invasion of gastric cancer cells by suppressing the expression of vasodilator-stimulated phosphoprotein. +other hsa-mir-122 Hepatitis C Virus Infection 22189820 "Here we show that HCV IRES-dependent translation efficiency in the hepatoma cell line Huh7 is highest during the G 0 and G 1 phases of the cell cycle but significantly drops during the S phase and even more in the G 2/M phase. The superimposed stimulation of HCV translation by ectopic miR-122 works best during the G 0, G 1 and G 2/M phases but is lower during the S phase. However, the levels of Ago2 protein do not substantially change during cell cycle phases, indicating that other cellular factors involved in HCV translation stimulation by miR-122 may be differentially expressed in different cell cycle phases. Moreover, the levels of endogenously expressed miR-122 in Huh7 cells are lowest in the S phase, indicating that the predominant G 0/G 1 state of non-dividing hepatocytes in the liver facilitates high expression of the HCV genome and stimulation by miR-122, with yet unknown factors involved in the differential extent of stimulation by miR-122." +other hsa-mir-195 Heart Failure 22190509 "microRNA-195(miR-195) is an important member of the micro-15/16/195/424/497 family, and which is activated in multiple diseases, such as cancers, heart failure, and schizophrenia." +other hsa-mir-195 Schizophrenia 22190509 "microRNA-195(miR-195) is an important member of the micro-15/16/195/424/497 family, and which is activated in multiple diseases, such as cancers, heart failure, and schizophrenia." +other hsa-mir-34a Melanoma 22198089 "Our preliminary study suggests that miR-34a, although having a role in late tumorigenesis, does not contribute to the inherited susceptibility to cutaneous melanoma. " +other hsa-mir-106a Colorectal Carcinoma 22202009 "miR-20a, miR-21, miR-106a, miR-181b, miR-203, and miR-324-5p were stable in colorectal cancer archival tissue blocks." +other hsa-mir-181b-1 Colorectal Carcinoma 22202009 "miR-20a, miR-21, miR-106a, miR-181b, miR-203, and miR-324-5p were stable in colorectal cancer archival tissue blocks." +other hsa-mir-181b-2 Colorectal Carcinoma 22202009 "miR-20a, miR-21, miR-106a, miR-181b, miR-203, and miR-324-5p were stable in colorectal cancer archival tissue blocks." +other hsa-mir-203 Colorectal Carcinoma 22202009 "miR-20a, miR-21, miR-106a, miR-181b, miR-203, and miR-324-5p were stable in colorectal cancer archival tissue blocks." +other hsa-mir-20a Colorectal Carcinoma 22202009 "miR-20a, miR-21, miR-106a, miR-181b, miR-203, and miR-324-5p were stable in colorectal cancer archival tissue blocks." +other hsa-mir-21 Colorectal Carcinoma 22202009 "miR-20a, miR-21, miR-106a, miR-181b, miR-203, and miR-324-5p were stable in colorectal cancer archival tissue blocks." +other hsa-mir-324 Colorectal Carcinoma 22202009 "miR-20a, miR-21, miR-106a, miR-181b, miR-203, and miR-324-5p were stable in colorectal cancer archival tissue blocks." +other hsa-mir-451 Glioblastoma 22205943 "The model provides an explanation for the growth-invasion cycling patterns of glioma cells in response to high/low glucose uptake in microenvironment in vitro, and suggests new targets for drugs,associated with miR-451 upregulation." +other hsa-mir-31 Gastric Neoplasms 22212233 PDCD4 expression inversely correlated with miR-21 levels in gastric cancers. +other hsa-mir-520e "Carcinoma, Hepatocellular" 22212428 A novel tumor suppressor miRNA miR-520e contributes to suppression of hepatoma. +other hsa-mir-21 Cholangiocarcinoma 22213145 "Based on our data, we conclude that Ars2 is overexpressed in human CCA and may be a diagnostic marker. Ars2 depletion increases PTEN and PDCD4 protein levels via the reduction of miR-21." +other hsa-mir-125b-1 Melanoma 22213330 "Treatment with 5-Aza, but not with TSA, reduced the expression of miR-125b in the 1,25(OH)(2)D(3)-responsive and -resistant melanoma cell lines and in the NHM." +other hsa-mir-125b-2 Melanoma 22213330 "Treatment with 5-Aza, but not with TSA, reduced the expression of miR-125b in the 1,25(OH)(2)D(3)-responsive and -resistant melanoma cell lines and in the NHM." +other hsa-mir-27b Melanoma 22213330 "Treatment with 1,25(OH)(2)D(3) and/or epigenetic drugs (5-Aza, TSA) reduced the miR-27b expression in three out of four melanoma cell lines." +other hsa-mir-21 "Muscular Dystrophy, Duchenne" 22213800 PAI-1-regulated miR-21 defines a novel age-associated fibrogenic pathway in muscular dystrophy. +other hsa-mir-126 Cardiovascular Diseases [unspecific] 22215713 miRNA-126 levels were reduced in SHRs with an increase of 51% in phosphoinositol-3 kinase regulatory subunit 2 expression but normalized in SHR-Ts. +other hsa-mir-26b Hypertrophy 22219180 GATA4 expression is primarily regulated via a miR-26b-dependent post-transcriptional mechanism during cardiac hypertrophy. +other hsa-mir-21 Pituitary Adenoma 22222153 "We speculated the mechanism of miR-21 is involved in tumorigenesis, leading to improvements in therapies and prevention of metastasis." +other hsa-mir-192 Diabetic Nephropathy 22223877 Inhibiting MicroRNA-192 Ameliorates Renal Fibrosis in Diabetic Nephropathy +other hsa-mir-650 "Leukemia, Lymphocytic, Chronic, B-Cell" 22234685 MicroRNA-650 expression is influenced by immunoglobulin gene rearrangement and affects the biology of chronic lymphocytic leukemia. +other hsa-mir-34a Prostate Neoplasms 22235332 MicroRNA-34a modulates c-Myc transcriptional complexes to suppress malignancy in human prostate cancer cells. +other hsa-mir-21 "Carcinoma, Lung, Non-Small-Cell" 22237007 "Increased miR-21 expression significantly increased the resistance of A549 cell to platinum, whereas reduced miR-21 decreased the resistance of A549/CDDP cell." +other hsa-mir-133b Parkinson Disease 22245218 "miR-133b is deficient in the PD midbrain as well as in mouse models, and miR-34b/34c are decreased in several affected brain regions in PD and incidental Lewy body disease." +other hsa-let-7c Pancreatic Neoplasms 22245693 "Metformin up-regulated the expression of miR-26a, miR-192 and let-7c in a dose-dependent manner." +other hsa-mir-192 Pancreatic Neoplasms 22245693 "Metformin up-regulated the expression of miR-26a, miR-192 and let-7c in a dose-dependent manner." +other hsa-mir-26a-1 Pancreatic Neoplasms 22245693 "Metformin up-regulated the expression of miR-26a, miR-192 and let-7c in a dose-dependent manner. Forced expression of miR-26a significantly inhibited cell proliferation, invasion, migration and increased cell apoptosis, whereas knockdown of miR-26a obtained the opposite effect." +other hsa-mir-26a-2 Pancreatic Neoplasms 22245693 "Metformin up-regulated the expression of miR-26a, miR-192 and let-7c in a dose-dependent manner. Forced expression of miR-26a significantly inhibited cell proliferation, invasion, migration and increased cell apoptosis, whereas knockdown of miR-26a obtained the opposite effect." +other hsa-mir-155 Breast Neoplasms 22245916 "Up-regulated miR-155 expression was associated with lymph node positivity (P=0.034), higher proliferation index (Ki-67 >10%) (P=0.019) and advanced breast cancer TNM clinical stage (P=0.002)." +other hsa-mir-100 "Carcinoma, Hepatocellular" 22249248 Sequential analysis of multistage hepatocarcinogenesis reveals that miR-100 and PLK1 dysregulation is an early event maintained along tumor progression. +other hsa-mir-155 Myelodysplastic Syndromes 22249254 Loss of SHIP-1 protein expression in high-risk myelodysplastic syndromes is associated with miR-210 and miR-155. +other hsa-mir-210 Myelodysplastic Syndromes 22249254 Loss of SHIP-1 protein expression in high-risk myelodysplastic syndromes is associated with miR-210 and miR-155. +other hsa-mir-21 "Carcinoma, Oral" 22249446 miR-21 inhibitor sensitizes human OSCC(oral squamous cell carcinoma) cells to cisplatin. +other hsa-mir-196a-1 Gastrointestinal Neoplasms 22258453 Upregulation of miR-196a and HOTAIR Drive Malignant Character in Gastrointestinal Stromal Tumors. +other hsa-mir-196a-2 Gastrointestinal Neoplasms 22258453 Upregulation of miR-196a and HOTAIR Drive Malignant Character in Gastrointestinal Stromal Tumors. +other hsa-mir-143 Breast Neoplasms 22260523 "E2 significantly induced bcl-2, cyclin D1 and survivin expression by suppressing the levels of a panel of miRNAs (miR-16, miR-143, miR-203) in MCF-7 cells." +other hsa-mir-16-1 Breast Neoplasms 22260523 "E2 significantly induced bcl-2, cyclin D1 and survivin expression by suppressing the levels of a panel of miRNAs (miR-16, miR-143, miR-203) in MCF-7 cells." +other hsa-mir-16-2 Breast Neoplasms 22260523 "E2 significantly induced bcl-2, cyclin D1 and survivin expression by suppressing the levels of a panel of miRNAs (miR-16, miR-143, miR-203) in MCF-7 cells." +other hsa-mir-203 Breast Neoplasms 22260523 "E2 significantly induced bcl-2, cyclin D1 and survivin expression by suppressing the levels of a panel of miRNAs (miR-16, miR-143, miR-203) in MCF-7 cells." +other hsa-mir-24-1 Myocardial Infarction 22260784 MicroRNA-24 Regulates Cardiac Fibrosis after Myocardial Infarction. +other hsa-mir-24-2 Myocardial Infarction 22260784 MicroRNA-24 Regulates Cardiac Fibrosis after Myocardial Infarction. +other hsa-mir-125b-1 Neoplasms [unspecific] 22268450 Camptothecin Induces Apoptosis in Cancer Cells via miR-125b Mediated Mitochondrial Pathways. +other hsa-mir-125b-2 Neoplasms [unspecific] 22268450 Camptothecin Induces Apoptosis in Cancer Cells via miR-125b Mediated Mitochondrial Pathways. +other hsa-mir-155 Lymphoma 22268450 Epstein-Barr virus latent membrane protein-1 protects B-cell lymphoma from rituximab-induced apoptosis through miR-155-mediated Akt activation and up-regulation of Mcl-1. +other hsa-mir-145 Glioma 22269208 Over-expression of miR-145 enhances the effectiveness of HSVtk gene therapy for malignant glioma. +other hsa-mir-140 Osteoarthritis 22273691 Expression of miRNA-140 and MMP-13 was elevated in IL-1¦Â-stimulated C28/I2 cells. +other hsa-mir-33a Atherosclerosis 22274626 microRNA-33a and b (miR-33a/b) were discovered as key regulators of metabolic programs including cholesterol and fatty acid homeostasis. +other hsa-mir-33b Atherosclerosis 22274626 microRNA-33a and b (miR-33a/b) were discovered as key regulators of metabolic programs including cholesterol and fatty acid homeostasis. +other hsa-mir-21 Colorectal Carcinoma 22281474 "Aging and DMH are associated with increases in CSLC biomarkers and miR21, each of which have been linked to colorectal cancer." +other hsa-mir-199a-1 Leukemia 22285730 Low microRNA-199a expression in human amniotic epithelial cell feeder layers maintains human-induced pluripotent stem cell pluripotency via increased leukemia inhibitory factor expression. +other hsa-mir-199a-2 Leukemia 22285730 Low microRNA-199a expression in human amniotic epithelial cell feeder layers maintains human-induced pluripotent stem cell pluripotency via increased leukemia inhibitory factor expression. +other hsa-mir-145 Urinary Bladder Cancer 22287315 Glucocorticoid regulation of a novel HPV E6-p53-miR-145 pathway modulates invasion and therapy resistance of cervical cancer cells. +other hsa-mir-200b Crohn Disease 22294131 miR-200b is involved in intestinal fibrosis of Crohn's disease. +other hsa-mir-106a "Carcinoma, Lung, Non-Small-Cell" 22295063 "The significantly altered angiogenesis-related miRs of high interest were miR-21, miR-106a, miR-126, miR-155, miR-182, miR-210 and miR-424. miR-155 correlated significantly with fibroblast growth factor 2 (FGF2) in the total cohort (r=0.17, P=0.002), though most prominent in the subgroup with nodal metastasis (r=0.34, P<0.001)." +other hsa-mir-126 "Carcinoma, Lung, Non-Small-Cell" 22295063 "The significantly altered angiogenesis-related miRs of high interest were miR-21, miR-106a, miR-126, miR-155, miR-182, miR-210 and miR-424. miR-155 correlated significantly with fibroblast growth factor 2 (FGF2) in the total cohort (r=0.17, P=0.002), though most prominent in the subgroup with nodal metastasis (r=0.34, P<0.001)." +other hsa-mir-155 "Carcinoma, Lung, Non-Small-Cell" 22295063 "The significantly altered angiogenesis-related miRs of high interest were miR-21, miR-106a, miR-126, miR-155, miR-182, miR-210 and miR-424. miR-155 correlated significantly with fibroblast growth factor 2 (FGF2) in the total cohort (r=0.17, P=0.002), though most prominent in the subgroup with nodal metastasis (r=0.34, P<0.001)." +other hsa-mir-182 "Carcinoma, Lung, Non-Small-Cell" 22295063 "The significantly altered angiogenesis-related miRs of high interest were miR-21, miR-106a, miR-126, miR-155, miR-182, miR-210 and miR-424. miR-155 correlated significantly with fibroblast growth factor 2 (FGF2) in the total cohort (r=0.17, P=0.002), though most prominent in the subgroup with nodal metastasis (r=0.34, P<0.001)." +other hsa-mir-21 "Carcinoma, Lung, Non-Small-Cell" 22295063 "The significantly altered angiogenesis-related miRs of high interest were miR-21, miR-106a, miR-126, miR-155, miR-182, miR-210 and miR-424. miR-155 correlated significantly with fibroblast growth factor 2 (FGF2) in the total cohort (r=0.17, P=0.002), though most prominent in the subgroup with nodal metastasis (r=0.34, P<0.001)." +other hsa-mir-210 "Carcinoma, Lung, Non-Small-Cell" 22295063 "The significantly altered angiogenesis-related miRs of high interest were miR-21, miR-106a, miR-126, miR-155, miR-182, miR-210 and miR-424. miR-155 correlated significantly with fibroblast growth factor 2 (FGF2) in the total cohort (r=0.17, P=0.002), though most prominent in the subgroup with nodal metastasis (r=0.34, P<0.001)." +other hsa-mir-424 "Carcinoma, Lung, Non-Small-Cell" 22295063 "The significantly altered angiogenesis-related miRs of high interest were miR-21, miR-106a, miR-126, miR-155, miR-182, miR-210 and miR-424. miR-155 correlated significantly with fibroblast growth factor 2 (FGF2) in the total cohort (r=0.17, P=0.002), though most prominent in the subgroup with nodal metastasis (r=0.34, P<0.001)." +other hsa-let-7a-1 Lung Neoplasms 22301433 Reduced miR-31 and let-7 maintain the balance between differentiation and quiescence in lung cancer stem-like side population cells. +other hsa-let-7a-2 Lung Neoplasms 22301433 Reduced miR-31 and let-7 maintain the balance between differentiation and quiescence in lung cancer stem-like side population cells. +other hsa-let-7a-3 Lung Neoplasms 22301433 Reduced miR-31 and let-7 maintain the balance between differentiation and quiescence in lung cancer stem-like side population cells. +other hsa-let-7b Lung Neoplasms 22301433 Reduced miR-31 and let-7 maintain the balance between differentiation and quiescence in lung cancer stem-like side population cells. +other hsa-let-7c Lung Neoplasms 22301433 Reduced miR-31 and let-7 maintain the balance between differentiation and quiescence in lung cancer stem-like side population cells. +other hsa-let-7d Lung Neoplasms 22301433 Reduced miR-31 and let-7 maintain the balance between differentiation and quiescence in lung cancer stem-like side population cells. +other hsa-let-7e Lung Neoplasms 22301433 Reduced miR-31 and let-7 maintain the balance between differentiation and quiescence in lung cancer stem-like side population cells. +other hsa-let-7f-1 Lung Neoplasms 22301433 Reduced miR-31 and let-7 maintain the balance between differentiation and quiescence in lung cancer stem-like side population cells. +other hsa-let-7f-2 Lung Neoplasms 22301433 Reduced miR-31 and let-7 maintain the balance between differentiation and quiescence in lung cancer stem-like side population cells. +other hsa-let-7g Lung Neoplasms 22301433 Reduced miR-31 and let-7 maintain the balance between differentiation and quiescence in lung cancer stem-like side population cells. +other hsa-let-7i Lung Neoplasms 22301433 Reduced miR-31 and let-7 maintain the balance between differentiation and quiescence in lung cancer stem-like side population cells. +other hsa-mir-31 Lung Neoplasms 22301433 Reduced miR-31 and let-7 maintain the balance between differentiation and quiescence in lung cancer stem-like side population cells. +other hsa-mir-31 Barrett Esophagus 22302717 "The authors propose miR-31 and -375 as novel candidate microRNAs specifically associated with early- and late-stage malignant progression, respectively, in Barrett's esophagus." +other hsa-mir-375 Barrett Esophagus 22302717 "The authors propose miR-31 and -375 as novel candidate microRNAs specifically associated with early- and late-stage malignant progression, respectively, in Barrett's esophagus." +other hsa-mir-181c Fanconi Anemia 22310912 Downregulated expression of hsa-miR-181c in Fanconi anemia patients: implications in TNF§Ø©ãregulation and proliferation of hematopoietic progenitor cells. +other hsa-mir-146a Pancreatic Neoplasms 22311263 Aberrant elevated microRNA-146a in dendritic cells (DC) induced by human pancreatic cancer cell line BxPC-3-conditioned medium inhibits DC maturation and activation. +other hsa-mir-125a Gastric Neoplasms 22322911 "Low expression levels of miR-125a-3p were associated with indicators of enhanced malignant potential such as tumor size (p=0.0002), tumor invasion (p=0.0149), lymph node metastasis (p=0.018), liver metastasis (p=0.016), peritoneal dissemination (p=0.03), advanced clinical stage (p=0.0037) and poor prognosis (p=0.0083)." +other hsa-mir-10b Colorectal Carcinoma 22322955 MicroRNA-10b is a Prognostic Indicator in Colorectal Cancer and Confers Resistance to the Chemotherapeutic Agent 5-Fluorouracil in Colorectal Cancer Cells. +other hsa-mir-1 Heart Failure 22326846 These findings demonstrate the importance of miR-1 in cardiac function and in the pathogenesis of heart failure via Sorcin-dependent calcium homeostasis. +other hsa-mir-22 Colon Neoplasms 22328083 "MicroRNA-22 is induced by vitamin D and contributes to its antiproliferative, antimigratory and gene regulatory effects in colon cancer cells." +other hsa-mir-145 "Carcinoma, Lung, Non-Small-Cell" 22331473 "miR-145* inhibits cell invasion and metastasis, and is associated with brain metastasis." +other hsa-mir-15a Breast Neoplasms 22335947 "The expression level of miR-15a in MCF-7 cells was lower than that in the MCF-10A cells (0.253:1, P < 0.0001). The expression of MiR-15a was significantly inhibited by Bcl-2 (P < 0.05)." +other hsa-mir-199a-2 Sezary Disease 22336940 Deep-Sequencing Analysis Reveals that the miR-199a2/214 Cluster within DNM3os Represents the Vast Majority of Aberrantly Expressed MicroRNAs in S§Ú§Øzary Syndrome. +other hsa-mir-214 Sezary Disease 22336940 Deep-Sequencing Analysis Reveals that the miR-199a2/214 Cluster within DNM3os Represents the Vast Majority of Aberrantly Expressed MicroRNAs in S§Ú§Øzary Syndrome. +other hsa-mir-122 Hepatitis C Virus Infection 22342424 Suppression of hepatitis C virus replicon by adenovirus vector-mediated expression of tough decoy RNA against miR-122a. +other hsa-mir-1-1 Colorectal Carcinoma 22343615 MicroRNA profiling in colorectal cancer highlights miR-1 involvement in MET-dependent proliferation. +other hsa-mir-31 Pancreatic Neoplasms 22344632 Both inhibition and enhanced expression of miR-31 lead to reduced migration and invasion of pancreatic cancer cells. +other hsa-mir-21 Renal Fibrosis 22344686 MicroRNA-21 Promotes Fibrosis of the Kidney by Silencing Metabolic Pathways. +other hsa-mir-21 Kidney Neoplasms 22347428 Up-Regulation of MicroRNA-21 Correlates with Lower Kidney Cancer Survival. +other hsa-mir-197 Thyroid Neoplasms 22351693 "A SVM model with 4 miRNAs (miR-222, miR-328, miR-197 and miR-21) was initially estimated to have 86% predictive accuracy using cross-validation to differentiate Malignant from Benign." +other hsa-mir-21 Thyroid Neoplasms 22351693 "A SVM model with 4 miRNAs (miR-222, miR-328, miR-197 and miR-21) was initially estimated to have 86% predictive accuracy using cross-validation to differentiate Malignant from Benign." +other hsa-mir-222 Thyroid Neoplasms 22351693 "A SVM model with 4 miRNAs (miR-222, miR-328, miR-197 and miR-21) was initially estimated to have 86% predictive accuracy using cross-validation to differentiate Malignant from Benign." +other hsa-mir-328 Thyroid Neoplasms 22351693 "A SVM model with 4 miRNAs (miR-222, miR-328, miR-197 and miR-21) was initially estimated to have 86% predictive accuracy using cross-validation to differentiate Malignant from Benign." +other hsa-mir-128b Lung Neoplasms 22352917 "Among them, 11 miRNAs including miR-7 and miR-128b were confirmed by published experimental data or literatures." +other hsa-mir-7 Lung Neoplasms 22352917 "Among them, 11 miRNAs including miR-7 and miR-128b were confirmed by published experimental data or literatures." +other hsa-mir-101-1 Colon Neoplasms 22353936 MicroRNA-101 (miR-101) post-transcriptionally regulates the expression of EP4 receptor in colon cancers. +other hsa-mir-101-2 Colon Neoplasms 22353936 MicroRNA-101 (miR-101) post-transcriptionally regulates the expression of EP4 receptor in colon cancers. +other hsa-mir-21 "Aortic Aneurysm, Abdominal" 22357537 MicroRNA-21 Blocks Abdominal Aortic Aneurysm Development and Nicotine-Augmented Expansion. +other hsa-mir-196a-1 Keloid 22358059 miR-196a Downregulation Increases the Expression of Type I and III Collagens in Keloid Fibroblasts. +other hsa-mir-196a-2 Keloid 22358059 miR-196a Downregulation Increases the Expression of Type I and III Collagens in Keloid Fibroblasts. +other hsa-mir-941-1 "Colitis, Ulcerative" 22359580 UC susceptibility +other hsa-mir-941-3 "Colitis, Ulcerative" 22359580 UC susceptibility +other hsa-mir-941-4 "Colitis, Ulcerative" 22359580 UC susceptibility +other hsa-mir-1-1 Heart Failure 22362515 SERCA2a gene therapy restores microRNA-1 expression in heart failure via an Akt/FoxO3A-dependent pathway. +other hsa-mir-1-2 Heart Failure 22362515 SERCA2a gene therapy restores microRNA-1 expression in heart failure via an Akt/FoxO3A-dependent pathway. +other hsa-mir-132 Inflammation 22362752 we propose an outline of the current knowledge about miR-132 and miR-212 functions in neurons and immune cells +other hsa-mir-212 Inflammation 22362752 we propose an outline of the current knowledge about miR-132 and miR-212 functions in neurons and immune cells +other hsa-mir-148b Glomerulonephritis 22362909 Abnormal miR-148b Expression Promotes Aberrant Glycosylation of IgA1 in IgA Nephropathy. +other hsa-mir-146a Prion Diseases 22363497 MicroRNA 146a (miR-146a) Is Over-Expressed during Prion Disease and Modulates the Innate Immune Response and the Microglial Activation State. +other hsa-mir-200c Breast Neoplasms 22364742 IL6-Mediated Suppression of miR-200c Directs Constitutive Activation of Inflammatory Signaling Circuit Driving Transformation and Tumorigenesis. +other hsa-mir-142 Hypertrophy 22367739 Repression of miR-142 by p300 and MAPK is required for survival signaling via gp130 during adaptive hypertrophy. +other hsa-mir-124-1 "Carcinoma, Lung, Non-Small-Cell" 22370637 "The authors found a number of miRNAs (miR-17, miR-135, miR-520, miR-124-1, and miR-34c) that may rescue cell viability from caspase-8 activation." +other hsa-mir-135a-1 "Carcinoma, Lung, Non-Small-Cell" 22370637 "The authors found a number of miRNAs (miR-17, miR-135, miR-520, miR-124-1, and miR-34c) that may rescue cell viability from caspase-8 activation." +other hsa-mir-135a-2 "Carcinoma, Lung, Non-Small-Cell" 22370637 "The authors found a number of miRNAs (miR-17, miR-135, miR-520, miR-124-1, and miR-34c) that may rescue cell viability from caspase-8 activation." +other hsa-mir-135b "Carcinoma, Lung, Non-Small-Cell" 22370637 "The authors found a number of miRNAs (miR-17, miR-135, miR-520, miR-124-1, and miR-34c) that may rescue cell viability from caspase-8 activation." +other hsa-mir-17 "Carcinoma, Lung, Non-Small-Cell" 22370637 "The authors found a number of miRNAs (miR-17, miR-135, miR-520, miR-124-1, and miR-34c) that may rescue cell viability from caspase-8 activation." +other hsa-mir-520a "Carcinoma, Lung, Non-Small-Cell" 22370637 "The authors found a number of miRNAs (miR-17, miR-135, miR-520, miR-124-1, and miR-34c) that may rescue cell viability from caspase-8 activation." +other hsa-mir-520b "Carcinoma, Lung, Non-Small-Cell" 22370637 "The authors found a number of miRNAs (miR-17, miR-135, miR-520, miR-124-1, and miR-34c) that may rescue cell viability from caspase-8 activation." +other hsa-mir-520c "Carcinoma, Lung, Non-Small-Cell" 22370637 "The authors found a number of miRNAs (miR-17, miR-135, miR-520, miR-124-1, and miR-34c) that may rescue cell viability from caspase-8 activation." +other hsa-mir-520d "Carcinoma, Lung, Non-Small-Cell" 22370637 "The authors found a number of miRNAs (miR-17, miR-135, miR-520, miR-124-1, and miR-34c) that may rescue cell viability from caspase-8 activation." +other hsa-mir-520e "Carcinoma, Lung, Non-Small-Cell" 22370637 "The authors found a number of miRNAs (miR-17, miR-135, miR-520, miR-124-1, and miR-34c) that may rescue cell viability from caspase-8 activation." +other hsa-mir-152 Atherosclerosis 22370758 Co-expression in plaque tissue and classical monocytes. +other hsa-mir-422a Atherosclerosis 22370758 Co-expression in plaque tissue and non-classical monocytes. +other hsa-mir-99b Atherosclerosis 22370758 Co-expression in plaque tissue and classical monocytes. +other hsa-mir-146a Inflammation 22371089 miR-146a and miR-147 are involved in the resolution phase of inflammation. +other hsa-mir-147 Inflammation 22371089 miR-146a and miR-147 are involved in the resolution phase of inflammation. +other hsa-mir-21 Hypertension 22371328 MicroRNA-21 Integrates Pathogenic Signaling to Control Pulmonary Hypertension +other hsa-mir-493 Colon Neoplasms 22373578 miR-493 induction during carcinogenesis blocks metastatic settlement of colon cancer cells in liver. +other hsa-mir-143 Atherosclerosis 22373869 Secreted miRNAs (miR-143/145) suppress atherogenesis. +other hsa-mir-145 Atherosclerosis 22373869 Secreted miRNAs (miR-143/145) suppress atherogenesis. +other hsa-mir-146a Rheumatoid Arthritis 22374446 "In 2008, miR-146a and miR-155 were reported to be involved in the pathology of rheumatoid arthritis." +other hsa-mir-155 Rheumatoid Arthritis 22374446 "In 2008, miR-146a and miR-155 were reported to be involved in the pathology of rheumatoid arthritis." +other hsa-mir-145 "Carcinoma, Hepatocellular" 22378186 Tumorigenicity of cancer stem-like cells derived from hepatocarcinoma is regulated by microRNA-145. +other hsa-mir-26a-1 Breast Neoplasms 22384020 Trastuzumab Produces Therapeutic Actions by Upregulating miR-26a and miR-30b in Breast Cancer Cells. +other hsa-mir-26a-2 Breast Neoplasms 22384020 Trastuzumab Produces Therapeutic Actions by Upregulating miR-26a and miR-30b in Breast Cancer Cells. +other hsa-mir-30b Breast Neoplasms 22384020 Trastuzumab Produces Therapeutic Actions by Upregulating miR-26a and miR-30b in Breast Cancer Cells. +other hsa-mir-302b Colon Neoplasms 22384170 Ascl2 Knockdown Results in Tumor Growth Arrest by miRNA-302b-Related Inhibition of Colon Cancer Progenitor Cells. +other hsa-let-7b Hepatitis C Virus Infection 22391672 Let-7b is a novel regulator of hepatitis C virus replication. +other hsa-mir-146b Obesity 22393448 Decrease of miR-146b-5p in Monocytes during Obesity Is Associated with Loss of the Anti-Inflammatory but Not Insulin Signaling Action of Adiponectin. +other hsa-mir-376b Myocardial Ischemic-Reperfusion Injury 22396777 M(3) Subtype of Muscarinic Acetylcholine Receptor Promotes Cardioprotection via the Suppression of miR-376b-5p. +other hsa-mir-29b-1 "Carcinoma, Lung, Non-Small-Cell" 22399498 increased after necitumumab in combination with cisplatin/gemcitabine +other hsa-mir-29b-2 "Carcinoma, Lung, Non-Small-Cell" 22399498 increased after necitumumab in combination with cisplatin/gemcitabine +other hsa-mir-29b-1 Prostate Neoplasms 22402125 MicroRNA-29b Suppresses Prostate Cancer Metastasis by Regulating Epithelial-Mesenchymal Transition Signaling. +other hsa-mir-29b-2 Prostate Neoplasms 22402125 MicroRNA-29b Suppresses Prostate Cancer Metastasis by Regulating Epithelial-Mesenchymal Transition Signaling. +other hsa-mir-133a-1 Atrial Fibrillation 22407060 both miR-133 and miR-30 play an important role in controlling structural changes in chronic AF +other hsa-mir-133a-2 Atrial Fibrillation 22407060 both miR-133 and miR-30 play an important role in controlling structural changes in chronic AF +other hsa-mir-133b Atrial Fibrillation 22407060 both miR-133 and miR-30 play an important role in controlling structural changes in chronic AF +other hsa-mir-30a Atrial Fibrillation 22407060 both miR-133 and miR-30 play an important role in controlling structural changes in chronic AF +other hsa-mir-30b Atrial Fibrillation 22407060 both miR-133 and miR-30 play an important role in controlling structural changes in chronic AF +other hsa-mir-30c-1 Atrial Fibrillation 22407060 both miR-133 and miR-30 play an important role in controlling structural changes in chronic AF +other hsa-mir-30c-2 Atrial Fibrillation 22407060 both miR-133 and miR-30 play an important role in controlling structural changes in chronic AF +other hsa-mir-30d Atrial Fibrillation 22407060 both miR-133 and miR-30 play an important role in controlling structural changes in chronic AF +other hsa-mir-126 Inflammation 22419694 MicroRNA-126 contributes to renal microvascular heterogeneity of VCAM-1 protein expression in acute inflammation. +other hsa-mir-223 "Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic" 22424712 Notch-mediated repression of miR-223 contributes to IGF1R regulation in T-ALL. +other hsa-mir-145 "Carcinoma, Hepatocellular" 22431718 MiR-145 modulates multiple components of the insulin-like growth factor pathway in hepatocellular carcinoma. +other hsa-mir-192 "Carcinoma, Hepatocellular" 22433310 HBx gene down-regulates miR-192 expression and inhibits apoptosis of human hepatoma cell line HepG2. +other hsa-mir-103 Metabolic Syndrome 22436747 "Other metabolic miRNAs, such as miR-103 and miR-107, regulate insulin and glucose homeostasis, whereas miRNAs such as miR-34a are emerging as key regulators of hepatic lipid homeostasis." +other hsa-mir-107 Metabolic Syndrome 22436747 "Other metabolic miRNAs, such as miR-103 and miR-107, regulate insulin and glucose homeostasis, whereas miRNAs such as miR-34a are emerging as key regulators of hepatic lipid homeostasis." +other hsa-mir-33a Metabolic Syndrome 22436747 "miR-33a and miR-33b have a crucial role in controlling cholesterol and lipid metabolism in concert with their host genes, the sterol-regulatory element-binding protein (SREBP) transcription factors." +other hsa-mir-33b Metabolic Syndrome 22436747 "miR-33a and miR-33b have a crucial role in controlling cholesterol and lipid metabolism in concert with their host genes, the sterol-regulatory element-binding protein (SREBP) transcription factors." +other hsa-mir-34a Metabolic Syndrome 22436747 "Other metabolic miRNAs, such as miR-103 and miR-107, regulate insulin and glucose homeostasis, whereas miRNAs such as miR-34a are emerging as key regulators of hepatic lipid homeostasis." +other hsa-mir-193a Prostate Neoplasms 22438885 miR-193a-3p and miRPlus-E1245 observed to be specific to XMRV infection in all 4 cell types (Two prostate cell lines (LNCaP and DU145) and two primary cells). +other hsa-mir-34b Breast Neoplasms 22439831 "MiR-34b is associated with clinical outcome in triple-negative breast cancer patients.Expression levels of miR-34b significantly correlate with disease free survival (DFS) (p = 0.0020, log-rank test) and overall survival (OS) (p = 0.0008, log-rank test) of TNBC patients." +other hsa-mir-421 "Carcinoma, Hepatocellular" 22446874 Downregulation of Human Farnesoid X Receptor by miR-421 Promotes Proliferation and Migration of Hepatocellular Carcinoma Cells. +other hsa-mir-25 Esophageal Neoplasms 22450326 MicroRNA-25 promotes cell migration and invasion in esophageal squamous cell carcinoma. +other hsa-mir-20a Hypertension 22450430 AntagomiR directed against miR-20a restores functional BMPR2 signalling and prevents vascular remodelling in hypoxia-induced pulmonary hypertension. +other hsa-let-7c Influenza 22452878 Cellular MicroRNA let-7c Inhibits M1 Protein Expression of the H1N1 Influenza A Virus in Infected Human Lung Epithelial Cells. +other hsa-mir-146a Neoplasms [unspecific] 22453030 In this review we focus on recent progress in analyzing the functional role of miR-146a in the control of normal and malignant hematopoiesis. +other hsa-mir-372 Colorectal Carcinoma 22456107 MicroRNA-372 Is Associated with Poor Prognosis in Colorectal Cancer. +other hsa-mir-125b Inflammation 22456625 "Targets of miR-125b include key proteins regulating apoptosis, innate immunity, inflammation and hematopoietic differentiation." +other hsa-mir-34a Osteosarcoma 22457788 MicroRNA-34a Inhibits the Proliferation and Metastasis of Osteosarcoma Cells Both In Vitro and In Vivo. +other hsa-mir-29a Liver Diseases [unspecific] 22469499 Hepatic miR-29ab1 expression modulates chronic hepatic injury. +other hsa-mir-29b-1 Liver Diseases [unspecific] 22469499 Hepatic miR-29ab1 expression modulates chronic hepatic injury. +other hsa-mir-29b-2 Liver Diseases [unspecific] 22469499 Hepatic miR-29ab1 expression modulates chronic hepatic injury. +other hsa-mir-106a "Squamous Cell Carcinoma, Cerevial" 22472886 "The miR-15a/miR-16/miR195/miR-497 family, miR-143/miR-145 and the miR-106-363 cluster appear to be important within the known HPV pathogenesis." +other hsa-mir-143 "Squamous Cell Carcinoma, Cerevial" 22472886 "The miR-15a/miR-16/miR195/miR-497 family, miR-143/miR-145 and the miR-106-363 cluster appear to be important within the known HPV pathogenesis." +other hsa-mir-145 "Squamous Cell Carcinoma, Cerevial" 22472886 "The miR-15a/miR-16/miR195/miR-497 family, miR-143/miR-145 and the miR-106-363 cluster appear to be important within the known HPV pathogenesis." +other hsa-mir-15a "Squamous Cell Carcinoma, Cerevial" 22472886 "The miR-15a/miR-16/miR195/miR-497 family, miR-143/miR-145 and the miR-106-363 cluster appear to be important within the known HPV pathogenesis." +other hsa-mir-16-1 "Squamous Cell Carcinoma, Cerevial" 22472886 "The miR-15a/miR-16/miR195/miR-497 family, miR-143/miR-145 and the miR-106-363 cluster appear to be important within the known HPV pathogenesis." +other hsa-mir-16-2 "Squamous Cell Carcinoma, Cerevial" 22472886 "The miR-15a/miR-16/miR195/miR-497 family, miR-143/miR-145 and the miR-106-363 cluster appear to be important within the known HPV pathogenesis." +other hsa-mir-18b "Squamous Cell Carcinoma, Cerevial" 22472886 "The miR-15a/miR-16/miR195/miR-497 family, miR-143/miR-145 and the miR-106-363 cluster appear to be important within the known HPV pathogenesis." +other hsa-mir-195 "Squamous Cell Carcinoma, Cerevial" 22472886 "The miR-15a/miR-16/miR195/miR-497 family, miR-143/miR-145 and the miR-106-363 cluster appear to be important within the known HPV pathogenesis." +other hsa-mir-19b-2 "Squamous Cell Carcinoma, Cerevial" 22472886 "The miR-15a/miR-16/miR195/miR-497 family, miR-143/miR-145 and the miR-106-363 cluster appear to be important within the known HPV pathogenesis." +other hsa-mir-20b "Squamous Cell Carcinoma, Cerevial" 22472886 "The miR-15a/miR-16/miR195/miR-497 family, miR-143/miR-145 and the miR-106-363 cluster appear to be important within the known HPV pathogenesis." +other hsa-mir-363 "Squamous Cell Carcinoma, Cerevial" 22472886 "The miR-15a/miR-16/miR195/miR-497 family, miR-143/miR-145 and the miR-106-363 cluster appear to be important within the known HPV pathogenesis." +other hsa-mir-497 "Squamous Cell Carcinoma, Cerevial" 22472886 "The miR-15a/miR-16/miR195/miR-497 family, miR-143/miR-145 and the miR-106-363 cluster appear to be important within the known HPV pathogenesis." +other hsa-mir-92a-2 "Squamous Cell Carcinoma, Cerevial" 22472886 "The miR-15a/miR-16/miR195/miR-497 family, miR-143/miR-145 and the miR-106-363 cluster appear to be important within the known HPV pathogenesis." +other hsa-mir-103a-1 Pancreatic Neoplasms 22479426 "The driving miRNAs were miR-103, miR-23a and miR-15b in pancreatic cancers." +other hsa-mir-103a-2 Pancreatic Neoplasms 22479426 "The driving miRNAs were miR-103, miR-23a and miR-15b in pancreatic cancers." +other hsa-mir-103b-1 Pancreatic Neoplasms 22479426 "The driving miRNAs were miR-103, miR-23a and miR-15b in pancreatic cancers." +other hsa-mir-103b-2 Pancreatic Neoplasms 22479426 "The driving miRNAs were miR-103, miR-23a and miR-15b in pancreatic cancers." +other hsa-mir-1246 Colorectal Carcinoma 22479426 "The driving miRNAs were miR-195, miR-1280, miR-140-3p and miR-1246 in colorectal tumors." +other hsa-mir-1280 Colorectal Carcinoma 22479426 "The driving miRNAs were miR-195, miR-1280, miR-140-3p and miR-1246 in colorectal tumors." +other hsa-mir-140 Colorectal Carcinoma 22479426 "The driving miRNAs were miR-195, miR-1280, miR-140-3p and miR-1246 in colorectal tumors." +other hsa-mir-15b Pancreatic Neoplasms 22479426 "The driving miRNAs were miR-103, miR-23a and miR-15b in pancreatic cancers." +other hsa-mir-195 Colorectal Carcinoma 22479426 "The driving miRNAs were miR-195, miR-1280, miR-140-3p and miR-1246 in colorectal tumors." +other hsa-mir-23a Pancreatic Neoplasms 22479426 "The driving miRNAs were miR-103, miR-23a and miR-15b in pancreatic cancers." +other hsa-mir-92a Breast Neoplasms 22482439 We found that miR-221 levels are prognostic in breast cancer illustrating the high-throughput method and confirming that miRNAs can be valuable biomarkers in cancer. +other hsa-mir-122 "Diabetes Mellitus, Type 2" 22488426 "Recent studies have shown key roles for miR-33 and miR-122 in regulation of lipid metabolism, and further evidence implicates miR-370 in regulation of miR-122." +other hsa-mir-33 "Diabetes Mellitus, Type 2" 22488426 "Recent studies have shown key roles for miR-33 and miR-122 in regulation of lipid metabolism, and further evidence implicates miR-370 in regulation of miR-122." +other hsa-mir-370 "Diabetes Mellitus, Type 2" 22488426 "Recent studies have shown key roles for miR-33 and miR-122 in regulation of lipid metabolism, and further evidence implicates miR-370 in regulation of miR-122." +other hsa-mir-143 Glioblastoma 22490015 Serial selection for invasiveness increases expression of miR-143/miR-145 in glioblastoma cell lines. +other hsa-mir-145 Glioblastoma 22490015 Serial selection for invasiveness increases expression of miR-143/miR-145 in glioblastoma cell lines. +other hsa-mir-107 Head And Neck Neoplasms 22491216 Lipid-based Nanoparticle Delivery of Pre-miR-107 Inhibits the Tumorigenicity of Head and Neck Squamous Cell Carcinoma. +other hsa-mir-193b "Carcinoma, Lung, Non-Small-Cell" 22491710 "MicroRNA-193b modulates proliferation, migration, and invasion of non-small cell lung cancer cells." +other hsa-mir-127 "Carcinoma, Renal Cell" 22492545 "miR-127-3p, miR-145, and miR-126 are significantly correlated with relapse-free survival of nonmetastatic RCC patients." +other hsa-mir-142 "Leukemia, Myeloid, Acute" 22493297 MicroRNA-29a and microRNA-142-3p are regulators of myeloid differentiation and acute myeloid leukemia. +other hsa-mir-29a "Leukemia, Myeloid, Acute" 22493297 MicroRNA-29a and microRNA-142-3p are regulators of myeloid differentiation and acute myeloid leukemia. +other hsa-mir-214 "Carcinoma, Lung, Non-Small-Cell" 22502680 MicroRNA-214 Regulates the Acquired Resistance to Gefitinib via the PTEN/AKT Pathway in EGFR-mutant Cell Lines. +other hsa-mir-125 Leukemia 22504525 Here we discuss new findings concerning PU.1-controlled microRNAs and miR-125-regulated networks in normal and malignant myelopoiesis. +other hsa-mir-181b Pancreatic Neoplasms 22504911 "miR-181b and miR-210 discriminatedPCa from normal individuals with receiver operating characteristic (ROC) curves and area under curve (AUC-ROC) of 0.745 and 0.772, respectively." +other hsa-mir-143 Prostate Neoplasms 22505520 The authors experientially validated the miRNA-KLK interaction by transfecting miR-331-3p and miR-143 into a PCa cell line. +other hsa-mir-331 Prostate Neoplasms 22505520 The authors experientially validated the miRNA-KLK interaction by transfecting miR-331-3p and miR-143 into a PCa cell line. +other hsa-mir-375 Breast Neoplasms 22508479 Re-expression of microRNA-375 reverses both tamoxifen resistance and accompanying EMT-like properties in breast cancer. +other hsa-mir-34a "Lymphoma, Large B-Cell, Diffuse" 22522790 Systemic microRNA-34a delivery induces apoptosis and abrogates growth of diffuse large B-cell lymphoma in vivo. +other hsa-mir-125b Human Immunodeficiency Virus Infection 22527633 "Researchers have recently demonstrated the presence of anti-HIV-1 microRNAs (miR-28, miR-125b, miR-150, miR-223, and miR-382) in monocytes, macrophages, and CD4+ T cells, which are the primary targets of HIV infection." +other hsa-mir-150 Human Immunodeficiency Virus Infection 22527633 "Researchers have recently demonstrated the presence of anti-HIV-1 microRNAs (miR-28, miR-125b, miR-150, miR-223, and miR-382) in monocytes, macrophages, and CD4+ T cells, which are the primary targets of HIV infection." +other hsa-mir-223 Human Immunodeficiency Virus Infection 22527633 "Researchers have recently demonstrated the presence of anti-HIV-1 microRNAs (miR-28, miR-125b, miR-150, miR-223, and miR-382) in monocytes, macrophages, and CD4+ T cells, which are the primary targets of HIV infection." +other hsa-mir-28 Human Immunodeficiency Virus Infection 22527633 "Researchers have recently demonstrated the presence of anti-HIV-1 microRNAs (miR-28, miR-125b, miR-150, miR-223, and miR-382) in monocytes, macrophages, and CD4+ T cells, which are the primary targets of HIV infection." +other hsa-mir-382 Human Immunodeficiency Virus Infection 22527633 "Researchers have recently demonstrated the presence of anti-HIV-1 microRNAs (miR-28, miR-125b, miR-150, miR-223, and miR-382) in monocytes, macrophages, and CD4+ T cells, which are the primary targets of HIV infection." +other hsa-mir-21 Glioblastoma 22528454 MicroRNA-21 inhibitor sensitizes human glioblastoma U251 stem cells to chemotherapeutic drug temozolomide. +other hsa-mir-21 Heart Failure 22529925 Transfection assay revealed that both Ago1 and Ago2 synergistically induced miR-21 and miR-21* when the mir-21 plasmid was co-transfected with either. +other hsa-mir-204 Hypertension 22534459 "This correlates with a down-regulation of miR-204 as well as an up-regulation of miR-21 in PLs, which in turn corresponds to enhanced cell proliferation." +other hsa-mir-21 Hypertension 22534459 "This correlates with a down-regulation of miR-204 as well as an up-regulation of miR-21 in PLs, which in turn corresponds to enhanced cell proliferation." +other hsa-mir-375 Colorectal Carcinoma 22535378 "In formalin-fixed paraffin-embedded surgical tissue samples, a combination of miR-375, miR-424 and miR-92a yielded an accuracy of 94% (AUC=0.968) in discriminating carcinomas from adenomas. " +other hsa-mir-424 Colorectal Carcinoma 22535378 "In formalin-fixed paraffin-embedded surgical tissue samples, a combination of miR-375, miR-424 and miR-92a yielded an accuracy of 94% (AUC=0.968) in discriminating carcinomas from adenomas. " +other hsa-mir-92a Colorectal Carcinoma 22535378 "In formalin-fixed paraffin-embedded surgical tissue samples, a combination of miR-375, miR-424 and miR-92a yielded an accuracy of 94% (AUC=0.968) in discriminating carcinomas from adenomas. " +other hsa-mir-206 Rhabdomyosarcoma 22541669 miR-206 integrates multiple components of differentiation pathways to control the transition from growth to differentiation in rhabdomyosarcoma cells. +other hsa-mir-125b Heart Failure 22545159 "These studies identified miR-125b as an important regulator of hESC differentiation in general, and the development of hESC-derived mesoderm and cardiac muscle in particular." +other hsa-mir-142 Systemic Lupus Erythematosus 22549634 Decreased miR-142-3p/5p expression causes CD4(+) T cell activation and B cell hyperstimulation in systemic lupus erythematosus. +other hsa-mir-126 "Carcinoma, Hepatocellular" 22552153 recurrence-related in hepatocellular carcinoma +other hsa-mir-147a "Carcinoma, Hepatocellular" 22552153 recurrence-related in hepatocellular carcinoma +other hsa-mir-19a "Carcinoma, Hepatocellular" 22552153 recurrence-related in hepatocellular carcinoma +other hsa-mir-223 "Carcinoma, Hepatocellular" 22552153 recurrence-related in hepatocellular carcinoma +other hsa-mir-24-1 "Carcinoma, Hepatocellular" 22552153 recurrence-related in hepatocellular carcinoma +other hsa-mir-24-2 "Carcinoma, Hepatocellular" 22552153 recurrence-related in hepatocellular carcinoma +other hsa-mir-708 Prostate Neoplasms 22552290 miRNA-708 control of CD44+ prostate cancer initiating cells. +other hsa-mir-21 Colorectal Carcinoma 22553926 "EGF/Ras efficiently induces the miR-21 primary transcript, but this does not rapidly and simply translate into higher mature miR-21 levels." +other hsa-mir-92a-1 Breast Neoplasms 22563438 Downregulation of miR-92a is associated with aggressive breast cancer features and increased tumour macrophage infiltration. +other hsa-mir-92a-2 Breast Neoplasms 22563438 Downregulation of miR-92a is associated with aggressive breast cancer features and increased tumour macrophage infiltration. +other hsa-mir-34a Glioma 22568628 MicroRNA-34a Suppresses Cell Proliferation and Induces Apoptosis in U87 Glioma Stem Cells. +other hsa-mir-22 Heart Failure 22570371 These data indicate that miR-22 functions as an integrator of Ca(2+) homeostasis and myofibrillar protein content during stress in the heart and shed light on the mechanisms that enhance propensity toward heart failure. +other hsa-mir-142 Glioblastoma 22570537 Integrated Analysis Reveals hsa-miR-142 as a Representative of a Lymphocyte-Specific Gene Expression and Methylation Signature. +other hsa-mir-145 Thrombocytosis 22571696 Recent evidence suggests that haploinsufficiency of the microRNA genes miR-145 and miR-146a may contribute to the thrombocytosis seen in the 5q- syndrome. +other hsa-mir-146a Thrombocytosis 22571696 Recent evidence suggests that haploinsufficiency of the microRNA genes miR-145 and miR-146a may contribute to the thrombocytosis seen in the 5q- syndrome. +other hsa-mir-221 Asthma 22572970 Inhibition of miRNA-221 Suppresses the Airway Inflammation in Asthma. +other hsa-mir-15a Colon Neoplasms 22574716 Vector-based miR-15a/16-1 plasmid inhibits colon cancer growth in vivo. +other hsa-mir-16-1 Colon Neoplasms 22574716 Vector-based miR-15a/16-1 plasmid inhibits colon cancer growth in vivo. +other hsa-mir-15a Immune System Disease [unspecific] 22578383 "In conclusion, our data support the involvement of elevated miR-15a in autoimmune disease development in B/W mice and suggest that decreasing this microRNA might be beneficial in B/W mice." +other hsa-mir-205 Breast Neoplasms 22578566 Oncosuppressive role of p53-induced miR-205 in triple negative breast cancer. +other hsa-mir-146a Asthma 22580216 "These observations suggest that microRNA-181a, -146a and -146b are proinflammatory factors in asthma, and that down-regulation of miRNA-146a may partially account for the anti-inflammatory effect of dexamethasone." +other hsa-mir-146b Asthma 22580216 "These observations suggest that microRNA-181a, -146a and -146b are proinflammatory factors in asthma, and that down-regulation of miRNA-146a may partially account for the anti-inflammatory effect of dexamethasone." +other hsa-mir-181a Asthma 22580216 "These observations suggest that microRNA-181a, -146a and -146b are proinflammatory factors in asthma, and that down-regulation of miRNA-146a may partially account for the anti-inflammatory effect of dexamethasone." +other hsa-mir-21 Cardiac Fibrosis 22580345 "we identify the protective transcriptome signature of enhanced PI3K¦Á signaling in the context of pathological hypertrophy, and demonstrate the regulation of TGF-¦Â/miR-21 by which enhanced PI3K¦Á signaling protects against cardiac fibrosis." +other hsa-mir-502 Colon Neoplasms 22580605 Inhibition of autophagy and tumor growth in colon cancer by miR-502. +other hsa-mir-9 Immune System Disease [unspecific] 22585398 "Using microarray and deep sequencing approaches, we detected an increase in the abundance of miR-9 in activated human CD4(+) T cells." +other hsa-mir-122 Hepatitis C Virus Infection 22593164 Expression of MicroRNA miR-122 Facilitates an Efficient Replication in Nonhepatic Cells upon Infection with Hepatitis C Virus. +other hsa-mir-155 "Lymphoma, Large B-Cell, Diffuse" 22609116 miR-155 Regulates the PI3K-AKT pathway in diffuse large B-cell lymphoma. +other hsa-mir-106b Myocardial Infarction 22613985 MiR-106b and MiR-15b modulate apoptosis and angiogenesis in myocardial infarction. +other hsa-let-7g Obesity 22614057 "Maternal obesity downregulates microRNA let-7g expression, a possible mechanism for enhanced adipogenesis during ovine fetal skeletal muscle development." +other hsa-mir-30a "Leukemia, Myeloid, Chronic" 22617440 microRNA 30A promotes autophagy in response to cancer therapy. +other hsa-mir-21 Breast Neoplasms 22618231 "Regulatory interplay between miR-21, JAG1 and 17beta-estradiol (E2) in breast cancer cells." +other hsa-mir-23a Colorectal Carcinoma 22628407 miR-23a promotes the transition from indolent to invasive colorectal cancer. +other hsa-mir-204 Breast Neoplasms 22629385 "Gene expression analysis of miR-204 and miR-379-transfected cells indicated that these miRNAs downregulated the expression of several genes involved in TGF-¦Â signaling, including prostaglandin-endoperoxide synthase 2 (PTGS2)." +other hsa-mir-379 Breast Neoplasms 22629385 "Gene expression analysis of miR-204 and miR-379-transfected cells indicated that these miRNAs downregulated the expression of several genes involved in TGF-¦Â signaling, including prostaglandin-endoperoxide synthase 2 (PTGS2)." +other hsa-mir-499a "Carcinoma, Hepatocellular" 22641068 Histone Deacetylases Activate Hepatocyte Growth Factor Signaling by Repressing MicroRNA-449 in Hepatocellular Carcinoma Cells. +other hsa-mir-499b "Carcinoma, Hepatocellular" 22641068 Histone Deacetylases Activate Hepatocyte Growth Factor Signaling by Repressing MicroRNA-449 in Hepatocellular Carcinoma Cells. +other hsa-let-7 Diffuse Lipomatosis 22642449 First description of inhibition of let-7 microRNA expression and HMGA2 overexpression in a case of deep-seated diffuse lipomatosis. +other hsa-mir-107 "Diabetes Mellitus, Type 2" 22645244 miR-107: a Toll-like receptor-regulated miRNA dysregulated in obesity and type II diabetes. +other hsa-mir-107 Obesity 22645244 miR-107: a Toll-like receptor-regulated miRNA dysregulated in obesity and type II diabetes. +other hsa-mir-20a Endometriosis 22648654 Hypoxia-induced microRNA-20a expression increases ERK phosphorylation and angiogenic gene expression in endometriotic stromal cells. +other hsa-mir-34a Cardiovascular Diseases [unspecific] 22651868 Micro-RNA-34a contributes to the impaired function of bone marrow-derived mononuclear cells from patients with cardiovascular disease. +other hsa-mir-31 Lung Fibrosis 22661007 miR-31 is a negative regulator of fibrogenesis and pulmonary fibrosis. +other hsa-mir-34a Neuroblastoma 22662276 Inhibition of neuroblastoma tumor growth by targeted delivery of microRNA-34a using anti-disialoganglioside GD2 coated nanoparticles. +other hsa-mir-9-1 Head And Neck Neoplasms 22664743 IRS-1 suppresses metastasis of head and neck cancer possibly through miR-9 +other hsa-mir-9-2 Head And Neck Neoplasms 22664743 IRS-1 suppresses metastasis of head and neck cancer possibly through miR-9 +other hsa-mir-9-3 Head And Neck Neoplasms 22664743 IRS-1 suppresses metastasis of head and neck cancer possibly through miR-9 +other hsa-mir-193b Melanoma 22665054 "Taken together, our study suggests that downregulation of miR-193b may contribute to increased STMN1 expression in melanoma, which consequently promotes migration and proliferation of tumor cells." +other hsa-mir-208a Hypertension 22666483 "this work reveals an original aldosterone-dependent inhibition of miR-208a in hypertension, resulting in the inhibition of ¦Â-myosin heavy chain expression through the induction of its transcriptional repressor Sox6." +other hsa-mir-208b Hypertension 22666483 "Besides, the AH-induced increase of ?MyHC and its intronic miRNA-208b was prevented in AS-Ren." +other hsa-mir-210 Pancreatic Neoplasms 22672828 "miR-210 expression in PC cells is induced by hypoxia through a HIF-1alpha-dependent pathway, but does not influence PC cell proliferation." +other hsa-mir-17 Colon Neoplasms 22677902 "miR-21, miR-17 and miR-19a induced by phosphatase of regenerating liver-3 promote the proliferation and metastasis of colon cancer." +other hsa-mir-19a Colon Neoplasms 22677902 "miR-21, miR-17 and miR-19a induced by phosphatase of regenerating liver-3 promote the proliferation and metastasis of colon cancer." +other hsa-mir-21 Colon Neoplasms 22677902 "miR-21, miR-17 and miR-19a induced by phosphatase of regenerating liver-3 promote the proliferation and metastasis of colon cancer." +other hsa-mir-155 "Leukemia, Myeloid, Acute" 22681934 MiR-424 and miR-155 deregulated expression in cytogenetically normal acute myeloid leukaemia: correlation with NPM1 and FLT3 mutation status. +other hsa-mir-424 "Leukemia, Myeloid, Acute" 22681934 MiR-424 and miR-155 deregulated expression in cytogenetically normal acute myeloid leukaemia: correlation with NPM1 and FLT3 mutation status. +other hsa-mir-10b Choriocarcinoma 22682079 The role of miR-10b in metastatic pancreatic ductal adenocarcinoma. +other hsa-mir-376a-1 "Carcinoma, Hepatocellular" 22684007 miR-376a suppresses proliferation and induces apoptosis in hepatocellular carcinoma. +other hsa-mir-376a-2 "Carcinoma, Hepatocellular" 22684007 miR-376a suppresses proliferation and induces apoptosis in hepatocellular carcinoma. +other hsa-mir-23a Colorectal Carcinoma 22684455 "miR-23a, a critical regulator of migRation and metastasis in colorectal cancer." +other hsa-mir-21 Esophageal Neoplasms 22689922 Dysregulation of miR-31 and miR-21 induced by zinc deficiency promotes esophageal cancer. +other hsa-mir-31 Esophageal Neoplasms 22689922 Dysregulation of miR-31 and miR-21 induced by zinc deficiency promotes esophageal cancer. +other hsa-mir-124 Glioblastoma 22701651 "Significantly, REST is highly expressed in self-renewing tumorigenic-competent GBM cells and its knock down strongly reduces their self-renewal in vitro and tumor-initiating capacity in vivo and affects levels of miR-124 and its downstream targets." +other hsa-mir-31 Esophageal Neoplasms 22706599 MicroRNA-31 modulates tumour sensitivity to radiation in oesophageal adenocarcinoma. +other hsa-mir-200c Cholangiocarcinoma 22707408 "Inactivation of miR-200c resulted in an induction of EMT, whereas activation of miR-200c led to a reduction of EMT including a reduced cell migration and invasion in ICC cells." +other hsa-mir-125b-1 Glioblastoma 22711523 miR-125b expression plays an essential role in the invasion of glioblastoma CD133-positive cells but not CD133-negative cells. +other hsa-mir-125b-2 Glioblastoma 22711523 miR-125b expression plays an essential role in the invasion of glioblastoma CD133-positive cells but not CD133-negative cells. +other hsa-mir-29b-1 Preeclampsia 22716646 "MicroRNA-29b contributes to pre-eclampsia through its effects on apoptosis, invasion and angiogenesis of trophoblast cells." +other hsa-mir-29b-2 Preeclampsia 22716646 "MicroRNA-29b contributes to pre-eclampsia through its effects on apoptosis, invasion and angiogenesis of trophoblast cells." +other hsa-mir-31 Oral Leukoplakia 22719913 Upregulation of miR-31* is negatively associated with recurrent/newly formed oral leukoplakia. +other hsa-mir-196b Glioblastoma 22723849 Upregulation of miR-196b confers a poor prognosis in glioblastoma patients via inducing a proliferative phenotype. +other hsa-mir-200c Colorectal Carcinoma 22735571 MicroRNA-200c modulates epithelial-to-mesenchymal transition (EMT) in human colorectal cancer metastasis. +other hsa-mir-31 Systemic Lupus Erythematosus 22736314 microRNA-31 is a novel regulator contributing to impaired IL-2 production in T cells from patients with systemic lupus erythematosus. +other hsa-mir-101 Bladder Neoplasms 22745731 "The combination of four (miR-101, miR-125a-5p, miR-148b, and miR-151-5p) or three (miR-148b, miR-181b, and miR-874,) reference miRNAs is recommended for normalization." +other hsa-mir-125a Bladder Neoplasms 22745731 "The combination of four (miR-101, miR-125a-5p, miR-148b, and miR-151-5p) or three (miR-148b, miR-181b, and miR-874,) reference miRNAs is recommended for normalization." +other hsa-mir-148b Bladder Neoplasms 22745731 "The combination of four (miR-101, miR-125a-5p, miR-148b, and miR-151-5p) or three (miR-148b, miR-181b, and miR-874,) reference miRNAs is recommended for normalization." +other hsa-mir-151 Bladder Neoplasms 22745731 "The combination of four (miR-101, miR-125a-5p, miR-148b, and miR-151-5p) or three (miR-148b, miR-181b, and miR-874,) reference miRNAs is recommended for normalization." +other hsa-mir-181b Bladder Neoplasms 22745731 "The combination of four (miR-101, miR-125a-5p, miR-148b, and miR-151-5p) or three (miR-148b, miR-181b, and miR-874,) reference miRNAs is recommended for normalization." +other hsa-mir-874 Bladder Neoplasms 22745731 "The combination of four (miR-101, miR-125a-5p, miR-148b, and miR-151-5p) or three (miR-148b, miR-181b, and miR-874,) reference miRNAs is recommended for normalization." +other hsa-mir-499 Heart Failure 22752967 "miR-499 is increased in human and murine cardiac hypertrophy and cardiomyopathy, is sufficient to cause murine heart failure, and accelerates maladaptation to pressure overloading. " +other hsa-mir-103 Breast Neoplasms 22753153 Identification of fifteen novel germline variants in the BRCA1 3'UTR reveals a variant in a breast cancer case that introduces a functional miR-103 target site. +other hsa-mir-21 Glioblastoma 22753745 MicroRNA-21 inhibition enhances in vitro chemosensitivity of temozolomide-resistant glioblastoma cells. +other hsa-mir-21 Myocardial Infarction 22760500 Activation of Rac1 by angiotensin II leads to a CTGF- and lysyl oxidase-mediated increase of miR-21 expression contributing to structural remodelling of the atrial myocardium. +other hsa-mir-21 "Carcinoma, Oral" 22761427 Keratinization-associated miR-7 and miR-21 Regulate Tumor Suppressor Reversion-inducing Cysteine-rich Protein with Kazal Motifs (RECK) in Oral Cancer. +other hsa-mir-7-1 "Carcinoma, Oral" 22761427 Keratinization-associated miR-7 and miR-21 Regulate Tumor Suppressor Reversion-inducing Cysteine-rich Protein with Kazal Motifs (RECK) in Oral Cancer. +other hsa-mir-7-2 "Carcinoma, Oral" 22761427 Keratinization-associated miR-7 and miR-21 Regulate Tumor Suppressor Reversion-inducing Cysteine-rich Protein with Kazal Motifs (RECK) in Oral Cancer. +other hsa-mir-7-3 "Carcinoma, Oral" 22761427 Keratinization-associated miR-7 and miR-21 Regulate Tumor Suppressor Reversion-inducing Cysteine-rich Protein with Kazal Motifs (RECK) in Oral Cancer. +other hsa-mir-24-1 Pancreatic Neoplasms 22761894 "We investigated this possibility by analysis of miR-24-1 expression profiles in parathyroid adenomatous tissues from MEN1 gene mutation carriers, in their sporadic non-MEN1 counterparts, and in normal parathyroid tissue." +other hsa-mir-10b Glioma 22766763 Co-inhibition of microRNA-10b and microRNA-21 exerts synergistic inhibition on the proliferation and invasion of human glioma cells. +other hsa-mir-21 Glioma 22766763 Co-inhibition of microRNA-10b and microRNA-21 exerts synergistic inhibition on the proliferation and invasion of human glioma cells. +other hsa-mir-182 Endometrial Neoplasms 22766795 "In distinguishing endometrial endometrial carcinoma from complex atypical hyperplasia, the composite panel of four miRNAs (miR-182, 183, 200a, 200c) produced 95% sensitivity and 91% specificity." +other hsa-mir-183 Endometrial Neoplasms 22766795 "In distinguishing endometrial endometrial carcinoma from complex atypical hyperplasia, the composite panel of four miRNAs (miR-182, 183, 200a, 200c) produced 95% sensitivity and 91% specificity." +other hsa-mir-200a Endometrial Neoplasms 22766795 "In distinguishing endometrial endometrial carcinoma from complex atypical hyperplasia, the composite panel of four miRNAs (miR-182, 183, 200a, 200c) produced 95% sensitivity and 91% specificity." +other hsa-mir-200c Endometrial Neoplasms 22766795 "In distinguishing endometrial endometrial carcinoma from complex atypical hyperplasia, the composite panel of four miRNAs (miR-182, 183, 200a, 200c) produced 95% sensitivity and 91% specificity." +other hsa-mir-221 Thyroid Neoplasms 22771635 While a combination of miR-221 and 222 when used in a diagnostic panel could provide fairly good accuracy additional markers may need to be investigated to augment their diagnostic utility. +other hsa-mir-222 Thyroid Neoplasms 22771635 While a combination of miR-221 and 222 when used in a diagnostic panel could provide fairly good accuracy additional markers may need to be investigated to augment their diagnostic utility. +other hsa-mir-93 "Carcinoma, Hepatocellular" 22773266 Downregulation of MiR-93 Expression Reduces Cell Proliferation and Clonogenicity of HepG2 Cells. +other hsa-mir-15a Multiple Myeloma 22781767 BMSCs suppress the proliferation of myeloma cells and regulate the drug sensitivity of myeloma cells through the inhibited expression of miRNA-15a/-16. IL-6 plays a pivotal role in the occurrence of drug resistance. +other hsa-mir-16 Multiple Myeloma 22781767 BMSCs suppress the proliferation of myeloma cells and regulate the drug sensitivity of myeloma cells through the inhibited expression of miRNA-15a/-16. IL-6 plays a pivotal role in the occurrence of drug resistance. +other hsa-mir-494 Cholangiocarcinoma 22785131 Coordinated effects of microRNA-494 induce G/M arrest in human cholangiocarcinoma. +other hsa-mir-21 Ischemia-Reperfusion Injury 22785173 "Thus, upregulation of miR-21 contributes to the protective effect of delayed ischemic preconditioning against subsequent renal ischemia-reperfusion injury." +other hsa-mir-21 Bladder Neoplasms 22788411 "The effect of normalization was tested with miR-21 as the target gene, as this was previously suggested to be upregulated in cancer patients' serum." +other hsa-mir-155 Lung Neoplasms 22796123 "The present study demonstrated that intracellular miR-155 could be successfully and quickly detected by novel miR-155 MBs. As a noninvasive monitoring approach, MBs could be used to diagnose lung cancer at early stage through molecular imaging." +other hsa-mir-335 Gastric Neoplasms 22802949 A high frequency recurrence and poor survival were observed in GC cases with high level of hsa-miR-335 (P<0.001). +other hsa-mir-200b Colorectal Carcinoma 22804917 In KRAS mutated tumours increased miR-200b and decreased miR-143 expression were associated with a good progression-free survival . +other hsa-mir-34a "Leukemia, Myeloid, Acute" 22810507 "Clinically, low miR-34a expression and TP53 alterations predicted for chemotherapy resistance and inferior outcome. Notably, in TP53(unaltered) CK-AML, high miR-34a expression predicted for inferior overall survival (OS), whereas in TP53(biallelic altered) CK-AML, high miR-34a expression pointed to better OS." +other hsa-mir-101-1 Endomyocardial Fibrosis 22811578 MicroRNA-101 Inhibited Postinfarct Cardiac Fibrosis and Improved Left Ventricular Compliance via the FBJ Osteosarcoma Oncogene/Transforming Growth Factor Pathway. +other hsa-mir-101-2 Endomyocardial Fibrosis 22811578 MicroRNA-101 Inhibited Postinfarct Cardiac Fibrosis and Improved Left Ventricular Compliance via the FBJ Osteosarcoma Oncogene/Transforming Growth Factor-§Ø©ã Pathway. +other hsa-let-7i Ovarian Neoplasms 22812695 Our study indicated that this MUC1/let-7i chimera can specifically reverse chemoresistance to paclitaxel. +other hsa-mir-205 Prostate Neoplasms 22815235 "Additionally, for two genes that are deregulated in PCa (heterogeneous nuclear ribonucleoprotein K, hnRNP-K, and vascular endothelial growth factor A, VEGF-A), we identified two regulatory miRNAs, miR-205 and miR-29b." +other hsa-mir-29b Prostate Neoplasms 22815235 "Additionally, for two genes that are deregulated in PCa (heterogeneous nuclear ribonucleoprotein K, hnRNP-K, and vascular endothelial growth factor A, VEGF-A), we identified two regulatory miRNAs, miR-205 and miR-29b." +other hsa-mir-122 "Carcinoma, Hepatocellular" 22820284 "Knockout mice also displayed hepatic inflammation, fibrosis, and a high incidence of hepatocellular carcinoma, suggesting that miR-122 has a tumor suppressor role in hepatocytes." +other hsa-mir-125b "Carcinoma, Hepatocellular" 22824797 "downregulation of miR-125b was a frequent event in hepatocellular carcinoma (HCC) tissues, and the miR-125b level was positively associated with the rate of apoptosis in HCC tissues." +other hsa-mir-9-1 Melanoma 22825752 MicroRNA-9 suppresses uveal melanoma cell migration and invasion through the NF-kB1 pathway. +other hsa-mir-9-2 Melanoma 22825752 MicroRNA-9 suppresses uveal melanoma cell migration and invasion through the NF-kB1 pathway. +other hsa-mir-9-3 Melanoma 22825752 MicroRNA-9 suppresses uveal melanoma cell migration and invasion through the NF-kB1 pathway. +other hsa-mir-124 Glioblastoma 22829753 "Our follow up topological and functional analyses of the subnetwork revealed that six miRNAs (miR-124, miR-137, miR-219-5p, miR-34a, miR-9, and miR-92b) might play important roles in GBM, including some results that are supported by previous studies." +other hsa-mir-137 Glioblastoma 22829753 "Our follow up topological and functional analyses of the subnetwork revealed that six miRNAs (miR-124, miR-137, miR-219-5p, miR-34a, miR-9, and miR-92b) might play important roles in GBM, including some results that are supported by previous studies." +other hsa-mir-219 Glioblastoma 22829753 "Our follow up topological and functional analyses of the subnetwork revealed that six miRNAs (miR-124, miR-137, miR-219-5p, miR-34a, miR-9, and miR-92b) might play important roles in GBM, including some results that are supported by previous studies." +other hsa-mir-34a Glioblastoma 22829753 "Our follow up topological and functional analyses of the subnetwork revealed that six miRNAs (miR-124, miR-137, miR-219-5p, miR-34a, miR-9, and miR-92b) might play important roles in GBM, including some results that are supported by previous studies." +other hsa-mir-9 Glioblastoma 22829753 "Our follow up topological and functional analyses of the subnetwork revealed that six miRNAs (miR-124, miR-137, miR-219-5p, miR-34a, miR-9, and miR-92b) might play important roles in GBM, including some results that are supported by previous studies." +other hsa-mir-92b Glioblastoma 22829753 "Our follow up topological and functional analyses of the subnetwork revealed that six miRNAs (miR-124, miR-137, miR-219-5p, miR-34a, miR-9, and miR-92b) might play important roles in GBM, including some results that are supported by previous studies." +other hsa-mir-210 Ischemic Diseases [unspecific] 22833359 miR-210 activates notch signaling pathway in angiogenesis induced by cerebral ischemia. +other hsa-mir-155 Glioblastoma 22834637 A relationship between knock-down of miR-155 and re-expression of GABRA 1 protein in vivo was recently individuated. +other hsa-mir-185 Glioma 22834685 LRRC4 inhibits glioma cell growth and invasion through a miR-185-dependent pathway. +other hsa-mir-210 Preeclampsia 22840297 MIR-210 modulates mitochondrial respiration in placenta with preeclampsia. +other hsa-mir-144 "Leukemia, Myeloid, Chronic" 22842456 Myc induced miR-144/451 contributes to the acquired imatinib resistance in chronic myelogenous leukemia cell K562. +other hsa-mir-451a "Leukemia, Myeloid, Chronic" 22842456 Myc induced miR-144/451 contributes to the acquired imatinib resistance in chronic myelogenous leukemia cell K562. +other hsa-mir-451b "Leukemia, Myeloid, Chronic" 22842456 Myc induced miR-144/451 contributes to the acquired imatinib resistance in chronic myelogenous leukemia cell K562. +other hsa-mir-21 Heart Failure 22842854 "TMZ improved RV function (as indicated by an increase in tricuspid annular plane systolic excursion), and inhibited fibrosis. TMZ also protects RVMCs againts apoptosis and increases miR-21 expression." +other hsa-mir-148b "Lymphoma, Non-Hodgkin" 22843616 MicroRNA-148b enhances the radiosensitivity of non-Hodgkin's Lymphoma cells by promoting radiation-induced apoptosis. +other hsa-mir-126 Colorectal Carcinoma 22848274 Elevated microRNA-126 is associated with high vascular endothelial growth factor receptor 2 expression levels and high microvessel density in colorectal cancer. +other hsa-mir-433 Myeloproliferative Neoplasms 22864358 miR-433 is aberrantly expressed in myeloproliferative neoplasms and suppresses hematopoietic cell growth and differentiation. +other hsa-mir-17 Retinoblastoma 22864477 "Synthetic lethality between Rb, p53 and Dicer or miR-17-92 in retinal progenitors suppresses retinoblastoma formation." +other hsa-mir-18a Retinoblastoma 22864477 "Synthetic lethality between Rb, p53 and Dicer or miR-17-92 in retinal progenitors suppresses retinoblastoma formation." +other hsa-mir-19b-1 Retinoblastoma 22864477 "Synthetic lethality between Rb, p53 and Dicer or miR-17-92 in retinal progenitors suppresses retinoblastoma formation." +other hsa-mir-20a Retinoblastoma 22864477 "Synthetic lethality between Rb, p53 and Dicer or miR-17-92 in retinal progenitors suppresses retinoblastoma formation." +other hsa-mir-92a-1 Retinoblastoma 22864477 "Synthetic lethality between Rb, p53 and Dicer or miR-17-92 in retinal progenitors suppresses retinoblastoma formation." +other hsa-mir-21 Lung Neoplasms 22866162 The detection of miR-21 expression yielded 78.80% sensitivity and 100.00% specificity in the diagnosis of lung cancer. +other hsa-mir-200a "Carcinoma, Hepatocellular" 22868917 MicroRNA-200a and -200b Mediated Hepatocellular Carcinoma Cell Migration Through the Epithelial to Mesenchymal Transition Markers. +other hsa-mir-200b "Carcinoma, Hepatocellular" 22868917 MicroRNA-200a and -200b Mediated Hepatocellular Carcinoma Cell Migration Through the Epithelial to Mesenchymal Transition Markers. +other hsa-mir-21 Hypertrophy 22879939 TGFbeta-Stimulated MicroRNA-21 Utilizes PTEN to Orchestrate AKT/mTORC1 Signaling for Mesangial Cell Hypertrophy and Matrix Expansion. +other hsa-mir-124-1 Colorectal Carcinoma 22885837 Downregulation of microRNA-124 is an independent prognostic factor in patients with colorectal cancer. +other hsa-mir-124-2 Colorectal Carcinoma 22885837 Downregulation of microRNA-124 is an independent prognostic factor in patients with colorectal cancer. +other hsa-mir-205 Melanoma 22890556 miR-205 is a tumor suppressor microRNAin malignant melanoma. +other hsa-mir-204 Neuroblastoma 22892391 MicroRNA-204 increases sensitivity of neuroblastoma cells to cisplatin and is associated with a favourable clinical outcome. +other hsa-mir-27b Metabolic Syndrome 22893262 "we thus speculate that Rb1 may act though PPAR¦Ã to downregulate mir-27b gene transcription and mature miR-27b activity, which in turn promotes PPAR¦Ã expression and adipogenesis." +other hsa-mir-141 Ovarian Neoplasms 22897840 "Some genes involved in EMT, such as BMP and activin membrane-bound inhibitor (BAMBI), and mir-141 resulted in association with overall or progression free survival." +other hsa-mir-126 "Carcinoma, Lung, Non-Small-Cell" 22900072 MicroRNA-126 Inhibits Tumor Cell Growth and Its Expression Level Correlates with Poor Survival in Non-Small Cell Lung Cancer Patients. +other hsa-mir-320a Diabetes Mellitus 22900199 miR-320 Regulates Glucose-Induced Gene Expression in Diabetes. +other hsa-mir-20a Breast Neoplasms 22901144 Differential Distribution of miR-20a and miR-20b may Underly Metastatic Heterogeneity of Breast Cancers. +other hsa-mir-153-1 Rectal Neoplasms 22903298 "These signatures consisted of three miRNA transcripts (miR-16, miR-590-5p and miR-153) to predict complete vs. incomplete response and two miRNA transcript (miR-519c-3p and miR-561) to predict good vs. poor response with a median accuracy of 100 %." +other hsa-mir-153-2 Rectal Neoplasms 22903298 "These signatures consisted of three miRNA transcripts (miR-16, miR-590-5p and miR-153) to predict complete vs. incomplete response and two miRNA transcript (miR-519c-3p and miR-561) to predict good vs. poor response with a median accuracy of 100 %." +other hsa-mir-16-1 Rectal Neoplasms 22903298 "These signatures consisted of three miRNA transcripts (miR-16, miR-590-5p and miR-153) to predict complete vs. incomplete response and two miRNA transcript (miR-519c-3p and miR-561) to predict good vs. poor response with a median accuracy of 100 %." +other hsa-mir-16-2 Rectal Neoplasms 22903298 "These signatures consisted of three miRNA transcripts (miR-16, miR-590-5p and miR-153) to predict complete vs. incomplete response and two miRNA transcript (miR-519c-3p and miR-561) to predict good vs. poor response with a median accuracy of 100 %." +other hsa-mir-519c Rectal Neoplasms 22903298 "These signatures consisted of three miRNA transcripts (miR-16, miR-590-5p and miR-153) to predict complete vs. incomplete response and two miRNA transcript (miR-519c-3p and miR-561) to predict good vs. poor response with a median accuracy of 100 %." +other hsa-mir-561 Rectal Neoplasms 22903298 "These signatures consisted of three miRNA transcripts (miR-16, miR-590-5p and miR-153) to predict complete vs. incomplete response and two miRNA transcript (miR-519c-3p and miR-561) to predict good vs. poor response with a median accuracy of 100 %." +other hsa-mir-590 Rectal Neoplasms 22903298 "These signatures consisted of three miRNA transcripts (miR-16, miR-590-5p and miR-153) to predict complete vs. incomplete response and two miRNA transcript (miR-519c-3p and miR-561) to predict good vs. poor response with a median accuracy of 100 %." +other hsa-mir-181 Endometrial Neoplasms 22911744 "Three miRNAs families, miR-181, miR-183 and miR-200, are down-regulated during the decidualization process." +other hsa-mir-183 Endometrial Neoplasms 22911744 "Three miRNAs families, miR-181, miR-183 and miR-200, are down-regulated during the decidualization process." +other hsa-mir-200 Endometrial Neoplasms 22911744 "Three miRNAs families, miR-181, miR-183 and miR-200, are down-regulated during the decidualization process." +other hsa-mir-338 Hepatitis B Virus Infection 22912826 The Effect of miR-338-3p on HBx Deletion-Mutant (HBx-d382) Mediated Liver-Cell Proliferation through CyclinD1 Regulation. +other hsa-mir-124-1 Glioma 22918790 CDA-2 induces cell differentiation through suppressing Twist/SLUG signaling via miR-124 in glioma. +other hsa-mir-124-2 Glioma 22918790 CDA-2 induces cell differentiation through suppressing Twist/SLUG signaling via miR-124 in glioma. +other hsa-mir-15b Cervical Neoplasms 22920753 "These data suggested that down-regulation of NDRG2 could enhance sensitivity of Hela cells to cisplatin through inhibiting Bcl-2 protein expression, which might be mediated by up-regulating miR-15b and miR-16." +other hsa-mir-16 Cervical Neoplasms 22920753 "These data suggested that down-regulation of NDRG2 could enhance sensitivity of Hela cells to cisplatin through inhibiting Bcl-2 protein expression, which might be mediated by up-regulating miR-15b and miR-16." +other hsa-mir-138-1 Glioma 22921398 miR-138 has a critical role in promoting growth and survival of bona fide tumor-initiating cells with self-renewal potential. +other hsa-mir-138-2 Glioma 22921398 miR-138 has a critical role in promoting growth and survival of bona fide tumor-initiating cells with self-renewal potential. +other hsa-mir-141 Melanoma 22927992 "The strongest inhibitors of melanoma cell proliferation, including the miR-15/16, miR-141/200a and miR-96/182 families of miRNAs and miR-203." +other hsa-mir-15a Melanoma 22927992 "The strongest inhibitors of melanoma cell proliferation, including the miR-15/16, miR-141/200a and miR-96/182 families of miRNAs and miR-203." +other hsa-mir-15b Melanoma 22927992 "The strongest inhibitors of melanoma cell proliferation, including the miR-15/16, miR-141/200a and miR-96/182 families of miRNAs and miR-203." +other hsa-mir-16-1 Melanoma 22927992 "The strongest inhibitors of melanoma cell proliferation, including the miR-15/16, miR-141/200a and miR-96/182 families of miRNAs and miR-203." +other hsa-mir-16-2 Melanoma 22927992 "The strongest inhibitors of melanoma cell proliferation, including the miR-15/16, miR-141/200a and miR-96/182 families of miRNAs and miR-203." +other hsa-mir-182 Melanoma 22927992 "The strongest inhibitors of melanoma cell proliferation, including the miR-15/16, miR-141/200a and miR-96/182 families of miRNAs and miR-203." +other hsa-mir-200a Melanoma 22927992 "The strongest inhibitors of melanoma cell proliferation, including the miR-15/16, miR-141/200a and miR-96/182 families of miRNAs and miR-203." +other hsa-mir-203 Melanoma 22927992 "The strongest inhibitors of melanoma cell proliferation, including the miR-15/16, miR-141/200a and miR-96/182 families of miRNAs and miR-203." +other hsa-mir-96 Melanoma 22927992 "The strongest inhibitors of melanoma cell proliferation, including the miR-15/16, miR-141/200a and miR-96/182 families of miRNAs and miR-203." +other hsa-mir-151a Prostate Neoplasms 22928040 Genistein Suppresses Prostate Cancer Growth through Inhibition of Oncogenic MicroRNA-151. +other hsa-mir-151b Prostate Neoplasms 22928040 Genistein Suppresses Prostate Cancer Growth through Inhibition of Oncogenic MicroRNA-151. +other hsa-mir-143 Prostate Neoplasms 22929553 "Several miRNAs such as miR-96, miR-182, and miR-143 demonstrated high influence on their target protein complexes and could explain most of the gene expression changes in our analyzed prostate cancer data set." +other hsa-mir-182 Prostate Neoplasms 22929553 "Several miRNAs such as miR-96, miR-182, and miR-143 demonstrated high influence on their target protein complexes and could explain most of the gene expression changes in our analyzed prostate cancer data set." +other hsa-mir-96 Prostate Neoplasms 22929553 "Several miRNAs such as miR-96, miR-182, and miR-143 demonstrated high influence on their target protein complexes and could explain most of the gene expression changes in our analyzed prostate cancer data set." +other hsa-mir-143 Myelodysplastic Syndromes 22929976 Lenalidomide selectively abrogated progenitor activity in cells depleted of miR-143 and miR-145 supporting a key role for miR-143/145 in the sensitivity to lenalidomide of del(5q) myelodysplastic syndrome patients. +other hsa-mir-145 Myelodysplastic Syndromes 22929976 Lenalidomide selectively abrogated progenitor activity in cells depleted of miR-143 and miR-145 supporting a key role for miR-143/145 in the sensitivity to lenalidomide of del(5q) myelodysplastic syndrome patients. +other hsa-let-7b "Carcinoma, Hepatocellular" 22934260 TLR4 signaling induces the release of microparticles by tumor cells that regulate inflammatory cytokine IL-6 of macrophages via microRNA let-7b. +other hsa-mir-296 Esophageal Neoplasms 22939244 differentially regulated +other hsa-mir-127 "Lymphoma, Burkitt" 22941339 Epstein-Barr nuclear antigen 1 induces expression of the cellular microRNA hsa-miR-127 and impairing B-cell differentiation in EBV-infected memory B cells. +other hsa-mir-125b-1 "Carcinoma, Hepatocellular" 22942733 MicroRNA-125b Functions as a Tumor Suppressor in Hepatocellular Carcinoma Cells. +other hsa-mir-125b-2 "Carcinoma, Hepatocellular" 22942733 MicroRNA-125b Functions as a Tumor Suppressor in Hepatocellular Carcinoma Cells. +other hsa-mir-101-1 Pancreatic Neoplasms 22943841 Restoration of E-cadherin expression in pancreatic ductal adenocarcinoma treated with microRNA-101. +other hsa-mir-101-2 Pancreatic Neoplasms 22943841 Restoration of E-cadherin expression in pancreatic ductal adenocarcinoma treated with microRNA-101. +other hsa-mir-125b-1 Myelodysplastic Syndromes 22944560 Myelodysplastic syndrome with a t(2;11)(p21;q23-24) and translocation breakpoint close to miR-125b-1. +other hsa-mir-143 Prostate Neoplasms 22948942 miR-143 and miR-145 inhibit stem cell characteristics of PC-3 prostate cancer cells. +other hsa-mir-145 Prostate Neoplasms 22948942 miR-143 and miR-145 inhibit stem cell characteristics of PC-3 prostate cancer cells. +other hsa-mir-146a Breast Neoplasms 22949171 MicroRNA-146a suppresses metastatic activity in brain metastasis. +other hsa-mir-15a Infection [unspecific] 22953717 "Moreover, miR-664-5p, miR-451 and miR-15a appear as very promising candidates for microRNAs involved in response to pathogen infection." +other hsa-mir-451 Infection [unspecific] 22953717 "Moreover, miR-664-5p, miR-451 and miR-15a appear as very promising candidates for microRNAs involved in response to pathogen infection." +other hsa-mir-664 Infection [unspecific] 22953717 "Moreover, miR-664-5p, miR-451 and miR-15a appear as very promising candidates for microRNAs involved in response to pathogen infection." +other hsa-mir-138-1 Urinary Bladder Cancer 22954303 Decreasing miR-138 increased the cisplatin sensitivity in half of the cell lines and increasing miR-27a and miR-642 generally increased cisplatin sensitivity. +other hsa-mir-138-2 Urinary Bladder Cancer 22954303 Decreasing miR-138 increased the cisplatin sensitivity in half of the cell lines and increasing miR-27a and miR-642 generally increased cisplatin sensitivity. +other hsa-mir-27a Urinary Bladder Cancer 22954303 Decreasing miR-138 increased the cisplatin sensitivity in half of the cell lines and increasing miR-27a and miR-642 generally increased cisplatin sensitivity. +other hsa-mir-642a Urinary Bladder Cancer 22954303 Decreasing miR-138 increased the cisplatin sensitivity in half of the cell lines and increasing miR-27a and miR-642 generally increased cisplatin sensitivity. +other hsa-mir-642b Urinary Bladder Cancer 22954303 Decreasing miR-138 increased the cisplatin sensitivity in half of the cell lines and increasing miR-27a and miR-642 generally increased cisplatin sensitivity. +other hsa-mir-944 Urinary Bladder Cancer 22954303 "Three miRNAs were associated with both response (to chemotherapy) and survival (886-3p, 923, 944)." +other hsa-mir-23b Atherosclerosis 22955103 "In addition, members of the miR-23-27-24 cluster are increased and specifically miR-23b blocks cell cycle progression, whereas miR-27b was shown to reduce endothelial cell repulsive signals." +other hsa-mir-27b Atherosclerosis 22955103 "In addition, members of the miR-23-27-24 cluster are increased and specifically miR-23b blocks cell cycle progression, whereas miR-27b was shown to reduce endothelial cell repulsive signals." +other hsa-mir-219-2 Inflammation 22957142 "Delayed resolution undermines endogenous resolution programs, altering miR-219-2 expression, increasing pro-inflammatory mediators and compromising SPM production that contribute to failed catabasis and homeostasis." +other hsa-mir-210 Melanoma 22962263 "Our findings show how miR-210 induction links hypoxia to immune escape from CTL-mediated lysis, by providing a mechanistic understanding of how this miRNA mediates immunosuppression in oxygen-deprived regions of tumors where cancer stem-like cells and metastatic cellular behaviors are known to evolve." +other hsa-let-7c "Leukemia, Myeloid, Acute" 22964640 miRNA let-7c promotes granulocytic differentiation in acute myeloid leukemia. +other hsa-mir-122 Hepatitis C Virus Infection 22965312 "these findings indicate that miR-122 and functional lipid metabolism are involved in the tissue tropism of HCV infection. In this review, we would like to focus on the role of miR-122 and lipid metabolism in the cell tropism of HCV." +other hsa-mir-122 Metabolic Syndrome 22965541 "These results suggest that proanthocyanidin treatment increased hepatic cholesterol efflux to produce new HDL particles by repressing miR-33, and it reduced lipogenesis by repressing miR-122." +other hsa-mir-33 Metabolic Syndrome 22965541 "These results suggest that proanthocyanidin treatment increased hepatic cholesterol efflux to produce new HDL particles by repressing miR-33, and it reduced lipogenesis by repressing miR-122." +other hsa-mir-10a Gastric Neoplasms 22969895 miRNA expression profile in primary gastric cancers and paired lymph node metastases indicates that miR-10a plays a role in metastasis from primary gastric cancer to lymph nodes. +other hsa-mir-106a Gastrointestinal Neoplasms 22994734 "Under these experimental conditions, MTg-AMOs demonstrated better suppression of the expression of miR-221, miR-106a, miR-21 in gastric cancer cells than that of single AMOs" +other hsa-mir-21 Gastrointestinal Neoplasms 22994734 "Under these experimental conditions, MTg-AMOs demonstrated better suppression of the expression of miR-221, miR-106a, miR-21 in gastric cancer cells than that of single AMOs" +other hsa-mir-221 Gastrointestinal Neoplasms 22994734 "Under these experimental conditions, MTg-AMOs demonstrated better suppression of the expression of miR-221, miR-106a, miR-21 in gastric cancer cells than that of single AMOs" +other hsa-mir-29c Gastric Neoplasms 23001726 The tumor suppressor microRNA-29c is downregulated and restored by celecoxib in human gastric cancer cells. +other hsa-mir-182 Glioma 23006329 "we found that TGF-¦Â induced miR-182 expression, leading to prolonged NF-¦ÊB activation." +other hsa-mir-1 Neuroblastoma 23022474 "FOXP1 is upregulated as a result of gene fusion or amplification in DLBCL and MALT lymphoma and also repression of miRNAs, such as miR-1, miR-34a and miR-504." +other hsa-mir-34a Neuroblastoma 23022474 "FOXP1 is upregulated as a result of gene fusion or amplification in DLBCL and MALT lymphoma and also repression of miRNAs, such as miR-1, miR-34a and miR-504." +other hsa-mir-504 Neuroblastoma 23022474 "FOXP1 is upregulated as a result of gene fusion or amplification in DLBCL and MALT lymphoma and also repression of miRNAs, such as miR-1, miR-34a and miR-504." +other hsa-mir-29a "Carcinoma, Hepatocellular" 23023935 Our findings demonstrate that the expression of miR-29a is important in the regulation of the SPARC-AKT pathway and HCC growth. +other hsa-mir-146 Lung Neoplasms 23035181 "Other significantly differentiated miR families included carcinogenesis-related miR-146, miR-26, and miR-17 (P (FCS) < 0.05)." +other hsa-mir-17 Lung Neoplasms 23035181 "Other significantly differentiated miR families included carcinogenesis-related miR-146, miR-26, and miR-17 (P (FCS) < 0.05)." +other hsa-mir-26 Lung Neoplasms 23035181 "Other significantly differentiated miR families included carcinogenesis-related miR-146, miR-26, and miR-17 (P (FCS) < 0.05)." +other hsa-mir-34a Lung Neoplasms 23036084 microRNA-34a Sensitizes Lung Cancer Cell Lines to DDP Treatment Independent of p53 Status. +other hsa-mir-155 Colon Neoplasms 23036199 Adrenaline promotes cell proliferation and increases chemoresistance in colon cancer HT29 cells through induction of miR-155 +other hsa-mir-17 "Adenocarcinoma, Lung" 23036707 "Moreover, the expression pattern of miR-17, miR-21, and miR-200a in rBM 3-D culture correlated with the expression of their targets and acinar morphogenesis, a differentiation behavior of lung epithelial cells in rBM 3-D culture" +other hsa-mir-200a "Adenocarcinoma, Lung" 23036707 "Moreover, the expression pattern of miR-17, miR-21, and miR-200a in rBM 3-D culture correlated with the expression of their targets and acinar morphogenesis, a differentiation behavior of lung epithelial cells in rBM 3-D culture" +other hsa-mir-21 "Adenocarcinoma, Lung" 23036707 "Moreover, the expression pattern of miR-17, miR-21, and miR-200a in rBM 3-D culture correlated with the expression of their targets and acinar morphogenesis, a differentiation behavior of lung epithelial cells in rBM 3-D culture" +other hsa-mir-200c Prostate Neoplasms 23041061 Epithelial-to-mesenchymal transition leads to docetaxel resistance in prostate cancer and is mediated by reduced expression of miR-200c and miR-205 +other hsa-mir-205 Prostate Neoplasms 23041061 Epithelial-to-mesenchymal transition leads to docetaxel resistance in prostate cancer and is mediated by reduced expression of miR-200c and miR-205 +other hsa-mir-205 "Adenocarcinoma, Lung" 23043084 "Two microRNA panels yielded high diagnostic accuracy in discriminating SCLC from NSCLC (miR-29a and miR-375; area under the curve [AUC], 0.991 and 0.982 for training and validation data set, respectively) and in differentiating SQ from AC (miR-205 and miR-34a; AUC, 0.977 and 0.982 for training and validation data set, respectively) in FFPE surgical lung specimens." +other hsa-mir-29a "Carcinoma, Lung, Small-Cell" 23043084 "Two microRNA panels yielded high diagnostic accuracy in discriminating SCLC from NSCLC (miR-29a and miR-375; area under the curve [AUC], 0.991 and 0.982 for training and validation data set, respectively) and in differentiating SQ from AC (miR-205 and miR-34a; AUC, 0.977 and 0.982 for training and validation data set, respectively) in FFPE surgical lung specimens." +other hsa-mir-34a "Adenocarcinoma, Lung" 23043084 "Two microRNA panels yielded high diagnostic accuracy in discriminating SCLC from NSCLC (miR-29a and miR-375; area under the curve [AUC], 0.991 and 0.982 for training and validation data set, respectively) and in differentiating SQ from AC (miR-205 and miR-34a; AUC, 0.977 and 0.982 for training and validation data set, respectively) in FFPE surgical lung specimens." +other hsa-mir-375 "Carcinoma, Lung, Small-Cell" 23043084 "Two microRNA panels yielded high diagnostic accuracy in discriminating SCLC from NSCLC (miR-29a and miR-375; area under the curve [AUC], 0.991 and 0.982 for training and validation data set, respectively) and in differentiating SQ from AC (miR-205 and miR-34a; AUC, 0.977 and 0.982 for training and validation data set, respectively) in FFPE surgical lung specimens." +other hsa-mir-34a Heart Diseases [unspecific] 23047694 Therapeutic inhibition of the miR-34 family attenuates pathological cardiac remodeling and improves heart function. +other hsa-mir-155 Waldenstrom Macroglobulinemia 23048077 "Importantly, everolimus targeted Waldenstrom macroglobulinemia cells even in the context of bone marrow milieu, where it affected migration, adhesion, and angiogenesis.Everolimus-dependent anti-Waldenstrom macroglobulinemia activity was partially driven by miRNA-155." +other hsa-mir-196b Glioma 23049982 "We have provided the first evidence that expression of miR-196b was associated with the occurrence of pre-operative seizures in low-grade gliomas,and may predict seizure prognosis in patients without pre-operative seizures" +other hsa-mir-155 "Carcinoma, Renal Cell" 23050614 MicroRNA-155 is a predictive marker for survival in patients with clear cell renal cell carcinoma +other hsa-mir-21 Breast Neoplasms 23052036 Endocrine Disruptors Fludioxonil and Fenhexamid Stimulate miR-21 Expression in Breast Cancer Cells +other hsa-mir-451a Esophageal Neoplasms 23053883 Effect of miR-451 on the Biological Behavior of the Esophageal Carcinoma Cell Line EC9706 +other hsa-mir-498 Neoplasms [unspecific] 23055531 "1,25-Dihydroxyvitamin D3 suppresses telomerase expression and human cancer growth through microRNA-498" +other hsa-mir-122 Hepatitis B Virus Infection 23055569 Inhibition of Alpha Interferon (IFN-alpha)-Induced MicroRNA-122 Negatively Affects the Anti-Hepatitis B Virus Efficiency of IFN-§Ø©ã +other hsa-mir-148a Colorectal Carcinoma 23056401 The clinical significance of MiR-148a as a predictive biomarker in patients with advanced colorectal cancer +other hsa-mir-205 Urinary Bladder Cancer 23056551 miR-205 expression promotes cell proliferation and migration of human cervical cancer cells +other hsa-mir-187 Breast Neoplasms 23060431 miR-187 Is an Independent Prognostic Factor in Breast Cancer and Confers Increased Invasive Potential In Vitro +other hsa-mir-218-1 Neoplasms [unspecific] 23060446 miR-218 Directs a Wnt Signaling Circuit to Promote Differentiation of Osteoblasts and Osteomimicry of Metastatic Cancer Cells +other hsa-mir-218-2 Neoplasms [unspecific] 23060446 miR-218 Directs a Wnt Signaling Circuit to Promote Differentiation of Osteoblasts and Osteomimicry of Metastatic Cancer Cells +other hsa-mir-371a Thyroid Neoplasms 23062364 Activation of the two microRNA clusters C19MC and miR-371-3 does not play prominent role in thyroid cancer +other hsa-mir-133a "Cardiomyopathy, Hypertrophic" 23070543 "Consistent with these structural changes, the expression of molecular markers of cardiac hypertrophy were also increased [Nppb(BNP), Myh7-Myh6(¦ÂMHC-¦ÁMHC) (both P < 0.05) and mir-133a (P < 0.01)]." +other hsa-mir-143 Pancreatic Neoplasms 23070684 miR-143 inhibits the metastasis of pancreatic cancer and an associated signaling pathway +other hsa-mir-146b Colitis 23071818 our data indicates that miRNA-146b and PPAR¦Ã activation may be implicated in the regulation of Th17 responses and colitis in C. difficile-infected mice. +other hsa-mir-200c Ovarian Neoplasms 23074172 Restoration of miR-200c to Ovarian Cancer Reduces Tumor Burden and Increases Sensitivity to Paclitaxel +other hsa-mir-376a-1 Glioblastoma 23093778 Attenuated adenosine-to-inosine editing of microRNA-376a* promotes invasiveness of glioblastoma cells +other hsa-mir-376a-2 Glioblastoma 23093778 Attenuated adenosine-to-inosine editing of microRNA-376a* promotes invasiveness of glioblastoma cells +other hsa-mir-150 Human Immunodeficiency Virus Infection 23094138 "Here, we observed that the expression levels of the cellular factors Trim5¦Á, CypA, APOBEC3G, SAMHD-1, Trim22, tetherin and TREX-1, and the anti-HIV miRNAs miR-28, miR-150, miR-223 and miR-382 was upregulated by IFN-¦Á and IFN-¦Â in macrophages, which may account for the inhibiting effect on viral replication and the antiviral state of these cells." +other hsa-mir-223 Human Immunodeficiency Virus Infection 23094138 "Here, we observed that the expression levels of the cellular factors Trim5¦Á, CypA, APOBEC3G, SAMHD-1, Trim22, tetherin and TREX-1, and the anti-HIV miRNAs miR-28, miR-150, miR-223 and miR-382 was upregulated by IFN-¦Á and IFN-¦Â in macrophages, which may account for the inhibiting effect on viral replication and the antiviral state of these cells." +other hsa-mir-28 Human Immunodeficiency Virus Infection 23094138 "Here, we observed that the expression levels of the cellular factors Trim5¦Á, CypA, APOBEC3G, SAMHD-1, Trim22, tetherin and TREX-1, and the anti-HIV miRNAs miR-28, miR-150, miR-223 and miR-382 was upregulated by IFN-¦Á and IFN-¦Â in macrophages, which may account for the inhibiting effect on viral replication and the antiviral state of these cells." +other hsa-mir-382 Human Immunodeficiency Virus Infection 23094138 "Here, we observed that the expression levels of the cellular factors Trim5¦Á, CypA, APOBEC3G, SAMHD-1, Trim22, tetherin and TREX-1, and the anti-HIV miRNAs miR-28, miR-150, miR-223 and miR-382 was upregulated by IFN-¦Á and IFN-¦Â in macrophages, which may account for the inhibiting effect on viral replication and the antiviral state of these cells." +other hsa-mir-18a Nasopharyngeal Neoplasms 23097559 miR-18a promotes malignant progression by impairing microRNA biogenesis in nasopharyngeal carcinoma +other hsa-mir-222 Glioblastoma 23099529 Electrochemical detection of miRNA-222 by use of a magnetic bead-based bioassay. +other hsa-mir-21 Glioma 23104517 MiR-21 expression in the tumor cell compartment holds unfavorable prognostic value in gliomas +other hsa-mir-20a Leukemia 23114118 "It is concluded that the miR-20a sponge is constructed successfully, and Jurkat-S stable cell line is established, in which the expression of miR-20a is inhibited stably." +other hsa-mir-17 Pulmonary Hypertension 23114789 "MEX suppressed the hypoxic activation of signal transducer and activator of transcription 3 (STAT3) and the upregulation of the miR-17 superfamily of microRNA clusters, whereas it increased lung levels of miR-204, a key microRNA, the expression of which is decreased in human pulmonary hypertension." +other hsa-mir-7-1 Head And Neck Neoplasms 23115635 Regulation of epidermal growth factor receptor signaling and erlotinib sensitivity in head and neck cancer cells by miR-7 +other hsa-mir-7-2 Head And Neck Neoplasms 23115635 Regulation of epidermal growth factor receptor signaling and erlotinib sensitivity in head and neck cancer cells by miR-7 +other hsa-mir-7-3 Head And Neck Neoplasms 23115635 Regulation of epidermal growth factor receptor signaling and erlotinib sensitivity in head and neck cancer cells by miR-7 +other hsa-mir-122 Hepatitis C Virus Infection 23126531 Alcohol Facilitates HCV RNA Replication Via Up-Regulation of miR-122 Expression and Inhibition of Cyclin G1 in Human Hepatoma Cells +other hsa-mir-143 Colorectal Carcinoma 23128394 Analysis of the combined action of miR-143 and miR-145 on oncogenic pathways in colorectal cancer cells reveals a coordinate program of gene repression +other hsa-mir-145 Colorectal Carcinoma 23128394 Analysis of the combined action of miR-143 and miR-145 on oncogenic pathways in colorectal cancer cells reveals a coordinate program of gene repression +other hsa-mir-125b-1 Gastric Neoplasms 23128435 MicroRNA-125b expression in gastric adenocarcinoma and its effect on the proliferation of gastric cancer cells +other hsa-mir-125b-2 Gastric Neoplasms 23128435 MicroRNA-125b expression in gastric adenocarcinoma and its effect on the proliferation of gastric cancer cells +other hsa-mir-9-1 Human Immunodeficiency Virus Infection 23129528 The microRNA-9/B-lymphocyte-induced maturation protein-1/IL-2 axis is differentially regulated in progressive HIV infection +other hsa-mir-9-2 Human Immunodeficiency Virus Infection 23129528 The microRNA-9/B-lymphocyte-induced maturation protein-1/IL-2 axis is differentially regulated in progressive HIV infection +other hsa-mir-21 Lepromatous Leprosy 23134990 "miR-21 and STAT3 are increased in LL lesions with PEH, given their association with epithelial hyperproliferation; and Cbl-b is diminished in LL lesions with PEH compared to classic LL lesions." +other hsa-mir-101-1 Pancreatic Neoplasms 23139258 "The good, the bad and the ugly: a tale of miR-101, miR-21 and miR-155 in pancreatic intraductal papillary mucinous neoplasms" +other hsa-mir-101-2 Pancreatic Neoplasms 23139258 "The good, the bad and the ugly: a tale of miR-101, miR-21 and miR-155 in pancreatic intraductal papillary mucinous neoplasms" +other hsa-mir-155 Pancreatic Neoplasms 23139258 "The good, the bad and the ugly: a tale of miR-101, miR-21 and miR-155 in pancreatic intraductal papillary mucinous neoplasms" +other hsa-mir-21 Pancreatic Neoplasms 23139258 "The good, the bad and the ugly: a tale of miR-101, miR-21 and miR-155 in pancreatic intraductal papillary mucinous neoplasms" +other hsa-mir-101-1 Systemic Lupus Erythematosus 23139385 "MicroRNA-101, mitogen-activated protein kinases and mitogen-activated protein kinases phosphatase-1 in systemic lupus erythematosus" +other hsa-mir-101-2 Systemic Lupus Erythematosus 23139385 "MicroRNA-101, mitogen-activated protein kinases and mitogen-activated protein kinases phosphatase-1 in systemic lupus erythematosus" +other hsa-mir-34a Pancreatic Neoplasms 23140286 Genistein Inhibits Cell Growth and Induces Apoptosis Through Up-regulation of miR-34a in Pancreatic Cancer Cell +other hsa-mir-29c Nasopharyngeal Neoplasms 23142283 MicroRNA-29c enhances the sensitivities of human nasopharyngeal carcinoma to cisplatin-based chemotherapy and radiotherapy +other hsa-mir-1290 Colon Neoplasms 23142292 Up-regulation of microRNA-1290 impairs cytokinesis and affects the reprogramming of colon cancer cells +other hsa-mir-326 Lung Neoplasms 23142363 miR-326 associates with biochemical markers of bone turnover in lung cancer bone metastasis +other hsa-mir-137 Huntington Disease 23145961 "We also identified several microRNAs (miRNAs) whose aberrant repression is directly mediated by REST, including miR-137, which has not previously been shown to be a direct REST target in mouse." +other hsa-mir-96 "Carcinoma, Hepatocellular" 23151657 Inhibition of miR-96 expression reduces cell proliferation and clonogenicity of HepG2 hepatoma cells +other hsa-mir-181 Porcine Reproductive and Respiratory Syndrome Virus Infection 23152505 "As expected, miR-181 and other potential PRRSV-targeting miRNAs (such as miR-206) are expressed much more abundantly in minimally permissive cells or tissues than in highly permissive cells or tissues." +other hsa-mir-638 Neoplasms [unspecific] 23155245 Expression of human endogenous retrovirus-K coincides with that of micro-RNA-663 and -638 in germ-cell tumor cells +other hsa-mir-663a Neoplasms [unspecific] 23155245 Expression of human endogenous retrovirus-K coincides with that of micro-RNA-663 and -638 in germ-cell tumor cells +other hsa-mir-663b Neoplasms [unspecific] 23155245 Expression of human endogenous retrovirus-K coincides with that of micro-RNA-663 and -638 in germ-cell tumor cells +other hsa-mir-34b Mesothelioma 23155254 MicroRNA miR-34b/c enhances cellular radiosensitivity of malignant pleural mesothelioma cells +other hsa-mir-34c Mesothelioma 23155254 MicroRNA miR-34b/c enhances cellular radiosensitivity of malignant pleural mesothelioma cells +other hsa-mir-211 Pancreatic Neoplasms 23155457 High-throughput microRNA (miRNAs) arrays unravel the prognostic role of MiR-211 in pancreatic cancer +other hsa-mir-199a-1 Melanoma 23162627 Let-7b and microRNA-199a inhibit the proliferation of B16F10 melanoma cells +other hsa-mir-199a-2 Melanoma 23162627 Let-7b and microRNA-199a inhibit the proliferation of B16F10 melanoma cells +other hsa-mir-99a "Carcinoma, Renal Cell" 23173671 MicroRNA-99a induces G1-phase cell cycle arrest and suppresses tumorigenicity in renal cell carcinoma +other hsa-mir-99b "Carcinoma, Renal Cell" 23173671 MicroRNA-99a induces G1-phase cell cycle arrest and suppresses tumorigenicity in renal cell carcinoma +other hsa-mir-210 Neoplasms [unspecific] 23173806 "Considering that the exact function of miR-210 is still not well characterized and understood, more investigations should be performed to promote the success of therapeutic-clinical use of miR-210 in cancer" +other hsa-mir-29c Neoplasms [unspecific] 23175151 MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression +other hsa-mir-27a Gastric Neoplasms 23175237 MicroRNA-27a inhibitors alone or in combination with perifosine suppress the growth of gastric cancer cells +other hsa-mir-302a Breast Neoplasms 23184229 MicroRNA-302 Replacement Therapy Sensitizes Breast Cancer Cells to Ionizing Radiation +other hsa-mir-22 Esophageal Neoplasms 23188185 Increased miRNA-22 expression sensitizes esophageal squamous cell carcinoma to irradiation +other hsa-mir-146a Cervical Neoplasms 23189617 "The oncogenic proteins E6, E7 and E5 expressed by HPV directly or indirectly lead to the dysregulation of multiple miRNAs such as miR-34a,miR-218, miR-29a and miR-146a" +other hsa-mir-218 Cervical Neoplasms 23189617 "The oncogenic proteins E6, E7 and E5 expressed by HPV directly or indirectly lead to the dysregulation of multiple miRNAs such as miR-34a,miR-218, miR-29a and miR-146a" +other hsa-mir-29a Cervical Neoplasms 23189617 "The oncogenic proteins E6, E7 and E5 expressed by HPV directly or indirectly lead to the dysregulation of multiple miRNAs such as miR-34a,miR-218, miR-29a and miR-146a" +other hsa-mir-34a Cervical Neoplasms 23189617 "The oncogenic proteins E6, E7 and E5 expressed by HPV directly or indirectly lead to the dysregulation of multiple miRNAs such as miR-34a,miR-218, miR-29a and miR-146a" +other hsa-mir-499 Acute Myocardial Infarction 23192357 "The target miRNA is miRNA-499, a biomarker candidate of AMI with low abundance in biological samples. " +other hsa-mir-7-1 Neuroblastoma 23192662 Overexpression of miR-7-1 Increases Efficacy of Green Tea Polyphenols for Induction of Apoptosis in Human Malignant Neuroblastoma SH-SY5Y and SK-N-DZ Cells +other hsa-mir-7-2 Neuroblastoma 23192662 Overexpression of miR-7-1 Increases Efficacy of Green Tea Polyphenols for Induction of Apoptosis in Human Malignant Neuroblastoma SH-SY5Y and SK-N-DZ Cells +other hsa-mir-133b Gastrointestinal Neoplasms 23196799 Fascin-1 overexpression and miR-133b downregulation in the progression of gastrointestinal stromal tumor +other hsa-mir-146a Neoplasms [unspecific] 23200854 Epistasis between MicroRNAs 155 and 146a during T Cell-Mediated Antitumor Immunity +other hsa-mir-155 Neoplasms [unspecific] 23200854 Epistasis between MicroRNAs 155 and 146a during T Cell-Mediated Antitumor Immunity +other hsa-mir-199a-1 Interstitial Cystitis 23201090 miR-199a-5p Regulates Urothelial Permeability and May Play a Role in Bladder Pain Syndrome +other hsa-mir-199a-2 Interstitial Cystitis 23201090 miR-199a-5p Regulates Urothelial Permeability and May Play a Role in Bladder Pain Syndrome +other hsa-mir-126 Cardiovascular Diseases [unspecific] 23201405 Synergistic induction of miR-126 by hypoxia and HDAC inhibitors in cardiac myocytes +other hsa-mir-21 Glioblastoma 23201752 MicroRNA-21 silencing enhances the cytotoxic effect of the antiangiogenic drug sunitinib in glioblastoma +other hsa-mir-146a Myocardial Ischemic-Reperfusion Injury 23208587 Increased expression of microRNA-146a decreases myocardial ischaemia/reperfusion injury +other hsa-mir-195 Gastrointestinal Neoplasms 23212612 We demonstrated that miR-195-5p is a novel tumor suppressor miRNA and may contribute to gastric carcinogenesis. +other hsa-mir-21 Breast Neoplasms 23216894 Radiation resistance due to high expression of miR-21 and G2/M checkpoint arrest in breast cancer cells +other hsa-mir-106a Melanoma 23217102 "Levels of miR-199a were positively correlated and miR-106a negatively correlated with CEC pre-therapy. Decreases in miR-126 and miR-199a and increases in miR-16 and miR-106a were observed after interferon-alfa-2b, but not after dacarbazine." +other hsa-mir-126 Melanoma 23217102 "Levels of miR-199a were positively correlated and miR-106a negatively correlated with CEC pre-therapy. Decreases in miR-126 and miR-199a and increases in miR-16 and miR-106a were observed after interferon-alfa-2b, but not after dacarbazine." +other hsa-mir-16 Melanoma 23217102 "Levels of miR-199a were positively correlated and miR-106a negatively correlated with CEC pre-therapy. Decreases in miR-126 and miR-199a and increases in miR-16 and miR-106a were observed after interferon-alfa-2b, but not after dacarbazine." +other hsa-mir-199a Melanoma 23217102 "Levels of miR-199a were positively correlated and miR-106a negatively correlated with CEC pre-therapy. Decreases in miR-126 and miR-199a and increases in miR-16 and miR-106a were observed after interferon-alfa-2b, but not after dacarbazine." +other hsa-mir-122 Hepatitis C Virus Infection 23218444 Can tobacco use promote HCV-induced miR-122 hijacking and hepatocarcinogenesis +other hsa-mir-181a-2 Inflammation 23220232 miR-181a and inflammation: miRNA homeostasis response to inflammatory stimuli in vivo +other hsa-mir-34a Anemia 23222379 "Thus, in FA patients, increased apoptosis occurs in target epithelial cells of severe aGVHD, and this deleterious effect is linked to overexpression of miR-34a but not TP53." +other hsa-mir-21 Inflammatory Bowel Diseases 23224068 PDCD4/miR-21 dysregulation in inflammatory bowel disease-associated carcinogenesis +other hsa-mir-449a Hepatitis C Virus Infection 23226395 Hepatitis C Virus Mediated Changes in miRNA-449a Modulates Inflammatory Biomarker YKL40 through Components of the NOTCH Signaling Pathway +other hsa-mir-7-1 Breast Neoplasms 23227519 "An induction of microRNA, miR-7 through estrogen treatment in breast carcinoma" +other hsa-mir-7-2 Breast Neoplasms 23227519 "An induction of microRNA, miR-7 through estrogen treatment in breast carcinoma" +other hsa-mir-7-3 Breast Neoplasms 23227519 "An induction of microRNA, miR-7 through estrogen treatment in breast carcinoma" +other hsa-mir-1-1 Osteosarcoma 23229283 miRNA expression profile in human osteosarcoma: Role of miR-1 and miR-133b in proliferation and cell cycle control +other hsa-mir-1-2 Osteosarcoma 23229283 miRNA expression profile in human osteosarcoma: Role of miR-1 and miR-133b in proliferation and cell cycle control +other hsa-mir-133b Osteosarcoma 23229283 miRNA expression profile in human osteosarcoma: Role of miR-1 and miR-133b in proliferation and cell cycle control +other hsa-mir-30d Prostate Neoplasms 23231923 Identification of miR-30d as a novel prognostic maker of prostate cancer +other hsa-mir-21 Spinal Cord Injuries 23238710 microRNA-21 Regulates Astrocytic Response Following Spinal Cord Injury +other hsa-mir-27a Breast Neoplasms 23240057 MiR-27 as a Prognostic Marker for Breast Cancer Progression and Patient Survival +other hsa-mir-27b Breast Neoplasms 23240057 MiR-27 as a Prognostic Marker for Breast Cancer Progression and Patient Survival +other hsa-mir-206 Heart Failure 23242657 Recent data indicate that these miRNAs as well as miR-206 change their expression quickly in response to physical activity. +other hsa-mir-190a Neuroblastoma 23245204 MiR-190 leads to aggressive phenotype of neuroblastoma through indirect activation of TrkB pathway +other hsa-mir-190b Neuroblastoma 23245204 MiR-190 leads to aggressive phenotype of neuroblastoma through indirect activation of TrkB pathway +other hsa-mir-122 Hepatitis C Virus Infection 23245472 MicroRNA-122-dependent and -independent replication of Hepatitis C Virus in Hep3B human hepatoma cells +other hsa-mir-25 Neoplasms [unspecific] 23246404 Downregulation of the Mitochondrial Calcium Uniporter by Cancer-Related miR-25 +other hsa-mir-21 Multiple Myeloma 23247593 "Set9, NF-kB, and microRNA-21 mediate berberine-induced apoptosis of human multiple myeloma cells" +other hsa-mir-122 Hepatitis C Virus Infection 23248316 Competing and noncompeting activities of miR-122 and the 5' exonuclease Xrn1 in regulation of hepatitis C virus replication +other hsa-let-7i Respiratory Syncytial Virus Pneumonia 23249809 we found that the RSV nonstructural genes NS1 and NS2 antagonized the upregulation of let-7i and miR-30b +other hsa-mir-30b Respiratory Syncytial Virus Pneumonia 23249809 we found that the RSV nonstructural genes NS1 and NS2 antagonized the upregulation of let-7i and miR-30b +other hsa-mir-196a-1 Breast Neoplasms 23250869 A MicroRNA196a2* and TP63 Circuit Regulated by Estrogen Receptor-alpha and ERK2 that Controls Breast Cancer Proliferation and Invasiveness Properties +other hsa-mir-196a-2 Breast Neoplasms 23250869 A MicroRNA196a2* and TP63 Circuit Regulated by Estrogen Receptor-alpha and ERK2 that Controls Breast Cancer Proliferation and Invasiveness Properties +other hsa-mir-155 Diabetes Mellitus 23250986 Global Remodeling of the Vascular Stem Cell Niche in Bone Marrow of Diabetic Patients: Implication of the miR-155/FOXO3a Signaling Pathway +other hsa-mir-125b-1 Human Immunodeficiency Virus Infection 23251514 Cocaine Enhances HIV-1 Replication in CD4+ T Cells by Down-Regulating MiR-125b +other hsa-mir-125b-2 Human Immunodeficiency Virus Infection 23251514 Cocaine Enhances HIV-1 Replication in CD4+ T Cells by Down-Regulating MiR-125b +other hsa-mir-182 Glioma 23252827 The miR-183/96/182 Cluster Regulates Oxidative Apoptosis and Sensitizes Cells to Chemotherapy in Gliomas +other hsa-mir-183 Glioma 23252827 The miR-183/96/182 Cluster Regulates Oxidative Apoptosis and Sensitizes Cells to Chemotherapy in Gliomas +other hsa-mir-96 Glioma 23252827 The miR-183/96/182 Cluster Regulates Oxidative Apoptosis and Sensitizes Cells to Chemotherapy in Gliomas +other hsa-mir-29b-1 Multiple Myeloma 23254643 miR-29b negatively regulates human osteoclastic cell differentiation and function: Implications for the treatment of multiple myeloma-related bone disease +other hsa-mir-29b-2 Multiple Myeloma 23254643 miR-29b negatively regulates human osteoclastic cell differentiation and function: Implications for the treatment of multiple myeloma-related bone disease +other hsa-mir-27a Ovarian Neoplasms 23254909 "The microRNA-27a: ZBTB10-specificity protein pathway is involved in follicle stimulating hormone-induced VEGF, Cox2 and survivin expression in ovarian epithelial cancer cells" +other hsa-mir-17 Lung Neoplasms 23263848 miR-17-5p may be potential biomarker for prediction the prognosis in patients with lung cancer. +other hsa-mir-146b Thyroid Neoplasms 23264400 Prognostic Implications of miR-146b Expression and Its Functional Role in Papillary Thyroid Carcinoma +other hsa-mir-21 Prostate Neoplasms 23272133 Resveratrol Reduces Prostate Cancer Growth and Metastasis by Inhibiting the Akt/MicroRNA-21 Pathway +other hsa-mir-194 Breast Neoplasms 23273170 Manipulation of the miR-194 expression level using a synthetic inhibiting RNA produced a small but significant suppression of cell proliferation and upregulation in the expression of several genes that are thought to act as tumor suppressors in MCF-7 and T47D breast cancer cells. +other hsa-mir-30d Neoplasms [unspecific] 23274497 mir-30d Regulates multiple genes in the autophagy pathway and impairs autophagy process in human cancer cells +other hsa-mir-137 Colorectal Carcinoma 23275153 Overexpression of paxillin induced by miR-137 suppression promotes tumor progression and metastasis in colorectal cancer +other hsa-mir-143 Esophageal Neoplasms 23276710 miR-143 may act as a tumor suppressor in ESCC +other hsa-mir-18a Rheumatoid Arthritis 23280137 The TNFa-induced miR-18a activates rheumatoid arthritis synovial fibroblasts through a feedback loop in NF-§Ø¨mB signaling +other hsa-mir-140 Osteoarthritis 23281373 Detection of the expression level of miR-140 using realtime fluorescent quantitative PCR in knee synovial fluid of osteoarthritis patients +other hsa-mir-7-1 Parkinson Disease 23281385 MiR-7 variation is not associated with PD in Chinese patients +other hsa-mir-7-2 Parkinson Disease 23281385 MiR-7 variation is not associated with PD in Chinese patients +other hsa-mir-7-3 Parkinson Disease 23281385 MiR-7 variation is not associated with PD in Chinese patients +other hsa-let-7e "Carcinoma, Hepatocellular" 23282077 "MiR-16, miR-30a, Let-7e and miR-204 were identified as key miRNA regulators contributed to HCC metastasis." +other hsa-mir-16 "Carcinoma, Hepatocellular" 23282077 "MiR-16, miR-30a, Let-7e and miR-204 were identified as key miRNA regulators contributed to HCC metastasis." +other hsa-mir-204 "Carcinoma, Hepatocellular" 23282077 "MiR-16, miR-30a, Let-7e and miR-204 were identified as key miRNA regulators contributed to HCC metastasis." +other hsa-mir-30a "Carcinoma, Hepatocellular" 23282077 "MiR-16, miR-30a, Let-7e and miR-204 were identified as key miRNA regulators contributed to HCC metastasis." +other hsa-mir-29a Hepatitis B Virus Infection 23285022 MicroRNA-29a-5p Is a Novel Predictor for Early Recurrence of Hepatitis B Virus-Related Hepatocellular Carcinoma after Surgical Resection +other hsa-mir-193b Lymphoma 23288923 "Interestingly, down-regulation of micro-RNAs mmu-miR-30a and mmu-miR-141 as well as hsa-miR-193b clearly contributes to enhance the expression of this gene in mouse and human lymphomas" +other hsa-mir-155 Inflammatory Bowel Diseases 23288924 OVER EXPRESSION OF MICRORNAS-155 AND 21 TARGETING MISMATCH REPAIR PROTEINS IN INFLAMMATORY BOWEL DISEASES +other hsa-mir-21 Inflammatory Bowel Diseases 23288924 OVER EXPRESSION OF MICRORNAS-155 AND 21 TARGETING MISMATCH REPAIR PROTEINS IN INFLAMMATORY BOWEL DISEASES +other hsa-mir-140 Osteoarthritis 23291479 "MiR-146a and -155 were mainly reported for RA, miR-140 was mainly reported for OA including cartilage development." +other hsa-mir-146a Rheumatoid Arthritis 23291479 "MiR-146a and -155 were mainly reported for RA, miR-140 was mainly reported for OA including cartilage development." +other hsa-mir-155 Rheumatoid Arthritis 23291479 "MiR-146a and -155 were mainly reported for RA, miR-140 was mainly reported for OA including cartilage development." +other hsa-mir-34a Neoplasms [unspecific] 23292172 Oncolytic adenovirus co-expressing miRNA-34a and IL-24 induces superior antitumor activity in experimental tumor model +other hsa-mir-146a Psychotic Disorders 23295264 Down-regulation of inflammation-protective microRNAs 146a and 212 in monocytes of patients with postpartum psychosis +other hsa-mir-212 Psychotic Disorders 23295264 Down-regulation of inflammation-protective microRNAs 146a and 212 in monocytes of patients with postpartum psychosis +other hsa-mir-200a Endometrial Neoplasms 23295740 Tamoxifen Represses miR-200 MicroRNAs and Promotes Epithelial-to-Mesenchymal Transition by Up-Regulating c-Myc in Endometrial Carcinoma Cell Lines +other hsa-mir-200b Endometrial Neoplasms 23295740 Tamoxifen Represses miR-200 MicroRNAs and Promotes Epithelial-to-Mesenchymal Transition by Up-Regulating c-Myc in Endometrial Carcinoma Cell Lines +other hsa-mir-200c Endometrial Neoplasms 23295740 Tamoxifen Represses miR-200 MicroRNAs and Promotes Epithelial-to-Mesenchymal Transition by Up-Regulating c-Myc in Endometrial Carcinoma Cell Lines +other hsa-mir-99a Glioblastoma 23298836 The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma +other hsa-mir-23b Prostate Neoplasms 23300597 The microRNA -23b/-27b Cluster Suppresses the Metastatic Phenotype of Castration-Resistant Prostate Cancer Cells +other hsa-mir-27b Prostate Neoplasms 23300597 The microRNA -23b/-27b Cluster Suppresses the Metastatic Phenotype of Castration-Resistant Prostate Cancer Cells +other hsa-mir-138-1 Neoplasms [unspecific] 23300839 MicroRNA-138 Suppresses Neutrophil Gelatinase-Associated Lipocalin Expression and Inhibits Tumorigenicity +other hsa-mir-138-2 Neoplasms [unspecific] 23300839 MicroRNA-138 Suppresses Neutrophil Gelatinase-Associated Lipocalin Expression and Inhibits Tumorigenicity +other hsa-mir-130a Glioblastoma 23302469 Interactions of miR-323/miR-326/miR-329 and miR-130a/miR-155/miR-210 as prognostic indicators for clinical outcome of glioblastoma patients +other hsa-mir-155 Glioblastoma 23302469 Interactions of miR-323/miR-326/miR-329 and miR-130a/miR-155/miR-210 as prognostic indicators for clinical outcome of glioblastoma patients +other hsa-mir-210 Glioblastoma 23302469 Interactions of miR-323/miR-326/miR-329 and miR-130a/miR-155/miR-210 as prognostic indicators for clinical outcome of glioblastoma patients +other hsa-mir-323a Glioblastoma 23302469 Interactions of miR-323/miR-326/miR-329 and miR-130a/miR-155/miR-210 as prognostic indicators for clinical outcome of glioblastoma patients +other hsa-mir-323b Glioblastoma 23302469 Interactions of miR-323/miR-326/miR-329 and miR-130a/miR-155/miR-210 as prognostic indicators for clinical outcome of glioblastoma patients +other hsa-mir-326 Glioblastoma 23302469 Interactions of miR-323/miR-326/miR-329 and miR-130a/miR-155/miR-210 as prognostic indicators for clinical outcome of glioblastoma patients +other hsa-mir-329-1 Glioblastoma 23302469 Interactions of miR-323/miR-326/miR-329 and miR-130a/miR-155/miR-210 as prognostic indicators for clinical outcome of glioblastoma patients +other hsa-mir-329-2 Glioblastoma 23302469 Interactions of miR-323/miR-326/miR-329 and miR-130a/miR-155/miR-210 as prognostic indicators for clinical outcome of glioblastoma patients +other hsa-mir-155 Breast Neoplasms 23302487 "miR-155, as an oncomir, promotes lymph node involvement and vascular invasion and accompanies over-expressed HER-2 on breast cancer FFPE tissue" +other hsa-mir-210 Heart Failure 23302636 MicroRNA 210 as a Biomarker for Congestive Heart Failure +other hsa-mir-10b Glioblastoma 23307328 Inhibition of miR-10b strongly reduced cell invasion and migration in glioblastoma cell and stem cell lines while overexpression of miR-10b induced cell migration and invasion +other hsa-mir-16-1 Colon Neoplasms 23308284 The Induction of microRNA-16 in Colon Cancer Cells by Protein Arginine Deiminase Inhibition Causes a p53-Dependent Cell Cycle Arrest +other hsa-mir-16-2 Colon Neoplasms 23308284 The Induction of microRNA-16 in Colon Cancer Cells by Protein Arginine Deiminase Inhibition Causes a p53-Dependent Cell Cycle Arrest +other hsa-mir-182 Urinary Bladder Cancer 23313739 MicroRNA-182 plays an onco-miRNA role in cervical cancer +other hsa-mir-34b Neoplasms [unspecific] 23314612 MicroRNA-34b functions as a tumor suppressor and acts as a nodal point in the feedback loop with Met +other hsa-mir-155 "Carcinoma, Hepatocellular" 23316018 These results suggest that S100A4 exerts its effects through the regulation of miR-155 expression in HCC cells +other hsa-mir-30b Vascular Disease [unspecific] 23316327 Bone Morphogenetic Protein-2 Decreases MicroRNA-30b and MicroRNA-30c to Promote Vascular Smooth Muscle Cell Calcification +other hsa-mir-30c-1 Vascular Disease [unspecific] 23316327 Bone Morphogenetic Protein-2 Decreases MicroRNA-30b and MicroRNA-30c to Promote Vascular Smooth Muscle Cell Calcification +other hsa-mir-30c-2 Vascular Disease [unspecific] 23316327 Bone Morphogenetic Protein-2 Decreases MicroRNA-30b and MicroRNA-30c to Promote Vascular Smooth Muscle Cell Calcification +other hsa-mir-200a Breast Neoplasms 23318438 WASF3 regulates miR-200 inactivation by ZEB1 through suppression of KISS1 leading to increased invasiveness in breast cancer cells +other hsa-mir-200b Breast Neoplasms 23318438 WASF3 regulates miR-200 inactivation by ZEB1 through suppression of KISS1 leading to increased invasiveness in breast cancer cells +other hsa-mir-200c Breast Neoplasms 23318438 WASF3 regulates miR-200 inactivation by ZEB1 through suppression of KISS1 leading to increased invasiveness in breast cancer cells +other hsa-mir-143 Prostate Neoplasms 23321517 Mir143 expression inversely correlates with nuclear ERK5 immunoreactivity in clinical prostate cancer +other hsa-mir-374a Breast Neoplasms 23321667 MicroRNA-374a activates Wnt/beta-catenin signaling to promote breast cancer metastasis +other hsa-mir-126 Atherosclerosis 23324496 whereas the endothelial cell-specific miRNA-126 signals the need for endothelial repair through its transfer from apoptotic endothelial cells in microvesicles +other hsa-mir-145 Atherosclerosis 23324496 "Downregulation of miR-145, which controls differentiation of smooth muscle cells, promotes lesion formation" +other hsa-mir-155 Atherosclerosis 23324496 Elevated miR-155 levels are characteristic of proinflammatory macrophages and atherosclerotic lesions +other hsa-mir-125a Colon Neoplasms 23327190 miR-125a/b Regulates the Activation of Cancer Stem Cells in Paclitaxel-resistant Colon Cancer +other hsa-mir-125b-1 Colon Neoplasms 23327190 miR-125a/b Regulates the Activation of Cancer Stem Cells in Paclitaxel-resistant Colon Cancer +other hsa-mir-125b-2 Colon Neoplasms 23327190 miR-125a/b Regulates the Activation of Cancer Stem Cells in Paclitaxel-resistant Colon Cancer +other hsa-mir-34a Choriocarcinoma 23327670 MiR-34a was either inhibited or ectopically expressed transiently in two choriocarcinoma cell lines (BeWo and JEG-3) respectively. +other hsa-mir-708 Breast Neoplasms 23328481 Our findings uncover a mechanistic role for miR-708 in metastasis and provide arationale for developing miR-708 as a therapeutic agent against metastatic breast cancer. +other hsa-mir-135b Gastric Neoplasms 23328512 "Quantitative real-time PCR was used to validate the reliability of microarray and detect miR-135b expression in the above clinical samples, as well as cell lines GES-1, BGC-823 and SGC-7901." +other hsa-let-7a Pancreatic Neoplasms 23335963 These data demonstrate an intricate post-transcriptional regulation of RRM2 and chemosensitivity by let-7a and that the manipulation of regulatory proteins involved in let-7a transcription/processing may provide a mechanism for improving chemotherapeutic and/or tumor growth control responses in pancreatic cancer. +other hsa-mir-199a-1 Breast Neoplasms 23337876 "our data identify miR-199a-5p as a novel and unique regulator of autophagy, which plays an important role in cancer biology and cancer therapy" +other hsa-mir-199a-2 Breast Neoplasms 23337876 "our data identify miR-199a-5p as a novel and unique regulator of autophagy, which plays an important role in cancer biology and cancer therapy" +other hsa-mir-124 Glioma 23338605 "Luciferase reporter assay confirmed that miR-124, miR-128, miR-146b and miR-218 conferred exogenous gene expression with glioma-specificity." +other hsa-mir-128 Glioma 23338605 "Luciferase reporter assay confirmed that miR-124, miR-128, miR-146b and miR-218 conferred exogenous gene expression with glioma-specificity." +other hsa-mir-146b Glioma 23338605 "Luciferase reporter assay confirmed that miR-124, miR-128, miR-146b and miR-218 conferred exogenous gene expression with glioma-specificity." +other hsa-mir-218 Glioma 23338605 "Luciferase reporter assay confirmed that miR-124, miR-128, miR-146b and miR-218 conferred exogenous gene expression with glioma-specificity." +other hsa-mir-23b Breast Neoplasms 23338610 "Pro-oncogenic factors miR-23b- and miR-27b are regulated by Her2/Neu, EGF, and TNFa in breast cancer" +other hsa-mir-146a Influenza 23343627 Host microRNA molecular signatures associated with human H1N1 and H3N2 influenza A viruses reveal an unanticipated antiviral activity for miR-146a +other hsa-let-7a "Carcinoma, Lung, Non-Small-Cell" 23349018 Expression levels of hsa-let-7a (P = 0.005) and miR-16 (P = 0.003) miRNA were significantly higher in squamous cell carcinoma than in adenocarcinoma samples. +other hsa-mir-16 "Carcinoma, Lung, Non-Small-Cell" 23349018 Expression levels of hsa-let-7a (P = 0.005) and miR-16 (P = 0.003) miRNA were significantly higher in squamous cell carcinoma than in adenocarcinoma samples. +other hsa-mir-15a Neoplasms [unspecific] 23353574 "Large-scale screening identifies a novel microRNA, miR-15a-3p, which induces apoptosis in human cancer cell lines" +other hsa-mir-21 Prostate Neoplasms 23353719 "miR-21, miR-221 and miR-222 expression and prostate cancer recurrence among obese and non-obese cases" +other hsa-mir-221 Prostate Neoplasms 23353719 "miR-21, miR-221 and miR-222 expression and prostate cancer recurrence among obese and non-obese cases" +other hsa-mir-222 Prostate Neoplasms 23353719 "miR-21, miR-221 and miR-222 expression and prostate cancer recurrence among obese and non-obese cases" +other hsa-mir-29b-1 Neoplasms [unspecific] 23354167 GATA3 suppresses metastasis and modulates the tumour microenvironment by regulating microRNA-29b expression +other hsa-mir-29b-2 Neoplasms [unspecific] 23354167 GATA3 suppresses metastasis and modulates the tumour microenvironment by regulating microRNA-29b expression +other hsa-mir-199a-1 Neoplasms [unspecific] 23354452 MicroRNA 199b-5p delivery through stable nucleic acid lipid particles (SNALPs) in tumorigenic cell lines +other hsa-mir-199a-2 Neoplasms [unspecific] 23354452 MicroRNA 199b-5p delivery through stable nucleic acid lipid particles (SNALPs) in tumorigenic cell lines +other hsa-mir-199b Neoplasms [unspecific] 23354452 MicroRNA 199b-5p delivery through stable nucleic acid lipid particles (SNALPs) in tumorigenic cell lines +other hsa-mir-92a Immune System Disease [unspecific] 23355465 "we have demonstrated that TLR-mediated miR-92a reduction feedback enhances TLR-triggered production of inflammatory cytokines in macrophages, thus outlining new mechanisms for fine-tuning the TLR-triggered inflammatory response." +other hsa-mir-132 Human Immunodeficiency Virus Infection 23357732 miR-132 enhances HIV-1 replication +other hsa-mir-18b Melanoma 23365201 The Role of miR-18b in MDM2-p53 Pathway Signaling and Melanoma Progression +other hsa-mir-451a Glioblastoma 23367447 "A computational multiscale model of glioblastoma growth: Regulation of cell migration and proliferation via microRNA-451, LKB1 and AMPK" +other hsa-mir-221 Osteosarcoma 23372675 MicroRNA-221 Induces Cell Survival and Cisplatin Resistance through PI3K/Akt Pathway in Human Osteosarcoma +other hsa-mir-376a-1 Retinoblastoma 23373993 Arsenic trioxide induced apoptosis in retinoblastoma cells by abnormal expression of microRNA-376a +other hsa-mir-376a-2 Retinoblastoma 23373993 Arsenic trioxide induced apoptosis in retinoblastoma cells by abnormal expression of microRNA-376a +other hsa-mir-7-1 Glioma 23373996 Regulation of Epidermal Growth Factor Receptor Signaling by plasmid-based MicroRNA-7 inhibits human malignant gliomas growth and metastasis in vivo +other hsa-mir-7-2 Glioma 23373996 Regulation of Epidermal Growth Factor Receptor Signaling by plasmid-based MicroRNA-7 inhibits human malignant gliomas growth and metastasis in vivo +other hsa-mir-7-3 Glioma 23373996 Regulation of Epidermal Growth Factor Receptor Signaling by plasmid-based MicroRNA-7 inhibits human malignant gliomas growth and metastasis in vivo +other hsa-mir-143 Glioblastoma 23376635 miR-143 inhibits glycolysis and depletes stemness of glioblastoma stem-like cells +other hsa-mir-24 Liver Neoplasms 23382622 "This feedback loop, governed by miR-24 and miR-629, promotes a hepatocyte nuclear factor-4¦Á transient inhibition resulting in miR-124 induction and signal transducer and activator of transcription 3 activation." +other hsa-mir-629 Liver Neoplasms 23382622 "This feedback loop, governed by miR-24 and miR-629, promotes a hepatocyte nuclear factor-4¦Á transient inhibition resulting in miR-124 induction and signal transducer and activator of transcription 3 activation." +other hsa-mir-210 Myocardial Infarction 23388440 These data demonstrated that a positive feedback loop involving miR-210 and HIF-1¦Á was important for MSC survival under hypoxic conditions. +other hsa-mir-200b Prostate Neoplasms 23389960 Down-regulation of miR-200b-3p by low p73 contributes to the androgen-independence of prostate cancer cells +other hsa-mir-198 "Carcinoma, Hepatocellular" 23391410 "Control of mitogenic and motogenic pathways by miR-198, diminishing hepatoma cell growth and migration" +other hsa-mir-181a-2 Leukemia 23393335 MicroRNA 181a Influences the Expression of HMGB1 and CD4 in Acute Leukemias +other hsa-mir-200c Ovarian Neoplasms 23394580 a model for the combined regulatory activity of miR-200c and HuR on TUBB3 expression in ovarian cancer +other hsa-mir-126 Breast Neoplasms 23396050 miR-126 and miR-126(*) repress recruitment of mesenchymal stem cells and inflammatory monocytes to inhibit breast cancer metastasis +other hsa-mir-142 Colorectal Carcinoma 23397547 Downregulation of anti-oncomirs miR-143/145 cluster occurs before APC gene aberration in the development of colorectal tumors +other hsa-mir-145 Colorectal Carcinoma 23397547 Downregulation of anti-oncomirs miR-143/145 cluster occurs before APC gene aberration in the development of colorectal tumors +other hsa-mir-29a Neoplasms [unspecific] 23401122 miR-29a inhibition normalizes HuR over-expression and aberrant AU-rich mRNA stability in invasive cancer +other hsa-mir-124-1 Melanoma 23404119 miR-124a could function as a potent tumor suppressor in the development of uveal melanoma +other hsa-mir-124-2 Melanoma 23404119 miR-124a could function as a potent tumor suppressor in the development of uveal melanoma +other hsa-mir-124-3 Melanoma 23404119 miR-124a could function as a potent tumor suppressor in the development of uveal melanoma +other hsa-mir-145 Prostate Neoplasms 23404342 Wild-type p53 suppresses the epithelial-mesenchymal transition and stemness in PC-3 prostate cancer cells by modulating miR-145 +other hsa-mir-7-1 Glioma 23404538 Poly(amido amine) is an ideal carrier of miR-7 for enhancing gene silencing effects on the EGFR pathway in U251 glioma cells +other hsa-mir-7-2 Glioma 23404538 Poly(amido amine) is an ideal carrier of miR-7 for enhancing gene silencing effects on the EGFR pathway in U251 glioma cells +other hsa-mir-7-3 Glioma 23404538 Poly(amido amine) is an ideal carrier of miR-7 for enhancing gene silencing effects on the EGFR pathway in U251 glioma cells +other hsa-mir-122 Hepatitis C Virus Infection 23405269 microRNA-122 Dependent Binding of Ago2 Protein to Hepatitis C Virus RNA Is Associated with Enhanced RNA Stability and Translation Stimulation +other hsa-mir-342 Breast Neoplasms 23408138 miR-342 is associated with estrogen receptor-§Ø©ãexpression and response to tamoxifen in breast cancer +other hsa-mir-99a Glioblastoma 23409016 Photofrin Based Photodynamic Therapy and miR-99a Transfection Inhibited FGFR3 and PI3K/Akt Signaling Mechanisms to Control Growth of Human Glioblastoma In Vitro and In Vivo +other hsa-mir-133a-1 Urinary Bladder Cancer 23410519 "A Common microRNA Signature Consisting of miR-133a, miR-139-3p, and miR-142-3p Clusters Bladder Carcinoma in Situ With Normal Umbrella Cells" +other hsa-mir-139 Urinary Bladder Cancer 23410519 "A Common microRNA Signature Consisting of miR-133a, miR-139-3p, and miR-142-3p Clusters Bladder Carcinoma in Situ With Normal Umbrella Cells" +other hsa-mir-142 Urinary Bladder Cancer 23410519 "A Common microRNA Signature Consisting of miR-133a, miR-139-3p, and miR-142-3p Clusters Bladder Carcinoma in Situ With Normal Umbrella Cells" +other hsa-mir-106a Glioblastoma 23416698 MiR-106a is an independent prognostic marker in patients with glioblastoma +other hsa-mir-146b Glioma 23419525 Intra-tumor injection of exosomes derived from miR-146-expressing MSCs significantly reduced glioma xenograft growth in a rat model of primary brain tumor. +other hsa-mir-181c Gastric Neoplasms 23425811 miR-181c expression level was significantly related to several clinicopathological features of gastric cancer +other hsa-mir-487b Lung Neoplasms 23426183 Cigarette smoke mediates epigenetic repression of miR-487b during pulmonary carcinogenesis +other hsa-mir-143 Osteosarcoma 23430952 "These effects were associated with decreased expression of Notch-1 and its downstream genes, such as vascular endothelial growth factor and matrix metalloproteinases, as well as increased expression of a panel of tumor-suppressive microRNAs (miRNAs), including miR-34a, miR-143, miR-145 and miR-200b/c that are typically lost in osteosarcoma. " +other hsa-mir-145 Osteosarcoma 23430952 "These effects were associated with decreased expression of Notch-1 and its downstream genes, such as vascular endothelial growth factor and matrix metalloproteinases, as well as increased expression of a panel of tumor-suppressive microRNAs (miRNAs), including miR-34a, miR-143, miR-145 and miR-200b/c that are typically lost in osteosarcoma. " +other hsa-mir-200b Osteosarcoma 23430952 "These effects were associated with decreased expression of Notch-1 and its downstream genes, such as vascular endothelial growth factor and matrix metalloproteinases, as well as increased expression of a panel of tumor-suppressive microRNAs (miRNAs), including miR-34a, miR-143, miR-145 and miR-200b/c that are typically lost in osteosarcoma. " +other hsa-mir-200c Osteosarcoma 23430952 "These effects were associated with decreased expression of Notch-1 and its downstream genes, such as vascular endothelial growth factor and matrix metalloproteinases, as well as increased expression of a panel of tumor-suppressive microRNAs (miRNAs), including miR-34a, miR-143, miR-145 and miR-200b/c that are typically lost in osteosarcoma. " +other hsa-mir-34a Osteosarcoma 23430952 "These effects were associated with decreased expression of Notch-1 and its downstream genes, such as vascular endothelial growth factor and matrix metalloproteinases, as well as increased expression of a panel of tumor-suppressive microRNAs (miRNAs), including miR-34a, miR-143, miR-145 and miR-200b/c that are typically lost in osteosarcoma. " +other hsa-mir-125b-1 Neoplasms [unspecific] 23437196 Forced expression of HER2 and HER3 rescued miR-199a- and miR-125b-inhibiting angiogenesis responses and Akt/p70S6K1/HIF-1§Ø©ãpathway. +other hsa-mir-125b-2 Neoplasms [unspecific] 23437196 Forced expression of HER2 and HER3 rescued miR-199a- and miR-125b-inhibiting angiogenesis responses and Akt/p70S6K1/HIF-1§Ø©ãpathway. +other hsa-mir-199a-1 Neoplasms [unspecific] 23437196 Forced expression of HER2 and HER3 rescued miR-199a- and miR-125b-inhibiting angiogenesis responses and Akt/p70S6K1/HIF-1§Ø©ãpathway. +other hsa-mir-199a-2 Neoplasms [unspecific] 23437196 Forced expression of HER2 and HER3 rescued miR-199a- and miR-125b-inhibiting angiogenesis responses and Akt/p70S6K1/HIF-1§Ø©ãpathway. +other hsa-mir-18a Colorectal Carcinoma 23437304 MicroRNA-18a Attenuates DNA Damage Repair through Suppressing the Expression of Ataxia Telangiectasia Mutated in Colorectal Cancer +other hsa-mir-200a Colorectal Carcinoma 23441132 Down-Regulation of the miRNA-200 Family at the Invasive Front of Colorectal Cancers with Degraded Basement Membrane Indicates EMT Is Involved in Cancer Progression +other hsa-mir-200b Colorectal Carcinoma 23441132 Down-Regulation of the miRNA-200 Family at the Invasive Front of Colorectal Cancers with Degraded Basement Membrane Indicates EMT Is Involved in Cancer Progression +other hsa-mir-200c Colorectal Carcinoma 23441132 Down-Regulation of the miRNA-200 Family at the Invasive Front of Colorectal Cancers with Degraded Basement Membrane Indicates EMT Is Involved in Cancer Progression +other hsa-mir-21 "Carcinoma, Hepatocellular" 23442323 Thyroid hormone regulation of miR-21 enhances migration and invasion of hepatoma +other hsa-mir-218-1 Urinary Bladder Cancer 23443110 MiR-218 Impairs Tumor Growth and Increases Chemo-Sensitivity to Cisplatin in Cervical Cancer +other hsa-mir-218-2 Urinary Bladder Cancer 23443110 MiR-218 Impairs Tumor Growth and Increases Chemo-Sensitivity to Cisplatin in Cervical Cancer +other hsa-mir-138-1 Head And Neck Neoplasms 23445815 Role of microRNA-138 as a Potential Tumor Suppressor in Head and Neck Squamous Cell Carcinoma +other hsa-mir-138-2 Head And Neck Neoplasms 23445815 Role of microRNA-138 as a Potential Tumor Suppressor in Head and Neck Squamous Cell Carcinoma +other hsa-mir-138 Cholangiocarcinoma 23446431 "Downregulation of microRNA-138 enhances the proliferation, migration and invasion of cholangiocarcinoma cells through the upregulation of RhoC/p-ERK/MMP-2/MMP-9." +other hsa-mir-208b Myocardial Infarction 23448306 During surgery miR-208b and miR-499-5p was released in the coronary sinus after cardioplegia-reperfusion to markedly higher levels than in a peripheral vein. +other hsa-mir-499 Myocardial Infarction 23448306 During surgery miR-208b and miR-499-5p was released in the coronary sinus after cardioplegia-reperfusion to markedly higher levels than in a peripheral vein. +other hsa-mir-195 Tongue Neoplasms 23451060 Prognostic Implications of MicoRNA miR-195 Expression in Human Tongue Squamous Cell Carcinoma +other hsa-mir-335 Prostate Neoplasms 23456549 Our data demonstrated for the first time the inhibitory effect of miR-335 on cell proliferation and invasion for PCa cells +other hsa-mir-126 Heart Failure 23465244 Expression of miR-126 and miR-508-5p in endothelial progenitor cells is associated with the prognosis of chronic heart failure patients +other hsa-mir-508 Heart Failure 23465244 Expression of miR-126 and miR-508-5p in endothelial progenitor cells is associated with the prognosis of chronic heart failure patients +other hsa-mir-27a "Carcinoma, Oral" 23472065 Primary Microcephaly Gene MCPH1 Shows Signatures of Tumor Suppressors and Is Regulated by miR-27a in Oral Squamous Cell Carcinoma +other hsa-mir-612 "Carcinoma, Hepatocellular" 23478189 miR-612 suppresses the invasive-metastatic cascade in hepatocellular carcinoma +other hsa-mir-21 Psoriasis 23479230 Mechanistic studies revealed a P2X7R-dependent mir-21 angiogenesis pathway that leads to the expression of vascular endothelial growth factor and IL-6 and that may be involved in the development of psoriatic lesions. +other hsa-mir-221 Multiple Myeloma 23479461 In Vitro and in Vivo Anti-tumor Activity of miR-221/222 Inhibitors in Multiple Myeloma +other hsa-mir-222 Multiple Myeloma 23479461 In Vitro and in Vivo Anti-tumor Activity of miR-221/222 Inhibitors in Multiple Myeloma +other hsa-mir-584 Breast Neoplasms 23479725 Micro-RNA-584 and the protein phosphatase and actin regulator 1 (PHACTR1): New Signaling Route Through Which Transforming Growth Factor-Beta Mediates the Migration and Actin Dynamics of Breast Cancer Cells +other hsa-mir-128-1 Glioblastoma 23482671 "NPV-LDE-225 (Erismodegib) inhibits epithelial mesenchymal transition and self-renewal of glioblastoma initiating cells by regulating miR-21, miR-128, and miR-200" +other hsa-mir-128-2 Glioblastoma 23482671 "NPV-LDE-225 (Erismodegib) inhibits epithelial mesenchymal transition and self-renewal of glioblastoma initiating cells by regulating miR-21, miR-128, and miR-200" +other hsa-mir-200 Glioblastoma 23482671 "NPV-LDE-225 (Erismodegib) inhibits epithelial mesenchymal transition and self-renewal of glioblastoma initiating cells by regulating miR-21, miR-128, and miR-200" +other hsa-mir-21 Glioblastoma 23482671 "NPV-LDE-225 (Erismodegib) inhibits epithelial mesenchymal transition and self-renewal of glioblastoma initiating cells by regulating miR-21, miR-128, and miR-200" +other hsa-mir-101-1 "Carcinoma, Hepatocellular" 23483142 miR-101 inhibits autophagy and enhances cisplatin-induced apoptosis in hepatocellular carcinoma cells +other hsa-mir-101-2 "Carcinoma, Hepatocellular" 23483142 miR-101 inhibits autophagy and enhances cisplatin-induced apoptosis in hepatocellular carcinoma cells +other hsa-mir-132 Epilepsy 23485811 "Functional studies employing antagomirs have identified contributions from miR-34a and miR-132 to seizure-induced neuronal death whereas silencing miR-134 potently reduced status epilepticus, seizure-damage and the later occurrence of spontaneous seizures." +other hsa-mir-34a Epilepsy 23485811 "Functional studies employing antagomirs have identified contributions from miR-34a and miR-132 to seizure-induced neuronal death whereas silencing miR-134 potently reduced status epilepticus, seizure-damage and the later occurrence of spontaneous seizures." +other hsa-mir-210 Lung Neoplasms 23492775 MiR-210 promotes a hypoxic phenotype and increases radioresistance in human lung cancer cell lines +other hsa-mir-133a Vascular Hypertrophy 23493786 "Our study unraveled for the first time the cardioprotection of choline against cardiac hypertrophy, with correction of expression of miR-133a and calcineurin as a possible mechanism. " +other hsa-mir-17 Feingold Syndrome 23495052 De novo 13q31.1-q32.1 interstitial deletion encompassing the miR-17-92 cluster in a patient with Feingold syndrome-2. +other hsa-mir-18 Feingold Syndrome 23495052 De novo 13q31.1-q32.1 interstitial deletion encompassing the miR-17-92 cluster in a patient with Feingold syndrome-2. +other hsa-mir-19a Feingold Syndrome 23495052 De novo 13q31.1-q32.1 interstitial deletion encompassing the miR-17-92 cluster in a patient with Feingold syndrome-2. +other hsa-mir-19b-1 Feingold Syndrome 23495052 De novo 13q31.1-q32.1 interstitial deletion encompassing the miR-17-92 cluster in a patient with Feingold syndrome-2. +other hsa-mir-20a Feingold Syndrome 23495052 De novo 13q31.1-q32.1 interstitial deletion encompassing the miR-17-92 cluster in a patient with Feingold syndrome-2. +other hsa-mir-92-1 Feingold Syndrome 23495052 De novo 13q31.1-q32.1 interstitial deletion encompassing the miR-17-92 cluster in a patient with Feingold syndrome-2. +other hsa-mir-125b-1 Neoplasms [unspecific] 23497288 miR-125b develops chemoresistance in Ewing sarcoma/primitive neuroectodermal tumor +other hsa-mir-125b-2 Neoplasms [unspecific] 23497288 miR-125b develops chemoresistance in Ewing sarcoma/primitive neuroectodermal tumor +other hsa-mir-133a Arrhythmia 23497314 Multiple miR-133a isomiRs with potential different mRNA target profiles are present in the atrium in humans and mice. +other hsa-mir-155 "Leukemia, Myeloid, Acute" 23497456 Silvestrol exhibits significant in vivo and in vitro antileukemic activities and inhibits FLT3 and miR-155 expressions in acute myeloid leukemia +other hsa-mir-92a-1 Ovarian Neoplasms 23499550 miR-92a Inhibits Peritoneal Dissemination of Ovarian Cancer Cells by Inhibiting Integrin Expression. +other hsa-mir-92a-2 Ovarian Neoplasms 23499550 miR-92a Inhibits Peritoneal Dissemination of Ovarian Cancer Cells by Inhibiting Integrin ¦Á5 Expression. +other hsa-mir-100 Prostate Neoplasms 23503652 "Tumor suppressor microRNAs, miR-100 and -125b, are regulated by 1,25-dihydroxyvitamin D in primary prostate cells and in patient tissue." +other hsa-mir-125b Prostate Neoplasms 23503652 "Tumor suppressor microRNAs, miR-100 and -125b, are regulated by 1,25-dihydroxyvitamin D in primary prostate cells and in patient tissue." +other hsa-mir-191 Breast Neoplasms 23505378 Estrogen Mediated-Activation of miR-191/425 Cluster Modulates Tumorigenicity of Breast Cancer Cells Depending on Estrogen Receptor Status +other hsa-mir-425 Breast Neoplasms 23505378 Estrogen Mediated-Activation of miR-191/425 Cluster Modulates Tumorigenicity of Breast Cancer Cells Depending on Estrogen Receptor Status +other hsa-mir-9-1 Human Immunodeficiency Virus Infection 23508624 Modulation of BK Channel by MicroRNA-9 in Neurons After Exposure to HIV and Methamphetamine +other hsa-mir-122 Hepatitis B Virus Infection 23508904 Circulating microRNA-22 correlates with microRNA-122 and represents viral replication and liver injury in patients with chronic hepatitis B +other hsa-mir-22 Hepatitis B Virus Infection 23508904 Circulating microRNA-22 correlates with microRNA-122 and represents viral replication and liver injury in patients with chronic hepatitis B +other hsa-mir-9-1 Leukemia 23509296 a unique role of miR-9 in myelopoiesis and in the pathogenesis of EVI1-induced myeloid neoplasms and provide insights into the epigenetic regulation of miR9 in tumorigenesis +other hsa-mir-9-2 Leukemia 23509296 a unique role of miR-9 in myelopoiesis and in the pathogenesis of EVI1-induced myeloid neoplasms and provide insights into the epigenetic regulation of miR9 in tumorigenesis +other hsa-mir-9-3 Leukemia 23509296 a unique role of miR-9 in myelopoiesis and in the pathogenesis of EVI1-induced myeloid neoplasms and provide insights into the epigenetic regulation of miR9 in tumorigenesis +other hsa-mir-155 Glioblastoma 23512614 "Cytokines (IL-1¦Â and TNF¦Á) also induce the expression of miR-155 and miR-155*, the microRNAs crucial in immunity and inflammation-induced oncogenesis and this is dose-dependently suppressed by IRF3. " +other hsa-mir-155 Atherosclerosis 23513069 The microRNA-342-5p Fosters Inflammatory Macrophage Activation Through an Akt1-and microRNA-155-Dependent Pathway during Atherosclerosis +other hsa-mir-342 Atherosclerosis 23513069 The microRNA-342-5p Fosters Inflammatory Macrophage Activation Through an Akt1-and microRNA-155-Dependent Pathway during Atherosclerosis +other hsa-mir-20a "Leukemia, Myeloid, Acute" 23515710 The clinical characteristics and prognostic significance of MN1 gene and MN1-associated microRNA expression in adult patients with de novo acute myeloid leukemia. +other hsa-mir-17 Rheumatoid Arthritis 23516027 The miR-17???92 Cluster: A Key Player in the Control of Inflammation during Rheumatoid Arthritis. +other hsa-mir-18 Rheumatoid Arthritis 23516027 The miR-17???92 Cluster: A Key Player in the Control of Inflammation during Rheumatoid Arthritis. +other hsa-mir-19a Rheumatoid Arthritis 23516027 The miR-17???92 Cluster: A Key Player in the Control of Inflammation during Rheumatoid Arthritis. +other hsa-mir-19b-1 Rheumatoid Arthritis 23516027 The miR-17???92 Cluster: A Key Player in the Control of Inflammation during Rheumatoid Arthritis. +other hsa-mir-20a Rheumatoid Arthritis 23516027 The miR-17???92 Cluster: A Key Player in the Control of Inflammation during Rheumatoid Arthritis. +other hsa-mir-92-1 Rheumatoid Arthritis 23516027 The miR-17???92 Cluster: A Key Player in the Control of Inflammation during Rheumatoid Arthritis. +other hsa-mir-125a Breast Neoplasms 23519125 "Functional cooperation of miR-125a, miR-125b, and miR-205 in entinostat-induced downregulation of erbB2/erbB3 and apoptosis in breast cancer cells" +other hsa-mir-125b-1 Breast Neoplasms 23519125 "Functional cooperation of miR-125a, miR-125b, and miR-205 in entinostat-induced downregulation of erbB2/erbB3 and apoptosis in breast cancer cells" +other hsa-mir-125b-2 Breast Neoplasms 23519125 "Functional cooperation of miR-125a, miR-125b, and miR-205 in entinostat-induced downregulation of erbB2/erbB3 and apoptosis in breast cancer cells" +other hsa-mir-205 Breast Neoplasms 23519125 "Functional cooperation of miR-125a, miR-125b, and miR-205 in entinostat-induced downregulation of erbB2/erbB3 and apoptosis in breast cancer cells" +other hsa-mir-222 "Leukemia, Acute" 23522449 MicroRNA profiling reveals aberrant microRNA expression in adult ETP-ALL and functional studies implicate a role for miR-222 in acute leukemia +other hsa-mir-26a-1 Pituitary Adenoma 23525216 miR-26a Plays an Important Role in Cell Cycle Regulation in ACTH-Secreting Pituitary Adenomas by Modulating Protein Kinase C +other hsa-mir-26a-2 Pituitary Adenoma 23525216 miR-26a Plays an Important Role in Cell Cycle Regulation in ACTH-Secreting Pituitary Adenomas by Modulating Protein Kinase C +other hsa-mir-34a "Leukemia, Lymphocytic, Chronic, B-Cell" 23525797 Inactivation of TP53 correlates with disease progression and low miR-34a expression in previously treated chronic lymphocytic leukemia patients +other hsa-mir-221 Breast Neoplasms 23529451 miR-221/222: promising biomarkers for breast cancer. +other hsa-mir-222 Breast Neoplasms 23529451 miR-221/222: promising biomarkers for breast cancer. +other hsa-mir-34a Glioma 23529798 These findings indicate the role of miR-34a in tumor progression may be closely associated with p53 mutation and inversely correlated to Bcl-2 expression +other hsa-mir-27a Colorectal Carcinoma 23530649 Resveratrol and Quercetin in Combination Have Anticancer Activity in Colon Cancer Cells and Repress Oncogenic microRNA-27a +other hsa-mir-215 Colorectal Carcinoma 23532818 MicroRNA-215 inhibits relapse of colorectal cancer patients following radical surgery +other hsa-mir-18a Glioma 23533157 Tumorigenic Potential of miR-18A* in Glioma Initiating Cells Requires NOTCH-1 Signaling +other hsa-mir-122 Hepatitis C Virus Infection 23537271 Down-regulating miR-122 expression by HCV core protein may give a new insight into the interaction between HCV and miR-122 and chronic HCV infection +other hsa-mir-155 Hematologic Neoplasms 23538486 Transfection of Kasumi-1 cells with a new type of polymer carriers loaded with miR-155 and antago-miR-155. +other hsa-mir-21 Colon Neoplasms 23544170 Down-regulation of miR-21 Induces Differentiation of Chemoresistant Colon Cancer Cells and Enhances Susceptibility to Therapeutic Regimens +other hsa-mir-200c Breast Neoplasms 23546450 miRNA-200c increases the sensitivity of breast cancer cells to doxorubicin through the suppression of E-cadherin-mediated PTEN/Akt signaling +other hsa-mir-92 "Carcinoma, Hepatocellular" 23546593 Expression and significance of PTEN and miR-92 in hepatocellular carcinoma +other hsa-mir-150 Myocardial Infarction 23547171 MicroRNA-150: A Novel Marker of Left Ventricular Remodeling After Acute Myocardial Infarction +other hsa-mir-21 "Lymphoma, B-Cell" 23548551 Inhibition of miR-21 Induces Biological and Behavioral Alterations in Diffuse Large B-Cell Lymphoma +other hsa-mir-515-1 Breast Neoplasms 23549953 Involvement of IGF-1R regulation by miR-515-5p modifies breast cancer risk among BRCA1 carriers +other hsa-mir-515-2 Breast Neoplasms 23549953 Involvement of IGF-1R regulation by miR-515-5p modifies breast cancer risk among BRCA1 carriers +other hsa-mir-181 Leukemia 23550642 We also present observations based on analyzes of miR-181 family genes that indicate the potential functions of primary and/or precursor miRNAs in target recognition and explore the impact of these findings on target identification. +other hsa-mir-17 Neoplasms [unspecific] 23550645 "Recent functional dissection of mir-17-92 indicates that individual mir-17-92 components perform distinct biological functions, which collectively regulate multiple related cellular processes during development and disease." +other hsa-mir-18 Neoplasms [unspecific] 23550645 "Recent functional dissection of mir-17-92 indicates that individual mir-17-92 components perform distinct biological functions, which collectively regulate multiple related cellular processes during development and disease." +other hsa-mir-19a Neoplasms [unspecific] 23550645 "Recent functional dissection of mir-17-92 indicates that individual mir-17-92 components perform distinct biological functions, which collectively regulate multiple related cellular processes during development and disease." +other hsa-mir-19b-1 Neoplasms [unspecific] 23550645 "Recent functional dissection of mir-17-92 indicates that individual mir-17-92 components perform distinct biological functions, which collectively regulate multiple related cellular processes during development and disease." +other hsa-mir-20a Neoplasms [unspecific] 23550645 "Recent functional dissection of mir-17-92 indicates that individual mir-17-92 components perform distinct biological functions, which collectively regulate multiple related cellular processes during development and disease." +other hsa-mir-92-1 Neoplasms [unspecific] 23550645 "Recent functional dissection of mir-17-92 indicates that individual mir-17-92 components perform distinct biological functions, which collectively regulate multiple related cellular processes during development and disease." +other hsa-mir-15a "Leukemia, B-Cell" 23551855 "DLEU2, which encodes miR-15a and miR-16-1, was discovered from 13q14 deletion in chronic lymphocytic leukemia, while C13orf25, which encodes six mature miRNA (miR-17, miR-18, miR-19a, miR-19b, miR-20a and miR-92a), was identified from 13q31 amplification in aggressive B-cell lymphomas." +other hsa-mir-16-1 "Leukemia, B-Cell" 23551855 "DLEU2, which encodes miR-15a and miR-16-1, was discovered from 13q14 deletion in chronic lymphocytic leukemia, while C13orf25, which encodes six mature miRNA (miR-17, miR-18, miR-19a, miR-19b, miR-20a and miR-92a), was identified from 13q31 amplification in aggressive B-cell lymphomas." +other hsa-mir-17 "Leukemia, B-Cell" 23551855 "DLEU2, which encodes miR-15a and miR-16-1, was discovered from 13q14 deletion in chronic lymphocytic leukemia, while C13orf25, which encodes six mature miRNA (miR-17, miR-18, miR-19a, miR-19b, miR-20a and miR-92a), was identified from 13q31 amplification in aggressive B-cell lymphomas." +other hsa-mir-18 "Leukemia, B-Cell" 23551855 "DLEU2, which encodes miR-15a and miR-16-1, was discovered from 13q14 deletion in chronic lymphocytic leukemia, while C13orf25, which encodes six mature miRNA (miR-17, miR-18, miR-19a, miR-19b, miR-20a and miR-92a), was identified from 13q31 amplification in aggressive B-cell lymphomas." +other hsa-mir-19a "Leukemia, B-Cell" 23551855 "DLEU2, which encodes miR-15a and miR-16-1, was discovered from 13q14 deletion in chronic lymphocytic leukemia, while C13orf25, which encodes six mature miRNA (miR-17, miR-18, miR-19a, miR-19b, miR-20a and miR-92a), was identified from 13q31 amplification in aggressive B-cell lymphomas." +other hsa-mir-19b "Leukemia, B-Cell" 23551855 "DLEU2, which encodes miR-15a and miR-16-1, was discovered from 13q14 deletion in chronic lymphocytic leukemia, while C13orf25, which encodes six mature miRNA (miR-17, miR-18, miR-19a, miR-19b, miR-20a and miR-92a), was identified from 13q31 amplification in aggressive B-cell lymphomas." +other hsa-mir-20a "Leukemia, B-Cell" 23551855 "DLEU2, which encodes miR-15a and miR-16-1, was discovered from 13q14 deletion in chronic lymphocytic leukemia, while C13orf25, which encodes six mature miRNA (miR-17, miR-18, miR-19a, miR-19b, miR-20a and miR-92a), was identified from 13q31 amplification in aggressive B-cell lymphomas." +other hsa-mir-92a "Leukemia, B-Cell" 23551855 "DLEU2, which encodes miR-15a and miR-16-1, was discovered from 13q14 deletion in chronic lymphocytic leukemia, while C13orf25, which encodes six mature miRNA (miR-17, miR-18, miR-19a, miR-19b, miR-20a and miR-92a), was identified from 13q31 amplification in aggressive B-cell lymphomas." +other hsa-mir-31 Ovarian Neoplasms 23552883 Downregulation of miRNA-31 induces taxane resistance in ovarian cancer cells through increase of receptor tyrosine kinase MET +other hsa-mir-101-1 Human Immunodeficiency Virus Infection 23554480 HIV-1 Tat C Modulates Expression of miRNA-101 to Suppress VE-Cadherin in Human Brain Microvascular Endothelial Cells +other hsa-mir-101-2 Human Immunodeficiency Virus Infection 23554480 HIV-1 Tat C Modulates Expression of miRNA-101 to Suppress VE-Cadherin in Human Brain Microvascular Endothelial Cells +other hsa-mir-181b Glioma 23554660 MiR-181b suppresses proliferation of and reduces chemoresistance to temozolomide in U87 glioma stem cells. +other hsa-mir-1228 Gastric Neoplasms 23554909 Restoration of miR-1228* Expression Suppresses Epithelial-Mesenchymal Transition in Gastric Cancer +other hsa-mir-574 Prostate Neoplasms 23554959 Genistein Up-Regulates Tumor Suppressor MicroRNA-574-3p in Prostate Cancer +other hsa-mir-221 Human Immunodeficiency Virus Infection 23555914 HIV Tat Induces Expression of ICAM-1 in HUVECs: Implications for miR-221/-222 in HIV-Associated Cardiomyopathy +other hsa-mir-222 Human Immunodeficiency Virus Infection 23555914 HIV Tat Induces Expression of ICAM-1 in HUVECs: Implications for miR-221/-222 in HIV-Associated Cardiomyopathy +other hsa-mir-146a Lung Neoplasms 23555954 "miR-146a Inhibits Cell Growth, Cell Migration and Induces Apoptosis in Non-Small Cell Lung Cancer Cells" +other hsa-mir-155 Diabetes Mellitus 23560074 Bone Marrow Progenitor Cell Therapy-Mediated Paracrine Regulation of Cardiac miRNA-155 Modulates Fibrotic Response in Diabetic Hearts +other hsa-let-7c "Adenocarcinoma, Lung" 23562878 "Ectopic let-7c expression increased the in vitro and in vivo chemo- or radiosensitivity of DTX-resistant LAD cells through enhanced apoptosis, reversal of epithelial-to-mesenchymal phenotypes, and inhibition of in vivo metastatic potential via inactivation of Akt phosphorylation, whereas a let-7c inhibitor decreased the chemo- or radiosensitivity of parental cells" +other hsa-mir-708 Bladder Neoplasms 23568547 miR-708 promotes the development of bladder carcinoma via direct repression of Caspase-2 +other hsa-mir-26 "Carcinoma, Hepatocellular" 23569435 Development of a miR-26 Companion Diagnostic Test for Adjuvant Interferon-alpha Therapy in Hepatocellular Carcinoma +other hsa-mir-107 Glioma 23572380 MicroRNA-107 Inhibits U87 Glioma Stem Cells Growth and Invasion +other hsa-mir-301a Diabetes Mellitus 23573265 MicroRNA-301a Mediated Regulation of Kv4.2 in Diabetes: Identification of Key Modulators +other hsa-mir-143 Colorectal Carcinoma 23574723 MicroRNA-143 inhibits tumor growth and angiogenesis and sensitizes chemosensitivity to oxaliplatin in colorectal cancers +other hsa-mir-19b-1 Osteosarcoma 23574781 MicroRNA-199b-5p is involved in the Notch signaling pathway in osteosarcoma +other hsa-mir-19b-2 Osteosarcoma 23574781 MicroRNA-199b-5p is involved in the Notch signaling pathway in osteosarcoma +other hsa-mir-345 "Carcinoma, Hepatocellular" 23577194 Hepatitis C Virus Core Protein Down-Regulates p21(Waf1/Cip1) and Inhibits Curcumin-Induced Apoptosis through MicroRNA-345 Targeting in Human Hepatoma Cells +other hsa-mir-221 Hepatitis E Virus Infection 23579640 Identification of miR-221 and -222 as important regulators in genotype IV swine hepatitis E virus ORF3-expressing HEK 293 cells +other hsa-mir-222 Hepatitis E Virus Infection 23579640 Identification of miR-221 and -222 as important regulators in genotype IV swine hepatitis E virus ORF3-expressing HEK 293 cells +other hsa-mir-378 "Leukemia, Myeloid, Acute" 23582927 Overexpression of miR-378 is frequent and may affect treatment outcomes in patients with acute myeloid leukemia. +other hsa-mir-223 Colon Neoplasms 23584479 Gain-of-function mutant p53 downregulates miR-223 contributing to chemoresistance of cultured tumor cells. +other hsa-let-7a Parkinson Disease 23600457 "Furthermore, the lack of LRRK2 leads to an up-regulation of neuronal differentiation-inducing processes, including the Let-7a pathway." +other hsa-mir-17 "Squamous Cell Carcinoma, Oral" 23602254 MicroRNA-17/20a functions to inhibit cell migration and can be used a prognostic marker in oral squamous cell carcinoma. +other hsa-mir-20a "Squamous Cell Carcinoma, Oral" 23602254 MicroRNA-17/20a functions to inhibit cell migration and can be used a prognostic marker in oral squamous cell carcinoma. +other hsa-mir-15a "Leukemia, Lymphocytic, Chronic, B-Cell" 23608884 Loss of p53 and altered miR15-a/16-1¯ýMCL-1 pathway in CLL: insights from TCL1-Tg:p53(-/-) mouse model and primary human leukemia cells. +other hsa-mir-16-1 "Leukemia, Lymphocytic, Chronic, B-Cell" 23608884 Loss of p53 and altered miR15-a/16-1¯ýMCL-1 pathway in CLL: insights from TCL1-Tg:p53(-/-) mouse model and primary human leukemia cells. +other hsa-mir-1 "Carcinoma, Lung, Non-Small-Cell" 23617628 "Interplay between heme oxygenase-1 and miR-378 affects non-small cell lung carcinoma growth, vascularization, and metastasis." +other hsa-mir-378 "Carcinoma, Lung, Non-Small-Cell" 23617628 "Interplay between heme oxygenase-1 and miR-378 affects non-small cell lung carcinoma growth, vascularization, and metastasis." +other hsa-mir-208a Cardiomegaly 23623871 MiRNA-208a and miRNA-208b are triggered in thyroid hormone-induced cardiac hypertrophy - role of type 1 Angiotensin II receptor (AT1R) on miRNA-208a/¦Á-MHC modulation. +other hsa-mir-208b Cardiomegaly 23623871 MiRNA-208a and miRNA-208b are triggered in thyroid hormone-induced cardiac hypertrophy - role of type 1 Angiotensin II receptor (AT1R) on miRNA-208a/¦Á-MHC modulation. +other hsa-mir-1 Myocardial Infarction 23625462 MicroRNA-1 enhances the angiogenic differentiation of human cardiomyocyte progenitor cells. +other hsa-mir-302a Testicular Germ Cell Tumor 23625774 "Up-regulation of miR-302a significantly increased the sensitivity of NT2 cells to cisplatin by enhancing cisplatin-induced G2/M phase arrest and the subsequent progression to apoptosis.MiR-302a also increased the killing effects of cisplatin by lowering the apoptotic threshold; the same result was also observed in another TGCT-derived cell line, NCCIT." +other hsa-mir-378 Cardiomegaly 23625957 MiR-378 controls cardiac hypertrophy by combined repression of mitogen-activated protein kinase pathway factors. +other hsa-mir-221 Breast Neoplasms 23637992 miR-221 promotes tumorigenesis in human triple negative breast cancer cells. +other hsa-mir-155 Pancreatic Serous Cystic Neoplasm 23638815 "Upregulation of miR-21, miR-155 and miR-708 was found to occur during IPMN malignant transformation." +other hsa-mir-21 Pancreatic Serous Cystic Neoplasm 23638815 "Upregulation of miR-21, miR-155 and miR-708 was found to occur during IPMN malignant transformation." +other hsa-mir-708 Pancreatic Serous Cystic Neoplasm 23638815 "Upregulation of miR-21, miR-155 and miR-708 was found to occur during IPMN malignant transformation." +other hsa-mir-34a Neuroblastoma 23647235 "using the TANA modified antisense oligonucleotide against miR-34a, intracellular levels of miR-34 can be reduced, and consequently, the expression of its target oncogene V-myc myelocytomatosis viral related oncogene, neuroblastoma derived (MYCN) is enhanced. " +other hsa-mir-15a "Carcinoma, Hepatocellular" 23649629 Hepatitis B viral RNA directly mediates down-regulation of the tumor suppressor microRNA miR-15a/miR-16-1 in hepatocytes. +other hsa-mir-16-1 "Carcinoma, Hepatocellular" 23649629 Hepatitis B viral RNA directly mediates down-regulation of the tumor suppressor microRNA miR-15a/miR-16-1 in hepatocytes. +other hsa-mir-183 Pheochromocytoma 23660872 We demonstrated that miR-183 and/or miR-96 impede NGF-induced differentiation in PC12 cells. +other hsa-mir-96 Pheochromocytoma 23660872 We demonstrated that miR-183 and/or miR-96 impede NGF-induced differentiation in PC12 cells. +other hsa-mir-19a Colon Neoplasms 23666757 MicroRNA-19a targets tissue factor to inhibit colon cancer cells migration and invasion. +other hsa-mir-150 "Carcinoma, Lung, Non-Small-Cell" 23670238 "These findings suggest that miR-150, p53 protein and relevant miRNAs are members of a regulatory network in NSCLC tumorigenesis." +other hsa-mir-186 "Carcinoma, Lung, Non-Small-Cell" 23671127 PTTG1 promotes migration and invasion of human non-small cell lung cancer cells and is modulated by miR-186. +other hsa-mir-449b Colorectal Carcinoma 23674142 These data suggest that miR-449b plays a tumor-suppressive role in colon cancer stem cells +other hsa-mir-103 Pancreatic Neoplasms 23674172 Our study demonstrates that the pathophysiology of HNF1A-MODY is associated with the overexpression of miR-103 and miR-224. +other hsa-mir-224 Pancreatic Neoplasms 23674172 Our study demonstrates that the pathophysiology of HNF1A-MODY is associated with the overexpression of miR-103 and miR-224. +other hsa-mir-200a Cervical Neoplasms 23679328 MiR-93 and miR-200a are associated with metastasis and invasion of cervical carcinoma. +other hsa-mir-93 Cervical Neoplasms 23679328 MiR-93 and miR-200a are associated with metastasis and invasion of cervical carcinoma. +other hsa-let-7d "Carcinoma, Hepatocellular" 23682578 "The MC recurrence-related miRNA included let-7d*, miR-328 and miR18a*, which potentially regulate K-ras gene expression. " +other hsa-mir-18a "Carcinoma, Hepatocellular" 23682578 "The MC recurrence-related miRNA included let-7d*, miR-328 and miR18a*, which potentially regulate K-ras gene expression. " +other hsa-mir-328 "Carcinoma, Hepatocellular" 23682578 "The MC recurrence-related miRNA included let-7d*, miR-328 and miR18a*, which potentially regulate K-ras gene expression. " +other hsa-mir-10a "Carcinoma, Thyroid, Medullary" 23685355 Overexpression of miR-10a and miR-375 and downregulation of YAP1 in medullary thyroid carcinoma. +other hsa-mir-375 "Carcinoma, Thyroid, Medullary" 23685355 Overexpression of miR-10a and miR-375 and downregulation of YAP1 in medullary thyroid carcinoma. +other hsa-mir-16 Lymphoma 23686310 Dysregulation of BMI1 and microRNA-16 collaborate to enhance an anti-apoptotic potential in the side population of refractory mantle cell lymphoma. +other hsa-mir-23a "Adenocarcinoma, Gastric" 23688986 "Suppression of miR-23a with ASO-23a obviously inhibited cell growth, colony formation and invasiveness of MGC803 cells and significantly enhanced the cell apoptosis." +other hsa-mir-1 Vascular Hypertrophy 23691029 "The synergistic effect of miR-21 and miR-1 were functionally validated for their significant influences on myocardial apoptosis, cardiac hypertrophy and fibrosis." +other hsa-mir-21 Vascular Hypertrophy 23691029 "The synergistic effect of miR-21 and miR-1 were functionally validated for their significant influences on myocardial apoptosis, cardiac hypertrophy and fibrosis." +other hsa-mir-124 Stroke 23696548 These data demonstrate that p53-mediated neuronal cell death after stroke can be nontranscriptionally regulated by a novel mechanism involving suppression of endogenous cell death inhibitors by miR-124. +other hsa-mir-375 Ovarian Neoplasms 23696927 Mir-375 enhances ruthenium-derived compound Rawq01 induced cell death in human ovarian cancer. +other hsa-mir-146a Chronic Inflammation 23705069 MicroRNA-146a (miR-146a) is a critical negative regulator of inflammation +other hsa-mir-200a "Carcinoma, Lung, Non-Small-Cell" 23708087 The microRNA-200 family targets multiple non-small cell lung cancer prognostic markers in H1299 cells and BEAS-2B cells. +other hsa-mir-200b "Carcinoma, Lung, Non-Small-Cell" 23708087 The microRNA-200 family targets multiple non-small cell lung cancer prognostic markers in H1299 cells and BEAS-2B cells. +other hsa-mir-197 Hepatitis B Virus Infection 23710316 miR-197 Expression in Peripheral Blood Mononuclear Cells from Hepatitis B Virus-Infected Patients. +other hsa-mir-21 Cardiovascular Diseases [unspecific] 23710745 MicroRNA-21 protects cardiomyocytes from tumor necrosis factor-¦Á induced apoptosis in vitro via modulating PTEN/AKT/FOXO3a pathway +other hsa-mir-1 Vascular Hypertrophy 23711953 the muscle-specific miR-1 and miR-133 are involved in cardiac development and hypertrophy +other hsa-mir-145 Pulmonary Hypertension 23713859 "Other microRNAs, such as miR-145, miR-21 and the miR17/92 cluster, have been associated with the disrupted BMPR2 pathway. " +other hsa-mir-17 Pulmonary Hypertension 23713859 "Other microRNAs, such as miR-145, miR-21 and the miR17/92 cluster, have been associated with the disrupted BMPR2 pathway. " +other hsa-mir-18 Pulmonary Hypertension 23713859 "Other microRNAs, such as miR-145, miR-21 and the miR17/92 cluster, have been associated with the disrupted BMPR2 pathway. " +other hsa-mir-19a Pulmonary Hypertension 23713859 "Other microRNAs, such as miR-145, miR-21 and the miR17/92 cluster, have been associated with the disrupted BMPR2 pathway. " +other hsa-mir-19b-1 Pulmonary Hypertension 23713859 "Other microRNAs, such as miR-145, miR-21 and the miR17/92 cluster, have been associated with the disrupted BMPR2 pathway. " +other hsa-mir-204 Pulmonary Hypertension 23713859 Recent studies demonstrated the role of miR-204 and miR- 206 in pulmonary artery smooth muscle cell (PASMC) proliferation. +other hsa-mir-206 Pulmonary Hypertension 23713859 Recent studies demonstrated the role of miR-204 and miR- 206 in pulmonary artery smooth muscle cell (PASMC) proliferation. +other hsa-mir-20a Pulmonary Hypertension 23713859 "Other microRNAs, such as miR-145, miR-21 and the miR17/92 cluster, have been associated with the disrupted BMPR2 pathway. " +other hsa-mir-21 Pulmonary Hypertension 23713859 "Other microRNAs, such as miR-145, miR-21 and the miR17/92 cluster, have been associated with the disrupted BMPR2 pathway. " +other hsa-mir-92-1 Pulmonary Hypertension 23713859 "Other microRNAs, such as miR-145, miR-21 and the miR17/92 cluster, have been associated with the disrupted BMPR2 pathway. " +other hsa-mir-126 Diabetes Mellitus 23713864 Recent studies identified circulating microRNA-126 as a biomarker for myocardial injury and vascular damage in diabetes. +other hsa-mir-125b-1 "Carcinoma, Lung, Non-Small-Cell" 23718732 MTA1 promotes the invasion and migration of non-small cell lung cancer cells by downregulating miR-125b. +other hsa-mir-125b-2 "Carcinoma, Lung, Non-Small-Cell" 23718732 MTA1 promotes the invasion and migration of non-small cell lung cancer cells by downregulating miR-125b. +other hsa-mir-21 Ischemia-Reperfusion Injury 23719532 MiR-21 expression is down-regulated and cell apoptosis is increased in rat myocardium during early ischemia-reperfusion injury. +other hsa-mir-34c Osteosarcoma 23720736 MicroRNA-34c inversely couples the biological functions of the runt-related transcription factor RUNX2 and the tumor suppressor p53 in osteosarcoma. +other hsa-mir-34a Bladder Neoplasms 23720881 These findings suggest that the relative low expression of miRNA-34a might be involved in the tumorigenesis of bladder cancer. +other hsa-mir-139 Breast Neoplasms 23722663 "Some novel miRNAs without known association to breast cancer were also found, and the putative functions of their PINs were also elucidated. These include miR-139 and miR-383. " +other hsa-mir-383 Breast Neoplasms 23722663 "Some novel miRNAs without known association to breast cancer were also found, and the putative functions of their PINs were also elucidated. These include miR-139 and miR-383. " +other hsa-let-7f "Diabetes Mellitus, Type 2" 23723366 "let-7f, a microRNA which has been related to endothelial angiogenic function, is found to play key role in TSP-2 increase, but let-7f did not directly interact with TSP-2 mRNA." +other hsa-mir-491 "Carcinoma, Hepatocellular" 23725476 MicroRNA-491 is involved in metastasis of hepatocellular carcinoma by inhibitions of matrix metalloproteinase and epithelial to mesenchymal transition. +other hsa-mir-148a Influenza 23731466 "QRT-PCR assay and ROC curve analyses revealed that miR-31, miR-29a and miR-148a all had significant potential diagnostic value for critically ill patients infected with H1N1 influenza virus" +other hsa-mir-29a Influenza 23731466 "QRT-PCR assay and ROC curve analyses revealed that miR-31, miR-29a and miR-148a all had significant potential diagnostic value for critically ill patients infected with H1N1 influenza virus" +other hsa-mir-31 Influenza 23731466 "QRT-PCR assay and ROC curve analyses revealed that miR-31, miR-29a and miR-148a all had significant potential diagnostic value for critically ill patients infected with H1N1 influenza virus" +other hsa-mir-485 "Carcinoma, Lung, Non-Small-Cell" 23734217 hsa-mir-485 Prostatic Neoplasms Prostatic Neoplasms Cytotoxic treatment of DU-145 cells enhanced the release of PCS-miRNAs with the exception of miR-485-3p which was retained by surviving cells. +other hsa-mir-181a-1 Osteosarcoma 23740615 "MicroRNA 181a improves proliferation and invasion, suppresses apoptosis of osteosarcoma cell." +other hsa-mir-181a-2 Osteosarcoma 23740615 "MicroRNA 181a improves proliferation and invasion, suppresses apoptosis of osteosarcoma cell." +other hsa-mir-224 "Carcinoma, Hepatocellular" 23741247 miR-224 functions as an onco-miRNA in hepatocellular carcinoma cells by activating AKT signaling. +other hsa-mir-199a-1 "Carcinoma, Hepatocellular" 23742776 Propofol inhibits the adhesion of hepatocellular carcinoma cells by upregulating microRNA-199a and downregulating MMP-9 expression. +other hsa-mir-199a-2 "Carcinoma, Hepatocellular" 23742776 Propofol inhibits the adhesion of hepatocellular carcinoma cells by upregulating microRNA-199a and downregulating MMP-9 expression. +other hsa-mir-200a Endometrial Neoplasms 23743934 ZEB1 overexpression associated with E-cadherin and microRNA-200 downregulation is characteristic of undifferentiated endometrial carcinoma. +other hsa-mir-200b Endometrial Neoplasms 23743934 ZEB1 overexpression associated with E-cadherin and microRNA-200 downregulation is characteristic of undifferentiated endometrial carcinoma. +other hsa-mir-200c Endometrial Neoplasms 23743934 ZEB1 overexpression associated with E-cadherin and microRNA-200 downregulation is characteristic of undifferentiated endometrial carcinoma. +other hsa-mir-29c Glioma 23744344 Tumor-suppressive effects of miR-29c on gliomas. +other hsa-mir-129-1 Colorectal Carcinoma 23744359 miR-129 promotes apoptosis and enhances chemosensitivity to 5-fluorouracil in colorectal cancer. +other hsa-mir-129-2 Colorectal Carcinoma 23744359 miR-129 promotes apoptosis and enhances chemosensitivity to 5-fluorouracil in colorectal cancer. +other hsa-let-7f-1 Stroke 23745809 "antagomirs to miR-145, -497, -181a, -1 and let-7f have been found to be neuroprotective in vivo." +other hsa-let-7f-2 Stroke 23745809 "antagomirs to miR-145, -497, -181a, -1 and let-7f have been found to be neuroprotective in vivo." +other hsa-mir-1-1 Stroke 23745809 "antagomirs to miR-145, -497, -181a, -1 and let-7f have been found to be neuroprotective in vivo." +other hsa-mir-1-2 Stroke 23745809 "antagomirs to miR-145, -497, -181a, -1 and let-7f have been found to be neuroprotective in vivo." +other hsa-mir-145 Stroke 23745809 "antagomirs to miR-145, -497, -181a, -1 and let-7f have been found to be neuroprotective in vivo." +other hsa-mir-181a-1 Stroke 23745809 "antagomirs to miR-145, -497, -181a, -1 and let-7f have been found to be neuroprotective in vivo." +other hsa-mir-181a-2 Stroke 23745809 "antagomirs to miR-145, -497, -181a, -1 and let-7f have been found to be neuroprotective in vivo." +other hsa-mir-497 Stroke 23745809 "antagomirs to miR-145, -497, -181a, -1 and let-7f have been found to be neuroprotective in vivo." +other hsa-mir-96 Pancreatic Neoplasms 23752186 EVI1 oncogene promotes KRAS pathway through suppression of microRNA-96 in pancreatic carcinogenesis. +other hsa-mir-140 Breast Neoplasms 23752191 Downregulation of miR-140 promotes cancer stem cell formation in basal-like early stage breast cancer. +other hsa-mir-21 Pancreatic Neoplasms 23752880 Endoscopically Acquired Pancreatic Cyst Fluid MicroRNA 21 and 221 Are Associated With Invasive Cancer. +other hsa-mir-221 Pancreatic Neoplasms 23752880 Endoscopically Acquired Pancreatic Cyst Fluid MicroRNA 21 and 221 Are Associated With Invasive Cancer. +other hsa-mir-708 Glioblastoma 23754151 miR-708 acts as a tumor suppressor in human glioblastoma cells. +other hsa-mir-200c "Carcinoma, Renal Cell" 23754305 microRNA-200c modulates the epithelial-to-mesenchymal transition in human renal cell carcinoma metastasis. +other hsa-mir-124-1 Cerebral Ischemia 23754622 MicroRNA-124 protects against focal cerebral ischemia via mechanisms involving Usp14-dependent REST degradation. +other hsa-mir-124-2 Cerebral Ischemia 23754622 MicroRNA-124 protects against focal cerebral ischemia via mechanisms involving Usp14-dependent REST degradation. +other hsa-mir-146a Sepsis 23756365 Morphine induced exacerbation of sepsis is mediated by tempering endotoxin tolerance through modulation of miR-146a. +other hsa-mir-193a Colorectal Carcinoma 23758639 "Potentiality of a triple microRNA classifier: miR-193a-3p, miR-23a and miR-338-5p for early detection of colorectal cancer." +other hsa-mir-23a Colorectal Carcinoma 23758639 "Potentiality of a triple microRNA classifier: miR-193a-3p, miR-23a and miR-338-5p for early detection of colorectal cancer." +other hsa-mir-338 Colorectal Carcinoma 23758639 "Potentiality of a triple microRNA classifier: miR-193a-3p, miR-23a and miR-338-5p for early detection of colorectal cancer." +other hsa-mir-181a-2 Breast Neoplasms 23759567 MicroRNA-181a/b: Novel biomarkers to stratify breast cancer patients for PARPi treatment. +other hsa-mir-181b-1 Breast Neoplasms 23759567 MicroRNA-181a/b: Novel biomarkers to stratify breast cancer patients for PARPi treatment. +other hsa-mir-181b-2 Breast Neoplasms 23759567 MicroRNA-181a/b: Novel biomarkers to stratify breast cancer patients for PARPi treatment. +other hsa-mir-125b-1 Multiple Myeloma 23759586 Attenuation of dexamethasone-induced cell death in multiple myeloma is mediated by miR-125b expression. +other hsa-mir-125b-2 Multiple Myeloma 23759586 Attenuation of dexamethasone-induced cell death in multiple myeloma is mediated by miR-125b expression. +other hsa-mir-17 Polycystic Kidney Disease 23759744 miR-17-92 miRNA cluster promotes kidney cyst growth in polycystic kidney disease. +other hsa-mir-18a Polycystic Kidney Disease 23759744 miR-17-92 miRNA cluster promotes kidney cyst growth in polycystic kidney disease. +other hsa-mir-19a Polycystic Kidney Disease 23759744 miR-17-92 miRNA cluster promotes kidney cyst growth in polycystic kidney disease. +other hsa-mir-19b-1 Polycystic Kidney Disease 23759744 miR-17-92 miRNA cluster promotes kidney cyst growth in polycystic kidney disease. +other hsa-mir-20a Polycystic Kidney Disease 23759744 miR-17-92 miRNA cluster promotes kidney cyst growth in polycystic kidney disease. +other hsa-mir-92a-1 Polycystic Kidney Disease 23759744 miR-17-92 miRNA cluster promotes kidney cyst growth in polycystic kidney disease. +other hsa-mir-200a "Carcinoma, Hepatocellular" 23760980 MicroRNA-200a/b influenced the therapeutic effects of curcumin in hepatocellular carcinoma (HCC) cells. +other hsa-mir-200b "Carcinoma, Hepatocellular" 23760980 MicroRNA-200a/b influenced the therapeutic effects of curcumin in hepatocellular carcinoma (HCC) cells. +other hsa-mir-99a "Diabetes Mellitus, Type 2" 23762265 Insulin Promotes Glucose Consumption via Regulation of miR-99a/mTOR/PKM2 Pathway. +other hsa-mir-155 "Leukemia-Lymphoma, Adult T-Cell" 23762762 Cellular MicroRNA miR-155 has Important Roles in Leukemogenesis by Human T-Cell Leukemia Virus Type 1 Infection. +other hsa-mir-18b Nasopharyngeal Neoplasms 23764853 Loss of connective tissue growth factor as an unfavorable prognosis factor activates miR-18b by PI3K/AKT/C-Jun and C-Myc and promotes cell growth in nasopharyngeal carcinoma. +other hsa-mir-221 Colorectal Carcinoma 23770133 "In metastatic CRC cells, reduced levels of mir-221* and mir-224 increase levels of MBD2, thereby decreasing expression of the metastasis suppressor maspin. Increased activities of mir-221* and mir-224 reduce growth and metastasis of CRC xenograft tumors in mice; these mirs might be developed as therapeutic reagents or biomarkers of CRC progression." +other hsa-mir-224 Colorectal Carcinoma 23770133 "In metastatic CRC cells, reduced levels of mir-221* and mir-224 increase levels of MBD2, thereby decreasing expression of the metastasis suppressor maspin. Increased activities of mir-221* and mir-224 reduce growth and metastasis of CRC xenograft tumors in mice; these mirs might be developed as therapeutic reagents or biomarkers of CRC progression." +other hsa-mir-768 Melanoma 23770856 Repression of microRNA-768-3p by MEK/ERK signalling contributes to enhanced mRNA translation in human melanoma. +other hsa-mir-122 Hepatitis C Virus Infection 23770926 mir-122 and the Hepatitis C RNA genome: more than just stability. +other hsa-mir-223 Neoplasms [unspecific] 23772809 "mir-223: infection, inflammation and cancer." +other hsa-mir-126 Atherosclerosis 23774505 MicroRNA-containing microvesicles regulating inflammation in association with atherosclerotic disease. +other hsa-mir-133 Atherosclerosis 23774505 MicroRNA-containing microvesicles regulating inflammation in association with atherosclerotic disease. +other hsa-mir-146 Atherosclerosis 23774505 MicroRNA-containing microvesicles regulating inflammation in association with atherosclerotic disease. +other hsa-mir-155 Atherosclerosis 23774505 MicroRNA-containing microvesicles regulating inflammation in association with atherosclerotic disease. +other hsa-mir-21 Atherosclerosis 23774505 MicroRNA-containing microvesicles regulating inflammation in association with atherosclerotic disease. +other hsa-mir-29 Atherosclerosis 23774505 MicroRNA-containing microvesicles regulating inflammation in association with atherosclerotic disease. +other hsa-let-7 Breast Neoplasms 23774803 MicroRNA-profiling in breast- and salivary gland-derived adenoid cystic carcinomas +other hsa-let-7 Salivary Gland Neoplasms 23774803 MicroRNA-profiling in breast- and salivary gland-derived adenoid cystic carcinomas +other hsa-mir-181a-2 Breast Neoplasms 23774803 MicroRNA-profiling in breast- and salivary gland-derived adenoid cystic carcinomas +other hsa-mir-181a-2 Salivary Gland Neoplasms 23774803 MicroRNA-profiling in breast- and salivary gland-derived adenoid cystic carcinomas +other hsa-mir-24 Breast Neoplasms 23774803 MicroRNA-profiling in breast- and salivary gland-derived adenoid cystic carcinomas +other hsa-mir-24 Salivary Gland Neoplasms 23774803 MicroRNA-profiling in breast- and salivary gland-derived adenoid cystic carcinomas +other hsa-mir-155 Pancreatic Neoplasms 23776656 "It is possible that mirNA participates in the pathophysiology of pancreatic cancer, but the current popular methods do not accurately reveal the real-time mirNA function. Thus, this report provided a convenient, accurate, and sensitive approach to mirNA research." +other hsa-mir-200b Pancreatic Neoplasms 23776656 "It is possible that mirNA participates in the pathophysiology of pancreatic cancer, but the current popular methods do not accurately reveal the real-time mirNA function. Thus, this report provided a convenient, accurate, and sensitive approach to mirNA research." +other hsa-mir-132 Encephalomyelitis 23780851 MicroRNA-132 suppresses autoimmune encephalomyelitis by inducing cholinergic anti-inflammation: a new Ahr-based exploration. +other hsa-mir-144 Thyroid Neoplasms 23783103 Almost all microRNAs exhibit isoforms of variable length and potentially distinct function in thyroid tumorigenesis. +other hsa-mir-146b Thyroid Neoplasms 23783103 Almost all microRNAs exhibit isoforms of variable length and potentially distinct function in thyroid tumorigenesis. +other hsa-mir-221 Thyroid Neoplasms 23783103 Almost all microRNAs exhibit isoforms of variable length and potentially distinct function in thyroid tumorigenesis. +other hsa-mir-486 Thyroid Neoplasms 23783103 Almost all microRNAs exhibit isoforms of variable length and potentially distinct function in thyroid tumorigenesis. +other hsa-mir-551b Thyroid Neoplasms 23783103 Almost all microRNAs exhibit isoforms of variable length and potentially distinct function in thyroid tumorigenesis. +other hsa-mir-7 Thyroid Neoplasms 23783103 Almost all microRNAs exhibit isoforms of variable length and potentially distinct function in thyroid tumorigenesis. +other hsa-mir-21 Neoplasms [unspecific] 23784029 MiR-21/Smad 7 signaling determines TGF-¦Â1-induced CAF formation. +other hsa-mir-22 Gastric Neoplasms 23786758 Reduced expression of miR-22 in gastric cancer is related to clinicopathologic characteristics or patient prognosis.. +other hsa-mir-30a "Carcinoma, Ovarian, Serous" 23787480 miRNA expression pattern associated with prognosis in elderly patients with advanced OPSC and OCC. +other hsa-mir-30e "Carcinoma, Ovarian, Serous" 23787480 miRNA expression pattern associated with prognosis in elderly patients with advanced OPSC and OCC. +other hsa-mir-505 "Carcinoma, Ovarian, Serous" 23787480 miRNA expression pattern associated with prognosis in elderly patients with advanced OPSC and OCC. +other hsa-mir-21 Colorectal Carcinoma 23788041 Pleiotropic actions of miR-21 highlight the critical role of deregulated stromal microRNAs during colorectal cancer progression. +other hsa-mir-217 "Carcinoma, Renal Cell, Clear-Cell" 23790169 miR-217 plays a tumor suppressor role in ccRCC. +other hsa-mir-122 "Carcinoma, Breast" 23791885 MicroRNA 'signature' during estrogen-mediated mammary carcinogenesis and its reversal by ellagic acid intervention. +other hsa-mir-127 "Carcinoma, Breast" 23791885 MicroRNA 'signature' during estrogen-mediated mammary carcinogenesis and its reversal by ellagic acid intervention. +other hsa-mir-182 "Carcinoma, Breast" 23791885 MicroRNA 'signature' during estrogen-mediated mammary carcinogenesis and its reversal by ellagic acid intervention. +other hsa-mir-183 "Carcinoma, Breast" 23791885 MicroRNA 'signature' during estrogen-mediated mammary carcinogenesis and its reversal by ellagic acid intervention. +other hsa-mir-206 "Carcinoma, Breast" 23791885 MicroRNA 'signature' during estrogen-mediated mammary carcinogenesis and its reversal by ellagic acid intervention. +other hsa-mir-375 "Carcinoma, Breast" 23791885 MicroRNA 'signature' during estrogen-mediated mammary carcinogenesis and its reversal by ellagic acid intervention. +other hsa-mir-122 Hepatitis C Virus Infection 23793894 A miRNA-responsive cell-free translation system facilitates isolation of hepatitis C virus miRNP complexes. +other hsa-mir-7 "Carcinoma, Renal Cell" 23793934 Identification of miR-7 as an oncogene in renal cell carcinoma. +other hsa-mir-146a Neoplasms [unspecific] 23796062 "Our results indicated that ectopic expression of miR-146a could not independently induce differentiation in lymphoblastic cells. However, the expression of multiple genes involved in T-cell differentiation and T-cell CD markers were found to be affected. These results have suggested a potential tumor suppressive, immunomodulatory and cell activator role for miR146-a." +other hsa-mir-125b Neoplasms [unspecific] 23800395 The expression and regulation of microRNA-125b in cancers. +other hsa-mir-153 Breast Neoplasms 23803066 miR-153 silencing induces apoptosis in the MDA-MB-231 breast cancer cell line. +other hsa-mir-17 Lesch-Nyhan Syndrome 23804752 Deficiency of the purine metabolic gene HPRT dysregulates microRNA-17 family cluster and guanine-based cellular functions: a role for EPAC in Lesch-Nyhan syndrome. +other hsa-mir-335 Neuroblastoma 23806264 "We report, for the first time, that GRP-R-mediated tumorigenicity and increased metastatic potential in neuroblastoma are regulated, in part, by miR-335 and miR-363. A better understanding of the anti-tumor functions of miRNAs could provide valuable insights to discerning molecular mechanisms responsible for neuroblastoma metastasis." +other hsa-mir-363 Neuroblastoma 23806264 "We report, for the first time, that GRP-R-mediated tumorigenicity and increased metastatic potential in neuroblastoma are regulated, in part, by miR-335 and miR-363. A better understanding of the anti-tumor functions of miRNAs could provide valuable insights to discerning molecular mechanisms responsible for neuroblastoma metastasis." +other hsa-mir-200c Neoplasms [unspecific] 23806972 Targeted delivery of miR-200c/DOC to inhibit cancer stem cells and cancer cells by the gelatinases-stimuli nanoparticles. +other hsa-mir-122 Chronic Hepatitis C 23808991 Serum microRNA-122 kinetics in patients with chronic hepatitis C virus infection during antiviral therapy. +other hsa-mir-181b Glioma 23810250 Involvement of FOS-mediated miR-181b/miR-21 signalling in the progression of malignant gliomas. +other hsa-mir-21 Glioma 23810250 Involvement of FOS-mediated miR-181b/miR-21 signalling in the progression of malignant gliomas. +other hsa-mir-196a Huntington Disease 23810380 "miR-196a ameliorates phenotypes of Huntington disease in cell, transgenic mouse, and induced pluripotent stem cell models." +other hsa-mir-126 Coxsackievirus Infection 23811937 MiR-126 promotes coxsackievirus replication by mediating cross-talk of ERK1/2 and Wnt/¦Â-catenin signal pathways. +other hsa-mir-21 Neoplasms [unspecific] 23811941 "AC1MMYR2, an inhibitor of dicer-mediated biogenesis of Oncomir miR-21, reverses epithelial-mesenchymal transition and suppresses tumor growth and progression." +other hsa-mir-203 Glioma 23813496 "Our data validate an important clinical significance of miR-203 in gliomas, and reveal that it might be an intrinsic regulator of tumor progression and a potential prognostic factor for this dismal disease." +other hsa-mir-145 Glioblastoma 23814265 "Our study demonstrates that miR-145 has a tumor-suppressive function in glioblastoma in that it reduces proliferation, adhesion, and invasion of glioblastoma cells, apparently by suppressing the activity of oncogenic proteins Sox9 and ADD3. Reduced levels of miR-145 may lead to neoplastic transformation and malignant progression in glioma due to unregulated activity of these proteins." +other hsa-mir-223 "Leukemia, Lymphoblastic" 23815897 Expression of microRNA-223 in lymphocytic leukemia cells and its action mechanism +other hsa-mir-155 Lymphoma 23815945 Influence of miRNA-155 on lymphoma. +other hsa-mir-155 Hematologic Neoplasms 23815946 Relationship between microRNA-155 and hematological malignancies +other hsa-mir-381 Kidney Neoplasms 23816136 miR-381 increases sensitivity of 786-O cells to 5-FU by inhibitory WEE1 and increase of Cdc2 activity. +other hsa-mir-155 "Carcinoma, Lung, Non-Small-Cell" 23817461 This meta-analysis provides evidence that miR-21 and miR-155 are predicting factors for non-small-cell lung cancer prognosis and lymphoid infiltration. +other hsa-mir-21 "Carcinoma, Lung, Non-Small-Cell" 23817461 This meta-analysis provides evidence that miR-21 and miR-155 are predicting factors for non-small-cell lung cancer prognosis and lymphoid infiltration. +other hsa-mir-30a Hypertension 23817492 miR-30a regulates endothelial tip cell formation and arteriolar branching. +other hsa-mir-155 Pancreatic Neoplasms 23817566 Regulation of miR-155 affects pancreatic cancer cell invasiveness and migration by modulating the STAT3 signaling pathway through SOCS1. +other hsa-mir-20a "Carcinoma, Cervical" 23819812 Our results suggested that the circulating miR-20a may be a potential biomarker for detecting the lymph node status of cervical cancer patients. +other hsa-mir-302c Neoplasms [unspecific] 23820258 "1,25(OH)2D3 facilitates the immuno-attack of NK cells against malignant cells partly through downregulation of miR-302c and miR-520c and hence upregulation of the NKG2D ligands MICA/B and ULBP2." +other hsa-mir-520c Neoplasms [unspecific] 23820258 "1,25(OH)2D3 facilitates the immuno-attack of NK cells against malignant cells partly through downregulation of miR-302c and miR-520c and hence upregulation of the NKG2D ligands MICA/B and ULBP2." +other hsa-let-7g "Carcinoma, Lung, Non-Small-Cell" 23820752 Let-7g and miR-21 expression in non-small cell lung cancer: correlation with clinicopathological and molecular features +other hsa-mir-21 "Carcinoma, Lung, Non-Small-Cell" 23820752 Let-7g and miR-21 expression in non-small cell lung cancer: correlation with clinicopathological and molecular features +other hsa-mir-155 "Leukemia, Lymphocytic, Chronic, B-Cell" 23821659 Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia. +other hsa-mir-200c Lung Neoplasms 23824089 NF-¦ÊB-mediated inflammation leading to EMT via miR-200c is involved in cell transformation induced by cigarette smoke extract. +other hsa-mir-29a Salmonellosis 23826261 "Our study outlines for the first time important regulation pathways in intestinal Salmonella infection pointing out that focal adhesion and organisation of actin cytoskeleton are regulated by microRNAs. Functional relevance is shown by miR-29a mediated Caveolin 2 regulation, modulating the activation state of CDC42. Further analysis of examined interactions may support the discovery of novel strategies impairing the uptake of intracellular pathogens." +other hsa-mir-122 Hepatitis C Virus Infection 23826300 Modulation of hepatitis C virus RNA accumulation and translation by DDX6 and miR-122 are mediated by separate mechanisms. +other hsa-mir-25 "Squamous Cell Carcinoma, Tongue" 23827155 MiR-25-3p attenuates the proliferation of tongue squamous cell carcinoma cell line Tca8113. +other hsa-mir-155 Atherosclerosis 23827206 MicroRNA-155 in the pathogenesis of atherosclerosis +other hsa-mir-21 "Carcinoma, Colon" 23827854 Aldose reductase inhibition suppresses colon cancer cell viability by modulating microRNA-21 mediated programmed cell death 4 (PDCD4) expression. +other hsa-mir-1 Mesothelioma 23828229 miR-1 induces growth arrest and apoptosis in malignant mesothelioma. +other hsa-mir-34 Neoplasms [unspecific] 23834144 Functional role of miR-34 family in human cancer. +other hsa-mir-145 Pancreatic Neoplasms 23834149 "insulingrowth factor-1 receptor expression (miR-7, miR-139, miR-145, miR-1); " +other hsa-mir-125 Glioblastoma 23835866 MicroRNA-125b inhibitor sensitizes human primary glioblastoma cells to chemotherapeutic drug temozolomide on invasion. +other hsa-mir-34a Neoplasms [unspecific] 23836017 TP53-independent function of miR-34a via HDAC1 and p21(CIP1/WAF1.). +other hsa-mir-24 Hypertension 23836801 MicroRNA-24 is a novel regulator of aldosterone and cortisol production in the human adrenal cortex. +other hsa-mir-208 Heart Failure 23839576 "Heart function has been restored in rodents by reprogramming non-myocytes into cardiomyocytes, by expressing transcription factors (GATA4, HAND2, myocyte-specific enhancer factor 2C (MEF2C) and T-box 5 (TBX5)) and microRNAs (miR-1, miR-133, miR-208 and miR-499) that control cardiomyocyte identity." +other hsa-mir-1234 "Lymphoma, Large B-Cell, Diffuse" 23841503 Expression of microRNA-1234 related signal transducer and activator of transcription 3 in patients with diffuse large B-cell lymphoma of activated B-cell like type from high and low infectious disease areas. +other hsa-mir-148a "Carcinoma, Lung, Non-Small-Cell" 23843100 Decreased miRNA-148a is associated with lymph node metastasis and poor clinical outcomes and functions as a suppressor of tumor metastasis in non-small cell lung cancer. +other hsa-mir-142 Testicular Germ Cell Tumor 23843459 Tumor-suppressive function of protein-tyrosine phosphatase non-receptor type 23 in testicular germ cell tumors is lost upon overexpression of miR142-3p microRNA. +other hsa-mir-302b Osteosarcoma 23845851 Epirubicin-mediated expression of miR-302b is involved in osteosarcoma apoptosis and cell cycle regulation. +other hsa-mir-21 Breast Neoplasms 23851508 The anti-metastatic activity of collagenase-2 in breast cancer cells is mediated by a signaling pathway involving decorin and miR-21. +other hsa-mir-29 Neoplasms [unspecific] 23857059 miR-29 represses the activities of DNA methyltransferases and DNA demethylases. +other hsa-mir-200 "Carcinoma, Hepatocellular" 23857252 MicroRNA/gene profiling unveils early molecular changes and nuclear factor erythroid related factor 2 (NRF2) activation in a rat model recapitulating human hepatocellular carcinoma (HCC). +other hsa-mir-21 Lung Neoplasms 23857284 Expression and significance of miRNA-21 and BTG2 in lung cancer. +other hsa-mir-133a Muscle Diseases [unspecific] 23858090 miRNA analysis for the assessment of exercise and amino acid effects on human skeletal muscle. +other hsa-mir-133b Muscle Diseases [unspecific] 23858090 miRNA analysis for the assessment of exercise and amino acid effects on human skeletal muscle. +other hsa-mir-206 Muscle Diseases [unspecific] 23858090 miRNA analysis for the assessment of exercise and amino acid effects on human skeletal muscle. +other hsa-mir-499 Muscle Diseases [unspecific] 23858090 miRNA analysis for the assessment of exercise and amino acid effects on human skeletal muscle. +other hsa-mir-21 Colorectal Carcinoma 23858763 Construction of microRNA-21 and PTEN eukaryotic expression and short hairpin RNA expression vectors +other hsa-mir-1 Vascular Hypertrophy 23859766 "In addition, microRNAs (miR) -133a, miR-208 and miR-1 which were elevated following high-fat feeding were attenuated by apelin treatment." +other hsa-mir-208 Vascular Hypertrophy 23859766 "In addition, microRNAs (miR) -133a, miR-208 and miR-1 which were elevated following high-fat feeding were attenuated by apelin treatment." +other hsa-mir-124 Stroke 23860031 We highlight interactions between the miR-124 and the miR17-92 cluster and the Notch and Sonic hedgehog signaling pathways in mediating stroke-induced neurogenesis. +other hsa-mir-625 Colorectal Carcinoma 23861214 Our results suggest that miR-625 may serve as an efficient clinical biomarker and a therapeutic tool for the inhibition of metastasis in CRC. +other hsa-mir-148a "Carcinoma, Hepatocellular" 23861222 Inhibitions of epithelial to mesenchymal transition and cancer stem cells-like properties are involved in miR-148a-mediated anti-metastasis of hepatocellular carcinoma. +other hsa-mir-190 Neoplasms [unspecific] 23863200 Transcriptional changes induced by the tumor dormancy-associated microRNA-190. +other hsa-mir-143 Colorectal Carcinoma 23866094 miR-143 blocks the TLR2 signalling pathway in human CRC cells. This knowledge may pave the way for new clinical applications utilising miR-143 mimics in the treatment of patients with CRC. +other hsa-mir-221 Obesity 23867206 Our results support the link between miR-221 and obesity development as well as obesity related inflammatory status. +other hsa-mir-148a Gastric Neoplasms 23869555 Quantitative proteomics reveals diverse roles of miR-148a from gastric cancer progression to neurological development. +other hsa-mir-29b "Aortic Aneurysm, Abdominal" 23871588 MicroRNA-29b regulation of abdominal aortic aneurysm development. +other hsa-mir-499 Acute Myocardial Infarction 23872321 We developed a novel reverse-transcription real-time PCR assay for human miR-499 quantification. The good reproducibility and wide linearity range may permit more use of it in the quantification of other human miRNAs in future. +other hsa-mir-148a Gastric Neoplasms 23873106 microRNA-148a suppresses human gastric cancer cell metastasis by reversing epithelial-to-mesenchymal transition. +other hsa-mir-145 Microvascular Disease 23875242 The role of miR-145 in microvasculature. +other hsa-mir-365 Schizophrenia 23876895 "This study analyzed possible circulating miRNAs in response to antipsychotic monotherapy for schizophrenia, the further mechanism need to be confirmed." +other hsa-let-7c Lung Neoplasms 23880305 "Additionally, antrocin increased microRNA let-7c expression and suppressed STAT signaling." +other hsa-mir-127 Gastric Neoplasms 23880861 The Tumor Suppressor Roles of miR-433 and miR-127 in Gastric Cancer. +other hsa-mir-433 Gastric Neoplasms 23880861 The Tumor Suppressor Roles of miR-433 and miR-127 in Gastric Cancer. +other hsa-mir-122 Hepatitis C Virus Infection 23881584 miR-122 promotion of the hepatitis C virus life cycle: sound in the silence. +other hsa-mir-497 Prostate Neoplasms 23886135 MicroRNA-497 suppresses proliferation and induces apoptosis in prostate cancer cells. +other hsa-mir-485 "Carcinoma, Breast" 23886178 miR-485 acts as a tumor suppressor by inhibiting cell growth and migration in breast carcinoma T47D cells. +other hsa-mir-146a "Leukemia, Lymphoblastic, Acute" 23888320 A functional polymorphism in the miR-146a gene is associated with the risk of childhood acute lymphoblastic leukemia: a preliminary report. +other hsa-mir-200a Ovarian Neoplasms 23888941 The biphasic expression pattern of miR-200a and E-cadherin in epithelial ovarian cancer and its correlation with clinicopathological features. +other hsa-mir-99a "Adenocarcinoma, Lung" 23893385 Clinic significance of microRNA-99a expression in human lung adenocarcinoma. +other hsa-mir-30b "Scleroderma, Systemic" 23893664 Down-regulation of miR-30b might be involved in the pathogenesis of SSc. +other hsa-mir-92a Ischemia-Reperfusion Injury 23897866 Inhibition of microRNA-92a protects against ischemia/reperfusion injury in a large-animal model. +other hsa-mir-143 "Adenocarcinoma, Gastric" 23898078 Differential miRNA expression patterns of gastric adenocarcinoma of the same histopathology from a small geographic region's population show homogenous correlations with the existence of common risk factors. +other hsa-mir-203 "Adenocarcinoma, Gastric" 23898078 Differential miRNA expression patterns of gastric adenocarcinoma of the same histopathology from a small geographic region's population show homogenous correlations with the existence of common risk factors. +other hsa-mir-205 "Adenocarcinoma, Gastric" 23898078 Differential miRNA expression patterns of gastric adenocarcinoma of the same histopathology from a small geographic region's population show homogenous correlations with the existence of common risk factors. +other hsa-mir-21 "Adenocarcinoma, Gastric" 23898078 Differential miRNA expression patterns of gastric adenocarcinoma of the same histopathology from a small geographic region's population show homogenous correlations with the existence of common risk factors. +other hsa-mir-223 "Adenocarcinoma, Gastric" 23898078 Differential miRNA expression patterns of gastric adenocarcinoma of the same histopathology from a small geographic region's population show homogenous correlations with the existence of common risk factors. +other hsa-mir-34a "Adenocarcinoma, Gastric" 23898078 Differential miRNA expression patterns of gastric adenocarcinoma of the same histopathology from a small geographic region's population show homogenous correlations with the existence of common risk factors. +other hsa-mir-93 "Adenocarcinoma, Gastric" 23898078 Differential miRNA expression patterns of gastric adenocarcinoma of the same histopathology from a small geographic region's population show homogenous correlations with the existence of common risk factors. +other hsa-mir-29a Pancreatic Neoplasms 23900458 MicroRNA-29a induces resistance to gemcitabine through the Wnt/¦Â-catenin signaling pathway in pancreatic cancer cells. +other hsa-mir-29 Neoplasms [unspecific] 23901138 miR-29 acts as a decoy in sarcomas to protect the tumor suppressor A20 mRNA from degradation by HuR. +other hsa-mir-210 "Carcinoma, Renal Cell" 23902947 "VHL, involved in tumorigenesis of PGLs and clear cell renal cell carcinomas, may be an important player in the pathogenesis of sporadic HNPGLs via activation of an HIF-1¦Á/miR-210 pHx pathway." +other hsa-mir-29 Ovarian Neoplasms 23904094 Downregulation of miR-29 contributes to cisplatin resistance of ovarian cancer cells. +other hsa-mir-21 Glioblastoma 23907387 "Furthermore, several modules associated with less well-reported molecular aberrations-such as chromosome 11 CNVs, CD40, PLXNB1 and GSTM1 methylations, and mir-21 expressions-were also validated by external information. " +other hsa-mir-100 Bladder Neoplasms 23911686 Aberrations in miR expression identified between non-muscle invasive BC and muscle-invasive BC provide insight into the molecular alterations known to distinguish the two parallel pathways of bladder carcinogenesis. The heterogeneity of tumor specimens and research methods limits the reproducibility of changes in miR expression profiles between studies and underscores theimportance of in vivo validation in a field that utilizes in silico miR target-prediction models. +other hsa-mir-101 Bladder Neoplasms 23911686 Aberrations in miR expression identified between non-muscle invasive BC and muscle-invasive BC provide insight into the molecular alterations known to distinguish the two parallel pathways of bladder carcinogenesis. The heterogeneity of tumor specimens and research methods limits the reproducibility of changes in miR expression profiles between studies and underscores theimportance of in vivo validation in a field that utilizes in silico miR target-prediction models. +other hsa-mir-145 Bladder Neoplasms 23911686 Aberrations in miR expression identified between non-muscle invasive BC and muscle-invasive BC provide insight into the molecular alterations known to distinguish the two parallel pathways of bladder carcinogenesis. The heterogeneity of tumor specimens and research methods limits the reproducibility of changes in miR expression profiles between studies and underscores theimportance of in vivo validation in a field that utilizes in silico miR target-prediction models. +other hsa-mir-21 Bladder Neoplasms 23911686 Aberrations in miR expression identified between non-muscle invasive BC and muscle-invasive BC provide insight into the molecular alterations known to distinguish the two parallel pathways of bladder carcinogenesis. The heterogeneity of tumor specimens and research methods limits the reproducibility of changes in miR expression profiles between studies and underscores theimportance of in vivo validation in a field that utilizes in silico miR target-prediction models. +other hsa-mir-373 Bladder Neoplasms 23911686 Aberrations in miR expression identified between non-muscle invasive BC and muscle-invasive BC provide insight into the molecular alterations known to distinguish the two parallel pathways of bladder carcinogenesis. The heterogeneity of tumor specimens and research methods limits the reproducibility of changes in miR expression profiles between studies and underscores theimportance of in vivo validation in a field that utilizes in silico miR target-prediction models. +other hsa-mir-99a Bladder Neoplasms 23911686 Aberrations in miR expression identified between non-muscle invasive BC and muscle-invasive BC provide insight into the molecular alterations known to distinguish the two parallel pathways of bladder carcinogenesis. The heterogeneity of tumor specimens and research methods limits the reproducibility of changes in miR expression profiles between studies and underscores theimportance of in vivo validation in a field that utilizes in silico miR target-prediction models. +other hsa-mir-106b "Carcinoma, Laryngeal" 23912048 MicroRNA-106b regulates the tumor suppressor RUNX3 in laryngeal carcinoma cells. +other hsa-mir-17 "Carcinoma, Hepatocellular" 23912452 Thyroid hormone receptor represses miR-17 expression to enhance tumor metastasis in human hepatoma cells. +other hsa-mir-31 Chordoma 23912551 MicroRNA expression profiling reveals the potential function of microRNA-31 in chordomas. +other hsa-mir-224 "Carcinoma, Hepatocellular" 23913306 "A noncanonical pathway links autophagy,miR-224, Smad4, and HBV-associated HCC. These findings open a new avenue for the treatment of HCC." +other hsa-mir-100 "Leukemia, Lymphoblastic, Acute" 23915977 "MiR-125b, miR-100 and miR-99a co-regulate vincristine resistance in childhood acute lymphoblastic leukemia." +other hsa-mir-125b "Leukemia, Lymphoblastic, Acute" 23915977 "MiR-125b, miR-100 and miR-99a co-regulate vincristine resistance in childhood acute lymphoblastic leukemia." +other hsa-mir-99a "Leukemia, Lymphoblastic, Acute" 23915977 "MiR-125b, miR-100 and miR-99a co-regulate vincristine resistance in childhood acute lymphoblastic leukemia." +other hsa-mir-34c Neoplasms [unspecific] 23922103 These findings provide a novel molecular mechanism of MET regulation in PCa and contribute to the increasing evidence that miR-34c has a key tumour suppressive role in PCa. +other hsa-mir-768 Lung Neoplasms 23928793 The brain microenvironment negatively regulates miRNA-768-3p to promote K-ras expression and lung cancer metastasis. +other hsa-mir-515 Breast Neoplasms 23928990 Downregulation of microRNA-515-5p by the estrogen receptor modulates sphingosine kinase 1 and breast cancer cell proliferation. +other hsa-mir-148a Colorectal Carcinoma 23933284 Clinical significance of microRNA-148a in patients with early relapse of stage II stage and III colorectal cancer after curative resection. +other hsa-mir-192 Influenza 23934176 MicroRNA-based strategy to mitigate the risk of gain-of-function influenza studies. +other hsa-mir-24 Multiple Myeloma 23934711 Contribution of microRNA 24-3p and Erk1/2 to interleukin-6 mediated plasma cell survival. +other hsa-mir-202 Gastric Neoplasms 23936094 "Decrease of miR-202-3p expression, a novel tumor suppressor, in gastric cancer." +other hsa-mir-140 Osteoarthritis 23942573 Molecular mechanisms of the cartilage-specific microRNA-140 in osteoarthritis. +other hsa-mir-29c Glioma 23943502 "MiR-29c inhibits glioma cell proliferation, migration, invasion and angiogenesis." +other hsa-mir-221 Asthma 23944957 Airway smooth muscle hyperproliferation is regulated by microRNA-221 in severe asthma. +other hsa-mir-100 Bladder Neoplasms 23945108 miRNA profiling identifies candidate mirnas for bladder cancer diagnosis and clinical outcome. +other hsa-mir-29c Multiple Sclerosis 23946286 MicroRNA-29c in urinary exosome/microvesicle as a biomarker of renal fibrosis. +other hsa-mir-186 "Carcinoma, Endometrioid Endometrial" 23946815 "The qRT-PCR analysis further identified a profile of four serum miRNAs (miR-222, miR-223, miR-186 and miR-204) as a fingerprint for EEC detection." +other hsa-mir-155 Immune System Disease [unspecific] 23949802 MicroRNA-155 drives TH17 immune response and tissue injury in experimental crescentic GN. +other hsa-mir-153 Colorectal Carcinoma 23950211 miR-153 supports colorectal cancer progression via pleiotropic effects that enhance invasion and chemotherapeutic resistance. +other hsa-mir-106a Colorectal Carcinoma 23950216 Fecal miR-106a is a good molecular marker to identify colorectal cancer patients from among those with negative iFOBT results. FmiRT combined with iFOBT may improve the sensitivity to detect colorectal cancer. +other hsa-mir-105 Neoplasms [unspecific] 23950948 miR-105 inhibits prostate tumour growth by suppressing CDK6 levels. +other hsa-mir-185 Prostate Neoplasms 23951060 MicroRNA-185 and 342 inhibit tumorigenicity and induce apoptosis through blockade of the SREBP metabolic pathway in prostate cancer cells. +other hsa-mir-342 Prostate Neoplasms 23951060 MicroRNA-185 and 342 inhibit tumorigenicity and induce apoptosis through blockade of the SREBP metabolic pathway in prostate cancer cells. +other hsa-mir-136 "Carcinoma, Lung, Non-Small-Cell" 23959478 "miR-146a-5p circuitry uncouples cell proliferation and migration, but not differentiation, in human mesenchymal stem cells." +other hsa-mir-214 "Carcinoma, Hepatocellular" 23962428 Downregulation of microRNA-214 and overexpression of FGFR-1 contribute to hepatocellular carcinoma metastasis. +other hsa-mir-137 Huntington Disease 23965969 "Regulation of huntingtin gene expression by miRNA-137, -214, -148a, and their respective isomiRs." +other hsa-mir-148a Huntington Disease 23965969 "Regulation of huntingtin gene expression by miRNA-137, -214, -148a, and their respective isomiRs." +other hsa-mir-214 Huntington Disease 23965969 "Regulation of huntingtin gene expression by miRNA-137, -214, -148a, and their respective isomiRs." +other hsa-mir-503 "Carcinoma, Hepatocellular" 23967867 "Our data highlight an important role for miR-503 in cell cycle regulation and in the molecular etiology of HCC, and implicate the potential application of miR-503 in prognosis prediction and miRNA-based HCC therapy." +other hsa-mir-133a Colorectal Carcinoma 23968734 "miR-133a may play a key role in CRC genesis and metastasis, which suggests its potential role in the molecular therapy of cancer." +other hsa-mir-222 Lung Neoplasms 23974492 Metformin inhibits lung cancer cells proliferation through repressing microRNA-222. +other hsa-mir-17 "Lymphoma, Large-Cell, Anaplastic" 23975180 The microRNA-17~92 cluster is involved in lymphomagenesis of STAT3(+) ALCL and that its inhibition might represent an alternative avenue to interfere with ALK signaling in anaplastic large cell lymphomas. +other hsa-mir-21 Renal Fibrosis 23978520 Microvesicle-mediated delivery of miR-21 among tubular epithelial cells might shed new light on the mechanism of progressive renal fibrosis. +other hsa-mir-26b "Lymphoma, Non-Hodgkin" 23978716 Hepatitis C-associated B-cell non-Hodgkin lymphomas: the emerging role of miRNA-26b. +other hsa-mir-433 Liver Neoplasms 23979134 MicroRNA-433 inhibits liver cancer cell migration by repressing the protein expression and function of cAMP response element-binding protein. +other hsa-mir-338 Neurodegenerative Diseases [unspecific] 23979835 "The EnSCs can differentiate to oligodendrocyte cells by the overexpression of miR-338, and these cells can be used as a unique source for cell therapy of neurodegenerative disease." +other hsa-mir-486 Lung Neoplasms 23980150 "Insulin growth factor signaling is regulated by microRNA-486, an underexpressed microRNA in lung cancer." +other hsa-mir-21 Kidney Neoplasms 23981302 NF¦ÊB-mediated cyclin D1 expression by microRNA-21 influences renal cancer cell proliferation. +other hsa-mir-23 Kaposi Sarcoma 23986579 Kaposi's sarcoma-associated herpesvirus encodes a mimic of cellular miR-23. +other hsa-mir-34a "Carcinoma, Colon" 23991105 MicroRNA-34a mediates the autocrine signaling of PAR2-activating proteinase and its role in colonic cancer cell proliferation. +other hsa-mir-16 Bladder Neoplasms 23991964 "miR-16 is an important regulator in bladder cancer, which will contribute to better understanding of important mis-regulated miRNAs." +other hsa-mir-222 Breast Neoplasms 23994196 MiR-222 and miR-29a contribute to the drug-resistance of breast cancer cells. +other hsa-mir-29a Breast Neoplasms 23994196 MiR-222 and miR-29a contribute to the drug-resistance of breast cancer cells. +other hsa-mir-216a Acute Pancreatitis 23995054 MiR-216a and miR-216b as markers for acute phased pancreatic injury. +other hsa-mir-216b Acute Pancreatitis 23995054 MiR-216a and miR-216b as markers for acute phased pancreatic injury. +other hsa-mir-126 Colorectal Adenocarcinoma 23996930 Pomegranate polyphenolics suppressed azoxymethane-induced colorectal aberrant crypt foci and inflammation: possible role of miR-126/VCAM-1 and miR-126/PI3K/AKT/mTOR. +other hsa-mir-21 "Carcinoma, Lung" 24004609 "Arsenite evokes IL-6 secretion, autocrine regulation of STAT3 signaling, and miR-21 expression, processes involved in the EMT and malignant transformation of human bronchial epithelial cells." +other hsa-mir-149 "Carcinoma, Lung, Non-Small-Cell" 24007627 A two miRNA signature (miR-149 and miR-375) was found predictive for response and was also associated to progression-free survival (p = 0.05). +other hsa-mir-1288 Colorectal Carcinoma 24009195 Regulation of microRNA-1288 in colorectal cancer: altered expression and its clinicopathological significance. +other hsa-mir-27a Ischemia-Reperfusion Injury 24009229 Regulation of vascular leak and recovery from ischemic injury by general and VE-cadherin-restricted miRNA antagonists of miR-27. +other hsa-mir-21 Lung Neoplasms 24012885 "Angiogenesis, mediated by miR-21, is involved arsenite-induced carcinogenesis." +other hsa-mir-146a Autoimmune Diseases [unspecific] 24014244 Our data unravel the crucial immunomodulatory role of miR-146a in pDCs and may add to our understanding of aberrant responses in autoimmune diseases. +other hsa-mir-7 Neoplasms [unspecific] 24014594 "we review the current knowledge about the ciRS-7/miR-7 axis in cancer-related pathways and discuss possible models explaining the relevance of coexpressing miR-7 along with a circRNA inhibitor. c-mir-221-3p,c-mir-223-3p" +other hsa-mir-200 Neoplasms [unspecific] 24018975 The role of miR-200 in blocking cancer angiogenesis in a cancer-dependent context defines its utility as a potential therapeutic agent. +other hsa-mir-34a Lung Neoplasms 24019906 the highly tumorigenic CD44(hi) cells are enriched for cells in the G2 phase of cell cycle. +other hsa-mir-126 Atherosclerosis 24022569 "Increased miR-146a and miR-126 and reduced miR-155 levels were observed in both treatment groups (all, P<0.001)" +other hsa-mir-204 Pancreatic Neoplasms 24025188 Triptolide mediated miR-204 increase causes pancreatic cancer cell death via loss of Mcl-1. +other hsa-mir-145 "Adenocarcinoma, Lung" 24026105 miR-145 may have a cell type-specific function and play important roles in the process of BM from lung adenocarcinoma. +other hsa-mir-222 Pancreatic Neoplasms 24026657 "This study provides the first evidence of a potential link between Ki67 and micro-RNA-222, which are both relevant to cell proliferation. Our data suggest the potential of micro-RNA-222 as a prognostic biomarker for the pancreatic cancer." +other hsa-mir-130b Colorectal Carcinoma 24027433 MicroRNA-130b promotes tumor development and is associated with poor prognosis in colorectal cancer. +other hsa-mir-30 Glomerulonephritis 24029422 Downregulation of microRNA-30 facilitates podocyte injury and is prevented by glucocorticoids. +other hsa-mir-126 "Lymphoma, T-Cell, Cutaneous" 24033365 "Taken together, our findings suggest that both malignant and non-malignant T cells express miR-155 in situ in CTCL. Moreover, they indicate heterogeneity in miR-155 expression among malignant T cells." +other hsa-mir-155 "Lymphoma, T-Cell, Cutaneous" 24033365 "Taken together, our findings suggest that both malignant and non-malignant T cells express miR-155 in situ in CTCL. Moreover, they indicate heterogeneity in miR-155 expression among malignant T cells." +other hsa-mir-146 Inflammation 24035832 Our findings reveal a novel regulatory module of two miRNA-mediated negative feedback loops that allows for the fine-tuning of the dynamics of key mediators in inflammation. +other hsa-mir-21 Inflammation 24035832 Our findings reveal a novel regulatory module of two miRNA-mediated negative feedback loops that allows for the fine-tuning of the dynamics of key mediators in inflammation. +other hsa-mir-221 Melanoma 24035906 we report the production of circular microRNA sponges against miR-21 or miR-221 in cell lines using the self-splicing permuted intron-exon sequences derived from T4 bacteriophage gene td. +other hsa-mir-146a Myasthenia Gravis 24036458 We conclude that abnormal expression/regulation of miR-146a may play an important role in the regulation of AchR specific B cells and contribute to the pathogenesis of MG. +other hsa-mir-144 Muscle Diseases [unspecific] 24036467 Our results reveal that there are changes in expression of known and novel miRNAs with skeletal muscle aging and that CR may reverse some of these changes to a younger phenotype. +other hsa-mir-15a Muscle Diseases [unspecific] 24036467 Our results reveal that there are changes in expression of known and novel miRNAs with skeletal muscle aging and that CR may reverse some of these changes to a younger phenotype. +other hsa-mir-181b Muscle Diseases [unspecific] 24036467 Our results reveal that there are changes in expression of known and novel miRNAs with skeletal muscle aging and that CR may reverse some of these changes to a younger phenotype. +other hsa-mir-18a Muscle Diseases [unspecific] 24036467 Our results reveal that there are changes in expression of known and novel miRNAs with skeletal muscle aging and that CR may reverse some of these changes to a younger phenotype. +other hsa-mir-451 Muscle Diseases [unspecific] 24036467 Our results reveal that there are changes in expression of known and novel miRNAs with skeletal muscle aging and that CR may reverse some of these changes to a younger phenotype. +other hsa-mir-200 Breast Neoplasms 24037528 MiR-200 can repress breast cancer metastasis through ZEB1-independent but moesin-dependent pathways. +other hsa-mir-103 Polycystic Ovarian Syndrome 24037889 The present results suggest that miRNAs that play an important role in metabolic and immune system processes are influenced by obesity and circulating androgen concentrations. +other hsa-mir-155 Polycystic Ovarian Syndrome 24037889 The present results suggest that miRNAs that play an important role in metabolic and immune system processes are influenced by obesity and circulating androgen concentrations. +other hsa-mir-21 Polycystic Ovarian Syndrome 24037889 The present results suggest that miRNAs that play an important role in metabolic and immune system processes are influenced by obesity and circulating androgen concentrations. +other hsa-mir-27b Polycystic Ovarian Syndrome 24037889 The present results suggest that miRNAs that play an important role in metabolic and immune system processes are influenced by obesity and circulating androgen concentrations. +other hsa-mir-495 "Carcinoma, Lung, Non-Small-Cell" 24038379 miR-495 enhances the sensitivity of non-small cell lung cancer cells to platinum by modulation of copper-transporting P-type adenosine triphosphatase A (ATP7A). +other hsa-mir-151 Myocardial Infarction 24039836 Downregulation of miR-151-5p contributes to increased susceptibility to arrhythmogenesis during myocardial infarction with estrogen deprivation. +other hsa-mir-21 "Squamous Cell Carcinoma, Esophageal" 24039846 "MiR-21 expression is mostly confined to the SCC stroma and its release from fibroblasts influences the migration and invasion capacity of SCC cells. Moreover, miR-21 may be an important factor in activating fibroblasts to CAFs. These findings provide new insights into the role of CAFs and the extracellular matrix in tumor microenvironment formation and in tumor cell maintenance, and suggest miR-21 may contribute to cellular crosstalk in the tumor microenvironment." +other hsa-mir-31 "Squamous Cell Carcinoma, Esophageal" 24039884 Dissection of miRNA-miRNA interaction in esophageal squamous cell carcinoma. +other hsa-mir-338 "Squamous Cell Carcinoma, Esophageal" 24039884 Dissection of miRNA-miRNA interaction in esophageal squamous cell carcinoma. +other hsa-let-7a Pancreatic Neoplasms 24040120 DCLK1 regulates pluripotency and angiogenic factors via microRNA-dependent mechanisms in pancreatic cancer. +other hsa-mir-145 Pancreatic Neoplasms 24040120 DCLK1 regulates pluripotency and angiogenic factors via microRNA-dependent mechanisms in pancreatic cancer. +other hsa-mir-200 Pancreatic Neoplasms 24040120 DCLK1 regulates pluripotency and angiogenic factors via microRNA-dependent mechanisms in pancreatic cancer. +other hsa-mir-21 Neoplasms [unspecific] 24041029 Here we summarize current knowledge on miR-21 functions in human cancers and discuss how this finding provides insight into the role of miR-21 as an oncogenic regulator in stem/progenitor cell populations of human cancers. +other hsa-mir-125a Lung Neoplasms 24044511 MicroRNA hsa-miR-125a-3p activates p53 and induces apoptosis in lung cancer cells. +other hsa-mir-122 "Leukemia, Lymphocytic, Chronic, B-Cell" 24047131 Four-way junction formation promoting ultrasensitive electrochemical detection of microRNA. +other hsa-mir-100 Vulvar Squamous Cell Carcinoma 24048714 "In conclusion, our study demonstrates that microRNAs may be clinically important in vulvar carcinomas and our findings may help for further studies on functional implications of miRNA deregulation in this type of cancer." +other hsa-mir-133a Vulvar Squamous Cell Carcinoma 24048714 "In conclusion, our study demonstrates that microRNAs may be clinically important in vulvar carcinomas and our findings may help for further studies on functional implications of miRNA deregulation in this type of cancer." +other hsa-mir-19b-1 Vulvar Squamous Cell Carcinoma 24048714 "In conclusion, our study demonstrates that microRNAs may be clinically important in vulvar carcinomas and our findings may help for further studies on functional implications of miRNA deregulation in this type of cancer." +other hsa-mir-223 Vulvar Squamous Cell Carcinoma 24048714 "In conclusion, our study demonstrates that microRNAs may be clinically important in vulvar carcinomas and our findings may help for further studies on functional implications of miRNA deregulation in this type of cancer." +other hsa-mir-519b Vulvar Squamous Cell Carcinoma 24048714 "In conclusion, our study demonstrates that microRNAs may be clinically important in vulvar carcinomas and our findings may help for further studies on functional implications of miRNA deregulation in this type of cancer." +other hsa-mir-29 Liver Injury 24052410 "Our results indicate that miR-29a decreases cholestatic liver injury and fibrosis after BDL, at least partially, by modulating the extrinsic rather than intrinsic pathway of apoptosis." +other hsa-mir-1321 Pediatric Glioma 24053158 In the present study we identified the changed expression pattern of microRNAs in pediatric gliamas. Our study also provides a better understanding of pediatric brain tumor biology and may assist in the development of less toxic therapies and in the search for better markers for disease stratification. +other hsa-mir-513b Pediatric Glioma 24053158 In the present study we identified the changed expression pattern of microRNAs in pediatric gliamas. Our study also provides a better understanding of pediatric brain tumor biology and may assist in the development of less toxic therapies and in the search for better markers for disease stratification. +other hsa-mir-769 Pediatric Glioma 24053158 In the present study we identified the changed expression pattern of microRNAs in pediatric gliamas. Our study also provides a better understanding of pediatric brain tumor biology and may assist in the development of less toxic therapies and in the search for better markers for disease stratification. +other hsa-mir-29 Crohn Disease 24054330 The intracellular sensor NOD2 induces microRNA-29 expression in human dendritic cells to limit IL-23 release. +other hsa-mir-129 Gastric Neoplasms 24055727 Growth inhibitory effects of three miR-129 family members on gastric cancer. +other hsa-mir-1246 "Carcinoma, Hepatocellular" 24060847 The manipulation of one or more of these miRNAs could be an important approach for the improved management of paclitaxel therapy. +other hsa-mir-1260b "Carcinoma, Hepatocellular" 24060847 The manipulation of one or more of these miRNAs could be an important approach for the improved management of paclitaxel therapy. +other hsa-mir-1274a "Carcinoma, Hepatocellular" 24060847 The manipulation of one or more of these miRNAs could be an important approach for the improved management of paclitaxel therapy. +other hsa-mir-1290 "Carcinoma, Hepatocellular" 24060847 The manipulation of one or more of these miRNAs could be an important approach for the improved management of paclitaxel therapy. +other hsa-mir-183 "Carcinoma, Hepatocellular" 24060847 The manipulation of one or more of these miRNAs could be an important approach for the improved management of paclitaxel therapy. +other hsa-mir-21 "Carcinoma, Hepatocellular" 24060847 The manipulation of one or more of these miRNAs could be an important approach for the improved management of paclitaxel therapy. +other hsa-mir-508 "Carcinoma, Hepatocellular" 24060847 The manipulation of one or more of these miRNAs could be an important approach for the improved management of paclitaxel therapy. +other hsa-mir-877 "Carcinoma, Hepatocellular" 24060847 The manipulation of one or more of these miRNAs could be an important approach for the improved management of paclitaxel therapy. +other hsa-mir-126 Allergy 24063594 "Expression kinetics of miRNA involved in dermal toluene 2,4-diisocyanate sensitization." +other hsa-mir-155 Allergy 24063594 "Expression kinetics of miRNA involved in dermal toluene 2,4-diisocyanate sensitization." +other hsa-mir-21 Allergy 24063594 "Expression kinetics of miRNA involved in dermal toluene 2,4-diisocyanate sensitization." +other hsa-mir-210 Allergy 24063594 "Expression kinetics of miRNA involved in dermal toluene 2,4-diisocyanate sensitization." +other hsa-mir-22 Allergy 24063594 "Expression kinetics of miRNA involved in dermal toluene 2,4-diisocyanate sensitization." +other hsa-mir-27b Allergy 24063594 "Expression kinetics of miRNA involved in dermal toluene 2,4-diisocyanate sensitization." +other hsa-mir-31 Allergy 24063594 "Expression kinetics of miRNA involved in dermal toluene 2,4-diisocyanate sensitization." +other hsa-mir-1290 Celiac Disease 24063611 microRNA profiles in coeliac patients distinguish different clinical phenotypes and are modulated by gliadin peptides in primary duodenal fibroblasts. +other hsa-mir-192 Celiac Disease 24063611 microRNA profiles in coeliac patients distinguish different clinical phenotypes and are modulated by gliadin peptides in primary duodenal fibroblasts. +other hsa-mir-194 Celiac Disease 24063611 microRNA profiles in coeliac patients distinguish different clinical phenotypes and are modulated by gliadin peptides in primary duodenal fibroblasts. +other hsa-mir-31 Celiac Disease 24063611 microRNA profiles in coeliac patients distinguish different clinical phenotypes and are modulated by gliadin peptides in primary duodenal fibroblasts. +other hsa-mir-551a Celiac Disease 24063611 microRNA profiles in coeliac patients distinguish different clinical phenotypes and are modulated by gliadin peptides in primary duodenal fibroblasts. +other hsa-mir-551b Celiac Disease 24063611 microRNA profiles in coeliac patients distinguish different clinical phenotypes and are modulated by gliadin peptides in primary duodenal fibroblasts. +other hsa-mir-638 Celiac Disease 24063611 microRNA profiles in coeliac patients distinguish different clinical phenotypes and are modulated by gliadin peptides in primary duodenal fibroblasts. +other hsa-mir-144 "Carcinoma, Lung, Non-Small-Cell" 24066116 "Our results for the first time showed mir-144-ZFX pathway is involved in the development of NSCLC, which sheds a light for further investigations on underlying mechanisms toward better understanding and management of NSCLC." +other hsa-mir-199 Liver Neoplasms 24069256 "We exploited this miR-199 differential expression to develop a conditionally replication-competent oncolytic adenovirus, Ad-199T, and achieve tumor-specific viral expression and replication. " +other hsa-mir-23b Pancreatic Adenocarcinoma 24070722 "Mir-23B might be used as a biomarker for PDAC resistance to radiotherapy or chemotherapy. Or, patients with low tumor levels of Mir-23B might benefit from pharmacologic inhibitors of autophagy." +other hsa-let-7 Squamous Cell Carcinoma 24070899 "Phospho-¦¤Np63¦Á regulates AQP3, ALOX12B, CASP14 and CLDN1 expression through transcription and microRNA modulation." +other hsa-mir-143 "Carcinoma, Endometrial" 24071015 Down-regulation of miR-145 and miR-143 might be associated with DNA methyltransferase 3B overexpression and worse prognosis in endometrioid carcinomas. +other hsa-mir-145 "Carcinoma, Endometrial" 24071015 Down-regulation of miR-145 and miR-143 might be associated with DNA methyltransferase 3B overexpression and worse prognosis in endometrioid carcinomas. +other hsa-mir-151 Hantavirus Infection 24074584 Our data suggest that differential immune responses following hantavirus infection may be regulated in part by cellular miRNA through dysregulation of genes critical to the inflammatory process. +other hsa-mir-1973 Hantavirus Infection 24074584 Our data suggest that differential immune responses following hantavirus infection may be regulated in part by cellular miRNA through dysregulation of genes critical to the inflammatory process. +other hsa-mir-182 "Carcinoma, Ovarian, Serous" 24077281 "We describe several mechanisms responsible for FOXO3a inactivity, including chromosomal deletion (chromosome 6q21), upregulation of miRNA-182 and destabilization by activated PI3K and MEK." +other hsa-mir-182 Choriocarcinoma 24078156 " We have also shown the alterations in expressing profile of miR-31, miR-133a, miR-141, miR-145, miR-149, miR-182 and miR-194, which were observed even in the early stage of disease, and identified a set of genes, which take place in correct assigning of patients in dependence of CRC stage." +other hsa-mir-194 Choriocarcinoma 24078156 " We have also shown the alterations in expressing profile of miR-31, miR-133a, miR-141, miR-145, miR-149, miR-182 and miR-194, which were observed even in the early stage of disease, and identified a set of genes, which take place in correct assigning of patients in dependence of CRC stage." +other hsa-mir-31 Choriocarcinoma 24078156 " We have also shown the alterations in expressing profile of miR-31, miR-133a, miR-141, miR-145, miR-149, miR-182 and miR-194, which were observed even in the early stage of disease, and identified a set of genes, which take place in correct assigning of patients in dependence of CRC stage." +other hsa-mir-34a Preeclampsia 24081307 "The results support a role for miR-34a in the pathophysiology of preeclampsia, through deregulation of the pri-miRNA expression and its altered maturation." +other hsa-mir-29 Atrial Fibrillation 24085039 These new insights into mir29¡¯s functions further support a role for the adaptive immune system in the immunopathogenesis of AF. We recommend that AF investigators team up with immunologists in search for pathogenic T cells. +other hsa-mir-33 Atherosclerosis 24086374 "These results reveal a novel mechanism for the BA-mediated ABCA1 expression, which may provide new insights for developing strategies for modulating vascular inflammation and atherosclerosis." +other hsa-mir-200a Breast Neoplasms 24086551 "MiR-200b eRNA may be involved in the regulation of miR-200b~200a~429 gene expression and silencing. Taken together, these findings reveal the presence of a novel enhancer, which contributes to miR-200b~200a~429 transcriptional regulation in epithelial cells." +other hsa-mir-200b Breast Neoplasms 24086551 "MiR-200b eRNA may be involved in the regulation of miR-200b~200a~429 gene expression and silencing. Taken together, these findings reveal the presence of a novel enhancer, which contributes to miR-200b~200a~429 transcriptional regulation in epithelial cells." +other hsa-mir-429 Breast Neoplasms 24086551 "MiR-200b eRNA may be involved in the regulation of miR-200b~200a~429 gene expression and silencing. Taken together, these findings reveal the presence of a novel enhancer, which contributes to miR-200b~200a~429 transcriptional regulation in epithelial cells." +other hsa-mir-150 "Leukemia, Acute" 24086639 "miR-150 promotes myeloid differentiation, a previously uncharacterized role for this miRNA, and that absent or low miR-150 expression contributes to blocked myeloid differentiation in acute leukemia cells." +other hsa-mir-1227 Prostate Neoplasms 24091630 "Large oncosomes enhanced migration of cancer-associated fibroblasts (CAFs), an effect that was increased by miR-1227, a miRNA abundant in large oncosomes produced by RWPE-2 cells. " +other hsa-mir-34a Malignant Neoplasms [unspecific] 24091633 miR-34a can potentially be exploited for DNA damage-effecting therapies of malignancies. +other hsa-mir-29b Multiple Myeloma 24091729 miR-29b is endowed with epigenetic activity and mediates previously unknown functions of bortezomib in MM cells. +other hsa-mir-210 Neoplasms [unspecific] 24098326 hypoxia related mir-210 and apoptosis-related mir-296-5p in the cancer mechanisms +other hsa-mir-296 Neoplasms [unspecific] 24098326 hypoxia related mir-210 and apoptosis-related mir-296-5p in the cancer mechanisms +other hsa-mir-125b Breast Neoplasms 24098452 "The expression of ENPEP and CK2-¦Á was inversely correlated with miR-125b expression in breast tumors,indicating the relevance of these potential oncogenic proteins in breast cancer patients. " +other hsa-mir-210 Leishmaniasis 24098824 MicroRNA expression profile in human macrophages in response to Leishmania major infection. +other hsa-mir-92b "Carcinoma, Lung, Non-Small-Cell" 24099768 "The miR-92b play an oncogene roles by regulatescell growth, cisplatin chemosensitivity phenotype, and could serve as a novel potential maker for NSCLC therapy." +other hsa-mir-33a Liver Fibrosis 24100264 "the expression of miR-33a increased with the progression of liver fibrosis. These results suggested that anti-miR-33a inhibit activation and extracellular matrix production, at least in part, via the activation of PI3K/Akt pathway and PPAR-¦Á and anti sense of miR-33a may be a novel potential therapeutic approach for treating hepatic fibrosis in the future." +other hsa-mir-29a Human Immunodeficiency Virus Infection 24103357 "The lack of significant negative correlation of miR-29a and TTP expression levels suggests that while miR-29a may contribute to TTP regulation, additional factors are involved. Reduced TTP expression during acute infection is consistent with increased cytokine production during this phase of infection, but the increases in TTP observed during late-stage infection were insufficient to halt runaway cytokine levels." +other hsa-let-7a Breast Neoplasms 24104964 Our data demonstrate that BRCAX hereditary breast tumours can be sub-classified into four previously unknown homogenous groups characterised by specific miRNA expression signatures and histopathological features. +other hsa-let-7b Breast Neoplasms 24104964 Our data demonstrate that BRCAX hereditary breast tumours can be sub-classified into four previously unknown homogenous groups characterised by specific miRNA expression signatures and histopathological features. +other hsa-let-7c Breast Neoplasms 24104964 Our data demonstrate that BRCAX hereditary breast tumours can be sub-classified into four previously unknown homogenous groups characterised by specific miRNA expression signatures and histopathological features. +other hsa-let-7d Breast Neoplasms 24104964 Our data demonstrate that BRCAX hereditary breast tumours can be sub-classified into four previously unknown homogenous groups characterised by specific miRNA expression signatures and histopathological features. +other hsa-let-7f Breast Neoplasms 24104964 Our data demonstrate that BRCAX hereditary breast tumours can be sub-classified into four previously unknown homogenous groups characterised by specific miRNA expression signatures and histopathological features. +other hsa-let-7g Breast Neoplasms 24104964 Our data demonstrate that BRCAX hereditary breast tumours can be sub-classified into four previously unknown homogenous groups characterised by specific miRNA expression signatures and histopathological features. +other hsa-let-7i Breast Neoplasms 24104964 Our data demonstrate that BRCAX hereditary breast tumours can be sub-classified into four previously unknown homogenous groups characterised by specific miRNA expression signatures and histopathological features. +other hsa-mir-141 Hereditary Breast Carcinoma 24104964 Our data demonstrate that BRCAX hereditary breast tumours can be sub-classified into four previously unknown homogenous groups characterised by specific miRNA expression signatures and histopathological features. +other hsa-mir-15a Hereditary Breast Carcinoma 24104964 Our data demonstrate that BRCAX hereditary breast tumours can be sub-classified into four previously unknown homogenous groups characterised by specific miRNA expression signatures and histopathological features. +other hsa-mir-15b Hereditary Breast Carcinoma 24104964 Our data demonstrate that BRCAX hereditary breast tumours can be sub-classified into four previously unknown homogenous groups characterised by specific miRNA expression signatures and histopathological features. +other hsa-mir-16 Hereditary Breast Carcinoma 24104964 Our data demonstrate that BRCAX hereditary breast tumours can be sub-classified into four previously unknown homogenous groups characterised by specific miRNA expression signatures and histopathological features. +other hsa-mir-195 Hereditary Breast Carcinoma 24104964 Our data demonstrate that BRCAX hereditary breast tumours can be sub-classified into four previously unknown homogenous groups characterised by specific miRNA expression signatures and histopathological features. +other hsa-mir-200a Hereditary Breast Carcinoma 24104964 Our data demonstrate that BRCAX hereditary breast tumours can be sub-classified into four previously unknown homogenous groups characterised by specific miRNA expression signatures and histopathological features. +other hsa-mir-200b Hereditary Breast Carcinoma 24104964 Our data demonstrate that BRCAX hereditary breast tumours can be sub-classified into four previously unknown homogenous groups characterised by specific miRNA expression signatures and histopathological features. +other hsa-mir-200c Hereditary Breast Carcinoma 24104964 Our data demonstrate that BRCAX hereditary breast tumours can be sub-classified into four previously unknown homogenous groups characterised by specific miRNA expression signatures and histopathological features. +other hsa-mir-29a Hereditary Breast Carcinoma 24104964 Our data demonstrate that BRCAX hereditary breast tumours can be sub-classified into four previously unknown homogenous groups characterised by specific miRNA expression signatures and histopathological features. +other hsa-mir-29b Hereditary Breast Carcinoma 24104964 Our data demonstrate that BRCAX hereditary breast tumours can be sub-classified into four previously unknown homogenous groups characterised by specific miRNA expression signatures and histopathological features. +other hsa-mir-29c Hereditary Breast Carcinoma 24104964 Our data demonstrate that BRCAX hereditary breast tumours can be sub-classified into four previously unknown homogenous groups characterised by specific miRNA expression signatures and histopathological features. +other hsa-mir-30a Hereditary Breast Carcinoma 24104964 Our data demonstrate that BRCAX hereditary breast tumours can be sub-classified into four previously unknown homogenous groups characterised by specific miRNA expression signatures and histopathological features. +other hsa-mir-30b Hereditary Breast Carcinoma 24104964 Our data demonstrate that BRCAX hereditary breast tumours can be sub-classified into four previously unknown homogenous groups characterised by specific miRNA expression signatures and histopathological features. +other hsa-mir-30c Hereditary Breast Carcinoma 24104964 Our data demonstrate that BRCAX hereditary breast tumours can be sub-classified into four previously unknown homogenous groups characterised by specific miRNA expression signatures and histopathological features. +other hsa-mir-30d Hereditary Breast Carcinoma 24104964 Our data demonstrate that BRCAX hereditary breast tumours can be sub-classified into four previously unknown homogenous groups characterised by specific miRNA expression signatures and histopathological features. +other hsa-mir-30e Hereditary Breast Carcinoma 24104964 Our data demonstrate that BRCAX hereditary breast tumours can be sub-classified into four previously unknown homogenous groups characterised by specific miRNA expression signatures and histopathological features. +other hsa-mir-143 Sepsis 24105952 "The toll-like receptor 3 ligand, poly(I:C), improves immunosuppressive function and therapeutic effect of mesenchymal stem cells on sepsis via inhibiting MiR-143." +other hsa-mir-122 Hepatitis C Virus Infection 24106328 "By use of duplex and precursor miR-122 mimetic molecules that carried mutations in the passenger strand of miR-122, the effects on viral and reporter gene expression could be pinpointed to the action of precursor miR-122 molecules." +other hsa-mir-29a "Scleroderma, Systemic" 24107002 Hair miR-29a levels are decreased in patients with scleroderma. +other hsa-mir-196a-2 Colorectal Carcinoma 24107909 Meta-analysis of the association between a polymorphism in microRNA-196a2 and susceptibility to colorectal cancer. +other hsa-mir-9 Viral Infectious Disease 24109243 Human coronavirus OC43 nucleocapsid protein binds microRNA 9 and potentiates NF-¦ÊB activation. +other hsa-mir-21 "Carcinoma, Hepatocellular" 24112539 MicroRNA-21 promotes hepatocellular carcinoma HepG2 cell proliferation through repression of mitogen-activated protein kinase-kinase 3. +other hsa-mir-122 Liver Injury 24118944 M65 and microRNA-122 are potential biomarkers of DILI superior to ALT with respect to sensitivity and specificity. +other hsa-mir-378 "Squamous Cell Carcinoma, Oral" 24120010 MicroRNA in oral squamous cell carcinoma +other hsa-mir-122 Liver Diseases [unspecific] 24121065 miR-122 is a liver-specific microRNA associated with many liver diseases +other hsa-mir-155 Neoplasms [unspecific] 24122356 microRNA-155 has functions in the control of various cancers +other hsa-mir-101 Liver Neoplasms 24123132 Another myc in the wall: microRNA-101 controls important functions in liver cancer formation. +other hsa-mir-483 "Carcinoma, Hepatocellular" 24127413 Exploration of genome-wide circulating microRNA in hepatocellular carcinoma:MiR-483-5p as a potential biomarker. +other hsa-mir-122 "Carcinoma, Hepatocellular" 24130799 The continued expression of miR-122 in HCV-associated HCC may signify an important role for HCV replication late in the progression to malignancy. +other hsa-mir-106b Prostate Neoplasms 24135225 Down-regulation of RE-1 silencing transcription factor (REST) in advanced prostate cancer by hypoxia-induced miR-106b~25. +other hsa-mir-141 "Carcinoma, Hepatocellular" 24135722 Simultaneous silencing of miR-200c and miR-141 was likely to be responsible for the development of HCC-BDTT via ZEB1-directed EMT activation and Sec24a-mediated secretome. +other hsa-mir-200 "Carcinoma, Hepatocellular" 24135722 Simultaneous silencing of miR-200c and miR-141 was likely to be responsible for the development of HCC-BDTT via ZEB1-directed EMT activation and Sec23a-mediated secretome. +other hsa-mir-200c "Carcinoma, Hepatocellular" 24135722 Simultaneous silencing of miR-200c and miR-141 was likely to be responsible for the development of HCC-BDTT via ZEB1-directed EMT activation and Sec25a-mediated secretome. +other hsa-mir-155 "Leukemia, Lymphocytic, Chronic, B-Cell" 24136167 MicroRNA-155 controls RB phosphorylation in normal and malignant B lymphocytes via the noncanonical TGF-¦Â1/SMAD5 signaling module. +other hsa-mir-320 "Adenocarcinoma, Gastric" 24136787 Strain-specific suppression of microRNA-320 by carcinogenic Helicobacter pylori promotes expression of the antiapoptotic protein Mcl-1. +other hsa-mir-122 Hepatitis C Virus Infection 24141094 "The P body protein LSm1 contributes to stimulation of hepatitis C virus translation, but not replication, by microRNA-122." +other hsa-let-7 Perlman Syndrome 24141620 Mammalian DIS3L2 exoribonuclease targets the uridylated precursors of let-7 miRNAs. +other hsa-mir-196a-1 "Lymphoma, Hodgkin" 24145479 MicroRNA and gene networks in human Hodgkin's lymphoma. +other hsa-mir-9 "Lymphoma, Hodgkin" 24145479 MicroRNA and gene networks in human Hodgkin's lymphoma. +other hsa-mir-203 "Carcinoma, Esophageal" 24154605 Protamine sulfate-nanodiamond hybrid nanoparticles as a vector for MiR-203 restoration in esophageal carcinoma cells. +other hsa-mir-127 Breast Neoplasms 24155205 MicroRNA-127 is downregulated by Tudor-SN protein and contributes to metastasis and proliferation in breast cancer cell line MDA-MB-231. +other hsa-mir-133a Lung Neoplasms 24157646 A high-throughput screen identifies miRNA inhibitors regulating lung cancer cell survival and response to paclitaxel. +other hsa-mir-133b Lung Neoplasms 24157646 A high-throughput screen identifies miRNA inhibitors regulating lung cancer cell survival and response to paclitaxel. +other hsa-mir-346 Lung Neoplasms 24157646 A high-throughput screen identifies miRNA inhibitors regulating lung cancer cell survival and response to paclitaxel. +other hsa-mir-361 Lung Neoplasms 24157646 A high-throughput screen identifies miRNA inhibitors regulating lung cancer cell survival and response to paclitaxel. +other hsa-mir-361 "Carcinoma, Cervical" 24158756 MicroRNA-361-5p facilitates cervical cancer progression through mediation of epithelial-to-mesenchymal transition. +other hsa-mir-139 Breast Neoplasms 24158791 miR-139-5p is a regulator of metastatic pathways in breast cancer. +other hsa-mir-214 Renal Fibrosis 24158985 MicroRNA-214 antagonism protects against renal fibrosis. +other hsa-mir-25 Heart Failure 24161931 Nfat and miR-25 cooperate to reactivate the transcription factor Hand2 in heart failure. +other hsa-mir-106a Breast Neoplasms 24164962 Downregulation of miR-106b induced breast cancer cell invasion and motility in association with overexpression of matrix metalloproteinase 2. +other hsa-mir-125b Breast Neoplasms 24165569 Taken together our results show a mechanism for EPO/EPOR and ERBB2 co-regulation in breast cancer and confirm the importance of miR-125b in controlling clinically-relevant cancer features. +other hsa-mir-122 Obesity 24165878 Resveratrol and EGCG bind directly and distinctively to miR-33a and miR-122 and modulate divergently their levels in hepatic cells. +other hsa-mir-33 Obesity 24165878 Resveratrol and EGCG bind directly and distinctively to miR-33a and miR-122 and modulate divergently their levels in hepatic cells. +other hsa-mir-375 Neoplasms [unspecific] 24166096 The emerging role of miR-375 in cancer. +other hsa-mir-154 Prostate Neoplasms 24166498 "MicroRNAs, miR-154, miR-299-5p, miR-376a, miR-376c, miR-377, miR-381, miR-487b,miR-485-3p, miR-495 and miR-654-3p, mapped to the 14q32.31 locus, regulate proliferation, apoptosis, migration and invasion in metastatic prostate cancer cells." +other hsa-mir-299 Prostate Neoplasms 24166498 "MicroRNAs, miR-154, miR-299-5p, miR-376a, miR-376c, miR-377, miR-381, miR-487b,miR-485-3p, miR-495 and miR-654-3p, mapped to the 14q32.31 locus, regulate proliferation, apoptosis, migration and invasion in metastatic prostate cancer cells." +other hsa-mir-376a Prostate Neoplasms 24166498 "MicroRNAs, miR-154, miR-299-5p, miR-376a, miR-376c, miR-377, miR-381, miR-487b,miR-485-3p, miR-495 and miR-654-3p, mapped to the 14q32.31 locus, regulate proliferation, apoptosis, migration and invasion in metastatic prostate cancer cells." +other hsa-mir-376c Prostate Neoplasms 24166498 "MicroRNAs, miR-154, miR-299-5p, miR-376a, miR-376c, miR-377, miR-381, miR-487b,miR-485-3p, miR-495 and miR-654-3p, mapped to the 14q32.31 locus, regulate proliferation, apoptosis, migration and invasion in metastatic prostate cancer cells." +other hsa-mir-377 Prostate Neoplasms 24166498 "MicroRNAs, miR-154, miR-299-5p, miR-376a, miR-376c, miR-377, miR-381, miR-487b,miR-485-3p, miR-495 and miR-654-3p, mapped to the 14q32.31 locus, regulate proliferation, apoptosis, migration and invasion in metastatic prostate cancer cells." +other hsa-mir-381 Prostate Neoplasms 24166498 "MicroRNAs, miR-154, miR-299-5p, miR-376a, miR-376c, miR-377, miR-381, miR-487b,miR-485-3p, miR-495 and miR-654-3p, mapped to the 14q32.31 locus, regulate proliferation, apoptosis, migration and invasion in metastatic prostate cancer cells." +other hsa-mir-485 Prostate Neoplasms 24166498 "MicroRNAs, miR-154, miR-299-5p, miR-376a, miR-376c, miR-377, miR-381, miR-487b,miR-485-3p, miR-495 and miR-654-3p, mapped to the 14q32.31 locus, regulate proliferation, apoptosis, migration and invasion in metastatic prostate cancer cells." +other hsa-mir-487b Prostate Neoplasms 24166498 "MicroRNAs, miR-154, miR-299-5p, miR-376a, miR-376c, miR-377, miR-381, miR-487b,miR-485-3p, miR-495 and miR-654-3p, mapped to the 14q32.31 locus, regulate proliferation, apoptosis, migration and invasion in metastatic prostate cancer cells." +other hsa-mir-654 Prostate Neoplasms 24166498 "MicroRNAs, miR-154, miR-299-5p, miR-376a, miR-376c, miR-377, miR-381, miR-487b,miR-485-3p, miR-495 and miR-654-3p, mapped to the 14q32.31 locus, regulate proliferation, apoptosis, migration and invasion in metastatic prostate cancer cells." +other hsa-mir-200b Cholangiocarcinoma 24169343 Our study shows that miR-200b/c has a critical role in the regulation of the tumorigenic and metastatic capacity of cholangiocarcinoma and reveals the probable underlying mechanisms. +other hsa-mir-200c Cholangiocarcinoma 24169343 Our study shows that miR-200b/c has a critical role in the regulation of the tumorigenic and metastatic capacity of cholangiocarcinoma and reveals the probable underlying mechanisms. +other hsa-mir-27a Kidney Neoplasms 24173369 Combination of quercetin and hyperoside has anticancer effects on renal cancer cells through inhibition of oncogenic microRNA-27a. +other hsa-mir-183 Endometriosis 24173391 Downregulation of miR-183 inhibits apoptosis and enhances the invasive potential of endometrial stromal cells in endometriosis. +other hsa-mir-10b "Carcinoma, Nasopharyngeal" 24175854 miR-10b promotes migration and invasion in nasopharyngeal carcinoma cells. +other hsa-mir-125b Chondrosarcoma 24178909 "mTORC 1 inhibitor PRP-1 caused significant upregulation of tumor suppressors, such as miR20a, miR125b, and miR192; and downregulation of onco miRNAs, miR509-3p, miR589, miR490-3p, miR 550 in human chondrosarcoma JJ012 cell line" +other hsa-mir-192 Chondrosarcoma 24178909 "mTORC 1 inhibitor PRP-1 caused significant upregulation of tumor suppressors, such as miR20a, miR125b, and miR192; and downregulation of onco miRNAs, miR509-3p, miR589, miR490-3p, miR 550 in human chondrosarcoma JJ012 cell line" +other hsa-mir-20a Chondrosarcoma 24178909 "mTORC 1 inhibitor PRP-1 caused significant upregulation of tumor suppressors, such as miR20a, miR125b, and miR192; and downregulation of onco miRNAs, miR509-3p, miR589, miR490-3p, miR 550 in human chondrosarcoma JJ012 cell line" +other hsa-mir-490 Chondrosarcoma 24178909 "mTORC 1 inhibitor PRP-1 caused significant upregulation of tumor suppressors, such as miR20a, miR125b, and miR192; and downregulation of onco miRNAs, miR509-3p, miR589, miR490-3p, miR 550 in human chondrosarcoma JJ012 cell line" +other hsa-mir-509 Chondrosarcoma 24178909 "mTORC 1 inhibitor PRP-1 caused significant upregulation of tumor suppressors, such as miR20a, miR125b, and miR192; and downregulation of onco miRNAs, miR509-3p, miR589, miR490-3p, miR 550 in human chondrosarcoma JJ012 cell line" +other hsa-mir-550 Chondrosarcoma 24178909 "mTORC 1 inhibitor PRP-1 caused significant upregulation of tumor suppressors, such as miR20a, miR125b, and miR192; and downregulation of onco miRNAs, miR509-3p, miR589, miR490-3p, miR 550 in human chondrosarcoma JJ012 cell line" +other hsa-mir-589 Chondrosarcoma 24178909 "mTORC 1 inhibitor PRP-1 caused significant upregulation of tumor suppressors, such as miR20a, miR125b, and miR192; and downregulation of onco miRNAs, miR509-3p, miR589, miR490-3p, miR 550 in human chondrosarcoma JJ012 cell line" +other hsa-mir-184 "Carcinoma, Hepatocellular" 24183204 miR-184 functions as an oncogenic regulator in hepatocellular carcinoma (HCC). +other hsa-mir-29b Multiple Myeloma 24189534 miR-29b: a new demethylator in multiple myeloma. +other hsa-mir-206 "Carcinoma, Lung" 24189536 "miR-206 is capable of suppressing a known oncogene, it might be a true tumor suppressor gene and, as such, be deleted, modified, or directly repressed in human tumors." +other hsa-mir-4423 Lung Neoplasms 24191054 A primate-specific microRNA enters the lung cancer landscape. +other hsa-mir-19a Psoriasis 24192448 Our results indicated hair root miR-19a levels are effective as a disease marker. +other hsa-mir-200 Prostate Neoplasms 24193225 Regulation of epithelial plasticity by miR-424 and miR-200 in a new prostate cancer metastasis model. +other hsa-mir-424 Prostate Neoplasms 24193225 Regulation of epithelial plasticity by miR-424 and miR-200 in a new prostate cancer metastasis model. +other hsa-mir-524 Glioma 24194606 Comprehensive analysis of the functional microRNA-mRNA regulatory network identifies miRNA signatures associated with glioma malignant progression. +other hsa-mir-628 Glioma 24194606 Comprehensive analysis of the functional microRNA-mRNA regulatory network identifies miRNA signatures associated with glioma malignant progression. +other hsa-mir-101 Alzheimer Disease 24194717 "we found microRNAs, including miR-20a, miR-17, miR-34a, miR-155, miR-18a, miR-22, miR-26a, miR-101, miR-106b, and miR-125b, that might regulate the expression of nodes in the sub-network." +other hsa-mir-106b Alzheimer Disease 24194717 "we found microRNAs, including miR-20a, miR-17, miR-34a, miR-155, miR-18a, miR-22, miR-26a, miR-101, miR-106b, and miR-125b, that might regulate the expression of nodes in the sub-network." +other hsa-mir-17 Alzheimer Disease 24194717 "we found microRNAs, including miR-20a, miR-17, miR-34a, miR-155, miR-18a, miR-22, miR-26a, miR-101, miR-106b, and miR-125b, that might regulate the expression of nodes in the sub-network." +other hsa-mir-20a Alzheimer Disease 24194717 "we found microRNAs, including miR-20a, miR-17, miR-34a, miR-155, miR-18a, miR-22, miR-26a, miR-101, miR-106b, and miR-125b, that might regulate the expression of nodes in the sub-network." +other hsa-mir-141 Prostate Neoplasms 24195675 Sensitive detection of microRNA in complex biological samples via enzymatic signal amplification using DNA polymerase coupled with nicking endonuclease. +other hsa-mir-221 Breast Neoplasms 24197133 14-3-3¦Æ orchestrates mammary tumor onset and progression via miR-221-mediated cell proliferation. +other hsa-mir-10b "Carcinoma, Lung, Non-Small-Cell" 24198203 "microRNA expression profiles associated with survival, disease progression, and response to gefitinib in completely resected non-small-cell lung cancer with EGFR mutation." +other hsa-mir-21 "Carcinoma, Lung, Non-Small-Cell" 24198203 "microRNA expression profiles associated with survival, disease progression, and response to gefitinib in completely resected non-small-cell lung cancer with EGFR mutation." +other hsa-mir-30 "Leukemia, Myeloid, Acute" 24199710 Adverse prognostic value of MYBL2 overexpression and association with microRNA-30 family in acute myeloid leukemia patients. +other hsa-mir-17 "Carcinoma, Lung, Non-Small-Cell" 24200043 "This work will provide a framework for constructing miRNA-TF synergistic regulatory networks, function analysis in diseases, and identification of the main regulators and regulatory motifs, which will be useful for understanding the putative regulatory motifs involving miRNAs and TFs, and for predicting new targets for cancer studies." +other hsa-mir-570 "Carcinoma, Lung, Non-Small-Cell" 24200043 "This work will provide a framework for constructing miRNA-TF synergistic regulatory networks, function analysis in diseases, and identification of the main regulators and regulatory motifs, which will be useful for understanding the putative regulatory motifs involving miRNAs and TFs, and for predicting new targets for cancer studies." +other hsa-mir-590 "Carcinoma, Lung, Non-Small-Cell" 24200043 "This work will provide a framework for constructing miRNA-TF synergistic regulatory networks, function analysis in diseases, and identification of the main regulators and regulatory motifs, which will be useful for understanding the putative regulatory motifs involving miRNAs and TFs, and for predicting new targets for cancer studies." +other hsa-mir-888 Prostate Neoplasms 24200968 miR-888 is an expressed prostatic secretions-derived microRNA that promotes prostate cell growth and migration. +other hsa-mir-223 Acute Coronary Syndrome 24202700 Decreased circulating microRNA-223 level predicts high on-treatment platelet reactivity in patients with troponin-negative non-ST elevation acute coronary syndrome. +other hsa-mir-130b Colorectal Carcinoma 24204200 MicroRNA-130b promotes tumor development and is associated with poor prognosis in colorectal cancer. +other hsa-mir-496 Breast Neoplasms 24204564 Methylated DNA binding domain protein 2 (MBD2) coordinately silences gene expression through activation of the microRNA hsa-mir-496 promoter in breast cancer cell line. +other hsa-mir-139 "Squamous Cell Carcinoma, Esophageal" 24204738 Tumor-suppressive function of miR-139-5p in esophageal squamous cell carcinoma. +other hsa-mir-125b "Carcinoma, Adrenocortical" 24205079 "miR-125b, miRNA-200b, miR-122, miRNA-466b, miR-138,vmiRNA-214, miRNA-503 and miRNA27a were down-regulated in response to 17¦Á-E2 treatment." +other hsa-mir-132 "Carcinoma, Adrenocortical" 24205079 "ACTH up-regulated the expression of miRNA-212, miRNA-182, miRNA-183, miRNA-132, and miRNA-96 and down-regulated the levels of miRNA-466b, miRNA-214, miRNA-503, and miRNA-27a." +other hsa-mir-212 "Carcinoma, Adrenocortical" 24205079 "The levels of miR-212,miRNA-183, miRNA-182, miRNA-132, miRNA-370, miRNA-377, and miRNA-96 were up-regulated, whereas miR-125b, miRNA-200b, miR-122, miRNA-466b, miR-138, miRNA-214, miRNA-503 and miRNA27a were down-regulated in response to 17¦Á-E2 treatment." +other hsa-mir-21 Glioblastoma 24205116 MiR-21 in the extracellular vesicles (EVs) of cerebrospinal fluid (CSF): a platform for glioblastoma biomarker development. +other hsa-mir-10b Head And Neck Neoplasms 24209638 The study of microRNA alterations in HNSCC is an essential step to the mechanistic understanding of tumor formation and could lead to the discovery of clinically relevant biomarkers. +other hsa-mir-196a Head And Neck Neoplasms 24209638 The study of microRNA alterations in HNSCC is an essential step to the mechanistic understanding of tumor formation and could lead to the discovery of clinically relevant biomarkers. +other hsa-mir-548a Influenza 24210102 Expression of non-structural-1A binding protein in lung epithelial cells is modulated by miRNA-548an on exposure to influenza A virus. +other hsa-mir-26a Glioblastoma 24211747 MiR-26a enhances the radiosensitivity of glioblastoma multiforme cells through targeting of ataxia-telangiectasia mutated. +other hsa-mir-27a Alzheimer Disease 24212398 Our pilot study highlights hsa-miR-27a-3p as a candidate biomarker for AD and provides the groundwork for further confirmation studies in larger cohorts and in other hospitals. +other hsa-mir-17 Cardiovascular Diseases [unspecific] 24212931 "The miR-17/92 cluster: a comprehensive update on its genomics, genetics,functions and increasingly important and numerous roles in health and disease." +other hsa-mir-18 Cardiovascular Diseases [unspecific] 24212931 "The miR-17/92 cluster: a comprehensive update on its genomics, genetics,functions and increasingly important and numerous roles in health and disease." +other hsa-mir-19a Cardiovascular Diseases [unspecific] 24212931 "The miR-17/92 cluster: a comprehensive update on its genomics, genetics,functions and increasingly important and numerous roles in health and disease." +other hsa-mir-19b-1 Cardiovascular Diseases [unspecific] 24212931 "The miR-17/92 cluster: a comprehensive update on its genomics, genetics,functions and increasingly important and numerous roles in health and disease." +other hsa-mir-20a Cardiovascular Diseases [unspecific] 24212931 "The miR-17/92 cluster: a comprehensive update on its genomics, genetics,functions and increasingly important and numerous roles in health and disease." +other hsa-mir-92-1 Cardiovascular Diseases [unspecific] 24212931 "The miR-17/92 cluster: a comprehensive update on its genomics, genetics,functions and increasingly important and numerous roles in health and disease." +other hsa-mir-185 Depression Disorder 24213247 "The involvement of microRNAs in major depression, suicidal behavior, and related disorders: a focus on miR-185 and miR-491-3p." +other hsa-mir-491 Depression Disorder 24213247 "The involvement of microRNAs in major depression, suicidal behavior, and related disorders: a focus on miR-185 and miR-491-3p." +other hsa-mir-192 "Carcinoma, Colon" 24213572 MicroRNA-192 suppresses liver metastasis of colon cancer. +other hsa-mir-21 Acute Kidney Failure 24214874 MicroRNA-21 in the pathogenesis of acute kidney injury. +other hsa-mir-125a Leukemia 24216483 ASXL1-MT resulted in derepression of homeobox A9 (Hoxa9) and microRNA-125a (miR-125a) expression through inhibition of polycomb repressive complex 2¨Cmediated (PRC2-mediated) methylation of histone H3K27. +other hsa-mir-320a Gastrointestinal Stromal Tumor 24217767 MiR-320a downregulation is associated with imatinib resistance in gastrointestinal stromal tumors. +other hsa-mir-203 "Carcinoma, Esophageal" 24219349 miR-203 inhibits the proliferation and self-renewal of esophageal cancer stem-like cells by suppressing stem renewal factor Bmi-1. +other hsa-mir-130 Neoplasms [unspecific] 24220575 Identification of a pan-cancer oncogenic microRNA superfamily anchored by a central core seed motif. +other hsa-mir-17 Neoplasms [unspecific] 24220575 Identification of a pan-cancer oncogenic microRNA superfamily anchored by a central core seed motif. +other hsa-mir-19 Neoplasms [unspecific] 24220575 Identification of a pan-cancer oncogenic microRNA superfamily anchored by a central core seed motif. +other hsa-mir-210 Neoplasms [unspecific] 24220575 Identification of a pan-cancer oncogenic microRNA superfamily anchored by a central core seed motif. +other hsa-mir-455 Neoplasms [unspecific] 24220575 Identification of a pan-cancer oncogenic microRNA superfamily anchored by a central core seed motif. +other hsa-mir-93 Neoplasms [unspecific] 24220575 Identification of a pan-cancer oncogenic microRNA superfamily anchored by a central core seed motif. +other hsa-mir-367 Ovarian Neoplasms 24220856 "Overexpression of miR-367 in the paclitaxel-sensitive cells [PA1; IC??, 1.69 nM, high miR-367 (2.997), low miR-30a-5p (-0.323)] further increased paclitaxel sensitivity, whereas miR-367 depletion decreased paclitaxel sensitivity." +other hsa-mir-1 Prostate Neoplasms 24222130 "In 22Rv1 cells, all AR isoforms were co-regulated by the cytoprotective factor HSPB1 and the tumor suppressor miR-1. Notably, our data provide evidence that HSPB1 inhibition is able to target expression of long as well as of short AR isoforms." +other hsa-mir-183 "Carcinoma, Hepatocellular" 24222732 Expression and significance of microRNA-183 in hepatocellular carcinoma. +other hsa-mir-196b Gastric Neoplasms 24222951 Co-activation of miR-196b and HOXA10 characterized a poor-prognosis subgroup of patients with gastric cancer. Elucidation of the biologic function of miR-196b and HOXA10 is warranted. +other hsa-mir-135b Multiple Myeloma 24223191 Upregulation of miR-135b is involved in the impaired osteogenic differentiation of mesenchymal stem cells derived from multiple myeloma patients. +other hsa-mir-4723 Prostate Neoplasms 24223753 MicroRNA-4723 inhibits prostate cancer growth through inactivation of the Abelson family of nonreceptor protein tyrosine kinases. +other hsa-mir-142 Neoplasms [unspecific] 24227773 Two specific miRNAs transferred efficiently between these cells--miR-142 and miR-223--and both were endogenously expressed in macrophages and not in HCCs. +other hsa-mir-429 Colorectal Carcinoma 24237355 miR-429 identified by dynamic transcriptome analysis is a new candidate biomarker for colorectal cancer prognosis. +other hsa-mir-4661 Inflammation 24238336 The bipolar role of miR-4661 in inflammation. +other hsa-mir-103a "Carcinoma, Colon" 24239208 "Our six-miRNA-based classifier is a reliable prognostic and predictive tool for disease recurrence in patients with stage II colon cancer,and might be able to predict which patients benefit from adjuvant chemotherapy.It might facilitate patient counselling and individualise management of patients with this disease." +other hsa-mir-106b "Carcinoma, Colon" 24239208 "Our six-miRNA-based classifier is a reliable prognostic and predictive tool for disease recurrence in patients with stage II colon cancer,and might be able to predict which patients benefit from adjuvant chemotherapy.It might facilitate patient counselling and individualise management of patients with this disease." +other hsa-mir-143 "Carcinoma, Colon" 24239208 "Our six-miRNA-based classifier is a reliable prognostic and predictive tool for disease recurrence in patients with stage II colon cancer,and might be able to predict which patients benefit from adjuvant chemotherapy.It might facilitate patient counselling and individualise management of patients with this disease." +other hsa-mir-20a "Carcinoma, Colon" 24239208 "Our six-miRNA-based classifier is a reliable prognostic and predictive tool for disease recurrence in patients with stage II colon cancer,and might be able to predict which patients benefit from adjuvant chemotherapy.It might facilitate patient counselling and individualise management of patients with this disease." +other hsa-mir-21 "Carcinoma, Colon" 24239208 "Our six-miRNA-based classifier is a reliable prognostic and predictive tool for disease recurrence in patients with stage II colon cancer,and might be able to predict which patients benefit from adjuvant chemotherapy.It might facilitate patient counselling and individualise management of patients with this disease." +other hsa-mir-215 "Carcinoma, Colon" 24239208 "Our six-miRNA-based classifier is a reliable prognostic and predictive tool for disease recurrence in patients with stage II colon cancer,and might be able to predict which patients benefit from adjuvant chemotherapy.It might facilitate patient counselling and individualise management of patients with this disease." +other hsa-mir-30c Adenovirus Infection 24239602 Comparison of RNAi with CCN2-modulating microRNA (miR) vectors expressing miR-30c or miR-133b showed higher efficacy of RNAi. +other hsa-mir-145 Pleural Mesothelioma 24240684 Protumorigenic effects of mir-145 loss in malignant pleural mesothelioma. +other hsa-mir-155 "Carcinoma, Nasopharyngeal" 24241359 MiR-155 up-regulation by LMP1 DNA contributes to increased nasopharyngeal carcinoma cell proliferation and migration. +other hsa-mir-141 "Adenocarcinoma, Pancreatic Ductal" 24242138 Prognostic significance of microRNA-141 expression and its tumor suppressor function in human pancreatic ductal adenocarcinoma. +other hsa-mir-31 Colorectal Carcinoma 24242331 "Association of microRNA-31 with BRAF mutation, colorectal cancer survival and serrated pathway." +other hsa-mir-663 Prostate Neoplasms 24243035 miR-663 induces castration-resistant prostate cancer transformation and predicts clinical recurrence. +other hsa-mir-124 Stroke 24244499 "miR-689, miR-124, and miR-155 were the most strongly associated miRNAs predicted to mediate pro-inflammatory pathways and M1-like activation phenotype." +other hsa-mir-155 Stroke 24244499 "miR-155, the most strongly up-regulated miRNA,regulates the signal transducer and activator of transcription 3 signaling pathway enabling the late phase response to M1-skewing stimulation. " +other hsa-mir-21 Breast Neoplasms 24248894 MicroRNA-21 in breast cancer: diagnostic and prognostic potential. +other hsa-mir-23a Colorectal Carcinoma 24249161 MicroRNA-23a antisense enhances 5-fluorouracil chemosensitivity through APAF-1/caspase-9 apoptotic pathway in colorectal cancer cells. +other hsa-let-7e Breast Neoplasms 24257477 "Our data provide novel evidence of the mechanisms behind miRNA dysregulation in breast cancer. The study contributes to the understanding of how methylation and copy number alterations influence miRNA expression, emphasizing miRNA functionality through redundant encoding, and suggests novel miRNAs important in breast cancer." +other hsa-mir-100 Neoplasms [unspecific] 24258109 Prognostic role of microRNA-100 in various carcinomas: evidence from six studies. +other hsa-mir-148a Osteoarthritis 24269634 "Overexpression of hsa-miR-148a inhibits hypertrophic differentiation and increases the production and deposition of type II collagen by OA chondrocytes, which is accompanied by an increased retention of proteoglycans.Hsa-miR-148a might be a potential disease-modifying compound in OA, as it promotes hyaline cartilage production." +other hsa-mir-23a Myocardial Infarction 24269648 MicroRNA-23a is involved in tumor necrosis factor-¦Á induced apoptosis in mesenchymal stem cells and myocardial infarction. +other hsa-mir-204 Pulmonary Hypertension 24270264 "We also showed that PARP-1 activation accounts for miR-204 downregulation (quantitative reverse transcription polymerase chain reaction) and the subsequent activation of the transcription factors nuclear factor of activated T cells and hypoxia-inducible factor 1-α in PAH-PASMCs, previously shown to be critical for PAH in several models." +other hsa-mir-9 "Leukemia, Myeloid, Acute" 24270738 miR-9 is a tumor suppressor in pediatric AML +other hsa-mir-122 Chronic Hepatitis C 24270780 "Reply to miR-122, IL28B genotype and the response to interferon in chronic hepatitis C virus infection." +other hsa-mir-122 Chronic Hepatitis C 24270782 "miR-122, IL28B genotype and the response to interferon in chronic hepatitis C virus infection." +other hsa-mir-214 Glioma 24277415 Combined aberrant expression of microRNA-214 and UBC9 is an independent unfavorable prognostic factor for patients with gliomas. +other hsa-mir-338 Colorectal Carcinoma 24277750 MicroRNA-338-3p could inhibit colorectal carcinoma cell invasion and migration by inhibiting smoothened expression. +other hsa-mir-503 Chikungunya Virus Infection 24278205 Combined miRNA and mRNA signature identifies key molecular players and pathways involved in chikungunya virus infection in human cells. +other hsa-mir-638 Chikungunya Virus Infection 24278205 Combined miRNA and mRNA signature identifies key molecular players and pathways involved in chikungunya virus infection in human cells. +other hsa-mir-744 Chikungunya Virus Infection 24278205 Combined miRNA and mRNA signature identifies key molecular players and pathways involved in chikungunya virus infection in human cells. +other hsa-mir-132 Epilepsy 24282394 "Targeting miR-34a, miR-132 and miR-184 has been reported to alter seizure-induced neuronal death, whereas targeting miR-134 was neuroprotective, reduced seizure severity during status epilepticus and reduced the later emergence of recurrent spontaneous seizures." +other hsa-mir-184 Epilepsy 24282394 "Targeting miR-34a, miR-132 and miR-184 has been reported to alter seizure-induced neuronal death, whereas targeting miR-134 was neuroprotective, reduced seizure severity during status epilepticus and reduced the later emergence of recurrent spontaneous seizures." +other hsa-mir-323 Alzheimer Disease 24283221 "MicroRNA-323-3p with clinical potential in rheumatoid arthritis, Alzheimer's disease and ectopic pregnancy." +other hsa-mir-155 "Aortic Aneurysm, Abdominal" 24283299 microRNA profiling in patients with abdominal aortic aneurysms: the significance of miR-155. +other hsa-mir-30b "Carcinoma, Lung, Non-Small-Cell" 24286402 Our study identified miR-30b and miR-30c as useful prognostic predictors in NSCLC patients who underwent first line treatment with TKIs. +other hsa-mir-30c "Carcinoma, Lung, Non-Small-Cell" 24286402 Our study identified miR-30b and miR-30c as useful prognostic predictors in NSCLC patients who underwent first line treatment with TKIs. +other hsa-mir-17 Breast Neoplasms 24287487 Cyclin D1 induction of Dicer governs microRNA processing and expression in breast cancer. +other hsa-mir-20a Breast Neoplasms 24287487 Cyclin D1 induction of Dicer governs microRNA processing and expression in breast cancer. +other hsa-mir-206 Dermatomyositis 24288551 Correlation between the frequency of Th17 cell and the expression of microRNA-206 in patients with dermatomyositis. +other hsa-mir-206 Melanoma 24289491 MicroRNA-206 induces G1 arrest in melanoma by inhibition of CDK4 and Cyclin D. +other hsa-mir-29 Breast Neoplasms 24289849 The inhibitory role of Mir-29 in growth of breast cancer cells. +other hsa-mir-196a-2 "Leukemia, Lymphoblastic, Acute" 24291415 Hsa-miR-196a2 polymorphism increases the risk of acute lymphoblastic leukemia in Chinese children. +other hsa-mir-146a Systemic Lupus Erythematosus 24292724 STAT1 and miR-146a may be upregulated during inflammation and via proinflammatory cytokines and chemokines in SLE. Prolonged upregulation of STAT1 and miR-146a appears to play an important role in anemia in SLE patients. +other hsa-mir-125b Alzheimer Disease 24293102 "Regulation of neurotropic signaling by the inducible, NF-kB-sensitive miRNA-125b in Alzheimer's disease (AD) and in primary human neuronal-glial (HNG) cells." +other hsa-let-7a Lung Neoplasms 24293999 Targeted delivery of let-7a microRNA encapsulated ephrin-A1 conjugated liposomal nanoparticles inhibit tumor growth in lung cancer. +other hsa-mir-26a "Carcinoma, Hepatocellular" 24296580 Hepatocellular carcinoma: New insight into angiogenesis in hepatocellular carcinoma: involvement of microRNA-26a. +other hsa-mir-205 "Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal" 24297308 MicroRNA-205 suppresses proliferation and promotes apoptosis in laryngeal squamous cell carcinoma. +other hsa-let-7b "Carcinoma, Hepatocellular" 24297460 Bioinformatic analysis of the membrane cofactor protein CD46 and microRNA expression in hepatocellular carcinoma. +other hsa-mir-17 "Carcinoma, Hepatocellular" 24297460 Bioinformatic analysis of the membrane cofactor protein CD46 and microRNA expression in hepatocellular carcinoma. +other hsa-mir-483 Neoplasms [unspecific] 24298054 The IGF2 intronic miR-483 selectively enhances transcription from IGF2 fetal promoters and enhances tumorigenesis. +other hsa-mir-218 Lung Fibrosis 24298938 Andrographolide antagonizes cigarette smoke extract-induced inflammatory response and oxidative stress in human alveolar epithelial A549 cells through induction of microRNA-218. +other hsa-mir-146b Prostate Neoplasms 24301753 "After Gene Set Functional Similarity analysis, we obtained 20 abnormal PC-related candidate miRNAs, including hsa-miR-26a, hsa-miR-152, hsa-miR-19a, hsa-miR-30c, hsa-miR-19b, and hsa-miR-146b-5p, among others." +other hsa-mir-30c Prostate Neoplasms 24301753 "After Gene Set Functional Similarity analysis, we obtained 20 abnormal PC-related candidate miRNAs, including hsa-miR-26a, hsa-miR-152, hsa-miR-19a, hsa-miR-30c, hsa-miR-19b, and hsa-miR-146b-5p, among others." +other hsa-mir-381 Neoplasms [unspecific] 24303078 Changes in the expression of miR-381 and miR-495 are inversely associated with the expression of the MDR1 gene and development of multi-drug resistance. +other hsa-mir-495 Neoplasms [unspecific] 24303078 Changes in the expression of miR-381 and miR-495 are inversely associated with the expression of the MDR1 gene and development of multi-drug resistance. +other hsa-mir-18b Melanoma 24303553 Role of miR-18b/MDM2/p53 circuitry in melanoma progression. +other hsa-mir-155 Immune System Disease [unspecific] 24303979 Role of miR-155 in the regulation of lymphocyte immune function and disease. +other hsa-mir-96 Neurodegenerative Diseases [unspecific] 24304186 Widespread microRNA dysregulation in multiple system atrophy - disease-related alteration in miR-96. +other hsa-mir-210 "Carcinoma, Lung, Non-Small-Cell" 24305009 "We show that miR-210 in stromal cells, and co-expressed in cancer cells and stromal cells mediates an independent prognostic impact. It is a candidate marker for prognostic stratification in NSCLC." +other hsa-mir-328 Glioma 24305703 MiR-328 promotes glioma cell invasion via SFRP1-dependent Wnt-signaling activation. +other hsa-mir-17 Pediatric Glioma 24305714 Our results suggest that microRNA profiling represents a tool to distinguishing pediatric from adult HGG and that miR-17-92 cluster sustains pHGG. +other hsa-mir-18 Pediatric Glioma 24305714 Our results suggest that microRNA profiling represents a tool to distinguishing pediatric from adult HGG and that miR-17-92 cluster sustains pHGG. +other hsa-mir-19a Pediatric Glioma 24305714 Our results suggest that microRNA profiling represents a tool to distinguishing pediatric from adult HGG and that miR-17-92 cluster sustains pHGG. +other hsa-mir-19b-1 Pediatric Glioma 24305714 Our results suggest that microRNA profiling represents a tool to distinguishing pediatric from adult HGG and that miR-17-92 cluster sustains pHGG. +other hsa-mir-20a Pediatric Glioma 24305714 Our results suggest that microRNA profiling represents a tool to distinguishing pediatric from adult HGG and that miR-17-92 cluster sustains pHGG. +other hsa-mir-92-1 Pediatric Glioma 24305714 Our results suggest that microRNA profiling represents a tool to distinguishing pediatric from adult HGG and that miR-17-92 cluster sustains pHGG. +other hsa-mir-141 Osteosarcoma 24307282 Tumor-suppressing effects of miR-141 in human osteosarcoma. +other hsa-mir-1 Glioblastoma 24310399 Extracellular vesicles modulate the glioblastoma microenvironment via a tumor suppression signaling network directed by miR-1. +other hsa-mir-30e Gastrointestinal Neoplasms 24312366 Identification of miR-30e* regulation of Bmi1 expression mediated by tumor-associated macrophages in gastrointestinal cancer. +other hsa-mir-149 Gastrointestinal Neoplasms 24312386 "The present meta-analysis indicates that miR-499 may be associated with the risk to colorectal cancer. MiR-149 may confer a marginally increased risk of susceptibility to gastrointestinal cancer, especially for Asians." +other hsa-mir-499 Gastrointestinal Neoplasms 24312386 "The present meta-analysis indicates that miR-499 may be associated with the risk to colorectal cancer. MiR-149 may confer a marginally increased risk of susceptibility to gastrointestinal cancer, especially for Asians." +other hsa-mir-153 Fetal Alcohol Spectrum Disorder 24313161 Dysregulation of microRNA expression and function contributes to the etiology of fetal alcohol spectrum disorders. +other hsa-mir-21 Fetal Alcohol Spectrum Disorder 24313161 Dysregulation of microRNA expression and function contributes to the etiology of fetal alcohol spectrum disorders. +other hsa-mir-335 Fetal Alcohol Spectrum Disorder 24313161 Dysregulation of microRNA expression and function contributes to the etiology of fetal alcohol spectrum disorders. +other hsa-mir-9 Fetal Alcohol Spectrum Disorder 24313161 Dysregulation of microRNA expression and function contributes to the etiology of fetal alcohol spectrum disorders. +other hsa-mir-34 Asthma 24313771 Subtypes of asthma defined by epithelial cell expression of messenger RNA and microRNA. +other hsa-mir-449 Asthma 24313771 Subtypes of asthma defined by epithelial cell expression of messenger RNA and microRNA. +other hsa-mir-146a "Carcinoma, Hepatocellular" 24314246 "Drug-resistant HCC cells have abnormal expressed miRNAs, which may be explored to further investigate the association of miRNA expressions with multidrugs resistance in HCC." +other hsa-mir-146b "Carcinoma, Hepatocellular" 24314246 "Drug-resistant HCC cells have abnormal expressed miRNAs, which may be explored to further investigate the association of miRNA expressions with multidrugs resistance in HCC." +other hsa-mir-15a "Carcinoma, Hepatocellular" 24314246 "Drug-resistant HCC cells have abnormal expressed miRNAs, which may be explored to further investigate the association of miRNA expressions with multidrugs resistance in HCC." +other hsa-mir-16 "Carcinoma, Hepatocellular" 24314246 "Drug-resistant HCC cells have abnormal expressed miRNAs, which may be explored to further investigate the association of miRNA expressions with multidrugs resistance in HCC." +other hsa-mir-181d "Carcinoma, Hepatocellular" 24314246 "Drug-resistant HCC cells have abnormal expressed miRNAs, which may be explored to further investigate the association of miRNA expressions with multidrugs resistance in HCC." +other hsa-mir-194 "Carcinoma, Hepatocellular" 24314246 "Drug-resistant HCC cells have abnormal expressed miRNAs, which may be explored to further investigate the association of miRNA expressions with multidrugs resistance in HCC." +other hsa-mir-27b "Carcinoma, Hepatocellular" 24314246 "Drug-resistant HCC cells have abnormal expressed miRNAs, which may be explored to further investigate the association of miRNA expressions with multidrugs resistance in HCC." +other hsa-mir-30b "Carcinoma, Hepatocellular" 24314246 "Drug-resistant HCC cells have abnormal expressed miRNAs, which may be explored to further investigate the association of miRNA expressions with multidrugs resistance in HCC." +other hsa-mir-205 Human Papilloma Virus Infection 24314651 miR-24 and miR-205 expression is dependent on HPV onco-protein expression in keratinocytes. +other hsa-mir-24 Human Papilloma Virus Infection 24314651 miR-24 and miR-205 expression is dependent on HPV onco-protein expression in keratinocytes. +other hsa-mir-122 Hepatitis B Virus Infection 24314655 microRNA expression in hepatitis B virus infected primary treeshrew hepatocytes and the independence of intracellular miR-122 level for de novo HBV infection in culture. +other hsa-mir-221 Gastric Neoplasms 24317477 Relapse-associated microRNA in gastric cancer patients after S-1 adjuvant chemotherapy. +other hsa-mir-422a Gastric Neoplasms 24317477 Relapse-associated microRNA in gastric cancer patients after S-1 adjuvant chemotherapy. +other hsa-mir-4732 Gastric Neoplasms 24317477 Relapse-associated microRNA in gastric cancer patients after S-1 adjuvant chemotherapy. +other hsa-mir-4758 Gastric Neoplasms 24317477 Relapse-associated microRNA in gastric cancer patients after S-1 adjuvant chemotherapy. +other hsa-mir-92b Gastric Neoplasms 24317477 Relapse-associated microRNA in gastric cancer patients after S-1 adjuvant chemotherapy. +other hsa-mir-127 "Adenocarcinoma, Lung" 24317514 Upregulation of the microRNA cluster at the Dlk1-Dio3 locus in lung adenocarcinoma. +other hsa-mir-376a "Adenocarcinoma, Lung" 24317514 Upregulation of the microRNA cluster at the Dlk1-Dio3 locus in lung adenocarcinoma. +other hsa-mir-26a Pulmonary Hypertension 24328779 miR-26a linked to pulmonary hypertension by global assessment of circulating extracellular microRNAs. +other hsa-mir-193a "Carcinoma, Hepatocellular" 24330766 Effects of miR-193a and sorafenib on hepatocellular carcinoma cells. +other hsa-mir-155 Encephalomyelitis 24332164 MicroRNA-155 modulates Th1 and Th17 cell differentiation and is associated with multiple sclerosis and experimental autoimmune encephalomyelitis. +other hsa-mir-92a Pancreatic Neoplasms 24332650 miR-92a/DUSP10/JNK signalling axis promotes human pancreatic cancer cells proliferation. +other hsa-mir-302 "Carcinoma, Endometrial" 24333727 MicroRNA miR-302 inhibits the tumorigenicity of endometrial cancer cells by suppression of Cyclin D1 and CDK1. +other hsa-mir-29 Fuchs Endothelial Dystrophy 24334445 Decreased endothelial expression of miR-29 family members may be associated with increased subendothelial extracellular matrix accumulation in FECD. +other hsa-mir-491 "Squamous Cell Carcinoma, Oral" 24335959 miRNA-491-5p and GIT1 serve as modulators and biomarkers for oral squamous cell carcinoma invasion and metastasis. +other hsa-mir-148a Prostate Neoplasms 24337069 Comparative microRNA profiling of prostate carcinomas with increasing tumor stage by deep sequencing. +other hsa-mir-200b Prostate Neoplasms 24337069 Comparative microRNA profiling of prostate carcinomas with increasing tumor stage by deep sequencing. +other hsa-mir-20a Prostate Neoplasms 24337069 Comparative microRNA profiling of prostate carcinomas with increasing tumor stage by deep sequencing. +other hsa-mir-375 Prostate Neoplasms 24337069 Comparative microRNA profiling of prostate carcinomas with increasing tumor stage by deep sequencing. +other hsa-mir-7 "Carcinoma, Hepatocellular" 24339204 Downregulation of miR-7 upregulates Cullin 5 (CUL5) to facilitate G1/S transition in human hepatocellular carcinoma cells. +other hsa-mir-608 "Adenocarcinoma, Lung" 24339958 Bcl-xL silencing induces alterations in hsa-miR-608 expression and subsequent cell death in A549 and SK-LU1 human lung adenocarcinoma cells. +other hsa-mir-29 Bladder Outlet Obstruction 24340017 Mir-29 repression in bladder outlet obstruction contributes to matrix remodeling and altered stiffness. +other hsa-mir-323b Hepatitis B Virus Infection 24341744 Association of a microRNA-323b polymorphism with the persistence of hepatitis B virus infection by the enhancement of viral replication. +other hsa-mir-26a "Squamous Cell Carcinoma, Tongue" 24343426 "Expression, regulation and roles of miR-26a and MEG3 in tongue squamous cell carcinoma." +other hsa-mir-155 Lymphoma 24345320 Primary vitreoretinal B-cell lymphoma and uveitis might be characterized by distinct microRNA signatures. Quantification of ocular microRNA-155 might be helpful in the differential diagnosis of these 2 diseases. +other hsa-mir-30d Thyroid Neoplasms 24345332 Regulation of autophagy by miR-30d impacts sensitivity of anaplastic thyroid carcinoma to cisplatin. +other hsa-mir-712 Atherosclerosis 24346612 The atypical mechanosensitive microRNA-712 derived from pre-ribosomal RNA induces endothelial inflammation and atherosclerosis. +other hsa-mir-29 "Diabetes Mellitus, Type 2" 24349318 "Urinary miR-29a correlated with albuminuria while urinary miR-29b correlated with carotid intima-media thickness (cIMT) in patients with type 2 diabetes. Therefore, they may have the potential to serve as alternative biomarker for diabetic nephropathy and atherosclerosis in type 2 diabetes." +other hsa-mir-19a "Leukemia, Myeloid, Acute" 24349422 HDAC inhibitors repress BARD1 isoform expression in acute myeloid leukemia cells via activation of miR-19a and/or b. +other hsa-mir-19b "Leukemia, Myeloid, Acute" 24349422 HDAC inhibitors repress BARD1 isoform expression in acute myeloid leukemia cells via activation of miR-19a and/or b. +other hsa-mir-126 Cardiovascular Diseases [unspecific] 24349482 miR-126 expression was depressed in the process of EPC EndMT. +other hsa-mir-494 Diabetes Mellitus 24349514 "MicroRNA-494, upregulated by tumor necrosis factor-¦Á, desensitizes insulin effect in C2C12 muscle cells." +other hsa-mir-217 Leukemia 24350829 "Downregulation of miR-217 correlates with resistance of Ph(+) leukemia cells to ABL tyrosine kinase inhibitors. miR-#-5p,miR-#-3p" +other hsa-mir-200 Gastric Neoplasms 24352645 We have uncovered a key microRNA regulatory network that defines the mesenchymal gastric cancer subtype significantly associated with poor overall survival in gastric cancer +other hsa-mir-185 Gastric Neoplasms 24352663 miR-185 is an independent prognosis factor and suppresses tumor metastasis in gastric cancer. +other hsa-mir-148b Alzheimer Disease 24352679 Constructing and characterizing a bioactive small molecule and microRNA association network for Alzheimer's disease. +other hsa-mir-15a Alzheimer Disease 24352679 Constructing and characterizing a bioactive small molecule and microRNA association network for Alzheimer's disease. +other hsa-mir-122 Liver Diseases [unspecific] 24354366 Roadmap of miR-122-related clinical application from bench to bedside. +other hsa-mir-106b "Carcinoma, Hepatocellular" 24358224 Global assessment of Antrodia cinnamomea-induced microRNA alterations in hepatocarcinoma cells. +other hsa-mir-17 "Carcinoma, Hepatocellular" 24358224 Global assessment of Antrodia cinnamomea-induced microRNA alterations in hepatocarcinoma cells. +other hsa-mir-18 "Carcinoma, Hepatocellular" 24358224 Global assessment of Antrodia cinnamomea-induced microRNA alterations in hepatocarcinoma cells. +other hsa-mir-191 "Carcinoma, Hepatocellular" 24358224 Global assessment of Antrodia cinnamomea-induced microRNA alterations in hepatocarcinoma cells. +other hsa-mir-19a "Carcinoma, Hepatocellular" 24358224 Global assessment of Antrodia cinnamomea-induced microRNA alterations in hepatocarcinoma cells. +other hsa-mir-19b-1 "Carcinoma, Hepatocellular" 24358224 Global assessment of Antrodia cinnamomea-induced microRNA alterations in hepatocarcinoma cells. +other hsa-mir-20a "Carcinoma, Hepatocellular" 24358224 Global assessment of Antrodia cinnamomea-induced microRNA alterations in hepatocarcinoma cells. +other hsa-mir-21 "Carcinoma, Hepatocellular" 24358224 Global assessment of Antrodia cinnamomea-induced microRNA alterations in hepatocarcinoma cells. +other hsa-mir-92-1 "Carcinoma, Hepatocellular" 24358224 Global assessment of Antrodia cinnamomea-induced microRNA alterations in hepatocarcinoma cells. +other hsa-mir-142 Systemic Mastocytosis 24361879 miR-142-3p enhances Fc¦ÅRI-mediated degranulation in mast cells. +other hsa-mir-2909 Viral Infectious Disease 24361962 Arsenic programmes cellular genomic-immunity through miR-2909 RNomics. +other hsa-mir-499 Myocardial Infarction 24363996 Treatment with cLA and nitrite significantly induced levels of miRNA-499 compared to untreated MI mice. +other hsa-mir-126 Neoplasms [unspecific] 24368110 miR-126 in human cancers: clinical roles and current perspectives. +other hsa-mir-144 "Carcinoma, Esophageal" 24369245 miRNA-144 in the saliva is a genetic marker for early diagnosis of esophageal cancer +other hsa-mir-205 Prostate Neoplasms 24370341 miR-205 impairs the autophagic flux and enhances cisplatin cytotoxicity in castration-resistant prostate cancer cells. +other hsa-mir-21 Diabetic Nephropathy 24370587 Tongxinluo ameliorates renal structure and function by regulating miR-21-induced epithelial-to-mesenchymal transition in diabetic nephropathy. +other hsa-mir-193b "Squamous Cell Carcinoma, Skin or Unspecific" 24374827 miR-193b/365a cluster controls progression of epidermal squamous cell carcinoma. +other hsa-mir-365a "Squamous Cell Carcinoma, Skin or Unspecific" 24374827 miR-193b/365a cluster controls progression of epidermal squamous cell carcinoma. +other hsa-mir-497 Colorectal Carcinoma 24375248 MicroRNA-497 and bufalin act synergistically to inhibit colorectal cancer metastasis. +other hsa-mir-200 Colorectal Carcinoma 24376848 The role of microRNA-200 in progression of human colorectal and breast cancer. +other hsa-mir-126 "Carcinoma, Cervical" 24377569 miR-126 Suppresses the proliferation of cervical cancer cells and alters cell sensitivity to the chemotherapeutic drug bleomycin +other hsa-mir-27b "Leukemia, Myeloid" 24378438 (6)-Gingerolinduced myeloid leukemia cell death is initiated by reactive oxygen species and activation of miR-27b expression. +other hsa-mir-92a "Diabetes Mellitus, Type 2" 24379347 "The updated subnetwork predicted that miR-126/-193b/-92a control CCL2 production by several TFs, including v-ets erythroblastosis virus E26 oncogene homolog 1 (avian) (ETS1), MYC-associated factor X (MAX), and specificity protein 12 (SP1)." +other hsa-mir-155 Hepatitis C Virus Infection 24383923 MicroRNA-155 controls Toll-like receptor 3- and hepatitis C virus-induced immune responses in the liver. +other hsa-mir-130a Hepatitis C Virus Infection 24383925 MicroRNA-130a inhibits HCV replication by restoring the innate immune response. +other hsa-mir-122 Liver Neoplasms 24386085 ADAR2-mediated editing of miR-214 and miR-122 precursor and antisense RNA transcripts in liver cancers. +other hsa-mir-214 Liver Neoplasms 24386085 ADAR2-mediated editing of miR-214 and miR-122 precursor and antisense RNA transcripts in liver cancers. +other hsa-mir-17 Cardiovascular Diseases [unspecific] 24386440 "These findings revealed the role of miRNAs in h-ERG trafficking, which may contribute to the cardiac electrical disturbances associated with oxidative stress." +other hsa-mir-200 "Lymphoma, Large B-Cell, Diffuse" 24390222 Inhibition of ZEB1 by miR-200 characterizes Helicobacter pylori-positive gastric diffuse large B-cell lymphoma with a less aggressive behavior. +other hsa-mir-206 Lung Neoplasms 24390363 Quantitative proteomics and protein network analysis of A549 lung cancer cells affected by miR-206. +other hsa-mir-9-1 Methylmalonic Acidemia 24390963 A Primary Study on Down-Regulated miR-9-1 and Its Biological Significances in Methylmalonic Acidemia. +other hsa-mir-21 Wound Inflammation 24391209 Engulfment of apoptotic cells by macrophages: a role of microRNA-21 in the resolution of wound inflammation. +other hsa-mir-23b Skin Neoplasms 24391759 UVA and UVB irradiation differentially regulate microRNA expression in human primary keratinocytes. +other hsa-mir-155 Human Immunodeficiency Virus Infection 24391808 Cocaine enhances HIV-1 infectivity in monocyte derived dendritic cells by suppressing microRNA-155. +other hsa-mir-200b Prostate Neoplasms 24391862 "miR-200b inhibits prostate cancer EMT, growth and metastasis." +other hsa-mir-1 Prostate Neoplasms 24391925 Coordinate microRNA-mediated regulation of protein complexes in prostate cancer. +other hsa-mir-16 Prostate Neoplasms 24391925 Coordinate microRNA-mediated regulation of protein complexes in prostate cancer. +other hsa-mir-15a "Leukemia, Lymphocytic, Chronic, B-Cell" 24392455 Hsa-miR-15a and Hsa-miR-16-1 expression is not related to proliferation centers abundance and other prognostic factors in chronic lymphocytic leukemia. +other hsa-mir-16-1 "Leukemia, Lymphocytic, Chronic, B-Cell" 24392455 Hsa-miR-15a and Hsa-miR-16-1 expression is not related to proliferation centers abundance and other prognostic factors in chronic lymphocytic leukemia. +other hsa-let-7 Ovarian Neoplasms 24393345 Ovarian cancer cell invasiveness is associated with discordant exosomal sequestration of Let-7 miRNA and miR-200. +other hsa-mir-200 Ovarian Neoplasms 24393345 Ovarian cancer cell invasiveness is associated with discordant exosomal sequestration of Let-7 miRNA and miR-200. +other hsa-mir-210 Breast Neoplasms 24395300 Emerging roles of miR-210 and other non-coding RNAs in the hypoxic response. +other hsa-mir-210 Pancreatic Neoplasms 24395300 Emerging roles of miR-210 and other non-coding RNAs in the hypoxic response. +other hsa-mir-15a Diabetic Vasculopathy 24397367 "Vitamin D manipulates miR-181c, miR-20b and miR-15a in human umbilical vein endothelial cells exposed to a diabetic-like environment." +other hsa-mir-181c Diabetic Vasculopathy 24397367 "Vitamin D manipulates miR-181c, miR-20b and miR-15a in human umbilical vein endothelial cells exposed to a diabetic-like environment." +other hsa-mir-20b Diabetic Vasculopathy 24397367 "Vitamin D manipulates miR-181c, miR-20b and miR-15a in human umbilical vein endothelial cells exposed to a diabetic-like environment." +other hsa-mir-503 Lung Neoplasms 24398307 "MiR-503 was able to reverse the cisplatin resistance of A549/DDP.MiR-503 processed this kind of effect by inhibiting the drug efflux,downregulating the expression of drug-resistant related proteins and promoting cell apoptosis." +other hsa-mir-17 Breast Neoplasms 24398324 Identification of distinct miRNA target regulation between breast cancer molecular subtypes using AGO2-PAR-CLIP and patient datasets. +other hsa-mir-182 Breast Neoplasms 24398324 Identification of distinct miRNA target regulation between breast cancer molecular subtypes using AGO2-PAR-CLIP and patient datasets. +other hsa-mir-19a Breast Neoplasms 24398324 Identification of distinct miRNA target regulation between breast cancer molecular subtypes using AGO2-PAR-CLIP and patient datasets. +other hsa-mir-200b Breast Neoplasms 24398324 Identification of distinct miRNA target regulation between breast cancer molecular subtypes using AGO2-PAR-CLIP and patient datasets. +other hsa-mir-22 Breast Neoplasms 24398324 Identification of distinct miRNA target regulation between breast cancer molecular subtypes using AGO2-PAR-CLIP and patient datasets. +other hsa-mir-24 Breast Neoplasms 24398324 Identification of distinct miRNA target regulation between breast cancer molecular subtypes using AGO2-PAR-CLIP and patient datasets. +other hsa-mir-25 Breast Neoplasms 24398324 Identification of distinct miRNA target regulation between breast cancer molecular subtypes using AGO2-PAR-CLIP and patient datasets. +other hsa-mir-602 "Carcinoma, Hepatocellular, HBV-Related" 24398562 Arctiin induces an UVB protective effect in human dermal fibroblast cells through microRNA expression changes. +other hsa-mir-194 "Adenocarcinoma, Pancreatic Ductal" 24398877 Upregulation of miR-194 contributes to tumor growth and progression in pancreatic ductal adenocarcinoma. +other hsa-mir-340 Pediatric Osteosarcoma 24398981 Combined microRNA-340 and ROCK1 mRNA profiling predicts tumor progression and prognosis in pediatric osteosarcoma. +other hsa-mir-223 Breast Neoplasms 24400121 miR-223 is a coordinator of breast cancer progression as revealed by bioinformatics predictions. +other hsa-let-7c "Carcinoma, Lung, Non-Small-Cell" 24400442 Modulation of let-7c altered the sensitivity of A549/DDP cells to DDP through regulating DDP-induced apopotis. +other hsa-mir-451 Rheumatoid Arthritis 24401767 Comprehensive analysis of miRNA expression in T-cell subsets of rheumatoid arthritis patients reveals defined signatures of naive and memory Tregs. +other hsa-mir-511 "Adenocarcinoma, Lung" 24402374 miR-511 induces the apoptosis of radioresistant lung adenocarcinoma cells by triggering BAX. +other hsa-mir-125b "Carcinoma, Cervical" 24402874 MicroRNAs as biomarkers of cervical cancer development: a literature review on miR-125b and miR-34a. +other hsa-mir-34a "Carcinoma, Cervical" 24402874 MicroRNAs as biomarkers of cervical cancer development: a literature review on miR-125b and miR-34a. +other hsa-mir-30a "Carcinoma, Renal Cell, Clear-Cell" 24402943 miR-30c-2-3p and miR-30a-3p: new pieces of the jigsaw puzzle in HIF2¦Á regulation. +other hsa-mir-30c-2 "Carcinoma, Renal Cell, Clear-Cell" 24402943 miR-30c-2-3p and miR-30a-3p: new pieces of the jigsaw puzzle in HIF2¦Á regulation. +other hsa-mir-375 "Carcinoma, Lung, Non-Small-Cell" 24404590 Decreased circulating miR-375: a potential biomarker for patients with non-small-cell lung cancer. +other hsa-mir-146a "Carcinoma, Cervical" 24406730 Increased exosomal microRNA-21 and microRNA-146a levels in the cervicovaginal lavage specimens of patients with cervical cancer. +other hsa-mir-21 "Carcinoma, Cervical" 24406730 Increased exosomal microRNA-21 and microRNA-146a levels in the cervicovaginal lavage specimens of patients with cervical cancer. +other hsa-mir-378a Colorectal Carcinoma 24412052 Clinical and biological significance of miR-378a-3p and miR-378a-5p in colorectal cancer. +other hsa-mir-23a "Carcinoma, Hepatocellular" 24417970 Correlation between miR-23a and onset of hepatocellular carcinoma. +other hsa-mir-16 Glioblastoma 24418124 MicroRNA-16 inhibits glioma cell growth and invasion through suppression of BCL2 and the nuclear factor-¦ÊB1/MMP9 signaling pathway. +other hsa-mir-337 Gastric Neoplasms 24422944 "These findings indicate that hsa-miR-337-3p plays a role in the reduction of gastric cancer cell invasion capacity, and further studies on the mechanism of hsa-miR-337-3p in gastric cancer metastasis are warranted." +other hsa-mir-107 Childhood Obesity 24423308 "Childhood obesity is associated with changes in immune cell frequency, inflammatory environment, and regulation of metabolic gene expression.These changes have been causally linked to the onset of metabolic disease in adulthood and suggest the future trajectory of obese children to the development of type 2 diabetes mellitus and premature cardiovascular disease." +other hsa-mir-33 Childhood Obesity 24423308 "Childhood obesity is associated with changes in immune cell frequency, inflammatory environment, and regulation of metabolic gene expression.These changes have been causally linked to the onset of metabolic disease in adulthood and suggest the future trajectory of obese children to the development of type 2 diabetes mellitus and premature cardiovascular disease." +other hsa-mir-20a Alzheimer Disease 24423585 "The results of microarray analysis showed that miR-329, miR-193b, miR-20a, miR-296, and miR-130b were all upregulated in H2O2-induced primary hippocampal neurons and different strains of senescence accelerated mice." +other hsa-mir-29b Uterine Leiomyoma 24424054 Down-regulation of miR-29b is essential for pathogenesis of uterine leiomyoma. +other hsa-mir-141 "Squamous Cell Carcinoma, Head and Neck" 24424572 Role of miR-200c/miR-141 in the regulation of epithelial-mesenchymal transition and migration in head and neck squamous cell carcinoma. +other hsa-mir-200c "Squamous Cell Carcinoma, Head and Neck" 24424572 Role of miR-200c/miR-141 in the regulation of epithelial-mesenchymal transition and migration in head and neck squamous cell carcinoma. +other hsa-mir-146a "Carcinoma, Nasopharyngeal" 24430575 Association of miR-146a gene polymorphism with risk of nasopharyngeal carcinoma in the central-southern Chinese population. +other hsa-mir-93 Inflammation 24433094 Expression of microRNA-93 and Interleukin-8 during Pseudomonas aeruginosa-mediated induction of proinflammatory responses. +other hsa-mir-215 Hepatitis B Virus Infection 24434140 Hepatitis B virus X protein mutant HBx¦¤127 promotes proliferation of hepatoma cells through up-regulating miR-215 targeting PTPRT. +other hsa-mir-125b Human Immunodeficiency Virus Infection 24434277 Methamphetamine inhibits HIV-1 replication in CD4+ T cells by modulating anti-HIV-1 miRNA expression. +other hsa-mir-150 Human Immunodeficiency Virus Infection 24434277 Methamphetamine inhibits HIV-1 replication in CD4+ T cells by modulating anti-HIV-1 miRNA expression. +other hsa-mir-28 Human Immunodeficiency Virus Infection 24434277 Methamphetamine inhibits HIV-1 replication in CD4+ T cells by modulating anti-HIV-1 miRNA expression. +other hsa-mir-21 Gastric Neoplasms 24434352 the effect of celastrol on apoptosis was due to miR-21 inhibiting the PI3K/Akt-dependent NF-¦ÊB pathway. +other hsa-mir-205 Lung Neoplasms 24434435 We have demonstrated for the first time a new molecular pathway that connects TMPRSS4 and integrin ¦Á5 through miR-205 to regulate cancer cell invasion and metastasis. +other hsa-mir-34a Cardiovascular Diseases [unspecific] 24438466 MicroRNA-34a: role in cancer and cardiovascular disease. +other hsa-mir-34a Neoplasms [unspecific] 24438466 MicroRNA-34a: role in cancer and cardiovascular disease. +other hsa-mir-342 Alzheimer Disease 24440716 miR-342-5p decreases ankyrin G levels in Alzheimer's disease transgenic mouse models. +other hsa-mir-146a Meningitis 24442429 Induction of endotoxin tolerance by pathogenic Neisseria is correlated with the inflammatory potential of lipooligosaccharides and regulated by microRNA-146a. +other hsa-mir-106a Pancreatic Neoplasms 24444603 Upregulated miR-106a plays an oncogenic role in pancreatic cancer. +other hsa-mir-34a "Carcinoma, Lung, Non-Small-Cell" 24444609 Restoration of p53/miR-34a regulatory axis decreases survival advantage and ensures Bax-dependent apoptosis of non-small cell lung carcinoma cells. +other hsa-mir-200 Ovarian Neoplasms 24447705 Sequence variation among members of the miR-200 microRNA family is correlated with variation in the ability to induce hallmarks of mesenchymal-epithelial transition in ovarian cancer cells. +other hsa-mir-21 Cardiovascular Diseases [unspecific] 24447911 "Ang II induced miR-21 expression in primary mouse cardiac fibroblasts (CFs) via ERK-dependent AP-1 and STAT3 activation, and while a miR-21 inhibitor reversed Ang II-induced RECK suppression, a miR-21 mimic inhibited both RECK expression and Ang II-induced CF migration." +other hsa-mir-30c Prostate Neoplasms 24452717 MicroRNA-30c serves as an independent biochemical recurrence predictor and potential tumor suppressor for prostate cancer. +other hsa-mir-21 "Carcinoma, Lung, Non-Small-Cell" 24452750 Expression of microRNA-21 in non-small cell lung cancer tissue increases with disease progression and is likely caused by growth conditional changes during malignant transformation. +other hsa-mir-147 Neoplasms [unspecific] 24454732 MicroRNA-147 induces a mesenchymal-to-epithelial transition (MET) and reverses EGFR inhibitor resistance. +other hsa-let-7 Osteosarcoma 24457375 the involvement of let-7 family miRNA in regulation of the cell proliferation as well as epithelial-mesenchymal transition of OS. +other hsa-mir-888 Prostate Neoplasms 24457835 miR-888 is an expressed prostatic secretions-derived microRNA that promotes prostate cell growth and migration. +other hsa-mir-10b Breast Neoplasms 24457988 Critical role of miR-10b in transforming growth factor-¦Â1-induced epithelial-mesenchymal transition in breast cancer. +other hsa-mir-520d "Carcinoma, Hepatocellular" 24458129 Hsa-miR-520d induces hepatoma cells to form normal liver tissues via a stemness-mediated process. +other hsa-mir-150 Atrial Fibrillation 24462065 Relation of reduced expression of MiR-150 in platelets to atrial fibrillation in patients with chronic systolic heart failure. +other hsa-mir-150 Heart Failure 24462065 Relation of reduced expression of MiR-150 in platelets to atrial fibrillation in patients with chronic systolic heart failure. +other hsa-mir-133a Colorectal Carcinoma 24464560 "DSS-induced chronic inflammation downregulates miR-133a and miR-143/145, which is reportedly associated with human colorectal cancer and PI3K/Akt activation." +other hsa-mir-300 Glioma 24464870 mir-300 promotes self-renewal and inhibits the differentiation of glioma stem-like cells. +other hsa-mir-206 Heart Failure 24465270 Provide a complex overview of microRNA-206. +other hsa-mir-137 Glioblastoma 24465609 Genomic analyses reveal broad impact of miR-137 on genes associated with malignant transformation and neuronal differentiation in glioblastoma cells. +other hsa-mir-26a Ovarian Neoplasms 24466274 MiR-26a promotes ovarian cancer proliferation and tumorigenesis. +other hsa-mir-21 IgA Nephropathy 24468088 Inhibition of miRNA-21 prevents fibrogenic activation in podocytes and tubular cells in IgA nephropathy. +other hsa-mir-1 Arrhythmia 24468403 Down-regulation of miR-1 could relieve arrhythmogenesis by the anti-miR-1 antisense oligonucleotides (AMO-1). +other hsa-mir-200c Lung Neoplasms 24468793 "Recent studies suggest that epithelial-mesenchymal transition (EMT) is the most important contributor to cancer metastasis. Induction of this complex process requires endogenously produced microRNAs; specifically, downregulation of the miRNA-200c causes an induction of EMT." +other hsa-mir-155 Cardiovascular Diseases [unspecific] 24475727 The role of miRNA-155 in cardiovascular diseases +other hsa-mir-182 Uterine Leiomyoma 24476133 "We observed that administration of MK-2206, an allosteric AKT inhibitor, increased levels of reactive oxygen species, up-regulated the microRNA miR-182 and several senescence-associated genes (including p16, p53, p21, and β-galactosidase), and drove leiomyoma cells into stress-induced premature senescence (SIPS)." +other hsa-mir-27a Pancreatic Neoplasms 24479798 Our findings demonstrated that genistein plays a tumor suppressor role in part through inhibition of miR-27a in pancreatic cancer cells. +other hsa-mir-92a Lipid Metabolism Disorder 24481837 MiR-92a: at the heart of lipid-driven endothelial dysfunction. +other hsa-mir-128 "Carcinoma, Breast, Triple Negative" 24485087 "This study provides evidence of posttranscriptional downregulation of Smurf2 in triple-negative breast cancers, and demonstrates that the loss of RB function is involved in microRNA-mediated interference with Smurf2 translation.The new link from RB inactivation to Smurf2 downregulation is likely to play a role in malignant phenotypes of triple-negative breast cancer cells." +other hsa-mir-15a "Carcinoma, Breast, Triple Negative" 24485087 "This study provides evidence of posttranscriptional downregulation of Smurf2 in triple-negative breast cancers, and demonstrates that the loss of RB function is involved in microRNA-mediated interference with Smurf2 translation.The new link from RB inactivation to Smurf2 downregulation is likely to play a role in malignant phenotypes of triple-negative breast cancer cells." +other hsa-mir-15b "Carcinoma, Breast, Triple Negative" 24485087 "This study provides evidence of posttranscriptional downregulation of Smurf2 in triple-negative breast cancers, and demonstrates that the loss of RB function is involved in microRNA-mediated interference with Smurf2 translation.The new link from RB inactivation to Smurf2 downregulation is likely to play a role in malignant phenotypes of triple-negative breast cancer cells." +other hsa-mir-16 "Carcinoma, Breast, Triple Negative" 24485087 "This study provides evidence of posttranscriptional downregulation of Smurf2 in triple-negative breast cancers, and demonstrates that the loss of RB function is involved in microRNA-mediated interference with Smurf2 translation.The new link from RB inactivation to Smurf2 downregulation is likely to play a role in malignant phenotypes of triple-negative breast cancer cells." +other hsa-mir-138 Cardiovascular Diseases [unspecific] 24486907 Induction of microRNA-138 by pro-inflammatory cytokines causes endothelial cell dysfunction. +other hsa-mir-21 Breast Neoplasms 24488617 The difference in miR-21 expression levels between invasive and non-invasive breast cancers emphasizes its role in breast cancer invasion. +other hsa-mir-1228 Neoplasms [unspecific] 24488924 Human miR-1228 as a stable endogenous control for the quantification of circulating microRNAs in cancer patients. +other hsa-mir-146b Breast Neoplasms 24498150 Unraveling the hidden heterogeneities of breast cancer based on functional miRNA cluster. +other hsa-mir-10b Neoplasms [unspecific] 24503738 Two-dimensional combinatorial screening enables the bottom-up design of a microRNA-10b inhibitor. +other hsa-mir-23b Glioma 24503899 A lentivirus-mediated miR-23b sponge diminishes the malignant phenotype of glioma cells in vitro and in vivo. +other hsa-let-7 Lung Neoplasms 24505620 Mechanistic links between COPD and lung cancer: a role of microRNA let-7 +other hsa-mir-423 Heart Failure 24506564 The difference in transcoronary gradients between HF outpatients and controls suggests that miR-423-5p has a cardiac origin. The positive correlation between miR-423-5p and BNP transcoronary gradients supports this hypothesis. +other hsa-mir-21 Neoplasms [unspecific] 24507038 "Our results demonstrated that HIF-1α could significantly upregulate α-smooth muscle actin expression, and reduced the E-cadherin expression in HK-2 cells during I/R injury. Moreover, miR-21 expression had a positive correlation with HIF-1α in this process." +other hsa-mir-145 Myelodysplastic Syndromes 24507813 "Other genes, as well as miR-145 and miR-146a, contribute to aberrant megakaryopoiesis and a selective advantage for the del(5q) clone." +other hsa-mir-192 Kidney Diseases [unspecific] 24508230 miR-192 induces G2/M growth arrest in aristolochic acid nephropathy. +other hsa-mir-429 Colorectal Carcinoma 24510588 "miR-200a, miR-200c, miR-141, and miR-429 expression levels may identify CRC patients, including those with stage II disease, who are most likely to benefit from adjuvant chemotherapy." +other hsa-mir-17 Feingold Syndrome 24511118 MicroRNA-17~92 is required for nephrogenesis and renal function. +other hsa-mir-18 Feingold Syndrome 24511118 MicroRNA-17~92 is required for nephrogenesis and renal function. +other hsa-mir-19a Feingold Syndrome 24511118 MicroRNA-17~92 is required for nephrogenesis and renal function. +other hsa-mir-19b-1 Feingold Syndrome 24511118 MicroRNA-17~92 is required for nephrogenesis and renal function. +other hsa-mir-20a Feingold Syndrome 24511118 MicroRNA-17~92 is required for nephrogenesis and renal function. +other hsa-mir-92-1 Feingold Syndrome 24511118 MicroRNA-17~92 is required for nephrogenesis and renal function. +other hsa-mir-335 "Carcinoma, Ovarian" 24515774 Our results indicate that miR-335 relates to the prognosis of patients with EOC and is a promising predictor of EOC recurrence. +other hsa-mir-155 Encephalitis 24516198 Critical role of microRNA-155 in herpes simplex encephalitis. miR-H2 +other hsa-mir-200 Breast Neoplasms 24518294 ¦Â1 integrin inhibition elicits a prometastatic switch through the TGF¦Â-miR-200-ZEB network in E-cadherin-positive triple-negative breast cancer. +other hsa-mir-92a Viral Infectious Disease 24518554 Reply to Shin and Bayry on An age-related decline of CD62L and vaccine response: a role of microRNA 92a. +other hsa-mir-203 "Squamous Cell Carcinoma, Esophageal" 24519530 Research on the typical miRNA and target genes in squamous cell carcinoma and adenocarcinoma of esophagus cancer with DNA microarray. +other hsa-mir-21 "Squamous Cell Carcinoma, Esophageal" 24519530 Research on the typical miRNA and target genes in squamous cell carcinoma and adenocarcinoma of esophagus cancer with DNA microarray. +other hsa-mir-155 Atopic Dermatitis 24521175 The presented concept offers a new option for the prevention of atopic diseases by the addition of physiological amounts of miR-155-enriched exosomes to infant formula for mothers incapable of breastfeeding. +other hsa-mir-200a Pancreatic Neoplasms 24521357 MiR-200a inhibits epithelial-mesenchymal transition of pancreatic cancer stem cell. +other hsa-mir-143 Osteosarcoma 24525123 Exosome-formed synthetic microRNA-143 is transferred to osteosarcoma cells and inhibits their migration. +other hsa-mir-155 Coronary Artery Disease 24525789 "miR-155 expression is associated inversely with complicated proatherogenic metabolic risk factors, and the severity of coronary stenotic lesions calculated by Gensini scores." +other hsa-mir-155 Lung Neoplasms 24528019 "As Hsa-miR-155 (miR-155) can be used as a diagnostic marker for non-small cell lung cancer (NSCLC), a smart molecular beacon of miR-155 was designed to image the expression of miR-155 in NSCLC cases." +other hsa-mir-150 Skin Disease [unspecific] 24530178 "miR-150 levels were significantly decreased in sera of scleroderma patients, and were inversely correlated with the prevalence of pitting scars/ulcers and the incidence of anti-topoisomerase I antibody." +other hsa-mir-140 "Carcinoma, Tounge" 24530397 Reciprocal effects between microRNA-140-5p and ADAM10 suppress migration and invasion of human tongue cancer cells. +other hsa-mir-95 "Carcinoma, Hepatocellular" 24530415 Role of microRNA-95 in the anticancer activity of Brucein D in hepatocellular carcinoma. +other hsa-mir-122 "Carcinoma, Hepatocellular" 24531873 Antitumor function of microRNA-122 against hepatocellular carcinoma. +other hsa-mir-34 Neoplasms [unspecific] 24532687 "Taken together, our results elucidated the intricate cross-talk between p53 and miR-34 miRNAs and revealed an important tumor suppressor effect generated by this positive feedback loop." +other hsa-mir-493 "Carcinoma, Colon" 24533778 MKK7 mediates miR-493-dependent suppression of liver metastasis of colon cancer cells. +other hsa-mir-132 Epilepsy 24553459 "miRNA represents a potentially important mechanism controlling protein levels in epilepsy. As such, miRNAs might be targeted to prevent or disrupt epilepsy as well as serve as diagnostic biomarkers of epileptogenesis." +other hsa-mir-146a Epilepsy 24553459 "miRNA represents a potentially important mechanism controlling protein levels in epilepsy. As such, miRNAs might be targeted to prevent or disrupt epilepsy as well as serve as diagnostic biomarkers of epileptogenesis." +other hsa-mir-23a Epilepsy 24553459 "miRNA represents a potentially important mechanism controlling protein levels in epilepsy. As such, miRNAs might be targeted to prevent or disrupt epilepsy as well as serve as diagnostic biomarkers of epileptogenesis." +other hsa-mir-34a Epilepsy 24553459 "miRNA represents a potentially important mechanism controlling protein levels in epilepsy. As such, miRNAs might be targeted to prevent or disrupt epilepsy as well as serve as diagnostic biomarkers of epileptogenesis." +other hsa-mir-34b Pleural Mesothelioma 24553485 Preclinical evaluation of microRNA-34b/c delivery for malignant pleural mesothelioma. +other hsa-mir-34c Pleural Mesothelioma 24553485 Preclinical evaluation of microRNA-34b/c delivery for malignant pleural mesothelioma. +other hsa-mir-137 Schizophrenia 24556472 Transcriptional consequences of schizophrenia candidate miR-137 manipulation in human neural progenitor cells. +other hsa-mir-548 Neoplasms [unspecific] 24556720 Identification of a tumor-suppressive human-specific microRNA within the FHIT tumor-suppressor gene. +other hsa-mir-124 Diabetic Nephropathy 24556741 These results provide a novel idea that curcumin prevents against podocytic adhesive capacity damage under mechanical stress by inhibitting miR-124 +other hsa-mir-146a Enterovirus Infection 24561744 Inhibition of miR-146a prevents enterovirus-induced death by restoring the production of type I interferon. +other hsa-mir-21 Atherosclerosis 24562307 "In ox-LDL treated VECs, transfection with a miR-21 mimic significantly increased miR-21 expression and inhibited PTEN expression, and attenuated the protective effects of paeonol pretreatment, whereas transfection with an miR-21 inhibitor significantly decreased miR-21 expression and increased PTEN expression, thus enhanced the protective effects of paeonol pretreatment." +other hsa-mir-137 Schizophrenia 24566148 miR-137: a new player in schizophrenia. +other hsa-mir-7 Gastric Neoplasms 24573489 miR-7 inhibits the invasion and metastasis of gastric cancer cells by suppressing epidermal growth factor receptor expression. +other hsa-mir-29 Neoplasms [unspecific] 24573597 Our review highlights the diverse relationship between miR-29 and cancer (particularly digestive system neoplasms). +other hsa-mir-21 Kidney Diseases [unspecific] 24576069 This review was performed to sum up the role of miR-21 and its signaling pathways in renal diseases. +other hsa-mir-146a Colorectal Carcinoma 24576899 A microRNA-operated switch of asymmetric-to-symmetric cancer stem cell divisions. +other hsa-mir-101 "Lymphoma, Burkitt" 24577510 "Histone deacetylase inhibitor prevents cell growth in Burkitt's lymphoma by regulating PI3K/Akt pathways and leads to upregulation of miR-143, miR-145, and miR-101." +other hsa-mir-143 "Lymphoma, Burkitt" 24577510 "Histone deacetylase inhibitor prevents cell growth in Burkitt's lymphoma by regulating PI3K/Akt pathways and leads to upregulation of miR-143, miR-145, and miR-101." +other hsa-mir-145 "Lymphoma, Burkitt" 24577510 "Histone deacetylase inhibitor prevents cell growth in Burkitt's lymphoma by regulating PI3K/Akt pathways and leads to upregulation of miR-143, miR-145, and miR-101." +other hsa-mir-146a Toxoplasma gondii Infection 24582962 miR-146a and miR-155 delineate a MicroRNA fingerprint associated with Toxoplasma persistence in the host brain. +other hsa-mir-155 Toxoplasma gondii Infection 24582962 miR-146a and miR-155 delineate a MicroRNA fingerprint associated with Toxoplasma persistence in the host brain. +other hsa-mir-17 Toxoplasma gondii Infection 24583285 "Taken together, we describe a novel STAT3-miR-17-92-Bim pathway, thus providing a mechanistic explanation for inhibition of apoptosis of host cells following Toxoplasma infection." +other hsa-mir-34a Neoplasms [unspecific] 24583844 miR-34a/SIRT6 in squamous differentiation and cancer. +other hsa-mir-183 Lung Neoplasms 24586048 TGF-¦Â-inducible microRNA-183 silences tumor-associated natural killer cells. +other hsa-mir-376a Viral Infectious Disease 24586166 MicroRNA editing facilitates immune elimination of HCMV infected cells. +other hsa-mir-210 Neoplasms [unspecific] 24586608 "This systematic review and meta-analysis suggests that miR-210 has a predictive effect on survival of patients with studied cancer types as indexed by disease-free survival, progression-free survival and relapse-free survival. While the predictive effect on overall survival, breast cancer overall survival, breast cancer disease-free survival, sarcoma overall survival and renal cancer overall survival was not statistically significant." +other hsa-mir-190b "Carcinoma, Hepatocellular" 24586785 Increased expression of miR-190 may cause decreased IGF-1 in HCC development. Insulin resistance appears to be a part of the physiopathologic significance of decreased IGF-1 levels in HCC progression. This study provides a novel miRNA-mediated regulatory mechanism for controlling IGF-1 expression in HCC and elucidates the biological relevance of this interaction in HCC. +other hsa-mir-34a Multiple Myeloma 24587182 In vivo activity of miR-34a mimics delivered by stable nucleic acid lipid particles (SNALPs) against multiple myeloma. +other hsa-mir-145 "Carcinoma, Endometrial" 24589415 Linc-RoR is a ceRNA and acts as a miR-145 sponge to inhibit mediation of the differentiation of ETs by miR-145. These results suggest that linc-RoR has an important role during endometrial carcinogenesis. +other hsa-mir-155 Hepatitis C Virus Infection 24591085 MicroRNA-155 and microRNA-196b: promising biomarkers in hepatitis C virus infection +other hsa-mir-196b Hepatitis C Virus Infection 24591085 MicroRNA-155 and microRNA-196b: promising biomarkers in hepatitis C virus infection +other hsa-mir-210 Breast Neoplasms 24591754 "Our studies suggested that microRNA-210 could predict the outcome of patients with varieties of tumors, especially in breast cancers." +other hsa-mir-499 Neoplasms [unspecific] 24593893 These results suggest that miR-499 delivered by the present system has excellent potency to treat cancer via integrative anticancer actions. +other hsa-mir-34a "Carcinoma, Lung, Non-Small-Cell" 24595209 The microRNA miR-34a inhibits non-small cell lung cancer (NSCLC) growth and the CD44hi stem-like NSCLC cells. +other hsa-mir-10 "Leukemia, Myeloid, Acute" 24596420 Implications of the miR-10 family in chemotherapy response of NPM1-mutated AML. +other hsa-mir-210 Chronic Hepatitis B 24597695 Studying the association of microRNA-210 level with chronic hepatitis B progression. +other hsa-mir-107 Kidney Diseases [unspecific] 24597825 This review was performed to sum up the role of miR-107 and its signaling pathways in renal diseases. +other hsa-mir-126 Multiple Sclerosis 24598267 "Our findings provided deeper insight into the mode of action of natalizumab, with possible implications for understanding both the effects of natalizumab on MS activity and its specific adverse event profile." +other hsa-mir-155 Sepsis 24598292 "The result of this study suggest that miR-155 is involved in the cell proliferation regulation of CD4(+)CD25(+) Treg cells, and play some role in the immunological dissonance in sepsis." +other hsa-mir-17 Neoplasms [unspecific] 24598644 Effect of microRNA-17-92 cluster on the biological characteristics of K562 cells and its mechanisms. +other hsa-mir-200 Viral Infectious Disease 24599990 Host microRNA regulation of human cytomegalovirus immediate early protein translation promotes viral latency. +other hsa-mir-16 Pancreatic Neoplasms 24600978 The combination of miR-16 and CA19-9 detections boosted the diagnostic performance in pancreatic cancer detection. +other hsa-mir-7 Glioblastoma 24603851 miR-7 inhibits glioblastoma growth by simultaneously interfering with the PI3K/ATK and Raf/MEK/ERK pathways. +other hsa-mir-155 Neuroinflammation 24604078 MicroRNA-155 negatively affects blood-brain barrier function during neuroinflammation. +other hsa-mir-208 Pancreatic Neoplasms 24604208 miR-208-induced epithelial to mesenchymal transition of pancreatic cancer cells promotes cell metastasis and invasion. +other hsa-mir-494 Gastric Neoplasms 24606447 Cinobufacin suppresses cell proliferation via miR-494 in BGC- 823 gastric cancer cells. +other hsa-mir-21 Retinoblastoma 24607444 Seed-targeting anti-miR-21 inhibiting malignant progression of retinoblastoma and analysis of their phosphorylation signaling pathways. +other hsa-mir-146a Inflammation 24607549 "In conclusion several aging-related mitomiRs may play a direct role in controlling mitochondrial function by regulating mitochondrial protein expression. Their modulation could thus mediate the loss of mitochondrial integrity and function in aging cells, inducing or contributing to the inflammatory response and to age-related diseases." +other hsa-mir-34a Inflammation 24607549 "In conclusion several aging-related mitomiRs may play a direct role in controlling mitochondrial function by regulating mitochondrial protein expression. Their modulation could thus mediate the loss of mitochondrial integrity and function in aging cells, inducing or contributing to the inflammatory response and to age-related diseases." +other hsa-mir-199a Kidney Neoplasms 24609899 miR-199a-3p inhibits hepatocyte growth factor/c-Met signaling in renal cancer carcinoma. +other hsa-mir-133b Prostate Neoplasms 24610824 "miR-133b might enhance tumor-promoting properties in less aggressive LNCaP cells, whereas this miR may act as a tumor suppressor in more aggressive PC-3 cells. miR-133b and RB1CC1 were independent prognostic indicators for prostate cancer." +other hsa-mir-214 Gastric Neoplasms 24614175 Clinicopathological significance of microRNA-214 in gastric cancer and its effect on cell biological behaviour. +other hsa-mir-27b "Carcinoma, Hepatocellular" 24614526 Fumonisin B modulates expression of human cytochrome P450 1b1 in human hepatoma (Hepg2) cells by repressing Mir-27b. +other hsa-mir-182 Colorectal Adenocarcinoma 24615484 The increased levels of the oncogene-like miR-182 increase the risk for disease progression and predict poor overall survival for colorectal adenocarcinoma patients. +other hsa-mir-214 Colorectal Carcinoma 24616020 Identification of microRNA-214 as a negative regulator of colorectal cancer liver metastasis by way of regulation of fibroblast growth factor receptor 1 expression. +other hsa-mir-648 Prostate Neoplasms 24618011 Our analysis revealed the scale-free features of the human miRNA-mRNA interaction network and showed the distinctive topological features of existing cancer miRNA biomarkers from previously published studies. A novel cancer miRNA biomarker prediction framework was designed based on these observations and applied to prostate cancer study. This method could be applied for miRNA biomarker prediction in other cancers. +other hsa-mir-150 "Lymphoma, T-Cell, Cutaneous" 24627548 "In this issue of Blood, Ito et al demonstrate pathogenic implications of microRNA-150 (miR-150) repression in an aggressive form of cutaneous T-cell lymphoma (CTCL)." +other hsa-mir-424 Psoriatic Arthritis 24628460 miR-424 levels in hair shaft are increased in psoriatic patients. +other hsa-mir-15a "Leukemia, Myeloid, Chronic" 24629639 "We found that dasatinib (DAS) modulated miR-let-7d, miR-let-7e, miR-15a, miR-16, miR-21, miR-130a and miR-142-3p expressions while IM modulated miR-15a and miR-130a levels. miR-16, miR-130a and miR-145 expressions were modulated by nilotinib (NIL)." +other hsa-mir-145 "Carcinoma, Hepatocellular" 24630966 MicroRNA-145: a promising biomarker for hepatocellular carcinoma (HCC). +other hsa-mir-210 Colorectal Carcinoma 24632577 Hypoxia-inducible MiR-210 is an independent prognostic factor and contributes to metastasis in colorectal cancer. +other hsa-mir-148b Colorectal Carcinoma 24632606 Altered p53 regulation of miR-148b and p55PIK contributes to tumor progression in colorectal cancer. +other hsa-mir-18a "Carcinoma, Breast" 24633304 Our findings identify a mechanically regulated microRNA circuit that can promote malignancy and suggest potential prognostic roles for HOXA9 and miR-18a levels in stratifying patients with luminal breast cancers. +other hsa-mir-150 Lymphoma 24633319 The previously reported up-regulation of miR-150 in marginal zone lymphoma of MALT type was verified in an independent cohort of lymphoma samples employing a modified methodology. This further substantiates the role of miR-150 as a potential oncomiR in MALT lymphoma. +other hsa-mir-150 Early-Stage Small-Cell Lung Carcinoma 24637927 A microRNA signature predicts survival in early stage small-cell lung cancer treated with surgery and adjuvant chemotherapy. +other hsa-mir-886 Early-Stage Small-Cell Lung Carcinoma 24637927 A microRNA signature predicts survival in early stage small-cell lung cancer treated with surgery and adjuvant chemotherapy. +other hsa-mir-29 Crohn Disease 24641356 In Crohn's disease fibrosis-reduced expression of the miR-29 family enhances collagen expression in intestinal fibroblasts. +other hsa-mir-144 Cardiovascular Diseases [unspecific] 24642088 7-Ketocholesterol inhibits isocitrate dehydrogenase 2 expression and impairs endothelial function via microRNA-144. +other hsa-let-7a Ovarian Neoplasms 24643702 "E(2) + P4 significantly inhibited the cell survival, promoted the cell apoptosis, induced the expression of let-7a and miR-34b, and reduced the expression of Bcl-2 in ovarian cancer cells." +other hsa-mir-34b Ovarian Neoplasms 24643702 "E(2) + P4 significantly inhibited the cell survival, promoted the cell apoptosis, induced the expression of let-7a and miR-34b, and reduced the expression of Bcl-2 in ovarian cancer cells." +other hsa-mir-106 Gastric Neoplasms 24643999 "Genetic association of gastric cancer with miRNA clusters including the cancer-related genes MIR29, MIR25, MIR93 and MIR106: results from the EPIC-EURGAST study." +other hsa-mir-25 Gastric Neoplasms 24643999 "Genetic association of gastric cancer with miRNA clusters including the cancer-related genes MIR29, MIR25, MIR93 and MIR106: results from the EPIC-EURGAST study." +other hsa-mir-29 Gastric Neoplasms 24643999 "Genetic association of gastric cancer with miRNA clusters including the cancer-related genes MIR29, MIR25, MIR93 and MIR106: results from the EPIC-EURGAST study." +other hsa-mir-93 Gastric Neoplasms 24643999 "Genetic association of gastric cancer with miRNA clusters including the cancer-related genes MIR29, MIR25, MIR93 and MIR106: results from the EPIC-EURGAST study." +other hsa-mir-200c Prostate Neoplasms 24646496 Words of wisdom: Re: TMPRSS2-ERG gene fusions induce prostate tumorigenesis by modulating microRNA miR-200c. +other hsa-mir-141 "Carcinoma, Renal Cell" 24647573 miR-141 serves as a potential biomarker for discriminating ccRCC from normal tissues and a crucial suppressor of ccRCC cell proliferation and metastasis by modulating the EphA2/p-FAK/p-AKT/MMPs signaling cascade. +other hsa-mir-200c Liver Neoplasms 24647918 Synergistic antitumor activity of resveratrol and miR-200c in human lung cancer. +other hsa-mir-452 Breast Neoplasms 24648265 MicroRNA-452 contributes to the docetaxel resistance of breast cancer cells. +other hsa-let-7a "Lymphoma, Non-Hodgkin" 24648290 "Accordingly, c-Myc-targeting microRNAs let-7a and miR-26a were induced in all treated lymphomas and the cap-dependent translation machinery components 4E-BP1, eIF4E and eIF4G, as well as their upstream regulators, Akt and PIM kinases, were inhibited in function of the cell sensitivity to ITF2357, and, in turn, c-Myc downregulation." +other hsa-mir-26a "Lymphoma, Non-Hodgkin" 24648290 "Accordingly, c-Myc-targeting microRNAs let-7a and miR-26a were induced in all treated lymphomas and the cap-dependent translation machinery components 4E-BP1, eIF4E and eIF4G, as well as their upstream regulators, Akt and PIM kinases, were inhibited in function of the cell sensitivity to ITF2357, and, in turn, c-Myc downregulation." +other hsa-mir-378a Neoplasms [unspecific] 24651706 A screen identifies the oncogenic micro-RNA miR-378a-5p as a negative regulator of oncogene-induced senescence. +other hsa-mir-223 Cardiovascular Diseases [unspecific] 24657505 miR-223 is one of the growing number of RNA biomarkers of various human metabolic diseases and is thus of special interest to both researchers and clinicians in the cardiovascular field. +other hsa-mir-132 Toxoplasma gondii Infection 24657774 MicroRNA-132 dysregulation in Toxoplasma gondii infection has implications for dopamine signaling pathway. +other hsa-mir-145 Neoplasms [unspecific] 24657914 miR-145 and its influence on tumor growth in systemic malignancies. +other hsa-mir-17 Breast Neoplasms 24658544 miR-17/20 sensitization of breast cancer cells to chemotherapy-induced apoptosis requires Akt1. +other hsa-mir-20 Breast Neoplasms 24658544 miR-17/20 sensitization of breast cancer cells to chemotherapy-induced apoptosis requires Akt1. +other hsa-let-7i Breast Neoplasms 24662829 "In breast cancer patients, significantly decreased let-7i levels were associated with missense mutations in p53." +other hsa-mir-122 Chronic Hepatitis C 24672032 Reduction of microRNA 122 expression in IFNL3 CT/TT carriers and during progression of fibrosis in patients with chronic hepatitis C. +other hsa-mir-221 Gastrointestinal Stromal Tumor 24674454 Multiple sporadic gastrointestinal stromal tumors concomitant with ampullary adenocarcinoma: a case report with KIT and PDGFRA mutational analysis and miR-221/222 expression profile. +other hsa-mir-222 Gastrointestinal Stromal Tumor 24674454 Multiple sporadic gastrointestinal stromal tumors concomitant with ampullary adenocarcinoma: a case report with KIT and PDGFRA mutational analysis and miR-221/222 expression profile. +other hsa-mir-940 Neoplasms [unspecific] 24675421 Retaining MKP1 expression and attenuating JNK-mediated apoptosis by RIP1 for cisplatin resistance through miR-940 inhibition. +other hsa-mir-21 Ischemia-Reperfusion Injury 24676391 microRNA-21 protects against ischemia-reperfusion and hypoxia-reperfusion-induced cardiocyte apoptosis via the phosphatase and tensin homolog/Akt-dependent mechanism. +other hsa-mir-21 "Squamous Cell Carcinoma, Oral" 24676554 STAT3 inhibitor WP1066 attenuates miRNA-21 to suppress human oral squamous cell carcinoma growth in vitro and in vivo. +other hsa-mir-24 Hyperlipidemia 24677249 Inhibition of microRNA-24 expression in liver prevents hepatic lipid accumulation and hyperlipidemia. +other hsa-mir-130a Fatty Liver [unspecific] 24677715 A novel function of microRNA 130a-3p in hepatic insulin sensitivity and liver steatosis. +other hsa-mir-203 "Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal" 24682952 MiR-203 is downregulated in laryngeal squamous cell carcinoma and can suppress proliferation and induce apoptosis of tumours. +other hsa-mir-155 Neoplasms [unspecific] 24687397 "In HepG2 cells, exogenous NO increases miR-155 expression, but endogenous basal NO inhibits it. Both effects are mediated via cGMP/PKG signaling. The upregulation of miR-155 by NO provides a new link between NO, inflammation, and cancer." +other hsa-mir-122 "Carcinoma, Hepatocellular, HCV-Related" 24690114 Regulation of gene expression by microRNA in HCV infection and HCV-mediated hepatocellular carcinoma. +other hsa-mir-194 "Adenocarcinoma, Colon" 24691499 miR-194 as a predictor for adenoma recurrence in patients with advanced colorectal adenoma after polypectomy. +other hsa-mir-138 Lung Neoplasms 24691972 Up-regulation of microRNA-138 induce radiosensitization in lung cancer cells. +other hsa-mir-203 "Squamous Cell Carcinoma, Esophageal" 24692008 MicroRNA-203 inhibits the progression of esophageal squamous cell carcinoma with restored epithelial tissue architecture in vivo. +other hsa-mir-101 "Carcinoma, Hepatocellular, HBV-Related" 24697700 Functional analysis of miR-101-3p and Rap1b involved in hepatitis B virus-related hepatocellular carcinoma pathogenesis. +other hsa-let-7 Neoplasms [unspecific] 24703842 We conclude that IMP3 RNPs may function as cytoplasmic safe houses and prevent miRNA-directed mRNA decay of oncogenes during tumor progression. +other hsa-mir-612 Liver Neoplasms 24704424 MiR-612 suppresses the stemness of liver cancer via Wnt/¦Â-catenin signaling. +other hsa-mir-302 Neoplasms [unspecific] 24705778 "In conclusion, the controversial role of miR-302-367 in different cell types may provide better understanding for its role in stemness level and its antitumorigenicity potential in different contexts." +other hsa-mir-218 Gastrointestinal Stromal Tumor 24706111 microRNA-218 increase the sensitivity of gastrointestinal stromal tumor to imatinib through PI3K/AKT pathway. +other hsa-mir-7 Breast Neoplasms 24707474 Trichostatin A suppresses EGFR expression through induction of microRNA-7 in an HDAC-independent manner in lapatinib-treated cells. +other hsa-mir-155 "Leukemia, Myeloid, Acute" 24708856 "This study provides evidence for an anti-leukaemic role for miR-155 in human FLT3-wildtype AML, by inducing cell apoptosis and myelomonocytic differentiation, which is in contrast to its previously hypothesized role as an oncogene. This highlights the complexity of gene regulation by microRNAs that may have tumour repressor or oncogenic effects depending on disease context or tissue type." +other hsa-mir-375 Neoplasms [unspecific] 24708873 "Taken together, miR-375-mediated suppression of multiple oncogenic components in HPV-associated carcinogenesis generates a cumulative biological response to rescue key tumor suppressors and diminish telomerase activity, which results in cell cycle arrest and cell proliferation inhibition." +other hsa-mir-208b Heart Failure 24714087 "These results demonstrated that circulating miR-208b and miR-34a could be useful biomarkers for predicting left ventricular remodeling after AMI, and the miRNA levels are associated with increased risk of mortality or heart failure." +other hsa-mir-34a Heart Failure 24714087 "These results demonstrated that circulating miR-208b and miR-34a could be useful biomarkers for predicting left ventricular remodeling after AMI, and the miRNA levels are associated with increased risk of mortality or heart failure." +other hsa-mir-451 Glioma 24714982 Selective ¦Â2 adrenergic agonist increases Cx43 and miR-451 expression via cAMP-Epac. +other hsa-mir-22 "Carcinoma, Endometrial" 24715036 miR-22 inhibits proliferation and invasion in estrogen receptor ¦Á-positive endometrial endometrioid carcinomas cells. +other hsa-mir-210 "Carcinoma, Ovarian" 24715221 Hypoxia-induced miR-210 in epithelial ovarian cancer enhances cancer cell viability via promoting proliferation and inhibiting apoptosis. +other hsa-mir-130b Prostate Neoplasms 24715691 "In addition to downregulation of the large tumor suppressor homolog2 and the programmed cell death protein 4, a neoplastic transformation inhibitor, the tumorigenic reprogramming of pASCs was associated with trafficking by PC cell-derived exosomes of oncogenic factors, including H-ras and K-ras transcripts, oncomiRNAs miR-125b, miR-130b, and miR-155 as well as the Ras superfamily of GTPases Rab1a, Rab1b, and Rab11a." +other hsa-mir-155 Neoplasms [unspecific] 24716910 "MiR-421, miR-155 and miR-650: emerging trends of regulation of cancer and apoptosis." +other hsa-mir-421 Neoplasms [unspecific] 24716910 "MiR-421, miR-155 and miR-650: emerging trends of regulation of cancer and apoptosis." +other hsa-mir-650 Neoplasms [unspecific] 24716910 "MiR-421, miR-155 and miR-650: emerging trends of regulation of cancer and apoptosis." +other hsa-mir-375 Gastric Neoplasms 24718681 miR-375 inhibits Helicobacter pylori-induced gastric carcinogenesis by blocking JAK2-STAT3 signaling. +other hsa-mir-214 "Carcinoma, Hepatocellular" 24719559 "Addition of NCTD to treat RAW264.7 or TAMs enhanced M1 polarization through increase of miR-214 expression. NCTD significantly inhibited β-catenin expression, which could be reversed by miR-214 inhibitor." +other hsa-mir-210 "Leukemia, Lymphoblastic, Acute, Childhood" 24720529 Effect of microRNA-210 on prognosis and response to chemotherapeutic drugs in pediatric acute lymphoblastic leukemia. +other hsa-mir-122 Hepatitis C Virus Infection 24721497 Hepatitis C virus and human miR-122: insights from the bench to the clinic. +other hsa-mir-34a "Carcinoma, Skin" 24726431 Our results demonstrate that p53 mutations increase apoptotic resistance in keratinocytes by interfering with miR-34a-mediated regulation of SIRT1 expression. +other hsa-mir-223 Breast Neoplasms 24727437 Contact inhibition modulates intracellular levels of miR-223 in a p27kip1-dependent manner. +other hsa-mir-20a Neoplasms [unspecific] 24732804 "Decreased expression of miR-27a/miR-20a:miR-17-5p by PEITC-induced ROS is a key step in triggering the miR-ZBTB Sp cascade leading to downregulation of Sp TFs, and this is due to ROS-dependent epigenetic effects associated with genome-wide shifts in repressor complexes, resulting in decreased expression of Myc and the Myc-regulated miRs." +other hsa-mir-155 Selective IgE Deficiency Disease 24734904 miRNA-155 controls mast cell activation by regulating the PI3K¦Ã pathway and anaphylaxis in a mouse model. +other hsa-mir-135b "Carcinoma, Colon" 24735923 MicroRNA-135b promotes cancer progression by acting as a downstream effector of oncogenic pathways in colon cancer. +other hsa-mir-155 Recurrent Spontaneous Abortion 24739646 "The expression of miR-155 and HIF-1¦Á is topically stimulated by oxygen signal.HIF-1¦Á adjusts the transcription and translation of VEGF, which together involved in placental trophoblast invasion and placental angiogenesis.The low expression of miR-155 could interfere with expression of HIF-1¦Á and VEGF,which might be involved in villous vascular dysplasia in URSA." +other hsa-mir-133b Parkinson Disease 24742361 Orchestrated increase of dopamine and PARK mRNAs but not miR-133b in dopamine neurons in Parkinson's disease. +other hsa-mir-21 Cardiomegaly 24743143 "In particular, a passenger strand miR, miR-21*, was identified as a potent paracrine factor that induces cardiomyocyte hypertrophy when shuttled through exosomes." +other hsa-mir-21 Heart Failure 24743143 "In particular, a passenger strand miR, miR-21*, was identified as a potent paracrine factor that induces cardiomyocyte hypertrophy when shuttled through exosomes." +other hsa-mir-146a Graves Ophthalmopathy 24743332 Increased microRNA-155 and decreased microRNA-146a may promote ocular inflammation and proliferation in Graves' ophthalmopathy. +other hsa-mir-155 Graves Ophthalmopathy 24743332 Increased microRNA-155 and decreased microRNA-146a may promote ocular inflammation and proliferation in Graves' ophthalmopathy. +other hsa-mir-491 Glioblastoma 24747968 Two mature products of MIR-491 coordinate to suppress key cancer hallmarks in glioblastoma. +other hsa-mir-122 "Carcinoma, Hepatocellular, HBV-Related" 24748463 Association of miRNA-122-binding site polymorphism at the interleukin-1 ¦Á gene and its interaction with hepatitis B virus mutations with hepatocellular carcinoma risk. +other hsa-mir-122 Chronic Hepatitis C 24752012 HMOX1 and miR-122 play an important role in the pathogenesis of CHC in HCV mono-and HIV/HCV co-infected patients. Reduced expression of HMOX1 in patients with HIV/HCV co-infection may indicate a worse prognosis in this group. Our results do not support the importance of Bach-1 in repression of HMOX1 in patients with chronic hepatitis C. +other hsa-mir-200c Breast Neoplasms 24754877 Glabridin attenuates the migratory and invasive capacity of breast cancer cells by activating microRNA-200c. +other hsa-mir-23b Neoplasms [unspecific] 24755453 Regulation of miR-23b expression and its dual role on ROS production and tumour development. +other hsa-mir-101 "Carcinoma, Hepatocellular" 24759835 "In human HCC, COX-2 mRNA but not COX-2 protein levels are associated with expression levels of angiogenic factors. MiR-21 levels are not associated with angiogenic molecules. MiR-16 and miR-101 levels do not correlate with COX-2 mRNA and protein levels." +other hsa-mir-16 "Carcinoma, Hepatocellular" 24759835 "In human HCC, COX-2 mRNA but not COX-2 protein levels are associated with expression levels of angiogenic factors. MiR-21 levels are not associated with angiogenic molecules. MiR-16 and miR-101 levels do not correlate with COX-2 mRNA and protein levels." +other hsa-mir-21 "Carcinoma, Hepatocellular" 24759835 "In human HCC, COX-2 mRNA but not COX-2 protein levels are associated with expression levels of angiogenic factors. MiR-21 levels are not associated with angiogenic molecules. MiR-16 and miR-101 levels do not correlate with COX-2 mRNA and protein levels." +other hsa-mir-143 Osteosarcoma 24762226 Propofol inhibits proliferation and invasion of osteosarcoma cells by regulation of microRNA-143 expression. +other hsa-mir-29b "Carcinoma, Ovarian" 24767251 Involvement of miR-29b signaling in the sensitivity to chemotherapy in patients with ovarian carcinoma. +other hsa-mir-155 Atherosclerosis 24767942 We hypothesized that native LDL and oxidized LDL played a key role in modulating the effects of miR-155 on macrophages at different stages of atherosclerosis. +other hsa-mir-552 "Adenocarcinoma, Lung" 24778034 "MicroRNA profiles predict the histology of primary lung carcinomas,and differentiate between primary lung adenocarcinomas and colorectal cancer metastases." +other hsa-mir-552 Colorectal Carcinoma 24778034 "MicroRNA profiles predict the histology of primary lung carcinomas,and differentiate between primary lung adenocarcinomas and colorectal cancer metastases." +other hsa-mir-592 "Adenocarcinoma, Lung" 24778034 "MicroRNA profiles predict the histology of primary lung carcinomas,and differentiate between primary lung adenocarcinomas and colorectal cancer metastases." +other hsa-mir-592 Colorectal Carcinoma 24778034 "MicroRNA profiles predict the histology of primary lung carcinomas,and differentiate between primary lung adenocarcinomas and colorectal cancer metastases." +other hsa-mir-125b Rheumatoid Arthritis 24778468 Circulating miRNA-125b is a potential biomarker predicting response to rituximab in rheumatoid arthritis. +other hsa-mir-31 "Carcinoma, Endometrial" 24779718 MIR31 functions as an oncogene in endometrial cancer by repressing the Hippo pathway. MIR31 is a potential new molecular marker for predicting the risk of recurrence and prognosis of endometrial cancer. +other hsa-mir-21 Colorectal Carcinoma 24780321 Correlation of over-expressions of miR-21 and Notch-1 in human colorectal cancer with clinical stages. +other hsa-mir-223 Osteosarcoma 24784921 Prognostic value of microRNA-223/epithelial cell transforming sequence 2 signaling in patients with osteosarcoma. +other hsa-mir-224 Glioblastoma 24785373 MiR-224 expression increases radiation sensitivity of glioblastoma cells. +other hsa-mir-26a Lung Neoplasms 24788552 MicroRNA-26a involved in Toll-like receptor 9-mediated lung cancer growth and migration. +other hsa-mir-126 "Squamous Cell Carcinoma, Oral" 24789258 Suppressive effect of microRNA-126 on oral squamous cell carcinoma in vitro. +other hsa-mir-486 Muscular Dystrophy 24789910 MicroRNA-486-dependent modulation of DOCK3/PTEN/AKT signaling pathways improves muscular dystrophy-associated symptoms. +other hsa-let-7g "Carcinoma, Hepatocellular" 24791593 Let-7g microRNA sensitizes fluorouracil-resistant human hepatoma cells. +other hsa-mir-96 "Squamous Cell Carcinoma, Cerevial" 24791792 Expressions of MicroRNA-96 before and after chemotherapy and its relationship with chemosensitivity in cervical squamous cell carcinoma. +other hsa-mir-200c Lung Neoplasms 24791940 Therapeutic delivery of miR-200c enhances radiosensitivity in lung cancer. +other hsa-mir-10b "Carcinoma, Renal Cell, Clear-Cell" 24793999 The miR(21/10b) ratio as a prognostic marker in clear cell renal cell carcinoma. +other hsa-mir-21 "Carcinoma, Renal Cell, Clear-Cell" 24793999 The miR(21/10b) ratio as a prognostic marker in clear cell renal cell carcinoma. +other hsa-mir-126 Essential Hypertension 24794206 MicroRNA-9 and microRNA-126 expression levels in patients with essential hypertension: potential markers of target-organ damage. +other hsa-mir-9 Essential Hypertension 24794206 MicroRNA-9 and microRNA-126 expression levels in patients with essential hypertension: potential markers of target-organ damage. +other hsa-mir-224 Gastric Neoplasms 24796455 Effect of antisense miR-224 on gastric cancer cell proliferation and apoptosis. +other hsa-mir-34a "Carcinoma, Gastric" 24796666 The RNA-binding protein PCBP2 facilitates gastric carcinoma growth by targeting miR-34a. +other hsa-mir-29 "Carcinoma, Hepatocellular" 24798303 Modulation of miR-29 expression by ¦Á-fetoprotein is linked to the hepatocellular carcinoma epigenome. +other hsa-mir-24 "Carcinoma, Hepatocellular" 24800232 MicroRNA-24 modulates aflatoxin B1-related hepatocellular carcinoma prognosis and tumorigenesis. +other hsa-mir-34c Osteosarcoma 24802328 MiR-34c inhibits osteosarcoma metastasis and chemoresistance. +other hsa-mir-148a "Carcinoma, Hepatocellular" 24806207 The repressive effect of miR-148a on TGF beta-SMADs signal pathway is involved in the glabridin-induced inhibition of the cancer stem cells-like properties in hepatocellular carcinoma cells. +other hsa-mir-23a "Carcinoma, Breast" 24806942 Downregulation of SP1 and increased miR-23a levels in MSCs after contact with tumor cell medium as well as enhanced TGFβ1 expression were identified as potential molecular regulators of CXCL12 activity in MSCs. +other hsa-mir-133a Long QT Syndrome 24809446 MicroRNAs in cardiac arrhythmia: DNA sequence variation of MiR-1 and MiR-133A in long QT syndrome. +other hsa-mir-141 "Carcinoma, Renal Cell" 24810210 Honokiol suppresses renal cancer cells' metastasis via dual-blocking epithelial-mesenchymal transition and cancer stem cell properties through modulating miR-141/ZEB2 signaling. +other hsa-mir-199a "Carcinoma, Thyroid, Papillary" 24810336 miR-199a-3p displays tumor suppressor functions in papillary thyroid carcinoma. +other hsa-mir-200a "Diabetes Mellitus, Type 2" 24812635 "miR-448, let-7b, miR-540, miR-296, miR-880, miR-200a, miR-500, miR-10b, miR-336, miR-30d, miR-208, let-7e, miR-142-5p, miR-874, miR-375, miR-879, miR-501, and miR-188 were upregulated, while miR-301b, miR-134, and miR-652 were downregulated in TMH group." +other hsa-mir-375 "Diabetes Mellitus, Type 2" 24812635 "Through target gene analysis and real-time PCR verification, we found that these miRNAs, especially miR-375 and miR-30d, can stimulate insulin secretion in islet." +other hsa-mir-1915 Colon Neoplasms 24814047 Tumor suppressor p53 induces miR-1915 processing to inhibit Bcl-2 in the apoptotic response to DNA damage. +other hsa-mir-200 Osteosarcoma 24815002 Busulfan inhibits growth of human osteosarcoma through miR-200 family microRNAs in vitro and in vivo. +other hsa-mir-34 Osteoporosis 24815299 "miR-34 has also been implicated in various non-cancerous diseases, such as brain disorders, osteoporosis, and cardiovascular complications." +other hsa-mir-100 Atherosclerosis 24815336 The co-inertia approach in identification of specific microRNA in early and advanced atherosclerosis plaque. +other hsa-mir-127 Atherosclerosis 24815336 The co-inertia approach in identification of specific microRNA in early and advanced atherosclerosis plaque. +other hsa-mir-145 Atherosclerosis 24815336 The co-inertia approach in identification of specific microRNA in early and advanced atherosclerosis plaque. +other hsa-mir-146 Atherosclerosis 24815336 The co-inertia approach in identification of specific microRNA in early and advanced atherosclerosis plaque. +other hsa-mir-155 Atherosclerosis 24815336 The co-inertia approach in identification of specific microRNA in early and advanced atherosclerosis plaque. +other hsa-mir-221 Atherosclerosis 24815336 The co-inertia approach in identification of specific microRNA in early and advanced atherosclerosis plaque. +other hsa-mir-222 Atherosclerosis 24815336 The co-inertia approach in identification of specific microRNA in early and advanced atherosclerosis plaque. +other hsa-mir-24 Atherosclerosis 24815336 The co-inertia approach in identification of specific microRNA in early and advanced atherosclerosis plaque. +other hsa-mir-718 Ovarian Neoplasms 24815691 MiR-718 represses VEGF and inhibits ovarian cancer cell progression. +other hsa-mir-223 Rheumatoid Arthritis 24816316 Increased miR-223 expression in T cells from patients with rheumatoid arthritis leads to decreased insulin-like growth factor-1-mediated interleukin-10 production. +other hsa-mir-133a "Carcinoma, Lung, Non-Small-Cell" 24816813 MicroRNA-133a suppresses multiple oncogenic membrane receptors and cell invasion in non-small cell lung carcinoma. +other hsa-mir-125b Glioblastoma 24817689 MicroRNA expression signatures and their correlation with clinicopathological features in glioblastoma multiforme +other hsa-mir-125a Multiple Myeloma 24819167 A p53-dependent tumor suppressor network is induced by selective miR-125a-5p inhibition in multiple myeloma cells. +other hsa-mir-223 Colorectal Carcinoma 24819398 MicroRNA-223 functions as an oncogene in human colorectal cancer cells. +other hsa-mir-422a Osteoporosis 24820117 MiR-422a as a potential cellular microRNA biomarker for postmenopausal osteoporosis. +other hsa-mir-27 Urinary Bladder Cancer 24821854 3'-Biotin-tagged microRNA-27 does not associate with Argonaute proteins in cells. +other hsa-mir-31 Hepatitis B Virus Infection 24824126 HBsAg regulation of miR-31 expression in HepG2 cells +other hsa-mir-125a Hepatitis B Virus Infection 24824183 Functional interplay between hepatitis B virus X protein and human miR-125a in HBV infection. +other hsa-mir-27a Hepatitis C Virus Infection 24824429 MicroRNA-27a modulates HCV infection in differentiated hepatocyte-like cells from adipose tissue-derived mesenchymal stem cells. +other hsa-mir-22 "Leukemia, Lymphocytic, Chronic, B-Cell" 24825182 Activation of the PI3K/AKT pathway by microRNA-22 results in CLL B-cell proliferation. +other hsa-mir-142 Glioma 24825189 MicroRNA 142-3p attenuates spread of replicating retroviral vector in hematopoietic lineage-derived cells while maintaining an antiviral immune response. +other hsa-mir-320 "Diabetes Mellitus, Type 2" 24825548 Cardiomyocytes mediate anti-angiogenesis in type 2 diabetic rats through the exosomal transfer of miR-320 into endothelial cells. +other hsa-mir-124 "Colitis, Ulcerative" 24825593 attenuation of ischemic and inflammatory injury in cardiomyocytes. +other hsa-mir-21 Myocardial Ischemic-Reperfusion Injury 24825878 Na2S induces cardioprotective effects through miR-21-dependent attenuation of ischemic and inflammatory injury in cardiomyocytes. +other hsa-mir-4728 Breast Neoplasms 24828673 "we present here an alternative mode of miRNA regulation and demonstrate this dual function of the HER2 locus, linking the two major biomarkers in breast cancer." +other hsa-mir-509 Cystic Fibrosis 24829907 Exploitation of a very small peptide nucleic acid as a new inhibitor of miR-509-3p involved in the regulation of cystic fibrosis disease-gene expression. +other hsa-mir-19 Breast Neoplasms 24831732 Curcumin modulates miR-19/PTEN/AKT/p53 axis to suppress bisphenol A-induced MCF-7 breast cancer cell proliferation. +other hsa-mir-21 Colorectal Carcinoma 24832083 nuclear translocation of ¦Â-catenin increased by miR-21 promotes tumour malignancy and a poor outcome in APC-mutated patients but not in APC-wild-type colorectal cancer. +other hsa-mir-221 Central Nervous System Embryonal Tumor 24832085 "Downregulation of SUN2, a novel tumor suppressor, mediates miR-221/222-induced malignancy in central nervous system embryonal tumors." +other hsa-mir-222 Central Nervous System Embryonal Tumor 24832085 "Downregulation of SUN2, a novel tumor suppressor, mediates miR-221/222-induced malignancy in central nervous system embryonal tumors." +other hsa-mir-134 Acute Myocardial Infarction 24833470 Predictive value of circulating miR-328 and miR-134 for acute myocardial infarction. +other hsa-mir-328 Acute Myocardial Infarction 24833470 Predictive value of circulating miR-328 and miR-134 for acute myocardial infarction. +other hsa-mir-126 Atherosclerosis 24833799 MicroRNA-126 in atherosclerosis +other hsa-mir-765 Prostate Neoplasms 24837491 "Hsa-miRNA-765 as a key mediator for inhibiting growth, migration and invasion in fulvestrant-treated prostate cancer." +other hsa-mir-155 Breast Neoplasms 24840899 Increased circulating microRNA-155 as a potential biomarker for breast cancer screening: a meta-analysis. +other hsa-mir-451 "Carcinoma, Hepatocellular" 24841638 miR-451: potential role as tumor suppressor of human hepatoma cell growth and invasion. +other hsa-mir-223 Colorectal Carcinoma 24841830 fecal miR-223 and miR-451 hold promise in detecting CRC. +other hsa-mir-451 Colorectal Carcinoma 24841830 fecal miR-223 and miR-451 hold promise in detecting CRC. +other hsa-mir-218 "Carcinoma, Cervical" 24843318 MicroRNA-218 enhances the radiosensitivity of human cervical cancer via promoting radiation induced apoptosis. +other hsa-mir-122 Hepatitis C Virus Infection 24844965 "Different types of IFN increase the expression of miRNAs that inhibit HCV replication and decrease the expression of miRNA-122 that supports HCV replication. Thus the regulation of HCV replication-related miRNA expression is a general anti-HCV mechanism by different types of IFN. However, the regulation pattern by type II IFN is different from those by other types of IFNs,implying that type II IFN has different anti-HCV mechanisms from other types of IFN at miRNA level." +other hsa-mir-21 "Carcinoma, Hepatocellular" 24845419 Dehydroepiandrosterone-induces miR-21 transcription in HepG2 cells through estrogen receptor ¦Â and androgen receptor. +other hsa-mir-497 Gastric Neoplasms 24845562 The putative tumor suppressor microRNA-497 modulates gastric cancer cell proliferation and invasion by repressing eIF4E. +other hsa-mir-128 "Leukemia, Myeloid, Acute" 24846063 Effect of miR-128 in DNA damage of HL-60 acute myeloid leukemia cells. +other hsa-mir-106b "Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal" 24846066 "miR-21, miR-106b and miR-375 as novel potential biomarkers for laryngeal squamous cell carcinoma." +other hsa-mir-21 "Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal" 24846066 "miR-21, miR-106b and miR-375 as novel potential biomarkers for laryngeal squamous cell carcinoma." +other hsa-mir-375 "Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal" 24846066 "miR-21, miR-106b and miR-375 as novel potential biomarkers for laryngeal squamous cell carcinoma." +other hsa-mir-200a Cervix Endometrial Stromal Tumor 24850415 "MicroRNA-200a locally attenuates progesterone signaling in the cervix, preventing embryo implantation." +other hsa-mir-26a Idiopathic Pulmonary Fibrosis 24853416 Integrated analyses identify the involvement of microRNA-26a in epithelial-mesenchymal transition during idiopathic pulmonary fibrosis. +other hsa-let-7a Salivary Gland Neoplasms 24853424 "Furthermore, WIF1 significantly increased the expression of microRNAs pri-let-7a and pri-miR-200c, negative regulators of stemness and cancer progression." +other hsa-mir-24 Ischemia-Reperfusion Injury 24854275 MicroRNA-24 antagonism prevents renal ischemia reperfusion injury. +other hsa-mir-127 "Carcinoma, Hepatocellular" 24854842 miR-127 plays a tumor-suppressor role and can serve as a potential diagnostic biomarker for HCC. +other hsa-mir-200a Meningioma 24858044 miR-200a-mediated suppression of non-muscle heavy chain IIb inhibits meningioma cell migration and tumor growth in vivo. +other hsa-mir-142 "Leukemia, Myeloid, Acute" 24858343 The protein phosphatase 2A regulatory subunit B55¦Á is a modulator of signaling and microRNA expression in acute myeloid leukemia cells. +other hsa-mir-191 "Leukemia, Myeloid, Acute" 24858343 The protein phosphatase 2A regulatory subunit B55¦Á is a modulator of signaling and microRNA expression in acute myeloid leukemia cells. +other hsa-mir-122 Glioma 24863942 MiR-122/Wnt/¦Â-catenin regulatory circuitry sustains glioma progression. +other hsa-mir-23 Myocardial Infarction 24864093 MicroRNA--a new diagnostic tool in coronary artery disease and myocardial infarction. +other hsa-mir-103a Breast Neoplasms 24865188 "Association of microRNA-93, 190, 200b and receptor status in core biopsies from stage III breast cancer patients." +other hsa-mir-190a "Carcinoma, Breast, Triple Negative" 24865188 "Association of microRNA-93, 190, 200b and receptor status in core biopsies from stage III breast cancer patients." +other hsa-mir-200b "Carcinoma, Breast, Triple Negative" 24865188 "Association of microRNA-93, 190, 200b and receptor status in core biopsies from stage III breast cancer patients." +other hsa-mir-93 "Carcinoma, Breast, Triple Negative" 24865188 "Association of microRNA-93, 190, 200b and receptor status in core biopsies from stage III breast cancer patients." +other hsa-mir-21 Ovarian Neoplasms 24865582 Upregulation of miR-21 in cisplatin resistant ovarian cancer via JNK-1/c-Jun pathway. +other hsa-mir-181c Brain Neoplasms 24867100 MiRNA-181c inhibits EGFR-signaling-dependent MMP9 activation via suppressing Akt phosphorylation in glioblastoma. +other hsa-mir-126 Atherosclerosis 24870014 These effects may explain the ability of pitavastatin to reduce the progression of atherosclerosis. The findings further suggest that inhibitory effect of pitavastatin on VCAM-1 is not related to miR-126 but depends on other ways. +other hsa-mir-122 Hepatitis C Virus Infection 24871972 "Representatively, miR-122 directly modulates the HCV life cycle by increasing HCV translation and genomic RNA stability." +other hsa-mir-196a Human Immunodeficiency Virus Infection 24872081 Involvement of miR-196a in HIV-associated neurocognitive disorders. +other hsa-mir-17 Leukemia 24872388 Inhibition of miR-17 and miR-20a by oridonin triggers apoptosis and reverses chemoresistance by derepressing BIM-S. +other hsa-mir-20a Leukemia 24872388 Inhibition of miR-17 and miR-20a by oridonin triggers apoptosis and reverses chemoresistance by derepressing BIM-S. +other hsa-mir-10b "Carcinoma, Hepatocellular" 24875649 the study reveals the comprehensive miRNome of hepatic tissue and provides new tools for investigation of microRNA dependent pathways in cirrhotic liver and hepatocellular carcinoma. This article is part of a Directed Issue entitled: Rare Cancers. +other hsa-mir-1269a "Carcinoma, Hepatocellular" 24875649 the study reveals the comprehensive miRNome of hepatic tissue and provides new tools for investigation of microRNA dependent pathways in cirrhotic liver and hepatocellular carcinoma. This article is part of a Directed Issue entitled: Rare Cancers. +other hsa-mir-183 "Carcinoma, Hepatocellular" 24875649 the study reveals the comprehensive miRNome of hepatic tissue and provides new tools for investigation of microRNA dependent pathways in cirrhotic liver and hepatocellular carcinoma. This article is part of a Directed Issue entitled: Rare Cancers. +other hsa-mir-199a "Carcinoma, Hepatocellular" 24875649 the study reveals the comprehensive miRNome of hepatic tissue and provides new tools for investigation of microRNA dependent pathways in cirrhotic liver and hepatocellular carcinoma. This article is part of a Directed Issue entitled: Rare Cancers. +other hsa-mir-199b "Carcinoma, Hepatocellular" 24875649 the study reveals the comprehensive miRNome of hepatic tissue and provides new tools for investigation of microRNA dependent pathways in cirrhotic liver and hepatocellular carcinoma. This article is part of a Directed Issue entitled: Rare Cancers. +other hsa-mir-214 "Carcinoma, Hepatocellular" 24875649 the study reveals the comprehensive miRNome of hepatic tissue and provides new tools for investigation of microRNA dependent pathways in cirrhotic liver and hepatocellular carcinoma. This article is part of a Directed Issue entitled: Rare Cancers. +other hsa-mir-3144 "Carcinoma, Hepatocellular" 24875649 the study reveals the comprehensive miRNome of hepatic tissue and provides new tools for investigation of microRNA dependent pathways in cirrhotic liver and hepatocellular carcinoma. This article is part of a Directed Issue entitled: Rare Cancers. +other hsa-mir-490 "Carcinoma, Hepatocellular" 24875649 the study reveals the comprehensive miRNome of hepatic tissue and provides new tools for investigation of microRNA dependent pathways in cirrhotic liver and hepatocellular carcinoma. This article is part of a Directed Issue entitled: Rare Cancers. +other hsa-mir-106b "Carcinoma, Hepatocellular" 24876719 miR-106b-25/miR-17-92 clusters: polycistrons with oncogenic roles in hepatocellular carcinoma. +other hsa-mir-17 "Carcinoma, Hepatocellular" 24876719 miR-106b-25/miR-17-92 clusters: polycistrons with oncogenic roles in hepatocellular carcinoma. +other hsa-mir-18 "Carcinoma, Hepatocellular" 24876719 miR-106b-25/miR-17-92 clusters: polycistrons with oncogenic roles in hepatocellular carcinoma. +other hsa-mir-19a "Carcinoma, Hepatocellular" 24876719 miR-106b-25/miR-17-92 clusters: polycistrons with oncogenic roles in hepatocellular carcinoma. +other hsa-mir-19b-1 "Carcinoma, Hepatocellular" 24876719 miR-106b-25/miR-17-92 clusters: polycistrons with oncogenic roles in hepatocellular carcinoma. +other hsa-mir-20a "Carcinoma, Hepatocellular" 24876719 miR-106b-25/miR-17-92 clusters: polycistrons with oncogenic roles in hepatocellular carcinoma. +other hsa-mir-92-1 "Carcinoma, Hepatocellular" 24876719 miR-106b-25/miR-17-92 clusters: polycistrons with oncogenic roles in hepatocellular carcinoma. +other hsa-mir-1291 Acute Myocardial Infarction 24885383 "This study demonstrated that the levels of miR-133, miR-1291 and miR-663b are associated with AMI. The potential of these miRNAs as biomarkers to improve patient stratification according to the risk of AMI and as circulating biomarkers for the AMI progonos warrants further study." +other hsa-mir-133 Acute Myocardial Infarction 24885383 "This study demonstrated that the levels of miR-133, miR-1291 and miR-663b are associated with AMI. The potential of these miRNAs as biomarkers to improve patient stratification according to the risk of AMI and as circulating biomarkers for the AMI progonos warrants further study." +other hsa-mir-663b Acute Myocardial Infarction 24885383 "This study demonstrated that the levels of miR-133, miR-1291 and miR-663b are associated with AMI. The potential of these miRNAs as biomarkers to improve patient stratification according to the risk of AMI and as circulating biomarkers for the AMI progonos warrants further study." +other hsa-mir-520b Hepatitis B Virus Infection 24886421 HBx accelerates hepatocarcinogenesis with partner survivin through modulating tumor suppressor miR-520b and oncoprotein HBXIP. +other hsa-mir-221 Breast Neoplasms 24886939 miR-221/222 promotes S-phase entry and cellular migration in control of basal-like breast cancer. +other hsa-mir-222 Breast Neoplasms 24886939 miR-221/222 promotes S-phase entry and cellular migration in control of basal-like breast cancer. +other hsa-mir-940 Tetralogy Of Fallot 24889693 miRNA-940 reduction contributes to human Tetralogy of Fallot development. +other hsa-mir-15b "Carcinoma, Pancreatic" 24892299 Expression of microRNA-15b and the glycosyltransferase GCNT3 correlates with antitumor efficacy of Rosemary diterpenes in colon and pancreatic cancer. +other hsa-mir-15b Colon Neoplasms 24892299 Expression of microRNA-15b and the glycosyltransferase GCNT3 correlates with antitumor efficacy of Rosemary diterpenes in colon and pancreatic cancer. +other hsa-mir-146a "Carcinoma, Hepatocellular" 24895573 Synergistic effect of MiR-146a mimic and cetuximab on hepatocellular carcinoma cells. +other hsa-mir-24 Pancreatic Neoplasms 24895587 The miR-24 was the most significantly powerful miRNA that regulated series of important genes. +other hsa-mir-16 Colorectal Carcinoma 24895601 "Our results have laid down a solid foundation in exploration of novel CRC mechanisms, and identification of miRNA roles as oncomirs or tumor suppressor mirs in CRC." +other hsa-mir-148a Pancreatic Neoplasms 24895996 miR-148a- and miR-216a-regulated oncolytic adenoviruses targeting pancreatic tumors attenuate tissue damage without perturbation of miRNA activity. +other hsa-mir-216a Pancreatic Neoplasms 24895996 miR-148a- and miR-216a-regulated oncolytic adenoviruses targeting pancreatic tumors attenuate tissue damage without perturbation of miRNA activity. +other hsa-mir-125a "Carcinoma, Nasopharyngeal" 24896104 Curcumin exerts inhibitory effects on undifferentiated nasopharyngeal carcinoma by inhibiting the expression of miR-125a-5p. +other hsa-mir-10b Breast Neoplasms 24897960 Our results provide evidences that the addition of miR-10b RERs to the prognostic factors used in clinical routine could improve the prediction abilities for both overall mortality and disease progression in breast cancer patients. +other hsa-mir-16 Multiple Sclerosis 24898268 "Further evidence indicated that DIM treatment significantly upregulated several miRNAs (miR-200c, miR-146a, miR-16, miR-93, and miR-22) in brain CD4(+) T cells during EAE while suppressing their associated target genes." +other hsa-mir-122 "Carcinoma, Colon" 24898807 Overexpression of microRNA-122 re-sensitizes 5-FU-resistant colon cancer cells to 5-FU through the inhibition of PKM2 in vitro and in vivo. +other hsa-mir-23a "Carcinoma, Lung, Non-Small-Cell" 24898878 There is an interaction between miR-23a and IRS-1 in the modulation of the migration and invasion of NSCLC cells. IRS-1 is variably expressed in NSCLC patients and correlates with NSCLC patient survival. +other hsa-mir-451 Glioblastoma 24899919 Those parameters are primarily linked to the reactions that involve the microRNA-451 and the thereof regulated protein MO25. +other hsa-mir-17 Multiple Sclerosis 24901013 Unraveling natalizumab effects on deregulated miR-17 expression in CD4+ T cells of patients with relapsing-remitting multiple sclerosis. +other hsa-mir-125a Obesity 24901105 Our results support the involvement of miR-125a-3p in regulating the insulin signalling pathway and imply that increased miR- 125a-3p expression in omental adipose tissues may be a characteristic feature of insulin resistance in obese men. +other hsa-mir-18a Ischemic Heart Disease 24903055 PNS treatment resulted in reduced expression of miR-18a in tumor and upregulated expression of miR-18a in heart. +other hsa-mir-100 Neoplasms [unspecific] 24903380 "the prognostic role of miR-100 in human cancers, and thus, much more works are needed in this field." +other hsa-mir-221 Breast Neoplasms 24905916 Trail resistance induces epithelial-mesenchymal transition and enhances invasiveness by suppressing PTEN via miR-221 in breast cancer. +other hsa-mir-21 "Carcinoma, Lung, Non-Small-Cell" 24906642 Downregulation of miR-21 increases cisplatin sensitivity of non-small-cell lung cancer. +other hsa-mir-210 Neoplasms [unspecific] 24909053 Multiple functions of hypoxia-regulated miR-210 in cancer. +other hsa-mir-630 Neoplasms [unspecific] 24909689 E2F1-regulated DROSHA promotes miR-630 biosynthesis in cisplatin-exposed cancer cells. +other hsa-mir-124 Colorectal Carcinoma 24909917 KITENIN-targeting microRNA-124 suppresses colorectal cancer cell motility and tumorigenesis. +other hsa-mir-27a Colorectal Carcinoma 24909917 KITENIN-targeting microRNA-124 suppresses colorectal cancer cell motility and tumorigenesis. +other hsa-mir-30b Colorectal Carcinoma 24909917 KITENIN-targeting microRNA-124 suppresses colorectal cancer cell motility and tumorigenesis. +other hsa-let-7i Acute Ischemic Stroke 24911610 "Several miRNA are differentially expressed in blood cells of patients with acute ischemic stroke. These miRNA may regulate leukocyte gene expression in ischemic stroke including pathways involved in immune activation,leukocyte extravasation and thrombosis." +other hsa-mir-21 Neoplasms [unspecific] 24912785 Exosomal miR-21 derived from arsenite-transformed human bronchial epithelial cells promotes cell proliferation associated with arsenite carcinogenesis. +other hsa-mir-124 Prostate Neoplasms 24913567 "It was clear that PACE4 level was closely associated with malignancy and invasiveness of PCa in vivo or in vitro MiR-124, played a crucial role inhibiting PACE4 transcription thus exhibiting obvious effects of antiproliferation and antiaggression of PCa." +other hsa-mir-581 "Carcinoma, Hepatocellular" 24913918 miR-581 during hepatocarcinogenesis may lead to a reduction in HBsAg expression and impede HCC development. +other hsa-mir-155 "Leukemia, Lymphocytic, Chronic, B-Cell" 24914134 MicroRNA-155 influences B-cell receptor signaling and associates with aggressive disease in chronic lymphocytic leukemia. +other hsa-mir-132 Colorectal Carcinoma 24914372 Our study indicated that miR-132 plays an important role in the invasion and metastasis of CRC. +other hsa-mir-146a Neurodegenerative Diseases [unspecific] 24917789 "These findings together with the reduced expression of microRNA (miR)-124, and miR-155, decreased autophagy, enhanced senescence associated beta-galactosidase activity and elevated miR-146a expression, are suggestive that 16 DIV cells mainly correspond to irresponsive/senescent microglia." +other hsa-mir-146a Cholangiocarcinoma 24918778 "Significant variability was observed in the temporal function of all six miRNAs, which may play an important role in the development of CCA." +other hsa-mir-155 Cholangiocarcinoma 24918778 "Significant variability was observed in the temporal function of all six miRNAs, which may play an important role in the development of CCA." +other hsa-mir-200a Cholangiocarcinoma 24918778 "Significant variability was observed in the temporal function of all six miRNAs, which may play an important role in the development of CCA." +other hsa-mir-200b Cholangiocarcinoma 24918778 "Significant variability was observed in the temporal function of all six miRNAs, which may play an important role in the development of CCA." +other hsa-mir-21 Cholangiocarcinoma 24918778 "Significant variability was observed in the temporal function of all six miRNAs, which may play an important role in the development of CCA." +other hsa-mir-221 Cholangiocarcinoma 24918778 "Significant variability was observed in the temporal function of all six miRNAs, which may play an important role in the development of CCA." +other hsa-mir-17 Melanoma 24920276 Differential regulation of aggressive features in melanoma cells by members of the miR-17-92 complex. +other hsa-mir-18 Melanoma 24920276 Differential regulation of aggressive features in melanoma cells by members of the miR-17-92 complex. +other hsa-mir-19a Melanoma 24920276 Differential regulation of aggressive features in melanoma cells by members of the miR-17-92 complex. +other hsa-mir-19b-1 Melanoma 24920276 Differential regulation of aggressive features in melanoma cells by members of the miR-17-92 complex. +other hsa-mir-20a Melanoma 24920276 Differential regulation of aggressive features in melanoma cells by members of the miR-17-92 complex. +other hsa-mir-92-1 Melanoma 24920276 Differential regulation of aggressive features in melanoma cells by members of the miR-17-92 complex. +other hsa-mir-103 Hematologic Neoplasms 24921248 could discriminate between colorectal recurrences to lymph nodes and liver and between colorectal liver metastasis and primary hepatic tumor. +other hsa-mir-21 Hematologic Neoplasms 24921248 could discriminate between colorectal recurrences to lymph nodes and liver and between colorectal liver metastasis and primary hepatic tumor. +other hsa-mir-31 Hematologic Neoplasms 24921248 could discriminate between colorectal recurrences to lymph nodes and liver and between colorectal liver metastasis and primary hepatic tumor. +other hsa-mir-566 Hematologic Neoplasms 24921248 could discriminate between colorectal recurrences to lymph nodes and liver and between colorectal liver metastasis and primary hepatic tumor. +other hsa-mir-93 Hematologic Neoplasms 24921248 could discriminate between colorectal recurrences to lymph nodes and liver and between colorectal liver metastasis and primary hepatic tumor. +other hsa-mir-222 Breast Neoplasms 24923427 "Overall, this study suggested that both celecoxib and aspirin could prevent breast cancer growth by regulating proteins in the cell cycle and apoptosis without blocking estrogen synthesis. Besides, celecoxib might affect miR expression in an undesirable fashion." +other hsa-mir-378 Obesity 24923530 Insight into the effects of adipose tissue inflammation factors on miR-378 expression and the underlying mechanism. +other hsa-mir-106b Atrial Fibrillation 24927531 "miR-17-92 and miR-106b-25 directly repress genes, such as Shox2 and Tbx3, that are required for sinoatrial node development.Together, to our knowledge, these findings provide the first genetic evidence for an miR loss-of-function that increases atrial fibrillation susceptibility." +other hsa-mir-33a Hyperlipidemia 24928089 "all selected miRNAs were detected in α-lipoprotein fraction from sera, and miR-33a was also present in β-lipoprotein fraction;" +other hsa-mir-188 Osteoarthritis 24928913 "In IL-1β-stimulated human chondrocytes, chosen as a model of differentiated phenotype loss implicating the PPi transporter ANK, miR-9, miR-188 and let7e levels increased." +other hsa-mir-19a Ovarian Neoplasms 24929208 miR-19a was also transported via TnTs connecting transfected K7M2 cells and nontransfected stromal MC3T3 murine osteoblast cells. +other hsa-mir-146b Obesity 24931160 MiR-146b is a regulator of human visceral preadipocyte proliferation and differentiation and its expression is altered in human obesity. +other hsa-mir-126 Atherosclerosis 24933211 "Furthermore, significantly increased aortic expression of miR-26a, miR-21, miR-126a, miR-132, miR-146 and miR-155 and decreased expression of miR-20a and miR-92a were observed in the vehicle-treated ApoE-/- mice. While NR1 treatment led to a significant reduction in the expression of miR-21, miR-26a, miR-126 and increased expression of miR-20a." +other hsa-mir-155 Atherosclerosis 24933211 "Furthermore, significantly increased aortic expression of miR-26a, miR-21, miR-126a, miR-132, miR-146 and miR-155 and decreased expression of miR-20a and miR-92a were observed in the vehicle-treated ApoE-/- mice. While NR1 treatment led to a significant reduction in the expression of miR-21, miR-26a, miR-126 and increased expression of miR-20a." +other hsa-mir-20a Atherosclerosis 24933211 "Furthermore, significantly increased aortic expression of miR-26a, miR-21, miR-126a, miR-132, miR-146 and miR-155 and decreased expression of miR-20a and miR-92a were observed in the vehicle-treated ApoE-/- mice. While NR1 treatment led to a significant reduction in the expression of miR-21, miR-26a, miR-126 and increased expression of miR-20a." +other hsa-mir-133a Hypertension 24937684 "These results suggest that high salt intervention could down-regulate the expression of myocardial microRNA-133a, which may be one of the mechanisms involved in myocardial fibrosis in salt-sensitive hypertension." +other hsa-mir-155 Down Syndrome 24938108 "Analysis of mtDNA, miR-155 and BACH1 expression in hearts from donors with and without Down syndrome." +other hsa-mir-145 Colorectal Adenocarcinoma 24938624 This might be attributable to the fact that effects of miRNA activity may oscillate between gene product repression and activation. +other hsa-mir-21 Colorectal Adenocarcinoma 24938624 This might be attributable to the fact that effects of miRNA activity may oscillate between gene product repression and activation. +other hsa-mir-146a Osteoarthritis 24939082 Role of miR-146a in human chondrocyte apoptosis in response to mechanical pressure injury in vitro. +other hsa-mir-675 "Carcinoma, Hepatocellular" 24939300 inhibition of LncRNAH19 and miR-675 expression can promote migration and invasion of HCC cells via AKT/GSK-3¦Â/Cdc25A signaling pathway. +other hsa-let-7a Breast Neoplasms 24942235 Expression status of let-7a and miR-335 among breast tumors in patients with and without germ-line BRCA mutations. +other hsa-mir-335 Breast Neoplasms 24942235 Expression status of let-7a and miR-335 among breast tumors in patients with and without germ-line BRCA mutations. +other hsa-mir-139 Colorectal Carcinoma 24942287 Post-transcriptional regulation of the tumor suppressor miR-139-5p and a network of miR-139-5p-mediated mRNA interactions in colorectal cancer. +other hsa-mir-107 "Stroke, Ischemic" 24943094 Up-regulation of brain-enriched miR-107 promotes excitatory neurotoxicity through down-regulation of glutamate transporter-1 expression following ischaemic stroke. +other hsa-mir-1 "Diabetes Mellitus, Type 2" 24944010 "Here, we highlight the role of miRNAs in different significant protein cascades within the insulin signaling pathway such as miR-320, miR-383, miR-181b with IGF-1, and its receptor (IGF1R); miR-128a, miR-96, miR-126 with insulin receptor substrate (IRS) proteins; miR-29, miR-384-5p, miR-1 with phosphatidylinositol 3-kinase (PI3K); miR-143, miR-145, miR-29, miR-383, miR-33a/b miR-21 with AKT/protein kinase B (PKB) and miR-133a/b, miR-223, miR-143 with glucose transporter 4 (GLUT4). " +other hsa-mir-103 "Diabetes Mellitus, Type 2" 24944010 "Insulin resistance, obesity, and hyperlipidemia (high lipid levels in the blood) have a strong connection with T2D and several miRNAs influence these clinical outcomes such as miR-143, miR-103, and miR-107, miR-29a, and miR-27b." +other hsa-mir-107 "Diabetes Mellitus, Type 2" 24944010 "Insulin resistance, obesity, and hyperlipidemia (high lipid levels in the blood) have a strong connection with T2D and several miRNAs influence these clinical outcomes such as miR-143, miR-103, and miR-107, miR-29a, and miR-27b." +other hsa-mir-124a "Diabetes Mellitus, Type 2" 24944010 "The influence of miRNAs (miR-7, miR-124a, miR-9, miR-96, miR-15a/b, miR-34a, miR-195, miR-376, miR-103, miR-107, and miR-146) in insulin secretion and beta (β) cell development has been well discussed." +other hsa-mir-126 "Diabetes Mellitus, Type 2" 24944010 "Here, we highlight the role of miRNAs in different significant protein cascades within the insulin signaling pathway such as miR-320, miR-383, miR-181b with IGF-1, and its receptor (IGF1R); miR-128a, miR-96, miR-126 with insulin receptor substrate (IRS) proteins; miR-29, miR-384-5p, miR-1 with phosphatidylinositol 3-kinase (PI3K); miR-143, miR-145, miR-29, miR-383, miR-33a/b miR-21 with AKT/protein kinase B (PKB) and miR-133a/b, miR-223, miR-143 with glucose transporter 4 (GLUT4). " +other hsa-mir-128a "Diabetes Mellitus, Type 2" 24944010 "Here, we highlight the role of miRNAs in different significant protein cascades within the insulin signaling pathway such as miR-320, miR-383, miR-181b with IGF-1, and its receptor (IGF1R); miR-128a, miR-96, miR-126 with insulin receptor substrate (IRS) proteins; miR-29, miR-384-5p, miR-1 with phosphatidylinositol 3-kinase (PI3K); miR-143, miR-145, miR-29, miR-383, miR-33a/b miR-21 with AKT/protein kinase B (PKB) and miR-133a/b, miR-223, miR-143 with glucose transporter 4 (GLUT4). " +other hsa-mir-133a "Diabetes Mellitus, Type 2" 24944010 "Here, we highlight the role of miRNAs in different significant protein cascades within the insulin signaling pathway such as miR-320, miR-383, miR-181b with IGF-1, and its receptor (IGF1R); miR-128a, miR-96, miR-126 with insulin receptor substrate (IRS) proteins; miR-29, miR-384-5p, miR-1 with phosphatidylinositol 3-kinase (PI3K); miR-143, miR-145, miR-29, miR-383, miR-33a/b miR-21 with AKT/protein kinase B (PKB) and miR-133a/b, miR-223, miR-143 with glucose transporter 4 (GLUT4)." +other hsa-mir-133b "Diabetes Mellitus, Type 2" 24944010 "Here, we highlight the role of miRNAs in different significant protein cascades within the insulin signaling pathway such as miR-320, miR-383, miR-181b with IGF-1, and its receptor (IGF1R); miR-128a, miR-96, miR-126 with insulin receptor substrate (IRS) proteins; miR-29, miR-384-5p, miR-1 with phosphatidylinositol 3-kinase (PI3K); miR-143, miR-145, miR-29, miR-383, miR-33a/b miR-21 with AKT/protein kinase B (PKB) and miR-133a/b, miR-223, miR-143 with glucose transporter 4 (GLUT4)." +other hsa-mir-143 "Diabetes Mellitus, Type 2" 24944010 "Here, we highlight the role of miRNAs in different significant protein cascades within the insulin signaling pathway such as miR-320, miR-383, miR-181b with IGF-1, and its receptor (IGF1R); miR-128a, miR-96, miR-126 with insulin receptor substrate (IRS) proteins; miR-29, miR-384-5p, miR-1 with phosphatidylinositol 3-kinase (PI3K); miR-143, miR-145, miR-29, miR-383, miR-33a/b miR-21 with AKT/protein kinase B (PKB) and miR-133a/b, miR-223, miR-143 with glucose transporter 4 (GLUT4)." +other hsa-mir-145 "Diabetes Mellitus, Type 2" 24944010 "Here, we highlight the role of miRNAs in different significant protein cascades within the insulin signaling pathway such as miR-320, miR-383, miR-181b with IGF-1, and its receptor (IGF1R); miR-128a, miR-96, miR-126 with insulin receptor substrate (IRS) proteins; miR-29, miR-384-5p, miR-1 with phosphatidylinositol 3-kinase (PI3K); miR-143, miR-145, miR-29, miR-383, miR-33a/b miR-21 with AKT/protein kinase B (PKB) and miR-133a/b, miR-223, miR-143 with glucose transporter 4 (GLUT4)." +other hsa-mir-146 "Diabetes Mellitus, Type 2" 24944010 "The influence of miRNAs (miR-7, miR-124a, miR-9, miR-96, miR-15a/b, miR-34a, miR-195, miR-376, miR-103, miR-107, and miR-146) in insulin secretion and beta (β) cell development has been well discussed." +other hsa-mir-15a "Diabetes Mellitus, Type 2" 24944010 "The influence of miRNAs (miR-7, miR-124a, miR-9, miR-96, miR-15a/b, miR-34a, miR-195, miR-376, miR-103, miR-107, and miR-146) in insulin secretion and beta (β) cell development has been well discussed." +other hsa-mir-15b "Diabetes Mellitus, Type 2" 24944010 "The influence of miRNAs (miR-7, miR-124a, miR-9, miR-96, miR-15a/b, miR-34a, miR-195, miR-376, miR-103, miR-107, and miR-146) in insulin secretion and beta (β) cell development has been well discussed." +other hsa-mir-181b "Diabetes Mellitus, Type 2" 24944010 "Here, we highlight the role of miRNAs in different significant protein cascades within the insulin signaling pathway such as miR-320, miR-383, miR-181b with IGF-1, and its receptor (IGF1R); miR-128a, miR-96, miR-126 with insulin receptor substrate (IRS) proteins; miR-29, miR-384-5p, miR-1 with phosphatidylinositol 3-kinase (PI3K); miR-143, miR-145, miR-29, miR-383, miR-33a/b miR-21 with AKT/protein kinase B (PKB) and miR-133a/b, miR-223, miR-143 with glucose transporter 4 (GLUT4)." +other hsa-mir-195 "Diabetes Mellitus, Type 2" 24944010 "The influence of miRNAs (miR-7, miR-124a, miR-9, miR-96, miR-15a/b, miR-34a, miR-195, miR-376, miR-103, miR-107, and miR-146) in insulin secretion and beta (β) cell development has been well discussed." +other hsa-mir-21 "Diabetes Mellitus, Type 2" 24944010 "Here, we highlight the role of miRNAs in different significant protein cascades within the insulin signaling pathway such as miR-320, miR-383, miR-181b with IGF-1, and its receptor (IGF1R); miR-128a, miR-96, miR-126 with insulin receptor substrate (IRS) proteins; miR-29, miR-384-5p, miR-1 with phosphatidylinositol 3-kinase (PI3K); miR-143, miR-145, miR-29, miR-383, miR-33a/b miR-21 with AKT/protein kinase B (PKB) and miR-133a/b, miR-223, miR-143 with glucose transporter 4 (GLUT4)." +other hsa-mir-223 "Diabetes Mellitus, Type 2" 24944010 "Here, we highlight the role of miRNAs in different significant protein cascades within the insulin signaling pathway such as miR-320, miR-383, miR-181b with IGF-1, and its receptor (IGF1R); miR-128a, miR-96, miR-126 with insulin receptor substrate (IRS) proteins; miR-29, miR-384-5p, miR-1 with phosphatidylinositol 3-kinase (PI3K); miR-143, miR-145, miR-29, miR-383, miR-33a/b miR-21 with AKT/protein kinase B (PKB) and miR-133a/b, miR-223, miR-143 with glucose transporter 4 (GLUT4)." +other hsa-mir-27b "Diabetes Mellitus, Type 2" 24944010 "Insulin resistance, obesity, and hyperlipidemia (high lipid levels in the blood) have a strong connection with T2D and several miRNAs influence these clinical outcomes such as miR-143, miR-103, and miR-107, miR-29a, and miR-27b" +other hsa-mir-29 "Diabetes Mellitus, Type 2" 24944010 "Here, we highlight the role of miRNAs in different significant protein cascades within the insulin signaling pathway such as miR-320, miR-383, miR-181b with IGF-1, and its receptor (IGF1R); miR-128a, miR-96, miR-126 with insulin receptor substrate (IRS) proteins; miR-29, miR-384-5p, miR-1 with phosphatidylinositol 3-kinase (PI3K); miR-143, miR-145, miR-29, miR-383, miR-33a/b miR-21 with AKT/protein kinase B (PKB) and miR-133a/b, miR-223, miR-143 with glucose transporter 4 (GLUT4)." +other hsa-mir-29a "Diabetes Mellitus, Type 2" 24944010 "Here, we highlight the role of miRNAs in different significant protein cascades within the insulin signaling pathway such as miR-320, miR-383, miR-181b with IGF-1, and its receptor (IGF1R); miR-128a, miR-96, miR-126 with insulin receptor substrate (IRS) proteins; miR-29, miR-384-5p, miR-1 with phosphatidylinositol 3-kinase (PI3K); miR-143, miR-145, miR-29, miR-383, miR-33a/b miR-21 with AKT/protein kinase B (PKB) and miR-133a/b, miR-223, miR-143 with glucose transporter 4 (GLUT4)." +other hsa-mir-320 "Diabetes Mellitus, Type 2" 24944010 "Here, we highlight the role of miRNAs in different significant protein cascades within the insulin signaling pathway such as miR-320, miR-383, miR-181b with IGF-1, and its receptor (IGF1R); miR-128a, miR-96, miR-126 with insulin receptor substrate (IRS) proteins; miR-29, miR-384-5p, miR-1 with phosphatidylinositol 3-kinase (PI3K); miR-143, miR-145, miR-29, miR-383, miR-33a/b miR-21 with AKT/protein kinase B (PKB) and miR-133a/b, miR-223, miR-143 with glucose transporter 4 (GLUT4)." +other hsa-mir-33a "Diabetes Mellitus, Type 2" 24944010 "Here, we highlight the role of miRNAs in different significant protein cascades within the insulin signaling pathway such as miR-320, miR-383, miR-181b with IGF-1, and its receptor (IGF1R); miR-128a, miR-96, miR-126 with insulin receptor substrate (IRS) proteins; miR-29, miR-384-5p, miR-1 with phosphatidylinositol 3-kinase (PI3K); miR-143, miR-145, miR-29, miR-383, miR-33a/b miR-21 with AKT/protein kinase B (PKB) and miR-133a/b, miR-223, miR-143 with glucose transporter 4 (GLUT4)." +other hsa-mir-33b "Diabetes Mellitus, Type 2" 24944010 "Here, we highlight the role of miRNAs in different significant protein cascades within the insulin signaling pathway such as miR-320, miR-383, miR-181b with IGF-1, and its receptor (IGF1R); miR-128a, miR-96, miR-126 with insulin receptor substrate (IRS) proteins; miR-29, miR-384-5p, miR-1 with phosphatidylinositol 3-kinase (PI3K); miR-143, miR-145, miR-29, miR-383, miR-33a/b miR-21 with AKT/protein kinase B (PKB) and miR-133a/b, miR-223, miR-143 with glucose transporter 4 (GLUT4)." +other hsa-mir-34a "Diabetes Mellitus, Type 2" 24944010 "The influence of miRNAs (miR-7, miR-124a, miR-9, miR-96, miR-15a/b, miR-34a, miR-195, miR-376, miR-103, miR-107, and miR-146) in insulin secretion and beta (β) cell development has been well discussed." +other hsa-mir-376 "Diabetes Mellitus, Type 2" 24944010 "The influence of miRNAs (miR-7, miR-124a, miR-9, miR-96, miR-15a/b, miR-34a, miR-195, miR-376, miR-103, miR-107, and miR-146) in insulin secretion and beta (β) cell development has been well discussed." +other hsa-mir-383 "Diabetes Mellitus, Type 2" 24944010 "Here, we highlight the role of miRNAs in different significant protein cascades within the insulin signaling pathway such as miR-320, miR-383, miR-181b with IGF-1, and its receptor (IGF1R); miR-128a, miR-96, miR-126 with insulin receptor substrate (IRS) proteins; miR-29, miR-384-5p, miR-1 with phosphatidylinositol 3-kinase (PI3K); miR-143, miR-145, miR-29, miR-383, miR-33a/b miR-21 with AKT/protein kinase B (PKB) and miR-133a/b, miR-223, miR-143 with glucose transporter 4 (GLUT4)." +other hsa-mir-384 "Diabetes Mellitus, Type 2" 24944010 "Here, we highlight the role of miRNAs in different significant protein cascades within the insulin signaling pathway such as miR-320, miR-383, miR-181b with IGF-1, and its receptor (IGF1R); miR-128a, miR-96, miR-126 with insulin receptor substrate (IRS) proteins; miR-29, miR-384-5p, miR-1 with phosphatidylinositol 3-kinase (PI3K); miR-143, miR-145, miR-29, miR-383, miR-33a/b miR-21 with AKT/protein kinase B (PKB) and miR-133a/b, miR-223, miR-143 with glucose transporter 4 (GLUT4)." +other hsa-mir-7 "Diabetes Mellitus, Type 2" 24944010 "The influence of miRNAs (miR-7, miR-124a, miR-9, miR-96, miR-15a/b, miR-34a, miR-195, miR-376, miR-103, miR-107, and miR-146) in insulin secretion and beta (β) cell development has been well discussed." +other hsa-mir-9 "Diabetes Mellitus, Type 2" 24944010 "The influence of miRNAs (miR-7, miR-124a, miR-9, miR-96, miR-15a/b, miR-34a, miR-195, miR-376, miR-103, miR-107, and miR-146) in insulin secretion and beta (β) cell development has been well discussed." +other hsa-mir-96 "Diabetes Mellitus, Type 2" 24944010 "The influence of miRNAs (miR-7, miR-124a, miR-9, miR-96, miR-15a/b, miR-34a, miR-195, miR-376, miR-103, miR-107, and miR-146) in insulin secretion and beta (β) cell development has been well discussed." +other hsa-mir-146b "Carcinoma, Thyroid" 24946010 The roles of the epithelial-mesenchymal transition marker PRRX1 and miR-146b-5p in papillary thyroid carcinoma progression. +other hsa-mir-29c Bladder Neoplasms 24952510 Down-regulation of miR-29c in human bladder cancer and the inhibition of proliferation in T24 cell via PI3K-AKT pathway. +other hsa-mir-33 Atherosclerosis 24953492 "Taken together, these results reveal that C. pneumoniae may negatively regulate ABCA1 expression via TLR2-NF-¦ÊB and miR-33 pathways in THP-1 macrophage-derived foam cells, which may provide new insights for understandingthe effects of C. pneumoniae on the pathogenesis of atherosclerosis." +other hsa-mir-29c Influenza 24953694 Induction of the cellular miR-29c by influenza virus inhibits the innate immune response through protection of A20 mRNA. +other hsa-mir-130a "Carcinoma, Gallbladder" 24953832 "Together, these results suggest that HOTAIR is a c-Myc-activated driver of malignancy, which acts in part through repression of miRNA-130a." +other hsa-mir-124 Glioblastoma 24954504 MicroRNA-124 expression counteracts pro-survival stress responses in glioblastoma. +other hsa-mir-222 "Carcinoma, Lung, Non-Small-Cell" 24955421 MicroRNA-222 expression and its prognostic potential in non-small cell lung cancer. +other hsa-mir-199a Osteosarcoma 24957404 MicroRNA-199a-3p and microRNA-34a regulate apoptosis in human osteosarcoma cells. +other hsa-mir-34a Osteosarcoma 24957404 MicroRNA-199a-3p and microRNA-34a regulate apoptosis in human osteosarcoma cells. +other hsa-mir-101 Lung Neoplasms 24958470 IL-1¦Â-mediated repression of microRNA-101 is crucial for inflammation-promoted lung tumorigenesis. +other hsa-mir-126 Chronic Heart Failure 24958738 "In conclusion, the present study shows that HDL isolated from CHF patients (NYHA-III) reduces the expression of pro-angiogenic miRs (i.e. miR-126 and miR-21), which may contribute to atherogenesis and endothelial dysfunction. However, exercise training was able to attenuate the HDL-induced reduction in pro-angiogenic miRs expression." +other hsa-mir-21 Chronic Heart Failure 24958738 "In conclusion, the present study shows that HDL isolated from CHF patients (NYHA-III) reduces the expression of pro-angiogenic miRs (i.e. miR-126 and miR-21), which may contribute to atherogenesis and endothelial dysfunction. However, exercise training was able to attenuate the HDL-induced reduction in pro-angiogenic miRs expression." +other hsa-mir-214 Chronic Heart Failure 24958738 "In conclusion, the present study shows that HDL isolated from CHF patients (NYHA-III) reduces the expression of pro-angiogenic miRs (i.e. miR-126 and miR-21), which may contribute to atherogenesis and endothelial dysfunction. However, exercise training was able to attenuate the HDL-induced reduction in pro-angiogenic miRs expression." +other hsa-mir-221 Chronic Heart Failure 24958738 "In conclusion, the present study shows that HDL isolated from CHF patients (NYHA-III) reduces the expression of pro-angiogenic miRs (i.e. miR-126 and miR-21), which may contribute to atherogenesis and endothelial dysfunction. However, exercise training was able to attenuate the HDL-induced reduction in pro-angiogenic miRs expression." +other hsa-mir-222 Chronic Heart Failure 24958738 "In conclusion, the present study shows that HDL isolated from CHF patients (NYHA-III) reduces the expression of pro-angiogenic miRs (i.e. miR-126 and miR-21), which may contribute to atherogenesis and endothelial dysfunction. However, exercise training was able to attenuate the HDL-induced reduction in pro-angiogenic miRs expression." +other hsa-mir-21 Human Immunodeficiency Virus Infection 24961346 Relevance of miR-21 in HIV and non-HIV-related lymphomas. +other hsa-mir-145 "Carcinoma, Gallbladder" 24966896 miR-1 and miR-145 act as tumor suppressor microRNAs in gallbladder cancer. +other hsa-mir-200 Ovarian Neoplasms 24966949 Clinicopathological and prognostic implications of the miR-200 family in patients with epithelial ovarian cancer. +other hsa-mir-200 Breast Neoplasms 24967704 The tetraindole SK228 reverses the epithelial-to-mesenchymal transition of breast cancer cells by up-regulating members of the miR-200 family. +other hsa-mir-424 Neoplasms [unspecific] 24967963 Hypoxia-induced miR-424 decreases tumor sensitivity to chemotherapy by inhibiting apoptosis. +other hsa-mir-20a Neoplasms [unspecific] 24969314 "Furthermore, we demonstrated that upregulation of the miR-17-92 cluster (miR-20a/miR-17-5p) is involved in the regulation of E2F1-mediated negative feedback of the c-Myc/hTERT pathway." +other hsa-mir-31 Medulloblastoma 24970811 MicroRNA-31 suppresses medulloblastoma cell growth by inhibiting DNA replication through minichromosome maintenance 2. +other hsa-mir-15a "Leukemia, Lymphocytic, Chronic, B-Cell" 24971479 Role of miR-15/16 in CLL. +other hsa-mir-16-1 "Leukemia, Lymphocytic, Chronic, B-Cell" 24971479 Role of miR-15/16 in CLL. +other hsa-mir-124 Osteosarcoma 24971902 The tumor suppressor role of miR-124 in osteosarcoma. +other hsa-mir-630 Prostate Neoplasms 24971999 Gefitinib and luteolin cause growth arrest of human prostate cancer PC-3 cells via inhibition of cyclin G-associated kinase and induction of miR-630. +other hsa-mir-122 "Fatty Liver, Non-Alcoholic" 24973316 miR-122 plays a role of physiological significance in the biology of NAFLD; circulating miRNAs mirror the histological and molecular events occurring in the liver. NAFLD has a distinguishing circulating miRNA profile associated with a global dysmetabolic disease state and cardiovascular risk. +other hsa-mir-142 Glioma 24974128 These data indicate a unique role of miR-142-3p in glioma immunity by modulating M2 macrophages through the transforming growth factor beta signaling pathway. +other hsa-mir-18a "Carcinoma, Hepatocellular" 24975878 Elevated p53 promotes the processing of miR-18a to decrease estrogen receptor-¦Á in female hepatocellular carcinoma. +other hsa-mir-483 Vascular Disease [unspecific] 24976017 Angiotensin II-regulated microRNA 483-3p directly targets multiple components of the renin-angiotensin system. +other hsa-mir-31 Lung Neoplasms 24978700 Allelic imbalance in the miR-31 host gene locus in lung cancer--its potential role in carcinogenesis. +other hsa-mir-21 Breast Malignant Phyllodes Tumor 24980553 miR-21 induces myofibroblast differentiation and promotes the malignant progression of breast phyllodes tumors. +other hsa-mir-21 Multiple Myeloma 24981236 MicroRNA-21 and multiple myeloma: small molecule and big function. +other hsa-mir-630 Colorectal Carcinoma 24981248 MicroRNA-630 is a prognostic marker for patients with colorectal cancer. +other hsa-mir-34a Gastric Neoplasms 24981249 MiRNA-34a inhibits EGFR-signaling-dependent MMP7 activation in gastric cancer. +other hsa-mir-29a "Tuberculosis, Pulmonary" 24981709 Dynamics of T-cell IFN-¦Ã and miR-29a expression during active pulmonary tuberculosis. +other hsa-mir-1 Prostate Neoplasms 24982356 Heat-shock protein HSPB1 attenuates microRNA miR-1 expression thereby restoring oncogenic pathways in prostate cancer cells. +other hsa-mir-23b Breast Neoplasms 24985346 Exosomes from bone marrow mesenchymal stem cells contain a microRNA that promotes dormancy in metastatic breast cancer cells. +other hsa-mir-34a Gastric Neoplasms 24988056 Luteolin Induces Apoptosis by Up-regulating miR-34a in Human Gastric Cancer Cells. +other hsa-mir-17 Synovial Sarcoma 24989082 SS18-SSX-regulated miR-17 promotes tumor growth of synovial sarcoma by inhibiting p21WAF1/CIP1. +other hsa-mir-155 "Lymphoma, Large B-Cell, Diffuse" 24989312 Role of miR-155 in pathogenesis of diffuse large B cell lymphoma and its possible mechanism +other hsa-mir-603 Glioblastoma 24994119 A genome-wide miRNA screen revealed miR-603 as a MGMT-regulating miRNA in glioblastomas. +other hsa-mir-146a Keratitis 24996260 Our data demonstrate that miR-146a controls nuclear factor kappa B-dependent inflammatory responses in keratinocytes and chronic skin inflammation in AD. +other hsa-mir-125b Alzheimer Disease 25001178 MicroRNA-125b induces tau hyperphosphorylation and cognitive deficits in Alzheimer's disease. +other hsa-mir-17 Breast Neoplasms 25001613 Systematic analysis of metastasis-associated genes identifies miR-17-5p as a metastatic suppressor of basal-like breast cancer. +other hsa-mir-203 Prostate Neoplasms 25004126 Loss of EGFR signaling regulated miR-203 promotes prostate cancer bone metastasis and tyrosine kinase inhibitors resistance. +other hsa-mir-125b Acute Lung Injury 25004393 Enforced expression of miR-125b attenuates LPS-induced acute lung injury. +other hsa-mir-152 Prostate Neoplasms 25004396 MicroRNA profiling of novel African American and Caucasian Prostate Cancer cell lines reveals a reciprocal regulatory relationship of miR-152 and DNA methyltranferase 1. +other hsa-mir-29b Hematologic Neoplasms 25004911 Recent research of miR-29 family in hematological malignancies has proven its oncogenic as well as tumor suppressive potential. +other hsa-mir-125b "Leukemia, Myeloid" 25006123 Dual mechanisms by which miR-125b represses IRF4 to induce myeloid and B-cell leukemias. +other hsa-mir-451 Pulmonary Hypertension 25006399 "In conclusion, transient inhibition of miR-451 attenuated the development of PAH in hypoxia-exposed rats." +other hsa-mir-204 Pulmonary Hypertension 25006436 "Novel research shows that miR-204, a microRNA recently found to be notably downregulated through induction of PARP-1 (poly [ADP-ribose] polymerase 1) by excessive DNA damage in PAH, inhibits activation of STAT3." +other hsa-mir-221 Breast Neoplasms 25007959 Exosomal miR-221/222 enhances tamoxifen resistance in recipient ER-positive breast cancer cells. +other hsa-mir-222 Breast Neoplasms 25007959 Exosomal miR-221/222 enhances tamoxifen resistance in recipient ER-positive breast cancer cells. +other hsa-mir-17 "Carcinoma, Renal Cell" 25011053 miR-17 inhibition enhances the formation of kidney cancer spheres with stem cell/tumor initiating cell properties. +other hsa-mir-101 Osteosarcoma 25013866 miR-101 blocks autophagy during the chemotherapy in osteosarcoma cells and enhances chemosensitivity in vitro. +other hsa-mir-34a Ewing Sarcoma 25015333 "By demonstrating its relationship with clinical outcome, we propose evaluation of miR-34a at diagnosis of EWS patients to allow early risk stratification. Validation of these results would nonetheless ultimately need a prospective assessment." +other hsa-mir-29a Osteosarcoma 25015394 Prognostic value of the microRNA-29 family in patients with primary osteosarcomas. +other hsa-mir-29b Osteosarcoma 25015394 Prognostic value of the microRNA-29 family in patients with primary osteosarcomas. +other hsa-mir-29c Osteosarcoma 25015394 Prognostic value of the microRNA-29 family in patients with primary osteosarcomas. +other hsa-mir-142 Liver Neoplasms 25015418 Regulatory role of miR-142-3p on the functional hepatic cancer stem cell marker CD133. +other hsa-mir-210 Myocardial Infarction 25016614 "MicroRNAs most highly enriched in EVs secreted by CPCs compared with fibroblasts included miR-210, miR-132, and miR-146a-3p." +other hsa-mir-1290 "Carcinoma, Lung, Non-Small-Cell" 25016979 miR-1290 suppresses cell viability and cell cycle progression. These data provide insight into miR-1290-mediated cellular mechanisms in asiatic acid-treated A549 non-small cell lung carcinoma cells. +other hsa-mir-9 Breast Neoplasms 25017439 FOXO1 3'UTR functions as a ceRNA in repressing the metastases of breast cancer cells via regulating miRNA activity. +other hsa-mir-128 Glioblastoma 25017996 miR-128 and miR-149 enhance the chemosensitivity of temozolomide by Rap1B-mediated cytoskeletal remodeling in glioblastoma. +other hsa-mir-149 Glioblastoma 25017996 miR-128 and miR-149 enhance the chemosensitivity of temozolomide by Rap1B-mediated cytoskeletal remodeling in glioblastoma. +other hsa-mir-122 "Carcinoma, Hepatocellular" 25023326 Baculovirus-mediated miRNA regulation to suppress hepatocellular carcinoma tumorigenicity and metastasis. +other hsa-mir-451 "Adenocarcinoma, Lung" 25026294 Acquisition of radioresistance in docetaxel-resistant human lung adenocarcinoma cells is linked with dysregulation of miR-451/c-Myc-survivin/rad-51 signaling. +other hsa-mir-302c "Carcinoma, Hepatocellular" 25027009 MiR-302c inhibits tumor growth of hepatocellular carcinoma by suppressing the endothelial-mesenchymal transition of endothelial cells. +other hsa-let-7 Epstein-Barr Virus Infection 25031339 Epstein-Barr virus EBNA1 protein regulates viral latency through effects on let-7 microRNA and dicer. +other hsa-mir-193b "Carcinoma, Hepatocellular" 25034398 Modulation of miRNAs expression might be a potential way to enhance response to sorafenib in HBV-associated HCC. +other hsa-mir-223 Gastric Neoplasms 25036956 Increased microRNA-223 in Helicobacter pylori-associated gastric cancer contributed to cancer cell proliferation and migration. +other hsa-mir-122 Liver Injury 25039534 "In mice and humans, miR-122 levels represent an independent and potent marker of ongoing liver injury and hepatic cell death regardless of the underlying disease." +other hsa-mir-340 Melanoma 25043973 MicroRNA-340 as a modulator of RAS-RAF-MAPK signaling in melanoma. +other hsa-mir-99a "Carcinoma, Lung, Non-Small-Cell" 25046358 A novel small-molecule compound diaporine A inhibits non-small cell lung cancer growth by regulating miR-99a/mTOR signaling. +other hsa-mir-941 "Carcinoma, Hepatocellular" 25049231 miR-941 and KDM6B regulated the epithelial-mesenchymal transition process and affected cell migratory/invasive properties. +other hsa-mir-21 Neoplasms [unspecific] 25049417 "PAPD5 and PARN mediate degradation of oncogenic miRNA miR-21 through a tailing and trimming process, and that this pathway is disrupted in cancer and other proliferative diseases." +other hsa-mir-133a Breast Neoplasms 25051376 both miR-148b and miR-133a have potential use as biomarkers for breast cancer detection +other hsa-mir-148b Breast Neoplasms 25051376 both miR-148b and miR-133a have potential use as biomarkers for breast cancer detection +other hsa-mir-34a Neoplasms [unspecific] 25052958 The well-formulated LPEI-CaPs with lc-miRNA-d have the potential to provide superior miRNA transfection efficiency and inhibition of cancer proliferation. +other hsa-mir-146a Osteoarthritis 25052989 "The mechanism underlying the inhibitory effects of denbinobin involved miR-146a induction, which in turn inhibited NF-κB signaling." +other hsa-mir-34a Prostate Neoplasms 25053345 "This study supports the extracellular environment as an important source of minimally invasive predictive biomarkers representing their cellular origin. Using miR-34a as example, we showed that biomarkers identified in this manner may also hold functional relevance." +other hsa-mir-150 Melanoma 25054912 Role of microRNA-150 and glycoprotein nonmetastatic melanoma protein B in angiogenesis during hyperoxia-induced neonatal lung injury. +other hsa-mir-200c Glioblastoma 25058589 Correlation between EGFR amplification and the expression of microRNA-200c in primary glioblastoma multiforme. +other hsa-mir-101 Breast Neoplasms 25059472 miR-101 promotes breast cancer cell apoptosis by targeting Janus kinase 2. +other hsa-mir-186 Diabetes Mellitus 25059983 Differentiation of human induced pluripotent stem cells into insulin-like cell clusters with miR-186 and miR-375 by using chemical transfection. +other hsa-mir-375 Diabetes Mellitus 25059983 Differentiation of human induced pluripotent stem cells into insulin-like cell clusters with miR-186 and miR-375 by using chemical transfection. +other hsa-mir-144 Ischemic Diseases [unspecific] 25060662 MicroRNA-144 is a circulating effector of remote ischemic preconditioning. +other hsa-mir-21 "Adenocarcinoma, Pancreatic Ductal" 25061297 "microRNAs miR-21, miR-221, miR-222, and miR-10 in PDCA cells, promoting an almost complete abolishment of microRNA expression. " +other hsa-mir-221 "Adenocarcinoma, Pancreatic Ductal" 25061297 "microRNAs miR-21, miR-221, miR-222, and miR-10 in PDCA cells, promoting an almost complete abolishment of microRNA expression. " +other hsa-mir-222 "Adenocarcinoma, Pancreatic Ductal" 25061297 "microRNAs miR-21, miR-221, miR-222, and miR-10 in PDCA cells, promoting an almost complete abolishment of microRNA expression. " +other hsa-mir-148a Breast Neoplasms 25063027 our findings offer important new insights into the ability of estrogenic GPER signaling to trigger HLA-G expression through inhibiting miR-148a that supports immune evasion in breast cancer. +other hsa-mir-26b Posterior Capsule Opacification 25063219 "MiRNA-26b inhibits the proliferation, migration, and epithelial-mesenchymal transition of lens epithelial cells." +other hsa-mir-34c Breast Neoplasms 25064703 "Together, our results support the role of miR-34c as a tumor suppressor miRNA also in breast cancer." +other hsa-mir-409 Prostate Neoplasms 25065597 Stromal fibroblast-derived miR-409 promotes epithelial-to-mesenchymal transition and prostate tumorigenesis. +other hsa-mir-26 Cardiovascular Diseases [unspecific] 25066487 An emerging role for the miR-26 family in cardiovascular disease. +other hsa-mir-34a Liver Cirrhosis 25068403 "This study demonstrates for the first time, that miRNA-34a mayoriginate to a large extent from the liver. Even though higher levels ofmiRNA-34a are possibly associated with better survival at long-term follow-up in cirrhotic patients with severe portal hypertension receiving TIPS, classical prognostic parameters predict the survival better." +other hsa-mir-100 Urinary Bladder Cancer 25071007 microRNAs-99a/100 mediate a direct relationship between FGFR3 and FOXA1 and potentially facilitate cross talk between these pathways in UCC. +other hsa-mir-99a Urinary Bladder Cancer 25071007 microRNAs-99a/100 mediate a direct relationship between FGFR3 and FOXA1 and potentially facilitate cross talk between these pathways in UCC. +other hsa-mir-146a Myelodysplastic Syndromes 25071842 "miR-146a is also implicated in the pathogenesis of human myelodysplastic syndromes (MDSs) as it is located within a commonly deleted region on chromosome 5, and miR-146a-deficient mice exhibit features of an MDS-like disease." +other hsa-mir-122 Breast Neoplasms 25078559 Neoadjuvant Chemotherapy in Breast Cancer Patients Induces miR-34a and miR-122 Expression. +other hsa-mir-34a Breast Neoplasms 25078559 Neoadjuvant Chemotherapy in Breast Cancer Patients Induces miR-34a and miR-122 Expression. +other hsa-mir-216b Breast Neoplasms 25078617 Regulation of the P2X7R by microRNA-216b in human breast cancer. +other hsa-mir-146a Gastric Neoplasms 25081668 MicroRNA-146a enhances Helicobacter pylori induced cell apoptosis in human gastric cancer epithelial cells. +other hsa-mir-487b Ischemic Diseases [unspecific] 25085941 The 14q32 microRNA gene cluster is highly involved in neovascularization. +other hsa-mir-494 Ischemic Diseases [unspecific] 25085941 The 14q32 microRNA gene cluster is highly involved in neovascularization. +other hsa-mir-495 Ischemic Diseases [unspecific] 25085941 The 14q32 microRNA gene cluster is highly involved in neovascularization. +other hsa-mir-155 Breast Neoplasms 25086633 "MicroRNA-9 is associated with epithelial-mesenchymal transition, breast cancer stem cell phenotype, and tumor progression in breast cancer." +other hsa-mir-200 Breast Neoplasms 25086633 "MicroRNA-9 is associated with epithelial-mesenchymal transition, breast cancer stem cell phenotype, and tumor progression in breast cancer." +other hsa-mir-9 Breast Neoplasms 25086633 "MicroRNA-9 is associated with epithelial-mesenchymal transition, breast cancer stem cell phenotype, and tumor progression in breast cancer." +other hsa-mir-210 Prostate Neoplasms 25091736 Senescent stroma promotes prostate cancer progression: the role of miR-210. +other hsa-mir-106b Renal Fibrosis 25094038 Expression of miR-106b-25 induced by salvianolic acid B inhibits epithelial-to-mesenchymal transition in HK-2 cells. +other hsa-mir-152 "Carcinoma, Laryngeal" 25095980 Expression and clinical significance of microRNA-152 in supragalottic laryngeal carcinoma. +other hsa-mir-508 "Squamous Cell Carcinoma, Esophageal" 25099196 miR-508 sustains phosphoinositide signalling and promotes aggressive phenotype of oesophageal squamous cell carcinoma. +other hsa-mir-146a Graves Ophthalmopathy 25100151 Circulating levels of miR-146a and IL-17 are significantly correlated with the clinical activity of Graves' ophthalmopathy. +other hsa-mir-34 Neoplasms [unspecific] 25102298 Role of microRNA-34 family in cancer with particular reference to cancer angiogenesis. +other hsa-mir-15 Cardiomegaly 25103110 We identified the miR-15 family as a novel regulator of cardiac hypertrophy and fibrosis acting by inhibition of the TGF¦Â-pathway. +other hsa-mir-133a Colorectal Carcinoma 25104873 The clinicopathological significance of miR-133a in colorectal cancer. +other hsa-mir-196a Focal Segmental Glomerulosclerosis 25107948 "The levels of urinary miR-196a, miR-30a-5p, and miR-490 are associated with FSGS disease activity." +other hsa-mir-30a Focal Segmental Glomerulosclerosis 25107948 "The levels of urinary miR-196a, miR-30a-5p, and miR-490 are associated with FSGS disease activity." +other hsa-mir-490 Focal Segmental Glomerulosclerosis 25107948 "The levels of urinary miR-196a, miR-30a-5p, and miR-490 are associated with FSGS disease activity." +other hsa-mir-100 "Squamous Cell Carcinoma, Esophageal" 25109390 MicroRNA-100 promotes migration and invasion through mammalian target of rapamycin in esophageal squamous cell carcinoma. +other hsa-mir-101 Bladder Neoplasms 25109742 Enforced expression of miR-101 enhances cisplatin sensitivity in human bladder cancer cells by modulating the cyclooxygenase-2 pathway. +other hsa-mir-218 "Carcinoma, Hepatocellular" 25110121 Prognostic significance of miR-218 in human hepatocellular carcinoma and its role in cell growth. +other hsa-mir-497 Acute Myocardial Infarction 25110754 High association between human circulating microRNA-497 and acute myocardial infarction. +other hsa-mir-499 Myocardial Infarction 25111390 "Our results demonstrate that circulating miR-499 is a novel, early biomarker for identifying perioperative myocardial infarction in cardiac surgery." +other hsa-mir-665 Heart Failure 25111814 MicroRNA-665 is involved in the regulation of the expression of the cardioprotective cannabinoid receptor CB2 in patients with severe heart failure. +other hsa-mir-124 Prostate Neoplasms 25115393 The miR-124-prolyl hydroxylase P4HA1-MMP1 axis plays a critical role in prostate cancer progression. +other hsa-mir-23b Prostate Neoplasms 25115396 The microRNA-23b/27b/24-1 cluster is a disease progression marker and tumor suppressor in prostate cancer. +other hsa-mir-24-1 Prostate Neoplasms 25115396 The microRNA-23b/27b/24-1 cluster is a disease progression marker and tumor suppressor in prostate cancer. +other hsa-mir-27b Prostate Neoplasms 25115396 The microRNA-23b/27b/24-1 cluster is a disease progression marker and tumor suppressor in prostate cancer. +other hsa-mir-1291 "Carcinoma, Pancreatic" 25115443 N-methylnicotinamide and nicotinamide N-methyltransferase are associated with microRNA-1291-altered pancreatic carcinoma cell metabolome and suppressed tumorigenesis. +other hsa-mir-138 Prostate Neoplasms 25116803 α-solanine downregulates oncogenic microRNA-21 (miR-21) and upregulates tumor suppressor miR-138 expression. +other hsa-mir-21 Prostate Neoplasms 25116803 α-solanine downregulates oncogenic microRNA-21 (miR-21) and upregulates tumor suppressor miR-138 expression. +other hsa-mir-122 "Fatty Liver, Non-Alcoholic" 25117675 Silencing of microRNA-122 is an early event during hepatocarcinogenesis from non-alcoholic steatohepatitis. +other hsa-mir-218 "Carcinoma, Hepatocellular" 25120782 miR-218 modulate hepatocellular carcinoma cell proliferation through PTEN/AKT/PI3K pathway and HoxA10. +other hsa-mir-30e Dengue Virus Infection 25122182 MicroRNA-30e* suppresses dengue virus replication by promoting NF-¦ÊB-dependent IFN production. +other hsa-mir-181b Pancreatic Neoplasms 25126577 "Some miRNAs were found to be specifically expressed in some ZHENGs, for instance, miR-17, miR-21, and miR-181b in Shi-Re ZHENG and miR-196a in Pi-Xu ZHENG." +other hsa-mir-1290 Prostate Neoplasms 25129854 Exosomal miR-1290 and miR-375 as prognostic markers in castration-resistant prostate cancer. +other hsa-mir-375 Prostate Neoplasms 25129854 Exosomal miR-1290 and miR-375 as prognostic markers in castration-resistant prostate cancer. +other hsa-mir-17 Leukemia 25130806 Anti-leukemia mechanism of miR-17 and miR-20a silencing mediated by miRNA sponge. +other hsa-mir-20a Leukemia 25130806 Anti-leukemia mechanism of miR-17 and miR-20a silencing mediated by miRNA sponge. +other hsa-mir-192 Cholangiocarcinoma 25131257 This finding indicates that elevated levels of miR-192 may be involved in CCA genesis and have a potential utility as a noninvasive prognostic indicator for CCA patients. +other hsa-mir-541 Prostate Neoplasms 25135278 Infiltrating T cells promote prostate cancer metastasis via modulation of FGF11¡úmiRNA-541¡úandrogen receptor (AR)¡úMMP9 signaling. +other hsa-mir-31 Neoplasms [unspecific] 25139099 Prognostic role of microRNA-31 in various cancers: a meta-analysis. +other hsa-mir-24 Osteosarcoma 25142229 Nucleotidyl transferase TUT1 inhibits lipogenesis in osteosarcoma cells through regulation of microRNA-24 and microRNA-29a. +other hsa-mir-29a Osteosarcoma 25142229 Nucleotidyl transferase TUT1 inhibits lipogenesis in osteosarcoma cells through regulation of microRNA-24 and microRNA-29a. +other hsa-mir-29a Cardiomegaly 25145535 MicroRNA-29a is a friend or foe for cardiac hypertrophy +other hsa-mir-618 Thyroid Neoplasms 25145559 MiR-618 inhibits anaplastic thyroid cancer by repressing XIAP in one ATC cell line. +other hsa-mir-21 Kidney Injury 25145934 MicroRNA-21 in glomerular injury. +other hsa-mir-15 Salmonellosis 25146723 Functional high-throughput screening identifies the miR-15 microRNA family as cellular restriction factors for Salmonella infection. +other hsa-mir-133a Muscle Diseases [unspecific] 25146754 These miRNAs are potential biomarkers of muscle damage or adaptation to exercise. +other hsa-mir-206 Muscle Diseases [unspecific] 25146754 These miRNAs are potential biomarkers of muscle damage or adaptation to exercise. +other hsa-mir-21 Neoplasms [unspecific] 25149066 miR-21-3p is a positive regulator of L1CAM in several human carcinomas. +other hsa-mir-7 Glioblastoma 25149532 Systemic miRNA-7 delivery inhibits tumor angiogenesis and growth in murine xenograft glioblastoma. +other hsa-mir-30a Neuroblastoma 25149854 Lithium/Valproic acid combination and L-glutamate induce similar pattern of changes in the expression of miR-30a-5p in SH-SY5Y neuroblastoma cells. +other hsa-mir-122 Breast Neoplasms 25150312 Breast cancer-specific TRAIL expression mediated by miRNA response elements of let-7 and miR-122. +other hsa-mir-451 Lung Neoplasms 25150396 MiR-451 suppresses cell proliferation and metastasis in A549 lung cancer cells. +other hsa-mir-130b Ovarian Neoplasms 25155039 MicroRNA 130b enhances drug resistance in human ovarian cancer cells. +other hsa-mir-125b "Carcinoma, Renal Cell, Clear-Cell" 25155155 Tumor miR-125b predicts recurrence and survival of patients with clear-cell renal cell carcinoma after surgical resection. +other hsa-mir-378 Aortic Stenosis 25157568 "Circulating levels of miR-1, miR-133 and miR-378 were decreased in AS patients, and miR-378 predicts LVH independent of the pressure gradient. Further prospective investigations are needed to elucidate whether these circulating miRs affect clinical outcome." +other hsa-mir-21 Ischemia-Reperfusion Injury 25159851 miR-21 in ischemia/reperfusion injury: a double-edged sword +other hsa-mir-106b Bladder Neoplasms 25168920 Urinary cell-free microRNA-106b as a novel biomarker for detection of bladder cancer. +other hsa-mir-520h Neoplasms [unspecific] 25169894 "PD-miRNAs that are currently implicated as cancer biomarkers or diagnostics: hsa-mir-202, hsa-mir-423, hsa-mir-196a-2, hsa-mir-520h, hsa-mir-647, hsa-mir-943, and hsa-mir-1908." +other hsa-mir-29 Breast Neoplasms 25174825 Aberrant miR-29 expression may account for reduced NMI expression in breast tumors and mesenchymal phenotype of cancer cells that promotes invasive growth. Reduction in NMI levels has a feed-forward impact on miR-29 levels. +other hsa-mir-29b-1 Osteosarcoma 25174983 "MicroRNA-29b-1 impairs in vitro cell proliferation, self-renewal and chemoresistance of human osteosarcoma 3AB-OS cancer stem cells." +other hsa-mir-124a Glioma 25175832 miR-124a restoration inhibits glioma cell proliferation and invasion by suppressing IQGAP1 and ¦Â-catenin. +other hsa-mir-21 "Squamous Cell Carcinoma, Head and Neck" 25175929 miR-21 increases the programmed cell death 4 gene-regulated cell proliferation in head and neck squamous carcinoma cell lines. +other hsa-mir-1 Heart Diseases [unspecific] 25177824 miRNA-1: functional roles and dysregulation in heart disease. +other hsa-mir-21 Colorectal Carcinoma 25178983 "Circulating miR21 level has potential value for colorectal cancer early detection, whereas high tissue miR21 level is associated with adverse colorectal cancer prognosis." +other hsa-mir-152 "Carcinoma, Lung, Non-Small-Cell" 25190353 MiR-152 suppresses the proliferation and invasion of NSCLC cells by inhibiting FGF2. +other hsa-mir-122 "Carcinoma, Ovarian" 25195148 A polymorphism at miRNA-122-binding site in the IL-1¦Á 3'UTR is associated with risk of epithelial ovarian cancer. +other hsa-mir-375 Neoplasms [unspecific] 25195536 "The CMAP database is a useful tool for identifying compounds affecting the same molecular pathways, particularly products that are difficult to apply via practical approaches, such as microRNAs." +other hsa-mir-1280 Melanoma 25195599 Antitumor activity of miR-1280 in melanoma by regulation of Src. +other hsa-mir-1 Colorectal Carcinoma 25196260 Tumor suppressor miR-1 restrains epithelial-mesenchymal transition and metastasis of colorectal carcinoma via the MAPK and PI3K/AKT pathway. +other hsa-mir-107 Colorectal Carcinoma 25197016 MiR-107 and miR-99a-3p were validated as predictors of response to standard fluoropyrimidine-based chemotherapy in patients with mCRC. +other hsa-mir-99a Colorectal Carcinoma 25197016 MiR-107 and miR-99a-3p were validated as predictors of response to standard fluoropyrimidine-based chemotherapy in patients with mCRC. +other hsa-mir-126 "Carcinoma, Colon" 25199818 The current population based study of patients operated for stage II colon cancer demonstrated correlations between several prognostic unfavourable characteristics and miRNA-126 and argues for a possible prognostic impact on overall survival. An influence on survival by the MVD estimate was not detected. +other hsa-mir-195 Aortic Aneurysm 25201911 "We provide the first evidence that miR-195 may contribute to the pathogenesis of aortic aneurysmal disease. Although inhibition of miR-29b proved more effective in preventing aneurysm formation in a preclinical model, miR-195represents a potent regulator of the aortic extracellular matrix. Notably, plasma levels of miR-195 were reduced in patients with abdominal aortic aneurysms suggesting that microRNAs might serve as a noninvasive biomarker of abdominal aortic aneurysms." +other hsa-mir-33a Glioma 25202981 miR-33a promotes glioma-initiating cell self-renewal via PKA and NOTCH pathways. +other hsa-mir-200a Liver Neoplasms 25203708 MiR-200a may play an important role in liver cancer development and may have diagnostic value for indicating early liver cancer. +other hsa-mir-21 Periodontal Diseases 25203845 microRNA-21 mediates stretch-induced osteogenic differentiation in human periodontal ligament stem cells. +other hsa-let-7d Glioblastoma 25212824 the current study is the first to demonstrate the effect of FCL on modulation of let-7d expression +other hsa-mir-193b Breast Neoplasms 25213330 Metformin-induced killing of triple-negative breast cancer cells is mediated by reduction in fatty acid synthase via miRNA-193b. +other hsa-mir-25 Heart Failure 25214573 miR-25 in heart failure. +other hsa-mir-185 "Carcinoma, Colon" 25216407 MicroRNA-185 suppresses growth and invasion of colon cancer cells through inhibition of the hypoxia-inducible factor-2¦Á pathway in vitro and in vivo. +other hsa-mir-199 Cholangiocarcinoma 25217977 the cell proliferation and inhibition of tumor suppression mediated by these miRNAs is common to both cancerous and non-cancerous cells. +other hsa-mir-22 Cardiovascular Diseases [unspecific] 25218673 miR-22 in cardiac remodeling and disease. +other hsa-mir-1246 Ebola Hemorrhagic Fever 25218824 "Hsa-miR-1246, hsa-miR-320a and hsa-miR-196b-5p inhibitors can reduce the cytotoxicity of Ebola virus glycoprotein in vitro." +other hsa-mir-133b Parkinson Disease 25218846 Our observations suggest that miR-133b might be involved in ceruloplasmin dysmetabolism in PD patients and a further investigation is warranted to confirm this hypothesis. +other hsa-mir-34a Neoplasms [unspecific] 25220161 Dual drugs (microRNA-34a and paclitaxel)-loaded functional solid lipid nanoparticles for synergistic cancer cell suppression. +other hsa-mir-214 Neoplasms [unspecific] 25223704 Tumor-secreted miR-214 induces regulatory T cells: a major link between immune evasion and tumor growth. +other hsa-mir-494 Lung Neoplasms 25226615 Overexpression of secretagogin inhibits cell apoptosis and induces chemoresistance in small cell lung cancer under the regulation of miR-494. +other hsa-mir-143 Osteosarcoma 25227664 MiR-143 inhibits EGFR-signaling-dependent osteosarcoma invasion. +other hsa-mir-34b Neoplasms [unspecific] 25227823 Association between a polymorphism in miR-34b/c and susceptibility to cancer--a meta-analysis. +other hsa-mir-34c Neoplasms [unspecific] 25227823 Association between a polymorphism in miR-34b/c and susceptibility to cancer--a meta-analysis. +other hsa-mir-155 Lung Neoplasms 25230125 Chitosan combined with molecular beacon for mir-155 detection and imaging in lung cancer. +other hsa-mir-34a "Carcinoma, Nasopharyngeal" 25231528 Hypofractionated radiotherapy induces miR-34a expression and enhances apoptosis in human nasopharyngeal carcinoma cells. +other hsa-mir-137 Glioblastoma 25232498 "OLE significantly induced the expression of miR-153, miR-145, and miR-137 and decreased the expression of the target genes of these miRNAs in GSCs" +other hsa-mir-145 Glioblastoma 25232498 "OLE significantly induced the expression of miR-153, miR-145, and miR-137 and decreased the expression of the target genes of these miRNAs in GSCs" +other hsa-mir-18a Colorectal Carcinoma 25233396 Stool-based miR-221 can be used as a non-invasive biomarker for the detection of CRC. +other hsa-mir-221 Colorectal Carcinoma 25233396 Stool-based miR-221 can be used as a non-invasive biomarker for the detection of CRC. +other hsa-mir-217 Lung Neoplasms 25234467 MicroRNA-217 functions as a tumour suppressor gene and correlates with cell resistance to cisplatin in lung cancer. +other hsa-mir-21 "Squamous Cell Carcinoma, Oral" 25236707 Human papillomavirus-stratified analysis of the prognostic role of miR-21 in oral cavity and oropharyngeal squamous cell carcinoma. +other hsa-mir-451a Melanoma 25237911 "A novel miR-451a isomiR, associated with amelanotypic phenotype, acts as a tumor suppressor in melanoma by retarding cell migration and invasion." +other hsa-mir-93 Breast Neoplasms 25238878 Identification of microRNA-93 as a functional dysregulated miRNA in triple-negative breast cancer. +other hsa-mir-92a Acute Myocardial Infarction 25240056 Early single intracoronary administration of encapsulated antagomir-92a in an adult pig model of reperfused AMI prevents left ventricular remodeling with no local or distant adverse effects +other hsa-mir-16 Glioma 25242314 MicroRNA-16 suppresses epithelial-mesenchymal transition-related gene expression in human glioma. +other hsa-mir-5481 Lung Neoplasms 25245053 These results suggested that miR-548l may play a causal role through AKT1 in NSCLC invasion and metastasis. +other hsa-mir-17 Diabetes Mellitus 25249581 "Ask1 deletion suppressed diabetes-induced IRE1α endoriboneclease activities, which led to X-box binding protein 1 mRNA cleavage, an ER stress marker, decreased expression of microRNAs, and increased expression of a miR-17 target" +other hsa-mir-137 Schizophrenia 25250332 Association of a miRNA-137 polymorphism with schizophrenia in a Southern Chinese Han population. +other hsa-mir-141 "Adenocarcinoma, Prostate" 25252191 "Based on this small pilot study, men with localized prostate cancers with lower miR-221 expression may have a greater risk for recurrence after surgery." +other hsa-mir-21 "Adenocarcinoma, Prostate" 25252191 "Based on this small pilot study, men with localized prostate cancers with lower miR-221 expression may have a greater risk for recurrence after surgery." +other hsa-mir-221 "Adenocarcinoma, Prostate" 25252191 "Based on this small pilot study, men with localized prostate cancers with lower miR-221 expression may have a greater risk for recurrence after surgery." +other hsa-mir-191 Lung Neoplasms 25252218 "MicroRNA-191, by promoting the EMT and increasing CSC-like properties, is involved in neoplastic and metastatic properties of transformed human bronchial epithelial cells." +other hsa-mir-132 Mycobacterium tuberculosis Infection 25252958 Mycobacterium tuberculosis decreases human macrophage IFN-¦Ã responsiveness through miR-132 and miR-26a. +other hsa-mir-26a Mycobacterium tuberculosis Infection 25252958 Mycobacterium tuberculosis decreases human macrophage IFN-¦Ã responsiveness through miR-132 and miR-26a. +other hsa-mir-96 Colorectal Carcinoma 25256312 MiR-96-5p influences cellular growth and is associated with poor survival in colorectal cancer patients. +other hsa-mir-148 Gastric Neoplasms 25261463 Polymorphisms and haplotypes of the miR-148/152 family are associated with the risk and clinicopathological features of gastric cancer in a Northern Chinese population. +other hsa-mir-152 Gastric Neoplasms 25261463 Polymorphisms and haplotypes of the miR-148/152 family are associated with the risk and clinicopathological features of gastric cancer in a Northern Chinese population. +other hsa-mir-210 "Adenocarcinoma, Lung" 25263437 Tissue inhibitor of metalloproteinases-1 induces a pro-tumourigenic increase of miR-210 in lung adenocarcinoma cells and their exosomes. +other hsa-mir-122 Viral Infectious Disease 25265013 MiR-122 directly inhibits human papillomavirus E6 gene and enhances interferon signaling through blocking suppressor of cytokine signaling 1 in SiHa cells. +other hsa-mir-148b Asthma 25266681 "We report that statins upregulate mir-148b and 152, and affect HLA-G expression in an rs1063320-dependent fashion." +other hsa-mir-152 Asthma 25266681 "We report that statins upregulate mir-148b and 152, and affect HLA-G expression in an rs1063320-dependent fashion." +other hsa-mir-21 Bladder Neoplasms 25266796 A lentiviral sponge for miRNA-21 diminishes aerobic glycolysis in bladder cancer T24 cells via the PTEN/PI3K/AKT/mTOR axis. +other hsa-mir-122 "Carcinoma, Hepatocellular" 25269820 MicroRNA sponge blocks the tumor-suppressing functions of microRNA-122 in human hepatoma and osteosarcoma cells. +other hsa-mir-122 Osteosarcoma 25269820 MicroRNA sponge blocks the tumor-suppressing functions of microRNA-122 in human hepatoma and osteosarcoma cells. +other hsa-mir-200 Gastric Neoplasms 25270520 MicroRNA-200 family members and ZEB2 are associated with brain metastasis in gastric adenocarcinoma. +other hsa-mir-34c Ovarian Neoplasms 25273528 Functional analysis of miR-34c as a putative tumor suppressor in high-grade serous ovarian cancer. +other hsa-mir-122 Hepatitis C Virus Infection 25275643 "Exosome-loading with a miR-122 inhibitor, or inhibition of HSP90, vacuolar H+-ATPases, and proton pumps, significantly suppressed exosome-mediated HCV transmission to naïve cells." +other hsa-mir-126 "Carcinoma, Renal Cell" 25279769 "Impact of miR-21, miR-126 and miR-221 as prognostic factors of clear cell renal cell carcinoma with tumor thrombus of the inferior vena cava." +other hsa-mir-21 "Carcinoma, Renal Cell" 25279769 "Impact of miR-21, miR-126 and miR-221 as prognostic factors of clear cell renal cell carcinoma with tumor thrombus of the inferior vena cava." +other hsa-mir-221 "Carcinoma, Renal Cell" 25279769 "Impact of miR-21, miR-126 and miR-221 as prognostic factors of clear cell renal cell carcinoma with tumor thrombus of the inferior vena cava." +other hsa-mir-105 "Carcinoma, Hepatocellular" 25280563 MicroRNA-105 suppresses cell proliferation and inhibits PI3K/AKT signaling in human hepatocellular carcinoma. +other hsa-mir-155 Prostate Neoplasms 25283513 Inhibition of transforming growth factor beta/SMAD signal by MiR-155 is involved in arsenic trioxide-induced anti-angiogenesis in prostate cancer. +other hsa-mir-3127 "Carcinoma, Lung, Non-Small-Cell" 25284075 Reduced miR-3127-5p expression promotes NSCLC proliferation/invasion and contributes to dasatinib sensitivity via the c-Abl/Ras/ERK pathway. +other hsa-mir-203 Squamous Cell Carcinoma 25284788 "Rewiring of an epithelial differentiation factor, miR-203, to inhibit human squamous cell carcinoma metastasis." +other hsa-mir-106b Neoplasms [unspecific] 25286029 miR-106b modulates cancer stem cell characteristics through TGF-¦Â/Smad signaling in CD44-positive gastric cancer cells. +other hsa-mir-495 "Carcinoma, Lung" 25286762 MicroRNA-495 mimics delivery inhibits lung tumor progression. +other hsa-mir-720 Lung Neoplasms 25286763 Evaluation of miR-720 prognostic significance in patients with colorectal cancer. +other hsa-mir-139 Colorectal Carcinoma 25286864 Gene module based regulator inference identifying miR-139 as a tumor suppressor in colorectal cancer. +other hsa-mir-7 "Carcinoma, Lung, Non-Small-Cell" 25289099 Upregulation of miR-7 enhanced the PTX-sensitivity of NSCLC cells by suppressing cell proliferation and promoting cell apoptosis +other hsa-mir-142 "Carcinoma, Hepatocellular" 25292173 This study reveals a novel role for propofol in the inhibition of HCC through MV-mediated transfer of miR-142-3p from macrophages to cancer cells in vivo. +other hsa-mir-204 Colorectal Carcinoma 25294901 Our results demonstrate for the first time that miR-204-5p acts as a tumor suppressor in colorectal cancer through inhibiting RAB22A and reveal RAB22A to be a new oncogene and prognostic factor for colorectal cancer. +other hsa-mir-490 Ovarian Neoplasms 25297343 microRNA 490-3P enhances the drug-resistance of human ovarian cancer cells. +other hsa-mir-212 "Carcinoma, Esophageal" 25299094 Overregulation of microRNA-212 in the poor prognosis of esophageal cancer patients. +other hsa-mir-122 Hepatitis B Virus Infection 25299106 Expression and clinical significance of miR-122 and miR-29 in hepatitis B virus-related liver disease. +other hsa-mir-29 Hepatitis B Virus Infection 25299106 Expression and clinical significance of miR-122 and miR-29 in hepatitis B virus-related liver disease. +other hsa-mir-491 "Carcinoma, Ovarian" 25299770 miR-491-5p-induced apoptosis in ovarian carcinoma depends on the direct inhibition of both BCL-XL and EGFR leading to BIM activation. +other hsa-mir-126 Inflammation 25300227 Polyphenolic extracts from cowpea (Vigna unguiculata) protect colonic myofibroblasts (CCD18Co cells) from lipopolysaccharide (LPS)-induced inflammation--modulation of microRNA 126. +other hsa-mir-30b Heart Failure 25301066 E2F1 transcriptionally represses miR-30b expression. +other hsa-mir-106a Helicobacter pylori Infection 25307786 A MDM2-dependent positive-feedback loop is involved in inhibition of miR-375 and miR-106b induced by Helicobacter pylori lipopolysaccharide. +other hsa-mir-375 Helicobacter pylori Infection 25307786 A MDM2-dependent positive-feedback loop is involved in inhibition of miR-375 and miR-106b induced by Helicobacter pylori lipopolysaccharide. +other hsa-mir-29a Vascular Hypertrophy 25308856 Effect of miR-29a inhibition on ventricular hypertrophy induced by pressure overload. +other hsa-mir-429 "Carcinoma, Hepatocellular, HBV-Related" 25312821 miR-429 represses cell proliferation and induces apoptosis in HBV-related HCC. +other hsa-mir-133a Cardiomegaly 25313674 Our observations supplied the possibility that circulating miR-133a could be a surrogate biomarker of cardiac hypertrophy in MHD patients. +other hsa-mir-126 Atherosclerosis 25315114 "MicroRNAs (miRNAs) encapsulated within microparticles (MPs) are likely to have a role in cell-to-cell signaling in a variety of diseases, including atherosclerosis." +other hsa-mir-21 "Carcinoma, Thyroid" 25316501 The PDCD4/miR-21 pathway in medullary thyroid carcinoma. +other hsa-mir-125b-1 "Leukemia, Myeloid" 25316507 "Myeloid neoplasm with translocation t(2;11)(p21;q23-24), elevated microRNA 125b-1, and JAK2 exon 12 mutation." +other hsa-mir-135a Gastric Neoplasms 25322930 Regulation of BGC-823 cell sensitivity to adriamycin via miRNA-135a-5p. +other hsa-mir-21 Lung Neoplasms 25323306 Effect of microRNA-21 on multidrug resistance reversal in A549/DDP human lung cancer cells. +other hsa-mir-146a Glioblastoma 25326894 The Downregulation of MicroRNA-146a Modulates TGF-¦Â Signaling Pathways Activityin Glioblastoma. +other hsa-mir-106b "Carcinoma, Hepatocellular" 25327652 Effects of miR-106b expression on the proliferation of human hepatocellular carcinoma cells. +other hsa-mir-200a Ovarian Neoplasms 25327865 Involvement of miR-200a in chemosensitivity regulation of ovarian cancer. +other hsa-mir-378 Colorectal Carcinoma 25328987 MicroRNA-378 inhibits cell growth and enhances L-OHP-induced apoptosis in human colorectal cancer. +other hsa-mir-33a Inflammation 25329888 Effects of miR-33a-5P on ABCA1/G1-mediated cholesterol efflux under inflammatory stress in THP-1 macrophages. +other hsa-mir-375 "Carcinoma, Cervical" 25330011 miR-375 mediated acquired chemo-resistance in cervical cancer by facilitating EMT. +other hsa-let-7a Colon Neoplasms 25330373 "63 miRNA are selectively enriched in the EVs--miR-19a/b-3p, miR-378a/c/d, and miR-577 and members of the let-7 and miR-8 families being the most prominent." +other hsa-let-7f Colon Neoplasms 25330373 "63 miRNA are selectively enriched in the EVs--miR-19a/b-3p, miR-378a/c/d, and miR-577 and members of the let-7 and miR-8 families being the most prominent." +other hsa-mir-96 Prostate Neoplasms 25333253 Biphasic regulation of autophagy by miR-96 in prostate cancer cells under hypoxia. +other hsa-mir-573 Breast Neoplasms 25333258 MiR-578 and miR-573 as potential players in BRCA-related breast cancer angiogenesis. +other hsa-mir-578 Breast Neoplasms 25333258 MiR-578 and miR-573 as potential players in BRCA-related breast cancer angiogenesis. +other hsa-mir-34a "Carcinoma, Colon" 25333573 Inhibition of lactate dehydrogenase A by microRNA-34a resensitizes colon cancer cells to 5-fluorouracil. +other hsa-mir-423 "Carcinoma, Laryngeal" 25337209 microRNA-423-3p promotes tumor progression via modulation of AdipoR2 in laryngeal carcinoma. +other hsa-mir-29b Osteosarcoma 25337211 A key role of microRNA-29b in suppression of osteosarcoma cell proliferation and migration via modulation of VEGF. +other hsa-mir-30c Lung Neoplasms 25340791 "Specifically, miR-30c, a FHIT-upregulated microRNA, contributes to FHIT function in suppression of EMT and metastasis" +other hsa-mir-92a Glioma 25342742 We conclude that glioma-derived miR-92a induces IL-6(+) IL-10(+) NKT cells; this fraction of NKT cells can suppress cytotoxic CD8(+) T cells. +other hsa-mir-29b Aortic Aneurysm 25342766 Battle of the bulge: miR-195 versus miR-29b in aortic aneurysm. +other hsa-mir-382 Osteosarcoma 25344865 miR-382 inhibits tumor growth and enhance chemosensitivity in osteosarcoma. +other hsa-mir-9 "Carcinoma, Cervical" 25344913 Activation of miR-9 by human papillomavirus in cervical cancer. +other hsa-mir-126 "Carcinoma, Hepatocellular" 25345948 Expression of miR-126/miR-126* in hepatocelluar carcinoma and its correlation with clinical outcomes. +other hsa-mir-939 "Squamous Cell Carcinoma, Esophageal" 25346128 Expression of microRNA-939 and its correlation with prognosis in esophageal squamous cell carcinoma. +other hsa-mir-23a Neoplasms [unspecific] 25347474 Targeting miR-23a in CD8+ cytotoxic T lymphocytes prevents tumor-dependent immunosuppression. +other hsa-mir-34a Medulloblastoma 25348795 MiR-34a deficiency accelerates medulloblastoma formation in vivo. +other hsa-mir-146a Systemic Lupus Erythematosus 25349113 The miR-146a polymorphism and susceptibility to systemic lupus erythematosus and rheumatoid arthritis : a meta-analysis. +other hsa-mir-132 Nervous System Diseases [unspecific] 25351997 Chronic infection of Toxoplasma gondii downregulates miR-132 expression in multiple brain regions in a sex-dependent manner. +other hsa-mir-24 "Aortic Aneurysm, Abdominal" 25358394 miR-24 limits aortic vascular inflammation and murine abdominal aneurysm development. +other hsa-mir-106b Melanoma 25361006 Down-regulation of miRNA-106b inhibits growth of melanoma cells by promoting G1-phase cell cycle arrest and reactivation of p21/WAF1/Cip1 protein. +other hsa-mir-34a Colorectal Carcinoma 25362853 miR-34a-5p suppresses colorectal cancer metastasis and predicts recurrence in patients with stage II/III colorectal cancer. +other hsa-mir-200c Prostate Neoplasms 25363395 Effects of miR-200c on the migration and invasion abilities of human prostate cancer Du145 cells and the corresponding mechanism. +other hsa-mir-214 Neoplasms [unspecific] 25364765 "By contrast, miR-24, miR-125b, miR-195, and miR-214 function as oncogenic or tumor suppressor miRNAs in a cancer (sub)type-dependent manner." +other hsa-mir-24 Neoplasms [unspecific] 25364765 "By contrast, miR-24, miR-125b, miR-195, and miR-214 function as oncogenic or tumor suppressor miRNAs in a cancer (sub)type-dependent manner." +other hsa-mir-21 "Carcinoma, Ovarian, Clear Cell" 25366985 MicroRNA-21 is a candidate driver gene for 17q23-25 amplification in ovarian clear cell carcinoma. +other hsa-mir-29 "Carcinoma, Hepatocellular" 25367851 Negative feedback of miR-29 family TET1 involves in hepatocellular cancer. +other hsa-mir-509 "Leukemia, Lymphoblastic" 25368993 Regulation of RAB5C is important for the growth inhibitory effects of MiR-509 in human precursor-B acute lymphoblastic leukemia. +other hsa-mir-145 Multiple Myeloma 25369735 Synthetic miR-145 mimic inhibits multiple myeloma cell growth in vitro and in vivo. +other hsa-mir-93 Colorectal Carcinoma 25371073 MicroRNA-93 suppress colorectal cancer development via Wnt/¦Â-catenin pathway downregulating. +other hsa-mir-25 Prostate Neoplasms 25372501 "These effects were strongly associated with changes in reduced expression of the miR-106b cluster (miR-106b, miR-93, and miR-25)" +other hsa-mir-93 Prostate Neoplasms 25372501 "These effects were strongly associated with changes in reduced expression of the miR-106b cluster (miR-106b, miR-93, and miR-25)" +other hsa-mir-1 Glioblastoma 25374033 Targeted delivery of tumor suppressor microRNA-1 by transferrin-conjugated lipopolyplex nanoparticles to patient-derived glioblastoma stem cells. +other hsa-mir-9 Neoplasms [unspecific] 25375090 MicroRNA-9 promotes tumor metastasis via repressing E-cadherin in esophageal squamous cell carcinoma. +other hsa-mir-21 Neoplasms [unspecific] 25376700 MicroRNA-21 and the clinical outcomes of various carcinomas: a systematic review and meta-analysis. +other hsa-mir-18a Colorectal Carcinoma 25379703 miR-18a inhibits CDC42 and plays a tumour suppressor role in colorectal cancer cells. +other hsa-mir-410 Osteosarcoma 25385479 VEGF-mediated suppression of cell proliferation and invasion by miR-410 in osteosarcoma. +other hsa-mir-130b "Carcinoma, Hepatocellular" 25387077 MicroRNA-130b promotes cell aggressiveness by inhibiting peroxisome proliferator-activated receptor gamma in human hepatocellular carcinoma. +other hsa-mir-451 Osteosarcoma 25391425 miR-451 may play an important role in tumor growth and metastasis in osteosarcoma. +other hsa-mir-193a Lung Neoplasms 25391651 our findings provide the first clues regarding the role of miR-193a-3p as a tumor suppressor in lung cancer through the inhibition of ERBB4 translation. +other hsa-mir-107 Kidney Diseases [unspecific] 25392232 "new strategies for probing autonomic circulatory control and ultimately, susceptibility to hypertensive renal sequelae." +other hsa-mir-9 Gastric Neoplasms 25395097 "membranous ALCAM expression and high serum sALCAM levels are independent prognostic markers of poor survival for patients with GC, and that the overexpression of ALCAM may be due to the downregulation of miR-9." +other hsa-mir-34a Atherosclerosis 25395581 miR-34a is involved in the flow-dependent regulation of endothelial inflammation. +other hsa-mir-200 Breast Neoplasms 25401471 metastatic capability can be transferred by the uptake of extracellular vesicles. +other hsa-mir-122 Hepatitis C Virus Infection 25403145 "Our study provides insight into the interaction between miR-122 and HCV, including viral adaptation to reduced miR-122 bioavailability, and has implications for the development of anti-miR-122-based HCV drugs." +other hsa-mir-125b Neoplasms [unspecific] 25403182 these findings illuminate miR-125b as an important microRNA regulator that is shared between normal skin progenitors and their early malignant counterparts. +other hsa-mir-141 Neoplasms [unspecific] 25403569 our comprehensive pan-cancer analysis provided not only biological insights into metastasis but also brought to bear the clinical relevance of the proposed recurrent miRNA-gene associations. +other hsa-mir-200 Neoplasms [unspecific] 25403569 our comprehensive pan-cancer analysis provided not only biological insights into metastasis but also brought to bear the clinical relevance of the proposed recurrent miRNA-gene associations. +other hsa-mir-429 Neoplasms [unspecific] 25403569 our comprehensive pan-cancer analysis provided not only biological insights into metastasis but also brought to bear the clinical relevance of the proposed recurrent miRNA-gene associations. +other hsa-mir-375 "Carcinoma, Esophageal" 25404787 The findings from this meta-analysis suggest that miR-375 expression is associated with OS of patients with malignant tumors and could be a useful clinical prognostic biomarker. +other hsa-mir-23b Bladder Neoplasms 25405368 RNA networks regulated by tumor-suppressive miR-23b/27b provide new insights into the potential mechanisms of BC oncogenesis and metastasis. +other hsa-mir-27b Bladder Neoplasms 25405368 RNA networks regulated by tumor-suppressive miR-23b/27b provide new insights into the potential mechanisms of BC oncogenesis and metastasis. +other hsa-mir-429 Breast Neoplasms 25405387 our results offer an opportunity for further understanding of the recondite mechanisms underlying the bone metastasis of breast cancer. +other hsa-let-7a Cholesteatoma 25405753 reveal the crucial role of let-7a miRNA in the inhibition of growth and invasion of cholesteatoma keratinocytes. +other hsa-mir-21 Cholesteatoma 25405753 reveal the crucial role of let-7a miRNA in the inhibition of growth and invasion of cholesteatoma keratinocytes. +other hsa-let-7f Nervous System Diseases [unspecific] 25406171 EW-induced mitochondrial respiratory suppression was exacerbated by TSA treatment in a manner that was attenuated by let-7f antagomir cotreatment. +other hsa-mir-183 Prostate Neoplasms 25409297 "miRNAs 200b, 30a, 1, and 183 and the genes Twist1 and Vimentin might play important roles in the progression of prostate cancer and may eventually become important prognostic markers." +other hsa-mir-203 Prostate Neoplasms 25409297 "miRNAs 200b, 30a, 1, and 183 and the genes Twist1 and Vimentin might play important roles in the progression of prostate cancer and may eventually become important prognostic markers." +other hsa-mir-205 Prostate Neoplasms 25409297 "miRNAs 200b, 30a, 1, and 183 and the genes Twist1 and Vimentin might play important roles in the progression of prostate cancer and may eventually become important prognostic markers." +other hsa-mir-21 Prostate Neoplasms 25409297 "miRNAs 200b, 30a, 1, and 183 and the genes Twist1 and Vimentin might play important roles in the progression of prostate cancer and may eventually become important prognostic markers." +other hsa-mir-373 Prostate Neoplasms 25409297 "miRNAs 200b, 30a, 1, and 183 and the genes Twist1 and Vimentin might play important roles in the progression of prostate cancer and may eventually become important prognostic markers." +other hsa-mir-204 Mesial Temporal Lobe Epilepsy 25410734 miR-204 and miR-218 are developmentally regulated in the hippocampus and may contribute to the molecular mechanisms underlying the pathogenesis of MTLE and HS. +other hsa-mir-218 Mesial Temporal Lobe Epilepsy 25410734 miR-204 and miR-218 are developmentally regulated in the hippocampus and may contribute to the molecular mechanisms underlying the pathogenesis of MTLE and HS. +other hsa-mir-106b Coronary Artery Disease 25415674 "a relationship between the miR-17-92 family and lipid metabolism, which merits further study." +other hsa-mir-17 Coronary Artery Disease 25415674 "a relationship between the miR-17-93 family and lipid metabolism, which merits further study." +other hsa-mir-18a Coronary Artery Disease 25415674 "a relationship between the miR-17-94 family and lipid metabolism, which merits further study." +other hsa-mir-92a Coronary Artery Disease 25415674 "a relationship between the miR-17-95 family and lipid metabolism, which merits further study." +other hsa-mir-449b Prostate Neoplasms 25416653 High miR-449b expression was shown to be an independent predictor of biochemical recurrence after radical prostatectomy. +other hsa-mir-200a Colorectal Carcinoma 25422078 "PZH can inhibit metastasis of colorectal cancer cells via modulating TGF-¦Â1/ZEB/miR-200 signaling network, which might be one of the mechanisms whereby PZH exerts its anticancer function." +other hsa-mir-200b Colorectal Carcinoma 25422078 "PZH can inhibit metastasis of colorectal cancer cells via modulating TGF-¦Â1/ZEB/miR-200 signaling network, which might be one of the mechanisms whereby PZH exerts its anticancer function." +other hsa-mir-200c Colorectal Carcinoma 25422078 "PZH can inhibit metastasis of colorectal cancer cells via modulating TGF-¦Â1/ZEB/miR-200 signaling network, which might be one of the mechanisms whereby PZH exerts its anticancer function." +other hsa-mir-449a "Carcinoma, Lung, Non-Small-Cell" 25424357 The tumor suppression role of microRNA-449a could be due to its promotion of tumor cell proliferation and its inhibition of tumor cell apoptosis. +other hsa-mir-141 "Carcinoma, Hepatocellular" 25425543 miR-141 functions as a tumor suppressor in HCC cells through the inhibition of HNF-3¦Â translation. +other hsa-mir-10b Neoplasms [unspecific] 25426550 "miR-520d-5p leads to reduced proliferation of tumor cells, and that high levels of miR-520d-5p correlate with higher survival rates of cancer patients." +other hsa-mir-520d Neoplasms [unspecific] 25426550 "miR-520d-5p leads to reduced proliferation of tumor cells, and that high levels of miR-520d-5p correlate with higher survival rates of cancer patients." +other hsa-mir-155 "Leukemia, Myeloid, Acute" 25428263 this 3-microRNA scoring system is simple and powerful for risk stratification of de novo AML patients. +other hsa-mir-203 "Leukemia, Myeloid, Acute" 25428263 this 3-microRNA scoring system is simple and powerful for risk stratification of de novo AML patients. +other hsa-mir-9 "Leukemia, Myeloid, Acute" 25428263 this 3-microRNA scoring system is simple and powerful for risk stratification of de novo AML patients. +other hsa-mir-23a Neoplasms [unspecific] 25429623 HSP70 could be beneficial to tumor cells by helping to maintain the expression of oncogenic miRNAs under conditions of cellular stress. +other hsa-mir-210 Tibial Meniscus Injuries 25430980 An intra-articular injection of ds miR-210 was effective in the healing of the damaged white zone meniscus through promotion of the collagen type 2 production from meniscus cells and through upregulated of VEGF and FGF2 from synovial cells. +other hsa-mir-193b Psoriasis 25431026 "the altered local miRNA changes seen in the RD are reflected in the circulating immune cells, suggesting that miRNAs may contribute to the pathogenesis of psoriasis." +other hsa-mir-223 Psoriasis 25431026 "the altered local miRNA changes seen in the RD are reflected in the circulating immune cells, suggesting that miRNAs may contribute to the pathogenesis of psoriasis." +other hsa-mir-26a Breast Neoplasms 25434799 miR-26a functions as a tumour suppressor in TNBC development and serves as a prognostic marker for breast cancer. +other hsa-mir-1181 Pancreatic Neoplasms 25444909 miR-1181 plays a vital role in inhibiting the CSCs-like phenotypes in pancreatic cancer and might represent a potential target for anti-pancreatic cancer. +other hsa-mir-23a Breast Neoplasms 25445205 "The overall concordance rates between miR-23a with HRG and FOXM1 tissue RNAs were 91% and 79%, respectively. The median follow-up period was 49 months. mi-23a and HRG RNA were significant independent prognostic markers in relapse-free survival. miR-23a may have an oncogenic function and enhance BC progression by directly activating FOXM1 and HRG at RNA level." +other hsa-mir-21 Neoplasms [unspecific] 25445583 "Further, during the transformation of HBE cells, inhibition of miR-21 with an miR-21 inhibitor increased levels of PDCD4, an inhibitor of neoplastic transformation;" +other hsa-mir-134 "Carcinoma, Embryonal" 25447206 FOXM1 is essential for human pluripotent stem cells and miR-134 attenuates its expression during differentiation. +other hsa-mir-21 "Carcinoma, Hepatocellular" 25447674 "I3C could function as a miR-21 regulator, leading to repression of the PTEN/AKT pathway and opening a new avenue for eradication of drug-resistant cells, thus potentially helping to improve the therapeutic outcome in patients diagnosed with HCC." +other hsa-mir-221 "Carcinoma, Hepatocellular" 25447674 "I3C could function as a miR-19 regulator, leading to repression of the PTEN/AKT pathway and opening a new avenue for eradication of drug-resistant cells, thus potentially helping to improve the therapeutic outcome in patients diagnosed with HCC." +other hsa-mir-222 "Carcinoma, Hepatocellular" 25447674 "I3C could function as a miR-20 regulator, leading to repression of the PTEN/AKT pathway and opening a new avenue for eradication of drug-resistant cells, thus potentially helping to improve the therapeutic outcome in patients diagnosed with HCC." +other hsa-mir-221 Breast Neoplasms 25447917 miR-221-3p may give crucial information about molecular mechanism of the disease upon PAK1 activity or different mechanisms with respect to histopathology and severity of breast cancer. +other hsa-mir-197 Lung Neoplasms 25451482 ER stress plays a major role in STAT6-induced apoptosis. +other hsa-mir-320a Colorectal Carcinoma 25458952 "microRNA-320b may function in competing with microRNA-320a. Thus, our study has proposed one novel mechanism for controlling colorectal cancer proliferation and invasion through homologous competition between microRNAs. This mechanism may be important for colorectal cancer metastasis." +other hsa-mir-320b Colorectal Carcinoma 25458952 "microRNA-320b may function in competing with microRNA-320a. Thus, our study has proposed one novel mechanism for controlling colorectal cancer proliferation and invasion through homologous competition between microRNAs. This mechanism may be important for colorectal cancer metastasis." +other hsa-mir-126 Prostate Neoplasms 25462564 The regulation of these factors by miR-126 and miR-149 is essential for syndecan-1-mediated development of androgen-refractory prostate cancer. +other hsa-mir-149 Prostate Neoplasms 25462564 The regulation of these factors by miR-126 and miR-149 is essential for syndecan-1-mediated development of androgen-refractory prostate cancer. +other hsa-mir-223 Atherosclerosis 25463083 "MiR-223-mediated suppression of TF expression provides a novel molecular mechanism for the regulation of coagulation cascade, and suggests a clue against thrombogenesis during the process of atherosclerotic plaque rupture." +other hsa-mir-29a Heart Failure 25464262 "MicroRNA-29a (miR-29a), a key regulator of tissue fibrosis, was highly expressed in the exosomes and the marginal area of the RIC group." +other hsa-mir-145 Acute Myocardial Infarction 25465803 Circulating miR-145 may be a novel biomarker for predicting long-term outcome after acute myocardial infarction. +other hsa-mir-144 Breast Neoplasms 25465851 "4 miRNAs that are generally dysregulated in human pathologies. Although these markers are not specific to certain diseases they may add to the diagnosis in combination with other markers, building a specific signature. Besides these dysregulated miRNAs, we propose a set of constant miRNAs that may be used as control markers." +other hsa-mir-146a Enterovirus Infection 25469565 EV71-induced cell apoptosis is partly governed by altered miRNAs. +other hsa-mir-370 Enterovirus Infection 25469565 EV71-induced cell apoptosis is partly governed by altered miRNAs. +other hsa-mir-122 "Fatty Liver, Non-Alcoholic" 25470250 "Finally, the liver appears to be an important source of circulating EVs in NAFLD animals as evidenced by the enrichment in blood with miR-122 and 192--two microRNAs previously described in chronic liver diseases, coupled with a corresponding decrease in expression of these microRNAs in the liver." +other hsa-mir-143 Colorectal Carcinoma 25474488 a role of the miR-143/145 cluster as a tumor suppressor in colorectal cancer through the inhibition of IGF1R translation. +other hsa-mir-145 Colorectal Carcinoma 25474488 a role of the miR-143/145 cluster as a tumor suppressor in colorectal cancer through the inhibition of IGF1R translation. +other hsa-mir-196b Leukemia 25475721 "miRNA-196b may play an essential role in the development of MLL-associated leukemias through inhibiting cell differentiation and apoptosis, while promoting cell proliferation." +other hsa-mir-153 Lung Neoplasms 25475731 significance of miR-153 and ADAM19 in the development and progression of NSCLC. +other hsa-mir-145 Neoplasms [unspecific] 25476854 large-scale prospective studies and additional improvements are urgently needed to confirm our findings and its utilization for routine clinical diagnosis in future. +other hsa-mir-143 Neoplasms [unspecific] 25477374 differences in these tumor suppressors might contribute to regional differences in normal colonic gene expression and modulate site-specific differences in malignant predisposition. +other hsa-mir-145 Neoplasms [unspecific] 25477374 differences in these tumor suppressors might contribute to regional differences in normal colonic gene expression and modulate site-specific differences in malignant predisposition. +other hsa-mir-200a "Carcinoma, Hepatocellular" 25482402 miR-200a may be recognized as a novel potential biomarker to predict the survival of patients with HCCs following liver transplantation. +other hsa-mir-155 Breast Neoplasms 25484137 a role of miR-155 in thiamine homeostasis and suggests a function of this oncogenic miRNA on breast cancer metabolism. +other hsa-mir-21 Peripheral Nerve Injury 25484256 miR-21 and miR-222 inhibited neuronal apoptosis at least partially through suppressing TIMP3 after peripheral nerve injury. +other hsa-mir-222 Peripheral Nerve Injury 25484256 miR-21 and miR-222 inhibited neuronal apoptosis at least partially through suppressing TIMP3 after peripheral nerve injury. +other hsa-mir-146a Neurodegenerative Diseases [unspecific] 25484882 "We particularly focus on the role played by miR-146a in the regulation and signaling mediated by one of the main pattern recognition receptors, toll/IL-1 receptors (TLRs)." +other hsa-mir-143 Neoplasms [unspecific] 25486198 "identify new molecules and mechanisms involved in the DDR, and to examine their role in tumor suppression and the clinical outcome of cancer patients." +other hsa-mir-16 Neoplasms [unspecific] 25486198 "identify new molecules and mechanisms involved in the DDR, and to examine their role in tumor suppression and the clinical outcome of cancer patients." +other hsa-mir-34 Neoplasms [unspecific] 25486198 "identify new molecules and mechanisms involved in the DDR, and to examine their role in tumor suppression and the clinical outcome of cancer patients." +other hsa-mir-203 Choriocarcinoma 25486432 "Besides EZH2, increases in miR-203 expression in the crypts at days 6 and 12 post infection correlated with reduced levels of its target WIF1; overexpression of miR-203 in primary colonocytes decreased WIF1 mRNA and protein levels." +other hsa-mir-142 Multiple Sclerosis 25486582 "AHSCT normalizes microRNA and gene expression, thereby improving the immunoregulatory network. These mechanisms may be important for disease control in the early periods after AHSCT." +other hsa-mir-155 Multiple Sclerosis 25486582 "AHSCT normalizes microRNA and gene expression, thereby improving the immunoregulatory network. These mechanisms may be important for disease control in the early periods after AHSCT." +other hsa-mir-16 Multiple Sclerosis 25486582 "AHSCT normalizes microRNA and gene expression, thereby improving the immunoregulatory network. These mechanisms may be important for disease control in the early periods after AHSCT." +other hsa-mir-155 Neoplasms [unspecific] 25486872 miR-155 expression is associated with chemoimmunotherapy outcome and is modulated by Bruton's tyrosine kinase inhibition with Ibrutinib. +other hsa-mir-148a Chronic Inflammation 25486906 "Twist1 and T-bet not only control the differentiation and function of Th1 cells, but also their persistence in chronic inflammation." +other hsa-mir-29a Human Immunodeficiency Virus Infection 25486977 links miR-29a to viral latency and suggests another approach to activate and destroy latent HIV-1 reservoirs. +other hsa-mir-34a Osteosarcoma 25490093 cell response to etoposide-induced DNA damage was not compromised in cells with dominant-negative p53 expression. +other hsa-mir-221 Melanoma 25492219 The hair shaft miR-221 levels were significantly higher in patients with MM than controls. +other hsa-mir-21 Rectal Neoplasms 25496125 "miR-21-5p as a promising predictive biomarker, which should aid in the selection of patients with cCR to nCRT that potentially could be spared from radical surgery." +other hsa-mir-21 Pleural Mesothelioma 25497279 a novel 6-microRNA signature (miR-Score) that can accurately predict prognosis of MPM patients. +other hsa-mir-221 Pleural Mesothelioma 25497279 a novel 6-microRNA signature (miR-Score) that can accurately predict prognosis of MPM patients. +other hsa-mir-222 Pleural Mesothelioma 25497279 a novel 6-microRNA signature (miR-Score) that can accurately predict prognosis of MPM patients. +other hsa-mir-23a Pleural Mesothelioma 25497279 a novel 6-microRNA signature (miR-Score) that can accurately predict prognosis of MPM patients. +other hsa-mir-30e Pleural Mesothelioma 25497279 a novel 6-microRNA signature (miR-Score) that can accurately predict prognosis of MPM patients. +other hsa-mir-31 Pleural Mesothelioma 25497279 a novel 6-microRNA signature (miR-Score) that can accurately predict prognosis of MPM patients. +other hsa-mir-137 Lung Neoplasms 25498886 miR-137 may be an independent favorable prognostic factor in NSCLC patients. +other hsa-mir-494 Oral Neoplasms 25500095 the role of miR-494 as a tumor suppressor miRNA in oral cancer. +other hsa-mir-2909 Immune System Disease [unspecific] 25500259 a mechanistic-pathway is proposed that links the epigenomic-interplay between MALT1 and miR-2909. +other hsa-mir-206 Pancreatic Adenocarcinoma 25500542 "miR-206 as a pleiotropic modulator of different hallmarks of cancer, and as such raising the intriguing possibility that miR-206 may be an attractive candidate for miRNA-based anticancer therapies." +other hsa-mir-23a "Squamous Cell Carcinoma, Tongue" 25501015 the molecular mechanisms underlying TSCC chemoresistance. +other hsa-mir-210 Osteoporosis 25503465 miR-210 played an important role in ameliorating the estrogen deficiency caused-postmenopausal osteoporosis through promotion the VEGF expression and osteoblast differentiation. +other hsa-mir-130 Pulmonary Hypertension 25505270 olecular cross-talk among the diverse cellular populations involved in PH. +other hsa-mir-301 Pulmonary Hypertension 25505270 olecular cross-talk among the diverse cellular populations involved in PH. +other hsa-mir-21 Glioma 25510379 An independent meta-analysis of five included studies was conducted to evaluate the diagnostic efficacy of miR-21 in patients with glioma +other hsa-mir-27a Obesity 25510894 "Correspondingly, the expression of miR-27a and miR-27b were up-regulated by persimmon tannin from Day 2 to Day 8 significantly." +other hsa-mir-27b Obesity 25510894 "Correspondingly, the expression of miR-27a and miR-27b were up-regulated by persimmon tannin from Day 2 to Day 8 significantly." +other hsa-mir-7 Breast Neoplasms 25511742 miR-7-5p has a critical function through blocking REG¦Ã in breast cancer cells. +other hsa-mir-25 "Carcinoma, Neuroendocrine" 25512615 "The pathogenesis of prostatic SCNC involves a p53 and Aurora Kinase A signaling mechanism, both potentially targetable pathways." +other hsa-mir-17 Retinoblastoma 25513843 "the antiproliferative property of pri-apt in RB cell lines, which can be readily modified by developing appropriate vectors for the delivery of the aptamer specifically to cancer cells." +other hsa-mir-18a Retinoblastoma 25513843 "the antiproliferative property of pri-apt in RB cell lines, which can be readily modified by developing appropriate vectors for the delivery of the aptamer specifically to cancer cells." +other hsa-mir-19b Retinoblastoma 25513843 "the antiproliferative property of pri-apt in RB cell lines, which can be readily modified by developing appropriate vectors for the delivery of the aptamer specifically to cancer cells." +other hsa-mir-92a Colorectal Carcinoma 25515201 miR-92a is involved in lymph node metastasis of CRC patients through PTEN-regulated PI3K/AKT signaling pathway. +other hsa-mir-122 Obesity 25515554 Elevated circulating miR-122 is positively associated with obesity and insulin resistance in young adults. These findings provide a better understanding regarding the role of miRNAs in adiposity and insulin sensitivity. +other hsa-mir-210 Endometriosis 25516558 "This work was supported in part by Grants-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (no. 13237327 to K.N., no. 25861500 to Y.K. and no. 23592407 to H.N.). There are no conflicts of interest to declare." +other hsa-mir-193b Laryngeal Neoplasms 25517434 Culturing the IL-10(+) Mos with effector CD8(+) T cells resulted in the suppression of CD8(+) T-cell activitie +other hsa-mir-99 Heart Failure 25517466 concept for identifying and activating conserved molecular programs to regenerate the damaged heart. +other hsa-mir-133a "Squamous Cell Carcinoma, Lung" 25518741 Further analysis of novel cancer signaling pathways modulated by the tumor-suppressive cluster miR-1/133a will provide insights into the molecular mechanisms of lung-SCC oncogenesis and metastasis +other hsa-mir-100 Coronary Atherosclerosis 25519160 miR-100 might be released into the coronary circulation from vulnerable coronary plaques. This study provides insights into the role of miRNAs in coronary atherosclerotic disease. +other hsa-mir-1226 Lung Neoplasms 25519225 the screening approach used in this study can identify clinically relevant synthetic lethal interactions and that vitamin D receptor agonists may show enhanced efficacy in p53-negative lung cancer patients. +other hsa-mir-92a Lung Neoplasms 25519225 the screening approach used in this study can identify clinically relevant synthetic lethal interactions and that vitamin D receptor agonists may show enhanced efficacy in p53-negative lung cancer patients. +other hsa-mir-155 "Adenocarcinoma, Pancreatic Ductal" 25520858 "MiR-21, miR-155 and miR-216 in stool have the potential of becoming biomarkers for screening PDAC." +other hsa-mir-126 "Squamous Cell Carcinoma, Lung" 25521201 rule discovery followed by distance separation is a powerful computational method to identify reliable miRNA biomarkers. The visualization of the rules and the clear separation between the normal and cancer samples by our rules will help biology experts for their analysis and biological interpretation. +other hsa-mir-205 "Squamous Cell Carcinoma, Lung" 25521201 rule discovery followed by distance separation is a powerful computational method to identify reliable miRNA biomarkers. The visualization of the rules and the clear separation between the normal and cancer samples by our rules will help biology experts for their analysis and biological interpretation. +other hsa-mir-98 "Squamous Cell Carcinoma, Lung" 25521201 rule discovery followed by distance separation is a powerful computational method to identify reliable miRNA biomarkers. The visualization of the rules and the clear separation between the normal and cancer samples by our rules will help biology experts for their analysis and biological interpretation. +other hsa-mir-375 Tongue Neoplasms 25521291 the four anti-cancer drugs examined in this study induce the expression of tumor suppressor miR-375 in tongue cancer. +other hsa-mir-155 Breast Neoplasms 25523096 "the miRNA and isomiR levels in BC, which indicates biological roles of isomiRs." +other hsa-mir-21 Breast Neoplasms 25523096 "the miRNA and isomiR levels in BC, which indicates biological roles of isomiRs." +other hsa-mir-221 Breast Neoplasms 25523096 "the miRNA and isomiR levels in BC, which indicates biological roles of isomiRs." +other hsa-mir-25 Breast Neoplasms 25523096 "the miRNA and isomiR levels in BC, which indicates biological roles of isomiRs." +other hsa-mir-30e Breast Neoplasms 25523096 "the miRNA and isomiR levels in BC, which indicates biological roles of isomiRs." +other hsa-mir-143 Myeloproliferative Neoplasms 25527813 Our findings of aberrant miR-143 expression support the concept that factors other than JAK2 V617F mutation may contribute to the pathogenesis and some clinical signs of MPNs. +other hsa-mir-134 "Carcinoma, Endometrial" 25528443 endogenous miR-134 regulation in HuECSCs may suppress tumourigenesis in human endometrial carcinoma. +other hsa-mir-22 Vascular Disease [unspecific] 25530680 Mox-LDL interferes with parameters associated with angiogenesis. They suggest that high LDL levels in patients would impair their endothelial cell capacity to cope with a damaged endothelium contributing negatively to the progression of the atheroma plaque. +other hsa-mir-486 "Leukemia, Myeloid" 25533034 "miR-486-5p cooperates with GATA1s in supporting the growth and survival, and the aberrant erythroid phenotype of the megakaryocytic leukemias of DS." +other hsa-mir-21 Ischemia-Reperfusion Injury 25536091 isoflurane mediates protection of cardiomyocytes against oxidative stress via an miR-21/programmed cell death protein 4 pathway. +other hsa-mir-146a Ovarian Neoplasms 25537514 a proportion of patients with wild-type BRCA1/2 ovarian cancers benefit from platinum-based chemotherapy and that the patients who benefit could be predicted from BRCA1/2-directed miRNA signature. +other hsa-mir-148a Ovarian Neoplasms 25537514 a proportion of patients with wild-type BRCA1/2 ovarian cancers benefit from platinum-based chemotherapy and that the patients who benefit could be predicted from BRCA1/2-directed miRNA signature. +other hsa-mir-545 Ovarian Neoplasms 25537514 a proportion of patients with wild-type BRCA1/2 ovarian cancers benefit from platinum-based chemotherapy and that the patients who benefit could be predicted from BRCA1/2-directed miRNA signature. +other hsa-mir-92b Gastric Neoplasms 25537895 "miR-92b promotes the migration, adhesion and invasion of human gastric cancer cell line SGC7901 by mediating epithelial-mesenchymal transition, and may accelerate tumor cell metastasis via signaling pathways other than PI3K/Akt pathway." +other hsa-let-7a Cervical Neoplasms 25539644 "existence of a functional loop involving Let-7a, STAT3 and miR-21 which were found potentially regulated by viral oncoprotein E6." +other hsa-mir-21 Cervical Neoplasms 25539644 "existence of a functional loop involving Let-7a, STAT3 and miR-21 which were found potentially regulated by viral oncoprotein E6." +other hsa-mir-125b Breast Neoplasms 25539763 "context-dependent roles are not clear in breast cancer, a diverse expression pattern of ALCAM mRNA was detected in a panel of breast cancer patient samples. Differentially expressed/regulated cancer-related genes upon miR-125b expression along with the significant increase of ALCAM are of future interest to understand how deregulated expression of miR-125b may have a tumor suppressor role in breast and other cancers." +other hsa-mir-15a Neoplasms [unspecific] 25540364 viral RNAs can exert their functions as competing endogenous RNAs (ceRNAs) toward microRNA and participate in important cellular processes. +other hsa-mir-155 "Lymphoma, B-Cell" 25541152 "Importantly, the targeting of miRNAs (like use of anti-miR-155 or miR-34a mimic) could provide a novel therapeutic approach as evidenced by tumour regression in xenograft mouse models and initial promising data from clinical trials." +other hsa-mir-34a "Lymphoma, B-Cell" 25541152 "Importantly, the targeting of miRNAs (like use of anti-miR-155 or miR-34a mimic) could provide a novel therapeutic approach as evidenced by tumour regression in xenograft mouse models and initial promising data from clinical trials." +other hsa-mir-125a Glioblastoma 25542152 "TAZ deregulation in glioma cells, and also demonstrated a tumor suppressor role of miR-125a-5p in glioblastoma cells." +other hsa-mir-31 Colorectal Carcinoma 25543122 Overexpression of miR-31 and -182 in CRC leads to more aggressive cancer. +other hsa-mir-21 "Leukemia, Myeloid, Acute" 25543261 deregulated miR-21 expression may contribute to disease pathogenesis in NPM1-mutated AMLs +other hsa-mir-33a Lung Neoplasms 25544258 the treatment of lung cancer and clarify the mechanism of its progression. +other hsa-mir-133a Muscle Diseases [unspecific] 25547110 human skeletal muscle differentiation and development in healthy and disease states. +other hsa-mir-133b Muscle Diseases [unspecific] 25547110 human skeletal muscle differentiation and development in healthy and disease states. +other hsa-mir-206 Muscle Diseases [unspecific] 25547110 human skeletal muscle differentiation and development in healthy and disease states. +other hsa-mir-20a Muscle Diseases [unspecific] 25547110 human skeletal muscle differentiation and development in healthy and disease states. +other hsa-mir-26 Muscle Diseases [unspecific] 25547110 human skeletal muscle differentiation and development in healthy and disease states. +other hsa-mir-30 Muscle Diseases [unspecific] 25547110 human skeletal muscle differentiation and development in healthy and disease states. +other hsa-mir-155 Neoplasms [unspecific] 25548153 "overexpression of miR-155 in tumor-specific T cells can be used to increase the effectiveness of adoptive immunotherapies in a cell-intrinsic manner without the need for life-threatening, lymphodepleting maneuvers." +other hsa-mir-150 "Carcinoma, Hepatocellular" 25549355 re-expression of MMP14 in hepatoma cells partially reverses the effect of miR-150-5p in inhibiting cell invasion +other hsa-mir-21 Neoplasms [unspecific] 25550434 ESCRT-I complex in the regulation of productive free uptake of anti-miRs and reveal potential avenues for improving oligonucleotide free uptake by cancer cells. +other hsa-mir-193b Breast Neoplasms 25550792 "miR-193b as a novel tumor suppressor plays an important role in breast cancer progression, understanding the mechanisms could account for the aggressive behaviour of breast cancer." +other hsa-mir-451 Bladder Neoplasms 25550801 "miR451 should be a tumor-suppressing gene in bladder cancer. miR-451 could maintain the bladder tumor cells in epithelial phenotype, inhibit EMT process, thereby reducing the invasion and migration of tumor cells." +other hsa-mir-139 "Carcinoma, Colon" 25550849 miR-139-3p has potential as a prognostic biomarker for colon cancer. Further prospective studies are required to validate this result. +other hsa-mir-145 "Adenocarcinoma, Esophageal" 25551563 "While expression of miR-145 in ESCC stopped proliferation and invasion, expression of miR-145 in EAC cells enhanced invasion and anoikis resistance. Although more work is required to understand how miR-145 conveys these effects, expression of miR-145 appears to promote EAC progression by enhancing invasion and protection against anoikis, which could in turn facilitate distant metastasis." +other hsa-mir-9 "Carcinoma, Hepatocellular" 25552204 the potential of miR-9 as a novel prognostic biomarker for HCC. Large well-designed studies with diverse populations and functional evaluations are warranted to confirm and extend our findings. +other hsa-mir-183 Prostate Neoplasms 25556023 the regulation of prostate-specific antigen and may eventually affect clinical decision making in prostate cancer. +other hsa-mir-574 Breast Neoplasms 25560734 functional screening mediated by miRNA libraries can provide new insights into the genes essential for tamoxifen response in breast cancer. +other hsa-mir-146a Liver Diseases [unspecific] 25562147 a critical role for miRNAs in the pathogenesis of NAFLD. +other hsa-mir-146b Liver Diseases [unspecific] 25562147 a critical role for miRNAs in the pathogenesis of NAFLD. +other hsa-mir-152 Liver Diseases [unspecific] 25562147 a critical role for miRNAs in the pathogenesis of NAFLD. +other hsa-mir-200a Liver Diseases [unspecific] 25562147 a critical role for miRNAs in the pathogenesis of NAFLD. +other hsa-mir-200b Liver Diseases [unspecific] 25562147 a critical role for miRNAs in the pathogenesis of NAFLD. +other hsa-mir-200c Liver Diseases [unspecific] 25562147 a critical role for miRNAs in the pathogenesis of NAFLD. +other hsa-mir-222 Breast Neoplasms 25562151 "¦Â-elemene could influence MDR related miRNA expression and subsequently regulate the expression of the target genes PTEN and Pgp, which may lead to reduction of the viability of the chemo-resistant breast cancer cells." +other hsa-mir-29a Breast Neoplasms 25562151 "¦Â-elemene could influence MDR related miRNA expression and subsequently regulate the expression of the target genes PTEN and Pgp, which may lead to reduction of the viability of the chemo-resistant breast cancer cells." +other hsa-mir-34a Breast Neoplasms 25562151 "¦Â-elemene could influence MDR related miRNA expression and subsequently regulate the expression of the target genes PTEN and Pgp, which may lead to reduction of the viability of the chemo-resistant breast cancer cells." +other hsa-mir-452 Breast Neoplasms 25562151 "¦Â-elemene could influence MDR related miRNA expression and subsequently regulate the expression of the target genes PTEN and Pgp, which may lead to reduction of the viability of the chemo-resistant breast cancer cells." +other hsa-mir-223 Liver Failure 25562161 "miR-223 acted to inhibit IL-1¦Â production via AIM2 pathway, suppressing Kupffer cells pro-inflammatory activation at the early stage of ALF. Thus, it played an important role in the pathogenesis of ALF." +other hsa-mir-212 Osteosarcoma 25562164 The miR-212/Sox4 interaction plays an important role of in the osteosarcoma progression. +other hsa-mir-145 Glioblastoma 25564360 Synthetic miR-145 Mimic Enhances the Cytotoxic Effect of the Antiangiogenic Drug Sunitinib in Glioblastoma. +other hsa-mir-215 Renal Fibrosis 25565137 MicroRNA-215 Regulates Fibroblast Function: Insights from a Human Fibrotic Disease. +other hsa-mir-192 Bladder Neoplasms 25566965 miR-192 may be a suppressor for bladder cancer cells by cell cycle regulation. +other hsa-mir-28 "Leukemia, T-Cell" 25568327 miR-28 may play an important role in HTLV-1 transmission. +other hsa-mir-218 "Carcinoma, Gallbladder" 25569100 "CCAT1 is a driver of malignancy, which acts in part through 'spongeing' miRNA-218-5p." +other hsa-mir-34a Bladder Neoplasms 25572695 polyphenols in PRE can be potential molecular clusters to suppress bladder cancer cell EJ proliferation via p53/miR-34a axis. +other hsa-mir-125b Lung Neoplasms 25573191 miR-125b may function as an oncogene in lung cancer. +other hsa-mir-214 Coronary Artery Disease 25575606 increased miR-214 level may be used to predict the presence and severity of coronary lesions in CAD patients. +other hsa-mir-129 Oral Leukoplakia 25576219 "a miRNA-mRNA regulatory network associated with the malignant transformation of OLK, and screened out some miRNAs and transcription factors that may have prominent roles during OLK malignant progression." +other hsa-mir-31 Oral Leukoplakia 25576219 "a miRNA-mRNA regulatory network associated with the malignant transformation of OLK, and screened out some miRNAs and transcription factors that may have prominent roles during OLK malignant progression." +other hsa-mir-339 Oral Leukoplakia 25576219 "a miRNA-mRNA regulatory network associated with the malignant transformation of OLK, and screened out some miRNAs and transcription factors that may have prominent roles during OLK malignant progression." +other hsa-mir-93 "Squamous Cell Carcinoma, Head and Neck" 25578493 miR-93 may be a valuable marker for the prediction of metastasis and prognosis in HNSCC. +other hsa-mir-152 Neoplasms [unspecific] 25578780 XIST in GSCs and important clues for understanding the key roles of lncRNA-miRNA functionalnetwork in human glioma. +other hsa-mir-210 "Leukemia, Myeloid" 25579461 The suitability of the method for biological samples was tested by detecting microRNA-210 from transfected K562 cells. +other hsa-mir-34a Neoplasms [unspecific] 25579512 Regulatory mechanisms and clinical perspectives of miR-34a in cancer. +other hsa-mir-21 Glioblastoma 25582055 ADAR2 is a key factor for maintaining edited-miRNA population and balancing the expression of several essential miRNAs involved in cancer. +other hsa-mir-221 Glioblastoma 25582055 ADAR2 is a key factor for maintaining edited-miRNA population and balancing the expression of several essential miRNAs involved in cancer. +other hsa-mir-222 Glioblastoma 25582055 ADAR2 is a key factor for maintaining edited-miRNA population and balancing the expression of several essential miRNAs involved in cancer. +other hsa-mir-16 "Cardiomyopathy, Hypertrophic" 25583328 "Attenuation of microRNA-16 derepresses the cyclins D1, D2 and E1 to provoke cardiomyocyte hypertrophy." +other hsa-mir-221 Bladder Neoplasms 25585941 "The expression of MMP-2, MMP-9 and VEGF-C were reduced, resulting in reduced invasiveness and infiltration capability of bladder cancer cells, thereby inhibiting the immune evasion of bladder cancer cells." +other hsa-mir-200a Neoplasms [unspecific] 25586904 exposure to arsenic rapidly induces a multifaceted dedifferentiation program and miR-205 has potential to be used as a marker of\ arsenic exposure as well as a maker of early urothelial carcinoma detection. +other hsa-mir-200b Neoplasms [unspecific] 25586904 exposure to arsenic rapidly induces a multifaceted dedifferentiation program and miR-205 has potential to be used as a marker of\ arsenic exposure as well as a maker of early urothelial carcinoma detection. +other hsa-mir-200c Neoplasms [unspecific] 25586904 exposure to arsenic rapidly induces a multifaceted dedifferentiation program and miR-205 has potential to be used as a marker of\ arsenic exposure as well as a maker of early urothelial carcinoma detection. +other hsa-mir-205 Neoplasms [unspecific] 25586904 exposure to arsenic rapidly induces a multifaceted dedifferentiation program and miR-205 has potential to be used as a marker of\ arsenic exposure as well as a maker of early urothelial carcinoma detection. +other hsa-mir-29b-2 Diabetes Mellitus 25587719 The pathogenic role of persistent milk signaling in mTORC1- and milk-microRNA-driven type 2 diabetes mellitus. +other hsa-mir-1 Myocardial Infarction 25588055 Downregulation of IGF1 specific miRNA-1 and -133 but not miR-145 expression was also confirmed. +other hsa-mir-15 Breast Neoplasms 25594541 the expression of the miR-15 family contributes to increased radiosensitivity of breast cancer cells by influencing G2/M checkpoint proteins. +other hsa-mir-500 Gastric Neoplasms 25595906 "we report the uncovering of a novel mechanism for constitutive NF-¦ÊB activation, indicating the potentially pivotal role of miR-500 in the progression of gastric cancer." +other hsa-mir-34a "Carcinoma, Hepatocellular" 25596083 the expression of miR-34a in HCC biopsy specimens has an independent predictive value of early recurrence after RFA. +other hsa-mir-22 Liver Neoplasms 25596928 "bile acid-activated FXR stimulates miR-22-silenced CCNA2, a novel pathway for FXR to exert its protective effect in the gastrointestinal tract." +other hsa-mir-125b Prostate Neoplasms 25597828 "use of a combination of different types of genetic markers in ejaculate together with serum PSA are at least as sensitive as those reported in DRE urine. Furthermore, a combination of serum PSA and selected miRNAs improved prediction of prostate cancer status. This approach may be helpful in triaging patients for MRI and biopsy, when confirmed by larger studies." +other hsa-mir-200b Prostate Neoplasms 25597828 "use of a combination of different types of genetic markers in ejaculate together with serum PSA are at least as sensitive as those reported in DRE urine. Furthermore, a combination of serum PSA and selected miRNAs improved prediction of prostate cancer status. This approach may be helpful in triaging patients for MRI and biopsy, when confirmed by larger studies." +other hsa-mir-200c Prostate Neoplasms 25597828 "use of a combination of different types of genetic markers in ejaculate together with serum PSA are at least as sensitive as those reported in DRE urine. Furthermore, a combination of serum PSA and selected miRNAs improved prediction of prostate cancer status. This approach may be helpful in triaging patients for MRI and biopsy, when confirmed by larger studies." +other hsa-mir-375 Prostate Neoplasms 25597828 "use of a combination of different types of genetic markers in ejaculate together with serum PSA are at least as sensitive as those reported in DRE urine. Furthermore, a combination of serum PSA and selected miRNAs improved prediction of prostate cancer status. This approach may be helpful in triaging patients for MRI and biopsy, when confirmed by larger studies." +other hsa-mir-205 "Carcinoma, Renal Cell" 25600645 how overexpression of MALAT1 confers an oncogenic function in RCC that may offer a novel theranostic marker in this disease. +other hsa-mir-10b Colorectal Carcinoma 25606801 miR-10b is potentially involved in the invasion of colorectal cancer. +other hsa-mir-100 Pancreatic Neoplasms 25607660 This pilot study highlights miRNAs that may aid in preoperative risk stratification of IPMNs and provides novel insights into miRNA-mediated progression to pancreatic malignancy. The miRNAs identified here and in other recent investigations warrant evaluation in biofluids in a well-powered prospective cohort of individuals newly-diagnosed with IPMNs and other pancreatic cysts and those at increased genetic risk for these lesions. +other hsa-mir-126 Pancreatic Neoplasms 25607660 This pilot study highlights miRNAs that may aid in preoperative risk stratification of IPMNs and provides novel insights into miRNA-mediated progression to pancreatic malignancy. The miRNAs identified here and in other recent investigations warrant evaluation in biofluids in a well-powered prospective cohort of individuals newly-diagnosed with IPMNs and other pancreatic cysts and those at increased genetic risk for these lesions. +other hsa-mir-130a Pancreatic Neoplasms 25607660 This pilot study highlights miRNAs that may aid in preoperative risk stratification of IPMNs and provides novel insights into miRNA-mediated progression to pancreatic malignancy. The miRNAs identified here and in other recent investigations warrant evaluation in biofluids in a well-powered prospective cohort of individuals newly-diagnosed with IPMNs and other pancreatic cysts and those at increased genetic risk for these lesions. +other hsa-mir-342 Pancreatic Neoplasms 25607660 This pilot study highlights miRNAs that may aid in preoperative risk stratification of IPMNs and provides novel insights into miRNA-mediated progression to pancreatic malignancy. The miRNAs identified here and in other recent investigations warrant evaluation in biofluids in a well-powered prospective cohort of individuals newly-diagnosed with IPMNs and other pancreatic cysts and those at increased genetic risk for these lesions. +other hsa-mir-99a Pancreatic Neoplasms 25607660 This pilot study highlights miRNAs that may aid in preoperative risk stratification of IPMNs and provides novel insights into miRNA-mediated progression to pancreatic malignancy. The miRNAs identified here and in other recent investigations warrant evaluation in biofluids in a well-powered prospective cohort of individuals newly-diagnosed with IPMNs and other pancreatic cysts and those at increased genetic risk for these lesions. +other hsa-mir-99b Pancreatic Neoplasms 25607660 This pilot study highlights miRNAs that may aid in preoperative risk stratification of IPMNs and provides novel insights into miRNA-mediated progression to pancreatic malignancy. The miRNAs identified here and in other recent investigations warrant evaluation in biofluids in a well-powered prospective cohort of individuals newly-diagnosed with IPMNs and other pancreatic cysts and those at increased genetic risk for these lesions. +other hsa-let-7b Colorectal Carcinoma 25611389 Genome-wide mRNA and miRNA expression profiling reveal multiple regulatory networks in colorectal cancer. +other hsa-mir-375 Breast Neoplasms 25613180 biochanin A promoted ER¦Á-positive cell proliferation through miR-375 activation and this mechanism is possibly involving in a miR-375 and ER¦Á feedback loop. +other hsa-mir-205 Malignant Neoplasms [unspecific] 25613953 "miRNA-205 is a promising biomarker for predicting the recurrence and progression of patients with adenocarcinomas or breast cancer. Owing to its complex roles, further relevant studies are warranted." +other hsa-mir-558 Neuroblastoma 25616966 "miR-558 induces the transcriptional activation of HPSE via the binding site within promoter, thus facilitating the tumorigenesis and aggressiveness of NB." +other hsa-mir-28 Neoplasms [unspecific] 25617309 miR-28-5p promotes chromosomal instability in VHL-associated cancers by inhibiting Mad2 translation. +other hsa-mir-146b Atrial Fibrillation 25617731 miR-146b-5p probably acts as an intracellular mediator in the maladaptive remodeling in atrial fibrosis in atrial fibrillation. +other hsa-mir-210 Gastric Neoplasms 25618442 MIR210 is often highly overexpressed in gastric cancer +other hsa-mir-10b Bladder Neoplasms 25620614 "urine miR-210, miR-10b, and miR-29c are promising tumor markers for BC: bilharzial and nonbilharzial." +other hsa-mir-210 Bladder Neoplasms 25620614 "urine miR-210, miR-10b, and miR-29c are promising tumor markers for BC: bilharzial and nonbilharzial." +other hsa-mir-221 Bladder Neoplasms 25620614 "urine miR-210, miR-10b, and miR-29c are promising tumor markers for BC: bilharzial and nonbilharzial." +other hsa-mir-23a Bladder Neoplasms 25620614 "urine miR-210, miR-10b, and miR-29c are promising tumor markers for BC: bilharzial and nonbilharzial." +other hsa-mir-29c Bladder Neoplasms 25620614 "urine miR-210, miR-10b, and miR-29c are promising tumor markers for BC: bilharzial and nonbilharzial." +other hsa-mir-122 Breast Neoplasms 25621950 "by modifying glucose utilization by recipient premetastatic niche cells, cancer-derived extracellular miR-122 is able to reprogram systemic energy metabolism to facilitate disease progression." +other hsa-mir-551b Gastric Neoplasms 25623763 Expression of miR-551b-3p in gastric cancer cell lines and tissues and its clinical significance. +other hsa-mir-21 Glioblastoma 25628933 Dox and miR-21 inhibitor therapy can sensitize GBM resistant cells to anthracyclines by enhancing apoptosis. +other hsa-mir-451a Glioma 25629604 Effective control of growing cells near BV sites in addition to relocalization of invisible migratory cells back to the resection site was suggested as a way of eradicating these migratory cells. +other hsa-mir-146a Rheumatoid Arthritis 25630616 "the miRNA-146 GG genotype might increase the risk of RA in females, and CC genotype may influence disease activity when evaluated with DAS28 score." +other hsa-mir-181b Glioblastoma 25633526 NF-¦ÊB activation by DNA damage in GBM cells confers resistance to radiation-induced death. +other hsa-mir-145 "Carcinoma, Endometrial" 25634023 "OCT4-pg5 can act as an RNA sponge to protect OCT4 transcripts from being inhibited by miR-145, providing novel insight into the control of OCT4 expression." +other hsa-mir-29 Gastric Neoplasms 25634213 a global mechanism for understanding the efficacious effects of cytotoxic chemotherapy in gastric cancer. +other hsa-let-7g Atypical Teratoid Tumor 25638158 LIN28A knockdown led to increased expression of let-7b and let-7g microRNAs and a down-regulation of KRAS mRNA. +other hsa-mir-210 Gallstones 25639987 An integrated analysis of differential miRNA and mRNA expressions in human gallstones. +other hsa-mir-1266 Breast Neoplasms 25640367 Association of miR-1266 with recurrence/metastasis potential in estrogen receptor positive breast cancer patients. +other hsa-mir-221 "Carcinoma, Lung, Non-Small-Cell" 25641933 Growth inhibitory effects of miR-221 and miR-222 in non-small cell lung cancer cells. +other hsa-mir-222 "Carcinoma, Lung, Non-Small-Cell" 25641933 Growth inhibitory effects of miR-221 and miR-222 in non-small cell lung cancer cells. +other hsa-mir-484 Breast Neoplasms 25643696 Cytidine Deaminase Axis Modulated by miR-484 Differentially Regulates Cell Proliferation and Chemoresistance in Breast Cancer. +other hsa-mir-206 Rhabdomyosarcoma 25644430 SMYD1 and G6PD modulation are critical events for miR-206-mediated differentiation of rhabdomyosarcoma. +other hsa-mir-21 Cardiomegaly 25644540 miR-21: a star player in cardiac hypertrophy. +other hsa-mir-200b Malignant Neoplasms [unspecific] 25644713 YY1 acts as novel critical interface between epigenetic code and miRNAs machinery under chronic hypoxia in malignancy. +other hsa-mir-200c Malignant Neoplasms [unspecific] 25644713 YY1 acts as novel critical interface between epigenetic code and miRNAs machinery under chronic hypoxia in malignancy. +other hsa-mir-3189 Glioblastoma 25645911 Anti-tumoral effects of miR-3189-3p in glioblastoma. +other hsa-mir-155 Lymphoma 25645925 miR-155 controls the outcome of the GC reaction by modulating its initiation (Aicda) and termination (Socs1/p53 response) +other hsa-mir-328 Lung Neoplasms 25646356 The predictive value and potential mechanisms of miRNA-328 and miRNA-378 for brain metastases in operable and advanced non-small-cell lung cancer. +other hsa-mir-378 Lung Neoplasms 25646356 The predictive value and potential mechanisms of miRNA-328 and miRNA-378 for brain metastases in operable and advanced non-small-cell lung cancer. +other hsa-mir-146a Gout 25646371 Role of miR-146a in regulation of the acute inflammatory response to monosodium urate crystals. +other hsa-mir-188 "Leukemia, Myeloid" 25646775 Identification of let-7a-2-3p or/and miR-188-5p as prognostic biomarkers in cytogenetically normal acute myeloid leukemia. +other hsa-mir-122 Hepatitis C Virus Infection 25646812 Circulating miRNA-122 levels are associated with hepatic necroinflammation and portal hypertension in HIV/HCV coinfection. +other hsa-mir-34b Breast Neoplasms 25647415 The regulation and function of miR-21-FOXO3a-miR-34b/c signaling in breast cancer. +other hsa-mir-34c Breast Neoplasms 25647415 The regulation and function of miR-21-FOXO3a-miR-34b/c signaling in breast cancer. +other hsa-mir-206 Gastric Neoplasms 25653235 Activation of PAX3-MET pathways due to miR-206 loss promotes gastric cancer metastasis. +other hsa-mir-30a "Carcinoma, Hepatocellular" 25654285 "Effect of miR-30a-5p on the proliferation, apoptosis, invasion and migration of SMCC-7721 human hepatocellular carcinoma cells" +other hsa-mir-143 Vascular Disease [unspecific] 25655189 Myocyte Enhancer Factor 2A Regulates Hydrogen Peroxide-Induced Senescence of Vascular Smooth Muscle Cells Via microRNA-143. +other hsa-mir-145 Vascular Disease [unspecific] 25655189 Myocyte Enhancer Factor 2A Regulates Hydrogen Peroxide-Induced Senescence of Vascular Smooth Muscle Cells Via microRNA-143. +other hsa-mir-143 Gastric Neoplasms 25656032 Expression of miR-143 and miR-145 and their functional study in gastric carcinoma. +other hsa-mir-145 Gastric Neoplasms 25656032 Expression of miR-143 and miR-145 and their functional study in gastric carcinoma. +other hsa-mir-21 Multiple Myeloma 25656574 PSMB4 promotes multiple myeloma cell growth by activating NF-¦ÊB-miR-21 signaling. +other hsa-mir-29a "Carcinoma, Breast" 25656908 Epigenetic Regulation of miR-29s Affects the Lactation Activity of Dairy Cow Mammary Epithelial Cells. +other hsa-mir-29b "Carcinoma, Breast" 25656908 Epigenetic Regulation of miR-29s Affects the Lactation Activity of Dairy Cow Mammary Epithelial Cells. +other hsa-mir-29c "Carcinoma, Breast" 25656908 Epigenetic Regulation of miR-29s Affects the Lactation Activity of Dairy Cow Mammary Epithelial Cells. +other hsa-mir-21 Coronary Artery Disease 25656948 "MiR-34a, miR-21 and miR-23a as potential biomarkers for coronary artery disease: a pilot microarray study and confirmation in a 32 patient cohort." +other hsa-mir-23a Coronary Artery Disease 25656948 "MiR-34a, miR-21 and miR-23a as potential biomarkers for coronary artery disease: a pilot microarray study" +other hsa-mir-34a Coronary Artery Disease 25656948 "MiR-34a, miR-21 and miR-23a as potential biomarkers for coronary artery disease: a pilot microarray study and confirmation in a 32 patient cohort." +other hsa-mir-101 Bladder Neoplasms 25658842 "miR-101 suppresses VEGF-C expression, inhibits cell migration and invasion, and increases cisplatin sensitivity in bladder cancer cells. " +other hsa-mir-509 Breast Neoplasms 25659578 suppresses brain metastasis of breast cancer cells by modulating RhoC and TNF-¦Á. +other hsa-mir-494 Preeclampsia 25660325 we report an unrecognized mechanism of miR-494 affecting dMSC proliferation and function in the pathology of PE. +other hsa-mir-760 Breast Neoplasms 25661353 Systematic analysis of gene expression pattern in has-miR-760 overexpressed resistance of the MCF-7 human breast cancer cell to doxorubicin. +other hsa-mir-592 Colorectal Carcinoma 25661360 Up-regulation of miR-592 correlates with tumor progression and poor prognosis in patients with colorectal cancer. +other hsa-mir-145 "Carcinoma, Lung, Non-Small-Cell" 25661374 Low miR-145 expression level is associated with poor pathological differentiation and poor prognosis in non-small cell lung cancer. +other hsa-mir-122 Hepatitis C Virus Infection 25662750 miR-122 stimulates hepatitis C virus RNA synthesis by altering the balance of viral RNAs engaged in replication versus translation. +other hsa-mir-494 Glioblastoma 25662849 "miR-494-3p Regulates Cellular Proliferation, Invasion, Migration, and Apoptosis by PTEN/AKT Signaling in Human Glioblastoma Cells." +other hsa-mir-375 Breast Neoplasms 25663261 This study demonstrated that formononetin promoted ER¦Á-positive cell proliferation through miR-375 activation and this mechanism is possibly involving in a miR-375 and ER¦Á feedback loop. +other hsa-mir-137 "Carcinoma, Gastric" 25663388 Epigenetic silencing of miR-137 is a frequent event in gastric carcinogenesis. +other hsa-mir-423 Breast Neoplasms 25663458 Genetic analysis and preliminary function study of miR-423 in breast cancer. +other hsa-mir-199a Cystic Fibrosis 25665524 Pharmacological modulation of the AKT/microRNA-199a-5p/CAV1 pathway ameliorates cystic fibrosis lung hyper-inflammation. +other hsa-mir-15b Vascular Disease [unspecific] 25665638 "We focus on the diverse roles of miR-15b in the occurrence, progression and prognosis of vascular diseases,with particular emphasis on preeclampsia, a hypertensive disorder related to endovascular dysfunction in the placenta." +other hsa-mir-31 Inflammatory Bowel Diseases 25665881 Differential expression of miR-31 between inflammatory bowel disease and microscopic colitis. +other hsa-mir-155 Osteosarcoma 25666090 miR-155 promotes the growth of osteosarcoma in a HBP1-dependent mechanism. +other hsa-mir-145 "Carcinoma, Cervical" 25666710 MicroRNA-145 contributes to enhancing radiosensitivity of cervical cancer cells. +other hsa-let-7a "Carcinoma, Breast" 25669981 Metabolic reprogramming of metastatic breast cancer and melanoma by let-7a microRNA. +other hsa-mir-95 Colorectal Carcinoma 25671802 Glargine Promotes Human Colorectal Cancer Cell Proliferation via Upregulation of miR-95. +other hsa-mir-155 Glioma 25672607 miR-155 contributes to the progression of glioma by enhancing Wnt/¦Â-catenin pathway. +other hsa-mir-200c "Carcinoma, Gastric" 25672630 DZNep raises miR-200c expression to delay the invasion and migration of MGC-803 gastric carcinoma cells +other hsa-mir-25 Neoplasms [unspecific] 25672882 miR-25 is suggested to be important in TNF-¦Á-induced abnormal proliferation of vascular smooth muscle cells (VSMCs). +other hsa-mir-199a Hepatoblastoma 25673149 The miR-199a/Brm/EGR1 axis is a determinant of anchorage-independent growth in epithelial tumor cell lines. +other hsa-mir-182 Urinary Bladder Cancer 25676538 This study shows that the level of miR-182 is higher in cytology specimens from high-grade UCC patients as compared to normal controls.Measuring miR-182 may provide a potential alternative or adjunct approach for screening high-grade UCC. +other hsa-mir-17 Glioblastoma 25677619 Our findings suggest that engineering of tumor antigen-specific CD8(+) T-cells to express miR-17-92 may improve the potency of cancer immunotherapy. +other hsa-mir-18 Glioblastoma 25677619 Our findings suggest that engineering of tumor antigen-specific CD8(+) T-cells to express miR-17-92 may improve the potency of cancer immunotherapy. +other hsa-mir-19a Glioblastoma 25677619 Our findings suggest that engineering of tumor antigen-specific CD8(+) T-cells to express miR-17-92 may improve the potency of cancer immunotherapy. +other hsa-mir-19b-1 Glioblastoma 25677619 Our findings suggest that engineering of tumor antigen-specific CD8(+) T-cells to express miR-17-92 may improve the potency of cancer immunotherapy. +other hsa-mir-20a Glioblastoma 25677619 Our findings suggest that engineering of tumor antigen-specific CD8(+) T-cells to express miR-17-92 may improve the potency of cancer immunotherapy. +other hsa-mir-92-1 Glioblastoma 25677619 Our findings suggest that engineering of tumor antigen-specific CD8(+) T-cells to express miR-17-92 may improve the potency of cancer immunotherapy. +other hsa-mir-193b "Squamous Cell Carcinoma, Head and Neck" 25677760 Alteration in miR-193b expression level does not show any significant association with cancer survival. +other hsa-mir-206 Muscle Diseases [unspecific] 25678853 "MiR-206, a key modulator of skeletal muscle development and disease." +other hsa-mir-211 "Carcinoma, Breast, Triple Negative" 25680404 "MicroRNA-211, a direct negative regulator of CDC25B expression, inhibits triple-negative breast cancer cells' growth and migration." +other hsa-mir-135a Breast Neoplasms 25680412 This study aimed to screen potential microRNAs (miRNAs) and genes related to human primary breast cancer. +other hsa-mir-139 Breast Neoplasms 25680412 This study aimed to screen potential microRNAs (miRNAs) and genes related to human primary breast cancer. +other hsa-mir-375 Breast Neoplasms 25680412 This study aimed to screen potential microRNAs (miRNAs) and genes related to human primary breast cancer. +other hsa-mir-592 Breast Neoplasms 25680412 This study aimed to screen potential microRNAs (miRNAs) and genes related to human primary breast cancer. +other hsa-mir-9 Breast Neoplasms 25680412 This study aimed to screen potential microRNAs (miRNAs) and genes related to human primary breast cancer. +other hsa-mir-603 Glioma 25681036 miR-603 promotes glioma cell growth via Wnt/¦Â-catenin pathway by inhibiting WIF1 and CTNNBIP1. +other hsa-mir-130a Pulmonary Hypertension 25681685 These data suggest that miRNA family miR-130 plays an important role in the repression of CDKN1A by hypoxia.miR-130 enhances hypoxia-induced smooth muscle proliferation and might be involved in the development of right ventricular hypertrophy and vascular remodeling in pulmonary hypertension. +other hsa-mir-31 Wounds and Injuries [unspecific] 25685928 MicroRNA-31 Promotes Skin Wound Healing by Enhancing Keratinocyte Proliferation and Migration. +other hsa-mir-455 Melanoma 25686251 Reduced adenosine-to-inosine miR-455-5p editing promotes melanoma growth and metastasis. +other hsa-mir-512 "Carcinoma, Lung, Non-Small-Cell" 25687035 Inhibition of RAC1-GEF DOCK3 by miR-512-3p contributes to suppression of metastasis in non-small cell lung cancer. +other hsa-mir-21 Vascular Hypertrophy 25689721 Ursolic acid down-regulated miRNA-21 expression and up-regulated PTEN protein and mRNA expression. +other hsa-mir-30 Muscle Diseases [unspecific] 25689854 These findings indicate that the miR-30 family may be an interesting biomarker of perturbed muscle homeostasis and muscle disease. +other hsa-mir-150 Immune System Disease [unspecific] 25690461 Our current studies characterized TsF as regulatory miRNA-150 carried by T suppressor cell-derived exosomes that are antigen specific due to a surface coat of IgM antibody light chains produced by B1a cells. +other hsa-mir-139 Neoplasms [unspecific] 25691250 MiR-139-5p: promising biomarker for cancer. +other hsa-mir-205 Lung Neoplasms 25695220 MiR-205 and MiR-375 microRNA assays to distinguish squamous cell carcinoma from adenocarcinoma in lung cancer biopsies. +other hsa-mir-375 Lung Neoplasms 25695220 MiR-205 and MiR-375 microRNA assays to distinguish squamous cell carcinoma from adenocarcinoma in lung cancer biopsies. +other hsa-mir-663 Alzheimer Disease 25695604 Our results indicate that AICD has a novel role in suppression of neuronal differentiation via transcriptional regulation of miR-663 in human neural stem cells. +other hsa-mir-27b Liver Neoplasms 25698578 we propose that miR-27b synergizes with anticancer drugs in a defined subgroup of liver and kidney cancer patients. +other hsa-mir-155 Keratitis 25700796 Role of miR-155 in the pathogenesis of herpetic stromal keratitis. +other hsa-mir-185 "Carcinoma, Renal Cell, Clear-Cell" 25700976 "Our results suggest that the miR-185, as a tumor suppressor, plays a pivotal role by inhibiting VEGFA in VHL-inactivated ccRCC." +other hsa-mir-126 Obesity 25701361 Our study provides a bioinformatic basis for further research of molecular mechanism in obesity. +other hsa-mir-16 Obesity 25701361 Our study provides a bioinformatic basis for further research of molecular mechanism in obesity. +other hsa-mir-425 Obesity 25701361 Our study provides a bioinformatic basis for further research of molecular mechanism in obesity. +other hsa-mir-634 Obesity 25701361 Our study provides a bioinformatic basis for further research of molecular mechanism in obesity. +other hsa-mir-143 "Carcinoma, Nasopharyngeal" 25701793 Identification of miR-143 as a tumour suppressor in nasopharyngeal carcinoma based on microRNA expression profiling. +other hsa-mir-100 Gastric Neoplasms 25703026 The role of miR-100-mediated Notch pathway in apoptosis of gastric tumor cells. +other hsa-let-7d Obesity 25704235 Nonivamide enhances miRNA let-7d expression and decreases adipogenesis PPARγ expression in 3T3-L1 cells. +other hsa-mir-708 "Leukemia, Lymphocytic, Chronic, B-Cell" 25704289 Epigenetic silencing of miR-708 enhances NF-¦ÊB signaling in chronic lymphocytic leukemia. +other hsa-mir-128 "Carcinoma, Hepatocellular" 25704921 Suppression of CYP2C9 by microRNA hsa-miR-128-3p in human liver cells and association with hepatocellular carcinoma. +other hsa-mir-31 Liver Injury 25706292 "Both compounds also down-regulated miR-31, which directly targets caspase-2 and influences apoptosis in SEB-activated cells." +other hsa-mir-199a Atrial Fibrillation 25706326 Our combined transcriptomic analysis and miRNA microarray study of atrial samples from pAF patients revealed novel pathways and miRNA-mRNA regulations that may be relevant in the development of pAF. Future studies are required to investigate the potential involvement of the gonadotropin releasing hormone receptor and p53 pathways in AF pathogenesis. +other hsa-mir-21 Breast Neoplasms 25706383 "Our results indicated that miR-21 can predict unfavorable prognoses in breast cancer patients, especially in Asians." +other hsa-mir-17 Hepatitis C Virus Infection 25707620 Our rule discovery method is useful for integrating binding information and expression profile for identifying HCV miRNA-mRNA regulatory modules and can be applied to the study of the expression profiles of other complex human diseases. +other hsa-mir-557 Hepatitis C Virus Infection 25707620 Our rule discovery method is useful for integrating binding information and expression profile for identifying HCV miRNA-mRNA regulatory modules and can be applied to the study of the expression profiles of other complex human diseases. +other hsa-mir-765 Hepatitis C Virus Infection 25707620 Our rule discovery method is useful for integrating binding information and expression profile for identifying HCV miRNA-mRNA regulatory modules and can be applied to the study of the expression profiles of other complex human diseases. +other hsa-mir-153 "Carcinoma, Hepatocellular" 25708809 MicroRNA-153 promotes Wnt/¦Â-catenin activation in hepatocellular carcinoma through suppression of WWOX. +other hsa-mir-223 "Leukemia, Myeloid, Acute" 25710580 De Novo Acute Myeloid Leukemia in Adults: Suppression of MicroRNA-223 is Independent of LMO2 Protein Expression BUT Associate With Adverse Cytogenetic Profile and Undifferentiated Blast Morphology. +other hsa-let-7f Obesity 25710930 "genes modulated in RO-treated cells were found to be validated miRNAs targets, such as let-7f-1, miR-17, and miR-143." +other hsa-mir-27a Colorectal Carcinoma 25712055 Novel Evidence for Curcumin and Boswellic Acid-Induced Chemoprevention through Regulation of miR-34a and miR-27a in Colorectal Cancer. +other hsa-mir-34a Colorectal Carcinoma 25712055 Novel Evidence for Curcumin and Boswellic Acid-Induced Chemoprevention through Regulation of miR-34a and miR-27a in Colorectal Cancer. +other hsa-mir-335 "Carcinoma, Cervical" 25712373 MicroRNA-335 represents an independent prognostic marker in cervical cancer. +other hsa-mir-30a "Carcinoma, Renal Cell" 25712526 MiRNA-30a-mediated autophagy inhibition sensitizes renal cell carcinoma cells to sorafenib. +other hsa-mir-199a "Carcinoma, Hepatocellular" 25714015 "Increase of miR-199a-5p by protoporphyrin IX, a photocatalyzer, directly inhibits E2F3, sensitizing mesenchymal tumor cells to anti-cancer agents." +other hsa-mir-372 "Squamous Cell Carcinoma, Head and Neck" 25714028 miR-372 inhibits p62 in head and neck squamous cell carcinoma in vitro and in vivo. +other hsa-mir-148a Adenovirus Infection 25714032 "Thus, miRNA-control of late proteins constitutes a novel strategy to provide selectivity to adenoviruses." +other hsa-let-7 "Carcinoma, Lung, Non-Small-Cell" 25714397 Combinatorial Action of MicroRNAs let-7 and miR-34 Effectively Synergizes with Erlotinib to Suppress Non-small Cell Lung Cancer Cell Proliferation. +other hsa-mir-34 "Carcinoma, Lung, Non-Small-Cell" 25714397 Combinatorial Action of MicroRNAs let-7 and miR-34 Effectively Synergizes with Erlotinib to Suppress Non-small Cell Lung Cancer Cell Proliferation. +other hsa-mir-133a "Carcinoma, Hepatocellular" 25714665 These findings for the first time demonstrated that the involvement of miR-133a and miR-326 in MDR is mediated by ABCC1 in hepatocellular carcinoma cell line HepG2 and suggested that miR-133a and miR-326 may be efficient agents for preventing and reversing ADM resistance in cancer cells. +other hsa-mir-326 "Carcinoma, Hepatocellular" 25714665 These findings for the first time demonstrated that the involvement of miR-133a and miR-326 in MDR is mediated by ABCC1 in hepatocellular carcinoma cell line HepG2 and suggested that miR-133a and miR-326 may be efficient agents for preventing and reversing ADM resistance in cancer cells. +other hsa-mir-424 Neoplasms [unspecific] 25716682 TWIST1-Induced miR-424 Reversibly Drives Mesenchymal Programming while Inhibiting Tumor Initiation. +other hsa-mir-27a Liver Diseases [unspecific] 25716995 our study demonstrates the regulatory role of miR-27a in alcohol-induced monocyte activation and polarization. +other hsa-let-7c Human Immunodeficiency Virus Infection 25717002 "Our data suggest that HIV-1 exploits the host miRNA cellular systems in order to block the innate inhibition mechanism, allowing a more efficient infection process." +other hsa-mir-124a Human Immunodeficiency Virus Infection 25717002 "Our data suggest that HIV-1 exploits the host miRNA cellular systems in order to block the innate inhibition mechanism, allowing a more efficient infection process." +other hsa-mir-34a Human Immunodeficiency Virus Infection 25717002 "Our data suggest that HIV-1 exploits the host miRNA cellular systems in order to block the innate inhibition mechanism, allowing a more efficient infection process." +other hsa-mir-21 "Carcinoma, Hepatocellular" 25720799 High-Mobility Group Box 1 Promotes Hepatocellular Carcinoma Progression through miR-21-Mediated Matrix Metalloproteinase Activity. +other hsa-let-7a Breast Neoplasms 25722304 These results point to using high levels of tRNA-derived small RNA fragments in combination with known miR signatures of tumors to distinguish tumor-derived EVs in circulation from EVs derived from other cell sources. Such biomarkers would be unique to the EVs where high abundances of tRNA fragments are amplified with respect to their cellular levels. +other hsa-mir-125b Breast Neoplasms 25722304 These results point to using high levels of tRNA-derived small RNA fragments in combination with known miR signatures of tumors to distinguish tumor-derived EVs in circulation from EVs derived from other cell sources. Such biomarkers would be unique to the EVs where high abundances of tRNA fragments are amplified with respect to their cellular levels. +other hsa-mir-1274b Breast Neoplasms 25722304 These results point to using high levels of tRNA-derived small RNA fragments in combination with known miR signatures of tumors to distinguish tumor-derived EVs in circulation from EVs derived from other cell sources. Such biomarkers would be unique to the EVs where high abundances of tRNA fragments are amplified with respect to their cellular levels. +other hsa-mir-205 Breast Neoplasms 25722304 These results point to using high levels of tRNA-derived small RNA fragments in combination with known miR signatures of tumors to distinguish tumor-derived EVs in circulation from EVs derived from other cell sources. Such biomarkers would be unique to the EVs where high abundances of tRNA fragments are amplified with respect to their cellular levels. +other hsa-mir-21 Breast Neoplasms 25722304 These results point to using high levels of tRNA-derived small RNA fragments in combination with known miR signatures of tumors to distinguish tumor-derived EVs in circulation from EVs derived from other cell sources. Such biomarkers would be unique to the EVs where high abundances of tRNA fragments are amplified with respect to their cellular levels. +other hsa-mir-720 Breast Neoplasms 25722304 These results point to using high levels of tRNA-derived small RNA fragments in combination with known miR signatures of tumors to distinguish tumor-derived EVs in circulation from EVs derived from other cell sources. Such biomarkers would be unique to the EVs where high abundances of tRNA fragments are amplified with respect to their cellular levels. +other hsa-mir-630 "Carcinoma, Hepatocellular" 25731670 These results suggest that miR-630 is associated with tumor progression of hepatocellular carcinoma and may be a potential prognosis indicator. +other hsa-mir-526b Breast Neoplasms 25733698 COX-2 Elevates Oncogenic miR-526b in Breast Cancer by EP4 Activation. +other hsa-mir-324 "Carcinoma, Nasopharyngeal" 25735100 The loss of miRNA-324-3p and ectopic WNT2B might co-induce the initiation and progression of NPC. +other hsa-mir-222 Breast Neoplasms 25735339 Ginsenoside Rh2 differentially mediates microRNA expression to prevent chemoresistance of breast cancer. +other hsa-mir-29a Breast Neoplasms 25735339 Ginsenoside Rh2 differentially mediates microRNA expression to prevent chemoresistance of breast cancer. +other hsa-mir-34a Breast Neoplasms 25735339 Ginsenoside Rh2 differentially mediates microRNA expression to prevent chemoresistance of breast cancer. +other hsa-mir-21 Breast Neoplasms 25735723 MiR-21 controls in situ expansion of CCR6 regulatory T cells through PTEN/AKT pathway in breast cancer. +other hsa-mir-205 Glioblastoma 25736407 Pterostilbene suppressed irradiation-resistant glioma stem cells by modulating GRP78/miR-205 axis. +other hsa-mir-24 "Diabetes Mellitus, Type 2" 25737017 Pioglitazone increases circulating microRNA-24 with decrease in coronary neointimal hyperplasia in type 2 diabetic patients- optical coherence tomography analysis. +other hsa-mir-29b Uterine Corpus Choriocarcinoma 25738313 BAG3 increases the invasiveness of uterine corpus carcinoma cells by suppressing miR-29b and enhancing MMP2 expression. +other hsa-mir-10b Glioblastoma 25738367 MicroRNA-10b inhibition reduces E2F1-mediated transcription and miR-15/16 activity in glioblastoma. +other hsa-mir-15 Glioblastoma 25738367 MicroRNA-10b inhibition reduces E2F1-mediated transcription and miR-15/16 activity in glioblastoma. +other hsa-mir-16 Glioblastoma 25738367 MicroRNA-10b inhibition reduces E2F1-mediated transcription and miR-15/16 activity in glioblastoma. +other hsa-mir-182 "Carcinoma, Hepatocellular" 25739014 "A pleiotropic effect of the single clustered hepatic metastamiRs miR-96-5p and miR-182-5p on insulin-like growth factor II, insulin-like growth factor-1 receptor and insulin-like growth factor-binding protein-3 in hepatocellular carcinoma." +other hsa-mir-133a Arteriosclerosis Obliterans 25740337 MicroRNA-133a in the Development of Arteriosclerosis Obliterans. +other hsa-mir-216b "Carcinoma, Hepatocellular" 25741595 MiR-216b is involved in pathogenesis and progression of hepatocellular carcinoma through HBx-miR-216b-IGF2BP2 signaling pathway. +other hsa-mir-186 "Adenocarcinoma, Pancreatic Ductal" 25742499 miR-186 and 326 predict the prognosis of pancreatic ductal adenocarcinoma and affect the proliferation and migration of cancer cells. +other hsa-mir-326 "Adenocarcinoma, Pancreatic Ductal" 25742499 miR-186 and 326 predict the prognosis of pancreatic ductal adenocarcinoma and affect the proliferation and migration of cancer cells. +other hsa-mir-155 Breast Neoplasms 25744731 Role of miR-155 in drug resistance of breast cancer. +other hsa-mir-33a Lipid Metabolism Disorder 25744742 "we describe the current understanding of the function of miR-33a/b in lipid homeostasis, focusing on the thrifty aspect." +other hsa-mir-33b Lipid Metabolism Disorder 25744742 "we describe the current understanding of the function of miR-33a/b in lipid homeostasis, focusing on the thrifty aspect." +other hsa-mir-200c Breast Neoplasms 25746005 "Expression of miR-200c in claudin-low breast cancer alters stem cell functionality, enhances chemosensitivity and reduces metastatic potential." +other hsa-mir-1270 Inflammation 25746225 This coordinated regulatory architecture suggests a vital function for the innate immune system in maintaining precise physiological type I IFN levels via post-transcriptional regulatory mechanisms. +other hsa-mir-141 "Squamous Cell Carcinoma, Lung" 25746592 MicroRNA-141 is a biomarker for progression of squamous cell carcinoma and adenocarcinoma of the lung: clinical analysis of 125 patients. +other hsa-mir-29a "Lymphoma, Burkitt" 25746661 "Deregulation of DNMT1, DNMT3B and miR-29s in Burkitt lymphoma suggests novel contribution for disease pathogenesis." +other hsa-mir-29b "Lymphoma, Burkitt" 25746661 "Deregulation of DNMT1, DNMT3B and miR-29s in Burkitt lymphoma suggests novel contribution for disease pathogenesis." +other hsa-mir-29c "Lymphoma, Burkitt" 25746661 "Deregulation of DNMT1, DNMT3B and miR-29s in Burkitt lymphoma suggests novel contribution for disease pathogenesis." +other hsa-mir-17 "Carcinoma, Thyroid, Follicular" 25748447 Sphingosine-1-phosphate induces the migration of thyroid follicular carcinoma cells through the microRNA-17/PTK6/ERK1/2 pathway. +other hsa-mir-27a Osteosarcoma 25749032 miR-27a and miR-27a* contribute to metastatic properties of osteosarcoma cells. +other hsa-mir-16 Prostate Neoplasms 25750034 This study highlights that commonly used endogenous controls can be responsive to radiation and validation is required prior to gene/miRNAs expression studies. +other hsa-mir-331 "Carcinoma, Hepatocellular" 25750939 This provided useful information in exploring the mechanism of HCC induced by HBV infection. +other hsa-mir-204 "Carcinoma, Nasopharyngeal" 25752113 Clinical significance of miRNA-204 in nasopharyngeal carcinoma. +other hsa-mir-124 Glioblastoma 25753094 Gap Junctions Enhance the Antiproliferative Effect of MicroRNA-124-3p in Glioblastoma Cells. +other hsa-mir-223 Hematologic Neoplasms 25753223 "C/EBPα interacts with AP-1 proteins to bind hybrid DNA elements during monopoiesis, and induction of Gfi-1, C/EBPε, KLF5, and miR-223 by C/EBPα enables granulopoiesis." +other hsa-mir-142 Endometrial Stromal Sarcoma 25754227 miR-142-3p is a novel regulator of cell viability and proinflammatory signalling in endometrial stroma cells. +other hsa-mir-1179 "Squamous Cell Carcinoma, Esophageal" 25755718 miR-1179 promotes cell invasion through SLIT2/ROBO1 axis in esophageal squamous cell carcinoma. +other hsa-mir-18a "Carcinoma, Lung, Non-Small-Cell" 25755757 Effect of miR-18a overexpression on the radiosensitivity of non-small cell lung cancer. +other hsa-let-7a Pleural Mesothelioma 25756049 Specific microRNAs and mRNAs may have diagnostic utility in differentiating patients with malignant pleural mesothelioma from benign asbestos-related pleural effusion. These studies may be particularly helpful in patients who reside in a region with a high incidence of mesothelioma. +other hsa-mir-125a Pleural Mesothelioma 25756049 Specific microRNAs and mRNAs may have diagnostic utility in differentiating patients with malignant pleural mesothelioma from benign asbestos-related pleural effusion. These studies may be particularly helpful in patients who reside in a region with a high incidence of mesothelioma. +other hsa-mir-320 Pleural Mesothelioma 25756049 Specific microRNAs and mRNAs may have diagnostic utility in differentiating patients with malignant pleural mesothelioma from benign asbestos-related pleural effusion. These studies may be particularly helpful in patients who reside in a region with a high incidence of mesothelioma. +other hsa-mir-484 Pleural Mesothelioma 25756049 Specific microRNAs and mRNAs may have diagnostic utility in differentiating patients with malignant pleural mesothelioma from benign asbestos-related pleural effusion. These studies may be particularly helpful in patients who reside in a region with a high incidence of mesothelioma. +other hsa-mir-1204 "Carcinoma, Nasopharyngeal" 25756509 MiR-1204 sensitizes nasopharyngeal carcinoma cells to paclitaxel both in vitro and in vivo. +other hsa-let-7a Alzheimer Disease 25759134 "we demonstrate in detail the power of DNA/RNA chimera/AgNC probes in detecting two human miRNAs,let-7a and miR-200c. The DNA/RNA chimera-based probes are highly efficient to determine the level of miRNAs in several human cell lines." +other hsa-let-7a Asthma 25759134 "we demonstrate in detail the power of DNA/RNA chimera/AgNC probes in detecting two human miRNAs,let-7a and miR-200c. The DNA/RNA chimera-based probes are highly efficient to determine the level of miRNAs in several human cell lines." +other hsa-let-7a Autoimmune Diseases [unspecific] 25759134 "we demonstrate in detail the power of DNA/RNA chimera/AgNC probes in detecting two human miRNAs,let-7a and miR-200c. The DNA/RNA chimera-based probes are highly efficient to determine the level of miRNAs in several human cell lines." +other hsa-let-7a Cardiovascular Diseases [unspecific] 25759134 "we demonstrate in detail the power of DNA/RNA chimera/AgNC probes in detecting two human miRNAs,let-7a and miR-200c. The DNA/RNA chimera-based probes are highly efficient to determine the level of miRNAs in several human cell lines." +other hsa-let-7a Diabetes Mellitus 25759134 "we demonstrate in detail the power of DNA/RNA chimera/AgNC probes in detecting two human miRNAs,let-7a and miR-200c. The DNA/RNA chimera-based probes are highly efficient to determine the level of miRNAs in several human cell lines." +other hsa-let-7a Neoplasms [unspecific] 25759134 "we demonstrate in detail the power of DNA/RNA chimera/AgNC probes in detecting two human miRNAs,let-7a and miR-200c. The DNA/RNA chimera-based probes are highly efficient to determine the level of miRNAs in several human cell lines." +other hsa-mir-200c Alzheimer Disease 25759134 "we demonstrate in detail the power of DNA/RNA chimera/AgNC probes in detecting two human miRNAs,let-7a and miR-200c. The DNA/RNA chimera-based probes are highly efficient to determine the level of miRNAs in several human cell lines." +other hsa-mir-200c Asthma 25759134 "we demonstrate in detail the power of DNA/RNA chimera/AgNC probes in detecting two human miRNAs,let-7a and miR-200c. The DNA/RNA chimera-based probes are highly efficient to determine the level of miRNAs in several human cell lines." +other hsa-mir-200c Autoimmune Diseases [unspecific] 25759134 "we demonstrate in detail the power of DNA/RNA chimera/AgNC probes in detecting two human miRNAs,let-7a and miR-200c. The DNA/RNA chimera-based probes are highly efficient to determine the level of miRNAs in several human cell lines." +other hsa-mir-200c Cardiovascular Diseases [unspecific] 25759134 "we demonstrate in detail the power of DNA/RNA chimera/AgNC probes in detecting two human miRNAs,let-7a and miR-200c. The DNA/RNA chimera-based probes are highly efficient to determine the level of miRNAs in several human cell lines." +other hsa-mir-200c Diabetes Mellitus 25759134 "we demonstrate in detail the power of DNA/RNA chimera/AgNC probes in detecting two human miRNAs,let-7a and miR-200c. The DNA/RNA chimera-based probes are highly efficient to determine the level of miRNAs in several human cell lines." +other hsa-mir-200c Neoplasms [unspecific] 25759134 "we demonstrate in detail the power of DNA/RNA chimera/AgNC probes in detecting two human miRNAs,let-7a and miR-200c. The DNA/RNA chimera-based probes are highly efficient to determine the level of miRNAs in several human cell lines." +other hsa-mir-106a "Carcinoma, Hepatocellular" 25760076 The PDGF-D/miR-106a/Twist1 pathway orchestrates epithelial-mesenchymal transition in gemcitabine resistance hepatoma cells. +other hsa-mir-449a Neoplasms [unspecific] 25760387 microRNA-449a functions as a tumor suppressor in neuroblastoma through inducing cell differentiation and cell cycle arrest. +other hsa-mir-155 Atopic Dermatitis 25761610 MicroRNA-155 may be involved in the pathogenesis of atopic dermatitis by modulating the differentiation and function of T helper type 17 (Th17) cells. +other hsa-mir-34a "Squamous Cell Carcinoma, Head and Neck" 25762634 MiR-34a suppresses amphiregulin and tumor metastatic potential of head and neck squamous cell carcinoma (HNSCC). +other hsa-mir-125b Heart Failure 25763857 "Measured microRNA profiles did not separate the samples according to the clinical features of the patients. However, several previously identified heart failure marker microRNAs were detected. The pericardial fluid microRNA profile appeared to be a result of an active and selective secretory process indicating that microRNAs may act as paracrine signalling factors by mediating the local crosstalk between cardiac cells." +other hsa-mir-16 Heart Failure 25763857 "Measured microRNA profiles did not separate the samples according to the clinical features of the patients. However, several previously identified heart failure marker microRNAs were detected. The pericardial fluid microRNA profile appeared to be a result of an active and selective secretory process indicating that microRNAs may act as paracrine signalling factors by mediating the local crosstalk between cardiac cells." +other hsa-mir-21 Heart Failure 25763857 "Measured microRNA profiles did not separate the samples according to the clinical features of the patients. However, several previously identified heart failure marker microRNAs were detected. The pericardial fluid microRNA profile appeared to be a result of an active and selective secretory process indicating that microRNAs may act as paracrine signalling factors by mediating the local crosstalk between cardiac cells." +other hsa-mir-451a Heart Failure 25763857 "Measured microRNA profiles did not separate the samples according to the clinical features of the patients. However, several previously identified heart failure marker microRNAs were detected. The pericardial fluid microRNA profile appeared to be a result of an active and selective secretory process indicating that microRNAs may act as paracrine signalling factors by mediating the local crosstalk between cardiac cells." +other hsa-mir-128 "Squamous Cell Carcinoma, Head and Neck" 25764126 Functions of MiRNA-128 on the regulation of head and neck squamous cell carcinoma growth and apoptosis. +other hsa-mir-577 Glioblastoma 25764520 miR-577 inhibits glioblastoma tumor growth via the Wnt signaling pathway. +other hsa-mir-19b Atherosclerosis 25765596 The present study demonstrates that Dgn enhances ABCA1-dependent cholesterol efflux and inhibits aortic atherosclerosis progression by suppressing macrophage miR-19b expression. +other hsa-mir-23b Gastric Neoplasms 25765901 Reciprocal repression between TUSC7 and miR-23b in gastric cancer. +other hsa-mir-122 Hepatitis C Virus Infection 25768906 Hepatitis C virus RNA functionally sequesters miR-122. +other hsa-mir-33a Obesity 25769350 "Deregulation of miR-33 and miR-122, as major regulators of lipid metabolism in liver, has been related to obesity and metabolic syndrome." +other hsa-mir-338 Kideny Transplant Rejection 25769569 miR-338-5p is closely correlated with the procedure of renal allograft antibody-mediated rejection. +other hsa-mir-125b "Carcinoma, Lung, Non-Small-Cell" 25772251 Matrix metalloproteinase 13: a potential intermediate between low expression of microRNA-125b and increasing metastatic potential of non-small cell lung cancer. +other hsa-mir-27a "Carcinoma, Lung, Non-Small-Cell" 25773791 Rs895819 within miR-27a might be involved in development of non small cell lung cancer in the Chinese Han population. +other hsa-mir-143 "Carcinoma, Renal Cell, Clear-Cell" 25776476 our data support the notion that sunitinib and everolimus are able to directly induce cell death in renal cancer cells and simultaneously affect the expression levels of their apoptosis-related microRNAs and BCL2 family members upon this process. +other hsa-mir-145 "Carcinoma, Renal Cell, Clear-Cell" 25776476 our data support the notion that sunitinib and everolimus are able to directly induce cell death in renal cancer cells and simultaneously affect the expression levels of their apoptosis-related microRNAs and BCL2 family members upon this process. +other hsa-mir-15a "Carcinoma, Renal Cell, Clear-Cell" 25776476 our data support the notion that sunitinib and everolimus are able to directly induce cell death in renal cancer cells and simultaneously affect the expression levels of their apoptosis-related microRNAs and BCL2 family members upon this process. +other hsa-mir-16 "Carcinoma, Renal Cell, Clear-Cell" 25776476 our data support the notion that sunitinib and everolimus are able to directly induce cell death in renal cancer cells and simultaneously affect the expression levels of their apoptosis-related microRNAs and BCL2 family members upon this process. +other hsa-mir-182 "Carcinoma, Renal Cell, Clear-Cell" 25776476 our data support the notion that sunitinib and everolimus are able to directly induce cell death in renal cancer cells and simultaneously affect the expression levels of their apoptosis-related microRNAs and BCL2 family members upon this process. +other hsa-mir-183 "Carcinoma, Renal Cell, Clear-Cell" 25776476 our data support the notion that sunitinib and everolimus are able to directly induce cell death in renal cancer cells and simultaneously affect the expression levels of their apoptosis-related microRNAs and BCL2 family members upon this process. +other hsa-mir-96 "Carcinoma, Renal Cell, Clear-Cell" 25776476 our data support the notion that sunitinib and everolimus are able to directly induce cell death in renal cancer cells and simultaneously affect the expression levels of their apoptosis-related microRNAs and BCL2 family members upon this process. +other hsa-mir-150 Prostate Neoplasms 25778313 miR-150 is a factor of survival in prostate cancer patients. +other hsa-mir-125a Androgenetic Alopecia 25778683 "These results demonstrated that the expression of miRNA was altered in the DHT-treated nHDPCs and suggest the potential mechanisms of DHT-induced cell growth repression, cell cycle arrest, cell death, senescence and induction of ROS." +other hsa-mir-485 Androgenetic Alopecia 25778683 "These results demonstrated that the expression of miRNA was altered in the DHT-treated nHDPCs and suggest the potential mechanisms of DHT-induced cell growth repression, cell cycle arrest, cell death, senescence and induction of ROS." +other hsa-mir-7 Androgenetic Alopecia 25778683 "These results demonstrated that the expression of miRNA was altered in the DHT-treated nHDPCs and suggest the potential mechanisms of DHT-induced cell growth repression, cell cycle arrest, cell death, senescence and induction of ROS." +other hsa-let-7b Neuroblastoma 25779425 Enterovirus 71 induces apoptosis of SH-SY5Y human neuroblastoma cells through stimulation of endogenous microRNA let-7b expression. +other hsa-mir-133a Gastric Neoplasms 25780292 Tumor suppressor role of miR-133a in gastric cancer by repressing IGF1R. +other hsa-mir-494 Neoplasms [unspecific] 25781916 "Specifically we have linked miR-134, miR-145, miR-146b-5p, miR-432 and miR-494 to the regulation of both apoptotic and anti-apoptotic genes expressed as a function of EGF treatment." +other hsa-mir-21 Breast Neoplasms 25784176 "3,6-Dihydroxyflavone Suppresses Breast Carcinogenesis by Epigenetically Regulating miR-34a and miR-21." +other hsa-mir-34a Breast Neoplasms 25784176 "3,6-Dihydroxyflavone Suppresses Breast Carcinogenesis by Epigenetically Regulating miR-34a and miR-21." +other hsa-mir-218-1 Hirschsprung Disease 25786906 SLIT2/ROBO1-miR-218-1-RET/PLAG1: a new disease pathway involved in Hirschsprung's disease. +other hsa-mir-16 Neoplasms [unspecific] 25787082 "In addition, we observed significantly reduced expression of microRNAs (miRNAs) including miR-16 and miR-19b, which are known to be significantly reduced in the semen of infertile men." +other hsa-mir-122 Chronic Hepatitis B 25788377 Clinical significance of circulating miR-122 in patients with dual chronic hepatitis B and C virus infection. +other hsa-let-7b Influenza 25788763 This approach provides an additional layer of biosafety and thus has great potential for the application in the rational development of safer and more effective influenza viral vaccines. +other hsa-mir-200a Liver Injury 25789565 our data indicate that the p53-dependent expression of miR-200a-3p promotes cell death by inhibiting a p38/p53/miR-200 feedback loop. +other hsa-mir-34a Breast Neoplasms 25789847 "Phytochemical regulation of the tumor suppressive microRNA, miR-34a, by p53-dependent and independent responses in human breast cancer cells." +other hsa-mir-205 "Carcinoma, Breast, Triple Negative" 25792283 Pterostilbene inhibits triple-negative breast cancer metastasis via inducing microRNA-205 expression and negatively modulates epithelial-to-mesenchymal transition. +other hsa-mir-486 "Adenocarcinoma, Gastric" 25793394 Expression and prognostic value of miR-486-5p in patients with gastric adenocarcinoma. +other hsa-mir-221 Ischemic Diseases [unspecific] 25796380 "Moreover, exosomes from MSCs and MSCs treated by BYHWD induced elevated microRNA (miRNA)-126 expression and reduced miR-221 and miR-222 expression." +other hsa-mir-222 Ischemic Diseases [unspecific] 25796380 "Moreover, exosomes from MSCs and MSCs treated by BYHWD induced elevated microRNA (miRNA)-126 expression and reduced miR-221 and miR-222 expression." +other hsa-mir-150 "Leukemia, Lymphoblastic, Acute" 25796601 "This study not only identifies differences in the pathways and networks of acute lymphocytic leukemia (ALL) relative to normal lymphocytes, but also identifies unique functional characteristics of lymphoid cells and distinct gene expression patterns during lymphoid development. The discovery of leukemia-related miRNAs may provide meaningful insights into the biology of the disease." +other hsa-mir-17 "Leukemia, Lymphoblastic, Acute" 25796601 "This study not only identifies differences in the pathways and networks of acute lymphocytic leukemia (ALL) relative to normal lymphocytes, but also identifies unique functional characteristics of lymphoid cells and distinct gene expression patterns during lymphoid development. The discovery of leukemia-related miRNAs may provide meaningful insights into the biology of the disease." +other hsa-mir-18 "Leukemia, Lymphoblastic, Acute" 25796601 "This study not only identifies differences in the pathways and networks of acute lymphocytic leukemia (ALL) relative to normal lymphocytes, but also identifies unique functional characteristics of lymphoid cells and distinct gene expression patterns during lymphoid development. The discovery of leukemia-related miRNAs may provide meaningful insights into the biology of the disease." +other hsa-mir-18a "Leukemia, Lymphoblastic, Acute" 25796601 "This study not only identifies differences in the pathways and networks of acute lymphocytic leukemia (ALL) relative to normal lymphocytes, but also identifies unique functional characteristics of lymphoid cells and distinct gene expression patterns during lymphoid development. The discovery of leukemia-related miRNAs may provide meaningful insights into the biology of the disease." +other hsa-mir-19a "Leukemia, Lymphoblastic, Acute" 25796601 "This study not only identifies differences in the pathways and networks of acute lymphocytic leukemia (ALL) relative to normal lymphocytes, but also identifies unique functional characteristics of lymphoid cells and distinct gene expression patterns during lymphoid development. The discovery of leukemia-related miRNAs may provide meaningful insights into the biology of the disease." +other hsa-mir-19b-1 "Leukemia, Lymphoblastic, Acute" 25796601 "This study not only identifies differences in the pathways and networks of acute lymphocytic leukemia (ALL) relative to normal lymphocytes, but also identifies unique functional characteristics of lymphoid cells and distinct gene expression patterns during lymphoid development. The discovery of leukemia-related miRNAs may provide meaningful insights into the biology of the disease." +other hsa-mir-20a "Leukemia, Lymphoblastic, Acute" 25796601 "This study not only identifies differences in the pathways and networks of acute lymphocytic leukemia (ALL) relative to normal lymphocytes, but also identifies unique functional characteristics of lymphoid cells and distinct gene expression patterns during lymphoid development. The discovery of leukemia-related miRNAs may provide meaningful insights into the biology of the disease." +other hsa-mir-222 "Leukemia, Lymphoblastic, Acute" 25796601 "This study not only identifies differences in the pathways and networks of acute lymphocytic leukemia (ALL) relative to normal lymphocytes, but also identifies unique functional characteristics of lymphoid cells and distinct gene expression patterns during lymphoid development. The discovery of leukemia-related miRNAs may provide meaningful insights into the biology of the disease." +other hsa-mir-92-1 "Leukemia, Lymphoblastic, Acute" 25796601 "This study not only identifies differences in the pathways and networks of acute lymphocytic leukemia (ALL) relative to normal lymphocytes, but also identifies unique functional characteristics of lymphoid cells and distinct gene expression patterns during lymphoid development. The discovery of leukemia-related miRNAs may provide meaningful insights into the biology of the disease." +other hsa-mir-92a "Leukemia, Lymphoblastic, Acute" 25796601 "This study not only identifies differences in the pathways and networks of acute lymphocytic leukemia (ALL) relative to normal lymphocytes, but also identifies unique functional characteristics of lymphoid cells and distinct gene expression patterns during lymphoid development. The discovery of leukemia-related miRNAs may provide meaningful insights into the biology of the disease." +other hsa-mir-200a "Carcinoma, Hepatocellular" 25797260 MicroRNA-200a suppresses metastatic potential of side population cells in human hepatocellular carcinoma by decreasing ZEB2. +other hsa-mir-432 "Carcinoma, Hepatocellular" 25797263 Downregulation of miR-432 activates Wnt/¦Â-catenin signaling and promotes human hepatocellular carcinoma proliferation. +other hsa-let-7e Cystic Fibrosis 25800681 "Ingenuity Pathway Analysis indicated that hsa-miR-99b and hsa-miR-125a could be associated with the phenotypes manifested by p.F508del patients. Here we provide novel elements in the mechanism of hsa-miR-99b and hsa-miR-125a biogenesis, and for the role of CFTR and DeltaF508-CFTR on the expression of this miRNA cluster. These findings augment existing data implicating miRNAs as putative CF modifiers." +other hsa-mir-125a Cystic Fibrosis 25800681 "Ingenuity Pathway Analysis indicated that hsa-miR-99b and hsa-miR-125a could be associated with the phenotypes manifested by p.F508del patients. Here we provide novel elements in the mechanism of hsa-miR-99b and hsa-miR-125a biogenesis, and for the role of CFTR and DeltaF508-CFTR on the expression of this miRNA cluster. These findings augment existing data implicating miRNAs as putative CF modifiers." +other hsa-mir-99b Cystic Fibrosis 25800681 "Ingenuity Pathway Analysis indicated that hsa-miR-99b and hsa-miR-125a could be associated with the phenotypes manifested by p.F508del patients. Here we provide novel elements in the mechanism of hsa-miR-99b and hsa-miR-125a biogenesis, and for the role of CFTR and DeltaF508-CFTR on the expression of this miRNA cluster. These findings augment existing data implicating miRNAs as putative CF modifiers." +other hsa-mir-548c Breast Neoplasms 25802200 "we showed that miR-548c-3p is implicated in doxorubicin-treated MCF-7 cell viability, suggesting a role for this miRNA in resistance." +other hsa-mir-130b Cholestasis 25802328 "These data support miR-130b as a potential negative regulator of drug metabolism by directly and/or indirectly affecting the expression of several ADME genes. This may be of relevance in pathophysiologic conditions such as cholestasis and inflammation, which are associated with increased miR-130b expression." +other hsa-let-7a "Squamous Cell Carcinoma, Lung" 25802847 "The novel candidate key drivers in this refined subnetwork, such as the methylation of ARHGDIB and HOXD3, microRNA let-7a and miR-31, and the CNV of AGAP2, were identified and analyzed." +other hsa-mir-20a "Carcinoma, Cervical" 25803820 MiR-20a promotes cervical cancer proliferation and metastasis in vitro and in vivo. +other hsa-mir-143 Bladder Neoplasms 25804644 "The cancer-related miR-143, miR-145 and miR-224 were investigated for the first time in the clinical setting of BlCa, and miR-143/145 cluster constitutes a novel marker helpful for providing an enhanced prediction of oncologic outcome for BlCa patients." +other hsa-mir-145 Bladder Neoplasms 25804644 "The cancer-related miR-143, miR-145 and miR-224 were investigated for the first time in the clinical setting of BlCa, and miR-143/145 cluster constitutes a novel marker helpful for providing an enhanced prediction of oncologic outcome for BlCa patients." +other hsa-mir-224 Bladder Neoplasms 25804644 "The cancer-related miR-143, miR-145 and miR-224 were investigated for the first time in the clinical setting of BlCa, and miR-143/145 cluster constitutes a novel marker helpful for providing an enhanced prediction of oncologic outcome for BlCa patients." +other hsa-mir-146a Inflammation 25805648 "the model of endotoxin tolerance is suitable for the antagonistic effects on the dysregulation of ABCA1/G1 induced by high dose of P.g LPS.Conversely, low-dose AGEs did not induce the model of P.g LPS-mediated tolerance." +other hsa-mir-1290 "Squamous Cell Carcinoma, Esophageal" 25805931 Our findings suggested that miR-1290 may play an oncogenic role in cellular processes of ESCC. +other hsa-mir-200c Neoplasms [unspecific] 25808651 "A Comprehensive Review on miR-200c, A Promising Cancer Biomarker with Therapeutic Potential." +other hsa-mir-29 Human Immunodeficiency Virus Infection 25808800 "The miRNA-29 family could influence the clinical progression of HIV-1 infection, the HIV-1 proviral load and the innate immune response against HIV-1." +other hsa-mir-9 "Adenocarcinoma, Cervical" 25809226 our results here present a tumor suppressor potential of miR-9 in cervical adenocarcinoma for the first time and suggest that miR-9 could repress tumorigenesis through inhibiting the activity of IL-6/Jak/STAT3 pathway.has-miR-146b-5p +other hsa-mir-210 Neoplasms [unspecific] 25809609 The role of hypoxia-induced miR-210 in cancer progression. +other hsa-mir-494 "Carcinoma, Nasopharyngeal" 25809707 Functional elucidation of miR-494 in the tumorigenesis of nasopharyngeal carcinoma. +other hsa-mir-15b Glioma 25811315 Decreased Expression of miR-15b in Human Gliomas is Associated with Poor Prognosis. +other hsa-mir-518a Colorectal Carcinoma 25812680 Downregulation of miR-518a-3p activates the NIK-dependent NF-¦ÊB pathway in colorectal cancer. +other hsa-mir-16 "Carcinoma, Renal Cell" 25815587 Upregulated microRNA-16 as an oncogene in renal cell carcinoma. +other hsa-mir-103-1 Bipolar Disorder 25817407 Our approach of integrating PGC findings with eQTL results can be used to generate specific hypotheses regarding the role of miRNAs in SZ and BD. +other hsa-mir-103-1 Schizophrenia 25817407 Our approach of integrating PGC findings with eQTL results can be used to generate specific hypotheses regarding the role of miRNAs in SZ and BD. +other hsa-mir-124 Bipolar Disorder 25817407 Our approach of integrating PGC findings with eQTL results can be used to generate specific hypotheses regarding the role of miRNAs in SZ and BD. +other hsa-mir-124 Schizophrenia 25817407 Our approach of integrating PGC findings with eQTL results can be used to generate specific hypotheses regarding the role of miRNAs in SZ and BD. +other hsa-mir-132 Bipolar Disorder 25817407 Our approach of integrating PGC findings with eQTL results can be used to generate specific hypotheses regarding the role of miRNAs in SZ and BD. +other hsa-mir-132 Schizophrenia 25817407 Our approach of integrating PGC findings with eQTL results can be used to generate specific hypotheses regarding the role of miRNAs in SZ and BD. +other hsa-mir-138 Bipolar Disorder 25817407 Our approach of integrating PGC findings with eQTL results can be used to generate specific hypotheses regarding the role of miRNAs in SZ and BD. +other hsa-mir-138 Schizophrenia 25817407 Our approach of integrating PGC findings with eQTL results can be used to generate specific hypotheses regarding the role of miRNAs in SZ and BD. +other hsa-mir-206 Bipolar Disorder 25817407 Our approach of integrating PGC findings with eQTL results can be used to generate specific hypotheses regarding the role of miRNAs in SZ and BD. +other hsa-mir-206 Schizophrenia 25817407 Our approach of integrating PGC findings with eQTL results can be used to generate specific hypotheses regarding the role of miRNAs in SZ and BD. +other hsa-mir-218-1 Bipolar Disorder 25817407 Our approach of integrating PGC findings with eQTL results can be used to generate specific hypotheses regarding the role of miRNAs in SZ and BD. +other hsa-mir-218-1 Schizophrenia 25817407 Our approach of integrating PGC findings with eQTL results can be used to generate specific hypotheses regarding the role of miRNAs in SZ and BD. +other hsa-mir-34a Bipolar Disorder 25817407 Our approach of integrating PGC findings with eQTL results can be used to generate specific hypotheses regarding the role of miRNAs in SZ and BD. +other hsa-mir-34a Schizophrenia 25817407 Our approach of integrating PGC findings with eQTL results can be used to generate specific hypotheses regarding the role of miRNAs in SZ and BD. +other hsa-mir-449a Bipolar Disorder 25817407 Our approach of integrating PGC findings with eQTL results can be used to generate specific hypotheses regarding the role of miRNAs in SZ and BD. +other hsa-mir-449a Schizophrenia 25817407 Our approach of integrating PGC findings with eQTL results can be used to generate specific hypotheses regarding the role of miRNAs in SZ and BD. +other hsa-mir-9-3 Bipolar Disorder 25817407 Our approach of integrating PGC findings with eQTL results can be used to generate specific hypotheses regarding the role of miRNAs in SZ and BD. +other hsa-mir-9-3 Schizophrenia 25817407 Our approach of integrating PGC findings with eQTL results can be used to generate specific hypotheses regarding the role of miRNAs in SZ and BD. +other hsa-mir-340 Glioblastoma 25817794 "miR-340 inhibits glioblastoma cell proliferation by suppressing CDK6, cyclin-D1 and cyclin-D2." +other hsa-mir-124 Colorectal Carcinoma 25818238 MicroRNA-124 inhibits cancer cell growth through PTB1/PKM1/PKM2 feedback cascade in colorectal cancer. +other hsa-mir-155 "Lymphoma, Large-Cell, Anaplastic" 25820993 Oncogenic role of miR-155 in anaplastic large cell lymphoma lacking the t(2;5) translocation. +other hsa-mir-122 "Carcinoma, Hepatocellular" 25823567 Regulation of the oncogenic function of distal-less 4 by microRNA-122 in hepatocellular carcinoma. +other hsa-mir-93 Glioma 25823655 miR-93 promotes cell proliferation in gliomas through activation of PI3K/Akt signaling pathway. +other hsa-mir-1323 Lung Neoplasms 25823795 Knockdown of microRNA-1323 restores sensitivity to radiation by suppression of PRKDC activity in radiation-resistant lung cancer cells. +other hsa-mir-328 Breast Neoplasms 25824027 Arsenic trioxide inhibits breast cancer cell growth via microRNA-328/hERG pathway in MCF-7 cells. +other hsa-mir-223 Pleural Mesothelioma 25824152 Loss of miR-223 and JNK Signaling Contribute to Elevated Stathmin in Malignant Pleural Mesothelioma. +other hsa-mir-210 Pulmonary Hypertension 25825391 Genetic and hypoxic alterations of the microRNA-210-ISCU1/2 axis promote iron-sulfur deficiency and pulmonary hypertension. +other hsa-mir-193a Neoplasms [unspecific] 25826780 "Our findings have provided new insights into mechanisms of CIK cells production and tumor cytotoxic function, and shed light on their safety for clinical trial." +other hsa-mir-181c Breast Neoplasms 25828099 Brain metastatic cancer cells release microRNA-181c-containing extracellular vesicles capable of destructing blood-brain barrier. +other hsa-mir-208a Myocardial Infarction 25828373 Targeting MicroRNA-208a to Suppress Adverse Postmyocardial Infarction Remodelling Related to RNA Activation of Endoglin Gene Expression. +other hsa-mir-23a Heart Failure 25829494 Heat shock inhibition of CDK5 increases NOXA levels through miR-23a repression. +other hsa-mir-21 Lung Neoplasms 25831148 Abnormal Expression of miR-21 and miR-95 in Cancer Stem-Like Cells is Associated with Radioresistance of Lung Cancer. +other hsa-mir-95 Lung Neoplasms 25831148 Abnormal Expression of miR-21 and miR-95 in Cancer Stem-Like Cells is Associated with Radioresistance of Lung Cancer. +other hsa-mir-340 Glioblastoma 25831237 miR-340 suppresses glioblastoma multiforme. +other hsa-mir-200 "Carcinoma, Colon" 25832648 Loss of miR-200 family in 5-fluorouracil resistant colon cancer drives lymphendothelial invasiveness in vitro. +other hsa-mir-451 Glioblastoma 25833239 low levels of glucose affect metabolism and activate cell migration through the miR-451-AMPK control system +other hsa-mir-150 "Leukemia, Lymphocytic, Chronic, B-Cell" 25833959 "this study successfully characterized CLL exosomes, demonstrated the control of BCR signaling in the release of CLL exosomes, and uncovered a disease-relevant exosome microRNA profile." +other hsa-mir-155 "Leukemia, Lymphocytic, Chronic, B-Cell" 25833959 "this study successfully characterized CLL exosomes, demonstrated the control of BCR signaling in the release of CLL exosomes, and uncovered a disease-relevant exosome microRNA profile." +other hsa-mir-223 "Leukemia, Lymphocytic, Chronic, B-Cell" 25833959 "this study successfully characterized CLL exosomes, demonstrated the control of BCR signaling in the release of CLL exosomes, and uncovered a disease-relevant exosome microRNA profile." +other hsa-mir-29 "Leukemia, Lymphocytic, Chronic, B-Cell" 25833959 "this study successfully characterized CLL exosomes, demonstrated the control of BCR signaling in the release of CLL exosomes, and uncovered a disease-relevant exosome microRNA profile." +other hsa-mir-122 Hepatitis C Virus Infection 25836383 The binding of p68 onto HCV RNA can be specifically inhibited by miR-122 via a competitive binding process. +other hsa-mir-182 Glioblastoma 25838542 "miR-182 integrates apoptosis, growth, and differentiation programs in glioblastoma." +other hsa-mir-199a "Carcinoma, Ovarian" 25839163 The hypoxia-related microRNA miR-199a-3p displays tumor suppressor functions in ovarian carcinoma. +other hsa-mir-208 Heart Failure 25840809 miR-208 family is closely associated with the development of cardiac diseases +other hsa-mir-208 Vascular Hypertrophy 25840809 miR-208 family is closely associated with the development of cardiac diseases +other hsa-mir-203 "Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal" 25840888 Effect of microRNA-203 on tumor growth in human hypopharyngeal squamous cell carcinoma. +other hsa-mir-132 Pancreatic Neoplasms 25840985 Xenograft tumors treated with ormeloxifene in combination with gemcitabine restored the tumor-suppressor miR-132 and inhibited stromal cell infiltration into the tumor tissues. +other hsa-mir-889 "Squamous Cell Carcinoma, Esophageal" 25841337 miR-889 promotes proliferation of esophageal squamous cell carcinomas through DAB2IP. +other hsa-mir-942 "Squamous Cell Carcinoma, Esophageal" 25844602 miR-942 promotes cancer stem cell-like traits in esophageal squamous cell carcinoma through activation of Wnt/¦Â-catenin signalling pathway. +other hsa-mir-99a Chronic Hepatitis C 25844942 "IFI35, mir-99a and HCV genotype to predict sustained virological response to pegylated-interferon plus ribavirin in chronic hepatitis C." +other hsa-mir-154 Lung Neoplasms 25846246 miR-154 suppresses non-small cell lung cancer growth in vitro and in vivo. +other hsa-mir-210 Prostate Neoplasms 25846647 "Treatment with MIB led to an induction of miR-210 expression, a hypoxia-related miRNA" +other hsa-mir-221 Prostate Neoplasms 25846647 This observation indicates that this miRNA may have a more complex role in prostate cancer development than considered previously.Thus examining the effect of androgen receptor (AR) agonists and antagonists on miRNA expression can provide novel insights into the response of cells to androgen receptor (AR) ligands and subsequent downstream events. +other hsa-mir-335 "Carcinoma, Renal Cell, Clear-Cell" 25846734 miR-335 inhibits the proliferation and invasion of clear cell renal cell carcinoma cells through direct suppression of BCL-W. +other hsa-mir-9 "Carcinoma, Ovarian" 25846738 MicroRNA-9 promotes tumorigenesis and mediates sensitivity to cisplatin in primary epithelial ovarian cancer cells. +other hsa-mir-27b Congenital Heart Diseases 25847058 "The current study revealed for the first time that microRNAs may be important regulators in pulmonary arterial hypertension secondary to congenital heart disease, and demonstrated the correlation between microRNA-27b and pulmonary arterial hypertension with the implication of NOTCH1." +other hsa-mir-144 Osteosarcoma 25854173 "MicroRNA-144 inhibits the proliferation, apoptosis, invasion, and migration of osteosarcoma cell line F5M2." +other hsa-mir-125a Vascular Disease [unspecific] 25854878 These translational data emphasize the pathogenetic role of miR-125a in pulmonary vascular remodeling. +other hsa-mir-122 Hepatitis C Virus Infection 25855736 Regulation of Hepatitis C Virus Genome Replication by Xrn1 and MicroRNA-122 Binding to Individual Sites in the 5' Untranslated Region. +other hsa-mir-183 Neoplasms [unspecific] 25856466 "Let-7, mir-98 and mir-183 as biomarkers for cancer and schizophrenia [corrected]." +other hsa-mir-98 Neoplasms [unspecific] 25856466 "Let-7, mir-98 and mir-183 as biomarkers for cancer and schizophrenia [corrected]." +other hsa-mir-100 Cardiovascular Diseases [unspecific] 25857370 "In endothelial cells, activation of PPAR-¦Ä decreased VLDL receptor expression and VLDL uptake via the induction of miR-100. These results provided a novel mechanism for the vascular protective effect of PPAR-¦Ä agonists." +other hsa-mir-29a "Scleroderma, Systemic" 25857445 MicroRNA-29a induces apoptosis via increasing the Bax:Bcl-2 ratio in dermal fibroblasts of patients with systemic sclerosis. +other hsa-mir-25 "Carcinoma, Prostate" 25858144 miR-25 Modulates Invasiveness and Dissemination of Human Prostate Cancer Cells via Regulation of ¦Áv- and ¦Á6-Integrin Expression. +other hsa-mir-93 Viral Infectious Disease 25858415 Generation of a safe and effective live viral vaccine by virus self-attenuation using species-specific artificial microRNA. +other hsa-mir-29c "Leukemia, Lymphocytic, Chronic, B-Cell" 25860243 "Our data identify biological characteristics associated with subset #4 patients, providing further evidence for the putative role of BCR in shaping the features of the tumor cells in CLL." +other hsa-mir-497 "Leukemia, Lymphocytic, Chronic, B-Cell" 25860243 "Our data identify biological characteristics associated with subset #4 patients, providing further evidence for the putative role of BCR in shaping the features of the tumor cells in CLL." +other hsa-mir-1234 Gastric Neoplasms 25861021 These data provide a theoretical basis for the potential interaction between miRNA and the ¦Â-catenin signaling pathway in GC. +other hsa-mir-135b Gastric Neoplasms 25861021 These data provide a theoretical basis for the potential interaction between miRNA and the ¦Â-catenin signaling pathway in GC. +other hsa-mir-20a Gastric Neoplasms 25861021 These data provide a theoretical basis for the potential interaction between miRNA and the ¦Â-catenin signaling pathway in GC. +other hsa-mir-210 Gastric Neoplasms 25861021 These data provide a theoretical basis for the potential interaction between miRNA and the ¦Â-catenin signaling pathway in GC. +other hsa-mir-23b Gastric Neoplasms 25861021 These data provide a theoretical basis for the potential interaction between miRNA and the ¦Â-catenin signaling pathway in GC. +other hsa-mir-423 Gastric Neoplasms 25861021 These data provide a theoretical basis for the potential interaction between miRNA and the ¦Â-catenin signaling pathway in GC. +other hsa-mir-455 Gastric Neoplasms 25861021 These data provide a theoretical basis for the potential interaction between miRNA and the ¦Â-catenin signaling pathway in GC. +other hsa-mir-4739 Gastric Neoplasms 25861021 These data provide a theoretical basis for the potential interaction between miRNA and the ¦Â-catenin signaling pathway in GC. +other hsa-mir-494 "Carcinoma, Lung, Non-Small-Cell" 25861022 Expression and clinical evidence of miR-494 and PTEN in non-small cell lung cancer. +other hsa-mir-106b Pituitary Neoplasms 25862551 "Our results suggest microRNA involvement in malignant pituitary progression, whereby increased miR-20a, miR-106b and miR-17-5p promote metastasis by attenuating PTEN and TIMP2 in pituitary carcinoma." +other hsa-mir-17 Pituitary Neoplasms 25862551 "Our results suggest microRNA involvement in malignant pituitary progression, whereby increased miR-20a, miR-106b and miR-17-5p promote metastasis by attenuating PTEN and TIMP2 in pituitary carcinoma." +other hsa-mir-20a Pituitary Neoplasms 25862551 "Our results suggest microRNA involvement in malignant pituitary progression, whereby increased miR-20a, miR-106b and miR-17-5p promote metastasis by attenuating PTEN and TIMP2 in pituitary carcinoma." +other hsa-mir-29c Pancreatic Neoplasms 25863127 miR-29c suppresses pancreatic cancer liver metastasis in an orthotopic implantation model in nude mice and affects survival in pancreatic cancer patients. +other hsa-mir-222 Cardiovascular Diseases [unspecific] 25863248 These studies implicate miR-222 as necessary for exercise-induced cardiomyocyte growth and proliferation in the adult mammalian heart and show that it is sufficient to protect the heart against adverse remodeling. +other hsa-mir-148a Bladder Neoplasms 25865490 miR-148a dependent apoptosis of bladder cancer cells is mediated in part by the epigenetic modifier DNMT1. +other hsa-mir-150 "Lymphoma, Large B-Cell, Diffuse" 25866097 miR signature from DLBCL biopsies can discriminate between patients with favorable and poor prognoses. +other hsa-mir-155 "Lymphoma, Large B-Cell, Diffuse" 25866097 miR signature from DLBCL biopsies can discriminate between patients with favorable and poor prognoses. +other hsa-mir-18a "Lymphoma, Large B-Cell, Diffuse" 25866097 miR signature from DLBCL biopsies can discriminate between patients with favorable and poor prognoses. +other hsa-mir-221 "Lymphoma, Large B-Cell, Diffuse" 25866097 miR signature from DLBCL biopsies can discriminate between patients with favorable and poor prognoses. +other hsa-mir-222 "Lymphoma, Large B-Cell, Diffuse" 25866097 miR signature from DLBCL biopsies can discriminate between patients with favorable and poor prognoses. +other hsa-mir-342 "Lymphoma, Large B-Cell, Diffuse" 25866097 miR signature from DLBCL biopsies can discriminate between patients with favorable and poor prognoses. +other hsa-mir-621 Breast Neoplasms 25867061 MiRNA-621 sensitizes breast cancer to chemotherapy by suppressing FBXO11 and enhancing p53 activity. +other hsa-mir-149 "Stroke, Ischemic" 25867405 Effect of a pre-microRNA-149 (miR-149) genetic variation on the risk of ischemic stroke in a Chinese Han population. +other hsa-mir-103 Myocardial Infarction 25867756 This study provides more details on gene expression regulation and regulators involved in MI progression and recurrence. It also linked up and interpreted many previous results. +other hsa-mir-16 Myocardial Infarction 25867756 This study provides more details on gene expression regulation and regulators involved in MI progression and recurrence. It also linked up and interpreted many previous results. +other hsa-mir-26 Myocardial Infarction 25867756 This study provides more details on gene expression regulation and regulators involved in MI progression and recurrence. It also linked up and interpreted many previous results. +other hsa-mir-320 Myocardial Infarction 25867756 This study provides more details on gene expression regulation and regulators involved in MI progression and recurrence. It also linked up and interpreted many previous results. +other hsa-let-7b Melanoma 25868368 The concomitant inhibition of MMP-9 and MMP-13 affects prognosis and survival in skin melanoma. +other hsa-mir-21 Melanoma 25868368 The concomitant inhibition of MMP-9 and MMP-13 affects prognosis and survival in skin melanoma. +other hsa-mir-451 Osteosarcoma 25869073 Suppression of liver receptor homolog-1 by microRNA-451 represses the proliferation of osteosarcoma cells. +other hsa-let-7i Glioblastoma 25869098 MicroRNA profiling of Chinese primary glioblastoma reveals a temozolomide-chemoresistant subtype. +other hsa-mir-1238 Glioblastoma 25869098 MicroRNA profiling of Chinese primary glioblastoma reveals a temozolomide-chemoresistant subtype. +other hsa-mir-1280 Glioblastoma 25869098 MicroRNA profiling of Chinese primary glioblastoma reveals a temozolomide-chemoresistant subtype. +other hsa-mir-151 Glioblastoma 25869098 MicroRNA profiling of Chinese primary glioblastoma reveals a temozolomide-chemoresistant subtype. +other hsa-mir-423 Glioblastoma 25869098 MicroRNA profiling of Chinese primary glioblastoma reveals a temozolomide-chemoresistant subtype. +other hsa-mir-93 Glioblastoma 25869098 MicroRNA profiling of Chinese primary glioblastoma reveals a temozolomide-chemoresistant subtype. +other hsa-mir-938 Glioblastoma 25869098 MicroRNA profiling of Chinese primary glioblastoma reveals a temozolomide-chemoresistant subtype. +other hsa-mir-17 Lymphoma 25870038 "Functional interactions among members of the miR-17-92 cluster in lymphocyte development, differentiation and malignant transformation." +other hsa-mir-18 Lymphoma 25870038 "Functional interactions among members of the miR-17-92 cluster in lymphocyte development, differentiation and malignant transformation." +other hsa-mir-19a Lymphoma 25870038 "Functional interactions among members of the miR-17-92 cluster in lymphocyte development, differentiation and malignant transformation." +other hsa-mir-19b-1 Lymphoma 25870038 "Functional interactions among members of the miR-17-92 cluster in lymphocyte development, differentiation and malignant transformation." +other hsa-mir-20a Lymphoma 25870038 "Functional interactions among members of the miR-17-92 cluster in lymphocyte development, differentiation and malignant transformation." +other hsa-mir-92-1 Lymphoma 25870038 "Functional interactions among members of the miR-17-92 cluster in lymphocyte development, differentiation and malignant transformation." +other hsa-mir-101 Graves Disease 25871842 Our study highlights the possibility that miRNA-target gene network may be involved in the pathogenesis of GD and could provide new insights into understanding the pathophysiological mechanisms of GD. +other hsa-mir-96 Pulmonary Hypertension 25871906 "Increased 5-HT1BR expression may be a consequence of decreased miRNA-96 expression in female patient human pulmonary artery smooth muscle cell(PASMCs), and this may contribute to the development of pulmonary arterial hypertension (PAH)." +other hsa-mir-203 Pancreatic Neoplasms 25872941 This led to the identification of both its target gene miR-203 as a major drug sensitizer +other hsa-mir-155 Human Immunodeficiency Virus Infection 25873391 "we demonstrate that TRIM32, an E3 ubiquitin ligase, promotes reactivation from latency by directly modifying I¦ÊB¦Á, leading to a novel mechanism of NF-¦ÊB induction not involving I¦ÊB kinase activation." +other hsa-mir-326 Thrombosis 25875481 "The effect of miR-326 appeared to be limited to apoptosis,with no significant effect on platelet activation. These results provide new insight into the molecular mechanisms affecting differential platelet gene regulation, which may increase understanding of the role of platelet apoptosis in multiple diseases." +other hsa-mir-494 "Carcinoma, Cervical" 25877755 MiRNA-494 inhibits metastasis of cervical cancer through Pttg1. +other hsa-mir-23a "Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal" 25879432 "miR-23a, an independent prognostic factor for laryngeal cancer,participates in the onset and progression of laryngeal cancer." +other hsa-mir-21 Breast Neoplasms 25880495 Formulation of Anti-miR-21 and 4-Hydroxytamoxifen Co-loaded Biodegradable Polymer Nanoparticles and Their Antiproliferative Effect on Breast Cancer Cells. +other hsa-mir-7 Schizophrenia 25882257 MicroRNA-7/Shank3 axis involved in schizophrenia pathogenesis. +other hsa-mir-21 Atherosclerosis 25882990 "In atherosclerosis, miR-21 is increased in the aorta and associated with vitamin D deficiency. Vitamin D deficiency may influence aberrant miR-21 expression in vasculature and bone contributing to the concurrent development of atherosclerosis and osteoporosis." +other hsa-mir-141 Bladder Neoplasms 25884322 "MiRNA-141 and miRNA-200b play important roles in the invasive ability and EMT phenotype of bladder cancer. Detection of miRNA-141 and miRNA-200b can help to identify patients undergoing cystectomy who are likely to have lymph node metastasis, and therefore those who may benefit from super-extended PLND." +other hsa-mir-200b Bladder Neoplasms 25884322 "MiRNA-141 and miRNA-200b play important roles in the invasive ability and EMT phenotype of bladder cancer. Detection of miRNA-141 and miRNA-200b can help to identify patients undergoing cystectomy who are likely to have lymph node metastasis, and therefore those who may benefit from super-extended PLND." +other hsa-mir-155 "Leukemia, Lymphocytic, Chronic, B-Cell" 25886051 Role of microRNA in chronic lymphocytic leukemia onset and progression. +other hsa-mir-15a "Leukemia, Lymphocytic, Chronic, B-Cell" 25886051 Role of microRNA in chronic lymphocytic leukemia onset and progression. +other hsa-mir-16-1 "Leukemia, Lymphocytic, Chronic, B-Cell" 25886051 Role of microRNA in chronic lymphocytic leukemia onset and progression. +other hsa-mir-17 "Leukemia, Lymphocytic, Chronic, B-Cell" 25886051 Role of microRNA in chronic lymphocytic leukemia onset and progression. +other hsa-mir-181b "Leukemia, Lymphocytic, Chronic, B-Cell" 25886051 Role of microRNA in chronic lymphocytic leukemia onset and progression. +other hsa-mir-29 "Leukemia, Lymphocytic, Chronic, B-Cell" 25886051 Role of microRNA in chronic lymphocytic leukemia onset and progression. +other hsa-mir-34 "Leukemia, Lymphocytic, Chronic, B-Cell" 25886051 Role of microRNA in chronic lymphocytic leukemia onset and progression. +other hsa-mir-92 "Leukemia, Lymphocytic, Chronic, B-Cell" 25886051 Role of microRNA in chronic lymphocytic leukemia onset and progression. +other hsa-mir-142 Crohn Disease 25886994 "A panel of miRNAs(miR-19a, miR-21, miR-31, miR-101, miR-146a, and miR-375) may be used as markers to identify and discriminate between CD and UC." +other hsa-mir-21 Crohn Disease 25886994 "A panel of miRNAs(miR-19a, miR-21, miR-31, miR-101, miR-146a, and miR-375) may be used as markers to identify and discriminate between CD and UC." +other hsa-mir-31 Crohn Disease 25886994 "A panel of miRNAs(miR-19a, miR-21, miR-31, miR-101, miR-146a, and miR-375) may be used as markers to identify and discriminate between CD and UC." +other hsa-mir-1307 Ovarian Neoplasms 25887170 Our results suggest that miRNA-1307 may play a role in the development of chemoresistance in ovarian cancer. +other hsa-mir-34a Cardiovascular Diseases [unspecific] 25887273 "Also, miR-125a-5p/-351, miR-200c/-429, miR-106b/-17, miR-363/-92b, miR-181b/-181d, miR-19a/-19b, let-7d/-7f, miR-18a/-18b, miR-128/-27b and miR-106a/-291a-3p pairs exhibited significant synergy and their association to aging and/or cardiovascular diseases is supported in many cases by a disease database and previous studies." +other hsa-mir-17 Neoplasms [unspecific] 25887381 "Our findings therefore identify the miR-17-92 cluster as a functionally determining family of miRNAs in CSCs, and highlight the putative potential of developing modulators of this cluster to overcome drug resistance in pancreatic CSCs." +other hsa-mir-18 Neoplasms [unspecific] 25887381 "Our findings therefore identify the miR-17-92 cluster as a functionally determining family of miRNAs in CSCs, and highlight the putative potential of developing modulators of this cluster to overcome drug resistance in pancreatic CSCs." +other hsa-mir-19a Neoplasms [unspecific] 25887381 "Our findings therefore identify the miR-17-92 cluster as a functionally determining family of miRNAs in CSCs, and highlight the putative potential of developing modulators of this cluster to overcome drug resistance in pancreatic CSCs." +other hsa-mir-19b-1 Neoplasms [unspecific] 25887381 "Our findings therefore identify the miR-17-92 cluster as a functionally determining family of miRNAs in CSCs, and highlight the putative potential of developing modulators of this cluster to overcome drug resistance in pancreatic CSCs." +other hsa-mir-20a Neoplasms [unspecific] 25887381 "Our findings therefore identify the miR-17-92 cluster as a functionally determining family of miRNAs in CSCs, and highlight the putative potential of developing modulators of this cluster to overcome drug resistance in pancreatic CSCs." +other hsa-mir-92-1 Neoplasms [unspecific] 25887381 "Our findings therefore identify the miR-17-92 cluster as a functionally determining family of miRNAs in CSCs, and highlight the putative potential of developing modulators of this cluster to overcome drug resistance in pancreatic CSCs." +other hsa-mir-125b "Carcinoma, Hepatocellular" 25889022 This finding provides the novel evidence for GLPS on inhibition of HCC through miR-125b inhibiting Tregs accumulation and function. +other hsa-mir-141 Neoplasms [unspecific] 25889350 "The DNA tweezers also show high selectivity toward the fuel strand and can be used to monitor miR-141 expression in cancer cells, which provides new opportunities for the application of the dynamic DNA devices in clinical diagnostics." +other hsa-mir-146a Japanese Encephalitis Virus Infection 25889446 Upregulation of miR-146a by JEV JaOArS982 strain leads to suppression of NF-¦ÊB activity and disruption of antiviral Jak-STAT signaling which helps the virus to evade the cellular immune response. This effect of JEV infection on miR-146a expression was found to be strain specific. +other hsa-mir-21 Muscular Dystrophy 25892183 Opposing roles of miR-21 and miR-29 in the progression of fibrosis in Duchenne muscular dystrophy. +other hsa-mir-29 Muscular Dystrophy 25892183 Opposing roles of miR-21 and miR-29 in the progression of fibrosis in Duchenne muscular dystrophy. +other hsa-mir-31 "Carcinoma, Cervical" 25894339 Our results suggested that miR-31 plays an oncogenetic role in the development and progression of cervical cancer. +other hsa-mir-129 Ovarian Neoplasms 25895125 A novel role for microRNA-129-5p in inhibiting ovarian cancer cell proliferation and survival via direct suppression of transcriptional co-activators YAP and TAZ. +other hsa-mir-34a Neoplasms [unspecific] 25896587 "miR-34a plays an important role in the anti-tumor effects of querctin in HCC, miR-34a may be a tiemolecule between the p53 and SIRT1 and is composed of a p53/miR-34a/SIRT1 signal feedback loop, which could enhance apoptosis signal and significantly promote cell apoptosis." +other hsa-mir-16 Gastric Neoplasms 25897338 Circulating MiR-16-5p and MiR-19b-3p as Two Novel Potential Biomarkers to Indicate Progression of Gastric Cancer. +other hsa-mir-19b Gastric Neoplasms 25897338 Circulating MiR-16-5p and MiR-19b-3p as Two Novel Potential Biomarkers to Indicate Progression of Gastric Cancer. +other hsa-mir-221 Gastrointestinal Stromal Tumor 25898773 miRNA-221 and miRNA-222 induce apoptosis via the KIT/AKT signalling pathway in gastrointestinal stromal tumours. +other hsa-mir-222 Gastrointestinal Stromal Tumor 25898773 miRNA-221 and miRNA-222 induce apoptosis via the KIT/AKT signalling pathway in gastrointestinal stromal tumours. +other hsa-mir-1 Neoplasms [unspecific] 25899823 "Our results suggest that the degradation status of ribosomal RNA is not always applicable to mRNA and microRNA. In fact, the stabilities of these RNA classes to exposure to ribonucleases are independent from each other, with microRNA being more stable than mRNA. The relative stability of microRNAs supports their potential and further development as biomarkers in a range of applications." +other hsa-mir-208 Neoplasms [unspecific] 25899823 "Our results suggest that the degradation status of ribosomal RNA is not always applicable to mRNA and microRNA. In fact, the stabilities of these RNA classes to exposure to ribonucleases are independent from each other, with microRNA being more stable than mRNA. The relative stability of microRNAs supports their potential and further development as biomarkers in a range of applications." +other hsa-mir-501 Neoplasms [unspecific] 25899823 "Our results suggest that the degradation status of ribosomal RNA is not always applicable to mRNA and microRNA. In fact, the stabilities of these RNA classes to exposure to ribonucleases are independent from each other, with microRNA being more stable than mRNA. The relative stability of microRNAs supports their potential and further development as biomarkers in a range of applications." +other hsa-mir-21 Lung Neoplasms 25901472 "The present study reports that DEPs increased miR-21 expression and then activated the PTEN/PI3K/AKT pathway in human bronchial epithelial (HBE) cells, which may serve as an important carcinogenic mechanism. However, the data revealed that short-term exposure to a high DEP concentration did not cause evident cell carcinogenesis in HBE cells." +other hsa-mir-21 Endomyocardial Fibrosis 25903305 Downregulation of miR-21 and p-ERK/ERK were observed in myocardial fibroblasts treated with UA in a dose-dependent manner compared with the control group both in vitro and in vivo. +other hsa-mir-21 Heart Failure 25903305 Downregulation of miR-21 and p-ERK/ERK were observed in myocardial fibroblasts treated with UA in a dose-dependent manner compared with the control group both in vitro and in vivo. +other hsa-mir-21 Vascular Hypertrophy 25903305 Downregulation of miR-21 and p-ERK/ERK were observed in myocardial fibroblasts treated with UA in a dose-dependent manner compared with the control group both in vitro and in vivo. +other hsa-let-7e Acute Coronary Syndrome 25903651 "These results demonstrate a significant reprogramming of the platelet miRNome during activation, with consequent significant changes in platelet proteome and provide for the first time substantial evidence that fine-tuning of resident mRNA translation by miRNAs is a key event in platelet pathophysiology." +other hsa-mir-107 Acute Coronary Syndrome 25903651 "These results demonstrate a significant reprogramming of the platelet miRNome during activation, with consequent significant changes in platelet proteome and provide for the first time substantial evidence that fine-tuning of resident mRNA translation by miRNAs is a key event in platelet pathophysiology." +other hsa-mir-15b Acute Coronary Syndrome 25903651 "These results demonstrate a significant reprogramming of the platelet miRNome during activation, with consequent significant changes in platelet proteome and provide for the first time substantial evidence that fine-tuning of resident mRNA translation by miRNAs is a key event in platelet pathophysiology." +other hsa-mir-486 Acute Coronary Syndrome 25903651 "These results demonstrate a significant reprogramming of the platelet miRNome during activation, with consequent significant changes in platelet proteome and provide for the first time substantial evidence that fine-tuning of resident mRNA translation by miRNAs is a key event in platelet pathophysiology." +other hsa-mir-92b Acute Coronary Syndrome 25903651 "These results demonstrate a significant reprogramming of the platelet miRNome during activation, with consequent significant changes in platelet proteome and provide for the first time substantial evidence that fine-tuning of resident mRNA translation by miRNAs is a key event in platelet pathophysiology." +other hsa-mir-103 Glioblastoma 25903655 "CSF exosomes were enriched for miRNAs relative to CSF microvesicles. In CSF, there is an average of one molecule of miRNA per 150-25,000 EVs. Most EVs derived from clinical biofluids are devoid of miRNA content." +other hsa-mir-125 Glioblastoma 25903655 "CSF exosomes were enriched for miRNAs relative to CSF microvesicles. In CSF, there is an average of one molecule of miRNA per 150-25,000 EVs. Most EVs derived from clinical biofluids are devoid of miRNA content." +other hsa-mir-21 Glioblastoma 25903655 "CSF exosomes were enriched for miRNAs relative to CSF microvesicles. In CSF, there is an average of one molecule of miRNA per 150-25,000 EVs. Most EVs derived from clinical biofluids are devoid of miRNA content." +other hsa-mir-24 Glioblastoma 25903655 "CSF exosomes were enriched for miRNAs relative to CSF microvesicles. In CSF, there is an average of one molecule of miRNA per 150-25,000 EVs. Most EVs derived from clinical biofluids are devoid of miRNA content." +other hsa-mir-145 "Adenocarcinoma, Gastric" 25904219 "Downregulation of the Genes Involved in Reprogramming (SOX2, c-MYC, miR-302,miR-145, and P21) in Gastric Adenocarcinoma." +other hsa-mir-302 "Adenocarcinoma, Gastric" 25904219 "Downregulation of the Genes Involved in Reprogramming (SOX2, c-MYC, miR-302,miR-145, and P21) in Gastric Adenocarcinoma." +other hsa-mir-146a "Lymphoma, B-Cell" 25906746 Together our findings illuminate a bona fide role for miR-146a in the modulation of B-cell oncogenesis and reveal the importance of understanding microRNA function in a cell- and disease-specific context. +other hsa-mir-150 Breast Neoplasms 25907662 "These results all indicated that when analyzing miRNAs in surgical pathology specimens of breast cancer as a biomarker, they should be examined as a cluster through miRNA profiling, rather than relying on the analysis of a single miRNA." +other hsa-mir-15b Breast Neoplasms 25907662 "These results all indicated that when analyzing miRNAs in surgical pathology specimens of breast cancer as a biomarker, they should be examined as a cluster through miRNA profiling, rather than relying on the analysis of a single miRNA." +other hsa-mir-191 Breast Neoplasms 25907662 "These results all indicated that when analyzing miRNAs in surgical pathology specimens of breast cancer as a biomarker, they should be examined as a cluster through miRNA profiling, rather than relying on the analysis of a single miRNA." +other hsa-mir-200c Breast Neoplasms 25907662 "These results all indicated that when analyzing miRNAs in surgical pathology specimens of breast cancer as a biomarker, they should be examined as a cluster through miRNA profiling, rather than relying on the analysis of a single miRNA." +other hsa-mir-21 Breast Neoplasms 25907662 "These results all indicated that when analyzing miRNAs in surgical pathology specimens of breast cancer as a biomarker, they should be examined as a cluster through miRNA profiling, rather than relying on the analysis of a single miRNA." +other hsa-mir-25 Breast Neoplasms 25907662 "These results all indicated that when analyzing miRNAs in surgical pathology specimens of breast cancer as a biomarker, they should be examined as a cluster through miRNA profiling, rather than relying on the analysis of a single miRNA." +other hsa-mir-96 Breast Neoplasms 25907662 "These results all indicated that when analyzing miRNAs in surgical pathology specimens of breast cancer as a biomarker, they should be examined as a cluster through miRNA profiling, rather than relying on the analysis of a single miRNA." +other hsa-mir-34a Lung Neoplasms 25909221 miR-497 and miR-34a retard lung cancer growth by co-inhibiting cyclin E1 (CCNE1). +other hsa-mir-497 Lung Neoplasms 25909221 miR-497 and miR-34a retard lung cancer growth by co-inhibiting cyclin E1 (CCNE1). +other hsa-let-7 Lung Neoplasms 25910758 MicroRNA as tools and therapeutics in lung cancer. +other hsa-mir-122 Lung Neoplasms 25910758 MicroRNA as tools and therapeutics in lung cancer. +other hsa-mir-126 Lung Neoplasms 25910758 MicroRNA as tools and therapeutics in lung cancer. +other hsa-mir-141 Lung Neoplasms 25910758 MicroRNA as tools and therapeutics in lung cancer. +other hsa-mir-182 Lung Neoplasms 25910758 MicroRNA as tools and therapeutics in lung cancer. +other hsa-mir-200 Lung Neoplasms 25910758 MicroRNA as tools and therapeutics in lung cancer. +other hsa-mir-205 Lung Neoplasms 25910758 MicroRNA as tools and therapeutics in lung cancer. +other hsa-mir-21 Lung Neoplasms 25910758 MicroRNA as tools and therapeutics in lung cancer. +other hsa-mir-221 Lung Neoplasms 25910758 MicroRNA as tools and therapeutics in lung cancer. +other hsa-mir-222 Lung Neoplasms 25910758 MicroRNA as tools and therapeutics in lung cancer. +other hsa-mir-29 Lung Neoplasms 25910758 MicroRNA as tools and therapeutics in lung cancer. +other hsa-mir-34 Lung Neoplasms 25910758 MicroRNA as tools and therapeutics in lung cancer. +other hsa-mir-522 Lung Neoplasms 25910758 MicroRNA as tools and therapeutics in lung cancer. +other hsa-mir-592 Lung Neoplasms 25910758 MicroRNA as tools and therapeutics in lung cancer. +other hsa-mir-7 Lung Neoplasms 25910758 MicroRNA as tools and therapeutics in lung cancer. +other hsa-mir-16 Lung Neoplasms 25912305 Lung tumorigenesis induced by human vascular endothelial growth factor (hVEGF)-A165 overexpression in transgenic mice and amelioration of tumor formation by miR-16. +other hsa-let-7e Systemic Lupus Erythematosus 25912736 "These data suggest that 17¦Â-estradiol amplifies the activation of IFN-¦Á signaling in B cells via IKK¦Å by down-regulating the expression of let-7e-5p, miR-98-5p and miR-145a-5p. Our findings may provide a new perspective for understanding the mechanism underlying the gender difference in the prevalence of SLE." +other hsa-mir-145a Systemic Lupus Erythematosus 25912736 "These data suggest that 17¦Â-estradiol amplifies the activation of IFN-¦Á signaling in B cells via IKK¦Å by down-regulating the expression of let-7e-5p, miR-98-5p and miR-145a-5p. Our findings may provide a new perspective for understanding the mechanism underlying the gender difference in the prevalence of SLE." +other hsa-mir-98 Systemic Lupus Erythematosus 25912736 "These data suggest that 17¦Â-estradiol amplifies the activation of IFN-¦Á signaling in B cells via IKK¦Å by down-regulating the expression of let-7e-5p, miR-98-5p and miR-145a-5p. Our findings may provide a new perspective for understanding the mechanism underlying the gender difference in the prevalence of SLE." +other hsa-mir-125b Leukemia 25915540 The Phosphoinositide 3-Kinase p110¦Á Isoform Regulates Leukemia Inhibitory Factor Receptor Expression via c-Myc and miR-125b to Promote Cell Proliferation in Medulloblastoma. +other hsa-mir-149 Neoplasms [unspecific] 25916550 Epigenetic silencing of microRNA-149 in cancer-associated fibroblasts mediates prostaglandin E2/interleukin-6 signaling in the tumor microenvironment. +other hsa-mir-155 Ischemia-Reperfusion Injury 25916938 MicroRNA-155 aggravates ischemia-reperfusion injury by modulation of inflammatory cell recruitment and the respiratory oxidative burst. +other hsa-mir-101 Thyroid Adenomas 25916957 "These results support a role for miRNA in the regulation of extracellular matrix proteins and tissue remodeling occurring during tumor development, and in the important negative feedback of the cAMP pathway, which limits the consequences of its constitutive activation in these tumors." +other hsa-mir-144 Thyroid Adenomas 25916957 "These results support a role for miRNA in the regulation of extracellular matrix proteins and tissue remodeling occurring during tumor development, and in the important negative feedback of the cAMP pathway, which limits the consequences of its constitutive activation in these tumors." +other hsa-mir-155 Neoplasms [unspecific] 25918453 "Our data suggest that single miR-155 profiling has a potential to be used as a screening test for various carcinomas, and parallel testing of miR-155 confers an improved specificity compared to single miR-155 analysis." +other hsa-mir-224 Colorectal Carcinoma 25919696 "We describe a novel mechanism of KRAS regulation, and highlight the clinical utility of colorectal cancer-specific miRNAs as disease progression or clinical response biomarkers." +other hsa-mir-141 "Carcinoma, Prostate" 25921227 The work demonstrated here thus offers new opportunities for the construction of functional DNA nanostructures and for the application of these DNA nanostructures as an effective signal amplification means in the sensitive detection of nucleic acid biomarkers. +other hsa-mir-302a Prostate Neoplasms 25922934 MicroRNA-302a Suppresses Tumor Cell Proliferation by Inhibiting AKT in Prostate Cancer. +other hsa-mir-150 Colorectal Carcinoma 25924769 "We identified two circulating miRNAs capable of distinguishing patient groups with different diseases of the colon from each other, and patients with advanced cancer from benign disease groups." +other hsa-mir-34a Colorectal Carcinoma 25924769 "We identified two circulating miRNAs capable of distinguishing patient groups with different diseases of the colon from each other, and patients with advanced cancer from benign disease groups." +other hsa-let-7 Multiple Myeloma 25925570 "Our study establishes that the ribonuclease DIS3, targeting LIN28B, sustains the maturation of let-7 miRNAs and suggests the increased translation of critical oncogenes as one of the biological outcomes of DIS3 inactivation." +other hsa-mir-497 Colorectal Carcinoma 25926384 MiR-497 promotes metastasis of colorectal cancer cells through Nrdp1 inhibition. +other hsa-mir-148a Breast Neoplasms 25928008 Estradiol induces HOTAIR levels via GPER-mediated miR-148a inhibition in breast cancer. +other hsa-mir-155 Systemic Lupus Erythematosus 25929465 "These findings provide new insight into the mechanism underlying decreased CD1d expression on B cells in SLE, suggesting that inhibition of inflammation may increase CD1d expression in B cells to ameliorate SLE via modulating iNKT cells." +other hsa-mir-497 Colorectal Carcinoma 25929865 miRNA-497 Enhances the Sensitivity of Colorectal Cancer Cells to Neoadjuvant Chemotherapeutic Drug. +other hsa-mir-429 "Carcinoma, Hepatocellular" 25931210 our results here defined miR-429 as a key inducer for HCC pathogenesis and metastasis with potential utility for tumor intervention. +other hsa-mir-199a Osteosarcoma 25931818 Polymeric nanoparticle-based delivery of microRNA-199a-3p inhibits proliferation and growth of osteosarcoma cells. +other hsa-mir-106b Ovary Mixed Epithelial Carcinoma 25933027 Inhibition of Ovarian Epithelial Carcinoma Tumorigenesis and Progression by microRNA 106b Mediated through the RhoC Pathway. +other hsa-mir-10a Breast Neoplasms 25934412 "The data presented supports a potential tumour suppressor role for miR-10a in breast cancer, and highlights retinoic acid as a positive regulator of the microRNA." +other hsa-let-7c Cerebral Ischemia 25934573 MicroRNA let-7c-5p protects against cerebral ischemia injury via mechanisms involving the inhibition of microglia activation. +other hsa-mir-19 Colorectal Carcinoma 25934693 miR-19-Mediated Inhibition of Transglutaminase-2 Leads to Enhanced Invasion and Metastasis in Colorectal Cancer. +other hsa-mir-99a Prostate Neoplasms 25937401 A combination of low Ku80 expression and highly-induced miR-99a expression could be a promising marker for predicting rectal bleeding after radiotherapy. +other hsa-mir-135b "Squamous Cell Carcinoma, Skin or Unspecific" 25938461 MicroRNA-135b Regulates Leucine Zipper Tumor Suppressor 1 in Cutaneous Squamous Cell Carcinoma. +other hsa-mir-141 Multiple Sclerosis 25938517 "According to our results, miR-141 and miR-200a may be key miRNAs in progression of symptoms of MS through inducing differentiation of Th17 cells and inhibiting differentiation to Treg cells. Our data suggest that these miRNAs may probably inhibit negative regulators of Th17 cell differentiation, thus promoting its differentiation." +other hsa-mir-200a Multiple Sclerosis 25938517 "According to our results, miR-141 and miR-200a may be key miRNAs in progression of symptoms of MS through inducing differentiation of Th17 cells and inhibiting differentiation to Treg cells. Our data suggest that these miRNAs may probably inhibit negative regulators of Th17 cell differentiation, thus promoting its differentiation." +other hsa-mir-203 Alopecia 25939713 RBM28 contributes to HF growth regulation through modulation of miR-203 and p63 activity. +other hsa-mir-34a Neoplasms [unspecific] 25939820 Multivalent aptamer-RNA based fluorescent probes for carrier-free detection of cellular microRNA-34a in mucin1-expressing cancer cells. +other hsa-mir-301a Prostate Neoplasms 25940439 Infiltrated pre-adipocytes increase prostate cancer metastasis via modulation of the miR-301a/androgen receptor (AR)/TGF-¦Â1/Smad/MMP9 signals. +other hsa-mir-940 "Carcinoma, Hepatocellular" 25940592 MiR-940 inhibits hepatocellular carcinoma growth and correlates with prognosis of hepatocellular carcinoma patients. +other hsa-mir-218 Neoplasms [unspecific] 25940608 "A feedback loop between c-Src and miR-218 was revealed where c-Src inhibits transcription of SLIT2, which intronically hosts miR-218. These results show a novel regulatory pathway for RPTP¦Á-c-Src signalling." +other hsa-mir-9 Colorectal Carcinoma 25940709 Regulation of UHRF1 by microRNA-9 modulates colorectal cancer cell proliferation and apoptosis. +other hsa-mir-371 Neoplasms [unspecific] 25941115 MiR-371-373 cluster acts as a tumor-suppressor-miR and promotes cell cycle arrest in unrestricted somatic stem cells. +other hsa-mir-373 Neoplasms [unspecific] 25941115 MiR-371-373 cluster acts as a tumor-suppressor-miR and promotes cell cycle arrest in unrestricted somatic stem cells. +other hsa-mir-409 Kaposi Sarcoma 25942495 our data provide a more detailed understanding of KSHV latency and guide further studies of the biological significance of these changes. +other hsa-mir-708 Kaposi Sarcoma 25942495 our data provide a more detailed understanding of KSHV latency and guide further studies of the biological significance of these changes. +other hsa-mir-21 Neoplasms [unspecific] 25943710 We believe that this proposed sensitive and specific assay has great potential as a quantification method for miRNA detection in biomedical research and clinical diagnosis. +other hsa-mir-223 Diabetes Mellitus 25944670 "Thus, calpain inhibition may be one means of normalizing platelet miRNA processing as well as platelet function in diabetes mellitus." +other hsa-mir-15a Neoplasms [unspecific] 25945419 these data demonstrate that miR-15a/16 induced autophagy contribute partly to their inhibition of cell proliferation and enhanced chemotherapeutic efficacy of camptothecin(CPT). +other hsa-mir-16 Neoplasms [unspecific] 25945419 these data demonstrate that miR-15a/16 induced autophagy contribute partly to their inhibition of cell proliferation and enhanced chemotherapeutic efficacy of camptothecin(CPT). +other hsa-let-7b Neoplasms [unspecific] 25946136 Let-7 may represent a new class of chemosensitizer for the treatment of KRAS mutant tumors. +other hsa-mir-148a Pancreatic Neoplasms 25950085 The Interplay Between miR-148a and DNMT1 Might be Exploited for Pancreatic Cancer Therapy. +other hsa-mir-106a Glioma 25950430 The Effects and Molecular Mechanisms of MiR-106a in Multidrug Resistance Reversal in Human Glioma U87/DDP and U251/G Cell Lines. +other hsa-mir-4728 Neoplasms [unspecific] 25950472 ErbB2-intronic microRNA-4728: a novel tumor suppressor and antagonist of oncogenic MAPK signaling. +other hsa-mir-638 Lung Neoplasms 25952770 miR-638 is a new biomarker for outcome prediction of non-small cell lung cancer patients receiving chemotherapy. +other hsa-mir-137 "Carcinoma, Ovarian" 25955305 MicroRNA-137 suppresses tumor growth in epithelial ovarian cancer in vitro and in vivo. +other hsa-mir-206 Thyroid Neoplasms 25955685 miR-206 inhibits metastasis-relevant traits by degrading MRTF-A in anaplastic thyroid cancer. +other hsa-mir-221 Pancreatic Neoplasms 25955843 Metformin Causes G1-Phase Arrest via Down-Regulation of MiR-221 and Enhances TRAIL Sensitivity through DR5 Up-Regulation in Pancreatic Cancer Cells. +other hsa-mir-650 Prostate Neoplasms 25956032 Oncogenic Activity of miR-650 in Prostate Cancer Is Mediated by Suppression of CSR1 Expression. +other hsa-mir-132 Brain Disease [unspecific] 25957996 "our findings demonstrate the novel role of TLR4-related microRNAs, especially miR-132, in the regulation of MRP8-induced astrocyte activation and highlight the importance of miR-132 in the modulation of innate immune response induced by endogenous ligands in neurological diseases." +other hsa-mir-146a Brain Disease [unspecific] 25957996 "our findings demonstrate the novel role of TLR4-related microRNAs, especially miR-132, in the regulation of MRP8-induced astrocyte activation and highlight the importance of miR-132 in the modulation of innate immune response induced by endogenous ligands in neurological diseases." +other hsa-mir-155 Brain Disease [unspecific] 25957996 "our findings demonstrate the novel role of TLR4-related microRNAs, especially miR-132, in the regulation of MRP8-induced astrocyte activation and highlight the importance of miR-132 in the modulation of innate immune response induced by endogenous ligands in neurological diseases." +other hsa-mir-126 Cardiovascular Diseases [unspecific] 25958013 "This review describes our current understanding of extracellular vesicle miRNA transfer, demonstrating the roles of miR-126, miR-146a, miR-143, and other miRNAs being shuttled from endothelial cells, stem cells, fibroblasts and others into myocytes, endothelial cells, and smooth muscle cells to activate cellular changes and modulate disease phenotypes." +other hsa-mir-143 Cardiovascular Diseases [unspecific] 25958013 "This review describes our current understanding of extracellular vesicle miRNA transfer, demonstrating the roles of miR-126, miR-146a, miR-143, and other miRNAs being shuttled from endothelial cells, stem cells, fibroblasts and others into myocytes, endothelial cells, and smooth muscle cells to activate cellular changes and modulate disease phenotypes." +other hsa-mir-146a Cardiovascular Diseases [unspecific] 25958013 "This review describes our current understanding of extracellular vesicle miRNA transfer, demonstrating the roles of miR-126, miR-146a, miR-143, and other miRNAs being shuttled from endothelial cells, stem cells, fibroblasts and others into myocytes, endothelial cells, and smooth muscle cells to activate cellular changes and modulate disease phenotypes." +other hsa-mir-194 "Squamous Cell Carcinoma, Oral" 25960215 miR-194 regulated AGK and inhibited cell proliferation of oral squamous cell carcinoma by reducing PI3K-Akt-FoxO3a signaling. +other hsa-mir-143 Breast Neoplasms 25961039 "In our integrated genomics analysis and experimental validation, a new frame to predict candidate biomarkers of breast cancer subtype is provided and offers assistance in order to understand the potential disease etiology of the breast cancer subtypes." +other hsa-mir-145 Breast Neoplasms 25961039 "In our integrated genomics analysis and experimental validation, a new frame to predict candidate biomarkers of breast cancer subtype is provided and offers assistance in order to understand the potential disease etiology of the breast cancer subtypes." +other hsa-mir-744 "Carcinoma, Nasopharyngeal" 25961434 MiR-744 functions as a proto-oncogene in nasopharyngeal carcinoma progression and metastasis via transcriptional control of ARHGAP5. +other hsa-mir-21 Atherosclerosis 25961718 resveratrol significantly reduced miR-21 expression +other hsa-mir-144 Uveal Melanoma 25961751 MiR-144 Inhibits Uveal Melanoma Cell Proliferation and Invasion by Regulating c-Met Expression. +other hsa-mir-30a "Carcinoma, Ovarian, Serous" 25962395 Urinary microRNA-30a-5p is a potential biomarker for ovarian serous adenocarcinoma. +other hsa-mir-214 "Squamous Cell Carcinoma, Tongue" 25962755 Cantharidin inhibits cell proliferation and promotes apoptosis in tongue squamous cell carcinoma through suppression of miR-214 and regulation of p53 and Bcl-2/Bax. +other hsa-mir-18a "Carcinoma, Cervical" 25963391 MicroRNA-18a enhances the radiosensitivity of cervical cancer cells by promoting radiation-induced apoptosis. +other hsa-mir-183 Liver Diseases [unspecific] 25963660 These results indicate that the modulation of miRNA processing by COX-2 is a key event in insulin signaling in liver and has potential clinical implications for the management of various hepatic dysfunctions. +other hsa-mir-122 Hepatitis C Virus Infection 25963774 The mechanism of HCV dyslipidemia is complex and could partly relate to the effect of miR-122 on lipid metabolism which requires further evaluation in a larger study. +other hsa-mir-125a Autoimmune Diseases [unspecific] 25963922 "Using a chemically synthesized miR-125a analogue,we show potential to re-programme the immune homeostasis in EAE models. These findings point to miR-125a as a critical factor that controls autoimmune diseases by stabilizing Treg-mediated immune homeostasis." +other hsa-mir-21 "Leukemia, Myeloid, Chronic" 25964959 "we demonstrate that in two CML cell lines exhibiting different biological characteristics, LQB-118 modulates NF¦ÊB subcellular localization, apparently independently of the AKT and MAPK pathways, partially inhibits proteasome activity, and alters the expression of microRNAs -9 and -21." +other hsa-mir-9 "Leukemia, Myeloid, Chronic" 25964959 "we demonstrate that in two CML cell lines exhibiting different biological characteristics, LQB-118 modulates NF¦ÊB subcellular localization, apparently independently of the AKT and MAPK pathways, partially inhibits proteasome activity, and alters the expression of microRNAs -9 and -21." +other hsa-mir-424 "Squamous Cell Carcinoma, Tongue" 25965165 "Our patient data show that microRNA-424 alterations are a marker of field cancerisation specific for tongue tumourigenesis, which also could have a role in development of tongue squamous cell carcinoma." +other hsa-mir-155 Bladder Neoplasms 25965824 MicroRNA-155 promotes bladder cancer growth by repressing the tumor suppressor DMTF1. +other hsa-let-7a Pregnancy Complications [unspecific] 25965838 "For samples measured preconception, ROC curve analysis demonstrated AUC 0.81 for adverse pregnancy outcome. Maternal PBMC microRNA can identify high-risk patients likely to benefit from immunotherapy with improved sensitivity and specificity compared with standard immune assays." +other hsa-mir-132 Pregnancy Complications [unspecific] 25965838 "For samples measured preconception, ROC curve analysis demonstrated AUC 0.81 for adverse pregnancy outcome. Maternal PBMC microRNA can identify high-risk patients likely to benefit from immunotherapy with improved sensitivity and specificity compared with standard immune assays." +other hsa-mir-146a Pregnancy Complications [unspecific] 25965838 "For samples measured preconception, ROC curve analysis demonstrated AUC 0.81 for adverse pregnancy outcome. Maternal PBMC microRNA can identify high-risk patients likely to benefit from immunotherapy with improved sensitivity and specificity compared with standard immune assays." +other hsa-mir-155 Pregnancy Complications [unspecific] 25965838 "For samples measured preconception, ROC curve analysis demonstrated AUC 0.81 for adverse pregnancy outcome. Maternal PBMC microRNA can identify high-risk patients likely to benefit from immunotherapy with improved sensitivity and specificity compared with standard immune assays." +other hsa-mir-16 Pregnancy Complications [unspecific] 25965838 "For samples measured preconception, ROC curve analysis demonstrated AUC 0.81 for adverse pregnancy outcome. Maternal PBMC microRNA can identify high-risk patients likely to benefit from immunotherapy with improved sensitivity and specificity compared with standard immune assays." +other hsa-mir-122 "Carcinoma, Hepatocellular" 25965999 "G¦Á12 overexpressed in hepatocellular carcinoma reduces microRNA-122 expression via HNF4¦Á inactivation, which causes c-Met induction." +other hsa-mir-200c "Carcinoma, Breast" 25967125 "our data suggests that expression of miR-200c-141 and ?Np63 in D492M can reverse EMT resulting in luminal- and myoepithelial differentiation, respectively,demonstrating the importance of these molecules in epithelial integrity in the human breast." +other hsa-mir-145 Prostate Neoplasms 25969144 miR-145 suppress the androgen receptor in prostate cancer cells and correlates to prostate cancer prognosis. +other hsa-mir-21 "Carcinoma, Hepatocellular" 25969534 Dehydroepiandrosterone Activation of G-protein-coupled Estrogen Receptor Rapidly Stimulates MicroRNA-21 Transcription in Human Hepatocellular Carcinoma Cells. +other hsa-mir-34a Oral Neoplasms 25973020 MiR-34a inhibits oral cancer progression partially by repression of interleukin-6-receptor. +other hsa-mir-101 Pheochromocytoma 25973039 Role of miR-101 in pheochromocytoma patients with SDHD mutation. +other hsa-mir-365 "Carcinoma, Hepatocellular" 25973057 Prognostic significance and anti-proliferation effect of microRNA-365 in hepatocellular carcinoma. +other hsa-mir-27a "Carcinoma, Renal Cell" 25973137 miR-27a promotes cell proliferation and metastasis in renal cell carcinoma. +other hsa-mir-122 Hepatitis [unspecific] 25973575 "These results demonstrate that first, exosomes mediate communication between hepatocytes and monocytes/macrophages and second, hepatocyte-derived miRNA-122 can reprogram monocytes inducing sensitization to LPS." +other hsa-mir-141 "Carcinoma, Renal Cell" 25974855 "We also constructed a five-miRNAs-based classifier as a reliable prognostic and predictive tool for CSS in patients with RCC, especially in clear cell RCC (ccRCC) (HR: 5.46, 95% CI: 1.51-19.66). This method might facilitate patient counselling and individualise management of RCC." +other hsa-mir-200c "Carcinoma, Renal Cell" 25974855 "We also constructed a five-miRNAs-based classifier as a reliable prognostic and predictive tool for CSS in patients with RCC, especially in clear cell RCC (ccRCC) (HR: 5.46, 95% CI: 1.51-19.66). This method might facilitate patient counselling and individualise management of RCC." +other hsa-mir-21 "Carcinoma, Renal Cell" 25974855 "We also constructed a five-miRNAs-based classifier as a reliable prognostic and predictive tool for CSS in patients with RCC, especially in clear cell RCC (ccRCC) (HR: 5.46, 95% CI: 1.51-19.66). This method might facilitate patient counselling and individualise management of RCC." +other hsa-mir-210 "Carcinoma, Renal Cell" 25974855 "We also constructed a five-miRNAs-based classifier as a reliable prognostic and predictive tool for CSS in patients with RCC, especially in clear cell RCC (ccRCC) (HR: 5.46, 95% CI: 1.51-19.66). This method might facilitate patient counselling and individualise management of RCC." +other hsa-mir-429 "Carcinoma, Renal Cell" 25974855 "We also constructed a five-miRNAs-based classifier as a reliable prognostic and predictive tool for CSS in patients with RCC, especially in clear cell RCC (ccRCC) (HR: 5.46, 95% CI: 1.51-19.66). This method might facilitate patient counselling and individualise management of RCC." +other hsa-mir-214 Bladder Neoplasms 25975233 "Urinary cell-free miR-214 is a hopeful biomarker for tumor stratification, early diagnosis and prognostic assessment of bladder cancer." +other hsa-mir-21 Cardiovascular Diseases [unspecific] 25975660 miR-21 and cardiac fibrosis: another brick in the wall +other hsa-mir-125a Myelodysplastic Syndromes 25976472 "In fact, regulatory factors have also been considered as miR-143/miR-145, miR-146a, miR-125a and MiR-21." +other hsa-mir-1307 Colorectal Carcinoma 25977444 The polymorphic terminal-loop of pre-miR-1307 binding with MBNL1 contributes to colorectal carcinogenesis via interference with Dicer1 recruitment. +other hsa-mir-17 Inflammation 25979460 Our finding that certain miRNAs may de-repress critical acute phase proteins within acute timeframes has important biological and clinical implications. +other hsa-mir-18 Inflammation 25979460 Our finding that certain miRNAs may de-repress critical acute phase proteins within acute timeframes has important biological and clinical implications. +other hsa-mir-19a Inflammation 25979460 Our finding that certain miRNAs may de-repress critical acute phase proteins within acute timeframes has important biological and clinical implications. +other hsa-mir-19b Inflammation 25979460 Our finding that certain miRNAs may de-repress critical acute phase proteins within acute timeframes has important biological and clinical implications. +other hsa-mir-19b-1 Inflammation 25979460 Our finding that certain miRNAs may de-repress critical acute phase proteins within acute timeframes has important biological and clinical implications. +other hsa-mir-20a Inflammation 25979460 Our finding that certain miRNAs may de-repress critical acute phase proteins within acute timeframes has important biological and clinical implications. +other hsa-mir-449c Inflammation 25979460 Our finding that certain miRNAs may de-repress critical acute phase proteins within acute timeframes has important biological and clinical implications. +other hsa-mir-455 Inflammation 25979460 Our finding that certain miRNAs may de-repress critical acute phase proteins within acute timeframes has important biological and clinical implications. +other hsa-mir-92-1 Inflammation 25979460 Our finding that certain miRNAs may de-repress critical acute phase proteins within acute timeframes has important biological and clinical implications. +other hsa-mir-21 Neoplasms [unspecific] 25979949 Dicer1 imparts essential survival cues in Notch-driven T-ALL via miR-21-mediated tumor suppressor Pdcd4 repression. +other hsa-mir-373 Prostate Neoplasms 25980442 TR4 nuclear receptor increases prostate cancer invasion via decreasing the miR-373-3p expression to alter TGF¦ÂR2/p-Smad3 signals. +other hsa-mir-659 Neuroblastoma 25980492 Deregulation of focal adhesion pathway mediated by miR-659-3p is implicated in bone marrow infiltration of stage M neuroblastoma patients. +other hsa-mir-140 Colorectal Carcinoma 25980495 Inhibition of colorectal cancer stem cell survival and invasive potential by hsa-miR-140-5p mediated suppression of Smad2 and autophagy. +other hsa-mir-21 Atherosclerosis 25981603 miR-21 is involved in ischemic stroke pathology through atherosclerosis and provides neuroprotection by its anti-apoptotic features. +other hsa-mir-210 Atherosclerosis 25981603 miR-497 induces neuronal death and miR-210 is upregulated in hypoxic cells. +other hsa-mir-34b Hypoxia 25982511 "Sevoflurane preconditioning-inhibited apoptosis and preconditioning-enhanced cell viability of PC12 cells were significantly attenuated by transfection of miR-101a mimetic or miR-34b inhibitors, but were significantly enhanced by transfection of miR-34b mimetic." +other hsa-mir-183 Lung Neoplasms 25983004 MiR-183 promotes growth of non-small cell lung cancer cells through FoxO1 inhibition. +other hsa-mir-132 Glioma 25983322 TGF-¦Â induced miR-132 enhances the activation of TGF-¦Â signaling through inhibiting SMAD7 expression in glioma cells. +other hsa-mir-215 Neoplasms [unspecific] 25984907 "This potential path highlights the crucial role of BMP2,hsa-miR-24, AP2 and MYC as the up-stream regulators of the path and hsa-miR-215 and TYMS as potential indicator of chemotherapeutic benefit in STS metastasis." +other hsa-mir-24 Neoplasms [unspecific] 25984907 "This potential path highlights the crucial role of BMP2,hsa-miR-24, AP2 and MYC as the up-stream regulators of the path and hsa-miR-215 and TYMS as potential indicator of chemotherapeutic benefit in STS metastasis." +other hsa-mir-126 "Diabetes Mellitus, Type 2" 25986735 Circulating miR-126 is a potential biomarker to predict the onset of type 2 diabetes mellitus in susceptible individuals. +other hsa-mir-10b "Carcinoma, Lung, Non-Small-Cell" 25988292 microRNA miR-10b inhibition reduces cell proliferation and promotes apoptosis in non-small cell lung cancer (NSCLC) cells. +other hsa-mir-302 Glioblastoma 25991553 Expression of the miR-302/367 cluster in glioblastoma cells suppresses tumorigenic gene expression patterns and abolishes transformation related phenotypes. +other hsa-mir-367 Glioblastoma 25991553 Expression of the miR-302/367 cluster in glioblastoma cells suppresses tumorigenic gene expression patterns and abolishes transformation related phenotypes. +other hsa-mir-138 Lung Neoplasms 25994569 FOXP4 modulates tumor growth and independently associates with miR-138 in non-small cell lung cancer cells. +other hsa-mir-223 Inflammation 25997943 "we found that different doses of acute aerobic exercise induced a distinct and specific c-inflammamiR response, which may be associated with control of the exercise-induced inflammatory cascade. Our findings point to c-inflammamiRs as potential biomarkers of exercise-induced inflammation, and hence, exercise dose." +other hsa-mir-29a Inflammation 25997943 "we found that different doses of acute aerobic exercise induced a distinct and specific c-inflammamiR response, which may be associated with control of the exercise-induced inflammatory cascade. Our findings point to c-inflammamiRs as potential biomarkers of exercise-induced inflammation, and hence, exercise dose." +other hsa-mir-34a Inflammation 25997943 "we found that different doses of acute aerobic exercise induced a distinct and specific c-inflammamiR response, which may be associated with control of the exercise-induced inflammatory cascade. Our findings point to c-inflammamiRs as potential biomarkers of exercise-induced inflammation, and hence, exercise dose." +other hsa-mir-424 Inflammation 25997943 "we found that different doses of acute aerobic exercise induced a distinct and specific c-inflammamiR response, which may be associated with control of the exercise-induced inflammatory cascade. Our findings point to c-inflammamiRs as potential biomarkers of exercise-induced inflammation, and hence, exercise dose." +other hsa-mir-193b "Carcinoma, Hepatocellular" 25997995 miR-193b acts as a cisplatin sensitizer via the caspase-3-dependent pathway in HCC chemotherapy. +other hsa-mir-126 Neoplasms [unspecific] 25999416 "This pioneering work was followed by studies that reported intercellular exchange of miRs-143/145 and miR-21* within the vascular wall and the myocardium, respectively." +other hsa-mir-143 Neoplasms [unspecific] 25999416 "This pioneering work was followed by studies that reported intercellular exchange of miRs-143/145 and miR-21* within the vascular wall and the myocardium, respectively." +other hsa-mir-145 Neoplasms [unspecific] 25999416 "This pioneering work was followed by studies that reported intercellular exchange of miRs-143/145 and miR-21* within the vascular wall and the myocardium, respectively." +other hsa-mir-206 "Muscular Dystrophy, Duchenne" 25999854 "In contrast, local expression of mIGF-1 promotes the modulation of other microRNAs, such as miR-206 and miR-24, along with the modulation of muscle specific genes" +other hsa-mir-29a Influenza 26000345 "With assay optimization, the detection limit of our MARS assay for miR-29a-3p was found to be 1 nM, and this new assay could be completed within 1 hour without thermal cycling. This non-PCR assay with high selectivity for mature microRNA provides a new platform for rapid disease diagnosis, quarantine and disease control." +other hsa-mir-205 "Carcinoma, Lung, Non-Small-Cell" 26001154 the MiR-205 can also increase in the case with severe inflammation and benign tumor.3 The possibility of false-positive because of noncancerous lesion has to be further studied. +other hsa-mir-205 Lung Neoplasms 26001155 Reply to MiR-205 and miR-375 microRNA Assays to Distinguish Squamous Cell Carcinoma From Adenocarcinoma in Lung Cancer Biopsies. +other hsa-mir-375 Lung Neoplasms 26001155 Reply to MiR-205 and miR-375 microRNA Assays to Distinguish Squamous Cell Carcinoma From Adenocarcinoma in Lung Cancer Biopsies. +other hsa-mir-126 Atherosclerosis 26001902 "Conversely, CXCL12 expression can be induced by miR-126 in ECs through an auto-amplifying feedback loop to facilitate endothelial regeneration, thus limiting atherosclerosis and mediating plaque stabilization." +other hsa-mir-129 Inflammatory Bowel Diseases 26003847 "TLR9 aptamers may hence potentiate miRNA regulation that enhances cholinergic signaling and the resolution of inflammation, which opens new venues for manipulating bowel diseases." +other hsa-mir-186 Inflammatory Bowel Diseases 26003847 "TLR9 aptamers may hence potentiate miRNA regulation that enhances cholinergic signaling and the resolution of inflammation, which opens new venues for manipulating bowel diseases." +other hsa-mir-200c Inflammatory Bowel Diseases 26003847 "TLR9 aptamers may hence potentiate miRNA regulation that enhances cholinergic signaling and the resolution of inflammation, which opens new venues for manipulating bowel diseases." +other hsa-mir-338 "Squamous Cell Carcinoma, Esophageal" 26004521 MicroRNA-338-3p suppresses tumor growth of esophageal squamous cell carcinoma in vitro and in vivo. +other hsa-mir-101 Neoplasms [unspecific] 26005707 "eight miRNAs including miR-17-5p, miR-20a, miR-223, miR-21, miR-155, miR-494, miR-690 and miR-101 are of particular interest regarding MDSC accumulation and function." +other hsa-mir-137 Schizophrenia 26005852 The schizophrenia risk gene product miR-137 alters presynaptic plasticity. +other hsa-mir-21 "Carcinoma, Thyroid, Papillary" 26007293 MiR-9 and miR-21 as prognostic biomarkers for recurrence in papillary thyroid cancer. +other hsa-mir-9 "Carcinoma, Thyroid, Papillary" 26007293 MiR-9 and miR-21 as prognostic biomarkers for recurrence in papillary thyroid cancer. +other hsa-mir-21 "Carcinoma, Breast" 26008976 Our data revealed tissue specific changes of extracellular circulating miRNAs that would be otherwise unraveled using blood samples. +other hsa-mir-145 Gastric Neoplasms 26010149 Reverse Correlation between MicroRNA-145 and FSCN1 Affecting Gastric Cancer Migration and Invasion. +other hsa-mir-21 Cervicitis 26010154 Up-Regulation of miR-21 Is Associated with Cervicitis and Human Papillomavirus Infection in Cervical Tissues. +other hsa-mir-15 "Leukemia, Lymphocytic, Chronic, B-Cell" 26010203 "A rare but recurrent t(8;13)(q24;q14) translocation in B-cell chronic lymphocytic leukaemia causing MYC up-regulation and concomitant loss of PVT1, miR-15/16 and DLEU7." +other hsa-mir-16 "Leukemia, Lymphocytic, Chronic, B-Cell" 26010203 "A rare but recurrent t(8;13)(q24;q14) translocation in B-cell chronic lymphocytic leukaemia causing MYC up-regulation and concomitant loss of PVT1, miR-15/16 and DLEU7." +other hsa-mir-200b Lung Neoplasms 26012256 Nobiletin inhibited hypoxia-induced epithelial-mesenchymal transition of lung cancer cells by inactivating of Notch-1 signaling and switching on miR-200b. +other hsa-mir-20a "Carcinoma, Colon" 26012475 The Effects of miR-20a on p21: Two Mechanisms Blocking Growth Arrest in TGF-¦Â-Responsive Colon Carcinoma. +other hsa-mir-467 Breast Neoplasms 26018675 Inhibition of hyperglycemia-induced angiogenesis and breast cancer tumor growth by systemic injection of microRNA-467 antagonist. +other hsa-mir-1 "Carcinoma, Hepatocellular" 26019452 "MiR-1 might be a potential tumor activator. Inhibiting its expression could decrease proliferation, induce apoptosis, and inhibit the migration and invasion of TECs of human HCC." +other hsa-mir-24 Hyperglycemia 26022048 "In this issue of Blood, Xiang et al identify a novel mechanism, involving activation of the polyol pathway and repression of microRNA-24 (miR-24), through which hyperglycemia augments von Willebrand factor (VWF) expression and secretion." +other hsa-mir-15b "Carcinoma, Hepatocellular" 26023735 "miR-15b-5p induces endoplasmic reticulum stress and apoptosis in human hepatocellular carcinoma, both in vitro and in vivo, by suppressing Rab1A." +other hsa-mir-218 "Carcinoma, Hepatocellular" 26024833 "Hotair silence activates P16(Ink4a) and P14(ARF) signaling by enhancing miR-218 expression and suppressing Bmi-1 expression, resulting in the suppression of tumorigenesis in HCC." +other hsa-mir-1202 Mandibular Prognathism 26025627 "Our results indicated a possible association between the differentially expressed miRNAs and MP pathogenesis, and the precise mechanisms are needed to be further validated." +other hsa-mir-629 Mandibular Prognathism 26025627 "Our results indicated a possible association between the differentially expressed miRNAs and MP pathogenesis, and the precise mechanisms are needed to be further validated." +other hsa-mir-638 Mandibular Prognathism 26025627 "Our results indicated a possible association between the differentially expressed miRNAs and MP pathogenesis, and the precise mechanisms are needed to be further validated." +other hsa-mir-143 Colon Neoplasms 26025964 The data also showed that the restoration of hsa-miR-143 expression in SW480 leads to a significant translation repression of the introduced reporter and suicide genes. +other hsa-mir-21 Breast Neoplasms 26026077 miR-21 is a potential biomarker for breast cancer prognosis. +other hsa-mir-27 "Carcinoma, Esophageal" 26026166 miR-27 is associated with chemoresistance in esophageal cancer through transformation of normal fibroblasts to cancer-associated fibroblasts. +other hsa-mir-138 Nervous System Diseases [unspecific] 26026282 "Many studies have emerged which link miRNAs with OL and myelin pathology in various central nervous system (CNS) diseases including multiple sclerosis (MS), ischemic stroke,spinal cord injury, and adult-onset autosomal dominant leukodystrophy (ADLD)." +other hsa-mir-219 Nervous System Diseases [unspecific] 26026282 "Many studies have emerged which link miRNAs with OL and myelin pathology in various central nervous system (CNS) diseases including multiple sclerosis (MS), ischemic stroke,spinal cord injury, and adult-onset autosomal dominant leukodystrophy (ADLD)." +other hsa-mir-338 Nervous System Diseases [unspecific] 26026282 "Many studies have emerged which link miRNAs with OL and myelin pathology in various central nervous system (CNS) diseases including multiple sclerosis (MS), ischemic stroke,spinal cord injury, and adult-onset autosomal dominant leukodystrophy (ADLD)." +other hsa-mir-9 Nervous System Diseases [unspecific] 26026282 "Many studies have emerged which link miRNAs with OL and myelin pathology in various central nervous system (CNS) diseases including multiple sclerosis (MS), ischemic stroke,spinal cord injury, and adult-onset autosomal dominant leukodystrophy (ADLD)." +other hsa-let-7a Lung Neoplasms 26026830 "According to our literature survey and database validation, many of these results are biologically meaningful for understanding the mechanism of the complex post-transcriptional regulations in lung cancer." +other hsa-let-7b Lung Neoplasms 26026830 "According to our literature survey and database validation, many of these results are biologically meaningful for understanding the mechanism of the complex post-transcriptional regulations in lung cancer." +other hsa-let-7c Lung Neoplasms 26026830 "According to our literature survey and database validation, many of these results are biologically meaningful for understanding the mechanism of the complex post-transcriptional regulations in lung cancer." +other hsa-let-7f Lung Neoplasms 26026830 "According to our literature survey and database validation, many of these results are biologically meaningful for understanding the mechanism of the complex post-transcriptional regulations in lung cancer." +other hsa-mir-17 Feingold Syndrome 26026879 "respectively, of miR-17-92?/+ in comparison with WT mice, thus suggesting a possible link between cognitive deficits and altered brain neurotransmission" +other hsa-mir-18 Feingold Syndrome 26026879 "respectively, of miR-17-92?/+ in comparison with WT mice, thus suggesting a possible link between cognitive deficits and altered brain neurotransmission" +other hsa-mir-19a Feingold Syndrome 26026879 "respectively, of miR-17-92?/+ in comparison with WT mice, thus suggesting a possible link between cognitive deficits and altered brain neurotransmission" +other hsa-mir-19b-1 Feingold Syndrome 26026879 "respectively, of miR-17-92?/+ in comparison with WT mice, thus suggesting a possible link between cognitive deficits and altered brain neurotransmission" +other hsa-mir-20a Feingold Syndrome 26026879 "respectively, of miR-17-92?/+ in comparison with WT mice, thus suggesting a possible link between cognitive deficits and altered brain neurotransmission" +other hsa-mir-92-1 Feingold Syndrome 26026879 "respectively, of miR-17-92?/+ in comparison with WT mice, thus suggesting a possible link between cognitive deficits and altered brain neurotransmission" +other hsa-mir-21 Lung Neoplasms 26026961 Nickel may contribute to EGFR mutation and synergistically promotes tumor invasion in EGFR-mutated lung cancer via nickel-induced microRNA-21 expression. +other hsa-mir-125b Narcolepsy 26028057 "we would suggest the possible overexpression of these miRNAs subtypes in N1 patients close to disease onset. Yet, larger investigations are needed in the future to better determine if there is a causal association among inflammation, miRNAs, and narcolepsy." +other hsa-mir-130a Narcolepsy 26028057 "we would suggest the possible overexpression of these miRNAs subtypes in N1 patients close to disease onset. Yet, larger investigations are needed in the future to better determine if there is a causal association among inflammation, miRNAs, and narcolepsy." +other hsa-mir-155 Narcolepsy 26028057 "we would suggest the possible overexpression of these miRNAs subtypes in N1 patients close to disease onset. Yet, larger investigations are needed in the future to better determine if there is a causal association among inflammation, miRNAs, and narcolepsy." +other hsa-mir-26a Narcolepsy 26028057 "we would suggest the possible overexpression of these miRNAs subtypes in N1 patients close to disease onset. Yet, larger investigations are needed in the future to better determine if there is a causal association among inflammation, miRNAs, and narcolepsy." +other hsa-mir-30c Narcolepsy 26028057 "we would suggest the possible overexpression of these miRNAs subtypes in N1 patients close to disease onset. Yet, larger investigations are needed in the future to better determine if there is a causal association among inflammation, miRNAs, and narcolepsy." +other hsa-mir-663 "Adenocarcinoma, Pancreatic Ductal" 26028359 MicroRNA-663 activates the canonical Wnt signaling through the adenomatous polyposis coli suppression. +other hsa-mir-21 "Squamous Cell Carcinoma, Skin or Unspecific" 26029210 "Conversely, small HA-CD44 interaction stimulates RhoA activation, NFκB/Stat-3 signaling, and miR-21 production, resulting in inflammation and proliferation as well as SCC progression." +other hsa-mir-302 Nervous System Diseases [unspecific] 26030913 These results show that neuroblasts can be generated directly from adult human and mouse astrocytes by miR-302/367-driven induction. This approach seems promising for converting glial scar cells into neuroblasts in a wide range of neurological diseases. +other hsa-mir-367 Nervous System Diseases [unspecific] 26030913 These results show that neuroblasts can be generated directly from adult human and mouse astrocytes by miR-302/367-driven induction. This approach seems promising for converting glial scar cells into neuroblasts in a wide range of neurological diseases. +other hsa-mir-16 Neoplasms [unspecific] 26031775 Our findings provide the first clues regarding the role of miR-16 as a tumor suppressor in cancer cells through the inhibition of FEAT translation. +other hsa-mir-208 Prostate Neoplasms 26032092 Curcumin inhibits growth of prostate carcinoma via miR-208-mediated CDKN1A activation. +other hsa-mir-20a Multiple Myeloma 26032093 Expressions of miR-181a and miR-20a in RPMI8226 cell line and their potential as biomarkers for multiple myeloma. +other hsa-mir-200 "Diabetes Mellitus, Type 2" 26032109 Preventing ¦Â-cell apoptosis and T2DM with microRNAs--a role for miR-200 +other hsa-mir-320e Colorectal Carcinoma 26035698 "In two clinical trial cohorts, a systematic biomarker discovery and validation approach identified miR-320e to be a novel prognostic biomarker that is associated with adverse clinical outcome in stage III CRC patients treated with 5-FU-based adjuvant chemotherapy. These findings have important implications for the personalised management of CRC patients." +other hsa-mir-185 Pituitary Adenoma 26036598 MiR-185 enhanced the cell proliferation and inhibited the apoptosis of GH3 cells. +other hsa-mir-1 "Carcinoma, Renal Cell, Clear-Cell" 26036633 MiR-1 downregulation correlates with poor survival in clear cell renal cell carcinoma where it interferes with cell cycle regulation and metastasis. +other hsa-mir-323b Hepatitis B Virus Infection 26037063 The association between microRNA-323b polymorphism and hepatitis B virus persistent infection - some problems should be addressed. +other hsa-mir-323b Hepatitis B Virus Infection 26037064 The association between microRNA-323b polymorphism and hepatitis B virus persistent infection - some problems should be addressed. +other hsa-mir-17 "Leukemia, Myeloid, Acute" 26038136 "CDK inhibitor SNS-032 can induce apoptosis of AML HL-60 cells, which is associated with the inhibition of MCL-1,C-MYC and JAK2/STAT3, and down-regulation of miR-17-92 family." +other hsa-mir-103 Myocardial Infarction 26038570 "Our results reveal a novel myocardial necrosis regulation model,which is composed of H19, miR-103/107, and FADD. Modulation of their levels may provide a new approach for preventing myocardial necrosis." +other hsa-mir-107 Myocardial Infarction 26038570 "Our results reveal a novel myocardial necrosis regulation model,which is composed of H19, miR-103/107, and FADD. Modulation of their levels may provide a new approach for preventing myocardial necrosis." +other hsa-mir-494 Lung Neoplasms 26040900 Tumor-derived microRNA-494 promotes angiogenesis in non-small cell lung cancer. +other hsa-mir-29c Renal Fibrosis 26040904 "Overall, miR-29c correlated with the degree of renal chronicity but not with renal function, suggesting it could be used as a novel non-invasive marker of early progression to fibrosis in patients with LN." +other hsa-mir-17 Leukemia 26041742 Microenvironmental interleukin-6 suppresses toll-like receptor signaling in human leukemia cells through miR-17/19A. +other hsa-mir-19a Leukemia 26041742 Microenvironmental interleukin-6 suppresses toll-like receptor signaling in human leukemia cells through miR-17/19A. +other hsa-mir-124 Nervous System Diseases [unspecific] 26041995 "the link between dysregulation of miR-124 and CNS disorders, such as neurodegeneration, CNS stress, neuroimmune disorders, stroke, and brain tumors, has become evident" +other hsa-mir-130a "Carcinoma, Ovarian" 26043084 MiR-130a and MiR-374a Function as Novel Regulators of Cisplatin Resistance in Human Ovarian Cancer A2780 Cells. +other hsa-mir-374a "Carcinoma, Ovarian" 26043084 MiR-130a and MiR-374a Function as Novel Regulators of Cisplatin Resistance in Human Ovarian Cancer A2780 Cells. +other hsa-mir-449b "Carcinoma, Thyroid" 26044563 Regulation of MET-mediated proliferation of thyroid carcinoma cells by miR-449b. +other hsa-mir-191 Acute Myocardial Infarction 26044724 "miR-208b was significantly increased in the AMI compared with healthy people, while miR-26a and miR-191 were decreased. miR-26a, miR-191, and miR-208b were potential indices of AMI, and miR-208b was more effective in patients with non-ST-elevation myocardial infarction." +other hsa-mir-208b Acute Myocardial Infarction 26044724 "miR-208b was significantly increased in the AMI compared with healthy people, while miR-26a and miR-191 were decreased. miR-26a, miR-191, and miR-208b were potential indices of AMI, and miR-208b was more effective in patients with non-ST-elevation myocardial infarction." +other hsa-mir-26a Acute Myocardial Infarction 26044724 "miR-208b was significantly increased in the AMI compared with healthy people, while miR-26a and miR-191 were decreased. miR-26a, miR-191, and miR-208b were potential indices of AMI, and miR-208b was more effective in patients with non-ST-elevation myocardial infarction." +other hsa-mir-24 Gastric Neoplasms 26045155 These results suggest that the measurement of miR-24 expression from formalin-fixed paraffin-embedded (FFPE) samples is useful to identify radiation-associated GC. +other hsa-mir-374b Colorectal Carcinoma 26045793 The potential value of miR-1 and miR-374b as biomarkers for colorectal cancer. +other hsa-mir-27a "Carcinoma, Renal Cell, Clear-Cell" 26046464 Expression of miR-27a-3p is an independent predictive factor for recurrence in clear cell renal cell carcinoma. +other hsa-mir-106b Breast Neoplasms 26046581 These observations have been validated using an independent publicly available breast cancer dataset from The Cancer Genome Atlas. +other hsa-mir-148a Breast Neoplasms 26046581 These observations have been validated using an independent publicly available breast cancer dataset from The Cancer Genome Atlas. +other hsa-mir-15 Breast Neoplasms 26046581 These observations have been validated using an independent publicly available breast cancer dataset from The Cancer Genome Atlas. +other hsa-mir-16 Breast Neoplasms 26046581 These observations have been validated using an independent publicly available breast cancer dataset from The Cancer Genome Atlas. +other hsa-mir-17 Breast Neoplasms 26046581 These observations have been validated using an independent publicly available breast cancer dataset from The Cancer Genome Atlas. +other hsa-mir-18 Breast Neoplasms 26046581 These observations have been validated using an independent publicly available breast cancer dataset from The Cancer Genome Atlas. +other hsa-mir-19a Breast Neoplasms 26046581 These observations have been validated using an independent publicly available breast cancer dataset from The Cancer Genome Atlas. +other hsa-mir-19b-1 Breast Neoplasms 26046581 These observations have been validated using an independent publicly available breast cancer dataset from The Cancer Genome Atlas. +other hsa-mir-20a Breast Neoplasms 26046581 These observations have been validated using an independent publicly available breast cancer dataset from The Cancer Genome Atlas. +other hsa-mir-29a Breast Neoplasms 26046581 These observations have been validated using an independent publicly available breast cancer dataset from The Cancer Genome Atlas. +other hsa-mir-29c Breast Neoplasms 26046581 These observations have been validated using an independent publicly available breast cancer dataset from The Cancer Genome Atlas. +other hsa-mir-92-1 Breast Neoplasms 26046581 These observations have been validated using an independent publicly available breast cancer dataset from The Cancer Genome Atlas. +other hsa-mir-21 Heart Failure 26047574 "Torasemide but not furosemide inhibits CYP11B2 activity and reduces the expression of CTGF, LOX, and miR-21." +other hsa-mir-1264 Atherosclerosis 26047583 This could be a causative epigenetic mechanism associated with TNF-¦Á and IGF-1 induced smooth muscle cell proliferation involved in the pathogenesis of coronary artery hyperplasia and restenosis. +other hsa-mir-126 Parkinson Disease 26047984 "Our study provides evidence for a general association of miRNAs with the cellular function and identity of SN DA neurons, and with deregulated gene expression networks and signaling pathways related to PD pathogenesis that may be sex-specific." +other hsa-mir-21 "Carcinoma, Cervical" 26051842 "Overall, our study suggests that the microRNAs, miR-21 and let-7a function as clinically relevant integral components of STAT3 signaling and are responsible for maintaining activated state of STAT3 in HPV-infected cells during cervical carcinogenesis." +other hsa-mir-196a Neuroendocrine Tumors 26052033 Roles of miR-196a on gene regulation of neuroendocrine tumor cells. +other hsa-mir-22 Prostate Neoplasms 26052614 miR-22 and miR-29a Are Members of the Androgen Receptor Cistrome Modulating LAMC1 and Mcl-1 in Prostate Cancer. +other hsa-mir-29a Prostate Neoplasms 26052614 miR-22 and miR-29a Are Members of the Androgen Receptor Cistrome Modulating LAMC1 and Mcl-1 in Prostate Cancer. +other hsa-mir-32 Colorectal Carcinoma 26054686 Oridonin triggers apoptosis in colorectal carcinoma cells and suppression of microRNA-32 expression augments oridonin-mediated apoptotic effects. +other hsa-mir-155 Systemic Lupus Erythematosus 26055806 "We demonstrate that SLE patients have reduced IL-21 signaling capacity, decreased miR-155 levels, and increased SOCS1 levels compared to HCs.The reduced IL-21 signaling in SLE could be rescued by overexpression of miR-155,suggesting an important role for miR-155 in the reduced IL-21 signaling observed in SLE." +other hsa-mir-204 Coloboma 26056285 MiR-204 is responsible for inherited retinal dystrophy associated with ocular coloboma. +other hsa-mir-30e Breast Neoplasms 26057454 We highlighted a relevant and subtype-specific role in breast cancer for miR-30e* and demonstrated that adding miRNA markers to gene signatures and clinico-pathological features can help for a better prognostication. +other hsa-mir-21 "Carcinoma, Hepatocellular" 26060089 "Our results demonstrate that cisplatin inhibits the growth of HCC, possibly through the induction of G1 cell cycle arrest and apoptosis through the alteration of microRNA expression." +other hsa-mir-338 "Carcinoma, Hepatocellular" 26060089 "Our results demonstrate that cisplatin inhibits the growth of HCC, possibly through the induction of G1 cell cycle arrest and apoptosis through the alteration of microRNA expression." +other hsa-mir-34a "Carcinoma, Hepatocellular" 26060089 "Our results demonstrate that cisplatin inhibits the growth of HCC, possibly through the induction of G1 cell cycle arrest and apoptosis through the alteration of microRNA expression." +other hsa-mir-99a "Carcinoma, Hepatocellular" 26060089 "Our results demonstrate that cisplatin inhibits the growth of HCC, possibly through the induction of G1 cell cycle arrest and apoptosis through the alteration of microRNA expression." +other hsa-mir-130a Hepatitis C Virus Infection 26060358 Vitamin D Potentiates the Inhibitory Effect of MicroRNA-130a in Hepatitis C Virus Replication Independent of Type I Interferon Signaling Pathway. +other hsa-mir-181c Osteosarcoma 26062442 miR-181c associates with tumor relapse of high grade osteosarcoma. +other hsa-mir-217 Osteosarcoma 26062553 Quercetin Enhances Cisplatin Sensitivity of Human Osteosarcoma Cells by Modulating microRNA-217-KRAS Axis. +other hsa-mir-215 "Carcinoma, Pancreatic" 26063036 miR-215 overexpression distinguishes ampullary carcinomas from pancreatic carcinomas. +other hsa-mir-513c Glioblastoma 26063413 microRNA-513c suppresses the proliferation of human glioblastoma cells by repressing low-density lipoprotein receptor-related protein 6. +other hsa-mir-146b Oral Lichen Planus 26064947 The TF-miRNA Coregulation Network in Oral Lichen Planus. +other hsa-mir-190 Oral Lichen Planus 26064947 The TF-miRNA Coregulation Network in Oral Lichen Planus. +other hsa-mir-26b Oral Lichen Planus 26064947 The TF-miRNA Coregulation Network in Oral Lichen Planus. +other hsa-mir-29a Oral Lichen Planus 26064947 The TF-miRNA Coregulation Network in Oral Lichen Planus. +other hsa-mir-595 Oral Lichen Planus 26064947 The TF-miRNA Coregulation Network in Oral Lichen Planus. +other hsa-mir-628 Oral Lichen Planus 26064947 The TF-miRNA Coregulation Network in Oral Lichen Planus. +other hsa-mir-205 Oral Leukoplakia 26064958 Identification of Gene and MicroRNA Signatures for Oral Cancer Developed from Oral Leukoplakia. +other hsa-mir-21 Oral Leukoplakia 26064958 Identification of Gene and MicroRNA Signatures for Oral Cancer Developed from Oral Leukoplakia. +other hsa-mir-323 Oral Leukoplakia 26064958 Identification of Gene and MicroRNA Signatures for Oral Cancer Developed from Oral Leukoplakia. +other hsa-mir-423 Oral Leukoplakia 26064958 Identification of Gene and MicroRNA Signatures for Oral Cancer Developed from Oral Leukoplakia. +other hsa-mir-491 Oral Leukoplakia 26064958 Identification of Gene and MicroRNA Signatures for Oral Cancer Developed from Oral Leukoplakia. +other hsa-mir-499 Oral Leukoplakia 26064958 Identification of Gene and MicroRNA Signatures for Oral Cancer Developed from Oral Leukoplakia. +other hsa-mir-525 Oral Leukoplakia 26064958 Identification of Gene and MicroRNA Signatures for Oral Cancer Developed from Oral Leukoplakia. +other hsa-mir-549 Oral Leukoplakia 26064958 Identification of Gene and MicroRNA Signatures for Oral Cancer Developed from Oral Leukoplakia. +other hsa-mir-155 "Carcinoma, Renal Cell" 26064968 miR-155 and miR-484 Are Associated with Time to Progression in Metastatic Renal Cell Carcinoma Treated with Sunitinib. +other hsa-mir-484 "Carcinoma, Renal Cell" 26064968 miR-155 and miR-484 Are Associated with Time to Progression in Metastatic Renal Cell Carcinoma Treated with Sunitinib. +other hsa-mir-1 Myocardial Infarction 26065643 spironolactone could increase miRNA-1 expression in ischemic rat myocardium after MI +other hsa-mir-199a Colorectal Carcinoma 26065676 "It was found that miR-199a would reduce the proliferation, migration and invasion. However, overexpression of miR-199a on the apoptosis rate and cell cycles showed no significant results. The potential functionary mechanism of miR-199a might through HIF-1¦Á/VEGF pathway." +other hsa-mir-27b Breast Neoplasms 26065921 Loss of microRNA-27b contributes to breast cancer stem cell generation by activating ENPP1. +other hsa-mir-7 Viral Infectious Disease 26067353 "Results of this study identify a molecular mechanism of RNAi for antiviral defense, and extend our knowledge of the complex interplay between host and PV, which will provide a basis for the development of effective RNAi-based therapies designed to inhibit PV replication and protect host cells." +other hsa-mir-101 Prostate Neoplasms 26067553 RLIP76-dependent suppression of PI3K/AKT/Bcl-2 pathway by miR-101 induces apoptosis in prostate cancer. +other hsa-mir-200 Breast Neoplasms 26068592 "The upregulation of fibronectin and lysyl oxidase directly by miR-200 or indirectly through Fli-1 or TCF12 contributed to ECM remodeling, triggering the invasion and metastasis of breast cancer cells both in vitro and vivo" +other hsa-mir-205 "Adenocarcinoma, Lung" 26068980 "Surprisingly, expression of classifier miR-205 was intermediate between that of classical adenocarcinoma and squamous cell carcinoma suggesting that adenosquamous carcinoma is a transitional stage between these tumor types." +other hsa-mir-200 Neoplasms [unspecific] 26069247 Network-Based Approaches to Understand the Roles of miR-200 and Other microRNAs in Cancer. +other hsa-mir-184 Breast Neoplasms 26070602 These studies elucidate a new layer of regulation in the PI3K/AKT/mTOR pathway with relevance to mammary development and tumour progression and identify miR-184 as a putative breast tumour suppressor. +other hsa-mir-433 Parkinson Disease 26070653 Variation in the miRNA-433 binding site of FGF20 is a risk factor for Parkinson's disease in Iranian population. +other hsa-mir-101 Colorectal Carcinoma 26071354 MicroRNA-101 down-regulates sphingosine kinase 1 in colorectal cancer cells. +other hsa-mir-155 Infection [unspecific] 26072128 An update on the role of miRNA-155 in pathogenic microbial infections. +other hsa-mir-145 Chromosome 5q Deletion Syndrome 26075044 Loss of the microRNA genes miR-145 and miR-146a has been associated with the thrombocytosis observed in 5q- syndrome patients. +other hsa-mir-146a Chromosome 5q Deletion Syndrome 26075044 Loss of the microRNA genes miR-145 and miR-146a has been associated with the thrombocytosis observed in 5q- syndrome patients. +other hsa-mir-206 Lung Neoplasms 26075299 Comprehensive gene and microRNA expression profiling reveals miR-206 inhibits MET in lung cancer metastasis. +other hsa-mir-150 Acute Myocardial Infarction 26077801 "Results indicated that the levels of circulating miR-486 and miR-150 are associated with AMI. They may be novel and powerful biomarkers for AMI,especially for NSTEMI." +other hsa-mir-486 Acute Myocardial Infarction 26077801 "Results indicated that the levels of circulating miR-486 and miR-150 are associated with AMI. They may be novel and powerful biomarkers for AMI,especially for NSTEMI." +other hsa-mir-191 Prostate Neoplasms 26078486 "Our results proved miR-191 to be the most stable gene, showing the lowest degree of variation and the highest stability value.miR-25 and SNORD48 values fell beyond the cutoff of acceptability. In conclusion,we recommend the use of miR-191 for normalization purposes in post-DRE urine sediments." +other hsa-mir-25 Prostate Neoplasms 26078486 "Our results proved miR-191 to be the most stable gene, showing the lowest degree of variation and the highest stability value.miR-25 and SNORD48 values fell beyond the cutoff of acceptability. In conclusion,we recommend the use of miR-191 for normalization purposes in post-DRE urine sediments." +other hsa-mir-210 Lung Disease [unspecific] 26079696 this study demonstrates the added value of an integrated miRNA-mRNA approach for identifying molecular events altered by environmental pollutants in an in vitro human model. +other hsa-let-7 Neoplasms [unspecific] 26080928 these results suggest that cytoplasmic uridylation pathway actively participates in blockade of let-7 biogenesis by Lin28B. +other hsa-mir-184 Hepatoblastoma 26081234 miRNA-184 lentivirus-mediated human lens epithelial cells (HLEC) can inhibit the occurrence of epithelial-mesenchymal transition (EMT). +other hsa-mir-222 Inflammation 26081516 "In pathological hyperglycaemic conditions, EMP-mediated miR-222-dependent anti-inflammatory effects are reduced." +other hsa-mir-449a Prostate Neoplasms 26081756 Capsaicin causes inactivation and degradation of the androgen receptor by inducing the restoration of miR-449a in prostate cancer. +other hsa-mir-337 Neuroblastoma 26084291 miRNA-337-3p suppresses neuroblastoma progression by repressing the transcription of matrix metalloproteinase 14. +other hsa-mir-223 Pulmonary Hypertension 26084306 miR-223 reverses experimental pulmonary arterial hypertension. +other hsa-mir-502 Colorectal Carcinoma 26086375 "While the approach is here validated for CRC, the implementation of disease-specific miRNA target prediction algorithms can be easily adopted for other applications too. The identification of disease-specific miRNA target interactions may also facilitate the identification of potential drug targets." +other hsa-mir-650 Colorectal Carcinoma 26086375 "While the approach is here validated for CRC, the implementation of disease-specific miRNA target prediction algorithms can be easily adopted for other applications too. The identification of disease-specific miRNA target interactions may also facilitate the identification of potential drug targets." +other hsa-mir-7 Colorectal Carcinoma 26086375 "While the approach is here validated for CRC, the implementation of disease-specific miRNA target prediction algorithms can be easily adopted for other applications too. The identification of disease-specific miRNA target interactions may also facilitate the identification of potential drug targets." +other hsa-mir-760 Colorectal Carcinoma 26086375 "While the approach is here validated for CRC, the implementation of disease-specific miRNA target prediction algorithms can be easily adopted for other applications too. The identification of disease-specific miRNA target interactions may also facilitate the identification of potential drug targets." +other hsa-mir-93 Colorectal Carcinoma 26086375 "While the approach is here validated for CRC, the implementation of disease-specific miRNA target prediction algorithms can be easily adopted for other applications too. The identification of disease-specific miRNA target interactions may also facilitate the identification of potential drug targets." +other hsa-mir-101 Inflammation 26087518 "Advances in understanding the roles of microRNA-101 in inflammation, fibrosis and cancer" +other hsa-mir-93 "Carcinoma, Ovarian" 26087719 The results suggested that berberine modulated the sensitivity of cisplatin through miR-93/PTEN/AKT signaling pathway in the ovarian cancer cells. +other hsa-mir-22 Inflammation 26088024 extracellular Adenosine and uridine triphosphate (ATP and UTP) can attenuate ICAM-1 expression and leukocyte adhesion in endothelial cells through miR-22. +other hsa-mir-200a Breast Neoplasms 26088362 miR-200a inhibits migration of triple-negative breast cancer cells through direct repression of the EPHA2 oncogene. +other hsa-mir-133a Prostate Neoplasms 26089375 "Our data suggest that AA-specific/-enriched miRNA-mRNA pairings may play a critical role in the activation of oncogenic pathways in AA prostate cancer. Our findings also suggest that miR-133a/MCL1, miR-513c/STAT1, and miR-96/FOXO3A may have clinical significance in the development of novel strategies for treating aggressive prostate cancer." +other hsa-mir-145 Prostate Neoplasms 26089375 "Our data suggest that AA-specific/-enriched miRNA-mRNA pairings may play a critical role in the activation of oncogenic pathways in AA prostate cancer. Our findings also suggest that miR-133a/MCL1, miR-513c/STAT1, and miR-96/FOXO3A may have clinical significance in the development of novel strategies for treating aggressive prostate cancer." +other hsa-mir-34a Prostate Neoplasms 26089375 "Our data suggest that AA-specific/-enriched miRNA-mRNA pairings may play a critical role in the activation of oncogenic pathways in AA prostate cancer. Our findings also suggest that miR-133a/MCL1, miR-513c/STAT1, and miR-96/FOXO3A may have clinical significance in the development of novel strategies for treating aggressive prostate cancer." +other hsa-mir-513c Prostate Neoplasms 26089375 "Our data suggest that AA-specific/-enriched miRNA-mRNA pairings may play a critical role in the activation of oncogenic pathways in AA prostate cancer. Our findings also suggest that miR-133a/MCL1, miR-513c/STAT1, and miR-96/FOXO3A may have clinical significance in the development of novel strategies for treating aggressive prostate cancer." +other hsa-mir-96 Prostate Neoplasms 26089375 "Our data suggest that AA-specific/-enriched miRNA-mRNA pairings may play a critical role in the activation of oncogenic pathways in AA prostate cancer. Our findings also suggest that miR-133a/MCL1, miR-513c/STAT1, and miR-96/FOXO3A may have clinical significance in the development of novel strategies for treating aggressive prostate cancer." +other hsa-mir-9 "Lymphoma, Hodgkin" 26089393 We report a high-resolution time series study of transcriptome dynamics following antimiR-mediated inhibition of miR-9 in a Hodgkin lymphoma cell-line-the first such dynamic study of the microRNA inhibition response-revealing both general and specific aspects of the physiological response. +other hsa-mir-221 Hepatitis C Virus Infection 26090579 IFN-¦Á-Induced Downregulation of miR-221 in Dendritic Cells: Implications for HCV Pathogenesis and Treatment. +other hsa-mir-34a Toxic Encephalopathy 26091620 We also found that inhibition of astrocytic miR-34a after Lipopolysaccharide(LPS) stimulation can postpone dopaminergic neuron loss under neurotoxin stress. +other hsa-mir-29 Pancreatic Neoplasms 26095125 Pathophysiological role of microRNA-29 in pancreatic cancer stroma. +other hsa-mir-146a Breast Neoplasms 26095299 "our study provided new insights into the function of CXCR4 in breast cancer: it promotes tumor progression as both a protein-coding gene and a non-coding RNA, complicating the mechanism by which oncogenes promote tumor progression." +other hsa-mir-137 Intellectual Disability 26095359 "Our findings suggest that miR-137 is a key factor in the control of synaptic efficacy and mGluR-dependent synaptic plasticity, supporting the notion that glutamatergic dysfunction contributes to the pathogenesis of miR-137-linked cognitive impairments." +other hsa-mir-150 Myasthenia Gravis 26095457 "The immuno-microRNAs miR-150-5p and miR-21-5p show a disease specific signature, which suggests these microRNAs as possible biological autoimmune markers of myasthenia gravis (MG)." +other hsa-mir-21 Myasthenia Gravis 26095457 "The immuno-microRNAs miR-150-5p and miR-21-5p show a disease specific signature, which suggests these microRNAs as possible biological autoimmune markers of myasthenia gravis (MG)." +other hsa-mir-122 Hepatitis C Virus Infection 26096908 Hepatitis C virus addiction to liver miR-122 takes its Toll on the host. +other hsa-mir-29b Spinal Cord Injuries 26097563 Combinatorial effects of miR-20a and miR-29b on neuronal apoptosis induced by spinal cord injury. +other hsa-mir-196a "Carcinoma, Ovarian" 26097603 "In conclusion, miR-196a may play an important role in the progression of ovarian carcinoma, and could be used as an independent prognostic biomarker for patients with ovarian carcinoma." +other hsa-mir-19 Lung Neoplasms 26098000 MicroRNA-19 triggers epithelial-mesenchymal transition of lung cancer cells accompanied by growth inhibition. +other hsa-mir-21 Neoplasms [unspecific] 26101800 The IL-6/STAT3 pathway via miR-21 is involved in the neoplastic and metastatic properties of arsenite-transformed human keratinocytes. +other hsa-mir-21 Breast Neoplasms 26106867 Successful attempts were made in applying the approach to detect miR-21 in human cell lysate samples of breast cancer patients. +other hsa-mir-26a Obesity 26107166 These results unravel a new mechanism by which bile acid receptor TGR5 activates a miRNA gene expression. +other hsa-mir-133a Breast Neoplasms 26107945 MiR-133a Is Functionally Involved in Doxorubicin-Resistance in Breast Cancer Cells MCF-7 via Its Regulation of the Expression of Uncoupling Protein 2. +other hsa-mir-7 Lung Neoplasms 26108539 miR-7 modulates chemoresistance of small cell lung cancer by repressing MRP1/ABCC1. +other hsa-mir-21 Glioma 26109525 Tamoxifen-Induced Cell Death of Malignant Glioma Cells Is Brought About by Oxidative-Stress-Mediated Alterations in the Expression of BCL2 Family Members and Is Enhanced on miR-21 Inhibition. +other hsa-mir-23a Prostate Neoplasms 26110567 "By inhibiting snail signaling and miR-23a-3p, osthole suppresses the EMT-mediated metastatic ability in prostate cancer." +other hsa-mir-218 Neoplasms [unspecific] 26111662 Opposite effects of two estrogen receptors on tau phosphorylation through disparate effects on the miR-218/PTPA pathway. +other hsa-mir-148a Osteosarcoma 26111756 Bufalin Inhibits the Differentiation and Proliferation of Cancer Stem Cells Derived from Primary Osteosarcoma Cells through Mir-148a. +other hsa-mir-22 Liver Cirrhosis 26112332 MiR-22 promotes the development of cirrhosis through BMP7 suppression. +other hsa-mir-33a "Carcinoma, Pancreatic" 26113407 miR-33a suppresses the nuclear translocation of ¦Â-catenin to enhance gemcitabine sensitivity in human pancreatic cancer cells. +other hsa-mir-146a Coronary Artery Disease 26114385 Meta-Analysis of miR-146a Polymorphisms Association with Coronary Artery Diseases and Ischemic Stroke. +other hsa-mir-21 Lymphoma 26116372 MiR-21: an environmental driver of malignant melanoma +other hsa-mir-153 Parkinson Disease 26116522 Tanshinone IIA protects dopaminergic neurons against 6-hydroxydopamine-induced neurotoxicity through miR-153/NF-E2-related factor 2/antioxidant response element signaling pathway. +other hsa-mir-21 "Leukemia, Myelogenous, Chronic, BCR-ABL Positive" 26116834 Curcumin inhibits in vitro and in vivo chronic myelogenous leukemia cells growth:a possible role for exosomal disposal of miR-21. +other hsa-mir-17 Neoplasms [unspecific] 26117336 Oncogenic miR-17/20a Forms a Positive Feed-forward Loop with the p53 Kinase DAPK3 to Promote Tumorigenesis. +other hsa-mir-20a Neoplasms [unspecific] 26117336 Oncogenic miR-17/20a Forms a Positive Feed-forward Loop with the p53 Kinase DAPK3 to Promote Tumorigenesis. +other hsa-let-7c Pancreatic Neoplasms 26121640 "Our novel findings indicate that salivary miRNA are discriminatory in pancreatic cancer patients that are not eligible for surgery. In addition, we demonstrate in experimental models that salivary miRNA detection precedes systemic detection of cancer cells markers. This study stems for the use of salivary miRNA as biomarker for the early diagnosis of patients with unresectable pancreatic cancer." +other hsa-mir-21 Pancreatic Neoplasms 26121640 "Our novel findings indicate that salivary miRNA are discriminatory in pancreatic cancer patients that are not eligible for surgery. In addition, we demonstrate in experimental models that salivary miRNA detection precedes systemic detection of cancer cells markers. This study stems for the use of salivary miRNA as biomarker for the early diagnosis of patients with unresectable pancreatic cancer." +other hsa-mir-210 Pancreatic Neoplasms 26121640 "Our novel findings indicate that salivary miRNA are discriminatory in pancreatic cancer patients that are not eligible for surgery. In addition, we demonstrate in experimental models that salivary miRNA detection precedes systemic detection of cancer cells markers. This study stems for the use of salivary miRNA as biomarker for the early diagnosis of patients with unresectable pancreatic cancer." +other hsa-mir-216 Pancreatic Neoplasms 26121640 "Our novel findings indicate that salivary miRNA are discriminatory in pancreatic cancer patients that are not eligible for surgery. In addition, we demonstrate in experimental models that salivary miRNA detection precedes systemic detection of cancer cells markers. This study stems for the use of salivary miRNA as biomarker for the early diagnosis of patients with unresectable pancreatic cancer." +other hsa-mir-23a Pancreatic Neoplasms 26121640 "Our novel findings indicate that salivary miRNA are discriminatory in pancreatic cancer patients that are not eligible for surgery. In addition, we demonstrate in experimental models that salivary miRNA detection precedes systemic detection of cancer cells markers. This study stems for the use of salivary miRNA as biomarker for the early diagnosis of patients with unresectable pancreatic cancer." +other hsa-mir-23b Pancreatic Neoplasms 26121640 "Our novel findings indicate that salivary miRNA are discriminatory in pancreatic cancer patients that are not eligible for surgery. In addition, we demonstrate in experimental models that salivary miRNA detection precedes systemic detection of cancer cells markers. This study stems for the use of salivary miRNA as biomarker for the early diagnosis of patients with unresectable pancreatic cancer." +other hsa-mir-29c Pancreatic Neoplasms 26121640 "Our novel findings indicate that salivary miRNA are discriminatory in pancreatic cancer patients that are not eligible for surgery. In addition, we demonstrate in experimental models that salivary miRNA detection precedes systemic detection of cancer cells markers. This study stems for the use of salivary miRNA as biomarker for the early diagnosis of patients with unresectable pancreatic cancer." +other hsa-mir-132 Wounds and Injuries [unspecific] 26121747 MicroRNA-132 enhances transition from inflammation to proliferation during wound healing. +other hsa-mir-21 Glioma 26121981 DEAD-box RNA helicase DDX23 modulates glioma malignancy via elevating miR-21 biogenesis. +other hsa-mir-373 Breast Neoplasms 26122224 INFLUENCE OF miR-373 ON THE INVASION AND MIGRATION OF BREAST CANCER AND THE EXPRESSION LEVEL OF TARGET GENES TXNIP. +other hsa-mir-148a Neoplasms [unspecific] 26124099 MicroRNA-148a reduces tumorigenesis and increases TRAIL-induced apoptosis in NSCLC. +other hsa-mir-193a Pleural Mesothelioma 26125439 miR-193a-3p is a potential tumor suppressor in malignant pleural mesothelioma. +other hsa-mir-21 "Carcinoma, Esophageal" 26125864 Association of miR-21 with esophageal cancer prognosis: a meta-analysis. +other hsa-mir-182 "Carcinoma, Hepatocellular" 26126858 Our data showed that hypoxia regulated the expression of miR-182 and RASA1 to promote HCC angiogenesis. +other hsa-mir-125a Breast Neoplasms 26130254 "Relative levels of let-7a, miR-17, miR-27b, miR-125a, miR-125b and miR-206 as potential molecular markers to evaluate grade, receptor status and molecular type in breast cancer." +other hsa-mir-125b Breast Neoplasms 26130254 "Relative levels of let-7a, miR-17, miR-27b, miR-125a, miR-125b and miR-206 as potential molecular markers to evaluate grade, receptor status and molecular type in breast cancer." +other hsa-mir-17 Breast Neoplasms 26130254 "Relative levels of let-7a, miR-17, miR-27b, miR-125a, miR-125b and miR-206 as potential molecular markers to evaluate grade, receptor status and molecular type in breast cancer." +other hsa-mir-206 Breast Neoplasms 26130254 "Relative levels of let-7a, miR-17, miR-27b, miR-125a, miR-125b and miR-206 as potential molecular markers to evaluate grade, receptor status and molecular type in breast cancer." +other hsa-mir-27b Breast Neoplasms 26130254 "Relative levels of let-7a, miR-17, miR-27b, miR-125a, miR-125b and miR-206 as potential molecular markers to evaluate grade, receptor status and molecular type in breast cancer." +other hsa-mir-203 "Carcinoma, Lung" 26132195 miR-203 Inhibits Frizzled-2 Expression via CD82/KAI1 Expression in Human Lung Carcinoma Cells. +other hsa-mir-100 Colorectal Carcinoma 26132860 These findings suggest that extracellular miRNAs can function in target cells and uncover a potential new mode of action for mutant KRAS in CRC. +other hsa-mir-216a Pancreatic Neoplasms 26134156 MicroRNA-216a enhances the radiosensitivity of pancreatic cancer cells by inhibiting beclin-1-mediated autophagy. +other hsa-mir-21 Lung Neoplasms 26134223 A prognostic classifier comprising three types of genomic and epigenomic data may help guide the postoperative management of stage I lung cancer patients at high risk of recurrence. +other hsa-mir-17 Coronary Artery Disease 26134369 MiR-17-5p as circulating biomarkers for the severity of coronary atherosclerosis in coronary artery disease. +other hsa-mir-222 Intervertebral Disc Degeneration 26134418 "a comprehensive microRNA-222 and microRNA-589 gene regulatory network was constructed, which was found to be important in IDD progression." +other hsa-mir-589 Intervertebral Disc Degeneration 26134418 "a comprehensive microRNA-222 and microRNA-589 gene regulatory network was constructed, which was found to be important in IDD progression." +other hsa-mir-204 Glioma 26134825 "Decreased Expression of MiRNA-204-5p Contributes to Glioma Progression and Promotes Glioma Cell Growth, Migration and Invasion." +other hsa-mir-135 Glomerulonephritis 26134897 miR-135 family members mediate podocyte injury through the activation of Wnt/¦Â-catenin signaling. +other hsa-mir-152 "Carcinoma, Nasopharyngeal" 26135619 Our findings provide new insights into the metastasis of NPC regulated by EBV and advocate for developing clinical intervention strategies against NPC. +other hsa-mir-195 "Carcinoma, Nasopharyngeal" 26135619 Our findings provide new insights into the metastasis of NPC regulated by EBV and advocate for developing clinical intervention strategies against NPC. +other hsa-mir-138 Costello Syndrome 26138095 "These results allow us to conclude that the H-Ras G12S mutation plays an important role in miRNA expression and open up a new line of study to understand the consequences of this mutation on Costello syndrome. Furthermore,they suggest that oncogenes may have a sufficiently important impact on miRNA expression to promote the development of numerous cancers." +other hsa-mir-138 Neoplasms [unspecific] 26138095 "These results allow us to conclude that the H-Ras G12S mutation plays an important role in miRNA expression and open up a new line of study to understand the consequences of this mutation on Costello syndrome. Furthermore,they suggest that oncogenes may have a sufficiently important impact on miRNA expression to promote the development of numerous cancers." +other hsa-mir-206 Costello Syndrome 26138095 "These results allow us to conclude that the H-Ras G12S mutation plays an important role in miRNA expression and open up a new line of study to understand the consequences of this mutation on Costello syndrome. Furthermore,they suggest that oncogenes may have a sufficiently important impact on miRNA expression to promote the development of numerous cancers." +other hsa-mir-206 Neoplasms [unspecific] 26138095 "These results allow us to conclude that the H-Ras G12S mutation plays an important role in miRNA expression and open up a new line of study to understand the consequences of this mutation on Costello syndrome. Furthermore,they suggest that oncogenes may have a sufficiently important impact on miRNA expression to promote the development of numerous cancers." +other hsa-mir-330 Costello Syndrome 26138095 "These results allow us to conclude that the H-Ras G12S mutation plays an important role in miRNA expression and open up a new line of study to understand the consequences of this mutation on Costello syndrome. Furthermore,they suggest that oncogenes may have a sufficiently important impact on miRNA expression to promote the development of numerous cancers." +other hsa-mir-330 Neoplasms [unspecific] 26138095 "These results allow us to conclude that the H-Ras G12S mutation plays an important role in miRNA expression and open up a new line of study to understand the consequences of this mutation on Costello syndrome. Furthermore,they suggest that oncogenes may have a sufficiently important impact on miRNA expression to promote the development of numerous cancers." +other hsa-mir-342 Costello Syndrome 26138095 "These results allow us to conclude that the H-Ras G12S mutation plays an important role in miRNA expression and open up a new line of study to understand the consequences of this mutation on Costello syndrome. Furthermore,they suggest that oncogenes may have a sufficiently important impact on miRNA expression to promote the development of numerous cancers." +other hsa-mir-342 Neoplasms [unspecific] 26138095 "These results allow us to conclude that the H-Ras G12S mutation plays an important role in miRNA expression and open up a new line of study to understand the consequences of this mutation on Costello syndrome. Furthermore,they suggest that oncogenes may have a sufficiently important impact on miRNA expression to promote the development of numerous cancers." +other hsa-mir-99b Costello Syndrome 26138095 "These results allow us to conclude that the H-Ras G12S mutation plays an important role in miRNA expression and open up a new line of study to understand the consequences of this mutation on Costello syndrome. Furthermore,they suggest that oncogenes may have a sufficiently important impact on miRNA expression to promote the development of numerous cancers." +other hsa-mir-99b Neoplasms [unspecific] 26138095 "These results allow us to conclude that the H-Ras G12S mutation plays an important role in miRNA expression and open up a new line of study to understand the consequences of this mutation on Costello syndrome. Furthermore,they suggest that oncogenes may have a sufficiently important impact on miRNA expression to promote the development of numerous cancers." +other hsa-mir-31 Psoriasis 26138368 NF-¦ÊB-induced microRNA-31 promotes epidermal hyperplasia by repressing protein phosphatase 6 in psoriasis. +other hsa-mir-125b Neoplasms [unspecific] 26138442 MAP3K11 might function as an important tumor suppressor neutralized by oncomiR-125b in B-cell leukemia. +other hsa-mir-133 Glioblastoma 26138587 Growth of glioblastoma is inhibited by miR-133-mediated EGFR suppression. +other hsa-mir-449c "Carcinoma, Gastric" 26141986 MiR-449c inhibits gastric carcinoma growth. +other hsa-mir-101 Neoplasms [unspecific] 26145175 MicroRNA-101 Suppresses Tumor Cell Proliferation by Acting as an Endogenous Proteasome Inhibitor via Targeting the Proteasome Assembly Factor POMP. +other hsa-mir-194 Lymphoma 26147452 modulation of microRNA-194 may constitute a novel approach to inhibiting proliferation of EBV(+) B cell lymphomas in PTLD. +other hsa-mir-15a Colorectal Adenoma 26148070 Oncogenic Role of miR-15a-3p in 13q Amplicon-Driven Colorectal Adenoma-to-Carcinoma Progression. +other hsa-mir-125a Obesity 26148871 miR-125a-3p and miR-483-5p promote adipogenesis via suppressing the RhoA/ROCK1/ERK1/2 pathway in multiple symmetric lipomatosis. +other hsa-mir-483 Obesity 26148871 miR-125a-3p and miR-483-5p promote adipogenesis via suppressing the RhoA/ROCK1/ERK1/2 pathway in multiple symmetric lipomatosis. +other hsa-mir-150 Influenza 26148929 The up-regulation of miR-150 is associated with poorer outcomes of A/H1N1 infection. The differential expression of miRNAs related with immune processes in severe A/H1N1 disease supports the potential role of these miRNAs as biomarkers of disease progression. +other hsa-mir-107 Glaucoma 26149270 "Experimental evidences indicate that the uveoscleral pathway, via suprachoroidal space, can provide a potential route of access from the anterior region to the posterior segment of the eye and could represent the path followed by biologic mediators to reach the inner layer of the peripapillary retina and transmit damage signals from the anterior to posterior segment during glaucoma course." +other hsa-mir-149 Glaucoma 26149270 "Experimental evidences indicate that the uveoscleral pathway, via suprachoroidal space, can provide a potential route of access from the anterior region to the posterior segment of the eye and could represent the path followed by biologic mediators to reach the inner layer of the peripapillary retina and transmit damage signals from the anterior to posterior segment during glaucoma course." +other hsa-mir-21 Glaucoma 26149270 "Experimental evidences indicate that the uveoscleral pathway, via suprachoroidal space, can provide a potential route of access from the anterior region to the posterior segment of the eye and could represent the path followed by biologic mediators to reach the inner layer of the peripapillary retina and transmit damage signals from the anterior to posterior segment during glaucoma course." +other hsa-mir-450 Glaucoma 26149270 "Experimental evidences indicate that the uveoscleral pathway, via suprachoroidal space, can provide a potential route of access from the anterior region to the posterior segment of the eye and could represent the path followed by biologic mediators to reach the inner layer of the peripapillary retina and transmit damage signals from the anterior to posterior segment during glaucoma course." +other hsa-mir-21 Lymphoma 26150475 Expression and clinicopathological significance of microRNA-21 and programmed cell death 4 in malignant melanoma. +other hsa-mir-1181 Ovarian Neoplasms 26151663 Activation of ARK5/miR-1181/HOXA10 axis promotes epithelial-mesenchymal transition in ovarian cancer. +other hsa-mir-133a Rhabdomyosarcoma 26153023 "ARS treatment in ERMS cells ROS-dependently induces the expression of the myo-miRs, miR-133a and miR-206, which are down-regulated in RMS, and reduces PAX7 protein levels." +other hsa-mir-126 Lung Neoplasms 26156018 most analyzed miRNA genes undergo substantial copy number alteration in lung cancer. +other hsa-mir-155 Lung Neoplasms 26156018 most analyzed miRNA genes undergo substantial copy number alteration in lung cancer. +other hsa-mir-17 Lung Neoplasms 26156018 most analyzed miRNA genes undergo substantial copy number alteration in lung cancer. +other hsa-mir-205 Lung Neoplasms 26156018 most analyzed miRNA genes undergo substantial copy number alteration in lung cancer. +other hsa-mir-21 Lung Neoplasms 26156018 "The most frequently amplified miRNA genes include the following: miR-30d, miR-21, miR-17 and miR-155." +other hsa-mir-30a Lung Neoplasms 26156018 "The most frequently amplified miRNA genes include the following: miR-30d, miR-21, miR-17 and miR-155." +other hsa-mir-30d Lung Neoplasms 26156018 "The most frequently amplified miRNA genes include the following: miR-30d, miR-21, miR-17 and miR-155." +other hsa-mir-31 Lung Neoplasms 26156018 most analyzed miRNA genes undergo substantial copy number alteration in lung cancer. +other hsa-mir-92 Lung Neoplasms 26156018 most analyzed miRNA genes undergo substantial copy number alteration in lung cancer. +other hsa-mir-21 Neoplasms [unspecific] 26156753 "This is the first study to demonstrate that kallistatin's heparin-binding site is crucial for preventing TGF-¦Â-induced miR-21 and oxidative stress, while its active site is key for stimulating the expression of antioxidant genes via interaction with an endothelial surface tyrosine kinase.These findings reveal novel mechanisms of kallistatin in protection against fibrosis and cancer by suppressing EndMT." +other hsa-mir-145 "Carcinoma, Esophageal" 26156802 The effect of recombinant lentiviral vector encoding miR-145 on human esophageal cancer cells. +other hsa-mir-146a "Squamous Cell Carcinoma, Oral" 26159827 Decrease of miR-146a is associated with the aggressiveness of human oral squamous cell carcinoma. +other hsa-mir-23a Osteosarcoma 26160225 MicroRNA-23a enhances migration and invasion through PTEN in osteosarcoma. +other hsa-mir-323 Prostate Neoplasms 26160610 Our data demonstrate that miR-323 may increase VEGF-A-mediated cancer vascularization in PC cells through AdipoR1 suppression. +other hsa-mir-451a Breast Neoplasms 26161389 miR-451a Inhibited Cell Proliferation and Enhanced Tamoxifen Sensitive in Breast Cancer via Macrophage Migration Inhibitory Factor. +other hsa-let-7b Influenza 26163223 These results indicate that the influenza virus containing microRNA response elements (MREs) is attenuated in vivo and can be used to design a live attenuated vaccine. +other hsa-mir-502 "Carcinoma, Hepatocellular" 26163264 miR-502 inhibits cell proliferation and tumor growth in hepatocellular carcinoma through suppressing phosphoinositide 3-kinase catalytic subunit gamma. +other hsa-mir-376c Prostate Neoplasms 26163549 Regulation of Human UGT2B15 and UGT2B17 by miR-376c in Prostate Cancer Cell Lines. +other hsa-mir-223 "Leukemia, Myeloid, Acute" 26163797 MicroRNA-223 dose levels fine tune proliferation and differentiation in human cord blood progenitors and acute myeloid leukemia. +other hsa-mir-141 Breast Neoplasms 26164002 miR-141 as potential suppressor of ¦Â-catenin in breast cancer. +other hsa-mir-451 "Carcinoma, Hepatocellular" 26164082 MicroRNA-451: epithelial-mesenchymal transition inhibitor and prognostic biomarker of hepatocelluar carcinoma. +other hsa-mir-31 Glioblastoma 26164206 Loss of tumor suppressive microRNA-31 enhances TRADD/NF-¦ÊB signaling in glioblastoma. +other hsa-mir-221 Prostate Neoplasms 26164758 Effects of microRNA-221/222 on cell proliferation and apoptosis in prostate cancer cells. +other hsa-mir-222 Prostate Neoplasms 26164758 Effects of microRNA-221/222 on cell proliferation and apoptosis in prostate cancer cells. +other hsa-mir-146 Cardiometabolic Disorders 26165231 Post-Transcriptional Regulation of Renalase Gene by miR-29 and miR-146 MicroRNAs:Implications for Cardiometabolic Disorders. +other hsa-mir-29 Cardiometabolic Disorders 26165231 Post-Transcriptional Regulation of Renalase Gene by miR-29 and miR-146 MicroRNAs:Implications for Cardiometabolic Disorders. +other hsa-mir-139 "Leukemia, Myeloid" 26165837 miR-139-5p controls translation in myeloid leukemia through EIF4G2. +other hsa-mir-15b Pancreatic Neoplasms 26166038 miR-15b promotes epithelial-mesenchymal transition by inhibiting SMURF2 in pancreatic cancer. +other hsa-mir-324 Breast Neoplasms 26166821 Sinomenine inhibits breast cancer cell invasion and migration by suppressing NF-¦ÊB activation mediated by IL-4/miR-324-5p/CUEDC2 axis. +other hsa-mir-21 Ischemia-Reperfusion Injury 26168042 "losartan treatment significantly increased microRNA (miR)-1, -15b, -92a, -133a, -133b, -210, and -499 expression but decreased miR-21 in the left ventricle." +other hsa-mir-21 Myocardial Infarction 26168042 "losartan treatment significantly increased microRNA (miR)-1, -15b, -92a, -133a, -133b, -210, and -499 expression but decreased miR-21 in the left ventricle." +other hsa-mir-145 Neoplasms [unspecific] 26168819 "Treatments of T-CIN+ cells with senescence-conditioned media induce sphere formation exclusively in cells with senescence-associated tumorigenicity, a capacity that depends on miR-145 repression." +other hsa-mir-125b Glioma 26170223 PI3K inhibitor combined with miR-125b inhibitor sensitize TMZ-induced anti-glioma stem cancer effects through inactivation of Wnt/¦Â-catenin signaling pathway. +other hsa-mir-183 Non-Sensory Diseases 26170234 the genomic organization and seeming redundancy of the miR-183 family cluster was conserved through 600 million years of evolution +other hsa-mir-150 Neoplasms [unspecific] 26170969 iR-150 may be a potential biomarker and therapeutic target in the diagnosis and treatment of various malignancies. +other hsa-mir-27a Sepsis 26171875 "RhTNFR:Fc improved cardiac function of sepsis mice, and markedly decreased miR-27a but increased Nrf2 expression level of myocardium in LPS treated mice." +other hsa-mir-375 "Squamous Cell Carcinoma, Head and Neck" 26172508 MicroRNA-375 Suppresses Extracellular Matrix Degradation and Invadopodial Activity in Head and Neck Squamous Cell Carcinoma. +other hsa-mir-31 Early-Stage Colon Carcinoma 26173758 The potential role of microRNA-31 expression in early colorectal cancer. +other hsa-mir-1246 Hemophilia A 26176629 Small ncRNA Expression-Profiling of Blood from Hemophilia A Patients Identifies miR-1246 as a Potential Regulator of Factor 8 Gene. +other hsa-mir-30a Atherosclerosis 26176854 "we here report the successful use of miRNA technology to silence a platelet protein in megakaryoblastic cells and demonstrate its usefulness in functional assays. Hence, we believe that artificial miRNAs are suitable tools to unravel the role of a protein of interest in stem cells, megakaryocytes and platelets, thereby expanding their application to novel fields of basic and translational research." +other hsa-mir-155 Melanoma 26176991 "hsa-mir-214-3p, hsa-miR-199a-3p,hsa-miR-155-5p in subsets of EVs released by melanoma cells, with significant similarities to clinical melanoma tissue, and provides unique insights into the contribution of EV associated extracellular RNA in cancer." +other hsa-mir-199a Melanoma 26176991 "hsa-mir-214-3p, hsa-miR-199a-3p,hsa-miR-155-5p in subsets of EVs released by melanoma cells, with significant similarities to clinical melanoma tissue, and provides unique insights into the contribution of EV associated extracellular RNA in cancer." +other hsa-mir-214 Melanoma 26176991 "hsa-mir-214-3p, hsa-miR-199a-3p,hsa-miR-155-5p in subsets of EVs released by melanoma cells, with significant similarities to clinical melanoma tissue, and provides unique insights into the contribution of EV associated extracellular RNA in cancer." +other hsa-mir-135b Colorectal Carcinoma 26178670 miR-135b and miR-146b-dependent silencing of calcium-sensing receptor expression in colorectal tumors. +other hsa-mir-146b Colorectal Carcinoma 26178670 miR-135b and miR-146b-dependent silencing of calcium-sensing receptor expression in colorectal tumors. +other hsa-mir-27a Colorectal Carcinoma 26178670 miR-135b and miR-146b-dependent silencing of calcium-sensing receptor expression in colorectal tumors. +other hsa-mir-9 Colorectal Carcinoma 26178670 miR-135b and miR-146b-dependent silencing of calcium-sensing receptor expression in colorectal tumors. +other hsa-let-7 Breast Neoplasms 26178901 "The most abundant exosome microRNAs (let-7a, miR-23b, miR-27a/b, miR-21, let-7, and miR-320b) are known to have anti-cancer and/or anti-angiogenic activity." +other hsa-let-7a Breast Neoplasms 26178901 "The most abundant exosome microRNAs (let-7a, miR-23b, miR-27a/b, miR-21, let-7, and miR-320b) are known to have anti-cancer and/or anti-angiogenic activity." +other hsa-mir-21 Breast Neoplasms 26178901 "The most abundant exosome microRNAs (let-7a, miR-23b, miR-27a/b, miR-21, let-7, and miR-320b) are known to have anti-cancer and/or anti-angiogenic activity." +other hsa-mir-23b Breast Neoplasms 26178901 "The most abundant exosome microRNAs (let-7a, miR-23b, miR-27a/b, miR-21, let-7, and miR-320b) are known to have anti-cancer and/or anti-angiogenic activity." +other hsa-mir-27a Breast Neoplasms 26178901 "The most abundant exosome microRNAs (let-7a, miR-23b, miR-27a/b, miR-21, let-7, and miR-320b) are known to have anti-cancer and/or anti-angiogenic activity." +other hsa-mir-27b Breast Neoplasms 26178901 "The most abundant exosome microRNAs (let-7a, miR-23b, miR-27a/b, miR-21, let-7, and miR-320b) are known to have anti-cancer and/or anti-angiogenic activity." +other hsa-mir-320b Breast Neoplasms 26178901 "The most abundant exosome microRNAs (let-7a, miR-23b, miR-27a/b, miR-21, let-7, and miR-320b) are known to have anti-cancer and/or anti-angiogenic activity." +other hsa-mir-141 Colorectal Carcinoma 26179333 Effects of Decitabine on Invasion and Exosomal Expression of miR-200c and miR-141 in Oxaliplatin-Resistant Colorectal Cancer Cells. +other hsa-mir-200c Colorectal Carcinoma 26179333 Effects of Decitabine on Invasion and Exosomal Expression of miR-200c and miR-141 in Oxaliplatin-Resistant Colorectal Cancer Cells. +other hsa-mir-122 "Carcinoma, Hepatocellular" 26179591 Single-Vehicular Delivery of Antagomir and Small Molecules to Inhibit miR-122 Function in Hepatocellular Carcinoma Cells by using Smart Mesoporous Silica Nanoparticles. +other hsa-mir-125b Human Papilloma Virus Infection 26180794 miR-34a and miR-125b Expression in HPV Infection and Cervical Cancer Development. +other hsa-mir-34a Human Papilloma Virus Infection 26180794 miR-34a and miR-125b Expression in HPV Infection and Cervical Cancer Development. +other hsa-mir-155 Human Immunodeficiency Virus Infection 26181817 Levels of miR-155 and miR-223 but not miR-92 were strongly correlated negatively with EV abundance and size in ART-naive patients. +other hsa-mir-223 Human Immunodeficiency Virus Infection 26181817 Levels of miR-155 and miR-223 but not miR-92 were strongly correlated negatively with EV abundance and size in ART-naive patients. +other hsa-mir-373 "Adenocarcinoma, Lung" 26182868 MiR-373-3p Promotes Invasion and Metastasis of Lung Adenocarcinoma Cells +other hsa-mir-3178 "Carcinoma, Hepatocellular" 26182877 Regulation of tumorigenesis and metastasis of hepatocellular carcinoma tumor endothelial cells by microRNA-3178 and underlying mechanism. +other hsa-mir-326 Glioma 26183397 Knockdown of long non-coding RNA HOTAIR inhibits malignant biological behaviors of human glioma cells via modulation of miR-326. +other hsa-mir-205 Colorectal Carcinoma 26183718 the integration of multiple omics methods allowed the comprehensive identification of direct and indirect effectors of p53 that provide new insights and leads into the mechanisms of p53-mediated tumor suppression. +other hsa-mir-34a Colorectal Carcinoma 26183718 the integration of multiple omics methods allowed the comprehensive identification of direct and indirect effectors of p53 that provide new insights and leads into the mechanisms of p53-mediated tumor suppression. +other hsa-mir-486 Colorectal Carcinoma 26183718 the integration of multiple omics methods allowed the comprehensive identification of direct and indirect effectors of p53 that provide new insights and leads into the mechanisms of p53-mediated tumor suppression. +other hsa-mir-142 "Carcinoma, Nasopharyngeal" 26183850 MiR-142-3p Suppresses SOCS6 Expression and Promotes Cell Proliferation in Nasopharyngeal Carcinoma. +other hsa-mir-21 Colorectal Carcinoma 26184038 IL6 Mediates Immune and Colorectal Cancer Cell Cross-talk via miR-21 and miR-29b. +other hsa-mir-29b Colorectal Carcinoma 26184038 IL6 Mediates Immune and Colorectal Cancer Cell Cross-talk via miR-21 and miR-29b. +other hsa-mir-33 Mitochondrial Metabolism Disease 26185207 Novel Role of miR-33 in Regulating of Mitochondrial Function. +other hsa-mir-206 Gastric Neoplasms 26186594 MicroRNA-206: Effective Inhibition of Gastric Cancer Progression through the c-Met Pathway. +other hsa-let-7 Neoplasms [unspecific] 26187994 "Our data reveal an unexpected role of Rho-associated, coiled-coil-containing protein kinase (ROCK1) as a cofactor of HNF4A in enhancing PAIP2 transcription. Rho-associated, coiled-coil-containing protein kinase (ROCK) inhibitors may be useful for the various pathologies associated with the impairment of global miRNA function." +other hsa-mir-122 Neoplasms [unspecific] 26187994 "Our data reveal an unexpected role of Rho-associated, coiled-coil-containing protein kinase (ROCK1) as a cofactor of HNF4A in enhancing PAIP2 transcription. Rho-associated, coiled-coil-containing protein kinase (ROCK) inhibitors may be useful for the various pathologies associated with the impairment of global miRNA function." +other hsa-mir-124 "Carcinoma, Hepatocellular" 26188282 PABPC1 interacts with AGO2 and is responsible for the microRNA mediated gene silencing in high grade hepatocellular carcinoma. +other hsa-mir-183 "Carcinoma, Hepatocellular" 26188282 PABPC1 interacts with AGO2 and is responsible for the microRNA mediated gene silencing in high grade hepatocellular carcinoma. +other hsa-mir-26a Pancreatic Neoplasms 26189069 Enhanced phosphorylation of p53 by microRNA-26a leading to growth inhibition of pancreatic cancer. +other hsa-mir-21 Neoplasms [unspecific] 26189797 RNA-binding protein HuR sequesters microRNA-21 to prevent translation repression of proinflammatory tumor suppressor gene programmed cell death 4. +other hsa-mir-155 Helicobacter pylori Infection 26191144 Inflammatory response of macrophages cultured with Helicobacter pylori strains was regulated by miR-155. +other hsa-mir-21 "Squamous Cell Carcinoma, Tongue" 26191145 The role of miR-21 in proliferation and invasion capacity of human tongue squamous cell carcinoma in vitro. +other hsa-mir-302a Ovarian Neoplasms 26191180 MiR-302a inhibits the tumorigenicity of ovarian cancer cells by suppression of SDC1. +other hsa-mir-188 Rheumatoid Arthritis 26191188 Expression and function of microRNA-188-5p in activated rheumatoid arthritis synovial fibroblasts. +other hsa-mir-34 Chronic Obstructive Pulmonary Disease 26191210 These proofs suggest that resveratrol inhibited dysfunction of dendritic cells (DCs) from COPD patients through promoting miR-34. +other hsa-mir-21 Neoplasms [unspecific] 26191606 The activated single-stranded DC can project the LAA headgroup into the hCA-II active site and is a robust hCA-II inhibitor (K(i) of 3.12 ¦ÌM). This work may spur research into developing new classes of cancer selective protein inhibitors. +other hsa-mir-155 Pancreatic Neoplasms 26195069 Pancreatic cancer-secreted miR-155 implicates in the conversion from normal fibroblasts to cancer-associated fibroblasts. +other hsa-mir-122 Growth Disorders 26198739 "Why is microRNA action tissue specific. A putative defense mechanism against growth disorders, tumor development or progression mediated by circulating microRNA" +other hsa-mir-15 Growth Disorders 26198739 "Why is microRNA action tissue specific. A putative defense mechanism against growth disorders, tumor development or progression mediated by circulating microRNA" +other hsa-mir-16 Growth Disorders 26198739 "Why is microRNA action tissue specific. A putative defense mechanism against growth disorders, tumor development or progression mediated by circulating microRNA" +other hsa-mir-21 Growth Disorders 26198739 "Why is microRNA action tissue specific. A putative defense mechanism against growth disorders, tumor development or progression mediated by circulating microRNA" +other hsa-mir-503 Growth Disorders 26198739 "Why is microRNA action tissue specific. A putative defense mechanism against growth disorders, tumor development or progression mediated by circulating microRNA" +other hsa-mir-221 "Carcinoma, Renal Cell" 26201448 Gain of function experiments showed that miR-221 and miR-222 decreased angiogenesis and cellular proliferation in human umbilical vein endothelial cells (HUVEC) while increasing cellular proliferation in ACHN cells. miRNAs represent potential predictive markers for sunitinib response. +other hsa-mir-222 "Carcinoma, Renal Cell" 26201448 Gain of function experiments showed that miR-221 and miR-222 decreased angiogenesis and cellular proliferation in human umbilical vein endothelial cells (HUVEC) while increasing cellular proliferation in ACHN cells. miRNAs represent potential predictive markers for sunitinib response. +other hsa-mir-573 "Carcinoma, Hepatocellular" 26201458 The miR-573/apoM/Bcl2A1-dependent signal transduction pathway is essential for hepatocyte apoptosis and hepatocarcinogenesis. +other hsa-mir-223 Pulmonary Hypertension 26201953 MicroRNAs and PARP: co-conspirators with ROS in pulmonary hypertension. Focus on miR-223 reverses experimental pulmonary arterial hypertension. +other hsa-mir-497 Osteosarcoma 26202364 "Taken together, our results suggest that miR-497 modulates the sensitivity to cisplatin at least in part through PI3K/Akt pathway in osteosarcoma cells." +other hsa-let-7a Digeorge Syndrome 26202964 "Collectively, our data suggest a novel mechanism that SUMOylation of DGCR8 controls direct functions of pri-miRNAs in gene silencing." +other hsa-mir-125b Aortic Insufficiency 26203686 MicroRNA-125b and chemokine CCL4 expression are associated with calcific aortic valve disease. +other hsa-mir-221 Viral Myocarditis 26206211 "The miR-221/-222 cluster orchestrates the antiviral and inflammatory immune response to viral infection of the heart. Its inhibition increases viral load, inflammation, and overall cardiac injury upon VM." +other hsa-mir-222 Viral Myocarditis 26206211 "The miR-221/-222 cluster orchestrates the antiviral and inflammatory immune response to viral infection of the heart. Its inhibition increases viral load, inflammation, and overall cardiac injury upon VM." +other hsa-mir-9 "Carcinoma, Hepatocellular" 26206264 this study revealed the involvement of the miR-9/PPARA/CDH1 signaling pathway in HCC oncogenesis. +other hsa-mir-100 Inflammation 26209130 Such delicately counterbalanced systems are a hallmark of immune plasticity and we propose that miR-100 editing is a novel mechanism toward this end. +other hsa-let-7a "Carcinoma, Cervical" 26209160 The effects of lanthanum chloride on proliferation and apoptosis of cervical cancer cells: involvement of let-7a and miR-34a microRNAs. +other hsa-mir-34a "Carcinoma, Cervical" 26209160 The effects of lanthanum chloride on proliferation and apoptosis of cervical cancer cells: involvement of let-7a and miR-34a microRNAs. +other hsa-mir-3651 "Squamous Cell Carcinoma, Esophageal" 26210449 Clinical potential of miR-3651 as a novel prognostic biomarker for esophageal squamous cell cancer. +other hsa-mir-203a "Carcinoma, Hepatocellular" 26210453 Downregulation of miRNA-30c and miR-204a is associated with hepatitis C virus core protein-induced epithelial-mesenchymal transition in normal hepatocytes and hepatocellular carcinoma cells. +other hsa-mir-30c "Carcinoma, Hepatocellular" 26210453 Downregulation of miRNA-30c and miR-203a is associated with hepatitis C virus core protein-induced epithelial-mesenchymal transition in normal hepatocytes and hepatocellular carcinoma cells. +other hsa-mir-146a Gastrointestinal Neoplasms 26211779 miR-146a cancer susceptibility gene polymorphism is closely associated with gastrointestinal cancers. +other hsa-mir-200 "Carcinoma, Ovarian" 26213923 The miR-200 Family: Versatile Players in Epithelial Ovarian Cancer. +other hsa-mir-17 Colorectal Carcinoma 26215320 Calycosin induces apoptosis by the regulation of ER¦Â/miR-17 signaling pathway in human colorectal cancer cells. +other hsa-mir-431 Muscle Diseases [unspecific] 26215566 our results suggest that the age-associated miR-431 plays a key role in maintaining the myogenic ability of skeletal muscle with age. +other hsa-mir-137 Breast Neoplasms 26215676 A contrasting function for miR-137 in embryonic mammogenesis and adult breast carcinogenesis. +other hsa-mir-150 "Carcinoma, Hepatocellular" 26215970 microRNA-150: a promising novel biomarker for hepatitis B virus-related hepatocellular carcinoma. +other hsa-mir-153 Lung Fibrosis 26216407 "These data suggest that miR-153 disturbs TGF-¦Â1 signal transduction and its effects on fibroblast activation, acting as an anti-fibrotic element in the development of pulmonary fibrosis." +other hsa-mir-375 Hypogonadism 26219823 "we identified miR-375 as an androgen regulated microRNA, which could play an important role for understanding the mechanism of the increase in visceral fat mass and the associated insulin resistance caused by testosterone deficiency." +other hsa-mir-21 Neoplasms [unspecific] 26220158 "preliminary mechanism of action studies propose a different mode of action compared to previously reported miR-21 inhibitors, thus affording a new chemical probe for future studies." +other hsa-mir-1 Atrial Fibrillation 26221584 The results suggest that immediate-early miRNA remodeling coupled with deregulation of TF expression underlies the onset of AF. +other hsa-mir-10a Atrial Fibrillation 26221584 The results suggest that immediate-early miRNA remodeling coupled with deregulation of TF expression underlies the onset of AF. +other hsa-mir-10b Atrial Fibrillation 26221584 The results suggest that immediate-early miRNA remodeling coupled with deregulation of TF expression underlies the onset of AF. +other hsa-mir-21 Atrial Fibrillation 26221584 The results suggest that immediate-early miRNA remodeling coupled with deregulation of TF expression underlies the onset of AF. +other hsa-mir-221 Atherosclerosis 26221589 Human miR-221/222 in Physiological and Atherosclerotic Vascular Remodeling. +other hsa-mir-222 Atherosclerosis 26221589 Human miR-221/222 in Physiological and Atherosclerotic Vascular Remodeling. +other hsa-mir-330 "Adenocarcinoma, Esophageal" 26221725 MicroRNA-330-5p as a Putative Modulator of Neoadjuvant Chemoradiotherapy Sensitivity in Oesophageal Adenocarcinoma. +other hsa-mir-106a "Carcinoma, Colon" 26224446 Long non-coding RNA Fer-1-like protein 4 suppresses oncogenesis and exhibits prognostic value by associating with miR-106a-5p in colon cancer. +other hsa-mir-124 "Squamous Cell Carcinoma, Head and Neck" 26227488 miR-124 Regulates the Epithelial-Restricted with Serine Box/Epidermal Growth Factor Receptor Signaling Axis in Head and Neck Squamous Cell Carcinoma. +other hsa-mir-34a Prostate Neoplasms 26231042 Registered report: the microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. +other hsa-mir-17 "Carcinoma, Hepatocellular" 26231474 MiR-17-95 cluster promotes hepatocarcinogenesis. +other hsa-mir-18 "Carcinoma, Hepatocellular" 26231474 MiR-17-95 cluster promotes hepatocarcinogenesis. +other hsa-mir-19a "Carcinoma, Hepatocellular" 26231474 MiR-17-95 cluster promotes hepatocarcinogenesis. +other hsa-mir-19b-1 "Carcinoma, Hepatocellular" 26231474 MiR-17-95 cluster promotes hepatocarcinogenesis. +other hsa-mir-20a "Carcinoma, Hepatocellular" 26231474 MiR-17-95 cluster promotes hepatocarcinogenesis. +other hsa-mir-92-1 "Carcinoma, Hepatocellular" 26231474 MiR-17-95 cluster promotes hepatocarcinogenesis. +other hsa-mir-4295 Thyroid Neoplasms 26231799 miR-4295 promotes cell proliferation and invasion in anaplastic thyroid carcinoma via CDKN1A. +other hsa-mir-17 "Carcinoma, Hepatocellular" 26232302 MiR-17-94 cluster promotes hepatocarcinogenesis. +other hsa-mir-18 "Carcinoma, Hepatocellular" 26232302 MiR-17-94 cluster promotes hepatocarcinogenesis. +other hsa-mir-19a "Carcinoma, Hepatocellular" 26232302 MiR-17-94 cluster promotes hepatocarcinogenesis. +other hsa-mir-19b-1 "Carcinoma, Hepatocellular" 26232302 MiR-17-94 cluster promotes hepatocarcinogenesis. +other hsa-mir-20a "Carcinoma, Hepatocellular" 26232302 MiR-17-94 cluster promotes hepatocarcinogenesis. +other hsa-mir-92-1 "Carcinoma, Hepatocellular" 26232302 MiR-17-94 cluster promotes hepatocarcinogenesis. +other hsa-mir-17 "Carcinoma, Hepatocellular" 26233130 MiR-17-93 cluster promotes hepatocarcinogenesis. +other hsa-mir-18 "Carcinoma, Hepatocellular" 26233130 MiR-17-93 cluster promotes hepatocarcinogenesis. +other hsa-mir-19a "Carcinoma, Hepatocellular" 26233130 MiR-17-93 cluster promotes hepatocarcinogenesis. +other hsa-mir-19b-1 "Carcinoma, Hepatocellular" 26233130 MiR-17-93 cluster promotes hepatocarcinogenesis. +other hsa-mir-20a "Carcinoma, Hepatocellular" 26233130 MiR-17-93 cluster promotes hepatocarcinogenesis. +other hsa-mir-92-1 "Carcinoma, Hepatocellular" 26233130 MiR-17-93 cluster promotes hepatocarcinogenesis. +other hsa-mir-106b Colorectal Carcinoma 26238857 MiR-106b induces cell radioresistance via the PTEN/PI3K/AKT pathways and p21 in colorectal cancer. +other hsa-mir-19a "Carcinoma, Gastric" 26239140 MicroRNA-19a mediates gastric carcinoma cell proliferation through the activation of nuclear factor-¦ÊB. +other hsa-mir-146a Glioblastoma 26239619 Induction of microRNA-146a is involved in curcumin-mediated enhancement of temozolomide cytotoxicity against human glioblastoma. +other hsa-mir-122 Osteoarthritis 26239639 An insertion/deletion polymorphism at the microRNA-122 binding site in the interleukin-1¦Á 3'-untranslated region is associated with a risk for osteoarthritis. +other hsa-let-7f Asthma 26242299 "17¦Â-E2+P4 increased IL-17A production from TH17 cells, providing a potential mechanism for the increased prevalence of severe asthma in women compared with men." +other hsa-mir-21 Meningioma 26242334 "Increased miR-21 and nestin mRNA levels were found in anaplastic meningiomas, in which recurrence is common, and the role of miR-21 and Nestin in meningiomas therefore warrants further investigation." +other hsa-mir-335 Osteoarthritis 26243143 Signature of microRNA expression during osteogenic differentiation of bone marrow MSCs reveals a putative role of miR-335-5p in osteoarthritis. +other hsa-mir-126 Thyroid Neoplasms 26244545 "To our knowledge, this is the first study to demonstrate that miR-126-3p has a tumor-suppressive function in thyroid cancer cells, and is associated with aggressive disease phenotype." +other hsa-mir-367 Medulloblastoma 26250335 miR-367 promotes proliferation and stem-like traits in medulloblastoma cells. +other hsa-mir-29a "Leukemia, Lymphoblastic, Acute" 26251039 Potential roles of microRNA-29a in the molecular pathophysiology of T-cell acute lymphoblastic leukemia. +other hsa-mir-199a Lymphoma 26251897 miR-199a and miR-497 Are Associated with Better Overall Survival due to Increased Chemosensitivity in Diffuse Large B-Cell Lymphoma Patients. +other hsa-mir-497 Lymphoma 26251897 miR-199a and miR-497 Are Associated with Better Overall Survival due to Increased Chemosensitivity in Diffuse Large B-Cell Lymphoma Patients. +other hsa-mir-144 Breast Neoplasms 26252024 "MicroRNA-144 affects radiotherapy sensitivity by promoting proliferation,migration and invasion of breast cancer cells." +other hsa-mir-374a "Carcinoma, Esophageal" 26252180 MicroRNA-374a promotes esophageal cancer cell proliferation via Axin2 suppression. +other hsa-mir-143 "Squamous Cell Carcinoma, Cerevial" 26252302 A Functional Polymorphism in the Promoter of MiR-143/145 Is Associated With the Risk of Cervical Squamous Cell Carcinoma in Chinese Women: A Case-Control Study. +other hsa-mir-145 "Squamous Cell Carcinoma, Cerevial" 26252302 A Functional Polymorphism in the Promoter of MiR-143/145 Is Associated With the Risk of Cervical Squamous Cell Carcinoma in Chinese Women: A Case-Control Study. +other hsa-mir-24 Respiratory Syncytial Virus Pneumonia 26253191 Human respiratory syncytial virus non-structural protein NS1 modifies miR-24 expression via transforming growth factor-¦Â. +other hsa-mir-148a "Squamous Cell Carcinoma, Skin or Unspecific" 26253263 Role of miR-148a in cutaneous squamous cell carcinoma by repression of MAPK pathway. +other hsa-mir-30a Glioma 26255203 MiR-30a-5p is induced by Wnt/¦Â-catenin pathway and promotes glioma cell invasion by repressing NCAM. +other hsa-mir-100 "Carcinoma, Rectal" 26255374 "The proposed methodology effectively made use of literature data and was able to show novel,significant miRNA-transcription associations in CRC." +other hsa-mir-630 "Carcinoma, Rectal" 26255374 "The proposed methodology effectively made use of literature data and was able to show novel,significant miRNA-transcription associations in CRC." +other hsa-mir-99a "Carcinoma, Rectal" 26255374 "The proposed methodology effectively made use of literature data and was able to show novel,significant miRNA-transcription associations in CRC." +other hsa-mir-17 Neoplasms [unspecific] 26255770 developmentally regulated pro-miRNA processing is a key step controlling miRNA expression and explains the posttranscriptional control of miR-17-92 expression in development. +other hsa-mir-451 Neoplasms [unspecific] 26257001 "Both, energy-conserving metabolic shift and resource-seeking behavioral change require brain tumor cell to shut down miR-451, while forced expression of miR-451 during stress leads to cytotoxicity [3]. The AMPK-dependent inactivation of the OCT1 transcriptional activator of miR-451 helps brain tumor cells to escape from metabolically stressful events/locations. MiR-451 thus provides an example of a molecule that is not deregulated in brain tumor cells, but is instead finely regulated by promoting or suppressing brain tumor cell phenotypes based on microenvironmental contexts." +other hsa-let-7i "Squamous Cell Carcinoma, Head and Neck" 26257063 IB suppresses EMT and stemness of HNSCC cells through inhibition of Twist1-mediated let-7i downregulation and Rac1 activation and the EMT signalling. +other hsa-mir-128 Neuroblastoma 26258008 Such miRNAs regulate genes involved in cellular processes +other hsa-mir-130a Neuroblastoma 26258008 Such miRNAs regulate genes involved in cellular processes +other hsa-mir-181a Neuroblastoma 26258008 Such miRNAs regulate genes involved in cellular processes +other hsa-mir-18a Neuroblastoma 26258008 Such miRNAs regulate genes involved in cellular processes +other hsa-mir-21 Neuroblastoma 26258008 Such miRNAs regulate genes involved in cellular processes +other hsa-mir-218 Neuroblastoma 26258008 Such miRNAs regulate genes involved in cellular processes +other hsa-mir-380 Neuroblastoma 26258008 Such miRNAs regulate genes involved in cellular processes +other hsa-mir-424 Neuroblastoma 26258008 Such miRNAs regulate genes involved in cellular processes +other hsa-mir-451 Neuroblastoma 26258008 Such miRNAs regulate genes involved in cellular processes +other hsa-mir-558 Neuroblastoma 26258008 Such miRNAs regulate genes involved in cellular processes +other hsa-mir-7 Neuroblastoma 26258008 Such miRNAs regulate genes involved in cellular processes +other hsa-mir-373 Breast Neoplasms 26258411 Epigenetic silencing of ITGA2 by MiR-373 promotes cell migration in breast cancer. +other hsa-mir-21 Ischemia-Reperfusion Injury 26259139 Isoflurane protects mouse hearts from ischemia-reperfusion injury by a microRNA-21-dependent mechanism. +other hsa-mir-15a Neoplasms [unspecific] 26260813 miRNA-15a/16: as tumor suppressors and more. +other hsa-mir-16 Neoplasms [unspecific] 26260813 miRNA-15a/16: as tumor suppressors and more. +other hsa-mir-127 Glioma 26261488 Knockdown of microRNA-127 reverses adriamycin resistance via cell cycle arrest and apoptosis sensitization in adriamycin-resistant human glioma cells. +other hsa-mir-1908 Glioblastoma 26265437 miRNA-1908 functions as an oncogene in glioblastoma by repressing the PTEN pathway. MiR-1908 is a potential new molecular marker for predicting the risk of recurrence and prognosis of glioblastoma. +other hsa-mir-21 Gastric Neoplasms 26265521 MicroRNA-21: Mechanisms of Oncogenesis and its Application in Diagnosis and Prognosis of Gastric Cancer. +other hsa-mir-124 Glioma 26269187 Our findings indicate a clear benefit in harnessing the wild-type virus replicative potency in development of next-generation oncolytic alphaviruses. +other hsa-mir-21 Breast Neoplasms 26270351 Breast Cancer/Stromal Cells Coculture on Polyelectrolyte Films Emulates Tumor Stages and miRNA Profiles of Clinical Samples. +other hsa-mir-21 Neoplasms [unspecific] 26271820 MicroRNA-Responsive Cancer Cell Imaging and Therapy with Functionalized Gold Nanoprobe. +other hsa-mir-429 Glioma 26272601 Our results indicated that BMK1 modulation by miR-429 has an important function in glioma invasion both in vitro and in vivo. +other hsa-let-7 Muscular Dystrophy 26272747 Our study therefore introduces additional biological players in the regulation of skeletal muscle structure and myogenesis that may contribute to unexplained disorders of MD. +other hsa-let-7e Muscular Dystrophy 26272747 Our study therefore introduces additional biological players in the regulation of skeletal muscle structure and myogenesis that may contribute to unexplained disorders of MD. +other hsa-mir-98 Muscular Dystrophy 26272747 Our study therefore introduces additional biological players in the regulation of skeletal muscle structure and myogenesis that may contribute to unexplained disorders of MD. +other hsa-mir-150 Autoimmune Diseases [unspecific] 26275076 dysregulated expression of miR-150 in immune cells might result in autoimmune diseases. +other hsa-mir-1 Breast Neoplasms 26275461 Our findings emphasized the potential role of miR-1 as tumor suppressive miRNA in breast cancer. +other hsa-mir-491 "Carcinoma, Esophageal" 26279431 miR-491 may play a critical role in EC. +other hsa-mir-132 Granulosa Cell Tumor 26282993 Our findings suggest that miR-132 is involved in the cAMP signaling pathway and promotes estradiol synthesis via the translational repression of Nurr1 in ovarian GCs. +other hsa-mir-200a Breast Neoplasms 26283635 Identification of miR-200a as a novel suppressor of connexin 43 in breast cancer cells. +other hsa-mir-92a Diabetes Mellitus 26283734 miR-92a Corrects CD34+ Cell Dysfunction in Diabetes by Modulating Core Circadian Genes Involved in Progenitor Differentiation. +other hsa-let-7 Malignant Neoplasms [unspecific] 26285684 "and messenger RNAs and microRNAs miR-21, miR-27a, let-7, miR-451, among others." +other hsa-mir-21 Malignant Neoplasms [unspecific] 26285684 "and messenger RNAs and microRNAs miR-21, miR-27a, let-7, miR-451, among others." +other hsa-mir-27a Malignant Neoplasms [unspecific] 26285684 "and messenger RNAs and microRNAs miR-21, miR-27a, let-7, miR-451, among others." +other hsa-mir-451 Malignant Neoplasms [unspecific] 26285684 "and messenger RNAs and microRNAs miR-21, miR-27a, let-7, miR-451, among others." +other hsa-mir-335 "Leukemia, Myeloid, Acute" 26287405 Our finding suggests that bone marrow miR-335 level may be used as a marker to predict the chemotherapy response and prognosis in adult AML patients. +other hsa-mir-200 Cystic Fibrosis 26292219 Transcription Factor Hepatocyte Nuclear Factor-1¦Â (HNF-1¦Â) Regulates MicroRNA-200 Expression through a Long Noncoding RNA. +other hsa-mir-21 Leukemia 26294715 "In this issue of Blood, Junker et al delineate a novel signaling axis involving miR-21 and the tumor suppressor Pdcd4 that is essential for Notch-mediated induction of T-cell acute lymphoblastic leukemia (T-ALL)." +other hsa-mir-24 Ovarian Neoplasms 26296081 Enrichment Analysis Identifies Functional MicroRNA-Disease Associations in Humans. +other hsa-mir-454 Uveal Melanoma 26296312 Our data revealed that ectopic expression of PTEN restored the effects of miR-454 on cell proliferation and invasion in uveal melanoma cells. These findings support an oncogene role of miR-454 in development of uveal melanoma. +other hsa-mir-30 Influenza 26296570 RNA interference of influenza A virus replication by microRNA-adapted lentiviral loop short hairpin RNA. +other hsa-mir-107 "Carcinoma, Hepatocellular" 26296971 miRNA-7/21/108 contribute to HBx-induced hepatocellular carcinoma progression through suppression of maspin. +other hsa-mir-21 "Carcinoma, Hepatocellular" 26296971 miRNA-7/21/109 contribute to HBx-induced hepatocellular carcinoma progression through suppression of maspin. +other hsa-mir-7 "Carcinoma, Hepatocellular" 26296971 miRNA-7/21/107 contribute to HBx-induced hepatocellular carcinoma progression through suppression of maspin. +other hsa-mir-137 "Diabetes Mellitus, Gestational" 26302821 Our data identified a miRNA signature involvement in GDM which may contribute to macrosomia through enhancing EGFR signaling. +other hsa-mir-27a "Diabetes Mellitus, Gestational" 26302821 Our data identified a miRNA signature involvement in GDM which may contribute to macrosomia through enhancing EGFR signaling. +other hsa-mir-30d "Diabetes Mellitus, Gestational" 26302821 Our data identified a miRNA signature involvement in GDM which may contribute to macrosomia through enhancing EGFR signaling. +other hsa-mir-33a "Diabetes Mellitus, Gestational" 26302821 Our data identified a miRNA signature involvement in GDM which may contribute to macrosomia through enhancing EGFR signaling. +other hsa-mir-362 "Diabetes Mellitus, Gestational" 26302821 Our data identified a miRNA signature involvement in GDM which may contribute to macrosomia through enhancing EGFR signaling. +other hsa-mir-502 "Diabetes Mellitus, Gestational" 26302821 Our data identified a miRNA signature involvement in GDM which may contribute to macrosomia through enhancing EGFR signaling. +other hsa-mir-508 "Diabetes Mellitus, Gestational" 26302821 Our data identified a miRNA signature involvement in GDM which may contribute to macrosomia through enhancing EGFR signaling. +other hsa-mir-9 "Diabetes Mellitus, Gestational" 26302821 Our data identified a miRNA signature involvement in GDM which may contribute to macrosomia through enhancing EGFR signaling. +other hsa-mir-92a "Diabetes Mellitus, Gestational" 26302821 Our data identified a miRNA signature involvement in GDM which may contribute to macrosomia through enhancing EGFR signaling. +other hsa-mir-19a Colorectal Carcinoma 26302825 "Collectively, miR-19a played an important role in mediating EMT and metastatic behavior in CRC. It may serve as a potential marker of lymph node metastasis." +other hsa-mir-22 Aortic Stenosis 26304936 "Despite holding great promise, circulating miRNA profiling requires further refinement before translation into clinical use as a biomarker in aortic stenosis." +other hsa-mir-24 Aortic Stenosis 26304936 "Despite holding great promise, circulating miRNA profiling requires further refinement before translation into clinical use as a biomarker in aortic stenosis." +other hsa-mir-382 Aortic Stenosis 26304936 "Despite holding great promise, circulating miRNA profiling requires further refinement before translation into clinical use as a biomarker in aortic stenosis." +other hsa-mir-451a Aortic Stenosis 26304936 "Despite holding great promise, circulating miRNA profiling requires further refinement before translation into clinical use as a biomarker in aortic stenosis." +other hsa-mir-223 Multiple Sclerosis 26305248 Variants of MicroRNA Genes: Gender-Specific Associations with Multiple Sclerosis Risk and Severity. +other hsa-mir-499a Multiple Sclerosis 26305248 Variants of MicroRNA Genes: Gender-Specific Associations with Multiple Sclerosis Risk and Severity. +other hsa-mir-23a "Carcinoma, Hepatocellular" 26305257 up-regulating the expression of miR-23a may activate the positive regulatory network of p53 and miR-23a involved in the mechanism underlying the anti-tumor effect of berberine in hepatocellular carcinoma (HCC). +other hsa-mir-663b "Leukemia, Lymphocytic, Chronic, B-Cell" 26305332 Interleukin 21 Controls mRNA and MicroRNA Expression in CD40-Activated Chronic Lymphocytic Leukemia Cells. +other hsa-mir-122 Hepatitis C Virus Infection 26305877 Supporting Role for GTPase Rab27a in Hepatitis C Virus RNA Replication through a Novel miR-122-Mediated Effect. +other hsa-mir-410 Diabetes Mellitus 26307561 miR-410 enhanced hESC-derived pancreatic endoderm transplant to alleviate gestational diabetes mellitus. +other hsa-mir-26b Colorectal Carcinoma 26308439 Clinical Value of miR-26b Discriminating Ulcerative Colitis-associated Colorectal Cancer in the Subgroup of Patients with Metastatic Disease. +other hsa-mir-29 Atherosclerosis 26309238 Transcriptional and posttranscriptional mechanisms contribute to the dysregulation of elastogenesis in Schimke immuno-osseous dysplasia. +other hsa-mir-30b Gastric Neoplasms 26309359 "Our findings describe a link between miR-30b and EIF5A2, which plays an important role in mediating epithelial-mesenchymal transition." +other hsa-mir-21 Coronary Artery Disease 26310808 Local anti-miR delivery: the latest in the arsenal of drug-eluting stents +other hsa-mir-200c Breast Neoplasms 26310899 "selected miRNAs, such as miR-200c and miR-34a, may influence response to chemotherapy in several tumor types" +other hsa-mir-205 "Carcinoma, Lung, Non-Small-Cell" 26311306 Validation for histology-driven diagnosis in non-small cell lung cancer using hsa-miR-205 and hsa-miR-21 expression by two different normalization strategies. +other hsa-mir-21 "Carcinoma, Lung, Non-Small-Cell" 26311306 Validation for histology-driven diagnosis in non-small cell lung cancer using hsa-miR-205 and hsa-miR-21 expression by two different normalization strategies. +other hsa-mir-10b Gastric Neoplasms 26311318 "miR-10b promotes migration and invasion through Hoxd10 in human gastric cancer cell lines and may play an important role in tumorigenesis,progression, and prognosis." +other hsa-mir-375 Diabetes Mellitus 26311337 "This review analyzes the role of miRNAs in obesity and insulin resistance, focusing on the miR-17/92, miR-143-145, miR-130, let-7, miR-221/222, miR-200, miR-223, miR-29 and miR-375 families, as well as miRNA changes by relevant tissue" +other hsa-mir-126 Atrial Fibrillation 26313139 Biological significance of miR-126 expression in atrial fibrillation and heart failure. +other hsa-mir-126 Heart Failure 26313139 Biological significance of miR-126 expression in atrial fibrillation and heart failure. +other hsa-mir-15b Pancreatic Neoplasms 26314585 Pancreatic tumours are usually very aggressive cancer with a poor prognosis. +other hsa-mir-186 Pancreatic Neoplasms 26314585 Pancreatic tumours are usually very aggressive cancer with a poor prognosis. +other hsa-mir-190 Pancreatic Neoplasms 26314585 Pancreatic tumours are usually very aggressive cancer with a poor prognosis. +other hsa-mir-200b Pancreatic Neoplasms 26314585 Pancreatic tumours are usually very aggressive cancer with a poor prognosis. +other hsa-mir-221 Pancreatic Neoplasms 26314585 Pancreatic tumours are usually very aggressive cancer with a poor prognosis. +other hsa-mir-222 Pancreatic Neoplasms 26314585 Pancreatic tumours are usually very aggressive cancer with a poor prognosis. +other hsa-mir-95 Pancreatic Neoplasms 26314585 Pancreatic tumours are usually very aggressive cancer with a poor prognosis. +other hsa-mir-15a "Carcinoma, Lung, Non-Small-Cell" 26314859 We found that induced expression of hsa-miR-15a-3p via mimic transfection sensitised cisplatin-resistant cells to apoptosis and autophagy. +other hsa-mir-338 "Carcinoma, Hepatocellular" 26315112 HBV preS2 promotes the expression of TAZ via miRNA-338-3p to enhance the tumorigenesis of hepatocellular carcinoma. +other hsa-mir-424 "Carcinoma, Hepatocellular" 26315541 MicroRNA-424 inhibits Akt3/E2F3 axis and tumor growth in hepatocellular carcinoma. +other hsa-mir-138 Colorectal Carcinoma 26316117 Downregulation of miR-138 as a Contributing Mechanism to Lcn-2 Overexpression in Colorectal Cancer with Liver Metastasis. +other hsa-mir-155 Neoplasms [unspecific] 26317550 Our results demonstrate that miR-155 inhibits the ability of cancer cells to extravasate and/or colonize at distant organs and brings additional insight into the complexity of miR-155 regulation in metastatic seeding. +other hsa-mir-31 Diabetes Mellitus 26318001 "Comparative Genomic, MicroRNA, and Tissue Analyses Reveal Subtle Differences between Non-Diabetic and Diabetic Foot Skin." +other hsa-mir-140 "Carcinoma, Embryonal" 26318829 Role of miR-140 in embryonic bone development and cancer. +other hsa-mir-21 Malignant Neoplasms [unspecific] 26320972 Toehold-mediated nonenzymatic amplification circuit on graphene oxide fluorescence switching platform for sensitive and homogeneous microRNA detection. +other hsa-mir-155 "Carcinoma, Lung, Non-Small-Cell" 26322518 These results suggest that miR-155 expression is not significantly related to non-small cell lung cancer patients except in patients from Asian and America. +other hsa-mir-145 Breast Neoplasms 26324407 Physicochemical and biological characterization of chitosan-microRNA nanocomplexes for gene delivery to MCF-7 breast cancer cells. +other hsa-mir-15b "Leukemia, Lymphocytic, Chronic, B-Cell" 26324892 "These results are the first, to our knowledge, to suggest an important role of miR-15b/16-2 loss in the pathogenesis of B-cell chronic lymphocytic leukemia." +other hsa-mir-16-1 "Leukemia, Lymphocytic, Chronic, B-Cell" 26324892 "These results are the first, to our knowledge, to suggest an important role of miR-15b/16-2 loss in the pathogenesis of B-cell chronic lymphocytic leukemia." +other hsa-mir-142 Heart Failure 26327117 miR-142-5p has been proposed to control adaptive growth in cardiomyocytes postnatally and its increase is associated with extensive apoptosis and cardiac dysfunction in a murine heart failure model. +other hsa-mir-122 Hepatitis C Virus Infection 26330540 These results show that hnRNP K is a cellular protein that binds and affects the accumulation of miR-122. Its ability to also bind HCV RNA near the miR-122 binding site suggests a role for miR-122 recognition of HCV RNA. +other hsa-mir-200c Neoplasms [unspecific] 26334100 "In summary, TKS5 and MYLK represent two mediators of invasive behavior of cancer cells that are regulated by the ZEB1/miR-200 feedback loop." +other hsa-mir-200b "Squamous Cell Carcinoma, Esophageal" 26334393 These data highlight that suppression of the Kindlin-2-integrin ¦Â1-AKT regulatory axis is an alternative mechanism underlying the tumor suppressor function of miR-200b in ESCC. +other hsa-mir-155 Leukemia 26337206 "Altogether, these data implicate QKI in the pathophysiology of inflammation and oncogenesis where miR-155 is involved." +other hsa-mir-222 Melanoma 26338962 miR-222 could function as a biomarker for the prediction of response to ipilimumab +other hsa-mir-205 Thyroid Neoplasms 26342107 The angiogenic and tumour-suppressive roles of miRNA-205 were demonstrated for the first time in thyroid cancer. The current experiments provided specific information on the functional consequences of VEGF manipulation via miRNA on cancer. +other hsa-mir-21 "Leukemia, Myeloid, Acute" 26344648 "GRh2 may be an effective treatment for pediatric leukemia, and GRh2 may induce apoptosis of leukemia cells through miR-21-modulated suppression of Bcl-2." +other hsa-mir-30a Nephrotic Syndrome 26345917 "Analysis of the expression of HMGB-1, CXCL16, miRNA-30a, and TGF-¦Â1 in primary nephritic syndrome patients and its significance." +other hsa-mir-223 Sepsis 26348153 Exosomal miR-223 Contributes to Mesenchymal Stem Cell-Elicited Cardioprotection in Polymicrobial Sepsis. +other hsa-let-7b Vascular Disease [unspecific] 26348824 only let-7b and miR-133a were markedly upregulated. +other hsa-mir-21 Breast Neoplasms 26349663 "These results indicate that miRNAs show promising associations with prognosis in breast cancer. Moreover, specific miRNAs such as miR-21 and miR-210 can predict poor survival rates in breast cancer patients." +other hsa-mir-210 Breast Neoplasms 26349663 "These results indicate that miRNAs show promising associations with prognosis in breast cancer. Moreover, specific miRNAs such as miR-21 and miR-210 can predict poor survival rates in breast cancer patients." +other hsa-mir-126 Malignant Neoplasms [unspecific] 26351404 Our results indicated that miR-126 could act as a significant biomarker in the prognosis of various cancers. +other hsa-mir-137 "Carcinoma, Hepatocellular" 26352279 Inhibition of cell proliferation and metastasis of human hepatocellular carcinoma by miR-137 is regulated by CDC42. +other hsa-mir-126 Aplastic Anemia 26354756 Identification of novel microRNA signatures linked to acquired aplastic anemia. +other hsa-mir-145 Aplastic Anemia 26354756 Identification of novel microRNA signatures linked to acquired aplastic anemia. +other hsa-mir-199a Aplastic Anemia 26354756 Identification of novel microRNA signatures linked to acquired aplastic anemia. +other hsa-mir-223 Aplastic Anemia 26354756 Identification of novel microRNA signatures linked to acquired aplastic anemia. +other hsa-mir-143 Bladder Neoplasms 26356996 Cisplatin and Paclitaxel Alter the Expression Pattern of miR-143/145 and miR-183/96/182 Clusters in T24 Bladder Cancer Cells. +other hsa-mir-145 Bladder Neoplasms 26356996 Cisplatin and Paclitaxel Alter the Expression Pattern of miR-143/145 and miR-183/96/182 Clusters in T24 Bladder Cancer Cells. +other hsa-mir-182 Bladder Neoplasms 26356996 Cisplatin and Paclitaxel Alter the Expression Pattern of miR-143/145 and miR-183/96/182 Clusters in T24 Bladder Cancer Cells. +other hsa-mir-183 Bladder Neoplasms 26356996 Cisplatin and Paclitaxel Alter the Expression Pattern of miR-143/145 and miR-183/96/182 Clusters in T24 Bladder Cancer Cells. +other hsa-mir-96 Bladder Neoplasms 26356996 Cisplatin and Paclitaxel Alter the Expression Pattern of miR-143/145 and miR-183/96/182 Clusters in T24 Bladder Cancer Cells. +other hsa-mir-34a Breast Neoplasms 26359358 These data provide evidence for the leptin-antagonist potential of HNK and reveal the involvement of LKB1 and miR-34a. +other hsa-mir-101 Breast Neoplasms 26360780 MiRNA-101 inhibits breast cancer growth and metastasis by targeting CX chemokine receptor 7. +other hsa-mir-122 Neoplasms [unspecific] 26360933 "In conclusion, administration of TSA in hepatogenic differentiation of hAT-MSCs resulted in higher expression levels of miR-122,facilitation of differentiation, and subsequently attenuation of AFP levels." +other hsa-mir-22 Panic Disorder 26361067 This is the first report to show possible associations of miR-22 and miR-491 with genetic susceptibility to PD in a Korean population. +other hsa-mir-491 Panic Disorder 26361067 This is the first report to show possible associations of miR-22 and miR-491 with genetic susceptibility to PD in a Korean population. +other hsa-mir-302 Kidney Neoplasms 26363379 Evolutionary conservation and function of the human embryonic stem cell specific miR-302/367 cluster. +other hsa-mir-367 Kidney Neoplasms 26363379 Evolutionary conservation and function of the human embryonic stem cell specific miR-302/367 cluster. +other hsa-mir-221 Gastric Neoplasms 26364844 The miR-221/miR-222-RECK axis might be an important path modulating H. pylori infection-related gastric cancer development. +other hsa-mir-222 Gastric Neoplasms 26364844 The miR-221/miR-222-RECK axis might be an important path modulating H. pylori infection-related gastric cancer development. +other hsa-mir-486 Lung Fibrosis 26370615 The Anti-fibrotic Effects and Mechanisms of MicroRNA-486-5p in Pulmonary Fibrosis. +other hsa-mir-16 Bladder Neoplasms 26373319 "Together, our results revealed that urothelial carcinoma-associated 1 regulated the expression of GLS2 through interfering with miR-16, and repressed ROS formation in bladder cancer cells." +other hsa-mir-148b "Carcinoma, Lung, Non-Small-Cell" 26377406 Our findings demonstrated that miR-148b may play a role as independent prognostic factor for patients with NSCLC. +other hsa-mir-140 Breast Neoplasms 26378051 the existence of common pathways driving breast carcinogenesis in both BRCA1 and BRCA2 germ-line mutation carriers. +other hsa-mir-320c Breast Neoplasms 26378051 the existence of common pathways driving breast carcinogenesis in both BRCA1 and BRCA2 germ-line mutation carriers. +other hsa-mir-335 Breast Neoplasms 26378051 the existence of common pathways driving breast carcinogenesis in both BRCA1 and BRCA2 germ-line mutation carriers. +other hsa-mir-486 Breast Neoplasms 26378051 the existence of common pathways driving breast carcinogenesis in both BRCA1 and BRCA2 germ-line mutation carriers. +other hsa-mir-200a Retinoblastoma 26379276 Novel miRNA-31 and miRNA-200a-Mediated Regulation of Retinoblastoma Proliferation. +other hsa-mir-31 Retinoblastoma 26379276 Novel miRNA-31 and miRNA-200a-Mediated Regulation of Retinoblastoma Proliferation. +other hsa-mir-375 Osteosarcoma 26381132 "Formononetin has inhibitory effects on the proliferation of U2SO cells, both in vitro and in vivo. This antitumor effect is directly correlated with formononetin concentration." +other hsa-mir-130a Myeloma 26389804 "Together, our data suggest connection between lower level of microRNA-130a and extramedullary disease and prompt further work to evaluate this miRNA as a marker of extramedullary disease in multiple myeloma." +other hsa-mir-122 "Carcinoma, Lung, Non-Small-Cell" 26389880 These results indicate that miR-122 would be a novel strategy for NSCLC radiation-therapy. +other hsa-mir-143 Colorectal Carcinoma 26392389 "These findings warrant further studies to investigate the relationship between miR-143, FXYD3 and fluoropyrimidines, and the clinical utility of miR-143 as biomarker." +other hsa-mir-221 Osteosarcoma 26397386 "Taken together, our results suggest that miR-221 enhances the proliferation,invasion and migration ability of osteosarcoma cells partly by suppressing PTEN." +other hsa-mir-146b Glioma 26397753 "In conclusion, the inhibition of miR-146b may increase hypoxia-induced cardiomyocyte apoptosis." +other hsa-mir-765 "Carcinoma, Breast" 26398721 These results provided novel insight into the regulatory mechanism of EMP3 in primary breast carcinoma. +other hsa-mir-199a Breast Neoplasms 26399456 "Thus, miR-199a/b-3p functions as a tumor suppressor and has an important role in breast cancer metastasis through PAK4/MEK/ERK signaling pathway." +other hsa-mir-199b Breast Neoplasms 26399456 "Thus, miR-199a/b-3p functions as a tumor suppressor and has an important role in breast cancer metastasis through PAK4/MEK/ERK signaling pathway." +other hsa-mir-183 Breast Neoplasms 26400174 "In conclusion,our findings provide evidence that post-transcriptional studies of BRCA will benefit from transcending the one-locus-one-miRNA paradigm and taking into account all isoforms from each miRNA locus as well as the patient's race." +other hsa-mir-23a Granulosa Cell Tumor 26400397 "These findings provide an improved understanding of the mechanisms underlying granulosa cell apoptosis, which could potentially be used for future clinical applications." +other hsa-mir-27a Granulosa Cell Tumor 26400397 "These findings provide an improved understanding of the mechanisms underlying granulosa cell apoptosis, which could potentially be used for future clinical applications." +other hsa-mir-183 "Carcinoma, Hepatocellular" 26400524 This study revealed a novel miR-21/miR-183-SOCS7 axis that might play an important role in modulating cell growth and invasion of HCC cells. +other hsa-mir-21 "Carcinoma, Hepatocellular" 26400524 This study revealed a novel miR-21/miR-183-SOCS6 axis that might play an important role in modulating cell growth and invasion of HCC cells. +other hsa-mir-1 Acute Kidney Failure 26400542 "Ramipril reduced cardiac hypertrophy, attenuated the increase in microRNA-212 and microRNA-132, and significantly increased microRNA-133 and microRNA-1 expression." +other hsa-mir-146 Immune System Disease [unspecific] 26400897 "Present review is focused on the current knowledge about the action of medicaments,microRNA molecules, exosomes and related vesicles on macrophages leading to modulation of their biological activity." +other hsa-mir-17 "Adenocarcinoma, Lung" 26402252 Identification of Biomarker and Co-Regulatory Motifs in Lung Adenocarcinoma Based on Differential Interactions. +other hsa-mir-423 Colorectal Carcinoma 26402653 "In conclusion, our findings demonstrated a critical impact of miR-423-3p on CRC growth." +other hsa-mir-532 Alzheimer Disease 26402772 "Although we could not consistently separate AD patients and controls in the whole group, we have found indications miRNA in CSF are able to reflect aging and perhaps also heterogeneity in AD. Further investigation requires optimizing RNA input, while maintaining strict age matching." +other hsa-mir-30c "Carcinoma, Esophageal" 26402921 "Factors such as core promoter-binding protein (CPBP), nuclear factor of activated T-cells 1 (NFAT-1), miR-30c-5p, were located in the central hub of this network, highlighting their vital roles in esophageal tumorigenesis." +other hsa-mir-34a Alcoholic Hepatitis 26403328 "These results constitute a demonstration of the altered regulation of miR-34a and miR-483-3p in the livers of AH and mice fed DDC where MDBs formed, providing further insight into the mechanism of MDB formation mediated by miR-34a and miR-483-3p in AH." +other hsa-mir-483 Alcoholic Hepatitis 26403328 "These results constitute a demonstration of the altered regulation of miR-34a and miR-483-3p in the livers of AH and mice fed DDC where MDBs formed, providing further insight into the mechanism of MDB formation mediated by miR-34a and miR-483-3p in AH." +other hsa-mir-34a "Carcinoma, Lung, Non-Small-Cell" 26406332 Aptamer-Dendrimer Bioconjugates for Targeted Delivery of miR-34a Expressing Plasmid and Antitumor Effects in Non-Small Cell Lung Cancer Cells. +other hsa-mir-21 Breast Neoplasms 26411332 The miR-21-triggered self-assembly of DNA nanostructures can also serve as a remarkable signal amplification platform to achieve ultrasensitive detection of miR-21 from as low as 10 MCF-7 human breast cancer cells. +other hsa-mir-124 Rhinosinusitis 26413631 The results from this study may further reveal the relationship between miRNA expressions and inflammation. These results can also provide an important mechanism (primitive data) on the occurrence of chronic sinusitis and nasal polyps. +other hsa-mir-125b Rhinosinusitis 26413631 The results from this study may further reveal the relationship between miRNA expressions and inflammation. These results can also provide an important mechanism (primitive data) on the occurrence of chronic sinusitis and nasal polyps. +other hsa-mir-146a Rhinosinusitis 26413631 The results from this study may further reveal the relationship between miRNA expressions and inflammation. These results can also provide an important mechanism (primitive data) on the occurrence of chronic sinusitis and nasal polyps. +other hsa-mir-155 Rhinosinusitis 26413631 The results from this study may further reveal the relationship between miRNA expressions and inflammation. These results can also provide an important mechanism (primitive data) on the occurrence of chronic sinusitis and nasal polyps. +other hsa-mir-181b Rhinosinusitis 26413631 The results from this study may further reveal the relationship between miRNA expressions and inflammation. These results can also provide an important mechanism (primitive data) on the occurrence of chronic sinusitis and nasal polyps. +other hsa-mir-26b Rhinosinusitis 26413631 The results from this study may further reveal the relationship between miRNA expressions and inflammation. These results can also provide an important mechanism (primitive data) on the occurrence of chronic sinusitis and nasal polyps. +other hsa-mir-92a Rhinosinusitis 26413631 The results from this study may further reveal the relationship between miRNA expressions and inflammation. These results can also provide an important mechanism (primitive data) on the occurrence of chronic sinusitis and nasal polyps. +other hsa-let-7e "Carcinoma, Thyroid, Papillary" 26414548 Further studies are needed to investigate whether miRs are independent predictors of aggressive clinicopathologic features before it can be recommended that miR expression levels should be incorporated into the management algorithm for patients with PTC. A well-designed prospective study is needed to assess these potential associations. +other hsa-mir-21 Renal Fibrosis 26415649 "Collectively, these data present a unified model for a key role for miR-21 in the regulation of renal tubular extracellular matrix (ECM) synthesis and accumulation and provide important insights into the molecular pathways implicated in the progression of DN." +other hsa-let-7a Prostate Neoplasms 26415820 "In this review, we focus on the regulation of miRNAs in prostate cancer and their mechanisms which contribute to prostate carcinogenesis. The relation of miRNAs with androgen signaling is highlighted and the prospects of miRNAs for clinical therapies are discussed." +other hsa-mir-145 Prostate Neoplasms 26415820 "In this review, we focus on the regulation of miRNAs in prostate cancer and their mechanisms which contribute to prostate carcinogenesis. The relation of miRNAs with androgen signaling is highlighted and the prospects of miRNAs for clinical therapies are discussed." +other hsa-mir-18a Prostate Neoplasms 26415820 "In this review, we focus on the regulation of miRNAs in prostate cancer and their mechanisms which contribute to prostate carcinogenesis. The relation of miRNAs with androgen signaling is highlighted and the prospects of miRNAs for clinical therapies are discussed." +other hsa-mir-218 Prostate Neoplasms 26415820 "In this review, we focus on the regulation of miRNAs in prostate cancer and their mechanisms which contribute to prostate carcinogenesis. The relation of miRNAs with androgen signaling is highlighted and the prospects of miRNAs for clinical therapies are discussed." +other hsa-mir-23b Prostate Neoplasms 26415820 "In this review, we focus on the regulation of miRNAs in prostate cancer and their mechanisms which contribute to prostate carcinogenesis. The relation of miRNAs with androgen signaling is highlighted and the prospects of miRNAs for clinical therapies are discussed." +other hsa-mir-296 Prostate Neoplasms 26415820 "In this review, we focus on the regulation of miRNAs in prostate cancer and their mechanisms which contribute to prostate carcinogenesis. The relation of miRNAs with androgen signaling is highlighted and the prospects of miRNAs for clinical therapies are discussed." +other hsa-mir-429 Prostate Neoplasms 26415820 "In this review, we focus on the regulation of miRNAs in prostate cancer and their mechanisms which contribute to prostate carcinogenesis. The relation of miRNAs with androgen signaling is highlighted and the prospects of miRNAs for clinical therapies are discussed." +other hsa-mir-497 Prostate Neoplasms 26415820 "In this review, we focus on the regulation of miRNAs in prostate cancer and their mechanisms which contribute to prostate carcinogenesis. The relation of miRNAs with androgen signaling is highlighted and the prospects of miRNAs for clinical therapies are discussed." +other hsa-mir-134 Breast Neoplasms 26416415 miR-134 in extracellular vesicles reduces triple-negative breast cancer aggression and increases drug sensitivity. +other hsa-mir-200b "Adenocarcinoma, Lung" 26416454 These results provide new evidence for the mechanisms governing the microRNA (miRNA)-ATG12 network and their possible contribution to autophagy modulation and LAD chemoresistance. +other hsa-mir-574 Breast Neoplasms 26416693 Next generation sequencing profiling identifies miR-574-3p and miR-660-5p as potential novel prognostic markers for breast cancer. +other hsa-mir-660 Breast Neoplasms 26416693 Next generation sequencing profiling identifies miR-574-3p and miR-660-5p as potential novel prognostic markers for breast cancer. +other hsa-mir-4286 Pregnancy Complications [unspecific] 26418635 The findings highlight miRNAs in the human cervix as novel responders to maternal chemical exposure during pregnancy. +other hsa-mir-575 Pregnancy Complications [unspecific] 26418635 The findings highlight miRNAs in the human cervix as novel responders to maternal chemical exposure during pregnancy. +other hsa-let-7a Neoplasms [unspecific] 26420675 "Target-Catalyzed DNA Four-Way Junctions for CRET Imaging of MicroRNA,Concatenated Logic Operations, and Self-Assembly of DNA Nanohydrogels for Targeted Drug Delivery." +other hsa-mir-29a Hepatitis C Virus Infection 26429314 "This study showed that HCV infection might abrogate NK cytotoxic potential through altering PU.1, NKG2D receptor and perforin molecules." +other hsa-mir-222 Breast Neoplasms 26432333 exosomes transmit drug resistance through delivering miR-222. +other hsa-mir-155 Sepsis 26433115 A higher level of miR-155 indicated a more severe condition and poorer prognosis in sepsis patients. The possible underlying mechanism could be that miR-155 induces an increased percentage of CD39(+) Tregs and thus immunosuppression. +other hsa-mir-21 Glioblastoma 26433199 Dissociated microglia and monocytes/macrophages from tumor-bearing brains revealed increased levels of miR-21 and reduced levels of c-Myc mRNA. +other hsa-mir-21 Glioma 26433199 Dissociated microglia and monocytes/macrophages from tumor-bearing brains revealed increased levels of miR-21 and reduced levels of c-Myc mRNA. +other hsa-mir-204 Breast Neoplasms 26436206 Trichostatin A and Tamoxifen inhibit breast cancer cell growth by miR-204 and ER¦Á reducing AKT/mTOR pathway. +other hsa-mir-196b "Leukemia, Myeloid, Acute" 26436590 "The lincRNA HOTAIRM1, located in the HOXA genomic region, is expressed in acute myeloid leukemia, impacts prognosis in patients in the intermediate-risk cytogenetic category, and is associated with a distinctive microRNA signature." +other hsa-mir-25 Thyroid Neoplasms 26437444 "Together, our data suggest that IL-23 induces migration and invasion in thyroid cancer cells by mediating the miR-25/SOCS4 signaling pathway." +other hsa-mir-141 Neoplasms [unspecific] 26439017 Coupling hybridization chain reaction with catalytic hairpin assembly enables non-enzymatic and sensitive fluorescent detection of microRNA cancer biomarkers. +other hsa-mir-143 Breast Neoplasms 26439035 "UCA1 can directly interact with miR-143, lower its expression and affect its downstream regulation. Therefore, the UCA1-miR-143 axis constitutes a part of the oncogenic role of UCA1 in breast cancer." +other hsa-mir-23a Liver Neoplasms 26439986 we found expression of miR-23a was related to p53 functional status in the male-derived liver cell-lines +other hsa-mir-212 Prostate Neoplasms 26439987 "In conclusion, our study indicates a functional role of miR-212 in PCa and suggests the development of miR-212 based therapies." +other hsa-mir-16 "Colitis, Ulcerative" 26440311 "miR-16 suppression during the colitis-to-cancer sequence in colon epithelial cells, which was rescued by drinking Cl-amidine." +other hsa-mir-10b Pancreatic Neoplasms 26444644 "Our findings suggest that this unique technique can be used to design novel diagnostic strategies for pancreatic and other cancers based on the direct quantitative measurement of plasma and exosome microRNAs, and can be readily extended to other diseases with identifiable microRNA signatures." +other hsa-mir-210 Neoplasms [unspecific] 26446394 Potential Role of MicroRNA-210 as Biomarker in Human Cancers Detection: A Meta-Analysis. +other hsa-mir-130b Osteosarcoma 26446495 "Taken together, our data indicated that high miR-130b level and low level of miR-218 are associated with poor clinicopathological characteristics.Furthermore, miR-130b may play a key role in the progression of osteosarcoma." +other hsa-mir-218 Osteosarcoma 26446495 "Taken together, our data indicated that high miR-130b level and low level of miR-218 are associated with poor clinicopathological characteristics.Furthermore, miR-130b may play a key role in the progression of osteosarcoma." +other hsa-mir-125b Coronary Artery Disease 26446730 "We found several synergistic effects between miR-125b and classical risk factors, such as age,sex, CR, FBG and HDL-C; the proportion of CHD attributable to the interaction of miR-125b and age was as high as 80%. Therefore, miR-125b was shown to play an important role in individual's susceptibility to developing CHD." +other hsa-mir-26b Schizophrenia 26450699 "the notion that microRNAs fine-tune the amount of proteins acting in the same biological pathways in schizophrenia, giving further support to the emerging theory of competing endogenous RNAs." +other hsa-mir-335 Schizophrenia 26450699 "the notion that microRNAs fine-tune the amount of proteins acting in the same biological pathways in schizophrenia, giving further support to the emerging theory of competing endogenous RNAs." +other hsa-mir-221 Atherosclerosis 26451018 "Atherosclerotic plaque rupture is accompanied by a loss of miR-221 and miR-222 and an increase in p27Kip1 mRNA expression in the plaque shoulder,suggesting an association between these miRNAs and atherosclerotic plaque stability." +other hsa-mir-222 Atherosclerosis 26451018 "Atherosclerotic plaque rupture is accompanied by a loss of miR-221 and miR-222 and an increase in p27Kip1 mRNA expression in the plaque shoulder,suggesting an association between these miRNAs and atherosclerotic plaque stability." +other hsa-mir-106a Lung Neoplasms 26451608 These results encourage exploiting the MSC test for lung cancer monitoring in LDCT screening for lung cancer. +other hsa-mir-17 Lung Neoplasms 26451608 These results encourage exploiting the MSC test for lung cancer monitoring in LDCT screening for lung cancer. +other hsa-mir-197 Lung Neoplasms 26451608 These results encourage exploiting the MSC test for lung cancer monitoring in LDCT screening for lung cancer. +other hsa-mir-19b Lung Neoplasms 26451608 These results encourage exploiting the MSC test for lung cancer monitoring in LDCT screening for lung cancer. +other hsa-mir-486 Lung Neoplasms 26451608 These results encourage exploiting the MSC test for lung cancer monitoring in LDCT screening for lung cancer. +other hsa-mir-92a Lung Neoplasms 26451608 These results encourage exploiting the MSC test for lung cancer monitoring in LDCT screening for lung cancer. +other hsa-mir-506 "Carcinoma, Colon" 26452129 "Taking together, our study sheds light on the role of miR-506 as a suppressor for tumor growth and metastasis and raises the intriguing possibility that miR-506 may serve as a new potential marker for monitoring and treating colon cancer." +other hsa-mir-1254 "Squamous Cell Carcinoma, Head and Neck" 26452218 "Together, we demonstrate the feasibility of using a miRNA signature to predict the clinical responsiveness of HNSCC radiotherapy." +other hsa-mir-150 "Squamous Cell Carcinoma, Head and Neck" 26452218 "Together, we demonstrate the feasibility of using a miRNA signature to predict the clinical responsiveness of HNSCC radiotherapy." +other hsa-mir-16 "Squamous Cell Carcinoma, Head and Neck" 26452218 "Together, we demonstrate the feasibility of using a miRNA signature to predict the clinical responsiveness of HNSCC radiotherapy." +other hsa-mir-21 "Squamous Cell Carcinoma, Head and Neck" 26452218 "Together, we demonstrate the feasibility of using a miRNA signature to predict the clinical responsiveness of HNSCC radiotherapy." +other hsa-mir-210 "Squamous Cell Carcinoma, Head and Neck" 26452218 "Together, we demonstrate the feasibility of using a miRNA signature to predict the clinical responsiveness of HNSCC radiotherapy." +other hsa-mir-29 "Squamous Cell Carcinoma, Head and Neck" 26452218 "Together, we demonstrate the feasibility of using a miRNA signature to predict the clinical responsiveness of HNSCC radiotherapy." +other hsa-mir-373 "Squamous Cell Carcinoma, Head and Neck" 26452218 "Together, we demonstrate the feasibility of using a miRNA signature to predict the clinical responsiveness of HNSCC radiotherapy." +other hsa-mir-21 "Carcinoma, Lung, Non-Small-Cell" 26453197 Up-Regulation of miR-21 Expression Predicate Advanced Clinicopathological Features and Poor Prognosis in Patients with Non-Small Cell Lung Cancer. +other hsa-mir-221 Astrocytoma 26454049 Loss of miR-221 function and cytotoxicity induced by the miR-221 DOXO MB provides combined therapeutic efficacy against cancers. +other hsa-mir-106b Hepatitis B Virus Infection 26456479 Our results provide important information for developing novel diagnostic tools for distinguishing chronic HBV hepatitis and their corresponding cirrhosis. +other hsa-mir-106b Liver Cirrhosis 26456479 Our results provide important information for developing novel diagnostic tools for distinguishing chronic HBV hepatitis and their corresponding cirrhosis. +other hsa-mir-122 Hepatitis B Virus Infection 26456479 Our results provide important information for developing novel diagnostic tools for distinguishing chronic HBV hepatitis and their corresponding cirrhosis. +other hsa-mir-122 Liver Cirrhosis 26456479 Our results provide important information for developing novel diagnostic tools for distinguishing chronic HBV hepatitis and their corresponding cirrhosis. +other hsa-mir-181b Hepatitis B Virus Infection 26456479 Our results provide important information for developing novel diagnostic tools for distinguishing chronic HBV hepatitis and their corresponding cirrhosis. +other hsa-mir-181b Liver Cirrhosis 26456479 Our results provide important information for developing novel diagnostic tools for distinguishing chronic HBV hepatitis and their corresponding cirrhosis. +other hsa-mir-185 Hepatitis B Virus Infection 26456479 Our results provide important information for developing novel diagnostic tools for distinguishing chronic HBV hepatitis and their corresponding cirrhosis. +other hsa-mir-185 Liver Cirrhosis 26456479 Our results provide important information for developing novel diagnostic tools for distinguishing chronic HBV hepatitis and their corresponding cirrhosis. +other hsa-mir-18a Hepatitis B Virus Infection 26456479 Our results provide important information for developing novel diagnostic tools for distinguishing chronic HBV hepatitis and their corresponding cirrhosis. +other hsa-mir-18a Liver Cirrhosis 26456479 Our results provide important information for developing novel diagnostic tools for distinguishing chronic HBV hepatitis and their corresponding cirrhosis. +other hsa-mir-21 Hepatitis B Virus Infection 26456479 Our results provide important information for developing novel diagnostic tools for distinguishing chronic HBV hepatitis and their corresponding cirrhosis. +other hsa-mir-21 Liver Cirrhosis 26456479 Our results provide important information for developing novel diagnostic tools for distinguishing chronic HBV hepatitis and their corresponding cirrhosis. +other hsa-mir-29c Hepatitis B Virus Infection 26456479 Our results provide important information for developing novel diagnostic tools for distinguishing chronic HBV hepatitis and their corresponding cirrhosis. +other hsa-mir-29c Liver Cirrhosis 26456479 Our results provide important information for developing novel diagnostic tools for distinguishing chronic HBV hepatitis and their corresponding cirrhosis. +other hsa-mir-5193 Hepatitis B Virus Infection 26456535 "Therefore, miR-5193 might be useful and have a vital role for inhibition of HBV replication in the future." +other hsa-mir-101-2 Gastric Neoplasms 26458815 "Our expression analyses and in vitro functional assays suggest that miR-101-2, miR-125b-2 and miR-451a act as potential tumor suppressors in primary GCs as well as in GC-derived AGS cells." +other hsa-mir-125b-2 Gastric Neoplasms 26458815 "Our expression analyses and in vitro functional assays suggest that miR-101-2, miR-125b-2 and miR-451a act as potential tumor suppressors in primary GCs as well as in GC-derived AGS cells." +other hsa-mir-451a Gastric Neoplasms 26458815 "Our expression analyses and in vitro functional assays suggest that miR-101-2, miR-125b-2 and miR-451a act as potential tumor suppressors in primary GCs as well as in GC-derived AGS cells." +other hsa-mir-19b Coronary Artery Disease 26459935 Therefore our results indicate that miR-19b plays a key role in the attenuation of TNF-¦Á-induced endothelial cell apoptosis and that this function is closely linked to the Apaf1/caspase-dependent pathway. +other hsa-mir-650 Influenza 26460926 Together these findings reveal a novel link between miR-650 and the innate immune response in human MDDCs. +other hsa-mir-214 "Adenocarcinoma, Lung" 26462018 "Collectively, this study uncovers a previously unappreciated miR-214-Sufu pathway in controlling EMT and metastasis of LAD and suggests that interfering with miR-214 and Sufu could be a viable approach to treat late stage metastatic LAD patients." +other hsa-mir-9 "Leukemia, Myeloid, Acute" 26464168 Expression of a passenger miR-9* predicts favorable outcome in adults with acute myeloid leukemia less than 60 years of age. +other hsa-mir-184 Glioma 26464691 Inhibitory effect of miR-184 on the potential of proliferation and invasion in human glioma and breast cancer cells in vitro. +other hsa-mir-155 Lung Neoplasms 26467212 The candidate oncogene (MCRS1) promotes the growth of human lung cancer cells via the miR-155-Rb1 pathway. +other hsa-mir-1290 Human Immunodeficiency Virus Infection 26469550 "Our study emphasizes the role of cellular miRNAs in HIV-1 latency regulation, and it suggests that inhibitors of miR-196b and miR-1290 could be used to activate latent HIV-1." +other hsa-mir-196b Human Immunodeficiency Virus Infection 26469550 "Our study emphasizes the role of cellular miRNAs in HIV-1 latency regulation, and it suggests that inhibitors of miR-196b and miR-1290 could be used to activate latent HIV-1." +other hsa-mir-21 Glioma 26473373 These results suggest that miR-21 is associated with regulation of the migratory ability and survival in human glioma cells. These findings suggest novel mechanisms of malignancy and new potential combinatorial strategies for the management of malignant glioma. +other hsa-mir-27b Neoplasms [unspecific] 26473412 These findings show that miR-27b functions as a tumor suppressor by controlling ARFGEF1 and the paxillin/c-Src circuit at focal adhesions. +other hsa-mir-21 Human Immunodeficiency Virus Infection 26473639 "These data reveal specific regulation of plasma miR-21 in HIV,HIV/HCV coinfection, and PAH and suggest that miR-21 may integrate complex disease-specific signaling in the setting of HIV infection." +other hsa-mir-17 Neoplasms [unspecific] 26479035 "Our findings signify the dynamic and reciprocal cross-talk between tumour cells and the metastatic niche; importantly, they provide new opportunities for effective anti-metastasis therapies, especially of consequence for brain metastasis patients" +other hsa-mir-18 Neoplasms [unspecific] 26479035 "Our findings signify the dynamic and reciprocal cross-talk between tumour cells and the metastatic niche; importantly, they provide new opportunities for effective anti-metastasis therapies, especially of consequence for brain metastasis patients" +other hsa-mir-19a Neoplasms [unspecific] 26479035 "Our findings signify the dynamic and reciprocal cross-talk between tumour cells and the metastatic niche; importantly, they provide new opportunities for effective anti-metastasis therapies, especially of consequence for brain metastasis patients" +other hsa-mir-19b Neoplasms [unspecific] 26479035 "Our findings signify the dynamic and reciprocal cross-talk between tumour cells and the metastatic niche; importantly, they provide new opportunities for effective anti-metastasis therapies, especially of consequence for brain metastasis patients" +other hsa-mir-19b-1 Neoplasms [unspecific] 26479035 "Our findings signify the dynamic and reciprocal cross-talk between tumour cells and the metastatic niche; importantly, they provide new opportunities for effective anti-metastasis therapies, especially of consequence for brain metastasis patients" +other hsa-mir-20a Neoplasms [unspecific] 26479035 "Our findings signify the dynamic and reciprocal cross-talk between tumour cells and the metastatic niche; importantly, they provide new opportunities for effective anti-metastasis therapies, especially of consequence for brain metastasis patients" +other hsa-mir-92 Neoplasms [unspecific] 26479035 "Our findings signify the dynamic and reciprocal cross-talk between tumour cells and the metastatic niche; importantly, they provide new opportunities for effective anti-metastasis therapies, especially of consequence for brain metastasis patients" +other hsa-mir-92-1 Neoplasms [unspecific] 26479035 "Our findings signify the dynamic and reciprocal cross-talk between tumour cells and the metastatic niche; importantly, they provide new opportunities for effective anti-metastasis therapies, especially of consequence for brain metastasis patients" +other hsa-mir-125b-1 Neuroblastoma 26480000 "Identification of linc-NeD125, a novel long non coding RNA that hosts miR-125b-1 and negatively controls proliferation of human neuroblastoma cells." +other hsa-mir-21 "Carcinoma, Esophageal" 26481465 "In this study, miR-21 was identified as an independent prognostic biomarker for DSS in patients with EAC whereas miR-21 failed to show independent prognostic significance in ESCC. High miR-375 was not associated with enhanced survival in either histology." +other hsa-mir-375 "Carcinoma, Esophageal" 26481465 "In this study, miR-21 was identified as an independent prognostic biomarker for DSS in patients with EAC whereas miR-21 failed to show independent prognostic significance in ESCC. High miR-375 was not associated with enhanced survival in either histology." +other hsa-mir-1236 Kidney Neoplasms 26481573 Kidney cancer: RNA activation in RCC: p21 and miR-1236 are a promising pair. +other hsa-mir-17 "Carcinoma, Lung, Non-Small-Cell" 26482648 Our study indicates that miR-17 and miR-92 families play important roles in cisplatin resistance and can be used as potential biomarkers for better predicting the clinical response to platinum-based chemotherapy in NSCLC. +other hsa-mir-92a "Carcinoma, Lung, Non-Small-Cell" 26482648 Our study indicates that miR-17 and miR-92 families play important roles in cisplatin resistance and can be used as potential biomarkers for better predicting the clinical response to platinum-based chemotherapy in NSCLC. +other hsa-mir-22 Emphysema 26482970 MicroRNA miR-22 drives T(H)17 responses in emphysema. +other hsa-mir-486 Coronary Artery Disease 26485305 MiR-486 and miR-92a Identified in Circulating HDL Discriminate between Stable and Vulnerable Coronary Artery Disease Patients. +other hsa-mir-92a Coronary Artery Disease 26485305 MiR-486 and miR-92a Identified in Circulating HDL Discriminate between Stable and Vulnerable Coronary Artery Disease Patients. +other hsa-mir-497 "Carcinoma, Lung, Non-Small-Cell" 26485685 "Together, our data demonstrate a previously unappreciated role for miR-497 in suppression of VEGF-A-mediated NSCLC cancer cell growth and invasion." +other hsa-mir-21 Breast Neoplasms 26486006 Advances in Research on miR-21 and Breast Cancer. +other hsa-mir-146a Leukemia 26487345 Transcription factor and miRNA co-regulatory network reveals shared and specific regulators in the development of B cell and T cell. +other hsa-mir-20 Leukemia 26487345 Transcription factor and miRNA co-regulatory network reveals shared and specific regulators in the development of B cell and T cell. +other hsa-mir-122 Kidney Injury 26489516 "In mice,miR-122-5p, miR-151a-3p and miR-382-5p specifically reported APAP toxicity -being unaffected by drug-induced kidney injury. Profiling of acetaminophen toxicity identified multiple miRNAs that report acute liver injury and potential biomarkers of drug-induced kidney injury." +other hsa-mir-122 Liver Injury 26489516 "In mice,miR-122-5p, miR-151a-3p and miR-382-5p specifically reported APAP toxicity -being unaffected by drug-induced kidney injury. Profiling of acetaminophen toxicity identified multiple miRNAs that report acute liver injury and potential biomarkers of drug-induced kidney injury." +other hsa-mir-151a Kidney Injury 26489516 "In mice,miR-122-5p, miR-151a-3p and miR-382-5p specifically reported APAP toxicity -being unaffected by drug-induced kidney injury. Profiling of acetaminophen toxicity identified multiple miRNAs that report acute liver injury and potential biomarkers of drug-induced kidney injury." +other hsa-mir-151a Liver Injury 26489516 "In mice,miR-122-5p, miR-151a-3p and miR-382-5p specifically reported APAP toxicity -being unaffected by drug-induced kidney injury. Profiling of acetaminophen toxicity identified multiple miRNAs that report acute liver injury and potential biomarkers of drug-induced kidney injury." +other hsa-mir-382 Kidney Injury 26489516 "In mice,miR-122-5p, miR-151a-3p and miR-382-5p specifically reported APAP toxicity -being unaffected by drug-induced kidney injury. Profiling of acetaminophen toxicity identified multiple miRNAs that report acute liver injury and potential biomarkers of drug-induced kidney injury." +other hsa-mir-382 Liver Injury 26489516 "In mice,miR-122-5p, miR-151a-3p and miR-382-5p specifically reported APAP toxicity -being unaffected by drug-induced kidney injury. Profiling of acetaminophen toxicity identified multiple miRNAs that report acute liver injury and potential biomarkers of drug-induced kidney injury." +other hsa-mir-122 Coronary Artery Disease 26490079 MicroRNA Biomarkers for Coronary Artery Disease +other hsa-mir-96 Congenital Deafness 26490746 "Cx26-mediated intercellular communication is required for cochlear development and that deficiency of Cx26 can impair miRNA-mediated intercellular genetic communication in the cochlea, which may lead to cochlear developmental disorders and eventually congenital deafness as previously reported." +other hsa-mir-26a Colorectal Carcinoma 26494299 microRNA-26a and -584 inhibit the colorectal cancer progression through inhibition of the binding of hnRNP A1-CDK6 mRNA. +other hsa-mir-584 Colorectal Carcinoma 26494299 microRNA-26a and -584 inhibit the colorectal cancer progression through inhibition of the binding of hnRNP A1-CDK6 mRNA. +other hsa-mir-130a "Leukemia, Myeloid, Chronic" 26494558 Functional studies of miR-130a on the inhibitory pathways of apoptosis in patients with chronic myeloid leukemia. +other hsa-let-7d Peritoneal Dialysis Failure 26495316 microRNA regulation of peritoneal cavity homeostasis in peritoneal dialysis. +other hsa-mir-100 Peritoneal Dialysis Failure 26495316 microRNA regulation of peritoneal cavity homeostasis in peritoneal dialysis. +other hsa-mir-107 Peritoneal Dialysis Failure 26495316 microRNA regulation of peritoneal cavity homeostasis in peritoneal dialysis. +other hsa-mir-129 Peritoneal Dialysis Failure 26495316 microRNA regulation of peritoneal cavity homeostasis in peritoneal dialysis. +other hsa-mir-132 Peritoneal Dialysis Failure 26495316 microRNA regulation of peritoneal cavity homeostasis in peritoneal dialysis. +other hsa-mir-136 Peritoneal Dialysis Failure 26495316 microRNA regulation of peritoneal cavity homeostasis in peritoneal dialysis. +other hsa-mir-146b Peritoneal Dialysis Failure 26495316 microRNA regulation of peritoneal cavity homeostasis in peritoneal dialysis. +other hsa-mir-148a Peritoneal Dialysis Failure 26495316 microRNA regulation of peritoneal cavity homeostasis in peritoneal dialysis. +other hsa-mir-152 Peritoneal Dialysis Failure 26495316 microRNA regulation of peritoneal cavity homeostasis in peritoneal dialysis. +other hsa-mir-15a Peritoneal Dialysis Failure 26495316 microRNA regulation of peritoneal cavity homeostasis in peritoneal dialysis. +other hsa-mir-15b Peritoneal Dialysis Failure 26495316 microRNA regulation of peritoneal cavity homeostasis in peritoneal dialysis. +other hsa-mir-160 Peritoneal Dialysis Failure 26495316 microRNA regulation of peritoneal cavity homeostasis in peritoneal dialysis. +other hsa-mir-192 Peritoneal Dialysis Failure 26495316 microRNA regulation of peritoneal cavity homeostasis in peritoneal dialysis. +other hsa-mir-193a Peritoneal Dialysis Failure 26495316 microRNA regulation of peritoneal cavity homeostasis in peritoneal dialysis. +other hsa-mir-193b Peritoneal Dialysis Failure 26495316 microRNA regulation of peritoneal cavity homeostasis in peritoneal dialysis. +other hsa-mir-194 Peritoneal Dialysis Failure 26495316 microRNA regulation of peritoneal cavity homeostasis in peritoneal dialysis. +other hsa-mir-200a Peritoneal Dialysis Failure 26495316 microRNA regulation of peritoneal cavity homeostasis in peritoneal dialysis. +other hsa-mir-200b Peritoneal Dialysis Failure 26495316 microRNA regulation of peritoneal cavity homeostasis in peritoneal dialysis. +other hsa-mir-203 Peritoneal Dialysis Failure 26495316 microRNA regulation of peritoneal cavity homeostasis in peritoneal dialysis. +other hsa-mir-205 Peritoneal Dialysis Failure 26495316 microRNA regulation of peritoneal cavity homeostasis in peritoneal dialysis. +other hsa-mir-26b Peritoneal Dialysis Failure 26495316 microRNA regulation of peritoneal cavity homeostasis in peritoneal dialysis. +other hsa-mir-29b Peritoneal Dialysis Failure 26495316 microRNA regulation of peritoneal cavity homeostasis in peritoneal dialysis. +other hsa-mir-30a Peritoneal Dialysis Failure 26495316 microRNA regulation of peritoneal cavity homeostasis in peritoneal dialysis. +other hsa-mir-30b Peritoneal Dialysis Failure 26495316 microRNA regulation of peritoneal cavity homeostasis in peritoneal dialysis. +other hsa-mir-31 Peritoneal Dialysis Failure 26495316 microRNA regulation of peritoneal cavity homeostasis in peritoneal dialysis. +other hsa-mir-335 Peritoneal Dialysis Failure 26495316 microRNA regulation of peritoneal cavity homeostasis in peritoneal dialysis. +other hsa-mir-497 Peritoneal Dialysis Failure 26495316 microRNA regulation of peritoneal cavity homeostasis in peritoneal dialysis. +other hsa-mir-664 Peritoneal Dialysis Failure 26495316 microRNA regulation of peritoneal cavity homeostasis in peritoneal dialysis. +other hsa-mir-703 Peritoneal Dialysis Failure 26495316 microRNA regulation of peritoneal cavity homeostasis in peritoneal dialysis. +other hsa-mir-709 Peritoneal Dialysis Failure 26495316 microRNA regulation of peritoneal cavity homeostasis in peritoneal dialysis. +other hsa-mir-801 Peritoneal Dialysis Failure 26495316 microRNA regulation of peritoneal cavity homeostasis in peritoneal dialysis. +other hsa-mir-923 Peritoneal Dialysis Failure 26495316 microRNA regulation of peritoneal cavity homeostasis in peritoneal dialysis. +other hsa-mir-93 Peritoneal Dialysis Failure 26495316 microRNA regulation of peritoneal cavity homeostasis in peritoneal dialysis. +other hsa-mir-125a Multiple Myeloma 26496024 "Members of the miR-99b/let-7e/miR-125a cluster, or of its paralog, upregulated in t(4;14), were connected with the specific transcription factors PBX1 and CEBPA and several target genes." +other hsa-mir-378 Colorectal Carcinoma 26496897 Lauric acid can improve the sensitization of Cetuximab in KRAS/BRAF mutated colorectal cancer cells by retrievable microRNA-378 expression. +other hsa-mir-1 Breast Neoplasms 26497855 MicroRNA-1 down-regulates proliferation and migration of breast cancer stem cells by inhibiting the Wnt/¦Â-catenin pathway. +other hsa-mir-135a Pain 26498117 "These results show that circulating miRNA predict persistent severe axial pain after MVC and suggest that they may be involved in the pathogenesis of post-traumatic musculoskeletal pain. However, further studies are needed to determine if these miRNA play a direct causal role." +other hsa-mir-3613 Pain 26498117 "These results show that circulating miRNA predict persistent severe axial pain after MVC and suggest that they may be involved in the pathogenesis of post-traumatic musculoskeletal pain. However, further studies are needed to determine if these miRNA play a direct causal role." +other hsa-mir-33a Influenza 26498766 "In conclusion, we found that miR-33a is a novel inhibitory factor for influenza A virus replication." +other hsa-mir-21 Neoplasms [unspecific] 26503645 "Therefore,this study presents an improved method with shorten time to prepare a (99m)Tc radiolabeled AMO. In addition, it supports the role of (99m)Tc-AMO for noninvasive visualization of miR-21 in malignant tumors." +other hsa-mir-122 Chronic Hepatitis C 26503793 We demonstrated a substantial and prolonged decrease in plasma miR-122 levels in patients dosed with miravirsen. Plasma levels of other miRNAs were not significantly affected by antagonising miR-122. +other hsa-mir-146a Sjogren Syndrome 26505653 Dysregulated co-stimulatory molecule expression in a Sj?gren's syndrome mouse model with potential implications by microRNA-146a. +other hsa-let-7d Epilepsy 26506013 This review highlights the immunological features underlying the pathogenesis of epileptic seizures and the possible miRNA mediated approaches for drug resistant epilepsies that modulate the immune-mediated pathogenesis. +other hsa-mir-106b Epilepsy 26506013 This review highlights the immunological features underlying the pathogenesis of epileptic seizures and the possible miRNA mediated approaches for drug resistant epilepsies that modulate the immune-mediated pathogenesis. +other hsa-mir-130a Epilepsy 26506013 This review highlights the immunological features underlying the pathogenesis of epileptic seizures and the possible miRNA mediated approaches for drug resistant epilepsies that modulate the immune-mediated pathogenesis. +other hsa-mir-146a Epilepsy 26506013 This review highlights the immunological features underlying the pathogenesis of epileptic seizures and the possible miRNA mediated approaches for drug resistant epilepsies that modulate the immune-mediated pathogenesis. +other hsa-mir-155 Epilepsy 26506013 This review highlights the immunological features underlying the pathogenesis of epileptic seizures and the possible miRNA mediated approaches for drug resistant epilepsies that modulate the immune-mediated pathogenesis. +other hsa-mir-15a Epilepsy 26506013 This review highlights the immunological features underlying the pathogenesis of epileptic seizures and the possible miRNA mediated approaches for drug resistant epilepsies that modulate the immune-mediated pathogenesis. +other hsa-mir-194 Epilepsy 26506013 This review highlights the immunological features underlying the pathogenesis of epileptic seizures and the possible miRNA mediated approaches for drug resistant epilepsies that modulate the immune-mediated pathogenesis. +other hsa-mir-221 Epilepsy 26506013 This review highlights the immunological features underlying the pathogenesis of epileptic seizures and the possible miRNA mediated approaches for drug resistant epilepsies that modulate the immune-mediated pathogenesis. +other hsa-mir-222 Epilepsy 26506013 This review highlights the immunological features underlying the pathogenesis of epileptic seizures and the possible miRNA mediated approaches for drug resistant epilepsies that modulate the immune-mediated pathogenesis. +other hsa-mir-223 Epilepsy 26506013 This review highlights the immunological features underlying the pathogenesis of epileptic seizures and the possible miRNA mediated approaches for drug resistant epilepsies that modulate the immune-mediated pathogenesis. +other hsa-mir-301a Epilepsy 26506013 This review highlights the immunological features underlying the pathogenesis of epileptic seizures and the possible miRNA mediated approaches for drug resistant epilepsies that modulate the immune-mediated pathogenesis. +other hsa-mir-30b Epilepsy 26506013 This review highlights the immunological features underlying the pathogenesis of epileptic seizures and the possible miRNA mediated approaches for drug resistant epilepsies that modulate the immune-mediated pathogenesis. +other hsa-mir-342 Epilepsy 26506013 This review highlights the immunological features underlying the pathogenesis of epileptic seizures and the possible miRNA mediated approaches for drug resistant epilepsies that modulate the immune-mediated pathogenesis. +other hsa-mir-4446 Epilepsy 26506013 This review highlights the immunological features underlying the pathogenesis of epileptic seizures and the possible miRNA mediated approaches for drug resistant epilepsies that modulate the immune-mediated pathogenesis. +other hsa-mir-33a Breast Neoplasms 26507842 These findings identified miR-33a as a negative regulator of breast cancer cell proliferation and metastasis. +other hsa-mir-34a Cardiomegaly 26508703 Neonatal HHR had higher cardiac telomerase activity and expression of Tert and miR-34a. +other hsa-mir-223 Disease of Metabolism 26512640 "the roles of miR-223 during the processes of osteoclast and osteoblast differentiation, as well as the potential clinical applications of miR-223 in bone metabolism disorders." +other hsa-mir-3619 "Carcinoma, Lung, Non-Small-Cell" 26512718 "Our data demonstrate a previously unappreciated role for miR-3619-5p,in suppression of ¦Â-catenin-mediated cancer growth and invasion in NSCLC cells,and highlight miR-3619-5p as a novel cancer suppressor in NSCLC." +other hsa-mir-22 Breast Neoplasms 26512777 These results provide mechanistic insight into TIP60 regulation and evidence for the utility of the combination of TIP60 and miR-22 as prognostic indicator of breast cancer progression. +other hsa-mir-371a Cardiomyopathy 26512958 "In conclusion, the presence of a g2252c polymorphism in the BAG3 3'-UTR determines loss of miR-371a-5p binding and results in an altered response to epi, potentially representing a new molecular mechanism that contributes to TTC pathogenesis." +other hsa-mir-429 "Carcinoma, Gastric" 26513239 Our data suggest that miR-429 suppression in GC promotes Bcl-2-mediated cancer cell survival against chemotherapy-induced cell death.Re-expression of miR-429 levels in GC cells may enhance cancer apoptosis during chemotherapy. +other hsa-mir-122 "Carcinoma, Hepatocellular" 26514126 The findings suggest that the export of miR-122 via AMSC exosomes represents a novel strategy to enhance HCC chemosensitivity. +other hsa-mir-24 "Carcinoma, Pancreatic" 26517093 The miR-24-Bim pathway promotes tumor growth and angiogenesis in pancreatic carcinoma. +other hsa-mir-155 "Lymphoma, Large B-Cell, Diffuse" 26523117 "In particular, it has been strongly implicated in the causation of diffuse large B-cell lymphomas." +other hsa-mir-185 Atherosclerosis 26523989 "These findings reveal that miR-185 controls cholesterol homeostasis as a key posttranscriptional LDLR modulator in hepatic cells, providing novel insight into the regulatory mechanism for LDLR expression and the anti-atherosclerosis effect of miR-185-inhibitor." +other hsa-mir-21 Lung Neoplasms 26525579 "These results, demonstrating the function of exosomal miR-21 from transformed HBE cells, provide a new perspective for intervention strategies to prevent carcinogenesis of lung cancer." +other hsa-mir-200 "Carcinoma, Skin" 26527515 only a functionally coherent group consisting of the miR-200 family members and miR-205-5p displays a pattern of progressive co-downregulation from the early toward the most aggressive stages of carcinogenesis. +other hsa-mir-124 Glioma 26530859 "In conclusion,miR-124 was found to suppress the migration and invasion of glioma cells in vitro via Capn4." +other hsa-mir-4697 Gastric Neoplasms 26531872 "The expression of TM4SF5, CTD-2354A18.1 and miR-4697-3P is in balance at physiological conditions, however, the balance is disrupted by some situations, which may contribute to gastric cancer. GO analysis and Pathway analysis also showed TM4SF5 played an important role in proliferation,differentiation and apoptosis. Therefore, TM4SF5-miR-4697-3P- CTD-2354A18.1 may play a key role in the pathogenesis of gastric cancer (Tab. 2, Fig. 4, Ref. 30)." +other hsa-mir-210 Melanoma 26536104 "methyl sulfone decreased expression of the master regulator of hypoxia, HIF-1α, and reduced levels of the glycolytic enzymes, PKM2, LDHA, GLUT1, the pro-angiogenic protein, VEGF, and the iron-sulfur metabolism molecules, miR-210 and transferrin, all of which promote metastasis." +other hsa-mir-122 Hepatitis B Virus Infection 26541590 Mopping up miRNA: An integrated HBV transcript disrupts liver homeostasis by sequestering miR-122. +other hsa-mir-10b "Squamous Cell Carcinoma, Oral" 26544609 "Results from both patient groups together stress the importance of miR196a-5p in OSCC malignancy in both never and ever smokers, and emphasize the overall similarity of miRNA expression in OSCCs in these two risk groups. It implies that there may be great similarity in etiology of OSCC in never and ever smokers and that classifying OSCC based on tobacco exposure may not be helpful in the clinic." +other hsa-mir-196a "Squamous Cell Carcinoma, Oral" 26544609 "Results from both patient groups together stress the importance of miR196a-5p in OSCC malignancy in both never and ever smokers, and emphasize the overall similarity of miRNA expression in OSCCs in these two risk groups. It implies that there may be great similarity in etiology of OSCC in never and ever smokers and that classifying OSCC based on tobacco exposure may not be helpful in the clinic." +other hsa-mir-31 "Squamous Cell Carcinoma, Oral" 26544609 "Results from both patient groups together stress the importance of miR196a-5p in OSCC malignancy in both never and ever smokers, and emphasize the overall similarity of miRNA expression in OSCCs in these two risk groups. It implies that there may be great similarity in etiology of OSCC in never and ever smokers and that classifying OSCC based on tobacco exposure may not be helpful in the clinic." +other hsa-mir-125b Prostate Neoplasms 26544868 "Thus, the dual action of hsa-miR-125b as a tumor suppressor and hsa-miR-22 as an oncomiR contributed to prostate tumorigenesis by modulations in PI3K/AKT and MAPK/ERK signaling pathways, key pathways known to influence prostate cancer progression." +other hsa-mir-17 Neoplasms [unspecific] 26545119 "In summary, our data demonstrate that vFLIP and vCyclin induce the oncogenic miR-17-92 cluster in endothelial cells and thereby interfere with the TGF-¦Â signaling pathway. Manipulation of the TGF-¦Â pathway via host miRNAs represents a novel mechanism that may be important for KSHV tumorigenesis and angiogenesis, a hallmark of KS." +other hsa-mir-18 Neoplasms [unspecific] 26545119 "In summary, our data demonstrate that vFLIP and vCyclin induce the oncogenic miR-17-92 cluster in endothelial cells and thereby interfere with the TGF-¦Â signaling pathway. Manipulation of the TGF-¦Â pathway via host miRNAs represents a novel mechanism that may be important for KSHV tumorigenesis and angiogenesis, a hallmark of KS." +other hsa-mir-19a Neoplasms [unspecific] 26545119 "In summary, our data demonstrate that vFLIP and vCyclin induce the oncogenic miR-17-92 cluster in endothelial cells and thereby interfere with the TGF-¦Â signaling pathway. Manipulation of the TGF-¦Â pathway via host miRNAs represents a novel mechanism that may be important for KSHV tumorigenesis and angiogenesis, a hallmark of KS." +other hsa-mir-19b-1 Neoplasms [unspecific] 26545119 "In summary, our data demonstrate that vFLIP and vCyclin induce the oncogenic miR-17-92 cluster in endothelial cells and thereby interfere with the TGF-¦Â signaling pathway. Manipulation of the TGF-¦Â pathway via host miRNAs represents a novel mechanism that may be important for KSHV tumorigenesis and angiogenesis, a hallmark of KS." +other hsa-mir-20a Neoplasms [unspecific] 26545119 "In summary, our data demonstrate that vFLIP and vCyclin induce the oncogenic miR-17-92 cluster in endothelial cells and thereby interfere with the TGF-¦Â signaling pathway. Manipulation of the TGF-¦Â pathway via host miRNAs represents a novel mechanism that may be important for KSHV tumorigenesis and angiogenesis, a hallmark of KS." +other hsa-mir-92-1 Neoplasms [unspecific] 26545119 "In summary, our data demonstrate that vFLIP and vCyclin induce the oncogenic miR-17-92 cluster in endothelial cells and thereby interfere with the TGF-¦Â signaling pathway. Manipulation of the TGF-¦Â pathway via host miRNAs represents a novel mechanism that may be important for KSHV tumorigenesis and angiogenesis, a hallmark of KS." +other hsa-mir-155 Down Syndrome 26546125 "The lentiviral miRNA-sponge strategy demonstrated the genome-wide regulatory effects of miR-155 and miR-802. Furthermore, the analysis combining predicted candidates and experimental transcriptomic data proved to retrieve genes with potential significance in DS-hippocampal phenotype bridging with DS other neurological-associated diseases such as Alzheimer's disease." +other hsa-mir-802 Down Syndrome 26546125 "The lentiviral miRNA-sponge strategy demonstrated the genome-wide regulatory effects of miR-155 and miR-802. Furthermore, the analysis combining predicted candidates and experimental transcriptomic data proved to retrieve genes with potential significance in DS-hippocampal phenotype bridging with DS other neurological-associated diseases such as Alzheimer's disease." +other hsa-mir-200 Neoplasms [unspecific] 26547426 "On the basis of these findings,we believe that this method has great potential for quantitative detection of miRNA in biomedical research and early clinical diagnostics." +other hsa-mir-155 "Leukemia, Myelogenous, Chronic, BCR-ABL Positive" 26548770 Analysis of microRNA and gene networks in human chronic myelogenous leukemia. +other hsa-mir-146a Neoplasms [unspecific] 26549232 Together our results uncover miRNAs as yet another negative mechanism controlling Merlin tumor suppressor functions. +other hsa-mir-223 Prostate Neoplasms 26552919 "For the first time, we disclose that celastrol could induce miR-223 in breast and prostate cancer cells, and that inhibiting miR-223 could further reduce the living cells in celastrol-treated cancer cell lines. We thus provide a novel way to increase celastrol's anti-cancer effects." +other hsa-mir-218 Lung Neoplasms 26553452 Our findings revealed an integrative tumor suppressor function of miR-218 in lung carcinogenesis and metastasis. +other hsa-mir-340 Melanoma 26554847 "This is the first study showing the relationship between miR-340-5p and expression of ABCB5, a transmembrane transporter involved in drug resistance considered as a marker of melanoma stem-like cells." +other hsa-mir-7 "Carcinoma, Lung, Non-Small-Cell" 26557760 We found that miR-7 significantly decreased the IC50 of gefitinib and inhibited cell growth +other hsa-mir-34 Cardiovascular Diseases [unspecific] 26559089 MicroRNA-34 Family and Its Role in Cardiovascular Disease. +other hsa-mir-146a Psoriasis 26559308 "It is found that genetic polymorphisms related to some of specific miRNAs, miR-146a for example, are associated with psoriasis susceptibility." +other hsa-mir-21 Glioblastoma 26559642 Nanoparticle-Delivered Antisense MicroRNA-21 Enhances the Effects of Temozolomide on Glioblastoma Cells. +other hsa-mir-214 Multiple Sclerosis 26563334 "Our data suggest that miR-27a may probably inhibit negative regulators of Th17 cell differentiation, thus promoting its differentiation while miR-214 has an adverse effect." +other hsa-mir-27a Multiple Sclerosis 26563334 "Our data suggest that miR-27a may probably inhibit negative regulators of Th17 cell differentiation, thus promoting its differentiation while miR-214 has an adverse effect." +other hsa-mir-377 Myocardial Infarction 26564601 "The present study is timely because the field is eagerly awaiting the results of the large phase III BAMI (Bone Marrow-Derived Mononuclear Cells on All-Cause Mortality in Myocardial Infarction; NCT01569178) clinical trial. If this clinical trial turns out positively, approaches such as the one developed by Joladarashi et al. will have additional relevance to the field." +other hsa-mir-130 Pulmonary Hypertension 26565914 Matrix Remodeling Promotes Pulmonary Hypertension through Feedback Mechanoactivation of the YAP/TAZ-miR-130/301 Circuit. +other hsa-mir-301 Pulmonary Hypertension 26565914 Matrix Remodeling Promotes Pulmonary Hypertension through Feedback Mechanoactivation of the YAP/TAZ-miR-130/301 Circuit. +other hsa-mir-124 Atrial Fibrillation 26567235 "In conclusion, the microRNA regulatory network sheds new light on the molecular mechanism of AF with this non-coding regulated model." +other hsa-mir-183 Atrial Fibrillation 26567235 "In conclusion, the microRNA regulatory network sheds new light on the molecular mechanism of AF with this non-coding regulated model." +other hsa-mir-192 Atrial Fibrillation 26567235 "In conclusion, the microRNA regulatory network sheds new light on the molecular mechanism of AF with this non-coding regulated model." +other hsa-mir-215 Atrial Fibrillation 26567235 "In conclusion, the microRNA regulatory network sheds new light on the molecular mechanism of AF with this non-coding regulated model." +other hsa-mir-26b Atrial Fibrillation 26567235 "In conclusion, the microRNA regulatory network sheds new light on the molecular mechanism of AF with this non-coding regulated model." +other hsa-mir-355p Atrial Fibrillation 26567235 "In conclusion, the microRNA regulatory network sheds new light on the molecular mechanism of AF with this non-coding regulated model." +other hsa-mir-21 "Carcinoma, Nasopharyngeal" 26568302 LMP1 greatly increased expression of miR-21 and downregulated expression of the miR-21 target +other hsa-mir-218 Glioma 26572167 MiR-218-5p inhibits the stem cell properties and invasive ability of the A2B5+CD133- subgroup of human glioma stem cells. +other hsa-mir-21 "Carcinoma, Renal Cell, Clear-Cell" 26572589 "Thus, a single miRNA may have an impact on the formation of highly tumorigenic cancer spheres in kidney cancer." +other hsa-mir-148b Kidney Neoplasms 26573018 The present study therefore suggested that miR-148b exerts an oncogenic function by enhancing the proliferation and apoptosis of renal cancer cells by inhibiting the MAPK/JNK pathway. +other hsa-mir-122 Liver Diseases [unspecific] 26574140 "miR-122 increased with moderate ethanol consumption, but the fold change was modest. As increases with acetaminophen toxicity are 100- to 10000-fold, moderate ethanol intoxication is unlikely to confound the use of this biomarker of hepatotoxicity." +other hsa-mir-122 Schizophrenia 26575446 Circulating miRNA biomarkers for schizophrenia +other hsa-mir-130 Schizophrenia 26575446 Circulating miRNA biomarkers for schizophrenia +other hsa-mir-652 Schizophrenia 26575446 Circulating miRNA biomarkers for schizophrenia +other hsa-mir-145 Prostate Neoplasms 26582710 Re: A Feedback Regulation between miR-145 and DNA Methyltransferase 3b in Prostate Cancer Cell and Their Responses to Irradiation. +other hsa-mir-34a Vascular Disease [unspecific] 26582729 overexpression of a miR-34a mimic prevents metformin-mediated protection. +other hsa-mir-494 Atherosclerosis 26583674 Treatment with GSO-494 results in smaller atherosclerotic lesions with increased plaque stability. Inhibition of miR-494 may decrease the risk of surgical complications or even avert endarterectomy surgery in some cases. +other hsa-mir-122 Hepatitis C Virus Infection 26587035 characteristics of the miR-122 and Let-7 families further highlight the suitability of tree shrew as the animal model in HCV research. +other hsa-let-7 Ischemic Heart Disease 26588727 Computational Model of MicroRNA Control of HIF-VEGF Pathway: Insights into the Pathophysiology of Ischemic Vascular Disease and Cancer. +other hsa-mir-17 Perlman Syndrome 26598317 "Our findings not only provide a novel insight into the molecular mechanisms of macrosomia, but also the clinical value of miR-17-92 cluster as a predictive biomarker for macrosomia." +other hsa-mir-18 Perlman Syndrome 26598317 "Our findings not only provide a novel insight into the molecular mechanisms of macrosomia, but also the clinical value of miR-17-92 cluster as a predictive biomarker for macrosomia." +other hsa-mir-19a Perlman Syndrome 26598317 "Our findings not only provide a novel insight into the molecular mechanisms of macrosomia, but also the clinical value of miR-17-92 cluster as a predictive biomarker for macrosomia." +other hsa-mir-19b-1 Perlman Syndrome 26598317 "Our findings not only provide a novel insight into the molecular mechanisms of macrosomia, but also the clinical value of miR-17-92 cluster as a predictive biomarker for macrosomia." +other hsa-mir-20a Perlman Syndrome 26598317 "Our findings not only provide a novel insight into the molecular mechanisms of macrosomia, but also the clinical value of miR-17-92 cluster as a predictive biomarker for macrosomia." +other hsa-mir-92-1 Perlman Syndrome 26598317 "Our findings not only provide a novel insight into the molecular mechanisms of macrosomia, but also the clinical value of miR-17-92 cluster as a predictive biomarker for macrosomia." +other hsa-mir-150 "Squamous Cell Carcinoma, Esophageal" 26606907 "Taken together, our results highlight the involvement of miRNAs in ribosomal regulation during tumorigenesis." +other hsa-mir-383 "Squamous Cell Carcinoma, Esophageal" 26606907 "Taken together, our results highlight the involvement of miRNAs in ribosomal regulation during tumorigenesis." +other hsa-mir-190a "Carcinoma, Hepatocellular" 26608035 Our results reveal the involvement of miR-190a-treRNA axis in hepatoma progression and shed light on lncRNA-based cancer therapies for hepatoma patients at high risk of metastasis. +other hsa-mir-21 Neoplasms [unspecific] 26610525 induction of miR-21 by type I IFN +other hsa-mir-1 Bladder Outlet Obstruction 26612603 "We discuss known and predicted functions of miR-1, miR-29, miR-30, miR-132/212, miR-204 and miR-221, all of which change in BOO." +other hsa-mir-132 Bladder Outlet Obstruction 26612603 "We discuss known and predicted functions of miR-1, miR-29, miR-30, miR-132/212, miR-204 and miR-221, all of which change in BOO." +other hsa-mir-204 Bladder Outlet Obstruction 26612603 "We discuss known and predicted functions of miR-1, miR-29, miR-30, miR-132/212, miR-204 and miR-221, all of which change in BOO." +other hsa-mir-212 Bladder Outlet Obstruction 26612603 "We discuss known and predicted functions of miR-1, miR-29, miR-30, miR-132/212, miR-204 and miR-221, all of which change in BOO." +other hsa-mir-221 Bladder Outlet Obstruction 26612603 "We discuss known and predicted functions of miR-1, miR-29, miR-30, miR-132/212, miR-204 and miR-221, all of which change in BOO." +other hsa-mir-29 Bladder Outlet Obstruction 26612603 "We discuss known and predicted functions of miR-1, miR-29, miR-30, miR-132/212, miR-204 and miR-221, all of which change in BOO." +other hsa-mir-30 Bladder Outlet Obstruction 26612603 "We discuss known and predicted functions of miR-1, miR-29, miR-30, miR-132/212, miR-204 and miR-221, all of which change in BOO." +other hsa-mir-34a Ewing Sarcoma 26616853 CD99 counteracts EWS-FLI1 in controlling NF-¦ÊB signaling through the miR-34a +other hsa-mir-106b Colorectal Carcinoma 26617763 "Taken together, these findings demonstrated that miR-106b knockdown could induce EMT which conferring cells migratory and invasive properties but could not accomplish distant metastatic colonization efficiently." +other hsa-mir-506 "Carcinoma, Esophageal" 26617801 "Taken together, our data identify a new role of miR-506 in esophageal cancer involving CREB1 suppression." +other hsa-mir-223 "Carcinoma, Cervical" 26617846 "In conclusion, miR-223 inhibited cell metastasis of human cervical cancer by modulating epithelial-mesenchymal transition." +other hsa-mir-146a "Squamous Cell Carcinoma, Head and Neck" 26621153 Characterizing the expression of miR-146a and miR-155 and their functional role in tumor biology underlined significantly their proliferation and migration potential suggesting relevance as potential prognostic markers in HNSCC. +other hsa-mir-155 "Squamous Cell Carcinoma, Head and Neck" 26621153 Characterizing the expression of miR-146a and miR-155 and their functional role in tumor biology underlined significantly their proliferation and migration potential suggesting relevance as potential prognostic markers in HNSCC. +other hsa-mir-125a Neoplasms [unspecific] 26625740 This review covers roles of microRNAs and chemopreventive agents and makes an attempt at outlining possible partnerships in maximizing cancer cell death with minimal normal cell damage. +other hsa-mir-125b Neoplasms [unspecific] 26625740 This review covers roles of microRNAs and chemopreventive agents and makes an attempt at outlining possible partnerships in maximizing cancer cell death with minimal normal cell damage. +other hsa-mir-15a Neoplasms [unspecific] 26625740 This review covers roles of microRNAs and chemopreventive agents and makes an attempt at outlining possible partnerships in maximizing cancer cell death with minimal normal cell damage. +other hsa-mir-16-1 Neoplasms [unspecific] 26625740 This review covers roles of microRNAs and chemopreventive agents and makes an attempt at outlining possible partnerships in maximizing cancer cell death with minimal normal cell damage. +other hsa-mir-195 Neoplasms [unspecific] 26625740 This review covers roles of microRNAs and chemopreventive agents and makes an attempt at outlining possible partnerships in maximizing cancer cell death with minimal normal cell damage. +other hsa-mir-205 Neoplasms [unspecific] 26625740 This review covers roles of microRNAs and chemopreventive agents and makes an attempt at outlining possible partnerships in maximizing cancer cell death with minimal normal cell damage. +other hsa-mir-24-2 Neoplasms [unspecific] 26625740 This review covers roles of microRNAs and chemopreventive agents and makes an attempt at outlining possible partnerships in maximizing cancer cell death with minimal normal cell damage. +other hsa-mir-29 Neoplasms [unspecific] 26625740 This review covers roles of microRNAs and chemopreventive agents and makes an attempt at outlining possible partnerships in maximizing cancer cell death with minimal normal cell damage. +other hsa-mir-34a Neoplasms [unspecific] 26625740 This review covers roles of microRNAs and chemopreventive agents and makes an attempt at outlining possible partnerships in maximizing cancer cell death with minimal normal cell damage. +other hsa-mir-365-2 Neoplasms [unspecific] 26625740 This review covers roles of microRNAs and chemopreventive agents and makes an attempt at outlining possible partnerships in maximizing cancer cell death with minimal normal cell damage. +other hsa-mir-504 Neoplasms [unspecific] 26625740 This review covers roles of microRNAs and chemopreventive agents and makes an attempt at outlining possible partnerships in maximizing cancer cell death with minimal normal cell damage. +other hsa-let-7d Lung Neoplasms 26627242 "microRNA classifiers are powerful diagnostic/prognostic tools in ALK-, EGFR-, and KRAS-driven lung cancers." +other hsa-mir-769 Lung Neoplasms 26627242 "microRNA classifiers are powerful diagnostic/prognostic tools in ALK-, EGFR-, and KRAS-driven lung cancers." +other hsa-mir-138 "Adenocarcinoma, Lung" 26631041 we discovered that α-solanine could affect the expression of miR-138 and focal adhesion kinase +other hsa-mir-21 Graft-Versus-Host Disease 26631756 MicroRNA-21 deficiency protects from lupus-like autoimmunity in the chronic graft-versus-host disease model of systemic lupus erythematosus. +other hsa-mir-197 Gastric Neoplasms 26632693 Associations of Il-1 Family-Related Polymorphisms With Gastric Cancer Risk and the Role of Mir-197 In Il-1f5 Expression. +other hsa-mir-145 Diabetes Mellitus 26636106 "CRT may lead to left ventricular reverse remodeling, with LVEF, NYHA functional class, and 6MWT improvement in both diabetic and nondiabetic adult patients.These observations have been confirmed by other authors in a population of elderly diabetic patients, a part of 6MWT improvement, that is not CRT-induced in elderly diabetes." +other hsa-mir-26b Diabetes Mellitus 26636106 "CRT may lead to left ventricular reverse remodeling, with LVEF, NYHA functional class, and 6MWT improvement in both diabetic and nondiabetic adult patients.These observations have been confirmed by other authors in a population of elderly diabetic patients, a part of 6MWT improvement, that is not CRT-induced in elderly diabetes." +other hsa-mir-29a Diabetes Mellitus 26636106 "CRT may lead to left ventricular reverse remodeling, with LVEF, NYHA functional class, and 6MWT improvement in both diabetic and nondiabetic adult patients.These observations have been confirmed by other authors in a population of elderly diabetic patients, a part of 6MWT improvement, that is not CRT-induced in elderly diabetes." +other hsa-mir-92a Diabetes Mellitus 26636106 "CRT may lead to left ventricular reverse remodeling, with LVEF, NYHA functional class, and 6MWT improvement in both diabetic and nondiabetic adult patients.These observations have been confirmed by other authors in a population of elderly diabetic patients, a part of 6MWT improvement, that is not CRT-induced in elderly diabetes." +other hsa-mir-200c Lymphoma 26639163 Coordinated loss of microRNA group causes defenseless signaling in malignant lymphoma. +other hsa-mir-203 Lymphoma 26639163 Coordinated loss of microRNA group causes defenseless signaling in malignant lymphoma. +other hsa-mir-31 Lymphoma 26639163 Coordinated loss of microRNA group causes defenseless signaling in malignant lymphoma. +other hsa-mir-381 "Carcinoma, Lung, Non-Small-Cell" 26640150 ADAR1 overexpression enhances the editing frequencies of target transcripts such as NEIL1 and miR-381. +other hsa-mir-210 Ovarian Neoplasms 26640557 "miR-923, miR-1246, miR-149*, miR-638 and miR-210 were upregulated and miR-99a, miR-181a-2* and miR-339-5p were downregulated following bafilomycin A1 treatment." +other hsa-mir-127 Lymphoma 26640803 "The result of cross validation indicates that MiRNAClassify significantly outperforms other methods and models. In addition, the newly added pre-miRNAs are used to further evaluate the ability of these methods to discover novel pre-miRNAs. MiRNAClassify still achieves consistently superior performance and can discover more pre-miRNAs." +other hsa-mir-192 Breast Neoplasms 26642352 MiR-192-Mediated Positive Feedback Loop Controls the Robustness of Stress-Induced p53 Oscillations in Breast Cancer Cells. +other hsa-mir-485 Viral Infectious Disease 26645583 These findings highlight the dual role of miR-485 in preventing spurious activation of antiviral signaling and restricting influenza virus infection. +other hsa-mir-1307 Liver Neoplasms 26646011 Transcriptomic Analysis of Chronic Hepatitis B and C and Liver Cancer Reveals MicroRNA-Mediated Control of Cholesterol Synthesis Programs. +other hsa-mir-21 Liver Neoplasms 26646011 Transcriptomic Analysis of Chronic Hepatitis B and C and Liver Cancer Reveals MicroRNA-Mediated Control of Cholesterol Synthesis Programs. +other hsa-mir-224 Liver Neoplasms 26646011 Transcriptomic Analysis of Chronic Hepatitis B and C and Liver Cancer Reveals MicroRNA-Mediated Control of Cholesterol Synthesis Programs. +other hsa-mir-27 Liver Neoplasms 26646011 Transcriptomic Analysis of Chronic Hepatitis B and C and Liver Cancer Reveals MicroRNA-Mediated Control of Cholesterol Synthesis Programs. +other hsa-mir-33 Liver Neoplasms 26646011 Transcriptomic Analysis of Chronic Hepatitis B and C and Liver Cancer Reveals MicroRNA-Mediated Control of Cholesterol Synthesis Programs. +other hsa-mir-144 Allergic Asthma 26646558 "Together, the pathogenesis of OVA-induced asthma is highly associated with oxidative stress,and DAS may be an effective supplement to alleviate this disease." +other hsa-mir-34a Allergic Asthma 26646558 "Together, the pathogenesis of OVA-induced asthma is highly associated with oxidative stress,and DAS may be an effective supplement to alleviate this disease." +other hsa-mir-34b Allergic Asthma 26646558 "Together, the pathogenesis of OVA-induced asthma is highly associated with oxidative stress,and DAS may be an effective supplement to alleviate this disease." +other hsa-mir-335 Prostate Neoplasms 26647850 "These findings suggested that miR-335 and -543 are associated with bone metastasis of PCa and indicated that they may have important roles in the bone metastasis, which may also be clinically used as novel biomarkers in discriminating the different stages of human PCa and predicting bone metastasis." +other hsa-mir-543 Prostate Neoplasms 26647850 "These findings suggested that miR-335 and -543 are associated with bone metastasis of PCa and indicated that they may have important roles in the bone metastasis, which may also be clinically used as novel biomarkers in discriminating the different stages of human PCa and predicting bone metastasis." +other hsa-mir-122 Infertility 26648257 Altered miRNA Signature of Developing Germ-cells in Infertile Patients Relates to the Severity of Spermatogenic Failure and Persists in Spermatozoa. +other hsa-mir-34c Infertility 26648257 Altered miRNA Signature of Developing Germ-cells in Infertile Patients Relates to the Severity of Spermatogenic Failure and Persists in Spermatozoa. +other hsa-mir-449a Infertility 26648257 Altered miRNA Signature of Developing Germ-cells in Infertile Patients Relates to the Severity of Spermatogenic Failure and Persists in Spermatozoa. +other hsa-mir-34a Neoplasms [unspecific] 26648462 "MiR-34a is associated with G1 cell cycle arrest, senescence and apoptosis, thereby possessing a tumor suppressor activity." +other hsa-let-7g "Carcinoma, Esophageal" 26655271 BAG3-mediated miRNA let-7g and let-7i inhibit proliferation and enhance apoptosis of human esophageal carcinoma cells by targeting the drug transporter ABCC10. +other hsa-let-7i "Carcinoma, Esophageal" 26655271 BAG3-mediated miRNA let-7g and let-7i inhibit proliferation and enhance apoptosis of human esophageal carcinoma cells by targeting the drug transporter ABCC10. +other hsa-mir-122 "Carcinoma, Hepatocellular" 26655273 Our data imply that an intimate correlation between miR-122 and IGF-1R abnormal expression is a critical determinant of sorafenib tolerance. +other hsa-mir-124 Ovarian Neoplasms 26655797 A genome-scale screen reveals context-dependent ovarian cancer sensitivity to miRNA overexpression. +other hsa-mir-155 Ovarian Neoplasms 26655797 A genome-scale screen reveals context-dependent ovarian cancer sensitivity to miRNA overexpression. +other hsa-mir-181b Ovarian Neoplasms 26655797 A genome-scale screen reveals context-dependent ovarian cancer sensitivity to miRNA overexpression. +other hsa-mir-517a Ovarian Neoplasms 26655797 A genome-scale screen reveals context-dependent ovarian cancer sensitivity to miRNA overexpression. +other hsa-mir-323 Glioma 26656446 MiRNA-323-5p inhibited human cerebral glioma U373 cell proliferation and promoted its apoptosis by reducing IGF-1R. +other hsa-mir-122 Inflammation 26657215 "In addition to the classical Jak-Stat antiviral signaling pathway,IFN-¦Ë1 inhibits HCV replication through the suppression of miRNA-122 transcription via an inflammatory Stat 3-HNF4¦Á feedback loop. Inflammatory feedback circuits activated by IFNs during chronic inflammation expose non-responders to the risk of hepatocellular carcinoma." +other hsa-mir-17 Diabetes Mellitus 26660634 miR-17 repression mediates the pro-apoptotic effect of high glucose +other hsa-mir-372 "Adenocarcinoma, Prostate" 26662140 "hsa-miR-372 and miR-373, we suggest that miR-ch21 down-regulation might be the result of specific silencing of miR genes mapped to chromosome 21" +other hsa-mir-27a Breast Neoplasms 26662313 knockdown of miR-27a by the specific inhibitors significantly increased the sensitivity of T-47D cells to cisplatin (CDDP) treatment. +other hsa-mir-126 Atherosclerosis 26662986 "In particular, the specific roles of miR-126 and miR-143/145, master regulators of EC and VSMC function, respectively, are deeply explored." +other hsa-mir-423 "Carcinoma, Hepatocellular" 26663009 miR423-5p contributed to the tumorigenesis and progression of HCC.It could be a new predictor in HCC patients beyond the Milan criteria and would help to improve patient outcomes and enlarge recipient pools of liver transplantation. +other hsa-mir-122 Liver Diseases [unspecific] 26669080 Biological function of miR-122 and its relationship with liver diseases. +other hsa-mir-34c Colorectal Carcinoma 26674205 "Res suppressed CRC by specifically activating miR-34c-KITLG in vitro and in vivo; and the effect was strengthened in the presence of p53. Besides, Resexerted a synergistic effect with Oxa in a miR-34c dependent manner. We also suggested that Res-increased miR-34c could interfere IL-6-triggered CRC progression." +other hsa-mir-155 Autoimmune Diseases [unspecific] 26674874 We have shown that mice in which the miR-155 host gene (MIR155HG) has been deactivated are resistant to EAE. +other hsa-let-7 Hematologic Neoplasms 26676759 "Taken together, our results reveal a previously unknown mechanism by which Myc induces apoptosis independent of the p53 pathway and as a response to HDACi in malignant hematopoietic cells." +other hsa-mir-15 Hematologic Neoplasms 26676759 "Taken together, our results reveal a previously unknown mechanism by which Myc induces apoptosis independent of the p53 pathway and as a response to HDACi in malignant hematopoietic cells." +other hsa-let-7d Osteosarcoma 26679758 Let-7d miRNA Shows Both Antioncogenic and Oncogenic Functions in Osteosarcoma-Derived 3AB-OS Cancer Stem Cells. +other hsa-mir-203 "Carcinoma, Lung, Non-Small-Cell" 26683818 "Our results suggest that LASP-1, mediated by miR-203,has crucial functions in the proliferation, migration and invasion of NSCLC." +other hsa-mir-196a "Carcinoma, Pancreatic" 26683934 "MiRNA-196a level may be a promising prognostic marker of recurrence in resected PanNETs, although further experimental investigation would be required." +other hsa-mir-520g Brain Neoplasms 26687818 Tissue Factor Regulation by miR-520g in Primitive Neuronal Brain Tumor Cells: A Possible Link between Oncomirs and the Vascular Tumor Microenvironment. +other hsa-mir-373 Laryngeal Neoplasms 26688807 Association of Polymorphic Variants of miRNA Processing Genes with Larynx Cancer Risk in a Polish Population. +other hsa-mir-202 Multiple Myeloma 26689580 miR-202 over-expression sensitized MM cells to bortezomib (Bort) but less to Thalidomide (Thal) and dexamethasone (Dex). +other hsa-let-7a Melanoma 26693896 "Aberrant activation of some known miRNAs, e.g. let-7a and b, miR-148, miR-155, miR-182, miR-200c, miR-211, miR-214, miR-221 and 222, has been recognised to be linked with melanoma-associated genes" +other hsa-mir-221 Melanoma 26693896 "Aberrant activation of some known miRNAs, e.g. let-7a and b, miR-148, miR-155, miR-182, miR-200c, miR-211, miR-214, miR-221 and 222, has been recognised to be linked with melanoma-associated genes" +other hsa-mir-125b Alzheimer Disease 26694372 MicroRNA (miRNA) Signaling in the Human CNS in Sporadic Alzheimer's Disease (AD)-Novel and Unique Pathological Features. +other hsa-mir-146a Alzheimer Disease 26694372 MicroRNA (miRNA) Signaling in the Human CNS in Sporadic Alzheimer's Disease (AD)-Novel and Unique Pathological Features. +other hsa-mir-155 Alzheimer Disease 26694372 MicroRNA (miRNA) Signaling in the Human CNS in Sporadic Alzheimer's Disease (AD)-Novel and Unique Pathological Features. +other hsa-mir-34a Alzheimer Disease 26694372 MicroRNA (miRNA) Signaling in the Human CNS in Sporadic Alzheimer's Disease (AD)-Novel and Unique Pathological Features. +other hsa-mir-7 Alzheimer Disease 26694372 MicroRNA (miRNA) Signaling in the Human CNS in Sporadic Alzheimer's Disease (AD)-Novel and Unique Pathological Features. +other hsa-mir-9 Alzheimer Disease 26694372 MicroRNA (miRNA) Signaling in the Human CNS in Sporadic Alzheimer's Disease (AD)-Novel and Unique Pathological Features. +other hsa-mir-1246 "Carcinoma, Lung, Non-Small-Cell" 26711929 "Anti-miR-1246 and anti-miR-1290 suppressed proliferation, sphere-formation, colony formation and invasion of NSCLC.CSCs-associated miR-1246, or miR-1290 may be important in the invasion or metastasis of NSCLC." +other hsa-mir-1290 "Carcinoma, Lung, Non-Small-Cell" 26711929 "Anti-miR-1246 and anti-miR-1290 suppressed proliferation, sphere-formation, colony formation and invasion of NSCLC.CSCs-associated miR-1246, or miR-1290 may be important in the invasion or metastasis of NSCLC." +other hsa-mir-21 Colorectal Carcinoma 26712035 "miR-21 followed by miR-34, miR-200 and miR-215 are the most reported miRNAs to have roles in colon CSC regulation." +other hsa-mir-215 Colorectal Carcinoma 26712035 "miR-21 followed by miR-34, miR-200 and miR-215 are the most reported miRNAs to have roles in colon CSC regulation." +other hsa-mir-208b Acute Myocardial Infarction 26712201 none +other hsa-mir-21 Neoplasms [unspecific] 26716902 LIF induces miR-21 expression through the activation of STAT3. +other hsa-mir-34a Neoplasms [unspecific] 26718338 MicroRNA-34a Negatively Regulates Efferocytosis by Tissue Macrophages in Part via SIRT1. +other hsa-mir-29b Multiple Myeloma 26718793 genistein could suppress the protein level of NF-κB and promote the expression of miR-29b in U266 cells. +other hsa-mir-106a Gastric Neoplasms 26722506 Diagnostic significance of miR-106a in gastric cancer. +other hsa-mir-340 Gastric Neoplasms 26722508 Effect of miR-340 on gastric cancer cell proliferation and apoptosis. +other hsa-mir-141 Ovarian Neoplasms 26725650 "These mechanisms have significant relevance in ovarian cancers and stress response, pathophysiological conditions in which miR-200c/141 exert key functions." +other hsa-mir-200c Ovarian Neoplasms 26725650 "These mechanisms have significant relevance in ovarian cancers and stress response, pathophysiological conditions in which miR-200c/141 exert key functions." +other hsa-mir-149 "Leukemia, Lymphoblastic, Acute" 26725775 miRNA-149* promotes cell proliferation and suppresses apoptosis by mediating JunB in T-cell acute lymphoblastic leukemia. +other hsa-mir-146a "Colitis, Ulcerative" 26730791 "Our results suggest that microRNAs may serve as a novel regulator in function and homoeostasis of UC Treg cells, providing a key role for them in pathophysiology of UC." +other hsa-mir-155 "Colitis, Ulcerative" 26730791 "Our results suggest that microRNAs may serve as a novel regulator in function and homoeostasis of UC Treg cells, providing a key role for them in pathophysiology of UC." +other hsa-mir-21 "Colitis, Ulcerative" 26730791 "Our results suggest that microRNAs may serve as a novel regulator in function and homoeostasis of UC Treg cells, providing a key role for them in pathophysiology of UC." +other hsa-mir-125 Malignant Neoplasms [unspecific] 26731991 "These results suggest that different members of the miR-125 family may have different functions in various cancers. Furthermore, miR-125a or miR-125b may be important clinical prognostic biomarkers for cancer patients." +other hsa-mir-143 Inflammation 26739093 Staphylococcal LTA-Induced miR-143 Inhibits Propionibacterium acnes-Mediated Inflammatory Response in Skin +other hsa-mir-155 "Carcinoma, Colon" 26744471 MicroRNA-155 deletion promotes tumorigenesis in the azoxymethane-dextran sulfate sodium model of colon cancer. +other hsa-mir-25 "Leukemia, Myeloid, Acute" 26744876 "Moreover, miR-155 level was positively associated with the white blood cell (WBC) count, serum lactate dehydrogenase (LDH) and C-reaction protein (CRP) value in peripheral blood (PB), as well as miR-25/miR-196b expression levels." +other hsa-mir-34a Gastric Neoplasms 26745070 Our study demonstrates chrysin loaded PLGA-PEG promises a natural and efficient system for anticancer drug delivery to fight gastric cancer. +other hsa-mir-892b Breast Neoplasms 26747895 miR-892b Silencing Activates NF-¦ÊB and Promotes Aggressiveness in Breast Cancer. +other hsa-let-7b Melanoma 26754091 EGCG up-regulated miRNA-let-7b expression through 67LR in melanoma cells. +other hsa-mir-142 Melanoma 26763444 "Identification, Review, and Systematic Cross-Validation of microRNA Prognostic Signatures in Metastatic Melanoma." +other hsa-mir-146b Melanoma 26763444 "Identification, Review, and Systematic Cross-Validation of microRNA Prognostic Signatures in Metastatic Melanoma." +other hsa-mir-150 Melanoma 26763444 "Identification, Review, and Systematic Cross-Validation of microRNA Prognostic Signatures in Metastatic Melanoma." +other hsa-mir-155 Melanoma 26763444 "Identification, Review, and Systematic Cross-Validation of microRNA Prognostic Signatures in Metastatic Melanoma." +other hsa-mir-342 Melanoma 26763444 "Identification, Review, and Systematic Cross-Validation of microRNA Prognostic Signatures in Metastatic Melanoma." +other hsa-mir-106b "Carcinoma, Cervical" 26769181 Our data suggest that the TGF-¦Â1/miR-106b/DAB2 axis may be involved in the pathogenesis of cervical carcinoma. +other hsa-mir-21 Breast Neoplasms 26769851 "miR-21, a well-documented oncogenic miRNA for promoting tumor cell metastasis, was also found to be involved in inhibitory activity of SSA in breast tumor cell motility through the modulation of TGFβ pathway." +other hsa-mir-590 Diabetes Mellitus 26770982 "In this study, we identified a LDHA-suppressing microRNA (hsa-miR-590-3p)and used it together with human embryonic stem cell (hESC) derived pancreatic endoderm (PE) transplantation into a high-fat diet induced T2D mouse model. The procedure significantly improved glucose metabolism and other symptoms of T2D." +other hsa-mir-155 Neoplasms [unspecific] 26771315 Screening of Pre-miRNA-155 Binding Peptides for Apoptosis Inducing Activity Using Peptide Microarrays. +other hsa-mir-194 Aneurysm 26771601 "Aneurysm miRNA Signature Differs, Depending on Disease Localization and Morphology." +other hsa-mir-19b-1 Aneurysm 26771601 "Aneurysm miRNA Signature Differs, Depending on Disease Localization and Morphology." +other hsa-mir-21 Aneurysm 26771601 "Aneurysm miRNA Signature Differs, Depending on Disease Localization and Morphology." +other hsa-mir-362 Aneurysm 26771601 "Aneurysm miRNA Signature Differs, Depending on Disease Localization and Morphology." +other hsa-mir-550 Aneurysm 26771601 "Aneurysm miRNA Signature Differs, Depending on Disease Localization and Morphology." +other hsa-mir-769 Aneurysm 26771601 "Aneurysm miRNA Signature Differs, Depending on Disease Localization and Morphology." +other hsa-mir-18a Gastric Neoplasms 26772615 "Down regulation of miR-18a, miR-21 and miR-221 genes in gastric cancer cell line by chrysin-loaded PLGA-PEG nanoparticles." +other hsa-mir-21 Gastric Neoplasms 26772615 "Down regulation of miR-18a, miR-21 and miR-221 genes in gastric cancer cell line by chrysin-loaded PLGA-PEG nanoparticles." +other hsa-mir-221 Gastric Neoplasms 26772615 "Down regulation of miR-18a, miR-21 and miR-221 genes in gastric cancer cell line by chrysin-loaded PLGA-PEG nanoparticles." +other hsa-mir-29b "Carcinoma, Lung, Non-Small-Cell" 26776158 knockdown of ETS1 led to upregulation of eight microRNAs and downregulation of miR-29b in the immune-evasion subtype. +other hsa-mir-145 "Carcinoma, Lung, Non-Small-Cell" 26780934 TP53 knockdown reduced the miRNA hsa-miR-145 +other hsa-mir-34a "Squamous Cell Carcinoma, Esophageal" 26782413 Clinical significance of microRNA-34a in esophageal squamous cell carcinoma. +other hsa-mir-29a Colorectal Carcinoma 26782449 Diagnostic performance of microRNA-29a for colorectal cancer: a meta-analysis. +other hsa-mir-125b Ewing Sarcoma 26782555 Circulating miR-125b as a biomarker of Ewing's sarcoma in Chinese children. +other hsa-let-7d Idiopathic Pulmonary Fibrosis 26787543 Lin28B causes epithelial-mesenchymal transition (EMT) by inhibition of let-7d. +other hsa-mir-203 Breast Neoplasms 26790955 Kallistatin induces breast cancer cell apoptosis and autophagy by modulating Wnt signaling and microRNA synthesis. +other hsa-mir-21 Breast Neoplasms 26790955 Kallistatin induces breast cancer cell apoptosis and autophagy by modulating Wnt signaling and microRNA synthesis. +other hsa-mir-34a Breast Neoplasms 26790955 Kallistatin induces breast cancer cell apoptosis and autophagy by modulating Wnt signaling and microRNA synthesis. +other hsa-mir-132 Alzheimer Disease 26792551 MicroRNA-132 and early growth response-1 in nucleus basalis of Meynert during the course of Alzheimer's disease. +other hsa-mir-155 Breast Neoplasms 26795347 miR-155 Drives Metabolic Reprogramming of ER+ Breast Cancer Cells Following Long-Term Estrogen Deprivation and Predicts Clinical Response to Aromatase Inhibitors. +other hsa-mir-34c "Carcinoma, Nasopharyngeal" 26795575 Our study presents the current knowledge of miRNA regulatory network in NPC with combination of bioinformatics analysis and literature research. The hypothesis of miR-34c regulatory pathway may be beneficial in guiding further studies on the molecular mechanism of NPC tumorigenesis. +other hsa-mir-221 "Squamous Cell Carcinoma, Oral" 26796268 depleting cells of miR-221 increases the sensitivity of the cells to Adriamycin. +other hsa-mir-151a Hepatitis B Virus Infection 26801621 "We identified miR-24-3p, miR-151a-5p, and miR-425-5p as the most valid combination of reference genes for microRNA RT-qPCR studies in our hepatitis B virus replicating HepG2 cell model." +other hsa-mir-24 Hepatitis B Virus Infection 26801621 "We identified miR-24-3p, miR-151a-5p, and miR-425-5p as the most valid combination of reference genes for microRNA RT-qPCR studies in our hepatitis B virus replicating HepG2 cell model." +other hsa-mir-425 Hepatitis B Virus Infection 26801621 "We identified miR-24-3p, miR-151a-5p, and miR-425-5p as the most valid combination of reference genes for microRNA RT-qPCR studies in our hepatitis B virus replicating HepG2 cell model." +other hsa-mir-17 "Carcinoma, Hepatocellular" 26804174 "SLU7 knockdown altered the splicing of the C13orf25 primary transcript, and markedly reduced the expression of its miR-17, miR-20 and miR-92a constituents." +other hsa-mir-92a "Carcinoma, Hepatocellular" 26804174 "SLU7 knockdown altered the splicing of the C13orf25 primary transcript, and markedly reduced the expression of its miR-17, miR-20 and miR-92a constituents." +other hsa-mir-132 Chronic Obstructive Pulmonary Disease 26807508 "Ectopic expression of PKR or miR-132 antagomiR alone failed to restore IFN-β induction, whereas cotreatment increased antiviral stress granule formation, induction of p300, and IFN-β in COPD pBECs." +other hsa-mir-301a Prostate Neoplasms 26813459 "Taken together, we demonstrated that miR-301a/b-NDRG2 might be an important axis modulating autophagy and viability of prostate cancer cells under hypoxia." +other hsa-mir-301b Prostate Neoplasms 26813459 "Taken together, we demonstrated that miR-301a/b-NDRG2 might be an important axis modulating autophagy and viability of prostate cancer cells under hypoxia." +other hsa-mir-223 Pulmonary Hypertension 26815432 "Inhibition of miR-223 did not attenuate MCT PAH, whereas human prostacyclin synthase overexpression restored miRNA levels in MCT PAH to levels detected in naive rats. These data may establish a paradigm linking attenuation of PAH to restoration of BMPR2 signaling." +other hsa-mir-205 "Carcinoma, Endometrial" 26817318 The role of miRNA in endometrial cancer in the context of miRNA 205 +other hsa-mir-199 Ovarian Neoplasms 26819477 "miR-199a-5p and miR-34a-5p showed specific association with the disease, including molecular and cellular functions" +other hsa-mir-34a Ovarian Neoplasms 26819477 "miR-199a-5p and miR-34a-5p showed specific association with the disease, including molecular and cellular functions" +other hsa-mir-150 Sepsis 26822049 "Lower microRNA-150 may indicate a poor prognosis, and Picco monitoring combined with microRNA 150 detection may improve the prognostic efficiency in septic shock patients." +other hsa-mir-224 Colorectal Carcinoma 26822534 Our research showed mechanistic links between miR-224 and Wnt/¦Â-catenin in the pathogenesis of CRC through modulation of GSK3¦Â and SFRP2. +other hsa-mir-143 Colon Neoplasms 26824186 miR-143 or miR-145 overexpression increases cetuximab-mediated antibody-dependent cellular cytotoxicity in human colon cancer cells +other hsa-mir-145 Colon Neoplasms 26824186 miR-143 or miR-145 overexpression increases cetuximab-mediated antibody-dependent cellular cytotoxicity in human colon cancer cells +other hsa-mir-21 Diabetes Mellitus 26826461 Role of microRNA 21 in diabetes and associated/related diseases. +other hsa-mir-101 Pancreatic Neoplasms 26828016 MicroRNA-101-3p reverses gemcitabine resistance by inhibition of ribonucleotide reductase M1 in pancreatic cancer. +other hsa-mir-126 "Leukemia, Myeloid, Acute" 26832662 miR-126 Regulates Distinct Self-Renewal Outcomes in Normal and Malignant Hematopoietic Stem Cells. +other hsa-mir-200c "Squamous Cell Carcinoma, Oral" 26839311 "suppression of the anti-inflammatory tumor suppressor microRNAs let-7d, miR-23b, and miR-200c was observed following PAR-2 stimulation." +other hsa-mir-148a Prostate Neoplasms 26843836 "decreased expressions of tumor suppressors: miR-34a, miR-143, miR-148a and miR-200 family are involved in resistance of anti-cancer drugs" +other hsa-mir-29a Myocardial Ischemic-Reperfusion Injury 26844226 "After Myocardial Ischemia-Reperfusion, miR-29a, and Let7 Could Affect Apoptosis through Regulating IGF-1." +other hsa-mir-155 Liver Injury 26844784 Role of miR-155 in fluorooctane sulfonate-induced oxidative hepatic damage via the Nrf2-dependent pathway. +other hsa-mir-133a Cardiomegaly 26845040 APN reversed miR-133a levels through AMPK activation +other hsa-mir-145 Cardiovascular Diseases [unspecific] 26845891 THERAPEUTIC POTENTIAL OF MICRORNA IN THE FIELD OF CARDIOVASCULAR SURGERY. +other hsa-mir-122 Hepatitis C Virus Infection 26845923 Mechanism of regulation of HCV replication by miR-122. +other hsa-mir-216b "Carcinoma, Lung, Non-Small-Cell" 26852748 microRNA (miR)-216b levels were significantly downregulated in paclitaxel-treated NSCLC cells. +other hsa-mir-145 Bladder Neoplasms 26852750 decreasing miR-145 expression reduced cisplatin sensitivity +other hsa-mir-30d Heart Failure 26858295 "Letter by Sardu et al Regarding Article, Circulating MicroRNA-30d Is Associated With Response to Cardiac Resynchronization Therapy in Heart Failure and Regulates Cardiomyocyte Apoptosis: A Translational Pilot Study." +other hsa-mir-30d Heart Failure 26858296 "Response to Letter Regarding Article, Circulating MicroRNA-30d Is Associated With Response to Cardiac Resynchronization Therapy in Heart Failure and Regulates Cardiomyocyte Apoptosis: A Translational Pilot Study." +other hsa-mir-126 Leukemia 26859449 miR-126 Drives Quiescence and Self-Renewal in Leukemic Stem Cells. +other hsa-mir-205 "Squamous Cell Carcinoma, Cerevial" 26864590 ΔNp63α attenuates tumor aggressiveness by suppressing miR-205/ZEB1-mediated epithelial-mesenchymal transition in cervical squamous cell carcinoma. +other hsa-mir-92a "Leukemia, Myeloid" 26866730 The human myeloid leukemia cell line K562 secretes exosomes containing a large amount of miR-92a that enhances angiogenesis under normoxic and hypoxic conditions. +other hsa-mir-182 Prostate Neoplasms 26870290 "mangiferin inhibited proliferation and induced apoptosis in PC3 human prostate cancer cells, and this effect was correlated with downregulation of Bcl-2 and upregulation of miR-182." +other hsa-mir-31 Colorectal Carcinoma 26871294 "In conclusion, an inverse association was identified between EZH2 and miR-31 in colorectal cancers." +other hsa-mir-26b Melanoma 26872428 MiR-26b inhibits melanoma cell proliferation and enhances apoptosis by suppressing TRAF5-mediated MAPK activation. +other hsa-mir-144 Bronchiolitis Obliterans Syndrome 26874429 MicroRNA-144 is unlikely to play a role in bronchiolitis obliterans syndrome. +other hsa-mir-375 "Carcinoma, Merkel Cell" 26877261 Roles for miR-375 in Neuroendocrine Differentiation and Tumor Suppression via Notch Pathway Suppression in Merkel Cell Carcinoma. +other hsa-mir-193b "Carcinoma, Esophageal" 26878873 These results highlight the importance of miR-193b in determining oesophageal cancer cell viability and demonstrate an enhancement of chemotoxicity that is independent of apoptosis induction. +other hsa-mir-200c "Squamous Cell Carcinoma, Oral" 26879838 Sulforaphane treatment resulted in a dose-dependent increase in the levels of tumor suppressive miR200c. +other hsa-mir-141 "Carcinoma, Gastrooesophageal" 26885979 "The miRNA profile predictive for sensitivity to cisplatin,epirubicine and capecitabine was shown to be independently associated with OS and DSS in patients with gastrooesophageal cancer." +other hsa-mir-200c "Carcinoma, Gastrooesophageal" 26885979 "The miRNA profile predictive for sensitivity to cisplatin,epirubicine and capecitabine was shown to be independently associated with OS and DSS in patients with gastrooesophageal cancer." +other hsa-mir-505 "Carcinoma, Gastrooesophageal" 26885979 "The miRNA profile predictive for sensitivity to cisplatin,epirubicine and capecitabine was shown to be independently associated with OS and DSS in patients with gastrooesophageal cancer." +other hsa-mir-99b "Carcinoma, Gastrooesophageal" 26885979 "The miRNA profile predictive for sensitivity to cisplatin,epirubicine and capecitabine was shown to be independently associated with OS and DSS in patients with gastrooesophageal cancer." +other hsa-mir-196a-2 Breast Neoplasms 26886638 "The Associations of Single Nucleotide Polymorphisms in miR196a2, miR-499, and miR-608 With Breast Cancer Susceptibility: A STROBE-Compliant Observational Study." +other hsa-mir-499 Breast Neoplasms 26886638 "The Associations of Single Nucleotide Polymorphisms in miR196a2, miR-499, and miR-608 With Breast Cancer Susceptibility: A STROBE-Compliant Observational Study." +other hsa-mir-608 Breast Neoplasms 26886638 "The Associations of Single Nucleotide Polymorphisms in miR196a2, miR-499, and miR-608 With Breast Cancer Susceptibility: A STROBE-Compliant Observational Study." +other hsa-mir-15a "Lymphoma, Burkitt" 26893685 Correlation between the overexpression of Yin Yang 1 and the expression levels of miRNAs +other hsa-mir-134 Colorectal Carcinoma 26897940 Decreased Expression of MIR-134 and its Clinical Significance in Human Colorectal Cancer. +other hsa-mir-23b Diabetic Nephropathy 26898629 Diabetic nephropathy: MiR-23b protects against fibrosis in diabetic nephropathy. +other hsa-mir-155 "Adenocarcinoma, Lung" 26899325 Role of miR-155 in invasion and metastasis of lung adenocarcinoma A549 cells. +other hsa-mir-328 Neurodegenerative Diseases [unspecific] 26900752 "These experiments reveal Dicer1-miR-328-Bace1 signalling as a determinant of BAT function, and highlight the potential of Bace1 inhibition as a therapeutic approach to improve not only neurodegenerative diseases" +other hsa-mir-146a "Adenocarcinoma, Lung" 26902276 Effects of microRNA-146a on Fas-associated factor 2 and inflammatory factors in human lung adenocarcinoma A549 cells under the stimulation of cigarette smoke extract. +other hsa-mir-200 Ovarian Neoplasms 26910180 The prognostic value of the miR-200 family in ovarian cancer: a meta-analysis. +other hsa-mir-222 Melanoma 26912358 vesicles released by miR-222-overexpressing cells were able to transfer miR-222-dependent malignancy when taken-up by recipient primary melanomas. +other hsa-mir-150 Stroke 26922365 "Upregulation of miR-150 expression could decrease vascular density of infarct border zone in rat after MCAO and decrease tube formation, proliferation, and migration of BMVECs." +other hsa-mir-296 Neurofibromatosis type 2 26923924 Neurofibromatosis 2 (NF2) controls the invasiveness of glioblastoma through YAP-dependent expression of CYR61/CCN1 and miR-296-3p. +other hsa-let-7a Breast Neoplasms 26924493 "Mir-206 and let-7 were up-regulated, and mir-21 expression was down-regulated in the exercise training compared to tumor group." +other hsa-mir-21 Breast Neoplasms 26924493 "Mir-206 and let-7 were up-regulated, and mir-21 expression was down-regulated in the exercise training compared to tumor group." +other hsa-mir-126 Breast Neoplasms 26926567 MALAT1 induced migration and invasion of human breast cancer cells by competitively binding miR-1 with cdc42. +other hsa-mir-122 Hepatitis C Virus Infection 26927063 miR-125a-5p and miR-1231 have been shown to directly target hepatitis B virus (HBV) transcripts +other hsa-mir-33 Alzheimer Disease 26936997 Understanding the Role of miR-33 in Brain Lipid Metabolism: Implications for Alzheimer's Disease. +other hsa-mir-376 Breast Neoplasms 26940843 MIR376 as an important microRNA family for cancer formation and progression +other hsa-mir-376 Glioma 26940843 MIR376 as an important microRNA family for cancer formation and progression +other hsa-mir-376 Leukemia 26940843 MIR376 as an important microRNA family for cancer formation and progression +other hsa-mir-376 Ovarian Neoplasms 26940843 MIR376 as an important microRNA family for cancer formation and progression +other hsa-mir-21 Liver Cirrhosis 26946098 "increasing concentrations of Corilagin improved the quality of life, inhibited the mRNA expression of miR-21, promoted smad7 protein expression, and inhibited CTGF protein expression (p<0.05 or 0.01)." +other hsa-mir-203 "Squamous Cell Carcinoma, Tongue" 26946357 miR-203 inhibits cell proliferation and promotes cisplatin induced cell death in tongue squamous cancer. +other hsa-mir-370 "Diabetes Mellitus, Type 2" 26948318 salidroside can directly decrease the expression of miR-370 in type 2 diabetic mice +other hsa-mir-155 Rheumatoid Arthritis 26950427 epigenetic regulators such as micro-RNAs (i.e. miR-155) are key regulators of myeloid cells activation in RA +other hsa-mir-125b Inflammation 26954942 MiRNA-Mediated Macrophage Polarization and its Potential Role in the Regulation of Inflammatory Response. +other hsa-mir-146a Inflammation 26956852 Effect of High MiR-146a Expression on the Inflammatory Reaction in BV2 Cells. +other hsa-mir-221 Neoplasms [unspecific] 26959615 biological significance of miR-221/222 in a variety of malignancies indicates that they will play a crucial role in the future of innovative therapeutic strategies +other hsa-mir-222 Neoplasms [unspecific] 26959615 biological significance of miR-221/222 in a variety of malignancies indicates that they will play a crucial role in the future of innovative therapeutic strategies +other hsa-mir-375 Breast Neoplasms 26962366 Hsa-miR-375 is a predictor of local control in early stage breast cancer. +other hsa-mir-223 Obesity 26962854 High-Density Lipoprotein-Associated miR-223 Is Altered after Diet-Induced Weight Loss in Overweight and Obese Males. +other hsa-mir-24 Neoplasms [unspecific] 26967561 "melatonin can inhibit cell proliferation and migration, at least in part, by downregulating miR-24." +other hsa-mir-211 Colorectal Carcinoma 26974151 Long Non-Coding RNA ucoo2kmd.1 Regulates CD44-Dependent Cell Growth by Competing for miR-211-3p in Colorectal Cancer. +other hsa-mir-203 Prostate Neoplasms 26976978 increase of miR-203 expression after ZA exposure +other hsa-mir-10a Ovarian Disease 26979400 AFSC-derived exosomes prevent ovarian follicular atresia in CTx-treated mice via the delivery of microRNAs in which both miR-146a and miR-10a are highly enriched and their potential target genes are critical to apoptosis. +other hsa-mir-146a Pneumonia 26984146 "pneumococci recognition induces a negative feedback loop, preventing excessive inflammation via miR-146a and potentially other miRNAs." +other hsa-mir-143 Neoplasms [unspecific] 26988859 The miR-143/miR-145 cluster and the tumor microenvironment: unexpected roles. +other hsa-mir-145 Neoplasms [unspecific] 26988859 The miR-143/miR-145 cluster and the tumor microenvironment: unexpected roles. +other hsa-mir-17 "Lymphoma, Follicular" 26997445 miR-31 and miR-17-5p levels change during transformation of follicular lymphoma. +other hsa-mir-31 "Lymphoma, Follicular" 26997445 miR-31 and miR-17-5p levels change during transformation of follicular lymphoma. +other hsa-mir-503 Neoplasms [unspecific] 26999740 miRNA-503 Promotes Tumor Progression and Is Associated with Early Recurrence and Poor Prognosis in Human Colorectal Cancer. +other hsa-mir-29a "Carcinoma, Gastric" 27000664 Cell-derived microvesicles mediate the delivery of miR-29a/c to suppress angiogenesis in gastric carcinoma. +other hsa-mir-29c "Carcinoma, Gastric" 27000664 Cell-derived microvesicles mediate the delivery of miR-29a/c to suppress angiogenesis in gastric carcinoma. +other hsa-mir-20a Leukemia 27010069 "Mechanistic study further shows that induction of SIRPα protein in APL cells by ATO is mediated through suppression of c-Myc, resulting in reduction of three SIRPα-targeting microRNAs: miR-17, miR-20a and miR-106a." +other hsa-mir-146 "Carcinoma, Thyroid, Papillary" 27011326 Family of microRNA-146 Regulates RAR¦Â in Papillary Thyroid Carcinoma. +other hsa-mir-153 Breast Neoplasms 27012032 MicroRNA-153 Regulates NRF2 Expression and is Associated with Breast Carcinogenesis. +other hsa-mir-186 "Leukemia, Myeloid, Acute" 27012040 Down-Regulation of miR-186 Correlates with Poor Survival in de novo Acute Myeloid Leukemia. +other hsa-mir-30e Breast Neoplasms 27012041 Abnormal miRNA-30e Expression is Associated with Breast Cancer Progression. +other hsa-mir-140 Chordoma 27016303 "This study uncovered the potential of miR-31, miR-140-3p, miR-148a, and miR-222-3p to be key molecules in the cell viability, cell cycle, and apoptosis in chordomas, as well as initiation,differentiation, and progression." +other hsa-mir-148a Chordoma 27016303 "This study uncovered the potential of miR-31, miR-140-3p, miR-148a, and miR-222-3p to be key molecules in the cell viability, cell cycle, and apoptosis in chordomas, as well as initiation,differentiation, and progression." +other hsa-mir-222 Chordoma 27016303 "This study uncovered the potential of miR-31, miR-140-3p, miR-148a, and miR-222-3p to be key molecules in the cell viability, cell cycle, and apoptosis in chordomas, as well as initiation,differentiation, and progression." +other hsa-mir-210 "Carcinoma, Hepatocellular" 27018975 Down-regulation of TIMP2 by HIF-1α/miR-210/HIF-3α regulatory feedback circuit enhances cancer metastasis in hepatocellular carcinoma. +other hsa-mir-139 Neoplasms [unspecific] 27022656 The loss of MiR-139-5p promotes colitis-associated tumorigenesis by mediating PI3K/AKT/Wnt signaling. +other hsa-mir-186 Alzheimer Disease 27029568 miR-186 in Alzheimer's disease: a big hope for a small RNA +other hsa-mir-221 Breast Neoplasms 27031715 "5-aza treatment caused an increase of miRNA-10b, -122, -200b levels in MCF-7/S cells, miRNA-34a, -10b, -122, -200b and -320a levels in MCF-7/Dox cells and miRNA-34a, -10b, -200b and -320a levels in MCF-7/DDP cells." +other hsa-mir-182 Keratitis 27035623 Inactivation of the miR-183/96/182 Cluster Decreases the Severity of Pseudomonas aeruginosa-Induced Keratitis. +other hsa-mir-183 Keratitis 27035623 Inactivation of the miR-183/96/182 Cluster Decreases the Severity of Pseudomonas aeruginosa-Induced Keratitis. +other hsa-mir-96 Keratitis 27035623 Inactivation of the miR-183/96/182 Cluster Decreases the Severity of Pseudomonas aeruginosa-Induced Keratitis. +other hsa-mir-126 Dengue Virus Infection 27039024 "GRP75 is involved in processing of host miRNA, hsa-mir-126, that down regulates dengue virus replication." +other hsa-mir-23b Neoplasms [unspecific] 27040799 Among down-regulators of PRODH/POX is an oncogenic transcription factor c-MYC and miR-23b*. +other hsa-mir-200 Glioma 27041571 SHP-2 acts together with PI3K/AKT to regulate a ZEB1-miR-200 feedback loop in PDGFRα-driven gliomas. +other hsa-mir-196a-2 Chronic Obstructive Pulmonary Disease 27043015 Association of MicroRNA-196a2 Variant with Response to Short-Acting ¦Â2-Agonist in COPD: An Egyptian Pilot Study. +other hsa-mir-92a "Lymphoma, Burkitt" 27044389 "Our results describe for the first time miR-17, miR-19a, miR-19b, miR-20a, and miR-92a expression profiles in pBL." +other hsa-mir-144 Bronchiolitis Obliterans Syndrome 27044533 MicroRNA-144 is unlikely to play a role in bronchiolitis obliterans syndrome. +other hsa-mir-3646 Breast Neoplasms 27045586 MicroRNA-3646 Contributes to Docetaxel Resistance in Human Breast Cancer Cells by GSK-3¦Â/¦Â-Catenin Signaling Pathway. +other hsa-mir-21 "Leukemia, Myelogenous, Chronic, BCR-ABL Positive" 27050372 Exosomes released by CML cells treated with Curcumin contain a high amount of miR-21 +other hsa-mir-16 Colorectal Carcinoma 27055667 Prodigiosin caused a significant increase in miRNA-16-1 expression +other hsa-mir-1 Myocardial Infarction 27056419 miR-1/133a control cardiac conductance and automaticity by regulating all phases of the cardiac action potential +other hsa-mir-1 Vascular Hypertrophy 27056419 miR-1/133a control cardiac conductance and automaticity by regulating all phases of the cardiac action potential +other hsa-mir-133a Vascular Hypertrophy 27056419 miR-1/133a control cardiac conductance and automaticity by regulating all phases of the cardiac action potential. +other hsa-mir-208 Vascular Hypertrophy 27056419 miR-208/499 located in introns of the heavy chain myosin genes regulate expression of sarcomeric contractile proteins. +other hsa-mir-499 Myocardial Infarction 27056419 miR-208/499 located in introns of the heavy chain myosin genes regulate expression of sarcomeric contractile proteins. +other hsa-mir-17 "Leukemia, Lymphocytic, Chronic, B-Cell" 27059597 "Interestingly, TLR1/2 triggering restored BCR functionality, likely breaching the anergic state, and this was accompanied by induction of the miR-17âˆ?2 cluster" +other hsa-mir-155 Pancreatic Neoplasms 27060060 "A vast number of miRNAs, including the well-studied miR-21, miR-155 and miR-34, has been shown to regulate PDAC growth, invasion and metastasis" +other hsa-mir-21 Pancreatic Neoplasms 27060060 "A vast number of miRNAs, including the well-studied miR-21, miR-155 and miR-34, has been shown to regulate PDAC growth, invasion and metastasis" +other hsa-mir-34 Pancreatic Neoplasms 27060060 "A vast number of miRNAs, including the well-studied miR-21, miR-155 and miR-34, has been shown to regulate PDAC growth, invasion and metastasis" +other hsa-mir-126 "Colitis, Ulcerative" 27061150 mango polyphenols attenuated inflammatory response by modulating the PI3K/AKT/mTOR pathway at least in part through upregulation of miRNA-126 expression both in vitro and in vivo +other hsa-let-7a Melanoma 27063098 two other miRNA modulators of EMT (miR-191 and let-7a) in serum exosomes +other hsa-let-7i Melanoma 27063098 two other miRNA modulators of EMT (miR-191 and let-7a) in serum exosomes +other hsa-mir-191 Melanoma 27063098 two other miRNA modulators of EMT (miR-191 and let-7a) in serum exosomes +other hsa-mir-146a Oral Lichen Planus 27063128 "Detection of miR-155, miR-146a in PBNCs and tissues from patients with oral lichen planus." +other hsa-mir-155 Oral Lichen Planus 27063128 "Detection of miR-155, miR-146a in PBNCs and tissues from patients with oral lichen planus." +other hsa-mir-663 Graft-Versus-Host Disease 27063175 Role of miR-663 in acute renal graft rejection: an in vitro study. +other hsa-mir-126 Thyroid Neoplasms 27067785 Interactive role of miR-126 on VEGF-A and progression of papillary and undifferentiated thyroid carcinoma. +other hsa-mir-182 "Carcinoma, Lung, Non-Small-Cell" 27073334 MiR-1244 sensitizes the resistance of non-small cell lung cancer A549 cell to cisplatin +other hsa-mir-21 Recurrent Wheezing 27075111 Extracellular microRNA-21 and microRNA-26a increase in body fluids from rats with antigen induced pulmonary inflammation and children with recurrent wheezing. +other hsa-mir-26a Recurrent Wheezing 27075111 Extracellular microRNA-21 and microRNA-26a increase in body fluids from rats with antigen induced pulmonary inflammation and children with recurrent wheezing. +other hsa-mir-155 "Adenocarcinoma, Lung" 27081085 "We identified a regulatory network including miR-15b and miR-155, and transcription factors with prognostic value in lung cancer." +other hsa-mir-31 Colorectal Carcinoma 27082577 MicroRNA Expression Signatures Associated With BRAF-Mutated Versus KRAS-Mutated Colorectal Cancers. +other hsa-mir-362 Colorectal Carcinoma 27082577 MicroRNA Expression Signatures Associated With BRAF-Mutated Versus KRAS-Mutated Colorectal Cancers. +other hsa-mir-425 Colorectal Carcinoma 27082577 MicroRNA Expression Signatures Associated With BRAF-Mutated Versus KRAS-Mutated Colorectal Cancers. +other hsa-mir-877 Colorectal Carcinoma 27082577 MicroRNA Expression Signatures Associated With BRAF-Mutated Versus KRAS-Mutated Colorectal Cancers. +other hsa-let-7c Neoplasms [unspecific] 27087117 microRNA let-7c (let-7c) contributed to the anisomycin-induced apoptosis +other hsa-mir-191 "Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic" 27093985 Expression of microRNA-191 in T lymphoblastic leukemia/lymphoma and its underlying mechanism. +other hsa-mir-200c Neoplasms [unspecific] 27094812 "miR-200c, an illustrious tumor suppressor, is one of the highly studied miRNAs in terms of development, stemness, proliferation, epithelial-mesenchymal transition (EMT), therapy resistance, and metastasis." +other hsa-let-7 Neoplasms [unspecific] 27097729 The insights of Let-7 miRNAs in oncogenesis and stem cell potency. +other hsa-mir-206 Myocardial Infarction 27103465 "In an acute model of myocardial infarction, transplanted hypoxic MSCs showed a significantly improved survival as compared with hypoxic MSCs overexpressing miR-206." +other hsa-mir-21 Atherosclerosis 27107761 "LaCM decreased apoptosis, necrosis and inflammatory miR-155 and conversely increased anti-apoptotic miR-21 in Ec-LPS-treated HUVECs." +other hsa-mir-21 Liver Diseases [unspecific] 27107786 "In L-02 cells exposed to arsenite, microRNA-21 (miRNA-21) is over-expressed" +other hsa-mir-200b Retinal Degeneration 27113191 Effect of MiR-200b on retinal endothelial cell function in high-glucose condition and the mechanism. +other hsa-mir-221 Asthma 27113449 The degranulation was found to be significantly increased in miR-221 overexpressed cells while it was found to be significantly decreased in miR-221 downregulated cells. +other hsa-let-7a Liver Cirrhosis 27115285 There was decreased expression of let-7a in BDL and Mdr2(-/-) cholangiocytes that was associated with increased NGF expression. +other hsa-mir-124 Neurodegenerative Diseases [unspecific] 27117821 MicroRNAs underlying memory deficits in neurodegenerative disorders. +other hsa-mir-132 Neurodegenerative Diseases [unspecific] 27117821 MicroRNAs underlying memory deficits in neurodegenerative disorders. +other hsa-mir-34 Neurodegenerative Diseases [unspecific] 27117821 MicroRNAs underlying memory deficits in neurodegenerative disorders. +other hsa-mir-363 "Leukemia, Lymphocytic, Chronic, B-Cell" 27118451 Our results reveal an enrichment of specific cellular miRNAs including miR-363 within EVs derived from CD40/IL-4-stimulated CLL cells compared with parental cell miRNA content and control EVs from unstimulated CLL cells. +other hsa-mir-21 Acute Kidney Failure 27122240 "In summary, we report noninvasive detection of AKI in humans by combining the sensitivity of KIM-1 along with mechanistic potentials of miR-21, -200c, and -423." +other hsa-mir-200c "Carcinoma, Renal Cell, Clear-Cell" 27123083 "Aza-induced upregulation of miR-200c may inhibit migration, invasion and EMT in ccRCC cells." +other hsa-mir-17 Leukemia 27123834 Combinatorial treatment against miR-17-5p and miR-19a-3p of the miR-17-92 cluster dramatically reduces colony forming ability of MLL-fusion containing cell lines relative to non-MLL acute myeloid leukemia (AML) controls. +other hsa-mir-124 Stroke 27126323 lithium increased miR-124 expression +other hsa-mir-20a Multiple Myeloma 27129167 "Moreover, nano-sized exosomes were isolated with significantly increasing internal RNAs and down-regulation of exosomal miR-16-5p, miR-15a-5p and miR-20a-5p, miR-17-5p was revealed in the patients resistant to Bz." +other hsa-mir-425 Cardiovascular Diseases [unspecific] 27132035 "After NaAsO2 treatment, we found the expression of microRNA-425-5p (miR-425-5p) was reduced in vitro and in vivo" +other hsa-mir-425 Hypertension 27132035 "After NaAsO2 treatment, we found the expression of microRNA-425-5p (miR-425-5p) was reduced in vitro and in vivo" +other hsa-mir-425 Peripheral Vascular Disease 27132035 "After NaAsO2 treatment, we found the expression of microRNA-425-5p (miR-425-5p) was reduced in vitro and in vivo" +other hsa-mir-103 Diabetes Mellitus 27137869 Long-term treatment with 500 μM CML during adipogenesis resulted in increases in miR-103 and miR-143 levels +other hsa-mir-143 Diabetes Mellitus 27137869 Long-term treatment with 500 μM CML during adipogenesis resulted in increases in miR-103 and miR-143 levels +other hsa-mir-203 Gastric Neoplasms 27142767 Berberine modulates cisplatin sensitivity of human gastric cancer cells by upregulation of miR-203. +other hsa-mir-107 Alzheimer Disease 27143098 osthole plays a neuroprotective activity role in part through up-regulate miR-107 in AD. +other hsa-mir-34a "Leukemia, Lymphoblastic, Acute" 27150988 Expression of miR-34a in Bone Marrow of Adult Acute Lymphoblastic Leukemia and Its Significance in Cell Drug Resistance. +other hsa-mir-34c Bone Disease [unspecific] 27156573 Vaspin regulates the osteogenic differentiation of MC3T3-E1 through the PI3K-Akt/miR-34c loop. +other hsa-mir-16 Gastric Neoplasms 27157613 MiR-16 mediates trastuzumab and lapatinib response in ErbB-2-positive breast and gastric cancer via its novel targets CCNJ and FUBP1. +other hsa-mir-21 Vascular Hypertrophy 27160852 Celastrol also inhibited the miR-21/ERK signalling pathway. +other hsa-mir-181a "Carcinoma, Thyroid, Papillary" 27164936 MiRNA-21 and MiRNA-181a-5p were found to be expressed reciprocally in the exosomes of patients with papillary and follicular TC +other hsa-mir-21 "Carcinoma, Thyroid, Papillary" 27164936 MiRNA-21 and MiRNA-181a-5p were found to be expressed reciprocally in the exosomes of patients with papillary and follicular TC +other hsa-mir-140 Arthritis 27165343 estrogen acts via ER and miR-140 to inhibit the catabolic activity of proteases within the chondrocyte extracellular matrix. +other hsa-mir-140 Osteoarthritis 27165343 estrogen acts via ER and miR-140 to inhibit the catabolic activity of proteases within the chondrocyte extracellular matrix. +other hsa-mir-489 Breast Neoplasms 27171498 miR-489 could reverse the chemoresistance of breast cancer via the PI3K-Akt pathway by targeting SPIN1. +other hsa-mir-139 Colorectal Carcinoma 27173050 miR-139-5p sensitizes colorectal cancer cells to 5-fluorouracil by targeting NOTCH-1. +other hsa-mir-451 Gastric Neoplasms 27173190 "Propofol effectively inhibited proliferation and induced apoptosis in gastric cancer cells, which was partly owing to the downregulation of MMP-2 expression by miR-451." +other hsa-mir-155 Colorectal Carcinoma 27176480 S100A8 activated the NF-κB pathway in the macrophages and promoted the expression of miR-155 +other hsa-mir-126 Heart Failure 27180261 miR-126 up-regulation activates EPCs and ECs and contributes to vascular healing and neovessel formation. +other hsa-mir-126 Myocardial Infarction 27180261 miR-126 up-regulation activates EPCs and ECs and contributes to vascular healing and neovessel formation. +other hsa-mir-494 Muscle Diseases [unspecific] 27181718 Effects of microRNA-494 on the fiber type-specific skeletal myogenesis in human induced pluripotent stem cells. +other hsa-mir-145 Vascular Disease [unspecific] 27186305 MicroRNA-145 regulates platelet-derived growth factor-induced human aortic vascular smooth muscle cell proliferation and migration by targeting CD40 +other hsa-mir-200 "Carcinoma, Lung" 27189341 AKT2 can regulate miR-200a in a histology- or stage-specific manner +other hsa-mir-200a "Carcinoma, Lung" 27189341 AKT2 can regulate miR-200a in a histology- or stage-specific manner and that +other hsa-mir-122 "Carcinoma, Hepatocellular" 27194671 High expression levels of plasma miR-122 are associated with early TACE refractoriness in HCC patients treated with TACE. +other hsa-mir-29b "Carcinoma, Lung, Non-Small-Cell" 27199349 "Overall, our results reveal a complexity in cancer for miR-29b, which can act as either an oncogene or tumor suppressor gene depending on signaling context." +other hsa-mir-4505 Oral Neoplasms 27207653 a microRNA (miR) analysis revealed that LCN2 can suppress CAIX expression and cell migration through miR-4505 induction. +other hsa-mir-92a Cardiovascular Diseases [unspecific] 27208561 PDW/miR-92a-score with a specificity of 97.5% and a sensitivity of 80.0% in relation to detect aspirin resistance. +other hsa-mir-497 Cerebral Ischemia 27209189 "amikacin inhibits miR-497 maturation and promotes ischemic neuronal survival by upregulating anti-apoptotic protein, bcl-2." +other hsa-mir-494 Breast Neoplasms 27216190 Elevating Dicer expression increased levels of the AXL kinase targeting miRNA miR-494 +other hsa-mir-126 Diabetic Retinopathy 27225425 MicroRNA-126 (miR-126) plays a potential role in the pathogenesis in DR +other hsa-mir-203 Colorectal Carcinoma 27236538 overexpression of miR-203 sensitizes colon cancer cells +other hsa-mir-20a Glioma 27242439 The expression levels of miR-20a decreased significantly after U-87 and U-251 cells were treated with EMAP-II. +other hsa-mir-92a Liver Cirrhosis 27246196 miR-92a expression closely correlated with the frequency of a subset of IL-17-producing T helper cells (Th17) +other hsa-mir-181a Ovarian Neoplasms 27249598 miR-181a overexpression decreased the PTX sensitivity of SKOV3 cells and while miR-181a inhibition increased the sensitivity of SKOV3/PTX cells. +other hsa-mir-449a Prostate Neoplasms 27250340 Overexpression of miR-449a or knockdown of c-Myc promoted the sensitivity of LNCaP cells to IR. +other hsa-mir-27b Chondrosarcoma 27252405 Adiponectin promotes VEGF-C-dependent lymphangiogenesis by inhibiting miR-27b through a CaMKII/AMPK/p38 signaling pathway in human chondrosarcoma cells +other hsa-mir-146a Inflammation 27256622 These effects were partially mediated through RvD2 induction of microRNA-146a +other hsa-mir-200 Breast Neoplasms 27257068 "miR-200 levels increase following hPMR1 knockdown, and changes in miR-200 family microRNAs were matched by corresponding changes in miR-200 targets and reporter expression." +other hsa-mir-30e Schizophrenia 27258654 miRNA-30e is associated with cognitive impairment in schizophrenia and depression. +other hsa-mir-30 "Adenocarcinoma, Colon" 27261459 miR-30 family likely plays an important role in IEC homeostasis +other hsa-mir-182 "Carcinoma, Hepatocellular" 27262453 "Upon forcing miR-182 expression in the HCC NK-cells, upregulation of both receptors was observed." +other hsa-mir-152 "Carcinoma, Endometrial" 27263284 Effect of Progesterone-induced MicroRNA-152 on the Proliferation of Endometrial Epithelial Cells. +other hsa-mir-4496 Gastric Neoplasms 27265143 "Here, we show that rebamipide suppresses H. pylori CagA-induced β-catenin and its target cancer-initiating cells (C-IC) marker gene expression via upregulation of miRNA-320a and -4496." +other hsa-mir-379 "Carcinoma, Hepatocellular" 27266355 "Effects of microRNA-379-5p on proliferation, migration and invasion of hepatocellular carcinoma cell line." +other hsa-mir-21 Lung Neoplasms 27266356 The effect and mechanism of microRNA-21 on cis-dichlorodiamineplatinum resistance in lung cancer cell strain. +other hsa-mir-34a Glioma 27268916 miR-34a was downregulated under hypoxia but upregulated by resveratrol +other hsa-mir-21 Autoimmune Diseases [unspecific] 27271606 miR-21 was found to be correlated with the pathogenesis of autoimmune diseases +other hsa-mir-146b Prostate Neoplasms 27273955 MicroRNA-146b acts as a potential tumor suppressor in human prostate cancer. +other hsa-mir-141 Prostate Neoplasms 27278879 "hub hsa-miR3176, -141-3p, -5004-5p, -16-5p, -3915, -488â€?p, -23c, -3673 and -3654 were potential targets to hub gene androgen receptor (AR) and phosphatase and tensin homolog (PTEN)." +other hsa-mir-16 Prostate Neoplasms 27278879 "hub hsa-miR3176, -141-3p, -5004-5p, -16-5p, -3915, -488â€?p, -23c, -3673 and -3654 were potential targets to hub gene androgen receptor (AR) and phosphatase and tensin homolog (PTEN)." +other hsa-mir-23c Prostate Neoplasms 27278879 "hub hsa-miR3176, -141-3p, -5004-5p, -16-5p, -3915, -488â€?p, -23c, -3673 and -3654 were potential targets to hub gene androgen receptor (AR) and phosphatase and tensin homolog (PTEN)." +other hsa-mir-3176 Prostate Neoplasms 27278879 "hub hsa-miR3176, -141-3p, -5004-5p, -16-5p, -3915, -488â€?p, -23c, -3673 and -3654 were potential targets to hub gene androgen receptor (AR) and phosphatase and tensin homolog (PTEN)." +other hsa-mir-32 Prostate Neoplasms 27278879 "hub hsa-miR3176, -141-3p, -5004-5p, -16-5p, -3915, -488â€?p, -23c, -3673 and -3654 were potential targets to hub gene androgen receptor (AR) and phosphatase and tensin homolog (PTEN)." +other hsa-mir-3654 Prostate Neoplasms 27278879 "hub hsa-miR3176, -141-3p, -5004-5p, -16-5p, -3915, -488â€?p, -23c, -3673 and -3654 were potential targets to hub gene androgen receptor (AR) and phosphatase and tensin homolog (PTEN)." +other hsa-mir-3673 Prostate Neoplasms 27278879 "hub hsa-miR3176, -141-3p, -5004-5p, -16-5p, -3915, -488â€?p, -23c, -3673 and -3654 were potential targets to hub gene androgen receptor (AR) and phosphatase and tensin homolog (PTEN)." +other hsa-mir-381 Prostate Neoplasms 27278879 "hub hsa-miR3176, -141-3p, -5004-5p, -16-5p, -3915, -488â€?p, -23c, -3673 and -3654 were potential targets to hub gene androgen receptor (AR) and phosphatase and tensin homolog (PTEN)." +other hsa-mir-3915 Prostate Neoplasms 27278879 "hub hsa-miR3176, -141-3p, -5004-5p, -16-5p, -3915, -488â€?p, -23c, -3673 and -3654 were potential targets to hub gene androgen receptor (AR) and phosphatase and tensin homolog (PTEN)." +other hsa-mir-429 Prostate Neoplasms 27278879 "hub hsa-miR3176, -141-3p, -5004-5p, -16-5p, -3915, -488â€?p, -23c, -3673 and -3654 were potential targets to hub gene androgen receptor (AR) and phosphatase and tensin homolog (PTEN)." +other hsa-mir-488 Prostate Neoplasms 27278879 "hub hsa-miR3176, -141-3p, -5004-5p, -16-5p, -3915, -488â€?p, -23c, -3673 and -3654 were potential targets to hub gene androgen receptor (AR) and phosphatase and tensin homolog (PTEN)." +other hsa-mir-5004 Prostate Neoplasms 27278879 "hub hsa-miR3176, -141-3p, -5004-5p, -16-5p, -3915, -488â€?p, -23c, -3673 and -3654 were potential targets to hub gene androgen receptor (AR) and phosphatase and tensin homolog (PTEN)." +other hsa-mir-606 Prostate Neoplasms 27278879 "hub hsa-miR3176, -141-3p, -5004-5p, -16-5p, -3915, -488â€?p, -23c, -3673 and -3654 were potential targets to hub gene androgen receptor (AR) and phosphatase and tensin homolog (PTEN)." +other hsa-mir-206 "Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal" 27279635 co-transfection of miR-375 and miR-206 exhibited a less effective inhibitory effect +other hsa-mir-221 Intrahepatic Cholangiocarcinoma 27280413 no correlation was found between the expression levels of these molecular markers and histopathological differentiation grade. +other hsa-mir-15a "Leukemia, Lymphoblastic, Acute" 27281445 Prednisolone in concentration of 700 ?M was significantly increased the expression of miR 16-1 and miR 15a after 24 h and 48 h treatment +other hsa-mir-16 "Leukemia, Lymphoblastic, Acute" 27281445 Prednisolone in concentration of 700 ?M was significantly increased the expression of miR 16-1 and miR 15a after 24 h and 48 h treatment +other hsa-mir-1 Neoplasms [unspecific] 27286699 miR-1 is classified to be a tumor suppressor +other hsa-mir-21 Heart Failure 27292200 heart failure (miR-21 and miR-133a) +other hsa-mir-146a Infection [unspecific] 27297392 miR-146a was found to be differentially regulated in THP-1 cells between probiotic and pathogenic bacteria. +other hsa-mir-410 Blindness 27297412 antisense microRNA-410 (anti-miR-410) induces RPE differentiation from amniotic epithelial stem cells. +other hsa-let-7d Lymphoma 27300436 "ΔNp63 inhibition decreases the levels of its transcriptional target, DGCR8, and the maturation of let-7d and miR-128" +other hsa-mir-128 Lymphoma 27300436 "ΔNp63 inhibition decreases the levels of its transcriptional target, DGCR8, and the maturation of let-7d and miR-128" +other hsa-mir-30a Breast Neoplasms 27302063 regulation of lumen formation by miR-342 +other hsa-mir-122 Hepatitis C Virus Infection 27303683 HCV infection requires miR-122 +other hsa-mir-125b Prostate Neoplasms 27305142 MiRNAs were shown to be differently distributed between different fractions of extracellular vesicles. +other hsa-mir-16 Prostate Neoplasms 27305142 MiRNAs were shown to be differently distributed between different fractions of extracellular vesicles. +other hsa-mir-19b Prostate Neoplasms 27305142 MiRNAs were shown to be differently distributed between different fractions of extracellular vesicles. +other hsa-mir-205 Prostate Neoplasms 27305142 MiRNAs were shown to be differently distributed between different fractions of extracellular vesicles. +other hsa-mir-25 Prostate Neoplasms 27305142 MiRNAs were shown to be differently distributed between different fractions of extracellular vesicles. +other hsa-let-7 "Carcinoma, Thyroid, Papillary" 27314338 "let-7 miRNA was found to reduce RAS levels, acting as a tumor suppressor gene." +other hsa-mir-125b Neoplasms [unspecific] 27321180 Forced expression of hsa-miR-125b in these cells resulted in radiosensitivity +other hsa-mir-128 Breast Neoplasms 27322220 miR-128 in exosomes negatively regulates the level of Bax in MCF-7 recipient cells and inhibits cell proliferation. +other hsa-mir-29b Bladder Neoplasms 27322434 miR-21 and miR-29b depression have been shown in Snail-1 suppressed group in EJ-138 cells in vitro. +other hsa-mir-27b Chondrosarcoma 27345723 expression of microRNA-27b was negatively regulated by leptin +other hsa-mir-21 Colorectal Carcinoma 27349026 Plasma Expression Levels of Circulating miR-21 are not Useful for Diagnosing and Monitoring Colorectal Cancer. +other hsa-mir-1 Gastric Neoplasms 27349337 "miR-1, -133 and -206 family in GC" +other hsa-mir-133 Gastric Neoplasms 27349337 "miR-1, -133 and -206 family in GC" +other hsa-mir-206 Gastric Neoplasms 27349337 "miR-1, -133 and -206 family in GC" +other hsa-mir-1 Ovarian Neoplasms 27354590 loss of growth-inhibitory functionality of miR-1 +other hsa-mir-141 Kidney Neoplasms 27358122 Invasion and metastasis ability of renal cancer cell strains 786-0: under the influence of miR-141. +other hsa-mir-210 Cardiovascular Diseases [unspecific] 27359286 "miR-210 has also been shown to be associated with the development of different human diseases including various types of cancers, cardiovascular and cerebrovascular diseases, and immunological diseases." +other hsa-mir-122 Hepatitis C Virus Infection 27366906 Hepatitis C Virus Core Protein Promotes miR-122 Destabilization by Inhibiting GLD-2. +other hsa-mir-21 Squamous Cell Carcinoma 27371785 Blueberry also modulated the expression of the oncomiR miR-21 and the tumor suppressor let-7. +other hsa-mir-21 Breast Neoplasms 27372573 "MCF-7 has a high level of miR-21, miR-375, and miR-27a as target miRNAs." +other hsa-mir-27a Breast Neoplasms 27372573 "MCF-7 has a high level of miR-21, miR-375, and miR-27a as target miRNAs." +other hsa-mir-375 Breast Neoplasms 27372573 "MCF-7 has a high level of miR-21, miR-375, and miR-27a as target miRNAs." +other hsa-mir-132 Neuroblastoma 27374124 New perspectives for multi-level regulations of neuronal acetylcholinesterase by dioxins. +other hsa-mir-212 Neuroblastoma 27374124 New perspectives for multi-level regulations of neuronal acetylcholinesterase by dioxins. +other hsa-mir-25 Neuroblastoma 27374124 New perspectives for multi-level regulations of neuronal acetylcholinesterase by dioxins. +other hsa-mir-132 Inflammation 27378528 LPS down-regulated the expression of miRNA-132. +other hsa-mir-34a Alzheimer Disease 27378912 Over-Expressed Pathogenic miRNAs in Alzheimer's Disease (AD) and Prion Disease (PrD) Drive Deficits in TREM2-Mediated A¦Â42 Peptide Clearance. +other hsa-let-7 Neuroblastoma 27383785 Multiple mechanisms disrupt the let-7 microRNA family in neuroblastoma. +other hsa-mir-19 Schizophrenia 27387650 Our study demonstrates the significance of posttranscriptional gene regulation by miR-19 in preventing the irregular migration of adult-born neurons that may contribute to the etiology of schizophrenia. +other hsa-mir-125b Wound Healing 27388239 "the uMSC-exosomal microRNAs were examined by high-throughput sequencing, with a group of specific microRNAs (miR-21, miR-23a, miR-125b, and miR-145) found to play key roles in suppressing myofibroblast formation by inhibiting excess α-smooth muscle actin and collagen deposition associated with activity of the transforming growth factor-β/SMAD2 signaling pathway." +other hsa-mir-145 Wound Healing 27388239 "the uMSC-exosomal microRNAs were examined by high-throughput sequencing, with a group of specific microRNAs (miR-21, miR-23a, miR-125b, and miR-145) found to play key roles in suppressing myofibroblast formation by inhibiting excess α-smooth muscle actin and collagen deposition associated with activity of the transforming growth factor-β/SMAD2 signaling pathway." +other hsa-mir-21 Wound Healing 27388239 "the uMSC-exosomal microRNAs were examined by high-throughput sequencing, with a group of specific microRNAs (miR-21, miR-23a, miR-125b, and miR-145) found to play key roles in suppressing myofibroblast formation by inhibiting excess α-smooth muscle actin and collagen deposition associated with activity of the transforming growth factor-β/SMAD2 signaling pathway." +other hsa-mir-23a Wound Healing 27388239 "the uMSC-exosomal microRNAs were examined by high-throughput sequencing, with a group of specific microRNAs (miR-21, miR-23a, miR-125b, and miR-145) found to play key roles in suppressing myofibroblast formation by inhibiting excess α-smooth muscle actin and collagen deposition associated with activity of the transforming growth factor-β/SMAD2 signaling pathway." +other hsa-mir-18a Wound Healing 27390086 "We found miR-18a was most susceptible to SH treatment, the target prediction of which were enriched in a bunch of pathways implicated in corneal wound healing." +other hsa-mir-122 "Carcinoma, Hepatocellular" 27391076 "we showed that the isomiR profiles of liver specific MiR122, and a few other miRNAs, correlated with MC-LR treatment." +other hsa-mir-122 Liver Cirrhosis 27391076 "we showed that the isomiR profiles of liver specific MiR122, and a few other miRNAs, correlated with MC-LR treatment." +other hsa-mir-122 Liver Diseases [unspecific] 27391076 "we showed that the isomiR profiles of liver specific MiR122, and a few other miRNAs, correlated with MC-LR treatment." +other hsa-mir-95 Colorectal Carcinoma 27393650 "In conclusion, calycosin exerts an inhibitory effect on proliferation of CRC cells in vivo and in vitro, through ERβ-mediated regulation of the IGF-1R, PI3K/Akt signaling pathways and of miR-95 expression." +other hsa-mir-9 Alzheimer Disease 27394443 These results demonstrated that osthole plays a neuroprotective activity role in part through upregulating miR-9 in AD. +other hsa-mir-17 Neuroblastoma 27396325 "Here, we demonstrate that this microRNA (miRNA) cluster selectively targets several members of the nuclear hormone receptor (NHR) superfamily, and we present a unique NHR signature associated with the survival of neuroblastoma patients." +other hsa-mir-518a Atrioventricular Septal Defect 27396555 "Furthermore, miRNA-DEG regulatory networks were constructed. IL1B was the hub-gene of PPI networks, and AUTS2 and KIAA2022 were predicted to be targeted by miR-518a, miR518e, miR-518f, miR-528a, and miR-96.IL1B, IL12RB2, AUTS2, and KIAA2022 might participate in AVSD in DS patients, and AUTS2 and KIAA2022 might be targeted by miR-518a, miR-518e, miR-518f, miR-528a, and miR-96." +other hsa-mir-518e Atrioventricular Septal Defect 27396555 "Furthermore, miRNA-DEG regulatory networks were constructed. IL1B was the hub-gene of PPI networks, and AUTS2 and KIAA2022 were predicted to be targeted by miR-518a, miR518e, miR-518f, miR-528a, and miR-96.IL1B, IL12RB2, AUTS2, and KIAA2022 might participate in AVSD in DS patients, and AUTS2 and KIAA2022 might be targeted by miR-518a, miR-518e, miR-518f, miR-528a, and miR-96." +other hsa-mir-518f Atrioventricular Septal Defect 27396555 "Furthermore, miRNA-DEG regulatory networks were constructed. IL1B was the hub-gene of PPI networks, and AUTS2 and KIAA2022 were predicted to be targeted by miR-518a, miR518e, miR-518f, miR-528a, and miR-96.IL1B, IL12RB2, AUTS2, and KIAA2022 might participate in AVSD in DS patients, and AUTS2 and KIAA2022 might be targeted by miR-518a, miR-518e, miR-518f, miR-528a, and miR-96." +other hsa-mir-528a Atrioventricular Septal Defect 27396555 "Furthermore, miRNA-DEG regulatory networks were constructed. IL1B was the hub-gene of PPI networks, and AUTS2 and KIAA2022 were predicted to be targeted by miR-518a, miR518e, miR-518f, miR-528a, and miR-96.IL1B, IL12RB2, AUTS2, and KIAA2022 might participate in AVSD in DS patients, and AUTS2 and KIAA2022 might be targeted by miR-518a, miR-518e, miR-518f, miR-528a, and miR-96." +other hsa-mir-96 Atrioventricular Septal Defect 27396555 "Furthermore, miRNA-DEG regulatory networks were constructed. IL1B was the hub-gene of PPI networks, and AUTS2 and KIAA2022 were predicted to be targeted by miR-518a, miR518e, miR-518f, miR-528a, and miR-96.IL1B, IL12RB2, AUTS2, and KIAA2022 might participate in AVSD in DS patients, and AUTS2 and KIAA2022 might be targeted by miR-518a, miR-518e, miR-518f, miR-528a, and miR-96." +other hsa-mir-200a "Carcinoma, Lung, Non-Small-Cell" 27396618 we show that down-regulating Zeb-1 by inducing miR-200a or β-Catenin siRNA can increase drug sensitivity of TKI-resistant cells. +other hsa-mir-494 Retinoblastoma 27399693 "The overexpression of miR-494-3p in SAS cells increased the population of senescence-associated β-galactosidase positive cells, the expression of p16(INK4a) and retinoblastoma 1 (RB1), as well as downregulated Bmi1." +other hsa-mir-494 "Squamous Cell Carcinoma, Oral" 27399693 "The overexpression of miR-494-3p in SAS cells increased the population of senescence-associated β-galactosidase positive cells, the expression of p16(INK4a) and retinoblastoma 1 (RB1), as well as downregulated Bmi1." +other hsa-mir-17 Pancreatic Neoplasms 27400681 "Mechanically, we discovered that high GFRα2 expression level leads to PTEN inactivation via enhancing Mir-17-5p level." +other hsa-mir-9 Osteoarthritis 27404795 IL-6 expression is achieved through increased recruitment of CEBPα to the MCPIP1 promoter and by relieving the miR-9-mediated inhibition of MCPIP1 expression in OA chondrocytes. +other hsa-mir-31 Psoriasis 27405090 Its own regulation is disrupted during the onset and progression of cancer and autoimmune disorders such as psoriasis and systemic lupus erythematosus. +other hsa-mir-31 Systemic Lupus Erythematosus 27405090 Its own regulation is disrupted during the onset and progression of cancer and autoimmune disorders such as psoriasis and systemic lupus erythematosus. +other hsa-mir-155 Ankylosing Spondylitis 27412942 Conclusion XFC could effectively improve hypercoagulative state in active AS patients. The potential mechanism may be associated with the inhibition of miR-155 and NF-κB signal pathway. +other hsa-let-7a "Carcinoma, Ovarian" 27419385 Identification of stably expressed reference small non-coding RNAs for microRNA quantification in high-grade serous ovarian carcinoma tissues. +other hsa-mir-103a "Carcinoma, Ovarian" 27419385 Identification of stably expressed reference small non-coding RNAs for microRNA quantification in high-grade serous ovarian carcinoma tissues. +other hsa-mir-16 "Carcinoma, Ovarian" 27419385 Identification of stably expressed reference small non-coding RNAs for microRNA quantification in high-grade serous ovarian carcinoma tissues. +other hsa-mir-191 "Carcinoma, Ovarian" 27419385 Identification of stably expressed reference small non-coding RNAs for microRNA quantification in high-grade serous ovarian carcinoma tissues. +other hsa-mir-423 "Carcinoma, Ovarian" 27419385 Identification of stably expressed reference small non-coding RNAs for microRNA quantification in high-grade serous ovarian carcinoma tissues. +other hsa-mir-92a "Carcinoma, Ovarian" 27419385 Identification of stably expressed reference small non-coding RNAs for microRNA quantification in high-grade serous ovarian carcinoma tissues. +other hsa-mir-221 Breast Neoplasms 27420990 "The expression of miR-221/222 in the serum of the patients with post-menopausal breast cancer was higher than that of T2DM patients (P < 0.05), but lower than that of the T2DM patients who were also positive for post-menopausal breast cancer (P < 0.05);" +other hsa-mir-221 "Diabetes Mellitus, Type 2" 27420990 "The expression of miR-221/222 in the serum of the patients with post-menopausal breast cancer was higher than that of T2DM patients (P < 0.05), but lower than that of the T2DM patients who were also positive for post-menopausal breast cancer (P < 0.05)" +other hsa-mir-222 Breast Neoplasms 27420990 "The expression of miR-221/222 in the serum of the patients with post-menopausal breast cancer was higher than that of T2DM patients (P < 0.05), but lower than that of the T2DM patients who were also positive for post-menopausal breast cancer (P < 0.05)" +other hsa-mir-222 "Diabetes Mellitus, Type 2" 27420990 "The expression of miR-221/222 in the serum of the patients with post-menopausal breast cancer was higher than that of T2DM patients (P < 0.05), but lower than that of the T2DM patients who were also positive for post-menopausal breast cancer (P < 0.05)" +other hsa-mir-130a "Leukemia, Myeloid, Chronic" 27421670 "Here, the L-amino acid oxidase from Calloselasma rhodostoma (CR-LAAO) venom altered the apoptotic machinery regulation by modulating the expression of the miR-145, miR-26a, miR-142-3p, miR-21, miR-130a, and miR-146a, and of the apoptosis-related proteins Bid, Bim, Bcl-2, Ciap-2, c-Flip, and Mcl-1 in Bcr-Abl(+) cells." +other hsa-mir-142 "Leukemia, Myeloid, Chronic" 27421670 "Here, the L-amino acid oxidase from Calloselasma rhodostoma (CR-LAAO) venom altered the apoptotic machinery regulation by modulating the expression of the miR-145, miR-26a, miR-142-3p, miR-21, miR-130a, and miR-146a, and of the apoptosis-related proteins Bid, Bim, Bcl-2, Ciap-2, c-Flip, and Mcl-1 in Bcr-Abl(+) cells." +other hsa-mir-145 "Leukemia, Myeloid, Chronic" 27421670 "Here, the L-amino acid oxidase from Calloselasma rhodostoma (CR-LAAO) venom altered the apoptotic machinery regulation by modulating the expression of the miR-145, miR-26a, miR-142-3p, miR-21, miR-130a, and miR-146a, and of the apoptosis-related proteins Bid, Bim, Bcl-2, Ciap-2, c-Flip, and Mcl-1 in Bcr-Abl(+) cells." +other hsa-mir-146a "Leukemia, Myeloid, Chronic" 27421670 "Here, the L-amino acid oxidase from Calloselasma rhodostoma (CR-LAAO) venom altered the apoptotic machinery regulation by modulating the expression of the miR-145, miR-26a, miR-142-3p, miR-21, miR-130a, and miR-146a, and of the apoptosis-related proteins Bid, Bim, Bcl-2, Ciap-2, c-Flip, and Mcl-1 in Bcr-Abl(+) cells." +other hsa-mir-21 "Leukemia, Myeloid, Chronic" 27421670 "Here, the L-amino acid oxidase from Calloselasma rhodostoma (CR-LAAO) venom altered the apoptotic machinery regulation by modulating the expression of the miR-145, miR-26a, miR-142-3p, miR-21, miR-130a, and miR-146a, and of the apoptosis-related proteins Bid, Bim, Bcl-2, Ciap-2, c-Flip, and Mcl-1 in Bcr-Abl(+) cells." +other hsa-mir-26a "Leukemia, Myeloid, Chronic" 27421670 "Here, the L-amino acid oxidase from Calloselasma rhodostoma (CR-LAAO) venom altered the apoptotic machinery regulation by modulating the expression of the miR-145, miR-26a, miR-142-3p, miR-21, miR-130a, and miR-146a, and of the apoptosis-related proteins Bid, Bim, Bcl-2, Ciap-2, c-Flip, and Mcl-1 in Bcr-Abl(+) cells." +other hsa-mir-21 "Lymphoma, T-Cell, Cutaneous" 27422033 "Our findings not only demonstrate a critical role for IL15-mediated inflammation in cutaneous T-cell lymphomagenesis, but also uncover a new oncogenic regulatory loop in CTCL involving IL15, HDAC1, HDAC6, and miR-21 that shows differential sensitivity to isotype-specific HDAC inhibitors." +other hsa-mir-98 "Squamous Cell Carcinoma, Esophageal" 27422937 "AmiR-98 mimic enforced the expression of miRNA-98 and made ESCC cells sensitive to radiotherapy, while anti-miR-98 reversed this process." +other hsa-mir-27a Osteosarcoma 27429847 "Moreover, our findings suggested that the modulatory effects of PG on EMMPRIN were due, at least in part, to regulation of an ROS-miR-27a/ZBTB10-Sp1 transcription factor pathway." +other hsa-mir-142 Periodontal Diseases 27429973 "In conclusion, five miRNAs have consistently been reported for periodontitis; however, their disease specificity, detectability, and expression in saliva and their importance as noninvasive markers are questionable." +other hsa-mir-146a Periodontal Diseases 27429973 "In conclusion, five miRNAs have consistently been reported for periodontitis; however, their disease specificity, detectability, and expression in saliva and their importance as noninvasive markers are questionable." +other hsa-mir-155 Periodontal Diseases 27429973 "In conclusion, five miRNAs have consistently been reported for periodontitis; however, their disease specificity, detectability, and expression in saliva and their importance as noninvasive markers are questionable." +other hsa-mir-203 Periodontal Diseases 27429973 "In conclusion, five miRNAs have consistently been reported for periodontitis; however, their disease specificity, detectability, and expression in saliva and their importance as noninvasive markers are questionable." +other hsa-mir-223 Periodontal Diseases 27429973 "In conclusion, five miRNAs have consistently been reported for periodontitis; however, their disease specificity, detectability, and expression in saliva and their importance as noninvasive markers are questionable." +other hsa-mir-16 Glioma 27430517 apigenin inhibits glioma cell growth through promoting miR?16 and suppression of BCL2 and NF-¦ÊB/MMP-9 +other hsa-mir-29b Multiple Myeloma 27430753 Paeoniflorin inhibits proliferation and promotes apoptosis of multiple myeloma cells via its effects on microRNAâ€?9b and matrix metalloproteinaseâ€?. +other hsa-mir-146b "Leukemia, Lymphocytic, Chronic, B-Cell" 27431016 "When evaluated in CLL cells from 38 patients pre and post treatment with ibrutinib, a subset of these miRNAs (miR-22, miR-34a, miR-146b and miR-181b) was significantly decreased in response to ibrutinib." +other hsa-mir-181b "Leukemia, Lymphocytic, Chronic, B-Cell" 27431016 "When evaluated in CLL cells from 38 patients pre and post treatment with ibrutinib, a subset of these miRNAs (miR-22, miR-34a, miR-146b and miR-181b) was significantly decreased in response to ibrutinib." +other hsa-mir-22 "Leukemia, Lymphocytic, Chronic, B-Cell" 27431016 "When evaluated in CLL cells from 38 patients pre and post treatment with ibrutinib, a subset of these miRNAs (miR-22, miR-34a, miR-146b and miR-181b) was significantly decreased in response to ibrutinib." +other hsa-mir-34a "Leukemia, Lymphocytic, Chronic, B-Cell" 27431016 "When evaluated in CLL cells from 38 patients pre and post treatment with ibrutinib, a subset of these miRNAs (miR-22, miR-34a, miR-146b and miR-181b) was significantly decreased in response to ibrutinib." +other hsa-mir-200c Kidney Injury 27431456 Chromium upper tertile was also associated with higher urinary miR-200c (500 copies/μl) and miR-423 (189 copies/μL). +other hsa-mir-423 Kidney Injury 27431456 Chromium upper tertile was also associated with higher urinary miR-200c (500 copies/μl) and miR-423 (189 copies/μL). +other hsa-mir-223 Spinal Cord Injuries 27432064 Naringenin inhibits spinal cord injury-induced activation of neutrophils through miR-223. +other hsa-mir-204 Diabetes Mellitus 27438705 "Its pathological functions have been observed in a few diseases including pulmonary arterial hypertension, diabetes, and various types of cancers." +other hsa-mir-204 Endometrial Neoplasms 27438705 "It is believed that miR-204 acts as a tumor-suppressor via promoting apoptosis, conferring the resistance of cancer cells to chemotherapy, and suppressing the self-renewal of cancer stem cells (CSCs) and the epithelial to mesenchymal transition (EMT)." +other hsa-mir-204 Hypertension 27438705 "Its pathological functions have been observed in a few diseases including pulmonary arterial hypertension, diabetes, and various types of cancers." +other hsa-mir-204 Prostate Neoplasms 27438705 "It is believed that miR-204 acts as a tumor-suppressor via promoting apoptosis, conferring the resistance of cancer cells to chemotherapy, and suppressing the self-renewal of cancer stem cells (CSCs) and the epithelial to mesenchymal transition (EMT)." +other hsa-mir-204 Pulmonary Hypertension 27438705 "Its pathological functions have been observed in a few diseases including pulmonary arterial hypertension, diabetes, and various types of cancers." +other hsa-mir-122 Hepatitis C Virus Infection 27440892 the expression of CAMP in nonhepatic 293T cells expressing claudin 1 and microRNA miR-122 confers complete propagation of HCV. +other hsa-mir-519d "Carcinoma, Lung, Non-Small-Cell" 27447710 "The aim of the study was to evaluate the expression levels of selected miRNAs: miR-26a, miR-29b and miR-519d, and their target gene, matrix metalloproteinase-2 (MMP-2) in patients with non-small cell lung cancer (NSCLC)." +other hsa-mir-137 Glioblastoma 27448441 "Furthermore, combining miR-137 and antimiR-10b synergizes with the receptor inhibitory function of aptamer carriers and prevents GSC expansion." +other hsa-mir-122 "Carcinoma, Hepatocellular" 27450327 "In this system, we developed a conditionally replicative adenovirus (CRAd) loaded on human umbilical cord-derived mesenchymal stem cells (HUMSCs), in which the CRAd contained an adenovirus E1A gene dual regulated by α-fetoprotein promoter and microRNA-122 target sequence." +other hsa-mir-7 Systemic Lupus Erythematosus 27450756 The clearest case is one circRNA CDR1as that serves as sponge of miR-7. +other hsa-mir-133a Preterm Labor 27452435 IAI is associated with a transcriptional signature consistent with acute inflammation in the villous trophoblast. +other hsa-mir-18a Preterm Labor 27452440 "MALP-2 did not cause apoptosis but did lead to significant secretion of IL-4, IL-6, and IL-8 (P < 0.05, 0.01, 0.001, respectively) and significant changes in miRNA-320a and miRNA-18a (P < 0.05)." +other hsa-mir-155 Pancreatic Adenocarcinoma 27456015 "whereas miRNA-30c, miRNA-21, and miRNA-155 levels and CK19 mRNA levels in station 8 nodes were variable and did not correlate with RFS or OS." +other hsa-mir-33b Gastric Neoplasms 27456358 Curcumin inhibits cell growth and induces cell apoptosis through upregulation of miR-33b in gastric cancer. +other hsa-mir-627 Colon Neoplasms 27458137 "In addition, overexpression of miR-627 or siRNA knockdown of CYP3A4 enhanced the efficacy of irinotecan in growth inhibition and apoptosis induction." +other hsa-mir-211 Chromosome 15q13.3 Microdeletion Syndrome 27459725 The 15q13.3 microdeletion syndrome is caused by a 1.5-MB hemizygous microdeletion located on 15q13.3 affecting seven genes: FAN1; MTMR10; TRPM1; miR-211; KLF13; OTUD7A; and CHRNA7 +other hsa-mir-326 "Adenocarcinoma, Lung" 27460077 Overexpression of miR-326 reversed cisplatin chemoresistance of LAD cells in vitro and in vivo. +other hsa-mir-200 "Carcinoma, Colon" 27460529 Niclosamide inhibits colon cancer progression through downregulation of the Notch pathway and upregulation of the tumor suppressor miR-200 family. +other hsa-mir-16 Osteosarcoma 27460987 "Moreover, GLIPR1 overexpression upregulated miR-16 in osteosarcoma cells." +other hsa-mir-146a Asthma 27463381 "Chitin induced the expression of miR-155, miR-146a and miR-21, each of which is known to up-regulate the expression of pro-inflammatory cytokines." +other hsa-mir-146a "Carcinoma, Lung" 27463381 "Chitin induced the expression of miR-155, miR-146a and miR-21, each of which is known to up-regulate the expression of pro-inflammatory cytokines." +other hsa-mir-155 Asthma 27463381 "Chitin induced the expression of miR-155, miR-146a and miR-21, each of which is known to up-regulate the expression of pro-inflammatory cytokines." +other hsa-mir-155 "Carcinoma, Lung" 27463381 "Chitin also induced the expression of the key pattern recognition receptors TLR2 and TLR4. Chitin induced the expression of miR-155, miR-146a and miR-21, each of which is known to up-regulate the expression of pro-inflammatory cytokines." +other hsa-mir-21 Asthma 27463381 "Chitin induced the expression of miR-155, miR-146a and miR-21, each of which is known to up-regulate the expression of pro-inflammatory cytokines." +other hsa-mir-21 "Carcinoma, Lung" 27463381 "Chitin induced the expression of miR-155, miR-146a and miR-21, each of which is known to up-regulate the expression of pro-inflammatory cytokines." +other hsa-mir-126 Rheumatoid Arthritis 27465842 CCN1 induced VEGF expression in osteoblasts and increased endothelial progenitor cells (EPCs) angiogenesis by inhibiting miR-126 via the protein kinase C-alpha (PKC-α) signaling pathway. +other hsa-mir-10b Glioblastoma 27467502 Regulation of Cell Proliferation and Migration by miR-203 via GAS41/miR-10b Axis in Human Glioblastoma Cells. +other hsa-mir-9 Breast Neoplasms 27468688 Exosome-mediated delivery of miR-9 induces cancer-associated fibroblast-like properties in human breast fibroblasts. +other hsa-mir-155 "Carcinoma, Breast" 27470349 "Therefore, through the anti-glycolytic effect and breakage of the JAK/STAT3/SOCS1 feedback loop via miR-155-5p, 3B may potentially serve as a potential therapeutic agent against breast cancer." +other hsa-mir-34a Holt-Oram Syndrome 27471727 This approach allowed to discover complex regulatory circuits involving novel miRNAs and protein coding genes not considered before in the HOS such as miR-34a and miR-30 and their targets. +other hsa-mir-195 Intrahepatic Cholangiocarcinoma 27474881 Extracellular vesicles carry microRNA-195 to intrahepatic cholangiocarcinoma and improve survival in a rat model. +other hsa-let-7a Cardiomyopathy 27475403 "Six miRNAs seem to be associated with these 2 pathways, which include hsa-miR-19b-1-5p, hsa-miR-1295a, hsa-let-7a-5p, hsa-miR-99b-3p, hsa-miR-16-1-3p, and hsa-miR-34b-3p" +other hsa-mir-1295a Cardiomyopathy 27475403 "Six miRNAs seem to be associated with these 2 pathways, which include hsa-miR-19b-1-5p, hsa-miR-1295a, hsa-let-7a-5p, hsa-miR-99b-3p, hsa-miR-16-1-3p, and hsa-miR-34b-3p" +other hsa-mir-16-1 Cardiomyopathy 27475403 "Six miRNAs seem to be associated with these 2 pathways, which include hsa-miR-19b-1-5p, hsa-miR-1295a, hsa-let-7a-5p, hsa-miR-99b-3p, hsa-miR-16-1-3p, and hsa-miR-34b-3p" +other hsa-mir-19b-1 Cardiomyopathy 27475403 "Six miRNAs seem to be associated with these 2 pathways, which include hsa-miR-19b-1-5p, hsa-miR-1295a, hsa-let-7a-5p, hsa-miR-99b-3p, hsa-miR-16-1-3p, and hsa-miR-34b-3p" +other hsa-mir-34b Cardiomyopathy 27475403 "Six miRNAs seem to be associated with these 2 pathways, which include hsa-miR-19b-1-5p, hsa-miR-1295a, hsa-let-7a-5p, hsa-miR-99b-3p, hsa-miR-16-1-3p, and hsa-miR-34b-3p" +other hsa-mir-99b Cardiomyopathy 27475403 "Six miRNAs seem to be associated with these 2 pathways, which include hsa-miR-19b-1-5p, hsa-miR-1295a, hsa-let-7a-5p, hsa-miR-99b-3p, hsa-miR-16-1-3p, and hsa-miR-34b-3p" +other hsa-mir-125b Psoriasis 27479112 "Based on our bioinformatical pipeline, ubiquitin-specific peptidase 2 was selected as a likely candidate for a mechanistic explanation for psoriasis association." +other hsa-mir-29a Liver Cirrhosis 27480597 MiR-29a exhibited anti-fibrotic effect without cell toxicity in vivo and directly suppressed the expression of PDGF-related genes as well as COL1A1 and induced apoptosis of LX-2 cells. +other hsa-mir-30d Choriocarcinoma 27481218 "Following transient transfection of mir-30d mimic, the disrupted attachment and outgrowth of JAR spheroids was partially restored in the model." +other hsa-mir-558 "Carcinoma, Lung" 27485693 "By contrast, in the cells exposed to 4, 6 or 8 Gy, the administration of miRâ€?58 mimics or AATK specific siRNA significantly promoted cell survival rate and overexpression of AATK reversed this effect." +other hsa-mir-206 Rhabdomyosarcoma 27488535 Heme Oxygenase-1 Controls an HDAC4-miR-206 Pathway of Oxidative Stress in Rhabdomyosarcoma. +other hsa-mir-17 Allergic Rhinitis 27491928 "The results showed that the levels of miR-19a, but not the rest of the 5 members (miR-17, miR-18a, miR-19b, miR-20a, and miR-92a), were significantly higher in peripheral B cells from AR patients as than in B cells from healthy participants." +other hsa-mir-18a Allergic Rhinitis 27491928 "The results showed that the levels of miR-19a, but not the rest of the 5 members (miR-17, miR-18a, miR-19b, miR-20a, and miR-92a), were significantly higher in peripheral B cells from AR patients as than in B cells from healthy participants." +other hsa-mir-19b Allergic Rhinitis 27491928 "The results showed that the levels of miR-19a, but not the rest of the 5 members (miR-17, miR-18a, miR-19b, miR-20a, and miR-92a), were significantly higher in peripheral B cells from AR patients as than in B cells from healthy participants." +other hsa-mir-20a Allergic Rhinitis 27491928 "The results showed that the levels of miR-19a, but not the rest of the 5 members (miR-17, miR-18a, miR-19b, miR-20a, and miR-92a), were significantly higher in peripheral B cells from AR patients as than in B cells from healthy participants." +other hsa-mir-92a Allergic Rhinitis 27491928 "The results showed that the levels of miR-19a, but not the rest of the 5 members (miR-17, miR-18a, miR-19b, miR-20a, and miR-92a), were significantly higher in peripheral B cells from AR patients as than in B cells from healthy participants." +other hsa-mir-23a "Adenocarcinoma, Lung" 27492069 "In addition, miR-23a was significantly enriched in the exosomes after mesenchymal transition." +other hsa-mir-34c Bone Disease [unspecific] 27492554 "Taken together, our studies suggested that Icariine restored LPS-induced bone loss by downregulating miR-34c level and suppressing JNKs, p38, and NF-kB pathways, which highlighted the potential use of Icariine as a therapeutic agent in the treatment of bacteria-induced bone loss diseases." +other hsa-mir-19b Neuroblastoma 27492819 Suppression of miR-19b may enhance the cytotoxic effects of mTOR inhibitors in neuroblastoma cells +other hsa-let-7 "Leukemia, Myeloid, Chronic" 27494666 "ADAR1 restores expression of let-7 and efficiently kills LSCs, providing an innovative therapeutic target in CML." +other hsa-mir-21 Multiple Myeloma 27494872 miR-21 and miR-221/222 could negatively modulate drug sensitivity of MM cells. +other hsa-let-7f Hepatitis C Virus Infection 27496568 "these functional miRNAs, mainly represented by let-7f, miR-145, miR-199a, and miR-221 released from uMSC-Exo, largely contributed to the suppression of HCV RNA replication." +other hsa-mir-145 Hepatitis C Virus Infection 27496568 "these functional miRNAs, mainly represented by let-7f, miR-145, miR-199a, and miR-221 released from uMSC-Exo, largely contributed to the suppression of HCV RNA replication." +other hsa-mir-199a Hepatitis C Virus Infection 27496568 "these functional miRNAs, mainly represented by let-7f, miR-145, miR-199a, and miR-221 released from uMSC-Exo, largely contributed to the suppression of HCV RNA replication." +other hsa-mir-221 Hepatitis C Virus Infection 27496568 "these functional miRNAs, mainly represented by let-7f, miR-145, miR-199a, and miR-221 released from uMSC-Exo, largely contributed to the suppression of HCV RNA replication." +other hsa-mir-29b "Carcinoma, Gastric" 27497248 "Taken together, our results suggested that RUNX3-mediated up-regulation of miR-29b inhibited the proliferation and migration of gastric cancer cells by targeting KDM2A, representing a novel molecular mechanism for the tumor suppression action of RUNX3." +other hsa-mir-200a Neoplasms [unspecific] 27497669 "In conclusion, LEFTY2 down-regulates MKi67 expression and FAK activity, up-regulates miR-200a and E-cadherin, and is thus a powerful negative regulator of endometrial cell proliferation and migration." +other hsa-mir-410 Neuroblastoma 27498840 "In conclusion, the present study demonstrates that the overexpression of SPARC in combination with radiation reduced tumor angiogenesis by downregulating VEGF-A via miR-410." +other hsa-let-7 Perlman Syndrome 27498873 we found that Dis3l2 specifically recognizes and degrades uridylated pre-let-7 microRNA +other hsa-mir-125b Neoplasms [unspecific] 27500388 "along with modulation of wt-p53 and miR-125b expression, we also show that the exosomes (i.e., wt-p53/exo, miR-125b/exo and combination/exo) have a reprogramed global miRNA profile." +other hsa-mir-21 Astrocytoma 27504157 "Our data showed that in 1321N1 cells, β-adrenergic-Epac pathway stimulation up and down-regulated Cx43 and miR-21 expression respectively." +other hsa-mir-21 Glioma 27504157 "Our data showed that in 1321N1 cells, E2-adrenergic-Epac pathway stimulation up and down-regulated Cx43 and miR-21 expression respectively." +other hsa-mir-4443 "Carcinoma, Breast" 27504971 "We revealed that miR-4443 induced malignancy of breast cancer mainly in chemo-resistance aspect for the very first time, providing a novel biomarker in breast cancer diagnosis and therapy." +other hsa-mir-17 Kaposi Sarcoma 27512057 "Here, we provide the first experimental evidence of JMRV miRNAs in vitro and demonstrate that one of these viral miRNAs can mimic the activity of the cellular miR-17/20/106 family." +other hsa-mir-17 Multiple Sclerosis 27512057 "Here, we provide the first experimental evidence of JMRV miRNAs in vitro and demonstrate that one of these viral miRNAs can mimic the activity of the cellular miR-17/20/106 family." +other hsa-mir-17 Polycystic Kidney Disease 27512774 One of the mechanisms through which the miR-17~92 cluster aggravates to cyst growth is by promoting proliferation of the cyst epithelial cells. +other hsa-mir-155 Myelodysplastic Syndromes 27513856 "In the current study, we identified overexpression of c-Fos-targeting miR-34a and miR-155 as the cause of impairment." +other hsa-mir-34a Myelodysplastic Syndromes 27513856 "In the current study, we identified overexpression of c-Fos-targeting miR-34a and miR-155 as the cause of impairment." +other hsa-mir-29a "Carcinoma, Breast" 27523474 miR-29a may be a potential target for the patients who acquired ADR-resistance during the treatment of breast cancer. +other hsa-mir-135a "Carcinoma, Prostate" 27524492 Our data support a model in which hsa-miR-135-1 acts as a potential tumor suppressor in metastatic prostate cancer. +other hsa-mir-210 Preeclampsia 27529341 "Some of the most frequently differentially expressed miRs in PE include miR-210, miR-223 and miR-126/126* which associate strongly with the etiological domains of hypoxia, immunology and angiogenesis." +other hsa-mir-126 "Leukemia, Lymphoblastic" 27535859 Bioinformatics analysis of microRNA comprehensive regulatory network in B- cell acute lymphoblastic leukemia. +other hsa-mir-138 "Carcinoma, Esophageal" 27536892 ¦Á-Solanine Modulates the Radiosensitivity of Esophageal Cancer Cells by Inducing MicroRNA 138 Expression. +other hsa-mir-214 "Carcinoma, Colon" 27537384 "MicroRNA-214 suppresses growth, migration and invasion through a novel target, high mobility group AT-hook 1, in human cervical and colorectal cancer cells." +other hsa-mir-124 Stroke 27539642 Dynamic Modulation of Microglia/Macrophage Polarization by miR-124 after Focal Cerebral Ischemia. +other hsa-mir-503 "Carcinoma, Breast" 27539783 An integrative transcriptomics approach identifies miR-503 as a candidate master regulator of the estrogen response in MCF-7 breast cancer cells. +other hsa-mir-1 "Carcinoma, Lung" 27541266 Reprogramming of Normal Fibroblasts into Cancer-Associated Fibroblasts by miRNAs-Mediated CCL2/VEGFA Signaling. +other hsa-mir-206 "Carcinoma, Lung" 27541266 Reprogramming of Normal Fibroblasts into Cancer-Associated Fibroblasts by miRNAs-Mediated CCL2/VEGFA Signaling. +other hsa-mir-31 "Carcinoma, Lung" 27541266 Reprogramming of Normal Fibroblasts into Cancer-Associated Fibroblasts by miRNAs-Mediated CCL2/VEGFA Signaling. +other hsa-mir-21 Vascular Hypertrophy 27542393 MicroRNA-21 Lowers Blood Pressure in Spontaneous Hypertensive Rats by Upregulating Mitochondrial Translation. +other hsa-mir-208b Atrial Fibrillation 27545043 miR-208b upregulation interferes with calcium handling in HL-1 atrial myocytes: Implications in human chronic atrial fibrillation. +other hsa-mir-21 "Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal" 27545281 MicroRNA-21 in laryngeal squamous cell carcinoma: Diagnostic and prognostic features. +other hsa-mir-211 Melanoma 27548915 Melanoma miRNA trafficking controls tumour primary niche formation. +other hsa-mir-429 "Carcinoma, Renal Cell, Clear-Cell" 27549611 Epithelial-mesenchymal transition-associated microRNA/mRNA signature is linked to metastasis and prognosis in clear-cell renal cell carcinoma. +other hsa-mir-146b "Leukemia, Lymphoblastic, Acute, T-Cell" 27550837 MiR-146b negatively regulates migration and delays progression of T-cell acute lymphoblastic leukemia. +other hsa-mir-210 "Carcinoma, Adrenocortical" 27550961 Preclinical progress and first translational steps for a liposomal chemotherapy protocol against adrenocortical carcinoma. +other hsa-mir-145 Osteogenesis Imperfecta 27551756 Ossotide promotes cell differentiation of human osteoblasts from osteogenesis imperfecta patients by up-regulating miR-145. +other hsa-mir-383 "Carcinoma, Lung, Non-Small-Cell" 27551765 MicroRNA-383 is a tumor suppressor and potential prognostic biomarker in human non-small cell lung caner. +other hsa-mir-483 "Carcinoma, Ovarian" 27554045 PKC-alpha modulation by miR-483-3p in platinum-resistant ovarian carcinoma cells. +other hsa-mir-29b "Carcinoma, Lung, Non-Small-Cell" 27555773 Aptamer-hybrid nanoparticle bioconjugate efficiently delivers miRNA-29b to non-small-cell lung cancer cells and inhibits growth by downregulating essential oncoproteins. +other hsa-mir-145 "Squamous Cell Carcinoma, Oral" 27557511 "Acquisition cancer stemness, mesenchymal transdifferentiation, and chemoresistance properties by chronic exposure of oral epithelial cells to arecoline." +other hsa-mir-206 Glioblastoma 27558109 MicroRNA-206 Inhibited the Progression of Glioblastoma Through BCL-2. +other hsa-let-7a "Diabetes Mellitus, Gestational" 27562513 Influence of gestational diabetes mellitus on human umbilical vein endothelial cell miRNA. +other hsa-let-7g "Diabetes Mellitus, Gestational" 27562513 Influence of gestational diabetes mellitus on human umbilical vein endothelial cell miRNA. +other hsa-mir-126 "Diabetes Mellitus, Gestational" 27562513 Influence of gestational diabetes mellitus on human umbilical vein endothelial cell miRNA. +other hsa-mir-130b "Diabetes Mellitus, Gestational" 27562513 Influence of gestational diabetes mellitus on human umbilical vein endothelial cell miRNA. +other hsa-mir-148a "Diabetes Mellitus, Gestational" 27562513 Influence of gestational diabetes mellitus on human umbilical vein endothelial cell miRNA. +other hsa-mir-30c "Diabetes Mellitus, Gestational" 27562513 Influence of gestational diabetes mellitus on human umbilical vein endothelial cell miRNA. +other hsa-mir-452 "Diabetes Mellitus, Gestational" 27562513 Influence of gestational diabetes mellitus on human umbilical vein endothelial cell miRNA. +other hsa-mir-139 "Carcinoma, Prostate" 27562849 MiR-139-5p is Increased in the Peripheral Blood of Patients with Prostate Cancer. +other hsa-mir-630 "Squamous Cell Carcinoma, Esophageal" 27563011 MiR-630 inhibits invasion and metastasis in esophageal squamous cell carcinoma. +other hsa-mir-21 Bronchiolitis Obliterans Syndrome 27564214 Identification of miRNAs Potentially Involved in Bronchiolitis Obliterans Syndrome: A Computational Study. +other hsa-mir-34a Bronchiolitis Obliterans Syndrome 27564214 Identification of miRNAs Potentially Involved in Bronchiolitis Obliterans Syndrome: A Computational Study. +other hsa-mir-222 "Carcinoma, Lung" 27566197 Panax notoginseng saponins attenuate lung cancer growth in part through modulating the level of Met/miR-222 axis. +other hsa-mir-383 "Carcinoma, Ovarian" 27567588 Inhibition of microRNA-383 has tumor suppressive effect in human epithelial ovarian cancer through the action on caspase-2 gene. +other hsa-mir-146a Psoriasis 27568078 MicroRNA-146a suppresses IL-17-mediated skin inflammation and is genetically associated with psoriasis. +other hsa-mir-222 "Carcinoma, Breast" 27569215 Mesenchymal Stem Cell-Derived Exosomes Stimulate Cycling Quiescence and Early Breast Cancer Dormancy in Bone Marrow. +other hsa-mir-223 "Carcinoma, Breast" 27569215 Mesenchymal Stem Cell-Derived Exosomes Stimulate Cycling Quiescence and Early Breast Cancer Dormancy in Bone Marrow. +other hsa-mir-29a "Adenocarcinoma, Lung" 27569280 Respiratory syncytial virus non-structural protein 1 facilitates virus replication through miR-29a-mediated inhibition of interferon-¦Á receptor. +other hsa-mir-21 Autism Spectrum Disorder 27571009 "Genome-wide, integrative analysis implicates microRNA dysregulation in autism spectrum disorder." +other hsa-mir-211 Melanoma 27571736 Pigmented melanosomes are now shown to have a relevant role in establishing a tumour niche in primary melanoma by reprogramming dermal fibroblasts into cancer-associated fibroblasts through the transfer of miR-211 +other hsa-mir-107 "Carcinoma, Hepatocellular" 27571925 Heme oxygenase-1 retards hepatocellular carcinoma progression through the microRNA pathway. +other hsa-mir-30d "Carcinoma, Hepatocellular" 27571925 Heme oxygenase-1 retards hepatocellular carcinoma progression through the microRNA pathway. +other hsa-mir-137 "Squamous Cell Carcinoma, Tongue" 27571935 "MicroRNA-137 suppresses tongue squamous carcinoma cell proliferation, migration and invasion." +other hsa-mir-204 Colorectal Carcinoma 27571956 Weighted gene co-expression network analysis of colorectal cancer liver metastasis genome sequencing data and screening of anti-metastasis drugs. +other hsa-mir-455 Colorectal Carcinoma 27571956 Weighted gene co-expression network analysis of colorectal cancer liver metastasis genome sequencing data and screening of anti-metastasis drugs. +other hsa-mir-195 Neoplasms [unspecific] 27572273 MicroRNA-195 targets VEGFR2 and has a tumor suppressive role in ACHN cells via PI3K/Akt and Raf/MEK/ERK signaling pathways. +other hsa-mir-144 "Carcinoma, Esophageal" 27572636 Possible tumor suppressive role of the miR-144/451 cluster in esophageal carcinoma as determined by principal component regression analysis. +other hsa-mir-451 "Carcinoma, Esophageal" 27572636 Possible tumor suppressive role of the miR-144/451 cluster in esophageal carcinoma as determined by principal component regression analysis. +other hsa-mir-194 Melanoma 27573550 miR-194 is a negative regulator of GEF-H1 pathway in melanoma. +other hsa-mir-1246 "Carcinoma, Biliary Tract" 27573701 miR?1246 and miR?4644 in salivary exosome as potential biomarkers for pancreatobiliary tract cancer. +other hsa-mir-4644 "Carcinoma, Biliary Tract" 27573701 miR?1246 and miR?4644 in salivary exosome as potential biomarkers for pancreatobiliary tract cancer. +other hsa-mir-892b "Carcinoma, Bladder" 27573859 "MicroRNA-892b influences proliferation, migration and invasion of bladder cancer cells by mediating the p19ARF/cyclin D1/CDK6 and Sp-1/MMP-9 pathways." +other hsa-mir-195 Glioma 27574009 TGF-¦Â1 regulating miR-205/miR-195 expression affects the TGF-¦Â signal pathway by respectively targeting SMAD2/SMAD7. +other hsa-mir-205 Glioma 27574009 TGF-¦Â1 regulating miR-205/miR-195 expression affects the TGF-¦Â signal pathway by respectively targeting SMAD2/SMAD7. +other hsa-let-7 "Carcinoma, Breast" 27574028 Let?7 miRNAs sensitize breast cancer stem cells to radiation?induced repression through inhibition of the cyclin?D1/Akt1/Wnt1 signaling pathway. +other hsa-mir-494 "Adenocarcinoma, Lung" 27575252 Discriminating between Terminal- and Non-Terminal Respiratory Unit-Type Lung Adenocarcinoma Based on MicroRNA Profiles. +other hsa-mir-551b "Adenocarcinoma, Lung" 27575252 Discriminating between Terminal- and Non-Terminal Respiratory Unit-Type Lung Adenocarcinoma Based on MicroRNA Profiles. +other hsa-mir-100 "Carcinoma, Hepatocellular" 27577856 MicroRNAs miR-125b and miR-100 suppress metastasis of hepatocellular carcinoma by disrupting the formation of vessels that encapsulate tumour clusters. +other hsa-mir-125b "Carcinoma, Hepatocellular" 27577856 MicroRNAs miR-125b and miR-100 suppress metastasis of hepatocellular carcinoma by disrupting the formation of vessels that encapsulate tumour clusters. +other hsa-mir-17 Neoplasms [unspecific] 27577994 "miR-17-5p is at the crossroads of aging, longevity and cancer and might represent a promising biomarker or even therapeutic tool and target in this context" +other hsa-mir-122 Hepatitis C Virus Infection 27578438 Unraveling the Mysterious Interactions Between Hepatitis C Virus RNA and Liver-Specific MicroRNA-122. +other hsa-mir-21 "Carcinoma, Breast" 27579604 Distinct Small RNA Signatures in Extracellular Vesicles Derived from Breast Cancer Cell Lines. +other hsa-mir-17 Psoriasis 27579777 miRNA miR-17-92 cluster is differentially regulated in the imiqumod-treated skin but is not required for imiqumod-induced psoriasis-like dermatitis in mice. +other hsa-mir-18 Psoriasis 27579777 miRNA miR-17-92 cluster is differentially regulated in the imiqumod-treated skin but is not required for imiqumod-induced psoriasis-like dermatitis in mice. +other hsa-mir-19a Psoriasis 27579777 miRNA miR-17-92 cluster is differentially regulated in the imiqumod-treated skin but is not required for imiqumod-induced psoriasis-like dermatitis in mice. +other hsa-mir-19b-1 Psoriasis 27579777 miRNA miR-17-92 cluster is differentially regulated in the imiqumod-treated skin but is not required for imiqumod-induced psoriasis-like dermatitis in mice. +other hsa-mir-20a Psoriasis 27579777 miRNA miR-17-92 cluster is differentially regulated in the imiqumod-treated skin but is not required for imiqumod-induced psoriasis-like dermatitis in mice. +other hsa-mir-92-1 Psoriasis 27579777 miRNA miR-17-92 cluster is differentially regulated in the imiqumod-treated skin but is not required for imiqumod-induced psoriasis-like dermatitis in mice. +other hsa-mir-200 "Carcinoma, Renal Cell" 27580029 Loss of fumarate hydratase is associated with suppression of miR-200 and the EMT signature in renal cancer and is associated with poor clinical outcome +other hsa-mir-146a Colorectal Carcinoma 27580100 Numb is involved in the non-random segregation of subcellular vesicles in colorectal cancer stem cells. +other hsa-mir-30a Multiple Sclerosis 27581464 Disulfiram and Diphenhydramine Hydrochloride Upregulate miR-30a to Suppress IL-17-Associated Autoimmune Inflammation. +other hsa-mir-126 Neoplasms [unspecific] 27583885 Potential role of microRNA-126 in the diagnosis of cancers: A systematic review and meta-analysis. +other hsa-mir-21 Psoriasis 27586798 the activation of S100A8/A9-dependent C3 complement as well as a miR-21-dependent TIMP-3/TACE pathway leading to TNF-¦Á shedding +other hsa-mir-155 Hypoxia 27587248 Effect of miR- 155 on immune- factors and its mechanism in mesenchymal stem cells under hypoxic environment. +other hsa-mir-141 "Carcinoma, Prostate" 27589398 Sensitive detection of microRNA in complex biological samples by using two stages DSN-assisted target recycling signal amplification method. +other hsa-mir-203 "Carcinoma, Nasopharyngeal" 27589832 A directly negative interaction of miR-203 and ZEB2 modulates tumor stemness and chemotherapy resistance in nasopharyngeal carcinoma. +other hsa-mir-148a Hepatitis C Virus Infection 27591428 "miR-148a and miR-30a limit HCV-dependent suppression of the lipid droplet protein, ADRP, in HCV infected cell models." +other hsa-mir-30a Chronic Hepatitis C 27591428 "miR-148a and miR-30a limit HCV-dependent suppression of the lipid droplet protein, ADRP, in HCV infected cell models." +other hsa-mir-122 "Diabetes Mellitus, Type 2" 27592052 HNF-4¦Á regulated miR-122 contributes to development of gluconeogenesis and lipid metabolism disorders in Type 2 diabetic mice and in palmitate-treated HepG2 cells. +other hsa-mir-183 Lung Neoplasms 27593936 TFAP2C promotes lung tumorigenesis and aggressiveness through miR-183- and miR-33a-mediated cell cycle regulation. +other hsa-mir-33a Lung Neoplasms 27593936 TFAP2C promotes lung tumorigenesis and aggressiveness through miR-183- and miR-33a-mediated cell cycle regulation. +other hsa-mir-582 "Carcinoma, Colon" 27595705 miR-582-5P induces colorectal cancer cell proliferation by targeting adenomatous polyposis coli. +other hsa-mir-146a Sepsis 27596437 "systemic inflammation induced an increase in EVs and associated pro-inflammatory miRNAs, including miR-146a and miR-155, in the CSF Interestingly, this was associated with an increase in amount of multivesicular bodies (MVBs) and exosomes per MVB in the CPE cells" +other hsa-mir-155 Sepsis 27596437 "systemic inflammation induced an increase in EVs and associated pro-inflammatory miRNAs, including miR-146a and miR-155, in the CSF Interestingly, this was associated with an increase in amount of multivesicular bodies (MVBs) and exosomes per MVB in the CPE cells" +other hsa-mir-4687 "Diabetes Mellitus, Type 2" 27597954 Role of miRNAs in Epicardial Adipose Tissue in CAD Patients with T2DM. +other hsa-mir-21 Retinoblastoma 27600360 MiR-21 inhibitor suppressed the progression of retinoblastoma via the modulation of PTEN/PI3K/AKT pathway. +other hsa-mir-17 Medulloblastoma 27600805 Dicer1 ablation impairs Shh-induced GNP proliferation by disrupting the expression of distinct cell cycle regulator genes that are targets of miR-17/92 cluster members +other hsa-mir-18 Medulloblastoma 27600805 Dicer1 ablation impairs Shh-induced GNP proliferation by disrupting the expression of distinct cell cycle regulator genes that are targets of miR-17/92 cluster members +other hsa-mir-19a Medulloblastoma 27600805 Dicer1 ablation impairs Shh-induced GNP proliferation by disrupting the expression of distinct cell cycle regulator genes that are targets of miR-17/92 cluster members +other hsa-mir-19b-1 Medulloblastoma 27600805 Dicer1 ablation impairs Shh-induced GNP proliferation by disrupting the expression of distinct cell cycle regulator genes that are targets of miR-17/92 cluster members +other hsa-mir-20a Medulloblastoma 27600805 Dicer1 ablation impairs Shh-induced GNP proliferation by disrupting the expression of distinct cell cycle regulator genes that are targets of miR-17/92 cluster members +other hsa-mir-92-1 Medulloblastoma 27600805 Dicer1 ablation impairs Shh-induced GNP proliferation by disrupting the expression of distinct cell cycle regulator genes that are targets of miR-17/92 cluster members +other hsa-mir-200c Ovarian Neoplasms 27601996 miR-200c Regulation of Metastases in Ovarian Cancer: Potential Role in Epithelial and Mesenchymal Transition. +other hsa-mir-143 "Carcinoma, Lung, Non-Small-Cell" 27602093 miR-143 suppresses the proliferation of NSCLC cells by inhibiting the epidermal growth factor receptor. +other hsa-mir-146b "Carcinoma, Thyroid, Anaplastic" 27602131 p21 participates in the regulation of anaplastic thyroid cancer cell proliferation by miR-146b. +other hsa-mir-27a Lung Neoplasms 27602162 Genistein inhibits A549 human lung cancer cell proliferation via miR-27a and MET signaling. +other hsa-mir-155 Neoplasms [unspecific] 27602769 MiR-155 promotes epithelial-mesenchymal transition in hepatocellular carcinoma cells through the activation of PI3K/SGK3/¦Â-catenin signaling pathways. +other hsa-mir-21 Chronic Kidney Disease 27610006 TGF-¦Â1/Smads and miR-21 in Renal Fibrosis and Inflammation. +other hsa-mir-10b Lymphoma 27611973 Profile of Exosomal and Intracellular microRNA in Gamma-Herpesvirus-Infected Lymphoma Cell Lines. +other hsa-mir-143 Lymphoma 27611973 Profile of Exosomal and Intracellular microRNA in Gamma-Herpesvirus-Infected Lymphoma Cell Lines. +other hsa-mir-27a Pulmonary Hypertension 27612006 Peroxisome Proliferator-Activated Receptor ¦Ã Regulates the V-Ets Avian Erythroblastosis Virus E26 Oncogene Homolog 1/microRNA-27a Axis to Reduce Endothelin-1 and Endothelial Dysfunction in the Sickle Cell Mouse Lung. +other hsa-mir-125b "Leukemia, Promyelocytic, Acute" 27613090 Identification of miR-125b targets involved in acute promyelocytic leukemia cell proliferation. +other hsa-mir-29b Schizophrenia 27613806 Epistatic and Independent Effects on Schizophrenia-Related Phenotypes Following Co-disruption of the Risk Factors Neuregulin-1 ¡Á DISC1. +other hsa-mir-122 Chronic Hepatitis C 27614072 TALEN/CRISPR-mediated engineering of a promoterless anti-viral RNAi hairpin into an endogenous miRNA locus. +other hsa-mir-7 "Carcinoma, Hepatocellular" 27614453 The circular RNA ciRS-7 (Cdr1as) acts as a risk factor of hepatic microvascular invasion in hepatocellular carcinoma. +other hsa-mir-616 Coronary Artery Disease 27615006 Relationship of microRNA 616 gene polymorphism with prognosis of patients with premature coronary artery disease. +other hsa-mir-141 Melanoma 27616325 Trans-nonachlor decreases miR-141-3p levels in human melanocytes in vitro promoting melanoma cell characteristics and shows a multigenerational impact on miR-8 levels in Drosophila. +other hsa-mir-429 "Carcinoma, Renal Cell" 27619681 MiR-429 is linked to metastasis and poor prognosis in renal cell carcinoma by affecting epithelial-mesenchymal transition. +other hsa-mir-92a Melanoma 27620505 miR-92a-3p and MYCBP2 are involved in MS-275-induced and c-myc-mediated TRAIL-sensitivity in melanoma cells. +other hsa-mir-196a "Carcinoma, Esophageal" 27621035 Inhibition of miR-196a affects esophageal cancer cell growth in vitro. +other hsa-mir-100 Vascular Injuries 27622243 Dicer generates a regulatory microRNA network in smooth muscle cells that limits neointima formation during vascular repair. +other hsa-mir-147 Vascular Injuries 27622243 Dicer generates a regulatory microRNA network in smooth muscle cells that limits neointima formation during vascular repair. +other hsa-mir-21 Vascular Injuries 27622243 Dicer generates a regulatory microRNA network in smooth muscle cells that limits neointima formation during vascular repair. +other hsa-mir-222 Vascular Injuries 27622243 Dicer generates a regulatory microRNA network in smooth muscle cells that limits neointima formation during vascular repair. +other hsa-mir-27a Vascular Injuries 27622243 Dicer generates a regulatory microRNA network in smooth muscle cells that limits neointima formation during vascular repair. +other hsa-mir-10b Cardiovascular Diseases [unspecific] 27624142 Potential role of microRNA-10b down-regulation in cardiomyocyte apoptosis in aortic stenosis patients. +other hsa-mir-4787 "Carcinoma, Pancreatic" 27624777 Inhibition of S-Adenosylmethionine-Dependent Methyltransferase Attenuates TGF¦Â1-Induced EMT and Metastasis in Pancreatic Cancer: Putative Roles of miR-663a and miR-4787-5p. +other hsa-mir-663a "Carcinoma, Pancreatic" 27624777 Inhibition of S-Adenosylmethionine-Dependent Methyltransferase Attenuates TGF¦Â1-Induced EMT and Metastasis in Pancreatic Cancer: Putative Roles of miR-663a and miR-4787-5p. +other hsa-mir-1284 "Carcinoma, Gastric" 27627897 MicroRNA-1284 inhibits proliferation and induces apoptosis in SGC-7901 human gastric cancer cells. +other hsa-mir-424 "Squamous Cell Carcinoma, Esophageal" 27628042 MiR-424-5p participates in esophageal squamous cell carcinoma invasion and metastasis via SMAD7 pathway mediated EMT. +other hsa-mir-490 "Squamous Cell Carcinoma, Skin or Unspecific" 27629145 Poly r(C) binding protein is post-transcriptionally repressed by MiR-490-3p to potentiate squamous cell carcinoma. +other hsa-mir-143 Colorectal Carcinoma 27629291 "we showed the importance of interactions between TP53, miR-143, KRAS, BCL2, and PLK1 with respect to colorectal cancer using bioinformatics approach" +other hsa-mir-31 "Carcinoma, Colon" 27630355 Efficacy and Toxicity of Panitumumab After Progression on Cetuximab and Predictive Value of MiR-31-5p in Metastatic Wild-type KRAS Colorectal Cancer Patients. +other hsa-mir-196a Huntington Disease 27631085 miR-196a Ameliorates Cytotoxicity and Cellular Phenotype in Transgenic Huntington's Disease Monkey Neural Cells. +other hsa-mir-378 Myelodysplastic Syndromes 27633496 miR-378 inhibits cell growth and enhances apoptosis in human myelodysplastic syndromes. +other hsa-mir-181a Glioblastoma 27633853 MicroRNA-181a promotes proliferation and inhibits apoptosis by suppressing CFIm25 in osteosarcoma. +other hsa-mir-34a Lung Fibrosis 27635790 miR-34a Inhibits Lung Fibrosis by Inducing Lung Fibroblast Senescence. +other hsa-mir-223 Ischemia-Reperfusion Injury 27635859 Neuroprotective effect of ischemic preconditioning via modulating the expression of cerebral miRNAs against transient cerebral ischemia in diabetic rats. +other hsa-mir-21 "Scleroderma, Systemic" 27637490 Inhibition of MicroRNA-21 induces apoptosis in dermal fibroblasts of patients with systemic sclerosis. +other hsa-mir-302f Congenital Heart Diseases 27637763 Copy-number variant analysis of classic heterotaxy highlights the importance of body patterning pathways. +other hsa-mir-122 Hepatitis C Virus Infection 27641985 "The history of hepatitis C virus (HCV): Basic research reveals unique features in phylogeny, evolution and the viral life cycle with new perspectives for epidemic control." +other hsa-mir-214 "Carcinoma, Lung" 27642589 cir-ITCH acted as sponge of oncogenic miR-7 and miR-214 to enhance ITCH expression and thus suppressed the activation of Wnt/¦Â-catenin signaling +other hsa-mir-7 "Carcinoma, Lung" 27642589 cir-ITCH acted as sponge of oncogenic miR-7 and miR-214 to enhance ITCH expression and thus suppressed the activation of Wnt/¦Â-catenin signaling +other hsa-mir-26a "Carcinoma, Lung, Small-Cell" 27644194 KH-type splicing regulatory protein (KHSRP) contributes to tumorigenesis by promoting miR-26a maturation in small cell lung cancer. +other hsa-mir-221 Atherosclerosis 27644883 Human aortic smooth muscle cell-derived exosomal miR-221/222 inhibits autophagy via a PTEN/Akt signaling pathway in human umbilical vein endothelial cells. +other hsa-mir-222 Atherosclerosis 27644883 Human aortic smooth muscle cell-derived exosomal miR-221/222 inhibits autophagy via a PTEN/Akt signaling pathway in human umbilical vein endothelial cells. +other hsa-mir-124a Neuropathic Pain 27646435 miR-124a and miR-155 enhance differentiation of regulatory T cells in patients with neuropathic pain. +other hsa-mir-155 Neuropathic Pain 27646435 miR-124a and miR-155 enhance differentiation of regulatory T cells in patients with neuropathic pain. +other hsa-mir-106b Multiple Myeloma 27647143 Integrative analysis of signaling pathways and diseases associated with the miR-106b/25 cluster and their function study in?berb?erine-induced multiple myeloma cells. +other hsa-mir-25 Multiple Myeloma 27647143 Integrative analysis of signaling pathways and diseases associated with the miR-106b/25 cluster and their function study in?berb?erine-induced multiple myeloma cells. +other hsa-let-7 Wilms Tumor 27647875 uridylated pre-let-7 miRNAs and mRNAs are targeted by the 3' to 5' exoribonuclease DIS3L2 +other hsa-mir-323b "Leukemia, Lymphoblastic, Acute, B-Cell" 27649261 MiR-pharmacogenetics of methotrexate in childhood B-cell acute lymphoblastic leukemia. +other hsa-mir-137 Glioblastoma 27649660 Circulating microRNA-137 is a potential biomarker for human glioblastoma. +other hsa-mir-137 Schizophrenia 27650867 MicroRNA-137 Inhibits EFNB2 Expression Affected by a Genetic Variant and Is Expressed Aberrantly in Peripheral Blood of Schizophrenia Patients. +other hsa-mir-205 Keloid 27651436 Upregulation of microRNA-205 suppresses vascular endothelial growth factor expression-mediated PI3K/Akt signaling transduction in human keloid fibroblasts. +other hsa-mir-125a "Carcinoma, Breast" 27651454 Structural dynamics control the MicroRNA maturation pathway. +other hsa-mir-628 Cardiac Allograft Vasculopathy 27653298 MicroRNA 628-5p as a Novel Biomarker for Cardiac Allograft Vasculopathy. +other hsa-mir-4697 Parkinson Disease 27653855 "SIPA1L2, MIR4697, GCH1 and VPS13C loci and risk of Parkinson's diseases in Iranian population: A case-control study." +other hsa-mir-203 "Carcinoma, Ovarian" 27655286 MiR-203 promotes the growth and migration of ovarian cancer cells by enhancing glycolytic pathway. +other hsa-mir-205 Endometrial Neoplasms 27655663 Locked nucleic acid-inhibitor of miR-205 decreases endometrial cancer cells proliferation in vitro and in vivo. +other hsa-let-7 Neoplasms [unspecific] 27659051 "Several proteins known to bind immature forms of these let-7 miRNAs were identified, but with an improved coverage compared to previous studies" +other hsa-let-7a Neoplasms [unspecific] 27659051 "Several proteins known to bind immature forms of these let-7 miRNAs were identified, but with an improved coverage compared to previous studies" +other hsa-let-7g Neoplasms [unspecific] 27659051 "Several proteins known to bind immature forms of these let-7 miRNAs were identified, but with an improved coverage compared to previous studies" +other hsa-mir-22 "Carcinoma, Gastric" 27662840 NTRK2 is an oncogene and associated with microRNA-22 regulation in human gastric cancer cell lines. +other hsa-mir-27b Hepatitis C Virus Infection 27665576 Lipoprotein lipase liberates free fatty acids to inhibit HCV infection and prevent hepatic lipid accumulation. +other hsa-mir-374 "Carcinoma, Pancreatic" 27665739 "MicroRNA miR-374, a potential radiosensitizer for carbon ion beam radiotherapy." +other hsa-let-7g Osteoporosis 27665867 An insertion/deletion polymorphism within the 3'?untranslated region of COL1A2 confers susceptibility to osteoporosis. +other hsa-mir-200 "Carcinoma, Colon" 27666412 Colorectal cancer cell-derived microRNA200 modulates the resistance of adjacent blood endothelial barriers in?vitro. +other hsa-mir-424 "Carcinoma, Lung, Non-Small-Cell" 27666545 Effects of miR-424 on Proliferation and Migration Abilities in Non-small Cell Lung Cancer A549 Cells and Its Molecular Mechanism. +other hsa-mir-21 "Cardiomyopathy, Ischemic" 27666568 "Trimetazidine protects against cardiac ischemia/reperfusion injury via effects on cardiac miRNA?21 expression, Akt and the Bcl?2/Bax pathway." +other hsa-mir-743a Wilms Tumor 27667021 Proliferation of metanephric mesenchymal cells is inhibited by miR-743a-mediated WT1 suppression in vitro. +other hsa-mir-139 Primary Biliary Cirrhosis 27668889 "MiR-139-5p is associated with inflammatory regulation through c-FOS suppression, and contributes to the progression of primary biliary cholangitis." +other hsa-mir-122 "Fatty Liver, Non-Alcoholic" 27669236 miR33a/miR33b* and miR122 as Possible Contributors to Hepatic Lipid Metabolism in Obese Women with Nonalcoholic Fatty Liver Disease. +other hsa-mir-33a "Fatty Liver, Non-Alcoholic" 27669236 miR33a/miR33b* and miR122 as Possible Contributors to Hepatic Lipid Metabolism in Obese Women with Nonalcoholic Fatty Liver Disease. +other hsa-mir-33b "Fatty Liver, Non-Alcoholic" 27669236 miR33a/miR33b* and miR122 as Possible Contributors to Hepatic Lipid Metabolism in Obese Women with Nonalcoholic Fatty Liver Disease. +other hsa-mir-146a Muscular Dystrophy 27671199 Chronic alcohol exposure induces muscle atrophy (myopathy) in zebrafish and alters the expression of microRNAs targeting the Notch pathway in skeletal muscle. +other hsa-mir-132 "Carcinoma, Ovarian" 27673409 "MicroRNA and long non-coding RNA have potential clinical utility in the diagnosis of ovarian cancer and predicting prognosis, metastasis, recurrence, and response to therapy" +other hsa-mir-26a "Carcinoma, Ovarian" 27673409 "MicroRNA and long non-coding RNA have potential clinical utility in the diagnosis of ovarian cancer and predicting prognosis, metastasis, recurrence, and response to therapy" +other hsa-mir-126 Hyperglycemia 27673690 Hyperglycemia and Advanced Glycation End Products Regulate miR-126 Expression in Endothelial Progenitor Cells. +other hsa-mir-223 Liver Injury 27679493 MicroRNA-223 ameliorates alcoholic liver injury by inhibiting the IL-6-p47phox-oxidative stress pathway in neutrophils. +other hsa-mir-210 Preeclampsia 27683514 Predictive value of miR-210 as a novel biomarker for pre-eclampsia: a systematic review protocol. +other hsa-mir-155 Hypertension 27683672 Vascular mineralocorticoid receptor regulates microRNA-155 to promote vasoconstriction and rising blood pressure with aging. +other hsa-mir-221 "Carcinoma, Breast" 27686606 A small RNA (miR-221) target was determined via the impedimetric measurement of the hybridization event in a label-free and PCR-free approach +other hsa-mir-22 Heart Failure 27687198 Preclinical Development of a MicroRNA-Based Therapy for Elderly Patients With Myocardial Infarction. +other hsa-mir-10a Autoimmune Diseases [unspecific] 27687891 "MicroRNAs such as miR-155, miR-126, and miR-10a also exert an important influence on the differentiation, development, and immunological functions of Tregs" +other hsa-mir-126 Autoimmune Diseases [unspecific] 27687891 "MicroRNAs such as miR-155, miR-126, and miR-10a also exert an important influence on the differentiation, development, and immunological functions of Tregs" +other hsa-mir-155 Autoimmune Diseases [unspecific] 27687891 "MicroRNAs such as miR-155, miR-126, and miR-10a also exert an important influence on the differentiation, development, and immunological functions of Tregs" +other hsa-mir-367 "Carcinoma, Hepatocellular" 27688096 The miR-367-3p Increases Sorafenib Chemotherapy Efficacy to Suppress Hepatocellular Carcinoma Metastasis through Altering the Androgen Receptor Signals. +other hsa-mir-21 "Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal" 27688683 "Metformin significantly inhibited FaDu cell proliferation , possibly via downregulation of miR-21-5p and upregulation of PDCD4" +other hsa-mir-146a Cystic Fibrosis 27689251 "miR-146a, miR-155, miR-370, and miR-708 Are CFTR-Dependent, Predicted FOXO1 Regulators and Change at Onset of CFRDs." +other hsa-mir-155 Cystic Fibrosis 27689251 "miR-146a, miR-155, miR-370, and miR-708 Are CFTR-Dependent, Predicted FOXO1 Regulators and Change at Onset of CFRDs." +other hsa-mir-370 Cystic Fibrosis 27689251 "miR-146a, miR-155, miR-370, and miR-708 Are CFTR-Dependent, Predicted FOXO1 Regulators and Change at Onset of CFRDs." +other hsa-mir-708 Cystic Fibrosis 27689251 "miR-146a, miR-155, miR-370, and miR-708 Are CFTR-Dependent, Predicted FOXO1 Regulators and Change at Onset of CFRDs." +other hsa-mir-122 Hepatitis C Virus Infection 27692039 Proposed update to the taxonomy of the genera Hepacivirus and Pegivirus within the Flaviviridae family. +other hsa-mir-195 Alzheimer Disease 27693395 MiR-195 dependent roles of mitofusin2 in the mitochondrial dysfunction of hippocampal neurons in SAMP8 mice. +other hsa-let-7a "Carcinoma, Hepatocellular" 27693636 Hepatitis B virus mRNAs functionally sequester let-7a and enhance hepatocellular carcinoma. +other hsa-mir-338 "Carcinoma, Hepatocellular" 27694002 Down-regulation of microRNA-338-3p promoted angiogenesis in hepatocellular carcinoma. +other hsa-mir-200 "Carcinoma, Lung" 27694892 ZEB1 induces LOXL2-mediated collagen stabilization and deposition in the extracellular matrix to drive lung cancer invasion and metastasis. +other hsa-mir-126 "Diabetes Mellitus, Type 2" 27696070 MicroRNA-126 and micro-/macrovascular complications of type 1 diabetes in the EURODIAB Prospective Complications Study. +other hsa-mir-494 "Leukemia, Myeloid, Acute" 27696394 MicroRNA-494 Activation Suppresses Bone Marrow Stromal Cell-Mediated Drug Resistance in Acute Myeloid Leukemia Cells. +other hsa-mir-133b "Carcinoma, Gastric" 27696637 MiR-133b inhibits growth of human gastric cancer cells by silencing pyruvate kinase muscle-splicer polypyrimidine tract-binding protein 1. +other hsa-mir-155 Systemic Lupus Erythematosus 27697141 Follicular T helper cells and IL-21 in rheumatic diseases. +other hsa-mir-21 Systemic Lupus Erythematosus 27697141 Follicular T helper cells and IL-21 in rheumatic diseases. +other hsa-mir-222 "Carcinoma, Breast" 27699665 miR-222 induces Adriamycin resistance in breast cancer through PTEN/Akt/p27kip1 pathway. +other hsa-mir-20b "Carcinoma, Esophageal" 27701465 "MicroRNA-20b (miR-20b) Promotes the Proliferation, Migration, Invasion, and Tumorigenicity in Esophageal Cancer Cells via the Regulation of Phosphatase and Tensin Homologue Expression." +other hsa-mir-129 Biliary Atresia 27706677 Effect of miR-29c and miR-129-5p on epithelial-mesenchymal transition in experimental biliary atresia mouse models. +other hsa-mir-29c Biliary Atresia 27706677 Effect of miR-29c and miR-129-5p on epithelial-mesenchymal transition in experimental biliary atresia mouse models. +other hsa-mir-137 Schizophrenia 27706734 Association between miR-137 polymorphism and risk of schizophrenia: a meta-analysis. +other hsa-mir-21 Myocardial Infarction 27708252 Effects of mir-21 on Cardiac Microvascular Endothelial Cells After Acute Myocardial Infarction in Rats: Role of Phosphatase and Tensin Homolog (PTEN)/Vascular Endothelial Growth Factor (VEGF) Signal Pathway. +other hsa-mir-133b "Carcinoma, Renal Cell" 27710896 miRNA-133b and miRNA-135a induce apoptosis via the JAK2/STAT3 signaling pathway in human renal carcinoma cells. +other hsa-mir-135a "Carcinoma, Renal Cell" 27710896 miRNA-133b and miRNA-135a induce apoptosis via the JAK2/STAT3 signaling pathway in human renal carcinoma cells. +other hsa-mir-155 "Diabetes Mellitus, Type 2" 27711113 MiR-155 Enhances Insulin Sensitivity by Coordinated Regulation of Multiple Genes in Mice. +other hsa-mir-877 Liver Injury 27713024 MicroRNA-877-5p is involved in the trovafloxacin-induced liver injury. +other hsa-mir-572 Neuroblastoma 27716787 Fluoxetine Increases the Expression of miR-572 and miR-663a in Human Neuroblastoma Cell Lines. +other hsa-mir-663a Neuroblastoma 27716787 Fluoxetine Increases the Expression of miR-572 and miR-663a in Human Neuroblastoma Cell Lines. +other hsa-mir-539 "Carcinoma, Hepatocellular" 27717846 microRNA-539 suppresses tumor growth and tumorigenesis and overcomes arsenic trioxide resistance in hepatocellular carcinoma. +other hsa-mir-155 "Carcinoma, Cervical" 27717891 The rs767649 polymorphism in the promoter of miR-155 contributes to the decreased risk for cervical cancer in a Chinese population. +other hsa-mir-378 Obesity 27721392 DNA methylation landscape of fat deposits and fatty acid composition in obese and lean pigs. +other hsa-mir-21 Epilepsy 27725160 Increased precursor microRNA-21 following status epilepticus can compete with mature microRNA-21 to alter translation. +other hsa-mir-21 "Carcinoma, Prostate" 27725205 "Methylated urolithin A, the modified ellagitannin-derived metabolite, suppresses cell viability of DU145 human prostate cancer cells via targeting miR-21." +other hsa-mir-34a "Carcinoma, Hepatocellular" 27725225 Glutaminase 2 stabilizes Dicer to repress Snail and metastasis in hepatocellular carcinoma cells. +other hsa-mir-140 Gout 27727249 microRNA-140 Inhibits Inflammation and Stimulates Chondrogenesis in a Model of Interleukin 1¦Â-induced Osteoarthritis. +other hsa-mir-30 "Carcinoma, Gastric" 27729002 miR-30 functions as an oncomiR in gastric cancer cells through regulation of P53-mediated mitochondrial apoptotic pathway. +other hsa-mir-372 "Carcinoma, Prostate" 27730751 Repression of MicroRNA-372 by Arsenic Sulphide Inhibits Prostate Cancer Cell Proliferation and Migration through Regulation of large tumour suppressor kinase 2. +other hsa-mir-224 Chronic Hepatitis B 27731343 MicroRNA-based diagnostic tools for advanced fibrosis and cirrhosis in patients with chronic hepatitis B and C. +other hsa-mir-224 Chronic Hepatitis C 27731343 MicroRNA-based diagnostic tools for advanced fibrosis and cirrhosis in patients with chronic hepatitis B and C. +other hsa-mir-221 Inflammation 27731391 Epithelial cell-derived microvesicles activate macrophages and promote inflammation via microvesicle-containing microRNAs. +other hsa-mir-940 "Carcinoma, Breast, Triple Negative" 27731867 MiR-940 Inhibited Cell Growth and Migration in Triple-Negative Breast Cancer. +other hsa-mir-9501 "Carcinoma, Lung, Non-Small-Cell" 27734264 "The novel miR-9501 inhibits cell proliferation, migration and activates apoptosis in non-small cell lung cancer." +other hsa-mir-6126 "Carcinoma, Ovarian" 27742688 Ubiquitous Release of Exosomal Tumor Suppressor miR-6126 from Ovarian Cancer Cells. +other hsa-mir-181c Heart Failure 27742689 Role of microRNA in metabolic shift during heart failure. +other hsa-mir-378 Heart Failure 27742689 Role of microRNA in metabolic shift during heart failure. +other hsa-mir-24 "Carcinoma, Gastric" 27743162 miR-24-3p Regulates Progression of Gastric Mucosal Lesions and Suppresses Proliferation and Invasiveness of N87 Via Peroxiredoxin 6. +other hsa-mir-223 "Carcinoma, Bladder" 27744452 Ginkgolide B Inhibits Human Bladder Cancer Cell Migration and Invasion Through MicroRNA-223-3p. +other hsa-mir-210 Preeclampsia 27746364 "Evaluation of MicroRNA-210 and Protein tyrosine phosphatase, non-receptor type 2 in Pre-eclampsia." +other hsa-mir-126 Atherosclerosis 27748840 Paeonol promotes microRNA-126 expression to inhibit monocyte adhesion to ox-LDL-injured vascular endothelial cells and block the activation of the PI3K/Akt/NF-¦ÊB pathway. +other hsa-mir-182 "Carcinoma, Ovarian" 27748882 Downregulation of DNMT3a expression increases miR-182-induced apoptosis of ovarian cancer through caspase-3?and?caspase-9-mediated apoptosis and DNA damage response. +other hsa-let-7a "Carcinoma, Cervical" 27748903 Let?7a suppresses cell proliferation via the TGF?¦Â/SMAD signaling pathway in cervical cancer. +other hsa-mir-100 "Carcinoma, Ovarian" 27748936 miR-100 resensitizes resistant epithelial ovarian cancer to cisplatin. +other hsa-mir-140 Infection [unspecific] 27749761 Microrna Expression Profiling of Macrophage Line Raw264.7 Infected by Candida Albicans. +other hsa-mir-29a Vascular Disease [unspecific] 27752152 Dynamic alteration of microRNA in high phosphorus induced calcification of vascular smooth muscle cell. +other hsa-mir-145 Multiple Sclerosis 27752929 miR-145 and miR20a-5p Potentially Mediate Pleiotropic Effects of Interferon-Beta Through Mitogen-Activated Protein Kinase Signaling Pathway in Multiple Sclerosis Patients. +other hsa-mir-20a Multiple Sclerosis 27752929 miR-145 and miR20a-5p Potentially Mediate Pleiotropic Effects of Interferon-Beta Through Mitogen-Activated Protein Kinase Signaling Pathway in Multiple Sclerosis Patients. +other hsa-mir-181b "Aortic Aneurysm, Abdominal" 27756793 MicroRNA-181b Controls Atherosclerosis and Aneurysms Through Regulation of TIMP-3 and Elastin. +other hsa-mir-21 Glioblastoma 27757032 Pluronic-based micelle encapsulation potentiates myricetin-induced cytotoxicity in human glioblastoma cells. +other hsa-mir-30a "Diabetes Mellitus, Type 2" 27758866 Mitochondrial Activity in Human White Adipocytes Is Regulated by the Ubiquitin Carrier Protein 9/microRNA-30a Axis. +other hsa-mir-376c "Squamous Cell Carcinoma, Head and Neck" 27760788 Dysregulation of RUNX2/Activin-A Axis upon miR-376c Downregulation Promotes Lymph Node Metastasis in Head and Neck Squamous Cell Carcinoma. +other hsa-mir-155 Chronic Hepatitis C 27765085 Differential Expression of MicroRNAs in Hepatitis C Virus-Mediated Liver Disease Between African Americans and Caucasians: Implications for Racial Health Disparities. +other hsa-mir-145 Pancreatic Adenocarcinoma 27765914 MiRNA-145 increases therapeutic sensibility to gemcitabine treatment of pancreatic adenocarcinoma cells. +other hsa-mir-145 "Squamous Cell Carcinoma, Lung" 27765924 Dual-strand tumor-suppressor microRNA-145 (miR-145-5p and miR-145-3p) coordinately targeted MTDH in lung squamous cell carcinoma. +other hsa-mir-214 Sezary Disease 27766406 "CD164 identifies CD4+ T cells highly expressing genes associated with malignancy in S¨¦zary syndrome: the S¨¦zary signature genes, FCRL3, Tox, and miR-214." +other hsa-mir-146a Colorectal Carcinoma 27769860 "microRNA-146a inhibits proliferation, migration and invasion of human cervical and colorectal cancer cells." +other hsa-mir-9 "Leukemia, Myeloid, Acute" 27770540 A minicircuitry of microRNA-9-1 and RUNX1-RUNX1T1 contributes to leukemogenesis in t(8;21) acute myeloid leukemia. +other hsa-mir-203 "Carcinoma, Colon" 27771718 Sodium Butyrate Upregulates miR-203 Expression to Exert Anti-Proliferation Effect on Colorectal Cancer Cells. +other hsa-let-7 "Carcinoma, Endometrial" 27775072 "Metformin acts by upregulating microRNA let-7 through AMPK activation, leading to degradation of H19 long noncoding RNA, which normally binds to and inactivates SAHH" +other hsa-mir-29b "Leukemia, Biphenotypic, Acute" 27775550 MicroRNA-29b mediates altered innate immune development in acute leukemia. +other hsa-mir-143 Atherosclerosis 27775792 miR-143 is involved in endothelial cell dysfunction through suppression of glycolysis and correlated with atherosclerotic plaques formation. +other hsa-mir-92b "Carcinoma, Lung, Non-Small-Cell" 27775799 Regulation of Twist in the metastasis of non-small cell lung cancer by miR-92b. +other hsa-mir-155 "Carcinoma, Thyroid, Papillary" 27777199 Expression of microRNA-155 in papillary thyroid carcinoma and its clinical significance. +other hsa-mir-29c Endometriosis 27778641 Progesterone Resistance in Endometriosis Is Modulated by the Altered Expression of MicroRNA-29c and FKBP4. +other hsa-mir-361 "Carcinoma, Lung, Non-Small-Cell" 27779659 "microRNA-361 targets Wilms' tumor 1 to inhibit the growth, migration and invasion of non-small-cell lung cancer cells." +other hsa-mir-129 "Carcinoma, Prostate" 27779679 miR-129 predicts prognosis and inhibits cell growth in human prostate carcinoma. +other hsa-mir-27a "Carcinoma, Breast" 27779715 miR-27a-mediated antiproliferative effects of metformin on the breast cancer cell line MCF-7. +other hsa-mir-106a Neoplasms [unspecific] 27780637 MiR-106a: Promising biomarker for cancer. +other hsa-mir-17 Neoplasms [unspecific] 27780637 MiR-106a: Promising biomarker for cancer. +other hsa-mir-7 "Leukemia, Myeloid, Acute" 27784745 Mutational Landscape and Gene Expression Patterns in Adult Acute Myeloid Leukemias with Monosomy 7 as a Sole Abnormality. +other hsa-let-7i Acute Ischemic Stroke 27784773 Leukocyte response is regulated by microRNA let7i in patients with acute ischemic stroke. +other hsa-let-7 "Carcinoma, Colon" 27789274 "H19 Noncoding RNA, an Independent Prognostic Factor, Regulates Essential Rb-E2F and CDK8-¦Â-Catenin Signaling in Colorectal Cancer." +other hsa-mir-206 Vascular Hypertrophy 27789288 Bladder overactivity involves overexpression of MicroRNA 132 and nerve growth factor. +other hsa-mir-130a Myocardial Infarction 27789328 Resveratrol increases microRNA-130a expression to promote angiogenesis and improve heart functions in mice after myocardial infarction. +other hsa-mir-126 Vascular Disease [unspecific] 27789478 MicroRNA-126a Directs Lymphangiogenesis Through Interacting With Chemokine and Flt4 Signaling in Zebrafish. +other hsa-mir-125b Tuberculosis 27789724 Downregulation of hsa-miR-337-3p and hsa-miR-125b-5p by miRNA sponges improved IL-23-mediated expansion of V¦Ã2V¦Ä2 T cells and restored the ability of these cells to produce anti-tuberculosis cytokines +other hsa-mir-337 Tuberculosis 27789724 Downregulation of hsa-miR-337-3p and hsa-miR-125b-5p by miRNA sponges improved IL-23-mediated expansion of V¦Ã2V¦Ä2 T cells and restored the ability of these cells to produce anti-tuberculosis cytokines +other hsa-mir-203a Gastric Cardia Adenocarcinoma 27791400 Downregulation of Potential Tumor Suppressor miR-203a by Promoter Methylation Contributes to the Invasiveness of Gastric Cardia Adenocarcinoma. +other hsa-mir-192 "Carcinoma, Colon" 27793841 Phospholipase D1 Acts through Akt/TopBP1 and RB1 to Regulate the E2F1-Dependent Apoptotic Program in Cancer Cells. +other hsa-mir-4465 "Carcinoma, Colon" 27793841 Phospholipase D1 Acts through Akt/TopBP1 and RB1 to Regulate the E2F1-Dependent Apoptotic Program in Cancer Cells. +other hsa-mir-489 "Carcinoma, Pancreatic" 27793842 KRAS/NF-¦ÊB/YY1/miR-489 Signaling Axis Controls Pancreatic Cancer Metastasis. +other hsa-mir-142 "Lymphoma, Burkitt" 27796281 Epstein-Barr Virus (EBV)-BamHI-A Rightward Transcript (BART)-6 and Cellular MicroRNA-142 Synergistically Compromise Immune Defense of Host Cells in EBV-Positive Burkitt Lymphoma. +other hsa-mir-155 IgA Nephropathy 27796698 MicroRNA-155-induced T lymphocyte subgroup drifting in IgA nephropathy. +other hsa-mir-146a Alzheimer Disease 27797173 Dipeptidyl Vinyl Sulfone as a Novel Chemical Tool to Inhibit HMGB1/NLRP3-Inflammasome and Inflamma-miRs in A¦Â-Mediated Microglial Inflammation. +other hsa-mir-21 "Carcinoma, Colon" 27798874 Prognostic Significance of MicroRNA-21 Expression in Patients with Unresectable Metastatic Colon Cancer. +other hsa-mir-324 "Carcinoma, Breast" 27798879 MicroRNA-324 in Human Cancer: miR-324-5p and miR-324-3p Have Distinct Biological Functions in Human Cancer. +other hsa-mir-193b "Carcinoma, Renal Cell" 27802451 MicroRNA 193b-3p as a predictive biomarker of chronic kidney disease in patients undergoing radical nephrectomy for renal cell carcinoma. +other hsa-mir-21 Ischemia-Reperfusion Injury 27804287 Fluorescent Nanocomposite for Visualizing Cross-Talk between MicroRNA-21 and Hydrogen Peroxide in Ischemia-Reperfusion Injury in Live Cells and In Vivo. +other hsa-mir-19b Heart Failure 27805004 miR-19b Regulates Ventricular Action Potential Duration in Zebrafish. +other hsa-mir-122 Chronic Hepatitis C 27805315 Inducing Hepatitis C Virus Resistance After Pig Liver Transplantation-A Proof of Concept of Liver Graft Modification Using Warm Ex Vivo Perfusion. +other hsa-mir-124 "Carcinoma, Cervical" 27806357 Virtues and Weaknesses of DNA Methylation as a Test for Cervical Cancer Prevention. +other hsa-mir-635 "Carcinoma, Lung, Non-Small-Cell" 27810784 The microRNA-635 suppresses tumorigenesis in non-small cell lung cancer. +other hsa-mir-17 "Carcinoma, Breast" 27811009 Penfluridol Represses Integrin Expression in Breast Cancer through Induction of Reactive Oxygen Species and Downregulation of Sp Transcription Factors. +other hsa-mir-20a "Carcinoma, Breast" 27811009 Penfluridol Represses Integrin Expression in Breast Cancer through Induction of Reactive Oxygen Species and Downregulation of Sp Transcription Factors. +other hsa-mir-27a "Carcinoma, Breast" 27811009 Penfluridol Represses Integrin Expression in Breast Cancer through Induction of Reactive Oxygen Species and Downregulation of Sp Transcription Factors. +other hsa-mir-129b "Carcinoma, Lung" 27813559 miR-129b suppresses cell proliferation in the human lung cancer cell lines A549 and H1299. +other hsa-mir-320 Melanoma 27816966 "HUR protects NONO from degradation by mir320, which is induced by p53 upon UV irradiation." +other hsa-mir-155 Biliary Atresia 27817193 Effect of microRNA-155 on the interferon-gamma signaling pathway in biliary atresia. +other hsa-mir-3658 "Carcinoma, Bladder" 27820650 Upregulation of miR-3658 in bladder cancer and tumor progression. +other hsa-let-7 "Carcinoma, Hepatocellular" 27821157 Let-7 inhibits self-renewal of hepatocellular cancer stem-like cells through regulating the epithelial-mesenchymal transition and the Wnt signaling pathway. +other hsa-mir-196b Glioma 27821299 Biomarkers related with seizure risk in glioma patients: A systematic review. +other hsa-mir-21 "Colitis, Ulcerative" 27824649 Downregulation of MicroRNA-21 in Colonic CD3+ T Cells in UC Remission. +other hsa-mir-126 Acute Brucellosis 27824867 MicroRNA Expression Patterns of CD8+ T Cells in Acute and Chronic Brucellosis. +other hsa-mir-4753 Acute Brucellosis 27824867 MicroRNA Expression Patterns of CD8+ T Cells in Acute and Chronic Brucellosis. +other hsa-mir-126 White Spot Syndrome Virus Infection 27825947 Characterization of microRNAs by deep sequencing in red claw crayfish Cherax quadricarinatus haematopoietic tissue cells after white spot syndrome virus infection. +other hsa-mir-184 White Spot Syndrome Virus Infection 27825947 Characterization of microRNAs by deep sequencing in red claw crayfish Cherax quadricarinatus haematopoietic tissue cells after white spot syndrome virus infection. +other hsa-mir-7 White Spot Syndrome Virus Infection 27825947 Characterization of microRNAs by deep sequencing in red claw crayfish Cherax quadricarinatus haematopoietic tissue cells after white spot syndrome virus infection. +other hsa-mir-206 Chondrosarcoma 27826039 Amphiregulin enhances VEGF-A production in human chondrosarcoma cells and promotes angiogenesis by inhibiting miR-206 via FAK/c-Src/PKC¦Ä pathway. +other hsa-mir-93 "Carcinoma, Endometrial" 27829043 MicroRNA-93 Promotes Epithelial-Mesenchymal Transition of Endometrial Carcinoma Cells. +other hsa-mir-155 Stroke 27829437 In vivo inhibition of miR-155 significantly alters post-stroke inflammatory response. +other hsa-mir-19a Myeloma 27830963 MicroRNA-19a functions as an oncogene by regulating PTEN/AKT/pAKT pathway in myeloma. +other hsa-mir-20b Myasthenia Gravis 27833920 miR-20b Inhibits T Cell Proliferation and Activation via NFAT Signaling Pathway in Thymoma-Associated Myasthenia Gravis. +other hsa-mir-125b Atherosclerosis 27835742 Silencing of CD40 in?vivo reduces progression of experimental atherogenesis through an NF-¦ÊB/miR-125b axis and reveals new potential mediators in the pathogenesis of atherosclerosis. +other hsa-mir-21 "Carcinoma, Breast" 27836600 A novel method for sensitive microRNA detection: Electropolymerization based doping. +other hsa-mir-221 Glioblastoma 27837435 Exosomal miR-221 targets DNM3 to induce tumor progression and temozolomide resistance in glioma. +other hsa-mir-200 Neoplasms [unspecific] 27837593 the full role of the miR-200 family in cancer progression and metastasis is not completely understood and seems to differ between different tumour types and different cellular backgrounds +other hsa-mir-152 "Carcinoma, Nasopharyngeal" 27840403 MicroRNA-152 Targets Phosphatase and Tensin Homolog to Inhibit Apoptosis and Promote Cell Migration of Nasopharyngeal Carcinoma Cells. +other hsa-mir-637 Glioma 27840895 Sevoflurane inhibits the migration and invasion of glioma cells by upregulating microRNA-637. +other hsa-mir-25 "Carcinoma, Hepatocellular" 27840896 Knockdown of miR-25 increases the sensitivity of liver cancer stem cells to TRAIL-induced apoptosis via PTEN/PI3K/Akt/Bad signaling pathway. +other hsa-mir-93 "Carcinoma, Breast, Triple Negative" 27840899 miR-93 inhibits the invasive potential of triple-negative breast cancer cells in vitro via protein kinase WNK1. +other hsa-mir-21 "Carcinoma, Ovarian" 27840916 Effects of celastrol on enhancing apoptosis of ovarian cancer cells via the downregulation of microRNA?21 and the suppression of the PI3K/Akt?NF?¦ÊB signaling pathway in an in?vitro model of ovarian carcinoma. +other hsa-mir-214 Osteosarcoma 27840941 Deregulated WWOX is involved in a negative feedback loop with microRNA-214-3p in osteosarcoma. +other hsa-mir-302a "Carcinoma, Colon" 27840990 MicroRNA-302a enhances 5-fluorouracil-induced cell death in human colon cancer cells. +other hsa-mir-208b Hepatitis [unspecific] 27841874 Hepatitis-C-virus-induced microRNAs dampen interferon-mediated antiviral signaling. +other hsa-mir-499a Hepatitis [unspecific] 27841874 Hepatitis-C-virus-induced microRNAs dampen interferon-mediated antiviral signaling. +other hsa-mir-135a Parkinson Disease 27842305 Involvement of microRNA-135a-5p in the Protective Effects of Hydrogen Sulfide Against Parkinson's Disease. +other hsa-mir-375 Neoplasms [unspecific] 27844328 Molecular Profiling of Thymoma and Thymic Carcinoma: Genetic Differences and Potential Novel Therapeutic Targets. +other hsa-mir-122 "Carcinoma, Hepatocellular" 27846390 ERK Activation Globally Downregulates miRNAs through Phosphorylating Exportin-5. +other hsa-mir-210 Spinal Cord Injuries 27847197 Synchrotron radiation micro-CT as a novel tool to evaluate the effect of agomir-210 in a rat spinal cord injury model. +other hsa-mir-29b Melanoma 27852308 Systems analysis identifies miR-29b regulation of invasiveness in melanoma. +other hsa-mir-219 Liver Cirrhosis 27855391 Suppression of MicroRNA-219-5p Activates Keratinocyte Growth Factor to Mitigate Severity of Experimental Cirrhosis. +other hsa-mir-34a Diabetic Nephropathy 27858840 Regulation of podocyte lesions in diabetic nephropathy via miR-34a in the Notch signaling pathway. +other hsa-mir-148a "Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal" 27859417 RUNX3 inhibits laryngeal squamous cell carcinoma malignancy under the regulation of miR-148a-3p/DNMT1 axis. +other hsa-mir-455 Colon Neoplasms 27861461 MicroRNA-455-3p Inhibits Tumor Cell Proliferation and Induces Apoptosis in HCT116 Human Colon Cancer Cells. +other hsa-let-7 Hemoglobin Diseases 27861570 HMGA2 Moderately Increases Fetal Hemoglobin Expression in Human Adult Erythroblasts. +other hsa-mir-375 "Adenocarcinoma, Pancreatic Ductal" 27862697 ZFP36L2 promotes cancer cell aggressiveness and is regulated by antitumor microRNA-375 in pancreatic ductal adenocarcinoma. +other hsa-mir-139 "Carcinoma, Breast" 27864119 Role of miR-139 as a surrogate marker for tumor aggression in breast cancer. +other hsa-mir-146a Wound Inflammation 27864711 Mesenchymal stem cells-derived exosomal microRNAs contribute to wound inflammation. +other hsa-mir-181 Wound Inflammation 27864711 Mesenchymal stem cells-derived exosomal microRNAs contribute to wound inflammation. +other hsa-mir-21 Wound Inflammation 27864711 Mesenchymal stem cells-derived exosomal microRNAs contribute to wound inflammation. +other hsa-mir-124 Hematologic Neoplasms 27864740 Expression Levels of Warburg-Effect Related microRNAs Correlate with each Other and that of Histone Deacetylase Enzymes in Adult Hematological Malignancies with Emphasis on Acute Myeloid Leukemia. +other hsa-mir-125b Hematologic Neoplasms 27864740 Expression Levels of Warburg-Effect Related microRNAs Correlate with each Other and that of Histone Deacetylase Enzymes in Adult Hematological Malignancies with Emphasis on Acute Myeloid Leukemia. +other hsa-mir-155 Hematologic Neoplasms 27864740 Expression Levels of Warburg-Effect Related microRNAs Correlate with each Other and that of Histone Deacetylase Enzymes in Adult Hematological Malignancies with Emphasis on Acute Myeloid Leukemia. +other hsa-mir-23b Hematologic Neoplasms 27864740 Expression Levels of Warburg-Effect Related microRNAs Correlate with each Other and that of Histone Deacetylase Enzymes in Adult Hematological Malignancies with Emphasis on Acute Myeloid Leukemia. +other hsa-mir-26a Hematologic Neoplasms 27864740 Expression Levels of Warburg-Effect Related microRNAs Correlate with each Other and that of Histone Deacetylase Enzymes in Adult Hematological Malignancies with Emphasis on Acute Myeloid Leukemia. +other hsa-mir-378 Hematologic Neoplasms 27864740 Expression Levels of Warburg-Effect Related microRNAs Correlate with each Other and that of Histone Deacetylase Enzymes in Adult Hematological Malignancies with Emphasis on Acute Myeloid Leukemia. +other hsa-mir-708 Bipolar Disorder 27864917 Genetic variation in the miR-708 gene and its binding targets in bipolar disorder. +other hsa-mir-182 Acute Kidney Failure 27865759 miRNA-Coordinated Networks as Promising Therapeutic Targets for Acute Kidney Injury. +other hsa-mir-126 "Cardiomyopathy, Ischemic" 27866054 Comparison of miRNA signature versus conventional biomarkers before and after off-pump coronary artery bypass graft. +other hsa-mir-155 "Cardiomyopathy, Ischemic" 27866054 Comparison of miRNA signature versus conventional biomarkers before and after off-pump coronary artery bypass graft. +other hsa-mir-499 "Cardiomyopathy, Ischemic" 27866054 Comparison of miRNA signature versus conventional biomarkers before and after off-pump coronary artery bypass graft. +other hsa-mir-502 "Carcinoma, Gastric" 27866197 Rs56288038 (C/G) in 3'UTR of IRF-1 Regulated by MiR-502-5p Promotes Gastric Cancer Development. +other hsa-mir-188 Azoospermia 27868267 Reduced microRNA-188-3p expression contributes to apoptosis of spermatogenic cells in patients with azoospermia. +other hsa-mir-192 Ischemia-Reperfusion Injury 27870736 Lidocaine Administration Controls MicroRNAs Alterations Observed After Lung Ischemia-Reperfusion Injury. +other hsa-mir-182 Kidney Injury 27870928 miR-182-5p Inhibition Ameliorates Ischemic Acute Kidney Injury. +other hsa-mir-326 Glioblastoma 27871300 PI3 kinase pathway regulated miRNome in glioblastoma: identification of miR-326 as a tumour suppressor miRNA. +other hsa-let-7 "Carcinoma, Laryngeal" 27874955 Expression and significances of MiRNA Let-7 and HMGA2 in laryngeal carcinoma. +other hsa-mir-30a "Carcinoma, Gastric" 27876712 MiR-30a Decreases Multidrug Resistance (MDR) of Gastric Cancer Cells. +other hsa-mir-590 "Carcinoma, Colon" 27878255 Roles of mitochondrial transcription factor A and microRNA?590?3p in the development of colon cancer. +other hsa-mir-20b "Carcinoma, Colon" 27878272 miR-20b reduces 5-FU resistance by suppressing the ADAM9/EGFR signaling pathway in colon cancer. +other hsa-mir-375 "Squamous Cell Carcinoma, Tongue" 27878285 Trichostatin A increases radiosensitization of tongue squamous cell carcinoma via miR?375. +other hsa-mir-148a Obesity 27878286 Obesity?associated miR?148a is regulated by cytokines and adipokines via a transcriptional mechanism. +other hsa-mir-196a Lung Neoplasms 27880728 Analysis of miRNA profiles identified miR-196a as a crucial mediator of aberrant PI3K/AKT signaling in lung cancer cells. +other hsa-mir-21 "Carcinoma, Esophageal" 27885434 Evaluation of miR-21 and miR-375 as prognostic biomarkers in oesophageal cancer in high-risk areas in China. +other hsa-mir-375 "Carcinoma, Esophageal" 27885434 Evaluation of miR-21 and miR-375 as prognostic biomarkers in oesophageal cancer in high-risk areas in China. +other hsa-mir-99 Hepatitis B Virus Infection 27886437 The microRNA-99 family modulates hepatitis B virus replication by promoting IGF-1R/PI3K/Akt/mTOR/ULK1 signaling-induced autophagy. +other hsa-mir-18a Leukemia 27888798 miR-103 inhibits proliferation and sensitizes hemopoietic tumor cells for glucocorticoid-induced apoptosis. +other hsa-mir-20a Leukemia 27888798 miR-103 inhibits proliferation and sensitizes hemopoietic tumor cells for glucocorticoid-induced apoptosis. +other hsa-mir-124 "Squamous Cell Carcinoma, Oral" 27889233 Icaritin induces mitochondrial apoptosis by up-regulating miR-124 in human oral squamous cell carcinoma cells. +other hsa-mir-616 "Carcinoma, Lung" 27890917 Sulforaphane suppresses EMT and metastasis in human lung cancer through miR-616-5p-mediated GSK3¦Â/¦Â-catenin signaling pathways. +other hsa-mir-338 Schizophrenia 27892953 Thalamic miR-338-3p mediates auditory thalamocortical disruption and its late onset in models of 22q11.2 microdeletion. +other hsa-mir-128 Glioblastoma 27893811 The Inhibition of microRNA-128 on IGF-1-Activating mTOR Signaling Involves in Temozolomide-Induced Glioma Cell Apoptotic Death. +other hsa-mir-30b "Carcinoma, Hepatocellular" 27894814 Tanshinone IIA induced cell death via miR30b-p53-PTPN11/SHP2 signaling pathway in human hepatocellular carcinoma cells. +other hsa-mir-142 Wound Healing 27894934 MiR-142 Is Required for Staphylococcus aureus Clearance at Skin Wound Sites via Small GTPase-Mediated Regulation of the Neutrophil Actin Cytoskeleton. +other hsa-mir-210 Atherosclerosis 27895035 MicroRNA-210 Enhances Fibrous Cap Stability in Advanced Atherosclerotic Lesions. +other hsa-mir-122 "Carcinoma, Hepatocellular" 27895094 Crosstalk between microRNA-122 and FOX family genes in HepG2 cells. +other hsa-mir-18a Neuroblastoma 27895778 Regulatory network analysis of genes and microRNAs in human hepatoblastoma. +other hsa-mir-21 Leukemia 27895788 Effects of microRNA-21 on the biological functions of T-cell acute lymphoblastic lymphoma/leukemia. +other hsa-mir-451 Esophageal Neoplasms 27896643 A novel signaling role for miR-451 in esophageal tumor microenvironment and its contribution to tumor progression. +other hsa-mir-122 "Diabetes Mellitus, Type 2" 27899485 Circulating MicroRNA-122 Is Associated With the Risk of New-Onset Metabolic Syndrome and Type 2 Diabetes. +other hsa-mir-150 Leukemia 27899822 miR-150 exerts antileukemia activity in vitro and in vivo through regulating genes in multiple pathways. +other hsa-mir-152 Leiomyosarcoma 27900663 miR-152 down-regulation is associated with MET up-regulation in leiomyosarcoma and undifferentiated pleomorphic sarcoma. +other hsa-mir-31 "Carcinoma, Gastric" 27904131 MiR-31 Regulates Rho-Associated Kinase-Myosin Light Chain (ROCK-MLC) Pathway and Inhibits Gastric Cancer Invasion +other hsa-mir-221 "Carcinoma, Hepatocellular" 27904678 miR-221 promotes growth and invasion of hepatocellular carcinoma cells by constitutive activation of NF¦ÊB. +other hsa-mir-128 Cerebral Ischemia 27905005 MicroRNA-128-3p Protects Mouse Against Cerebral Ischemia Through Reducing p38¦Á Mitogen-Activated Protein Kinase Activity. +other hsa-mir-26a "Carcinoma, Hepatocellular" 27906498 "Sialyltransferase ST3GAL6 mediates the effect of microRNA-26a on cell growth, migration, and invasion in hepatocellular carcinoma through the protein kinase B/mammalian target of rapamycin pathway." +other hsa-mir-144 "Diabetes Mellitus, Type 2" 27906902 Comparison of Transcriptome Between Type 2 Diabetes Mellitus and Impaired Fasting Glucose. +other hsa-mir-192 "Diabetes Mellitus, Type 2" 27906902 Comparison of Transcriptome Between Type 2 Diabetes Mellitus and Impaired Fasting Glucose. +other hsa-mir-29a "Diabetes Mellitus, Type 2" 27906902 Comparison of Transcriptome Between Type 2 Diabetes Mellitus and Impaired Fasting Glucose. +other hsa-mir-145 Spinal Cord Injuries 27907012 The Signature of MicroRNA Dysregulation in Muscle Paralyzed by Spinal Cord Injury Includes Downregulation of MicroRNAs that Target Myostatin Signaling. +other hsa-mir-23a Spinal Cord Injuries 27907012 The Signature of MicroRNA Dysregulation in Muscle Paralyzed by Spinal Cord Injury Includes Downregulation of MicroRNAs that Target Myostatin Signaling. +other hsa-mir-21 Glioma 27909726 MicroRNA?21 promotes migration and invasion of glioma cells via activation of Sox2 and ¦Â?catenin signaling. +other hsa-mir-181a Vascular Disease [unspecific] 27911586 miRNA-181a/b Regulates Phenotypes of Vessel Smooth Muscle Cells Through Serum Response Factor. +other hsa-mir-181b Vascular Disease [unspecific] 27911586 miRNA-181a/b Regulates Phenotypes of Vessel Smooth Muscle Cells Through Serum Response Factor. +other hsa-mir-98 Inflammation 27913008 MicroRNA-98 plays a critical role in experimental myocarditis. +other hsa-mir-155 "Carcinoma, Hepatocellular" 27913196 NF-kB-regulated exosomal miR-155 promotes the inflammation associated with arsenite carcinogenesis. +other hsa-mir-155 Adenovirus Infection 27916071 The effect of curcumin on the expression of miR-155 to apoptosis and invasion of extravillus trophoblast cells treated by lipopolysaccharide. +other hsa-mir-34a Pain 27917453 "Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors." +other hsa-mir-200c Colorectal Carcinoma 27918105 "Resveratrol Inhibits Proliferation, Invasion, and Epithelial-Mesenchymal Transition by Increasing miR-200c Expression in HCT-116 Colorectal Cancer Cells." +other hsa-mir-497 Atherosclerosis 27918592 MicroRNA-497 Induces Apoptosis and Suppresses Proliferation via the Bcl-2/Bax-Caspase9-Caspase3 Pathway and Cyclin D2 Protein in HUVECs. +other hsa-mir-7 Colorectal Carcinoma 27919977 MicroRNA-7 Is Associated with Malignant Potential and Poor Prognosis in Human Colorectal Cancer. +other hsa-mir-33 Atherosclerosis 27920122 MicroRNA-33 Controls Adaptive Fibrotic Response in the Remodeling Heart by Preserving Lipid Raft Cholesterol. +other hsa-mir-328 "Carcinoma, Gastric" 27923017 Expression of microRNA-328 Functions as a Biomarker for Recurrence of Early Gastric Cancer (EGC) After Endoscopic Submucosal Dissection (ESD) by Modulating CD44. +other hsa-mir-126 Atherosclerosis 27923459 MicroRNAs in lipid metabolism and atherosclerosis. +other hsa-mir-33a Atherosclerosis 27923459 MicroRNAs in lipid metabolism and atherosclerosis. +other hsa-mir-92a Atherosclerosis 27923459 MicroRNAs in lipid metabolism and atherosclerosis. +other hsa-mir-29 Cardiovascular Diseases [unspecific] 27932253 Regulation of cyclin D1 by arsenic and microRNA inhibits adipogenesis. +other hsa-mir-29b Cardiovascular Diseases [unspecific] 27932253 Regulation of cyclin D1 by arsenic and microRNA inhibits adipogenesis. +other hsa-mir-550a Diabetes Mellitus 27935135 Micro RNA-550a interferes with vitamin D metabolism in peripheral B cells of patients with diabetes. +other hsa-mir-221 Liver Cirrhosis 27935974 Epigallocatechin-3-Gallate Upregulates miR-221 to Inhibit Osteopontin-Dependent Hepatic Fibrosis. +other hsa-mir-92a Cardiovascular Diseases [unspecific] 27936205 Hyperhomocysteinemia in ApoE-/- Mice Leads to Overexpression of Enhancer of Zeste Homolog 2 via miR-92a Regulation. +other hsa-mir-132 Intracerebral Hemorrhage 27940326 MicroRNA-132 attenuates neurobehavioral and neuropathological changes associated with intracerebral hemorrhage in mice. +other hsa-mir-221 "Carcinoma, Breast" 27940575 mda-7/IL-24 Mediates Cancer Cell-Specific Death via Regulation of miR-221 and the Beclin-1 Axis. +other hsa-mir-200 "Carcinoma, Biliary Tract" 27941621 Relevance of MicroRNA200 Family and MicroRNA205 for Epithelial to Mesenchymal Transition and Clinical Outcome in Biliary Tract Cancer Patients. +other hsa-mir-205 "Carcinoma, Biliary Tract" 27941621 Relevance of MicroRNA200 Family and MicroRNA205 for Epithelial to Mesenchymal Transition and Clinical Outcome in Biliary Tract Cancer Patients. +other hsa-mir-142 Autoimmune Diseases [unspecific] 27943367 Analysis of miR-146a and miR-142-3p as Potential Markers of Freshly Isolated or In Vitro-Expanded Human Treg cells. +other hsa-mir-146a Autoimmune Diseases [unspecific] 27943367 Analysis of miR-146a and miR-142-3p as Potential Markers of Freshly Isolated or In Vitro-Expanded Human Treg cells. +other hsa-mir-145 "Aortic Aneurysm, Abdominal" 27956160 MicroRNA-145 Mediates the Formation of Angiotensin II-Induced Murine Abdominal Aortic Aneurysm. +other hsa-mir-1271 Multiple Myeloma 27959416 MicroRNA-1271 inhibits proliferation and promotes apoptosis of multiple myeloma cells through inhibiting smoothened-mediated Hedgehog signaling pathway. +other hsa-mir-376c Gastric Neoplasms 27965982 hsa-miR-376c-3p Regulates Gastric Tumor Growth Both In Vitro and In Vivo. +other hsa-mir-205 "Squamous Cell Carcinoma, Esophageal" 27974696 Sp1-mediated transcriptional activation of miR-205 promotes radioresistance in esophageal squamous cell carcinoma. +other hsa-mir-9 Glioma 27975329 Density-Dependent Regulation of Glioma Cell Proliferation and Invasion Mediated by miR-9. +other hsa-mir-34a Diabetic Retinopathy 27977785 LGR4 Is a Direct Target of MicroRNA-34a and Modulates the Proliferation and Migration of Retinal Pigment Epithelial ARPE-19 Cells. +other hsa-mir-376a "Carcinoma, Ovarian" 27979415 MiR-376a promotion of proliferation and metastases in ovarian cancer +other hsa-mir-122 "Carcinoma, Hepatocellular" 27980102 Blocking the CCL2-CCR2 Axis Using CCL2-Neutralizing Antibody Is an Effective Therapy for Hepatocellular Cancer in a Mouse Model. +other hsa-mir-155 Inflammation 27981414 MicroRNA-155: a Novel Armamentarium Against Inflammatory Diseases. +other hsa-mir-760 "Carcinoma, Breast" 27981531 miR-760 mediates chemoresistance through inhibition of epithelial mesenchymal transition in breast cancer cells. +other hsa-mir-155 Human Immunodeficiency Virus Infection 27981723 MicroRNA-155 is a biomarker of T-cell activation and immune dysfunction in HIV-1-infected patients. +other hsa-mir-125a "Carcinoma, Hepatocellular" 27982429 MicroRNA-125a-5p Is a Downstream Effector of Sorafenib in Its Antiproliferative Activity Toward Human Hepatocellular Carcinoma Cells. +other hsa-mir-221 "Carcinoma, Hepatocellular" 27983537 Clinical potential of miRNA-221 as a novel prognostic biomarker for hepatocellular carcinoma. +other hsa-mir-210 Inflammation 27983913 Precise Regulation of miR-210 Is Critical for the Cellular Homeostasis Maintenance and Transplantation Efficacy Enhancement of Mesenchymal Stem Cells in Acute Liver Failure Therapy. +other hsa-mir-9 Rhabdomyosarcoma 27984116 MicroRNA and gene co-expression networks characterize biological and clinical behavior of rhabdomyosarcomas. +other hsa-mir-29a "Carcinoma, Breast" 27986463 Tamoxifen differentially regulates miR-29b-1 and miR-29a expression depending on endocrine-sensitivity in breast cancer cells. +other hsa-mir-29b "Carcinoma, Breast" 27986463 Tamoxifen differentially regulates miR-29b-1 and miR-29a expression depending on endocrine-sensitivity in breast cancer cells. +other hsa-mir-101 "Carcinoma, Pancreatic" 27988337 micorRNA-101 silences DNA-PKcs and sensitizes pancreatic cancer cells to gemcitabine. +other hsa-mir-125b Osteosarcoma 27990096 miR-125b and miR-100 Are Predictive Biomarkers of Response to Induction Chemotherapy in Osteosarcoma. +other hsa-mir-21 Neoplasms [unspecific] 27992999 Systematic Evaluation of Biophysical and Functional Characteristics of Selenomethylene-Locked Nucleic Acid-Mediated Inhibition of miR-21. +other hsa-mir-601 "Carcinoma, Pancreatic" 27993677 Identification of miR-601 as a novel regulator in the development of pancreatic cancer. +other hsa-mir-196a-2 Behcet Disease 27993883 Association of Reduced Heme Oxygenase-1 with Decreased MicroRNA-196a2 Expression in Peripheral Blood Mononuclear Cells of Patients with Intestinal Behcet's Disease. +other hsa-mir-34c Human Immunodeficiency Virus Infection 27993935 miRNA profiling of human naive CD4 T cells links miR-34c-5p to cell activation and HIV replication. +other hsa-mir-206 Coronary Artery Disease 27994218 MiR-206 Suppresses the Progression of Coronary Artery Disease by Modulating Vascular Endothelial Growth Factor (VEGF) Expression. +other hsa-mir-21 Leukemia 27995885 Targeted suppression of miRNA-21 inhibit K562 cells growth through PTEN-PI3K/AKT signaling pathway. +other hsa-mir-1 Viral Myocarditis 27997912 "Analysis of the Indicating Value of Cardiac Troponin I, Tumor Necrosis Factor-¦Á, Interleukin-18, Mir-1 and Mir-146b for Viral Myocarditis among Children." +other hsa-mir-146b Viral Myocarditis 27997912 "Analysis of the Indicating Value of Cardiac Troponin I, Tumor Necrosis Factor-¦Á, Interleukin-18, Mir-1 and Mir-146b for Viral Myocarditis among Children." +other hsa-mir-223 "Carcinoma, Hepatocellular" 27998765 MiR-223 modulates hepatocellular carcinoma cell proliferation through promoting apoptosis via the Rab1-mediated mTOR activation. +other hsa-mir-146a Inflammation 27998828 "we reported an anti-inflammatory effect of resveratrol and hydroxytyrosol at low, nutritionally relevant concentrations, involving the inhibition of granulocytes and monocytes activation, the modulation of miR-146a expression and the activation of Nrf2" +other hsa-mir-223 Inflammation 27999792 Inflammation Related MicroRNAs Are Modulated in Total Plasma and in Extracellular Vesicles from Rats with Chronic Ingestion of Sucrose. +other hsa-mir-22 Malignant Neoplasms [unspecific] 28000852 Molecular mechanisms and clinical applications of miR-22 in regulating malignant progression in human cancer +other hsa-mir-27a "Carcinoma, Thyroid" 28002594 "Effects of miR-27a upregulation on thyroid cancer cells migration, invasion, and angiogenesis." +other hsa-mir-200c "Carcinoma, Breast" 28003747 MicroRNA-200c delivered by solid lipid nanoparticles enhances the effect of paclitaxel on breast cancer stem cell. +other hsa-let-7 Neoplasms [unspecific] 28004230 "In Silico Mining of Conserved miRNAs of Indian Catfish Clarias batrachus (Linnaeus, 1758) from the Contigs, ESTs, and BAC End Sequences." +other hsa-mir-133 Neoplasms [unspecific] 28004230 "In Silico Mining of Conserved miRNAs of Indian Catfish Clarias batrachus (Linnaeus, 1758) from the Contigs, ESTs, and BAC End Sequences." +other hsa-mir-137 Neoplasms [unspecific] 28004230 "In Silico Mining of Conserved miRNAs of Indian Catfish Clarias batrachus (Linnaeus, 1758) from the Contigs, ESTs, and BAC End Sequences." +other hsa-mir-455 Neoplasms [unspecific] 28004230 "In Silico Mining of Conserved miRNAs of Indian Catfish Clarias batrachus (Linnaeus, 1758) from the Contigs, ESTs, and BAC End Sequences." +other hsa-mir-140 "Adenocarcinoma, Lung" 28005074 MiR-206 and miR-140 also suppressed lung adenocarcinoma cell metastasis in vitro and in vivo by regulating EMT-related factors +other hsa-mir-206 "Adenocarcinoma, Lung" 28005074 MiR-206 and miR-140 also suppressed lung adenocarcinoma cell metastasis in vitro and in vivo by regulating EMT-related factors +other hsa-mir-4286 Melanoma 28005927 Antiproliferative and Pro-Apoptotic Effects of MiR-4286 Inhibition in Melanoma Cells. +other hsa-mir-371 "Carcinoma, Prostate" 28005952 MicroRNA and Transcription Factor Gene Regulatory Network Analysis Reveals Key Regulatory Elements Associated with Prostate Cancer Progression. +other hsa-mir-512 "Carcinoma, Prostate" 28005952 MicroRNA and Transcription Factor Gene Regulatory Network Analysis Reveals Key Regulatory Elements Associated with Prostate Cancer Progression. +other hsa-mir-663 "Carcinoma, Prostate" 28005952 MicroRNA and Transcription Factor Gene Regulatory Network Analysis Reveals Key Regulatory Elements Associated with Prostate Cancer Progression. +other hsa-mir-665 "Carcinoma, Prostate" 28005952 MicroRNA and Transcription Factor Gene Regulatory Network Analysis Reveals Key Regulatory Elements Associated with Prostate Cancer Progression. +other hsa-mir-671 "Carcinoma, Prostate" 28005952 MicroRNA and Transcription Factor Gene Regulatory Network Analysis Reveals Key Regulatory Elements Associated with Prostate Cancer Progression. +other hsa-mir-21 Sepsis 28006751 miR-375 ameliorates sepsis by downregulating miR-21 level via inhibiting JAK2-STAT3 signaling. +other hsa-mir-375 Sepsis 28006751 miR-375 ameliorates sepsis by downregulating miR-21 level via inhibiting JAK2-STAT3 signaling. +other hsa-mir-215 Colorectal Carcinoma 28006930 Systemic administration of miRNA mimics by liposomal delivery system in animal model of colorectal carcinoma. +other hsa-mir-335 "Carcinoma, Breast" 28008602 MicroRNA-335-5p and -3p synergize to inhibit estrogen receptor alpha expression and promote tamoxifen resistance. +other hsa-mir-122 Chronic Hepatitis C 28008821 Cooperative enhancement of translation by two adjacent microRNA-122/Argonaute 2 complexes binding to the 5' untranslated region of hepatitis C virus RNA. +other hsa-let-7a "Carcinoma, Hepatocellular" 28012864 Germline and somatic DICER1 mutations in familial and sporadic liver tumors. +other hsa-mir-205 "Squamous Cell Carcinoma, Skin or Unspecific" 28013372 MiR-21 and miR-205 are induced in invasive cutaneous squamous cell carcinomas. +other hsa-mir-21 "Squamous Cell Carcinoma, Skin or Unspecific" 28013372 MiR-21 and miR-205 are induced in invasive cutaneous squamous cell carcinomas. +other hsa-mir-155 Cardiovascular Diseases [unspecific] 28018919 a recent clinical trial of Miravirsen targeting microRNA-122 sheds light on exploiting microRNA-155 as a novel target to develop effective therapeutic strategies for cardiovascular diseases in the near future +other hsa-mir-124 Myelodysplastic Syndromes 28024498 Reactivated Expression of MicroRNA-124 in Patients with Myelodysplastic Syndromes after Demethylating Therapy. +other hsa-mir-218 Gastrointestinal Neoplasms 28024574 miRNA-218-loaded carboxymethyl chitosan - Tocopherol nanoparticle to suppress the proliferation of gastrointestinal stromal tumor growth. +other hsa-mir-155 Stroke 28025572 Influence of miR-155 on Cell Apoptosis in Rats with Ischemic Stroke: Role of the Ras Homolog Enriched in Brain (Rheb)/mTOR Pathway. +other hsa-mir-200a Liver Cirrhosis 28025657 miR-200a controls hepatic stellate cell activation and fibrosis via SIRT1/Notch1 signal pathway. +other hsa-mir-1 Chronic Obstructive Pulmonary Disease 28025995 Prediction of key genes and miRNAs responsible for loss of muscle force in patients during an acute exacerbation of chronic obstructive pulmonary disease. +other hsa-mir-15a Chronic Obstructive Pulmonary Disease 28025995 Prediction of key genes and miRNAs responsible for loss of muscle force in patients during an acute exacerbation of chronic obstructive pulmonary disease. +other hsa-mir-16 Chronic Obstructive Pulmonary Disease 28025995 Prediction of key genes and miRNAs responsible for loss of muscle force in patients during an acute exacerbation of chronic obstructive pulmonary disease. +other hsa-mir-23a Chronic Obstructive Pulmonary Disease 28025995 Prediction of key genes and miRNAs responsible for loss of muscle force in patients during an acute exacerbation of chronic obstructive pulmonary disease. +other hsa-mir-9 Chronic Obstructive Pulmonary Disease 28025995 Prediction of key genes and miRNAs responsible for loss of muscle force in patients during an acute exacerbation of chronic obstructive pulmonary disease. +other hsa-mir-200a "Carcinoma, Esophageal" 28025999 miR-200a-3p promotes the proliferation of human esophageal cancer cells by post-transcriptionally regulating cytoplasmic collapsin response mediator protein-1. +other hsa-mir-9 Infection [unspecific] 28031262 Pseudomonas aeruginosa GroEL Stimulates Production of PTX3 by Activating the NF-¦ÊB Pathway and Simultaneously Downregulating MicroRNA-9. +other hsa-mir-15 Malignant Neoplasms [unspecific] 28032148 The relationship between platinum drug resistance and epithelial-mesenchymal transition. +other hsa-mir-186 Malignant Neoplasms [unspecific] 28032148 The relationship between platinum drug resistance and epithelial-mesenchymal transition. +other hsa-mir-210 Osteosarcoma 28032372 MicroRNA-210 is increased and it is required for dedifferentiation of osteosarcoma cell line. +other hsa-mir-192 Ischemia-Reperfusion Injury 28035621 Implications of dynamic changes in miR-192 expression in ischemic acute kidney injury. +other hsa-mir-210 Neoplasms [unspecific] 28036268 "Role of VHL, HIF1A and SDH on the expression of miR-210: Implications for tumoral pseudo-hypoxic fate." +other hsa-mir-143 Neoplasms [unspecific] 28038917 A positive feedback loop between GRP78 and VPS34 is critical for GRP78-mediated autophagy in cancer cells. +other hsa-mir-21 Systemic Lupus Erythematosus 28039018 Estrogen-regulated STAT1 activation promotes TLR8 expression to facilitate signaling via microRNA-21 in systemic lupus erythematosus. +other hsa-mir-192 Glioma 28039611 Alternative new mesenchymal stem cell source exerts tumor tropism through ALCAM and N-cadherin via regulation of microRNA-192 and -218. +other hsa-mir-218 Glioma 28039611 Alternative new mesenchymal stem cell source exerts tumor tropism through ALCAM and N-cadherin via regulation of microRNA-192 and -218. +other hsa-mir-1 "Leukemia, Myeloid, Acute" 28042875 "the PI3K/mTOR dual inhibitor BEZ235 effectively chemosensitizes AML cells via increasing miR-1-3p and subsequently down-regulating BAG4, EDN1 and ABCB1" +other hsa-mir-31 "Carcinoma, Nasopharyngeal" 28042945 Minicircle-oriP-miR-31 as a Novel EBNA1-Specific miRNA Therapy Approach for Nasopharyngeal Carcinoma. +other hsa-mir-190b "Carcinoma, Gastric" 28044223 MicroRNA-190b confers radio-sensitivity through negative regulation of Bcl-2 in gastric cancer cells. +other hsa-mir-34a "Carcinoma, Renal Cell" 28045889 Metformin Induces Growth Inhibition and Cell Cycle Arrest by Upregulating MicroRNA34a in Renal Cancer Cells. +other hsa-mir-182 Inflammation 28045967 Induction of Multiple miR-200/182 Members in the Brains of Mice Are Associated with Acute Herpes Simplex Virus 1 Encephalitis. +other hsa-mir-183 Inflammation 28045967 Induction of Multiple miR-200/182 Members in the Brains of Mice Are Associated with Acute Herpes Simplex Virus 1 Encephalitis. +other hsa-mir-210 Neoplasms [unspecific] 28046107 RNA Sequencing Reveals that Kaposi Sarcoma-Associated Herpesvirus Infection Mimics Hypoxia Gene Expression Signature. +other hsa-mir-214 "Carcinoma, Breast" 28051254 MiR-214 negatively regulates proliferation and WNT/¦Â-catenin signaling in breast cancer. +other hsa-mir-361 "Carcinoma, Lung, Non-Small-Cell" 28051257 Downregulation of miR-361-5p associates with aggressive clinicopathological features and unfavorable prognosis in non-small cell lung cancer. +other hsa-mir-379 "Carcinoma, Hepatocellular" 28051262 Bioinformatic identification of IGF1 as a hub gene in hepatocellular carcinoma (HCC) and in-vitro analysis of the chemosensitizing effect of miR-379 via suppressing the IGF1/IGF1R signaling pathway. +other hsa-mir-125a "Leukemia, Myeloid, Acute" 28053194 miR-125b promotes MLL-AF9-driven murine acute myeloid leukemia involving a VEGFA-mediated non-cell-intrinsic mechanism. +other hsa-mir-125b "Leukemia, Myeloid, Acute" 28053194 miR-125b promotes MLL-AF9-driven murine acute myeloid leukemia involving a VEGFA-mediated non-cell-intrinsic mechanism. +other hsa-mir-378 Renal Fibrosis 28053239 miR-378 reduces mesangial hypertrophy and kidney tubular fibrosis via MAPK signalling. +other hsa-mir-181a Chronic Hepatitis B 28053323 HBx promotes cell proliferation by disturbing the cross-talk between miR-181a and PTEN. +other hsa-mir-1292 Colorectal Carcinoma 28054337 Combined miRNA profiling and proteomics demonstrates that different miRNAs target a common set of proteins to promote colorectal cancer metastasis. +other hsa-mir-424 Colorectal Carcinoma 28054337 Combined miRNA profiling and proteomics demonstrates that different miRNAs target a common set of proteins to promote colorectal cancer metastasis. +other hsa-mir-503 Colorectal Carcinoma 28054337 Combined miRNA profiling and proteomics demonstrates that different miRNAs target a common set of proteins to promote colorectal cancer metastasis. +other hsa-mir-124 Ewing Sarcoma 28055964 miR-124 represses the mesenchymal features and suppresses metastasis in Ewing sarcoma. +other hsa-mir-504 Glioblastoma 28056026 "Integration of MicroRNA, mRNA, and Protein Expression Data for the Identification of Cancer-Related MicroRNAs." +other hsa-mir-152 "Carcinoma, Gastric" 28056089 Helicobacter Pylori Promote B7-H1 Expression by Suppressing miR-152 and miR-200b in Gastric Cancer Cells. +other hsa-mir-200b "Carcinoma, Gastric" 28056089 Helicobacter Pylori Promote B7-H1 Expression by Suppressing miR-152 and miR-200b in Gastric Cancer Cells. +other hsa-mir-497 "Adenocarcinoma, Lung" 28057758 Down-regulation of Claudin-2 Expression and Proliferation by Epigenetic Inhibitors in Human Lung Adenocarcinoma A549 Cells. +other hsa-mir-340 "Carcinoma, Gastric" 28057912 "miR-340 Inhibits Proliferation and Induces Apoptosis in Gastric Cancer Cell Line SGC-7901, Possibly via the AKT Pathway." +other hsa-let-7b Myocardial Infarction 28062497 Increased Proangiogenic Activity of Mobilized CD34+ Progenitor Cells of Patients With Acute ST-Segment-Elevation Myocardial Infarction: Role of Differential MicroRNA-378 Expression. +other hsa-mir-378 Myocardial Infarction 28062497 Increased Proangiogenic Activity of Mobilized CD34+ Progenitor Cells of Patients With Acute ST-Segment-Elevation Myocardial Infarction: Role of Differential MicroRNA-378 Expression. +other hsa-mir-9 "Carcinoma, Hepatocellular" 28062574 Loss of N-Acetylgalactosaminyltransferase-4 Orchestrates Oncogenic MicroRNA-9 in Hepatocellular Carcinoma. +other hsa-mir-181b "Adenocarcinoma, Pancreatic Ductal" 28064436 "MicroRNA-181b-5p, ETS1, and the c-Met pathway exacerbate the prognosis of pancreatic ductal adenocarcinoma after radiation therapy." +other hsa-mir-192 Lung Neoplasms 28067164 "pharmacological effects of curcumin in lung cancer are also mediated by modulation of several miRNAs, such as downregulation of oncogenic miR-21 and upregulation of oncosuppressive miR-192-5p and miR-215" +other hsa-mir-21 Lung Neoplasms 28067164 "pharmacological effects of curcumin in lung cancer are also mediated by modulation of several miRNAs, such as downregulation of oncogenic miR-21 and upregulation of oncosuppressive miR-192-5p and miR-215" +other hsa-mir-215 Lung Neoplasms 28067164 "pharmacological effects of curcumin in lung cancer are also mediated by modulation of several miRNAs, such as downregulation of oncogenic miR-21 and upregulation of oncosuppressive miR-192-5p and miR-215" +other hsa-mir-122 Chronic Hepatitis C 28067225 Hepatitis C virus has a genetically determined lymphotropism through co-receptor B7.2. +other hsa-mir-16 "Carcinoma, Ovarian" 28067383 The functional consequences and prognostic value of dosage sensitivity in ovarian cancer. +other hsa-mir-98 "Carcinoma, Ovarian" 28067383 The functional consequences and prognostic value of dosage sensitivity in ovarian cancer. +other hsa-mir-34c "Carcinoma, Breast, Triple Negative" 28069384 Regulation of cancerous progression and epithelial-mesenchymal transition by miR-34c-3p via modulation of MAP3K2 signaling in triple-negative breast cancer cells. +other hsa-mir-133b "Squamous Cell Carcinoma, Esophageal" 28069586 SQLE induces epithelial-to-mesenchymal transition by regulating of miR-133b in esophageal squamous cell carcinoma. +other hsa-let-7 Neoplasms [unspecific] 28070818 "Entangling Relation of Micro RNA-let7, miRNA-200 and miRNA-125 with Various Cancers." +other hsa-mir-181 Leukemia 28072759 Induction of K562 Cell Apoptosis by As4S4 via Down-Regulating miR181. +other hsa-mir-221 Osteosarcoma 28074104 Bufalin Inhibits Proliferation and Induces Apoptosis in Osteosarcoma Cells by Downregulating MicroRNA-221. +other hsa-mir-124 "Carcinoma, Oral" 28077301 MiR-124 down-regulation is critical for cancer associated fibroblasts-enhanced tumor growth of oral carcinoma. +other hsa-mir-193b Polycystic Kidney Disease 28077374 "Expression of ErbB4 in vivo was increased in human ADPKD and Pkd1 cystic kidneys, both transcriptionally and posttranscriptionally by mir-193b-3p" +other hsa-mir-199a Cardiac Myocyte Injury 28077443 Single-Dose Intracardiac Injection of Pro-Regenerative MicroRNAs Improves Cardiac Function After Myocardial Infarction. +other hsa-mir-19a Hepatitis C Virus Infection 28077652 "Furthermore, we demonstrate the role of exosomal miR-19a in activation of the STAT3-TGF-¦Â pathway in HSC" +other hsa-mir-205 "Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal" 28078305 miR-375 and miR-205 Regulate the Invasion and Migration of Laryngeal Squamous Cell Carcinoma Synergistically via AKT-Mediated EMT. +other hsa-mir-375 "Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal" 28078305 miR-375 and miR-205 Regulate the Invasion and Migration of Laryngeal Squamous Cell Carcinoma Synergistically via AKT-Mediated EMT. +other hsa-mir-26a "Carcinoma, Hepatocellular" 28079894 MiR-26 enhances chemosensitivity and promotes apoptosis of hepatocellular carcinoma cells through inhibiting autophagy. +other hsa-mir-92a "Carcinoma, Cervical" 28081742 MicroRNA-92a Promotes Cell Proliferation in Cervical Cancer via Inhibiting p21 Expression and Promoting Cell Cycle Progression. +other hsa-mir-19a Asthma 28081849 Constitutive high expression of protein arginine methyltransferase 1 in asthmatic airway smooth muscle cells is caused by reduced microRNA-19a expression and leads to enhanced remodeling. +other hsa-mir-21 Infection [unspecific] 28083515 Genome-Wide Transcriptional and Post-transcriptional Regulation of Innate Immune and Defense Responses of Bovine Mammary Gland to Staphylococcus aureus. +other hsa-mir-223 Infection [unspecific] 28083515 Genome-Wide Transcriptional and Post-transcriptional Regulation of Innate Immune and Defense Responses of Bovine Mammary Gland to Staphylococcus aureus. +other hsa-mir-19b Liver Diseases [unspecific] 28083843 MicroRNA-19b Expression in Human Biliary Atresia Specimens and Its Role in BA-Related Fibrosis. +other hsa-mir-16 "Carcinoma, Thyroid, Papillary" 28085013 Expressions of miRNAs in papillary thyroid carcinoma and their associations with the clinical characteristics of PTC. +other hsa-mir-122 Chronic Hepatitis C 28087069 "Safety, tolerability, and antiviral effect of RG-101 in patients with chronic hepatitis C: a phase 1B, double-blind, randomised controlled trial." +other hsa-mir-24 Cholangiocarcinoma 28087162 miR-24 Inhibition Increases Menin Expression and Decreases Cholangiocarcinoma Proliferation. +other hsa-mir-143 Metabolic Syndrome 28088407 Far-off and close-up dry matter intake modulate indicators of immunometabolic adaptations to lactation in subcutaneous adipose tissue of pasture-based transition dairy cows. +other hsa-mir-29c "Carcinoma, Pancreatic" 28088520 Palmitic acid increases invasiveness of pancreatic cancer cells AsPC-1 through TLR4/ROS/NF-¦ÊB/MMP-9 signaling pathway. +other hsa-mir-21 "Adenocarcinoma, Lung" 28089356 Insertions and Deletions Target Lineage-Defining Genes in Human Cancers. +other hsa-mir-126 "Adenocarcinoma, Prostate" 28089917 "microRNAs and DICER1 are regulated by 1,25-dihydroxyvitamin D in prostate stroma." +other hsa-mir-154 "Adenocarcinoma, Prostate" 28089917 "microRNAs and DICER1 are regulated by 1,25-dihydroxyvitamin D in prostate stroma." +other hsa-mir-21 "Adenocarcinoma, Prostate" 28089917 "microRNAs and DICER1 are regulated by 1,25-dihydroxyvitamin D in prostate stroma." +other hsa-mir-125b Amyotrophic Lateral Sclerosis 28090150 M1 and M2 Functional Imprinting of Primary Microglia: Role of P2X7 Activation and miR-125b. +other hsa-mir-146a Sepsis 28090688 Exosomal miR-146a Contributes to the Enhanced Therapeutic Efficacy of Interleukin-1¦Â-Primed Mesenchymal Stem Cells Against Sepsis. +other hsa-mir-19b Heart Failure 28091585 MicroRNA-19b is a potential biomarker of increased myocardial collagen cross-linking in patients with aortic stenosis and heart failure. +other hsa-mir-1227 Glioma 28091986 miR-1227 may be associated with increased migration and miR-32 and miR-222 with decreased migration +other hsa-mir-222 Glioma 28091986 miR-1227 may be associated with increased migration and miR-32 and miR-222 with decreased migration +other hsa-mir-32 Glioma 28091986 miR-1227 may be associated with increased migration and miR-32 and miR-222 with decreased migration +other hsa-mir-29b Wound Healing 28092445 miR-29b promotes skin wound healing and reduces excessive scar formation by inhibition of the TGF-¦Â1/Smad/CTGF signaling pathway. +other hsa-mir-21 Breast Adenocarcinoma 28092843 "Moreover siRNA transfection had effects on breast adenocarcinoma cells and inhibits the migration (p<0.0001), proliferation (p<0.0001), cell cycle arrest (p=0.03) and induces apoptosis (p<0.0001) and reduces the expression of miR-21 (P=0.0014)" +other hsa-mir-4775 Colorectal Carcinoma 28095858 miR-4775 promotes colorectal cancer invasion and metastasis via the Smad7/TGF¦Â-mediated epithelial to mesenchymal transition. +other hsa-mir-221 "Carcinoma, Hepatocellular" 28096271 In Hepatocellular Carcinoma miR-221 Modulates Sorafenib Resistance through Inhibition of Caspase-3-Mediated Apoptosis. +other hsa-mir-21 "Carcinoma, Lung, Non-Small-Cell" 28096685 The role of microRNA-21 in predicting brain metastases from non-small cell lung cancer. +other hsa-mir-34a Myelofibrosis 28098757 "the increased expression of miR-34a-5p in PMF HPCs could be important for the skewing of megakaryopoiesis and the production of monocytes, that are key players in BM fibrosis in PMF patients" +other hsa-mir-133b Colorectal Carcinoma 28098895 MicroRNA-133b is regulated by TAp63 while no gene mutation is present in colorectal cancer. +other hsa-mir-152 Colorectal Carcinoma 28098901 "after treatment with berberine and evodiamine for 24?h, respectively, increased expression of DNMT1, DNMT3A, DNMT3B and miR-152, miR-429, miR-29a was noted" +other hsa-mir-29a Colorectal Carcinoma 28098901 "after treatment with berberine and evodiamine for 24?h, respectively, increased expression of DNMT1, DNMT3A, DNMT3B and miR-152, miR-429, miR-29a was noted" +other hsa-mir-429 Colorectal Carcinoma 28098901 "after treatment with berberine and evodiamine for 24?h, respectively, increased expression of DNMT1, DNMT3A, DNMT3B and miR-152, miR-429, miR-29a was noted" +other hsa-mir-15a "Carcinoma, Renal Cell" 28098906 miR?15a?5p acts as an oncogene in renal cell carcinoma. +other hsa-mir-203 "Carcinoma, Hepatocellular" 28100026 miR-203 inhibits augmented proliferation and metastasis of hepatocellular carcinoma residual in the promoted regenerating liver. +other hsa-mir-142 Multiple Sclerosis 28100738 miR-142-3p Is a Key Regulator of IL-1¦Â-Dependent Synaptopathy in Neuroinflammation. +other hsa-mir-25 "Adenocarcinoma, Lung" 28101226 Evaluation of plasma microRNA levels to predict insensitivity of patients with advanced lung adenocarcinomas to pemetrexed and platinum. +other hsa-mir-146a "Carcinoma, Prostate" 28101571 Upregulation of miR-146a by YY1 depletion correlates with delayed progression of prostate cancer. +other hsa-mir-650 "Carcinoma, Breast" 28101578 A 22q11.2 amplification in the region encoding microRNA-650 correlates with the epithelial to mesenchymal transition in breast cancer primary cultures of Mexican patients. +other hsa-mir-126 Stroke 28101763 MiR-126 Affects Brain-Heart Interaction after Cerebral Ischemic Stroke. +other hsa-mir-125b Cervical Neoplasms 28102867 "Gene regulation of the DEGs also revealed important TFs and miRNAs such as ELF1, SRF, has-mir-125b-5p and has-mir-644a" +other hsa-mir-644a Cervical Neoplasms 28102867 "Gene regulation of the DEGs also revealed important TFs and miRNAs such as ELF1, SRF, has-mir-125b-5p and has-mir-644a" +other hsa-mir-146a "Carcinoma, Thyroid" 28103112 "Potassium Iodate Differently Regulates the Proliferation, Migration, and Invasion of Human Thyroid Cancer Cells via Modulating miR-146a." +other hsa-mir-133a Inflammatory Bowel Diseases 28104982 "miRNA-133a-UCP2 pathway regulates inflammatory bowel disease progress by influencing inflammation, oxidative stress and energy metabolism." +other hsa-mir-145 "Carcinoma, Bladder" 28106737 A Novel Combination RNAi toward Warburg Effect by Replacement with miR-145 and Silencing of PTBP1 Induces Apoptotic Cell Death in Bladder Cancer Cells. +other hsa-mir-130b Glioma 28107197 MTDH promotes glioma invasion through regulating miR-130b-ceRNAs. +other hsa-mir-142 Adrenal Cortex Neoplasms 28110695 "MEN1 and microRNAs: The link between sporadic pituitary, parathyroid and adrenocortical tumors" +other hsa-mir-24 Adrenal Cortex Neoplasms 28110695 "MEN1 and microRNAs: The link between sporadic pituitary, parathyroid and adrenocortical tumors" +other hsa-mir-382 Hemangioma 28112362 Downregulation of miR-382 by propranolol inhibits the progression of infantile hemangioma via the PTEN-mediated AKT/mTOR pathway. +other hsa-mir-145 "Carcinoma, Cervical" 28112371 MicroRNA-145 inhibits tumorigenesis and invasion of cervical cancer stem cells. +other hsa-mir-126 Intracerebral Hemorrhage 28112373 Protective role of microRNA-126 in intracerebral hemorrhage. +other hsa-mir-342 Glioma 28112756 Long noncoding RNA FTX is upregulated in gliomas and promotes proliferation and invasion of glioma cells by negatively regulating miR-342-3p. +other hsa-mir-200c "Carcinoma, Gastric" 28113080 "MicroRNA-200c binding to FN1 suppresses the proliferation, migration and invasion of gastric cancer cells." +other hsa-mir-1 Vascular Hypertrophy 28114137 Hydrogen Sulfide Protects Cardiomyocytes against Apoptosis in Ischemia/Reperfusion through MiR-1-Regulated Histone Deacetylase 4 Pathway. +other hsa-mir-26b Adenovirus Infection 28114818 Functional Screening Identifies Human miRNAs that Modulate Adenovirus Propagation in Prostate Cancer Cells. +other hsa-mir-122 "Carcinoma, Hepatocellular" 28114997 Targeted imaging and induction of apoptosis of drug-resistant hepatoma cells by miR-122-loaded graphene-InP nanocompounds. +other hsa-mir-183 "Adenocarcinoma, Lung" 28115792 Identification of Factors for the Preoperative Prediction of Tumour Subtype and Prognosis in Patients with T1 Lung Adenocarcinoma. +other hsa-mir-21 "Carcinoma, Breast" 28115844 Simultaneous delivery of anti-miR21 with doxorubicin prodrug by mimetic lipoprotein nanoparticles for synergistic effect against drug resistance in cancer cells. +other hsa-mir-155 Rheumatoid Arthritis 28118944 MicroRNA-155 contributes to enhanced resistance to apoptosis in monocytes from patients with rheumatoid arthritis. +other hsa-mir-508 Glioma 28121353 MiR-508-5p is a prognostic marker and inhibits cell proliferation and migration in glioma. +other hsa-mir-29b "Carcinoma, Cervical" 28122338 Chemotherapy-mediated miR-29b expression inhibits the invasion and angiogenesis of cervical cancer. +other hsa-mir-375 "Adenocarcinoma, Pancreatic Ductal" 28122349 The prognostic relevance of primary tumor location in patients undergoing resection for pancreatic ductal adenocarcinoma. +other hsa-mir-27a "Carcinoma, Laryngeal" 28122350 Transcriptional suppression of microRNA-27a contributes to laryngeal cancer differentiation via GSK-3¦Â-involved Wnt/¦Â-catenin pathway. +other hsa-mir-30e Atherosclerosis 28123167 "miR-30e in VSMCs exerted an anti-atherosclerosis effect via inhibiting proliferation and migration, and promoting apoptosis of VSMCs" +other hsa-mir-143 Bladder Neoplasms 28123579 miR-143 inhibits bladder cancer cell proliferation and enhances their sensitivity to gemcitabine by repressing IGF-1R signaling. +other hsa-mir-486 Lung Neoplasms 28124991 mir-660-p53-mir-486 Network: A New Key Regulatory Pathway in Lung Tumorigenesis. +other hsa-mir-660 Lung Neoplasms 28124991 mir-660-p53-mir-486 Network: A New Key Regulatory Pathway in Lung Tumorigenesis. +other hsa-mir-21 Pleural Mesothelioma 28125734 MiR-21-5p is suggested as novel regulator of MSLN with a possible functional role in cellular growth +other hsa-mir-126 "Carcinoma, Breast" 28125889 Micro RNA-126 coordinates cell behavior and signaling cascades according to characteristics of breast cancer cells. +other hsa-mir-133b Testicular Neoplasms 28126411 Perfluorooctanoic acid affects endocytosis involving clathrin light chain A and microRNA-133b-3p in mouse testes. +other hsa-mir-125b "Leukemia, Lymphocytic, Chronic, B-Cell" 28126961 miR-125b and miR-532-3p predict the efficiency of rituximab-mediated lymphodepletion in chronic lymphocytic leukemia patients. A French Innovative Leukemia Organization study. +other hsa-mir-532 "Leukemia, Lymphocytic, Chronic, B-Cell" 28126961 miR-125b and miR-532-3p predict the efficiency of rituximab-mediated lymphodepletion in chronic lymphocytic leukemia patients. A French Innovative Leukemia Organization study. +other hsa-mir-222 Cardiovascular Diseases [unspecific] 28127557 MiR-222 in Cardiovascular Diseases: Physiology and Pathology. +other hsa-mir-30c Diabetic Nephropathy 28127848 MiR-30c protects diabetic nephropathy by suppressing epithelial-to-mesenchymal transition in db/db mice. +other hsa-mir-155 Myocardial Infarction 28129114 Macrophage-Derived mir-155-Containing Exosomes Suppress Fibroblast Proliferation and Promote Fibroblast Inflammation during Cardiac Injury. +other hsa-mir-625 Melanoma 28129648 "microRNA-625 inhibits tumorigenicity by suppressing proliferation, migration and invasion in malignant melanoma." +other hsa-mir-155 Myelodysplastic Syndromes 28130497 Mechanisms of Impaired Neutrophil Migration by MicroRNAs in Myelodysplastic Syndromes. +other hsa-mir-34a Myelodysplastic Syndromes 28130497 Mechanisms of Impaired Neutrophil Migration by MicroRNAs in Myelodysplastic Syndromes. +other hsa-mir-204 "Carcinoma, Gastric" 28133610 Histological and Pathological Assessment of miR-204 and SOX4 Levels in Gastric Cancer Patients. +other hsa-mir-155 Neuroinflammation 28139244 MicroRNA 155 and viral-induced neuroinflammation. +other hsa-mir-483 Osteoarthritis 28139355 Intra-articular Delivery of Antago-miR-483-5p Inhibits Osteoarthritis by Modulating Matrilin 3 and Tissue Inhibitor of Metalloproteinase 2. +other hsa-mir-21 "Carcinoma, Bladder" 28139790 Formononetin inhibits human bladder cancer cell proliferation and invasiveness via regulation of miR-21 and PTEN. +other hsa-mir-125a Melanoma 28140520 MicroRNA-125a promotes resistance to BRAF inhibitors through suppression of the intrinsic apoptotic pathway. +other hsa-mir-126 Arteriosclerosis Obliterans 28143713 Intercellular transfer of miR-126-3p by endothelial microparticles reduces vascular smooth muscle cell proliferation and limits neointima formation by inhibiting LRP6. +other hsa-mir-34a Neuroblastoma 28145567 nanoparticles encapsulating miR©\34a and conjugated to a GD2 antibody facilitated tumor©\specific delivery following systemic administration into tumor bearing mice +other hsa-mir-135a Sepsis 28147298 MicroRNA-135a is up-regulated and aggravates myocardial depression in sepsis via regulating p38 MAPK/NF-¦ÊB pathway. +other hsa-mir-132 Alzheimer Disease 28148775 microRNA-132: a key noncoding RNA operating in the cellular phase of Alzheimer's disease. +other hsa-mir-126a Persistent Fetal Circulation Syndrome 28148930 MiR-126a-5p is involved in the hypoxia-induced endothelial-to-mesenchymal transition of neonatal pulmonary hypertension. +other hsa-mir-200b "Carcinoma, Breast" 28152297 miR-200b and miR-217 negatively regulated the expression of autophagy marker proteins +other hsa-mir-217 "Carcinoma, Breast" 28152297 miR-200b and miR-217 negatively regulated the expression of autophagy marker proteins +other hsa-mir-10b Glioblastoma 28153089 Genome Editing Reveals Glioblastoma Addiction to MicroRNA-10b. +other hsa-mir-24 "Carcinoma, Prostate" 28157714 The role of miR-24 as a race related genetic factor in prostate cancer. +other hsa-mir-30a "Carcinoma, Lung, Non-Small-Cell" 28158983 CD73/NT5E is a target of miR-30a-5p and plays an important role in the pathogenesis of non-small cell lung cancer. +other hsa-let-7b Cardiovascular Diseases [unspecific] 28159509 Human Pericardial Fluid Contains Exosomes Enriched with Cardiovascular-Expressed MicroRNAs and Promotes Therapeutic Angiogenesis. +other hsa-mir-598 "Carcinoma, Colon" 28161537 miR-598 inhibits metastasis in colorectal cancer by suppressing JAG1/Notch2 pathway stimulating EMT. +other hsa-mir-155 Neoplasms [unspecific] 28162271 Nitric Oxide: Genomic Instability And Synthetic Lethality. +other hsa-mir-200 "Carcinoma, Colon" 28163188 Transcriptional repression of miR-200 family members by Nanog in colon cancer cells induces epithelial-mesenchymal transition (EMT). +other hsa-mir-200b "Carcinoma, Colon" 28163188 Transcriptional repression of miR-200 family members by Nanog in colon cancer cells induces epithelial-mesenchymal transition (EMT). +other hsa-mir-200c "Carcinoma, Colon" 28163188 Transcriptional repression of miR-200 family members by Nanog in colon cancer cells induces epithelial-mesenchymal transition (EMT). +other hsa-mir-29b Lung Neoplasms 28164574 Expression and Function Analysis of MicroRNA-29b in Xuanwei Lung Cancer. +other hsa-mir-143 Aortic Aneurysm 28167124 P38 MAPK Signaling Pathway Mediates Angiotensin II-Induced miR143/145 Gene Cluster Downregulation during Aortic Dissection Formation. +other hsa-mir-145 Aortic Aneurysm 28167124 P38 MAPK Signaling Pathway Mediates Angiotensin II-Induced miR143/145 Gene Cluster Downregulation during Aortic Dissection Formation. +other hsa-mir-29a Fatty Liver [unspecific] 28167804 miR-29a modulates SCD expression and is regulated in response to a saturated fatty acid diet in juvenile genetically improved farmed tilapia (Oreochromis niloticus). +other hsa-mir-21 Myocardial Infarction 28170197 Enhanced Cardioprotection by Human Endometrium Mesenchymal Stem Cells Driven by Exosomal MicroRNA-21. +other hsa-mir-146b Diabetic Retinopathy 28170537 Adenosine Deaminase-2-Induced Hyperpermeability in Human Retinal Vascular Endothelial Cells Is Suppressed by MicroRNA-146b-3p. +other hsa-mir-1285 Wound Healing 28175294 miRNAs that associate with conjunctival inflammation and ocular Chlamydia trachomatis infection do not predict progressive disease. +other hsa-mir-147b Wound Healing 28175294 miRNAs that associate with conjunctival inflammation and ocular Chlamydia trachomatis infection do not predict progressive disease. +other hsa-mir-155 Wound Healing 28175294 miRNAs that associate with conjunctival inflammation and ocular Chlamydia trachomatis infection do not predict progressive disease. +other hsa-mir-184 Wound Healing 28175294 miRNAs that associate with conjunctival inflammation and ocular Chlamydia trachomatis infection do not predict progressive disease. +other hsa-mir-214 "Carcinoma, Ovarian" 28175963 Curcumin suppresses cisplatin resistance development partly via modulating extracellular vesicle-mediated transfer of MEG3 and miR-214 in ovarian cancer. +other hsa-mir-21 Colon Neoplasms 28176652 Mechanisms for the Inhibition of Colon Cancer Cells by Sulforaphane through Epigenetic Modulation of MicroRNA-21 and Human Telomerase Reverse Transcriptase (hTERT) Down-regulation. +other hsa-mir-944 "Carcinoma, Endometrial" 28178620 miR-944 acts as a prognostic marker and promotes the tumor progression in endometrial cancer. +other hsa-mir-17 "Carcinoma, Breast" 28178652 STAT3 is required for MiR-17-5p-mediated sensitization to chemotherapy-induced apoptosis in breast cancer cells. +other hsa-mir-191 Glioblastoma 28178667 "Anti-GD2-ch14.18/CHO coated nanoparticles mediate glioblastoma (GBM)-specific delivery of the aromatase inhibitor, Letrozole, reducing proliferation, migration and chemoresistance in patient-derived GBM tumor cells." +other hsa-mir-122 "Carcinoma, Hepatocellular" 28179291 Synergistic Inhibitory Effect of Traditional Chinese Medicine Astragaloside IV and Curcumin on Tumor Growth and Angiogenesis in an Orthotopic Nude-Mouse Model of Human Hepatocellular Carcinoma. +other hsa-mir-100 Infection [unspecific] 28181552 MicroRNA-100 is involved in shrimp immune response to white spot syndrome virus (WSSV) and Vibrio alginolyticus infection. +other hsa-mir-216 Acute Pancreatitis 28183420 Circulating microRNA 216 as a Marker for the Early Identification of Severe Acute Pancreatitis. +other hsa-mir-183 Glioma 28184912 "Interaction between transcription factors PAX6/PAX6-5a and specific members of miR-183-96-182 cluster, may contribute to glioma progression in glioblastoma cell lines." +other hsa-mir-365 "Carcinoma, Hepatocellular" 28184920 miR-365 targets ADAM10 and suppresses the cell growth and metastasis of hepatocellular carcinoma. +other hsa-mir-181a "Leukemia, Lymphoblastic, Acute" 28184923 "miR-181a-5p, an inducer of Wnt-signaling, facilitates cell proliferation in acute lymphoblastic leukemia." +other hsa-mir-34a "Diabetes Mellitus, Type 1" 28185128 Effects of TRPM7/miR-34a Gene Silencing on Spatial Cognitive Function and Hippocampal Neurogenesis in Mice with Type 1 Diabetes Mellitus. +other hsa-mir-29b Neoplasms [unspecific] 28185889 MicroRNA hsa-miR-29b potentiates etoposide toxicity in HeLa cells via down-regulation of Mcl-1. +other hsa-mir-196b Pancreatic Neoplasms 28186267 MicroRNA-196b is an independent prognostic biomarker in patients with pancreatic cancer. +other hsa-mir-375 Colorectal Carcinoma 28186962 microRNA-375 inhibits colorectal cancer cells proliferation by downregulating JAK2/STAT3 and MAP3K8/ERK signaling pathways. +other hsa-mir-29a "Carcinoma, Breast" 28186968 XIAP 3'-untranslated region as a ceRNA promotes FSCN1 function in inducing the progression of breast cancer by binding endogenous miR-29a-5p. +other hsa-let-7a Vascular Hypertrophy 28187784 Let-7a-transfected mesenchymal stem cells ameliorate monocrotaline-induced pulmonary hypertension by suppressing pulmonary artery smooth muscle cell growth through STAT3-BMPR2 signaling. +other hsa-mir-210 Inflammation 28188219 Distinct Effects of miR-210 Reduction on Neurogenesis: Increased Neuronal Survival of Inflammation But Reduced Proliferation Associated with Mitochondrial Enhancement. +other hsa-mir-498 "Squamous Cell Carcinoma, Esophageal" 28188753 MiR-498 in esophageal squamous cell carcinoma: clinicopathological impacts and functional interactions. +other hsa-mir-29b Crohn Disease 28190086 MCL-1 is modulated in Crohn's disease fibrosis by miR-29b via IL-6 and IL-8. +other hsa-mir-221 "Carcinoma, Breast" 28191469 RNA-Binding Protein Dnd1 Promotes Breast Cancer Apoptosis by Stabilizing the Bim mRNA in a miR-221 Binding Site. +other hsa-mir-30a Glioma 28192116 PRRT2 inhibits the proliferation of glioma cells by modulating unfolded protein response pathway. +other hsa-mir-21 Colorectal Carcinoma 28192117 NR2F2 inhibits Smad7 expression and promotes TGF-¦Â-dependent epithelial-mesenchymal transition of CRC via transactivation of miR-21. +other hsa-mir-346 Graves Disease 28192819 MiR-346 and TRAb as Predicative Factors for Relapse in Graves' Disease Within One Year. +other hsa-mir-301a "Carcinoma, Colon" 28193514 MicroRNA 301A Promotes Intestinal Inflammation and Colitis-Associated Cancer Development by Inhibiting BTG1. +other hsa-mir-22 Preeclampsia 28193709 Testosterone Represses Estrogen Signaling by Upregulating miR-22: A Mechanism for Imbalanced Steroid Hormone Production in Preeclampsia. +other hsa-mir-34b Melanoma 28194372 MiR-34b-5p Suppresses Melanoma Differentiation-Associated Gene 5 (MDA5) Signaling Pathway to Promote Avian Leukosis Virus Subgroup J (ALV-J)-Infected Cells Proliferaction and ALV-J Replication. +other hsa-mir-125a Neoplasms [unspecific] 28197019 Inflammation and Cancer: Extra- and Intracellular Determinants of Tumor-Associated Macrophages as Tumor Promoters. +other hsa-mir-146a Neoplasms [unspecific] 28197019 Inflammation and Cancer: Extra- and Intracellular Determinants of Tumor-Associated Macrophages as Tumor Promoters. +other hsa-mir-155 Neoplasms [unspecific] 28197019 Inflammation and Cancer: Extra- and Intracellular Determinants of Tumor-Associated Macrophages as Tumor Promoters. +other hsa-mir-223 Neoplasms [unspecific] 28197019 Inflammation and Cancer: Extra- and Intracellular Determinants of Tumor-Associated Macrophages as Tumor Promoters. +other hsa-mir-511 Neoplasms [unspecific] 28197019 Inflammation and Cancer: Extra- and Intracellular Determinants of Tumor-Associated Macrophages as Tumor Promoters. +other hsa-mir-31 Lung Neoplasms 28197369 The transcriptome of lung tumor-infiltrating dendritic cells reveals a tumor-supporting phenotype and a microRNA signature with negative impact on clinical outcome. +other hsa-mir-21 Cholangiocarcinoma 28197636 miR-21 and KLF4 jointly augment epithelial?mesenchymal transition via the Akt/ERK1/2 pathway. +other hsa-mir-155 "Adenocarcinoma, Pancreatic Ductal" 28198398 MicroRNA-155 Controls Exosome Synthesis and Promotes Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma. +other hsa-mir-185 Stroke 28199366 MicroRNAs regulating cluster of differentiation 46 (CD46) in cardioembolic and non-cardioembolic stroke. +other hsa-mir-19a Stroke 28199366 MicroRNAs regulating cluster of differentiation 46 (CD46) in cardioembolic and non-cardioembolic stroke. +other hsa-mir-20a Stroke 28199366 MicroRNAs regulating cluster of differentiation 46 (CD46) in cardioembolic and non-cardioembolic stroke. +other hsa-mir-374b Stroke 28199366 MicroRNAs regulating cluster of differentiation 46 (CD46) in cardioembolic and non-cardioembolic stroke. +other hsa-mir-221 "Carcinoma, Breast" 28202520 Evolution of Cancer Stem-like Cells in Endocrine-Resistant Metastatic Breast Cancers Is Mediated by Stromal Microvesicles. +other hsa-mir-21 Glioma 28208619 "AKT Axis, miR-21, and RECK Play Pivotal Roles in Dihydroartemisinin Killing Malignant Glioma Cells." +other hsa-mir-17 Celiac Disease 28208686 Identification of Autophagy-Related Genes and Their Regulatory miRNAs Associated with Celiac Disease in Children. +other hsa-mir-30a Celiac Disease 28208686 Identification of Autophagy-Related Genes and Their Regulatory miRNAs Associated with Celiac Disease in Children. +other hsa-mir-132 Inflammation 28209997 Antisense miR-132 blockade via the AChE-R splice variant mitigates cortical inflammation. +other hsa-mir-375 "Squamous Cell Carcinoma, Lung" 28214218 Implication of downregulation and prospective pathway signaling of microRNA-375 in lung squamous cell carcinoma. +other hsa-mir-29b Cerebral Aneurysm 28214880 MiR-29b Downregulation Induces Phenotypic Modulation of Vascular Smooth Muscle Cells: Implication for Intracranial Aneurysm Formation and Progression to Rupture. +other hsa-mir-7 "Carcinoma, Ovarian" 28216373 TWEAK-stimulated macrophages inhibit metastasis of epithelial ovarian cancer via exosomal shuttling of microRNA. +other hsa-mir-21 Leukemia 28218044 Leukemia microvesicles affect healthy hematopoietic stem cells. +other hsa-mir-29a Leukemia 28218044 Leukemia microvesicles affect healthy hematopoietic stem cells. +other hsa-mir-18a "Carcinoma, Hepatocellular" 28219903 MYC-driven inhibition of the glutamate-cysteine ligase promotes glutathione depletion in liver cancer. +other hsa-mir-223 "Carcinoma, Bladder" 28222670 MicroRNA-223-3p inhibits human bladder cancer cell migration and invasion. +other hsa-mir-137 Neuroblastoma 28223126 Targeted inhibition of HDAC8 increases the doxorubicin sensitivity of neuroblastoma cells via up regulation of miR-137. +other hsa-mir-125b "Carcinoma, Endometrial" 28225751 Proliferation and migration capability of endometrial carcinoma cells were detected after transfection of endometrial carcinoma cells with mir-125b mimic +other hsa-mir-100 "Carcinoma, Bladder" 28229968 Cytotoxic and toxicogenomic effects of silibinin in bladder cancer cells with different TP53 status. +other hsa-mir-203 "Carcinoma, Bladder" 28229968 Cytotoxic and toxicogenomic effects of silibinin in bladder cancer cells with different TP53 status. +other hsa-mir-7 "Carcinoma, Lung, Non-Small-Cell" 28229971 Breviscapine suppresses the growth of non-small cell lung cancer by enhancing microRNA-7 expression. +other hsa-mir-98 "Carcinoma, Breast" 28232182 SNHG16 contributes to breast cancer cell migration by competitively binding miR-98 with E2F5. +other hsa-mir-181a Machado-Joseph Disease 28236575 Unravelling Endogenous MicroRNA System Dysfunction as a New Pathophysiological Mechanism in Machado-Joseph Disease. +other hsa-mir-494 Machado-Joseph Disease 28236575 Unravelling Endogenous MicroRNA System Dysfunction as a New Pathophysiological Mechanism in Machado-Joseph Disease. +other hsa-mir-9 Machado-Joseph Disease 28236575 Unravelling Endogenous MicroRNA System Dysfunction as a New Pathophysiological Mechanism in Machado-Joseph Disease. +other hsa-mir-21 Colorectal Carcinoma 28236743 Direct binding of microRNA-21 pre-element with Regorafenib: An alternative mechanism for anti-colorectal cancer chemotherapy +other hsa-mir-185 "Carcinoma, Hepatocellular" 28240051 MicroRNA-185 induces potent autophagy via AKT signaling in hepatocellular carcinoma. +other hsa-mir-210 Neoplasms [unspecific] 28240549 Small Molecule Inhibition of microRNA-210 Reprograms an Oncogenic Hypoxic Circuit. +other hsa-mir-30d "Carcinoma, Prostate" 28241827 MicroRNA-30d promotes angiogenesis and tumor growth via MYPT1/c-JUN/VEGFA pathway and predicts aggressive outcome in prostate cancer. +other hsa-mir-142 "Carcinoma, Hepatocellular" 28243631 Identifying microRNA panels specifically associated with hepatocellular carcinoma and its different etiologies. +other hsa-mir-135b Multiple Myeloma 28245421 "Compared with those of the normal ones, exosomes in MM have less miR-15a and/or more miR-135b and miR-21" +other hsa-mir-15a Multiple Myeloma 28245421 "Compared with those of the normal ones, exosomes in MM have less miR-15a and/or more miR-135b and miR-21" +other hsa-mir-21 Multiple Myeloma 28245421 "Compared with those of the normal ones, exosomes in MM have less miR-15a and/or more miR-135b and miR-21" +other hsa-mir-200 "Carcinoma, Ovarian" 28245631 Role of Nerve Growth Factor (NGF) and miRNAs in Epithelial Ovarian Cancer. +other hsa-mir-23b "Carcinoma, Ovarian" 28245631 Role of Nerve Growth Factor (NGF) and miRNAs in Epithelial Ovarian Cancer. +other hsa-mir-17 Leukemia 28247308 Differential Maturation of miR-17?~?92 Cluster Members in Human Cancer Cell Lines. +other hsa-mir-20a Leukemia 28247308 Differential Maturation of miR-17?~?92 Cluster Members in Human Cancer Cell Lines. +other hsa-mir-92a Leukemia 28247308 Differential Maturation of miR-17?~?92 Cluster Members in Human Cancer Cell Lines. +other hsa-mir-210 Heart Failure 28249798 "Mesenchymal stem cells-derived extracellular vesicles, via miR-210, improve infarcted cardiac function by promotion of angiogenesis." +other hsa-mir-126 Human Immunodeficiency Virus Infection 28250134 MicroRNA miR-126-5p Enhances the Inflammatory Responses of Monocytes to Lipopolysaccharide Stimulation by Suppressing Cylindromatosis in Chronic HIV-1 Infection. +other hsa-mir-660 "Carcinoma, Breast" 28252173 Inhibition of miR-660-5p expression suppresses tumor development and metastasis in human breast cancer. +other hsa-mir-126 Cardiovascular Diseases [unspecific] 28253326 Prevention of neointimal formation using miRNA-126-containing nanoparticle-conjugated stents in a rabbit model. +other hsa-mir-423 "Carcinoma, Gastric" 28254439 The microRNA-423-3p-Bim Axis Promotes Cancer Progression and Activates Oncogenic Autophagy in Gastric Cancer. +other hsa-mir-150 Atherosclerosis 28254813 MicroRNA-150 Modulates Ischemia-Induced Neovascularization in Atherosclerotic Conditions. +other hsa-mir-200c Lung Fibrosis 28255128 Recent advances in miR-200c and fibrosis in organs. +other hsa-mir-195 Colorectal Carcinoma 28255246 miR-195 enhances the radiosensitivity of colorectal cancer cells by suppressing CARM1. +other hsa-mir-155 Neoplasms [unspecific] 28256712 Oncogenic role of microRNA-155 in mycosis fungoides: an in vitro and xenograft mouse model study. +other hsa-mir-138 "Carcinoma, Hepatocellular" 28258280 HCV core inhibits hepatocellular carcinoma cell replicative senescence through downregulating microRNA-138 expression. +other hsa-mir-155 "Carcinoma, Colon" 28259135 "miR-155 is positively regulated by CBX7 in mouse embryonic fibroblasts and colon carcinomas, and targets the KRAS oncogene." +other hsa-mir-30b "Carcinoma, Renal Cell" 28259953 Identification of miR?30b as an oncogene in renal cell carcinoma. +other hsa-mir-34a Parkinson Disease 28259991 The involvement of Eag1 potassium channels and miR-34a in rotenone-induced death of dopaminergic SH-SY5Y cells. +other hsa-mir-197 "Lymphoma, Burkitt" 28259992 EBV?BART?6?3p and cellular microRNA?197 compromise the immune defense of host cells in EBV?positive Burkitt lymphoma. +other hsa-mir-145 "Osteoporosis, Postmenopausal" 28260003 Estrogen stimulates osteoprotegerin expression via the suppression of miR-145 expression in MG-63 cells. +other hsa-mir-195 "Carcinoma, Renal Cell" 28260025 Identification of miR?195?3p as an oncogene in RCC. +other hsa-mir-149 Crohn Disease 28260036 Comprehensive bioinformatics analyses of Crohn's disease. +other hsa-mir-4447 Crohn Disease 28260036 Comprehensive bioinformatics analyses of Crohn's disease. +other hsa-mir-106a Parkinson Disease 28260060 Bioinformatics analysis on the differentiation of bone mesenchymal stem cells into osteoblasts and adipocytes. +other hsa-mir-203 Parkinson Disease 28260060 Bioinformatics analysis on the differentiation of bone mesenchymal stem cells into osteoblasts and adipocytes. +other hsa-mir-376a Parkinson Disease 28260060 Bioinformatics analysis on the differentiation of bone mesenchymal stem cells into osteoblasts and adipocytes. +other hsa-mir-382 Parkinson Disease 28260060 Bioinformatics analysis on the differentiation of bone mesenchymal stem cells into osteoblasts and adipocytes. +other hsa-mir-495 Parkinson Disease 28260060 Bioinformatics analysis on the differentiation of bone mesenchymal stem cells into osteoblasts and adipocytes. +other hsa-mir-543 Parkinson Disease 28260060 Bioinformatics analysis on the differentiation of bone mesenchymal stem cells into osteoblasts and adipocytes. +other hsa-mir-373 Breast Neoplasms 28260305 Effects of microRNA-373 on the proliferation and invasiveness of breast carcinoma and its mechanisms. +other hsa-mir-149 Chronic Obstructive Pulmonary Disease 28260877 Repression of Toll-like receptor-4 by microRNA-149-3p is associated with smoking-related COPD. +other hsa-mir-143 "Diabetes Mellitus, Type 2" 28270439 Comprehensive functional screening of miRNAs involved in fat cell insulin sensitivity among women. +other hsa-mir-652 "Diabetes Mellitus, Type 2" 28270439 Comprehensive functional screening of miRNAs involved in fat cell insulin sensitivity among women. +other hsa-mir-21 Diabetic Retinopathy 28270521 Pathogenic Role of microRNA-21 in Diabetic Retinopathy Through Downregulation of PPAR¦Á. +other hsa-mir-145 "Carcinoma, Colon" 28272349 The Influence of Spirulina platensis Filtrates on Caco-2 Proliferative Activity and Expression of Apoptosis-Related microRNAs and mRNA. +other hsa-mir-146 "Carcinoma, Colon" 28272349 The Influence of Spirulina platensis Filtrates on Caco-2 Proliferative Activity and Expression of Apoptosis-Related microRNAs and mRNA. +other hsa-mir-17 "Carcinoma, Colon" 28272349 The Influence of Spirulina platensis Filtrates on Caco-2 Proliferative Activity and Expression of Apoptosis-Related microRNAs and mRNA. +other hsa-mir-9 "Leukemia, Myeloid, Acute" 28272704 A minicircuitry comprised of microRNA-9 and SIRT1 contributes to leukemogenesis in t(8;21) acute myeloid leukemia. +other hsa-mir-34a Lung Fibrosis 28273432 p53 and miR-34a Feedback Promotes Lung Epithelial Injury and Pulmonary Fibrosis. +other hsa-mir-34a Hepatoblastoma 28277300 Exosomal miR-34s panel as potential novel diagnostic and prognostic biomarker in patients with hepatoblastoma. +other hsa-mir-34b Hepatoblastoma 28277300 Exosomal miR-34s panel as potential novel diagnostic and prognostic biomarker in patients with hepatoblastoma. +other hsa-mir-34c Hepatoblastoma 28277300 Exosomal miR-34s panel as potential novel diagnostic and prognostic biomarker in patients with hepatoblastoma. +other hsa-mir-27a Diabetic Nephropathy 28277542 MicroRNA-27a promotes podocyte injury via PPAR¦Ã-mediated ¦Â-catenin activation in diabetic nephropathy. +other hsa-mir-17 "Carcinoma, Pancreatic" 28280038 The NOP14/mutp53 axis suppressed p21 expression at both the transcriptional and posttranscriptional levels via induction of miR-17-5p in PDAC cells +other hsa-mir-194 Colorectal Carcinoma 28280361 MicroRNA-194 modulates epithelial-mesenchymal transition in human colorectal cancer metastasis. +other hsa-mir-489 "Carcinoma, Bladder" 28281959 miR-489 Suppresses Proliferation and Invasion of Human Bladder Cancer Cells. +other hsa-mir-183 "Squamous Cell Carcinoma, Tongue" 28281960 miR-183 Modulates Cell Apoptosis and Proliferation in Tongue Squamous Cell Carcinoma SCC25 Cell Line. +other hsa-mir-223 "Carcinoma, Lung" 28281961 MicroRNA-223 Promotes Tumor Progression in Lung Cancer A549 Cells via Activation of the NF-¦ÊB Signaling Pathway. +other hsa-mir-155 "Lymphoma, Large B-Cell, Diffuse" 28281962 MicroRNA-155 Downregulation Promotes Cell Cycle Arrest and Apoptosis in Diffuse Large B-Cell Lymphoma. +other hsa-mir-1284 "Carcinoma, Ovarian" 28281963 MicroRNA-1284 Inhibits Cell Viability and Induces Apoptosis of Ovarian Cancer Cell Line OVCAR3. +other hsa-mir-126 Influenza 28282445 Endothelial cell tropism is a determinant of H5N1 pathogenesis in mammalian species. +other hsa-mir-375 Prostate Neoplasms 28282880 Astaxanthin Inhibits PC-3 Xenograft Prostate Tumor Growth in Nude Mice. +other hsa-mir-487b Prostate Neoplasms 28282880 Astaxanthin Inhibits PC-3 Xenograft Prostate Tumor Growth in Nude Mice. +other hsa-mir-21 "Carcinoma, Lung" 28283413 Solasodine inhibits invasion of human lung cancer cell through downregulation of miR-21 and MMPs expression. +other hsa-mir-133a Heart Failure 28283551 A novel role for miR-133a in centrally mediated activation of the renin-angiotensin system in congestive heart failure. +other hsa-mir-122 Heart Diseases [unspecific] 28287427 The Role and Molecular Mechanism of Non-Coding RNAs in Pathological Cardiac Remodeling. +other hsa-mir-184 Heart Diseases [unspecific] 28287427 The Role and Molecular Mechanism of Non-Coding RNAs in Pathological Cardiac Remodeling. +other hsa-mir-34a Heart Diseases [unspecific] 28287427 The Role and Molecular Mechanism of Non-Coding RNAs in Pathological Cardiac Remodeling. +other hsa-mir-942 Preeclampsia 28287888 MiR-942 decreased before 20 weeks gestation in women with preeclampsia and was associated with the pathophysiology of preeclampsia in vitro. +other hsa-mir-106b Pituitary Adenoma 28288092 Effect of miR-106b on Invasiveness of Pituitary Adenoma via PTEN-PI3K/AKT. +other hsa-mir-200 "Colitis, Ulcerative" 28288169 The miR-200 family is increased in dysplastic lesions in ulcerative colitis patients. +other hsa-mir-15a "Diabetes Mellitus, Type 2" 28289072 Down-regulation of miR-15a/b accelerates fibrotic remodelling in the Type?2 diabetic human and mouse heart. +other hsa-mir-15b "Diabetes Mellitus, Type 2" 28289072 Down-regulation of miR-15a/b accelerates fibrotic remodelling in the Type?2 diabetic human and mouse heart. +other hsa-mir-223 Liver Injury 28295449 Hepatic mitochondrial DNA/Toll-like receptor 9/MicroRNA-223 forms a negative feedback loop to limit neutrophil overactivation and acetaminophen hepatotoxicity in mice. +other hsa-mir-122 Chronic Hepatitis C 28295463 "Immune phenotype and function of natural killer and T cells in chronic hepatitis C patients who received a single dose of anti-MicroRNA-122, RG-101." +other hsa-mir-33 Atherosclerosis 28296196 SIRT6 reduces macrophage foam cell formation by inducing autophagy and cholesterol efflux under ox-LDL condition. +other hsa-mir-7 Alzheimer Disease 28296235 the circular RNA circular RNA sponge for miR-7 (ciRS-7) has an important role in regulating BACE1 and APP protein levels +other hsa-mir-221 "Carcinoma, Thyroid, Papillary" 28297755 Expression of microRNA-221 and IL-17 in papillary thyroid carcinoma and correlation with clinicopathologic features. +other hsa-mir-146a "Adenocarcinoma, Lung" 28299977 Identification of lymph node metastasis-related microRNAs in lung adenocarcinoma and analysis of the underlying mechanisms using a bioinformatics approach. +other hsa-mir-150 "Adenocarcinoma, Lung" 28299977 Identification of lymph node metastasis-related microRNAs in lung adenocarcinoma and analysis of the underlying mechanisms using a bioinformatics approach. +other hsa-mir-342 "Adenocarcinoma, Lung" 28299977 Identification of lymph node metastasis-related microRNAs in lung adenocarcinoma and analysis of the underlying mechanisms using a bioinformatics approach. +other hsa-mir-375 "Carcinoma, Breast" 28300567 9-cis Retinoic acid modulates myotrophin expression and its miR in physiological and pathophysiological cell models. +other hsa-mir-18a "Carcinoma, Hepatocellular" 28302149 Identification and interaction analysis of key genes and microRNAs in hepatocellular carcinoma by bioinformatics analysis. +other hsa-mir-221 "Carcinoma, Hepatocellular" 28302149 Identification and interaction analysis of key genes and microRNAs in hepatocellular carcinoma by bioinformatics analysis. +other hsa-mir-21 Neoplasms [unspecific] 28302473 Quantitative relationship between chemical properties and bioactivities of anti-microRNA oligonucleotides targeted to tumor-associated microRNA-21. +other hsa-mir-4306 Neurodegenerative Diseases [unspecific] 28302480 Comprehensive investigation of aberrant microRNAs expression in cells culture model of MnCl2-induced neurodegenerative disease. +other hsa-mir-186 "Carcinoma, Colon" 28302487 TUG1 mediates methotrexate resistance in colorectal cancer via miR-186/CPEB2 axis. +other hsa-mir-205 "Carcinoma, Cervical" 28304186 miR-205 mediates the inhibition of cervical cancer cell proliferation using olmesartan. +other hsa-mir-21 Pancreatic Neoplasms 28304379 Development of bioluminescent chick chorioallantoic membrane (CAM) models for primary pancreatic cancer cells: a platform for drug testing. +other hsa-mir-7 "Squamous Cell Carcinoma, Esophageal" 28314263 Significance and Function of MicroRNA-7 in Oesophageal Squamous Cell Carcinoma. +other hsa-mir-21 "Squamous Cell Carcinoma, Oral" 28314265 Next-generation Sequencing for microRNA Profiling: MicroRNA-21-3p Promotes Oral Cancer Metastasis. +other hsa-mir-155 Lung Neoplasms 28315615 MIR155 Regulation of Ubiquilin1 and Ubiquilin2: Implications in Cellular Protection and Tumorigenesis. +other hsa-mir-135b Multiple Myeloma 28316065 Identification of key genes and construction of microRNA-mRNA regulatory networks in multiple myeloma by integrated multiple GEO datasets using bioinformatics analysis. +other hsa-mir-148a Multiple Myeloma 28316065 Identification of key genes and construction of microRNA-mRNA regulatory networks in multiple myeloma by integrated multiple GEO datasets using bioinformatics analysis. +other hsa-mir-181 Vascular Injuries 28316180 Effect and related mechanism of microRNA-181 attenuates oxidized low density lipoprotein induced vascular endothelial cell injury. +other hsa-mir-1 "Carcinoma, Prostate" 28317618 "MiR-1, a Potential Predictive Biomarker for Recurrence in Prostate Cancer After Radical Prostatectomy." +other hsa-mir-32 Cardiovascular Diseases [unspecific] 28319142 MicroRNA-32 promotes calcification in vascular smooth muscle cells: Implications as a novel marker for coronary artery calcification. +other hsa-mir-146a Infection [unspecific] 28319200 Induction of immunomodulatory miR-146a and miR-155 in small intestinal epithelium of Vibrio cholerae infected patients at acute stage of cholera. +other hsa-mir-155 Infection [unspecific] 28319200 Induction of immunomodulatory miR-146a and miR-155 in small intestinal epithelium of Vibrio cholerae infected patients at acute stage of cholera. +other hsa-mir-1 "Carcinoma, Prostate" 28320379 miRNAs associated with prostate cancer risk and progression. +other hsa-mir-145 "Carcinoma, Prostate" 28320379 miRNAs associated with prostate cancer risk and progression. +other hsa-mir-205 "Carcinoma, Prostate" 28320379 miRNAs associated with prostate cancer risk and progression. +other hsa-mir-21 "Carcinoma, Prostate" 28320379 miRNAs associated with prostate cancer risk and progression. +other hsa-mir-221 "Carcinoma, Prostate" 28320379 miRNAs associated with prostate cancer risk and progression. +other hsa-mir-375 "Carcinoma, Prostate" 28320379 miRNAs associated with prostate cancer risk and progression. +other hsa-mir-19b Wilms Tumor 28322459 "Effects of MicroRNA-19b on the Proliferation, Apoptosis, and Migration of Wilms' Tumor Cells Via the PTEN/PI3K/AKT Signaling Pathway." +other hsa-mir-133 "Cardiomyopathy, Hypertrophic" 28322824 MicroRNA-133 mediates cardiac diseases: Mechanisms and clinical implications. +other hsa-mir-608 Neuroinflammation 28326544 Personalized genetics of the cholinergic blockade of neuroinflammation. +other hsa-mir-29c Meningioma 28327132 Simultaneous analysis of miRNA-mRNA in human meningiomas by integrating transcriptome: A relationship between PTX3 and miR-29c. +other hsa-mir-30c Mitochondrial Metabolism Disease 28330939 Chlamydia preserves the mitochondrial network necessary for replication via microRNA-dependent inhibition of fission. +other hsa-mir-34a "Carcinoma, Breast" 28334277 "In bone metastasis miR-34a-5p absence inversely correlates with Met expression, while Met oncogene is unaffected by miR-34a-5p in non-metastatic and metastatic breast carcinomas." +other hsa-mir-200c "Carcinoma, Breast" 28334634 E3 Ubiquitin Ligase Cbl-b Prevents Tumor Metastasis by Maintaining the Epithelial Phenotype in Multiple Drug-Resistant Gastric and Breast Cancer Cells. +other hsa-mir-184 "Carcinoma, Breast" 28335433 Evaluation and Adaptation of a Laboratory-Based cDNA Library Preparation Protocol for Retrospective Sequencing of Archived MicroRNAs from up to 35-Year-Old Clinical FFPE Specimens. +other hsa-mir-221 "Carcinoma, Breast" 28335433 Evaluation and Adaptation of a Laboratory-Based cDNA Library Preparation Protocol for Retrospective Sequencing of Archived MicroRNAs from up to 35-Year-Old Clinical FFPE Specimens. +other hsa-mir-29a "Carcinoma, Breast" 28335433 Evaluation and Adaptation of a Laboratory-Based cDNA Library Preparation Protocol for Retrospective Sequencing of Archived MicroRNAs from up to 35-Year-Old Clinical FFPE Specimens. +other hsa-mir-363 "Carcinoma, Breast" 28335433 Evaluation and Adaptation of a Laboratory-Based cDNA Library Preparation Protocol for Retrospective Sequencing of Archived MicroRNAs from up to 35-Year-Old Clinical FFPE Specimens. +other hsa-mir-375 "Carcinoma, Breast" 28335433 Evaluation and Adaptation of a Laboratory-Based cDNA Library Preparation Protocol for Retrospective Sequencing of Archived MicroRNAs from up to 35-Year-Old Clinical FFPE Specimens. +other hsa-mir-455 "Carcinoma, Breast" 28335433 Evaluation and Adaptation of a Laboratory-Based cDNA Library Preparation Protocol for Retrospective Sequencing of Archived MicroRNAs from up to 35-Year-Old Clinical FFPE Specimens. +other hsa-mir-548p Atherosclerosis 28336556 Human MicroRNA-548p Decreases Hepatic Apolipoprotein B Secretion and Lipid Synthesis. +other hsa-mir-15a Breast Neoplasms 28337296 Tumor suppressor p53 induces miR-15a processing to inhibit neuronal apoptosis inhibitory protein (NAIP) in the apoptotic response DNA damage in breast cancer cell. +other hsa-mir-155 "Carcinoma, Breast" 28338193 Oncogenic miR-155 down-regulated upon activation of antitumor cytotoxic T lymphocytes by the fusion of dendritic cells with breast carcinoma cells. +other hsa-mir-576 "Carcinoma, Bladder" 28338199 MiR-576-3p is a novel marker correlated with poor clinical outcome in bladder cancer. +other hsa-mir-486 Osteosarcoma 28339053 miR-486 suppresses the development of osteosarcoma by regulating PKC-¦Ä pathway. +other hsa-mir-152 "Carcinoma, Hepatocellular" 28339081 HBx represses RIZ1 expression by DNA methyltransferase?1 involvement in decreased miR-152 in hepatocellular carcinoma. +other hsa-mir-126 Sjogren Syndrome 28339625 Cystatin S-a candidate biomarker for severity of submandibular gland involvement in Sj?gren's syndrome. +other hsa-mir-335 Sjogren Syndrome 28339625 Cystatin S-a candidate biomarker for severity of submandibular gland involvement in Sj?gren's syndrome. +other hsa-mir-122 Liver Injury 28341748 Drug-induced liver injury: recent advances in diagnosis and risk assessment. +other hsa-mir-124 Sepsis 28342874 Activation of PPAR¦Ã inhibits pro-inflammatory cytokines production by upregulation of miR-124 in?vitro and in?vivo. +other hsa-mir-503 Hepatitis C Virus Infection 28343379 Hepatitis C Virus Nonstructural 5A Protein (HCV-NS5A) Inhibits Hepatocyte Apoptosis through the NF-¦Êb/miR-503/bcl-2 Pathway. +other hsa-mir-551a "Carcinoma, Ovarian" 28345465 Demethoxycurcumin inhibited human epithelia ovarian cancer cells' growth via up-regulating miR-551a. +other hsa-mir-9 Breast Neoplasms 28345661 Stepwise analysis of MIR9 loci identifies miR-9-5p to be involved in Oestrogen regulated pathways in breast cancer patients. +other hsa-mir-21 Neoplasms [unspecific] 28346427 MiR-21 is required for anti-tumor immune response in mice: an implication for its bi-directional roles. +other hsa-mir-205 "Carcinoma, Breast" 28346474 The microRNA-205-5p is correlated to metastatic potential of 21T series: A breast cancer progression model. +other hsa-mir-145 "Carcinoma, Lung, Non-Small-Cell" 28347234 "Clinical value of miR-145-5p in NSCLC and potential molecular mechanism exploration: A retrospective study based on GEO, qRT-PCR, and TCGA data." +other hsa-mir-30 "Carcinoma, Breast" 28347244 The miR-30 family: Versatile players in breast cancer. +other hsa-mir-125b "Carcinoma, Bladder" 28347246 MicroRNA-125b predicts clinical outcome and suppressed tumor proliferation and migration in human gallbladder cancer. +other hsa-mir-186 Glioma 28351322 PVT1 affects growth of glioma microvascular endothelial cells by negatively regulating miR-186. +other hsa-mir-203 Liver Cirrhosis 28355233 Coding and non-coding gene regulatory networks underlie the immune response in liver cirrhosis. +other hsa-mir-219 Liver Cirrhosis 28355233 Coding and non-coding gene regulatory networks underlie the immune response in liver cirrhosis. +other hsa-mir-34a "Carcinoma, Hepatocellular" 28356025 Regulation of Apoptosis by SYB in HepG2 Liver Cancer Cells is Mediated by the P53/Caspase 9 Axis. +other hsa-mir-195 Colorectal Carcinoma 28356122 Integrated analysis identifies microRNA-195 as a suppressor of Hippo-YAP pathway in colorectal cancer. +other hsa-mir-149 "Squamous Cell Carcinoma, Tongue" 28356969 MicroRNA-149 targets specificity protein 1 to suppress human tongue squamous cell carcinoma cell proliferation and motility. +other hsa-mir-126 Multiple Sclerosis 28358058 MiR-126 and miR-126* regulate shear-resistant firm leukocyte adhesion to human brain endothelium. +other hsa-mir-92a Leukemia 28358188 Effective Integration of Targeted Tumor Imaging and Therapy Using Functionalized InP QDs with VEGFR2 Monoclonal Antibody and miR-92a Inhibitor. +other hsa-mir-608 Muscle Diseases [unspecific] 28358823 Genome-wide association screens for Achilles tendon and ACL tears and tendinopathy. +other hsa-mir-10b "Carcinoma, Renal Cell, Clear-Cell" 28360191 miR-10b is a prognostic marker in clear cell renal cell carcinoma. +other hsa-mir-155 Hypertension 28360962 Novel Immune Mechanisms in Hypertension and Cardiovascular Risk. +other hsa-mir-21 Hypertension 28360962 Novel Immune Mechanisms in Hypertension and Cardiovascular Risk. +other hsa-mir-1249 "Carcinoma, Hepatocellular" 28365245 Induced MiR-1249 expression by aberrant activation of Hedegehog signaling pathway in hepatocellular carcinoma. +other hsa-mir-181a Neuroblastoma 28365714 MicroRNA-181a Regulates Apoptosis and Autophagy Process in Parkinson's Disease by Inhibiting p38 Mitogen-Activated Protein Kinase (MAPK)/c-Jun N-Terminal Kinases (JNK) Signaling Pathways. +other hsa-mir-210 Atherosclerosis 28367268 Protection of Human Umbilical Vein Endothelial Cells against Oxidative Stress by MicroRNA-210. +other hsa-mir-21 Vascular Hypertrophy 28368454 Role and Regulation of MicroRNAs in Aldosterone-Mediated Cardiac Injury and Dysfunction in Male Rats. +other hsa-mir-200b Colitis 28370348 miR-200b-containing microvesicles attenuate experimental colitis associated intestinal fibrosis by inhibiting epithelial-mesenchymal transition. +other hsa-mir-451 Infection [unspecific] 28378118 miR-451 limits CD4+ T cell proliferative responses to infection in mice. +other hsa-mir-21 Asthma 28379062 Inhibition of MicroRNA-21 by an antagomir ameliorates allergic inflammation in a mouse model of asthma. +other hsa-mir-100 "Carcinoma, Gastric" 28381156 Characterization of exosomal RNAs derived from human gastric cancer cells by deep sequencing. +other hsa-mir-148a "Carcinoma, Gastric" 28381156 Characterization of exosomal RNAs derived from human gastric cancer cells by deep sequencing. +other hsa-mir-21 "Carcinoma, Gastric" 28381156 Characterization of exosomal RNAs derived from human gastric cancer cells by deep sequencing. +other hsa-mir-30a "Carcinoma, Gastric" 28381156 Characterization of exosomal RNAs derived from human gastric cancer cells by deep sequencing. +other hsa-let-7 "Carcinoma, Endometrial" 28381177 Dicer1 dysfunction promotes stemness and aggression in endometrial carcinoma. +other hsa-mir-125a Leukemia 28381182 Involvement of miR-125a in resistance to daunorubicin by inhibiting apoptosis in leukemia cell lines. +other hsa-mir-132 Fatty Liver [unspecific] 28381526 miRNA-132 induces hepatic steatosis and hyperlipidaemia by synergistic multitarget suppression. +other hsa-mir-16 Bronchopulmonary Dysplasia 28381639 Thus the intergenerational effects of gestational SS involve epigenetic regulation of HIF-1¦Á through specific miRs contributing to increased incidence of AA and BPD in the progenies +other hsa-mir-203 Pancreatic Neoplasms 28382422 The Role of Exosomes in Pancreatic Cancer Microenvironment. +other hsa-mir-21 Pancreatic Neoplasms 28382422 The Role of Exosomes in Pancreatic Cancer Microenvironment. +other hsa-mir-133a "Cardiomyopathy, Hypertrophic" 28382463 MicroRNAs Association in the Cardiac Hypertrophy Secondary to Complex Congenital Heart Disease in Children. +other hsa-mir-21 "Cardiomyopathy, Hypertrophic" 28382463 MicroRNAs Association in the Cardiac Hypertrophy Secondary to Complex Congenital Heart Disease in Children. +other hsa-mir-23b "Cardiomyopathy, Hypertrophic" 28382463 MicroRNAs Association in the Cardiac Hypertrophy Secondary to Complex Congenital Heart Disease in Children. +other hsa-mir-24 "Cardiomyopathy, Hypertrophic" 28382463 MicroRNAs Association in the Cardiac Hypertrophy Secondary to Complex Congenital Heart Disease in Children. +other hsa-mir-101 "Carcinoma, Prostate" 28384067 miR-101 Enhances Cisplatin-Induced DNA Damage Through Decreasing Nicotinamide Adenine Dinucleotide Phosphate Levels by Directly Repressing Tp53-Induced Glycolysis and Apoptosis Regulator Expression in Prostate Cancer Cells. +other hsa-let-7d Lung Fibrosis 28385811 Modified mesenchymal stem cells using miRNA transduction alter lung injury in a bleomycin model. +other hsa-mir-154 Lung Fibrosis 28385811 Modified mesenchymal stem cells using miRNA transduction alter lung injury in a bleomycin model. +other hsa-mir-122 Chronic Hepatitis C 28389707 The Race of 10 Synthetic RNAi-Based Drugs to the Pharmaceutical Market. +other hsa-mir-29c "Carcinoma, Colon" 28392396 p53 target miR-29c-3p suppresses colon cancer cell invasion and migration through inhibition of PHLDB2. +other hsa-mir-155 Influenza 28392443 Enhanced immunogenicity following miR-155 incorporation into the influenza A virus genome. +other hsa-mir-29b Infection [unspecific] 28394930 Analysis of host microRNA function uncovers a role for miR-29b-2-5p in Shigella capture by filopodia. +other hsa-mir-21 Graft-Versus-Host Disease 28396121 Antagonism of profibrotic microRNA-21 improves?outcome of murine chronic renal allograft dysfunction. +other hsa-mir-27b Ovarian Neoplasms 28396577 MicroRNA-27b functions as a new inhibitor of ovarian cancer-mediated vasculogenic mimicry through suppression of VE-cadherin expression. +other hsa-mir-200b Ovarian Neoplasms 28399108 Decreased levels of baseline and drug-induced tubulin polymerisation are hallmarks of resistance to taxanes in ovarian cancer cells and are associated with epithelial-to-mesenchymal transition. +other hsa-mir-200c Ovarian Neoplasms 28399108 Decreased levels of baseline and drug-induced tubulin polymerisation are hallmarks of resistance to taxanes in ovarian cancer cells and are associated with epithelial-to-mesenchymal transition. +other hsa-mir-155 "Carcinoma, Lung" 28400205 "Titanium dioxide aggregating nanoparticles induce autophagy and under-expression of microRNA 21 and 30a in A549 cell line: A comparative study with cobalt(II, III) oxide nanoparticles." +other hsa-mir-30a "Carcinoma, Lung" 28400205 "Titanium dioxide aggregating nanoparticles induce autophagy and under-expression of microRNA 21 and 30a in A549 cell line: A comparative study with cobalt(II, III) oxide nanoparticles." +other hsa-mir-10a "Lymphoma, Burkitt" 28400759 Human and Epstein-Barr Virus miRNA Profiling as Predictive Biomarkers for Endemic Burkitt Lymphoma. +other hsa-mir-21 Colorectal Carcinoma 28401648 Current Status and Perspectives Regarding LNA-Anti-miR Oligonucleotides and microRNA miR-21 Inhibitors as a Potential Therapeutic Option in Treatment of Colorectal Cancer. +other hsa-mir-210 "Carcinoma, Breast, Triple Negative" 28402752 The MicroRNA miR-210 Is Expressed by Cancer Cells but Also by the Tumor Microenvironment in Triple-Negative Breast Cancer. +other hsa-mir-155 Psoriasis 28402921 MiR-155 promotes cell proliferation and inhibits apoptosis by PTEN signaling pathway in the psoriasis. +other hsa-mir-29 "Diabetes Mellitus, Type 2" 28404597 Altered miR-29 Expression in Type 2 Diabetes Influences Glucose and Lipid Metabolism in Skeletal Muscle. +other hsa-mir-155 Atherosclerosis 28407320 Role of TLR4 and miR-155 in peripheral blood mononuclear cell-mediated inflammatory reaction in coronary slow flow and coronary arteriosclerosis patients. +other hsa-mir-21 "Carcinoma, Gastric" 28407783 Exosomal transfer of tumor-associated macrophage-derived miR-21 confers cisplatin resistance in gastric cancer cells. +other hsa-let-7e "Squamous Cell Carcinoma, Esophageal" 28408353 ZEB1 induced miR-99b/let-7e/miR-125a cluster promotes invasion and metastasis in esophageal squamous cell carcinoma. +other hsa-mir-125a "Squamous Cell Carcinoma, Esophageal" 28408353 ZEB1 induced miR-99b/let-7e/miR-125a cluster promotes invasion and metastasis in esophageal squamous cell carcinoma. +other hsa-mir-99b "Squamous Cell Carcinoma, Esophageal" 28408353 ZEB1 induced miR-99b/let-7e/miR-125a cluster promotes invasion and metastasis in esophageal squamous cell carcinoma. +other hsa-mir-122 Multiple Sclerosis 28411393 Global exosome transcriptome profiling reveals biomarkers for multiple sclerosis. +other hsa-mir-24 "Squamous Cell Carcinoma, Tongue" 28413152 Loss of PTEN Expression Is Associated With High MicroRNA 24 Level and Poor Prognosis in Patients With Tongue Squamous Cell Carcinoma. +other hsa-mir-21 Cardiovascular Diseases [unspecific] 28418864 Bone marrow-derived mesenchymal stem cells overexpressing MiR-21 efficiently repair myocardial damage in rats. +other hsa-mir-519b Osteoarthritis 28423042 Transforming growth factor ¦Â1 enhances heme oxygenase 1 expression in human synovial fibroblasts by inhibiting microRNA 519b synthesis. +other hsa-mir-155 Graft-Versus-Host Disease 28423578 Endothelial microparticles delivering microRNA-155 into T lymphocytes are involved in the initiation of acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation. +other hsa-mir-940 Ovarian Neoplasms 28423620 Exosomal miR-940 maintains SRC-mediated oncogenic activity in cancer cells: a possible role for exosomal disposal of tumor suppressor miRNAs. +other hsa-mir-143 Glaucoma 28424493 Regulation of intraocular pressure by microRNA cluster miR-143/145. +other hsa-mir-145 Glaucoma 28424493 Regulation of intraocular pressure by microRNA cluster miR-143/145. +other hsa-mir-21 Neoplasms [unspecific] 28427524 Kallistatin suppresses cancer development by multi-factorial actions. +other hsa-mir-33 Atherosclerosis 28428217 microRNA-33 Regulates Macrophage Autophagy in Atherosclerosis. +other hsa-mir-106b Glioma 28431179 miRNA Regulation in Gliomas: Usual Suspects in Glial Tumorigenesis and Evolving Clinical Applications. +other hsa-mir-21 Glioma 28431179 miRNA Regulation in Gliomas: Usual Suspects in Glial Tumorigenesis and Evolving Clinical Applications. +other hsa-mir-219 Glioma 28431179 miRNA Regulation in Gliomas: Usual Suspects in Glial Tumorigenesis and Evolving Clinical Applications. +other hsa-mir-26a Glioma 28431179 miRNA Regulation in Gliomas: Usual Suspects in Glial Tumorigenesis and Evolving Clinical Applications. +other hsa-mir-338 Glioma 28431179 miRNA Regulation in Gliomas: Usual Suspects in Glial Tumorigenesis and Evolving Clinical Applications. +other hsa-mir-203 Colon Neoplasms 28431272 Specific microRNA-mRNA Regulatory Network of Colon Cancer Invasion Mediated by Tissue Kallikrein-Related Peptidase 6. +other hsa-mir-155 "Leukemia, Myeloid, Acute" 28432220 miR-155 promotes FLT3-ITD-induced myeloproliferative disease through inhibition of the interferon response. +other hsa-mir-130b Diabetes Mellitus 28433632 inhibition of miR-130b-3p appears to improve mitochondrial biogenesis signaling and protect placental trophoblast cells from oxidative stress +other hsa-mir-93 "Carcinoma, Esophageal" 28434073 Direct Downregulation of B-Cell Translocation Gene 3 by microRNA-93 Is Required for Desensitizing Esophageal Cancer to Radiotherapy. +other hsa-mir-34a "Carcinoma, Rectal" 28435028 Antagonistic Effects of p53 and HIF1A on microRNA-34a Regulation of PPP1R11 and STAT3 and Hypoxia-induced Epithelial to Mesenchymal Transition in Colorectal Cancer Cells. +other hsa-mir-98 Atherosclerosis 28436142 Cortisol is associated with low frequency of interleukin 10-producing B cells in patients with atherosclerosis. +other hsa-mir-21 Sepsis 28437377 MicroRNA-21 Is Required for Local and Remote Ischemic Preconditioning in Multiple Organ Protection Against Sepsis. +other hsa-mir-214 Liver Diseases [unspecific] 28438567 A systematic evaluation of microRNAs in regulating human hepatic CYP2E1. +other hsa-mir-942 Liver Diseases [unspecific] 28438567 A systematic evaluation of microRNAs in regulating human hepatic CYP2E1. +other hsa-mir-21 Pancreatic Neoplasms 28438662 Never let it go: Stopping key mechanisms underlying metastasis to fight pancreatic cancer. +other hsa-mir-451 Glioblastoma 28440461 "The role of miR-451 in the switching between proliferation and migration in malignant glioma cells: AMPK signaling, mTOR modulation and Rac1 activation required." +other hsa-mir-122 Chronic Hepatitis C 28442604 Hepatitis C Virus Indirectly Disrupts DNA Damage-Induced p53 Responses by Activating Protein Kinase R. +other hsa-mir-140 Glioma 28443475 MicroRNA-140-5p inhibits cell proliferation and invasion by regulating VEGFA/MMP2 signaling in glioma. +other hsa-let-7 Neoplasms [unspecific] 28446596 Dicer loss and recovery induce an oncogenic switch driven by transcriptional activation of the oncofetal Imp1-3 family. +other hsa-mir-21 Cervical Neoplasms 28447761 miR-21 inhibitor suppresses cell proliferation and colony formation through regulating the PTEN/AKT pathway and improves paclitaxel sensitivity in cervical cancer cells. +other hsa-mir-7 "Carcinoma, Pancreatic" 28450156 microRNA-7 impairs autophagy-derived pools of glucose to suppress pancreatic cancer progression. +other hsa-mir-21 Brain Disease [unspecific] 28452880 Acute and subacute microRNA dysregulation is associated with cytokine responses in the rodent model of penetrating ballistic-like brain injury. +other hsa-mir-122 Chronic Hepatitis C 28456022 Cellular DEAD-box RNA helicase DDX6 modulates interaction of miR-122 with the 5' untranslated region of hepatitis C virus RNA. +other hsa-mir-372 "Carcinoma, Ovarian" 28456593 The role of miR-372 in ovarian carcinoma cell proliferation. +other hsa-mir-210 "Squamous Cell Carcinoma, Oral" 28459203 "Leptin acts on neoplastic behavior and expression levels of genes related to hypoxia, angiogenesis, and invasiveness in oral squamous cell carcinoma." +other hsa-mir-7 "Carcinoma, Hepatocellular" 28459371 Role of microRNA-7 and selenoprotein P in hepatocellular carcinoma. +other hsa-mir-7 Glioblastoma 28459998 Identification of miRNA-7 by genome-wide analysis as a critical sensitizer for TRAIL-induced apoptosis in glioblastoma cells. +other hsa-mir-30a Breast Neoplasms 28461244 miR-30a-5p suppresses breast tumor growth and metastasis through inhibition of LDHA-mediated Warburg effect. +other hsa-mir-21 Cardiovascular Diseases [unspecific] 28465657 The MicroRNA-21 signaling pathway is involved in prorenin receptor (PRR) -induced VEGF expression in ARPE-19 cells under a hyperglycemic condition. +other hsa-mir-21 Vascular Hypertrophy 28465975 "Review in Translational Cardiology: MicroRNAs and Myocardial Fibrosis in Aortic Valve Stenosis, a Deep Insight on Left Ventricular Remodeling." +other hsa-mir-146a "Carcinoma, Colon" 28466779 MicroRNA-146a induces immune suppression and drug-resistant colorectal cancer cells. +other hsa-mir-1 Preeclampsia 28466998 Cardiac remodelling and preeclampsia: an overview of overlapping miRNAs. +other hsa-mir-195 Preeclampsia 28466998 Cardiac remodelling and preeclampsia: an overview of overlapping miRNAs. +other hsa-mir-29b Preeclampsia 28466998 Cardiac remodelling and preeclampsia: an overview of overlapping miRNAs. +other hsa-mir-21 Prostate Neoplasms 28467474 Tonic suppression of PCAT29 by the IL-6 signaling pathway in prostate cancer: Reversal by resveratrol. +other hsa-mir-1180 "Carcinoma, Hepatocellular" 28468075 Bioinformatics on vascular invasion markers in hepatocellular carcinoma via Big-Data analysis. +other hsa-mir-149 "Carcinoma, Hepatocellular" 28468075 Bioinformatics on vascular invasion markers in hepatocellular carcinoma via Big-Data analysis. +other hsa-mir-744 "Carcinoma, Hepatocellular" 28468075 Bioinformatics on vascular invasion markers in hepatocellular carcinoma via Big-Data analysis. +other hsa-mir-940 "Carcinoma, Hepatocellular" 28468075 Bioinformatics on vascular invasion markers in hepatocellular carcinoma via Big-Data analysis. +other hsa-mir-155 Preeclampsia 28471953 "Association of microRNA-155, interleukin 17A, and proteinuria in preeclampsia." +other hsa-mir-29b Bronchopulmonary Dysplasia 28473324 miR-29b supplementation decreases expression of matrix proteins and improves alveolarization in mice exposed to maternal inflammation and neonatal hyperoxia. +other hsa-mir-204 Hypertension 28473439 Implication of Inflammation and Epigenetic Readers in Coronary Artery Remodeling in Patients With Pulmonary Arterial Hypertension. +other hsa-mir-223 Hypertension 28473439 Implication of Inflammation and Epigenetic Readers in Coronary Artery Remodeling in Patients With Pulmonary Arterial Hypertension. +other hsa-mir-122 Hepatitis C Virus Infection 28475652 Serum microRNA-122 and Wisteria floribunda agglutinin-positive Mac-2 binding protein are useful tools for liquid biopsy of the patients with hepatitis B virus and advanced liver fibrosis. +other hsa-mir-26a "Squamous Cell Carcinoma, Esophageal" 28476684 miR-26a and miR-26b inhibit esophageal squamous cancer cell proliferation through suppression of c-MYC pathway. +other hsa-mir-26b "Squamous Cell Carcinoma, Esophageal" 28476684 miR-26a and miR-26b inhibit esophageal squamous cancer cell proliferation through suppression of c-MYC pathway. +other hsa-mir-9 "Carcinoma, Gastric" 28476807 Expression of hsa-miR-9 and MYC Copy Number Variation in Hereditary Diffuse Gastric Cancer. +other hsa-mir-18a Retinoblastoma 28481041 Reduction of the tumorigenic potential of human retinoblastoma cell lines by TFF1 overexpression involves p53/caspase signaling and miR-18a regulation. +other hsa-let-7 Melanoma 28482074 The overexpression of Lin28B reduced mature let-7 microRNA expression in melanoma cell lines +other hsa-mir-181a "Carcinoma, Prostate" 28485104 MicroRNA-181a promotes docetaxel resistance in prostate cancer cells. +other hsa-mir-1 Gastric Neoplasms 28493075 MicroRNA-1 acts as a tumor suppressor microRNA by inhibiting angiogenesis-related growth factors in human gastric cancer. +other hsa-mir-122 Chronic Hepatitis C 28494029 Characterization of miR-122-independent propagation of HCV. +other hsa-let-7a Glioblastoma 28494471 Inhibition of neurotensin receptor 1 induces intrinsic apoptosis via let-7a-3p/Bcl-w axis in glioblastoma. +other hsa-mir-21 Peritoneal Dialysis Failure 28495592 miR-21 Promotes Fibrogenesis in Peritoneal Dialysis. +other hsa-mir-15a Chronic Hepatitis B 28498453 The inhibition of microRNA-15a suppresses hepatitis?B virus-associated liver cancer cell growth through the Smad/TGF-¦Â pathway. +other hsa-mir-125a "Carcinoma, Pancreatic" 28498896 "targeting the overexpression of PRDM14 suppresses cancer stem-like phenotypes, including liver metastasis, via miRNA regulation and siRNA-based therapy targeting it shows promise as a treatment for patients with pancreatic cancer" +other hsa-mir-24 Neoplasms [unspecific] 28500171 Platelet microparticles infiltrating solid tumors transfer miRNAs that suppress tumor growth. +other hsa-mir-200b Liver Cirrhosis 28502477 Knockdown of Hepatic Gonadotropin-Releasing Hormone by Vivo-Morpholino Decreases Liver Fibrosis in Multidrug Resistance Gene 2 Knockout Mice by Down-Regulation of miR-200b. +other hsa-mir-15a Breast Neoplasms 28509572 Effect of silibinin-loaded nano-niosomal coated with trimethyl chitosan on miRNAs expression in 2D and 3D models of T47D breast cancer cell line. +other hsa-mir-21 Breast Neoplasms 28509572 Effect of silibinin-loaded nano-niosomal coated with trimethyl chitosan on miRNAs expression in 2D and 3D models of T47D breast cancer cell line. +other hsa-mir-133a Coronary Artery Disease 28511772 Transcoronary Concentration Gradient of microRNA-133a and Outcome in Patients With Coronary Artery Disease. +other hsa-mir-34a Neoplasms [unspecific] 28511876 Chondroitin sulfate-functionalized polyamidoamine as a tumor-targeted carrier for miR-34a delivery. +other hsa-mir-34 "Adenocarcinoma, Lung" 28512015 The association between miR-34 dysregulation and distant metastases formation in lung adenocarcinoma. +other hsa-mir-10b Breast Ductal Carcinoma 28512126 Tumor-associated myoepithelial cells promote the invasive progression of ductal carcinoma in situ through activation of TGF¦Â signaling. +other hsa-mir-378 Melanoma 28513838 The emerging role of NPNT in tissue injury repair and bone homeostasis. +other hsa-mir-146a Rheumatoid Arthritis 28514293 The role of circulating miR-146a in patients with rheumatoid arthritis treated by Tripterygium wilfordii Hook F. +other hsa-mir-223 Sepsis 28515178 A model-specific role of microRNA-223 as a mediator of kidney injury during experimental sepsis. +other hsa-mir-125b "Carcinoma, Hepatocellular" 28521446 Candidate miRNAs and pathogenesis investigation for hepatocellular carcinoma based on bioinformatics analysis. +other hsa-mir-21 Polycythemia Vera 28522758 Decreased CAT results from hypoxia-induced miR-21 that downregulates CAT +other hsa-mir-133a Vascular Hypertrophy 28526870 these c-miRNAs may serve as markers for monitoring the RT responses +other hsa-mir-21 Vascular Hypertrophy 28526870 these c-miRNAs may serve as markers for monitoring the RT responses +other hsa-mir-199a "Carcinoma, Hepatocellular" 28529584 Anti-microRNA-21/221 and microRNA-199a transfected by ultrasound microbubbles induces the apoptosis of human hepatoma HepG2 cells. +other hsa-mir-21 "Carcinoma, Hepatocellular" 28529584 Anti-microRNA-21/221 and microRNA-199a transfected by ultrasound microbubbles induces the apoptosis of human hepatoma HepG2 cells. +other hsa-mir-221 "Carcinoma, Hepatocellular" 28529584 Anti-microRNA-21/221 and microRNA-199a transfected by ultrasound microbubbles induces the apoptosis of human hepatoma HepG2 cells. +other hsa-mir-375 "Adenocarcinoma, Lung" 28533502 miR-375 is essential for the progression of LUAD +other hsa-mir-92a "Carcinoma, Lung, Non-Small-Cell" 28534966 MicroRNA-92a promotes epithelial-mesenchymal transition through activation of PTEN/PI3K/AKT signaling pathway in non-small cell lung cancer metastasis. +other hsa-mir-129 Chondrosarcoma 28535514 MiR-129-5p Inhibits Proliferation and Invasion of Chondrosarcoma Cells by Regulating SOX4/Wnt/¦Â-Catenin Signaling Pathway. +other hsa-mir-145 "Adenocarcinoma, Lung" 28535533 MALAT1 Modulates TGF-¦Â1-Induced Endothelial-to-Mesenchymal Transition through Downregulation of miR-145. +other hsa-mir-33b Endometriosis 28537685 "MiR-33b can mediate cell apoptosis, alter VEGF and MMP-9 expression and affect proliferation and apoptosis of uterus endometrial cells, thus participating endometriosis formation" +other hsa-mir-126 Hemangioma 28538565 Urinary Excretion of MicroRNA-126 Is a Biomarker for Hemangioma Proliferation. +other hsa-mir-199a "Carcinoma, Colon" 28542779 Downregulation of miR-199a/b-5p is associated with GCNT2 induction upon epithelial-mesenchymal transition in colon cancer. +other hsa-mir-199b "Carcinoma, Colon" 28542779 Downregulation of miR-199a/b-5p is associated with GCNT2 induction upon epithelial-mesenchymal transition in colon cancer. +other hsa-mir-34a Bone Disease [unspecific] 28543623 Regulatory effect of microRNA-34a on osteogenesis and angiogenesis in glucocorticoid-induced osteonecrosis of the femoral head. +other hsa-mir-146a Arthritis 28545737 MicroRNA-146a governs fibroblast activation and joint pathology in arthritis. +other hsa-mir-146a Human Papilloma Virus Infection 28551628 Regulation of miRNA-146a and miRNA-150 Levels by Celecoxib in Premalignant Lesions of K14-HPV16 Mice. +other hsa-mir-150 Human Papilloma Virus Infection 28551628 Regulation of miRNA-146a and miRNA-150 Levels by Celecoxib in Premalignant Lesions of K14-HPV16 Mice. +other hsa-let-7a Spinal Cord Injuries 28552531 A causal relationship between the neurotherapeutic effects of miR182/7a and decreased expression of PRDM5. +other hsa-mir-182 Spinal Cord Injuries 28552531 A causal relationship between the neurotherapeutic effects of miR182/7a and decreased expression of PRDM5. +other hsa-mir-1 "Carcinoma, Colon" 28560697 The Cardiotoxic Mechanism of Doxorubicin (DOX) and Pegylated Liposomal DOX in Mice Bearing C-26 Colon Carcinoma: a Study Focused on microRNA Role for Toxicity Assessment of New Formulations. +other hsa-mir-21 "Carcinoma, Colon" 28560697 The Cardiotoxic Mechanism of Doxorubicin (DOX) and Pegylated Liposomal DOX in Mice Bearing C-26 Colon Carcinoma: a Study Focused on microRNA Role for Toxicity Assessment of New Formulations. +other hsa-mir-204 Hypertension 28565757 An exploratory study into the role of miR-204-5p in pregnancy-induced hypertension. +other hsa-mir-214 "Carcinoma, Gingival" 28565877 Elucidating the mechanism of miRNA-214 in the regulation of gingival carcinoma. +other hsa-mir-200c Colorectal Carcinoma 28567416 Negative Correlation between miR-200c and Decorin Plays an Important Role in the Pathogenesis of Colorectal Carcinoma. +other hsa-mir-7 "Carcinoma, Breast" 28571043 MicroRNA-7 suppresses the homing and migration potential of human endothelial cells to highly metastatic human breast cancer cells. +other hsa-mir-183 Neuropathic Pain 28572455 miR-183 cluster scales mechanical pain sensitivity by regulating basal and neuropathic pain genes. +other hsa-mir-375 "Carcinoma, Hepatocellular" 28577837 MiR-375 delivered by lipid-coated doxorubicin-calcium carbonate nanoparticles overcomes chemoresistance in hepatocellular carcinoma. +other hsa-mir-502 "Carcinoma, Prostate" 28578017 Functional polymorphism at the miR-502-binding site in the 3' untranslated region of the SETD8 gene increased the risk of prostate cancer in a sample of Iranian population. +other hsa-mir-21 Infection [unspecific] 28589100 MicroRNA-21 Limits Uptake of Listeria monocytogenes by Macrophages to Reduce the Intracellular Niche and Control Infection. +other hsa-mir-21 Human Cytomegalovirus Infection 28589873 Human cytomegalovirus microRNAs are carried by virions and dense bodies and are delivered to target cells. +other hsa-mir-218 Human Cytomegalovirus Infection 28589873 Human cytomegalovirus microRNAs are carried by virions and dense bodies and are delivered to target cells. +other hsa-mir-128 Glioblastoma 28591575 MicroRNA-Mediated Dynamic Bidirectional Shift between the Subclasses of Glioblastoma Stem-like Cells. +other hsa-mir-34a Acute Pancreatitis 28592850 NAD+ augmentation ameliorates acute pancreatitis through regulation of inflammasome signalling. +other hsa-mir-500 Human Immunodeficiency Virus Infection 28594894 "MicroRNAs upregulated during HIV infection target peroxisome biogenesis factors: Implications for virus biology, disease mechanisms and neuropathology." +other hsa-mir-93 Human Immunodeficiency Virus Infection 28594894 "MicroRNAs upregulated during HIV infection target peroxisome biogenesis factors: Implications for virus biology, disease mechanisms and neuropathology." +other hsa-mir-146a Psoriasis 28595995 miR-146b Probably Assists miRNA-146a in?the Suppression of Keratinocyte Proliferation and Inflammatory Responses?in Psoriasis. +other hsa-mir-146b Psoriasis 28595995 miR-146b Probably Assists miRNA-146a in?the Suppression of Keratinocyte Proliferation and Inflammatory Responses?in Psoriasis. +other hsa-mir-143 Preterm Labor 28596604 "miR-143 and miR-145 disrupt the cervical epithelial barrier through dysregulation of cell adhesion, apoptosis and proliferation." +other hsa-mir-145 Preterm Labor 28596604 "miR-143 and miR-145 disrupt the cervical epithelial barrier through dysregulation of cell adhesion, apoptosis and proliferation." +other hsa-mir-125b "Carcinoma, Renal Cell" 28599452 "miR-125b is associated with renal cell carcinoma cell migration, invasion and apoptosis." +other hsa-mir-21 Neuroblastoma 28599474 Reduction of miR-21 induces SK-N-SH cell apoptosis and inhibits proliferation via PTEN/PDCD4. +other hsa-mir-34a Ischemia-Reperfusion Injury 28599575 Suppression of miR-34a Expression in the Myocardium Protects Against Ischemia-Reperfusion Injury Through SIRT1 Protective Pathway. +other hsa-mir-494 Spinal Cord Injuries 28601045 MicroRNA-494 improves functional recovery and inhibits apoptosis by modulating PTEN/AKT/mTOR pathway in rats after spinal cord injury. +other hsa-mir-101 "Carcinoma, Ovarian" 28601063 "Clusters of microRNAs (miR-145, miR-31, miR-506, miR-101) most essential for metastasis of ovarian cancer including the families of microRNAs (miR-200, miR-214, miR-25) with dual role" +other hsa-mir-145 "Carcinoma, Ovarian" 28601063 "Clusters of microRNAs (miR-145, miR-31, miR-506, miR-101) most essential for metastasis of ovarian cancer including the families of microRNAs (miR-200, miR-214, miR-25) with dual role" +other hsa-mir-200 "Carcinoma, Ovarian" 28601063 "Clusters of microRNAs (miR-145, miR-31, miR-506, miR-101) most essential for metastasis of ovarian cancer including the families of microRNAs (miR-200, miR-214, miR-25) with dual role" +other hsa-mir-214 "Carcinoma, Ovarian" 28601063 "Clusters of microRNAs (miR-145, miR-31, miR-506, miR-101) most essential for metastasis of ovarian cancer including the families of microRNAs (miR-200, miR-214, miR-25) with dual role" +other hsa-mir-25 "Carcinoma, Ovarian" 28601063 "Clusters of microRNAs (miR-145, miR-31, miR-506, miR-101) most essential for metastasis of ovarian cancer including the families of microRNAs (miR-200, miR-214, miR-25) with dual role" +other hsa-mir-31 "Carcinoma, Ovarian" 28601063 "Clusters of microRNAs (miR-145, miR-31, miR-506, miR-101) most essential for metastasis of ovarian cancer including the families of microRNAs (miR-200, miR-214, miR-25) with dual role" +other hsa-mir-506 "Carcinoma, Ovarian" 28601063 "Clusters of microRNAs (miR-145, miR-31, miR-506, miR-101) most essential for metastasis of ovarian cancer including the families of microRNAs (miR-200, miR-214, miR-25) with dual role" +other hsa-mir-24 Liver Fibrosis 28602220 Inhibition of microRNA-24 increases liver fibrosis by enhanced menin expression in Mdr2-/- mice. +other hsa-mir-146a Amyotrophic Lateral Sclerosis 28612258 Downregulated Glia Interplay and Increased miRNA-155 as Promising Markers to Track ALS at an?Early Stage. +other hsa-mir-155 Amyotrophic Lateral Sclerosis 28612258 Downregulated Glia Interplay and Increased miRNA-155 as Promising Markers to Track ALS at an?Early Stage. +other hsa-mir-371a Testicular Germ Cell Tumor 28612337 microRNA-371a-3p as informative biomarker for the follow-up of testicular germ cell cancer patients. +other hsa-mir-125b Melanoma 28614272 Quantification of microRNA-21 and microRNA-125b in melanoma tissue. +other hsa-mir-205 Melanoma 28614272 Quantification of microRNA-21 and microRNA-125b in melanoma tissue. +other hsa-mir-182 Autism Spectrum Disorder 28617945 microRNA cluster 106a~363 is involved in T helper 17 cell differentiation. +other hsa-mir-212 Autism Spectrum Disorder 28617945 microRNA cluster 106a~363 is involved in T helper 17 cell differentiation. +other hsa-mir-363 Autism Spectrum Disorder 28617945 microRNA cluster 106a~363 is involved in T helper 17 cell differentiation. +other hsa-mir-124 Stroke 28624203 Exosome Mediated Delivery of miR-124 Promotes Neurogenesis after Ischemia. +other hsa-mir-494 Ischemic Diseases [unspecific] 28624225 Inhibition of Mef2a Enhances Neovascularization via Post-transcriptional Regulation of 14q32 MicroRNAs miR-329 and miR-494. +other hsa-mir-21 Breast Neoplasms 28628833 Urtica dioica extract suppresses miR-21 and metastasis-related genes in breast cancer. +other hsa-mir-451 Glioblastoma 28629521 Erythropoietin Promotes Glioblastoma via miR-451 Suppression. +other hsa-mir-200a Esophageal Neoplasms 28635228 MALAT1 functions as a competing endogenous RNA to regulate the expressions of ZEB1 and ZEB2 by sponging miR-200a and promotes invasion and migration of esophageal cancer cells through inducing epithelial-mesenchymal transition +other hsa-mir-34a Osteosarcoma 28635396 MicroRNA-34a inhibits tumor invasion and metastasis in osteosarcoma partly by effecting C-IAP2 and Bcl-2. +other hsa-mir-146a Muscular Dystrophy 28637335 Astrocyte-produced miR-146a as a mediator of motor neuron loss in spinal muscular atrophy. +other hsa-mir-146a Atherosclerosis 28637783 Paradoxical Suppression of Atherosclerosis in the Absence of microRNA-146a. +other hsa-mir-155 Ischemia-Reperfusion Injury 28640790 MicroRNA-155 Deficiency in Kupffer Cells Ameliorates Liver Ischemia-Reperfusion Injury in Mice. +other hsa-mir-145 Prostate Neoplasms 28641312 Impact of novel miR-145-3p regulatory networks on survival in patients with castration-resistant prostate cancer. +other hsa-mir-155 Human Cytomegalovirus Infection 28642130 mir-155 expression is downregulated in kidney transplant patients with human cytomegalovirus infection. +other hsa-mir-122 "Carcinoma, Hepatocellular" 28642869 Detection of MicroRNA in Hepatic Cirrhosis and Hepatocellular Carcinoma in Hepatitis C Genotype-4 in Egyptian Patients. +other hsa-mir-122 Chronic Hepatitis C 28642978 Ectopic delivery of miR-200c diminishes hepatitis C virus infectivity through transcriptional and translational repression of Occludin. +other hsa-mir-140 Gout 28647469 Intra-articular injection of microRNA-140 (miRNA-140) alleviates osteoarthritis (OA) progression by modulating extracellular matrix (ECM) homeostasis in rats. +other hsa-mir-30d "Carcinoma, Colon" 28651493 Mir-30d suppresses cell proliferation of colon cancer cells by inhibiting cell autophagy and promoting cell apoptosis. +other hsa-mir-34a Alzheimer Disease 28652929 TNF-¦Á and Beyond: Rapid Mitochondrial Dysfunction Mediates TNF-¦Á-Induced Neurotoxicity. +other hsa-mir-125b "Carcinoma, Hepatocellular" 28654261 Astragalin Reduces Hexokinase 2 through Increasing miR-125b to Inhibit the Proliferation of Hepatocellular Carcinoma Cells in Vitro and in Vivo. +other hsa-mir-96 "Carcinoma, Lung, Non-Small-Cell" 28656287 "Identification and characterization of miR-96, a potential biomarker of NSCLC, through bioinformatic analysis." +other hsa-mir-34a Neoplasms [unspecific] 28657476 Comparison of Peptide- and Lipid-Based Delivery of miR-34a-5p Mimic into PPC-1 Cells. +other hsa-mir-23a Vascular Disease [unspecific] 28662151 Bone marrow mesenchymal stem cell-derived vascular endothelial growth factor attenuates cardiac apoptosis via regulation of cardiac miRNA-23a and miRNA-92a in a rat model of myocardial infarction. +other hsa-mir-92a Vascular Disease [unspecific] 28662151 Bone marrow mesenchymal stem cell-derived vascular endothelial growth factor attenuates cardiac apoptosis via regulation of cardiac miRNA-23a and miRNA-92a in a rat model of myocardial infarction. +other hsa-mir-155 Systemic Lupus Erythematosus 28665018 "MiR-155*, miR-34b and miR-34a levels in T lymphocytes and corresponding MVs were deregulated in SLE when compared to healthy individuals" +other hsa-mir-34a Systemic Lupus Erythematosus 28665018 "MiR-155*, miR-34b and miR-34a levels in T lymphocytes and corresponding MVs were deregulated in SLE when compared to healthy individuals" +other hsa-mir-34b Systemic Lupus Erythematosus 28665018 "MiR-155*, miR-34b and miR-34a levels in T lymphocytes and corresponding MVs were deregulated in SLE when compared to healthy individuals" +other hsa-mir-155 "Carcinoma, Hepatocellular" 28670383 "MiR-155 up-regulated by TGF-¦Â promotes epithelial-mesenchymal transition, invasion and metastasis of human hepatocellular carcinoma cells in vitro." +other hsa-mir-16 Neoplasms [unspecific] 28670496 Resistance to cancer chemotherapeutic drugs is determined by pivotal microRNA regulators. +other hsa-mir-1 Sepsis 28673002 IGF-1 may predict the severity and outcome of patients with sepsis and be associated with microRNA-1 level changes. +other hsa-mir-21 Atherosclerosis 28674080 "Macrophage deficiency of miR-21 promotes apoptosis, plaque necrosis, and vascular inflammation during atherogenesis." +other hsa-mir-200c Lung Neoplasms 28675952 A novel fine tuning scheme of miR-200c in modulating lung cell redox homeostasis. +other hsa-let-7b Glioblastoma 28677425 IKBKE promotes glioblastoma progression by establishing the regulatory feedback loop of IKBKE/YAP1/miR-Let-7b/i. +other hsa-mir-200a "Squamous Cell Carcinoma, Head and Neck" 28677748 Salivary miR-93 and miR-200a as post-radiotherapy biomarkers in head and neck squamous cell carcinoma. +other hsa-mir-93 "Squamous Cell Carcinoma, Head and Neck" 28677748 Salivary miR-93 and miR-200a as post-radiotherapy biomarkers in head and neck squamous cell carcinoma. +other hsa-mir-126 Atherosclerosis 28678312 Identification of miRNAs as atherosclerosis biomarkers and functional role of miR-126 in atherosclerosis progression through MAPK signalling pathway. +other hsa-mir-122a "Carcinoma, Hepatocellular" 28686599 Flux balance analysis predicts Warburg-like effects of mouse hepatocyte deficient in miR-122a. +other hsa-mir-29a Bladder Neoplasms 28687357 Circular RNA MYLK as a competing endogenous RNA promotes bladder cancer progression through modulating VEGFA/VEGFR2 signaling pathway. +other hsa-let-7a "Carcinoma, Hepatocellular" 28691642 XIAP 3'-untranslated region serves as a competitor for HMGA2 by arresting endogenous let-7a-5p in human hepatocellular carcinoma. +other hsa-mir-125b "Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal" 28693195 MicroRNA-125b targeted STAT3 to inhibit laryngeal squamous cell carcinoma cell growth and motility. +other hsa-mir-92b Ovarian Neoplasms 28693226 Screening of potentially crucial genes and regulatory factors involved in epithelial ovarian cancer using microarray analysis. +other hsa-mir-92b Colorectal Carcinoma 28693229 MicroRNAs as outcome predictors in patients with metastatic colorectal cancer treated with bevacizumab in combination with FOLFOX. +other hsa-mir-106a Colorectal Carcinoma 28693239 Biological effects and clinical characteristics of microRNA-106a in human colorectal cancer +other hsa-mir-296 Nasal Cavity Inverting Papilloma 28693263 Role of microRNA-296-3p in the malignant transformation of sinonasal inverted papilloma. +other hsa-mir-210 Prostate Neoplasms 28693582 Oncogenic miR-210-3p promotes prostate cancer cell EMT and bone metastasis via NF-¦ÊB signaling pathway. +other hsa-mir-24 Blood Coagulation Disorders 28694557 Overexpression of miR-24 Is Involved in the Formation of Hypocoagulation State after Severe Trauma by Inhibiting the Synthesis of Coagulation Factor X. +other hsa-mir-92a Cardiovascular Diseases [unspecific] 28696247 MicroRNA-92a Mediates Endothelial Dysfunction in CKD. +other hsa-mir-548f Leukemia 28698179 A Novel Regulatory Mechanism of Smooth Muscle ¦Á-Actin Expression by NRG-1/circACTA2/miR-548f-5p Axis. +other hsa-mir-27b "Diabetes Mellitus, Type 2" 28698281 MiR-27b augments bone marrow progenitor cell survival via suppressing the mitochondrial apoptotic pathway in Type 2 diabetes. +other hsa-mir-21 Myocardial Infarction 28699517 Circadian MicroRNAs in Cardioprotection. +other hsa-mir-29a Breast Neoplasms 28701793 The miR-29 transcriptome in endocrine-sensitive and resistant breast cancer cells. +other hsa-mir-21 "Carcinoma, Lung" 28705115 MicroRNA-21 versus microRNA-34: Lung cancer promoting and inhibitory microRNAs analysed in silico and in vitro and their clinical impact. +other hsa-mir-34 "Carcinoma, Lung" 28705115 MicroRNA-21 versus microRNA-34: Lung cancer promoting and inhibitory microRNAs analysed in silico and in vitro and their clinical impact. +other hsa-mir-21 Vascular Disease [unspecific] 28707876 Fluorescence Light-Up Biosensor for MicroRNA Based on the Distance-Dependent Photoinduced Electron Transfer. +other hsa-mir-34a Ischemia-Reperfusion Injury 28709867 Attenuation of the hypoxia-induced miR-34a protects cardiomyocytes through maintenance of glucose metabolism. +other hsa-mir-375 Oral Neoplasms 28713923 The differential regulation of microRNAs is associated with oral cancer +other hsa-mir-204 Ischemia-Reperfusion Injury 28714326 "miR-204 inhibitor upregulated the activity and expression of RAP2C, while miR-204 mimic played the opposite role" +other hsa-mir-21 "Carcinoma, Renal Cell" 28714373 Targeting miR-21 decreases expression of multi-drug resistant genes and promotes chemosensitivity of renal carcinoma. +other hsa-mir-424 Early-Stage Colon Adenocarcinoma 28714374 Screening key genes and miRNAs in early-stage colon adenocarcinoma by RNA-sequencing. +other hsa-mir-548am Early-Stage Colon Adenocarcinoma 28714374 Screening key genes and miRNAs in early-stage colon adenocarcinoma by RNA-sequencing. +other hsa-mir-548c Early-Stage Colon Adenocarcinoma 28714374 Screening key genes and miRNAs in early-stage colon adenocarcinoma by RNA-sequencing. +other hsa-mir-548i Early-Stage Colon Adenocarcinoma 28714374 Screening key genes and miRNAs in early-stage colon adenocarcinoma by RNA-sequencing. +other hsa-mir-661 "Carcinoma, Lung, Non-Small-Cell" 28716024 MiR-661 promotes tumor invasion and metastasis by directly inhibiting RB1 in non small cell lung cancer +other hsa-mir-613 Glioblastoma 28718378 MicroRNA-613 is downregulated in HCMV-positive glioblastoma and inhibits tumour progression by targeting arginase-2. +other hsa-mir-29b Myocardial Infarction 28722488 Berberine promotes ischemia-induced angiogenesis in mice heart via upregulation of microRNA-29b. +other hsa-mir-155 Glioma 28724215 Melatonin inhibits proliferation and invasion via repression of miRNA-155 in glioma cells. +other hsa-mir-21 Glioblastoma 28727188 we highlighted utilization of miR-21 as diagnostic and therapeutic biomarker for GBM patients +other hsa-mir-30a "Carcinoma, Hepatocellular" 28732393 MicroRNA-30a suppresses tumor progression by blocking Ras/Raf/MEK/ERK signaling pathway in hepatocellular carcinoma +other hsa-mir-18a Endomyocardial Fibrosis 28733035 MiR-18a-5p inhibits endothelial-mesenchymal transition and cardiac fibrosis through the Notch2 pathway. +other hsa-let-7 Neuroinflammation 28737113 "Key pro-inflammatory ( miR-155, miR-27b, miR-326), anti-inflammatory ( miR-124, miR-146a, miR-21, miR-223), and mixed immunomodulatory ( let-7 family) miRNAs regulate neuroinflammation in various pathologies" +other hsa-mir-124 Neuroinflammation 28737113 "Key pro-inflammatory ( miR-155, miR-27b, miR-326), anti-inflammatory ( miR-124, miR-146a, miR-21, miR-223), and mixed immunomodulatory ( let-7 family) miRNAs regulate neuroinflammation in various pathologies" +other hsa-mir-146a Neuroinflammation 28737113 "Key pro-inflammatory ( miR-155, miR-27b, miR-326), anti-inflammatory ( miR-124, miR-146a, miR-21, miR-223), and mixed immunomodulatory ( let-7 family) miRNAs regulate neuroinflammation in various pathologies" +other hsa-mir-155 Neuroinflammation 28737113 "Key pro-inflammatory ( miR-155, miR-27b, miR-326), anti-inflammatory ( miR-124, miR-146a, miR-21, miR-223), and mixed immunomodulatory ( let-7 family) miRNAs regulate neuroinflammation in various pathologies" +other hsa-mir-21 Neuroinflammation 28737113 "Key pro-inflammatory ( miR-155, miR-27b, miR-326), anti-inflammatory ( miR-124, miR-146a, miR-21, miR-223), and mixed immunomodulatory ( let-7 family) miRNAs regulate neuroinflammation in various pathologies" +other hsa-mir-223 Neuroinflammation 28737113 "Key pro-inflammatory ( miR-155, miR-27b, miR-326), anti-inflammatory ( miR-124, miR-146a, miR-21, miR-223), and mixed immunomodulatory ( let-7 family) miRNAs regulate neuroinflammation in various pathologies" +other hsa-mir-27b Neuroinflammation 28737113 "Key pro-inflammatory ( miR-155, miR-27b, miR-326), anti-inflammatory ( miR-124, miR-146a, miR-21, miR-223), and mixed immunomodulatory ( let-7 family) miRNAs regulate neuroinflammation in various pathologies" +other hsa-mir-326 Neuroinflammation 28737113 "Key pro-inflammatory ( miR-155, miR-27b, miR-326), anti-inflammatory ( miR-124, miR-146a, miR-21, miR-223), and mixed immunomodulatory ( let-7 family) miRNAs regulate neuroinflammation in various pathologies" +other hsa-mir-141 "Carcinoma, Colon" 28739727 miR-141 Inhibits Proliferation and Migration of Colorectal Cancer SW480 Cells. +other hsa-mir-96 "Adenocarcinoma, Colon" 28742206 Bioinformatics analysis of RNA-seq data revealed critical genes in colon adenocarcinoma +other hsa-mir-200c Colorectal Carcinoma 28745318 Core 3 mucin-type O-glycan restoration in colorectal cancer cells promotes MUC1/p53/miR-200c-dependent epithelial identity. +other hsa-mir-34a Hearing Loss 28756190 miR-34a/Bcl-2 signaling pathway contributes to age-related hearing loss by modulating hair cell apoptosis. +other hsa-mir-30a Medulloblastoma 28757413 "Restoration of miR-30a expression inhibits growth, tumorigenicity of medulloblastoma cells accompanied by autophagy inhibition." +other hsa-mir-34a Melanoma 28759238 Ternary Nanoparticles with a Sheddable Shell Efficiently Deliver MicroRNA-34a against CD44-Positive Melanoma. +other hsa-mir-375 "Carcinoma, Hepatocellular" 28769563 Delivery of miR-375 and doxorubicin hydrochloride by lipid-coated hollow mesoporous silica nanoparticles to overcome multiple drug resistance in hepatocellular carcinoma +other hsa-mir-16 "Carcinoma, Hepatocellular" 28770611 Clinical significance of miRNA-autophagy transcript expression in patients with hepatocellular carcinoma +other hsa-mir-221 Bladder Neoplasms 28770966 Inhibition of miR-221 influences bladder cancer cell proliferation and apoptosis. +other hsa-mir-146a Ischemia-Reperfusion Injury 28771774 MiR-146a protects small intestine against ischemia/reperfusion injury by down-regulating TLR4/TRAF6/NF-¦ÊB pathway. +other hsa-mir-1274a Neoplasms [unspecific] 28774834 "the present review discussed the role of FoxOs in association with miRNAs such as miR-182, miR-135b, miR-499-5p, miR-1274a, miR-150, miR-34b/c and miR-625" +other hsa-mir-135b Neoplasms [unspecific] 28774834 "the present review discussed the role of FoxOs in association with miRNAs such as miR-182, miR-135b, miR-499-5p, miR-1274a, miR-150, miR-34b/c and miR-623" +other hsa-mir-150 Neoplasms [unspecific] 28774834 "the present review discussed the role of FoxOs in association with miRNAs such as miR-182, miR-135b, miR-499-5p, miR-1274a, miR-150, miR-34b/c and miR-626" +other hsa-mir-182 Neoplasms [unspecific] 28774834 "the present review discussed the role of FoxOs in association with miRNAs such as miR-182, miR-135b, miR-499-5p, miR-1274a, miR-150, miR-34b/c and miR-622" +other hsa-mir-34b Neoplasms [unspecific] 28774834 "the present review discussed the role of FoxOs in association with miRNAs such as miR-182, miR-135b, miR-499-5p, miR-1274a, miR-150, miR-34b/c and miR-627" +other hsa-mir-34c Neoplasms [unspecific] 28774834 "the present review discussed the role of FoxOs in association with miRNAs such as miR-182, miR-135b, miR-499-5p, miR-1274a, miR-150, miR-34b/c and miR-628" +other hsa-mir-499 Neoplasms [unspecific] 28774834 "the present review discussed the role of FoxOs in association with miRNAs such as miR-182, miR-135b, miR-499-5p, miR-1274a, miR-150, miR-34b/c and miR-624" +other hsa-mir-622 Neoplasms [unspecific] 28774834 "the present review discussed the role of FoxOs in association with miRNAs such as miR-182, miR-135b, miR-499-5p, miR-1274a, miR-150, miR-34b/c and miR-629" +other hsa-mir-155 "Leukemia, Lymphocytic, Chronic, B-Cell" 28783166 Anti-leukemic activity of microRNA-26a in a chronic lymphocytic leukemia mouse model. +other hsa-mir-26a "Leukemia, Lymphocytic, Chronic, B-Cell" 28783166 Anti-leukemic activity of microRNA-26a in a chronic lymphocytic leukemia mouse model. +other hsa-mir-33b Asthma 28785038 Inhibition of airway inflammation in a cockroach allergen model of asthma by agonists of miRNA-33b. +other hsa-mir-20a Ovarian Neoplasms 28789409 MicroRNA-20a contributes to cisplatin-resistance and migration of OVCAR3 ovarian cancer cell line. +other hsa-mir-29c Lung Fibrosis 28799781 MicroRNA-29c Prevents Pulmonary Fibrosis by Regulating Epithelial Cell Renewal and Apoptosis. +other hsa-mir-223 Traumatic Brain Injury 28804446 Induction of miR-155 after Brain Injury Promotes Type 1 Interferon and has a Neuroprotective Effect. +other hsa-let-7a Multiple Myeloma 28808676 "a thymidine-kinase-deleted let-7a-regulated vaccinia virus was safe and effective for mice, warranting clinical trials in humans" +other hsa-mir-1275 "Carcinoma, Hepatocellular" 28817968 Destabilizing the interplay between miR-1275 and IGF2BPs by Tamarix articulata and quercetin in hepatocellular carcinoma. +other hsa-mir-18a Pancreatic Neoplasms 28822990 ¦ÁM and ¦ÃM can induce apoptosis and autophagy in pancreatic cancer cells and that their anti-cancer effect is likely to be associated with miR-18a +other hsa-mir-222 "Leukemia, Lymphocytic, Chronic, B-Cell" 28824233 Inhibition of MicroRNA miR-222 with LNA Inhibitor Can Reduce Cell Proliferation in B Chronic Lymphoblastic Leukemia +other hsa-mir-155 Neuronal Apoptosis-Related Diseases 28831740 "Expression of miR-155 associated with Toll-like receptors 3, 7, and 9 transcription in the olfactory bulbs of cattle naturally infected with BHV5." +other hsa-mir-145 Prostate Neoplasms 28843521 Curcumin suppresses proliferation and in vitro invasion of human prostate cancer stem cells by ceRNA effect of miR-145 and lncRNA-ROR. +other hsa-mir-122 Chronic Hepatitis C 28844749 Immune responses in DAA treated chronic hepatitis C patients with and without prior RG-101 dosing. +other hsa-mir-195 "Carcinoma, Lung, Non-Small-Cell" 28848163 Knockdown of Lncrna PVT1 Enhances Radiosensitivity in Non-Small Cell Lung Cancer by Sponging Mir-195. +other hsa-mir-140 Autism Spectrum Disorder 28848387 "Expression and Regulatory Network Analysis of miR-140-3p, a New Potential Serum Biomarker for Autism Spectrum Disorder." +other hsa-mir-205 Heart Failure 28849082 Short?term vagus nerve stimulation reduces myocardial apoptosis by downregulating microRNA?205 in rats with chronic heart failure. +other hsa-mir-146a Graft-Versus-Host Disease 28853768 Systemic Treatment with a miR-146a Mimic Suppresses Endotoxin Sensitivity and Partially Protects Mice from the Progression of Acute Graft-versus-Host Disease. +other hsa-mir-30a Stroke 28854438 Down-Regulation of Lncrna MALAT1 Attenuates Neuronal Cell Death Through Suppressing Beclin1-Dependent Autophagy by Regulating Mir-30a in Cerebral Ischemic Stroke. +other hsa-mir-222 Melanoma 28858076 KIT and mir-222 might be key genomic contributors toward the clinical differences observed +other hsa-mir-214 Sepsis 28858140 miRNA-214 Protects Sepsis-Induced Myocardial Injury. +other hsa-mir-223 Chronic Hepatitis C 28864162 "Treatment-Induced Viral Cure of Hepatitis C Virus-Infected Patients Involves a Dynamic Interplay among three Important Molecular Players in Lipid Homeostasis: Circulating microRNA (miR)-24, miR-223, and Proprotein Convertase Subtilisin/Kexin Type 9." +other hsa-mir-24 Chronic Hepatitis C 28864162 "Treatment-Induced Viral Cure of Hepatitis C Virus-Infected Patients Involves a Dynamic Interplay among three Important Molecular Players in Lipid Homeostasis: Circulating microRNA (miR)-24, miR-223, and Proprotein Convertase Subtilisin/Kexin Type 9." +other hsa-mir-31 Myocardial Infarction 28865712 MicroRNA-31 promotes adverse cardiac remodeling and dysfunction in ischemic heart disease. +other hsa-mir-29b Lung Neoplasms 28869603 "DNMT1 and KIT form a positive regulatory loop, in which ectopic DNMT1 expression increases, whereas targeted DNMT1 depletion abrogates KIT signaling cascade through Sp1/miR-29b network" +other hsa-mir-143 Infection [unspecific] 28870451 MicroRNA-based transcriptomic responses of Atlantic salmon during infection by the intracellular bacterium Piscirickettsia salmonis. +other hsa-mir-181 Infection [unspecific] 28870451 MicroRNA-based transcriptomic responses of Atlantic salmon during infection by the intracellular bacterium Piscirickettsia salmonis. +other hsa-mir-21 Infection [unspecific] 28870451 MicroRNA-based transcriptomic responses of Atlantic salmon during infection by the intracellular bacterium Piscirickettsia salmonis. +other hsa-mir-194 Rectum Adenocarcinoma 28870889 miR-194 as predictive biomarker of responsiveness to neoadjuvant chemoradiotherapy in patients with locally advanced rectal adenocarcinoma. +other hsa-mir-449a Colon Neoplasms 28878284 MicroRNA-449a deficiency promotes colon carcinogenesis. +other hsa-mir-494 Ischemic Diseases [unspecific] 28880896 Extract of Spatholobus suberctus Dunn ameliorates ischemia-induced injury by targeting miR-494. +other hsa-mir-200b Retinal Vascular Disease 28882646 Protective effect of miR-200b/c by inhibiting vasohibin-2 in human retinal microvascular endothelial cells. +other hsa-mir-200c Retinal Vascular Disease 28882646 Protective effect of miR-200b/c by inhibiting vasohibin-2 in human retinal microvascular endothelial cells. +other hsa-mir-146a Atherosclerosis 28882869 "EV-derived miRNAs from atherogenic macrophages, in particular miR-146a, may accelerate the development of atherosclerosis by decreasing cell migration and promoting macrophage entrapment in the vessel wall" +other hsa-mir-193b Liposarcoma 28882999 miR-193b-Regulated Signaling Networks Serve as Tumor Suppressors in Liposarcoma and Promote Adipogenesis in Adipose-Derived Stem Cells. +other hsa-mir-29 Alveolar Rhabdomyosarcoma 28883017 "the NF¦ÊB-YY1-miR-29 regulatory circuit is dysregulated, resulting in repression of miR-29 and loss of the associated tumor suppressor activity" +other hsa-mir-15a Heart Valve Disease 28888871 Interplay of mitochondria apoptosis regulatory factors and microRNAs in valvular heart disease. +other hsa-mir-29a Heart Valve Disease 28888871 Interplay of mitochondria apoptosis regulatory factors and microRNAs in valvular heart disease. +other hsa-mir-1 Myocardial Infarction 28894747 "regulatory effects on miR-1, miR-133, Cx43, and Cx45 might be a possible mechanism of WXKL in the treatment of MI at the gene level" +other hsa-mir-133 Myocardial Infarction 28894747 "regulatory effects on miR-1, miR-133, Cx43, and Cx45 might be a possible mechanism of WXKL in the treatment of MI at the gene level" +other hsa-mir-200b Colorectal Carcinoma 28899657 HIF-1¦Á/Ascl2/miR-200b regulatory feedback circuit modulated the epithelial-mesenchymal transition (EMT) in colorectal cancer cells. +other hsa-mir-17 Glioblastoma 28903422 The E2F1-regulated miR-17/92 cluster and its analogs are shown to be highly expressed in proneural GBM and in GSC lines +other hsa-mir-18 Glioblastoma 28903422 The E2F1-regulated miR-17/92 cluster and its analogs are shown to be highly expressed in proneural GBM and in GSC lines +other hsa-mir-19a Glioblastoma 28903422 The E2F1-regulated miR-17/92 cluster and its analogs are shown to be highly expressed in proneural GBM and in GSC lines +other hsa-mir-19b-1 Glioblastoma 28903422 The E2F1-regulated miR-17/92 cluster and its analogs are shown to be highly expressed in proneural GBM and in GSC lines +other hsa-mir-20a Glioblastoma 28903422 The E2F1-regulated miR-17/92 cluster and its analogs are shown to be highly expressed in proneural GBM and in GSC lines +other hsa-mir-92-1 Glioblastoma 28903422 The E2F1-regulated miR-17/92 cluster and its analogs are shown to be highly expressed in proneural GBM and in GSC lines +other hsa-mir-17 "Carcinoma, Hepatocellular" 28904393 MicroRNA pharmacogenomics based integrated model of miR-17-92 cluster in sorafenib resistant HCC cells reveals a strategy to forestall drug resistance. +other hsa-mir-18 "Carcinoma, Hepatocellular" 28904393 MicroRNA pharmacogenomics based integrated model of miR-17-92 cluster in sorafenib resistant HCC cells reveals a strategy to forestall drug resistance. +other hsa-mir-19a "Carcinoma, Hepatocellular" 28904393 MicroRNA pharmacogenomics based integrated model of miR-17-92 cluster in sorafenib resistant HCC cells reveals a strategy to forestall drug resistance. +other hsa-mir-19b-1 "Carcinoma, Hepatocellular" 28904393 MicroRNA pharmacogenomics based integrated model of miR-17-92 cluster in sorafenib resistant HCC cells reveals a strategy to forestall drug resistance. +other hsa-mir-20a "Carcinoma, Hepatocellular" 28904393 MicroRNA pharmacogenomics based integrated model of miR-17-92 cluster in sorafenib resistant HCC cells reveals a strategy to forestall drug resistance. +other hsa-mir-92-1 "Carcinoma, Hepatocellular" 28904393 MicroRNA pharmacogenomics based integrated model of miR-17-92 cluster in sorafenib resistant HCC cells reveals a strategy to forestall drug resistance. +other hsa-mir-155 Neoplasms [unspecific] 28912267 Antitumor immunity is defective in T cell-specific microRNA-155-deficient mice and is rescued by immune checkpoint blockade. +other hsa-mir-124 Alzheimer Disease 28912710 "A¦Â downregulated miR-155 and miR-124, and reduced the CD11b+ subpopulation in 2 DIV microglia" +other hsa-mir-155 Alzheimer Disease 28912710 "A¦Â downregulated miR-155 and miR-124, and reduced the CD11b+ subpopulation in 2 DIV microglia" +other hsa-mir-375 "Carcinoma, Hepatocellular" 28915706 The role of autophagy in hepatocellular carcinoma: friend or foe. +other hsa-mir-31 Mesothelioma 28918032 MicroRNA-31 Regulates Chemosensitivity in Malignant Pleural Mesothelioma. +other hsa-mir-146a Lymphoma 28918474 Induction of Immunogenic Cell Death in Lymphoma Cells by Wharton's Jelly Mesenchymal Stem Cell Conditioned Medium. +other hsa-mir-222 "Squamous Cell Carcinoma, Skin or Unspecific" 28925390 Alterations of microRNAs throughout the malignant evolution of cutaneous squamous cell carcinoma: the role of miR-497 in epithelial to mesenchymal transition of keratinocytes. +other hsa-mir-7 Colorectal Carcinoma 28929494 CRHR2/Ucn2 signaling is a novel regulator of miR-7/YY1/Fas circuitry contributing to reversal of colorectal cancer cell resistance to Fas-mediated apoptosis. +other hsa-mir-223 Lung Injury [unspecific] 28931657 Neutrophil transfer of miR-223 to lung epithelial cells dampens acute lung injury in mice. +other hsa-mir-335 Neoplasms [unspecific] 28932769 MicroRNA expression in a phosphaturic mesenchymal tumour. +other hsa-mir-143 Breast Neoplasms 28933584 Circular RNA hsa_circ_0001982 Promotes Breast Cancer Cell Carcinogenesis Through Decreasing miR-143. +other hsa-mir-181b Sepsis 28934717 the CCAAT enhancer-binding protein C/EBP¦Â activates microRNA (miR)-21 and miR-181b expressions +other hsa-mir-21 Sepsis 28934717 the CCAAT enhancer-binding protein C/EBP¦Â activates microRNA (miR)-21 and miR-181b expressions +other hsa-mir-221 Melanoma 28936555 Resveratrol suppresses melanoma by inhibiting NF-¦ÊB/miR-221 and inducing TFG expression. +other hsa-mir-125b Bladder Neoplasms 28938585 The trophoblast cell surface antigen 2 and miR-125b axis in urothelial bladder cancer. +other hsa-let-7d "Squamous Cell Carcinoma, Head and Neck" 28941018 "The available literature supports differential expression of both microRNAs and long non-coding RNAs, which include oncogenic ncRNAs (miR-21, miR-31, miR-155, miR-211, HOTAIR, and MALAT1) and tumor suppressor ncRNAs (let7d, miR-17, miR-375, miR-139, and MEG3) in HPV+ve HNSCC tumors as compared to HPV-ve tumors and they have distinct role in the pathophysiology of these two types of HNSCCs" +other hsa-mir-139 "Squamous Cell Carcinoma, Head and Neck" 28941018 "The available literature supports differential expression of both microRNAs and long non-coding RNAs, which include oncogenic ncRNAs (miR-21, miR-31, miR-155, miR-211, HOTAIR, and MALAT1) and tumor suppressor ncRNAs (let7d, miR-17, miR-375, miR-139, and MEG3) in HPV+ve HNSCC tumors as compared to HPV-ve tumors and they have distinct role in the pathophysiology of these two types of HNSCCs" +other hsa-mir-155 "Squamous Cell Carcinoma, Head and Neck" 28941018 "The available literature supports differential expression of both microRNAs and long non-coding RNAs, which include oncogenic ncRNAs (miR-21, miR-31, miR-155, miR-211, HOTAIR, and MALAT1) and tumor suppressor ncRNAs (let7d, miR-17, miR-375, miR-139, and MEG3) in HPV+ve HNSCC tumors as compared to HPV-ve tumors and they have distinct role in the pathophysiology of these two types of HNSCCs" +other hsa-mir-17 "Squamous Cell Carcinoma, Head and Neck" 28941018 "The available literature supports differential expression of both microRNAs and long non-coding RNAs, which include oncogenic ncRNAs (miR-21, miR-31, miR-155, miR-211, HOTAIR, and MALAT1) and tumor suppressor ncRNAs (let7d, miR-17, miR-375, miR-139, and MEG3) in HPV+ve HNSCC tumors as compared to HPV-ve tumors and they have distinct role in the pathophysiology of these two types of HNSCCs" +other hsa-mir-21 "Squamous Cell Carcinoma, Head and Neck" 28941018 "The available literature supports differential expression of both microRNAs and long non-coding RNAs, which include oncogenic ncRNAs (miR-21, miR-31, miR-155, miR-211, HOTAIR, and MALAT1) and tumor suppressor ncRNAs (let7d, miR-17, miR-375, miR-139, and MEG3) in HPV+ve HNSCC tumors as compared to HPV-ve tumors and they have distinct role in the pathophysiology of these two types of HNSCCs" +other hsa-mir-211 "Squamous Cell Carcinoma, Head and Neck" 28941018 "The available literature supports differential expression of both microRNAs and long non-coding RNAs, which include oncogenic ncRNAs (miR-21, miR-31, miR-155, miR-211, HOTAIR, and MALAT1) and tumor suppressor ncRNAs (let7d, miR-17, miR-375, miR-139, and MEG3) in HPV+ve HNSCC tumors as compared to HPV-ve tumors and they have distinct role in the pathophysiology of these two types of HNSCCs" +other hsa-mir-31 "Squamous Cell Carcinoma, Head and Neck" 28941018 "The available literature supports differential expression of both microRNAs and long non-coding RNAs, which include oncogenic ncRNAs (miR-21, miR-31, miR-155, miR-211, HOTAIR, and MALAT1) and tumor suppressor ncRNAs (let7d, miR-17, miR-375, miR-139, and MEG3) in HPV+ve HNSCC tumors as compared to HPV-ve tumors and they have distinct role in the pathophysiology of these two types of HNSCCs" +other hsa-mir-375 "Squamous Cell Carcinoma, Head and Neck" 28941018 "The available literature supports differential expression of both microRNAs and long non-coding RNAs, which include oncogenic ncRNAs (miR-21, miR-31, miR-155, miR-211, HOTAIR, and MALAT1) and tumor suppressor ncRNAs (let7d, miR-17, miR-375, miR-139, and MEG3) in HPV+ve HNSCC tumors as compared to HPV-ve tumors and they have distinct role in the pathophysiology of these two types of HNSCCs" +other hsa-mir-130a Coronary Artery Disease 28947970 Circular RNAs promote TRPM3 expression by inhibiting hsa-miR-130a-3p in coronary artery disease patients. +other hsa-mir-210 Myocardial Infarction 28948298 "MicroRNA-210-mediated proliferation, survival, and angiogenesis promote cardiac repair post myocardial infarction in rodents." +other hsa-mir-182 Glioma 28956430 The feasibility of the method for sensitive determination of miRNA-182 and miRNA-381 from serum samples of glioma patients at different stages was demonstrated +other hsa-mir-381 Glioma 28956430 The feasibility of the method for sensitive determination of miRNA-182 and miRNA-381 from serum samples of glioma patients at different stages was demonstrated +other hsa-mir-10a "Carcinoma, Hepatocellular" 28958640 "our data showed potential role of miR-10a, miR-30e, miR-215, miR-125b and miR-148a as important mediators in HCC progression" +other hsa-mir-125b "Carcinoma, Hepatocellular" 28958640 "our data showed potential role of miR-10a, miR-30e, miR-215, miR-125b and miR-148a as important mediators in HCC progression" +other hsa-mir-148a "Carcinoma, Hepatocellular" 28958640 "our data showed potential role of miR-10a, miR-30e, miR-215, miR-125b and miR-148a as important mediators in HCC progression" +other hsa-mir-215 "Carcinoma, Hepatocellular" 28958640 "our data showed potential role of miR-10a, miR-30e, miR-215, miR-125b and miR-148a as important mediators in HCC progression" +other hsa-mir-30e "Carcinoma, Hepatocellular" 28958640 "our data showed potential role of miR-10a, miR-30e, miR-215, miR-125b and miR-148a as important mediators in HCC progression" +other hsa-mir-138 "Squamous Cell Carcinoma, Oral" 28962163 "miR-138 is able to inhibit the proliferation, migration and invasion of OSCC cell lines" +other hsa-mir-675 Dental Enamel Hypoplasia 28963438 DLX3 promotes bone marrow mesenchymal stem cell proliferation through H19/miR-675 axis. +other hsa-mir-16 Lymphoma 28976967 A viral Sm-class RNA base-pairs with mRNAs and recruits microRNAs to inhibit apoptosis. +other hsa-mir-1224 Leukemia 28977780 a similar expression pattern of hsa-miR-1224-3p and hsa-miR-21 were observed in urine samples collected from human leukemia patients preconditioned with TBI +other hsa-mir-21 Leukemia 28977780 a similar expression pattern of hsa-miR-1224-3p and hsa-miR-21 were observed in urine samples collected from human leukemia patients preconditioned with TBI +other hsa-mir-30d Mesothelioma 28979837 miR-30d is related to asbestos exposure and inhibits migration and invasion in NCI-H2452 cells. +other hsa-mir-145 Myocardial Infarction 28980287 Inducible miR-145 expression by HIF-1a protects cardiomyocytes against apoptosis via regulating SGK1 in simulated myocardial infarction hypoxic microenvironment. +other hsa-mir-1 Cardiomegaly 28985746 Porcine model of progressive cardiac hypertrophy and fibrosis with secondary postcapillary pulmonary hypertension. +other hsa-mir-29a Cardiomegaly 28985746 Porcine model of progressive cardiac hypertrophy and fibrosis with secondary postcapillary pulmonary hypertension. +other hsa-mir-7 "Leukemia, Myeloid, Chronic" 28986256 MicroRNA-7 inhibits cell proliferation of chronic myeloid leukemia and sensitizes it to imatinib in?vitro. +other hsa-mir-433 Parkinson Disease 28986288 Linking down-regulation of miRNA-7 and miRNA-433 with ¦Á-synuclein overexpression and risk of idiopathic Parkinson's disease. +other hsa-mir-7 Parkinson Disease 28986288 Linking down-regulation of miRNA-7 and miRNA-433 with ¦Á-synuclein overexpression and risk of idiopathic Parkinson's disease. +other hsa-mir-146a Gastric Neoplasms 28987948 MiR-146a functions as a small silent player in gastric cancer. +other hsa-mir-10b Neoplasms [unspecific] 28989695 Simultaneous visualization of the subfemtomolar expression of microRNA and microRNA target gene using HILO microscopy. +other hsa-mir-21 Glioblastoma 29023168 Development and characterization of cationic solid lipid nanoparticles for co-delivery of pemetrexed and miR-21 antisense oligonucleotide to glioblastoma cells. +other hsa-mir-132 Heart Failure 29027324 Circulating microRNA-132 levels improve risk prediction for heart failure hospitalization in patients with chronic heart failure. +other hsa-mir-200c Neoplasms [unspecific] 29029445 MicroRNA-200c increases radiosensitivity of human cancer cells with activated EGFR-associated signaling. +other hsa-mir-192 "Diabetes Mellitus, Type 2" 29040025 "Lower concentrations of miR-192 and miR-375 were also found, which correlated positively with HOMA-IR" +other hsa-mir-375 "Diabetes Mellitus, Type 2" 29040025 "Lower concentrations of miR-192 and miR-375 were also found, which correlated positively with HOMA-IR" +other hsa-mir-181a Melanoma 29041990 Piceatannol induced apoptosis through up-regulation of microRNA-181a in melanoma cells. +other hsa-mir-326 Multiple Sclerosis 29043654 "Evaluation of Selected MicroRNAs Expression in Remission Phase of Multiple Sclerosis and Their Potential Link to Cognition, Depression, and Disability." +other hsa-mir-181b Cystic Fibrosis 29044225 microRNA-181b is increased in cystic fibrosis cells and impairs lipoxin A4 receptor-dependent mechanisms of inflammation resolution and antimicrobial defense. +other hsa-mir-27b Brain Disease [unspecific] 29050310 MicroRNA-27b inhibition promotes Nrf2/ARE pathway activation and alleviates intracerebral hemorrhage-induced brain injury +other hsa-mir-206 Myocardial Infarction 29055786 Carbon monoxide releasing molecule improves structural and functional cardiac recovery after myocardial injury. +other hsa-mir-155 "Carcinoma, Renal Cell" 29056573 Noncoding RNA Expression and Targeted Next-Generation Sequencing Distinguish Tubulocystic Renal Cell Carcinoma (TC-RCC) from Other Renal Neoplasms. +other hsa-mir-21 Melanoma 29058784 MicroRNA-21 antisense oligonucleotide improves the sensitivity of A375 human melanoma cell to Cisplatin +other hsa-mir-30a "Carcinoma, Hepatocellular" 29061507 MicroRNA-30a suppresses autophagy-mediated anoikis resistance and metastasis in hepatocellular carcinoma. +other hsa-mir-22 Myocardial Infarction 29063105 miR-22 plays critical roles in MI and subsequent cardiac remodeling +other hsa-mir-375 Colorectal Carcinoma 29068474 The PI3K/AKT signaling pathway: Associations of miRNAs with dysregulated gene expression in colorectal cancer. +other hsa-let-7i Infection [unspecific] 29069656 Cyclosporine A Induces MicroRNAs Controlling Innate Immunity during Renal Bacterial Infection. +other hsa-mir-148a Ovarian Neoplasms 29069830 "The selected signature composed by VAT1L, CALR, LINC01456, RP11-484L8.1, MIR196A1 and MIR148A, separated the training group patients into high-risk or low-risk subgroup with significantly different survival time" +other hsa-mir-196a-1 Ovarian Neoplasms 29069830 "The selected signature composed by VAT1L, CALR, LINC01456, RP11-484L8.1, MIR196A1 and MIR148A, separated the training group patients into high-risk or low-risk subgroup with significantly different survival time" +other hsa-mir-21 "Carcinoma, Renal Cell" 29070781 Cordycepin induces apoptotic cell death and inhibits cell migration in renal cell carcinoma via regulation of microRNA-21 and PTEN phosphatase. +other hsa-mir-124 Neuroblastoma 29073265 MiRNA-124 is a link between measles virus persistent infection and cell division of human neuroblastoma cells. +other hsa-mir-9 "Squamous Cell Carcinoma, Oral" 29073835 miR-9 induces cell arrest and apoptosis of oral squamous cell carcinoma via CDK 4/6 pathway. +other hsa-mir-155 Neuroinflammation 29079998 Role of 3-Acetyl-11-Keto-Beta-Boswellic Acid in Counteracting LPS-Induced Neuroinflammation via Modulation of miRNA-155. +other hsa-mir-378 Glioblastoma 29081036 MicroRNA-378 enhances radiation response in ectopic and orthotopic implantation models of glioblastoma. +other hsa-mir-122 Chronic Hepatitis C 29084265 miRNA independent hepacivirus variants suggest a strong evolutionary pressure to maintain miR-122 dependence. +other hsa-mir-15a Laryngeal Neoplasms 29085504 "Curcumin inhibits cell proliferation and promotes apoptosis of laryngeal cancer cells through Bcl-2 and PI3K/Akt, and by upregulating miR-15a." +other hsa-mir-29b Brain Disease [unspecific] 29087603 MiR-29b expression is associated with a dexmedetomidine-mediated protective effect against oxygen-glucose deprivation-induced injury to SK-N-SH cells in vitro. +other hsa-mir-138 "Squamous Cell Carcinoma, Oral" 29088820 "Knockdown of fascin in OSCC cells promoted cell adhesion and inhibited migration, invasion and EMT, and forced expression of miR-138 in OSCC cells significantly decreased the expression of fascin" +other hsa-mir-21 Liver Neoplasms 29091291 Genetic and pharmacologic manipulation of miR-21 does not inhibit the development of liver fibrosis and liver cancer +other hsa-mir-1 Myocardial Infarction 29094045 Effect of Wenxin Granules on Gap Junction and MiR-1 in Rats with Myocardial Infarction. +other hsa-mir-140 Osteoarthritis 29095952 Computer simulation models as a tool to investigate the role of microRNAs in osteoarthritis. +other hsa-mir-222 Gastric Neoplasms 29098549 The GAS5/miR-222 Axis Regulates Proliferation of Gastric Cancer Cells Through the PTEN/Akt/mTOR Pathway. +other hsa-mir-24 Breast Neoplasms 29103019 Propofol induces apoptosis of breast cancer cells by downregulation of miR-24 signal pathway. +other hsa-mir-155 Allergic Asthma 29104649 Small interfering RNA directed against microRNA-155 delivered by a lentiviral vector attenuates asthmatic features in a mouse model of allergic asthma. +other hsa-mir-34a "Carcinoma, Renal Cell" 29104726 MicroRNA-34a: A Key Regulator in the Hallmarks of Renal Cell Carcinoma. +other hsa-mir-676 Hypohidrotic Ectodermal Dysplasia 29106399 A microRNA screen reveals that elevated hepatic ectodysplasin A expression contributes to obesity-induced insulin resistance in skeletal muscle. +other hsa-mir-132 Salivary Gland Neoplasms 29108921 "miR-17, miR-132, miR-195 and miR-221 seem to play an important role as tumor suppressor in salivary gland tumors" +other hsa-mir-17 Salivary Gland Neoplasms 29108921 "miR-17, miR-132, miR-195 and miR-221 seem to play an important role as tumor suppressor in salivary gland tumors" +other hsa-mir-195 Salivary Gland Neoplasms 29108921 "miR-17, miR-132, miR-195 and miR-221 seem to play an important role as tumor suppressor in salivary gland tumors" +other hsa-mir-221 Salivary Gland Neoplasms 29108921 "miR-17, miR-132, miR-195 and miR-221 seem to play an important role as tumor suppressor in salivary gland tumors" +other hsa-mir-210 Stroke 29111308 Inhibition of microRNA-210 suppresses pro-inflammatory response and reduces acute brain injury of ischemic stroke in mice. +other hsa-mir-10a Breast Neoplasms 29113237 MicroRNA-10a suppresses breast cancer progression via PI3K/Akt/mTOR pathway. +other hsa-mir-1 Heart Failure 29117535 Rescuing infusion of miRNA-1 prevents cardiac remodeling in a heart-selective miRNA deficient mouse. +other hsa-mir-17 Allergy 29122948 MicroRNA regulation of type 2 innate lymphoid cell homeostasis and function in allergic inflammation. +other hsa-mir-34a "Carcinoma, Hepatocellular" 29128099 Regulation of Cellular Senescence by miR-34a in Alcoholic Liver Injury. +other hsa-mir-214 Gastric Neoplasms 29129783 Hypoxia-induced miR-214 expression promotes tumour cell proliferation and migration by enhancing the Warburg effect in gastric carcinoma cells. +other hsa-mir-16 "Carcinoma, Hepatocellular" 29136911 "microRNA-155 expression, essential in NK cell activation, was elevated in Foxo3-/- NK cells while its inhibition led to diminished IFN¦Ã production" +other hsa-mir-145 "Adenocarcinoma, Pancreatic Ductal" 29137251 Exportin 1 (XPO1) inhibition leads to restoration of tumor suppressor miR-145 and consequent suppression of pancreatic cancer cell proliferation and migration. +other hsa-mir-146a Status Epilepticus 29144992 Intracerebroventricular injection of miR-146a relieves seizures in an immature rat model of lithium-pilocarpine induced status epilepticus. +other hsa-mir-223 Hepatitis [unspecific] 29145157 BMSCs-derived miR-223-containing exosomes contribute to liver protection in experimental autoimmune hepatitis +other hsa-mir-21 Salivary Gland Disease 29154818 MicroRNA-21 promotes wound healing via the Smad7-Smad2/3-Elastin pathway. +other hsa-mir-221 Leukemia 29156756 "Increasing knowledge of biological changes, due to altered miRNA dynamics, is expected to have relevant translational implications for leukemia detection and treatment" +other hsa-mir-20a "Lymphoma, Large B-Cell, Diffuse" 29156774 MicroRNAs as predictors for CNS relapse of systemic diffuse large B-cell lymphoma +other hsa-mir-21 Multiple Myeloma 29158801 Gambogenic Acid Exerts Antitumor Activity in Hypoxic Multiple Myeloma Cells by Regulation of miR-21 +other hsa-mir-503 Bladder Neoplasms 29169421 miR-503-5p inhibits the proliferation of T24 and EJ bladder cancer cells by interfering with the Rb/E2F signaling pathway +other hsa-let-7b Alzheimer Disease 29170128 let-7b has an important association with the pathology of AD and can be used as an adjunct to improve the diagnostic performance of traditional AD biomarkers +other hsa-mir-21 Ischemia-Reperfusion Injury 29170412 Ischemic Postconditioning Protects Against Intestinal Ischemia/Reperfusion Injury via the HIF-1¦Á/miR-21 Axis +other hsa-mir-146a Human Papilloma Virus Infection 29181576 "HPV16 induces the overexpression of miR-146a in the initial stages of carcinogenesis (hyperplasia and dysplasia), whereas decreases its expression at later stages (CIS)" +other hsa-mir-21 Gastric Neoplasms 29185784 miR-21 Inhibitors Modulate Biological Functions of Gastric Cancer Cells via PTEN/PI3K/mTOR Pathway +other hsa-mir-21 Ischemia-Reperfusion Injury 29187695 the activation of the Akt pathway regulated by miR-21 participates in the protective effects of H2S against I/R-induced liver injury +other hsa-mir-133a Asthma 29191361 "The relative expression of miRNA-133a increased in the low-dose anti-IgE, high-dose anti-IgE, fluticasone+anti-IgE and anti-TNF groups" +other hsa-mir-106b Multiple Sclerosis 29194612 "our data revealed that the expression of a number of microRNAs including miR-16, miR-17-92, miR-27, miR-29b, miR-126, miR-128, miR-132, miR-155, miR-326, miR-550, miR-15a, miR-19b, miR-106b, miR-320a, miR-363, miR-31, miR-150, and miR-340 is regulated by nanocurcumin" +other hsa-mir-126 Multiple Sclerosis 29194612 "our data revealed that the expression of a number of microRNAs including miR-16, miR-17-92, miR-27, miR-29b, miR-126, miR-128, miR-132, miR-155, miR-326, miR-550, miR-15a, miR-19b, miR-106b, miR-320a, miR-363, miR-31, miR-150, and miR-340 is regulated by nanocurcumin" +other hsa-mir-128 Multiple Sclerosis 29194612 "our data revealed that the expression of a number of microRNAs including miR-16, miR-17-92, miR-27, miR-29b, miR-126, miR-128, miR-132, miR-155, miR-326, miR-550, miR-15a, miR-19b, miR-106b, miR-320a, miR-363, miR-31, miR-150, and miR-340 is regulated by nanocurcumin" +other hsa-mir-132 Multiple Sclerosis 29194612 "our data revealed that the expression of a number of microRNAs including miR-16, miR-17-92, miR-27, miR-29b, miR-126, miR-128, miR-132, miR-155, miR-326, miR-550, miR-15a, miR-19b, miR-106b, miR-320a, miR-363, miR-31, miR-150, and miR-340 is regulated by nanocurcumin" +other hsa-mir-150 Multiple Sclerosis 29194612 "our data revealed that the expression of a number of microRNAs including miR-16, miR-17-92, miR-27, miR-29b, miR-126, miR-128, miR-132, miR-155, miR-326, miR-550, miR-15a, miR-19b, miR-106b, miR-320a, miR-363, miR-31, miR-150, and miR-340 is regulated by nanocurcumin" +other hsa-mir-155 Multiple Sclerosis 29194612 "our data revealed that the expression of a number of microRNAs including miR-16, miR-17-92, miR-27, miR-29b, miR-126, miR-128, miR-132, miR-155, miR-326, miR-550, miR-15a, miR-19b, miR-106b, miR-320a, miR-363, miR-31, miR-150, and miR-340 is regulated by nanocurcumin" +other hsa-mir-15a Multiple Sclerosis 29194612 "our data revealed that the expression of a number of microRNAs including miR-16, miR-17-92, miR-27, miR-29b, miR-126, miR-128, miR-132, miR-155, miR-326, miR-550, miR-15a, miR-19b, miR-106b, miR-320a, miR-363, miR-31, miR-150, and miR-340 is regulated by nanocurcumin" +other hsa-mir-16 Multiple Sclerosis 29194612 "our data revealed that the expression of a number of microRNAs including miR-16, miR-17-92, miR-27, miR-29b, miR-126, miR-128, miR-132, miR-155, miR-326, miR-550, miR-15a, miR-19b, miR-106b, miR-320a, miR-363, miR-31, miR-150, and miR-340 is regulated by nanocurcumin" +other hsa-mir-17 Multiple Sclerosis 29194612 "our data revealed that the expression of a number of microRNAs including miR-16, miR-17-92, miR-27, miR-29b, miR-126, miR-128, miR-132, miR-155, miR-326, miR-550, miR-15a, miR-19b, miR-106b, miR-320a, miR-363, miR-31, miR-150, and miR-340 is regulated by nanocurcumin" +other hsa-mir-18 Multiple Sclerosis 29194612 "our data revealed that the expression of a number of microRNAs including miR-16, miR-17-92, miR-27, miR-29b, miR-126, miR-128, miR-132, miR-155, miR-326, miR-550, miR-15a, miR-19b, miR-106b, miR-320a, miR-363, miR-31, miR-150, and miR-340 is regulated by nanocurcumin" +other hsa-mir-19a Multiple Sclerosis 29194612 "our data revealed that the expression of a number of microRNAs including miR-16, miR-17-92, miR-27, miR-29b, miR-126, miR-128, miR-132, miR-155, miR-326, miR-550, miR-15a, miR-19b, miR-106b, miR-320a, miR-363, miR-31, miR-150, and miR-340 is regulated by nanocurcumin" +other hsa-mir-19b Multiple Sclerosis 29194612 "our data revealed that the expression of a number of microRNAs including miR-16, miR-17-92, miR-27, miR-29b, miR-126, miR-128, miR-132, miR-155, miR-326, miR-550, miR-15a, miR-19b, miR-106b, miR-320a, miR-363, miR-31, miR-150, and miR-340 is regulated by nanocurcumin" +other hsa-mir-19b-1 Multiple Sclerosis 29194612 "our data revealed that the expression of a number of microRNAs including miR-16, miR-17-92, miR-27, miR-29b, miR-126, miR-128, miR-132, miR-155, miR-326, miR-550, miR-15a, miR-19b, miR-106b, miR-320a, miR-363, miR-31, miR-150, and miR-340 is regulated by nanocurcumin" +other hsa-mir-20a Multiple Sclerosis 29194612 "our data revealed that the expression of a number of microRNAs including miR-16, miR-17-92, miR-27, miR-29b, miR-126, miR-128, miR-132, miR-155, miR-326, miR-550, miR-15a, miR-19b, miR-106b, miR-320a, miR-363, miR-31, miR-150, and miR-340 is regulated by nanocurcumin" +other hsa-mir-27 Multiple Sclerosis 29194612 "our data revealed that the expression of a number of microRNAs including miR-16, miR-17-92, miR-27, miR-29b, miR-126, miR-128, miR-132, miR-155, miR-326, miR-550, miR-15a, miR-19b, miR-106b, miR-320a, miR-363, miR-31, miR-150, and miR-340 is regulated by nanocurcumin" +other hsa-mir-29b Multiple Sclerosis 29194612 "our data revealed that the expression of a number of microRNAs including miR-16, miR-17-92, miR-27, miR-29b, miR-126, miR-128, miR-132, miR-155, miR-326, miR-550, miR-15a, miR-19b, miR-106b, miR-320a, miR-363, miR-31, miR-150, and miR-340 is regulated by nanocurcumin" +other hsa-mir-31 Multiple Sclerosis 29194612 "our data revealed that the expression of a number of microRNAs including miR-16, miR-17-92, miR-27, miR-29b, miR-126, miR-128, miR-132, miR-155, miR-326, miR-550, miR-15a, miR-19b, miR-106b, miR-320a, miR-363, miR-31, miR-150, and miR-340 is regulated by nanocurcumin" +other hsa-mir-320a Multiple Sclerosis 29194612 "our data revealed that the expression of a number of microRNAs including miR-16, miR-17-92, miR-27, miR-29b, miR-126, miR-128, miR-132, miR-155, miR-326, miR-550, miR-15a, miR-19b, miR-106b, miR-320a, miR-363, miR-31, miR-150, and miR-340 is regulated by nanocurcumin" +other hsa-mir-326 Multiple Sclerosis 29194612 "our data revealed that the expression of a number of microRNAs including miR-16, miR-17-92, miR-27, miR-29b, miR-126, miR-128, miR-132, miR-155, miR-326, miR-550, miR-15a, miR-19b, miR-106b, miR-320a, miR-363, miR-31, miR-150, and miR-340 is regulated by nanocurcumin" +other hsa-mir-340 Multiple Sclerosis 29194612 "our data revealed that the expression of a number of microRNAs including miR-16, miR-17-92, miR-27, miR-29b, miR-126, miR-128, miR-132, miR-155, miR-326, miR-550, miR-15a, miR-19b, miR-106b, miR-320a, miR-363, miR-31, miR-150, and miR-340 is regulated by nanocurcumin" +other hsa-mir-363 Multiple Sclerosis 29194612 "our data revealed that the expression of a number of microRNAs including miR-16, miR-17-92, miR-27, miR-29b, miR-126, miR-128, miR-132, miR-155, miR-326, miR-550, miR-15a, miR-19b, miR-106b, miR-320a, miR-363, miR-31, miR-150, and miR-340 is regulated by nanocurcumin" +other hsa-mir-550 Multiple Sclerosis 29194612 "our data revealed that the expression of a number of microRNAs including miR-16, miR-17-92, miR-27, miR-29b, miR-126, miR-128, miR-132, miR-155, miR-326, miR-550, miR-15a, miR-19b, miR-106b, miR-320a, miR-363, miR-31, miR-150, and miR-340 is regulated by nanocurcumin" +other hsa-mir-92-1 Multiple Sclerosis 29194612 "our data revealed that the expression of a number of microRNAs including miR-16, miR-17-92, miR-27, miR-29b, miR-126, miR-128, miR-132, miR-155, miR-326, miR-550, miR-15a, miR-19b, miR-106b, miR-320a, miR-363, miR-31, miR-150, and miR-340 is regulated by nanocurcumin" +other hsa-mir-204 Hypertension 29196166 "1,25(OH)2D3 was a promising therapeutic modality for treatment of PAH, function of which was exerted through miR-204 mediated Tgfbr2 signaling" +other hsa-mir-1273g Diabetic Retinopathy 29197896 miRNA-1273g-3p Involvement in Development of Diabetic Retinopathy by Modulating the Autophagy-Lysosome Pathway. +other hsa-mir-126 Atherosclerosis 29203244 MicroRNA-126 alleviates endothelial cells injury in atherosclerosis by restoring autophagic flux via inhibiting of PI3K/Akt/mTOR pathway +other hsa-mir-15b Alzheimer Disease 29207665 miR-15b play an important role in the cellular AD phenotype and might be involved in the pathogenesis of AD +other hsa-mir-211 Cone Dystrophy 29209045 MiR-211 is essential for adult cone photoreceptor maintenance and visual function. +other hsa-mir-1 Myocardial Infarction 29212255 "Soluble epoxide hydrolase inhibitors, t-AUCB, regulated microRNA-1 and its target genes in myocardial infarction mice" +other hsa-mir-155 Breast Neoplasms 29214365 "Profiling differential microRNA expression between in situ, infiltrative and lympho-vascular space invasive breast cancer: a pilot study" +other hsa-mir-10a Alzheimer Disease 29215712 miR-10a restrains synapse remodeling and neuronal cell proliferation while promoting apoptosis in AD rats via inhibiting BDNF-TrkB signaling pathway +other hsa-mir-193a Prostate Neoplasms 29216925 Silencing of miR-193a-5p increases the chemosensitivity of prostate cancer cells to docetaxel. +other hsa-mir-29a Neoplasms [unspecific] 29217524 "we discussed the functions of miR-29a and its potential application in the diagnosis, treatment and stages of carcinoma, which could provide additional insight to develop a novel therapeutic strategy" +other hsa-mir-124 Stroke 29221142 D-4F increases microRNA-124a and reduces neuroinflammation in diabetic stroke rats +other hsa-mir-130a Colon Neoplasms 29225578 Curcumin Suppresses the Colon Cancer Proliferation by Inhibiting Wnt/¦Â-Catenin Pathways via miR-130a +other hsa-mir-34a Breast Neoplasms 29226432 the intracellular function of miR-34a delivered by the nanocomplex to upregulate active Caspase-3 was imaged in real-time +other hsa-mir-155 Lymphoma 29228427 MiR-155 regulates lymphoma cell proliferation and apoptosis through targeting SOCS3/JAK-STAT3 signaling pathway +other hsa-mir-204 Prostate Neoplasms 29228612 MiR-204 enhances mitochondrial apoptosis in doxorubicin-treated prostate cancer cells by targeting SIRT1/p53 pathway +other hsa-mir-21 Liver Injury 29229992 miRNA-21 ablation protects against liver injury and necroptosis in cholestasis +other hsa-mir-128 Asthma 29231896 Downregulated miR-128 and miR-744 supports a Th2/Th17 type immune response in severe equine asthma +other hsa-mir-744 Asthma 29231896 Downregulated miR-128 and miR-744 supports a Th2/Th17 type immune response in severe equine asthma +other hsa-mir-126 Ischemia 29242072 Therapeutic angiogenesis by local sustained release of microRNA-126 using poly lactic-co-glycolic acid nanoparticles in murine hindlimb ischemia +other hsa-mir-27b Endometriosis 29247225 "Rg3 effectively altered fibrotic properties of HESCs from patients with endometriosis, which is likely associated with miR-27b-3p modulation" +other hsa-mir-124 "Carcinoma, Pancreatic" 29255366 circRNA_100782 regulates BxPC3 cell proliferation by acting as miR-124 sponge through the IL6-STAT3 pathway +other hsa-mir-30a "Squamous Cell Carcinoma, Esophageal" 29259372 Down-regulation of miR-30a-3p/5p promotes esophageal squamous cell carcinoma cell proliferation by activating the Wnt signaling pathway +other hsa-mir-144 Melanoma 29260980 Baohuoside-I suppresses cell proliferation and migration by up-regulating miR-144 in melanoma +other hsa-mir-155 Crohn Disease 29263823 a small subset had inflammatory responses almost comparable to wild-type patients on both gene and miR-155 regulatory levels +other hsa-mir-145 "Carcinoma, Lung, Non-Small-Cell" 29266356 Effect of microRNA-145 on proliferation and apoptosis of human non-small cell lung cancer A549 cells by regulating mTOR signaling pathway +other hsa-mir-320 IgA Nephropathy 29266359 MiR-320 promotes B cell proliferation and the production of aberrant glycosylated IgA1 in IgA nephropathy. +other hsa-mir-146a "Squamous Cell Carcinoma, Oral" 29269299 the activation of TLR2 by bacterial components can enhance the progression of OSCC and may be implicated in acquired resistance to cisplatin-induced apoptosis through regulation of the miR-146a pathway +other hsa-mir-144 Anemia 29269522 miR-144/451 represses the LKB1/AMPK/mTOR pathway to promote red cell precursor survival during recovery from acute anemia +other hsa-mir-221 Prostate Neoplasms 29281088 "Combining radiation dose parameters with microRNA expression in PBLs may be useful for predicting acute gastrointestinal toxicity of radiation therapy, thus contributing to personalized treatment of prostate cancer" +other hsa-mir-21 Allergic Contact Dermatitis 29282578 "MicroRNA-21-Mediated Inhibition of Mast Cell Degranulation Involved in the Protective Effect of Berberine on 2,4-Dinitrofluorobenzene-Induced Allergic Contact Dermatitis in Rats via p38 Pathway" +other hsa-mir-503 Diabetes Mellitus 29285014 microRNA-503 contribute to pancreatic beta cell dysfunction by targeting the mTOR pathway in gestational diabetes mellitus +other hsa-mir-106b Cholangiocarcinoma 29286255 miR-106b-responsive gene landscape identifies regulation of Kruppel-like factor family +other hsa-mir-214 "Adenocarcinoma, Lung" 29288987 Machine Learning Based Prediction of Brain Metastasis of Patients with IIIA-N2 Lung Adenocarcinoma by a Three-miRNA Signature +other hsa-mir-146a Osteoarthritis 29292727 the modification of miR-146a and miR-34a in OA chondrocytes subjected to H2O2 stimulus and we confirmed the antioxidant effect of taurine +other hsa-mir-34a Osteoarthritis 29292727 the modification of miR-146a and miR-34a in OA chondrocytes subjected to H2O2 stimulus and we confirmed the antioxidant effect of taurine +other hsa-mir-34a Pancreatic Neoplasms 29295989 Amphiphilic nanocarrier-induced modulation of PLK1 and miR-34a leads to improved therapeutic response in pancreatic cancer +other hsa-mir-21 Neurilemmoma 29298734 Ailanthone promotes human vestibular schwannoma cells apoptosis and autophagy by down-regulation of miR-21 +other hsa-mir-16 Coronary Artery Disease 29306454 "HDLs are depleted of miR-16, miR-92a and miR-223 during the transcoronary passage in patients with ACS compared to patients with stable CAD" +other hsa-mir-223 Coronary Artery Disease 29306454 "HDLs are depleted of miR-16, miR-92a and miR-223 during the transcoronary passage in patients with ACS compared to patients with stable CAD" +other hsa-mir-92a Coronary Artery Disease 29306454 "HDLs are depleted of miR-16, miR-92a and miR-223 during the transcoronary passage in patients with ACS compared to patients with stable CAD" +other hsa-mir-21 Multiple Myeloma 29320977 Ibrutinib targets microRNA-21 in multiple myeloma cells by inhibiting NF-¦ÊB and STAT3 +other hsa-mir-212 Prostate Neoplasms 29321092 MicroRNA-212 Targets Mitogen-Activated Protein Kinase 1 to Inhibit Proliferation and Invasion of Prostate Cancer Cells. +other hsa-mir-130a Hepatitis C Virus Infection 29321333 MicroRNA 130a Regulates both Hepatitis C Virus and Hepatitis B Virus Replication through a Central Metabolic Pathway. +other hsa-mir-15a Mitochondrial Metabolism Disease 29322081 Data of expression status of miR-29a and its putative target mitochondrial apoptosis regulatory gene DRP1 upon miR-15a and miR-214 inhibition +other hsa-mir-214 Mitochondrial Metabolism Disease 29322081 Data of expression status of miR-29a and its putative target mitochondrial apoptosis regulatory gene DRP1 upon miR-15a and miR-214 inhibition +other hsa-mir-221 "Carcinoma, Hepatocellular" 29322790 miR-221 and miR-222 might affect the pathogenesis of HCC +other hsa-mir-222 "Carcinoma, Hepatocellular" 29322790 miR-221 and miR-223 might affect the pathogenesis of HCC +other hsa-mir-1 Myocardial Infarction 29324314 "up-regulation of miR-1 and miR-208 in remote myocardium might play a role in cardiac remodeling after MI, at least to certain degree" +other hsa-mir-208 Myocardial Infarction 29324314 "up-regulation of miR-1 and miR-208 in remote myocardium might play a role in cardiac remodeling after MI, at least to certain degree" +other hsa-mir-181b "Adenocarcinoma, Lung" 29324442 ZEB1 initiates a miR-181b-regulated ceRNA network to drive metastasis +other hsa-mir-184 Age-Related Macular Degeneration 29325388 "miR-184 plays crucial regulatory roles in several ocular diseases, such as neovascularization, keratoconus, endothelial dystrophy, iris hypoplasia, congenital cataract, stromal thinning syndrome, corneal squamous cell carcinoma, age-related macular degeneration and cataract" +other hsa-mir-184 Cataract 29325388 "miR-184 plays crucial regulatory roles in several ocular diseases, such as neovascularization, keratoconus, endothelial dystrophy, iris hypoplasia, congenital cataract, stromal thinning syndrome, corneal squamous cell carcinoma, age-related macular degeneration and cataract" +other hsa-mir-184 Cornea Squamous Cell Carcinoma 29325388 "miR-184 plays crucial regulatory roles in several ocular diseases, such as neovascularization, keratoconus, endothelial dystrophy, iris hypoplasia, congenital cataract, stromal thinning syndrome, corneal squamous cell carcinoma, age-related macular degeneration and cataract" +other hsa-mir-122 Chronic Hepatitis C 29327233 DCAF1 is involved in HCV replication through regulation of miR-122 and thus provides new insights into the interaction between HCV and the host cell +other hsa-mir-203 "Carcinoma, Endometrial" 29331043 Role of miR-203 in estrogen receptor-mediated signaling in the rat uterus and endometrial carcinoma +other hsa-mir-146a Multiple Myeloma 29333170 Multiple Myeloma-Derived Exosomes Regulate the Functions of Mesenchymal Stem Cells Partially via Modulating miR-21 and miR-146a +other hsa-mir-21 Multiple Myeloma 29333170 Multiple Myeloma-Derived Exosomes Regulate the Functions of Mesenchymal Stem Cells Partially via Modulating miR-21 and miR-146a +other hsa-mir-466 Colorectal Carcinoma 29338680 MicroRNA-466 (miR-466) functions as a tumor suppressor and prognostic factor in colorectal cancer (CRC). +other hsa-mir-122 Chronic Hepatitis C 29343570 the 5'-proximal EHcV-specific region enhances viral replication and RNA stability in a miR-122-independent manner +other hsa-mir-16 "Carcinoma, Hepatocellular" 29344256 Pien Tze Huang inhibits the growth of hepatocellular carcinoma cells by upregulating miR-16 expression +other hsa-mir-155 Hepatitis B Virus Infection 29349567 HBeAg induces the expression of macrophage miR-155 to accelerate liver injury via promoting production of inflammatory cytokines. +other hsa-mir-17 Glioma 29351283 "The reduced miR-17 levels in glioma cells increased cell viability and migration, which correlates with increased expression of Cyclin D1, p-Akt and Akt" +other hsa-mir-125b Inflammation 29354323 "Up-Regulation of the Pro-Inflammatory Cytokines IL-6 and TNF¦Á, C-Reactive Protein (CRP) and miRNA-146a in Blood Serum" +other hsa-mir-146b Sciatic Nerve Injury 29356943 Inhibition of KLF7-Targeting MicroRNA 146b Promotes Sciatic Nerve Regeneration. +other hsa-mir-193a Wilms Tumor 29357419 Modulation of apolipoprotein L1-microRNA-193a axis prevents podocyte dedifferentiation in high-glucose milieu. +other hsa-mir-143 Colon Neoplasms 29360852 miR-143 might circumvent resistance of colon cancer cells to oxaliplatin via increased oxidative stress in HCT116 human colon cancer cells +other hsa-mir-145 "Carcinoma, Colon" 29360852 We show that approximately 100 proteins are differentially expressed in HCT116 human colon cancer cells stably transduced with miR-143 or miR-145 compared to Empty control cells +other hsa-mir-18a Hypoxia 29363860 ACE-EPCs-EXs have better protective effects on H/R injury in ageing ECs which could be through their carried miR-18a and subsequently down-regulating the Nox2/ROS pathway +other hsa-mir-31 Prostate Neoplasms 29364469 Estramustine phosphate induces prostate cancer cell line PC3 apoptosis by down-regulating miR-31 levels +other hsa-mir-155 Neoplasms [unspecific] 29366836 Increased miR-155 expression was associated with poorer survival in human carcinoma and as such may be valuable in predicting outcome +other hsa-mir-31 "Adenocarcinoma, Lung" 29367106 down-regulation of MIR31HG had no effect on the expression of miR-31 in lung adenocarcinoma cells +other hsa-mir-221 Alveolar Rhabdomyosarcoma 29367756 PAX3-FOXO1 drives miR-486-5p and represses miR-221 contributing to pathogenesis of alveolar rhabdomyosarcoma. +other hsa-mir-486 Alveolar Rhabdomyosarcoma 29367756 PAX3-FOXO1 drives miR-486-5p and represses miR-221 contributing to pathogenesis of alveolar rhabdomyosarcoma. +other hsa-mir-372 Neoplasms [unspecific] 29374231 Modulation of oncogenic miRNA biogenesis using functionalized polyamines +other hsa-mir-31 Medulloblastoma 29377269 Ginsenoside Rh2 inhibits proliferation and migration of medulloblastoma Daoy by down-regulation of microRNA-31 +other hsa-mir-124 Pediatric Ependymoma 29383182 "The tumor suppressor, hsa-miR-124, was down regulated in pediatric SEPN and it normally represses genes involved in cell-cell communication and metabolic processes" +other hsa-mir-17 Bladder Neoplasms 29386015 "Circular RNA circ-ITCH inhibits bladder cancer progression by sponging miR-17/miR-224 and regulating p21, PTEN expression" +other hsa-mir-224 Bladder Neoplasms 29386015 "Circular RNA circ-ITCH inhibits bladder cancer progression by sponging miR-17/miR-224 and regulating p21, PTEN expression" +other hsa-mir-224 "Carcinoma, Lung, Non-Small-Cell" 29387235 "Predictive relevance of miR-34a, miR-224 and miR-342 in patients with advanced squamous cell carcinoma of the lung undergoing palliative chemotherapy" +other hsa-mir-342 "Carcinoma, Lung, Non-Small-Cell" 29387235 "Predictive relevance of miR-34a, miR-224 and miR-342 in patients with advanced squamous cell carcinoma of the lung undergoing palliative chemotherapy" +other hsa-mir-34a "Carcinoma, Lung, Non-Small-Cell" 29387235 "Predictive relevance of miR-34a, miR-224 and miR-342 in patients with advanced squamous cell carcinoma of the lung undergoing palliative chemotherapy" +other hsa-mir-23a Neoplasms [unspecific] 29387410 the miR-23a/24-2/27a cluster may be a useful marker for predicting cancer prognosis and tumor progression +other hsa-mir-24-2 Neoplasms [unspecific] 29387410 the miR-23a/24-2/27a cluster may be a useful marker for predicting cancer prognosis and tumor progression +other hsa-mir-27a Neoplasms [unspecific] 29387410 the miR-23a/24-2/27a cluster may be a useful marker for predicting cancer prognosis and tumor progression +other hsa-mir-34a Liver Diseases [unspecific] 29391755 "After normalization of the steatosis-related circRNA by expression vector, analysis of miR-34a activity, peroxisome proliferator-activated receptor (PPAR)¦Á level, and expression of downstream genes were carried out so as to reveal its impact on the miR-34a/PPAR¦Á regulatory system" +other hsa-mir-27a Breast Neoplasms 29393459 Liraglutide inhibits the proliferation and promotes the apoptosis of MCF-7 human breast cancer cells through downregulation of microRNA-27a expression +other hsa-mir-17 Hypoxic-Ischemic Encephalopathy 29394934 IRE1¦Á inhibition decreased TXNIP/NLRP3 inflammasome activation through miR-17-5p after neonatal hypoxic-ischemic brain injury in rats +other hsa-mir-17 Infertility 29402772 Ablation of the MiR-17-92 MicroRNA Cluster in Germ Cells Causes Subfertility in Female Mice +other hsa-mir-18 Infertility 29402772 Ablation of the MiR-17-92 MicroRNA Cluster in Germ Cells Causes Subfertility in Female Mice +other hsa-mir-19a Infertility 29402772 Ablation of the MiR-17-92 MicroRNA Cluster in Germ Cells Causes Subfertility in Female Mice +other hsa-mir-19b-1 Infertility 29402772 Ablation of the MiR-17-92 MicroRNA Cluster in Germ Cells Causes Subfertility in Female Mice +other hsa-mir-20a Infertility 29402772 Ablation of the MiR-17-92 MicroRNA Cluster in Germ Cells Causes Subfertility in Female Mice +other hsa-mir-92-1 Infertility 29402772 Ablation of the MiR-17-92 MicroRNA Cluster in Germ Cells Causes Subfertility in Female Mice +other hsa-mir-592 Ischemia 29402808 Effects of MicroRNA-592-5p on Hippocampal Neuron Injury Following Hypoxic-Ischemic Brain Damage in Neonatal Mice - Involvement of PGD2/DP and PTGDR. +other hsa-mir-16 Vascular Disease [unspecific] 29402872 "This revascularization is associated with a decrease in miRNA-16 expression permissive for increased VEGF protein expression, suggesting a mechanism for potential therapeutic application in vascular diseases" +other hsa-mir-370 Ovarian Neoplasms 29403287 Long noncoding RNA H19 promotes transforming growth factor-¦Â-induced epithelial-mesenchymal transition by acting as a competing endogenous RNA of miR-370-3p in ovarian cancer cells +other hsa-mir-145 Colorectal Carcinoma 29404790 the pattern of miRNA expression and its correlation with histological markers are potentially valuable to apply as diagnostic biomarkers for CRC +other hsa-mir-20a Colorectal Carcinoma 29404790 the pattern of miRNA expression and its correlation with histological markers are potentially valuable to apply as diagnostic biomarkers for CRC +other hsa-mir-21 Colorectal Carcinoma 29404790 the pattern of miRNA expression and its correlation with histological markers are potentially valuable to apply as diagnostic biomarkers for CRC +other hsa-mir-155 Allergic Contact Dermatitis 29404871 Involvement of the Negative Feedback of IL-33 Signaling in the Anti-Inflammatory Effect of Electro-acupuncture on Allergic Contact Dermatitis via Targeting MicroRNA-155 in Mast Cells +other hsa-let-7 Brain Disease [unspecific] 29408500 MicroRNA let-7c-5p improves neurological outcomes in a murine model of traumatic brain injury by suppressing neuroinflammation and regulating microglial activation +other hsa-mir-122 Hepatitis C Virus Infection 29411512 This result along with the idea about the driver function of circulating miRNAs will promote further investigations that eventually lead to the development of novel strategies to treat HCV infection-associated extrahepatic comorbidities +other hsa-mir-7 Ovarian Neoplasms 29411964 Enhanced Chemotherapeutic Efficacy of Paclitaxel Nanoparticles Co-delivered with MicroRNA-7 by Inhibiting Paclitaxel-Induced EGFR/ERK pathway Activation for Ovarian Cancer Therapy +other hsa-mir-21 Gastric Neoplasms 29422082 CBX7 regulates stem cell-like properties of gastric cancer cells via p16 and AKT-NF-¦ÊB-miR-21 pathways +other hsa-mir-181a Neuroblastoma 29426375 Triptolide inhibits proliferation and migration of human neuroblastoma SH-SY5Y cells by up-regulating microRNA-181a +other hsa-mir-409 Sarcoma [unspecific] 29430619 "A Regulatory Circuitry Between Gria2, miR-409, and miR-495 Is Affected by ALS FUS Mutation in ESC-Derived Motor Neurons." +other hsa-mir-495 Sarcoma [unspecific] 29430619 "A Regulatory Circuitry Between Gria2, miR-409, and miR-495 Is Affected by ALS FUS Mutation in ESC-Derived Motor Neurons." +other hsa-mir-449a Breast Neoplasms 29431182 Comprehensive circular RNA profiling reveals the regulatory role of the circRNA-000911/miR-449a pathway in breast carcinogenesis +other hsa-mir-181b "Adenocarcinoma, Lung" 29434967 Celastrol suppresses the proliferation of lung adenocarcinoma cells by regulating microRNA-24 and microRNA-181b +other hsa-mir-24 "Adenocarcinoma, Lung" 29434967 Celastrol suppresses the proliferation of lung adenocarcinoma cells by regulating microRNA-24 and microRNA-181b +other hsa-mir-146a Atrial Fibrillation 29437577 MiR-146a Regulates Neutrophil Extracellular Trap Formation That Predicts Adverse Cardiovascular Events in Patients With Atrial Fibrillation +other hsa-mir-21 Ischemic Heart Disease 29444190 Bone marrow mesenchymal stem cell-derived exosomal miR-21 protects C-kit+ cardiac stem cells from oxidative injury through the PTEN/PI3K/Akt axis +other hsa-mir-223 Inflammation 29444433 MicroRNA-223 Suppresses the Canonical NF-¦ÊB Pathway in Basal Keratinocytes to Dampen Neutrophilic Inflammation +other hsa-mir-146a Atherosclerosis 29449647 "they express a remarkably high basal level of miR-146a, a microRNA known to negatively regulate the TLR pathway" +other hsa-mir-146a Osteoarthritis 29449647 "they express a remarkably high basal level of miR-147a, a microRNA known to negatively regulate the TLR pathway" +other hsa-mir-630 Ovarian Neoplasms 29452092 MicroRNA-630 inhibitor sensitizes chemoresistant ovarian cancer to chemotherapy by enhancing apoptosis. +other hsa-let-7f Asthma 29455573 A CREB-mediated increase in miRNA let-7f during prolonged ¦Â-agonist exposure: a novel mechanism of ¦Â2-adrenergic receptor down-regulation in airway smooth muscle +other hsa-mir-214 Gastric Neoplasms 29456019 Exosomes Serve as Nanoparticles to Deliver Anti-miR-214 to Reverse Chemoresistance to Cisplatin in Gastric Cancer +other hsa-mir-21 Cardiovascular Diseases [unspecific] 29456377 the stability of both DIM and pre-miR-21 was found to be inversely correlated to each other in binding condition +other hsa-mir-21 Vascular Disease [unspecific] 29456377 the stability of both DIM and pre-miR-22 was found to be inversely correlated to each other in binding condition +other hsa-mir-21 Colorectal Carcinoma 29456985 Evaluation of miR-21 Inhibition and its Impact on Cancer Susceptibility Candidate 2 Long Noncoding RNA in Colorectal Cancer Cell Line +other hsa-mir-145 Gastrointestinal Neoplasms 29459716 "miR-145, which blocked EGFR endocytosis, prolonged EGFR membrane signaling and altered responsiveness of colon cancer cells to EGFR-targeting drugs" +other hsa-mir-17 Gastrointestinal Neoplasms 29459716 "The regulation of EGF receptor (EGFR) endocytosis by two predicted miRNAs, namely miR-17 and miR-145, was confirmed experimentally" +other hsa-mir-125b Spinal Cord Injuries 29461585 MicroRNA-125b promotes the regeneration and repair of spinal cord injury through regulation of JAK/STAT pathway +other hsa-mir-143 Endometriosis 29463003 "miR-17-5p/20a, miR-200, miR-199a, miR-143, and miR-145 were explored for their pivotal role in the aetiopathogenesis of endometriosis" +other hsa-mir-145 Endometriosis 29463003 "miR-17-5p/20a, miR-200, miR-199a, miR-143, and miR-145 were explored for their pivotal role in the aetiopathogenesis of endometriosis" +other hsa-mir-17 Endometriosis 29463003 "miR-17-5p/20a, miR-200, miR-199a, miR-143, and miR-145 were explored for their pivotal role in the aetiopathogenesis of endometriosis" +other hsa-mir-199a Endometriosis 29463003 "miR-17-5p/20a, miR-200, miR-199a, miR-143, and miR-145 were explored for their pivotal role in the aetiopathogenesis of endometriosis" +other hsa-mir-200 Endometriosis 29463003 "miR-17-5p/20a, miR-200, miR-199a, miR-143, and miR-145 were explored for their pivotal role in the aetiopathogenesis of endometriosis" +other hsa-mir-20a Endometriosis 29463003 "miR-17-5p/20a, miR-200, miR-199a, miR-143, and miR-145 were explored for their pivotal role in the aetiopathogenesis of endometriosis" +other hsa-mir-145 Pancreatic Neoplasms 29464032 Selective packaging of miRNAs into EVs led to enrichment of stromal specific miR-145 in EVs secreted by TAS cells +other hsa-mir-155 Atherosclerosis 29465752 both the atherosclerosis inducer ox-LDL and atheroprotective factor KLF2 regulated inflammation-associated microRNA-155 (miR-155) expression in human umbilical vein endothelial cells (HUVECs) +other hsa-mir-675 Neuroblastoma 29465760 "Angelica sinensis polysaccharide inhibits proliferation, migration, and invasion by downregulating microRNA-675 in human neuroblastoma cell line SH-SY5Y." +other hsa-mir-132 Infection [unspecific] 29467760 MicroRNA Regulation of Host Immune Responses following Fungal Exposure +other hsa-mir-146a Infection [unspecific] 29467760 MicroRNA Regulation of Host Immune Responses following Fungal Exposure +other hsa-mir-126 Status Epilepticus 29468563 the analysis of miRNA levels in serum could provide clinicians with a tool to evaluate disease evolution and the efficacy of ¦Á-T therapy in SE +other hsa-mir-590 Gastric Neoplasms 29473240 Loss of PPM1F expression predicts tumour recurrence and is negatively regulated by miR-590-3p in gastric cancer. +other hsa-mir-371a Germ Cell Tumor 29474847 Serum miRNA Predicts Viable Disease after Chemotherapy in Patients with Testicular Nonseminoma Germ Cell Tumor. +other hsa-mir-182 Sensorineural Hearing Loss 29476110 "A mouse model of miR-96, miR-182 and miR-183 misexpression implicates miRNAs in cochlear cell fate and homeostasis" +other hsa-mir-183 Sensorineural Hearing Loss 29476110 "A mouse model of miR-96, miR-182 and miR-183 misexpression implicates miRNAs in cochlear cell fate and homeostasis" +other hsa-mir-96 Sensorineural Hearing Loss 29476110 "A mouse model of miR-96, miR-182 and miR-183 misexpression implicates miRNAs in cochlear cell fate and homeostasis" +other hsa-mir-126 Diabetes Mellitus 29477147 "While both miRs have differential functions on endothelial VCAM expression, miR-19a and miR-126 cooperate to exhibit anti-thrombotic properties via regulating vascular TF expression" +other hsa-mir-19a Diabetes Mellitus 29477147 "While both miRs have differential functions on endothelial VCAM expression, miR-19a and miR-126 cooperate to exhibit anti-thrombotic properties via regulating vascular TF expression" +other hsa-mir-30c Cardiovascular Diseases [unspecific] 29483230 Cocaine Exposure Increases Blood Pressure and Aortic Stiffness via the miR-30c-5p-Malic Enzyme 1-Reactive Oxygen Species Pathway. +other hsa-mir-210 Myocardial Infarction 29484401 MicroRNA-210 promotes angiogenesis in acute myocardial infarction +other hsa-mir-16 Acute Lung Injury 29484411 miR-16 inhibits hyperoxia-induced cell apoptosis in human alveolar epithelial cells +other hsa-mir-146a Non-Syndromic Orofacial Clefts 29484780 A functional polymorphism in the pre-miR-146a gene is associated with the risk of nonsyndromic orofacial cleft. +other hsa-mir-206 Amyotrophic Lateral Sclerosis 29486297 Muscle microRNA signatures as biomarkers of disease progression in amyotrophic lateral sclerosis. +other hsa-mir-31 "Adenocarcinoma, Pancreatic Ductal" 29486633 The AT-rich interactive domain 1A expression level in the cells was increased following microRNA-31 (miR-31) inhibitor transfection +other hsa-mir-122 Chronic Hepatitis C 29486652 Functional sequestration of microRNA-122 from Hepatitis C Virus by circular RNA sponges +other hsa-mir-133b Diabetic Retinopathy 29488353 Effects of microRNA-133b on retinal vascular endothelial cell proliferation and apoptosis through angiotensinogen-mediated angiotensin II- extracellular signal-regulated kinase 1/2 signalling pathway in rats with diabetic retinopathy. +other hsa-mir-9 "Adenocarcinoma, Lung" 29492899 differences in cell response (both miR-9 and proliferation) to dexamethasone in na?ve and desialylated cells may point to non-genomic dexamethasone effects +other hsa-mir-20a Colon Neoplasms 29492958 Targeting liver sinusoidal endothelial cells with miR-20a-loaded nanoparticles reduces murine colon cancer metastasis to the liver. +other hsa-mir-124 Stroke 29494665 MicroRNA-124-loaded nanoparticles increase survival and neuronal differentiation of neural stem cells in vitro but do not contribute to stroke outcome in vivo +other hsa-mir-9 Human Immunodeficiency Virus Infection 29497921 Exosomal miR-9 Released from HIV Tat Stimulated Astrocytes Mediates Microglial Migration +other hsa-mir-21 Lung Neoplasms 29501572 "Involvement of HIF-1¦Á-regulated miR-21, acting via the Akt/NF-¦ÊB pathway, in malignant transformation of HBE cells induced by cigarette smoke extract." +other hsa-mir-21 Atherosclerosis 29503197 Local Delivery of miR-21 Stabilizes Fibrous Caps in Vulnerable Atherosclerotic Lesions +other hsa-mir-144 "Carcinoma, Thyroid, Anaplastic" 29504819 Effects of miR-144 on the sensitivity of human anaplastic thyroid carcinoma cells to cisplatin by autophagy regulation. +other hsa-mir-126 "Leukemia, Myelogenous, Chronic, BCR-ABL Positive" 29505034 Bone marrow niche trafficking of miR-126 controls the self-renewal of leukemia stem cells in chronic myelogenous leukemia +other hsa-mir-1 Myocardial Ischemic-Reperfusion Injury 29505745 Cardioprotective effect of paeonol against epirubicin-induced heart injury via regulating miR-1 and PI3K/AKT pathway +other hsa-mir-137 "Diabetes Mellitus, Gestational" 29505767 High glucose induces dysfunction of human umbilical vein endothelial cells by upregulating miR-137 in gestational diabetes mellitus. +other hsa-mir-208b Hypertension 29506053 "miR-26b, miR-208b and miR-499 show a distinct in profile in hypertensive patients with HFpEF that is related with functional capacity" +other hsa-mir-26b Hypertension 29506053 "miR-26b, miR-208b and miR-499 show a distinct in profile in hypertensive patients with HFpEF that is related with functional capacity" +other hsa-mir-499 Hypertension 29506053 "miR-26b, miR-208b and miR-499 show a distinct in profile in hypertensive patients with HFpEF that is related with functional capacity" +other hsa-mir-208a Myocardial Infarction 29506703 Droplet digital PCR as a novel detection method for quantifying microRNAs in acute myocardial infarction +other hsa-mir-21 Arteriosclerosis Obliterans 29506703 Droplet digital PCR as a novel detection method for quantifying microRNAs in acute myocardial infarction +other hsa-mir-21 Ischemia-Reperfusion Injury 29506703 Droplet digital PCR as a novel detection method for quantifying microRNAs in acute myocardial infarction +other hsa-mir-21 Myocardial Infarction 29506703 Droplet digital PCR as a novel detection method for quantifying microRNAs in acute myocardial infarction +other hsa-mir-499 Myocardial Infarction 29506703 Droplet digital PCR as a novel detection method for quantifying microRNAs in acute myocardial infarction +other hsa-mir-384 Diabetic Encephalopathy 29511445 Control of macrophage autophagy by miR-384-5p in the development of diabetic encephalopathy. +other hsa-mir-191 "Carcinoma, Breast" 29511965 levels of miR-191-5p significantly increased during the six-month intervention +other hsa-mir-21 Colorectal Adenocarcinoma 29512659 An amplification-free electrochemical detection of exosomal miRNA-21 in serum samples +other hsa-mir-155 "Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal" 29517281 YB-1 promotes laryngeal squamous cell carcinoma progression by inducing miR-155 expression via c-Myb. +other hsa-mir-196a "Carcinoma, Hepatocellular" 29518473 Gene expression network regulated by DNA methylation and microRNA during microcystin-leucine arginine induced malignant transformation in human hepatocyte L02 cells. +other hsa-mir-221 "Carcinoma, Hepatocellular" 29518473 Gene expression network regulated by DNA methylation and microRNA during microcystin-leucine arginine induced malignant transformation in human hepatocyte L02 cells. +other hsa-mir-26a "Carcinoma, Hepatocellular" 29518473 Gene expression network regulated by DNA methylation and microRNA during microcystin-leucine arginine induced malignant transformation in human hepatocyte L02 cells. +other hsa-mir-320a "Carcinoma, Hepatocellular" 29518473 Gene expression network regulated by DNA methylation and microRNA during microcystin-leucine arginine induced malignant transformation in human hepatocyte L02 cells. +other hsa-mir-331 "Carcinoma, Hepatocellular" 29518473 Gene expression network regulated by DNA methylation and microRNA during microcystin-leucine arginine induced malignant transformation in human hepatocyte L02 cells. +other hsa-mir-145 Glioblastoma 29521593 Inhibition of glioblastoma cell invasion by hsa-miR-145-5p and hsa-miR-31-5p co-overexpression in human mesenchymal stem cells +other hsa-mir-31 Glioblastoma 29521593 Inhibition of glioblastoma cell invasion by hsa-miR-145-5p and hsa-miR-31-6p co-overexpression in human mesenchymal stem cells +other hsa-mir-204 Melanoma 29523154 "miR-204 represents a relevant mechanism in melanoma, with potential prognostic value and its loss seems to act in the CDKN2A pathway, in cooperation with NRAS" +other hsa-mir-124 Stroke 29524052 "this network-based approach to delineate miRNA, TF, and gene interactions might promote the development of effective therapeutics against ischemic stroke" +other hsa-mir-155 Stroke 29527155 the functions of the miRNA miR-155 and the effect of its in vivo inhibition on brain recovery following experimental cerebral ischemia +other hsa-mir-122 Hepatitis C Virus Infection 29528577 microRNA-122 is a potential marker of progression of hepatocytes injury in patients infected with HCV but not a reliable marker for diagnosis of HCC +other hsa-mir-27a "Adenocarcinoma, Cervical" 29531222 miR-27a inhibits cervical adenocarcinoma progression by downregulating the TGF-¦ÂRI signaling pathway. +other hsa-mir-200c Breast Neoplasms 29532351 Bioluminescence Imaging for Monitoring miR-200c Expression in Breast Cancer Cells and its Effects on Epithelial-Mesenchymal Transition Progress in Living Animals +other hsa-mir-130a Osteoarthritis 29532889 MicroRNA-130a regulates chondrocyte proliferation and alleviates osteoarthritis through PTEN/PI3K/Akt signaling pathway +other hsa-let-7i Diabetic Polyneuropathy 29533535 "let-7i is widely expressed in sensory neurons, supports their growth and is depleted in experimental DPN" +other hsa-mir-122 "Carcinoma, Hepatocellular" 29534065 "We identified a miRNA panel comprised of four miRNAs (miR-192, miR-122, miR-181b and miR-125a-5p) that may serve as a molecular tool for characterization of the CD134+ cells associated with different stages of hepatocarinogensis" +other hsa-mir-125a "Carcinoma, Hepatocellular" 29534065 "We identified a miRNA panel comprised of four miRNAs (miR-192, miR-122, miR-181b and miR-125a-5p) that may serve as a molecular tool for characterization of the CD136+ cells associated with different stages of hepatocarinogensis" +other hsa-mir-181b "Carcinoma, Hepatocellular" 29534065 "We identified a miRNA panel comprised of four miRNAs (miR-192, miR-122, miR-181b and miR-125a-5p) that may serve as a molecular tool for characterization of the CD135+ cells associated with different stages of hepatocarinogensis" +other hsa-mir-192 "Carcinoma, Hepatocellular" 29534065 "We identified a miRNA panel comprised of four miRNAs (miR-192, miR-122, miR-181b and miR-125a-5p) that may serve as a molecular tool for characterization of the CD133+ cells associated with different stages of hepatocarinogensis" +other hsa-mir-425 Respiratory System Disease 29535266 Prader-Willi region non-protein coding RNA 1 suppressed gastric cancer growth as a competing endogenous RNA of miR-425-5p. +other hsa-mir-181a Inflammation 29535629 we provide the first evidence for the negative regulation of miR-181a in LPS-induced inflammation via the suppression of ROS generation and TLR4-NF-¦ÊB pathway +other hsa-mir-21 "Carcinoma, Hepatocellular" 29538313 our analysis identified novel miR-21 targets that are likely to play a causal role in hepatocarcinogenesis +other hsa-mir-122 Hepatitis E Virus Infection 29540601 Positive regulation of hepatitis E virus replication by microRNA-122 +other hsa-mir-21 Chronic Obstructive Pulmonary Disease 29543496 MicroRNA-21 aggravates chronic obstructive pulmonary disease by promoting autophagy +other hsa-mir-29b Colon Neoplasms 29545333 A miR-29b Byproduct Sequence Exhibits Potent Tumor-Suppressive Activities via Inhibition of NF-¦ÊB Signaling in KRAS-Mutant Colon Cancer Cells +other hsa-mir-106b Brain Neoplasms 29547527 The Oncogenic Relevance of miR-17-92 Cluster and Its Paralogous miR-106b-25 and miR-106a-363 Clusters in Brain Tumors +other hsa-mir-17 Brain Neoplasms 29547527 The Oncogenic Relevance of miR-17-92 Cluster and Its Paralogous miR-106b-25 and miR-106a-363 Clusters in Brain Tumors +other hsa-mir-18 Brain Neoplasms 29547527 The Oncogenic Relevance of miR-17-92 Cluster and Its Paralogous miR-106b-25 and miR-106a-363 Clusters in Brain Tumors +other hsa-mir-19a Brain Neoplasms 29547527 The Oncogenic Relevance of miR-17-92 Cluster and Its Paralogous miR-106b-25 and miR-106a-363 Clusters in Brain Tumors +other hsa-mir-19b-1 Brain Neoplasms 29547527 The Oncogenic Relevance of miR-17-92 Cluster and Its Paralogous miR-106b-25 and miR-106a-363 Clusters in Brain Tumors +other hsa-mir-20a Brain Neoplasms 29547527 The Oncogenic Relevance of miR-17-92 Cluster and Its Paralogous miR-106b-25 and miR-106a-363 Clusters in Brain Tumors +other hsa-mir-25 Brain Neoplasms 29547527 The Oncogenic Relevance of miR-17-92 Cluster and Its Paralogous miR-106b-25 and miR-106a-363 Clusters in Brain Tumors +other hsa-mir-92-1 Brain Neoplasms 29547527 The Oncogenic Relevance of miR-17-92 Cluster and Its Paralogous miR-106b-25 and miR-106a-363 Clusters in Brain Tumors +other hsa-mir-93 Brain Neoplasms 29547527 The Oncogenic Relevance of miR-17-92 Cluster and Its Paralogous miR-106b-25 and miR-106a-363 Clusters in Brain Tumors +other hsa-mir-122 Hepatitis C Virus Infection 29549787 Identification of nucleotides in the 5'UTR and amino acids substitutions that are essential for the infectivity of 5'UTR-NS5A recombinant of hepatitis C virus genotype 1b (strain Con1). +other hsa-mir-106b "Squamous Cell Carcinoma, Esophageal" 29552108 miR-106b promotes cell invasion and metastasis via PTEN mediated EMT in ESCC +other hsa-mir-375 "Carcinoma, Hepatocellular" 29555460 "miR-375/Sf-LCC NPs can deliver sorafenib and miR-375 into HCC cells and tumor tissues, increase drug retention time in tumor, significantly inhibit autophagy and produce enhanced anti-tumor effect" +other hsa-mir-34a Myocardial Infarction 29559958 "miR-34a, a microRNA known to promote pro-apoptotic role in myocardial infarction during degenerative process of cardiac injuries thus indicating intrinsic differences in the nature of the mechanisms underlying the heart failure triggered by Trypanosoma cruzi infection." +other hsa-mir-155 Infectious Bursal Disease Virus 29564226 gga-miR-155 plays a critical role in cell response to IBDV infection +other hsa-mir-132 "Carcinoma, Breast" 29567542 MicroRNA-132 and microRNA-212 mediate doxorubicin resistance by down-regulating the PTEN-AKT/NF-¦ÊB signaling pathway in breast cancer. +other hsa-mir-212 "Carcinoma, Breast" 29567542 MicroRNA-132 and microRNA-212 mediate doxorubicin resistance by down-regulating the PTEN-AKT/NF-¦ÊB signaling pathway in breast cancer. +other hsa-let-7a Gastric Neoplasms 29567564 Simultaneous detection of gastric cancer-involved miR-106a and let-7a through a dual-signal-marked electrochemical nanobiosensor. +other hsa-mir-106a Gastric Neoplasms 29567564 Simultaneous detection of gastric cancer-involved miR-106a and let-7a through a dual-signal-marked electrochemical nanobiosensor. +other hsa-mir-135b Colorectal Carcinoma 29569786 The aggressive function of IL-13/STAT6/ZEB1 axis in colorectal cancer was impaired by propofol through miR-361 and miR-135b +other hsa-mir-361 Colorectal Carcinoma 29569786 The aggressive function of IL-13/STAT6/ZEB1 axis in colorectal cancer was impaired by propofol through miR-361 and miR-135b +other hsa-mir-192 "Squamous Cell Carcinoma, Lung" 29571988 MiR-192 and miR-662 enhance chemoresistance and invasiveness of squamous cell lung carcinoma +other hsa-mir-662 "Squamous Cell Carcinoma, Lung" 29571988 MiR-192 and miR-662 enhance chemoresistance and invasiveness of squamous cell lung carcinoma +other hsa-mir-92a Neoplasms [unspecific] 29574928 Our results show that miR-92a possesses a cell-type dependent function +other hsa-mir-19a "Carcinoma, Gallbladder" 29575299 The PLGF/c-MYC/miR-19a axis promotes metastasis and stemness in gallbladder cancer. +other hsa-mir-146a Osteoarthritis 29575548 miR-146a may be used to counter both aging-associated OA and mechanical injury-/inflammation-induced PTOA +other hsa-mir-155 Rheumatoid Arthritis 29575671 Rituximab may cause increased hepatitis C virus viremia in rheumatoid arthritis patients through declining exosomal microRNA-155 +other hsa-mir-34a "Carcinoma, Gastric" 29577459 "abnormal glycolysis was relieved by ASIV via regulation of the expressions of LDHA, p53, TIGAR, MCT1, MCT4, HIF-1¦Á, CD147, and miRNA-34a" +other hsa-mir-34a Toxic Encephalopathy 29578002 microRNA-34a could improve anesthesia-induced cognitive dysfunction by suppressing cell apoptosis and recovering the expression of genes associated with the MAPK/ERK signaling pathway +other hsa-mir-34a Hypoxia 29581146 Inhibition of miR-34a-5p alleviates hypoxia-reoxygenation injury by enhancing autophagy in steatotic hepatocytes +other hsa-mir-23a Renal Fibrosis 29582582 miRNA-23a/27a attenuates muscle atrophy and renal fibrosis through muscle-kidney crosstalk. +other hsa-mir-27a Renal Fibrosis 29582582 miRNA-23a/27a attenuates muscle atrophy and renal fibrosis through muscle-kidney crosstalk. +other hsa-mir-214 Heart Failure 29584819 "ROCR acted as a microRNA-214 sponge to release PTEN, which blocked activation of the PI3 kinase/Akt pathway to inhibit cardiomyocyte proliferation and ROCR may be a novel therapeutic target for preventing and treating heart failure" +other hsa-let-7i Colon Neoplasms 29588449 "Available gene expression data allowed us to associate miR-30b expression with axon guidance and let-7i expression with cell adhesion, migration, and motility" +other hsa-mir-30b Colon Neoplasms 29588449 "Available gene expression data allowed us to associate miR-30b expression with axon guidance and let-7i expression with cell adhesion, migration, and motility" +other hsa-mir-10b Breast Ductal Carcinoma 29599829 "miR-10b-positive expression was correlated with the expression of ER-¦Á, Her-2 and the molecular subtypes of early invasive ductal carcinoma of the breast" +other hsa-let-7a Monocytic Leukemia 29599918 FC-99 ameliorates sepsis-induced liver dysfunction by modulating monocyte/macrophage differentiation via Let-7a related monocytes apoptosis. +other hsa-mir-146 Inflammation 29601548 "the NF-¦ÊB-miR-146 and NF-¦ÊB-miR-155 networks fine-tune the activity, intensity, and duration of inflammation, while the NF-¦ÊB-miR-21 and NF-¦ÊB-miR-181b-1 amplifying loops link inflammation to cancer" +other hsa-mir-155 Inflammation 29601548 "the NF-¦ÊB-miR-146 and NF-¦ÊB-miR-155 networks fine-tune the activity, intensity, and duration of inflammation, while the NF-¦ÊB-miR-21 and NF-¦ÊB-miR-181b-1 amplifying loops link inflammation to cancer" +other hsa-mir-181b Neoplasms [unspecific] 29601548 "the NF-¦ÊB-miR-146 and NF-¦ÊB-miR-155 networks fine-tune the activity, intensity, and duration of inflammation, while the NF-¦ÊB-miR-21 and NF-¦ÊB-miR-181b-2 amplifying loops link inflammation to cancer" +other hsa-mir-21 Neoplasms [unspecific] 29601548 "the NF-¦ÊB-miR-146 and NF-¦ÊB-miR-155 networks fine-tune the activity, intensity, and duration of inflammation, while the NF-¦ÊB-miR-21 and NF-¦ÊB-miR-181b-3 amplifying loops link inflammation to cancer" +other hsa-mir-141 Neoplasms [unspecific] 29602800 The microRNA-200 family coordinately regulates cell adhesion and proliferation in hair morphogenesis. +other hsa-mir-200a Neoplasms [unspecific] 29602800 The microRNA-200 family coordinately regulates cell adhesion and proliferation in hair morphogenesis. +other hsa-mir-200b Neoplasms [unspecific] 29602800 The microRNA-200 family coordinately regulates cell adhesion and proliferation in hair morphogenesis. +other hsa-mir-200c Neoplasms [unspecific] 29602800 The microRNA-200 family coordinately regulates cell adhesion and proliferation in hair morphogenesis. +other hsa-mir-429 Neoplasms [unspecific] 29602800 The microRNA-200 family coordinately regulates cell adhesion and proliferation in hair morphogenesis. +other hsa-mir-566 "Carcinoma, Renal Cell" 29604591 miR-566 functions as an oncogene and a potential biomarker for prognosis in renal cell carcinoma. +other hsa-mir-31 Wound Healing 29605672 "these findings identify miR-31 as an important cell-autonomous mediator during the transition from inflammation to re-epithelialization phases of wound healing, suggesting a therapeutic potential for miR-31 in skin injury repair" +other hsa-mir-181a Vascular Disease [unspecific] 29608244 microRNA-181a inhibits ocular neovascularization by interfering with vascular endothelial growth factor expression. +other hsa-mir-146a Alzheimer Disease 29615954 Microbiome-Mediated Upregulation of MicroRNA-146a in Sporadic Alzheimer's Disease +other hsa-mir-150 Age-Related Macular Degeneration 29618664 miR-150 as pathogenic in AMD and provide potentially novel molecular insights into diseases of aging +other hsa-mir-642a "Carcinoma, Breast" 29620153 we examined the effects of synthetic miR-762 and miR-642a-3p inhibitors on SAHA-induced downregulation of Her2/neu and SAHA-induced apoptosis and PARP cleavage in BT474 cells +other hsa-mir-762 "Carcinoma, Breast" 29620153 we examined the effects of synthetic miR-762 and miR-642a-3p inhibitors on SAHA-induced downregulation of Her2/neu and SAHA-induced apoptosis and PARP cleavage in BT474 cells +other hsa-mir-210 Mitochondrial Metabolism Disease 29621777 Loading MiR-210 in Endothelial Progenitor Cells Derived Exosomes Boosts Their Beneficial Effects on Hypoxia/Reoxygeneation-Injured Human Endothelial Cells via Protecting Mitochondrial Function +other hsa-mir-20a Glioblastoma 29625108 "The findings of the current study demonstrate presence of the IDH1 R132H mutation in primary human glioblastoma cell lines with upregulated HIF-1¦Á expression, downregulating c-MYC activity and resulting in a consequential decrease in miR-20a, which is responsible for cell proliferation and resistance to standard temozolomide treatment" +other hsa-mir-20a Glioma 29625108 Oncogenic MicroRNA-20a is downregulated by the HIF-1¦Á/c-MYC pathway in IDH1 R132H-mutant glioma +other hsa-mir-378 Fatty Liver [unspecific] 29625129 A negative feedback loop between microRNA-378 and Nrf1 promotes the development of hepatosteatosis in mice treated with a high fat diet. +other hsa-mir-155 "Carcinoma, Cervical" 29627439 MiR-155-5p inhibits PDK1 and promotes autophagy via the mTOR pathway in cervical cancer. +other hsa-mir-21 Alzheimer Disease 29635890 "miR-21 can exert protective roles in AD, which might be dependent on PDCD4/PI3K/AKT/GSK-3¦Â signaling pathway in vitro" +other hsa-mir-21 Neuroblastoma 29635890 MiR-21 attenuates apoptosis-triggered by amyloid-¦Â via modulating PDCD4/PI3K/AKT/GSK-3¦Â pathway in SH-SY5Y cells +other hsa-mir-17 Feingold Syndrome 29636449 Distinct molecular pathways mediate Mycn and Myc-regulated miR-17-92 microRNA action in Feingold syndrome mouse models. +other hsa-mir-18 Feingold Syndrome 29636449 Distinct molecular pathways mediate Mycn and Myc-regulated miR-17-92 microRNA action in Feingold syndrome mouse models. +other hsa-mir-19a Feingold Syndrome 29636449 Distinct molecular pathways mediate Mycn and Myc-regulated miR-17-92 microRNA action in Feingold syndrome mouse models. +other hsa-mir-19b-1 Feingold Syndrome 29636449 Distinct molecular pathways mediate Mycn and Myc-regulated miR-17-92 microRNA action in Feingold syndrome mouse models. +other hsa-mir-20a Feingold Syndrome 29636449 Distinct molecular pathways mediate Mycn and Myc-regulated miR-17-92 microRNA action in Feingold syndrome mouse models. +other hsa-mir-92-1 Feingold Syndrome 29636449 Distinct molecular pathways mediate Mycn and Myc-regulated miR-17-92 microRNA action in Feingold syndrome mouse models. +other hsa-mir-1 Neoplasms [unspecific] 29642568 "A single sub-lethal dose of irradiation has been shown to result in compensatory up-regulation of the myocardial connexin-43 (Cx43), activation of the protein kinase C (PKC) signaling along with the decline of microRNA (miR)-1 and an increase of miR-21 levels in the left ventricle (LV)" +other hsa-mir-21 Neoplasms [unspecific] 29642568 Irradiation-Induced Cardiac Connexin-43 and miR-21 Responses Are Hampered by Treatment with Atorvastatin and Aspirin +other hsa-let-7 Neoplasms [unspecific] 29644076 These observations emphasize the central importance of IGF signaling pathways in the mediation of intragenomic conflicts over embryonic growth and identify possible targets for therapeutic interventions in cancer +other hsa-mir-2113 Proliferative Diabetic Retinopathy 29654764 Rg1 inhibits high glucose-induced mesenchymal activation and fibrosis via regulating miR-2113/RP11-982M15.8/Zeb1 pathway. +other hsa-mir-200c Colorectal Carcinoma 29656186 DCLK1 plays an important role in colorectal cancer tumorgenesis through the regulation of miR-200c. +other hsa-mir-146a "Leukemia, Myeloid, Acute" 29657293 miR-146 (146a and 146b) and miR-155 are among the first and most studied miRs for their multiple roles in the control of the innate and adaptive immune processes and for their deregulation and oncogenic role in some tumors +other hsa-mir-146b "Leukemia, Myeloid, Acute" 29657293 miR-146 (146a and 146b) and miR-155 are among the first and most studied miRs for their multiple roles in the control of the innate and adaptive immune processes and for their deregulation and oncogenic role in some tumors +other hsa-let-7 Ovarian Neoplasms 29658612 let-7d-3p is associated with apoptosis and response to neoadjuvant chemotherapy in ovarian cancer +other hsa-mir-21 Atherosclerosis 29659130 its involvement in the complex development of atherosclerosis has yet to be ascertained +other hsa-mir-21 Cardiovascular Diseases [unspecific] 29659130 "MicroRNA-21 (miR-21) is a short, non-coding RNA that has been implicated in cardiovascular diseases including proliferative vascular disease and ischaemic heart disease" +other hsa-mir-21 Vascular Disease [unspecific] 29659130 "MicroRNA-21 (miR-21) is a short, non-coding RNA that has been implicated in cardiovascular diseases including proliferative vascular disease and ischaemic heart disease" +other hsa-mir-449a Bladder Neoplasms 29659560 Androgen Receptor Is Inactivated and Degraded in Bladder Cancer Cells by Phenyl Glucosamine via miR-449a Restoration. +other hsa-mir-214 Endometriosis 29660008 Exosomal miR-214 from endometrial stromal cells inhibits endometriosis fibrosis. +other hsa-mir-148a "Carcinoma, Pancreatic Ductal" 29660218 Molecular pathogenesis of pancreatic ductal adenocarcinoma: Impact of passenger strand of pre-miR-148a on gene regulation. +other hsa-mir-30e Cholangiocarcinoma 29662654 Extracellular vesicle-encapsulated miR-30e suppresses cholangiocarcinoma cell invasion and migration via inhibiting epithelial-mesenchymal transition +other hsa-mir-200c "Carcinoma, Breast, Triple Negative" 29666469 the new p53/miR-30a/ZEB2 axis controls tumor cell invasion and distal spreading and impinges upon miR-200c expression +other hsa-mir-10b "Carcinoma, Renal Cell, Clear-Cell" 29672315 MicroRNA-10b Promotes Apoptosis via JNK Pathway in Clear Cell Renal Cell Carcinoma +other hsa-mir-122 Chronic Hepatitis C 29672716 "miR-122 does not impact recognition of the HCV genome by innate sensors of RNA but rather protects the 5' end from the cellular pyrophosphatases, DOM3Z and DUSP11" +other hsa-mir-155 "Carcinoma, Gastric" 29675003 Role of microRNAs and Exosomes in Helicobacter pylori and Epstein-Barr Virus Associated Gastric Cancers +other hsa-mir-155 Gastric Neoplasms 29675003 Role of microRNAs and Exosomes in Helicobacter pylori and Epstein-Barr Virus Associated Gastric Cancers +other hsa-mir-590 Influenza 29677213 IFN-¦Ë and microRNAs are important modulators of the pulmonary innate immune response against influenza A (H1N2) infection in pigs +other hsa-mir-143 "Diabetes Mellitus, Type 2" 29680463 "we will summarize the involvement of miR-143 in regulating the development of T2DM and the underlying mechanisms for potential diagnosis, prevention, and treatments, including exercise intervention for T2DM by targeting miR-143" +other hsa-mir-19a Multiple Myeloma 29687521 "Signal pathways, diseases, and functions associated with the miR-19a/92a cluster and the use of berberine to modulate the expression of this cluster in multiple myeloma cells." +other hsa-mir-92a Multiple Myeloma 29687521 "Signal pathways, diseases, and functions associated with the miR-19a/92a cluster and the use of berberine to modulate the expression of this cluster in multiple myeloma cells." +other hsa-mir-199a Arteriovenous Malformations of the Brain 29689389 "Functional annotation suggested that 15 of the predicted miRNA-targeted genes were involved in vascular endothelial growth factor signaling, in which 3 critical miRNAs were involved: miR-7-5p, miR-199a-5p, and miR-200b-3p" +other hsa-mir-200b Arteriovenous Malformations of the Brain 29689389 "Functional annotation suggested that 15 of the predicted miRNA-targeted genes were involved in vascular endothelial growth factor signaling, in which 3 critical miRNAs were involved: miR-7-5p, miR-199a-5p, and miR-200b-3p" +other hsa-mir-7 Arteriovenous Malformations of the Brain 29689389 "Functional annotation suggested that 15 of the predicted miRNA-targeted genes were involved in vascular endothelial growth factor signaling, in which 3 critical miRNAs were involved: miR-7-5p, miR-199a-5p, and miR-200b-3p" +other hsa-mir-181a "Carcinoma, Renal Cell" 29693121 microRNA?181a?5p functions as an oncogene in renal cell carcinoma. +other hsa-mir-214 "Adenocarcinoma, Lung" 29693173 TWIST1 upregulates miR-214 to promote epithelial-to-mesenchymal transition and metastasis in lung adenocarcinoma. +other hsa-mir-155 Rheumatoid Arthritis 29693176 PU.1 attenuates TNF?¦Á?induced proliferation and cytokine release of rheumatoid arthritis fibroblast?like synoviocytes by regulating miR?155 activity. +other hsa-mir-604 Gastric Neoplasms 29693274 miR-604 could become a new indicator in the diagnosis of drug-resistant GC and may be used to investigate the pathogenesis of resistance in GC +other hsa-mir-339 Acute Pancreatitis 29693276 MicroRNA-339-3p alleviates inflammation and edema and suppresses pulmonary microvascular endothelial cell apoptosis in mice with severe acute pancreatitis-associated acute lung injury by regulating Anxa3 via the Akt/mTOR signaling pathway. +other hsa-mir-139 "Carcinoma, Hepatocellular" 29693285 Higher variety and quantity of microRNA-139-5p isoforms confer suppressive role in hepatocellular carcinoma. +other hsa-mir-383 Coronary Artery Disease 29693751 The anti-inflammatory effect of microRNA-383-3p interacting with IL1R2 against homocysteine-induced endothelial injury in rat coronary arteries. +other hsa-mir-196a "Carcinoma, Renal Cell, Clear-Cell" 29695508 "ANKHD1 positively drives ccRCC cell mitosis via binding to and suppressing mainly miR-29a and to a lesser degree via miR-196a/205, leading to up-regulation in proliferative genes such as CCDN1" +other hsa-mir-205 "Carcinoma, Renal Cell, Clear-Cell" 29695508 "ANKHD1 positively drives ccRCC cell mitosis via binding to and suppressing mainly miR-29a and to a lesser degree via miR-196a/205, leading to up-regulation in proliferative genes such as CCDN1" +other hsa-mir-29a "Carcinoma, Renal Cell, Clear-Cell" 29695508 "ANKHD1 positively drives ccRCC cell mitosis via binding to and suppressing mainly miR-29a and to a lesser degree via miR-196a/205, leading to up-regulation in proliferative genes such as CCDN1" +other hsa-mir-221 Infection [unspecific] 29698854 Avian leukosis virus subgroup J promotes cell proliferation and cell cycle progression through miR-221 by targeting CDKN1B. +other hsa-mir-200b "Carcinoma, Breast" 29702103 The miR-200b/200a/429 cluster prevents metastasis and induces dormancy in a murine claudin-low mammary tumor cell line. +other hsa-mir-200c "Carcinoma, Breast" 29702103 The miR-200b/200a/429 cluster prevents metastasis and induces dormancy in a murine claudin-low mammary tumor cell line. +other hsa-mir-429 "Carcinoma, Breast" 29702103 The miR-200b/200a/429 cluster prevents metastasis and induces dormancy in a murine claudin-low mammary tumor cell line. +other hsa-mir-34c Becker Muscular Dystrophy 29703249 miR-708-5p and miR-34c-5p are involved in nNOS regulation in dystrophic context. +other hsa-mir-708 Becker Muscular Dystrophy 29703249 miR-708-5p and miR-34c-5p are involved in nNOS regulation in dystrophic context. +other hsa-mir-145 Atherosclerosis 29710501 Microrna-145 accelerates the inflammatory reaction through activation of NF-¦ÊB signaling in atherosclerosis cells and mice. +other hsa-mir-29c Colorectal Carcinoma 29710520 Inhibition of miR-29c could dramatically reverse Astragaloside IV-induced B7-H3 decrease and cell growth arrest +other hsa-mir-126 "Diabetes Mellitus, Type 2" 29710530 Resveratrol improves uric acid-induced pancreatic ¦Â-cells injury and dysfunction through regulation of miR-126. +other hsa-mir-125b "Carcinoma, Lung, Non-Small-Cell" 29722542 Repolarization of Tumor-Associated Macrophages in a Genetically Engineered Nonsmall Cell Lung Cancer Model by Intraperitoneal Administration of Hyaluronic Acid-Based Nanoparticles Encapsulating MicroRNA-125b. +other hsa-mir-142 Asthma 29722559 miR-142-3p is associated with aberrant WNT signaling during airway remodeling in asthma. +other hsa-mir-222 Glioblastoma 29723631 "the microRNAs (miRNAs) miR-27a, miR-222, miR-449 was observed after exposure to curcumin" +other hsa-mir-27a Glioblastoma 29723631 "the microRNAs (miRNAs) miR-27a, miR-222, miR-449 was observed after exposure to curcumin" +other hsa-mir-449 Glioblastoma 29723631 "the microRNAs (miRNAs) miR-27a, miR-222, miR-449 was observed after exposure to curcumin" +other hsa-mir-486 Hyperlipidemia 29725814 Inhibition of miR-486 and miR-92a decreases liver and plasma cholesterol levels by modulating lipid-related genes in hyperlipidemic hamsters. +other hsa-mir-92a Hyperlipidemia 29725814 Inhibition of miR-486 and miR-92a decreases liver and plasma cholesterol levels by modulating lipid-related genes in hyperlipidemic hamsters. +other hsa-mir-1910 Colorectal Carcinoma 29729381 STAT1-mediated upregulation of lncRNA LINC00174 functions a ceRNA for miR-1910-3p to facilitate colorectal carcinoma progression through regulation of TAZ. +other hsa-mir-186 Chondrosarcoma 29730230 Resistin facilitates VEGF-C-associated lymphangiogenesis by inhibiting miR-186 in human chondrosarcoma cells. +other hsa-mir-21 "Adenocarcinoma, Lung" 29730429 Lung adenocarcinoma cell-derived exosomal miR-21 facilitates osteoclastogenesis. +other hsa-mir-199 Cystic Fibrosis 29732561 Small RNA and transcriptome sequencing reveal the role of miR-199a-3p in inflammatory processes in cystic fibrosis airways. +other hsa-mir-221 Atherosclerosis 29737876 MicroRNA-221/222 expression in atherosclerotic coronary artery plaque versus internal mammarian artery and in peripheral blood samples. +other hsa-mir-222 Atherosclerosis 29737876 MicroRNA-221/222 expression in atherosclerotic coronary artery plaque versus internal mammarian artery and in peripheral blood samples. +other hsa-mir-141 "Squamous Cell Carcinoma, Esophageal" 29738771 "MiR-141-3p is upregulated in esophageal squamous cell carcinoma and targets pleckstrin homology domain leucine-rich repeat protein phosphatase-2, a negative regulator of the PI3K/AKT pathway." +other hsa-mir-1 "Muscular Dystrophy, Facioscapulohumeral" 29741619 Small noncoding RNAs in FSHD2 muscle cells reveal both DUX4- and SMCHD1-specific signatures. +other hsa-mir-133a "Muscular Dystrophy, Facioscapulohumeral" 29741619 Small noncoding RNAs in FSHD2 muscle cells reveal both DUX4- and SMCHD1-specific signatures. +other hsa-mir-206 "Muscular Dystrophy, Facioscapulohumeral" 29741619 Small noncoding RNAs in FSHD2 muscle cells reveal both DUX4- and SMCHD1-specific signatures. +other hsa-mir-1 Ischemia-Reperfusion Injury 29741915 The role of microRNA-1 targeting of MAPK3 in myocardial ischemia-reperfusion injury in rats undergoing sevoflurane preconditioning via the PI3K/Akt pathway. +other hsa-mir-380 Neoplasms [unspecific] 29743236 "2-hydroxyglutarate (2-HG) stabilizes hypoxia-inducible factor-2¦Á, which in turn activates the expression of miR-380-5p, a characterized microRNA against p53 expression" +other hsa-mir-10a Atherosclerosis 29748186 miR-10a expression was negatively correlated to the progression of atherosclerosis in humans +other hsa-mir-345 Prostate Neoplasms 29748958 Functional roles and potential clinical application of miRNA-345-5p in prostate cancer. +other hsa-mir-25 Breast Neoplasms 29765562 A myriad of roles of miR-25 in health and disease. +other hsa-mir-27a Bronchopneumonia 29772436 Tanshinone IIA ameliorates lipopolysaccharide-induced inflammatory response in bronchial epithelium cell line BEAS-2B by down-regulating miR-27a. +other hsa-mir-199a "Carcinoma, Renal Cell, Clear-Cell" 29773428 MiR-199a-3p acts as a tumor suppressor in clear cell renal cell carcinoma. +other hsa-mir-34a Chronic Inflammation 29773953 miR-34a-mediated regulation of XIST in female cells under inflammation. +other hsa-mir-1 Myocardial Infarction 29775643 Myocardial infarction-induced hippocampal microtubule damage by cardiac originating microRNA-1 in mice. +other hsa-mir-135a Cardiac Fibrosis 29775892 MicroRNA-135a inhibits cardiac fibrosis induced by isoproterenol via TRPM7 channel. +other hsa-mir-24 Hypertrophy 29786048 Cardiac Hypertrophy is Positively Regulated by MicroRNA?24 in Rats +other hsa-mir-200b Cardiac Fibrosis 29786779 DNMT3A controls miR-200b in cardiac fibroblast autophagy and cardiac fibrosis. +other hsa-mir-30e Sepsis 29787988 MicroRNA-30e promotes hepatocyte proliferation and inhibits apoptosis in cecal ligation and puncture-induced sepsis through the JAK/STAT signaling pathway by binding to FOSL2. +other hsa-let-7b Monocytic Leukemia 29790117 Regulatory roles of miR-155 and let-7b on the expression of inflammation-related genes in THP-1 cells: effects of fatty acids. +other hsa-mir-155 Monocytic Leukemia 29790117 Regulatory roles of miR-155 and let-7b on the expression of inflammation-related genes in THP-1 cells: effects of fatty acids. +other hsa-mir-146a Neoplasms [unspecific] 29800683 "We will specifically focus on three miRNAs that have been shown to regulate different aspects of T cell biology in both physiological and pathological conditions, namely miR-155, miR-146a and miR-181a" +other hsa-mir-155 Neoplasms [unspecific] 29800683 "We will specifically focus on three miRNAs that have been shown to regulate different aspects of T cell biology in both physiological and pathological conditions, namely miR-155, miR-146a and miR-181a" +other hsa-mir-181a Neoplasms [unspecific] 29800683 "We will specifically focus on three miRNAs that have been shown to regulate different aspects of T cell biology in both physiological and pathological conditions, namely miR-155, miR-146a and miR-181a" +other hsa-mir-15a Prostate Neoplasms 29803177 miR-15a/miR-16 cluster inhibits invasion of prostate cancer cells by suppressing TGF-¦Â signaling pathway. +other hsa-mir-16 Prostate Neoplasms 29803177 miR-15a/miR-16 cluster inhibits invasion of prostate cancer cells by suppressing TGF-¦Â signaling pathway. +other hsa-mir-204 "Carcinoma, Renal Cell, Clear-Cell" 29805586 hsa-miR-204 and hsa-miR-218 may be involved in the pathogenesis of ccRCC +other hsa-mir-218 "Carcinoma, Renal Cell, Clear-Cell" 29805586 hsa-miR-204 and hsa-miR-218 may be involved in the pathogenesis of ccRCC +other hsa-mir-106a Colorectal Carcinoma 29805629 MicroRNA-106a inhibits cell proliferation and induces apoptosis in colorectal cancer cells. +other hsa-mir-127 Glioma 29805677 Tudor-staphylococcal nuclease regulates the expression and biological function of alkylglycerone phosphate synthase via nuclear factor-¦ÊB and microRNA-127 in human glioma U87MG cells. +other hsa-mir-181b "Stroke, Ischemic" 29807144 Neuroprotective effects of isosteviol sodium through increasing CYLD by the downregulation of miRNA-181b. +other hsa-mir-21 Lung Fibrosis 29843043 Resveratrol inhibits pulmonary fibrosis by regulating miR-21 through MAPK/AP-1 pathways. +other hsa-mir-221 Retinoblastoma 29843209 Upregulated miR-221/222 promotes cell proliferation and invasion and is associated with invasive features in retinoblastoma. +other hsa-mir-222 Retinoblastoma 29843209 Upregulated miR-221/222 promotes cell proliferation and invasion and is associated with invasive features in retinoblastoma. +other hsa-mir-206 Rhabdomyosarcoma 29844345 "SNAIL silencing induces myogenic differentiation by upregulation of myogenic factors and muscle-specific microRNAs, such as miR-206." +other hsa-mir-143 Liver Neoplasms 29844837 The mechanism of miR-143 inducing apoptosis of liver carcinoma cells through regulation of the NF-¦ÊB pathway. +other hsa-mir-133 Acute Myocardial Infarction 29845217 "By searching the mir2disease database, four miRNAs associated with AMI were identified, including hsa-miR-21, hsa-miR-133, hsa-miR-29 and hsa-miR-30c." +other hsa-mir-21 Acute Myocardial Infarction 29845217 "By searching the mir2disease database, four miRNAs associated with AMI were identified, including hsa-miR-21, hsa-miR-133, hsa-miR-29 and hsa-miR-30c." +other hsa-mir-29 Acute Myocardial Infarction 29845217 "By searching the mir2disease database, four miRNAs associated with AMI were identified, including hsa-miR-21, hsa-miR-133, hsa-miR-29 and hsa-miR-30c." +other hsa-mir-30c Acute Myocardial Infarction 29845217 "By searching the mir2disease database, four miRNAs associated with AMI were identified, including hsa-miR-21, hsa-miR-133, hsa-miR-29 and hsa-miR-30c." +other hsa-mir-24 Aneurysmal Subarachnoid Hemorrhage 29845232 Upregulation of microRNA?24 causes vasospasm following subarachnoid hemorrhage by suppressing the expression of endothelial nitric oxide synthase. +other hsa-mir-16 Rheumatic Myocarditis 29845432 "significant downregulation of hsa-miR-16-5p, hsa-miR-223-3p and hsa-miR-92a-3p in children with rheumatic carditis" +other hsa-mir-223 Rheumatic Myocarditis 29845432 "significant downregulation of hsa-miR-16-5p, hsa-miR-223-3p and hsa-miR-92a-3p in children with rheumatic carditis" +other hsa-mir-92a Rheumatic Myocarditis 29845432 "significant downregulation of hsa-miR-16-5p, hsa-miR-223-3p and hsa-miR-92a-3p in children with rheumatic carditis" +other hsa-mir-130a "Diabetes Mellitus, Type 2" 29855803 Aerobic training improves platelet function in type 2 diabetic patients: role of microRNA-130a and GPIIb. +other hsa-mir-22 Neoplasms [unspecific] 29856481 "Triose-phosphate isomerase is a novel target of miR-22 and miR-28, with implications in tumorigenesis." +other hsa-mir-28 Neoplasms [unspecific] 29856481 "Triose-phosphate isomerase is a novel target of miR-22 and miR-28, with implications in tumorigenesis." +other hsa-mir-210 "Carcinoma, Hepatocellular" 29858059 Hepatocellular Carcinoma Cell-Secreted Exosomal MicroRNA-210 Promotes Angiogenesis In?Vitro and In?Vivo. +other hsa-mir-326 Lupus Nephritis 29858063 MicroRNA-326?Upregulates B Cell Activity and Autoantibody Production in Lupus Disease of MRL/lpr Mice. +other hsa-mir-449a "Carcinoma, Lung, Non-Small-Cell" 29858080 Targeting Nicotinamide N-Methyltransferase and miR-449a in EGFR-TKI-Resistant Non-Small-Cell Lung Cancer Cells. +other hsa-mir-122 Muscle Diseases [unspecific] 29858088 miR-24 and miR-122 Negatively Regulate the Transforming Growth Factor-¦Â/Smad Signaling Pathway in Skeletal Muscle Fibrosis. +other hsa-mir-24 Muscle Diseases [unspecific] 29858088 miR-24 and miR-122 Negatively Regulate the Transforming Growth Factor-¦Â/Smad Signaling Pathway in Skeletal Muscle Fibrosis. +other hsa-mir-132 Huntington Disease 29858092 Supplemental Treatment for Huntington's Disease with miR-132 that Is Deficient in Huntington's Disease Brain. +other hsa-mir-182 Parkinson Disease 29858093 miR-182-5p and miR-183-5p Act as GDNF Mimics in Dopaminergic Midbrain Neurons. +other hsa-mir-183 Parkinson Disease 29858093 miR-182-5p and miR-183-5p Act as GDNF Mimics in Dopaminergic Midbrain Neurons. +other hsa-mir-483 Neoplasms [unspecific] 29867024 The Glucose-Regulated MiR-483-3p Influences Key Signaling Pathways in Cancer. +other hsa-mir-101 Gastric Neoplasms 29872807 "miR-101-3p, miR-16-5p and miR-19b-3p were found to be located in the nuclei of MGC803 cells with granulated shapes" +other hsa-mir-16 Gastric Neoplasms 29872807 "miR-101-3p, miR-16-5p and miR-19b-3p were found to be located in the nuclei of MGC803 cells with granulated shapes" +other hsa-mir-19b Gastric Neoplasms 29872807 "miR-101-3p, miR-16-5p and miR-19b-3p were found to be located in the nuclei of MGC803 cells with granulated shapes" +other hsa-mir-106b Allergic Asthma 29875322 "This method identified 5 Th2-related miRs (mir27b, mir206, mir106b, mir203, and mir23b) whose antagonization led to a sharp reduction of the Th2 phenotype" +other hsa-mir-203 Allergic Asthma 29875322 "This method identified 5 Th2-related miRs (mir27b, mir206, mir106b, mir203, and mir23b) whose antagonization led to a sharp reduction of the Th2 phenotype" +other hsa-mir-206 Allergic Asthma 29875322 "This method identified 5 Th2-related miRs (mir27b, mir206, mir106b, mir203, and mir23b) whose antagonization led to a sharp reduction of the Th2 phenotype" +other hsa-mir-23b Allergic Asthma 29875322 "This method identified 5 Th2-related miRs (mir27b, mir206, mir106b, mir203, and mir23b) whose antagonization led to a sharp reduction of the Th2 phenotype" +other hsa-mir-27b Allergic Asthma 29875322 "This method identified 5 Th2-related miRs (mir27b, mir206, mir106b, mir203, and mir23b) whose antagonization led to a sharp reduction of the Th2 phenotype" +other hsa-mir-7 Glioma 29877083 Inhibition of the Proliferation and Invasion of C6 Glioma Cells by Tricin via the Upregulation of Focal-Adhesion-Kinase-Targeting MicroRNA-7. +other hsa-mir-208a Cardiac Myocyte Injury 29877301 MicroRNA-208a Correlates Apoptosis and Oxidative Stress Induced by H2O2 through Protein Tyrosine Kinase/Phosphatase Balance in Cardiomyocytes. +other hsa-mir-100 "Squamous Cell Carcinoma, Head and Neck" 29880533 "the expression of MIR100HG-embedded microRNA, miR-100, was significantly associated with overall survival in an independent cohort of HNSCC cases " +other hsa-mir-342 "Leukemia, Myeloid, Acute" 29880818 Aberrant mannosylation profile and FTX/miR-342/ALG3-axis contribute to development of drug resistance in acute myeloid leukemia. +other hsa-mir-514b Colorectal Carcinoma 29880874 The distinct role of strand-specific miR-514b-3p and miR-514b-5p in colorectal cancer metastasis. +other hsa-mir-139 Colorectal Carcinoma 29883634 miR-139 could be a potential biomarker for diagnosis of digestive system tumors especially colorectal cancer +other hsa-mir-21a Spinal Cord Injuries 29883711 MicroRNA-21a-5p promotes fibrosis in spinal fibroblasts after mechanical trauma. +other hsa-mir-145 Diabetic Retinopathy 29883722 MicroRNA-145 attenuates high glucose-induced oxidative stress and inflammation in retinal endothelial cells through regulating TLR4/NF-¦ÊB signaling. +other hsa-mir-187 "Carcinoma, Bladder" 29883941 "Oncogene miR-187-5p is associated with cellular proliferation, migration, invasion, apoptosis and an increased risk of recurrence in bladder cancer." +other hsa-mir-410 Cardiomyopathy 29884823 MicroRNA-410-5p exacerbates high-fat diet-induced cardiac remodeling in mice in an endocrine fashion. +other hsa-mir-1 Atrial Fibrillation 29885959 Increased right atrial appendage apoptosis is associated with differential regulation of candidate MicroRNAs 1 and 133A in patients who developed atrial fibrillation after cardiac surgery. +other hsa-mir-133a Atrial Fibrillation 29885959 Increased right atrial appendage apoptosis is associated with differential regulation of candidate MicroRNAs 1 and 133A in patients who developed atrial fibrillation after cardiac surgery. +other hsa-mir-31 "Colitis, Ulcerative" 29889228 "Our data suggest a role for TSLP in promoting mucosal healing and regulating inflammation in UC, whereas miR-31 can directly block this effect" +other hsa-mir-425 Myocardial Infarction 29890520 Overcoming Heparin-Associated RT-qPCR Inhibition and Normalization Issues for microRNA Quantification in Patients with Acute Myocardial Infarction. +other hsa-mir-197 "Lymphoma, Large B-Cell, Diffuse" 29890998 Clinicopathologic implication of microRNA-197 in diffuse large B cell lymphoma. +other hsa-mir-30 "Carcinoma, Breast" 29894647 MicroRNA-30 mediates cell invasion and metastasis in breast cancer. +other hsa-mir-200c Lung Neoplasms 29898461 miR-200c can be used as a highly sensitive molecular staging biomarker that will enhance nodal staging of lung cancer +other hsa-mir-210 Prostate Neoplasms 29901117 Effects of microRNA?210 on the diagnosis and treatment of prostate cancer. +other hsa-mir-122 Atrial Fibrillation 29901138 Upregulation of miR?122 is associated with cardiomyocyte apoptosis in atrial fibrillation. +other hsa-mir-381 "Carcinoma, Hepatocellular" 29904424 Expression and role of VEGFA and miR-381 in portal vein tumor thrombi in patients with hepatocellular carcinoma. +other hsa-mir-124a Kidney Diseases [unspecific] 29904949 Combination with miR-124a improves the protective action of BMSCs in rescuing injured rat podocytes from abnormal apoptosis and autophagy. +other hsa-mir-203 "Carcinoma, Hepatocellular" 29906128 MicroRNA-203 Increases Cell Radiosensitivity via Directly Targeting Bmi-1 in Hepatocellular Carcinoma. +other hsa-mir-199b Pulmonary Hypertension 29906222 "This study describes a novel microRNA signature of adaptive right ventricular hypertrophy, with particular attention to miR-199b and miR-29a" +other hsa-mir-29a Pulmonary Hypertension 29906222 "This study describes a novel microRNA signature of adaptive right ventricular hypertrophy, with particular attention to miR-199b and miR-29a" +other hsa-mir-505 Glioblastoma 29906532 Combination with TMZ and miR-505 inhibits the development of glioblastoma by regulating the WNT7B/Wnt/¦Â-catenin signaling pathway. +other hsa-mir-181a "Carcinoma, Breast" 29907248 Micro-RNA-181a suppresses progestin-promoted breast cancer cell growth. +other hsa-mir-98 Myocardial Infarction 29913449 Pre-Treatment with Melatonin Enhances Therapeutic Efficacy of Cardiac Progenitor Cells for Myocardial Infarction. +other hsa-mir-6853 "Diabetes Mellitus, Type 2" 29916530 miR?6835?3p regulates the function of pancreatic islet cells by modulating the expression of AdipoR1. +other hsa-mir-184 Osteosarcoma 29916553 Regulatory effects of microRNA?184 on osteosarcoma via the Wnt/¦Â?catenin signaling pathway. +other hsa-mir-26a Acute Cerebral Infarction 29917203 MiRNA-26a promotes angiogenesis in a rat model of cerebral infarction via PI3K/AKT and MAPK/ERK pathway. +other hsa-mir-499 Cardiovascular Diseases [unspecific] 29920798 Unlockable Nanocomplexes with Self-Accelerating Nucleic Acid Release for Effective Staged Gene Therapy of Cardiovascular Diseases. +other hsa-mir-107 "Carcinoma, Breast" 29921315 Expression of ID4 protein in breast cancer cells induces reprogramming of tumour-associated macrophages. +other hsa-mir-15b "Carcinoma, Breast" 29921315 Expression of ID4 protein in breast cancer cells induces reprogramming of tumour-associated macrophages. +other hsa-let-7g Lung Neoplasms 29923982 "Three miRNAs (let-7g-5p, miR-143-3p, and miR-374a-5p) were associated with postoperative recurrence in both microarray and TCGA data sets" +other hsa-mir-143 Lung Neoplasms 29923982 "Three miRNAs (let-7g-5p, miR-143-3p, and miR-374a-5p) were associated with postoperative recurrence in both microarray and TCGA data sets" +other hsa-mir-374a Lung Neoplasms 29923982 "Three miRNAs (let-7g-5p, miR-143-3p, and miR-374a-5p) were associated with postoperative recurrence in both microarray and TCGA data sets" +other hsa-mir-320b Acute Ischemic Stroke 29926387 Unique MicroRNAs Signature of Lymphocyte of Yang and Yin Syndromes in Acute Ischemic Stroke Patients. +other hsa-mir-93 Acute Ischemic Stroke 29926387 Unique MicroRNAs Signature of Lymphocyte of Yang and Yin Syndromes in Acute Ischemic Stroke Patients. +other hsa-mir-888 Colorectal Carcinoma 29928331 miR-888 functions as an oncogene and predicts poor prognosis in colorectal cancer. +other hsa-mir-148a "Carcinoma, Lung, Non-Small-Cell" 29928367 miR-148a may regulate a panel of tumor-associated proteins to suppress metastasis in NSCLC +other hsa-mir-130a Diabetic Peripheral Neuropathy 29932869 Exosomes derived from high-glucose-stimulated Schwann cells promote development of diabetic peripheral neuropathy. +other hsa-mir-28 Diabetic Peripheral Neuropathy 29932869 Exosomes derived from high-glucose-stimulated Schwann cells promote development of diabetic peripheral neuropathy. +other hsa-mir-31a Diabetic Peripheral Neuropathy 29932869 Exosomes derived from high-glucose-stimulated Schwann cells promote development of diabetic peripheral neuropathy. +other hsa-mir-496 "Carcinoma, Oropharyngeal" 29935424 Human papillomavirus 16 E6 modulates the expression of miR-496 in oropharyngeal cancer. +other hsa-mir-26b Ischemic Diseases [unspecific] 29937716 MicroRNA-26b Regulates the Microglial Inflammatory Response in Hypoxia/Ischemia and Affects the Development of Vascular Cognitive Impairment. +other hsa-mir-126 Fabry Disease 29937989 "miR-199a-5p, and miR-126-3p are involved in endothelial dysfunction and miR-423-5p and miR-451a in myocardial remodeling" +other hsa-mir-199a Fabry Disease 29937989 "miR-199a-5p, and miR-126-3p are involved in endothelial dysfunction and miR-423-5p and miR-451a in myocardial remodeling" +other hsa-mir-423 Fabry Disease 29937989 "miR-199a-5p, and miR-126-3p are involved in endothelial dysfunction and miR-423-5p and miR-451a in myocardial remodeling" +other hsa-mir-451a Fabry Disease 29937989 "miR-199a-5p, and miR-126-3p are involved in endothelial dysfunction and miR-423-5p and miR-451a in myocardial remodeling" +other hsa-mir-383 Colorectal Carcinoma 29938829 MicroRNA-383 acts as a tumor suppressor in colorectal cancer by modulating CREPT/RPRD1B expression. +other hsa-mir-7 "Carcinoma, Breast" 29941867 Association of microRNA-7 and its binding partner CDR1-AS with the prognosis and prediction of 1st-line tamoxifen therapy in breast cancer. +other hsa-mir-205 Ovarian Neoplasms 29943422 Tanshinone IIA induced cell apoptosis in ovarian carcinoma TOV-21G cells via direct upregulation of miR-205 +other hsa-mir-198 "Carcinoma, Lung, Non-Small-Cell" 29943841 MicroRNA-198 inhibition of HGF/c-MET signaling pathway overcomes resistance to radiotherapy and induces apoptosis in human non-small-cell lung cancer. +other hsa-mir-106a Gastric Neoplasms 29948558 Negative Regulation of Kruppel-Like Factor 4 on microRNA-106a at Upstream Transcriptional Level and the Role in Gastric Cancer Metastasis. +other hsa-mir-19 Ischemia-Reperfusion Injury 29953651 MicroRNA-19 restores vascular endothelial cell function in lower limb ischemia-reperfusion injury through the KLF10-dependent TGF-¦Â1/Smad signaling pathway in rats. +other hsa-mir-17 Gastric Neoplasms 29953965 MicroRNA-17 inhibition overcomes chemoresistance and suppresses epithelial-mesenchymal transition through a DEDD-dependent mechanism in gastric cancer. +other hsa-mir-26a "Aortic Aneurysm, Abdominal" 29956734 MicroRNA?26a protects vascular smooth muscle cells against H2O2?induced injury through activation of the PTEN/AKT/mTOR pathway. +other hsa-mir-361 Gastric Neoplasms 29960070 MiR-361-5p inhibits the mobility of gastric cancer cells through suppressing epithelial-mesenchymal transition via the Wnt/¦Â-catenin pathway. +other hsa-mir-19b Ovarian Neoplasms 29963131 MicroRNA-19b promotes the migration and invasion of ovarian cancer cells by inhibiting the PTEN/AKT signaling pathway. +other hsa-mir-202 "Carcinoma, Breast" 29963190 miR-202 acts as a potential tumor suppressor in breast cancer. +other hsa-mir-140 Porcine Reproductive and Respiratory Syndrome Virus Infection 29969475 Utilizing host endogenous microRNAs to negatively regulate the replication of porcine reproductive and respiratory syndrome virus in MARC-145 cells. +other hsa-mir-181 "Leukemia, Myeloid, Acute" 29969755 Circ-ANAPC7 is Upregulated in Acute Myeloid Leukemia and Appears to Target the MiR-181 Family. +other hsa-mir-106b "Carcinoma, Bladder" 29970902 Identification of microR-106b as a prognostic biomarker of p53-like bladder cancers by ActMiR. +other hsa-mir-155 Atherosclerosis 29977930 TRIF Regulates BIC/miR-155 via the ERK Signaling Pathway to Control the ox-LDL-Induced Macrophage Inflammatory Response. +other hsa-mir-199a "Lymphoma, Mantle-Cell" 29979193 MiR-199a mediated the dissemination of human mantle cell lymphoma by interacting with the CCR7/CCL21 pair. +other hsa-mir-142 Coronary Artery Disease 29979444 miR-142-3p and miR-17-5p might be potential targets for follow-up research in evaluating biomarkers of coronary artery disease +other hsa-mir-17 Coronary Artery Disease 29979444 miR-142-3p and miR-17-5p might be potential targets for follow-up research in evaluating biomarkers of coronary artery disease +other hsa-mir-132 Alzheimer Disease 29982852 MicroRNA-132 provides neuroprotection for tauopathies via multiple signaling pathways. +other hsa-mir-181 Cardiovascular Diseases [unspecific] 29985373 In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge. +other hsa-mir-135b Gastric Neoplasms 29985646 Helicobacter pylori-induced miR-135b-5p promotes cisplatin resistance in gastric cancer. +other hsa-mir-196a "Carcinoma, Pancreatic" 29986379 miR-196a Is Able to Restore the Aggressive Phenotype of Annexin A1 Knock-Out in Pancreatic Cancer Cells by CRISPR/Cas9 Genome Editing. +other hsa-mir-663 Neoplasms [unspecific] 29987196 "MiR-663, a MicroRNA Linked with Inflammation and Cancer That Is under the Influence of Resveratrol." +other hsa-mir-101 "Adenocarcinoma, Esophageal" 29987600 Two miRNA ratios (miR-4521/miR-340-5p and miR-101-3p/miR-451a) that predicted the pathological response to neoadjuvant chemoradiotherapy were found to be associated with relapse-free survival +other hsa-mir-340 "Adenocarcinoma, Esophageal" 29987600 Two miRNA ratios (miR-4521/miR-340-5p and miR-101-3p/miR-451a) that predicted the pathological response to neoadjuvant chemoradiotherapy were found to be associated with relapse-free survival +other hsa-mir-451a "Adenocarcinoma, Esophageal" 29987600 Two miRNA ratios (miR-4521/miR-340-5p and miR-101-3p/miR-451a) that predicted the pathological response to neoadjuvant chemoradiotherapy were found to be associated with relapse-free survival +other hsa-mir-4521 "Adenocarcinoma, Esophageal" 29987600 Two miRNA ratios (miR-4521/miR-340-5p and miR-101-3p/miR-451a) that predicted the pathological response to neoadjuvant chemoradiotherapy were found to be associated with relapse-free survival +other hsa-let-7b Rectum Adenocarcinoma 29988972 we identified an association between increased let-7b and worse clinical outcomes +other hsa-mir-152 "Carcinoma, Breast, Triple Negative" 29990486 Melatonin restrains angiogenic factors in triple-negative breast cancer by targeting miR-152-3p: In vivo and in vitro studies. +other hsa-mir-155 Heart Failure 29990505 Osteoglycin post-transcriptional regulation by miR-155 induces cellular architecture changes in H9c2 cardiomyoblasts. +other hsa-mir-21 "Carcinoma, Renal Cell" 29993250 Small Molecule Inhibition of MicroRNA miR-21 Rescues Chemosensitivity of Renal-Cell Carcinoma to Topotecan. +other hsa-mir-146a Amyotrophic Lateral Sclerosis 29995256 Data indicate that astrocytes in mSOD1 mice model acquire early phenotypic aberrancies and highlight downregulated miR-146a as a biomarker and drug target in ALS +other hsa-mir-149 Neoplasms [unspecific] 29999552 Regulation and functions of MicroRNA-149 in human cancers. +other hsa-mir-30a Obesity 30002134 miR-30a Remodels Subcutaneous Adipose Tissue Inflammation to Improve Insulin Sensitivity in Obesity. +other hsa-mir-4455 Gastric Neoplasms 30002604 "Vasodilator-stimulated phosphoprotein (VASP), a novel target of miR-4455, promotes gastric cancer cell proliferation, migration, and invasion, through activating the PI3K/AKT signaling pathway." +other hsa-mir-128 "Carcinoma, Breast" 30004628 TGF¦Â1 regulates HGF-induced cell migration and hepatocyte growth factor receptor MET expression via C-ets-1 and miR-128-3p in basal-like breast cancer. +other hsa-mir-200a "Carcinoma, Thyroid, Papillary" 30005075 A potential biomarker hsa-miR-200a-5p distinguishing between benign thyroid tumors with papillary hyperplasia and papillary thyroid carcinoma. +other hsa-mir-218 Amyotrophic Lateral Sclerosis 30007309 motor neuron-derived miR-218 may have a functional role in amyotrophic lateral sclerosis +other hsa-mir-218 Prostate Neoplasms 30008871 "MicroRNA-218 inhibits the migration, epithelial-mesenchymal transition and cancer stem cell properties of prostate cancer cells." +other hsa-mir-425 "Carcinoma, Renal Cell" 30008916 "Oncogenic miR-425-5p is associated with cellular migration, proliferation and apoptosis in renal cell carcinoma." +other hsa-mir-23a Gastric Neoplasms 30008935 MicroRNA-23a/27a/24-2 cluster promotes gastric cancer cell proliferation synergistically. +other hsa-mir-24-2 Gastric Neoplasms 30008935 MicroRNA-23a/27a/24-2 cluster promotes gastric cancer cell proliferation synergistically. +other hsa-mir-27a Gastric Neoplasms 30008935 MicroRNA-23a/27a/24-2 cluster promotes gastric cancer cell proliferation synergistically. +other hsa-mir-10a "Carcinoma, Breast" 30010434 "high expression of miR-134, miR-125b-5P, miRNA-30a, miR-10a-5p and miR-222 were significantly associated with short relapse-free time" +other hsa-mir-125b "Carcinoma, Breast" 30010434 "high expression of miR-134, miR-125b-5P, miRNA-30a, miR-10a-5p and miR-222 were significantly associated with short relapse-free time" +other hsa-mir-134 "Carcinoma, Breast" 30010434 "high expression of miR-134, miR-125b-5P, miRNA-30a, miR-10a-5p and miR-222 were significantly associated with short relapse-free time" +other hsa-mir-222 "Carcinoma, Breast" 30010434 "high expression of miR-134, miR-125b-5P, miRNA-30a, miR-10a-5p and miR-222 were significantly associated with short relapse-free time" +other hsa-mir-30a "Carcinoma, Breast" 30010434 "high expression of miR-134, miR-125b-5P, miRNA-30a, miR-10a-5p and miR-222 were significantly associated with short relapse-free time" +other hsa-mir-146a Periodontitis 30012943 "These results suggest that CyP may modulate the pro-inflammatory response induced by Pg-LPS, not only by blocking TLR4-MD2 complex, but also by preserving miR-146a expression" +other hsa-mir-9 Lung Neoplasms 30012957 Lamins in Lung Cancer: Biomarkers and Key Factors for Disease Progression through miR-9 Regulation +other hsa-mir-127 Ovarian Neoplasms 30013629 miR-127 was negatively associated with tumor grade +other hsa-mir-431 "Leukemia, Myeloid, Acute" 30013666 The transfection of miR-431 suppressed the migration and invasion of AML cells +other hsa-mir-122 Ischemia-Reperfusion Injury 30014282 "The Effect of Zinc Sulfate on miR-122, miR-34a, Atioxidants, Biochemical and Histopathological Parameters Following Hepatic Ischemia/Reperfusion Injury in Rats." +other hsa-mir-34a Ischemia-Reperfusion Injury 30014282 "The Effect of Zinc Sulfate on miR-122, miR-34a, Atioxidants, Biochemical and Histopathological Parameters Following Hepatic Ischemia/Reperfusion Injury in Rats." +other hsa-mir-133b Peripheral Nerve Injury 30018017 Intrathecal Injection of miR-133b-3p or miR-143-3p Prevents the Development of Persistent Cold and Mechanical Allodynia Following a Peripheral Nerve Injury in Rats. +other hsa-mir-143 Peripheral Nerve Injury 30018017 Intrathecal Injection of miR-133b-3p or miR-143-3p Prevents the Development of Persistent Cold and Mechanical Allodynia Following a Peripheral Nerve Injury in Rats. +other hsa-let-7f Thyroid Neoplasms 30018229 "Treatment with selumetinib caused a down-regulation of hsa-let-7f-5p, hsa-miR-146b-5p and hsa-miR-146b-3p in TPC1 and BCPAP cells" +other hsa-mir-146b Thyroid Neoplasms 30018229 "Treatment with selumetinib caused a down-regulation of hsa-let-7f-5p, hsa-miR-146b-5p and hsa-miR-146b-3p in TPC1 and BCPAP cells" +other hsa-let-7 "Carcinoma, Breast" 30018709 "microRNAs (miR-21, miR-155-5p and let-7) may participate in the ILF2 expression network in breast cancer" +other hsa-mir-155 "Carcinoma, Breast" 30018709 "microRNAs (miR-21, miR-155-5p and let-7) may participate in the ILF2 expression network in breast cancer" +other hsa-mir-21 "Carcinoma, Breast" 30018709 "microRNAs (miR-21, miR-155-5p and let-7) may participate in the ILF2 expression network in breast cancer" +other hsa-mir-4319 "Carcinoma, Breast, Triple Negative" 30021199 MiR-4319 Suppress the Malignancy of Triple-Negative Breast Cancer by Regulating Self-Renewal and Tumorigenesis of Stem Cells. +other hsa-mir-21 "Carcinoma, Salivary Adenoid Cystic" 30021341 Effect of simvastatin and microRNA-21 inhibitor on metastasis and progression of human salivary adenoid cystic carcinoma. +other hsa-mir-663a "Carcinoma, Renal Cell" 30021352 Oncogenic miR-663a is associated with cellular function and poor prognosis in renal cell carcinoma. +other hsa-mir-34a Sepsis 30021364 MicroRNA-34a promotes iNOS secretion from pulmonary macrophages in septic suckling rats through activating STAT3 pathway. +other hsa-mir-449a Osteoarthritis 30021388 MicroRNA-449a upregulation promotes chondrocyte extracellular matrix degradation in osteoarthritis. +other hsa-mir-7 "Carcinoma, Lung, Non-Small-Cell" 30022841 Overexpressed CDR1as functions as an oncogene to promote the tumor progression via miR-7 in non-small-cell lung cancer. +other hsa-mir-486 Lung Neoplasms 30023372 miR-486 inhibits PM2.5-induced apoptosis and oxidative stress in human lung alveolar epithelial A549 cells. +other hsa-mir-218 Chronic Obstructive Pulmonary Disease 30024625 "miR-218-5p may, therefore, play an important role in the pathogenesis of COPD" +other hsa-mir-137 Schizophrenia 30026708 Association of MIR137 With Symptom Severity and Cognitive Functioning in Belarusian Schizophrenia Patients. +other hsa-mir-10b Neoplasms [unspecific] 30028875 Potent and selective effect of the mir-10b inhibitor MN-anti-mir10b in human cancer cells of diverse primary disease origin. +other hsa-mir-1 Cardiac Myocyte Injury 30029588 "Six of them (miR-1, miR-208a-3p, miR-199a-5p, miR-21-5p, miR-146a-5p, and miR-30c-5p) were reported to be related to cardiac pathological functions" +other hsa-mir-146a Cardiac Myocyte Injury 30029588 "Six of them (miR-1, miR-208a-3p, miR-199a-5p, miR-21-5p, miR-146a-5p, and miR-30c-5p) were reported to be related to cardiac pathological functions" +other hsa-mir-199a Cardiac Myocyte Injury 30029588 "Six of them (miR-1, miR-208a-3p, miR-199a-5p, miR-21-5p, miR-146a-5p, and miR-30c-5p) were reported to be related to cardiac pathological functions" +other hsa-mir-208a Cardiac Myocyte Injury 30029588 "Six of them (miR-1, miR-208a-3p, miR-199a-5p, miR-21-5p, miR-146a-5p, and miR-30c-5p) were reported to be related to cardiac pathological functions" +other hsa-mir-21 Cardiac Myocyte Injury 30029588 "Six of them (miR-1, miR-208a-3p, miR-199a-5p, miR-21-5p, miR-146a-5p, and miR-30c-5p) were reported to be related to cardiac pathological functions" +other hsa-mir-30c Cardiac Myocyte Injury 30029588 "Six of them (miR-1, miR-208a-3p, miR-199a-5p, miR-21-5p, miR-146a-5p, and miR-30c-5p) were reported to be related to cardiac pathological functions" +other hsa-mir-124 Chronic Hepatitis B 30031388 "miRNA-15, miRNA-124, miRNA-218-5P with significant activation of Z-Score" +other hsa-mir-15 Chronic Hepatitis B 30031388 "miRNA-15, miRNA-124, miRNA-218-5P with significant activation of Z-Score" +other hsa-mir-218 Chronic Hepatitis B 30031388 "miRNA-15, miRNA-124, miRNA-218-5P with significant activation of Z-Score" +other hsa-mir-374a "Carcinoma, Bladder" 30032142 MicroRNA-374a Inhibits Aggressive Tumor Biological Behavior in Bladder Carcinoma by Suppressing Wnt/¦Â-Catenin Signaling. +other hsa-mir-16 Prostate Neoplasms 30032144 MiR-195/-16 Family Enhances Radiotherapy via T Cell Activation in the Tumor Microenvironment by Blocking the PD-L1 Immune Checkpoint. +other hsa-mir-195 Prostate Neoplasms 30032144 MiR-195/-16 Family Enhances Radiotherapy via T Cell Activation in the Tumor Microenvironment by Blocking the PD-L1 Immune Checkpoint. +other hsa-mir-141 Glioma 30034253 The miR-200 family: multiple effects on gliomas. +other hsa-mir-200a Glioma 30034253 The miR-200 family: multiple effects on gliomas. +other hsa-mir-200b Glioma 30034253 The miR-200 family: multiple effects on gliomas. +other hsa-mir-200c Glioma 30034253 The miR-200 family: multiple effects on gliomas. +other hsa-mir-429 Glioma 30034253 The miR-200 family: multiple effects on gliomas. +other hsa-mir-494 Spinal Cord Injuries 30036869 Effects of MicroRNA-494 on Astrocyte Proliferation and Synaptic Remodeling in the Spinal Cord of a Rat Model of Chronic Compressive Spinal Cord Injury by Regulating the Nogo/Ngr Signaling Pathway. +other hsa-mir-363 Ovarian Neoplasms 30037365 MiR-363 inhibits cisplatin chemoresistance of epithelial ovarian cancer by regulating snail-induced epithelial-mesenchymal transition. +other hsa-mir-17 "Lymphoma, Non-Hodgkin" 30038718 "Lymphomas clustered according to histological subtypes, driven by two miRNA clusters (the miR-29 family and the miR-17-92 cluster)" +other hsa-mir-18 "Lymphoma, Non-Hodgkin" 30038718 "Lymphomas clustered according to histological subtypes, driven by two miRNA clusters (the miR-29 family and the miR-17-92 cluster)" +other hsa-mir-19a "Lymphoma, Non-Hodgkin" 30038718 "Lymphomas clustered according to histological subtypes, driven by two miRNA clusters (the miR-29 family and the miR-17-92 cluster)" +other hsa-mir-19b-1 "Lymphoma, Non-Hodgkin" 30038718 "Lymphomas clustered according to histological subtypes, driven by two miRNA clusters (the miR-29 family and the miR-17-92 cluster)" +other hsa-mir-20a "Lymphoma, Non-Hodgkin" 30038718 "Lymphomas clustered according to histological subtypes, driven by two miRNA clusters (the miR-29 family and the miR-17-92 cluster)" +other hsa-mir-29a "Lymphoma, Non-Hodgkin" 30038718 "Lymphomas clustered according to histological subtypes, driven by two miRNA clusters (the miR-29 family and the miR-17-92 cluster)" +other hsa-mir-29b "Lymphoma, Non-Hodgkin" 30038718 "Lymphomas clustered according to histological subtypes, driven by two miRNA clusters (the miR-29 family and the miR-17-92 cluster)" +other hsa-mir-29c "Lymphoma, Non-Hodgkin" 30038718 "Lymphomas clustered according to histological subtypes, driven by two miRNA clusters (the miR-29 family and the miR-17-92 cluster)" +other hsa-mir-92-1 "Lymphoma, Non-Hodgkin" 30038718 "Lymphomas clustered according to histological subtypes, driven by two miRNA clusters (the miR-29 family and the miR-17-92 cluster)" +other hsa-mir-29c "Carcinoma, Renal Cell, Clear-Cell" 30041179 Upregulation of MIAT Regulates LOXL2 Expression by Competitively Binding MiR-29c in Clear Cell Renal Cell Carcinoma. +other hsa-mir-134 Parkinson Disease 30041414 Delivery of miRNA-Targeted Oligonucleotides in the Rat Striatum by Magnetofection with Neuromag?. +other hsa-mir-141 "Adenocarcinoma, Pancreatic Ductal" 30041660 WIPF1 antagonizes the tumor suppressive effect of miR-141/200c and is associated with poor survival in patients with PDAC. +other hsa-mir-200c "Adenocarcinoma, Pancreatic Ductal" 30041660 WIPF1 antagonizes the tumor suppressive effect of miR-141/200c and is associated with poor survival in patients with PDAC. +other hsa-mir-135a Lung Injury [unspecific] 30045018 MiR-135a Protects Vascular Endothelial Cells Against Ventilator-Induced Lung Injury by Inhibiting PHLPP2 to Activate PI3K/Akt Pathway. +other hsa-mir-21 Rheumatoid Arthritis 30045854 Maresin 1 improves the Treg/Th17 imbalance in rheumatoid arthritis through miR-21. +other hsa-mir-132 Inflammatory Bowel Diseases 30046303 "Regarding autophagy-related pathways, miR-146b, miR-221-5p, miR-132, miR-223, miR-155, and miR-21 regulate NF-¦ÊB or mTOR signaling to induce or inhibit autophagy in intestinal cells by releasing anti- or proinflammatory factors, respectively" +other hsa-mir-146b Inflammatory Bowel Diseases 30046303 "Regarding autophagy-related pathways, miR-146b, miR-221-5p, miR-132, miR-223, miR-155, and miR-21 regulate NF-¦ÊB or mTOR signaling to induce or inhibit autophagy in intestinal cells by releasing anti- or proinflammatory factors, respectively" +other hsa-mir-155 Inflammatory Bowel Diseases 30046303 "Regarding autophagy-related pathways, miR-146b, miR-221-5p, miR-132, miR-223, miR-155, and miR-21 regulate NF-¦ÊB or mTOR signaling to induce or inhibit autophagy in intestinal cells by releasing anti- or proinflammatory factors, respectively" +other hsa-mir-21 Inflammatory Bowel Diseases 30046303 "Regarding autophagy-related pathways, miR-146b, miR-221-5p, miR-132, miR-223, miR-155, and miR-21 regulate NF-¦ÊB or mTOR signaling to induce or inhibit autophagy in intestinal cells by releasing anti- or proinflammatory factors, respectively" +other hsa-mir-221 Inflammatory Bowel Diseases 30046303 "Regarding autophagy-related pathways, miR-146b, miR-221-5p, miR-132, miR-223, miR-155, and miR-21 regulate NF-¦ÊB or mTOR signaling to induce or inhibit autophagy in intestinal cells by releasing anti- or proinflammatory factors, respectively" +other hsa-mir-223 Inflammatory Bowel Diseases 30046303 "Regarding autophagy-related pathways, miR-146b, miR-221-5p, miR-132, miR-223, miR-155, and miR-21 regulate NF-¦ÊB or mTOR signaling to induce or inhibit autophagy in intestinal cells by releasing anti- or proinflammatory factors, respectively" +other hsa-mir-15a Neoplasms [unspecific] 30047999 miR-15a/16 deletion in macrophages holds a distinct biological significance from that of the microRNA deficiency in tumour cells +other hsa-mir-16 Neoplasms [unspecific] 30047999 miR-15a/16 deletion in macrophages holds a distinct biological significance from that of the microRNA deficiency in tumour cells +other hsa-mir-101 Neoplasms [unspecific] 30049386 A Nucleolar Stress-Specific p53-miR-101 Molecular Circuit Functions as an Intrinsic Tumor-Suppressor Network. +other hsa-mir-214 Hypertension 30049682 MicroRNA-214-3p in the Kidney Contributes to the Development of Hypertension. +other hsa-mir-26b Colorectal Carcinoma 30051451 miR-26b may promote the invasion and metastasis of colorectal cancer by accelerating the migration and invasion of colorectal cancer cells +other hsa-mir-190b "Carcinoma, Breast" 30055304 "Tree-based machine learning modelstrained in my analysis used hsa-miR-139 with hsa-miR-183 to classify breast tumors from normal samples, and hsa-miR4728 with hsa-miR190b to further classify these tumors into three major subtypes of breast cancer" +other hsa-mir-4728 "Carcinoma, Breast" 30055304 "Tree-based machine learning modelstrained in my analysis used hsa-miR-139 with hsa-miR-183 to classify breast tumors from normal samples, and hsa-miR4728 with hsa-miR190b to further classify these tumors into three major subtypes of breast cancer" +other hsa-mir-146a Colon Neoplasms 30056535 Fascin protein stabilization by miR-146a implicated in the process of a chronic inflammation-related colon carcinogenesis model. +other hsa-mir-122 Hepatitis C Virus Infection 30058773 Hepatitis C Virus Infection of Cultured Cells and Primary Human Hepatocytes. +other hsa-mir-145 Bicuspid Aortic Valve Disease 30059548 MiR-145 expression and rare NOTCH1 variants in bicuspid aortic valve-associated aortopathy. +other hsa-mir-192 Hepatitis B Virus Infection 30059664 HBV upregulates the expression of miR-192-5p and miR-194-5p in the host cell +other hsa-mir-194 Hepatitis B Virus Infection 30059664 HBV upregulates the expression of miR-192-5p and miR-194-5p in the host cell +other hsa-mir-218 Preeclampsia 30061037 MicroRNA-218-5p Promotes Endovascular Trophoblast Differentiation and Spiral Artery Remodeling. +other hsa-mir-205 "Carcinoma, Renal Cell, Clear-Cell" 30061948 Comparison of exosomal microRNAs secreted by 786-O clear cell renal carcinoma cells and HK-2 proximal tubule-derived cells in culture identifies microRNA-205 as a potential biomarker of clear cell renal carcinoma. +other hsa-mir-786 "Carcinoma, Renal Cell, Clear-Cell" 30061948 Comparison of exosomal microRNAs secreted by 786-O clear cell renal carcinoma cells and HK-2 proximal tubule-derived cells in culture identifies microRNA-205 as a potential biomarker of clear cell renal carcinoma. +other hsa-mir-331 "Carcinoma, Breast" 30063890 A comprehensive clinicopathological evaluation of the differential expression of microRNA-331 in breast tumors and its diagnostic significance. +other hsa-mir-21 Traumatic Brain Injury 30066160 MicroRNA-21 in the Pathogenesis of Traumatic Brain Injury. +other hsa-mir-142 "Leukemia, Lymphoblastic, Acute" 30066657 "We successfully identified two microRNAs, hsa-miR-142-3p and hsa-miR-17-5p, which are computationally predicted to closely relate to glucocorticoid resistance" +other hsa-mir-17 "Leukemia, Lymphoblastic, Acute" 30066657 "We successfully identified two microRNAs, hsa-miR-142-3p and hsa-miR-17-5p, which are computationally predicted to closely relate to glucocorticoid resistance" +other hsa-mir-205 Prostate Neoplasms 30066866 Ultrasound?targeted microbubble destruction?mediated miR?205 enhances cisplatin cytotoxicity in prostate cancer cells. +other hsa-mir-320a Neoplasms [unspecific] 30066913 "Transcriptional activation of miR-320a by ATF2, ELK1 and YY1 induces cancer cell apoptosis under ionizing radiation conditions." +other hsa-mir-124 Gastric Neoplasms 30068360 The targets of circHIPK3-miR-124/miR-29b axes involved in the progression of GC +other hsa-mir-29b Gastric Neoplasms 30068360 The targets of circHIPK3-miR-124/miR-29b axes involved in the progression of GC +other hsa-mir-146a Osteoarthritis 30071609 the reduced expression of miR-146a was found to be coupled to reduced type II collagen (COL2) in OA cartilage +other hsa-mir-24 Mesothelioma 30072395 A Polysome-Based microRNA Screen Identifies miR-24-3p as a Novel Promigratory miRNA in Mesothelioma. +other hsa-mir-146b Vascular Disease [unspecific] 30073586 Loss of miR-146b-3p Inhibits Perivascular Adipocyte Browning with Cold Exposure During Aging. +other hsa-mir-302b "Carcinoma, Bladder" 30075175 MiR-302b regulates cell functions and acts as a potential biomarker to predict recurrence in bladder cancer. +other hsa-mir-17 Leukemia 30076175 Transcriptional activation of the miR-17-92 cluster is involved in the growth-promoting effects of MYB in human Ph-positive leukemia cells. +other hsa-mir-18 Leukemia 30076175 Transcriptional activation of the miR-17-92 cluster is involved in the growth-promoting effects of MYB in human Ph-positive leukemia cells. +other hsa-mir-19a Leukemia 30076175 Transcriptional activation of the miR-17-92 cluster is involved in the growth-promoting effects of MYB in human Ph-positive leukemia cells. +other hsa-mir-19b-1 Leukemia 30076175 Transcriptional activation of the miR-17-92 cluster is involved in the growth-promoting effects of MYB in human Ph-positive leukemia cells. +other hsa-mir-20a Leukemia 30076175 Transcriptional activation of the miR-17-92 cluster is involved in the growth-promoting effects of MYB in human Ph-positive leukemia cells. +other hsa-mir-92-1 Leukemia 30076175 Transcriptional activation of the miR-17-92 cluster is involved in the growth-promoting effects of MYB in human Ph-positive leukemia cells. +other hsa-mir-214 Muscle Diseases [unspecific] 30076721 MiR-214 is an important regulator of the musculoskeletal metabolism and disease. +other hsa-mir-142 Colitis 30076847 "administration of tetracyclines led to increased mucosal protection, associated with up-regulated expression of CCL2, miR-142 and miR-375" +other hsa-mir-375 Colitis 30076847 "administration of tetracyclines led to increased mucosal protection, associated with up-regulated expression of CCL2, miR-142 and miR-375" +other hsa-mir-548 Subacute Sclerosing Panencephalitis 30077763 "IL28B, IL29 and micro-RNA 548 in subacute sclerosing panencephalitis as a rare disease." +other hsa-mir-195 Preeclampsia 30078346 Regulatory effect of miR-195 in the placental dysfunction of preeclampsia. +other hsa-mir-142 Rheumatoid Arthritis 30081592 "Experimental and bioinformatics analyses revealed 8 miRNAs (miR-22, miR-27a, miR-96, miR-142, miR-223, miR-296, miR-298, and miR-451) and their target genes in functional pathways important for RA pathogenesis" +other hsa-mir-22 Rheumatoid Arthritis 30081592 "Experimental and bioinformatics analyses revealed 8 miRNAs (miR-22, miR-27a, miR-96, miR-142, miR-223, miR-296, miR-298, and miR-451) and their target genes in functional pathways important for RA pathogenesis" +other hsa-mir-223 Rheumatoid Arthritis 30081592 "Experimental and bioinformatics analyses revealed 8 miRNAs (miR-22, miR-27a, miR-96, miR-142, miR-223, miR-296, miR-298, and miR-451) and their target genes in functional pathways important for RA pathogenesis" +other hsa-mir-27a Rheumatoid Arthritis 30081592 "Experimental and bioinformatics analyses revealed 8 miRNAs (miR-22, miR-27a, miR-96, miR-142, miR-223, miR-296, miR-298, and miR-451) and their target genes in functional pathways important for RA pathogenesis" +other hsa-mir-296 Rheumatoid Arthritis 30081592 "Experimental and bioinformatics analyses revealed 8 miRNAs (miR-22, miR-27a, miR-96, miR-142, miR-223, miR-296, miR-298, and miR-451) and their target genes in functional pathways important for RA pathogenesis" +other hsa-mir-298 Rheumatoid Arthritis 30081592 "Experimental and bioinformatics analyses revealed 8 miRNAs (miR-22, miR-27a, miR-96, miR-142, miR-223, miR-296, miR-298, and miR-451) and their target genes in functional pathways important for RA pathogenesis" +other hsa-mir-451 Rheumatoid Arthritis 30081592 "Experimental and bioinformatics analyses revealed 8 miRNAs (miR-22, miR-27a, miR-96, miR-142, miR-223, miR-296, miR-298, and miR-451) and their target genes in functional pathways important for RA pathogenesis" +other hsa-mir-96 Rheumatoid Arthritis 30081592 "Experimental and bioinformatics analyses revealed 8 miRNAs (miR-22, miR-27a, miR-96, miR-142, miR-223, miR-296, miR-298, and miR-451) and their target genes in functional pathways important for RA pathogenesis" +other hsa-mir-145 "Adenocarcinoma, Lung" 30082847 Dual strands of the miR-145 duplex (miR-145-5p and miR-145-3p) regulate oncogenes in lung adenocarcinoma pathogenesis. +other hsa-mir-388 Pemphigus 30083474 Usefulness of miRNA-338-3p in the diagnosis of pemphigus and its correlation with disease severity. +other hsa-mir-144 Myocardial Infarction 30084039 Intravenous miR-144 reduces left ventricular remodeling after myocardial infarction. +other hsa-mir-199a "Carcinoma, Breast, Triple Negative" 30086965 "Design, development and evaluation of microRNA-199a-5p detecting electrochemical nanobiosensor with diagnostic application in Triple Negative Breast Cancer." +other hsa-mir-373 Hepatitis C Virus Infection 30089699 Association between MicroRNA-373 and Long Noncoding RNA NORAD in Hepatitis C Virus-Infected Hepatocytes Impairs Wee1 Expression for Growth Promotion. +other hsa-mir-17 Intervertebral Disc Degeneration 30089772 whereas circRNA_104670 and miRNA-17-3p inhibition mice had a higher IDD grade compared with circRNA_104670 inhibition mice +other hsa-mir-203 "Carcinoma, Breast" 30091053 Lack of effective translational regulation of PLD expression and exosome biogenesis in triple-negative breast cancer cells. +other hsa-mir-142 "Carcinoma, Breast" 30091683 miR-142-3p attenuates breast cancer stem cell characteristics and decreases radioresistance in vitro. +other hsa-mir-17 Liver Diseases [unspecific] 30092337 Bone marrow mesenchymal stromal cells attenuate liver allograft rejection may via upregulation PD-L1 expression through downregulation of miR-17-5p. +other hsa-mir-15a Premature Ovarian Failure 30092342 Induction of miR-15a expression by tripterygium glycosides caused premature ovarian failure by suppressing the Hippo-YAP/TAZ signaling effector Lats1. +other hsa-mir-1 Viral Myocarditis 30097120 Astragalus Root dry extract restores connexin43 expression by targeting miR-1 in viral myocarditis. +other hsa-mir-885 "Carcinoma, Salivary Adenoid Cystic" 30098429 Comprehensive and in-depth analysis of microRNA and mRNA expression profile in salivary adenoid cystic carcinoma. +other hsa-mir-9 Myocardial Infarction 30101604 Inhibition of MicroRNA-9-5p Protects Against Cardiac Remodeling Following Myocardial Infarction in Mice. +other hsa-mir-324 Colorectal Carcinoma 30103475 4-Acetyl-Antroquinonol B Suppresses SOD2-Enhanced Cancer Stem Cell-Like Phenotypes and Chemoresistance of Colorectal Cancer Cells by Inducing hsa-miR-324 re-Expression. +other hsa-mir-675 "Squamous Cell Carcinoma, Esophageal" 30106155 MicroRNA?675?3p promotes esophageal squamous cell cancer cell migration and invasion. +other hsa-mir-221 Parkinson Disease 30107296 The Parkinson's disease gene product DJ-1 modulates miR-221 to promote neuronal survival against oxidative stress. +other hsa-mir-449a "Carcinoma, Hepatocellular" 30108016 MicroRNA-449a suppresses hepatocellular carcinoma cell growth via G1 phase arrest and the HGF/MET c-Met pathway. +other hsa-mir-144 Lung Neoplasms 30108506 Lico A Causes ER Stress and Apoptosis via Up-Regulating miR-144-3p in Human Lung Cancer Cell Line H292. +other hsa-mir-15a Neoplasms [unspecific] 30110127 "TEC treated with HLSC-EVs significantly enhanced expression of miR-15a, miR-181b, miR-320c and miR-874 associated with the down-regulation of FGF1 and PLAU" +other hsa-mir-181b Neoplasms [unspecific] 30110127 "TEC treated with HLSC-EVs significantly enhanced expression of miR-15a, miR-181b, miR-320c and miR-874 associated with the down-regulation of FGF1 and PLAU" +other hsa-mir-320c Neoplasms [unspecific] 30110127 "TEC treated with HLSC-EVs significantly enhanced expression of miR-15a, miR-181b, miR-320c and miR-874 associated with the down-regulation of FGF1 and PLAU" +other hsa-mir-874 Neoplasms [unspecific] 30110127 "TEC treated with HLSC-EVs significantly enhanced expression of miR-15a, miR-181b, miR-320c and miR-874 associated with the down-regulation of FGF1 and PLAU" +other hsa-mir-199a Autism Spectrum Disorder 30111726 Alterations in the MicroRNA of the Blood of Autism Spectrum Disorder Patients: Effects on Epigenetic Regulation and Potential Biomarkers. +other hsa-mir-16 Gastric Neoplasms 30112563 "The miR-16-5p, which has binding sites with hsa_circ_0008106 and hsa_circ_0060456, has been confirmed to be involved in the development of gastric cancer" +other hsa-mir-21 Neoplasms [unspecific] 30113161 we used an alternative target (miR-21) and FRET pair for direct and absolute quantification of miR-21 in RNA extracts from human cancer and normal cell lines +other hsa-mir-199a Hypertension 30116316 MicroRNA-199a-5p aggravates primary hypertension by damaging vascular endothelial cells through inhibition of autophagy and promotion of apoptosis. +other hsa-mir-1826 "Carcinoma, Hepatocellular" 30116730 "we identified 7 DV-only miRNAs (hsa-miR-1826, hsa-miR-191, hsa-miR-194-star, hsa-miR-222, hsa-miR-502-3p, hsa-miR-93, and hsa-miR-99b) using the proposed method, one (hsa-miR-1826) of which has not yet been reported to be related to HCC in the literature" +other hsa-mir-191 "Carcinoma, Hepatocellular" 30116730 "we identified 7 DV-only miRNAs (hsa-miR-1826, hsa-miR-191, hsa-miR-194-star, hsa-miR-222, hsa-miR-502-3p, hsa-miR-93, and hsa-miR-99b) using the proposed method, one (hsa-miR-1826) of which has not yet been reported to be related to HCC in the literature" +other hsa-mir-194 "Carcinoma, Hepatocellular" 30116730 "we identified 7 DV-only miRNAs (hsa-miR-1826, hsa-miR-191, hsa-miR-194-star, hsa-miR-222, hsa-miR-502-3p, hsa-miR-93, and hsa-miR-99b) using the proposed method, one (hsa-miR-1826) of which has not yet been reported to be related to HCC in the literature" +other hsa-mir-222 "Carcinoma, Hepatocellular" 30116730 "we identified 7 DV-only miRNAs (hsa-miR-1826, hsa-miR-191, hsa-miR-194-star, hsa-miR-222, hsa-miR-502-3p, hsa-miR-93, and hsa-miR-99b) using the proposed method, one (hsa-miR-1826) of which has not yet been reported to be related to HCC in the literature" +other hsa-mir-502 "Carcinoma, Hepatocellular" 30116730 "we identified 7 DV-only miRNAs (hsa-miR-1826, hsa-miR-191, hsa-miR-194-star, hsa-miR-222, hsa-miR-502-3p, hsa-miR-93, and hsa-miR-99b) using the proposed method, one (hsa-miR-1826) of which has not yet been reported to be related to HCC in the literature" +other hsa-mir-93 "Carcinoma, Hepatocellular" 30116730 "we identified 7 DV-only miRNAs (hsa-miR-1826, hsa-miR-191, hsa-miR-194-star, hsa-miR-222, hsa-miR-502-3p, hsa-miR-93, and hsa-miR-99b) using the proposed method, one (hsa-miR-1826) of which has not yet been reported to be related to HCC in the literature" +other hsa-mir-99b "Carcinoma, Hepatocellular" 30116730 "we identified 7 DV-only miRNAs (hsa-miR-1826, hsa-miR-191, hsa-miR-194-star, hsa-miR-222, hsa-miR-502-3p, hsa-miR-93, and hsa-miR-99b) using the proposed method, one (hsa-miR-1826) of which has not yet been reported to be related to HCC in the literature" +other hsa-mir-21 Osteoporosis 30116953 The pivotal role of microRNA-21 in osteoclastogenesis inhibition by anthracycline glycoside aloin. +other hsa-mir-1 Heart Failure 30117672 Lycium barbarum polysaccharides restore adverse structural remodelling and cardiac contractile dysfunction induced by overexpression of microRNA-1. +other hsa-mir-92a Wound Healing 30118158 A synthetic microRNA-92a inhibitor (MRG-110) accelerates angiogenesis and wound healing in diabetic and nondiabetic wounds. +other hsa-mir-192 Mild Cognitive Impairment 30118321 Up-regulated miR-192-5p expression rescues cognitive impairment and restores neural function in mice with depression via the Fbln2-mediated TGF-¦Â1 signaling pathway. +other hsa-mir-144 "Adenocarcinoma, Lung" 30121641 IL-1¦Â-Mediated Up-Regulation of WT1D via miR-144-3p and Their Synergistic Effect with NF-¦ÊB/COX-2/HIF-1¦Á Pathway on Cell Proliferation in LUAD. +other hsa-mir-26b Glioma 30124166 the TFAP2C and hsa-miR-26b-5p might play important roles in the development and progression mechanisms of DIPG +other hsa-mir-146a Lichen Planus 30125971 Forkhead box p3 controls progression of oral lichen planus by regulating microRNA-146a. +other hsa-mir-21 "Carcinoma, Lung, Non-Small-Cell" 30127862 MicroRNA-21: A promising biomarker for the prognosis and diagnosis of non-small cell lung cancer. +other hsa-mir-182 Amyotrophic Lateral Sclerosis 30128653 Memory Decline and Its Reversal in Aging and Neurodegeneration Involve miR-183/96/182 Biogenesis. +other hsa-mir-183 Amyotrophic Lateral Sclerosis 30128653 Memory Decline and Its Reversal in Aging and Neurodegeneration Involve miR-183/96/182 Biogenesis. +other hsa-mir-96 Amyotrophic Lateral Sclerosis 30128653 Memory Decline and Its Reversal in Aging and Neurodegeneration Involve miR-183/96/182 Biogenesis. +other hsa-mir-31 Cutaneous Lupus Erythematosus 30130620 MicroRNA Expression Profiling Identifies miR-31 and miR-485-3p as Regulators in the Pathogenesis of Discoid Cutaneous Lupus. +other hsa-mir-485 Cutaneous Lupus Erythematosus 30130620 MicroRNA Expression Profiling Identifies miR-31 and miR-485-3p as Regulators in the Pathogenesis of Discoid Cutaneous Lupus. +other hsa-mir-299 "Diabetes Mellitus, Type 2" 30131392 Glucolipotoxicity-Inhibited miR-299-5p Regulates Pancreatic ¦Â-Cell Function and Survival. +other hsa-mir-181 Chronic Kidney Disease 30132347 Electrically stimulated acupuncture increases renal blood flow through exosomes-carried miR-181. +other hsa-mir-132 "Carcinoma, Cervical" 30132864 HPV16 E7-induced upregulation of KDM2A promotes cervical cancer progression by regulating miR-132-radixin pathway. +other hsa-mir-199 Hepatitis C Virus Infection 30133717 "miR-23b and miR-106 might be a useful biomarker for chronic hepatitis C (CHC). MiR-27a, miR-93, and miR-199 might have a potential role in the progression of liver diseases" +other hsa-mir-27a Hepatitis C Virus Infection 30133717 "miR-23b and miR-106 might be a useful biomarker for chronic hepatitis C (CHC). MiR-27a, miR-93, and miR-199 might have a potential role in the progression of liver diseases" +other hsa-mir-93 Hepatitis C Virus Infection 30133717 "miR-23b and miR-106 might be a useful biomarker for chronic hepatitis C (CHC). MiR-27a, miR-93, and miR-199 might have a potential role in the progression of liver diseases" +other hsa-mir-145 Prostate Neoplasms 30136305 MiR-145 affected the circular RNA expression in prostate cancer LNCaP cells. +other hsa-mir-92a Acute Lung Injury 30138892 MicroRNA-92a antagonism attenuates lipopolysaccharide (LPS)-induced pulmonary inflammation and injury in mice through suppressing the PTEN/AKT/NF-¦ÊB signaling pathway. +other hsa-mir-195 Wound Healing 30141361 Negative-Pressure Wound Therapy Promotes Wound Healing by Enhancing Angiogenesis Through Suppression of NLRX1 via miR-195 Upregulation. +other hsa-mir-1908 Autoimmune Diseases [unspecific] 30143393 Evidence for a potential role of miR-1908-5p and miR-3614-5p in autoimmune disease risk using integrative bioinformatics. +other hsa-mir-3614 Autoimmune Diseases [unspecific] 30143393 Evidence for a potential role of miR-1908-5p and miR-3614-5p in autoimmune disease risk using integrative bioinformatics. +other hsa-mir-200a Hypertrophy 30144391 miR-200a-5p augments cardiomyocyte hypertrophy induced by glucose metabolism disorder via the regulation of selenoproteins. +other hsa-mir-205 Prostate Neoplasms 30149628 miRNA-205 Nanoformulation Sensitizes Prostate Cancer Cells to Chemotherapy. +other hsa-mir-375 "Diabetes Mellitus, Type 1" 30150203 Several types of miRNAs are playing important roles in type 1 diabetes mellitus including miR-375 and miR-375 with intolerance to glucose and decreased beta cells account due to impaired proliferation +other hsa-mir-320a Chronic Pain 30150364 A Functional riboSNitch in the 3' Untranslated Region of FKBP5 Alters MicroRNA-320a Binding Efficiency and Mediates Vulnerability to Chronic Post-Traumatic Pain. +other hsa-mir-155 Melanoma 30150674 Inhibition of miR-155 and miR-210 activity by transfection of miRNA inhibitors into HMEX reversed the exosome-induced metabolic reprogramming of HADF +other hsa-mir-210 Melanoma 30150674 Inhibition of miR-155 and miR-210 activity by transfection of miRNA inhibitors into HMEX reversed the exosome-induced metabolic reprogramming of HADF +other hsa-mir-139 "Carcinoma, Lung, Non-Small-Cell" 30153566 BMP4?Upregulation Is Associated with Acquired Drug Resistance and Fatty Acid Metabolism in EGFR-Mutant Non-Small-Cell Lung Cancer Cells. +other hsa-mir-16 "Carcinoma, Breast" 30154547 "Different signatures of miR-16, miR-30b and miR-93 in exosomes from breast cancer and DCIS patients." +other hsa-mir-30b "Carcinoma, Breast" 30154547 "Different signatures of miR-16, miR-30b and miR-93 in exosomes from breast cancer and DCIS patients." +other hsa-mir-93 "Carcinoma, Breast" 30154547 "Different signatures of miR-16, miR-30b and miR-93 in exosomes from breast cancer and DCIS patients." +other hsa-mir-124 Bone Disease [unspecific] 30155647 miR-124-3p is a chronic regulator of gene expression after brain injury. +other hsa-mir-570 Chronic Obstructive Pulmonary Disease 30156909 MicroRNA-570 is a novel regulator of cellular senescence and inflammaging. +other hsa-mir-214 Colorectal Carcinoma 30157478 Down-Regulation of MicroRNA-214 Contributed to the Enhanced Mitochondrial Transcription Factor A and Inhibited Proliferation of Colorectal Cancer Cells. +other hsa-mir-410 Lung Fibrosis 30157485 Prodigiosin Alleviates Pulmonary Fibrosis Through Inhibiting miRNA-410 and TGF-¦Â1/ADAMTS-1 Signaling Pathway. +other hsa-mir-218 Rheumatoid Arthritis 30157923 Osteogenic differentiation of fibroblast-like synovial cells in rheumatoid arthritis is induced by microRNA-218 through a ROBO/Slit pathway. +other hsa-mir-182 "Diabetes Mellitus, Type 2" 30160993 Intestinal bile acid sequestration improves glucose control by stimulating hepatic miR-182-5p in type 2 diabetes. +other hsa-mir-10b Neoplasms [unspecific] 30166612 "we further propose that miR-10b expression levels, due to the newly described ""hijacking"" effect, may be used as a biomarker to select patients for linifanib treatment" +other hsa-mir-187 Retinal Vascular Disease 30170060 Down-regulated miR-187 promotes oxidative stress-induced retinal cell apoptosis through P2X7 receptor. +other hsa-mir-17 Gastric Neoplasms 30170406 miR-17-92 cluster is connected with disease progression and oxaliplatin/capecitabine chemotherapy efficacy in advanced gastric cancer patients: A preliminary study. +other hsa-mir-18 Gastric Neoplasms 30170406 miR-17-92 cluster is connected with disease progression and oxaliplatin/capecitabine chemotherapy efficacy in advanced gastric cancer patients: A preliminary study. +other hsa-mir-19a Gastric Neoplasms 30170406 miR-17-92 cluster is connected with disease progression and oxaliplatin/capecitabine chemotherapy efficacy in advanced gastric cancer patients: A preliminary study. +other hsa-mir-19b-1 Gastric Neoplasms 30170406 miR-17-92 cluster is connected with disease progression and oxaliplatin/capecitabine chemotherapy efficacy in advanced gastric cancer patients: A preliminary study. +other hsa-mir-20a Gastric Neoplasms 30170406 miR-17-92 cluster is connected with disease progression and oxaliplatin/capecitabine chemotherapy efficacy in advanced gastric cancer patients: A preliminary study. +other hsa-mir-92-1 Gastric Neoplasms 30170406 miR-17-92 cluster is connected with disease progression and oxaliplatin/capecitabine chemotherapy efficacy in advanced gastric cancer patients: A preliminary study. +other hsa-mir-372 Colorectal Carcinoma 30171794 miR-372 and miR-373 enhance the stemness of colorectal cancer cells by repressing differentiation signaling pathways. +other hsa-mir-373 Colorectal Carcinoma 30171794 miR-372 and miR-373 enhance the stemness of colorectal cancer cells by repressing differentiation signaling pathways. +other hsa-mir-30c-2 "Carcinoma, Breast" 30182731 Circular RNA hsa_circ_0072995 promotes breast cancer cell migration and invasion through sponge for miR-30c-2-3p. +other hsa-mir-497 "Carcinoma, Renal Cell, Clear-Cell" 30183478 MicroRNA-497-5p down-regulation increases PD-L1 expression in clear cell renal cell carcinoma. +other hsa-mir-27a Gastric Neoplasms 30184548 Exosomal miR-27a Derived from Gastric Cancer Cells Regulates the Transformation of Fibroblasts into Cancer-Associated Fibroblasts. +other hsa-mir-3607 "Carcinoma, Hepatocellular" 30186744 "mir-424, miR-93 and miR-3607 are three hub DEmiRNAs of the HCC-specific DEmiRNA-DEmRNA interaction network." +other hsa-mir-424 "Carcinoma, Hepatocellular" 30186744 "mir-424, miR-93 and miR-3607 are three hub DEmiRNAs of the HCC-specific DEmiRNA-DEmRNA interaction network." +other hsa-mir-93 "Carcinoma, Hepatocellular" 30186744 "mir-424, miR-93 and miR-3607 are three hub DEmiRNAs of the HCC-specific DEmiRNA-DEmRNA interaction network." +other hsa-mir-17 Gastric Neoplasms 30186751 "MicroRNA-17 as a promising diagnostic biomarker of gastric cancer: An investigation combining TCGA, GEO, meta-analysis, and bioinformatics." +other hsa-mir-106b Recurrent Spontaneous Abortion 30187472 Altered T-cell subpopulations in recurrent pregnancy loss patients with cellular immune abnormalities. +other hsa-mir-25 Recurrent Spontaneous Abortion 30187472 Altered T-cell subpopulations in recurrent pregnancy loss patients with cellular immune abnormalities. +other hsa-mir-93 Recurrent Spontaneous Abortion 30187472 Altered T-cell subpopulations in recurrent pregnancy loss patients with cellular immune abnormalities. +other hsa-mir-520a Hepatitis B Virus Infection 30191752 MicroRNA-520a suppresses HBV replication in HepG2.2.15 cells by inactivating AKT. +other hsa-mir-21 Colorectal Carcinoma 30191984 Fusobacterium nucleatum and colorectal cancer: A mechanistic overview. +other hsa-mir-199a Coronary Artery Disease 30192743 MicroRNA 199a Is Downregulated in Patients After Coronary Artery Bypass Graft Surgery and Is Associated with Increased Levels of Sirtuin 1 (SIRT 1) Protein and Major Adverse Cardiovascular Events at 3-Year Follow-Up. +other hsa-mir-215 "Carcinoma, Breast" 30194145 Pax-5 Inhibits Breast Cancer Proliferation Through MiR-215 Up-regulation. +other hsa-mir-17 Prostate Neoplasms 30194146 "we identified a panel of 5-miRNA (miR-17-3p, miR-27a-3p, miR-200a-3p, miR-375, and miR-376b-3p) with a risk score strongly associated with metastasis" +other hsa-mir-200a Prostate Neoplasms 30194146 "we identified a panel of 5-miRNA (miR-17-3p, miR-27a-3p, miR-200a-3p, miR-375, and miR-376b-3p) with a risk score strongly associated with metastasis" +other hsa-mir-27a Prostate Neoplasms 30194146 "we identified a panel of 5-miRNA (miR-17-3p, miR-27a-3p, miR-200a-3p, miR-375, and miR-376b-3p) with a risk score strongly associated with metastasis" +other hsa-mir-375 Prostate Neoplasms 30194146 "we identified a panel of 5-miRNA (miR-17-3p, miR-27a-3p, miR-200a-3p, miR-375, and miR-376b-3p) with a risk score strongly associated with metastasis" +other hsa-mir-376b Prostate Neoplasms 30194146 "we identified a panel of 5-miRNA (miR-17-3p, miR-27a-3p, miR-200a-3p, miR-375, and miR-376b-3p) with a risk score strongly associated with metastasis" +other hsa-mir-155 "Squamous Cell Carcinoma, Oral" 30194167 Potential Oncogenic Role and Prognostic Implication of MicroRNA-155-5p in Oral Squamous Cell Carcinoma. +other hsa-mir-96 "Adenocarcinoma, Prostate" 30195637 "The lncRNAs MESTIT1, PCA3, and UCA1; mRNAs CYP19A1 and TDRD1; as well as miR-96 might affect the pathogenesis of PRAD" +other hsa-mir-1271 Colorectal Carcinoma 30195762 "sequester miR-135a, miR-143, miR-214, and miR-1271, protecting ANLN, BIRC5, IPO7, KIF2A, and KIF23 from microRNA (miRNA)-induced degradation" +other hsa-mir-135a Colorectal Carcinoma 30195762 "sequester miR-135a, miR-143, miR-214, and miR-1271, protecting ANLN, BIRC5, IPO7, KIF2A, and KIF23 from microRNA (miRNA)-induced degradation" +other hsa-mir-143 Colorectal Carcinoma 30195762 "sequester miR-135a, miR-143, miR-214, and miR-1271, protecting ANLN, BIRC5, IPO7, KIF2A, and KIF23 from microRNA (miRNA)-induced degradation" +other hsa-mir-214 Colorectal Carcinoma 30195762 "sequester miR-135a, miR-143, miR-214, and miR-1271, protecting ANLN, BIRC5, IPO7, KIF2A, and KIF23 from microRNA (miRNA)-induced degradation" +other hsa-mir-501 Gastric Neoplasms 30195794 miR-501 might be a potential target for doxorubicin resistance and gastric cancer therapy +other hsa-mir-126 Johne Disease 30197143 "A model was developed using a combination of 4 miRNA (miR-1976, miR-873-3p, miR-520f-3p, and miR-126-3p), which distinguished moderate and severely infected animals from noninfected animal" +other hsa-mir-1976 Johne Disease 30197143 "A model was developed using a combination of 4 miRNA (miR-1976, miR-873-3p, miR-520f-3p, and miR-126-3p), which distinguished moderate and severely infected animals from noninfected animal" +other hsa-mir-520f Johne Disease 30197143 "A model was developed using a combination of 4 miRNA (miR-1976, miR-873-3p, miR-520f-3p, and miR-126-3p), which distinguished moderate and severely infected animals from noninfected animal" +other hsa-mir-873 Johne Disease 30197143 "A model was developed using a combination of 4 miRNA (miR-1976, miR-873-3p, miR-520f-3p, and miR-126-3p), which distinguished moderate and severely infected animals from noninfected animal" +other hsa-mir-193b Melanoma 30197759 "miR-193b and miR-30c-1* inhibit, whereas miR-576-5p enhances melanoma cell invasion in vitro." +other hsa-mir-30c-1 Melanoma 30197759 "miR-193b and miR-30c-1* inhibit, whereas miR-576-5p enhances melanoma cell invasion in vitro." +other hsa-mir-576 Melanoma 30197759 "miR-193b and miR-30c-1* inhibit, whereas miR-576-5p enhances melanoma cell invasion in vitro." +other hsa-mir-143 Intracranial Aneurysm 30201338 The miR-143/145 cluster reverses the regulation effect of KLF5 in smooth muscle cells with proliferation and contractility in intracranial aneurysm. +other hsa-mir-145 Intracranial Aneurysm 30201338 The miR-143/145 cluster reverses the regulation effect of KLF5 in smooth muscle cells with proliferation and contractility in intracranial aneurysm. +other hsa-mir-9 "Carcinoma, Renal Cell" 30201928 miR-9-5p in Nephrectomy Specimens is a Potential Predictor of Primary Resistance to First-Line Treatment with Tyrosine Kinase Inhibitors in Patients with Metastatic Renal Cell Carcinoma. +other hsa-mir-128 Inflammation 30203508 NEAT1 contributes to ox-LDL-induced inflammation and oxidative stress in macrophages through inhibiting miR-128. +other hsa-mir-4633 Melanoma 30205394 Identification and Functional Evaluation of miR-4633-5p as a Biomarker and Tumor Suppressor in Metastatic Melanoma. +other hsa-mir-21 "Fatty Liver, Non-Alcoholic" 30206377 Targeting a phospho-STAT3-miRNAs pathway improves vesicular hepatic steatosis in an in vitro and in vivo model. +other hsa-mir-520a "Carcinoma, Thyroid, Papillary" 30206929 "MicroRNA-520a-3p suppresses epithelial-mesenchymal transition, invasion, and migration of papillary thyroid carcinoma cells via the JAK1-mediated JAK/STAT signaling pathway." +other hsa-mir-146a "Leukemia, Myeloid, Acute" 30208330 Upregulated microRNA-146a expression induced by granulocyte colony-stimulating factor enhanced low-dosage chemotherapy response in aged acute myeloid leukemia patients. +other hsa-mir-122 Hepatitis C Virus Infection 30209483 Simple and rational design of a polymer nano-platform for high performance of HCV related miR-122 reduction in the liver. +other hsa-mir-146a Obesity 30212608 Physical Activity Modulates the Overexpression of the Inflammatory miR-146a-5p in Obese Patients. +other hsa-mir-200c "Carcinoma, Breast" 30213797 Reversal of Triple-negative Breast Cancer EMT by miR-200c Decreases Tryptophan Catabolism and a Program of Immune-Suppression. +other hsa-mir-203 "Carcinoma, Lung, Non-Small-Cell" 30214583 H19 contributes to poor clinical features in NSCLC patients and leads to enhanced invasion in A549 cells through regulating miRNA-203-mediated epithelial-mesenchymal transition. +other hsa-mir-214 Gastric Neoplasms 30215537 hsa_circ_0000993 may inhibit metastasis of gastric cancer through sequestering miR-214-5p +other hsa-mir-198 "Lymphoma, Large B-Cell, Diffuse" 30216798 Bortezomib inhibited the progression of diffuse large B-cell lymphoma via targeting miR-198. +other hsa-mir-27b "Adenocarcinoma, Esophageal" 30217293 microRNAs: Key regulators of chemotherapy response and metastatic potential via complex control of target pathways in esophageal adenocarcinoma. +other hsa-mir-1290 "Carcinoma, Cervical" 30219071 Exosomal miR-1290 is a potential biomarker of high-grade serous ovarian carcinoma and can discriminate patients from those with malignancies of other histological types. +other hsa-mir-146a Lung Injury [unspecific] 30220173 Effect and mechanism of MicroRNA-146a on TLR4 inflammatory signal pathway in the lung tissues of rats with mechanical ventilator-induced lung injury +other hsa-mir-155 Acute Lung Injury 30220274 miR-155 ASO has the effect of inhibiting LPS-induced inflammatory response and improving prognosis in ALI mice +other hsa-mir-142 Colon Neoplasms 30220706 BM-MSC-derived exosomes promote colon cancer stem cell-like traits via miR-142-3p +other hsa-mir-30 "Carcinoma, Pancreatic" 30221677 Establishment of a non?coding RNAomics screening platform for the regulation of KRAS in pancreatic cancer by RNA sequencing. +other hsa-mir-34 "Carcinoma, Pancreatic" 30221677 Establishment of a non?coding RNAomics screening platform for the regulation of KRAS in pancreatic cancer by RNA sequencing. +other hsa-mir-320 Inflammation 30224451 IL-33 promotes recovery from acute colitis by inducing miR-320 to stimulate epithelial restitution and repair. +other hsa-mir-124 Amyotrophic Lateral Sclerosis 30233312 we observed enhanced retrograde transport of miR-124-Cy3 +other hsa-mir-199a "Diabetes Mellitus, Type 2" 30233719 Reduced expression of microRNA-199a-3p is associated with vascular endothelial cell injury induced by type 2 diabetes mellitus. +other hsa-mir-191 Cholangiocarcinoma 30235453 miR-191 Inhibition Induces Apoptosis Through Reactivating Secreted Frizzled-Related Protein-1 in Cholangiocarcinoma. +other hsa-mir-21 Neoplasms [unspecific] 30237038 "we discuss the role of miR-21 and miR-375 in the RAS pathway as well as their role in cancer diagnosis and progression, along with the role of other select miRNAs in cancer immune surveillance" +other hsa-mir-375 Neoplasms [unspecific] 30237038 "we discuss the role of miR-21 and miR-375 in the RAS pathway as well as their role in cancer diagnosis and progression, along with the role of other select miRNAs in cancer immune surveillance" +other hsa-mir-221 Neoplasms [unspecific] 30237739 The correlation between microRNA-221/222 cluster overexpression and malignancy: an updated meta-analysis including 2693 patients. +other hsa-mir-222 Neoplasms [unspecific] 30237739 The correlation between microRNA-221/222 cluster overexpression and malignancy: an updated meta-analysis including 2693 patients. +other hsa-mir-106 "Carcinoma, Hepatocellular" 30238497 Development and validation of serum exosomal microRNAs as diagnostic and prognostic biomarkers for hepatocellular carcinoma. +other hsa-mir-17 Acute Respiratory Distress Syndrome 30239899 transfer of miR-17-5p strongly downregulated expression of the antiviral factor Mx1 and significantly enhanced IAV replication +other hsa-let-7a "Leukemia, Lymphoblastic, Acute, T-Cell" 30241379 "we then showed the utility of the combination of three miRNAs as endogenous normalizers (hsa-miR-16-5p, hsa-miR-25-3p, and hsa-let-7a-5p)" +other hsa-mir-16 "Leukemia, Lymphoblastic, Acute, T-Cell" 30241379 "we then showed the utility of the combination of three miRNAs as endogenous normalizers (hsa-miR-16-5p, hsa-miR-25-3p, and hsa-let-7a-5p)" +other hsa-mir-25 "Leukemia, Lymphoblastic, Acute, T-Cell" 30241379 "we then showed the utility of the combination of three miRNAs as endogenous normalizers (hsa-miR-16-5p, hsa-miR-25-3p, and hsa-let-7a-5p)" +other hsa-mir-34a Oral Neoplasms 30243489 Cancer-associated fibroblasts contribute to oral cancer cells proliferation and metastasis via exosome-mediated paracrine miR-34a-5p. +other hsa-mir-142 Idiopathic Pulmonary Fibrosis 30244194 we found a negative correlation between miR-142-3p and diffusing capacity of the lungs for carbon monoxide/alveolar volume +other hsa-mir-148a Ischemia-Reperfusion Injury 30244246 Role of miR-148a in Mitigating Hepatic Ischemia-Reperfusion Injury by Repressing the TLR4 Signaling Pathway via Targeting CaMKII¦Á in Vivo and in Vitro. +other hsa-mir-126 Sepsis 30244405 Application of Deacetylated Poly-N-Acetyl Glucosamine Nanoparticles for the Delivery of miR-126 for the Treatment of Cecal Ligation and Puncture-Induced Sepsis. +other hsa-mir-206 "Carcinoma, Lung, Non-Small-Cell" 30245277 "miR-206 and miR-613, were significantly associated with NSCLC" +other hsa-mir-613 "Carcinoma, Lung, Non-Small-Cell" 30245277 "miR-206 and miR-613, were significantly associated with NSCLC" +other hsa-mir-155 Asthma 30245919 MiR-155 may play a role in mediating allergic inflammation in T-cells and could be an anti-inflammatory target of steroids +other hsa-mir-146a "Carcinoma, Breast" 30245930 "The role of miRNAs 34a, 146a, 320a and 542 in the synergistic anticancer effects of methyl 2-(5-fluoro-2-hydroxyphenyl)-1H- benzo[d]imidazole-5-carboxylate (MBIC) with doxorubicin in breast cancer cells." +other hsa-mir-320a "Carcinoma, Breast" 30245930 "The role of miRNAs 34a, 146a, 320a and 542 in the synergistic anticancer effects of methyl 2-(5-fluoro-2-hydroxyphenyl)-1H- benzo[d]imidazole-5-carboxylate (MBIC) with doxorubicin in breast cancer cells." +other hsa-mir-34a "Carcinoma, Breast" 30245930 "The role of miRNAs 34a, 146a, 320a and 542 in the synergistic anticancer effects of methyl 2-(5-fluoro-2-hydroxyphenyl)-1H- benzo[d]imidazole-5-carboxylate (MBIC) with doxorubicin in breast cancer cells." +other hsa-mir-542 "Carcinoma, Breast" 30245930 "The role of miRNAs 34a, 146a, 320a and 542 in the synergistic anticancer effects of methyl 2-(5-fluoro-2-hydroxyphenyl)-1H- benzo[d]imidazole-5-carboxylate (MBIC) with doxorubicin in breast cancer cells." +other hsa-mir-15a Neoplasms [unspecific] 30246332 The miR-15a/16 gene cluster in human cancer: A systematic review. +other hsa-mir-16 Neoplasms [unspecific] 30246332 The miR-15a/16 gene cluster in human cancer: A systematic review. +other hsa-mir-1271 Glioblastoma 30248541 Chemo-resistance of A172 glioblastoma cells is controlled by miR-1271-regulated Bcl-2. +other hsa-mir-125a Gastrointestinal Stromal Tumor 30249101 Hsa-miR-28-5p and hsa-miR-125a-5p may be involved in the development and progression of GIST +other hsa-mir-28 Gastrointestinal Stromal Tumor 30249101 Hsa-miR-28-5p and hsa-miR-125a-5p may be involved in the development and progression of GIST +other hsa-mir-1247 "Carcinoma, Breast" 30249392 Downregulated miR-1247-5p associates with poor prognosis and facilitates tumor cell growth via DVL1/Wnt/¦Â-catenin signaling in breast cancer. +other hsa-mir-23 Coronary Artery Disease 30249504 miR-23 regulates cell proliferation and apoptosis of vascular smooth muscle cells in coronary heart disease. +other hsa-mir-195 "Carcinoma, Hepatocellular" 30249878 "Identification of potential transcription factors, long noncoding RNAs, and microRNAs associated with hepatocellular carcinoma." +other hsa-mir-196a "Squamous Cell Carcinoma, Esophageal" 30249885 Association of serum annexin A1 with treatment response and prognosis in patients with esophageal squamous cell carcinoma. +other hsa-mir-130a "Carcinoma, Breast" 30250584 Target gene prediction and pathway analysis revealed the involvement of miR-130a and miR-425 in pathways associated with malignant cell proliferation +other hsa-mir-425 "Carcinoma, Breast" 30250584 Target gene prediction and pathway analysis revealed the involvement of miR-130a and miR-425 in pathways associated with malignant cell proliferation +other hsa-mir-17 Small Intestine Carcinoma 30255827 Adherence to the World Cancer Research Fund/American Institute for Cancer Research cancer prevention recommendations and WNT-pathway-related markers of bowel cancer risk. +other hsa-mir-374a "Carcinoma, Hepatocellular" 30257238 "Propofol Inhibits Proliferation, Migration, Invasion and Promotes Apoptosis Through Down-Regulating miR-374a in Hepatocarcinoma Cell Lines." +other hsa-mir-23a Hypoxia 30257251 Astragaloside IV Protects Rat Cardiomyocytes from Hypoxia-Induced Injury by Down-Regulation of miR-23a and miR-92a. +other hsa-mir-92a Hypoxia 30257251 Astragaloside IV Protects Rat Cardiomyocytes from Hypoxia-Induced Injury by Down-Regulation of miR-23a and miR-92a. +other hsa-mir-106b Neoplasms [unspecific] 30257332 The emerging roles of the polycistronic miR-106b?25 cluster in cancer - A comprehensive review. +other hsa-mir-106 "Carcinoma, Bladder" 30257376 Baicalein inhibits proliferation and migration of bladder cancer cell line T24 by down-regulation of microRNA-106. +other hsa-mir-18a Glioma 30257388 c-Fos/microRNA-18a feedback loop modulates the tumor growth via HMBOX1 in human gliomas. +other hsa-mir-204 Diabetes Mellitus 30257973 miR-29c overexpression and miR-204 inhibition per se attenuated VSMC phenotypic switch in DM +other hsa-mir-29c Diabetes Mellitus 30257973 miR-29c overexpression and miR-204 inhibition per se attenuated VSMC phenotypic switch in DM +other hsa-mir-10a "Carcinoma, Breast" 30259272 MicroRNA Profiling of Salivary Duct Carcinoma Versus Her2/Neu Overexpressing Breast Carcinoma Identify miR-10a as a Putative Breast Related Oncogene. +other hsa-mir-124a Cardiovascular Diseases [unspecific] 30260095 "Pearson analysis revealed a correlation between MPs miR-124a and miR150 and adiponectin, TNF¦Á, or IL-6 levels" +other hsa-mir-150 Cardiovascular Diseases [unspecific] 30260095 "Pearson analysis revealed a correlation between MPs miR-124a and miR150 and adiponectin, TNF¦Á, or IL-6 levels" +other hsa-let-7e Melanoma 30260323 "we describe a set of microRNAs (miR-146a, miR-155, miR-125b, miR-100, let-7e, miR-125a, miR-146b, miR-99b) that are associated with MDSCs and with resistance to treatment with immune checkpoint inhibitors in melanoma patients" +other hsa-mir-100 Melanoma 30260323 "we describe a set of microRNAs (miR-146a, miR-155, miR-125b, miR-100, let-7e, miR-125a, miR-146b, miR-99b) that are associated with MDSCs and with resistance to treatment with immune checkpoint inhibitors in melanoma patients" +other hsa-mir-125a Melanoma 30260323 "we describe a set of microRNAs (miR-146a, miR-155, miR-125b, miR-100, let-7e, miR-125a, miR-146b, miR-99b) that are associated with MDSCs and with resistance to treatment with immune checkpoint inhibitors in melanoma patients" +other hsa-mir-125b Melanoma 30260323 "we describe a set of microRNAs (miR-146a, miR-155, miR-125b, miR-100, let-7e, miR-125a, miR-146b, miR-99b) that are associated with MDSCs and with resistance to treatment with immune checkpoint inhibitors in melanoma patients" +other hsa-mir-146a Melanoma 30260323 "we describe a set of microRNAs (miR-146a, miR-155, miR-125b, miR-100, let-7e, miR-125a, miR-146b, miR-99b) that are associated with MDSCs and with resistance to treatment with immune checkpoint inhibitors in melanoma patients" +other hsa-mir-146b Melanoma 30260323 "we describe a set of microRNAs (miR-146a, miR-155, miR-125b, miR-100, let-7e, miR-125a, miR-146b, miR-99b) that are associated with MDSCs and with resistance to treatment with immune checkpoint inhibitors in melanoma patients" +other hsa-mir-155 Melanoma 30260323 "we describe a set of microRNAs (miR-146a, miR-155, miR-125b, miR-100, let-7e, miR-125a, miR-146b, miR-99b) that are associated with MDSCs and with resistance to treatment with immune checkpoint inhibitors in melanoma patients" +other hsa-mir-99b Melanoma 30260323 "we describe a set of microRNAs (miR-146a, miR-155, miR-125b, miR-100, let-7e, miR-125a, miR-146b, miR-99b) that are associated with MDSCs and with resistance to treatment with immune checkpoint inhibitors in melanoma patients" +other hsa-mir-350 Inflammation 30260716 miR-350-3p Contributes to Age-Associated Impairment of IL-6 Production by Macrophages. +other hsa-mir-146a "Diabetes Mellitus, Type 1" 30260972 miR-146a-5p could play a role in type 1 diabetes development +other hsa-mir-200 Lung Neoplasms 30268479 Exosomal RNA-profiling of pleural effusions identifies adenocarcinoma patients through elevated miR-200 and LCN2 expression. +other hsa-mir-326 Cataract 30268497 MiR-326 antagomir delays the progression of age-related cataract by upregulating FGF1-mediated expression of betaB2-crystallin. +other hsa-mir-145 Psoriasis 30269330 Downregulation of miR-145-5p contributes to hyperproliferation of keratinocytes and skin inflammation in psoriasis. +other hsa-mir-122 "Fatty Liver, Non-Alcoholic" 30271077 "miR-34a, miR-122 and miR-155 are most involved in the pathogenesis of NAFLD" +other hsa-mir-155 "Fatty Liver, Non-Alcoholic" 30271077 "miR-34a, miR-122 and miR-155 are most involved in the pathogenesis of NAFLD" +other hsa-mir-34a "Fatty Liver, Non-Alcoholic" 30271077 "miR-34a, miR-122 and miR-155 are most involved in the pathogenesis of NAFLD" +other hsa-mir-132 Myocardial Infarction 30271437 "MicroRNA-132, Delivered by Mesenchymal Stem Cell-Derived Exosomes, Promote Angiogenesis in Myocardial Infarction." +other hsa-mir-3148 Neoplasms [unspecific] 30275189 miR-3148 Is a Novel Onco-microRNA that Potentiates Tumor Growth In Vivo. +other hsa-mir-138 Neoplasms [unspecific] 30278099 apigenin-induced apoptotic rate was significantly higher when used in combination with miR-423-5p inhibitors or miR-138 mimics +other hsa-mir-423 Neoplasms [unspecific] 30278099 apigenin-induced apoptotic rate was significantly higher when used in combination with miR-423-5p inhibitors or miR-138 mimics +other hsa-mir-141 Aneurysm 30280445 The mir-200 family regulates key pathogenic events in ascending aortas of individuals with bicuspid aortic valves. +other hsa-mir-200a Aneurysm 30280445 The mir-200 family regulates key pathogenic events in ascending aortas of individuals with bicuspid aortic valves. +other hsa-mir-200b Aneurysm 30280445 The mir-200 family regulates key pathogenic events in ascending aortas of individuals with bicuspid aortic valves. +other hsa-mir-200c Aneurysm 30280445 The mir-200 family regulates key pathogenic events in ascending aortas of individuals with bicuspid aortic valves. +other hsa-mir-429 Aneurysm 30280445 The mir-200 family regulates key pathogenic events in ascending aortas of individuals with bicuspid aortic valves. +other hsa-mir-378 Fatty Liver [unspecific] 30281809 LXR¦Á Promotes Hepatosteatosis in Part via Activation of MicroRNA-378 Transcription and Inhibition of Ppargc1¦Â Expression. +other hsa-mir-223 Diabetes Mellitus 30287053 "celastrol reverses PA-induced IR-related alterations, in part via miR-223 in HepG2 cells" +other hsa-mir-181a Osteoarthritis 30287418 microRNA-181a-5p antisense oligonucleotides attenuate osteoarthritis in facet and knee joints. +other hsa-mir-495 Thrombosis 30287499 Effect of microRNA-495 on lower extremity deep vein thrombosis through the TLR4 signaling pathway by regulation of IL1R1. +other hsa-mir-133a "Carcinoma, Oropharyngeal" 30289952 Smoking-induced control of miR-133a-3p alters the expression of EGFR and HuR in HPV-infected oropharyngeal cancer. +other hsa-mir-296 Neoplasms [unspecific] 30293950 Epigenetic mechanisms and upstream transcription factors are responsible for the regulation of miR-296 expression in cancer +other hsa-mir-15b Cardiovascular Diseases [unspecific] 30295821 "Our bioinformatic analysis revealed three highly expressed eNOS-targeting miRNAs (miR-15b, miR-16, and miR-30b) in human endothelial cells (ECs)" +other hsa-mir-16 Cardiovascular Diseases [unspecific] 30295821 "Our bioinformatic analysis revealed three highly expressed eNOS-targeting miRNAs (miR-15b, miR-16, and miR-30b) in human endothelial cells (ECs)" +other hsa-mir-30b Cardiovascular Diseases [unspecific] 30295821 "Our bioinformatic analysis revealed three highly expressed eNOS-targeting miRNAs (miR-15b, miR-16, and miR-30b) in human endothelial cells (ECs)" +other hsa-mir-29a Intervertebral Disc Degeneration 30296017 Sustained and Bioresponsive Two-Stage Delivery of Therapeutic miRNA via Polyplex Micelle-Loaded Injectable Hydrogels for Inhibition of Intervertebral Disc Fibrosis. +other hsa-mir-34 Heart Failure 30298011 Generation of MicroRNA-34 Sponges and Tough Decoys for the Heart: Developments and Challenges. +other hsa-mir-101 Atherosclerosis 30300747 "miR-10a, -19a, -23b, -17~92, -21, -663, -92a, -143/145, -101, -126, -712, -205, and -155 that play a critical role in endothelial function and atherosclerosis by targeting inflammation, cell cycle, proliferation, migration, apoptosis, and nitric oxide signaling" +other hsa-mir-10a Atherosclerosis 30300747 "miR-10a, -19a, -23b, -17~92, -21, -663, -92a, -143/145, -101, -126, -712, -205, and -155 that play a critical role in endothelial function and atherosclerosis by targeting inflammation, cell cycle, proliferation, migration, apoptosis, and nitric oxide signaling" +other hsa-mir-126 Atherosclerosis 30300747 "miR-10a, -19a, -23b, -17~92, -21, -663, -92a, -143/145, -101, -126, -712, -205, and -155 that play a critical role in endothelial function and atherosclerosis by targeting inflammation, cell cycle, proliferation, migration, apoptosis, and nitric oxide signaling" +other hsa-mir-143 Atherosclerosis 30300747 "miR-10a, -19a, -23b, -17~92, -21, -663, -92a, -143/145, -101, -126, -712, -205, and -155 that play a critical role in endothelial function and atherosclerosis by targeting inflammation, cell cycle, proliferation, migration, apoptosis, and nitric oxide signaling" +other hsa-mir-145 Atherosclerosis 30300747 "miR-10a, -19a, -23b, -17~92, -21, -663, -92a, -143/145, -101, -126, -712, -205, and -155 that play a critical role in endothelial function and atherosclerosis by targeting inflammation, cell cycle, proliferation, migration, apoptosis, and nitric oxide signaling" +other hsa-mir-155 Atherosclerosis 30300747 "miR-10a, -19a, -23b, -17~92, -21, -663, -92a, -143/145, -101, -126, -712, -205, and -155 that play a critical role in endothelial function and atherosclerosis by targeting inflammation, cell cycle, proliferation, migration, apoptosis, and nitric oxide signaling" +other hsa-mir-17 Atherosclerosis 30300747 "miR-10a, -19a, -23b, -17~92, -21, -663, -92a, -143/145, -101, -126, -712, -205, and -155 that play a critical role in endothelial function and atherosclerosis by targeting inflammation, cell cycle, proliferation, migration, apoptosis, and nitric oxide signaling" +other hsa-mir-18 Atherosclerosis 30300747 "miR-10a, -19a, -23b, -17~92, -21, -663, -92a, -143/145, -101, -126, -712, -205, and -155 that play a critical role in endothelial function and atherosclerosis by targeting inflammation, cell cycle, proliferation, migration, apoptosis, and nitric oxide signaling" +other hsa-mir-19a Atherosclerosis 30300747 "miR-10a, -19a, -23b, -17~92, -21, -663, -92a, -143/145, -101, -126, -712, -205, and -155 that play a critical role in endothelial function and atherosclerosis by targeting inflammation, cell cycle, proliferation, migration, apoptosis, and nitric oxide signaling" +other hsa-mir-19b-1 Atherosclerosis 30300747 "miR-10a, -19a, -23b, -17~92, -21, -663, -92a, -143/145, -101, -126, -712, -205, and -155 that play a critical role in endothelial function and atherosclerosis by targeting inflammation, cell cycle, proliferation, migration, apoptosis, and nitric oxide signaling" +other hsa-mir-205 Atherosclerosis 30300747 "miR-10a, -19a, -23b, -17~92, -21, -663, -92a, -143/145, -101, -126, -712, -205, and -155 that play a critical role in endothelial function and atherosclerosis by targeting inflammation, cell cycle, proliferation, migration, apoptosis, and nitric oxide signaling" +other hsa-mir-20a Atherosclerosis 30300747 "miR-10a, -19a, -23b, -17~92, -21, -663, -92a, -143/145, -101, -126, -712, -205, and -155 that play a critical role in endothelial function and atherosclerosis by targeting inflammation, cell cycle, proliferation, migration, apoptosis, and nitric oxide signaling" +other hsa-mir-21 Atherosclerosis 30300747 "miR-10a, -19a, -23b, -17~92, -21, -663, -92a, -143/145, -101, -126, -712, -205, and -155 that play a critical role in endothelial function and atherosclerosis by targeting inflammation, cell cycle, proliferation, migration, apoptosis, and nitric oxide signaling" +other hsa-mir-23b Atherosclerosis 30300747 "miR-10a, -19a, -23b, -17~92, -21, -663, -92a, -143/145, -101, -126, -712, -205, and -155 that play a critical role in endothelial function and atherosclerosis by targeting inflammation, cell cycle, proliferation, migration, apoptosis, and nitric oxide signaling" +other hsa-mir-663 Atherosclerosis 30300747 "miR-10a, -19a, -23b, -17~92, -21, -663, -92a, -143/145, -101, -126, -712, -205, and -155 that play a critical role in endothelial function and atherosclerosis by targeting inflammation, cell cycle, proliferation, migration, apoptosis, and nitric oxide signaling" +other hsa-mir-712 Atherosclerosis 30300747 "miR-10a, -19a, -23b, -17~92, -21, -663, -92a, -143/145, -101, -126, -712, -205, and -155 that play a critical role in endothelial function and atherosclerosis by targeting inflammation, cell cycle, proliferation, migration, apoptosis, and nitric oxide signaling" +other hsa-mir-92-1 Atherosclerosis 30300747 "miR-10a, -19a, -23b, -17~92, -21, -663, -92a, -143/145, -101, -126, -712, -205, and -155 that play a critical role in endothelial function and atherosclerosis by targeting inflammation, cell cycle, proliferation, migration, apoptosis, and nitric oxide signaling" +other hsa-mir-92a Atherosclerosis 30300747 "miR-10a, -19a, -23b, -17~92, -21, -663, -92a, -143/145, -101, -126, -712, -205, and -155 that play a critical role in endothelial function and atherosclerosis by targeting inflammation, cell cycle, proliferation, migration, apoptosis, and nitric oxide signaling" +other hsa-mir-155 "Carcinoma, Breast" 30301470 Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trial. +other hsa-mir-301 "Carcinoma, Breast" 30301470 Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trial. +other hsa-mir-155 Atrial Fibrillation 30302809 Ablation alleviates atrial fibrillation by regulating the signaling pathways of endothelial nitric oxide synthase/nitric oxide via miR-155-5p and miR-24-3p. +other hsa-mir-24 Atrial Fibrillation 30302809 Ablation alleviates atrial fibrillation by regulating the signaling pathways of endothelial nitric oxide synthase/nitric oxide via miR-155-5p and miR-24-3p. +other hsa-mir-125b "Carcinoma, Lung, Non-Small-Cell" 30305431 Reduced miR-125a-5p level in non-small-cell lung cancer is associated with tumour progression. +other hsa-mir-194 Spinal Cord Injuries 30308510 Lycium Barbarum Polysaccharides Alleviates Oxidative Damage Induced by H2O2 Through Down-Regulating MicroRNA-194 in PC-12 and SH-SY5Y Cells. +other hsa-mir-19a Giant Cell Tumor of Bone 30309658 Downregulation of miR-223 and miR-19a induces differentiation and promotes recruitment of osteoclast cells in giant-cell tumor of the bone via the Runx2/TWIST-RANK/RANKL pathway. +other hsa-mir-223 Giant Cell Tumor of Bone 30309658 Downregulation of miR-223 and miR-19a induces differentiation and promotes recruitment of osteoclast cells in giant-cell tumor of the bone via the Runx2/TWIST-RANK/RANKL pathway. +other hsa-mir-106a "Carcinoma, Breast" 30311168 "The three-miRNAs risk score (miR-19a, miR-93, and miR-106a) was developed using the TCGA cohort, which predicted poor prognosis (p?=?0.0005) independently of known clinical risk factors" +other hsa-mir-19a "Carcinoma, Breast" 30311168 "The three-miRNAs risk score (miR-19a, miR-93, and miR-106a) was developed using the TCGA cohort, which predicted poor prognosis (p?=?0.0005) independently of known clinical risk factors" +other hsa-mir-93 "Carcinoma, Breast" 30311168 "The three-miRNAs risk score (miR-19a, miR-93, and miR-106a) was developed using the TCGA cohort, which predicted poor prognosis (p?=?0.0005) independently of known clinical risk factors" +other hsa-mir-494 Cholangiocarcinoma 30314946 "MicroRNA-494-dependent WDHDI inhibition suppresses epithelial-mesenchymal transition, tumor growth and metastasis in cholangiocarcinoma." +other hsa-mir-224 Acute Coronary Syndrome 30317569 Downregulated microRNA-224 aggravates vulnerable atherosclerotic plaques and vascular remodeling in acute coronary syndrome through activation of the TGF-¦Â/Smad pathway. +other hsa-mir-370 Diabetic Nephropathy 30317577 Effects of microRNA-370 on mesangial cell proliferation and extracellular matrix accumulation by binding to canopy 1 in a rat model of diabetic nephropathy. +other hsa-mir-101 Neoplasms [unspecific] 30319254 Cationic graphene oxide nanoplatform mediates miR-101 delivery to promote apoptosis by regulating autophagy and stress. +other hsa-mir-143 Glioblastoma 30322013 Targeting MicroRNA-143 Leads to Inhibition of Glioblastoma Tumor Progression. +other hsa-mir-708 "Osteoporosis, Postmenopausal" 30322266 Identification of miR-708-5p in peripheral blood monocytes: Potential marker for postmenopausal osteoporosis in Mexican-Mestizo population. +other hsa-mir-143 Helicobacter pylori Infection 30324743 "the expression of miR-28-3p, miR-143-3p, miR-151a-3p, and miR-148a-3p were closely associated with H pylori infection" +other hsa-mir-148a Helicobacter pylori Infection 30324743 "the expression of miR-28-3p, miR-143-3p, miR-151a-3p, and miR-148a-3p were closely associated with H pylori infection" +other hsa-mir-151a Helicobacter pylori Infection 30324743 "the expression of miR-28-3p, miR-143-3p, miR-151a-3p, and miR-148a-3p were closely associated with H pylori infection" +other hsa-mir-28 Helicobacter pylori Infection 30324743 "the expression of miR-28-3p, miR-143-3p, miR-151a-3p, and miR-148a-3p were closely associated with H pylori infection" +other hsa-mir-449a Osteoarthritis 30326428 Inhibition of miR-449a Promotes Cartilage Regeneration and Prevents Progression of Osteoarthritis in In?Vivo Rat Models. +other hsa-mir-192 Polycystic Kidney Disease 30332302 Impact of miR-192 and miR-194 on cyst enlargement through EMT in autosomal dominant polycystic kidney disease. +other hsa-mir-194 Polycystic Kidney Disease 30332302 Impact of miR-192 and miR-194 on cyst enlargement through EMT in autosomal dominant polycystic kidney disease. +other hsa-mir-21 "Carcinoma, Cervical" 30332981 Deregulation of miR-21 and miR-29a in Cervical Cancer Related to HPV Infection. +other hsa-mir-29a "Carcinoma, Cervical" 30332981 Deregulation of miR-21 and miR-29a in Cervical Cancer Related to HPV Infection. +other hsa-mir-107 Graft-Versus-Host Disease 30333363 Decreased Expression of MicroRNA-107 in B Lymphocytes of Patients with Antibody-Mediated Renal Allograft Rejection. +other hsa-mir-3158 "Diabetes Mellitus, Gestational" 30335885 "The key transcription factors include Sp1 transcription factor, pancreatic and duodenal homeobox 1, and hepatocyte nuclear factor 4 alpha, whereas miRNA includes has-miR-5699-5p and has-miR-3158-3p" +other hsa-mir-5699 "Diabetes Mellitus, Gestational" 30335885 "The key transcription factors include Sp1 transcription factor, pancreatic and duodenal homeobox 1, and hepatocyte nuclear factor 4 alpha, whereas miRNA includes has-miR-5699-5p and has-miR-3158-3p" +other hsa-mir-315 White Spot Syndrome Virus Infection 30337920 White Spot Syndrome Virus-Induced Shrimp miR-315 Attenuates Prophenoloxidase Activation via PPAE3 Gene Suppression. +other hsa-mir-711 Ischemic Diseases [unspecific] 30338821 Dexmedetomidine protects liver cell line L-02 from oxygen-glucose deprivation-induced injury by down-regulation of microRNA-711. +other hsa-mir-485 "Carcinoma, Pancreatic" 30341009 Bioselection Reveals miR-99b and miR-485 as Enhancers of Adenoviral Oncolysis in Pancreatic Cancer. +other hsa-mir-99b "Carcinoma, Pancreatic" 30341009 Bioselection Reveals miR-99b and miR-485 as Enhancers of Adenoviral Oncolysis in Pancreatic Cancer. +other hsa-mir-133a Lung Neoplasms 30341388 Up-regulated miR-133a orchestrates epithelial-mesenchymal transition of airway epithelial cells. +other hsa-mir-132 Psychiatric Disorders 30342060 miR-132/212 is induced by stress and its dysregulation triggers anxiety-related behavior. +other hsa-mir-212 Psychiatric Disorders 30342060 miR-132/212 is induced by stress and its dysregulation triggers anxiety-related behavior. +other hsa-mir-31 "Carcinoma, Hepatocellular" 30342168 CircRNA has_circ_0078710 acts as the sponge of microRNA-31 involved in hepatocellular carcinoma progression. +other hsa-mir-19b "Carcinoma, Breast" 30343695 MiR-19b non-canonical binding is directed by HuR and confers chemosensitivity through regulation of P-glycoprotein in breast cancer. +other hsa-mir-122 Fatty Liver [unspecific] 30344495 "High Fat Diet-Induced miR-122 Regulates Lipid Metabolism and Fat Deposition in Genetically Improved Farmed Tilapia (GIFT, Oreochromis niloticus) Liver." +other hsa-mir-146a Coronary Artery Disease 30344699 Endothelial stem cells attenuate cardiac apoptosis via downregulating cardiac microRNA-146a in a rat model of coronary heart disease. +other hsa-mir-21 Neoplasms [unspecific] 30346694 Tumor Cell-Derived Extracellular Vesicle-Coated Nanocarriers: An Efficient Theranostic Platform for the Cancer-Specific Delivery of Anti-miR-21 and Imaging Agents. +other hsa-mir-28 "Leukemia, Lymphocytic, Chronic, B-Cell" 30348117 NDRG2 mRNA levels and miR-28-5p and miR-650 activity in chronic lymphocytic leukemia. +other hsa-mir-650 "Leukemia, Lymphocytic, Chronic, B-Cell" 30348117 NDRG2 mRNA levels and miR-28-5p and miR-650 activity in chronic lymphocytic leukemia. +other hsa-mir-106b "Carcinoma, Breast" 30348127 "Several age-related miRNAs correlated with clinical frailty (miR-106b, miR-191, miR-301a, miR-320b, miR-374a), as well as with other biomarkers of aging, particularly Interleukin-6 (IL-6) and Monocyte Chemoattractant Protein-1 (MCP-1) (miR-106b, miR-301a, miR-374a-5p, miR-378a-3p)" +other hsa-mir-191 "Carcinoma, Breast" 30348127 "Several age-related miRNAs correlated with clinical frailty (miR-106b, miR-191, miR-301a, miR-320b, miR-374a), as well as with other biomarkers of aging, particularly Interleukin-6 (IL-6) and Monocyte Chemoattractant Protein-1 (MCP-1) (miR-106b, miR-301a, miR-374a-5p, miR-378a-3p)" +other hsa-mir-301a "Carcinoma, Breast" 30348127 "Several age-related miRNAs correlated with clinical frailty (miR-106b, miR-191, miR-301a, miR-320b, miR-374a), as well as with other biomarkers of aging, particularly Interleukin-6 (IL-6) and Monocyte Chemoattractant Protein-1 (MCP-1) (miR-106b, miR-301a, miR-374a-5p, miR-378a-3p)" +other hsa-mir-320b "Carcinoma, Breast" 30348127 "Several age-related miRNAs correlated with clinical frailty (miR-106b, miR-191, miR-301a, miR-320b, miR-374a), as well as with other biomarkers of aging, particularly Interleukin-6 (IL-6) and Monocyte Chemoattractant Protein-1 (MCP-1) (miR-106b, miR-301a, miR-374a-5p, miR-378a-3p)" +other hsa-mir-374a "Carcinoma, Breast" 30348127 "Several age-related miRNAs correlated with clinical frailty (miR-106b, miR-191, miR-301a, miR-320b, miR-374a), as well as with other biomarkers of aging, particularly Interleukin-6 (IL-6) and Monocyte Chemoattractant Protein-1 (MCP-1) (miR-106b, miR-301a, miR-374a-5p, miR-378a-3p)" +other hsa-mir-6798 Glioblastoma 30349053 Ars2 promotes cell proliferation and tumorigenicity in glioblastoma through regulating miR-6798-3p. +other hsa-mir-132 Neuropsychiatric Disorders [unspecific] 30352481 MicroRNA-132 directs human periodontal ligament-derived neural crest stem cell neural differentiation. +other hsa-mir-34a "Carcinoma, Cervical" 30354014 co-incubation of these two MINRCs with U87MG and HeLa cells led to cell-selective delivery of miR-34a +other hsa-mir-148b IgA Nephropathy 30355654 Renal microRNA-148b is associated with megalin downregulation in IgA nephropathy. +other hsa-mir-122 Sepsis 30355788 "a group of host cellular microRNAs (miRNAs; miR-34a-5p, miR-122-5p, miR-145-5p, miR-146a-5p, miR-210-3p) are released into the blood during sepsis, some of which are capable of inducing complement activation, cytokine production, and leukocyte migration" +other hsa-mir-145 Sepsis 30355788 "a group of host cellular microRNAs (miRNAs; miR-34a-5p, miR-122-5p, miR-145-5p, miR-146a-5p, miR-210-3p) are released into the blood during sepsis, some of which are capable of inducing complement activation, cytokine production, and leukocyte migration" +other hsa-mir-146a Sepsis 30355788 "a group of host cellular microRNAs (miRNAs; miR-34a-5p, miR-122-5p, miR-145-5p, miR-146a-5p, miR-210-3p) are released into the blood during sepsis, some of which are capable of inducing complement activation, cytokine production, and leukocyte migration" +other hsa-mir-210 Sepsis 30355788 "a group of host cellular microRNAs (miRNAs; miR-34a-5p, miR-122-5p, miR-145-5p, miR-146a-5p, miR-210-3p) are released into the blood during sepsis, some of which are capable of inducing complement activation, cytokine production, and leukocyte migration" +other hsa-mir-34a Sepsis 30355788 "a group of host cellular microRNAs (miRNAs; miR-34a-5p, miR-122-5p, miR-145-5p, miR-146a-5p, miR-210-3p) are released into the blood during sepsis, some of which are capable of inducing complement activation, cytokine production, and leukocyte migration" +other hsa-mir-224 Colorectal Carcinoma 30361904 "The study highlighted the involvement of non-target genes VEGFA, TGF¦Â1, IGF1, CD105 and CD44 in mediating anti- and pro-migratory effect of miR-375 and miR-224, respectively, and validated MAP4K4 as a direct target of anti-migratory miR-145" +other hsa-mir-375 Colorectal Carcinoma 30361904 "The study highlighted the involvement of non-target genes VEGFA, TGF¦Â1, IGF1, CD105 and CD44 in mediating anti- and pro-migratory effect of miR-375 and miR-224, respectively, and validated MAP4K4 as a direct target of anti-migratory miR-145" +other hsa-mir-1972 "Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal" 30362598 hsa-miR-20a-3p and hsa-miR-1972 were noted to be important in the etiology of larynx cancer +other hsa-mir-20a "Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal" 30362598 hsa-miR-20a-3p and hsa-miR-1972 were noted to be important in the etiology of larynx cancer +other hsa-mir-126 "Carcinoma, Lung, Small-Cell" 30364292 "MiR-126, DACH1, GRM8, MET, GSR, and HCP5 were implicated in the lymph node metastasis process of SCLC" +other hsa-mir-27a "Carcinoma, Breast" 30365154 miR?27a promotes human breast cancer cell migration by inducing EMT in a FBXW7?dependent manner. +other hsa-mir-34a Stroke 30365981 MiR-34a and stroke: Assessment of non-modifiable biological risk factors in cerebral ischemia. +other hsa-mir-146a Behcet Disease 30366049 Determination of mir-155 and mir-146a expression rates and its association with expression level of TNF-¦Á and CTLA4 genes in patients with Behcet's disease. +other hsa-mir-155 Behcet Disease 30366049 Determination of mir-155 and mir-146a expression rates and its association with expression level of TNF-¦Á and CTLA4 genes in patients with Behcet's disease. +other hsa-mir-135 "Diabetes Mellitus, Type 2" 30368872 "Network of three specific microRNAs(miR-135, miR-202, and miR-214) influence type 2 diabetes through inducing insulin resistance in muscle cell lines." +other hsa-mir-202 "Diabetes Mellitus, Type 2" 30368872 "Network of three specific microRNAs(miR-135, miR-202, and miR-214) influence type 2 diabetes through inducing insulin resistance in muscle cell lines." +other hsa-mir-214 "Diabetes Mellitus, Type 2" 30368872 "Network of three specific microRNAs(miR-135, miR-202, and miR-214) influence type 2 diabetes through inducing insulin resistance in muscle cell lines." +other hsa-mir-155 Atherosclerosis 30369883 Increased Expression of Resistin in MicroRNA-155-Deficient White Adipose Tissues May Be a Possible Driver of Metabolically Healthy Obesity Transition to Classical Obesity. +other hsa-mir-31 Neoplasms [unspecific] 30372817 Functions and mechanisms of microRNA-31 in human cancers. +other hsa-mir-378 Muscular Dystrophy 30373812 microRNA-378 promotes autophagy and inhibits apoptosis in skeletal muscle. +other hsa-mir-22 Hypertension 30375479 platelet miR-22 and miR-223 levels are reduced according to the hypertension status and they are negatively correlated with SBP levels +other hsa-mir-223 Hypertension 30375479 platelet miR-22 and miR-223 levels are reduced according to the hypertension status and they are negatively correlated with SBP levels +other hsa-mir-144 "Squamous Cell Carcinoma, Lung" 30375717 Involvement of dual-strand of the miR-144 duplex and their targets in the pathogenesis of lung squamous cell carcinoma. +other hsa-mir-122 "Carcinoma, Hepatocellular" 30377095 "we unveiled how HBV is deciphering the cellular miRNAs like miR-26a, miR-15a, miR-16-1, miR-148a, miR-132, miR-122, miR-34a, miR-21, miR-29a, miR-222 and miR-199a/b-3p to modulate the Wnt/FZD/¦Â-catenin signaling pathway and develop HCC" +other hsa-mir-132 "Carcinoma, Hepatocellular" 30377095 "we unveiled how HBV is deciphering the cellular miRNAs like miR-26a, miR-15a, miR-16-1, miR-148a, miR-132, miR-122, miR-34a, miR-21, miR-29a, miR-222 and miR-199a/b-3p to modulate the Wnt/FZD/¦Â-catenin signaling pathway and develop HCC" +other hsa-mir-148a "Carcinoma, Hepatocellular" 30377095 "we unveiled how HBV is deciphering the cellular miRNAs like miR-26a, miR-15a, miR-16-1, miR-148a, miR-132, miR-122, miR-34a, miR-21, miR-29a, miR-222 and miR-199a/b-3p to modulate the Wnt/FZD/¦Â-catenin signaling pathway and develop HCC" +other hsa-mir-15a "Carcinoma, Hepatocellular" 30377095 "we unveiled how HBV is deciphering the cellular miRNAs like miR-26a, miR-15a, miR-16-1, miR-148a, miR-132, miR-122, miR-34a, miR-21, miR-29a, miR-222 and miR-199a/b-3p to modulate the Wnt/FZD/¦Â-catenin signaling pathway and develop HCC" +other hsa-mir-16 "Carcinoma, Hepatocellular" 30377095 "we unveiled how HBV is deciphering the cellular miRNAs like miR-26a, miR-15a, miR-16-1, miR-148a, miR-132, miR-122, miR-34a, miR-21, miR-29a, miR-222 and miR-199a/b-3p to modulate the Wnt/FZD/¦Â-catenin signaling pathway and develop HCC" +other hsa-mir-199a "Carcinoma, Hepatocellular" 30377095 "we unveiled how HBV is deciphering the cellular miRNAs like miR-26a, miR-15a, miR-16-1, miR-148a, miR-132, miR-122, miR-34a, miR-21, miR-29a, miR-222 and miR-199a/b-3p to modulate the Wnt/FZD/¦Â-catenin signaling pathway and develop HCC" +other hsa-mir-199b "Carcinoma, Hepatocellular" 30377095 "we unveiled how HBV is deciphering the cellular miRNAs like miR-26a, miR-15a, miR-16-1, miR-148a, miR-132, miR-122, miR-34a, miR-21, miR-29a, miR-222 and miR-199a/b-3p to modulate the Wnt/FZD/¦Â-catenin signaling pathway and develop HCC" +other hsa-mir-21 "Carcinoma, Hepatocellular" 30377095 "we unveiled how HBV is deciphering the cellular miRNAs like miR-26a, miR-15a, miR-16-1, miR-148a, miR-132, miR-122, miR-34a, miR-21, miR-29a, miR-222 and miR-199a/b-3p to modulate the Wnt/FZD/¦Â-catenin signaling pathway and develop HCC" +other hsa-mir-222 "Carcinoma, Hepatocellular" 30377095 "we unveiled how HBV is deciphering the cellular miRNAs like miR-26a, miR-15a, miR-16-1, miR-148a, miR-132, miR-122, miR-34a, miR-21, miR-29a, miR-222 and miR-199a/b-3p to modulate the Wnt/FZD/¦Â-catenin signaling pathway and develop HCC" +other hsa-mir-26a "Carcinoma, Hepatocellular" 30377095 "we unveiled how HBV is deciphering the cellular miRNAs like miR-26a, miR-15a, miR-16-1, miR-148a, miR-132, miR-122, miR-34a, miR-21, miR-29a, miR-222 and miR-199a/b-3p to modulate the Wnt/FZD/¦Â-catenin signaling pathway and develop HCC" +other hsa-mir-29a "Carcinoma, Hepatocellular" 30377095 "we unveiled how HBV is deciphering the cellular miRNAs like miR-26a, miR-15a, miR-16-1, miR-148a, miR-132, miR-122, miR-34a, miR-21, miR-29a, miR-222 and miR-199a/b-3p to modulate the Wnt/FZD/¦Â-catenin signaling pathway and develop HCC" +other hsa-mir-34a "Carcinoma, Hepatocellular" 30377095 "we unveiled how HBV is deciphering the cellular miRNAs like miR-26a, miR-15a, miR-16-1, miR-148a, miR-132, miR-122, miR-34a, miR-21, miR-29a, miR-222 and miR-199a/b-3p to modulate the Wnt/FZD/¦Â-catenin signaling pathway and develop HCC" +other hsa-mir-122 Liver Neoplasms 30378424 Multiple MicroRNA Quantification Based on Acoustic Levitation of Single Microspheres after One-Pot Sandwich Interparticle Hybridizations. +other hsa-mir-21 Liver Neoplasms 30378424 Multiple MicroRNA Quantification Based on Acoustic Levitation of Single Microspheres after One-Pot Sandwich Interparticle Hybridizations. +other hsa-mir-168 Colorectal Carcinoma 30378765 "Plant-derived miR-168 is ubiquitously present in feces, normal mucosa and cancer" +other hsa-mir-155 Leukemia 30382602 "we discuss miR-155 dose-dependent effects in leukemias, and analyze results showing that miR-155 intermediate levels tend to be detrimental, while high levels of miR-155 expression usually prove beneficial" +other hsa-mir-105 Amyotrophic Lateral Sclerosis 30385300 MiR-105 and miR-9 regulate the mRNA stability of neuronal intermediate filaments. Implications for the pathogenesis of amyotrophic lateral sclerosis (ALS). +other hsa-mir-9 Amyotrophic Lateral Sclerosis 30385300 MiR-105 and miR-9 regulate the mRNA stability of neuronal intermediate filaments. Implications for the pathogenesis of amyotrophic lateral sclerosis (ALS). +other hsa-mir-30a Colorectal Carcinoma 30387187 miR-30a promoter variation contributes to the increased risk of colorectal cancer in an Iranian population. +other hsa-mir-21 Ischemia-Reperfusion Injury 23988020 "Our results demonstrate that besides miR-21, miR-17-5p, and miR-106a are additionally activated during the maintenance and recovery phases of renal I/R injury." +other hsa-mir-17 Ischemia-Reperfusion Injury 23988020 "Our results demonstrate that besides miR-21, miR-17-5p, and miR-106a are additionally activated during the maintenance and recovery phases of renal I/R injury." +other hsa-mir-106a Ischemia-Reperfusion Injury 23988020 "Our results demonstrate that besides miR-21, miR-17-5p, and miR-106a are additionally activated during the maintenance and recovery phases of renal I/R injury." +lncRNA target hsa-let-7a-1 Neoplasms [unspecific] 19211792 let-7a: Lin-28B transactivation is necessary for Myc-mediated let-7 repression and proliferation +lncRNA target hsa-let-7a-2 Neoplasms [unspecific] 19211792 let-7a: Lin-28B transactivation is necessary for Myc-mediated let-7 repression and proliferation +lncRNA target hsa-let-7a-3 Neoplasms [unspecific] 19211792 let-7a: Lin-28B transactivation is necessary for Myc-mediated let-7 repression and proliferation +lncRNA target hsa-let-7b Neoplasms [unspecific] 19211792 let-7b: Lin-28B transactivation is necessary for Myc-mediated let-7 repression and proliferation +lncRNA target hsa-let-7c Neoplasms [unspecific] 19211792 let-7c: Lin-28B transactivation is necessary for Myc-mediated let-7 repression and proliferation +lncRNA target hsa-let-7d Neoplasms [unspecific] 19211792 let-7d: Lin-28B transactivation is necessary for Myc-mediated let-7 repression and proliferation +lncRNA target hsa-let-7e Neoplasms [unspecific] 19211792 let-7e: Lin-28B transactivation is necessary for Myc-mediated let-7 repression and proliferation +lncRNA target hsa-let-7f-1 Neoplasms [unspecific] 19211792 let-7f: Lin-28B transactivation is necessary for Myc-mediated let-7 repression and proliferation +lncRNA target hsa-let-7f-2 Neoplasms [unspecific] 19211792 let-7f: Lin-28B transactivation is necessary for Myc-mediated let-7 repression and proliferation +lncRNA target hsa-let-7g Neoplasms [unspecific] 19211792 let-7g: Lin-28B transactivation is necessary for Myc-mediated let-7 repression and proliferation +lncRNA target hsa-let-7i Neoplasms [unspecific] 19211792 let-7i: Lin-28B transactivation is necessary for Myc-mediated let-7 repression and proliferation +lncRNA target hsa-let-7g Lung Neoplasms 19745602 increased with response to ionizing radiation when knockdown LIN28B +lncRNA target hsa-let-7a-1 Neoplasms [unspecific] 20005451 Lin28-let7 modulates radiosensitivity of human cancer cells with activation of K-Ras +lncRNA target hsa-let-7a-2 Neoplasms [unspecific] 20005451 Lin28-let7 modulates radiosensitivity of human cancer cells with activation of K-Ras +lncRNA target hsa-let-7a-3 Neoplasms [unspecific] 20005451 Lin28-let7 modulates radiosensitivity of human cancer cells with activation of K-Ras +lncRNA target hsa-let-7b Neoplasms [unspecific] 20005451 Lin28-let7 modulates radiosensitivity of human cancer cells with activation of K-Ras +lncRNA target hsa-let-7c Neoplasms [unspecific] 20005451 Lin28-let7 modulates radiosensitivity of human cancer cells with activation of K-Ras +lncRNA target hsa-let-7d Neoplasms [unspecific] 20005451 Lin28-let7 modulates radiosensitivity of human cancer cells with activation of K-Ras +lncRNA target hsa-let-7e Neoplasms [unspecific] 20005451 Lin28-let7 modulates radiosensitivity of human cancer cells with activation of K-Ras +lncRNA target hsa-let-7f-1 Neoplasms [unspecific] 20005451 Lin28-let7 modulates radiosensitivity of human cancer cells with activation of K-Ras +lncRNA target hsa-let-7f-2 Neoplasms [unspecific] 20005451 Lin28-let7 modulates radiosensitivity of human cancer cells with activation of K-Ras +lncRNA target hsa-let-7g Neoplasms [unspecific] 20005451 Lin28-let7 modulates radiosensitivity of human cancer cells with activation of K-Ras +lncRNA target hsa-let-7i Neoplasms [unspecific] 20005451 Lin28-let7 modulates radiosensitivity of human cancer cells with activation of K-Ras +lncRNA target hsa-let-7a Retinal Degeneration 20935637 The opposing actions of Lin-28 and let-7 miRNAs on M¨¹ller glia differentiation and dedifferentiation are similar to that of embryonic stem cells and suggest novel targets for stimulating M¨¹ller glia dedifferentiation and retinal regeneration in mammals. +lncRNA target hsa-let-7b Retinal Degeneration 20935637 The opposing actions of Lin-28 and let-7 miRNAs on M¨¹ller glia differentiation and dedifferentiation are similar to that of embryonic stem cells and suggest novel targets for stimulating M¨¹ller glia dedifferentiation and retinal regeneration in mammals. +lncRNA target hsa-let-7c Retinal Degeneration 20935637 The opposing actions of Lin-28 and let-7 miRNAs on M¨¹ller glia differentiation and dedifferentiation are similar to that of embryonic stem cells and suggest novel targets for stimulating M¨¹ller glia dedifferentiation and retinal regeneration in mammals. +lncRNA target hsa-let-7d Retinal Degeneration 20935637 The opposing actions of Lin-28 and let-7 miRNAs on M¨¹ller glia differentiation and dedifferentiation are similar to that of embryonic stem cells and suggest novel targets for stimulating M¨¹ller glia dedifferentiation and retinal regeneration in mammals. +lncRNA target hsa-let-7e Retinal Degeneration 20935637 The opposing actions of Lin-28 and let-7 miRNAs on M¨¹ller glia differentiation and dedifferentiation are similar to that of embryonic stem cells and suggest novel targets for stimulating M¨¹ller glia dedifferentiation and retinal regeneration in mammals. +lncRNA target hsa-let-7f Retinal Degeneration 20935637 The opposing actions of Lin-28 and let-7 miRNAs on M¨¹ller glia differentiation and dedifferentiation are similar to that of embryonic stem cells and suggest novel targets for stimulating M¨¹ller glia dedifferentiation and retinal regeneration in mammals. +lncRNA target hsa-let-7g Retinal Degeneration 20935637 The opposing actions of Lin-28 and let-7 miRNAs on M¨¹ller glia differentiation and dedifferentiation are similar to that of embryonic stem cells and suggest novel targets for stimulating M¨¹ller glia dedifferentiation and retinal regeneration in mammals. +lncRNA target hsa-let-7i Retinal Degeneration 20935637 The opposing actions of Lin-28 and let-7 miRNAs on M¨¹ller glia differentiation and dedifferentiation are similar to that of embryonic stem cells and suggest novel targets for stimulating M¨¹ller glia dedifferentiation and retinal regeneration in mammals. +lncRNA target hsa-let-7a Neoplasms [unspecific] 21045151 "Our data provide evidence that cancer stem cells may arise through a ""reprogramming-like"" mechanism. A rebalancing of the LIN28/let-7 regulatory loop could be a novel therapeutic strategy to target ALDH1+ cancer stem cells." +lncRNA target hsa-let-7b Neoplasms [unspecific] 21045151 "Our data provide evidence that cancer stem cells may arise through a ""reprogramming-like"" mechanism. A rebalancing of the LIN28/let-7 regulatory loop could be a novel therapeutic strategy to target ALDH1+ cancer stem cells." +lncRNA target hsa-let-7c Neoplasms [unspecific] 21045151 "Our data provide evidence that cancer stem cells may arise through a ""reprogramming-like"" mechanism. A rebalancing of the LIN28/let-7 regulatory loop could be a novel therapeutic strategy to target ALDH1+ cancer stem cells." +lncRNA target hsa-let-7d Neoplasms [unspecific] 21045151 "Our data provide evidence that cancer stem cells may arise through a ""reprogramming-like"" mechanism. A rebalancing of the LIN28/let-7 regulatory loop could be a novel therapeutic strategy to target ALDH1+ cancer stem cells." +lncRNA target hsa-let-7e Neoplasms [unspecific] 21045151 "Our data provide evidence that cancer stem cells may arise through a ""reprogramming-like"" mechanism. A rebalancing of the LIN28/let-7 regulatory loop could be a novel therapeutic strategy to target ALDH1+ cancer stem cells." +lncRNA target hsa-let-7f Neoplasms [unspecific] 21045151 "Our data provide evidence that cancer stem cells may arise through a ""reprogramming-like"" mechanism. A rebalancing of the LIN28/let-7 regulatory loop could be a novel therapeutic strategy to target ALDH1+ cancer stem cells." +lncRNA target hsa-let-7g Neoplasms [unspecific] 21045151 "Our data provide evidence that cancer stem cells may arise through a ""reprogramming-like"" mechanism. A rebalancing of the LIN28/let-7 regulatory loop could be a novel therapeutic strategy to target ALDH1+ cancer stem cells." +lncRNA target hsa-let-7i Neoplasms [unspecific] 21045151 "Our data provide evidence that cancer stem cells may arise through a ""reprogramming-like"" mechanism. A rebalancing of the LIN28/let-7 regulatory loop could be a novel therapeutic strategy to target ALDH1+ cancer stem cells." +lncRNA target hsa-let-7a-1 Breast Neoplasms 22081076 LIN28: A regulator of tumor-suppressing activity of let-7 microRNA in human breast cancer. +lncRNA target hsa-let-7a-2 Breast Neoplasms 22081076 LIN28: A regulator of tumor-suppressing activity of let-7 microRNA in human breast cancer. +lncRNA target hsa-let-7a-3 Breast Neoplasms 22081076 LIN28: A regulator of tumor-suppressing activity of let-7 microRNA in human breast cancer. +lncRNA target hsa-let-7c Breast Neoplasms 22081076 LIN28: A regulator of tumor-suppressing activity of let-7 microRNA in human breast cancer. +lncRNA target hsa-let-7d Breast Neoplasms 22081076 LIN28: A regulator of tumor-suppressing activity of let-7 microRNA in human breast cancer. +lncRNA target hsa-let-7f-1 Breast Neoplasms 22081076 LIN28: A regulator of tumor-suppressing activity of let-7 microRNA in human breast cancer. +lncRNA target hsa-let-7f-2 Breast Neoplasms 22081076 LIN28: A regulator of tumor-suppressing activity of let-7 microRNA in human breast cancer. +lncRNA target hsa-let-7a-1 Breast Neoplasms 22808086 "Lin28 Mediates Paclitaxel Resistance by Modulating p21, Rb and Let-7a miRNA in Breast Cancer Cells." +lncRNA target hsa-let-7a-2 Breast Neoplasms 22808086 "Lin28 Mediates Paclitaxel Resistance by Modulating p21, Rb and Let-7a miRNA in Breast Cancer Cells." +lncRNA target hsa-let-7a-3 Breast Neoplasms 22808086 "Lin28 Mediates Paclitaxel Resistance by Modulating p21, Rb and Let-7a miRNA in Breast Cancer Cells." +lncRNA target hsa-let-7 Perlman Syndrome 23594738 A role for the Perlman syndrome exonuclease Dis3l2 in the Lin28-let-7 pathway. +lncRNA target hsa-mir-221 Atherosclerosis 23697773 "We further discovered that an Ang II-regulated lncRNA functions as the host transcript for miR-221 and miR-222, 2 microRNAs implicated in cell proliferation. " +lncRNA target hsa-mir-675 Gastric Neoplasms 24388988 The long non-coding RNA H19-derived miR-675 modulates human gastric cancer cell proliferation by targeting tumor suppressor RUNX1. +lncRNA target hsa-mir-675 Glioma 24466011 Long non-coding RNA H19 promotes glioma cell invasion by deriving miR-675. +lncRNA target hsa-mir-21 Osteoarthritis 25196583 "A long non-coding RNA, GAS5, plays a critical role in the regulation of miR-21 during osteoarthritis." +lncRNA target hsa-mir-216b "Carcinoma, Hepatocellular" 25760077 Upregulated lncRNA-UCA1 contributes to progression of hepatocellular carcinoma through inhibition of miR-216b and activation of FGFR1/ERK signaling pathway. +lncRNA target hsa-mir-193a "Leukemia, Myeloid, Acute" 25979172 Long non-coding RNA HOTAIR modulates c-KIT expression through sponging miR-193a in acute myeloid leukemia. +lncRNA target hsa-mir-200c Gastric Neoplasms 25986864 LncRNA-ATB plays an important role in EMT to promote invasion and metastasis through the TGF-β/miR-200s/ZEB axis +lncRNA target hsa-let-7 Melanoma 26071398 "we discovered that Lin28B, a well-characterized inhibitor of let-7 miRNA biogenesis, was a direct target of miR-125a-5p in melanoma." +lncRNA target hsa-mir-107 Neoplasms [unspecific] 26158177 Lin28 could mediate cancer chemotherapy resistance via regulation of miR107 and Let-7 MiRNA. +lncRNA target hsa-mir-152 Gastric Neoplasms 26187665 Long non-coding RNA HOTAIR promotes HLA-G expression via inhibiting miR-152 in gastric cancer cells. +lncRNA target hsa-mir-145 Cervical Neoplasms 26311052 Long non-coding RNA MALAT1 modulates radiosensitivity of HR-HPV+ cervical cancer via sponging miR-145. +lncRNA target hsa-let-7 Neoplasms [unspecific] 26440890 These findings refine the current model of let-7 regulation by LIN28 proteins and have important implications for understanding the LIN28/let-7 axis in development and disease. +lncRNA target hsa-mir-222 Liver Fibrosis 26446789 GAS5 could directly bind to miR-222. +lncRNA target hsa-mir-141 "Carcinoma, Renal Cell, Clear-Cell" 26461224 LncRNA MALAT1 functions as a competing endogenous RNA to regulate ZEB2 expression by sponging miR-200s in clear cell kidney carcinoma. +lncRNA target hsa-mir-200a "Carcinoma, Renal Cell, Clear-Cell" 26461224 LncRNA MALAT1 functions as a competing endogenous RNA to regulate ZEB2 expression by sponging miR-200s in clear cell kidney carcinoma. +lncRNA target hsa-mir-200b "Carcinoma, Renal Cell, Clear-Cell" 26461224 LncRNA MALAT1 functions as a competing endogenous RNA to regulate ZEB2 expression by sponging miR-200s in clear cell kidney carcinoma. +lncRNA target hsa-mir-200c "Carcinoma, Renal Cell, Clear-Cell" 26461224 LncRNA MALAT1 functions as a competing endogenous RNA to regulate ZEB2 expression by sponging miR-200s in clear cell kidney carcinoma. +lncRNA target hsa-mir-429 "Carcinoma, Renal Cell, Clear-Cell" 26461224 LncRNA MALAT1 functions as a competing endogenous RNA to regulate ZEB2 expression by sponging miR-200s in clear cell kidney carcinoma. +lncRNA target hsa-mir-103 "Carcinoma, Endometrial" 26511107 "In summary, we demonstrate that GAS5 acts as an tumor suppressor lncRNA in endometrial cancer. Through inhibiting the expression of miR-103, GAS5 significantly enhanced the expression of PTEN to promote cancer cell apoptosis,and, thus, could be an important mediator in the pathogenesis of endometrial cancer." +lncRNA target hsa-mir-320a Embryonal Testis Carcinoma 26539909 "The accumulation of NLC1-C in the nucleus repressed miR-320a and miR-383 transcript and promoted testicular embryonal carcinoma cell proliferation by binding to Nucleolin. Here, we define a novel mechanism by which lncRNAs modulate miRNA expression at the transcriptional level by binding to RNA-binding proteins to regulate human spermatogenesis." +lncRNA target hsa-mir-193b "Adenocarcinoma, Pancreatic Ductal" 26549028 MIR31HG is negatively regulated by miR-193b. +lncRNA target hsa-mir-107 Gastric Neoplasms 26636340 Our results suggest that the Lin28/miR-107 pathway could be one of many signaling pathways regulated by Lin28 and associated with gastric cancer chemo-resistance. +lncRNA target hsa-mir-145 Pancreatic Neoplasms 26636540 ROR functions as a ceRNA to regulate Nanog expression by sponging miR-145 and predicts poor prognosis in pancreatic cancer. +lncRNA target hsa-mir-194 "Carcinoma, Gallbladder" 26803515 "overexpression of H19 in GBC-SD cells downregulated miR-194-5p and markedly increased AKT2 expression, and miR-194-5p mimic reversed these effects." +lncRNA target hsa-mir-485 Ovarian Neoplasms 26867765 UCA1 could function as an endogenous sponge by directly binding to miR-485-5p. +lncRNA target hsa-mir-9 Atherosclerosis 26981838 HULC regulated TNF-α-induced apoptosis through regulation of miR-9 expression. +lncRNA target hsa-mir-10a "Carcinoma, Hepatocellular" 27002617 Long non-coding RNA TUSC7 acts a molecular sponge for miR-10a and suppresses EMT in hepatocellular carcinoma. +lncRNA target hsa-mir-204 "Carcinoma, Nasopharyngeal" 27020592 The long non-coding RNA NEAT1 regulates epithelial to mesenchymal transition and radioresistance in through miR-204/ZEB1 axis in nasopharyngeal carcinoma. +lncRNA target hsa-mir-384 Glioma 27058823 "Moreover, CRNDE promoted cell malignant behavior by decreasing miR-384 expression." +lncRNA target hsa-mir-374a "Carcinoma, Hepatocellular" 27065331 Long noncoding RNA FTX inhibits hepatocellular carcinoma proliferation and metastasis by binding MCM2 and miR-374a. +lncRNA target hsa-mir-145 Colon Neoplasms 27071407 "Knockdown of lincRNA-ROR restored the expression of miR-145, and had a significant influence on colon cancer cell proliferation, migration and invasion." +lncRNA target hsa-mir-206 Gastric Neoplasms 27192121 "Acting as a miR-206 sponge, RMRP modulated cell cycle by regulating Cyclin D2 expression." +lncRNA target hsa-mir-218 Lung Neoplasms 27212446 miR-218 is negatively regulated by CCAT1 in HBE cells exposed to CSE. +lncRNA target hsa-mir-143 Neuroblastoma 27263970 Binding and release of miR-143-3p by LncND control the expression of Notch receptors. +lncRNA target hsa-mir-10a Glioblastoma 27270310 Long noncoding RNA RP11-838N2.4 enhances the cytotoxic effects of temozolomide by inhibiting the functions of miR-10a in glioblastoma cell lines. +lncRNA target hsa-mir-299 Glioblastoma 27345398 TUG1 enhances tumor-induced angiogenesis and VEGF expression through inhibiting miR-299. +lncRNA target hsa-mir-26a "Carcinoma, Gallbladder" 27345740 Upregulation of MINCR and enhancer of zeste homolog 2 (EZH2) in GBC coincided with the downregulation of miR-26a-5p in GBC. +lncRNA target hsa-mir-26a Glioma 27363339 Long non-coding RNA TUG1 acts as a miR-26a sponge in human glioma cells +lncRNA target hsa-mir-507 Melanoma 27389544 "We found that miR-507 could directly bind to UCA1 at the miRNA recognition site, and that there was a negative correlation between miR-507 and UCA1." +lncRNA target hsa-mir-139 Glioma 27434586 "HCP5 regulated the malignant behavior of glioma cells by binding to microRNA-139, which functions as a tumor suppressor." +lncRNA target hsa-mir-34a "Carcinoma, Nasopharyngeal" 27461945 Long non-coding RNA XIST exerts oncogenic functions in human nasopharyngeal carcinoma by targeting miR-34a-5p +lncRNA target hsa-mir-373 "Carcinoma, Ovarian" 27484896 LncRNA HOTAIR controls the expression of Rab22a by sponging miR-373 in ovarian cancer. +lncRNA target hsa-let-7a Cervical Neoplasms 27487126 LncRNA RSU1P2 contributes to tumorigenesis by acting as a ceRNA against let-7a in cervical cancer cells. +lncRNA target hsa-mir-125a Immune Thrombocytopenic Purpura 27522004 Long non-coding RNA MEG3 inhibits microRNA-125a-5p expression and induces immune imbalance of Treg/Th17 in immune thrombocytopenic purpura. +lncRNA target hsa-mir-34a Osteoarthritis 27529373 "Furthermore, we found that UFC1 regulates survival of OA chondrocytes through physically association with miR-34a." +lncRNA target hsa-let-7 Neoplasms [unspecific] 27548809 "We anticipate that much can be learned from the use of this first reported small molecule antagonist of Lin28, including the potential of the Lin28/let-7 interaction as a new drug target for selected cancers" +lncRNA target hsa-let-7c "Adenocarcinoma, Lung" 27566568 the oncogenic function of CCAT1 in docetaxel-resistant LAD cells depended on the sponging of let-7c +lncRNA target hsa-mir-148a "Carcinoma, Cervical" 27574106 Long non-coding RNA HOTAIR modulates HLA-G expression by absorbing miR-148a in human cervical cancer. +lncRNA target hsa-mir-196a "Carcinoma, Bladder" 27591936 Long non-coding RNA UCA1 promotes cisplatin/gemcitabine resistance through CREB modulating miR-196a-5p in bladder cancer cells. +lncRNA target hsa-mir-140 "Carcinoma, Hepatocellular" 27597739 Long non-coding RNA Unigene56159 promotes epithelial-mesenchymal transition by acting as a ceRNA of miR-140-5p in hepatocellular carcinoma cells. +lncRNA target hsa-mir-645 Osteosarcoma 27609068 Long non-coding RNA LINC00161 sensitises osteosarcoma cells to cisplatin-induced apoptosis by regulating the miR-645-IFIT2 axis. +lncRNA target hsa-mir-181b Liver Cirrhosis 27610008 Identification of a Novel lincRNA-p21-miR-181b-PTEN Signaling Cascade in Liver Fibrosis. +lncRNA target hsa-mir-18a "Carcinoma, Breast" 27629141 Long non-coding RNA UCA1 enhances tamoxifen resistance in breast cancer cells through a miR-18a-HIF1¦Á feedback regulatory loop. +lncRNA target hsa-mir-197 "Carcinoma, Bladder" 27631965 LINC00312 inhibits the migration and invasion of bladder cancer cells by targeting miR-197-3p. +lncRNA target hsa-mir-193a "Carcinoma, Colon" 27633443 the involvement of competing endogenous RNAs mechanism in Linc00152/miR-193a-3p/ERBB4/AKT signaling axis may provide a novel choice in the investigation of drug resistance +lncRNA target hsa-mir-150 Myocardial Infarction 27649667 LncRNA MIAT enhances cardiac hypertrophy partly through sponging miR-150. +lncRNA target hsa-mir-1297 "Carcinoma, Gastric" 27651312 "HOXA11-AS/miR-1297/EZH2 cross-talk serve as critical effectors in gastric cancer tumorigenesis and progression, suggesting new therapeutic directions in gastric cancer" +lncRNA target hsa-mir-9 Osteosarcoma 27658774 Long non-coding RNA TUG1 contributes to tumorigenesis of human osteosarcoma by sponging miR-9-5p and regulating POU2F1 expression. +lncRNA target hsa-mir-204 "Carcinoma, Esophageal" 27667646 lncRNA-UCA1 enhances cell proliferation through functioning as a ceRNA of Sox4 in esophageal cancer. +lncRNA target hsa-mir-494 "Carcinoma, Hepatocellular" 27689326 An artificial lncRNA targeting multiple miRNAs overcomes sorafenib resistance in hepatocellular carcinoma cells. +lncRNA target hsa-mir-140 Glioma 27693036 The lncRNA H19 interacts with miR-140 to modulate glioma growth by targeting iASPP. +lncRNA target hsa-mir-200c "Carcinoma, Endometrioid Endometrial" 27693631 Disrupting MALAT1/miR-200c sponge decreases invasion and migration in endometrioid endometrial carcinoma. +lncRNA target hsa-mir-27b "Carcinoma, Gastric" 27694794 Long Non-Coding RNA (LncRNA) Urothelial Carcinoma Associated 1 (UCA1) Increases Multi-Drug Resistance of Gastric Cancer via Downregulating miR-27b. +lncRNA target hsa-mir-125b Leukemia 27740626 "HOTAIRM1 was revealed to act as a microRNA sponge in a pathway that included miR-20a/106b, miR-125b and their targets ULK1, E2F1 and DRAM2" +lncRNA target hsa-mir-410 Glioma 27765628 Long non-coding RNA CCAT1 promotes glioma cell proliferation via inhibiting microRNA-410. +lncRNA target hsa-mir-124 "Carcinoma, Pancreatic" 27785603 Linc-ROR confers gemcitabine resistance to pancreatic cancer cells via inducing autophagy and modulating the miR-124/PTBP1/PKM2 axis. +lncRNA target hsa-mir-146a Prostate Neoplasms 27794184 LncRNA PVT1 regulates prostate cancer cell growth by inducing the methylation of miR-146a. +lncRNA target hsa-mir-195 Osteosarcoma 27813492 Long non-coding RNA PVT1 promotes osteosarcoma development by acting as a molecular sponge to regulate miR-195. +lncRNA target hsa-mir-200 "Carcinoma, Lung" 27852821 MEG3 regulated the recruitment of JARID2 and EZH2 and histone H3 methylation on the regulatory regions of CDH1 and microRNA-200 family genes for transcriptional repression +lncRNA target hsa-mir-16 Leukemia 27854515 lncRNA UCA1 Contributes to Imatinib Resistance by Acting as a ceRNA Against miR-16 in Chronic Myeloid Leukemia Cells. +lncRNA target hsa-mir-32 "Carcinoma, Gastric" 27871067 The lncRNA SNHG5/miR-32 axis regulates gastric cancer cell proliferation and migration by targeting KLF4. +lncRNA target hsa-mir-107 Glioma 27878295 Silencing of the long non-coding RNA NEAT1 suppresses glioma stem-like properties through modulation of the miR-107/CDK6 pathway. +lncRNA target hsa-mir-506 "Carcinoma, Pancreatic" 27888106 Long non-coding RNA NEAT1 facilitates pancreatic cancer progression through negative modulation of miR-506-3p. +lncRNA target hsa-mir-206 "Carcinoma, Lung" 27906963 "RMRP acted as an oncogene LncRNA to promote the expression of KRAS, FMNL2 and SOX9 by inhibiting miR-206 expression in lung cancer" +lncRNA target hsa-mir-195 "Carcinoma, Hepatocellular" 27932778 Expression of Long Non-Coding RNA (lncRNA) Small Nucleolar RNA Host Gene 1 (SNHG1) Exacerbates Hepatocellular Carcinoma Through Suppressing miR-195. +lncRNA target hsa-mir-23c Diabetic Nephropathy 27964927 Long noncoding RNA MALAT1 regulates renal tubular epithelial pyroptosis by modulated miR-23c targeting of ELAVL1 in diabetic nephropathy. +lncRNA target hsa-mir-183 Melanoma 27966454 Deregulation of miR-183 promotes melanoma development via lncRNA MALAT1 regulation and ITGB1 signal activation. +lncRNA target hsa-mir-675 Glioma 27981546 "LncRNA H19 is overexpressed in glioma tissue, is negatively associated with patient survival, and promotes tumor growth through its derivative miR-675." +lncRNA target hsa-mir-101 "Carcinoma, Bladder" 27998761 LncRNA SPRY4-IT1 sponges miR-101-3p to promote proliferation and metastasis of bladder cancer cells through up-regulating EZH2. +lncRNA target hsa-mir-214 "Carcinoma, Thyroid" 28000845 Long non-coding RNA NEAT1 promotes malignant progression of thyroid carcinoma by regulating miRNA-214. +lncRNA target hsa-mir-101 "Carcinoma, Breast" 28034643 The long non-coding RNA NEAT1 interacted with miR-101 modulates breast cancer growth by targeting EZH2. +lncRNA target hsa-mir-15a "Carcinoma, Hepatocellular" 28035067 "Long non-coding RNA AK058003, as a precursor of miR-15a, interacts with HuR to inhibit the expression of ¦Ã-synuclein in hepatocellular carcinoma cells." +lncRNA target hsa-mir-9 Breast Neoplasms 28053623 LncRNA Taurine-Upregulated Gene 1 Promotes Cell Proliferation by Inhibiting MicroRNA-9 in MCF-7 Cells. +lncRNA target hsa-mir-204 Choriocarcinoma 28059437 "Long Non-Coding RNA MALAT1 Interacts With miR-204 to Modulate Human Hilar Cholangiocarcinoma Proliferation, Migration, and Invasion by Targeting CXCR4." +lncRNA target hsa-mir-205 "Carcinoma, Breast" 28063065 Effects of long noncoding RNA-ROR on tamoxifen resistance of breast cancer cells by regulating microRNA-205. +lncRNA target hsa-mir-200a "Leukemia, Myeloid, Chronic" 28069548 HULC could modulate c-Myc and Bcl-2 by miR-200a as an endogenous sponge +lncRNA target hsa-mir-218 Colorectal Carcinoma 28069878 "the interaction between lncRNA MALAT1 and miR-218 was observed, which further indicated its prognostic value in patients who received standard FOLFOX treatment" +lncRNA target hsa-let-7 Malignant Neoplasms [unspecific] 28076679 Molecular Dynamics Simulations for Deciphering the Structural Basis of Recognition of Pre-let-7 miRNAs by LIN28. +lncRNA target hsa-mir-181a Colorectal Carcinoma 28086904 The lncRNA CRNDE promotes colorectal cancer cell proliferation and chemoresistance via miR-181a-5p-mediated regulation of Wnt/¦Â-catenin signaling. +lncRNA target hsa-mir-218 Retinoblastoma 28088735 Long non-coding RNA CCAT1 promotes human retinoblastoma SO-RB50 and Y79 cells through negative regulation of miR-218-5p. +lncRNA target hsa-mir-224 "Squamous Cell Carcinoma, Oral" 28093311 Long non-coding RNA FTH1P3 facilitates oral squamous cell carcinoma progression by acting as a molecular sponge of miR-224-5p to modulate fizzled 5 expression. +lncRNA target hsa-let-7a "Carcinoma, Nasopharyngeal" 28117929 Downregulation of lncRNA ANRIL represses tumorigenicity and enhances cisplatin-induced cytotoxicity via regulating microRNA let-7a in nasopharyngeal carcinoma. +lncRNA target hsa-mir-181a Glioma 28121023 LncRNA CASC2 Interacts With miR-181a to Modulate Glioma Growth and Resistance to TMZ Through PTEN Pathway. +lncRNA target hsa-mir-186 "Carcinoma, Gastric" 28122299 The long noncoding RNA PVT1 functions as a competing endogenous RNA by sponging miR-186 in gastric cancer. +lncRNA target hsa-mir-29b Liver Cirrhosis 28129115 HOTAIR Epigenetically Modulates PTEN Expression via MicroRNA-29b: A Novel Mechanism in Regulation of Liver Fibrosis. +lncRNA target hsa-mir-100 "Carcinoma, Colon" 28130225 "Cellular Model of Colon Cancer Progression Reveals Signatures of mRNAs, miRNA, lncRNAs, and Epigenetic Modifications Associated with Metastasis." +lncRNA target hsa-mir-125b "Carcinoma, Colon" 28130225 "Cellular Model of Colon Cancer Progression Reveals Signatures of mRNAs, miRNA, lncRNAs, and Epigenetic Modifications Associated with Metastasis." +lncRNA target hsa-mir-99a "Carcinoma, Colon" 28130225 "Cellular Model of Colon Cancer Progression Reveals Signatures of mRNAs, miRNA, lncRNAs, and Epigenetic Modifications Associated with Metastasis." +lncRNA target hsa-mir-182 Glioma 28137422 The lncRNA UCA1 interacts with miR-182 to modulate glioma proliferation and migration by targeting iASPP. +lncRNA target hsa-mir-101 "Carcinoma, Lung, Non-Small-Cell" 28147312 Upregulated lncRNA SNHG1 contributes to progression of non-small cell lung cancer through inhibition of miR-101-3p and activation of Wnt/¦Â-catenin signaling pathway. +lncRNA target hsa-mir-34c Inflammatory Bowel Diseases 28153728 MiR-34c and PlncRNA1 mediated the function of intestinal epithelial barrier by regulating tight junction proteins in inflammatory bowel disease. +lncRNA target hsa-mir-200a Colorectal Carcinoma 28164117 The lncRNA H19 Promotes Cell Proliferation by Competitively Binding to miR-200a and Derepressing ¦Â-Catenin Expression in Colorectal Cancer. +lncRNA target hsa-mir-300 "Carcinoma, Bladder" 28178615 Long non-coding RNA TUG1 promotes cell proliferation and metastasis by negatively regulating miR-300 in gallbladder carcinoma. +lncRNA target hsa-mir-200 "Carcinoma, Breast" 28187158 Role of the long non-coding RNA PVT1 in the dysregulation of the ceRNA-ceRNA network in human breast cancer. +lncRNA target hsa-mir-21 Leukemia 28190319 LncRNA MEG3 Regulates Imatinib Resistance in Chronic Myeloid Leukemia via Suppressing MicroRNA-21. +lncRNA target hsa-mir-17 Non-Traumatic Osteonecrosis 28207735 Long non-coding RNA HOTAIR inhibits miR-17-5p to regulate osteogenic differentiation and proliferation in non-traumatic osteonecrosis of femoral head. +lncRNA target hsa-mir-211 "Carcinoma, Colon" 28214867 The Novel Long Noncoding RNA TUSC7 Inhibits Proliferation by Sponging MiR-211 in Colorectal Cancer. +lncRNA target hsa-mir-139 "Carcinoma, Hepatocellular" 28231734 Long non-coding RNA XIST promotes cell growth by regulating miR-139-5p/PDK1/AKT axis in hepatocellular carcinoma. +lncRNA target hsa-mir-214 "Carcinoma, Nasopharyngeal" 28245169 Long Noncoding RNA LINC0086 Functions as a Tumor Suppressor in Nasopharyngeal Carcinoma by Targeting miR-214. +lncRNA target hsa-mir-29b Diabetic Retinopathy 28246353 Long non-coding RNA MIAT acts as a biomarker in diabetic retinopathy by absorbing miR-29b and regulating cell apoptosis. +lncRNA target hsa-mir-449a "Carcinoma, Lung, Non-Small-Cell" 28248928 "The lncRNA XIST exhibits oncogenic properties via regulation of miR-449a and Bcl-2 in human non-small cell lung cancerThis article has been corrected since Advanced Online Publication, and an erratum is also printed in this issue." +lncRNA target hsa-mir-124 "Carcinoma, Tounge" 28260102 Long non-coding RNA MALAT1 interacts with miR-124 and modulates tongue cancer growth by targeting JAG1. +lncRNA target hsa-mir-125b Hepatitis B Virus Infection 28267418 MicroRNA-125b-5p mediates post-transcriptional regulation of hepatitis B virus replication via the LIN28B/let-7 axis. +lncRNA target hsa-mir-203 "Carcinoma, Hepatocellular" 28271214 Long non-coding RNA UCA1 regulates the expression of Snail2 by miR-203 to promote hepatocellular carcinoma progression. +lncRNA target hsa-mir-204 Uterine Corpus Endometrial Carcinoma 28280730 Cancer-Related Triplets of mRNA-lncRNA-miRNA Revealed by Integrative Network in Uterine Corpus Endometrial Carcinoma. +lncRNA target hsa-mir-320 Uterine Corpus Endometrial Carcinoma 28280730 Cancer-Related Triplets of mRNA-lncRNA-miRNA Revealed by Integrative Network in Uterine Corpus Endometrial Carcinoma. +lncRNA target hsa-mir-150 Myocardial Infarction 28295592 Knockdown of Long Non-Coding RNA-ZFAS1 Protects Cardiomyocytes Against Acute Myocardial Infarction Via Anti-Apoptosis by Regulating miR-150/CRP. +lncRNA target hsa-mir-200a Hepatitis C Virus Infection 28302418 LncRNA-ATB/microRNA-200a/¦Â-catenin regulatory axis involved in the progression of HCV-related hepatic fibrosis. +lncRNA target hsa-mir-200b Hepatitis C Virus Infection 28302418 LncRNA-ATB/microRNA-200a/¦Â-catenin regulatory axis involved in the progression of HCV-related hepatic fibrosis. +lncRNA target hsa-mir-24 "Carcinoma, Colon" 28306719 "Chromosome 19q13 disruption alters expressions of CYP2A7, MIA and MIA-RAB4B lncRNA and contributes to FAP-like phenotype in APC mutation-negative familial colorectal cancer patients." +lncRNA target hsa-mir-770 Gastric Cardia Adenocarcinoma 28345805 "Promoter hypermethylation-mediated downregulation of miR-770 and its host gene MEG3, a long non-coding RNA, in the development of gastric cardia adenocarcinoma." +lncRNA target hsa-mir-129 Osteosarcoma 28346809 MALAT1 promotes osteosarcoma development by regulation of HMGB1 via miR-142-3p and miR-129-5p. +lncRNA target hsa-mir-142 Osteosarcoma 28346809 MALAT1 promotes osteosarcoma development by regulation of HMGB1 via miR-142-3p and miR-129-5p. +lncRNA target hsa-mir-181a "Carcinoma, Nasopharyngeal" 28358263 LncRNA CCAT1 modulates the sensitivity of paclitaxel in nasopharynx cancers cells via miR-181a/CPEB2 axis. +lncRNA target hsa-mir-138 "Carcinoma, Colon" 28358427 H19 promotes the migration and invasion of colon cancer by sponging miR-138 to upregulate the expression of HMGA1. +lncRNA target hsa-mir-490 "Carcinoma, Colon" 28381168 Long non-coding RNA colon cancer-associated transcript 1 functions as a competing endogenous RNA to regulate cyclin-dependent kinase 1 expression by sponging miR-490-3p in hepatocellular carcinoma progression. +lncRNA target hsa-mir-145 "Adenocarcinoma, Lung" 28388536 Long noncoding RNA ROR regulates chemoresistance in docetaxel-resistant lung adenocarcinoma cells via epithelial mesenchymal transition pathway. +lncRNA target hsa-mir-199a "Carcinoma, Prostate" 28400279 SNHG1 lncRNA negatively regulates miR-199a-3p to enhance CDK7 expression and promote cell proliferation in prostate cancer. +lncRNA target hsa-mir-200a "Carcinoma, Hepatocellular" 28403886 The long non-coding RNA TP73-AS1 modulates HCC cell proliferation through miR-200a-dependent HMGB1/RAGE regulation. +lncRNA target hsa-mir-26b Melanoma 28409552 Long Noncoding RNA PVT1 Promotes Melanoma Progression via Endogenous Sponging miR-26b. +lncRNA target hsa-mir-153 Osteosarcoma 28411362 Knockdown of Long Noncoding RNA TUG1 Inhibits the Proliferation and Cellular Invasion of Osteosarcoma Cells by Sponging miR-153. +lncRNA target hsa-mir-210 Osteosarcoma 28415557 "lncRNA CTA is an essential regulator in DOX-induced OS cell apoptosis, and the lncRNA CTA-miR-210 axis plays an important role in reducing OS chemoresistance" +lncRNA target hsa-mir-19b Medulloblastoma 28415684 The long noncoding RNA linc-NeD125 controls the expression of medulloblastoma driver genes by microRNA sponge activity. +lncRNA target hsa-mir-372 "Carcinoma, Hepatocellular" 28415780 Long noncoding RNA PCAT-14 induces proliferation and invasion by hepatocellular carcinoma cells by inducing methylation of miR-372. +lncRNA target hsa-mir-21 Glioblastoma 28423669 "The novel long non-coding RNA TALNEC2, regulates tumor cell growth and the stemness and radiation response of glioma stem cells." +lncRNA target hsa-mir-145 "Carcinoma, Oral" 28443494 Expression profiling of long non-coding RNA identifies linc-RoR as a prognostic biomarker in oral cancer. +lncRNA target hsa-mir-186 "Carcinoma, Lung, Non-Small-Cell" 28448993 The Long Non-Coding RNA XIST Controls Non-Small Cell Lung Cancer Proliferation and Invasion by Modulating miR-186-5p. +lncRNA target hsa-mir-495 "Carcinoma, Renal Cell" 28466784 LncRNA UCA1 promotes renal cell carcinoma proliferation through epigenetically repressing p21 expression and negatively regulating miR-495. +lncRNA target hsa-mir-217 "Carcinoma, Colon" 28472810 The Long Non-Coding RNA CRNDE Promotes Colorectal Carcinoma Progression by Competitively Binding miR-217 with TCF7L2 and Enhancing the Wnt/¦Â-Catenin Signaling Pathway. +lncRNA target hsa-mir-200b Melanoma 28487474 "Long noncoding RNA HEIH promotes melanoma cell proliferation, migration and invasion via inhibition of miR-200b/a/429." +lncRNA target hsa-mir-429 Melanoma 28487474 "Long noncoding RNA HEIH promotes melanoma cell proliferation, migration and invasion via inhibition of miR-200b/a/429." +lncRNA target hsa-mir-145 "Carcinoma, Gastric" 28490034 Long Noncoding RNA CRNDE Promotes Proliferation of Gastric Cancer Cells by Targeting miR-145. +lncRNA target hsa-mir-26a Glioblastoma 28499919 Long non-coding RNA AC023115.3 suppresses chemoresistance of glioblastoma by reducing autophagy. +lncRNA target hsa-mir-221 Osteosarcoma 28519068 Long Noncoding RNA GAS5 Suppresses Cell Growth and Epithelial-Mesenchymal Transition in Osteosarcoma by Regulating the miR-221/ARHI Pathway. +lncRNA target hsa-mir-9 "Carcinoma, Hepatocellular" 28520103 Circular RNA circMTO1 acts as the sponge of microRNA-9 to suppress hepatocellular carcinoma progression. +lncRNA target hsa-mir-21 Cardiac Fibrosis 28526319 LncRNA GAS5 controls cardiac fibroblast activation and fibrosis by targeting miR-21 via PTEN/MMP-2 signaling pathway. +lncRNA target hsa-mir-129 "Carcinoma, Hepatocellular" 28526689 Long non-coding RNA NEAT1 promotes hepatocellular carcinoma cell proliferation through the regulation of miR-129-5p-VCP-I¦ÊB. +lncRNA target hsa-mir-9 "Carcinoma, Esophageal" 28539329 Aberrant Methylation-Mediated Silencing of lncRNA MEG3 Functions as a ceRNA in Esophageal Cancer. +lncRNA target hsa-mir-20a Neoplasms [unspecific] 28542387 LncRNA-AF113014 promotes the expression of Egr2 by interaction with miR-20a to inhibit proliferation of hepatocellular carcinoma cells. +lncRNA target hsa-let-7 Pancreatic Neoplasms 28580169 "linc-ROR functioned as a competing endogenous RNA (ceRNA) to several tumor suppressor microRNAs, particularly some members of let-7 family" +lncRNA target hsa-mir-7 Gastric Neoplasms 28608528 Overexpression of Circular RNA ciRS-7 Abrogates the Tumor Suppressive Effect of miR-7 on Gastric Cancer via PTEN/PI3K/AKT Signaling Pathway. +lncRNA target hsa-mir-335 "Carcinoma, Gastric" 28618927 Long non-coding RNA MSTO2P promotes the proliferation and colony formation in gastric cancer by indirectly regulating miR-335 expression. +lncRNA target hsa-mir-143 Colorectal Carcinoma 28619512 PART-1 functions as a competitive endogenous RNA for promoting tumor progression by sponging miR-143 in colorectal cancer. +lncRNA target hsa-mir-218 "Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal" 28631575 Long non-coding RNA CCAT1/miR-218/ZFX axis modulates the progression of laryngeal squamous cell cancer. +lncRNA target hsa-mir-214 "Carcinoma, Pancreatic" 28639886 "A competing endogenous RNA network identifies novel mRNA, miRNA and lncRNA markers for the prognosis of diabetic pancreatic cancer." +lncRNA target hsa-mir-429 "Carcinoma, Pancreatic" 28639886 "A competing endogenous RNA network identifies novel mRNA, miRNA and lncRNA markers for the prognosis of diabetic pancreatic cancer." +lncRNA target hsa-mir-200b "Squamous Cell Carcinoma, Esophageal" 28640252 Long non-coding RNA ATB promotes malignancy of esophageal squamous cell carcinoma by regulating miR-200b/Kindlin-2 axis. +lncRNA target hsa-mir-23b "Carcinoma, Endometrial" 28653877 Long non-coding RNA tumor suppressor candidate 7 advances chemotherapy sensitivity of endometrial carcinoma through targeted silencing of miR-23b. +lncRNA target hsa-mir-150 Lung Injury [unspecific] 28655711 Long noncoding RNA FOXD3-AS1 regulates oxidative stress-induced apoptosis via sponging microRNA-150. +lncRNA target hsa-mir-186 "Carcinoma, Hepatocellular" 28656879 Long non-coding RNA PVT1 serves as a competing endogenous RNA for miR-186-5p to promote the tumorigenesis and metastasis of hepatocellular carcinoma. +lncRNA target hsa-mir-196a "Carcinoma, Cervical" 28671039 LncRNA GAS5 suppresses the tumorigenesis of cervical cancer by downregulating miR-196a and miR-205. +lncRNA target hsa-mir-205 "Carcinoma, Cervical" 28671039 LncRNA GAS5 suppresses the tumorigenesis of cervical cancer by downregulating miR-196a and miR-205. +lncRNA target hsa-mir-17 Atherosclerosis 28676341 "The Circular RNA Interacts with STAT3, Increasing Its Nuclear Translocation and Wound Repair by Modulating Dnmt3a and miR-17 Function." +lncRNA target hsa-let-7 "Leukemia, Myeloid, Acute" 28693523 "LIN28B/let-7/IGF2BP1, in leukemogenesis and provide a rationale to target this pathway as effective therapeutic strategy" +lncRNA target hsa-mir-125b Osteosarcoma 28695772 "Circular RNA GLI2 promotes osteosarcoma cell proliferation, migration, and invasion by targeting miR-125b-5p." +lncRNA target hsa-mir-204 "Carcinoma, Hepatocellular" 28720061 The long non-coding RNA MALAT1 promotes the migration and invasion of hepatocellular carcinoma by sponging miR-204 and releasing SIRT1. +lncRNA target hsa-mir-101 "Carcinoma, Colon" 28720069 Long non-coding RNA SPRY4-IT1 promotes proliferation and invasion by acting as a ceRNA of miR-101-3p in colorectal cancer cells. +lncRNA target hsa-mir-195 "Carcinoma, Hepatocellular" 28722813 Knockdown of long non-coding RNA MALAT1 inhibits growth and motility of human hepatoma cells via modulation of miR-195. +lncRNA target hsa-mir-19a "Carcinoma, Hepatocellular" 28724429 its pro-metastatic phenotype can partially be attributed to the HOXD-AS1/miR19a/ARHGAP11A signaling axis +lncRNA target hsa-mir-134 "Carcinoma, Nasopharyngeal" 28728844 Long non-coding RNA PCAT7 regulates ELF2 signaling through inhibition of miR-134-5p in nasopharyngeal carcinoma. +lncRNA target hsa-mir-19b Breast Neoplasms 28731027 PTENP1 acts as a ceRNA to regulate PTEN by sponging miR-19b and explores the biological role of PTENP1 in breast cancer +lncRNA target hsa-mir-92a Coronary Artery Disease 28760552 CDKN2B-AS may indirectly regulate coronary artery disease-associated genes via targeting miR-92a. +lncRNA target hsa-mir-144 Lung Neoplasms 28762326 Long Noncoding RNA Urothelial Carcinoma Associated 1 Promotes the Proliferation and Metastasis of Human Lung Tumor Cells by Regulating MicroRNA-144. +lncRNA target hsa-mir-29c Osteosarcoma 28789596 WITHDRAWN: Circular RNA hsa_circ_0001564 facilitates tumorigenesis of osteosarcoma via sponging miR-29c-3p. +lncRNA target hsa-mir-21 Multiple Myeloma 28801664 "we identified microRNA-21 as a STAT3 target gene with strong anti-apoptotic potential, suggesting that noncoding RNAs have an impact on the pathogenesis of human multiple myeloma" +lncRNA target hsa-mir-34a Osteosarcoma 28810936 "lncRNA C2dat1 Promotes Cell Proliferation, Migration, and Invasion by Targeting miR-34a-5p in Osteosarcoma Cells." +lncRNA target hsa-mir-205 Neoplasms [unspecific] 28825698 Functionally the lncRNA-PNUTS serves as a competitive sponge for miR-205 during epithelial-mesenchymal transition (EMT) +lncRNA target hsa-mir-150 Myocardial Infarction 28843520 The long non-coding RNA MIAT regulates zinc finger E-box binding homeobox 1 expression by sponging miR-150 and promoteing cell invasion in non-small-cell lung cancer. +lncRNA target hsa-let-7 Neoplasms [unspecific] 28846452 "Concise Review: LIN28/let-7 Signaling, a Critical Double-Negative Feedback Loop During Pluripotency, Reprogramming, and Tumorigenicity." +lncRNA target hsa-mir-106b "Carcinoma, Ovarian" 28864116 lncRNA PCA3 may coordinate EOC tumorigenesis through disrupting miR-106b regulated gene expression +lncRNA target hsa-mir-138 "Carcinoma, Lung, Non-Small-Cell" 28872894 Knockdown of Long Noncoding RNA Small Nucleolar RNA Host Gene 12 Inhibits Cell Growth and Induces Apoptosis by Upregulating miR-138 in Nonsmall Cell Lung Cancer. +lncRNA target hsa-mir-125b "Squamous Cell Carcinoma, Oral" 28926115 Long non-coding RNA MALAT1 promotes oral squamous cell carcinoma development via microRNA-125b/STAT3 axis. +lncRNA target hsa-let-7 "Adenocarcinoma, Pancreatic Ductal" 28947981 "Lin28B, a Lin28 homologue, represses the biogenesis of let-7 microRNAs (miRNAs), has a role in tumorigenesis, and is considered a potential therapeutic target for various human malignancies" +lncRNA target hsa-mir-21 Colon Neoplasms 28954383 Long non-coding RNA CASC7 inhibits the proliferation and migration of colon cancer cells via inhibiting microRNA-21. +lncRNA target hsa-mir-31 Chordoma 28963737 Long non-coding RNA LOC554202 modulates chordoma cell proliferation and invasion by recruiting EZH2 and regulating miR-31 expression. +lncRNA target hsa-mir-124 "Carcinoma, Lung, Non-Small-Cell" 29034803 LncRNA HOXA11-AS promotes proliferation and invasion by targeting miR-124 in human non-small cell lung cancer cells. +lncRNA target hsa-mir-34a Breast Neoplasms 29037220 circGFRA1 and GFRA1 act as ceRNAs in triple negative breast cancer by regulating miR-34a. +lncRNA target hsa-mir-124 Cardiovascular Diseases [unspecific] 29042195 Circular RNA WDR77 target FGF-2 to regulate vascular smooth muscle cells proliferation and migration by sponging miR-124. +lncRNA target hsa-mir-34a Gastric Neoplasms 29080815 Knockdown of long non-coding RNA HOTAIR inhibits cisplatin resistance of gastric cancer cells through inhibiting the PI3K/Akt and Wnt/¦Â-catenin signaling pathways by up-regulating miR-34a. +lncRNA target hsa-mir-939 Colorectal Carcinoma 29081216 Long Noncoding RNA HEIH Promotes Colorectal Cancer Tumorigenesis via Counteracting miR-939?Mediated Transcriptional Repression of Bcl-xL. +lncRNA target hsa-mir-200c Lung Fibrosis 29113749 Long non-coding RNA-ATB promotes EMT during silica-induced pulmonary fibrosis by competitively binding miR-200c. +lncRNA target hsa-mir-184 "Squamous Cell Carcinoma, Oral" 29125238 LncRNA UCA1 promotes proliferation and cisplatin resistance of oral squamous cell carcinoma by sunppressing miR-184 expression. +lncRNA target hsa-mir-9 Glioma 29137410 LINC00461 knockdown decreased expression levels of microRNA miR-9 and flanking genes MEF2C and TMEM161B +lncRNA target hsa-mir-195 Wilms Tumor 29159834 LINC00473 as an oncogene is up-regulated to participate into the molecular pathogenesis of Wilms tumour via miR-195/IKK¦Á +lncRNA target hsa-mir-613 "Carcinoma, Lung, Non-Small-Cell" 29187267 Long Noncoding RNA (lncRNA) HOTAIR Affects Tumorigenesis and Metastasis of Non-Small Cell Lung Cancer by Upregulating miR-613. +lncRNA target hsa-mir-215 Colorectal Carcinoma 29187907 Long non-coding RNA UICLM promotes colorectal cancer liver metastasis by acting as a ceRNA for microRNA-215 to regulate ZEB2 expression +lncRNA target hsa-mir-34a Cervical Neoplasms 29218240 "The long noncoding RNA LINC00473, a target of microRNA 34a, promotes tumorigenesis by inhibiting ILF2 degradation in cervical cancer" +lncRNA target hsa-mir-32 Pancreatic Neoplasms 29225772 Long non-coding RNA GAS5 suppresses pancreatic cancer metastasis through modulating miR-32-5p/PTEN axis +lncRNA target hsa-mir-125b Sepsis 29227823 "MALAT1 aggravates cardiac inflammation and dysfunction in sepsis, which is achieved via interaction with miR-125b and p38 MAPK/NF¦ÊB" +lncRNA target hsa-mir-21 "Stroke, Ischemic" 29238035 "our data uncovers a novel mechanism of lncRNA MEG3 as a ceRNA by targeting miR-21/PDCD4 signaling pathway in regulating ischemic neuronal death, which may help develop new strategies for the therapeutic interventions in cerebral ischemic stroke" +lncRNA target hsa-mir-373 Glioma 29310118 Long Non-Coding RNA HOXA-AS2 Regulates Malignant Glioma Behaviors and Vasculogenic Mimicry Formation via the MiR-373/EGFR Axis +lncRNA target hsa-mir-21 Osteosarcoma 29323740 "Long non-coding RNA ASBEL promotes osteosarcoma cell proliferation, migration and invasion by regulating microRNA-21" +lncRNA target hsa-mir-27a Diabetic Nephropathy 29334763 Long Noncoding RNA LINC01619 Regulates MicroRNA-27a/Forkhead Box Protein O1 and Endoplasmic Reticulum Stress-Mediated Podocyte Injury in Diabetic Nephropathy +lncRNA target hsa-let-7a "Squamous Cell Carcinoma, Esophageal" 29393461 Lin28/microRNA-let-7a promotes metastasis under circumstances of hyperactive Wnt signaling in esophageal squamous cell carcinoma +lncRNA target hsa-mir-10a Glioblastoma 29397407 Long non-coding RNA TUSC7 inhibits temozolomide resistance by targeting miR-10a in glioblastoma +lncRNA target hsa-mir-196a Lung Fibrosis 29411215 The lncRNA H19 Mediates Pulmonary Fibrosis by Regulating the miR-196a/COL1A1 Axis. +lncRNA target hsa-mir-124 Glioma 29412778 TP73-AS1 was specificallyupregulated in brain glioma cell lines and promoted glioma cell growth through targeting miR-124TP73-AS1 was specifically upregulated in brain glioma cell lines and promoted glioma cell growth through targeting miR-124 +lncRNA target hsa-mir-23a Hypoxic-Ischemic Encephalopathy 29428721 GAS5 regulated hippocampal neuron function by sponging miR-23a +lncRNA target hsa-mir-18a Prostate Neoplasms 29465000 Long non-coding RNA FENDRR reduces prostate cancer malignancy by competitively binding miR-18a-5p with RUNX1. +lncRNA target hsa-mir-145 "Carcinoma, Lung, Non-Small-Cell" 29466052 Long noncoding RNA SNHG1 promotes non-small cell lung cancer progression by up-regulating MTDH via sponging miR-145-5p. +lncRNA target hsa-mir-101 Glioblastoma 29479863 Long noncoding RNA MALAT1 knockdown reverses chemoresistance to temozolomide via promoting microRNA-101 in glioblastoma +lncRNA target hsa-mir-21 "Carcinoma, Lung" 29503447 "We found that LIN28B overexpression significantly increased the number of CD44+/CD326+ tumor cells, upregulated VEGF-A and miR-21 and promoted tumor angiogenesis and epithelial-to-mesenchymal transition (EMT) accompanied by enhanced AKT phosphorylation and nuclear translocation of c-MYC" +lncRNA target hsa-mir-181a "Carcinoma, Skin" 29514220 Long non-coding RNA CASC2 inhibits tumorigenesis via the miR-181a/PLXNC1 axis in melanoma. +lncRNA target hsa-mir-145 "Carcinoma, Hepatocellular" 29559320 Long non-coding RNA ROR promotes radioresistance in hepatocelluar carcinoma cells by acting as a ceRNA for microRNA-145 to regulate RAD18 expression +lncRNA target hsa-mir-503 Prostate Neoplasms 29571017 Long noncoding RNA SNHG7 accelerates prostate cancer proliferation and cycle progression through cyclin D1 by sponging miR-503. +lncRNA target hsa-mir-513c "Carcinoma, Hepatocellular" 29574975 "LncRNA FLVCR1-AS1 acts as miR-513c sponge to modulate cancer cell proliferation, migration, and invasion in hepatocellular carcinoma." +lncRNA target hsa-mir-140 "Carcinoma, Cervical" 29604594 LncRNA SNHG20 promotes cell proliferation and invasion via miR-140-5p-ADAM10 axis in cervical cancer. +lncRNA target hsa-mir-26b "Carcinoma, Breast" 29620147 lncRNA PVT1 promotes the angiogenesis of vascular endothelial cell by targeting miR?26b to activate CTGF/ANGPT2. +lncRNA target hsa-mir-5095 Cholangiocarcinoma 29620172 Long noncoding RNA LINC01296 promotes tumor growth and progression by sponging miR-5095 in human cholangiocarcinoma. +lncRNA target hsa-let-7 "Colitis, Ulcerative" 29621481 "H19 lncRNA bound to p53 and microRNAs that inhibit cell proliferation, including microRNA 34a and let-7; H19 lncRNA binding blocked their function, leading to increased expression of genes that promote regeneration of the epithelium" +lncRNA target hsa-mir-125a Oral Neoplasms 29635126 The role of long non-coding RNA ANRIL in the carcinogenesis of oral cancer by targeting miR-125a. +lncRNA target hsa-mir-758 "Carcinoma, Lung, Non-Small-Cell" 29635134 The long non-coding RNA-DANCR exerts oncogenic functions in non-small cell lung cancer via miR-758-3p. +lncRNA target hsa-mir-329 "Carcinoma, Bladder" 29653362 The long noncoding RNA ZFAS1 facilitates bladder cancer tumorigenesis by sponging miR-329. +lncRNA target hsa-mir-34c Osteosarcoma 29654165 Knockdown of the oncogene LncRNA NEAT1 restores the availability of miR-34c and improves the sensitivity to cisplatin in osteosarcoma +lncRNA target hsa-mir-182 Glioblastoma 29655792 Long non-coding RNA UCA1/miR-182/PFKFB2 axis modulates glioblastoma-associated stromal cells-mediated glycolysis and invasion of glioma cells. +lncRNA target hsa-mir-125a "Leukemia, Myeloid, Acute" 29663500 Knockdown of LncRNA-UCA1 suppresses chemoresistance of pediatric AML by inhibiting glycolysis through the microRNA-125a/hexokinase 2 pathway +lncRNA target hsa-mir-204 Acute Kidney Failure 29669307 Long non-coding RNA NEAT1 plays an important role in sepsis-induced acute kidney injury by targeting miR-204 and modulating the NF-¦ÊB pathway +lncRNA target hsa-mir-100 Pneumonia 29673591 Long noncoding RNA HAGLROS regulates cell apoptosis and autophagy in lipopolysaccharides-induced WI-38?cells via modulating miR-100/NF-¦ÊB axis. +lncRNA target hsa-mir-143 "Carcinoma, Bladder" 29674277 Long noncoding RNA FOXD2-AS1 accelerates the gemcitabine-resistance of bladder cancer by sponging miR-143. +lncRNA target hsa-mir-1253 Osteosarcoma 29678578 Circular RNA circNASP modulates the malignant behaviors in osteosarcoma via miR-1253/FOXF1 pathway. +lncRNA target hsa-mir-34a Colon Neoplasms 29679755 Long non-coding RNA XIST sponges miR-34a to promotes colon cancer progression via Wnt/¦Â-catenin signaling pathway. +lncRNA target hsa-mir-125a "Carcinoma, Hepatocellular" 29689270 Mutual suppression of miR-125a and Lin28b in human hepatocellular carcinoma cells. +lncRNA target hsa-mir-145 Colon Neoplasms 29690669 "LincRNA-ROR functions as a ceRNA to regulate Oct4, Sox2, and Nanog expression by sponging miR-145 and its effect on biologic characteristics of colonic cancer stem cells" +lncRNA target hsa-mir-4302 Lung Neoplasms 29698681 Circular RNA hsa_circRNA_103809 promotes lung cancer progression via facilitating ZNF121-dependent MYC expression by sequestering miR-4302. +lncRNA target hsa-mir-142 "Diabetes Mellitus, Type 2" 29704494 "Metformin, a first-line drug for type 2 diabetes mellitus, disrupts the MALAT1/miR-142-3p sponge to decrease invasion and migration in cervical cancer cells." +lncRNA target hsa-let-7 Neoplasms [unspecific] 29724816 Modulation of LIN28B/Let-7 Signaling by Propranolol Contributes to Infantile Hemangioma Involution. +lncRNA target hsa-mir-124 Invasive Bladder Transitional Cell Carcinoma 29736319 LncRNA MALAT1 promotes tumor growth and metastasis by targeting miR-124/foxq1 in bladder transitional cell carcinoma (BTCC). +lncRNA target hsa-mir-185 Colorectal Carcinoma 29737580 Long non-coding RNA FOXD2-AS1 contributes to colorectal?cancer proliferation through its interaction with?microRNA-185-5p. +lncRNA target hsa-mir-148a Prostate Neoplasms 29749452 MEF2?activated long non?coding RNA PCGEM1 promotes cell proliferation in hormone?refractory prostate cancer through downregulation of miR?148a. +lncRNA target hsa-mir-204 "Carcinoma, Pancreatic" 29753015 LncRNA ZEB2-AS1 promotes pancreatic cancer cell growth and invasion through regulating the miR-204/HMGB1 axis. +lncRNA target hsa-mir-30a Gastric Neoplasms 29761936 upregulated expression of linc00483 in gastric cancer acts as a sponge to absorb endogenous tumour suppressor miR-30a-3p +lncRNA target hsa-mir-30b Osteosarcoma 29772430 "LncRNA DICER1-AS1 promotes the proliferation, invasion and autophagy of osteosarcoma cells via miR-30b/ATG5." +lncRNA target hsa-mir-133 "Carcinoma, Pancreatic" 29772434 The interaction of long non-coding RNA MIAT and miR-133 play a role in the proliferation and metastasis of pancreatic carcinoma. +lncRNA target hsa-mir-21 "Leukemia, Myeloid, Chronic" 29772439 Long noncoding RNA MEG3 inhibits proliferation of chronic myeloid leukemia cells by sponging microRNA21. +lncRNA target hsa-mir-369 Colorectal Carcinoma 29773344 LncRNA OIP5-AS1 regulates radioresistance by targeting DYRK1A through miR-369-3p in colorectal cancer cells. +lncRNA target hsa-mir-141 "Carcinoma, Endometrial" 29775889 LncRNA MIR22HG negatively regulates miR-141-3p to enhance DAPK1 expression and inhibits endometrial carcinoma cells proliferation. +lncRNA target hsa-mir-23b "Carcinoma, Hepatocellular" 29778425 LncRNA HOTAIR contributes to the malignancy of hepatocellular carcinoma by enhancing epithelial-mesenchymal transition via sponging miR-23b-3p from ZEB1. +lncRNA target hsa-mir-150 Hypertrophy 29786749 Long noncoding RNA myocardial infarction?associated transcript is associated with the microRNA?150?5p/P300 pathway in cardiac hypertrophy. +lncRNA target hsa-mir-138 "Carcinoma, Renal Cell" 29789714 Estrogen receptor ¦Â promotes renal cell carcinoma progression via regulating LncRNA HOTAIR-miR-138/200c/204/217 associated CeRNA network. +lncRNA target hsa-mir-200c "Carcinoma, Renal Cell" 29789714 Estrogen receptor ¦Â promotes renal cell carcinoma progression via regulating LncRNA HOTAIR-miR-138/200c/204/217 associated CeRNA network. +lncRNA target hsa-mir-204 "Carcinoma, Renal Cell" 29789714 Estrogen receptor ¦Â promotes renal cell carcinoma progression via regulating LncRNA HOTAIR-miR-138/200c/204/217 associated CeRNA network. +lncRNA target hsa-mir-217 "Carcinoma, Renal Cell" 29789714 Estrogen receptor ¦Â promotes renal cell carcinoma progression via regulating LncRNA HOTAIR-miR-138/200c/204/217 associated CeRNA network. +lncRNA target hsa-mir-382 Ovarian Neoplasms 29790629 Long non-coding RNA NEAT1 promoted ovarian cancer cells' metastasis through regulation of miR-382-3p/ROCK1 axial. +lncRNA target hsa-mir-873 Lung Neoplasms 29790668 The effects of aberrant expression of LncRNA DGCR5/miR-873-5p/TUSC3 in lung cancer cell progression. +lncRNA target hsa-mir-196a "Carcinoma, Breast, Triple Negative" 29793177 Long noncoding RNA GAS5 suppresses triple negative breast cancer progression through inhibition of proliferation and invasion by competitively binding miR-196a-5p. +lncRNA target hsa-let-7b Epilepsy 29795132 Long non-coding RNA H19 contributes to apoptosis of hippocampal neurons by inhibiting let-7b in a rat model of temporal lobe epilepsy. +lncRNA target hsa-mir-223 Lupus Nephritis 29800915 Long non-coding RNA TUG1 protects renal tubular epithelial cells against injury induced by lipopolysaccharide via regulating microRNA-223. +lncRNA target hsa-mir-30a "Carcinoma, Thyroid, Papillary" 29803929 Long noncoding RNA PVT1 enhances the viability and invasion of papillary thyroid carcinoma cells by functioning as ceRNA of microRNA-30a through mediating expression of insulin like growth factor 1 receptor. +lncRNA target hsa-mir-449a "Carcinoma, Lung, Non-Small-Cell" 29803931 Long noncoding RNA TP73-AS1 promotes non-small cell lung cancer progression by competitively sponging miR-449a/EZH2. +lncRNA target hsa-mir-9 "Carcinoma, Lung, Non-Small-Cell" 29805671 "Regulatory interactions between long noncoding RNA LINC00968 and miR-9-3p in non-small cell lung cancer: A bioinformatic analysis based on miRNA microarray, GEO and TCGA." +lncRNA target hsa-mir-29a Colorectal Carcinoma 29807108 Functional role of a long non-coding RNA LIFR-AS1/miR-29a/TNFAIP3 axis in colorectal cancer resistance to pohotodynamic therapy. +lncRNA target hsa-mir-137 "Carcinoma, Lung, Non-Small-Cell" 29812958 Knockdown of LncRNA-XIST Suppresses Proliferation and TGF-¦Â1-Induced EMT in NSCLC Through the Notch-1 Pathway by Regulation of miR-137. +lncRNA target hsa-mir-129 Lung Neoplasms 29857296 "LncRNA NNT-AS1 promotes the proliferation, and invasion of lung cancer cells via regulating miR-129-5p expression." +lncRNA target hsa-mir-142 Osteosarcoma 29864904 Knockdown of long non-coding RNA TP73-AS1 inhibits osteosarcoma cell proliferation and invasion through sponging miR-142. +lncRNA target hsa-mir-124 Myocardial Infarction 29864957 TUG1 alleviates hypoxia injury by targeting miR-124 in H9c2 cells. +lncRNA target hsa-mir-610 Multiple Myeloma 29864963 Long non-coding RNA FEZF1-AS1 promotes cell growth in multiple myeloma via miR-610/Akt3 axis. +lncRNA target hsa-mir-211 "Carcinoma, Ovarian" 29874124 miR-211 sponges lncRNA MALAT1 to suppress tumor growth and progression through inhibiting PHF19 in ovarian carcinoma. +lncRNA target hsa-mir-137 "Carcinoma, Renal Cell" 29874202 Long Noncoding RNA Small Nucleolar RNA Host Gene 1 (SNHG1) Promotes Renal Cell Carcinoma Progression and Metastasis by Negatively Regulating miR-137. +lncRNA target hsa-mir-6873 Chronic Hepatitis B 29888838 regression analysis of gene expression revealed a strong positive correlation between hsa_circ_0000650 and TGF¦Â2 and a negative correlation between hsa_circ_0000650 and miR-6873-3p +lncRNA target hsa-mir-30 Cardiac Fibrosis 29889825 Long Noncoding RNA (lncRNA) n379519 Promotes Cardiac Fibrosis in Post-Infarct Myocardium by Targeting miR-30. +lncRNA target hsa-mir-1245 Lung Neoplasms 29891014 Hsa_circ_0046264 up-regulated BRCA2 to suppress lung cancer through targeting hsa-miR-1245. +lncRNA target hsa-mir-4695 Osteosarcoma 29901121 Long noncoding RNA AFAP1?AS1 enhances cell proliferation and invasion in osteosarcoma through regulating miR?4695?5p/TCF4?¦Â?catenin signaling. +lncRNA target hsa-mir-122 Metabolic Syndrome 29922126 "Those include the HOTAIR and MIAT lncRNAs and their targets, such as miR-122, -150, -155, -182, -197, -375, -608 and HLA-DRA" +lncRNA target hsa-mir-150 Metabolic Syndrome 29922126 "Those include the HOTAIR and MIAT lncRNAs and their targets, such as miR-122, -150, -155, -182, -197, -375, -608 and HLA-DRA" +lncRNA target hsa-mir-155 Metabolic Syndrome 29922126 "Those include the HOTAIR and MIAT lncRNAs and their targets, such as miR-122, -150, -155, -182, -197, -375, -608 and HLA-DRA" +lncRNA target hsa-mir-182 Metabolic Syndrome 29922126 "Those include the HOTAIR and MIAT lncRNAs and their targets, such as miR-122, -150, -155, -182, -197, -375, -608 and HLA-DRA" +lncRNA target hsa-mir-197 Metabolic Syndrome 29922126 "Those include the HOTAIR and MIAT lncRNAs and their targets, such as miR-122, -150, -155, -182, -197, -375, -608 and HLA-DRA" +lncRNA target hsa-mir-375 Metabolic Syndrome 29922126 "Those include the HOTAIR and MIAT lncRNAs and their targets, such as miR-122, -150, -155, -182, -197, -375, -608 and HLA-DRA" +lncRNA target hsa-mir-608 Metabolic Syndrome 29922126 "Those include the HOTAIR and MIAT lncRNAs and their targets, such as miR-122, -150, -155, -182, -197, -375, -608 and HLA-DRA" +lncRNA target hsa-mir-21 Colorectal Carcinoma 29928882 CircRNA circ_0026344 as a prognostic biomarker suppresses colorectal cancer progression via microRNA-21 and microRNA-31. +lncRNA target hsa-mir-31 Colorectal Carcinoma 29928882 CircRNA circ_0026344 as a prognostic biomarker suppresses colorectal cancer progression via microRNA-21 and microRNA-31. +lncRNA target hsa-mir-378a "Carcinoma, Pancreatic" 29930719 this circRNA was most likely to regulate the expression of miR-378a-3p +lncRNA target hsa-mir-375 "Adenocarcinoma, Lung" 29932500 "We built a network of hsa_circ_0000792-targeted miRNA gene interactions, including miR-375 and the corresponding messenger RNAs" +lncRNA target hsa-mir-324 Alzheimer Disease 29956723 Regulatory effects of the long non?coding RNA RP11?543N12.1 and microRNA?324?3p axis on the neuronal apoptosis induced by the inflammatory reactions of microglia. +lncRNA target hsa-mir-4310 Colon Neoplasms 29956772 LncRNA CASC15 promotes colon cancer cell proliferation and metastasis by regulating the miR?4310/LGR5/Wnt/¦Â?catenin signaling pathway. +lncRNA target hsa-mir-125b Sepsis 29962507 "Expression of the Long Intergenic Non-Coding RNA (lincRNA) of the NED25 Gene Modulates the microRNA-125b, STAT3, Nitric Oxide, and Procalcitonin Signaling Pathways in Patients with Sepsis." +lncRNA target hsa-mir-5003 Gastric Neoplasms 29991048 Long Non-Coding RNA RP11-789C1.1 Suppresses Epithelial to Mesenchymal Transition in Gastric Cancer Through the RP11-789C1.1/MiR-5003/E-Cadherin Axis. +lncRNA target hsa-mir-199a "Carcinoma, Breast" 30001527 Linc00518 Contributes to Multidrug Resistance Through Regulating the MiR-199a/MRP1 Axis in Breast Cancer. +lncRNA target hsa-mir-23a "Carcinoma, Breast" 30007957 Effect of the LncRNA GAS5-MiR-23a-ATG3 Axis in Regulating Autophagy in Patients with Breast Cancer. +lncRNA target hsa-mir-518d "Carcinoma, Cervical" 30007986 "CircRNA8924 Promotes Cervical Cancer Cell Proliferation, Migration and Invasion by Competitively Binding to MiR-518d-5p /519-5p Family and Modulating the Expression of CBX8." +lncRNA target hsa-mir-519 "Carcinoma, Cervical" 30007986 "CircRNA8924 Promotes Cervical Cancer Cell Proliferation, Migration and Invasion by Competitively Binding to MiR-518d-5p /519-5p Family and Modulating the Expression of CBX8." +lncRNA target hsa-mir-874 Sepsis 30021355 LncRNA H19 functions as an Aquaporin 1 competitive endogenous RNA to regulate microRNA-874 expression in LPS sepsis. +lncRNA target hsa-mir-182 "Carcinoma, Thyroid" 30021359 LncRNA MEG3 enhances 131I sensitivity in thyroid carcinoma via sponging miR-182. +lncRNA target hsa-mir-193a "Adenocarcinoma, Lung" 30036873 The LncRNA NEAT1 Accelerates Lung Adenocarcinoma Deterioration and Binds to Mir-193a-3p as a Competitive Endogenous RNA. +lncRNA target hsa-mir-203 Ischemia-Reperfusion Injury 30041794 LncRNA MALAT1 sponges miR-203 to promote inflammation in myocardial ischemia-reperfusion injury. +lncRNA target hsa-mir-302 Pituitary Neoplasms 30048990 Lnc-SNHG1 Activates the TGFBR2/SMAD3 and RAB11A/Wnt/¦Â-Catenin Pathway by Sponging MiR-302/372/373/520 in Invasive Pituitary Tumors. +lncRNA target hsa-mir-372 Pituitary Neoplasms 30048990 Lnc-SNHG1 Activates the TGFBR2/SMAD3 and RAB11A/Wnt/¦Â-Catenin Pathway by Sponging MiR-302/372/373/520 in Invasive Pituitary Tumors. +lncRNA target hsa-mir-373 Pituitary Neoplasms 30048990 Lnc-SNHG1 Activates the TGFBR2/SMAD3 and RAB11A/Wnt/¦Â-Catenin Pathway by Sponging MiR-302/372/373/520 in Invasive Pituitary Tumors. +lncRNA target hsa-mir-520 Pituitary Neoplasms 30048990 Lnc-SNHG1 Activates the TGFBR2/SMAD3 and RAB11A/Wnt/¦Â-Catenin Pathway by Sponging MiR-302/372/373/520 in Invasive Pituitary Tumors. +lncRNA target hsa-mir-132 Glioma 30053878 Knockdown of long non-coding RNA NEAT1 inhibits c cell migration and invasion via modulation of SOX2 targeted by miR-132. +lncRNA target hsa-mir-637 Hirschsprung Disease 30062828 Long non-coding RNA FAL1 functions as a ceRNA to antagonize the effect of miR-637 on the down-regulation of AKT1 in Hirschsprung's disease. +lncRNA target hsa-mir-124 "Squamous Cell Carcinoma, Oral" 30078268 Circular RNA circHIPK3 acts as the sponge of microRNA-124 to promote human oral squamous cell carcinoma cells proliferation +lncRNA target hsa-mir-155 "Carcinoma, Hepatocellular" 30091314 XIST Induced by JPX Suppresses Hepatocellular Carcinoma by Sponging miR-155-5p. +lncRNA target hsa-mir-219a Osteosarcoma 30099814 "TUG1 accelerated osteosarcoma proliferation, migration, and invasion by competitively sponging miR-219a-5p, leading to upregulation of Phosphatidylinositol-4, 5-Bisphosphate 3-Kinase Catalytic Subunit Alpha and activation of the protein kinase B (AKT) signaling pathway" +lncRNA target hsa-mir-454 "Adenocarcinoma, Lung" 30099826 LncRNA HOXA11-AS drives cisplatin resistance of human LUAD cells via modulating miR-454-3p/Stat3. +lncRNA target hsa-mir-126 Melanoma 30104884 LINC00888 promoted tumorigenicity of melanoma via miR-126/CRK signaling axis. +lncRNA target hsa-mir-140 Multiple Myeloma 30121664 Knockdown of Linc00515 Inhibits Multiple Myeloma Autophagy and Chemoresistance by Upregulating miR-140-5p and Downregulating ATG14. +lncRNA target hsa-mir-15a Colorectal Carcinoma 30126852 LINC00473 promotes the Taxol resistance via miR-15a in colorectal cancer. +lncRNA target hsa-mir-22 Sepsis 30130540 LncRNA HOX transcript antisense RNA accelerated kidney injury induced by urine-derived sepsis through the miR-22/high mobility group box 1 pathway. +lncRNA target hsa-mir-181a Multiple Myeloma 30134227 Long Non-Coding RNA MEG3 Functions as a Competing Endogenous RNA to Regulate HOXA11 Expression by Sponging miR-181a in Multiple Myeloma. +lncRNA target hsa-mir-593 "Carcinoma, Breast" 30139516 Downregulation of hsa_circ_0007534 suppresses breast cancer cell proliferation and invasion by targeting miR-593/MUC19 signal pathway. +lncRNA target hsa-mir-185 Melanoma 30144501 Long non-coding RNA UCA1 targets miR-185-5p and regulates cell mobility by affecting epithelial-mesenchymal transition in melanoma via Wnt/¦Â-catenin signaling pathway. +lncRNA target hsa-mir-134 Atherosclerosis 30158376 LncRNA DIGIT Accelerates Tube Formation of Vascular Endothelial Cells by Sponging miR-134. +lncRNA target hsa-mir-120 Thrombosis 30171660 "LncRNA WTAPP1 promotes migration and angiogenesis of endothelial progenitor cells via MMP1 through microRNA 3,120 and Akt/PI3K/autophagy pathways." +lncRNA target hsa-mir-3 Thrombosis 30171660 "LncRNA WTAPP1 promotes migration and angiogenesis of endothelial progenitor cells via MMP1 through microRNA 3,120 and Akt/PI3K/autophagy pathways." +lncRNA target hsa-mir-214 Glioma 30179681 LncRNA LOC728196/miR-513c axis facilitates glioma carcinogenesis by targeting TCF7. +lncRNA target hsa-mir-136 Neuropathic Pain 30203524 LINC00657 expedites neuropathic pain development by modulating miR-136/ZEB1 axis in a rat model. +lncRNA target hsa-mir-26a Gastric Neoplasms 30205370 miR-26a/HOXC9 Dysregulation Promotes Metastasis and Stem Cell-Like Phenotype of Gastric Cancer. +lncRNA target hsa-mir-206 Ovarian Neoplasms 30205383 LncRNA HOTAIR Regulates CCND1 and CCND2 Expression by Sponging miR-206 in Ovarian Cancer. +lncRNA target hsa-mir-331 "Carcinoma, Cervical" 30207103 LncRNA XLOC_006390 facilitates cervical cancer tumorigenesis and metastasis as a ceRNA against miR-331-3p and miR-338-3p. +lncRNA target hsa-mir-338 "Carcinoma, Cervical" 30207103 LncRNA XLOC_006390 facilitates cervical cancer tumorigenesis and metastasis as a ceRNA against miR-331-3p and miR-338-3p. +lncRNA target hsa-mir-214 Ovarian Neoplasms 30207107 Upregulation of long non-coding RNA XIST has anticancer effects on epithelial ovarian cancer cells through inverse downregulation of hsa-miR-214-3p. +lncRNA target hsa-mir-143 "Carcinoma, Salivary Adenoid Cystic" 30217729 ADAMTS9-AS2 promotes migration and invasion in SACC by competing with miR-143-3p +lncRNA target hsa-mir-107 "Carcinoma, Cervical" 30231238 lncRNA DLG1-AS1 Promotes Cell Proliferation by Competitively Binding with miR-107 and Up-Regulating ZHX1 Expression in Cervical Cancer. +lncRNA target hsa-mir-1207 Nasopharyngeal Neoplasms 30243935 Long non-coding RNA 319 facilitates nasopharyngeal carcinoma carcinogenesis through regulation of miR-1207-5p/KLF12 axis. +lncRNA target hsa-mir-671 "Carcinoma, Hepatocellular" 30250300 Hypoxia-induced TUFT1 promotes the growth and metastasis of hepatocellular carcinoma by activating the Ca2+/PI3K/AKT pathway. +lncRNA target hsa-mir-451 Osteoarthritis 30272288 LncRNA?p21 promotes chondrocyte apoptosis in osteoarthritis by acting as a sponge for miR?451. +lncRNA target hsa-mir-144 "Carcinoma, Renal Cell, Clear-Cell" 30278113 Construction and comprehensive analysis of dysregulated long non-coding RNA-associated competing endogenous RNA network in clear cell renal cell carcinoma. +lncRNA target hsa-mir-155 "Carcinoma, Renal Cell, Clear-Cell" 30278113 Construction and comprehensive analysis of dysregulated long non-coding RNA-associated competing endogenous RNA network in clear cell renal cell carcinoma. +lncRNA target hsa-mir-21 "Carcinoma, Renal Cell, Clear-Cell" 30278113 Construction and comprehensive analysis of dysregulated long non-coding RNA-associated competing endogenous RNA network in clear cell renal cell carcinoma. +lncRNA target hsa-mir-30a "Carcinoma, Hepatocellular" 30278452 Long Non-Coding MALAT1 Functions as a Competing Endogenous RNA to Regulate Vimentin Expression by Sponging miR-30a-5p in Hepatocellular Carcinoma. +lncRNA target hsa-mir-130a Glioma 30282068 H19 Functions as a Competing Endogenous RNA to Regulate EMT by Sponging miR-130a-3p in Glioma. +lncRNA target hsa-mir-182 "Carcinoma, Bladder" 30285878 Circular RNA BCRC-3 suppresses bladder cancer proliferation through miR-182-5p/p27 axis. +lncRNA target hsa-mir-675 Cataract 30286462 H19 regulates HLECs function through miR-675-mediated CRYAA expression. This finding would provide a novel insight into the pathogenesis of nuclear ARC +lncRNA target hsa-mir-34a Neoplasms [unspecific] 30289954 Dual biomarkers long non-coding RNA GAS5 and microRNA-34a co-expression signature in common solid tumors. +lncRNA target hsa-mir-330 Cardiovascular Diseases [unspecific] 30297107 The long noncoding RNA XIST protects cardiomyocyte hypertrophy by targeting miR-330-3p. +lncRNA target hsa-mir-154 Neuropathic Pain 30335888 LncRNA X inactive specific transcript contributes to neuropathic pain development by sponging miR-154-5p via inducing toll-like receptor 5 in CCI rat models. +lncRNA target hsa-mir-20b Ischemia-Reperfusion Injury 30367982 Long noncoding RNA HOTAIR regulates autophagy via the miR-20b-5p/ATG7 axis in hepatic ischemia/reperfusion injury. +lncRNA target hsa-mir-129 Neoplasms [unspecific] 30374364 "NEAT1 functions as a scaffold RNA molecule by interacting with EZH2 (a subunit of the polycomb repressive complex) to influence the expression of downstream effectors of EZH2, it also acts as a microRNA (miRNA) sponge to suppress the interactions between miRNAs and target mRNAs, and affects the expression of miR-129 by promoting the DNA methylation of the miR-129 promoter region" +lncRNA target hsa-mir-153 Intervertebral Disc Degeneration 30378116 LINC00641 regulates autophagy and intervertebral disc degeneration by acting as a competitive endogenous RNA of miR-153-3p under nutrition deprivation stress. +target gene hsa-let-7a-1 Lung Neoplasms 15172979 decreased abundance; negatively regulate the RAS gene. +target gene hsa-let-7a-2 Lung Neoplasms 15172979 decreased abundance; negatively regulate the RAS gene. +target gene hsa-let-7a-3 Lung Neoplasms 15172979 decreased abundance; negatively regulate the RAS gene. +target gene hsa-let-7b Lung Neoplasms 15172979 decreased abundance; negatively regulate the RAS gene. +target gene hsa-let-7c Lung Neoplasms 15172979 decreased abundance; negatively regulate the RAS gene. +target gene hsa-let-7d Lung Neoplasms 15172979 decreased abundance; negatively regulate the RAS gene. +target gene hsa-let-7e Lung Neoplasms 15172979 decreased abundance; negatively regulate the RAS gene. +target gene hsa-let-7f-1 Lung Neoplasms 15172979 decreased abundance; negatively regulate the RAS gene. +target gene hsa-let-7f-2 Lung Neoplasms 15172979 decreased abundance; negatively regulate the RAS gene. +target gene hsa-let-7g Lung Neoplasms 15172979 decreased abundance; negatively regulate the RAS gene. +target gene hsa-let-7i Lung Neoplasms 15172979 decreased abundance; negatively regulate the RAS gene. +target gene hsa-mir-143 Obesity 16195701 "Modified oligonucleotide complementary to miR-143 effectively suppressed adipocyte differentiation by modulation of its putative target ERK5, a protein previously known to be implicated in MAP kinase signaling pathways." +target gene hsa-mir-372 Testicular Neoplasms 16564011 A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors. +target gene hsa-mir-373 Testicular Neoplasms 16564011 A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors. +target gene hsa-mir-122 "Carcinoma, Hepatocellular" 16777601 inhibite CAT-1 +target gene hsa-mir-155 Gastrointestinal Neoplasms 16875667 "Therefore, we concluded that artificial miRNA can depress the expression of PRL-3, and that PRL-3 might be a potential therapeutic target for gastric cancer peritoneal metastasis." +target gene hsa-mir-20a Breast Neoplasms 17011485 "TGF-b-2 receptor is expressed in the epithelium of breast cancer and can be regulated by miR-20a, which is down- regulated in breast cancer." +target gene hsa-mir-127 Neoplasms [unspecific] 17012848 "For example, mir-127, which is generally expressed in normal cells but absent in cancer cells, was markedly induced after treatment. Intriguingly, a predicted target of mir-127, BCL6, was translationally downregulated after treatment." +target gene hsa-mir-146a Thyroid Neoplasms 17012848 "Mir-221, mir-22 and mir-146 are significantly upregulated in this disease, whereas the expression of their predicted target gene KIT is lost, concurrently with the miRNA upregulation." +target gene hsa-mir-146b Thyroid Neoplasms 17012848 "Mir-221, mir-22 and mir-146 are significantly upregulated in this disease, whereas the expression of their predicted target gene KIT is lost, concurrently with the miRNA upregulation." +target gene hsa-mir-22 Thyroid Neoplasms 17012848 "Mir-221, mir-22 and mir-146 are significantly upregulated in this disease, whereas the expression of their predicted target gene KIT is lost, concurrently with the miRNA upregulation." +target gene hsa-mir-221 Thyroid Neoplasms 17012848 "Mir-221, mir-22 and mir-146 are significantly upregulated in this disease, whereas the expression of their predicted target gene KIT is lost, concurrently with the miRNA upregulation." +target gene hsa-mir-19a "Carcinoma, Hepatocellular" 17188425 miRNA-19a/b activates PI3K by blocking expression of the tumor suppressor PTEN. +target gene hsa-mir-19b-1 "Carcinoma, Hepatocellular" 17188425 miRNA-19a/b activates PI3K by blocking expression of the tumor suppressor PTEN. +target gene hsa-mir-19b-2 "Carcinoma, Hepatocellular" 17188425 miRNA-19a/b activates PI3K by blocking expression of the tumor suppressor PTEN. +target gene hsa-mir-200a "Carcinoma, Hepatocellular" 17188425 "Integration at FRA1A may silence expression of miRNA-200a, which is known to be decreased in HCC compared to nontumor [59] and [65]. Since most miRNAs suppress their target proteins, and miRNA-200a is known to regulate the expression of RAB30, a member of" +target gene hsa-mir-224 Hepatitis C Virus Infection 17188425 "miRNA-224 regulates PDGFR expression, and decreases as disease progresses from chronic hepatitis to cirrhosis [59], suggesting that miRNA normally suppresses PDGFR in the liver until HBV integration and genetic instability upsets this balance. miRNA-224 a" +target gene hsa-let-7c Leiomyoma 17243163 HMGA2 was identified as one of target genes of the let-7 family of miRNAs and has been found to be suppressed by let-7 in vitro. +target gene hsa-mir-206 Breast Neoplasms 17312270 The micro-ribonucleic acid (miRNA) miR-206 targets the human estrogen receptor-alpha (ERalpha) and represses ERalpha messenger RNA and protein expression in breast cancer cell lines. +target gene hsa-let-7a-1 Neoplasms [unspecific] 17322030 Disrupting the pairing between let-7 and Hmga2 +target gene hsa-let-7a-2 Neoplasms [unspecific] 17322030 Disrupting the pairing between let-7 and Hmga2 +target gene hsa-let-7a-3 Neoplasms [unspecific] 17322030 Disrupting the pairing between let-7 and Hmga2 +target gene hsa-let-7b Neoplasms [unspecific] 17322030 Disrupting the pairing between let-7 and Hmga2 +target gene hsa-let-7c Neoplasms [unspecific] 17322030 Disrupting the pairing between let-7 and Hmga2 +target gene hsa-let-7d Neoplasms [unspecific] 17322030 Disrupting the pairing between let-7 and Hmga2 +target gene hsa-let-7e Neoplasms [unspecific] 17322030 Disrupting the pairing between let-7 and Hmga2 +target gene hsa-let-7f-1 Neoplasms [unspecific] 17322030 Disrupting the pairing between let-7 and Hmga2 +target gene hsa-let-7f-2 Neoplasms [unspecific] 17322030 Disrupting the pairing between let-7 and Hmga2 +target gene hsa-let-7g Neoplasms [unspecific] 17322030 Disrupting the pairing between let-7 and Hmga2 +target gene hsa-let-7i Neoplasms [unspecific] 17322030 Disrupting the pairing between let-7 and Hmga2 +target gene hsa-mir-302b Thyroid Neoplasms 17355635 "Genetically PTC is defined by several alterations which cause abnormal activation of the mitogen-activated protein kinase (MAPK) pathway, the most prevalent being point mutations in the intracellular signalling kinase BRAF. Of particular interest in this study is the downregulation of miR-323 and miR-302b in BRAF mutated cell line. miRBASE target database predicted that the BRAF transcript has binding sites for miR-323 and miR-302b to potentially bind and down- regulate BRAF expression." +target gene hsa-mir-323a Thyroid Neoplasms 17355635 "Genetically PTC is defined by several alterations which cause abnormal activation of the mitogen-activated protein kinase (MAPK) pathway, the most prevalent being point mutations in the intracellular signalling kinase BRAF. Of particular interest in this study is the downregulation of miR-323 and miR-302b in BRAF mutated cell line. miRBASE target database predicted that the BRAF transcript has binding sites for miR-323 and miR-302b to potentially bind and down- regulate BRAF expression." +target gene hsa-mir-122 Hepatitis C Virus Infection 17462786 "Although miRNA regulation of cellular target genes through 3'UTR binding seems to be only negative, the hepatitis C virus (HCV) has creatively made use of the liver-specific and abundantly expressed miR-122 to promote viral replication." +target gene hsa-mir-32 Viral Infectious Disease 17462786 "This has been reported for the retrovirus primate foamy virus-1 (PFV-1), which can be targeted by the host miR-32 [150], which was suggested to restrict its infection." +target gene hsa-mir-124a Pancreatic Neoplasms 17462994 MicroRNA-124a regulates Foxa2 expression and intracellular signaling in pancreatic beta-cell lines. +target gene hsa-mir-1 Arrhythmia 17516552 "we also designed the microRNA-masking antisense based on the miR-1 and miR-133 target sites in the 3'UTRs of HCN2 and HCN4 and found that these antisense oligodeoxynucleotides markedly enhanced HCN2/HCN4 expression and function, as reflected by increased protein levels of HCN2/HCN4 and If conductance, by removing the repression of HCN2/HCN4 expression induced by endogenous miR-1/miR-133." +target gene hsa-mir-133 Arrhythmia 17516552 "we also designed the microRNA-masking antisense based on the miR-1 and miR-133 target sites in the 3'UTRs of HCN2 and HCN4 and found that these antisense oligodeoxynucleotides markedly enhanced HCN2/HCN4 expression and function, as reflected by increased protein levels of HCN2/HCN4 and If conductance, by removing the repression of HCN2/HCN4 expression induced by endogenous miR-1/miR-133." +target gene hsa-mir-221 Prostate Neoplasms 17569667 miR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kip1. +target gene hsa-mir-222 Prostate Neoplasms 17569667 miR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kip1. +target gene hsa-mir-122 "Carcinoma, Hepatocellular" 17616664 "Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma." +target gene hsa-mir-125b Alzheimer Disease 17629564 "The main finding was that these ROS-generating neurotoxic metal sulfates also up-regulate a specific set of miRNAs that includes miR-9, miR-125b and miR-128. Notably, these same miRNAs are up-regulated in AD brain." +target gene hsa-let-7i Immune System Disease [unspecific] 17660297 These results indicate that let-7i regulates TLR4 expression in cholangiocytes and contributes to epithelial immune responses against C. parvum infection. +target gene hsa-mir-155 Hypertension 17668390 "Since hsa-miR-155 is on chromosome 21, we hypothesize that the observed lower blood pressure in trisomy 21 is partially caused by the overexpression of hsa-miR-155 leading to allele-specific underexpression of AGTR1." +target gene hsa-mir-103a-1 Myotonic Muscular Dystrophy 17697356 "These results support a role for miRNAs in DM1 pathogenesis, and, in particular, highlight mir-107 and mir-103 as attractive candidates for binding to DMPK." +target gene hsa-mir-103a-2 Myotonic Muscular Dystrophy 17697356 "These results support a role for miRNAs in DM1 pathogenesis, and, in particular, highlight mir-107 and mir-103 as attractive candidates for binding to DMPK." +target gene hsa-mir-107 Myotonic Muscular Dystrophy 17697356 "These results support a role for miRNAs in DM1 pathogenesis, and, in particular, highlight mir-107 and mir-103 as attractive candidates for binding to DMPK." +target gene hsa-mir-145 Colon Neoplasms 17827156 Micro RNA 145 targets the insulin receptor substrate-1 and inhibits the growth of colon cancer cells. +target gene hsa-mir-17 Neuroblastoma 17894887 miRNAs from the miR-17-92 cluster modulate tumor formation and function as oncogenes by influencing the translation of E2F1 mRNA. +target gene hsa-mir-18 Neuroblastoma 17894887 miRNAs from the miR-17-92 cluster modulate tumor formation and function as oncogenes by influencing the translation of E2F1 mRNA. +target gene hsa-mir-19a Neuroblastoma 17894887 miRNAs from the miR-17-92 cluster modulate tumor formation and function as oncogenes by influencing the translation of E2F1 mRNA. +target gene hsa-mir-19b-1 Neuroblastoma 17894887 miRNAs from the miR-17-92 cluster modulate tumor formation and function as oncogenes by influencing the translation of E2F1 mRNA. +target gene hsa-mir-20a Neuroblastoma 17894887 miRNAs from the miR-17-92 cluster modulate tumor formation and function as oncogenes by influencing the translation of E2F1 mRNA. +target gene hsa-mir-34a Neuroblastoma 17894887 miR-34a acts as a suppressor of neuroblastoma tumorigenesis by targeting the mRNA encoding E2F3 and reducing E2F3 protein levels. +target gene hsa-mir-92-1 Neuroblastoma 17894887 miRNAs from the miR-17-92 cluster modulate tumor formation and function as oncogenes by influencing the translation of E2F1 mRNA. +target gene hsa-mir-125b Human Immunodeficiency Virus Infection 17906637 "We have found that the 3' ends of HIV-1 messenger RNAs are targeted by a cluster of cellular miRNAs including miR-28, miR-125b, miR-150, miR-223 and miR-382, which are enriched in resting CD4+ T cells as compared to activated CD4+ T cells." +target gene hsa-mir-150 Human Immunodeficiency Virus Infection 17906637 "We have found that the 3' ends of HIV-1 messenger RNAs are targeted by a cluster of cellular miRNAs including miR-28, miR-125b, miR-150, miR-223 and miR-382, which are enriched in resting CD4+ T cells as compared to activated CD4+ T cells." +target gene hsa-mir-223 Human Immunodeficiency Virus Infection 17906637 "We have found that the 3' ends of HIV-1 messenger RNAs are targeted by a cluster of cellular miRNAs including miR-28, miR-125b, miR-150, miR-223 and miR-382, which are enriched in resting CD4+ T cells as compared to activated CD4+ T cells." +target gene hsa-mir-28 Human Immunodeficiency Virus Infection 17906637 "We have found that the 3' ends of HIV-1 messenger RNAs are targeted by a cluster of cellular miRNAs including miR-28, miR-125b, miR-150, miR-223 and miR-382, which are enriched in resting CD4+ T cells as compared to activated CD4+ T cells." +target gene hsa-mir-382 Human Immunodeficiency Virus Infection 17906637 "We have found that the 3' ends of HIV-1 messenger RNAs are targeted by a cluster of cellular miRNAs including miR-28, miR-125b, miR-150, miR-223 and miR-382, which are enriched in resting CD4+ T cells as compared to activated CD4+ T cells." +target gene hsa-mir-155 Pancreatic Neoplasms 17911264 "Tumor protein 53-induced nuclear protein 1 expression is repressed by miR-155, and its restoration inhibits pancreatic tumor development." +target gene hsa-mir-130a Neoplasms [unspecific] 17957028 "From these data, we conclude that miR-130a is a regulator of the angiogenic phenotype of vascular ECs largely through its ability to modulate the expression of GAX and HOXA5." +target gene hsa-mir-133a-1 Arrhythmia 17965831 miR-133 was shown to inhibit the expression of ERG (ether-a-go-go-related gene) and cause depression of the potassium channel I(Kr). This inhibition contributed to long QT syndrome and arrhythmia in a diabetic rat model. +target gene hsa-mir-133a-1 Long QT Syndrome 17965831 miR-133 was shown to inhibit the expression of ERG (ether-a-go-go-related gene) and cause depression of the potassium channel I(Kr). This inhibition contributed to long QT syndrome and arrhythmia in a diabetic rat model. +target gene hsa-mir-133a-2 Arrhythmia 17965831 miR-133 was shown to inhibit the expression of ERG (ether-a-go-go-related gene) and cause depression of the potassium channel I(Kr). This inhibition contributed to long QT syndrome and arrhythmia in a diabetic rat model. +target gene hsa-mir-133a-2 Long QT Syndrome 17965831 miR-133 was shown to inhibit the expression of ERG (ether-a-go-go-related gene) and cause depression of the potassium channel I(Kr). This inhibition contributed to long QT syndrome and arrhythmia in a diabetic rat model. +target gene hsa-mir-181b Neoplasms [unspecific] 17965831 "Many miRNAs are located at chromosomal break points or fragile sites associated with cancer. Indeed miR-29a and miR-29b are associated with the fragile site FRA7H. In addition, miR-29b along with miR-181b may target the oncogene TCL1 in CLL patients [163]" +target gene hsa-mir-21 Brain Neoplasms 17965831 "The overexpression of miR-21 was recognized in malignant brain tumours, and knockdown of this miRNA in cultured glioblastoma cells resulted in caspase activation and apoptosis. The tumour suppressor tropomyosin 1 (TPM1) was demonstrated to be a target for miR-21, explaining why inhibition of miR-21 results in reduced tumour growth." +target gene hsa-mir-29a Neoplasms [unspecific] 17965831 "Many miRNAs are located at chromosomal break points or fragile sites associated with cancer. Indeed miR-29a and miR-29b are associated with the fragile site FRA7H. In addition, miR-29b along with miR-181b may target the oncogene TCL1 in CLL patients [163], while miR-29b reduced Mcl-1 protein and rendered cholangiocarcinoma cells more susceptible to apoptosis." +target gene hsa-mir-29b-1 Neoplasms [unspecific] 17965831 "Many miRNAs are located at chromosomal break points or fragile sites associated with cancer. Indeed miR-29a and miR-29b are associated with the fragile site FRA7H. In addition, miR-29b along with miR-181b may target the oncogene TCL1 in CLL patients [163], while miR-29b reduced Mcl-1 protein and rendered cholangiocarcinoma cells more susceptible to apoptosis." +target gene hsa-mir-29b-2 Neoplasms [unspecific] 17965831 "Many miRNAs are located at chromosomal break points or fragile sites associated with cancer. Indeed miR-29a and miR-29b are associated with the fragile site FRA7H. In addition, miR-29b along with miR-181b may target the oncogene TCL1 in CLL patients [163]" +target gene hsa-mir-34a Neuroblastoma 17965831 "miR-34a induces apoptosis in neuroblastoma cells, possibly by targeting the transcription factor E2F3. This p53-induced up-regulation of miR-34a results in an enhanced reduction in cell proliferation, strongly suggesting that miR-34a reinforces the tumour suppressor function of p53." +target gene hsa-mir-134 Fragile X Syndrome 17982590 spine morphology in patients with Fragile-X mental retardation syndrome (FXS) is not dissimilar from the spine structure observed on miR-134 overexpression or in neurons deficient for the miR-134 target Limk1 +target gene hsa-let-7a-1 Neoplasms [unspecific] 17989227 let-7 family members have been suggested to serve as tumor suppressors by directly inhibiting the Hmg2A and RAS protooncogenes +target gene hsa-let-7a-2 Neoplasms [unspecific] 17989227 let-7 family members have been suggested to serve as tumor suppressors by directly inhibiting the Hmg2A and RAS protooncogenes +target gene hsa-let-7a-3 Neoplasms [unspecific] 17989227 let-7 family members have been suggested to serve as tumor suppressors by directly inhibiting the Hmg2A and RAS protooncogenes +target gene hsa-let-7b Neoplasms [unspecific] 17989227 let-7 family members have been suggested to serve as tumor suppressors by directly inhibiting the Hmg2A and RAS protooncogenes +target gene hsa-let-7c Neoplasms [unspecific] 17989227 let-7 family members have been suggested to serve as tumor suppressors by directly inhibiting the Hmg2A and RAS protooncogenes +target gene hsa-let-7d Neoplasms [unspecific] 17989227 let-7 family members have been suggested to serve as tumor suppressors by directly inhibiting the Hmg2A and RAS protooncogenes +target gene hsa-let-7e Neoplasms [unspecific] 17989227 let-7 family members have been suggested to serve as tumor suppressors by directly inhibiting the Hmg2A and RAS protooncogenes +target gene hsa-let-7f-1 Neoplasms [unspecific] 17989227 let-7 family members have been suggested to serve as tumor suppressors by directly inhibiting the Hmg2A and RAS protooncogenes +target gene hsa-let-7f-2 Neoplasms [unspecific] 17989227 let-7 family members have been suggested to serve as tumor suppressors by directly inhibiting the Hmg2A and RAS protooncogenes +target gene hsa-let-7g Neoplasms [unspecific] 17989227 let-7 family members have been suggested to serve as tumor suppressors by directly inhibiting the Hmg2A and RAS protooncogenes +target gene hsa-let-7i Neoplasms [unspecific] 17989227 let-7 family members have been suggested to serve as tumor suppressors by directly inhibiting the Hmg2A and RAS protooncogenes +target gene hsa-mir-372 Neoplasms [unspecific] 17989227 "the related miR-372/373 miRNAs promote tumorigenesis in combination with oncogenic RAS, at least in part by directly inhibiting the tumor suppressor LATS2." +target gene hsa-mir-373 Neoplasms [unspecific] 17989227 "the related miR-372/373 miRNAs promote tumorigenesis in combination with oncogenic RAS, at least in part by directly inhibiting the tumor suppressor LATS2." +target gene hsa-mir-218 Cervical Neoplasms 17998940 We also show that LAMB3 expression is increased in the presence of the HPV-16 E6 oncogene and this effect is mediated through miR-218. These findings may contribute to a better understanding of the molecular mechanisms involved in cervical carcinogenesis. +target gene hsa-let-7c Neoplasms [unspecific] 18006822 "In addition to known genes, siRNAs targeting CDK4, PTGS1, ALG2, CLCN3, IRAK4, and MAP3K8 altered TRAIL-induced caspase-3 activation responses. Introduction of the miRNAs let-7c, mir-10a, mir-144, mir-150, mir-155, and mir-193 also affected the activation of the caspase cascade." +target gene hsa-mir-10a Neoplasms [unspecific] 18006822 "In addition to known genes, siRNAs targeting CDK4, PTGS1, ALG2, CLCN3, IRAK4, and MAP3K8 altered TRAIL-induced caspase-3 activation responses. Introduction of the miRNAs let-7c, mir-10a, mir-144, mir-150, mir-155, and mir-193 also affected the activation of the caspase cascade." +target gene hsa-mir-144 Neoplasms [unspecific] 18006822 "In addition to known genes, siRNAs targeting CDK4, PTGS1, ALG2, CLCN3, IRAK4, and MAP3K8 altered TRAIL-induced caspase-3 activation responses. Introduction of the miRNAs let-7c, mir-10a, mir-144, mir-150, mir-155, and mir-193 also affected the activation of the caspase cascade." +target gene hsa-mir-150 Neoplasms [unspecific] 18006822 "In addition to known genes, siRNAs targeting CDK4, PTGS1, ALG2, CLCN3, IRAK4, and MAP3K8 altered TRAIL-induced caspase-3 activation responses. Introduction of the miRNAs let-7c, mir-10a, mir-144, mir-150, mir-155, and mir-193 also affected the activation of the caspase cascade." +target gene hsa-mir-155 Neoplasms [unspecific] 18006822 "In addition to known genes, siRNAs targeting CDK4, PTGS1, ALG2, CLCN3, IRAK4, and MAP3K8 altered TRAIL-induced caspase-3 activation responses. Introduction of the miRNAs let-7c, mir-10a, mir-144, mir-150, mir-155, and mir-193 also affected the activation of the caspase cascade." +target gene hsa-mir-193 Neoplasms [unspecific] 18006822 "In addition to known genes, siRNAs targeting CDK4, PTGS1, ALG2, CLCN3, IRAK4, and MAP3K8 altered TRAIL-induced caspase-3 activation responses. Introduction of the miRNAs let-7c, mir-10a, mir-144, mir-150, mir-155, and mir-193 also affected the activation of the caspase cascade." +target gene hsa-mir-27a Breast Neoplasms 18006846 The oncogenic microRNA-27a targets genes that regulate specificity protein transcription factors and the G2-M checkpoint in MDA-MB-231 breast cancer cells. +target gene hsa-let-7b Retinoblastoma 18026111 We experimentally verified our predictions by investigating the result of let-7b downregulation in retinoblastoma using quantitative reverse transcriptase (RT)-PCR and microarray profiling: some of our verified let-7b targets include CDC25A and BCL7A. +target gene hsa-mir-221 Vascular Disease [unspecific] 18068232 "miR-221 and miR-222 block endothelial cell migration, proliferation and angiogenesis in vitro by targeting the stem cell factor receptor c-Kit and indirectly regulating expression of endothelial nitric oxide synthase." +target gene hsa-mir-222 Vascular Disease [unspecific] 18068232 "miR-221 and miR-222 block endothelial cell migration, proliferation and angiogenesis in vitro by targeting the stem cell factor receptor c-Kit and indirectly regulating expression of endothelial nitric oxide synthase." +target gene hsa-mir-378 Neoplasms [unspecific] 18077375 "Our results suggest that miR-378 transfection enhanced cell survival, tumor growth, and angiogenesis through repression of the expression of two tumor suppressors, Sufu and Fus-1." +target gene hsa-mir-101 Neoplasms [unspecific] 18096665 "The most up-regulated miR-196b and its precursors are highly expressed in the skin and showed similar tissue-specific expression patterns after treatment, indicating a common pattern of regulation by E(2). MiR-196b was shown to fine-tune the expression of its target gene Hoxb8a after treatment in whole-body homogenates." +target gene hsa-mir-146a Prostate Neoplasms 18174313 "Given that ROCK1 is one of the key kinases for the activation of hyaluronan (HA)-mediated HRPC transformation in vivo and in PC3 cells, mir-146a may function as a tumor-suppressor gene in modulating HA/ROCK1-mediated tumorigenecity in androgen-dependent prostate cancer." +target gene hsa-mir-433 Parkinson Disease 18252210 Variation in the miRNA-433 binding site of FGF20 confers risk for Parkinson disease by overexpression of alpha-synuclein. +target gene hsa-mir-224 "Carcinoma, Hepatocellular" 18319255 Profiling microRNA expression in hepatocellular carcinoma reveals microRNA-224 up-regulation and apoptosis inhibitor-5 as a microRNA-224-specific target. +target gene hsa-mir-106b Gastrointestinal Neoplasms 18328430 "Together, these results suggest that the miR-106b-25 cluster is involved in E2F1 posttranscriptional regulation and may play a key role in the development of TGFbeta resistance in gastric cancer." +target gene hsa-mir-21 Neoplasms [unspecific] 18372920 The demonstration that miR-21 promotes cell transformation supports the concept that mir-21 functions as an oncogene by a mechanism that involves translational repression of the tumor suppressor Pdcd4. +target gene hsa-mir-141 Breast Neoplasms 18376396 The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. +target gene hsa-mir-200a Breast Neoplasms 18376396 The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. +target gene hsa-mir-200b Breast Neoplasms 18376396 The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. +target gene hsa-mir-200c Breast Neoplasms 18376396 The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. +target gene hsa-mir-205 Breast Neoplasms 18376396 The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. +target gene hsa-mir-429 Breast Neoplasms 18376396 The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. +target gene hsa-let-7b Melanoma 18379589 MicroRNA let-7b targets important cell cycle molecules in malignant melanoma cells and interferes with anchorage-independent growth. +target gene hsa-let-7c Leiomyoma 18403645 Our findings suggest that the Let-7-mediated repression of HMGA2 mechanism can be an important molecular event in leiomyoma growth. +target gene hsa-mir-199a Ovarian Neoplasms 18408758 "Furthermore, we describe for the first time the identification of the microRNA hsa-miR-199a as a regulator of IKKbeta expression. Our study describes the property of ovarian cancer cells to enhance the inflammatory microenvironment as a result of the expression of an active IKKbeta pathway." +target gene hsa-let-7a Gastric Neoplasms 18413822 Clinical significance of high mobility group A2 in human gastric cancer and its relationship to let-7 microRNA family. +target gene hsa-mir-15b Gastric Neoplasms 18449891 miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. +target gene hsa-mir-16-1 Gastric Neoplasms 18449891 miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. +target gene hsa-mir-16-2 Gastric Neoplasms 18449891 miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. +target gene hsa-mir-1-1 Hypertrophy 18458081 Down-regulation of miR-1/miR-133 contributes to re-expression of pacemaker channel genes HCN2 and HCN4 in hypertrophic heart. +target gene hsa-mir-1-2 Hypertrophy 18458081 Down-regulation of miR-1/miR-133 contributes to re-expression of pacemaker channel genes HCN2 and HCN4 in hypertrophic heart. +target gene hsa-mir-133a-1 Hypertrophy 18458081 Down-regulation of miR-1/miR-133 contributes to re-expression of pacemaker channel genes HCN2 and HCN4 in hypertrophic heart. +target gene hsa-mir-133a-2 Hypertrophy 18458081 Down-regulation of miR-1/miR-133 contributes to re-expression of pacemaker channel genes HCN2 and HCN4 in hypertrophic heart. +target gene hsa-mir-133b Hypertrophy 18458081 Down-regulation of miR-1/miR-133 contributes to re-expression of pacemaker channel genes HCN2 and HCN4 in hypertrophic heart. +target gene hsa-mir-16-1 "Lymphoma, Mantle-Cell" 18483394 Truncation in CCND1 mRNA alters miR-16-1 regulation in mantle cell lymphoma. +target gene hsa-mir-203 "Squamous Cell Carcinoma, Head and Neck" 18483491 "we have shown that miR-203 can regulate DeltaNp63 levels upon genotoxic damage in head and neck squamous cell carcinoma cells, thus controlling cell survival." +target gene hsa-mir-17 Neuroblastoma 18493594 Antagomir-17-5p abolishes the growth of therapy-resistant neuroblastoma through p21 and BIM +target gene hsa-mir-34a Neuroblastoma 18504438 The MYCN oncogene is a direct target of miR-34a. +target gene hsa-mir-34a Neuroblastoma 18505919 A functional screen identifies miR-34a as a candidate neuroblastoma tumor suppressor gene. +target gene hsa-mir-106a Colon Neoplasms 18521848 Deregulated expression of miR-106a predicts survival in human colon cancer patients. +target gene hsa-mir-17 Colon Neoplasms 18521848 Deregulated expression of miR-106a predicts survival in human colon cancer patients. +target gene hsa-mir-221 Vascular Disease [unspecific] 18550634 "In contrast, miR-221 and miR-222 inhibit endothelial cell migration, proliferation, and angiogenesis in vitro by targeting the stem cell factor receptor c-kit and indirectly regulating endothelial nitric oxide synthase expression." +target gene hsa-mir-222 Vascular Disease [unspecific] 18550634 "In contrast, miR-221 and miR-222 inhibit endothelial cell migration, proliferation, and angiogenesis in vitro by targeting the stem cell factor receptor c-kit and indirectly regulating endothelial nitric oxide synthase expression." +target gene hsa-mir-21 Glioma 18591254 MicroRNA 21 promotes glioma invasion by targeting matrix metalloproteinase regulators. +target gene hsa-mir-206 Breast Neoplasms 18593897 miR-206 Expression is down-regulated in estrogen receptor alpha-positive human breast cancer. +target gene hsa-mir-20a Leukemia 18596985 "Here we report, for the first time, that LRF is post-transcriptionally regulated by miR-20a. Using a gene reporter assay, direct interaction of miR-20a with the LRF 3'UTR is demonstrated." +target gene hsa-mir-124-1 Medulloblastoma 18607543 miR-124: regulates cyclin dependent kinase 6 +target gene hsa-mir-124-2 Medulloblastoma 18607543 miR-124: regulates cyclin dependent kinase 6 +target gene hsa-mir-124-3 Medulloblastoma 18607543 miR-124: regulates cyclin dependent kinase 6 +target gene hsa-mir-27a Neoplasms [unspecific] 18619946 miR-27a: miR-27a and miR-451 regulate expression of MDR1/P-glycoprotein +target gene hsa-mir-451a Neoplasms [unspecific] 18619946 miR-451: miR-27a and miR-451 regulate expression of MDR1/P-glycoprotein +target gene hsa-mir-135a-1 Colorectal Carcinoma 18632633 miR-135a: miR-135 family: Regulation of the adenomatous polyposis coli gene +target gene hsa-mir-135a-2 Colorectal Carcinoma 18632633 miR-135a: miR-135 family: Regulation of the adenomatous polyposis coli gene +target gene hsa-mir-135b Colorectal Carcinoma 18632633 miR-135b: miR-135 family: Regulation of the adenomatous polyposis coli gene +target gene hsa-mir-196b Neoplasms [unspecific] 18663355 miR-196: MicroRNA-196a targets annexin A1: a microRNA-mediated mechanism of annexin A1 downregulation in cancers +target gene hsa-let-7a-1 Melanoma 18679415 let-7a: Integrin beta 3 expression is regulated by let-7a miRNA in malignant melanoma +target gene hsa-let-7a-2 Melanoma 18679415 let-7a: Integrin beta 3 expression is regulated by let-7a miRNA in malignant melanoma +target gene hsa-let-7a-3 Melanoma 18679415 let-7a: Integrin beta 3 expression is regulated by let-7a miRNA in malignant melanoma +target gene hsa-let-7b Melanoma 18679415 let-7b: Integrin beta 3 expression is regulated by let-7a miRNA in malignant melanoma +target gene hsa-let-7c Melanoma 18679415 let-7c: Integrin beta 3 expression is regulated by let-7a miRNA in malignant melanoma +target gene hsa-let-7d Melanoma 18679415 let-7d: Integrin beta 3 expression is regulated by let-7a miRNA in malignant melanoma +target gene hsa-let-7e Melanoma 18679415 let-7e: Integrin beta 3 expression is regulated by let-7a miRNA in malignant melanoma +target gene hsa-let-7f-1 Melanoma 18679415 let-7f: Integrin beta 3 expression is regulated by let-7a miRNA in malignant melanoma +target gene hsa-let-7f-2 Melanoma 18679415 let-7f: Integrin beta 3 expression is regulated by let-7a miRNA in malignant melanoma +target gene hsa-let-7g Melanoma 18679415 let-7g: Integrin beta 3 expression is regulated by let-7a miRNA in malignant melanoma +target gene hsa-let-7i Melanoma 18679415 let-7i: Integrin beta 3 expression is regulated by let-7a miRNA in malignant melanoma +target gene hsa-mir-122 "Carcinoma, Hepatocellular" 18692484 "miR-122 targets an anti-apoptotic gene, Bcl-w, in human hepatocellular carcinoma cell lines." +target gene hsa-mir-17 Breast Neoplasms 18695042 A cyclin D1/microRNA 17/20 regulatory feedback loop in control of breast cancer cell proliferation. +target gene hsa-mir-20a Breast Neoplasms 18695042 A cyclin D1/microRNA 17/20 regulatory feedback loop in control of breast cancer cell proliferation. +target gene hsa-mir-181a Immune System Disease [unspecific] 18701320 "In addition to facilitating cell fate decisions of immune cells (e.g. miR-181a and miR-223), miRs also regulate central elements of the adaptive immune response such as antigen presentation (e.g. miR-155) and T cell receptor signaling (mir-181a)." +target gene hsa-mir-221 Breast Neoplasms 18708351 miR-221: MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1 +target gene hsa-mir-222 Breast Neoplasms 18708351 miR-222: MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1 +target gene hsa-mir-34a Neoplasms [unspecific] 18755897 "Finally, miR-34a itself is a transcriptional target of p53, suggesting a positive feedback loop between p53 and miR-34a. Thus, miR-34a functions as a tumor suppressor, in part, through a SIRT1-p53 pathway." +target gene hsa-mir-125b Medulloblastoma 18756266 "Specifically, we identify miR-125b and miR-326 as suppressors of the pathway activator Smoothened together with miR-324-5p, which also targets the downstream transcription factor Gli1." +target gene hsa-mir-324 Medulloblastoma 18756266 "Specifically, we identify miR-125b and miR-326 as suppressors of the pathway activator Smoothened together with miR-324-5p, which also targets the downstream transcription factor Gli1." +target gene hsa-mir-326 Medulloblastoma 18756266 "Specifically, we identify miR-125b and miR-326 as suppressors of the pathway activator Smoothened together with miR-324-5p, which also targets the downstream transcription factor Gli1." +target gene hsa-let-7a-1 Neoplasms [unspecific] 18758960 Let-7a: Let-7a microRNA suppresses therapeutics-induced cancer cell death by targeting caspase-3 +target gene hsa-let-7a-2 Neoplasms [unspecific] 18758960 Let-7a: Let-7a microRNA suppresses therapeutics-induced cancer cell death by targeting caspase-3 +target gene hsa-let-7a-3 Neoplasms [unspecific] 18758960 Let-7a: Let-7a microRNA suppresses therapeutics-induced cancer cell death by targeting caspase-3 +target gene hsa-mir-223 Inflammation 18791161 "miR-223, which is markedly enhanced by estrogen,regulates LPS-induced IFNgamma, but not iNOS or nitric oxide in splenic lymphocytes. Inhibition of miR-223 activity decreased LPS-induced IFNgamma in splenic lymphocytes from estrogen-treated mice." +target gene hsa-mir-221 "Carcinoma, Thyroid, Papillary" 18794255 Microarray analysis showed thousands of genes were directly and indirectly regulated by miR-221 and shifted the gene expression pattern of normal thyroid cells toward PTC. +target gene hsa-mir-155 Breast Neoplasms 18794355 These data suggest that miR-155 may play an important role in TGF-beta-induced EMT and cell migration and invasion by targeting RhoA and indicate that it is a potential therapeutic target for breast cancer intervention. +target gene hsa-mir-146a Alzheimer Disease 18801740 An NF-kB-sensitive microRNA-146a-mediated inflammatory circuit in Alzheimer's disease and in stressed human brain cells. +target gene hsa-mir-128 Glioma 18810376 MicroRNA-128 inhibits glioma cells proliferation by targeting transcription factor E2F3a. +target gene hsa-mir-215 Glioma 18810376 MicroRNA-128 inhibits glioma cells proliferation by targeting transcription factor E2F3a. +target gene hsa-mir-15a Leukemia 18818396 "Using a luciferase reporter assay, we found that miR-15a directly binds the 3'-UTR of c-myb mRNA. By transfecting K562 myeloid leukemia cells with a miR-15a mimic, functionality of binding was shown." +target gene hsa-mir-192 Inflammation 18835392 "Macrophage inflammatory peptide (MIP)-2 alpha, a chemokine expressed by epithelial cells, was identified as a target of miR-192." +target gene hsa-mir-302b "Carcinoma, Embryonal" 18930031 miR-302b: miR-302b maintains stemness of human embryonal carcinoma cells by post-transcriptional regulation of Cyclin D2 expression +target gene hsa-mir-15a Prostate Neoplasms 18931683 The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. +target gene hsa-mir-16-1 Prostate Neoplasms 18931683 The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. +target gene hsa-mir-16-2 Prostate Neoplasms 18931683 miR-16: The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities +target gene hsa-mir-15a Polycystic Kidney Disease 18949056 miR-15a: MicroRNA15a modulates expression of the cell-cycle regulator Cdc25A and affects hepatic cystogenesis +target gene hsa-mir-296 Brain Neoplasms 18977327 "Growth factor-induced miR-296 contributes significantly to angiogenesis by directly targeting the hepatocyte growth factor-regulated tyrosine kinase substrate (HGS) mRNA, leading to decreased levels of HGS and thereby reducing HGS-mediated degradation of the growth factor receptors VEGFR2 and PDGFRbeta." +target gene hsa-mir-128 Glioblastoma 19010882 This showed that miR-128 specifically blocked glioma self-renewal consistent with Bmi-1 down-regulation. +target gene hsa-mir-21 Glioblastoma 19013014 miR-21: MicroRNA-21 down-regulates the expression of tumor suppressor PDCD4 in human glioblastoma cell T98G +target gene hsa-mir-223 Leukemia 19017354 "Thus,our results suggest that miR-223 reversibly regulates erythroid and megakaryocytic differentiation of K562 cells via down-modulation of LMO2." +target gene hsa-mir-34a Melanoma 19029026 miR-34a: MicroRNA-34a inhibits uveal melanoma cell proliferation and migration through downregulation of c-Met +target gene hsa-mir-143 "Carcinoma, Colon" 19062714 "The increased accumulation of miR-143 inhibits the proliferation of transfected cells, and results in down-regulation of K-ras protein in colorectal carcinoma." +target gene hsa-mir-29a Neoplasms [unspecific] 19079265 "miR-29a: miR-29 directly suppress p85 alpha and CDC42, both of which negatively regulate p53" +target gene hsa-mir-221 Vascular Disease [unspecific] 19088079 "Our study demonstrates that PDGF signaling, by modulating the expression of miR-221, regulates two critical determinants of the vSMC phenotype; they are SMC gene expression and cell proliferation." +target gene hsa-mir-106b "Leukemia, Lymphocytic, Chronic, B-Cell" 19096009 "miR-106b: Specific activation of microRNA106b enables the p73 apoptotic response in chronic lymphocytic leukemia by targeting the ubiquitin ligase, Itch for degradation" +target gene hsa-mir-15a Head And Neck Neoplasms 19117988 "miR-15a: feed-forward loop: PKCalpha down-regulates miR-15a, which directly inhibits protein synthesis of cyclin E" +target gene hsa-mir-221 Melanoma 19126397 miR-221: mir-221 can directly interact with c-kit 3'UTR and inhibit cKit protein translation +target gene hsa-mir-1-1 Arrhythmia 19131648 miR-1 overexpression enhances Ca(2+) release and promotes cardiac arrhythmogenesis by targeting PP2A regulatory subunit B56alpha and causing CaMKII-dependent hyperphosphorylation of RyR2 +target gene hsa-mir-1-2 Arrhythmia 19131648 miR-1 overexpression enhances Ca(2+) release and promotes cardiac arrhythmogenesis by targeting PP2A regulatory subunit B56alpha and causing CaMKII-dependent hyperphosphorylation of RyR2 +target gene hsa-mir-101-1 "Carcinoma, Hepatocellular" 19133651 miR-101: MicroRNA-101 regulates expression of the v-fos FBJ murine osteosarcoma viral oncogene homolog (FOS) oncogene +target gene hsa-mir-101-2 "Carcinoma, Hepatocellular" 19133651 miR-101: MicroRNA-101 regulates expression of the v-fos FBJ murine osteosarcoma viral oncogene homolog (FOS) oncogene +target gene hsa-mir-15b Glioma 19135980 MicroRNA-15b regulates cell cycle progression by targeting cyclins in glioma cells. +target gene hsa-mir-143 Colorectal Carcinoma 19137007 miR-143 directly recognize the 3'-untranslated region of KRAS transcripts +target gene hsa-mir-155 Immune System Disease [unspecific] 19144316 "Our studies suggest that Foxp3-dependent regulation of miR155 maintains competitive fitness of Treg cell subsets by targeting SOCS1, and they provide experimental support for a proposed role for miRNAs in ensuring the robustness of cellular phenotypes." +target gene hsa-mir-15a "Carcinoma, Nasopharyngeal" 19144710 "We found that the tumor suppressor BRCA-1 is a target of miR-15a as well as miR-16, suggesting a miRNA role in NPC pathogenesis." +target gene hsa-mir-106b Gastric Neoplasms 19153141 "miR-106b: inhibite p21,p27, and p57" +target gene hsa-mir-221 Gastric Neoplasms 19153141 "miR-221: inhibite p21,p27, and p57" +target gene hsa-mir-222 Gastric Neoplasms 19153141 "miR-222: inhibite p21,p27, and p57" +target gene hsa-mir-25 Gastric Neoplasms 19153141 "miR-25: inhibite p21,p27, and p57" +target gene hsa-mir-93 Gastric Neoplasms 19153141 "miR-93: inhibite p21,p27, and p57" +target gene hsa-mir-141 Neoplasms [unspecific] 19182522 "miR-141: miR-200 family:inhibit the initiating step of metastasis, epithelial-mesenchymal transition (EMT), by maintaining the epithelial phenotype through direct targeting of transcriptional repressors of E-cadherin, ZEB1 and ZEB2" +target gene hsa-mir-200a Neoplasms [unspecific] 19182522 "miR-200a: miR-200 family:inhibit the initiating step of metastasis, epithelial-mesenchymal transition (EMT), by maintaining the epithelial phenotype through direct targeting of transcriptional repressors of E-cadherin, ZEB1 and ZEB2" +target gene hsa-mir-200b Neoplasms [unspecific] 19182522 "miR-200b: miR-200 family:inhibit the initiating step of metastasis, epithelial-mesenchymal transition (EMT), by maintaining the epithelial phenotype through direct targeting of transcriptional repressors of E-cadherin, ZEB1 and ZEB2" +target gene hsa-mir-200c Neoplasms [unspecific] 19182522 "miR-200c: miR-200 family:inhibit the initiating step of metastasis, epithelial-mesenchymal transition (EMT), by maintaining the epithelial phenotype through direct targeting of transcriptional repressors of E-cadherin, ZEB1 and ZEB2" +target gene hsa-mir-429 Neoplasms [unspecific] 19182522 "miR-429: miR-200 family:inhibit the initiating step of metastasis, epithelial-mesenchymal transition (EMT), by maintaining the epithelial phenotype through direct targeting of transcriptional repressors of E-cadherin, ZEB1 and ZEB2" +target gene hsa-mir-1-1 Cardiomegaly 19188439 miR-1: MicroRNA-1 negatively regulates expression of the hypertrophy-associated calmodulin and Mef2a genes +target gene hsa-mir-1-2 Cardiomegaly 19188439 miR-1: MicroRNA-1 negatively regulates expression of the hypertrophy-associated calmodulin and Mef2a genes +target gene hsa-mir-182 Melanoma 19188590 miR-182: Aberrant miR-182 expression promotes melanoma metastasis by repressing FOXO3 and microphthalmia-associated transcription factor +target gene hsa-mir-18a "Carcinoma, Hepatocellular" 19203451 miR-18: target BTG2 +target gene hsa-mir-18b "Carcinoma, Hepatocellular" 19203451 miR-18: target BTG2 +target gene hsa-mir-34 Neoplasms [unspecific] 19221490 "Based on this observation, we propose a positive feedback loop, in which p53 induces expression of miR-34a which suppresses SIRT1, increasing p53 activity." +target gene hsa-mir-30e Neoplasms [unspecific] 19223510 miR-30e: directly targets Ubc9 +target gene hsa-mir-10a Breast Neoplasms 19232136 miR-10a: miR-10a inhibits transcriptional of Hoxd4 +target gene hsa-mir-16-1 Breast Neoplasms 19250063 "Two new miR-16 targets: Caprin-1 and HMGA1, proteins implicated in cell proliferation" +target gene hsa-mir-16-2 Breast Neoplasms 19250063 "Two new miR-16 targets: Caprin-1 and HMGA1, proteins implicated in cell proliferation" +target gene hsa-mir-449a Prostate Neoplasms 19252524 miR-449a targets HDAC-1 and induces growth arrest in prostate cancer. +target gene hsa-mir-34b "Leukemia, Myeloid, Acute" 19258499 miR-34b: miR-34b targets cyclic AMP-responsive element binding protein +target gene hsa-mir-101-1 Urinary Bladder Cancer 19258506 miR-101: putative tumor suppressor microRNA-101 modulates the cancer epigenome by repressing the polycomb group protein EZH2 +target gene hsa-mir-101-2 Urinary Bladder Cancer 19258506 miR-101: putative tumor suppressor microRNA-101 modulates the cancer epigenome by repressing the polycomb group protein EZH2 +target gene hsa-mir-221 Marek Disease 19264608 miR-221: miR-221/222 target p27Kip1 in Marek's disease virus-transformed tumour cell line MSB-1 +target gene hsa-mir-222 Marek Disease 19264608 miR-222: miR-221/222 target p27Kip1 in Marek's disease virus-transformed tumour cell line MSB-1 +target gene hsa-mir-146b Glioma 19265686 microRNA-146b inhibits glioma cell migration and invasion by targeting MMPs. +target gene hsa-mir-328 Breast Neoplasms 19270061 MicroRNA-328 negatively regulates the expression of breast cancer resistance protein (BCRP/ABCG2) in human cancer cells. +target gene hsa-mir-205 Breast Neoplasms 19276373 miR-205: a new oncosuppressor regulates HER3 +target gene hsa-mir-21 Prostate Neoplasms 19302977 miR-21: MicroRNA-21 directly targets MARCKS and promotes apoptosis resistance and invasion in prostate cancer cells +target gene hsa-mir-21 "Cardiomyopathy, Hypertrophic" 19336275 miR-21: miR-21 can protect this by targeting PDCD4 +target gene hsa-mir-21 Heart Failure 19336275 miR-21: miR-21 can protect this by targeting PDCD4 +target gene hsa-mir-21 Myocardial Infarction 19336275 miR-21: miR-21 can protect this by targeting PDCD4 +target gene hsa-mir-21 Myocardial Ischemic-Reperfusion Injury 19336275 miR-21: miR-21 can protect this by targeting PDCD4 +target gene hsa-mir-532 Melanoma 19336521 "miR-532-5p: miR-532-5p is a regulatory factor of RUNX3, which is down-regulated during melanoma progression" +target gene hsa-mir-92a-1 "Leukemia, Lymphocytic, Chronic, B-Cell" 19336759 "miR-92-1: overexpressed, can target the VHL transcript" +target gene hsa-mir-145 Breast Neoplasms 19360360 miR-145 inhibits breast cancer cell growth through RTKN. +target gene hsa-mir-18a "Adenocarcinoma, Colon" 19372139 The miR-18a* microRNA functions as a potential tumor suppressor by targeting on K-Ras +target gene hsa-mir-15a Multiple Myeloma 19401561 MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma. +target gene hsa-mir-16 Multiple Myeloma 19401561 MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma. +target gene hsa-mir-22 Breast Neoplasms 19414598 miR-22 inhibits estrogen signaling by directly targeting the estrogen receptor alpha mRNA. +target gene hsa-mir-106b Barrett Esophagus 19422085 "MiRs-93 and -106b targeted and inhibited p21, whereas miR-25 targeted and inhibited Bim" +target gene hsa-mir-25 Barrett Esophagus 19422085 "MiRs-93 and -106b targeted and inhibited p21, whereas miR-25 targeted and inhibited Bim" +target gene hsa-mir-93 Barrett Esophagus 19422085 "MiRs-93 and -106b targeted and inhibited p21, whereas miR-25 targeted and inhibited Bim" +target gene hsa-mir-221 Glioma 19424584 Co-suppression of miR-221/222 cluster suppresses human glioma cell growth by targeting p27kip1 in vitro and in vivo. +target gene hsa-mir-222 Glioma 19424584 Co-suppression of miR-221/222 cluster suppresses human glioma cell growth by targeting p27kip1 in vitro and in vivo. +target gene hsa-mir-124 Medulloblastoma 19427019 miR-124 is frequently down-regulated in medulloblastoma and is a negative regulator of SLC16A1. +target gene hsa-mir-143 Hepatoblastoma 19472311 Up-regulated microRNA-143 transcribed by nuclear factor kappa B enhances hepatocarcinoma metastasis by repressing fibronectin expression. +target gene hsa-mir-222 "Squamous Cell Carcinoma, Tongue" 19487542 MicroRNA-222 regulates cell invasion by targeting matrix metalloproteinase 1(MMP1) and manganese superoxide dismutase 2 (SOD2) in tongue squamous cellcarcinoma cell lines. +target gene hsa-mir-15a "Leukemia, Lymphocytic, Chronic, B-Cell" 19498445 "miR-15a and miR-16-1 function by targeting multiple oncogenes, including BCL2, MCL1, CCND1, and WNT3A. Down-regulation of these miRNAs has been reported in chronic lymphocytic lymphoma (CLL), pituitary adenomas, and prostate carcinoma." +target gene hsa-mir-16-1 "Leukemia, Lymphocytic, Chronic, B-Cell" 19498445 "miR-15a and miR-16-1 function by targeting multiple oncogenes, including BCL2, MCL1, CCND1, and WNT3A. Down-regulation of these miRNAs has been reported in chronic lymphocytic lymphoma (CLL), pituitary adenomas, and prostate carcinoma." +target gene hsa-mir-373 Esophageal Neoplasms 19501585 we demonstrated that the direct inhibition of LATS2 protein was mediated by miR-373 and manipulated the expression of miR-373 to affect esophageal cancer cells growth. +target gene hsa-mir-105 Inflammation 19509287 We identified miRNA (miR)-105 as a modulator of TLR-2 protein translation in human gingival keratinocytes. +target gene hsa-mir-127 "Lymphoma, Burkitt" 19530237 B cell differentiation in EBV-positive Burkitt Lymphoma is impaired at post-transcriptional level by miRNA altered expression. +target gene hsa-mir-34b "Leukemia, Lymphocytic, Chronic, B-Cell" 19536169 miR-34b/miR-34c: a regulator of TCL1 expression in 11q- chronic lymphocytic leukaemia +target gene hsa-mir-34c "Leukemia, Lymphocytic, Chronic, B-Cell" 19536169 miR-34b/miR-34c: a regulator of TCL1 expression in 11q- chronic lymphocytic leukaemia +target gene hsa-mir-25 Inflammation 19541842 Our study demonstrates that inhibition of miR-25 in cytokine-stimulated ASM cells up-regulates KLF4 expression via a post-transcriptional mechanism. +target gene hsa-mir-145 Prostate Neoplasms 19544444 "regulates PDGF-D, which mediate epithelial-mesenchymal transition, adhesion, and invasion, which was associated with the downregulation of ZEB1, ZEB2,and Snail2 expression;" +target gene hsa-mir-155 Glioblastoma 19559015 overexpressed; contributes to tumor resistance to VM-26 chemotherapy; targets LRRFIP1; +target gene hsa-mir-21 Glioblastoma 19559015 MicroRNA-21 targets LRRFIP1 and contributes to VM-26 resistance in glioblastoma multiforme. +target gene hsa-mir-21 Human Immunodeficiency Virus Infection 19560422 highly abundant; specifically targets the HIV-1 3'UTR region; Inhibiting miR-29a enhanced HIV-1 viral production and infectivity; specific miR-29a-HIV-1 mRNA interactions enhance viral mRNA association with RISC and P body proteins +target gene hsa-mir-200b "Adenocarcinoma, Pancreatic Ductal" 19569050 "regulate EP300, a metastasis suppressor gene; these miRs are related to reduced EP300 mRNA and protein;" +target gene hsa-mir-200c "Adenocarcinoma, Pancreatic Ductal" 19569050 "regulate EP300, a metastasis suppressor gene; these miRs are related to reduced EP300 mRNA and protein;" +target gene hsa-mir-429 "Adenocarcinoma, Pancreatic Ductal" 19569050 "regulate EP300, a metastasis suppressor gene; these miRs are related to reduced EP300 mRNA and protein;" +target gene hsa-mir-125b Breast Neoplasms 19570947 "In conclusion, this study clearly demonstrates that miR-125b post-transcriptionally regulates the CYP24, which serves as a possible mechanism for the high CYP24 expression in cancer tissues." +target gene hsa-mir-182 Breast Neoplasms 19574223 "Coordinate Regulate FOXO1; highly expressed; a novel mechanism of FOXO1 regulation, and targeting of FOXO1 by microRNAs may contribute to transformation or maintenance of an oncogenic state in breast cancer cells" +target gene hsa-mir-27a Breast Neoplasms 19574223 "Coordinate Regulation of FOXO1 by miR-27a, miR-96, and miR-182 in Breast Cancer Cells." +target gene hsa-mir-31 Breast Neoplasms 19574223 "Coordinate Regulate FOXO1; highly expressed; a novel mechanism of FOXO1 regulation, and targeting of FOXO1 by microRNAs may contribute to transformation or maintenance of an oncogenic state in breast cancer cells" +target gene hsa-mir-96 Breast Neoplasms 19574223 "Coordinate Regulate FOXO1; highly expressed; a novel mechanism of FOXO1 regulation, and targeting of FOXO1 by microRNAs may contribute to transformation or maintenance of an oncogenic state in breast cancer cells" +target gene hsa-mir-27a Prostate Neoplasms 19584056 "decreased in prostate cancer; Regulates ERBB-2 Expression; blocked downstream phosphatidylinositol 3-kinase/AKT signaling, reducing activity of an androgen-stimulated prostate-specific antigen promoter and blocking prostate-specific antigen expression" +target gene hsa-mir-331 Prostate Neoplasms 19584056 miR-311-3p regulate ERBB-2 expression and androgen receptor signaling in prostate cancer +target gene hsa-mir-331 Neoplasms [unspecific] 19584269 "miR-331-3p; a c/EBPalpha target,; Inhibits metastatic tumor antigen 1" +target gene hsa-mir-122 Neoplasms [unspecific] 19584290 "down-regulated; modulates expression of immunoinhibitory molecule B7-H3;directly target B7-H3 3' untranslated region, and knock-in and knockdown of miR-29a led to down-regulation and up-regulation of B7-H3 protein expression; potential immune based therapy" +target gene hsa-mir-122 Multiple Sclerosis 19617918 The genes targeted by hsa-miR-96 are involved inimmunological pathways as Interleukin signaling and in other pathways as wnt signaling +target gene hsa-mir-143 Colorectal Carcinoma 19638978 MicroRNA-143 targets DNA methyltransferases 3A in colorectal cancer. +target gene hsa-mir-143 Melanoma 19639204 miR-27a and its target gene ZBTB10 significantly different based on the dose of genistein +target gene hsa-mir-210 Lung Neoplasms 19654003 "low expression, targets pro-survival molecules MCL-1 and BCL2L2" +target gene hsa-mir-200b Breast Neoplasms 19665978 "downregulated, modulate Expression of BMI1, suppressed tumor formation of normal stem cell" +target gene hsa-mir-200c Neoplasms [unspecific] 19665999 inhibits through down-regulating LRP1 +target gene hsa-mir-17 Lymphoma 19666108 "The expression of these genes was also reduced in response to miR-17 and miR-20a transfection, and more specifically they were also shown to contain functional miRNA recognition elements for members of the miR-17 family by reporter gene assay." +target gene hsa-mir-20a Lymphoma 19666108 "The expression of these genes was also reduced in response to miR-17 and miR-20a transfection, and more specifically they were also shown to contain functional miRNA recognition elements for members of the miR-17 family by reporter gene assay." +target gene hsa-mir-205 "Lymphoma, Hodgkin" 19666866 "Regulates JAK2, prognostic impact" +target gene hsa-mir-197 Lung Neoplasms 19671678 regulate tumor suppressor gene FUS1 +target gene hsa-mir-93 Lung Neoplasms 19671678 regulate tumor suppressor gene FUS1 +target gene hsa-mir-98 Lung Neoplasms 19671678 regulate tumor suppressor gene FUS1 +target gene hsa-mir-221 "Carcinoma, Hepatocellular" 19671867 MicroRNA-221 targets Bmf in hepatocellular carcinoma and correlates with tumor multifocality. +target gene hsa-mir-17 Glioblastoma 19676043 "inhibite Bcl-2 and Mcl-1, induce apoptosis" +target gene hsa-mir-18a Glioblastoma 19676043 "inhibite Bcl-2 and Mcl-1, induce apoptosis" +target gene hsa-mir-19a Glioblastoma 19676043 "inhibite Bcl-2 and Mcl-1, induce apoptosis" +target gene hsa-mir-145 Vascular Disease [unspecific] 19690387 MicroRNA-modulated targeting of vascular smooth muscle cells +target gene hsa-mir-17 Vascular Disease [unspecific] 19690387 miR-17-92 and miR-17-5p/miR-20a; MicroRNA-modulated targeting of vascular smooth muscle cells +target gene hsa-mir-18a Vascular Disease [unspecific] 19690387 miR-17-92 and miR-17-5p/miR-20a; MicroRNA-modulated targeting of vascular smooth muscle cells +target gene hsa-mir-19a Vascular Disease [unspecific] 19690387 miR-17-92 and miR-17-5p/miR-20a; MicroRNA-modulated targeting of vascular smooth muscle cells +target gene hsa-mir-20a Vascular Disease [unspecific] 19690387 miR-17-92 and miR-17-5p/miR-20a; MicroRNA-modulated targeting of vascular smooth muscle cells +target gene hsa-mir-193b Breast Neoplasms 19701247 Downregulation of miR-193b contributes to enhance urokinase-type plasminogen activator (uPA) expression and tumor progression and invasion in human breast cancer. +target gene hsa-mir-9 Ovarian Neoplasms 19702828 "Ovarian cancer tissues display significantly low expression of miR-9 and a high level of NF-kappaB1 compared with normal tissues, indicating that regulation of NF-kappaB1 by miR-9 is an important mechanism for miR-9 to inhibit ovarian cancer proliferation." +target gene hsa-let-7d Cocaine Abuse 19703567 downregulated;These miRNAs target many genes involved in cocaine addiction. Precursor and mature miRNA quantification by qRT-PCR showed that miR-124 and let-7d are significantly downregulated +target gene hsa-mir-124-1 Cocaine Abuse 19703567 downregulated;These miRNAs target many genes involved in cocaine addiction. Precursor and mature miRNA quantification by qRT-PCR showed that miR-124 and let-7d are significantly downregulated +target gene hsa-mir-124-2 Cocaine Abuse 19703567 downregulated;These miRNAs target many genes involved in cocaine addiction. Precursor and mature miRNA quantification by qRT-PCR showed that miR-124 and let-7d are significantly downregulated +target gene hsa-mir-124-3 Cocaine Abuse 19703567 downregulated;These miRNAs target many genes involved in cocaine addiction. Precursor and mature miRNA quantification by qRT-PCR showed that miR-124 and let-7d are significantly downregulated +target gene hsa-mir-181a-2 Cocaine Abuse 19703567 "miR-124, let-7d and miR-181a may be involved in a complex feedback loop with cocaine-responsive plasticity genes" +target gene hsa-mir-1-1 Rhabdomyosarcoma 19710019 inhibits rhabdomyosarcoma through downregulating c-Met +target gene hsa-mir-1-2 Rhabdomyosarcoma 19710019 inhibits rhabdomyosarcoma through downregulating c-Met +target gene hsa-mir-206 Rhabdomyosarcoma 19710019 inhibits rhabdomyosarcoma through downregulating c-Met +target gene hsa-mir-15a Arthritis 19714650 "induction of apoptosis in the synovium of mice,suppresses apoptosis through inhibition of Bcl-2" +target gene hsa-mir-15a Psoriatic Arthritis 19714650 suppresses apoptosis through inhibition of Bcl-2 +target gene hsa-mir-133a-1 Cardiovascular Diseases [unspecific] 19720047 MicroRNA-133 regulates the expression of GLUT4 by targeting KLF15 and is involved in metabolic control in cardiac myocytes +target gene hsa-mir-133a-2 Cardiovascular Diseases [unspecific] 19720047 MicroRNA-133 regulates the expression of GLUT4 by targeting KLF15 and is involved in metabolic control in cardiac myocytes +target gene hsa-mir-133b Cardiovascular Diseases [unspecific] 19720047 MicroRNA-133 regulates the expression of GLUT4 by targeting KLF15 and is involved in metabolic control in cardiac myocytes +target gene hsa-mir-206 Neoplasms [unspecific] 19723635 inhibits Notch3 +target gene hsa-mir-122 "Carcinoma, Hepatocellular" 19726678 "The liver specific miR-122 is frequently suppressed in primary hepatocellular carcinomas (HCCs). ADAM-10 (a distintegrin and metalloprotease family-10), SRF (serum response factor), and Igf1R (insulin like growth factor 1 receptor) that promote tumorigenesis were validated as targets of miR- 122 and were repressed by the microRNA." +target gene hsa-mir-125b-1 Breast Neoplasms 19738052 hsa-mir-125b binding site in BMPR1B is Associated with Breast cancer pathogenesis +target gene hsa-mir-125b-2 Breast Neoplasms 19738052 hsa-mir-125b binding site in BMPR1B is Associated with Breast cancer pathogenesis +target gene hsa-mir-100 Nasopharyngeal Neoplasms 19739117 miR-100 can directly target Plk1 +target gene hsa-mir-196a "Adenocarcinoma, Esophageal" 19773200 "Recent findings include the following: firstly, miRNA expression profiles can distinguish between BE and EAC; secondly, miR-196a is upregulated in EAC tissues targeting annexin A1, thereby exerting antiapoptotic effects and contributing to EAC cell survival" +target gene hsa-mir-34a Glioblastoma 19773441 MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes +target gene hsa-mir-10b "Fatty Liver, Non-Alcoholic" 19780876 "Effect of miRNA-10b in regulating cellular steatosis level by targeting PPAR-alpha expression, a novel mechanism for the pathogenesis of NAFLD" +target gene hsa-mir-125b Breast Neoplasms 19825990 "Thus, the short hairpin-looped ODN-Raf, targeting the same region of c-raf-1 as miR-125b, is a multifunctional molecule reducing the expression of oncoproteins and stimulating cell death. Both features may be useful to interfere with tumor growth." +target gene hsa-mir-449a Neoplasms [unspecific] 19833767 "Our study reveals a tumor suppressor function of miR-449a/b through regulating Rb/E2F1 activity, and suggests that escape from this regulation through an aberrant epigenetic event contributes to E2F1 deregulation and unrestricted proliferation in human cancer." +target gene hsa-mir-449b Neoplasms [unspecific] 19833767 "Our study reveals a tumor suppressor function of miR-449a/b through regulating Rb/E2F1 activity, and suggests that escape from this regulation through an aberrant epigenetic event contributes to E2F1 deregulation and unrestricted proliferation in human cancer." +target gene hsa-mir-214 Cervical Neoplasms 19859982 these results suggest that miR-214 negatively regulates HeLa cell proliferation by targeting the noncoding regions of MEK3 and JNK1 mRNAs. +target gene hsa-mir-125a Breast Neoplasms 19875930 MicroRNA-125a represses cell growth by targeting HuR in breast cancer +target gene hsa-mir-513 Infection [unspecific] 19916867 These data suggest a role of miR-513 in regulating B7-H1 expression by cholangiocytes in response to C. parvum infection. +target gene hsa-mir-372 Gastric Neoplasms 19937137 "Taken together, these findings demonstrate an oncogenic role for miR-372 in controlling cell growth, cell cycle, and apoptosis through down-regulation of a tumor suppressor gene, LATS2." +target gene hsa-mir-17 Inflammation 19949084 "In this study, we report that TNF-mediated induction of endothelial adhesion molecules can be regulated by miRNAs that are induced by TNF. Specifically, E-selectin and ICAM-1 are targets of TNF-induced miRNAs miR-31 and miR-17-3p, respectively." +target gene hsa-mir-31 Inflammation 19949084 "In this study, we report that TNF-mediated induction of endothelial adhesion molecules can be regulated by miRNAs that are induced by TNF. Specifically, E-selectin and ICAM-1 are targets of TNF-induced miRNAs miR-31 and miR-17-3p, respectively." +target gene hsa-mir-221 Glioblastoma 19953484 Up-regulation of p27(kip1) by miR-221/222 antisense oligonucleotides enhances the radiosensitivity of U251 glioblastoma] +target gene hsa-mir-222 Glioblastoma 19953484 Up-regulation of p27(kip1) by miR-221/222 antisense oligonucleotides enhances the radiosensitivity of U251 glioblastoma] +target gene hsa-mir-181b "Carcinoma, Hepatocellular" 20023698 TGFbeta-mediated upregulation of hepatic miR-181b promotes hepatocarcinogenesis by targeting TIMP3. +target gene hsa-let-7a-1 Neoplasms [unspecific] 20033209 let-7a:The let-7a microRNA protects from growth of lung carcinoma by suppression of k-Ras and c-Myc in nude mice +target gene hsa-let-7a-2 Neoplasms [unspecific] 20033209 let-7a:The let-7a microRNA protects from growth of lung carcinoma by suppression of k-Ras and c-Myc in nude mice +target gene hsa-let-7a-3 Neoplasms [unspecific] 20033209 let-7a:The let-7a microRNA protects from growth of lung carcinoma by suppression of k-Ras and c-Myc in nude mice +target gene hsa-mir-491 Colorectal Carcinoma 20039318 "miR-491:Functional screening identifies a microRNA, miR-491 that induces apoptosis by targeting Bcl-X(L) in colorectal cancer cells" +target gene hsa-mir-106a Neoplasms [unspecific] 20049626 "miR-106:Our results also indicated that miR-16/34a-c, miR-17-5p, miR-125, miR-106, and miR-150 were the upstream factors, which could regulate the expression of BCL-2, E2F1, E2F3, RB1, and P53" +target gene hsa-mir-125a Neoplasms [unspecific] 20049626 "miR-125:Our results also indicated that miR-16/34a-c, miR-17-5p, miR-125, miR-106, and miR-150 were the upstream factors, which could regulate the expression of BCL-2, E2F1, E2F3, RB1, and P53" +target gene hsa-mir-150 Neoplasms [unspecific] 20049626 "miR-150:Our results also indicated that miR-16/34a-c, miR-17-5p, miR-125, miR-106, and miR-150 were the upstream factors, which could regulate the expression of BCL-2, E2F1, E2F3, RB1, and P53" +target gene hsa-mir-16-1 Neoplasms [unspecific] 20049626 "miR-16:Our results also indicated that miR-16/34a-c, miR-17-5p, miR-125, miR-106, and miR-150 were the upstream factors, which could regulate the expression of BCL-2, E2F1, E2F3, RB1, and P53" +target gene hsa-mir-16-2 Neoplasms [unspecific] 20049626 "miR-16:Our results also indicated that miR-16/34a-c, miR-17-5p, miR-125, miR-106, and miR-150 were the upstream factors, which could regulate the expression of BCL-2, E2F1, E2F3, RB1, and P53" +target gene hsa-mir-17 Neoplasms [unspecific] 20049626 "miR-17:miR-16, miR-17, miR-34a-c, and miR-125 served as tumor suppressor miRNAs, while miR-20, miR-106, and miR-150 acted as oncogenic miRNAs" +target gene hsa-mir-20a Neoplasms [unspecific] 20049626 "miR-20:miR-16, miR-17, miR-34a-c, and miR-125 served as tumor suppressor miRNAs, while miR-20, miR-106, and miR-150 acted as oncogenic miRNAs" +target gene hsa-mir-34a Neoplasms [unspecific] 20049626 "miR-34a:Our results also indicated that miR-16/34a-c, miR-17-5p, miR-125, miR-106, and miR-150 were the upstream factors, which could regulate the expression of BCL-2, E2F1, E2F3, RB1, and P53" +target gene hsa-mir-34b Neoplasms [unspecific] 20049626 "miR-34c:Our results also indicated that miR-16/34a-c, miR-17-5p, miR-125, miR-106, and miR-150 were the upstream factors, which could regulate the expression of BCL-2, E2F1, E2F3, RB1, and P53" +target gene hsa-mir-34c Neoplasms [unspecific] 20049626 "miR-34c:Our results also indicated that miR-16/34a-c, miR-17-5p, miR-125, miR-106, and miR-150 were the upstream factors, which could regulate the expression of BCL-2, E2F1, E2F3, RB1, and P53" +target gene hsa-mir-497 Cerebral Ischemia 20053374 "Taken together, our data suggest that miR-497 promotes ischemic neuronal death by negatively regulating antiapoptotic proteins, bcl-2 and bcl-w." +target gene hsa-mir-27a Obesity 20060380 "Together, these results suggest that miR-27a would suppress adipocyte differentiation through targeting PPARgamma and thereby down-regulation of miR-27a might be associated with adipose tissue dysregulation in obesity." +target gene hsa-mir-24 Gastrointestinal Neoplasms 20062076 These findings establish a novel regulation of miR-24-related AE1 expression in gastric carcinogenesis and erythropoiesis. +target gene hsa-mir-150 Gastric Neoplasms 20067763 MiR-150 promotes gastric cancer proliferation by negatively regulating the pro-apoptotic gene EGR2 +target gene hsa-mir-15a Leukemia 20068100 "Compared with M non-IGHV3-23 CLL, the gene expression profile of M IGHV3-23 CLL was deprived in genes, including the growth/tumor suppressor genes PDCD4, TIA1, and RASSF5, whose downregulation is under control of miR-15a and miR-16-1." +target gene hsa-mir-16-1 Leukemia 20068100 "Compared with M non-IGHV3-23 CLL, the gene expression profile of M IGHV3-23 CLL was deprived in genes, including the growth/tumor suppressor genes PDCD4, TIA1, and RASSF5, whose downregulation is under control of miR-15a and miR-16-1." +target gene hsa-mir-18a Neuroblastoma 20080637 miR-18a and miR-19a target and repress the expression of estrogen receptor-alpha (ESR1) +target gene hsa-mir-19a Neuroblastoma 20080637 miR-18a and miR-19a target and repress the expression of estrogen receptor-alpha (ESR1) +target gene hsa-mir-223 "Diabetes Mellitus, Type 2" 20080987 "These data demonstrate a role for miR-223 in Glut4 regulation and glucose metabolism in the heart, reveal the pleiotropic effects of miRNAs across tissues, and show that miRNAs can upregulate target genes in terminally differentiated cardiomyocytes." +target gene hsa-mir-126 Immune System Disease [unspecific] 20083669 These data show that miR-126 is differentially regulated in CF versus non-CF airway epithelial cells and that TOM1 is a miR-126 target that may have an important role in regulating innate immune responses in the CF lung. +target gene hsa-mir-145 Colon Neoplasms 20098684 MicroRNA-145 targets YES and STAT1 in colon cancer cells. +target gene hsa-mir-7-1 Breast Neoplasms 20099276 miR-7:miR-345 and miR-7 target the human multidrug resistance-associated protein 1 +target gene hsa-mir-7-2 Breast Neoplasms 20099276 miR-7:miR-345 and miR-7 target the human multidrug resistance-associated protein 1 +target gene hsa-mir-7-3 Breast Neoplasms 20099276 miR-7:miR-345 and miR-7 target the human multidrug resistance-associated protein 1 +target gene hsa-mir-9-1 Gastric Neoplasms 20102618 miR-9 targets NF-kappaB1 and regulates gastric cancer cell growth +target gene hsa-mir-9-2 Gastric Neoplasms 20102618 miR-9 targets NF-kappaB1 and regulates gastric cancer cell growth +target gene hsa-mir-9-3 Gastric Neoplasms 20102618 miR-9 targets NF-kappaB1 and regulates gastric cancer cell growth +target gene hsa-mir-181a "Carcinoma, Lung, Non-Small-Cell" 20145152 miR-181a and miR-630 regulate cisplatin-induced cancer cell death. +target gene hsa-mir-630 "Carcinoma, Lung, Non-Small-Cell" 20145152 miR-181a and miR-630 regulate cisplatin-induced cancer cell death. +target gene hsa-mir-148a Cholangiocarcinoma 20146264 "These data indicate that IL-6 can regulate the activity of DNMT-1 and expression of methylation-dependent tumor suppressor genes by modulation of miR-148a and miR-152, and provide a link between this inflammation-associated cytokine and oncogenesis in cholangiocarcinoma." +target gene hsa-mir-152 Cholangiocarcinoma 20146264 "These data indicate that IL-6 can regulate the activity of DNMT-1 and expression of methylation-dependent tumor suppressor genes by modulation of miR-148a and miR-152, and provide a link between this inflammation-associated cytokine and oncogenesis in cholangiocarcinoma." +target gene hsa-mir-17 Multiple Sclerosis 20148420 Functional experiments with a synthetic inhibitor of miR-17 supported the link between miRNA expression and the altered target gene expression. +target gene hsa-mir-15b Neoplasms [unspecific] 20154725 "miR-15b:RECK is a target of at least three groups of miRNAs (miR-15b/16, miR-21 and miR-372/373)" +target gene hsa-mir-16-1 Neoplasms [unspecific] 20154725 "miR-16:RECK is a target of at least three groups of miRNAs (miR-15b/16, miR-21 and miR-372/373)" +target gene hsa-mir-16-2 Neoplasms [unspecific] 20154725 "miR-16:RECK is a target of at least three groups of miRNAs (miR-15b/16, miR-21 and miR-372/373)" +target gene hsa-mir-21 Neoplasms [unspecific] 20154725 "miR-21:RECK is a target of at least three groups of miRNAs (miR-15b/16, miR-21 and miR-372/373)" +target gene hsa-mir-372 Neoplasms [unspecific] 20154725 "miR-372:RECK is a target of at least three groups of miRNAs (miR-15b/16, miR-21 and miR-372/373)" +target gene hsa-mir-373 Neoplasms [unspecific] 20154725 "miR-373:RECK is a target of at least three groups of miRNAs (miR-15b/16, miR-21 and miR-372/373)" +target gene hsa-mir-181b-1 Gastric Neoplasms 20162574 miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines +target gene hsa-mir-181b-1 Lung Neoplasms 20162574 miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines +target gene hsa-mir-181b-2 Gastric Neoplasms 20162574 miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines +target gene hsa-mir-181b-2 Lung Neoplasms 20162574 miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines +target gene hsa-mir-9 Breast Neoplasms 20173740 "Here we show that miR-9, which is upregulated in breast cancer cells, directly targets CDH1, the E-cadherin-encoding messenger RNA, leading to increased cell motility and invasiveness. " +target gene hsa-mir-130b Gastric Neoplasms 20176475 miR-130b:MicroRNA-130b regulates the tumour suppressor RUNX3 in gastric cancer +target gene hsa-mir-133a Cardiomegaly 20177001 Our data show that reciprocal repression between miR-133 and calcineurin regulates cardiac hypertrophy. +target gene hsa-mir-133b Cardiomegaly 20177001 Our data show that reciprocal repression between miR-133 and calcineurin regulates cardiac hypertrophy. +target gene hsa-mir-146a Human Immunodeficiency Virus Infection 20181935 mir-146a:CCL8/MCP-2 is a target for mir-146a in HIV-1-infected human microglial cells +target gene hsa-mir-29a Alzheimer Disease 20202123 miR-29a decreased in Alzheimer disease brains targets neuron navigator-3 +target gene hsa-mir-181a Glioblastoma 20204284 MicroRNA-181a sensitizes human malignant glioma U87MG cells to radiation by targeting Bcl-2. +target gene hsa-mir-29a "Leukemia, Myeloid, Acute" 20212066 Our data indicate that miR-29a regulates early hematopoiesis and suggest that miR-29a initiates AML by converting myeloid progenitors into self-renewing LSC. +target gene hsa-mir-21 Lung Neoplasms 20223231 MicroRNA-21 (miR-21) represses tumor suppressor PTEN and promotes growth and invasion in non-small cell lung cancer (NSCLC) +target gene hsa-mir-375 Liver Neoplasms 20226166 MicroRNA-375 targets Hippo-signaling effector YAP in liver cancer and inhibits tumor properties +target gene hsa-mir-20b Breast Neoplasms 20232316 miR-20b modulates VEGF expression by targeting HIF-1alpha and STAT3 in MCF-7 breast cancer cells +target gene hsa-mir-138-1 Neoplasms [unspecific] 20232393 we demonstrate that miR-138 suppresses TSCC cell migration and invasion by regulating two key genes in the Rho GTPase signaling pathway +target gene hsa-mir-138-2 Neoplasms [unspecific] 20232393 we demonstrate that miR-138 suppresses TSCC cell migration and invasion by regulating two key genes in the Rho GTPase signaling pathway +target gene hsa-mir-218-1 Gastric Neoplasms 20300657 MiR-218 inhibits invasion and metastasis of gastric cancer by targeting the Robo1 receptor. +target gene hsa-mir-218-2 Gastric Neoplasms 20300657 MiR-218 inhibits invasion and metastasis of gastric cancer by targeting the Robo1 receptor. +target gene hsa-mir-193b Melanoma 20304954 MicroRNA-193b Represses Cell Proliferationand Regulates Cyclin D1 in Melanoma +target gene hsa-mir-107 Neoplasms [unspecific] 20308559 Taken together these data suggest that miR-107 can mediate p53 regulation of hypoxic signaling and tumor angiogenesis. +target gene hsa-let-7g "Carcinoma, Hepatocellular" 20309945 Hsa-let-7g inhibits proliferation of hepatocellular carcinoma Cells by down-regulation of c-Myc and Up-regulation of p16(INK4A). +target gene hsa-mir-145 Prostate Neoplasms 20332243 MicroRNA145 targets BNIP3 and suppresses prostate cancer progression. +target gene hsa-let-7g "Carcinoma, Hepatocellular" 20338660 Let-7g targets collagen type I alpha2 and inhibits cell migration in hepatocellular carcinoma. +target gene hsa-mir-21 Breast Neoplasms 20346171 our data suggests that miR-21 could promote invasion in breast cancer cells via its regulation of TIMP3 +target gene hsa-let-7a-1 "Carcinoma, Hepatocellular" 20347499 hsa-let-7a:The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma +target gene hsa-let-7a-2 "Carcinoma, Hepatocellular" 20347499 hsa-let-7a:The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma +target gene hsa-let-7a-3 "Carcinoma, Hepatocellular" 20347499 hsa-let-7a:The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma +target gene hsa-let-7b "Carcinoma, Hepatocellular" 20347499 hsa-let-7b:The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma +target gene hsa-let-7c "Carcinoma, Hepatocellular" 20347499 hsa-let-7c:The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma +target gene hsa-let-7d "Carcinoma, Hepatocellular" 20347499 hsa-let-7d:The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma +target gene hsa-let-7e "Carcinoma, Hepatocellular" 20347499 hsa-let-7e:The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma +target gene hsa-let-7f-1 "Carcinoma, Hepatocellular" 20347499 hsa-let-7f:The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma +target gene hsa-let-7f-2 "Carcinoma, Hepatocellular" 20347499 hsa-let-7f:The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma +target gene hsa-let-7g "Carcinoma, Hepatocellular" 20347499 hsa-let-7g:The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma +target gene hsa-let-7i "Carcinoma, Hepatocellular" 20347499 hsa-let-7i:The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma +target gene hsa-mir-34a Neoplasms [unspecific] 20351093 miR-34a:MicroRNA-34a suppresses invasion through downregulation of Notch1 and Jagged1 in cervical carcinoma and choriocarcinoma cells +target gene hsa-mir-143 Prostate Neoplasms 20353999 Our data indicate that miR-143 and miR-145 are involved in the regulation of MYO6 expression and possibly in the development of prostate cancer +target gene hsa-mir-145 Prostate Neoplasms 20353999 Our data indicate that miR-143 and miR-145 are involved in the regulation of MYO6 expression and possibly in the development of prostate cancer +target gene hsa-mir-155 Breast Neoplasms 20354188 MicroRNA-155 functions as an OncomiR in breast cancer by targeting the suppressor of cytokine signaling 1 gene +target gene hsa-let-7f-1 Ovarian Neoplasms 20354523 "When we co-transfected cells with pMIR-KLK10 and either let-7f, miR-224, or mR-516a, we saw decreased luciferase signal, suggesting that these miRNAs can target KLK10." +target gene hsa-let-7f-2 Ovarian Neoplasms 20354523 "When we co-transfected cells with pMIR-KLK10 and either let-7f, miR-224, or mR-516a, we saw decreased luciferase signal, suggesting that these miRNAs can target KLK10." +target gene hsa-mir-224 Ovarian Neoplasms 20354523 "When we co-transfected cells with pMIR-KLK10 and either let-7f, miR-224, or mR-516a, we saw decreased luciferase signal, suggesting that these miRNAs can target KLK10." +target gene hsa-mir-516a-1 Ovarian Neoplasms 20354523 "When we co-transfected cells with pMIR-KLK10 and either let-7f, miR-224, or mR-516a, we saw decreased luciferase signal, suggesting that these miRNAs can target KLK10." +target gene hsa-mir-516a-2 Ovarian Neoplasms 20354523 "When we co-transfected cells with pMIR-KLK10 and either let-7f, miR-224, or mR-516a, we saw decreased luciferase signal, suggesting that these miRNAs can target KLK10." +target gene hsa-mir-181 "Leukemia, Lymphocytic, Chronic, B-Cell" 20357824 We recently reported that levels of TCL1 expression in B-CLL are regulated by miR-29 and miR-181 that target 3' UTR of TCL1. +target gene hsa-mir-29 "Leukemia, Lymphocytic, Chronic, B-Cell" 20357824 We recently reported that levels of TCL1 expression in B-CLL are regulated by miR-29 and miR-181 that target 3' UTR of TCL1. +target gene hsa-mir-602 "Carcinoma, Hepatocellular" 20364114 MicroRNA-602 regulating tumor suppressive gene RASSF1A is overexpressed in hepatitis B virus-infected liver and hepatocellular carcinoma +target gene hsa-mir-602 Hepatitis B Virus Infection 20364114 MicroRNA-602 regulating tumor suppressive gene RASSF1A is overexpressed in hepatitis B virus-infected liver and hepatocellular carcinoma +target gene hsa-mir-155 Breast Neoplasms 20371610 "MicroRNA-155 regulates cell survival, growth and chemosensitivity by targeting FOXO3a in breast cancer" +target gene hsa-mir-512-1 "Carcinoma, Hepatocellular" 20372864 miR-512-3p:Inhibition of c-FLIP expression by miR-512-3p contributes to taxol-induced apoptosis in hepatocellular carcinoma cells +target gene hsa-mir-512-2 "Carcinoma, Hepatocellular" 20372864 miR-512-3p:Inhibition of c-FLIP expression by miR-512-3p contributes to taxol-induced apoptosis in hepatocellular carcinoma cells +target gene hsa-mir-219 "Child Development Disorders, Pervasive" 20374639 "Putative gene targets (ID3 and PLK2) of two RT-PCR-confirmed brain-specific miRNAs (hsa-miR-29b and hsa-miR-219-5p),were validated by miRNA overexpression or knockdown assays" +target gene hsa-mir-29b "Child Development Disorders, Pervasive" 20374639 "Putative gene targets (ID3 and PLK2) of two RT-PCR-confirmed brain-specific miRNAs (hsa-miR-29b and hsa-miR-219-5p),were validated by miRNA overexpression or knockdown assays" +target gene hsa-mir-15 Neoplasms [unspecific] 20385127 "Our data thus imply that miR-15a regulates cell size and proliferation by fine-tuning Dlk1 among others, and further emphasize miR-15a and DLK1 levels to play important roles in growth signaling networks." +target gene hsa-mir-212 "Carcinoma, Lung, Non-Small-Cell" 20388802 miR-212:miR-212 increases tumor necrosis factor-related apoptosis-inducing ligand sensitivity in non-small cell lung cancer by targeting the antiapoptotic protein PED +target gene hsa-mir-101 Alzheimer Disease 20395292 "Thus, miR-101 is a negative regulator of APP expression and affects the accumulation of Abeta, suggesting a possible role for miR-101 in neuropathological conditions." +target gene hsa-mir-129 Colorectal Carcinoma 20404570 our data indicate that miR-129 plays an important role in regulating cell proliferation by downregulation of Cdk6. +target gene hsa-mir-148a Prostate Neoplasms 20406806 "miR-148a:MiR-148a attenuates paclitaxel resistance of hormone-refractory, drug-resistant prostate cancer PC3 cells by regulating MSK1 expression" +target gene hsa-mir-17 Leukemia 20406979 The miR-17-92 microRNA Polycistron Regulates MLL Leukemia Stem Cell Potential by Modulating p21 Expression +target gene hsa-mir-17 "Leukemia, Myeloid, Acute" 20406979 miR-17:The miR-17-92 microRNA polycistron regulates MLL leukemia stem cell potential by modulating p21 expression +target gene hsa-mir-18a Leukemia 20406979 The miR-17-92 microRNA Polycistron Regulates MLL Leukemia Stem Cell Potential by Modulating p21 Expression +target gene hsa-mir-18a "Leukemia, Myeloid, Acute" 20406979 miR-18a:The miR-17-92 microRNA polycistron regulates MLL leukemia stem cell potential by modulating p21 expression +target gene hsa-mir-19a Leukemia 20406979 The miR-17-92 microRNA Polycistron Regulates MLL Leukemia Stem Cell Potential by Modulating p21 Expression +target gene hsa-mir-19a "Leukemia, Myeloid, Acute" 20406979 miR-19a:The miR-17-92 microRNA polycistron regulates MLL leukemia stem cell potential by modulating p21 expression +target gene hsa-mir-19b-1 Leukemia 20406979 The miR-17-92 microRNA Polycistron Regulates MLL Leukemia Stem Cell Potential by Modulating p21 Expression +target gene hsa-mir-19b-1 "Leukemia, Myeloid, Acute" 20406979 miR-19b:The miR-17-92 microRNA polycistron regulates MLL leukemia stem cell potential by modulating p21 expression +target gene hsa-mir-19b-2 Leukemia 20406979 The miR-17-92 microRNA Polycistron Regulates MLL Leukemia Stem Cell Potential by Modulating p21 Expression +target gene hsa-mir-19b-2 "Leukemia, Myeloid, Acute" 20406979 miR-19b:The miR-17-92 microRNA polycistron regulates MLL leukemia stem cell potential by modulating p21 expression +target gene hsa-mir-20a Leukemia 20406979 The miR-17-92 microRNA Polycistron Regulates MLL Leukemia Stem Cell Potential by Modulating p21 Expression +target gene hsa-mir-20a "Leukemia, Myeloid, Acute" 20406979 miR-20a:The miR-17-92 microRNA polycistron regulates MLL leukemia stem cell potential by modulating p21 expression +target gene hsa-mir-92a-1 "Leukemia, Myeloid, Acute" 20406979 miR-92a:The miR-17-92 microRNA polycistron regulates MLL leukemia stem cell potential by modulating p21 expression +target gene hsa-mir-92a-2 "Leukemia, Myeloid, Acute" 20406979 miR-92a:The miR-17-92 microRNA polycistron regulates MLL leukemia stem cell potential by modulating p21 expression +target gene hsa-mir-145 Atherosclerosis 20415654 "MicroRNAs also regulate smooth muscle cell phenotypes and control neointima formation and atherosclerosis. In this respect, miR-143 and miR-145 have been shown to play a crucial role." +target gene hsa-mir-182 Lung Neoplasms 20420807 mir-182:Hsa-mir-182 suppresses lung tumorigenesis through down regulation of RGS17 expression in vitro +target gene hsa-mir-26a Lymphoma 20441582 MicroRNA-26a-mediated regulation of interleukin-2 expression in transformed avian lymphocyte lines. +target gene hsa-mir-151a Neoplasms [unspecific] 20445018 "miR-151:down-modulating MPL and other targets of miR-28, and of related miR-708 and miR-151, could contribute to MPN pathogenicity" +target gene hsa-mir-28 Neoplasms [unspecific] 20445018 "miR-28:down-modulating MPL and other targets of miR-28, and of related miR-708 and miR-151, could contribute to MPN pathogenicity" +target gene hsa-mir-708 Neoplasms [unspecific] 20445018 "miR-708:down-modulating MPL and other targets of miR-28, and of related miR-708 and miR-151, could contribute to MPN pathogenicity" +target gene hsa-mir-155 Preeclampsia 20452491 miR-155:MicroRNA-155 contributes to preeclampsia by down-regulating CYR61 +target gene hsa-mir-20a Ovarian Neoplasms 20458444 miR-20a:miR-20a promotes proliferation and invasion by targeting APP in human ovarian cancer cells +target gene hsa-mir-125b-1 Breast Neoplasms 20460378 MicroRNA-125b:MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression +target gene hsa-mir-125b-2 Breast Neoplasms 20460378 MicroRNA-125b:MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression +target gene hsa-mir-133b Parkinson Disease 20468068 MiR-133b has been implicated in Parkinson's disease (PD) by a mechanism that involves the regulation of the transcription factor PITX3. +target gene hsa-mir-34a Glioma 20470934 "Our results demonstrate that miR-34a acts as a tumor suppressor in p53-mutant glioma cells U251, partially through regulating SIRT1." +target gene hsa-mir-21 Osteosarcoma 20480266 MicroRNA-21 is involved in osteosarcoma cell invasion and migration. +target gene hsa-mir-92a-1 Breast Neoplasms 20484043 miR-92:Estrogen receptor {beta}1 expression is regulated by miR-92 in breast cancer +target gene hsa-mir-92a-2 Breast Neoplasms 20484043 miR-92:Estrogen receptor {beta}1 expression is regulated by miR-92 in breast cancer +target gene hsa-mir-146a Chronic Heart Failure 20495188 These findings suggested that the up-regulation of miR-146a after Dox treatment is involved in acute Dox-induced cardiotoxicity by targeting ErbB4. +target gene hsa-mir-146a Psoriatic Arthritis 20500689 miR-146a:The role of microRNA-146a (miR-146a) and its target IL-1R-associated kinase (IRAK1) in psoriatic arthritis susceptibility +target gene hsa-mir-199a-1 "Carcinoma, Hepatocellular" 20501828 MiR-199a-3p:MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells +target gene hsa-mir-199a-2 "Carcinoma, Hepatocellular" 20501828 MiR-199a-3p:MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells +target gene hsa-mir-17 Breast Neoplasms 20505989 These findings suggest that miR-17-5p plays an important role in breast cancer cell invasion and migration by suppressing HBP1 and subsequent activation of Wnt/¦Â-catenin. +target gene hsa-mir-331 Gastric Neoplasms 20510161 miRNA-331-3p:miRNA-331-3p directly targets E2F1 and induces growth arrest in human gastric cancer +target gene hsa-mir-200a Breast Neoplasms 20514023 miR-200a:Our results suggest that the miR-200 family has a tumor-suppressor function by negatively regulating EGF-driven cell invasion +target gene hsa-mir-200b Breast Neoplasms 20514023 miR-200b:Our results suggest that the miR-200 family has a tumor-suppressor function by negatively regulating EGF-driven cell invasion +target gene hsa-mir-200c Breast Neoplasms 20514023 mir-200c:Our results suggest that the miR-200 family has a tumor-suppressor function by negatively regulating EGF-driven cell invasion +target gene hsa-mir-1226 Hematologic Neoplasms 20514397 These findings indicate that expression of the MUC1 oncoprotein is downregulated by miR-1226 and that miR-1226 thereby functions as a tumor suppressor by promoting the induction of cell death. +target gene hsa-mir-25 "Muscular Dystrophy, Facioscapulohumeral" 20519410 "miR-25:We report for the first time that FXR1P is regulated through miRNA binding, with one site being the miR-25/32/92/363/367 seed sequence" +target gene hsa-mir-32 "Muscular Dystrophy, Facioscapulohumeral" 20519410 "miR-32:We report for the first time that FXR1P is regulated through miRNA binding, with one site being the miR-25/32/92/363/367 seed sequence" +target gene hsa-mir-363 "Muscular Dystrophy, Facioscapulohumeral" 20519410 "miR-363:We report for the first time that FXR1P is regulated through miRNA binding, with one site being the miR-25/32/92/363/367 seed sequence" +target gene hsa-mir-367 "Muscular Dystrophy, Facioscapulohumeral" 20519410 "miR-367:We report for the first time that FXR1P is regulated through miRNA binding, with one site being the miR-25/32/92/363/367 seed sequence" +target gene hsa-mir-92a-1 "Muscular Dystrophy, Facioscapulohumeral" 20519410 "miR-92:We report for the first time that FXR1P is regulated through miRNA binding, with one site being the miR-25/32/92/363/367 seed sequence" +target gene hsa-mir-92a-2 "Muscular Dystrophy, Facioscapulohumeral" 20519410 "miR-92:We report for the first time that FXR1P is regulated through miRNA binding, with one site being the miR-25/32/92/363/367 seed sequence" +target gene hsa-mir-661 Breast Neoplasms 20543867 miR-661:miR-661 expression in SNAI1-induced epithelial to mesenchymal transition contributes to breast cancer cell invasion by targeting Nectin-1 and StarD10 messengers +target gene hsa-mir-375 Gastric Neoplasms 20548334 MiR-375:MiR-375 frequently downregulated in gastric cancer inhibits cell proliferation by targeting JAK2 +target gene hsa-mir-155 Cardiovascular Diseases [unspecific] 20550618 MicroRNA-155 prevents necrotic cell death in human cardiomyocyte progenitor cells via targeting RIP1. +target gene hsa-mir-200a Pancreatic Neoplasms 20551052 miR-200a:The elevated serum levels of miR-200a and miR-200b in most patients with pancreatic cancer could have diagnostic utility +target gene hsa-mir-200b Pancreatic Neoplasms 20551052 miR-200b:The elevated serum levels of miR-200a and miR-200b in most patients with pancreatic cancer could have diagnostic utility +target gene hsa-mir-23b Kidney Neoplasms 20562915 "miR-23b:miR-23b targets proline oxidase, a novel tumor suppressor protein in renal cancer" +target gene hsa-mir-22 Neoplasms [unspecific] 20562918 miR-22:miR-22 acts as a tumor suppressor through direct repression of MYCBP expression and subsequent reduction of oncogenic c-Myc activities. +target gene hsa-mir-1 Cardiomegaly 20571053 "Taken together, our results demonstrate that the cytoskeleton regulatory protein twinfilin-1 is a novel target of miR-1, and that reduction of miR-1 by hypertrophic stimuli induces the upregulation of twinfilin-1, which in turn evokes hypertrophy through the regulation of cardiac cytoskeleton." +target gene hsa-mir-101-1 Neoplasms [unspecific] 20586854 miR-101:Targeting DNA-PKcs and ATM with miR-101 sensitizes tumors to radiation +target gene hsa-mir-101-2 Neoplasms [unspecific] 20586854 miR-101:Targeting DNA-PKcs and ATM with miR-101 sensitizes tumors to radiation +target gene hsa-mir-185 Neoplasms [unspecific] 20603620 miRNA-185:MicroRNA-185 suppresses tumor growth and progression by targeting the Six1 oncogene in human cancers +target gene hsa-mir-96 Pancreatic Neoplasms 20610624 miRNA-96:miRNA-96 suppresses KRAS and functions as a tumor suppressor gene in pancreatic cancer +target gene hsa-mir-149 Neoplasms [unspecific] 20623644 miR-149:miR-149* induces apoptosis by inhibiting Akt1 and E2F1 in human cancer cells +target gene hsa-mir-27a Ovarian Neoplasms 20624637 MiR-27a:MiR-27a modulates MDR1/P-glycoprotein expression by targeting HIPK2 in human ovarian cancer cells +target gene hsa-mir-10a Atherosclerosis 20624982 miR-10a:miR-10a contributes to the regulation of proinflammatory endothelial phenotypes in athero-susceptible regions in vivo +target gene hsa-mir-135a Inflammation 20634564 "Specifically, miR-181a and b, miR-9, miR-204, miR-199b, and miR-135a suppressed SIRT1 protein expression." +target gene hsa-mir-181a Inflammation 20634564 "Specifically, miR-181a and b, miR-9, miR-204, miR-199b, and miR-135a suppressed SIRT1 protein expression." +target gene hsa-mir-181b Inflammation 20634564 "Specifically, miR-181a and b, miR-9, miR-204, miR-199b, and miR-135a suppressed SIRT1 protein expression." +target gene hsa-mir-199b Inflammation 20634564 "Specifically, miR-181a and b, miR-9, miR-204, miR-199b, and miR-135a suppressed SIRT1 protein expression." +target gene hsa-mir-204 Inflammation 20634564 "Specifically, miR-181a and b, miR-9, miR-204, miR-199b, and miR-135a suppressed SIRT1 protein expression." +target gene hsa-mir-9 Inflammation 20634564 "Specifically, miR-181a and b, miR-9, miR-204, miR-199b, and miR-135a suppressed SIRT1 protein expression." +target gene hsa-mir-137 Melanoma 20644734 miR-137:Our data show that miR-148 and miR-137 present an additional level of regulating Mitf expression in melanocytes and melanoma cells. +target gene hsa-mir-148a Melanoma 20644734 miR-148:Our data show that miR-148 and miR-137 present an additional level of regulating Mitf expression in melanocytes and melanoma cells. +target gene hsa-mir-27a Ovarian Neoplasms 20646448 "The expression of miR-27a is upregulated in A2780/Taxol cells, which may regulate MDR1 and P-gp expression by targeting HIPK2." +target gene hsa-mir-326 Glioma 20667897 Pyruvate kinase M2 is a target of the tumor-suppressive microRNA-326 and regulates the survival of glioma cells +target gene hsa-mir-217 Pancreatic Neoplasms 20675343 The miR-217 microRNA functions as a potential tumor suppressor in pancreatic ductal adenocarcinoma by targeting KRAS. +target gene hsa-mir-489 "Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal" 20700123 miR-489:miR-489 is a tumour-suppressive miRNA target PTPN11 in hypopharyngeal squamous cell carcinoma +target gene hsa-mir-21 Barrett Esophagus 20702469 "These data support a significant role for PDCD4 downregulation in the progression of BM to BAc, and confirm miR-21 as a negative regulator of PDCD4 in vivo. Further efforts are needed to validate PDCD4 as a potential prognostic marker in patients with Barrett's oesophagus." +target gene hsa-mir-106b Alzheimer Disease 20709030 miR-106b aberrantly expressed in a double transgenic mouse model for Alzheimer's disease targets TGF-¦Â type II receptor. +target gene hsa-mir-146a "Carcinoma, Renal Cell" 20709800 Loss of inducible nitric oxide synthase expression in the mouse renal cell carcinoma cell line RENCA is mediated by microRNA miR-146a. +target gene hsa-mir-101-1 Gastric Neoplasms 20712078 miR-101-3p: MicroRNA-101 is down-regulated in gastric cancer and involved in cell migration and invasion +target gene hsa-mir-101-2 Gastric Neoplasms 20712078 miR-101-3p: MicroRNA-101 is down-regulated in gastric cancer and involved in cell migration and invasion +target gene hsa-mir-125a "Carcinoma, Lung, Non-Small-Cell" 20723344 hsa-miR-125a-5p could up-regulate Rock-1 and enhance invasion in lung cancer cells. +target gene hsa-mir-145 Colon Neoplasms 20737575 "Taken together, these results suggest that miR-145 functions as a tumor suppressor by down-regulating oncogenic FLI1 in colon cancer." +target gene hsa-mir-221 Glioblastoma 20813046 "To our knowledge, these data indicate for the first time that miR-221/222 directly regulate apoptosis by targeting PUMA in glioblastoma and that miR-221/222 could be potential therapeutic targets for glioblastoma intervention." +target gene hsa-mir-222 Glioblastoma 20813046 "To our knowledge, these data indicate for the first time that miR-221/222 directly regulate apoptosis by targeting PUMA in glioblastoma and that miR-221/222 could be potential therapeutic targets for glioblastoma intervention." +target gene hsa-mir-24-1 "Squamous Cell Carcinoma, Tongue" 20816961 miR-24:MicroRNA-24 targeting RNA-binding protein DND1 in tongue squamous cell carcinoma +target gene hsa-mir-24-2 "Squamous Cell Carcinoma, Tongue" 20816961 miR-24:MicroRNA-24 targeting RNA-binding protein DND1 in tongue squamous cell carcinoma +target gene hsa-mir-148a Prostate Neoplasms 20820187 miR-148a is an androgen-responsive microRNA that promotes LNCaP prostate cell growth by repressing its target CAND1 expression. +target gene hsa-mir-21 "Carcinoma, Colon" 20826792 miR-21 and miR-31 converge on TIAM1 to regulate migration and invasion of colon carcinoma cells. +target gene hsa-mir-31 "Carcinoma, Colon" 20826792 miR-21 and miR-31 converge on TIAM1 to regulate migration and invasion of colon carcinoma cells. +target gene hsa-mir-21 "Squamous Cell Carcinoma, Oral" 20831814 Programmed cell death 4 loss increases tumor cell invasion and is regulated by miR-21 in oral squamous cell carcinoma. +target gene hsa-mir-494 Ischemia 20837890 miR-494:MicroRNA-494 targeting both proapoptotic and antiapoptotic proteins protects against ischemia/reperfusion-induced cardiac injury +target gene hsa-mir-494 Ischemia-Reperfusion Injury 20837890 miR-494:MicroRNA-494 targeting both proapoptotic and antiapoptotic proteins protects against ischemia/reperfusion-induced cardiac injury +target gene hsa-mir-145 Vascular Injuries 20841497 "In addition, specific miRNAs such as miR-145, miR-21, and miR-221 have been found to regulate neointimal hyperplasia following vascular injury, which provides interesting possibilities for future herapeutical targets against vascular disease." +target gene hsa-mir-1 Bladder Neoplasms 20843712 "Our data indicate that LASP1 may have an oncogenic function and that it might be regulated by miR-1, miR-133a, and miR-218, which may function as tumor suppressive miRNAs in BC." +target gene hsa-mir-133a Bladder Neoplasms 20843712 "Our data indicate that LASP1 may have an oncogenic function and that it might be regulated by miR-1, miR-133a, and miR-218, which may function as tumor suppressive miRNAs in BC." +target gene hsa-mir-145 Bladder Neoplasms 20843712 "Our data indicate that LASP1 may have an oncogenic function and that it might be regulated by miR-1, miR-133a, and miR-218, which may function as tumor suppressive miRNAs in BC." +target gene hsa-mir-17 Neoplasms [unspecific] 20851997 "miR-17-92 inhibits apoptosis by suppressing Pten via the miR-19 components, our results indicate that this miRNA cluster promotes tumorigenesis by antagonizing both tumor-suppressing mechanisms, apoptosis, and senescence, through the activities of different miRNA components encoded in this cluster" +target gene hsa-mir-18 Neoplasms [unspecific] 20851997 "miR-17-92 inhibits apoptosis by suppressing Pten via the miR-19 components, our results indicate that this miRNA cluster promotes tumorigenesis by antagonizing both tumor-suppressing mechanisms, apoptosis, and senescence, through the activities of different miRNA components encoded in this cluster" +target gene hsa-mir-19a Neoplasms [unspecific] 20851997 "miR-17-92 inhibits apoptosis by suppressing Pten via the miR-19 components, our results indicate that this miRNA cluster promotes tumorigenesis by antagonizing both tumor-suppressing mechanisms, apoptosis, and senescence, through the activities of different miRNA components encoded in this cluster" +target gene hsa-mir-19b-1 Neoplasms [unspecific] 20851997 "miR-17-92 inhibits apoptosis by suppressing Pten via the miR-19 components, our results indicate that this miRNA cluster promotes tumorigenesis by antagonizing both tumor-suppressing mechanisms, apoptosis, and senescence, through the activities of different miRNA components encoded in this cluster" +target gene hsa-mir-20a Neoplasms [unspecific] 20851997 "miR-17-92 inhibits apoptosis by suppressing Pten via the miR-19 components, our results indicate that this miRNA cluster promotes tumorigenesis by antagonizing both tumor-suppressing mechanisms, apoptosis, and senescence, through the activities of different miRNA components encoded in this cluster" +target gene hsa-mir-92-1 Neoplasms [unspecific] 20851997 "miR-17-92 inhibits apoptosis by suppressing Pten via the miR-19 components, our results indicate that this miRNA cluster promotes tumorigenesis by antagonizing both tumor-suppressing mechanisms, apoptosis, and senescence, through the activities of different miRNA components encoded in this cluster" +target gene hsa-mir-107 Leukemia 20884628 "Recent findings indicate that GRN is regulated strongly by the microRNA miR-107, which functionally overlaps with miR-15, miR-16, and miR-195 due to a common 5' sequence critical for target specificity. " +target gene hsa-mir-15 Leukemia 20884628 "Recent findings indicate that GRN is regulated strongly by the microRNA miR-107, which functionally overlaps with miR-15, miR-16, and miR-195 due to a common 5' sequence critical for target specificity. " +target gene hsa-mir-16 Leukemia 20884628 "Recent findings indicate that GRN is regulated strongly by the microRNA miR-107, which functionally overlaps with miR-15, miR-16, and miR-195 due to a common 5' sequence critical for target specificity. " +target gene hsa-mir-195 Leukemia 20884628 "Recent findings indicate that GRN is regulated strongly by the microRNA miR-107, which functionally overlaps with miR-15, miR-16, and miR-195 due to a common 5' sequence critical for target specificity. " +target gene hsa-mir-181a Congenital Heart Diseases 20884876 "We showed that Dicer loss of function was, at least in part, mediated by miRNA-21 (miR-21) and miRNA-181a (miR-181a), which in turn repressed the protein level of Sprouty 2, an inhibitor of Erk1/2 signaling." +target gene hsa-mir-21 Congenital Heart Diseases 20884876 "We showed that Dicer loss of function was, at least in part, mediated by miRNA-21 (miR-21) and miRNA-181a (miR-181a), which in turn repressed the protein level of Sprouty 2, an inhibitor of Erk1/2 signaling." +target gene hsa-mir-196b "Leukemia, Lymphoblastic, Acute" 20924650 Results of the present study revealed that miR-196b becomes non-functional in T-cell ALL as a consequence of mutations in 3'-UTR of c-myc gene in T-cell ALL cellular models. +target gene hsa-mir-125b Neoplasms [unspecific] 20935678 "Thus, beyond miR-125b and miR-504, the human TP53 gene is negatively regulated by two more miRNAs: miR-25 and miR-30d." +target gene hsa-mir-25 Neoplasms [unspecific] 20935678 "Thus, beyond miR-125b and miR-504, the human TP53 gene is negatively regulated by two more miRNAs: miR-25 and miR-30d." +target gene hsa-mir-30d Neoplasms [unspecific] 20935678 "Thus, beyond miR-125b and miR-504, the human TP53 gene is negatively regulated by two more miRNAs: miR-25 and miR-30d." +target gene hsa-mir-504 Neoplasms [unspecific] 20935678 "Thus, beyond miR-125b and miR-504, the human TP53 gene is negatively regulated by two more miRNAs: miR-25 and miR-30d." +target gene hsa-mir-146b Inflammation 20956612 "e.g., miR-146b targeted NF-¦ÊB signaling, and miR-219 targeted 5-lipoxygenase and reduced leukotriene production." +target gene hsa-mir-219 Inflammation 20956612 "e.g., miR-146b targeted NF-¦ÊB signaling, and miR-219 targeted 5-lipoxygenase and reduced leukotriene production." +target gene hsa-mir-93 Glioblastoma 20956944 MicroRNA miR-93 promotes tumor growth and angiogenesis by targeting integrin-¦Â8. +target gene hsa-mir-16 Multiple Myeloma 20962322 "We validated designated genes showing binding sites within the conserved 3'-UTR and also within the mRNA coding region as direct miR-16 targets, thus indicating that the miRNAs may have many more targets than anticipated by conventional prediction methods." +target gene hsa-mir-31 Endometrial Neoplasms 20980827 "These findings provide new insights into tumor-stroma interaction and document that miR-31 and its target gene SATB2, are involved in regulation of tumor cell motility." +target gene hsa-mir-107 Gastrointestinal Neoplasms 21029372 "MicroRNA-107, an oncogene microRNA that regulates tumour invasion and metastasis by targeting DICER1 in gastric cancer." +target gene hsa-mir-137 Melanoma 21051724 The results showed that miR-137 can act as a tumor suppressor in uveal melanoma cell proliferation through downregulation of the targets MITF and CDK6. miR-137 may be epigenetically silenced during uveal melanoma tumorigenesis. +target gene hsa-mir-34a "Carcinoma, Rectal" 21067862 "These findings suggest that miR-34a targeting the Sirt1 and E2F3 genes could negatively regulate, at least in part, the resistance to 5-FU in human colorectal cancer DLD-1 cells." +target gene hsa-mir-101 Immune System Disease [unspecific] 21068409 "Together, these results indicate that miR-101 regulates the innate immune responses of macrophages to LPS through targeting MKP-1." +target gene hsa-mir-221 Prostate Neoplasms 21071579 This study demonstrates for the first time that prostate cancer cells have decreased level of ARHI which could be caused by direct targeting of 3'UTR of ARHI by miR221/222. +target gene hsa-mir-211 Melanoma 21072171 "our findings that miR-211 is a direct posttranscriptional regulator of KCNMA1 expression as well as the dependence of this miRNA's expression on MITF activity, establishes miR-211 as an important regulatory agent in human melanoma." +target gene hsa-mir-196a Melanoma 21077158 "As it was stated before that miR-196a might negatively regulate expression of the transcription factor HOX-C8, we analyzed HOX-C8 levels in NHEMs and melanoma cells and found a strong up-regulation of HOX-C8 expression in malignant melanoma cell lines and tissue samples compared with melanocytes." +target gene hsa-mir-138 "Squamous Cell Carcinoma, Tongue" 21079996 Identification and experimental validation of G protein alpha inhibiting activity polypeptide 2 (GNAI2) as a microRNA-138 target in tongue squamous cell carcinoma. +target gene hsa-mir-191 Ovarian Neoplasms 21084273 "We conclude that acquisition of an illegitimate miR-191 target site causes downregulation of MDM4 expression,thereby significantly delaying ovarian carcinoma progression and tumor-related death." +target gene hsa-mir-373 Cholangiocarcinoma 21086164 "miR-373 is one negative regulator of MBD2. In hilar cholangiocarcinoma, down-expression of miR-373 leads to increase of MBD2, which in turn suppresses the methylation-mediated gene such as RASSF1A." +target gene hsa-mir-145 Lung Neoplasms 21092188 miRNA-145 inhibits non-small cell lung cancer cell proliferation by targeting c-Myc. +target gene hsa-mir-221 Glioblastoma 21109963 "These results were confirmed by the protein expression of p27kip1, the validated target of miR-221/222, the effect on cell cycle arrest in G1 phase, and the impact on cell apoptosis." +target gene hsa-mir-222 Glioblastoma 21109963 "These results were confirmed by the protein expression of p27kip1, the validated target of miR-221/222, the effect on cell cycle arrest in G1 phase, and the impact on cell apoptosis." +target gene hsa-let-7 Ovarian Neoplasms 21109987 Involvement of let-7/miR-98 microRNAs in the regulation of progesterone receptor membrane component 1 expression in ovarian cancer cells. +target gene hsa-mir-98 Ovarian Neoplasms 21109987 Involvement of let-7/miR-98 microRNAs in the regulation of progesterone receptor membrane component 1 expression in ovarian cancer cells. +target gene hsa-mir-10a Neuroblastoma 21118818 MicroRNAs-10a and -10b contribute to retinoic acid-induced differentiation of neuroblastoma cells and target the alternative splicing regulatory factor SFRS1 +target gene hsa-mir-296 Prostate Neoplasms 21138859 Regulation of HMGA1 expression by microRNA296 affects prostate cancer growth and invasion +target gene hsa-mir-128-1 Neuroblastoma 21143953 Overexpression of miR-128 specifically inhibits the truncated isoform of NTRK3 and upregulates BCL2 in SH-SY5Y neuroblastoma cells. +target gene hsa-mir-128-2 Neuroblastoma 21143953 Overexpression of miR-128 specifically inhibits the truncated isoform of NTRK3 and upregulates BCL2 in SH-SY5Y neuroblastoma cells. +target gene hsa-mir-17 Neuroblastoma 21145484 The miR-17-92 MicroRNA Cluster Regulates Multiple Components of the TGF-beta Pathway in Neuroblastoma. +target gene hsa-mir-18a Neuroblastoma 21145484 The miR-17-92 MicroRNA Cluster Regulates Multiple Components of the TGF-beta Pathway in Neuroblastoma. +target gene hsa-mir-19a Neuroblastoma 21145484 The miR-17-92 MicroRNA Cluster Regulates Multiple Components of the TGF-beta Pathway in Neuroblastoma. +target gene hsa-mir-19b-1 Neuroblastoma 21145484 The miR-17-92 MicroRNA Cluster Regulates Multiple Components of the TGF-beta Pathway in Neuroblastoma. +target gene hsa-mir-20a Neuroblastoma 21145484 The miR-17-92 MicroRNA Cluster Regulates Multiple Components of the TGF-beta Pathway in Neuroblastoma. +target gene hsa-mir-92a-1 Neuroblastoma 21145484 The miR-17-92 MicroRNA Cluster Regulates Multiple Components of the TGF-beta Pathway in Neuroblastoma. +target gene hsa-mir-43c Gastrointestinal Neoplasms 21156161 "Furthermore, a luciferase reporter assay demonstrates that miR-43c directly targets adherens junctions' transmembrane protein (VEZT) and suppresses VEZT protein expression." +target gene hsa-mir-218-1 "Carcinoma, Lung, Non-Small-Cell" 21159652 Paxillin Predicts Survival and Relapse in Non-Small Cell Lung Cancer by MicroRNA-218 Targeting. +target gene hsa-mir-218-2 "Carcinoma, Lung, Non-Small-Cell" 21159652 Paxillin Predicts Survival and Relapse in Non-Small Cell Lung Cancer by MicroRNA-218 Targeting. +target gene hsa-mir-146a Thyroid Neoplasms 21159845 Papillary Thyroid Carcinoma (PTC). Direct interaction with THRB was shown for miR-21 and miR-146a. +target gene hsa-mir-21 Thyroid Neoplasms 21159845 Papillary Thyroid Carcinoma (PTC). Direct interaction with THRB was shown for miR-21 and miR-146a. +target gene hsa-mir-181a-1 "Squamous Cell Carcinoma, Oral" 21167132 miR-181a shows tumor suppressive effect against oral squamous cell carcinoma cells by downregulating K-ras +target gene hsa-mir-181a-2 "Squamous Cell Carcinoma, Oral" 21167132 miR-181a shows tumor suppressive effect against oral squamous cell carcinoma cells by downregulating K-ras +target gene hsa-mir-21 Dementia 21170291 MicroRNA-21 dysregulates the expression of MEF2C in neurons in monkey and human SIV/HIV neurological disease. +target gene hsa-mir-593 Esophageal Neoplasms 21170987 Polo-like kinase 1 regulates cell proliferation and is targeted by miR-593* in esophageal cancer. +target gene hsa-mir-103a-1 Alzheimer Disease 21179570 "microRNAs 103 and 107 repress translation of cofilin, and that reduced levels of miR-103 or miR-107 are associated with elevated cofilin protein levels and formation of rod-like structures in a transgenic mouse model of AD" +target gene hsa-mir-103a-2 Alzheimer Disease 21179570 "microRNAs 103 and 107 repress translation of cofilin, and that reduced levels of miR-103 or miR-107 are associated with elevated cofilin protein levels and formation of rod-like structures in a transgenic mouse model of AD" +target gene hsa-mir-107 Alzheimer Disease 21179570 "microRNAs 103 and 107 repress translation of cofilin, and that reduced levels of miR-103 or miR-107 are associated with elevated cofilin protein levels and formation of rod-like structures in a transgenic mouse model of AD" +target gene hsa-mir-34a Neuroblastoma 21182263 "YY1 is a negative regulator of p53, and it plays an essential role in cancer biology. Therefore, YY1 is another important direct target of miR-34a which closely regulates TP53 activities." +target gene hsa-mir-185 Colorectal Carcinoma 21186079 "miR-185 targets RhoA and Cdc42 expression and inhibits the proliferation potential of human colorectal cells.miR-185 is a negative regulator of RhoA and Cdc42 and their cellular activities, and could inhibit proliferation and invasion of colorectal cancer" +target gene hsa-mir-21 Leukemia 21187093 Involvement of miR-21 in resistance to daunorubicin by regulating PTEN expression in the leukaemia K562 cell line. +target gene hsa-mir-199a-1 Neoplasms [unspecific] 21189327 microRNAs miR-199a-5p and -3p target the Brm subunit of SWI/SNF to generate a double-negative feedback loop in a variety of human cancers. +target gene hsa-mir-199a-2 Neoplasms [unspecific] 21189327 microRNAs miR-199a-5p and -3p target the Brm subunit of SWI/SNF to generate a double-negative feedback loop in a variety of human cancers. +target gene hsa-mir-135a "Carcinoma, Rectal" 21192341 "In this issue, Li and colleagues describe a novel way of targeting miRNA, by using a naturally occurring anti-cancer compound found in mistletoe which they showed to down-regulate miR-135a&b, which target the 3' untranslated region of adenomatous polyposis coli gene, the inactivation of which is a major initiating event in colorectal tumourigenesis." +target gene hsa-mir-135b "Carcinoma, Rectal" 21192341 "In this issue, Li and colleagues describe a novel way of targeting miRNA, by using a naturally occurring anti-cancer compound found in mistletoe which they showed to down-regulate miR-135a&b, which target the 3' untranslated region of adenomatous polyposis coli gene, the inactivation of which is a major initiating event in colorectal tumourigenesis." +target gene hsa-mir-143 Prostate Neoplasms 21197560 miR-143 decreases prostate cancer cells proliferation and migration and enhances their sensitivity to docetaxel through suppression of KRAS +target gene hsa-mir-26a-1 Nasopharyngeal Neoplasms 21199804 MiR-26a Inhibits Cell Growth and Tumorigenesis of Nasopharyngeal Carcinoma through Repression of EZH2 +target gene hsa-mir-26a-2 Nasopharyngeal Neoplasms 21199804 MiR-26a Inhibits Cell Growth and Tumorigenesis of Nasopharyngeal Carcinoma through Repression of EZH2 +target gene hsa-mir-96 Breast Neoplasms 21203424 Unregulated miR-96 Induces Cell Proliferation in Human Breast Cancer by Downregulating Transcriptional Factor FOXO3a. +target gene hsa-mir-203 Urinary Bladder Cancer 21205209 microRNA-203 suppresses bladder cancer development by repressing bcl-w expression. +target gene hsa-mir-15a Patau Syndrome 21205891 MicroRNA-15a and -16-1 act via MYB to elevate fetal hemoglobin expression in human trisomy 13. +target gene hsa-mir-16-1 Patau Syndrome 21205891 MicroRNA-15a and -16-1 act via MYB to elevate fetal hemoglobin expression in human trisomy 13. +target gene hsa-mir-16-2 Patau Syndrome 21205891 MicroRNA-15a and -16-1 act via MYB to elevate fetal hemoglobin expression in human trisomy 13. +target gene hsa-mir-15a "Leukemia, Lymphocytic, Chronic, B-Cell" 21205967 A microRNA/TP53 feedback circuitry is associated with CLL pathogenesis and outcome. Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia. +target gene hsa-mir-15b "Leukemia, Lymphocytic, Chronic, B-Cell" 21205967 A microRNA/TP53 feedback circuitry is associated with CLL pathogenesis and outcome. Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia. +target gene hsa-mir-16-1 "Leukemia, Lymphocytic, Chronic, B-Cell" 21205967 A microRNA/TP53 feedback circuitry is associated with CLL pathogenesis and outcome. Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia. +target gene hsa-mir-16-2 "Leukemia, Lymphocytic, Chronic, B-Cell" 21205967 A microRNA/TP53 feedback circuitry is associated with CLL pathogenesis and outcome. Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia. +target gene hsa-mir-195 "Leukemia, Lymphocytic, Chronic, B-Cell" 21205967 A microRNA/TP53 feedback circuitry is associated with CLL pathogenesis and outcome. Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia. +target gene hsa-mir-34b "Leukemia, Lymphocytic, Chronic, B-Cell" 21205967 A microRNA/TP53 feedback circuitry is associated with CLL pathogenesis and outcome. Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia. +target gene hsa-mir-34c "Leukemia, Lymphocytic, Chronic, B-Cell" 21205967 A microRNA/TP53 feedback circuitry is associated with CLL pathogenesis and outcome. Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia. +target gene hsa-mir-10a Neuroblastoma 21212796 MicroRNAs 10a and 10b are potent inducers of neuroblastoma cell differentiation through targeting of nuclear receptor corepressor 2. +target gene hsa-mir-10b Neuroblastoma 21212796 MicroRNAs 10a and 10b are potent inducers of neuroblastoma cell differentiation through targeting of nuclear receptor corepressor 2. +target gene hsa-mir-31 "Muscular Dystrophy, Duchenne" 21212803 miR-31 represses dystrophin expression by targeting its 3' untranslated region. +target gene hsa-mir-214 Urinary Bladder Cancer 21216304 Plexin-B1 is a target of miR-214 in cervical cancer and promotes the growth and invasion of HeLa Cells. +target gene hsa-mir-328 Breast Neoplasms 21219875 Breast cancer resistance protein BCRP/ABCG2 regulatory microRNAs (hsa-miR-328; -519c and -520h) and their differential expression in stem-like ABCG2+ cancer cells. +target gene hsa-mir-519c Breast Neoplasms 21219875 Breast cancer resistance protein BCRP/ABCG2 regulatory microRNAs (hsa-miR-328; -519c and -520h) and their differential expression in stem-like ABCG2+ cancer cells. +target gene hsa-mir-520h Breast Neoplasms 21219875 Breast cancer resistance protein BCRP/ABCG2 regulatory microRNAs (hsa-miR-328; -519c and -520h) and their differential expression in stem-like ABCG2+ cancer cells. +target gene hsa-mir-125a Gastric Neoplasms 21220473 "MicroRNA-125a-5p is an independent prognostic factor in gastric cancer,and inhibits the proliferation of human gastric cancer cells in combination with trastuzumab." +target gene hsa-mir-137 Gastric Neoplasms 21221794 miR-137 Is Frequently Down-Regulated in Gastric Cancer and Is a Negative Regulator of Cdc42. +target gene hsa-mir-616 Prostate Neoplasms 21224345 microRNA-616 Induces Androgen-Independent Growth of Prostate Cancer Cells by Suppressing Expression of Tissue Factor Pathway Inhibitor TFPI-2. +target gene hsa-mir-376c Ovarian Neoplasms 21224400 MicroRNA 376c enhances ovarian cancer cell survival by targeting activin receptor-like kinase 7: implications for chemoresistance. +target gene hsa-mir-200a Prostate Neoplasms 21224847 Targeting Notch signalling by the conserved miR-8/200 microRNA family in development and cancer cells. +target gene hsa-mir-200b Prostate Neoplasms 21224847 Targeting Notch signalling by the conserved miR-8/200 microRNA family in development and cancer cells. +target gene hsa-mir-200c Prostate Neoplasms 21224847 Targeting Notch signalling by the conserved miR-8/200 microRNA family in development and cancer cells. +target gene hsa-mir-200a Breast Neoplasms 21224848 The ZEB1/miR-200 feedback loop controls Notch signalling in cancer cells. +target gene hsa-mir-200a Pancreatic Neoplasms 21224848 The ZEB1/miR-200 feedback loop controls Notch signalling in cancer cells. +target gene hsa-mir-200b Breast Neoplasms 21224848 The ZEB1/miR-200 feedback loop controls Notch signalling in cancer cells. +target gene hsa-mir-200b Pancreatic Neoplasms 21224848 The ZEB1/miR-200 feedback loop controls Notch signalling in cancer cells. +target gene hsa-mir-200c Breast Neoplasms 21224848 The ZEB1/miR-200 feedback loop controls Notch signalling in cancer cells. +target gene hsa-mir-200c Pancreatic Neoplasms 21224848 The ZEB1/miR-200 feedback loop controls Notch signalling in cancer cells. +target gene hsa-mir-9-1 Gastric Neoplasms 21225631 MiR-9 down-regulates CDX2 expression in gastric cancer cells. +target gene hsa-mir-9-2 Gastric Neoplasms 21225631 MiR-9 down-regulates CDX2 expression in gastric cancer cells. +target gene hsa-mir-9-3 Gastric Neoplasms 21225631 MiR-9 down-regulates CDX2 expression in gastric cancer cells. +target gene hsa-mir-340 Breast Neoplasms 21225860 miR-340 inhibition of breast cancer cell migration and invasion through targeting of oncoprotein c-Met +target gene hsa-mir-885 Neuroblastoma 21233845 "MicroRNA miR-885-5p targets CDK2 and MCM5, activates p53 and inhibits proliferation and survival." +target gene hsa-mir-155 Preeclampsia 21234519 microRNA-155 regulates angiotensin II type 1 receptor expression in umbilical vein endothelial cells from severely pre-eclamptic pregnant women. +target gene hsa-mir-146a Atherosclerosis 21236257 Our study clearly revealed that miRNA-146a regulates the maturation process and pro-inflammatory cytokine secretion in DCs by targeting CD40L in ox-LDL-stimulated DCs. +target gene hsa-mir-34a Prostate Neoplasms 21240262 The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. +target gene hsa-mir-20a Colorectal Carcinoma 21242194 miR-20a targets BNIP2 and contributes chemotherapeutic resistance in colorectal adenocarcinoma SW480 and SW620 cell lines. +target gene hsa-mir-126 Breast Neoplasms 21249429 Endothelial-specific intron-derived miR-126 is down-regulated in human breast cancer and targets both VEGFA and PIK3R2. +target gene hsa-mir-485 Leukemia 21252292 Novel regulation of NF-YB by miR-485-3p affects expression of DNA topoisomerase II{alpha} and drug responsiveness in human lymphoblastic leukemia CEM cells. +target gene hsa-mir-145 Prostate Neoplasms 21258769 "Restoration of miR-145 expression suppresses cell proliferation, migration and invasion in prostate cancer by targeting FSCN1." +target gene hsa-mir-497 Gastrointestinal Neoplasms 21258880 miR-497 modulates multidrug resistance of human cancer cell lines by targeting BCL2. +target gene hsa-mir-497 Lung Neoplasms 21258880 miR-497 modulates multidrug resistance of human cancer cell lines by targeting BCL2. +target gene hsa-mir-26b Glioma 21264258 "This study demonstrated that miR-26b may act as a tumor suppressor in glioma and it directly regulates EphA2 expression. EphA2 is a direct target of miR-26b, and the down-regulation of EphA2 mediated by miR-26b is dependent on the binding of miR-26b to a" +target gene hsa-mir-107 Gastrointestinal Neoplasms 21264532 "miR-107 targets cyclin-dependent kinase 6 expression, induces cell cycle G1 arrest and inhibits invasion in gastric cancer cells." +target gene hsa-mir-101-1 "Carcinoma, Lung, Non-Small-Cell" 21270667 MicroRNA-101 Exerts Tumor-Suppressive Functions in Non-small Cell Lung Cancer through Directly Targeting Enhancer of Zeste Homolog 2. +target gene hsa-mir-101-2 "Carcinoma, Lung, Non-Small-Cell" 21270667 MicroRNA-101 Exerts Tumor-Suppressive Functions in Non-small Cell Lung Cancer through Directly Targeting Enhancer of Zeste Homolog 2. +target gene hsa-mir-19a Esophageal Neoplasms 21271217 TNF-alpha is a novel target of miR-19a. +target gene hsa-mir-381 Systemic Mastocytosis 21273305 We found that miR-539 and miR-381 are downregulated by KIT signaling and they repressed MITF expression through conserved miRNA binding sites in the MITF 3' UTR. +target gene hsa-mir-539 Systemic Mastocytosis 21273305 We found that miR-539 and miR-381 are downregulated by KIT signaling and they repressed MITF expression through conserved miRNA binding sites in the MITF 3' UTR. +target gene hsa-mir-29a Inflammation 21276447 microRNA-29a could regulate pro-inflammatory cytokine secretion and scavenger receptor expression by targeting lipoprotein lipase in oxLDL-stimulated dendritic cells. +target gene hsa-mir-221 Colorectal Carcinoma 21278784 MicroRNA-221 inhibits CDKN1C/p57 expression in human colorectal carcinoma. +target gene hsa-mir-21 Glioma 21278789 Downregulation of Spry2 by miR-21 triggers malignancy in human gliomas. +target gene hsa-mir-137 Melanoma 21278922 MicroRNA-137 Targets Carboxyl-terminal Binding Protein 1 in Melanoma Cell Lines. +target gene hsa-mir-145 Lung Neoplasms 21289483 MiR-145 inhibits cell proliferation of human lung adenocarcinoma by targeting EGFR and NUDT1. +target gene hsa-mir-141 Esophageal Neoplasms 21289630 MicroRNA-141 confers resistance to cisplatin-induced apoptosis by targeting YAP1 in human esophageal squamous cell carcinoma. +target gene hsa-mir-101 Glioblastoma 21297974 Down-regulation of miR-101 in endothelial cells promotes blood vessel formation through reduced repression of EZH2. +target gene hsa-mir-203 Esophageal Neoplasms 21299870 MicroRNA-203 inhibits cell proliferation by repressing DeltaNp63 expression in human esophageal squamous cell carcinoma. +target gene hsa-mir-203 "Squamous Cell Carcinoma, Esophageal" 21299870 MicroRNA-203 inhibits cell proliferation by repressing DeltaNp63 expression in human esophageal squamous cell carcinoma. +target gene hsa-mir-1-1 Urinary Bladder Cancer 21304530 The tumour-suppressive function of miR-1 and miR-133a targeting TAGLN2 in bladder cancer. +target gene hsa-mir-1-2 Urinary Bladder Cancer 21304530 The tumour-suppressive function of miR-1 and miR-133a targeting TAGLN2 in bladder cancer. +target gene hsa-mir-133a-1 Urinary Bladder Cancer 21304530 The tumour-suppressive function of miR-1 and miR-133a targeting TAGLN2 in bladder cancer. +target gene hsa-mir-133a-2 Urinary Bladder Cancer 21304530 The tumour-suppressive function of miR-1 and miR-133a targeting TAGLN2 in bladder cancer. +target gene hsa-mir-126 Gastrointestinal Neoplasms 21304604 "miR-126 is a novel miRNA that targets SOX2, and PLAC1 may be a novel downstream target gene of SOX2 in gastric cancer cells. These findings suggest that aberrant over-expression of miR-126 and consequent SOX2 down-regulation may contribute to gastric carc" +target gene hsa-mir-125b-1 Prostate Neoplasms 21308711 "miR-125b suppresses MUC1 translation in LNCaP cells and that an anti-sense miR-125b upregulates expression of MUC1 protein. In addition, stable expression of miR-125b in DU145 cells resulted in decreases in MUC1 levels." +target gene hsa-mir-125b-2 Prostate Neoplasms 21308711 "miR-125b suppresses MUC1 translation in LNCaP cells and that an anti-sense miR-125b upregulates expression of MUC1 protein. In addition, stable expression of miR-125b in DU145 cells resulted in decreases in MUC1 levels." +target gene hsa-mir-155 Inflammation 21310411 "HUVECs highly expressed miR-155 may co-target AT1R and Ets-1 while miR-221/222 targets Ets-1, which indirectly regulate the expression of several inflammatory molecules of ECs, and therefore attenuate the adhesion of Jurkat T cells to activated HUVECs and" +target gene hsa-mir-221 Inflammation 21310411 "HUVECs highly expressed miR-155 may co-target AT1R and Ets-1 while miR-221/222 targets Ets-1, which indirectly regulate the expression of several inflammatory molecules of ECs, and therefore attenuate the adhesion of Jurkat T cells to activated HUVECs and" +target gene hsa-mir-222 Inflammation 21310411 "HUVECs highly expressed miR-155 may co-target AT1R and Ets-1 while miR-221/222 targets Ets-1, which indirectly regulate the expression of several inflammatory molecules of ECs, and therefore attenuate the adhesion of Jurkat T cells to activated HUVECs and" +target gene hsa-mir-29c Diabetes Mellitus 21310958 "MicroRNA-29c is a signature MicroRNA under high glucose conditions which targets sprouty homolog 1, and its in vivo knockdown prevents progression of diabetic nephropathy." +target gene hsa-mir-21 Prostate Neoplasms 21317927 MicroRNA-21 targets tumor suppressor genes ANP32A and SMARCA4 +target gene hsa-mir-21 Neoplasms [unspecific] 21328460 miR-21 downregulates the tumor suppressor P12(CDK2AP1) and Stimulates Cell Proliferation and Invasion. +target gene hsa-mir-132 Pancreatic Neoplasms 21329664 "miR-132 and miR-212 are increased in pancreatic cancer and target the retinoblastoma tumor suppressor, rb1." +target gene hsa-mir-212 Pancreatic Neoplasms 21329664 miR-132 and miR-212 are increased in pancreatic cancer and target the retinoblastoma tumor suppressor. +target gene hsa-mir-34b Colorectal Carcinoma 21329882 "MK5 regulates translation of Myc, since it is required for expression of miR-34b and miR-34c that bind to the 3'UTR of MYC. MK5 activates miR-34b/c expression via phosphorylation of FoxO3a, thereby promoting nuclear localization of FoxO3a and enabling it" +target gene hsa-mir-34c Colorectal Carcinoma 21329882 "MK5 regulates translation of Myc, since it is required for expression of miR-34b and miR-34c that bind to the 3'UTR of MYC. MK5 activates miR-34b/c expression via phosphorylation of FoxO3a, thereby promoting nuclear localization of FoxO3a and enabling it" +target gene hsa-mir-520b Breast Neoplasms 21343296 miR-520b regulates migration of breast cancer cells through targeting hepatitis B X-interacting protein and interleukin-8. +target gene hsa-mir-135b Prostate Neoplasms 21343391 "3'UTR-binding assays validated 13 miRNAs that are able to regulate this long AR 3'UTR (miR-135b, miR-185, miR-297, miR-299-3p, miR-34a, miR-34c, miR-371-3p, miR-421, miR-449a, miR-449b, miR-634, miR-654-5p, and miR-9)." +target gene hsa-mir-127 Breast Neoplasms 21343399 "Analyses of miRNA expression profiles identified numerous miRNAs implicated in cell proliferation including miR-127, -197, -222, and -223 targeting CXCL12." +target gene hsa-let-7a-1 Gastrointestinal Neoplasms 21349817 let-7a is significant in suppressing gastric cancer growth in vivo and in vitro and provided the first evidence that RAB40C is negatively regulated by let-7a at the post-transcriptional level via binding to the 3'-untranslated region of RAB40C mRNA in gas +target gene hsa-let-7a-2 Gastrointestinal Neoplasms 21349817 let-7a is significant in suppressing gastric cancer growth in vivo and in vitro and provided the first evidence that RAB40C is negatively regulated by let-7a at the post-transcriptional level via binding to the 3'-untranslated region of RAB40C mRNA in gas +target gene hsa-let-7a-3 Gastrointestinal Neoplasms 21349817 let-7a is significant in suppressing gastric cancer growth in vivo and in vitro and provided the first evidence that RAB40C is negatively regulated by let-7a at the post-transcriptional level via binding to the 3'-untranslated region of RAB40C mRNA in gas +target gene hsa-mir-133a-1 "Squamous Cell Carcinoma, Esophageal" 21351259 "miR-145, miR-133a and miR-133b: Tumor-suppressive miRNAs target FSCN1 in esophageal squamous cell carcinoma." +target gene hsa-mir-133a-2 "Squamous Cell Carcinoma, Esophageal" 21351259 "miR-145, miR-133a and miR-133b: Tumor-suppressive miRNAs target FSCN1 in esophageal squamous cell carcinoma." +target gene hsa-mir-133b "Squamous Cell Carcinoma, Esophageal" 21351259 "miR-145, miR-133a and miR-133b: Tumor-suppressive miRNAs target FSCN1 in esophageal squamous cell carcinoma." +target gene hsa-mir-145 "Squamous Cell Carcinoma, Esophageal" 21351259 "miR-145, miR-133a and miR-133b: Tumor-suppressive miRNAs target FSCN1 in esophageal squamous cell carcinoma." +target gene hsa-mir-451a "Carcinoma, Lung, Non-Small-Cell" 21358675 MicroRNA-451 functions as a tumor suppressor in human non-small cell lung cancer by targeting ras-related protein 14 (RAB14). +target gene hsa-mir-16-1 Laryngeal Neoplasms 21360639 MicroRNA-16 targets zyxin and promotes cell motility in human laryngeal carcinoma cell line HEp-2. +target gene hsa-mir-16-2 Laryngeal Neoplasms 21360639 MicroRNA-16 targets zyxin and promotes cell motility in human laryngeal carcinoma cell line HEp-2. +target gene hsa-mir-145 "Adenocarcinoma, Endometrial" 21365617 Up-regulation of microRNA-145 promotes differentiation by repressing OCT4 in human endometrial adenocarcinoma cells. +target gene hsa-mir-34a Leukemia 21367750 miR-34a induces the down-regulation of both E2F1 and B-Myb oncogenes in leukemic cells. +target gene hsa-mir-101-1 Nasopharyngeal Neoplasms 21368858 "Enhancer of Zeste homolog 2 (EZH2) is overexpressed in recurrent nasopharyngeal carcinoma and is regulated by miR-26a, miR-101, and miR-98." +target gene hsa-mir-101-2 Nasopharyngeal Neoplasms 21368858 "Enhancer of Zeste homolog 2 (EZH2) is overexpressed in recurrent nasopharyngeal carcinoma and is regulated by miR-26a, miR-101, and miR-98." +target gene hsa-mir-26a-1 Nasopharyngeal Neoplasms 21368858 "Enhancer of Zeste homolog 2 (EZH2) is overexpressed in recurrent nasopharyngeal carcinoma and is regulated by miR-26a, miR-101, and miR-98." +target gene hsa-mir-26a-2 Nasopharyngeal Neoplasms 21368858 "Enhancer of Zeste homolog 2 (EZH2) is overexpressed in recurrent nasopharyngeal carcinoma and is regulated by miR-26a, miR-101, and miR-98." +target gene hsa-mir-98 Nasopharyngeal Neoplasms 21368858 "Enhancer of Zeste homolog 2 (EZH2) is overexpressed in recurrent nasopharyngeal carcinoma and is regulated by miR-26a, miR-101, and miR-98." +target gene hsa-mir-21 Pancreatic Neoplasms 21376256 Bcl-2 Upregulation Induced by miR-21 Via a Direct Interaction Is Associated with Apoptosis and Chemoresistance in MIA PaCa-2 Pancreatic Cancer Cells. +target gene hsa-mir-1-1 Head And Neck Neoplasms 21378409 miR-1 as a tumor suppressive microRNA targeting TAGLN2 in head and neck squamous cell carcinoma. +target gene hsa-mir-1-1 "Squamous Cell Carcinoma, Head and Neck" 21378409 miR-1 as a tumor suppressive microRNA targeting TAGLN2 in head and neck squamous cell carcinoma. +target gene hsa-mir-1-2 Head And Neck Neoplasms 21378409 miR-1 as a tumor suppressive microRNA targeting TAGLN2 in head and neck squamous cell carcinoma. +target gene hsa-mir-1-2 "Squamous Cell Carcinoma, Head and Neck" 21378409 miR-1 as a tumor suppressive microRNA targeting TAGLN2 in head and neck squamous cell carcinoma. +target gene hsa-mir-9-1 Glioblastoma 21385897 miR-9 suppresses mesenchymal differentiation in glioblastoma by downregulating expression of JAK kinases and inhibiting activation of STAT3. +target gene hsa-mir-9-2 Glioblastoma 21385897 miR-9 suppresses mesenchymal differentiation in glioblastoma by downregulating expression of JAK kinases and inhibiting activation of STAT3. +target gene hsa-mir-9-3 Glioblastoma 21385897 miR-9 suppresses mesenchymal differentiation in glioblastoma by downregulating expression of JAK kinases and inhibiting activation of STAT3. +target gene hsa-mir-218-1 Nasopharyngeal Neoplasms 21385904 miR-218 Suppresses Nasopharyngeal Cancer Progression through Downregulation of Survivin and the SLIT2-ROBO1 Pathway. +target gene hsa-mir-218-2 Nasopharyngeal Neoplasms 21385904 miR-218 Suppresses Nasopharyngeal Cancer Progression through Downregulation of Survivin and the SLIT2-ROBO1 Pathway. +target gene hsa-mir-133a-1 Urinary Bladder Cancer 21396852 MiR-133a induces apoptosis through direct regulation of GSTP1 in bladder cancer cell lines. +target gene hsa-mir-204 Endometrial Neoplasms 21400511 Dysregulation of microRNA-204 mediates migration and invasion of endometrial cancer by regulating FOXC1. +target gene hsa-mir-125b-1 Psoriasis 21412257 "MiR-125b, a MicroRNA Downregulated in Psoriasis, Modulates Keratinocyte Proliferation by Targeting FGFR2." +target gene hsa-mir-125b-2 Psoriasis 21412257 "MiR-125b, a MicroRNA Downregulated in Psoriasis, Modulates Keratinocyte Proliferation by Targeting FGFR2." +target gene hsa-mir-204 Gastric Neoplasms 21416062 "MiR-204, which was predicted to target ezrin, was downregulated in gastric cancer cells and gastric carcinomas. MiR-204 inhibited ezrin expression, Ras activation, cell growth and cell migration" +target gene hsa-mir-10b Glioblastoma 21419107 MicroRNA-10b induces glioma cell invasion by modulating MMP-14 and uPAR expression via HOXD10. +target gene hsa-mir-205 Esophageal Neoplasms 21426561 MiRNA-205 modulates cellular invasion and migration via regulating zinc finger E-box binding homeobox 2 expression in esophageal squamous cell carcinoma cells. +target gene hsa-mir-205 "Squamous Cell Carcinoma, Esophageal" 21426561 MiRNA-205 modulates cellular invasion and migration via regulating zinc finger E-box binding homeobox 2 expression in esophageal squamous cell carcinoma cells. +target gene hsa-mir-95 Colorectal Carcinoma 21427358 MicroRNA-95 Promotes Cell Proliferation and Targets Sorting Nexin 1 in Human Colorectal Carcinoma. +target gene hsa-mir-126 "Carcinoma, Lung, Non-Small-Cell" 21439283 miR-126 inhibits proliferation of small cell lung cancer cells by targeting SLC7A5. +target gene hsa-mir-125b-1 Breast Neoplasms 21444677 miR-125b is Methylated and Functions as A Tumor Suppressor by Regulating the ETS1 proto-oncogene in Human Invasive Breast Cancer. +target gene hsa-mir-125b-2 Breast Neoplasms 21444677 miR-125b is Methylated and Functions as A Tumor Suppressor by Regulating the ETS1 proto-oncogene in Human Invasive Breast Cancer. +target gene hsa-mir-204 Prostate Neoplasms 21446014 "PDEF expression is regulated via a functional microRNA-204 (miR-204) binding site within the 3'UTR. Furthermore, we demonstrate the biologic significance of miR-204 expression and that miR-204 is over-expressed in human prostate cancer specimens." +target gene hsa-mir-205 Melanoma 21454583 miR-205 suppresses melanoma cell proliferation and induces senescence via regulation of E2F1. +target gene hsa-mir-7-1 Neurofibromatosis type 2 21454924 "We found that miR-7 functions as a tumor suppressor by targeting proteins in three major oncogenic pathways - EGFR, Pak1, and Ack1." +target gene hsa-mir-7-2 Neurofibromatosis type 2 21454924 "We found that miR-7 functions as a tumor suppressor by targeting proteins in three major oncogenic pathways - EGFR, Pak1, and Ack1." +target gene hsa-mir-7-3 Neurofibromatosis type 2 21454924 "We found that miR-7 functions as a tumor suppressor by targeting proteins in three major oncogenic pathways - EGFR, Pak1, and Ack1." +target gene hsa-mir-148a Colorectal Carcinoma 21455217 MiR-148a promotes apoptosis by targeting Bcl-2 in colorectal cancer. +target gene hsa-mir-24-2 Breast Neoplasms 21463514 miR-24-2 controls H2AFX expression regardless of gene copy number alteration and induces apoptosis by targeting anti-apoptotic gene BCL-2: a potential for therapeutic intervention. +target gene hsa-let-7g Lung Neoplasms 21464588 miR-9 and let-7g enhance the sensitivity to ionizing radiation by suppression of NFKB1. +target gene hsa-mir-9-1 Lung Neoplasms 21464588 miR-9 and let-7g enhance the sensitivity to ionizing radiation by suppression of NFKB1. +target gene hsa-mir-9-2 Lung Neoplasms 21464588 miR-9 and let-7g enhance the sensitivity to ionizing radiation by suppression of NFKB1. +target gene hsa-mir-9-3 Lung Neoplasms 21464588 miR-9 and let-7g enhance the sensitivity to ionizing radiation by suppression of NFKB1. +target gene hsa-mir-155 Melanoma 21466664 MicroRNA-155 Targets the SKI Gene in Human Melanoma Cell Lines +target gene hsa-mir-214 Melanoma 21468029 miR-214 is highly expressed in human melanomas and contributes to melanoma tumour progression through suppression of TFAP2C +target gene hsa-mir-100 Endometrial Neoplasms 21472251 "hsa-mir-100 and hsa-miR-99a were predicted to target ESR1, and hsa-miR-378 and hsa-miR-768-3p to target PGR. Hsa-miR-100 was significantly down-regulated in the estrogen-dependent endometrial cancer samples as compared to the estrogen-independent samples and thus has the potential to target ESR1." +target gene hsa-mir-378a Endometrial Neoplasms 21472251 "hsa-mir-100 and hsa-miR-99a were predicted to target ESR1, and hsa-miR-378 and hsa-miR-768-3p to target PGR. Hsa-miR-100 was significantly down-regulated in the estrogen-dependent endometrial cancer samples as compared to the estrogen-independent samples and thus has the potential to target ESR1." +target gene hsa-mir-99a Endometrial Neoplasms 21472251 "hsa-mir-100 and hsa-miR-99a were predicted to target ESR1, and hsa-miR-378 and hsa-miR-768-3p to target PGR. Hsa-miR-100 was significantly down-regulated in the estrogen-dependent endometrial cancer samples as compared to the estrogen-independent samples and thus has the potential to target ESR1." +target gene hsa-mir-145 Lung Neoplasms 21479367 microRNA-145 suppresses lung adenocarcinoma-initiating cell proliferation by targeting OCT4. +target gene hsa-mir-373 "Carcinoma, Hepatocellular" 21481188 miR-373 can regulate cell cycle progression by targeting PPP6C transcripts and promotes the growth activity of hepatocellular carcinoma cells in vitro. This miRNA functions as an oncogene in hepatocellular carcinoma. +target gene hsa-mir-142 "Carcinoma, Hepatocellular" 21482222 "MicroRNA-142-3p, a new regulator of RAC1, suppresses the migration and invasion of hepatocellular carcinoma cells." +target gene hsa-mir-221 Prostate Neoplasms 21487968 MiR-221 expression affects invasion potential of human prostate carcinoma cell lines by targeting DVL2. +target gene hsa-mir-223 "Carcinoma, Hepatocellular" 21492514 microRNA-223 and its target gene oncogene c-myc have roles in hepatocellular carcinoma pathogenesis. +target gene hsa-mir-145 Lung Neoplasms 21496429 miR-145 Inhibits Lung Adenocarcinoma Stem Cells Proliferation by Targeting OCT4 Gene. +target gene hsa-mir-18a Heart Failure 21501375 MicroRNA-18 and microRNA-19 regulate CTGF and TSP-1 expression in age-related heart failure. +target gene hsa-mir-18b Heart Failure 21501375 MicroRNA-18 and microRNA-19 regulate CTGF and TSP-1 expression in age-related heart failure. +target gene hsa-mir-19a Heart Failure 21501375 MicroRNA-18 and microRNA-19 regulate CTGF and TSP-1 expression in age-related heart failure. +target gene hsa-mir-19b-1 Heart Failure 21501375 MicroRNA-18 and microRNA-19 regulate CTGF and TSP-1 expression in age-related heart failure. +target gene hsa-mir-19b-2 Heart Failure 21501375 MicroRNA-18 and microRNA-19 regulate CTGF and TSP-1 expression in age-related heart failure. +target gene hsa-mir-26b Breast Neoplasms 21510944 MicroRNA-26b is underexpressed in human breast cancer and induces cell apoptosis by targeting SLC7A11. +target gene hsa-mir-143 Leukemia 21518477 "the expression of miR-143 was negatively correlated with the expression of DNMT3A mRNA, a known target gene of miR-143." +target gene hsa-mir-519d "Carcinoma, Hepatocellular" 21524841 MicroRNA-519d targets MKi67 and suppresses cell growth in the hepatocellular carcinoma cell line QGY-7703. +target gene hsa-mir-622 Gastric Neoplasms 21528065 Down-regulation of miR-622 in gastric cancer promotes cellular invasion and tumor metastasis by targeting ING1 gene. +target gene hsa-mir-200a Ovarian Neoplasms 21529905 MicroRNA-200a inhibits CD133/1+ ovarian cancer stem cells migration and invasion by targeting E-cadherin repressor ZEB2. +target gene hsa-mir-9-1 Glioblastoma 21531766 ID4 Imparts Chemoresistance and Cancer Stemness to Glioma Cells by Derepressing miR-9*-Mediated Suppression of SOX2. +target gene hsa-mir-9-2 Glioblastoma 21531766 ID4 Imparts Chemoresistance and Cancer Stemness to Glioma Cells by Derepressing miR-9*-Mediated Suppression of SOX2. +target gene hsa-mir-9-3 Glioblastoma 21531766 ID4 Imparts Chemoresistance and Cancer Stemness to Glioma Cells by Derepressing miR-9*-Mediated Suppression of SOX2. +target gene hsa-mir-101-1 "Squamous Cell Carcinoma, Head and Neck" 21532618 The tumor suppressor gene rap1GAP is silenced by miR-101-mediated EZH2 overexpression in invasive squamous cell carcinoma. +target gene hsa-mir-101-2 "Squamous Cell Carcinoma, Head and Neck" 21532618 The tumor suppressor gene rap1GAP is silenced by miR-101-mediated EZH2 overexpression in invasive squamous cell carcinoma. +target gene hsa-let-7f-1 Gastric Neoplasms 21533124 MicroRNA Let-7f Inhibits Tumor Invasion and Metastasis by Targeting MYH9 in Human Gastric Cancer. +target gene hsa-let-7f-2 Gastric Neoplasms 21533124 MicroRNA Let-7f Inhibits Tumor Invasion and Metastasis by Targeting MYH9 in Human Gastric Cancer. +target gene hsa-mir-221 Colorectal Carcinoma 21538272 MicroRNA-221 controls CDKN1C/P57 expression in human colorectal carcinoma +target gene hsa-mir-379 "Carcinoma, Hepatocellular" 21540293 Down-regulation of ABCC2 protein expression in HepG2 cells after rifampicin treatment is mediated by microRNA-379. +target gene hsa-mir-21 Colorectal Carcinoma 21546206 "This study demonstrates the inverse relationship between miR-21 and PDCD4, thus suggesting that miR-21 post-transcriptionally modulates PDCD4 via mRNA degradation. Pharmacological manipulation of the miR-21/PDCD4 axis could represent a novel therapeutic strategy in the treatment of colorectal cancer." +target gene hsa-mir-29c Esophageal Neoplasms 21551130 miR-29c induces cell cycle arrest in Esophageal Squamous Cell Carcinoma by modulating Cyclin E expression. +target gene hsa-mir-29c "Squamous Cell Carcinoma, Esophageal" 21551130 miR-29c induces cell cycle arrest in Esophageal Squamous Cell Carcinoma by modulating Cyclin E expression. +target gene hsa-mir-148a Gastric Neoplasms 21552422 miR-148a Promoted Cell Proliferation by Targeting p27 in Gastric Cancer Cells. +target gene hsa-mir-375 Gastrointestinal Neoplasms 21557705 "The genes targeted by miR-375, including JAK2 and 3'-phosphoinositide dependent protein kinase-1(PDK1), are also candidates for gastric cancer therapy" +target gene hsa-mir-146a Sepsis 21562054 MicroRNA-146a regulates both transcription silencing and translation disruption of TNF-¦Á during TLR4-induced gene reprogramming. +target gene hsa-mir-342 Colorectal Carcinoma 21565830 MicroRNA-342 Inhibits Colorectal Cancer Cell Proliferation and Invasion by Directly Targeting DNA Methyltransferase 1. +target gene hsa-mir-34a "Leukemia, Lymphocytic, Chronic, B-Cell" 21565980 Nicotinamide blocks proliferation and induces apoptosis of chronic lymphocytic leukemia cells through activation of the p53/miR-34a/SIRT1 tumor suppressor network. +target gene hsa-mir-29a "Carcinoma, Hepatocellular" 21573166 Upregulated MicroRNA-29a by Hepatitis B Virus X Protein Enhances Hepatoma Cell Migration by Targeting PTEN in Cell Culture Model. +target gene hsa-mir-150 Inflammatory Bowel Diseases 21590770 "Together, the present study presents the first evidence that miR-150 and its targeting of c-Myb may serve as a new mechanism underlying the colonic epithelial disruption in DSS-induced murine experimental colitis and in active human IBD." +target gene hsa-mir-375 Prostate Neoplasms 21593139 miRNA-375 Downregulated Sec23A protein in prostate carcinoma. +target gene hsa-mir-22 Colorectal Carcinoma 21594648 Overexpression of miR-22 reverses paclitaxel-induced chemoresistance through activation of PTEN signaling in p53-mutated colon cancer cells. +target gene hsa-let-7a Esophageal Neoplasms 21600139 "Eighteen miRNAs had their target genes, 10 of them had the potential to individually target up to 200 mRNAs. Hsa-let-7a, hsa-miR-185, hsa-miR-141, hsa-miR-92b, hsa-miR-22 and hsa-miR-301a were known as important genes associated with radioresistance." +target gene hsa-mir-141 Esophageal Neoplasms 21600139 "Eighteen miRNAs had their target genes, 10 of them had the potential to individually target up to 200 mRNAs. Hsa-let-7a, hsa-miR-185, hsa-miR-141, hsa-miR-92b, hsa-miR-22 and hsa-miR-301a were known as important genes associated with radioresistance." +target gene hsa-mir-185 Esophageal Neoplasms 21600139 "Eighteen miRNAs had their target genes, 10 of them had the potential to individually target up to 200 mRNAs. Hsa-let-7a, hsa-miR-185, hsa-miR-141, hsa-miR-92b, hsa-miR-22 and hsa-miR-301a were known as important genes associated with radioresistance." +target gene hsa-mir-22 Esophageal Neoplasms 21600139 "Eighteen miRNAs had their target genes, 10 of them had the potential to individually target up to 200 mRNAs. Hsa-let-7a, hsa-miR-185, hsa-miR-141, hsa-miR-92b, hsa-miR-22 and hsa-miR-301a were known as important genes associated with radioresistance." +target gene hsa-mir-301a Esophageal Neoplasms 21600139 "Eighteen miRNAs had their target genes, 10 of them had the potential to individually target up to 200 mRNAs. Hsa-let-7a, hsa-miR-185, hsa-miR-141, hsa-miR-92b, hsa-miR-22 and hsa-miR-301a were known as important genes associated with radioresistance." +target gene hsa-mir-92b Esophageal Neoplasms 21600139 "Eighteen miRNAs had their target genes, 10 of them had the potential to individually target up to 200 mRNAs. Hsa-let-7a, hsa-miR-185, hsa-miR-141, hsa-miR-92b, hsa-miR-22 and hsa-miR-301a were known as important genes associated with radioresistance." +target gene hsa-mir-21 Systemic Lupus Erythematosus 21602271 miR-21 regulates aberrant T cell responses through regulation of PDCD4 expression.Upregulated miR-21 affects PDCD4 expression and regulates aberrant T cell responses in human SLE. +target gene hsa-mir-372 Hepatitis B Virus Infection 21608007 MicroRNAs-372/373 promote the expression of hepatitis B Virus through the targeting of nuclear factor I/B. +target gene hsa-mir-373 Hepatitis B Virus Infection 21608007 MicroRNAs-372/373 promote the expression of hepatitis B Virus through the targeting of nuclear factor I/B. +target gene hsa-mir-146a Lymphoma 21610143 "MicroRNA-146a downregulates NF{kappa}B activity via targeting TRAF6, and functions as a tumor suppressor having strong prognostic implications in NK/T cell lymphoma." +target gene hsa-let-7a-1 Inflammation 21616524 Let-7 microRNAs inhibit IL-13 expression and represent a major regulatory mechanism for modulating IL-13 secretion in IL-13-producing cell types and thereby T(H)2 inflammation. +target gene hsa-let-7a-2 Inflammation 21616524 Let-7 microRNAs inhibit IL-13 expression and represent a major regulatory mechanism for modulating IL-13 secretion in IL-13-producing cell types and thereby T(H)2 inflammation. +target gene hsa-let-7a-3 Inflammation 21616524 Let-7 microRNAs inhibit IL-13 expression and represent a major regulatory mechanism for modulating IL-13 secretion in IL-13-producing cell types and thereby T(H)2 inflammation. +target gene hsa-let-7b Inflammation 21616524 Let-7 microRNAs inhibit IL-13 expression and represent a major regulatory mechanism for modulating IL-13 secretion in IL-13-producing cell types and thereby T(H)2 inflammation. +target gene hsa-let-7c Inflammation 21616524 Let-7 microRNAs inhibit IL-13 expression and represent a major regulatory mechanism for modulating IL-13 secretion in IL-13-producing cell types and thereby T(H)2 inflammation. +target gene hsa-let-7d Inflammation 21616524 Let-7 microRNAs inhibit IL-13 expression and represent a major regulatory mechanism for modulating IL-13 secretion in IL-13-producing cell types and thereby T(H)2 inflammation. +target gene hsa-let-7e Inflammation 21616524 Let-7 microRNAs inhibit IL-13 expression and represent a major regulatory mechanism for modulating IL-13 secretion in IL-13-producing cell types and thereby T(H)2 inflammation. +target gene hsa-let-7f-1 Inflammation 21616524 Let-7 microRNAs inhibit IL-13 expression and represent a major regulatory mechanism for modulating IL-13 secretion in IL-13-producing cell types and thereby T(H)2 inflammation. +target gene hsa-let-7f-2 Inflammation 21616524 Let-7 microRNAs inhibit IL-13 expression and represent a major regulatory mechanism for modulating IL-13 secretion in IL-13-producing cell types and thereby T(H)2 inflammation. +target gene hsa-let-7g Inflammation 21616524 Let-7 microRNAs inhibit IL-13 expression and represent a major regulatory mechanism for modulating IL-13 secretion in IL-13-producing cell types and thereby T(H)2 inflammation. +target gene hsa-let-7i Inflammation 21616524 Let-7 microRNAs inhibit IL-13 expression and represent a major regulatory mechanism for modulating IL-13 secretion in IL-13-producing cell types and thereby T(H)2 inflammation. +target gene hsa-mir-335 Breast Neoplasms 21618216 "Breast miR-335 regulates the known BRCA1 activators ER§Ø©ã IGF1R, SP1 and the repressor ID4, including a feedback regulation of miR-335 expression by estrogens. Overexpression of miR-335 resulted in an upregulation of BRCA1 mRNA expression.miR-335 affects different targets in the upstream BRCA1-regulatory cascade with impact on key cellular functions such as proliferation and apoptosis." +target gene hsa-mir-195 Cardiovascular Diseases [unspecific] 21622680 MicroRNA-195 promotes palmitate-induced apoptosis in cardiomyocytes by down-regulating Sirt1. +target gene hsa-mir-143 Pancreatic Neoplasms 21622730 "Two miRNA candidates known to be downregulated in the majority of pancreatic cancers were selected for nanovector delivery: miR-34a, which is a component of the p53 transcriptional network and regulates cancer stem cell survival, and the miR-143/145 cluster, which together repress the expression of KRAS2 and its downstream effector Ras-responsive element binding protein-1 (RREB1)." +target gene hsa-mir-145 Pancreatic Neoplasms 21622730 "Two miRNA candidates known to be downregulated in the majority of pancreatic cancers were selected for nanovector delivery: miR-34a, which is a component of the p53 transcriptional network and regulates cancer stem cell survival, and the miR-143/145 cluster, which together repress the expression of KRAS2 and its downstream effector Ras-responsive element binding protein-1 (RREB1)." +target gene hsa-mir-29a "Carcinoma, Hepatocellular" 21625215 microRNA-29 can regulate expression of the long non-coding RNA gene MEG3 in hepatocellular cancer. +target gene hsa-mir-29b-1 "Carcinoma, Hepatocellular" 21625215 microRNA-29 can regulate expression of the long non-coding RNA gene MEG3 in hepatocellular cancer. +target gene hsa-mir-29b-2 "Carcinoma, Hepatocellular" 21625215 microRNA-29 can regulate expression of the long non-coding RNA gene MEG3 in hepatocellular cancer. +target gene hsa-mir-29c "Carcinoma, Hepatocellular" 21625215 microRNA-29 can regulate expression of the long non-coding RNA gene MEG3 in hepatocellular cancer. +target gene hsa-mir-223 Gastric Neoplasms 21628394 miRNA-223 Promotes Gastric Cancer Invasion and Metastasis by Targeting Tumor Suppressor EPB41L3. +target gene hsa-mir-100 Breast Neoplasms 21634028 micro-RNA 100 Regulated beta-tubulin isotypes in MCF7 breast cancer cells. +target gene hsa-mir-100 Urinary Bladder Cancer 21636267 Reduced expression and had carcinogenic effect through targeting PLK1 protein. +target gene hsa-mir-21 Glioblastoma 21636706 Downregulation of Pdcd4 by mir-21 facilitates glioblastoma proliferation in vivo. +target gene hsa-mir-21 Inflammation 21636785 MicroRNA-21 targets peroxisome proliferators-activated receptor-alpha in an autoregulatory loop to modulate flow-induced endothelial inflammation. +target gene hsa-mir-100 "Leukemia, Myeloid, Acute" 21643017 "MiR-100 regulates cell differentiation and survival by targeting RBSP3, a phosphatase-like tumor suppressor in acute myeloid leukemia." +target gene hsa-mir-372 Urinary Bladder Cancer 21646351 "MicroRNA-372 Is Down-regulated and Targets Cyclin-dependent Kinase 2 (CDK2) and Cyclin A1 in Human Cervical Cancer, Which May Contribute to Tumorigenesis." +target gene hsa-mir-106a Glioblastoma 21656380 MiR-106a inhibits glioma cell growth by targeting E2F1 independent of p53 status. +target gene hsa-mir-198 "Carcinoma, Hepatocellular" 21658389 miR-198 inhibits migration and invasion of hepatocellular carcinoma cells by targeting the HGF/c-MET pathway. +target gene hsa-let-7i "Carcinoma, Hepatocellular" 21665888 "In addition, we showed that HBx up-regulated CD59 by let-7i at post-transcriptional regulation level. " +target gene hsa-mir-338 "Carcinoma, Hepatocellular" 21671467 miR-338-3p suppresses invasion of liver cancer cell by targeting smoothened. +target gene hsa-mir-192 "Carcinoma, Hepatocellular" 21672525 MiR-192 inhibits nucleotide excision repair by targeting ERCC3 and ERCC4 in HepG2.2.15 cells. +target gene hsa-mir-124-1 "Carcinoma, Hepatocellular" 21672940 The putative tumour suppressor microRNA-124 modulates hepatocellular carcinoma cell aggressiveness by repressing ROCK2 and EZH2. +target gene hsa-mir-124-2 "Carcinoma, Hepatocellular" 21672940 The putative tumour suppressor microRNA-124 modulates hepatocellular carcinoma cell aggressiveness by repressing ROCK2 and EZH2. +target gene hsa-mir-124-3 "Carcinoma, Hepatocellular" 21672940 The putative tumour suppressor microRNA-124 modulates hepatocellular carcinoma cell aggressiveness by repressing ROCK2 and EZH2. +target gene hsa-mir-200c Breast Neoplasms 21682933 "Decreased expression of miRNAs of the miR-200 family has been implicated in the growth and metastasis of breast cancer cells. Of this family, miR-200c has garnered particular attention as a consequence of its ability to target ZEB1 and ZEB2, mediators of epithelial- mesenchymal transition." +target gene hsa-mir-9-1 Cardiovascular Diseases [unspecific] 21684288 MicroRNA-9 is an activation-induced regulator of PDGFR-beta expression in cardiomyocytes. +target gene hsa-mir-9-2 Cardiovascular Diseases [unspecific] 21684288 MicroRNA-9 is an activation-induced regulator of PDGFR-beta expression in cardiomyocytes. +target gene hsa-mir-9-3 Cardiovascular Diseases [unspecific] 21684288 MicroRNA-9 is an activation-induced regulator of PDGFR-beta expression in cardiomyocytes. +target gene hsa-mir-99a Psoriasis 21687694 differentially expressed. miR-99a is one of the regulators of the IGF-1R signaling pathway in keratinocytes. Activation of IGF1 signaling results in elevation of miR-99a which represses the expression of IGF-1R. +target gene hsa-mir-214 Gastric Neoplasms 21688200 Down-Regulated miRNA-214 Induces a Cell Cycle G1 Arrest in Gastric Cancer Cells by Up-Regulating the PTEN Protein. +target gene hsa-mir-340 Breast Neoplasms 21692045 miR-340 inhibites breast cancer cell migration and invasion through targeting of oncoprotein c-Met. +target gene hsa-mir-130a "Carcinoma, Lung, Non-Small-Cell" 21706050 miR-130a targets MET and induces TRAIL-sensitivity in NSCLC by downregulating miR-221 and 222. +target gene hsa-mir-221 "Carcinoma, Lung, Non-Small-Cell" 21706050 miR-130a targets MET and induces TRAIL-sensitivity in NSCLC by downregulating miR-221 and 222. +target gene hsa-mir-222 "Carcinoma, Lung, Non-Small-Cell" 21706050 miR-130a targets MET and induces TRAIL-sensitivity in NSCLC by downregulating miR-221 and 222. +target gene hsa-mir-155 Intervertebral Disc Degeneration 21706480 Deregulated miR-155 promotes Fas-mediated apoptosis in human intervertebral disc degeneration by targeting FADD and caspase-3. +target gene hsa-mir-23a Ischemia 21709246 miR-23a regulation of X-linked inhibitor of apoptosis (XIAP) contributes to sex differences in the response to cerebral ischemia. +target gene hsa-mir-148a Pancreatic Neoplasms 21709669 MicroRNA-148a is down-regulated in human pancreatic ductal adenocarcinomas and regulates cell survival by targeting CDC25B. +target gene hsa-mir-488 Prostate Neoplasms 21710544 miR 488* inhibits androgen receptor expression in prostate carcinoma cells. +target gene hsa-mir-302a Glioblastoma 21720384 The miR 302-367 cluster drastically affects self-renewal and infiltration properties of glioma-initiating cells through CXCR4 repression and consequent disruption of the SHH-GLI-NANOG network. +target gene hsa-mir-302b Glioblastoma 21720384 The miR 302-367 cluster drastically affects self-renewal and infiltration properties of glioma-initiating cells through CXCR4 repression and consequent disruption of the SHH-GLI-NANOG network. +target gene hsa-mir-302c Glioblastoma 21720384 The miR 302-367 cluster drastically affects self-renewal and infiltration properties of glioma-initiating cells through CXCR4 repression and consequent disruption of the SHH-GLI-NANOG network. +target gene hsa-mir-302d Glioblastoma 21720384 The miR 302-367 cluster drastically affects self-renewal and infiltration properties of glioma-initiating cells through CXCR4 repression and consequent disruption of the SHH-GLI-NANOG network. +target gene hsa-mir-367 Glioblastoma 21720384 The miR 302-367 cluster drastically affects self-renewal and infiltration properties of glioma-initiating cells through CXCR4 repression and consequent disruption of the SHH-GLI-NANOG network. +target gene hsa-mir-181c Alzheimer Disease 21720722 "Taken together, our study identifies putative target genes of miRNAs miR-9 and 181c, which may function in brain homeostasis and disease pathogenesis." +target gene hsa-mir-9 Alzheimer Disease 21720722 "Taken together, our study identifies putative target genes of miRNAs miR-9 and 181c, which may function in brain homeostasis and disease pathogenesis." +target gene hsa-mir-193b "Leukemia, Myeloid, Acute" 21724256 MicroRNA-193b regulates c-Kit proto-oncogene and represses cell proliferation in acute myeloid leukemia. +target gene hsa-mir-187 Ovarian Neoplasms 21725366 microRNA-187 Regulates of ovarian cancer progression through targeting Disabled homolog-2. +target gene hsa-mir-15b Tongue Neoplasms 21725369 MiR-200b and miR-15b regulate chemotherapy-induced epithelial-mesenchymal transition in human tongue cancer cells by targeting BMI1. +target gene hsa-mir-200b Tongue Neoplasms 21725369 MiR-200b and miR-15b regulate chemotherapy-induced epithelial-mesenchymal transition in human tongue cancer cells by targeting BMI1. +target gene hsa-mir-122 "Carcinoma, Hepatocellular" 21725618 miR-122 inhibits viral replication and cell proliferation in hepatitis B virus-related hepatocellular carcinoma and targets NDRG3. +target gene hsa-mir-206 Myocardial Infarction 21731608 "HMGB1 injected into chronically failing hearts enhanced LV function and attenuated LV remodelling; these effects were associated with cardiac regeneration, increased collagenolytic activity, miR-206 overexpression and miR-206 -mediated inhibition of TIMP-3." +target gene hsa-mir-10 Pancreatic Neoplasms 21738581 Predicted target mRNAs FGFR1 (miR-10) and MLH1 (miR-155) were found downregulated. +target gene hsa-mir-155 Pancreatic Neoplasms 21738581 Predicted target mRNAs FGFR1 (miR-10) and MLH1 (miR-155) were found downregulated. +target gene hsa-mir-34a Glioblastoma 21743299 MicroRNA-34a targets notch1 and inhibits cell proliferation in glioblastoma multiforme. +target gene hsa-mir-221 Glioblastoma 21743492 miR-221/222 overexpession in human glioblastoma increases invasiveness by targeting the protein phosphate PTP mu. +target gene hsa-mir-222 Glioblastoma 21743492 miR-221/222 overexpession in human glioblastoma increases invasiveness by targeting the protein phosphate PTP mu. +target gene hsa-mir-7-1 "Carcinoma, Lung, Non-Small-Cell" 21750649 MicroRNA-7 inhibits the growth of human non-small cell lung cancer A549 cells through targeting BCL-2. +target gene hsa-mir-7-2 "Carcinoma, Lung, Non-Small-Cell" 21750649 MicroRNA-7 inhibits the growth of human non-small cell lung cancer A549 cells through targeting BCL-2. +target gene hsa-mir-7-3 "Carcinoma, Lung, Non-Small-Cell" 21750649 MicroRNA-7 inhibits the growth of human non-small cell lung cancer A549 cells through targeting BCL-2. +target gene hsa-mir-1-1 Thyroid Neoplasms 21752897 "MiR-1 suppress Thyroid Cancer by Targeting CCND2, CXCR4, and SDF-1{alpha}" +target gene hsa-mir-1-2 Thyroid Neoplasms 21752897 "MiR-1 suppress Thyroid Cancer by Targeting CCND2, CXCR4, and SDF-1{alpha}" +target gene hsa-mir-375 "Squamous Cell Carcinoma, Head and Neck" 21753766 Tumor suppressive microRNA-375 regulates oncogene AEG-1/MTDH in head and neck squamous cell carcinoma (HNSCC). +target gene hsa-mir-21 Breast Neoplasms 21761201 "3,3'-Diindolylmethane inhibits breast cancer cell growth via miR-21-mediated Cdc25A degradation." +target gene hsa-mir-29c "Carcinoma, Hepatocellular" 21763284 "miR-29c targets TNFAIP3, inhibits cell proliferation and induces apoptosis in hepatitis B virus-related hepatocellular carcinoma." +target gene hsa-mir-106a Breast Neoplasms 21765466 "The experimental results using MDA-MB-231 and MCF-7 human breast cancer cells confirm that miRNAs derived from these clusters, containing miR-17-5p, miR-20a, miR-106a, miR-106b and miR-93, negatively regulate ZBTB4 expression." +target gene hsa-mir-106b Breast Neoplasms 21765466 "The experimental results using MDA-MB-231 and MCF-7 human breast cancer cells confirm that miRNAs derived from these clusters, containing miR-17-5p, miR-20a, miR-106a, miR-106b and miR-93, negatively regulate ZBTB4 expression." +target gene hsa-mir-17 Breast Neoplasms 21765466 "The experimental results using MDA-MB-231 and MCF-7 human breast cancer cells confirm that miRNAs derived from these clusters, containing miR-17-5p, miR-20a, miR-106a, miR-106b and miR-93, negatively regulate ZBTB4 expression." +target gene hsa-mir-20a Breast Neoplasms 21765466 "The experimental results using MDA-MB-231 and MCF-7 human breast cancer cells confirm that miRNAs derived from these clusters, containing miR-17-5p, miR-20a, miR-106a, miR-106b and miR-93, negatively regulate ZBTB4 expression." +target gene hsa-mir-93 Breast Neoplasms 21765466 "The experimental results using MDA-MB-231 and MCF-7 human breast cancer cells confirm that miRNAs derived from these clusters, containing miR-17-5p, miR-20a, miR-106a, miR-106b and miR-93, negatively regulate ZBTB4 expression." +target gene hsa-mir-133a-1 Hypertension 21769867 "MiR-133a regulates collagen 1A1, which has potential role in myocardial fibrosis in angiotensin II dependent hypertension." +target gene hsa-mir-133a-2 Hypertension 21769867 "MiR-133a regulates collagen 1A1, which has potential role in myocardial fibrosis in angiotensin II dependent hypertension." +target gene hsa-mir-125a Lung Neoplasms 21777146 MicroRNA HSA-miR-125a-5p induces apoptosis by activating p53 in lung cancer cells. +target gene hsa-mir-143 Urinary Bladder Cancer 21790228 Expression of miR-143 Reduces Growth and Migration of Human Bladder Carcinoma Cells by Targeting Cyclooxygenase-2. +target gene hsa-mir-29b-1 "Carcinoma, Hepatocellular" 21793034 "MicroRNA-29b suppresses tumor angiogenesis, invasion and metastasis by regulating MMP-2 expression." +target gene hsa-mir-29b-2 "Carcinoma, Hepatocellular" 21793034 "MicroRNA-29b suppresses tumor angiogenesis, invasion and metastasis by regulating MMP-2 expression." +target gene hsa-mir-218-1 "Squamous Cell Carcinoma, Oral" 21795477 The tumor suppressive microRNA miR-218 targets the mTOR component Rictor and inhibits AKT phosphorylation in oral cancer. +target gene hsa-mir-218-2 "Squamous Cell Carcinoma, Oral" 21795477 The tumor suppressive microRNA miR-218 targets the mTOR component Rictor and inhibits AKT phosphorylation in oral cancer. +target gene hsa-mir-17 Neuroblastoma 21796614 Dickkopf-3 is regulated by the MYCN-induced miR-17-92 cluster in neuroblastoma +target gene hsa-mir-18a Neuroblastoma 21796614 Dickkopf-3 is regulated by the MYCN-induced miR-17-92 cluster in neuroblastoma +target gene hsa-mir-19a Neuroblastoma 21796614 Dickkopf-3 is regulated by the MYCN-induced miR-17-92 cluster in neuroblastoma +target gene hsa-mir-19b-1 Neuroblastoma 21796614 Dickkopf-3 is regulated by the MYCN-induced miR-17-92 cluster in neuroblastoma +target gene hsa-mir-20a Neuroblastoma 21796614 Dickkopf-3 is regulated by the MYCN-induced miR-17-92 cluster in neuroblastoma +target gene hsa-mir-92a-1 Neuroblastoma 21796614 Dickkopf-3 is regulated by the MYCN-induced miR-17-92 cluster in neuroblastoma +target gene hsa-mir-210 Preeclampsia 21801864 miR-210 Targets Iron-Sulfur Cluster Scaffold Homologue +target gene hsa-mir-491 Hepatitis C Virus Infection 21802413 miR-491 was involved in regulation of HCV replication via the PI3 kinase/Akt pathway. +target gene hsa-mir-122 "Carcinoma, Hepatocellular" 21802841 MicroRNA-122 sensitizes HCC cancer cells to adriamycin and vincristine through modulating expression of MDR and inducing cell cycle arrest. +target gene hsa-mir-199a-1 "Carcinoma, Hepatocellular" 21807947 MicroRNA miR-199a-3p regulates cell proliferation and survival by targeting caveolin-2. +target gene hsa-mir-199a-1 Urinary Bladder Cancer 21807947 MicroRNA miR-199a-3p regulates cell proliferation and survival by targeting caveolin-2. +target gene hsa-mir-199a-2 "Carcinoma, Hepatocellular" 21807947 MicroRNA miR-199a-3p regulates cell proliferation and survival by targeting caveolin-2. +target gene hsa-mir-199a-2 Urinary Bladder Cancer 21807947 MicroRNA miR-199a-3p regulates cell proliferation and survival by targeting caveolin-2. +target gene hsa-mir-147 Dengue Virus Infection 21810247 "a microRNA which may negatively regulate pro-inflammatory cytokines in dengue infected peripheral blood cells, mIR-147 (NMES1)." +target gene hsa-mir-375 "Squamous Cell Carcinoma, Esophageal" 21813472 MicroRNA-375 inhibits tumour growth and metastasis in oesophageal squamous cell carcinoma through repressing insulin-like growth factor 1 receptor. +target gene hsa-mir-34a Breast Neoplasms 21814748 Identification of the receptor tyrosine kinase AXL in breast cancer as a target for the human miR-34a microRNA. +target gene hsa-mir-106b Laryngeal Neoplasms 21819631 MiR-106b promotes cell proliferation via targeting RB in laryngeal carcinoma. +target gene hsa-mir-21 "Carcinoma, Renal Cell" 21820586 miR-21 Modulates Cell Apoptosis by Targeting Multiple Genes in Renal Cell Carcinoma. +target gene hsa-mir-21 Breast Neoplasms 21820606 MicroRNA-21 Modulates Chemosensitivity of Breast Cancer Cells to Doxorubicin by Targeting PTEN. +target gene hsa-mir-335 Gastric Neoplasms 21822301 MicroRNA-335 acts as a metastasis suppressor in gastric cancer by targeting Bcl-w and specificity protein 1. +target gene hsa-mir-146b Pancreatic Neoplasms 21823013 miR-146b-5p has inhibitory effects of on cell migration and invasion of pancreatic cancer by targeting MMP16. +target gene hsa-mir-125b-1 Ovarian Neoplasms 21823019 miR-125b confers resistance of ovarian cancer cells to cisplatin by targeting pro-apoptotic Bcl-2 antagonist killer 1. +target gene hsa-mir-125b-2 Ovarian Neoplasms 21823019 miR-125b confers resistance of ovarian cancer cells to cisplatin by targeting pro-apoptotic Bcl-2 antagonist killer 1. +target gene hsa-mir-21 Prostate Neoplasms 21826097 Spry1 is a target for miR-21-mediated gene silencing. +target gene hsa-mir-451a Diabetic Nephropathy 21827757 MicroRNA-451 regulates p38 MAPK signaling by targeting of Ywhaz and suppresses the mesangial hypertrophy in early Diabetic Nephropathies. +target gene hsa-let-7e Ischemia-Reperfusion Injury 21827835 MicroRNA let-7e regulates the expression of caspase-3 during apoptosis of PC12 cells following anoxia/reoxygenation injury. +target gene hsa-mir-144 "Diabetes Mellitus, Type 2" 21829658 MicroRNA 144 Impairs Insulin Signaling by Inhibiting the Expression of Insulin Receptor Substrate 1 in Type 2 Diabetes Mellitus. +target gene hsa-mir-107 Breast Neoplasms 21841313 miR-107 promotes tumor progression by targeting the let-7 microRNA in mice and humans. +target gene hsa-mir-194-1 Endometrial Neoplasms 21851624 MicroRNA-194 inhibits epithelial to mesenchymal transition of endometrial cancer cells by targeting oncogene BMI-1. +target gene hsa-mir-194-2 Endometrial Neoplasms 21851624 MicroRNA-194 inhibits epithelial to mesenchymal transition of endometrial cancer cells by targeting oncogene BMI-1. +target gene hsa-let-7a-1 Ewing Sarcoma 21853155 Let-7a Is a Direct EWS-FLI-1 Target Implicated in Ewing's Sarcoma Development. +target gene hsa-let-7a-2 Ewing Sarcoma 21853155 Let-7a Is a Direct EWS-FLI-1 Target Implicated in Ewing's Sarcoma Development. +target gene hsa-let-7a-3 Ewing Sarcoma 21853155 Let-7a Is a Direct EWS-FLI-1 Target Implicated in Ewing's Sarcoma Development. +target gene hsa-mir-375 Lung Neoplasms 21856745 miR-375 is activated by ASH1 and inhibits YAP1 in a lineage dependent manner in lung cancer. +target gene hsa-mir-9-1 Glioblastoma 21857646 CAMTA1 is a novel tumour suppressor regulated by miR-9/9(*) in glioblastoma stem cells. +target gene hsa-mir-9-2 Glioblastoma 21857646 CAMTA1 is a novel tumour suppressor regulated by miR-9/9(*) in glioblastoma stem cells. +target gene hsa-mir-9-3 Glioblastoma 21857646 CAMTA1 is a novel tumour suppressor regulated by miR-9/9(*) in glioblastoma stem cells. +target gene hsa-mir-494 Urinary Bladder Cancer 21859890 miR-494 Competitively regulates Nucleolin expression with HuR. +target gene hsa-mir-542 Neoplasms [unspecific] 21860426 downregulation of miR-542-3p is significantly correlated with the upregulation of c-Src and ILK. Our results suggest that the novel c-Src-miR-542-3p-ILK-FAK circuit plays a crucial role in controlling tumor progression. +target gene hsa-mir-221 Breast Neoplasms 21868360 miR-221/222 Targeting of Trichorhinophalangeal 1 (TRPS1) Promotes Epithelial-to-Mesenchymal Transition in Breast Cancer. +target gene hsa-mir-222 Breast Neoplasms 21868360 miR-221/222 Targeting of Trichorhinophalangeal 1 (TRPS1) Promotes Epithelial-to-Mesenchymal Transition in Breast Cancer. +target gene hsa-let-7a-1 Mesothelioma 21869823 "EphrinA1 inhibits malignant mesothelioma tumor growth via let-7 microRNA-mediated repression of the RAS oncogene.EphrinA1 activation induced several fold increases in let-7a1, let-7a3, let-7f1 and let-7f2 miRNA expression in MMCs." +target gene hsa-let-7a-3 Mesothelioma 21869823 "EphrinA1 inhibits malignant mesothelioma tumor growth via let-7 microRNA-mediated repression of the RAS oncogene.EphrinA1 activation induced several fold increases in let-7a1, let-7a3, let-7f1 and let-7f2 miRNA expression in MMCs." +target gene hsa-let-7f-1 Mesothelioma 21869823 "EphrinA1 inhibits malignant mesothelioma tumor growth via let-7 microRNA-mediated repression of the RAS oncogene.EphrinA1 activation induced several fold increases in let-7a1, let-7a3, let-7f1 and let-7f2 miRNA expression in MMCs." +target gene hsa-let-7f-2 Mesothelioma 21869823 "EphrinA1 inhibits malignant mesothelioma tumor growth via let-7 microRNA-mediated repression of the RAS oncogene.EphrinA1 activation induced several fold increases in let-7a1, let-7a3, let-7f1 and let-7f2 miRNA expression in MMCs." +target gene hsa-mir-140 Osteoarthritis 21872590 MiR-140 is co-expressed with Wwp2-C transcript and activated by Sox9 to target Sp1 in maintaining the chondrocyte proliferation. +target gene hsa-mir-21 Colorectal Carcinoma 21872591 "miR-21 targets the tumor suppressor RhoB and regulates proliferation, invasion and apoptosis in colorectal cancer cells." +target gene hsa-mir-146b Thyroid Neoplasms 21874046 MicroRNA miR-146b-5p regulates signal transduction of TGF-beta by repressing SMAD4 in thyroid cancer. +target gene hsa-mir-216b Nasopharyngeal Neoplasms 21878506 miR-216b suppresses tumor growth and invasion by targeting KRAS in nasopharyngeal carcinoma. +target gene hsa-mir-98 "Carcinoma, Lung, Non-Small-Cell" 21880462 miR-98 regulates cisplatin-induced A549 cell death by inhibiting TP53 pathway. +target gene hsa-mir-125b-1 Huntington Disease 21887328 "The authors conclude that (i) miR-125b and miR-150 target p53, which in turn regulates RelA/NFkB and miR-146a expressions; (ii) reduced miR-125b and miR-150 expressions, increased p53 level and decreased RelA/NFkB and miR-146a expressions originate from mutant HTT (iii) p53 directly or indirectly regulates the expression of miR-146a." +target gene hsa-mir-125b-2 Huntington Disease 21887328 "The authors conclude that (i) miR-125b and miR-150 target p53, which in turn regulates RelA/NFkB and miR-146a expressions; (ii) reduced miR-125b and miR-150 expressions, increased p53 level and decreased RelA/NFkB and miR-146a expressions originate from mutant HTT (iii) p53 directly or indirectly regulates the expression of miR-146a." +target gene hsa-mir-146a Huntington Disease 21887328 "The authors conclude that (i) miR-125b and miR-150 target p53, which in turn regulates RelA/NFkB and miR-146a expressions; (ii) reduced miR-125b and miR-150 expressions, increased p53 level and decreased RelA/NFkB and miR-146a expressions originate from mutant HTT (iii) p53 directly or indirectly regulates the expression of miR-146a." +target gene hsa-mir-150 Huntington Disease 21887328 "The authors conclude that (i) miR-125b and miR-150 target p53, which in turn regulates RelA/NFkB and miR-146a expressions; (ii) reduced miR-125b and miR-150 expressions, increased p53 level and decreased RelA/NFkB and miR-146a expressions originate from mutant HTT (iii) p53 directly or indirectly regulates the expression of miR-146a." +target gene hsa-mir-423 "Carcinoma, Hepatocellular" 21890460 MicroRNA-423 Promotes Cell Growth and Regulates G1/S Transition by Targeting p21Cip1/Waf1 in Hepatocellular Carcinoma +target gene hsa-mir-193b Melanoma 21893020 "miR-193b is expressed at a significantly lower level in malignant melanoma than in benign nevi. In a survey of melanoma samples, the level of Mcl-1 is inversely correlated with the level of miR-193b. Overexpression of miR-193b in melanoma cells represses Mcl-1 expression. Furthermore, the effect of miR-193b on the expression of Mcl-1 seems to be mediated by direct interaction between miR-193b and seed and seedless pairing sequences in the 3' untranslated region of Mcl-1 mRNA." +target gene hsa-mir-373 Fibrosarcoma 21898400 miR-520c and miR-373 increased the expression of MMP9 by directly targeting the 3'UTRs of mRNAs of mTOR and SIRT1 and suppressing their translation; resulting in activation of the Ras/Raf/MEK/Erk signaling pathway and NF-§Ø¨mB; and finally increasing the mRN +target gene hsa-mir-520c Fibrosarcoma 21898400 miR-520c and miR-373 increased the expression of MMP9 by directly targeting the 3'UTRs of mRNAs of mTOR and SIRT1 and suppressing their translation; resulting in activation of the Ras/Raf/MEK/Erk signaling pathway and NF-§Ø¨mB; and finally increasing the mRN +target gene hsa-mir-200c Head And Neck Neoplasms 21899661 "The expression of ZEB1, a target mRNA for miR-200c, was up-regulated 3 and 6 hours after HGF stimulation." +target gene hsa-mir-200c "Squamous Cell Carcinoma, Head and Neck" 21899661 "The expression of ZEB1, a target mRNA for miR-200c, was up-regulated 3 and 6 hours after HGF stimulation." +target gene hsa-mir-27b Head And Neck Neoplasms 21899661 "The expression of ST14/matriptase an enzyme for extracellular matrix (ECM) degradation and HGF activation and a target mRNA for miR-27b, was drastically up-regulated in protein level after HGF stimulation." +target gene hsa-mir-27b "Squamous Cell Carcinoma, Head and Neck" 21899661 "The expression of ST14/matriptase an enzyme for extracellular matrix (ECM) degradation and HGF activation and a target mRNA for miR-27b, was drastically up-regulated in protein level after HGF stimulation." +target gene hsa-let-7i Coronary Artery Disease 21899916 "This study suggests that atorvastatin down-regulates TLR4 signal via let-7i expression in CAD patients, possibly contributing to the beneficial effects of atorvastatin on let-7i-mediated TLR4 signal in this disorder." +target gene hsa-mir-26b Lung Neoplasms 21901137 "Expression of miR-26b was down regulated, and its target activating transcription factor 2 (ATF2) mRNA was up regulated in §Ø©ãirradiated H1299 cells." +target gene hsa-mir-224 "Carcinoma, Renal Cell" 21912701 MiR-224 Targets the 3'UTR of Type 1 5'-Iodothyronine Deiodinase Possibly Contributing to Tissue Hypothyroidism in Renal Cancer. +target gene hsa-mir-145 Colon Neoplasms 21917858 The expression of miR-145 is downregulated in colon and ovarian cancer tissues and cell lines. MiR-145 directly targets p70S6K1 in cancer cells to inhibit tumor growth and angiogenesis. +target gene hsa-mir-145 Ovarian Neoplasms 21917858 The expression of miR-145 is downregulated in colon and ovarian cancer tissues and cell lines. MiR-145 directly targets p70S6K1 in cancer cells to inhibit tumor growth and angiogenesis. +target gene hsa-mir-1-1 Laryngeal Neoplasms 21924268 miRNA-1 targets fibronectin1 and suppresses the migration and invasion of the HEp2 laryngeal squamous carcinoma cell line. +target gene hsa-mir-1-1 "Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal" 21924268 miRNA-1 targets fibronectin1 and suppresses the migration and invasion of the HEp2 laryngeal squamous carcinoma cell line. +target gene hsa-mir-1-2 Laryngeal Neoplasms 21924268 miRNA-1 targets fibronectin1 and suppresses the migration and invasion of the HEp2 laryngeal squamous carcinoma cell line. +target gene hsa-mir-1-2 "Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal" 21924268 miRNA-1 targets fibronectin1 and suppresses the migration and invasion of the HEp2 laryngeal squamous carcinoma cell line. +target gene hsa-mir-200a Breast Neoplasms 21926171 miR-200a regulates Nrf2 activation by targeting Keap1 mRNA in breast cancer cells. +target gene hsa-mir-23a Muscular Dystrophy 21926429 miR-23a suppresses the translation of both MAFbx/atrogin-1 and MuRF1 in a 3UTR-dependent manner. Ectopic expression of miR-23a is sufficient to protect muscles from atrophy in vitro and in vivo. +target gene hsa-mir-504 "Squamous Cell Carcinoma, Oral" 21927029 Connective tissue growth factor modulates oral squamous cell carcinoma invasion by activating a miR-504/FOXP1 signalling. +target gene hsa-mir-34a Medulloblastoma 21931765 MiR-34a Targeting of Notch Ligand Delta-Like 1 Impairs CD15/CD133 Tumor-Propagating Cells and Supports Neural Differentiation in Medulloblastoma. +target gene hsa-mir-499a Colorectal Carcinoma 21934092 microRNA-499-5p promotes cellular invasion and tumor metastasis in colorectal cancer by targeting FOXO4 and PDCD4. +target gene hsa-mir-18a Urinary Bladder Cancer 21935572 "microRNA-18a, a member of the oncogenic miR-17-92 cluster, targets Dicer and suppresses cell proliferation in bladder cancer T24 cells." +target gene hsa-mir-375 Urinary Bladder Cancer 21945323 "miR-375, Down-Regulated in Squamous Cervical Cancer, Inhibits Cell Migration and Invasion via Targeting Transcription Factor SP1." +target gene hsa-mir-145 Atherosclerosis 21945499 We showed that miR-145 can regulate the fate and phenotype of human ES-pre-SMCs as they become fully differentiated SMCs. +target gene hsa-mir-195 "Carcinoma, Hepatocellular" 21947305 miRNA-195 sensitizes human hepatocellular carcinoma cells to 5-FU by targeting BCL-w. +target gene hsa-mir-191 Gastric Neoplasms 21947487 MicroRNA-191 targets N-deacetylase/N-sulfotransferase 1 and promotes cell growth in human gastric carcinoma cell line MGC803. +target gene hsa-mir-29b-1 Multiple Myeloma 21951844 Overexpression of microRNA-29b induces apoptosis of multiple myeloma cells through down regulating Mcl-1. +target gene hsa-mir-25 Cholangiocarcinoma 21953056 miR-25 targets TRAIL death Receptor-4 and promotes apoptosis resistance in cholangiocarcinoma. +target gene hsa-mir-128-1 Breast Neoplasms 21953503 Reduced miR-128 in breast tumor-initiating cells induces chemotherapeutic resistance via Bmi-1 and ABCC5. +target gene hsa-mir-106a "Lymphoma, Hodgkin" 21953646 MiR-17/106b seed family regulates p21 in Hodgkin's lymphoma. +target gene hsa-mir-106b "Lymphoma, Hodgkin" 21953646 MiR-17/106b seed family regulates p21 in Hodgkin's lymphoma. +target gene hsa-mir-17 "Lymphoma, Hodgkin" 21953646 MiR-17/106b seed family regulates p21 in Hodgkin's lymphoma. +target gene hsa-mir-191 Thyroid Neoplasms 21956418 miR-191 Down-Regulation Plays a Role in Thyroid Follicular Tumors through CDK6 Targeting. +target gene hsa-mir-135a-1 Endometriosis 21956427 miR-135a Regulates HOXA10 Expression in Endometriosis. +target gene hsa-mir-135a-2 Endometriosis 21956427 miR-135a Regulates HOXA10 Expression in Endometriosis. +target gene hsa-mir-135b Endometriosis 21956427 miR-135b Regulates HOXA10 Expression in Endometriosis. +target gene hsa-mir-93 Osteosarcoma 21959981 "Levels of miR-93 were significantly higher in metastases from osteosarcoma than in paired primary tumours. When 143B and MG-63 were transfected with miR-93, clones appeared to respond differently to microRNA overexpression. Ectopic expression of miR-93 more significantly increased cell proliferation and invasivity in 143B than in MG-63 clones. Furthermore, increased mRNA and protein levels of E2F1, one of the potential miR-93 targets, were seen in osteosarcoma cellular clones and its involvement in 143B cell proliferation was confirmed by E2F1 silencing." +target gene hsa-mir-125b-1 Endometrial Neoplasms 21970405 MiR-125b promotes proliferation and migration of type II endometrial carcinoma cells through targeting TP53INP1 tumor suppressor in vitro and in vivo. +target gene hsa-mir-125b-2 Endometrial Neoplasms 21970405 MiR-125b promotes proliferation and migration of type II endometrial carcinoma cells through targeting TP53INP1 tumor suppressor in vitro and in vivo. +target gene hsa-mir-142 "Leukemia-Lymphoma, Adult T-Cell" 21979877 miR-142-3p plans an oncogenic role in human T-cell acute lymphoblastic leukemia (T-ALL) by targeting glucocorticoid receptor-§Ø©ãand cAMP/PKA pathways. +target gene hsa-mir-150 Pancreatic Neoplasms 21983127 MicroRNA-150 directly targets MUC4 and suppresses growth and malignant behavior of pancreatic cancer cells. +target gene hsa-mir-181a-2 Ischemia 21983159 miR-181 regulates GRP78 and influences outcome from cerebral ischemia in vitro and in vivo. +target gene hsa-mir-1293 Kaposi Sarcoma 21984125 "We show a direct repression of vIL-6 by hsa-miR-1293 and hIL-6 by hsa-miR-608. The repression of vIL-6 by miR-1293 was reversed by disruption of the vIL-6 miR-1293 seed match through the introduction of point mutations. In addition, expression of vIL-6 or" +target gene hsa-mir-608 Kaposi Sarcoma 21984125 "We show a direct repression of vIL-6 by hsa-miR-1293 and hIL-6 by hsa-miR-608. The repression of vIL-6 by miR-1293 was reversed by disruption of the vIL-6 miR-1293 seed match through the introduction of point mutations. In addition, expression of vIL-6 or" +target gene hsa-let-7c Colorectal Carcinoma 21984339 Let-7c functions as a metastasis suppressor by targeting MMP11 and PBX3 in colorectal cancer. +target gene hsa-mir-24-1 Breast Neoplasms 21986943 miR-24 was found to be implicated in the regulation of the EMT program in response to TGF-beta and was shown to be directly involved in the TGF-§Ø©ãinduced breast cancer cell invasiveness through Net1A regulation. +target gene hsa-mir-24-2 Breast Neoplasms 21986943 miR-24 was found to be implicated in the regulation of the EMT program in response to TGF-beta and was shown to be directly involved in the TGF-§Ø©ãinduced breast cancer cell invasiveness through Net1A regulation. +target gene hsa-mir-199a-1 Endometriosis 21989168 MiR-199a attenuates endometrial stromal cell invasiveness through suppression of the IKK{beta}/NF-kB pathway and reduced interleukin-8 expression. +target gene hsa-mir-199a-2 Endometriosis 21989168 MiR-199a attenuates endometrial stromal cell invasiveness through suppression of the IKK{beta}/NF-kB pathway and reduced interleukin-8 expression. +target gene hsa-mir-155 "Carcinoma, Hepatocellular" 21989846 Aberrant expression of microRNA 155 may accelerate cell proliferation by targeting sex-determining region Y box 6 in hepatocellular carcinoma. +target gene hsa-mir-200b "Carcinoma, Lung, Non-Small-Cell" 21993663 miR-200bc/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP. +target gene hsa-mir-200b Gastric Neoplasms 21993663 miR-200bc/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP. +target gene hsa-mir-200c "Carcinoma, Lung, Non-Small-Cell" 21993663 miR-200bc/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP. +target gene hsa-mir-200c Gastric Neoplasms 21993663 miR-200bc/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP. +target gene hsa-mir-429 "Carcinoma, Lung, Non-Small-Cell" 21993663 miR-200bc/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP. +target gene hsa-mir-429 Gastric Neoplasms 21993663 miR-200bc/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP. +target gene hsa-mir-148a Gastric Neoplasms 21994419 MicroRNA-148a Suppresses Tumor Cell Invasion and Metastasis by Downregulating ROCK1 in Gastric Cancer. +target gene hsa-mir-1-1 Chronic Obstructive Pulmonary Disease 21998125 "A reduction in expression of miR-1 (2.5-fold, p=0.01) and the myocardin-related transcription factors (MRTFs) A and B was observed in patients compared with controls (MRTF-A mRNA: twofold, p=0.028; MRTF-B mRNA: fourfold, p=0.011). miR-1 expression was associated with smoking history, lung function, fat-free mass index, 6 min walk distance and percentage of type 1 fibres. miR-133 and miR-206 were negatively correlated with daily physical activity. Insulin-like growth factor 1 mRNA was increased in the patients and miR-1 was negatively correlated with phosphorylation of the kinase Akt. Furthermore, the protein levels of histone deacetylase 4, another miR-1 target, were increased in the patients." +target gene hsa-mir-1-2 Chronic Obstructive Pulmonary Disease 21998125 "A reduction in expression of miR-1 (2.5-fold, p=0.01) and the myocardin-related transcription factors (MRTFs) A and B was observed in patients compared with controls (MRTF-A mRNA: twofold, p=0.028; MRTF-B mRNA: fourfold, p=0.011). miR-1 expression was associated with smoking history, lung function, fat-free mass index, 6 min walk distance and percentage of type 1 fibres. miR-133 and miR-206 were negatively correlated with daily physical activity. Insulin-like growth factor 1 mRNA was increased in the patients and miR-1 was negatively correlated with phosphorylation of the kinase Akt. Furthermore, the protein levels of histone deacetylase 4, another miR-1 target, were increased in the patients." +target gene hsa-mir-133a-1 Chronic Obstructive Pulmonary Disease 21998125 "A reduction in expression of miR-1 (2.5-fold, p=0.01) and the myocardin-related transcription factors (MRTFs) A and B was observed in patients compared with controls (MRTF-A mRNA: twofold, p=0.028; MRTF-B mRNA: fourfold, p=0.011). miR-1 expression was associated with smoking history, lung function, fat-free mass index, 6 min walk distance and percentage of type 1 fibres. miR-133 and miR-206 were negatively correlated with daily physical activity. Insulin-like growth factor 1 mRNA was increased in the patients and miR-1 was negatively correlated with phosphorylation of the kinase Akt. Furthermore, the protein levels of histone deacetylase 4, another miR-1 target, were increased in the patients." +target gene hsa-mir-133a-2 Chronic Obstructive Pulmonary Disease 21998125 "A reduction in expression of miR-1 (2.5-fold, p=0.01) and the myocardin-related transcription factors (MRTFs) A and B was observed in patients compared with controls (MRTF-A mRNA: twofold, p=0.028; MRTF-B mRNA: fourfold, p=0.011). miR-1 expression was associated with smoking history, lung function, fat-free mass index, 6 min walk distance and percentage of type 1 fibres. miR-133 and miR-206 were negatively correlated with daily physical activity. Insulin-like growth factor 1 mRNA was increased in the patients and miR-1 was negatively correlated with phosphorylation of the kinase Akt. Furthermore, the protein levels of histone deacetylase 4, another miR-1 target, were increased in the patients." +target gene hsa-mir-133b Chronic Obstructive Pulmonary Disease 21998125 "A reduction in expression of miR-1 (2.5-fold, p=0.01) and the myocardin-related transcription factors (MRTFs) A and B was observed in patients compared with controls (MRTF-A mRNA: twofold, p=0.028; MRTF-B mRNA: fourfold, p=0.011). miR-1 expression was associated with smoking history, lung function, fat-free mass index, 6 min walk distance and percentage of type 1 fibres. miR-133 and miR-206 were negatively correlated with daily physical activity. Insulin-like growth factor 1 mRNA was increased in the patients and miR-1 was negatively correlated with phosphorylation of the kinase Akt. Furthermore, the protein levels of histone deacetylase 4, another miR-1 target, were increased in the patients." +target gene hsa-mir-206 Chronic Obstructive Pulmonary Disease 21998125 "A reduction in expression of miR-1 (2.5-fold, p=0.01) and the myocardin-related transcription factors (MRTFs) A and B was observed in patients compared with controls (MRTF-A mRNA: twofold, p=0.028; MRTF-B mRNA: fourfold, p=0.011). miR-1 expression was associated with smoking history, lung function, fat-free mass index, 6 min walk distance and percentage of type 1 fibres. miR-133 and miR-206 were negatively correlated with daily physical activity. Insulin-like growth factor 1 mRNA was increased in the patients and miR-1 was negatively correlated with phosphorylation of the kinase Akt. Furthermore, the protein levels of histone deacetylase 4, another miR-1 target, were increased in the patients." +target gene hsa-mir-29a Gastric Neoplasms 21998710 MiR-29a Inhibits Cell Proliferation and Induces Cell Cycle Arrest through the Downregulation of p42.3 in Human Gastric Cancer. +target gene hsa-mir-21 Urinary Bladder Cancer 22001440 MiR-21 is involved in cervical squamous cell tumorigenesis and regulates CCL20. +target gene hsa-mir-137 Intellectual Disability 22003227 "The patients displayed a significantly decreased expression of both precursor and mature miR-137 levels, as well as significantly increased expression of the validated downstream targets microphthalmia-associated transcription factor (MITF) and Enhancer of Zeste, Drosophila, Homologue 2 (EZH2), and the newly identified target Kruppel-like factor 4 (KLF4). The study also demonstrated significant enrichment of miR-137 at the synapses of cortical and hippocampal neurons, suggesting a role of miR-137 in regulating local synaptic protein synthesis machinery." +target gene hsa-mir-126 Endometriosis 22012249 "The expression level of miR-126 was significantly downregulated in ECs versus EUs (p = 5.45E(-5)) in the experimental group and in EUs versus ENs (p = 0.019).miR-126 may play an initial role in the development and progression of EMs. Crk may be regulated by miR-126, and synergism between abnormal expressions may play an important role in the pathogenesis of EMs." +target gene hsa-let-7a-1 Endometrial Neoplasms 22014978 "The activated estrogen receptor can suppress the expression of BAX by upregulating a group of microRNAs including hsa-let-7 family members and hsa-miR-27a, thereby promoting an increased BCL2/BAX ratio as well as enhanced survival and proliferation in the affected cells." +target gene hsa-let-7a-2 Endometrial Neoplasms 22014978 "The activated estrogen receptor can suppress the expression of BAX by upregulating a group of microRNAs including hsa-let-7 family members and hsa-miR-27a, thereby promoting an increased BCL2/BAX ratio as well as enhanced survival and proliferation in the affected cells." +target gene hsa-let-7a-3 Endometrial Neoplasms 22014978 "The activated estrogen receptor can suppress the expression of BAX by upregulating a group of microRNAs including hsa-let-7 family members and hsa-miR-27a, thereby promoting an increased BCL2/BAX ratio as well as enhanced survival and proliferation in the affected cells." +target gene hsa-let-7b Endometrial Neoplasms 22014978 "The activated estrogen receptor can suppress the expression of BAX by upregulating a group of microRNAs including hsa-let-7 family members and hsa-miR-27a, thereby promoting an increased BCL2/BAX ratio as well as enhanced survival and proliferation in the affected cells." +target gene hsa-let-7c Endometrial Neoplasms 22014978 "The activated estrogen receptor can suppress the expression of BAX by upregulating a group of microRNAs including hsa-let-7 family members and hsa-miR-27a, thereby promoting an increased BCL2/BAX ratio as well as enhanced survival and proliferation in the affected cells." +target gene hsa-let-7d Endometrial Neoplasms 22014978 "The activated estrogen receptor can suppress the expression of BAX by upregulating a group of microRNAs including hsa-let-7 family members and hsa-miR-27a, thereby promoting an increased BCL2/BAX ratio as well as enhanced survival and proliferation in the affected cells." +target gene hsa-let-7e Endometrial Neoplasms 22014978 "The activated estrogen receptor can suppress the expression of BAX by upregulating a group of microRNAs including hsa-let-7 family members and hsa-miR-27a, thereby promoting an increased BCL2/BAX ratio as well as enhanced survival and proliferation in the affected cells." +target gene hsa-let-7f-1 Endometrial Neoplasms 22014978 "The activated estrogen receptor can suppress the expression of BAX by upregulating a group of microRNAs including hsa-let-7 family members and hsa-miR-27a, thereby promoting an increased BCL2/BAX ratio as well as enhanced survival and proliferation in the affected cells." +target gene hsa-let-7f-2 Endometrial Neoplasms 22014978 "The activated estrogen receptor can suppress the expression of BAX by upregulating a group of microRNAs including hsa-let-7 family members and hsa-miR-27a, thereby promoting an increased BCL2/BAX ratio as well as enhanced survival and proliferation in the affected cells." +target gene hsa-let-7g Endometrial Neoplasms 22014978 "The activated estrogen receptor can suppress the expression of BAX by upregulating a group of microRNAs including hsa-let-7 family members and hsa-miR-27a, thereby promoting an increased BCL2/BAX ratio as well as enhanced survival and proliferation in the affected cells." +target gene hsa-let-7i Endometrial Neoplasms 22014978 "The activated estrogen receptor can suppress the expression of BAX by upregulating a group of microRNAs including hsa-let-7 family members and hsa-miR-27a, thereby promoting an increased BCL2/BAX ratio as well as enhanced survival and proliferation in the affected cells." +target gene hsa-mir-200c Endometrial Neoplasms 22015043 "We found that miR-200c expression was increased in endometrial carcinoma compared with normal endometrial tissues. Anti-miR or pre-miR-200c could regulate cell survival, proliferation, and apoptosis and affect cytotoxicity in endometrial cancer cells. Through mRNA microarray analysis, we found that miR-200c inhibits the expression of BRD7, which was recently reported as a potential tumor suppressor gene. MiR-200c regulated the translocation of §Ø©ãcatenin from the cytoplasm to the nucleus via inhibition of BRD7, resulting in increased expression of its transcriptional target genes, cyclinD1 and c-myc." +target gene hsa-let-7a-1 Colorectal Carcinoma 22018986 NIRF is frequently upregulated in colorectal cancer and its oncogenicity can be suppressed by let-7a microRNA. +target gene hsa-let-7a-2 Colorectal Carcinoma 22018986 NIRF is frequently upregulated in colorectal cancer and its oncogenicity can be suppressed by let-7a microRNA. +target gene hsa-let-7a-3 Colorectal Carcinoma 22018986 NIRF is frequently upregulated in colorectal cancer and its oncogenicity can be suppressed by let-7a microRNA. +target gene hsa-mir-148b Colorectal Carcinoma 22020560 MicroRNA-148b suppresses cell growth by targeting cholecystokinin-2 receptor in colorectal cancer. +target gene hsa-mir-146a Gastric Neoplasms 22020746 Increased miR-146a in gastric cancer directly targets SMAD4 and is involved in modulating cell proliferation and apoptosis. +target gene hsa-mir-30c-1 Ovarian Neoplasms 22024689 MicroRNA-30c-2* expressed in ovarian cancer cells suppresses growth factor induced cellular proliferation and downregulates the oncogene BCL9. +target gene hsa-mir-30c-2 Ovarian Neoplasms 22024689 MicroRNA-30c-2* expressed in ovarian cancer cells suppresses growth factor induced cellular proliferation and downregulates the oncogene BCL9. +target gene hsa-mir-150 "Carcinoma, Hepatocellular" 22025269 microRNA-150 inhibits human CD133-positive liver cancer stem cells through negative regulation of the transcription factor c-Myb. +target gene hsa-mir-155 Lung Neoplasms 22027557 "Hypoxic conditions induce miR-155 expression in lung cancer cells and trigger a corresponding decrease in a validated target, FOXO3A. Furthermore, we find that increased levels of miR-155 radioprotects lung cancer cells, while inhibition of miR-155 radiosensitizes these cells. Moreover, we reveal a therapeutically important link between miR-155 expression, hypoxia, and irradiation by demonstrating that anti-miR-155 molecules also sensitize hypoxic lung cancer cells to irradiation. Our study helps explain how miR-155 becomes elevated in lung cancers, which contain extensive hypoxic microenvironments, and demonstrates that inhibition of miR-155 may have important therapeutic potential as a means to radiosensitize hypoxic lung cancer cells." +target gene hsa-mir-194-1 Colorectal Carcinoma 22028325 p53-responsive miR-194 inhibits thrombospondin-1 and promotes angiogenesis in colon cancers. +target gene hsa-mir-194-2 Colorectal Carcinoma 22028325 p53-responsive miR-194 inhibits thrombospondin-1 and promotes angiogenesis in colon cancers. +target gene hsa-mir-375 Head And Neck Neoplasms 22031094 "MiR-375 expression was significantly reduced (p=0.01), and conversely, MTDH was significantly increased (p=0.0001) in NPC samples. Quantitative RT-PCR, western blots and luciferase assays corroborated MTDH as a target of miR-375. Re-expression of miR-375 and siRNA knock-down of MTDH both decreased cell viability and clonogenic survival, cell migration/invasion, as well as in vivo tumour formation. NPC patients whose tumours expressed high levels of MTDH experienced significantly lower survival, and in particular, higher distant relapse rates (5-year distant relapse rates: 26% vs. 5%; p=0.005)." +target gene hsa-mir-506 Colon Neoplasms 22036718 MicroRNA 506 regulates expression of PPAR alpha in hydroxycamptothecin-resistant human colon cancer cells. +target gene hsa-mir-23a Vascular Disease [unspecific] 22038739 Our results suggest that miR-23a may be involved in TNF-¦Á-induced endothelial cell apoptosis through regulation of the caspase-7 and serine/threonine kinase?4-caspase-3 pathways. +target gene hsa-mir-150 Myocardial Infarction 22039399 microRNA-150 regulates mobilization and migration of bone marrow-derived mononuclear cells by targeting Cxcr4. +target gene hsa-mir-7-1 Glioblastoma 22040413 MicroRNA-7 regulates glioblastoma cell invasion via targeting focal adhesion kinase expression. +target gene hsa-mir-7-2 Glioblastoma 22040413 MicroRNA-7 regulates glioblastoma cell invasion via targeting focal adhesion kinase expression. +target gene hsa-mir-7-3 Glioblastoma 22040413 MicroRNA-7 regulates glioblastoma cell invasion via targeting focal adhesion kinase expression. +target gene hsa-mir-494 Gastrointestinal Neoplasms 22042971 MicroRNA-494 Downregulates KIT and Inhibits Gastrointestinal Stromal Tumor Cell Proliferation. +target gene hsa-mir-1 Heart Failure 22045061 MicroRNA-1 represses Cx43 expression in viral myocarditis. +target gene hsa-mir-125b-1 Huntington Disease 22048026 "Micro RNA -214,-150,-146a and-125b target Huntingtin gene." +target gene hsa-mir-125b-2 Huntington Disease 22048026 "Micro RNA -214,-150,-146a and-125b target Huntingtin gene." +target gene hsa-mir-146a Huntington Disease 22048026 "Micro RNA -214,-150,-146a and-125b target Huntingtin gene." +target gene hsa-mir-150 Huntington Disease 22048026 "Micro RNA -214,-150,-146a and-125b target Huntingtin gene." +target gene hsa-mir-214 Huntington Disease 22048026 "Micro RNA -214,-150,-146a and-125b target Huntingtin gene." +target gene hsa-mir-375 "Carcinoma, Hepatocellular" 22056881 MicroRNA-375 targets AEG-1 in hepatocellular carcinoma and suppresses liver cancer cell growth in vitro and in vivo. +target gene hsa-mir-493 Urinary Bladder Cancer 22057916 Tumor suppressor microRNA-493 decreases cell motility and migration ability in human bladder cancer cells by down-regulating RhoC and FZD4. +target gene hsa-mir-1-1 Nasopharyngeal Neoplasms 22059741 MicroRNA-1 induces apoptosis by targeting prothymosin alpha in nasopharyngeal carcinoma cells. +target gene hsa-mir-1-2 Nasopharyngeal Neoplasms 22059741 MicroRNA-1 induces apoptosis by targeting prothymosin alpha in nasopharyngeal carcinoma cells. +target gene hsa-mir-126 Pancreatic Neoplasms 22064652 MiR-126 acts as a tumor suppressor in pancreatic cancer cells via the regulation of ADAM9. +target gene hsa-mir-1-1 Prostate Neoplasms 22068816 Tumour suppressors miR-1 and miR-133a target the oncogenic function of purine nucleoside phosphorylase (PNP) in prostate cancer. +target gene hsa-mir-1-2 Prostate Neoplasms 22068816 Tumour suppressors miR-1 and miR-133a target the oncogenic function of purine nucleoside phosphorylase (PNP) in prostate cancer. +target gene hsa-mir-133a-1 Prostate Neoplasms 22068816 Tumour suppressors miR-1 and miR-133a target the oncogenic function of purine nucleoside phosphorylase (PNP) in prostate cancer. +target gene hsa-mir-133a-2 Prostate Neoplasms 22068816 Tumour suppressors miR-1 and miR-133a target the oncogenic function of purine nucleoside phosphorylase (PNP) in prostate cancer. +target gene hsa-mir-433 Ovarian Neoplasms 22069160 "MAD2 protein expression levels were downregulated in pre-miR-433 transfected A2780 cells. Secondly, Pre-miR-433 suppressed the activity of a reporter construct containing the 3'-UTR of MAD2. Thirdly, blocking miR-433 binding to the MAD2 3'UTR protected MAD2 from miR-433 induced protein downregulation. Importantly, reduced MAD2 protein expression in pre-miR-433 transfected A2780 cells rendered these cells less sensitive to paclitaxel. In conclusion, loss of MAD2 protein expression results in increased resistance to paclitaxel in EOC cells." +target gene hsa-mir-885 "Squamous Cell Carcinoma, Head and Neck" 22071691 "miR-885-3p modulated the cisplatin-induced TP53-dependent mitochondrial apoptosis by up regulation of MDM4 levels and down regulation of BCL2 levels in mitochondria. Altogether, our results support the notion that miR-885-3p might contribute in regulation of cell viability, apoptosis and/or autophagy in squamous cell carcinoma cells upon cisplatin exposure." +target gene hsa-mir-21 Colon Neoplasms 22072622 MicroRNA-21 induces stemness by downregulating transforming growth factor beta receptor 2 (TGFbetaR2) in colon cancer cells. +target gene hsa-mir-221 Glioma 22075712 Downregulation of miR-221/222 sensitizes glioma cells to temozolomide by regulating apoptosis independently of p53 status. +target gene hsa-mir-222 Glioma 22075712 Downregulation of miR-221/222 sensitizes glioma cells to temozolomide by regulating apoptosis independently of p53 status. +target gene hsa-mir-25 Ovarian Neoplasms 22076535 MiR-25 regulates apoptosis by targeting Bim in human ovarian cancer. +target gene hsa-mir-155 Human Immunodeficiency Virus Infection 22080513 "microRNA-223 levels were significantly enriched in HIV-1-infected CD4(+)CD8(-) PBMCs, microRNA-29a/b, microRNA-155 and microRNA-21 levels were significantly reduced. Based on the potential for microRNA binding sites in a conserved sequence of the Nef-3'-LTR, several host microRNAs potentially could affect HIV-1 gene expression. Among those microRNAs, the microRNA-29 family has seed complementarity in the HIV-1 3'-UTR, but the potential suppressive effect of microRNA-29 on HIV-1 is severely blocked by the secondary structure of the target region." +target gene hsa-mir-21 Human Immunodeficiency Virus Infection 22080513 "microRNA-223 levels were significantly enriched in HIV-1-infected CD4(+)CD8(-) PBMCs, microRNA-29a/b, microRNA-155 and microRNA-21 levels were significantly reduced. Based on the potential for microRNA binding sites in a conserved sequence of the Nef-3'-LTR, several host microRNAs potentially could affect HIV-1 gene expression. Among those microRNAs, the microRNA-29 family has seed complementarity in the HIV-1 3'-UTR, but the potential suppressive effect of microRNA-29 on HIV-1 is severely blocked by the secondary structure of the target region." +target gene hsa-mir-223 Human Immunodeficiency Virus Infection 22080513 "microRNA-223 levels were significantly enriched in HIV-1-infected CD4(+)CD8(-) PBMCs, microRNA-29a/b, microRNA-155 and microRNA-21 levels were significantly reduced. Based on the potential for microRNA binding sites in a conserved sequence of the Nef-3'-LTR, several host microRNAs potentially could affect HIV-1 gene expression. Among those microRNAs, the microRNA-29 family has seed complementarity in the HIV-1 3'-UTR, but the potential suppressive effect of microRNA-29 on HIV-1 is severely blocked by the secondary structure of the target region." +target gene hsa-mir-29a Human Immunodeficiency Virus Infection 22080513 "microRNA-223 levels were significantly enriched in HIV-1-infected CD4(+)CD8(-) PBMCs, microRNA-29a/b, microRNA-155 and microRNA-21 levels were significantly reduced. Based on the potential for microRNA binding sites in a conserved sequence of the Nef-3'-LTR, several host microRNAs potentially could affect HIV-1 gene expression. Among those microRNAs, the microRNA-29 family has seed complementarity in the HIV-1 3'-UTR, but the potential suppressive effect of microRNA-29 on HIV-1 is severely blocked by the secondary structure of the target region." +target gene hsa-mir-124-1 Breast Neoplasms 22085528 miR-124 suppresses multiple steps of breast cancer metastasis by targeting a cohort of pro-metastatic genes in vitro. +target gene hsa-mir-124-2 Breast Neoplasms 22085528 miR-124 suppresses multiple steps of breast cancer metastasis by targeting a cohort of pro-metastatic genes in vitro. +target gene hsa-mir-124-3 Breast Neoplasms 22085528 miR-124 suppresses multiple steps of breast cancer metastasis by targeting a cohort of pro-metastatic genes in vitro. +target gene hsa-mir-31 Glioma 22089331 Human miR-31 targets radixin and inhibits migration and invasion of glioma cells. +target gene hsa-mir-199a-1 "Carcinoma, Renal Cell" 22093618 Re-expression of miR-199a suppresses renal cancer cell proliferation and survival by targeting GSK-3 +target gene hsa-mir-145 Glioblastoma 22098779 "The expression of miR145 (a tumor-suppressive miRNA) is inversely correlated with the levels of Oct4 and Sox2 in GBM-CD133(+) cells and malignant glioma specimens.miR145 negatively regulates GBM tumorigenesis by targeting Oct4 and Sox2 in GBM-CD133(+). Using polyurethane-short branch polyethylenimine (PU-PEI) as a therapeutic-delivery vehicle, PU-PEI-mediated miR145 delivery to GBM-CD133(+) significantly inhibited their tumorigenic and CSC-like abilities and facilitated their differentiation into CD133(-)-non-CSCs. Furthermore, PU-PEI-miR145-treated GBM-CD133(+) effectively suppressed the expression of drug-resistance and anti-apoptotic genes and increased the sensitivity of the cells to radiation and temozolomide. Finally, the in vivo delivery of PU-PEI-miR145 alone significantly suppressed tumorigenesis with stemness, and synergistically improved the survival rate when used in combination with radiotherapy and temozolomide in orthotopic GBM-CD133(+)-transplanted immunocompromised mice. Therefore, PU-PEI-miR145 is a novel therapeutic approach for malignant brain tumors." +target gene hsa-mir-21 Colorectal Carcinoma 22099878 miR-21 functionally interacts with the 3'UTR of chemokine CCL20 and down-regulates CCL20 expression in miR-21 transfected colorectal cancer cells. +target gene hsa-mir-520e "Carcinoma, Hepatocellular" 22105365 MicroRNA-520e suppresses growth of hepatoma cells by targeting the NF-kB-inducing kinase (NIK). +target gene hsa-mir-19a Rheumatoid Arthritis 22105995 "TLR2 Expression Is Regulated by MicroRNA miR-19 in Rheumatoid Fibroblast-like Synoviocytes.Downregulation of miR-19b and miR-19a, which belongs to the same cluster, was confirmed by real-time quantitative PCR. Transfection of RA FLS with miR-19a/b mimics decreased TLR2 protein expression. In parallel, we found that both IL-6 and matrix metalloproteinase 3 secretion was significantly downregulated in activated FLS transfected with either mimic. Moreover, using a luciferase assay, we showed that miR-19a/b directly target Tlr2 mRNA." +target gene hsa-mir-19b-1 Rheumatoid Arthritis 22105995 "TLR2 Expression Is Regulated by MicroRNA miR-19 in Rheumatoid Fibroblast-like Synoviocytes.Downregulation of miR-19b and miR-19a, which belongs to the same cluster, was confirmed by real-time quantitative PCR. Transfection of RA FLS with miR-19a/b mimics decreased TLR2 protein expression. In parallel, we found that both IL-6 and matrix metalloproteinase 3 secretion was significantly downregulated in activated FLS transfected with either mimic. Moreover, using a luciferase assay, we showed that miR-19a/b directly target Tlr2 mRNA." +target gene hsa-mir-19b-2 Rheumatoid Arthritis 22105995 "TLR2 Expression Is Regulated by MicroRNA miR-19 in Rheumatoid Fibroblast-like Synoviocytes.Downregulation of miR-19b and miR-19a, which belongs to the same cluster, was confirmed by real-time quantitative PCR. Transfection of RA FLS with miR-19a/b mimics decreased TLR2 protein expression. In parallel, we found that both IL-6 and matrix metalloproteinase 3 secretion was significantly downregulated in activated FLS transfected with either mimic. Moreover, using a luciferase assay, we showed that miR-19a/b directly target Tlr2 mRNA." +target gene hsa-mir-143 Urinary Bladder Cancer 22108519 The miR-143/-145 cluster regulates plasminogen activator inhibitor-1 in bladder cancer. +target gene hsa-mir-145 Urinary Bladder Cancer 22108519 The miR-143/-145 cluster regulates plasminogen activator inhibitor-1 in bladder cancer. +target gene hsa-mir-206 Laryngeal Neoplasms 22110210 Down-regulation of MiR-206 Promotes Proliferation and Invasion of Laryngeal Cancer by Regulating VEGF Expression. +target gene hsa-mir-34b Breast Neoplasms 22113133 "In this study, we identified one such estrogen down-regulated microRNA, miR-34b, as an onco-suppressor that targets cyclin D1 and JAG-1 (jagged 1) in a ER-positive/wild-type p53 breast cancer cell line (MCF-7) as well as in ovarian and endometrial cells," +target gene hsa-mir-17 "Lymphoma, Mantle-Cell" 22116552 The miRNA-17-92 cluster mediates chemoresistance and enhances tumor growth in mantle cell lymphoma via PI3K/AKT pathway activation. +target gene hsa-mir-18a "Lymphoma, Mantle-Cell" 22116552 The miRNA-17-92 cluster mediates chemoresistance and enhances tumor growth in mantle cell lymphoma via PI3K/AKT pathway activation. +target gene hsa-mir-19a "Lymphoma, Mantle-Cell" 22116552 The miRNA-17-92 cluster mediates chemoresistance and enhances tumor growth in mantle cell lymphoma via PI3K/AKT pathway activation. +target gene hsa-mir-19b-1 "Lymphoma, Mantle-Cell" 22116552 The miRNA-17-92 cluster mediates chemoresistance and enhances tumor growth in mantle cell lymphoma via PI3K/AKT pathway activation. +target gene hsa-mir-20a "Lymphoma, Mantle-Cell" 22116552 The miRNA-17-92 cluster mediates chemoresistance and enhances tumor growth in mantle cell lymphoma via PI3K/AKT pathway activation. +target gene hsa-mir-92a-1 "Lymphoma, Mantle-Cell" 22116552 The miRNA-17-92 cluster mediates chemoresistance and enhances tumor growth in mantle cell lymphoma via PI3K/AKT pathway activation. +target gene hsa-mir-378a Cardiovascular Diseases [unspecific] 22119805 Overexpression of microRNA-378 attenuates ischemia-induced apoptosis by inhibiting caspase-3 expression in cardiac myocytes. +target gene hsa-mir-100 Lung Neoplasms 22120675 MiR-100 Resensitizes Docetaxel-Resistant Human Lung Adenocarcinoma Cells (SPC-A1) to Docetaxel by Targeting Plk1. +target gene hsa-mir-27b Neuroblastoma 22120719 "MiR-27b targets PPARgamma to inhibit growth, tumor progression and the inflammatory response in neuroblastoma cells." +target gene hsa-mir-1915 Colorectal Carcinoma 22121083 miR-1915 inhibits Bcl-2 to modulate multidrug resistance by increasing drug-sensitivity in human colorectal carcinoma cells. +target gene hsa-mir-221 Colon Neoplasms 22126772 MicroRNA-221 promotes colon carcinoma cell proliferation in vitro by inhibiting CDKN1C/p57 expression. +target gene hsa-let-7c Prostate Neoplasms 22128178 MicroRNA let-7c suppresses androgen receptor expression and activity via regulation of Myc expression in prostate cancer cells. +target gene hsa-mir-21 Melanoma 22130252 "Increased levels of microRNA-21 expression were shown from dysplastic nevi to primary cutaneous melanomas to melanoma metastases. Moreover, high miR-21 expression was found to be correlated with Breslow thickness and advanced clinical stage. Patients with high microRNA-21 expression showed shorter 5-year disease-free or overall survival than those with low microRNA-21 expression. Furthermore, multivariate regression analysis showed that the status of microRNA-21 expression was an independent prognostic factor for overall survival of patients. Antisense-mediated microRNA-21 inhibition could significantly suppress growth, increase apoptosis and enhance chemo- or radiosensitivity of human cutaneous melanoma cells by inducing the increased Bax/Bcl-2 ratio. Thus, the status of microRNA-21 might be an independent prognostic factor for patients with cutaneous melanoma, and microRNA-21 has the potential of being a novel molecular target for the treatment of human cutaneous melanoma." +target gene hsa-mir-17 Colorectal Carcinoma 22132820 "Up-regulated miR-17 promotes cell proliferation, tumor growth and cell cycle progression by targeting RND3 tumor suppressor gene in colorectal carcinoma." +target gene hsa-mir-330 Colon Neoplasms 22132977 "Expression of miR-330 in various colon and lung cancer cell lines, as measured by QRT-PCR, varied five-fold between samples and correlated with in-vitro gemcitabine resistance (R = 0.82, p = 0.04). Exposure to gemcitabine also appeared to influence miR-330 levels in these cell lines. Furthermore, in our cell line panel, miR-330 expression negatively correlated with dCK mRNA expression (R = 0.74), suggesting a role of miR-330 in post-transcriptional regulation of dCK." +target gene hsa-mir-330 Lung Neoplasms 22132977 "Expression of miR-330 in various colon and lung cancer cell lines, as measured by QRT-PCR, varied five-fold between samples and correlated with in-vitro gemcitabine resistance (R = 0.82, p = 0.04). Exposure to gemcitabine also appeared to influence miR-330 levels in these cell lines. Furthermore, in our cell line panel, miR-330 expression negatively correlated with dCK mRNA expression (R = 0.74), suggesting a role of miR-330 in post-transcriptional regulation of dCK." +target gene hsa-mir-15a "Leukemia, Lymphocytic, Chronic, B-Cell" 22133358 miR-15a and miR-16-1 inhibit the proliferation of leukemic cells by down-regulating WT1 protein level. +target gene hsa-mir-15a "Leukemia, Myeloid, Acute" 22133358 miR-15a and miR-16-1 inhibit the proliferation of leukemic cells by down-regulating WT1 protein level. +target gene hsa-mir-15a Multiple Myeloma 22133358 miR-15a and miR-16-1 inhibit the proliferation of leukemic cells by down-regulating WT1 protein level. +target gene hsa-mir-320a Colorectal Carcinoma 22134529 microRNA-320a inhibits tumor invasion by targeting neuropilin 1 and is associated with liver metastasis in colorectal cancer. +target gene hsa-mir-24-1 Laryngeal Neoplasms 22139384 miR-24 functions as a tumor suppressor in Hep2 laryngeal carcinoma cells partly through down-regulation of the S100A8 protein. +target gene hsa-mir-24-2 Laryngeal Neoplasms 22139384 miR-24 functions as a tumor suppressor in Hep2 laryngeal carcinoma cells partly through down-regulation of the S100A8 protein. +target gene hsa-mir-200b Lung Neoplasms 22139708 MicroRNA-200b reverses chemoresistance of docetaxel-resistant human lung adenocarcinoma cells by targeting E2F3. +target gene hsa-mir-125b-1 "Leukemia, B-Cell" 22139839 MiR-125b and miR-155 contribute to BCL2 repression and proliferation in response to CD40 ligand (CD154) in human leukemic B-cells. +target gene hsa-mir-125b-2 "Leukemia, B-Cell" 22139839 MiR-125b and miR-155 contribute to BCL2 repression and proliferation in response to CD40 ligand (CD154) in human leukemic B-cells. +target gene hsa-mir-155 "Leukemia, B-Cell" 22139839 MiR-125b and miR-155 contribute to BCL2 repression and proliferation in response to CD40 ligand (CD154) in human leukemic B-cells. +target gene hsa-mir-210 "Carcinoma, Hepatocellular" 22144109 Hypoxia-inducible MicroRNA-210 augments the metastatic potential of tumor cells by targeting vacuole membrane protein 1 in hepatocellular carcinoma. +target gene hsa-mir-200c Breast Neoplasms 22144583 MicroRNA-200c represses migration and invasion of breast cancer cells by targeting actin-regulatory proteins FHOD1 and PPM1F. +target gene hsa-mir-421 Biliary Tract Neoplasms 22146319 MicroRNA-421 functions as an oncogenic miRNA in biliary tract cancer through down-regulating farnesoid X receptor expression. +target gene hsa-mir-23b Pain 22149086 MiR23b Ameliorates Neuropathic Pain in Spinal Cord by Silencing NOX4. +target gene hsa-mir-221 "Carcinoma, Hepatocellular" 22152314 MiR-221 contributes to the growth of hepatocellular carcinoma cells and miR-221 inhibition can induce cell apoptosis. miR-221 has the potential to become one of the new molecular targets for liver cancer therapy. +target gene hsa-let-7a "Carcinoma, Renal Cell" 22155254 Our results suggest for the first time that let-7a acts as a tumor suppressor in RCC cell lines by down-regulating c-myc and c-myc target genes. +target gene hsa-mir-103a-1 Lung Neoplasms 22157681 "Here we report that miR-30b, miR-30c, miR-221 and miR-222 are modulated by both epidermal growth factor (EGF) and MET receptors, whereas miR-103 and miR-203 are controlled only by MET. We showed that these miRNAs have important roles in gefitinib-induced apoptosis and epithelial-mesenchymal transition of NSCLC cells in vitro and in vivo by inhibiting the expression of the genes encoding BCL2-like 11 (BIM), apoptotic peptidase activating factor 1 (APAF-1), protein kinase C ? (PKC-?) and sarcoma viral oncogene homolog (SRC)." +target gene hsa-mir-103a-2 Lung Neoplasms 22157681 "Here we report that miR-30b, miR-30c, miR-221 and miR-222 are modulated by both epidermal growth factor (EGF) and MET receptors, whereas miR-103 and miR-203 are controlled only by MET. We showed that these miRNAs have important roles in gefitinib-induced apoptosis and epithelial-mesenchymal transition of NSCLC cells in vitro and in vivo by inhibiting the expression of the genes encoding BCL2-like 11 (BIM), apoptotic peptidase activating factor 1 (APAF-1), protein kinase C ? (PKC-?) and sarcoma viral oncogene homolog (SRC)." +target gene hsa-mir-103b-1 Lung Neoplasms 22157681 "Here we report that miR-30b, miR-30c, miR-221 and miR-222 are modulated by both epidermal growth factor (EGF) and MET receptors, whereas miR-103 and miR-203 are controlled only by MET. We showed that these miRNAs have important roles in gefitinib-induced apoptosis and epithelial-mesenchymal transition of NSCLC cells in vitro and in vivo by inhibiting the expression of the genes encoding BCL2-like 11 (BIM), apoptotic peptidase activating factor 1 (APAF-1), protein kinase C ? (PKC-?) and sarcoma viral oncogene homolog (SRC)." +target gene hsa-mir-103b-2 Lung Neoplasms 22157681 "Here we report that miR-30b, miR-30c, miR-221 and miR-222 are modulated by both epidermal growth factor (EGF) and MET receptors, whereas miR-103 and miR-203 are controlled only by MET. We showed that these miRNAs have important roles in gefitinib-induced apoptosis and epithelial-mesenchymal transition of NSCLC cells in vitro and in vivo by inhibiting the expression of the genes encoding BCL2-like 11 (BIM), apoptotic peptidase activating factor 1 (APAF-1), protein kinase C ? (PKC-?) and sarcoma viral oncogene homolog (SRC)." +target gene hsa-mir-203 Lung Neoplasms 22157681 "Here we report that miR-30b, miR-30c, miR-221 and miR-222 are modulated by both epidermal growth factor (EGF) and MET receptors, whereas miR-103 and miR-203 are controlled only by MET. We showed that these miRNAs have important roles in gefitinib-induced apoptosis and epithelial-mesenchymal transition of NSCLC cells in vitro and in vivo by inhibiting the expression of the genes encoding BCL2-like 11 (BIM), apoptotic peptidase activating factor 1 (APAF-1), protein kinase C ? (PKC-?) and sarcoma viral oncogene homolog (SRC)." +target gene hsa-mir-221 Lung Neoplasms 22157681 "Here we report that miR-30b, miR-30c, miR-221 and miR-222 are modulated by both epidermal growth factor (EGF) and MET receptors, whereas miR-103 and miR-203 are controlled only by MET. We showed that these miRNAs have important roles in gefitinib-induced apoptosis and epithelial-mesenchymal transition of NSCLC cells in vitro and in vivo by inhibiting the expression of the genes encoding BCL2-like 11 (BIM), apoptotic peptidase activating factor 1 (APAF-1), protein kinase C ? (PKC-?) and sarcoma viral oncogene homolog (SRC)." +target gene hsa-mir-222 Lung Neoplasms 22157681 "Here we report that miR-30b, miR-30c, miR-221 and miR-222 are modulated by both epidermal growth factor (EGF) and MET receptors, whereas miR-103 and miR-203 are controlled only by MET. We showed that these miRNAs have important roles in gefitinib-induced apoptosis and epithelial-mesenchymal transition of NSCLC cells in vitro and in vivo by inhibiting the expression of the genes encoding BCL2-like 11 (BIM), apoptotic peptidase activating factor 1 (APAF-1), protein kinase C ? (PKC-?) and sarcoma viral oncogene homolog (SRC)." +target gene hsa-mir-30b Lung Neoplasms 22157681 "Here we report that miR-30b, miR-30c, miR-221 and miR-222 are modulated by both epidermal growth factor (EGF) and MET receptors, whereas miR-103 and miR-203 are controlled only by MET. We showed that these miRNAs have important roles in gefitinib-induced apoptosis and epithelial-mesenchymal transition of NSCLC cells in vitro and in vivo by inhibiting the expression of the genes encoding BCL2-like 11 (BIM), apoptotic peptidase activating factor 1 (APAF-1), protein kinase C ? (PKC-?) and sarcoma viral oncogene homolog (SRC)." +target gene hsa-mir-30c-1 Lung Neoplasms 22157681 "Here we report that miR-30b, miR-30c, miR-221 and miR-222 are modulated by both epidermal growth factor (EGF) and MET receptors, whereas miR-103 and miR-203 are controlled only by MET. We showed that these miRNAs have important roles in gefitinib-induced apoptosis and epithelial-mesenchymal transition of NSCLC cells in vitro and in vivo by inhibiting the expression of the genes encoding BCL2-like 11 (BIM), apoptotic peptidase activating factor 1 (APAF-1), protein kinase C ? (PKC-?) and sarcoma viral oncogene homolog (SRC)." +target gene hsa-mir-30c-2 Lung Neoplasms 22157681 "Here we report that miR-30b, miR-30c, miR-221 and miR-222 are modulated by both epidermal growth factor (EGF) and MET receptors, whereas miR-103 and miR-203 are controlled only by MET. We showed that these miRNAs have important roles in gefitinib-induced apoptosis and epithelial-mesenchymal transition of NSCLC cells in vitro and in vivo by inhibiting the expression of the genes encoding BCL2-like 11 (BIM), apoptotic peptidase activating factor 1 (APAF-1), protein kinase C ? (PKC-?) and sarcoma viral oncogene homolog (SRC)." +target gene hsa-mir-30a Breast Neoplasms 22157765 MicroRNA-30a sensitizes tumor cells to cis-platinum via suppressing beclin 1-mediated autophagy. +target gene hsa-mir-30a "Carcinoma, Hepatocellular" 22157765 MicroRNA-30a sensitizes tumor cells to cis-platinum via suppressing beclin 1-mediated autophagy. +target gene hsa-mir-30a Ovarian Neoplasms 22157765 MicroRNA-30a sensitizes tumor cells to cis-platinum via suppressing beclin 1-mediated autophagy. +target gene hsa-mir-373 Breast Neoplasms 22158050 MicroRNA-520/373 family functions as a tumor suppressor in estrogen receptor negative breast cancer by targeting NF-kB and TGF-beta signaling pathways. +target gene hsa-mir-520a Breast Neoplasms 22158050 MicroRNA-520/373 family functions as a tumor suppressor in estrogen receptor negative breast cancer by targeting NF-kB and TGF-beta signaling pathways. +target gene hsa-mir-520b Breast Neoplasms 22158050 MicroRNA-520/373 family functions as a tumor suppressor in estrogen receptor negative breast cancer by targeting NF-kB and TGF-beta signaling pathways. +target gene hsa-mir-520c Breast Neoplasms 22158050 MicroRNA-520/373 family functions as a tumor suppressor in estrogen receptor negative breast cancer by targeting NF-kB and TGF-beta signaling pathways. +target gene hsa-mir-520d Breast Neoplasms 22158050 MicroRNA-520/373 family functions as a tumor suppressor in estrogen receptor negative breast cancer by targeting NF-kB and TGF-beta signaling pathways. +target gene hsa-mir-1245a Breast Neoplasms 22158906 Upregulation of miR-1245 by c-myc targets BRCA2 and impairs DNA repair. +target gene hsa-mir-1245b Breast Neoplasms 22158906 Upregulation of miR-1245 by c-myc targets BRCA2 and impairs DNA repair. +target gene hsa-mir-34a "Carcinoma, Renal Cell" 22159222 MicroRNA-34a suppresses malignant transformation by targeting c-Myc transcriptional complexes in human renal cell carcinoma. +target gene hsa-mir-205 Glioblastoma 22159356 MicroRNA-205 functions as a tumor suppressor in human glioblastoma cells by targeting VEGF-A. +target gene hsa-mir-143 Urinary Bladder Cancer 22160209 miR-143 is downregulated in cervical cancer and promotes apoptosis and inhibits tumor formation by targeting Bcl-2. +target gene hsa-mir-34a Neuroblastoma 22160687 "Notably, the axis TAp73/miR-34a/synaptotagmin-1 is conserved in brains from Alzheimer's patients. " +target gene hsa-mir-146a Prostate Neoplasms 22161865 MiR-146a suppresses tumor growth and progression by targeting EGFR pathway and in a p-ERK-dependent manner in castration-resistant prostate cancer. +target gene hsa-mir-146a "Carcinoma, Hepatocellular" 22167321 "The authors demonstrate that miR-146a, miR-99b and miR-205, induced in HCC1937 BRCA1-expressing cells, bind and regulate TRAF2 gene. In addition, re-expression of miR-146a, miR-99b or miR-205 in HCC1937 BRCA1-null cells was sufficient to modulate NF-§Ø¨mB activity." +target gene hsa-mir-205 "Carcinoma, Hepatocellular" 22167321 "The authors demonstrate that miR-146a, miR-99b and miR-205, induced in HCC1937 BRCA1-expressing cells, bind and regulate TRAF2 gene. In addition, re-expression of miR-146a, miR-99b or miR-205 in HCC1937 BRCA1-null cells was sufficient to modulate NF-§Ø¨mB activity." +target gene hsa-mir-99b "Carcinoma, Hepatocellular" 22167321 "The authors demonstrate that miR-146a, miR-99b and miR-205, induced in HCC1937 BRCA1-expressing cells, bind and regulate TRAF2 gene. In addition, re-expression of miR-146a, miR-99b or miR-205 in HCC1937 BRCA1-null cells was sufficient to modulate NF-§Ø¨mB activity." +target gene hsa-mir-21 Ovarian Neoplasms 22176994 miR-21 might play an important role in the proliferation and apoptosis of ovarian epithelial carcinoma cells through negatively control the expression of PDCD4. +target gene hsa-mir-1-1 Urinary Bladder Cancer 22178073 Tumor suppressive microRNA-1 mediated novel apoptosis pathways through direct inhibition of splicing factor serine/arginine-rich 9 (SRSF9/SRp30c) in bladder cancer. +target gene hsa-mir-1-2 Urinary Bladder Cancer 22178073 Tumor suppressive microRNA-1 mediated novel apoptosis pathways through direct inhibition of splicing factor serine/arginine-rich 9 (SRSF9/SRp30c) in bladder cancer. +target gene hsa-mir-124-1 Alzheimer Disease 22178568 The miR-124 regulates the expression of BACE1/-secretase correlated with cell death in Alzheimer's disease. +target gene hsa-mir-124-2 Alzheimer Disease 22178568 The miR-124 regulates the expression of BACE1/-secretase correlated with cell death in Alzheimer's disease. +target gene hsa-mir-124-3 Alzheimer Disease 22178568 The miR-124 regulates the expression of BACE1/-secretase correlated with cell death in Alzheimer's disease. +target gene hsa-mir-320a Breast Neoplasms 22179046 Expression of the Pten-miR-320-Ets2-regulated secretome distinguished human normal breast stroma from tumour stroma and robustly correlated with recurrence in breast cancer patients. This work reveals miR-320 as a critical component of the Pten tumour-suppressor axis that acts in stromal fibroblasts to reprogramme the tumour microenvironment and curtail tumour progression. +target gene hsa-mir-320b-1 Breast Neoplasms 22179046 Expression of the Pten-miR-320-Ets2-regulated secretome distinguished human normal breast stroma from tumour stroma and robustly correlated with recurrence in breast cancer patients. This work reveals miR-320 as a critical component of the Pten tumour-suppressor axis that acts in stromal fibroblasts to reprogramme the tumour microenvironment and curtail tumour progression. +target gene hsa-mir-320b-2 Breast Neoplasms 22179046 Expression of the Pten-miR-320-Ets2-regulated secretome distinguished human normal breast stroma from tumour stroma and robustly correlated with recurrence in breast cancer patients. This work reveals miR-320 as a critical component of the Pten tumour-suppressor axis that acts in stromal fibroblasts to reprogramme the tumour microenvironment and curtail tumour progression. +target gene hsa-mir-320c-1 Breast Neoplasms 22179046 Expression of the Pten-miR-320-Ets2-regulated secretome distinguished human normal breast stroma from tumour stroma and robustly correlated with recurrence in breast cancer patients. This work reveals miR-320 as a critical component of the Pten tumour-suppressor axis that acts in stromal fibroblasts to reprogramme the tumour microenvironment and curtail tumour progression. +target gene hsa-mir-320c-2 Breast Neoplasms 22179046 Expression of the Pten-miR-320-Ets2-regulated secretome distinguished human normal breast stroma from tumour stroma and robustly correlated with recurrence in breast cancer patients. This work reveals miR-320 as a critical component of the Pten tumour-suppressor axis that acts in stromal fibroblasts to reprogramme the tumour microenvironment and curtail tumour progression. +target gene hsa-mir-320d-1 Breast Neoplasms 22179046 Expression of the Pten-miR-320-Ets2-regulated secretome distinguished human normal breast stroma from tumour stroma and robustly correlated with recurrence in breast cancer patients. This work reveals miR-320 as a critical component of the Pten tumour-suppressor axis that acts in stromal fibroblasts to reprogramme the tumour microenvironment and curtail tumour progression. +target gene hsa-mir-320d-2 Breast Neoplasms 22179046 Expression of the Pten-miR-320-Ets2-regulated secretome distinguished human normal breast stroma from tumour stroma and robustly correlated with recurrence in breast cancer patients. This work reveals miR-320 as a critical component of the Pten tumour-suppressor axis that acts in stromal fibroblasts to reprogramme the tumour microenvironment and curtail tumour progression. +target gene hsa-mir-320e Breast Neoplasms 22179046 Expression of the Pten-miR-320-Ets2-regulated secretome distinguished human normal breast stroma from tumour stroma and robustly correlated with recurrence in breast cancer patients. This work reveals miR-320 as a critical component of the Pten tumour-suppressor axis that acts in stromal fibroblasts to reprogramme the tumour microenvironment and curtail tumour progression. +target gene hsa-mir-451a Glioma 22179124 MicroRNA miR-451 downregulates the PI3K/AKT pathway through CAB39 in human glioma. +target gene hsa-mir-409 Gastric Neoplasms 22179828 MicroRNA-409 suppresses tumour cell invasion and metastasis by directly targeting radixin in gastric cancers. +target gene hsa-mir-137 Schizophrenia 22182936 "Schizophrenia-associated genes CSMD1, C10orf26, CACNA1C and TCF4 are miR-137 targets." +target gene hsa-mir-200a Lymphoma 22183793 "MicroRNA-200 is commonly repressed in conjunctival MALT lymphoma, and targets cyclin E2." +target gene hsa-mir-200b Lymphoma 22183793 "MicroRNA-200 is commonly repressed in conjunctival MALT lymphoma, and targets cyclin E2." +target gene hsa-mir-200c Lymphoma 22183793 "MicroRNA-200 is commonly repressed in conjunctival MALT lymphoma, and targets cyclin E2." +target gene hsa-mir-365a Lung Neoplasms 22185756 MiR-365 regulates lung cancer and developmental gene thyroid transcription factor 1. +target gene hsa-mir-365b Lung Neoplasms 22185756 MiR-365 regulates lung cancer and developmental gene thyroid transcription factor 1. +target gene hsa-mir-20a Osteosarcoma 22186140 miR-20a increases the metastatic potential of osteosarcoma cells by regulating Fas expression. +target gene hsa-mir-34a Colon Neoplasms 22198213 MicroRNA-34a inhibits migration and invasion of colon cancer cells via targeting to Fra-1. +target gene hsa-mir-210 Preeclampsia 22203747 Hydroxysteroid (17-beta) Dehydrogenase 1 Is Dysregulated by Mir-210 and Mir-518c That Are Aberrantly Expressed in Preeclamptic Placentas. +target gene hsa-mir-518c Preeclampsia 22203747 Hydroxysteroid (17-beta) Dehydrogenase 1 Is Dysregulated by Mir-210 and Mir-518c That Are Aberrantly Expressed in Preeclamptic Placentas. +target gene hsa-mir-181d Glioma 22207524 MiR-181d acts as a tumor suppressor in glioma by targeting K-ras and Bcl-2. +target gene hsa-mir-203 Breast Neoplasms 22207897 Anti-miR-203 Upregulates SOCS3 Expression in Breast Cancer Cells and Enhances Cisplatin Chemosensitivity. +target gene hsa-mir-195 Glioblastoma 22217655 MicroRNA-195 plays a tumor-suppressor role in human glioblastoma cells by targeting signaling pathways involved in cellular proliferation and invasion. +target gene hsa-mir-1236 Inflammation 22223733 Mirtron MicroRNA-1236 Inhibits VEGFR-3 Signaling During Inflammatory Lymphangiogenesis. +target gene hsa-mir-17 Schizophrenia 22228753 Expression of NPAS3 in the Human Cortex is regulated by miR-17 During Development and has Implications for Schizophrenia. +target gene hsa-mir-7-1 "Carcinoma, Hepatocellular" 22234835 miR-7 inhibits tumor growth and metastasis by targeting the PI3K/AKT pathway in hepatocellular carcinoma. +target gene hsa-mir-7-2 "Carcinoma, Hepatocellular" 22234835 miR-7 inhibits tumor growth and metastasis by targeting the PI3K/AKT pathway in hepatocellular carcinoma. +target gene hsa-mir-7-3 "Carcinoma, Hepatocellular" 22234835 miR-7 inhibits tumor growth and metastasis by targeting the PI3K/AKT pathway in hepatocellular carcinoma. +target gene hsa-mir-122 Lymphoma 22235305 miR-122 regulates p53/Akt signalling and the chemotherapy-induced apoptosis in cutaneous T-cell lymphoma. +target gene hsa-mir-211 Colorectal Carcinoma 22235338 MicroRNA-211 expression promotes colorectal cancer cell growth in vitro and in vivo by targeting tumor suppressor CHD5. +target gene hsa-mir-212 "Leukemia, Myeloid, Chronic" 22241070 ABCG2 protein was 7.2-fold elevated after long-term treatment with imatinib and decreased gradually at higher concentrations. miRNAs miR-212 and miR-328 were identified to correlate inversely with ABCG2 expression under these conditions. +target gene hsa-mir-328 "Leukemia, Myeloid, Chronic" 22241070 ABCG2 protein was 7.2-fold elevated after long-term treatment with imatinib and decreased gradually at higher concentrations. miRNAs miR-212 and miR-328 were identified to correlate inversely with ABCG2 expression under these conditions. +target gene hsa-mir-34a Laryngeal Neoplasms 22246523 MicroRNA-34a affects the occurrence of laryngeal squamous cell carcinoma by targeting the antiapoptotic gene survivin. +target gene hsa-mir-663a Nasopharyngeal Neoplasms 22249270 "MiR-663, a microRNA targeting p21(WAF1/CIP1), promotes the proliferation and tumorigenesis of nasopharyngeal carcinoma." +target gene hsa-mir-124-1 Medulloblastoma 22249617 hsa-mir-124a targeted 3'UTR of HMGA1 and negatively modulated the expression in MB cells. +target gene hsa-let-7a-1 Breast Neoplasms 22251626 MicroRNA let-7a suppresses breast cancer cell migration and invasion through downregulation of C-C chemokine receptor type 7. +target gene hsa-let-7a-2 Breast Neoplasms 22251626 MicroRNA let-7a suppresses breast cancer cell migration and invasion through downregulation of C-C chemokine receptor type 7. +target gene hsa-let-7a-3 Breast Neoplasms 22251626 MicroRNA let-7a suppresses breast cancer cell migration and invasion through downregulation of C-C chemokine receptor type 7. +target gene hsa-let-7i Pancreatic Neoplasms 22261338 "The miRNAs, let-7i and miR-143 was found to target Ras, and forced re-expression of let-7i and miR-143 inhibited Ras activity, cell proliferation and colony formation in vitro." +target gene hsa-mir-143 Pancreatic Neoplasms 22261338 "The miRNAs, let-7i and miR-143 was found to target Ras, and forced re-expression of let-7i and miR-143 inhibited Ras activity, cell proliferation and colony formation in vitro." +target gene hsa-mir-31 Leukemia 22264793 Polycomb-mediated loss of miR-31 activates NIK-dependent NF-kB pathway in adult T cell leukemia and other cancers. +target gene hsa-mir-195 Urinary Bladder Cancer 22265971 MicroRNA-195-5p suppresses glucose uptake and proliferation of human bladder cancer T24 cells by regulating GLUT3 expression. +target gene hsa-mir-449a Urinary Bladder Cancer 22266187 MicroRNA-449a acts as a tumor suppressor in human bladder cancer through the regulation of pocket proteins. +target gene hsa-mir-133a-1 Head And Neck Neoplasms 22266319 Tumor suppressive microRNA-133a regulates novel targets: Moesin contributes to cancer cell proliferation and invasion in head and neck squamous cell carcinoma. +target gene hsa-mir-32 Prostate Neoplasms 22266859 Androgen-regulated miR-32 targets BTG2 and is overexpressed in castration-resistant prostate cancer. +target gene hsa-mir-21 Gastric Neoplasms 22267008 microRNA-21 promotes tumor proliferation and invasion in gastric cancer by targeting PTEN. +target gene hsa-mir-21 Colorectal Carcinoma 22267128 Significant inverse correlations were demonstrated between PDCD4 and miR-21. +target gene hsa-mir-223 Gastric Neoplasms 22270966 MicroRNA-223 functions as an oncogene in human gastric cancer by targeting FBXW7/hCdc4. +target gene hsa-mir-221 Hypertrophy 22275134 MiR-221 promotes cardiac hypertrophy in vitro through the modulation of p27 expression. +target gene hsa-mir-122 "Carcinoma, Hepatocellular" 22276989 MicroRNA-122 suppresses cell proliferation and induces cell apoptosis in hepatocellular carcinoma by directly targeting Wnt/§Ø©ãcatenin pathway. +target gene hsa-mir-181a-2 Leukemia 22285729 miR-181a sensitizes a multidrug-resistant leukemia cell line K562/A02 to daunorubicin by targeting BCL-2. +target gene hsa-mir-21 Leprosy 22286305 MicroRNA-21 targets the vitamin D-dependent antimicrobial pathway in leprosy +target gene hsa-mir-106b Breast Neoplasms 22286770 "The miR-106b-25 cluster targets Smad7, activates TGF-beta signaling, and induces EMT and tumor initiating cell characteristics downstream of Six1 in human breast cancer." +target gene hsa-mir-25 Breast Neoplasms 22286770 "The miR-106b-25 cluster targets Smad7, activates TGF-beta signaling, and induces EMT and tumor initiating cell characteristics downstream of Six1 in human breast cancer." +target gene hsa-mir-30a Colon Neoplasms 22287560 MiR-30a-5p suppresses tumor growth in colon carcinoma by targeting DTL. +target gene hsa-mir-127 Inflammation 22287715 MicroRNA-127 Inhibits Lung Inflammation by Targeting IgG Fcgamma Receptor I. +target gene hsa-mir-195 Urinary Bladder Cancer 22289176 Cyclin-dependent kinase 4 is a novel target in micoRNA-195-mediated cell cycle arrest in bladder cancer cells. +target gene hsa-mir-29b-1 "Carcinoma, Lung, Non-Small-Cell" 22290228 miR-29b is an upstream molecule of PTEN. miR-29b regulates PTEN gene expression through downregulating Dnmts expression and subsequently induces hypomethylation in PTEN promoter. +target gene hsa-mir-29b-2 "Carcinoma, Lung, Non-Small-Cell" 22290228 miR-29b is an upstream molecule of PTEN. miR-29b regulates PTEN gene expression through downregulating Dnmts expression and subsequently induces hypomethylation in PTEN promoter. +target gene hsa-mir-125b-1 "Carcinoma, Hepatocellular" 22293115 MicroRNA-125b induces cancer cell apoptosis through suppression of Bcl-2 expression. +target gene hsa-mir-125b-2 "Carcinoma, Hepatocellular" 22293115 MicroRNA-125b induces cancer cell apoptosis through suppression of Bcl-2 expression. +target gene hsa-mir-10b Gastric Neoplasms 22293682 miR-10b promotes cell invasion through RhoC-AKT signaling pathway by targeting HOXD10 in gastric cancer. +target gene hsa-mir-221 Glioblastoma 22294051 miR-221/222 is the regulator of Cx43 expression in human glioblastoma cells. +target gene hsa-mir-1285-1 "Carcinoma, Renal Cell" 22294552 Tumor suppressive microRNA-1285 regulates novel molecular targets: Aberrant expression and functional significance in renal cell carcinoma. +target gene hsa-mir-1285-2 "Carcinoma, Renal Cell" 22294552 Tumor suppressive microRNA-1285 regulates novel molecular targets: Aberrant expression and functional significance in renal cell carcinoma. +target gene hsa-mir-125b-1 Alzheimer Disease 22302353 miR-125b and miR-146a regulate Complement Factor H (CFH) in Alzheimer's Disease (AD) Brain. +target gene hsa-mir-125b-2 Alzheimer Disease 22302353 miR-125b and miR-146a regulate Complement Factor H (CFH) in Alzheimer's Disease (AD) Brain. +target gene hsa-mir-146a Alzheimer Disease 22302353 miR-125b and miR-146a regulate Complement Factor H (CFH) in Alzheimer's Disease (AD) Brain. +target gene hsa-mir-203 Laryngeal Neoplasms 22306317 MicroRNA-203 leads to G1 phase cell cycle arrest in laryngeal carcinoma cells by directly targeting survivin. +target gene hsa-mir-205 Nasopharyngeal Neoplasms 22306986 MiR-205 determines the radioresistance of human nasopharyngeal carcinoma by directly targeting PTEN. +target gene hsa-mir-125b-1 Breast Neoplasms 22307404 miR-125b targets ARID3B in breast cancer cells. +target gene hsa-mir-125b-2 Breast Neoplasms 22307404 miR-125b targets ARID3B in breast cancer cells. +target gene hsa-mir-155 "Carcinoma, Renal Cell" 22307849 microRNA-155 silencing inhibits proliferation and migration and induces apoptosis by upregulating BACH1 in renal cancer cells. +target gene hsa-mir-9-1 "Lymphoma, Hodgkin" 22310293 Inhibition of miR-9 de-represses HuR and DICER1 and impairs Hodgkin lymphoma tumour outgrowth in vivo. +target gene hsa-mir-9-2 "Lymphoma, Hodgkin" 22310293 Inhibition of miR-9 de-represses HuR and DICER1 and impairs Hodgkin lymphoma tumour outgrowth in vivo. +target gene hsa-mir-9-3 "Lymphoma, Hodgkin" 22310293 Inhibition of miR-9 de-represses HuR and DICER1 and impairs Hodgkin lymphoma tumour outgrowth in vivo. +target gene hsa-mir-135a-1 Gastric Neoplasms 22310976 MiR-135a targets JAK2 and inhibits gastric cancer cell proliferation. +target gene hsa-mir-135a-2 Gastric Neoplasms 22310976 MiR-135a targets JAK2 and inhibits gastric cancer cell proliferation. +target gene hsa-mir-499a "Carcinoma, Hepatocellular" 22311030 "hsa-mir-499 (rs3746444; adenine to guanine [C-T]) .Significant differences were found in frequency and distribution of the genotypes of miRNA-499 between the HCC and the control group. Compared with miRNA-499 T/T, the odds ratio (OR) of patients with miRNA-499 C/C for developing HCC was 3.630 (95% CI: 1.545-8.532), and OR for developing HBV-related HCC was 3.133 (95% CI: 1.248-7.861)." +target gene hsa-mir-200b Gastric Neoplasms 22311119 "MicroRNA-200b Regulates Cell Proliferation, Invasion, and Migration by Directly Targeting ZEB2 in Gastric Carcinoma." +target gene hsa-mir-141 Prostate Neoplasms 22314666 miR-141 modulates androgen receptor transcriptional activity in human prostate cancer cells through targeting the small heterodimer partner protein. +target gene hsa-mir-23a "Carcinoma, Hepatocellular" 22318941 Stat3-mediated activation of miR-23a suppresses gluconeogenesis in hepatocellular carcinoma by downregulating G6PC and PGC-1§Ø©ã +target gene hsa-mir-520b "Carcinoma, Hepatocellular" 22319632 MicroRNA-520b inhibits growth of hepatoma cells by targeting MEKK2 and cyclin D1. +target gene hsa-mir-30c-1 "Carcinoma, Hepatocellular" 22320217 miR-30c-1* promotes natural killer cell cytotoxicity against human hepatoma cells by targeting the transcription factor HMBOX1. +target gene hsa-mir-30c-2 "Carcinoma, Hepatocellular" 22320217 miR-30c-1* promotes natural killer cell cytotoxicity against human hepatoma cells by targeting the transcription factor HMBOX1. +target gene hsa-mir-222 Gastric Neoplasms 22321642 Increased miR-222 in H. pylori-associated gastric cancer correlated with tumor progression by promoting cancer cell proliferation and targeting RECK. +target gene hsa-mir-21 "Carcinoma, Hepatocellular" 22322403 miR-21 promotes migration and invasion by the miR-21-PDCD4-AP-1 feedback loop in human hepatocellular carcinoma. +target gene hsa-mir-21 Colon Neoplasms 22322462 microRNA-21-mediated regulation of Sprouty2 protein expression enhances the cytotoxic effect of 5-fluorouracil and metformin in colon cancer cells. +target gene hsa-mir-182 Gastric Neoplasms 22325466 MicroRNA-182 targets cAMP-responsive element-binding protein 1 and suppresses cell growth in human gastric adenocarcinoma. +target gene hsa-mir-195 Breast Neoplasms 22328513 "miR-195, miR-24-2 and miR-365-2 act as negative regulators of BCL2 through direct binding to their respective binding sites in the 3' UTR of human BCL2 gene.over expression of these miRNAs not only caused an increase in apoptosis but also augmented the ap" +target gene hsa-mir-24-2 Breast Neoplasms 22328513 "miR-195, miR-24-2 and miR-365-2 act as negative regulators of BCL2 through direct binding to their respective binding sites in the 3' UTR of human BCL2 gene.over expression of these miRNAs not only caused an increase in apoptosis but also augmented the ap" +target gene hsa-mir-365b Breast Neoplasms 22328513 "miR-195, miR-24-2 and miR-365-2 act as negative regulators of BCL2 through direct binding to their respective binding sites in the 3' UTR of human BCL2 gene.over expression of these miRNAs not only caused an increase in apoptosis but also augmented the ap" +target gene hsa-mir-106a Rhabdomyosarcoma 22330340 "Downregulation of microRNAs miR-1, -206 and -29 stabilizes PAX3 and CCND2 expression in rhabdomyosarcoma." +target gene hsa-mir-1-1 Rhabdomyosarcoma 22330340 "Downregulation of microRNAs miR-1, -206 and -29 stabilizes PAX3 and CCND2 expression in rhabdomyosarcoma." +target gene hsa-mir-1-2 Rhabdomyosarcoma 22330340 "Downregulation of microRNAs miR-1, -206 and -29 stabilizes PAX3 and CCND2 expression in rhabdomyosarcoma." +target gene hsa-mir-29a Rhabdomyosarcoma 22330340 "Downregulation of microRNAs miR-1, -206 and -29 stabilizes PAX3 and CCND2 expression in rhabdomyosarcoma." +target gene hsa-mir-29b-1 Rhabdomyosarcoma 22330340 "Downregulation of microRNAs miR-1, -206 and -29 stabilizes PAX3 and CCND2 expression in rhabdomyosarcoma." +target gene hsa-mir-29b-2 Rhabdomyosarcoma 22330340 "Downregulation of microRNAs miR-1, -206 and -29 stabilizes PAX3 and CCND2 expression in rhabdomyosarcoma." +target gene hsa-mir-29c Rhabdomyosarcoma 22330340 "Downregulation of microRNAs miR-1, -206 and -29 stabilizes PAX3 and CCND2 expression in rhabdomyosarcoma." +target gene hsa-mir-29a Breast Neoplasms 22330642 "Progestin treatment decreases miR-29, thereby relieving repression of one of its direct targets, the gene encoding ATPase, Na(+)/K(+) transporting, beta 1 polypeptide (ATP1B1). ATP1B1 serves to limit migration and invasion in breast cancer cells. Lastly," +target gene hsa-mir-29b-1 Breast Neoplasms 22330642 "Progestin treatment decreases miR-29, thereby relieving repression of one of its direct targets, the gene encoding ATPase, Na(+)/K(+) transporting, beta 1 polypeptide (ATP1B1). ATP1B1 serves to limit migration and invasion in breast cancer cells. Lastly," +target gene hsa-mir-29b-2 Breast Neoplasms 22330642 "Progestin treatment decreases miR-29, thereby relieving repression of one of its direct targets, the gene encoding ATPase, Na(+)/K(+) transporting, beta 1 polypeptide (ATP1B1). ATP1B1 serves to limit migration and invasion in breast cancer cells. Lastly," +target gene hsa-mir-29c Breast Neoplasms 22330642 "Progestin treatment decreases miR-29, thereby relieving repression of one of its direct targets, the gene encoding ATPase, Na(+)/K(+) transporting, beta 1 polypeptide (ATP1B1). ATP1B1 serves to limit migration and invasion in breast cancer cells. Lastly," +target gene hsa-mir-513a-1 Breast Neoplasms 22330642 "Progestin treatment decreases miR-29, thereby relieving repression of one of its direct targets, the gene encoding ATPase, Na(+)/K(+) transporting, beta 1 polypeptide (ATP1B1). ATP1B1 serves to limit migration and invasion in breast cancer cells. Lastly," +target gene hsa-mir-513a-2 Breast Neoplasms 22330642 "Progestin treatment decreases miR-29, thereby relieving repression of one of its direct targets, the gene encoding ATPase, Na(+)/K(+) transporting, beta 1 polypeptide (ATP1B1). ATP1B1 serves to limit migration and invasion in breast cancer cells. Lastly," +target gene hsa-mir-124-1 Breast Neoplasms 22333974 "miR-124, miR-147 and miR-193a-3p are three novel tumor suppressors that co-target EGFR-driven cell-cycle network proteins and inhibit cell-cycle progression and proliferation in breast cancer." +target gene hsa-mir-124-2 Breast Neoplasms 22333974 "miR-124, miR-147 and miR-193a-3p are three novel tumor suppressors that co-target EGFR-driven cell-cycle network proteins and inhibit cell-cycle progression and proliferation in breast cancer." +target gene hsa-mir-124-3 Breast Neoplasms 22333974 "miR-124, miR-147 and miR-193a-3p are three novel tumor suppressors that co-target EGFR-driven cell-cycle network proteins and inhibit cell-cycle progression and proliferation in breast cancer." +target gene hsa-mir-147a Breast Neoplasms 22333974 "miR-124, miR-147 and miR-193a-3p are three novel tumor suppressors that co-target EGFR-driven cell-cycle network proteins and inhibit cell-cycle progression and proliferation in breast cancer." +target gene hsa-mir-193a Breast Neoplasms 22333974 "miR-124, miR-147 and miR-193a-3p are three novel tumor suppressors that co-target EGFR-driven cell-cycle network proteins and inhibit cell-cycle progression and proliferation in breast cancer." +target gene hsa-mir-24-1 Retinoblastoma 22336108 Regulation of p14ARF expression by miR-24: a potential mechanism compromising the p53 response during retinoblastoma development. +target gene hsa-mir-24-2 Retinoblastoma 22336108 Regulation of p14ARF expression by miR-24: a potential mechanism compromising the p53 response during retinoblastoma development. +target gene hsa-mir-141 Aortic Stenosis 22336757 miRNA-141 is a novel regulator of BMP-2-mediated calcification in aortic stenosis. +target gene hsa-mir-196a-1 Gastric Neoplasms 22343731 MiR-196a Is Up-regulated in Gastric cancer and Promotes Cell proliferation by Down-regulating p27kip1. +target gene hsa-mir-196a-2 Gastric Neoplasms 22343731 MiR-196a Is Up-regulated in Gastric cancer and Promotes Cell proliferation by Down-regulating p27kip1. +target gene hsa-mir-17 "Leukemia, Lymphocytic, Chronic, B-Cell" 22343732 The miR-17-92 family regulates the response to toll-like receptor 9 triggering of CLL cells with unmutated IGHV genes. +target gene hsa-mir-18a "Leukemia, Lymphocytic, Chronic, B-Cell" 22343732 The miR-17-92 family regulates the response to toll-like receptor 9 triggering of CLL cells with unmutated IGHV genes. +target gene hsa-mir-19a "Leukemia, Lymphocytic, Chronic, B-Cell" 22343732 The miR-17-92 family regulates the response to toll-like receptor 9 triggering of CLL cells with unmutated IGHV genes. +target gene hsa-mir-19b-1 "Leukemia, Lymphocytic, Chronic, B-Cell" 22343732 The miR-17-92 family regulates the response to toll-like receptor 9 triggering of CLL cells with unmutated IGHV genes. +target gene hsa-mir-20a "Leukemia, Lymphocytic, Chronic, B-Cell" 22343732 The miR-17-92 family regulates the response to toll-like receptor 9 triggering of CLL cells with unmutated IGHV genes. +target gene hsa-mir-92a-1 "Leukemia, Lymphocytic, Chronic, B-Cell" 22343732 The miR-17-92 family regulates the response to toll-like receptor 9 triggering of CLL cells with unmutated IGHV genes. +target gene hsa-mir-127 Lung Neoplasms 22349807 "Bberrant expression of miRNAs such as miR-29ab, miR-183, miR-17-5p and miR-127-3P may play an important role in regulating the bio-behavior of TICs (tumor initiating cells)." +target gene hsa-mir-17 Lung Neoplasms 22349807 "Bberrant expression of miRNAs such as miR-29ab, miR-183, miR-17-5p and miR-127-3P may play an important role in regulating the bio-behavior of TICs (tumor initiating cells)." +target gene hsa-mir-183 Lung Neoplasms 22349807 "Bberrant expression of miRNAs such as miR-29ab, miR-183, miR-17-5p and miR-127-3P may play an important role in regulating the bio-behavior of TICs (tumor initiating cells)." +target gene hsa-mir-29a Lung Neoplasms 22349807 "Bberrant expression of miRNAs such as miR-29ab, miR-183, miR-17-5p and miR-127-3P may play an important role in regulating the bio-behavior of TICs (tumor initiating cells)." +target gene hsa-mir-29b-1 Lung Neoplasms 22349807 "Bberrant expression of miRNAs such as miR-29ab, miR-183, miR-17-5p and miR-127-3P may play an important role in regulating the bio-behavior of TICs (tumor initiating cells)." +target gene hsa-mir-29b-2 Lung Neoplasms 22349807 "Bberrant expression of miRNAs such as miR-29ab, miR-183, miR-17-5p and miR-127-3P may play an important role in regulating the bio-behavior of TICs (tumor initiating cells)." +target gene hsa-mir-155 Liposarcoma 22350414 MiR-155 is a liposarcoma oncogene that targets casein kinase-1§Ø©ãand enhances §Ø©ãcatenin signaling. +target gene hsa-mir-130a "Leukemia, Lymphocytic, Chronic, B-Cell" 22350415 MicroRNA-130a targets ATG2B and DICER1 to inhibit autophagy and trigger killing of chronic lymphocytic leukemia cells. +target gene hsa-mir-21 Glioblastoma 22353043 Ursolic Acid Inhibits Proliferation and Induces Apoptosis in Human Glioblastoma Cell Lines U251 by Suppressing TGF-beta1/miR-21 /PDCD4 Pathway. +target gene hsa-mir-196b Leukemia 22353710 miR-196b directly targets both HOXA9/MEIS1 oncogenes and FAS tumour suppressor in MLL-rearranged leukaemia. +target gene hsa-mir-143 Breast Neoplasms 22354042 A novel miR-155/miR-143 cascade controls glycolysis by regulating hexokinase 2 in breast cancer cells. +target gene hsa-mir-155 Breast Neoplasms 22354042 A novel miR-155/miR-143 cascade controls glycolysis by regulating hexokinase 2 in breast cancer cells. +target gene hsa-mir-203 Melanoma 22354972 Anti-oncogenic MicroRNA-203 Induces Senescence by Targeting E2F3 in Human Melanoma Cells. +target gene hsa-mir-223 Melanoma 22356618 "MiRTrail identified several deregulated miRNAs that target deregulated mRNAs including miRNAs hsa-miR-23b and hsa-miR-223, which target the highest numbers of deregulated mRNAs and regulate the pathway ""basal cell carcinoma""." +target gene hsa-mir-23b Melanoma 22356618 "MiRTrail identified several deregulated miRNAs that target deregulated mRNAs including miRNAs hsa-miR-23b and hsa-miR-223, which target the highest numbers of deregulated mRNAs and regulate the pathway ""basal cell carcinoma""." +target gene hsa-mir-212 "Carcinoma, Lung, Non-Small-Cell" 22357618 MiR-212 displays Tumor Promoting properties in NSCLC Cells and targets the Hedgehog Pathway Receptor PTCH1. +target gene hsa-mir-138-1 "Carcinoma, Hepatocellular" 22362728 MiR-138 induces cell cycle arrest by targeting cyclin D3 in hepatocellular carcinoma. +target gene hsa-mir-138-2 "Carcinoma, Hepatocellular" 22362728 MiR-138 induces cell cycle arrest by targeting cyclin D3 in hepatocellular carcinoma. +target gene hsa-mir-19a "Leukemia-Lymphoma, Adult T-Cell" 22362744 miR-19 inhibits CYLD in T-cell acute lymphoblastic leukemia. +target gene hsa-mir-19b-1 "Leukemia-Lymphoma, Adult T-Cell" 22362744 miR-19 inhibits CYLD in T-cell acute lymphoblastic leukemia. +target gene hsa-mir-19b-2 "Leukemia-Lymphoma, Adult T-Cell" 22362744 miR-19 inhibits CYLD in T-cell acute lymphoblastic leukemia. +target gene hsa-mir-34a Coronary Artery Disease 22364258 "MicroRNA-34a regulates the longevity-associated protein, SIRT1, in coronary artery disease." +target gene hsa-mir-125b-1 Leukemia 22366319 Oncomir miR-125b regulates hematopoiesis by targeting the gene Lin28A. +target gene hsa-mir-125b-2 Leukemia 22366319 Oncomir miR-125b regulates hematopoiesis by targeting the gene Lin28A. +target gene hsa-mir-34c "Carcinoma, Lung, Non-Small-Cell" 22370637 "The authors found a number of miRNAs (miR-17, miR-135, miR-520, miR-124-1, and miR-34c) that may rescue cell viability from caspase-8 activation. miR-34c-5p markedly increased resistance to paclitaxel-induced apoptosis. We demonstrate that Bmf (Bcl-2-modifying factor) is a target of miR-34c-5p, and that its silencing, together with that of c-myc, a known target of miR-34c-5p, contributes to resistance to apoptosis induced by paclitaxel through p53 downregulation." +target gene hsa-mir-1-1 Prostate Neoplasms 22370643 "Mir-1 and miR-200 were reduced with progression of prostate adenocarcinoma, and we identify Slug as one of the phylogenetically conserved targets of these miRs. The authors demonstrate that SLUG is a direct repressor of miR-1 and miR-200 transcription. Th" +target gene hsa-mir-1-2 Prostate Neoplasms 22370643 "Mir-1 and miR-200 were reduced with progression of prostate adenocarcinoma, and we identify Slug as one of the phylogenetically conserved targets of these miRs. The authors demonstrate that SLUG is a direct repressor of miR-1 and miR-200 transcription. Th" +target gene hsa-mir-200a Prostate Neoplasms 22370643 "Mir-1 and miR-200 were reduced with progression of prostate adenocarcinoma, and we identify Slug as one of the phylogenetically conserved targets of these miRs. The authors demonstrate that SLUG is a direct repressor of miR-1 and miR-200 transcription. Th" +target gene hsa-mir-200b Prostate Neoplasms 22370643 "Mir-1 and miR-200 were reduced with progression of prostate adenocarcinoma, and we identify Slug as one of the phylogenetically conserved targets of these miRs. The authors demonstrate that SLUG is a direct repressor of miR-1 and miR-200 transcription. Th" +target gene hsa-mir-200c Prostate Neoplasms 22370643 "Mir-1 and miR-200 were reduced with progression of prostate adenocarcinoma, and we identify Slug as one of the phylogenetically conserved targets of these miRs. The authors demonstrate that SLUG is a direct repressor of miR-1 and miR-200 transcription. Th" +target gene hsa-mir-301a "Carcinoma, Hepatocellular" 22373864 miR-301a Is a Candidate Oncogene that Targets the Homeobox Gene Gax in Human Hepatocellular Carcinoma. +target gene hsa-mir-15b Liver Failure 22374434 miR-15b and miR-16 regulate TNF mediated hepatocyte apoptosis via BCL2 in acute liver failure. +target gene hsa-mir-16-1 Liver Failure 22374434 miR-15b and miR-16 regulate TNF mediated hepatocyte apoptosis via BCL2 in acute liver failure. +target gene hsa-mir-16-2 Liver Failure 22374434 miR-15b and miR-16 regulate TNF mediated hepatocyte apoptosis via BCL2 in acute liver failure. +target gene hsa-mir-205 Nasopharyngeal Neoplasms 22374676 MiR-205 determines the radioresistance of human nasopharyngeal carcinoma by directly targeting PTEN. +target gene hsa-mir-199b "Leukemia, Myeloid, Acute" 22374871 miR-199b-5p directly targets PODXL and DDR1 and decreased levels of miR-199b-5p correlate with elevated expressions of PODXL and DDR1 in acute myeloid leukemia. +target gene hsa-mir-133a Head And Neck Neoplasms 22378351 The genome-wide gene expression analysis and bioinformatics study showed that actin-related protein 2/3 complex subunit 5 (ARPC5) is a candidate target of miR-133a. +target gene hsa-mir-1 Bladder Neoplasms 22378464 Novel molecular targets regulated by tumor suppressors microRNA-1 and microRNA-133a in bladder cancer. +target gene hsa-mir-133a Bladder Neoplasms 22378464 Novel molecular targets regulated by tumor suppressors microRNA-1 and microRNA-133a in bladder cancer. +target gene hsa-mir-335 Neuroblastoma 22382496 MiRNA-335 Suppresses Neuroblastoma Cell Invasiveness By Direct Targeting of Multiple Genes from the non-Canonical TGF-§Ø©ãSignalling Pathway. +target gene hsa-mir-506 Liver Cirrhosis 22383162 Upregulation of mir-506 leads to decreased AE2 expression in biliary epithelium of patients with primary biliary cirrhosis +target gene hsa-mir-17 Hemangiosarcoma 22383169 The miR-17-92 cluster and its target THBS1 are differentially expressed in angiosarcomas dependent on MYC amplification. +target gene hsa-mir-18a Hemangiosarcoma 22383169 The miR-17-92 cluster and its target THBS1 are differentially expressed in angiosarcomas dependent on MYC amplification. +target gene hsa-mir-19a Hemangiosarcoma 22383169 The miR-17-92 cluster and its target THBS1 are differentially expressed in angiosarcomas dependent on MYC amplification. +target gene hsa-mir-19b-1 Hemangiosarcoma 22383169 The miR-17-92 cluster and its target THBS1 are differentially expressed in angiosarcomas dependent on MYC amplification. +target gene hsa-mir-20a Hemangiosarcoma 22383169 The miR-17-92 cluster and its target THBS1 are differentially expressed in angiosarcomas dependent on MYC amplification. +target gene hsa-mir-92a-1 Hemangiosarcoma 22383169 The miR-17-92 cluster and its target THBS1 are differentially expressed in angiosarcomas dependent on MYC amplification. +target gene hsa-let-7d Pancreatic Neoplasms 22384141 The miRNA is downregulated and regulate known PDAC oncogenes +target gene hsa-mir-126 Pancreatic Neoplasms 22384141 The miRNA is downregulated and regulate known PDAC oncogenes +target gene hsa-mir-16-1 Pancreatic Neoplasms 22384141 The miRNA is downregulated and regulate known PDAC oncogenes +target gene hsa-mir-16-2 Pancreatic Neoplasms 22384141 The miRNA is downregulated and regulate known PDAC oncogenes +target gene hsa-mir-409 Gastric Neoplasms 22388101 MicroRNA-409-3p regulates cell proliferation and apoptosis by targeting PHF10 in gastric cancer. +target gene hsa-mir-216a "Carcinoma, Hepatocellular" 22392644 The androgen pathway stimulates microRNA-216a transcription to suppress the TSLC1 tumor suppressor gene in early hepatocarcinogenesis. +target gene hsa-mir-328 Hypertension 22392900 The MicroRNA-328 Regulates Hypoxic Pulmonary Hypertension by Targeting at Insulin Growth Factor 1 Receptor and L-Type Calcium Channel-alpha1C. +target gene hsa-mir-30a "Leukemia, Myeloid, Chronic-Phase" 22395361 Targeting microRNA-30a-mediated autophagy enhances imatinib activity against human chronic myeloid leukemia cells. +target gene hsa-mir-221 "Carcinoma, Hepatocellular" 22396537 SND1-induced activation of NF-kappaB resulted in induction of miR-221 and subsequent induction of angiogenic factors Angiogenin and CXCL16. Inhibition of either of these components resulted in significant inhibition of SND1-induced angiogenesis thus highlighting the importance of this molecular cascade in regulating SND1 function. +target gene hsa-mir-214 Urinary Bladder Cancer 22399294 MicroRNA-214 Suppresses The Growth and Invasiveness of Cervical Cancer Cells by Targeting UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 7. +target gene hsa-mir-25 Thyroid Neoplasms 22399519 Down-Regulation of the miR-25 and miR-30d Contributes to the Development of Anaplastic Thyroid Carcinoma Targeting the Polycomb Protein EZH2. +target gene hsa-mir-30d Thyroid Neoplasms 22399519 Down-Regulation of the miR-25 and miR-30d Contributes to the Development of Anaplastic Thyroid Carcinoma Targeting the Polycomb Protein EZH2. +target gene hsa-mir-182 Medulloblastoma 22402744 "Pleiotropic effects of miR-183~96~182 converge to regulate cell survival, proliferation and migration in medulloblastoma." +target gene hsa-mir-183 Medulloblastoma 22402744 "Pleiotropic effects of miR-183~96~182 converge to regulate cell survival, proliferation and migration in medulloblastoma." +target gene hsa-mir-96 Medulloblastoma 22402744 "Pleiotropic effects of miR-183~96~182 converge to regulate cell survival, proliferation and migration in medulloblastoma." +target gene hsa-mir-133a-1 Prostate Neoplasms 22407299 "microRNA-133 inhibits cell proliferation, migration and invasion in prostate cancer cells by targeting the epidermal growth factor receptor." +target gene hsa-mir-133a-2 Prostate Neoplasms 22407299 "microRNA-133 inhibits cell proliferation, migration and invasion in prostate cancer cells by targeting the epidermal growth factor receptor." +target gene hsa-mir-133b Prostate Neoplasms 22407299 "microRNA-133 inhibits cell proliferation, migration and invasion in prostate cancer cells by targeting the epidermal growth factor receptor." +target gene hsa-mir-200c Colorectal Carcinoma 22407310 miR-200c inhibits invasion and migration in human colon cancer cells SW480/620 by targeting ZEB1.miR-200c inhibits metastatic ability by targeting ZEB1 in colon cancer cells SW480/620 and suggested that modulation of miR-200c could serve as therapeutic to +target gene hsa-mir-10a Pancreatic Neoplasms 22407312 "Based on the microarray data, the authors found frequent and marked overexpression of miR-10a, miR-92, and miR-17-5p in pancreatic cancer cell lines. MicroRNA-10a is Overexpressed in Human Pancreatic Cancer and Involved in Its Invasiveness Partially via Suppression of the HOXA1 Gene." +target gene hsa-mir-17 Pancreatic Neoplasms 22407312 "Based on the microarray data, the authors found frequent and marked overexpression of miR-10a, miR-92, and miR-17-5p in pancreatic cancer cell lines. MicroRNA-10a is Overexpressed in Human Pancreatic Cancer and Involved in Its Invasiveness Partially via Suppression of the HOXA1 Gene." +target gene hsa-mir-92a-1 Pancreatic Neoplasms 22407312 "Based on the microarray data, the authors found frequent and marked overexpression of miR-10a, miR-92, and miR-17-5p in pancreatic cancer cell lines. MicroRNA-10a is Overexpressed in Human Pancreatic Cancer and Involved in Its Invasiveness Partially via Suppression of the HOXA1 Gene." +target gene hsa-mir-27a Breast Neoplasms 22407812 "Betulinic acid decreases ER-negative breast cancer cell growth in vitro and in vivo: Role of Sp transcription factors and microRNA-27a:ZBTB10.BA induced cell cycle arrest in the G2/M phase and increased Myt-1 mRNA (a microRNA-27a target gene), which causes inhibition in G2/M by phosphorylation of cdc2." +target gene hsa-let-7f-1 Breast Neoplasms 22407818 "Aromatase inhibitor treatment of breast cancer cells increases the expression of let-7f, a microRNA targeting CYP19A1." +target gene hsa-mir-148a Myositis Ossificans 22408438 "ACVR1, a Therapeutic Target of Fibrodysplasia Ossificans Progressiva, Is Negatively Regulated by miR-148a." +target gene hsa-mir-520h Lung Neoplasms 22410781 MiR-520h-mediated FOXC2 regulation is critical for inhibition of lung cancer progression by resveratrol. +target gene hsa-mir-365a Polycystic Kidney Disease 22411058 PKHD1 post-transcriptionally modulated by miR-365-1 inhibits cell-cell adhesion. +target gene hsa-mir-125b-1 Glioblastoma 22415301 Myc-associated zinc finger protein (MAZ) is regulated by miR-125b and mediates VEGF-induced angiogenesis in glioblastoma. +target gene hsa-mir-125b-2 Glioblastoma 22415301 Myc-associated zinc finger protein (MAZ) is regulated by miR-125b and mediates VEGF-induced angiogenesis in glioblastoma. +target gene hsa-mir-34b Melanoma 22419847 MicroRNA-34b/c suppresses uveal melanoma cell proliferation and migration through multiple targets. +target gene hsa-mir-34c Melanoma 22419847 MicroRNA-34b/c suppresses uveal melanoma cell proliferation and migration through multiple targets. +target gene hsa-mir-542 Lung Neoplasms 22426479 miR-542-5p targets EGFR and inhibited the growth of human lung cancer cells. +target gene hsa-mir-25 Glioblastoma 22431589 "In this study, two miRNAs, miR-25 and -32, are identified as p53-repressed miRNAs by p53-dependent negative regulation of their transcriptional regulators, E2F1 and MYC. However, miR-25 and -32 result in p53 accumulation by directly targeting Mdm2 and TSC1, which are negative regulators of p53." +target gene hsa-mir-32 Glioblastoma 22431589 "In this study, two miRNAs, miR-25 and -32, are identified as p53-repressed miRNAs by p53-dependent negative regulation of their transcriptional regulators, E2F1 and MYC. However, miR-25 and -32 result in p53 accumulation by directly targeting Mdm2 and TSC1, which are negative regulators of p53." +target gene hsa-mir-141 Kidney Neoplasms 22431721 "miR-192, miR-194, miR-215, miR-200c and miR-141 are downregulated and their common target ACVR2B is strongly expressed in renal childhood neoplasms." +target gene hsa-mir-192 Kidney Neoplasms 22431721 "miR-192, miR-194, miR-215, miR-200c and miR-141 are downregulated and their common target ACVR2B is strongly expressed in renal childhood neoplasms." +target gene hsa-mir-200c Kidney Neoplasms 22431721 "miR-192, miR-194, miR-215, miR-200c and miR-141 are downregulated and their common target ACVR2B is strongly expressed in renal childhood neoplasms." +target gene hsa-mir-215 Kidney Neoplasms 22431721 "miR-192, miR-194, miR-215, miR-200c and miR-141 are downregulated and their common target ACVR2B is strongly expressed in renal childhood neoplasms." +target gene hsa-let-7c "Carcinoma, Hepatocellular" 22433309 let-7c can inhibit proliferation of HCCLM3 cells and increase the proportion of cells in G1 phase. The mechanism may be that let-7c represses the expressions of cyclin D1 at both protein and mRNA levels. +target gene hsa-mir-21 Breast Neoplasms 22435731 MiR-21 regulates EMT phenotype and HIF-1§Ø©ãexpression in third-sphereforming breast cancer stem cell-like cells. +target gene hsa-mir-17 Preeclampsia 22438230 "Preeclampsia Up-Regulates Angiogenesis-Associated MicroRNA (i.e., miR-17, -20a, and -20b) That Target Ephrin-B2 and EPHB4 in Human Placenta." +target gene hsa-mir-20a Preeclampsia 22438230 "Preeclampsia Up-Regulates Angiogenesis-Associated MicroRNA (i.e., miR-17, -20a, and -20b) That Target Ephrin-B2 and EPHB4 in Human Placenta." +target gene hsa-mir-20b Preeclampsia 22438230 "Preeclampsia Up-Regulates Angiogenesis-Associated MicroRNA (i.e., miR-17, -20a, and -20b) That Target Ephrin-B2 and EPHB4 in Human Placenta." +target gene hsa-mir-135a-1 Breast Neoplasms 22439757 miRNA-135a promotes breast cancer cell migration and invasion by targeting HOXA10. +target gene hsa-mir-135a-2 Breast Neoplasms 22439757 miRNA-135a promotes breast cancer cell migration and invasion by targeting HOXA10. +target gene hsa-mir-128-1 Glioma 22442669 miR-128 expression levels were decreased in glioma. MiR-128 Inhibits Tumor Growth and Angiogenesis by Targeting p70S6K1. +target gene hsa-mir-128-2 Glioma 22442669 miR-128 expression levels were decreased in glioma. MiR-128 Inhibits Tumor Growth and Angiogenesis by Targeting p70S6K1. +target gene hsa-mir-181b-1 Liver Cirrhosis 22446332 miR-181b Promotes hepatic stellate cells proliferation by targeting p27 and is elevated in the serum of cirrhosis patients. +target gene hsa-mir-181b-2 Liver Cirrhosis 22446332 miR-181b Promotes hepatic stellate cells proliferation by targeting p27 and is elevated in the serum of cirrhosis patients. +target gene hsa-mir-328 Myopia 22447870 MicroRNA-328 may influence myopia development by mediating the PAX6 gene. +target gene hsa-mir-219 "Carcinoma, Hepatocellular" 22449976 MiR-219-5p inhibits hepatocellular carcinoma cell proliferation by targeting glypican-3. +target gene hsa-mir-20a Urinary Bladder Cancer 22449978 miR-20a promotes migration and invasion by regulating TNKS2 in human cervical cancer cells. +target gene hsa-mir-124-1 Gastric Neoplasms 22450659 MiR-124 Inhibits Cell Proliferation in Gastric Cancer through Downregulation of SPHK1. +target gene hsa-mir-124-2 Gastric Neoplasms 22450659 MiR-124 Inhibits Cell Proliferation in Gastric Cancer through Downregulation of SPHK1. +target gene hsa-mir-124-3 Gastric Neoplasms 22450659 MiR-124 Inhibits Cell Proliferation in Gastric Cancer through Downregulation of SPHK1. +target gene hsa-mir-372 Lung Neoplasms 22451061 "In addition, there is evidence that miR-372 posttranscriptionally downregulates large tumor suppressor, homolog 2 (Lats2), resulting in tumorigenesis and proliferation. " +target gene hsa-mir-133a-1 Ovarian Neoplasms 22452920 "Other pairs of potentially biological relevance include: hsa-miR-145/E2F3, hsa-miR-139-5p/TOP2A, and hsa-miR-133a/GCLC." +target gene hsa-mir-133a-2 Ovarian Neoplasms 22452920 "Other pairs of potentially biological relevance include: hsa-miR-145/E2F3, hsa-miR-139-5p/TOP2A, and hsa-miR-133a/GCLC." +target gene hsa-mir-145 Ovarian Neoplasms 22452920 "Other pairs of potentially biological relevance include: hsa-miR-145/E2F3, hsa-miR-139-5p/TOP2A, and hsa-miR-133a/GCLC." +target gene hsa-mir-328 Colorectal Carcinoma 22453125 MicroRNA expression profiling identifies miR-328 regulates cancer stem cell-like SP cells in colorectal cancer. +target gene hsa-mir-23a Colorectal Carcinoma 22455847 "MiR-23a expression promotes colon carcinoma cell growth, invasion and metastasis through inhibition of MTSS gene." +target gene hsa-mir-143 Esophageal Neoplasms 22457808 The Cluster of miR-143 and miR-145 Affects the Risk for Esophageal Squamous Cell Carcinoma through Co-Regulating Fascin Homolog 1. +target gene hsa-mir-145 Esophageal Neoplasms 22457808 The Cluster of miR-143 and miR-145 Affects the Risk for Esophageal Squamous Cell Carcinoma through Co-Regulating Fascin Homolog 1. +target gene hsa-mir-320a Colorectal Carcinoma 22459450 MicroRNA-320a suppresses human colon cancer cell proliferation by directly targeting beta-catenin. +target gene hsa-mir-125b-1 Endometrial Neoplasms 22460089 MicroRNA-125b down-regulation mediates endometrial cancer invasion by targeting ERBB2. +target gene hsa-mir-125b-2 Endometrial Neoplasms 22460089 MicroRNA-125b down-regulation mediates endometrial cancer invasion by targeting ERBB2. +target gene hsa-mir-21 Gastric Neoplasms 22464652 "MicroRNA-21 inhibits Serpini1, a gene with novel tumour suppressive effects in gastric cancer." +target gene hsa-mir-483 Glioma 22465663 MiR-483-5p suppresses the proliferation of glioma cells via directly targeting ERK1. +target gene hsa-mir-93 Ovarian Neoplasms 22465665 "Involvement of microRNA-93, a new regulator of PTEN/Akt signaling pathway, in regulation of chemotherapeutic drug cisplatin chemosensitivity in ovarian cancer cells." +target gene hsa-mir-26a-1 Lung Neoplasms 22469510 MicroRNA-26a regulates tumorigenic properties of EZH2 in human lung carcinoma cells. +target gene hsa-mir-26a-2 Lung Neoplasms 22469510 MicroRNA-26a regulates tumorigenic properties of EZH2 in human lung carcinoma cells. +target gene hsa-mir-125b-1 "Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic" 22469780 B-cell regulator of immunoglobulin heavy chain transcription (Bright)/ARID3a is a direct target of the oncomir microRNA-125b in progenitor B-cells. +target gene hsa-mir-125b-2 "Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic" 22469780 B-cell regulator of immunoglobulin heavy chain transcription (Bright)/ARID3a is a direct target of the oncomir microRNA-125b in progenitor B-cells. +target gene hsa-mir-495 Gastric Neoplasms 22469786 MiR-495 and miR-551a inhibit the migration and invasion of human gastric cancer cells by directly interacting with PRL-3. +target gene hsa-mir-551a Gastric Neoplasms 22469786 MiR-495 and miR-551a inhibit the migration and invasion of human gastric cancer cells by directly interacting with PRL-3. +target gene hsa-mir-183 Ovarian Neoplasms 22469921 "Tiam1, negatively regulated by miR-22, miR-183 and miR-31, is involved in migration, invasion and viability of ovarian cancer cells." +target gene hsa-mir-22 Ovarian Neoplasms 22469921 "Tiam1, negatively regulated by miR-22, miR-183 and miR-31, is involved in migration, invasion and viability of ovarian cancer cells." +target gene hsa-mir-31 Ovarian Neoplasms 22469921 "Tiam1, negatively regulated by miR-22, miR-183 and miR-31, is involved in migration, invasion and viability of ovarian cancer cells." +target gene hsa-mir-143 Head And Neck Neoplasms 22469988 miR-143 regulates hexokinase 2 expression in cancer cells. +target gene hsa-mir-155 Glioblastoma 22470130 miR-155 is up-regulated in primary and secondary glioblastoma and promotes tumour growth by inhibiting GABA receptors. +target gene hsa-mir-140 "Squamous Cell Carcinoma, Oral" 22470160 "miR-140-3p, miR-29c, and miR-29a were differentially expressed in metastasis versus nonmetastatic samples and had a strong positive correlation with their DNA copy numbers and a negative correlation with the expression of their target genes." +target gene hsa-mir-29a "Squamous Cell Carcinoma, Oral" 22470160 "miR-140-3p, miR-29c, and miR-29a were differentially expressed in metastasis versus nonmetastatic samples and had a strong positive correlation with their DNA copy numbers and a negative correlation with the expression of their target genes." +target gene hsa-mir-29c "Squamous Cell Carcinoma, Oral" 22470160 "miR-140-3p, miR-29c, and miR-29a were differentially expressed in metastasis versus nonmetastatic samples and had a strong positive correlation with their DNA copy numbers and a negative correlation with the expression of their target genes." +target gene hsa-mir-223 Gastric Neoplasms 22470493 Stathmin1 Plays Oncogenic Role and Is a Target of MicroRNA-223 in Gastric Cancer. +target gene hsa-mir-145 Osteosarcoma 22472569 MicroRNA-145 targets vascular endothelial growth factor and inhibits invasion and metastasis of osteosarcoma cells. +target gene hsa-mir-135b Prostate Neoplasms 22473899 The results show that MUC1-C activates a posttranscriptional mechanism involving miR-135b-mediated downregulation of AR mRNA levels. +target gene hsa-mir-30a Breast Neoplasms 22476851 MicroRNA-30a inhibits cell migration and invasion by downregulating vimentin expression and is a potential prognostic marker in breast cancer. +target gene hsa-mir-34a Colon Neoplasms 22479251 "miR-34a induces colon cancer apoptosis through SIRT1, and miR-34a also promotes senescence in endothelial cells via SIRT1." +target gene hsa-mir-34a Glioma 22479456 miR-34a Repression in Proneural Malignant Gliomas Upregulates Expression of Its Target PDGFRA and Promotes Tumorigenesis. +target gene hsa-mir-141 Hepatitis B Virus Infection 22479552 MicroRNA-141 Represses HBV Replication by Targeting PPARA +target gene hsa-mir-107 Myocardial Infarction 22482882 IPC enhances stem cell survival via the combined participation of hypoxia responsive miRs miR-107 and miR-210 via their respective putative target genes Pdcd10 and Casp8ap2. +target gene hsa-mir-210 Myocardial Infarction 22482882 IPC enhances stem cell survival via the combined participation of hypoxia responsive miRs miR-107 and miR-210 via their respective putative target genes Pdcd10 and Casp8ap2. +target gene hsa-mir-26a-1 Cholangiocarcinoma 22484120 MicroRNA-26a Promotes Cholangiocarcinoma Growth by Activating beta-catenin. +target gene hsa-mir-26a-2 Cholangiocarcinoma 22484120 MicroRNA-26a Promotes Cholangiocarcinoma Growth by Activating beta-catenin. +target gene hsa-mir-22 Lung Neoplasms 22484852 miR-22 suppresses lung cancer cell progression through post-transcriptional regulation of ErbB3. +target gene hsa-mir-302c Skin Neoplasms 22486352 "Co-treatment with decitabine and doxorubicin results first in increased OCT4 and mir-145, then a decrease in both, suggesting that OCT4 and mir-145 regulate each other." +target gene hsa-mir-1258 "Carcinoma, Lung, Non-Small-Cell" 22488243 The miR-1258 regulates the expression level of HPSE to influence the morbidity and metastasis of NSCLC. +target gene hsa-mir-574 Colorectal Carcinoma 22490519 miR-574-5p negatively regulates Qki6/7 to impact §Ø©ãcatenin/Wnt signalling and the development of colorectal cancer. +target gene hsa-mir-199a-1 Ovarian Neoplasms 22498306 MicroRNA-199a targets CD44 to suppress the tumorigenicity and multi-drug resistance of ovarian cancer-initiating cells. +target gene hsa-mir-199a-2 Ovarian Neoplasms 22498306 MicroRNA-199a targets CD44 to suppress the tumorigenicity and multi-drug resistance of ovarian cancer-initiating cells. +target gene hsa-mir-375 "Carcinoma, Hepatocellular" 22504094 miR-375 was down-regulated in HCC cells and tissues; it inhibited autophagy under hypoxic conditions by suppressing the conversion of LC3I to LC3II and thereby autophagic flux. +target gene hsa-mir-145 Barrett Esophagus 22504665 microRNA-145 in Barrett's oesophagus: regulating BMP4 signalling via GATA6. +target gene hsa-mir-27a Prostate Neoplasms 22505583 "Androgen regulated processing of the oncomir MiR-27a, which targets Prohibitin in prostate cancer." +target gene hsa-mir-101 Prostate Neoplasms 22505648 The repressing activity of EZH2 on RKIP expression was dependent on histone deacetylase promoter recruitment and was negatively regulated upstream by miR-101. +target gene hsa-mir-126 "Carcinoma, Lung, Non-Small-Cell" 22510476 miR-126 enhances the sensitivity of non-small cell lung cancer cells to anticancer agents by targeting vascular endothelial growth factor A. +target gene hsa-mir-204 "Carcinoma, Renal Cell" 22516261 VHL-Regulated MiR-204 Suppresses Tumor Growth through Inhibition of LC3B-Mediated Autophagy in Renal Clear Cell Carcinoma. +target gene hsa-mir-301a Demyelinating Diseases 22517757 "Both in vivo and in vitro, myelin antigen stimulation resulted in significant up-regulation of miR-301a, miR-21, and miR-155. miR-301a has a role in regulating the function of myelin-reactive T-helper type 17 cells, supporting a role for miR-301a as candidate for therapeutic targets for controlling of autoimmune demyelination." +target gene hsa-mir-298 Breast Neoplasms 22521303 Increased expression of P-glycoprotein and doxorubicin chemoresistance of metastatic breast cancer is regulated by miR-298. +target gene hsa-mir-126 Diabetes Mellitus 22525256 "Downregulation of microRNA-126 in endothelial progenitor cells from diabetes patients, impairs their functional properties, via target gene Spred-1." +target gene hsa-mir-183 Osteosarcoma 22525461 Down-regulation of miR-183 promotes migration and invasion of osteosarcoma by targeting Ezrin. +target gene hsa-mir-10b "Carcinoma, Hepatocellular" 22528944 MicroRNA-10b promotes migration and invasion through CADM1 in human hepatocellular carcinoma cells. +target gene hsa-mir-3151 "Leukemia, Myeloid, Acute" 22529287 miR-3151 interplays with its host gene BAALC and independently affects outcome of patients with cytogenetically normal acute myeloid leukemia. +target gene hsa-mir-143 Colorectal Carcinoma 22533346 MicroRNA-143 targets MACC1 to inhibit cell invasion and migration in colorectal cancer. +target gene hsa-mir-181b-1 Gastric Neoplasms 22539488 MicroRNA-181b targets cAMP responsive element binding protein 1 in gastric adenocarcinomas. +target gene hsa-mir-181b-2 Gastric Neoplasms 22539488 MicroRNA-181b targets cAMP responsive element binding protein 1 in gastric adenocarcinomas. +target gene hsa-mir-214 Cholangiocarcinoma 22540680 Downregulated miR-214 contributes to intrahepatic cholangiocarcinoma metastasis by targeting Twist. +target gene hsa-mir-143 Colorectal Carcinoma 22549179 Down-regulation of KRAS-interacting miRNA-143 predicts poor prognosis but not response to EGFR-targeted agents in colorectal cancer. +target gene hsa-mir-27a Breast Neoplasms 22553354 Betulinic Acid Targets YY1 and ErbB2 through Cannabinoid Receptor-dependent Disruption of MicroRNA-27a:ZBTB10 in Breast Cancer. +target gene hsa-mir-205 Prostate Neoplasms 22555458 miR-205 regulates basement membrane deposition in human prostate. +target gene hsa-mir-106b Leiomyoma 22556343 "miR-93/106b and Their Host Gene, MCM7, Are Differentially Expressed in Leiomyomas and Functionally Target F3 and IL-8." +target gene hsa-mir-93 Leiomyoma 22556343 "miR-93/106b and Their Host Gene, MCM7, Are Differentially Expressed in Leiomyomas and Functionally Target F3 and IL-8." +target gene hsa-mir-10a Glioblastoma 22558405 "a tumor suppressor, CSMD1, as a downstream target of miR-10a and miR-10b, two of the up-regulated miRNAs." +target gene hsa-mir-10b Glioblastoma 22558405 "a tumor suppressor, CSMD1, as a downstream target of miR-10a and miR-10b, two of the up-regulated miRNAs." +target gene hsa-mir-19a Urinary Bladder Cancer 22561557 MicroRNA-19a and -19b regulate cervical carcinoma cell proliferation and invasion by targeting CUL5. +target gene hsa-mir-19b-1 Urinary Bladder Cancer 22561557 MicroRNA-19a and -19b regulate cervical carcinoma cell proliferation and invasion by targeting CUL5. +target gene hsa-mir-19b-2 Urinary Bladder Cancer 22561557 MicroRNA-19a and -19b regulate cervical carcinoma cell proliferation and invasion by targeting CUL5. +target gene hsa-mir-9-1 Neuroblastoma 22564723 "microRNA-9 targets matrix metalloproteinase 14 to inhibit invasion, metastasis, and angiogenesis of neuroblastoma cells." +target gene hsa-mir-9-2 Neuroblastoma 22564723 "microRNA-9 targets matrix metalloproteinase 14 to inhibit invasion, metastasis, and angiogenesis of neuroblastoma cells." +target gene hsa-mir-9-3 Neuroblastoma 22564723 "microRNA-9 targets matrix metalloproteinase 14 to inhibit invasion, metastasis, and angiogenesis of neuroblastoma cells." +target gene hsa-mir-181d Glioblastoma 22570426 miR-181d: a predictive glioblastoma biomarker that downregulates MGMT expression. +target gene hsa-mir-10b Breast Neoplasms 22573479 Targeting of syndecan-1 by microRNA miR-10b promotes breast cancer cell motility and invasiveness via a Rho-GTPase- and E-cadherin-dependent mechanism. +target gene hsa-mir-139 Colorectal Carcinoma 22580051 MiR-139 inhibits invasion and metastasis of colorectal cancer by targeting the type I insulin-like growth factor receptor. +target gene hsa-mir-34a Glioblastoma 22580610 miR-34a functions as a tumor suppressor modulating EGFR in glioblastoma multiforme. +target gene hsa-mir-181a-2 Gastric Neoplasms 22581522 MicroRNA-181a promotes gastric cancer by negatively regulating tumor suppressor KLF6. +target gene hsa-mir-93 Colorectal Carcinoma 22581829 MicroRNA-93 inhibits tumor growth and early relapse of human colorectal cancer by affecting genes involved in the cell cycle. +target gene hsa-mir-381 Lung Neoplasms 22592211 MicroRNA-381 represses ID1 and is deregulated in lung adenocarcinoma. +target gene hsa-mir-145 Breast Neoplasms 22592534 MiR-145 inhibits tumor angiogenesis and growth by N-RAS and VEGF. +target gene hsa-mir-103a-1 Colorectal Carcinoma 22593189 miR-103/107 Promote Metastasis of Colorectal Cancer by Targeting the Metastasis Suppressors DAPK and KLF4. +target gene hsa-mir-103a-2 Colorectal Carcinoma 22593189 miR-103/107 Promote Metastasis of Colorectal Cancer by Targeting the Metastasis Suppressors DAPK and KLF4. +target gene hsa-mir-103b-1 Colorectal Carcinoma 22593189 miR-103/107 Promote Metastasis of Colorectal Cancer by Targeting the Metastasis Suppressors DAPK and KLF4. +target gene hsa-mir-103b-2 Colorectal Carcinoma 22593189 miR-103/107 Promote Metastasis of Colorectal Cancer by Targeting the Metastasis Suppressors DAPK and KLF4. +target gene hsa-mir-107 Colorectal Carcinoma 22593189 miR-103/107 Promote Metastasis of Colorectal Cancer by Targeting the Metastasis Suppressors DAPK and KLF4. +target gene hsa-mir-150 Adenovirus Infection 22595456 Our study demonstrates that miR-150 regulates surfactant secretion through P2X7R. +target gene hsa-mir-181a-2 "Leukemia, Lymphocytic, Chronic, B-Cell" 22610076 miR-181a/b significantly enhances drug sensitivity in chronic lymphocytic leukemia cells via targeting multiple anti-apoptosis genes. +target gene hsa-mir-181b-1 "Leukemia, Lymphocytic, Chronic, B-Cell" 22610076 miR-181a/b significantly enhances drug sensitivity in chronic lymphocytic leukemia cells via targeting multiple anti-apoptosis genes. +target gene hsa-mir-181b-2 "Leukemia, Lymphocytic, Chronic, B-Cell" 22610076 miR-181a/b significantly enhances drug sensitivity in chronic lymphocytic leukemia cells via targeting multiple anti-apoptosis genes. +target gene hsa-mir-7-1 Gastric Neoplasms 22614005 MicroRNA-7 functions as an anti-metastatic microRNA in gastric cancer by targeting insulin-like growth factor-1 receptor. +target gene hsa-mir-7-2 Gastric Neoplasms 22614005 MicroRNA-7 functions as an anti-metastatic microRNA in gastric cancer by targeting insulin-like growth factor-1 receptor. +target gene hsa-mir-7-3 Gastric Neoplasms 22614005 MicroRNA-7 functions as an anti-metastatic microRNA in gastric cancer by targeting insulin-like growth factor-1 receptor. +target gene hsa-mir-27a Glioma 22614734 Lentiviral expression of anti-microRNAs targeting miR-27a inhibits proliferation and invasiveness of U87 glioma cells. +target gene hsa-mir-27b Cryptosporidium infection 22615562 miR-27b targets KSRP to coordinate TLR4-mediated epithelial defense against Cryptosporidium parvum infection. +target gene hsa-mir-181b Inflammation 22622040 MicroRNA-181b regulates NF-¦ÊB-mediated vascular inflammation. +target gene hsa-mir-21 Glioma 22630347 MicroRNA-21 expression is regulated by §Ø©ãcatenin/STAT3 pathway and promotes glioma cell invasion by direct targeting RECK. +target gene hsa-mir-10a Urinary Bladder Cancer 22634495 "MicroRNA-10a targets CHL1 and promotes cell growth, migration and invasion in human cervical cancer cells." +target gene hsa-mir-200a Pancreatic Neoplasms 22637745 Re-expression of miR-200 by novel approaches regulates the expression of PTEN and MT1-MMP in pancreatic cancer. +target gene hsa-mir-200b Pancreatic Neoplasms 22637745 Re-expression of miR-200 by novel approaches regulates the expression of PTEN and MT1-MMP in pancreatic cancer. +target gene hsa-mir-200c Pancreatic Neoplasms 22637745 Re-expression of miR-200 by novel approaches regulates the expression of PTEN and MT1-MMP in pancreatic cancer. +target gene hsa-mir-133a-1 Esophageal Neoplasms 22641236 CD47 expression regulated by the miR-133a tumor suppressor is a novel prognostic marker in esophageal squamous cell carcinoma. +target gene hsa-mir-133a-2 Esophageal Neoplasms 22641236 CD47 expression regulated by the miR-133a tumor suppressor is a novel prognostic marker in esophageal squamous cell carcinoma. +target gene hsa-mir-139 Colorectal Carcinoma 22642900 Regulation of RAP1B by miR-139 suppresses human colorectal carcinoma cell proliferation. +target gene hsa-mir-21 Prostate Neoplasms 22642976 "miR-21 may acts as an oncomir by targeting RECK, a matrix metalloproteinase regulator, in prostate cancer." +target gene hsa-mir-23b Inflammation 22660635 "The microRNA miR-23b suppresses IL-17-associated autoimmune inflammation by targeting TAB2, TAB3 and IKK-a." +target gene hsa-mir-26a Heart Failure 22664106 Up-regulation of miR-26a promotes apoptosis of hypoxic rat neonatal cardiomyocytes by repressing GSK-3¦Â protein expression. +target gene hsa-mir-1-1 "Carcinoma, Hepatocellular" 22664953 MicroRNA-1 and microRNA-499 downregulate the expression of the ets1 proto-oncogene in HepG2 cells. +target gene hsa-mir-1-2 "Carcinoma, Hepatocellular" 22664953 MicroRNA-1 and microRNA-499 downregulate the expression of the ets1 proto-oncogene in HepG2 cells. +target gene hsa-mir-499a "Carcinoma, Hepatocellular" 22664953 MicroRNA-1 and microRNA-499 downregulate the expression of the ets1 proto-oncogene in HepG2 cells. +target gene hsa-mir-499b "Carcinoma, Hepatocellular" 22664953 MicroRNA-1 and microRNA-499 downregulate the expression of the ets1 proto-oncogene in HepG2 cells. +target gene hsa-mir-193b Colorectal Carcinoma 22674437 "MicroRNA-199a-3p, microRNA-193b, and microRNA-320c are correlated to aging and regulate human cartilage metabolism." +target gene hsa-mir-199a-1 Colorectal Carcinoma 22674437 "MicroRNA-199a-3p, microRNA-193b, and microRNA-320c are correlated to aging and regulate human cartilage metabolism." +target gene hsa-mir-199a-2 Colorectal Carcinoma 22674437 "MicroRNA-199a-3p, microRNA-193b, and microRNA-320c are correlated to aging and regulate human cartilage metabolism." +target gene hsa-mir-320c-1 Colorectal Carcinoma 22674437 "MicroRNA-199a-3p, microRNA-193b, and microRNA-320c are correlated to aging and regulate human cartilage metabolism." +target gene hsa-mir-320c-2 Colorectal Carcinoma 22674437 "MicroRNA-199a-3p, microRNA-193b, and microRNA-320c are correlated to aging and regulate human cartilage metabolism." +target gene hsa-mir-297 Colorectal Carcinoma 22676135 miR-297 modulates multidrug resistance in human colorectal carcinoma by down-regulating MRP-2. +target gene hsa-mir-222 Colorectal Carcinoma 22677042 MiR-222 modulates multidrug resistance in human colorectal carcinoma by down-regulating ADAM-17. +target gene hsa-mir-625 Gastric Neoplasms 22677169 Down-regulated miR-625 suppresses invasion and metastasis of gastric cancer by targeting ILK. +target gene hsa-mir-101 "Leukemia, Lymphoblastic, Acute" 22677230 We also found that p23 was regulated by hsa-miR-101 which was down-regulated in childhood ALL cases. +target gene hsa-mir-21 Breast Neoplasms 22678116 miR-21 is targeted by omega-3 polyunsaturated fatty acid to regulate breast tumor CSF-1 expression. +target gene hsa-mir-203 Inflammation 22679274 The top-ranked predicted target of the highly down-regulated miRNA-203 in asthmatic cells was the aquaporin gene AQP4. +target gene hsa-mir-34a Glioma 22684560 MicroRNA-34a inhibits human brain glioma cell growth by down-regulation of Notch1. +target gene hsa-mir-34a Urinary Bladder Cancer 22684561 microRNA-34a inhibit cell migration and invasion of invasive urothelial bladder carcinoma by targeting Notch1. +target gene hsa-mir-15a Odontogenic Tumors 22684875 miR-15a/16-1 influences BCL2 expression in keratocystic odontogenic tumors. +target gene hsa-mir-16-1 Odontogenic Tumors 22684875 miR-15a/16-1 influences BCL2 expression in keratocystic odontogenic tumors. +target gene hsa-mir-16-2 Odontogenic Tumors 22684875 miR-15a/16-1 influences BCL2 expression in keratocystic odontogenic tumors. +target gene hsa-mir-590 "Carcinoma, Hepatocellular" 22684895 MicroRNA-590-5p regulates proliferation and invasion in human hepatocellular carcinoma cells by targeting TGF-beta RII. +target gene hsa-mir-200a Leiomyoma 22685266 "miR-200c is aberrantly expressed in leiomyomas in an ethnic-dependent manner and targets ZEBs, VEGFA, TIMP2, and FBLN5." +target gene hsa-mir-200c Leiomyoma 22685266 "miR-200c is aberrantly expressed in leiomyomas in an ethnic-dependent manner and targets ZEBs, VEGFA, TIMP2, and FBLN5." +target gene hsa-mir-93 Breast Neoplasms 22685420 MicroRNA93 regulates proliferation and differentiation of normal and malignant breast stem cells. +target gene hsa-mir-21 "Carcinoma, Renal Cell" 22685542 microRNA-21 governs TORC1 activation in renal cancer cell proliferation and invasion. +target gene hsa-mir-143 Colon Neoplasms 22691140 microRNA-143 down-regulates Hexokinase 2 in colon cancer cells. +target gene hsa-mir-125b-1 Breast Neoplasms 22693547 MicroRNA-125b induces metastasis by targeting STARD13 in MCF-7 and MDA-MB-231 breast cancer cells. +target gene hsa-mir-125b-2 Breast Neoplasms 22693547 MicroRNA-125b induces metastasis by targeting STARD13 in MCF-7 and MDA-MB-231 breast cancer cells. +target gene hsa-mir-30c-1 Breast Neoplasms 22701724 miR-30c overexpression inhibited proliferation of breast cancer cells.miR-30c binds the 3'UTR of KRAS transcripts and expression of pre-miR-30c down-regulated KRAS mRNA and protein. +target gene hsa-mir-30c-2 Breast Neoplasms 22701724 miR-30c overexpression inhibited proliferation of breast cancer cells.miR-30c binds the 3'UTR of KRAS transcripts and expression of pre-miR-30c down-regulated KRAS mRNA and protein. +target gene hsa-mir-34a Neuroblastoma 22703967 Inhibition of cyclin-dependent kinase 1-induced cell death in neuroblastoma cells through the microRNA-34a-MYCN-survivin pathway. +target gene hsa-mir-21 Glioblastoma 22709411 MiR-21 Modulates hTERT Through a STAT3-Dependent Manner on Glioblastoma Cell Growth. +target gene hsa-mir-23b Prostate Neoplasms 22710126 MicroRNA-23b downregulates peroxiredoxin III in human prostate cancer. +target gene hsa-mir-497 Colorectal Carcinoma 22710713 MicroRNA-497 targets insulin-like growth factor 1 receptor and has a tumour suppressive role in human colorectal cancer. +target gene hsa-mir-632 Breast Neoplasms 22710984 Micro-RNA-632 downregulates DNAJB6 in breast cancer. +target gene hsa-mir-146a Gastric Neoplasms 22711166 microRNA-146a targets the L1 cell adhesion molecule and suppresses the metastatic potential of gastric cancer. +target gene hsa-mir-203 Breast Neoplasms 22713668 MicroRNA-203 suppresses cell proliferation and migration by targeting BIRC5 and LASP1 in human triple-negative breast cancer cells. +target gene hsa-mir-204 Nervous System Diseases [unspecific] 22718995 MicroRNA-204 critically regulates carcinogenesis in malignant peripheral nerve sheath tumors. +target gene hsa-mir-155 Gastrointestinal Neoplasms 22719182 "As a possible new mechanism underlying MSI, overexpression of miR-155 has been shown to downregulate expression of MLH1, MSH2, and MSH6. Thus, a subset of MSI-positive (MSI+) cancers without known MMR defects may result from miR-155 overexpression. " +target gene hsa-mir-195 Alzheimer Disease 22721728 MicroRNA-195 downregulates Alzheimer's disease amyloid-beta production by targeting BACE1. +target gene hsa-mir-708 Ewing Sarcoma 22723308 "EWS/FLI1 Regulates EYA3 in Ewing Sarcoma via Modulation of miRNA-708, Resulting in Increased Cell Survival and Chemoresistance." +target gene hsa-mir-195 Preeclampsia 22723898 Downregulated miR-195 detected in preeclamptic placenta affects trophoblast cell invasion via modulating ActRIIA expression. +target gene hsa-mir-137 Breast Neoplasms 22723937 MiR-137 targets estrogen-related receptor alpha and impairs the proliferative and migratory capacity of breast cancer cells. +target gene hsa-mir-337 "Carcinoma, Lung, Non-Small-Cell" 22723956 miR-337-3p and its targets STAT3 and RAP1A modulate taxane sensitivity in non-small cell lung cancers. +target gene hsa-mir-17 Urinary Bladder Cancer 22730212 MiR-17-5p targets TP53INP1 and regulates cell proliferation and apoptosis of cervical cancer cells. +target gene hsa-mir-153-1 Alzheimer Disease 22733824 MicroRNA-153 physiologically inhibits expression of amyloid-beta precursor protein in cultured human fetal brain cells and is dysregulated in a subset of Alzheimer disease patients. +target gene hsa-mir-153-2 Alzheimer Disease 22733824 MicroRNA-153 physiologically inhibits expression of amyloid-beta precursor protein in cultured human fetal brain cells and is dysregulated in a subset of Alzheimer disease patients. +target gene hsa-mir-155 Breast Neoplasms 22736789 This is the first review examining the role of miR-155 in breast cancer progression. The collated data of target genes and biologic pathways of miR-155 identified in this review suggest new avenues of research for this oncogenic miRNA. +target gene hsa-mir-138-1 Nasopharyngeal Neoplasms 22739938 MiR-138 suppressed nasopharyngeal carcinoma growth and tumorigenesis by targeting the CCND1 oncogene. +target gene hsa-mir-138-2 Nasopharyngeal Neoplasms 22739938 MiR-138 suppressed nasopharyngeal carcinoma growth and tumorigenesis by targeting the CCND1 oncogene. +target gene hsa-mir-23b Glioblastoma 22745829 miRNA expression profiling in migrating glioblastoma cells: regulation of cell migration and invasion by miR-23b via targeting of Pyk2. +target gene hsa-mir-513a-1 Lung Neoplasms 22749944 miR-513a-3p sensitizes human lung adenocarcinoma cells to chemotherapy by targeting GSTP1. +target gene hsa-mir-513a-2 Lung Neoplasms 22749944 miR-513a-3p sensitizes human lung adenocarcinoma cells to chemotherapy by targeting GSTP1. +target gene hsa-mir-410 Glioma 22750473 MiR-410 regulates MET to influence the proliferation and invasion of glioma. +target gene hsa-mir-34a Glioblastoma 22750848 microRNA Regulatory Network Inference Identifies miR-34a as a Novel Regulator of TGF-beta Signaling in Glioblastoma. +target gene hsa-mir-29a Breast Neoplasms 22751119 Progestin suppression of miR-29 potentiates dedifferentiation of breast cancer cells via KLF4. +target gene hsa-mir-29b-1 Breast Neoplasms 22751119 Progestin suppression of miR-29 potentiates dedifferentiation of breast cancer cells via KLF4. +target gene hsa-mir-29b-2 Breast Neoplasms 22751119 Progestin suppression of miR-29 potentiates dedifferentiation of breast cancer cells via KLF4. +target gene hsa-mir-29c Breast Neoplasms 22751119 Progestin suppression of miR-29 potentiates dedifferentiation of breast cancer cells via KLF4. +target gene hsa-mir-23a Lung Neoplasms 22752005 MiR-23a regulates TGF-beta-induced epithelial-mesenchymal transition by targeting E-cadherin in lung cancer cells. +target gene hsa-mir-9-1 Breast Neoplasms 22761433 MicroRNA-9 Inhibition of Cell Proliferation and Identification of Novel miR-9 Targets by Transcriptome Profiling in Breast Cancer Cells. +target gene hsa-mir-9-2 Breast Neoplasms 22761433 MicroRNA-9 Inhibition of Cell Proliferation and Identification of Novel miR-9 Targets by Transcriptome Profiling in Breast Cancer Cells. +target gene hsa-mir-9-3 Breast Neoplasms 22761433 MicroRNA-9 Inhibition of Cell Proliferation and Identification of Novel miR-9 Targets by Transcriptome Profiling in Breast Cancer Cells. +target gene hsa-mir-145 Colon Neoplasms 22766504 MiR-145 regulates PAK4 via the MAPK pathway and exhibits an antitumor effect in human colon cells. +target gene hsa-mir-138-1 "Carcinoma, Renal Cell" 22766839 Tumor suppressive microRNA-138 contributes to cell migration and invasion through its targeting of vimentin in renal cell carcinoma. +target gene hsa-mir-138-2 "Carcinoma, Renal Cell" 22766839 Tumor suppressive microRNA-138 contributes to cell migration and invasion through its targeting of vimentin in renal cell carcinoma. +target gene hsa-mir-218-1 Glioblastoma 22766851 MiR-218 reverses high invasiveness of glioblastoma cells by targeting the oncogenic transcription factor LEF1. +target gene hsa-mir-218-2 Glioblastoma 22766851 MiR-218 reverses high invasiveness of glioblastoma cells by targeting the oncogenic transcription factor LEF1. +target gene hsa-mir-125a "Carcinoma, Hepatocellular" 22768249 Ectopic expression of MiR-125a inhibits the proliferation and metastasis of hepatocellular carcinoma by targeting MMP11 and VEGF. +target gene hsa-mir-21 Cholangiocarcinoma 22770403 PTEN and PDCD4 are bona fide targets of microRNA-21 in human cholangiocarcinoma. +target gene hsa-mir-29a Multiple Sclerosis 22772450 miR-29ab Deficiency Identifies a Negative Feedback Loop Controlling Th1 Bias That Is Dysregulated in Multiple Sclerosis. +target gene hsa-mir-29b-1 Multiple Sclerosis 22772450 miR-29ab Deficiency Identifies a Negative Feedback Loop Controlling Th1 Bias That Is Dysregulated in Multiple Sclerosis. +target gene hsa-mir-29b-2 Multiple Sclerosis 22772450 miR-29ab Deficiency Identifies a Negative Feedback Loop Controlling Th1 Bias That Is Dysregulated in Multiple Sclerosis. +target gene hsa-mir-125b-1 "Squamous Cell Carcinoma, Skin or Unspecific" 22782903 "MicroRNA-125b Down-regulates Matrix Metallopeptidase 13 and Inhibits Cutaneous Squamous Cell Carcinoma Cell Proliferation, Migration, and Invasion." +target gene hsa-mir-125b-2 "Squamous Cell Carcinoma, Skin or Unspecific" 22782903 "MicroRNA-125b Down-regulates Matrix Metallopeptidase 13 and Inhibits Cutaneous Squamous Cell Carcinoma Cell Proliferation, Migration, and Invasion." +target gene hsa-mir-103a-1 Endometrial Neoplasms 22783422 microRNA-103 regulates the growth and invasion of endometrial cancer cells through the downregulation of tissue inhibitor of metalloproteinase 3. +target gene hsa-mir-103a-2 Endometrial Neoplasms 22783422 microRNA-103 regulates the growth and invasion of endometrial cancer cells through the downregulation of tissue inhibitor of metalloproteinase 3. +target gene hsa-mir-103b-1 Endometrial Neoplasms 22783422 microRNA-103 regulates the growth and invasion of endometrial cancer cells through the downregulation of tissue inhibitor of metalloproteinase 3. +target gene hsa-mir-103b-2 Endometrial Neoplasms 22783422 microRNA-103 regulates the growth and invasion of endometrial cancer cells through the downregulation of tissue inhibitor of metalloproteinase 3. +target gene hsa-mir-20a Prostate Neoplasms 22785209 CX43 expression is suppressed by miR-20a in the progression of human prostate cancer. +target gene hsa-mir-21 Gastric Neoplasms 22792096 miR-21 Is a Promising Novel Biomarker for Lymph Node Metastasis in Patients with Gastric Cancer. +target gene hsa-mir-125b-1 Melanoma 22797068 MicroRNA miR-125b controls melanoma progression by direct regulation of c-Jun protein expression. +target gene hsa-mir-125b-2 Melanoma 22797068 MicroRNA miR-125b controls melanoma progression by direct regulation of c-Jun protein expression. +target gene hsa-mir-193b Prostate Neoplasms 22797075 CFTR suppresses tumor progression through miR-193b targeting urokinase plasminogen activator (uPA) in prostate cancer. +target gene hsa-mir-200a Thyroid Neoplasms 22797360 The miR-200 family regulates the epithelial-mesenchymal transition induced by EGF/EGFR in anaplastic thyroid cancer cells. +target gene hsa-mir-200b Thyroid Neoplasms 22797360 The miR-200 family regulates the epithelial-mesenchymal transition induced by EGF/EGFR in anaplastic thyroid cancer cells. +target gene hsa-mir-200c Thyroid Neoplasms 22797360 The miR-200 family regulates the epithelial-mesenchymal transition induced by EGF/EGFR in anaplastic thyroid cancer cells. +target gene hsa-mir-155 "Leukemia, Lymphocytic, Chronic, B-Cell" 22797699 "In the present study, we show that an 8-mer locked nucleic acid anti-miR-155 oligonucleotide targeting the seed region of miR-155 inhibits WM and chronic lymphocytic leukemia cell proliferation in vitro." +target gene hsa-mir-21 Lung Neoplasms 22806311 miR-21 induces cell cycle at S phase and modulates cell proliferation by down-regulating hMSH2 in lung cancer. +target gene hsa-mir-224 Breast Neoplasms 22809510 MicroRNA-224 targets RKIP to control cell invasion and expression of metastasis genes in human breast cancer cells. +target gene hsa-mir-107 Pituitary Neoplasms 22811466 MicroRNA miR-107 is overexpressed in pituitary adenomas and in vitro inhibits the expression of aryl hydrocarbon receptor-interacting protein (AIP). +target gene hsa-mir-324 Kidney Diseases [unspecific] 22822076 MicroRNA-324-3p Promotes Renal Fibrosis and Is a Target of ACE Inhibition. +target gene hsa-mir-124-1 "Squamous Cell Carcinoma, Skin or Unspecific" 22828925 Down-regulation of miR-124/-214 in cutaneous squamous cell carcinoma mediates abnormal cell proliferation via the induction of ERK. +target gene hsa-mir-124-2 "Squamous Cell Carcinoma, Skin or Unspecific" 22828925 Down-regulation of miR-124/-214 in cutaneous squamous cell carcinoma mediates abnormal cell proliferation via the induction of ERK. +target gene hsa-mir-214 "Squamous Cell Carcinoma, Skin or Unspecific" 22828925 Down-regulation of miR-124/-214 in cutaneous squamous cell carcinoma mediates abnormal cell proliferation via the induction of ERK. +target gene hsa-mir-146a "Leukemia, Myeloid, Acute" 22829170 "miR-146a and AMD3100, acting through different mechanism, downmodulate CXCR4 protein levels, impair leukemic cell proliferation and then may be used in combination with anti-leukemia drugs, for development of new therapeutic strategies." +target gene hsa-mir-194-1 Breast Neoplasms 22829924 Modulation of MicroRNA-194 and Cell Migration by HER2-Targeting Trastuzumab in Breast Cancer. +target gene hsa-mir-194-2 Breast Neoplasms 22829924 Modulation of MicroRNA-194 and Cell Migration by HER2-Targeting Trastuzumab in Breast Cancer. +target gene hsa-mir-21 Breast Neoplasms 22832383 Matrine Inhibits Breast Cancer Growth Via miR-21/PTEN/Akt Pathway in MCF-7 Cells. +target gene hsa-mir-126 "Carcinoma, Oral" 22836510 Downregulation of miR-126 induces angiogenesis and lymphangiogenesis by activation of VEGF-A in oral cancer. +target gene hsa-mir-130a "Carcinoma, Hepatocellular" 22846564 Upregulated miR-130a increases drug resistance by regulating RUNX3 and Wnt signaling in cisplatin-treated HCC cell. +target gene hsa-mir-203 Inflammation 22846677 "miR-203 may regulate expression of the novel nociceptive mediator PLAA after incision. Furthermore, the regulation of miR-203 and PLAA levels is reliant upon intact substance P signaling." +target gene hsa-mir-10b Breast Neoplasms 22847191 MicroRNA-10b targets E-cadherin and modulates breast cancer metastasis. +target gene hsa-mir-181a-1 Urinary Bladder Cancer 22847611 MiR-181a confers resistance of cervical cancer to radiation therapy through targeting the pro-apoptotic PRKCD gene. +target gene hsa-mir-181a-2 Urinary Bladder Cancer 22847611 MiR-181a confers resistance of cervical cancer to radiation therapy through targeting the pro-apoptotic PRKCD gene. +target gene hsa-mir-182 Melanoma 22848417 "miR-182, a p53 dependent miRNA, suppressed the expression of MITF, BCL2, cyclin D2 and functioned as a potent tumor suppressor in uveal melanoma cells." +target gene hsa-mir-31 "Carcinoma, Oral" 22854067 Passenger strand miRNA miR-31* regulates the phenotypes of oral cancer cells by targeting RhoA. +target gene hsa-mir-222 Prostate Neoplasms 22854542 Tumor suppressive microRNAs (miR-222 and miR-31) regulate molecular pathways based on microRNA expression signature in prostate cancer. +target gene hsa-mir-31 Prostate Neoplasms 22854542 Tumor suppressive microRNAs (miR-222 and miR-31) regulate molecular pathways based on microRNA expression signature in prostate cancer. +target gene hsa-mir-15a Leukemia 22856663 "we review the main achievements made on targeting of prosurvival Bcl-2 proteins through the use of different approaches, i.e. anti-sense methodology, small molecules that mimic the action of BH3 domain and microRNAs (mainly miRNA-15a and miRNA-16-1)." +target gene hsa-mir-29b-1 Breast Neoplasms 22864815 "Three mRNAs (C1QTNF6, SPARC, and COL4A2) that are down-regulated by microRNA-29b and promote invasion ability in the breast cancer cell line MCF-7." +target gene hsa-mir-29b-2 Breast Neoplasms 22864815 "Three mRNAs (C1QTNF6, SPARC, and COL4A2) that are down-regulated by microRNA-29b and promote invasion ability in the breast cancer cell line MCF-7." +target gene hsa-mir-1271 "Carcinoma, Hepatocellular" 22865282 "miR-96, miR-129-1-3p, miR-1271, miR-1291 and miR-1303 differentially control GPC3 expression in HCC cells." +target gene hsa-mir-129-1 "Carcinoma, Hepatocellular" 22865282 "miR-96, miR-129-1-3p, miR-1271, miR-1291 and miR-1303 differentially control GPC3 expression in HCC cells." +target gene hsa-mir-129-2 "Carcinoma, Hepatocellular" 22865282 "miR-96, miR-129-1-3p, miR-1271, miR-1291 and miR-1303 differentially control GPC3 expression in HCC cells." +target gene hsa-mir-1303 "Carcinoma, Hepatocellular" 22865282 "miR-96, miR-129-1-3p, miR-1271, miR-1291 and miR-1303 differentially control GPC3 expression in HCC cells." +target gene hsa-mir-96 "Carcinoma, Hepatocellular" 22865282 "miR-96, miR-129-1-3p, miR-1271, miR-1291 and miR-1303 differentially control GPC3 expression in HCC cells." +target gene hsa-mir-214 Esophageal Neoplasms 22867052 microRNA-98 and microRNA-214 post-transcriptionally regulate enhancer of zeste homolog 2 and inhibit migration and invasion in human esophageal squamous cell carcinoma. +target gene hsa-mir-98 Esophageal Neoplasms 22867052 microRNA-98 and microRNA-214 post-transcriptionally regulate enhancer of zeste homolog 2 and inhibit migration and invasion in human esophageal squamous cell carcinoma. +target gene hsa-mir-145 Glioblastoma 22869051 "NEDD9, a novel target of miR-145, increases the invasiveness of glioblastoma." +target gene hsa-mir-542 Glioma 22871495 The Putative Tumor Suppressor miR-524-5p Directly Targets Jagged-1 and Hes-1 in Glioma. +target gene hsa-mir-205 Melanoma 22871739 E2F1 confers anticancer drug resistance by targeting ABC transporter family members and Bcl-2 via the p73/DNp73-miR-205 circuitry. +target gene hsa-mir-7-1 Breast Neoplasms 22876288 MicroRNA-7 Inhibits Epithelial-to-Mesenchymal Transition and Metastasis of Breast Cancer Cells via Targeting FAK Expression. +target gene hsa-mir-7-2 Breast Neoplasms 22876288 MicroRNA-7 Inhibits Epithelial-to-Mesenchymal Transition and Metastasis of Breast Cancer Cells via Targeting FAK Expression. +target gene hsa-mir-7-3 Breast Neoplasms 22876288 MicroRNA-7 Inhibits Epithelial-to-Mesenchymal Transition and Metastasis of Breast Cancer Cells via Targeting FAK Expression. +target gene hsa-mir-196a-1 "Carcinoma, Lung, Non-Small-Cell" 22876840 MicroRNA-196a promotes non-small cell lung cancer cell proliferation and invasion through targeting HOXA5. +target gene hsa-mir-196a-2 "Carcinoma, Lung, Non-Small-Cell" 22876840 MicroRNA-196a promotes non-small cell lung cancer cell proliferation and invasion through targeting HOXA5. +target gene hsa-mir-1 Coronary Artery Disease 22883088 Association study on the microRNA-1 target gene polymorphism and the risk of premature coronary artery disease +target gene hsa-mir-137 Schizophrenia 22883350 Candidate schizophrenia gene ZNF804A is a target for hsa-miR-137. +target gene hsa-mir-133b "Carcinoma, Lung, Non-Small-Cell" 22883469 MicroRNA-133b Inhibits the Growth of Non-small Cell Lung Cancer by Targeting the Epidermal Growth Factor Receptor. +target gene hsa-mir-26a-1 Lung Neoplasms 22885155 MiR-26a enhances metastasis potential of lung cancer cells via AKT pathway by targeting PTEN. +target gene hsa-mir-26a-2 Lung Neoplasms 22885155 MiR-26a enhances metastasis potential of lung cancer cells via AKT pathway by targeting PTEN. +target gene hsa-mir-203 "Carcinoma, Hepatocellular" 22886454 miR-203 inhibits proliferation of hepatocellular carcinoma cells by targeting survivin. +target gene hsa-mir-335 Meningioma 22886530 miR-335 promotes cell proliferation by directly targeting Rb1 in meningiomas. +target gene hsa-mir-195 "Carcinoma, Hepatocellular" 22888524 MiR-195 regulates cell apoptosis of human hepatocellular carcinoma cells by targeting LATS2. +target gene hsa-mir-24 Heart Failure 22891046 MiR-24-mediated suppression of JP2 expression provides a novel molecular mechanism for E-C coupling regulation in heart cells and suggests a new target against heart failure. +target gene hsa-mir-124-1 Colorectal Carcinoma 22895557 "miR-124, miR-137 and miR-340 regulate colorectal cancer growth via inhibition of the Warburg effect." +target gene hsa-mir-124-2 Colorectal Carcinoma 22895557 "miR-124, miR-137 and miR-340 regulate colorectal cancer growth via inhibition of the Warburg effect." +target gene hsa-mir-137 Colorectal Carcinoma 22895557 "miR-124, miR-137 and miR-340 regulate colorectal cancer growth via inhibition of the Warburg effect." +target gene hsa-mir-340 Colorectal Carcinoma 22895557 "miR-124, miR-137 and miR-340 regulate colorectal cancer growth via inhibition of the Warburg effect." +target gene hsa-mir-92a-1 Glioblastoma 22895567 miR-92a is a critical regulator of the apoptosis pathway in glioblastoma with inverse expression of BCL2L11. +target gene hsa-mir-92a-2 Glioblastoma 22895567 miR-92a is a critical regulator of the apoptosis pathway in glioblastoma with inverse expression of BCL2L11. +target gene hsa-mir-132 Dementia 22895706 "TMEM106B, the Risk Gene for Frontotemporal Dementia, Is Regulated by the microRNA-132/212 Cluster and Affects Progranulin Pathways." +target gene hsa-mir-212 Dementia 22895706 "TMEM106B, the Risk Gene for Frontotemporal Dementia, Is Regulated by the microRNA-132/212 Cluster and Affects Progranulin Pathways." +target gene hsa-mir-140 "Carcinoma, Hepatocellular" 22898998 MiRNA-140 acts as a liver tumor suppressor by controlling NF-kB activity via directly targeting Dnmt1 expression. +target gene hsa-mir-370 "Leukemia, Myeloid, Acute" 22900969 The tumor suppressive role of miRNA-370 by targeting FoxM1 in acute myeloid leukemia. +target gene hsa-mir-193a Endometrial Neoplasms 22907428 YY1 overexpression was found to be a consequence of miR-193a-5p downregulation through direct miR-193a-5p-YY1 interplay. +target gene hsa-mir-331 Prostate Neoplasms 22908221 "Regulation of expression of deoxyhypusine hydroxylase (DOHH), the enzyme that catalyzes the activation of eIF5A, by miR-331-3p and miR-642-5p in prostate cancer cells." +target gene hsa-mir-642a Prostate Neoplasms 22908221 "Regulation of expression of deoxyhypusine hydroxylase (DOHH), the enzyme that catalyzes the activation of eIF5A, by miR-331-3p and miR-642-5p in prostate cancer cells." +target gene hsa-mir-642b Prostate Neoplasms 22908221 "Regulation of expression of deoxyhypusine hydroxylase (DOHH), the enzyme that catalyzes the activation of eIF5A, by miR-331-3p and miR-642-5p in prostate cancer cells." +target gene hsa-mir-128-1 Ovarian Neoplasms 22909061 "Both miR-128 and miR-152 down-regulate CSF-1 mRNA and protein expression in ovarian cancer cells leading to decreased cell motility and adhesion in vitro, two major aspects of the metastatic potential of cancer cells." +target gene hsa-mir-128-2 Ovarian Neoplasms 22909061 "Both miR-128 and miR-152 down-regulate CSF-1 mRNA and protein expression in ovarian cancer cells leading to decreased cell motility and adhesion in vitro, two major aspects of the metastatic potential of cancer cells." +target gene hsa-mir-24-2 Breast Neoplasms 22911661 Preferential star strand biogenesis of pre-miR-24-2 targets PKC-alpha and suppresses cell survival in MCF-7 breast cancer cells. +target gene hsa-mir-106a Colorectal Carcinoma 22912877 "MiR-106a inhibits the expression of transforming growth factor-beta receptor 2 (TGFBR2), leading to increased CRC cell migration and invasion. Importantly, miR-106a expression levels in primary CRCs are correlated with clinical cancer progression." +target gene hsa-mir-122 Prostate Neoplasms 22914437 "miR122 regulation of Ad6 significantly improves its safety profile after systemic administration, which allows increasing therapeutic doses leading to improved anticancer efficacy of systemic treatment for castration-resistant prostate cancer." +target gene hsa-mir-10b Neoplasms [unspecific] 22915757 "MiR-10b downregulates the stress-induced cell surface molecule MICB, a critical ligand for cancer cell recognition by natural killer cells." +target gene hsa-let-7c Atherosclerosis 22917031 Our data suggest that let-7c contributes to endothelial apoptosis through suppression of Bcl-xl +target gene hsa-mir-182 Peripheral Nerve Injury 22917588 "Our data indicate that nerve injury inhibits SC proliferation and migration through rapid regulation of miR-182 by targeting FGF9 and NTM, providing novel insights into the roles of miRNAs in nerve injury and repair." +target gene hsa-mir-203 Psoriasis 22917968 Our findings suggest that miR-203 serves to fine-tune cytokine signaling and may dampen skin immune responses by repressing key pro-inflammatory cytokines. +target gene hsa-mir-183 Osteosarcoma 22922800 miR-183 inhibits the metastasis of osteosarcoma via downregulation of the expression of Ezrin in F5M2 cells. +target gene hsa-mir-15a Osteosarcoma 22922827 miR-15a and miR-16-1 downregulate CCND1 and induce apoptosis and cell cycle arrest in osteosarcoma. +target gene hsa-mir-16-1 Osteosarcoma 22922827 miR-15a and miR-16-1 downregulate CCND1 and induce apoptosis and cell cycle arrest in osteosarcoma. +target gene hsa-mir-100 Breast Neoplasms 22926517 miR-100 suppresses IGF2 and inhibits breast tumorigenesis by interfering with proliferation and survival signaling. +target gene hsa-mir-214 Ovarian Neoplasms 22927443 MiR-214 regulates ovarian cancer cell stemness by targeting p53/nanog. +target gene hsa-mir-214 "Carcinoma, Lung, Non-Small-Cell" 22929890 "miRNA-214 modulates radiotherapy response of non-small cell lung cancer cells through regulation of p38MAPK, apoptosis and senescence." +target gene hsa-mir-29b-1 Nervous System Diseases [unspecific] 22932723 Exosome-mediated shuttling of microRNA-29b regulates HIV Tat and morphine-mediated Neuronal dysfunction. +target gene hsa-mir-29b-2 Nervous System Diseases [unspecific] 22932723 Exosome-mediated shuttling of microRNA-29b regulates HIV Tat and morphine-mediated Neuronal dysfunction. +target gene hsa-mir-544a Gastric Neoplasms 22934698 Oncogenic miR-544 is an Important Molecular Target in Gastric Cancer. +target gene hsa-mir-544b Gastric Neoplasms 22934698 Oncogenic miR-544 is an Important Molecular Target in Gastric Cancer. +target gene hsa-mir-148a Breast Neoplasms 22935141 "Overexpression of miR-148a or miR-152 significantly inhibits BC cell proliferation, colony formation and tumor angiogenesis via targeting IGF-IR and IRS1 and suppressing their downstream AKT and MAPK/ERK signaling pathways." +target gene hsa-mir-152 Breast Neoplasms 22935141 "Overexpression of miR-148a or miR-152 significantly inhibits BC cell proliferation, colony formation and tumor angiogenesis via targeting IGF-IR and IRS1 and suppressing their downstream AKT and MAPK/ERK signaling pathways." +target gene hsa-mir-124-1 "Carcinoma, Hepatocellular" 22940133 MiR-124 suppresses cell proliferation in hepatocellular carcinoma by targeting PIK3CA. +target gene hsa-mir-124-2 "Carcinoma, Hepatocellular" 22940133 MiR-124 suppresses cell proliferation in hepatocellular carcinoma by targeting PIK3CA. +target gene hsa-mir-203 Esophageal Neoplasms 22940702 miR-203 inhibits the migration and invasion of esophageal squamous cell carcinoma by regulating LASP1. +target gene hsa-mir-338 Hepatitis B Virus Infection 22942717 miR-338-3p Is Down-Regulated by Hepatitis B Virus X and Inhibits Cell Proliferation by Targeting the 3'-UTR Region of CyclinD1. +target gene hsa-mir-205 Prostate Neoplasms 22949650 Loss of p63 and its microRNA-205 target results in enhanced cell migration and metastasis in prostate cancer. +target gene hsa-mir-19a Breast Neoplasms 22952885 "These results suggest that the IMPDH1 and NPEPL1 genes are direct targets of miR-19a in breast cancer, while the exogenous expression of these genes is not associated with the growth suppression of MCF-7 cells." +target gene hsa-mir-21 "Carcinoma, Lung, Non-Small-Cell" 22956424 "MicroRNA-21 (miR-21) expression promotes growth, metastasis, and chemo- or radioresistance in non-small cell lung cancer cells by targeting PTEN." +target gene hsa-mir-181a Atherosclerosis 22956783 "Thus, abundance of miR-181a reduced c-Fos protein, whereas inhibition of miR-181a increased c-Fos protein in BMDCs. We therefore suggest that miR-181a attenuates ox-LDL-stimulated immune inflammation responses by targeting c-Fos in DCs." +target gene hsa-mir-122 Hepatitis C Virus Infection 22957141 Silencing of microRNA-122 enhances interferon-alpha signaling in the liver through regulating SOCS3 promoter methylation. +target gene hsa-let-7a Lung Neoplasms 22970031 "The upregulation of let-7a/7g repressed the expression of their targets,C-MYC and the regulatory protein of LIN-28, at the mRNA and protein levels." +target gene hsa-let-7g Lung Neoplasms 22970031 "The upregulation of let-7a/7g repressed the expression of their targets,C-MYC and the regulatory protein of LIN-28, at the mRNA and protein levels." +target gene hsa-mir-16 "Leukemia, Myeloid, Acute" 22970245 our data demonstrated that over-expression of miR-16 mimics suppressed Pim-1 expression in FD-FLT3/ITD cells suggesting that increased miR-16 expression contributes to depletion of Pim-1 after FLT3 inhibition and that miR-16 repression may be associated with up-regulated Pim-1 in FLT3/ITD expressing cells. +target gene hsa-mir-101 Lung Neoplasms 22977606 Overexpression of miR-101 induced a marked reduction in EZH2 mRNA levels in several lung cancer cell lines +target gene hsa-mir-200c Melanoma 22982443 miR-200c inhibits melanoma progression and drug resistance through down-regulation of BMI-1. +target gene hsa-mir-10a "Carcinoma, Hepatocellular" 22996586 Our findings highlight the importance of miR-10a in regulating the metastatic properties of HCC by directly targeting EphA4 and may provide new insights into the pathogenesis of HCC +target gene hsa-mir-34a Breast Neoplasms 23001043 Our results demonstrate that miR-34a/c functions as a metastasis suppressor to regulate breast cancer migration and invasion through targeting Fra-1 oncogene and suggest a therapeutic application of miR-34 in breast cancer. +target gene hsa-mir-34c Breast Neoplasms 23001043 Our results demonstrate that miR-34a/c functions as a metastasis suppressor to regulate breast cancer migration and invasion through targeting Fra-1 oncogene and suggest a therapeutic application of miR-34 in breast cancer. +target gene hsa-mir-494 "Carcinoma, Lung, Non-Small-Cell" 23012423 MiR-494 is regulated by ERK1/2 and modulates TRAIL-induced apoptosis in non-small-cell lung cancer through BIM down-regulation. +target gene hsa-mir-125a Myeloproliferative Neoplasms 23012470 "we demonstrate that miR-125a targets multiple protein phosphatases. Our data demonstrate that miR-125a-induced MPN is addicted to its sustained overexpression, and highlight the complex nature of oncogenic miRNA dependence in an early neoplastic state." +target gene hsa-let-7c Bladder Neoplasms 23013190 "Expression of 5 miRNAs (miR-34a, let-7c, miR-16, miR-103b, and miR-106b) that target p53, Rb, or Bcl-2 protein pathways was determined for bladder samples and cells via quantitative real-time PCR assay." +target gene hsa-mir-103b Bladder Neoplasms 23013190 "Expression of 5 miRNAs (miR-34a, let-7c, miR-16, miR-103b, and miR-106b) that target p53, Rb, or Bcl-2 protein pathways was determined for bladder samples and cells via quantitative real-time PCR assay." +target gene hsa-mir-106b Bladder Neoplasms 23013190 "Expression of 5 miRNAs (miR-34a, let-7c, miR-16, miR-103b, and miR-106b) that target p53, Rb, or Bcl-2 protein pathways was determined for bladder samples and cells via quantitative real-time PCR assay." +target gene hsa-mir-16 Bladder Neoplasms 23013190 "Expression of 5 miRNAs (miR-34a, let-7c, miR-16, miR-103b, and miR-106b) that target p53, Rb, or Bcl-2 protein pathways was determined for bladder samples and cells via quantitative real-time PCR assay." +target gene hsa-mir-34a Bladder Neoplasms 23013190 "Expression of 5 miRNAs (miR-34a, let-7c, miR-16, miR-103b, and miR-106b) that target p53, Rb, or Bcl-2 protein pathways was determined for bladder samples and cells via quantitative real-time PCR assay." +target gene hsa-mir-135a "Carcinoma, Rectal" 23017832 MiR-135a promotes growth and invasion of colorectal cancer via metastasis suppressor 1 in vitro. +target gene hsa-mir-146a Psoriasis 23018031 Inability of miR-146a inhibiting target gene IRAK1 may contribute to the persistent inflammation in lesions of psoriasis. +target gene hsa-mir-200c Vascular Hypertrophy 23020145 "Increased miR-21 and miR-200c contents were associated with reduced expression of their targets, Sprouty-1 and ZEB2, respectively." +target gene hsa-mir-21 Vascular Hypertrophy 23020145 "Increased miR-21 and miR-200c contents were associated with reduced expression of their targets, Sprouty-1 and ZEB2, respectively." +target gene hsa-mir-128 "Leukemia, Myeloid, Acute" 23022987 "A Renilla-luciferase assay and flow cytometry after transfection with pre-microRNAs confirmed that RET is regulated by miR-218, miR-128, miR-27b, miR-15a and miR-195." +target gene hsa-mir-15a "Leukemia, Myeloid, Acute" 23022987 "A Renilla-luciferase assay and flow cytometry after transfection with pre-microRNAs confirmed that RET is regulated by miR-218, miR-128, miR-27b, miR-15a and miR-195." +target gene hsa-mir-195 "Leukemia, Myeloid, Acute" 23022987 "A Renilla-luciferase assay and flow cytometry after transfection with pre-microRNAs confirmed that RET is regulated by miR-218, miR-128, miR-27b, miR-15a and miR-195." +target gene hsa-mir-218 "Leukemia, Myeloid, Acute" 23022987 "A Renilla-luciferase assay and flow cytometry after transfection with pre-microRNAs confirmed that RET is regulated by miR-218, miR-128, miR-27b, miR-15a and miR-195." +target gene hsa-mir-27b "Leukemia, Myeloid, Acute" 23022987 "A Renilla-luciferase assay and flow cytometry after transfection with pre-microRNAs confirmed that RET is regulated by miR-218, miR-128, miR-27b, miR-15a and miR-195." +target gene hsa-mir-1 Heart Failure 23024758 "Time-course analysis revealed that decreased expression of miR-1 and miR-133a commences at a pre-disease stage, and precedes upregulation of target genes causal of cardiac hypertrophy and extracellular matrix remodelling, suggesting a role for miR-1 and miR-133a in early disease development." +target gene hsa-mir-133a Heart Failure 23024758 "Time-course analysis revealed that decreased expression of miR-1 and miR-133a commences at a pre-disease stage, and precedes upregulation of target genes causal of cardiac hypertrophy and extracellular matrix remodelling, suggesting a role for miR-1 and miR-133a in early disease development." +target gene hsa-mir-155 Atherosclerosis 23041630 MicroRNA-155 promotes atherosclerosis by repressing Bcl6 in macrophages +target gene hsa-mir-141 Ovarian Neoplasms 23045278 miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells +target gene hsa-mir-145 Breast Neoplasms 23049906 MiR-145 regulates epithelial to mesenchymal transition of breast cancer cells by targeting Oct4 +target gene hsa-mir-1280 Urinary Bladder Cancer 23056431 MicroRNA-1280 inhibits invasion and metastasis by targeting ROCK1 in bladder cancer +target gene hsa-mir-17 Leukemia 23056458 we demonstrated that physiological re-expression of exogenous miR-17 and miR-20a are able to partially rescue the proliferation loss induced by Fli-1 knock-down and identified HBP1 as a target of these miRNA in erythroleukemic cells. +target gene hsa-mir-20a Leukemia 23056458 we demonstrated that physiological re-expression of exogenous miR-17 and miR-20a are able to partially rescue the proliferation loss induced by Fli-1 knock-down and identified HBP1 as a target of these miRNA in erythroleukemic cells. +target gene hsa-mir-122 Breast Neoplasms 23056576 MiR-122 inhibits cell proliferation and tumorigenesis of breast cancer by targeting IGF1R +target gene hsa-mir-17 "Leukemia, Myeloid" 23059786 HIF-1a downregulates miR-17/20a directly targeting p21 and STAT3: a role in myeloid leukemic cell differentiation +target gene hsa-mir-20a "Leukemia, Myeloid" 23059786 HIF-1a downregulates miR-17/20a directly targeting p21 and STAT3: a role in myeloid leukemic cell differentiation +target gene hsa-mir-153-1 Prostate Neoplasms 23060044 Upregulation of miR-153 promotes cell proliferation via downregulation of the PTEN tumor suppressor gene in human prostate cancer +target gene hsa-mir-153-2 Prostate Neoplasms 23060044 Upregulation of miR-153 promotes cell proliferation via downregulation of the PTEN tumor suppressor gene in human prostate cancer +target gene hsa-mir-214 "Carcinoma, Hepatocellular" 23068095 MiR-214 inhibits cell growth in hepatocellular carcinoma through suppression of beta-catenin +target gene hsa-mir-198 Prostate Neoplasms 23069480 Livin expression may be regulated by miR-198 in human prostate cancer cell lines +target gene hsa-mir-124-1 Prostate Neoplasms 23069658 Tumor suppressive miR-124 targets androgen receptor and inhibits proliferation of prostate cancer cells +target gene hsa-mir-124-2 Prostate Neoplasms 23069658 Tumor suppressive miR-124 targets androgen receptor and inhibits proliferation of prostate cancer cells +target gene hsa-mir-124-3 Prostate Neoplasms 23069658 Tumor suppressive miR-124 targets androgen receptor and inhibits proliferation of prostate cancer cells +target gene hsa-mir-133a Cardiac Myocyte Injury 23069713 We also discovered that luciferase activity is exclusively decreased by targeting EGFR in hMSCs transfected with miR-133a mimic. These results suggest that EGFR plays a key role in the regulation of cardiogenic differentiation in hMSCs. +target gene hsa-mir-1297 Lung Neoplasms 23071539 miR-511 and miR-1297 inhibit human lung adenocarcinoma cell proliferation by targeting oncogene TRIB2 +target gene hsa-mir-511 Lung Neoplasms 23071539 miR-511 and miR-1297 inhibit human lung adenocarcinoma cell proliferation by targeting oncogene TRIB2 +target gene hsa-mir-101-1 Breast Neoplasms 23071542 MiR-101 is involved in human breast carcinogenesis by targeting Stathmin1 +target gene hsa-mir-101-2 Breast Neoplasms 23071542 MiR-101 is involved in human breast carcinogenesis by targeting Stathmin1 +target gene hsa-mir-203 Lung Neoplasms 23073851 miR-203 negatively regulates survivin protein expression and inhibits the proliferation and invasion of lung cancer cells +target gene hsa-mir-145 Glioma 23076445 MiR-145 reduces ADAM17 expression and inhibits in vitro migration and invasion of glioma cells +target gene hsa-mir-125a "Carcinoma, Hepatocellular" 23079745 SIRT7 oncogenic potential in human hepatocellular carcinoma and its regulation by the tumor suppressors mir-125a-5p and mir-125b +target gene hsa-mir-125b-1 "Carcinoma, Hepatocellular" 23079745 SIRT7 oncogenic potential in human hepatocellular carcinoma and its regulation by the tumor suppressors mir-125a-5p and mir-125b +target gene hsa-mir-125b-2 "Carcinoma, Hepatocellular" 23079745 SIRT7 oncogenic potential in human hepatocellular carcinoma and its regulation by the tumor suppressors mir-125a-5p and mir-125b +target gene hsa-mir-21 Neuroblastoma 23084187 Micro-RNA-21 regulates the sensitivity to cisplatin in human neuroblastoma cells +target gene hsa-mir-34a Breast Neoplasms 23085450 MicroRNA-34a modulates chemosensitivity of breast cancer cells to adriamycin by targeting Notch1 +target gene hsa-mir-181a-1 Neoplasms [unspecific] 23085757 "miR-30d, miR-181a and miR-199a-5p cooperatively suppress the endoplasmic reticulum chaperone and signaling regulator GRP78 in cancer" +target gene hsa-mir-181a-2 Neoplasms [unspecific] 23085757 "miR-30d, miR-181a and miR-199a-5p cooperatively suppress the endoplasmic reticulum chaperone and signaling regulator GRP78 in cancer" +target gene hsa-mir-199a-1 Neoplasms [unspecific] 23085757 "miR-30d, miR-181a and miR-199a-5p cooperatively suppress the endoplasmic reticulum chaperone and signaling regulator GRP78 in cancer" +target gene hsa-mir-199a-2 Neoplasms [unspecific] 23085757 "miR-30d, miR-181a and miR-199a-5p cooperatively suppress the endoplasmic reticulum chaperone and signaling regulator GRP78 in cancer" +target gene hsa-mir-30d Neoplasms [unspecific] 23085757 "miR-30d, miR-181a and miR-199a-5p cooperatively suppress the endoplasmic reticulum chaperone and signaling regulator GRP78 in cancer" +target gene hsa-mir-17 Prostate Neoplasms 23095762 miR-17-5p targets the p300/CBP-associated factor and modulates androgen receptor transcriptional activity in cultured prostate cancer cells +target gene hsa-mir-26a-1 "Leukemia, Myeloid, Acute" 23096114 The microRNA-26a target E2F7 sustains cell proliferation and inhibits monocytic differentiation of acute myeloid leukemia cells +target gene hsa-mir-26a-2 "Leukemia, Myeloid, Acute" 23096114 The microRNA-26a target E2F7 sustains cell proliferation and inhibits monocytic differentiation of acute myeloid leukemia cells +target gene hsa-mir-181a-2 "Leukemia, Myeloid, Acute" 23100311 Lenalidomide-mediated enhanced translation of C/EBPalpha-p30 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemia +target gene hsa-mir-133a Ischemia-Reperfusion Injury 23102905 "Therefore, targeting of microRNA-133a represents a potentially novel means for regulating the cascade of profibrotic events after ischemia-reperfusion." +target gene hsa-mir-15a Multiple Myeloma 23104180 miR-15a and miR-16 affect the angiogenesis of multiple myeloma by targeting VEGF +target gene hsa-mir-16-1 Multiple Myeloma 23104180 miR-15a and miR-16 affect the angiogenesis of multiple myeloma by targeting VEGF +target gene hsa-mir-16-2 Multiple Myeloma 23104180 miR-15a and miR-16 affect the angiogenesis of multiple myeloma by targeting VEGF +target gene hsa-mir-143 Urinary Bladder Cancer 23104321 Replacement treatment with microRNA-143 and -145 induces synergistic inhibition of the growth of human bladder cancer cells by regulating PI3K/Akt and MAPK signaling pathways +target gene hsa-mir-145 Urinary Bladder Cancer 23104321 Replacement treatment with microRNA-143 and -145 induces synergistic inhibition of the growth of human bladder cancer cells by regulating PI3K/Akt and MAPK signaling pathways +target gene hsa-mir-21 Laryngeal Neoplasms 23104547 Downregulation of miR-21 regulates MMP-2 expression and suppress migration of Laryngeal squamous cell carcinoma +target gene hsa-mir-210 Neuroblastoma 23108914 MicroRNA-210 targets antiapoptotic Bcl-2 expression and mediates hypoxia-induced apoptosis of neuroblastoma cells +target gene hsa-mir-26a-1 Esophageal Neoplasms 23108995 MiR-26a regulates cell cycle and anoikis of human esophageal adenocarcinoma cells through Rb1-E2F1 signaling pathway +target gene hsa-mir-26a-2 Esophageal Neoplasms 23108995 MiR-26a regulates cell cycle and anoikis of human esophageal adenocarcinoma cells through Rb1-E2F1 signaling pathway +target gene hsa-mir-429 Colorectal Carcinoma 23111103 MiR-429 is an independent prognostic factor in colorectal cancer and exerts its anti-apoptotic function by targeting SOX2 +target gene hsa-mir-29a Osteosarcoma 23113351 data obtained highlight the role of miRNA-29a in the regulation of osteoblastic cell apoptosis by silencing Bcl-2 and Mcl-1 and inducing E2F1 and E2F3 expression +target gene hsa-mir-29a "Leukemia, Myeloid, Chronic-Phase" 23113544 Regulation of Human RNase-L by the miR-29 Family Reveals a Novel Oncogenic Role in Chronic Myelogenous Leukemia +target gene hsa-mir-29b-1 "Leukemia, Myeloid, Chronic-Phase" 23113544 Regulation of Human RNase-L by the miR-29 Family Reveals a Novel Oncogenic Role in Chronic Myelogenous Leukemia +target gene hsa-mir-29b-2 "Leukemia, Myeloid, Chronic-Phase" 23113544 Regulation of Human RNase-L by the miR-29 Family Reveals a Novel Oncogenic Role in Chronic Myelogenous Leukemia +target gene hsa-mir-27a Lung Neoplasms 23117485 miR-27a regulates the self renewal of the H446 small cell lung cancer cell line in vitro +target gene hsa-mir-144 Nasopharyngeal Neoplasms 23125220 "MicroRNA-144 promotes cell proliferation, migration and invasion in nasopharyngeal carcinoma through repression of PTEN" +target gene hsa-mir-205 Parkinson Disease 23125283 MicroRNA-205 regulates the expression of Parkinson's disease-related leucine-rich repeat kinase 2 protein +target gene hsa-mir-17 Sarcoma [unspecific] 23128393 "Interestingly, the levels of onco-miR-17 locus coded miRNAs (miR-17-5p and miR-20a) were decreased upon TAF15 depletion and shown to affect the post-transcriptional regulation of TAF15-dependent genes,such as CDKN1A/p21." +target gene hsa-mir-20a Sarcoma [unspecific] 23128393 "Interestingly, the levels of onco-miR-17 locus coded miRNAs (miR-17-5p and miR-20a) were decreased upon TAF15 depletion and shown to affect the post-transcriptional regulation of TAF15-dependent genes,such as CDKN1A/p21." +target gene hsa-mir-574 Lung Neoplasms 23133627 MicroRNA-574-5p was pivotal for TLR9 signaling enhanced tumor progression via down-regulating checkpoint suppressor 1 in human lung cancer +target gene hsa-mir-7-1 Lung Neoplasms 23135998 "MicroRNA-7-regulated TLR9 signaling-enhanced growth and metastatic potential of human lung cancer cells by altering the phosphoinositide-3-kinase, regulatory subunit 3/Akt pathway" +target gene hsa-mir-7-2 Lung Neoplasms 23135998 "MicroRNA-7-regulated TLR9 signaling-enhanced growth and metastatic potential of human lung cancer cells by altering the phosphoinositide-3-kinase, regulatory subunit 3/Akt pathway" +target gene hsa-mir-7-3 Lung Neoplasms 23135998 "MicroRNA-7-regulated TLR9 signaling-enhanced growth and metastatic potential of human lung cancer cells by altering the phosphoinositide-3-kinase, regulatory subunit 3/Akt pathway" +target gene hsa-let-7a Ovarian Neoplasms 23136250 The hsa-let-7 family member hsa-let-7a is a modulator of KLK6 protein expression that is independent of the KLK6 copy number status. +target gene hsa-mir-186 Colorectal Carcinoma 23137536 "miR-186, miR-216b, miR-337-3p, and miR-760 cooperatively induce cellular senescence by targeting alpha subunit of protein kinase CKII in human colorectal cancer cells" +target gene hsa-mir-216b Colorectal Carcinoma 23137536 "miR-186, miR-216b, miR-337-3p, and miR-760 cooperatively induce cellular senescence by targeting alpha subunit of protein kinase CKII in human colorectal cancer cells" +target gene hsa-mir-337 Colorectal Carcinoma 23137536 "miR-186, miR-216b, miR-337-3p, and miR-760 cooperatively induce cellular senescence by targeting alpha subunit of protein kinase CKII in human colorectal cancer cells" +target gene hsa-mir-760 Colorectal Carcinoma 23137536 "miR-186, miR-216b, miR-337-3p, and miR-760 cooperatively induce cellular senescence by targeting alpha subunit of protein kinase CKII in human colorectal cancer cells" +target gene hsa-mir-196a-1 Colorectal Carcinoma 23138850 "miR-186, miR-216b, miR-337-3p, and miR-760 cooperatively induce cellular senescence by targeting alpha subunit of protein kinase CKII in human colorectal cancer cells" +target gene hsa-mir-196a-2 Colorectal Carcinoma 23138850 "miR-186, miR-216b, miR-337-3p, and miR-760 cooperatively induce cellular senescence by targeting alpha subunit of protein kinase CKII in human colorectal cancer cells" +target gene hsa-mir-197 Pancreatic Neoplasms 23139153 MiR-197 induces epithelial-mesenchymal transition in pancreatic cancer cells by targeting p120 catenin +target gene hsa-mir-1 Heart Failure 23141496 Biochemical assays and an inducible cardiac-specific transgenic mouse model overexpressing miR-1 were used to demonstrate that heart-type fatty acid-binding protein-3 (FABP3) is a target of miR-1. +target gene hsa-mir-1-1 Lung Neoplasms 23142026 MicroRNA-1 targets Slug and endows lung cancer A549 cells with epithelial and anti-tumorigenic properties +target gene hsa-mir-1-2 Lung Neoplasms 23142026 MicroRNA-1 targets Slug and endows lung cancer A549 cells with epithelial and anti-tumorigenic properties +target gene hsa-mir-152 Glioma 23142217 MiR-15b and miR-152 reduce glioma cell invasion and angiogenesis via NRP-2 and MMP-3 +target gene hsa-mir-15b Glioma 23142217 MiR-15b and miR-152 reduce glioma cell invasion and angiogenesis via NRP-2 and MMP-3 +target gene hsa-mir-24-1 Glioma 23142218 MiR-24 regulates the proliferation and invasion of glioma by ST7L via beta-catenin/Tcf-4 signaling +target gene hsa-mir-24-2 Glioma 23142218 MiR-24 regulates the proliferation and invasion of glioma by ST7L via beta-catenin/Tcf-4 signaling +target gene hsa-mir-517a "Carcinoma, Hepatocellular" 23142219 Down-regulation of miR-517a and miR-517c promotes proliferation of hepatocellular carcinoma cells via targeting Pyk2 +target gene hsa-mir-517c "Carcinoma, Hepatocellular" 23142219 Down-regulation of miR-517a and miR-517c promotes proliferation of hepatocellular carcinoma cells via targeting Pyk2 +target gene hsa-mir-27a Cardiomyopathy 23143062 MicroRNA-27a regulates cardiomyocytic apoptosis during cardioplegia-induced cardiac arrest by targeting interleukin 10-related pathways +target gene hsa-mir-135b Colorectal Carcinoma 23143558 Estradiol regulates miR-135b and mismatch repair gene expressions via estrogen receptor-beta in colorectal cells +target gene hsa-mir-146a Ischemia-Reperfusion Injury 23143987 MicroRNA-146a-mediated downregulation of IRAK1 protects mouse and human small intestine against ischemia/reperfusion injury. +target gene hsa-mir-149 Gastric Neoplasms 23144691 MicroRNA-149 inhibits proliferation and cell cycle progression through the targeting of ZBTB2 in human gastric cancer +target gene hsa-mir-550a-1 "Carcinoma, Hepatocellular" 23145039 MicroRNA-550a acts as a pro-metastatic gene and directly targets cytoplasmic polyadenylation element-binding protein 4 in hepatocellular carcinoma +target gene hsa-mir-550a-2 "Carcinoma, Hepatocellular" 23145039 MicroRNA-550a acts as a pro-metastatic gene and directly targets cytoplasmic polyadenylation element-binding protein 4 in hepatocellular carcinoma +target gene hsa-mir-550a-3 "Carcinoma, Hepatocellular" 23145039 MicroRNA-550a acts as a pro-metastatic gene and directly targets cytoplasmic polyadenylation element-binding protein 4 in hepatocellular carcinoma +target gene hsa-mir-100 Lung Neoplasms 23151088 MicroRNA-100 is a potential molecular marker of non-small cell lung cancer and functions as a tumor suppressor by targeting polo-like kinase 1 +target gene hsa-mir-137 Melanoma 23151846 miR-137 Inhibits the Invasion of Melanoma Cells through Downregulation of Multiple Oncogenic Target Genes +target gene hsa-mir-204 Gastric Neoplasms 23152059 miR-204 targets Bcl-2 expression and enhances responsiveness of gastric cancer +target gene hsa-mir-182 Human Immunodeficiency Virus Infection 23153509 Down-regulation of NAMPT expression by miR-182 is involved in Tat-induced HIV-1 long terminal repeat (LTR) transactivation +target gene hsa-mir-1-1 Cardiomegaly 23156720 Effects of microRNA-1 on negatively regulating L-type calcium channel beta2 subunit gene expression during cardiac hypertrophy +target gene hsa-mir-1-2 Cardiomegaly 23156720 Effects of microRNA-1 on negatively regulating L-type calcium channel beta2 subunit gene expression during cardiac hypertrophy +target gene hsa-mir-200c Urinary Bladder Cancer 23159064 "Epithelial-mesenchymal transition, a novel target of sulforaphane via COX-2/MMP2,9/Snail, ZEB1 and miR-200c/ZEB1 pathways in human bladder cancer cells" +target gene hsa-mir-21 Wounds and Injuries [unspecific] 23159215 miR-21 regulates skin wound healing by targeting multiple aspects of the healing process +target gene hsa-mir-218-1 "Squamous Cell Carcinoma, Head and Neck" 23159910 Tumor suppressive microRNA-218 inhibits cancer cell migration and invasion through targeting laminin-332 in head and neck squamous cell carcinoma +target gene hsa-mir-218-2 "Squamous Cell Carcinoma, Head and Neck" 23159910 Tumor suppressive microRNA-218 inhibits cancer cell migration and invasion through targeting laminin-332 in head and neck squamous cell carcinoma +target gene hsa-mir-125b-1 Urinary Bladder Cancer 23160634 MiR-125b Inhibits Tumor Growth and Promotes Apoptosis of Cervical Cancer Cells by Targeting Phosphoinositide 3-Kinase Catalytic Subunit Delta +target gene hsa-mir-125b-2 Urinary Bladder Cancer 23160634 MiR-125b Inhibits Tumor Growth and Promotes Apoptosis of Cervical Cancer Cells by Targeting Phosphoinositide 3-Kinase Catalytic Subunit Delta +target gene hsa-mir-195 Osteosarcoma 23162665 microRNA-195 suppresses osteosarcoma cell invasion and migration in vitro by targeting FASN +target gene hsa-mir-133a-1 Cardiomegaly 23166348 Mutual antagonism between IP(3)RII and miRNA-133a regulates calcium signals and cardiac hypertrophy +target gene hsa-mir-133a-2 Cardiomegaly 23166348 Mutual antagonism between IP(3)RII and miRNA-133a regulates calcium signals and cardiac hypertrophy +target gene hsa-mir-361 "Squamous Cell Carcinoma, Skin or Unspecific" 23166713 The expression levels of microRNA-361-5p and its target VEGFA are inversely correlated in human cutaneous squamous cell carcinoma +target gene hsa-mir-222 Colorectal Carcinoma 23173124 "On the other hand, miR-222 targeting ADAM-17, a disintegrin and metalloproteinase, and miR-328 interacting with ABCG2, an ABC transporter, may overcome drug resistance of cancer cells." +target gene hsa-mir-29a Colorectal Carcinoma 23173124 "microRNA levels may serve as a predictive CRC marker, which was confirmed by the serum level of miR-29a targeting KLF4, a marker of cell stemness, and the plasma level of miR-221 down-regulating c-Kit, Stat5A and ETS1, which are signal transducers and transcription factor, respectively" +target gene hsa-mir-21 Colorectal Carcinoma 23174819 MiR-21 regulates biological behavior through the PTEN/PI-3 K/Akt signaling pathway in human colorectal cancer cells +target gene hsa-mir-16-1 Glioma 23175429 Zyxin may be one of putative target genes of miR-16-1 +target gene hsa-mir-16-2 Glioma 23175429 Zyxin may be one of putative target genes of miR-16-1 +target gene hsa-mir-657 "Carcinoma, Hepatocellular" 23175432 MiR-657 promotes tumorigenesis in hepatocellular carcinoma by targeting transducin-like enhancer protein 1 through NF-kB pathways +target gene hsa-mir-15a Neuroblastoma 23176145 MicroRNA-15a promotes neuroblastoma migration by targeting reversion-inducing cysteine-rich protein with Kazal motifs (RECK) and regulating matrix metalloproteinase-9 expression +target gene hsa-mir-135a-1 "Carcinoma, Renal Cell" 23176581 Tumor-suppressive microRNA-135a inhibits cancer cell proliferation by targeting the c-MYC oncogene in renal cell carcinoma +target gene hsa-mir-135a-2 "Carcinoma, Renal Cell" 23176581 Tumor-suppressive microRNA-135a inhibits cancer cell proliferation by targeting the c-MYC oncogene in renal cell carcinoma +target gene hsa-mir-21 Pancreatic Neoplasms 23177026 "The serum miR-21 level serves as a predictor for the chemosensitivity of advanced pancreatic cancer, and miR-21 expression confers chemoresistance by targeting FasL" +target gene hsa-mir-137 Lung Neoplasms 23178712 miR-137 inhibits the proliferation of lung cancer cells by targeting Cdc42 and Cdk6 +target gene hsa-mir-101-1 Neoplasms [unspecific] 23178713 MicroRNA-101 suppresses SOX9-dependent tumorigenicity and promotes favorable prognosis of human hepatocellular carcinoma +target gene hsa-mir-101-2 Neoplasms [unspecific] 23178713 MicroRNA-101 suppresses SOX9-dependent tumorigenicity and promotes favorable prognosis of human hepatocellular carcinoma +target gene hsa-mir-137 Neoplasms [unspecific] 23178914 miR-137 restoration sensitizes multidrug-resistant MCF-7/ADM cells to anticancer agents by targeting YB-1 +target gene hsa-mir-1290 Breast Neoplasms 23183268 MiR-1290 and its potential targets are associated with characteristics of estrogen receptor alpha-positive breast cancer +target gene hsa-mir-133a-1 Liver Cirrhosis 23183523 miR-133a mediates TGF-beta-dependent de-repression of collagen-synthesis in hepatic stellate cells during liver fibrosis +target gene hsa-mir-133a-2 Liver Cirrhosis 23183523 miR-133a mediates TGF-beta-dependent de-repression of collagen-synthesis in hepatic stellate cells during liver fibrosis +target gene hsa-mir-302a Urinary Bladder Cancer 23185040 The microRNA-302-367 cluster suppresses the proliferation of cervical carcinoma cells through the novel target AKT1 +target gene hsa-mir-367 Urinary Bladder Cancer 23185040 The microRNA-302-367 cluster suppresses the proliferation of cervical carcinoma cells through the novel target AKT1 +target gene hsa-mir-214 Glioma 23187003 microRNA-214-mediated UBC9 expression in glioma +target gene hsa-mir-320a Prostate Neoplasms 23188675 MicroRNA-320 suppresses the stem cell-like characteristics of prostate cancer cells by downregulating the Wnt/beta-catenin signaling pathway +target gene hsa-mir-98 Prostate Neoplasms 23188821 Identification of microRNA-98 as a Therapeutic Target Inhibiting Prostate Cancer Growth and a Biomarker Induced by Vitamin D +target gene hsa-mir-23b "Carcinoma, Renal Cell" 23189187 Inhibition of PTEN gene expression by oncogenic miR-23b-3p in renal cancer +target gene hsa-mir-17 Pancreatic Neoplasms 23194063 "The mechanism of curcumin-/RL197-induced repression of Sp transcription factors was ROS-dependent and due to induction of the Sp repressors ZBTB10 and ZBTB4 and downregulation of microRNAs (miR)-27a, miR-20a and miR-17-5p that regulate these repressors." +target gene hsa-mir-20a Pancreatic Neoplasms 23194063 "The mechanism of curcumin-/RL197-induced repression of Sp transcription factors was ROS-dependent and due to induction of the Sp repressors ZBTB10 and ZBTB4 and downregulation of microRNAs (miR)-27a, miR-20a and miR-17-5p that regulate these repressors." +target gene hsa-mir-27a Pancreatic Neoplasms 23194063 "The mechanism of curcumin-/RL197-induced repression of Sp transcription factors was ROS-dependent and due to induction of the Sp repressors ZBTB10 and ZBTB4 and downregulation of microRNAs (miR)-27a, miR-20a and miR-17-5p that regulate these repressors." +target gene hsa-mir-320a Myasthenia Gravis 23196978 MiR-320a is Downregulated in Patients with Myasthenia Gravis and Modulates Inflammatory Cytokines Production by Targeting Mitogen-activated Protein Kinase 1 +target gene hsa-mir-200b Endometrial Neoplasms 23205572 MicroRNA-200b Is Overexpressed in Endometrial Adenocarcinomas and Enhances MMP2 Activity by Downregulating TIMP2 in Human Endometrial Cancer Cell Line HEC-1A Cells +target gene hsa-mir-133a-1 Urinary Bladder Cancer 23206218 "MicroRNA-133 inhibits cell proliferation, migration and invasion by targeting epidermal growth factor receptor and its downstream effector proteins in bladder cancer" +target gene hsa-mir-133a-2 Urinary Bladder Cancer 23206218 "MicroRNA-133 inhibits cell proliferation, migration and invasion by targeting epidermal growth factor receptor and its downstream effector proteins in bladder cancer" +target gene hsa-mir-133b Urinary Bladder Cancer 23206218 "MicroRNA-133 inhibits cell proliferation, migration and invasion by targeting epidermal growth factor receptor and its downstream effector proteins in bladder cancer" +target gene hsa-mir-375 Lung Neoplasms 23206448 miR-375 is a novel prognostic indicator in NSCLC and might be a potential target for diagnosis and gene therapy +target gene hsa-mir-7-1 Melanoma 23206698 "miR-7-5p may represent a novel tumor suppressor miRNA in melanoma, acting at least in part via its inhibition of IRS-2 expression and oncogenic Akt signaling" +target gene hsa-mir-7-2 Melanoma 23206698 "miR-7-5p may represent a novel tumor suppressor miRNA in melanoma, acting at least in part via its inhibition of IRS-2 expression and oncogenic Akt signaling" +target gene hsa-mir-7-3 Melanoma 23206698 "miR-7-5p may represent a novel tumor suppressor miRNA in melanoma, acting at least in part via its inhibition of IRS-2 expression and oncogenic Akt signaling" +target gene hsa-mir-10b Endometriosis 23206733 Targeting of syndecan-1 by micro-ribonucleic acid miR-10b modulates invasiveness of endometriotic cells via dysregulation of the proteolytic milieu and interleukin-6 secretion +target gene hsa-mir-21 "Carcinoma, Renal Cell" 23206776 miR-21 Downregulated TCF21 to Inhibit KISS1 in Renal Cancer +target gene hsa-mir-223 Osteosarcoma 23208072 Heat Shock Protein 90B1 Plays an Oncogenic Role and is a Target of microRNA-223 in Human Osteosarcoma +target gene hsa-mir-7-1 Colorectal Carcinoma 23208495 microRNA-7 is a novel inhibitor of YY1 contributing to colorectal tumorigenesis +target gene hsa-mir-7-2 Colorectal Carcinoma 23208495 microRNA-7 is a novel inhibitor of YY1 contributing to colorectal tumorigenesis +target gene hsa-mir-7-3 Colorectal Carcinoma 23208495 microRNA-7 is a novel inhibitor of YY1 contributing to colorectal tumorigenesis +target gene hsa-mir-200a Breast Neoplasms 23209748 miR-200c Sensitizes Breast Cancer Cells to Doxorubicin Treatment by Decreasing TrkB and Bmi1 Expression +target gene hsa-mir-200b Breast Neoplasms 23209748 miR-200c Sensitizes Breast Cancer Cells to Doxorubicin Treatment by Decreasing TrkB and Bmi1 Expression +target gene hsa-mir-200c Breast Neoplasms 23209748 miR-200c Sensitizes Breast Cancer Cells to Doxorubicin Treatment by Decreasing TrkB and Bmi1 Expression +target gene hsa-mir-98 Neoplasms [unspecific] 23211491 MicroRNA miR-98 inhibits tumor angiogenesis and invasion by targeting activin receptor-like kinase-4 and matrix metalloproteinase-11 +target gene hsa-mir-150 Cardiomegaly 23211718 miR-150 regulates high glucose-induced cardiomyocyte hypertrophy by targeting the transcriptional co-activator p300 +target gene hsa-mir-205 "Carcinoma, Oral" 23212344 "MicroRNA-205 directly regulates the tumor suppressor, interleukin-24, in human KB oral cancer cells" +target gene hsa-mir-218-1 Medulloblastoma 23212916 MicroRNA 218 acts as a tumor suppressor by targeting multiple cancer phenotype associated genes in medulloblastoma +target gene hsa-mir-218-2 Medulloblastoma 23212916 MicroRNA 218 acts as a tumor suppressor by targeting multiple cancer phenotype associated genes in medulloblastoma +target gene hsa-mir-145 Neuroblastoma 23222716 "MicroRNA-145 inhibits the growth, invasion, metastasis and angiogenesis of neuroblastoma cells through targeting hypoxia-inducible factor 2 alpha" +target gene hsa-mir-30c-1 Breast Neoplasms 23224145 MicroRNA-30c targets cytoskeleton genes involved in breast cancer cell invasion. +target gene hsa-mir-30c-2 Breast Neoplasms 23224145 MicroRNA-30c targets cytoskeleton genes involved in breast cancer cell invasion. +target gene hsa-mir-16-1 "Carcinoma, Hepatocellular" 23226427 Cyclooxygenase-2 Is a Target of MicroRNA-16 in Human Hepatoma Cells +target gene hsa-mir-16-2 "Carcinoma, Hepatocellular" 23226427 Cyclooxygenase-2 Is a Target of MicroRNA-16 in Human Hepatoma Cells +target gene hsa-mir-182 Urinary Bladder Cancer 23226455 Oncogenic miRNA-182-5p Targets Smad4 and RECK in Human Bladder Cancer +target gene hsa-mir-21 "Carcinoma, Endometrioid Endometrial" 23226804 microRNA-21 overexpression contributes to cell proliferation by targeting PTEN in endometrioid endometrial cancer +target gene hsa-mir-383 Medulloblastoma 23227829 MiR-383 is Downregulated in Medulloblastoma and Targets Peroxiredoxin 3 (PRDX3) +target gene hsa-mir-125b-1 "Carcinoma, Oral" 23230394 "Subsite-based alterations in miR-21, miR-125b, and miR-203 in squamous cell carcinoma of the oral cavity and correlation to important target proteins" +target gene hsa-mir-125b-2 "Carcinoma, Oral" 23230394 "Subsite-based alterations in miR-21, miR-125b, and miR-203 in squamous cell carcinoma of the oral cavity and correlation to important target proteins" +target gene hsa-mir-203 "Carcinoma, Oral" 23230394 "Subsite-based alterations in miR-21, miR-125b, and miR-203 in squamous cell carcinoma of the oral cavity and correlation to important target proteins" +target gene hsa-mir-21 "Carcinoma, Oral" 23230394 "Subsite-based alterations in miR-21, miR-125b, and miR-203 in squamous cell carcinoma of the oral cavity and correlation to important target proteins" +target gene hsa-mir-370 "Carcinoma, Oral" 23231387 miR-370 modulates insulin receptor substrate-1 expression and inhibits the tumor phenotypes of oral carcinoma +target gene hsa-mir-335 Lung Neoplasms 23232114 Genetic variation in a miR-335 binding site in BIRC5 alters susceptibility to lung cancer in Chinese Han populations +target gene hsa-mir-145 Gastric Neoplasms 23233482 "microRNA-145 targets v-ets erythroblastosis virus E26 oncogene homolog 1 to suppress the invasion, metastasis and angiogenesis of gastric cancer cells" +target gene hsa-mir-148b Breast Neoplasms 23233531 "miR148b is a major coordinator of breast cancer progression in a relapse-associated microRNA signature by targeting ITGA5, ROCK1, PIK3CA, NRAS,and CSF1" +target gene hsa-mir-31 Psoriasis 23233723 MicroRNA-31 Is Overexpressed in Psoriasis and Modulates Inflammatory Cytokine and Chemokine Production in Keratinocytes via Targeting Serine/Threonine Kinase 40 +target gene hsa-mir-596 "Carcinoma, Oral" 23233740 Potential of tumor-suppressive miR-596 targeting LGALS3BP as a therapeutic agent in oral cancer +target gene hsa-mir-27a "Leukemia, Myeloid, Acute" 23236401 MiR-27a Functions as a Tumor Suppressor in Acute Leukemia by Regulating 14-3-3 +target gene hsa-mir-372 Gastric Neoplasms 23242208 microRNA-372 maintains oncogene characteristics by targeting TNFAIP1 and affects NFkB signaling in human gastric carcinoma cells +target gene hsa-mir-218-1 Glioma 23243056 MiR-218 sensitizes glioma cells to apoptosis and inhibits tumorigenicity by regulating ECOP-mediated suppression of NF-kB activity +target gene hsa-mir-218-2 Glioma 23243056 MiR-218 sensitizes glioma cells to apoptosis and inhibits tumorigenicity by regulating ECOP-mediated suppression of NF-kB activity +target gene hsa-mir-29a Melanoma 23245396 Interferon-gamma-induced activation of Signal Transducer and Activator of Transcription 1 (STAT1) up-regulates the tumor suppressing microRNA-29 family in melanoma cells +target gene hsa-mir-29b-1 Melanoma 23245396 Interferon-gamma-induced activation of Signal Transducer and Activator of Transcription 1 (STAT1) up-regulates the tumor suppressing microRNA-29 family in melanoma cells +target gene hsa-mir-29b-2 Melanoma 23245396 Interferon-gamma-induced activation of Signal Transducer and Activator of Transcription 1 (STAT1) up-regulates the tumor suppressing microRNA-29 family in melanoma cells +target gene hsa-mir-17 Myelodysplastic Syndromes 23246221 "Expression analysis of mir-17-5p, mir-20a and let-7a microRNAs and their target proteins in CD34+ bone marrow cells of patients with myelodysplastic syndromes" +target gene hsa-mir-20a Myelodysplastic Syndromes 23246221 "Expression analysis of mir-17-5p, mir-20a and let-7a microRNAs and their target proteins in CD34+ bone marrow cells of patients with myelodysplastic syndromes" +target gene hsa-mir-363 Head And Neck Neoplasms 23246488 Dysregulated miR-363 affects head and neck cancer invasion and metastasis by targeting podoplanin +target gene hsa-mir-18a Glioblastoma 23249750 Targeting of TGFbeta signature and its essential component CTGF by miR-18 correlates with improved survival in glioblastoma +target gene hsa-mir-143 Glioma 23250070 Rapamycin inhibits human glioma cell proliferation through down-regulating mammalian target of rapamycin pathway and up-regulating microRNA-143 +target gene hsa-mir-17 Colorectal Carcinoma 23250421 Elevated oncofoetal miR-17-5p expression regulates colorectal cancer progression by repressing its target gene P130 +target gene hsa-mir-124-1 Breast Neoplasms 23250910 MiR-124 targets Slug to regulate epithelial-mesenchymal transition and metastasis of breast cancer +target gene hsa-mir-124-2 Breast Neoplasms 23250910 MiR-124 targets Slug to regulate epithelial-mesenchymal transition and metastasis of breast cancer +target gene hsa-mir-124-3 Breast Neoplasms 23250910 MiR-124 targets Slug to regulate epithelial-mesenchymal transition and metastasis of breast cancer +target gene hsa-mir-145 Choriocarcinoma 23251245 Cell proliferation and invasion ability of human choriocarcinoma cells lessened due to inhibition of Sox2 expression by microRNA-145 +target gene hsa-mir-137 Oligodendroglioma 23252729 "MIR-137 Suppresses Growth and Invasion, is Downregulated in Oligodendroglial Tumors and Targets CSE1L" +target gene hsa-mir-21 Cholangiocarcinoma 23254774 "These data indicated that TPM1 is downregulated in HuCCT1 cells and that the Ras signaling pathway as well as DNA methylation, histone deacetylation and miR-21 upregulation play important roles in the suppression of TPM1 expression in HuCCT1 cells. Thus, compounds that inhibit genetic and epigenetic mechanisms may be promising agents in treating cholangiocarcinoma." +target gene hsa-mir-24-1 Glioma 23254855 miR-24-3p and miR-27a-3p promote cell proliferation in glioma cells via cooperative regulation of MXI1 +target gene hsa-mir-24-2 Glioma 23254855 miR-24-3p and miR-27a-3p promote cell proliferation in glioma cells via cooperative regulation of MXI1 +target gene hsa-mir-27a Glioma 23254855 miR-24-3p and miR-27a-3p promote cell proliferation in glioma cells via cooperative regulation of MXI1 +target gene hsa-mir-218-1 Colon Neoplasms 23255074 MicroRNA-218 inhibits cell cycle progression and promotes apoptosis in colon cancer by downregulating oncogene BMI-1 +target gene hsa-mir-218-2 Colon Neoplasms 23255074 MicroRNA-218 inhibits cell cycle progression and promotes apoptosis in colon cancer by downregulating oncogene BMI-1 +target gene hsa-mir-491 Acute Cerebral Infarction 23257658 A functional polymorphism at miR-491-5p binding site in the 3'-UTR of MMP-9 gene confers increased risk for atherosclerotic cerebral infarction in a Chinese population +target gene hsa-mir-31 Colon Neoplasms 23258531 miR-31 acts as an oncogene in colon cancer and identified RhoBTB1 as a new target of miR-31 further study demonstrated that miR-31 contributed to the development of colon cancer at least partly by targeting RhoBTB1 +target gene hsa-mir-122 Atherosclerosis 23260873 "Several miRNAs have been described to finely regulate lipid metabolism and the progression and regression of atherosclerosis including, miR-33, miR-122." +target gene hsa-mir-33 Atherosclerosis 23260873 "Several miRNAs have been described to finely regulate lipid metabolism and the progression and regression of atherosclerosis including, miR-33, miR-122." +target gene hsa-mir-424 Hypertension 23263626 An endothelial apelin-FGF link mediated by miR-424 and miR-503 is disrupted in pulmonary arterial hypertension +target gene hsa-mir-503 Hypertension 23263626 An endothelial apelin-FGF link mediated by miR-424 and miR-503 is disrupted in pulmonary arterial hypertension +target gene hsa-mir-34a Gastric Neoplasms 23264087 Expression and regulatory function of miRNA-34a in targeting survivin in gastric cancer cells +target gene hsa-mir-501 Hepatitis B Virus Infection 23266610 MicroRNA-501 promotes HBV replication by targeting HBXIP +target gene hsa-let-7d Ovarian Neoplasms 23268403 Construction of let-7d expression vector and its inhibitory effect on HMGA2 and ras expression in human ovarian cancer cells in vitro +target gene hsa-mir-100 Urinary Bladder Cancer 23270926 MicroRNA-100 inhibits human bladder urothelial carcinogenesis by directly targeting mTOR +target gene hsa-mir-21 "Lymphoma, Large B-Cell, Diffuse" 23275230 MicroRNA-21 regulates the sensitivity of diffuse large B-cell lymphoma cells to the CHOP chemotherapy regimen +target gene hsa-mir-362 Colorectal Carcinoma 23280316 "MiRNA-362-3p induces cell cycle arrest through targeting of E2F1, USF2 and PTPN1 and is associated with recurrence of colorectal cancer" +target gene hsa-mir-182 Urinary Bladder Cancer 23284967 Synthetic miRNA-Mowers Targeting miR-183-96-182 Cluster or miR-210 Inhibit Growth and Migration and Induce Apoptosis in Bladder Cancer Cells +target gene hsa-mir-183 Urinary Bladder Cancer 23284967 Synthetic miRNA-Mowers Targeting miR-183-96-182 Cluster or miR-210 Inhibit Growth and Migration and Induce Apoptosis in Bladder Cancer Cells +target gene hsa-mir-210 Urinary Bladder Cancer 23284967 Synthetic miRNA-Mowers Targeting miR-183-96-182 Cluster or miR-210 Inhibit Growth and Migration and Induce Apoptosis in Bladder Cancer Cells +target gene hsa-mir-96 Urinary Bladder Cancer 23284967 Synthetic miRNA-Mowers Targeting miR-183-96-182 Cluster or miR-210 Inhibit Growth and Migration and Induce Apoptosis in Bladder Cancer Cells +target gene hsa-mir-126 "Colitis, Ulcerative" 23285182 Up-Regulation of microRNA-126 May Contribute to Pathogenesis of Ulcerative Colitis via Regulating NF-kappaB Inhibitor I§Ø¨mB§Ø©ã +target gene hsa-mir-9-1 Nasopharyngeal Neoplasms 23291181 miR-9 modulates the expression of interferon-regulated genes and MHC class I molecules in human nasopharyngeal carcinoma cells +target gene hsa-mir-9-2 Nasopharyngeal Neoplasms 23291181 miR-9 modulates the expression of interferon-regulated genes and MHC class I molecules in human nasopharyngeal carcinoma cells +target gene hsa-mir-100 Esophageal Neoplasms 23292834 MicroRNA-99a/100 promotes apoptosis by targeting mTOR in human esophageal squamous cell carcinoma +target gene hsa-mir-99a Esophageal Neoplasms 23292834 MicroRNA-99a/100 promotes apoptosis by targeting mTOR in human esophageal squamous cell carcinoma +target gene hsa-mir-196b Endometriosis 23293219 "miR-196b targets c-myc and Bcl-2 expression, inhibits proliferation and induces apoptosis in endometriotic stromal cells" +target gene hsa-mir-133b Gastric Neoplasms 23296701 miR-133b acts as a tumor suppressor and negatively regulates FGFR1 in gastric cancer +target gene hsa-mir-199b Breast Neoplasms 23296799 MiR-199b-5p targets HER2 in breast cancer cells +target gene hsa-mir-182 Ovarian Neoplasms 23296900 "MicroRNA-182 promotes cell growth, invasion and chemoresistance by targeting programmed cell death 4 (PDCD4) in human ovarian carcinomas" +target gene hsa-mir-149 Glioma 23298478 MicroRNA-149 inhibits proliferation and invasion of glioma cells via blockade of AKT1 signaling +target gene hsa-mir-107 Glioma 23299462 MicroRNA-107 inhibits glioma cell migration and invasion by modulating Notch2 expression +target gene hsa-mir-150 Esophageal Neoplasms 23301507 MiR-150 regulates the EMT-inducer ZEB1 in esophageal squamous cell carcinoma.Wound healing assays of premiR-150-treated esophageal squamous cell carcinoma TE-8 cells +target gene hsa-mir-16-1 Ovarian Neoplasms 23302126 "MicroRNA-16 regulates the proliferation, invasion and apoptosis of ovarian epithelial carcinoma cells in vitro" +target gene hsa-mir-16-2 Ovarian Neoplasms 23302126 "MicroRNA-16 regulates the proliferation, invasion and apoptosis of ovarian epithelial carcinoma cells in vitro" +target gene hsa-mir-34b Pancreatic Neoplasms 23305226 MicroRNA-34b inhibits pancreatic cancer metastasis through repressing Smad3 +target gene hsa-mir-636 "Carcinoma, Hepatocellular" 23306701 "ANT2 suppression by shRNA restores miR-636 expression, thereby downregulating Ras and inhibiting tumorigenesis of hepatocellular carcinoma" +target gene hsa-mir-145 Endometriosis 23312222 "MicroRNA miR-145 inhibits proliferation, invasiveness, and stem cell phenotype of an in vitro endometriosis model by targeting multiple cytoskeletal elements and pluripotency factors" +target gene hsa-mir-34a Osteosarcoma 23314380 miR-34a inhibits the metastasis of osteosarcoma cells by repressing the expression of CD44. +target gene hsa-mir-384 Myocardial Ischemic-Reperfusion Injury 23315007 "MicroRNA-384-5p regulates ischemia-induced cardioprotection by targeting phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit delta (PI3Kp110§Ø©¤)" +target gene hsa-mir-152 Ovarian Neoplasms 23318422 MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine +target gene hsa-mir-185 Ovarian Neoplasms 23318422 MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine +target gene hsa-mir-138 "Squamous Cell Carcinoma, Esophageal" 23319823 Downregulation of miR-138 sustains NF-¦ÊB activation and promotes lipid raft formation in esophageal squamous cell carcinoma. +target gene hsa-mir-18a Gastric Neoplasms 23322197 MicroRNA-18a modulates STAT3 activity through negative regulation of PIAS3 during gastric adenocarcinogenesis +target gene hsa-mir-31 Colorectal Carcinoma 23322774 MicroRNA-31 activates the Ras pathway and functions as an oncogenic microRNA in human colorectal cancer by repressing RAS p21 GTPase activating protein 1(RASA1). +target gene hsa-mir-30a "Cardiomyopathy, Hypertrophic" 23326547 miR-30a induced alterations in beclin-1 gene expression and autophagy in cardiomyocytes. +target gene hsa-mir-122 Infertility 23327642 MicroRNA-122 influences the development of sperm abnormalities from human induced pluripotent stem cells by regulating TNP2 expression. +target gene hsa-mir-182 Prostate Neoplasms 23329838 MicroRNA-182 and microRNA-200a control G-protein subunit alpha-13 (GNA13) expression and cell invasion synergistically in prostate cancer cells. +target gene hsa-mir-200a Prostate Neoplasms 23329838 MicroRNA-182 and microRNA-200a control G-protein subunit alpha-13 (GNA13) expression and cell invasion synergistically in prostate cancer cells. +target gene hsa-mir-221 Coronary Artery Disease 23333386 "Overall, these findings demonstrate that miR-221 affects the MEK/ERK pathway by targeting PAK1 to inhibit the proliferation of EPCs." +target gene hsa-mir-182 Breast Neoplasms 23333633 Up-regulation of miR-182 by beta-catenin in breast cancer increases tumorigenicity and invasiveness by targeting the matrix metalloproteinase inhibitor RECK +target gene hsa-mir-193b Neoplasms [unspecific] 23335975 MicroRNA-193b enhances tumor progression via down regulation of neurofibromin 1 +target gene hsa-mir-330 Colorectal Carcinoma 23337504 miR-330 regulates the proliferation of colorectal cancer cells by targeting Cdc42 +target gene hsa-mir-301a Gastric Neoplasms 23338485 Overexpressed miR-301a promotes cell proliferation and invasion by targeting RUNX3 in gastric cancer +target gene hsa-mir-200a Breast Neoplasms 23340296 MicroRNA-200a Promotes Anoikis Resistance and Metastasis by Targeting YAP1 in Human Breast Cancer +target gene hsa-let-7a Head And Neck Neoplasms 23340306 "miR-21, miR-31, miR-504 and miR-10b are important oncogenic miRNAs that are involved in HNSCC and target tumour suppressor genes. The tumour suppressor roles of the let-7 family, the miR-99 family, miR-107, miR-133a, miR-137, miR-138 and miR-375 with respect to their targeting of oncogenes are unequivocal and have been confirmed by many studies." +target gene hsa-let-7b Head And Neck Neoplasms 23340306 "miR-21, miR-31, miR-504 and miR-10b are important oncogenic miRNAs that are involved in HNSCC and target tumour suppressor genes. The tumour suppressor roles of the let-7 family, the miR-99 family, miR-107, miR-133a, miR-137, miR-138 and miR-375 with respect to their targeting of oncogenes are unequivocal and have been confirmed by many studies." +target gene hsa-let-7c Head And Neck Neoplasms 23340306 "miR-21, miR-31, miR-504 and miR-10b are important oncogenic miRNAs that are involved in HNSCC and target tumour suppressor genes. The tumour suppressor roles of the let-7 family, the miR-99 family, miR-107, miR-133a, miR-137, miR-138 and miR-375 with respect to their targeting of oncogenes are unequivocal and have been confirmed by many studies." +target gene hsa-let-7d Head And Neck Neoplasms 23340306 "miR-21, miR-31, miR-504 and miR-10b are important oncogenic miRNAs that are involved in HNSCC and target tumour suppressor genes. The tumour suppressor roles of the let-7 family, the miR-99 family, miR-107, miR-133a, miR-137, miR-138 and miR-375 with respect to their targeting of oncogenes are unequivocal and have been confirmed by many studies." +target gene hsa-let-7e Head And Neck Neoplasms 23340306 "miR-21, miR-31, miR-504 and miR-10b are important oncogenic miRNAs that are involved in HNSCC and target tumour suppressor genes. The tumour suppressor roles of the let-7 family, the miR-99 family, miR-107, miR-133a, miR-137, miR-138 and miR-375 with respect to their targeting of oncogenes are unequivocal and have been confirmed by many studies." +target gene hsa-let-7f Head And Neck Neoplasms 23340306 "miR-21, miR-31, miR-504 and miR-10b are important oncogenic miRNAs that are involved in HNSCC and target tumour suppressor genes. The tumour suppressor roles of the let-7 family, the miR-99 family, miR-107, miR-133a, miR-137, miR-138 and miR-375 with respect to their targeting of oncogenes are unequivocal and have been confirmed by many studies." +target gene hsa-let-7g Head And Neck Neoplasms 23340306 "miR-21, miR-31, miR-504 and miR-10b are important oncogenic miRNAs that are involved in HNSCC and target tumour suppressor genes. The tumour suppressor roles of the let-7 family, the miR-99 family, miR-107, miR-133a, miR-137, miR-138 and miR-375 with respect to their targeting of oncogenes are unequivocal and have been confirmed by many studies." +target gene hsa-let-7i Head And Neck Neoplasms 23340306 "miR-21, miR-31, miR-504 and miR-10b are important oncogenic miRNAs that are involved in HNSCC and target tumour suppressor genes. The tumour suppressor roles of the let-7 family, the miR-99 family, miR-107, miR-133a, miR-137, miR-138 and miR-375 with respect to their targeting of oncogenes are unequivocal and have been confirmed by many studies." +target gene hsa-mir-10b Head And Neck Neoplasms 23340306 "miR-21, miR-31, miR-504 and miR-10b are important oncogenic miRNAs that are involved in HNSCC and target tumour suppressor genes. The tumour suppressor roles of the let-7 family, the miR-99 family, miR-107, miR-133a, miR-137, miR-138 and miR-375 with respect to their targeting of oncogenes are unequivocal and have been confirmed by many studies." +target gene hsa-mir-21 Head And Neck Neoplasms 23340306 "miR-21, miR-31, miR-504 and miR-10b are important oncogenic miRNAs that are involved in HNSCC and target tumour suppressor genes. The tumour suppressor roles of the let-7 family, the miR-99 family, miR-107, miR-133a, miR-137, miR-138 and miR-375 with respect to their targeting of oncogenes are unequivocal and have been confirmed by many studies." +target gene hsa-mir-31 Head And Neck Neoplasms 23340306 "miR-21, miR-31, miR-504 and miR-10b are important oncogenic miRNAs that are involved in HNSCC and target tumour suppressor genes. The tumour suppressor roles of the let-7 family, the miR-99 family, miR-107, miR-133a, miR-137, miR-138 and miR-375 with respect to their targeting of oncogenes are unequivocal and have been confirmed by many studies." +target gene hsa-mir-504 Head And Neck Neoplasms 23340306 "miR-21, miR-31, miR-504 and miR-10b are important oncogenic miRNAs that are involved in HNSCC and target tumour suppressor genes. The tumour suppressor roles of the let-7 family, the miR-99 family, miR-107, miR-133a, miR-137, miR-138 and miR-375 with respect to their targeting of oncogenes are unequivocal and have been confirmed by many studies." +target gene hsa-mir-30c-1 Breast Neoplasms 23340433 MicroRNA-30c inhibits human breast tumour chemotherapy resistance by regulating TWF1 and IL-11 +target gene hsa-mir-30c-2 Breast Neoplasms 23340433 MicroRNA-30c inhibits human breast tumour chemotherapy resistance by regulating TWF1 and IL-11 +target gene hsa-mir-138-1 Lung Neoplasms 23343715 MiR-138 Inhibits Tumor Growth Through Repression of EZH2 in Non-Small Cell Lung Cancer +target gene hsa-mir-138-2 Lung Neoplasms 23343715 MiR-138 Inhibits Tumor Growth Through Repression of EZH2 in Non-Small Cell Lung Cancer +target gene hsa-mir-206 Gastric Neoplasms 23348698 MiR-206 inhibits gastric cancer proliferation in part by repressing CyclinD2 +target gene hsa-mir-30a Glioma 23348703 PRDM1 is directly targeted by miR-30a-5p and modulates the Wnt/beta-catenin pathway in a Dkk1-dependent manner during glioma growth +target gene hsa-mir-34a Lung Neoplasms 23349340 "Ectopic expression of miR-34a enhances radiosensitivity of non-small cell lung cancer cells, partly by suppressing the LyGDI signaling pathway" +target gene hsa-mir-22 Huntington Disease 23349832 MicroRNA-22 (miR-22) Overexpression Is Neuroprotective via General Anti-Apoptotic Effects and May also Target Specific Huntington's Disease-Related Mechanisms +target gene hsa-mir-296 Gastric Neoplasms 23353818 MicroRNA-296-5p increases proliferation in gastric cancer through repression of Caudal-related homeobox 1 +target gene hsa-mir-155 Breast Neoplasms 23353819 Upregulation of miRNA-155 promotes tumour angiogenesis by targeting VHL and is associated with poor prognosis and triple-negative breast cance +target gene hsa-mir-145 Prostate Neoplasms 23355420 HEF1 promotes epithelial mesenchymal transition and bone invasion in prostate cancer under the regulation of microRNA-145 +target gene hsa-mir-21 Pancreatic Neoplasms 23359184 Resveratrol induces apoptosis of pancreatic cancers cells by inhibiting miR-21 regulation of BCL-2 expression +target gene hsa-mir-24 Breast Neoplasms 23359482 "Downregulation of HR genes correlated with increased levels of their predicted microRNAs (miRNAs), miR-183 (predicted target RAD50) and miR-24 (predicted target BRCA1), suggesting that PE may regulate miRNAs involved in DNA repair processes." +target gene hsa-mir-199a-1 Cardiomyopathy 23360823 TWIST1 regulates the activity of ubiquitin proteasome system via the miR-199/214 cluster in human end-stage dilated cardiomyopathy +target gene hsa-mir-199a-2 Cardiomyopathy 23360823 TWIST1 regulates the activity of ubiquitin proteasome system via the miR-199/214 cluster in human end-stage dilated cardiomyopathy +target gene hsa-mir-199b Cardiomyopathy 23360823 TWIST1 regulates the activity of ubiquitin proteasome system via the miR-199/214 cluster in human end-stage dilated cardiomyopathy +target gene hsa-mir-214 Cardiomyopathy 23360823 TWIST1 regulates the activity of ubiquitin proteasome system via the miR-199/214 cluster in human end-stage dilated cardiomyopathy +target gene hsa-mir-34a Neoplasms [unspecific] 23361983 Modeling miRNA Regulation in Cancer Signaling Systems: miR-34a Regulation of the p53/Sirt1 Signaling Module +target gene hsa-mir-31 Breast Neoplasms 23364795 microRNA-31 sensitizes human breast cells to apoptosis by direct targeting of protein kinase C epsilon +target gene hsa-mir-100 Pancreatic Neoplasms 23373509 MicroRNA-100 regulates IGF1-receptor expression in metastatic pancreatic cancer cells +target gene hsa-mir-122 Liver Neoplasms 23373973 Effect of miR-122 and its target gene cationic amino acid transporter 1 on colorectal liver metastasis +target gene hsa-mir-26b Breast Neoplasms 23374284 MiRNA-26b inhibits proliferation by targeting PTGS2 in breast cancer +target gene hsa-mir-106b Glioma 23377830 miR-106b facilitates glioma cell growth by promoting cell cycle progression through the negative regulation of RBL2 +target gene hsa-mir-16-1 Colorectal Carcinoma 23380758 microRNA-16 represses colorectal cancer cell growth in vitro by regulating the p53/survivin signaling pathway +target gene hsa-mir-16-2 Colorectal Carcinoma 23380758 microRNA-16 represses colorectal cancer cell growth in vitro by regulating the p53/survivin signaling pathway +target gene hsa-mir-200a Gastric Neoplasms 23381389 Downregulated microRNA-200a promotes EMT and tumor growth through the wnt/beta-catenin pathway by targeting the E-cadherin repressors ZEB1/ZEB2 in gastric adenocarcinoma +target gene hsa-mir-195 Glioma 23383003 MicroRNA-195 Inhibits the Proliferation of Human Glioma Cells by Directly Targeting Cyclin D1 and Cyclin E1 +target gene hsa-mir-30a Glioma 23383034 MiR-30a-5p Antisense Oligonucleotide Suppresses Glioma Cell Growth by Targeting SEPT7 +target gene hsa-mir-182 Prostate Neoplasms 23383207 "MicroRNA-182-5p Promotes Cell Invasion and Proliferation by Down Regulating FOXF2, RECK and MTSS1 Genes in Human Prostate Cancer" +target gene hsa-mir-9-1 Gastric Neoplasms 23383271 "microRNA-9 Suppresses the Proliferation, Invasion and Metastasis of Gastric Cancer Cells through Targeting Cyclin D1 and Ets1" +target gene hsa-mir-9-2 Gastric Neoplasms 23383271 "microRNA-9 Suppresses the Proliferation, Invasion and Metastasis of Gastric Cancer Cells through Targeting Cyclin D1 and Ets1" +target gene hsa-mir-9-3 Gastric Neoplasms 23383271 "microRNA-9 Suppresses the Proliferation, Invasion and Metastasis of Gastric Cancer Cells through Targeting Cyclin D1 and Ets1" +target gene hsa-mir-143 Prostate Neoplasms 23383988 Up-regulated microRNA-143 in cancer stem cells differentiation promotes prostate cancer cells metastasis by modulating FNDC3B expression +target gene hsa-mir-7-1 Breast Neoplasms 23384942 miR-7 Suppresses Brain Metastasis of Breast Cancer Stem-Like Cells By Modulating KLF4 +target gene hsa-mir-7-2 Breast Neoplasms 23384942 miR-7 Suppresses Brain Metastasis of Breast Cancer Stem-Like Cells By Modulating KLF4 +target gene hsa-mir-7-3 Breast Neoplasms 23384942 miR-7 Suppresses Brain Metastasis of Breast Cancer Stem-Like Cells By Modulating KLF4 +target gene hsa-mir-138-1 Ovarian Neoplasms 23389731 MicroRNA-138 suppresses ovarian cancer cell invasion and metastasis by targeting SOX4 and HIF-1a +target gene hsa-mir-138-2 Ovarian Neoplasms 23389731 MicroRNA-138 suppresses ovarian cancer cell invasion and metastasis by targeting SOX4 and HIF-1a +target gene hsa-mir-26a-1 "Carcinoma, Hepatocellular" 23389848 MicroRNA-26a suppresses tumor growth and metastasis of human hepatocellular carcinoma by targeting IL-6-Stat3 pathway +target gene hsa-mir-26a-2 "Carcinoma, Hepatocellular" 23389848 MicroRNA-26a suppresses tumor growth and metastasis of human hepatocellular carcinoma by targeting IL-6-Stat3 pathway +target gene hsa-mir-145 Glioma 23390502 MicroRNA-145 Is Downregulated in Glial Tumors and Regulates Glioma Cell Migration by Targeting Connective Tissue Growth Factor +target gene hsa-mir-17 Glioblastoma 23391506 Stress Response of Glioblastoma Cells Mediated by miR-17-5p Targeting PTEN and the Passenger Strand miR-17-3p Targeting MDM2 +target gene hsa-mir-145 Urinary Bladder Cancer 23392170 "socs7, a target gene of microRNA-145, regulates interferon-alpha induction through STAT3 nuclear translocation in bladder cancer cells" +target gene hsa-mir-130b Endometrial Neoplasms 23392577 miR-130b is an EMT-related microRNA that targets DICER1 for aggression in endometrial cancer +target gene hsa-mir-130a Colorectal Carcinoma 23393589 The Oncogenic Role of microRNA-130a/301a/454 in Human Colorectal Cancer via Targeting Smad4 Expression +target gene hsa-mir-301a Colorectal Carcinoma 23393589 The Oncogenic Role of microRNA-130a/301a/454 in Human Colorectal Cancer via Targeting Smad4 Expression +target gene hsa-mir-454 Colorectal Carcinoma 23393589 The Oncogenic Role of microRNA-130a/301a/454 in Human Colorectal Cancer via Targeting Smad4 Expression +target gene hsa-mir-17 Ovarian Neoplasms 23396109 Downregulation of miR-17~92 Expression Increase Paclitaxel Sensitivity in Human Ovarian Carcinoma SKOV3-TR30 Cells via BIM Instead of PTEN +target gene hsa-mir-92a-1 Ovarian Neoplasms 23396109 Downregulation of miR-17~92 Expression Increase Paclitaxel Sensitivity in Human Ovarian Carcinoma SKOV3-TR30 Cells via BIM Instead of PTEN +target gene hsa-mir-92a-2 Ovarian Neoplasms 23396109 Downregulation of miR-17~92 Expression Increase Paclitaxel Sensitivity in Human Ovarian Carcinoma SKOV3-TR30 Cells via BIM Instead of PTEN +target gene hsa-mir-224 Inflammatory Bowel Diseases 23399735 MicroRNA-224 Negatively Regulates p21 Expression During Late Neoplastic Progression in Inflammatory Bowel Disease +target gene hsa-mir-137 Neuroblastoma 23400681 "miR-137 directly targets KDM1A mRNA in neuroblastoma cells, and activates cell properties consistent with tumor suppression" +target gene hsa-mir-140 "Carcinoma, Hepatocellular" 23401231 MicroRNA-140-5p suppresses tumor growth and metastasis by targeting TGFBR1 and FGF9 in hepatocellular carcinoma +target gene hsa-mir-34c Endometrial Neoplasms 23412924 "Furthermore, miR-34c mimics significantly enhanced apoptosis in Ishikawa cells by inhibiting IL-6R expression. Therefore, a combination of miR-34c mimics and DDP could be an effective therapeutic strategy for controlling Ishikawa cell proliferation." +target gene hsa-mir-92b Glioma 23416699 miR-92b controls glioma proliferation and invasion through regulating Wnt/beta-catenin signaling via Nemo-like kinase +target gene hsa-mir-125b-1 Head And Neck Neoplasms 23416980 Loss of miR-125b-1 contributes to head and neck cancer development by dysregulating TACSTD2 and MAPK pathway +target gene hsa-mir-125b-2 Head And Neck Neoplasms 23416980 Loss of miR-125b-1 contributes to head and neck cancer development by dysregulating TACSTD2 and MAPK pathway +target gene hsa-mir-185 Prostate Neoplasms 23417242 "MicroRNA-185 suppresses proliferation, invasion, migration, and tumorigenicity of human prostate cancer cells through targeting androgen receptor" +target gene hsa-mir-21 Liver Cirrhosis 23417858 Overexpression of microRNA-21 regulating PDCD4 during tumorigenesis of liver fluke-associated cholangiocarcinoma contributes to tumor growth and metastasis +target gene hsa-mir-17 "Carcinoma, Hepatocellular" 23418359 "Mature MiR-17-5p and passenger miR-17-3p induce hepatocellular carcinoma by targeting PTEN, GalNT7, and vimentin in different signal pathways" +target gene hsa-mir-24-1 Neoplasms [unspecific] 23418360 MicroRNA miR-24 Enhances Tumor Invasion and Metastasis by Targeting PTPN9 and PTPRF to Promote EGF Signaling +target gene hsa-mir-24-2 Neoplasms [unspecific] 23418360 MicroRNA miR-24 Enhances Tumor Invasion and Metastasis by Targeting PTPN9 and PTPRF to Promote EGF Signaling +target gene hsa-mir-320d-1 Kaposi Sarcoma 23418466 Cellular MicroRNAs 498 and 320d Regulate Herpes Simplex Virus 1 Induction of Kaposi's Sarcoma-Associated Herpesvirus Lytic Replication by Targeting RTA +target gene hsa-mir-320d-2 Kaposi Sarcoma 23418466 Cellular MicroRNAs 498 and 320d Regulate Herpes Simplex Virus 1 Induction of Kaposi's Sarcoma-Associated Herpesvirus Lytic Replication by Targeting RTA +target gene hsa-mir-498 Kaposi Sarcoma 23418466 Cellular MicroRNAs 498 and 320d Regulate Herpes Simplex Virus 1 Induction of Kaposi's Sarcoma-Associated Herpesvirus Lytic Replication by Targeting RTA +target gene hsa-mir-34c Gastric Neoplasms 23423488 Regulation of microtubule-associated protein tau (MAPT) by miR-34c-5p determines the chemosensitivity of gastric cancer to paclitaxel +target gene hsa-mir-125b-1 Urinary Bladder Cancer 23425975 microRNA-125b inhibits cell migration and invasion by targeting matrix metallopeptidase 13 in bladder cancer +target gene hsa-mir-125b-2 Urinary Bladder Cancer 23425975 microRNA-125b inhibits cell migration and invasion by targeting matrix metallopeptidase 13 in bladder cancer +target gene hsa-mir-34a Acute Myocardial Infarction 23426265 "these results identify age-induced expression of miR-34a and inhibition of its target PNUTS as a key mechanism that regulates cardiac contractile function during ageing and after acute myocardial infarction, by inducing DNA damage responses and telomere attrition." +target gene hsa-mir-154 Prostate Neoplasms 23428540 miR-154 inhibits prostate cancer cell proliferation by targeting CCND2 +target gene hsa-mir-570 Gastric Neoplasms 23430453 A miR-570 binding site polymorphism in the B7-H1 gene is associated with the risk of gastric adenocarcinoma +target gene hsa-mir-182 Breast Neoplasms 23430586 Expression and regulatory function of miRNA-182 in triple-negative breast cancer cells through its targeting of profilin 1 +target gene hsa-mir-181b-1 Glioma 23431408 MiRNA-181b suppresses IGF-1R and functions as a tumor suppressor gene in gliomas +target gene hsa-mir-181b-2 Glioma 23431408 MiRNA-181b suppresses IGF-1R and functions as a tumor suppressor gene in gliomas +target gene hsa-mir-25 Colorectal Carcinoma 23435373 MicroRNA-25 functions as a potential tumor suppressor in colon cancer by targeting Smad7 +target gene hsa-mir-146a Gastric Neoplasms 23435376 MicroRNA-146a acts as a metastasis suppressor in gastric cancer by targeting WASF2 +target gene hsa-mir-1 Heart Failure 23436819 The decrease of miR-1 and increase of AnxA5 appear as important modulators of NCX1 expression and activity during heart failure. +target gene hsa-mir-155 Laryngeal Neoplasms 23437123 Overexpression of miR -155 Promotes Proliferation and Invasion of Human Laryngeal Squamous Cell Carcinoma via Targeting SOCS1 and STAT3 +target gene hsa-mir-23a "Adenocarcinoma, Lung" 23437179 "Among them, we confirmed TGF-¦Â-mediated induction of miR-23a in lung epithelial cell lines,target genes of which were further identified by gene expression profiling." +target gene hsa-mir-126 Melanoma 23437250 miR-126&126* Restored Expressions Play a Tumor Suppressor Role by Directly Regulating ADAM9 and MMP7 in Melanoma +target gene hsa-mir-27a Ovarian Neoplasms 23438830 Oncogenic MicroRNA-27a is a Target for Genistein in Ovarian Cancer Cells +target gene hsa-mir-135a-1 Neoplasms [unspecific] 23438844 "MiR-138 and MiR-135 Directly Target Focal Adhesion Kinase, Inhibit Cell Invasion, and Increase Sensitivity to Chemotherapy in Cancer Cells" +target gene hsa-mir-135a-2 Neoplasms [unspecific] 23438844 "MiR-138 and MiR-135 Directly Target Focal Adhesion Kinase, Inhibit Cell Invasion, and Increase Sensitivity to Chemotherapy in Cancer Cells" +target gene hsa-mir-138-1 Neoplasms [unspecific] 23438844 "MiR-138 and MiR-135 Directly Target Focal Adhesion Kinase, Inhibit Cell Invasion, and Increase Sensitivity to Chemotherapy in Cancer Cells" +target gene hsa-mir-138-2 Neoplasms [unspecific] 23438844 "MiR-138 and MiR-135 Directly Target Focal Adhesion Kinase, Inhibit Cell Invasion, and Increase Sensitivity to Chemotherapy in Cancer Cells" +target gene hsa-mir-181b "Adenocarcinoma, Pancreatic Ductal" 23440261 miRNA-181b increases the sensitivity of pancreatic ductal adenocarcinoma cells to gemcitabine in vitro and in nude mice by targeting BCL-2. +target gene hsa-mir-145 "Carcinoma, Renal Cell" 23441135 MicroRNA-145 Targets the Metalloprotease ADAM17 and Is Suppressed in Renal Cell Carcinoma Patients +target gene hsa-mir-29c Gastric Neoplasms 23442884 MiR-29c is downregulated in gastric carcinomas and regulates cell proliferation by targeting RCC2 +target gene hsa-mir-30a Breast Neoplasms 23445407 MicroRNA miR-30 family regulates non-attachment growth of breast cancer cells +target gene hsa-mir-21 Multiple Myeloma 23446999 Targeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growth +target gene hsa-mir-378a Cardiomegaly 23447532 "A cardiac enriched microRNA, miR-378 blocks cardiac hypertrophy by targeting Ras-signaling" +target gene hsa-mir-210 "Carcinoma, Renal Cell" 23449350 "miR-210 is a target of hypoxia-inducible factors 1 and 2 in renal cancer, regulates ISCU and correlates with good prognosis" +target gene hsa-mir-27a Hepatitis C Virus Infection 23449803 MicroRNA-27a regulates lipid metabolism and inhibits hepatitis C virus replication in human hepatoma cells +target gene hsa-mir-23a Endometriosis 23450049 MicroRNA23a and MicroRNA23b Deregulation Derepresses SF-1 and Upregulates Estrogen Signaling in Ovarian Endometriosis +target gene hsa-mir-23b Endometriosis 23450049 MicroRNA23a and MicroRNA23b Deregulation Derepresses SF-1 and Upregulates Estrogen Signaling in Ovarian Endometriosis +target gene hsa-mir-30a Systemic Lupus Erythematosus 23450709 MicroRNA-30a promotes B cell hyperactivity in patient with SLE by direct interaction with LYN +target gene hsa-mir-133b Prostate Neoplasms 23451058 "miR-133b is directly up-regulated by AR, and represses CDC2L5, PTPRK, RB1CC1, and CPNE3, respectively. Moreover, we found miR-133b is essential to PCa cell survival. " +target gene hsa-mir-19a Prostate Neoplasms 23451058 "miR-19a is directly up-regulated by AR, and represses SUZ12, RAB13, SC4MOL, PSAP and ABCA1, respectively. " +target gene hsa-mir-27a Prostate Neoplasms 23451058 "miR-27a is directly up-regulated by AR, and represses ABCA1 and PDS5B. " +target gene hsa-mir-497 Urinary Bladder Cancer 23453369 MicroRNA-497 is a potential prognostic marker in human cervical cancer and functions as a tumor suppressor by targeting the insulin-like growth factor 1 receptor +target gene hsa-let-7i "Squamous Cell Carcinoma, Head and Neck" 23454123 "In clinical HNSCC samples, let-7i expression was inversely correlated with BMP4 expression. Our results revealed that let-7i attenuates mesenchymal-mode migration of HNSCC cells through repression of a novel target, BMP4." +target gene hsa-mir-218-1 "Carcinoma, Renal Cell" 23454155 microRNA-218 inhibits cell migration and invasion in renal cell carcinoma through targeting caveolin-2 involved in focal adhesion pathway +target gene hsa-mir-218-2 "Carcinoma, Renal Cell" 23454155 microRNA-218 inhibits cell migration and invasion in renal cell carcinoma through targeting caveolin-2 involved in focal adhesion pathway +target gene hsa-mir-146a Thyroid Neoplasms 23457043 MicroRNA-146a targets PRKCE to modulate papillary thyroid tumor development +target gene hsa-mir-152 Prostate Neoplasms 23460133 miR-152 controls migration and invasive potential by targeting TGF¦Á in prostate cancer cell lines +target gene hsa-mir-21 Gastric Neoplasms 23466500 miR-21 confers cisplatin resistance in gastric cancer cells by regulating PTEN +target gene hsa-mir-134 Glioblastoma 23467648 MiR-134 regulates the proliferation and invasion of glioblastoma cells by reducing Nanog expression +target gene hsa-mir-195 "Carcinoma, Hepatocellular" 23468064 "MicroRNA-195 suppresses angiogenesis and metastasis of hepatocellular carcinoma by inhibiting the expression of VEGF, VAV2 and CDC42" +target gene hsa-mir-3148 Systemic Lupus Erythematosus 23468661 MicroRNA-3148 Modulates Allelic Expression of Toll-Like Receptor 7 Variant Associated with Systemic Lupus Erythematosus +target gene hsa-mir-216a "Carcinoma, Hepatocellular" 23471579 MiR-216a/217-induced epithelial-mesenchymal transition targets PTEN and SMAD7 to promote drug resistance and recurrence of liver cancer +target gene hsa-mir-217 "Carcinoma, Hepatocellular" 23471579 MiR-216a/217-induced epithelial-mesenchymal transition targets PTEN and SMAD7 to promote drug resistance and recurrence of liver cancer +target gene hsa-mir-27a Colorectal Carcinoma 23471840 The drug resistance suppression induced by curcuminoids in colon cancer SW-480 cells is mediated by reactive oxygen species-induced disruption of the microRNA-27a-ZBTB10-Sp axis +target gene hsa-mir-183 Sensorineural Hearing Loss 23472202 The miR-183/Taok1 target pair is implicated in cochlear responses to acoustic trauma. +target gene hsa-mir-182 Breast Neoplasms 23474751 Suppression of MIM by microRNA-182 activates RhoA and promotes breast cancer metastasis +target gene hsa-mir-486 Lung Neoplasms 23474761 Downregulation of miR-486-5p contributes to tumor progression and metastasis by targeting protumorigenic ARHGAP5 in lung cancer +target gene hsa-mir-214 Nasopharyngeal Neoplasms 23479198 miR-214 promotes tumorigenesis by targeting lactotransferrin in nasopharyngeal carcinoma +target gene hsa-mir-21 Cholangiocarcinoma 23480766 "The expression level of miR-21 had an inverse correlation with the mRNA level of its target RECK, a metastasis suppressor, in human CCA" +target gene hsa-mir-145 Prostate Neoplasms 23480797 The proto-oncogene ERG is a target of microRNA miR-145 in prostate cancer +target gene hsa-mir-218-1 Cervical Neoplasms 23483249 Tumor suppressive microRNA-218 inhibits cancer cell migration and invasion by targeting focal adhesion pathways in cervical squamous cell carcinoma +target gene hsa-mir-218-2 Cervical Neoplasms 23483249 Tumor suppressive microRNA-218 inhibits cancer cell migration and invasion by targeting focal adhesion pathways in cervical squamous cell carcinoma +target gene hsa-mir-30a Colorectal Carcinoma 23486085 miR-30a Suppresses Cell Migration and Invasion Through Downregulation of PIK3CD in Colorectal Carcinoma +target gene hsa-mir-195 "Carcinoma, Hepatocellular" 23487264 Genome-wide screening revealed that miR-195 targets the TNF-alpha/NF-kB pathway by downregulating IKK and TAB3 in hepatocellular carcinoma +target gene hsa-mir-205 Neoplasms [unspecific] 23487795 Arf tumor suppressor and miR-205 regulate cell adhesion and formation of extraembryonic endoderm from pluripotent stem cells +target gene hsa-mir-93 Breast Neoplasms 23492819 MicroRNA-93 regulates NRF2 expression and is associated with breast carcinogenesis. +target gene hsa-mir-29b-1 "Leukemia, Myeloid, Acute" 23493348 Targeted Delivery of microRNA-29b by Transferrin Conjugated Anionic Lipopolyplex Nanoparticles: A Novel Therapeutic Strategy in Acute Myeloid Leukemia +target gene hsa-mir-29b-2 "Leukemia, Myeloid, Acute" 23493348 Targeted Delivery of microRNA-29b by Transferrin Conjugated Anionic Lipopolyplex Nanoparticles: A Novel Therapeutic Strategy in Acute Myeloid Leukemia +target gene hsa-mir-93 Polycystic Ovarian Syndrome 23493574 miRNA-93 inhibits GLUT4 and is overexpressed in adipose tissue of Polycystic Ovary Syndrome patients and women with insulin resistance +target gene hsa-mir-145 Colorectal Carcinoma 23499891 Tumor-suppressive microRNA-145 targets catenin to regulate Wnt/beta-catenin signaling in human colon cancer cells +target gene hsa-mir-145 "Carcinoma, Hepatocellular" 23499894 MiR-145 functions as a tumor suppressor by directly targeting histone deacetylase 2 in liver cancer +target gene hsa-mir-21 Esophageal Neoplasms 23504349 "miR-21 Down-Regulation Suppresses Cell Growth, Invasion and Induces Cell Apoptosis by Targeting FASL, TIMP3, and RECK Genes in Esophageal Carcinoma" +target gene hsa-mir-16-1 Osteosarcoma 23507142 miR-16 inhibits cell proliferation by targeting IGF1R and the Raf1-MEK1/2-ERK1/2 pathway in osteosarcoma +target gene hsa-mir-16-2 Osteosarcoma 23507142 miR-16 inhibits cell proliferation by targeting IGF1R and the Raf1-MEK1/2-ERK1/2 pathway in osteosarcoma +target gene hsa-mir-30e Renal Fibrosis 23515048 A microRNA-30e/mitochondrial uncoupling protein 2 axis mediates TGF-¦Â1-induced tubular epithelial cell extracellular matrix production and kidney fibrosis. +target gene hsa-mir-181a Inflammation 23516523 we provide the first evidence for anti-inflammatory effects of miR-181a mediated at least in part by down-regulating IL1a. +target gene hsa-mir-150 Lymphoma 23521217 Re-expression of miR-150 induces EBV-positive Burkitt lymphoma differentiation by modulating c-Myb in vitro +target gene hsa-mir-9 Inflammation 23525285 MicroRNA-9 regulates the expression of peroxisome proliferator-activated receptor ¦Ä in human monocytes during the inflammatory response. +target gene hsa-mir-195 Colorectal Carcinoma 23526568 MicroRNA-195 chemosensitizes colon cancer cells to the chemotherapeutic drug doxorubicin by targeting the first binding site of BCL2L2 mRNA +target gene hsa-mir-128-1 Breast Neoplasms 23526655 Downregulation of miRNA-128 sensitizes breast cancer cell to chemodrugs by targeting Bax +target gene hsa-mir-128-2 Breast Neoplasms 23526655 Downregulation of miRNA-128 sensitizes breast cancer cell to chemodrugs by targeting Bax +target gene hsa-mir-22 Gastric Neoplasms 23529765 "miR-22 is down-regulated in gastric cancer, and its overexpression inhibits cell migration and invasion via targeting transcription factor Sp1" +target gene hsa-mir-9-1 Breast Neoplasms 23530058 miR-9-3p targets integrin beta 1 to sensitize claudin-low breast cancer cells to MEK inhibition +target gene hsa-mir-9-2 Breast Neoplasms 23530058 miR-9-3p targets integrin beta 1 to sensitize claudin-low breast cancer cells to MEK inhibition +target gene hsa-mir-9-3 Breast Neoplasms 23530058 miR-9-3p targets integrin beta 1 to sensitize claudin-low breast cancer cells to MEK inhibition +target gene hsa-mir-497 Neuroblastoma 23531080 MicroRNA-497 increases apoptosis in MYCN amplified neuroblastoma cells by targeting the key cell cycle regulator WEE1 +target gene hsa-mir-34a Neoplasms [unspecific] 23533633 "CD24 Induces Expression of the Oncomir miR-21 via Src, and CD24 and Src Are Both Post-Transcriptionally Downregulated by the Tumor Suppressor miR-34a" +target gene hsa-mir-148a Asthma 23534973 These combined results are consistent with +3142 allele-specific targeting of HLA-G by the miR-152 family and support our hypothesis that miRNA regulation of sHLA-G in the airway is influenced by both the asthma status of the subject's mother and the subject's genotype. +target gene hsa-mir-148b Asthma 23534973 These combined results are consistent with +3142 allele-specific targeting of HLA-G by the miR-152 family and support our hypothesis that miRNA regulation of sHLA-G in the airway is influenced by both the asthma status of the subject's mother and the subject's genotype. +target gene hsa-mir-152 Asthma 23534973 These combined results are consistent with +3142 allele-specific targeting of HLA-G by the miR-152 family and support our hypothesis that miRNA regulation of sHLA-G in the airway is influenced by both the asthma status of the subject's mother and the subject's genotype. +target gene hsa-mir-183 Prostate Neoplasms 23538390 microRNA-183 is an oncogene targeting Dkk-3 and SMAD4 in prostate cancer +target gene hsa-mir-31 Neoplasms [unspecific] 23539435 MicroRNA-31-5p modulates cell cycle by targeting human mutL homolog 1 in human cancer cells +target gene hsa-mir-200b Glioma 23543137 MicroRNA-200b targets CREB1 and suppresses cell growth in human malignant glioma +target gene hsa-mir-195 "Carcinoma, Hepatocellular" 23544130 The Tumor-Suppressive miR-497-195 Cluster Targets Multiple Cell-Cycle Regulators in Hepatocellular Carcinoma +target gene hsa-mir-497 "Carcinoma, Hepatocellular" 23544130 The Tumor-Suppressive miR-497-195 Cluster Targets Multiple Cell-Cycle Regulators in Hepatocellular Carcinoma +target gene hsa-mir-145 Head And Neck Neoplasms 23548270 miR145 targets the SOX9/ADAM17 axis to inhibit tumor initiating cells and IL-6-mediated paracrine effects in head and neck cancer +target gene hsa-mir-148a Gastric Neoplasms 23549984 MicroRNA-148a can regulate runt-related transcription factor 3 gene expression via modulation of DNA methyltransferase 1 in gastric cancer +target gene hsa-mir-139 Glioma 23551751 MiR-139 Inhibits Mcl-1 Expression and Potentiates TMZ-Induced Apoptosis in Glioma +target gene hsa-mir-15a Leukemia 23551855 miR-15a/16-1 is known to regulate Bcl2 in chronic lymphocytic leukemia +target gene hsa-mir-16-1 Leukemia 23551855 miR-15a/16-1 is known to regulate Bcl2 in chronic lymphocytic leukemia +target gene hsa-mir-23a Gastric Neoplasms 23553990 MiR-23a in Amplified 19p13.13 Loci Targets Metallothionein 2A and Promotes Growth in Gastric Cancer Cells +target gene hsa-mir-874 "Squamous Cell Carcinoma, Head and Neck" 23558898 Tumour-suppressive microRNA-874 contributes to cell proliferation through targeting of histone deacetylase 1 in head and neck squamous cell carcinoma +target gene hsa-mir-21 "Carcinoma, Renal Cell" 23558936 "MiR-21 is overexpressed in RCC tissue and modulates the growth, apoptosis and cell cycle progression of RCC cells and regulates the expression of PDCD4 and TPM1" +target gene hsa-mir-205 "Carcinoma, Nasopharyngeal" 23564023 "Our research group established the radioresistant NPC cell line CNE2R derived from the CNE2 cell line, and demonstrated that irradiation-induced miR-205 determined the resistance of NPC through directly targeting PTEN." +target gene hsa-mir-383 Glioma 23564324 Downregulation of miR-383 promotes glioma cell invasion by targeting insulin-like growth factor 1 receptor +target gene hsa-mir-34a Osteosarcoma 23569431 MicroRNA-34a Inhibits Human Osteosarcoma Proliferation by Downregulating Ether go-go 1 Expression +target gene hsa-mir-205 Prostate Neoplasms 23571738 miR-205 negatively regulates the androgen receptor and is associated with adverse outcome of prostate cancer patients +target gene hsa-mir-155 Viral Infectious Disease 23572582 "NK cells constitutively expressing Noxa and SOCS1 exhibit profound defects in expansion during the response to MCMV infection, suggesting that their regulation by miR-155 promotes antiviral immunity." +target gene hsa-mir-370 Gastric Neoplasms 23576572 Fork head box M1 is overexpressed in Helicobacter pylori-induced gastric carcinogenesis and is negatively regulated by hsa-miR-370 +target gene hsa-mir-24-1 Osteosarcoma 23578572 MicroRNA-24 Inhibits Osteosarcoma Cell Proliferation Both In Vitro and In Vivo by Targeting LPAAT +target gene hsa-mir-24-2 Osteosarcoma 23578572 MicroRNA-24 Inhibits Osteosarcoma Cell Proliferation Both In Vitro and In Vivo by Targeting LPAAT +target gene hsa-mir-193a Ovarian Neoplasms 23588298 We demonstrated that miR-193a decreased the amount of MCL1 protein by binding 3'UTR of its mRNA. +target gene hsa-mir-155 "Leukemia, Lymphocytic, Chronic, B-Cell" 23597135 "Here we review studies that provide evidence suggesting that certain miRNAs (e.g. miR-155, miR-17-92, miR-181, miR-29) can regulate the activated phenotype of CLL cells and/or fitness of the surface-immunoglobulin (sIg) B cell receptor (BCR) complex expressed by CLL cells, thereby accounting for the differential leukemia-cell expression of these miRNAs in different CLL prognostic subgroups." +target gene hsa-mir-17 "Leukemia, Lymphocytic, Chronic, B-Cell" 23597135 "Here we review studies that provide evidence suggesting that certain miRNAs (e.g. miR-155, miR-17-92, miR-181, miR-29) can regulate the activated phenotype of CLL cells and/or fitness of the surface-immunoglobulin (sIg) B cell receptor (BCR) complex expressed by CLL cells, thereby accounting for the differential leukemia-cell expression of these miRNAs in different CLL prognostic subgroups." +target gene hsa-mir-18 "Leukemia, Lymphocytic, Chronic, B-Cell" 23597135 "Here we review studies that provide evidence suggesting that certain miRNAs (e.g. miR-155, miR-17-92, miR-181, miR-29) can regulate the activated phenotype of CLL cells and/or fitness of the surface-immunoglobulin (sIg) B cell receptor (BCR) complex expressed by CLL cells, thereby accounting for the differential leukemia-cell expression of these miRNAs in different CLL prognostic subgroups." +target gene hsa-mir-181 "Leukemia, Lymphocytic, Chronic, B-Cell" 23597135 "Here we review studies that provide evidence suggesting that certain miRNAs (e.g. miR-155, miR-17-92, miR-181, miR-29) can regulate the activated phenotype of CLL cells and/or fitness of the surface-immunoglobulin (sIg) B cell receptor (BCR) complex expressed by CLL cells, thereby accounting for the differential leukemia-cell expression of these miRNAs in different CLL prognostic subgroups." +target gene hsa-mir-19a "Leukemia, Lymphocytic, Chronic, B-Cell" 23597135 "Here we review studies that provide evidence suggesting that certain miRNAs (e.g. miR-155, miR-17-92, miR-181, miR-29) can regulate the activated phenotype of CLL cells and/or fitness of the surface-immunoglobulin (sIg) B cell receptor (BCR) complex expressed by CLL cells, thereby accounting for the differential leukemia-cell expression of these miRNAs in different CLL prognostic subgroups." +target gene hsa-mir-19b-1 "Leukemia, Lymphocytic, Chronic, B-Cell" 23597135 "Here we review studies that provide evidence suggesting that certain miRNAs (e.g. miR-155, miR-17-92, miR-181, miR-29) can regulate the activated phenotype of CLL cells and/or fitness of the surface-immunoglobulin (sIg) B cell receptor (BCR) complex expressed by CLL cells, thereby accounting for the differential leukemia-cell expression of these miRNAs in different CLL prognostic subgroups." +target gene hsa-mir-20a "Leukemia, Lymphocytic, Chronic, B-Cell" 23597135 "Here we review studies that provide evidence suggesting that certain miRNAs (e.g. miR-155, miR-17-92, miR-181, miR-29) can regulate the activated phenotype of CLL cells and/or fitness of the surface-immunoglobulin (sIg) B cell receptor (BCR) complex expressed by CLL cells, thereby accounting for the differential leukemia-cell expression of these miRNAs in different CLL prognostic subgroups." +target gene hsa-mir-29 "Leukemia, Lymphocytic, Chronic, B-Cell" 23597135 "Here we review studies that provide evidence suggesting that certain miRNAs (e.g. miR-155, miR-17-92, miR-181, miR-29) can regulate the activated phenotype of CLL cells and/or fitness of the surface-immunoglobulin (sIg) B cell receptor (BCR) complex expressed by CLL cells, thereby accounting for the differential leukemia-cell expression of these miRNAs in different CLL prognostic subgroups." +target gene hsa-mir-92-1 "Leukemia, Lymphocytic, Chronic, B-Cell" 23597135 "Here we review studies that provide evidence suggesting that certain miRNAs (e.g. miR-155, miR-17-92, miR-181, miR-29) can regulate the activated phenotype of CLL cells and/or fitness of the surface-immunoglobulin (sIg) B cell receptor (BCR) complex expressed by CLL cells, thereby accounting for the differential leukemia-cell expression of these miRNAs in different CLL prognostic subgroups." +target gene hsa-mir-19a Gastrointestinal Neoplasms 23603256 MicroRNA-19a/b regulates multidrug resistance in human gastric cancer cells by targeting PTEN. +target gene hsa-mir-19b Gastrointestinal Neoplasms 23603256 MicroRNA-19a/b regulates multidrug resistance in human gastric cancer cells by targeting PTEN. +target gene hsa-mir-150 Leukemia 23604034 "In conclusion, we demonstrate that miR-150 is a potent leukemic tumor suppressor that regulates multiple oncogenes." +target gene hsa-mir-101 Bladder Neoplasms 23618864 MicroRNA-101 suppresses motility of bladder cancer cells by targeting c-Met. +target gene hsa-mir-21 Cholangiocarcinoma 23621247 MicroRNA-21 regulates the invasion and metastasis in cholangiocarcinoma and may be a potential biomarker for cancer prognosis. +target gene hsa-mir-19a Gastrointestinal Neoplasms 23621248 miR-19a promotes cell growth and tumorigenesis through targeting SOCS1 in gastric cancer. +target gene hsa-mir-145 "Carcinoma, Hepatocellular" 23621665 miR-145 suppresses cell invasion in hepatocellular carcinoma cells: miR-145 targets ADAM17. +target gene hsa-mir-135b Breast Neoplasms 23623609 miR-135b coordinates progression of ErbB2-driven mammary carcinomas through suppression of MID1 and MTCH2. +target gene hsa-mir-124 Glioblastoma 23624869 Downregulation of miR-124 promotes the growth and invasiveness of glioblastoma cells involving upregulation of PPP1R13L. +target gene hsa-mir-124 Glioblastoma 23636127 miR-124 inhibits STAT3 signaling to enhance T cell-mediated immune clearance of glioma. +target gene hsa-mir-205 Melanoma 23638671 Our data suggest that miR-203 is a new prognostic factor in canine oral MMs and that miR-205 functions as a tumour suppressor by targeting erbb3 in both canine and human MM cells. +target gene hsa-mir-143 "Adenocarcinoma, Pancreatic Ductal" 23661430 "SEL1L mRNA expression levels were found to correlate inversely with the expression of hsa-mir-143, hsa-mir-155, and hsa-mir-223 (P?A mutation in the GFPT1 gene leads to illegitimate binding of microRNA resulting in reduced protein expression. We confirm that c.*22C>A is a causative mutation and suggest that formation of microRNA target sites might be a relevant pathomechanism in Mendelian disorders. Variants in the 3'-UTRs should be considered in genetic diagnostic procedures. +target gene hsa-mir-940 "Adenocarcinoma, Pancreatic Ductal" 25766528 Low level of miR-940 and high level of MyD88 in PDAC promoted PDAC cells growth which might be related to the low survival rate of PDAC patients.MiR-940 exerted its effect by targeting MyD88. +target gene hsa-mir-122 Hepatitis B Virus Infection 25766860 Down-regulation of suppressor of cytokine signaling 3 by miR-122 enhances interferon-mediated suppression of hepatitis B virus. +target gene hsa-mir-21 "Carcinoma, Cervical" 25769949 miR-21 modulates resistance of HR-HPV positive cervical cancer cells to radiation through targeting LATS1. +target gene hsa-mir-199a Colorectal Carcinoma 25772759 FZD6 expression is negatively regulated by miR-199a-5p in human colorectal cancer. +target gene hsa-mir-155 Chronic Hepatitis C 25772938 MicroRNA-155 regulates interferon-¦Ã production in natural killer cells via Tim-3 signalling in chronic hepatitis C virus infection. +target gene hsa-mir-191 Osteosarcoma 25773391 MicroRNA-191 promotes osteosarcoma cells proliferation by targeting checkpoint kinase 2. +target gene hsa-mir-196a Gastric Neoplasms 25773825 "Overexpression of mir-196a-5p is associated with lymph node metastasis and clinical stage, and enriched KEGG pathway analyses showed that targeted genes regulated by mir-196a-5p may contribute to tumorgenesis,suggesting roles as an oncogenic miRNA biomarker in gastric cancer." +target gene hsa-mir-155 Systemic Lupus Erythematosus 25775145 "The results of the present study demonstrated for the first time that there is a differential expression and inverse correlation between the levels the miR-155, miR-17, and miR-181b and target molecules, AID and IFN-¦Á mRNAs, in PBMCs of untreated SLE patients. These alterations may contribute to the pathogenesis of SLE." +target gene hsa-mir-17 Systemic Lupus Erythematosus 25775145 "The results of the present study demonstrated for the first time that there is a differential expression and inverse correlation between the levels the miR-155, miR-17, and miR-181b and target molecules, AID and IFN-¦Á mRNAs, in PBMCs of untreated SLE patients. These alterations may contribute to the pathogenesis of SLE." +target gene hsa-mir-181b Systemic Lupus Erythematosus 25775145 "The results of the present study demonstrated for the first time that there is a differential expression and inverse correlation between the levels the miR-155, miR-17, and miR-181b and target molecules, AID and IFN-¦Á mRNAs, in PBMCs of untreated SLE patients. These alterations may contribute to the pathogenesis of SLE." +target gene hsa-mir-215 Colorectal Carcinoma 25775580 The CDX1-microRNA-215 axis regulates colorectal cancer stem cell differentiation. +target gene hsa-mir-377 "Carcinoma, Renal Cell, Clear-Cell" 25776481 miR-377 functions as a tumor suppressor in human clear cell renal cell carcinoma by targeting ETS1. +target gene hsa-mir-325 "Carcinoma, Lung, Non-Small-Cell" 25776482 Expression of MicroRNA-325-3p and its potential functions by targeting HMGB1 in non-small cell lung cancer. +target gene hsa-mir-183 Pancreatic Neoplasms 25776494 "miR-183 induces cell proliferation, migration, and invasion by regulating PDCD4 expression in the SW1990 pancreatic cancer cell line." +target gene hsa-mir-411 "Carcinoma, Hepatocellular" 25776495 miR-411 regulated ITCH expression and promoted cell proliferation in human hepatocellular carcinoma cells. +target gene hsa-mir-522 Glioblastoma 25776496 MiR-522 contributes to cell proliferation of human glioblastoma cells by suppressing PHLPP1 expression. +target gene hsa-mir-423 Chronic Heart Failure 25776937 the results of the present study indicated that miR-423-5p was involved in CHF via the direct targeting of OGT and the induction of apoptosis in cardiomyocytes. +target gene hsa-mir-27a Glioma 25777779 Emerging role of microRNA-27a in human malignant glioma cell survival via targeting of prohibitin. +target gene hsa-mir-128 Glioma 25781272 Proteomic screening and identification of microRNA-128 targets in glioma cells. +target gene hsa-mir-224 Meningioma 25783051 MicroRNA-224 targets ERG2 and contributes to malignant progressions of meningioma. +target gene hsa-mir-15b Breast Neoplasms 25783158 EGF induces microRNAs that target suppressors of cell migration: miR-15b targets MTSS1 in breast cancer. +target gene hsa-mir-34a Breast Neoplasms 25783790 MicroRNA-34a suppresses the breast cancer stem cell-like characteristics by downregulating Notch1 pathway. +target gene hsa-mir-191 Colorectal Carcinoma 25784653 miR-191 promotes tumorigenesis of human colorectal cancer through targeting C/EBP¦Â. +target gene hsa-mir-17 Atherosclerosis 25785043 miR-93 and miR-17 repress ABCA1 expression through directly targeting 3'UTR. +target gene hsa-mir-29a "Carcinoma, Nasopharyngeal" 25786138 miR-29a/b enhances cell migration and invasion in nasopharyngeal carcinoma progression by regulating SPARC and COL3A1 gene expression. +target gene hsa-mir-29b "Carcinoma, Nasopharyngeal" 25786138 miR-29a/b enhances cell migration and invasion in nasopharyngeal carcinoma progression by regulating SPARC and COL3A1 gene expression. +target gene hsa-mir-34a Leukemia 25788289 MiR-34a regulates blood-tumor barrier function by targeting protein kinase C¦Å. +target gene hsa-mir-200c Cardiovascular Diseases [unspecific] 25791170 These results demonstrate that induction of a miR-200c-SUMOylated KLF4 feedback loop is a significant aspect of the PDGF-BB proliferative response in VSMCs and that targeting Ubc9 represents a novel approach for the prevention of restenosis. +target gene hsa-mir-153 Osteosarcoma 25793604 MicroRNA-153 inhibits osteosarcoma cells proliferation and invasion by targeting TGF-¦Â2. +target gene hsa-mir-153 Breast Neoplasms 25794773 MiR-153 inhibits epithelial-mesenchymal transition by targeting metadherin in human breast cancer. +target gene hsa-mir-204 Prostate Neoplasms 25797256 A dual yet opposite growth-regulating function of miR-204 and its target XRN1 in prostate adenocarcinoma cells and neuroendocrine-like prostate cancer cells. +target gene hsa-mir-31 Liver Neoplasms 25797269 MicroRNA-31 functions as a tumor suppressor by regulating cell cycle and epithelial-mesenchymal transition regulatory proteins in liver cancer. +target gene hsa-mir-182 Lung Neoplasms 25798833 The miR-200 family and the miR-183~96~182 cluster target Foxf2 to inhibit invasion and metastasis in lung cancers. +target gene hsa-mir-183 Lung Neoplasms 25798833 The miR-200 family and the miR-183~96~182 cluster target Foxf2 to inhibit invasion and metastasis in lung cancers. +target gene hsa-mir-200 Lung Neoplasms 25798833 The miR-200 family and the miR-183~96~182 cluster target Foxf2 to inhibit invasion and metastasis in lung cancers. +target gene hsa-mir-96 Lung Neoplasms 25798833 The miR-200 family and the miR-183~96~182 cluster target Foxf2 to inhibit invasion and metastasis in lung cancers. +target gene hsa-mir-30c Colorectal Carcinoma 25799050 Role of microRNA-30c targeting ADAM19 in colorectal cancer. +target gene hsa-mir-194 "Adenocarcinoma, Gastric" 25800782 "We showed evidence that HNF4γ (upregulated in intestinal metaplasia) is targeted by miR-30 and that miR-194 targets a known co-regulator of HNF4 activity, NR2F2 (downregulated in intestinal metaplasia)." +target gene hsa-mir-30a "Adenocarcinoma, Gastric" 25800782 "We showed evidence that HNF4γ (upregulated in intestinal metaplasia) is targeted by miR-30 and that miR-194 targets a known co-regulator of HNF4 activity, NR2F2 (downregulated in intestinal metaplasia)." +target gene hsa-mir-26a Atherosclerosis 25801675 MicroRNA-26a prevents endothelial cell apoptosis by directly targeting TRPC6 in the setting of atherosclerosis. +target gene hsa-mir-152 Diabetic Retinopathy 25802486 "We have demonstrated that miR-152 interacting with PRR regulates downstream VEGF, VRGFR-2, and TGF¦Â1 expressions in hRECs in HG conditions. These studies suggest miR-152 and PRR may play a role in the pathogenesis of diabetic retinopathy (DR)." +target gene hsa-mir-21 Cholangiocarcinoma 25803229 MiR-21 promotes intrahepatic cholangiocarcinoma proliferation and growth in vitro and in vivo by targeting PTPN14 and PTEN. +target gene hsa-mir-146a Hepatitis B Virus Infection 25805734 Upregulation of microRNA-146a by hepatitis B virus X protein contributes to hepatitis development by downregulating complement factor H. +target gene hsa-mir-28 Ischemic Diseases [unspecific] 25807426 These findings suggest that miR-28 promotes myocardial ischemia through the inhibition of ALDH2 expression in mus. miRNAs is as a probable index in identification of myocardial ischemia after acute myocardial infarction. +target gene hsa-mir-106b Pancreatic Neoplasms 25807437 Our findings may provide new insights into the knowledge of molecular mechanisms of pancreatic cancer and development of novel targeting therapies. +target gene hsa-mir-125a Pancreatic Neoplasms 25807437 Our findings may provide new insights into the knowledge of molecular mechanisms of pancreatic cancer and development of novel targeting therapies. +target gene hsa-mir-153 Pancreatic Neoplasms 25807437 Our findings may provide new insights into the knowledge of molecular mechanisms of pancreatic cancer and development of novel targeting therapies. +target gene hsa-mir-181c Pancreatic Neoplasms 25807437 Our findings may provide new insights into the knowledge of molecular mechanisms of pancreatic cancer and development of novel targeting therapies. +target gene hsa-mir-101 "Carcinoma, Hepatocellular" 25808945 Our results demonstrate that miR-101 regulates HCC cell phenotype by upregulating the epithelial marker genes and suppressing the mesenchymal ones. +target gene hsa-mir-221 Inflammation 25810396 "Moreover, downregulation of KIT expression by miRNA-221 overexpression or the proteasome inhibitor bortezomib also reduced 3BP2 and MITF expression." +target gene hsa-mir-134 "Carcinoma, Renal Cell" 25811077 miR-134 functions as a tumor suppressor in cell proliferation and epithelial-to-mesenchymal Transition by targeting KRAS in renal cell carcinoma cells. +target gene hsa-mir-155 Stroke 25811992 miR-155 mediates inflammatory responses in ischemic cerebral tissue by modulating TLR4/MyD88 and SOCS1 expression +target gene hsa-mir-218 Cardiac Myxoma 25812649 miR-218 suppresses cardiac myxoma proliferation by targeting myocyte enhancer factor 2D. +target gene hsa-mir-200a "Carcinoma, Renal Cell" 25813153 Tumor suppressive microRNA-200a inhibits renal cell carcinoma development by directly targeting TGFB2. +target gene hsa-mir-141 Breast Neoplasms 25813250 miR-141 confers docetaxel chemoresistance of breast cancer cells via regulation of EIF4E expression. +target gene hsa-mir-7 Parkinson Disease 25814668 "microRNA-7, by down-regulating RelA,augments Glut3 expression, promotes glycolysis, and subsequently prevents MPP(+)-induced cell death. This protective effect of microRNA-7 could be exploited to correct the defects in oxidative phosphorylation in Parkinson disease." +target gene hsa-mir-200b "Diabetes Mellitus, Type 2" 25814674 This study reports that (1) inflammation underlying nonhealing wounds in patients with type 2 diabetes mellitus influences plasma miRNA concentrations and (2) miR-191 modulates cellular migration and angiogenesis via paracrine regulation of zonula occludens-1 to delay the tissue repair process. +target gene hsa-mir-191 "Carcinoma, Hepatocellular, HBV-Related" 25814782 "These findings highlight the importance of validating reference genes before quantifying target miRNAs.Furthermore, our findings will improve studies that monitor hepatitis progression and will aid in the discovery of noninvasive biomarkers to diagnose early stage HCC." +target gene hsa-mir-221 "Carcinoma, Hepatocellular, HBV-Related" 25814782 "These findings highlight the importance of validating reference genes before quantifying target miRNAs.Furthermore, our findings will improve studies that monitor hepatitis progression and will aid in the discovery of noninvasive biomarkers to diagnose early stage HCC." +target gene hsa-mir-26a "Carcinoma, Hepatocellular, HBV-Related" 25814782 "These findings highlight the importance of validating reference genes before quantifying target miRNAs.Furthermore, our findings will improve studies that monitor hepatitis progression and will aid in the discovery of noninvasive biomarkers to diagnose early stage HCC." +target gene hsa-mir-146b Diabetes Mellitus 25815338 MicroRNA-146b-3p regulates retinal inflammation by suppressing adenosine deaminase-2 in diabetes. +target gene hsa-mir-133a "Carcinoma, Gastric" 25815687 "MicroRNA-133a inhibits proliferation and invasion, and induces apoptosis in gastric carcinoma cells via targeting fascin actin-bundling protein 1." +target gene hsa-mir-509 "Carcinoma, Renal Cell" 25815776 MicroRNA-509-3p inhibits cancer cell proliferation and migration by targeting the mitogen-activated protein kinase kinase kinase 8 oncogene in renal cell carcinoma. +target gene hsa-mir-218 "Carcinoma, Hepatocellular" 25816091 MicroRNA-218 and microRNA-520a inhibit cell proliferation by downregulating E2F2 in hepatocellular carcinoma. +target gene hsa-mir-520a "Carcinoma, Hepatocellular" 25816091 MicroRNA-218 and microRNA-520a inhibit cell proliferation by downregulating E2F2 in hepatocellular carcinoma. +target gene hsa-let-7g Follicular Atresia 25817543 let-7g regulates the apoptosis of GCs in the pig ovary by targeting TGFBR1 and down-regulating the TGF-β signaling pathway. +target gene hsa-mir-93 Intervertebral Disc Degeneration 25818544 "Taken together, we demonstrated that miR-93 contributed to abnormal NP cell type II collagen expression by targeting MMP3, involved in intervertebral disc degeneration." +target gene hsa-mir-709 "Carcinoma, Hepatocellular" 25818666 These results suggest that miR-709 may positively regulate invasion and metastasis of HCC through targeting GPC5. +target gene hsa-mir-449a Lung Neoplasms 25818739 "Our data indicate that miR-449a may function as a suppressor of lung cancer, and affects the expression of NEAT1 in lung cancer cells." +target gene hsa-mir-200a Colorectal Carcinoma 25818799 "miR-200a plays a role in regulating the invasiveness and metastasis of CRC, and overexpression of miR-200a causes a significant reduction of cell proliferation and migration and promotes apoptosis and cell-cell adhesion in LoVo cells." +target gene hsa-mir-490 Ovary Mixed Epithelial Carcinoma 25819031 MicroRNA-490-3P targets CDK1 and inhibits ovarian epithelial carcinoma tumorigenesis and progression. +target gene hsa-mir-191 Endometriosis 25819812 "miR-191 can directly regulate TIMP3 expression, thereby affecting cell proliferation rate and invasion ability. The miR-191-TIMP3 axis might be critical in the malignant transformation of endometriosis to EAOC." +target gene hsa-mir-494 "Carcinoma, Hepatocellular" 25820676 MicroRNA-494 is a master epigenetic regulator of multiple invasion-suppressor microRNAs by targeting ten eleven translocation 1 in invasive human hepatocellular carcinoma tumors. +target gene hsa-mir-195 Osteosarcoma 25823925 MicroRNA profiling identifies MiR-195 suppresses osteosarcoma cell metastasis by targeting CCND1. +target gene hsa-mir-155 "Squamous Cell Carcinoma, Esophageal" 25823933 "a novel pattern of differential miRNA-target expression was constructed, which with further investigation, may provide novel targets for diagnosing and understanding the mechanism of ESCC." +target gene hsa-mir-202 "Squamous Cell Carcinoma, Esophageal" 25823933 "a novel pattern of differential miRNA-target expression was constructed, which with further investigation, may provide novel targets for diagnosing and understanding the mechanism of ESCC." +target gene hsa-mir-107 "Adenocarcinoma, Gastric" 25824045 miR-107 and miR-25 simultaneously target LATS2 and regulate proliferation and invasion of gastric adenocarcinoma (GAC) cells. +target gene hsa-mir-25 "Adenocarcinoma, Gastric" 25824045 miR-107 and miR-25 simultaneously target LATS2 and regulate proliferation and invasion of gastric adenocarcinoma (GAC) cells. +target gene hsa-mir-520b "Carcinoma, Hepatocellular" 25824049 MiR-520b suppresses proliferation of hepatoma cells through targeting ten-eleven translocation 1 (TET1) mRNA. +target gene hsa-mir-146b Inflammation 25824148 "Ang-1 disrupts TLR4 signalling, resulting in inhibition of LPS-induced inflammatory responses in endothelial cells. This inhibition occurs through selective targeting of IRAK1 and TRAF6 proteins by miR-146b-5p." +target gene hsa-mir-454 Colorectal Carcinoma 25824771 MiR-454 prompts cell proliferation of human colorectal cancer cells by repressing CYLD expression. +target gene hsa-mir-21 Multiple Myeloma 25825239 "Downregulation of Sprouty homolog 2 by microRNA-21 inhibits proliferation,metastasis and invasion, however promotes the apoptosis of multiple myeloma cells." +target gene hsa-mir-34a Breast Neoplasms 25826085 Dysregulation of the miR-34a-SIRT1 axis inhibits breast cancer stemness. +target gene hsa-mir-200b Colorectal Carcinoma 25826661 microRNA-200b and microRNA-200c promote colorectal cancer cell proliferation via targeting the reversion-inducing cysteine-rich protein with Kazal motifs. +target gene hsa-mir-200c Colorectal Carcinoma 25826661 microRNA-200b and microRNA-200c promote colorectal cancer cell proliferation via targeting the reversion-inducing cysteine-rich protein with Kazal motifs. +target gene hsa-mir-16 Breast Neoplasms 25830480 MicroRNA-16 modulates HuR regulation of cyclin E1 in breast cancer cells. +target gene hsa-mir-142 Vascular Disease [unspecific] 25832008 this study demonstrates that miR-142-3p is a key regulator of the TGF¦Â-mediated contractile phenotype of VSMCs that acts through inhibiting cell migration through targeting DOCK6. +target gene hsa-mir-193a "Carcinoma, Lung, Non-Small-Cell" 25833338 miR-193a-3p inhibited the metastasis of lung cancer cells by deregulating the expression of tumor-related proteins. These findings may improve the understanding of the molecular mechanisms underlying the metastatic-inhibitory effect of miR-193a-3p on lung cancer cells. +target gene hsa-mir-429 "Adenocarcinoma, Pancreatic Ductal" 25833382 Low level of miR-429 and high level of TBK1 in PDAC promoted PDAC cells growth which might be related to the low survival rate of PDAC patients.MiR-429 play its role in PDAC by targeting TBK1. +target gene hsa-mir-489 "Carcinoma, Lung, Non-Small-Cell" 25833694 Down-regulation of miR-489 contributes into NSCLC cell invasion through targeting SUZ12. +target gene hsa-mir-197 Ovarian Neoplasms 25833695 MiR-197 induces Taxol resistance in human ovarian cancer cells by regulating NLK. +target gene hsa-mir-139 Neoplasms [unspecific] 25833697 miR-139-5p suppresses cancer cell migration and invasion through targeting ZEB1 and ZEB2 in GBM. +target gene hsa-mir-125a "Carcinoma, Lung, Small-Cell" 25833836 Chemotherapy-Regulated microRNA-125-HER2 Pathway as a Novel Therapeutic Target for Trastuzumab-Mediated Cellular Cytotoxicity in Small Cell Lung Cancer. +target gene hsa-mir-195 "Carcinoma, Lung, Non-Small-Cell" 25840419 MiR-195 suppresses non-small cell lung cancer by targeting CHEK1. +target gene hsa-mir-30 Glioma 25840690 miR-30 overexpression promotes glioma stem cells by regulating Jak/STAT3 signaling pathway. +target gene hsa-mir-483 "Squamous Cell Carcinoma, Tongue" 25843291 miR-483-5p determines mitochondrial fission and cisplatin sensitivity in tongue squamous cell carcinoma by targeting FIS1. +target gene hsa-mir-30d "Carcinoma, Lung, Non-Small-Cell" 25843294 MicroRNA-30d-5p inhibits tumour cell proliferation and motility by directly targeting CCNE2 in non-small cell lung cancer. +target gene hsa-mir-21 "Carcinoma, Ovarian" 25845681 "Icariin regulates the proliferation and apoptosis of human ovarian cancer cells through microRNA-21 by targeting PTEN, RECK and Bcl-2." +target gene hsa-mir-34c "Carcinoma, Endometrial" 25846116 "our study demonstrated that miR-34c plays a role of tumor suppressor in HEC-1-B cells, and E2F3 protein may be a target of miR-34c." +target gene hsa-mir-21 "Adenocarcinoma, Pancreatic Ductal" 25846727 "Our results demonstrate that p85¦Á expression is a determinant of chemosensitivity in PDAC. Additionally, we provide novel evidence that miR-21 can influence PI3K-AKT signaling via its direct regulation of p85¦Á. These data provide insight into potential mechanisms for the known relationship between increased p85¦Á expression and improved survival in PDAC." +target gene hsa-mir-506 Gastric Neoplasms 25846731 MicroRNA-506 inhibits gastric cancer proliferation and invasion by directly targeting Yap1. +target gene hsa-mir-4717 Anxiety Disorders 25847876 data indicate that MIR4717 regulates human RGS2 and contributes to the genetic risk towards anxiety-related traits. +target gene hsa-mir-210 Hemoglobin Diseases 25849663 microRNA-210 and raptor are involved in mithramycin-mediated erythroid differentiation of K562 cells and participate to the fine-tuning and control of ¦Ã-globin gene expression in erythroid precursor cells. +target gene hsa-mir-3127 "Carcinoma, Hepatocellular" 25849943 MicroRNA-3127 promotes cell proliferation and tumorigenicity in hepatocellular carcinoma by disrupting of PI3K/AKT negative regulation. +target gene hsa-mir-107 "Carcinoma, Breast, Triple Negative" 25851994 MiR-107 down-regulates SIAH1 expression in human breast cancer cells and silencing of miR-107 inhibits tumor growth in a nude mouse model of triple-negative breast cancer. +target gene hsa-mir-155 Melanoma 25853464 "microRNA-155, induced by interleukin-1?, represses the expression of microphthalmia-associated transcription factor (MITF-M) in melanoma cells." +target gene hsa-mir-199a Glioma 25854175 MicroRNA-199a-3p suppresses glioma cell proliferation by regulating the AKT/mTOR signaling pathway. +target gene hsa-mir-506 "Carcinoma, Nasopharyngeal" 25856555 MiR-506 suppresses tumor proliferation and invasion by targeting FOXQ1 in nasopharyngeal carcinoma. +target gene hsa-mir-192 Hirschsprung Disease 25857602 Nidogen-1 is a common target of microRNAs MiR-192/215 in the pathogenesis of Hirschsprung's disease. +target gene hsa-mir-215 Hirschsprung Disease 25857602 Nidogen-1 is a common target of microRNAs MiR-192/215 in the pathogenesis of Hirschsprung's disease. +target gene hsa-mir-200c Ovarian Neoplasms 25860109 "This network included four separate types of interactions among miRNAs and genes. Simply analyzing each interaction component in isolation, such as the eQTL associations, the miRNA-target interactions or the protein-protein interactions, would create a much more limited network than the integrated one." +target gene hsa-mir-22 Ovarian Neoplasms 25860109 "This network included four separate types of interactions among miRNAs and genes. Simply analyzing each interaction component in isolation, such as the eQTL associations, the miRNA-target interactions or the protein-protein interactions, would create a much more limited network than the integrated one." +target gene hsa-mir-124 "Carcinoma, Renal Cell" 25861751 miR-124 represses FZD5 to attenuate P-glycoprotein-mediated chemo-resistance in renal cell carcinoma. +target gene hsa-mir-492 "Carcinoma, Colon" 25862460 MiR-492 is functionally involved in Oxaliplatin resistance in colon cancer cells LS174T via its regulating the expression of CD147. +target gene hsa-mir-7 "Carcinoma, Ovarian" 25862909 "There is a link between miR-7 expression and TP53 status and tumour grade in serous OC. Molecular mechanisms of these relationships need to be elucidated. Of the two postulated miR-7 target genes we examined, BCL2, but not EGFR, seems to be a possible miR-7 target in OC." +target gene hsa-mir-375 Neuroblastoma 25864587 Targeting MYCN IRES in MYCN-amplified neuroblastoma with miR-375 inhibits tumor growth and sensitizes tumor cells to radiation. +target gene hsa-mir-221 Inflammation 25865302 these results indicated that miR-221 targets AdipoR1 to regulate endothelial inflammatory response. +target gene hsa-mir-186 Ovarian Neoplasms 25867064 miR-186 regulation of Twist1 and ovarian cancer sensitivity to cisplatin. +target gene hsa-mir-133 "Adenocarcinoma, Lung" 25868726 Metastasis-associated lung adenocarcinoma transcript 1 (Malat1) regulates serum response factor through miR-133 as a competing endogenous RNA in myogenesis. +target gene hsa-mir-33b Melanoma 25868853 "Cordycepin (3'-deoxyadenosine) suppressed HMGA2, Twist1 and ZEB1-dependent melanoma invasion and metastasis by targeting miR-33b." +target gene hsa-mir-217 Gastric Neoplasms 25869101 microRNA-217 inhibits tumor progression and metastasis by downregulating EZH2 and predicts favorable prognosis in gastric cancer. +target gene hsa-mir-155 Down Syndrome 25869329 These results suggest that regulation of TFAM by hsa-miR-155-5p impacts mitochondrial biogenesis in the diploid setting but not in the DS setting. +target gene hsa-mir-124 Lung Neoplasms 25869366 "Novel potential regulatory miRNAs for RHOA (miR-9-1/-3, -34b/c, -129-2, -125b-1, -375, -1258) and NKIRAS1 (miR-34b/c, -129-2, -125b-1, -193a, -124a-1/-2/-3, -212, -132) genes in lung cancer were identified." +target gene hsa-mir-1258 Lung Neoplasms 25869366 "Novel potential regulatory miRNAs for RHOA (miR-9-1/-3, -34b/c, -129-2, -125b-1, -375, -1258) and NKIRAS1 (miR-34b/c, -129-2, -125b-1, -193a, -124a-1/-2/-3, -212, -132) genes in lung cancer were identified." +target gene hsa-mir-129 Lung Neoplasms 25869366 "Novel potential regulatory miRNAs for RHOA (miR-9-1/-3, -34b/c, -129-2, -125b-1, -375, -1258) and NKIRAS1 (miR-34b/c, -129-2, -125b-1, -193a, -124a-1/-2/-3, -212, -132) genes in lung cancer were identified." +target gene hsa-mir-132 Lung Neoplasms 25869366 "Novel potential regulatory miRNAs for RHOA (miR-9-1/-3, -34b/c, -129-2, -125b-1, -375, -1258) and NKIRAS1 (miR-34b/c, -129-2, -125b-1, -193a, -124a-1/-2/-3, -212, -132) genes in lung cancer were identified." +target gene hsa-mir-193a Lung Neoplasms 25869366 "Novel potential regulatory miRNAs for RHOA (miR-9-1/-3, -34b/c, -129-2, -125b-1, -375, -1258) and NKIRAS1 (miR-34b/c, -129-2, -125b-1, -193a, -124a-1/-2/-3, -212, -132) genes in lung cancer were identified." +target gene hsa-mir-212 Lung Neoplasms 25869366 "Novel potential regulatory miRNAs for RHOA (miR-9-1/-3, -34b/c, -129-2, -125b-1, -375, -1258) and NKIRAS1 (miR-34b/c, -129-2, -125b-1, -193a, -124a-1/-2/-3, -212, -132) genes in lung cancer were identified." +target gene hsa-mir-34b Lung Neoplasms 25869366 "Novel potential regulatory miRNAs for RHOA (miR-9-1/-3, -34b/c, -129-2, -125b-1, -375, -1258) and NKIRAS1 (miR-34b/c, -129-2, -125b-1, -193a, -124a-1/-2/-3, -212, -132) genes in lung cancer were identified." +target gene hsa-mir-34c Lung Neoplasms 25869366 "Novel potential regulatory miRNAs for RHOA (miR-9-1/-3, -34b/c, -129-2, -125b-1, -375, -1258) and NKIRAS1 (miR-34b/c, -129-2, -125b-1, -193a, -124a-1/-2/-3, -212, -132) genes in lung cancer were identified." +target gene hsa-mir-375 Lung Neoplasms 25869366 "Novel potential regulatory miRNAs for RHOA (miR-9-1/-3, -34b/c, -129-2, -125b-1, -375, -1258) and NKIRAS1 (miR-34b/c, -129-2, -125b-1, -193a, -124a-1/-2/-3, -212, -132) genes in lung cancer were identified." +target gene hsa-mir-9 Lung Neoplasms 25869366 "Novel potential regulatory miRNAs for RHOA (miR-9-1/-3, -34b/c, -129-2, -125b-1, -375, -1258) and NKIRAS1 (miR-34b/c, -129-2, -125b-1, -193a, -124a-1/-2/-3, -212, -132) genes in lung cancer were identified." +target gene hsa-mir-183 Graves Disease 25871842 Our study highlights the possibility that miRNA-target gene network may be involved in the pathogenesis of GD and could provide new insights into understanding the pathophysiological mechanisms of GD. +target gene hsa-mir-197 Graves Disease 25871842 Our study highlights the possibility that miRNA-target gene network may be involved in the pathogenesis of GD and could provide new insights into understanding the pathophysiological mechanisms of GD. +target gene hsa-mir-22 Graves Disease 25871842 Our study highlights the possibility that miRNA-target gene network may be involved in the pathogenesis of GD and could provide new insights into understanding the pathophysiological mechanisms of GD. +target gene hsa-mir-660 Graves Disease 25871842 Our study highlights the possibility that miRNA-target gene network may be involved in the pathogenesis of GD and could provide new insights into understanding the pathophysiological mechanisms of GD. +target gene hsa-mir-203 Oral Submucous Fibrosis 25872484 "Thus, we provide evidence to illustrate that miR-203 plays a role in the pathogenesis of OSF, which may be a target for OSF management." +target gene hsa-mir-181b Retinoblastoma 25872572 Hypoxia-induced miR-181b enhances angiogenesis of retinoblastoma cells by targeting PDCD10 and GATA6. +target gene hsa-mir-494 "Carcinoma, Colon" 25873402 MicroRNA-494 sensitizes colon cancer cells to fluorouracil through regulation of DPYD. +target gene hsa-mir-15a "Carcinoma, Lung, Non-Small-Cell" 25874488 MicroRNA-15a induces cell apoptosis and inhibits metastasis by targeting BCL2L2 in non-small cell lung cancer. +target gene hsa-mir-1 Gastric Neoplasms 25874496 MicroRNA-1 (miR-1) inhibits gastric cancer cell proliferation and migration by targeting MET. +target gene hsa-mir-10b "Carcinoma, Laryngeal" 25875782 MicroRNA-10b Triggers the Epithelial-Mesenchymal Transition (EMT) of Laryngeal Carcinoma Hep-2 Cells by Directly Targeting the E-cadherin. +target gene hsa-mir-200b Glioma 25877314 miR-200b may suppress cell invasion by targeting PROM1 in glioma. +target gene hsa-mir-34a Bladder Neoplasms 25878394 miR-34a inhibits proliferation and invasion of bladder cancer cells by targeting orphan nuclear receptor HNF4G. +target gene hsa-mir-33a Osteoarthritis 25880168 "Our findings suggest, for the first time to our knowledge, that miR-33a regulates cholesterol synthesis through the TGF-¦Â1/Akt/SREBP-2 pathway,as well as cholesterol efflux-related genes ABCA1 and ApoA1, in OA chondrocytes, pointing to its identification as a novel target for ameliorating the OA phenotype." +target gene hsa-mir-372 "Carcinoma, Hepatocellular" 25880458 miR-372 may play an important role in hepatic carcinogenesis and may serve as a new target or method to detect and treat HCC in the future. +target gene hsa-mir-7 Lung Neoplasms 25880778 KCNJ2/Kir2.1 modulates cell growth and drug resistance by regulating MRP1/ABCC1 expression and is simultaneously regulated by the Ras/MAPK pathway and miR-7. KCNJ2/Kir2.1 may be a prognostic predictor and a potentially novel target for interfering with chemoresistance in SCLC. +target gene hsa-mir-223 Lung Neoplasms 25881295 Our study demonstrates for the first time that platelet-secreted miR-223 via P-MVs can promote lung cancer cell invasion via targeting tumor suppressor EPB41L3. +target gene hsa-mir-221 Pancreatic Neoplasms 25883224 miR-221/222 induces pancreatic cancer progression through the regulation of matrix metalloproteinases. +target gene hsa-mir-222 Pancreatic Neoplasms 25883224 miR-221/222 induces pancreatic cancer progression through the regulation of matrix metalloproteinases. +target gene hsa-mir-200b Diabetes Mellitus 25884496 Polycomb repressive complex 2 regulates MiR-200b in retinal endothelial cells:potential relevance in diabetic retinopathy. +target gene hsa-mir-132 Autism Spectrum Disorder 25885346 We found that through p-CREB/miR-132 signaling cascade is involved in MeCP2-mediated pain transduction. +target gene hsa-mir-200 Breast Neoplasms 25886595 "The ADAM12-L 3'UTR is a direct target of miR-29 and miR-200 family members. Since the miR-29 and miR-200 families play important roles in breast cancer progression, these results may help explain the different prognostic and chemopredictive values of ADAM12-L and ADAM12-S in breast cancer." +target gene hsa-mir-29 Breast Neoplasms 25886595 "The ADAM12-L 3'UTR is a direct target of miR-29 and miR-200 family members. Since the miR-29 and miR-200 families play important roles in breast cancer progression, these results may help explain the different prognostic and chemopredictive values of ADAM12-L and ADAM12-S in breast cancer." +target gene hsa-mir-126 Obesity 25887648 We identified 23 active miRNA-TF-gene regulatory pathways that were significantly related to obesity-related inflammation. +target gene hsa-mir-145 Obesity 25887648 We identified 23 active miRNA-TF-gene regulatory pathways that were significantly related to obesity-related inflammation. +target gene hsa-mir-193b Obesity 25887648 We identified 23 active miRNA-TF-gene regulatory pathways that were significantly related to obesity-related inflammation. +target gene hsa-mir-21 Obesity 25887648 We identified 23 active miRNA-TF-gene regulatory pathways that were significantly related to obesity-related inflammation. +target gene hsa-mir-29b Obesity 25887648 We identified 23 active miRNA-TF-gene regulatory pathways that were significantly related to obesity-related inflammation. +target gene hsa-mir-223 "Carcinoma, Gastric" 25888377 Our findings revealed the roles of miR-223/FBXW7 signaling in the DDP resistance of GC cells and targeting it will be a potential strategic approach for reversing the DDP resistance in human GC. +target gene hsa-mir-29c "Carcinoma, Hepatocellular" 25888625 A suppressive role of ionizing radiation-responsive miR-29c in the development of liver carcinoma via targeting WIP1. +target gene hsa-mir-211 "Carcinoma, Hepatocellular" 25888635 miR-211 suppresses hepatocellular carcinoma by downregulating SATB2. +target gene hsa-mir-135a "Carcinoma, Bladder" 25888950 "Our study demonstrates that miR-135a promotes cell proliferation in bladder cancer by targeting PHLPP2 and FOXO1, and is performed as an onco-miR." +target gene hsa-mir-31 Breast Neoplasms 25889182 These data provide strong evidence that GNA13 expression in breast cancer cells is regulated by post-transcriptional mechanisms involving miR-31.Additionally our data shows that miR-31 regulates breast cancer cell invasion partially via targeting GNA13 expression in breast cancer cells. Loss of miR-31 expression and increased GNA13 expression could be used as biomarkers of breast cancer progression. +target gene hsa-mir-196b Neoplasms [unspecific] 25889892 we identified IGF2BP1 as a direct and functional target of miR-196b and showed that miR-196b overexpression reverses the chemoresistance induced by hypoxia. These results emphasize that the chemoresistance induced by hypoxia is a complex mechanism. +target gene hsa-mir-203 Kidney Neoplasms 25890121 Our study suggested that miR-203 could be a potential prognostic marker and functions as a tumor suppressor in human renal cancer by post-transcriptionally targeting FGF2. +target gene hsa-mir-21 Prostate Neoplasms 25890570 Androgen receptor and microRNA-21 axis downregulates transforming growth factor beta receptor II (TGFBR2) expression in prostate cancer. +target gene hsa-mir-9 "Carcinoma, Nasopharyngeal" 25891118 "These data demonstrated that miR-9 did not modulate the sensitivity of the CNE2 cells to UV radiation through E-cadherin, but suggested that miR-9 regulated radiosensitivity through its effects on glutathione. These findings suggest that miR-9 may be a potential target for modulating the radiosensitivity of NPC cells." +target gene hsa-mir-155 Inflammation 25892184 "miR-155-dependent regulation of mammalian sterile 20-like kinase 2 (MST2) coordinates inflammation, oxidative stress and proliferation in vascular smooth muscle cells." +target gene hsa-mir-93 "Carcinoma, Nasopharyngeal" 25892549 MicroRNA-93 promotes cell growth and invasion in nasopharyngeal carcinoma by targeting disabled homolog-2. +target gene hsa-mir-572 "Carcinoma, Ovarian" 25893382 Upregulation of miR-572 transcriptionally suppresses SOCS1 and p21 and contributes to human ovarian cancer progression. +target gene hsa-mir-4717 Hepatitis B Virus Infection 25895129 microRNA-4717 differentially interacts with its polymorphic target in the PD1 3' untranslated region: A mechanism for regulating PD-1 expression and function in HBV-associated liver diseases. +target gene hsa-mir-34a Ovarian Neoplasms 25895459 MiR-34a suppresses ovarian cancer proliferation and motility by targeting AXL. +target gene hsa-mir-342 Obesity 25895816 "miR-342-3p is a powerful enhancer of the adipogenesis of human adipose-derived MSCs that acts by inhibiting CtBP2 and releasing the key adipogenic regulator C/EBP¦Á from CtBP2 binding, subsequently activating the expression of adipogenic transcription factors and markers." +target gene hsa-mir-141 "Carcinoma, Hepatocellular" 25896253 "Our study showed that miR-141 plays a key role in 5-FU resistance by down-regulating Keap1 expression, thereby reactivating the Nrf2-dependent antioxidant pathway, which may serve as a potential target for overcoming 5-FU resistance in hepatocellular carcinoma cells." +target gene hsa-mir-21 Cardiovascular Diseases [unspecific] 25898844 "In cardiac fibrosis related to Ang II, miR-21 is transcriptionally activated and targets PTEN/SMAD7 resulting in increased fibroblast survival. OPN KO animals are protected from miR-21 increase and fibrosis development due to impaired AP-1 activation and fibroblast activation." +target gene hsa-mir-218 Breast Neoplasms 25900794 miR-218 targets survivin and regulates resistance to chemotherapeutics in breast cancer. +target gene hsa-mir-320 Glioma 25901521 MicroRNA-320 inhibits cell proliferation in glioma by targeting E2F1. +target gene hsa-mir-15b Glioma 25901555 Mangiferin regulates proliferation and apoptosis in glioma cells by induction of microRNA-15b and inhibition of MMP-9 expression. +target gene hsa-mir-148a Glioblastoma 25903473 "miR-31 and miR-148a regulate glioma growth by maintaining tumor stem cells and their niche, and providing the tumor a way to activate angiogenesis even in a normoxic environment.This is the first study that demonstrates intratumoral uptake and growth-inhibiting effects of uncomplexed antagomirs in orthotopic glioma." +target gene hsa-mir-31 Glioblastoma 25903473 "miR-31 and miR-148a regulate glioma growth by maintaining tumor stem cells and their niche, and providing the tumor a way to activate angiogenesis even in a normoxic environment.This is the first study that demonstrates intratumoral uptake and growth-inhibiting effects of uncomplexed antagomirs in orthotopic glioma." +target gene hsa-mir-193b Pancreatic Neoplasms 25905463 Deregulation of the MiR-193b-KRAS Axis Contributes to Impaired Cell Growth in Pancreatic Cancer. +target gene hsa-mir-135b Prostate Neoplasms 25907805 "MicroRNA-135b regulates ER¦Á, AR and HIF1AN and affects breast and prostate cancer cell growth." +target gene hsa-mir-144 Neoplasms [unspecific] 25907866 MicroRNA-144 suppresses tumorigenesis and tumor progression of astrocytoma by targeting EZH2. +target gene hsa-mir-218 "Carcinoma, Cervical" 25908215 MicroRNA-218 increases cellular sensitivity to Rapamycin via targeting Rictor in cervical cancer. +target gene hsa-mir-200b "Carcinoma, Hepatocellular" 25909223 MiR-200b/200c/429 subfamily negatively regulates Rho/ROCK signaling pathway to suppress hepatocellular carcinoma metastasis. +target gene hsa-mir-200c "Carcinoma, Hepatocellular" 25909223 MiR-200b/200c/428 subfamily negatively regulates Rho/ROCK signaling pathway to suppress hepatocellular carcinoma metastasis. +target gene hsa-mir-429 "Carcinoma, Hepatocellular" 25909223 MiR-200b/200c/427 subfamily negatively regulates Rho/ROCK signaling pathway to suppress hepatocellular carcinoma metastasis. +target gene hsa-mir-21 "Lymphoma, B-Cell" 25909227 MicroRNA-21 plays an oncogenic role by targeting FOXO1 and activating the PI3K/AKT pathway in diffuse large B-cell lymphoma. +target gene hsa-let-7c "Carcinoma, Hepatocellular" 25909324 MicroRNA let-7c Inhibits Cell Proliferation and Induces Cell Cycle Arrest by Targeting CDC25A in Human Hepatocellular Carcinoma. +target gene hsa-mir-21 "Leukemia, Lymphocytic, Chronic, B-Cell" 25909590 IL-4 Up-Regulates MiR-21 and the MiRNAs Hosted in the CLCN5 Gene in Chronic Lymphocytic Leukemia. +target gene hsa-mir-144 Osteosarcoma 25912304 MicroRNA-144 suppresses osteosarcoma growth and metastasis by targeting ROCK1 and ROCK2. +target gene hsa-mir-129 "Carcinoma, Hepatocellular" 25912876 MicroRNA-129-5p inhibits hepatocellular carcinoma cell metastasis and invasion via targeting ETS1. +target gene hsa-mir-3144 Human Papilloma Virus Infection 25913515 Two less common human microRNAs miR-875 and miR-3144 target a conserved site of E6 oncogene in most high-risk human papillomavirus subtypes. +target gene hsa-mir-875 Human Papilloma Virus Infection 25913515 Two less common human microRNAs miR-875 and miR-3144 target a conserved site of E6 oncogene in most high-risk human papillomavirus subtypes. +target gene hsa-mir-145 Colorectal Carcinoma 25913620 Tumor suppressor miR-145 reverses drug resistance by directly targeting DNA damage-related gene RAD18 in colorectal cancer. +target gene hsa-mir-185 Hepatitis C Virus Infection 25914460 HCV core protein disturbs the cholesterol homeostasis in HepG2 cells via the SREBP2 pathway; miR-185-5p is involved in the regulation of SREBP2 by the core protein. +target gene hsa-mir-451 Multiple Myeloma 25915427 MicroRNA-451 regulates stemness of side population cells via PI3K/Akt/mTOR signaling pathway in multiple myeloma. +target gene hsa-mir-33b Breast Neoplasms 25919570 "MicroRNA-33b Inhibits Breast Cancer Metastasis by Targeting HMGA2, SALL4 and Twist1." +target gene hsa-mir-18a Neoplasms [unspecific] 25923049 "this probe can be used for cell-specific intracellular miRNA sensing with a confocal microscope. Using miRNA-18a as a target model, the dynamic changes of its expression level inside living cells can be monitored with the proposed method. This method possesses promising applications in the study of miRNA related bioprocesses and biomedicine." +target gene hsa-mir-144 Gastric Neoplasms 25927670 MicroRNA-144 inhibits the metastasis of gastric cancer by targeting MET expression. +target gene hsa-mir-148b "Carcinoma, Lung, Non-Small-Cell" 25927928 miR-148b reverses cisplatin-resistance in non-small cell cancer cells via negatively regulating DNMT1 expression. +target gene hsa-mir-145 "Carcinoma, Colon" 25928322 "Our current observations suggest that miR-21, miR-145, and their networks play critical roles in regulating CSCs growth and/or differentiation in the colon cancer and progression of chemo-resistance." +target gene hsa-mir-21 "Carcinoma, Colon" 25928322 "Our current observations suggest that miR-21, miR-145, and their networks play critical roles in regulating CSCs growth and/or differentiation in the colon cancer and progression of chemo-resistance." +target gene hsa-mir-124 "Carcinoma, Esophageal" 25928665 "Collectively, these data suggest that miR-124 functions as a tumor suppressor in esophageal cancer through, at least partially, targeting STAT3 signaling pathway." +target gene hsa-mir-23a Colorectal Carcinoma 25929864 Elevated microRNA-23a Expression Enhances the Chemoresistance of Colorectal Cancer Cells with Microsatellite Instability to 5-Fluorouracil by Directly Targeting ABCF1. +target gene hsa-mir-193a Inflammatory Bowel Diseases 25931122 "These findings suggest that miR-193a-3p regulation of PepT1 mediates the uptake of bacterial products and is a potent mechanism during the colonic inflammation process. Overall, we believe miR-193a-3p may be a potent regulator of colonic PepT1 for maintaining intestinal homeostasis." +target gene hsa-mir-1291 Neoplasms [unspecific] 25934574 Chimeric MicroRNA-1291 Biosynthesized Efficiently in Escherichia coli Is Effective to Reduce Target Gene Expression in Human Carcinoma Cells and Improve Chemosensitivity. +target gene hsa-mir-330 "Carcinoma, Lung, Non-Small-Cell" 25935837 miR-330-3p controls cell proliferation by targeting early growth response 2 in non-small-cell lung cancer. +target gene hsa-mir-383 Glioma 25936342 "MicroRNA-383 expression regulates proliferation, migration, invasion, and apoptosis in human glioma cells." +target gene hsa-mir-135b Glioblastoma 25936394 MicroRNA-135b exerts oncogenic activity in glioblastoma via the inhibition of glycerol kinase 5 expression. +target gene hsa-mir-16 Spinal Cord Injuries 25936407 "A number of microRNAs (e.g. miR210, miR-487b and miR-16) were observed to target cholesterol metabolism-associated DGEs." +target gene hsa-mir-19a Prostate Neoplasms 25936765 MicroRNA-19a regulates proliferation and apoptosis of castration-resistant prostate cancer cells by targeting BTG1. +target gene hsa-mir-145 "Carcinoma, Ovarian" 25937243 Quercetin induces the apoptosis of human ovarian carcinoma cells by upregulating the expression of microRNA-145. +target gene hsa-mir-137 Glioblastoma 25939439 MiR-137 inhibits proliferation and angiogenesis of human glioblastoma cells by targeting EZH2. +target gene hsa-mir-137 Colorectal Carcinoma 25940441 Tumor suppressive microRNA-137 negatively regulates Musashi-1 and colorectal cancer progression. +target gene hsa-mir-25 Gastric Neoplasms 25944166 "MicroRNA-25 promotes gastric cancer proliferation, invasion, and migration by directly targeting F-box and WD-40 Domain Protein 7, FBXW7." +target gene hsa-mir-132 Ischemic Diseases [unspecific] 25945589 The miR-132/212 cluster promotes arteriogenesis by modulating Ras-MAPK signalling via direct targeting of its inhibitors Rasa1 and Spred1. +target gene hsa-mir-212 Ischemic Diseases [unspecific] 25945589 The miR-132/212 cluster promotes arteriogenesis by modulating Ras-MAPK signalling via direct targeting of its inhibitors Rasa1 and Spred1. +target gene hsa-mir-338 Gastric Neoplasms 25945841 MiR-338-3p inhibits epithelial-mesenchymal transition in gastric cancer cells by targeting ZEB2 and MACC1/Met/Akt signaling. +target gene hsa-mir-2278 Leukemia 25953263 Revealing genome-wide mRNA and microRNA expression patterns in leukemic cells highlighted hsa-miR-2278 as a tumor suppressor for regain of chemotherapeutic imatinib response due to targeting STAT5A. +target gene hsa-mir-429 "Carcinoma, Renal Cell" 25953723 These results revealed a tumor suppressive role for miR-429 in renal cell carcinoma through directly targeting BMI1 and E2F3. +target gene hsa-mir-125b Liver Neoplasms 25953743 MicroRNA-125b attenuates epithelial-mesenchymal transitions and targets stem-like liver cancer cells through small mothers against decapentaplegic 2 and 4. +target gene hsa-mir-34a "Squamous Cell Carcinoma, Esophageal" 25954903 miR-34a inhibits the migration and invasion of esophageal squamous cell carcinoma by targeting Yin Yang-1. +target gene hsa-mir-153 Ovarian Neoplasms 25954928 MicroRNA-153 functions as a tumor suppressor by targeting SET7 and ZEB2 in ovarian cancer cells. +target gene hsa-mir-1 "Carcinoma, Endometrial" 25955017 The tumor-suppressive microRNA-1/133a cluster targets PDE7A and inhibits cancer cell migration and invasion in endometrial cancer. +target gene hsa-mir-133a "Carcinoma, Endometrial" 25955017 The tumor-suppressive microRNA-1/133a cluster targets PDE7A and inhibits cancer cell migration and invasion in endometrial cancer. +target gene hsa-mir-494 Breast Neoplasms 25955111 miR-494 suppresses the progression of breast cancer in vitro by targeting CXCR4 through the Wnt/¦Â-catenin signaling pathway. +target gene hsa-mir-139 Pancreatic Neoplasms 25955258 miR-139 and miR-200c regulate pancreatic cancer endothelial cell migration and angiogenesis. +target gene hsa-mir-200c Pancreatic Neoplasms 25955258 miR-139 and miR-200c regulate pancreatic cancer endothelial cell migration and angiogenesis. +target gene hsa-mir-18a Pregnancy Complications [unspecific] 25955393 "The results of the present study suggested that miR-18a expression suppression led to a decrease in JEG-3 cell invasion and an increase in JEG-3 cell apoptosis, by inducing ESR¦Á expression. The present study provides evidence for the involvement of miR-18a in the pathogenesis of pre-eclamptic pregnancies." +target gene hsa-mir-29a Breast Neoplasms 25955714 MicroRNA-29a inhibits cell migration and invasion by targeting Roundabout 1 in breast cancer cells. +target gene hsa-mir-216a "Squamous Cell Carcinoma, Oral" 25955794 MicroRNA-216a inhibits the growth and metastasis of oral squamous cell carcinoma by targeting eukaryotic translation initiation factor 4B. +target gene hsa-mir-29 Ependymoma 25958202 microRNA network analysis identifies miR-29 cluster as key regulator of LAMA2 in ependymoma. +target gene hsa-mir-25 Glioma 25960208 miR-25 promotes glioma cell proliferation by targeting CDKN1C. +target gene hsa-mir-939 "Carcinoma, Ovarian" 25960217 MiR-939 promotes the proliferation of human ovarian cancer cells by repressing APC2 expression. +target gene hsa-mir-20a Glioblastoma 25960225 miR-20a mediates temozolomide-resistance in glioblastoma cells via negatively regulating LRIG1 expression. +target gene hsa-mir-146b "Carcinoma, Thyroid" 25960292 Inhibition of miR-146b expression increases radioiodine-sensitivity in poorly differential thyroid carcinoma via positively regulating NIS expression. +target gene hsa-mir-1225 Breast Neoplasms 25961594 "our study demonstrates that HIPK2-kinase and the PLCXD1-phospholipase-C are novel targets of miR-193a-5p/miR-210-3p and miR-575/miR-1225-5p, respectively." +target gene hsa-mir-125a Breast Neoplasms 25961594 "our study demonstrates that HIPK2-kinase and the PLCXD1-phospholipase-C are novel targets of miR-193a-5p/miR-210-3p and miR-575/miR-1225-5p, respectively." +target gene hsa-mir-193 Breast Neoplasms 25961594 "our study demonstrates that HIPK2-kinase and the PLCXD1-phospholipase-C are novel targets of miR-193a-5p/miR-210-3p and miR-575/miR-1225-5p, respectively." +target gene hsa-mir-210 Breast Neoplasms 25961594 "our study demonstrates that HIPK2-kinase and the PLCXD1-phospholipase-C are novel targets of miR-193a-5p/miR-210-3p and miR-575/miR-1225-5p, respectively." +target gene hsa-mir-29a Breast Neoplasms 25961594 "our study demonstrates that HIPK2-kinase and the PLCXD1-phospholipase-C are novel targets of miR-193a-5p/miR-210-3p and miR-575/miR-1225-5p, respectively." +target gene hsa-mir-575 Breast Neoplasms 25961594 "our study demonstrates that HIPK2-kinase and the PLCXD1-phospholipase-C are novel targets of miR-193a-5p/miR-210-3p and miR-575/miR-1225-5p, respectively." +target gene hsa-mir-874 Breast Neoplasms 25961594 "our study demonstrates that HIPK2-kinase and the PLCXD1-phospholipase-C are novel targets of miR-193a-5p/miR-210-3p and miR-575/miR-1225-5p, respectively." +target gene hsa-mir-622 Colorectal Carcinoma 25961730 Radiation-induced microRNA-622 causes radioresistance in colorectal cancer cells by down-regulating Rb. +target gene hsa-mir-125a Leukemia 25961914 microRNA-125a (miR-125a) was identified as a miRNA that suppressed WT1 expression via binding to the WT1-3'UTR. +target gene hsa-mir-125a Breast Neoplasms 25962054 MicroRNA-125a influences breast cancer stem cells by targeting leukemia inhibitory factor receptor which regulates the Hippo signaling pathway. +target gene hsa-mir-1973 Lung Neoplasms 25962089 This may open the door for using epigenetic profile/miRNA expression of some cancer cells as resistance markers/targets to improve response of resistant cells to doxorubicin and for the use of combination doxorubicin/epigenetic modifiers to reduce doxorubicin toxicity. +target gene hsa-mir-29b Lung Neoplasms 25962089 This may open the door for using epigenetic profile/miRNA expression of some cancer cells as resistance markers/targets to improve response of resistant cells to doxorubicin and for the use of combination doxorubicin/epigenetic modifiers to reduce doxorubicin toxicity. +target gene hsa-mir-4286 Lung Neoplasms 25962089 This may open the door for using epigenetic profile/miRNA expression of some cancer cells as resistance markers/targets to improve response of resistant cells to doxorubicin and for the use of combination doxorubicin/epigenetic modifiers to reduce doxorubicin toxicity. +target gene hsa-mir-494 Lung Neoplasms 25962089 This may open the door for using epigenetic profile/miRNA expression of some cancer cells as resistance markers/targets to improve response of resistant cells to doxorubicin and for the use of combination doxorubicin/epigenetic modifiers to reduce doxorubicin toxicity. +target gene hsa-mir-128 "Carcinoma, Hepatocellular" 25962360 miR-128-3p suppresses hepatocellular carcinoma proliferation by regulating PIK3R1 and is correlated with the prognosis of HCC patients. +target gene hsa-mir-9 "Carcinoma, Breast, Triple Negative" 25963903 Overexpression of Notch signaling via Notch1 intracellular domain in MDA-MB-231 cell line was suppressed by lentiviruses expressing miR-9. +target gene hsa-mir-494 Pancreatic Neoplasms 25965392 "Ectopic expression of miR-494 inhibited the proliferation, invasion and chemoresistance of pancreatic cancer by regulating SIRT1 and c-Myc." +target gene hsa-mir-361 Colorectal Carcinoma 25965817 MiR-361-5p inhibits colorectal and gastric cancer growth and metastasis by targeting staphylococcal nuclease domain containing-1. +target gene hsa-mir-212 "Carcinoma, Hepatocellular" 25965836 MicroRNA-212 suppresses tumor growth of human hepatocellular carcinoma by targeting FOXA1. +target gene hsa-mir-218 Bladder Neoplasms 25967457 "MicroRNA-218 inhibits bladder cancer cell proliferation, migration, and invasion by targeting BMI-1." +target gene hsa-mir-125b Liver Diseases [unspecific] 25968989 "Our data suggest a mechanism for the marked changes in hepatic gene expression between the fetal and pediatric developmental periods, and support a role for these age-dependent miRNAs in regulating drug disposition." +target gene hsa-mir-34a Liver Diseases [unspecific] 25968989 "Our data suggest a mechanism for the marked changes in hepatic gene expression between the fetal and pediatric developmental periods, and support a role for these age-dependent miRNAs in regulating drug disposition." +target gene hsa-mir-448 "Carcinoma, Hepatocellular" 25969175 miR-448 may contribute to the progression of HCC via regulating ROCK2 expression. +target gene hsa-mir-124 Prostate Neoplasms 25969668 overexpression of miR-124 by transient transfection of mimics led to a significant decrease in talin 1 levels. +target gene hsa-mir-187 Prostate Neoplasms 25969992 MiR-187 Targets the Androgen-Regulated Gene ALDH1A3 in Prostate Cancer. +target gene hsa-mir-33a "Carcinoma, Pancreatic" 25971209 MicroRNA-33a-mediated downregulation of Pim-3 kinase expression renders human pancreatic cancer cells sensitivity to gemcitabine. +target gene hsa-mir-155 "Leukemia, Myeloid, Acute" 25971362 Pharmacological targeting of miR-155 via the NEDD8-activating enzyme inhibitor MLN4924 (Pevonedistat) in FLT3-ITD acute myeloid leukemia. +target gene hsa-mir-148a Glioblastoma 25971746 "These findings uncover a plausible mechanism for NF-¦ÊB-sustained TGF-¦Â/Smad activation via miR-148a in glioblastoma, and may suggest a new target for clinical intervention in human cancer." +target gene hsa-let-7g Gastric Neoplasms 25972194 Hsa-let-7g miRNA regulates the anti-tumor effects of gastric cancer cells under oxidative stress through the expression of DDR genes. +target gene hsa-mir-205 Neoplasms [unspecific] 25973003 These results indicate that miR-205 might inhibitor the proliferation of A549 cells by regulating the expression of PTEN. +target gene hsa-mir-145 Colorectal Carcinoma 25973017 MicroRNA-145 suppresses cell migration and invasion by targeting paxillin in human colorectal cancer cells. +target gene hsa-mir-1247 Osteosarcoma 25973030 MiRNA profile of osteosarcoma with CD117 and stro-1 expression: miR-1247 functions as an onco-miRNA by targeting MAP3K9. +target gene hsa-mir-877 "Carcinoma, Hepatocellular" 25973036 Up-regulation of miR-877 induced by paclitaxel inhibits hepatocellular carcinoma cell proliferation though targeting FOXM1. +target gene hsa-mir-126 Liver Cirrhosis 25974152 "Further, miR-126 promoted TNF-a-induced TGF-¦Â1 and collagen I mRNA expression in LX-2 cells. miR-126 may play an important role in hepatic fibrosis by downregulating the expression of I¦ÊB¦Á partly through the NF-¦ÊB signaling pathway." +target gene hsa-mir-141 Gastric Neoplasms 25975736 MicroRNA-141 inhibits migration of gastric cancer by targeting zinc finger E-box-binding homeobox 2. +target gene hsa-mir-24 Osteomyelitis 25976273 "The Role of MicroRNA, miR-24, and Its Target CHI3L1 in Osteomyelitis Caused by Staphylococcus aureus." +target gene hsa-mir-370 "Carcinoma, Lung, Non-Small-Cell" 25976502 MicroRNA-370 inhibits the progression of non-small cell lung cancer by downregulating oncogene TRAF4. +target gene hsa-mir-142 "Carcinoma, Cervical" 25976503 MicroRNA-142-3p inhibits cell proliferation and invasion of cervical cancer cells by targeting FZD7. +target gene hsa-mir-34 Wounds and Injuries [unspecific] 25978377 "our results provide compelling evidence supporting the existence of 106 novel miRNAs and the dynamic expression of miRNAs that extensively targets the TGF-¦Â pathway at different gestational ages in fetal KCs.MiRNAs showing altered expression at different gestational ages in fetal KCs may contribute to scarless wound healing in early- to mid-gestational fetal Keratinocytes (KCs), and thus may be new targets for potential scar prevention and reduction therapies." +target gene hsa-mir-144 Bronchiolitis Obliterans Syndrome 25979625 "miR-144 is a critical regulator of the TGF-¦Â signaling cascade and is over-expressed in lungs with BOS. Therefore, miR-144 is a potential target toward preventing fibrosis leading to BOS after lung transplant." +target gene hsa-mir-514a Melanoma 25980496 miR-514a regulates the tumour suppressor NF1 and modulates BRAFi sensitivity in melanoma. +target gene hsa-mir-194 Inflammation 25984739 We conclude that miR-194 negatively regulates the TLR4 signal pathway which is activated by PA through directly negative TRAF6 expression. +target gene hsa-mir-19a "Carcinoma, Hepatocellular" 25985117 A systematic investigation based on microRNA-mediated gene regulatory network reveals that dysregulation of microRNA-19a/Cyclin D1 axis confers an oncogenic potential and a worse prognosis in human hepatocellular carcinoma. +target gene hsa-mir-200 "Diabetes Mellitus, Type 2" 25985365 The microRNA-200 family regulates pancreatic beta cell survival in type 2 diabetes. +target gene hsa-mir-125b Myeloma 25987254 Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo. +target gene hsa-mir-197 Uterine Leiomyoma 25990270 Upregulation of miR-197 inhibits cell proliferation by directly targeting IGFBP5 in human uterine leiomyoma cells. +target gene hsa-mir-184 "Carcinoma, Lung, Non-Small-Cell" 25990966 MiR-184 as a tumor suppressor miR inhibits cell proliferation and invasion capability via targeting CDC25A and c-Myc. Low miR-184 level may predict worse prognosis in NSCLC patients. +target gene hsa-mir-21 "Carcinoma, Lung, Non-Small-Cell" 25990966 MiR-184 as a tumor suppressor miR inhibits cell proliferation and invasion capability via targeting CDC25A and c-Myc. Low miR-184 level may predict worse prognosis in NSCLC patients. +target gene hsa-mir-409 Colorectal Carcinoma 25991585 MicroRNA-409-3p suppresses colorectal cancer invasion and metastasis partly by targeting GAB1 expression. +target gene hsa-mir-193a Bladder Neoplasms 25991669 The miR-193a-3p-regulated ING5 gene activates the DNA damage response pathway and inhibits multi-chemoresistance in bladder cancer. +target gene hsa-mir-191 Neoplasms [unspecific] 25992613 MiR-191 Regulates Primary Human Fibroblast Proliferation and Directly Targets Multiple Oncogenes. +target gene hsa-mir-100 Alzheimer Disease 25992776 "Referring to the Ingenuity database we could identify a set of AD associated genes that are targeted by these miRNAs. Highly predicted targets included genes involved in the regulation of tau and amyloid pathways in AD like MAPT, BACE1 and mTOR." +target gene hsa-mir-103 Alzheimer Disease 25992776 "Referring to the Ingenuity database we could identify a set of AD associated genes that are targeted by these miRNAs. Highly predicted targets included genes involved in the regulation of tau and amyloid pathways in AD like MAPT, BACE1 and mTOR." +target gene hsa-mir-21 Alzheimer Disease 25992776 "Referring to the Ingenuity database we could identify a set of AD associated genes that are targeted by these miRNAs. Highly predicted targets included genes involved in the regulation of tau and amyloid pathways in AD like MAPT, BACE1 and mTOR." +target gene hsa-mir-219 Alzheimer Disease 25992776 "Referring to the Ingenuity database we could identify a set of AD associated genes that are targeted by these miRNAs. Highly predicted targets included genes involved in the regulation of tau and amyloid pathways in AD like MAPT, BACE1 and mTOR." +target gene hsa-mir-296 Alzheimer Disease 25992776 "Referring to the Ingenuity database we could identify a set of AD associated genes that are targeted by these miRNAs. Highly predicted targets included genes involved in the regulation of tau and amyloid pathways in AD like MAPT, BACE1 and mTOR." +target gene hsa-mir-3622b Alzheimer Disease 25992776 "Referring to the Ingenuity database we could identify a set of AD associated genes that are targeted by these miRNAs. Highly predicted targets included genes involved in the regulation of tau and amyloid pathways in AD like MAPT, BACE1 and mTOR." +target gene hsa-mir-375 Alzheimer Disease 25992776 "Referring to the Ingenuity database we could identify a set of AD associated genes that are targeted by these miRNAs. Highly predicted targets included genes involved in the regulation of tau and amyloid pathways in AD like MAPT, BACE1 and mTOR." +target gene hsa-mir-4467 Alzheimer Disease 25992776 "Referring to the Ingenuity database we could identify a set of AD associated genes that are targeted by these miRNAs. Highly predicted targets included genes involved in the regulation of tau and amyloid pathways in AD like MAPT, BACE1 and mTOR." +target gene hsa-mir-505 Alzheimer Disease 25992776 "Referring to the Ingenuity database we could identify a set of AD associated genes that are targeted by these miRNAs. Highly predicted targets included genes involved in the regulation of tau and amyloid pathways in AD like MAPT, BACE1 and mTOR." +target gene hsa-mir-708 Alzheimer Disease 25992776 "Referring to the Ingenuity database we could identify a set of AD associated genes that are targeted by these miRNAs. Highly predicted targets included genes involved in the regulation of tau and amyloid pathways in AD like MAPT, BACE1 and mTOR." +target gene hsa-mir-766 Alzheimer Disease 25992776 "Referring to the Ingenuity database we could identify a set of AD associated genes that are targeted by these miRNAs. Highly predicted targets included genes involved in the regulation of tau and amyloid pathways in AD like MAPT, BACE1 and mTOR." +target gene hsa-mir-15a "Aortic Aneurysm, Abdominal" 25993295 Our data emphasize the potential of miR-15a-3p and miR-30a-5p as biomarkers of AAA but also as triggers of ATLO evolution. Further investigations will be required to evaluate their targets in order to better understand AAA pathophysiology. +target gene hsa-mir-30a "Aortic Aneurysm, Abdominal" 25993295 Our data emphasize the potential of miR-15a-3p and miR-30a-5p as biomarkers of AAA but also as triggers of ATLO evolution. Further investigations will be required to evaluate their targets in order to better understand AAA pathophysiology. +target gene hsa-mir-489 "Aortic Aneurysm, Abdominal" 25993295 Our data emphasize the potential of miR-15a-3p and miR-30a-5p as biomarkers of AAA but also as triggers of ATLO evolution. Further investigations will be required to evaluate their targets in order to better understand AAA pathophysiology. +target gene hsa-mir-1 Myocardial Infarction 25995211 These experiments revealed the role of inducible cAMP early repressor as a repressor of miR-1 and Ito +target gene hsa-mir-1 Vascular Hypertrophy 25995211 These experiments revealed the role of inducible cAMP early repressor as a repressor of miR-1 and Ito +target gene hsa-mir-23b Gastric Neoplasms 25996293 miR-23b-3p regulates the chemoresistance of gastric cancer cells by targeting ATG12 and HMGB2. +target gene hsa-mir-21 Neoplasms [unspecific] 25997617 Our results suggest that miR-21 may regulate intestinal epithelial tight junction permeability through PTEN/PI3K/Akt signalling pathway. This promotes the feasibility of targeting miR-21 in the clinical to preserve the intestinal barrier. +target gene hsa-mir-148b Liver Neoplasms 25997710 miRNA-148b suppresses hepatic cancer stem cell by targeting neuropilin-1. +target gene hsa-mir-335 Neoplasms [unspecific] 25997740 miR-335 Targets SIAH2 and Confers Sensitivity to Anti-Cancer Drugs by Increasing the Expression of HDAC3. +target gene hsa-mir-29a Gastric Neoplasms 25997819 MicroRNA-29a inhibits cell migration and invasion via targeting Roundabout homolog 1 in gastric cancer cells. +target gene hsa-mir-377 Gastric Neoplasms 25998046 MicroRNA-377 predicts poor clinical outcome of gastric cancer and induces tumorigenesis by targeting multiple tumor-suppressor genes. +target gene hsa-mir-125a "Carcinoma, Lung, Non-Small-Cell" 25998575 "miR-125a-3p targets MTA1 to suppress NSCLC cell proliferation, migration, and invasion." +target gene hsa-mir-204 Osteosarcoma 25998694 "MicroRNA-204 inhibits proliferation, migration, invasion and epithelial-mesenchymal transition in osteosarcoma cells via targeting Sirtuin 1." +target gene hsa-mir-155 "Colitis, Ulcerative" 25998827 MiR-155 modulates the inflammatory phenotype of intestinal myofibroblasts by targeting SOCS1 in ulcerative colitis. +target gene hsa-mir-25 Lung Neoplasms 25998847 miR-25 targets the modulator of apoptosis 1 gene in lung cancer. +target gene hsa-mir-218 "Squamous Cell Carcinoma, Esophageal" 25999024 MicroRNA-218 inhibits the proliferation and metastasis of esophageal squamous cell carcinoma cells by targeting BMI1. +target gene hsa-mir-103 Adenovirus Infection 26000071 miR-103 Regulates Oxidative Stress by Targeting the BCL2/Adenovirus E1B 19kDa Interacting Protein 3 in HUVECs. +target gene hsa-mir-182 "Fatty Liver, Non-Alcoholic" 26001595 E3 ubiquitin protein ligase (FBXW7) as potential targets of miR-182 +target gene hsa-mir-526a Neoplasms [unspecific] 26002288 miR-526a regulates apoptotic cell growth in human carcinoma cells. +target gene hsa-mir-582 "Carcinoma, Hepatocellular" 26002580 miR-582-5p inhibits proliferation of hepatocellular carcinoma by targeting CDK1 and AKT3. +target gene hsa-mir-148a Ovarian Neoplasms 26004124 MicroRNA-148a inhibits the proliferation and promotes the paclitaxel-induced apoptosis of ovarian cancer cells by targeting PDIA3. +target gene hsa-mir-148a Ovarian Neoplasms 26004261 MicroRNA-148a inhibits migration and invasion of ovarian cancer cells via targeting sphingosine-1-phosphate receptor 1. +target gene hsa-mir-300 Osteosarcoma 26010572 Up-Regulation of MiR-300 Promotes Proliferation and Invasion of Osteosarcoma by Targeting BRD7. +target gene hsa-mir-200b Breast Neoplasms 26011542 53BP1 suppresses epithelial-mesenchymal transition by downregulating ZEB1 through microRNA-200b/429 in breast cancer. +target gene hsa-mir-429 Breast Neoplasms 26011542 53BP1 suppresses epithelial-mesenchymal transition by downregulating ZEB1 through microRNA-200b/429 in breast cancer. +target gene hsa-mir-155 Vascular Disease [unspecific] 26012521 "knockdown of miR155 could modulate ROS production, NO generation, apoptosis and function of HBMECs via regulating diverse gene expression, such as caspase-3, ICAM-1 and EGFR/ERK/p38 MAPK and PI3K/Akt pathways." +target gene hsa-mir-218 Glioblastoma 26012781 MiR-218 Inhibited Growth and Metabolism of Human Glioblastoma Cells by Directly Targeting E2F2. +target gene hsa-mir-106b Vascular Disease [unspecific] 26013412 The knowledge of molecular targets that change during the senescence can ultimately contribute to a better understanding and prevention of age-related vascular diseases. +target gene hsa-mir-16 Vascular Disease [unspecific] 26013412 The knowledge of molecular targets that change during the senescence can ultimately contribute to a better understanding and prevention of age-related vascular diseases. +target gene hsa-mir-28 Vascular Disease [unspecific] 26013412 The knowledge of molecular targets that change during the senescence can ultimately contribute to a better understanding and prevention of age-related vascular diseases. +target gene hsa-mir-376a Vascular Disease [unspecific] 26013412 The knowledge of molecular targets that change during the senescence can ultimately contribute to a better understanding and prevention of age-related vascular diseases. +target gene hsa-mir-886 Vascular Disease [unspecific] 26013412 The knowledge of molecular targets that change during the senescence can ultimately contribute to a better understanding and prevention of age-related vascular diseases. +target gene hsa-mir-133 Osteoporosis 26013661 "Estrogen deficiency is associated with miR-133 overexpression.MiR-133 can induce postmenopausal osteoporosis by weakening osteogenic differentiation of hMSCs, at least partly through repressing SLC39A1 expression." +target gene hsa-mir-26b Obesity 26016996 Obesity-associated microRNA-26b regulates the proliferation of human preadipocytes via arrest of the G1/S transition. +target gene hsa-mir-106a Kidney Neoplasms 26018509 miR-106a* inhibits the proliferation of renal carcinoma cells by targeting IRS-2. +target gene hsa-mir-301a Pancreatic Neoplasms 26019136 MiR-301a-3p functions as a novel oncogene in PDAC and the oncogenic activity may involve its inhibition of the target gene SMAD4. +target gene hsa-mir-495 Breast Neoplasms 26020378 Downregulated miR-495 [Corrected] Inhibits the G1-S Phase Transition by Targeting Bmi-1 in Breast Cancer. +target gene hsa-mir-483 Prostate Neoplasms 26020509 "Based on our findings, we suggest that blood-based miRNA expression profiling can be used in the diagnosis and maybe even prognosis of the disease.In the future, miRNA profiling could possibly be used in targeted screening,together with Prostate Specific Antigene (PSA) testing, to identify men with an elevated PrCa risk." +target gene hsa-mir-26a "Carcinoma, Hepatocellular" 26021873 miR-26a expression reduced M-CSF expression and recruitment of macrophages in hepatocellular carcinoma(HCC). +target gene hsa-mir-139 "Carcinoma, Hepatocellular" 26022123 "miR-139-5p inhibits epithelial-mesenchymal transition, migration and invasion of hepatocellular carcinoma cells by targeting ZEB1 and ZEB2." +target gene hsa-mir-101 Rheumatic Heart Diseases 26022377 The present study confirmed that miR-101 targets TLR2 3'UTR and represses TLR2 expression. This work also found an association between down-regulated miR-101 and rheumatic heart disease. +target gene hsa-mir-30a Lung Neoplasms 26025408 MiR-30a suppresses non-small cell lung cancer progression through AKT signaling pathway by targeting IGF1R. +target gene hsa-mir-200 "Carcinoma, Ovarian" 26025631 The miR-200 family differentially regulates sensitivity to paclitaxel and carboplatin in human ovarian carcinoma OVCAR-3 and MES-OV cells. +target gene hsa-mir-150 "Leukemia-Lymphoma, Adult T-Cell" 26025667 STAT1: A Novel Target of miR-150 and miR-223 Is Involved in the Proliferation of HTLV-I-Transformed and ATL Cells. +target gene hsa-mir-223 "Leukemia-Lymphoma, Adult T-Cell" 26025667 STAT1: A Novel Target of miR-150 and miR-223 Is Involved in the Proliferation of HTLV-I-Transformed and ATL Cells. +target gene hsa-mir-199a "Squamous Cell Carcinoma, Skin or Unspecific" 26026896 "These results suggested that miR-199a-5p plays a role in pathogenesis of cSCC via inhibition of invasiveness through regulation of BCAM, FZD6 and DDR1 expression." +target gene hsa-mir-199a Hepatitis C Virus Infection 26027911 Inhibition of microRNA-199a-5p reduces the replication of HCV via regulating the pro-survival pathway. +target gene hsa-let-7 Glioma 26028311 MDM4 regulation by the let-7 miRNA family in the DNA damage response of glioma cells. +target gene hsa-mir-101 Atherosclerosis 26033364 miR-101 promotes intracellular cholesterol retention under inflammatory conditions through suppressing ABCA1 expression and suggests that the miR-101-ABCA1 axis may play an intermediary role in the development of NAFLD and vascular atherosclerosis. +target gene hsa-mir-491 "Carcinoma, Cervical" 26034994 MicroRNA-491-5p suppresses cervical cancer cell growth by targeting hTERT. +target gene hsa-mir-126 "Adenocarcinoma, Lung" 26035298 "These DEGs, and DEG-related histone modifications, TFs and miRNAs may be important in the pathogenesis of lung adenocarcinoma. The present results may indicate directions for the next step in the study of the further elucidation and targeted prevention of lung adenocarcinoma." +target gene hsa-mir-30c-2 "Adenocarcinoma, Lung" 26035298 "These DEGs, and DEG-related histone modifications, TFs and miRNAs may be important in the pathogenesis of lung adenocarcinoma. The present results may indicate directions for the next step in the study of the further elucidation and targeted prevention of lung adenocarcinoma." +target gene hsa-mir-153 "Carcinoma, Hepatocellular" 26035427 miR-153 inhibits epithelial-to-mesenchymal transition in hepatocellular carcinoma by targeting Snail. +target gene hsa-mir-34a Gastric Neoplasms 26035691 Depletion of histone deacetylase 1 inhibits metastatic abilities of gastric cancer cells by regulating the miR-34a/CD44 pathway. +target gene hsa-mir-29a Pancreatic Neoplasms 26036346 Micro-RNAs miR-29a and miR-330-5p function as tumor suppressors by targeting the MUC1 mucin in pancreatic cancer cells. +target gene hsa-mir-330 Pancreatic Neoplasms 26036346 Micro-RNAs miR-29a and miR-330-5p function as tumor suppressors by targeting the MUC1 mucin in pancreatic cancer cells. +target gene hsa-mir-101 "Carcinoma, Breast, Triple Negative" 26036638 MicroRNA-101 inhibits cell progression and increases paclitaxel sensitivity by suppressing MCL-1 expression in human triple-negative breast cancer. +target gene hsa-mir-375 Osteosarcoma 26036761 MicroRNA-375 functions as a tumor suppressor in osteosarcoma by targeting PIK3CA. +target gene hsa-mir-18b "Leukemia, Promyelocytic, Acute" 26041820 PML/RAR¦Á-Regulated miR-181a/b Cluster Targets the Tumor Suppressor RASSF1A in Acute Promyelocytic Leukemia. +target gene hsa-mir-522 "Carcinoma, Colon" 26043974 MicroRNA-522 reverses drug resistance of doxorubicin-induced HT29 colon cancer cell by targeting ABCB5. +target gene hsa-mir-24 Breast Neoplasms 26044523 miRNA-24-3p promotes cell proliferation and inhibits apoptosis in human breast cancer by targeting p27Kip1. +target gene hsa-mir-494 "Carcinoma, Hepatocellular" 26045065 "miR-494 promotes cell proliferation, migration and invasion, and increased sorafenib resistance in hepatocellular carcinoma by targeting PTEN." +target gene hsa-mir-138 Psoriasis 26045321 MicroRNA-138 regulates the balance of Th1/Th2 via targeting RUNX3 in psoriasis. +target gene hsa-mir-98 "Aortic Aneurysm, Abdominal" 26045772 "our data provide compelling evidence on the association between hypoxia and inflammation triggered by hypoxia and then mediated by MCP-1/miR-98/IL-6/p38 regulatory loop, which leads to hASMCs apoptosis via Stat1 activation to contribute to AAA formation and progression." +target gene hsa-mir-570 "Carcinoma, Lung" 26045791 MicroRNA-570 promotes lung carcinoma proliferation through targeting tumor suppressor KLF9. +target gene hsa-mir-503 "Carcinoma, Breast" 26047605 MiR-503 inhibited cell proliferation of human breast cancer cells by suppressing CCND1 expression. +target gene hsa-let-7 "Carcinoma, Cervical" 26051842 "Overall, our study suggests that the microRNAs, miR-21 and let-7a function as clinically relevant integral components of STAT3 signaling and are responsible for maintaining activated state of STAT3 in HPV-infected cells during cervical carcinogenesis." +target gene hsa-mir-206 "Carcinoma, Breast, Triple Negative" 26053033 "Consistent with increased levels of miR-206 in MaCSCs, the expression of both PDCD4 and CX43 was suppressed in these cells relative to control cells." +target gene hsa-mir-106b Giant Cell Tumor of Bone 26053181 MicroRNA-106b inhibits osteoclastogenesis and osteolysis by targeting RANKL in giant cell tumor of bone. +target gene hsa-mir-199a Liver Neoplasms 26054020 MiR-199a-5p is negatively associated with malignancies and regulates glycolysis and lactate production by targeting hexokinase 2 in liver cancer. +target gene hsa-mir-498 Ovarian Neoplasms 26054675 MiR-498 regulated FOXO3 expression and inhibited the proliferation of human ovarian cancer cells. +target gene hsa-mir-485 "Carcinoma, Hepatocellular" 26054676 Involvement of miR-485-5p in hepatocellular carcinoma progression targeting EMMPRIN. +target gene hsa-mir-126 Gastric Neoplasms 26054677 MicroRNA-126 inhibits cell proliferation in gastric cancer by targeting LAT-1. +target gene hsa-mir-892a Colorectal Carcinoma 26054685 miR-892a regulated PPP2R2A expression and promoted cell proliferation of human colorectal cancer cells. +target gene hsa-mir-217 Osteosarcoma 26054690 miR-217 targeting Wnt5a in osteosarcoma functions as a potential tumor suppressor. +target gene hsa-mir-197 Colorectal Carcinoma 26055341 miR-197 mediates the response of colorectal cancer cells to 5-FU by regulating TYMS expression. +target gene hsa-mir-99a Thrombocytopenia 26055579 "We believe that miR-99a regulates CTDSPL, which induces the G1/Stransition by increasing Cyclin expression and play a significant role in proliferation of CB-MKs." +target gene hsa-mir-223 "Carcinoma, Nasopharyngeal" 26055874 "MiR-223 negatively regulates the growth and migration of NPC cells via reducing MAFB expression, and this finding provides a novel insight into understanding miR-223 regulation mechanism in nasopharyngeal carcinoma tumorigenesis." +target gene hsa-mir-29a Atherosclerosis 26056009 "our study demonstrates that miR-29a inhibits QKI, which in turn results in upregulation of scavenger receptor A (SRA) and lipid uptake." +target gene hsa-mir-144 Bladder Neoplasms 26057453 miR-144-5p functions as tumour suppressor in BC cells. CCNE1 and CCNE2 were directly regulated by miR-144-5p and might be good prognostic markers for survival of BC patients. +target gene hsa-mir-429 "Carcinoma, Colon" 26058485 MicroRNA-429 inhibits the migration and invasion of colon cancer cells by targeting PAK6/cofilin signaling. +target gene hsa-mir-19a "Carcinoma, Renal Cell" 26058752 Downregulation of miR-19a exhibits inhibitory effects on metastatic renal cell carcinoma by targeting PIK3CA and inactivating Notch signaling in vitro. +target gene hsa-mir-16 "Adenocarcinoma, Lung" 26061016 Quercetin Decreases Claudin-2 Expression Mediated by Up-Regulation of microRNA miR-16 in Lung Adenocarcinoma A549 Cells. +target gene hsa-mir-135b Colorectal Carcinoma 26061281 miR-135b Promotes Cancer Progression by Targeting Transforming Growth Factor Beta Receptor II (TGFBR2) in Colorectal Cancer. +target gene hsa-mir-141 Prostate Neoplasms 26062412 miR-141-3p regulates the expression of androgen receptor by targeting its 3'UTR in prostate cancer LNCaP cells +target gene hsa-mir-221 Bone Disease [unspecific] 26062554 Intercellular adhesion molecule-1 was upregulated by microRNA-221 in mesenchymal stem cells because microRNAs are key regulators of various biological functions via gene expression. +target gene hsa-mir-92a Neoplasms [unspecific] 26062558 An In Vivo Method to Identify microRNA Targets Not Predicted by Computation Algorithms: p21 Targeting by miR-92a in Cancer. +target gene hsa-mir-200b "Carcinoma, Breast, Triple Negative" 26062653 Dual regulation by microRNA-200b-3p and microRNA-200b-5p in the inhibition of epithelial-to-mesenchymal transition in triple-negative breast cancer. +target gene hsa-mir-153 "Adenocarcinoma, Pancreatic Ductal" 26062664 MicroRNA-153 is a prognostic marker and inhibits cell migration and invasion by targeting SNAI1 in human pancreatic ductal adenocarcinoma. +target gene hsa-mir-183 "Carcinoma, Thyroid, Papillary" 26063221 miR-183 regulates biological behavior in papillary thyroid carcinoma by targeting the programmed cell death 4. +target gene hsa-mir-26a Prostate Neoplasms 26063484 MicroRNA-26a/b directly regulate La-related protein 1 and inhibit cancer cell invasion in prostate cancer. +target gene hsa-mir-26b Prostate Neoplasms 26063484 MicroRNA-26a/b directly regulate La-related protein 1 and inhibit cancer cell invasion in prostate cancer. +target gene hsa-mir-141 "Carcinoma, Prostate" 26065649 "The presence of the microRNA-141 target molecules activates the DNA molecular machine powered by the DNA fuel strands, leading to non-enzymatic target cyclic reuse of microRNA-141 and significantly amplified fluorescent signals for sensitive monitoring of microRNA-141 from low numbers of human prostate cancer cells." +target gene hsa-mir-26b Lung Neoplasms 26068649 Down-regulation of microRNA-26b modulates non-small cell lung cancer cells chemoresistance and migration through the association of PTEN. +target gene hsa-mir-145 "Carcinoma, Hepatocellular" 26068913 miR-145 regulates chemoresistance in hepatocellular carcinoma via epithelial mesenchymal transition. +target gene hsa-mir-620 Neoplasms [unspecific] 26068950 miR-620 promotes tumor radioresistance by targeting 15-hydroxyprostaglandin dehydrogenase (HPGD). +target gene hsa-let-7c Moyamoya Disease 26070522 "Increased expression of let-7c in MMD patients may contribute to MMD pathogenesis by targeting RNF213. Thus, let-7c may be a potential biomarker for the diagnosis of MMD." +target gene hsa-mir-125a Melanoma 26071398 "we discovered that Lin28B, a well-characterized inhibitor of let-7 miRNA biogenesis, was a direct target of miR-125a-5p in melanoma." +target gene hsa-mir-365 "Squamous Cell Carcinoma, Skin or Unspecific" 26072217 microRNA-365-targeted nuclear factor I/B transcriptionally represses cyclin-dependent kinase 6 and 4 to inhibit the progression of cutaneous squamous cell carcinoma. +target gene hsa-mir-362 Neuroblastoma 26073258 miR-362-5p inhibits proliferation and migration of neuroblastoma cells by targeting phosphatidylinositol 3-kinase-C2¦Â. +target gene hsa-mir-21 "Adenocarcinoma, Pancreatic Ductal" 26077422 The role of miR-21 and miR-211 on MMP9 regulation in pancreatic ductal adenocarcinoma: cooperation in invasiveness behaviors +target gene hsa-mir-211 "Adenocarcinoma, Pancreatic Ductal" 26077422 The role of miR-21 and miR-211 on MMP9 regulation in pancreatic ductal adenocarcinoma: cooperation in invasiveness behaviors +target gene hsa-mir-34a Cholangiocarcinoma 26077733 microRNA-34a inhibits epithelial mesenchymal transition in human cholangiocarcinoma by targeting Smad4 through transforming growth factor-beta/Smad pathway. +target gene hsa-mir-144 Leukemia 26078353 The long noncoding RNA TUG1 regulates blood-tumor barrier permeability by targeting miR-144. +target gene hsa-mir-200b Neoplasms [unspecific] 26079153 Our results demonstrate that the p53 target miR-200b/200c/429 miRNAs are negative regulators of the CRKL oncogene. +target gene hsa-mir-200c Neoplasms [unspecific] 26079153 Our results demonstrate that the p53 target miR-200b/200c/429 miRNAs are negative regulators of the CRKL oncogene. +target gene hsa-mir-429 Neoplasms [unspecific] 26079153 Our results demonstrate that the p53 target miR-200b/200c/429 miRNAs are negative regulators of the CRKL oncogene. +target gene hsa-mir-199a Osteosarcoma 26079799 CD44 is a direct target of miR-199a-3p and contributes to aggressive progression in osteosarcoma. +target gene hsa-mir-139 Breast Neoplasms 26079880 MicroRNA-139 suppresses proliferation in luminal type breast cancer cells by targeting Topoisomerase II alpha. +target gene hsa-mir-144 Osteosarcoma 26081423 MicroRNA-144 acts as a tumor suppressor by targeting Rho-associated coiled-coil containing protein kinase 1 in osteosarcoma cells. +target gene hsa-mir-219 Glioblastoma 26081620 MicroRNA-219-5p exerts tumor suppressor function by targeting ROBO1 in glioblastoma. +target gene hsa-mir-4649 "Carcinoma, Nasopharyngeal" 26081980 MicroRNA-4649-3p inhibits cell proliferation by targeting protein tyrosine phosphatase SHP-1 in nasopharyngeal carcinoma cells. +target gene hsa-mir-21 Neoplasms [unspecific] 26082192 "we describe the ever-expanding role of miR-21 and its target genes in different cancers, and provide insight into how this oncogenic miRNA regulates cancer cell proliferation, migration, and apoptosis by suppressing the expression of tumor suppressors." +target gene hsa-mir-340 Heart Failure 26084457 microRNA-340-5p Functions Downstream of Cardiotrophin-1 to Regulate Cardiac Eccentric Hypertrophy and Heart Failure via Target Gene Dystrophin. +target gene hsa-mir-107 Glioma 26084601 Upregulation of miR-107 Inhibits Glioma Angiogenesis and VEGF Expression. +target gene hsa-mir-570 "Carcinoma, Hepatocellular" 26084609 MiR-570 inhibited the cell proliferation and invasion through directly targeting B7-H1 in hepatocellular carcinoma. +target gene hsa-mir-15b Myasthenia Gravis 26087886 "This study is the first to report the miR-15b-IL-15 axis can directly regulate IL15 expression, which helps to further explain the abnormal IL-15 expression in MG patients and the pathogenesis of MG." +target gene hsa-mir-26b Rheumatoid Arthritis 26088648 "MiR-26b regulates ¦Â-catenin and CyclinD1 levels by inhibiting GSK-3¦Â expression, which in-turn alters the Wnt/GSK-3¦Â/¦Â-catenin pathway to lower RAFLS proliferation and elevate cell apoptosis and the secretion of TNF-¦Á,IL-1¦Â and IL-6 cytokines. Therefore, our results show that miR-26B plays a central role in inhibiting the inflammation associated with rheumatoid arthritis." +target gene hsa-mir-9 Neoplasms [unspecific] 26091714 our findings have identified a critical role of miR-9 in regulating the differentiation and function of Myeloid-derived suppressor cells (MDSCs). +target gene hsa-mir-206 Breast Neoplasms 26093295 "Overexpression of miR-206 suppresses glycolysis, proliferation and migration in breast cancer cells via PFKFB3 targeting." +target gene hsa-mir-132 Liver Neoplasms 26096363 Hsa-miR-132 inhibits proliferation of hepatic carcinoma cells by targeting YAP. +target gene hsa-mir-29a Neoplasms [unspecific] 26096783 Tumour-suppressive microRNA-29s directly regulate LOXL2 expression and inhibit cancer cell migration and invasion in renal cell carcinoma. +target gene hsa-mir-29b Neoplasms [unspecific] 26096783 Tumour-suppressive microRNA-29s directly regulate LOXL2 expression and inhibit cancer cell migration and invasion in renal cell carcinoma. +target gene hsa-mir-29c Neoplasms [unspecific] 26096783 Tumour-suppressive microRNA-29s directly regulate LOXL2 expression and inhibit cancer cell migration and invasion in renal cell carcinoma. +target gene hsa-mir-34c "Carcinoma, Gastric" 26097561 PABPC1 exerts carcinogenesis in gastric carcinoma by targeting miR-34c. +target gene hsa-mir-106a Lung Neoplasms 26097565 miR-106a promotes growth and metastasis of non-small cell lung cancer by targeting PTEN. +target gene hsa-mir-139 Lung Neoplasms 26097570 Our results indicated that miR-139-5p acts as a tumor suppressor in non-small cell lung cancer (NSCLC) partially via down-regulating IGF1R expression. +target gene hsa-mir-144 Liver Fibrosis 26097586 miR-144 regulates transforming growth factor-¦Â1 iduced hepatic stellate cell activation in human fibrotic liver. +target gene hsa-mir-217 Gastric Neoplasms 26098560 The MicroRNA-217 Functions as a Potential Tumor Suppressor in Gastric Cancer by Targeting GPC5. +target gene hsa-mir-21 Breast Neoplasms 26098771 The LPA1/ZEB1/miR-21-activation pathway regulates metastasis in basal breast cancer. +target gene hsa-mir-34a Liver Diseases [unspecific] 26100857 miR-34a-HNF4¦Á pathway is activated under common conditions of metabolic stress and may have a role in the pathogenesis of Non-alcoholic fatty liver disease(NAFLD) and in regulating plasma lipoprotein metabolism. +target gene hsa-mir-137 "Carcinoma, Gastric" 26102366 MicroRNA-137 Contributes to Dampened Tumorigenesis in Human Gastric Cancer by Targeting AKT2. +target gene hsa-mir-34a Colorectal Carcinoma 26103003 MicroRNA-34a targets FMNL2 and E2F5 and suppresses the progression of colorectal cancer. +target gene hsa-mir-370 Osteoarthritis 26103880 "miR-370 and miR-373 regulate the pathogenesis of osteoarthritis by modulating one-carbon metabolism via SHMT-2 and MECP-2, respectively." +target gene hsa-mir-373 Osteoarthritis 26103880 "miR-370 and miR-373 regulate the pathogenesis of osteoarthritis by modulating one-carbon metabolism via SHMT-2 and MECP-2, respectively." +target gene hsa-mir-448 Ovarian Neoplasms 26103953 "Our data indicate that miR-448 functions as a tumor suppressor in ovarian cancer, which exerts its activity by suppressing the expression of CXCL12." +target gene hsa-mir-9 Melanoma 26104682 These results identify a novel YY1~miR-9~RYBP axis involved in melanoma tumorigenesis and reinforce the idea that regulatory circuitries involving miRNAs and TFs are prevalent mechanisms. +target gene hsa-mir-9 Osteosarcoma 26107195 miR-9 Modulates Osteosarcoma Cell Growth by Targeting the GCIP Tumor Suppressor. +target gene hsa-mir-34b Prostate Neoplasms 26107383 Deregulation of MiR-34b/Sox2 Predicts Prostate Cancer Progression. +target gene hsa-mir-326 "Adenocarcinoma, Lung" 26111641 "Adam17, a Target of Mir-326, Promotes Emt-Induced Cells Invasion in Lung Adenocarcinoma." +target gene hsa-mir-129 "Carcinoma, Hepatocellular" 26116538 miR-129 suppresses tumor cell growth and invasion by targeting PAK5 in hepatocellular carcinoma. +target gene hsa-mir-15a Multiple Myeloma 26117022 "High expression of miR-15a can induce cell cycle arrest and apoptosis of MM cells, then inhibit their growth. The mechanisms may be related with the negative regulation of BMI-1 and BCL-2 genes in post-transcription level caused by miR-15a." +target gene hsa-mir-1 Ovarian Neoplasms 26117268 "The mRNA level of HOTAIR and MAPK1 in ovarian SKOV3 decreased when transected with miR-1, miR-214-3p, or miR-330-5p compared to negative control (p<0.05)." +target gene hsa-mir-19b Atherosclerosis 26117405 "Taken together, these results demonstrate that PGC-1¦Á plays a protective role against the vascular complications of atherosclerosis. Moreover, the posttranscriptional regulation of PGC-1¦Á by miR-19b/221/222 was unveiled,which provides a novel mechanism in which a panel of microRNAs can modulate endothelial cell apoptosis via the regulation mitochondrial function." +target gene hsa-mir-221 Atherosclerosis 26117405 "Taken together, these results demonstrate that PGC-1¦Á plays a protective role against the vascular complications of atherosclerosis. Moreover, the posttranscriptional regulation of PGC-1¦Á by miR-19b/221/222 was unveiled,which provides a novel mechanism in which a panel of microRNAs can modulate endothelial cell apoptosis via the regulation mitochondrial function." +target gene hsa-mir-222 Atherosclerosis 26117405 "Taken together, these results demonstrate that PGC-1¦Á plays a protective role against the vascular complications of atherosclerosis. Moreover, the posttranscriptional regulation of PGC-1¦Á by miR-19b/221/222 was unveiled,which provides a novel mechanism in which a panel of microRNAs can modulate endothelial cell apoptosis via the regulation mitochondrial function." +target gene hsa-mir-193 Liver Fibrosis 26120970 These results suggest that miR-30 and miR-193 are members of a network of miRNAs modifying the TGF-¦Â-dependent regulation of extracellular matrix-related genes in HSCs in the manifestation and resolution of liver fibrosis. +target gene hsa-mir-30 Liver Fibrosis 26120970 These results suggest that miR-30 and miR-193 are members of a network of miRNAs modifying the TGF-¦Â-dependent regulation of extracellular matrix-related genes in HSCs in the manifestation and resolution of liver fibrosis. +target gene hsa-mir-153 Glioma 26124081 MicroRNA-153/Nrf-2/GPx1 pathway regulates radiosensitivity and stemness of glioma stem cells via reactive oxygen species. +target gene hsa-mir-106b Prostate Neoplasms 26124181 miR-93/miR-106b/miR-375-CIC-CRABP1: a novel regulatory axis in prostate cancer progression. +target gene hsa-mir-375 Prostate Neoplasms 26124181 miR-93/miR-106b/miR-375-CIC-CRABP1: a novel regulatory axis in prostate cancer progression. +target gene hsa-mir-93 Prostate Neoplasms 26124181 miR-93/miR-106b/miR-375-CIC-CRABP1: a novel regulatory axis in prostate cancer progression. +target gene hsa-mir-155 "Diabetes Mellitus, Type 2" 26125263 "In type 2 diabetes mellitus (T2DM) retinopathy, miR-155 may play an important role in the pathogenesis of T2DM retinopathy by regulating the Treg cells with TGF-¦Â." +target gene hsa-mir-206 Breast Neoplasms 26125274 Our results suggest hsa-miR-206 may repress the tumor proliferation and invasion in breast cancer by targeting Cx43. +target gene hsa-mir-9 "Carcinoma, Hepatocellular" 26125451 MicroRNA-9-3p was identified as the tumour-suppressor miR targetting TAZ expression in HCC cells. +target gene hsa-mir-410 Pituitary Neoplasms 26125663 Downregulation of miR-410 targeting the cyclin B1 gene plays a role in pituitary gonadotroph tumors. +target gene hsa-let-7 "Carcinoma, Nasopharyngeal" 26125802 The let-7 and miR-29 families may be related to the development of NPC by regulating the genes involved in cell cycle and ECM-receptor interaction. +target gene hsa-mir-29 "Carcinoma, Nasopharyngeal" 26125802 The let-7 and miR-29 families may be related to the development of NPC by regulating the genes involved in cell cycle and ECM-receptor interaction. +target gene hsa-mir-193b Prostate Neoplasms 26129688 Epigenetically altered miR-193b targets cyclin D1 in prostate cancer. +target gene hsa-mir-205 "Carcinoma, Hepatocellular" 26129839 MicroRNA-205 regulates ubiquitin specific peptidase 7 protein expression in hepatocellular carcinoma cells. +target gene hsa-mir-100 Breast Neoplasms 26130569 The role of miR-100 in regulating apoptosis of breast cancer cells. +target gene hsa-mir-130a Gastric Neoplasms 26134263 "miR-130a acts as a potential diagnostic biomarker and promotes gastric cancer migration, invasion and proliferation by targeting RUNX3." +target gene hsa-mir-133a "Carcinoma, Cervical" 26134491 miR-133a inhibits cervical cancer growth by targeting EGFR. +target gene hsa-mir-99b "Carcinoma, Hepatocellular" 26134929 miR-99b promotes metastasis of hepatocellular carcinoma through inhibition of claudin 11 expression and may serve as a prognostic marker. +target gene hsa-mir-7 Lung Neoplasms 26135959 MicroRNA-7 inhibits the malignant phenotypes of non-small cell lung cancer in vitro by targeting Pax6. +target gene hsa-mir-203 Neuroblastoma 26136151 MicroRNA-203 inhibits the malignant progression of neuroblastoma by targeting Sam68. +target gene hsa-mir-196 Neoplasms [unspecific] 26141604 The miR-196 miRNA gene family located within the Hox gene clusters hsa been shown to function during embryogenesis and to be aberrantly expressed in various malignancies +target gene hsa-mir-21 Glioblastoma 26142886 Targeting strategies on miRNA-21 and PDCD4 for glioblastoma. +target gene hsa-mir-216a Pancreatic Neoplasms 26149212 miR-216a may inhibit pancreatic tumor growth by targeting JAK2. +target gene hsa-mir-410 Lung Neoplasms 26149213 MicroRNA-410 promotes cell proliferation by targeting BRD7 in non-small cell lung cancer. +target gene hsa-mir-1283 Hypertension 26149214 inhibition of miR-1283 in HA-VSMCs enhanced the expression of Activating transcription factor 1 mRNA as well as the ROS levels. +target gene hsa-mir-9 Bladder Neoplasms 26150338 miR-9 promotes cell proliferation and inhibits apoptosis by targeting LASS2 in bladder cancer. +target gene hsa-mir-221 Epstein-Barr Virus Infection 26153983 Epstein-Barr Virus Proteins EBNA3A and EBNA3C Together Induce Expression of the Oncogenic MicroRNA Cluster miR-221/miR-222 and Ablate Expression of Its Target p57KIP2. ebv-miR-BART20-5p +target gene hsa-mir-222 Epstein-Barr Virus Infection 26153983 Epstein-Barr Virus Proteins EBNA3A and EBNA3C Together Induce Expression of the Oncogenic MicroRNA Cluster miR-221/miR-222 and Ablate Expression of Its Target p57KIP2. ebv-miR-BART20-5p +target gene hsa-mir-29b Glioblastoma 26155940 miR-29b attenuates tumorigenicity and stemness maintenance in human glioblastoma multiforme by directly targeting BCL2L2. +target gene hsa-mir-133a "Carcinoma, Hepatocellular" 26156803 MicroRNA-133a functions as a tumor suppressor by targeting IGF-1R in hepatocellular carcinoma. +target gene hsa-mir-612 Colorectal Carcinoma 26158514 miR-612 negatively regulates colorectal cancer growth and metastasis by targeting AKT2. +target gene hsa-mir-101 "Carcinoma, Hepatocellular" 26158762 MiR-101 targets DUSP1 to regulate the TGF-¦Â secretion in sorafenib inhibits macrophage-induced growth of hepatocarcinoma. +target gene hsa-mir-17 Melanoma 26158900 miR-17 regulates melanoma cell motility by inhibiting the translation of ETV1. +target gene hsa-mir-155 Atherosclerosis 26159489 microRNA-155 works as a promoter in the atherosclerotic procession. Its mechanism may include enhancing inflammatory response in atherosclerosis by increasing STAT3 and NF-¦ÊB signaling via targeting SOCS1. +target gene hsa-mir-1271 Gastric Neoplasms 26159618 "MiR-1271 Inhibits Cell Proliferation, Invasion and EMT in Gastric Cancer by Targeting FOXQ1." +target gene hsa-mir-499 "Carcinoma, Esophageal" 26159783 MiR-499 Enhances the Cisplatin Sensitivity of Esophageal Carcinoma Cell Lines by Targeting DNA Polymerase ¦Â. +target gene hsa-mir-141 Gastric Neoplasms 26160158 "These results were the first to demonstrate that H19 and miR-141 could compete with each other and affect their target genes in gastric cancer,which provide important clues for understanding the key roles of lncRNA-miRNA functional network in cancer." +target gene hsa-mir-495 Medulloblastoma 26160158 Our results suggest that miR-495 may be a prognostic predictor in medulloblastoma and that Gfi1 is a potential functional target of miR-495. +target gene hsa-mir-28 "Carcinoma, Hepatocellular" 26160280 Down-regulated miR-28-5p in human hepatocellular carcinoma correlated with tumor proliferation and migration by targeting insulin-like growth factor-1 (IGF-1). +target gene hsa-mir-1275 "Carcinoma, Hepatocellular" 26160756 miR-1275: A single microRNA that targets the three IGF2-mRNA-binding proteins hindering tumor growth in hepatocellular carcinoma. +target gene hsa-mir-503 "Carcinoma, Hepatocellular" 26163260 miR-503 suppresses metastasis of hepatocellular carcinoma cell by targeting PRMT1. +target gene hsa-mir-137 Schizophrenia 26163462 Experimental validation of candidate schizophrenia gene CALN1 as a target for microRNA-137. +target gene hsa-mir-99a "Carcinoma, Thyroid, Anaplastic" 26163618 MiR-99a Inhibits Cell Proliferation and Tumorigenesis through Targeting mTOR in Human Anaplastic Thyroid Cancer. +target gene hsa-mir-27a Glioma 26164457 MiR-27a regulates Wnt/beta-catenin signaling through targeting SFRP1 in glioma. +target gene hsa-mir-95 Glioma 26165303 "Downregulation of miR-95-3p inhibits proliferation, and invasion promoting apoptosis of glioma cells by targeting CELF2." +target gene hsa-mir-20a Kidney Injury 26165754 MiR-20a-5p mediates hypoxia-induced autophagy by targeting ATG16L1 in ischemic kidney injury. +target gene hsa-mir-20b Bladder Neoplasms 26166554 "MicroRNA-20b inhibits the proliferation, migration and invasion of bladder cancer EJ cells via the targeting of cell cycle regulation and Sp-1-mediated MMP-2 expression." +target gene hsa-mir-134 Lung Neoplasms 26166818 MicroRNA-134 regulates lung cancer cell H69 growth and apoptosis by targeting WWOX gene and suppressing the ERK1/2 signaling pathway. +target gene hsa-mir-208 "Carcinoma, Hepatocellular" 26169693 miR-208-3p promotes hepatocellular carcinoma cell proliferation and invasion through regulating ARID2 expression. +target gene hsa-mir-144 Neoplasms [unspecific] 26169798 Our approach provides important insights into miRNAs and their role in regulatory networks. The methodology can be applied to systematically investigate the differences in target genes and pathways of arbitrary miRNA sets. +target gene hsa-mir-205 Osteoporosis 26170952 The miR-205 antisense largely abolished the inhibitory effect of STAT3 activation on the levels of CHOP protein. +target gene hsa-mir-7 Prostate Neoplasms 26172296 MicroRNA-7 inhibits the stemness of prostate cancer stem-like cells and tumorigenesis by repressing KLF4/PI3K/Akt/p21 pathway. +target gene hsa-mir-133a "Carcinoma, Hepatocellular" 26173501 "MicroRNA-145 and MicroRNA-133a Inhibited Proliferation, Migration, and Invasion, While Promoted Apoptosis in Hepatocellular Carcinoma Cells Via Targeting FSCN1." +target gene hsa-mir-145 "Carcinoma, Hepatocellular" 26173501 "MicroRNA-145 and MicroRNA-133a Inhibited Proliferation, Migration, and Invasion, While Promoted Apoptosis in Hepatocellular Carcinoma Cells Via Targeting FSCN1." +target gene hsa-mir-18a Gastric Neoplasms 26173586 MicroRNA-18a modulates P53 expression by targeting IRF2 in gastric cancer patients. +target gene hsa-mir-206 Coronary Artery Disease 26175229 "Role of the microRNA, miR-206, and its target PIK3C2¦Á in endothelial progenitor cell function ¨C potential link with coronary artery disease." +target gene hsa-mir-17 Systemic Lupus Erythematosus 26175399 Targeting E2F1 and c-Myc expression by microRNA-17-5p represses interferon-stimulated gene MxA in peripheral blood mononuclear cells of pediatric systemic lupus erythematosus patients. +target gene hsa-mir-139 Ischemic Heart Disease 26175501 "Gene enrichment studies of hsa-miR-139-5p,hsa-miR-483-3p targets demonstrated an association with cardiovascular disease, cell death,and metabolism." +target gene hsa-mir-483 Ischemic Heart Disease 26175501 "Gene enrichment studies of hsa-miR-139-5p,hsa-miR-483-3p targets demonstrated an association with cardiovascular disease, cell death,and metabolism." +target gene hsa-mir-302c Glioma 26176806 MiR-302c-3p suppresses invasion and proliferation of glioma cells via down-regulating metadherin (MTDH) expression. +target gene hsa-mir-324 "Carcinoma, Hepatocellular" 26177288 MiR-324-5p Suppresses Hepatocellular Carcinoma Cell Invasion by Counteracting ECM Degradation through Post-Transcriptionally Downregulating ETS1 and SP1. +target gene hsa-mir-203a Lung Neoplasms 26177443 "ERGIC3, which is regulated by miR-203a, is a potential biomarker for non-small cell lung cancer." +target gene hsa-mir-129 Glioblastoma 26180082 Neurotensin signaling stimulates glioblastoma cell proliferation by upregulating c-Myc and inhibiting miR-29b-1 and miR-129-3p. +target gene hsa-mir-29b-1 Glioblastoma 26180082 Neurotensin signaling stimulates glioblastoma cell proliferation by upregulating c-Myc and inhibiting miR-29b-1 and miR-129-3p. +target gene hsa-mir-4487 Neuroblastoma 26183158 we identified that miR-4487 and miR-595 could target ULK1 and experimentally verified they could negatively or positively regulate ULK1-mediated autophagy +target gene hsa-mir-595 Neuroblastoma 26183158 Identification of ULK1 as a novel biomarker involved in miR-4487 and miR-595 regulation in neuroblastoma SH-SY5Y cell autophagy. +target gene hsa-mir-200a Lung Neoplasms 26184032 "MicroRNA-200a Targets EGFR and c-Met to Inhibit Migration, Invasion, and Gefitinib Resistance in Non-Small Cell Lung Cancer." +target gene hsa-mir-16 Infection [unspecific] 26184511 miR- 16 targeted the 3â€?untranslated region of IL-6 and suppressed its translation in mesangial cells induced by SIgA. +target gene hsa-mir-135b Atherosclerosis 26184978 MiR-135b-5p and MiR-499a-3p Promote Cell Proliferation and Migration in Atherosclerosis by Directly Targeting MEF2C. +target gene hsa-mir-499a Atherosclerosis 26184978 MiR-135b-5p and MiR-499a-3p Promote Cell Proliferation and Migration in Atherosclerosis by Directly Targeting MEF2C. +target gene hsa-mir-34a Human Immunodeficiency Virus Infection 26188041 "The miRNA miR-34a enhances HIV-1 replication by targeting PNUTS/PPP1R10, which negatively regulates HIV-1 transcriptional complex formation." +target gene hsa-mir-1238 Lung Neoplasms 26189214 miR-1238 inhibits cell proliferation by targeting LHX2 in non-small cell lung cancer. +target gene hsa-mir-122a "Carcinoma, Hepatocellular" 26189916 Targeted Regression of Hepatocellular Carcinoma by Cancer-Specific RNA Replacement through miR-122a Regulation. +target gene hsa-mir-302a Colorectal Carcinoma 26191138 Up-regulation of microRNA-302a inhibited the proliferation and invasion of colorectal cancer cells by regulation of the MAPK and PI3K/Akt signaling pathways. +target gene hsa-mir-139 Oral Neoplasms 26191149 MiRNA-139 regulates oral cancer Tca8113 cells apoptosis through Akt signaling pathway. +target gene hsa-mir-21 Cholangiocarcinoma 26191158 MicroRNA-21 regulates biological behavior by inducing EMT in human cholangiocarcinoma. +target gene hsa-mir-199a Endometriosis 26191163 MiR-199a inhibits the angiogenic potential of endometrial stromal cells under hypoxia by targeting HIF-1¦Á/VEGF pathway. +target gene hsa-mir-126 "Squamous Cell Carcinoma, Esophageal" 26191164 MicroRNA-126 is down-regulated in human esophageal squamous cell carcinoma and inhibits the proliferation and migration in EC109 cell via PI3K/AKT signaling pathway. +target gene hsa-mir-182 "Carcinoma, Cervical" 26191165 miR-182 induces cervical cancer cell apoptosis through inhibiting the expression of DNMT3a. +target gene hsa-mir-21 "Squamous Cell Carcinoma, Tongue" 26191167 Targeting miR-21 with AS-miR-21 suppresses aggressive growth of human tongue squamous cell carcinoma in vivo. +target gene hsa-mir-26b "Carcinoma, Hepatocellular" 26191168 "MiR-26b inhibits hepatocellular carcinoma cell proliferation, migration, and invasion by targeting EphA2." +target gene hsa-mir-365 Lymphoma 26191184 "MicroRNA-365 inhibits growth, invasion and metastasis of malignant melanoma by targeting NRP1 expression." +target gene hsa-mir-191 Endometriosis 26191186 MiR-191 inhibits TNF-¦Á induced apoptosis of ovarian endometriosis and endometrioid carcinoma cells by targeting DAPK1. +target gene hsa-mir-1297 "Carcinoma, Hepatocellular" 26191190 MicroRNA-1297 regulates hepatocellular carcinoma cell proliferation and apoptosis by targeting EZH2. +target gene hsa-mir-204 Breast Neoplasms 26191195 MicroRNA-204 targets JAK2 in breast cancer and induces cell apoptosis through the STAT3/BCl-2/survivin pathway. +target gene hsa-mir-185 Gastric Neoplasms 26191199 TRIM29 functions as an oncogene in gastric cancer and is regulated by miR-185. +target gene hsa-mir-10b "Carcinoma, Gastric" 26191201 Augmented miR-10b expression associated with depressed expression of its target gene KLF4 involved in gastric carcinoma. +target gene hsa-mir-107 "Carcinoma, Hepatocellular" 26191213 Our observations suggested that miR-107 could promote HCC cells proliferation via targeting Axin2 and might represent a potential therapeutic target for HCC. +target gene hsa-mir-144 Lung Neoplasms 26191328 "Expression of miR-144 is reduced in malignant SPN tissues and peripheral blood, being of clinical value in the diagnosis of malignant SPN.miR-144 promotes the apoptosis of lung cancer cells, and inhibits the proliferation, invasion and migration of lung cancer by regulating ZEB1 gene." +target gene hsa-mir-21 "Carcinoma, Colon" 26193421 The S100P/RAGE signaling pathway regulates expression of microRNA-21 in colon cancer cells. +target gene hsa-mir-325 "Carcinoma, Hepatocellular" 26194496 These findings implied that miR-325 regulates cell invasion and proliferation via targeting HMGB1 and may be a potential prognostic marker for HCC. +target gene hsa-mir-21 Neoplasms [unspecific] 26194786 "the miRNA-21 target is cyclically reused, and many MB-DNA fuel strands are attached to the sensor surface, leading to a significantly amplified current response for sensitive detection of miRNA-21 down to 1.4 fM. The developed sensor also shows high sequence discrimination capability and can be used to monitor miRNA-21 expression levels in cancer cells. Moreover, this sensor avoids the involvement of any enzymes for target recycling amplification and features with highly minimized background noise for miRNA detection, which makes this method hold great potential for convenient monitoring of different miRNA biomarkers for early diagnosis of various cancers." +target gene hsa-mir-34a Bladder Neoplasms 26198939 MicroRNA-34a regulates cell cycle by targeting CD44 in human bladder carcinoma cells. +target gene hsa-mir-720 Chronic Hepatitis B 26199080 therapies targeting miR-720 may help restore impaired immunity in chronic HBV infection (CHB) patients. +target gene hsa-mir-29a Diabetes Mellitus 26199111 "Using gain- and loss-of-function studies, five of these genes were confirmed as endogenous targets of miR-29a" +target gene hsa-mir-15b Japanese Encephalitis Virus Infection 26202983 MicroRNA-15b Modulates Japanese Encephalitis Virus-Mediated Inflammation via Targeting RNF125. +target gene hsa-mir-200c Neoplasms [unspecific] 26203557 miR-200c dampens cancer cell migration via regulation of protein kinase A subunits. +target gene hsa-mir-26b "Carcinoma, Ovarian" 26204489 MiR-26b/KPNA2 axis inhibits epithelial ovarian carcinoma proliferation and metastasis through downregulating OCT4. +target gene hsa-mir-335 Neoplasms [unspecific] 26204513 Our data suggest that differences in response to miR-335 by tumor cells may lie in part in the mechanism of regulation of MT1-MMP production. +target gene hsa-mir-539 Thyroid Neoplasms 26206083 MiR-539 inhibits thyroid cancer cell migration and invasion by directly targeting CARMA1. +target gene hsa-mir-21 Pulmonary Hypertension 26208095 these results demonstrate that PPAR¦Ã ligands regulate proliferative responses to hypoxia by preventing hypoxic increases in miR-21 and reductions in PTEN. These findings further clarify molecular mechanisms that support targeting PPAR¦Ã to attenuate pathogenic derangements in PH. +target gene hsa-mir-25 Glioblastoma 26209061 miR-25 promotes glioblastoma cell proliferation and invasion by directly targeting NEFL. +target gene hsa-mir-1246 "Carcinoma, Lung, Non-Small-Cell" 26209100 "These results suggested that the miR-1246 may promote cell metastasis by targeting CPEB4. Meanwhile, the level of CPEB4 could be used as a potential marker in NSCLC patients. Our findings unraveled novel functions of miR-1246 in lung cancer cells and shed light on NSCLC prognosis." +target gene hsa-mir-21 "Carcinoma, Hepatocellular" 26210448 MiR-21 promoted proliferation and migration in hepatocellular carcinoma through negative regulation of Navigator-3. +target gene hsa-mir-205 Prostate Neoplasms 26211479 Editorial Comment to MicroRNA-205 inhibits cancer cell migration and invasion via modulation of centromere protein F regulating pathways in prostate cancer. +target gene hsa-mir-29c Alzheimer Disease 26212654 miR-29c regulates NAV3 protein expression in a transgenic mouse model of Alzheimer's disease. +target gene hsa-mir-335 Gastrointestinal Stromal Tumor 26214687 "Our results suggest that miR-34a and miR-335 are candidate tumor suppressive miRNAs in GISTs, and that they are frequent targets of epigenetic silencing in GISTs." +target gene hsa-mir-34a Gastrointestinal Stromal Tumor 26214687 "Our results suggest that miR-34a and miR-335 are candidate tumor suppressive miRNAs in GISTs, and that they are frequent targets of epigenetic silencing in GISTs." +target gene hsa-mir-194 "Carcinoma, Hepatocellular" 26221053 NF-¦ÊB signaling relieves negative regulation by miR-194 in hepatocellular carcinoma by suppressing the transcription factor HNF-1¦Á. +target gene hsa-mir-143 Cardiovascular Diseases [unspecific] 26221598 We discuss the potential role of miR-143/-145 as valuable biomarkers for cardiovascular diseases and explore the potential strategy of targeting miR-143 and miR-145. +target gene hsa-mir-145 Cardiovascular Diseases [unspecific] 26221598 We discuss the potential role of miR-143/-145 as valuable biomarkers for cardiovascular diseases and explore the potential strategy of targeting miR-143 and miR-145. +target gene hsa-mir-223 Coronary Artery Disease 26221610 "our recent data demonstrated that the level of both intraplatelet and circulating miR-223 is an independent predictor for HTPR, thus providing a link between miR-223 and MACE. These lines of evidence indicate that miR-223 may serve as a potential regulatory target for HTPR, as well as a diagnostic tool for identification of HTPR in clinical settings." +target gene hsa-mir-149 Ovarian Neoplasms 26223974 Our findings suggest that miRNA-149 mediates the susceptibility of paclitaxel by regulating MyD88 expression in ovarian cancer cells. +target gene hsa-mir-375 "Carcinoma, Cervical" 26224081 miR-375 Modulates Radiosensitivity of HR-HPV-Positive Cervical Cancer Cells by Targeting UBE3A through the p53 Pathway. +target gene hsa-mir-204 Pulmonary Hypertension 26224795 BRD4 expression in PAH is microRNA-204 dependent +target gene hsa-mir-198 Neoplasms [unspecific] 26225959 we have identified that miR-198 inhibited HaCaT cell proliferation by directly targeting CCND2. +target gene hsa-mir-320a "Leukemia, Myeloid, Chronic" 26228085 MicroRNA-320a acts as a tumor suppressor by targeting BCR/ABL oncogene in chronic myeloid leukemia. +target gene hsa-mir-21 Bladder Neoplasms 26230405 microRNA-21 Regulates Cell Proliferation and Migration and Cross Talk with PTEN and p53 in Bladder Cancer. +target gene hsa-mir-503 Prostate Neoplasms 26231797 miR-503 suppresses tumor cell proliferation and metastasis by directly targeting RNF31 in prostate cancer. +target gene hsa-mir-214 "Squamous Cell Carcinoma, Esophageal" 26234674 Overexpression of miR-214-3p in esophageal squamous cancer cells enhances sensitivity to cisplatin by targeting survivin directly and indirectly through CUG-BP1. +target gene hsa-mir-135a Lung Neoplasms 26235874 MiR-135a inhibits migration and invasion and regulates EMT-related marker genes by targeting KLF8 in lung cancer cells. +target gene hsa-mir-219 "Carcinoma, Colon" 26238082 miR-219-5p plays a tumor suppressive role in colon cancer by targeting oncogene Sall4. +target gene hsa-mir-497 Ovarian Neoplasms 26238185 MiR-497 decreases cisplatin resistance in ovarian cancer cells by targeting mTOR/P70S6K1. +target gene hsa-mir-145 "Carcinoma, Lung, Non-Small-Cell" 26238532 MicroRNA-145 inhibits migration and invasion via inhibition of fascin 1 protein expression in non-small-cell lung cancer cells. +target gene hsa-mir-146a "Carcinoma, Lung, Non-Small-Cell" 26238771 MicroRNA-146a inhibits epithelial mesenchymal transition in non-small cell lung cancer by targeting insulin receptor substrate 2. +target gene hsa-mir-138 "Squamous Cell Carcinoma, Oral" 26239136 miR-138 suppresses the proliferation of oral squamous cell carcinoma cells by targeting Yes-associated protein 1. +target gene hsa-mir-126 "Carcinoma, Thyroid" 26239517 miR-126 inhibits papillary thyroid carcinoma growth by targeting LRP6. +target gene hsa-mir-205 Breast Neoplasms 26239614 MicroRNA-205 inhibits the proliferation and invasion of breast cancer by regulating AMOT expression. +target gene hsa-mir-29b-2 Glioblastoma 26240386 "our findings reveal a novel function of YB-1 in regulating non-coding RNA expression, which has important implications in tumorigenesis." +target gene hsa-mir-224 "Squamous Cell Carcinoma, Esophageal" 26245343 "The current study demonstrated that miR-224 acts as an oncogenic miRNA in esophageal squamous cell carcinoma (ESCC), possibly by targeting PHLPP1 and PHLPP2." +target gene hsa-mir-587 Colorectal Carcinoma 26247730 MicroRNA-587 antagonizes 5-FU-induced apoptosis and confers drug resistance by regulating PPP2R1B expression in colorectal cancer. +target gene hsa-mir-124 Colorectal Carcinoma 26248089 miR124 inhibits DNA synthesis and proliferation by reducing levels of pentose phosphate pathway enzymes in CRC cells. Expression of miR124 and its targets correlate with survival times and might be used in prognosis. +target gene hsa-mir-200c "Carcinoma, Renal Cell" 26248649 miR-200c Targets CDK2 and Suppresses Tumorigenesis in Renal Cell Carcinoma. +target gene hsa-mir-221 Multiple Myeloma 26249174 Targeting the miR-221-222/PUMA/BAK/BAX Pathway Abrogates Dexamethasone Resistance in Multiple Myeloma. +target gene hsa-mir-222 Multiple Myeloma 26249174 Targeting the miR-221-222/PUMA/BAK/BAX Pathway Abrogates Dexamethasone Resistance in Multiple Myeloma. +target gene hsa-mir-638 "Carcinoma, Gastric" 26250158 MicroRNA-638 inhibits cell proliferation by targeting phospholipase D1 in human gastric carcinoma. +target gene hsa-mir-34c "Carcinoma, Lung, Non-Small-Cell" 26250586 "miR-34c-3p directly targeted eIF4E and reduced miR-34c-3p expression in NSCLC, promoting cell cycle progression, proliferation, migration and invasion." +target gene hsa-mir-144 Glioblastoma 26250785 miR-144-3p exerts anti-tumor effects in glioblastoma by targeting c-Met. +target gene hsa-mir-221 "Carcinoma, Hepatocellular" 26251599 Targeted delivery of chemically modified anti-miR-221 to hepatocellular carcinoma with negatively charged liposomes. +target gene hsa-mir-24 Bladder Neoplasms 26252200 "MicroRNA-24 upregulation inhibits proliferation, metastasis and induces apoptosis in bladder cancer cells by targeting CARMA3." +target gene hsa-mir-122 "Carcinoma, Hepatocellular" 26252254 MicroRNA-122 affects cell aggressiveness and apoptosis by targeting PKM2 in human hepatocellular carcinoma. +target gene hsa-mir-21 Prostate Neoplasms 26252635 IL-6 Inhibits the Targeted Modulation of PDCD4 by miR-21 in Prostate Cancer. +target gene hsa-mir-132 "Carcinoma, Hepatocellular" 26252738 "MiR-132 inhibits cell proliferation, invasion and migration of hepatocellular carcinoma by targeting PIK3R3." +target gene hsa-mir-338 Breast Neoplasms 26252944 MicroRNA-338-3p functions as tumor suppressor in breast cancer by targeting SOX4. +target gene hsa-let-7a Allergic Asthma 26253882 "miRNAs are important post-transcriptional regulators of gene expression and have a role in allergic type 2 immune responses through their activity in multiple immune and non-immune cell subsets. Detailed mechanistic studies are critically needed to understand and leverage miRNAs to advance the field and inform clinical investigation. miRNAs act through multiple direct targets to regulate networks of genes, and their specificity and potency depends on the dynamics of individual miRNA-target interactions. Identifying which miRNAs and which targets are important for promoting or restraining allergy will help to identify vulnerable nodes in allergic inflammation, enhancing our mechanistic understanding of miRNA in the immune system and providing novel, possibly druggable, targets for these increasingly prevalent diseases." +target gene hsa-mir-106a Allergic Asthma 26253882 "miRNAs are important post-transcriptional regulators of gene expression and have a role in allergic type 2 immune responses through their activity in multiple immune and non-immune cell subsets. Detailed mechanistic studies are critically needed to understand and leverage miRNAs to advance the field and inform clinical investigation. miRNAs act through multiple direct targets to regulate networks of genes, and their specificity and potency depends on the dynamics of individual miRNA-target interactions. Identifying which miRNAs and which targets are important for promoting or restraining allergy will help to identify vulnerable nodes in allergic inflammation, enhancing our mechanistic understanding of miRNA in the immune system and providing novel, possibly druggable, targets for these increasingly prevalent diseases." +target gene hsa-mir-124 Allergic Asthma 26253882 "miRNAs are important post-transcriptional regulators of gene expression and have a role in allergic type 2 immune responses through their activity in multiple immune and non-immune cell subsets. Detailed mechanistic studies are critically needed to understand and leverage miRNAs to advance the field and inform clinical investigation. miRNAs act through multiple direct targets to regulate networks of genes, and their specificity and potency depends on the dynamics of individual miRNA-target interactions. Identifying which miRNAs and which targets are important for promoting or restraining allergy will help to identify vulnerable nodes in allergic inflammation, enhancing our mechanistic understanding of miRNA in the immune system and providing novel, possibly druggable, targets for these increasingly prevalent diseases." +target gene hsa-mir-126 Allergic Asthma 26253882 "miRNAs are important post-transcriptional regulators of gene expression and have a role in allergic type 2 immune responses through their activity in multiple immune and non-immune cell subsets. Detailed mechanistic studies are critically needed to understand and leverage miRNAs to advance the field and inform clinical investigation. miRNAs act through multiple direct targets to regulate networks of genes, and their specificity and potency depends on the dynamics of individual miRNA-target interactions. Identifying which miRNAs and which targets are important for promoting or restraining allergy will help to identify vulnerable nodes in allergic inflammation, enhancing our mechanistic understanding of miRNA in the immune system and providing novel, possibly druggable, targets for these increasingly prevalent diseases." +target gene hsa-mir-135 Allergic Asthma 26253882 "miRNAs are important post-transcriptional regulators of gene expression and have a role in allergic type 2 immune responses through their activity in multiple immune and non-immune cell subsets. Detailed mechanistic studies are critically needed to understand and leverage miRNAs to advance the field and inform clinical investigation. miRNAs act through multiple direct targets to regulate networks of genes, and their specificity and potency depends on the dynamics of individual miRNA-target interactions. Identifying which miRNAs and which targets are important for promoting or restraining allergy will help to identify vulnerable nodes in allergic inflammation, enhancing our mechanistic understanding of miRNA in the immune system and providing novel, possibly druggable, targets for these increasingly prevalent diseases." +target gene hsa-mir-142 Allergic Asthma 26253882 "miRNAs are important post-transcriptional regulators of gene expression and have a role in allergic type 2 immune responses through their activity in multiple immune and non-immune cell subsets. Detailed mechanistic studies are critically needed to understand and leverage miRNAs to advance the field and inform clinical investigation. miRNAs act through multiple direct targets to regulate networks of genes, and their specificity and potency depends on the dynamics of individual miRNA-target interactions. Identifying which miRNAs and which targets are important for promoting or restraining allergy will help to identify vulnerable nodes in allergic inflammation, enhancing our mechanistic understanding of miRNA in the immune system and providing novel, possibly druggable, targets for these increasingly prevalent diseases." +target gene hsa-mir-145 Allergic Asthma 26253882 "miRNAs are important post-transcriptional regulators of gene expression and have a role in allergic type 2 immune responses through their activity in multiple immune and non-immune cell subsets. Detailed mechanistic studies are critically needed to understand and leverage miRNAs to advance the field and inform clinical investigation. miRNAs act through multiple direct targets to regulate networks of genes, and their specificity and potency depends on the dynamics of individual miRNA-target interactions. Identifying which miRNAs and which targets are important for promoting or restraining allergy will help to identify vulnerable nodes in allergic inflammation, enhancing our mechanistic understanding of miRNA in the immune system and providing novel, possibly druggable, targets for these increasingly prevalent diseases." +target gene hsa-mir-146 Allergic Asthma 26253882 "miRNAs are important post-transcriptional regulators of gene expression and have a role in allergic type 2 immune responses through their activity in multiple immune and non-immune cell subsets. Detailed mechanistic studies are critically needed to understand and leverage miRNAs to advance the field and inform clinical investigation. miRNAs act through multiple direct targets to regulate networks of genes, and their specificity and potency depends on the dynamics of individual miRNA-target interactions. Identifying which miRNAs and which targets are important for promoting or restraining allergy will help to identify vulnerable nodes in allergic inflammation, enhancing our mechanistic understanding of miRNA in the immune system and providing novel, possibly druggable, targets for these increasingly prevalent diseases." +target gene hsa-mir-150 Allergic Asthma 26253882 "miRNAs are important post-transcriptional regulators of gene expression and have a role in allergic type 2 immune responses through their activity in multiple immune and non-immune cell subsets. Detailed mechanistic studies are critically needed to understand and leverage miRNAs to advance the field and inform clinical investigation. miRNAs act through multiple direct targets to regulate networks of genes, and their specificity and potency depends on the dynamics of individual miRNA-target interactions. Identifying which miRNAs and which targets are important for promoting or restraining allergy will help to identify vulnerable nodes in allergic inflammation, enhancing our mechanistic understanding of miRNA in the immune system and providing novel, possibly druggable, targets for these increasingly prevalent diseases." +target gene hsa-mir-155 Allergic Asthma 26253882 "miRNAs are important post-transcriptional regulators of gene expression and have a role in allergic type 2 immune responses through their activity in multiple immune and non-immune cell subsets. Detailed mechanistic studies are critically needed to understand and leverage miRNAs to advance the field and inform clinical investigation. miRNAs act through multiple direct targets to regulate networks of genes, and their specificity and potency depends on the dynamics of individual miRNA-target interactions. Identifying which miRNAs and which targets are important for promoting or restraining allergy will help to identify vulnerable nodes in allergic inflammation, enhancing our mechanistic understanding of miRNA in the immune system and providing novel, possibly druggable, targets for these increasingly prevalent diseases." +target gene hsa-mir-193 Allergic Asthma 26253882 "miRNAs are important post-transcriptional regulators of gene expression and have a role in allergic type 2 immune responses through their activity in multiple immune and non-immune cell subsets. Detailed mechanistic studies are critically needed to understand and leverage miRNAs to advance the field and inform clinical investigation. miRNAs act through multiple direct targets to regulate networks of genes, and their specificity and potency depends on the dynamics of individual miRNA-target interactions. Identifying which miRNAs and which targets are important for promoting or restraining allergy will help to identify vulnerable nodes in allergic inflammation, enhancing our mechanistic understanding of miRNA in the immune system and providing novel, possibly druggable, targets for these increasingly prevalent diseases." +target gene hsa-mir-21 Allergic Asthma 26253882 "miRNAs are important post-transcriptional regulators of gene expression and have a role in allergic type 2 immune responses through their activity in multiple immune and non-immune cell subsets. Detailed mechanistic studies are critically needed to understand and leverage miRNAs to advance the field and inform clinical investigation. miRNAs act through multiple direct targets to regulate networks of genes, and their specificity and potency depends on the dynamics of individual miRNA-target interactions. Identifying which miRNAs and which targets are important for promoting or restraining allergy will help to identify vulnerable nodes in allergic inflammation, enhancing our mechanistic understanding of miRNA in the immune system and providing novel, possibly druggable, targets for these increasingly prevalent diseases." +target gene hsa-mir-221 Allergic Asthma 26253882 "miRNAs are important post-transcriptional regulators of gene expression and have a role in allergic type 2 immune responses through their activity in multiple immune and non-immune cell subsets. Detailed mechanistic studies are critically needed to understand and leverage miRNAs to advance the field and inform clinical investigation. miRNAs act through multiple direct targets to regulate networks of genes, and their specificity and potency depends on the dynamics of individual miRNA-target interactions. Identifying which miRNAs and which targets are important for promoting or restraining allergy will help to identify vulnerable nodes in allergic inflammation, enhancing our mechanistic understanding of miRNA in the immune system and providing novel, possibly druggable, targets for these increasingly prevalent diseases." +target gene hsa-mir-223 Allergic Asthma 26253882 "miRNAs are important post-transcriptional regulators of gene expression and have a role in allergic type 2 immune responses through their activity in multiple immune and non-immune cell subsets. Detailed mechanistic studies are critically needed to understand and leverage miRNAs to advance the field and inform clinical investigation. miRNAs act through multiple direct targets to regulate networks of genes, and their specificity and potency depends on the dynamics of individual miRNA-target interactions. Identifying which miRNAs and which targets are important for promoting or restraining allergy will help to identify vulnerable nodes in allergic inflammation, enhancing our mechanistic understanding of miRNA in the immune system and providing novel, possibly druggable, targets for these increasingly prevalent diseases." +target gene hsa-mir-29 Allergic Asthma 26253882 "miRNAs are important post-transcriptional regulators of gene expression and have a role in allergic type 2 immune responses through their activity in multiple immune and non-immune cell subsets. Detailed mechanistic studies are critically needed to understand and leverage miRNAs to advance the field and inform clinical investigation. miRNAs act through multiple direct targets to regulate networks of genes, and their specificity and potency depends on the dynamics of individual miRNA-target interactions. Identifying which miRNAs and which targets are important for promoting or restraining allergy will help to identify vulnerable nodes in allergic inflammation, enhancing our mechanistic understanding of miRNA in the immune system and providing novel, possibly druggable, targets for these increasingly prevalent diseases." +target gene hsa-mir-365 Allergic Asthma 26253882 "miRNAs are important post-transcriptional regulators of gene expression and have a role in allergic type 2 immune responses through their activity in multiple immune and non-immune cell subsets. Detailed mechanistic studies are critically needed to understand and leverage miRNAs to advance the field and inform clinical investigation. miRNAs act through multiple direct targets to regulate networks of genes, and their specificity and potency depends on the dynamics of individual miRNA-target interactions. Identifying which miRNAs and which targets are important for promoting or restraining allergy will help to identify vulnerable nodes in allergic inflammation, enhancing our mechanistic understanding of miRNA in the immune system and providing novel, possibly druggable, targets for these increasingly prevalent diseases." +target gene hsa-mir-375 Allergic Asthma 26253882 "miRNAs are important post-transcriptional regulators of gene expression and have a role in allergic type 2 immune responses through their activity in multiple immune and non-immune cell subsets. Detailed mechanistic studies are critically needed to understand and leverage miRNAs to advance the field and inform clinical investigation. miRNAs act through multiple direct targets to regulate networks of genes, and their specificity and potency depends on the dynamics of individual miRNA-target interactions. Identifying which miRNAs and which targets are important for promoting or restraining allergy will help to identify vulnerable nodes in allergic inflammation, enhancing our mechanistic understanding of miRNA in the immune system and providing novel, possibly druggable, targets for these increasingly prevalent diseases." +target gene hsa-mir-452 Allergic Asthma 26253882 "miRNAs are important post-transcriptional regulators of gene expression and have a role in allergic type 2 immune responses through their activity in multiple immune and non-immune cell subsets. Detailed mechanistic studies are critically needed to understand and leverage miRNAs to advance the field and inform clinical investigation. miRNAs act through multiple direct targets to regulate networks of genes, and their specificity and potency depends on the dynamics of individual miRNA-target interactions. Identifying which miRNAs and which targets are important for promoting or restraining allergy will help to identify vulnerable nodes in allergic inflammation, enhancing our mechanistic understanding of miRNA in the immune system and providing novel, possibly druggable, targets for these increasingly prevalent diseases." +target gene hsa-mir-615 Allergic Asthma 26253882 "miRNAs are important post-transcriptional regulators of gene expression and have a role in allergic type 2 immune responses through their activity in multiple immune and non-immune cell subsets. Detailed mechanistic studies are critically needed to understand and leverage miRNAs to advance the field and inform clinical investigation. miRNAs act through multiple direct targets to regulate networks of genes, and their specificity and potency depends on the dynamics of individual miRNA-target interactions. Identifying which miRNAs and which targets are important for promoting or restraining allergy will help to identify vulnerable nodes in allergic inflammation, enhancing our mechanistic understanding of miRNA in the immune system and providing novel, possibly druggable, targets for these increasingly prevalent diseases." +target gene hsa-mir-130a Liver Fibrosis 26255201 These findings suggest that miR-130a and miR-130b are involved in downregulation of PPARγ in liver fibrosis. +target gene hsa-mir-27b Liver Fibrosis 26255201 "In carbon tetrachloride injection (CCl4) and common bile duct ligation (CBDL) liver fibrosis models, miRNAs miR-130a, miR-130b, miR-301a, miR-27b and miR-340 levels were found to be increased and PPARγ expression decreased." +target gene hsa-mir-378a Breast Neoplasms 26255816 miR-378a-3p modulates tamoxifen sensitivity in breast cancer MCF-7 cells through targeting GOLT1A. +target gene hsa-mir-145 Intrahepatic Cholangiocarcinoma 26255969 MiR-145 functions as a tumor suppressor targeting NUAK1 in human intrahepatic cholangiocarcinoma. +target gene hsa-mir-512 "Squamous Cell Carcinoma, Head and Neck" 26258591 miR-512-5p suppresses tumor growth by targeting hTERT in telomerase positive head and neck squamous cell carcinoma in vitro and in vivo. +target gene hsa-mir-512 Alzheimer Disease 26258756 Reduced miR-512 and the Elevated Expression of Its Targets cFLIP and MCL1 Localize to Neurons With Hyperphosphorylated Tau Protein in Alzheimer Disease. +target gene hsa-mir-99b Colorectal Carcinoma 26259252 miRNA-99b-5p suppresses liver metastasis of colorectal cancer by down-regulating mTOR. +target gene hsa-mir-124 Osteosarcoma 26259653 MicroRNA-124 suppresses the migration and invasion of osteosarcoma cells via targeting ROR2-mediated non-canonical Wnt signaling. +target gene hsa-mir-744 Inflammation 26259828 "our data indicate that by targeting PTP1B, miR-744 plays a feed-forward role in regulating type I IFN signaling pathway. These findings give us new insights into the functions of renal miRNAs in regulating important signaling pathways." +target gene hsa-mir-338 "Carcinoma, Nasopharyngeal" 26260688 MicroRNA-338 inhibits migration and proliferation by targeting hypoxia-induced factor 1¦Á in nasopharyngeal carcinoma. +target gene hsa-mir-155 Lymphoma 26261072 Oncogenic microRNA-155 and its target PU.1: an integrative gene expression study in six of the most prevalent lymphomas. +target gene hsa-mir-7 "Carcinoma, Gastric" 26261179 MicroRNA-7/NF-¦ÊB signaling regulatory feedback circuit regulates gastric carcinogenesis. +target gene hsa-mir-218 Gastric Neoplasms 26261515 These findings suggest that miR-218 inhibits MDR of gastric cancer cells by down-regulating SMO expression. +target gene hsa-mir-15a Osteosarcoma 26261520 "MiRNA-15a inhibits proliferation, migration and invasion by targeting TNFAIP1 in human osteosarcoma cells." +target gene hsa-mir-126 Breast Neoplasms 26261534 "Thus, our study revealed that miR-126 may act as a tumor suppressor via inhibition of cell invasion by downregulating ADAM9 in breast cancer development." +target gene hsa-mir-630 Colorectal Carcinoma 26263387 CREB-miR-630-BCL2L2 and TP53RK comprise a novel signaling cascade regulating radiosensitivity in CRC cell lines by inducing cell apoptosis and death. +target gene hsa-mir-17 Myocardial Infarction 26265044 "The delivery of exogenous miR-17 suppressed Apaf-1 expression and consequently attenuated formation of the apoptosome complex containing caspase-9, as demonstrated by co-immunoprecipitation and immunocytochemistry." +target gene hsa-mir-106a Cardiovascular Diseases [unspecific] 26266261 Our current special issue presents a series of original researches and reviews on recent advances in miRNAs regulating the pathophysiology aspects of CVD that will hopefully set the stage for future research initiatives aimed at expanding our understanding of these important mediators of cardiovascular function. +target gene hsa-mir-106b Cardiovascular Diseases [unspecific] 26266261 Our current special issue presents a series of original researches and reviews on recent advances in miRNAs regulating the pathophysiology aspects of CVD that will hopefully set the stage for future research initiatives aimed at expanding our understanding of these important mediators of cardiovascular function. +target gene hsa-mir-125 Cardiovascular Diseases [unspecific] 26266261 Our current special issue presents a series of original researches and reviews on recent advances in miRNAs regulating the pathophysiology aspects of CVD that will hopefully set the stage for future research initiatives aimed at expanding our understanding of these important mediators of cardiovascular function. +target gene hsa-mir-126 Cardiovascular Diseases [unspecific] 26266261 Our current special issue presents a series of original researches and reviews on recent advances in miRNAs regulating the pathophysiology aspects of CVD that will hopefully set the stage for future research initiatives aimed at expanding our understanding of these important mediators of cardiovascular function. +target gene hsa-mir-143 Cardiovascular Diseases [unspecific] 26266261 Our current special issue presents a series of original researches and reviews on recent advances in miRNAs regulating the pathophysiology aspects of CVD that will hopefully set the stage for future research initiatives aimed at expanding our understanding of these important mediators of cardiovascular function. +target gene hsa-mir-145 Cardiovascular Diseases [unspecific] 26266261 Our current special issue presents a series of original researches and reviews on recent advances in miRNAs regulating the pathophysiology aspects of CVD that will hopefully set the stage for future research initiatives aimed at expanding our understanding of these important mediators of cardiovascular function. +target gene hsa-mir-17 Cardiovascular Diseases [unspecific] 26266261 Our current special issue presents a series of original researches and reviews on recent advances in miRNAs regulating the pathophysiology aspects of CVD that will hopefully set the stage for future research initiatives aimed at expanding our understanding of these important mediators of cardiovascular function. +target gene hsa-mir-18 Cardiovascular Diseases [unspecific] 26266261 Our current special issue presents a series of original researches and reviews on recent advances in miRNAs regulating the pathophysiology aspects of CVD that will hopefully set the stage for future research initiatives aimed at expanding our understanding of these important mediators of cardiovascular function. +target gene hsa-mir-19a Cardiovascular Diseases [unspecific] 26266261 Our current special issue presents a series of original researches and reviews on recent advances in miRNAs regulating the pathophysiology aspects of CVD that will hopefully set the stage for future research initiatives aimed at expanding our understanding of these important mediators of cardiovascular function. +target gene hsa-mir-19b-1 Cardiovascular Diseases [unspecific] 26266261 Our current special issue presents a series of original researches and reviews on recent advances in miRNAs regulating the pathophysiology aspects of CVD that will hopefully set the stage for future research initiatives aimed at expanding our understanding of these important mediators of cardiovascular function. +target gene hsa-mir-20a Cardiovascular Diseases [unspecific] 26266261 Our current special issue presents a series of original researches and reviews on recent advances in miRNAs regulating the pathophysiology aspects of CVD that will hopefully set the stage for future research initiatives aimed at expanding our understanding of these important mediators of cardiovascular function. +target gene hsa-mir-221 Cardiovascular Diseases [unspecific] 26266261 Our current special issue presents a series of original researches and reviews on recent advances in miRNAs regulating the pathophysiology aspects of CVD that will hopefully set the stage for future research initiatives aimed at expanding our understanding of these important mediators of cardiovascular function. +target gene hsa-mir-222 Cardiovascular Diseases [unspecific] 26266261 Our current special issue presents a series of original researches and reviews on recent advances in miRNAs regulating the pathophysiology aspects of CVD that will hopefully set the stage for future research initiatives aimed at expanding our understanding of these important mediators of cardiovascular function. +target gene hsa-mir-223 Cardiovascular Diseases [unspecific] 26266261 Our current special issue presents a series of original researches and reviews on recent advances in miRNAs regulating the pathophysiology aspects of CVD that will hopefully set the stage for future research initiatives aimed at expanding our understanding of these important mediators of cardiovascular function. +target gene hsa-mir-2861 Cardiovascular Diseases [unspecific] 26266261 Our current special issue presents a series of original researches and reviews on recent advances in miRNAs regulating the pathophysiology aspects of CVD that will hopefully set the stage for future research initiatives aimed at expanding our understanding of these important mediators of cardiovascular function. +target gene hsa-mir-3960 Cardiovascular Diseases [unspecific] 26266261 Our current special issue presents a series of original researches and reviews on recent advances in miRNAs regulating the pathophysiology aspects of CVD that will hopefully set the stage for future research initiatives aimed at expanding our understanding of these important mediators of cardiovascular function. +target gene hsa-mir-92-1 Cardiovascular Diseases [unspecific] 26266261 Our current special issue presents a series of original researches and reviews on recent advances in miRNAs regulating the pathophysiology aspects of CVD that will hopefully set the stage for future research initiatives aimed at expanding our understanding of these important mediators of cardiovascular function. +target gene hsa-mir-138 "Squamous Cell Carcinoma, Cerevial" 26267680 "miR-138 and miR-720 are the down-regulated target miRNAs in HPV16-positive squamous carcinoma of the cervix in the Uygur of southern Xinjiang. The common target gene for miR-138 and miR-720 is EZH2, which might be related to cervical squamous carcinoma invasion and metastasis." +target gene hsa-mir-720 "Squamous Cell Carcinoma, Cerevial" 26267680 "miR-138 and miR-720 are the down-regulated target miRNAs in HPV16-positive squamous carcinoma of the cervix in the Uygur of southern Xinjiang. The common target gene for miR-138 and miR-720 is EZH2, which might be related to cervical squamous carcinoma invasion and metastasis." +target gene hsa-mir-503 Microvascular Disease 26268439 "Collectively, our data demonstrate that miR-503 regulates pericyte-endothelial crosstalk in microvascular diabetic complications." +target gene hsa-mir-126 "Leukemia, Promyelocytic, Acute" 26274316 "These results demonstrate that ATO inhibits the growth of HUVECs and induces apoptosis by downregulating VEGFA. One mechanism by which this occurs is Ets-2 upregulation, which results in an increase in miR-126 levels and downregulation of VEGFA expression." +target gene hsa-mir-202 Osteosarcoma 26276504 This study provides new insights into miRNA-202 in osteosarcoma as a potential molecular target for chemotherapy. +target gene hsa-mir-761 "Carcinoma, Lung, Non-Small-Cell" 26278569 miR-761 promotes progression and metastasis of NSCLC by targeting ING4 and TIMP2. +target gene hsa-mir-205 "Carcinoma, Laryngeal" 26281062 miRNA-205 might promote the proliferation of Hep-2 cells by regulating the expression of PTEN. +target gene hsa-mir-185 Congenital Microtia 26282502 "The expression of has-miR-203, has-miR-200c and has-miR-451 were significantly different in microtia. Target gene of SOCS3, TFs of STAT1 and STAT2, and lncRNA of MALAT1 may play important roles in the development of the external ear." +target gene hsa-mir-200c Congenital Microtia 26282502 "The expression of has-miR-203, has-miR-200c and has-miR-451 were significantly different in microtia. Target gene of SOCS3, TFs of STAT1 and STAT2, and lncRNA of MALAT1 may play important roles in the development of the external ear." +target gene hsa-mir-203 Congenital Microtia 26282502 "The expression of has-miR-203, has-miR-200c and has-miR-451 were significantly different in microtia. Target gene of SOCS3, TFs of STAT1 and STAT2, and lncRNA of MALAT1 may play important roles in the development of the external ear." +target gene hsa-mir-451 Congenital Microtia 26282502 "The expression of has-miR-203, has-miR-200c and has-miR-451 were significantly different in microtia. Target gene of SOCS3, TFs of STAT1 and STAT2, and lncRNA of MALAT1 may play important roles in the development of the external ear." +target gene hsa-mir-664 Lymphoma 26287415 "Taken together, our results suggest that miR-664 may play an important role in suppressing proliferation of CMM cells and present a novel mechanism of miR-mediated direct suppression of PLP2 expression in cancer cells." +target gene hsa-mir-215 Colorectal Carcinoma 26287603 Identification of miR-215 mediated targets/pathways via translational immunoprecipitation expression analysis (TrIP-chip). +target gene hsa-mir-34a "Carcinoma, Rectal" 26287733 "Although miR-34a and miR-34c can regulate Axl expression in vitro,our data indicates that the miR-34 family members are not the primary regulators of Axl expression in RCC." +target gene hsa-mir-411 Rhabdomyosarcoma 26291313 "These results establish an autoregulatory loop between TGF-¦Â1/miR-411-5p/SPRY4 and MAPK in RMS, which governs the switch between proliferation and differentiation." +target gene hsa-mir-223 Tuberculosis 26296289 It is concluded that miR-223 can regulate macrophage function by inhibition of cytokine production and NF-¦ÊB activation. +target gene hsa-let-7b Ischemia-Reperfusion Injury 26296645 we report that let-7b targets caspase-3 to regulate apoptosis and autophagy in MSCs exposed to ROS. +target gene hsa-mir-139 Breast Neoplasms 26299922 MiR-139-5p not only attenuated the development of breast cancer cells but also mediated drug-resistance by regulating the expression of the downstream target gene Notch1. +target gene hsa-mir-137 Osteosarcoma 26302771 "We revealed novel functional role of miR-137 in osteosarcoma regulation, likely through FXYD6 binding." +target gene hsa-mir-155 Colorectal Carcinoma 26303353 "Thus, it is hypothesized that miR-155 may be a promising target for antagonizing COX-2 expression in colorectal and other cancers." +target gene hsa-mir-195 "Colitis, Ulcerative" 26303523 miR-195 plays a role in steroid resistance of ulcerative colitis by targeting Smad7. +target gene hsa-mir-203 "Carcinoma, Nasopharyngeal" 26304234 MiRNA-203 Reduces Nasopharyngeal Carcinoma Radioresistance by Targeting IL8/AKT Signaling. +target gene hsa-mir-17 "Lymphoma, Large B-Cell, Diffuse" 26305986 "In the present review, we focus on the role of the miR-17-92 cluster in lymphoproliferative disorders, including diagnostic/prognostic implications, and on the potential applications of anti-miRNAs based therapies targeting miRNAs belonging to the cluster." +target gene hsa-mir-18 "Lymphoma, Large B-Cell, Diffuse" 26305986 "In the present review, we focus on the role of the miR-17-92 cluster in lymphoproliferative disorders, including diagnostic/prognostic implications, and on the potential applications of anti-miRNAs based therapies targeting miRNAs belonging to the cluster." +target gene hsa-mir-19a "Lymphoma, Large B-Cell, Diffuse" 26305986 "In the present review, we focus on the role of the miR-17-92 cluster in lymphoproliferative disorders, including diagnostic/prognostic implications, and on the potential applications of anti-miRNAs based therapies targeting miRNAs belonging to the cluster." +target gene hsa-mir-19b-1 "Lymphoma, Large B-Cell, Diffuse" 26305986 "In the present review, we focus on the role of the miR-17-92 cluster in lymphoproliferative disorders, including diagnostic/prognostic implications, and on the potential applications of anti-miRNAs based therapies targeting miRNAs belonging to the cluster." +target gene hsa-mir-20a "Lymphoma, Large B-Cell, Diffuse" 26305986 "In the present review, we focus on the role of the miR-17-92 cluster in lymphoproliferative disorders, including diagnostic/prognostic implications, and on the potential applications of anti-miRNAs based therapies targeting miRNAs belonging to the cluster." +target gene hsa-mir-92-1 "Lymphoma, Large B-Cell, Diffuse" 26305986 "In the present review, we focus on the role of the miR-17-92 cluster in lymphoproliferative disorders, including diagnostic/prognostic implications, and on the potential applications of anti-miRNAs based therapies targeting miRNAs belonging to the cluster." +target gene hsa-mir-214 Huntington Disease 26307536 "In summary, we have shown that increased expression of miR-214 observed in HD cell model could target MFN2, altered mitochondrial morphology and deregulated cell cycle. Inhibition of miR-214 could be a possible target of intervention in HD pathogenesis." +target gene hsa-mir-712 Atherosclerosis 26308181 Multifunctional Nanoparticles Facilitate Molecular Targeting and miRNA Delivery to Inhibit Atherosclerosis in ApoE(-/-) Mice. +target gene hsa-mir-15a Pituitary Neoplasms 26309203 GAA-induced decrease in cell proliferation is associated with decreased expression of Bcl-2 and increased miR-15a. +target gene hsa-mir-18a Leukemia 26314433 The miR-18a can regulated the sensitivity of leukemia HL-60 cells to VP-16 and VCR by targeting ATM. +target gene hsa-mir-26a "Lymphoma, T-Cell" 26314438 that abnormal expression of miR-26a may participate in genesis and development of ENKTCL through regulating the expression of its target gene CDK6. +target gene hsa-mir-23a "Carcinoma, Nasopharyngeal" 26314966 MiR-23a sensitizes nasopharyngeal carcinoma to irradiation by targeting IL-8/Stat3 pathway. +target gene hsa-mir-99b "Squamous Cell Carcinoma, Oral" 26315788 miRNA-99b-3p functions as a potential tumor suppressor by targeting glycogen synthase kinase-3¦Â in oral squamous cell carcinoma Tca-8113 cells. +target gene hsa-mir-340 "Carcinoma, Esophageal" 26316084 MiR-340 functions as a tumor suppressor by modulating the expression of PSAT1 and may contribute to the progression and invasiveness of ESCC. +target gene hsa-mir-130b Lupus Nephritis 26316103 MiR-130b-3p negatively regulated ERBB2IP expression by directly targeting the 3'-UTR of ERBB2IP The circulating miR-130b-3p might serve as a biomarker and play an important role in renal damage in early stage LN patients. +target gene hsa-mir-10a "Carcinoma, Lung, Non-Small-Cell" 26317552 We found that PTEN was a direct target of miR-10a in NSCLC. Also miR-10a activated the PTEN/AKT/ERK pathway. We suggest that miR-10a contributes to NSCLC by targeting PTEN. +target gene hsa-mir-494 Chondrosarcoma 26317788 MicroRNA-494 inhibits cell proliferation and invasion of chondrosarcoma cells in vivo and in vitro by directly targeting SOX9. +target gene hsa-mir-940 Gastric Neoplasms 26317898 MicroRNA-940 promotes tumor cell invasion and metastasis by downregulating ZNF24 in gastric cancer. +target gene hsa-mir-134 Breast Neoplasms 26318721 MicroRNA-134 modulates resistance to doxorubicin in breast cancer cells by downregulating the expression of ABCC1 which is known to encode the multidrug resistance-associated protein 1. +target gene hsa-mir-34a "Squamous Cell Carcinoma, Head and Neck" 26323460 MicroRNA-34a regulates epithelial-mesenchymal transition and cancer stem cell phenotype of head and neck squamous cell carcinoma in vitro. +target gene hsa-mir-542 "Carcinoma, Esophageal" 26323919 "Taken together, our results indicated that miR-542-3p is a tumor suppressor of esophageal cancer acting at steps that regulate cell growth." +target gene hsa-mir-155 Tuberculosis 26324048 "From these results, it was concluded that mycobacteria can improve the level of miR-155, while BCG can induce apoptosis in THP-1 cells. The results suggested FOXO3 is a downstream target gene of miR-155, which combines 3'-UTRs to inhibit the expression of FOXO3." +target gene hsa-mir-34a "Carcinoma, Colon" 26324236 These findings demonstrate that miR-34a may act as a negative regulator in colon cancer by targeting PDGFRA. +target gene hsa-mir-221 Prostate Neoplasms 26325107 Loss of the tumour-suppressive miR-221/222 cluster enhanced migration and invasion in PCa cells. Our data describing targets regulated by the tumour-suppressive miR-221/222 cluster provide insights into the mechanisms of PCa and CRPC progression. +target gene hsa-mir-222 Prostate Neoplasms 26325107 Loss of the tumour-suppressive miR-221/222 cluster enhanced migration and invasion in PCa cells. Our data describing targets regulated by the tumour-suppressive miR-221/222 cluster provide insights into the mechanisms of PCa and CRPC progression. +target gene hsa-mir-206 Neoplasms [unspecific] 26325180 "Taken together, our results demonstrated that miR-206 suppressed c-Met and Bcl2 expression in NSCLS and could function as a potent tumor suppressor in c-Met/Bcl2-over expressing tumors. Inhibition of miR-206 function could contribute to aberrant cell proliferation, migration, invasion and apoptosis,leading to NSCLS development." +target gene hsa-mir-1908 Osteosarcoma 26328886 "Collectively, the results showed that, miR-1908 promotes proliferation and invasion of osteosarcoma cells by repressing PTEN expression." +target gene hsa-mir-372 "Carcinoma, Renal Cell" 26332146 Our data indicated that miR-372 seemed to function as a tumour suppressor in renal cell carcinoma progression by inhibiting the IGF2BP1 expression. +target gene hsa-mir-29a "Scleroderma, Systemic" 26335042 miRNA-29a in systemic sclerosis: A valid target. +target gene hsa-mir-212 Pancreatic Neoplasms 26337469 Pancreatic cancer-derived exosomes transfer miRNAs to dendritic cells and inhibit RFXAP expression via miR-212-3p. +target gene hsa-mir-1207 "Carcinoma, Lung, Non-Small-Cell" 26338522 "The three miR-1207-5p, miR-1228* and miR-939 are the most connected miRNA that regulated a large number of genes." +target gene hsa-mir-1228 "Carcinoma, Lung, Non-Small-Cell" 26338522 "The three miR-1207-5p, miR-1228* and miR-939 are the most connected miRNA that regulated a large number of genes." +target gene hsa-mir-939 "Carcinoma, Lung, Non-Small-Cell" 26338522 "The three miR-1207-5p, miR-1228* and miR-939 are the most connected miRNA that regulated a large number of genes." +target gene hsa-mir-182 Lung Neoplasms 26338969 These results suggest that modulation of miR-182 and miR-185 and their target genes may contribute to lung carcinogenesis attributable to PM2.5 exposure. +target gene hsa-mir-185 Lung Neoplasms 26338969 These results suggest that modulation of miR-182 and miR-185 and their target genes may contribute to lung carcinogenesis attributable to PM2.5 exposure. +target gene hsa-mir-124 Osteosarcoma 26339404 Our findings may help to understand the molecular mechanisms of OS and identify targets of effective targeted therapies for OS. +target gene hsa-mir-19b Osteosarcoma 26339404 Our findings may help to understand the molecular mechanisms of OS and identify targets of effective targeted therapies for OS. +target gene hsa-mir-20a Osteosarcoma 26339404 Our findings may help to understand the molecular mechanisms of OS and identify targets of effective targeted therapies for OS. +target gene hsa-mir-155 Colorectal Carcinoma 26340059 We further showed that miR-155 acted to repress the Warburg effect through the mechanism of inactivating the IL-6/STAT3 pathway. +target gene hsa-mir-200a "Squamous Cell Carcinoma, Esophageal" 26341629 These results reaffirm the potential role of MSA as a chemopreventive agent via the regulation of KLF4/miR-200a/Keap1/Nrf2 axis in ESCC cells. +target gene hsa-mir-21 "Carcinoma, Esophageal" 26345812 "Together,these results suggest that miR- 21 might be involved in the development and metastasis of esophageal cancer, through interaction with its PDCD4 and K-ras target genes." +target gene hsa-mir-101 Lung Neoplasms 26349988 miR-101 represses lung cancer by inhibiting interaction of fibroblasts and cancer cells by down-regulating CXCL12. +target gene hsa-mir-16 Osteoarthritis 26350536 Our results indicate that miR-16-5p is an important regulator of SMAD3 expression in human chondrocytes and may contribute to the development of OA. +target gene hsa-mir-128 Colorectal Carcinoma 26352220 "Taken together, these data suggested that miR-128 serves as a tumor suppressor and blocks CRC growth and metastasis by targeting IRS1." +target gene hsa-mir-675 Breast Neoplasms 26353930 H19 non coding RNA-derived miR-675 enhances tumorigenesis and metastasis of breast cancer cells by downregulating c-Cbl and Cbl-b. +target gene hsa-mir-183 Endometriosis 26357653 "These findings, together with the fact that ITGB1 is a critical factor for cell adhesion and invasiveness, suggest that miR-183 may be involved in the development of endometriosis by regulating ITGB1 in endometrial stromal cells." +target gene hsa-mir-10b Breast Neoplasms 26359455 Combining miR-10b-Targeted Nanotherapy with Low-Dose Doxorubicin Elicits Durable Regressions of Metastatic Breast Cancer. +target gene hsa-mir-326 Gastric Neoplasms 26359764 "Our study demonstrated that miR-326 overexpression was a poor prognostic marker for gastric cancer patients, and miR-326 served as a tumor suppressor in gastric cancer via directly regulating FSCN1." +target gene hsa-mir-506 Gastric Neoplasms 26362716 "In conclusion, miR-506 was identified as an ETS1 targeting suppressor of metastatic invasion and angiogenesis in gastric cancer." +target gene hsa-mir-21 Breast Neoplasms 26363493 An immobilization-free electrochemical impedance biosensor based on duplex-specific nuclease assisted target recycling for amplified detection of microRNA. +target gene hsa-mir-19a Lung Neoplasms 26367773 Uncovering Direct Targets of MiR-19a Involved in Lung Cancer Progression. +target gene hsa-mir-141 Ischemic Heart Disease 26371161 MicroRNA-141 regulates the expression level of ICAM-1 on endothelium to decrease myocardial ischemia-reperfusion injury. +target gene hsa-mir-203 Osteosarcoma 26382657 "Take together, our results demonstrated that miR-203 act as a tumor suppressor miRNA through regulating RAB22A expression and suggested its involvement in osteosarcoma progression and carcinogenesis." +target gene hsa-mir-21 Coronary Artery Disease 26383248 "Because the smad7 expression pattern was similar to that of TGF-¦Â,our study suggests that miR-21 can negatively regulate the frequency of circulating Treg cells through a TGF-¦Â1/smad-independent signaling pathway in PBMCs." +target gene hsa-mir-34a "Carcinoma, Hepatocellular" 26385595 MiR-34a is Involved in the Decrease of ATP Contents Induced by Resistin Through Target on ATP5S in HepG2 Cells. +target gene hsa-mir-519c Colorectal Carcinoma 26386386 Exploiting a novel miR-519c-HuR-ABCG2 regulatory pathway to overcome chemoresistance in colorectal cancer. +target gene hsa-mir-185 "Carcinoma, Nasopharyngeal" 26390174 "Combined low miR-185-3p and miR-324-3p might be important markers for prediction of low response to RT/CRT and poor overall survival and recurrence-free survival.MiR-185-3p and miR-324-3p can modulate NPC cell growth and apoptosis, at least partly through targeting SMAD7." +target gene hsa-mir-324 "Carcinoma, Nasopharyngeal" 26390174 "Combined low miR-185-3p and miR-324-3p might be important markers for prediction of low response to RT/CRT and poor overall survival and recurrence-free survival.MiR-185-3p and miR-324-3p can modulate NPC cell growth and apoptosis, at least partly through targeting SMAD7." +target gene hsa-mir-10b Breast Neoplasms 26392359 Our work provides evidence for the involvement of specific miRNAs in triple-negative breast cancer development through regulating BRCA1 expression. +target gene hsa-mir-146a Breast Neoplasms 26392359 Our work provides evidence for the involvement of specific miRNAs in triple-negative breast cancer development through regulating BRCA1 expression. +target gene hsa-mir-153 Breast Neoplasms 26392359 Our work provides evidence for the involvement of specific miRNAs in triple-negative breast cancer development through regulating BRCA1 expression. +target gene hsa-mir-26a Breast Neoplasms 26392359 Our work provides evidence for the involvement of specific miRNAs in triple-negative breast cancer development through regulating BRCA1 expression. +target gene hsa-mir-32 Neoplasms [unspecific] 26394836 SETD1A modulates cell cycle progression through a miRNA network that regulates p53 target genes +target gene hsa-mir-590 Neoplasms [unspecific] 26394836 SETD1A modulates cell cycle progression through a miRNA network that regulates p53 target genes +target gene hsa-mir-133b Ovarian Neoplasms 26396496 "MicroRNA-133b may reduce ovarian cancer drug resistance by silencing the expression of the drug-resistance-related proteins, GST-¦Ð and MDR1. In future, the combination of miR-133b with chemotherapy agents may prevent the development of drug resistance in ovarian cancers." +target gene hsa-mir-205 "Carcinoma, Adrenocortical" 26397843 "In conclusion, miR-205 suppresses the growth of ACC SW-13 cells via targeting the anti-apoptotic gene Bcl-2." +target gene hsa-mir-18a Colorectal Carcinoma 26398009 "These findings demonstrate that miR-18a exhibits a protective role in CRC via inhibiting proliferation, invasion and migration of CRC cells by directly targeting the TBPL1 gene." +target gene hsa-mir-125a Gastric Neoplasms 26398444 "Collectively, our results indicated that miR-125a regulated the paracrine of VEGF-A in gastric cancer and thereby controlled the angiogenesis of the tumor." +target gene hsa-mir-222 Alzheimer Disease 26398571 "In conclusion, these results suggest that the abnormal expression of miR-222 may contribute to dysregulation of the cell-cycle in AD, at least in part by affecting the expression of p27Kip1." +target gene hsa-mir-211 "Carcinoma, Hepatocellular" 26398845 miR-211 promotes invasion of carcinoma cells by directly targeting ESR1. +target gene hsa-mir-200c Pancreatic Neoplasms 26400206 "More importantly, garcinol treatment led to the upregulation of several tumor suppressor microRNAs, and miR-200c increased by garcinol treatment was found to target and downregulate Notch1." +target gene hsa-mir-200c Breast Neoplasms 26400441 PDCD10 is a target gene of miR-200c and also a possible mechanism by which miR-200c plays a role in regulating the stemness of BCSCs and MaSCs. +target gene hsa-mir-34c Alzheimer Disease 26402112 MicroRNA-34c Downregulation Ameliorates Amyloid-¦Â-Induced Synaptic Failure and Memory Deficits by Targeting VAMP2. +target gene hsa-mir-140 Colorectal Carcinoma 26402430 Our results suggested a tumor suppressive role of miR-140-5p in CRC tumorigenesis and progression by targeting VEGFA. +target gene hsa-mir-100 Gastric Neoplasms 26404754 This study demonstrated that miR-100 could be induced by C/EBP¦Á and may act as a tumor suppressor gene by inhibiting ZBTB7A. +target gene hsa-mir-584 "Carcinoma, Thyroid" 26405762 "These results indicate that miR-584 could inhibit the expression of ROCK1, and ROCK1 knockdown would further affect the migration ability of K1 cells." +target gene hsa-mir-217 Lung Neoplasms 26415832 "The results indicate that miR-217 regulation of EZH2/H3K27me3 via MALAT1 is involved in CSE-induced EMT and malignant transformation of HBE cells. The posttranscriptional silencing of MALAT1 by miR-217 provides a link, through EZH2,between ncRNAs and the EMT and establishes a mechanism for CSE-induced lung carcinogenesis." +target gene hsa-mir-25 Lung Neoplasms 26416661 Elevated microRNA-25 inhibits cell apoptosis in lung cancer by targeting RGS3. +target gene hsa-mir-21 "Carcinoma, Colon" 26418978 "MiR-21 can mediate the drug resistance to 5-FU by inhibiting its target PDCD4,which can regulate the expression of ABCC5 and CD44 genes." +target gene hsa-mir-96 "Carcinoma, Renal Cell" 26419932 These results suggest that miR-96 suppresses RCC invasion by modulating Ezrin expression. +target gene hsa-mir-21 Colorectal Carcinoma 26419959 Our data support a possible role of tumor epigenetic deregulation by noncoding RNA in suppressing the antitumor T-cell-mediated adaptive immune response and suggest MIR21 as a potential target for immunotherapy and prevention in colorectal cancer. +target gene hsa-mir-222 "Carcinoma, Hepatocellular" 26420065 all the four miRNAs synergistically target PBX3 +target gene hsa-mir-21 Polycystic Ovarian Syndrome 26427146 "In comparison with normal subjects, serum miR-21 is obviously increased in PCOS patients. Through targeting LATS1, miR-21 could prompt PCOS progression and could act as a novel non-invasive biomarker for diagnosis of PCOS." +target gene hsa-mir-135b "Carcinoma, Hepatocellular" 26429530 miR-135b promotes the invasion and metastasis possibly by targeting the Hippo pathway genes. +target gene hsa-mir-133 Roberts Syndrome 26434741 miR-133-dependent cx43 overexpression rescues esco2-dependent growth defects +target gene hsa-mir-130a Chronic Inflammation 26436920 "Therefore,miR-142-5p and miR-130a-3p regulate macrophage profibrogenic gene expression in chronic inflammation." +target gene hsa-mir-142 Chronic Inflammation 26436920 "Therefore,miR-142-5p and miR-130a-3p regulate macrophage profibrogenic gene expression in chronic inflammation." +target gene hsa-mir-92 Breast Neoplasms 26437339 miR-92 is gradually lost in breast epithelial cells during cancer progression correlating with a shift in ER¦Â1 immunoreactivity from nuclei to the cytoplasm. Our data support a functional role in fibroblasts where modification of miR-92 expression can influence the invasive capacity of breast cancer epithelial cells. However in silico analysis suggests that ER¦Â1 may not be the most important miR-92 target in breast cancer. +target gene hsa-mir-137 Astrocytoma 26440052 miR-137 acts as a tumor suppressor in astrocytoma by targeting RASGRF1. +target gene hsa-mir-145 Lung Neoplasms 26440147 "In aggregate, our results attribute to miR-145-5p and its direct targets pivotal roles in malignancy progression and in metastasis." +target gene hsa-mir-133a Heart Failure 26440278 miR-133a acts as a repressor of SRF and CTGF expression +target gene hsa-mir-139 Glioblastoma 26449464 We concluded that ectopic expression of miR-139-5p in GBM cell lines significantly suppressed cell proliferation and inducing apoptosis. Bioinformatics coupled with luciferase and western blot assays also revealed that miR-139-5p suppresses glioma cell proliferation by targeting ELTD1 and regulating cell cycle. +target gene hsa-mir-93 Glioma 26449498 "In conclusion, our results suggest an increasing role of miR-93 in regulating the level of expression of several genes involved in the angiogenesis of gliomas." +target gene hsa-mir-19b "Carcinoma, Hepatocellular" 26453548 "The overexpression of miR-19b was significantly correlated with better disease-free and overall survival in patients with HCC presenting with vascular invasion or multifocal disease after curative surgery. MiR-19b may influence the expression of NDRG1, EPCAM, HMGB2, HIF1A, and MAPK14." +target gene hsa-mir-29c Uterine Leiomyoma 26453978 "MiR-29c expression is suppressed in leiomyoma, resulting in an increase in expression of its targets COL3A1 and DNMT3A. The suppression of miR-29c in LSMC is primarily mediated by SP1, NF-¦ÊB signaling, and epigenetic modification. Collectively, these results indicate a significant role for miR-29c in leiomyoma pathogenesis." +target gene hsa-mir-302b "Carcinoma, Hepatocellular" 26457704 This study showed that miR-302b could enhance the sensitivity to 5-FU in HCC cell lines and verified its two putative targeted genes responsible for its 5-FU sensitivity. +target gene hsa-mir-26a Gastric Neoplasms 26458859 "Our results suggest that miR-26a can improve the sensitivity of GC cells to cisplatin-based chemotherapies through targeting NRAS and E2F2, and provide the first evidence of the potential utility of miR-26a as a sensitizer in chemotherapy for GC." +target gene hsa-let-7a Breast Neoplasms 26460550 "Our research revealed the mechanisms through which miR-208a functioned in breast cancer and BrCSCs, and identified the miR-208a-SOX2/¦Â-catenin-LIN28-let-7a-DICER1 regulatory feedback loop in regulations of stem cells renewal." +target gene hsa-mir-208a Breast Neoplasms 26460550 "Our research revealed the mechanisms through which miR-208a functioned in breast cancer and BrCSCs, and identified the miR-208a-SOX2/¦Â-catenin-LIN28-let-7a-DICER1 regulatory feedback loop in regulations of stem cells renewal." +target gene hsa-mir-101 Gastric Neoplasms 26460960 "We conclude that miR-27b,miR-101 and miR-128 inhibit angiogenesis by down-regulating VEGF-C expression in gastric cancers." +target gene hsa-mir-128 Gastric Neoplasms 26460960 "We conclude that miR-27b,miR-101 and miR-128 inhibit angiogenesis by down-regulating VEGF-C expression in gastric cancers." +target gene hsa-mir-27b Gastric Neoplasms 26460960 "We conclude that miR-27b,miR-101 and miR-128 inhibit angiogenesis by down-regulating VEGF-C expression in gastric cancers." +target gene hsa-mir-221 Cardiovascular Diseases [unspecific] 26461283 "Among differentially-expressed miRNAs are those involved in the regulation of inflammation or cell adhesion, such as miR-221 and miR-181." +target gene hsa-mir-7 "Carcinoma, Lung, Non-Small-Cell" 26464649 This study further extends the biological role of miR-7 in NSCLC A549 and H460 cells and identifies BCL-2 as a novel target possibly involved in miR-7-mediated growth suppression and apoptosis induction of NSCLC cells. +target gene hsa-mir-29 Neoplasms [unspecific] 26470025 MiR-29 restrained K562 cell growth and proliferation. MiR-29 induced K562 cell apoptosis through down-regulating FoxM1. +target gene hsa-mir-182 Ovarian Neoplasms 26472020 "In normal FTSE cells, miR-182 overexpression triggers cellular senescence by p53-mediated upregulation of p21." +target gene hsa-mir-320a "Carcinoma, Cervical" 26472185 CREB1-driven expression of miR-320a promotes mitophagy by down-regulating VDAC1 expression during serum starvation in cervical cancer cells. +target gene hsa-mir-378g Neoplasms [unspecific] 26473472 "MiR-378g enhanced radiosensitivity partially by targeting SHP-1 in NPC cells. Cell invasion was also partially inhibited by miR-378g, but the effect was not mediated by SHP-1." +target gene hsa-mir-30a Neoplasms [unspecific] 26473838 "In summary, we uncovered the protective function of miR30a targeting NFATc3 in the regulation of podocyte injury response to EMT." +target gene hsa-mir-138 Prostate Neoplasms 26474967 "miR-138 specifically targeted K2 and inhibited its expression, thereby regulating a miR-138/K2/β1-integrin signaling axis in mCRPC that is critical for the modulation of sensitivity to chemotherapeutics." +target gene hsa-mir-1 Cardiomegaly 26476318 "Further findings indicated that miR-1, which was depressed by Nkx2.5, might play a fundamental role in mediating cardiac hypertrophy and arrhythmia via its target genes Mef2a and Irx5 after HBCD treatment." +target gene hsa-mir-1271 Ovarian Neoplasms 26477861 Low levels of miR-1271 in ovarian cancer tissues promoted cancer cell growth. MiR-1271 may be a new predictor of prognosis in ovarian cancer.MiR-1271 exerted its role by targeting CCNG1. +target gene hsa-mir-125b Sepsis 26482503 miR-125b modulates PCT expression by manipulating the amount and transcriptional activity of Stat3. +target gene hsa-mir-19a Atherosclerosis 26483345 Endothelial Hypoxia-Inducible Factor-1¦Á Promotes Atherosclerosis and Monocyte Recruitment by Upregulating MicroRNA-19a. +target gene hsa-mir-342 Lung Neoplasms 26483346 miR-342-3p regulates MYC transcriptional activity via direct repression of E2F1 in human lung cancer. +target gene hsa-mir-30 Atherosclerosis 26488467 Upregulation of miR-30 by HFD may impair the protective effects of endothelial cell autophagy against development of atherosclerosis through suppressing protein translation of ATG6. +target gene hsa-mir-146a Osteoarthritis 26492575 "Simply, hypoxia induced HIF-1α, and HIF-1α increased miR-146a, but miR-146a suppressed Bcl-2, an autophagy inhibitor." +target gene hsa-mir-124 Colorectal Carcinoma 26497367 "In conclusion, our data showed that miR-124 and miR-506 inhibit progression and increase sensitivity to chemotherapy by targeting DNMT3B and DNMT1 in CRC. These findings may provide novel avenues for the development of targeted therapies." +target gene hsa-mir-506 Colorectal Carcinoma 26497367 "In conclusion, our data showed that miR-124 and miR-506 inhibit progression and increase sensitivity to chemotherapy by targeting DNMT3B and DNMT1 in CRC. These findings may provide novel avenues for the development of targeted therapies." +target gene hsa-mir-331 "Carcinoma, Hepatocellular" 26497554 "Upregulated in Hepatitis B virus-associated hepatocellular carcinoma cells,miR-331-3p promotes proliferation of hepatocellular carcinoma cells by targeting ING5." +target gene hsa-mir-155 "Lymphoma, B-Cell" 26497687 "miR-155 targeting of DET1, NIAM, TRIM32, HOMEZ, PSIP1 and JARID2." +target gene hsa-mir-139 Lung Neoplasms 26497851 "Taken together, our results demonstrated that miR-139-5p plays a pivotal role in lung cancer through inhibiting cell proliferation, metastasis, and promoting apoptosis by targeting oncogenic c-Met." +target gene hsa-mir-542 Osteosarcoma 26498360 "Taken together, our results indicated that miR-542-5p plays a critical role in the proliferation of osteosarcoma and targets HUWE1." +target gene hsa-mir-652 Pancreatic Neoplasms 26498682 MiR-652 inhibits acidic microenvironment-induced epithelial-mesenchymal transition of pancreatic cancer cells by targeting ZEB1. +target gene hsa-mir-34a Prostate Neoplasms 26499184 "Collectively, miR-34a enhances chemosensitivity by directly downregulating ATG4B-induced autophagy through AMPK/mTOR pathway in PCa." +target gene hsa-mir-616 "Carcinoma, Hepatocellular" 26499912 "Based on these results, we conclude that miR-616 is a promising prognostic biomarker of HCC and targeting miR-616 may be a potential option to prevent the progression of HCC." +target gene hsa-mir-519 "Leukemia, Myeloid, Acute" 26499919 The results of the present study indicate that miR-519 may contribute to HL60 cell apoptosis by regulating the expression of HuR. +target gene hsa-mir-221 Choriocarcinoma 26501139 "In conclusion, our results suggested that miR-221 promotes EMT through targeting PTEN and forms a positive feedback loop with ¦Â-catenin/c-Jun signaling pathway in EHCC." +target gene hsa-mir-19a "Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal" 26502748 "Our preliminary outcomes suggest the utility of miR-19a in the challenging differential diagnosis of laryngeal VSCC. Although miR-19a has been found to regulate SOCS-1 expression, this evidence was not confirmed by this investigation." +target gene hsa-mir-449a Glioma 26502848 "The expression of microRNA-449a is low in patients with glioma,which may inhibit the proliferation of glioma and promote its cell apoptosis via affecting the expression of PKC¦Á." +target gene hsa-mir-221 Breast Neoplasms 26503209 "a pro-apoptotic Bcl-2 family protein, was up-regulated by the knockdown of miR-221." +target gene hsa-mir-154 "Carcinoma, Hepatocellular" 26503460 "In conclusion, these results indicate that miR-154 functions as a tumor suppressor in HCC by suppressing ZEB2,suggesting that miR-154 may serve as a potential target for HCC." +target gene hsa-mir-125b Gastric Neoplasms 26504803 miR-125b Suppresses Proliferation and Invasion by Targeting MCL1 in Gastric Cancer. +target gene hsa-mir-223 Tuberculosis 26505221 "Our data provide new clues for the essential role of miR-223 in the regulation of anti-Mtb-directed immune responses, which relies on the regulation of FOXO3 expression." +target gene hsa-mir-223 Prostate Neoplasms 26509963 Tumor-suppressive microRNA-223 inhibits cancer cell migration and invasion by targeting ITGA3/ITGB1 signaling in prostate cancer. +target gene hsa-mir-7 "Carcinoma, Breast, Triple Negative" 26513016 "Our results not only revealed IL-6 as a key regulator of lapatinib-induced metastasis, but also explored the requirement of miR7/Raf-1/MAPK/AP-1 axis in lapatinib-induced IL-6 expression." +target gene hsa-mir-30a Enterovirus Infection 26515789 "We provided further evidence that by modulating cellular miR-30a level through either overexpression or inhibition, one can inhibit or promote EV71 replication, respectively, through regulating autophagic activity." +target gene hsa-mir-451 Breast Neoplasms 26516138 "Increased miR-451 expression may negatively regulate Bcl-2 mRNA and protein expression, followed by affecting the protein expression of caspase 3,and accelerate the apoptosis in breast cancer, indicating that miR-451 might influence the drug resistances of the Paclitaxel-resistant breast cancer cell line." +target gene hsa-mir-182 Hepatitis C Virus Infection 26518141 "miR-182 was never investigated before, neither in HCV infection nor in NK cells, and we found it to have dysregulated expression in both liver tissues and NK cells of HCV-infected patients compared to control. In addition to that, miR-182 was found to have a contradicting effect in both effector cell and its HCV-infected target cell regarding HCV replication." +target gene hsa-mir-346 "Carcinoma, Cervical" 26518874 miR-346 Up-regulates Argonaute 2 (AGO2) Protein Expression to Augment the Activity of Other MicroRNAs (miRNAs) and Contributes to Cervical Cancer Cell Malignancy. +target gene hsa-mir-27b Atherosclerosis 26520906 The results presented here provide evidence that short-term modulation of miR-27b expression in wild-type mice regulates hepatic LDLR and ABCA1 expression but does not influence plasma and hepatic lipid levels. +target gene hsa-mir-126 Systemic Lupus Erythematosus 26531267 miRNA-126 expression is reduced in SLE patients. miRNA-126 may be involved in the initiation and development of SLE by inhibiting the production of IFN. +target gene hsa-mir-125b Breast Neoplasms 26531722 miR-125a-5p/miR-125b suppress the expression of TSTA3 +target gene hsa-mir-21 Breast Neoplasms 26531758 "In conclusion, our results demonstrated that plasma miR-21 levels may serve as a diagnostic marker in breast cancers, whereas miR-21 promotes breast cancer cell proliferation and invasion by suppressing smad7, which enhances EGF and TGF-¦Â pathways." +target gene hsa-mir-19 Pancreatic Neoplasms 26531836 A positive feedback loop of p53/miR-19/TP53INP1 modulates pancreatic cancer cell proliferation and apoptosis. +target gene hsa-let-7b Prostate Neoplasms 26540468 "Finally, we hypothesized that miR-218, miR-145, miR-197, miR-149, miR-122, and let-7b may contribute to the development of CRPC through the influence of Ras, Rho proteins,and the SCF complex. Further investigation is needed to verify the functions of the identified novel pathways in CRPC development." +target gene hsa-mir-122 Prostate Neoplasms 26540468 "Finally, we hypothesized that miR-218, miR-145, miR-197, miR-149, miR-122, and let-7b may contribute to the development of CRPC through the influence of Ras, Rho proteins,and the SCF complex. Further investigation is needed to verify the functions of the identified novel pathways in CRPC development." +target gene hsa-mir-124 Prostate Neoplasms 26540468 "Finally, we hypothesized that miR-218, miR-145, miR-197, miR-149, miR-122, and let-7b may contribute to the development of CRPC through the influence of Ras, Rho proteins,and the SCF complex. Further investigation is needed to verify the functions of the identified novel pathways in CRPC development." +target gene hsa-mir-125b Prostate Neoplasms 26540468 "Finally, we hypothesized that miR-218, miR-145, miR-197, miR-149, miR-122, and let-7b may contribute to the development of CRPC through the influence of Ras, Rho proteins,and the SCF complex. Further investigation is needed to verify the functions of the identified novel pathways in CRPC development." +target gene hsa-mir-145 Prostate Neoplasms 26540468 "Finally, we hypothesized that miR-218, miR-145, miR-197, miR-149, miR-122, and let-7b may contribute to the development of CRPC through the influence of Ras, Rho proteins,and the SCF complex. Further investigation is needed to verify the functions of the identified novel pathways in CRPC development." +target gene hsa-mir-149 Prostate Neoplasms 26540468 "Finally, we hypothesized that miR-218, miR-145, miR-197, miR-149, miR-122, and let-7b may contribute to the development of CRPC through the influence of Ras, Rho proteins,and the SCF complex. Further investigation is needed to verify the functions of the identified novel pathways in CRPC development." +target gene hsa-mir-197 Prostate Neoplasms 26540468 "Finally, we hypothesized that miR-218, miR-145, miR-197, miR-149, miR-122, and let-7b may contribute to the development of CRPC through the influence of Ras, Rho proteins,and the SCF complex. Further investigation is needed to verify the functions of the identified novel pathways in CRPC development." +target gene hsa-mir-218 Prostate Neoplasms 26540468 "Finally, we hypothesized that miR-218, miR-145, miR-197, miR-149, miR-122, and let-7b may contribute to the development of CRPC through the influence of Ras, Rho proteins,and the SCF complex. Further investigation is needed to verify the functions of the identified novel pathways in CRPC development." +target gene hsa-mir-340 "Squamous Cell Carcinoma, Oral" 26541225 The findings suggest that miR-340 might act as a molecular switch that contributes to the regulation of glycolysis in OSCC by regulating Glut1 expression. +target gene hsa-mir-381 Kidney Neoplasms 26541837 "MiRNA-381 can inhibit cell invasion in renal cancer by block the function of CBP, ¦Â-catenin and LEF-1." +target gene hsa-mir-33a "Carcinoma, Cervical" 26541838 "Twist1 is critical for the invasiveness of cervical cancer cells;miR-33a, as a tumor suppressor gene, functions as an upstream regulator of Twist1 and is involved in the invasiveness of cervical cancer cell." +target gene hsa-mir-506 Liver Neoplasms 26549227 "Thus, we conclude that miR-506 depresses the angiogenesis of liver cancer through targeting 3'UTR of SPHK1 mRNA. Our finding provides new insights into the mechanism of tumor angiogenesis." +target gene hsa-mir-21 Breast Neoplasms 26549725 "Our data suggest that miR-21 expression is increased in breast cancer and plays an important role as a tumor gene by targeting STAT3, which may act as a double-response controller in breast cancer." +target gene hsa-mir-150 Inflammation 26549736 "miR-150 can effectively prevent CD28/B7 co-stimulatory signaling transduction, decrease production of inflammatory cytokines, such as IL-2 and TNF, and elicit the induction of immune tolerance." +target gene hsa-mir-133a Vascular Hypertrophy 26553694 Of 37 direct targets of miR-133a defined in unstressed hearts +target gene hsa-mir-30a Preeclampsia 26555189 MiR-30a attenuates immunosuppressive functions of IL-1¦Â-elicited mesenchymal stem cells via targeting TAB3 +target gene hsa-mir-590 Glioblastoma 26556542 "miR-590-3p suppresses cancer cell migration, invasion and epithelial-mesenchymal transition in glioblastoma multiforme by targeting ZEB1 and ZEB2." +target gene hsa-mir-21 Glioblastoma 26558781 "Further, analysis of the miR-21-Sox2 relationship in mouse neural stem cells and in the mouse brain at different developmental stages indicates that miR-21 and Sox2 are predominantly expressed in mutually exclusive patterns, suggesting a role in normal neural development." +target gene hsa-mir-29b Gastric Neoplasms 26564501 miR-29b can enhance the sensitivity of S gastric cancer cell by directly targeting PI3K/Akt pathway. +target gene hsa-mir-181b Breast Neoplasms 26572075 "In summary, the results of the present study suggest that miR-181b functions as an oncogene during breast cancer development, and the miR-181b/Bim pathway may be a novel target used to overcome the chemoresistance in breast cancer." +target gene hsa-mir-214 Cardiomegaly 26572862 These results provide the first clear link between miRNAs and direct regulation of XBP1 in heart failure and reveal that miR-214 and miR-30* synergistically regulates cardiac VEGF expression and angiogenesis by targeting XBP1 in the progression from adaptive hypertrophy to heart failure. +target gene hsa-mir-214 Heart Failure 26572862 These results provide the first clear link between miRNAs and direct regulation of XBP1 in heart failure and reveal that miR-214 and miR-30* synergistically regulates cardiac VEGF expression and angiogenesis by targeting XBP1 in the progression from adaptive hypertrophy to heart failure. +target gene hsa-mir-30 Cardiomegaly 26572862 These results provide the first clear link between miRNAs and direct regulation of XBP1 in heart failure and reveal that miR-214 and miR-30* synergistically regulates cardiac VEGF expression and angiogenesis by targeting XBP1 in the progression from adaptive hypertrophy to heart failure. +target gene hsa-mir-30 Heart Failure 26572862 These results provide the first clear link between miRNAs and direct regulation of XBP1 in heart failure and reveal that miR-214 and miR-30* synergistically regulates cardiac VEGF expression and angiogenesis by targeting XBP1 in the progression from adaptive hypertrophy to heart failure. +target gene hsa-mir-130a Ovarian Neoplasms 26573160 "NRP1 is targeted by miR-130a and miR-130b, and is associated with multidrug resistance in epithelial ovarian cancer based on integrated gene network analysis." +target gene hsa-mir-130b Ovarian Neoplasms 26573160 "NRP1 is targeted by miR-130a and miR-130b, and is associated with multidrug resistance in epithelial ovarian cancer based on integrated gene network analysis." +target gene hsa-mir-101 Gastric Neoplasms 26573417 "In conclusion, the results of the present study suggested that miR-101 inhibited the proliferation and promoted DDP-induced apoptosis of DDP-resistant gastric cancer cells, at least in part via targeting VEGF-C." +target gene hsa-mir-382 Ovarian Neoplasms 26575700 "these findings revealed that miR-382 inhibits migration and invision by targeting ROR1 through regulating EMT in ovarian cancer, and might serve as a tumor suppressor in ovarian cancer." +target gene hsa-mir-181a "Leukemia, Lymphoblastic, Acute" 26580398 ectopic expression of miR-181a also resulted in decreased CD10 hyperexpression in ETV6/RUNX1+ primary patient samples. +target gene hsa-mir-197 Enterovirus Infection 26581983 Host MicroRNA miR-197 Plays a Negative Regulatory Role in the Enterovirus 71 Infectious Cycle by Targeting the RAN Protein. +target gene hsa-mir-3151 Malignant Neoplasms [unspecific] 26582795 "In conclusion, we identify miR-3151 as a previously unidentified player in MM and PTC pathogenesis, which is driven by BRAF-dependent and BRAF-independent mechanisms. Characterization of TP53 as a downstream effector of miR-3151 provides evidence for a causal link between BRAF mutations and TP53 inactivation." +target gene hsa-mir-661 Glioma 26585488 "These results indicate that miR-661 can inhibit glioma cell proliferation,migration and invasion by targeting hTERT." +target gene hsa-mir-196b "Carcinoma, Lung, Non-Small-Cell" 26586336 homeobox A9 (HOXA9) as a target gene of miR-196b +target gene hsa-mir-205 Neoplasms [unspecific] 26586569 miR-205 is upregulated upon NF-κB activation and suppresses COMMD1 expression in stemness-enriched cancer cells. +target gene hsa-mir-124 Alzheimer Disease 26592243 "our study indicates that miR-124 plays neuroprotective roles in AD Drosophila by targeting Delta in Notch signaling pathway, which helps further our understanding of miRNAs in the molecular pathology of AD." +target gene hsa-mir-762 Breast Neoplasms 26597380 These results demonstrate that miR-762 tumour effect was achieved by targeting IRF7 in human breast cancer specimens. +target gene hsa-mir-211 Melanoma 26599548 Overexpression of mature miR-211 in Bcl-2 overexpressing cells rescued Bcl-2 ability to increase cell migration. +target gene hsa-mir-203 Bladder Neoplasms 26599571 "In conclusion, decreased miR-203 predicts progression and poor prognosis for BC patients treated with cisplatin-based chemotherapy while miR-203 overexpression can enhance cisplatin sensitization by promoting apoptosis via directly targeting Bcl-w and Survivin." +target gene hsa-mir-302c Influenza 26602079 Mir-302c mediates influenza A virus-induced IFN¦Â expression by targeting NF-¦ÊB inducing kinase. +target gene hsa-mir-181c Neoplasms [unspecific] 26607087 Transfection with miR-181 mimics can suppress glycolysis in CAFs by inhibiting HK2 expression. +target gene hsa-mir-4458 "Carcinoma, Colon" 26607110 "In conclusion, our findings suggested that miR-4458 inhibited the progression of colon cancer cells by inhibition of glycolysis and lactate production via directly targeting HK2 mRNA." +target gene hsa-mir-99 Neoplasms [unspecific] 26608597 "We have developed an efficient SVM-based model for miRNA target prediction using recent CLIP-seq data, demonstrating superior performance, evaluated using ROC curves, specifically about 20 % better than the state-of-the-art, for different species (human or mouse), or different target types (canonical or non-canonical). To the best of our knowledge we provide the first distributed framework for microRNA target prediction based on Apache Hadoop and Spark." +target gene hsa-mir-200c Pancreatic Neoplasms 26609108 "Paradoxically, targeting eIF4E, the best-characterized effector of MNKs, increases ZEB1 mRNA expression through repression of ZEB1-targeting miRNAs, miR-200c and miR-141." +target gene hsa-mir-200b Retinal Degeneration 26617758 MiR-200b can regulate RECs growth and proliferation by changing VEGF and TGF¦Â1 expression to delay DR. +target gene hsa-mir-133b Ovarian Neoplasms 26617770 "Altogether, our results indicated that miR-133b overexpression was shown to inhibit proliferation and invasion of OC cells through suppression of the MAPK and PI3K/Akt signaling pathways by targeting EGFR." +target gene hsa-mir-203 Chronic Obstructive Pulmonary Disease 26617776 miR-203 represses NF-¦ÊB signaling via targeting TAK1 and PI3KCA and miR-203 overexpression may contribute to the COPD initiation. +target gene hsa-mir-631 Prostate Neoplasms 26620225 "In all, our study demonstrates that miR-631 decreases PCa cell migration and invasion by dampening ZAP70 expression." +target gene hsa-mir-181b "Carcinoma, Lung, Non-Small-Cell" 26620926 "Consequently, miR-181b functions as a tumor suppressor and has an important role in proliferation, chemosensitivity to DDP and metastasis of NSCLC by targeting TGF¦ÂR1/Smad signaling pathway." +target gene hsa-mir-181b Acute Lung Injury 26622531 he overexpression of miR-181b resulted in the induction of an increment in interleukin (IL)-6 levels. +target gene hsa-mir-143 "Squamous Cell Carcinoma, Oral" 26625772 "Low levels of miR-380-5p and miR-504 that directly target the 3'UTR of TP53 suggest that p53 may not be repressed by these two miRNAs in OSCC. On the other hand, low levels of miR-34a or miR-143 may relieve MDM4 and SIRT1 or MDM2 respectively, which will sequester p53 indicating an indirect mode of p53 suppression in oral tumors." +target gene hsa-mir-34a "Squamous Cell Carcinoma, Oral" 26625772 "Low levels of miR-380-5p and miR-504 that directly target the 3'UTR of TP53 suggest that p53 may not be repressed by these two miRNAs in OSCC. On the other hand, low levels of miR-34a or miR-143 may relieve MDM4 and SIRT1 or MDM2 respectively, which will sequester p53 indicating an indirect mode of p53 suppression in oral tumors." +target gene hsa-mir-151a Asthenozoospermia 26626315 These results indicate that miR-151a-5p may participate in the regulation of cellular respiration and ATP production through targeting Cytb. +target gene hsa-mir-186 Ovarian Neoplasms 26626440 Our results are the first to demonstrate that miR-186 may sensitize ovarian cancer cell to paclitaxel and cisplatin by targeting ABCB1 and modulating the expression of GST-¦Ð. +target gene hsa-mir-96 "Squamous Cell Carcinoma, Tongue" 26629033 MiR-96 is confirmed to be a direct target of MTSS1 gene and could regulate MTSS1 mediated Tca8113 cells proliferation and metastasis. +target gene hsa-mir-16 Cervical Neoplasms 26629104 CCNE1 gene is targeted by miR-16-1 in CC cells. +target gene hsa-mir-212 Post-Traumatic Stress Disorder 26632874 "DICER1 is an enzyme that generates mature microRNAs (miRNAs), which regulate gene expression post-transcriptionally in brain and other tissues and is involved in synaptic maturation and plasticity. Here, through genome-wide differential gene expression survey of post-traumatic stress disorder (PTSD) with comorbid depression (PTSD&Dep), we find that blood DICER1 expression is significantly reduced in cases versus controls, and replicate this in two independent cohorts. " +target gene hsa-mir-3130 Post-Traumatic Stress Disorder 26632874 "DICER1 is an enzyme that generates mature microRNAs (miRNAs), which regulate gene expression post-transcriptionally in brain and other tissues and is involved in synaptic maturation and plasticity. Here, through genome-wide differential gene expression survey of post-traumatic stress disorder (PTSD) with comorbid depression (PTSD&Dep), we find that blood DICER1 expression is significantly reduced in cases versus controls, and replicate this in two independent cohorts. " +target gene hsa-mir-153 Neuroblastoma 26633009 A Proteomics Approach to Investigate miR-153-3p and miR-205-5p Targets in Neuroblastoma Cells. +target gene hsa-mir-205 Neuroblastoma 26633009 A Proteomics Approach to Investigate miR-153-3p and miR-205-5p Targets in Neuroblastoma Cells. +target gene hsa-mir-150 Prostate Neoplasms 26636522 Increased miR-150 expression might participate in the development and progression of human prostate CSC by suppressing p27. This supported our previous study which found miR-150 was positively correlated with prostate tumor recurrence or metastasis. +target gene hsa-mir-375 Lung Neoplasms 26642205 "Thus, our study demonstrates the differential expression profiles of miR-375 in 3 subtypes of lung carcinomas and finds thatmiR-375 directly targets ITPKB and promoted cell growth in SCLC cell line." +target gene hsa-mir-512 "Carcinoma, Lung, Non-Small-Cell" 26648284 "In conclusion, our present study revealed miR-512-5p was able to target p21 to induce apoptosis and inhibit glycolysis in A549 and H1299 cell lines." +target gene hsa-mir-1908 Renal Fibrosis 26648305 miR-1908 could inhibit renal fibrosis through targeting TGF-¦Â1. +target gene hsa-mir-200b Glioma 26648487 MicroRNA-200b inhibits the growth and metastasis of glioma cells via targeting ZEB2. +target gene hsa-mir-1290 "Squamous Cell Carcinoma, Esophageal" 26653554 "Taken together, our findings suggested that miR-1290 functions as a tumor oncogene in the progression of ESCC by targeting NFIX." +target gene hsa-mir-30b Osteoarthritis 26653555 "In conclusion, miR-30b was involved in the process of OA, and it probably functioned through its target gene ERG." +target gene hsa-mir-130b Glioma 26653558 "In conclusion, miR-130b is an independent prognostic biomarker for indicating survival of glioma patients and promotes glioma cell migration and invasion by targeting PPAR¦Ã." +target gene hsa-mir-193a Lung Neoplasms 26655272 "Overall, we concluded that UCA1 functions as an oncogene in NSCLC, acting mechanistically by upregulating ERBB4 in part through 'spongeing' miR-193a-3p." +target gene hsa-mir-127 Neoplasms [unspecific] 26655997 "Restoration of miR-127-3p and miR-376a-3p counteracts the neoplastic phenotype of giant cell tumor of bone derived stromal cells by targeting COA1, GLE1 and PDIA6." +target gene hsa-mir-376a Neoplasms [unspecific] 26655997 "Restoration of miR-127-3p and miR-376a-3p counteracts the neoplastic phenotype of giant cell tumor of bone derived stromal cells by targeting COA1, GLE1 and PDIA6." +target gene hsa-mir-142 "Carcinoma, Breast" 26657485 "microRNA miR-142-3p Inhibits Breast Cancer Cell Invasiveness by Synchronous Targeting of WASL, Integrin Alpha V, and Additional Cytoskeletal Elements. HrC-9698" +target gene hsa-mir-31 Lung Neoplasms 26657862 Our study distinguishes miR-31 as a driver of lung tumorigenesis that promotes mutant KRAS-mediated oncogenesis and reveals that miR-31 directly targets and reduces expression of negative regulators of RAS/MAPK signaling. +target gene hsa-mir-31 Neoplasms [unspecific] 26663584 "We identified VAV3, a regulator of actin remodeling and MRTF-A activity, as a miR-31 target." +target gene hsa-mir-34a Lung Neoplasms 26667302 "Therefore, we propose that AXL is autoregulated by miR-34a in a feedback loop; this may provide a novel opportunity for developing AXL-targeted anticancer therapies." +target gene hsa-mir-29 "Squamous Cell Carcinoma, Lung" 26676674 Elucidation of the novel lung SCC molecular pathways and targets regulated by tumor-suppressive miR-29s will provide new insights into the potential mechanisms of oncogenesis and metastasis of the disease. +target gene hsa-mir-203 Glioma 26678661 "These data demonstrate that miR-203 potentially controls DNA damage repair via the PI3K/AKT and JAK/STAT3 pathways and may collectively contribute to the modulation of radiation sensitivity in MG cells by inhibiting DNA damage repair, prosurvival signaling, and epithelium-mesenchyme transition. Taken together, these findings demonstrate that miR-203 could be a target for overcoming the radiation resistance of GBM." +target gene hsa-mir-26b Osteosarcoma 26681033 "miR- 26b may inhibit osteosarcoma cell proliferation, migration, and invasion by regulating PFKFB3 protein expression.miR-26b may have a tumor suppressor role in tumor occurrence and development." +target gene hsa-mir-145 Glioblastoma 26681767 ISO attenuated SOX2 expression by specific induction of miR-145 +target gene hsa-mir-494 Neoplasms [unspecific] 26686085 the regulatory effect of p100 on PTEN expression is mediated by its downregulation of miR-494 as a result of the inactivation of extracellular signal-regulated kinase 2 +target gene hsa-mir-15a Neoplasms [unspecific] 26686086 In vivo inhibition of a PPARγ-regulated miR-15a/angiopoietin-1 pathway blocked increased angiogenesis and MSC expansion. +target gene hsa-mir-27a Neoplasms [unspecific] 26687066 "Importantly, we find that Six1 expression leads to marked resistance to therapies targeting the p53-MDM2 interaction. Thus, we identify a competitive mechanism of p53 regulation, which may have consequences for drugs aimed at reinstating p53 function in tumours." +target gene hsa-mir-21 Multiple Myeloma 26687742 "STAT3 and hsa-miR-125b, PIAS3 and hsa-miR-21 respectively formed self adaptation feedback regulations." +target gene hsa-mir-155 Asthma 26693910 MicroRNA Expression Is Altered in an Ovalbumin-Induced Asthma Model and Targeting miR-155 with Antagomirs Reveals Cellular Specificity. +target gene hsa-mir-155 "Squamous Cell Carcinoma, Head and Neck" 26694378 MicroRNA-Target Network Inference and Local Network Enrichment Analysis Identify Two microRNA Clusters with Distinct Functions in Head and Neck Squamous Cell Carcinoma. +target gene hsa-mir-106a "Squamous Cell Carcinoma, Head and Neck" 26694379 MicroRNA-Target Network Inference and Local Network Enrichment Analysis Identify Two microRNA Clusters with Distinct Functions in Head and Neck Squamous Cell Carcinoma. +target gene hsa-mir-125b "Squamous Cell Carcinoma, Head and Neck" 26694379 MicroRNA-Target Network Inference and Local Network Enrichment Analysis Identify Two microRNA Clusters with Distinct Functions in Head and Neck Squamous Cell Carcinoma. +target gene hsa-mir-15b "Squamous Cell Carcinoma, Head and Neck" 26694379 MicroRNA-Target Network Inference and Local Network Enrichment Analysis Identify Two microRNA Clusters with Distinct Functions in Head and Neck Squamous Cell Carcinoma. +target gene hsa-mir-193b "Squamous Cell Carcinoma, Head and Neck" 26694379 MicroRNA-Target Network Inference and Local Network Enrichment Analysis Identify Two microRNA Clusters with Distinct Functions in Head and Neck Squamous Cell Carcinoma. +target gene hsa-mir-20b "Squamous Cell Carcinoma, Head and Neck" 26694379 MicroRNA-Target Network Inference and Local Network Enrichment Analysis Identify Two microRNA Clusters with Distinct Functions in Head and Neck Squamous Cell Carcinoma. +target gene hsa-mir-548b "Squamous Cell Carcinoma, Head and Neck" 26694379 MicroRNA-Target Network Inference and Local Network Enrichment Analysis Identify Two microRNA Clusters with Distinct Functions in Head and Neck Squamous Cell Carcinoma. +target gene hsa-mir-582 "Squamous Cell Carcinoma, Head and Neck" 26694379 MicroRNA-Target Network Inference and Local Network Enrichment Analysis Identify Two microRNA Clusters with Distinct Functions in Head and Neck Squamous Cell Carcinoma. +target gene hsa-mir-9-1 "Squamous Cell Carcinoma, Head and Neck" 26694379 MicroRNA-Target Network Inference and Local Network Enrichment Analysis Identify Two microRNA Clusters with Distinct Functions in Head and Neck Squamous Cell Carcinoma. +target gene hsa-mir-9-2 "Squamous Cell Carcinoma, Head and Neck" 26694379 MicroRNA-Target Network Inference and Local Network Enrichment Analysis Identify Two microRNA Clusters with Distinct Functions in Head and Neck Squamous Cell Carcinoma. +target gene hsa-mir-27b Diabetic Retinopathy 26696637 "The authors assessed 155 baseline or DR progressors and 145 control samples (selected from 3,326 study participants) for a panel of 29 candidate miRNAs that were based on previous studies related to diabetes and myocardial infarction. They identified miR-27b and miR-320a as being significantly and independently associated with high DR risk. Complementing this analysis, they also elucidated the potential mechanism using cultured human endothelial cells and identified antiangiogenic thrombospondin-1 as a common target of these two miRNAs." +target gene hsa-mir-320a Diabetic Retinopathy 26696637 "The authors assessed 155 baseline or DR progressors and 145 control samples (selected from 3,326 study participants) for a panel of 29 candidate miRNAs that were based on previous studies related to diabetes and myocardial infarction. They identified miR-27b and miR-320a as being significantly and independently associated with high DR risk. Complementing this analysis, they also elucidated the potential mechanism using cultured human endothelial cells and identified antiangiogenic thrombospondin-1 as a common target of these two miRNAs." +target gene hsa-mir-155 "Carcinoma, Nasopharyngeal" 26698246 This study found that aberrant miR-155 expression driven by LMP1 can modulate radio-sensitivity of the NPC cell at least partly through targeting UBQLN1. +target gene hsa-mir-705 Osteoporosis 26700816 "Mechanistically, TNF-¦Á activated NF-¦ÊB pathway to promote microRNA-705 expression, which function as a repressor of FoxO1 through post-transcriptional regulation." +target gene hsa-mir-21 Glioma 26701969 "These findings suggest that miR-21 is linked to glioma angiogenesis,that miR-21 is unlikely to regulate PTEN, and that miR-21-positive tumor cells do not possess stem cell characteristics." +target gene hsa-mir-218 Iron Metabolism Disease 26703568 "Taken together, our results show that miR-218 inhibits erythroid differentiation and alters iron metabolism by targeting ALAS2 in K562 cells." +target gene hsa-mir-125b "Carcinoma, Hepatocellular" 26704017 miR-125b has been reported to down-regulate SIRT7 by binding to its 3'UTR +target gene hsa-mir-1275 Lymphoma 26705180 "MiR-664b-5p, miR-1275, miR-4739, miR-4736 and miR-504-5p may become an important indicator in the differentiation ALK-negative anaplastic large cell lymphoma from CD30-positive peripheral T cell lymphoma (not otherwise specified).MiR-4739, miR-4736 and miR-1275 may play important role in pathogenesis of negative-anaplastic large cell lymphoma by target genes: TNFRSF8 and TMOD1." +target gene hsa-mir-4736 Lymphoma 26705180 "MiR-664b-5p, miR-1275, miR-4739, miR-4736 and miR-504-5p may become an important indicator in the differentiation ALK-negative anaplastic large cell lymphoma from CD30-positive peripheral T cell lymphoma (not otherwise specified).MiR-4739, miR-4736 and miR-1275 may play important role in pathogenesis of negative-anaplastic large cell lymphoma by target genes: TNFRSF8 and TMOD1." +target gene hsa-mir-4739 Lymphoma 26705180 "MiR-664b-5p, miR-1275, miR-4739, miR-4736 and miR-504-5p may become an important indicator in the differentiation ALK-negative anaplastic large cell lymphoma from CD30-positive peripheral T cell lymphoma (not otherwise specified).MiR-4739, miR-4736 and miR-1275 may play important role in pathogenesis of negative-anaplastic large cell lymphoma by target genes: TNFRSF8 and TMOD1." +target gene hsa-mir-504 Lymphoma 26705180 "MiR-664b-5p, miR-1275, miR-4739, miR-4736 and miR-504-5p may become an important indicator in the differentiation ALK-negative anaplastic large cell lymphoma from CD30-positive peripheral T cell lymphoma (not otherwise specified).MiR-4739, miR-4736 and miR-1275 may play important role in pathogenesis of negative-anaplastic large cell lymphoma by target genes: TNFRSF8 and TMOD1." +target gene hsa-mir-664b Lymphoma 26705180 "MiR-664b-5p, miR-1275, miR-4739, miR-4736 and miR-504-5p may become an important indicator in the differentiation ALK-negative anaplastic large cell lymphoma from CD30-positive peripheral T cell lymphoma (not otherwise specified).MiR-4739, miR-4736 and miR-1275 may play important role in pathogenesis of negative-anaplastic large cell lymphoma by target genes: TNFRSF8 and TMOD1." +target gene hsa-mir-106b Liver Transplant Rejection 26707312 "These results suggest that miR-18b, miR-340, and miR-106b, which regulate the expression of specific immunophenotypes, can be used as potential biomarkers to identify long-term stable liver transplant recipients from recipients with acute rejection." +target gene hsa-mir-18b Liver Transplant Rejection 26707312 "These results suggest that miR-18b, miR-340, and miR-106b, which regulate the expression of specific immunophenotypes, can be used as potential biomarkers to identify long-term stable liver transplant recipients from recipients with acute rejection." +target gene hsa-mir-340 Liver Transplant Rejection 26707312 "These results suggest that miR-18b, miR-340, and miR-106b, which regulate the expression of specific immunophenotypes, can be used as potential biomarkers to identify long-term stable liver transplant recipients from recipients with acute rejection." +target gene hsa-mir-205 Osteosarcoma 26708425 "In conclusion, our study suggested that miR-205 may function as a tumor suppressor via targeting TGF-¦Á in OS, and the abnormal expression of miR-205 might be a key factor in OS progression." +target gene hsa-mir-363 Gastric Neoplasms 26709677 MiR-363-3p showed low levels in GC tissues and cells. Enforced expression of miR-363-3p inhibited cell growth and migration of GC cells and vice versa. NOTCH1 is the targeted gene of miR-363-3p. CONCLUSIONS MiR-363-3p plays a tumor suppressor role in GC. +target gene hsa-mir-135b "Carcinoma, Breast, Triple Negative" 26711213 "The expressions of miRNA-135b were higher in most triple-negative breast cancer cell lines than others. miRNA-135b could promote the proliferation,invasion and migration in triple-negative breast cancer cell lines MDA-MB-231 and MDA-MB-468, and APC was one of the target genes of miRNA- 135b by participating in the process of regulation." +target gene hsa-mir-199a Ovarian Neoplasms 26711828 "miR-199a regulates the sensitivity of ovarian cancer cells to cisplatin through modulating expression of mTOR, and involves in the cisplatin resistance process of ovarian cancer cells." +target gene hsa-mir-125a Leukemia 26713860 miR-125a suppressed Zbtb7a expression through its direct binding to the Zbtb7a-3'UTR. +target gene hsa-mir-125a Neoplasms [unspecific] 26713860 miR-125a suppressed Zbtb7a expression through its direct binding to the Zbtb7a-3'UTR. +target gene hsa-mir-150 "Carcinoma, Cervical" 26715362 "Taken together, our data demonstrated that elevated miR-150 targets FOXO4 expression and therefore regulates multiple genes expression, resulting in cervical cancer cell growth and survival." +target gene hsa-mir-663 Glioblastoma 26717894 "MicroRNA-663 inhibits the proliferation, migration and invasion of glioblastoma cells via targeting TGF-¦Â1." +target gene hsa-mir-92a Intracranial Aneurysm 26718427 "In conclusion, our research demonstrated that miR-92a and KLF2 were negative correlation in intracranial aneurysm model, and miR-92a could directly target KLF2 in endothelial cells through complementary sequence of 3'UTR region." +target gene hsa-mir-331 Colorectal Carcinoma 26718987 "Overall, we identified that miR-331-3p is underexpressed in CRC and contributes to cell growth regulation by targeting HER2 through activating the PI3K/Akt and ERK1/2 signaling pathways." +target gene hsa-mir-129 Breast Neoplasms 26720492 The miR-129-5p/HMGB1 axis can regulate irradiation-induced autophagy in breast cancer and might be an important pathway in regulating radiosensitivity of breast cancer cells. +target gene hsa-mir-194 "Carcinoma, Hepatocellular" 26722431 MicroRNA-194 acts as a prognostic marker and inhibits proliferation in hepatocellular carcinoma by targeting MAP4K4. +target gene hsa-mir-592 "Carcinoma, Hepatocellular" 26722432 MicroRNA-592 targets DEK oncogene and suppresses cell growth in the hepatocellular carcinoma cell line HepG2. +target gene hsa-mir-214 Glioma 26722446 "In summary, our data indicate that miR-214 may function as tumor suppressor in glioma by targeting PCBP2." +target gene hsa-mir-34c "Carcinoma, Hepatocellular" 26722462 "miR-34c-3p inhibits cell proliferation, migration and invasion of hepatocellular carcinoma by targeting MARCKS." +target gene hsa-mir-204 "Carcinoma, Esophageal" 26722467 miR-204 inhibits invasion and epithelial-mesenchymal transition by targeting FOXM1 in esophageal cancer. +target gene hsa-mir-140 Lung Neoplasms 26722475 "MicroRNA-140-3p inhibits proliferation, migration and invasion of lung cancer cells by targeting ATP6AP2." +target gene hsa-mir-365 Osteosarcoma 26728377 miR-365 could inhibit the proliferation and promote the apoptosis in SOSP-9607 osteosarcoma cells probably by mediating the expression of KRAS. +target gene hsa-let-7b Retinoblastoma 26730174 "Several critical miRNAs were identified in RB progression.Hsa-miR-373 might regulate RB invasion and metastasis, hsa-miR-181a might involve in the CDKN1B-mediated cell cycle pathway, and hsa-miR-125b and hsa-let-7b might serve as tumor suppressors by coregulating CDK6, CDC25A, and LIN28A. The miRNAs hsa-miR-25, hsa-miR-18a, and hsa-miR-20a might exert their function by coregulating BCL2L1." +target gene hsa-mir-125b Retinoblastoma 26730174 "Several critical miRNAs were identified in RB progression.Hsa-miR-373 might regulate RB invasion and metastasis, hsa-miR-181a might involve in the CDKN1B-mediated cell cycle pathway, and hsa-miR-125b and hsa-let-7b might serve as tumor suppressors by coregulating CDK6, CDC25A, and LIN28A. The miRNAs hsa-miR-25, hsa-miR-18a, and hsa-miR-20a might exert their function by coregulating BCL2L1." +target gene hsa-mir-18a Retinoblastoma 26730174 "Several critical miRNAs were identified in RB progression.Hsa-miR-373 might regulate RB invasion and metastasis, hsa-miR-181a might involve in the CDKN1B-mediated cell cycle pathway, and hsa-miR-125b and hsa-let-7b might serve as tumor suppressors by coregulating CDK6, CDC25A, and LIN28A. The miRNAs hsa-miR-25, hsa-miR-18a, and hsa-miR-20a might exert their function by coregulating BCL2L1." +target gene hsa-mir-20a Retinoblastoma 26730174 "Several critical miRNAs were identified in RB progression.Hsa-miR-373 might regulate RB invasion and metastasis, hsa-miR-181a might involve in the CDKN1B-mediated cell cycle pathway, and hsa-miR-125b and hsa-let-7b might serve as tumor suppressors by coregulating CDK6, CDC25A, and LIN28A. The miRNAs hsa-miR-25, hsa-miR-18a, and hsa-miR-20a might exert their function by coregulating BCL2L1." +target gene hsa-mir-25 Retinoblastoma 26730174 "Several critical miRNAs were identified in RB progression.Hsa-miR-373 might regulate RB invasion and metastasis, hsa-miR-181a might involve in the CDKN1B-mediated cell cycle pathway, and hsa-miR-125b and hsa-let-7b might serve as tumor suppressors by coregulating CDK6, CDC25A, and LIN28A. The miRNAs hsa-miR-25, hsa-miR-18a, and hsa-miR-20a might exert their function by coregulating BCL2L1." +target gene hsa-mir-373 Retinoblastoma 26730174 "Several critical miRNAs were identified in RB progression.Hsa-miR-373 might regulate RB invasion and metastasis, hsa-miR-181a might involve in the CDKN1B-mediated cell cycle pathway, and hsa-miR-125b and hsa-let-7b might serve as tumor suppressors by coregulating CDK6, CDC25A, and LIN28A. The miRNAs hsa-miR-25, hsa-miR-18a, and hsa-miR-20a might exert their function by coregulating BCL2L1." +target gene hsa-mir-31 "Carcinoma, Thyroid, Papillary" 26731986 Down regulation of miR-31 contributed to the malignant progression of papillary thyroid carcinoma cells by targeting HuR. +target gene hsa-mir-935 "Carcinoma, Gastric, Signet Ring Cell" 26742429 miR-935 suppresses gastric signet ring cell carcinoma tumorigenesis by targeting Notch1 expression. +target gene hsa-mir-193a "Carcinoma, Esophageal" 26743123 miR-193a-3p regulation of chemoradiation resistance in oesophageal cancer cells via the PSEN1 gene. +target gene hsa-mir-320 Inflammatory Bowel Diseases 26752466 Exogenous miR-320 transfection in HT29 cells leads to a significant decrease of NOD2 expression +target gene hsa-mir-19 Gastric Neoplasms 26762410 "MEF2D is a direct target of miR-19, which was found to be decreased in gastric cancer clinical specimens." +target gene hsa-mir-4480 Macular Degeneration 26765636 Functional single nucleotide polymorphism in IL-17A 3' untranslated region is targeted by miR-4480 in vitro and may be associated with age-related macular degeneration. +target gene hsa-mir-215 Glioma 26766590 MiR-215 Is Induced Post-transcriptionally via HIF-Drosha Complex and Mediates Glioma-Initiating Cell Adaptation to Hypoxia by Targeting KDM1B. +target gene hsa-mir-328 "Carcinoma, Esophageal" 26773497 MiR-328 suppresses the survival of esophageal cancer cells by targeting PLCE1. +target gene hsa-mir-367 "Squamous Cell Carcinoma, Esophageal" 26777997 MiR-367 is a potential biomarker for ESCC and may act as an oncogene in regulating ESCC development. +target gene hsa-mir-155 Ovarian Neoplasms 26779627 miR-155 mediates cisplatin-induced apoptosis by targeting XIAP in ovarian cancer +target gene hsa-mir-205 "Aortic Aneurysm, Abdominal" 26781079 a significant downregulation of LRP1 protein expression was shown in miR-205-overexpressing VSMCs +target gene hsa-mir-96 Cardiomegaly 26782545 miR-96 inhibits cardiac hypertrophy by targeting growth factor receptor-bound 2. +target gene hsa-mir-141 "Carcinoma, Hepatocellular" 26790956 MiR-141 suppression may cause aberrant expression of SPAG9 and promote HCC tumorigenesis via JNK pathway. +target gene hsa-mir-148a Lupus Nephritis 26791485 miR-148a-3p overexpression contributes to glomerular cell proliferation by targeting PTEN in lupus nephritis. +target gene hsa-mir-200a "Carcinoma, Renal Cell" 26797273 MicroRNA-200a-3p suppresses tumor proliferation and induces apoptosis by targeting SPAG9 in renal cell carcinoma. +target gene hsa-mir-31 Glioma 26801671 the suppressive effect of miR-31 on glioma cell migration and invasion is p21-dependent +target gene hsa-mir-29a "Carcinoma, Breast" 26802653 "inhibitors of microRNA-29a promote apoptosis through upregulation of HSP60 level and downregulation of HSP27, HSP40, HSP70, and HSP90 levels" +target gene hsa-mir-142 Neoplasms [unspecific] 26805039 Our observations suggest that miR-142-3p functioned as a tumor suppressor by targeting CDC25C. +target gene hsa-mir-625 Breast Neoplasms 26806308 miR-625 suppresses cell proliferation and migration by targeting HMGA1 in breast cancer. +target gene hsa-mir-143 "Squamous Cell Carcinoma, Esophageal" 26806810 MiR-143 inhibits tumor cell proliferation and invasion by targeting STAT3 in esophageal squamous cell carcinoma. +target gene hsa-mir-34c Prostate Neoplasms 26808578 Functional analysis revealed that miR-34c and miR-297 overexpression down-regulated AR expression and inhibited the expression of downstream AR targets +target gene hsa-mir-21 Colorectal Carcinoma 26811607 "MicroRNA-21 increases the levels of IL-10 and prostaglandin E2, which suppress antitumor T-cell-mediated adaptive immunity" +target gene hsa-mir-133a Dengue Virus Infection 26818704 miRNA-133a regulates DENV replication possibly through the modulation of a host factor such as PTB. Further investigations are needed to verify whether miRNA-133a has an anti-DENV effect in vivo. +target gene hsa-mir-33a Japanese Encephalitis Virus Infection 26819305 MicroRNA-33a-5p Modulates Japanese Encephalitis Virus Replication by Targeting Eukaryotic Translation Elongation Factor 1A1. +target gene hsa-mir-519 Gastric Neoplasms 26819420 MiR-may inhibit the gastric cancer cell activity through suppression of HuR expression. +target gene hsa-mir-187 Colorectal Carcinoma 26820227 "MicroRNA-187, a downstream effector of TGF¦Â pathway, suppresses Smad-mediated epithelial-mesenchymal transition in colorectal cancer." +target gene hsa-mir-142 Fever 26825461 "RBM3 regulates temperature sensitive miR-142-5p and miR-143 (thermomiRs), which target immune genes and control fever." +target gene hsa-mir-143 Fever 26825461 "RBM3 regulates temperature sensitive miR-142-5p and miR-143 (thermomiRs), which target immune genes and control fever." +target gene hsa-mir-26b "Carcinoma, Lung, Non-Small-Cell" 26827826 MicroRNA-26b suppresses the metastasis of non-small cell lung cancer by targeting MIEN1 via NF-¦ÊB/MMP-9/VEGF pathways. +target gene hsa-mir-489 Breast Neoplasms 26828271 GSE1 negative regulation by miR-489-5p promotes breast cancer cell proliferation and invasion. +target gene hsa-mir-20a Breast Neoplasms 26829385 MiR-20a and miR-20b negatively regulate autophagy by targeting RB1CC1/FIP200 in breast cancer cells. +target gene hsa-mir-20b Breast Neoplasms 26829385 MiR-20a and miR-20b negatively regulate autophagy by targeting RB1CC1/FIP200 in breast cancer cells. +target gene hsa-mir-205 Neoplasms [unspecific] 26831618 "This alteration inverts relative expression levels of ZEB1 and its antagonizing microRNAs, miR-205 and miR-200c" +target gene hsa-mir-7 "Carcinoma, Hepatocellular" 26831666 miR-7 suppressed the expression of VDAC1 +target gene hsa-mir-505 "Carcinoma, Endometrial" 26832151 "Taken together, this study demonstrates that miR-505 acts as tumor suppressor in EC by regulating TGF-¦Á." +target gene hsa-mir-103 Atherosclerosis 26837267 Endothelial Dicer promotes atherosclerosis and vascular inflammation by miRNA-103-mediated suppression of KLF4. +target gene hsa-mir-497 Colorectal Carcinoma 26840372 Thus our results provide evidence that miR-497 might function as a metastasis suppressor in CRC. Targeting miR-497 may provide a strategy for blocking its metastasis. +target gene hsa-mir-302a Breast Neoplasms 26842910 Our results indicate that miR-302 cooperatively sensitizes breast cancer cells to adriamycin via suppressing P-glycoprotein by targeting MEKK1 of ERK pathway. miR-302 gene cluster may be a potential target for reversing P-gp-mediated chemoresistance in breast cancer. +target gene hsa-mir-302b Breast Neoplasms 26842910 Our results indicate that miR-302 cooperatively sensitizes breast cancer cells to adriamycin via suppressing P-glycoprotein by targeting MEKK1 of ERK pathway. miR-302 gene cluster may be a potential target for reversing P-gp-mediated chemoresistance in breast cancer. +target gene hsa-mir-302c Breast Neoplasms 26842910 Our results indicate that miR-302 cooperatively sensitizes breast cancer cells to adriamycin via suppressing P-glycoprotein by targeting MEKK1 of ERK pathway. miR-302 gene cluster may be a potential target for reversing P-gp-mediated chemoresistance in breast cancer. +target gene hsa-mir-302d Breast Neoplasms 26842910 Our results indicate that miR-302 cooperatively sensitizes breast cancer cells to adriamycin via suppressing P-glycoprotein by targeting MEKK1 of ERK pathway. miR-302 gene cluster may be a potential target for reversing P-gp-mediated chemoresistance in breast cancer. +target gene hsa-mir-26b "Carcinoma, Hepatocellular" 26843134 MicroRNA-26b Enhances the Radiosensitivity of Hepatocellular Carcinoma Cells by Targeting EphA2. +target gene hsa-let-7 Myocardial Ischemic-Reperfusion Injury 26844226 "After Myocardial Ischemia-Reperfusion, miR-29a, and Let7 Could Affect Apoptosis through Regulating IGF-1." +target gene hsa-mir-15a Myasthenia Gravis 26845678 MiR-15a contributes abnormal immune response in myasthenia gravis by targeting CXCL10. +target gene hsa-mir-182 "Adenocarcinoma, Endometrial" 26847831 miR-182 expression is epigenetically increased leading to decreased CUL5 expression and increased cellular proliferation. +target gene hsa-mir-34a Colon Neoplasms 26849305 miR-34a directly suppresses Numb in early-stage colon cancer stem cells (CCSCs) +target gene hsa-mir-873 Ovarian Neoplasms 26850595 overexpression of miR-873 increased the sensitivity of ovarian cancer cells to cisplatin and paclitaxel by targeting MDR1 expression. +target gene hsa-mir-320a Ischemia-Reperfusion Injury 26850728 intrathecal infusion of miR-320a mimic attenuated IR-induced lower limb motor function deficits +target gene hsa-mir-1 "Carcinoma, Nasopharyngeal" 26852690 "miR-1, regulated by LMP1, suppresses tumour growth and metastasis by targeting K-ras in nasopharyngeal carcinoma." +target gene hsa-mir-504 Glioma 26854715 "A tumor-suppressive microRNA, miR-504, inhibits cell proliferation and promotes apoptosis by targeting FOXP1 in human glioma." +target gene hsa-mir-26a Osteoarthritis 26854724 MicroRNA-26a-5p regulates the expression of inducible nitric oxide synthase via activation of NF-¦ÊB pathway in human osteoarthritis chondrocytes. +target gene hsa-mir-133b Glioblastoma 26857280 "several miRNAs (miR-133b, miR-30b-3p, miR-145-5p, and miR-146a-5p) targeting EGFR" +target gene hsa-mir-145 Glioblastoma 26857280 "several miRNAs (miR-133b, miR-30b-3p, miR-145-5p, and miR-146a-5p) targeting EGFR" +target gene hsa-mir-146a Glioblastoma 26857280 "several miRNAs (miR-133b, miR-30b-3p, miR-145-5p, and miR-146a-5p) targeting EGFR" +target gene hsa-mir-193b Glioblastoma 26857280 "microRNAs (miRNAs) (miR-193b-3p, miR-518b, miR-520f-3p, and miR-506-5p) targeting PDGFRB were downregulated" +target gene hsa-mir-30b Glioblastoma 26857280 "miRNAs (miR-133b, miR-30b-3p, miR-145-5p, and miR-146a-5p) targeting EGFR" +target gene hsa-mir-506 Glioblastoma 26857280 "microRNAs (miRNAs) (miR-193b-3p, miR-518b, miR-520f-3p, and miR-506-5p) targeting PDGFRB were downregulated" +target gene hsa-mir-518b Glioblastoma 26857280 "microRNAs (miRNAs) (miR-193b-3p, miR-518b, miR-520f-3p, and miR-506-5p) targeting PDGFRB were downregulated" +target gene hsa-mir-520f Glioblastoma 26857280 "microRNAs (miRNAs) (miR-193b-3p, miR-518b, miR-520f-3p, and miR-506-5p) targeting PDGFRB were downregulated" +target gene hsa-mir-17 Diabetes Mellitus 26858253 "In fact, miR-17 knockdown was able to mimic the IFNγ effects on TXNIP, whereas miR-17 overexpression blunted the cytokine effect." +target gene hsa-mir-146 "Carcinoma, Renal Cell" 26859141 "We identified novel target genes of dysregulated miRNAs, which are involved in the transition from primary RCC without metastases into tumors generating distant metastasis." +target gene hsa-mir-208a Myocardial Infarction 26861724 miR-208a can promote Ang II-induced cardiomyocyte apoptosis via negatively regulating NLK expression +target gene hsa-mir-92a "Carcinoma, Rectal" 26865277 Integrated genomic profiling identifies microRNA-92a regulation of IQGAP2 in locally advanced rectal cancer. +target gene hsa-mir-124 Viral Infectious Disease 26865716 "Our data show that microRNA targeting can be used to further increase the safety of an attenuated mengovirus, providing a basis for its development as an oncolytic platform." +target gene hsa-mir-125 Viral Infectious Disease 26865716 "Our data show that microRNA targeting can be used to further increase the safety of an attenuated mengovirus, providing a basis for its development as an oncolytic platform." +target gene hsa-mir-133 Viral Infectious Disease 26865716 "Our data show that microRNA targeting can be used to further increase the safety of an attenuated mengovirus, providing a basis for its development as an oncolytic platform." +target gene hsa-mir-142 Viral Infectious Disease 26865716 "Our data show that microRNA targeting can be used to further increase the safety of an attenuated mengovirus, providing a basis for its development as an oncolytic platform." +target gene hsa-mir-208 Viral Infectious Disease 26865716 "Our data show that microRNA targeting can be used to further increase the safety of an attenuated mengovirus, providing a basis for its development as an oncolytic platform." +target gene hsa-mir-499 Oral Neoplasms 26867589 This study describes the regulation of PDCD4 specifically in tonsil SCC by miR-499 and miR-21 and has documented the loss of PDCD4 in tonsil SCCs.These findings highlight the complex interplay between miRNAs and tumour suppressor gene regulation and suggest that PDCD4 loss may be an important step in tonsillar carcinogenesis. +target gene hsa-mir-486 Ovarian Neoplasms 26871282 "OLFM4 is downregulated by miR-486-5p, which contributes to ovarian cancer tumorigenesis." +target gene hsa-mir-23b Ovarian Neoplasms 26872615 Our findings show that miR-23b may inhibit ovarian cancer tumorigenesis and progression by downregulating CCNG1 and the expression of the relevant genes. MiR-23b is a potentially novel application for regulating ovarian carcinoma progression. +target gene hsa-mir-130b Colorectal Carcinoma 26873488 colorectal cancer +target gene hsa-mir-206 Breast Neoplasms 26879016 significantly negative correlation between miR-206 and Cx43 expression +target gene hsa-mir-503 Nephrotic Syndrome 26882816 "In this study, we determined that serum miR-503 was significantly decreased in NS children. MiR-503 contributes to the aberrant proliferation of RMCs by targeting cyclin E, which may represent potential diagnostic and prognostic biomarkers for idiopathic pediatric NS." +target gene hsa-mir-195 "Squamous Cell Carcinoma, Tongue" 26885901 Relationships between microRNA expressions and prognosis in patients with tongue squamous cell carcinoma and the mechanisms microRNA regulating tongue squamous cell carcinoma biological behavior. +target gene hsa-mir-26a "Squamous Cell Carcinoma, Tongue" 26885901 Relationships between microRNA expressions and prognosis in patients with tongue squamous cell carcinoma and the mechanisms microRNA regulating tongue squamous cell carcinoma biological behavior. +target gene hsa-mir-29b "Squamous Cell Carcinoma, Tongue" 26885901 Relationships between microRNA expressions and prognosis in patients with tongue squamous cell carcinoma and the mechanisms microRNA regulating tongue squamous cell carcinoma biological behavior. +target gene hsa-mir-34a "Squamous Cell Carcinoma, Tongue" 26885901 Relationships between microRNA expressions and prognosis in patients with tongue squamous cell carcinoma and the mechanisms microRNA regulating tongue squamous cell carcinoma biological behavior. +target gene hsa-mir-375 "Squamous Cell Carcinoma, Tongue" 26885901 Relationships between microRNA expressions and prognosis in patients with tongue squamous cell carcinoma and the mechanisms microRNA regulating tongue squamous cell carcinoma biological behavior. +target gene hsa-mir-199a Atrial Fibrillation 26888839 "miRNAs regulate the occurrence and development of AF. RFA can change the expression of miRNAs in AF patients, which may be important for reversing the electrical and structural remodeling and maintaining sinus rhythm after RFA.miRNAs, such as miR-30b-5p, miR-377-5p and miR-199a-3p/miR-199b-3p etc., might become the target markers for early diagnosis and intervention of AF in future." +target gene hsa-mir-199b Atrial Fibrillation 26888839 "miRNAs regulate the occurrence and development of AF. RFA can change the expression of miRNAs in AF patients, which may be important for reversing the electrical and structural remodeling and maintaining sinus rhythm after RFA.miRNAs, such as miR-30b-5p, miR-377-5p and miR-199a-3p/miR-199b-3p etc., might become the target markers for early diagnosis and intervention of AF in future." +target gene hsa-mir-30b Atrial Fibrillation 26888839 "miRNAs regulate the occurrence and development of AF. RFA can change the expression of miRNAs in AF patients, which may be important for reversing the electrical and structural remodeling and maintaining sinus rhythm after RFA.miRNAs, such as miR-30b-5p, miR-377-5p and miR-199a-3p/miR-199b-3p etc., might become the target markers for early diagnosis and intervention of AF in future." +target gene hsa-mir-377 Atrial Fibrillation 26888839 "miRNAs regulate the occurrence and development of AF. RFA can change the expression of miRNAs in AF patients, which may be important for reversing the electrical and structural remodeling and maintaining sinus rhythm after RFA.miRNAs, such as miR-30b-5p, miR-377-5p and miR-199a-3p/miR-199b-3p etc., might become the target markers for early diagnosis and intervention of AF in future." +target gene hsa-mir-122 Sepsis 26889043 These findings demonstrate that host cellular RNA and specific miRNAs are released into the circulation during polymicrobial sepsis and may function as extracellular mediators capable of promoting cfB production and AP activation through specific TLR7 and MyD88 signaling. +target gene hsa-mir-145 Sepsis 26889043 These findings demonstrate that host cellular RNA and specific miRNAs are released into the circulation during polymicrobial sepsis and may function as extracellular mediators capable of promoting cfB production and AP activation through specific TLR7 and MyD88 signaling. +target gene hsa-mir-146a Sepsis 26889043 These findings demonstrate that host cellular RNA and specific miRNAs are released into the circulation during polymicrobial sepsis and may function as extracellular mediators capable of promoting cfB production and AP activation through specific TLR7 and MyD88 signaling. +target gene hsa-mir-210 Sepsis 26889043 These findings demonstrate that host cellular RNA and specific miRNAs are released into the circulation during polymicrobial sepsis and may function as extracellular mediators capable of promoting cfB production and AP activation through specific TLR7 and MyD88 signaling. +target gene hsa-mir-34a Sepsis 26889043 These findings demonstrate that host cellular RNA and specific miRNAs are released into the circulation during polymicrobial sepsis and may function as extracellular mediators capable of promoting cfB production and AP activation through specific TLR7 and MyD88 signaling. +target gene hsa-mir-96 "Carcinoma, Lung, Non-Small-Cell" 26893673 "overexpression of miR-96 in NSCLC cells markedly decreased SAMD9 expression and cisplatin-induced apoptosis, and increased the cisplatin IC50" +target gene hsa-mir-451a Breast Neoplasms 26896688 "Over-expression of miR-451a can enhance the sensitivity of breast cancer cells to tamoxifen by regulating 14-3-3¦Æ, estrogen receptor ¦Á, and autophagy." +target gene hsa-mir-9 Diabetic Cardiomyopathies 26898797 Inhibition of miR-9 upregulates ELAVL1 expression and activates caspase-1. +target gene hsa-mir-34a Breast Neoplasms 26902416 LDHA was a direct target of miR-34a +target gene hsa-mir-27a Colorectal Carcinoma 26913609 miR-27a modulates a group of proteins involved in MHC class I cell surface exposure +target gene hsa-mir-193a Osteosarcoma 26913720 "MiR-193a-3p and miR-193a-5p suppress the metastasis of human osteosarcoma cells by down-regulating Rab27B and SRR, respectively." +target gene hsa-mir-21 Granular Corneal Dystrophy 26915797 "TGF-¦Â regulates TGFBIp expression in corneal fibroblasts via miR-21, miR-181a,and Smad signaling." +target gene hsa-mir-30a Breast Neoplasms 26918943 we linked miR-30a to increased expression of claudins +target gene hsa-mir-26b Prostate Neoplasms 26920049 MiR-26b inhibits autophagy by targeting ULK2 in prostate cancer cells. +target gene hsa-mir-137 Schizophrenia 26925706 MicroRNA-137 (miR-137) is a brain-enriched RNA with a critical role in regulating brain development and in mediating synaptic plasticity. +target gene hsa-mir-101 Breast Neoplasms 26927545 miR-101 inhibits the proliferation and migration of breast cancer cells via downregulating the expression of DNA methyltransferase 3a. +target gene hsa-mir-1227 Diabetic Nephropathy 26930277 "In conclusion, urinary exosomal miRNA content is altered in type II diabetic patients with DN. Deregulated miR-320c, which might have an impact on the TGF-¦Â-signaling pathway via targeting thrombospondin 1 (TSP-1) shows promise as a novel candidate marker for disease progression in type II DN that should be evaluated in future studies." +target gene hsa-mir-1234 Diabetic Nephropathy 26930277 "In conclusion, urinary exosomal miRNA content is altered in type II diabetic patients with DN. Deregulated miR-320c, which might have an impact on the TGF-¦Â-signaling pathway via targeting thrombospondin 1 (TSP-1) shows promise as a novel candidate marker for disease progression in type II DN that should be evaluated in future studies." +target gene hsa-mir-1915 Diabetic Nephropathy 26930277 "In conclusion, urinary exosomal miRNA content is altered in type II diabetic patients with DN. Deregulated miR-320c, which might have an impact on the TGF-¦Â-signaling pathway via targeting thrombospondin 1 (TSP-1) shows promise as a novel candidate marker for disease progression in type II DN that should be evaluated in future studies." +target gene hsa-mir-2861 Diabetic Nephropathy 26930277 "In conclusion, urinary exosomal miRNA content is altered in type II diabetic patients with DN. Deregulated miR-320c, which might have an impact on the TGF-¦Â-signaling pathway via targeting thrombospondin 1 (TSP-1) shows promise as a novel candidate marker for disease progression in type II DN that should be evaluated in future studies." +target gene hsa-mir-30d Diabetic Nephropathy 26930277 "In conclusion, urinary exosomal miRNA content is altered in type II diabetic patients with DN. Deregulated miR-320c, which might have an impact on the TGF-¦Â-signaling pathway via targeting thrombospondin 1 (TSP-1) shows promise as a novel candidate marker for disease progression in type II DN that should be evaluated in future studies." +target gene hsa-mir-30e Diabetic Nephropathy 26930277 "In conclusion, urinary exosomal miRNA content is altered in type II diabetic patients with DN. Deregulated miR-320c, which might have an impact on the TGF-¦Â-signaling pathway via targeting thrombospondin 1 (TSP-1) shows promise as a novel candidate marker for disease progression in type II DN that should be evaluated in future studies." +target gene hsa-mir-320c Diabetic Nephropathy 26930277 "In conclusion, urinary exosomal miRNA content is altered in type II diabetic patients with DN. Deregulated miR-320c, which might have an impact on the TGF-¦Â-signaling pathway via targeting thrombospondin 1 (TSP-1) shows promise as a novel candidate marker for disease progression in type II DN that should be evaluated in future studies." +target gene hsa-mir-371b Diabetic Nephropathy 26930277 "In conclusion, urinary exosomal miRNA content is altered in type II diabetic patients with DN. Deregulated miR-320c, which might have an impact on the TGF-¦Â-signaling pathway via targeting thrombospondin 1 (TSP-1) shows promise as a novel candidate marker for disease progression in type II DN that should be evaluated in future studies." +target gene hsa-mir-4270 Diabetic Nephropathy 26930277 "In conclusion, urinary exosomal miRNA content is altered in type II diabetic patients with DN. Deregulated miR-320c, which might have an impact on the TGF-¦Â-signaling pathway via targeting thrombospondin 1 (TSP-1) shows promise as a novel candidate marker for disease progression in type II DN that should be evaluated in future studies." +target gene hsa-mir-4739 Diabetic Nephropathy 26930277 "In conclusion, urinary exosomal miRNA content is altered in type II diabetic patients with DN. Deregulated miR-320c, which might have an impact on the TGF-¦Â-signaling pathway via targeting thrombospondin 1 (TSP-1) shows promise as a novel candidate marker for disease progression in type II DN that should be evaluated in future studies." +target gene hsa-mir-4778 Diabetic Nephropathy 26930277 "In conclusion, urinary exosomal miRNA content is altered in type II diabetic patients with DN. Deregulated miR-320c, which might have an impact on the TGF-¦Â-signaling pathway via targeting thrombospondin 1 (TSP-1) shows promise as a novel candidate marker for disease progression in type II DN that should be evaluated in future studies." +target gene hsa-mir-572 Diabetic Nephropathy 26930277 "In conclusion, urinary exosomal miRNA content is altered in type II diabetic patients with DN. Deregulated miR-320c, which might have an impact on the TGF-¦Â-signaling pathway via targeting thrombospondin 1 (TSP-1) shows promise as a novel candidate marker for disease progression in type II DN that should be evaluated in future studies." +target gene hsa-mir-6068 Diabetic Nephropathy 26930277 "In conclusion, urinary exosomal miRNA content is altered in type II diabetic patients with DN. Deregulated miR-320c, which might have an impact on the TGF-¦Â-signaling pathway via targeting thrombospondin 1 (TSP-1) shows promise as a novel candidate marker for disease progression in type II DN that should be evaluated in future studies." +target gene hsa-mir-6126 Diabetic Nephropathy 26930277 "In conclusion, urinary exosomal miRNA content is altered in type II diabetic patients with DN. Deregulated miR-320c, which might have an impact on the TGF-¦Â-signaling pathway via targeting thrombospondin 1 (TSP-1) shows promise as a novel candidate marker for disease progression in type II DN that should be evaluated in future studies." +target gene hsa-mir-6133 Diabetic Nephropathy 26930277 "In conclusion, urinary exosomal miRNA content is altered in type II diabetic patients with DN. Deregulated miR-320c, which might have an impact on the TGF-¦Â-signaling pathway via targeting thrombospondin 1 (TSP-1) shows promise as a novel candidate marker for disease progression in type II DN that should be evaluated in future studies." +target gene hsa-mir-638 Diabetic Nephropathy 26930277 "In conclusion, urinary exosomal miRNA content is altered in type II diabetic patients with DN. Deregulated miR-320c, which might have an impact on the TGF-¦Â-signaling pathway via targeting thrombospondin 1 (TSP-1) shows promise as a novel candidate marker for disease progression in type II DN that should be evaluated in future studies." +target gene hsa-mir-200b Cervical Neoplasms 26935796 miRâ€?00b was shown to inhibit the function of RhoE and suppress the EMT of cervical cancer +target gene hsa-mir-16 Atherosclerosis 26936421 miRâ€?6 is a direct negative regulator of PDCD4 in atherosclerosis. +target gene hsa-mir-19b Japanese Encephalitis Virus Infection 26937036 MicroRNA-19b-3p Modulates Japanese Encephalitis Virus-Mediated Inflammation via Targeting RNF11. +target gene hsa-mir-34a Complex Regional Pain Syndrome 26940669 We show that hsa-miR-34a is a negative regulator of CRHR1; overexpression of hsa-miR-34a in Jurkat cells resulted in reduction of CRH-mediated POMC expression. +target gene hsa-mir-1271 Pancreatic Neoplasms 26940738 "miR-1271 inhibits migration, invasion and epithelial-mesenchymal transition by targeting ZEB1 and TWIST1 in pancreatic cancer cells." +target gene hsa-mir-34a Sickle Cell Anemia 26940952 "miR-34a promoted cell differentiation supported by increased expression of KLF1, glycophorin A, and the erythropoietin receptor." +target gene hsa-mir-200c "Carcinoma, Renal Cell, Clear-Cell" 26941587 "miRNA-200c that could regulate COL5A2 and COL5A3, miRNA-15a that could regulate ATP6V0B and miRNA-155 may play key roles in ccRCC progression." +target gene hsa-mir-126 Leishmaniasis 26941729 Development of Th2 type specific immune response can be suppressed by binding of miR-135 and miR-126 miRNAs over the 3'-UTR region of GATA-3 transcription factor of Th2 specific CD4(+) T helper cells. +target gene hsa-mir-21 Oral Submucous Fibrosis 26943153 PDGF-BB Enhances the Proliferation of Cells in Human Orbital Fibroblasts by Suppressing PDCD4 Expression Via Up-Regulation of microRNA-21. +target gene hsa-mir-379 "Carcinoma, Hepatocellular" 26944318 MicroRNA-379-5p inhibits tumor invasion and metastasis by targeting FAK/AKT signaling in hepatocellular carcinoma. +target gene hsa-mir-133b Liver Neoplasms 26945106 miR-133b regulation of CTGF is a novel mechanism critical for the proliferation and migration of HCC cells and OC response. +target gene hsa-mir-33a Alcoholic Hepatitis 26945479 The relative expression of miR-33a and miR-144 correlated inversely with ABCA1 but not with ABCG1 protein levels. +target gene hsa-let-7c "Carcinoma, Lung, Non-Small-Cell" 26945572 "Also, let-7c directly targeted the 3'-untranslated regions of JMJD1A and EZH2." +target gene hsa-mir-183 "Adenocarcinoma, Lung" 26951513 overexpression of miR-183 in CSLCs decreased PTPN4 protein levels while inhibition of miR-183 increased PTPN4 protein levels. +target gene hsa-mir-183 Choriocarcinoma 26951513 overexpression of miR-183 in CSLCs decreased PTPN4 protein levels while inhibition of miR-183 increased PTPN4 protein levels. +target gene hsa-mir-130b Lung Fibrosis 26953888 miR-130b-3p Modulates Epithelial-Mesenchymal Crosstalk in Lung Fibrosis by Targeting IGF-1. +target gene hsa-mir-3162 Asthma 26959414 MiR-3162-3p Is a Novel MicroRNA That Exacerbates Asthma by Regulating ¦Â-Catenin. +target gene hsa-mir-30 Pancreatic Neoplasms 26965588 high expression of the miR-30 family modulated by CD133 promotes migratory and invasive abilities in CD133(+) pancreatic cancer cells. +target gene hsa-mir-30e "Carcinoma, Hepatocellular" 26966067 MiR-30e suppresses proliferation of hepatoma cells via targeting prolyl 4-hydroxylase subunit alpha-1 (P4HA1) mRNA. +target gene hsa-mir-125b Neoplasms [unspecific] 26966351 miR-125b acts as a tumor suppressor in chondrosarcoma cells by the sensitization to doxorubicin through direct targeting the ErbB2-regulated glucose metabolism. +target gene hsa-mir-138 "Leukemia, Myeloid, Chronic" 26967056 miR-138 in BCR-ABL tyrosine kinase +target gene hsa-mir-17 "Leukemia, Myeloid, Chronic" 26967056 "and miR-17, miR-19a, miR-17-92 cluster with MAPK/ERK proteins." +target gene hsa-mir-181a "Leukemia, Myeloid, Chronic" 26967056 "miR-155, miR-181a with SOS proteins;" +target gene hsa-mir-19a "Leukemia, Myeloid, Chronic" 26967056 "miR-155, miR-19a, with KRAS proteins; miR-19a with RAF1 protein;" +target gene hsa-mir-21 Endomyocardial Fibrosis 26968995 miR-21 specific degradation of Smad7 may decrease the inhibitory feedback regulation of TGF-β1/Smad signaling +target gene hsa-mir-198 Osteosarcoma 26970302 MicroRNA-198 inhibited tumorous behaviors of human osteosarcoma through directly targeting ROCK1. +target gene hsa-mir-31 Sepsis 26978146 Down-regulation of MicroRNA-31 in CD4+ T Cells Contributes to Immunosuppression in Human Sepsis by Promoting TH2 Skewing. +target gene hsa-mir-203 Gastric Neoplasms 26980572 MicroRNA-203 suppresses gastric cancer growth by targeting PIBF1/Akt signaling. +target gene hsa-mir-26a "Carcinoma, Renal Cell" 26983694 "two genes promoting metastasis, LOXL2 and PLOD2, were epigenetically regulated by tumor-suppressive microRNAs, miR-26a and miR-26b" +target gene hsa-mir-124 Alzheimer Disease 26984601 The activation of EPAC-Rap1 pathway was involved in the inhibition of miR-124 in hippocampus under hypoxia or Aβ insult. +target gene hsa-mir-122 Liver Neoplasms 26987776 Differential TGF¦Â pathway targeting by miR-122 in humans and mice affects liver cancer metastasis. +target gene hsa-mir-203 Essential Thrombocythemia 26990535 miR-203 and miR-221 regulate SOCS1 and SOCS3 in essential thrombocythemia. +target gene hsa-mir-221 Essential Thrombocythemia 26990535 miR-203 and miR-221 regulate SOCS1 and SOCS3 in essential thrombocythemia. +target gene hsa-let-7a Hirschsprung Disease 26991540 Our study demonstrates that the miR-24-1*/let-7a*-ARP2/3 complex-RAC isoforms pathway may represent a novel pathogenic mechanism for HSCR. +target gene hsa-mir-24 Hirschsprung Disease 26991540 Our study demonstrates that the miR-24-1*/let-7a*-ARP2/3 complex-RAC isoforms pathway may represent a novel pathogenic mechanism for HSCR. +target gene hsa-mir-145 Atherosclerosis 26992033 miR-145 modulates the phenotypic switch of VSMCs from a contractile to a proliferative state via KLF5 and MYOCD in atherosclerosis. +target gene hsa-mir-409 Osteosarcoma 26992637 MicroRNA-409-3p inhibits osteosarcoma cell migration and invasion by targeting catenin-¦Ä1. +target gene hsa-mir-16 Breast Neoplasms 26993770 miR-16 sensitizes breast cancer cells to Taxol through the suppression of IKBKB expression +target gene hsa-mir-200a Pterygium 26995143 Up-regulated miR-200a levels were positively correlated with and p53 protein expression +target gene hsa-mir-138 Cerebral Ischemia 26998035 The expression of Lcn-2 was inhibited by miR-138 mimics and enhanced by miR-138 inhibitors +target gene hsa-mir-27a "Leukemia, Myeloid, Acute" 27013583 "Overexpression of miR-424&27a, by targeting the 3'UTR of PLAG1, enhanced TRAIL sensitivity in AML cells." +target gene hsa-mir-26b Psoriasis 27015452 Psoriasis Skin Inflammation-Induced microRNA-26b Targets NCEH1 in Underlying Subcutaneous Adipose Tissue. +target gene hsa-mir-138 Osteosarcoma 27019355 MiR-138 Acts as a Tumor Suppressor by Targeting EZH2 and Enhances Cisplatin-Induced Apoptosis in Osteosarcoma Cells. +target gene hsa-mir-495 Prostate Neoplasms 27031291 MicroRNA-495 Regulates Migration and Invasion in Prostate Cancer Cells Via Targeting Akt and mTOR Signaling. +target gene hsa-mir-181a Breast Neoplasms 27033456 "miR-181a, already demonstrated to inhibit ABCG2 translation, was down-regulated by GNT, explaining translational induction." +target gene hsa-mir-140 "Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal" 27033573 miR-140-5p affects the migration and invasion of hypopharyngeal carcinoma cells by downregulating ADAM10 expression. +target gene hsa-mir-720 "Carcinoma, Breast, Triple Negative" 27039296 miR-720 is a downstream target of an ADAM8-induced ERK signaling cascade that promotes the migratory and invasive phenotype of triple-negative breast cancer cells. +target gene hsa-mir-130a Cervical Neoplasms 27040383 miR-130a accelerates cervical cancer cell proliferation by targeting the phosphatase and tensin homolog on chromosome 10 (PTEN) +target gene hsa-mir-192 Neoplasms [unspecific] 27041221 A miR-192-EGR1-HOXB9 regulatory network controls the angiogenic switch in cancer. +target gene hsa-mir-143 Atopic Dermatitis 27048505 "The forced expression of microRNA-143 mimic blocked the IL-13-induced downregulation of filaggrin, loricrin, and involucrin in epidermal keratinocytes." +target gene hsa-mir-491 "Carcinoma, Hepatocellular" 27053618 "miR-491 inhibits the proliferation, invasion and migration of hepatocellular carcinoma cell via down-regulating TPX2 expression." +target gene hsa-mir-181b Osteosarcoma 27063156 microRNA-181b promotes migration and invasion of osteosarcoma cells by targeting N-myc downstream regulated gene 2. +target gene hsa-mir-155 Breast Neoplasms 27065318 miR-155 potently suppresses ErbB2 in breast cancer cells. +target gene hsa-mir-221 "Carcinoma, Thyroid, Papillary" 27077469 miR-221 exacerbated PTC by downregulating the expression of TIMP3. +target gene hsa-mir-192 Choriocarcinoma 27079614 microRNA-192 suppresses the expression of FXR and FXR target genes in vitro and in vivo. +target gene hsa-mir-143 Glioblastoma 27081712 "miRâ€?43 inhibited the proliferation, migration and invasion of the glioblastoma cells." +target gene hsa-mir-205 Gastric Neoplasms 27082508 "transfection with miRâ€?05, the epithelial marker CDH1 (E‑cadherin) was upregulated, and the mesenchymal markers CDH2 (N‑cadherin) and vimentin were suppressed." +target gene hsa-mir-30c Malignant Neoplasms [unspecific] 27085140 "miR-30c-1-3p altered basal and induced expression of cytochrome P450 3A4 (CYP3A4), a prototypical target gene of PXR." +target gene hsa-mir-4701 "Leukemia, Myeloid, Chronic" 27088512 miR-4701-5p directly targeted ST3GAL1 to reduce CML cells resistance to multiple chemotherapeutics in vitro and to convert tumor cells from adriamycin resistant to susceptible in vivo of mice. +target gene hsa-mir-124 Astrocytoma 27088547 "We showed that the repression of PIM1 in astrocytoma cancer cells by miR-124-3p suppressed proliferation, invasion, and aerobic glycolysis and promoted apoptosis." +target gene hsa-mir-3188 "Carcinoma, Nasopharyngeal" 27095304 miR-3188 regulates nasopharyngeal carcinoma proliferation and chemosensitivity through a FOXO1-modulated positive feedback loop with mTOR-p-PI3K/AKT-c-JUN. +target gene hsa-mir-144 Thyroid Neoplasms 27099512 "Transcription factor zinc finger E-box-binding homeobox 1 (ZEB1), as one of the key inducers of epithelial-mesenchymal transition, has been reported to be regulated by microRNA-144 and Bcl-2-associated athanogene 3" +target gene hsa-mir-206 Breast Neoplasms 27100732 Tbx3 is directly repressed by miR-206 +target gene hsa-mir-181b Breast Neoplasms 27102539 miR-181b-3p promotes epithelial-mesenchymal transition in breast cancer cells through Snail stabilization by directly targeting YWHAG. +target gene hsa-mir-155 Gastric Neoplasms 27113301 Target research on tumor biology characteristics of mir-155-5p regulation on gastric cancer cell. +target gene hsa-mir-200a Diabetes Mellitus 27121251 "Transfection with an miR-200a inhibitor increased Rheb protein levels and enhanced the feedback action on insulin receptor substrate-dependent insulin signaling, whereas transfection with an miR-200a mimic produced the opposite effects." +target gene hsa-mir-29b Thyroid Neoplasms 27125250 Functional assays confirmed PATZ1 as a target of miR-29b +target gene hsa-mir-126 Diabetes Mellitus 27127202 low miR-126 levels to be associated with markedly increased TF protein and TF-mediated thrombogenicity. +target gene hsa-mir-200a "Carcinoma, Gastric" 27144885 "Depleting endogenous Bart9 of SNU-719 induced a surged expression of miR-200a and miR-141, accompanied by decreased proliferative and invasive ability." +target gene hsa-mir-204 Pulmonary Hypertension 27149112 miR-204 diminution promotes RUNX2 up-regulation +target gene hsa-mir-183 Breast Neoplasms 27155522 "among MTUS1 targeting miRNAs, miR-183-5p was identified to be overexpressed in breast cancer and down-regulated in fibroadenoma tissues." +target gene hsa-mir-138 Breast Neoplasms 27155849 Only 8 APOBEC3B targeting miRNAs were observed to regulate the fusion transcript of which miR-34b-3p and miR-138-5p were found to be frequently downregulated in cancers suggesting miRNA-mediated deregulation of APOBEC3A expression in cancer patients harbouring this particular deletion polymorphism. +target gene hsa-mir-34b Breast Neoplasms 27155849 Only 8 APOBEC3B targeting miRNAs were observed to regulate the fusion transcript of which miR-34b-3p and miR-138-5p were found to be frequently downregulated in cancers suggesting miRNA-mediated deregulation of APOBEC3A expression in cancer patients harbouring this particular deletion polymorphism. +target gene hsa-mir-146a Infection [unspecific] 27156837 The in?vitro study suggested that transfected mmu-miR-146a-5p inhibitor upregulated TNF-¦Á and its target gene Traf6 in microglia following stimulation with A. cantonensis larval antigen. +target gene hsa-mir-135b Myxoid Liposarcoma 27157622 "Decreased THBS2 expression by miR-135b increases the total amount of matrix metalloproteinase 2 (MMP2) and influences cellular density and an extracellular matrix structure, thereby resulting in morphological change in tumor." +target gene hsa-mir-7 Parkinson Disease 27158385 The altered molecular expressions downstream of Bax and Sirt2 are also involved in miR-7 regulation of the MPP(+)-triggered neuronal apoptosis. +target gene hsa-mir-21 "Carcinoma, Basal Cell" 27159391 "Moreover, our results identify a miR21/GRHL3/D3 axis that reduces TH in the tumor microenvironment and has potential to be targeted as a therapeutic approach to BCC." +target gene hsa-mir-29 "Carcinoma, Hepatocellular" 27164857 "SETDB1 is a target of miR-29, which is frequently downregulated in human HCCs." +target gene hsa-mir-146a Breast Neoplasms 27175941 invasion activity in MDA-MB-231 breast cancer cells could be directly influenced by altering miR-146a expression. +target gene hsa-mir-195 Preeclampsia 27176145 miR-195 could directly target and suppress the expression of ActRIIB +target gene hsa-mir-143 Cervical Neoplasms 27177038 upregulation of miRâ€?43 expression reduced Bclâ€? expression and increased Bax expression in HeLa cells. +target gene hsa-mir-577 "Fatty Liver, Non-Alcoholic" 27179781 "NS5ATP6 regulated the expression of miR-577, which directly targeted and regulated FGF21." +target gene hsa-mir-105 Heart Failure 27185878 "miR-155 and miR-105, were found to modulate ANP production in human cardiomyocytes" +target gene hsa-mir-105 Hypertension 27185878 "miR-155 and miR-105, were found to modulate ANP production in human cardiomyocytes" +target gene hsa-mir-155 Heart Failure 27185878 "miR-155 and miR-105, were found to modulate ANP production in human cardiomyocytes" +target gene hsa-mir-155 Hypertension 27185878 "miR-155 and miR-105, were found to modulate ANP production in human cardiomyocytes" +target gene hsa-mir-425 Heart Failure 27185878 microRNA 425 (miR-425) was found to regulate ANP production +target gene hsa-mir-425 Hypertension 27185878 microRNA 425 (miR-425) was found to regulate ANP production +target gene hsa-mir-296 Ovarian Neoplasms 27186401 deregulated miR-296/S100A4 promotes tumor progression +target gene hsa-mir-23a "Leukemia, Myeloid, Acute" 27197200 overexpression of miR-23a decreased RKIP mRNA and protein expression +target gene hsa-mir-186 Myocardial Infarction 27205869 MicroRNA-186 promotes macrophage lipid accumulation and pro-inflammatory cytokine secretion by targeting cystathionine γ-lyase in THP-1 macrophages. +target gene hsa-mir-1 Heart Failure 27213338 miR-1 repressed the expression of gap junction protein α1 (GJA1) in VMC +target gene hsa-mir-19b Heart Failure 27213338 "a miR-19b inhibitor increased, while its mimics suppressed the expression of GJA1 in HL-1 cells." +target gene hsa-mir-31 "Adenocarcinoma, Lung" 27215092 MiR-31 Functions as a Tumor Suppressor in Lung Adenocarcinoma Mainly by Targeting HuR. +target gene hsa-mir-4271 Parkinson Disease 27217159 "hsa-miR-4271 was downregulated, which could influence EFNA3 translation" +target gene hsa-mir-21 Cervical Neoplasms 27220494 "MiR-21 overexpression decreases PTEN, increases p-Akt, and subsequently increases HIF-1α expression" +target gene hsa-mir-194 Breast Neoplasms 27221739 These findings demonstrate that nucleolin expression is down-regulated by miR-194 and miR-206 and upregulated by HuR +target gene hsa-mir-377 "Carcinoma, Hepatocellular" 27222047 IRX3 is a direct target of miR-377 +target gene hsa-mir-135b "Carcinoma, Endometrial" 27222184 MiR-135b promotes proliferation of endometrial carcinoma cells by targeting FOXO1. +target gene hsa-mir-21 "Carcinoma, Renal Cell" 27222255 miRâ€?1 was able to decrease the expression of CASC2 in 786‑O and A498 cells. +target gene hsa-mir-143 "Muscular Dystrophy, Duchenne" 27223470 miRNA-143 as a direct regulator of β-dystrobrevin expression +target gene hsa-mir-206 Pancreatic Neoplasms 27233476 "Mechanistically, the Nampt expression was independent of Kras and p16 status, but it was directly regulated by miR-206" +target gene hsa-mir-203 "Carcinoma, Lung, Non-Small-Cell" 27237033 Both miR-145 and miR-203 can directly target the 3'-untranslated region (3'-UTR) of SMAD3 +target gene hsa-mir-183 Neuroblastoma 27239679 Our results reveal the MCM complex to be a critical and directly regulated node within the miR-183 signaling network in MYCN-amplified neuroblastoma cells. +target gene hsa-mir-182 Glioma 27246830 miR-182-5p negatively regulated PCDH8 expression by directly targeting its 3'-untranslated region. +target gene hsa-mir-21 "Carcinoma, Hepatocellular" 27261510 "Here, we demonstrated that TNFα stimulation induced transcriptional downregulation of MSH2, a member of the mismatch repair family, via NF-κB-dependent miR-21 expression in hepatocytes." +target gene hsa-mir-374a "Carcinoma, Nasopharyngeal" 27270423 miR-374a direct targeting of CCND1 is modulated by tumor suppressor PDCD4 via suppressing pPI3K/pAKT/c-JUN signaling. +target gene hsa-mir-375 Prostate Neoplasms 27270433 The transcription factor YAP1 was found to be a direct target of miR-375 in prostate cancer. +target gene hsa-mir-17 Colon Neoplasms 27278684 miRâ€?7 overexpression led to the degradation of CYP7B1 mRNA expression in DLD1 cells. +target gene hsa-mir-218 Prostate Neoplasms 27278788 ectopic expression of these miRNAs suppressed PCa cell aggressiveness +target gene hsa-mir-26a Prostate Neoplasms 27278788 the lysyl oxidase-like 2 (LOXL2) gene was directly controlled by these tumor-suppressive miRNAs +target gene hsa-mir-26b Prostate Neoplasms 27278788 the lysyl oxidase-like 2 (LOXL2) gene was directly controlled by these tumor-suppressive miRNAs +target gene hsa-mir-29a Prostate Neoplasms 27278788 the lysyl oxidase-like 2 (LOXL2) gene was directly controlled by these tumor-suppressive miRNAs +target gene hsa-mir-29b Prostate Neoplasms 27278788 the lysyl oxidase-like 2 (LOXL2) gene was directly controlled by these tumor-suppressive miRNAs +target gene hsa-mir-29c Prostate Neoplasms 27278788 the lysyl oxidase-like 2 (LOXL2) gene was directly controlled by these tumor-suppressive miRNAs +target gene hsa-mir-23a "Carcinoma, Hepatocellular" 27279136 "the miR-23a mimic downregulated IFNγ-induced IRF-1 protein expression, while the miR-23a inhibitor increased IRF-1." +target gene hsa-mir-205 "Carcinoma, Lung, Non-Small-Cell" 27279345 overexpression of miRâ€?05 suppressed the expression of Smad4 +target gene hsa-let-7b Hypertension 27286171 micro-RNA Let-7b in post-transcriptional regulation +target gene hsa-mir-381 Tuberculosis 27296666 inhibition of miR-381-3p could reverse suppression of CD1c expression and promote T cell responses against BCG infection. +target gene hsa-mir-34a Diabetes Mellitus 27297797 "Subsequent overexpression of miR-34a inhibited Fndc5 expression, whereas blockade of miR-34a increased Fndc5 expression in myoblasts." +target gene hsa-mir-122 "Carcinoma, Hepatocellular" 27302319 "miR-122*, the passenger strand of miR-122, regulates the activity of p53 by targeting Mdm2." +target gene hsa-mir-183 Leukemia 27307158 FOXP3-induced miR-183 expression reduced β-TrCP mRNA stability and suppressed β-TrCP-mediated Sp1 degradation +target gene hsa-mir-200b Osteosarcoma 27307751 "miR-200b inhibits the proliferation, migration, and invasion of osteosarcoma cells, probably via the inhibition of ZEB1 expression." +target gene hsa-mir-200c Colorectal Carcinoma 27315529 ZEB1 expression was seen in connection with decreased miR-200c expression +target gene hsa-mir-134 Liver Fibrosis 27321552 Dieckol suppresses liver fibrosis via caspase activation and miR134 mediated JNK activation and NF-kB inhibition. +target gene hsa-mir-301a Osteosarcoma 27323075 Upregulated microRNA-301a in osteosarcoma promotes tumor progression by targeting CDC14A. +target gene hsa-mir-22 Vascular Disease [unspecific] 27325558 "miR-22-3p, had its binding site on the 3' UTR of VASH1 mRNA" +target gene hsa-mir-511 Alzheimer Disease 27334923 miR-511 is a functional regulator of FKBP5 and can contribute to neuronal differentiation. +target gene hsa-mir-335 "Carcinoma, Lung, Small-Cell" 27336605 miR-335 negatively regulated the MDR of WBP5 by targeting its 3'UTR +target gene hsa-mir-330 "Leukemia, Myeloid, Acute" 27341144 miR-330-5p is able to strongly silence TIM-3 expression (98.15% silencing) in HL-60 cell line (p = 0.0001). +target gene hsa-mir-128 Breast Neoplasms 27341528 AurkA suppressed the expression of miR-128 +target gene hsa-mir-103 Alzheimer Disease 27343180 "miR-103 and miR-107, regulate CDK5R1 expression and affect the levels of p35" +target gene hsa-let-7a Breast Neoplasms 27345399 let-7a and let-7b mimics attenuated p62-mediated MYC mRNA stabilization +target gene hsa-let-7b Breast Neoplasms 27345399 let-7a and let-7b mimics attenuated p62-mediated MYC mRNA stabilization +target gene hsa-mir-21 Anaplastic Astrocytoma 27347075 PTEN and miR-21 have been observed to form feedback loops. +target gene hsa-mir-25 Anaplastic Astrocytoma 27347075 "PTEN which is targeted by miR-21 and miR-106b, regulates miR-25 which in turn targets TP53" +target gene hsa-mir-21 Colorectal Carcinoma 27350731 PTEN is one of the direct target genes of miR-21. +target gene hsa-mir-144 Neurodegenerative Diseases [unspecific] 27370936 the expression of 14-3-3γ was upregulated following transfection with miR-7 and miR-144 mimics. +target gene hsa-mir-203 Neurodegenerative Diseases [unspecific] 27370936 miR-203 resulted in a down-regulation of 14-3-3θ transcript +target gene hsa-mir-7 Neurodegenerative Diseases [unspecific] 27370936 the expression of 14-3-3γ was upregulated following transfection with miR-7 and miR-144 mimics. +target gene hsa-mir-106a Lung Neoplasms 27372519 An inverse correlation of miR-106a and ULK1 expression was seen in lung adenocarcinoma. +target gene hsa-mir-155 Preeclampsia 27375191 These miRNAs have previously been linked to PE and are predicted to regulate members of the TGF-β pathway. +target gene hsa-mir-26a Preeclampsia 27375191 These miRNAs have previously been linked to PE and are predicted to regulate members of the TGF-β pathway. +target gene hsa-mir-204 Diabetes Mellitus 27384111 "Taken together, we have identified PERK as a novel target of miR-204 and show that miR-204 inhibits PERK signaling and increases ER stress-induced cell death, revealing for the first time a link between this miRNA and UPR." +target gene hsa-mir-145 Human Papilloma Virus Infection 27386862 KLF4 levels are increased in HPV-positive cells through a post-transcriptional mechanism involving E7-mediated suppression of cellular miR-145 +target gene hsa-mir-21 "Carcinoma, Renal Cell" 27388719 "in cells treated with AU-1, transient elevation of miR-34 leads to the downregulation of SIRT1, thereby miR-21 is freed from SIRT1-dependent suppression." +target gene hsa-mir-34 "Carcinoma, Renal Cell" 27388719 "in cells treated with AU-1, transient elevation of miR-34 leads to the downregulation of SIRT1, thereby miR-21 is freed from SIRT1-dependent suppression. Then, elevated miR-21 upregulates p21/Cip1 protein, followed by the suppression of miR-34 expression." +target gene hsa-mir-99a Atherosclerosis 27403035 MiR-99a inhibited the LPS-induced HUVECs inflammation via inhibition of the mTOR/NF-κB signal. +target gene hsa-mir-99a Cardiovascular Diseases [unspecific] 27403035 MiR-99a inhibited the LPS-induced HUVECs inflammation via inhibition of the mTOR/NF-κB signal. +target gene hsa-mir-133a Diabetes Mellitus 27411382 "Our results revealed that miR-133a mimic treatment improved the contractility of the diabetic rat's heart concomitant with upregulation of TH, cardiac NE, β-AR, and downregulation of TAT and plasma levels of NE." +target gene hsa-mir-145 Cardiovascular Diseases [unspecific] 27412561 miR-145 is involved in the anti-proliferation and anti-inflammation effects of aspirin on VSMCs by inhibiting the expression of CD40. +target gene hsa-mir-26a Retinoblastoma 27421000 "Beclin 1 is the target of miR-26a in human RB cell lines Y79 and WERi-RB-1, and miR-26a inhibits the expression of Beclin 1 by reducing its mRNA and protein levels." +target gene hsa-mir-20b Diabetic Retinopathy 27421659 "Transfection of miR-20b mimic in high glucose (HG)-treated human retinal endothelial cells (HRECs) increased miR-20b expression and decreased the expression level of VEGF mRNA, while transfection of miR-20b inhibitor in control HRECs reduced the miR-20b expression with a corresponding increase of VEGF mRNA." +target gene hsa-mir-1273g Hepatitis C Virus Infection 27423040 "Overexpression of miR-1273g-3p could inhibit translation of PTEN, increase the expression of α-SMA, Col1A1, and reduce apoptosis in HSCs." +target gene hsa-mir-1273g Liver Cirrhosis 27423040 "Overexpression of miR-1273g-3p could inhibit translation of PTEN, increase the expression of α-SMA, Col1A1, and reduce apoptosis in HSCs." +target gene hsa-mir-696 "Diabetes Mellitus, Type 2" 27432632 "Taken together, our findings demonstrate that miR-696 plays an important role in the development of hepatic gluconeogenesis and insulin resistance through the inhibition of PGC-1α translation in the liver." +target gene hsa-mir-29a Focal Segmental Glomerulosclerosis 27460630 We also demonstrated that miR-29a acts as a positive regulator of Wnt/β-catenin signaling in cultured mesangial cells and functions to protect cell apoptosis and fibrosis. +target gene hsa-mir-203 "Carcinoma, Cervical" 27466497 "Although preliminary, the expression levels of ΔNp63 mRNA and miR-203 seem to be promising for cervical cancer screening." +target gene hsa-mir-23b "Diabetes Mellitus, Type 2" 27467285 Survival of autoreactive T lymphocytes by microRNA-mediated regulation of apoptosis through TRAIL and Fas in type 1 diabetes. +target gene hsa-mir-590 "Diabetes Mellitus, Type 2" 27467285 "Transcriptome analysis revealed reduced expression of TRAIL, TRAIL-R2, FAS and FASLG (members of the extrinsic apoptosis pathway) in patient-derived compared with healthy donor-derived T cells. This was mirrored by increased expression of microRNAs predicted to regulate these particular genes, namely miR-98, miR-23b and miR-590-5p." +target gene hsa-mir-98 "Diabetes Mellitus, Type 2" 27467285 "Transcriptome analysis revealed reduced expression of TRAIL, TRAIL-R2, FAS and FASLG (members of the extrinsic apoptosis pathway) in patient-derived compared with healthy donor-derived T cells. This was mirrored by increased expression of microRNAs predicted to regulate these particular genes, namely miR-98, miR-23b and miR-590-5p." +target gene hsa-mir-124 Breast Neoplasms 27468577 Decreased miR-124-3p Expression Prompted Breast Cancer Cell Progression Mainly by Targeting Beclin-1. +target gene hsa-mir-216b "Carcinoma, Hepatocellular" 27474751 Regulation of UGT2B Expression and Activity by miR-216b-5p in Liver Cancer Cell Lines. +target gene hsa-mir-21 Choriocarcinoma 27475963 "We find various mechanisms of PTEN protein loss in the different tumour cell populations, including allelic PTEN deletions, gross chromosomal 10 aberrations and altered miR-21 expression." +target gene hsa-mir-214 "Carcinoma, Lung" 27494742 miR-214 inhibits lung cancer progression by targeting CPD. +target gene hsa-mir-34a Gastric Neoplasms 27497057 "Our NVs-mediated miR-34a delivery system specifically increased endogenous target miR levels, thereby attenuating proliferation and migration of gastric cancer cells by repressing the expression of CD44 with decreased levels of Bcl-2, Oct 3/4 and Nanog genes." +target gene hsa-mir-128 Glioblastoma 27507538 We demonstrated that miR-31 and miR-128 can bind to the 3'UTR of PVRL4 and decrease PVRL4 levels while anti-miR-31/128 increase PVRL4 levels suggesting that PVRL4 is miRNA targeted. +target gene hsa-mir-6734 "Carcinoma, Colon" 27509128 "Collectively, our results demonstrated that miR-6734 inhibits the growth of colon cancer cells by up-regulating p21 gene expression and subsequent induction of cell cycle arrest and apoptosis, suggesting its role as an important endogenous regulator of cancer cell proliferation and survival." +target gene hsa-mir-199a Osteoarthritis 27515563 Transfection of OA chondrocytes with anti-miR-199a-3p significantly enhanced COX-2 expression and PGE2 production (P < 0.001). +target gene hsa-mir-9 "Carcinoma, Breast" 27520371 CYP4Z1 3'UTR was the potential target of miR-9. CYP4Z1 3'UTR could inhibit the migration and EMT of breast cancer cells via acting as a ceRNA for E-cadherin. +target gene hsa-mir-106b Alzheimer Disease 27520374 miR-106b inhibits A¦Â1-42-induced tau phosphorylation at Tyr18 by targeting Fyn. +target gene hsa-mir-216b "Carcinoma, Hepatocellular" 27524242 this study firstly revealed that there is a HIF-2¦Á-MALAT1-miR-216b axis regulating MDR of HCC cells via modulating autophagy. +target gene hsa-mir-125a Retinal Degeneration 27527066 "Possibly more than 30 miRNAs interact with Rac1 in retina, targeting both UTRs and coding regions." +target gene hsa-mir-142 Retinal Degeneration 27527066 "Possibly more than 30 miRNAs interact with Rac1 in retina, targeting both UTRs and coding regions." +target gene hsa-mir-96 Retinal Degeneration 27527066 "Validation of miRNA-target mRNA interactions for miR-1, miR-96/182 and miR-96 targeting Ctbp2, Rac1 and Slc6a9, respectively, was demonstrated in vitro." +target gene hsa-mir-155 "Leukemia, Myeloid, Acute" 27530922 "our evidence show that IRF3 overexpression in AML promotes cell growth and survival, and miR-155 is involved, indicating that IRF3 may be a potential new biomarker and therapeutic target for AML." +target gene hsa-mir-137 Multiple Myeloma 27531781 The miR137-MITF is an important index in judging the prognosis of multiple myeloma. +target gene hsa-mir-144 "Carcinoma, Hepatocellular" 27536132 "MiR-144 suppresses cell proliferation, migration, and invasion in hepatocellular carcinoma by targeting SMAD4." +target gene hsa-mir-23a "Carcinoma, Ovarian" 27537390 miR-23a promotes IKK¦Á expression but suppresses ST7L expression to contribute to the malignancy of epithelial ovarian cancer cells. +target gene hsa-mir-1283 Vascular Injuries 27537404 miRNA-1283 Regulates the PERK/ATF4 Pathway in Vascular Injury by Targeting ATF4. +target gene hsa-mir-22 Coronary Artery Disease 27537567 miR-22 contributes to the pathogenesis of patients with coronary artery disease by targeting MCP-1: An observational study. +target gene hsa-mir-24 "Carcinoma, Nasopharyngeal" 27538493 Exosomal miR-24-3p impedes T-cell function by targeting FGF11 and serves as a potential prognostic biomarker for nasopharyngeal carcinoma. +target gene hsa-mir-98 Alzheimer Disease 27541017 miR-98-5p Acts as a Target for Alzheimer's Disease by Regulating A¦Â Production Through Modulating SNX6 Expression. +target gene hsa-mir-146a Juvenile Rheumatoid Arthritis 27541693 MiR-146a modulates macrophage polarization in systemic juvenile idiopathic arthritis by targeting INHBA. +target gene hsa-mir-200a "Carcinoma, Hepatocellular" 27542259 Elevated CXCL1 increases hepatocellular carcinoma aggressiveness and is inhibited by miRNA-200a. +target gene hsa-mir-203 "Carcinoma, Gastric" 27542403 MiR-203 inhibits tumor invasion and metastasis in gastric cancer by ATM. +target gene hsa-mir-154 "Cardiomyopathy, Ischemic" 27542661 MiR-154 directly suppresses DKK2 to activate Wnt signaling pathway and enhance activation of cardiac fibroblasts. +target gene hsa-mir-384 "Carcinoma, Hepatocellular" 27542674 MiR-384 regulated IRS1 expression and suppressed cell proliferation of human hepatocellular carcinoma. +target gene hsa-mir-100 IgA Nephropathy 27542871 MiR-100-3p and miR-877-3p regulate overproduction of IL-8 and IL-1¦Â in mesangial cells activated by secretory IgA from IgA nephropathy patients. +target gene hsa-mir-877 IgA Nephropathy 27542871 MiR-100-3p and miR-877-3p regulate overproduction of IL-8 and IL-1¦Â in mesangial cells activated by secretory IgA from IgA nephropathy patients. +target gene hsa-mir-29a Glioma 27543358 Long non-coding RNA H19 regulates glioma angiogenesis and the biological behavior of glioma-associated endothelial cells by inhibiting microRNA-29a. +target gene hsa-mir-187 "Carcinoma, Hepatocellular" 27544906 miR-187-3p inhibits the metastasis and epithelial-mesenchymal transition of hepatocellular carcinoma by targeting S100A4. +target gene hsa-mir-613 Alzheimer Disease 27545218 MicroRNA-613 regulates the expression of brain-derived neurotrophic factor in Alzheimer's disease. +target gene hsa-mir-21 Cardiovascular Diseases [unspecific] 27545313 Viral Vector-Based Targeting of miR-21 in Cardiac Nonmyocyte Cells Reduces Pathologic Remodeling of the Heart. +target gene hsa-mir-200b Glioma 27545608 MicroRNA-200b-3p suppresses epithelial-mesenchymal transition and inhibits tumor growth of glioma through down-regulation of ERK5. +target gene hsa-mir-331 "Carcinoma, Cervical" 27548144 MicroRNA-331-3p Suppresses Cervical Cancer Cell Proliferation and E6/E7 Expression by Targeting NRP2. +target gene hsa-mir-29a "Carcinoma, Colon" 27548517 MiR-29a Regulates Radiosensitivity in Human Intestinal Cells by Targeting PTEN Gene. +target gene hsa-mir-297 "Adenocarcinoma, Lung" 27554041 miR-297 acts as an oncogene by targeting GPC5 in lung adenocarcinoma. +target gene hsa-mir-33b "Carcinoma, Lung" 27559850 DNA damage responsive miR-33b-3p promoted lung cancer cells survival and cisplatin resistance by targeting p21WAF1/CIP1. +target gene hsa-mir-138 "Carcinoma, Prostate" 27562865 MiR-26a and miR-138 block the G1/S transition by targeting the cell cycle regulating network in prostate cancer cells. +target gene hsa-mir-26a "Carcinoma, Prostate" 27562865 MiR-26a and miR-138 block the G1/S transition by targeting the cell cycle regulating network in prostate cancer cells. +target gene hsa-mir-106a "Cardiomyopathy, Hypertrophic" 27565029 miR-106a promotes cardiac hypertrophy by targeting mitofusin 2. +target gene hsa-mir-124 "Carcinoma, Cervical" 27571703 "MicroRNA-124 inhibits proliferation, invasion, migration and epithelial-mesenchymal transition of cervical carcinoma cells by targeting astrocyte-elevated gene-1." +target gene hsa-mir-127 "Carcinoma, Ovarian" 27571744 MicroRNA-127-3p acts as a tumor suppressor in epithelial ovarian cancer by regulating the BAG5 gene. +target gene hsa-mir-451 "Carcinoma, Bladder" 27571748 miR-451 suppresses bladder cancer cell migration and invasion via directly targeting c-Myc. +target gene hsa-mir-21 "Carcinoma, Hepatocellular" 27571873 HBx-induced miR-21 suppresses cell apoptosis in hepatocellular carcinoma by targeting interleukin-12. +target gene hsa-mir-588 "Squamous Cell Carcinoma, Lung" 27571908 MicroRNA-588 suppresses tumor cell migration and invasion by targeting GRN in lung squamous cell carcinoma. +target gene hsa-mir-145 Colorectal Carcinoma 27572146 miR-145 suppresses colorectal cancer cell migration and invasion by targeting an ETS-related gene. +target gene hsa-mir-181d "Squamous Cell Carcinoma, Esophageal" 27572270 MicroRNA-181d is a tumor suppressor in human esophageal squamous cell carcinoma inversely regulating Derlin-1. +target gene hsa-mir-411 "Carcinoma, Breast" 27572271 miRNA-411 acts as a potential tumor suppressor miRNA via the downregulation of specificity protein 1 in breast cancer. +target gene hsa-mir-19b "Carcinoma, Gastric" 27572553 MicroRNA-19b inhibits proliferation of gastric cancer cells by targeting B-cell CLL/lymphoma 3. +target gene hsa-mir-15a Human Papilloma Virus Infection 27573302 miR-15a induces cell apoptosis by targeting BCL2L2 and BCL2 in HPV-positive hypopharyngeal squamous cell carcinoma. +target gene hsa-mir-23b "Squamous Cell Carcinoma, Oral" 27573718 The tumor-suppressive microRNA-23b/27b cluster regulates the MET oncogene in oral squamous cell carcinoma. +target gene hsa-mir-27b "Squamous Cell Carcinoma, Oral" 27573718 The tumor-suppressive microRNA-23b/27b cluster regulates the MET oncogene in oral squamous cell carcinoma. +target gene hsa-mir-328 Inflammation 27573788 UPF1 regulates myeloid cell functions and S100A9 expression by the hnRNP E2/miRNA-328 balance. +target gene hsa-mir-195 "Carcinoma, Hepatocellular" 27574422 Aptamer-functionalized peptide H3CR5C as a novel nanovehicle for codelivery of fasudil and miRNA-195 targeting hepatocellular carcinoma. +target gene hsa-mir-491 Hypercholesterolaemia 27575876 Atorvastatin attenuation of ABCB1 expression is mediated by microRNA miR-491-3p in Caco-2 cells. +target gene hsa-mir-30a Colorectal Carcinoma 27576787 MiR-30a-5p Suppresses Tumor Metastasis of Human Colorectal Cancer by Targeting ITGB3. +target gene hsa-mir-216 Bladder Neoplasms 27578985 MiR-126 regulates proliferation and invasion in the bladder cancer BLS cell line by targeting the PIK3R2-mediated PI3K/Akt signaling pathway. +target gene hsa-mir-19a "Squamous Cell Carcinoma, Oral" 27581787 Micronome revealed miR-19a/b as key regulator of SOCS3 during cancer related inflammation of oral squamous cell carcinoma. +target gene hsa-mir-19b "Squamous Cell Carcinoma, Oral" 27581787 Micronome revealed miR-19a/b as key regulator of SOCS3 during cancer related inflammation of oral squamous cell carcinoma. +target gene hsa-mir-421 "Carcinoma, Breast" 27583980 MicroRNA-421 inhibits breast cancer metastasis by targeting metastasis associated 1. +target gene hsa-mir-7 Intervertebral Disc Degeneration 27583982 MicroRNA-7 regulates IL-1¦Â-induced extracellular matrix degeneration by targeting GDF5 in human nucleus pulposus cells. +target gene hsa-mir-98 Osteoarthritis 27590063 MiR-98 promotes chondrocyte apoptosis by decreasing Bcl-2 expression in a rat model of osteoarthritis. +target gene hsa-mir-125b Heart Failure 27592695 MiR-125b regulates SFRP5 expression to promote growth and activation of cardiac fibroblasts. +target gene hsa-mir-31 "Carcinoma, Breast, Triple Negative" 27593563 MiR-31 inhibits migration and invasion by targeting SATB2 in triple negative breast cancer. +target gene hsa-mir-27a Prostate Neoplasms 27594411 Androgen-induced miR-27A acted as a tumor suppressor by targeting MAP2K4 and mediated prostate cancer progression. +target gene hsa-mir-15a "Carcinoma, Breast" 27596816 miR-15a/miR-16 induces mitochondrial dependent apoptosis in breast cancer cells by suppressing oncogene BMI1. +target gene hsa-mir-16 "Carcinoma, Breast" 27596816 miR-15a/miR-16 induces mitochondrial dependent apoptosis in breast cancer cells by suppressing oncogene BMI1. +target gene hsa-mir-141 "Carcinoma, Breast" 27596953 p16INK4A induces senescence and inhibits EMT through microRNA-141/microRNA-146b-5p-dependent repression of AUF1. +target gene hsa-mir-146b "Carcinoma, Breast" 27596953 p16INK4A induces senescence and inhibits EMT through microRNA-141/microRNA-146b-5p-dependent repression of AUF1. +target gene hsa-mir-15a Myeloma 27596960 "MiR-15a/16 regulates the growth of myeloma cells, angiogenesis and antitumor immunity by inhibiting Bcl-2, VEGF-A and IL-17 expression in multiple myeloma." +target gene hsa-mir-16 Myeloma 27596960 "MiR-15a/16 regulates the growth of myeloma cells, angiogenesis and antitumor immunity by inhibiting Bcl-2, VEGF-A and IL-17 expression in multiple myeloma." +target gene hsa-mir-199a "Carcinoma, Hepatocellular" 27599545 Anti-invasion and anti-migration effects of miR-199a-3p in hepatocellular carcinoma are due in part to targeting CD151. +target gene hsa-mir-3666 "Carcinoma, Lung, Non-Small-Cell" 27599551 MicroRNA-3666-induced suppression of SIRT7 inhibits the growth of non-small cell lung cancer cells. +target gene hsa-mir-181a Osteosarcoma 27600004 miR-181a promotes the proliferation and metastasis of osteosarcoma cells by targeting RASSF1A. +target gene hsa-mir-150 "Leukemia, Myeloid, Acute" 27601730 AML suppresses hematopoiesis by releasing exosomes that contain microRNAs targeting c-MYB. +target gene hsa-mir-155 "Leukemia, Myeloid, Acute" 27601730 AML suppresses hematopoiesis by releasing exosomes that contain microRNAs targeting c-MYB. +target gene hsa-mir-23a "Carcinoma, Endometrioid Endometrial" 27601936 MicroRNA-23a regulates epithelial-to-mesenchymal transition in endometrial endometrioid adenocarcinoma by targeting SMAD3. +target gene hsa-mir-19b Breast Neoplasms 27602768 MiR-19b suppresses PTPRG to promote breast tumorigenesis. +target gene hsa-mir-9 Knee Osteoarthritis 27603333 MicroRNA-9 regulates the development of knee osteoarthritis through the NF-kappaB1 pathway in chondrocytes. +target gene hsa-mir-139 Leukemia 27605510 MicroRNA-139-5p regulates proliferation of hematopoietic progenitors and is repressed during BCR-ABL-mediated leukemogenesis. +target gene hsa-mir-15a Endometriosis 27608888 miRNA-15a-5p regulates VEGFA in endometrial mesenchymal stem cells and contributes to the pathogenesis of endometriosis. +target gene hsa-mir-141 Glioma 27608897 MiR-200c and miR-141 inhibit ZEB1 synergistically and suppress glioma cell growth and migration. +target gene hsa-mir-200c Glioma 27608897 MiR-200c and miR-141 inhibit ZEB1 synergistically and suppress glioma cell growth and migration. +target gene hsa-mir-135a "Carcinoma, Hepatocellular" 27609066 "HBXIP is able to depress the gluconeogenesis through suppressing PCK1 to promote hepatocarcinogenesis, involving miR-135a/FOXO1 axis and PI3K/Akt/p-FOXO1 pathway" +target gene hsa-mir-148a Ischemia-Reperfusion Injury 27609576 The miR-148a alleviates hepatic ischemia/reperfusion injury in mice via targeting CaMKII¦Á. +target gene hsa-mir-34a Influenza 27610823 MicroRNA 34a contributes to virus-mediated apoptosis through binding to its target gene Bax in influenza A virus infection. +target gene hsa-mir-126 Neoplasms [unspecific] 27611944 MicroRNA-126 inhibits tumor proliferation and angiogenesis of hepatocellular carcinoma by down-regulating EGFL7 expression. +target gene hsa-mir-21 Gastric Neoplasms 27611950 MicroRNA-21 promotes TGF-¦Â1-induced epithelial-mesenchymal transition in gastric cancer through up-regulating PTEN expression. +target gene hsa-mir-34a "Carcinoma, Oral" 27612478 "miR5423p and miR34a targets the CD44v6-Nanog-PTEN axis, thus playing a vital role in regulating the CSC properties" +target gene hsa-mir-542 "Carcinoma, Oral" 27612478 "miR5423p and miR34a targets the CD44v6-Nanog-PTEN axis, thus playing a vital role in regulating the CSC properties" +target gene hsa-mir-451 Colorectal Carcinoma 27612504 Expression pattern of miR-451 and its target MIF (macrophage migration inhibitory factor) in colorectal cancer. +target gene hsa-mir-1271 "Diabetes Mellitus, Type 2" 27613089 MiR-1271 upregulated by saturated fatty acid palmitate provokes impaired insulin signaling by repressing INSR and IRS-1 expression in HepG2 cells. +target gene hsa-mir-26a Neoplasms [unspecific] 27613140 MiR-26a inhibits proliferation and migration of HaCaT keratinocytes through regulating PTEN expression. +target gene hsa-mir-223 "Carcinoma, Breast, Triple Negative" 27618431 MicroRNA-223 Increases the Sensitivity of Triple-Negative Breast Cancer Stem Cells to TRAIL-Induced Apoptosis by Targeting HAX-1. +target gene hsa-mir-106b "Squamous Cell Carcinoma, Esophageal" 27619676 MiR-106b promotes migration and invasion through enhancing EMT via downregulation of Smad 7 in Kazakh's esophageal squamous cell carcinoma. +target gene hsa-mir-214 "Squamous Cell Carcinoma, Esophageal" 27619677 miR-214 inhibits invasion and migration via downregulating GALNT7 in esophageal squamous cell cancer. +target gene hsa-mir-346 Preeclampsia 27619846 miR-346 and miR-582-3p-regulated EG-VEGF expression and trophoblast invasion via matrix metalloproteinases 2 and 9. +target gene hsa-mir-582 Preeclampsia 27619846 miR-346 and miR-582-3p-regulated EG-VEGF expression and trophoblast invasion via matrix metalloproteinases 2 and 9. +target gene hsa-let-7 "Carcinoma, Bladder" 27620744 A let-7 microRNA binding site polymorphism in the KRAS 3'UTR is associated with increased risk and reduced survival for gallbladder cancer in North Indian population. +target gene hsa-mir-126 "Carcinoma, Gastric" 27622325 MicroRNA-126 increases chemosensitivity in drug-resistant gastric cancer cells by targeting EZH2. +target gene hsa-mir-224 "Carcinoma, Cervical" 27626930 Over-Expressed miR-224 Promotes the Progression of Cervical Cancer via Targeting RASSF8. +target gene hsa-mir-4262 "Carcinoma, Breast" 27629257 miR-4262 Promotes Proliferation and Invasion of Human Breast Cancer Cells Through Directly Targeting KLF6 and KLF15. +target gene hsa-mir-22 Parkinson Disease 27631550 Neuroprotective Role of MicroRNA-22 in a 6-Hydroxydopamine-Induced Cell Model of Parkinson's Disease via Regulation of Its Target Gene TRPM7. +target gene hsa-mir-7 "Carcinoma, Thyroid, Papillary" 27633373 "MicroRNA-7 inhibits proliferation, migration and invasion of thyroid papillary cancer cells via targeting CKS2." +target gene hsa-mir-330 "Carcinoma, Colon" 27633518 MicroRNA-330-5p negatively regulates ITGA5 expression in human colorectal cancer. +target gene hsa-mir-218 "Squamous Cell Carcinoma, Lung" 27633630 Regulation of TPD52 by antitumor microRNA-218 suppresses cancer cell migration and invasion in lung squamous cell carcinoma. +target gene hsa-mir-30c Heart Failure 27633839 MiRNA-30e mediated cardioprotection of ACE2 in rats with Doxorubicin-induced heart failure through inhibiting cardiomyocytes autophagy. +target gene hsa-mir-30e Heart Failure 27633839 MiRNA-30e mediated cardioprotection of ACE2 in rats with Doxorubicin-induced heart failure through inhibiting cardiomyocytes autophagy. +target gene hsa-let-7g Glioblastoma 27634309 Let-7g-5p inhibits epithelial-mesenchymal transition consistent with reduction of glioma stem cell phenotypes by targeting VSIG4 in glioblastoma. +target gene hsa-mir-187 "Carcinoma, Lung" 27634346 MicroRNA?187 is an independent prognostic factor in lung cancer and promotes lung cancer cell invasion via targeting of PTRF. +target gene hsa-mir-377 "Carcinoma, Pancreatic" 27638830 MiR-377 inhibits the proliferation of pancreatic cancer by targeting Pim-3. +target gene hsa-mir-17 Pulmonary Hypertension 27640178 Upregulated miR-17 Regulates Hypoxia-Mediated Human Pulmonary Artery Smooth Muscle Cell Proliferation and Apoptosis by Targeting Mitofusin 2. +target gene hsa-mir-182 Lung Neoplasms 27641336 The microRNA-182-PDK4 axis regulates lung tumorigenesis by modulating pyruvate dehydrogenase and lipogenesis. +target gene hsa-mir-181b Psoriasis 27641447 MicroRNA-181b negatively regulates the proliferation of human epidermal keratinocytes in psoriasis through targeting TLR4. +target gene hsa-mir-361 "Carcinoma, Hepatocellular" 27641667 miR-361-5p inhibits hepatocellular carcinoma cell proliferation and invasion by targeting VEGFA. +target gene hsa-mir-1304 "Carcinoma, Lung, Non-Small-Cell" 27641735 MicroRNA-1304 suppresses human non-small cell lung cancer cell growth in vitro by targeting heme oxygenase-1. +target gene hsa-mir-218 "Carcinoma, Gastric" 27642088 "miR-218 Inhibits Proliferation, Migration, and EMT of Gastric Cancer Cells by Targeting WASF3." +target gene hsa-mir-135b "Carcinoma, Lung, Non-Small-Cell" 27643554 miR-135b reverses chemoresistance of non-small cell lung cancer cells by downregulation of FZD1. +target gene hsa-mir-185 "Carcinoma, Hepatocellular" 27643556 our findings enlarged our knowledge about the roles of PLAC8 in HCC progression and miR-185-5p/PLAC8/¦Â-catenin axis might be a novel pathway for HCC treatment +target gene hsa-mir-141 "Carcinoma, Esophageal" 27644195 Involvement of microRNA-141-3p in 5-fluorouracil and oxaliplatin chemo-resistance in esophageal cancer cells via regulation of PTEN. +target gene hsa-mir-124 Osteosarcoma 27644254 The tumor suppressor miR-124 inhibits cell proliferation and invasion by targeting B7-H3 in osteosarcoma. +target gene hsa-mir-21 Leukemia 27644439 Bmi-1 regulates stem cell-like properties of gastric cancer cells via modulating miRNAs. +target gene hsa-mir-127 "Squamous Cell Carcinoma, Esophageal" 27645894 MicroRNA-127 is a tumor suppressor in human esophageal squamous cell carcinoma through the regulation of oncogene FMNL3. +target gene hsa-mir-181b Colorectal Carcinoma 27647131 miR-181b functions as an oncomiR in colorectal cancer by targeting PDCD4. +target gene hsa-mir-494 "Carcinoma, Colon" 27648301 Targeting the metabolic pathway of human colon cancer overcomes resistance to TRAIL-induced apoptosis. +target gene hsa-mir-138 Pulmonary Hypertension 27648837 "MicroRNA-138 and MicroRNA-25 Down-regulate Mitochondrial Calcium Uniporter, Causing the Pulmonary Arterial Hypertension Cancer Phenotype." +target gene hsa-mir-25 Pulmonary Hypertension 27648837 "MicroRNA-138 and MicroRNA-25 Down-regulate Mitochondrial Calcium Uniporter, Causing the Pulmonary Arterial Hypertension Cancer Phenotype." +target gene hsa-mir-29 Osteosarcoma 27649654 Targeting miR-29 induces apoptosis of osteosarcoma MG-63 cells via regulation of TGF-¦Â1/PUMA signal. +target gene hsa-mir-24 "Carcinoma, Hepatocellular" 27650047 MiR-24-3p enhances cell growth in hepatocellular carcinoma by targeting metallothionein 1M. +target gene hsa-mir-185 "Carcinoma, Breast" 27651238 RKIP suppresses the proliferation and metastasis of breast cancer cell lines through up-regulation of miR-185 targeting HMGA2. +target gene hsa-mir-30a "Carcinoma, Nasopharyngeal" 27656832 IGF-I Induces Epithelial-to-Mesenchymal Transition via the IGF-IR-Src-MicroRNA-30a-E-Cadherin Pathway in Nasopharyngeal Carcinoma Cells. +target gene hsa-mir-124 Melanoma 27657824 Upregulation of miR-124 by physcion 8-O-¦Â-glucopyranoside inhibits proliferation and invasion of malignant melanoma cells via repressing RLIP76. +target gene hsa-mir-92b "Squamous Cell Carcinoma, Esophageal" 27659550 "RAB23, regulated by miR-92b, promotes the progression of esophageal squamous cell carcinoma." +target gene hsa-mir-33b Osteosarcoma 27662380 MicroRNA-33b Inhibits the Proliferation and Migration of Osteosarcoma Cells via Targeting Hypoxia-Inducible Factor-1¦Á. +target gene hsa-mir-199a Liver Cirrhosis 27662798 Fibrogenic Signaling Is Suppressed in Hepatic Stellate Cells through Targeting of Connective Tissue Growth Factor (CCN2) by Cellular or Exosomal MicroRNA-199a-5p. +target gene hsa-mir-21 Cardiovascular Diseases [unspecific] 27663503 "DDAH1 3'-UTR as a target for miR-21, and endogenous miR-21 showed increased inhibitory effect on DDAH1-V3 transcript" +target gene hsa-mir-215 "Carcinoma, Colon" 27663660 "MicroRNA-215 suppresses cell proliferation, migration and invasion of colon cancer by repressing Yin-Yang 1." +target gene hsa-mir-224 "Carcinoma, Ovarian" 27663866 Upregulated microRNA-224 promotes ovarian cancer cell proliferation by targeting KLLN. +target gene hsa-mir-463 Diabetes Mellitus 27664094 MicroRNA-463-3p/ABCG4: A new axis in glucose-stimulated insulin secretion. +target gene hsa-mir-181a "Carcinoma, Renal Cell" 27664584 microRNAs target SRSF7 splicing factor to modulate the expression of osteopontin splice variants in renal cancer cells. +target gene hsa-mir-30a "Carcinoma, Renal Cell" 27664584 microRNAs target SRSF7 splicing factor to modulate the expression of osteopontin splice variants in renal cancer cells. +target gene hsa-mir-370 Hepatitis B Virus Infection 27664977 miR-370 suppresses HBV gene expression and replication by targeting nuclear factor IA. +target gene hsa-mir-138 "Carcinoma, Lung, Non-Small-Cell" 27665963 MicroRNA-138 inhibits migration and invasion of non-small cell lung cancer cells by targeting LIMK1. +target gene hsa-mir-200c "Carcinoma, Lung" 27666124 miR-200c regulates crizotinib-resistant ALK-positive lung cancer cells by reversing epithelial-mesenchymal transition via targeting ZEB1. +target gene hsa-let-7a "Squamous Cell Carcinoma, Lung" 27666488 MicroRNAs modulate the expression of the SOX18 transcript in lung squamous cell carcinoma. +target gene hsa-mir-24 "Squamous Cell Carcinoma, Lung" 27666488 MicroRNAs modulate the expression of the SOX18 transcript in lung squamous cell carcinoma. +target gene hsa-mir-210 "Carcinoma, Hepatocellular" 27666683 MicroRNA-210 promotes cancer angiogenesis by targeting fibroblast growth factor receptor-like?1 in hepatocellular carcinoma. +target gene hsa-mir-19a Diabetes Mellitus 27666763 "MicroRNA-19a-3p enhances the proliferation and insulin secretion, while it inhibits the apoptosis of pancreatic ¦Â?cells via the inhibition of SOCS3." +target gene hsa-mir-101 "Leukemia, Lymphoblastic, Acute, T-Cell" 27666896 MicroRNA-101 regulates T-cell acute lymphoblastic leukemia progression and chemotherapeutic sensitivity by targeting Notch1. +target gene hsa-mir-372 "Carcinoma, Prostate" 27673408 microRNA-372 Suppresses Migration and Invasion by Targeting p65 in Human Prostate Cancer Cells. +target gene hsa-mir-122 Chronic Hepatitis C 27677491 microRNA-122 target sites in the hepatitis C virus RNA NS5B coding region and 3' untranslated region: function in replication and influence of RNA secondary structure. +target gene hsa-mir-16 "Carcinoma, Gastric" 27683052 Direct targeting of HGF by miR-16 regulates proliferation and migration in gastric cancer. +target gene hsa-mir-192 Osteosarcoma 27683056 Upregulation of miR-192 inhibits cell growth and invasion and induces cell apoptosis by targeting TCF7 in human osteosarcoma. +target gene hsa-mir-490 "Carcinoma, Lung" 27683057 MicroRNA-490 regulates lung cancer metastasis by targeting poly r(C)-binding protein 1. +target gene hsa-mir-204 "Carcinoma, Prostate" 27686228 The UCA1/miR-204/Sirt1 axis modulates docetaxel sensitivity of prostate cancer cells. +target gene hsa-mir-451 "Carcinoma, Lung" 27686452 MicroRNA-451 sensitizes lung cancer cells to cisplatin through regulation of Mcl-1. +target gene hsa-mir-122 "Carcinoma, Hepatocellular" 27687586 WNT1 Gene from WNT Signaling Pathway Is a Direct Target of miR-122 in Hepatocellular Carcinoma. +target gene hsa-mir-483 Cervical Neoplasms 27693430 miR-483 is a self-regulating microRNA and can activate its own expression via USF1 in HeLa cells. +target gene hsa-mir-214 "Carcinoma, Breast" 27693451 "Crosstalk between the vitamin D receptor (VDR) and miR-214 in regulating SuFu, a hedgehog pathway inhibitor in breast cancer cells." +target gene hsa-mir-939 "Carcinoma, Breast" 27693459 Breast cancer-secreted miR-939 downregulates VE-cadherin and destroys the barrier function of endothelial monolayers. +target gene hsa-mir-1207 "Carcinoma, Prostate" 27693493 miR-1207-3p regulates the androgen receptor in prostate cancer via FNDC1/fibronectin. +target gene hsa-mir-125a "Carcinoma, Breast" 27693788 Enforced expression of hsa-miR-125a-3p in breast cancer cells potentiates docetaxel sensitivity via modulation of BRCA1 signaling. +target gene hsa-mir-9 "Carcinoma, Laryngeal" 27694005 Enhanced miR-9 promotes laryngocarcinoma cell survival via down-regulating PTEN. +target gene hsa-mir-34a Cardiovascular Diseases [unspecific] 27694688 it could be considered as a circulating biomarker for anthracycline-induced cardiac damage +target gene hsa-mir-218 "Carcinoma, Gastric" 27696291 "MicroRNA-218 inhibits the proliferation, migration, and invasion and promotes apoptosis of gastric cancer cells by targeting LASP1." +target gene hsa-mir-935 "Carcinoma, Hepatocellular" 27697092 miR-935 Promotes Liver Cancer Cell Proliferation and Migration by Targeting SOX7. +target gene hsa-mir-509 "Carcinoma, Gastric" 27697095 MicroRNA-509-3p Inhibits Cancer Cell Proliferation and Migration via Upregulation of XIAP in Gastric Cancer Cells. +target gene hsa-mir-1298 Lung Neoplasms 27698189 miR-1298 Inhibits Mutant KRAS-Driven Tumor Growth by Repressing FAK and LAMB3. +target gene hsa-mir-186 Melanoma 27698793 miR-186 suppressed CYLD expression and promoted cell proliferation in human melanoma. +target gene hsa-mir-182 "Squamous Cell Carcinoma, Tongue" 27698823 miRNA-335 and miRNA-182 affect the occurrence of tongue squamous cell carcinoma by targeting survivin. +target gene hsa-mir-101 "Carcinoma, Hepatocellular" 27702662 Upregulation of SNHG6 regulates ZEB1 expression by competitively binding miR-101-3p and interacting with UPF1 in hepatocellular carcinoma. +target gene hsa-mir-34c "Carcinoma, Hepatocellular" 27704267 MicroRNA-34c-3p promotes cell proliferation and invasion in hepatocellular carcinoma by regulation of NCKAP1 expression. +target gene hsa-mir-27b "Carcinoma, Hepatocellular" 27704356 MicroRNA-27b exerts an oncogenic function by targeting Fbxw7 in human hepatocellular carcinoma. +target gene hsa-mir-491 Osteosarcoma 27704627 Up-regulation of microRNA-491-5p suppresses cell proliferation and promotes apoptosis by targeting FOXP4 in human osteosarcoma. +target gene hsa-mir-15a Breast Neoplasms 27713175 Fatty acid synthase is a primary target of MiR-15a and MiR-16-1 in breast cancer. +target gene hsa-mir-16 Breast Neoplasms 27713175 Fatty acid synthase is a primary target of MiR-15a and MiR-16-1 in breast cancer. +target gene hsa-mir-186 "Carcinoma, Lung, Non-Small-Cell" 27714074 miR-186 regulates chemo-sensitivity to paclitaxel via targeting MAPT in non-small cell lung cancer (NSCLC). +target gene hsa-mir-296 "Carcinoma, Hepatocellular" 27714806 miR-296 inhibits proliferation and induces apoptosis by targeting FGFR1 in human hepatocellular carcinoma. +target gene hsa-mir-144 "Carcinoma, Renal Cell" 27717821 miR-144-3p serves as a tumor suppressor for renal cell carcinoma and inhibits its invasion and metastasis by targeting MAP3K8. +target gene hsa-mir-216b "Carcinoma, Breast" 27720715 miR-216b suppresses breast cancer growth and metastasis by targeting SDCBP. +target gene hsa-mir-320 Osteosarcoma 27721258 Inhibitory roles of miR-320 in osteosarcoma via regulating E2F1. +target gene hsa-mir-326 Osteosarcoma 27723574 MiR-326 is a diagnostic biomarker and regulates cell survival and apoptosis by targeting Bcl-2 in osteosarcoma. +target gene hsa-mir-221 Pancreatic Neoplasms 27726102 MiRNA-221-3p desensitizes pancreatic cancer cells to 5-fluorouracil by targeting RB1. +target gene hsa-mir-126 Rheumatoid Arthritis 27729613 MicroRNA-126 affects rheumatoid arthritis synovial fibroblast proliferation and apoptosis by targeting PIK3R2 and regulating PI3K-AKT signal pathway. +target gene hsa-mir-133a "Carcinoma, Laryngeal" 27730543 "MicroRNA-133a suppresses the proliferation, migration, and invasion of laryngeal carcinoma cells by targeting CD47." +target gene hsa-mir-145 Atherosclerosis 27731400 miRNA-145 inhibits VSMC proliferation by targeting CD40. +target gene hsa-mir-139 Epilepsy 27731509 MicroRNA-139-5p negatively regulates NR2A-containing NMDA receptor in the rat pilocarpine model and patients with temporal lobe epilepsy. +target gene hsa-mir-203 "Adenocarcinoma, Lung" 27733346 Direct interaction between miR-203 and ZEB2 suppresses epithelial-mesenchymal transition signaling and reduces lung adenocarcinoma chemoresistance. +target gene hsa-mir-494 "Carcinoma, Gastric" 27735036 miR-494 inhibits invasion and proliferation of gastric cancer by targeting IGF-1R. +target gene hsa-mir-124 "Carcinoma, Lung" 27735038 MicroRNA-124 suppresses Slug-mediated lung cancer metastasis. +target gene hsa-mir-132 "Carcinoma, Lung, Non-Small-Cell" 27735039 "MicroRNA-132 inhibits migration, invasion and epithelial-mesenchymal transition by regulating TGF¦Â1/Smad2 in human non-small cell lung cancer." +target gene hsa-mir-21 Wound Healing 27735045 microRNA-21 mediates the TGF-¦Â1-induced migration of keratinocytes via targeting PTEN. +target gene hsa-mir-590 "Carcinoma, Colon" 27735951 MiR-590-5p inhibits colorectal cancer angiogenesis and metastasis by regulating nuclear factor 90/vascular endothelial growth factor A axis. +target gene hsa-mir-105 Glioma 27736002 MicroRNA-105 targets SOX9 and inhibits human glioma cell progression. +target gene hsa-mir-149 "Diabetes Mellitus, Type 1" 27737950 "MicroRNAs miR-23a-3p, miR-23b-3p, and miR-149-5p Regulate the Expression of Proapoptotic BH3-Only Proteins DP5 and PUMA in Human Pancreatic ¦Â-Cells." +target gene hsa-mir-23a "Diabetes Mellitus, Type 1" 27737950 "MicroRNAs miR-23a-3p, miR-23b-3p, and miR-149-5p Regulate the Expression of Proapoptotic BH3-Only Proteins DP5 and PUMA in Human Pancreatic ¦Â-Cells." +target gene hsa-mir-23b "Diabetes Mellitus, Type 1" 27737950 "MicroRNAs miR-23a-3p, miR-23b-3p, and miR-149-5p Regulate the Expression of Proapoptotic BH3-Only Proteins DP5 and PUMA in Human Pancreatic ¦Â-Cells." +target gene hsa-mir-183 "Leukemia, Myeloid, Acute, Pediatric" 27738758 MicroRNA-183 promotes cell proliferation via regulating programmed cell death 6 in pediatric acute myeloid leukemia. +target gene hsa-mir-585 "Carcinoma, Lung, Non-Small-Cell" 27743168 MicroRNA-585 acts as a tumor suppressor in non-small-cell lung cancer by targeting hSMG-1. +target gene hsa-mir-551b "Carcinoma, Ovarian" 27743201 "Downregulation of Foxo3 and TRIM31 by miR-551b in side population promotes cell proliferation, invasion, and drug resistance of ovarian cancer." +target gene hsa-mir-124 Osteosarcoma 27743351 MicroRNA-124 upregulation inhibits proliferation and invasion of osteosarcoma cells by targeting sphingosine kinase 1. +target gene hsa-mir-25 "Carcinoma, Cervical" 27743413 miR-25-3p reverses epithelial-mesenchymal transition via targeting Sema4C in cisplatin-resistance cervical cancer cells. +target gene hsa-mir-96 "Carcinoma, Prostate" 27746161 Epidermal growth factor receptor signaling promotes metastatic prostate cancer through microRNA-96-mediated downregulation of the tumor suppressor ETV6. +target gene hsa-mir-1297 "Carcinoma, Prostate" 27746178 MicroRNA-1297 inhibits prostate cancer cell proliferation and invasion by targeting the AEG-1/Wnt signaling pathway. +target gene hsa-mir-155 Idiopathic Pulmonary Fibrosis 27746237 The role of microRNA-155/liver X receptor pathway in experimental and idiopathic pulmonary fibrosis. +target gene hsa-mir-16 Recurrent Spontaneous Abortion 27748453 MicroRNA-16 inhibits feto-maternal angiogenesis and causes recurrent spontaneous abortion by targeting vascular endothelial growth factor. +target gene hsa-mir-204 "Carcinoma, Hepatocellular" 27748572 miR-204-5p targeting SIRT1 regulates hepatocellular carcinoma progression. +target gene hsa-mir-16 Glioma 27748823 "MicroRNA-16 inhibits the proliferation, migration and invasion of glioma cells by targeting Sal-like protein?4." +target gene hsa-mir-203 Myeloma 27748826 miR-203 inhibits cell growth and regulates G1/S transition by targeting Bmi-1 in myeloma cells. +target gene hsa-mir-382 "Carcinoma, Prostate" 27748848 MicroRNA-382 inhibits prostate cancer cell proliferation and metastasis through targeting COUP-TFII. +target gene hsa-mir-455 "Carcinoma, Hepatocellular" 27748890 MicroRNA-455 regulates migration and invasion of human hepatocellular carcinoma by targeting Runx2. +target gene hsa-mir-124 "Carcinoma, Breast" 27748910 MicroRNA-124 inhibits cell proliferation and migration by regulating SNAI2 in breast cancer. +target gene hsa-mir-20a "Carcinoma, Hepatocellular" 27748919 MicroRNA-20a-5p targets RUNX3 to regulate proliferation and migration of human hepatocellular cancer cells. +target gene hsa-mir-520a "Carcinoma, Lung, Non-Small-Cell" 27748920 microRNA-520a-3p inhibits proliferation and cancer stem cell phenotype by targeting HOXD8 in non-small cell lung cancer. +target gene hsa-mir-132 "Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal" 27751825 MiR-132 plays an oncogenic role in laryngeal squamous cell carcinoma by targeting FOXO1 and activating the PI3K/AKT pathway. +target gene hsa-mir-27b Atherosclerosis 27755984 miRNA-27b modulates endothelial cell angiogenesis by directly targeting Naa15 in atherogenesis. +target gene hsa-mir-10b "Carcinoma, Hepatocellular" 27756250 miR-10b exerts oncogenic activity in human hepatocellular carcinoma cells by targeting expression of CUB and sushi multiple domains 1 (CSMD1). +target gene hsa-mir-302 Neoplasms [unspecific] 27756792 A MicroRNA302-367-Erk1/2-Klf2-S1pr1 Pathway Prevents Tumor Growth via Restricting Angiogenesis and Improving Vascular Stability. +target gene hsa-mir-9 Cardiac Fibrosis 27756824 "MicroRNA-9 inhibits high glucose-induced proliferation, differentiation and collagen accumulation of cardiac fibroblasts by down-regulation of TGFBR2." +target gene hsa-mir-9 "Fatty Liver, Non-Alcoholic" 27756894 Altered microRNA-9 Expression Level is Directly Correlated with Pathogenesis of Nonalcoholic Fatty Liver Disease by Targeting Onecut2 and SIRT1. +target gene hsa-mir-182 Heart Failure 27763637 miR-182 negatively regulated Nogo-C expression and was downregulated during MI +target gene hsa-mir-10b Osteosarcoma 27764757 miR-10b promotes invasion by targeting KLF4 in osteosarcoma cells. +target gene hsa-mir-451 "Leukemia, Myeloid, Acute" 27764807 c-Myc suppresses miR-451?YWTAZ/AKT axis via recruiting HDAC3 in acute myeloid leukemia. +target gene hsa-mir-21 Arteriosclerosis Obliterans 27765464 Cigarette smoking represses expression of cytokine IL-12 and its regulator miR-21-An observational study in patients with coronary artery disease. +target gene hsa-mir-29c Idiopathic Pulmonary Fibrosis 27765762 "MicroRNA-29c regulates apoptosis sensitivity via modulation of the cell-surface death receptor, Fas, in lung fibroblasts." +target gene hsa-mir-33a "Carcinoma, Gallbladder" 27769047 The microRNA miR-33a suppresses IL-6-induced tumor progression by binding Twist in gallbladder cancer. +target gene hsa-mir-16 Chronic Inflammatory Pain 27770129 MicroRNA-16 Alleviates Inflammatory Pain by Targeting Ras-Related Protein 23 (RAB23) and Inhibiting p38 MAPK Activation. +target gene hsa-mir-590 "Carcinoma, Lung, Non-Small-Cell" 27770372 microRNA-590 suppresses the tumorigenesis and invasiveness of non-small cell lung cancer cells by targeting ADAM9. +target gene hsa-let-7i Neoplasms [unspecific] 27770612 Let-7i-Induced Atg4B Suppression Is Essential for Autophagy of Placental Trophoblast in Preeclampsia. +target gene hsa-mir-145 "Squamous Cell Carcinoma, Esophageal" 27771733 MicroRNA-145 Inhibits Cell Migration and Invasion and Regulates Epithelial-Mesenchymal Transition (EMT) by Targeting Connective Tissue Growth Factor (CTGF) in Esophageal Squamous Cell Carcinoma. +target gene hsa-mir-218 "Carcinoma, Colon" 27773352 DCC Confers Susceptibility to Depression-like Behaviors in Humans and Mice and Is Regulated by miR-218. +target gene hsa-mir-107 "Carcinoma, Hepatocellular" 27773820 MiR-107 suppresses proliferation of hepatoma cells through targeting HMGA2 mRNA 3'UTR. +target gene hsa-mir-125b Diabetic Nephropathy 27775793 microRNA-125b contributes to high glucose-induced reactive oxygen species generation and apoptosis in HK-2 renal tubular epithelial cells by targeting angiotensin-converting enzyme 2. +target gene hsa-mir-1 Osteosarcoma 27777493 "miR-1 Inhibits Cell Growth, Migration, and Invasion by Targeting VEGFA in Osteosarcoma Cells." +target gene hsa-mir-375 "Squamous Cell Carcinoma, Esophageal" 27779648 Regulation of MMP13 by antitumor microRNA-375 markedly inhibits cancer cell migration and invasion in esophageal squamous cell carcinoma. +target gene hsa-mir-19a "Carcinoma, Renal Cell, Clear-Cell" 27779660 miR-19a correlates with poor prognosis of clear cell renal cell carcinoma patients via promoting cell proliferation and suppressing PTEN/SMAD4 expression. +target gene hsa-mir-4262 Cutaneous Melanoma 27779691 miR-4262 promotes the proliferation of human cutaneous malignant melanoma cells through KLF6-mediated EGFR inactivation and p21 upregulation. +target gene hsa-mir-574 "Carcinoma, Prostate" 27779701 Downregulation of microRNA?574 in cancer stem cells causes recurrence of prostate cancer via targeting REL. +target gene hsa-mir-300 "Carcinoma, Colon" 27779716 miR-300 promotes proliferation and EMT-mediated colorectal cancer migration and invasion by targeting p53. +target gene hsa-mir-148a "Carcinoma, Thyroid" 27779717 miR-148a inhibits self-renewal of thyroid cancer stem cells via repressing INO80 expression. +target gene hsa-mir-218 Colorectal Carcinoma 27779719 Downregulation of YEATS4 by miR-218 sensitizes colorectal cancer cells to L-OHP-induced cell apoptosis by inhibiting cytoprotective autophagy. +target gene hsa-mir-24 "Carcinoma, Hepatocellular" 27780140 MicroRNA-24 increases hepatocellular carcinoma cell metastasis and invasion by targeting p53: miR-24 targeted p53. +target gene hsa-mir-34b Spinal Cord Injuries 27780189 Changes in the Expression of miR-34a and its Target Genes Following Spinal Cord Injury In Rats. +target gene hsa-mir-34c Spinal Cord Injuries 27780189 Changes in the Expression of miR-34a and its Target Genes Following Spinal Cord Injury In Rats. +target gene hsa-mir-203a "Carcinoma, Hepatocellular" 27780730 miR-203a is involved in HBx-induced inflammation by targeting Rap1a. +target gene hsa-mir-379 Osteosarcoma 27781416 MicroRNA-379 suppresses osteosarcoma progression by targeting PDK1. +target gene hsa-mir-155 "Leukemia, Myeloid, Acute" 27786352 Targeting miR-155 suppresses proliferation and induces apoptosis of HL-60 cells by targeting Slug/PUMA signal. +target gene hsa-mir-101 Glioblastoma 27792996 MicroRNA-101 reverses temozolomide resistance by inhibition of GSK3¦Â in glioblastoma. +target gene hsa-mir-637 Pulmonary Hypertension 27794186 Downregulation of microRNA-637 Increases Risk of Hypoxia-Induced Pulmonary Hypertension by Modulating Expression of Cyclin Dependent Kinase 6 (CDK6) in Pulmonary Smooth Muscle Cells. +target gene hsa-mir-133a Osteosarcoma 27794430 Down-regulation of RBP-J mediated by microRNA-133a suppresses dendritic cells and functions as a potential tumor suppressor in osteosarcoma. +target gene hsa-mir-182 "Carcinoma, Pancreatic" 27797718 MicroRNA-182 promotes pancreatic cancer cell proliferation and migration by targeting ¦Â-TrCP2. +target gene hsa-mir-106b "Carcinoma, Lung" 27797825 "MCM7 and its hosted miR-25, 93 and 106b cluster elicit YAP/TAZ oncogenic activity in lung cancer." +target gene hsa-mir-25 "Carcinoma, Lung" 27797825 "MCM7 and its hosted miR-25, 93 and 106b cluster elicit YAP/TAZ oncogenic activity in lung cancer." +target gene hsa-mir-93 "Carcinoma, Lung" 27797825 "MCM7 and its hosted miR-25, 93 and 106b cluster elicit YAP/TAZ oncogenic activity in lung cancer." +target gene hsa-mir-145 Polycystic Ovarian Syndrome 27799458 MicroRNA-145 Negatively Regulates Cell Proliferation Through Targeting IRS1 in Isolated Ovarian Granulosa Cells From Patients With Polycystic Ovary Syndrome. +target gene hsa-mir-25 Melanoma 27801786 Upregulated MicroRNA-25 Mediates the Migration of Melanoma Cells by Targeting DKK3 through the WNT/¦Â-Catenin Pathway. +target gene hsa-mir-92a Glioma 27801803 miR-92a-3p Exerts Various Effects in Glioma and Glioma Stem-Like Cells Specifically Targeting CDH1/¦Â-Catenin and Notch-1/Akt Signaling Pathways. +target gene hsa-mir-133b "Carcinoma, Ovarian" 27802259 Down-Regulation of MicroRNA-133b Suppresses Apoptosis of Lens Epithelial Cell by Up-Regulating BCL2L2 in Age-Related Cataracts. +target gene hsa-mir-181a Acute Lung Injury 27802900 Downregulation of miR-181a protects mice from LPS-induced acute lung injury by targeting Bcl-2. +target gene hsa-mir-20a Tuberculosis 27803889 microRNA-20a Inhibits Autophagic Process by Targeting ATG7 and ATG16L1 and Favors Mycobacterial Survival in Macrophage Cells. +target gene hsa-mir-92a "Lymphoma, Large B-Cell" 27806315 Primary mediastinal large B-cell lymphoma: transcriptional regulation by miR-92a through FOXP1 targeting. +target gene hsa-mir-940 "Carcinoma, Hepatocellular" 27807540 miR-940 Suppresses Tumor Cell Invasion and Migration via Regulation of CXCR2 in Hepatocellular Carcinoma. +target gene hsa-mir-27b "Carcinoma, Breast" 27809310 Downregulation of microRNA-27b-3p enhances tamoxifen resistance in breast cancer by increasing NR5A2 and CREB1 expression. +target gene hsa-mir-222 Ovarian Neoplasms 27811362 MicroRNA-222-3p/GNAI2/AKT axis inhibits epithelial ovarian cancer cell growth and associates with good overall survival. +target gene hsa-mir-155 "Carcinoma, Lung, Non-Small-Cell" 27811366 "MiR-21 and MiR-155 promote non-small cell lung cancer progression by downregulating SOCS1, SOCS6, and PTEN." +target gene hsa-mir-214 "Carcinoma, Colon" 27811858 The FOXD3/miR-214/MED19 axis suppresses tumour growth and metastasis in human colorectal cancer. +target gene hsa-let-7f Cerebral Ischemia 27812761 Let-7f Regulates the Hypoxic Response in Cerebral Ischemia by Targeting NDRG3. +target gene hsa-mir-34a "Carcinoma, Breast" 27813227 MiR-34a modulates ErbB2 in breast cancer. +target gene hsa-mir-199a "Carcinoma, Bladder" 27814720 miR-199a-5p suppresses human bladder cancer cell metastasis by targeting CCR7. +target gene hsa-mir-542 "Carcinoma, Hepatocellular" 27815069 MicroRNA-542-3p inhibits the growth of hepatocellular carcinoma cells by targeting FZD7/Wnt signaling pathway. +target gene hsa-mir-106a Glioblastoma 27815074 MicroRNA-106a-5p facilitates human glioblastoma cell proliferation and invasion by targeting adenomatosis polyposis coli protein. +target gene hsa-mir-10a "Lymphoma, Large B-Cell, Diffuse" 27815824 miR-10a inhibits cell proliferation and promotes cell apoptosis by targeting BCL6 in diffuse large B-cell lymphoma. +target gene hsa-mir-124 "Carcinoma, Breast" 27815936 MicroRNA-124 enhances response to radiotherapy in human epidermal growth factor receptor 2-positive breast cancer cells by targeting signal transducer and activator of transcription 3. +target gene hsa-mir-1 Neoplasms [unspecific] 27819721 miR-1 association with cell proliferation inhibition and apoptosis in vestibular schwannoma by targeting VEGFA. +target gene hsa-mir-203 Glioblastoma 27820599 Tissue mechanics promote IDH1-dependent HIF1¦Á-tenascin C feedback to regulate glioblastoma?aggression. +target gene hsa-mir-3117 "Carcinoma, Hepatocellular" 27822662 miR-3117 regulates hepatocellular carcinoma cell proliferation by targeting PHLPPL. +target gene hsa-mir-143 "Carcinoma, Colon" 27827523 MicroRNA-143 inhibits colorectal cancer cell proliferation by targeting MMP7. +target gene hsa-mir-639 "Carcinoma, Thyroid" 27829546 MiR-639 promoted cell proliferation and cell cycle in human thyroid cancer by suppressing CDKN1A expression. +target gene hsa-mir-503 Atherosclerosis 27829550 miR-503 inhibits platelet-derived growth factor-induced human aortic vascular smooth muscle cell proliferation and migration through targeting the insulin receptor. +target gene hsa-mir-17 "Carcinoma, Breast" 27831559 Decreased expression of microRNA-17 and microRNA-20b promotes breast cancer resistance to taxol therapy by upregulation of NCOA3. +target gene hsa-mir-20b "Carcinoma, Breast" 27831559 Decreased expression of microRNA-17 and microRNA-20b promotes breast cancer resistance to taxol therapy by upregulation of NCOA3. +target gene hsa-mir-129 "Carcinoma, Breast" 27831649 MiR-129-5p is downregulated in breast cancer cells partly due to promoter H3K27m3 modification and regulates epithelial-mesenchymal transition and multi-drug resistance. +target gene hsa-mir-378a Liver Cirrhosis 27832641 Activation of Hepatic Stellate Cells is Inhibited by microRNA-378a-3p via Wnt10a. +target gene hsa-mir-146a "Squamous Cell Carcinoma, Esophageal" 27832663 miR-146a-5p mediates epithelial-mesenchymal transition of oesophageal squamous cell carcinoma via targeting Notch2. +target gene hsa-mir-199a "Carcinoma, Hepatocellular" 27832779 "miR-199a-3p inhibits cell proliferation and induces apoptosis by targeting YAP1, suppressing Jagged1-Notch signaling in human hepatocellular carcinoma." +target gene hsa-mir-375 "Carcinoma, Prostate" 27832783 miR-375 induces docetaxel resistance in prostate cancer by targeting SEC23A and YAP1. +target gene hsa-mir-22 Astrocytoma 27834627 Promotion of astrocytoma cell invasion by micro RNA-22 targeting of tissue inhibitor of matrix metalloproteinase-2. +target gene hsa-mir-125a Inflammation 27836539 these findings identify a PPAR¦Ã-miR-125a-NOD1 signaling axis in endothelial cells that is critical in the regulation of inflammation-mediated angiogenesis +target gene hsa-mir-34a "Carcinoma, Lung" 27836543 miR-34a sensitizes lung cancer cells to cisplatin via p53/miR-34a/MYCN axis. +target gene hsa-mir-215 Glioma 27837373 MicroRNA-215 enhances invasion and migration by targeting retinoblastoma tumor suppressor gene 1 in high-grade glioma. +target gene hsa-mir-141 "Carcinoma, Lung, Non-Small-Cell" 27840955 miR-141 regulation of EIF4E expression affects docetaxel chemoresistance of non-small cell lung cancer. +target gene hsa-mir-503 "Carcinoma, Hepatocellular" 27840964 miR-503 inhibits proliferation making human hepatocellular carcinoma cells susceptible to 5?fluorouracil by targeting EIF4E. +target gene hsa-mir-34a Cataract 27840975 miR?34a suppresses proliferation and induces apoptosis of human lens epithelial cells by targeting E2F3. +target gene hsa-mir-124 Breast Neoplasms 27842510 miR-124-3p functions as a tumor suppressor in breast cancer by targeting CBL. +target gene hsa-mir-148a Multiple Myeloma 27842905 MiR-148a participates in the growth of RPMI8226 multiple myeloma cells by regulating CDKN1B. +target gene hsa-mir-27b "Carcinoma, Gastric" 27844448 miR-27b inhibits gastric cancer metastasis by targeting NR2F2. +target gene hsa-mir-146a Osteoarthritis 27845876 Hypoxia-induced microRNA-146a represses Bcl-2 through Traf6/IRAK1 but not Smad4 to promote chondrocyte autophagy. +target gene hsa-mir-33a "Carcinoma, Lung, Non-Small-Cell" 27856248 MiR-33a suppresses proliferation of NSCLC cells via targeting METTL3 mRNA. +target gene hsa-mir-16 Colorectal Carcinoma 27857191 Deregulation of the miR-16-KRAS axis promotes colorectal cancer. +target gene hsa-mir-383 "Carcinoma, Lung" 27862077 MicroRNA-383 is a tumor suppressor in human lung cancer by targeting endothelial PAS domain-containing protein 1. +target gene hsa-mir-187 "Carcinoma, Gastric" 27864146 MicroRNA-187 regulates gastric cancer progression by targeting the tumor suppressor CRMP1. +target gene hsa-mir-335 "Carcinoma, Lung, Small-Cell" 27871924 MiR-335 regulates the chemo-radioresistance of small cell lung cancer cells by targeting PARP-1. +target gene hsa-mir-377 "Carcinoma, Lung, Non-Small-Cell" 27874949 miR-377 inhibited tumorous behaviors of non-small cell lung cancer through directly targeting CDK6. +target gene hsa-mir-194 "Carcinoma, Gastric" 27874950 miR-194 inhibits gastric cancer cell proliferation and tumorigenesis by targeting KDM5B. +target gene hsa-mir-373 "Lymphoma, T-Cell" 27874957 Restoration of microRNA-373 suppresses growth of human T-cell lymphoma cells by repressing CCND1. +target gene hsa-mir-137 "Carcinoma, Ovarian" 27875524 microRNA-137 promotes apoptosis in ovarian cancer cells via the regulation of XIAP. +target gene hsa-mir-371 Lupus Nephritis 27878241 Hsa?miR?371?5p inhibits human mesangial cell proliferation and promotes apoptosis in lupus nephritis by directly targeting hypoxia?inducible factor 1¦Á. +target gene hsa-mir-200b "Carcinoma, Pancreatic" 27878247 Oridonin inhibition and miR?200b?3p/ZEB1 axis in human pancreatic cancer. +target gene hsa-mir-362 "Carcinoma, Cervical" 27878258 "MicroRNA-362 is downregulated in cervical cancer and inhibits cell proliferation, migration and invasion by directly targeting SIX1." +target gene hsa-mir-3619 "Carcinoma, Prostate" 27878260 miR-3619-5p inhibits prostate cancer cell growth by activating CDKN1A expression. +target gene hsa-mir-638 "Carcinoma, Hepatocellular" 27878280 Loss of miR-638 promotes invasion and epithelial-mesenchymal transition by targeting SOX2 in hepatocellular carcinoma. +target gene hsa-mir-148a "Carcinoma, Renal Cell" 27878305 miR-148a suppresses human renal cell carcinoma malignancy by targeting AKT2. +target gene hsa-mir-429 "Carcinoma, Cervical" 27883176 miR-429 is involved in regulation of NF-¦ÊBactivity by targeting IKK¦Â and suppresses oncogenic activity in cervical cancer cells. +target gene hsa-mir-421 "Carcinoma, Cervical" 27886335 microRNA 421 induces apoptosis of c-33a cervical cancer cells via down-regulation of Bcl-xL. +target gene hsa-mir-202 "Adenocarcinoma, Lung" 27887846 Long non-coding RNA metastasis-associated lung adenocarcinoma transcript 1 regulates the expression of Gli2 by miR-202 to strengthen gastric cancer progression. +target gene hsa-mir-136 "Carcinoma, Ovarian" 27887917 MicroRNA-136 inhibits cancer stem cell activity and enhances the anti-tumor effect of paclitaxel against chemoresistant ovarian cancer cells by targeting Notch3. +target gene hsa-mir-24 Colon Neoplasms 27888625 "TRIM11, a direct target of miR-24-3p, promotes cell proliferation and inhibits apoptosis in colon cancer." +target gene hsa-let-7g Pulmonary Hypertension 27889560 MicroRNA let-7g inhibited hypoxia-induced proliferation of PASMCs via G0/G1 cell cycle arrest by targeting c-myc. +target gene hsa-mir-22 "Leukemia, Myeloid, Chronic" 27889568 FosB regulates expression of miR-22 during PMA induced differentiation of K562?cells to megakaryocytes. +target gene hsa-mir-181 "Leukemia, T-Cell" 27889686 MicroRNA-181 contributes to downregulation of SAMHD1 expression in CD4+ T-cells derived from S¨¨zary syndrome patients. +target gene hsa-mir-146a Dermatomyositis 27889748 MiR-146a Regulates Inflammatory Infiltration by Macrophages in Polymyositis/Dermatomyositis by Targeting TRAF6 and Affecting IL-17/ICAM-1 Pathway. +target gene hsa-mir-98 "Carcinoma, Hepatocellular" 27890434 miR-98 inhibits hepatocellular carcinoma cell proliferation via targeting EZH2 and suppressing Wnt/¦Â-catenin signaling pathway. +target gene hsa-mir-383 "Carcinoma, Prostate" 27893706 MicroRNA-383 located in frequently deleted chromosomal locus 8p22 regulates CD44 in prostate cancer. +target gene hsa-mir-214 Ischemia-Reperfusion Injury 27894079 MicroRNA-214 protects against hypoxia/reoxygenation induced cell damage and myocardial ischemia/reperfusion injury via suppression of PTEN and Bim1 expression. +target gene hsa-mir-509 "Carcinoma, Lung, Non-Small-Cell" 27894843 "MiR-509-5p suppresses the proliferation, migration, and invasion of non-small cell lung cancer by targeting YWHAG." +target gene hsa-mir-9 Melanoma 27895497 "MicroRNA-9 suppresses the growth, migration, and invasion of malignant melanoma cells via targeting NRP1." +target gene hsa-mir-15b Glioblastoma 27896672 miR-15b Inhibits the Progression of Glioblastoma Cells Through Targeting Insulin-like Growth Factor Receptor 1. +target gene hsa-mir-26a Prostate Neoplasms 27900011 Downregulated microRNA-26a modulates prostate cancer cell proliferation and apoptosis by targeting COX-2. +target gene hsa-mir-150 Osteosarcoma 27900020 MicroRNA-150 upregulation reduces osteosarcoma cell invasion and metastasis by downregulating Ezrin. +target gene hsa-mir-138 Cervical Neoplasms 27900047 "MicroRNA-138 inhibits proliferation, migration and invasion through targeting hTERT in cervical cancer." +target gene hsa-mir-31 Colitis 27901018 The signaling axis of microRNA-31/interleukin-25 regulates Th1/Th17-mediated inflammation response in colitis. +target gene hsa-mir-145 Asthma 27902892 MicroRNA-145 influences the balance of Th1/Th2 via regulating RUNX3 in asthma patients. +target gene hsa-mir-125b Myeloma 27903272 "BETi-mediated inhibition of cMYC correlates with the upregulation of miR-125b-5p and the downregulation of the cMYC/miR-125b-5p target gene IRF4, a transcriptional repressor of MICA" +target gene hsa-mir-206 Bladder Neoplasms 27904673 MicroRNA-206 acts as a tumor suppressor in bladder cancer via targeting YRDC. +target gene hsa-mir-101 "Squamous Cell Carcinoma, Oral" 27904690 miRNA-101 acts as a tumor suppressor in oral squamous cell carcinoma by targeting CX chemokine receptor 7. +target gene hsa-mir-491 Glioma 27905892 miR-491 regulates glioma cells proliferation by targeting TRIM28 in vitro. +target gene hsa-mir-140 Gout 27906093 microRNA -140-5p inhibits colorectal cancer invasion and metastasis by targeting ADAMTS5 and IGFBP5. +target gene hsa-mir-185 "Carcinoma, Lung, Non-Small-Cell" 27906433 MicroRNA-185-5p modulates chemosensitivity of human non-small cell lung cancer to cisplatin via targeting ABCC1. +target gene hsa-mir-451 Osteosarcoma 27908732 "miR-451 inhibits cell growth, migration and angiogenesis in human osteosarcoma via down-regulating IL 6R." +target gene hsa-mir-146a Vascular Disease [unspecific] 27908889 MicroRNA-146a Induces Lineage-Negative Bone Marrow Cell Apoptosis and Senescence by Targeting Polo-Like Kinase 2 Expression. +target gene hsa-mir-101 Glioblastoma 27911279 "MicroRNA-101 inhibits proliferation, migration and invasion of human glioblastoma by targeting SOX9." +target gene hsa-mir-346 "Carcinoma, Breast" 27913185 MiR-346 promotes the biological function of breast cancer cells by targeting SRCIN1 and reduces chemosensitivity to docetaxel. +target gene hsa-mir-181a Keloid 27915346 MiR-181a Targets PHLPP2 to Augment AKT Signaling and Regulate Proliferation and Apoptosis in Human Keloid Fibroblasts. +target gene hsa-mir-21 Lung Fibrosis 27916096 miR-21 promotes pulmonary fibrosis in rats via down-regulating the expression of ADAMTS-1. +target gene hsa-mir-217 "Carcinoma, Breast" 27916422 PGC-1 alpha interacts with microRNA-217 to functionally regulate breast cancer cell proliferation. +target gene hsa-mir-223 Colorectal Carcinoma 27916606 FBX8 is a metastasis suppressor downstream of miR-223 and targeting mTOR for degradation in colorectal carcinoma. +target gene hsa-mir-139 "Carcinoma, Breast" 27916718 Loss of the Opa interacting protein 5 inhibits breast cancer proliferation through miR-139-5p/NOTCH1 pathway. +target gene hsa-mir-15a Osteoarthritis 27916780 MiR-15a-5p regulates viability and matrix degradation of human osteoarthritis chondrocytes via targeting VEGFA. +target gene hsa-mir-33a "Carcinoma, Prostate" 27921232 Biological function and mechanism of miR-33a in prostate cancer survival and metastasis: via downregulating Engrailed-2. +target gene hsa-mir-145 Osteoarthritis 27922673 Effects of miR-145 on the inhibition of chondrocyte proliferation and fibrosis by targeting TNFRSF11B in human osteoarthritis. +target gene hsa-mir-152 "Carcinoma, Hepatocellular" 27922690 MicroRNA-152 inhibits tumor cell growth by directly targeting RTKN in hepatocellular carcinoma. +target gene hsa-mir-211 "Carcinoma, Cervical" 27923652 MiR-211 inhibits invasion and epithelial-to-mesenchymal transition (EMT) of cervical cancer cells via targeting MUC4. +target gene hsa-mir-483 Kawasaki Syndrome 27923814 miR-483 Targeting of CTGF Suppresses Endothelial-to-Mesenchymal Transition: Therapeutic Implications in Kawasaki Disease. +target gene hsa-mir-124 "Carcinoma, Lung, Non-Small-Cell" 27924500 miR-124 modulates gefitinib resistance through SNAI2 and STAT3 in non-small cell lung cancer. +target gene hsa-mir-206 "Carcinoma, Renal Cell" 27924503 miR-206 inhibits renal cell cancer growth by targeting GAK. +target gene hsa-mir-205 Cervical Neoplasms 27929537 Upregulation of MiR-205 under hypoxia promotes epithelial-mesenchymal transition by targeting ASPP2. +target gene hsa-mir-205 Lung Neoplasms 27929537 Upregulation of MiR-205 under hypoxia promotes epithelial-mesenchymal transition by targeting ASPP2. +target gene hsa-mir-151 "Carcinoma, Breast" 27930738 miR-151-3p Targets TWIST1 to Repress Migration of Human Breast Cancer Cells. +target gene hsa-mir-200c "Carcinoma, Lung, Non-Small-Cell" 27930974 miR-200c enhances sensitivity of drug-resistant non-small cell lung cancer to gefitinib by suppression of PI3K/Akt signaling pathway and inhibites cell migration via targeting ZEB1. +target gene hsa-let-7a "Carcinoma, Hepatocellular" 27932893 Let-7a enhances the sensitivity of hepatocellular carcinoma cells to cetuximab by regulating STAT3 expression. +target gene hsa-mir-145 "Carcinoma, Cervical" 27933466 "microRNA-145 modulates epithelial-mesenchymal transition and suppresses proliferation, migration and invasion by targeting SIP1 in human cervical cancer cells." +target gene hsa-mir-125b Preeclampsia 27935985 miR-125b Enhances IL-8 Production in Early-Onset Severe Preeclampsia by Targeting Sphingosine-1-Phosphate Lyase 1. +target gene hsa-mir-138 Psoriasis 27936398 MicroRNA138 regulates keratin 17 protein expression to affect HaCaT cell proliferation and apoptosis by targeting hTERT in psoriasis vulgaris. +target gene hsa-mir-23a Rheumatoid Arthritis 27936459 MiR-23a inhibited IL-17-mediated proinflammatory mediators expression via targeting IKK¦Á in articular chondrocytes. +target gene hsa-mir-181b Glioma 27938503 MicroRNA-181b Inhibits Cellular Proliferation and Invasion of Glioma Cells via Targeting Sal-Like Protein 4. +target gene hsa-mir-98 "Carcinoma, Lung, Non-Small-Cell" 27938506 MicroRNA-98 Plays a Suppressive Role in Non-Small Cell Lung Cancer Through Inhibition of SALL4 Protein Expression. +target gene hsa-mir-150 Systemic Lupus Erythematosus 27940256 Enhanced expression of TREM-1 in splenic cDCs in lupus prone mice and it was modulated by miRNA-150. +target gene hsa-mir-141 "Carcinoma, Prostate" 27956179 MiR-141-3p promotes prostate cancer cell proliferation through inhibiting kruppel-like factor-9 expression. +target gene hsa-mir-7 "Squamous Cell Carcinoma, Esophageal" 27956498 "In cytoplasm, CCAT1 regulates HOXB13 as a molecular decoy for miR-7, a microRNA that targets both CCAT1 and HOXB13, thus facilitating cell growth and migration" +target gene hsa-mir-194 "Carcinoma, Prostate" 27959429 MicroRNA-194 suppresses prostate cancer migration and invasion by downregulating human nuclear distribution protein. +target gene hsa-mir-326 Neoplasms [unspecific] 27960279 Resveratrol Induces Cancer Cell Apoptosis through MiR-326/PKM2-Mediated ER Stress and Mitochondrial Fission. +target gene hsa-mir-320a Polycystic Ovarian Syndrome 27965096 Deregulation of RUNX2 by miR-320a deficiency impairs steroidogenesis in cumulus granulosa cells from polycystic ovary syndrome (PCOS) patients. +target gene hsa-mir-451a Cardiomyopathy 27974462 Down-regulation of microRNA-451a facilitates the activation and proliferation of CD4+ T cells by targeting Myc in patients with dilated cardiomyopathy. +target gene hsa-mir-124 Inflammatory Bowel Diseases 27977009 Downregulated expression of microRNA-124 in pediatric intestinal failure patients modulates macrophages activation by inhibiting STAT3 and AChE. +target gene hsa-mir-138 "Carcinoma, Bladder" 27978829 miR-138-5p contributes to cell proliferation and invasion by targeting Survivin in bladder cancer cells. +target gene hsa-mir-200b Inflammatory Bowel Diseases 27979826 miR-200b inhibits TNF-¦Á-induced IL-8 secretion and tight junction disruption of intestinal epithelial cells in vitro. +target gene hsa-mir-200a "Carcinoma, Colon" 27983967 MiR-200a acts as an oncogene in colorectal carcinoma by targeting PTEN. +target gene hsa-mir-494 "Carcinoma, Ovarian" 27983981 CUL4A functions as an oncogene in ovarian cancer and is directly regulated by miR-494. +target gene hsa-mir-130a "Carcinoma, Prostate" 27984115 Epigenetic disruption of miR-130a promotes prostate cancer by targeting SEC23B and DEPDC1. +target gene hsa-mir-497 Heart Failure 27992564 MicroRNA-497 Inhibits Cardiac Hypertrophy by Targeting Sirt4. +target gene hsa-mir-126 Atherosclerosis 27993686 MicroRNA-126 suppresses inflammation in endothelial cells under hyperglycemic condition by targeting HMGB1. +target gene hsa-mir-506 "Carcinoma, Colon" 27993882 MicroRNA-506 Inhibits Malignancy of Colorectal Carcinoma Cells by Targeting LAMC1. +target gene hsa-mir-29c Breast Neoplasms 27994679 Brown Seaweed Fucoidan Inhibits Cancer Progression by Dual Regulation of mir-29c/ADAM12 and miR-17-5p/PTEN Axes in Human Breast Cancer Cells. +target gene hsa-mir-22 Heart Failure 27997889 MiR-22 may Suppress Fibrogenesis by Targeting TGF¦ÂR I in Cardiac Fibroblasts. +target gene hsa-mir-520b "Carcinoma, Gastric" 27997901 MiR-520b/e Regulates Proliferation and Migration by Simultaneously Targeting EGFR in Gastric Cancer. +target gene hsa-mir-520e "Carcinoma, Gastric" 27997901 MiR-520b/e Regulates Proliferation and Migration by Simultaneously Targeting EGFR in Gastric Cancer. +target gene hsa-mir-143 "Carcinoma, Cervical" 27998464 miR-143 inhibits cell proliferation through targeted regulating the expression of K-ras gene in HeLa cells. +target gene hsa-mir-340 "Carcinoma, Hepatocellular" 27998770 MicroRNA-340 inhibits the proliferation and invasion of hepatocellular carcinoma cells by targeting JAK1. +target gene hsa-mir-130a Osteoarthritis 27999816 "miR-204, which targets RUNX2, and miR-130a, which inhibits PPAR¦Ã, were lower and higher, respectively, in F versus OA serum samples" +target gene hsa-mir-204 Osteoarthritis 27999816 "miR-204, which targets RUNX2, and miR-130a, which inhibits PPAR¦Ã, were lower and higher, respectively, in F versus OA serum samples" +target gene hsa-mir-487b Colorectal Carcinoma 28000854 Identification of microRNA-487b as a negative regulator of liver metastasis by regulation of KRAS in colorectal cancer. +target gene hsa-mir-101 Colorectal Carcinoma 28000868 Methyl jasmonate induces the apoptosis of human colorectal cancer cells via downregulation of EZH2 expression by microRNA?101. +target gene hsa-mir-1290 "Leukemia, Lymphoblastic, Acute" 28000876 miR-196b/miR-1290 participate in the antitumor effect of resveratrol via regulation of IGFBP3 expression in acute lymphoblastic leukemia. +target gene hsa-mir-196b Leukemia 28000876 miR-196b/miR-1290 participate in the antitumor effect of resveratrol via regulation of IGFBP3 expression in acute lymphoblastic leukemia. +target gene hsa-mir-302a Glioma 28000880 "MicroRNA-302a targets GAB2 to suppress cell proliferation, migration and invasion of glioma." +target gene hsa-mir-152 "Carcinoma, Nasopharyngeal" 28000885 "MicroRNA?152 inhibits cell proliferation, migration and invasion by directly targeting MAFB in nasopharyngeal carcinoma." +target gene hsa-mir-631 Multiple Myeloma 28000886 hsa-miR-631 resensitizes bortezomib-resistant multiple myeloma cell lines by inhibiting UbcH10. +target gene hsa-mir-26a "Adenocarcinoma, Lung" 28000891 Expression of miR?26a exhibits a negative correlation with HMGA1 and regulates cancer progression by targeting HMGA1 in lung adenocarcinoma cells. +target gene hsa-mir-223 Testicular Germ Cell Tumor 28000896 miR?223?3p regulates cell growth and apoptosis via FBXW7 suggesting an oncogenic role in human testicular germ cell tumors. +target gene hsa-mir-367 "Carcinoma, Lung, Non-Small-Cell" 28000899 miR-367 promotes the proliferation and invasion of non-small cell lung cancer via targeting FBXW7. +target gene hsa-mir-24 "Carcinoma, Bladder" 28000900 "miR-24-3p regulates bladder cancer cell proliferation, migration, invasion and autophagy by targeting DEDD." +target gene hsa-mir-375 "Squamous Cell Carcinoma, Oral" 28000902 MicroRNA?375 inhibits oral squamous cell carcinoma cell migration and invasion by targeting platelet?derived growth factor?A. +target gene hsa-mir-221 Neuroblastoma 28003306 microRNA-221 Enhances MYCN via Targeting Nemo-like Kinase and Functions as an Oncogene Related to Poor Prognosis in Neuroblastoma. +target gene hsa-mir-20a Colorectal Carcinoma 28004114 miR-20a-directed regulation of BID is associated with the TRAIL sensitivity in colorectal cancer. +target gene hsa-mir-592 "Carcinoma, Lung, Non-Small-Cell" 28004116 miR-592 functions as a tumor suppressor in human non-small cell lung cancer by targeting SOX9. +target gene hsa-mir-382 "Carcinoma, Lung, Non-Small-Cell" 28006750 miR-382 inhibits tumor progression by targeting SETD8 in non-small cell lung cancer. +target gene hsa-mir-155 Ischemia-Reperfusion Injury 28006785 MiR-155 is Involved in Renal Ischemia-Reperfusion Injury via Direct Targeting of FoxO3a and Regulating Renal Tubular Cell Pyroptosis. +target gene hsa-mir-215 Hirschsprung Disease 28006787 Role of MiR-215 in Hirschsprung's Disease Pathogenesis by Targeting SIGLEC-8. +target gene hsa-mir-320a "Carcinoma, Gastric" 28008607 "MicroRNA-320a and microRNA-4496 attenuate Helicobacter pylori cytotoxin-associated gene A (CagA)-induced cancer-initiating potential and chemoresistance by targeting ¦Â-catenin and ATP-binding cassette, subfamily G, member 2." +target gene hsa-mir-4496 "Carcinoma, Gastric" 28008607 "MicroRNA-320a and microRNA-4496 attenuate Helicobacter pylori cytotoxin-associated gene A (CagA)-induced cancer-initiating potential and chemoresistance by targeting ¦Â-catenin and ATP-binding cassette, subfamily G, member 2." +target gene hsa-mir-194 "Carcinoma, Prostate" 28011622 MicroRNA-194 Promotes Prostate Cancer Metastasis by Inhibiting SOCS2. +target gene hsa-mir-3941 "Adenocarcinoma, Lung" 28012229 miR-3941: A novel microRNA that controls IGBP1 expression and is associated with malignant progression of lung adenocarcinoma. +target gene hsa-mir-381 "Carcinoma, Breast" 28012397 "miR-381 inhibited breast cancer cells proliferation, epithelial-to-mesenchymal transition and metastasis by targeting CXCR4." +target gene hsa-mir-129 "Carcinoma, Gastric" 28012924 MiR-129 regulates cisplatin-resistance in human gastric cancer cells by targeting P-gp. +target gene hsa-mir-590 "Adenocarcinoma, Lung" 28012926 miR-590 accelerates lung adenocarcinoma migration and invasion through directly suppressing functional target OLFM4. +target gene hsa-mir-149 "Leukemia, Myeloid, Acute" 28013316 Inhibition of MicroRNA-149-5p Induces Apoptosis of Acute Myeloid Leukemia Cell Line THP-1 by Targeting Fas Ligand (FASLG). +target gene hsa-mir-98 "Carcinoma, Colon" 28025745 MicroRNA-98 Suppress Warburg Effect by Targeting HK2 in Colon Cancer Cells. +target gene hsa-mir-33b "Carcinoma, Hepatocellular" 28026002 MicroRNA-33b suppresses the proliferation and metastasis of hepatocellular carcinoma cells through the inhibition of Sal-like protein 4 expression. +target gene hsa-mir-19b Antiphospholipid Syndrome 28028298 MicroRNA expression in antiphospholipid syndrome: a systematic review and microRNA target genes analysis. +target gene hsa-mir-20a Antiphospholipid Syndrome 28028298 MicroRNA expression in antiphospholipid syndrome: a systematic review and microRNA target genes analysis. +target gene hsa-mir-200b "Carcinoma, Prostate" 28028835 TIMP4 expression is regulated by miR-200b-3p in prostate cancer cells. +target gene hsa-mir-200c Neoplasms [unspecific] 28029649 MiR-200c is a cMyc-activated miRNA that promotes nasopharyngeal carcinoma by downregulating PTEN. +target gene hsa-mir-195 Osteosarcoma 28032380 MicroRNA-195-5p suppresses osteosarcoma cell proliferation and invasion by suppressing naked cuticle homolog 1. +target gene hsa-mir-216a "Carcinoma, Pancreatic" 28034748 "MiR-216a decreases MALAT1 expression, induces G2/M arrest and apoptosis in pancreatic cancer cells." +target gene hsa-mir-137 "Carcinoma, Colon" 28035913 MicroRNA-137 chemosensitizes colon cancer cells to the chemotherapeutic drug oxaliplatin (OXA) by targeting YBX1. +target gene hsa-mir-603 "Carcinoma, Breast, Triple Negative" 28036267 MicroRNA 603 acts as a tumor suppressor and inhibits triple-negative breast cancer tumorigenesis by targeting elongation factor 2 kinase. +target gene hsa-mir-224 Pancreatic Neoplasms 28036293 A retrospective study of NENs and miR-224 promotes apoptosis of BON-1 cells by targeting PCSK9 inhibition. +target gene hsa-mir-96 "Diabetes Mellitus, Type 2" 28036389 Induction of miR-96 by Dietary Saturated Fatty Acids Exacerbates Hepatic Insulin Resistance through the Suppression of INSR and IRS-1. +target gene hsa-mir-10b Ankylosing Spondylitis 28039186 miR-10b-5p is a novel Th17 regulator present in Th17 cells from ankylosing spondylitis. +target gene hsa-mir-194 Psoriasis 28040329 MicroRNA-194 regulates keratinocyte proliferation and differentiation by targeting Grainyhead-like 2 in psoriasis. +target gene hsa-mir-124 Glioblastoma 28040710 REST represses miR-124 and miR-203 to regulate distinct oncogenic properties of glioblastoma stem cells. +target gene hsa-mir-203 Glioblastoma 28040710 REST represses miR-124 and miR-203 to regulate distinct oncogenic properties of glioblastoma stem cells. +target gene hsa-mir-130b "Carcinoma, Bladder" 28042869 Genome-Wide Screen of miRNAs and Targeting mRNAs Reveals the Negatively Regulatory Effect of miR-130b-3p on PTEN by PI3K and Integrin ¦Â1 Signaling Pathways in Bladder Carcinoma. +target gene hsa-mir-486 Leukemia 28043832 Exosomal miR-486 regulates hypoxia-induced erythroid differentiation of erythroleukemia cells through targeting Sirt1. +target gene hsa-mir-181a "Carcinoma, Gastric" 28043911 miR-181a-5p promotes the progression of gastric cancer via RASSF6-mediated MAPK signalling activation. +target gene hsa-mir-134 "Carcinoma, Ovarian" 28043921 MicroRNA-134-3p is a novel potential inhibitor of human ovarian cancer stem cells by targeting RAB27A. +target gene hsa-mir-330 "Carcinoma, Hepatocellular" 28050784 Roles of microRNA-330 and Its Target Gene ING4 in the Development of Aggressive Phenotype in Hepatocellular Carcinoma Cells. +target gene hsa-mir-204 "Carcinoma, Prostate" 28050800 Micro-RNA-204 Participates in TMPRSS2/ERG Regulation and Androgen Receptor Reprogramming in Prostate Cancer. +target gene hsa-mir-365 Atherosclerosis 28051250 MiR-365 participates in coronary atherosclerosis through regulating IL-6. +target gene hsa-mir-145 Osteosarcoma 28051259 "MicroRNA-145 inhibits tumour growth and metastasis in osteosarcoma by targeting cyclin-dependent kinase, CDK6." +target gene hsa-mir-138 "Carcinoma, Pancreatic" 28052003 miR-138-5p suppresses autophagy in pancreatic cancer by targeting SIRT1. +target gene hsa-mir-761 "Carcinoma, Breast, Triple Negative" 28054302 microRNA-761 induces aggressive phenotypes in triple-negative breast cancer cells by repressing TRIM29 expression. +target gene hsa-mir-223 Rheumatoid Arthritis 28056105 miR-223-3p may contribute to the pathogenesis of RA by downregulating the expression of IL-17RD and upregulating that of IL-6 in synovial cells +target gene hsa-mir-93 Osteosarcoma 28056303 MiR-93 targets NKD2 to promote proliferation and inhibit apoptosis of osteosarcoma cells +target gene hsa-let-7a Neoplasms [unspecific] 28057739 the let-7-HMGA2 axis plays a prominent role in the pathogenesis of the disease that leads to unique clinical phenotypes +target gene hsa-mir-92a "Leukemia, Myeloid, Acute" 28059050 miR-92a Inhibits Proliferation and Induces Apoptosis by Regulating Methylenetetrahydrofolate Dehydrogenase 2 (MTHFD2) Expression in Acute Myeloid Leukemia. +target gene hsa-let-7a Heart Failure 28060734 Let-7a regulates expression of ¦Â1-adrenoceptors and forms a negative feedback circuit with the ¦Â1-adrenoceptor signaling pathway in chronic ischemic heart failure. +target gene hsa-mir-107 Acute Kidney Failure 28063928 MiR-107 induces TNF-¦Á secretion in endothelial cells causing tubular cell injury in patients with septic acute kidney injury. +target gene hsa-mir-148a "Carcinoma, Breast" 28063929 MiR-148a and miR-152 reduce tamoxifen resistance in ER+ breast cancer via downregulating ALCAM. +target gene hsa-mir-152 "Carcinoma, Breast" 28063929 MiR-148a and miR-152 reduce tamoxifen resistance in ER+ breast cancer via downregulating ALCAM. +target gene hsa-mir-129 Glioblastoma 28068630 "Potential mechanisms of microRNA-129-5p in inhibiting cell processes including viability, proliferation, migration and invasiveness of glioblastoma cells U87 through targeting FNDC3B." +target gene hsa-mir-202 "Scleroderma, Systemic" 28068631 MicroRNA-202-3p regulates scleroderma fibrosis by targeting matrix metalloproteinase 1. +target gene hsa-mir-495 "Carcinoma, Bladder" 28069380 microRNA-495 promotes bladder cancer cell growth and invasion by targeting phosphatase and tensin homolog. +target gene hsa-mir-375 "Squamous Cell Carcinoma, Esophageal" 28069583 MiR-375 suppresses invasion and metastasis by direct targeting of SHOX2 in esophageal squamous cell carcinoma. +target gene hsa-mir-150 Osteosarcoma 28070040 MicroRNA-150 inhibits osteosarcoma cell proliferation by targeting RUNX2 gene. +target gene hsa-mir-718 "Carcinoma, Hepatocellular" 28070994 "Involvement of microRNA-718, a new regulator of EGR3, in regulation of malignant phenotype of HCC cells." +target gene hsa-mir-34c Osteosarcoma 28075441 miR?34c?3p acts as a tumor suppressor gene in osteosarcoma by targeting MARCKS. +target gene hsa-mir-191 "Carcinoma, Lung, Non-Small-Cell" 28075452 "A novel pathway in NSCLC cells: miR?191, targeting NFIA, is induced by chronic hypoxia, and promotes cell proliferation and migration." +target gene hsa-mir-375 "Carcinoma, Breast" 28075453 miR-375 inhibits cancer stem cell phenotype and tamoxifen resistance by degrading HOXB3 in human ER-positive breast cancer. +target gene hsa-mir-138 "Carcinoma, Nasopharyngeal" 28075468 MicroRNA-138-5p controls sensitivity of nasopharyngeal carcinoma to radiation by targeting EIF4EBP1. +target gene hsa-mir-134 "Carcinoma, Lung, Non-Small-Cell" 28075475 miR-134 suppresses the migration and invasion of non?small cell lung cancer by targeting ITGB1. +target gene hsa-mir-214 "Carcinoma, Lung, Non-Small-Cell" 28076844 Sulforaphane inhibits cancer stem-like cell properties and cisplatin resistance through miR-214-mediated downregulation of c-MYC in non-small cell lung cancer. +target gene hsa-mir-15a Intervertebral Disc Degeneration 28081468 Role of miR-15a in intervertebral disc degeneration through targeting MAP3K9. +target gene hsa-mir-200a "Carcinoma, Hepatocellular" 28081727 MicroRNA-200a Suppresses Cell Invasion and Migration by Directly Targeting GAB1 in Hepatocellular Carcinoma. +target gene hsa-mir-377 "Carcinoma, Hepatocellular" 28081730 MicroRNA-377 Downregulates Bcl-xL and Increases Apoptosis in Hepatocellular Carcinoma Cells. +target gene hsa-mir-17 Glioma 28081732 Inhibition of Beclin-1-Mediated Autophagy by MicroRNA-17-5p Enhanced the Radiosensitivity of Glioma Cells. +target gene hsa-mir-214 Osteosarcoma 28081735 miR-214-5p Targets ROCK1 and Suppresses Proliferation and Invasion of Human Osteosarcoma Cells. +target gene hsa-mir-940 "Carcinoma, Ovarian" 28081739 miR-940 Upregulation Suppresses Cell Proliferation and Induces Apoptosis by Targeting PKC-¦Ä in Ovarian Cancer OVCAR3 Cells. +target gene hsa-mir-424 "Carcinoma, Cervical" 28082020 miR424-5p functions as an anti-oncogene in cervical cancer cell growth by targeting KDM5B via the Notch signaling pathway. +target gene hsa-mir-125b Inflammatory Bowel Diseases 28082316 miR-16 and miR-125b are involved in barrier function dysregulation through the modulation of claudin-2 and cingulin expression in the jejunum in IBS with diarrhoea. +target gene hsa-mir-16 Inflammatory Bowel Diseases 28082316 miR-16 and miR-125b are involved in barrier function dysregulation through the modulation of claudin-2 and cingulin expression in the jejunum in IBS with diarrhoea. +target gene hsa-mir-23b Chondrosarcoma 28085008 Inhibition of Src by microRNA-23b increases the cisplatin sensitivity of chondrosarcoma cells. +target gene hsa-mir-130a Psoriasis 28085489 microRNA-130a Promotes Human Keratinocyte Viability and Migration and Inhibits Apoptosis Through Direct Regulation of STK40-Mediated NF-¦ÊB Pathway and Indirect Regulation of SOX9-Meditated JNK/MAPK Pathway: A Potential Role in Psoriasis. +target gene hsa-mir-451 Osteosarcoma 28086136 "MiR-451 suppresses proliferation, migration and promotes apoptosis of the human osteosarcoma by targeting macrophage migration inhibitory factor." +target gene hsa-mir-1307 "Carcinoma, Ovarian" 28086946 MiR-1307 promotes ovarian cancer cell chemoresistance by targeting the ING5 expression. +target gene hsa-mir-449a Liver Neoplasms 28088579 The microRNA-449 family inhibits TGF-¦Â-mediated liver cancer cell migration by targeting SOX4. +target gene hsa-mir-449b Liver Neoplasms 28088579 The microRNA-449 family inhibits TGF-¦Â-mediated liver cancer cell migration by targeting SOX4. +target gene hsa-mir-30c "Fatty Liver, Non-Alcoholic" 28088781 MiR-30c-5p ameliorates hepatic steatosis in leptin receptor-deficient (db/db) mice via down-regulating FASN. +target gene hsa-mir-195 "Carcinoma, Renal Cell, Clear-Cell" 28089832 Androgen receptor (AR) promotes clear cell renal cell carcinoma (ccRCC) migration and invasion via altering the circHIAT1/miR-195-5p/29a-3p/29c-3p/CDC42 signals. +target gene hsa-mir-29a "Carcinoma, Renal Cell, Clear-Cell" 28089832 Androgen receptor (AR) promotes clear cell renal cell carcinoma (ccRCC) migration and invasion via altering the circHIAT1/miR-195-5p/29a-3p/29c-3p/CDC42 signals. +target gene hsa-mir-29c "Carcinoma, Renal Cell, Clear-Cell" 28089832 Androgen receptor (AR) promotes clear cell renal cell carcinoma (ccRCC) migration and invasion via altering the circHIAT1/miR-195-5p/29a-3p/29c-3p/CDC42 signals. +target gene hsa-mir-141 "Carcinoma, Ovarian" 28095864 MicroRNA-141 enhances anoikis resistance in metastatic progression of ovarian cancer through targeting KLF12/Sp1/survivin axis. +target gene hsa-mir-155 Human Immunodeficiency Virus Infection 28096489 "miR-155 and miR-92a, were reported previously to at least weakly bind HIV-1 transcripts" +target gene hsa-mir-92a Human Immunodeficiency Virus Infection 28096489 "miR-155 and miR-92a, were reported previously to at least weakly bind HIV-1 transcripts" +target gene hsa-mir-345 "Carcinoma, Hepatocellular" 28098858 miR-345 inhibits tumor metastasis and EMT by targeting IRF1-mediated mTOR/STAT3/AKT pathway in hepatocellular carcinoma. +target gene hsa-mir-34b "Carcinoma, Hepatocellular" 28098861 Triptolide inhibits viability and induces apoptosis in liver cancer cells through activation of the tumor suppressor gene p53. +target gene hsa-mir-34c "Carcinoma, Hepatocellular" 28098861 Triptolide inhibits viability and induces apoptosis in liver cancer cells through activation of the tumor suppressor gene p53. +target gene hsa-mir-187 "Carcinoma, Gastric" 28098868 MicroRNA-187 promotes growth and metastasis of gastric cancer by inhibiting FOXA2. +target gene hsa-mir-148a "Carcinoma, Renal Cell" 28098870 miR-148a increases the sensitivity to cisplatin by targeting Rab14 in renal cancer cells. +target gene hsa-mir-375 "Carcinoma, Lung, Non-Small-Cell" 28098887 miRNA?375 regulates the cell survival and apoptosis of human non?small cell carcinoma by targeting HER2. +target gene hsa-mir-194 Glioma 28098896 MicroRNA-194 represses glioma cell epithelial?to?mesenchymal transition by targeting Bmi1. +target gene hsa-mir-9 Liver Cirrhosis 28098912 MicroRNA-9 limits hepatic fibrosis by suppressing the activation and proliferation of hepatic stellate cells by directly targeting MRP1/ABCC1. +target gene hsa-mir-1296 "Carcinoma, Gastric" 28099468 miR 1296-5p Inhibits the Migration and Invasion of Gastric Cancer Cells by Repressing ERBB2 Expression. +target gene hsa-mir-27a "Carcinoma, Breast" 28099945 "In vivo and in vitro effects of microRNA-27a on proliferation, migration and invasion of breast cancer cells through targeting of SFRP1 gene via Wnt/¦Â-catenin signaling pathway." +target gene hsa-mir-221 "Squamous Cell Carcinoma, Oral" 28101204 Downregulation of miR-221/222 by a microRNA sponge promotes apoptosis in oral squamous cell carcinoma cells through upregulation of PTEN. +target gene hsa-mir-222 "Squamous Cell Carcinoma, Oral" 28101204 Downregulation of miR-221/222 by a microRNA sponge promotes apoptosis in oral squamous cell carcinoma cells through upregulation of PTEN. +target gene hsa-mir-15a "Leukemia, Lymphoblastic, Acute, B-Cell" 28101583 we proposed a cellular model to discuss MYC/miR-15a-5p/FLT3 feed-forward loop?(FFL) with Jak-STAT signaling pathway in B-ALL +target gene hsa-mir-181a "Leukemia, Myelogenous, Chronic, BCR-ABL Positive" 28103766 inhibition of miR-181a using a microRNA sponge inhibitor resulted in decreased transcription of SOX2 and SALL4 +target gene hsa-mir-145 "Carcinoma, Hepatocellular" 28104805 MicroRNA-145 Modulates N6-Methyladenosine Levels by Targeting the 3'-Untranslated mRNA Region of the N6-Methyladenosine Binding YTH Domain Family 2 Protein. +target gene hsa-mir-150 Lung Neoplasms 28108217 CDK3 is a major target of miR-150 in cell proliferation and anti-cancer effect. +target gene hsa-mir-543 Osteosarcoma 28108312 CTGF promotes osteosarcoma angiogenesis by regulating miR-543/angiopoietin 2 signaling. +target gene hsa-mir-125b Melanoma 28108732 FAK regulates E-cadherin expression via p-SrcY416/p-ERK1/2/p-Stat3Y705 and PPAR¦Ã/miR-125b/Stat3 signaling pathway in B16F10 melanoma cells. +target gene hsa-mir-143 "Carcinoma, Prostate" 28109198 miR-143 Induces the Apoptosis of Prostate Cancer LNCap Cells by Suppressing Bcl-2 Expression. +target gene hsa-mir-214 Bone Disease [unspecific] 28109866 "miR-214 suppresses osteogenesis by targeting BIRC7, providing a possible therapeutic target for bone degenerative diseases" +target gene hsa-mir-150 Atherosclerosis 28110404 MicroRNA-150 targets ELK1 and modulates the apoptosis induced by ox-LDL in endothelial cells. +target gene hsa-mir-144 "Carcinoma, Gastric" 28111340 MicroRNA-144-3p suppresses gastric cancer progression by inhibiting epithelial-to-mesenchymal transition through targeting PBX3. +target gene hsa-mir-191a Inflammatory Bowel Diseases 28111380 Baicalin Protects against TNF-¦Á-Induced Injury by Down-Regulating miR-191a That Targets the Tight Junction Protein ZO-1 in IEC-6 Cells. +target gene hsa-mir-520c "Carcinoma, Breast" 28112380 miR520c blocks EMT progression of human breast cancer cells by repressing STAT3. +target gene hsa-mir-22 Heart Failure 28112401 MicroRNA-22 regulates inflammation and angiogenesis via targeting VE-cadherin. +target gene hsa-mir-206 Vascular Hypertrophy 28114137 MiR-206 affected the process of cardiomyocytes hypertrophy by regulating histone deacetylase 4 (HDAC4) +target gene hsa-mir-939 Coronary Artery Disease 28115160 MicroRNA-939 governs vascular integrity and angiogenesis through targeting ¦Ã-catenin in endothelial cells. +target gene hsa-mir-141 "Carcinoma, Gastric" 28115163 Lnc-ATB contributes to gastric cancer growth through a MiR-141-3p/TGF¦Â2 feedback loop. +target gene hsa-mir-379 "Carcinoma, Lung, Non-Small-Cell" 28117895 Suppression of EIF4G2 by miR-379 potentiates the cisplatin chemosensitivity in nonsmall cell lung cancer cells. +target gene hsa-mir-518 "Squamous Cell Carcinoma, Esophageal" 28119087 miR-518 inhibited the proliferation and invasion of esophageal squamous cell carcinoma (ESCC) cells possibly by targeting RAP1B +target gene hsa-mir-145 "Adenocarcinoma, Lung" 28120164 MiRNA-145 suppresses lung adenocarcinoma cell invasion and migration by targeting N-cadherin. +target gene hsa-mir-542 "Carcinoma, Breast" 28121348 miR-542-3p targets sphingosine-1-phosphate receptor 1 and regulates cell proliferation and invasion of breast cancer cells. +target gene hsa-mir-590 "Carcinoma, Breast" 28121351 MicroRNA miR-590-5p inhibits breast cancer cell stemness and metastasis by targeting SOX2. +target gene hsa-mir-1307 "Carcinoma, Prostate" 28122308 miR-1307 promotes the proliferation of prostate cancer by targeting FOXO3A. +target gene hsa-mir-125b "Carcinoma, Thyroid, Anaplastic" 28122310 MiR-125b inhibits anaplastic thyroid cancer cell migration and invasion by targeting PIK3CD. +target gene hsa-mir-182 "Carcinoma, Thyroid, Medullary" 28122586 MiR-182 promotes cancer invasion by linking RET oncogene activated NF-¦ÊB to loss of the HES1/Notch1 regulatory circuit. +target gene hsa-let-7a Vascular Hypertrophy 28123343 Let-7a Is an Antihypertrophic Regulator in the Heart via Targeting Calmodulin. +target gene hsa-mir-18a Glioblastoma 28123848 The malignancy of miR-18a in human glioblastoma via directly targeting CBX7. +target gene hsa-mir-34c Neoplasms [unspecific] 28125315 miRNA-34c inhibits myoblasts proliferation by targeting YY1. +target gene hsa-mir-199a "Carcinoma, Breast" 28126676 MiR-199a-3p enhances breast cancer cell sensitivity to cisplatin by downregulating TFAM (TFAM). +target gene hsa-mir-26a Neoplasms [unspecific] 28126920 Sustained expression of miR-26a promotes chromosomal instability and tumorigenesis through regulation of CHFR. +target gene hsa-mir-9 "Carcinoma, Gastric" 28127811 MicroRNA-9 inhibits the gastric cancer cell proliferation by targeting TNFAIP8. +target gene hsa-mir-187 "Carcinoma, Cervical" 28128400 miR-187 induces apoptosis of SiHa cervical carcinoma cells by downregulating Bcl-2. +target gene hsa-mir-146 Breast Neoplasms 28128741 miR-146a and miR-146-5p silencing BRCA1 may trigger formation of triple-negative and basal-like sporadic BC cases +target gene hsa-mir-92a Alzheimer Disease 28129110 "the AD-like tau accumulation induces anxiety through disrupting miR92a-vGAT-GABA signaling, which reveals molecular mechanisms underlying the anxiety behavior in AD patients and potentially leads to the development of new therapeutics for tauopathies" +target gene hsa-mir-21 Immune System Disease [unspecific] 28129531 MicroRNA-21 contributes to suppress cytokines production by targeting TLR28 in teleost fish. +target gene hsa-mir-650 Rheumatoid Arthritis 28129626 "MiR-650 inhibits proliferation, migration and invasion of rheumatoid arthritis synovial fibroblasts by targeting AKT2." +target gene hsa-mir-34a "Carcinoma, Hepatocellular" 28129650 MicroRNA-34a regulates liver regeneration and the development of liver cancer in rats by targeting Notch signaling pathway. +target gene hsa-mir-365 Heart Failure 28130111 MicroRNA-365 accelerates cardiac hypertrophy by inhibiting autophagy via the modulation of Skp2 expression. +target gene hsa-mir-18a Lung Fibrosis 28131417 miR-18a-5p Inhibits Sub-pleural Pulmonary Fibrosis by Targeting TGF-¦Â Receptor II. +target gene hsa-mir-146a Influenza 28131813 MicroRNA-146a induction during influenza H3N2 virus infection targets and regulates TRAF6 levels in human nasal epithelial cells (hNECs). +target gene hsa-mir-141 Hepatitis B Virus Infection 28135713 MicroRNA-141 Targets Sirt1 and Inhibits Autophagy to Reduce HBV Replication. +target gene hsa-mir-214 "Carcinoma, Cervical" 28137590 miR-214 down-regulates ARL2 and suppresses growth and invasion of cervical cancer cells. +target gene hsa-mir-21 "Squamous Cell Carcinoma, Head and Neck" 28138036 Suppression of the Growth and Invasion of Human Head and Neck Squamous Cell Carcinomas via Regulating STAT3 Signaling and the miR-21/¦Â-catenin Axis with HJC0152. +target gene hsa-mir-410 Osteosarcoma 28138700 MicroRNA-410 regulates autophagy-related gene ATG16L1 expression and enhances chemosensitivity via autophagy inhibition in osteosarcoma. +target gene hsa-mir-101 "Carcinoma, Renal Cell, Clear-Cell" 28138701 Hypoxia-induced hsa-miR-101 promotes glycolysis by targeting TIGAR mRNA in clear cell renal cell carcinoma. +target gene hsa-mir-155 "Carcinoma, Pancreatic" 28152544 "Exosomes confer chemoresistance to pancreatic cancer cells by promoting ROS detoxification and miR-155-mediated suppression of key gemcitabine-metabolising enzyme, DCK." +target gene hsa-mir-138 Leukemia 28153721 MiR-138 indirectly regulates the MDR1 promoter by NF-¦ÊB/p65 silencing. +target gene hsa-mir-1271 "Carcinoma, Prostate" 28153722 Inhibition of DIXDC1 by microRNA-1271 suppresses the proliferation and invasion of prostate cancer cells. +target gene hsa-mir-34a "Leukemia, Myeloid, Chronic" 28157629 The epigenetically-regulated miR-34a targeting c-SRC suppresses RAF/MEK/ERK signaling pathway in K-562 cells. +target gene hsa-mir-1 Breast Neoplasms 28159933 Tumor suppressor miR-1 inhibits tumor growth and metastasis by simultaneously targeting multiple genes. +target gene hsa-mir-495 "Carcinoma, Gastric" 28159956 MicroRNA-495 Inhibits Gastric Cancer Cell Migration and Invasion Possibly via Targeting High Mobility Group AT-Hook 2 (HMGA2). +target gene hsa-mir-320a Glioma 28160566 "miR-320a functions as a suppressor for gliomas by targeting SND1 and ¦Â-catenin, and predicts the prognosis of patients." +target gene hsa-mir-130b "Carcinoma, Breast" 28163094 miR-130b-3p inhibits cell invasion and migration by targeting the Notch ligand Delta-like 1 in breast carcinoma. +target gene hsa-mir-29b Cardiovascular Diseases [unspecific] 28164126 The Involvement of miR-29b-3p in Arterial Calcification by Targeting Matrix Metalloproteinase-2. +target gene hsa-mir-15b "Squamous Cell Carcinoma, Skin or Unspecific" 28165568 MicroRNA15b regulates apoptosis of cutaneous squamous cell carcinoma SCL-1 cell line: a mechanism study. +target gene hsa-mir-212 "Carcinoma, Cervical" 28165569 Effect of miR-212 targeting TCF7L2 on the proliferation and metastasis of cervical cancer. +target gene hsa-mir-599 "Carcinoma, Lung, Non-Small-Cell" 28167280 The miR-599 promotes non-small cell lung cancer cell invasion via SATB2. +target gene hsa-mir-29c Gastric Neoplasms 28173777 microRNA-29c inhibits cell proliferation by targeting NASP in human gastric cancer. +target gene hsa-mir-224 "Carcinoma, Gastric" 28173803 "Hypoxia-inducible microRNA-224 promotes the cell growth, migration and invasion by directly targeting RASSF8 in gastric cancer." +target gene hsa-mir-143 "Squamous Cell Carcinoma, Oral" 28174335 "MicroRNA-143 suppresses oral squamous cell carcinoma cell growth, invasion and glucose metabolism through targeting hexokinase 2." +target gene hsa-mir-181 Osteoarthritis 28177757 MicroRNA-181 inhibits proliferation and promotes apoptosis of chondrocytes in osteoarthritis by targeting PTEN. +target gene hsa-mir-361 Glioma 28184914 MicroRNA-361-5p inhibits epithelial-to-mesenchymal transition of glioma cells through targeting Twist1. +target gene hsa-mir-30d "Squamous Cell Carcinoma, Esophageal" 28184915 MicroRNA-30d inhibits the migration and invasion of human esophageal squamous cell carcinoma cells via the post?transcriptional regulation of enhancer of zeste homolog?2. +target gene hsa-mir-922 "Carcinoma, Hepatocellular" 28184924 miR-922 regulates CYLD expression and promotes the cell proliferation of human hepatocellular carcinoma. +target gene hsa-mir-217 "Carcinoma, Hepatocellular" 28184926 "miR-217 suppresses proliferation, migration, and invasion promoting apoptosis via targeting MTDH in hepatocellular carcinoma." +target gene hsa-mir-520c Glioma 28184932 MicroRNA-520c inhibits glioma cell migration and invasion by the suppression of transforming growth factor-¦Â receptor type?2. +target gene hsa-mir-93 Bone Disease [unspecific] 28186136 FOXO1-suppressed miR-424 regulates the proliferation and osteogenic differentiation of MSCs by targeting FGF2 under oxidative stress. +target gene hsa-mir-28 "Lymphoma, Hodgkin" 28188132 miR-28 regulates the germinal center reaction and blocks tumor growth in preclinical models of non-Hodgkin lymphoma. +target gene hsa-mir-125a "Carcinoma, Breast" 28188287 A-to-I RNA Editing Up-regulates Human Dihydrofolate Reductase in Breast Cancer. +target gene hsa-mir-25 "Carcinoma, Breast" 28188287 A-to-I RNA Editing Up-regulates Human Dihydrofolate Reductase in Breast Cancer. +target gene hsa-mir-675 "Carcinoma, Colon" 28189050 "H19 Overexpression Induces Resistance to 1,25(OH)2D3 by Targeting VDR Through miR-675-5p in Colon Cancer Cells." +target gene hsa-mir-29a Diabetic Retinopathy 28189547 Role of microRNA-29a in the development of diabetic retinopathy by targeting AGT gene in a rat model. +target gene hsa-mir-24 Osteosarcoma 28189676 miR-24 represses metastasis of human osteosarcoma cells by targeting Ack1 via AKT/MMPs pathway. +target gene hsa-mir-30b "Carcinoma, Esophageal" 28189678 "miR-30b inhibits cancer cell growth, migration, and invasion by targeting homeobox A1 in esophageal cancer." +target gene hsa-mir-218 "Carcinoma, Lung" 28192397 Downregulation of miR-218 contributes to epithelial-mesenchymal transition and tumor metastasis in lung cancer by targeting Slug/ZEB2 signaling. +target gene hsa-mir-143 "Adenocarcinoma, Pancreatic Ductal" 28194669 MiR-143 Targeting TAK1 Attenuates Pancreatic Ductal Adenocarcinoma Progression via MAPK and NF-¦ÊB Pathway In Vitro. +target gene hsa-mir-451 "Carcinoma, Pancreatic" 28197410 MiR-451 Promotes Cell Proliferation and Metastasis in Pancreatic Cancer through Targeting CAB39. +target gene hsa-mir-133a Ischemia-Reperfusion Injury 28198596 Propofol protects against hepatic ischemia/reperfusion injury via miR-133a-5p regulating the expression of MAPK6. +target gene hsa-mir-205 Lung Neoplasms 28199217 MicroRNA-205 targets SMAD4 in non-small cell lung cancer and promotes lung cancer cell growth in vitro and in vivo. +target gene hsa-mir-146a "Carcinoma, Lung, Non-Small-Cell" 28202053 Up-regulation of miR-146a increases the sensitivity of non-small cell lung cancer to DDP by downregulating cyclin J. +target gene hsa-mir-146a Stroke 28202285 Decreased miR-146a expression in acute ischemic stroke directly targets the Fbxl10 mRNA and is involved in modulating apoptosis. +target gene hsa-mir-101 Alzheimer Disease 28202389 Targeting the HDAC2/HNF-4A/miR-101b/AMPK Pathway Rescues Tauopathy and Dendritic Abnormalities in Alzheimer's Disease. +target gene hsa-mir-520f Neoplasms [unspecific] 28209612 miRNA-520f Reverses Epithelial-to-Mesenchymal Transition by Targeting ADAM9 and TGFBR2. +target gene hsa-mir-92a "Carcinoma, Ovarian" 28209618 The STAT3-miRNA-92-Wnt Signaling Pathway Regulates Spheroid Formation and Malignant Progression in Ovarian Cancer. +target gene hsa-mir-718 Sepsis 28209713 miR-718 represses proinflammatory cytokine production through targeting phosphatase and tensin homolog (PTEN). +target gene hsa-mir-124 "Squamous Cell Carcinoma, Head and Neck" 28212569 MiR-124 acts as a tumor suppressor by inhibiting the expression of sphingosine kinase 1 and its downstream signaling in head and neck squamous cell carcinoma. +target gene hsa-mir-216a "Carcinoma, Colon" 28213952 Down-regulation of KIAA1199/CEMIP by miR-216a suppresses tumor invasion and metastasis in colorectal cancer. +target gene hsa-mir-155 Osteosarcoma 28214207 MicroRNA-155 targets MAP3K10 and regulates osteosarcoma cell growth. +target gene hsa-mir-15a "Aortic Aneurysm, Abdominal" 28214350 Upregulation of MicroRNA-15a Contributes to Pathogenesis of Abdominal Aortic Aneurysm (AAA) by Modulating the Expression of Cyclin-Dependent Kinase Inhibitor 2B (CDKN2B). +target gene hsa-mir-183 Pain 28214854 MicroRNA-183 Suppresses Neuropathic Pain and Expression of AMPA Receptors by Targeting mTOR/VEGF Signaling Pathway. +target gene hsa-mir-26a "Adenocarcinoma, Lung" 28214878 MiRNA-26a Contributes to the Acquisition of Malignant Behaviors of Doctaxel-Resistant Lung Adenocarcinoma Cells through Targeting EZH2. +target gene hsa-mir-32 Mycobacterium tuberculosis Infection 28215633 TLR-4/miRNA-32-5p/FSTL1 signaling regulates mycobacterial survival and inflammatory responses in Mycobacterium tuberculosis-infected macrophages. +target gene hsa-mir-153 Glioblastoma 28218035 MicroRNA-153 regulates glutamine metabolism in glioblastoma through targeting glutaminase. +target gene hsa-mir-139 Alzheimer Disease 28218780 MicroRNA-139 modulates Alzheimer's-associated pathogenesis in SAMP8 mice by targeting cannabinoid receptor type 2. +target gene hsa-mir-218 "Carcinoma, Bladder" 28222430 MicroRNA-218 Increases the Sensitivity of Bladder Cancer to Cisplatin by Targeting Glut1. +target gene hsa-mir-29b "Carcinoma, Endometrial" 28222438 MicroRNA-29b Inhibits Angiogenesis by Targeting VEGFA through the MAPK/ERK and PI3K/Akt Signaling Pathways in Endometrial Carcinoma. +target gene hsa-mir-29a Breast Neoplasms 28222663 miR-29a suppresses MCF-7 cell growth by downregulating tumor necrosis factor receptor 1. +target gene hsa-mir-181 "Carcinoma, Breast" 28224609 miR-181 elevates Akt signaling by co-targeting PHLPP2 and INPP4B phosphatases in luminal breast cancer. +target gene hsa-mir-216a Melanoma 28225180 microRNA-216b inhibits cell proliferation and migration in human melanoma by targeting FOXM1 in vitro and in vivo. +target gene hsa-mir-15b Multiple Sclerosis 28228555 MicroRNA-15b Suppresses Th17 Differentiation and Is Associated with Pathogenesis of Multiple Sclerosis by Targeting O-GlcNAc Transferase. +target gene hsa-mir-144 "Carcinoma, Hepatocellular" 28229969 "MicroRNA-144 inhibits hepatocellular carcinoma cell proliferation, invasion and migration by targeting ZFX." +target gene hsa-mir-21 Diabetes Mellitus 28230206 MiRNA-21 mediates the antiangiogenic activity of metformin through targeting PTEN and SMAD7 expression and PI3K/AKT pathway. +target gene hsa-mir-302b "Carcinoma, Lung" 28231299 miR-34a-5p/miR-34c-5p/miR-302b-3p-LEF1-CCND1/WNT2/MYC axis may be a crucial mechanism in inhibition of lung cancer metastasis by curcumin +target gene hsa-mir-34a "Carcinoma, Lung" 28231299 miR-34a-5p/miR-34c-5p/miR-302b-3p-LEF1-CCND1/WNT5/MYC axis may be a crucial mechanism in inhibition of lung cancer metastasis by curcumin +target gene hsa-mir-34c "Carcinoma, Lung" 28231299 miR-34a-5p/miR-34c-5p/miR-302b-3p-LEF1-CCND1/WNT6/MYC axis may be a crucial mechanism in inhibition of lung cancer metastasis by curcumin +target gene hsa-mir-22 "Carcinoma, Prostate" 28231399 MTA1-activated Epi-microRNA-22 regulates E-cadherin and prostate cancer invasiveness. +target gene hsa-mir-543 "Carcinoma, Cervical" 28231728 MicroRNA-543 acts as a prognostic marker and promotes the cell proliferation in cervical cancer by BRCA1-interacting protein 1. +target gene hsa-mir-122 "Carcinoma, Renal Cell" 28231730 MiR-122 promotes renal cancer cell proliferation by targeting Sprouty2. +target gene hsa-mir-221 Liver Injury 28232457 Dicer-dependent production of microRNA221 in hepatocytes inhibits p27 and is required for liver regeneration in mice. +target gene hsa-let-7 "Carcinoma, Lung, Non-Small-Cell" 28235063 Disturbance of the let-7/LIN28 double-negative feedback loop is associated with radio- and chemo-resistance in non-small cell lung cancer. +target gene hsa-mir-106b Acute Myocardial Infarction 28235791 High-throughput screening identifies microRNAs that target Nox2 and improve function after acute myocardial infarction. +target gene hsa-mir-148b Acute Myocardial Infarction 28235791 High-throughput screening identifies microRNAs that target Nox2 and improve function after acute myocardial infarction. +target gene hsa-mir-204 Acute Myocardial Infarction 28235791 High-throughput screening identifies microRNAs that target Nox2 and improve function after acute myocardial infarction. +target gene hsa-mir-181b Aortic Valve Disease 28236165 Mechanosensitive microRNA-181b Regulates Aortic Valve Endothelial Matrix Degradation by Targeting TIMP3. +target gene hsa-mir-26a "Carcinoma, Lung" 28237093 MiR-26a enhances invasive capacity by suppressing GSK3¦Â in human lung cancer cells. +target gene hsa-mir-15b "Carcinoma, Hepatocellular" 28239814 microRNA15b induced SMCC7721 apoptosis via down-regulation of XIAP. +target gene hsa-mir-137 "Carcinoma, Lung, Non-Small-Cell" 28239819 MiR-137 and its target TGFA modulate cell growth and tumorigenesis of non-small cell lung cancer. +target gene hsa-mir-29c "Adenocarcinoma, Lung" 28241836 MicroRNA-29c functions as a tumor suppressor by targeting VEGFA in lung adenocarcinoma. +target gene hsa-mir-520e "Carcinoma, Lung, Non-Small-Cell" 28242196 MicroRNA-520e suppresses non-small-cell lung cancer cell growth by targeting Zbtb7a-mediated Wnt signaling pathway. +target gene hsa-mir-124 Glioblastoma 28242198 miR-124 suppresses glioblastoma growth and potentiates chemosensitivity by inhibiting AURKA. +target gene hsa-mir-130 Obesity 28242765 APCDD1 positively regulates adipogenic differentiation and that its down-regulation by miR-130 during DIO may contribute to impaired adipogenic differentiation and obesity-related metabolic disease +target gene hsa-mir-98 "Carcinoma, Hepatocellular" 28244848 MicroRNA-98-5p Inhibits Cell Proliferation and Induces Cell Apoptosis in Hepatocellular Carcinoma via Targeting IGF2BP1. +target gene hsa-mir-543 "Carcinoma, Prostate" 28245474 MiR-543 Promotes Proliferation and Epithelial-Mesenchymal Transition in Prostate Cancer via Targeting RKIP. +target gene hsa-mir-155 Wound Healing 28247149 miR-155 promotes cutaneous wound healing through enhanced keratinocytes migration by MMP-2. +target gene hsa-mir-20b Viral Myocarditis 28247213 MicroRNA-20b suppresses the expression of ZFP-148 in viral myocarditis. +target gene hsa-mir-98 Endomyocardial Fibrosis 28251559 MicroRNA-98 inhibits TGF-¦Â1-induced differentiation and collagen production of cardiac fibroblasts by targeting TGFBR1. +target gene hsa-mir-15b Coronary Artery Disease 28254819 MiR-15b-5p Regulates Collateral Artery Formation by Targeting AKT3 (Protein Kinase B-3). +target gene hsa-mir-19a "Carcinoma, Colon" 28257633 miR-19a promotes colorectal cancer proliferation and migration by targeting TIA1. +target gene hsa-mir-133a Atherosclerosis 28257760 Induction of MiR133a expression by IL-19 targets LDLRAP1 and reduces oxLDL uptake in VSMC. +target gene hsa-mir-185 Keloid 28259900 MicroRNA?185 regulates transforming growth factor?¦Â1 and collagen?1 in hypertrophic scar fibroblasts. +target gene hsa-mir-7 "Carcinoma, Pancreatic" 28259961 MicroRNA-7 functions as a tumor-suppressor gene by regulating ILF2 in pancreatic carcinoma. +target gene hsa-mir-30a "Carcinoma, Lung, Non-Small-Cell" 28259977 miR-30a radiosensitizes non-small cell lung cancer by targeting ATF1 that is involved in the phosphorylation of ATM. +target gene hsa-mir-365 Glioma 28260020 "MicroRNA-365 inhibits proliferation, migration and invasion of glioma by targeting PIK3R3." +target gene hsa-mir-134 "Carcinoma, Gastric" 28260021 MicroRNA-134 suppresses cell proliferation in gastric cancer cells via targeting of GOLPH3. +target gene hsa-mir-125b "Carcinoma, Nasopharyngeal" 28260044 microRNA-125b reverses the multidrug resistance of nasopharyngeal carcinoma cells via targeting of Bcl-2. +target gene hsa-mir-126 "Carcinoma, Gastric" 28260063 ADAM9 functions as a promoter of gastric cancer growth which is negatively and post-transcriptionally regulated by miR-126. +target gene hsa-mir-125b Osteoarthritis 28260078 Upregulation of microRNA-125b-5p is involved in the pathogenesis of osteoarthritis by downregulating SYVN1. +target gene hsa-mir-1271 "Carcinoma, Lung, Non-Small-Cell" 28260088 Foxk2 inhibits non-small cell lung cancer epithelial-mesenchymal transition and proliferation through the repression of different key target genes. +target gene hsa-mir-92a Osteosarcoma 28260104 miR-92a promotes tumor growth of osteosarcoma by targeting PTEN/AKT signaling pathway. +target gene hsa-mir-21 Osteosarcoma 28260111 miR-21-5p may be associated with metastasis via target genes +target gene hsa-mir-9 "Leukemia, Myeloid, Chronic" 28260112 miR-9 regulates the multidrug resistance of chronic myelogenous leukemia by targeting ABCB1. +target gene hsa-mir-199a "Carcinoma, Hepatocellular" 28261837 MiR-199a-5p suppresses tumorigenesis by targeting clathrin heavy chain in hepatocellular carcinoma. +target gene hsa-mir-23b "Carcinoma, Hepatocellular" 28262617 microRNA-23b suppresses epithelial-mesenchymal transition (EMT) and metastasis in hepatocellular carcinoma via targeting Pyk2. +target gene hsa-mir-377 "Squamous Cell Carcinoma, Oral" 28267394 Downregulation of miR-377 Promotes Oral Squamous Cell Carcinoma Growth and Migration by Targeting HDAC9. +target gene hsa-mir-1 "Carcinoma, Bladder" 28268231 "MiR-1-3p Suppresses the Proliferation, Invasion and Migration of Bladder Cancer Cells by Up-Regulating SFRP1 Expression." +target gene hsa-mir-31 "Carcinoma, Hepatocellular" 28269758 MicroRNA31-NDRG3 regulation axes are essential for hepatocellular carcinoma survival and drug resistance. +target gene hsa-mir-124 Glioma 28272711 Down-regulation of miR-124 target protein SCP-1 inhibits neuroglioma cell migration. +target gene hsa-mir-875 "Carcinoma, Prostate" 28274892 miR-875-5p counteracts epithelial-to-mesenchymal transition and enhances radiation response in prostate cancer through repression of the EGFR-ZEB1 axis. +target gene hsa-mir-34a Osteosarcoma 28275089 "The miR-34a/STMN1/¦ÂIII-tubulin axis maintains the microtubule cytoskeleton in osteosarcoma, and combining miR-34a with microtubule inhibitors can be investigated as a novel therapeutic strategy" +target gene hsa-mir-142 Inflammation 28275790 MiR-142-3p inhibits lipopolysaccharide-induced inflammatory response in human periodontal ligament cells through targeting IRAK1. +target gene hsa-mir-422a Glioma 28277190 miR-422a Inhibits Glioma Proliferation and Invasion by Targeting IGF1 and IGF1R. +target gene hsa-mir-202 "Squamous Cell Carcinoma, Esophageal" 28277193 miR-202 Promotes Cell Apoptosis in Esophageal Squamous Cell Carcinoma by Targeting HSF2. +target gene hsa-mir-146a Graves Disease 28278511 Mechanism of MicroRNA-146a/Notch2 Signaling Regulating IL-6 in Graves Ophthalmopathy. +target gene hsa-mir-181a Osteoarthritis 28280258 miR-181a Modulates Chondrocyte Apoptosis by Targeting Glycerol-3-Phosphate Dehydrogenase 1-Like Protein (GPD1L) in Osteoarthritis. +target gene hsa-mir-21 "Diabetes Mellitus, Type 1" 28280903 MicroRNA 21 targets BCL2 mRNA to increase apoptosis in rat and human beta cells. +target gene hsa-mir-200a Pancreatic Neoplasms 28281184 TGF-¦Â1-miR-200a-PTEN induces epithelial-mesenchymal transition and fibrosis of pancreatic stellate cells. +target gene hsa-mir-93 Neuropathic Pain 28284149 MicroRNA-93 alleviates neuropathic pain through targeting signal transducer and activator of transcription 3. +target gene hsa-mir-181d Glioblastoma 28286260 miR-181d/MALT1 regulatory axis attenuates mesenchymal phenotype through NF-¦ÊB pathways in glioblastoma. +target gene hsa-mir-133a "Carcinoma, Pancreatic" 28286270 "USP39, a direct target of microRNA-133a, promotes progression of pancreatic cancer via the AKT pathway." +target gene hsa-mir-181a "Carcinoma, Breast" 28288641 "SOX2 regulates multiple malignant processes of breast cancer development through the SOX2/miR-181a-5p, miR-30e-5p/TUSC3 axis." +target gene hsa-mir-30e "Carcinoma, Breast" 28288641 "SOX2 regulates multiple malignant processes of breast cancer development through the SOX2/miR-181a-5p, miR-30e-5p/TUSC3 axis." +target gene hsa-mir-146a Sepsis 28288804 MiR-146a potentially promotes IVIg-mediated inhibition of TLR4 signaling in LPS-activated human monocytes. +target gene hsa-mir-214 "Carcinoma, Oral" 28290615 MiR-214 regulates oral cancer KB cell apoptosis through targeting RASSF5. +target gene hsa-mir-30a Idiopathic Pulmonary Fibrosis 28294974 miR-30a as Potential Therapeutics by Targeting TET1 through Regulation of Drp-1 Promoter Hydroxymethylation in Idiopathic Pulmonary Fibrosis. +target gene hsa-mir-182 "Leukemia, Promyelocytic, Acute" 28298075 Inducing cell proliferative prevention in human acute promyelocytic leukemia by miR-182 inhibition through modulation of CASP9 expression. +target gene hsa-mir-146a Diabetes Mellitus 28301595 miR-146a regulates glucose induced upregulation of inflammatory cytokines extracellular matrix proteins in the retina and kidney in diabetes. +target gene hsa-mir-495 "Carcinoma, Lung, Small-Cell" 28302484 TSPAN12 promotes chemoresistance and proliferation of SCLC under the regulation of miR-495. +target gene hsa-mir-146a Osteoarthritis 28314786 Effects of microRNA-146a on the proliferation and apoptosis of human osteoarthritis chondrocytes by targeting TRAF6 through the NF-¦ÊB signalling pathway. +target gene hsa-mir-519 "Carcinoma, Nasopharyngeal" 28315691 miR-519 suppresses nasopharyngeal carcinoma cell proliferation by targeting oncogene URG4/URGCP. +target gene hsa-mir-186 "Carcinoma, Lung, Non-Small-Cell" 28317368 MiR-186 Inhibited Migration of NSCLC via Targeting cdc42 and Effecting EMT Process. +target gene hsa-mir-218 "Carcinoma, Gastric" 28323002 miR-218 inhibited tumor angiogenesis by targeting ROBO1 in gastric cancer. +target gene hsa-mir-302b Glioma 28323865 The microRNA-302b-inhibited insulin-like growth factor-binding protein 2 signaling pathway induces glioma cell apoptosis by targeting nuclear factor IA. +target gene hsa-mir-181b Cardiovascular Diseases [unspecific] 28323879 miR-181b regulates vascular stiffness age dependently in part by regulating TGF-¦Â signaling. +target gene hsa-mir-199 "Carcinoma, Bladder" 28324890 Regulation of ITGA3 by the dual-stranded microRNA-199 family as a potential prognostic marker in bladder cancer. +target gene hsa-mir-27a Gastric Neoplasms 28327189 MicroRNA-27a contributes to the malignant behavior of gastric cancer cells by directly targeting PH domain and leucine-rich repeat protein phosphatase 2. +target gene hsa-mir-3908 "Carcinoma, Breast" 28327197 Lipid raft-mediated miR-3908 inhibition of migration of breast cancer cell line MCF-7 by regulating the interactions between AdipoR1 and Flotillin-1. +target gene hsa-mir-488 Melanoma 28328082 MicroRNA-488-3p sensitizes malignant melanoma cells to cisplatin by targeting PRKDC. +target gene hsa-mir-9 Atherosclerosis 28334721 MicroRNA-9 Inhibits NLRP3 Inflammasome Activation in Human Atherosclerosis Inflammation Cell Models through the JAK1/STAT Signaling Pathway. +target gene hsa-mir-122 Gastric Neoplasms 28337380 MicroRNA-122 inhibits proliferation and invasion in gastric cancer by targeting CREB1. +target gene hsa-mir-373 "Squamous Cell Carcinoma, Tongue" 28337453 miR-373-3p Targets DKK1 to Promote EMT-Induced Metastasis via the Wnt/¦Â-Catenin Pathway in Tongue Squamous Cell Carcinoma. +target gene hsa-mir-370 Cerebral Aneurysm 28338184 MicroRNA-370-3p inhibits human vascular smooth muscle cell proliferation via targeting KDR/AKT signaling pathway in cerebral aneurysm. +target gene hsa-mir-146a Lupus Nephritis 28338190 The role of miR-146a in modulating TRAF6-induced inflammation during lupus nephritis. +target gene hsa-mir-155 Neoplasms [unspecific] 28338203 "MiR-155 regulates oral squamous cell carcinoma Tca8113 cell proliferation, cycle, and apoptosis via regulating p27Kip1." +target gene hsa-mir-374b "Carcinoma, Colon" 28339062 p53/microRNA-374b/AKT1 regulates colorectal cancer cell apoptosis in response to DNA damage. +target gene hsa-mir-140 Osteosarcoma 28341864 MicroRNA-140-5p regulates osteosarcoma chemoresistance by targeting HMGN5 and autophagy. +target gene hsa-mir-206 Atherosclerosis 28342807 Myocardin inhibited the gap protein connexin 43 via promoted miR-206 to regulate vascular smooth muscle cell phenotypic switch. +target gene hsa-mir-29a "Carcinoma, Hepatocellular" 28342862 miR-29a suppresses growth and migration of hepatocellular carcinoma by regulating CLDN1. +target gene hsa-mir-448 Multiple Sclerosis 28342869 MicroRNA-448 promotes multiple sclerosis development through induction of Th17 response through targeting protein tyrosine phosphatase non-receptor type 2 (PTPN2). +target gene hsa-mir-373 Osteoarthritis 28343378 Adipose-Derived Stem Cells Suppress Inflammation Induced by IL-1¦Â through Down-Regulation of P2X7R Mediated by miR-373 in Chondrocytes of Osteoarthritis. +target gene hsa-mir-29c "Carcinoma, Lung" 28345453 Tumor suppressor miR-29c regulates radioresistance in lung cancer cells. +target gene hsa-mir-195 Colorectal Carcinoma 28345460 Coactivator-associated arginine methyltransferase 1 promotes cell growth and is targeted by microRNA-195-5p in human colorectal cancer. +target gene hsa-mir-590 "Carcinoma, Prostate" 28345464 MicroRNA-590-3p promotes cell proliferation and invasion by targeting inositol polyphosphate 4-phosphatase type II in human prostate cancer cells. +target gene hsa-mir-21 Colorectal Carcinoma 28347230 Inhibition of microRNA-21 via locked nucleic acid-anti-miR suppressed metastatic features of colorectal cancer cells through modulation of programmed cell death 4. +target gene hsa-mir-22 Colorectal Carcinoma 28347238 "The predicted target gene validation, function, and prognosis studies of miRNA-22 in colorectal cancer tissue." +target gene hsa-mir-34a Colorectal Carcinoma 28348487 miR-34a mediates oxaliplatin resistance of colorectal cancer cells by inhibiting macroautophagy via transforming growth factor-¦Â/Smad4 pathway. +target gene hsa-mir-200 "Carcinoma, Pancreatic" 28349057 Interleukin-9 Promotes Pancreatic Cancer Cells Proliferation and Migration via the miR-200a/Beta-Catenin Axis. +target gene hsa-mir-200a "Carcinoma, Pancreatic" 28349057 Interleukin-9 Promotes Pancreatic Cancer Cells Proliferation and Migration via the miR-200a/Beta-Catenin Axis. +target gene hsa-mir-145 "Carcinoma, Breast" 28349828 "Silencing of bach1 gene by small interfering RNA-mediation regulates invasive and expression level of miR-203, miR-145, matrix metalloproteinase-9, and CXCR4 receptor in MDA-MB-468 breast cancer cells." +target gene hsa-mir-203 "Carcinoma, Breast" 28349828 "Silencing of bach1 gene by small interfering RNA-mediation regulates invasive and expression level of miR-203, miR-145, matrix metalloproteinase-9, and CXCR4 receptor in MDA-MB-468 breast cancer cells." +target gene hsa-mir-590 "Carcinoma, Hepatocellular" 28349829 MiR-590-3p suppresses hepatocellular carcinoma growth by targeting TEAD1. +target gene hsa-mir-203 "Carcinoma, Lung, Non-Small-Cell" 28350100 Overexpression of miR-203 increases the sensitivity of NSCLC A549/H460 cell lines to cisplatin by targeting Dickkopf-1. +target gene hsa-mir-455 "Carcinoma, Prostate" 28350134 MicroRNA-455-3p functions as a tumor suppressor by targeting eIF4E in prostate cancer. +target gene hsa-mir-15b "Squamous Cell Carcinoma, Tongue" 28350138 miR-15b inhibits cancer-initiating cell phenotypes and chemoresistance of cisplatin by targeting TRIM14 in oral tongue squamous cell cancer. +target gene hsa-mir-613 Retinoblastoma 28351331 "MiR-613 suppresses retinoblastoma cell proliferation, invasion, and tumor formation by targeting E2F5." +target gene hsa-mir-145 Pituitary Adenoma 28352194 MicroRNA-145 inhibits the activation of the mTOR signaling pathway to suppress the proliferation and invasion of invasive pituitary adenoma cells by targeting AKT3 in vivo and in vitro. +target gene hsa-mir-302d "Carcinoma, Hepatocellular" 28352351 MicroRNA-302d downregulates TGFBR2 expression and promotes hepatocellular carcinoma growth and invasion. +target gene hsa-mir-24 Glioblastoma 28352781 SOX7 inhibits tumor progression of glioblastoma and is regulated by miRNA-24. +target gene hsa-mir-155 Biliary Atresia 28355202 MicroRNA-155 modulates bile duct inflammation by targeting the suppressor of cytokine signaling 1 in biliary atresia. +target gene hsa-mir-532 "Carcinoma, Gastric" 28356225 miR-532 promoted gastric cancer migration and invasion by targeting NKD1. +target gene hsa-mir-27 Adenovirus Infection 28356525 MicroRNA miR-27 Inhibits Adenovirus Infection by Suppressing the Expression of SNAP25 and TXN2. +target gene hsa-mir-27a Adenovirus Infection 28356525 MicroRNA miR-27 Inhibits Adenovirus Infection by Suppressing the Expression of SNAP25 and TXN2. +target gene hsa-mir-27b Adenovirus Infection 28356525 MicroRNA miR-27 Inhibits Adenovirus Infection by Suppressing the Expression of SNAP25 and TXN2. +target gene hsa-mir-103a "Aortic Aneurysm, Abdominal" 28357407 Role of MicroRNA-103a Targeting ADAM10 in Abdominal Aortic Aneurysm. +target gene hsa-mir-194 Melanoma 28358423 Circulating microRNA-194 regulates human melanoma cells via PI3K/AKT/FoxO3a and p53/p21 signaling pathway. +target gene hsa-mir-200 Glioma 28362995 Targeting effect of microRNA on CD133 and its impact analysis on proliferation and invasion of glioma cells. +target gene hsa-mir-200b Glioma 28362995 Targeting effect of microRNA on CD133 and its impact analysis on proliferation and invasion of glioma cells. +target gene hsa-mir-199a "Carcinoma, Lung" 28363780 miR-199a-5p and miR-495 target GRP78 within UPR pathway of lung cancer. +target gene hsa-mir-495 "Carcinoma, Lung" 28363780 miR-199a-5p and miR-495 target GRP78 within UPR pathway of lung cancer. +target gene hsa-mir-19a "Carcinoma, Lung" 28364280 Oncogenic miR-19a and miR-19b co-regulate tumor suppressor MTUS1 to promote cell proliferation and migration in lung cancer. +target gene hsa-mir-19b "Carcinoma, Lung" 28364280 Oncogenic miR-19a and miR-19b co-regulate tumor suppressor MTUS1 to promote cell proliferation and migration in lung cancer. +target gene hsa-mir-29b Breast Neoplasms 28365400 MiRNA-29b suppresses tumor growth through simultaneously inhibiting angiogenesis and tumorigenesis by targeting Akt3. +target gene hsa-mir-200a "Carcinoma, Hepatocellular" 28367241 MicroRNA-200a inhibits cell growth and metastasis by targeting Foxa2 in hepatocellular carcinoma. +target gene hsa-mir-126 Obesity 28367267 Obesity Downregulates MicroRNA-126 Inducing Capillary Rarefaction in Skeletal Muscle: Effects of Aerobic Exercise Training. +target gene hsa-mir-494 Spinal Cord Injuries 28368292 Long Coding RNA XIST Contributes to Neuronal Apoptosis through the Downregulation of AKT Phosphorylation and Is Negatively Regulated by miR-494 in Rat Spinal Cord Injury. +target gene hsa-mir-294 "Carcinoma, Bladder" 28371605 MicroRNA-294 Promotes Cellular Proliferation and Motility through the PI3K/AKT and JAK/STAT Pathways by Upregulation of NRAS in Bladder Cancer. +target gene hsa-mir-34 "Carcinoma, Prostate" 28373004 Natural killer cells suppress enzalutamide resistance and cell invasion in the castration resistant prostate cancer via targeting the androgen receptor splicing variant 7 (ARv7). +target gene hsa-mir-449 "Carcinoma, Prostate" 28373004 Natural killer cells suppress enzalutamide resistance and cell invasion in the castration resistant prostate cancer via targeting the androgen receptor splicing variant 7 (ARv7). +target gene hsa-mir-375 Colorectal Carcinoma 28374902 Impact of microRNA-375 and its target gene SMAD-7 polymorphism on susceptibility of colorectal cancer. +target gene hsa-mir-363 Rheumatoid Arthritis 28376277 Dendritic Cells from Rheumatoid Arthritis Patient Peripheral Blood Induce Th17 Cell Differentiation via miR-363/Integrin ¦Áv/TGF-¦Â Axis. +target gene hsa-let-7e "Carcinoma, Ovarian" 28376831 Let-7e sensitizes epithelial ovarian cancer to cisplatin through repressing DNA double strand break repair. +target gene hsa-mir-874 "Carcinoma, Pancreatic" 28377226 Aquaporin 3 facilitates tumor growth in pancreatic cancer by modulating mTOR signaling. +target gene hsa-mir-486 Aortic Valve Disease 28377507 miR-486 inhibits Smurf2 expression to augment the miR-204 down-regulation +target gene hsa-mir-20a "Carcinoma, Hepatocellular" 28378640 Bioinformatics prediction and experimental validation of microRNA-20a targeting Cyclin D1 in hepatocellular carcinoma. +target gene hsa-mir-125b "Carcinoma, Lung, Non-Small-Cell" 28378642 Targeting insulin-like growth factor-binding protein-3 by microRNA-125b promotes tumor invasion and poor outcomes in non-small-cell lung cancer. +target gene hsa-mir-144 Influenza 28380049 miR-144 attenuates the host response to influenza virus by targeting the TRAF6-IRF7 signaling axis. +target gene hsa-mir-181a Osteosarcoma 28381158 Triptolide inhibits the growth of osteosarcoma by regulating microRNA-181a via targeting PTEN gene in vivo and vitro. +target gene hsa-mir-181d "Carcinoma, Pancreatic" 28381166 Downregulation of microRNA-181d had suppressive effect on pancreatic cancer development through inverse regulation of KNAIN2. +target gene hsa-mir-146a Osteoarthritis 28383548 miR-146a facilitates osteoarthritis by regulating cartilage homeostasis via targeting Camk2d and Ppp3r2. +target gene hsa-mir-200b "Carcinoma, Hepatocellular" 28383782 The miR-200b-ZEB1 circuit regulates diverse stemness of human hepatocellular carcinoma. +target gene hsa-mir-138 "Carcinoma, Cervical" 28385388 MicroRNA-138 is a potential biomarker and tumor suppressor in human cervical carcinoma by reversely correlated with TCF3 gene. +target gene hsa-mir-137 Glioblastoma 28386374 MicroRNA-137 inhibits growth of glioblastoma through EGFR suppression. +target gene hsa-mir-370 "Carcinoma, Hepatocellular" 28387905 miRNA-370 acts as a tumor suppressor via the downregulation of PIM1 in hepatocellular carcinoma. +target gene hsa-mir-181a Glioblastoma 28389242 Upregulation of miR-181a suppresses the formation of glioblastoma stem cells by targeting the Notch2 oncogene and correlates with good prognosis in patients with glioblastoma multiforme. +target gene hsa-mir-125b Leukemia 28389358 MicroRNA-125b inhibits AML cells differentiation by directly targeting Fes. +target gene hsa-mir-135a "Carcinoma, Hepatocellular" 28389526 Regulation of UDP-Glucuronosyltransferases UGT2B4 and UGT2B7 by MicroRNAs in Liver Cancer Cells. +target gene hsa-mir-216b "Carcinoma, Hepatocellular" 28389526 Regulation of UDP-Glucuronosyltransferases UGT2B4 and UGT2B7 by MicroRNAs in Liver Cancer Cells. +target gene hsa-mir-3664 "Carcinoma, Hepatocellular" 28389526 Regulation of UDP-Glucuronosyltransferases UGT2B4 and UGT2B7 by MicroRNAs in Liver Cancer Cells. +target gene hsa-mir-410 "Carcinoma, Hepatocellular" 28389526 Regulation of UDP-Glucuronosyltransferases UGT2B4 and UGT2B7 by MicroRNAs in Liver Cancer Cells. +target gene hsa-mir-181d Glioblastoma 28389653 Identification of IGF-1-enhanced cytokine expressions targeted by miR-181d in glioblastomas via an integrative miRNA/mRNA regulatory network analysis. +target gene hsa-mir-21 Acute Cerebral Infarction 28389999 Effects of microRNA-21 on Nerve Cell Regeneration and Neural Function Recovery in Diabetes Mellitus Combined with Cerebral Infarction Rats by Targeting PDCD4. +target gene hsa-mir-661 Osteosarcoma 28391262 MicroRNA-661 Enhances TRAIL or STS Induced Osteosarcoma Cell Apoptosis by Modulating the Expression of Cytochrome c1. +target gene hsa-mir-143 "Carcinoma, Prostate" 28391351 Curcumin inhibits prostate cancer by targeting PGK1 in the FOXD3/miR-143 axis. +target gene hsa-mir-206 "Carcinoma, Breast" 28391353 WBP2 modulates G1/S transition in ER+?breast cancer cells and is a direct target of miR-206. +target gene hsa-mir-221 "Carcinoma, Lung, Non-Small-Cell" 28392366 miRNA-221 acts as an oncogenic role by directly targeting TIMP2 in non-small-cell lung carcinoma. +target gene hsa-mir-145 "Carcinoma, Breast" 28393176 miR-145 inhibits proliferation and migration of breast cancer cells by directly or indirectly regulating TGF-¦Â1 expression. +target gene hsa-mir-107 "Squamous Cell Carcinoma, Esophageal" 28393193 miR-107 functions as a tumor suppressor in human esophageal squamous cell carcinoma and targets Cdc42. +target gene hsa-mir-187 "Carcinoma, Lung, Non-Small-Cell" 28393200 MicroRNA-187 modulates epithelial-mesenchymal transition by targeting PTRF in non-small cell lung cancer. +target gene hsa-mir-539 "Carcinoma, Hepatocellular" 28393215 miR-539 inhibits FSCN1 expression and suppresses hepatocellular carcinoma migration and invasion. +target gene hsa-mir-124 Glioma 28393219 Inhibition of the Hedgehog signaling pathway suppresses cell proliferation by regulating the Gli2/miR-124/AURKA axis in human glioma cells. +target gene hsa-mir-27a "Carcinoma, Nasopharyngeal" 28393229 Dysregulated miR-27a-3p promotes nasopharyngeal carcinoma cell proliferation and migration by targeting Mapk10. +target gene hsa-mir-329 "Carcinoma, Cervical" 28393232 "MicroRNA-329-3p targets MAPK1 to suppress cell proliferation, migration and invasion in cervical cancer." +target gene hsa-mir-130a Neoplasms [unspecific] 28393235 Epigenetic silencing of miR-130a ameliorates hemangioma by targeting tissue factor pathway inhibitor?2 through FAK/PI3K/Rac1/mdm2 signaling. +target gene hsa-mir-10b Glioblastoma 28393237 "MicroRNA-10b mediates TGF-¦Â1-regulated glioblastoma proliferation, migration and epithelial-mesenchymal transition." +target gene hsa-mir-597 "Carcinoma, Breast" 28393251 "miR-597 inhibits breast cancer cell proliferation, migration and invasion through FOSL2." +target gene hsa-mir-4417 "Carcinoma, Hepatocellular" 28394882 miR-4417 Targets Tripartite Motif-Containing 35 (TRIM35) and Regulates Pyruvate Kinase Muscle 2 (PKM2) Phosphorylation to Promote Proliferation and Suppress Apoptosis in Hepatocellular Carcinoma Cells. +target gene hsa-mir-9 Breast Neoplasms 28397066 "MicroRNA-9 promotes the proliferation, migration, and invasion of breast cancer cells via down-regulating FOXO1." +target gene hsa-mir-150 Psoriasis 28399173 MiR-150 regulates human keratinocyte proliferation in hypoxic conditions through targeting HIF-1¦Á and VEGFA: Implications for psoriasis treatment. +target gene hsa-mir-34a "Carcinoma, Gastric" 28399871 IGF2BP3 functions as a potential oncogene and is a crucial target of miR-34a in gastric carcinogenesis. +target gene hsa-mir-18a "Carcinoma, Hepatocellular" 28399983 microRNA-18a Promotes Cell Migration and Invasion Through Inhibiting Dicer l Expression in Hepatocellular Carcinoma In Vitro. +target gene hsa-mir-146a Neoplasms [unspecific] 28401709 The role of microRNA-93 regulating angiopoietin2 in the formation of malignant pleural effusion. +target gene hsa-mir-93 Neoplasms [unspecific] 28401709 The role of microRNA-93 regulating angiopoietin2 in the formation of malignant pleural effusion. +target gene hsa-mir-210 Cervical Neoplasms 28401751 Down-Regulation of MicroRNA-210 Confers Sensitivity towards 1'S-1'-Acetoxychavicol Acetate (ACA) in Cervical Cancer Cells by Targeting SMAD4. +target gene hsa-mir-200 "Carcinoma, Lung, Non-Small-Cell" 28405157 Decitabine reverses TGF-¦Â1-induced epithelial-mesenchymal transition in non-small-cell lung cancer by regulating miR-200/ZEB axis. +target gene hsa-mir-30a "Carcinoma, Lung, Non-Small-Cell" 28405690 MicroRNA-30a-5p suppresses epithelial-mesenchymal transition by targeting profilin-2 in high invasive non-small cell lung cancer cell lines. +target gene hsa-mir-381 Osteosarcoma 28406476 "WISP-1 enhances VEGF-A expression and angiogenesis through the FAK/JNK/HIF-1¦Á signaling pathways, as well as via down-regulation of miR-381 expression" +target gene hsa-mir-137 Breast Neoplasms 28407692 MicroRNA-137 inhibits BMP7 to enhance the epithelial-mesenchymal transition of breast cancer cells. +target gene hsa-mir-18a "Adenocarcinoma, Colon" 28408657 Negative Regulation of Human Pregnane X Receptor by MicroRNA-18a-5p: Evidence for Suppression of MicroRNA-18a-5p Expression by Rifampin and Rilpivirine. +target gene hsa-mir-106b "Carcinoma, Hepatocellular" 28410209 MiR-106b inhibitors sensitize TRAIL-induced apoptosis in hepatocellular carcinoma through increase of death receptor 4. +target gene hsa-mir-21 Glioblastoma 28410224 Glioma stem cells-derived exosomes promote the angiogenic ability of endothelial cells through miR-21/VEGF signal. +target gene hsa-mir-302c "Carcinoma, Renal Cell" 28412750 microRNA-302c-3p inhibits renal cell carcinoma cell proliferation by targeting Grb2-associated binding 2 (Gab2). +target gene hsa-mir-98 "Carcinoma, Lung, Non-Small-Cell" 28415380 miR-98 inhibits expression of TWIST to prevent progression of non-small cell lung cancers. +target gene hsa-mir-330 "Carcinoma, Breast" 28419078 Targeting of CCBE1 by miR-330-3p in human breast cancer promotes metastasis. +target gene hsa-mir-193a "Carcinoma, Prostate" 28422308 Androgen receptor-regulated miRNA-193a-3p targets AJUBA to promote prostate cancer cell migration. +target gene hsa-mir-16 Myocardial Infarction 28423616 Suppression of microRNA-16 protects against acute myocardial infarction by reversing beta2-adrenergic receptor down-regulation in rats. +target gene hsa-mir-223 Pancreatic Neoplasms 28423622 HnRNPK/miR-223/FBXW7 feedback cascade promotes pancreatic cancer cell growth and invasion. +target gene hsa-mir-126 Atherosclerosis 28425867 MiR-126 activates the endothelial production of a chemokine CXCL12 via self-multiplying feedback loop to promote re-endothelialization and support lesion stability +target gene hsa-mir-299 Neoplasms [unspecific] 28426762 Human microRNA-299-3p decreases invasive behavior of cancer cells by downregulation of Oct4 expression and causes apoptosis. +target gene hsa-mir-142 "Carcinoma, Lung, Non-Small-Cell" 28427045 MiR-142-3p Overexpression Increases Chemo-Sensitivity of NSCLC by Inhibiting HMGB1-Mediated Autophagy. +target gene hsa-mir-494 Intervertebral Disc Degeneration 28427186 MicroRNA-494 promotes ECM degradation and apoptosis of degenerative human NP cells by directly targeting SOX9 +target gene hsa-mir-146b "Carcinoma, Thyroid, Follicular" 28427206 "miR-146a and miR-146b promote proliferation, migration and invasion of follicular thyroid carcinoma via inhibition of ST8SIA4." +target gene hsa-mir-205 Endometrial Neoplasms 28427207 miR-205 inhibits cell growth by targeting AKT-mTOR signaling in progesterone-resistant endometrial cancer Ishikawa cells. +target gene hsa-mir-218 "Carcinoma, Lung, Non-Small-Cell" 28429357 Inhibition of pulmonary carcinoma proliferation or metastasis of miR-218 via down-regulating CDCP1 expression. +target gene hsa-mir-148a Breast Neoplasms 28430743 MicroRNA-148a promotes apoptosis and suppresses growth of breast cancer cells by targeting B-cell lymphoma 2. +target gene hsa-mir-9 Glioma 28430789 MiR-9-3p augments apoptosis induced by H2O2 through down regulation of Herpud1 in glioma. +target gene hsa-mir-429 Fibrosarcoma 28432002 miR-429 inhibits metastasis by targeting KIAA0101 in Soft Tissue Sarcoma. +target gene hsa-mir-590 Colorectal Carcinoma 28433598 "MiR-590-5p, a density-sensitive microRNA, inhibits tumorigenesis by targeting YAP1 in colorectal cancer." +target gene hsa-mir-146a Diabetic Retinopathy 28433754 miR-146a suppresses STAT3/VEGF pathways and reduces apoptosis through IL-6 signaling in primary human retinal microvascular endothelial cells in high glucose conditions. +target gene hsa-let-7b Nervous System Diseases [unspecific] 28436683 Dexmedetomidine Protects PC12 Cells from Lidocaine-Induced Cytotoxicity Through Downregulation of COL3A1 Mediated by miR-let-7b. +target gene hsa-mir-217 "Carcinoma, Breast, Triple Negative" 28437471 "miR-217 inhibits triple-negative breast cancer cell growth, migration, and invasion through targeting KLF5." +target gene hsa-mir-124 Pediatric Ependymoma 28437838 Prognostic relevance of miR-124-3p and its target TP53INP1 in pediatric ependymoma. +target gene hsa-mir-200a "Carcinoma, Hepatocellular" 28440466 miR-200a targets Gelsolin: A novel mechanism regulating secretion of microvesicles in hepatocellular carcinoma cells. +target gene hsa-mir-200a "Carcinoma, Breast" 28440475 "A nine-miRNA signature as a potential diagnostic marker for breast carcinoma: An integrated study of 1,110 cases." +target gene hsa-mir-15a Ischemia-Reperfusion Injury 28440490 MicroRNA-15a inhibition protects against hypoxia/reoxygenation-induced apoptosis of cardiomyocytes by targeting mothers against decapentaplegic homolog 7. +target gene hsa-mir-1185 Atherosclerosis 28441650 MicroRNA-1185 Induces Endothelial Cell Apoptosis by Targeting UVRAG and KRIT1. +target gene hsa-mir-1185 Atherosclerosis 28441665 MicroRNA-1185 Promotes Arterial Stiffness though Modulating VCAM-1 and E-Selectin Expression. +target gene hsa-mir-221 "Carcinoma, Hepatocellular" 28442344 miR-221 regulates CD44 in hepatocellular carcinoma through the PI3K-AKT-mTOR pathway. +target gene hsa-mir-30a Diabetic Cataract 28442786 MicroRNA-30a Regulation of Epithelial-Mesenchymal Transition in Diabetic Cataracts Through Targeting SNAI1. +target gene hsa-mir-1202 Glioma 28443461 MiR-1202 functions as a tumor suppressor in glioma cells by targeting Rab1A. +target gene hsa-mir-30c "Carcinoma, Lung, Non-Small-Cell" 28443468 Curcumin increases the sensitivity of Paclitaxel-resistant NSCLC cells to Paclitaxel through microRNA-30c-mediated MTA1 reduction. +target gene hsa-mir-590 "Carcinoma, Breast" 28443471 Suppressing the molecular signaling pathways involved in inflammation and cancer in breast cancer cell lines MDA-MB-231 and MCF-7 by miR-590. +target gene hsa-mir-26a Colorectal Carcinoma 28443472 MiR-26a downregulates retinoblastoma in colorectal cancer. +target gene hsa-mir-340 Osteosarcoma 28443990 MicroRNA-340-5p modulates cisplatin resistance by targeting LPAAT¦Â in osteosarcoma. +target gene hsa-mir-125a "Carcinoma, Hepatocellular" 28445974 "Lowered expression of microRNA-125a-5p in human hepatocellular carcinoma and up-regulation of its oncogenic targets sirtuin-7, matrix metalloproteinase-11, and c-Raf." +target gene hsa-mir-181a Gastric Neoplasms 28447759 "miR-181a modulates proliferation, migration and autophagy in AGS gastric cancer cells and downregulates MTMR3." +target gene hsa-mir-193a Neoplasms [unspecific] 28449010 "Excess of a Rassf1-targeting microRNA, miR-193a-3p, perturbs cell division fidelity." +target gene hsa-mir-31 "Squamous Cell Carcinoma, Skin or Unspecific" 28454216 MicroRNA-31 functions as an oncogenic microRNA in cutaneous squamous cell carcinoma cells by targeting RhoTBT1. +target gene hsa-mir-29a "Fatty Liver, Non-Alcoholic" 28454323 MicroRNA-29a/b/c targets iNOS and is involved in protective remote ischemic preconditioning in an ischemia-reperfusion rat model of non-alcoholic fatty liver disease. +target gene hsa-mir-29b "Fatty Liver, Non-Alcoholic" 28454323 MicroRNA-29a/b/c targets iNOS and is involved in protective remote ischemic preconditioning in an ischemia-reperfusion rat model of non-alcoholic fatty liver disease. +target gene hsa-mir-29c "Fatty Liver, Non-Alcoholic" 28454323 MicroRNA-29a/b/c targets iNOS and is involved in protective remote ischemic preconditioning in an ischemia-reperfusion rat model of non-alcoholic fatty liver disease. +target gene hsa-mir-150 Osteosarcoma 28454380 "miR-150 is downregulated in osteosarcoma and suppresses cell proliferation, migration and invasion by targeting ROCK1." +target gene hsa-mir-409 "Carcinoma, Breast" 28459205 MicroRNA-409-5p is upregulated in breast cancer and its downregulation inhibits cancer development through downstream target of RSU1. +target gene hsa-mir-200c "Carcinoma, Nasopharyngeal" 28459373 MicroRNA-200c plays an oncogenic role in nasopharyngeal carcinoma by targeting PTEN. +target gene hsa-mir-181b Glioblastoma 28459461 MiR-181b modulates EGFR-dependent VCAM-1 expression and monocyte adhesion in glioblastoma. +target gene hsa-mir-21 Atherosclerosis 28460288 Thrombin-activated platelet-derived exosomes regulate endothelial cell expression of ICAM-1 via microRNA-223 during the thrombosis-inflammation response. +target gene hsa-mir-223 Atherosclerosis 28460288 Thrombin-activated platelet-derived exosomes regulate endothelial cell expression of ICAM-1 via microRNA-223 during the thrombosis-inflammation response. +target gene hsa-mir-19b "Leukemia, Myeloid, Chronic" 28461114 miR-17-92 promotes leukemogenesis in chronic myeloid leukemia via targeting A20 and activation of NF-¦ÊB signaling. +target gene hsa-mir-155 "Colitis, Ulcerative" 28461115 MiR-155 contributes to Th17 cells differentiation in dextran sulfate sodium (DSS)-induced colitis mice via Jarid2. +target gene hsa-mir-1228 "Carcinoma, Gastric" 28465246 microRNA-1228? impairs the pro-angiogenic activity of gastric cancer cells by targeting macrophage migration inhibitory factor. +target gene hsa-mir-145 Obstructive Sleep Apnea 28465478 Chronic obstructive sleep apnea promotes aortic remodeling in canines through miR-145/Smad3 signaling pathway. +target gene hsa-mir-133a "Carcinoma, Colon" 28466778 miR-133a acts as a tumor suppressor in colorectal cancer by targeting eIF4A1. +target gene hsa-mir-1 Colorectal Carcinoma 28471448 MiR-1 suppresses tumor cell proliferation in colorectal cancer by inhibition of Smad3-mediated tumor glycolysis. +target gene hsa-mir-19a Osteosarcoma 28475001 MiR-19a regulates the cell growth and apoptosis of osteosarcoma stem cells by targeting PTEN. +target gene hsa-mir-493 Melanoma 28475006 Downregulation of miR-493 promoted melanoma proliferation by suppressing IRS4 expression. +target gene hsa-mir-34a "Leukemia, Myeloid, Acute" 28478444 MiR-34a Promotes Apoptosis and Inhibits Autophagy by Targeting HMGB1 in Acute Myeloid Leukemia Cells. +target gene hsa-mir-1301 Prostate Neoplasms 28483517 MicroRNA-1301 suppresses tumor cell migration and invasion by targeting the p53/UBE4B pathway in multiple human cancer cells. +target gene hsa-mir-34a Atherosclerosis 28485501 miR-34a Targets HDAC1-Regulated H3K9 Acetylation on Lipid Accumulation Induced by Homocysteine in Foam Cells. +target gene hsa-mir-146a Thyroid-Associated Ophthalmopathy 28485799 Decreased microRNA-146a in CD4+T cells promote ocular inflammation in thyroid-associated ophthalmopathy by targeting NUMB. +target gene hsa-mir-223 Inflammatory Bowel Diseases 28487310 Myeloid-derived miR-223 regulates intestinal inflammation via repression of the NLRP3 inflammasome. +target gene hsa-mir-23b Colorectal Carcinoma 28487386 "our results define a critical function for miR-23b, which, by targeting LGR5, contributes to overpopulation of ALDH+ CSCs and colorectal cancer" +target gene hsa-mir-195 "Carcinoma, Esophageal" 28487599 miR-195 Regulates Proliferation and Apoptosis through Inhibiting the mTOR/p70s6k Signaling Pathway by Targeting HMGA2 in Esophageal Carcinoma Cells. +target gene hsa-mir-124 "Carcinoma, Lung, Non-Small-Cell" 28488541 MicroRNA-124 suppresses proliferation and glycolysis in non-small cell lung cancer cells by targeting AKT-GLUT1/HKII. +target gene hsa-mir-106b Gastric Neoplasms 28489839 Deregulation of microRNAs in gastric cancer: up regulation by miR-21 and miR-106. +target gene hsa-let-7a Psoriasis 28494466 Let-7a Inhibits T-Cell Proliferation and IFN-¦Ã Secretion by Down-Regulating STAT3 Expression in Patients with Psoriasis. +target gene hsa-mir-21 Atrial Fibrillation 28495464 MicroRNA-21 via Dysregulation of WW Domain-Containing Protein 1 Regulate Atrial Fibrosis in Atrial Fibrillation. +target gene hsa-mir-21 "Carcinoma, Cervical" 28495512 Modulation of CASC2/miR-21/PTEN pathway sensitizes cervical cancer to cisplatin. +target gene hsa-mir-16 Glioblastoma 28497156 Tumor suppressors microRNA-302d and microRNA-16 inhibit human glioblastoma multiforme by targeting NF-¦ÊB and FGF2. +target gene hsa-mir-302d Glioblastoma 28497156 Tumor suppressors microRNA-302d and microRNA-16 inhibit human glioblastoma multiforme by targeting NF-¦ÊB and FGF2. +target gene hsa-mir-15 "Carcinoma, Lung, Non-Small-Cell" 28498424 MicroRNA-15b promotes proliferation and invasion of non?small cell lung carcinoma cells by directly targeting TIMP2. +target gene hsa-mir-24-1 Liver Neoplasms 28499244 MicroRNA-24-1 suppresses mouse hepatoma cell invasion and metastasis via directly targeting O-GlcNAc transferase. +target gene hsa-mir-375 "Squamous Cell Carcinoma, Head and Neck" 28499703 miR-375 Regulates Invasion-Related Proteins Vimentin and L-Plastin. +target gene hsa-mir-140 Spinal Cord Injuries 28501777 MiR-140/BDNF axis regulates normal human astrocyte proliferation and LPS-induced IL-6 and TNF-¦Á secretion. +target gene hsa-mir-874 "Carcinoma, Lung, Non-Small-Cell" 28501870 Long Non-Coding RNA XLOC_008466 Functions as an Oncogene in Human Non-Small Cell Lung Cancer by Targeting miR-874. +target gene hsa-mir-181b Glioblastoma 28501897 MiR-181b modulates chemosensitivity of glioblastoma multiforme cells to temozolomide by targeting the epidermal growth factor receptor. +target gene hsa-mir-183 "Carcinoma, Pancreatic" 28506766 "Effects of microRNA-183 on epithelial-mesenchymal transition, proliferation, migration, invasion and apoptosis in human pancreatic cancer SW1900 cells by targeting MTA1." +target gene hsa-mir-21 "Hand, Foot And Mouth Disease" 28506791 Enterovirus 71-induced has-miR-21 contributes to evasion of host immune system by targeting MyD88 and IRAK1. +target gene hsa-mir-143 Breast Adenocarcinoma 28511343 Restoration of miR-143 expression could inhibit migration and growth of MDA-MB-468 cells through down-regulating the expression of invasion-related factors. +target gene hsa-mir-513b Embryonal Testis Carcinoma 28512062 Hsa-miR-513b-5p suppresses cell proliferation and promotes P53 expression by targeting IRF2 in testicular embryonal carcinoma cells. +target gene hsa-mir-130a Pulmonary Hypertension 28514291 Role of microRNA-130a in the pathogeneses of obstructive sleep apnea hypopnea syndrome-associated pulmonary hypertension by targeting the GAX gene. +target gene hsa-mir-106b Breast Neoplasms 28518139 MiR-106b and miR-93 regulate cell progression by suppression of PTEN via PI3K/Akt pathway in breast cancer. +target gene hsa-mir-29a "Carcinoma, Lung, Non-Small-Cell" 28521487 MicroRNA-29a functions as a potential tumor suppressor through directly targeting CDC42 in non-small cell lung cancer. +target gene hsa-mir-181a Stroke 28522364 Inhibition of miR-181a protects female mice from transient focal cerebral ischemia by targeting astrocyte estrogen receptor-¦Á. +target gene hsa-mir-34b Neuroblastoma 28525978 miRNA-34b is able to significantly downregulate DLL1 mRNA expression levels +target gene hsa-mir-200a Melanoma 28526299 MiR-200a Regulates CDK4/6 Inhibitor Effect by Targeting CDK6 in Metastatic?Melanoma. +target gene hsa-mir-195 "Carcinoma, Hepatocellular" 28529562 miR-195 inhibits cell proliferation via targeting AEG-1 in hepatocellular carcinoma. +target gene hsa-mir-200b "Carcinoma, Endometrial" 28529604 "knockdown of DICER1 significantly downregulated miR-200b and let-7i, which may then regulate their targets SUZ12 and EZH2" +target gene hsa-mir-16 Hypertension 28531963 MiR-19b and miR-16 cooperatively signaling target the regulator ADRA1A in Hypertensive heart disease. +target gene hsa-mir-19b Hypertension 28531963 MiR-19b and miR-16 cooperatively signaling target the regulator ADRA1A in Hypertensive heart disease. +target gene hsa-mir-145 Colorectal Carcinoma 28534337 MiR-145 inhibits drug resistance to Oxaliplatin in colorectal cancer cells through regulating G protein coupled receptor 98. +target gene hsa-mir-204 Breast Neoplasms 28534958 miR-204 regulates the biological behavior of breast cancer MCF-7 cells by directly targeting FOXA1. +target gene hsa-mir-34a "Squamous Cell Carcinoma, Esophageal" 28534990 Tumor suppressor microRNA-34a inhibits cell migration and invasion by targeting MMP-2/MMP-9/FNDC3B in esophageal squamous cell carcinoma. +target gene hsa-mir-424 "Carcinoma, Lung, Non-Small-Cell" 28535539 MiR-424 Promotes Non-Small Cell Lung Cancer Progression and Metastasis through Regulating the Tumor Suppressor Gene TNFAIP1. +target gene hsa-mir-181a "Carcinoma, Lung, Small-Cell" 28535543 MicroRNA-181a-5p Impedes IL-17-Induced Nonsmall Cell Lung Cancer Proliferation and Migration through Targeting VCAM-1. +target gene hsa-mir-200b Melanoma 28535666 A miR-200b inhibitor induced the direct regulation of SOX-2 by DDX53 +target gene hsa-mir-30b "Carcinoma, Renal Cell" 28536082 "MiR-30b-5p functions as a tumor suppressor in cell proliferation, metastasis and epithelial-to-mesenchymal transition by targeting G-protein subunit ¦Á-13 in renal cell carcinoma." +target gene hsa-let-7 Liver Injury 28536261 The let-7/Lin28 axis regulates activation of hepatic stellate cells in alcoholic liver injury. +target gene hsa-mir-126 "Carcinoma, Esophageal" 28536606 The crucial role of miR-126 on suppressing progression of esophageal cancer by targeting VEGF-A. +target gene hsa-mir-210 Atherosclerosis 28536634 MicroRNA-210 induces endothelial cell apoptosis by directly targeting PDK1 in the setting of atherosclerosis. +target gene hsa-mir-129 Neoplasms [unspecific] 28536635 "the regulation of NG2 expression underlies inflammation and hypoxia and is mediated by methyltransferases, transcription factors, including Sp1, paired box (Pax) 3 and Egr-1, and the microRNA miR129-2" +target gene hsa-mir-19a Ileus 28537131 Acupuncture Ameliorates Postoperative Ileus via IL-6-miR-19a-KIT Axis to Protect Interstitial Cells of Cajal. +target gene hsa-mir-20a "Carcinoma, Hepatocellular" 28537677 Targeting of miR-20a against CFLAR to potentiate TRAIL-induced apoptotic sensitivity in HepG2 cells. +target gene hsa-mir-221 "Carcinoma, Hepatocellular" 28539268 MiR-221 mediates the epithelial-mesenchymal transition of hepatocellular carcinoma by targeting AdipoR1. +target gene hsa-mir-29c Diabetes Mellitus 28539664 MiRNA-29c regulates the expression of inflammatory cytokines in diabetic nephropathy by targeting tristetraprolin. +target gene hsa-mir-200c Colorectal Carcinoma 28543447 Fas signaling induces stemness properties in colorectal cancer by regulation of Bmi1. +target gene hsa-mir-106b Preeclampsia 28545271 Effect of microRNA-106b on the invasion and proliferation of trophoblasts through targeting MMP-2. +target gene hsa-mir-182 Breast Neoplasms 28546132 "Identification of direct target genes of miR-7, miR-9, miR-96, and miR-182 in the human breast cancer cell lines MCF-7 and MDA-MB-231." +target gene hsa-mir-7 Breast Neoplasms 28546132 "Identification of direct target genes of miR-7, miR-9, miR-96, and miR-182 in the human breast cancer cell lines MCF-7 and MDA-MB-231." +target gene hsa-mir-9 Breast Neoplasms 28546132 "Identification of direct target genes of miR-7, miR-9, miR-96, and miR-182 in the human breast cancer cell lines MCF-7 and MDA-MB-231." +target gene hsa-mir-96 Breast Neoplasms 28546132 "Identification of direct target genes of miR-7, miR-9, miR-96, and miR-182 in the human breast cancer cell lines MCF-7 and MDA-MB-231." +target gene hsa-mir-150 Osteosarcoma 28547952 Mir-150 Up-Regulates Glut1 and Increases Glycolysis in Osteosarcoma Cells +target gene hsa-mir-26a Mycobacterium tuberculosis Infection 28558034 "MicroRNA 26a (miR-26a)/KLF4 and CREB-C/EBP¦Â regulate innate immune signaling, the polarization of macrophages and the trafficking of Mycobacterium tuberculosis to lysosomes during infection." +target gene hsa-mir-143 Breast Neoplasms 28559978 miR-143-3p targeting LIM domain kinase 1 suppresses the progression of triple-negative breast cancer cells. +target gene hsa-mir-146b Colorectal Carcinoma 28560062 "miR-146b-5p regulates cell growth, invasion, and metabolism by targeting PDHB in colorectal cancer." +target gene hsa-mir-17 Neuroblastoma 28560387 Reciprocal antagonistic regulation of N-myc mRNA by miR?17 and the neuronal-specific RNA-binding protein HuD. +target gene hsa-mir-20a Neuroblastoma 28560387 Reciprocal antagonistic regulation of N-myc mRNA by miR?17 and the neuronal-specific RNA-binding protein HuD. +target gene hsa-mir-146a Gastric Neoplasms 28560435 MicroRNA-146a promotes gastric cancer cell apoptosis by targeting transforming growth factor ¦Â-activated kinase 1. +target gene hsa-mir-155 "Carcinoma, Renal Cell, Clear-Cell" 28565840 Overexpression of miR-155 in clear-cell renal cell carcinoma and its oncogenic effect through targeting FOXO3a. +target gene hsa-mir-125b "Carcinoma, Nasopharyngeal" 28569771 MiR-125b regulates proliferation and apoptosis of nasopharyngeal carcinoma by targeting A20/NF-¦ÊB signaling pathway. +target gene hsa-mir-211 "Carcinoma, Breast, Triple Negative" 28571042 "MicroRNA-211-5p suppresses tumour cell proliferation, invasion, migration and metastasis in triple-negative breast cancer by directly targeting SETBP1." +target gene hsa-mir-21 Neoplasms [unspecific] 28571917 Targeting miR-21 with Sophocarpine Inhibits Tumor Progression and Reverses Epithelial-Mesenchymal Transition in Head and Neck Cancer. +target gene hsa-mir-124 "Leukemia, Lymphoblastic, Acute" 28578002 "MiR-124 contributes to glucocorticoid resistance in acute lymphoblastic leukemia by promoting proliferation, inhibiting apoptosis and targeting the glucocorticoid receptor." +target gene hsa-mir-124 "Carcinoma, Nasopharyngeal" 28579809 miR-124 suppresses proliferation and invasion of nasopharyngeal carcinoma cells through the Wnt/¦Â-catenin signaling pathway by targeting Capn4. +target gene hsa-mir-873 Glioma 28583401 miR-873 suppresses H9C2 cardiomyocyte proliferation by targeting GLI1. +target gene hsa-mir-199b "Carcinoma, Hepatocellular" 28588321 MicroRNA-199b-5p attenuates TGF-¦Â1-induced epithelial-mesenchymal transition in hepatocellular carcinoma. +target gene hsa-mir-18a Ovarian Neoplasms 28588697 MicroRNA-18a inhibits ovarian cancer growth via directly targeting TRIAP1 and IPMK. +target gene hsa-mir-141 Glioma 28595907 miR-141-3p functions as a tumor suppressor modulating activating transcription factor 5 in glioma. +target gene hsa-mir-150 Myocardial Infarction 28597963 miR-181a and miR-150 regulate dendritic cell immune inflammatory responses and cardiomyocyte apoptosis via targeting JAK1-STAT1/c-Fos pathway. +target gene hsa-mir-181a Myocardial Infarction 28597963 miR-181a and miR-150 regulate dendritic cell immune inflammatory responses and cardiomyocyte apoptosis via targeting JAK1-STAT1/c-Fos pathway. +target gene hsa-mir-126 Diabetes Mellitus 28598282 MicroRNA-126 Regulates Inflammatory Cytokine Secretion in Human Gingival Fibroblasts Under High Glucose via Targeting Tumor Necrosis Factor Receptor Associated Factor 6. +target gene hsa-mir-155 Prostate Neoplasms 28599307 Morin promotes prostate cancer cells chemosensitivity to paclitaxel through miR-155/GATA3 axis. +target gene hsa-mir-375 Esophageal Neoplasms 28599478 MicroRNA-375 suppresses esophageal cancer cell growth and invasion by repressing metadherin expression. +target gene hsa-mir-630 "Carcinoma, Gastric" 28601080 MicroRNA-630 Suppresses Epithelial-to-Mesenchymal Transition by Regulating FoxM1 in Gastric Cancer Cells. +target gene hsa-mir-200c "Carcinoma, Hepatocellular" 28609841 MiR-200c-5p suppresses proliferation and metastasis of human hepatocellular carcinoma (HCC) via suppressing MAD2L1. +target gene hsa-mir-137 "Carcinoma, Lung, Non-Small-Cell" 28610956 Upregulation of microRNA-137 expression by Slug promotes tumor invasion and metastasis of non-small cell lung cancer cells through suppression of TFAP2C. +target gene hsa-mir-222 "Adenocarcinoma, Lung" 28617551 "MiR-222 promotes proliferation, migration and invasion of lung adenocarcinoma cells by targeting ETS1." +target gene hsa-mir-1 "Carcinoma, Bladder" 28618950 MiR-1-3p inhibits the proliferation and invasion of bladder cancer cells by suppressing CCL2 expression. +target gene hsa-mir-105 Glioma 28618952 MicroRNA-105 inhibits human glioma cell malignancy by directly targeting SUZ12. +target gene hsa-mir-208b Osteosarcoma 28618961 MicroRNA-208b inhibits human osteosarcoma progression by targeting ROR2. +target gene hsa-mir-221 "Carcinoma, Gastric" 28618968 miR-221 and miR-222 synergistically regulate hepatocyte growth factor activator inhibitor type 1 to promote cell proliferation and migration in gastric cancer. +target gene hsa-mir-222 "Carcinoma, Gastric" 28618968 miR-221 and miR-222 synergistically regulate hepatocyte growth factor activator inhibitor type 1 to promote cell proliferation and migration in gastric cancer. +target gene hsa-mir-31 "Carcinoma, Hepatocellular" 28623129 "Increased expression of microRNA-31-5p inhibits cell proliferation, migration, and invasion via regulating Sp1 transcription factor in HepG2 hepatocellular carcinoma cell line." +target gene hsa-mir-375 "Squamous Cell Carcinoma, Oral" 28627030 MiR-375/SLC7A11 axis regulates oral squamous cell carcinoma proliferation and invasion. +target gene hsa-mir-495 Preeclampsia 28628915 MiR-495 Promotes Senescence of Mesenchymal Stem Cells by Targeting Bmi-1. +target gene hsa-mir-330 "Carcinoma, Lung, Non-Small-Cell" 28629431 MicroRNA-330-3p promotes cell invasion and metastasis in non-small cell lung cancer through GRIA3 by activating MAPK/ERK signaling pathway. +target gene hsa-mir-500 "Carcinoma, Prostate" 28631332 Inhibition of microRNA-500 has anti-cancer effect through its conditional downstream target of TFPI in human prostate cancer. +target gene hsa-mir-1285 "Carcinoma, Lung, Non-Small-Cell" 28631567 MicroRNA-1285-5p influences the proliferation and metastasis of non-small-cell lung carcinoma cells via downregulating CDH1 and Smad4. +target gene hsa-mir-1236 "Carcinoma, Lung" 28631573 Effects of miR-1236-3p and miR-370-5p on activation of p21 in various tumors and its inhibition on the growth of lung cancer cells. +target gene hsa-mir-370 "Carcinoma, Lung" 28631573 Effects of miR-1236-3p and miR-370-5p on activation of p21 in various tumors and its inhibition on the growth of lung cancer cells. +target gene hsa-mir-125a "Carcinoma, Lung" 28631574 MicroRNA-125a-5p plays a role as a tumor suppressor in lung carcinoma cells by directly targeting STAT3. +target gene hsa-mir-646 "Carcinoma, Gastric" 28632723 MiR-646 inhibited cell proliferation and EMT-induced metastasis by targeting FOXK1 in gastric cancer. +target gene hsa-mir-146a Osteoarthritis 28634214 Effects of microRNA-146a on the proliferation and apoptosis of human osteochondrocytes by targeting TRAF6 through the NF- ¦ÊB signalling pathway. +target gene hsa-mir-148a Glomerulonephritis 28637300 "The type of diet intake also influenced cytokine production, fecal microbiota (increased Lachnospiraceae in mice fed on 2018), altered microRNAs (miRNAs; higher levels of lupus-associated miR-148a and miR-183 in mice fed on 7013 and/or 2018) and altered DNA methylation." +target gene hsa-mir-183 Glomerulonephritis 28637300 "The type of diet intake also influenced cytokine production, fecal microbiota (increased Lachnospiraceae in mice fed on 2018), altered microRNAs (miRNAs; higher levels of lupus-associated miR-148a and miR-183 in mice fed on 7013 and/or 2018) and altered DNA methylation." +target gene hsa-mir-26a "Carcinoma, Breast" 28637868 Post-transcriptional regulation of ERBB2 by miR26a/b and HuR confers resistance to tamoxifen in estrogen receptor-positive breast cancer cells. +target gene hsa-mir-26b "Carcinoma, Breast" 28637868 Post-transcriptional regulation of ERBB2 by miR26a/b and HuR confers resistance to tamoxifen in estrogen receptor-positive breast cancer cells. +target gene hsa-mir-195 "Carcinoma, Pancreatic" 28639885 MicroRNA-195 inhibits the proliferation and invasion of pancreatic cancer cells by targeting the fatty acid synthase/Wnt signaling pathway. +target gene hsa-mir-138 "Carcinoma, Hepatocellular" 28639887 MicroRNA-138 enhances TRAIL-induced apoptosis through interferon-stimulated gene 15 downregulation in hepatocellular carcinoma cells. +target gene hsa-mir-557 "Carcinoma, Lung" 28639890 MiR-557 works as a tumor suppressor in human lung cancers by negatively regulating LEF1 expression. +target gene hsa-mir-193a "Carcinoma, Renal Cell" 28639901 Downregulation of miR-193a-3p inhibits cell growth and migration in renal cell carcinoma by targeting PTEN. +target gene hsa-mir-26a "Lymphoma, Large B-Cell, Diffuse" 28640256 "MicroRNA-26a/cyclin-dependent kinase 5 axis controls proliferation, apoptosis and in vivo tumor growth of diffuse large B-cell lymphoma cell lines." +target gene hsa-mir-26a Colorectal Carcinoma 28640257 Tumor-suppressive miR-26a and miR-26b inhibit cell aggressiveness by regulating FUT4 in colorectal cancer. +target gene hsa-mir-26b Colorectal Carcinoma 28640257 Tumor-suppressive miR-26a and miR-26b inhibit cell aggressiveness by regulating FUT4 in colorectal cancer. +target gene hsa-mir-337 "Carcinoma, Cervical" 28641487 MicroRNA-337 inhibits cell proliferation and invasion of cervical cancer through directly targeting specificity protein 1. +target gene hsa-mir-133b "Carcinoma, Lung" 28641694 MiR-133b Affect the Proliferation and Drug Sensitivity in A549 Lung Cancer Stem Cells by Targeting PKM2. +target gene hsa-mir-217 Cardiac Myxoma 28642131 miR-217 suppresses proliferation and promotes apoptosis in cardiac myxoma by targeting Interleukin-6. +target gene hsa-mir-205 "Carcinoma, Cervical" 28651495 MiR-205 serves as a prognostic factor and suppresses proliferation and invasion by targeting insulin-like growth factor receptor 1 in human cervical cancer. +target gene hsa-mir-144 "Carcinoma, Pancreatic" 28653602 "miR-144-3p Targets FosB Proto-oncogene, AP-1 Transcription Factor Subunit (FOSB) to Suppress Proliferation, Migration, and Invasion of PANC-1 Pancreatic Cancer Cells." +target gene hsa-mir-181a "Carcinoma, Cervical" 28653606 miR-181a-5p Promotes Proliferation and Invasion and Inhibits Apoptosis of Cervical Cancer Cells via Regulating Inositol Polyphosphate-5-Phosphatase A (INPP5A). +target gene hsa-mir-129 "Carcinoma, Gastric" 28653880 MiR-129-5p influences the progression of gastric cancer cells through interacting with SPOCK1. +target gene hsa-mir-150 "Carcinoma, Thyroid, Papillary" 28656254 "MicroRNA-150 targets Rho-associated protein kinase 1 to inhibit cell proliferation, migration and invasion in papillary thyroid carcinoma." +target gene hsa-mir-148b Melanoma 28656878 Proteasome beta-4 subunit contributes to the development of melanoma and is regulated by miR-148b. +target gene hsa-mir-136 "Carcinoma, Gastric" 28656883 MiR-136 inhibits gastric cancer-specific peritoneal metastasis by targeting HOXC10. +target gene hsa-mir-210 Ischemic Diseases [unspecific] 28661226 MicroRNA-210 alleviates oxidative stress-associated cardiomyocyte apoptosis by regulating BNIP3. +target gene hsa-mir-146a Sepsis 28662100 "miR-146a, miR-146b, and miR-155 increase expression of IL-6 and IL-8 and support HSP10 in an In vitro sepsis model." +target gene hsa-mir-146b Sepsis 28662100 "miR-146a, miR-146b, and miR-155 increase expression of IL-6 and IL-8 and support HSP10 in an In vitro sepsis model." +target gene hsa-mir-155 Sepsis 28662100 "miR-146a, miR-146b, and miR-155 increase expression of IL-6 and IL-8 and support HSP10 in an In vitro sepsis model." +target gene hsa-mir-34a "Carcinoma, Hepatocellular" 28667294 0404 inhibits hepatocellular carcinoma through a p53/miR-34a/SIRT1 positive feedback loop. +target gene hsa-mir-34a "Carcinoma, Hepatocellular" 28667334 3'UTR polymorphisms of carbonic anhydrase IX determine the miR-34a targeting efficiency and prognosis of hepatocellular carcinoma. +target gene hsa-mir-16 Gastric Neoplasms 28667493 MiR-16-1 Targeted Silences Far Upstream Element Binding Protein 1 to Advance the Chemosensitivity to Adriamycin in Gastric Cancer. +target gene hsa-mir-155 "Carcinoma, Salivary Adenoid Cystic" 28668836 MicroRNA Profiling and Target Genes Related to Metastasis of Salivary Adenoid Cystic Carcinoma. +target gene hsa-mir-205 "Carcinoma, Salivary Adenoid Cystic" 28668836 MicroRNA Profiling and Target Genes Related to Metastasis of Salivary Adenoid Cystic Carcinoma. +target gene hsa-mir-664a Osteosarcoma 28669734 Inhibition of miR-664a interferes with the migration of osteosarcoma cells via modulation of MEG3. +target gene hsa-let-7b "Carcinoma, Hepatocellular" 28671046 Let7b modulates the Wnt/¦Â-catenin pathway in liver cancer cells via downregulated Frizzled4. +target gene hsa-mir-204 "Carcinoma, Breast" 28675122 MiR-204/ZEB2 axis functions as key mediator for MALAT1-induced epithelial-mesenchymal transition in breast cancer. +target gene hsa-mir-372 Pancreatic Adenocarcinoma 28677209 Downregulation of ULK1 by microRNA-372 inhibits the survival of human pancreatic adenocarcinoma cells. +target gene hsa-mir-138 "Carcinoma, Hepatocellular" 28677784 MicroRNA-138 inhibits cell proliferation in hepatocellular carcinoma by targeting Sirt1. +target gene hsa-mir-30a Lung Neoplasms 28678320 MiR-30 suppresses lung cancer cell 95D epithelial mesenchymal transition and invasion through targeted regulating Snail. +target gene hsa-mir-107 Osteosarcoma 28682874 In vitro effect of microRNA-107 targeting Dkk-1 by regulation of Wnt/¦Â-catenin signaling pathway in osteosarcoma +target gene hsa-mir-150 Neuropathic Pain 28685867 MiR-150 alleviates neuropathic pain via inhibiting toll-like receptor 5. +target gene hsa-mir-34a Atherosclerosis 28688900 MiR-34a/sirtuin-1/foxo3a is involved in genistein protecting against ox-LDL-induced oxidative damage in HUVECs. +target gene hsa-mir-155 Lung Neoplasms 28688901 MicroRNA-155 regulates arsenite-induced malignant transformation by targeting Nrf2-mediated oxidative damage in human bronchial epithelial cells. +target gene hsa-mir-200b "Carcinoma, Hepatocellular" 28695771 MicroRNA-200b suppresses the invasion and migration of hepatocellular carcinoma by downregulating RhoA and circRNA_000839. +target gene hsa-mir-125b "Carcinoma, Nasopharyngeal" 28698199 MiR-125b Increases Nasopharyngeal Carcinoma Radioresistance by Targeting A20/NF-¦ÊB Signaling Pathway. +target gene hsa-let-7a Melanoma 28698805 MicroRNA-26a inhibits the growth and invasiveness of malignant melanoma and directly targets on MITF gene. +target gene hsa-mir-26a Melanoma 28698805 MicroRNA-26a inhibits the growth and invasiveness of malignant melanoma and directly targets on MITF gene. +target gene hsa-mir-613 Gastric Neoplasms 28701053 MicroRNA-613 inhibits the progression of gastric cancer by targeting CDK9. +target gene hsa-mir-25 Osteosarcoma 28705117 "MicroRNA-25 suppresses proliferation, migration, and invasion of osteosarcoma by targeting SOX4." +target gene hsa-mir-145 Retinoblastoma 28706438 Genistein suppresses retinoblastoma cell viability and growth and induces apoptosis by upregulating miR-145 and inhibiting its target ABCE1. +target gene hsa-mir-138 Colorectal Carcinoma 28707774 "Hsa_circ_0020397 regulates colorectal cancer cell viability, apoptosis and invasion by promoting the expression of the miR-138 targets TERT and PD-L1." +target gene hsa-mir-320 Gastric Neoplasms 28713899 miR-320a serves as a negative regulator in the progression of gastric cancer by targeting RAB14. +target gene hsa-mir-34a "Carcinoma, Colon" 28713966 Spica Prunellae extract suppresses the growth of human colon carcinoma cells by targeting multiple oncogenes via activating miR-34a. +target gene hsa-mir-125b "Carcinoma, Lung, Non-Small-Cell" 28713974 miRNA-125b regulates apoptosis of human non-small cell lung cancer via the PI3K/Akt/GSK3¦Â signaling pathway. +target gene hsa-mir-219 "Carcinoma, Lung, Non-Small-Cell" 28714014 MicroRNA-219 is downregulated in non-small cell lung cancer and inhibits cell growth and metastasis by targeting HMGA2. +target gene hsa-mir-200a "Carcinoma, Renal Cell" 28717923 MiRNA-200a induce cell apoptosis in renal cell carcinoma by directly targeting SIRT1. +target gene hsa-mir-143 "Carcinoma, Gastric" 28718369 MiR-143 inhibits cell proliferation and invasion by targeting DNMT3A in gastric cancer. +target gene hsa-mir-592 Glioma 28718372 MiR-592 functions as a tumor suppressor in glioma by targeting IGFBP2. +target gene hsa-mir-139 "Carcinoma, Bladder" 28720065 MicroRNA-139-5p inhibits bladder cancer proliferation and self-renewal by targeting the Bmi1 oncogene. +target gene hsa-mir-375 Melanoma 28723760 "CXCL8 interacted with STAT1, CCL27, and IGF1R targeted by hsa-miR-375" +target gene hsa-mir-378 Colon Neoplasms 28725241 "miR-378 suppresses the proliferation, migration and invasion of colon cancer cells by inhibiting SDAD1." +target gene hsa-mir-200c Lung Neoplasms 28727734 "MicroRNA-200c inhibits epithelial-mesenchymal transition, invasion, and migration of lung cancer by targeting HMGB1." +target gene hsa-let-7c Breast Neoplasms 28731186 Let-7c-5p inhibits cell proliferation and induces cell apoptosis by targeting ERCC6 in breast cancer +target gene hsa-mir-181a "Leukemia, Lymphoblastic, Acute" 28732737 MicroRNA-181a and its target Smad 7 as potential biomarkers for tracking child acute lymphoblastic leukemia +target gene hsa-mir-143 Osteosarcoma 28734729 MiR-143 regulates the proliferation and migration of osteosarcoma cells through targeting MAPK7. +target gene hsa-mir-27b "Squamous Cell Carcinoma, Oral" 28735227 MicroRNA-27b inhibits cell proliferation in oral squamous cell carcinoma by targeting FZD7 and Wnt signaling pathway. +target gene hsa-mir-143 Lymphoma 28736328 Down regulation of miR-143 promotes radiation - Induced thymic lymphoma by targeting B7H1. +target gene hsa-mir-21 Ischemia-Reperfusion Injury 28737660 Renal Protection Mediated by Hypoxia Inducible Factor-1¦Á Depends on Proangiogenesis Function of miR-21 by Targeting Thrombospondin 1. +target gene hsa-mir-21 Pituitary Neoplasms 28742208 Effects of microRNA-21 targeting PITX2 on proliferation and apoptosis of pituitary tumor cells. +target gene hsa-mir-133a Colorectal Carcinoma 28748780 miR-133a-3p Targets SUMO-Specific Protease 1 to Inhibit Cell Proliferation and Cell Cycle Progress in Colorectal Cancer. +target gene hsa-mir-429 Glioblastoma 28749077 MiR-429 suppresses glioblastoma multiforme by targeting SOX2. +target gene hsa-mir-1254 "Carcinoma, Lung, Non-Small-Cell" 28749936 MiR-1254 suppresses HO-1 expression through seed region-dependent silencing and non-seed interaction with TFAP2A transcript to attenuate NSCLC growth. +target gene hsa-mir-195 Lung Neoplasms 28752530 "HMGA2 regulation by microRNA-195 (miR-195) was validated by real time-PCR, Western blotting, and luciferase reporter assays" +target gene hsa-mir-155 Marek Disease 28757026 Marek's disease virus type 1 encoded analog of miR-155 promotes proliferation of chicken embryo fibroblast and DF-1 cells by targeting hnRNPAB. +target gene hsa-mir-137 Melanoma 28757416 "The tumour suppressor, miR-137, inhibits malignant melanoma migration by targetting the TBX3 transcription factor." +target gene hsa-mir-21 Cardio-Renal Syndrome 28760335 "MicroRNA-21 regulates peroxisome proliferator-activated receptor alpha, a molecular mechanism of cardiac pathology in Cardiorenal Syndrome Type 4." +target gene hsa-mir-143 "Carcinoma, Hepatocellular" 28765889 Downregulation of microRNA-143 promotes cell proliferation by regulating PKC¦Å in hepatocellular carcinoma cells. +target gene hsa-mir-206 Encephalitis 28765968 Downregulation of CCL2 induced by the upregulation of microRNA-206 is associated with the severity of HEV71 encephalitis +target gene hsa-mir-182 Colorectal Carcinoma 28767179 Upregulation of microRNA-135b and microRNA-182 promotes chemoresistance of colorectal cancer by targeting ST6GALNAC2 via PI3K/AKT pathway. +target gene hsa-mir-132 Melanoma 28767374 "hsa-mir-132,downregulates expression levels of p120RasGAP" +target gene hsa-mir-144 Preeclampsia 28772212 "miR-144 may regulate the proliferation, migration and invasion of trophoblastic cells through targeting PTEN in preeclampsia." +target gene hsa-mir-524 Glioma 28778566 EGFR/c-myc axis regulates TGF¦Â/Hippo/Notch pathway via epigenetic silencing miR-524 in gliomas. +target gene hsa-mir-203 "Carcinoma, Hepatocellular" 28781949 miR-203a-3p.1 targets IL-24 to modulate hepatocellular carcinoma cell growth and metastasis. +target gene hsa-mir-18a Muscle Atrophy 28782600 miR-18a induces myotubes atrophy by down-regulating IgfI. +target gene hsa-mir-124 Glioma 28791348 MicroRNA-124 inhibits the proliferation of C6 glioma cells by targeting Smad4. +target gene hsa-mir-195 "Carcinoma, Laryngeal" 28791411 MicroRNA-195 inhibits growth and invasion of laryngeal carcinoma cells by directly targeting DCUN1D1. +target gene hsa-mir-133a Vascular Hypertrophy 28795305 microRNA-133a attenuates cardiomyocyte hypertrophy by targeting PKC¦Ä and Gq. +target gene hsa-mir-3144 Arrhythmia 28796037 miR-3144-5p overexpression plays a role in HCMs by regulating these genes and TF +target gene hsa-mir-4262 "Carcinoma, Cervical" 28800784 Upregulation of MicroRNA-4262 Targets Kaiso (ZBTB33) to Inhibit the Proliferation and EMT of Cervical Cancer Cells. +target gene hsa-mir-449a "Carcinoma, Lung, Non-Small-Cell" 28800787 MiR-449a Suppresses LDHA-Mediated Glycolysis to Enhance the Sensitivity of Non-Small Cell Lung Cancer Cells to Ionizing Radiation. +target gene hsa-mir-204 Cervical Neoplasms 28800788 MiR-204 Regulates Cell Proliferation and Invasion by Targeting EphB2 in Human Cervical Cancer +target gene hsa-mir-641 Lung Neoplasms 28800790 miR-641 Functions as a Tumor Suppressor by Targeting MDM2 in Human Lung Cancer. +target gene hsa-mir-154 Gastric Neoplasms 28800791 MicroRNA-154 Inhibits the Growth and Invasion of Gastric Cancer Cells by Targeting DIXDC1/WNT Signaling. +target gene hsa-mir-145 Colorectal Carcinoma 28802228 MTDH and MAP3K1 are direct targets of apoptosis-regulating miRNAs in colorectal carcinoma +target gene hsa-mir-375 Colorectal Carcinoma 28802228 MTDH and MAP3K1 are direct targets of apoptosis-regulating miRNAs in colorectal carcinoma +target gene hsa-mir-181c Lung Neoplasms 28806967 MicroRNA-181c inhibits cigarette smoke-induced chronic obstructive pulmonary disease by regulating CCN1 expression. +target gene hsa-mir-21 Kidney Diseases [unspecific] 28808068 Overexpression of renal Smad7 protects against hypertensive nephropathy by inactivating angiotensin II-induced TGF-¦Â/Smad3 and NF-¦ÊB pathways and by targeting the Smad3-dependent microRNA-21 axis +target gene hsa-mir-375 "Squamous Cell Carcinoma, Oral" 28810236 MicroRNA-375 Inhibits Growth and Enhances Radiosensitivity in Oral Squamous Cell Carcinoma by Targeting Insulin Like Growth Factor 1 Receptor. +target gene hsa-mir-9 Melanoma 28810544 MicroRNA-9 inhibits the proliferation and migration of malignant melanoma cells via targeting sirituin 1. +target gene hsa-mir-152 Osteosarcoma 28810933 MicroRNA-152 Suppresses Human Osteosarcoma Cell Proliferation and Invasion by Targeting E2F Transcription Factor 3. +target gene hsa-mir-21 Myocardial Infarction 28817807 Mir-21 Promotes Cardiac Fibrosis After Myocardial Infarction Via Targeting Smad7. +target gene hsa-mir-200a Neoplasms [unspecific] 28817830 MicroRNA-200a Inhibits Transforming Growth Factor ¦Â1-Induced Proximal Tubular Epithelial-Mesenchymal Transition by Targeting ¦Â-Catenin. +target gene hsa-mir-21 Atherosclerosis 28823833 MicroRNA-21 suppresses ox-LDL-induced human aortic endothelial cells injuries in atherosclerosis through enhancement of autophagic flux: Involvement in promotion of lysosomal function. +target gene hsa-mir-124 Gastric Neoplasms 28829503 MicroRNA-124 inhibits cell invasion and epithelial-mesenchymal transition by directly repressing Snail2 in gastric cancer +target gene hsa-mir-200c Breast Neoplasms 28829888 MiR-200c inhibits metastasis of breast tumor via the downregulation of Foxf2. +target gene hsa-mir-367 Melanoma 28829890 miR-367 promotes uveal melanoma cell proliferation and migration by regulating PTEN. +target gene hsa-mir-130a Gastric Neoplasms 28831264 microRNA-130a is an oncomir suppressing the expression of CRMP4 in gastric cancer +target gene hsa-mir-31 "Adenocarcinoma, Gastric" 28836853 MicroRNA-31 inhibits RhoA-mediated tumor invasion and chemotherapy resistance in MKN-45 gastric adenocarcinoma cells. +target gene hsa-mir-204 Hypertension 28839162 MicroRNA-204 promotes vascular endoplasmic reticulum stress and endothelial dysfunction by targeting Sirtuin1. +target gene hsa-mir-494 Ischemia-Reperfusion Injury 28842516 miR-494 up-regulates the PI3K/Akt pathway via targetting PTEN and attenuates hepatic ischemia/reperfusion injury in a rat model. +target gene hsa-mir-22 Arteriosclerosis Obliterans 28848136 Our results indicate that miR-22-3p is a key molecule in regulating HASMC proliferation and migration by targeting HMGB1 and that miR-22-3p and HMGB1 may be therapeutic targets in the treatment of human ASO. +target gene hsa-mir-15a "Carcinoma, Renal Cell" 28849086 Downregulation of microRNA-15a suppresses the proliferation and invasion of renal cell carcinoma via direct targeting of eIF4E. +target gene hsa-mir-130a Colorectal Carcinoma 28849155 MicroRNA-130a is upregulated in colorectal cancer and promotes cell growth and motility by directly targeting forkhead box F2. +target gene hsa-mir-182 Atherosclerosis 28855441 MicroRNA-182 Promotes Lipoprotein Lipase Expression and Atherogenesisby Targeting Histone Deacetylase 9 in Apolipoprotein E-Knockout Mice. +target gene hsa-mir-222 Colorectal Carcinoma 28855850 MicroRNA-222 influences migration and invasion through MIA3 in colorectal cancer +target gene hsa-mir-34a Glioma 28859546 MicroRNA-34a induces transdifferentiation of glioma stem cells into vascular endothelial cells by targeting Notch pathway. +target gene hsa-mir-204 Prostate Neoplasms 28861151 microRNA-204 modulates chemosensitivity and apoptosis of prostate cancer cells by targeting zinc-finger E-box-binding homeobox 1 (ZEB1). +target gene hsa-mir-138 "Carcinoma, Renal Cell, Clear-Cell" 28861152 MicroRNA-138 attenuates epithelial-to-mesenchymal transition by targeting SOX4 in clear cell renal cell carcinoma. +target gene hsa-mir-127 Bone Cancer 28866093 MiR-127 and miR-376a act as tumor suppressors by in?vivo targeting of COA1 and PDIA6 in giant cell tumor of bone. +target gene hsa-mir-376a Bone Cancer 28866093 MiR-127 and miR-376a act as tumor suppressors by in?vivo targeting of COA1 and PDIA6 in giant cell tumor of bone. +target gene hsa-mir-107 "Carcinoma, Hepatocellular" 28867541 miR-107-mediated decrease of HMGCS2 indicates poor outcomes and promotes cell migration in hepatocellular carcinoma +target gene hsa-mir-15a Arthritis 28877850 Gabapentin regulates expression of FGF2 and FGFR1 in dorsal root ganglia via microRNA-15a in the arthritis rat model. +target gene hsa-mir-4317 Gastric Neoplasms 28880489 miRNA-4317 suppresses human gastric cancer cell proliferation by targeting ZNF322. +target gene hsa-mir-126 "Carcinoma, Hepatocellular" 28881749 "Effects of microRNA-126 on cell proliferation, apoptosis and tumor angiogenesis via the down-regulating ERK signaling pathway by targeting EGFL7 in hepatocellular carcinoma" +target gene hsa-mir-106b Cholangiocarcinoma 28881782 miR-106b regulates the 5-fluorouracil resistance by targeting Zbtb7a in cholangiocarcinoma +target gene hsa-mir-106a Prostate Neoplasms 28889725 Oncogene miR-106a promotes proliferation and metastasis of prostate cancer cells by directly targeting PTEN in vivo and in vitro. +target gene hsa-mir-150 Lung Neoplasms 28891208 Serum MicroRNA-150 Predicts Prognosis for Early-Stage Non-Small Cell Lung Cancer and Promotes Tumor Cell Proliferation by Targeting Tumor Suppressor Gene SRCIN1. +target gene hsa-mir-96 hepatocellular carcinoma 28892647 "miR-96 targets SOX6 and promotes proliferation, migration, and invasion of hepatocellular carcinoma" +target gene hsa-mir-34a "Fatty Liver, Non-Alcoholic" 28899784 MiR-181b regulates steatosis in nonalcoholic fatty liver disease via targeting SIRT1. +target gene hsa-mir-149 "Carcinoma, Renal Cell" 28902136 Dual Strands of Pre-miR-149 Inhibit Cancer Cell Migration and Invasion through Targeting FOXM1 in Renal Cell Carcinoma. +target gene hsa-mir-217 Colorectal Carcinoma 28905214 "miR-217-5p induces apoptosis by directly targeting PRKCI, BAG3, ITGAV and MAPK1 in colorectal cancer cells." +target gene hsa-mir-16 Cholangiocarcinoma 28915618 Suppression of miR-16 promotes tumor growth and metastasis through reversely regulating YAP1 in human cholangiocarcinoma. +target gene hsa-mir-25 Neoplasms [unspecific] 28920955 miR-25/93 mediates hypoxia-induced immunosuppression by repressing cGAS. +target gene hsa-mir-21 Rectal Neoplasms 28927090 Downregulation of PDCD4 by miR-21 suppresses tumor transformation and proliferation in a nude mouse renal cancer model. +target gene hsa-mir-181a "Carcinoma, Hepatocellular" 28930552 MicroRNA-181a inhibits autophagy by targeting Atg5 in hepatocellular carcinoma +target gene hsa-mir-181a "Squamous Cell Carcinoma, Skin or Unspecific" 28931048 miR-181a decelerates proliferation in cutaneous squamous cell carcinoma by targeting the proto-oncogene KRAS. +target gene hsa-mir-200c Breast Neoplasms 28933253 The role of p53-microRNA 200-Moesin axis in invasion and drug resistance of breast cancer cells. +target gene hsa-mir-320 Glioma 28934982 MiR-320 inhibits the growth of glioma cells through downregulating PBX3. +target gene hsa-mir-21 Breast Neoplasms 28935174 TIMP-3 mRNA expression levels positively correlates with levels of miR-21 in in situ BC and negatively in PR positive invasive BC. +target gene hsa-mir-130a Neoplasms [unspecific] 28935812 miR-130a Deregulates PTEN and Stimulates Tumor Growth. +target gene hsa-mir-124 Gastric Neoplasms 28941308 In vivo and in vitro effects of microRNA-124 on human gastric cancer by targeting JAG1 through the Notch signaling pathway. +target gene hsa-mir-126 Diabetic Retinopathy 28943945 MicroRNA-126 inhibits cell viability and invasion in a diabetic retinopathy model via targeting IRS-1. +target gene hsa-mir-26b Breast Neoplasms 28944451 Expression of miRNA-26b-5p and its target TRPS1 is associated with radiation exposure in post-Chernobyl breast cancer. +target gene hsa-mir-181a "Carcinoma, Lung, Non-Small-Cell" 28946554 MiR-181a inhibits non-small cell lung cancer cell proliferation by targeting CDK1. +target gene hsa-mir-21 Leukemia 28947822 "Microenvironment regulates the expression of miR-21 and tumor suppressor genes PTEN, PIAS3 and PDCD4 through ZAP-70 in chronic lymphocytic leukemia." +target gene hsa-mir-125a Osteosarcoma 28950256 MicroRNA-125a Regulates Cell Proliferation Via Directly Targeting E2F2 in Osteosarcoma +target gene hsa-mir-500a Neoplasms [unspecific] 28952053 Cancer-associated genes LIF and PAPPA are possible targets of miR-500a-3p +target gene hsa-mir-214 "Squamous Cell Carcinoma, Esophageal" 28954387 MiR-214 inhibits the proliferation and invasion of esophageal squamous cell carcinoma cells by targeting CDC25B. +target gene hsa-mir-18a Alzheimer Disease 28956815 "hsa-mir-18a, having common key targets in the BARHL1-ESR1 network and AD pathway" +target gene hsa-mir-21 Colorectal Carcinoma 28957811 MicroRNA-21 (Mir-21) Promotes Cell Growth and Invasion by Repressing Tumor Suppressor PTEN in Colorectal Cancer. +target gene hsa-mir-138 "Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal" 28962111 MicroRNA-138 suppresses cell proliferation in laryngeal squamous cell carcinoma via inhibiting EZH2 and PI3K/AKT signaling. +target gene hsa-mir-191 "Diabetes Mellitus, Type 2" 28963693 "MicroRNA-191, acting via the IRS-1/Akt signaling pathway, is involved in the hepatic insulin resistance induced by cigarette smoke extract." +target gene hsa-mir-124 Pulmonary Hypertension 28972001 Metabolic and Proliferative State of Vascular Adventitial Fibroblasts in Pulmonary Hypertension Is Regulated Through a MicroRNA-124/PTBP1 (Polypyrimidine Tract Binding Protein 1)/Pyruvate Kinase Muscle Axis. +target gene hsa-mir-629 Ovarian Neoplasms 28972400 Knockdown of miR-629 Inhibits Ovarian Cancer Malignant Behaviors by Targeting Testis-Specific Y-Like Protein 5. +target gene hsa-mir-200b "Carcinoma, Breast" 28972876 miR-200b regulates epithelial-mesenchymal transition of chemo-resistant breast cancer cells by targeting FN1. +target gene hsa-mir-26a "Carcinoma, Skin" 28977801 MiR-26a Mediates Ultraviolet B-Induced Apoptosis by Targeting Histone Methyltransferase EZH2 Depending on Myc Expression. +target gene hsa-mir-23b Gastric Neoplasms 28981115 miR-23a/b promote tumor growth and suppress apoptosis by targeting PDCD4 in gastric cancer. +target gene hsa-mir-1 Rhabdomyosarcoma 28981396 miR-133b also knock downed PAX3-FOXO1 +target gene hsa-mir-17 "Adenocarcinoma, Pancreatic Ductal" 28987387 MiR-17-5p enhances pancreatic cancer proliferation by altering cell cycle profiles via disruption of RBL2/E2F4-repressing complexes. +target gene hsa-mir-29a Rheumatoid Arthritis 28987940 MicroRNA-29a inhibits proliferation and induces apoptosis in rheumatoid arthritis fibroblast-like synoviocytes by repressing STAT3. +target gene hsa-mir-205 Gastric Neoplasms 28987942 miR-205 regulation of ICT1 has an oncogenic potential via promoting the migration and invasion of gastric cancer cells. +target gene hsa-mir-206 "Squamous Cell Carcinoma, Head and Neck" 28987947 MiR-206 inhibits Head and neck squamous cell carcinoma cell progression by targeting HDAC6 via PTEN/AKT/mTOR pathway. +target gene hsa-mir-205 Colorectal Carcinoma 28990808 MicroRNA-205 Mediates Proteinase-Activated Receptor 2 (PAR2) -Promoted Cancer Cell Migration. +target gene hsa-mir-16 Melanoma 28991221 TYRP1-dependent miR-16 sequestration can also be overcome in vivo by using small oligonucleotides that mask miR-16-binding sites on TYRP1 mRNA +target gene hsa-mir-7 Brain Neoplasms 29016934 microRNA-7 upregulates death receptor 5 and primes resistant brain tumors to caspase-mediated apoptosis. +target gene hsa-mir-210 Pheochromocytoma 29018330 MicroRNA-210 Protects PC-12 Cells Against Hypoxia-Induced Injury by Targeting BNIP3. +target gene hsa-mir-34a Liver Diseases [unspecific] 29018509 These findings indicate a circRNA_0046367/miR-34a/PPAR¦Á regulatory system underlying hepatic steatosis +target gene hsa-mir-34a Preeclampsia 29022890 Elevated microRNA-34a contributes to trophoblast cell apoptosis in preeclampsia by targeting BCL-2. +target gene hsa-mir-150 Thyroid Neoplasms 29023429 MiR-150 Inhibits Cell Growth In Vitro and In Vivo by Restraining the RAB11A/WNT/¦Â-Catenin Pathway in Thyroid Cancer. +target gene hsa-mir-29a Neurilemmoma 29023945 MicroRNA-29a inhibits proliferation and motility of schwannoma cells by targeting CDK6. +target gene hsa-mir-29c Neurilemmoma 29023945 MicroRNA-29a inhibits proliferation and motility of schwannoma cells by targeting CDK6. +target gene hsa-mir-1 Diabetic Cardiomyopathies 29024600 Liver X receptor ¦Á is targeted by microRNA-1 to inhibit cardiomyocyte apoptosis through a ROS-mediated mitochondrial pathway. +target gene hsa-mir-373 "Carcinoma, Lung, Non-Small-Cell" 29025258 MicroRNA-373 Inhibits Cell Proliferation and Invasion via Targeting BRF2 in Human Non-small Cell Lung Cancer A549 Cell Line. +target gene hsa-mir-124 "Carcinoma, Lung, Non-Small-Cell" 29039564 Evaluation of microRNA-203 in bone metastasis of patients with non-small cell lung cancer through TGF-¦Â/SMAD2 expression. +target gene hsa-mir-124 Melanoma 29042947 "miR-124 inhibits proliferation, migration and invasion of malignant melanoma cells via targeting versican." +target gene hsa-mir-138 Osteosarcoma 29042962 MicroRNA-138 directly targets TNFAIP8 and acts as a tumor suppressor in osteosarcoma. +target gene hsa-mir-17 Endometriosis 29042983 MicroRNA-17 downregulates expression of the PTEN gene to promote the occurrence and development of adenomyosis. +target gene hsa-mir-29b Ovarian Neoplasms 29050034 Mir-29b Regulates Oxidative Stress by Targeting SIRT1 in Ovarian Cancer Cells. +target gene hsa-let-7a "Carcinoma, Thyroid, Papillary" 29050238 "Let-7a inhibits migration, invasion and tumor growth by targeting AKT2 in papillary thyroid carcinoma." +target gene hsa-mir-574 Spinal Chordoma 29051990 Clinicopathologic implications of CD8+/Foxp3+ ratio and miR-574-3p/PD-L1 axis in spinal chordoma patients. +target gene hsa-mir-767 Melanoma 29054757 MiR-767 promoted cell proliferation in human melanoma by suppressing CYLD expression. +target gene hsa-mir-145 Stroke 29057271 Overexpression of MicroRNA-145 Ameliorates Astrocyte Injury by Targeting Aquaporin 4 in Cerebral Ischemic Stroke +target gene hsa-mir-302a Periodontitis 29058810 miR-302a-3p regulates RANKL expression in human mandibular osteoblast-like cells. +target gene hsa-mir-181a "Carcinoma, Renal Cell, Clear-Cell" 29066014 "Up-regulation of miR-181a in clear cell renal cell carcinoma is associated with lower KLF6 expression, enhanced cell proliferation, accelerated cell cycle transition, and diminished apoptosis." +target gene hsa-mir-155 Neoplasms [unspecific] 29066622 MicroRNA-155 induction via TNF-¦Á and IFN-¦Ã suppresses expression of programmed death ligand-1 (PD-L1) in human primary cells. +target gene hsa-mir-148a "Squamous Cell Carcinoma, Esophageal" 29067119 MiR-148a modulates HLA-G expression and influences tumor apoptosis in esophageal squamous cell carcinoma. +target gene hsa-mir-21 "Lymphoma, Large B-Cell, Diffuse" 29067124 MicroRNA-21 regulates the viability and apoptosis of diffuse large B-cell lymphoma cells by upregulating B cell lymphoma-2. +target gene hsa-mir-140 Cartilage Disease [unspecific] 29067438 miRNA-140 inhibits C3H10T1/2 mesenchymal stem cell proliferation by targeting CXCL12 during transforming growth factor-¦Â3-induced chondrogenic differentiation. +target gene hsa-mir-489 Colorectal Carcinoma 29071516 MiR-489 suppresses tumor growth and invasion by targeting HDAC7 in colorectal cancer. +target gene hsa-mir-106a Kidney Osteogenic Sarcoma 29072688 MiR-106a-5p inhibits the cell migration and invasion of renal cell carcinoma through targeting PAK5. +target gene hsa-mir-1 Hypertrophy 29073097 Content of mitochondrial calcium uniporter (MCU) in cardiomyocytes is regulated by microRNA-1 in physiologic and pathologic hypertrophy. +target gene hsa-mir-30a "Carcinoma, Renal Cell" 29073630 MicroRNA-30a-5p Inhibits the Growth of Renal Cell Carcinoma by Modulating GRP78 Expression. +target gene hsa-mir-107 Cervical Neoplasms 29073938 "Musashi-2, a novel oncoprotein promoting cervical cancer cell growth and invasion, is negatively regulated by p53-induced miR-143 and miR-107 activation." +target gene hsa-mir-143 Cervical Neoplasms 29073938 "Musashi-2, a novel oncoprotein promoting cervical cancer cell growth and invasion, is negatively regulated by p53-induced miR-143 and miR-107 activation." +target gene hsa-mir-146a Inflammation 29074132 "MicroRNA-146a promotes red spotted grouper nervous necrosis virus (RGNNV) replication by targeting TRAF6 in orange spotted grouper, Epinephelus coioides." +target gene hsa-mir-204 Melanoma 29075789 BANCR contributes to the growth and invasion of melanoma by functioning as a competing endogenous RNA to upregulate Notch2 expression by sponging miR?204. +target gene hsa-mir-223 "Carcinoma, Ovarian, Serous" 29079174 miR-223 potentially targets SWI/SNF complex protein SMARCD1 in atypical proliferative serous tumor and high-grade ovarian serous carcinoma. +target gene hsa-mir-200c "Carcinoma, Endometrial" 29080395 MicroRNA-200c Inhibits Epithelial-Mesenchymal Transition by Targeting the BMI-1 Gene Through the Phospho-AKT Pathway in Endometrial Carcinoma Cells In Vitro. +target gene hsa-let-7d Parkinson Disease 29082467 Let-7d microRNA Attenuates 6-OHDA-Induced Injury by Targeting Caspase-3 in MN9D Cells. +target gene hsa-mir-21 Lung Fibrosis 29084974 Mir-21 Mediates the Inhibitory Effect of Ang (1-7) on AngII-induced NLRP3 Inflammasome Activation by Targeting Spry1 in lung fibroblasts. +target gene hsa-mir-106b Retinoblastoma 29085029 HBeAg-induced miR-106b promotes cell growth by targeting the retinoblastoma gene. +target gene hsa-mir-21 Rectal Neoplasms 29085468 miR-21 inhibition of LATS1 promotes proliferation and metastasis of renal cancer cells and tumor stem cell phenotype. +target gene hsa-mir-27a Polycystic Ovarian Syndrome 29089199 MicroRNA-27a-3p affects estradiol and androgen imbalance by targeting Creb1 in the granulosa cells in mouse polycytic ovary syndrome model. +target gene hsa-mir-491 Neoplasms [unspecific] 29091292 Functional SNP in microRNA-491-5p binding site of MMP9 3'-UTR affects cancer susceptibility. +target gene hsa-mir-613 "Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal" 29091303 MiR-613 suppressed the laryngeal squamous cell carcinoma progression through regulating PDK1. +target gene hsa-mir-150 Cervical Neoplasms 29091902 "MicroRNA-150 promotes cell proliferation, migration, and invasion of cervical cancer through targeting PDCD4." +target gene hsa-mir-34a "Squamous Cell Carcinoma, Esophageal" 29094237 MicroRNA-34a suppresses invasion and metastatic in esophageal squamous cell carcinoma by regulating CD44. +target gene hsa-mir-137 Melanoma 29097210 miR-137 inhibits glutamine catabolism and growth of malignant melanoma by targeting glutaminase. +target gene hsa-mir-130a Cervical Neoplasms 29099271 SOX9/miR-130a/CTR1 axis modulates DDP-resistance of cervical cancer cell. +target gene hsa-mir-21 "Leukemia, Myeloid, Acute" 29100302 A tyrosine kinase-STAT5-miR21-PDCD4 regulatory axis in chronic and acute myeloid leukemia cells. +target gene hsa-mir-30a Diabetic Cataract 29100392 MiR-30a inhibits BECN1-mediated autophagy in diabetic cataract. +target gene hsa-mir-27a Diabetes Mellitus 29100869 Oxidative stress-induced miR-27a targets the redox gene nuclear factor erythroid 2-related factor 2 in diabetic embryopathy. +target gene hsa-mir-21 Gastric Neoplasms 29101039 miR-21 modulates prostaglandin signaling and promotes gastric tumorigenesis by targeting 15-PGDH. +target gene hsa-mir-27a "Fatty Liver, Non-Alcoholic" 29101357 MicroRNA-27a regulates hepatic lipid metabolism and alleviates NAFLD via repressing FAS and SCD1. +target gene hsa-mir-4326 Lung Neoplasms 29101731 miR-4326 promotes lung cancer cell proliferation through targeting tumor suppressor APC2. +target gene hsa-mir-146a Asthma 29101850 MicroRNA-146a promotes IgE class switch in B cells via upregulating 14-3-3¦Ò expression. +target gene hsa-mir-155 Colon Neoplasms 29104623 "MicroRNA-155 regulates the proliferation, cell cycle, apoptosis and migration of colon cancer cells and targets CBL." +target gene hsa-mir-150 "Fatty Liver, Non-Alcoholic" 29107687 MiR-150 deficiency ameliorated hepatosteatosis and insulin resistance in nonalcoholic fatty liver disease via targeting CASP8 and FADD-like apoptosis regulator. +target gene hsa-mir-30a "Carcinoma, Hepatocellular" 29108194 MicroRNA-30a inhibits proliferation of hepatocellular carcinoma cells via targeted regulation of forkhead-box protein A1. +target gene hsa-mir-10a Lupus Nephritis 29109423 Transcriptomic profiling in human mesangial cells using patient-derived lupus autoantibodies identified miR-10a as a potential regulator of IL8. +target gene hsa-mir-223 Hypertrophy 29110214 SOX2-mediated inhibition of miR-223 contributes to STIM1 activation in phenylephrine-induced hypertrophic cardiomyocytes. +target gene hsa-mir-107 "Adenocarcinoma, Pancreatic Ductal" 29111166 Deregulated expression of miR-107 inhibits metastasis of PDAC through inhibition PI3K/Akt signaling via caveolin-1 and PTEN. +target gene hsa-mir-181b Gastric Neoplasms 29113265 The present study confirmed that CDX2 was suppressed by activation of the IL-6/STAT3 signaling pathway via miR-181b in vitro +target gene hsa-mir-488 Ovarian Neoplasms 29113360 microRNA-488 inhibits chemoresistance of ovarian cancer cells by targeting Six1 and mitochondrial function. +target gene hsa-mir-222 "Carcinoma, Nasopharyngeal" 29115464 microRNA-222 promotes tumor growth and confers radioresistance in nasopharyngeal carcinoma by targeting PTEN. +target gene hsa-mir-200c Endometriosis 29116025 miR-200c suppresses endometriosis by targeting MALAT1 in vitro and in vivo. +target gene hsa-mir-449a Osteosarcoma 29117539 Hsa_circ_0009910 promotes carcinogenesis by promoting the expression of miR-449a target IL6R in osteosarcoma. +target gene hsa-mir-21 Rectal Neoplasms 29131259 MicroRNA-21 functions as an oncogene and promotes cell proliferation and invasion via TIMP3 in renal cancer. +target gene hsa-mir-155 Viral Myocarditis 29136142 The forkhead transcription factor Foxo3 negatively regulates natural killer cell function and viral clearance in myocarditis. +target gene hsa-mir-143 "Squamous Cell Carcinoma, Esophageal" 29137232 "Integration of metabolomics, transcriptomics, and microRNA expression profiling reveals a miR-143-HK2-glucose network underlying zinc-deficiency-associated esophageal neoplasia." +target gene hsa-let-7d "Adenocarcinoma, Pancreatic Ductal" 29137251 selinexor induced the expression of two important tumor suppressive miRNAs miR-34c and let-7d leading to the up-regulation of p21WAF1 +target gene hsa-mir-34c "Adenocarcinoma, Pancreatic Ductal" 29137251 selinexor induced the expression of two important tumor suppressive miRNAs miR-34c and let-7d leading to the up-regulation of p21WAF1 +target gene hsa-mir-200c Gastric Neoplasms 29138864 Expression level of microRNA-200c is associated with cell morphology in vitro and histological differentiation through regulation of ZEB1/2 and E-cadherin in gastric carcinoma. +target gene hsa-mir-23a "Carcinoma, Pancreatic" 29141872 miR-23a acts as an oncogene in pancreatic carcinoma by targeting FOXP2. +target gene hsa-mir-24 Osteoarthritis 29143973 "Effects of microRNA-24 targeting C-myc on apoptosis, proliferation and cytokine expressions in chondrocytes of rats with osteoarthritis via MAPK signaling pathway." +target gene hsa-mir-27a "Carcinoma, Hepatocellular" 29143999 MicroRNA-27a-3p inhibits cell viability and migration through down-regulating DUSP16 in hepatocellular carcinoma. +target gene hsa-mir-146a Ankylosing Spondylitis 29145150 MicroRNA-146a knockdown suppresses the progression of ankylosing spondylitis by targeting dickkopf 1 +target gene hsa-mir-34b Acute Lung Injury 29150939 miR-34b-5p inhibition attenuates lung inflammation and apoptosis in an LPS-induced acute lung injury mouse model by targeting progranulin. +target gene hsa-mir-205 "Squamous Cell Carcinoma, Oral" 29150940 Tumor-suppressive roles of ¦¤Np63¦Â-miR-205 axis in epithelial-mesenchymal transition of oral squamous cell carcinoma via targeting ZEB1 and ZEB2 +target gene hsa-mir-200c Neuropathic Pain 29150958 Inhibition of miR-200b/miR-429 contributes to neuropathic pain development through targeting zinc finger E box binding protein-1. +target gene hsa-mir-429 Neuropathic Pain 29150958 Inhibition of miR-200b/miR-429 contributes to neuropathic pain development through targeting zinc finger E box binding protein-1. +target gene hsa-mir-31 "Carcinoma, Hepatocellular" 29152108 MicroRNA-31 suppresses the self-renewal capability of ¦Á2¦Ä1+ liver tumor-initiating cells by targeting ISL1 +target gene hsa-mir-27a Liver Injury 29156532 paclitaxel significantly attenuated septic induced liver injury through reducing inflammatory response via miR-27a/TAB3/NF-¦ÊB signaling pathway +target gene hsa-mir-31 Cervical Neoplasms 29159179 miR-31 Functions as an Oncomir Which Promotes Epithelial-Mesenchymal Transition via Regulating BAP1 in Cervical Cancer +target gene hsa-mir-145 Neuropathic Pain 29162479 MiR-145 ameliorates neuropathic pain via inhibiting inflammatory responses and mTOR signaling pathway by targeting Akt3 in a rat model. +target gene hsa-mir-20b Prostate Neoplasms 29163708 miR-20b promotes cellular proliferation and migration by directly regulating phosphatase and tensin homolog in prostate cancer +target gene hsa-mir-34a Congenital Heart Diseases 29175286 miR-34a increases the risk of CHD through its downregulation of NOTCH-1 by modulating the Notch signaling pathway +target gene hsa-mir-23a "Carcinoma, Hepatocellular" 29176948 The Oncogenic Role of Tribbles 1 in Hepatocellular Carcinoma Is Mediated by a Feedback Loop Involving microRNA-23a and p53 +target gene hsa-mir-21 Cervical Neoplasms 29177591 "MicroRNA-21 promotes proliferation, migration, and invasion of cervical cancer through targeting TIMP3" +target gene hsa-mir-326 Multiple Sclerosis 29181619 MicroRNA-326 contributes to autoimmune thyroiditis by targeting the Ets-1 protein +target gene hsa-mir-122 Chronic Hepatitis C 29182758 miR-122 regulates ALDOB and PKM2 expression at the mRNA level +target gene hsa-mir-146a Osteoarthritis 29183039 MiR-146a Aggravates LPS-Induced Inflammatory Injury by Targeting CXCR4 in the Articular Chondrocytes +target gene hsa-mir-519d "Carcinoma, Breast" 29188531 MiR-519d-3p suppresses breast cancer cell growth and motility via targeting LIM domain kinase 1. +target gene hsa-mir-34a "Squamous Cell Carcinoma, Esophageal" 29190930 MicroRNA-34a functions as a tumor suppressor by directly targeting oncogenic PLCE1 in Kazakh esophageal squamous cell carcinoma +target gene hsa-mir-361 Obesity 29191698 MicroRNAs-361-5p and miR-574-5p associate with human adipose morphology and regulate EBF1 expression in white adipose tissue. +target gene hsa-mir-574 Obesity 29191698 MicroRNAs-361-5p and miR-574-5p associate with human adipose morphology and regulate EBF1 expression in white adipose tissue. +target gene hsa-mir-19a Multiple Myeloma 29201171 the results of the present study indicate that targets genes of miR-19a are potential candidate biomarkers for MM +target gene hsa-mir-513a Lung Neoplasms 29204818 Mir-513a-3p contributes to the controlling of cellular migration processes in the A549 lung tumor cells by modulating integrin ¦Â-8 expression. +target gene hsa-mir-6869 Colorectal Carcinoma 29206292 MicroRNA-6869-5p acts as a tumor suppressor via targeting TLR4/NF-¦ÊB signaling pathway in colorectal cancer. +target gene hsa-mir-26a Osteoarthritis 29208566 miR-26a/-26b/FUT4/NF-¦ÊB axis may serve as a predictive biomarker and a potential therapeutic target in OA treatment +target gene hsa-mir-1202 "Carcinoma, Hepatocellular" 29217161 MiR-1202 suppresses hepatocellular carcinoma cells migration and invasion by targeting cyclin dependent kinase 14 +target gene hsa-mir-200a "Carcinoma, Breast, Triple Negative" 29217458 The identified IMP2/3-miR-200a-PR axis represents a novel double-negative feedback loop and serves as a new potential therapeutic target for the treatment of TNBC +target gene hsa-mir-200c Lung Neoplasms 29219949 A miRNA-200c/cathepsin L feedback loop determines paclitaxel resistance in human lung cancer A549 cells in vitro through regulating epithelial-mesenchymal transition. +target gene hsa-mir-210 Glioblastoma 29226333 "p53 and miR-210 regulated NeuroD2, a neuronal basic helix-loop-helix transcription factor, is downregulated in glioblastoma patients and functions as a tumor suppressor under hypoxic microenvironment" +target gene hsa-mir-182 Atherosclerosis 29226948 MiR-182-5p inhibited oxidative stress and apoptosis triggered by oxidized low-density lipoprotein via targeting toll-like receptor 4. +target gene hsa-mir-29c Hyperlipidemia 29226968 Study of microRNAs targeted Dvl2 on the osteoblasts differentiation of rat BMSCs in hyperlipidemia environment. +target gene hsa-mir-155 Kidney Neoplasms 29228417 "Inhibition of miR-155 increased GSK-3¦Â expression, attenuated Wnt/¦Â-catenin signaling pathway, weakened proliferation and invasion, and facilitated apoptosis in renal carcinoma cells" +target gene hsa-mir-21 Glioblastoma 29228449 miR-21 enhances the resistance of human glioma cells to BCNU by decreasing the expression of Spry2 protein +target gene hsa-mir-21 Glioma 29228450 MiR-21 enhanced glioma cells resistance to carmustine via decreasing Spry2 expression +target gene hsa-mir-143 Melanoma 29230879 "These results support a functional role for miR-143-5p in regulating alpaca melanocyte migration, proliferation and melanogenesis through direct targeting of TAK1" +target gene hsa-mir-150 "Squamous Cell Carcinoma, Head and Neck" 29233721 Antitumor miR-150-5p and miR-150-3p inhibit cancer cell aggressiveness by targeting SPOCK1 in head and neck squamous cell carcinoma. +target gene hsa-mir-124 Gastric Neoplasms 29234151 "SRGAP1, a crucial target of miR-340 and miR-124, functions as a potential oncogene in gastric tumorigenesis" +target gene hsa-mir-340 Gastric Neoplasms 29234151 "SRGAP1, a crucial target of miR-340 and miR-124, functions as a potential oncogene in gastric tumorigenesis" +target gene hsa-mir-155 "Carcinoma, Hepatocellular" 29234238 miR-155-5p modulates malignant behaviors of hepatocellular carcinoma by directly targeting CTHRC1 and indirectly regulating GSK-3¦Â-involved Wnt/¦Â-catenin signaling +target gene hsa-mir-23b Osteoporosis 29234953 Involvement of microRNA-23b in TNF-¦Á-reduced BMSC osteogenic differentiation via targeting runx2 +target gene hsa-mir-29a Ischemia-Reperfusion Injury 29238305 MiR-29a Suppresses Spermatogenic Cell Apoptosis in Testicular Ischemia-Reperfusion Injury by Targeting TRPV4 Channels +target gene hsa-mir-92a Osteoarthritis 29241192 MiR-92a-3p is an important regulator of ADAMTS-4/5 in human chondrocytes and may contribute to the development of OA +target gene hsa-mir-296 "Carcinoma, Cervical" 29241478 MicroRNA-296 Targets Specificity Protein 1 to Suppress Cell Proliferation and Invasion in Cervical Cancer. +target gene hsa-mir-203 Inflammation 29242191 The inducible microRNA-203 in fish represses the inflammatory responses to Gram-negative bacteria by targeting IL-1 receptor-associated kinase 4 +target gene hsa-mir-185 Cleidocranial Dysplasia 29242628 Mutant Runx2 regulates amelogenesis and osteogenesis through a miR-185-5p-Dlx2 axis. +target gene hsa-mir-24 Atherosclerosis 29250154 MicroRNA-24 inhibits the proliferation and migration of endothelial cells in patients with atherosclerosis by targeting importin-¦Á3 and regulating inflammatory responses +target gene hsa-mir-25 "Squamous Cell Carcinoma, Esophageal" 29250158 "PTEN, TP53, MDM2, E2F1, PRMT5, MCM2, RB1, CDKN1A, SHAD7 and EZH2 may be targeted by the miR-106b-25 cluster, and act together to regulate the development of ESCC" +target gene hsa-mir-21 Liver Cirrhosis 29250171 The miRNA-target regulatory network may provide additional insight into the current data regarding the role of miRNAs in liver cirrhosis +target gene hsa-mir-29a Retinoblastoma 29251322 miR-29a inhibits human retinoblastoma progression by targeting STAT3 +target gene hsa-mir-21 "Carcinoma, Hepatocellular" 29253196 miR-122 participates in the regulation of HCC cell apoptosis through modulating the miR-21-targeted programmed cell death 4 (PDCD4) signal pathway +target gene hsa-mir-140 "Carcinoma, Renal Cell, Clear-Cell" 29253611 "miRNA-429, miRNA-206, and miRNA-184 and their target gene CCND1, as well as miRNA-140-3p and miRNA-142-5p and their target gene ATP1B1, might play key roles in ccRCC progression and could be useful biomarkers during ccRCC development" +target gene hsa-mir-142 "Carcinoma, Renal Cell, Clear-Cell" 29253611 "miRNA-429, miRNA-206, and miRNA-184 and their target gene CCND1, as well as miRNA-140-3p and miRNA-142-5p and their target gene ATP1B1, might play key roles in ccRCC progression and could be useful biomarkers during ccRCC development" +target gene hsa-mir-184 "Carcinoma, Renal Cell, Clear-Cell" 29253611 "miRNA-429, miRNA-206, and miRNA-184 and their target gene CCND1, as well as miRNA-140-3p and miRNA-142-5p and their target gene ATP1B1, might play key roles in ccRCC progression and could be useful biomarkers during ccRCC development" +target gene hsa-mir-206 "Carcinoma, Renal Cell, Clear-Cell" 29253611 "miRNA-429, miRNA-206, and miRNA-184 and their target gene CCND1, as well as miRNA-140-3p and miRNA-142-5p and their target gene ATP1B1, might play key roles in ccRCC progression and could be useful biomarkers during ccRCC development" +target gene hsa-mir-429 "Carcinoma, Renal Cell, Clear-Cell" 29253611 "miRNA-429, miRNA-206, and miRNA-184 and their target gene CCND1, as well as miRNA-140-3p and miRNA-142-5p and their target gene ATP1B1, might play key roles in ccRCC progression and could be useful biomarkers during ccRCC development" +target gene hsa-let-7g Atherosclerosis 29254143 Let-7g suppresses both canonical and non-canonical NF-¦ÊB pathways in macrophages leading to anti-atherosclerosis +target gene hsa-mir-182 Osteosarcoma 29254169 "MicroRNA-182 downregulates Wnt/¦Â-catenin signaling, inhibits proliferation, and promotes apoptosis in human osteosarcoma cells by targeting HOXA9" +target gene hsa-mir-29b Breast Neoplasms 29256222 "MiRNA-29b can inhibit the proliferation, invasion and metastasis of breast cancer cells by inhibiting the expression of RTKN" +target gene hsa-mir-296 Melanoma 29260433 Coordinated targeting of MMP-2/MMP-9 by miR-296-3p/FOXCUT exerts tumor-suppressing effects in choroidal malignant melanoma. +target gene hsa-mir-188 Glioma 29268818 miR-188 Inhibits Glioma Cell Proliferation and Cell Cycle Progression Through Targeting ¦Â-Catenin. +target gene hsa-mir-143 Cervical Neoplasms 29271989 MicroRNA-143 regulates the proliferation and apoptosis of cervical cancer cells by targeting HIF-1¦Á +target gene hsa-mir-181a Thyroid Neoplasms 29271997 MiR-181a promotes growth of thyroid cancer cells by targeting tumor suppressor RB1 +target gene hsa-mir-30e Parkinson Disease 29274035 MicroRNA-30e regulates neuroinflammation in MPTP model of Parkinson's disease by targeting Nlrp3. +target gene hsa-mir-146b Psoriasis 29279330 MicroRNA-146 and cell trauma down-regulate expression of the psoriasis-associated atypical chemokine receptor ACKR2 +target gene hsa-mir-34a Neoplasms [unspecific] 29285066 miR-34a may serve an important role in hyperthermia-regulated apoptosis and proliferation in HCT116 cells by influencing the transcriptional activity of p53 +target gene hsa-mir-34a "Squamous Cell Carcinoma, Skin or Unspecific" 29285100 "MicroRNA-34a directly targets high-mobility group box 1 and inhibits the cancer cell proliferation, migration and invasion in cutaneous squamous cell carcinoma" +target gene hsa-mir-200c "Carcinoma, Gastric" 29286062 "miR-200c regulates the proliferation, apoptosis and invasion of gastric carcinoma cells through the downregulation of EDNRA expression" +target gene hsa-mir-124a Liver Neoplasms 29286137 MicroRNA-124a inhibits cell proliferation and migration in liver cancer by regulating interleukin-11 +target gene hsa-mir-146a Inflammation 29288795 miR-146a inhibits inflammatory cytokine production in B cells through directly targeting IRAK1 +target gene hsa-mir-34a Huntington Disease 29289683 Perturbations in the p53/miR-34a/SIRT1 pathway in the R6/2 Huntington's disease model +target gene hsa-mir-206 "Carcinoma, Ovarian" 29291022 NFE2L2/NRF2 silencing-inducible miR-206 targets c-MET/EGFR and suppresses BCRP/ABCG2 in cancer cells +target gene hsa-mir-346 "Carcinoma, Hepatocellular" 29295726 miR-346 Promotes HCC Progression by Suppressing Breast Cancer Metastasis Suppressor 1 Expression. +target gene hsa-mir-136 "Carcinoma, Hepatocellular" 29295728 miR-136 Inhibits Malignant Progression of Hepatocellular Carcinoma Cells by Targeting Cyclooxygenase 2. +target gene hsa-mir-34a "Carcinoma, Hepatocellular" 29298665 "Our results may lead researchers to understand the molecular mechanism of miR-34a in the diagnosis, prognosis and therapy of HCC" +target gene hsa-mir-34a Cataract 29299142 MicroRNA-34a promotes mitochondrial dysfunction-induced apoptosis in human lens epithelial cells by targeting Notch2 +target gene hsa-mir-19a Osteoarthritis 29306212 MicroRNA-19a promotes cell viability and migration of chondrocytes via up-regulating SOX9 through NF-¦ÊB pathway +target gene hsa-mir-137 Melanoma 29307109 miR-137 inhibits melanoma cell proliferation through downregulation of GLO1 +target gene hsa-mir-373 "Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal" 29307338 Expression of miR-373 and its predicted target genes E-cadherin and CD44 in patients with laryngeal squamous cell carcinoma +target gene hsa-mir-34a Osteosarcoma 29312491 MicroRNA-34a promotes cell cycle arrest and apoptosis and suppresses cell adhesion by targeting DUSP1 in osteosarcoma. +target gene hsa-mir-423 "Carcinoma, Hepatocellular" 29312509 MicroRNA-423 enhances the invasiveness of hepatocellular carcinoma via regulation of BRMS1 +target gene hsa-mir-492 Hepatoblastoma 29314711 MiR-492 regulates metastatic properties of hepatoblastoma via CD44 +target gene hsa-mir-26a Inflammation 29315680 "the effect of bta-miR-26a in mastitis, mediated at least in part by enhancing FGA expression, involves host defense, inflammation and tissue damage" +target gene hsa-mir-21 Glioma 29316313 MicroRNA-21 promotes glioma cell proliferation and inhibits senescence and apoptosis by targeting SPRY1 via the PTEN/PI3K/AKT signaling pathway +target gene hsa-mir-22 "Squamous Cell Carcinoma, Oral" 29319163 "MicroRNA-22 suppresses cell proliferation, migration and invasion in oral squamous cell carcinoma by targeting NLRP3." +target gene hsa-mir-125b "Diabetes Mellitus, Type 2" 29319168 Hepatic miR-125b inhibits insulin signaling pathway by targeting PIK3CD. +target gene hsa-mir-143 Gastric Neoplasms 29321084 miR-143 inhibits cell proliferation of gastric cancer cells through targeting GATA6 +target gene hsa-mir-519d "Carcinoma, Cervical" 29321085 MicroRNA-519d-3p Inhibits Proliferation and Promotes Apoptosis by Targeting HIF-2¦Á in Cervical Cancer Under Hypoxic Conditions. +target gene hsa-mir-29a Mitochondrial Metabolism Disease 29322081 Data of expression status of miR-29a and its putative target mitochondrial apoptosis regulatory gene DRP1 upon miR-15a and miR-214 inhibition +target gene hsa-mir-150 Neuropathic Pain 29323698 It was revealed that XIST/miR-150/ZEB1 axis can be provided as a therapeutic target in neuropathic pain +target gene hsa-mir-501 Autosomal Dominant Polycystic Kidney Disease 29323708 MicroRNA501-5p induces p53 proteasome degradation through the activation of the mTOR/MDM2 pathway in ADPKD cells. +target gene hsa-mir-15b Glioma 29323737 MiR-15b/HOTAIR/p53 form a regulatory loop that affects the growth of glioma cells +target gene hsa-mir-145 Atherosclerosis 29324316 MicroRNA-145 alleviates high glucose-induced proliferation and migration of vascular smooth muscle cells through targeting ROCK1 +target gene hsa-mir-21 "Carcinoma, Salivary Adenoid Cystic" 29328455 "miR-21 may promote SACC progression via PDCD4, PTEN and Bcl-2" +target gene hsa-mir-200a Breast Neoplasms 29329575 MicroRNA-200a confers chemoresistance by antagonizing TP53INP1 and YAP1 in human breast cancer +target gene hsa-mir-195 Heart Failure 29330215 increased levels of miR-195 in failing myocardium regulate a novel pathway that involves direct SIRT3 suppression and enzymatic inhibition via increased acetylation of PDH and ATP synthase that are essential for cardiac energy metabolism +target gene hsa-mir-301a Prostate Neoplasms 29331421 Hyperglycaemia-induced miR-301a promotes cell proliferation by repressing p21 and Smad4 in prostate cancer. +target gene hsa-mir-494 Diabetes Mellitus 29333131 miR-494 protects pancreatic ¦Â-cell function by targeting PTEN in gestational diabetes mellitus +target gene hsa-mir-155 Melanoma 29333944 MiR-155 Promotes Uveal Melanoma Cell Proliferation and Invasion by Regulating NDFIP1 Expression +target gene hsa-mir-21 Asthma 29334241 Disordered expression of genes under the regulation of miRNAs may play an important role in CARAS +target gene hsa-mir-21 Autism Spectrum Disorder 29334241 Disordered expression of genes under the regulation of miRNAs may play an important role in CARAS +target gene hsa-mir-92a Asthma 29334241 Disordered expression of genes under the regulation of miRNAs may play an important role in CARAS +target gene hsa-mir-92a Autism Spectrum Disorder 29334241 Disordered expression of genes under the regulation of miRNAs may play an important role in CARAS +target gene hsa-mir-93 Asthma 29334241 Disordered expression of genes under the regulation of miRNAs may play an important role in CARAS +target gene hsa-mir-93 Autism Spectrum Disorder 29334241 Disordered expression of genes under the regulation of miRNAs may play an important role in CARAS +target gene hsa-mir-144 Osteoporosis 29334613 Reduced miR-144-3p expression in serum and bone mediates osteoporosis pathogenesis by targeting RANK. +target gene hsa-mir-181a Preeclampsia 29339719 miR-181a-5p suppresses invasion and migration of HTR-8/SVneo cells by directly targeting IGF2BP2. +target gene hsa-mir-19 Glioma 29340016 MiR-19 regulates the proliferation and invasion of glioma by RUNX3 via ¦Â-catenin/Tcf-4 signaling +target gene hsa-mir-34a "Carcinoma, Hepatocellular" 29344126 microRNA-34a overexpression inhibits cell migration and invasion via regulating SIRT1 in hepatocellular carcinoma +target gene hsa-mir-10a "Carcinoma, Thyroid, Follicular" 29344146 "Network analysis indicated a co-regulatory association between miR-296-5p, miR-10a, miR-139-5p, miR-452, miR-493, miR-7, miR-137, miR-144, miR-145 and corresponding targeted mRNAs, including TNF receptor superfamily member 11b, benzodiazepine receptor (peripheral) -associated protein 1, and transforming growth factor ¦Â receptor 2" +target gene hsa-mir-137 "Carcinoma, Thyroid, Follicular" 29344146 "Network analysis indicated a co-regulatory association between miR-296-5p, miR-10a, miR-139-5p, miR-452, miR-493, miR-7, miR-137, miR-144, miR-145 and corresponding targeted mRNAs, including TNF receptor superfamily member 11b, benzodiazepine receptor (peripheral) -associated protein 1, and transforming growth factor ¦Â receptor 2" +target gene hsa-mir-139 "Carcinoma, Thyroid, Follicular" 29344146 "Network analysis indicated a co-regulatory association between miR-296-5p, miR-10a, miR-139-5p, miR-452, miR-493, miR-7, miR-137, miR-144, miR-145 and corresponding targeted mRNAs, including TNF receptor superfamily member 11b, benzodiazepine receptor (peripheral) -associated protein 1, and transforming growth factor ¦Â receptor 2" +target gene hsa-mir-144 "Carcinoma, Thyroid, Follicular" 29344146 "Network analysis indicated a co-regulatory association between miR-296-5p, miR-10a, miR-139-5p, miR-452, miR-493, miR-7, miR-137, miR-144, miR-145 and corresponding targeted mRNAs, including TNF receptor superfamily member 11b, benzodiazepine receptor (peripheral) -associated protein 1, and transforming growth factor ¦Â receptor 2" +target gene hsa-mir-145 "Carcinoma, Thyroid, Follicular" 29344146 "Network analysis indicated a co-regulatory association between miR-296-5p, miR-10a, miR-139-5p, miR-452, miR-493, miR-7, miR-137, miR-144, miR-145 and corresponding targeted mRNAs, including TNF receptor superfamily member 11b, benzodiazepine receptor (peripheral) -associated protein 1, and transforming growth factor ¦Â receptor 2" +target gene hsa-mir-296 "Carcinoma, Thyroid, Follicular" 29344146 "Network analysis indicated a co-regulatory association between miR-296-5p, miR-10a, miR-139-5p, miR-452, miR-493, miR-7, miR-137, miR-144, miR-145 and corresponding targeted mRNAs, including TNF receptor superfamily member 11b, benzodiazepine receptor (peripheral) -associated protein 1, and transforming growth factor ¦Â receptor 2" +target gene hsa-mir-452 "Carcinoma, Thyroid, Follicular" 29344146 "Network analysis indicated a co-regulatory association between miR-296-5p, miR-10a, miR-139-5p, miR-452, miR-493, miR-7, miR-137, miR-144, miR-145 and corresponding targeted mRNAs, including TNF receptor superfamily member 11b, benzodiazepine receptor (peripheral) -associated protein 1, and transforming growth factor ¦Â receptor 2" +target gene hsa-mir-493 "Carcinoma, Thyroid, Follicular" 29344146 "Network analysis indicated a co-regulatory association between miR-296-5p, miR-10a, miR-139-5p, miR-452, miR-493, miR-7, miR-137, miR-144, miR-145 and corresponding targeted mRNAs, including TNF receptor superfamily member 11b, benzodiazepine receptor (peripheral) -associated protein 1, and transforming growth factor ¦Â receptor 2" +target gene hsa-mir-7 "Carcinoma, Thyroid, Follicular" 29344146 "Network analysis indicated a co-regulatory association between miR-296-5p, miR-10a, miR-139-5p, miR-452, miR-493, miR-7, miR-137, miR-144, miR-145 and corresponding targeted mRNAs, including TNF receptor superfamily member 11b, benzodiazepine receptor (peripheral) -associated protein 1, and transforming growth factor ¦Â receptor 2" +target gene hsa-mir-124 Ovarian Neoplasms 29344168 MiR-124 inhibits invasion and induces apoptosis of ovarian cancer cells by targeting programmed cell death 6 +target gene hsa-mir-138 "Carcinoma, Renal Cell" 29344205 MicroRNA-138 suppresses cell proliferation and invasion of renal cell carcinoma by directly targeting SOX9 +target gene hsa-mir-146a "Carcinoma, Lung, Non-Small-Cell" 29344219 Upregulation of miR-146a increases cisplatin sensitivity of the non-small cell lung cancer A549 cell line by targeting JNK-2 +target gene hsa-mir-1827 "Adenocarcinoma, Lung" 29344280 "MiR-378 and MiR-1827 Regulate Tumor Invasion, Migration and Angiogenesis in Human Lung Adenocarcinoma by Targeting RBX1 and CRKL, Respectively" +target gene hsa-mir-378 "Adenocarcinoma, Lung" 29344280 "MiR-378 and MiR-1827 Regulate Tumor Invasion, Migration and Angiogenesis in Human Lung Adenocarcinoma by Targeting RBX1 and CRKL, Respectively" +target gene hsa-let-7b Hypohidrotic Ectodermal Dysplasia 29344666 Let-7b regulates alpaca hair growth by downregulating ectodysplasin A. +target gene hsa-mir-595 "Leukemia, Lymphoblastic, Acute" 29345051 MiR-595 Suppresses the Cellular Uptake and Cytotoxic Effects of Methotrexate by Targeting SLC19A1 in CEM/C1 Cells. +target gene hsa-mir-137 Melanoma 29348676 miR-137 regulates ferroptosis by targeting glutamine transporter SLC1A5 in melanoma +target gene hsa-mir-199a Acute Respiratory Distress Syndrome 29351405 Acute downregulation of miR-199a attenuates sepsis-induced acute lung injury by targeting SIRT1 +target gene hsa-mir-182 "Squamous Cell Carcinoma, Head and Neck" 29356167 "there is frequent and concordant upregulation of miR-31, miR-96, and miR-182 during HNSCC and these miRNAs co-target Numb" +target gene hsa-mir-31 "Squamous Cell Carcinoma, Head and Neck" 29356167 "there is frequent and concordant upregulation of miR-31, miR-96, and miR-182 during HNSCC and these miRNAs co-target Numb" +target gene hsa-mir-96 "Squamous Cell Carcinoma, Head and Neck" 29356167 "there is frequent and concordant upregulation of miR-31, miR-96, and miR-182 during HNSCC and these miRNAs co-target Numb" +target gene hsa-mir-16 Pineal Gland Cancer 29359963 Melatonin Inhibits the Proliferation of Gastric Cancer Cells Through Regulating the miR-16-5p-Smad3 Pathway. +target gene hsa-mir-15b Prostate Neoplasms 29363862 miR-15b-5p facilitates the tumorigenicity by targeting RECK and predicts tumour recurrence in prostate cancer +target gene hsa-mir-30c Pediatric Osteosarcoma 29364496 Biological function of microRNA-30c/SOX9 in pediatric osteosarcoma cell growth and metastasis. +target gene hsa-mir-448 Breast Neoplasms 29368542 "miR-448 inhibits cell migration, invasion, and EMT by targeting to the 3'UTR of ZEB1/2" +target gene hsa-mir-330 Alzheimer Disease 29369410 "Protective effects of microRNA-330 on amyloid ¦Â-protein production, oxidative stress, and mitochondrial dysfunction in Alzheimer's disease by targeting VAV1 via the MAPK signaling pathway." +target gene hsa-mir-424 "Carcinoma, Endometrial" 29371986 "MicroRNA-424/E2F6 feedback loop modulates cell invasion, migration and EMT in endometrial carcinoma" +target gene hsa-mir-760 "Carcinoma, Lung, Non-Small-Cell" 29372517 MiR-760 suppresses non-small cell lung cancer proliferation and metastasis by targeting ROS1. +target gene hsa-mir-34a Chronic Obstructive Pulmonary Disease 29373969 miR-34a is involved in CSE-induced apoptosis of human pulmonary microvascular endothelial cells by targeting Notch-1 receptor protein +target gene hsa-mir-328 Colon Neoplasms 29374351 miR-328 mediates a metabolic shift in colon cancer cells by targeting SLC2A1/GLUT1. +target gene hsa-mir-10b "Carcinoma, Hepatocellular" 29375271 MicroRNA-10b regulates epithelial-mesenchymal transition by modulating KLF4/KLF11/Smads in hepatocellular carcinoma +target gene hsa-mir-20a "Carcinoma, Lung, Non-Small-Cell" 29375712 MicroRNA-20a promotes proliferation and invasion by directly targeting early growth response 2 in non-small cell lung carcinoma +target gene hsa-mir-132 Inflammation 29377244 MicroRNA-132 attenuates LPS-induced inflammatory injury by targeting TRAF6 in neuronal cell line HT-22 +target gene hsa-mir-21 Atrial Fibrillation 29380561 These changes can be explained by alterations in the MMP and miR-21/ERK signaling pathways +target gene hsa-mir-130a "Carcinoma, Breast" 29384218 microRNA-130a suppresses breast cancer cell migration and invasion by targeting FOSL1 and upregulating ZO-1. +target gene hsa-mir-522 Colorectal Carcinoma 29386092 miR-522-3p promotes tumorigenesis in human colorectal cancer via targeting bloom syndrome protein. +target gene hsa-mir-383 Lymphoma 29387204 western blot analysis identified zinc finger E-box binding homeobox 2 (ZEB2) as a direct target gene of miR-383 +target gene hsa-mir-144 Osteosarcoma 29387244 miR-144 suppresses proliferation and induces apoptosis of osteosarcoma cells via direct regulation of mTOR expression. +target gene hsa-mir-138 "Carcinoma, Hepatocellular" 29387246 " miR-138 targeted SP1 to repress the growth, migration and invasion of HCC cells, and may therefore represent a therapeutic target in human HCC" +target gene hsa-mir-206 Legg-Calve-Perthes Disease 29387248 Downregulated SOX9 mediated by miR-206 promoted cell apoptosis in Legg-Calv¨¦-Perthes disease. +target gene hsa-mir-210 Kidney Injury 29387863 miR-210 protects renal cell against hypoxia-induced apoptosis by targeting HIF-1 alpha +target gene hsa-mir-646 Colorectal Carcinoma 29391877 Low-level miR-646 in colorectal cancer inhibits cell proliferation and migration by targeting NOB1 expression +target gene hsa-mir-27b Gastric Neoplasms 29393383 "miR-27b may act as a potential biomarker for differentiating patients with GC from healthy controls, and serve as a tumor suppressor in GC by targeting VEGFC" +target gene hsa-mir-29b Neuroblastoma 29399057 MicroRNA-29b alleviates oxygen and glucose deprivation/reperfusion-induced injury via inhibition of the p53-dependent apoptosis pathway in N2a neuroblastoma cells +target gene hsa-mir-9 "Carcinoma, Hepatocellular" 29399149 MicroRNA-9 enhances sensitivity to cetuximab in epithelial phenotypehepatocellular carcinoma cells through regulation of the eukaryotic translation initiation factor 5A-2 +target gene hsa-mir-15a Myeloma 29399181 Downregulation of miRNA-15a and miRNA-16 promote tumor proliferation in multiple myeloma by increasing CABIN1 expression +target gene hsa-mir-16 Myeloma 29399181 Downregulation of miRNA-15a and miRNA-16 promote tumor proliferation in multiple myeloma by increasing CABIN2 expression +target gene hsa-mir-16 Pituitary Neoplasms 29399695 MicroRNA?16/VEGFR2/p38/NF?¦ÊB signaling pathway regulates cell growth of human pituitary neoplasms. +target gene hsa-mir-204 Colorectal Carcinoma 29402343 microRNA-204 inhibits the growth and motility of colorectal cancer cells by downregulation of CXCL8 +target gene hsa-mir-127 "Leukemia, Myeloid, Acute" 29402726 "mRNA and miRNA integrative analyses showed aberrant expression of several hub oncogenes appear to be regulated by some miRNAs like miR-127-5p, miR-494, miR-21 and miR-616 in high TET1 expressers" +target gene hsa-mir-21 "Leukemia, Myeloid, Acute" 29402726 "mRNA and miRNA integrative analyses showed aberrant expression of several hub oncogenes appear to be regulated by some miRNAs like miR-127-5p, miR-494, miR-21 and miR-616 in high TET1 expressers" +target gene hsa-mir-494 "Leukemia, Myeloid, Acute" 29402726 "mRNA and miRNA integrative analyses showed aberrant expression of several hub oncogenes appear to be regulated by some miRNAs like miR-127-5p, miR-494, miR-21 and miR-616 in high TET1 expressers" +target gene hsa-mir-616 "Leukemia, Myeloid, Acute" 29402726 "mRNA and miRNA integrative analyses showed aberrant expression of several hub oncogenes appear to be regulated by some miRNAs like miR-127-5p, miR-494, miR-21 and miR-616 in high TET1 expressers" +target gene hsa-mir-429 "Carcinoma, Hepatocellular" 29403024 The newly identified miR-429-CRKL axis represents a novel potential therapeutic target for HCC treatment +target gene hsa-mir-31 Arteriosclerosis Obliterans 29403548 MicroRNA-31 promotes arterial smooth muscle cell proliferation and migration by targeting mitofusin-2 in arteriosclerosis obliterans of the lower extremitie +target gene hsa-mir-101 "Carcinoma, Endometrial" 29404887 MicroRNA-101 inhibits angiogenesis via COX-2 in endometrial carcinoma. +target gene hsa-mir-29a Diabetic Retinopathy 29409329 Downregulation of MicroRNA 29a/b exacerbated diabetic retinopathy by impairing the function of M¨¹ller cells via Forkhead box protein O4. +target gene hsa-mir-29b Diabetic Retinopathy 29409329 Downregulation of MicroRNA 29a/b exacerbated diabetic retinopathy by impairing the function of M¨¹ller cells via Forkhead box protein O4. +target gene hsa-mir-195 "Carcinoma, Lung, Non-Small-Cell" 29416000 miR-195 targets cyclin D3 and survivin to modulate the tumorigenesis of non-small cell lung cancer +target gene hsa-mir-143 "Carcinoma, Gallbladder" 29416013 miR-143-3p targeting of ITGA6 suppresses tumour growth and angiogenesis by downregulating PLGF expression via the PI3K/AKT pathway in gallbladder carcinoma. +target gene hsa-mir-493 Prostate Neoplasms 29423080 Downregulation of N6-methyladenosine binding YTHDF2 protein mediated by miR-493-3p suppresses prostate cancer by elevating N6-methyladenosine levels. +target gene hsa-mir-199a "Carcinoma, Thyroid, Papillary" 29427661 miR-199a-5p inhibits the progression of papillary thyroid carcinoma by targeting SNAI1. +target gene hsa-mir-145 "Squamous Cell Carcinoma, Esophageal" 29430188 The ROR/miR-145/FSCN1 pathway was shown to take part in the metastasis of ESCC. ROR is likely an oncogene biomarker for ESCC early diagnosis and prognosis +target gene hsa-mir-152 Ovarian Neoplasms 29434752 MicroRNA-152 inhibits ovarian cancer cell proliferation and migration and may infer improved outcomes in ovarian cancer through targeting FOXP1. +target gene hsa-mir-221 Colorectal Carcinoma 29434757 miR-221 inhibits autophagy and targets TP53INP1 in colorectal cancer cells +target gene hsa-mir-150 Melanoma 29434838 MicroRNA-150 inhibitors enhance cell apoptosis of melanoma by targeting PDCD4 +target gene hsa-mir-125b Breast Neoplasms 29434858 miR-125b regulates the drug-resistance of breast cancer cells to doxorubicin by targeting HAX-1 +target gene hsa-mir-34c Laryngeal Neoplasms 29435079 "miR-34c may be involved in the pathogenesis of laryngeal cancer, and BCL2 may be negatively regulated by miR-34c in M4e cell" +target gene hsa-mir-340 Thyroid Neoplasms 29441462 Up-regulation of miR-340-5p promotes progression of thyroid cancer by inhibiting BMP4. +target gene hsa-mir-150 Prostate Neoplasms 29441850 MiR-150 promotes the cell invasion of prostate cancer cells by directly regulating the expression of p53 +target gene hsa-mir-200a Endometrial Neoplasms 29442045 MiR-200a promotes epithelial-mesenchymal transition of endometrial cancer cells by negatively regulating FOXA2 expression +target gene hsa-mir-598 Glioblastoma 29444745 MicroRNA-598 Inhibits Cell Proliferation and Invasion of Glioblastoma by Directly Targeting Metastasis Associated in Colon Cancer-1 (MACC1). +target gene hsa-mir-365 Stroke 29451327 MicroRNA-365 modulates astrocyte conversion into neuron in adult rat brain after stroke by targeting Pax6. +target gene hsa-mir-19b "Carcinoma, Lung, Non-Small-Cell" 29455644 miR-19b enhances proliferation and apoptosis resistance via the EGFR signaling pathway by targeting PP2A and BIM in non-small cell lung cancer +target gene hsa-mir-372 Breast Neoplasms 29456685 miR-372 functions as an oncogenic miRNA in breast cancer by targeting LATS2 +target gene hsa-mir-144 Gastric Neoplasms 29456712 MicroRNA-144 functions as a tumor suppressor in gastric cancer by targeting cyclooxygenase-2 +target gene hsa-mir-4295 Prostate Neoplasms 29457293 Ginsenoside Rh2 inhibits prostate cancer cell growth through suppression of microRNA-4295 that activates CDKN1A. +target gene hsa-mir-24 Heart Failure 29457789 miR-24 potently suppresses SCN5A expression and that rs1805126 modulates this regulation +target gene hsa-mir-17 "Lymphoma, Burkitt" 29458013 "In contrast to normal B cells, miRNA target genes in BL were enriched for targets of the oncogenic miR-17 to 92 cluster, and were involved mainly in cell cycle and cell death" +target gene hsa-mir-18 "Lymphoma, Burkitt" 29458013 "In contrast to normal B cells, miRNA target genes in BL were enriched for targets of the oncogenic miR-17 to 93 cluster, and were involved mainly in cell cycle and cell death" +target gene hsa-mir-19a "Lymphoma, Burkitt" 29458013 "In contrast to normal B cells, miRNA target genes in BL were enriched for targets of the oncogenic miR-17 to 94 cluster, and were involved mainly in cell cycle and cell death" +target gene hsa-mir-19b-1 "Lymphoma, Burkitt" 29458013 "In contrast to normal B cells, miRNA target genes in BL were enriched for targets of the oncogenic miR-17 to 96 cluster, and were involved mainly in cell cycle and cell death" +target gene hsa-mir-20a "Lymphoma, Burkitt" 29458013 "In contrast to normal B cells, miRNA target genes in BL were enriched for targets of the oncogenic miR-17 to 95 cluster, and were involved mainly in cell cycle and cell death" +target gene hsa-mir-92-1 "Lymphoma, Burkitt" 29458013 "In contrast to normal B cells, miRNA target genes in BL were enriched for targets of the oncogenic miR-17 to 97 cluster, and were involved mainly in cell cycle and cell death" +target gene hsa-mir-204 Colon Neoplasms 29460671 Targeted delivery of miRNA-204-5p by PEGylated polymer nanoparticles for colon cancer therapy +target gene hsa-mir-210 Ischemia-Reperfusion Injury 29461605 "miR-210, as an upstream factor, plays a protective role in cardiomyocytes through directly inhibiting the protein expression of its target gene E2F3" +target gene hsa-mir-27a Diabetes Mellitus 29462799 miR-27a may contribute to detrusor fibrosis in STZ-induced diabetic rats by targeting PRKAA2 via the TGF-¦Â1/Smad3 signaling pathway +target gene hsa-mir-206 Osteosarcoma 29462818 "Effects of MicroRNA-206 on Osteosarcoma Cell Proliferation, Apoptosis, Migration and Invasion by Targeting ANXA2 Through the AKT Signaling Pathway" +target gene hsa-mir-31 Colorectal Carcinoma 29463215 miR-31 down-regulated c-MET in DLD-1 colon cancer cells +target gene hsa-mir-150 Atherosclerosis 29463607 the decreases in phosphorylated p65 expression and inflammatory cytokine secretion induced by miR-150 ablation were reversed by PDLIM1 knockdown +target gene hsa-mir-21 Pancreatic Neoplasms 29464088 "the expression of two miRComb miR-21 predicted targets, PDCD4 and BTG2, was significantly upregulated in these cells in comparison to control PANC-1" +target gene hsa-mir-7 Gastric Neoplasms 29467883 "YCS inhibits proliferation and induces apoptosis of GC cells mediated by miR-7 targeting EGFR, which may be one of the mechanisms whereby YZSJD exerts its effects on GC" +target gene hsa-mir-96 Bladder Neoplasms 29467898 HERG1 was an important target of miR-96 +target gene hsa-mir-17 "Diabetes Mellitus, Type 2" 29477089 miR-17 improved inflammation-induced insulin resistance by suppressing ASK1 expression in macrophages +target gene hsa-mir-216b Diabetic Vasculopathy 29477872 MicroRNA-216b actively modulates diabetic angiopathy through inverse regulation on FZD5. +target gene hsa-mir-210 Cerebral Ischemia 29478968 miR-210 promoted neovascularization and NPC migration via the SOCS1-STAT3-VEGF-C pathway +target gene hsa-mir-330 Ovarian Neoplasms 29485916 S100A7 Regulates Ovarian Cancer Cell Metastasis and Chemoresistance Through MAPK Signaling and Is Targeted by miR-330-5p. +target gene hsa-mir-140 Osteoarthritis 29488053 "miR-140-5p/miR-149 Affects Chondrocyte Proliferation, Apoptosis, and Autophagy by Targeting FUT1 in Osteoarthritis." +target gene hsa-mir-149 Osteoarthritis 29488053 "miR-140-5p/miR-149 Affects Chondrocyte Proliferation, Apoptosis, and Autophagy by Targeting FUT1 in Osteoarthritis." +target gene hsa-mir-150 Evans Syndrome 29488168 miR-150 regulates B lymphocyte in autoimmune hemolytic anemia/Evans syndrome by c-Myb. +target gene hsa-mir-378 Osteosarcoma 29490146 MiR-378 promotes the cell proliferation of osteosarcoma through down-regulating the expression of Kruppel-like factor 9. +target gene hsa-mir-342 Melanoma 29495972 MicroRNA-342 prohibits proliferation and invasion of melanoma cells by directly targeting Zinc-finger E-box binding homeobox 1 +target gene hsa-mir-140 Colorectal Carcinoma 29499953 miR-140 might be a key suppressor of CRC progression and metastasis through inhibiting EMT process by targeting Smad3 +target gene hsa-mir-23b Sepsis 29506272 "Inhibition of MicroRNA-23b Attenuates Immunosuppression During Late Sepsis Through NIK, TRAF1, and XIAP." +target gene hsa-mir-10b "Carcinoma, Hepatocellular" 29506532 "CADM2, as a new target of miR-10b, promotes tumor metastasis through FAK/AKT pathway in hepatocellular carcinoma" +target gene hsa-mir-223 Atopic Dermatitis 29506638 miR-223 participates in AD through upregulating HNMT indirectly to degrade the excessive histamine +target gene hsa-mir-3147 Vulvar Squamous Cell Carcinoma 29512734 miR?3147 serves as an oncomiR in vulvar squamous cell cancer via Smad4 suppression. +target gene hsa-mir-29c "Carcinoma, Lung, Non-Small-Cell" 29512752 MicroRNA-29c inhibits proliferation and promotes apoptosis in non-small cell lung cancer cells by targeting VEGFA +target gene hsa-mir-139 "Carcinoma, Adrenocortical" 29516499 MiR-483-5p and miR-139-5p promote aggressiveness by targeting N-myc downstream-regulated gene family members in adrenocortical cancer. +target gene hsa-mir-483 "Carcinoma, Adrenocortical" 29516499 MiR-483-5p and miR-139-5p promote aggressiveness by targeting N-myc downstream-regulated gene family members in adrenocortical cancer. +target gene hsa-mir-181a "Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal" 29517349 miR-181a targets GATA6 to inhibit the progression of human laryngeal squamous cell carcinoma. +target gene hsa-mir-449a Breast Neoplasms 29518546 LINC0092 was co-expressed with SFRP1 and RGMA and regulated by hsa-miR-449a and hsa-miR-452-5p +target gene hsa-mir-452 Breast Neoplasms 29518546 LINC0092 was co-expressed with SFRP1 and RGMA and regulated by hsa-miR-449a and hsa-miR-452-5p +target gene hsa-mir-223 Prostate Neoplasms 29518547 MicroRNA-223-3p regulates cell chemo-sensitivity by targeting FOXO3 in prostatic cancer. +target gene hsa-mir-23a "Carcinoma, Nasopharyngeal" 29520105 Metastasis-associated miR-23a from nasopharyngeal carcinoma-derived exosomes mediates angiogenesis by repressing a novel target gene TSGA10 +target gene hsa-let-7a "Squamous Cell Carcinoma, Tongue" 29523225 "These findings revealed that H19/let-7a/HMGA2/EMT axis plays a critical role in the regulation of TSCC migration and invasion, which may provide a new therapeutic target for TSCC cancers" +target gene hsa-mir-223 Viral Myocarditis 29524390 "the data suggest that miR-223 protects against CVB3-induced inflammation and myocardial damage, which may partly attribute to the regulation of macrophage polarization via targeting Pknox1" +target gene hsa-mir-128 Glioma 29524580 MicroRNA-128 inhibits proliferation and invasion of glioma cells by targeting COX-2. +target gene hsa-mir-124 Cerebrovascular Disease 29530526 Levels of tight junction protein CLDND1 are regulated by microRNA-124 in the cerebellum of stroke-prone spontaneously hypertensive rats +target gene hsa-mir-320a Interstitial Cystitis 29531336 "three transcription factors, E2F-1, E2F-2 and TUB, are regulated by miR-320 family miRNAs" +target gene hsa-mir-320b Interstitial Cystitis 29531336 "three transcription factors, E2F-1, E2F-2 and TUB, are regulated by miR-321 family miRNAs" +target gene hsa-mir-320c Interstitial Cystitis 29531336 "three transcription factors, E2F-1, E2F-2 and TUB, are regulated by miR-322 family miRNAs" +target gene hsa-mir-320d Interstitial Cystitis 29531336 "three transcription factors, E2F-1, E2F-2 and TUB, are regulated by miR-323 family miRNAs" +target gene hsa-mir-30a "Carcinoma, Gallbladder" 29540696 "MicroRNA-30a-5p inhibits gallbladder cancer cell proliferation, migration and metastasis by targeting E2F7." +target gene hsa-mir-124 Angiomyolipoma 29540858 "miR-9-5p, miR-124-3p, and miR-132-3p regulate BCL2L11 in tuberous sclerosis complex angiomyolipoma." +target gene hsa-mir-132 Angiomyolipoma 29540858 "miR-9-5p, miR-124-3p, and miR-132-3p regulate BCL2L11 in tuberous sclerosis complex angiomyolipoma." +target gene hsa-mir-9 Angiomyolipoma 29540858 "miR-9-5p, miR-124-3p, and miR-132-3p regulate BCL2L11 in tuberous sclerosis complex angiomyolipoma." +target gene hsa-mir-145 "Carcinoma, Lung, Non-Small-Cell" 29541201 "miR-145 suppresses the proliferation, invasion and migration of NSCLC cells by regulating the BAX/BCL-2 ratio and the caspase-3 cascade" +target gene hsa-mir-155 Diabetic Peripheral Neuropathy 29545091 MiR-155 targets PTCH1 to mediate endothelial progenitor cell dysfunction caused by high glucose. +target gene hsa-mir-205 Rheumatic Heart Diseases 29548280 Hsa miR-205-3p and hsa-miR-3909 were predicted to target the 3'UTR of IL-1¦Â and IL1R1 respectively +target gene hsa-mir-3909 Rheumatic Heart Diseases 29548280 Hsa miR-205-3p and hsa-miR-3909 were predicted to target the 3'UTR of IL-1¦Â and IL1R1 respectively +target gene hsa-mir-320 Cerebral Ischemia 29549732 MicRNA-320 facilitates the brain parenchyma injury via regulating IGF-1 during cerebral I/R injury in mice. +target gene hsa-mir-98 Atherosclerosis 29549823 MicroRNA-98 regulates foam cell formation and lipid accumulation through repression of LOX-1. +target gene hsa-mir-424 "Carcinoma, Breast" 29550638 "miR-424-5p regulates cell proliferation, migration and invasion by targeting doublecortin-like kinase 1 in basal-like breast cancer." +target gene hsa-mir-125b Osteoarthritis 29550827 miR-125b could play an important role in inflammatory injury of chondrogenic cells and miR-125b affected inflammatory injury of ATDC5 cells via regulating expression of MIP-1¦Á and regulating NF-¦ÊB and JNK signaling pathways +target gene hsa-mir-613 "Carcinoma, Hepatocellular" 29551505 MiR-613 functions as tumor suppressor in hepatocellular carcinoma by targeting YWHAZ. +target gene hsa-mir-124 Osteosarcoma 29552134 MicroRNA-124 acts as a tumor-suppressive miRNA by inhibiting the expression of Snail2 in osteosarcoma +target gene hsa-mir-183 "Carcinoma, Renal Cell" 29552228 MicroRNA-183 promotes the proliferation and metastasis of renal cell carcinoma through targeting Dickkopf-related protein 3 +target gene hsa-mir-34a Cardiovascular Diseases [unspecific] 29554593 MiR-34a-5p mediates sevoflurane preconditioning induced inhibition of hypoxia/reoxygenation injury through STX1A in cardiomyocytes. +target gene hsa-mir-155 Colorectal Carcinoma 29556299 MicroRNA-155 acts as a tumor suppressor in colorectal cancer by targeting CTHRC1 in vitro +target gene hsa-mir-200c "Carcinoma, Lung, Non-Small-Cell" 29557087 Anti-invasive effect of Cyclamen pseudibericum extract on A549 non-small cell lung carcinoma cells via inhibition of ZEB1 mediated by miR-200c +target gene hsa-mir-145 Aneurysm 29558369 "miR-145 - pivotal in regulating VSMC plasticity, which is reduced in vascular diseases - was found to control Uhrf1 mRNA translation" +target gene hsa-mir-625 Thyroid Neoplasms 29558717 "MicroRNA-625-3p promotes the proliferation, migration and invasion of thyroid cancer cells by up-regulating astrocyte elevated gene 1." +target gene hsa-mir-532 Ovarian Neoplasms 29558748 Ginsenoside 20(S)-Rg3 Inhibits the Warburg Effect Via Modulating DNMT3A/ MiR-532-3p/HK2 Pathway in Ovarian Cancer Cells. +target gene hsa-mir-199 "Carcinoma, Hepatocellular" 29559347 "MicroRNA-199 suppresses cell proliferation, migration and invasion by downregulating RGS17 in hepatocellular carcinoma." +target gene hsa-mir-24 Hyperglycemia 29559348 MicroRNA-24 regulates vascular remodeling via inhibiting PDGF-BB pathway in diabetic rat model. +target gene hsa-mir-143 Crohn Disease 29562274 MicroRNA-143 Targets ATG2B to Inhibit Autophagy and Increase Inflammatory Responses in Crohn's Disease +target gene hsa-let-7a Hypoxic-Ischemic Encephalopathy 29562785 "The expression levels of the microRNAs (miRs) let-7a and let-7e, known regulators of Casp3, were inversely correlated to Casp3" +target gene hsa-let-7e Hypoxic-Ischemic Encephalopathy 29562785 "The expression levels of the microRNAs (miRs) let-7a and let-7e, known regulators of Casp3, were inversely correlated to Casp3" +target gene hsa-mir-302a Osteosarcoma 29563995 MicroRNA-302a inhibits osteosarcoma cell migration and invasion by directly targeting IGF-1R. +target gene hsa-mir-21 Colon Neoplasms 29564000 Berberine regulates the microRNA-21-ITG¦¢4-PDCD4 axis and inhibits colon cancer viability +target gene hsa-mir-155 "Carcinoma, Hepatocellular" 29565484 "MiR-155 targeted and inhibited FoxO3a expression to suppress the BIM, depress caspase-3 and caspase-9 activities, therefore inhibiting the HCC cell apoptosis and facilitating proliferation" +target gene hsa-mir-145 Breast Neoplasms 29565493 "MiR-145 affects breast cancer BS524 cell proliferation, infiltration, and migration via positively regulating OCT4 gene expression" +target gene hsa-mir-422a Colorectal Carcinoma 29566993 MiR-422a targets MAPKK6 and regulates cell growth and apoptosis in colorectal cancer cells. +target gene hsa-mir-149 Neoplasms [unspecific] 29568059 Cell-autonomous and cell non-autonomous downregulation of tumor suppressor DAB2IP by microRNA-149-3p promotes aggressiveness of cancer cells. +target gene hsa-mir-128 Neoplasms [unspecific] 29568354 miR-128 inhibits telomerase activity by targeting TERT mRNA +target gene hsa-mir-19a Gastric Neoplasms 29568890 miR-19a/b and MeCP2 repress reciprocally to regulate multidrug resistance in gastric cancer cells. +target gene hsa-mir-19b Gastric Neoplasms 29568890 miR-19a/b and MeCP2 repress reciprocally to regulate multidrug resistance in gastric cancer cells. +target gene hsa-mir-29b Renal Fibrosis 29568897 miR-29b regulates Ang II-induced EMT of rat renal tubular epithelial cells via targeting PI3K/AKT signaling pathway. +target gene hsa-mir-124 Acute Kidney Failure 29568906 miR-124/MCP-1 signaling pathway modulates the protective effect of itraconazole on acute kidney injury in a mouse model of disseminated candidiasis. +target gene hsa-mir-375 "Fatty Liver, Non-Alcoholic" 29569260 Down-regulation of microRNA-375 regulates adipokines and inhibits inflammatory cytokines by targeting AdipoR2 in non-alcoholic fatty liver disease +target gene hsa-mir-491 Gastric Neoplasms 29569792 Downregulation of miR-491-5p promotes gastric cancer metastasis by regulating SNAIL and FGFR4. +target gene hsa-mir-17 Neoplasms [unspecific] 29574928 "The role of miR-17/92 family in development and progression of various cancers has been established. The members of this miRNA family have been shown to be over expressed and target various genes within proliferation, metastasis and angiogenesis pathways." +target gene hsa-mir-18 Neoplasms [unspecific] 29574928 "The role of miR-17/92 family in development and progression of various cancers has been established. The members of this miRNA family have been shown to be over expressed and target various genes within proliferation, metastasis and angiogenesis pathways." +target gene hsa-mir-19a Neoplasms [unspecific] 29574928 "The role of miR-17/92 family in development and progression of various cancers has been established. The members of this miRNA family have been shown to be over expressed and target various genes within proliferation, metastasis and angiogenesis pathways." +target gene hsa-mir-19b-1 Neoplasms [unspecific] 29574928 "The role of miR-17/92 family in development and progression of various cancers has been established. The members of this miRNA family have been shown to be over expressed and target various genes within proliferation, metastasis and angiogenesis pathways." +target gene hsa-mir-20a Neoplasms [unspecific] 29574928 "The role of miR-17/92 family in development and progression of various cancers has been established. The members of this miRNA family have been shown to be over expressed and target various genes within proliferation, metastasis and angiogenesis pathways." +target gene hsa-mir-92-1 Neoplasms [unspecific] 29574928 "The role of miR-17/92 family in development and progression of various cancers has been established. The members of this miRNA family have been shown to be over expressed and target various genes within proliferation, metastasis and angiogenesis pathways." +target gene hsa-mir-374b "Carcinoma, Cervical" 29575013 MicroRNA-374b inhibits cervical cancer cell proliferation and induces apoptosis through the p38/ERK signaling pathway by binding to JAM-2. +target gene hsa-mir-34a Gastric Neoplasms 29581731 MicroRNA-34a regulates proliferation and apoptosis of gastric cancer cells by targeting silent information regulator 1 +target gene hsa-mir-155 Sezary Disease 29582620 HERV-K and HERV-W expression is regulated by mir-155 in S¨¦zary syndrome +target gene hsa-mir-9 Metabolic Syndrome 29584810 Identification of miR-9-5p as direct regulator of ABCA1 and HDL-driven reverse cholesterol transport in circulating CD14+ cells of patients with metabolic syndrome. +target gene hsa-mir-30a Liver Fibrosis 29587268 "miR-30a inhibits EMT process, at least in part, via reduction of Snai1, leading to the suppression of HSC activation in liver fibrosis" +target gene hsa-mir-146a Mesial Temporal Lobe Epilepsy 29590637 modulation of the miR-146a-CFH-IL-1¦Â loop circuit could be a novel therapeutic target for TLE +target gene hsa-mir-122 Chronic Hepatitis C 29593672 the liver-specific microRNA-122 (miR-122) binds to two target sites at the 5' end of the viral RNA genome as well as to at least three additional target sites in the coding region and the 3' UTR +target gene hsa-mir-326 Sickle Cell Disease 29601850 miR-326 regulates HbF synthesis by targeting EKLF in human erythroid cells. +target gene hsa-mir-9 "Carcinoma, Cervical" 29602130 The mechanisms involved in miR-9 regulated apoptosis in cervical cancer by targeting FOXO3. +target gene hsa-mir-451a "Fatty Liver, Non-Alcoholic" 29604329 MiR-451a attenuates free fatty acids-mediated hepatocyte steatosis by targeting the thyroid hormone responsive spot 14 gene. +target gene hsa-mir-181c Diabetes Mellitus 29605252 miR-181c-3p and -5p promotes high-glucose-induced dysfunction in human umbilical vein endothelial cells by regulating leukemia inhibitory factor. +target gene hsa-mir-370 "Squamous Cell Carcinoma, Esophageal" 29605603 Downregulation of microRNA-370 in esophageal squamous-cell carcinoma is associated with cancer progression and promotes cancer cell proliferation via upregulating PIN1. +target gene hsa-mir-6086 Cardiovascular Diseases [unspecific] 29605606 Inhibition of hsa-miR-6086 protects human umbilical vein endothelial cells against TNF¦Á-induced proliferation inhibition and apoptosis via CDH5. +target gene hsa-mir-204 Neuroblastoma 29610116 Network Modeling of microRNA-mRNA Interactions in Neuroblastoma Tumorigenesis Identifies miR-204 as a Direct Inhibitor of MYCN. +target gene hsa-mir-125b "Meningitis, Pneumococcal" 29611100 "hsa-miR-25-3p and hsa-miR-125b-5p target the transcription factor TEF-1, for which there are binding sites in Il-1¦Â, Ccl 2 , and Ccl 3 genes" +target gene hsa-mir-25 "Meningitis, Pneumococcal" 29611100 "hsa-miR-25-3p and hsa-miR-125b-5p target the transcription factor TEF-1, for which there are binding sites in Il-1¦Â, Ccl 2 , and Ccl 3 genes" +target gene hsa-mir-7 Breast Neoplasms 29614984 Our data uncovered a crucial role of TINCR-miR-7-KLF4 axis in human breast cancer +target gene hsa-mir-140 "Carcinoma, Lung, Non-Small-Cell" 29617683 MiR-140 Expression Regulates Cell Proliferation and Targets PD-L1 in NSCLC +target gene hsa-mir-145 Neuroblastoma 29619741 Expression of miR-145 and Its Target Proteins Are Regulated by miR-29b in Differentiated Neurons +target gene hsa-mir-29b Neuroblastoma 29619741 Expression of miR-145 and Its Target Proteins Are Regulated by miR-29b in Differentiated Neurons +target gene hsa-mir-200a "Carcinoma, Ovarian" 29620165 FOXD1 is targeted by miR-30a-5p and miR-200a-5p and suppresses the proliferation of human ovarian carcinoma cells by promoting p21 expression in a p53-independent manner. +target gene hsa-mir-30a "Carcinoma, Ovarian" 29620165 FOXD1 is targeted by miR-30a-5p and miR-200a-5p and suppresses the proliferation of human ovarian carcinoma cells by promoting p21 expression in a p53-independent manner. +target gene hsa-mir-31a Hypertension 29620173 Deregulation of microRNA?31a?5p is involved in the development of primary hypertension by suppressing apoptosis of pulmonary artery smooth muscle cells via targeting TP53. +target gene hsa-mir-612 "Carcinoma, Bladder" 29620192 Tumor-suppressing effects of microRNA-612 in bladder cancer cells by targeting malic enzyme 1 expression. +target gene hsa-mir-130b Lupus Nephritis 29620214 Dysregulation of PTEN caused by the underexpression of microRNA?130b is associated with the severity of lupus nephritis. +target gene hsa-mir-149 "Carcinoma, Colon" 29620230 Formononetin inhibits colon carcinoma cell growth and invasion by microRNA?149?mediated EphB3 downregulation and inhibition of PI3K/AKT and STAT3 signaling pathways. +target gene hsa-mir-328 "Carcinoma, Breast" 29620238 miR-328-5p inhibits MDA-MB-231 breast cancer cell proliferation by targeting RAGE. +target gene hsa-mir-142 "Carcinoma, Breast" 29620260 MicroRNA?142?5p modulates breast cancer cell proliferation and apoptosis by targeting phosphatase and tensin homolog. +target gene hsa-mir-152 Renal Fibrosis 29620271 miR?152 regulates TGF?¦Â1?induced epithelial?mesenchymal transition by targeting HPIP in tubular epithelial cells. +target gene hsa-mir-429 Peripheral Nerve Injury 29624520 Inhibition of microRNA-429 attenuates oxygen-glucose deprivation/reoxygenation-induced neuronal injury by promoting expression of GATA-binding protein 4. +target gene hsa-mir-675 Osteosarcoma 29626470 Exosomal miR-675 from metastatic osteosarcoma promotes cell migration and invasion by targeting CALN1. +target gene hsa-mir-767 "Carcinoma, Hepatocellular" 29627570 Circular RNA hsa_circ_0000673 promotes hepatocellular carcinoma malignance by decreasing miR-767-3p targeting SET. +target gene hsa-mir-145 "Carcinoma, Hepatocellular" 29630879 Atorvastatin induces MicroRNA-145 expression in HEPG2 cells via regulation of the PI3K/AKT signalling pathway +target gene hsa-mir-4319 Prostate Neoplasms 29633185 Re-expression of microRNA-4319 inhibits growth of prostate cancer via Her-2 suppression. +target gene hsa-mir-103a "Carcinoma, Hepatocellular" 29637568 Hepatoma cell-secreted exosomal microRNA-103 increases vascular permeability and promotes metastasis by targeting junction proteins. +target gene hsa-mir-26a "Carcinoma, Hepatocellular" 29653269 MicroRNA-26a is a key regulon that inhibits progression and metastasis of c-Myc/EZH2 double high advanced hepatocellular carcinoma. +target gene hsa-mir-20a Atherosclerosis 29653364 MicroRNA-20a protects human aortic endothelial cells from Ox-LDL-induced inflammation through targeting TLR4 and TXNIP signaling. +target gene hsa-mir-130b Lung Neoplasms 29653464 MicroRNA-130b targets PTEN to induce resistance to cisplatin in lung cancer cells by activating Wnt/¦Â-catenin pathway. +target gene hsa-mir-449a Breast Neoplasms 29653747 MiR-449a suppresses cell migration and invasion by targeting PLAGL2 in breast cancer +target gene hsa-mir-96 Osteosarcoma 29656060 microRNA-96 acts as a tumor suppressor gene in human osteosarcoma via target regulation of EZRIN +target gene hsa-mir-146a Acute Lung Injury 29658581 MicroRNA?146a/Toll?like receptor 4 signaling protects against severe burn?induced remote acute lung injury in rats via anti?inflammation. +target gene hsa-mir-96 "Carcinoma, Hepatocellular" 29658604 Oncogenic miR-96-5p inhibits apoptosis by targeting the caspase-9 gene in hepatocellular carcinoma. +target gene hsa-mir-155 "Leukemia, Lymphocytic, Chronic, B-Cell" 29658610 Overexpression of IL-9 induced by STAT3 phosphorylation is mediated by miR-155 and miR-21 in chronic lymphocytic leukemia +target gene hsa-mir-21 "Leukemia, Lymphocytic, Chronic, B-Cell" 29658610 Overexpression of IL-9 induced by STAT3 phosphorylation is mediated by miR-155 and miR-21 in chronic lymphocytic leukemia +target gene hsa-mir-222 Hypertrophic Scar 29658663 microRNA-222 regulates proliferation and apoptosis of fibroblasts in hypertrophic scar via matrix metalloproteinase 1 +target gene hsa-mir-223 "Adenocarcinoma, Colon" 29660302 miR-223-RhoB signaling pathway regulates the proliferation and apoptosis of colon adenocarcinoma +target gene hsa-mir-92a Diabetes Mellitus 29660330 MiRNA-92a protects pancreatic B-cell function by targeting KLF2 in diabetes mellitus +target gene hsa-mir-155 Esophageal Neoplasms 29660336 MicroRNA-155 inversely correlates with esophageal cancer progression through regulating tumor-associated macrophage FGF2 expression. +target gene hsa-mir-758 Atherosclerosis 29660520 miR-758 mediates oxLDL-dependent vascular endothelial cell damage by suppressing the succinate receptor SUCNR1. +target gene hsa-mir-32 Breast Neoplasms 29661250 "oncogenic miR-32 and miR-92b were identified to suppress IDH1 expression, leading to the inhibition of cell migration and invasion" +target gene hsa-mir-92b Breast Neoplasms 29661250 "oncogenic miR-32 and miR-92b were identified to suppress IDH1 expression, leading to the inhibition of cell migration and invasion" +target gene hsa-mir-548k Myasthenia Gravis 29661539 miR-548k regulates CXCL13 expression in myasthenia gravis patients with thymic hyperplasia and in Jurkat cells. +target gene hsa-mir-27b Mycobacterium tuberculosis Infection 29661829 we revealed a novel role of the miR-27b/Bag2 axis in the regulation of inflammatory response and apoptosis and provide a potential molecular host defense mechanism against mycobacteria +target gene hsa-mir-29b Pulmonary Hypertension 29662889 Effect of miR-29b on the Proliferation and Apoptosis of Pulmonary Artery Smooth Muscle Cells by Targeting Mcl-1 and CCND2 +target gene hsa-mir-370 Atherosclerosis 29663491 miR-370 can reduce inflammatory reaction and inhibit the ROS production by targeting TLR4 in THP-1 cells +target gene hsa-mir-135a Atherosclerosis 29663503 MiR-135a represses oxidative stress and vascular inflammatory events via targeting toll-like receptor 4 in atherogenesis. +target gene hsa-mir-21 "Adenocarcinoma, Lung" 29663730 MiR-21 improves invasion and migration of drug-resistant lung adenocarcinoma cancer cell and transformation of EMT through targeting HBP1 +target gene hsa-mir-19a Hypertrophy 29664809 MicroRNA-19a/b-3p protect the heart from hypertension-induced pathological cardiac hypertrophy through PDE5A. +target gene hsa-mir-19b Hypertrophy 29664809 MicroRNA-19a/b-3p protect the heart from hypertension-induced pathological cardiac hypertrophy through PDE5A. +target gene hsa-mir-195 Prostate Neoplasms 29665645 MicroRNA-195 regulates docetaxel resistance by targeting clusterin in prostate cancer +target gene hsa-mir-29b Inflammation 29665646 miR-29b could regulate LPS-induced endothelial cells inflammatory injury through regulation of NF-¦ÊB and JNK signaling pathways +target gene hsa-mir-30a "Carcinoma, Breast, Triple Negative" 29666469 A p53/miR-30a/ZEB2 axis controls triple negative breast cancer aggressiveness +target gene hsa-mir-146a Cor Pulmonale 29667303 miR-146a can negatively feedback regulate PM1 -induced inflammation via NF-¦ÊB signaling pathway in BEAS-2B cells +target gene hsa-mir-193a "Carcinoma, Renal Cell" 29667779 "MiR-193a-3p and miR-224 mediate renal cell carcinoma progression by targeting alpha-2,3-sialyltransferase IV and the phosphatidylinositol 3 kinase/Akt pathway." +target gene hsa-mir-224 "Carcinoma, Renal Cell" 29667779 "MiR-193a-3p and miR-224 mediate renal cell carcinoma progression by targeting alpha-2,3-sialyltransferase IV and the phosphatidylinositol 3 kinase/Akt pathway." +target gene hsa-mir-122 Chronic Hepatitis C 29669014 miR-122 positively regulates HCV replication by a direct interaction with the 5' untranslated region (UTR) of the viral RNA +target gene hsa-mir-182 Myocardial Infarction 29671338 Inhibition of miR-182-5p protects cardiomyocytes from hypoxia-induced apoptosis by targeting CIAPIN1. +target gene hsa-mir-145 "Carcinoma, Breast, Triple Negative" 29673594 LincRNA-RoR/miR-145 promote invasion and metastasis in triple-negative breast cancer via targeting MUC1. +target gene hsa-mir-373 Lung Neoplasms 29673878 Down-regulation of miR-373 increases the radiosensitivity of lung cancer cells by targeting TIMP2. +target gene hsa-mir-21 Ischemia-Reperfusion Injury 29674977 the programmed cell death 4 (PDCD4) expression was identified as a target gene of miR-21 +target gene hsa-mir-21 Myocardial Infarction 29674977 the programmed cell death 4 (PDCD4) expression was identified as a target gene of miR-21 +target gene hsa-mir-375 Allergic Rhinitis 29677549 miR-375 prevents nasal mucosa cells from apoptosis and ameliorates allergic rhinitis via inhibiting JAK2/STAT3 pathway. +target gene hsa-mir-577 Osteoarthritis 29678573 Long non-protein coding RNA DANCR functions as a competing endogenous RNA to regulate osteoarthritis progression via miR-577/SphK2 axis. +target gene hsa-mir-485 "Carcinoma, Breast" 29678577 miR-485-5p suppresses breast cancer progression and chemosensitivity by targeting survivin. +target gene hsa-mir-338 "Carcinoma, Salivary Adenoid Cystic" 29678584 miR-338-5p/3p target LAMC2 to impair motility and invasion of ACC-M and MDA-MB-231?cells +target gene hsa-mir-876 "Carcinoma, Hepatocellular" 29679906 MicroRNA-876-5p inhibits epithelial-mesenchymal transition and metastasis of hepatocellular carcinoma by targeting BCL6 corepressor like 1. +target gene hsa-mir-485 Colorectal Carcinoma 29680296 MicroRNA-485-5p reduces O-GlcNAcylation of Bmi-1 and inhibits colorectal cancer proliferation. +target gene hsa-mir-155 Cardiovascular Diseases [unspecific] 29686722 Analysis of microRNA-155 expression also suggests its intervention in the regulation of eNOS expression. +target gene hsa-mir-21 Gastric Neoplasms 29687845 miRNA-21 may promote the growth of gastric cancer cells by adjusting and controlling PTEN/Akt signal passage mediated PEG2 +target gene hsa-mir-150 Sepsis 29689269 MiR-150 predicts survival in patients with sepsis and inhibits LPS-induced inflammatory factors and apoptosis by targeting NF-¦ÊB1 in human umbilical vein endothelial cells. +target gene hsa-mir-125b Arteriosclerosis Obliterans 29689557 Exogenous miR-125b expression modulated SRF expression and inhibited vascular neointimal formation in balloon-injured rat carotid arteries +target gene hsa-mir-34a Breast Neoplasms 29689563 MicroRNA-34a Inhibition of the TLR Signaling Pathway Via CXCL10 Suppresses Breast Cancer Cell Invasion and Migration +target gene hsa-mir-96 Diabetic Peripheral Neuropathy 29689688 Swimming Exercise Induced Reversed Expression of miR-96 and Its Target Gene NaV1.3 in Diabetic Peripheral Neuropathy in Rats +target gene hsa-mir-222 Liver Neoplasms 29693134 "miRNA?222 promotes liver cancer cell proliferation, migration and invasion and inhibits apoptosis by targeting BBC3." +target gene hsa-mir-145 Bladder Neoplasms 29693148 microRNA?145 modulates migration and invasion of bladder cancer cells by targeting N?cadherin. +target gene hsa-mir-125 Colorectal Carcinoma 29693153 MicroRNA?125 inhibits RKO colorectal cancer cell growth by targeting VEGF. +target gene hsa-mir-221 Myocardial Ischemic-Reperfusion Injury 29693157 MicroRNA?221?3p contributes to cardiomyocyte injury in H2O2?treated H9c2 cells and a rat model of myocardial ischemia?reperfusion by targeting p57. +target gene hsa-mir-146a "Carcinoma, Cervical" 29693168 miR-146a promotes cervical cancer cell viability via targeting IRAK1 and TRAF6. +target gene hsa-mir-384 "Carcinoma, Breast" 29693185 MicroRNA-384 inhibits the progression of breast cancer by targeting ACVR1. +target gene hsa-mir-27a Heart Diseases [unspecific] 29694513 miR-27a protects human mitral valve interstitial cell from TNF-¦Á-induced inflammatory injury via up-regulation of NELL-1. +target gene hsa-mir-1307 "Carcinoma, Breast" 29697201 Mir-1307 regulates cisplatin resistance by targeting Mdm4 in breast cancer expressing wild type P53. +target gene hsa-mir-382 Diabetic Nephropathy 29701296 Repression of microRNA-382 inhibits glomerular mesangial cell proliferation and extracellular matrix accumulation via FoxO1 in mice with diabetic nephropathy. +target gene hsa-mir-223 Colorectal Carcinoma 29701752 MiR-223 promotes the doxorubicin resistance of colorectal cancer cells via regulating epithelial-mesenchymal transition by targeting FBXW7. +target gene hsa-mir-98 "Carcinoma, Hepatocellular" 29702181 MiR-98 suppresses the effects of tumor-associated macrophages on promoting migration and invasion of hepatocellular carcinoma cells by regulating IL-10. +target gene hsa-mir-19 Osteosarcoma 29702193 miR-19a-mediated downregulation of RhoB inhibits the dephosphorylation of AKT1 and induces osteosarcoma cell metastasis. +target gene hsa-mir-124a "Carcinoma, Lung, Non-Small-Cell" 29702194 Tumor suppressive microRNA-124a inhibits stemness and enhances gefitinib sensitivity of non-small cell lung cancer cells by targeting ubiquitin-specific protease 14. +target gene hsa-mir-146a Coronavirus Infections 29702211 miR-146a-5p promotes replication of infectious bronchitis virus by targeting IRAK2 and TNFRSF18. +target gene hsa-mir-34a Atherosclerosis 29704100 Downregulation of miR-34a promotes endothelial cell growth and suppresses apoptosis in atherosclerosis by regulating Bcl-2. +target gene hsa-mir-502 Esophageal Neoplasms 29709473 MiR-502 mediates esophageal cancer cell TE1 proliferation by promoting AKT phosphorylation. +target gene hsa-mir-600 Colorectal Carcinoma 29710537 Hsa_circ_0071589 promotes carcinogenesis via the miR-600/EZH2 axis in colorectal cancer. +target gene hsa-mir-338 Melanoma 29710538 MiR-338-5p promotes the growth and metastasis of malignant melanoma cells via targeting CD82. +target gene hsa-mir-210 Myocardial Infarction 29710553 MicroRNA-210 aggravates hypoxia-induced injury in cardiomyocyte H9c2 cells by targeting CXCR4. +target gene hsa-mir-361 "Carcinoma, Thyroid, Papillary" 29710554 MicroRNA-361-5p inhibits papillary thyroid carcinoma progression by targeting ROCK1. +target gene hsa-mir-20a "Carcinoma, Cervical" 29710555 Up-regulation of miR-20a by HPV16 E6 exerts growth-promoting effects by targeting PDCD6 in cervical carcinoma cells. +target gene hsa-mir-340 Angiosarcoma 29710664 MicroRNA-340 inhibits the growth and invasion of angiosarcoma cells by targeting SIRT7. +target gene hsa-mir-30a Giant Cell Tumor of Bone 29710674 Norcantharidin modulates the miR-30a/Metadherin/AKT signaling axis to suppress proliferation and metastasis of stromal tumor cells in giant cell tumor of bone. +target gene hsa-mir-10a Glioma 29713056 Immunosuppressive effects of hypoxia-induced glioma exosomes through myeloid-derived suppressor cells via the miR-10a/Rora and miR-21/Pten Pathways. +target gene hsa-mir-21 Glioma 29713056 Immunosuppressive effects of hypoxia-induced glioma exosomes through myeloid-derived suppressor cells via the miR-10a/Rora and miR-21/Pten Pathways. +target gene hsa-mir-122 Stroke 29715465 Up-regulation of miR-122 protects against neuronal cell death in ischemic stroke through the heat shock protein 70-dependent NF-¦ÊB pathway by targeting FOXO3. +target gene hsa-mir-29c Prostate Neoplasms 29715514 Up-regulated miR-29c inhibits cell proliferation and glycolysis by inhibiting SLC2A3 expression in prostate cancer. +target gene hsa-mir-146a Human Immunodeficiency Virus Infection 29717615 HIV-1-Induced miR-146a Attenuates Monocyte Migration by Targeting CCL5 in Human Primary Macrophages. +target gene hsa-mir-652 Prostate Neoplasms 29721191 MicroRNA-652 induces NED in LNCaP and EMT in PC3 prostate cancer cells. +target gene hsa-mir-146 Colorectal Carcinoma 29722931 "miR-146b-5p was shown to increase EMT by targeting Smad4, and the miR-146b-5p-Smad4 cascade regulated EMT in CRC" +target gene hsa-mir-146b Colorectal Carcinoma 29722931 "MiR-146b-5p was shown to increase EMT by targeting Smad4, and the miR-146b-5p-Smad4 cascade regulated EMT in CRC" +target gene hsa-mir-876 "Carcinoma, Hepatocellular" 29724530 MiR-876-5p acts as an inhibitor in hepatocellular carcinoma progression by targeting DNMT3A. +target gene hsa-mir-505 Colorectal Carcinoma 29726011 MiR-505 mediates methotrexate resistance in colorectal cancer by targeting RASSF8. +target gene hsa-mir-154 "Squamous Cell Carcinoma, Skin or Unspecific" 29727714 Inhibitory effect of microRNA-154 targeting WHSC1 on cell proliferation of human skin squamous cell carcinoma through mediating the P53 signaling pathway. +target gene hsa-mir-545 Gastric Neoplasms 29733519 MiRNA-545 negatively regulates the oncogenic activity of EMS1 in gastric cancer. +target gene hsa-mir-301b Diabetes Mellitus 29733818 The miR-301b-AMPD3 axis may be a novel therapeutic target for intervening enegy metabolism in diabetic hearts +target gene hsa-mir-182 Acute Kidney Failure 29733821 miR-182 enhances acute kidney injury by promoting apoptosis involving the targeting and regulation of TCF7L2/Wnt/¦Â-catenins pathway. +target gene hsa-mir-339 "Leukemia, Lymphoblastic, Acute" 29735550 miR-339 Promotes Development of Stem Cell Leukemia/Lymphoma Syndrome via Downregulation of the BCL2L11 and BAX Proapoptotic Genes. +target gene hsa-mir-181a Atherosclerosis 29737518 MiR-181a inhibits vascular inflammation induced by ox-LDL via targeting TLR4 in human macrophages. +target gene hsa-mir-411 Spinal Cord Injuries 29738767 miR-411 suppresses acute spinal cord injury via downregulation of Fas ligand in rats. +target gene hsa-mir-130a "Carcinoma, Breast" 29746865 MiR-130a-3p inhibits migration and invasion by regulating RAB5B in human breast cancer stem cell-like cells. +target gene hsa-mir-26a Lung Neoplasms 29746867 MiR-26a-5p potentiates metastasis of human lung cancer cells by regulating ITG¦Â8- JAK2/STAT3 axis. +target gene hsa-mir-302e Allergic Asthma 29748238 MiR-302e attenuates allergic inflammation in vitro model by targeting RelA. +target gene hsa-mir-129 Wound Healing 29748291 MicroRNA-129 and -335 Promote Diabetic Wound Healing by Inhibiting Sp1-Mediated MMP-9 Expression. +target gene hsa-mir-335 Wound Healing 29748291 MicroRNA-129 and -335 Promote Diabetic Wound Healing by Inhibiting Sp1-Mediated MMP-9 Expression. +target gene hsa-mir-215 Hepatitis C Virus Infection 29749134 miR-215 Enhances HCV Replication by Targeting TRIM22 and Inactivating NF-¦ÊB Signaling. +target gene hsa-mir-145 "Carcinoma, Lung, Non-Small-Cell" 29749434 miR?145 inhibits human non?small-cell lung cancer growth by dual-targeting RIOK2 and NOB1. +target gene hsa-mir-125a "Carcinoma, Pancreatic" 29749475 "miR-125a induces apoptosis, metabolism disorder and migrationimpairment in pancreatic cancer cells by targeting Mfn2-related mitochondrial fission." +target gene hsa-mir-23a "Carcinoma, Pancreatic" 29749476 miR?23a suppresses pancreatic cancer cell progression by inhibiting PLK?1 expression. +target gene hsa-mir-486 Osteoarthritis 29749497 miR?486?5p is upregulated in osteoarthritis and inhibits chondrocyte proliferation and migration by suppressing SMAD2. +target gene hsa-mir-125b "Squamous Cell Carcinoma, Esophageal" 29749531 MicroRNA-125b inhibits cell proliferation and induces cell apoptosis in esophageal squamous cell carcinoma by targeting BMF. +target gene hsa-mir-23b "Squamous Cell Carcinoma, Esophageal" 29750239 MiR-23b-3p induces the proliferation and metastasis of esophageal squamous cell carcinomas cells through the inhibition of EBF3. +target gene hsa-mir-150 Colorectal Carcinoma 29750311 MicroRNA-150 inhibits the proliferation and metastasis potential of colorectal cancer cells by targeting iASPP. +target gene hsa-mir-196b "Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal" 29753737 miR-196b is a prognostic factor of human laryngeal squamous cell carcinoma and promotes tumor progression by targeting SOCS2. +target gene hsa-mir-665 Intervertebral Disc Degeneration 29761869 microRNA-665 promotes the proliferation and matrix degradation of nucleus pulposus through targeting GDF5 in intervertebral disc degeneration. +target gene hsa-mir-130 Myocardial Infarction 29761875 miR-130 aggravates acute myocardial infarction-induced myocardial injury by targeting PPAR-¦Ã. +target gene hsa-mir-216a Melanoma 29763606 MiR-216a-5p/Hexokinase 2 axis regulates uveal melanoma growth through modulation of Warburg effect. +target gene hsa-mir-141 Gastric Cardia Adenocarcinoma 29765447 MicroRNA-141 inhibits proliferation of gastric cardia adenocarcinoma by targeting MACC1. +target gene hsa-mir-142 "Carcinoma, Lung, Non-Small-Cell" 29767245 miR-142-5p regulates CD4+ T cells in human non-small cell lung cancer through PD-L1 expression via the PTEN pathway. +target gene hsa-mir-155 Lymphocytic Choriomeningitis 29768211 Long-Term Persistence of Exhausted CD8?T Cells in Chronic Infection Is Regulated by MicroRNA-155. +target gene hsa-mir-1247 Pneumonia 29768218 MicroRNA-1247 inhibits lipopolysaccharides-induced acute pneumonia in A549 cells via targeting CC chemokine ligand 16. +target gene hsa-mir-520h "Leukemia, Lymphoblastic, Acute" 29768346 "Additionally, POLD1 and MCM2 were found to be regulated by miR-520H via E2F1" +target gene hsa-let-7e Dengue Shock Syndrome 29768655 Let-7e inhibits TNF-¦Á expression by targeting the methyl transferase EZH2 in DENV2-infected THP-1 cells. +target gene hsa-mir-340 Osteosarcoma 29769415 "Upregulation of microRNA-340 promotes osteosarcoma cell apoptosis while suppressing proliferation, migration and invasion by inactivating the CTNNB1-mediated Notch signaling pathway." +target gene hsa-mir-92a "Squamous Cell Carcinoma, Oral" 29772443 MiR-92a regulates oral squamous cell carcinoma (OSCC) cell growth by targeting FOXP1 expression. +target gene hsa-mir-1231 Glioma 29774498 MicroRNA-1231 exerts a tumor suppressor role through regulating the EGFR/PI3K/AKT axis in glioma. +target gene hsa-mir-7 White Spot Syndrome Virus Infection 29775740 Eriocheir sinensis microRNA-7 targets crab Myd88 to enhance white spot syndrome virus replication. +target gene hsa-mir-608 "Carcinoma, Hepatocellular" 29777702 microRNA-608 inhibits human hepatocellular carcinoma cell proliferation via targeting the BET family protein BRD4. +target gene hsa-mir-616 Gastric Neoplasms 29777710 MiR-616-3p promotes angiogenesis and EMT in gastric cancer via the PTEN/AKT/mTOR pathway. +target gene hsa-mir-129 Ovarian Neoplasms 29777711 UCA1 confers paclitaxel resistance to ovarian cancer through miR-129/ABCB1 axis. +target gene hsa-mir-663a "Carcinoma, Gallbladder" 29778567 "EMP3, which is regulated by miR-663a, suppresses gallbladder cancer progression via interference with the MAPK/ERK pathway." +target gene hsa-mir-485 Colorectal Carcinoma 29781037 MicroRNA-485 plays tumour-suppressive roles in colorectal cancer by directly targeting GAB2. +target gene hsa-mir-1178 Tuberculosis 29781535 MiR-1178 regulates mycobacterial survival and inflammatory responses in Mycobacterium tuberculosis-infected macrophages partly via TLR4. +target gene hsa-mir-19a Ovarian Neoplasms 29783075 MiR-19a negatively regulated the expression of PTEN and promoted the growth of ovarian cancer cells. +target gene hsa-mir-155 Hypertrophic Scar 29785488 miR-155 inhibits the formation of hypertrophic scar fibroblasts by targeting HIF-1¦Á via PI3K/AKT pathway. +target gene hsa-mir-494 Gastric Neoplasms 29786108 miR?494 inhibits cancer?initiating cell phenotypes and reverses resistance to lapatinib by downregulating FGFR2 in HER2?positive gastric cancer. +target gene hsa-mir-137 "Diabetes Mellitus, Gestational" 29786111 High glucose suppresses the viability and proliferation of HTR?8/SVneo cells through regulation of the miR?137/PRKAA1/IL?6 axis. +target gene hsa-mir-137 Osteoporosis 29786747 MicroRNA-137 dysregulation predisposes to osteoporotic fracture by impeding ALP activity and expression via suppression of leucine-rich repeat-containing G-protein-coupled receptor 4 expression. +target gene hsa-mir-20b Ischemia-Reperfusion Injury 29786750 MicroRNA?20b?5p promotes ventricular remodeling by targeting the TGF?¦Â/Smad signaling pathway in a rat model of ischemia?reperfusion injury. +target gene hsa-mir-24 Obesity 29787826 Obesity-induced overexpression of miRNA-24 regulates cholesterol uptake and lipid metabolism by targeting SR-B1. +target gene hsa-mir-216b Glioma 29787989 Downregulation of microRNA-216b contributes to glioma cell growth and migration by promoting AEG-1-mediated signaling. +target gene hsa-mir-320a MALT Lymphoma 29788729 "the TF MYC was a co-target of miR-320a, miR-622, and miR-429" +target gene hsa-mir-429 MALT Lymphoma 29788729 "the TF MYC was a co-target of miR-320a, miR-622, and miR-429" +target gene hsa-mir-622 MALT Lymphoma 29788729 "the TF MYC was a co-target of miR-320a, miR-622, and miR-429" +target gene hsa-mir-378 Diabetic Nephropathy 29792879 Astragaloside suppresses apoptosis of the podocytes in rats with diabetic nephropathy via miR-378/TRAF5 signaling pathway. +target gene hsa-mir-20a Toxoplasma gondii Infection 29800695 miR-20a inhibition using locked nucleic acid (LNA) technology and its effects on apoptosis of human macrophages infected by Toxoplasma gondii RH strain. +target gene hsa-mir-505 "Carcinoma, Hepatocellular" 29803174 miR-505 enhances doxorubicin-induced cytotoxicity in hepatocellular carcinoma through repressing the Akt pathway by directly targeting HMGB1. +target gene hsa-mir-155 Atherosclerosis 29803178 MiR-155 inhibits transformation of macrophages into foam cells via regulating CEH expression. +target gene hsa-mir-320a "Carcinoma, Lung, Non-Small-Cell" 29803922 MiR-320a-3p/ELF3 axis regulates cell metastasis and invasion in non-small cell lung cancer via PI3K/Akt pathway. +target gene hsa-mir-33a "Squamous Cell Carcinoma, Tongue" 29804249 Long non-coding RNA CASC15 promotes tongue squamous carcinoma progression through targeting miR-33a-5p. +target gene hsa-mir-124 Congenital Hypothyroidism 29805523 microRNA-124-3p inhibits the progression of congenital hypothyroidism via targeting programmed cell death protein 6. +target gene hsa-mir-128 "Carcinoma, Pancreatic" 29805525 miR-128 induces pancreas cancer cell apoptosis by targeting MDM4. +target gene hsa-mir-381 Viral Myocarditis 29805552 MicroRNA-381 protects myocardial cell function in children and mice with viral myocarditis via targeting cyclooxygenase-2 expression. +target gene hsa-mir-206 Prostate Neoplasms 29805562 MicroRNA-206 regulates the epithelial-mesenchymal transition and inhibits the invasion and metastasis of prostate cancer cells by targeting Annexin A2. +target gene hsa-mir-100 Nasopharyngeal Neoplasms 29805566 miR-100 inhibits the migration and invasion of nasopharyngeal carcinoma by targeting IGF1R. +target gene hsa-mir-23a Gastric Neoplasms 29805579 microRNA-23a promotes cell growth and metastasis in gastric cancer via targeting SPRY2-mediated ERK signaling. +target gene hsa-mir-128 Osteosarcoma 29805606 Regulatory mechanism of microRNA-128 in osteosarcoma tumorigenesis and evolution through targeting SASH1. +target gene hsa-mir-126 Prostate Neoplasms 29805636 MicroRNA-126 inhibits proliferation and metastasis in prostate cancer via regulation of ADAM9. +target gene hsa-mir-3160 Prostate Neoplasms 29805667 Prostate cancer cell proliferation is suppressed by microRNA-3160-5p via targeting of F-box and WD repeat domain containing 8. +target gene hsa-mir-206 Ovarian Neoplasms 29807226 MiR-206 inhibits epithelial ovarian cancer cells growth and invasion via blocking c-Met/AKT/mTOR signaling pathway. +target gene hsa-mir-155 Lichen Planus 29813046 MicroRNA Microarray-Based Identification of Involvement of miR-155 and miR-19a in Development of Oral Lichen Planus (OLP) by Modulating Th1/Th2 Balance via Targeting eNOS and Toll-Like Receptor 2 (TLR2). +target gene hsa-mir-19a Lichen Planus 29813046 MicroRNA Microarray-Based Identification of Involvement of miR-155 and miR-19a in Development of Oral Lichen Planus (OLP) by Modulating Th1/Th2 Balance via Targeting eNOS and Toll-Like Receptor 2 (TLR2). +target gene hsa-mir-4497 "Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal" 29843929 MicroRNA-4497 functions as a tumor suppressor in laryngeal squamous cell carcinoma via negatively modulation the GBX2. +target gene hsa-mir-148b Wound Healing 29843955 MicroRNA-148b Targets the TGF-¦Â Pathway to Regulate Angiogenesis and Endothelial-to-Mesenchymal Transition during Skin Wound Healing. +target gene hsa-mir-181a Osteoporosis 29845202 Regulatory effects of miRNA?181a on FasL expression in bone marrow mesenchymal stem cells and its effect on CD4+T lymphocyte apoptosis in estrogen deficiency?induced osteoporosis. +target gene hsa-mir-148a Endometriosis 29845209 G protein?coupled estrogen receptor/miR?148a/human leukocyte antigen?G signaling pathway mediates cell apoptosis of ovarian endometriosis. +target gene hsa-mir-215 Endometrial Neoplasms 29845221 miR?215 promotes epithelial to mesenchymal transition and proliferation by regulating LEFTY2 in endometrial cancer. +target gene hsa-mir-449a "Squamous Cell Carcinoma, Esophageal" 29845226 Downregulation of microRNA?449a?5p promotes esophageal squamous cell carcinoma cell proliferation via cyclin D1 regulation. +target gene hsa-mir-19b Melanoma 29845233 Matrine exerts inhibitory effects in melanoma through the regulation of miR-19b-3p/PTEN. +target gene hsa-mir-1 Colon Neoplasms 29845255 miR?1 inhibits the progression of colon cancer by regulating the expression of vascular endothelial growth factor. +target gene hsa-mir-23a Sepsis 29845275 miR?23a downregulation modulates the inflammatory response by targeting ATG12?mediated autophagy. +target gene hsa-mir-183 Osteosarcoma 29845278 Baicalein inhibits osteosarcoma cell proliferation and invasion through the miR?183/Ezrin pathway. +target gene hsa-mir-613 Osteosarcoma 29845707 CXCR4-mediated osteosarcoma growth and pulmonary metastasis is suppressed by MicroRNA-613. +target gene hsa-mir-193a Gastric Neoplasms 29848678 MiR-193a-5p and -3p Play a Distinct Role in Gastric Cancer: miR-193a-3p Suppresses Gastric Cancer Cell Growth by Targeting ETS1 and CCND1. +target gene hsa-mir-203 Oral Neoplasms 29848700 MicroRNA-203 Induces Apoptosis by Targeting Bmi-1 in YD-38 Oral Cancer Cells. +target gene hsa-mir-204 Arterial Calcification of Infancy 29850805 Arterial Calcification Is Regulated Via an miR-204/DNMT3a Regulatory Circuit Both In Vitro and in Female Mice. +target gene hsa-mir-497 Ischemia-Reperfusion Injury 29852387 MicroRNA-497 promotes proliferation and inhibits apoptosis of cardiomyocytes through the downregulation of Mfn2 in a mouse model of myocardial ischemia-reperfusion injury. +target gene hsa-mir-124 Lichen Planus 29852392 Total glucosides of paeony improves the immunomodulatory capacity of MSCs partially via the miR-124/STAT3 pathway in oral lichen planus. +target gene hsa-mir-143 Myocardial Infarction 29858017 By Targeting Atg7 MicroRNA-143 Mediates Oxidative Stress-Induced Autophagy of c-Kit+ Mouse Cardiac Progenitor Cells. +target gene hsa-mir-106a Osteoarthritis 29858052 Cryptotanshinone Protects Cartilage against Developing Osteoarthritis through the miR-106a-5p/GLIS3 Axis. +target gene hsa-mir-411 "Carcinoma, Bladder" 29858066 MicroRNA-411 Downregulation Enhances Tumor Growth by Upregulating MLLT11 Expression in Human Bladder Cancer. +target gene hsa-mir-199a "Carcinoma, Hepatocellular" 29858083 miR-199a-3p Modulates MTOR and PAK4 Pathways and Inhibits Tumor Growth in a Hepatocellular Carcinoma Transgenic Mouse Model. +target gene hsa-mir-27b Ocular Motility Disease 29858119 Down-regulation of microRNA-27b promotes retinal pigment epithelial cell proliferation and migration by targeting Nox2. +target gene hsa-mir-365 Melanoma 29858490 MicroRNA-365 Inhibits Cell Growth and Promotes Apoptosis in Melanoma by Targeting BCL2 and Cyclin D1 (CCND1). +target gene hsa-mir-487a "Diabetes Mellitus, Type 1" 29859273 miR-487a-3p upregulated in type 1 diabetes targets CTLA4 and FOXO3. +target gene hsa-mir-1179 "Carcinoma, Pancreatic" 29859832 "MicroRNA-1179 inhibits the proliferation, migration and invasion of human pancreatic cancer cells by targeting E2F5." +target gene hsa-mir-18a Lung Neoplasms 29860718 Radiosensitizing effects of miR-18a-5p on lung cancer stem-like cells via downregulating both ATM and HIF-1¦Á. +target gene hsa-mir-19 "Carcinoma, Breast" 29864457 miR-19 targeting of PTEN mediates butyl benzyl phthalate-induced proliferation in both ER(+) and ER(-) breast cancer cells. +target gene hsa-mir-214 "Squamous Cell Carcinoma, Esophageal" 29864623 MiR-214 promotes cell meastasis and inhibites apoptosis of esophageal squamous cell carcinoma via PI3K/AKT/mTOR signaling pathway. +target gene hsa-mir-196b Gastric Neoplasms 29864624 MicroRNA-196b enhances the radiosensitivity of SNU-638 gastric cancer cells by targeting RAD23B. +target gene hsa-mir-876 Psoriasis 29864894 MiR-876-5p suppresses cell proliferation by targeting Angiopoietin-1 in the psoriasis. +target gene hsa-mir-125b "Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal" 29864898 MiR-125b-5p suppressed the glycolysis of laryngeal squamous cell carcinoma by down-regulating hexokinase-2. +target gene hsa-mir-23a Pulmonary Hypertension 29864909 MiR-23a regulates the proliferation and migration of human pulmonary artery smooth muscle cells (HPASMCs) through targeting BMPR2/Smad1 signaling. +target gene hsa-mir-101 Endometrial Neoplasms 29864910 Berberine suppresses growth and metastasis of endometrial cancer cells via miR-101/COX-2. +target gene hsa-mir-129 Neuroblastoma 29864913 miR-129 inhibits tumor growth and potentiates chemosensitivity of neuroblastoma by targeting MYO10. +target gene hsa-mir-20a "Carcinoma, Breast, Triple Negative" 29864933 MiRNA-20a-5p promotes the growth of triple-negative breast cancer cells through targeting RUNX3. +target gene hsa-mir-200b Metabolic Syndrome 29864940 MicroRNA-200b regulates preadipocyte proliferation and differentiation by targeting KLF4. +target gene hsa-mir-300 "Carcinoma, Hepatocellular" 29864952 miR-300 regulates the epithelial-mesenchymal transition and invasion of hepatocellular carcinoma by targeting the FAK/PI3K/AKT signaling pathway. +target gene hsa-mir-140 Cardiovascular Diseases [unspecific] 29864954 miR-140-5p aggravates hypoxia-induced cell injury via regulating MLK3 in H9c2 cells. +target gene hsa-mir-199a Osteosarcoma 29866054 MiR-199a-3p affects the multi-chemoresistance of osteosarcoma through targeting AK4. +target gene hsa-mir-363 "Adenocarcinoma, Cervical" 29871972 MiR-362-3p functions as a tumor suppressor through targeting MCM5 in cervical adenocarcinoma. +target gene hsa-mir-1247 "Carcinoma, Bladder" 29872024 Inhibition of miR-1247 on cell proliferation and invasion in bladder cancer through its downstream target of RAB36. +target gene hsa-mir-154 "Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal" 29874469 MiR-154 inhibits the growth of laryngeal squamous cell carcinoma by targeting the GALNT7. +target gene hsa-mir-17 Sciatic Nerve Injury 29877111 PEITC promotes neurite growth in primary sensory neurons via the miR-17-5p/STAT3/GAP-43 axis. +target gene hsa-mir-129 Gastric Neoplasms 29879625 MiR-129-5p functions as a tumor suppressor in gastric cancer progression through targeting ADAM9. +target gene hsa-mir-21 Periodontitis 29884447 MicroRNA-21 down-regulates inflammation and inhibits periodontitis. +target gene hsa-mir-1 "Cardiomyopathy, Hypertrophic" 29885652 Clcn3 as a direct target of miR-1-3p which sheds light on the mechanism of HCM +target gene hsa-mir-125a "Adenocarcinoma, Esophageal" 29885883 "microRNA 125a Regulates MHC-I Expression on Esophageal Adenocarcinoma Cells, Associated With Suppression of Antitumor Immune Response and Poor Outcomes of Patients." +target gene hsa-mir-206 "Carcinoma, Breast" 29886033 Down-regulation of NAMPT expression by mir-206 reduces cell survival of breast cancer cells. +target gene hsa-mir-20a Skin Disease [unspecific] 29886071 MiR-20a-3p regulates TGF-¦Â1/Survivin pathway to affect keratinocytes proliferation and apoptosis by targeting SFMBT1 in vitro. +target gene hsa-mir-208a Gastric Neoplasms 29886152 MiR-208a enhances cell proliferation and invasion of gastric cancer by targeting SFRP1 and negatively regulating MEG3. +target gene hsa-mir-199a "Leukemia, Myeloid, Chronic" 29890129 microRNA-199a/b-5p enhance imatinib efficacy via repressing WNT2 signaling-mediated protective autophagy in imatinib-resistant chronic myeloid leukemia cells. +target gene hsa-mir-199b "Leukemia, Myeloid, Chronic" 29890129 microRNA-199a/b-5p enhance imatinib efficacy via repressing WNT2 signaling-mediated protective autophagy in imatinib-resistant chronic myeloid leukemia cells. +target gene hsa-mir-873 Esophageal Neoplasms 29890466 MicroRNA-873 acts as a tumor suppressor in esophageal cancer by inhibiting differentiated embryonic chondrocyte expressed gene 2. +target gene hsa-mir-3200 Osteosarcoma 29890825 MicroRNA-3200-5p Promotes Osteosarcoma Cell Invasion via Suppression of BRMS1. +target gene hsa-mir-744 Ovarian Neoplasms 29899543 MiR-744-5p inducing cell death by directly targeting HNRNPC and NFIX in ovarian cancer cells. +target gene hsa-mir-30a Melanoma 29901141 "miR?30a?5p inhibits the proliferation, migration and invasion of melanoma cells by targeting SOX4." +target gene hsa-mir-125b Alzheimer Disease 29901156 MicroRNA?125b regulates Alzheimer's disease through SphK1 regulation. +target gene hsa-mir-23b "Carcinoma, Hepatocellular" 29901200 miR?23b inhibits proliferation of SMMC?7721 cells by directly targeting IL?11. +target gene hsa-mir-142 Ovarian Neoplasms 29904404 MicroRNA-142-3p inhibits cell proliferation and chemoresistance in ovarian cancer via targeting sirtuin 1. +target gene hsa-mir-106b Cholesteatoma 29905392 Down-regulation of exosomal miR-106b-5p derived from cholesteatoma perimatrix fibroblasts promotes angiogenesis in endothelial cells by overexpression of Angiopoietin 2. +target gene hsa-mir-149 Diabetes Mellitus 29905828 miR-149 negative regulation of mafA is involved in the arsenite-induced dysfunction of insulin synthesis and secretion in pancreatic beta cells. +target gene hsa-mir-145 Idiopathic Scoliosis 29906249 Aberrant miR-145-5p/¦Â-catenin signal impairs osteocyte function in adolescent idiopathic scoliosis. +target gene hsa-mir-302c Colorectal Carcinoma 29906744 MicroRNA-302c represses epithelial-mesenchymal transition and metastasis by targeting transcription factor AP-4 in colorectal cancer. +target gene hsa-mir-30 Neoplasms [unspecific] 29907771 miR-30 disrupts senescence and promotes cancer by targeting both p16INK4A and DNA damage pathways. +target gene hsa-mir-181a Myocardial Infarction 29908129 upregulation of miR-181a suppressed the expression of TGF-¦Â receptor III (T¦ÂRIII) by binding with 3'-UTR +target gene hsa-mir-499a Glioma 29908894 MicroRNA-499a decelerates glioma cell proliferation while accelerating apoptosis through the suppression of Notch1 and the MAPK signaling pathway. +target gene hsa-mir-590 Crohn Disease 29912317 MicroRNA-590-5p Inhibits Intestinal Inflammation by Targeting YAP. +target gene hsa-mir-146a "Carcinoma, Breast" 29915929 Identification of miR-146a is Associated with the Aggressiveness and Suppresses Proliferation via Targeting CDKN2A in Breast Cancer. +target gene hsa-mir-590 Osteosarcoma 29916536 miR?590?5p suppresses osteosarcoma cell proliferation and invasion via targeting KLF5. +target gene hsa-mir-1297 "Carcinoma, Cervical" 29916735 MicroRNA-1297 contributes to the progression of human cervical carcinoma through PTEN. +target gene hsa-mir-324 Polycystic Ovarian Syndrome 29917177 The role of MiR-324-3p in polycystic ovary syndrome (PCOS) via targeting WNT2B. +target gene hsa-mir-148a Glioblastoma 29921422 Exosomes of glioma cells deliver miR-148a to promote proliferation and metastasis of glioblastoma via targeting CADM1. +target gene hsa-mir-370 "Adenocarcinoma, Colon" 29922946 Hsa-miR-370 inhibited P-selectin-induced cell adhesion in human colon adenocarcinoma cells. +target gene hsa-mir-96 "Carcinoma, Bladder" 29923283 miR-96 regulates migration and invasion of bladder cancer through epithelial-mesenchymal transition in response to transforming growth factor-¦Â1. +target gene hsa-mir-182 "Carcinoma, Breast" 29925897 miR-182 regulates trastuzumab resistance by targeting MET in breast cancer cells. +target gene hsa-mir-197 "Carcinoma, Cervical" 29928375 miR-197 is downregulated in cervical carcinogenesis and suppresses cell proliferation and invasion through targeting forkhead box M1. +target gene hsa-mir-216b "Carcinoma, Lung, Non-Small-Cell" 29928377 MicroRNA-216b regulated proliferation and invasion of non-small cell lung cancer by targeting SOX9. +target gene hsa-mir-154 "Carcinoma, Lung, Non-Small-Cell" 29928380 MicroRNA-154 functions as a tumor suppressor in non-small cell lung cancer through directly targeting B-cell-specific Moloney murine leukemia virus insertion site 1. +target gene hsa-mir-423 Glioma 29928399 MicroRNA-423-3p promotes glioma growth by targeting PANX2. +target gene hsa-mir-196b Lung Neoplasms 29928408 miR-196b promotes lung cancer cell migration and invasion through the targeting of GATA6. +target gene hsa-mir-449c Gastric Neoplasms 29928430 miR-449c inhibits migration and invasion of gastric cancer cells by targeting PFKFB3. +target gene hsa-mir-409 "Squamous Cell Carcinoma, Tongue" 29928443 "miR-409-3p suppresses the proliferation, invasion and migration of tongue squamous cell carcinoma via targeting RDX." +target gene hsa-mir-455 "Carcinoma, Renal Cell" 29928475 Anti-tumor roles of both strands of the miR-455 duplex: their targets SKA1 and SKA3 are involved in the pathogenesis of renal cell carcinoma. +target gene hsa-mir-146a Lung Neoplasms 29928483 miR-146a suppresses 5-lipoxygenase activating protein (FLAP) expression and Leukotriene B4 production in lung cancer cells. +target gene hsa-mir-26a Acute Kidney Failure 29932234 miR-26a modulates HGF and STAT3 effects on the kidney repair process in a glycerol-induced AKI model in rats. +target gene hsa-mir-455 Diabetic Nephropathy 29932921 MiR-455-3p suppresses renal fibrosis through repression of ROCK2 expression in diabetic nephropathy. +target gene hsa-mir-16 "Carcinoma, Hepatocellular" 29935185 Inhibition of microRNA-16 facilitates the paclitaxel resistance by targeting IKBKB via NF-¦ÊB signaling pathway in hepatocellular carcinoma. +target gene hsa-mir-17 Neoplasms [unspecific] 29935344 MicroRNAs of miR-17-92 cluster increase gene expression by targeting mRNA-destabilization pathways. +target gene hsa-mir-18 Neoplasms [unspecific] 29935344 MicroRNAs of miR-17-92 cluster increase gene expression by targeting mRNA-destabilization pathways. +target gene hsa-mir-19a Neoplasms [unspecific] 29935344 MicroRNAs of miR-17-92 cluster increase gene expression by targeting mRNA-destabilization pathways. +target gene hsa-mir-19b-1 Neoplasms [unspecific] 29935344 MicroRNAs of miR-17-92 cluster increase gene expression by targeting mRNA-destabilization pathways. +target gene hsa-mir-20a Neoplasms [unspecific] 29935344 MicroRNAs of miR-17-92 cluster increase gene expression by targeting mRNA-destabilization pathways. +target gene hsa-mir-92-1 Neoplasms [unspecific] 29935344 MicroRNAs of miR-17-92 cluster increase gene expression by targeting mRNA-destabilization pathways. +target gene hsa-mir-340 "Carcinoma, Lung, Non-Small-Cell" 29935356 Lower miR-340 expression predicts poor prognosis of non-small cell lung cancer and promotes cell proliferation by targeting CDK4. +target gene hsa-mir-30a Osteosarcoma 29936179 MiR-30a-5p inhibits c cell proliferation and migration by targeting FOXD1. +target gene hsa-mir-200a Alzheimer Disease 29936262 Modulation in miR-200a/SIRT1axis is associated with apoptosis in MPP+-induced SH-SY5Y cells. +target gene hsa-mir-30a Parkinson Disease 29936662 these DEGs may be regulated by miRNAs of the miR-30 family and TFs STAT1 and GRHL3 +target gene hsa-mir-30b Parkinson Disease 29936662 these DEGs may be regulated by miRNAs of the miR-30 family and TFs STAT1 and GRHL3 +target gene hsa-mir-30c-1 Parkinson Disease 29936662 these DEGs may be regulated by miRNAs of the miR-30 family and TFs STAT1 and GRHL3 +target gene hsa-mir-30c-2 Parkinson Disease 29936662 these DEGs may be regulated by miRNAs of the miR-30 family and TFs STAT1 and GRHL3 +target gene hsa-mir-30d Parkinson Disease 29936662 these DEGs may be regulated by miRNAs of the miR-30 family and TFs STAT1 and GRHL3 +target gene hsa-mir-30e Parkinson Disease 29936662 these DEGs may be regulated by miRNAs of the miR-30 family and TFs STAT1 and GRHL3 +target gene hsa-mir-155 Acute Pancreatitis 29937734 MiRNA-155 Regulates the Th17/Treg Ratio by Targeting SOCS1 in Severe Acute Pancreatitis. +target gene hsa-mir-483 Perlman Syndrome 29939354 IGF2-derived miR-483-3p contributes to macrosomia through regulating trophoblast proliferation by targeting RB1CC1. +target gene hsa-mir-204 Gastric Neoplasms 29940566 Sensitization of Gastric Cancer Cells to 5-FU by MicroRNA-204 Through Targeting the TGFBR2-Mediated Epithelial to Mesenchymal Transition. +target gene hsa-mir-20a Colorectal Carcinoma 29940575 Knockdown of MiR-20a Enhances Sensitivity of Colorectal Cancer Cells to Cisplatin by Increasing ASK1 Expression. +target gene hsa-mir-29b-2 "Adenocarcinoma, Pancreatic Ductal" 29940895 MicroRNA-29b-2-5p inhibits cell proliferation by directly targeting Cbl-b in pancreatic ductal adenocarcinoma. +target gene hsa-mir-126 Diabetes Mellitus 29942117 Icariside II ameliorates endothelial dysfunction by regulating the MAPK pathway via miR-126/SPRED1 in diabetic human cavernous endothelial cells. +target gene hsa-mir-488 "Squamous Cell Carcinoma, Tongue" 29946339 MicroRNA-488 inhibits tongue squamous carcinoma cell invasion and EMT by directly targeting ATF3. +target gene hsa-mir-195 Colon Neoplasms 29948330 MiR-195 suppresses colon cancer proliferation and metastasis by targeting WNT3A. +target gene hsa-mir-199a Spinal Cord Injuries 29948551 Upregulation of miR-199a-5p Protects Spinal Cord Against Ischemia/Reperfusion-Induced Injury via Downregulation of ECE1 in Rat. +target gene hsa-mir-378 Glioma 29949160 "MicroRNA-378 acts as a prognosis marker and inhibits cell migration, invasion and epithelial-mesenchymal transition in human glioma by targeting IRG1." +target gene hsa-mir-592 Gastric Neoplasms 29949784 "MiR-592 Promotes Gastric Cancer Proliferation, Migration, and Invasion Through the PI3K/AKT and MAPK/ERK Signaling Pathways by Targeting Spry2." +target gene hsa-mir-142 Atherosclerosis 29949787 MicroRNA-142-3p Induces Atherosclerosis-Associated Endothelial Cell Apoptosis by Directly Targeting Rictor. +target gene hsa-mir-146b Sepsis 29951922 MiR-146b protect against sepsis induced mice myocardial injury through inhibition of Notch1. +target gene hsa-mir-155 Ischemia-Reperfusion Injury 29951932 minocycline is neuroprotective against ischemic brain injury through their modulation of miR-155-mediated BDNF repression +target gene hsa-mir-351 Ischemia-Reperfusion Injury 29952043 MicroRNA-351-5p aggravates intestinal ischaemia/reperfusion injury through the targeting of MAPK13 and Sirtuin-6. +target gene hsa-mir-26a Idiopathic Pulmonary Fibrosis 29952219 Inhibition of lncRNA PFRL prevents pulmonary fibrosis by disrupting the miR-26a/smad2 loop. +target gene hsa-mir-210 Cholangiocarcinoma 29953500 Potential role of HIF-1-responsive microRNA210/HIF3 axis on gemcitabine resistance in cholangiocarcinoma cells. +target gene hsa-mir-1287 "Carcinoma, Hepatocellular" 29953647 "Mir-1287 suppresses the proliferation, invasion, and migration in hepatocellular carcinoma by targeting PIK3R3." +target gene hsa-mir-146a Liver Fibrosis 29953648 microRNA-146a is involved in rSjP40-inhibited activation of LX-2 cells by targeting Smad4 expression. +target gene hsa-mir-34a Liver Fibrosis 29957876 MicroRNA-34a-5p inhibits liver fibrosis by regulating TGF-¦Â1/Smad3 pathway in hepatic stellate cells. +target gene hsa-mir-9 "Carcinoma, Head And Neck" 29959873 "MicroRNA-9 inhibits growth and invasion of head and neck cancer cells and is a predictive biomarker of response to plerixafor, an inhibitor of its target CXCR4." +target gene hsa-mir-320 Diabetes Mellitus 29960867 miR-320 mediates diabetes amelioration after duodenal-jejunal bypass via targeting adipoR1. +target gene hsa-mir-135 "Squamous Cell Carcinoma, Esophageal" 29961392 miR-135 promotes proliferation and stemness of oesophageal squamous cell carcinoma by targeting RERG. +target gene hsa-mir-15b Alzheimer Disease 29961672 miR-15b Reduces Amyloid-¦Â Accumulation in SH-SY5Y Cell Line through Targeting NF-¦ÊB signaling and BACE1. +target gene hsa-mir-20a Multiple Myeloma 29963125 "Effects of microRNA-20a on the proliferation, migration and apoptosis of multiple myeloma via the PTEN/PI3K/AKT signaling pathway." +target gene hsa-mir-139 Prostate Neoplasms 29963147 MicroRNA-139-5P inhibits human prostate cancer cell proliferation by targeting Notch1. +target gene hsa-mir-222 "Carcinoma, Ovarian" 29963173 miR-222 promotes invasion and migration of ovarian carcinoma by targeting PTEN. +target gene hsa-mir-599 Glioma 29963197 MicroRNA-599 suppresses glioma progression by targeting RAB27B. +target gene hsa-mir-328 "Carcinoma, Breast, Triple Negative" 29964098 Dihydrotestosterone regulates expression of CD44 via miR-328-3p in triple-negative breast cancer cells. +target gene hsa-mir-144 "Carcinoma, Renal Cell" 29968393 Regulation of antitumor miR-144-5p targets oncogenes: Direct regulation of syndecan-3 and its clinical significance. +target gene hsa-mir-760 "Carcinoma, Hepatocellular" 29968951 MicroRNA-760 Inhibits Doxorubicin Resistance in Hepatocellular Carcinoma through Regulating Notch1/Hes1-PTEN/Akt Signaling Pathway. +target gene hsa-mir-31 Melanoma 29969627 The miR-31-SOX10 axis regulates tumor growth and chemotherapy resistance of melanoma via PI3K/AKT pathway. +target gene hsa-mir-500a "Carcinoma, Hepatocellular" 29969781 MicroRNA-500a Promotes the Progression of Hepatocellular Carcinoma by Post-Transcriptionally Targeting BID. +target gene hsa-mir-98 "Adenocarcinoma, Pancreatic Ductal" 29970191 Downregulated miR-98-5p promotes PDAC proliferation and metastasis by reversely regulating MAP4K4. +target gene hsa-mir-378 Melanoma 29972255 MicroRNA-378 regulates epithelial-mesenchymal transition and metastasis of melanoma by inhibiting FOXN3 expression through the Wnt/¦Â-catenin pathway. +target gene hsa-mir-203a Gastric Neoplasms 29973668 MiR-99b-5p and miR-203a-3p Function as Tumor Suppressors by Targeting IGF-1R in Gastric Cancer. +target gene hsa-mir-99b Gastric Neoplasms 29973668 MiR-99b-5p and miR-203a-3p Function as Tumor Suppressors by Targeting IGF-1R in Gastric Cancer. +target gene hsa-let-7a Atopic Dermatitis 29974487 "Hsa-let-7a-5p may target CCR7, and hsa-miR-26a-5p probably targets HAS3" +target gene hsa-mir-26a Atopic Dermatitis 29974487 "Hsa-let-7a-5p may target CCR7, and hsa-miR-26a-5p probably targets HAS3" +target gene hsa-mir-106b "Carcinoma, Hepatocellular" 29975452 MiR-106b regulates the apoptosis and tumorigenesis of hepatocellular carcinoma via targeting Zinc finger and BTB domain-containing protein 7A (Zbtb7a). +target gene hsa-mir-137 "Carcinoma, Breast, Triple Negative" 29975921 MiR-137 Suppresses Triple-Negative Breast Cancer Stemness and Tumorigenesis by Perturbing BCL11A-DNMT1 Interaction. +target gene hsa-mir-424 "Carcinoma, Hepatocellular" 29975928 "Focusing on the new insight of the PVT1/miR-424-5p/INCENP axis, this study provides a novel perspective for HCC therapeutic strategies" +target gene hsa-mir-100 "Carcinoma, Breast" 29975932 miR-100 Reverses Cisplatin Resistance in Breast Cancer by Suppressing HAX-1. +target gene hsa-mir-711 Kaposi Sarcoma 29976660 Upregulation of MicroRNA 711 Mediates HIV-1 Vpr Promotion of Kaposi's Sarcoma-Associated Herpesvirus Latency and Induction of Pro-proliferation and Pro-survival Cytokines by Targeting the Notch/NF-¦ÊB-Signaling Axis. +target gene hsa-mir-103 Atherosclerosis 29980665 miR-103 promotes endothelial maladaptation by targeting lncWDR59. +target gene hsa-mir-340 Age-Related Macular Degeneration 29982095 MiR-340/iASPP axis affects UVB-mediated retinal pigment epithelium (RPE) cell damage. +target gene hsa-mir-92a Osteosarcoma 29984257 MiR-92a Inhibits the Progress of Osteosarcoma Cells and Increases the Cisplatin Sensitivity by Targeting Notch1. +target gene hsa-mir-498 "Carcinoma, Breast" 29985991 MicroRNA-498 promotes proliferation and migration by targeting the tumor suppressor PTEN in breast cancer cells. +target gene hsa-mir-124 "Adenocarcinoma, Pancreatic Ductal" 29988949 Involvement of anti-tumor miR-124-3p and its targets in the pathogenesis of pancreatic ductal adenocarcinoma: direct regulation of ITGA3 and ITGB1 by miR-124-3p. +target gene hsa-mir-146a Infection [unspecific] 29990507 MiR-146a-3p and miR-216a-5p inhibited the expression of type-I IFN and the Mx1 gene induced by IHNV +target gene hsa-mir-216a Infection [unspecific] 29990507 MiR-146a-3p and miR-216a-5p inhibited the expression of type-I IFN and the Mx1 gene induced by IHNV +target gene hsa-mir-193b Liver Injury 29990747 MicroRNA-193b-3p regulates hepatocyte apoptosis in selenium-deficient broilers by targeting MAML1. +target gene hsa-mir-298 "Carcinoma, Hepatocellular" 29990836 MicroRNA-298 represses hepatocellular carcinoma progression by inhibiting CTNND1-mediated Wnt/¦Â-catenin signaling. +target gene hsa-mir-218 "Squamous Cell Carcinoma, Oral" 29990854 Downregulation of miR-218-5p promotes invasion of oral squamous cell carcinoma cells via activation of CD44-ROCK signaling. +target gene hsa-mir-34a Osteosarcoma 29991717 miR-34a exerts as a key regulator in the dedifferentiation of osteosarcoma via PAI-1-Sox2 axis. +target gene hsa-mir-223 Osteosarcoma 29991755 "miR-223-5p/(CLSTN2, AC009951.1, LINC01705, AC090673.1), miR-378b/(ALX4, IGSF3, SULF1), and miR-323b-3p/TGFBR3 were involved in both tumorigenesis and pulmonary metastasis of OS." +target gene hsa-mir-323b Osteosarcoma 29991755 "miR-223-5p/(CLSTN2, AC009951.1, LINC01705, AC090673.1), miR-378b/(ALX4, IGSF3, SULF1), and miR-323b-3p/TGFBR3 were involved in both tumorigenesis and pulmonary metastasis of OS." +target gene hsa-mir-378b Osteosarcoma 29991755 "miR-223-5p/(CLSTN2, AC009951.1, LINC01705, AC090673.1), miR-378b/(ALX4, IGSF3, SULF1), and miR-323b-3p/TGFBR3 were involved in both tumorigenesis and pulmonary metastasis of OS." +target gene hsa-mir-186 Alzheimer Disease 29995978 Effect of microRNA-186 on oxidative stress injury of neuron by targeting interleukin 2 through the janus kinase-signal transducer and activator of transcription pathway in a rat model of Alzheimer's disease. +target gene hsa-mir-150 Osteoarthritis 29996115 Down-Regulation of MiR-150 Alleviates Inflammatory Injury Induced by Interleukin 1 via Targeting Kruppel-Like Factor 2 in Human Chondrogenic Cells. +target gene hsa-mir-17 Prostate Neoplasms 30001402 The deregulation of miR-17/CCND1 axis during neuroendocrine transdifferentiation of LNCaP prostate cancer cells. +target gene hsa-mir-34a "Carcinoma, Bladder" 30001529 MicroRNA-34a Attenuates Metastasis and Chemoresistance of Bladder Cancer Cells by Targeting the TCF1/LEF1 Axis. +target gene hsa-mir-135b Cerebral Ischemia 30002689 MicroRNA-135b-5p prevents oxygen-glucose deprivation and reoxygenation-induced neuronal injury through regulation of the GSK-3¦Â/Nrf2/ARE signaling pathway. +target gene hsa-mir-181b "Carcinoma, Lung, Small-Cell" 30002690 miR-181b inhibits chemoresistance in cisplatin-resistant H446 small cell lung cancer cells by targeting Bcl-2. +target gene hsa-mir-874 Ovarian Neoplasms 30004169 Upregulation of miR-874-3p and miR-874-5p inhibits epithelial ovarian cancer malignancy via SIK2. +target gene hsa-mir-6126 Hepatitis B Virus Infection 30004437 miR-6126 was able to suppress HBsAg production and HBV replication +target gene hsa-mir-34a Fatty Liver [unspecific] 30006135 Ablation of carotenoid cleavage enzymes (BCO1 and BCO2) induced hepatic steatosis by altering the farnesoid X receptor/miR-34a/sirtuin 1 pathway. +target gene hsa-mir-9 "Carcinoma, Hepatocellular" 30006781 "miR-9 inhibits the metastatic ability of hepatocellular carcinoma via targeting beta galactoside alpha-2,6-sialyltransferase 1." +target gene hsa-mir-15a Diabetes Mellitus 30007975 "experiments in MIN6 cells illustrated that miR-15a, miR-424, miR-497, and miR-185 positively regulated insulin biosynthesis by co-inhibiting UCP2 expression" +target gene hsa-mir-185 Diabetes Mellitus 30007975 "experiments in MIN6 cells illustrated that miR-15a, miR-424, miR-497, and miR-185 positively regulated insulin biosynthesis by co-inhibiting UCP2 expression" +target gene hsa-mir-424 Diabetes Mellitus 30007975 "experiments in MIN6 cells illustrated that miR-15a, miR-424, miR-497, and miR-185 positively regulated insulin biosynthesis by co-inhibiting UCP2 expression" +target gene hsa-mir-497 Diabetes Mellitus 30007975 "experiments in MIN6 cells illustrated that miR-15a, miR-424, miR-497, and miR-185 positively regulated insulin biosynthesis by co-inhibiting UCP2 expression" +target gene hsa-mir-204 Glioblastoma 30008822 "miR-204 functions as a tumor suppressor gene, at least partly by suppressing CYP27A1 in glioblastoma." +target gene hsa-mir-29c Liver Neoplasms 30008835 MicroRNA-29c restores cisplatin sensitivity in liver cancer through direct inhibition of sirtuin 1 expression. +target gene hsa-mir-205 "Carcinoma, Hepatocellular" 30008920 MicroRNA-205 is downregulated in hepatocellular carcinoma and inhibits cell growth and metastasis via directly targeting vascular endothelial growth factor A. +target gene hsa-mir-210 Osteosarcoma 30008923 miR-210 promotes human osteosarcoma cell migration and invasion by targeting FGFRL1. +target gene hsa-mir-650 Colorectal Carcinoma 30008936 MicroRNA-650 targets inhibitor of growth 4 to promote colorectal cancer progression via mitogen activated protein kinase signaling. +target gene hsa-mir-155 Gastric Neoplasms 30008945 Mitogen-activated protein kinase kinase kinase 10 was demonstrated to be a potential target gene of miR-155-5p +target gene hsa-mir-638 Glioma 30010402 hsa_circ_0000177-miR-638-FZD7-Wnt Signaling Cascade Contributes to the Malignant Behaviors in Glioma. +target gene hsa-mir-106a Colorectal Carcinoma 30011263 miR-106a Reduces 5-Fluorouracil (5-FU) Sensitivity of Colorectal Cancer by Targeting Dual-Specificity Phosphatases 2 (DUSP2). +target gene hsa-mir-27b "Carcinoma, Breast" 30012170 Suppression of PDHX by microRNA-27b deregulates cell metabolism and promotes growth in breast cancer. +target gene hsa-mir-589 Gastric Neoplasms 30012200 miR-589 promotes gastric cancer aggressiveness by a LIFR-PI3K/AKT-c-Jun regulatory feedback loop. +target gene hsa-mir-340 Psoriasis 30012847 miR-340 Alleviates Psoriasis in Mice through Direct Targeting of IL-17A. +target gene hsa-mir-488 Osteosarcoma 30015825 "MicroRNA-488 inhibits proliferation, invasion and EMT in osteosarcoma cell lines by targeting aquaporin 3." +target gene hsa-mir-655 "Squamous Cell Carcinoma, Oral" 30015840 MicroRNA?655 suppresses cell proliferation and invasion in oral squamous cell carcinoma by directly targeting metadherin and regulating the PTEN/AKT pathway. +target gene hsa-mir-199a Testicular Neoplasms 30015851 miR?199a?3p/Sp1/LDHA axis controls aerobic glycolysis in testicular tumor cells. +target gene hsa-mir-665 Ovarian Neoplasms 30015865 MicroRNA?665 suppresses the growth and migration of ovarian cancer cells by targeting HOXA10. +target gene hsa-mir-155 "Carcinoma, Breast" 30015868 NT21MP negatively regulates paclitaxel-resistant cells by targeting miR?155?3p and miR?155-5p via the CXCR4 pathway in breast cancer. +target gene hsa-mir-577 "Carcinoma, Lung, Non-Small-Cell" 30015869 miR-577 suppresses cell proliferation and epithelial-mesenchymal transition by regulating the WNT2B mediated Wnt/¦Â-catenin pathway in non-small cell lung cancer. +target gene hsa-mir-200b Colorectal Carcinoma 30015876 miR?200b?3p inhibits proliferation and induces apoptosis in colorectal cancer by targeting Wnt1. +target gene hsa-mir-500a Glioblastoma 30015879 "MiR?500a?5p promotes glioblastoma cell proliferation, migration and invasion by targeting chromodomain helicase DNA binding protein 5." +target gene hsa-mir-155 Atherosclerosis 30015881 MicroRNA?155 promotes ox?LDL?induced autophagy in human umbilical vein endothelial cells by targeting the PI3K/Akt/mTOR pathway. +target gene hsa-mir-185 "Carcinoma, Breast" 30015912 miR?185?5p inhibits F?actin polymerization and reverses epithelial mesenchymal transition of human breast cancer cells by modulating RAGE. +target gene hsa-mir-218 Osteoporosis 30016774 MicroRNA-218 Negatively Regulates Osteoclastogenic Differentiation by Repressing the Nuclear Factor-¦ÊB Signaling Pathway and Targeting Tumor Necrosis Factor Receptor 1. +target gene hsa-mir-410 "Carcinoma, Breast" 30016800 MiR-410 Acts as a Tumor Suppressor in Estrogen Receptor-Positive Breast Cancer Cells by Directly Targeting ERLIN2 via the ERS Pathway. +target gene hsa-mir-148a Thyroid Neoplasms 30018720 PKM2 functions as a potential oncogene and is a crucial target of miR-148a and miR-326 in thyroid tumorigenesis. +target gene hsa-mir-326 Thyroid Neoplasms 30018720 PKM2 functions as a potential oncogene and is a crucial target of miR-148a and miR-326 in thyroid tumorigenesis. +target gene hsa-mir-92a-1 Bone Disease [unspecific] 30019248 MicroRNA-92a-1-5p influences osteogenic differentiation of MC3T3-E1 cells by regulating ¦Â-catenin. +target gene hsa-mir-335 Ovarian Neoplasms 30019389 MiR-335-5p restores cisplatin sensitivity in ovarian cancer cells through targeting BCL2L2. +target gene hsa-mir-153 "Carcinoma, Endometrial" 30019459 "miRNAs,including miR-182, miR-183, miR-153, miR-27a, and miR-96, were predicted to bind LINC00261 and FOXO1, and functioned to attenuate expression of LINC00261 and FOXO1" +target gene hsa-mir-182 "Carcinoma, Endometrial" 30019459 "miRNAs,including miR-182, miR-183, miR-153, miR-27a, and miR-96, were predicted to bind LINC00261 and FOXO1, and functioned to attenuate expression of LINC00261 and FOXO1" +target gene hsa-mir-183 "Carcinoma, Endometrial" 30019459 "miRNAs,including miR-182, miR-183, miR-153, miR-27a, and miR-96, were predicted to bind LINC00261 and FOXO1, and functioned to attenuate expression of LINC00261 and FOXO1" +target gene hsa-mir-27a "Carcinoma, Endometrial" 30019459 "miRNAs,including miR-182, miR-183, miR-153, miR-27a, and miR-96, were predicted to bind LINC00261 and FOXO1, and functioned to attenuate expression of LINC00261 and FOXO1" +target gene hsa-mir-96 "Carcinoma, Endometrial" 30019459 "miRNAs,including miR-182, miR-183, miR-153, miR-27a, and miR-96, were predicted to bind LINC00261 and FOXO1, and functioned to attenuate expression of LINC00261 and FOXO1" +target gene hsa-mir-21a Obesity 30020817 Long Noncoding RNA GAS5 Suppresses 3T3-L1 Cells Adipogenesis Through miR-21a-5p/PTEN Signal Pathway. +target gene hsa-mir-298 "Stroke, Ischemic" 30021197 MiR-298 Exacerbates Ischemia/Reperfusion Injury Following Ischemic Stroke by Targeting Act1. +target gene hsa-mir-129 "Carcinoma, Thyroid, Papillary" 30021343 MiR-129 regulates growth and invasion by targeting MAL2 in papillary thyroid carcinoma. +target gene hsa-mir-149 "Carcinoma, Cervical" 30021347 miR-149 regulates the proliferation and apoptosis of cervical cancer cells by targeting GIT1. +target gene hsa-mir-19a "Carcinoma, Hepatocellular" 30021351 microRNA-19a-3p promotes tumor metastasis and chemoresistance through the PTEN/Akt pathway in hepatocellular carcinoma. +target gene hsa-mir-15a "Carcinoma, Cervical" 30021370 Over-expression of miR-15a-3p enhances the radiosensitivity of cervical cancer by targeting tumor protein D52. +target gene hsa-mir-519d Colorectal Carcinoma 30021381 MicroRNA-519d-3p inhibits cell proliferation and migration by targeting TROAP in colorectal cancer. +target gene hsa-mir-373 "Carcinoma, Pancreatic" 30021382 MiR-373-3p enhances the chemosensitivity of gemcitabine through cell cycle pathway by targeting CCND2 in pancreatic carcinoma cells. +target gene hsa-mir-363 Colorectal Carcinoma 30021386 MiR-363-3p suppresses tumor growth and metastasis of c via targeting SphK2. +target gene hsa-mir-26a Lung Injury [unspecific] 30024304 MicroRNA dysregulation in lung injury: the role of the miR-26a/EphA2 axis in regulation of endothelial permeability. +target gene hsa-mir-550a "Carcinoma, Lung, Non-Small-Cell" 30024604 MiR-550a-3p promotes non-small cell lung cancer cell proliferation and metastasis through down-regulating TIMP2. +target gene hsa-mir-132 Glioma 30024792 miR-132-3p boosts caveolae-mediated transcellular transport in glioma endothelial cells by targeting PTEN/PI3K/PKB/Src/Cav-1 signaling pathway. +target gene hsa-mir-16 Polycystic Ovarian Syndrome 30025387 MicroRNA-16 Promotes Ovarian Granulosa Cell Proliferation and Suppresses Apoptosis Through Targeting PDCD4 in Polycystic Ovarian Syndrome. +target gene hsa-mir-29b Cardiac Fibrosis 30025410 MicroRNA-29b Regulates the Mitochondria-Dependent Apoptotic Pathway by Targeting Bax in Doxorubicin Cardiotoxicity. +target gene hsa-mir-1296 Colorectal Carcinoma 30026827 "MicroRNA-1296 Facilitates Proliferation, Migration And Invasion Of Colorectal Cancer Cells By Targeting SFPQ." +target gene hsa-mir-616 Preeclampsia 30028057 MiR-616-3p modulates cell proliferation and migration through targeting tissue factor pathway inhibitor 2 in preeclampsia. +target gene hsa-mir-219a Sepsis 30028330 MicroRNA-219 alleviates glutamate-induced neurotoxicity in cultured hippocampal neurons by targeting calmodulin-dependent protein kinase II gamma. +target gene hsa-mir-5590 Gastric Neoplasms 30029874 miR-5590-3p inhibited tumor growth in gastric cancer by targeting DDX5/AKT/m-TOR pathway. +target gene hsa-mir-30d Lung Fibrosis 30029934 MicroRNA-30d/JAG1 axis modulates pulmonary fibrosis through Notch signaling pathway. +target gene hsa-mir-204 Gastric Neoplasms 30031110 oxaliplatin impairs sensory neurons arborization through up-regulation of miR-204 that decreases PlexinA2 expression and neurite length +target gene hsa-mir-181d Osteosarcoma 30031607 miR-181d-5p-FOXP1 feedback loop modulates the progression of osteosarcoma. +target gene hsa-mir-140 "Carcinoma, Breast" 30032164 miR-140-5p inhibits the proliferation and enhances the efficacy of doxorubicin to breast cancer stem cells by targeting Wnt1. +target gene hsa-mir-181a Glioma 30036882 "Kaiso (ZBTB33) Downregulation by Mirna-181a Inhibits Cell Proliferation, Invasion, and the Epithelial-Mesenchymal Transition in Glioma Cells." +target gene hsa-mir-135b Hypertrophy 30037628 Overexpression of miR-135b attenuates pathological cardiac hypertrophy by targeting CACNA1C. +target gene hsa-mir-384 Glioma 30038507 MicroRNA-384 inhibits proliferation migration and invasion of glioma by targeting at CDC42. +target gene hsa-mir-19b "Carcinoma, Breast" 30038508 miR-19b serves as a prognostic biomarker of breast cancer and promotes tumor progression through PI3K/AKT signaling pathway. +target gene hsa-mir-194 Hepatitis B Virus Infection 30044042 MicroRNA-194 protects against chronic hepatitis B-related liver damage by promoting hepatocyte growth via ACVR2B. +target gene hsa-mir-324 Hemophilus Influenzae Infection 30045983 MicroRNA hsa-miR-324-5p Suppresses H5N1 Virus Replication by Targeting the Viral PB1 and Host CUEDC2. +target gene hsa-mir-26a Rheumatoid Arthritis 30046030 miR-26a-5p Regulates Synovial Fibroblast Invasion in Patients with Rheumatoid Arthritis by Targeting Smad 1. +target gene hsa-mir-363 Ovarian Neoplasms 30046387 "miR-363 confers taxane resistance in ovarian cancer by targeting the Hippo pathway member, LATS2." +target gene hsa-mir-34a Osteoarthritis 30048987 "MiR-34a Enhances Chondrocyte Apoptosis, Senescence and Facilitates Development of Osteoarthritis by Targeting DLL1 and Regulating PI3K/AKT Pathway." +target gene hsa-mir-143 "Leukemia, Myeloid, Acute" 30050105 MicroRNA-143 targets ERK5 in granulopoiesis and predicts outcome of patients with acute myeloid leukemia. +target gene hsa-mir-29 "Diabetes Mellitus, Type 2" 30050458 "Among the enriched miRNAs was miR-29, a regulator of GLUT4 mRNA expression" +target gene hsa-mir-106 Hyperglycemia 30055307 MicroRNA-106 attenuates hyperglycemia-induced vascular endothelial cell dysfunction by targeting HMGB1. +target gene hsa-mir-1273g Colorectal Carcinoma 30056111 miR-1273g silences MAGEA3/6 to inhibit human colorectal cancer cell growth via activation of AMPK signaling. +target gene hsa-mir-384 Osteoarthritis 30057417 Inhibition of microRNA-384-5p alleviates osteoarthritis through its effects on inhibiting apoptosis of cartilage cells via the NF-¦ÊB signaling pathway by targeting SOX9. +target gene hsa-mir-28 Neuropathic Pain 30058089 miR-28-5p/Zeb1 axis can be a novel therapeutic target for neuropathic pain treatment +target gene hsa-mir-485 Lung Neoplasms 30058740 Epigallocatechin-3-gallate inhibited cancer stem cell-like properties by targeting hsa-mir-485-5p/RXR¦Á in lung cancer. +target gene hsa-mir-7 Neoplasms [unspecific] 30060955 it suggests that the level of NF90 is increased by a negative feedback loop between NF90 and miR-7 in tumor tissues under physiological conditions +target gene hsa-mir-455 "Carcinoma, Bladder" 30061227 dysfunction of the miR-455-TJP1 axis is involved in bladder cancer cell growth and metastasis +target gene hsa-mir-342 Nasopharyngeal Neoplasms 30061949 MicroRNA-342 inhibits cell proliferation and invasion in nasopharyngeal carcinoma by directly targeting ZEB1. +target gene hsa-mir-95 Osteoarthritis 30063117 Exosomal miR-95-5p regulates chondrogenesis and cartilage degradation via histone deacetylase 2/8. +target gene hsa-mir-145 "Carcinoma, Lung, Non-Small-Cell" 30065618 miR-145 and miR-497 suppress TGF-¦Â-induced epithelial-mesenchymal transition of non-small cell lung cancer by targeting MTDH. +target gene hsa-mir-497 "Carcinoma, Lung, Non-Small-Cell" 30065618 miR-145 and miR-497 suppress TGF-¦Â-induced epithelial-mesenchymal transition of non-small cell lung cancer by targeting MTDH. +target gene hsa-mir-26a "Carcinoma, Breast" 30066905 A miR-26a/E2F7 feedback loop contributes to tamoxifen resistance in ER-positive breast cancer. +target gene hsa-mir-22 Asthma 30068332 "Influenza A virus infection dysregulates the expression of microRNA-22 and its targets; CD147 and HDAC4, in epithelium of asthmatics." +target gene hsa-mir-1258 "Carcinoma, Lung, Non-Small-Cell" 30069987 MicroRNA-1258 suppresses tumour progression via GRB2/Ras/Erk pathway in non-small-cell lung cancer. +target gene hsa-mir-340 Colorectal Carcinoma 30070320 MiR-340-5p is a potential prognostic indicator of colorectal cancer and modulates ANXA3. +target gene hsa-mir-1269a Colorectal Carcinoma 30070324 MiR-1269a acts as an onco-miRNA in non-small cell lung cancer via down-regulating SOX6. +target gene hsa-mir-608 "Adenocarcinoma, Lung" 30070326 MiR-608 exerts tumor suppressive function in lung adenocarcinoma by directly targeting MIF. +target gene hsa-mir-122 Glioma 30070328 MiR-122 inhibits cell proliferation and induces apoptosis by targeting runt-related transcription factors 2 in human glioma. +target gene hsa-mir-135b Colorectal Carcinoma 30071508 Knockdown of Mir-135b Sensitizes Colorectal Cancer Cells to Oxaliplatin-Induced Apoptosis Through Increase of FOXO1. +target gene hsa-mir-543 Esophageal Neoplasms 30071514 "MiR-543 Promotes Migration, Invasion and Epithelial-Mesenchymal Transition of Esophageal Cancer Cells by Targeting Phospholipase A2 Group IVA." +target gene hsa-mir-34a Ovarian Neoplasms 30071534 c-Myc re-expression targeting by miR-34a inhibitors protected cells from apoptosis or reversed cisplatin resistance following HDAC1 knockdown or/and cisplatin exposure +target gene hsa-let-7a Chronic Obstructive Pulmonary Disease 30072506 "KRAS and EDN1 were identified as key regulators of CMH and were negatively correlated predicted targets of miR-134-5p and let-7a-5p, let-7d-5p, and let-7f-5p" +target gene hsa-let-7d Chronic Obstructive Pulmonary Disease 30072506 "KRAS and EDN1 were identified as key regulators of CMH and were negatively correlated predicted targets of miR-134-5p and let-7a-5p, let-7d-5p, and let-7f-5p" +target gene hsa-let-7f Chronic Obstructive Pulmonary Disease 30072506 "KRAS and EDN1 were identified as key regulators of CMH and were negatively correlated predicted targets of miR-134-5p and let-7a-5p, let-7d-5p, and let-7f-5p" +target gene hsa-mir-134 Chronic Obstructive Pulmonary Disease 30072506 "KRAS and EDN1 were identified as key regulators of CMH and were negatively correlated predicted targets of miR-134-5p and let-7a-5p, let-7d-5p, and let-7f-5p" +target gene hsa-mir-31 Hypertrophy 30074205 Atorvastatin Attenuates Myocardial Hypertrophy Induced by Chronic Intermittent Hypoxia In Vitro Partly through miR-31/PKC¦Å Pathway. +target gene hsa-mir-31a Hypertrophic Scar 30075370 Inhibition of miR-31a-5p decreases inflammation by down-regulating IL-25 expression in human dermal fibroblast cells (CC-2511 cells) under hyperthermic stress via Wnt/¦Â-catenin pathway. +target gene hsa-mir-29c Allergic Asthma 30075787 The role of miR-29c/B7-H3 axis in children with allergic asthma +target gene hsa-mir-638 Asthma 30076719 MicroRNA-638 inhibits human airway smooth muscle cell proliferation and migration through targeting cyclin D1 and NOR1. +target gene hsa-mir-125a "Carcinoma, Breast" 30076753 MiR-125a-5p functions as a tumour suppressor in breast cancer by downregulating BAP1. +target gene hsa-mir-590 "Carcinoma, Breast" 30076901 miR-590-3p inhibits proliferation and promotes apoptosis by targeting activating transcription factor 3 in human breast cancer cells. +target gene hsa-mir-224 "Carcinoma, Pancreatic" 30078003 MicroRNA-224 Promotes Pancreatic Cancer Cell Proliferation and Migration by Targeting the TXNIP-Mediated HIF1¦Á Pathway. +target gene hsa-mir-27b Kawasaki Syndrome 30078021 miR-27b Suppresses Endothelial Cell Proliferation and Migration by Targeting Smad7 in Kawasaki Disease. +target gene hsa-mir-141 Hyperglycemia 30078183 miR-141-3p targets not only protein-coding genes but also the lncRNA H19 +target gene hsa-mir-181a Vascular Disease [unspecific] 30080293 FMRP regulates endothelial cell proliferation and angiogenesis via the miR-181a-CaM-CaMKII pathway. +target gene hsa-mir-506 Retinoblastoma 30080301 "MiR-506-3p inhibits cell proliferation, induces cell cycle arrest and apoptosis in retinoblastoma by directly targeting NEK6." +target gene hsa-mir-29b Asthma 30081328 miR-29b directly targets activation-induced cytidine deaminase in human B cells and can limit its inappropriate expression in na?ve B cells. +target gene hsa-mir-301b Melanoma 30081934 Isoliquiritigenin suppresses human melanoma growth by targeting miR-301b/LRIG1 signaling. +target gene hsa-mir-125b "Carcinoma, Lung" 30082521 MiR-125b-1-3p Exerts Antitumor Functions in Lung Carcinoma Cells by Targeting S1PR1. +target gene hsa-mir-375 "Carcinoma, Renal Cell, Clear-Cell" 30082525 MicroRNA-375 Suppresses the Tumor Aggressive Phenotypes of Clear Cell Renal Cell Carcinomas through Regulating YWHAZ. +target gene hsa-mir-218 Parkinson Disease 30083784 "Our results reveal that SLC6A3, TH, and EBF3 targeted by miR-218 could be involved in PD" +target gene hsa-mir-191 "Carcinoma, Breast" 30084985 Amplification of Hsa-miR-191/425 Locus Promotes Breast Cancer Proliferation and Metastasis by Targeting DICER1. +target gene hsa-mir-425 "Carcinoma, Breast" 30084985 Amplification of Hsa-miR-191/425 Locus Promotes Breast Cancer Proliferation and Metastasis by Targeting DICER1. +target gene hsa-mir-133a "Carcinoma, Hepatocellular" 30086463 MiR-133a acts as an anti-oncogene in Hepatocellular carcinoma by inhibiting FOSL2 through TGF-¦Â/Smad3 signaling pathway. +target gene hsa-mir-485 Colorectal Carcinoma 30087700 microRNA-485-5p Functions as a Tumor Suppressor in Colorectal Cancer Cells by Targeting CD147. +target gene hsa-mir-302c "Carcinoma, Hepatocellular" 30087710 The tumor suppressive miR-302c-3p inhibits migration and invasion of hepatocellular carcinoma cells by targeting TRAF4. +target gene hsa-mir-323a Osteosarcoma 30088225 MiR-323a-3p suppressed the glycolysis of osteosarcoma via targeting LDHA. +target gene hsa-mir-21 Neoplasms [unspecific] 30092298 MiR-21 regulates the ACAT1 gene in MCF-7 cells. +target gene hsa-mir-613 "Carcinoma, Breast, Triple Negative" 30092563 miR-613 directly bound to the 3'-untranslated region (3'-UTR) of WBP2 and regulated the expression of WBP2 +target gene hsa-mir-142 "Carcinoma, Hepatocellular" 30092578 lncRNA TUG1-Mediated Mir-142-3p Downregulation Contributes to Metastasis and the Epithelial-to-Mesenchymal Transition of Hepatocellular Carcinoma by Targeting ZEB1. +target gene hsa-mir-1292 "Carcinoma, Gastric" 30094096 "MicroRNA-1292-5p inhibits cell growth, migration and invasion of gastric carcinoma by targeting DEK." +target gene hsa-mir-942 Liver Fibrosis 30097701 MicroRNA-942 mediates hepatic stellate cell activation by regulating BAMBI expression in human liver fibrosis. +target gene hsa-mir-499 Obesity 30097922 MiR-499/PRDM16 axis modulates the adipogenic differentiation of mouse skeletal muscle satellite cells. +target gene hsa-mir-143 Melanoma 30098313 MicroRNA-143-3p inhibits growth and invasiveness of melanoma cells by targeting cyclooxygenase-2 and inversely correlates with malignant melanoma progression. +target gene hsa-mir-93 "Carcinoma, Cervical" 30098344 Clinical significance and functions of microRNA-93/CDKN1A axis in human cervical cancer. +target gene hsa-mir-101 "Carcinoma, Hepatocellular" 30098428 LINC00052/miR-101-3p axis inhibits cell proliferation and metastasis by targeting SOX9 in hepatocellular carcinoma. +target gene hsa-mir-101 Glioma 30098431 Long noncoding RNA SNHG12 facilitates the tumorigenesis of glioma through miR-101-3p/FOXP1 axis. +target gene hsa-mir-217 "Carcinoma, Bladder" 30098434 Downregulation of circular RNA hsa_circ_0000144 inhibits bladder cancer progression via stimulating miR-217 and suppressing RUNX2 expression. +target gene hsa-mir-132 Schizophrenia 30099093 "Moreover, the polycomb-associated H3K27 methyltransferase, EZH1, is regulated by miR-132 and upregulated in the PFC of schizophrenics" +target gene hsa-mir-148b Kidney Neoplasms 30099339 MiR-148b-3p inhibits renal carcinoma cell growth and pro-angiogenic phenotype of endothelial cell potentially by modulating FGF2. +target gene hsa-mir-758 Glioblastoma 30099442 "Mir-758-5p Suppresses Glioblastoma Proliferation, Migration and Invasion by Targeting ZBTB20." +target gene hsa-mir-33a Laryngeal Neoplasms 30102806 Antiproliferative potential of miR-33a in laryngeal cancer Hep-2 cells via targeting PIM1. +target gene hsa-mir-34a Lung Neoplasms 30102929 miR-34a negatively regulates the expression of BCL2 and c-MET (genes associated with survival of tumor cells) +target gene hsa-mir-23c "Carcinoma, Hepatocellular" 30103114 miR-23c suppresses tumor growth of human hepatocellular carcinoma by attenuating ERBB2IP. +target gene hsa-mir-520b Lung Neoplasms 30106218 MiR-520b restrains cell growth by targeting HDAC4 in lung cancer. +target gene hsa-mir-498 "Leukemia, Myeloid, Acute" 30107988 Evaluation of the effect of TIM-3 suppression by miR-498 and its effect on apoptosis and proliferation rate of HL-60 cell line. +target gene hsa-mir-96 "Carcinoma, Cervical" 30108433 MiR-96 enhances cellular proliferation and tumorigenicity of human cervical carcinoma cells through PTPN9. +target gene hsa-mir-1297 "Squamous Cell Carcinoma, Oral" 30108442 microRNA-1297 involves in the progression of oral squamous cell carcinoma through PTEN. +target gene hsa-mir-30b Glioma 30108445 MiR-30b-5p modulates glioma cell proliferation by direct targeting MTDH. +target gene hsa-mir-582 "Carcinoma, Endometrial" 30108448 Upregulation of miR-582-5p regulates cell proliferation and apoptosis by targeting AKT3 in human endometrial carcinoma. +target gene hsa-mir-4728 "Lymphoma, Burkitt" 30108451 MicroRNA-4728 serves as a suppressor and antagonist of oncogenic MAPK in Burkitt lymphoma. +target gene hsa-mir-4728 "Carcinoma, Thyroid, Papillary" 30108452 MicroRNA-4728 mediated regulation of MAPK oncogenic signaling in papillary thyroid carcinoma. +target gene hsa-mir-204 Kidney Diseases [unspecific] 30110560 MicroRNA-204-5p suppresses IL6-mediated inflammatory response and chemokine generation in HK-2 renal tubular epithelial cells by targeting IL6R. +target gene hsa-mir-206 Soft Tissue Sarcoma 30111166 The oncomir face of microRNA-206: A permanent miR-206 transfection study. +target gene hsa-mir-34a "Leukemia, Lymphocytic, Chronic, B-Cell" 30111844 MicroRNA miR-34a downregulates FOXP1 during DNA damage response to limit BCR signalling in chronic lymphocytic leukaemia B cells. +target gene hsa-mir-153 Gastric Neoplasms 30112020 MicroRNA-153 functions as a tumor suppressor in gastric cancer via targeting Kruppel-like factor 5. +target gene hsa-mir-340 Acute Ischemic Stroke 30112629 "Acute stroke induces the downregulation of miR-340-5p, which subsequently upregulates ARG1 protein expression" +target gene hsa-mir-369 "Carcinoma, Thyroid, Papillary" 30114378 Downregulation of TSPAN13 by miR-369-3p inhibits cell proliferation in papillary thyroid cancer (PTC). +target gene hsa-mir-6852 Colorectal Carcinoma 30116340 miR-6852 serves as a prognostic biomarker in colorectal cancer and inhibits tumor growth and metastasis by targeting TCF7. +target gene hsa-mir-379 Nasopharyngeal Neoplasms 30116374 "MicroRNA-379 suppresses cell proliferation, migration and invasion in nasopharyngeal carcinoma by targeting tumor protein D52." +target gene hsa-mir-26a Neuropathic Pain 30118880 Effects of miR-26a-5p on neuropathic pain development by targeting MAPK6 in in CCI rat models. +target gene hsa-mir-539 "Carcinoma, Lung, Non-Small-Cell" 30119173 miR-539 enhances chemosensitivity to cisplatin in non-small cell lung cancer by targeting DCLK1. +target gene hsa-mir-30c Atherosclerosis 30119891 MicroRNA-30c-5p inhibits NLRP3 inflammasome-mediated endothelial cell pyroptosis through FOXO3 down-regulation in atherosclerosis. +target gene hsa-mir-30a Hidradenitis Suppurativa 30120935 Nicastrin/miR-30a-3p/RAB31 Axis Regulates Keratinocyte Differentiation by Impairing EGFR Signaling in Familial Acne Inversa. +target gene hsa-mir-494 Acute Respiratory Distress Syndrome 30121199 MicroRNA-494 inhibition alleviates acute lung injury through Nrf2 signaling pathway via NQO1 in sepsis-associated acute respiratory distress syndrome. +target gene hsa-mir-122 "Carcinoma, Biliary Tract" 30121648 "miR-122-5p Inhibits the Proliferation, Invasion and Growth of Bile Duct Carcinoma Cells by Targeting ALDOA." +target gene hsa-mir-486 Myocardial Infarction 30121658 MicroRNA-486 Alleviates Hypoxia-Induced Damage in H9c2 Cells by Targeting NDRG2 to Inactivate JNK/C-Jun and NF-¦ÊB Signaling Pathways. +target gene hsa-mir-223 "Lymphoma, Mantle-Cell" 30122018 "The expression of miR-223 was repressed in MCL and was associated with poor clinical outcomes, which may be probably attributed to its direct targeting SOX11" +target gene hsa-mir-140 Rheumatoid Arthritis 30123050 "the novel miR-140-3p-FGF9 interaction was validated in different microRNA prediction databases, and proposed to participate in the pathogenesis of joint destruction through dysregulated cell growth in RA" +target gene hsa-mir-524 Osteosarcoma 30123092 MicroRNA-524 promotes cell proliferation by down-regulating PTEN expression in osteosarcoma. +target gene hsa-mir-151a Visceral Leishmaniasis 30125570 "we identified target gene of differentially expressed miRNAs (target miRNAs: hsa-mir-15b, hsa-mir-671, hsa-mir-151a and has-mir-30c) which was confirmed by real time stem-loop PCR" +target gene hsa-mir-15b Visceral Leishmaniasis 30125570 "we identified target gene of differentially expressed miRNAs (target miRNAs: hsa-mir-15b, hsa-mir-671, hsa-mir-151a and has-mir-30c) which was confirmed by real time stem-loop PCR" +target gene hsa-mir-30c Visceral Leishmaniasis 30125570 "we identified target gene of differentially expressed miRNAs (target miRNAs: hsa-mir-15b, hsa-mir-671, hsa-mir-151a and has-mir-30c) which was confirmed by real time stem-loop PCR" +target gene hsa-mir-671 Visceral Leishmaniasis 30125570 "we identified target gene of differentially expressed miRNAs (target miRNAs: hsa-mir-15b, hsa-mir-671, hsa-mir-151a and has-mir-30c) which was confirmed by real time stem-loop PCR" +target gene hsa-mir-150 "Carcinoma, Thyroid, Papillary" 30126001 "MicroRNA-150-5p affects cell proliferation, apoptosis, and EMT by regulation of the BRAFV600E mutation in papillary thyroid cancer cells." +target gene hsa-mir-181a "Carcinoma, Breast" 30126376 "Several miRNAs including miR-18a, miR-19a and miR-181a were predicted in silico to target the canine estrogen receptor (ESR1¦Á)" +target gene hsa-mir-18a "Carcinoma, Breast" 30126376 "Several miRNAs including miR-18a, miR-19a and miR-181a were predicted in silico to target the canine estrogen receptor (ESR1¦Á)" +target gene hsa-mir-19a "Carcinoma, Breast" 30126376 "Several miRNAs including miR-18a, miR-19a and miR-181a were predicted in silico to target the canine estrogen receptor (ESR1¦Á)" +target gene hsa-mir-16 Gastric Neoplasms 30127890 miR-16 targets SALL4 to repress the proliferation and migration of gastric cancer. +target gene hsa-mir-106b "Carcinoma, Hepatocellular" 30127897 miR-106b targets DAB2 to promote hepatocellular carcinoma cell proliferation and metastasis. +target gene hsa-mir-18a Osteosarcoma 30127908 miR-18a-5p promotes cell invasion and migration of osteosarcoma by directly targeting IRF2. +target gene hsa-mir-375 Liver Neoplasms 30127930 Upregulation of miR-375 inhibits human liver cancer cell growth by modulating cell proliferation and apoptosis via targeting ErbB2. +target gene hsa-mir-2682 Osteosarcoma 30127935 "MicroRNA-2682-3p inhibits osteosarcoma cell proliferation by targeting CCND2, MMP8 and Myd88." +target gene hsa-mir-761 Gastric Neoplasms 30127949 microRNA-761 regulates glycogen synthase kinase 3¦Â expression and promotes the proliferation and cell cycle of human gastric cancer cells. +target gene hsa-mir-449b "Carcinoma, Lung, Non-Small-Cell" 30128865 Inhibitory Effect of MiR-449b on Cancer Cell Growth and Invasion through LGR4 in Non-Small-Cell Lung Carcinoma. +target gene hsa-mir-224 "Carcinoma, Cervical" 30129088 MicroRNA-224 inhibition prevents progression of cervical carcinoma by targeting PTX3. +target gene hsa-mir-5582 Neoplasms [unspecific] 30129155 "Hsa-miR-5582-3P regulatory effect on TGF¦Â signaling through targeting of TGF¦Â-R1, TGF¦Â-R2, SMAD3, and SMAD4 transcripts." +target gene hsa-mir-766 "Carcinoma, Hepatocellular" 30130435 MicroRNA-766 promotes cancer progression by targeting NR3C2 in hepatocellular carcinoma. +target gene hsa-mir-124a Glioma 30131250 "microRNA-124a suppresses PHF19 over-expression, EZH2 hyper-activation, and aberrant cell proliferation in human glioma." +target gene hsa-mir-211 Glaucoma 30131252 Intraocular miR-211 exacerbates pressure-induced cell death in retinal ganglion cells via direct repression of FRS2 signaling. +target gene hsa-mir-1254 "Carcinoma, Breast" 30132526 MicroRNA-1254 exerts?oncogenic effects by directly targeting RASSF9 in human breast cancer. +target gene hsa-mir-424 Hemangioma 30132564 MicroRNA?424 suppresses the proliferation of hemangioma?derived endothelial cells by targeting VEGFR?2. +target gene hsa-mir-6089 Rheumatoid Arthritis 30132861 Exosome-encapsulated miR-6089 regulates inflammatory response via targeting TLR4. +target gene hsa-mir-26a Ischemia-Reperfusion Injury 30132885 Effect of microRNA-26a on vascular endothelial cell injury caused by lower extremity ischemia-reperfusion injury through the AMPK pathway by targeting PFKFB3. +target gene hsa-mir-30e Ovarian Neoplasms 30134224 the expression of YWHAZ was directly down-regulated by miR-30e in resistant ovarian cancer cells +target gene hsa-mir-96 Chronic Cerebral Hypoperfusion 30134226 miR-96 may play a key role in autophagy under CCH by regulating mTOR +target gene hsa-mir-16 "Squamous Cell Carcinoma, Oral" 30136280 MicroRNA-16 functions as a tumor-suppressor gene in oral squamous cell carcinoma by targeting AKT3 and BCL2L2. +target gene hsa-mir-381 "Carcinoma, Bladder" 30138038 Dual regulatory role of CCNA2 in modulating CDK6 and MET-mediated cell-cycle pathway and EMT progression is blocked by miR-381-3p in bladder cancer. +target gene hsa-mir-154 "Carcinoma, Renal Cell" 30138594 Oncogene miR-154-5p regulates cellular function and acts as a molecular marker with poor prognosis in renal cell carcinoma. +target gene hsa-mir-27a Ovarian Neoplasms 30138596 Integrated microarray meta-analysis identifies miRNA-27a as an oncogene in ovarian cancer by inhibiting FOXO1. +target gene hsa-mir-135a Ovarian Neoplasms 30138893 MicroRNA-135a-3p is downregulated and serves as a tumour suppressor in ovarian cancer by targeting CCR2. +target gene hsa-mir-454 Preeclampsia 30138897 "MicroRNA-454 is involved in regulating trophoblast cell proliferation, apoptosis, and invasion in preeclampsia by modulating the expression of ephrin receptor B4." +target gene hsa-mir-504 "Carcinoma, Hepatocellular" 30142536 MicroRNA-504 functions as a tumor suppressor in hepatocellular carcinoma through inhibiting Frizzled-7-mediated-Wnt/¦Â-catenin signaling. +target gene hsa-mir-1258 Colorectal Carcinoma 30144184 Upregulated miR-1258 regulates cell cycle and inhibits cell proliferation by directly targeting E2F8 in CRC. +target gene hsa-mir-202 Colorectal Carcinoma 30144500 MicroRNA-202-5p functions as a tumor suppressor in colorectal carcinoma by directly targeting SMARCC1. +target gene hsa-mir-383 Cholangiocarcinoma 30145803 "miR-383 promotes cholangiocarcinoma cell proliferation, migration, and invasion through targeting IRF1." +target gene hsa-mir-27a Ischemia-Reperfusion Injury 30145824 MiR-27a-5p regulates apoptosis of liver ischemia-reperfusion injury in mice by targeting Bach1. +target gene hsa-mir-766 "Carcinoma, Hepatocellular" 30145863 MicroRNA-766-3p Inhibits Tumour Progression by Targeting Wnt3a in Hepatocellular Carcinoma. +target gene hsa-mir-495 "Carcinoma, Lung, Non-Small-Cell" 30146342 The miR 495-UBE2C-ABCG2/ERCC1 axis reverses cisplatin resistance by downregulating drug resistance genes in cisplatin-resistant non-small cell lung cancer cells. +target gene hsa-mir-133a Asthma 30146725 MicroRNA-133a alleviates airway remodeling in asthtama through PI3K/AKT/mTOR signaling pathway by targeting IGF1R. +target gene hsa-mir-126 Acute Kidney Failure 30146769 "Gain-and-loss-of-function studies demonstrated that miRNAs, such as miR-24, miR-126, miR-494, and miR-687, may bind to the 3'-untranslated region of their target genes to regulate inflammation, programmed cell death, and cell cycle in the injury and repair stages of AKI" +target gene hsa-mir-24 Acute Kidney Failure 30146769 "Gain-and-loss-of-function studies demonstrated that miRNAs, such as miR-24, miR-126, miR-494, and miR-687, may bind to the 3'-untranslated region of their target genes to regulate inflammation, programmed cell death, and cell cycle in the injury and repair stages of AKI" +target gene hsa-mir-494 Acute Kidney Failure 30146769 "Gain-and-loss-of-function studies demonstrated that miRNAs, such as miR-24, miR-126, miR-494, and miR-687, may bind to the 3'-untranslated region of their target genes to regulate inflammation, programmed cell death, and cell cycle in the injury and repair stages of AKI" +target gene hsa-mir-687 Acute Kidney Failure 30146769 "Gain-and-loss-of-function studies demonstrated that miRNAs, such as miR-24, miR-126, miR-494, and miR-687, may bind to the 3'-untranslated region of their target genes to regulate inflammation, programmed cell death, and cell cycle in the injury and repair stages of AKI" +target gene hsa-mir-181c Machado-Joseph Disease 30147021 MiR-32 and miR-181c effectively targeted the 3¡¯UTR of ATXN3 and suppressed the expression of ATXN3 +target gene hsa-mir-32 Machado-Joseph Disease 30147021 MiR-32 and miR-181c effectively targeted the 3¡¯UTR of ATXN3 and suppressed the expression of ATXN3 +target gene hsa-mir-495 Gastric Neoplasms 30147110 MicroRNA-495 Confers Increased Sensitivity to Chemotherapeutic Agents in Gastric Cancer via the Mammalian Target of Rapamycin (mTOR) Signaling Pathway by Interacting with Human Epidermal Growth Factor Receptor 2 (ERBB2). +target gene hsa-mir-7641 "Carcinoma, Bladder" 30149755 Curcumin Suppresses microRNA-7641-Mediated Regulation of p16 Expression in Bladder Cancer. +target gene hsa-mir-451 Osteoporosis 30151091 MicroRNA-451 blockade promotes osteoblastic differentiation and skeletal anabolic effects by promoting YWHAZ-mediated RUNX2 protein stabilization. +target gene hsa-mir-27a Peri-Implantitis 30151888 MiR-27a targets DKK2 and SFRP1 to promote reosseointegration in the regenerative treatment of peri-implantitis. +target gene hsa-mir-29 "Carcinoma, Renal Cell" 30153702 Genes regulated by the anti-tumor miR-29 family are closely involved in the molecular pathogenesis of renal cell carcinoma +target gene hsa-mir-590 Asthma 30154893 MicroRNA-590-5p represses proliferation of human fetal airway smooth muscle cells by targeting signal transducer and activator of transcription 3. +target gene hsa-mir-362 Lung Neoplasms 30155491 Aberrant Expression of miR-362 Promotes Lung Cancer Metastasis through Downregulation of Sema3A. +target gene hsa-mir-145 "Carcinoma, Breast" 30157476 The Dysregulated Expression of KCNQ1OT1 and Its Interaction with Downstream Factors miR-145/CCNE2 in Breast Cancer Cells. +target gene hsa-mir-138 Sepsis 30157481 MicroRNA-138 Aggravates Inflammatory Responses of Macrophages by Targeting SIRT1 and Regulating the NF-¦ÊB and AKT Pathways. +target gene hsa-mir-381 "Carcinoma, Cervical" 30161290 miR-381-3p restrains cervical cancer progression by downregulating FGF7. +target gene hsa-mir-34a Gastric Neoplasms 30165351 Increased Lactate in Gastric Cancer Tumor-Infiltrating Lymphocytes Is Related to Impaired T Cell Function Due to miR-34a Deregulated Lactate Dehydrogenase A. +target gene hsa-mir-718 "Carcinoma, Thyroid, Papillary" 30166214 miR-718 is involved in malignancy of papillary thyroid cancer through repression of PDPK1. +target gene hsa-mir-889 Neoplasms [unspecific] 30167605 "Circ008913, via miR-889 regulation of DAB2IP/ZEB1, is involved in the arsenite-induced acquisition of CSC-like properties by human keratinocytes in carcinogenesis." +target gene hsa-mir-299 "Carcinoma, Hepatocellular" 30170358 MiR-299-3p functions as a tumor suppressor via targeting Sirtuin 5 in hepatocellular carcinoma. +target gene hsa-mir-126 Kaposi Sarcoma 30170375 MicroRNA-126 regulates the phosphatidylinositol-3 kinase (PI3K)/protein kinase B (AKT) pathway in SLK cells in vitro and the expression of its pathway members in Kaposi's sarcoma tissue. +target gene hsa-mir-139 Glioma 30170559 Targeting the Notch1 oncogene by miR-139-5p inhibits glioma metastasis and epithelial-mesenchymal transition (EMT). +target gene hsa-mir-483 "Carcinoma, Thyroid, Anaplastic" 30171257 "MicroRNA 483-3p targets Pard3 to potentiate TGF-¦Â1-induced cell migration, invasion, and epithelial-mesenchymal transition in anaplastic thyroid cancer cells." +target gene hsa-mir-874 Diabetic Nephropathy 30171701 MiR-874 alleviates renal injury and inflammatory response in diabetic nephropathy through targeting toll-like receptor-4. +target gene hsa-mir-200c Colorectal Carcinoma 30171714 Anticancer effects of miR-200c in colorectal cancer through BMI1. +target gene hsa-mir-200a Kidney Neoplasms 30171729 Decreased miR-200a-3p is a key regulator of renal carcinoma growth and migration by directly targeting CBL. +target gene hsa-mir-497 Glioma 30171955 miR-497/Wnt3a/c-jun feedback loop regulates growth and epithelial-to-mesenchymal transition phenotype in glioma cells. +target gene hsa-mir-1301 Osteosarcoma 30172867 MicroRNA-1301 inhibits migration and invasion of osteosarcoma cells by targeting BCL9. +target gene hsa-mir-29a Spinal Cord Injuries 30173324 Lentivirus-Mediated Overexpression of miR-29a Promotes Axonal Regeneration and Functional Recovery in Experimental Spinal Cord Injury via PI3K/Akt/mTOR Pathway. +target gene hsa-mir-483 Colon Neoplasms 30173777 Mir-483 inhibits colon cancer cell proliferation and migration by targeting TRAF1. +target gene hsa-mir-205 "Diabetes Mellitus, Type 2" 30174230 "miR-205-5p gain-of-function increases AKT phosphorylation and decreases SHIP2 in primary hepatocytes, resulting in FOXO inhibition" +target gene hsa-mir-543 Gastric Neoplasms 30174445 miRNA-543 promotes cell migration and invasion by targeting SPOP in gastric cancer. +target gene hsa-mir-1228 Lung Neoplasms 30176158 CircRNA hsa_circ_100395 regulates miR-1228/TCF21 pathway to inhibit lung cancer progression. +target gene hsa-mir-575 "Carcinoma, Hepatocellular" 30176933 Long noncoding RNA MIR31HG inhibits hepatocellular carcinoma proliferation and metastasis by sponging microRNA-575 to modulate ST7L expression. +target gene hsa-mir-125b "Carcinoma, Breast" 30177391 "miR-125b-5p inhibits breast cancer cell proliferation, migration and invasion by targeting KIAA1522." +target gene hsa-mir-214 Osteosarcoma 30178836 MicroRNA-214 functions as an oncogene in human osteosarcoma by targeting TRAF3. +target gene hsa-mir-192 Hepatitis B Virus Infection 30180281 Hepatitis B Virus Induces Autophagy to Promote its Replication by the Axis of miR-192-3p-XIAP via NF-¦ÊB Signaling. +target gene hsa-mir-451 Glioma 30180756 MiRNA-451 Inhibits Glioma Cell Proliferation and Invasion Through the mTOR/HIF-1¦Á/VEGF Signaling Pathway by Targeting CAB39. +target gene hsa-mir-214 Acute Kidney Failure 30180910 miR-214 ameliorates acute kidney injury via targeting DKK3 and activating of Wnt/¦Â-catenin signaling pathway. +target gene hsa-mir-1228 Osteosarcoma 30180920 Exosomal miR-1228 from cancer-associated fibroblasts promotes cell migration and invasion of osteosarcoma by directly targeting SCAI. +target gene hsa-mir-1179 "Carcinoma, Lung, Non-Small-Cell" 30180955 MicroRNA-1179 suppresses cell growth and invasion by targeting sperm-associated antigen 5-mediated Akt signaling in human non-small cell lung cancer. +target gene hsa-mir-876 "Squamous Cell Carcinoma, Head and Neck" 30181714 MiR-876-5p modulates head and neck squamous cell carcinoma metastasis and invasion by targeting vimentin. +target gene hsa-mir-320 Ischemia-Reperfusion Injury 30181740 MiR-320 regulates cardiomyocyte apoptosis induced by ischemia-reperfusion injury by targeting AKIP1. +target gene hsa-mir-21 "Lymphoma, Hodgkin" 30184526 MiR-21-5p is upregulated in cHL compared to GC-B cells and protects cHL cells from apoptosis possibly via targeting BTG2 and PELI1 +target gene hsa-mir-146a "Carcinoma, Renal Cell, Clear-Cell" 30184528 "Hypoxia-Regulated miR-146a Targets Cell Adhesion Molecule 2 to Promote Proliferation, Migration, and Invasion of Clear Cell Renal Cell Carcinoma." +target gene hsa-mir-137 Hypertrophic Scar 30184530 miR-137 Inhibits Proliferation and Metastasis of Hypertrophic Scar Fibroblasts via Targeting Pleiotrophin. +target gene hsa-mir-338 Rheumatoid Arthritis 30184542 "miR-338-5p Regulates the Viability, Proliferation, Apoptosis and Migration of Rheumatoid Arthritis Fibroblast-Like Synoviocytes by Targeting NFAT5." +target gene hsa-mir-1 Prostate Neoplasms 30185212 The putative tumour suppressor miR-1-3p modulates prostate cancer cell aggressiveness by repressing E2F5 and PFTK1. +target gene hsa-mir-301a Neoplasms [unspecific] 30185897 Malignant Transformation of Human Bronchial Epithelial Cells Induced by Arsenic through STAT3/miR-301a/SMAD4 Loop. +target gene hsa-mir-21 Colorectal Carcinoma 30186399 Gambogic acid regulates the migration and invasion of colorectal cancer via microRNA-21-mediated activation of phosphatase and tensin homolog. +target gene hsa-mir-192 "Diabetes Mellitus, Type 1" 30186503 "miR-192 is upregulated in T1DM, regulates pancreatic ¦Â-cell development and inhibits insulin secretion through suppressing GLP-1 expression." +target gene hsa-mir-134 Neuropathic Pain 30187947 MiR-134-5p attenuates neuropathic pain progression through targeting Twist1. +target gene hsa-mir-210 "Carcinoma, Breast" 30188754 "Up-regulation of miR-210 induced by a hypoxic microenvironment promotes breast cancer stem cells metastasis, proliferation, and self-renewal by targeting E-cadherin." +target gene hsa-mir-23b Wound Healing 30188966 miR-23b promotes cutaneous wound healing through inhibition of the inflammatory responses by targeting ASK1. +target gene hsa-mir-590 Intracerebral Hemorrhage 30190124 MiR-590-5p alleviates intracerebral hemorrhage-induced brain injury through targeting Peli1 gene expression. +target gene hsa-mir-384 Diabetic Retinopathy 30191948 MicroRNA-384-3p inhibits retinal neovascularization through targeting hexokinase 2 in mice with diabetic retinopathy. +target gene hsa-mir-125b Ischemia-Reperfusion Injury 30193876 MicroRNA-125b mimic inhibits ischemia reperfusion-induced neuroinflammation and aberrant p53 apoptotic signalling activation through targeting TP53INP1. +target gene hsa-mir-324 Osteoarthritis 30193893 miR-324-5p is up regulated in end-stage osteoarthritis and regulates Indian Hedgehog signalling by differing mechanisms in human and mouse. +target gene hsa-mir-217 "Leukemia, Myeloid, Chronic" 30195077 miR-217 sensitizes chronic myelogenous leukemia cells to tyrosine kinase inhibitors by targeting pro-oncogenic anterior gradient 2. +target gene hsa-mir-98 Coronary Artery Disease 30195495 MicroRNA-98 regulates hepatic cholesterol metabolism via targeting sterol regulatory element-binding protein 2. +target gene hsa-mir-429 "Leukemia, Lymphoblastic, Acute, T-Cell" 30195757 A regulatory loop miR-429-MYCN-MFHAS1 was found potentially associated with the remission of T-ALL +target gene hsa-mir-663a Male Infertility 30195770 "miR-663a has been identified as the first microRNA that promotes the proliferation and DNA synthesis and suppresses the early apoptosis of human SSCs by targeting NFIX via cell cycle regulators Cyclin A2, Cyclin B1, and Cyclin E1" +target gene hsa-mir-327 Ischemia-Reperfusion Injury 30196287 Down-Regulation of miR-327 Alleviates Ischemia/Reperfusion-Induced Myocardial Damage by Targeting RP105. +target gene hsa-mir-423 Ischemia-Reperfusion Injury 30202848 "CFs participate in cardioprotective effects via an exosomes/microvesicles pathway during the acute phase of ischemia-reperfusion injury and Postcon can enhance this effect by upregulating the expression of CFs exosomes/microvesicles miR-423-3p, which targets the downstream effector RAP2C" +target gene hsa-mir-7 Lung Fibrosis 30202956 The CDR1as/miR-7/TGFBR2 axis modulates EMT in silica-induced pulmonary fibrosis. +target gene hsa-mir-182 "Squamous Cell Carcinoma, Oral" 30205384 miR-182-5p Promotes Growth in Oral Squamous Cell Carcinoma by Inhibiting CAMK2N1. +target gene hsa-mir-150 "Carcinoma, Hepatocellular" 30205391 "Long Non-Coding RNA PVT1/miR-150/ HIG2 Axis Regulates the Proliferation, Invasion and the Balance of Iron Metabolism of Hepatocellular Carcinoma." +target gene hsa-mir-214 "Carcinoma, Hepatocellular" 30206974 miR-214-5p targets KLF5 and suppresses proliferation of human hepatocellular carcinoma cells. +target gene hsa-mir-146b "Carcinoma, Renal Cell" 30206978 Inhibition of miR146b-5p suppresses CT-guided renal cell carcinoma by targeting TRAF6. +target gene hsa-mir-200c "Carcinoma, Breast" 30209363 Phosphodiesterase 7B/microRNA-200c relationship regulates triple-negative breast cancer cell growth. +target gene hsa-mir-451a "Carcinoma, Basal Cell" 30209892 miRNA-451a/TBX1 axis played a pivotal role in BCC tumorigenesis +target gene hsa-mir-298 Epilepsy 30210283 MicroRNA-298 Reverses Multidrug Resistance to Antiepileptic Drugs by Suppressing MDR1/P-gp Expression in vitro. +target gene hsa-mir-218 "Carcinoma, Cervical" 30210595 miRNA-218 regulates the proliferation and apoptosis of cervical cancer cells via targeting Gli3. +target gene hsa-mir-124 "Carcinoma, Hepatocellular" 30210622 Identification of microRNA-124 in regulation of Hepatocellular carcinoma through BIRC3 and the NF-¦ÊB pathway. +target gene hsa-mir-7702 Colorectal Carcinoma 30210694 Species-specific function of microRNA-7702 in human colorectal cancer cells via targeting TADA1. +target gene hsa-mir-506 "Carcinoma, Hepatocellular" 30210926 MicroRNA-506 suppresses invasiveness and metastasis of human hepatocellular carcinoma cells by targeting IL8. +target gene hsa-mir-21 Colon Neoplasms 30212824 "The CircRNA-ACAP2/Hsa-miR-21-5p/ Tiam1 Regulatory Feedback Circuit Affects the Proliferation, Migration, and Invasion of Colon Cancer SW480 Cells." +target gene hsa-mir-21 Renal Fibrosis 30212825 Total Flavonoids from Leaves of Carya Cathayensis Ameliorate Renal Fibrosis via the miR-21/Smad7 Signaling Pathway. +target gene hsa-mir-33b Osteosarcoma 30213286 MiR-33b inhibits osteosarcoma cell proliferation through suppression of glycolysis by targeting Lactate Dehydrogenase A (LDHA). +target gene hsa-mir-637 Melanoma 30213289 MiR-637 suppresses melanoma progression through directly targeting P-REX2a and inhibiting PTEN/AKT signaling pathway. +target gene hsa-mir-124 "Carcinoma, Bladder" 30214503 "MicroRNA-124 inhibits cell proliferation, invasion and migration by targeting CAV1 in bladder cancer." +target gene hsa-mir-6852 Gastric Neoplasms 30214548 MicroRNA-6852 suppresses cell proliferation and invasion via targeting forkhead box J1 in gastric cancer. +target gene hsa-mir-199a Ovarian Neoplasms 30214589 miRNA-199a-5p suppresses proliferation and invasion by directly targeting NF-¦ÊB1 in human ovarian cancer cells. +target gene hsa-mir-1265 Ovarian Neoplasms 30214617 Identifying miRNA-mRNA regulation network of major depressive disorder in ovarian cancer patients. +target gene hsa-mir-23b Ovarian Neoplasms 30214617 Identifying miRNA-mRNA regulation network of major depressive disorder in ovarian cancer patients. +target gene hsa-mir-33b Ovarian Neoplasms 30214617 Identifying miRNA-mRNA regulation network of major depressive disorder in ovarian cancer patients. +target gene hsa-mir-629 Ovarian Neoplasms 30214617 Identifying miRNA-mRNA regulation network of major depressive disorder in ovarian cancer patients. +target gene hsa-mir-933 Ovarian Neoplasms 30214617 Identifying miRNA-mRNA regulation network of major depressive disorder in ovarian cancer patients. +target gene hsa-mir-346 "Carcinoma, Hepatocellular" 30216442 LncRNA DGCR5 represses the development of hepatocellular carcinoma by targeting the miR-346/KLF14 axis. +target gene hsa-mir-409 "Carcinoma, Renal Cell, Clear-Cell" 30218446 Phosphoinositide-dependent kinase 1-associated glycolysis is regulated by miR-409-3p in clear cell renal cell carcinoma. +target gene hsa-mir-1306 "Carcinoma, Hepatocellular" 30219228 miR-1306-3p targets FBXL5 to promote metastasis of hepatocellular carcinoma through suppressing snail degradation. +target gene hsa-mir-34a Parkinson Disease 30221494 miR-34a/BCL-2 signaling axis contributes to apoptosis in MPP+ -induced SH-SY5Y cells. +target gene hsa-mir-501 Glioma 30221699 miR?501?3p sensitizes glioma cells to cisplatin by targeting MYCN. +target gene hsa-mir-184 Nasopharyngeal Neoplasms 30223264 "miR-184 Inhibits Tumor Invasion, Migration and Metastasis in Nasopharyngeal Carcinoma by Targeting Notch2." +target gene hsa-mir-146a Sepsis 30224945 miR-146a Attenuates Sepsis-Induced Myocardial Dysfunction by Suppressing IRAK1 and TRAF6 via Targeting ErbB4 Expression. +target gene hsa-mir-338 Glioma 30225541 MicroRNA-338-5p plays a tumor suppressor role in glioma through inhibition of the MAPK-signaling pathway by binding to FOXD1. +target gene hsa-mir-23a Atherosclerosis 30227118 MicroRNA-23a-5p promotes atherosclerotic plaque progression and vulnerability by repressing ATP-binding cassette transporter A1/G1 in macrophages. +target gene hsa-mir-4317 "Carcinoma, Lung, Non-Small-Cell" 30227870 miR-4317 suppresses non-small cell lung cancer (NSCLC) by targeting fibroblast growth factor 9 (FGF9) and cyclin D2 (CCND2). +target gene hsa-mir-204 "Carcinoma, Breast, Triple Negative" 30228364 Molecular pathogenesis of triple-negative breast cancer based on microRNA expression signatures: antitumor miR-204-5p targets AP1S3. +target gene hsa-mir-363 "Carcinoma, Renal Cell" 30229899 "MicroRNA-363 inhibits angiogenesis, proliferation, invasion, and migration of renal cell carcinoma via inactivation of the Janus tyrosine kinases 2-signal transducers and activators of transcription 3 axis by suppressing growth hormone receptor gene." +target gene hsa-let-7e Multiple Myeloma 30230597 "The miR-125a-3p, miR-125a-5p, miR-99b-5p, and let-7e were powerful miRNAs correlating with the FGFR3, MAP1B, MYRIP, and CDC42BPA under the relevance analysis in the subnetwork." +target gene hsa-mir-125a Multiple Myeloma 30230597 "The miR-125a-3p, miR-125a-5p, miR-99b-5p, and let-7e were powerful miRNAs correlating with the FGFR3, MAP1B, MYRIP, and CDC42BPA under the relevance analysis in the subnetwork." +target gene hsa-mir-99b Multiple Myeloma 30230597 "The miR-125a-3p, miR-125a-5p, miR-99b-5p, and let-7e were powerful miRNAs correlating with the FGFR3, MAP1B, MYRIP, and CDC42BPA under the relevance analysis in the subnetwork." +target gene hsa-mir-143 Heart Failure 30230713 "miR-143 (P? T might contribute to the increased risk and poor prognosis of NSCLC, highlighting the importance of rs767649 in the prevention and therapy of NSCLC." +therapeutic target hsa-mir-145 Bladder Neoplasms 26544536 "Taken together, our results identified that lncRNA-UCA1 enhances bladder cancer cell migration and invasion in part through the hsa-miR-145/ZEB1/2/FSCN1 pathway. Therefore, lncRNA-UCA1 might act as a promising therapeutic target for the invasion and metastasis of bladder cancer." +therapeutic target hsa-mir-137 Gastric Neoplasms 26545111 "In conclusion, the results reinforced the critical role for the down-regulated miR-137 expression in gastric cancer and suggested that miR-137 expression could be a prognostic indicator for this disease. In addition, these patients with TNM stage III gastric cancer and low miR-137 expression might need more aggressive postoperative treatment and closer follow-up." +therapeutic target hsa-mir-362 "Leukemia, Myelogenous, Chronic, BCR-ABL Positive" 26545365 "miR-362-5p acts as an oncomiR that down-regulates GADD45¦Á, which consequently activates the JNK1/2 and P38 signalling. This finding provides novel insights into CML leukaemogenesis and may help identify new diagnostic and therapeutic targets." +therapeutic target hsa-mir-134 Atherosclerosis 26546816 "Collectively, our findings indicate that miR-134 may regulate lipid accumulation and proinfiammatory cytokine secretion in macrophages by targeting the ANGPTL4 gene. Our results have also suggested a promising and potential therapeutic target for atherosclerosis." +therapeutic target hsa-mir-9 "Carcinoma, Hepatocellular" 26547929 "Our study suggests that miR-9 functions as a tumor suppressor in HCC progression by inhibiting a series of target genes, including the newly validated miR-9/IGF2BP1/AKT&ERK axis, thus providing potential therapeutic targets and novel prognostic biomarkers for HCC patients." +therapeutic target hsa-mir-326 "Carcinoma, Lung, Non-Small-Cell" 26548724 "Our study demonstrated a direct target relationship between NSBP1 and miR-326 through which miR-326 inhibited cell proliferation and invasion of NSCLC cells. Thus, miR-326-NSBP1 is a promising candidate target for developing novel anticancer therapeutics for NSCLC." +therapeutic target hsa-mir-296 "Carcinoma, Lung, Non-Small-Cell" 26549165 "Taken together, the present study indicated that miR-296-5p regulated PLK1 expression and could function as a tumor suppressor in NSCLC progression, which provides a potential target for gene therapy of NSCLC." +therapeutic target hsa-mir-146b Osteosarcoma 26549292 "These results indicated that miR-146b-5p promoted proliferation, migration and invasiveness. It also increased resistance to chemotherapy through the regulation of ZNRF3, and suggested novel potential therapeutic targets for the treatment of osteosarcoma." +therapeutic target hsa-mir-885 Neoplasms [unspecific] 26554827 Our work shows how DNp73 promotes cancer stem-like features and provides a mechanistic rationale to target the DNp73-IGF1R cascade as a therapeutic strategy to eradicate CSC. +therapeutic target hsa-mir-506 Glioma 26554866 "These results showed that miR-506 functions as a tumor suppressor in glioma by targeting STAT3, suggesting that miR-506 may serve as a potential target in the treatment of human glioma." +therapeutic target hsa-mir-143 "Adenocarcinoma, Pancreatic Ductal" 26554910 "miRNA expression profiles should be investigated to evaluate the potential function as biomarkers for early diagnosis, disease progression, response to therapy, and prognosis because of their characteristics of high stability, tissue specificity and ease of availability." +therapeutic target hsa-mir-145 "Adenocarcinoma, Pancreatic Ductal" 26554910 "miRNA expression profiles should be investigated to evaluate the potential function as biomarkers for early diagnosis, disease progression, response to therapy, and prognosis because of their characteristics of high stability, tissue specificity and ease of availability." +therapeutic target hsa-mir-96 "Adenocarcinoma, Pancreatic Ductal" 26554910 "miRNA expression profiles should be investigated to evaluate the potential function as biomarkers for early diagnosis, disease progression, response to therapy, and prognosis because of their characteristics of high stability, tissue specificity and ease of availability." +therapeutic target hsa-mir-320a Osteoporosis 26555194 "We identified two osteoblast miRNAs over-expressed in osteoporotic fractures, which opens novel prospects for research and therapy." +therapeutic target hsa-mir-483 Osteoporosis 26555194 "We identified two osteoblast miRNAs over-expressed in osteoporotic fractures, which opens novel prospects for research and therapy." +therapeutic target hsa-mir-101 "Squamous Cell Carcinoma, Esophageal" 26556718 "Overexpression of miR-101 in ESCC inhibits proliferation and metastasis. Therefore, the miR-101/COX-2 pathway might be a therapeutic target in ESCC." +therapeutic target hsa-mir-543 Hypertension 26562529 "In summary, our study suggested that the downregulation of the miR-543 could alleviate the insulin resistance via the modulation of the SIRT1 expression, which might be a potential new strategy for treating insulin resistance and a promising therapeutic method for hypertension." +therapeutic target hsa-mir-182 Breast Neoplasms 26563369 downregulation of miR-182 might find therapeutical value for overcoming trastuzumab resistance. +therapeutic target hsa-mir-3175 Neoplasms [unspecific] 26565624 "Our results suggest that HOXB1 functions as a tumor suppressor, regulated by miR-3175 in glioma. These results clarify the pathogenesis of glioma and offer a potential target for its treatment." +therapeutic target hsa-mir-186 "Squamous Cell Carcinoma, Esophageal" 26568291 "Our findings established that the miR-186 has a suppressive role in ESCC progression via SKP2-mediated pathway, and this implies that miR-186 could be a potential therapeutic target for ESCC." +therapeutic target hsa-mir-224 Cholangiocarcinoma 26573191 IL-6 may promote the invasive and metastatic properties of CCA through upregulated miR-224. Studies of the differentially expressed serum miRNAs in CCA may help to further elucidate the pathogenic processes of this disease and aid in the development of a novel and effective therapeutic strategy. +therapeutic target hsa-mir-1246 Colorectal Carcinoma 26573378 "Consequently, these findings provided a molecular basis for the role of miR-1246/CCNG2 in the progression of human CRC and suggested a novel target for the treatment of CRC." +therapeutic target hsa-mir-340 Breast Neoplasms 26573744 "In brief, miR-340 plays an important role in breast cancer progression. Thus, miR-340 may be further explored as a novel biomarker for breast cancer metastasis and prognosis,and potentially a therapeutic target." +therapeutic target hsa-mir-124 Prostate Neoplasms 26573802 "Taken together, our results offer a preclinical rationale to evaluate miR-124 for cancer treatment." +therapeutic target hsa-mir-27b Gastric Neoplasms 26576539 These results show that miR-27b-3p suppresses ROR1 expression through the binding site in the 3'UTR inhibiting the cell proliferation. These findings indicate that miR-27b-3p exerts tumor-suppressive effects in GC through the suppression of oncogene ROR1 expression and suggest a therapeutic application of miR-27b-3p in GC. +therapeutic target hsa-mir-449a Gastric Neoplasms 26576674 "Our results demonstrated that miR-449a suppressed Flot2 expression results in decreased cell invasion through repressing TGF-¦Â-mediated-EMT, and provides a new theoretical basis to further investigate miR-449a-regulated Flot2 as a potential biomarker and a promising approach for GC treatment." +therapeutic target hsa-mir-634 Ovarian Neoplasms 26576679 miR-634 levels determine chemosensitivity in ovarian cancer cells. We identify miR-634 as a therapeutic candidate to resensitize chemotherapy resistant ovarian tumors. +therapeutic target hsa-mir-34a Neoplasms [unspecific] 26580663 microRNA-34a as a Therapeutic Agent against Human Cancer. +therapeutic target hsa-mir-1274a Breast Neoplasms 26581147 "Biomarkers of DNA repair and cell cycle control can identify patients at high risk of treatment failure in those receiving radiation therapy for early breast cancer in independent cohorts. These should be further investigated prospectively, especially TOP2A and SKP2, for which targeted therapies are available." +therapeutic target hsa-mir-139 Breast Neoplasms 26581147 "Biomarkers of DNA repair and cell cycle control can identify patients at high risk of treatment failure in those receiving radiation therapy for early breast cancer in independent cohorts. These should be further investigated prospectively, especially TOP2A and SKP2, for which targeted therapies are available." +therapeutic target hsa-mir-148a "Carcinoma, Lung, Non-Small-Cell" 26584284 Evidence from this study demonstrated that miR-148a exerts tumor-suppressive effects in NSCLC and suggests a new therapeutic option for NSCLC. +therapeutic target hsa-mir-203 Osteosarcoma 26584294 "Taken together, these findings suggest that miR-203 acts as a tumor suppressor via regulation of TBK1 expression in OS progression, and miR-203 may be a promising therapeutic target for OS." +therapeutic target hsa-mir-4792 "Carcinoma, Nasopharyngeal" 26585487 "These findings suggest that miR-4792 functions as a tumor suppressor in NPC development and progression by targeting FOXC1, which could act as a novel potential therapeutic target for NPC treatment,and miR-4792/FOXC1 pathway that we studied might be used for NPC treatment in future." +therapeutic target hsa-mir-125b Endomyocardial Fibrosis 26585673 "In conclusion, miR-125b is critical for induction of cardiac fibrosis and acts as a potent repressor of multiple anti-fibrotic mechanisms.Inhibition of miR-125b may represent a novel therapeutic approach for the treatment of human cardiac fibrosis and other fibrotic diseases." +therapeutic target hsa-mir-143 Lung Neoplasms 26586766 "This study shows that miR-143/145 expressed from the tumor microenvironment stimulates neoangiogenesis and supports tumor expansion in the lung, demonstrating a surprising role for the putative tumor suppressor miRNA cluster in promoting tumorigenesis. We propose inhibition of miR-143/145 as a therapeutic avenue to modulate tumor neoangiogenesis." +therapeutic target hsa-mir-145 Lung Neoplasms 26586766 "This study shows that miR-143/145 expressed from the tumor microenvironment stimulates neoangiogenesis and supports tumor expansion in the lung, demonstrating a surprising role for the putative tumor suppressor miRNA cluster in promoting tumorigenesis. We propose inhibition of miR-143/145 as a therapeutic avenue to modulate tumor neoangiogenesis." +therapeutic target hsa-mir-155 Pneumonia 26589478 Our findings suggest that antagonizing certain microRNA might serve as a potential therapeutic strategy against secondary bacterial infection. +therapeutic target hsa-mir-27a Breast Neoplasms 26592661 Our findings provide a novel anti-tumor mechanism of ATO involved in miR-27a for the treatment of breast cancer. +therapeutic target hsa-mir-9 "Carcinoma, Lung, Non-Small-Cell" 26593208 "These findings suggest that oncogenic miR-9 targeted FoxO1 to promote cell growth, and downregulation of this axis was involved in erlotinib's growth inhibitory effects. Clarifying the regulation of miRNAs by erlotinib may indicate novel strategies for enhancing EGFR-targeted cancer therapy." +therapeutic target hsa-mir-148a "Carcinoma, Hepatocellular" 26599259 miR-148a is an inhibitor of the I¦ÊB kinase alpha/NUMB/NOTCH pathway and an inducer of hepatocytic differentiation that when deregulated promotes HCC initiation and progression. Differentiation-targeted therapy may be a promising strategy to treat and prevent HCC. +therapeutic target hsa-mir-184 Ovarian Neoplasms 26601424 "Altogether, our results suggest that miR-184 together with pathologic diagnosis is critical for prognosis determination in EOC patients and help select treatment strategy." +therapeutic target hsa-mir-100 "Adenocarcinoma, Pancreatic Ductal" 26606261 "Consistent miR expression profiles, in part regulated by mutant TP53 gene, were identified in gemcitabine-resistant PDAC with significant MRP-1 and Bcl-2 overexpression. These results provide a basis for further elucidation of chemoresistance mechanisms and therapeutic approaches to overcome chemoresistance in PDAC." +therapeutic target hsa-mir-125b "Adenocarcinoma, Pancreatic Ductal" 26606261 "Consistent miR expression profiles, in part regulated by mutant TP53 gene, were identified in gemcitabine-resistant PDAC with significant MRP-1 and Bcl-2 overexpression. These results provide a basis for further elucidation of chemoresistance mechanisms and therapeutic approaches to overcome chemoresistance in PDAC." +therapeutic target hsa-mir-138 "Adenocarcinoma, Pancreatic Ductal" 26606261 "Consistent miR expression profiles, in part regulated by mutant TP53 gene, were identified in gemcitabine-resistant PDAC with significant MRP-1 and Bcl-2 overexpression. These results provide a basis for further elucidation of chemoresistance mechanisms and therapeutic approaches to overcome chemoresistance in PDAC." +therapeutic target hsa-mir-21 "Adenocarcinoma, Pancreatic Ductal" 26606261 "Consistent miR expression profiles, in part regulated by mutant TP53 gene, were identified in gemcitabine-resistant PDAC with significant MRP-1 and Bcl-2 overexpression. These results provide a basis for further elucidation of chemoresistance mechanisms and therapeutic approaches to overcome chemoresistance in PDAC." +therapeutic target hsa-mir-210 "Adenocarcinoma, Pancreatic Ductal" 26606261 "Consistent miR expression profiles, in part regulated by mutant TP53 gene, were identified in gemcitabine-resistant PDAC with significant MRP-1 and Bcl-2 overexpression. These results provide a basis for further elucidation of chemoresistance mechanisms and therapeutic approaches to overcome chemoresistance in PDAC." +therapeutic target hsa-mir-31 "Adenocarcinoma, Pancreatic Ductal" 26606261 "Consistent miR expression profiles, in part regulated by mutant TP53 gene, were identified in gemcitabine-resistant PDAC with significant MRP-1 and Bcl-2 overexpression. These results provide a basis for further elucidation of chemoresistance mechanisms and therapeutic approaches to overcome chemoresistance in PDAC." +therapeutic target hsa-mir-330 "Adenocarcinoma, Pancreatic Ductal" 26606261 "Consistent miR expression profiles, in part regulated by mutant TP53 gene, were identified in gemcitabine-resistant PDAC with significant MRP-1 and Bcl-2 overexpression. These results provide a basis for further elucidation of chemoresistance mechanisms and therapeutic approaches to overcome chemoresistance in PDAC." +therapeutic target hsa-mir-378 "Adenocarcinoma, Pancreatic Ductal" 26606261 "Consistent miR expression profiles, in part regulated by mutant TP53 gene, were identified in gemcitabine-resistant PDAC with significant MRP-1 and Bcl-2 overexpression. These results provide a basis for further elucidation of chemoresistance mechanisms and therapeutic approaches to overcome chemoresistance in PDAC." +therapeutic target hsa-mir-99a "Adenocarcinoma, Pancreatic Ductal" 26606261 "Consistent miR expression profiles, in part regulated by mutant TP53 gene, were identified in gemcitabine-resistant PDAC with significant MRP-1 and Bcl-2 overexpression. These results provide a basis for further elucidation of chemoresistance mechanisms and therapeutic approaches to overcome chemoresistance in PDAC." +therapeutic target hsa-mir-140 Osteoarthritis 26608362 miR-29a and miR-140 combination treatment may be a possible treatment for OA +therapeutic target hsa-mir-22 Gastric Neoplasms 26610210 These findings provide a better understanding of the development and progression of GC and may be an important implication for future therapy of the GC. +therapeutic target hsa-mir-543 Gastric Neoplasms 26612257 "Our results identify a new regulatory mechanism of miR-543 on SIRT1 expression in gastric cancer, and raise the possibility that the miR-543/SIRT1 pathway may serve as a potential target for the treatment of gastric cancer." +therapeutic target hsa-mir-20b "Carcinoma, Hepatocellular" 26612965 "The whole study suggests that miR-20b, HIF-1¦Á, and VEGF serve as a potential therapeutic agent for hepatocellular carcinoma." +therapeutic target hsa-mir-142 Peritoneal Fibrosis 26616819 These results suggest that several miRNAs are involved in PF and that they may be useful as novel diagnostic biomarkers and therapeutic targets for PF. +therapeutic target hsa-mir-21 Peritoneal Fibrosis 26616819 These results suggest that several miRNAs are involved in PF and that they may be useful as novel diagnostic biomarkers and therapeutic targets for PF. +therapeutic target hsa-mir-221 Peritoneal Fibrosis 26616819 These results suggest that several miRNAs are involved in PF and that they may be useful as novel diagnostic biomarkers and therapeutic targets for PF. +therapeutic target hsa-mir-223 Peritoneal Fibrosis 26616819 These results suggest that several miRNAs are involved in PF and that they may be useful as novel diagnostic biomarkers and therapeutic targets for PF. +therapeutic target hsa-mir-34a Peritoneal Fibrosis 26616819 These results suggest that several miRNAs are involved in PF and that they may be useful as novel diagnostic biomarkers and therapeutic targets for PF. +therapeutic target hsa-mir-96 "Carcinoma, Thyroid, Papillary" 26617698 "The data from the present study demonstrated that miR-96 can promote proliferation, and inhibit apoptosis in PTC cell lines K1 and TPC1, thus miR-96 may play an oncogenic role in PTC by inhibiting the FOXO1 and regulating AKT/FOXO1/Bim pathway, and it may serve as a novel therapeutic target for miRNA-based PTC therapy." +therapeutic target hsa-mir-200a "Carcinoma, Hepatocellular" 26617701 "Our study reveals an important role of miR-200a in inhibiting EMT,proliferation and migration in HCC cells, suggesting the possibility of miR-200a-based therapeutics in HCC." +therapeutic target hsa-mir-299 Lung Neoplasms 26617714 "Therefore, the disordered decreased of miR-299-3p and resulting ABCE1 up-expression may contribute to chemoresistance of lung cancer, and miR-299-3p-ABCE1 may represent a new potential therapeutic target for the treatment of chemoresistance of lung cancer." +therapeutic target hsa-mir-101 "Carcinoma, Cervical" 26617722 "MiR-101 likely acts as a tumor suppressor in cervical cancer.Overexpression of miR-101 decreased expression of its target gene Cox-2 and inhibited proliferation and invasion, and promoted apoptosis to suppress tumorigenicity. MiR-101 is a promising new target for the development of therapeutic strategies for the clinical treatment of cervical cancer." +therapeutic target hsa-mir-126 Glioma 26617742 "Taken together, these findings showed that miR-126 functions as a tumor suppressor in glioma cells by targeting IRS-1 expression via the PI3K/AKT signaling pathways, suggesting that miR-126 might be a novel target for therapeutic strategies in glioma." +therapeutic target hsa-mir-10b "Carcinoma, Renal Cell, Clear-Cell" 26617769 Our results suggest that miR-10b plays a tumor-suppressive role in ccRCC. Demethylation of miR-10b may be therapeutically beneficial for ccRCC treatment. +therapeutic target hsa-mir-374a Osteosarcoma 26617789 "Our study suggested that miR-374a functions as an oncogene in OS, and the miR-374a/Axin2 axis might represent a potential therapeutic target for OS intervention." +therapeutic target hsa-mir-142 "Carcinoma, Lung, Non-Small-Cell" 26617792 These results suggest that miR-142-3p may be a tumor suppressor through the downregulation of HMGB1 in NSCLC. miR-142-3p may be a tumor suppressor and a potential therapeutic agent for patients with NSCLC. +therapeutic target hsa-mir-137 "Carcinoma, Lung, Non-Small-Cell" 26617798 "Taken together, our findings suggested that miR-137/BMP7 axis could contribute to the progression of NSCLC, suggesting miR-137 as a potential therapeutic target for the treatment of NSCLC." +therapeutic target hsa-mir-338 Gastric Neoplasms 26617808 "Our study suggested that miR-338-3p is significantly decreased in gastric cancer, and inhibits cell proliferation, migration and invasion partially via the downregulation of ADAM17. Thus, miR-338-3p may represent a potential therapeutic target for gastric cancer intervention." +therapeutic target hsa-mir-185 "Carcinoma, Lung, Non-Small-Cell" 26617940 "Collectively, we conclude that miR-185 has a critical function by blocking AKT1 in NSCLC cells, and it may be a novel therapeutic agent for miRNA based NSCLC therapy." +therapeutic target hsa-mir-140 Glioma 26619802 "Taken together, we have demonstrated the fact that knockdown of MALAT1 resulted in the increased permeability of BTB, which might contribute to establishing potential therapeutic strategies for human gliomas." +therapeutic target hsa-mir-34a Multiple Myeloma 26620594 Delivery of miR-34a by chitosan/PLGA nanoplexes for the anticancer treatment of multiple myeloma. +therapeutic target hsa-mir-152 Gastric Neoplasms 26627200 "TGF-¦Â could induce HLA-G expression in GC by inhibiting miR-152,involving its negative regulation on HLA-G. Since TGF-¦Â induced HLA-G up-regulation plays important role in immune escape, a potential application of miR-152 was suggested in GC treatment, or miR-152 might be one potential biomarker for GC." +therapeutic target hsa-mir-17 "Carcinoma, Breast, Triple Negative" 26629823 "Our results imply that therapeutic antisense sequences against miRNAs should be designed to target the miRNA strand with the greatest number of putative binding sites in the target mRNAs, while minimizing affinity for the minor strand." +therapeutic target hsa-mir-133a Gastric Neoplasms 26629938 These outcomes might be secondary to the increased expression of miR-133a after the treatment with UA. +therapeutic target hsa-mir-15a Melanoma 26631117 Our results support a key role of IL-10R¦Á in the development and progression of melanoma and suggest that the IL-10/IL-10 receptor system may become a new therapeutic target for melanoma treatment. +therapeutic target hsa-mir-185 Melanoma 26631117 Our results support a key role of IL-10R¦Á in the development and progression of melanoma and suggest that the IL-10/IL-10 receptor system may become a new therapeutic target for melanoma treatment. +therapeutic target hsa-mir-211 Melanoma 26631117 Our results support a key role of IL-10R¦Á in the development and progression of melanoma and suggest that the IL-10/IL-10 receptor system may become a new therapeutic target for melanoma treatment. +therapeutic target hsa-mir-409 Breast Neoplasms 26631969 "Our data collectively indicate that miR-409-3p functions as a tumor suppressor in BC through downregulating Akt1, supporting the targeting of the novel miR-409-3p/Akt1 axis as a potentially effective therapeutic approach for BC." +therapeutic target hsa-mir-145 Prostate Neoplasms 26632856 This novel study shows a role for miR-145 in modulating radiosensitivity in vivo and highlights the need for further study investigating the potential role of miR-145 as both a predictive marker of response and a novel therapeutic agent with which to enhance the efficacy of radiation therapy. +therapeutic target hsa-mir-324 Cardiovascular Diseases [unspecific] 26633713 "Our study defines the NFAT4/ miR-324-5p/Mtfr1 axis, which participates in the regulation of mitochondrial fission and cardiomyocyte apoptosis, and suggests potential new treatment avenues for cardiac diseases." +therapeutic target hsa-mir-122 Liver Diseases [unspecific] 26636761 "Taken together, our study indicates that miR-122 may downregulate cytokine production in HSCs and macrophage chemotaxis and that the targeting of miR-122 may have therapeutic potential for preventing the progression of liver diseases." +therapeutic target hsa-mir-424 "Carcinoma, Endometrial" 26638889 "Taken together, our study suggests that increased miR-424 suppresses E2-induced cell growth, and providing a potential therapeutic target for estrogen-associated endometrial carcinoma." +therapeutic target hsa-mir-134 Lung Neoplasms 26642897 "Altogether, our data demonstrated an altered expression of two development-related miRNAs namely miR-134 and miR-187 in lung tumors for the first time. Moreover we have shown that miR-134 and miR-187 expression alternation were in accordance with their approved regulatory roles, therefore these miRNAs could serve as new biomarkers with potential usefulness in lung cancer diagnosis and treatments. In addition, miR-187 expression in tumor cells could perturb cell cycle which supported its possible role as tumor suppressor." +therapeutic target hsa-mir-187 Lung Neoplasms 26642897 "Altogether, our data demonstrated an altered expression of two development-related miRNAs namely miR-134 and miR-187 in lung tumors for the first time. Moreover we have shown that miR-134 and miR-187 expression alternation were in accordance with their approved regulatory roles, therefore these miRNAs could serve as new biomarkers with potential usefulness in lung cancer diagnosis and treatments. In addition, miR-187 expression in tumor cells could perturb cell cycle which supported its possible role as tumor suppressor." +therapeutic target hsa-mir-150 "Leukemia, Myeloid" 26644403 "Our findings indicate that decreased KLF4 expression mediates antileukemic effects through regulation of gene and microRNA networks,containing miR-150, CDKN1A, and MYC, and provide mechanistic support for therapeutic strategies increasing KLF4 expression." +therapeutic target hsa-mir-33a Atherosclerosis 26645139 "This review summarizes the current understanding of the functions of miR-33a/b and the progress in miRNA therapeutics for treatment of various diseases, including atherosclerosis." +therapeutic target hsa-mir-33b Atherosclerosis 26645139 "This review summarizes the current understanding of the functions of miR-33a/b and the progress in miRNA therapeutics for treatment of various diseases, including atherosclerosis." +therapeutic target hsa-mir-23b Diabetic Nephropathy 26646104 "Taken together, we showed for the first time that miR-23b acts as a suppressor of EMT in diabetic nephropathy through repressing PI3K-AKT signalling pathway activation by targeting HMGA2, which maybe a potential therapeutic target for diabetes-induced renal dysfunction." +therapeutic target hsa-mir-103 "Carcinoma, Hepatocellular" 26646106 "These findings indicate that miR-103 potentially acts as an oncogene in HCC by inhibiting AKAP12 expression and raise the possibility that miR-103 increases telomerase activity by increasing PKC¦Á activity. Thus, miR-103 may represent a new potential diagnostic and therapeutic target for HCC treatment." +therapeutic target hsa-mir-362 Kidney Neoplasms 26647877 "These results suggested that miR-362-3p functions as a tumor suppressor in RCC, and may serve as a potential molecular target in the treatment of RCC." +therapeutic target hsa-mir-21 Diabetes Mellitus 26655730 These results suggest that endogenous miRNAs involved in the formation of IPCs from PPCs should be considered in the development of an effective cell transplant therapy for diabetes. +therapeutic target hsa-mir-340 "Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal" 26656176 "Taken together, these data suggest that miR-340 impedes LSCC progression by targeting EZH2 with the possible mechanism to enhance the expression of anti-oncogene p27 and suppress PI3K/Akt activation, providing a novel target and a potential therapeutic pathway against LSCC." +therapeutic target hsa-mir-204 Breast Neoplasms 26656364 Our study reveals that Sam68 is regulated by miR-204 and may play an important role in the self-renewal of BCSCs via activating the Wnt/beta-catenin pathway. Sam68 may represent a novel therapeutic target for breast cancer. +therapeutic target hsa-mir-126 Thrombosis 26659078 Overexpressed miR-126 inhibits apoptosis of VECs and DVT through targeting the anti-apoptotic pathway PI3K/Akt via PIK3R2.GENERAL SIGNIFICANCE: These findings may provide a new target for the therapy of DVT. +therapeutic target hsa-mir-215 Pancreatic Neoplasms 26662405 "These findings indicate that miR-215 may act as a tumor suppressor in pancreatic cancer cells, and could serve as a novel therapeutic target for miR-based therapy." +therapeutic target hsa-mir-548d Breast Neoplasms 26663100 Our study showed that miR-548d-3p/TP53BP2 pathway is critically involved in the proliferation and apoptosis of breast cancer cells and may be new therapeutic target of breast cancer cells. +therapeutic target hsa-mir-146a Allergy 26663191 "Further characterization of microRNA functions is important, as similar to other conditions, the modulation of microRNA expression could potentially be used for therapeutic purposes in allergic diseases in the future. In addition, miRNAs could be implemented as biomarkers for endotyping complex allergic conditions." +therapeutic target hsa-mir-155 Allergy 26663191 "Further characterization of microRNA functions is important, as similar to other conditions, the modulation of microRNA expression could potentially be used for therapeutic purposes in allergic diseases in the future. In addition, miRNAs could be implemented as biomarkers for endotyping complex allergic conditions." +therapeutic target hsa-mir-21 Allergy 26663191 "Further characterization of microRNA functions is important, as similar to other conditions, the modulation of microRNA expression could potentially be used for therapeutic purposes in allergic diseases in the future. In addition, miRNAs could be implemented as biomarkers for endotyping complex allergic conditions." +therapeutic target hsa-mir-214 Breast Neoplasms 26666173 MiR-214 increased the sensitivity of breast cancer cells to TAM and FUL through inhibition of autophagy by targeting UCP2. MiR-214 shows potential as a novel therapeutic strategy for overcoming endocrine resistance in ER(+) breast cancers. +therapeutic target hsa-mir-1 Arrhythmia 26671473 "We aim at emphasizing the relationship between miR-1 and ion channels and proteins involved in the process of arrhythmia. In addition, we will pay attention to its future therapeutic prospects." +therapeutic target hsa-mir-21 Breast Neoplasms 26676464 "Taken together, we provide novel evidence that miR-21 knockdown suppresses cell growth, migration and invasion partly by inhibiting PI3K/AKT activation via direct targeting PIK3R1 and reversing EMT in breast cancer. p85¦Á downregulation defined a specific subgroup of breast cancer with shorter 5-year DFS and OS, which may require more aggressive treatment." +therapeutic target hsa-mir-34a "Carcinoma, Breast, Triple Negative" 26676753 "Together, our results demonstrate that miR-34a exerts potent antitumorigenic effects in vitro and in vivo and suggests that miR-34a replacement therapy, which is currently being tested in human clinical trials, represents a promising therapeutic strategy for TNBC." +therapeutic target hsa-mir-186 Multiple Myeloma 26679605 "Our collective results clearly indicate that miR-186 functions as a tumor suppressor in MM, supporting its potential as a therapeutic target for the disease." +therapeutic target hsa-mir-134 Osteosarcoma 26681023 These findings indicate that miR-134 may act as a tumor suppressor in osteosarcoma and could serve as a novel therapeutic agent for miRNA-based therapy. +therapeutic target hsa-mir-181c Glioblastoma 26682928 "our study found that miR-181c plays a key role in glioblastoma cell invasion, migration and mesenchymal transition suggesting potential therapeutic applications." +therapeutic target hsa-mir-555 Viral Infectious Disease 26683768 These findings provide the first evidence for the role of miR-555 in PV replication and reveal that miR-555 could contribute to the development of antiviral therapeutic strategies against PV. +therapeutic target hsa-mir-1290 "Leukemia, Lymphoblastic, Acute, B-Cell" 26684414 "Our results identify an expression profile of miR-151-5p, miR-451, and miR-1290 as a novel biomarker for outcome in pediatric precursor B-cell ALL patients, regardless of treatment protocol. The use of these markers may lead to improved risk stratification at diagnosis and allow early therapeutic interventions in an attempt to improve survival of high risk patients." +therapeutic target hsa-mir-151 "Leukemia, Lymphoblastic, Acute, B-Cell" 26684414 "Our results identify an expression profile of miR-151-5p, miR-451, and miR-1290 as a novel biomarker for outcome in pediatric precursor B-cell ALL patients, regardless of treatment protocol. The use of these markers may lead to improved risk stratification at diagnosis and allow early therapeutic interventions in an attempt to improve survival of high risk patients." +therapeutic target hsa-mir-451 "Leukemia, Lymphoblastic, Acute, B-Cell" 26684414 "Our results identify an expression profile of miR-151-5p, miR-451, and miR-1290 as a novel biomarker for outcome in pediatric precursor B-cell ALL patients, regardless of treatment protocol. The use of these markers may lead to improved risk stratification at diagnosis and allow early therapeutic interventions in an attempt to improve survival of high risk patients." +therapeutic target hsa-mir-125b Lung Neoplasms 26686386 these results show tremendous promise of wt-p53 and miR-125b gene therapy using dual CD44/EGFR-targeting HA NP vector for effective treatment of lung cancer. +therapeutic target hsa-mir-122 Cholangiocarcinoma 26686459 "MiR-122 expression was significantly weaker in CC tissues, and miR-122 overexpression might play pivotal roles in inhibiting proliferation, stimulating apoptosis and suppressing invasion of CC cells, suggesting a new target for CC diagnosis and treatment." +therapeutic target hsa-mir-145 "Adenocarcinoma, Lung" 26687391 "MicroRNA 25, microRNA 145, and microRNA 210 as biomarkers for predicting the efficacy of maintenance treatment with pemetrexed in lung adenocarcinoma patients who are negative for epidermal growth factor receptor mutations or anaplastic lymphoma kinase translocations." +therapeutic target hsa-mir-210 "Adenocarcinoma, Lung" 26687391 "MicroRNA 25, microRNA 145, and microRNA 210 as biomarkers for predicting the efficacy of maintenance treatment with pemetrexed in lung adenocarcinoma patients who are negative for epidermal growth factor receptor mutations or anaplastic lymphoma kinase translocations." +therapeutic target hsa-mir-25 "Adenocarcinoma, Lung" 26687391 "MicroRNA 25, microRNA 145, and microRNA 210 as biomarkers for predicting the efficacy of maintenance treatment with pemetrexed in lung adenocarcinoma patients who are negative for epidermal growth factor receptor mutations or anaplastic lymphoma kinase translocations." +therapeutic target hsa-mir-21 "Squamous Cell Carcinoma, Head and Neck" 26690371 miR-21 cooperates with CDK5 to promote EMT and invasion in HNSCC.This finding suggests that CDK5 may be an important cofactor for targeting when designing metastasis-blocking therapy by targeting STAT3/miR-21 axis with STAT3 inhibitor or miR-21 antisense oligonucleotide. This is the first demonstration of the novel role of STAT3/miR-21 axis and CDK5/CDK5R1 (p35) in metastasis of HNSCC. +therapeutic target hsa-mir-1914 Colorectal Carcinoma 26695693 Plasma miR-1914* and -1915 interact with NFIX RNA and reduce its level in chemoresistant CRC cells to first-line chemotherapy. Up-regulation of miR-1914* and -1915 decreased the chemoresistance abilities of chemoresistant CRC cells. The plasma miR-1914* and -1915 may play a role in colorectal cancer therapy and diagnosis. +therapeutic target hsa-mir-1915 Colorectal Carcinoma 26695693 Plasma miR-1914* and -1915 interact with NFIX RNA and reduce its level in chemoresistant CRC cells to first-line chemotherapy. Up-regulation of miR-1914* and -1915 decreased the chemoresistance abilities of chemoresistant CRC cells. The plasma miR-1914* and -1915 may play a role in colorectal cancer therapy and diagnosis. +therapeutic target hsa-mir-155 Rheumatoid Arthritis 26697483 "Taken together, our results suggest that genome editing of miR-155 holds the potential as a therapeutic strategy in RA." +therapeutic target hsa-mir-146a Allergic Rhinitis 26700406 miR-146a can enforce OVA-specific immunotherapy via inducing antigen-specific regulatory T cells. miR-146a may have therapeutic potential to be used in the immunotherapy of allergic diseases. +therapeutic target hsa-mir-224 Breast Neoplasms 26701615 "Our results indicate that FUT4 and miR-224-3p are crucial regulators of cancer response to chemotherapy, and may serve as therapeutic targets to reverse chemotherapy resistance in breast cancer." +therapeutic target hsa-mir-613 Prostate Neoplasms 26703210 "In conclusion, our study suggests that miR-613 functions as a tumor suppressor, partially through targeting Fzd7, and is a potential therapeutic target for prostate cancer." +therapeutic target hsa-mir-195 Sepsis 26704614 "Silencing of miR-195 reduced multiple-organ injury and improved the survival in sepsis, and the protective effects of miR-195 inhibition were associated with upregulation of Bcl-2, Sirt1, and Pim-1. Thus, inhibition of miR-195 may represent a new therapeutic approach for sepsis." +therapeutic target hsa-mir-127 Osteosarcoma 26707641 "Overall, the results revealed that miR-127-3p acts as a tumor suppressor and that its down-regulation in cancer may contribute to OS progression and metastasis, suggesting that miR-127-3p could be a potential therapeutic target in the treatment of OS." +therapeutic target hsa-mir-127 "Carcinoma, Hepatocellular" 26708147 "In summary, we found that miR-127-5p suppressed NF-¦ÊB activity by directly targeting BLVRB in HCC cells, and this finding improves our understanding of the molecular mechanism of inflammation-induced HCC growth and proliferation and the successful inhibition of NF-¦ÊB activity by cancer treatment." +therapeutic target hsa-mir-221 Glioma 26708164 increased pro-apoptotic effects were obtained with the co-administration of both anti-miRâ€?21 and anti-miRâ€?22 PNAs. +therapeutic target hsa-let-7b "Leukemia, Lymphoblastic, Acute" 26708866 "In the patients with ALL, the expression of microRNA let-7b is regulated by methylation of CpG islands in the region of genomic promoter. The microRNA let-7b may act as a tumor suppressor, whose low expression is involved in ALL development, indicating the microRNA let-7b may become a new therapeutic target for ALL." +therapeutic target hsa-mir-192 "Carcinoma, Hepatocellular" 26710269 "These results elucidate that the miR-192/-204-HOTTIP axis might be an important molecular pathway during hepatic cell tumorigenesis. Our data in clinical HCC samples highlight miR-192, miR-204 and HOTTIP with prognostic and potentially therapeutic implications." +therapeutic target hsa-mir-204 "Carcinoma, Hepatocellular" 26710269 "These results elucidate that the miR-192/-204-HOTTIP axis might be an important molecular pathway during hepatic cell tumorigenesis. Our data in clinical HCC samples highlight miR-192, miR-203 and HOTTIP with prognostic and potentially therapeutic implications." +therapeutic target hsa-let-7 Breast Neoplasms 26717565 "Taken together, these findings provide evidence that a miRNA expression signature can be developed to aid existing methods to determine the risk of recurrence for women with estrogen receptor positive breast cancers treated with endocrine therapy." +therapeutic target hsa-mir-3648 Breast Neoplasms 26717565 "Taken together, these findings provide evidence that a miRNA expression signature can be developed to aid existing methods to determine the risk of recurrence for women with estrogen receptor positive breast cancers treated with endocrine therapy." +therapeutic target hsa-mir-377 Breast Neoplasms 26717565 "Taken together, these findings provide evidence that a miRNA expression signature can be developed to aid existing methods to determine the risk of recurrence for women with estrogen receptor positive breast cancers treated with endocrine therapy." +therapeutic target hsa-mir-548t Breast Neoplasms 26717565 "Taken together, these findings provide evidence that a miRNA expression signature can be developed to aid existing methods to determine the risk of recurrence for women with estrogen receptor positive breast cancers treated with endocrine therapy." +therapeutic target hsa-mir-633b Breast Neoplasms 26717565 "Taken together, these findings provide evidence that a miRNA expression signature can be developed to aid existing methods to determine the risk of recurrence for women with estrogen receptor positive breast cancers treated with endocrine therapy." +therapeutic target hsa-mir-340 Prostate Neoplasms 26718483 "Our findings suggest that miR-340 may function as a novel tumor suppressor in PCa through the MDM2-p53 pathway by directly targeting MDM2, which may be a promising miRNA-targeted therapy for PCa." +therapeutic target hsa-mir-142 Fungal Keratitis 26720440 "This is, to our knowledge, the first report on comprehensive human corneal miRNA expression profile in fungal keratitis. Several miRNAs with high expression in fungal keratitis point toward their potential role in regulation of pathogenesis. Further insights in understanding their role in corneal wound inflammation may help design new therapeutic strategies." +therapeutic target hsa-mir-155 Fungal Keratitis 26720440 "This is, to our knowledge, the first report on comprehensive human corneal miRNA expression profile in fungal keratitis. Several miRNAs with high expression in fungal keratitis point toward their potential role in regulation of pathogenesis. Further insights in understanding their role in corneal wound inflammation may help design new therapeutic strategies." +therapeutic target hsa-mir-451a Fungal Keratitis 26720440 "This is, to our knowledge, the first report on comprehensive human corneal miRNA expression profile in fungal keratitis. Several miRNAs with high expression in fungal keratitis point toward their potential role in regulation of pathogenesis. Further insights in understanding their role in corneal wound inflammation may help design new therapeutic strategies." +therapeutic target hsa-mir-511 Fungal Keratitis 26720440 "This is, to our knowledge, the first report on comprehensive human corneal miRNA expression profile in fungal keratitis. Several miRNAs with high expression in fungal keratitis point toward their potential role in regulation of pathogenesis. Further insights in understanding their role in corneal wound inflammation may help design new therapeutic strategies." +therapeutic target hsa-mir-142 Inflammation 26721185 "These results suggest that PPAR¦Ã-mediated upregulation of miR-142-3p inhibits the HMGB1 expression, which,in turn, is a novel anti-inflammatory mechanism of PPAR¦Ã and has an important role in the treatment of inflammatory diseases." +therapeutic target hsa-mir-16 Glioma 26722459 "In conclusion, MiR-16 mediated temozolomide-resistance in glioma cells by modulation of apoptosis via targeting Bcl-2, which suggesting that miR-16 and Bcl-2 would be potential therapeutic targets for glioma therapy." +therapeutic target hsa-mir-212 Habitual Abortion 26722471 "In summary, we describe a unique myometrial miRNA expression pattern in human spontaneous preterm labor and discuss their possible role by predicting the target genes of each miRNA. Our results suggest that miRNA play a critical role in the process of partuition in myometrium. The identification of myometrial miRNA profile throws a new light upon the molecule mechanism and provides an insight into the potential diagnosis and treatment of preterm labor." +therapeutic target hsa-mir-223 Habitual Abortion 26722471 "In summary, we describe a unique myometrial miRNA expression pattern in human spontaneous preterm labor and discuss their possible role by predicting the target genes of each miRNA. Our results suggest that miRNA play a critical role in the process of partuition in myometrium. The identification of myometrial miRNA profile throws a new light upon the molecule mechanism and provides an insight into the potential diagnosis and treatment of preterm labor." +therapeutic target hsa-mir-5096 Habitual Abortion 26722471 "In summary, we describe a unique myometrial miRNA expression pattern in human spontaneous preterm labor and discuss their possible role by predicting the target genes of each miRNA. Our results suggest that miRNA play a critical role in the process of partuition in myometrium. The identification of myometrial miRNA profile throws a new light upon the molecule mechanism and provides an insight into the potential diagnosis and treatment of preterm labor." +therapeutic target hsa-mir-503 Colorectal Carcinoma 26722476 "miR-503 inhibits cell proliferation and induces apoptosis by directly targeting E2F3 in CRC cells, indicating its potential application in CRC diagnosis and therapy." +therapeutic target hsa-mir-203 Melanoma 26722525 "This study for the first time provided evidence that miR-203 could be an independent potential prognostic marker for patients with melanoma, and might even become a new therapeutic target for the treatment of melanoma." +therapeutic target hsa-mir-542 Bladder Neoplasms 26723509 "MiR-542-3p and its target gene survivin may play crucial roles in the aggressive progression of human bladder cancer. More interestingly, miR-542-3p may function as a tumor suppressor and inhibit the proliferation of bladder cancer cells, implying that miR-542-3p-survivin signal axis might be a novel therapeutic target of this disease." +therapeutic target hsa-mir-126 Rheumatoid Arthritis 26723864 "Our study demonstrated that down-regulation of miR-126 may indirectly inhibit PI3K/AKT signaling pathway to disrupt the imbalance between growth and death of RASFs by targeting PIK3R2, which may be clinically helpful to find therapeutic strategies directed toward miR-126 function for RA patients." +therapeutic target hsa-mir-302b Breast Neoplasms 26744520 "Collectively, our findings reveal new insights underlying increased breast cancer mortality in obese individuals and provide a novel preclinical rationale to test the efficacy of Src inhibitors for breast cancer treatment." +therapeutic target hsa-mir-26b Lung Neoplasms 26744864 "Taken together, our results demonstrate that miR-26b could suppress lung cancer cells proliferation, migration and invasion by directly negative regulation of COX-2. MiR-26b could serve as a novel potential marker for NSCLC therapy." +therapeutic target hsa-mir-483 Glaucoma 26747772 "MicroRNA-483-3p has an inhibitory effect on ECM production in HTMCs through downregulating Smad4, which indicates that miR-483-3p may serve as a potential therapeutic target in glaucoma." +therapeutic target hsa-mir-28 "Carcinoma, Hepatocellular" 26754294 A miR-28-5p-IL-34-macrophage feedback loop modulates HCC metastasis and serves as a novel prognostic factor as well as a therapeutic target for HCC. +therapeutic target hsa-mir-208a Lung Neoplasms 26754670 "The present study provides evidence that miR-208a can affect the proliferation and radiosensitivity of human lung cancer cells by targeting p21 and can be transported by exosomes. Thus, miR-208a may serve as a potential therapeutic target for lung cancer patients." +therapeutic target hsa-mir-511 "Leukemia, Myeloid, Acute" 26762252 Our study provides new insights into the understanding of miRNAs as functional mediators of the leukemogenic fusion gene MLL-AF9 and opens new opportunities to further investigate specific therapeutic options for AML via the miRNA level. +therapeutic target hsa-mir-548c Ovarian Neoplasms 26762267 "These findings suggest that miR-548c directly downregulates Twist,and provide a novel mechanism for Twist upregulation in both endometrial and ovarian cancers. The use of miR-548c may hold therapeutic potential for the treatment of Twist-overexpressing tumors." +therapeutic target hsa-mir-125a "Carcinoma, Cervical" 26766902 The molecular pathway of miR-125a-5p/ABL2 plays an important role in human cervical carcinoma. Targeting miR-125a-5p/ABL2 pathway may provide a new treatment strategy for patients with cervical carcinoma. +therapeutic target hsa-mir-15a Uterine Leiomyosarcoma 26768834 "Differential miRNA signatures of ESS and LMS provide novel data regarding transcriptional regulation in these cancers, based on which new potential diagnostic markers, prognostic biomarkers and therapeutic targets may be explored. Differences in miRNA profiles of primary and metastatic LMS may improve our understanding of disease progression in this aggressive malignancy." +therapeutic target hsa-mir-31 Uterine Leiomyosarcoma 26768834 "Differential miRNA signatures of ESS and LMS provide novel data regarding transcriptional regulation in these cancers, based on which new potential diagnostic markers, prognostic biomarkers and therapeutic targets may be explored. Differences in miRNA profiles of primary and metastatic LMS may improve our understanding of disease progression in this aggressive malignancy." +therapeutic target hsa-mir-92a Uterine Leiomyosarcoma 26768834 "Differential miRNA signatures of ESS and LMS provide novel data regarding transcriptional regulation in these cancers, based on which new potential diagnostic markers, prognostic biomarkers and therapeutic targets may be explored. Differences in miRNA profiles of primary and metastatic LMS may improve our understanding of disease progression in this aggressive malignancy." +therapeutic target hsa-mir-103 Prostate Neoplasms 26771762 "Therefore, our data collectively demonstrate that miR-103 is a proto-oncogene miRNA that can suppress prostate cancer proliferation and migration by down-regulating the oncogene PDCD10, indicating that miR-103 may represent a new potential diagnostic and therapeutic target for prostate cancer treatment." +therapeutic target hsa-let-7 Hemangioma 26772808 microRNA-regulated pathways may play a role in infantile hemangioma development and progression and may be potentially useful for future development of novel therapeutic strategies for patients with infantile hemangioma. +therapeutic target hsa-mir-9 Hemangioma 26772808 microRNA-regulated pathways may play a role in infantile hemangioma development and progression and may be potentially useful for future development of novel therapeutic strategies for patients with infantile hemangioma. +therapeutic target hsa-mir-939 Hemangioma 26772808 microRNA-regulated pathways may play a role in infantile hemangioma development and progression and may be potentially useful for future development of novel therapeutic strategies for patients with infantile hemangioma. +therapeutic target hsa-mir-367 "Carcinoma, Hepatocellular" 26772880 "This study indicated that miR-367 negatively regulates PTEN and promotes proliferation and invasion of HCC cells. Thus, miR-367 may represent a potential therapeutic target for HCC intervention." +therapeutic target hsa-mir-1182 Bladder Neoplasms 26772886 "In conclusion, these results demonstrate that miR-1182 acts as a tumor suppressor and may be a potential biomarker for bladder cancer diagnosis and treatment." +therapeutic target hsa-mir-206 "Carcinoma, Cervical" 26775359 "miR-206 may act not only as a novel diagnostic and prognostic marker, but also as a potential target for molecular therapy of cervical cancer." +therapeutic target hsa-mir-451 "Carcinoma, Renal Cell" 26779781 MiR-451 acts as an anti-oncogene in RCC. Our data offer a new therapeutic target for further research. +therapeutic target hsa-mir-509 Ovarian Neoplasms 26786897 Our data suggest that restoring certain dysregulated miRNAs to their normal levels could increase the therapeutic effects of anticancer drugs. +therapeutic target hsa-mir-211 Melanoma 26787841 "These findings highlight a novel mechanism of melanoma formation: miR-211 is a molecular switch that is turned off in melanoma cells, raising the hope that in the future we might be able to turn the switch back on, thus providing a better treatment option for melanoma." +therapeutic target hsa-mir-508 "Carcinoma, Gastric" 26801246 All these findings supports that canonical NF-¦ÊB signaling pathway is activated in GC at least by the inactivation of miR-508-3p and this might have therapeutic potential in GC treatment. +therapeutic target hsa-mir-483 Thrombosis 26801758 "miR-483-3p is upregulated in EPCs from DVT patients, and it targets SRF to decrease EPCs migration and tube formation and increase apoptosis in vitro, while decrease EPCs homing and thrombus resolution in vivo. MiR-483-3p is a potential therapeutic target in DVT treatment." +therapeutic target hsa-mir-206 "Carcinoma, Renal Cell" 26808577 All these results suggested that miR-206 functioned as a novel cell cycle regulator and tumor suppressor in ccRCC and could be considered as a potential target for ccRCC therapy. +therapeutic target hsa-mir-205 Prostate Neoplasms 26813458 The miR-205/TP53INP1 mediated autophagy pathway might be an important molecular mechanism regulating radiosensitivity of prostate cancer cells and represents a potential therapeutic target for prostate cancer. +therapeutic target hsa-mir-130a "Carcinoma, Hepatocellular" 26817584 "Our findings provide a molecular insight on understanding drug resistance in HCC cells. Therefore, activation of miR-130a-3p or inactivation of Smad4 could be a novel approach for the treatment of HCC." +therapeutic target hsa-mir-107 "Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal" 26822763 NEAT1 plays an oncogenic role in the tumorigenesis of LSCC and may serve as a potential target for therapeutic intervention. +therapeutic target hsa-mir-122 Cholangiocarcinoma 26825606 "The results indicate that HNF6 may serve as a tumor suppressor by regulating miR-122, and its overexpression may represent a mechanism-based therapy for CCA." +therapeutic target hsa-mir-23b Gastric Neoplasms 26835790 "Our results indicated that plasma miR-23b was overexpressed in GC patients and high plasma miR-23b expression was associated with poor clinical outcome. Thus, plasma miR-23b may serve as a potential diagnostic biomarker and therapeutic target for GC." +therapeutic target hsa-mir-124 Medulloblastoma 26840408 "In all, we have discovered miR-124 to be downregulated in instances of medulloblastoma in which Nur77 is upregulated, resulting in a proliferative state that abets cancer progression. This study provides evidence for increasing miR-124 expression as a potential therapy for cancers with elevated levels of Nur77." +therapeutic target hsa-mir-24 Prostate Neoplasms 26847530 These findings provide evidence that miR-24 has a tumor suppressor role in prostate cancer and also targets p27 and p16 in prostate cancer cells. We propose that it may be a useful progression biomarker or focus of therapeutic intervention for this disease. +therapeutic target hsa-mir-200c Cholangiocarcinoma 26855082 The ability of the combined PCX/miR-200c treatment to obstruct two migratory pathways represents a promising antimetastatic strategy in cholangiocarcinoma. +therapeutic target hsa-mir-183 "Carcinoma, Cervical" 26873866 "In conclusion, our study revealed that miR-183 might be a tumor suppressor via inhibiting the invasion and metastasis of cervical cancer cells through targeting MMP-9, indicating that miR-183 may be a novel potential therapeutic target for cervical cancer." +therapeutic target hsa-mir-21 Asthma 26874829 "This study suggested that serum miRNA-21 is stable and detectable in serum of asthmatic children, which could promise potential biomarker in diagnosis as well as in response to therapy of asthma." +therapeutic target hsa-mir-874 Colorectal Carcinoma 26875895 "These data demonstrate that miR-874 functions as a tumor suppressor by repression of STAT3, suggesting its potential therapeutic value in CRC treatment." +therapeutic target hsa-mir-100 Multiple Sclerosis 26943961 Dicer and microRNA expression in multiple sclerosis and response to interferon therapy. +therapeutic target hsa-mir-107 Multiple Sclerosis 26943961 Dicer and microRNA expression in multiple sclerosis and response to interferon therapy. +therapeutic target hsa-mir-145 Multiple Sclerosis 26943961 Dicer and microRNA expression in multiple sclerosis and response to interferon therapy. +therapeutic target hsa-mir-146b Multiple Sclerosis 26943961 Dicer and microRNA expression in multiple sclerosis and response to interferon therapy. +therapeutic target hsa-mir-323 Multiple Sclerosis 26943961 Dicer and microRNA expression in multiple sclerosis and response to interferon therapy. +therapeutic target hsa-mir-3614 Multiple Sclerosis 26943961 Dicer and microRNA expression in multiple sclerosis and response to interferon therapy. +therapeutic target hsa-mir-369 Multiple Sclerosis 26943961 Dicer and microRNA expression in multiple sclerosis and response to interferon therapy. +therapeutic target hsa-mir-494 Multiple Sclerosis 26943961 Dicer and microRNA expression in multiple sclerosis and response to interferon therapy. +therapeutic target hsa-mir-874 Multiple Sclerosis 26943961 Dicer and microRNA expression in multiple sclerosis and response to interferon therapy. +therapeutic target hsa-mir-9 Multiple Sclerosis 26943961 Dicer and microRNA expression in multiple sclerosis and response to interferon therapy. +therapeutic target hsa-mir-146a Atherosclerosis 26956647 delivery of microRNA (miR)-146a and miR-181b with an E-selectin-targeting multistage vector (ESTA-MSV) to inflamed endothelium covering atherosclerotic plaques inhibits atherosclerosis +therapeutic target hsa-mir-181b Atherosclerosis 26956647 delivery of microRNA (miR)-146a and miR-181b with an E-selectin-targeting multistage vector (ESTA-MSV) to inflamed endothelium covering atherosclerotic plaques inhibits atherosclerosis +therapeutic target hsa-mir-146b Glioma 26983831 a novel treatment whereby mesenchymal stromal cells were employed to package tumor-suppressing miR-146b into exosomes +therapeutic target hsa-mir-708 Asthma 26998837 These results demonstrate that miR-708 and miR-140-3p exert distinct effects on inflammation-associated gene expression and biological function of ASM cells. Targeting these miRNA networks may provide a novel therapeutic mechanism to down-regulate airway inflammation and ASM proliferation in asthma. +therapeutic target hsa-mir-124 Stroke 27031810 These neuroprotective and anti-inflammatory effects of the early miR-124 treatment were pronounced during the first week with Arg-1. +therapeutic target hsa-mir-122 "Carcinoma, Hepatocellular" 27059462 "MicroRNA profiling of distinct tumor foci, coupled with methods that address within-subject tumor heterogeneity, has the potential to significantly improve prediction of HCC recurrence post-transplantation. The development of a clinically applicable HCC biomarker would inform treatment options for patients and contribute to liver transplant selection criteria for practitioners." +therapeutic target hsa-mir-126 "Carcinoma, Hepatocellular" 27059462 "MicroRNA profiling of distinct tumor foci, coupled with methods that address within-subject tumor heterogeneity, has the potential to significantly improve prediction of HCC recurrence post-transplantation. The development of a clinically applicable HCC biomarker would inform treatment options for patients and contribute to liver transplant selection criteria for practitioners." +therapeutic target hsa-mir-15a "Carcinoma, Hepatocellular" 27059462 "MicroRNA profiling of distinct tumor foci, coupled with methods that address within-subject tumor heterogeneity, has the potential to significantly improve prediction of HCC recurrence post-transplantation. The development of a clinically applicable HCC biomarker would inform treatment options for patients and contribute to liver transplant selection criteria for practitioners." +therapeutic target hsa-mir-22 "Carcinoma, Hepatocellular" 27059462 "MicroRNA profiling of distinct tumor foci, coupled with methods that address within-subject tumor heterogeneity, has the potential to significantly improve prediction of HCC recurrence post-transplantation. The development of a clinically applicable HCC biomarker would inform treatment options for patients and contribute to liver transplant selection criteria for practitioners." +therapeutic target hsa-mir-30a "Carcinoma, Hepatocellular" 27059462 "MicroRNA profiling of distinct tumor foci, coupled with methods that address within-subject tumor heterogeneity, has the potential to significantly improve prediction of HCC recurrence post-transplantation. The development of a clinically applicable HCC biomarker would inform treatment options for patients and contribute to liver transplant selection criteria for practitioners." +therapeutic target hsa-mir-146a Melanoma 27059647 "two miRNAs that are particularly relevant in human melanoma progression, miR-146a and miR-214." +therapeutic target hsa-mir-205 Breast Neoplasms 27064979 Variations in serum miRNA levels during NAC treatment may be therapeutically significant for predicting response and survival outcomes. +therapeutic target hsa-mir-21 Breast Neoplasms 27064979 Variations in serum miRNA levels during NAC treatment may be therapeutically significant for predicting response and survival outcomes. +therapeutic target hsa-mir-3200 Breast Neoplasms 27064979 Variations in serum miRNA levels during NAC treatment may be therapeutically significant for predicting response and survival outcomes. +therapeutic target hsa-mir-451 Breast Neoplasms 27064979 Variations in serum miRNA levels during NAC treatment may be therapeutically significant for predicting response and survival outcomes. +therapeutic target hsa-mir-21 Glioblastoma 27079911 Here we show that rationally designed hammerhead ribozymes and DNAzymes can target miR-21 and/or its precursors. +therapeutic target hsa-mir-21 Glioma 27079911 Here we show that rationally designed hammerhead ribozymes and DNAzymes can target miR-21 and/or its precursors. +therapeutic target hsa-mir-24 Diabetic Vasculopathy 27085480 elevation of miR-24 in vascular system may be a novel therapeutic strategy to prevent the development of diabetic atherosclerosis. +therapeutic target hsa-mir-23a Acute Erythroid Leukemia 27086927 "indicating the therapeutic significance of miR-23a, -27a and -24 for AEL treatment." +therapeutic target hsa-mir-24 Acute Erythroid Leukemia 27086927 "indicating the therapeutic significance of miR-23a, -27a and -24 for AEL treatment." +therapeutic target hsa-mir-27a Acute Erythroid Leukemia 27086927 "indicating the therapeutic significance of miR-23a, -27a and -24 for AEL treatment." +therapeutic target hsa-mir-487b Lung Neoplasms 27097129 miR-487b-5p inhibition can be further explored as a chemotherapy target in the treatment of TMZ-resistant lung carcinoma. +therapeutic target hsa-mir-17 Prostate Neoplasms 27125502 RNA nanoparticles were constructed by bottom-up self-assembly containing the anti-prostate-specific membrane antigen (PSMA) RNA aptamer as a targeting ligand and anti-miR17 or anti-miR21 as therapeutic modules. +therapeutic target hsa-mir-21 Prostate Neoplasms 27125502 RNA nanoparticles were constructed by bottom-up self-assembly containing the anti-prostate-specific membrane antigen (PSMA) RNA aptamer as a targeting ligand and anti-miR17 or anti-miR21 as therapeutic modules. +therapeutic target hsa-mir-96 "Carcinoma, Breast, Triple Negative" 27170187 3 directly engages pri-miR-96 in breast cancer cells. +therapeutic target hsa-mir-29b Multiple Myeloma 27196750 miR-29b-based epi-therapeutic approaches in the treatment of this malignancy +therapeutic target hsa-mir-124 Breast Neoplasms 27266580 miR-124-M-Oba may have potential applications in breast cancer therapy. +therapeutic target hsa-mir-21 Glioblastoma 27277750 co-delivery of anti-miR-21 significantly improved accumulation of LPNs in the nucleus of U87MG cells. +therapeutic target hsa-mir-150 "Leukemia, Myeloid, Acute" 27280396 "using FLT3L-guided miR-150-based nanoparticles, to treat FLT3-overexpressing AML with high efficacy and minimal side effects." +therapeutic target hsa-mir-181a Mitochondrial Metabolism Disease 27281615 Knock down of endogenous miR-181a accelerates the autophagic degradation of damaged mitochondria. +therapeutic target hsa-mir-222 Breast Neoplasms 27282281 downregulation of miR-222 in MCF-7/Adr increased sensitivity to Adr and Adr-induced apoptosis +therapeutic target hsa-mir-215 Cervical Neoplasms 27295129 "dysregulation of miR-29C, miR-34A, miR-98, and miR-215" +therapeutic target hsa-mir-29c Cervical Neoplasms 27295129 "dysregulation of miR-29C, miR-34A, miR-98, and miR-215" +therapeutic target hsa-mir-34a Cervical Neoplasms 27295129 "dysregulation of miR-29C, miR-34A, miR-98, and miR-215" +therapeutic target hsa-mir-98 Cervical Neoplasms 27295129 "dysregulation of miR-29C, miR-34A, miR-98, and miR-215" +therapeutic target hsa-mir-155 Lung Neoplasms 27315591 Inhibition of microRNA-155 sensitizes lung cancer cells to irradiation +therapeutic target hsa-mir-150 Graft-Versus-Host Disease 27329362 microRNA-150 (miR-150) induces immunological tolerance in CD4(+) T cells after transplantation +therapeutic target hsa-mir-18a "Carcinoma, Breast, Triple Negative" 27338043 MiR-18a overexpression significantly increased PTX IC50 and reduced PTX induced cell apoptosis +therapeutic target hsa-mir-93 Age-Related Macular Degeneration 27349759 these results highlight the therapeutic potential of miR-93 +therapeutic target hsa-mir-21 Glioblastoma 27355932 Anti-cancer effect of R3V6 peptide-mediated delivery of an anti-microRNA-21 antisense-oligodeoxynucleotide in a glioblastoma animal model. +therapeutic target hsa-mir-20a Gastric Neoplasms 27357419 Altering miRâ€?0a expression may be a potential therapeutic strategy for the treatment of chemoresistance in GC in the future. +therapeutic target hsa-mir-221 "Leukemia, Lymphoblastic, Acute" 27358112 Niche-influenced miR-221/222 may define a novel therapeutic target in ALL +therapeutic target hsa-mir-222 "Leukemia, Lymphoblastic, Acute" 27358112 Niche-influenced miR-221/222 may define a novel therapeutic target in ALL +therapeutic target hsa-mir-30e Gastric Neoplasms 27372603 DIM may through the miR-30e-ATG5 modulating autophagy inhibit the proliferation of gastric cancer cells. +therapeutic target hsa-mir-493 Breast Neoplasms 27375041 The miR-493-5p/FUT4 pathway has therapeutic potential in breast cancer. +therapeutic target hsa-mir-30e Glioblastoma 27388765 "Collectively, combination of miR-30e and PAC is a promising therapeutic strategy to inhibit autophagy and increase apoptosis in GSC and SNB19 cells." +therapeutic target hsa-mir-210 Acute Myocardial Infarction 27392480 "HAR could reduce the infarction area, alleviate the interstitial fibrosis and improve the cardiac function of AMI rats. Those effects could be related to promoting myocardium angiogenesis of HAR by up-regulating miR-210 and VEGF." +therapeutic target hsa-mir-155 Colitis 27395764 IL-10/miR-155/SHIP-1 pathways play a critical role in commensal bacteria induced colitis and miR-15 +therapeutic target hsa-mir-214 Breast Neoplasms 27422604 "In conclusion, miR-214 functions as a tumor suppressor by regulating the RFWD2-p53 cascade, thus delivery of miR-214 analogs could be a potential adjunct therapy in breast cancer harboring wild type p53." +therapeutic target hsa-mir-21 Neoplasms [unspecific] 27428511 Targeted inhibition of oncogenic miR-21 maturation with designed RNA-binding proteins +therapeutic target hsa-mir-7 Melanoma 27448964 "Collectively, our study demonstrated that miR-7 could reverse the resistance to BRAF inhibitors in certain vemurafenib resistant melanoma cell lines." +therapeutic target hsa-mir-145 "Carcinoma, Colon" 27482839 "The results in this work show that miR-145 has been effectively delivered to colon carcinomas through a PLGA/PEI/HA vehicle, indicating a promising miRNA replacement therapy strategy." +therapeutic target hsa-mir-122 Asthma 27485847 "First clinical trials using the blockade of liver specific miR-122 showed very promising results in the treatment of chronic hepatitis C virus infection. Results of preclinical and animal studies are also promising providing future rationale for the development of new therapeutics for various internal diseases including heart failure, bronchial asthma or inflammatory bowel diseases." +therapeutic target hsa-mir-122 Chronic Hepatitis C 27485847 "First clinical trials using the blockade of liver specific miR-122 showed very promising results in the treatment of chronic hepatitis C virus infection. Results of preclinical and animal studies are also promising providing future rationale for the development of new therapeutics for various internal diseases including heart failure, bronchial asthma or inflammatory bowel diseases." +therapeutic target hsa-mir-122 Heart Failure 27485847 "First clinical trials using the blockade of liver specific miR-122 showed very promising results in the treatment of chronic hepatitis C virus infection. Results of preclinical and animal studies are also promising providing future rationale for the development of new therapeutics for various internal diseases including heart failure, bronchial asthma or inflammatory bowel diseases." +therapeutic target hsa-mir-122 Inflammatory Bowel Diseases 27485847 "First clinical trials using the blockade of liver specific miR-122 showed very promising results in the treatment of chronic hepatitis C virus infection. Results of preclinical and animal studies are also promising providing future rationale for the development of new therapeutics for various internal diseases including heart failure, bronchial asthma or inflammatory bowel diseases." +therapeutic target hsa-mir-145 Pancreatic Neoplasms 27507554 "miR-145 re-expression resulted in downregulation of MUC13, HER2, pAKT, and inhibition of cell proliferation, clonogenicity, migration, and invasion of pancreatic cancer cells." +therapeutic target hsa-mir-21 Glioblastoma 27508339 Coinhibition of miR-21 and miR-10b significantly reduced the number of viable cells (by 24%; p < 0.01) and increased (2.9-fold) cell cycle arrest at G2/M phase upon Temozolomide treatment in U87 MG cells. +therapeutic target hsa-mir-146b "Carcinoma, Thyroid, Papillary" 27533309 "In conjunction with current therapeutic regimens, targeting the miR-146b-IRAK1 axis may provide a potential approach for PTC management." +therapeutic target hsa-mir-146b Neoplasms [unspecific] 27533309 "In conjunction with current therapeutic regimens, targeting the miR-146b-IRAK1 axis may provide a potential approach for PTC management." +therapeutic target hsa-mir-223 Periodontal Diseases 27552373 "Knowledge gained from future studies will be beneficial in developing alternative therapeutic approaches, especially ones that use miRNA delivery systems to treat periodontal disease" +therapeutic target hsa-mir-22 Rhabdomyosarcoma 27569217 Deep Sequencing Reveals a Novel miR-22 Regulatory Network with Therapeutic Potential in Rhabdomyosarcoma. +therapeutic target hsa-mir-34a Glioblastoma 27569663 Functionalized nanogels carrying an anticancer microRNA for glioblastoma therapy. +therapeutic target hsa-let-7i Neoplasms [unspecific] 27588466 Involvement of let-7 microRNA for the therapeutic effects of Rhenium-188-embedded liposomal nanoparticles on orthotopic human head and neck cancer model. +therapeutic target hsa-mir-143 Obesity 27623943 Tumour biology of obesity-related cancers: understanding the molecular concept for better diagnosis and treatment. +therapeutic target hsa-mir-1246 Corneal Neovascularization 27625050 Curcumin inhibits angiogenesis by up-regulation of microRNA-1275 and microRNA-1246: a promising therapy for treatment of corneal neovascularization. +therapeutic target hsa-mir-1275 Corneal Neovascularization 27625050 Curcumin inhibits angiogenesis by up-regulation of microRNA-1275 and microRNA-1246: a promising therapy for treatment of corneal neovascularization. +therapeutic target hsa-mir-145 Neoplasms [unspecific] 27655328 "our results indicated that mir-145, through targeting its common potential targets, may significantly contribute to tumor pathogenesis in distinct cancer types and might serve as an important target for cancer therapy" +therapeutic target hsa-mir-193a Neoplasms [unspecific] 27669434 the broader applicability of using miR-193a-3p as a therapeutic agent to target KRas-mutant cancer +therapeutic target hsa-mir-495 Neoplasms [unspecific] 27697751 MiR-495 functions as an adjuvant to radiation therapy by reducing the radiation-induced bystander effect. +therapeutic target hsa-let-7a Colorectal Carcinoma 27737877 Our data support the role of let-7a in suppressing antitumor immunity in colorectal cancer and suggest let-7a as a potential target of immunotherapy +therapeutic target hsa-mir-124 Glioblastoma 27765835 Immune modulatory nanoparticle therapeutics for intracerebral glioma. +therapeutic target hsa-mir-155 Allergic Asthma 27783037 miR-155: A Novel Target in Allergic Asthma. +therapeutic target hsa-mir-129 Neoplasms [unspecific] 27802440 we summarized the roles of miR-129 family members and their target genes in tumorigenesis and clinical treatment of human cancers +therapeutic target hsa-mir-126 Kidney Injury 27832640 "non-coding RNAs (ncRNAs), such as microRNAs (miRNAs) and long non-coding RNAs (lncRNAs), have significant potential to aid the development of diagnostic and therapeutic strategies of AKI" +therapeutic target hsa-mir-127 Kidney Injury 27832640 "non-coding RNAs (ncRNAs), such as microRNAs (miRNAs) and long non-coding RNAs (lncRNAs), have significant potential to aid the development of diagnostic and therapeutic strategies of AKI" +therapeutic target hsa-mir-150 Kidney Injury 27832640 "non-coding RNAs (ncRNAs), such as microRNAs (miRNAs) and long non-coding RNAs (lncRNAs), have significant potential to aid the development of diagnostic and therapeutic strategies of AKI" +therapeutic target hsa-mir-21 Kidney Injury 27832640 "non-coding RNAs (ncRNAs), such as microRNAs (miRNAs) and long non-coding RNAs (lncRNAs), have significant potential to aid the development of diagnostic and therapeutic strategies of AKI" +therapeutic target hsa-mir-24 Kidney Injury 27832640 "non-coding RNAs (ncRNAs), such as microRNAs (miRNAs) and long non-coding RNAs (lncRNAs), have significant potential to aid the development of diagnostic and therapeutic strategies of AKI" +therapeutic target hsa-mir-30 Kidney Injury 27832640 "non-coding RNAs (ncRNAs), such as microRNAs (miRNAs) and long non-coding RNAs (lncRNAs), have significant potential to aid the development of diagnostic and therapeutic strategies of AKI" +therapeutic target hsa-mir-494 Kidney Injury 27832640 "non-coding RNAs (ncRNAs), such as microRNAs (miRNAs) and long non-coding RNAs (lncRNAs), have significant potential to aid the development of diagnostic and therapeutic strategies of AKI" +therapeutic target hsa-mir-687 Kidney Injury 27832640 "non-coding RNAs (ncRNAs), such as microRNAs (miRNAs) and long non-coding RNAs (lncRNAs), have significant potential to aid the development of diagnostic and therapeutic strategies of AKI" +therapeutic target hsa-mir-106a Rheumatoid Arthritis 27834806 "X-linked miRNAs, in the context of sex differences, might provide novel insight into new molecular mechanisms and potential therapeutic targets in RA for disease treatment and prevention" +therapeutic target hsa-mir-221 Rheumatoid Arthritis 27834806 "X-linked miRNAs, in the context of sex differences, might provide novel insight into new molecular mechanisms and potential therapeutic targets in RA for disease treatment and prevention" +therapeutic target hsa-mir-222 Rheumatoid Arthritis 27834806 "X-linked miRNAs, in the context of sex differences, might provide novel insight into new molecular mechanisms and potential therapeutic targets in RA for disease treatment and prevention" +therapeutic target hsa-mir-532 Rheumatoid Arthritis 27834806 "X-linked miRNAs, in the context of sex differences, might provide novel insight into new molecular mechanisms and potential therapeutic targets in RA for disease treatment and prevention" +therapeutic target hsa-mir-92a Rheumatoid Arthritis 27834806 "X-linked miRNAs, in the context of sex differences, might provide novel insight into new molecular mechanisms and potential therapeutic targets in RA for disease treatment and prevention" +therapeutic target hsa-mir-98 Rheumatoid Arthritis 27834806 "X-linked miRNAs, in the context of sex differences, might provide novel insight into new molecular mechanisms and potential therapeutic targets in RA for disease treatment and prevention" +therapeutic target hsa-mir-122 Diabetes Mellitus 27966196 "MicroRNAs 33, 122, and 208: a potential novel targets in the treatment of obesity, diabetes, and heart-related diseases." +therapeutic target hsa-mir-208 Diabetes Mellitus 27966196 "MicroRNAs 33, 122, and 208: a potential novel targets in the treatment of obesity, diabetes, and heart-related diseases." +therapeutic target hsa-mir-33 Diabetes Mellitus 27966196 "MicroRNAs 33, 122, and 208: a potential novel targets in the treatment of obesity, diabetes, and heart-related diseases." +therapeutic target hsa-mir-34a Neoplasms [unspecific] 28010900 Emergence of miR-34a in radiation therapy. +therapeutic target hsa-mir-15a "Leukemia, Lymphocytic, Chronic, B-Cell" 28053325 Effects of miRNA-15 and miRNA-16 expression replacement in chronic lymphocytic leukemia: implication for therapy. +therapeutic target hsa-mir-16 "Leukemia, Lymphocytic, Chronic, B-Cell" 28053325 Effects of miRNA-15 and miRNA-16 expression replacement in chronic lymphocytic leukemia: implication for therapy. +therapeutic target hsa-mir-21 "Carcinoma, Breast" 28067096 Differential response of normal and transformed mammary epithelial cells to combined treatment of anti-miR-21 and radiation. +therapeutic target hsa-mir-30a Schizophrenia 28072411 The early growth response protein 1-miR-30a-5p-neurogenic differentiation factor 1 axis as a novel biomarker for schizophrenia diagnosis and treatment monitoring. +therapeutic target hsa-mir-21 Hypertrophic Scar 28075443 MicroRNA expression signature and the therapeutic effect of the microRNA?21 antagomir in hypertrophic scarring. +therapeutic target hsa-mir-21 Neoplasms [unspecific] 28096467 "Our results not only elucidate miR-21-mediated radioresistance, but also provide potential new targets for improving radiotherapy" +therapeutic target hsa-mir-1 Intrahepatic Cholangiocarcinoma 28098904 "has-miR-96, has-miR-1 and has-miR-25, may be potential therapeutic targets for the future treatment of ICC" +therapeutic target hsa-mir-25 Intrahepatic Cholangiocarcinoma 28098904 "has-miR-96, has-miR-1 and has-miR-25, may be potential therapeutic targets for the future treatment of ICC" +therapeutic target hsa-mir-96 Intrahepatic Cholangiocarcinoma 28098904 "has-miR-96, has-miR-1 and has-miR-25, may be potential therapeutic targets for the future treatment of ICC" +therapeutic target hsa-mir-647 "Carcinoma, Gastric" 28098914 "miR-647 exerts powerful antitumorigenic effects in?vitro and in?vivo, and may represent a promising therapeutic agent against GC" +therapeutic target hsa-mir-21 Glioblastoma 28109960 RNA Nanoparticle-Based Targeted Therapy for Glioblastoma through Inhibition of Oncogenic miR-21. +therapeutic target hsa-mir-141 "Carcinoma, Colon" 28112364 MicroRNA-141 inhibits tumor growth and minimizes therapy resistance in colorectal cancer. +therapeutic target hsa-mir-206 Alzheimer Disease 28123152 "miR-206-3p is involved in the anti-dementia effects of donepezil, and could be a novel pharmacological target for treating AD" +therapeutic target hsa-mir-21 Diabetic Nephropathy 28129112 Therapeutic miR-21 Silencing Ameliorates Diabetic Kidney Disease in Mice. +therapeutic target hsa-mir-31 "Carcinoma, Colon" 28147317 EZH2 expression is a prognostic biomarker in patients with colorectal cancer treated with anti-EGFR therapeutics. +therapeutic target hsa-mir-1254 "Squamous Cell Carcinoma, Oral" 28161631 miR-1254 is a potential target for the treatment of OSCCs +therapeutic target hsa-let-7b Melanoma 28167449 Curcumin and treatment of melanoma: The potential role of microRNAs. +therapeutic target hsa-mir-21 Melanoma 28167449 Curcumin and treatment of melanoma: The potential role of microRNAs. +therapeutic target hsa-mir-122 Neoplasms [unspecific] 28209991 MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. +therapeutic target hsa-mir-34 Neoplasms [unspecific] 28209991 MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. +therapeutic target hsa-mir-126 "Carcinoma, Renal Cell" 28257806 Pseudohypoxia induced by miR-126 deactivation promotes migration and therapeutic resistance in renal cell carcinoma. +therapeutic target hsa-mir-146b "Carcinoma, Thyroid, Papillary" 28294980 MicroRNA-146b: A Novel Biomarker and Therapeutic Target for Human Papillary Thyroid Cancer. +therapeutic target hsa-mir-223 Hematologic Neoplasms 28322994 "The role of miRNA-223 in cancer: Function, diagnosis and therapy." +therapeutic target hsa-mir-27b Neoplasms [unspecific] 28351320 Promising therapeutic role of miR-27b in tumor. +therapeutic target hsa-mir-30a Neoplasms [unspecific] 28359057 miR-30a may serve as a potential target in the diagnosis and therapy of human cancer +therapeutic target hsa-mir-383 Spinal Cord Injuries 28365701 Suppression of MicroRNA-383 Enhances Therapeutic Potential of Human Bone-Marrow-Derived Mesenchymal Stem Cells in Treating Spinal Cord Injury via GDNF. +therapeutic target hsa-mir-149 Colorectal Carcinoma 28370854 miR-149 may serve as a therapeutic target for colorectal cancer treatment +therapeutic target hsa-mir-138 Malignant Neoplasms [unspecific] 28378633 MiR-138: A promising therapeutic target for cancer. +therapeutic target hsa-mir-17 Kidney Diseases [unspecific] 28399020 Therapeutic microRNAs in polycystic kidney disease. +therapeutic target hsa-mir-146 Cardiovascular Diseases [unspecific] 28407626 Exogenous miRNA-146a Enhances the Therapeutic Efficacy of Human Mesenchymal Stem Cells by Increasing Vascular Endothelial Growth Factor Secretion in the Ischemia/Reperfusion-Injured Heart. +therapeutic target hsa-mir-126 Diabetes Mellitus 28440196 miR-126 as a Therapeutic Agent for Diabetes Mellitus. +therapeutic target hsa-mir-210 Neurilemmoma 28440459 miR-210 could be a potential marker for judging tumor malignancy and be taken as an effective target for clinical auxiliary treatment of neurilemmoma +therapeutic target hsa-mir-21 Pancreatic Neoplasms 28444967 Co-delivery of microRNA-21 antisense oligonucleotides and gemcitabine using nanomedicine for pancreatic cancer therapy. +therapeutic target hsa-mir-143 Neoplasms [unspecific] 28448866 Function of microRNA-143 in different signal pathways in cancer: New insights into cancer therapy. +therapeutic target hsa-mir-92a Diabetes Mellitus 28462946 Light-inducible antimiR-92a as a therapeutic strategy to promote skin repair in healing-impaired diabetic mice. +therapeutic target hsa-mir-130a Myocardial Infarction 28498815 The optimization of cell therapy by combinational application with apicidin-treated mesenchymal stem cells after myocardial infarction. +therapeutic target hsa-mir-373 Glioma 28617546 Down-expression of miR-373 predicts poor prognosis of glioma and could be a potential therapeutic target. +therapeutic target hsa-mir-200c Uterine Carcinosarcoma 28620240 miR-200c-driven Mesenchymal-To-Epithelial Transition is a Therapeutic Target in Uterine Carcinosarcomas. +therapeutic target hsa-mir-143 "Carcinoma, Breast, Triple Negative" 28621239 A microRNA signature associated with pathological complete response to novel neoadjuvant therapy regimen in triple-negative breast cancer. +therapeutic target hsa-mir-30a "Carcinoma, Breast, Triple Negative" 28621239 A microRNA signature associated with pathological complete response to novel neoadjuvant therapy regimen in triple-negative breast cancer. +therapeutic target hsa-mir-770 "Carcinoma, Breast, Triple Negative" 28621239 A microRNA signature associated with pathological complete response to novel neoadjuvant therapy regimen in triple-negative breast cancer. +therapeutic target hsa-mir-9 "Carcinoma, Breast, Triple Negative" 28621239 A microRNA signature associated with pathological complete response to novel neoadjuvant therapy regimen in triple-negative breast cancer. +therapeutic target hsa-mir-375 "Carcinoma, Hepatocellular" 28624193 MiR-375 and Doxorubicin Co-delivered by Liposomes for Combination Therapy of Hepatocellular Carcinoma. +therapeutic target hsa-mir-499 Cardiovascular Diseases [unspecific] 28627982 miRNAs as potential therapeutic targets and diagnostic biomarkers for cardiovascular disease with a particular focus on WO2010091204. +therapeutic target hsa-mir-629 Breast Neoplasms 28629464 miR-629-3p may serve as a novel biomarker and potential therapeutic target for lung metastases of triple-negative breast cancer. +therapeutic target hsa-mir-15a "Lymphoma, Follicular" 28653191 MicroRNA Dysregulation to Identify Novel Therapeutic Targets. +therapeutic target hsa-mir-26a Glaucoma 28685590 miR-26a plays an essential role in the formation of filtering tract scar and function as a potential drug target +therapeutic target hsa-mir-503 Endometriosis 28720098 "Arcyriaflavin a, a cyclin D1-cyclin-dependent kinase4 inhibitor, induces apoptosis and inhibits proliferation of human endometriotic stromal cells: a potential therapeutic agent in endometriosis" +therapeutic target hsa-mir-140 "Carcinoma, Lung, Non-Small-Cell" 28739724 Therapeutic Role of MiR-140-5p for the Treatment of Non-small Cell Lung Cancer. +therapeutic target hsa-mir-433 Endomyocardial Fibrosis 28740551 Modulating microRNAs as Novel Therapeutic Targets in Cardiac Fibrosis. +therapeutic target hsa-mir-145 "Carcinoma, Ovarian" 28804560 Using miR-145 mimics may be a rational approach for therapeutic applications in ovarian carcinoma in the future +therapeutic target hsa-mir-132 Wound Healing 28807666 MicroRNA-132 with Therapeutic Potential in Chronic Wounds. +therapeutic target hsa-mir-122 "Leukemia, Myeloid, Acute" 28822593 Decreased expression of microRNA-122 is associated with an unfavorable prognosis in childhood acute myeloid leukemia and function analysis indicates a therapeutic potential. +therapeutic target hsa-mir-122 Cholangiocarcinoma 28832247 "miRNA profiling for diagnosis, prognosis and stratification of cancer treatment in cholangiocarcinoma." +therapeutic target hsa-mir-34b "Carcinoma, Thyroid" 28840508 It could be a target for developing treatment strategies of thyroid carcinoma with aggressive clinical behaviour +therapeutic target hsa-mir-21 Glioblastoma 28840962 Biomarkers and therapeutic advances in glioblastoma multiforme. +therapeutic target hsa-mir-155 Intraductal Papillary Mucinous Neoplasms 28938594 these miRNAs might serve as new risk biomarkers of IPMN and could be useful for future targeted therapies +therapeutic target hsa-mir-137 Bipolar Disorder 28969861 "miRNA findings in BD significantly vary between studies, but are consistent to suggest a key role for these molecules in BD's pathophysiology and treatment, particularly miR-34a and miR-137" +therapeutic target hsa-mir-34a Bipolar Disorder 28969861 "miRNA findings in BD significantly vary between studies, but are consistent to suggest a key role for these molecules in BD's pathophysiology and treatment, particularly miR-34a and miR-137" +therapeutic target hsa-mir-20a Myeloma 28979138 miR-20a plays a crucial role in the biology of MM and represents a potential target for novel therapies for MM patients +therapeutic target hsa-mir-122 Chronic Hepatitis C 28993299 Circulating microRNAs as a biomarker to predict therapy efficacy in hepatitis C patients with different genotypes. +therapeutic target hsa-mir-124a Glioblastoma 29016843 Mesenchymal stem cells as natural biofactories for exosomes carrying miR-124a in the treatment of gliomas. +therapeutic target hsa-mir-132 Colon Neoplasms 29017096 miR-132 as a promising therapeutic candidate to control autoimmune inflammation and tumorigenesis in CAC patients +therapeutic target hsa-mir-449a Neoplasms [unspecific] 29023247 miR-449a: a potential therapeutic agent for cancer. +therapeutic target hsa-mir-146a "Carcinoma, Thyroid, Papillary" 29048684 miR-146a and miR-146b in the diagnosis and prognosis of papillary thyroid carcinoma. +therapeutic target hsa-mir-146b "Carcinoma, Thyroid, Papillary" 29048684 miR-146a and miR-146b in the diagnosis and prognosis of papillary thyroid carcinoma. +therapeutic target hsa-mir-134 Epilepsy 29069823 MicroRNA-134 plasma levels before and after treatment with valproic acid for epilepsy patients. +therapeutic target hsa-mir-16 Cardiovascular Diseases [unspecific] 29104843 miR-16 was a potential therapeutic target by participating in the Ang II-associated multiple signaling pathways in cardiovascular diseases +therapeutic target hsa-mir-155 Rheumatoid Arthritis 29105307 Hopefully the information obtained will benefit the development of novel therapeutic strategies +therapeutic target hsa-mir-130a Cardiac Fibrosis 29114000 "MicroRNA-130a, a Potential Antifibrotic Target in Cardiac Fibrosis." +therapeutic target hsa-mir-145 "Carcinoma, Hepatocellular" 29156696 The interaction between pSmad3C/3L and microRNA-145/21 regulates HCC progression and the switch of pSmad3C/3L may serve as an important target for HCC therapy +therapeutic target hsa-mir-29b Glioblastoma 29176935 miR-29b may serve as a putative therapeutic molecule when its expression is restored using a nanoparticle delivery system in GBM +therapeutic target hsa-mir-20a Breast Neoplasms 29179464 Therapy directed at uPAR-induced miR-17/20a is a potential option for breast cancer and TNBC +therapeutic target hsa-mir-124 Glioblastoma 29185191 MicroRNAs (miRs) are potential therapeutic targets in glioblastoma multiforme (GBM) +therapeutic target hsa-mir-21 Keloid 29190966 "inhibition of microRNA-21 induces mitochondrial-mediated apoptosis in keloid fibroblasts, proposing microRNA-21 as a potential therapeutic target in keloid fibroblasts" +therapeutic target hsa-mir-126 Pancreatic Adenocarcinoma 29200874 The therapeutic system co-expressing miR-126 and miR-34a mediated by oncolytic adenovirus is a promising system for PAC target therapy +therapeutic target hsa-mir-34a Pancreatic Adenocarcinoma 29200874 The therapeutic system co-expressing miR-126 and miR-34a mediated by oncolytic adenovirus is a promising system for PAC target therapy +therapeutic target hsa-mir-150 Chronic Obstructive Pulmonary Disease 29205062 Restoration of miR-150 expression may represent a potential therapeutic strategy for CS-related COPD +therapeutic target hsa-mir-100 Atherosclerosis 29208678 "Our findings of miR-100 as a potential protective anti-athero-miR suggest that the therapeutic replacement of this microRNA could be a potential strategy for the treatment of chronic inflammatory diseases, such as atherosclerosis, in the future" +therapeutic target hsa-mir-21 Atherosclerosis 29228671 "our results demonstrated that metformin improved IRSM by inhibiting miR-21 expression, and that miR-21 may be one of the therapeutic targets for IR" +therapeutic target hsa-let-7a Prostate Neoplasms 29236328 the therapeutic potential of Let-7a as an antitumor and antimetastatic manager in prostate cancer and CCR7 may be regarded as a therapeutic target for the prostate cancer treatment +therapeutic target hsa-mir-34a Multiple Myeloma 29263373 Evidence of novel miR-34a-based therapeutic approaches for multiple myeloma treatment +therapeutic target hsa-mir-1 Myocardial Infarction 29269324 Delivery of microRNA-1 inhibitor by dendrimer-based nanovector: An early targeting therapy for myocardial infarction in mice +therapeutic target hsa-mir-204 "Adenocarcinoma, Lung" 29281186 "Clinically, the miR-204/JAK2/STAT3 signaling pathway is a putative therapeutic target in lung adenocarcinoma" +therapeutic target hsa-mir-155 Neoplasms [unspecific] 29282605 miR-155 in cancer drug resistance and as target for miRNA-based therapeutics +therapeutic target hsa-mir-34a Heart Diseases [unspecific] 29302057 "inhibition of miR-34a activity has differential effects depending on the cell type, thereby warranting the need to eliminate off-target effects when introducing miR-based therapy" +therapeutic target hsa-mir-205 "Carcinoma, Thyroid, Anaplastic" 29317480 This may open avenues to exploit miR-205 as an alternative cancer therapeutic strategy in the future +therapeutic target hsa-mir-19a Cervical Neoplasms 29332345 "Overall, inhibiting miR-19a significantly improves the sensitivity of SiHa cells to radiotherapy, which could lead to new methods for the treatment of cervical cancer" +therapeutic target hsa-let-7 Breast Neoplasms 29336465 the findings identified a biochemical and functional link between Let-7 and endocrine therapy in breast CSCs +therapeutic target hsa-mir-21 Glioblastoma 29340361 DP-Cur is an efficient carrier of miR21ASO and the combined delivery of miR21ASO and curcumin may be useful in the development of combination therapy for glioblastoma +therapeutic target hsa-mir-221 "Carcinoma, Thyroid" 29351231 These ceRNAs are critical in revealing the secrets behind thyroid cancer progression and may serve as future therapeutic biomarkers +therapeutic target hsa-mir-222 "Carcinoma, Thyroid" 29351231 These ceRNAs are critical in revealing the secrets behind thyroid cancer progression and may serve as future therapeutic biomarkers +therapeutic target hsa-mir-375 "Carcinoma, Thyroid" 29351231 These ceRNAs are critical in revealing the secrets behind thyroid cancer progression and may serve as future therapeutic biomarkers +therapeutic target hsa-mir-155 Arthritis 29354135 "we review the evidence for the pathogenic role of miR-155 in driving aberrant activation of the immune system in rheumatoid arthritis, and its potential as a disease biomarker and therapeutic target" +therapeutic target hsa-mir-16 Short Bowel Syndrome 29364022 Modulation of these pathways may represent a new therapeutic option for the management of short bowel syndrome +therapeutic target hsa-mir-5338 Prostate Disease 29382326 Study on the inhibition of Mfn1 by plant-derived miR5338 mediating the treatment of BPH with rape bee pollen. +therapeutic target hsa-mir-155 Polycystic Ovarian Syndrome 29385860 Serum miRNAs in women affected by hyperandrogenic polycystic ovary syndrome: the potential role of miR-155 as a biomarker for monitoring the estroprogestinic treatment. +therapeutic target hsa-mir-200a Colorectal Carcinoma 29388209 The miR200 family has potential for both prognostic and therapeutic management of CRC. +therapeutic target hsa-mir-200c Colorectal Carcinoma 29388209 The miR201 family has potential for both prognostic and therapeutic management of CRC. +therapeutic target hsa-mir-19a "Carcinoma, Hepatocellular" 29393488 miR?19a may have potential as a novel molecular marker for HCC and Pter may be a promising clinical target with the potential to be developed as a HCC therapy +therapeutic target hsa-mir-15a Breast Neoplasms 29394261 modulatingspecific miRNAs may serve as a therapeutic approach for the treatment of breast cancer +therapeutic target hsa-let-7b Intestinal Barrier Dysfunction 29402773 Let-7b was identified as a novel diagnosis biomarker or a potential treatment target for preventing intestinal barrier dysfunction +therapeutic target hsa-mir-221 Parkinson Disease 29405726 miR-221 may serve as a potential therapeutic target for Parkinson's disease treatment +therapeutic target hsa-mir-155 Liver Injury 29420849 maintaining miR-155 expression in inflammatory cells might be a potential strategy to modulate liver injury +therapeutic target hsa-mir-145 Hypertension 29434681 miR-145 is a potential target for the treatment of hypertension +therapeutic target hsa-mir-1268a Neoplasms [unspecific] 29435930 "Quantum Language of MicroRNA: Application for New Cancer Therapeutic Targets(the top 5 of high DNS were in rmiRNAs, rmiR-4466 in 5¡äETS, rmiR-3656 in 28S, rmiR-1268a and rmiR-1268b in 3¡äETS, and rmiR-6729)" +therapeutic target hsa-mir-1268b Neoplasms [unspecific] 29435930 "Quantum Language of MicroRNA: Application for New Cancer Therapeutic Targets(the top 5 of high DNS were in rmiRNAs, rmiR-4466 in 5¡äETS, rmiR-3656 in 28S, rmiR-1268a and rmiR-1268b in 3¡äETS, and rmiR-6729)" +therapeutic target hsa-mir-3656 Neoplasms [unspecific] 29435930 "Quantum Language of MicroRNA: Application for New Cancer Therapeutic Targets(the top 5 of high DNS were in rmiRNAs, rmiR-4466 in 5¡äETS, rmiR-3656 in 28S, rmiR-1268a and rmiR-1268b in 3¡äETS, and rmiR-6729)" +therapeutic target hsa-mir-4466 Neoplasms [unspecific] 29435930 "Quantum Language of MicroRNA: Application for New Cancer Therapeutic Targets(the top 5 of high DNS were in rmiRNAs, rmiR-4466 in 5¡äETS, rmiR-3656 in 28S, rmiR-1268a and rmiR-1268b in 3¡äETS, and rmiR-6729)" +therapeutic target hsa-mir-6729 Neoplasms [unspecific] 29435930 "Quantum Language of MicroRNA: Application for New Cancer Therapeutic Targets(the top 5 of high DNS were in rmiRNAs, rmiR-4466 in 5¡äETS, rmiR-3656 in 28S, rmiR-1268a and rmiR-1268b in 3¡äETS, and rmiR-6729)" +therapeutic target hsa-mir-10a Atherosclerosis 29459264 EC miR-10a induction by RAR¦Á/RXR¦Á-specific agonists is a potential hemodynamics-based strategy for atherosclerosis treatment +therapeutic target hsa-mir-17 "Carcinoma, Hepatocellular" 29464015 "Hence, anti-miR-17 is an effective therapy for MYC-driven HCC" +therapeutic target hsa-mir-22 Heart Failure 29486470 "Our findings demonstrate that miR-22 accelerates cardiac fibrosis through the miR-22-Cav3-PKC¦Å pathway, which, therefore, may represent a new therapeutic target for treatment of excessive fibrosis-associated cardiac diseases" +therapeutic target hsa-mir-146a Ischemia-Reperfusion Injury 29505740 our findings demonstrate that the elevation of miR-146a may be one of the compensatory responses after the cerebral I/R injury and suggest miR-146a as a potential therapeutic target for cerebral I/R injury +therapeutic target hsa-mir-134 Diabetic Nephropathy 29532746 MiR-150 and miR-134 may be essential microRNAs in the treatment of MSCs for DN +therapeutic target hsa-mir-150 Diabetic Nephropathy 29532746 MiR-150 and miR-134 may be essential microRNAs in the treatment of MSCs for DN +therapeutic target hsa-mir-155 "Carcinoma, Renal Cell, Clear-Cell" 29534467 Our results further support a role for miR-155 as a promising cancer classifier and potentially as a therapeutic target in ccRCC that merits further investigation +therapeutic target hsa-mir-192 "Carcinoma, Bladder" 29536411 miR-192-5p might serve as a promising target in bladder cancer diagnosis and therapy +therapeutic target hsa-mir-125b Hepatitis C Virus Infection 29541414 This study elucidates a novel pathway for miR-125b in the pathogenesis of chronic HCV infection and suggests it as a possible target for treating HCV infection +therapeutic target hsa-let-7d Alzheimer Disease 29543360 The potential functions of these miRNAs as diagnostic and therapeutic targets of the AD were revealed by this study +therapeutic target hsa-let-7g Alzheimer Disease 29543360 The potential functions of these miRNAs as diagnostic and therapeutic targets of the AD were revealed by this study +therapeutic target hsa-mir-101 Alzheimer Disease 29543360 The potential functions of these miRNAs as diagnostic and therapeutic targets of the AD were revealed by this study +therapeutic target hsa-mir-125b Alzheimer Disease 29543360 The potential functions of these miRNAs as diagnostic and therapeutic targets of the AD were revealed by this study +therapeutic target hsa-mir-155 Alzheimer Disease 29543360 The potential functions of these miRNAs as diagnostic and therapeutic targets of the AD were revealed by this study +therapeutic target hsa-mir-15b Alzheimer Disease 29543360 The potential functions of these miRNAs as diagnostic and therapeutic targets of the AD were revealed by this study +therapeutic target hsa-mir-191 Alzheimer Disease 29543360 The potential functions of these miRNAs as diagnostic and therapeutic targets of the AD were revealed by this study +therapeutic target hsa-mir-26b Alzheimer Disease 29543360 The potential functions of these miRNAs as diagnostic and therapeutic targets of the AD were revealed by this study +therapeutic target hsa-mir-29b Alzheimer Disease 29543360 The potential functions of these miRNAs as diagnostic and therapeutic targets of the AD were revealed by this study +therapeutic target hsa-mir-342 Alzheimer Disease 29543360 The potential functions of these miRNAs as diagnostic and therapeutic targets of the AD were revealed by this study +therapeutic target hsa-mir-34a Alzheimer Disease 29543360 The potential functions of these miRNAs as diagnostic and therapeutic targets of the AD were revealed by this study +therapeutic target hsa-mir-9 Alzheimer Disease 29543360 The potential functions of these miRNAs as diagnostic and therapeutic targets of the AD were revealed by this study +therapeutic target hsa-mir-7 Colorectal Carcinoma 29549306 therapeutic targeting of the c-Myb/circHIPK3/miR-7 axis may be a promising treatment approach for CRC patients +therapeutic target hsa-mir-21 Breast Neoplasms 29567152 chemically modified miRNA-21 inhibitor based on gold nanoparticles would be as a promising diagnostic and therapeutic platform for breast cancer clinically +therapeutic target hsa-mir-21 "Squamous Cell Carcinoma, Esophageal" 29568234 MiR-21 is a potential novel target for developing specific treatment interventions in ESCC in future +therapeutic target hsa-mir-186 Melanoma 29578151 "miR-186 exhibit an inhibitory effect on CMM cell proliferation, migration, and invasion; thus, may serve as a potential therapeutic target for human CMM intervention" +therapeutic target hsa-mir-200c Chronic Hepatitis B 29593314 an HBV-pSTAT3-SALL4-miR-200c axis regulates PD-L1. Therapeutic strategies to influence this axis might reverse virus-induced immune exhaustion +therapeutic target hsa-mir-124 Neoplasms [unspecific] 29602831 "This novel ncRNA bioengineering platform can be easily adapted to produce various ncRNA molecules, and biologic ncRNAs hold the promise as new cancer therapeutics" +therapeutic target hsa-mir-34a Neoplasms [unspecific] 29602831 "This novel ncRNA bioengineering platform can be easily adapted to produce various ncRNA molecules, and biologic ncRNAs hold the promise as new cancer therapeutics" +therapeutic target hsa-mir-21 Inflammation 29620442 It may provide a novel therapeutic strategy to regulate the odontoblast differentiation of DPSCs +therapeutic target hsa-mir-21 Endometriosis 29625267 Identification of small-molecule ligands that bind to MiR-21 as potential therapeutics for endometriosis by screening ZINC database and in-vitro assays. +therapeutic target hsa-mir-143 Endometrial Neoplasms 29661100 these miRNAs are potential candidates for the diagnosis of endometrial cancer and therapeutic targets +therapeutic target hsa-mir-145 Endometrial Neoplasms 29661100 these miRNAs are potential candidates for the diagnosis of endometrial cancer and therapeutic targets +therapeutic target hsa-mir-378 Bone Disease [unspecific] 29686962 "miR378 was an ideal target to osteogenesis-angiogenesis coupling for bone regeneration, which provides a potential tool for the gene therapy of bone regeneration." +therapeutic target hsa-mir-139 Ovarian Neoplasms 29719173 miR-139-5p overexpression might be a future therapeutic strategy for OC. +therapeutic target hsa-mir-145 Urinary Bladder Cancer 29723992 "MicroRNAs in Smoking-Related Carcinogenesis: Biomarkers, Functions, and Therapy." +therapeutic target hsa-mir-224 "Carcinoma, Lung, Non-Small-Cell" 29723992 "MicroRNAs in Smoking-Related Carcinogenesis: Biomarkers, Functions, and Therapy." +therapeutic target hsa-mir-21 Seizures 29751355 The miR-21-5p/PTEN/mTOR axis may be a potential target for preventing and treating seizures and epileptic damage +therapeutic target hsa-mir-204 "Leukemia, Myeloid, Acute" 29764561 MiR-204 acts as a potential therapeutic target in acute myeloid leukemia by increasing BIRC6-mediated apoptosis. +therapeutic target hsa-mir-107 Burns 29802017 "Expression of junctional proteins such as claudin-1, loricrin, filaggrin, ZO-1, and ZO-2 were significantly upregulated following TLN¦Ê/anti-miR-107 treatment" +therapeutic target hsa-mir-145 "Carcinoma, Hepatocellular" 29805683 "certain miRNAs (including miR-96, miR-145 and miR-183) and mRNAs may be therapeutic targets of ribavirin in hepatocellular carcinoma." +therapeutic target hsa-mir-183 "Carcinoma, Hepatocellular" 29805683 "certain miRNAs (including miR-96, miR-145 and miR-183) and mRNAs may be therapeutic targets of ribavirin in hepatocellular carcinoma." +therapeutic target hsa-mir-96 "Carcinoma, Hepatocellular" 29805683 "certain miRNAs (including miR-96, miR-145 and miR-183) and mRNAs may be therapeutic targets of ribavirin in hepatocellular carcinoma." +therapeutic target hsa-mir-106a Prostate Neoplasms 29845714 "Our research provides the first report of miR-106a and LITAF in prostate cancer radiation resistance and high-grade disease, and presents a viable therapeutic strategy that may ultimately improve patient outcomes" +therapeutic target hsa-mir-543 Periodontitis 29851072 miR-543 may be a potential therapy for bone loss in periodontitis +therapeutic target hsa-mir-145 Prostate Neoplasms 29858716 Treating metastatic prostate cancer with microRNA-145. +therapeutic target hsa-mir-335 Sepsis 29866515 upregulation of miR-335-5p is therapeutic strategy for sepsis +therapeutic target hsa-mir-1297 Melanoma 29873263 seed-targeted anti-miR-1297 might serve as a new tactic for miR-1297-based therapies +therapeutic target hsa-mir-9 Gastric Neoplasms 29879907 Targeting miR-9 in gastric cancer cells using locked nucleic acid oligonucleotides. +therapeutic target hsa-mir-143 Neoplasms [unspecific] 29929447 Hsa-miR-143-3p and hsa-miR-193b-3p were found to be up-regulated by the use of different non-viral vectors and can thus serve as potential targets of non-viral cancer gene therapy +therapeutic target hsa-mir-193b Neoplasms [unspecific] 29929447 Hsa-miR-143-3p and hsa-miR-193b-3p were found to be up-regulated by the use of different non-viral vectors and can thus serve as potential targets of non-viral cancer gene therapy +therapeutic target hsa-mir-146a Autism Spectrum Disorder 29951184 miR-146a may be new therapeutic targets and strategies +therapeutic target hsa-mir-214 Human Papilloma Virus Infection 29952653 MiR-214-3p can possibly serve as a valuable biomarker and a therapeutic target for SNIP +therapeutic target hsa-mir-29a Liver Fibrosis 29954104 "This review focuses on the evolving view of the molecular mechanisms by which HSC activation by miR-29a signaling may moderate the profibrogenic phenotype of these cells, thus supporting the use of miR-29a agonists as a potential therapy for treating liver fibrosis in the future" +therapeutic target hsa-mir-21 Hypertension 29973661 The potential role of miR-21 as a new target for predicting and treating hypertension is also explored +therapeutic target hsa-mir-21 "Carcinoma, Breast" 29981261 Dynamic microRNA activity identifies therapeutic targets in trastuzumab-resistant HER2+ breast cancer. +therapeutic target hsa-mir-17 Multiple Myeloma 29997223 "Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92." +therapeutic target hsa-mir-18 Multiple Myeloma 29997223 "Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92." +therapeutic target hsa-mir-19a Multiple Myeloma 29997223 "Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92." +therapeutic target hsa-mir-19b-1 Multiple Myeloma 29997223 "Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92." +therapeutic target hsa-mir-20a Multiple Myeloma 29997223 "Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92." +therapeutic target hsa-mir-92-1 Multiple Myeloma 29997223 "Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92." +therapeutic target hsa-mir-155 Mesial Temporal Lobe Epilepsy 30006293 regulation of the miR-155/TNF-¦Á axis may be a new therapeutic target for TLE +therapeutic target hsa-mir-135a Glioma 30015885 "miR?135A/B, and the target FOXO1, may be potential therapy targets for glioma treatment" +therapeutic target hsa-mir-135b Glioma 30015885 "miR?135A/B, and the target FOXO1, may be potential therapy targets for glioma treatment" +therapeutic target hsa-mir-338 Bone Disease [unspecific] 30029590 "new miRNAs like MIR-338 and MIR-376A were identified, which may serve as potential therapeutic targets for the effective treatment of cerebral ischemic injury" +therapeutic target hsa-mir-367a Bone Disease [unspecific] 30029590 "new miRNAs like MIR-338 and MIR-376A were identified, which may serve as potential therapeutic targets for the effective treatment of cerebral ischemic injury" +therapeutic target hsa-mir-122 Hepatitis C Virus Infection 30038017 "MicroRNA-122 (miR-122), a target of current phase II anti-HCV drugs, is known to protect HCV transcripts against XRNs" +therapeutic target hsa-mir-34a "Carcinoma, Breast, Triple Negative" 30072748 MicroRNA in diagnosis and therapy monitoring of early-stage triple-negative breast cancer. +therapeutic target hsa-mir-1290 Colon Neoplasms 30073936 "particularly hsa-miR-424-5p, hsa-miR-96-5p, hsa-miR-1290, hsa-miR-224, hsa-miR-133a and has-miR-363-3p present possible targets for colon cancer" +therapeutic target hsa-mir-133a Colon Neoplasms 30073936 "particularly hsa-miR-424-5p, hsa-miR-96-5p, hsa-miR-1290, hsa-miR-224, hsa-miR-133a and has-miR-363-3p present possible targets for colon cancer" +therapeutic target hsa-mir-224 Colon Neoplasms 30073936 "particularly hsa-miR-424-5p, hsa-miR-96-5p, hsa-miR-1290, hsa-miR-224, hsa-miR-133a and has-miR-363-3p present possible targets for colon cancer" +therapeutic target hsa-mir-363 Colon Neoplasms 30073936 "particularly hsa-miR-424-5p, hsa-miR-96-5p, hsa-miR-1290, hsa-miR-224, hsa-miR-133a and has-miR-363-3p present possible targets for colon cancer" +therapeutic target hsa-mir-424 Colon Neoplasms 30073936 "particularly hsa-miR-424-5p, hsa-miR-96-5p, hsa-miR-1290, hsa-miR-224, hsa-miR-133a and has-miR-363-3p present possible targets for colon cancer" +therapeutic target hsa-mir-96 Colon Neoplasms 30073936 "particularly hsa-miR-424-5p, hsa-miR-96-5p, hsa-miR-1290, hsa-miR-224, hsa-miR-133a and has-miR-363-3p present possible targets for colon cancer" +therapeutic target hsa-mir-26a "Carcinoma, Hepatocellular" 30076741 Lower expression of tumor microRNA-26a is associated with higher recurrence in patients with hepatocellular carcinoma undergoing surgical treatment. +therapeutic target hsa-mir-326 Autoimmune Diseases [unspecific] 30078204 "The MicroRNA-326: Autoimmune diseases, diagnostic biomarker, and therapeutic target." +therapeutic target hsa-mir-141 "Carcinoma, Hepatocellular" 30083268 Tumor-suppressing miR-141 gene complex-loaded tissue-adhesive glue for the locoregional treatment of hepatocellular carcinoma. +therapeutic target hsa-mir-33 Atherosclerosis 30092598 miR-33 represents a novel target for the treatment of atherosclerosis +therapeutic target hsa-mir-187 Gastric Neoplasms 30112051 miR-187 may be a potential biomarker and therapeutic target in GC +therapeutic target hsa-mir-143 Neoplasms [unspecific] 30150287 Our findings will encourage the development of new strategies targeting miR-143 in both cancer cells and T cells +therapeutic target hsa-mir-21 Primary Aldosteronism 30153065 miR-21 supplementation may be a novel therapeutic approach to abolish or mitigate excess aldosterone-mediated cardiovascular deleterious effects in primary aldosteronism +therapeutic target hsa-mir-30a Neoplasms [unspecific] 30158978 MiR-30a: A Novel Biomarker and Potential Therapeutic Target for Cancer. +therapeutic target hsa-mir-10a "Carcinoma, Breast" 30160115 Anti-breast-Cancer Activity Exerted by ¦Â-Sitosterol-d-glucoside from Sweet Potato via Upregulation of MicroRNA-10a and via the PI3K-Akt Signaling Pathway. +therapeutic target hsa-mir-223 Wound Healing 30171089 Targeting miR-223 in neutrophils enhances the?clearance of Staphylococcus aureus in infected?wounds. +therapeutic target hsa-mir-636 Hepatitis C Virus Infection 30174796 miR-636 might be one of the essential targetable molecules in HCV patients who undergo DAA therapy and still suffer from a sustained HCV infection +therapeutic target hsa-mir-383 Heart Failure 30206318 Multipoint targeting of TGF-¦Â/Wnt transactivation circuit with microRNA 384-5p for cardiac fibrosis. +therapeutic target hsa-mir-126 Vascular Injuries 30213595 Dicer promotes endothelial recovery and limits lesion formation after vascular injury through miR-126-5p. +therapeutic target hsa-mir-210 Cholangiocarcinoma 30214622 Cholangiocarcinoma therapy with nanoparticles that combine downregulation of MicroRNA-210 with inhibition of cancer cell invasiveness. +therapeutic target hsa-mir-150 Rheumatoid Arthritis 30224512 Therapeutic Potential of Mesenchymal Cell-Derived miRNA-150-5p-Expressing Exosomes in Rheumatoid Arthritis Mediated by the Modulation of MMP14 and VEGF. +therapeutic target hsa-mir-423 "Adenocarcinoma, Lung" 30224667 MiR-423-5p has the potential to be a marker of BM and/or a therapeutic target in LAD +therapeutic target hsa-mir-126 "Carcinoma, Hepatocellular" 30268144 Targeting miR-494-3p and miR-126-3p may provide effective and promising approaches to suppress invasion and metastasis of HCC +therapeutic target hsa-mir-494 "Carcinoma, Hepatocellular" 30268144 Targeting miR-494-3p and miR-126-3p may provide effective and promising approaches to suppress invasion and metastasis of HCC +therapeutic target hsa-mir-17 Rectal Neoplasms 30277504 Expression profile of miR-17/92 cluster is predictive of treatment response in rectal cancer. +therapeutic target hsa-mir-18 Rectal Neoplasms 30277504 Expression profile of miR-17/92 cluster is predictive of treatment response in rectal cancer. +therapeutic target hsa-mir-19a Rectal Neoplasms 30277504 Expression profile of miR-17/92 cluster is predictive of treatment response in rectal cancer. +therapeutic target hsa-mir-19b-1 Rectal Neoplasms 30277504 Expression profile of miR-17/92 cluster is predictive of treatment response in rectal cancer. +therapeutic target hsa-mir-20a Rectal Neoplasms 30277504 Expression profile of miR-17/92 cluster is predictive of treatment response in rectal cancer. +therapeutic target hsa-mir-92-1 Rectal Neoplasms 30277504 Expression profile of miR-17/92 cluster is predictive of treatment response in rectal cancer. +therapeutic target hsa-mir-425 "Leukemia, Myeloid, Acute" 30285885 MiR-425 expression profiling in acute myeloid leukemia might guide the treatment choice between allogeneic transplantation and chemotherapy. +therapeutic target hsa-mir-221 "Fatty Liver, Non-Alcoholic" 30316865 Targeting hepatic miR-221/222 for therapeutic intervention of nonalcoholic steatohepatitis in mice. +therapeutic target hsa-mir-222 "Fatty Liver, Non-Alcoholic" 30316865 Targeting hepatic miR-221/222 for therapeutic intervention of nonalcoholic steatohepatitis in mice. +therapeutic target hsa-mir-155 Neoplasms [unspecific] 30319757 "a DNA nanotube structure that carries functional DNA segments (single-stranded, duplex and hairpin forms) was designed and synthesized to capture two well-known overexpressed miRNAs, miR-21 and miR-155" +therapeutic target hsa-mir-21 Neoplasms [unspecific] 30319757 "a DNA nanotube structure that carries functional DNA segments (single-stranded, duplex and hairpin forms) was designed and synthesized to capture two well-known overexpressed miRNAs, miR-21 and miR-155" +therapeutic target hsa-mir-20a "Leukemia, T-Cell" 30336537 miR-20a may act as a tumor suppressor in CD4+ T cells and also has a potential therapeutic in these kinds of cancers +therapeutic target hsa-mir-34c "Carcinoma, Lung, Non-Small-Cell" 30340138 the GL21.T/miR-34c chimera exerts dual inhibition of AXL at functional and transcriptional levels and represents a novel therapeutic tool for the treatment of NSCLC +therapeutic target hsa-mir-200b "Carcinoma, Breast" 30342533 The miR-200b presents a great potential for the future advancements in the diagnostic/prognostic and therapeutic approach of TNBC +therapeutic target hsa-mir-647 "Carcinoma, Lung, Non-Small-Cell" 30349310 MicroRNA-647 promotes the therapeutic effectiveness of argon-helium cryoablation and inhibits cell proliferation through targeting TRAF2 via the NF-¦ÊB signaling pathway in non-small cell lung cancer. +therapeutic target hsa-mir-33b Atherosclerosis 30354203 miR-33b is a promising target for treating atherosclerosis +therapeutic target hsa-mir-1247 Prostate Neoplasms 30378132 our data highlight miR-1247 as a potential target for molecular therapies aimed to block the progression and diffusion of PCa +therapeutic target hsa-mir-20b Tuberculosis 30378171 miR-20b-5p and exosomes as the potential therapeutic targets of TB +transcription factor target hsa-mir-451 "Leukemia, Myeloid, Chronic" 27825294 Downregulation of miR-451 in Tunisian chronic myeloid leukemia patients: potential implication in imatinib resistance. +transcription factor target hsa-mir-20a Retinoblastoma 17135249 "Altogether, these results suggest that the autoregulation between E2F1-3 and miR-20a is important for preventing an abnormal accumulation of E2F1-3 and may play a role in the regulation of cellular proliferation and apoptosis." +transcription factor target hsa-mir-21 Multiple Myeloma 17496199 Ectopically raising miR-21 expression in myeloma cells in the absence of IL-6 significantly reduced their apoptosis levels. These data provide strong evidence that miR-21 induction contributes to the oncogenic potential of Stat3. +transcription factor target hsa-mir-34a Neoplasms [unspecific] 17656095 "Taken together, the data suggest the miRNA34s might be key effectors of p53 tumor-suppressor function, and their inactivation might contribute to certain cancers." +transcription factor target hsa-mir-34b Neoplasms [unspecific] 17656095 "Taken together, the data suggest the miRNA34s might be key effectors of p53 tumor-suppressor function, and their inactivation might contribute to certain cancers." +transcription factor target hsa-mir-34c Neoplasms [unspecific] 17656095 "Taken together, the data suggest the miRNA34s might be key effectors of p53 tumor-suppressor function, and their inactivation might contribute to certain cancers." +transcription factor target hsa-mir-34b "Carcinoma, Ovarian" 17823410 "Importantly, miR-34b and miR-34c cooperate in suppressing proliferation and soft-agar colony formation of neoplastic epithelial ovarian cells, in agreement with the partially overlapping spectrum of their predicted targets." +transcription factor target hsa-mir-34c "Carcinoma, Ovarian" 17823410 "Importantly, miR-34b and miR-34c cooperate in suppressing proliferation and soft-agar colony formation of neoplastic epithelial ovarian cells, in agreement with the partially overlapping spectrum of their predicted targets." +transcription factor target hsa-mir-106a Neuroblastoma 17943719 The miR-17-92 polycistron also acts as an oncogene in haematopoietic progenitor cells. We show here that miR-221 is also induced by MYCN in neuroblastoma. +transcription factor target hsa-mir-17 Neuroblastoma 17943719 The miR-17-92 polycistron also acts as an oncogene in haematopoietic progenitor cells. We show here that miR-221 is also induced by MYCN in neuroblastoma. +transcription factor target hsa-mir-18 Neuroblastoma 17943719 The miR-17-92 polycistron also acts as an oncogene in haematopoietic progenitor cells. We show here that miR-221 is also induced by MYCN in neuroblastoma. +transcription factor target hsa-mir-19a Neuroblastoma 17943719 The miR-17-92 polycistron also acts as an oncogene in haematopoietic progenitor cells. We show here that miR-221 is also induced by MYCN in neuroblastoma. +transcription factor target hsa-mir-19b-1 Neuroblastoma 17943719 The miR-17-92 polycistron also acts as an oncogene in haematopoietic progenitor cells. We show here that miR-221 is also induced by MYCN in neuroblastoma. +transcription factor target hsa-mir-20a Neuroblastoma 17943719 The miR-17-92 polycistron also acts as an oncogene in haematopoietic progenitor cells. We show here that miR-221 is also induced by MYCN in neuroblastoma. +transcription factor target hsa-mir-221 Neuroblastoma 17943719 The miR-17-92 polycistron also acts as an oncogene in haematopoietic progenitor cells. We show here that miR-221 is also induced by MYCN in neuroblastoma. +transcription factor target hsa-mir-92-1 Neuroblastoma 17943719 The miR-17-92 polycistron also acts as an oncogene in haematopoietic progenitor cells. We show here that miR-221 is also induced by MYCN in neuroblastoma. +transcription factor target hsa-mir-125b Prostate Neoplasms 18056640 "Our results suggest that miR-125b acts as an oncogene, contributing to the pathogenesis of CaP." +transcription factor target hsa-mir-184 Autism Spectrum Disorder 18203756 The restricted release of MeCP2 from the paternal allele results in paternal allele-specific expression of miR-184. Our finding provides a clue to the link between the microRNA and DNA methylation pathways. +transcription factor target hsa-mir-21 Neoplasms [unspecific] 18384814 "Since exogenous miR-21 expression moderately induced endogenous miR-21, an evolutionarily conserved double-negative feedback regulation would be operating as a mechanism to sustain miR-21 expression." +transcription factor target hsa-mir-23a "Carcinoma, Hepatocellular" 18508316 We also explore that miR-23a approximately 27a approximately 24 can function as an antiapoptotic and proliferation-promoting factor in liver cancer cells. +transcription factor target hsa-mir-24 "Carcinoma, Hepatocellular" 18508316 We also explore that miR-23a approximately 27a approximately 24 can function as an antiapoptotic and proliferation-promoting factor in liver cancer cells. +transcription factor target hsa-mir-27a "Carcinoma, Hepatocellular" 18508316 We also explore that miR-23a approximately 27a approximately 24 can function as an antiapoptotic and proliferation-promoting factor in liver cancer cells. +transcription factor target hsa-mir-146a Leukemia 18568019 "In leukaemic cell lines PLZF overexpression downmodulated miR-146a and upregulated CXCR4 protein, whereas PLZF knockdown induced the opposite effects." +transcription factor target hsa-mir-34a "Leukemia, Lymphocytic, Chronic, B-Cell" 18818704 17p13/TP53 deletion in B-CLL patients is associated with microRNA-34a downregulation. +transcription factor target hsa-mir-141 Neoplasms [unspecific] 18829540 These findings establish a double-negative feedback loop controlling ZEB1-SIP1 and miR-200 family expression that regulates cellular phenotype and has direct relevance to the role of these factors in tumor progression. +transcription factor target hsa-mir-200a Neoplasms [unspecific] 18829540 These findings establish a double-negative feedback loop controlling ZEB1-SIP1 and miR-200 family expression that regulates cellular phenotype and has direct relevance to the role of these factors in tumor progression. +transcription factor target hsa-mir-200b Neoplasms [unspecific] 18829540 These findings establish a double-negative feedback loop controlling ZEB1-SIP1 and miR-200 family expression that regulates cellular phenotype and has direct relevance to the role of these factors in tumor progression. +transcription factor target hsa-mir-200c Neoplasms [unspecific] 18829540 These findings establish a double-negative feedback loop controlling ZEB1-SIP1 and miR-200 family expression that regulates cellular phenotype and has direct relevance to the role of these factors in tumor progression. +transcription factor target hsa-mir-429 Neoplasms [unspecific] 18829540 These findings establish a double-negative feedback loop controlling ZEB1-SIP1 and miR-200 family expression that regulates cellular phenotype and has direct relevance to the role of these factors in tumor progression. +transcription factor target hsa-mir-7 Breast Neoplasms 18922890 "Finally, we show that miR-7 introduction inhibits the motility, invasiveness, anchorage-independent growth, and tumorigenic potential of highly invasive breast cancer cells." +transcription factor target hsa-mir-155 Inflammation 18940871 "Finally, we demonstrate that LMP1-mediated activation of miR-155 in an EBV-negative background correlates with reduction of protein PU.1, which is a possible miR target." +transcription factor target hsa-mir-146a Neoplasms [unspecific] 19021527 "In the present article, we review the evidence for a role of miR-146a in innate immunity and cancer and assess whether changes in miR-146a might link these two biological responses." +transcription factor target hsa-mir-17 Neoplasms [unspecific] 19066217 "Using the concept and model prediction of a ""cancer zone,"" the oncogenic and tumor suppressor properties of miR-17-92 is demonstrated to parallel the same properties of E2F and Myc." +transcription factor target hsa-mir-18 Neoplasms [unspecific] 19066217 "Using the concept and model prediction of a ""cancer zone,"" the oncogenic and tumor suppressor properties of miR-17-92 is demonstrated to parallel the same properties of E2F and Myc." +transcription factor target hsa-mir-19a Neoplasms [unspecific] 19066217 "Using the concept and model prediction of a ""cancer zone,"" the oncogenic and tumor suppressor properties of miR-17-92 is demonstrated to parallel the same properties of E2F and Myc." +transcription factor target hsa-mir-19b-1 Neoplasms [unspecific] 19066217 "Using the concept and model prediction of a ""cancer zone,"" the oncogenic and tumor suppressor properties of miR-17-92 is demonstrated to parallel the same properties of E2F and Myc." +transcription factor target hsa-mir-20a Neoplasms [unspecific] 19066217 "Using the concept and model prediction of a ""cancer zone,"" the oncogenic and tumor suppressor properties of miR-17-92 is demonstrated to parallel the same properties of E2F and Myc." +transcription factor target hsa-mir-92-1 Neoplasms [unspecific] 19066217 "Using the concept and model prediction of a ""cancer zone,"" the oncogenic and tumor suppressor properties of miR-17-92 is demonstrated to parallel the same properties of E2F and Myc." +transcription factor target hsa-mir-192 Colon Neoplasms 19074875 "Hence, miR-192 and miR-215 can act as effectors as well as regulators of p53; they seem to suppress cancerogenesis through p21 accumulation and cell cycle arrest." +transcription factor target hsa-mir-215 Colon Neoplasms 19074875 "Hence, miR-192 and miR-215 can act as effectors as well as regulators of p53; they seem to suppress cancerogenesis through p21 accumulation and cell cycle arrest." +transcription factor target hsa-mir-34a Neoplasms [unspecific] 19074875 "Accordingly, the tumor suppressor p53 up-regulates miR-34a, a microRNA that contributes to apoptosis and acute senescence. " +transcription factor target hsa-mir-1 Cardiomegaly 19933931 Our results reveal a critical role of miR-1 in mediating the effects of the IGF-1 pathway and demonstrate a feedback loop between miR-1 expression and the IGF-1 signal transduction cascade. +transcription factor target hsa-mir-183 "Carcinoma, Rectal" 19935649 "Moreover, miR-200c, miR-203 and miR-183 cooperate to suppress expression of stem cell factors in cancer cells and mouse embryonic stem (ES) cells, as demonstrated for the polycomb repressor Bmi1." +transcription factor target hsa-mir-200c "Carcinoma, Rectal" 19935649 "Moreover, miR-200c, miR-203 and miR-183 cooperate to suppress expression of stem cell factors in cancer cells and mouse embryonic stem (ES) cells, as demonstrated for the polycomb repressor Bmi1." +transcription factor target hsa-mir-203 "Carcinoma, Rectal" 19935649 "Moreover, miR-200c, miR-203 and miR-183 cooperate to suppress expression of stem cell factors in cancer cells and mouse embryonic stem (ES) cells, as demonstrated for the polycomb repressor Bmi1." +transcription factor target hsa-mir-15a Myeloproliferative Neoplasms 20008792 "STAT5 requires the N-domain for suppression of miR15/16, induction of bcl-2, and survival signaling in myeloproliferative disease." +transcription factor target hsa-mir-15b Myeloproliferative Neoplasms 20008792 "STAT5 requires the N-domain for suppression of miR15/16, induction of bcl-2, and survival signaling in myeloproliferative disease." +transcription factor target hsa-mir-16 Myeloproliferative Neoplasms 20008792 "STAT5 requires the N-domain for suppression of miR15/16, induction of bcl-2, and survival signaling in myeloproliferative disease." +transcription factor target hsa-mir-17 "Lymphoma, B-Cell" 20008931 The miR-17 approximately 92 cluster is frequently amplified or overexpressed in human cancers and has emerged as the prototypical oncogenic polycistron microRNA (miRNA) +transcription factor target hsa-mir-18 "Lymphoma, B-Cell" 20008931 The miR-17 approximately 93 cluster is frequently amplified or overexpressed in human cancers and has emerged as the prototypical oncogenic polycistron microRNA (miRNA) +transcription factor target hsa-mir-19a "Lymphoma, B-Cell" 20008931 The miR-17 approximately 94 cluster is frequently amplified or overexpressed in human cancers and has emerged as the prototypical oncogenic polycistron microRNA (miRNA) +transcription factor target hsa-mir-19b-1 "Lymphoma, B-Cell" 20008931 The miR-17 approximately 95 cluster is frequently amplified or overexpressed in human cancers and has emerged as the prototypical oncogenic polycistron microRNA (miRNA) +transcription factor target hsa-mir-20a "Lymphoma, B-Cell" 20008931 The miR-17 approximately 96 cluster is frequently amplified or overexpressed in human cancers and has emerged as the prototypical oncogenic polycistron microRNA (miRNA) +transcription factor target hsa-mir-92-1 "Lymphoma, B-Cell" 20008931 The miR-17 approximately 96 cluster is frequently amplified or overexpressed in human cancers and has emerged as the prototypical oncogenic polycistron microRNA (miRNA) +transcription factor target hsa-mir-24 Vascular Disease [unspecific] 20019669 Inhibition of miR-24 by antisense oligonuclotides abrogates the downregulation of Trb3 as well as pro-synthetic activity of the PDGF-signalling pathway. +transcription factor target hsa-mir-223 "Leukemia, Myeloid, Acute" 20029046 "Our study supports a molecular network involving miR-223, C/EBPalpha, and E2F1 as major components of the granulocyte differentiation program, which is deregulated in AML." +transcription factor target hsa-mir-141 "Carcinoma, Nasopharyngeal" 20053927 "We propose that miR-141- and tumor-related genes c-MYC, SPLUNC1, BRD3, UBAP1 and PTEN may constitute a gene-miRNA network to contribute to NPC development." +transcription factor target hsa-mir-21 "Adenocarcinoma, Pancreatic Ductal" 20093556 Our findings indicate that miR-21 warrants further investigation as a marker for early detection of PDAC. +transcription factor target hsa-mir-21 Gliosis 20130193 We find that the two receptors exert opposing effects on the posttranscriptional regulation of astrocytic microRNA-21. +transcription factor target hsa-mir-9 Breast Neoplasms 20173743 "The microRNA miR-9 is induced by Myc in breast cancer cells where it targets the major epithelial adherens junction protein, E-cadherin." +transcription factor target hsa-mir-155 "Adenocarcinoma, Gastric" 20209161 "Taken together, our study describes, in the context of an H. pylori infection, a direct link between Foxp3 and miR-155 in human T cells and highlights the significance of cAMP in this miR-155 induction cascade." +transcription factor target hsa-mir-126 Vascular Disease [unspecific] 20364122 "We further find that angiogenic sprouting of AA vessels requires a flow-induced genetic pathway in which the mechano-sensitive zinc finger transcription factor klf2a induces expression of an endothelial-specific microRNA, mir-126, to activate Vegf signalling." +transcription factor target hsa-mir-34a Acute Kidney Failure 20386864 MicroRNA-34a is induced via p53 during cisplatin nephrotoxicity and contributes to cell survival. +transcription factor target hsa-let-7d Idiopathic Pulmonary Fibrosis 20395557 The down-regulation of let-7d in IPF and the profibrotic effects of this down-regulation in vitro and in vivo suggest a key regulatory role for this microRNA in preventing lung fibrosis. +transcription factor target hsa-mir-200a Bladder Neoplasms 20473948 "we observe that the mesoderm transcription factor TWIST1 and miR-200 expression are inversely correlated in bladder tumor samples and cell lines. TWIST1 associates directly with the miR-200 and miR-205 promoters, and may act as a repressor of miR-200 and miR-205 expression." +transcription factor target hsa-mir-200b Bladder Neoplasms 20473948 "we observe that the mesoderm transcription factor TWIST1 and miR-200 expression are inversely correlated in bladder tumor samples and cell lines. TWIST1 associates directly with the miR-200 and miR-205 promoters, and may act as a repressor of miR-200 and miR-205 expression." +transcription factor target hsa-mir-200c Bladder Neoplasms 20473948 "we observe that the mesoderm transcription factor TWIST1 and miR-200 expression are inversely correlated in bladder tumor samples and cell lines. TWIST1 associates directly with the miR-200 and miR-205 promoters, and may act as a repressor of miR-200 and miR-205 expression." +transcription factor target hsa-mir-205 Bladder Neoplasms 20473948 "we observe that the mesoderm transcription factor TWIST1 and miR-200 expression are inversely correlated in bladder tumor samples and cell lines. TWIST1 associates directly with the miR-200 and miR-205 promoters, and may act as a repressor of miR-200 and miR-205 expression." +transcription factor target hsa-mir-22 Neoplasms [unspecific] 20523723 Our results suggest that miR-22 acts to fine-tune the dynamics of PTEN/AKT/FoxO1 pathway. +transcription factor target hsa-mir-107 Neoplasms [unspecific] 20833636 p53 activates the PANK1/miRNA-107 gene leading to downregulation of CDK6 and p130 cell cycle proteins. +transcription factor target hsa-mir-1 "Leukemia, Myeloid, Acute" 20842122 Our data showed that EVI1 controls proliferation in AML through modulation of miR-1-2. This study contributes to further understand the transcriptional networks involving transcription factors and miRNAs in AML. +transcription factor target hsa-mir-106a Neoplasms [unspecific] 20878079 "The miR-17 family, composed of miR-17-5p, miR-20a/b, miR-106a/b and miR-93, has been demonstrated to take part in critical pathways that regulate cellular life and death decisions during normal development and in malignancy." +transcription factor target hsa-mir-106b Neoplasms [unspecific] 20878079 "The miR-17 family, composed of miR-17-5p, miR-20a/b, miR-106a/b and miR-93, has been demonstrated to take part in critical pathways that regulate cellular life and death decisions during normal development and in malignancy." +transcription factor target hsa-mir-17 Neoplasms [unspecific] 20878079 "The miR-17 family, composed of miR-17-5p, miR-20a/b, miR-106a/b and miR-93, has been demonstrated to take part in critical pathways that regulate cellular life and death decisions during normal development and in malignancy." +transcription factor target hsa-mir-20a Neoplasms [unspecific] 20878079 "The miR-17 family, composed of miR-17-5p, miR-20a/b, miR-106a/b and miR-93, has been demonstrated to take part in critical pathways that regulate cellular life and death decisions during normal development and in malignancy." +transcription factor target hsa-mir-20b Neoplasms [unspecific] 20878079 "The miR-17 family, composed of miR-17-5p, miR-20a/b, miR-106a/b and miR-93, has been demonstrated to take part in critical pathways that regulate cellular life and death decisions during normal development and in malignancy." +transcription factor target hsa-mir-93 Neoplasms [unspecific] 20878079 "The miR-17 family, composed of miR-17-5p, miR-20a/b, miR-106a/b and miR-93, has been demonstrated to take part in critical pathways that regulate cellular life and death decisions during normal development and in malignancy." +transcription factor target hsa-mir-322 Myocardial Infarction 20972335 These results suggest that miR-322/424 plays an important physiological role in post-ischemic vascular remodeling and angiogenesis. +transcription factor target hsa-mir-424 Myocardial Infarction 20972335 These results suggest that miR-322/424 plays an important physiological role in post-ischemic vascular remodeling and angiogenesis. +transcription factor target hsa-mir-16 Gastric Neoplasms 21081469 NF-¦ÊB targets miR-16 and miR-21 in gastric cancer: involvement of prostaglandin E receptors. +transcription factor target hsa-mir-21 Gastric Neoplasms 21081469 NF-¦ÊB targets miR-16 and miR-21 in gastric cancer: involvement of prostaglandin E receptors. +transcription factor target hsa-mir-143 Pancreatic Neoplasms 21159816 "Additionally, KRAS and RREB1 are targets of miR-143/miR-145, revealing a feed-forward mechanism that potentiates Ras signaling." +transcription factor target hsa-mir-145 Pancreatic Neoplasms 21159816 "Additionally, KRAS and RREB1 are targets of miR-143/miR-145, revealing a feed-forward mechanism that potentiates Ras signaling." +transcription factor target hsa-mir-499 Myocardial Infarction 21186368 Here we report that modulation of microRNA-499 (miR-499) levels affects apoptosis and the severity of myocardial infarction and cardiac dysfunction induced by ischemia-reperfusion. +transcription factor target hsa-mir-200c Breast Neoplasms 21336307 "This study elucidates a role for p53 in regulating EMT-MET (mesenchymal-epithelial transition) and stemness or differentiation plasticity, and reveals a potential therapeutic implication to suppress EMT-associated cancer stem cells through activation of the p53-miR-200c pathway." +transcription factor target hsa-mir-193a Squamous Cell Carcinoma 21436470 "The resulting feed-forward circuit involving p63, miR-193a-5p and p73 controls p73 levels, cell viability and DNA damage susceptibility in certain cancers including squamous cell carcinoma." +transcription factor target hsa-mir-15a Retinoblastoma 21454377 "In particular, miRs encoded by the miR-15a, miR-16-1 cluster seem to act as tumor suppressors. Here, we evidence that the miR-15a, miR-16-1 cluster and related miR-15b, miR-16-2 cluster comprise miRs regulated by E2F1, a pivotal transcription factor that can induce both proliferation and cell death." +transcription factor target hsa-mir-15b Retinoblastoma 21454377 "In particular, miRs encoded by the miR-15a, miR-16-1 cluster seem to act as tumor suppressors. Here, we evidence that the miR-15a, miR-16-1 cluster and related miR-15b, miR-16-2 cluster comprise miRs regulated by E2F1, a pivotal transcription factor that can induce both proliferation and cell death." +transcription factor target hsa-mir-16-1 Retinoblastoma 21454377 "In particular, miRs encoded by the miR-15a, miR-16-1 cluster seem to act as tumor suppressors. Here, we evidence that the miR-15a, miR-16-1 cluster and related miR-15b, miR-16-2 cluster comprise miRs regulated by E2F1, a pivotal transcription factor that can induce both proliferation and cell death." +transcription factor target hsa-mir-16-2 Retinoblastoma 21454377 "In particular, miRs encoded by the miR-15a, miR-16-1 cluster seem to act as tumor suppressors. Here, we evidence that the miR-15a, miR-16-1 cluster and related miR-15b, miR-16-2 cluster comprise miRs regulated by E2F1, a pivotal transcription factor that can induce both proliferation and cell death." +transcription factor target hsa-mir-34a Ovarian Neoplasms 21516127 "MiRIDIAN-based knockdown and induction of miR-34a evidenced a direct regulatory link between miR-34a and E2F3a, and the tumor-suppressive character of miR-34a was documented by its association with improved survival." +transcription factor target hsa-mir-193a "Adenocarcinoma, Colon" 21670079 "Finally, expression of miR-193a is inversely correlated with PLAU and K-Ras in human colon adenocarcinomas." +transcription factor target hsa-mir-21 "Carcinoma, Colon" 21956205 our findings identify direct transcriptional regulation of miR-21 by TCF4 and suggest a role for miR-21 in cancer cell proliferation and invasion upon activation of ¦Â-catenin/TCF4 signaling. +transcription factor target hsa-mir-182 Breast Neoplasms 22086602 We demonstrated that DDX5 regulated a subset of MicroRNAs including miR-21 and miR-182 in basal breast cancer cells. +transcription factor target hsa-mir-21 Breast Neoplasms 22086602 We demonstrated that DDX5 regulated a subset of MicroRNAs including miR-21 and miR-182 in basal breast cancer cells. +transcription factor target hsa-mir-124 Liver Neoplasms 22153071 "we show that transient inhibition of HNF4¦Á initiates hepatocellular transformation through a microRNA-inflammatory feedback loop circuit consisting of miR-124, IL6R, STAT3, miR-24, and miR-629." +transcription factor target hsa-mir-24 Liver Neoplasms 22153071 "we show that transient inhibition of HNF4¦Á initiates hepatocellular transformation through a microRNA-inflammatory feedback loop circuit consisting of miR-124, IL6R, STAT3, miR-24, and miR-629." +transcription factor target hsa-mir-629 Liver Neoplasms 22153071 "we show that transient inhibition of HNF4¦Á initiates hepatocellular transformation through a microRNA-inflammatory feedback loop circuit consisting of miR-124, IL6R, STAT3, miR-24, and miR-629." +transcription factor target hsa-mir-21 "Squamous Cell Carcinoma, Skin or Unspecific" 22614019 These findings indicate that decreased Grhl3 expression contributes to tumor progression and upregulation of the oncomir miR-21 in squamous cell carcinoma of the skin. +transcription factor target hsa-mir-143 Colorectal Carcinoma 22751122 These results establish a complex network of regulation through which the miR-143/145 cluster is able to modulate KRAS signaling in colorectal cancer. +transcription factor target hsa-mir-145 Colorectal Carcinoma 22751122 These results establish a complex network of regulation through which the miR-143/145 cluster is able to modulate KRAS signaling in colorectal cancer. +transcription factor target hsa-mir-103 Breast Neoplasms 22908280 "Aside from the previously identified miR-200 family, these include the miR-15/16 (miR-16, miR-15b) and miR-103/107 (miR-103, miR-107) families as well as miR-145, miR-335, and miR-128b." +transcription factor target hsa-mir-107 Breast Neoplasms 22908280 "Aside from the previously identified miR-200 family, these include the miR-15/16 (miR-16, miR-15b) and miR-103/107 (miR-103, miR-107) families as well as miR-145, miR-335, and miR-128b." +transcription factor target hsa-mir-128b Breast Neoplasms 22908280 "Aside from the previously identified miR-200 family, these include the miR-15/16 (miR-16, miR-15b) and miR-103/107 (miR-103, miR-107) families as well as miR-145, miR-335, and miR-128b." +transcription factor target hsa-mir-145 Breast Neoplasms 22908280 "Aside from the previously identified miR-200 family, these include the miR-15/16 (miR-16, miR-15b) and miR-103/107 (miR-103, miR-107) families as well as miR-145, miR-335, and miR-128b." +transcription factor target hsa-mir-15b Breast Neoplasms 22908280 "Aside from the previously identified miR-200 family, these include the miR-15/16 (miR-16, miR-15b) and miR-103/107 (miR-103, miR-107) families as well as miR-145, miR-335, and miR-128b." +transcription factor target hsa-mir-16 Breast Neoplasms 22908280 "Aside from the previously identified miR-200 family, these include the miR-15/16 (miR-16, miR-15b) and miR-103/107 (miR-103, miR-107) families as well as miR-145, miR-335, and miR-128b." +transcription factor target hsa-mir-335 Breast Neoplasms 22908280 "Aside from the previously identified miR-200 family, these include the miR-15/16 (miR-16, miR-15b) and miR-103/107 (miR-103, miR-107) families as well as miR-145, miR-335, and miR-128b." +transcription factor target hsa-mir-199a Liver Cirrhosis 22942713 This review provides a comprehensive survey of the literature on miR-199a as an example of the complexity of miRNA biology and suggests future directions for miRNA research. +transcription factor target hsa-mir-26a Lymphoma 23338972 "Our investigation of the mechanisms underlying the decrease in miR-26a in this lymphoma revealed novel evidence that STAT3, a major downstream substrate of NPM-ALK tyrosine kinase activity,suppresses MIR26A1 gene expression." +transcription factor target hsa-mir-205 Breast Neoplasms 23474752 Loss of the polycomb protein Mel-18 enhances the epithelial-mesenchymal transition by ZEB1 and ZEB2 expression through the downregulation of miR-205 in breast cancer. +transcription factor target hsa-mir-26a Lymphoma 23538750 Loss- or gain-of-function approaches revealed that miR-26a functioned as a tumor suppressor miRNA and mediated the combinatorial effects of JQ1 and DZNep. +transcription factor target hsa-mir-183 Neuroblastoma 23625969 MYCN and HDAC2 cooperate to repress miR-183 signaling in neuroblastoma. +transcription factor target hsa-mir-155 "Leukemia, Myeloid, Acute" 24263100 "The silencing of Ago2 impairs the D3-dependent miR-17-5p/20a/106a, miR-125b and miR-155 downregulation, the accumulation of their translational targets AML1, VDR and C/EBPβ and monocytic cell differentiation." +transcription factor target hsa-mir-17 "Leukemia, Myeloid, Acute" 24263100 "The silencing of Ago2 impairs the D3-dependent miR-17-5p/20a/106a, miR-125b and miR-155 downregulation, the accumulation of their translational targets AML1, VDR and C/EBPβ and monocytic cell differentiation." +transcription factor target hsa-mir-17 Toxoplasma gondii Infection 24341525 "We demonstrated that miR-30c-1, miR-125b-2, miR-23b-27b-24-1 and miR-17 ~â€?2 cluster genes were transactivated through promoter binding of the STAT3 following T. gondii infection." +transcription factor target hsa-mir-126 Myocardial Infarction 25200057 Exosomes purified from endothelial cells overexpressing HIF1 had higher contents of miR-126 and miR-210. +transcription factor target hsa-mir-98 Atherosclerosis 25623956 Coculturing ECs with sSMCs under static condition causes initial increases of 4 anti-inflammatory miRs (146a/708/451/98) in ECs followed by decreases below basal levels at 7 days; +transcription factor target hsa-mir-182 Colorectal Carcinoma 25755709 Fentanyl also downregulated the expression of β-catenin and miR-182 in both xenograft tumors and HCT116 cells +transcription factor target hsa-mir-146a Inflammation 26718614 miR-146a inhibits inflammatory activation. +transcription factor target hsa-mir-21 Colon Neoplasms 26853468 a DHA-enriched diet induced a decrease of human miR-21 expression and an increase of human TNFα mRNA expression limiting tumor growth in a cancer cell-derived TNFα dependent manner. +transcription factor target hsa-let-7a Lung Neoplasms 26962302 The present study reveals that decreased C/EBPα contributes to the down-regulation of miRNA let-7a-1 in lung cancer cells. +transcription factor target hsa-mir-200b "Adenocarcinoma, Lung" 27027446 the double-negative feedback loop between E2F3b and miR-200b regulates docetaxel chemosensitivity of human LAD cells +transcription factor target hsa-mir-142 "Leukemia, Promyelocytic, Acute" 27480083 Our results suggest the existence of a Vav1/PU.1/miR-142-3p network that supports ATRA-induced differentiation in APL-derived cells +transcription factor target hsa-mir-7 "Carcinoma, Hepatocellular" 27519414 Suppression of MicroRNA-7 (miR-7) Biogenesis by Nuclear Factor 90-Nuclear Factor 45 Complex (NF90-NF45) Controls Cell Proliferation in Hepatocellular Carcinoma. +transcription factor target hsa-mir-199a-2 Sickle Cell Disease 27573019 Activated Transcription Factor 3 in Association with Histone Deacetylase 6 Negatively Regulates MicroRNA 199a2 Transcription by Chromatin Remodeling and Reduces Endothelin-1 Expression. +transcription factor target hsa-mir-34a "Adenocarcinoma, Pancreatic Ductal" 27594424 EZH2 coupled with HOTAIR to silence MicroRNA-34a by the induction of heterochromatin formation in human pancreatic ductal adenocarcinoma. +transcription factor target hsa-mir-22 "Leukemia, Myeloid, Acute" 27617961 The PU.1-Modulated MicroRNA-22 Is a Regulator of Monocyte/Macrophage Differentiation and Acute Myeloid Leukemia. +transcription factor target hsa-mir-1246 "Carcinoma, Hepatocellular" 27639189 Octamer 4/microRNA-1246 signaling axis drives Wnt/¦Â-catenin activation in liver cancer stem cells. +transcription factor target hsa-mir-126 Vascular Disease [unspecific] 27780851 "GATA2-mediated regulation of miR-126 and miR-221 has an important impact on endothelial biology. Hence, modulation of GATA2 and its targets miR-126 and miR-221 is a promising therapeutic strategy for treatment of many vascular diseases" +transcription factor target hsa-mir-221 Vascular Disease [unspecific] 27780851 "GATA2-mediated regulation of miR-126 and miR-221 has an important impact on endothelial biology. Hence, modulation of GATA2 and its targets miR-126 and miR-221 is a promising therapeutic strategy for treatment of many vascular diseases" +transcription factor target hsa-mir-424 Prostate Neoplasms 27820701 MicroRNA-424 impairs ubiquitination to activate STAT3 and promote prostate tumor progression. +transcription factor target hsa-mir-29b "Carcinoma, Ovarian" 27832631 A Double-Negative Feedback Interaction between MicroRNA-29b and DNMT3A/3B Contributes to Ovarian Cancer Progression. +transcription factor target hsa-mir-127 "Carcinoma, Lung" 27869168 miR-127 promotes EMT and stem-like traits in lung cancer through a feed-forward regulatory loop. +transcription factor target hsa-mir-126 Atherosclerosis 27870587 17¦Â-Estradiol Enhances Vascular Endothelial Ets-1/miR-126-3p Expression: The Possible Mechanism for Attenuation of Atherosclerosis. +transcription factor target hsa-mir-33 Atherosclerosis 27905947 Fibroblast growth factor 21 potentially inhibits microRNA-33 expression to affect macrophage actions. +transcription factor target hsa-mir-148a "Carcinoma, Bladder" 27906180 miR-148a-3p represses proliferation and EMT by establishing regulatory circuits between ERBB3/AKT2/c-myc and DNMT1 in bladder cancer. +transcription factor target hsa-mir-31 "Carcinoma, Hepatocellular" 27909734 Klf4 inhibits tumor growth and metastasis by targeting microRNA-31 in human hepatocellular carcinoma. +transcription factor target hsa-mir-3158 Neoplasms [unspecific] 27919789 "Unravelling a p73-regulated network: The role of a novel p73-dependent target, MIR3158, in cancer cell migration and invasiveness." +transcription factor target hsa-mir-31 Colon Neoplasms 27926494 p38 and JNK pathways control E-selectin-dependent extravasation of colon cancer cells by modulating miR-31 transcription. +transcription factor target hsa-mir-493 Neoplasms [unspecific] 27956702 Snail-Modulated MicroRNA 493 Forms a Negative Feedback Loop with the Insulin-Like Growth Factor 1 Receptor Pathway and Blocks Tumorigenesis. +transcription factor target hsa-mir-520d "Carcinoma, Gastric" 28011625 Gastric Cancer Cell Proliferation and Survival Is Enabled by a Cyclophilin B/STAT3/miR-520d-5p Signaling Feedback Loop. +transcription factor target hsa-mir-574 "Carcinoma, Gastric" 28042090 Upregulation of microRNA-574-3p in a human gastric cancer cell line AGS by TGF-¦Â1. +transcription factor target hsa-mir-23b "Carcinoma, Cervical" 28077801 Human papillomavirus type 16 E6 suppresses microRNA-23b expression in human cervical cancer cells through DNA methylation of the host gene C9orf3. +transcription factor target hsa-mir-101 "Carcinoma, Breast" 28109909 ERK2-ZEB1-miR-101-1 axis contributes to epithelial-mesenchymal transition and cell migration in cancer. +transcription factor target hsa-mir-139 Neoplasms [unspecific] 28119089 The p53 protein induces stable miRNAs that have the potential to modify subsequent p53 responses. +transcription factor target hsa-mir-143 Neoplasms [unspecific] 28119089 The p53 protein induces stable miRNAs that have the potential to modify subsequent p53 responses. +transcription factor target hsa-mir-145 Neoplasms [unspecific] 28119089 The p53 protein induces stable miRNAs that have the potential to modify subsequent p53 responses. +transcription factor target hsa-mir-34a Neoplasms [unspecific] 28119089 The p53 protein induces stable miRNAs that have the potential to modify subsequent p53 responses. +transcription factor target hsa-mir-519d "Carcinoma, Ovarian" 28146423 E2F-1 targets miR-519d to regulate the expression of the ras homolog gene family member C. +transcription factor target hsa-mir-181b "Carcinoma, Prostate" 28184935 Involvement of EZH2 in aerobic glycolysis of prostate cancer through miR-181b/HK2 axis. +transcription factor target hsa-mir-30a "Carcinoma, Ovarian" 28222434 A Feedback Loop Between miR-30a/c-5p and DNMT1 Mediates Cisplatin Resistance in Ovarian Cancer Cells. +transcription factor target hsa-mir-30c "Carcinoma, Ovarian" 28222434 A Feedback Loop Between miR-30a/c-5p and DNMT1 Mediates Cisplatin Resistance in Ovarian Cancer Cells. +transcription factor target hsa-mir-146a "Leukemia, Myeloid, Acute" 28399410 Hoxa9 and Meis1 Cooperatively Induce Addiction to Syk Signaling by Suppressing miR-146a in Acute Myeloid Leukemia. +transcription factor target hsa-mir-423 "Diabetes Mellitus, Type 2" 28411267 NFE2 Induces miR-423-5p to Promote Gluconeogenesis and Hyperglycemia by Repressing the Hepatic FAM3A-ATP-Akt Pathway. +transcription factor target hsa-mir-182 Melanoma 28412746 Kr¨¹ppel-like factor 4 (KLF4) regulates the miR-183~96~182 cluster under physiologic and pathologic conditions. +transcription factor target hsa-mir-183 Melanoma 28412746 Kr¨¹ppel-like factor 4 (KLF4) regulates the miR-183~96~182 cluster under physiologic and pathologic conditions. +transcription factor target hsa-mir-96 Melanoma 28412746 Kr¨¹ppel-like factor 4 (KLF4) regulates the miR-183~96~182 cluster under physiologic and pathologic conditions. +transcription factor target hsa-mir-192 "Carcinoma, Hepatocellular" 28465351 An HNF4¦Á-microRNA-194/192 signaling axis maintains hepatic cell function. +transcription factor target hsa-mir-194 "Carcinoma, Hepatocellular" 28465351 An HNF4¦Á-microRNA-194/192 signaling axis maintains hepatic cell function. +transcription factor target hsa-mir-21 Pulmonary Hypertension 28522568 Peroxisome proliferator-activated receptor-¦Ã enhances human pulmonary artery smooth muscle cell apoptosis through microRNA-21 and programmed cell death 4. +transcription factor target hsa-mir-29a Atherosclerosis 28593745 ox-LDL increases microRNA-29a transcription through upregulating YY1 and STAT1 in macrophages. +transcription factor target hsa-mir-182 "Leukemia, Myeloid, Acute" 28663557 Disruption of the C/EBP¦Á-miR-182 balance impairs granulocytic differentiation. +transcription factor target hsa-mir-192 Neoplasms [unspecific] 19074876 Our results showing a role for miR-192/215 in cell proliferation combined with recent observations that these miRNAs are underexpressed in primary cancers support the idea that miR-192 and miR-215 function as tumor suppressors. +transcription factor target hsa-mir-215 Neoplasms [unspecific] 19074876 Our results showing a role for miR-192/215 in cell proliferation combined with recent observations that these miRNAs are underexpressed in primary cancers support the idea that miR-192 and miR-215 function as tumor suppressors. +transcription factor target hsa-mir-1-1 Inflammation 20098732 "Low density miR array demonstrated that TWEAK inhibits the expression of several miRs including muscle-specific miR-1-1, miR-1-2, miR-133a, miR-133b and miR-206." +transcription factor target hsa-mir-1-2 Inflammation 20098732 "Low density miR array demonstrated that TWEAK inhibits the expression of several miRs including muscle-specific miR-1-1, miR-1-2, miR-133a, miR-133b and miR-206." +transcription factor target hsa-mir-133a Inflammation 20098732 "Low density miR array demonstrated that TWEAK inhibits the expression of several miRs including muscle-specific miR-1-1, miR-1-2, miR-133a, miR-133b and miR-206." +transcription factor target hsa-mir-133b Inflammation 20098732 "Low density miR array demonstrated that TWEAK inhibits the expression of several miRs including muscle-specific miR-1-1, miR-1-2, miR-133a, miR-133b and miR-206." +transcription factor target hsa-mir-206 Inflammation 20098732 "Low density miR array demonstrated that TWEAK inhibits the expression of several miRs including muscle-specific miR-1-1, miR-1-2, miR-133a, miR-133b and miR-206." +transcription factor target hsa-mir-34a Breast Neoplasms 26553365 Here we show that SNAI2 down-regulates miR34a expression in hypoxic MCF7 cell-derived mammospheres. +transcription factor target hsa-let-7 Prostate Neoplasms 27197175 "In cancer cells, reduced expression of ESE3/EHF upregulated Lin28A and Lin28B and downregulated the let-7 microRNAs." +transcription factor target hsa-mir-132 Glioma 27522003 "The expression of miR-132 was low in human glioma tissues, and the downregulated expression was associated with advanced glioma grades." +transcription factor target hsa-mir-124 Hepatitis C Virus Infection 27753084 Decline of miR-124 in myeloid cells promotes regulatory T-cell development in hepatitis C virus infection. +transcription factor target hsa-mir-26a "Lymphoma, Burkitt" 18713946 "Interestingly, miR-26a was also found to be deregulated in primary human Burkitt lymphoma samples, thereby probably being of clinical relevance." +transcription factor target hsa-mir-141 Liver Neoplasms 19167416 "the livers of 2-AAF-exposed rats were characterized by the substantial deregulation of expression of miR-18, miR-21, miR-182, and miR-200 family, microRNAs involved in control of apoptosis/cell proliferation and cell-cell contact pathways, two major pathways disrupted during the promotion stage of hepatocarcinogenesis" +transcription factor target hsa-mir-18 Liver Neoplasms 19167416 "the livers of 2-AAF-exposed rats were characterized by the substantial deregulation of expression of miR-18, miR-21, miR-182, and miR-200 family, microRNAs involved in control of apoptosis/cell proliferation and cell-cell contact pathways, two major pathways disrupted during the promotion stage of hepatocarcinogenesis" +transcription factor target hsa-mir-182 Liver Neoplasms 19167416 "the livers of 2-AAF-exposed rats were characterized by the substantial deregulation of expression of miR-18, miR-21, miR-182, and miR-200 family, microRNAs involved in control of apoptosis/cell proliferation and cell-cell contact pathways, two major pathways disrupted during the promotion stage of hepatocarcinogenesis" +transcription factor target hsa-mir-200a Liver Neoplasms 19167416 "the livers of 2-AAF-exposed rats were characterized by the substantial deregulation of expression of miR-18, miR-21, miR-182, and miR-200 family, microRNAs involved in control of apoptosis/cell proliferation and cell-cell contact pathways, two major pathways disrupted during the promotion stage of hepatocarcinogenesis" +transcription factor target hsa-mir-200b Liver Neoplasms 19167416 "the livers of 2-AAF-exposed rats were characterized by the substantial deregulation of expression of miR-18, miR-21, miR-182, and miR-200 family, microRNAs involved in control of apoptosis/cell proliferation and cell-cell contact pathways, two major pathways disrupted during the promotion stage of hepatocarcinogenesis" +transcription factor target hsa-mir-200c Liver Neoplasms 19167416 "the livers of 2-AAF-exposed rats were characterized by the substantial deregulation of expression of miR-18, miR-21, miR-182, and miR-200 family, microRNAs involved in control of apoptosis/cell proliferation and cell-cell contact pathways, two major pathways disrupted during the promotion stage of hepatocarcinogenesis" +transcription factor target hsa-mir-21 Liver Neoplasms 19167416 "the livers of 2-AAF-exposed rats were characterized by the substantial deregulation of expression of miR-18, miR-21, miR-182, and miR-200 family, microRNAs involved in control of apoptosis/cell proliferation and cell-cell contact pathways, two major pathways disrupted during the promotion stage of hepatocarcinogenesis" +transcription factor target hsa-mir-429 Liver Neoplasms 19167416 "the livers of 2-AAF-exposed rats were characterized by the substantial deregulation of expression of miR-18, miR-21, miR-182, and miR-200 family, microRNAs involved in control of apoptosis/cell proliferation and cell-cell contact pathways, two major pathways disrupted during the promotion stage of hepatocarcinogenesis" +transcription factor target hsa-mir-143 Atherosclerosis 20351064 "Thus, dysregulation of the miR-143 and -145 genes is causally involved in the aberrant SMC plasticity encountered during vascular disease, in part through the up-regulation of an autoregulatory loop that promotes podosome formation." +transcription factor target hsa-mir-145 Atherosclerosis 20351064 "Thus, dysregulation of the miR-143 and -145 genes is causally involved in the aberrant SMC plasticity encountered during vascular disease, in part through the up-regulation of an autoregulatory loop that promotes podosome formation." +transcription factor target hsa-mir-1275 Glioblastoma 25129238 "We show miR-210-3p, miR-1275, miR-376c-3p, miR-23b-3p, miR-193a-3p and miR-145-5p to be up-regulated, while miR-92b-3p, miR-20a-5p, miR-10b-5p, miR-181a-2-3p and miR-185-5p are down-regulated by hypoxia." +transcription factor target hsa-mir-146a "Carcinoma, Thyroid, Anaplastic" 20061417 Nuclear factor-{kappa}B contributes to anaplastic thyroid carcinomas through up-regulation of miR-146a. +transcription factor target hsa-mir-146a Inflammation 20098732 The expression of a few miRs including miR-146a and miR-455 was found to be significantly increased in response to TWEAK treatment. +transcription factor target hsa-mir-455 Inflammation 20098732 The expression of a few miRs including miR-146a and miR-455 was found to be significantly increased in response to TWEAK treatment. +transcription factor target hsa-mir-221 Melanoma 21711453 "MicroRNAs-221 and -222 are highly upregulated in several solid tumors, including melanomas." +transcription factor target hsa-mir-222 Melanoma 21711453 "MicroRNAs-221 and -222 are highly upregulated in several solid tumors, including melanomas." +transcription factor target hsa-mir-145 Bladder Neoplasms 26196183 The most hypoxia-upregulated miRNA was miR-145. +transcription factor target hsa-mir-34a Alzheimer Disease 27235866 miR-34a over expression in patient's tissue +transcription factor target hsa-mir-146a "Lymphoma, B-Cell" 18066065 c-Myc repressed this miRNA +transcription factor target hsa-mir-150 "Lymphoma, B-Cell" 18066065 c-Myc repressed this miRNA +transcription factor target hsa-mir-15a "Lymphoma, B-Cell" 18066065 c-Myc repressed this miRNA +transcription factor target hsa-mir-195 "Lymphoma, B-Cell" 18066065 c-Myc repressed this miRNA +transcription factor target hsa-mir-22 "Lymphoma, B-Cell" 18066065 c-Myc repressed this miRNA +transcription factor target hsa-mir-26b "Lymphoma, B-Cell" 18066065 c-Myc repressed this miRNA +transcription factor target hsa-mir-29a "Lymphoma, B-Cell" 18066065 c-Myc repressed this miRNA +transcription factor target hsa-mir-29c "Lymphoma, B-Cell" 18066065 c-Myc repressed this miRNA +transcription factor target hsa-mir-30e "Lymphoma, B-Cell" 18066065 c-Myc repressed this miRNA +transcription factor target hsa-mir-34a "Lymphoma, B-Cell" 18066065 c-Myc repressed this miRNA +transcription factor target hsa-mir-210 Breast Neoplasms 18316553 induced +transcription factor target hsa-mir-221 Melanoma 18417445 suppressing +transcription factor target hsa-mir-222 Melanoma 18417445 suppressing +transcription factor target hsa-mir-19a PTEN Hamartoma Tumor Tyndrome 18460397 overexpressed +transcription factor target hsa-mir-21 PTEN Hamartoma Tumor Tyndrome 18460397 overexpressed +transcription factor target hsa-mir-425 Glioblastoma 18765229 up-regulation in the CD133-cells +transcription factor target hsa-mir-451a Glioblastoma 18765229 miR-451: MIR-451 and Imatinib mesylate inhibit tumor growth of Glioblastoma stem cells +transcription factor target hsa-mir-486 Glioblastoma 18765229 up-regulation in the CD133-cells +transcription factor target hsa-mir-1-1 Lung Neoplasms 18818206 miR-1: Down-regulation +transcription factor target hsa-mir-1-2 Lung Neoplasms 18818206 miR-1: Down-regulation +transcription factor target hsa-mir-21 Neoplasms [unspecific] 18850008 "miR-21: oncomir, An autoregulatory loop mediated by miR-21 and PDCD4 controls the AP-1 activity in RAS transformation" +transcription factor target hsa-mir-29a Rhabdomyosarcoma 18977326 miR-29: NF-kappaB-YY1-miR-29 regulatory circuitry +transcription factor target hsa-mir-192 Colon Neoplasms 19088023 miR-192: the effect of miR-192 on cellular proliferation is mainly p53 dependent +transcription factor target hsa-mir-17 "Leukemia-Lymphoma, Adult T-Cell" 19148830 miR-17: Activation of miR-17-92 by NK-like homeodomain proteins suppresses apoptosis via reduction of E2F1 in T-cell acute lymphoblastic leukemia +transcription factor target hsa-mir-18a "Leukemia-Lymphoma, Adult T-Cell" 19148830 miR-18a: Activation of miR-17-92 by NK-like homeodomain proteins suppresses apoptosis via reduction of E2F1 in T-cell acute lymphoblastic leukemia +transcription factor target hsa-mir-19a "Leukemia-Lymphoma, Adult T-Cell" 19148830 miR-19a: Activation of miR-17-92 by NK-like homeodomain proteins suppresses apoptosis via reduction of E2F1 in T-cell acute lymphoblastic leukemia +transcription factor target hsa-mir-19b-1 "Leukemia-Lymphoma, Adult T-Cell" 19148830 miR-19b: Activation of miR-17-92 by NK-like homeodomain proteins suppresses apoptosis via reduction of E2F1 in T-cell acute lymphoblastic leukemia +transcription factor target hsa-mir-19b-2 "Leukemia-Lymphoma, Adult T-Cell" 19148830 miR-19b: Activation of miR-17-92 by NK-like homeodomain proteins suppresses apoptosis via reduction of E2F1 in T-cell acute lymphoblastic leukemia +transcription factor target hsa-mir-20a "Leukemia-Lymphoma, Adult T-Cell" 19148830 miR-20a: Activation of miR-17-92 by NK-like homeodomain proteins suppresses apoptosis via reduction of E2F1 in T-cell acute lymphoblastic leukemia +transcription factor target hsa-mir-92a-1 "Leukemia-Lymphoma, Adult T-Cell" 19148830 miR-92a: Activation of miR-17-92 by NK-like homeodomain proteins suppresses apoptosis via reduction of E2F1 in T-cell acute lymphoblastic leukemia +transcription factor target hsa-mir-92a-2 "Leukemia-Lymphoma, Adult T-Cell" 19148830 miR-92a: Activation of miR-17-92 by NK-like homeodomain proteins suppresses apoptosis via reduction of E2F1 in T-cell acute lymphoblastic leukemia +transcription factor target hsa-mir-146a Breast Neoplasms 19190326 "miR-146: Breast cancer metastasis suppressor 1 up-regulates miR-146, which suppresses breast cancer metastasis" +transcription factor target hsa-mir-146b Breast Neoplasms 19190326 "miR-146: Breast cancer metastasis suppressor 1 up-regulates miR-146, which suppresses breast cancer metastasis" +transcription factor target hsa-mir-26a-1 Lymphoma 19197161 miR-26a: repressed by MYC +transcription factor target hsa-mir-26a-2 Lymphoma 19197161 miR-26a: repressed by MYC +transcription factor target hsa-mir-145 Neoplasms [unspecific] 19202062 "miR-145: putative tumor suppressor, miR-145 provides a direct link between p53 and c-Myc in this gene regulatory network" +transcription factor target hsa-mir-21 Breast Neoplasms 19264808 miR-21: Estradiol downregulates miR-21 expression and increases miR-21 target gene expression in MCF-7 breast cancer cells. +transcription factor target hsa-mir-21 Breast Neoplasms 19308091 miR-21: BMP-6 inhibits microRNA-21 expression in breast cancer through repressing deltaEF1 and AP-1 +transcription factor target hsa-mir-146a Osteoarthritis 19333945 miR-146a: miR-146 is intensely expressed in low-grade OA cartilage and that its expression is induced by stimulation of IL-1beta +transcription factor target hsa-mir-17 Medulloblastoma 19351822 miR-17: the most highly up-regulated miRNAs in medulloblastoma +transcription factor target hsa-mir-18a Medulloblastoma 19351822 miR-18a: the most highly up-regulated miRNAs in medulloblastoma +transcription factor target hsa-mir-19a Medulloblastoma 19351822 miR-19a: the most highly up-regulated miRNAs in medulloblastoma +transcription factor target hsa-mir-19b-1 Medulloblastoma 19351822 miR-19b: the most highly up-regulated miRNAs in medulloblastoma +transcription factor target hsa-mir-19b-2 Medulloblastoma 19351822 miR-19b: the most highly up-regulated miRNAs in medulloblastoma +transcription factor target hsa-mir-20a Medulloblastoma 19351822 miR-20a: the most highly up-regulated miRNAs in medulloblastoma +transcription factor target hsa-mir-92a-1 Medulloblastoma 19351822 miR-92a: the most highly up-regulated miRNAs in medulloblastoma +transcription factor target hsa-mir-92a-2 Medulloblastoma 19351822 miR-92a: the most highly up-regulated miRNAs in medulloblastoma +transcription factor target hsa-mir-222 Brain Neoplasms 19351827 miR-222: Overexpression +transcription factor target hsa-mir-222 Prostate Neoplasms 19351827 miR-222: Overexpression +transcription factor target hsa-mir-23a "Cardiomyopathy, Hypertrophic" 19574461 miR-23a functions downstream of NFATc3 to regulate cardiac hypertrophy +transcription factor target hsa-mir-18a Neoplasms [unspecific] 19706389 "significantly upregulated, downregulate Eralpha" +transcription factor target hsa-mir-143 Wounds and Injuries [unspecific] 19720868 modulate cytoskeletal dynamics and responsiveness +transcription factor target hsa-mir-145 Wounds and Injuries [unspecific] 19720868 modulate cytoskeletal dynamics and responsiveness +transcription factor target hsa-mir-21 Prostate Neoplasms 19738047 hsa-mir-21: an androgen receptor-regulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth +transcription factor target hsa-mir-223 "Leukemia, Myeloid, Acute" 20018373 miR-223:miR-223 suppression in AML is caused by impaired miR-223 upstream factors +transcription factor target hsa-mir-195 Schizophrenia 20156358 EGR3 and hsa-miR-195 were core regulators +transcription factor target hsa-mir-34a Disease of Metabolism 20185821 Our study demonstrates an unexpected role of the FXR/SHP pathway in controlling SIRT1 levels via miR-34a inhibition and that elevated miR-34a levels in obese mice contribute to decreased SIRT1 levels +transcription factor target hsa-mir-34a Neoplasms [unspecific] 20185821 Our study demonstrates an unexpected role of the FXR/SHP pathway in controlling SIRT1 levels via miR-34a inhibition and that elevated miR-34a levels in obese mice contribute to decreased SIRT1 levels +transcription factor target hsa-mir-221 "Leukemia, Lymphocytic, Chronic, B-Cell" 20203269 miR-221:miR-221/222 and p27 may represent a regulatory loop that helps maintaining CLL cells in a resting condition +transcription factor target hsa-mir-222 "Leukemia, Lymphocytic, Chronic, B-Cell" 20203269 miR-222:miR-221/222 and p27 may represent a regulatory loop that helps maintaining CLL cells in a resting condition +transcription factor target hsa-mir-519c Neoplasms [unspecific] 20233879 MicroRNA-519c suppresses hypoxia-inducible factor-1alpha expression and tumor angiogenesis +transcription factor target hsa-mir-210 Ischemia 20308562 demonstrated a key role of miR-210 in limiting keratinocyte proliferation +transcription factor target hsa-mir-221 Breast Neoplasms 20388878 These findings suggest that the negative regulatory loop involving miR-221-222 and ERalpha may confer proliferative advantage and migratory activity to breast cancer cells and promote the transition from ER-positive to ER-negative tumors +transcription factor target hsa-mir-222 Breast Neoplasms 20388878 These findings suggest that the negative regulatory loop involving miR-221-222 and ERalpha may confer proliferative advantage and migratory activity to breast cancer cells and promote the transition from ER-positive to ER-negative tumors +transcription factor target hsa-mir-106b Prostate Neoplasms 20388916 We showed that miR-22 and the miR-106b~25 cluster are aberrantly overexpressed in human prostate cancer +transcription factor target hsa-mir-22 Prostate Neoplasms 20388916 We showed that miR-22 and the miR-106b~25 cluster are aberrantly overexpressed in human prostate cancer +transcription factor target hsa-mir-25 Prostate Neoplasms 20388916 We showed that miR-22 and the miR-106b~25 cluster are aberrantly overexpressed in human prostate cancer +transcription factor target hsa-mir-93 Prostate Neoplasms 20388916 We showed that miR-22 and the miR-106b~25 cluster are aberrantly overexpressed in human prostate cancer +transcription factor target hsa-mir-23a "Leukemia, Myeloid" 20399246 the 23a cluster is the first downstream miRNA target implicated in regulating the development of myeloid versus lymphoid cells. +transcription factor target hsa-let-7a-1 Neoplasms [unspecific] 20404092 "let-7a:let-7a-d, let-7i, mir-15b-16-2, and mir-106b-25, are direct targets of E2F1 and E2F3 during G(1)/S and are repressed in E2F1/3-null cells" +transcription factor target hsa-let-7a-2 Neoplasms [unspecific] 20404092 "let-7a:let-7a-d, let-7i, mir-15b-16-2, and mir-106b-25, are direct targets of E2F1 and E2F3 during G(1)/S and are repressed in E2F1/3-null cells" +transcription factor target hsa-let-7a-3 Neoplasms [unspecific] 20404092 "let-7a:let-7a-d, let-7i, mir-15b-16-2, and mir-106b-25, are direct targets of E2F1 and E2F3 during G(1)/S and are repressed in E2F1/3-null cells" +transcription factor target hsa-let-7i Neoplasms [unspecific] 20404092 "let-7i:let-7a-d, let-7i, mir-15b-16-2, and mir-106b-25, are direct targets of E2F1 and E2F3 during G(1)/S and are repressed in E2F1/3-null cells" +transcription factor target hsa-mir-106b Neoplasms [unspecific] 20404092 "mir-106b-25:let-7a-d, let-7i, mir-15b-16-2, and mir-106b-25, are direct targets of E2F1 and E2F3 during G(1)/S and are repressed in E2F1/3-null cells" +transcription factor target hsa-mir-15b Neoplasms [unspecific] 20404092 "mir-15b-16-2:let-7a-d, let-7i, mir-15b-16-2, and mir-106b-25, are direct targets of E2F1 and E2F3 during G(1)/S and are repressed in E2F1/3-null cells" +transcription factor target hsa-mir-25 Neoplasms [unspecific] 20404092 "mir-106b-25:let-7a-d, let-7i, mir-15b-16-2, and mir-106b-25, are direct targets of E2F1 and E2F3 during G(1)/S and are repressed in E2F1/3-null cells" +transcription factor target hsa-mir-93 Neoplasms [unspecific] 20404092 "mir-106b-25:let-7a-d, let-7i, mir-15b-16-2, and mir-106b-25, are direct targets of E2F1 and E2F3 during G(1)/S and are repressed in E2F1/3-null cells" +transcription factor target hsa-mir-192 Renal Fibrosis 20488955 miR-192:miR-192 mediates TGF-beta/Smad3-driven renal fibrosis +transcription factor target hsa-mir-21 Heart Failure 20546595 We show that the transcription factor p53 piggy-backs onto NF-kappaB/RELA and utilizes the kappaB-motif at a cis-regulatory region to control mir-21 expression. +transcription factor target hsa-mir-10b Nasopharyngeal Neoplasms 20732742 MicroRNA-10b induced by Epstein-Barr virus-encoded latent membrane protein-1 promotes the metastasis of human nasopharyngeal carcinoma cells +transcription factor target hsa-mir-155 Pancreatic Neoplasms 20871480 miR-155:Human SMG-1 is Involved in Gemcitabine-Induced Primary microRNA-155/BIC Up-Regulation in Human Pancreatic Cancer PANC-1 Cells +transcription factor target hsa-mir-199b Heart Failure 21102440 "miR-199b is a direct calcineurin/NFAT target gene that increases in expression in mouse and human heart failure, and targets the nuclear NFAT kinase dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1a (Dyrk1a)" +transcription factor target hsa-mir-221 Glioblastoma 21245048 NF-kB and c-Jun induce the expression of the oncogenic miR-221 and miR-222 in prostate carcinoma and glioblastoma cells. +transcription factor target hsa-mir-221 Prostate Neoplasms 21245048 NF-kB and c-Jun induce the expression of the oncogenic miR-221 and miR-222 in prostate carcinoma and glioblastoma cells. +transcription factor target hsa-mir-155 "Leukemia, Lymphocytic, Chronic, B-Cell" 21296997 MYB transcriptionally regulates the miR-155 host gene in chronic lymphocytic leukemia. +transcription factor target hsa-let-7a-2 Lung Neoplasms 21365266 "9-cis-RA, all-trans-RA,lithium chloride and CEBP might play important regulatory roles in let-7a2 gene expression in A549 cells" +transcription factor target hsa-mir-200a Lung Neoplasms 21403400 The Notch ligand Jagged2 promotes lung adenocarcinoma metastasis through a miR-200-dependent pathway in mice. +transcription factor target hsa-mir-200b Lung Neoplasms 21403400 The Notch ligand Jagged2 promotes lung adenocarcinoma metastasis through a miR-200-dependent pathway in mice. +transcription factor target hsa-mir-200c Lung Neoplasms 21403400 The Notch ligand Jagged2 promotes lung adenocarcinoma metastasis through a miR-200-dependent pathway in mice. +transcription factor target hsa-mir-451a "Leukemia-Lymphoma, Adult T-Cell" 21464222 Repression of tumor suppressor miR-451 is essential for NOTCH1-induced oncogenesis in T-ALL. +transcription factor target hsa-mir-122 "Carcinoma, Hepatocellular" 21654638 MicroRNA122 is a key regulator of alpha-fetoprotein expression and influences the aggressiveness of hepatocellular carcinoma. +transcription factor target hsa-mir-222 Lung Neoplasms 21656127 High-mobility group A1 proteins enhance the expression of the oncogenic miR-222 in lung cancer cells. +transcription factor target hsa-mir-181a-2 "Carcinoma, Hepatocellular" 21711587 Wnt/beta-catenin signaling activates microRNA-181 expression in hepatocellular carcinoma. +transcription factor target hsa-mir-181b-1 "Carcinoma, Hepatocellular" 21711587 Wnt/beta-catenin signaling activates microRNA-181 expression in hepatocellular carcinoma. +transcription factor target hsa-mir-181b-2 "Carcinoma, Hepatocellular" 21711587 Wnt/beta-catenin signaling activates microRNA-181 expression in hepatocellular carcinoma. +transcription factor target hsa-mir-181c "Carcinoma, Hepatocellular" 21711587 Wnt/beta-catenin signaling activates microRNA-181 expression in hepatocellular carcinoma. +transcription factor target hsa-mir-181d "Carcinoma, Hepatocellular" 21711587 Wnt/beta-catenin signaling activates microRNA-181 expression in hepatocellular carcinoma. +transcription factor target hsa-mir-132 Myocardial Infarction 21868695 Transplantation of Human Pericyte Progenitor Cells Improves the Repair of Infarcted Heart Through Activation of an Angiogenic Program Involving Micro-RNA-132. +transcription factor target hsa-mir-135a-1 "Carcinoma, Hepatocellular" 21888875 MicroRNA-135a Contributes to the Development of Portal Vein Tumor Thrombus by Promoting Metastasis in Hepatocellular Carcinoma. +transcription factor target hsa-mir-135a-2 "Carcinoma, Hepatocellular" 21888875 MicroRNA-135a Contributes to the Development of Portal Vein Tumor Thrombus by Promoting Metastasis in Hepatocellular Carcinoma. +transcription factor target hsa-mir-125b-1 Hematologic Neoplasms 21903586 "Mir-125b, a target of CDX2, regulates cell differentiation through the repression of the core binding factor in hematopoietic malignancies." +transcription factor target hsa-mir-125b-2 Hematologic Neoplasms 21903586 "Mir-125b, a target of CDX2, regulates cell differentiation through the repression of the core binding factor in hematopoietic malignancies." +transcription factor target hsa-let-7a-1 "Carcinoma, Hepatocellular" 21903590 C-myc Inhibits the Transcription of the MicroRNA Cluster MC-let-7a-1~let-7d via a Non-Canonical E-box. +transcription factor target hsa-let-7d "Carcinoma, Hepatocellular" 21903590 C-myc Inhibits the Transcription of the MicroRNA Cluster MC-let-7a-1~let-7d via a Non-Canonical E-box. +transcription factor target hsa-let-7f-1 "Carcinoma, Hepatocellular" 21903590 C-myc Inhibits the Transcription of the MicroRNA Cluster MC-let-7a-1~let-7d via a Non-Canonical E-box. +transcription factor target hsa-mir-135b Lymphoma 22042699 miR-135b mediates NPM-ALK-driven oncogenicity and renders IL-17-producing immunophenotype to anaplastic large cell lymphoma. +transcription factor target hsa-mir-143 "Leukemia, Myeloid, Acute" 22093444 "miR-143 and miR-145 expression is significantly repressed in primary AML patient samples as compared to neutrophils of healthy donors. Further analysis revealed impaired neutrophil differentiation of APL cells upon inhibition of miR-145 expression. Lastly, we identified p73 as transcriptional regulator of miR-143/145 during neutrophil differentiation of APL cells. Our data suggest that low miR-145 levels in APL, possibly due to aberrant expression of p73 transcription factors, contribute to the differentiation block seen in this disease." +transcription factor target hsa-mir-145 "Leukemia, Myeloid, Acute" 22093444 "miR-143 and miR-145 expression is significantly repressed in primary AML patient samples as compared to neutrophils of healthy donors. Further analysis revealed impaired neutrophil differentiation of APL cells upon inhibition of miR-145 expression. Lastly, we identified p73 as transcriptional regulator of miR-143/145 during neutrophil differentiation of APL cells. Our data suggest that low miR-145 levels in APL, possibly due to aberrant expression of p73 transcription factors, contribute to the differentiation block seen in this disease." +transcription factor target hsa-mir-125b-1 Osteosarcoma 22093834 miR-125b suppresses the proliferation and migration of osteosarcoma cells through down-regulation of STAT3. +transcription factor target hsa-mir-125b-2 Osteosarcoma 22093834 miR-125b suppresses the proliferation and migration of osteosarcoma cells through down-regulation of STAT3. +transcription factor target hsa-mir-155 Inflammation 22170100 Interferon regulatory factor 3 inhibits astrocyte inflammatory gene expression through suppression of the proinflammatory miR-155 and miR-155*. +transcription factor target hsa-mir-224 "Carcinoma, Hepatocellular" 22178270 Transcriptional regulation of mir-224 upregulated in human HCCs by NFkB inflammatory pathways. +transcription factor target hsa-mir-23b Breast Neoplasms 22231442 "ERalpha downregulates miR-30a by binding to two specific sites proximal to the gene and thereby inhibiting pri-miR synthesis. On the other hand, the receptor promotes miR-23b, -27b and 24-1 accumulation in the cell by binding in close proximity of the corresponding gene cluster and preventing in situ the inhibitory effects of ER§Ø©ãon pri-miR maturation by the p68/DDX5-Drosha microprocessor complex." +transcription factor target hsa-mir-24-1 Breast Neoplasms 22231442 "ERalpha downregulates miR-30a by binding to two specific sites proximal to the gene and thereby inhibiting pri-miR synthesis. On the other hand, the receptor promotes miR-23b, -27b and 24-1 accumulation in the cell by binding in close proximity of the corresponding gene cluster and preventing in situ the inhibitory effects of ER§Ø©ãon pri-miR maturation by the p68/DDX5-Drosha microprocessor complex." +transcription factor target hsa-mir-27b Breast Neoplasms 22231442 "ERalpha downregulates miR-30a by binding to two specific sites proximal to the gene and thereby inhibiting pri-miR synthesis. On the other hand, the receptor promotes miR-23b, -27b and 24-1 accumulation in the cell by binding in close proximity of the corresponding gene cluster and preventing in situ the inhibitory effects of ER§Ø©ãon pri-miR maturation by the p68/DDX5-Drosha microprocessor complex." +transcription factor target hsa-mir-30a Breast Neoplasms 22231442 "ERalpha downregulates miR-30a by binding to two specific sites proximal to the gene and thereby inhibiting pri-miR synthesis. On the other hand, the receptor promotes miR-23b, -27b and 24-1 accumulation in the cell by binding in close proximity of the corresponding gene cluster and preventing in situ the inhibitory effects of ER§Ø©ãon pri-miR maturation by the p68/DDX5-Drosha microprocessor complex." +transcription factor target hsa-mir-29b-1 Lung Neoplasms 22249264 MicroRNA-29b is involved in the Src-ID1 signaling pathway and is dysregulated in human lung adenocarcinoma. +transcription factor target hsa-mir-29b-2 Lung Neoplasms 22249264 MicroRNA-29b is involved in the Src-ID1 signaling pathway and is dysregulated in human lung adenocarcinoma. +transcription factor target hsa-mir-10b Breast Neoplasms 22286762 Sulindac inhibits tumor cell invasion by suppressing NF-kB-mediated transcription of microRNAs. +transcription factor target hsa-mir-10b Colon Neoplasms 22286762 Sulindac inhibits tumor cell invasion by suppressing NF-kB-mediated transcription of microRNAs. +transcription factor target hsa-mir-17 Breast Neoplasms 22286762 Sulindac inhibits tumor cell invasion by suppressing NF-kB-mediated transcription of microRNAs. +transcription factor target hsa-mir-17 Colon Neoplasms 22286762 Sulindac inhibits tumor cell invasion by suppressing NF-kB-mediated transcription of microRNAs. +transcription factor target hsa-mir-21 Breast Neoplasms 22286762 Sulindac inhibits tumor cell invasion by suppressing NF-kB-mediated transcription of microRNAs. +transcription factor target hsa-mir-21 Colon Neoplasms 22286762 Sulindac inhibits tumor cell invasion by suppressing NF-kB-mediated transcription of microRNAs. +transcription factor target hsa-mir-9-1 Breast Neoplasms 22286762 Sulindac inhibits tumor cell invasion by suppressing NF-kB-mediated transcription of microRNAs. +transcription factor target hsa-mir-9-1 Colon Neoplasms 22286762 Sulindac inhibits tumor cell invasion by suppressing NF-kB-mediated transcription of microRNAs. +transcription factor target hsa-mir-9-2 Breast Neoplasms 22286762 Sulindac inhibits tumor cell invasion by suppressing NF-kB-mediated transcription of microRNAs. +transcription factor target hsa-mir-9-2 Colon Neoplasms 22286762 Sulindac inhibits tumor cell invasion by suppressing NF-kB-mediated transcription of microRNAs. +transcription factor target hsa-mir-9-3 Breast Neoplasms 22286762 Sulindac inhibits tumor cell invasion by suppressing NF-kB-mediated transcription of microRNAs. +transcription factor target hsa-mir-9-3 Colon Neoplasms 22286762 Sulindac inhibits tumor cell invasion by suppressing NF-kB-mediated transcription of microRNAs. +transcription factor target hsa-mir-200a Colorectal Carcinoma 22286765 SIX1-induced CDH1 repression and EMT in CRC cells were correlated at least in part with posttranscriptional ZEB1 activation and miR-200-family transcriptional repression. +transcription factor target hsa-mir-200b Colorectal Carcinoma 22286765 SIX1-induced CDH1 repression and EMT in CRC cells were correlated at least in part with posttranscriptional ZEB1 activation and miR-200-family transcriptional repression. +transcription factor target hsa-mir-200c Colorectal Carcinoma 22286765 SIX1-induced CDH1 repression and EMT in CRC cells were correlated at least in part with posttranscriptional ZEB1 activation and miR-200-family transcriptional repression. +transcription factor target hsa-mir-34a Esophageal Neoplasms 22292433 Transcriptional activation of microRNA-34a by NF-kappa B in human esophageal cancer cells. +transcription factor target hsa-mir-196b Gastric Neoplasms 22298639 miR-196b expression was significantly repressed by ETS2 during gastric cancer oncogenesis. +transcription factor target hsa-mir-199a-1 "Carcinoma, Hepatocellular" 22359598 ER Stress Negatively Modulates the Expression of the miR-199a/214 Cluster to Regulates Tumor Survival and Progression in Human Hepatocellular Cancer. +transcription factor target hsa-mir-199a-2 "Carcinoma, Hepatocellular" 22359598 ER Stress Negatively Modulates the Expression of the miR-199a/214 Cluster to Regulates Tumor Survival and Progression in Human Hepatocellular Cancer. +transcription factor target hsa-mir-214 "Carcinoma, Hepatocellular" 22359598 ER Stress Negatively Modulates the Expression of the miR-199a/214 Cluster to Regulates Tumor Survival and Progression in Human Hepatocellular Cancer. +transcription factor target hsa-let-7a-1 Breast Neoplasms 22388088 "SHP2 activated stemness-associated transcription factors, including v-myc myelocytomatosis viral oncogene homolog (c-Myc) and zinc finger E-box binding homeobox 1 (ZEB1), which resulted in the repression of let-7 microRNA and the expression of a set of 'SHP2 signature' genes." +transcription factor target hsa-let-7a-2 Breast Neoplasms 22388088 "SHP2 activated stemness-associated transcription factors, including v-myc myelocytomatosis viral oncogene homolog (c-Myc) and zinc finger E-box binding homeobox 1 (ZEB1), which resulted in the repression of let-7 microRNA and the expression of a set of 'SHP2 signature' genes." +transcription factor target hsa-let-7a-3 Breast Neoplasms 22388088 "SHP2 activated stemness-associated transcription factors, including v-myc myelocytomatosis viral oncogene homolog (c-Myc) and zinc finger E-box binding homeobox 1 (ZEB1), which resulted in the repression of let-7 microRNA and the expression of a set of 'SHP2 signature' genes." +transcription factor target hsa-let-7b Breast Neoplasms 22388088 "SHP2 activated stemness-associated transcription factors, including v-myc myelocytomatosis viral oncogene homolog (c-Myc) and zinc finger E-box binding homeobox 1 (ZEB1), which resulted in the repression of let-7 microRNA and the expression of a set of 'SHP2 signature' genes." +transcription factor target hsa-let-7c Breast Neoplasms 22388088 "SHP2 activated stemness-associated transcription factors, including v-myc myelocytomatosis viral oncogene homolog (c-Myc) and zinc finger E-box binding homeobox 1 (ZEB1), which resulted in the repression of let-7 microRNA and the expression of a set of 'SHP2 signature' genes." +transcription factor target hsa-let-7d Breast Neoplasms 22388088 "SHP2 activated stemness-associated transcription factors, including v-myc myelocytomatosis viral oncogene homolog (c-Myc) and zinc finger E-box binding homeobox 1 (ZEB1), which resulted in the repression of let-7 microRNA and the expression of a set of 'SHP2 signature' genes." +transcription factor target hsa-let-7e Breast Neoplasms 22388088 "SHP2 activated stemness-associated transcription factors, including v-myc myelocytomatosis viral oncogene homolog (c-Myc) and zinc finger E-box binding homeobox 1 (ZEB1), which resulted in the repression of let-7 microRNA and the expression of a set of 'SHP2 signature' genes." +transcription factor target hsa-let-7f-1 Breast Neoplasms 22388088 "SHP2 activated stemness-associated transcription factors, including v-myc myelocytomatosis viral oncogene homolog (c-Myc) and zinc finger E-box binding homeobox 1 (ZEB1), which resulted in the repression of let-7 microRNA and the expression of a set of 'SHP2 signature' genes." +transcription factor target hsa-let-7f-2 Breast Neoplasms 22388088 "SHP2 activated stemness-associated transcription factors, including v-myc myelocytomatosis viral oncogene homolog (c-Myc) and zinc finger E-box binding homeobox 1 (ZEB1), which resulted in the repression of let-7 microRNA and the expression of a set of 'SHP2 signature' genes." +transcription factor target hsa-let-7g Breast Neoplasms 22388088 "SHP2 activated stemness-associated transcription factors, including v-myc myelocytomatosis viral oncogene homolog (c-Myc) and zinc finger E-box binding homeobox 1 (ZEB1), which resulted in the repression of let-7 microRNA and the expression of a set of 'SHP2 signature' genes." +transcription factor target hsa-let-7i Breast Neoplasms 22388088 "SHP2 activated stemness-associated transcription factors, including v-myc myelocytomatosis viral oncogene homolog (c-Myc) and zinc finger E-box binding homeobox 1 (ZEB1), which resulted in the repression of let-7 microRNA and the expression of a set of 'SHP2 signature' genes." +transcription factor target hsa-mir-155 Breast Neoplasms 22797073 Mutant p53 drives invasion in breast tumors through up-regulation of miR-155. +transcription factor target hsa-mir-302a Head And Neck Neoplasms 22847005 "Hyaluronan-CD44v3 interaction with Oct4/Sox2/Nanog promotes miR-302 expression leading to self-renewal, clonal formation and cisplatin resistance in cancer stem cells from head and neck squamous cell carcinoma." +transcription factor target hsa-mir-302b Head And Neck Neoplasms 22847005 "Hyaluronan-CD44v3 interaction with Oct4/Sox2/Nanog promotes miR-302 expression leading to self-renewal, clonal formation and cisplatin resistance in cancer stem cells from head and neck squamous cell carcinoma." +transcription factor target hsa-mir-302c Head And Neck Neoplasms 22847005 "Hyaluronan-CD44v3 interaction with Oct4/Sox2/Nanog promotes miR-302 expression leading to self-renewal, clonal formation and cisplatin resistance in cancer stem cells from head and neck squamous cell carcinoma." +transcription factor target hsa-mir-302d Head And Neck Neoplasms 22847005 "Hyaluronan-CD44v3 interaction with Oct4/Sox2/Nanog promotes miR-302 expression leading to self-renewal, clonal formation and cisplatin resistance in cancer stem cells from head and neck squamous cell carcinoma." +transcription factor target hsa-mir-302e Head And Neck Neoplasms 22847005 "Hyaluronan-CD44v3 interaction with Oct4/Sox2/Nanog promotes miR-302 expression leading to self-renewal, clonal formation and cisplatin resistance in cancer stem cells from head and neck squamous cell carcinoma." +transcription factor target hsa-mir-302f Head And Neck Neoplasms 22847005 "Hyaluronan-CD44v3 interaction with Oct4/Sox2/Nanog promotes miR-302 expression leading to self-renewal, clonal formation and cisplatin resistance in cancer stem cells from head and neck squamous cell carcinoma." +transcription factor target hsa-mir-29c Influenza 22850539 Induction of the cellular microRNA-29c by influenza virus contributes to virus-mediated apoptosis through repression of antiapoptotic factors BCL2L2. +transcription factor target hsa-mir-373 Cholangiocarcinoma 22876037 Mutual regulation between microRNA-373 and methyl-CpG-binding domain protein 2 in hilar cholangiocarcinoma. +transcription factor target hsa-mir-132 Prostate Neoplasms 22916239 Luteolin Induces microRNA-132 Expression and Modulates Neurite Outgrowth in PC12 Cells. +transcription factor target hsa-mir-9-1 Colon Neoplasms 23045246 Prospero homeobox 1 promotes epithelial-mesenchymal transition in colon cancer cells by inhibiting E-cadherin via miR-9 +transcription factor target hsa-mir-9-2 Colon Neoplasms 23045246 Prospero homeobox 1 promotes epithelial-mesenchymal transition in colon cancer cells by inhibiting E-cadherin via miR-9 +transcription factor target hsa-mir-720 Esophageal Neoplasms 23154181 SnoN/SKIL modulates proliferation through control of hsa-miR-720 transcription in esophageal cancer cells +transcription factor target hsa-mir-150 "Scleroderma, Systemic" 23159943 miR-150 Down-Regulation Contributes to the Constitutive Type I Collagen Overexpression in Scleroderma Dermal Fibroblasts via the Induction of Integrin §Ø©ã +transcription factor target hsa-mir-9-1 Glioma 23185366 The CREB-miR-9 negative feedback minicircuitry coordinates the migration and proliferation of glioma cells +transcription factor target hsa-mir-9-2 Glioma 23185366 The CREB-miR-9 negative feedback minicircuitry coordinates the migration and proliferation of glioma cells +transcription factor target hsa-mir-29b-1 Multiple Myeloma 23190608 miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1 +transcription factor target hsa-mir-29b-2 Multiple Myeloma 23190608 miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1 +transcription factor target hsa-mir-138-1 "Leukemia, Myeloid" 23208504 BCR-ABL/GATA1/miR-138 mini circuitry contributes to the leukemogenesis of chronic myeloid leukemia +transcription factor target hsa-mir-138-2 "Leukemia, Myeloid" 23208504 BCR-ABL/GATA1/miR-138 mini circuitry contributes to the leukemogenesis of chronic myeloid leukemia +transcription factor target hsa-mir-205 Urinary Bladder Cancer 23239884 The p63 isoform deltaNp63§Ø©ãinhibits epithelial-mesenchymal transition in human bladder cancer cells: Role of miR205 +transcription factor target hsa-mir-370 Neoplasms [unspecific] 23333300 Stat3 inhibits WTX expression through up-regulation of microRNA-370 in Wilms tumor +transcription factor target hsa-mir-21 Liver Neoplasms 23355454 microRNA 21-mediated suppression of Sprouty1 by Pokemon affects liver cancer cell growth and proliferation +transcription factor target hsa-mir-221 Melanoma 23400877 The abrogation of the HOXB7/PBX2 complex induces apoptosis in melanoma through the miR-221&222-c-FOS pathway +transcription factor target hsa-mir-222 Melanoma 23400877 The abrogation of the HOXB7/PBX2 complex induces apoptosis in melanoma through the miR-221&222-c-FOS pathway +transcription factor target hsa-mir-30d "Carcinoma, Renal Cell" 23416459 MiR-30d induces apoptosis and is regulated by the Akt/FOXO pathway in renal cell carcinoma +transcription factor target hsa-mir-203 Breast Neoplasms 23447531 Signaling between TGF-beta and Transcription factor SNAI2 Represses Expression of microRNA miR-203 to Promote Epithelial-Mesenchymal Transition and Tumor Metastasis +transcription factor target hsa-mir-125b-1 Prostate Neoplasms 23503464 Regulation of several androgen-induced genes through the repression of the miR-99a/let-7c/miR-125b-2 miRNA cluster in prostate cancer cells +transcription factor target hsa-mir-125b-2 Prostate Neoplasms 23503464 Regulation of several androgen-induced genes through the repression of the miR-99a/let-7c/miR-125b-2 miRNA cluster in prostate cancer cells +transcription factor target hsa-mir-99a Prostate Neoplasms 23503464 Regulation of several androgen-induced genes through the repression of the miR-99a/let-7c/miR-125b-2 miRNA cluster in prostate cancer cells +transcription factor target hsa-mir-125b-1 "Lymphoma, T-Cell" 23527180 cMyc/miR-125b-5p Signalling Determines Sensitivity to Bortezomib in Preclinical Model of Cutaneous T-Cell Lymphomas +transcription factor target hsa-mir-125b-2 "Lymphoma, T-Cell" 23527180 cMyc/miR-125b-5p Signalling Determines Sensitivity to Bortezomib in Preclinical Model of Cutaneous T-Cell Lymphomas +transcription factor target hsa-mir-191 Breast Neoplasms 23542418 "MicroRNA-191, an estrogen responsive microRNA, functions as an oncogenic regulator in human breast cancer" +transcription factor target hsa-mir-144 Alzheimer Disease 23546882 MicroRNA-144 Is Regulated by Activator Protein-1 (AP-1) and Decreases Expression of Alzheimer's Disease-related A Disintegrin And Metalloprotease 10 (ADAM10) +transcription factor target hsa-mir-506 Breast Neoplasms 23717581 miR-506 Regulates Epithelial Mesenchymal Transition in Breast Cancer Cell Lines. +transcription factor target hsa-mir-370 "Carcinoma, Hepatocellular" 23728999 Perturbation of miR-370-LIN28A-NF-¦ÊB regulatory circuit contributes to the development of hepatocellular carcinoma. +transcription factor target hsa-mir-155 "Leukemia, Lymphocytic, Chronic, B-Cell" 23750211 Signal Transducer and Activator of Transcription-3 Induces MicroRNA-155 Expression in Chronic Lymphocytic Leukemia. +transcription factor target hsa-mir-27a Breast Neoplasms 23752185 miR-27a regulates endothelial differentiation of breast cancer stem like cells. +transcription factor target hsa-mir-200a Neoplasms [unspecific] 23759590 KDM5B histone demethylase controls epithelial-mesenchymal transition of cancer cells by regulating the expression of the microRNA-200 family. +transcription factor target hsa-mir-200b Neoplasms [unspecific] 23759590 KDM5B histone demethylase controls epithelial-mesenchymal transition of cancer cells by regulating the expression of the microRNA-200 family. +transcription factor target hsa-mir-200c Neoplasms [unspecific] 23759590 KDM5B histone demethylase controls epithelial-mesenchymal transition of cancer cells by regulating the expression of the microRNA-200 family. +transcription factor target hsa-mir-127 "Carcinoma, Hepatocellular" 23762330 A Feedback Inhibition between miRNA-127 and TGFbeta/c-Jun Cascade in HCC Cell Migration via MMP13. +transcription factor target hsa-mir-199a-1 "Muscular Dystrophy, Duchenne" 23764775 "MicroRNA-199a is induced in dystrophic muscle and affects WNT signaling, cell proliferation, and myogenic differentiation." +transcription factor target hsa-mir-199a-2 "Muscular Dystrophy, Duchenne" 23764775 "MicroRNA-199a is induced in dystrophic muscle and affects WNT signaling, cell proliferation, and myogenic differentiation." +transcription factor target hsa-mir-134 "Carcinoma, Hepatocellular" 23775631 Hepatocyte nuclear factor-4¦Á reverses malignancy of hepatocellular carcinoma through regulating mir-134 in the DLK1-DIO3 region. +transcription factor target hsa-mir-373 Pancreatic Neoplasms 23857777 A novel epigenetic CREB-miR-373 axis mediates ZIP4-induced pancreatic cancer growth. +transcription factor target hsa-mir-1 Neoplasms [unspecific] 23921124 Transcription factor NRF2 regulates miR-1 and miR-206 to drive tumorigenesis. +transcription factor target hsa-mir-206 Neoplasms [unspecific] 23921124 Transcription factor NRF2 regulates miR-1 and miR-206 to drive tumorigenesis. +transcription factor target hsa-mir-205 Prostate Neoplasms 23924028 The evidence that miR-205 replacement in PCa cells is able not only to prevent but also to revert the oxidative/pro-inflammatory axis leading to EMT induced by CAFs sets the rationale for developing miRNA-based approaches to prevent and treat metastatic disease. +transcription factor target hsa-mir-125b "Carcinoma, Cervical" 23928699 OCT4 promotes tumorigenesis and inhibits apoptosis of cervical cancer cells by miR-125b/BAK1 pathway. +transcription factor target hsa-mir-23a Gastrointestinal Neoplasms 23929433 miR-23a inhibits E-cadherin expression and is regulated by AP-1 and NFAT4 complex during Fas-induced EMT in gastrointestinal cancer. +transcription factor target hsa-mir-143 Neoplasms [unspecific] 23932921 DDX6 post-transcriptionally down-regulates miR-143/145 expression through host gene NCR143/145 in cancer cells. +transcription factor target hsa-mir-145 Neoplasms [unspecific] 23932921 DDX6 post-transcriptionally down-regulates miR-143/145 expression through host gene NCR143/145 in cancer cells. +transcription factor target hsa-mir-20b Breast Neoplasms 23945289 Crucial role for early growth response-1 in the transcriptional regulation of miR-20b in breast cancer. +transcription factor target hsa-mir-30c "Leukemia, Myeloid, Acute" 23974200 Transcription factor C/EBP¦Á-induced microRNA-30c inactivates Notch1 during granulopoiesis and is downregulated in acute myeloid leukemia. +transcription factor target hsa-mir-204 Diabetes Mellitus 23975026 The newly identified TXNIP-miR-204-MAFA-insulin pathway may contribute to diabetes progression and provides new insight into TXNIP function and microRNA biology in health and disease. +transcription factor target hsa-mir-141 Breast Neoplasms 23975430 Significance of PELP1/HDAC2/miR-200 regulatory network in EMT and metastasis of breast cancer. +transcription factor target hsa-mir-200a Breast Neoplasms 23975430 Significance of PELP1/HDAC2/miR-200 regulatory network in EMT and metastasis of breast cancer. +transcription factor target hsa-mir-224 "Carcinoma, Hepatocellular" 23988648 miR-224 is critical for celastrol-induced inhibition of migration and invasion of hepatocellular carcinoma cells. +transcription factor target hsa-mir-198 Pancreatic Neoplasms 23989979 "miR-198 acts as a central tumor suppressor and modulates the molecular makeup of a critical interactome in pancreatic cancer, indicating a potential prognostic marker signature and the therapeutic potential of attacking this tumorigenic network through a central vantage point." +transcription factor target hsa-mir-122 "Carcinoma, Hepatocellular" 24038073 Reciprocal regulation of microRNA-122 and c-Myc in hepatocellular cancer: role of E2F1 and transcription factor dimerization partner 2. +transcription factor target hsa-mir-155 Breast Neoplasms 24080728 MicroRNA-155 broadly orchestrates inflammation-induced changes of microRNA expression in breast cancer +transcription factor target hsa-mir-26a Glioblastoma 24140063 C-Myc negatively controls the tumor suppressor PTEN by upregulating miR-26a in glioblastoma multiforme cells. +transcription factor target hsa-mir-203 "Carcinoma, Colon" 24145190 Maintenance of the stemness in CD44(+) HCT-15 and HCT-116 human colon cancer cells requires miR-203 suppression. +transcription factor target hsa-mir-365 Gastric Neoplasms 24149576 Akt-p53-miR-365-cyclin D1/cdc25A axis contributes to gastric tumorigenesis induced by PTEN deficiency. +transcription factor target hsa-mir-184 "Carcinoma, Nasopharyngeal" 24157866 Tumor suppressor PDCD4 modulates miR-184-mediated direct suppression of C-MYC and BCL2 blocking cell growth and survival in nasopharyngeal carcinoma. +transcription factor target hsa-mir-200c Prostate Neoplasms 24186205 TMPRSS2-ERG gene fusions induce prostate tumorigenesis by modulating microRNA miR-200c. +transcription factor target hsa-mir-548 "Lymphoma, Non-Hodgkin" 24216476 A microenvironment-mediated c-Myc/miR-548m/HDAC6 amplification loop in non-Hodgkin B cell lymphomas. +transcription factor target hsa-mir-183 Neoplasms [unspecific] 24277930 A p21-ZEB1 complex inhibits epithelial-mesenchymal transition through the microRNA 183-96-182 cluster. +transcription factor target hsa-mir-15a Colorectal Carcinoma 24285725 p53-induced miR-15a/16-1 and AP4 form a double-negative feedback loop to regulate epithelial-mesenchymal transition and metastasis in colorectal cancer. +transcription factor target hsa-mir-16-1 Colorectal Carcinoma 24285725 p53-induced miR-15a/16-1 and AP4 form a double-negative feedback loop to regulate epithelial-mesenchymal transition and metastasis in colorectal cancer. +transcription factor target hsa-mir-106b Breast Neoplasms 24292682 high level of miR-106b induced by TGF-¦Â determines the tumor-promoting effects of TGF-¦Â in breast cancer. +transcription factor target hsa-mir-221 Glioblastoma 24295494 miR-221/222 confers radioresistance in glioblastoma cells through activating Akt independent of PTEN status. +transcription factor target hsa-mir-222 Glioblastoma 24295494 miR-221/222 confers radioresistance in glioblastoma cells through activating Akt independent of PTEN status. +transcription factor target hsa-mir-183 Gastric Neoplasms 24335145 Glycogen synthase kinase 3 beta inhibits microRNA-183-96-182 cluster via the ¦Â-Catenin/TCF/LEF-1 pathway in gastric cancer cells. +transcription factor target hsa-mir-96 Gastric Neoplasms 24335145 Glycogen synthase kinase 3 beta inhibits microRNA-183-96-182 cluster via the ¦Â-Catenin/TCF/LEF-1 pathway in gastric cancer cells. +transcription factor target hsa-mir-17 Cardiovascular Diseases [unspecific] 24378993 Crosstalk between TGF-¦Â/Smad3 and BMP/BMPR2 signaling pathways via miR-17-92 cluster in carotid artery restenosis. +transcription factor target hsa-mir-18 Cardiovascular Diseases [unspecific] 24378993 Crosstalk between TGF-¦Â/Smad3 and BMP/BMPR2 signaling pathways via miR-17-92 cluster in carotid artery restenosis. +transcription factor target hsa-mir-19a Cardiovascular Diseases [unspecific] 24378993 Crosstalk between TGF-¦Â/Smad3 and BMP/BMPR2 signaling pathways via miR-17-92 cluster in carotid artery restenosis. +transcription factor target hsa-mir-19b-1 Cardiovascular Diseases [unspecific] 24378993 Crosstalk between TGF-¦Â/Smad3 and BMP/BMPR2 signaling pathways via miR-17-92 cluster in carotid artery restenosis. +transcription factor target hsa-mir-20a Cardiovascular Diseases [unspecific] 24378993 Crosstalk between TGF-¦Â/Smad3 and BMP/BMPR2 signaling pathways via miR-17-92 cluster in carotid artery restenosis. +transcription factor target hsa-mir-92-1 Cardiovascular Diseases [unspecific] 24378993 Crosstalk between TGF-¦Â/Smad3 and BMP/BMPR2 signaling pathways via miR-17-92 cluster in carotid artery restenosis. +transcription factor target hsa-mir-199a Testicular Germ Cell Tumor 24391856 Molecular mechanisms of regulation and action of microRNA-199a in testicular germ cell tumor and glioblastomas. +transcription factor target hsa-mir-134 Glioblastoma 24440911 "Multiple receptor tyrosine kinases converge on microRNA-134 to control KRAS,STAT5B, and glioblastoma." +transcription factor target hsa-mir-320a Colorectal Carcinoma 24454819 E2A predicts prognosis of colorectal cancer patients and regulates cancer cell growth by targeting miR-320a. +transcription factor target hsa-mir-145 "Diabetes Mellitus, Type 2" 24548410 miR-145 plays a role in the development of resistin-induced insulin resistance via the p65 pathway. +transcription factor target hsa-mir-146a Colorectal Carcinoma 24561623 MicroRNA-146a directs the symmetric division of Snail-dominant colorectal cancer stem cells. +transcription factor target hsa-mir-31 Breast Neoplasms 24582497 The breast cancer oncogene EMSY represses transcription of antimetastatic microRNA miR-31. +transcription factor target hsa-mir-100 Neoplasms [unspecific] 24586203 "miR-100 induces epithelial-mesenchymal transition but suppresses tumorigenesis, migration and invasion." +transcription factor target hsa-mir-146b "Carcinoma, Esophageal" 24589738 Transcriptional regulation of miR-146b by C/EBP¦Â LAP2 in esophageal cancer cells. +transcription factor target hsa-mir-26a Idiopathic Pulmonary Fibrosis 24594795 The antifibrotic effects and mechanisms of microRNA-26a action in idiopathic pulmonary fibrosis. +transcription factor target hsa-mir-204 "Carcinoma, Nasopharyngeal" 24613926 Down-regulation of miRNA-204 by LMP-1 enhances CDC42 activity and facilitates invasion of EBV-associated nasopharyngeal carcinoma cells. +transcription factor target hsa-mir-124 Colorectal Carcinoma 24619225 The pro-apoptotic role of the regulatory feedback loop between miR-124 and PKM1/HNF4¦Á in colorectal cancer cells. +transcription factor target hsa-mir-145 Colorectal Carcinoma 24631504 Peroxisome proliferator-activated receptor ¦Ã-mediated induction of microRNA-145 opposes tumor phenotype in colorectal cancer. +transcription factor target hsa-mir-34a Colorectal Carcinoma 24642471 IL-6R/STAT3/miR-34a feedback loop promotes EMT-mediated colorectal cancer invasion and metastasis. +transcription factor target hsa-mir-29 "Diabetes Mellitus, Type 2" 24722248 MicroRNA-29 fine-tunes the expression of key FOXA2-activated lipid metabolism genes and is dysregulated in animal models of insulin resistance and diabetes. +transcription factor target hsa-mir-223 "Leukemia, Lymphoblastic, Acute, T-Cell" 24727676 Notch and NF-kB signaling pathways regulate miR-223/FBXW7 axis in T-cell acute lymphoblastic leukemia. +transcription factor target hsa-mir-210 Melanoma 24767210 Distinct microRNA expression signatures are associated with melanoma subtypes and are regulated by HIF1A. +transcription factor target hsa-mir-218 Melanoma 24767210 Distinct microRNA expression signatures are associated with melanoma subtypes and are regulated by HIF1A. +transcription factor target hsa-mir-224 Melanoma 24767210 Distinct microRNA expression signatures are associated with melanoma subtypes and are regulated by HIF1A. +transcription factor target hsa-mir-452 Melanoma 24767210 Distinct microRNA expression signatures are associated with melanoma subtypes and are regulated by HIF1A. +transcription factor target hsa-mir-181c Hepatitis C Virus Infection 24789793 Transcriptional suppression of miR-181c by hepatitis C virus enhances homeobox A1 expression. +transcription factor target hsa-mir-200b "Adenocarcinoma, Lung" 24830600 the HDAC1/4/Sp1/miR-200b/E2F3 pathway is responsible for chemoresistance of docetaxel-resistant LAD cells. +transcription factor target hsa-mir-28 "Lymphoma, B-Cell" 24843176 MicroRNA 28 controls cell proliferation and is down-regulated in B-cell lymphomas. +transcription factor target hsa-mir-509 "Carcinoma, Hepatocellular" 24882622 The oncoprotein HBXIP up-regulates SCG3 through modulating E2F1 and miR-509-3p in hepatoma cells. +transcription factor target hsa-mir-210 Idiopathic Pulmonary Fibrosis 24951777 miR-210 promotes IPF fibroblast proliferation in response to hypoxia. +transcription factor target hsa-mir-128 Glioma 24959930 "An axis involving SNAI1, microRNA-128 and SP1 modulates glioma progression." +transcription factor target hsa-mir-21 Myocardial Ischemic-Reperfusion Injury 24983504 A feedback regulatory loop between HIF-1¦Á and miR-21 in response to hypoxia in cardiomyocytes. +transcription factor target hsa-mir-203 "Squamous Cell Carcinoma, Esophageal" 24994936 EGF-induced C/EBP¦Â participates in EMT by decreasing the expression of miR-203 in esophageal squamous cell carcinoma cells. +transcription factor target hsa-mir-199a Gastric Neoplasms 25080937 SRF expedites metastasis and modulates the epithelial to mesenchymal transition by regulating miR-199a-5p expression in human gastric cancer. +transcription factor target hsa-mir-21 "Carcinoma, Hepatocellular" 25087183 Hepatitis B virus X protein promotes hepatocellular carcinoma transformation through interleukin-6 activation of microRNA-21 expression. +transcription factor target hsa-mir-155 "Leukemia, Myeloid, Acute" 25092123 LIFR¦Á-CT3 induces differentiation of a human acute myelogenous leukemia cell line HL-60 by suppressing miR-155 expression through the JAK/STAT pathway. +transcription factor target hsa-mir-191 Pancreatic Neoplasms 25119596 The clinical significance and regulation mechanism of hypoxia-inducible factor-1 and miR-191 expression in pancreatic cancer. +transcription factor target hsa-mir-9 MELAS Syndrome 25149473 The ROS-sensitive microRNA-9/9* controls the expression of mitochondrial tRNA-modifying enzymes and is involved in the molecular mechanism of MELAS syndrome. +transcription factor target hsa-mir-590 Breast Neoplasms 25150595 A feedback expression of microRNA-590 and activating transcription factor-3 in human breast cancer cells. +transcription factor target hsa-mir-425 Gastric Neoplasms 25154996 There is a critical role for NF-kappa B-dependent up-regulation of miR-425. And it represents a new pathway for the repression of phosphatase and tensin homolog activation and the promotion of cell survival upon IL-1¦Â induction. +transcription factor target hsa-mir-31 "Carcinoma, Oral" 25229239 EGF up-regulates miR-31 through the C/EBP¦Â signal cascade in oral carcinoma. +transcription factor target hsa-mir-1 "Carcinoma, Nasopharyngeal" 25237831 EZH2 promotes angiogenesis through inhibition of miR-1/Endothelin-1 axis in nasopharyngeal carcinoma. +transcription factor target hsa-mir-200b "Adenocarcinoma, Lung" 25279705 Histone deacetylase 1/Sp1/microRNA-200b signaling accounts for maintenance of cancer stem-like cells in human lung adenocarcinoma. +transcription factor target hsa-mir-21 Glioma 25305446 Kr¨¹ppel-like factor 9 inhibits glioma cell proliferation and tumorigenicity via downregulation of miR-21. +transcription factor target hsa-mir-125b-1 "Leukemia, Myeloid, Acute" 25323587 NRF2-driven miR-125B1 and miR-29B1 transcriptional regulation controls a novel anti-apoptotic miRNA regulatory network for AML survival. +transcription factor target hsa-mir-29b-1 "Leukemia, Myeloid, Acute" 25323587 NRF2-driven miR-125B1 and miR-29B1 transcriptional regulation controls a novel anti-apoptotic miRNA regulatory network for AML survival. +transcription factor target hsa-mir-31 Prostate Neoplasms 25341040 Polycomb protein EZH2 suppresses apoptosis by silencing the proapoptotic miR-31. +transcription factor target hsa-mir-224 Melanoma 25341426 E2F1 induces miR-224/452 expression to drive EMT through TXNIP downregulation. +transcription factor target hsa-mir-452 Melanoma 25341426 E2F1 induces miR-224/452 expression to drive EMT through TXNIP downregulation. +transcription factor target hsa-mir-200 "Carcinoma, Colon" 25371200 MicroRNA-200 (miR-200) cluster regulation by achaete scute-like 2 (Ascl2): impact on the epithelial-mesenchymal transition in colon cancer cells. +transcription factor target hsa-mir-188 Alzheimer Disease 25378159 Synaptic and cognitive improvements by inhibition of 2-AG metabolism are through upregulation of microRNA-188-3p in a mouse model of Alzheimer's disease. +transcription factor target hsa-let-7c Breast Neoplasms 25388283 "HER2 protein expression and activity are negatively correlated with let-7c expression in TCGA. In summary, we identified an ER-regulated miRNA cluster that regulates HER2, is lost with progression to estrogen independence, and may serve as a biomarker of poor outcome in ER(+) luminal A breast cancer patients." +transcription factor target hsa-mir-125b Breast Neoplasms 25388283 "HER2 protein expression and activity are negatively correlated with let-7c expression in TCGA. In summary, we identified an ER-regulated miRNA cluster that regulates HER2, is lost with progression to estrogen independence, and may serve as a biomarker of poor outcome in ER(+) luminal A breast cancer patients." +transcription factor target hsa-mir-99a Breast Neoplasms 25388283 "HER2 protein expression and activity are negatively correlated with let-7c expression in TCGA. In summary, we identified an ER-regulated miRNA cluster that regulates HER2, is lost with progression to estrogen independence, and may serve as a biomarker of poor outcome in ER(+) luminal A breast cancer patients." +transcription factor target hsa-mir-182 Breast Neoplasms 25394902 The miR-183/-96/-182 cluster is up-regulated in most breast cancer. It functions as an oncogene in breast cancer as it increases cell proliferation and migration. +transcription factor target hsa-mir-183 Breast Neoplasms 25394902 The miR-183/-96/-182 cluster is up-regulated in most breast cancer. It functions as an oncogene in breast cancer as it increases cell proliferation and migration. +transcription factor target hsa-mir-96 Breast Neoplasms 25394902 The miR-183/-96/-182 cluster is up-regulated in most breast cancer. It functions as an oncogene in breast cancer as it increases cell proliferation and migration. +transcription factor target hsa-mir-648 Pulmonary Hypertension 25403488 These studies provide a novel link wherein PlGF-mediated downregulation of PAX5 attenuates miR-648 expression leading to increased ET-1 levels that are known to induce PHT in SCA. +transcription factor target hsa-mir-139 Gastric Neoplasms 25499265 "Given that miR-139 and Jun are deregulated in many cancers, our findings here might have broader implication in other types of human cancers" +transcription factor target hsa-mir-96 Prostate Neoplasms 25531317 a novel mechanism accounting for the TGF¦Â signaling and bone metastasis. +transcription factor target hsa-mir-17 "Leukemia, Myeloid, Acute" 25612891 the extent of KIT-induced proliferation itself can modulate myeloid differentiation of cells with wild type RUNX1 function. +transcription factor target hsa-mir-31 "Carcinoma, Esophageal" 25644061 SOX4 interacts with EZH2 and HDAC3 to suppress microRNA-31 in invasive esophageal cancer cells. +transcription factor target hsa-mir-638 Melanoma 25650662 miR-638 promotes melanoma metastasis and protects melanoma cells from apoptosis and autophagy. +transcription factor target hsa-mir-203 "Carcinoma, Cervical" 25658920 BANF1 is downregulated by IRF1-regulated microRNA-203 in cervical cancer. +transcription factor target hsa-mir-203 Helicobacter pylori Infection 25689935 Our results demonstrated that H. pylori infection induced hepatic insulin resistance by the c-Jun/miR-203/SOCS3 signaling pathway and provide possible implications with regard to resolving insulin resistance. +transcription factor target hsa-mir-148a Neoplasms [unspecific] 25703326 Regulatory circuit of PKM2/NF-¦ÊB/miR-148a/152-modulated tumor angiogenesis and cancer progression. +transcription factor target hsa-mir-152 Neoplasms [unspecific] 25703326 Regulatory circuit of PKM2/NF-¦ÊB/miR-148a/152-modulated tumor angiogenesis and cancer progression. +transcription factor target hsa-mir-146 Breast Neoplasms 25712342 FOXP3 Controls an miR-146/NF-¦ÊB Negative Feedback Loop That Inhibits Apoptosis in Breast Cancer Cells. +transcription factor target hsa-mir-31 "Carcinoma, Breast" 25737447 "These studies further suggest that manipulation of miR-31 expression can be used to modulate senescence-related pathological conditions such as cancer,and the aging process." +transcription factor target hsa-mir-100 "Carcinoma, Cervical" 25757558 "Transcriptional regulation of microRNA-100, -146a, and -150 genes by p53 and NF¦ÊB p65/RelA in mouse striatal STHdh(Q7)/ Hdh(Q7) cells and human cervical carcinoma HeLa cells." +transcription factor target hsa-mir-146a "Carcinoma, Cervical" 25757558 "Transcriptional regulation of microRNA-100, -146a, and -150 genes by p53 and NF¦ÊB p65/RelA in mouse striatal STHdh(Q7)/ Hdh(Q7) cells and human cervical carcinoma HeLa cells." +transcription factor target hsa-mir-150 "Carcinoma, Cervical" 25757558 "Transcriptional regulation of microRNA-100, -146a, and -150 genes by p53 and NF¦ÊB p65/RelA in mouse striatal STHdh(Q7)/ Hdh(Q7) cells and human cervical carcinoma HeLa cells." +transcription factor target hsa-mir-21 "Carcinoma, Lung, Non-Small-Cell" 25799148 Modulation of the NF-¦ÊB/miR-21/PTEN pathway in NSCLC showed that inhibition of this pathway may increase cisplatin sensitivity. +transcription factor target hsa-mir-182 "Carcinoma, Hepatocellular" 25813403 Wnt/¦Â-Catenin activates MiR-183/96/182 expression in hepatocellular carcinoma that promotes cell invasion. +transcription factor target hsa-mir-183 "Carcinoma, Hepatocellular" 25813403 Wnt/¦Â-Catenin activates MiR-183/96/182 expression in hepatocellular carcinoma that promotes cell invasion. +transcription factor target hsa-mir-96 "Carcinoma, Hepatocellular" 25813403 Wnt/¦Â-Catenin activates MiR-183/96/182 expression in hepatocellular carcinoma that promotes cell invasion. +transcription factor target hsa-mir-210 Obesity 25833255 "Our data suggest that the inflammatory intrauterine environment associated with maternal obesity induces an NF¦ÊB1-mediated increase in miR-210 in a fetal sex-dependent manner, leading to inhibition of mitochondrial respiration and placental dysfunction in the placentas of female fetuses." +transcription factor target hsa-mir-191 Breast Neoplasms 25867965 HIF-inducible miR-191 promotes migration in breast cancer through complex regulation of TGF¦Â-signaling in hypoxic microenvironment. +transcription factor target hsa-mir-371 Colorectal Carcinoma 25868860 "The SOX17/miR-371-5p/SOX2 axis inhibits EMT, stem cell properties and metastasis in colorectal cancer." +transcription factor target hsa-mir-182 Breast Neoplasms 25873390 Autocrine/Paracrine Human Growth Hormone-stimulated MicroRNA 96-182-183 Cluster Promotes Epithelial-Mesenchymal Transition and Invasion in Breast Cancer. +transcription factor target hsa-mir-183 Breast Neoplasms 25873390 Autocrine/Paracrine Human Growth Hormone-stimulated MicroRNA 96-182-183 Cluster Promotes Epithelial-Mesenchymal Transition and Invasion in Breast Cancer. +transcription factor target hsa-mir-96 Breast Neoplasms 25873390 Autocrine/Paracrine Human Growth Hormone-stimulated MicroRNA 96-182-183 Cluster Promotes Epithelial-Mesenchymal Transition and Invasion in Breast Cancer. +transcription factor target hsa-mir-214 Sickle Cell Disease 25876995 Erythropoietin-mediated expression of placenta growth factor is regulated via activation of hypoxia-inducible factor-1¦Á and post-transcriptionally by miR-214 in sickle cell disease. +transcription factor target hsa-mir-494 Lymphoma 25907832 The PTEN-AKT-mTOR/RICTOR Pathway in Nasal Natural Killer Cell Lymphoma Is Activated by miR-494-3p via PTEN But Inhibited by miR-142-3p via RICTOR. +transcription factor target hsa-mir-593 "Squamous Cell Carcinoma, Tongue" 25912308 Mitochondrial fission determines cisplatin sensitivity in tongue squamous cell carcinoma through the BRCA1-miR-593-5p-MFF axis. +transcription factor target hsa-mir-124 "Lymphoma, B-Cell" 25915824 MicroRNA-124 links p53 to the NF-¦ÊB pathway in B-cell lymphomas. +transcription factor target hsa-mir-31 Breast Neoplasms 25927669 A novel mechanism of regulation of the anti-metastatic miR-31 by EMSY in breast cancer. +transcription factor target hsa-mir-451 Glioblastoma 25937278 "These findings uncover miR-451 as a major effector of glucose-regulated AMPK signaling, allowing tumor cell adaptation to variations in nutrient availability in the tumor microenvironment." +transcription factor target hsa-mir-218 Glioblastoma 25943352 Feedback circuitry between miR-218 repression and RTK activation in glioblastoma. +transcription factor target hsa-mir-125b Ovarian Neoplasms 25944662 PPAR¦Ã inhibits ovarian cancer cells proliferation through upregulation of miR-125b. +transcription factor target hsa-mir-30 Heart Failure 25950484 "we describe that DOX causes acute and sustained miR-30 downregulation in cardiomyocytes via GATA-6. miR-30 overexpression protects cardiac cells from DOX-induced apoptosis, and its maintenance represents a potential cardioprotective and anti-tumorigenic strategy for anthracyclines." +transcription factor target hsa-mir-200a Breast Neoplasms 25972084 "our results suggest that Restin inhibits EMT and tumor metastasis by controlling the expression of the tumor metastasis suppressor mir-200a/b via association with p73. Our findings not only establish a mechanistic link between Restin, EMT and tumor metastasis, but also provide strong evidence supporting the notion that MAGE Group II proteins may exert a tumor suppressive effect in vivo." +transcription factor target hsa-mir-200b Breast Neoplasms 25972084 "our results suggest that Restin inhibits EMT and tumor metastasis by controlling the expression of the tumor metastasis suppressor mir-200a/b via association with p73. Our findings not only establish a mechanistic link between Restin, EMT and tumor metastasis, but also provide strong evidence supporting the notion that MAGE Group II proteins may exert a tumor suppressive effect in vivo." +transcription factor target hsa-mir-125b "Leukemia, Myeloid, Acute" 25982911 The deregulated expression of miR-125b in acute myeloid leukemia is dependent on the transcription factor C/EBP¦Á. +transcription factor target hsa-mir-615 "Carcinoma, Hepatocellular" 25987019 PU.1 Is Identified as a Novel Metastasis Suppressor in Hepatocellular Carcinoma Regulating the miR-615-5p/IGF2 Axis. +transcription factor target hsa-mir-148a Obesity 26001136 "The results suggest that miR-148a is a biomarker of obesity in human subjects and mouse model, which represents a CREB-modulated miRNA that acts to repress Wnt1, thereby promoting adipocyte differentiation." +transcription factor target hsa-mir-34a Obesity 26036628 These data provide first in vitro and in vivo evidence for the leptin-antagonist potential of honokiol (HNK) revealing a crosstalk between HNK and miR34a and Wnt1-MTA1-¦Â-catenin axis. +transcription factor target hsa-mir-19a Pancreatic Neoplasms 26041879 Sp1-driven up-regulation of miR-19a decreases RHOB and promotes pancreatic cancer. +transcription factor target hsa-mir-23b "Carcinoma, Gastric" 26041881 The reciprocal regulation loop of Notch2 pathway and miR-23b in controlling gastric carcinogenesis. +transcription factor target hsa-mir-146a Leukemia 26045293 Differential hypoxic regulation of the microRNA-146a/CXCR4 pathway in normal and leukemic monocytic cells: impact on response to chemotherapy. +transcription factor target hsa-mir-1 Prostate Neoplasms 26071255 EGF Receptor Promotes Prostate Cancer Bone Metastasis by Downregulating miR-1 and Activating TWIST1. +transcription factor target hsa-mir-338 "Carcinoma, Hepatocellular" 26082033 Mineralocorticoid receptor suppresses cancer progression and the Warburg effect by modulating the miR-338-3p-PKLR axis in hepatocellular carcinoma. +transcription factor target hsa-mir-29 Human Immunodeficiency Virus Infection 26108174 IL-21 induces antiviral microRNA-29 in CD4 T cells to limit HIV-1 infection. +transcription factor target hsa-mir-155 Neoplasms [unspecific] 26156524 the losing equilibrium of the regulatory feedback loop between STAT1 and miR-155-5p influencing tumorigenesis. +transcription factor target hsa-mir-224 Lung Neoplasms 26187928 MicroRNA-224 promotes tumor progression in nonsmall cell lung cancer. +transcription factor target hsa-mir-29b Glaucoma 26191170 "This study suggests that TGF-¦Â2 has a time-effect relationship with Tenon's capsule fibroblasts proliferation from glaucoma patients, and it stimulates Tenon's capsule fibroblast proliferation via suppression of miR-29b expression regulated by Nrf2." +transcription factor target hsa-mir-373 Breast Neoplasms 26196741 MiR-373 drives the epithelial-to-mesenchymal transition and metastasis via the miR-373-TXNIP-HIF1¦Á-TWIST signaling axis in breast cancer. +transcription factor target hsa-mir-214 Liver Fibrosis 26229009 These findings reveal a unique function for cellular or exosomal Twist1 in CCN2-dependent fibrogenesis. +transcription factor target hsa-mir-182 Soft Tissue Sarcoma 26234681 these results suggest that sarcoma metastasis can be partially controlled through Pax7/MyoD-dependent activation of miR-182 and provide insight into the role that myogenic transcription factors have in sarcoma progression. +transcription factor target hsa-mir-22 Lymphoma 26244872 "Jak3, STAT3, and STAT5 inhibit expression of miR-22, a novel tumor suppressor microRNA, in cutaneous T-Cell lymphoma." +transcription factor target hsa-mir-150 "Lymphoma, Large-Cell, Anaplastic" 26258416 "our results suggest that hypomethylating drugs,alone or in combination with other agents, may benefit ALK(+) patients harboring tumors resistant to crizotinib and other anti-ALK tyrosine kinase inhibitors (TKIs). Moreover, these results support further work on miR-150 in these and other ALK(+) malignancies." +transcription factor target hsa-mir-130a Neoplasms [unspecific] 26272168 These findings reveal an evolutionarily conserved positive feedback mechanism underlying robustness of the Hippo pathway in size control and tumorigenesis. +transcription factor target hsa-mir-206 Muscle Diseases [unspecific] 26272918 MyoD transcription factor induces myogenesis by inhibiting Twist-1 through miR-206. +transcription factor target hsa-mir-27a Gastric Neoplasms 26292288 HIF-1¦Á Induces Multidrug Resistance in Gastric Cancer Cells by Inducing MiR-27a. +transcription factor target hsa-mir-140 Lung Fibrosis 26300493 "Using these models we showed that IR induces overexpression of Brca1, Nrf2 and miR-140 in lung tissue after irradiation. These data reveal a novel radioprotective mechanism in which IR promotes NRF2 nuclear translocation and subsequent activation of miR-140 transcription in HLFs." +transcription factor target hsa-mir-145 "Carcinoma, Renal Cell" 26304926 Androgen receptor (AR) suppresses miRNA-145 to promote renal cell carcinoma (RCC) progression independent of VHL status. +transcription factor target hsa-mir-143 Pulmonary Hypertension 26311719 "MiR-143-3p modulated both cellular and exosome-mediated responses in pulmonary vascular cells, whereas inhibition of miR-143-3p blocked experimental pulmonary hypertension. Taken together, these findings confirm an important role for the miR-143/145 cluster in PAH pathobiology." +transcription factor target hsa-mir-190a Prostate Neoplasms 26314494 "Taken together, our findings identified a biochemical and functional link between miR-190a with reduced expression in advanced prostate cancer, YB-1 and AR signaling in prostate cancer." +transcription factor target hsa-mir-128a Glioma 26324126 IDH1R132H decreases the proliferation of U87 glioma cells through upregulation of microRNA-128a. +transcription factor target hsa-mir-204 Lymphoma 26350953 "This study demonstrated that HIF-1¦Á-miR-204-BCL-2 pathway contributed to apoptosis of neuronal cells induced by hypoxia, which could potentially be exploited to prevent spinal cord ischemia-reperfusion injury." +transcription factor target hsa-mir-132 Breast Neoplasms 26377202 "Taken together, the findings provide the first evidences of the synergistic anti-metastatic properties of miR-212/132 cluster through suppression of SOX4. Also, current study suggest a new miRNA-based mechanism elucidating the anti-metastatic properties of Ahr agonists, suggesting possibility of using miR-212/132 to control metastasis in breast cancer patients." +transcription factor target hsa-mir-212 Breast Neoplasms 26377202 "Taken together, the findings provide the first evidences of the synergistic anti-metastatic properties of miR-212/132 cluster through suppression of SOX4. Also, current study suggest a new miRNA-based mechanism elucidating the anti-metastatic properties of Ahr agonists, suggesting possibility of using miR-212/132 to control metastasis in breast cancer patients." +transcription factor target hsa-mir-22 Emphysema 26437241 "Thus, miR-22 is a critical regulator of both emphysema and T(H)17 responses." +transcription factor target hsa-mir-129 Breast Neoplasms 26460733 "Thus,miR-129-5p down-regulation fosters EMT in breast cancer by increasing Twist1-Snail and activating a negative feedback loop." +transcription factor target hsa-mir-101 "Carcinoma, Hepatocellular" 26718325 These findings show that elevated EZH2 contributes to miR-101 deregulation in HCC and highlight the coordinated role of miR-101 and EZH2 in hepatocarcinogenesis. +transcription factor target hsa-mir-101-1 "Carcinoma, Hepatocellular" 26718325 These findings show that elevated EZH2 contributes to miR-101 deregulation in HCC and highlight the coordinated role of miR-101 and EZH2 in hepatocarcinogenesis. +transcription factor target hsa-mir-23b Multiple Myeloma 26771806 miR-23b/SP1/c-myc forms a feed-forward loop supporting multiple myeloma cell growth. +transcription factor target hsa-mir-124 "Carcinoma, Lung, Non-Small-Cell" 26818357 The feedback loop between miR-124 and TGF-¦Â pathway plays a significant role in non-small cell lung cancer metastasis. +transcription factor target hsa-mir-146a Inflammation 26855180 Super enhancers at the miR-146a and miR-155 genes contribute to self-regulation of inflammation. +transcription factor target hsa-mir-155 Inflammation 26855180 Super enhancers at the miR-146a and miR-155 genes contribute to self-regulation of inflammation. +transcription factor target hsa-mir-130b "Carcinoma, Colon" 27082112 The infinity software that we have developed is a powerful tool to underscore new TF/miRNA regulatory networks. +transcription factor target hsa-mir-17 "Carcinoma, Colon" 27082112 The infinity software that we have developed is a powerful tool to underscore new TF/miRNA regulatory networks. +transcription factor target hsa-mir-181b "Carcinoma, Colon" 27082112 The infinity software that we have developed is a powerful tool to underscore new TF/miRNA regulatory networks. +transcription factor target hsa-mir-21 "Carcinoma, Colon" 27082112 The infinity software that we have developed is a powerful tool to underscore new TF/miRNA regulatory networks. +transcription factor target hsa-mir-301b "Carcinoma, Colon" 27082112 The infinity software that we have developed is a powerful tool to underscore new TF/miRNA regulatory networks. +transcription factor target hsa-mir-195 "Carcinoma, Hepatocellular" 27179445 Expression of microRNA-195 is transactivated by Sp1 but inhibited by histone deacetylase 3 in hepatocellular carcinoma cells. +tissue_expression_down hsa-mir-125a Breast Neoplasms 16103053 downregulation +tissue_expression_down hsa-mir-125b-1 Breast Neoplasms 16103053 downregulation +tissue_expression_down hsa-mir-125b-2 Breast Neoplasms 16103053 downregulation +tissue_expression_down hsa-mir-145 Breast Neoplasms 16103053 downregulation +tissue_expression_down hsa-mir-125a "Carcinoma, Hepatocellular" 16331254 downregulated +tissue_expression_down hsa-mir-126 Hepatitis C Virus Infection 16331254 downregulated +tissue_expression_down hsa-mir-143 Hepatitis C Virus Infection 16331254 downregulated +tissue_expression_down hsa-mir-195 "Carcinoma, Hepatocellular" 16331254 downregulated +tissue_expression_down hsa-mir-199a-1 "Carcinoma, Hepatocellular" 16331254 downregulated +tissue_expression_down hsa-mir-199a-1 Hepatitis C Virus Infection 16331254 downregulated +tissue_expression_down hsa-mir-199a-2 "Carcinoma, Hepatocellular" 16331254 downregulated +tissue_expression_down hsa-mir-199a-2 Hepatitis C Virus Infection 16331254 downregulated +tissue_expression_down hsa-mir-200a "Carcinoma, Hepatocellular" 16331254 downregulated +tissue_expression_down hsa-mir-28 Hepatitis C Virus Infection 16331254 downregulated +tissue_expression_down hsa-mir-342 Hepatitis C Virus Infection 16331254 downregulated +tissue_expression_down hsa-mir-372 Hepatitis C Virus Infection 16331254 downregulated +tissue_expression_down hsa-mir-376c Hepatitis C Virus Infection 16331254 downregulated +tissue_expression_down hsa-mir-101-1 Lung Neoplasms 16530703 downregulation +tissue_expression_down hsa-mir-125a Lung Neoplasms 16530703 downregulation +tissue_expression_down hsa-mir-126 Lung Neoplasms 16530703 downregulation +tissue_expression_down hsa-mir-140 Lung Neoplasms 16530703 downregulation +tissue_expression_down hsa-mir-143 Lung Neoplasms 16530703 downregulation +tissue_expression_down hsa-mir-145 Lung Neoplasms 16530703 downregulation +tissue_expression_down hsa-mir-181c Lung Neoplasms 16530703 downregulation +tissue_expression_down hsa-mir-192 Lung Neoplasms 16530703 mir-192-prec downregulation +tissue_expression_down hsa-mir-198 Lung Neoplasms 16530703 downregulation +tissue_expression_down hsa-mir-199b Lung Neoplasms 16530703 downregulation +tissue_expression_down hsa-mir-216a Lung Neoplasms 16530703 downregulation +tissue_expression_down hsa-mir-216b Lung Neoplasms 16530703 downregulation +tissue_expression_down hsa-mir-218-2 Lung Neoplasms 16530703 downregulation +tissue_expression_down hsa-mir-219-1 Lung Neoplasms 16530703 downregulation +tissue_expression_down hsa-mir-224 Lung Neoplasms 16530703 downregulation +tissue_expression_down hsa-mir-26a-1 Lung Neoplasms 16530703 downregulation +tissue_expression_down hsa-mir-27b Lung Neoplasms 16530703 downregulation +tissue_expression_down hsa-mir-29b-1 Lung Neoplasms 16530703 downregulation +tissue_expression_down hsa-mir-30a Lung Neoplasms 16530703 downregulation +tissue_expression_down hsa-mir-32 Lung Neoplasms 16530703 downregulation +tissue_expression_down hsa-mir-33a Lung Neoplasms 16530703 downregulation +tissue_expression_down hsa-mir-33b Lung Neoplasms 16530703 downregulation +tissue_expression_down hsa-mir-9-1 Lung Neoplasms 16530703 downregulation +tissue_expression_down hsa-mir-9-2 Lung Neoplasms 16530703 downregulation +tissue_expression_down hsa-mir-9-3 Lung Neoplasms 16530703 downregulation +tissue_expression_down hsa-mir-95 Lung Neoplasms 16530703 downregulation +tissue_expression_down hsa-mir-1 Vascular Hypertrophy 17008435 MicroRNA-1 and microRNA-133a expression are decreased during skeletal muscle hypertrophy. +tissue_expression_down hsa-mir-133a Vascular Hypertrophy 17008435 MicroRNA-1 and microRNA-133a expression are decreased during skeletal muscle hypertrophy. +tissue_expression_down hsa-let-7a-1 Neoplasms [unspecific] 17028596 "let-7a-1 downregulated in six solid cancer types by PAM and SAM (Volinia et al., 2006);" +tissue_expression_down hsa-let-7a-2 Breast Neoplasms 17028596 "let-7a-2, 7a-3, 7d, 7f-2 downregulated in breast cancer" +tissue_expression_down hsa-let-7a-2 Neoplasms [unspecific] 17028596 "Let-7/mir-98 expression is reduced in tumours, potentially contributing to elevated activity of the Ras pathway and effects on growth control." +tissue_expression_down hsa-let-7a-3 Breast Neoplasms 17028596 "let-7a-2, 7a-3, 7d, 7f-2 downregulated in breast cancer" +tissue_expression_down hsa-let-7a-3 Neoplasms [unspecific] 17028596 "Let-7/mir-98 expression is reduced in tumours, potentially contributing to elevated activity of the Ras pathway and effects on growth control." +tissue_expression_down hsa-let-7b Neoplasms [unspecific] 17028596 "Let-7/mir-98 expression is reduced in tumours, potentially contributing to elevated activity of the Ras pathway and effects on growth control." +tissue_expression_down hsa-let-7c Neoplasms [unspecific] 17028596 "Let-7/mir-98 expression is reduced in tumours, potentially contributing to elevated activity of the Ras pathway and effects on growth control." +tissue_expression_down hsa-let-7d Breast Neoplasms 17028596 "let-7a-2, 7a-3, 7d, 7f-2 downregulated in breast cancer" +tissue_expression_down hsa-let-7d Neoplasms [unspecific] 17028596 "Let-7/mir-98 expression is reduced in tumours, potentially contributing to elevated activity of the Ras pathway and effects on growth control." +tissue_expression_down hsa-let-7e Neoplasms [unspecific] 17028596 "Let-7/mir-98 expression is reduced in tumours, potentially contributing to elevated activity of the Ras pathway and effects on growth control." +tissue_expression_down hsa-let-7f-1 Neoplasms [unspecific] 17028596 "Let-7/mir-98 expression is reduced in tumours, potentially contributing to elevated activity of the Ras pathway and effects on growth control." +tissue_expression_down hsa-let-7f-2 Breast Neoplasms 17028596 "let-7a-2, 7a-3, 7d, 7f-2 downregulated in breast cancer" +tissue_expression_down hsa-let-7f-2 Neoplasms [unspecific] 17028596 "Let-7/mir-98 expression is reduced in tumours, potentially contributing to elevated activity of the Ras pathway and effects on growth control." +tissue_expression_down hsa-let-7g Neoplasms [unspecific] 17028596 "Let-7/mir-98 expression is reduced in tumours, potentially contributing to elevated activity of the Ras pathway and effects on growth control." +tissue_expression_down hsa-let-7i Neoplasms [unspecific] 17028596 "Let-7/mir-98 expression is reduced in tumours, potentially contributing to elevated activity of the Ras pathway and effects on growth control." +tissue_expression_down hsa-mir-10b Breast Neoplasms 17028596 "mir-10b downregulated in breast cancer (Iorio et al., 2005);" +tissue_expression_down hsa-mir-124-1 Lung Neoplasms 17028596 "mir-124, mir-183, mir-223, mir-29 mir-124a-3 downregulated in lung cancer (Yanaihara et al., 2006);" +tissue_expression_down hsa-mir-124-2 Lung Neoplasms 17028596 "mir-124, mir-183, mir-223, mir-29 mir-124a-3 downregulated in lung cancer (Yanaihara et al., 2006);" +tissue_expression_down hsa-mir-124-3 Lung Neoplasms 17028596 "mir-124, mir-183, mir-223, mir-29 mir-124a-3 downregulated in lung cancer (Yanaihara et al., 2006);" +tissue_expression_down hsa-mir-125a Breast Neoplasms 17028596 "mir-125a, b1, b2 downregulated in breast cancer (Iorio et al., 2005);" +tissue_expression_down hsa-mir-125b-1 Breast Neoplasms 17028596 "mir-125a, b1, b2 downregulated in breast cancer (Iorio et al., 2005);" +tissue_expression_down hsa-mir-125b-2 Breast Neoplasms 17028596 "mir-125a, b1, b2 downregulated in breast cancer (Iorio et al., 2005);" +tissue_expression_down hsa-mir-145 Breast Neoplasms 17028596 "mir-145 downregulated in breast cancer (Iorio et al., 2005) and lung cancer and deleted in prostate cancer (Yanaihara et al., 2006);" +tissue_expression_down hsa-mir-145 Lung Neoplasms 17028596 "mir-145 downregulated in breast cancer (Iorio et al., 2005) and lung cancer and deleted in prostate cancer (Yanaihara et al., 2006);" +tissue_expression_down hsa-mir-145 Prostate Neoplasms 17028596 "mir-145 downregulated in breast cancer (Iorio et al., 2005) and lung cancer and deleted in prostate cancer (Yanaihara et al., 2006);" +tissue_expression_down hsa-mir-181c Lung Neoplasms 17028596 "mir-181c-prec downregulated in lung cancer (Yanaihara et al., 2006);" +tissue_expression_down hsa-mir-218-2 Lung Neoplasms 17028596 "mir-218-2 downregulated in lung cancer (Yanaihara et al., 2006)" +tissue_expression_down hsa-mir-223 Lung Neoplasms 17028596 "mir-124, mir-183, mir-223, mir-29 mir-124a-3 downregulated in lung cancer (Yanaihara et al., 2006);" +tissue_expression_down hsa-mir-26a-1 Lung Neoplasms 17028596 "mir-26a-1-prec downregulated in lung cancer, deleted in epithelial cancers (Yanaihara et al., 2006)" +tissue_expression_down hsa-mir-29a Lung Neoplasms 17028596 "mir-124, mir-183, mir-223, mir-29 mir-124a-3 downregulated in lung cancer (Yanaihara et al., 2006);" +tissue_expression_down hsa-mir-29b-1 Lung Neoplasms 17028596 "mir-124, mir-183, mir-223, mir-29 mir-124a-3 downregulated in lung cancer (Yanaihara et al., 2006);" +tissue_expression_down hsa-mir-29b-2 Lung Neoplasms 17028596 "mir-124, mir-183, mir-223, mir-29 mir-124a-3 downregulated in lung cancer (Yanaihara et al., 2006);" +tissue_expression_down hsa-mir-29c Lung Neoplasms 17028596 "mir-124, mir-183, mir-223, mir-29 mir-124a-3 downregulated in lung cancer (Yanaihara et al., 2006);" +tissue_expression_down hsa-mir-30a Lung Neoplasms 17028596 "mir-30a-5p downregulated in lung cancer (Yanaihara et al., 2006);" +tissue_expression_down hsa-mir-30b Lung Neoplasms 17028596 "mir-30, mir-34 mir-30a-5p downregulated in lung cancer (Yanaihara et al., 2006)" +tissue_expression_down hsa-mir-30c-1 Lung Neoplasms 17028596 "mir-30, mir-34 mir-30a-5p downregulated in lung cancer (Yanaihara et al., 2006)" +tissue_expression_down hsa-mir-30c-2 Lung Neoplasms 17028596 "mir-30, mir-34 mir-30a-5p downregulated in lung cancer (Yanaihara et al., 2006)" +tissue_expression_down hsa-mir-30d Lung Neoplasms 17028596 "mir-30, mir-34 mir-30a-5p downregulated in lung cancer (Yanaihara et al., 2006)" +tissue_expression_down hsa-mir-30d Neoplasms [unspecific] 17028596 "mir-30d downregulated in six solid cancer types by SAM (Volinia et al., 2006);" +tissue_expression_down hsa-mir-30e Lung Neoplasms 17028596 "mir-30, mir-34 mir-30a-5p downregulated in lung cancer (Yanaihara et al., 2006)" +tissue_expression_down hsa-mir-32 Lung Neoplasms 17028596 "mir-32 downregulated in lung cancer (Yanaihara et al., 2006);" +tissue_expression_down hsa-mir-34a Breast Neoplasms 17028596 "mir-34 downregulated in breast cancer (Iorio et al., 2005)" +tissue_expression_down hsa-mir-34a Lung Neoplasms 17028596 "mir-30, mir-34 mir-30a-5p downregulated in lung cancer (Yanaihara et al., 2006)" +tissue_expression_down hsa-mir-34b Breast Neoplasms 17028596 "mir-34 downregulated in breast cancer (Iorio et al., 2005)" +tissue_expression_down hsa-mir-34b Lung Neoplasms 17028596 "mir-30, mir-34 mir-30a-5p downregulated in lung cancer (Yanaihara et al., 2006)" +tissue_expression_down hsa-mir-34c Breast Neoplasms 17028596 "mir-34 downregulated in breast cancer (Iorio et al., 2005)" +tissue_expression_down hsa-mir-34c Lung Neoplasms 17028596 "mir-30, mir-34 mir-30a-5p downregulated in lung cancer (Yanaihara et al., 2006)" +tissue_expression_down hsa-mir-92a-1 Neoplasms [unspecific] 17028596 "mir-92 downregulated in six solid cancer types by PAM (Volinia et al., 2006)" +tissue_expression_down hsa-mir-92a-2 Neoplasms [unspecific] 17028596 "mir-92 downregulated in six solid cancer types by PAM (Volinia et al., 2006)" +tissue_expression_down hsa-mir-92b Neoplasms [unspecific] 17028596 "mir-92 downregulated in six solid cancer types by PAM (Volinia et al., 2006)" +tissue_expression_down hsa-mir-98 Neoplasms [unspecific] 17028596 "Let-7/mir-98 expression is reduced in tumours, potentially contributing to elevated activity of the Ras pathway and effects on growth control." +tissue_expression_down hsa-mir-150 "Cardiomyopathy, Hypertrophic" 17108080 downregulated +tissue_expression_down hsa-mir-181b-1 "Cardiomyopathy, Hypertrophic" 17108080 downregulated +tissue_expression_down hsa-mir-181b-2 "Cardiomyopathy, Hypertrophic" 17108080 downregulated +tissue_expression_down hsa-mir-133a "Adenocarcinoma, Pancreatic Ductal" 17237814 The expression of miR-216 and -217 and lack of expression of miR-133a were identified as characteristic of pancreas tissue. +tissue_expression_down hsa-mir-195 Schizophrenia 17326821 downregulation +tissue_expression_down hsa-mir-20b Schizophrenia 17326821 downregulation +tissue_expression_down hsa-mir-212 Schizophrenia 17326821 downregulation +tissue_expression_down hsa-mir-24-1 Schizophrenia 17326821 downregulation +tissue_expression_down hsa-mir-24-2 Schizophrenia 17326821 downregulation +tissue_expression_down hsa-mir-26b Schizophrenia 17326821 downregulation +tissue_expression_down hsa-mir-29a Schizophrenia 17326821 downregulation +tissue_expression_down hsa-mir-29b-1 Schizophrenia 17326821 downregulation +tissue_expression_down hsa-mir-29c Schizophrenia 17326821 downregulation +tissue_expression_down hsa-mir-30a Schizophrenia 17326821 downregulation +tissue_expression_down hsa-mir-30b Schizophrenia 17326821 downregulation +tissue_expression_down hsa-mir-30d Schizophrenia 17326821 downregulation +tissue_expression_down hsa-mir-30e Schizophrenia 17326821 downregulation +tissue_expression_down hsa-mir-7-1 Schizophrenia 17326821 downregulation +tissue_expression_down hsa-mir-7-2 Schizophrenia 17326821 downregulation +tissue_expression_down hsa-mir-7-3 Schizophrenia 17326821 downregulation +tissue_expression_down hsa-mir-9-1 Schizophrenia 17326821 downregulation +tissue_expression_down hsa-mir-9-2 Schizophrenia 17326821 downregulation +tissue_expression_down hsa-mir-92a-1 Schizophrenia 17326821 downregulation +tissue_expression_down hsa-mir-92a-2 Schizophrenia 17326821 downregulation +tissue_expression_down hsa-mir-92b Schizophrenia 17326821 downregulation +tissue_expression_down hsa-mir-9-3 Schizophrenia 17326821 downregulation +tissue_expression_down hsa-mir-16-1 Autoimmune Diseases [unspecific] 17351108 "New Zealand black (NZB) mice (NZB) tissue sourcesof RNA showed a decrease in miR-16 in the spleen; however, theNZB kidney was not decreased in miR-16 expression compared withthe control strain expression. In addition, the NZB-derivedmalignant B-cell line, LNC, had an even greater decreased expressionof miR-16 compared with C57Bl6 spleen." +tissue_expression_down hsa-mir-16-1 "Leukemia, Lymphocytic, Chronic, B-Cell" 17351108 "New Zealand black (NZB) mice (NZB) tissue sourcesof RNA showed a decrease in miR-16 in the spleen; however, theNZB kidney was not decreased in miR-16 expression compared withthe control strain expression. In addition, the NZB-derivedmalignant B-cell line, LNC, had an even greater decreased expressionof miR-16 compared with C57Bl6 spleen." +tissue_expression_down hsa-mir-16-2 Autoimmune Diseases [unspecific] 17351108 "New Zealand black (NZB) mice (NZB) tissue sourcesof RNA showed a decrease in miR-16 in the spleen; however, theNZB kidney was not decreased in miR-16 expression compared withthe control strain expression. In addition, the NZB-derivedmalignant B-cell line, LNC, had an even greater decreased expressionof miR-16 compared with C57Bl6 spleen." +tissue_expression_down hsa-mir-16-2 "Leukemia, Lymphocytic, Chronic, B-Cell" 17351108 "New Zealand black (NZB) mice (NZB) tissue sourcesof RNA showed a decrease in miR-16 in the spleen; however, theNZB kidney was not decreased in miR-16 expression compared withthe control strain expression. In addition, the NZB-derivedmalignant B-cell line, LNC, had an even greater decreased expressionof miR-16 compared with C57Bl6 spleen." +tissue_expression_down hsa-mir-125b "Carcinoma, Thyroid, Anaplastic" 17563749 "The overexpression of these four miRs in two human ATC-derived cell lines suggests a critical role of miR-125b and miR-26a downregulation in thyroid carcinogenesis, since a cell growth inhibition was achieved." +tissue_expression_down hsa-mir-26a "Carcinoma, Thyroid, Anaplastic" 17563749 "The overexpression of these four miRs in two human ATC-derived cell lines suggests a critical role of miR-125b and miR-26a downregulation in thyroid carcinogenesis, since a cell growth inhibition was achieved." +tissue_expression_down hsa-mir-107 Heart Failure 17606841 downregulated +tissue_expression_down hsa-mir-130b Heart Failure 17606841 downregulated +tissue_expression_down hsa-mir-135a-1 Heart Failure 17606841 downregulated +tissue_expression_down hsa-mir-135a-2 Heart Failure 17606841 downregulated +tissue_expression_down hsa-mir-136 Heart Failure 17606841 downregulated +tissue_expression_down hsa-mir-148a Heart Failure 17606841 downregulated +tissue_expression_down hsa-mir-150 Heart Failure 17606841 downregulated +tissue_expression_down hsa-mir-16-1 Heart Failure 17606841 downregulated +tissue_expression_down hsa-mir-16-2 Heart Failure 17606841 downregulated +tissue_expression_down hsa-mir-17 Heart Failure 17606841 downregulated +tissue_expression_down hsa-mir-182 Heart Failure 17606841 downregulated +tissue_expression_down hsa-mir-186 Heart Failure 17606841 downregulated +tissue_expression_down hsa-mir-192 Heart Failure 17606841 downregulated +tissue_expression_down hsa-mir-19b-1 Heart Failure 17606841 downregulated +tissue_expression_down hsa-mir-19b-2 Heart Failure 17606841 downregulated +tissue_expression_down hsa-mir-218-1 Heart Failure 17606841 downregulated +tissue_expression_down hsa-mir-218-2 Heart Failure 17606841 downregulated +tissue_expression_down hsa-mir-22 Heart Failure 17606841 downregulated +tissue_expression_down hsa-mir-23b Heart Failure 17606841 downregulated +tissue_expression_down hsa-mir-24-1 Heart Failure 17606841 downregulated +tissue_expression_down hsa-mir-24-2 Heart Failure 17606841 downregulated +tissue_expression_down hsa-mir-27a Heart Failure 17606841 downregulated +tissue_expression_down hsa-mir-299 Heart Failure 17606841 downregulated +tissue_expression_down hsa-mir-302b Heart Failure 17606841 downregulated +tissue_expression_down hsa-mir-302c Heart Failure 17606841 downregulated +tissue_expression_down hsa-mir-30a Heart Failure 17606841 downregulated +tissue_expression_down hsa-mir-30b Heart Failure 17606841 downregulated +tissue_expression_down hsa-mir-30c-1 Heart Failure 17606841 downregulated +tissue_expression_down hsa-mir-30c-2 Heart Failure 17606841 downregulated +tissue_expression_down hsa-mir-30e Heart Failure 17606841 downregulated +tissue_expression_down hsa-mir-325 Heart Failure 17606841 downregulated +tissue_expression_down hsa-mir-339 Heart Failure 17606841 downregulated +tissue_expression_down hsa-mir-342 Heart Failure 17606841 downregulated +tissue_expression_down hsa-mir-452 Heart Failure 17606841 downregulated +tissue_expression_down hsa-mir-494 Heart Failure 17606841 downregulated +tissue_expression_down hsa-mir-497 Heart Failure 17606841 downregulated +tissue_expression_down hsa-mir-499a Heart Failure 17606841 downregulated +tissue_expression_down hsa-mir-507 Heart Failure 17606841 downregulated +tissue_expression_down hsa-mir-512-1 Heart Failure 17606841 downregulated +tissue_expression_down hsa-mir-512-2 Heart Failure 17606841 downregulated +tissue_expression_down hsa-mir-515-1 Heart Failure 17606841 downregulated +tissue_expression_down hsa-mir-515-2 Heart Failure 17606841 downregulated +tissue_expression_down hsa-mir-520a Heart Failure 17606841 downregulated +tissue_expression_down hsa-mir-520b Heart Failure 17606841 downregulated +tissue_expression_down hsa-mir-520d Heart Failure 17606841 downregulated +tissue_expression_down hsa-mir-520e Heart Failure 17606841 downregulated +tissue_expression_down hsa-mir-520f Heart Failure 17606841 downregulated +tissue_expression_down hsa-mir-520g Heart Failure 17606841 downregulated +tissue_expression_down hsa-mir-520h Heart Failure 17606841 downregulated +tissue_expression_down hsa-mir-523 Heart Failure 17606841 downregulated +tissue_expression_down hsa-mir-526a-1 Heart Failure 17606841 downregulated +tissue_expression_down hsa-mir-526a-2 Heart Failure 17606841 downregulated +tissue_expression_down hsa-mir-526b Heart Failure 17606841 downregulated +tissue_expression_down hsa-mir-125b-1 Atopic Dermatitis 17622355 The level of this miRNA significantly (p<0.001 for both) decreased both in psoriasis and atopic eczema. +tissue_expression_down hsa-mir-125b-1 Psoriasis 17622355 The level of this miRNA significantly (p<0.001 for both) decreased both in psoriasis and atopic eczema. +tissue_expression_down hsa-mir-125b-2 Atopic Dermatitis 17622355 The level of this miRNA significantly (p<0.001 for both) decreased both in psoriasis and atopic eczema. +tissue_expression_down hsa-mir-125b-2 Psoriasis 17622355 The level of this miRNA significantly (p<0.001 for both) decreased both in psoriasis and atopic eczema. +tissue_expression_down hsa-mir-125b-1 Ovarian Neoplasms 17875710 "The most significantly overexpressed miRNAs were miR-200a, miR-141, miR-200c, and miR-200b, whereas miR-199a, miR-140, miR-145, and miR-125b1 were among the most down-modulated miRNAs." +tissue_expression_down hsa-mir-1-1 Musculoskeletal Abnormalities [unspecific] 17917533 "Studies performed to determine whether skeletal muscle hypertrophy affects miRNA expression showed that miR-1 and miR-133 were decreased, suggesting that these muscle-specific miRNAs may contribute to regulating the initial response of skeletal muscle to functional overload." +tissue_expression_down hsa-mir-1-2 Musculoskeletal Abnormalities [unspecific] 17917533 "Studies performed to determine whether skeletal muscle hypertrophy affects miRNA expression showed that miR-1 and miR-133 were decreased, suggesting that these muscle-specific miRNAs may contribute to regulating the initial response of skeletal muscle to functional overload." +tissue_expression_down hsa-mir-133a-1 Musculoskeletal Abnormalities [unspecific] 17917533 "Studies performed to determine whether skeletal muscle hypertrophy affects miRNA expression showed that miR-1 and miR-133 were decreased, suggesting that these muscle-specific miRNAs may contribute to regulating the initial response of skeletal muscle to functional overload." +tissue_expression_down hsa-mir-133a-2 Musculoskeletal Abnormalities [unspecific] 17917533 "Studies performed to determine whether skeletal muscle hypertrophy affects miRNA expression showed that miR-1 and miR-133 were decreased, suggesting that these muscle-specific miRNAs may contribute to regulating the initial response of skeletal muscle to functional overload." +tissue_expression_down hsa-mir-206 Musculoskeletal Abnormalities [unspecific] 17917533 Studies to evaluate the role of miRNAs in muscular dystrophy showed a dramatic increase in miR-206 expression in the diaphragm of the mdx mouse. +tissue_expression_down hsa-let-7c "Carcinoma, Hepatocellular" 18006136 These mice do not exhibit downregulation of let-7c gene expression thus forming the basis for the resistance to hepatocellular carcinogenesis. +tissue_expression_down hsa-mir-1 Retinitis Pigmentosa 18034880 "Expression of miR-1 and miR-133 decreased by more than 2.5-fold (P < 0.001), whereas expression of miR-96 and miR-183 increased by more than 3-fold (P < 0.001) in Pro347Ser retinas, as validated by qPCR." +tissue_expression_down hsa-mir-133 Retinitis Pigmentosa 18034880 "Expression of miR-1 and miR-133 decreased by more than 2.5-fold (P < 0.001), whereas expression of miR-96 and miR-183 increased by more than 3-fold (P < 0.001) in Pro347Ser retinas, as validated by qPCR." +tissue_expression_down hsa-mir-143 "Carcinoma, Rectal" 18196926 "Expression levels of analyzed miRNAs significantly differed among tumors and adjacent non-tumor tissues: miR-21 (p = 0.0001) and miR-31 (p = 0.0006) were upregulated, and miR-143 (p = 0.011) and miR-145 (p = 0.003) were downregulated in tumors." +tissue_expression_down hsa-mir-145 "Carcinoma, Rectal" 18196926 "Expression levels of analyzed miRNAs significantly differed among tumors and adjacent non-tumor tissues: miR-21 (p = 0.0001) and miR-31 (p = 0.0006) were upregulated, and miR-143 (p = 0.011) and miR-145 (p = 0.003) were downregulated in tumors." +tissue_expression_down hsa-mir-107 Alzheimer Disease 18234899 downregulated +tissue_expression_down hsa-mir-145 "Carcinoma, Hepatocellular" 18307259 "miR-122, miR-100, and miR-10a were overexpressed whereas miR-198 and miR-145 were up to 5-fold down-regulated in hepatic tumors compared to normal liver parenchyma." +tissue_expression_down hsa-mir-198 "Carcinoma, Hepatocellular" 18307259 "miR-122, miR-100, and miR-10a were overexpressed whereas miR-198 and miR-145 were up to 5-fold down-regulated in hepatic tumors compared to normal liver parenchyma." +tissue_expression_down hsa-mir-96 "Carcinoma, Hepatocellular" 18433021 "miR-96 was overexpressed in HBV tumors, and miR-126* was down-regulated in alcohol-related hepatocellular carcinoma." +tissue_expression_down hsa-let-7b Ovarian Neoplasms 18451233 lower +tissue_expression_down hsa-mir-106a Retinal Neovascularization 18500251 decreased +tissue_expression_down hsa-mir-214 Retinal Neovascularization 18500251 decreased +tissue_expression_down hsa-mir-424 Retinal Neovascularization 18500251 decreased +tissue_expression_down hsa-mir-221 Ovarian Neoplasms 18560586 "we identify several miRNAs aberrantly expressed in human ovarian cancer tissues and cell lines. miR-221 stands out as a highly elevated miRNA in ovarian cancer, while miR-21 and several members of the let-7 family are found downregulated." +tissue_expression_down hsa-mir-126 Urinary Bladder Cancer 18596939 miR-126: downregulated +tissue_expression_down hsa-mir-143 Urinary Bladder Cancer 18596939 miR-143: downregulated +tissue_expression_down hsa-mir-145 Urinary Bladder Cancer 18596939 miR-145: downregulated +tissue_expression_down hsa-mir-15a "Carcinoma, Pancreatic" 18665421 "In addition, when analyzed according to specific cancer phenotypes, miR-15a and miR-16 show a significant downregulation in canine ductal carcinomas while miRsR-181b, -21, -29b, and let-7f show a significant upregulation in canine tubular papillary carcinomas." +tissue_expression_down hsa-mir-16 "Carcinoma, Pancreatic" 18665421 "In addition, when analyzed according to specific cancer phenotypes, miR-15a and miR-16 show a significant downregulation in canine ductal carcinomas while miRsR-181b, -21, -29b, and let-7f show a significant upregulation in canine tubular papillary carcinomas." +tissue_expression_down hsa-mir-499a Head And Neck Neoplasms 18798260 miR-499: underexpressed +tissue_expression_down hsa-let-7c "Lymphoma, Burkitt" 18802929 "In particular, down-regulation of hsa-let-7c was observed in BL cases, compared to normal controls." +tissue_expression_down hsa-mir-145 Prostate Neoplasms 18949015 miR-145: down-regulated +tissue_expression_down hsa-mir-221 Prostate Neoplasms 18949015 miR-221: down-regulated +tissue_expression_down hsa-mir-222 Prostate Neoplasms 18949015 miR-222: down-regulated +tissue_expression_down hsa-mir-23b Prostate Neoplasms 18949015 miR-23b: down-regulated +tissue_expression_down hsa-mir-127 Ovarian Neoplasms 18954897 miR-127: under-expression +tissue_expression_down hsa-mir-155 Ovarian Neoplasms 18954897 miR-155: under-expression +tissue_expression_down hsa-mir-99b Ovarian Neoplasms 18954897 miR-99b: under-expression +tissue_expression_down hsa-mir-31 Medulloblastoma 18973228 miR-31: downregulated in all MBs +tissue_expression_down hsa-mir-1-1 Heart Failure 19059107 miR-1: decreased expression +tissue_expression_down hsa-mir-1-2 Heart Failure 19059107 miR-1: decreased expression +tissue_expression_down hsa-mir-133a-1 Heart Failure 19059107 miR-133a: decreased expression +tissue_expression_down hsa-mir-133a-2 Heart Failure 19059107 miR-133a: decreased expression +tissue_expression_down hsa-mir-133b Heart Failure 19059107 miR-133b: decreased expression +tissue_expression_down hsa-mir-141 Endometriosis 19074548 miR-141: downregulated +tissue_expression_down hsa-mir-142 Endometriosis 19074548 miR-142-3p: downregulated +tissue_expression_down hsa-mir-196b Endometriosis 19074548 miR-196b: downregulated +tissue_expression_down hsa-mir-200a Endometriosis 19074548 miR-200a: downregulated +tissue_expression_down hsa-mir-200b Endometriosis 19074548 miR-200b: downregulated +tissue_expression_down hsa-mir-20a Endometriosis 19074548 miR-20a: downregulated +tissue_expression_down hsa-mir-34c Endometriosis 19074548 miR-34c: downregulated +tissue_expression_down hsa-mir-424 Endometriosis 19074548 miR-424: downregulated +tissue_expression_down hsa-mir-193b "Adenocarcinoma, Endometrial" 19077565 miR-193b: downregulated +tissue_expression_down hsa-mir-204 "Adenocarcinoma, Endometrial" 19077565 miR-204: downregulated +tissue_expression_down hsa-mir-99b "Adenocarcinoma, Endometrial" 19077565 miR-99b: downregulated +tissue_expression_down hsa-mir-129-1 Gastric Neoplasms 19148490 miR-129: downregulated in undifferentiated gastric cancer +tissue_expression_down hsa-mir-129-2 Gastric Neoplasms 19148490 miR-129: downregulated in undifferentiated gastric cancer +tissue_expression_down hsa-mir-148a Gastric Neoplasms 19148490 miR-148: downregulated in undifferentiated gastric cancer +tissue_expression_down hsa-mir-148b Gastric Neoplasms 19148490 miR-148: downregulated in undifferentiated gastric cancer +tissue_expression_down hsa-let-7a-1 Digestive System Neoplasms 19156147 let-7a: downregulation +tissue_expression_down hsa-let-7a-2 Digestive System Neoplasms 19156147 let-7a: downregulation +tissue_expression_down hsa-let-7a-3 Digestive System Neoplasms 19156147 let-7a: downregulation +tissue_expression_down hsa-let-7b Digestive System Neoplasms 19156147 let-7b: downregulation +tissue_expression_down hsa-let-7c Digestive System Neoplasms 19156147 let-7c: downregulation +tissue_expression_down hsa-let-7d Digestive System Neoplasms 19156147 let-7d: downregulation +tissue_expression_down hsa-let-7e Digestive System Neoplasms 19156147 let-7e: downregulation +tissue_expression_down hsa-let-7f-1 Digestive System Neoplasms 19156147 let-7f: downregulation +tissue_expression_down hsa-let-7f-2 Digestive System Neoplasms 19156147 let-7f: downregulation +tissue_expression_down hsa-let-7g Digestive System Neoplasms 19156147 let-7g: downregulation +tissue_expression_down hsa-let-7i Digestive System Neoplasms 19156147 let-7i: downregulation +tissue_expression_down hsa-mir-373 Prostate Neoplasms 19158933 "miR-373: MicroRNAs 373 and 520c Are Downregulated in Prostate Cancer, Suppress CD44" +tissue_expression_down hsa-mir-520c Prostate Neoplasms 19158933 "miR-520c: MicroRNAs 373 and 520c Are Downregulated in Prostate Cancer, Suppress CD44" +tissue_expression_down hsa-mir-181b-1 Astrocytoma 19159078 miR-181b: downregulation +tissue_expression_down hsa-mir-181b-2 Astrocytoma 19159078 miR-181b: downregulation +tissue_expression_down hsa-mir-143 Neoplasms [unspecific] 19175697 "The expression of a subset of miRs (e.g. miR-21 and miR-155) was found to be consistently up-regulated, whereas another subset of miRs (e.g.miR-143 and miR-145) was consistently down-regulated across different cancer types suggesting their involvement in regulating common cellular processes whose deregulation may lead to tumourigenesis." +tissue_expression_down hsa-mir-145 Neoplasms [unspecific] 19175697 "The expression of a subset of miRs (e.g. miR-21 and miR-155) was found to be consistently up-regulated, whereas another subset of miRs (e.g.miR-143 and miR-145) was consistently down-regulated across different cancer types suggesting their involvement in regulating common cellular processes whose deregulation may lead to tumourigenesis." +tissue_expression_down hsa-mir-133b Gastric Neoplasms 19175831 miR-133b: down-regulated +tissue_expression_down hsa-mir-139 Gastric Neoplasms 19175831 miR-139-5p: down-regulated +tissue_expression_down hsa-mir-195 Gastric Neoplasms 19175831 miR-195: down-regulated +tissue_expression_down hsa-mir-31 Gastric Neoplasms 19175831 miR-31: down-regulated +tissue_expression_down hsa-mir-378a Gastric Neoplasms 19175831 miR-378: down-regulated +tissue_expression_down hsa-mir-497 Gastric Neoplasms 19175831 miR-497: down-regulated +tissue_expression_down hsa-let-7d Head And Neck Neoplasms 19179615 let-7d: show lower expression levels relative to normal adjacent tissue +tissue_expression_down hsa-mir-1-1 Head And Neck Neoplasms 19179615 miR-1: show lower expression levels relative to normal adjacent tissue +tissue_expression_down hsa-mir-1-2 Head And Neck Neoplasms 19179615 miR-1: show lower expression levels relative to normal adjacent tissue +tissue_expression_down hsa-mir-133a-1 Head And Neck Neoplasms 19179615 miR-133a: show lower expression levels relative to normal adjacent tissue +tissue_expression_down hsa-mir-133a-2 Head And Neck Neoplasms 19179615 miR-133a: show lower expression levels relative to normal adjacent tissue +tissue_expression_down hsa-mir-205 Head And Neck Neoplasms 19179615 miR-205: show lower expression levels relative to normal adjacent tissue +tissue_expression_down hsa-mir-15a Hepatitis B Virus Infection 19187610 miR-15a: down-regulated +tissue_expression_down hsa-mir-141 "Carcinoma, Renal Cell" 19228262 miR-141: down-regulated in malignant cancer than non-malignant one +tissue_expression_down hsa-mir-200b "Carcinoma, Renal Cell" 19228262 miR-200b: down-regulated in malignant cancer than non-malignant one +tissue_expression_down hsa-mir-200c "Carcinoma, Renal Cell" 19228262 miR-200c: down-regulated in malignant cancer than non-malignant one +tissue_expression_down hsa-mir-363 "Carcinoma, Renal Cell" 19228262 miR-363: down-regulated in malignant cancer than non-malignant one +tissue_expression_down hsa-mir-429 "Carcinoma, Renal Cell" 19228262 miR-429: down-regulated in malignant cancer than non-malignant one +tissue_expression_down hsa-mir-514a-1 "Carcinoma, Renal Cell" 19228262 miR-514: down-regulated in malignant cancer than non-malignant one +tissue_expression_down hsa-mir-514a-2 "Carcinoma, Renal Cell" 19228262 miR-514: down-regulated in malignant cancer than non-malignant one +tissue_expression_down hsa-mir-514a-3 "Carcinoma, Renal Cell" 19228262 miR-514: down-regulated in malignant cancer than non-malignant one +tissue_expression_down hsa-mir-205 Breast Neoplasms 19238171 miR-205: Suppress cell growth and invasion by target ErbB3 and VEGF-A +tissue_expression_down hsa-let-7a-1 Kaposi Sarcoma 19252139 let-7a: down-regulated +tissue_expression_down hsa-let-7a-1 "Lymphoma, Primary Effusion" 19252139 let-7a: down-regulated +tissue_expression_down hsa-let-7a-2 Kaposi Sarcoma 19252139 let-7a: down-regulated +tissue_expression_down hsa-let-7a-2 "Lymphoma, Primary Effusion" 19252139 let-7a: down-regulated +tissue_expression_down hsa-let-7a-3 Kaposi Sarcoma 19252139 let-7a: down-regulated +tissue_expression_down hsa-let-7a-3 "Lymphoma, Primary Effusion" 19252139 let-7a: down-regulated +tissue_expression_down hsa-let-7b Kaposi Sarcoma 19252139 let-7b: down-regulated +tissue_expression_down hsa-let-7b "Lymphoma, Primary Effusion" 19252139 let-7b: down-regulated +tissue_expression_down hsa-let-7c Kaposi Sarcoma 19252139 let-7c: down-regulated +tissue_expression_down hsa-let-7c "Lymphoma, Primary Effusion" 19252139 let-7c: down-regulated +tissue_expression_down hsa-let-7d Kaposi Sarcoma 19252139 let-7d: down-regulated +tissue_expression_down hsa-let-7d "Lymphoma, Primary Effusion" 19252139 let-7d: down-regulated +tissue_expression_down hsa-let-7e Kaposi Sarcoma 19252139 let-7e: down-regulated +tissue_expression_down hsa-let-7e "Lymphoma, Primary Effusion" 19252139 let-7e: down-regulated +tissue_expression_down hsa-let-7f-1 Kaposi Sarcoma 19252139 let-7f: down-regulated +tissue_expression_down hsa-let-7f-1 "Lymphoma, Primary Effusion" 19252139 let-7f: down-regulated +tissue_expression_down hsa-let-7f-2 Kaposi Sarcoma 19252139 let-7f: down-regulated +tissue_expression_down hsa-let-7f-2 "Lymphoma, Primary Effusion" 19252139 let-7f: down-regulated +tissue_expression_down hsa-let-7g Kaposi Sarcoma 19252139 let-7g: down-regulated +tissue_expression_down hsa-let-7g "Lymphoma, Primary Effusion" 19252139 let-7g: down-regulated +tissue_expression_down hsa-let-7i Kaposi Sarcoma 19252139 let-7i: down-regulated +tissue_expression_down hsa-let-7i "Lymphoma, Primary Effusion" 19252139 let-7i: down-regulated +tissue_expression_down hsa-mir-221 Kaposi Sarcoma 19252139 miR-221: down-regulated +tissue_expression_down hsa-mir-221 "Lymphoma, Primary Effusion" 19252139 miR-221: down-regulated +tissue_expression_down hsa-mir-222 Kaposi Sarcoma 19252139 miR-222: down-regulated +tissue_expression_down hsa-mir-222 "Lymphoma, Primary Effusion" 19252139 miR-222: down-regulated +tissue_expression_down hsa-mir-98 Kaposi Sarcoma 19252139 miR-98: down-regulated +tissue_expression_down hsa-mir-98 "Lymphoma, Primary Effusion" 19252139 miR-98: down-regulated +tissue_expression_down hsa-let-7g Endotoxemia 19284987 "Data analysis revealed that five miRNAs consistently responded to LPS-infusion, four of which were down-regulated (miR-146b, miR-150, miR-342, and let-7g) and one was up-regulated (miR-143). The miR-150 and mir-342 response was confirmed by real-time PCR." +tissue_expression_down hsa-mir-146b Endotoxemia 19284987 "Data analysis revealed that five miRNAs consistently responded to LPS-infusion, four of which were down-regulated (miR-146b, miR-150, miR-342, and let-7g) and one was up-regulated (miR-143). The miR-150 and mir-342 response was confirmed by real-time PCR." +tissue_expression_down hsa-mir-150 Endotoxemia 19284987 "Data analysis revealed that five miRNAs consistently responded to LPS-infusion, four of which were down-regulated (miR-146b, miR-150, miR-342, and let-7g) and one was up-regulated (miR-143). The miR-150 and mir-342 response was confirmed by real-time PCR." +tissue_expression_down hsa-mir-342 Endotoxemia 19284987 "Data analysis revealed that five miRNAs consistently responded to LPS-infusion, four of which were down-regulated (miR-146b, miR-150, miR-342, and let-7g) and one was up-regulated (miR-143). The miR-150 and mir-342 response was confirmed by real-time PCR." +tissue_expression_down hsa-mir-143 Colorectal Carcinoma 19287964 miR-143: down-regualted +tissue_expression_down hsa-mir-145 Colorectal Carcinoma 19287964 miR-145: down-regulated +tissue_expression_down hsa-mir-125b Breast Neoplasms 19290006 "Compared with normal breast samples, a panel of miRs was consistently dysregulated in breast cancer, including earlier-reported breast cancer-related miRs, such as upregulated miR-21, miR-155, miR-191, and miR-196a, and downregulated miR-125b and miR-221." +tissue_expression_down hsa-mir-221 Breast Neoplasms 19290006 "Compared with normal breast samples, a panel of miRs was consistently dysregulated in breast cancer, including earlier-reported breast cancer-related miRs, such as upregulated miR-21, miR-155, miR-191, and miR-196a, and downregulated miR-125b and miR-221." +tissue_expression_down hsa-mir-122a Primary Biliary Cirrhosis 19345069 A total of 35 independent miRNAs were found to be differentially expressed in PBC (p < 0.001).Quantitative PCR was employed to validate down-regulation of microRNA-122a (miR-122a) and miR-26a and the increased expression of miR-328 and miR-299-5p. +tissue_expression_down hsa-mir-26a Primary Biliary Cirrhosis 19345069 A total of 35 independent miRNAs were found to be differentially expressed in PBC (p < 0.001).Quantitative PCR was employed to validate down-regulation of microRNA-122a (miR-122a) and miR-26a and the increased expression of miR-328 and miR-299-5p. +tissue_expression_down hsa-mir-17 "Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic" 19347736 miR-17-5p: down-regulated +tissue_expression_down hsa-mir-29a "Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic" 19347736 miR-29: down-regulated +tissue_expression_down hsa-mir-29b-1 "Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic" 19347736 miR-29: down-regulated +tissue_expression_down hsa-mir-29b-2 "Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic" 19347736 miR-29: down-regulated +tissue_expression_down hsa-mir-29c "Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic" 19347736 miR-29: down-regulated +tissue_expression_down hsa-mir-34a "Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic" 19347736 miR-34a: down-regulated +tissue_expression_down hsa-let-7a-1 Salivary Gland Neoplasms 19347935 let-7a: down-regulated +tissue_expression_down hsa-let-7a-2 Salivary Gland Neoplasms 19347935 let-7a: down-regulated +tissue_expression_down hsa-let-7a-3 Salivary Gland Neoplasms 19347935 let-7a: down-regulated +tissue_expression_down hsa-mir-144 Salivary Gland Neoplasms 19347935 miR-144: down-regulated +tissue_expression_down hsa-mir-20b Salivary Gland Neoplasms 19347935 miR-20b: down-regulated +tissue_expression_down hsa-mir-375 Salivary Gland Neoplasms 19347935 miR-375: down-regulated +tissue_expression_down hsa-mir-106b "Carcinoma, Adrenocortical" 19351815 miR-106b: down-regulated +tissue_expression_down hsa-mir-139 "Carcinoma, Adrenocortical" 19351815 miR-139: down-regulated +tissue_expression_down hsa-mir-148a "Carcinoma, Adrenocortical" 19351815 miR-148a: down-regulated +tissue_expression_down hsa-mir-196a-1 "Carcinoma, Adrenocortical" 19351815 miR-196a: down-regulated +tissue_expression_down hsa-mir-196a-2 "Carcinoma, Adrenocortical" 19351815 miR-196a: down-regulated +tissue_expression_down hsa-mir-210 "Carcinoma, Adrenocortical" 19351815 miR-210: down-regulated +tissue_expression_down hsa-mir-301a "Carcinoma, Adrenocortical" 19351815 miR-301: down-regulated +tissue_expression_down hsa-mir-301b "Carcinoma, Adrenocortical" 19351815 miR-301: down-regulated +tissue_expression_down hsa-mir-376a-1 "Carcinoma, Adrenocortical" 19351815 miR-376: down-regulated +tissue_expression_down hsa-mir-376a-2 "Carcinoma, Adrenocortical" 19351815 miR-376: down-regulated +tissue_expression_down hsa-mir-376b "Carcinoma, Adrenocortical" 19351815 miR-376: down-regulated +tissue_expression_down hsa-mir-376c "Carcinoma, Adrenocortical" 19351815 miR-376: down-regulated +tissue_expression_down hsa-mir-424 "Carcinoma, Adrenocortical" 19351815 miR-424: down-regulated +tissue_expression_down hsa-mir-484 "Carcinoma, Adrenocortical" 19351815 miR-484: down-regulated +tissue_expression_down hsa-mir-491 "Carcinoma, Adrenocortical" 19351815 miR-491: down-regulated +tissue_expression_down hsa-mir-1-1 Hepatitis C Virus Infection 19360909 miR-1: down-regulated +tissue_expression_down hsa-mir-1-2 Hepatitis C Virus Infection 19360909 miR-1: down-regulated +tissue_expression_down hsa-mir-122 "Carcinoma, Hepatocellular" 19360909 miR-122: be decreased in HCC compared to non-tumoral tissue +tissue_expression_down hsa-mir-145 "Carcinoma, Hepatocellular" 19360909 miR-145: be decreased in HCC compared to non-tumoral tissue +tissue_expression_down hsa-mir-15a Liver Diseases [unspecific] 19360909 miR-15a: decreased +tissue_expression_down hsa-mir-196a-1 Hepatitis C Virus Infection 19360909 miR-196: down-regulated +tissue_expression_down hsa-mir-196a-2 Hepatitis C Virus Infection 19360909 miR-196: down-regulated +tissue_expression_down hsa-mir-196b Hepatitis C Virus Infection 19360909 miR-196: down-regulated +tissue_expression_down hsa-mir-198 "Carcinoma, Hepatocellular" 19360909 miR-198: up to five-fold down-regulated in hepatic tumors compared to normal liver parenchyma +tissue_expression_down hsa-mir-199a-1 "Carcinoma, Hepatocellular" 19360909 miR-199a: be decreased in HCC compared to non-tumoral tissue +tissue_expression_down hsa-mir-199a-2 "Carcinoma, Hepatocellular" 19360909 miR-199a: be decreased in HCC compared to non-tumoral tissue +tissue_expression_down hsa-mir-296 Hepatitis C Virus Infection 19360909 miR-296: down-regulated +tissue_expression_down hsa-mir-30a Hepatitis C Virus Infection 19360909 miR-30: down-regulated +tissue_expression_down hsa-mir-30b Hepatitis C Virus Infection 19360909 miR-30: down-regulated +tissue_expression_down hsa-mir-30c-1 Hepatitis C Virus Infection 19360909 miR-30: down-regulated +tissue_expression_down hsa-mir-30c-2 Hepatitis C Virus Infection 19360909 miR-30: down-regulated +tissue_expression_down hsa-mir-30d Hepatitis C Virus Infection 19360909 miR-30: down-regulated +tissue_expression_down hsa-mir-431 Hepatitis C Virus Infection 19360909 miR-431: down-regulated +tissue_expression_down hsa-mir-448 Hepatitis C Virus Infection 19360909 miR-448: down-regulated +tissue_expression_down hsa-mir-141 Gastric Neoplasms 19363643 miR-141: significantly down-regulated in gastric cancer +tissue_expression_down hsa-mir-125b Bladder Neoplasms 19378336 "We identified a subset of 7 miRNAs (miR-145, miR-30a-3p, miR-133a, miR-133b, miR-195, miR-125b and miR-199a*) that were significantly downregulated in BCs." +tissue_expression_down hsa-mir-133a Bladder Neoplasms 19378336 "We identified a subset of 7 miRNAs (miR-145, miR-30a-3p, miR-133a, miR-133b, miR-195, miR-125b and miR-199a*) that were significantly downregulated in BCs." +tissue_expression_down hsa-mir-133b Bladder Neoplasms 19378336 "We identified a subset of 7 miRNAs (miR-145, miR-30a-3p, miR-133a, miR-133b, miR-195, miR-125b and miR-199a*) that were significantly downregulated in BCs." +tissue_expression_down hsa-mir-145 Bladder Neoplasms 19378336 "We identified a subset of 7 miRNAs (miR-145, miR-30a-3p, miR-133a, miR-133b, miR-195, miR-125b and miR-199a*) that were significantly downregulated in BCs." +tissue_expression_down hsa-mir-195 Bladder Neoplasms 19378336 "We identified a subset of 7 miRNAs (miR-145, miR-30a-3p, miR-133a, miR-133b, miR-195, miR-125b and miR-199a*) that were significantly downregulated in BCs." +tissue_expression_down hsa-mir-199a Bladder Neoplasms 19378336 "We identified a subset of 7 miRNAs (miR-145, miR-30a-3p, miR-133a, miR-133b, miR-195, miR-125b and miR-199a*) that were significantly downregulated in BCs." +tissue_expression_down hsa-mir-30a Bladder Neoplasms 19378336 "We identified a subset of 7 miRNAs (miR-145, miR-30a-3p, miR-133a, miR-133b, miR-195, miR-125b and miR-199a*) that were significantly downregulated in BCs." +tissue_expression_down hsa-mir-1 Essential Thrombocythemia 19497108 Gene and microRNA analysis of neutrophils from patients with polycythemia vera and essential thrombocytosis: down-regulation of micro RNA-1 and -133a. +tissue_expression_down hsa-mir-133a Essential Thrombocythemia 19497108 Gene and microRNA analysis of neutrophils from patients with polycythemia vera and essential thrombocytosis: down-regulation of micro RNA-1 and -133a. +tissue_expression_down hsa-mir-141 Ovarian Neoplasms 19501389 "miR-200b-429 may be used as a prognostic marker for ovarian cancer outcome, and low-level expression of miR-200 miRNAs in this cluster predicts poor survival." +tissue_expression_down hsa-mir-200a Ovarian Neoplasms 19501389 "miR-200b-429 may be used as a prognostic marker for ovarian cancer outcome, and low-level expression of miR-200 miRNAs in this cluster predicts poor survival." +tissue_expression_down hsa-mir-200b Ovarian Neoplasms 19501389 "miR-200b-429 may be used as a prognostic marker for ovarian cancer outcome, and low-level expression of miR-200 miRNAs in this cluster predicts poor survival." +tissue_expression_down hsa-mir-200c Ovarian Neoplasms 19501389 "miR-200b-429 may be used as a prognostic marker for ovarian cancer outcome, and low-level expression of miR-200 miRNAs in this cluster predicts poor survival." +tissue_expression_down hsa-mir-429 Ovarian Neoplasms 19501389 "miR-200b-429 may be used as a prognostic marker for ovarian cancer outcome, and low-level expression of miR-200 miRNAs in this cluster predicts poor survival." +tissue_expression_down hsa-mir-433 Gastrointestinal Neoplasms 19531230 Down-regulated miR-9 and miR-433 in human gastric carcinoma. +tissue_expression_down hsa-mir-9 Gastrointestinal Neoplasms 19531230 Down-regulated miR-9 and miR-433 in human gastric carcinoma. +tissue_expression_down hsa-mir-214 Adrenal Cortex Neoplasms 19546168 significantly lower expressed +tissue_expression_down hsa-mir-183 Fatty Liver [unspecific] 19572984 down-regulated after Lieber-DeCarli ; +tissue_expression_down hsa-mir-122 Melanoma 19578755 down-regulated +tissue_expression_down hsa-mir-146b Melanoma 19578755 down-regulated +tissue_expression_down hsa-mir-155 Melanoma 19578755 down-regulated +tissue_expression_down hsa-mir-221 Prostate Neoplasms 19585579 miR-221:Expression of microRNA-221 is progressively reduced in aggressive prostate cancer and metastasis +tissue_expression_down hsa-mir-15a "Leukemia, Lymphocytic, Chronic, B-Cell" 19591824 "The microRNAs miR-15a and miR-16-1 are downregulated in multiple tumor types and are frequently deleted in chronic lymphocytic leukemia (CLL), myeloma and mantle cell lymphoma." +tissue_expression_down hsa-mir-16-1 "Leukemia, Lymphocytic, Chronic, B-Cell" 19591824 "The microRNAs miR-15a and miR-16-1 are downregulated in multiple tumor types and are frequently deleted in chronic lymphocytic leukemia (CLL), myeloma and mantle cell lymphoma." +tissue_expression_down hsa-mir-155 Lung Neoplasms 19597153 down-regulated miR +tissue_expression_down hsa-mir-17 Gastric Neoplasms 19598010 miR-17-92a cluster; expression lwere significantly lower than non-cancer tissue; may help to clarify the molecular mechanisms; may be a novel diagnostic biomarker +tissue_expression_down hsa-mir-18a Gastric Neoplasms 19598010 miR-17-92a cluster; expression lwere significantly lower than non-cancer tissue; may help to clarify the molecular mechanisms; may be a novel diagnostic biomarker +tissue_expression_down hsa-mir-19a Gastric Neoplasms 19598010 miR-17-92a cluster; expression lwere significantly lower than non-cancer tissue; may help to clarify the molecular mechanisms; may be a novel diagnostic biomarker +tissue_expression_down hsa-mir-142 Lung Neoplasms 19618089 "miR-34c, miR-145, or miR-142-5p expression markedly diminished proliferation of lung cancer cell lines, clinical implications discussed" +tissue_expression_down hsa-mir-145 Lung Neoplasms 19618089 "miR-34c, miR-145, or miR-142-5p expression markedly diminished proliferation of lung cancer cell lines, clinical implications discussed" +tissue_expression_down hsa-mir-18b Lung Neoplasms 19618089 "miR-34c, miR-145, or miR-142-5p expression markedly diminished proliferation of lung cancer cell lines, clinical implications discussed" +tissue_expression_down hsa-mir-133b Pancreatic Neoplasms 19654291 "downregulated, Up-regulation leads to the reversal of EMT" +tissue_expression_down hsa-mir-182 Breast Neoplasms 19665978 downregulated in human BCSCs +tissue_expression_down hsa-mir-183 Breast Neoplasms 19665978 downregulated in human BCSCs +tissue_expression_down hsa-mir-200a Breast Neoplasms 19665978 downregulated in human BCSCs +tissue_expression_down hsa-mir-429 Breast Neoplasms 19665978 downregulated in human BCSCs +tissue_expression_down hsa-mir-96 Breast Neoplasms 19665978 downregulated in human BCSCs +tissue_expression_down hsa-mir-143 Prostate Neoplasms 19671871 "Although miR-143 and miR-145 are highly expressed in normal tissues, they are significantly down-regulated in prostate cancer cells. " +tissue_expression_down hsa-mir-145 Prostate Neoplasms 19671871 "Although miR-143 and miR-145 are highly expressed in normal tissues, they are significantly down-regulated in prostate cancer cells. " +tissue_expression_down hsa-mir-145 Neoplasms [unspecific] 19676045 down-regulated +tissue_expression_down hsa-mir-149 Neoplasms [unspecific] 19676045 down-regulated +tissue_expression_down hsa-mir-182 Neoplasms [unspecific] 19676045 down-regulated +tissue_expression_down hsa-mir-184 Neoplasms [unspecific] 19676045 down-regulated +tissue_expression_down hsa-mir-205 Neoplasms [unspecific] 19676045 down-regulated +tissue_expression_down hsa-mir-221 Neoplasms [unspecific] 19676045 down-regulated +tissue_expression_down hsa-mir-222 Neoplasms [unspecific] 19676045 down-regulated +tissue_expression_down hsa-mir-31 Neoplasms [unspecific] 19676045 down-regulated +tissue_expression_down hsa-mir-499a Lymphoma 19690137 "deregulated, hypermutations" +tissue_expression_down hsa-mir-148a Hepatoblastoma 19701500 downregulated +tissue_expression_down hsa-mir-122 "Carcinoma, Hepatocellular" 19711427 down-regulation at early stage +tissue_expression_down hsa-mir-155 "Carcinoma, Hepatocellular" 19711427 "Real-time reverse transcription polymerase chain reaction (RT-PCR) analysis demonstrated up-regulation of oncogenic miR-155, miR-221/222, and miR-21 and down-regulation of the most abundant liver-specific miR-122 at early stages of hepatocarcinogenesis." +tissue_expression_down hsa-mir-21 "Carcinoma, Hepatocellular" 19711427 "Real-time reverse transcription polymerase chain reaction (RT-PCR) analysis demonstrated up-regulation of oncogenic miR-155, miR-221/222, and miR-21 and down-regulation of the most abundant liver-specific miR-122 at early stages of hepatocarcinogenesis." +tissue_expression_down hsa-mir-221 "Carcinoma, Hepatocellular" 19711427 "Real-time reverse transcription polymerase chain reaction (RT-PCR) analysis demonstrated up-regulation of oncogenic miR-155, miR-221/222, and miR-21 and down-regulation of the most abundant liver-specific miR-122 at early stages of hepatocarcinogenesis." +tissue_expression_down hsa-mir-222 "Carcinoma, Hepatocellular" 19711427 "Real-time reverse transcription polymerase chain reaction (RT-PCR) analysis demonstrated up-regulation of oncogenic miR-155, miR-221/222, and miR-21 and down-regulation of the most abundant liver-specific miR-122 at early stages of hepatocarcinogenesis." +tissue_expression_down hsa-mir-140 Osteoarthritis 19714579 down-regulated IL-1beta-induced ADAMTS5 +tissue_expression_down hsa-mir-16-1 Prostate Neoplasms 19738602 "microRNA (miR)-16, which is expressed at lower levels in prostate cancer cells, affects the proliferation of human prostate cancer cell lines both in vitro and in vivo" +tissue_expression_down hsa-mir-16-2 Prostate Neoplasms 19738602 "microRNA (miR)-16, which is expressed at lower levels in prostate cancer cells, affects the proliferation of human prostate cancer cell lines both in vitro and in vivo" +tissue_expression_down hsa-mir-1 Lung Neoplasms 19748927 "miR-21, mir-31, miR-130a, miR-146b and miR-377 were consistently upregulated, whereas miR-1 and miR-143 were downregulated in lung tumors relative to normal lungs." +tissue_expression_down hsa-mir-143 Lung Neoplasms 19748927 "miR-21, mir-31, miR-130a, miR-146b and miR-377 were consistently upregulated, whereas miR-1 and miR-143 were downregulated in lung tumors relative to normal lungs." +tissue_expression_down hsa-mir-203 Squamous Cell Carcinoma 19789312 "In adenocarcinoma patients, miR-21, miR-223, miR-192, and miR-194 expression was elevated, whereas miR-203 expression was reduced in cancerous compared with noncancerous tissue." +tissue_expression_down hsa-mir-34a Melanoma 19830692 "miR-34a:MiR-15b and miR-210 were significantly upregulated, miR-34a was significantly downregulated in melanomas" +tissue_expression_down hsa-mir-200b Adrenal Cortex Neoplasms 19849700 down-regulated +tissue_expression_down hsa-mir-203 Adrenal Cortex Neoplasms 19849700 down-regulated +tissue_expression_down hsa-mir-218 Gastrointestinal Neoplasms 19890957 "miR-218 expression was reduced significantly in gastric cancer tissues, in H. pylori-infected gastric mucosa, and in H. pylori-infected AGS cells." +tissue_expression_down hsa-mir-10b "Adenocarcinoma, Endometrial" 19891660 down-regulated +tissue_expression_down hsa-mir-152 "Adenocarcinoma, Endometrial" 19891660 down-regulated +tissue_expression_down hsa-mir-145 Bladder Neoplasms 19915607 Our data indicate that reduction in miR-145 expression may provide bladder cancer cells with a selective advantage by inhibition of cell death otherwise triggered in malignant cells. +tissue_expression_down hsa-mir-128-1 Glioblastoma 19941032 "miR-128:Micro-RNA-128 (miRNA-128) down-regulation in glioblastoma targets ARP5 (ANGPTL6), Bmi-1 and E2F-3a, key regulators of brain cell proliferation" +tissue_expression_down hsa-mir-128-2 Glioblastoma 19941032 "miR-128:Micro-RNA-128 (miRNA-128) down-regulation in glioblastoma targets ARP5 (ANGPTL6), Bmi-1 and E2F-3a, key regulators of brain cell proliferation" +tissue_expression_down hsa-mir-133b Breast Neoplasms 19946373 downregulated +tissue_expression_down hsa-mir-133b Colon Neoplasms 19946373 downregulated +tissue_expression_down hsa-mir-133b Liver Neoplasms 19946373 downregulated +tissue_expression_down hsa-mir-133b Lung Neoplasms 19946373 downregulated +tissue_expression_down hsa-mir-133b Lymphoma 19946373 downregulated +tissue_expression_down hsa-mir-133b Ovarian Neoplasms 19946373 downregulated +tissue_expression_down hsa-mir-133b Prostate Neoplasms 19946373 downregulated +tissue_expression_down hsa-mir-133b Testicular Neoplasms 19946373 downregulated +tissue_expression_down hsa-mir-486 Breast Neoplasms 19946373 miR-486-5p: downregulated +tissue_expression_down hsa-mir-486 Colon Neoplasms 19946373 miR-486-5p: downregulated +tissue_expression_down hsa-mir-486 Liver Neoplasms 19946373 miR-486-5p: downregulated +tissue_expression_down hsa-mir-486 Lung Neoplasms 19946373 miR-486-5p: downregulated +tissue_expression_down hsa-mir-486 Lymphoma 19946373 miR-486-5p: downregulated +tissue_expression_down hsa-mir-486 Ovarian Neoplasms 19946373 miR-486-5p: downregulated +tissue_expression_down hsa-mir-486 Prostate Neoplasms 19946373 miR-486-5p: downregulated +tissue_expression_down hsa-mir-486 Testicular Neoplasms 19946373 miR-486-5p: downregulated +tissue_expression_down hsa-mir-130a Gastric Neoplasms 19948396 "different miRNAs have been found to predict sensitivity to anticancer treatment: miR-30c, miR-130a and miR-335 are downregulated in various chemoresistant cell lines, hsa-Let-7g and hsa-miR-181b are strongly associated with response to 5-fluorouracil-based antimetabolite S-1" +tissue_expression_down hsa-mir-30c Gastric Neoplasms 19948396 "different miRNAs have been found to predict sensitivity to anticancer treatment: miR-30c, miR-130a and miR-335 are downregulated in various chemoresistant cell lines, hsa-Let-7g and hsa-miR-181b are strongly associated with response to 5-fluorouracil-based antimetabolite S-1" +tissue_expression_down hsa-mir-335 Gastric Neoplasms 19948396 "different miRNAs have been found to predict sensitivity to anticancer treatment: miR-30c, miR-130a and miR-335 are downregulated in various chemoresistant cell lines, hsa-Let-7g and hsa-miR-181b are strongly associated with response to 5-fluorouracil-based antimetabolite S-1" +tissue_expression_down hsa-mir-1826 Colon Neoplasms 19956872 "The down-regulations of miR-197, miR-191, miR-92a, miR-93, miR-222 and miR-1826, whose expression was significantly down-regulated in both cell lines after the treatment of one drug or in one cell line following exposure to either drug, were further validated." +tissue_expression_down hsa-mir-191 Colon Neoplasms 19956872 "The down-regulations of miR-197, miR-191, miR-92a, miR-93, miR-222 and miR-1826, whose expression was significantly down-regulated in both cell lines after the treatment of one drug or in one cell line following exposure to either drug, were further validated." +tissue_expression_down hsa-mir-197 Colon Neoplasms 19956872 "The down-regulations of miR-197, miR-191, miR-92a, miR-93, miR-222 and miR-1826, whose expression was significantly down-regulated in both cell lines after the treatment of one drug or in one cell line following exposure to either drug, were further validated." +tissue_expression_down hsa-mir-222 Colon Neoplasms 19956872 "The down-regulations of miR-197, miR-191, miR-92a, miR-93, miR-222 and miR-1826, whose expression was significantly down-regulated in both cell lines after the treatment of one drug or in one cell line following exposure to either drug, were further validated." +tissue_expression_down hsa-mir-92a Colon Neoplasms 19956872 "The down-regulations of miR-197, miR-191, miR-92a, miR-93, miR-222 and miR-1826, whose expression was significantly down-regulated in both cell lines after the treatment of one drug or in one cell line following exposure to either drug, were further validated." +tissue_expression_down hsa-mir-93 Colon Neoplasms 19956872 "The down-regulations of miR-197, miR-191, miR-92a, miR-93, miR-222 and miR-1826, whose expression was significantly down-regulated in both cell lines after the treatment of one drug or in one cell line following exposure to either drug, were further validated." +tissue_expression_down hsa-mir-195 Adrenal Cortex Neoplasms 19996210 miR-335 and miR-195 were significantly downregulated in adrenocortical carcinomas +tissue_expression_down hsa-mir-483 Adrenal Cortex Neoplasms 19996210 miR-335 and miR-195 were significantly downregulated in adrenocortical carcinomas +tissue_expression_down hsa-mir-320a Interstitial Cystitis 20008142 "demonstrate a direct correlation between miR-449b, miR-500, miR-328, and miR-320 and a down-regulation of NK1R mRNA and/or protein levels" +tissue_expression_down hsa-mir-320b-1 Interstitial Cystitis 20008142 "demonstrate a direct correlation between miR-449b, miR-500, miR-328, and miR-320 and a down-regulation of NK1R mRNA and/or protein levels" +tissue_expression_down hsa-mir-320b-2 Interstitial Cystitis 20008142 "demonstrate a direct correlation between miR-449b, miR-500, miR-328, and miR-320 and a down-regulation of NK1R mRNA and/or protein levels" +tissue_expression_down hsa-mir-320c-1 Interstitial Cystitis 20008142 "demonstrate a direct correlation between miR-449b, miR-500, miR-328, and miR-320 and a down-regulation of NK1R mRNA and/or protein levels" +tissue_expression_down hsa-mir-320c-2 Interstitial Cystitis 20008142 "demonstrate a direct correlation between miR-449b, miR-500, miR-328, and miR-320 and a down-regulation of NK1R mRNA and/or protein levels" +tissue_expression_down hsa-mir-320d-1 Interstitial Cystitis 20008142 "demonstrate a direct correlation between miR-449b, miR-500, miR-328, and miR-320 and a down-regulation of NK1R mRNA and/or protein levels" +tissue_expression_down hsa-mir-320d-2 Interstitial Cystitis 20008142 "demonstrate a direct correlation between miR-449b, miR-500, miR-328, and miR-320 and a down-regulation of NK1R mRNA and/or protein levels" +tissue_expression_down hsa-mir-328 Interstitial Cystitis 20008142 "demonstrate a direct correlation between miR-449b, miR-500, miR-328, and miR-320 and a down-regulation of NK1R mRNA and/or protein levels" +tissue_expression_down hsa-mir-449b Interstitial Cystitis 20008142 "demonstrate a direct correlation between miR-449b, miR-500, miR-328, and miR-320 and a down-regulation of NK1R mRNA and/or protein levels" +tissue_expression_down hsa-mir-500a Interstitial Cystitis 20008142 "demonstrate a direct correlation between miR-449b, miR-500, miR-328, and miR-320 and a down-regulation of NK1R mRNA and/or protein levels" +tissue_expression_down hsa-let-7g Gastric Neoplasms 20022810 low expression +tissue_expression_down hsa-mir-433 Gastric Neoplasms 20022810 Low expression +tissue_expression_down hsa-mir-153-1 Endometrial Neoplasms 20028871 "Expression of miR-9, miR-27, miR-96, miR-153, miR-182, miR-183, or miR-186, but not miR-29a, miR-128, miR-152, or miR-486 mimetics in HEC-1B cells was sufficient to significantly reduce the abundance of FOXO1" +tissue_expression_down hsa-mir-153-2 Endometrial Neoplasms 20028871 "Expression of miR-9, miR-27, miR-96, miR-153, miR-182, miR-183, or miR-186, but not miR-29a, miR-128, miR-152, or miR-486 mimetics in HEC-1B cells was sufficient to significantly reduce the abundance of FOXO1" +tissue_expression_down hsa-mir-182 Endometrial Neoplasms 20028871 "Expression of miR-9, miR-27, miR-96, miR-153, miR-182, miR-183, or miR-186, but not miR-29a, miR-128, miR-152, or miR-486 mimetics in HEC-1B cells was sufficient to significantly reduce the abundance of FOXO1" +tissue_expression_down hsa-mir-183 Endometrial Neoplasms 20028871 "Expression of miR-9, miR-27, miR-96, miR-153, miR-182, miR-183, or miR-186, but not miR-29a, miR-128, miR-152, or miR-486 mimetics in HEC-1B cells was sufficient to significantly reduce the abundance of FOXO1" +tissue_expression_down hsa-mir-186 Endometrial Neoplasms 20028871 "Expression of miR-9, miR-27, miR-96, miR-153, miR-182, miR-183, or miR-186, but not miR-29a, miR-128, miR-152, or miR-486 mimetics in HEC-1B cells was sufficient to significantly reduce the abundance of FOXO1" +tissue_expression_down hsa-mir-27a Endometrial Neoplasms 20028871 "Expression of miR-9, miR-27, miR-96, miR-153, miR-182, miR-183, or miR-186, but not miR-29a, miR-128, miR-152, or miR-486 mimetics in HEC-1B cells was sufficient to significantly reduce the abundance of FOXO1" +tissue_expression_down hsa-mir-27b Endometrial Neoplasms 20028871 "Expression of miR-9, miR-27, miR-96, miR-153, miR-182, miR-183, or miR-186, but not miR-29a, miR-128, miR-152, or miR-486 mimetics in HEC-1B cells was sufficient to significantly reduce the abundance of FOXO1" +tissue_expression_down hsa-mir-9-1 Endometrial Neoplasms 20028871 "Expression of miR-9, miR-27, miR-96, miR-153, miR-182, miR-183, or miR-186, but not miR-29a, miR-128, miR-152, or miR-486 mimetics in HEC-1B cells was sufficient to significantly reduce the abundance of FOXO1" +tissue_expression_down hsa-mir-9-2 Endometrial Neoplasms 20028871 "Expression of miR-9, miR-27, miR-96, miR-153, miR-182, miR-183, or miR-186, but not miR-29a, miR-128, miR-152, or miR-486 mimetics in HEC-1B cells was sufficient to significantly reduce the abundance of FOXO1" +tissue_expression_down hsa-mir-9-3 Endometrial Neoplasms 20028871 "Expression of miR-9, miR-27, miR-96, miR-153, miR-182, miR-183, or miR-186, but not miR-29a, miR-128, miR-152, or miR-486 mimetics in HEC-1B cells was sufficient to significantly reduce the abundance of FOXO1" +tissue_expression_down hsa-mir-96 Endometrial Neoplasms 20028871 "Expression of miR-9, miR-27, miR-96, miR-153, miR-182, miR-183, or miR-186, but not miR-29a, miR-128, miR-152, or miR-486 mimetics in HEC-1B cells was sufficient to significantly reduce the abundance of FOXO1" +tissue_expression_down hsa-mir-133b Myocardial Infarction 20029200 downregulated +tissue_expression_down hsa-let-7a-1 Ovarian Neoplasms 20035894 hsa-let-7a:The most frequently deregulated miRNAs are members of the let-7 and miR-200 families +tissue_expression_down hsa-let-7a-2 Ovarian Neoplasms 20035894 hsa-let-7a:The most frequently deregulated miRNAs are members of the let-7 and miR-200 families +tissue_expression_down hsa-let-7a-3 Ovarian Neoplasms 20035894 hsa-let-7a:The most frequently deregulated miRNAs are members of the let-7 and miR-200 families +tissue_expression_down hsa-let-7b Ovarian Neoplasms 20035894 hsa-let-7b:The most frequently deregulated miRNAs are members of the let-7 and miR-200 families +tissue_expression_down hsa-let-7c Ovarian Neoplasms 20035894 hsa-let-7c:The most frequently deregulated miRNAs are members of the let-7 and miR-200 families +tissue_expression_down hsa-let-7d Ovarian Neoplasms 20035894 hsa-let-7d:The most frequently deregulated miRNAs are members of the let-7 and miR-200 families +tissue_expression_down hsa-let-7e Ovarian Neoplasms 20035894 hsa-let-7e:The most frequently deregulated miRNAs are members of the let-7 and miR-200 families +tissue_expression_down hsa-let-7f-1 Ovarian Neoplasms 20035894 hsa-let-7f:The most frequently deregulated miRNAs are members of the let-7 and miR-200 families +tissue_expression_down hsa-let-7f-2 Ovarian Neoplasms 20035894 hsa-let-7f:The most frequently deregulated miRNAs are members of the let-7 and miR-200 families +tissue_expression_down hsa-let-7g Ovarian Neoplasms 20035894 hsa-let-7g:The most frequently deregulated miRNAs are members of the let-7 and miR-200 families +tissue_expression_down hsa-let-7i Ovarian Neoplasms 20035894 hsa-let-7i:The most frequently deregulated miRNAs are members of the let-7 and miR-200 families +tissue_expression_down hsa-mir-34a Pancreatic Neoplasms 20037478 "Finally,restituted expression of miR-34a, a miRNA whose expression is frequently lost in PDAC cell lines, abrogates growth, demonstrating that the anti-proliferative activity of this miRNA is operative in PDAC." +tissue_expression_down hsa-mir-378 Colon Neoplasms 20132431 "A total of 14 miRNAs were found to be associated with colonic cancer, in which the expression of miR-106b, miR-135b, miR-18a, miR-18b, miR-196b, miR-19a, miR-224, miR-335, miR-424, miR-20a*, miR-301b and miR-374a were up-regulated and the expression of miR-378 and miR-378* were downregulated in colonic cancer tissues, compared with the para-cancerous control." +tissue_expression_down hsa-mir-34b Ovarian Neoplasms 20145172 reduced expression of miR-34b*/c may be particularly important for progression to the most advanced stages +tissue_expression_down hsa-mir-34c Ovarian Neoplasms 20145172 reduced expression of miR-34b*/c may be particularly important for progression to the most advanced stages +tissue_expression_down hsa-mir-10a Neoplasms [unspecific] 20145181 downregulation +tissue_expression_down hsa-mir-10a "Squamous Cell Carcinoma, Head and Neck" 20145181 downregulation +tissue_expression_down hsa-mir-10b Neoplasms [unspecific] 20145181 downregulation +tissue_expression_down hsa-mir-125b-1 Neoplasms [unspecific] 20145181 underexpression +tissue_expression_down hsa-mir-125b-2 Neoplasms [unspecific] 20145181 underexpression +tissue_expression_down hsa-mir-375 Neoplasms [unspecific] 20145181 underexpression +tissue_expression_down hsa-mir-375 "Squamous Cell Carcinoma, Head and Neck" 20145181 underexpression +tissue_expression_down hsa-mir-34c Prostate Neoplasms 20162671 miR-34c is down regulated in prostate cancer and exerts tumor suppressive functions +tissue_expression_down hsa-mir-133a-1 Cardiovascular Diseases [unspecific] 20173049 miR-133a:NFATc4 is negatively regulated in miR-133a-mediated cardiomyocyte hypertrophic repression +tissue_expression_down hsa-mir-126 Myocardial Infarction 20187981 we found that AMI is associated with altered miRNA expression level and the differentially expressed miRNAs may be novel biomarkers of AMI +tissue_expression_down hsa-mir-31 Myocardial Infarction 20187981 we found that AMI is associated with altered miRNA expression level and the differentially expressed miRNAs may be novel biomarkers of AMI +tissue_expression_down hsa-mir-499a Myocardial Infarction 20187981 miR-499-5p; we found that AMI is associated with altered miRNA expression level and the differentially expressed miRNAs may be novel biomarkers of AMI +tissue_expression_down hsa-mir-375 Neoplasms [unspecific] 20215506 MicroRNA-375 is downregulated in gastric carcinomas +tissue_expression_down hsa-mir-150 Polycythemia Vera 20218812 We observed that miR-451 up-regulation and miR-150 down-regulation are associated with progression of erythroid maturation in K562 cells. +tissue_expression_down hsa-mir-106a Astrocytoma 20219352 "miR-106a:hsa-miR-21, hsa-miR-181b and hsa-miR-106a as prognostic indicators of astrocytoma" +tissue_expression_down hsa-mir-137 Astrocytoma 20219352 miR-137:The down-regulation of hsa-miR-137 in astrocytomas was shown to be associated with advanced clinical stages of this disease +tissue_expression_down hsa-mir-181b-1 Astrocytoma 20219352 "miR-181b:hsa-miR-21, hsa-miR-181b and hsa-miR-106a as prognostic indicators of astrocytoma" +tissue_expression_down hsa-mir-181b-2 Astrocytoma 20219352 "miR-181b:hsa-miR-21, hsa-miR-181b and hsa-miR-106a as prognostic indicators of astrocytoma" +tissue_expression_down hsa-let-7b "Carcinoma, Oral" 20232482 "Together, these data demonstrate that elevated expression levels of Dicer in oral cancer cells correlate with downregulation of let-7b and increased cell proliferation." +tissue_expression_down hsa-mir-145 Breast Neoplasms 20331864 down-regulated in male breast cancer +tissue_expression_down hsa-mir-497 Breast Neoplasms 20331864 down-regulated in male breast cancer +tissue_expression_down hsa-mir-34a Choriocarcinoma 20351093 MicroRNA-34a suppresses invasion through down-regulation of Notch1 and Jagged1 in cervical carcinoma and choriocarcinoma cells +tissue_expression_down hsa-mir-191 Melanoma 20357817 "Furthermore, low expression of miR-191 and high expression of miR-193b were associated with poor melanoma-specific survive" +tissue_expression_down hsa-mir-193a Melanoma 20357817 "In melanomas, miR-193a, miR-338, and miR-565 were underexpressed in cases with a BRAF mutation." +tissue_expression_down hsa-mir-338 Melanoma 20357817 "In melanomas, miR-193a, miR-338, and miR-565 were underexpressed in cases with a BRAF mutation." +tissue_expression_down hsa-mir-143 "Carcinoma, Lung, Non-Small-Cell" 20363096 "miR-143:Deregulated expression of miR-21, miR-143 and miR-181a in non small cell lung cancer is related to clinicopathologic characteristics or patient prognosis" +tissue_expression_down hsa-mir-143 Lung Neoplasms 20363096 "downregulated; Deregulated expression of miR-21, miR-143 and miR-181a in non small cell lung cancer is related to clinicopathologic characteristics or patient prognosis" +tissue_expression_down hsa-mir-181a-2 "Carcinoma, Lung, Non-Small-Cell" 20363096 "miR-181a:Deregulated expression of miR-21, miR-143 and miR-181a in non small cell lung cancer is related to clinicopathologic characteristics or patient prognosis" +tissue_expression_down hsa-mir-181a-2 Lung Neoplasms 20363096 "downregulated; Deregulated expression of miR-21, miR-143 and miR-181a in non small cell lung cancer is related to clinicopathologic characteristics or patient prognosis" +tissue_expression_down hsa-mir-21 "Carcinoma, Lung, Non-Small-Cell" 20363096 "miR-21:Deregulated expression of miR-21, miR-143 and miR-181a in non small cell lung cancer is related to clinicopathologic characteristics or patient prognosis" +tissue_expression_down hsa-mir-145 Neoplasms [unspecific] 20370992 under-expressed +tissue_expression_down hsa-mir-155 Neoplasms [unspecific] 20370992 under-expressed +tissue_expression_down hsa-let-7a-1 Colorectal Adenocarcinoma 20413677 "let-7a:nine(miR-192, -215, -26b, -143, -145, -191, -196a, -16, and let-7a) were under-expressed in CRC" +tissue_expression_down hsa-let-7a-2 Colorectal Adenocarcinoma 20413677 "let-7a:nine(miR-192, -215, -26b, -143, -145, -191, -196a, -16, and let-7a) were under-expressed in CRC" +tissue_expression_down hsa-let-7a-3 Colorectal Adenocarcinoma 20413677 "let-7a:nine(miR-192, -215, -26b, -143, -145, -191, -196a, -16, and let-7a) were under-expressed in CRC" +tissue_expression_down hsa-mir-143 Colorectal Adenocarcinoma 20413677 "miR-143:nine(miR-192, -215, -26b, -143, -145, -191, -196a, -16, and let-7a) were under-expressed in CRC" +tissue_expression_down hsa-mir-145 Colorectal Adenocarcinoma 20413677 "miR-145:nine(miR-192, -215, -26b, -143, -145, -191, -196a, -16, and let-7a) were under-expressed in CRC" +tissue_expression_down hsa-mir-16-1 Colorectal Adenocarcinoma 20413677 "miR-16:nine(miR-192, -215, -26b, -143, -145, -191, -196a, -16, and let-7a) were under-expressed in CRC" +tissue_expression_down hsa-mir-16-2 Colorectal Adenocarcinoma 20413677 "miR-16:nine(miR-192, -215, -26b, -143, -145, -191, -196a, -16, and let-7a) were under-expressed in CRC" +tissue_expression_down hsa-mir-191 Colorectal Adenocarcinoma 20413677 "miR-191:nine(miR-192, -215, -26b, -143, -145, -191, -196a, -16, and let-7a) were under-expressed in CRC" +tissue_expression_down hsa-mir-192 Colorectal Adenocarcinoma 20413677 "miR-192:nine(miR-192, -215, -26b, -143, -145, -191, -196a, -16, and let-7a) were under-expressed in CRC" +tissue_expression_down hsa-mir-196a-1 Colorectal Adenocarcinoma 20413677 "miR-196a:nine(miR-192, -215, -26b, -143, -145, -191, -196a, -16, and let-7a) were under-expressed in CRC" +tissue_expression_down hsa-mir-196a-2 Colorectal Adenocarcinoma 20413677 "miR-196a:nine(miR-192, -215, -26b, -143, -145, -191, -196a, -16, and let-7a) were under-expressed in CRC" +tissue_expression_down hsa-mir-215 Colorectal Adenocarcinoma 20413677 "miR-215:nine(miR-192, -215, -26b, -143, -145, -191, -196a, -16, and let-7a) were under-expressed in CRC" +tissue_expression_down hsa-mir-26b Colorectal Adenocarcinoma 20413677 "miR-26b:nine(miR-192, -215, -26b, -143, -145, -191, -196a, -16, and let-7a) were under-expressed in CRC" +tissue_expression_down hsa-mir-148a Gastrointestinal Neoplasms 20422307 MiR-148a:MiR-148a and miR-152 may be involved in the carcinogenesis of gastrointestinal cancers and might be potential biomarkers +tissue_expression_down hsa-mir-152 Gastrointestinal Neoplasms 20422307 MiR-152:MiR-148a and miR-152 may be involved in the carcinogenesis of gastrointestinal cancers and might be potential biomarkers +tissue_expression_down hsa-mir-103a-1 Neoplasms [unspecific] 20439436 "miR-103:hsa-miR-103/106 were downgraded in cancer, whereas hsa-miR-30 became most prominent" +tissue_expression_down hsa-mir-103a-2 Neoplasms [unspecific] 20439436 "miR-103:hsa-miR-103/106 were downgraded in cancer, whereas hsa-miR-30 became most prominent" +tissue_expression_down hsa-mir-106a Neoplasms [unspecific] 20439436 "miR-106:hsa-miR-103/106 were downgraded in cancer, whereas hsa-miR-30 became most prominent" +tissue_expression_down hsa-mir-200c Melanoma 20442294 "miRNA-200c:miRNA-200c to be consistently downregulated in melanocytes, melanoma cell lines, and patient samples, whereas miRNA-205 and miRNA-23b were markedly reduced only in patient samples" +tissue_expression_down hsa-mir-205 Melanoma 20442294 "miRNA-205:miRNA-200c to be consistently downregulated in melanocytes, melanoma cell lines, and patient samples, whereas miRNA-205 and miRNA-23b were markedly reduced only in patient samples" +tissue_expression_down hsa-mir-23b Melanoma 20442294 "miRNA-23b:miRNA-200c to be consistently downregulated in melanocytes, melanoma cell lines, and patient samples, whereas miRNA-205 and miRNA-23b were markedly reduced only in patient samples" +tissue_expression_down hsa-mir-34a Cervical Neoplasms 20442590 Reduced miR-34a expression in normal cervical tissues and cervical lesions with high-risk human papillomavirus infection. +tissue_expression_down hsa-mir-17 "Lymphoma, T-Cell" 20448109 mir-17:down-regulation of the miR-17-92 cluster in malignancy +tissue_expression_down hsa-mir-18a "Lymphoma, T-Cell" 20448109 mir-18a:down-regulation of the miR-17-92 cluster in malignancy +tissue_expression_down hsa-mir-19a "Lymphoma, T-Cell" 20448109 mir-19a:down-regulation of the miR-17-92 cluster in malignancy +tissue_expression_down hsa-mir-19b-1 "Lymphoma, T-Cell" 20448109 mir-19b:down-regulation of the miR-17-92 cluster in malignancy +tissue_expression_down hsa-mir-19b-2 "Lymphoma, T-Cell" 20448109 mir-19b:down-regulation of the miR-17-92 cluster in malignancy +tissue_expression_down hsa-mir-20a "Lymphoma, T-Cell" 20448109 mir-20a:down-regulation of the miR-17-92 cluster in malignancy +tissue_expression_down hsa-mir-92a-1 "Lymphoma, T-Cell" 20448109 mir-92a:down-regulation of the miR-17-92 cluster in malignancy +tissue_expression_down hsa-mir-92a-2 "Lymphoma, T-Cell" 20448109 mir-92a:down-regulation of the miR-17-92 cluster in malignancy +tissue_expression_down hsa-mir-132 Osteoarthritis 20470394 "In RA and OA, synovial fluid concentrations of miR-16, miR-132, miR-146a, and miR-223 were significantly lower than their plasma concentrations, and there were no correlation between plasma and synovial fluid miRNAs." +tissue_expression_down hsa-mir-146a Osteoarthritis 20470394 "In RA and OA, synovial fluid concentrations of miR-16, miR-132, miR-146a, and miR-223 were significantly lower than their plasma concentrations, and there were no correlation between plasma and synovial fluid miRNAs." +tissue_expression_down hsa-mir-16 Osteoarthritis 20470394 "In RA and OA, synovial fluid concentrations of miR-16, miR-132, miR-146a, and miR-223 were significantly lower than their plasma concentrations, and there were no correlation between plasma and synovial fluid miRNAs." +tissue_expression_down hsa-mir-223 Osteoarthritis 20470394 "In RA and OA, synovial fluid concentrations of miR-16, miR-132, miR-146a, and miR-223 were significantly lower than their plasma concentrations, and there were no correlation between plasma and synovial fluid miRNAs." +tissue_expression_down hsa-mir-200a Neoplasms [unspecific] 20484038 miR-200a:Downregulation of microRNA-200 in EBV-associated gastric carcinoma +tissue_expression_down hsa-mir-200b Neoplasms [unspecific] 20484038 miR-200b:Downregulation of microRNA-200 in EBV-associated gastric carcinoma +tissue_expression_down hsa-mir-200c Neoplasms [unspecific] 20484038 miR-200c:Downregulation of microRNA-200 in EBV-associated gastric carcinoma +tissue_expression_down hsa-mir-107 Heart Failure 20484156 miR-107: downregulated +tissue_expression_down hsa-mir-139 Heart Failure 20484156 miR-139: downregulated +tissue_expression_down hsa-mir-142 Heart Failure 20484156 miR-142-5p: downregulated +tissue_expression_down hsa-mir-100 Lung Neoplasms 20508945 "Seven miRNAs of hsa-miR-21, hsa-miR-31, hsa-miR-34a, hsa-miR-22*, hsa-miR-504, hsa-miR-18a, and hsa-miR-412 were observed to be upregulated greater than twofold in the squamous cell lung carcinoma tissues compared with normal tissues, whereas 23 miRNAs of hsa-miR-30a, hsa-miR-30d, hsa-miR-126, hsa-miR-652, hsa-miR-100, hsa-miR-143, hsa-miR-130a, hsa-miR-145, hsa-miR-30e, hsa-miR-126*, hsa-miR-181a, hsa-miR-125b, hsa-miR-886-3p, hsa-miR-451, hsa-miR-29c, hsa-miR-26b, hsa-miR-101, hsa-miR-320, hsa-miR-30b, hsa-miR-886-5p, hsa-miR-29a, hsa-miR-26a, and hsa-miR-99a were found to be downregulated greater than twofold." +tissue_expression_down hsa-mir-101 Lung Neoplasms 20508945 "Seven miRNAs of hsa-miR-21, hsa-miR-31, hsa-miR-34a, hsa-miR-22*, hsa-miR-504, hsa-miR-18a, and hsa-miR-412 were observed to be upregulated greater than twofold in the squamous cell lung carcinoma tissues compared with normal tissues, whereas 23 miRNAs of hsa-miR-30a, hsa-miR-30d, hsa-miR-126, hsa-miR-652, hsa-miR-100, hsa-miR-143, hsa-miR-130a, hsa-miR-145, hsa-miR-30e, hsa-miR-126*, hsa-miR-181a, hsa-miR-125b, hsa-miR-886-3p, hsa-miR-451, hsa-miR-29c, hsa-miR-26b, hsa-miR-101, hsa-miR-320, hsa-miR-30b, hsa-miR-886-5p, hsa-miR-29a, hsa-miR-26a, and hsa-miR-99a were found to be downregulated greater than twofold." +tissue_expression_down hsa-mir-125b Lung Neoplasms 20508945 "Seven miRNAs of hsa-miR-21, hsa-miR-31, hsa-miR-34a, hsa-miR-22*, hsa-miR-504, hsa-miR-18a, and hsa-miR-412 were observed to be upregulated greater than twofold in the squamous cell lung carcinoma tissues compared with normal tissues, whereas 23 miRNAs of hsa-miR-30a, hsa-miR-30d, hsa-miR-126, hsa-miR-652, hsa-miR-100, hsa-miR-143, hsa-miR-130a, hsa-miR-145, hsa-miR-30e, hsa-miR-126*, hsa-miR-181a, hsa-miR-125b, hsa-miR-886-3p, hsa-miR-451, hsa-miR-29c, hsa-miR-26b, hsa-miR-101, hsa-miR-320, hsa-miR-30b, hsa-miR-886-5p, hsa-miR-29a, hsa-miR-26a, and hsa-miR-99a were found to be downregulated greater than twofold." +tissue_expression_down hsa-mir-126 Lung Neoplasms 20508945 "Seven miRNAs of hsa-miR-21, hsa-miR-31, hsa-miR-34a, hsa-miR-22*, hsa-miR-504, hsa-miR-18a, and hsa-miR-412 were observed to be upregulated greater than twofold in the squamous cell lung carcinoma tissues compared with normal tissues, whereas 23 miRNAs of hsa-miR-30a, hsa-miR-30d, hsa-miR-126, hsa-miR-652, hsa-miR-100, hsa-miR-143, hsa-miR-130a, hsa-miR-145, hsa-miR-30e, hsa-miR-126*, hsa-miR-181a, hsa-miR-125b, hsa-miR-886-3p, hsa-miR-451, hsa-miR-29c, hsa-miR-26b, hsa-miR-101, hsa-miR-320, hsa-miR-30b, hsa-miR-886-5p, hsa-miR-29a, hsa-miR-26a, and hsa-miR-99a were found to be downregulated greater than twofold." +tissue_expression_down hsa-mir-130a Lung Neoplasms 20508945 "Seven miRNAs of hsa-miR-21, hsa-miR-31, hsa-miR-34a, hsa-miR-22*, hsa-miR-504, hsa-miR-18a, and hsa-miR-412 were observed to be upregulated greater than twofold in the squamous cell lung carcinoma tissues compared with normal tissues, whereas 23 miRNAs of hsa-miR-30a, hsa-miR-30d, hsa-miR-126, hsa-miR-652, hsa-miR-100, hsa-miR-143, hsa-miR-130a, hsa-miR-145, hsa-miR-30e, hsa-miR-126*, hsa-miR-181a, hsa-miR-125b, hsa-miR-886-3p, hsa-miR-451, hsa-miR-29c, hsa-miR-26b, hsa-miR-101, hsa-miR-320, hsa-miR-30b, hsa-miR-886-5p, hsa-miR-29a, hsa-miR-26a, and hsa-miR-99a were found to be downregulated greater than twofold." +tissue_expression_down hsa-mir-143 Lung Neoplasms 20508945 "Seven miRNAs of hsa-miR-21, hsa-miR-31, hsa-miR-34a, hsa-miR-22*, hsa-miR-504, hsa-miR-18a, and hsa-miR-412 were observed to be upregulated greater than twofold in the squamous cell lung carcinoma tissues compared with normal tissues, whereas 23 miRNAs of hsa-miR-30a, hsa-miR-30d, hsa-miR-126, hsa-miR-652, hsa-miR-100, hsa-miR-143, hsa-miR-130a, hsa-miR-145, hsa-miR-30e, hsa-miR-126*, hsa-miR-181a, hsa-miR-125b, hsa-miR-886-3p, hsa-miR-451, hsa-miR-29c, hsa-miR-26b, hsa-miR-101, hsa-miR-320, hsa-miR-30b, hsa-miR-886-5p, hsa-miR-29a, hsa-miR-26a, and hsa-miR-99a were found to be downregulated greater than twofold." +tissue_expression_down hsa-mir-145 Lung Neoplasms 20508945 "Seven miRNAs of hsa-miR-21, hsa-miR-31, hsa-miR-34a, hsa-miR-22*, hsa-miR-504, hsa-miR-18a, and hsa-miR-412 were observed to be upregulated greater than twofold in the squamous cell lung carcinoma tissues compared with normal tissues, whereas 23 miRNAs of hsa-miR-30a, hsa-miR-30d, hsa-miR-126, hsa-miR-652, hsa-miR-100, hsa-miR-143, hsa-miR-130a, hsa-miR-145, hsa-miR-30e, hsa-miR-126*, hsa-miR-181a, hsa-miR-125b, hsa-miR-886-3p, hsa-miR-451, hsa-miR-29c, hsa-miR-26b, hsa-miR-101, hsa-miR-320, hsa-miR-30b, hsa-miR-886-5p, hsa-miR-29a, hsa-miR-26a, and hsa-miR-99a were found to be downregulated greater than twofold." +tissue_expression_down hsa-mir-181a Lung Neoplasms 20508945 "Seven miRNAs of hsa-miR-21, hsa-miR-31, hsa-miR-34a, hsa-miR-22*, hsa-miR-504, hsa-miR-18a, and hsa-miR-412 were observed to be upregulated greater than twofold in the squamous cell lung carcinoma tissues compared with normal tissues, whereas 23 miRNAs of hsa-miR-30a, hsa-miR-30d, hsa-miR-126, hsa-miR-652, hsa-miR-100, hsa-miR-143, hsa-miR-130a, hsa-miR-145, hsa-miR-30e, hsa-miR-126*, hsa-miR-181a, hsa-miR-125b, hsa-miR-886-3p, hsa-miR-451, hsa-miR-29c, hsa-miR-26b, hsa-miR-101, hsa-miR-320, hsa-miR-30b, hsa-miR-886-5p, hsa-miR-29a, hsa-miR-26a, and hsa-miR-99a were found to be downregulated greater than twofold." +tissue_expression_down hsa-mir-26a Lung Neoplasms 20508945 "Seven miRNAs of hsa-miR-21, hsa-miR-31, hsa-miR-34a, hsa-miR-22*, hsa-miR-504, hsa-miR-18a, and hsa-miR-412 were observed to be upregulated greater than twofold in the squamous cell lung carcinoma tissues compared with normal tissues, whereas 23 miRNAs of hsa-miR-30a, hsa-miR-30d, hsa-miR-126, hsa-miR-652, hsa-miR-100, hsa-miR-143, hsa-miR-130a, hsa-miR-145, hsa-miR-30e, hsa-miR-126*, hsa-miR-181a, hsa-miR-125b, hsa-miR-886-3p, hsa-miR-451, hsa-miR-29c, hsa-miR-26b, hsa-miR-101, hsa-miR-320, hsa-miR-30b, hsa-miR-886-5p, hsa-miR-29a, hsa-miR-26a, and hsa-miR-99a were found to be downregulated greater than twofold." +tissue_expression_down hsa-mir-26b Lung Neoplasms 20508945 "Seven miRNAs of hsa-miR-21, hsa-miR-31, hsa-miR-34a, hsa-miR-22*, hsa-miR-504, hsa-miR-18a, and hsa-miR-412 were observed to be upregulated greater than twofold in the squamous cell lung carcinoma tissues compared with normal tissues, whereas 23 miRNAs of hsa-miR-30a, hsa-miR-30d, hsa-miR-126, hsa-miR-652, hsa-miR-100, hsa-miR-143, hsa-miR-130a, hsa-miR-145, hsa-miR-30e, hsa-miR-126*, hsa-miR-181a, hsa-miR-125b, hsa-miR-886-3p, hsa-miR-451, hsa-miR-29c, hsa-miR-26b, hsa-miR-101, hsa-miR-320, hsa-miR-30b, hsa-miR-886-5p, hsa-miR-29a, hsa-miR-26a, and hsa-miR-99a were found to be downregulated greater than twofold." +tissue_expression_down hsa-mir-29a Lung Neoplasms 20508945 "Seven miRNAs of hsa-miR-21, hsa-miR-31, hsa-miR-34a, hsa-miR-22*, hsa-miR-504, hsa-miR-18a, and hsa-miR-412 were observed to be upregulated greater than twofold in the squamous cell lung carcinoma tissues compared with normal tissues, whereas 23 miRNAs of hsa-miR-30a, hsa-miR-30d, hsa-miR-126, hsa-miR-652, hsa-miR-100, hsa-miR-143, hsa-miR-130a, hsa-miR-145, hsa-miR-30e, hsa-miR-126*, hsa-miR-181a, hsa-miR-125b, hsa-miR-886-3p, hsa-miR-451, hsa-miR-29c, hsa-miR-26b, hsa-miR-101, hsa-miR-320, hsa-miR-30b, hsa-miR-886-5p, hsa-miR-29a, hsa-miR-26a, and hsa-miR-99a were found to be downregulated greater than twofold." +tissue_expression_down hsa-mir-29c Lung Neoplasms 20508945 "Seven miRNAs of hsa-miR-21, hsa-miR-31, hsa-miR-34a, hsa-miR-22*, hsa-miR-504, hsa-miR-18a, and hsa-miR-412 were observed to be upregulated greater than twofold in the squamous cell lung carcinoma tissues compared with normal tissues, whereas 23 miRNAs of hsa-miR-30a, hsa-miR-30d, hsa-miR-126, hsa-miR-652, hsa-miR-100, hsa-miR-143, hsa-miR-130a, hsa-miR-145, hsa-miR-30e, hsa-miR-126*, hsa-miR-181a, hsa-miR-125b, hsa-miR-886-3p, hsa-miR-451, hsa-miR-29c, hsa-miR-26b, hsa-miR-101, hsa-miR-320, hsa-miR-30b, hsa-miR-886-5p, hsa-miR-29a, hsa-miR-26a, and hsa-miR-99a were found to be downregulated greater than twofold." +tissue_expression_down hsa-mir-30a Lung Neoplasms 20508945 "Seven miRNAs of hsa-miR-21, hsa-miR-31, hsa-miR-34a, hsa-miR-22*, hsa-miR-504, hsa-miR-18a, and hsa-miR-412 were observed to be upregulated greater than twofold in the squamous cell lung carcinoma tissues compared with normal tissues, whereas 23 miRNAs of hsa-miR-30a, hsa-miR-30d, hsa-miR-126, hsa-miR-652, hsa-miR-100, hsa-miR-143, hsa-miR-130a, hsa-miR-145, hsa-miR-30e, hsa-miR-126*, hsa-miR-181a, hsa-miR-125b, hsa-miR-886-3p, hsa-miR-451, hsa-miR-29c, hsa-miR-26b, hsa-miR-101, hsa-miR-320, hsa-miR-30b, hsa-miR-886-5p, hsa-miR-29a, hsa-miR-26a, and hsa-miR-99a were found to be downregulated greater than twofold." +tissue_expression_down hsa-mir-30b Lung Neoplasms 20508945 "Seven miRNAs of hsa-miR-21, hsa-miR-31, hsa-miR-34a, hsa-miR-22*, hsa-miR-504, hsa-miR-18a, and hsa-miR-412 were observed to be upregulated greater than twofold in the squamous cell lung carcinoma tissues compared with normal tissues, whereas 23 miRNAs of hsa-miR-30a, hsa-miR-30d, hsa-miR-126, hsa-miR-652, hsa-miR-100, hsa-miR-143, hsa-miR-130a, hsa-miR-145, hsa-miR-30e, hsa-miR-126*, hsa-miR-181a, hsa-miR-125b, hsa-miR-886-3p, hsa-miR-451, hsa-miR-29c, hsa-miR-26b, hsa-miR-101, hsa-miR-320, hsa-miR-30b, hsa-miR-886-5p, hsa-miR-29a, hsa-miR-26a, and hsa-miR-99a were found to be downregulated greater than twofold." +tissue_expression_down hsa-mir-30d Lung Neoplasms 20508945 "Seven miRNAs of hsa-miR-21, hsa-miR-31, hsa-miR-34a, hsa-miR-22*, hsa-miR-504, hsa-miR-18a, and hsa-miR-412 were observed to be upregulated greater than twofold in the squamous cell lung carcinoma tissues compared with normal tissues, whereas 23 miRNAs of hsa-miR-30a, hsa-miR-30d, hsa-miR-126, hsa-miR-652, hsa-miR-100, hsa-miR-143, hsa-miR-130a, hsa-miR-145, hsa-miR-30e, hsa-miR-126*, hsa-miR-181a, hsa-miR-125b, hsa-miR-886-3p, hsa-miR-451, hsa-miR-29c, hsa-miR-26b, hsa-miR-101, hsa-miR-320, hsa-miR-30b, hsa-miR-886-5p, hsa-miR-29a, hsa-miR-26a, and hsa-miR-99a were found to be downregulated greater than twofold." +tissue_expression_down hsa-mir-30e Lung Neoplasms 20508945 "Seven miRNAs of hsa-miR-21, hsa-miR-31, hsa-miR-34a, hsa-miR-22*, hsa-miR-504, hsa-miR-18a, and hsa-miR-412 were observed to be upregulated greater than twofold in the squamous cell lung carcinoma tissues compared with normal tissues, whereas 23 miRNAs of hsa-miR-30a, hsa-miR-30d, hsa-miR-126, hsa-miR-652, hsa-miR-100, hsa-miR-143, hsa-miR-130a, hsa-miR-145, hsa-miR-30e, hsa-miR-126*, hsa-miR-181a, hsa-miR-125b, hsa-miR-886-3p, hsa-miR-451, hsa-miR-29c, hsa-miR-26b, hsa-miR-101, hsa-miR-320, hsa-miR-30b, hsa-miR-886-5p, hsa-miR-29a, hsa-miR-26a, and hsa-miR-99a were found to be downregulated greater than twofold." +tissue_expression_down hsa-mir-320 Lung Neoplasms 20508945 "Seven miRNAs of hsa-miR-21, hsa-miR-31, hsa-miR-34a, hsa-miR-22*, hsa-miR-504, hsa-miR-18a, and hsa-miR-412 were observed to be upregulated greater than twofold in the squamous cell lung carcinoma tissues compared with normal tissues, whereas 23 miRNAs of hsa-miR-30a, hsa-miR-30d, hsa-miR-126, hsa-miR-652, hsa-miR-100, hsa-miR-143, hsa-miR-130a, hsa-miR-145, hsa-miR-30e, hsa-miR-126*, hsa-miR-181a, hsa-miR-125b, hsa-miR-886-3p, hsa-miR-451, hsa-miR-29c, hsa-miR-26b, hsa-miR-101, hsa-miR-320, hsa-miR-30b, hsa-miR-886-5p, hsa-miR-29a, hsa-miR-26a, and hsa-miR-99a were found to be downregulated greater than twofold." +tissue_expression_down hsa-mir-451 Lung Neoplasms 20508945 "Seven miRNAs of hsa-miR-21, hsa-miR-31, hsa-miR-34a, hsa-miR-22*, hsa-miR-504, hsa-miR-18a, and hsa-miR-412 were observed to be upregulated greater than twofold in the squamous cell lung carcinoma tissues compared with normal tissues, whereas 23 miRNAs of hsa-miR-30a, hsa-miR-30d, hsa-miR-126, hsa-miR-652, hsa-miR-100, hsa-miR-143, hsa-miR-130a, hsa-miR-145, hsa-miR-30e, hsa-miR-126*, hsa-miR-181a, hsa-miR-125b, hsa-miR-886-3p, hsa-miR-451, hsa-miR-29c, hsa-miR-26b, hsa-miR-101, hsa-miR-320, hsa-miR-30b, hsa-miR-886-5p, hsa-miR-29a, hsa-miR-26a, and hsa-miR-99a were found to be downregulated greater than twofold." +tissue_expression_down hsa-mir-652 Lung Neoplasms 20508945 "Seven miRNAs of hsa-miR-21, hsa-miR-31, hsa-miR-34a, hsa-miR-22*, hsa-miR-504, hsa-miR-18a, and hsa-miR-412 were observed to be upregulated greater than twofold in the squamous cell lung carcinoma tissues compared with normal tissues, whereas 23 miRNAs of hsa-miR-30a, hsa-miR-30d, hsa-miR-126, hsa-miR-652, hsa-miR-100, hsa-miR-143, hsa-miR-130a, hsa-miR-145, hsa-miR-30e, hsa-miR-126*, hsa-miR-181a, hsa-miR-125b, hsa-miR-886-3p, hsa-miR-451, hsa-miR-29c, hsa-miR-26b, hsa-miR-101, hsa-miR-320, hsa-miR-30b, hsa-miR-886-5p, hsa-miR-29a, hsa-miR-26a, and hsa-miR-99a were found to be downregulated greater than twofold." +tissue_expression_down hsa-mir-886 Lung Neoplasms 20508945 "Seven miRNAs of hsa-miR-21, hsa-miR-31, hsa-miR-34a, hsa-miR-22*, hsa-miR-504, hsa-miR-18a, and hsa-miR-412 were observed to be upregulated greater than twofold in the squamous cell lung carcinoma tissues compared with normal tissues, whereas 23 miRNAs of hsa-miR-30a, hsa-miR-30d, hsa-miR-126, hsa-miR-652, hsa-miR-100, hsa-miR-143, hsa-miR-130a, hsa-miR-145, hsa-miR-30e, hsa-miR-126*, hsa-miR-181a, hsa-miR-125b, hsa-miR-886-3p, hsa-miR-451, hsa-miR-29c, hsa-miR-26b, hsa-miR-101, hsa-miR-320, hsa-miR-30b, hsa-miR-886-5p, hsa-miR-29a, hsa-miR-26a, and hsa-miR-99a were found to be downregulated greater than twofold." +tissue_expression_down hsa-mir-99a Lung Neoplasms 20508945 "Seven miRNAs of hsa-miR-21, hsa-miR-31, hsa-miR-34a, hsa-miR-22*, hsa-miR-504, hsa-miR-18a, and hsa-miR-412 were observed to be upregulated greater than twofold in the squamous cell lung carcinoma tissues compared with normal tissues, whereas 23 miRNAs of hsa-miR-30a, hsa-miR-30d, hsa-miR-126, hsa-miR-652, hsa-miR-100, hsa-miR-143, hsa-miR-130a, hsa-miR-145, hsa-miR-30e, hsa-miR-126*, hsa-miR-181a, hsa-miR-125b, hsa-miR-886-3p, hsa-miR-451, hsa-miR-29c, hsa-miR-26b, hsa-miR-101, hsa-miR-320, hsa-miR-30b, hsa-miR-886-5p, hsa-miR-29a, hsa-miR-26a, and hsa-miR-99a were found to be downregulated greater than twofold." +tissue_expression_down hsa-mir-218 Gastrointestinal Neoplasms 20510072 miR-218 expression is reduced in gastric cancer. miR-218 may function as a tumor suppressor in gastric carcinoma. +tissue_expression_down hsa-mir-125a "Carcinoma, Lung, Non-Small-Cell" 20569443 miR-125a-3p:Hsa-miR-125a-3p and hsa-miR-125a-5p are downregulated in non-small cell lung cancer +tissue_expression_down hsa-mir-34a Melanoma 20606648 miR-34a delivered by the GC4-targeted nanoparticles significantly downregulated the survivin expression in the metastatic tumor and reduced tumor load in the lung. +tissue_expression_down hsa-mir-106b "Carcinoma, Renal Cell" 20609231 miRNA-106b:Expression of miRNA-106b in conventional renal cell carcinoma is a potential marker for prediction of early metastasis after nephrectomy +tissue_expression_down hsa-mir-101-1 "Squamous Cell Carcinoma, Lung" 20620595 "miR-101:Seven human miRNAs (miR-126, miR-193a-3p, miR-30d, miR-30a, miR-101, let-7i, and miR-15a) were found to be significantly downregulated in lung SCC" +tissue_expression_down hsa-mir-101-2 "Squamous Cell Carcinoma, Lung" 20620595 "miR-101:Seven human miRNAs (miR-126, miR-193a-3p, miR-30d, miR-30a, miR-101, let-7i, and miR-15a) were found to be significantly downregulated in lung SCC" +tissue_expression_down hsa-mir-126 "Squamous Cell Carcinoma, Lung" 20620595 "miR-126:Seven human miRNAs (miR-126, miR-193a-3p, miR-30d, miR-30a, miR-101, let-7i, and miR-15a) were found to be significantly downregulated in lung SCC" +tissue_expression_down hsa-mir-15a "Squamous Cell Carcinoma, Lung" 20620595 "miR-15a:Seven human miRNAs (miR-126, miR-193a-3p, miR-30d, miR-30a, miR-101, let-7i, and miR-15a) were found to be significantly downregulated in lung SCC" +tissue_expression_down hsa-mir-193a "Squamous Cell Carcinoma, Lung" 20620595 "miR-193a-3p:Seven human miRNAs (miR-126, miR-193a-3p, miR-30d, miR-30a, miR-101, let-7i, and miR-15a) were found to be significantly downregulated in lung SCC" +tissue_expression_down hsa-mir-30a "Squamous Cell Carcinoma, Lung" 20620595 "miR-30a:Seven human miRNAs (miR-126, miR-193a-3p, miR-30d, miR-30a, miR-101, let-7i, and miR-15a) were found to be significantly downregulated in lung SCC" +tissue_expression_down hsa-mir-30d "Squamous Cell Carcinoma, Lung" 20620595 "miR-30d:Seven human miRNAs (miR-126, miR-193a-3p, miR-30d, miR-30a, miR-101, let-7i, and miR-15a) were found to be significantly downregulated in lung SCC" +tissue_expression_down hsa-mir-520h Pancreatic Neoplasms 20628378 "miR-520h:miR-520h downregulates ABCG2 in pancreatic cancer cells to inhibit migration, invasion, and side populations" +tissue_expression_down hsa-let-7e Adenovirus Infection 20634878 let-7e:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control +tissue_expression_down hsa-mir-101-1 Adenovirus Infection 20634878 miR-101-1:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control +tissue_expression_down hsa-mir-101-2 Adenovirus Infection 20634878 miR-101-2:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control +tissue_expression_down hsa-mir-1180 Adenovirus Infection 20634878 hsa-mir-1180:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control +tissue_expression_down hsa-mir-1184-1 Adenovirus Infection 20634878 miR-1184:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control +tissue_expression_down hsa-mir-125b-1 Adenovirus Infection 20634878 miR-125b-1:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control +tissue_expression_down hsa-mir-125b-2 Adenovirus Infection 20634878 miR-125b-2:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control +tissue_expression_down hsa-mir-148a Adenovirus Infection 20634878 miR-148a:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control +tissue_expression_down hsa-mir-148b Adenovirus Infection 20634878 miR-148b:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control +tissue_expression_down hsa-mir-181b-1 Adenovirus Infection 20634878 miR-181b-1:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control +tissue_expression_down hsa-mir-181b-2 Adenovirus Infection 20634878 miR-181b-2:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control +tissue_expression_down hsa-mir-18b Adenovirus Infection 20634878 miR-18b:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control +tissue_expression_down hsa-mir-196b Adenovirus Infection 20634878 miR-196b:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control +tissue_expression_down hsa-mir-19b-1 Adenovirus Infection 20634878 miR-19b-1:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control +tissue_expression_down hsa-mir-19b-2 Adenovirus Infection 20634878 miR-19b-2:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control +tissue_expression_down hsa-mir-210 Adenovirus Infection 20634878 miR-210:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control +tissue_expression_down hsa-mir-219-1 Adenovirus Infection 20634878 miR-219-1:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control +tissue_expression_down hsa-mir-25 Adenovirus Infection 20634878 miR-25:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control +tissue_expression_down hsa-mir-26b Adenovirus Infection 20634878 miR-26b:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control +tissue_expression_down hsa-mir-27a Adenovirus Infection 20634878 miR-27a:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control +tissue_expression_down hsa-mir-27b Adenovirus Infection 20634878 miR-27b:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control +tissue_expression_down hsa-mir-30a Adenovirus Infection 20634878 miR-30a:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control +tissue_expression_down hsa-mir-30b Adenovirus Infection 20634878 miR-30b:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control +tissue_expression_down hsa-mir-30c-1 Adenovirus Infection 20634878 miR-30c-1:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control +tissue_expression_down hsa-mir-30c-2 Adenovirus Infection 20634878 miR-30c-2:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control +tissue_expression_down hsa-mir-338 Adenovirus Infection 20634878 miR-338:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control +tissue_expression_down hsa-mir-33a Adenovirus Infection 20634878 miR-33a:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control +tissue_expression_down hsa-mir-34a Adenovirus Infection 20634878 miR-34a:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control +tissue_expression_down hsa-mir-362 Adenovirus Infection 20634878 miR-362:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control +tissue_expression_down hsa-mir-374b Adenovirus Infection 20634878 miR-374b:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control +tissue_expression_down hsa-mir-421 Adenovirus Infection 20634878 miR-421:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control +tissue_expression_down hsa-mir-433 Adenovirus Infection 20634878 miR-433:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control +tissue_expression_down hsa-mir-452 Adenovirus Infection 20634878 miR-452:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control +tissue_expression_down hsa-mir-519a-1 Adenovirus Infection 20634878 miR-519a-1:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control +tissue_expression_down hsa-mir-582 Adenovirus Infection 20634878 miR-582:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control +tissue_expression_down hsa-mir-619 Adenovirus Infection 20634878 miR-619:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control +tissue_expression_down hsa-mir-650 Adenovirus Infection 20634878 miR-650:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control +tissue_expression_down hsa-mir-655 Adenovirus Infection 20634878 miR-655:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control +tissue_expression_down hsa-mir-92a-2 Adenovirus Infection 20634878 miR-92a-2:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control +tissue_expression_down hsa-mir-451 Glioblastoma 20647762 We initially identified miR-451 due to its downregulation in a glioma cell migration assay. +tissue_expression_down hsa-mir-142 Squamous Cell Carcinoma 20652977 "The miRNAs miR-363, miR-33, and miR-497 were upregulated, whereas miR-155, miR-181a, miR-181b, miR-29a, miR-218, miR-222, miR-221, and miR-142-5p were downregulated in HPV-positive cells compared to both HPV-negative SCCHN and normal oral keratinocytes." +tissue_expression_down hsa-mir-155 Squamous Cell Carcinoma 20652977 "The miRNAs miR-363, miR-33, and miR-497 were upregulated, whereas miR-155, miR-181a, miR-181b, miR-29a, miR-218, miR-222, miR-221, and miR-142-5p were downregulated in HPV-positive cells compared to both HPV-negative SCCHN and normal oral keratinocytes." +tissue_expression_down hsa-mir-181a Squamous Cell Carcinoma 20652977 "The miRNAs miR-363, miR-33, and miR-497 were upregulated, whereas miR-155, miR-181a, miR-181b, miR-29a, miR-218, miR-222, miR-221, and miR-142-5p were downregulated in HPV-positive cells compared to both HPV-negative SCCHN and normal oral keratinocytes." +tissue_expression_down hsa-mir-181b Squamous Cell Carcinoma 20652977 "The miRNAs miR-363, miR-33, and miR-497 were upregulated, whereas miR-155, miR-181a, miR-181b, miR-29a, miR-218, miR-222, miR-221, and miR-142-5p were downregulated in HPV-positive cells compared to both HPV-negative SCCHN and normal oral keratinocytes." +tissue_expression_down hsa-mir-218 Squamous Cell Carcinoma 20652977 "The miRNAs miR-363, miR-33, and miR-497 were upregulated, whereas miR-155, miR-181a, miR-181b, miR-29a, miR-218, miR-222, miR-221, and miR-142-5p were downregulated in HPV-positive cells compared to both HPV-negative SCCHN and normal oral keratinocytes." +tissue_expression_down hsa-mir-221 Squamous Cell Carcinoma 20652977 "The miRNAs miR-363, miR-33, and miR-497 were upregulated, whereas miR-155, miR-181a, miR-181b, miR-29a, miR-218, miR-222, miR-221, and miR-142-5p were downregulated in HPV-positive cells compared to both HPV-negative SCCHN and normal oral keratinocytes." +tissue_expression_down hsa-mir-222 Squamous Cell Carcinoma 20652977 "The miRNAs miR-363, miR-33, and miR-497 were upregulated, whereas miR-155, miR-181a, miR-181b, miR-29a, miR-218, miR-222, miR-221, and miR-142-5p were downregulated in HPV-positive cells compared to both HPV-negative SCCHN and normal oral keratinocytes." +tissue_expression_down hsa-mir-29a Squamous Cell Carcinoma 20652977 "The miRNAs miR-363, miR-33, and miR-497 were upregulated, whereas miR-155, miR-181a, miR-181b, miR-29a, miR-218, miR-222, miR-221, and miR-142-5p were downregulated in HPV-positive cells compared to both HPV-negative SCCHN and normal oral keratinocytes." +tissue_expression_down hsa-mir-218 Astrocytoma 20711171 Inhibition of two glioblastoma-upregulated miRNAs (miR-21 and miR-23a) and exogenous overexpression of two glioblastoma-downregulated miRNAs (miR-218 and miR-219-5p) resulted in reduced soft agar colony formation but showed varying effects on cell proliferation and chemosensitivity. +tissue_expression_down hsa-mir-219 Astrocytoma 20711171 Inhibition of two glioblastoma-upregulated miRNAs (miR-21 and miR-23a) and exogenous overexpression of two glioblastoma-downregulated miRNAs (miR-218 and miR-219-5p) resulted in reduced soft agar colony formation but showed varying effects on cell proliferation and chemosensitivity. +tissue_expression_down hsa-mir-17 Multiple Sclerosis 20711463 "In all MS subtypes miR-17 and miR-20a were significantly under-expressed in MS, confirmed by RT-PCR. " +tissue_expression_down hsa-mir-20a Multiple Sclerosis 20711463 "In all MS subtypes miR-17 and miR-20a were significantly under-expressed in MS, confirmed by RT-PCR. " +tissue_expression_down hsa-mir-145 Ovarian Neoplasms 20716115 "Reduced miR-145 and miR-214 and elevated let-7f, miR-182, miR-210, miR-200c, miR-222 and miR-23a levels were found in effusions in both sets." +tissue_expression_down hsa-mir-214 Ovarian Neoplasms 20716115 "Reduced miR-145 and miR-214 and elevated let-7f, miR-182, miR-210, miR-200c, miR-222 and miR-23a levels were found in effusions in both sets." +tissue_expression_down hsa-mir-126 Breast Neoplasms 20801493 "A high correlation of miRNA expression level was found between breast tumor tissues and sera. MiR-21, miR-106a and miR-155 were significantly over-expressed in the tumor specimens compared with those in normal controls (P < 0.05), whereas miR-126, miR-199a and miR-335 were significantly under-expressed (P < 0.05)." +tissue_expression_down hsa-mir-199a Breast Neoplasms 20801493 "A high correlation of miRNA expression level was found between breast tumor tissues and sera. MiR-21, miR-106a and miR-155 were significantly over-expressed in the tumor specimens compared with those in normal controls (P < 0.05), whereas miR-126, miR-199a and miR-335 were significantly under-expressed (P < 0.05)." +tissue_expression_down hsa-mir-335 Breast Neoplasms 20801493 "A high correlation of miRNA expression level was found between breast tumor tissues and sera. MiR-21, miR-106a and miR-155 were significantly over-expressed in the tumor specimens compared with those in normal controls (P < 0.05), whereas miR-126, miR-199a and miR-335 were significantly under-expressed (P < 0.05)." +tissue_expression_down hsa-mir-1-1 Laryngeal Neoplasms 20806854 downregulated by 5 multiple +tissue_expression_down hsa-mir-1-2 Laryngeal Neoplasms 20806854 downregulated by 5 multiple +tissue_expression_down hsa-mir-133a-1 Laryngeal Neoplasms 20806854 downregulated by 5 multiple +tissue_expression_down hsa-mir-133a-2 Laryngeal Neoplasms 20806854 downregulated by 5 multiple +tissue_expression_down hsa-mir-144 Laryngeal Neoplasms 20806854 downregulated by 5 multiple +tissue_expression_down hsa-mir-206 Laryngeal Neoplasms 20806854 downregulated by 5 multiple +tissue_expression_down hsa-mir-375 Laryngeal Neoplasms 20806854 downregulated by 5 multiple +tissue_expression_down hsa-mir-378a Laryngeal Neoplasms 20806854 downregulated by 5 multiple +tissue_expression_down hsa-mir-384 Laryngeal Neoplasms 20806854 downregulated by 5 multiple +tissue_expression_down hsa-mir-422a Laryngeal Neoplasms 20806854 downregulated by 5 multiple +tissue_expression_down hsa-mir-486 Laryngeal Neoplasms 20806854 miR-486-5p: downregulated by 5 multiple +tissue_expression_down hsa-mir-487a Laryngeal Neoplasms 20806854 downregulated by 5 multiple +tissue_expression_down hsa-mir-21 Spinal Cord Injuries 20816819 "spinal cord injury (SCI)results in increased expression of miR Let-7a and miR16 while exercise leads to elevated levels of miR21 and decreased levels of miR15b. These changes in miR expression are correlated with changes in expression of their target genes: pro-apoptotic (decreased PTEN, PDCD4, and RAS mRNA) and anti-apoptotic (increased Bcl-2 mRNA) target genes. This is accompanied by a down-regulation of mRNA for caspase-7 and caspase-9 and reduced levels of caspase-7 protein." +tissue_expression_down hsa-mir-125b Melanoma 20827223 Downregulation of miR-125b in metastatic cutaneous malignant melanoma. +tissue_expression_down hsa-mir-195 Aortic Insufficiency 20845893 "miR-195:MiR-26a, miR-30b, and miR-195 were each decreased in the aortic valves of patients requiring AVR due to AS, compared to those requiring replacement due to AI." +tissue_expression_down hsa-mir-195 Aortic Stenosis 20845893 "miR-195:MiR-26a, miR-30b, and miR-195 were each decreased in the aortic valves of patients requiring AVR due to AS, compared to those requiring replacement due to AI." +tissue_expression_down hsa-mir-195 Chronic Heart Failure 20845893 "miR-195:MiR-26a, miR-30b, and miR-195 were each decreased in the aortic valves of patients requiring AVR due to AS, compared to those requiring replacement due to AI." +tissue_expression_down hsa-mir-26a-1 Aortic Insufficiency 20845893 "MiR-26a:MiR-26a, miR-30b, and miR-195 were each decreased in the aortic valves of patients requiring AVR due to AS, compared to those requiring replacement due to AI." +tissue_expression_down hsa-mir-26a-1 Aortic Stenosis 20845893 "MiR-26a:MiR-26a, miR-30b, and miR-195 were each decreased in the aortic valves of patients requiring AVR due to AS, compared to those requiring replacement due to AI." +tissue_expression_down hsa-mir-26a-1 Chronic Heart Failure 20845893 "MiR-26a:MiR-26a, miR-30b, and miR-195 were each decreased in the aortic valves of patients requiring AVR due to AS, compared to those requiring replacement due to AI." +tissue_expression_down hsa-mir-26a-2 Aortic Insufficiency 20845893 "MiR-26a:MiR-26a, miR-30b, and miR-195 were each decreased in the aortic valves of patients requiring AVR due to AS, compared to those requiring replacement due to AI." +tissue_expression_down hsa-mir-26a-2 Aortic Stenosis 20845893 "MiR-26a:MiR-26a, miR-30b, and miR-195 were each decreased in the aortic valves of patients requiring AVR due to AS, compared to those requiring replacement due to AI." +tissue_expression_down hsa-mir-26a-2 Chronic Heart Failure 20845893 "MiR-26a:MiR-26a, miR-30b, and miR-195 were each decreased in the aortic valves of patients requiring AVR due to AS, compared to those requiring replacement due to AI." +tissue_expression_down hsa-mir-30b Aortic Insufficiency 20845893 "MiR-30b:MiR-26a, miR-30b, and miR-195 were each decreased in the aortic valves of patients requiring AVR due to AS, compared to those requiring replacement due to AI." +tissue_expression_down hsa-mir-30b Aortic Stenosis 20845893 "MiR-30b:MiR-26a, miR-30b, and miR-195 were each decreased in the aortic valves of patients requiring AVR due to AS, compared to those requiring replacement due to AI." +tissue_expression_down hsa-mir-30b Chronic Heart Failure 20845893 "MiR-30b:MiR-26a, miR-30b, and miR-195 were each decreased in the aortic valves of patients requiring AVR due to AS, compared to those requiring replacement due to AI." +tissue_expression_down hsa-mir-21 Neuroma 20856158 miR-21:Elevated levels of hsa-microRNA-21 (miR-21) in vestibular schwannomas (VSs) may contribute to tumor growth by downregulating the tumor suppressor phosphatase and tensin homolog (PTEN) and consequent hyperactivation of protein kinase B +tissue_expression_down hsa-mir-126 Colon Neoplasms 20859756 "miR-126:In particular, miR-126, miR-142-3p, miR-155, miR-552, and miR-630 were all upregulated, whereas miR-146a, miR-152, miR-205, miR-365, miR-449, miR-518c, miR-584, miR-615, and miR-622 were downregulated after NGX6 transfection." +tissue_expression_down hsa-mir-142 Colon Neoplasms 20859756 "miR-142-3p:In particular, miR-126, miR-142-3p, miR-155, miR-552, and miR-630 were all upregulated, whereas miR-146a, miR-152, miR-205, miR-365, miR-449, miR-518c, miR-584, miR-615, and miR-622 were downregulated after NGX6 transfection." +tissue_expression_down hsa-mir-146a Colon Neoplasms 20859756 "miR-146a:In particular, miR-126, miR-142-3p, miR-155, miR-552, and miR-630 were all upregulated, whereas miR-146a, miR-152, miR-205, miR-365, miR-449, miR-518c, miR-584, miR-615, and miR-622 were downregulated after NGX6 transfection." +tissue_expression_down hsa-mir-152 Colon Neoplasms 20859756 "miR-152:In particular, miR-126, miR-142-3p, miR-155, miR-552, and miR-630 were all upregulated, whereas miR-146a, miR-152, miR-205, miR-365, miR-449, miR-518c, miR-584, miR-615, and miR-622 were downregulated after NGX6 transfection." +tissue_expression_down hsa-mir-155 Colon Neoplasms 20859756 "miR-155:In particular, miR-126, miR-142-3p, miR-155, miR-552, and miR-630 were all upregulated, whereas miR-146a, miR-152, miR-205, miR-365, miR-449, miR-518c, miR-584, miR-615, and miR-622 were downregulated after NGX6 transfection." +tissue_expression_down hsa-mir-205 Colon Neoplasms 20859756 "miR-205:In particular, miR-126, miR-142-3p, miR-155, miR-552, and miR-630 were all upregulated, whereas miR-146a, miR-152, miR-205, miR-365, miR-449, miR-518c, miR-584, miR-615, and miR-622 were downregulated after NGX6 transfection." +tissue_expression_down hsa-mir-365a Colon Neoplasms 20859756 "miR-365:In particular, miR-126, miR-142-3p, miR-155, miR-552, and miR-630 were all upregulated, whereas miR-146a, miR-152, miR-205, miR-365, miR-449, miR-518c, miR-584, miR-615, and miR-622 were downregulated after NGX6 transfection." +tissue_expression_down hsa-mir-365b Colon Neoplasms 20859756 "miR-365:In particular, miR-126, miR-142-3p, miR-155, miR-552, and miR-630 were all upregulated, whereas miR-146a, miR-152, miR-205, miR-365, miR-449, miR-518c, miR-584, miR-615, and miR-622 were downregulated after NGX6 transfection." +tissue_expression_down hsa-mir-449a Colon Neoplasms 20859756 "miR-449:In particular, miR-126, miR-142-3p, miR-155, miR-552, and miR-630 were all upregulated, whereas miR-146a, miR-152, miR-205, miR-365, miR-449, miR-518c, miR-584, miR-615, and miR-622 were downregulated after NGX6 transfection." +tissue_expression_down hsa-mir-518c Colon Neoplasms 20859756 "miR-518c:In particular, miR-126, miR-142-3p, miR-155, miR-552, and miR-630 were all upregulated, whereas miR-146a, miR-152, miR-205, miR-365, miR-449, miR-518c, miR-584, miR-615, and miR-622 were downregulated after NGX6 transfection." +tissue_expression_down hsa-mir-552 Colon Neoplasms 20859756 "miR-552:In particular, miR-126, miR-142-3p, miR-155, miR-552, and miR-630 were all upregulated, whereas miR-146a, miR-152, miR-205, miR-365, miR-449, miR-518c, miR-584, miR-615, and miR-622 were downregulated after NGX6 transfection." +tissue_expression_down hsa-mir-584 Colon Neoplasms 20859756 "miR-584:In particular, miR-126, miR-142-3p, miR-155, miR-552, and miR-630 were all upregulated, whereas miR-146a, miR-152, miR-205, miR-365, miR-449, miR-518c, miR-584, miR-615, and miR-622 were downregulated after NGX6 transfection." +tissue_expression_down hsa-mir-615 Colon Neoplasms 20859756 "miR-615:In particular, miR-126, miR-142-3p, miR-155, miR-552, and miR-630 were all upregulated, whereas miR-146a, miR-152, miR-205, miR-365, miR-449, miR-518c, miR-584, miR-615, and miR-622 were downregulated after NGX6 transfection." +tissue_expression_down hsa-mir-622 Colon Neoplasms 20859756 "miR-622:In particular, miR-126, miR-142-3p, miR-155, miR-552, and miR-630 were all upregulated, whereas miR-146a, miR-152, miR-205, miR-365, miR-449, miR-518c, miR-584, miR-615, and miR-622 were downregulated after NGX6 transfection." +tissue_expression_down hsa-mir-630 Colon Neoplasms 20859756 "miR-630:In particular, miR-126, miR-142-3p, miR-155, miR-552, and miR-630 were all upregulated, whereas miR-146a, miR-152, miR-205, miR-365, miR-449, miR-518c, miR-584, miR-615, and miR-622 were downregulated after NGX6 transfection." +tissue_expression_down hsa-mir-122 "Carcinoma, Hepatocellular" 20859956 miR-122a:microRNA-122a (miR-122a) is a liver-specific miRNA that is frequently downregulated in hepatocellular carcinoma (HCC) +tissue_expression_down hsa-mir-106b Prostate Neoplasms 20878953 Down-regulation of microRNA 106b is involved in p21-mediated cell cycle arrest in response to radiation in prostate cancer cells. +tissue_expression_down hsa-mir-135a "Carcinoma, Rectal" 20955366 The miR-135a&b were the miRNAs most down-regulated by CM-1. +tissue_expression_down hsa-mir-135b "Carcinoma, Rectal" 20955366 The miR-135a&b were the miRNAs most down-regulated by CM-1. +tissue_expression_down hsa-mir-122 "Fatty Liver, Non-Alcoholic" 20956972 "The miRNAs analysis showed the significant downregulation of three miRNAs (miR-122, miR-451 and miR-27) and the upregulation of miR-200a, miR-200b and miR-429 in HFD, SD-HF and HFD-HF rats" +tissue_expression_down hsa-mir-21 "Fatty Liver, Non-Alcoholic" 20956972 "Besides, miR-21 expression was significantly decreased only in fructose-enriched diets." +tissue_expression_down hsa-mir-27 "Fatty Liver, Non-Alcoholic" 20956972 "The miRNAs analysis showed the significant downregulation of three miRNAs (miR-122, miR-451 and miR-27) and the upregulation of miR-200a, miR-200b and miR-429 in HFD, SD-HF and HFD-HF rats" +tissue_expression_down hsa-mir-451 "Fatty Liver, Non-Alcoholic" 20956972 "The miRNAs analysis showed the significant downregulation of three miRNAs (miR-122, miR-451 and miR-27) and the upregulation of miR-200a, miR-200b and miR-429 in HFD, SD-HF and HFD-HF rats" +tissue_expression_down hsa-mir-15a Lymphoma 21118128 "Both decreased expression of miR-15a and miR-16-1 and increased nucleolin have been shown to be associated with increased Bcl2 expression and resistance to apoptosis in the common human disease, chronic lymphocytic leukaemia." +tissue_expression_down hsa-mir-16-1 Lymphoma 21118128 "Both decreased expression of miR-15a and miR-16-1 and increased nucleolin have been shown to be associated with increased Bcl2 expression and resistance to apoptosis in the common human disease, chronic lymphocytic leukaemia." +tissue_expression_down hsa-mir-221 Gastrointestinal Neoplasms 21132270 Down-regulation of miR-221 and miR-222 correlates with pronounced Kit expression in gastrointestinal stromal tumors +tissue_expression_down hsa-mir-222 Gastrointestinal Neoplasms 21132270 Down-regulation of miR-221 and miR-222 correlates with pronounced Kit expression in gastrointestinal stromal tumors +tissue_expression_down hsa-mir-145 Hepatoblastoma 21145831 downregulated in early stages of HBV-associated multistep hepatocarcinogenesis. +tissue_expression_down hsa-mir-199b Hepatoblastoma 21145831 downregulated in early stages of HBV-associated multistep hepatocarcinogenesis. +tissue_expression_down hsa-mir-29b-1 Myotonic Muscular Dystrophy 21169019 "We found that miR-1 and miR-335 were up-regulated, whereas miR-29b and c, and miR-33 were down-regulated in DM1 biopsies compared to controls." +tissue_expression_down hsa-mir-29b-2 Myotonic Muscular Dystrophy 21169019 "We found that miR-1 and miR-335 were up-regulated, whereas miR-29b and c, and miR-33 were down-regulated in DM1 biopsies compared to controls." +tissue_expression_down hsa-mir-29c Myotonic Muscular Dystrophy 21169019 "We found that miR-1 and miR-335 were up-regulated, whereas miR-29b and c, and miR-33 were down-regulated in DM1 biopsies compared to controls." +tissue_expression_down hsa-mir-33a Myotonic Muscular Dystrophy 21169019 "We found that miR-1 and miR-335 were up-regulated, whereas miR-29b and c, and miR-33 were down-regulated in DM1 biopsies compared to controls." +tissue_expression_down hsa-mir-33b Myotonic Muscular Dystrophy 21169019 "We found that miR-1 and miR-335 were up-regulated, whereas miR-29b and c, and miR-33 were down-regulated in DM1 biopsies compared to controls." +tissue_expression_down hsa-mir-342 Breast Neoplasms 21172025 Downregulation of miR-342 is Associated with Tamoxifen Resistant Breast Tumors. +tissue_expression_down hsa-mir-148b Liver Neoplasms 21176238 mir-148b* is underexpressed in side population of HCC cells compared to fetal liver cells +tissue_expression_down hsa-mir-200a Liver Neoplasms 21176238 mir-200a* is underexpressed in side population of HCC cells compared to fetal liver cells +tissue_expression_down hsa-mir-21 Prostate Neoplasms 21177307 "We also observed a significant down-regulation of androgen-regulated miRNA-21 and up-regulation of a tumor suppressor, miRNA-330, in tumors of mice treated with EGCG" +tissue_expression_down hsa-mir-124-2 Glioblastoma 21196113 miR-124a is frequently down-regulated in glioblastoma and is involved in migration and invasion. +tissue_expression_down hsa-mir-148b Gastric Neoplasms 21205300 MicroRNA-148b is frequently down-regulated in gastric cancer and acts as a tumor suppressor by inhibiting cell proliferation. +tissue_expression_down hsa-mir-143 Glioblastoma 21211035 "down regulation of miR-143, -145, -253-5p and miR-452 by SOX2" +tissue_expression_down hsa-mir-145 Glioblastoma 21211035 "down regulation of miR-143, -145, -253-5p and miR-452 by SOX2" +tissue_expression_down hsa-mir-452 Glioblastoma 21211035 "down regulation of miR-143, -145, -253-5p and miR-452 by SOX2" +tissue_expression_down hsa-mir-146a Myelodysplastic Syndromes 21211043 miR-378 and miR-146a showed reduced gene expression in the patients. +tissue_expression_down hsa-mir-378a Myelodysplastic Syndromes 21211043 miR-378 and miR-146a showed reduced gene expression in the patients. +tissue_expression_down hsa-mir-143 Esophageal Neoplasms 21218087 MiRNA profile in esophageal squamous cell carcinoma: Downregulation of miR-143 and miR-145. +tissue_expression_down hsa-mir-145 Esophageal Neoplasms 21218087 MiRNA profile in esophageal squamous cell carcinoma: Downregulation of miR-143 and miR-145. +tissue_expression_down hsa-mir-300 Urinary Bladder Cancer 21223810 "In grade I, grade II, grade III, grade I + II + III, infiltrating and non-infiltrating groups, hsa-miR-29b-1* was up-regulated while hsa-miR-923 and hsa-miR-300 were down-regulated" +tissue_expression_down hsa-mir-135b "Squamous Cell Carcinoma, Oral" 21244772 "Thirteen miRNA were significantly overexpressed (miR-489, miR-129, miR-23a, miR-214, miR-23b, miR-92, miR-25, miR-210, miR-212, miR-515, miR-146b, miR-21, miR-338) and 6 miRNA were underexpressed (miR-520h, miR-197, miR-378, miR-135b, miR-224, miR-34a) in oral tumours. Underexpression of mir-155, let-7i, mir-146a was found to characterize progression to metastastatic tumours." +tissue_expression_down hsa-mir-197 "Squamous Cell Carcinoma, Oral" 21244772 "Thirteen miRNA were significantly overexpressed (miR-489, miR-129, miR-23a, miR-214, miR-23b, miR-92, miR-25, miR-210, miR-212, miR-515, miR-146b, miR-21, miR-338) and 6 miRNA were underexpressed (miR-520h, miR-197, miR-378, miR-135b, miR-224, miR-34a) in oral tumours. Underexpression of mir-155, let-7i, mir-146a was found to characterize progression to metastastatic tumours." +tissue_expression_down hsa-mir-224 "Squamous Cell Carcinoma, Oral" 21244772 "Thirteen miRNA were significantly overexpressed (miR-489, miR-129, miR-23a, miR-214, miR-23b, miR-92, miR-25, miR-210, miR-212, miR-515, miR-146b, miR-21, miR-338) and 6 miRNA were underexpressed (miR-520h, miR-197, miR-378, miR-135b, miR-224, miR-34a) in oral tumours. Underexpression of mir-155, let-7i, mir-146a was found to characterize progression to metastastatic tumours." +tissue_expression_down hsa-mir-34a "Squamous Cell Carcinoma, Oral" 21244772 "Thirteen miRNA were significantly overexpressed (miR-489, miR-129, miR-23a, miR-214, miR-23b, miR-92, miR-25, miR-210, miR-212, miR-515, miR-146b, miR-21, miR-338) and 6 miRNA were underexpressed (miR-520h, miR-197, miR-378, miR-135b, miR-224, miR-34a) in oral tumours. Underexpression of mir-155, let-7i, mir-146a was found to characterize progression to metastastatic tumours." +tissue_expression_down hsa-mir-378a "Squamous Cell Carcinoma, Oral" 21244772 "Thirteen miRNA were significantly overexpressed (miR-489, miR-129, miR-23a, miR-214, miR-23b, miR-92, miR-25, miR-210, miR-212, miR-515, miR-146b, miR-21, miR-338) and 6 miRNA were underexpressed (miR-520h, miR-197, miR-378, miR-135b, miR-224, miR-34a) in oral tumours. Underexpression of mir-155, let-7i, mir-146a was found to characterize progression to metastastatic tumours." +tissue_expression_down hsa-mir-520h "Squamous Cell Carcinoma, Oral" 21244772 "Thirteen miRNA were significantly overexpressed (miR-489, miR-129, miR-23a, miR-214, miR-23b, miR-92, miR-25, miR-210, miR-212, miR-515, miR-146b, miR-21, miR-338) and 6 miRNA were underexpressed (miR-520h, miR-197, miR-378, miR-135b, miR-224, miR-34a) in oral tumours. Underexpression of mir-155, let-7i, mir-146a was found to characterize progression to metastastatic tumours." +tissue_expression_down hsa-mir-518b Esophageal Neoplasms 21269950 hsa-mir-126 is upregulated and hsa-miR-518b is downregulated in esophageal squamous carcinoma +tissue_expression_down hsa-mir-181a-1 "Squamous Cell Carcinoma, Head and Neck" 21274007 "deltaNp63alpha-dependent miRNA miR-181a, miR-519a, and miR-374a downregulation in HNSCC,miR-630 upregulation in HNSCC" +tissue_expression_down hsa-mir-181a-2 "Squamous Cell Carcinoma, Head and Neck" 21274007 "deltaNp63alpha-dependent miRNA miR-181a, miR-519a, and miR-374a downregulation in HNSCC,miR-630 upregulation in HNSCC" +tissue_expression_down hsa-mir-519a-1 "Squamous Cell Carcinoma, Head and Neck" 21274007 "deltaNp63alpha-dependent miRNA miR-181a, miR-519a, and miR-374a downregulation in HNSCC,miR-630 upregulation in HNSCC" +tissue_expression_down hsa-mir-519a-2 "Squamous Cell Carcinoma, Head and Neck" 21274007 "deltaNp63alpha-dependent miRNA miR-181a, miR-519a, and miR-374a downregulation in HNSCC,miR-630 upregulation in HNSCC" +tissue_expression_down hsa-mir-141 Learned Helplessness 21275079 "mir-96, 141, 182, 183, 183*, 298, 200a, 200a*, 200b, 200b*, 200c, 429 are significantly downregulated in non-learned helplessness relative to tested controls in rat brain." +tissue_expression_down hsa-mir-182 Learned Helplessness 21275079 "mir-96, 141, 182, 183, 183*, 298, 200a, 200a*, 200b, 200b*, 200c, 429 are significantly downregulated in non-learned helplessness relative to tested controls in rat brain." +tissue_expression_down hsa-mir-183 Learned Helplessness 21275079 "mir-96, 141, 182, 183, 183*, 298, 200a, 200a*, 200b, 200b*, 200c, 429 are significantly downregulated in non-learned helplessness relative to tested controls in rat brain." +tissue_expression_down hsa-mir-200a Learned Helplessness 21275079 "mir-96, 141, 182, 183, 183*, 298, 200a, 200a*, 200b, 200b*, 200c, 429 are significantly downregulated in non-learned helplessness relative to tested controls in rat brain." +tissue_expression_down hsa-mir-200b Learned Helplessness 21275079 "mir-96, 141, 182, 183, 183*, 298, 200a, 200a*, 200b, 200b*, 200c, 429 are significantly downregulated in non-learned helplessness relative to tested controls in rat brain." +tissue_expression_down hsa-mir-200c Learned Helplessness 21275079 "mir-96, 141, 182, 183, 183*, 298, 200a, 200a*, 200b, 200b*, 200c, 429 are significantly downregulated in non-learned helplessness relative to tested controls in rat brain." +tissue_expression_down hsa-mir-429 Learned Helplessness 21275079 "mir-96, 141, 182, 183, 183*, 298, 200a, 200a*, 200b, 200b*, 200c, 429 are significantly downregulated in non-learned helplessness relative to tested controls in rat brain." +tissue_expression_down hsa-mir-96 Learned Helplessness 21275079 "mir-96, 141, 182, 183, 183*, 298, 200a, 200a*, 200b, 200b*, 200c, 429 are significantly downregulated in non-learned helplessness relative to tested controls in rat brain." +tissue_expression_down hsa-let-7g Gastrointestinal Neoplasms 21293479 "In the HCPT-resistant gastric cancer cells, the levels of 25 miRNAs were deregulated, including miR-196a, miR-200 family, miR-338, miR-126, miR-31, miR-98, let-7g, and miR-7." +tissue_expression_down hsa-mir-126 Gastrointestinal Neoplasms 21293479 "In the HCPT-resistant gastric cancer cells, the levels of 25 miRNAs were deregulated, including miR-196a, miR-200 family, miR-338, miR-126, miR-31, miR-98, let-7g, and miR-7." +tissue_expression_down hsa-mir-196a-1 Gastrointestinal Neoplasms 21293479 "In the HCPT-resistant gastric cancer cells, the levels of 25 miRNAs were deregulated, including miR-196a, miR-200 family, miR-338, miR-126, miR-31, miR-98, let-7g, and miR-7." +tissue_expression_down hsa-mir-196a-2 Gastrointestinal Neoplasms 21293479 "In the HCPT-resistant gastric cancer cells, the levels of 25 miRNAs were deregulated, including miR-196a, miR-200 family, miR-338, miR-126, miR-31, miR-98, let-7g, and miR-7." +tissue_expression_down hsa-mir-200a Gastrointestinal Neoplasms 21293479 "In the HCPT-resistant gastric cancer cells, the levels of 25 miRNAs were deregulated, including miR-196a, miR-200 family, miR-338, miR-126, miR-31, miR-98, let-7g, and miR-7." +tissue_expression_down hsa-mir-200b Gastrointestinal Neoplasms 21293479 "In the HCPT-resistant gastric cancer cells, the levels of 25 miRNAs were deregulated, including miR-196a, miR-200 family, miR-338, miR-126, miR-31, miR-98, let-7g, and miR-7." +tissue_expression_down hsa-mir-200c Gastrointestinal Neoplasms 21293479 "In the HCPT-resistant gastric cancer cells, the levels of 25 miRNAs were deregulated, including miR-196a, miR-200 family, miR-338, miR-126, miR-31, miR-98, let-7g, and miR-7." +tissue_expression_down hsa-mir-31 Gastrointestinal Neoplasms 21293479 "In the HCPT-resistant gastric cancer cells, the levels of 25 miRNAs were deregulated, including miR-196a, miR-200 family, miR-338, miR-126, miR-31, miR-98, let-7g, and miR-7." +tissue_expression_down hsa-mir-338 Gastrointestinal Neoplasms 21293479 "In the HCPT-resistant gastric cancer cells, the levels of 25 miRNAs were deregulated, including miR-196a, miR-200 family, miR-338, miR-126, miR-31, miR-98, let-7g, and miR-7." +tissue_expression_down hsa-mir-7-1 Gastrointestinal Neoplasms 21293479 "In the HCPT-resistant gastric cancer cells, the levels of 25 miRNAs were deregulated, including miR-196a, miR-200 family, miR-338, miR-126, miR-31, miR-98, let-7g, and miR-7." +tissue_expression_down hsa-mir-7-2 Gastrointestinal Neoplasms 21293479 "In the HCPT-resistant gastric cancer cells, the levels of 25 miRNAs were deregulated, including miR-196a, miR-200 family, miR-338, miR-126, miR-31, miR-98, let-7g, and miR-7." +tissue_expression_down hsa-mir-7-3 Gastrointestinal Neoplasms 21293479 "In the HCPT-resistant gastric cancer cells, the levels of 25 miRNAs were deregulated, including miR-196a, miR-200 family, miR-338, miR-126, miR-31, miR-98, let-7g, and miR-7." +tissue_expression_down hsa-mir-98 Gastrointestinal Neoplasms 21293479 "In the HCPT-resistant gastric cancer cells, the levels of 25 miRNAs were deregulated, including miR-196a, miR-200 family, miR-338, miR-126, miR-31, miR-98, let-7g, and miR-7." +tissue_expression_down hsa-mir-218-1 "Carcinoma, Cervical" 21309487 infection with high-risk HPV lowered the expression of miR-218 and that down-regulation of miR-218 was involved in the pathogenesis of cervical cancer +tissue_expression_down hsa-mir-218-2 "Carcinoma, Cervical" 21309487 infection with high-risk HPV lowered the expression of miR-218 and that down-regulation of miR-218 was involved in the pathogenesis of cervical cancer +tissue_expression_down hsa-mir-30c-1 Mesothelioma 21317924 Hsa-miR-17* was significantly upregulated and hsa-miR-30c was significantly downregulated by Onconase treatment in all cell lines +tissue_expression_down hsa-mir-30c-2 Mesothelioma 21317924 Hsa-miR-17* was significantly upregulated and hsa-miR-30c was significantly downregulated by Onconase treatment in all cell lines +tissue_expression_down hsa-mir-34c Ovarian Neoplasms 21321636 "miR-449b and miR-34c on inducing down-regulation of cell cycle-related proteins and cycle arrests in SKOV3-ipl cell, an ovarian cancer cell line." +tissue_expression_down hsa-mir-499a Ovarian Neoplasms 21321636 "miR-449b and miR-34c on inducing down-regulation of cell cycle-related proteins and cycle arrests in SKOV3-ipl cell, an ovarian cancer cell line." +tissue_expression_down hsa-mir-34b Lung Neoplasms 21339737 "A microRNA, miR-34b, that suppresses the expression of alpha4 through specific binding to the 3'-untranslated region of alpha4 is downregulated in transformed or human lung tumors." +tissue_expression_down hsa-mir-200c Ovarian Neoplasms 21345725 "miR-200c has potential as a predictor of survival, and is a biomarker of relapse, in stage I EOC." +tissue_expression_down hsa-mir-146a Gastrointestinal Neoplasms 21347720 MicroRNA-146a is down-regulated in gastric cancer and regulates cell proliferation and apoptosis. +tissue_expression_down hsa-mir-34c Prostate Neoplasms 21351256 miR-34c is downregulated in prostate cancer and exerts tumor suppressive functions. +tissue_expression_down hsa-mir-21 Psoriasis 21373745 "Real-time PCR and immunohistochemistry showed that p63 expression was not significantly affected, whereas NB-UVB phototherapy significantly decreased expression ofmiR-21 (p = 0.003) and increased miR-125b levels (p = 0.003). The results indicate that the unresolved p63 abnormality in treated epidermis may play a role in maintenance of this disease." +tissue_expression_down hsa-let-7a-1 Nasopharyngeal Neoplasms 21373758 underexpressed +tissue_expression_down hsa-let-7a-2 Nasopharyngeal Neoplasms 21373758 underexpressed +tissue_expression_down hsa-let-7a-3 Nasopharyngeal Neoplasms 21373758 underexpressed +tissue_expression_down hsa-let-7b Nasopharyngeal Neoplasms 21373758 underexpressed +tissue_expression_down hsa-let-7c Nasopharyngeal Neoplasms 21373758 underexpressed +tissue_expression_down hsa-let-7d Nasopharyngeal Neoplasms 21373758 underexpressed +tissue_expression_down hsa-let-7e Nasopharyngeal Neoplasms 21373758 underexpressed +tissue_expression_down hsa-let-7f-1 Nasopharyngeal Neoplasms 21373758 underexpressed +tissue_expression_down hsa-let-7f-2 Nasopharyngeal Neoplasms 21373758 underexpressed +tissue_expression_down hsa-let-7g Nasopharyngeal Neoplasms 21373758 underexpressed +tissue_expression_down hsa-let-7i Nasopharyngeal Neoplasms 21373758 underexpressed +tissue_expression_down hsa-mir-34b Nasopharyngeal Neoplasms 21373758 underexpressed +tissue_expression_down hsa-mir-34c Nasopharyngeal Neoplasms 21373758 underexpressed +tissue_expression_down hsa-mir-221 Prostate Neoplasms 21378318 miR-221 Is Down-regulated in TMPRSS2:ERG Fusion-positive Prostate Cancer. +tissue_expression_down hsa-mir-222 Prostate Neoplasms 21378318 miR-221 Is Down-regulated in TMPRSS2:ERG Fusion-positive Prostate Cancer. +tissue_expression_down hsa-mir-99a Neoplasms [unspecific] 21383697 miR-99a-mediated downregulation of mTOR/FGFR3 controls tumor growth induced by Src-related oncogenic pathways. +tissue_expression_down hsa-mir-181a-1 Systemic Lupus Erythematosus 21385555 miR-181-a was significantly downregulated in SLE pediatrics as compared to healthy controls. +tissue_expression_down hsa-mir-181a-2 Systemic Lupus Erythematosus 21385555 miR-181-a was significantly downregulated in SLE pediatrics as compared to healthy controls. +tissue_expression_down hsa-mir-195 Colorectal Carcinoma 21390519 Downregulation of miR-195 correlates with lymph node metastasis and poor prognosis in colorectal cancer. +tissue_expression_down hsa-mir-1-1 Hypertrophy 21418519 IGF-1 deficiency retards AAC-induced cardiac hypertrophic and contractile changes via alleviating downregulation of miR-1 and miR-133a in response to left ventricular pressure overload. +tissue_expression_down hsa-mir-1-2 Hypertrophy 21418519 IGF-1 deficiency retards AAC-induced cardiac hypertrophic and contractile changes via alleviating downregulation of miR-1 and miR-133a in response to left ventricular pressure overload. +tissue_expression_down hsa-mir-133a-1 Hypertrophy 21418519 IGF-1 deficiency retards AAC-induced cardiac hypertrophic and contractile changes via alleviating downregulation of miR-1 and miR-133a in response to left ventricular pressure overload. +tissue_expression_down hsa-mir-133a-2 Hypertrophy 21418519 IGF-1 deficiency retards AAC-induced cardiac hypertrophic and contractile changes via alleviating downregulation of miR-1 and miR-133a in response to left ventricular pressure overload. +tissue_expression_down hsa-mir-449a Gastric Neoplasms 21418558 miR-449 inhibits cell proliferation and is down-regulated in gastric cancer. +tissue_expression_down hsa-mir-449b Gastric Neoplasms 21418558 miR-449 inhibits cell proliferation and is down-regulated in gastric cancer. +tissue_expression_down hsa-mir-449c Gastric Neoplasms 21418558 miR-449 inhibits cell proliferation and is down-regulated in gastric cancer. +tissue_expression_down hsa-mir-10a Endometriosis 21436257 down-regulated in endometriomas compared with endometrium. +tissue_expression_down hsa-mir-141 Endometriosis 21436257 down-regulated in endometriomas compared with endometrium. +tissue_expression_down hsa-mir-200a Endometriosis 21436257 down-regulated in endometriomas compared with endometrium. +tissue_expression_down hsa-mir-200b Endometriosis 21436257 down-regulated in endometriomas compared with endometrium. +tissue_expression_down hsa-mir-200c Endometriosis 21436257 down-regulated in endometriomas compared with endometrium. +tissue_expression_down hsa-mir-203 Endometriosis 21436257 down-regulated in endometriomas compared with endometrium. +tissue_expression_down hsa-mir-34c Endometriosis 21436257 miR-34c-5p down-regulated in endometriomas compared with endometrium. +tissue_expression_down hsa-mir-375 Endometriosis 21436257 down-regulated in endometriomas compared with endometrium. +tissue_expression_down hsa-mir-429 Endometriosis 21436257 down-regulated in endometriomas compared with endometrium. +tissue_expression_down hsa-mir-449b Endometriosis 21436257 down-regulated in endometriomas compared with endometrium. +tissue_expression_down hsa-mir-504 Endometriosis 21436257 down-regulated in endometriomas compared with endometrium. +tissue_expression_down hsa-mir-873 Endometriosis 21436257 down-regulated in endometriomas compared with endometrium. +tissue_expression_down hsa-mir-141 Barrett Esophagus 21448356 miR-200 family expression is downregulated upon neoplastic progression of Barrett's esophagus. +tissue_expression_down hsa-mir-200a Barrett Esophagus 21448356 miR-200 family expression is downregulated upon neoplastic progression of Barrett's esophagus. +tissue_expression_down hsa-mir-200b Barrett Esophagus 21448356 miR-200 family expression is downregulated upon neoplastic progression of Barrett's esophagus. +tissue_expression_down hsa-mir-200c Barrett Esophagus 21448356 miR-200 family expression is downregulated upon neoplastic progression of Barrett's esophagus. +tissue_expression_down hsa-mir-429 Barrett Esophagus 21448356 miR-200 family expression is downregulated upon neoplastic progression of Barrett's esophagus. +tissue_expression_down hsa-mir-125b-1 Melanoma 21460750 the expression of miRNA-125b (miR-125b) was two-fold lower in malignant melanoma producing lymph node micrometastases than in nonmetastasizing tumors. MicroRNA miR-125b induces senescence in human melanoma cells.We propose that downregulation of miR-125b in an early cutaneous malignant melanoma can contribute to the increased metastatic capability of this tumor. +tissue_expression_down hsa-mir-125b-2 Melanoma 21460750 the expression of miRNA-125b (miR-125b) was two-fold lower in malignant melanoma producing lymph node micrometastases than in nonmetastasizing tumors. MicroRNA miR-125b induces senescence in human melanoma cells.We propose that downregulation of miR-125b in an early cutaneous malignant melanoma can contribute to the increased metastatic capability of this tumor. +tissue_expression_down hsa-let-7a-1 Pancreatic Neoplasms 21463919 "over-expression of Notch-1 leads to increased expression of miR-21, and decreased expression of miR-200b, miR-200c, let-7a, let-7b, and let-7c. over-expression of Notch-1 led to the induction of EMT phenotype" +tissue_expression_down hsa-let-7a-2 Pancreatic Neoplasms 21463919 "over-expression of Notch-1 leads to increased expression of miR-21, and decreased expression of miR-200b, miR-200c, let-7a, let-7b, and let-7c. over-expression of Notch-1 led to the induction of EMT phenotype" +tissue_expression_down hsa-let-7a-3 Pancreatic Neoplasms 21463919 "over-expression of Notch-1 leads to increased expression of miR-21, and decreased expression of miR-200b, miR-200c, let-7a, let-7b, and let-7c. over-expression of Notch-1 led to the induction of EMT phenotype" +tissue_expression_down hsa-let-7b Pancreatic Neoplasms 21463919 "over-expression of Notch-1 leads to increased expression of miR-21, and decreased expression of miR-200b, miR-200c, let-7a, let-7b, and let-7c. over-expression of Notch-1 led to the induction of EMT phenotype" +tissue_expression_down hsa-let-7c Pancreatic Neoplasms 21463919 "over-expression of Notch-1 leads to increased expression of miR-21, and decreased expression of miR-200b, miR-200c, let-7a, let-7b, and let-7c. over-expression of Notch-1 led to the induction of EMT phenotype" +tissue_expression_down hsa-mir-200b Pancreatic Neoplasms 21463919 "over-expression of Notch-1 leads to increased expression of miR-21, and decreased expression of miR-200b, miR-200c, let-7a, let-7b, and let-7c. over-expression of Notch-1 led to the induction of EMT phenotype" +tissue_expression_down hsa-mir-200c Pancreatic Neoplasms 21463919 "over-expression of Notch-1 leads to increased expression of miR-21, and decreased expression of miR-200b, miR-200c, let-7a, let-7b, and let-7c. over-expression of Notch-1 led to the induction of EMT phenotype" +tissue_expression_down hsa-mir-143 Urinary Bladder Cancer 21464941 "Compared to matched histologically normal urothelium, downregulated." +tissue_expression_down hsa-mir-145 Urinary Bladder Cancer 21464941 "Compared to matched histologically normal urothelium, downregulated." +tissue_expression_down hsa-let-7a-1 "Carcinoma, Lung, Non-Small-Cell" 21468581 "Let-7a miRNAs were under-expressed in the blood of NSCLC patients, as well as NSCLC cells and NSCLC tissues, compared to normal controls." +tissue_expression_down hsa-let-7a-2 "Carcinoma, Lung, Non-Small-Cell" 21468581 "Let-7a miRNAs were under-expressed in the blood of NSCLC patients, as well as NSCLC cells and NSCLC tissues, compared to normal controls." +tissue_expression_down hsa-let-7a-3 "Carcinoma, Lung, Non-Small-Cell" 21468581 "Let-7a miRNAs were under-expressed in the blood of NSCLC patients, as well as NSCLC cells and NSCLC tissues, compared to normal controls." +tissue_expression_down hsa-mir-125b-1 "Carcinoma, Adrenocortical" 21472710 "miRs -100, -125b, and -195 were significantly down-regulated, whereas miR-483-5p was significantly up-regulated in malignant as compared with benign tumors." +tissue_expression_down hsa-mir-125b-2 "Carcinoma, Adrenocortical" 21472710 "miRs -100, -125b, and -195 were significantly down-regulated, whereas miR-483-5p was significantly up-regulated in malignant as compared with benign tumors." +tissue_expression_down hsa-mir-195 "Carcinoma, Adrenocortical" 21472710 "miRs -100, -125b, and -195 were significantly down-regulated, whereas miR-483-5p was significantly up-regulated in malignant as compared with benign tumors." +tissue_expression_down hsa-mir-20a Glioblastoma 21483847 "miR-20a upregulated in Glioblastoma vs Normal. Ten miRNAs (miR-20a, miR-106a, miR-17-5p, miR-31, miR-222, miR-148a, miR-221, miR-146b, miR-200b, and miR-193a) could be a signature predicding survival in Glioblastoma." +tissue_expression_down hsa-mir-221 Glioblastoma 21483847 "miR-221 downregulated in Glioblastoma vs Normal. Ten miRNAs (miR-20a, miR-106a, miR-17-5p, miR-31, miR-222, miR-148a, miR-221, miR-146b, miR-200b, and miR-193a) could be a signature predicding survival in Glioblastoma." +tissue_expression_down hsa-mir-222 Glioblastoma 21483847 "miR-222 downregulated in Glioblastoma vs Normal. Ten miRNAs (miR-20a, miR-106a, miR-17-5p, miR-31, miR-222, miR-148a, miR-221, miR-146b, miR-200b, and miR-193a) could be a signature predicding survival in Glioblastoma." +tissue_expression_down hsa-mir-31 Glioblastoma 21483847 "miR-31 downregulated in Glioblastoma vs Normal. Ten miRNAs (miR-20a, miR-106a, miR-17-5p, miR-31, miR-222, miR-148a, miR-221, miR-146b, miR-200b, and miR-193a) could be a signature predicding survival in Glioblastoma." +tissue_expression_down hsa-mir-145 Melanoma 21509659 significantly down-regulated in uveal melanomas compared with normal uveal tissues +tissue_expression_down hsa-mir-204 Melanoma 21509659 significantly down-regulated in uveal melanomas compared with normal uveal tissues +tissue_expression_down hsa-mir-15a Prostate Neoplasms 21532615 miR-15 and miR-16 are downregulated in fibroblasts surrounding the prostate tumors of the majority of 23 patients analyzed. +tissue_expression_down hsa-mir-15b Prostate Neoplasms 21532615 miR-15 and miR-16 are downregulated in fibroblasts surrounding the prostate tumors of the majority of 23 patients analyzed. +tissue_expression_down hsa-mir-16-1 Prostate Neoplasms 21532615 miR-15 and miR-16 are downregulated in fibroblasts surrounding the prostate tumors of the majority of 23 patients analyzed. +tissue_expression_down hsa-mir-16-2 Prostate Neoplasms 21532615 miR-15 and miR-16 are downregulated in fibroblasts surrounding the prostate tumors of the majority of 23 patients analyzed. +tissue_expression_down hsa-mir-1-1 Thyroid Neoplasms 21537871 "miR-146b, miR-221, miR-222, miR-155, miR-31 upregulation and miR-1, miR-34b, miR-130b, miR-138 downregulation in aggressive compared with nonaggressive PTC." +tissue_expression_down hsa-mir-1-2 Thyroid Neoplasms 21537871 "miR-146b, miR-221, miR-222, miR-155, miR-31 upregulation and miR-1, miR-34b, miR-130b, miR-138 downregulation in aggressive compared with nonaggressive PTC." +tissue_expression_down hsa-mir-133b Thyroid Neoplasms 21537871 "miR-146b, miR-221, miR-222, miR-155, miR-31 upregulation and miR-1, miR-34b, miR-130b, miR-138 downregulation in aggressive compared with nonaggressive PTC." +tissue_expression_down hsa-mir-138-1 Thyroid Neoplasms 21537871 "miR-146b, miR-221, miR-222, miR-155, miR-31 upregulation and miR-1, miR-34b, miR-130b, miR-138 downregulation in aggressive compared with nonaggressive PTC." +tissue_expression_down hsa-mir-138-2 Thyroid Neoplasms 21537871 "miR-146b, miR-221, miR-222, miR-155, miR-31 upregulation and miR-1, miR-34b, miR-130b, miR-138 downregulation in aggressive compared with nonaggressive PTC." +tissue_expression_down hsa-mir-34b Thyroid Neoplasms 21537871 "miR-146b, miR-221, miR-222, miR-155, miR-31 upregulation and miR-1, miR-34b, miR-130b, miR-138 downregulation in aggressive compared with nonaggressive PTC." +tissue_expression_down hsa-let-7a-1 "Carcinoma, Lung, Non-Small-Cell" 21544802 "The expression of miR-146b, miR-221, let-7a, miR-155, miR-17-5p, miR-27a and miR-106a were significantly reduced in the serum of NSCLC cases while miR-29c was significantly increased." +tissue_expression_down hsa-let-7a-2 "Carcinoma, Lung, Non-Small-Cell" 21544802 "The expression of miR-146b, miR-221, let-7a, miR-155, miR-17-5p, miR-27a and miR-106a were significantly reduced in the serum of NSCLC cases while miR-29c was significantly increased." +tissue_expression_down hsa-let-7a-3 "Carcinoma, Lung, Non-Small-Cell" 21544802 "The expression of miR-146b, miR-221, let-7a, miR-155, miR-17-5p, miR-27a and miR-106a were significantly reduced in the serum of NSCLC cases while miR-29c was significantly increased." +tissue_expression_down hsa-let-7b "Carcinoma, Lung, Non-Small-Cell" 21544802 Reduced plasma expression of let-7b was modestly associated with worse cancer-specific mortality in all patients and reduced serum expression of miR-223 was modestly associated with cancer-specific mortality in stage IA/B patients. +tissue_expression_down hsa-mir-143 Colorectal Carcinoma 21551242 "MiR-20a and miR-31 were found to be significantly upregulated in more than one study, and miR-143 and miR-145 were found to be significantly downregulated in CRC tissue in six or more studies." +tissue_expression_down hsa-mir-145 Colorectal Carcinoma 21551242 "MiR-20a and miR-31 were found to be significantly upregulated in more than one study, and miR-143 and miR-145 were found to be significantly downregulated in CRC tissue in six or more studies." +tissue_expression_down hsa-mir-143 "Colitis, Ulcerative" 21557394 miR-143 and miR-145 are downregulated in ulcerative colitis +tissue_expression_down hsa-mir-145 "Colitis, Ulcerative" 21557394 miR-143 and miR-145 are downregulated in ulcerative colitis +tissue_expression_down hsa-mir-199b "Carcinoma, Hepatocellular" 21557766 "hsa-mir-199b-5p: Patients with lower levels of miR-199b expression had poorer overall survival and progression-free survival rates, whereas patients with higher levels of miR-199b expression had better survival." +tissue_expression_down hsa-mir-34b Parkinson Disease 21558425 "This miRNA was downregulated in brain areas with variable neuropathological affectation at clinical (motor) stages (Braak stages 4 and 5) of the disease,including the amygdala, frontal cortex, substantia nigra and cerebellum. This miRNA modulate mitochondrial function." +tissue_expression_down hsa-mir-34c Parkinson Disease 21558425 "This miRNA was downregulated in brain areas with variable neuropathological affectation at clinical (motor) stages (Braak stages 4 and 5) of the disease,including the amygdala, frontal cortex, substantia nigra and cerebellum. This miRNA modulate mitochondrial function." +tissue_expression_down hsa-mir-100 Head And Neck Neoplasms 21560177 "Docetaxel resistant cells showed significant downregulation of miR-100, miR-130a, and miR-197 and upregulation in miR-101, miR-181b, miR-181d, and miR-195 expression when compared with their parent cells (p < .01)." +tissue_expression_down hsa-mir-100 "Squamous Cell Carcinoma, Head and Neck" 21560177 "Docetaxel resistant cells showed significant downregulation of miR-100, miR-130a, and miR-197 and upregulation in miR-101, miR-181b, miR-181d, and miR-195 expression when compared with their parent cells (p < .01)." +tissue_expression_down hsa-mir-130a Head And Neck Neoplasms 21560177 "Docetaxel resistant cells showed significant downregulation of miR-100, miR-130a, and miR-197 and upregulation in miR-101, miR-181b, miR-181d, and miR-195 expression when compared with their parent cells (p < .01)." +tissue_expression_down hsa-mir-130a "Squamous Cell Carcinoma, Head and Neck" 21560177 "Docetaxel resistant cells showed significant downregulation of miR-100, miR-130a, and miR-197 and upregulation in miR-101, miR-181b, miR-181d, and miR-195 expression when compared with their parent cells (p < .01)." +tissue_expression_down hsa-mir-197 Head And Neck Neoplasms 21560177 "Docetaxel resistant cells showed significant downregulation of miR-100, miR-130a, and miR-197 and upregulation in miR-101, miR-181b, miR-181d, and miR-195 expression when compared with their parent cells (p < .01)." +tissue_expression_down hsa-mir-197 "Squamous Cell Carcinoma, Head and Neck" 21560177 "Docetaxel resistant cells showed significant downregulation of miR-100, miR-130a, and miR-197 and upregulation in miR-101, miR-181b, miR-181d, and miR-195 expression when compared with their parent cells (p < .01)." +tissue_expression_down hsa-mir-1224 Lung Neoplasms 21563230 "Specifically, thirteen novel asbestos-related miRNAs (over-expressed: miR-148b, miR-374a, miR-24-1*, Let-7d, Let-7e, miR-199b-5p, miR-331-3p, and miR-96 and under-expressed: miR-939, miR-671-5p, miR-605, miR-1224-5p and miR-202) and inversely correlated target genes (e.g., GADD45A, LTBP1, FOSB, NCALD, CACNA2D2, MTSS1, EPB41L3) were identified. " +tissue_expression_down hsa-mir-202 Lung Neoplasms 21563230 "Specifically, thirteen novel asbestos-related miRNAs (over-expressed: miR-148b, miR-374a, miR-24-1*, Let-7d, Let-7e, miR-199b-5p, miR-331-3p, and miR-96 and under-expressed: miR-939, miR-671-5p, miR-605, miR-1224-5p and miR-202) and inversely correlated target genes (e.g., GADD45A, LTBP1, FOSB, NCALD, CACNA2D2, MTSS1, EPB41L3) were identified. " +tissue_expression_down hsa-mir-605 Lung Neoplasms 21563230 "Specifically, thirteen novel asbestos-related miRNAs (over-expressed: miR-148b, miR-374a, miR-24-1*, Let-7d, Let-7e, miR-199b-5p, miR-331-3p, and miR-96 and under-expressed: miR-939, miR-671-5p, miR-605, miR-1224-5p and miR-202) and inversely correlated target genes (e.g., GADD45A, LTBP1, FOSB, NCALD, CACNA2D2, MTSS1, EPB41L3) were identified. " +tissue_expression_down hsa-mir-671 Lung Neoplasms 21563230 "Specifically, thirteen novel asbestos-related miRNAs (over-expressed: miR-148b, miR-374a, miR-24-1*, Let-7d, Let-7e, miR-199b-5p, miR-331-3p, and miR-96 and under-expressed: miR-939, miR-671-5p, miR-605, miR-1224-5p and miR-202) and inversely correlated target genes (e.g., GADD45A, LTBP1, FOSB, NCALD, CACNA2D2, MTSS1, EPB41L3) were identified. " +tissue_expression_down hsa-mir-939 Lung Neoplasms 21563230 "Specifically, thirteen novel asbestos-related miRNAs (over-expressed: miR-148b, miR-374a, miR-24-1*, Let-7d, Let-7e, miR-199b-5p, miR-331-3p, and miR-96 and under-expressed: miR-939, miR-671-5p, miR-605, miR-1224-5p and miR-202) and inversely correlated target genes (e.g., GADD45A, LTBP1, FOSB, NCALD, CACNA2D2, MTSS1, EPB41L3) were identified. " +tissue_expression_down hsa-mir-133b Colorectal Carcinoma 21573504 "High expression of miR-185 and low expression of miR-133b were correlated with poor survival (p=0.001 and 0.028, respectively) and metastasis (p=0.007 and 0.036, respectively) in colorectal cancer." +tissue_expression_down hsa-mir-17 Prostate Neoplasms 21592394 "Among these miR-22, miR-29ab, miR-134, miR-1207-5p and miR-371-5p are up regulated, while miR-17 and miR-20a, members of the miR-17/92 cluster are down regulated." +tissue_expression_down hsa-mir-18 Prostate Neoplasms 21592394 "Among these miR-22, miR-29ab, miR-134, miR-1207-5p and miR-371-5p are up regulated, while miR-17 and miR-20a, members of the miR-17/92 cluster are down regulated." +tissue_expression_down hsa-mir-19a Prostate Neoplasms 21592394 "Among these miR-22, miR-29ab, miR-134, miR-1207-5p and miR-371-5p are up regulated, while miR-17 and miR-20a, members of the miR-17/92 cluster are down regulated." +tissue_expression_down hsa-mir-19b-1 Prostate Neoplasms 21592394 "Among these miR-22, miR-29ab, miR-134, miR-1207-5p and miR-371-5p are up regulated, while miR-17 and miR-20a, members of the miR-17/92 cluster are down regulated." +tissue_expression_down hsa-mir-20a Prostate Neoplasms 21592394 "Among these miR-22, miR-29ab, miR-134, miR-1207-5p and miR-371-5p are up regulated, while miR-17 and miR-20a, members of the miR-17/92 cluster are down regulated." +tissue_expression_down hsa-mir-92-1 Prostate Neoplasms 21592394 "Among these miR-22, miR-29ab, miR-134, miR-1207-5p and miR-371-5p are up regulated, while miR-17 and miR-20a, members of the miR-17/92 cluster are down regulated." +tissue_expression_down hsa-mir-21 Prostate Neoplasms 21594291 "In addition, anti-invasive microRNAs such as miR-335, miR-205, miR-200, and miR-126, were up-regulated, whereas pro-invasive microRNA such as miR-21 and miR-373, were down-regulated." +tissue_expression_down hsa-mir-373 Prostate Neoplasms 21594291 "In addition, anti-invasive microRNAs such as miR-335, miR-205, miR-200, and miR-126, were up-regulated, whereas pro-invasive microRNA such as miR-21 and miR-373, were down-regulated." +tissue_expression_down hsa-mir-205 "Carcinoma, Lung, Non-Small-Cell" 21622546 "Eighteen cases were classified as AD and 13 as SCC by light microscopy and immunocytochemistry. miRNA expression profiles demonstrated considerable, statistically significant differences between AD and SCC, showing an upregulation of hsa-let-7a, hsa-let-7b, hsa-let-7c,hsa-let-7f, hsa-let-7g, hsa-let-7i, and hsa-miR-98 and a downregulation of hsa-miR-205 in AD specimens" +tissue_expression_down hsa-mir-15a "Carcinoma, Hepatocellular" 21629246 Hepatitis B virus X protein downregulates expression of the miR-16 family in malignant hepatocytes in vitro. +tissue_expression_down hsa-mir-16-1 "Carcinoma, Hepatocellular" 21629246 Hepatitis B virus X protein downregulates expression of the miR-16 family in malignant hepatocytes in vitro. +tissue_expression_down hsa-mir-16-2 "Carcinoma, Hepatocellular" 21629246 Hepatitis B virus X protein downregulates expression of the miR-16 family in malignant hepatocytes in vitro. +tissue_expression_down hsa-mir-30a "Carcinoma, Lung, Non-Small-Cell" 21633953 MicroRNA-30a inhibits epithelial-to-mesenchymal transition by targeting Snai1 and is downregulated in non-small cell lung cancer. +tissue_expression_down hsa-mir-101-1 Head And Neck Neoplasms 21637912 hsa-mir-101 was downregulated compared with normal tissue. +tissue_expression_down hsa-mir-101-2 Head And Neck Neoplasms 21637912 hsa-mir-101 was downregulated compared with normal tissue. +tissue_expression_down hsa-mir-141 Head And Neck Neoplasms 21637912 hsa-mir-141 was downregulated compared with normal tissue. +tissue_expression_down hsa-mir-95 Head And Neck Neoplasms 21637912 hsa-mir-95 was downregulated compared with normal tissue. +tissue_expression_down hsa-mir-199a-1 Osteosarcoma 21666078 MicroRNA-199a-3p Is Downregulated in Human Osteosarcoma and Regulates Cell Proliferation and Migration. +tissue_expression_down hsa-mir-199a-2 Osteosarcoma 21666078 MicroRNA-199a-3p Is Downregulated in Human Osteosarcoma and Regulates Cell Proliferation and Migration. +tissue_expression_down hsa-mir-451a Breast Neoplasms 21666713 Tamoxifen downregulation of miR-451 increases 14-3-3 and promotes breast cancer cell survival and endocrine resistance. +tissue_expression_down hsa-mir-370 Gastric Neoplasms 21666718 Overexpression of miR-370 and downregulation of its novel target TGFbeta-RII contribute to the progression of gastric carcinoma. +tissue_expression_down hsa-mir-125a "Carcinoma, Rectal" 21671476 "One of the most up-regulated miRNAs, miRNA-106a, was consistently reported to be differentially expressed in six studies and the five most down-regulated miRNAs, miR-30a-3p, miR-139, miR-145, miR-125a and miR-133a, were consistently reported to be differentially expressed in four studies." +tissue_expression_down hsa-mir-133a "Carcinoma, Rectal" 21671476 "One of the most up-regulated miRNAs, miRNA-106a, was consistently reported to be differentially expressed in six studies and the five most down-regulated miRNAs, miR-30a-3p, miR-139, miR-145, miR-125a and miR-133a, were consistently reported to be differentially expressed in four studies." +tissue_expression_down hsa-mir-139 "Carcinoma, Rectal" 21671476 "One of the most up-regulated miRNAs, miRNA-106a, was consistently reported to be differentially expressed in six studies and the five most down-regulated miRNAs, miR-30a-3p, miR-139, miR-145, miR-125a and miR-133a, were consistently reported to be differentially expressed in four studies." +tissue_expression_down hsa-mir-145 "Carcinoma, Rectal" 21671476 "One of the most up-regulated miRNAs, miRNA-106a, was consistently reported to be differentially expressed in six studies and the five most down-regulated miRNAs, miR-30a-3p, miR-139, miR-145, miR-125a and miR-133a, were consistently reported to be differentially expressed in four studies." +tissue_expression_down hsa-mir-30a "Carcinoma, Rectal" 21671476 "One of the most up-regulated miRNAs, miRNA-106a, was consistently reported to be differentially expressed in six studies and the five most down-regulated miRNAs, miR-30a-3p, miR-139, miR-145, miR-125a and miR-133a, were consistently reported to be differentially expressed in four studies." +tissue_expression_down hsa-mir-128-1 Alzheimer Disease 21686130 miR-128a/b levels were significantly reduced in the temporal cortex and miR-128b in the frontal cortex in AD. +tissue_expression_down hsa-mir-128-2 Alzheimer Disease 21686130 miR-128a/b levels were significantly reduced in the temporal cortex and miR-128b in the frontal cortex in AD. +tissue_expression_down hsa-mir-211 Melanoma 21687938 Downregulation of microRNA-211 is involved in expression of preferentially expressed antigen of melanoma in melanoma cells. +tissue_expression_down hsa-mir-296 Heart Failure 21690488 "The absolute expression levels of hcmv-miR-UL112, miR-296-5p, and let-7e were further determined in 127 patients and 67 control subjects (fold changes are 2.5, 0.5, and 1.7 respectively; all P<0.0001)." +tissue_expression_down hsa-mir-106a Prostate Neoplasms 21714127 The down-regulated miRs included miR-17-92 and miR-106ab clusters with well recognized oncogenic properties while the up-regulated miRs included several tumor suppressors +tissue_expression_down hsa-mir-106b Prostate Neoplasms 21714127 The down-regulated miRs included miR-17-92 and miR-106ab clusters with well recognized oncogenic properties while the up-regulated miRs included several tumor suppressors +tissue_expression_down hsa-mir-17 Prostate Neoplasms 21714127 The down-regulated miRs included miR-17-92 and miR-106ab clusters with well recognized oncogenic properties while the up-regulated miRs included several tumor suppressors +tissue_expression_down hsa-mir-18 Prostate Neoplasms 21714127 The down-regulated miRs included miR-17-92 and miR-106ab clusters with well recognized oncogenic properties while the up-regulated miRs included several tumor suppressors +tissue_expression_down hsa-mir-19a Prostate Neoplasms 21714127 The down-regulated miRs included miR-17-92 and miR-106ab clusters with well recognized oncogenic properties while the up-regulated miRs included several tumor suppressors +tissue_expression_down hsa-mir-19b-1 Prostate Neoplasms 21714127 The down-regulated miRs included miR-17-92 and miR-106ab clusters with well recognized oncogenic properties while the up-regulated miRs included several tumor suppressors +tissue_expression_down hsa-mir-20a Prostate Neoplasms 21714127 The down-regulated miRs included miR-17-92 and miR-106ab clusters with well recognized oncogenic properties while the up-regulated miRs included several tumor suppressors +tissue_expression_down hsa-mir-92-1 Prostate Neoplasms 21714127 The down-regulated miRs included miR-17-92 and miR-106ab clusters with well recognized oncogenic properties while the up-regulated miRs included several tumor suppressors +tissue_expression_down hsa-mir-221 Kaposi Sarcoma 21715310 "In the present study, we show that Kaposi sarcoma-associated herpesvirus (KSHV), the etiological agent of KS, induces global miRNA changes in lymphatic endothelial cells (LECs). Specifically, the miR-221/miR-222 cluster is down-regulated, whereas miR-31 is up-regulated." +tissue_expression_down hsa-mir-222 Kaposi Sarcoma 21715310 "In the present study, we show that Kaposi sarcoma-associated herpesvirus (KSHV), the etiological agent of KS, induces global miRNA changes in lymphatic endothelial cells (LECs). Specifically, the miR-221/miR-222 cluster is down-regulated, whereas miR-31 is up-regulated." +tissue_expression_down hsa-mir-21 "Carcinoma, Lung, Small-Cell" 21731696 "The authors observed significantly lower miR-21, miR-29b, and miR-34a expression in SCLC cell lines than in NSCLC cell lines." +tissue_expression_down hsa-mir-29b-1 "Carcinoma, Lung, Small-Cell" 21731696 "The authors observed significantly lower miR-21, miR-29b, and miR-34a expression in SCLC cell lines than in NSCLC cell lines." +tissue_expression_down hsa-mir-29b-2 "Carcinoma, Lung, Small-Cell" 21731696 "The authors observed significantly lower miR-21, miR-29b, and miR-34a expression in SCLC cell lines than in NSCLC cell lines." +tissue_expression_down hsa-mir-34a "Carcinoma, Lung, Small-Cell" 21731696 "The authors observed significantly lower miR-21, miR-29b, and miR-34a expression in SCLC cell lines than in NSCLC cell lines." +tissue_expression_down hsa-mir-1 "Carcinoma, Renal Cell" 21745735 Our data indicate that up-regulation of the oncogenic TAGLN2 was due to down-regulation of tumour-suppressive miR-1 and miR-133a in human RCC. +tissue_expression_down hsa-mir-133a "Carcinoma, Renal Cell" 21745735 Our data indicate that up-regulation of the oncogenic TAGLN2 was due to down-regulation of tumour-suppressive miR-1 and miR-133a in human RCC. +tissue_expression_down hsa-mir-122 "Carcinoma, Hepatocellular" 21750653 The down-regulation of miR-122 activated the CDK4-PSMD10-UPR pathway to decrease tumor cell anticancer drug-mediated apoptosis. +tissue_expression_down hsa-mir-155 Melanoma 21763111 "Early steps in skin tumor formation in HPV8-CER mice were associated with an upregulation of the oncogenic miRNA-17-5p, -21 and -106a and a downregulation of the tumor-suppressive miRNA-155 and -206, which could be demonstrated by qPCR and in situ hybridization." +tissue_expression_down hsa-mir-206 Melanoma 21763111 "Early steps in skin tumor formation in HPV8-CER mice were associated with an upregulation of the oncogenic miRNA-17-5p, -21 and -106a and a downregulation of the tumor-suppressive miRNA-155 and -206, which could be demonstrated by qPCR and in situ hybridization." +tissue_expression_down hsa-mir-16-1 Lymphoma 21778999 Hypoxia-microRNA-16 downregulation induces VEGF expression in anaplastic lymphoma kinase (ALK)-positive anaplastic large-cell lymphomas. +tissue_expression_down hsa-mir-16-2 Lymphoma 21778999 Hypoxia-microRNA-16 downregulation induces VEGF expression in anaplastic lymphoma kinase (ALK)-positive anaplastic large-cell lymphomas. +tissue_expression_down hsa-mir-200c "Carcinoma, Renal Cell" 21784468 Underexpression +tissue_expression_down hsa-mir-218-1 "Carcinoma, Renal Cell" 21784468 Underexpression +tissue_expression_down hsa-mir-218-2 "Carcinoma, Renal Cell" 21784468 Underexpression +tissue_expression_down hsa-mir-335 "Carcinoma, Renal Cell" 21784468 Underexpression +tissue_expression_down hsa-mir-494 Cholangiocarcinoma 21809359 miRNA-494 downregulated in human cholangiocarcinoma controls cell cycle through multiple targets involved in the G1/S checkpoint. +tissue_expression_down hsa-mir-143 Colorectal Carcinoma 21826996 downregulated in colon cancer compared to normal colonic mucosa +tissue_expression_down hsa-mir-145 Colorectal Carcinoma 21826996 downregulated in colon cancer compared to normal colonic mucosa +tissue_expression_down hsa-mir-214 Breast Neoplasms 21828058 "Decreased MicroRNA-214 Levels In Breast Cancer Cells Coincides with Increased Cell Proliferation, Invasion, and Accumulation of the Polycomb Ezh2 Methyltransferase." +tissue_expression_down hsa-mir-146a "Carcinoma, Hepatocellular" 21829663 "miRNAs miR-26a, -29c, -146a and -190 were significantly down-regulated in a subset of HCC tissues with carboxyl-terminal HBx truncation compared to their matching non-tumor tissues." +tissue_expression_down hsa-mir-190a "Carcinoma, Hepatocellular" 21829663 "miRNAs miR-26a, -29c, -146a and -190 were significantly down-regulated in a subset of HCC tissues with carboxyl-terminal HBx truncation compared to their matching non-tumor tissues." +tissue_expression_down hsa-mir-26a-1 "Carcinoma, Hepatocellular" 21829663 "miRNAs miR-26a, -29c, -146a and -190 were significantly down-regulated in a subset of HCC tissues with carboxyl-terminal HBx truncation compared to their matching non-tumor tissues." +tissue_expression_down hsa-mir-26a-2 "Carcinoma, Hepatocellular" 21829663 "miRNAs miR-26a, -29c, -146a and -190 were significantly down-regulated in a subset of HCC tissues with carboxyl-terminal HBx truncation compared to their matching non-tumor tissues." +tissue_expression_down hsa-mir-29c "Carcinoma, Hepatocellular" 21829663 "miRNAs miR-26a, -29c, -146a and -190 were significantly down-regulated in a subset of HCC tissues with carboxyl-terminal HBx truncation compared to their matching non-tumor tissues." +tissue_expression_down hsa-mir-145 Melanoma 21836381 "MiR-145 was significantly down-regulated in canine malignant melanoma tissues. The ectopic expression of miR-145 showed a significant growth inhibition in both canine and human melanoma cells tested, and the effect was achieved partly by suppressing c-MYC in canine melanoma LMeC, and human melanoma A2058 and Mewo cells." +tissue_expression_down hsa-mir-195 "Carcinoma, Adrenocortical" 21859927 "Among others, miR-483-3p, miR-483-5p, miR-210, and miR-21 were found overexpressed,while miR-195, miR-497, and miR-1974 were underexpressed in ACC. " +tissue_expression_down hsa-mir-1974 "Carcinoma, Adrenocortical" 21859927 "Among others, miR-483-3p, miR-483-5p, miR-210, and miR-21 were found overexpressed,while miR-195, miR-497, and miR-1974 were underexpressed in ACC. " +tissue_expression_down hsa-mir-497 "Carcinoma, Adrenocortical" 21859927 "Among others, miR-483-3p, miR-483-5p, miR-210, and miR-21 were found overexpressed,while miR-195, miR-497, and miR-1974 were underexpressed in ACC. " +tissue_expression_down hsa-mir-224 Colorectal Carcinoma 21864507 Underexpression in methotrexate resistant human colon cancer cells. +tissue_expression_down hsa-let-7g Breast Neoplasms 21868760 "Treatment with estrogen or EGF specifically reduced the expression of mature let-7g through activation of p44/42 MAPK and subsequently stimulated expression of GAB2 and FN1, which in turn promoted tumor invasion. We thus identify let-7g as a unique member of the let-7 miRNA family which can serve as a prognostic biomarker in breast cancer and also propose a paradigm utilized by specific signaling molecules via let-7g to cooperatively promote breast cancer invasion and metastasis." +tissue_expression_down hsa-mir-451a "Carcinoma, Lung, Non-Small-Cell" 21875770 "This study showed that miRNA-451 expression decreased in non-small cell lung cancer (NSCLC) tissues and that its expression was negatively associated with lymph node metastasis, the stage of TNM classification and poor prognosis of NSCLC patients. Moreover, significantly different miRNA-451 expression levels were found between smoking and non-smoking patients. The overexpression of miRNA-451 inhibited cell cycle progression, cellular migration and the invasive ability of NSCLC cells.Increased miRNA-451 expression also promoted anoikis of NSCLC cells." +tissue_expression_down hsa-mir-221 "Carcinoma, Hepatocellular" 21876625 "downregulated in acute HBV infection, normally expressed in chronic HBV infection, and upregulated in HCC" +tissue_expression_down hsa-mir-221 Hepatitis B Virus Infection 21876625 "downregulated in acute HBV infection, normally expressed in chronic HBV infection, and upregulated in HCC" +tissue_expression_down hsa-mir-99a "Carcinoma, Hepatocellular" 21878637 "Lower miR-99a expression in HCC tissues significantly correlated with shorter survival of HCC patients, and miR-99a was identified to be an independent predictor for prognosis of HCC patients. Furthermore, restoration of miR-99a dramatically suppressed HCC cell growth in vitro by inducing G1 phase cell cycle arrest." +tissue_expression_down hsa-let-7c Prostate Neoplasms 21880514 significantly changed during the progression of cancer +tissue_expression_down hsa-mir-100 Prostate Neoplasms 21880514 significantly changed during the progression of cancer +tissue_expression_down hsa-mir-143 Prostate Neoplasms 21880514 significantly changed during the progression of cancer +tissue_expression_down hsa-mir-145 Prostate Neoplasms 21880514 significantly changed during the progression of cancer +tissue_expression_down hsa-mir-146a Prostate Neoplasms 21880514 significantly changed during the progression of cancer +tissue_expression_down hsa-mir-15a Prostate Neoplasms 21880514 significantly changed during the progression of cancer +tissue_expression_down hsa-mir-16-1 Prostate Neoplasms 21880514 significantly changed during the progression of cancer +tissue_expression_down hsa-mir-16-2 Prostate Neoplasms 21880514 significantly changed during the progression of cancer +tissue_expression_down hsa-mir-191 Prostate Neoplasms 21880514 significantly changed during the progression of cancer +tissue_expression_down hsa-mir-199a-1 Prostate Neoplasms 21880514 significantly changed during the progression of cancer +tissue_expression_down hsa-mir-199a-2 Prostate Neoplasms 21880514 significantly changed during the progression of cancer +tissue_expression_down hsa-mir-218-1 Prostate Neoplasms 21880514 significantly changed during the progression of cancer +tissue_expression_down hsa-mir-25 Prostate Neoplasms 21880514 significantly changed during the progression of cancer +tissue_expression_down hsa-mir-32 Prostate Neoplasms 21880514 significantly changed during the progression of cancer +tissue_expression_down hsa-mir-146a Diabetes Mellitus 21885871 "A total of 25 mmol/L glucose decreased miR-146a expression and increased FN expression compared with 5 mmol/L glucose in both cell types. miR-146a mimic transfection prevented such change, whereas miR-146a antagomir transfection in the cells in 5 mmol/L glucose caused FN upregulation. A luciferase assay confirmed miR-146a's binding to FN 3'-UTR. miR-146a was localized in the retinal endothelial cells and was decreased in diabetes. Intravitreal miR-146a mimic injection restored retinal miR-146a and increased FN in diabetes. Additional experiments showed that p300 regulates miR-146a." +tissue_expression_down hsa-mir-124-1 Glioblastoma 21912681 Significantly down-regulated in glioblastomas. +tissue_expression_down hsa-mir-124-2 Glioblastoma 21912681 Significantly down-regulated in glioblastomas. +tissue_expression_down hsa-mir-124-3 Glioblastoma 21912681 Significantly down-regulated in glioblastomas. +tissue_expression_down hsa-mir-128-1 Glioblastoma 21912681 Significantly down-regulated in glioblastomas. +tissue_expression_down hsa-mir-128-2 Glioblastoma 21912681 Significantly down-regulated in glioblastomas. +tissue_expression_down hsa-mir-139 Glioblastoma 21912681 Significantly down-regulated in glioblastomas. +tissue_expression_down hsa-mir-7-1 Glioblastoma 21912681 Significantly down-regulated in glioblastomas. +tissue_expression_down hsa-mir-7-2 Glioblastoma 21912681 Significantly down-regulated in glioblastomas. +tissue_expression_down hsa-mir-7-3 Glioblastoma 21912681 Significantly down-regulated in glioblastomas. +tissue_expression_down hsa-mir-873 Glioblastoma 21912681 Significantly down-regulated in glioblastomas. +tissue_expression_down hsa-mir-95 Glioblastoma 21912681 Significantly down-regulated in glioblastomas. +tissue_expression_down hsa-mir-146a Asthma 21917308 Measurement of the microRNA expression profile showed selective downregulation of miR-28-5p in CD8(+) T cells and reduction of miR-146a and miR-146b in both CD4(+) and CD8(+) T cells. +tissue_expression_down hsa-mir-146b Asthma 21917308 Measurement of the microRNA expression profile showed selective downregulation of miR-28-5p in CD8(+) T cells and reduction of miR-146a and miR-146b in both CD4(+) and CD8(+) T cells. +tissue_expression_down hsa-mir-28 Asthma 21917308 Measurement of the microRNA expression profile showed selective downregulation of miR-28-5p in CD8(+) T cells and reduction of miR-146a and miR-146b in both CD4(+) and CD8(+) T cells. +tissue_expression_down hsa-mir-101-1 "Lymphoma, T-Cell" 21921041 "Re-expression of downregulated miRNAs, such as mir-101, mir-26a, mir26b, mir-28-5 and mir-363, reduced the growth of NK cell line and modulated the expression of their predicted target genes." +tissue_expression_down hsa-mir-101-2 "Lymphoma, T-Cell" 21921041 "Re-expression of downregulated miRNAs, such as mir-101, mir-26a, mir26b, mir-28-5 and mir-363, reduced the growth of NK cell line and modulated the expression of their predicted target genes." +tissue_expression_down hsa-mir-26a-1 "Lymphoma, T-Cell" 21921041 "Re-expression of downregulated miRNAs, such as mir-101, mir-26a, mir26b, mir-28-5 and mir-363, reduced the growth of NK cell line and modulated the expression of their predicted target genes." +tissue_expression_down hsa-mir-26a-2 "Lymphoma, T-Cell" 21921041 "Re-expression of downregulated miRNAs, such as mir-101, mir-26a, mir26b, mir-28-5 and mir-363, reduced the growth of NK cell line and modulated the expression of their predicted target genes." +tissue_expression_down hsa-mir-26b "Lymphoma, T-Cell" 21921041 "Re-expression of downregulated miRNAs, such as mir-101, mir-26a, mir26b, mir-28-5 and mir-363, reduced the growth of NK cell line and modulated the expression of their predicted target genes." +tissue_expression_down hsa-mir-127 Colorectal Carcinoma 21922590 "The presence of the KRAS mutation was associated with up-regulation of miR-127-3p, miR-92a, and miR-486-3p and down-regulation of miR-378." +tissue_expression_down hsa-mir-486 Colorectal Carcinoma 21922590 "The presence of the KRAS mutation was associated with up-regulation of miR-127-3p, miR-92a, and miR-486-3p and down-regulation of miR-378." +tissue_expression_down hsa-mir-92a-1 Colorectal Carcinoma 21922590 "The presence of the KRAS mutation was associated with up-regulation of miR-127-3p, miR-92a, and miR-486-3p and down-regulation of miR-378." +tissue_expression_down hsa-mir-92a-2 Colorectal Carcinoma 21922590 "The presence of the KRAS mutation was associated with up-regulation of miR-127-3p, miR-92a, and miR-486-3p and down-regulation of miR-378." +tissue_expression_down hsa-mir-106a Medulloblastoma 21931624 hsa-mir-106a* was significantly down-regulated in primary Medulloblastoma specimens relative to CD133+ NSCs (Neural Stem Cells). +tissue_expression_down hsa-mir-10a Medulloblastoma 21931624 hsa-mir-10a was significantly down-regulated in primary Medulloblastoma specimens relative to CD133+ NSCs (Neural Stem Cells). +tissue_expression_down hsa-mir-219 Medulloblastoma 21931624 hsa-mir-219-5p was significantly down-regulated in primary Medulloblastoma specimens relative to CD133+ NSCs (Neural Stem Cells). +tissue_expression_down hsa-mir-219-1 Medulloblastoma 21931624 hsa-mir-219-1-3p was significantly down-regulated in primary Medulloblastoma specimens relative to CD133+ NSCs (Neural Stem Cells). +tissue_expression_down hsa-mir-302b Medulloblastoma 21931624 hsa-mir-302b* was significantly down-regulated in primary Medulloblastoma specimens relative to CD133+ NSCs (Neural Stem Cells). +tissue_expression_down hsa-mir-302d Medulloblastoma 21931624 hsa-mir-302d* was significantly down-regulated in primary Medulloblastoma specimens relative to CD133+ NSCs (Neural Stem Cells). +tissue_expression_down hsa-mir-373 Medulloblastoma 21931624 hsa-mir-373 was significantly down-regulated in primary Medulloblastoma specimens relative to CD133+ NSCs (Neural Stem Cells). +tissue_expression_down hsa-mir-483 Medulloblastoma 21931624 hsa-mir-483-5p was significantly down-regulated in primary Medulloblastoma specimens relative to CD133+ NSCs (Neural Stem Cells). +tissue_expression_down hsa-mir-504 Medulloblastoma 21931624 hsa-mir-504 was significantly down-regulated in primary Medulloblastoma specimens relative to CD133+ NSCs (Neural Stem Cells). +tissue_expression_down hsa-mir-92b Medulloblastoma 21931624 hsa-mir-92b* was significantly down-regulated in primary Medulloblastoma specimens relative to CD133+ NSCs (Neural Stem Cells). +tissue_expression_down hsa-mir-935 Medulloblastoma 21931624 hsa-mir-935 was significantly down-regulated in primary Medulloblastoma specimens relative to CD133+ NSCs (Neural Stem Cells). +tissue_expression_down hsa-mir-122 Asthenozoospermia 21933900 miR-122 was markedly decreased in azoospermia but increased in asthenozoospermia. +tissue_expression_down hsa-mir-146b Asthenozoospermia 21933900 miR-146b was markedly decreased in azoospermia but increased in asthenozoospermia. +tissue_expression_down hsa-mir-181a-2 Asthenozoospermia 21933900 miR-181a was markedly decreased in azoospermia but increased in asthenozoospermia. +tissue_expression_down hsa-mir-34c Asthenozoospermia 21933900 miR-34c-5p was markedly decreased in azoospermia but increased in asthenozoospermia. +tissue_expression_down hsa-mir-374b Asthenozoospermia 21933900 miR-374b was markedly decreased in azoospermia but increased in asthenozoospermia. +tissue_expression_down hsa-mir-509-1 Asthenozoospermia 21933900 miR-509-5p was markedly decreased in azoospermia but increased in asthenozoospermia. +tissue_expression_down hsa-mir-509-2 Asthenozoospermia 21933900 miR-509-5p was markedly decreased in azoospermia but increased in asthenozoospermia. +tissue_expression_down hsa-mir-509-3 Asthenozoospermia 21933900 miR-509-5p was markedly decreased in azoospermia but increased in asthenozoospermia. +tissue_expression_down hsa-mir-513a-1 Asthenozoospermia 21933900 miR-513a-5p was markedly decreased in azoospermia but increased in asthenozoospermia. +tissue_expression_down hsa-mir-513a-2 Asthenozoospermia 21933900 miR-513a-5p was markedly decreased in azoospermia but increased in asthenozoospermia. +tissue_expression_down hsa-let-7c Ovarian Neoplasms 21939554 The miRNA was downregulated in cis-platin resistant (A2780/CP70) vs. cis-platin sensitive (A2780) ovarian cancer cell lines. +tissue_expression_down hsa-mir-20b Ovarian Neoplasms 21939554 The miRNA was downregulated in cis-platin resistant (A2780/CP70) vs. cis-platin sensitive (A2780) ovarian cancer cell lines. +tissue_expression_down hsa-mir-542 Ovarian Neoplasms 21939554 The miRNA hsa-miR-542-3p was downregulated in cis-platin resistant (A2780/CP70) vs. cis-platin sensitive (A2780) ovarian cancer cell lines. +tissue_expression_down hsa-mir-625 Ovarian Neoplasms 21939554 The miRNA was downregulated in cis-platin resistant (A2780/CP70) vs. cis-platin sensitive (A2780) ovarian cancer cell lines. +tissue_expression_down hsa-mir-125b-1 Lichen Planus 21943223 "Increased expression of miR-21 and miR-203, decreased expression of miR-125, and down-regulation of p53 and deltaNp63 RNA were seen in OLP compared to normal oral mucosa. When comparing microRNA expression to levels of p53 and p63 RNA, a significant negative correlation was seen between deltaNp63 and miR-203 and between miR-21 and p53, respectively." +tissue_expression_down hsa-mir-125b-2 Lichen Planus 21943223 "Increased expression of miR-21 and miR-203, decreased expression of miR-125, and down-regulation of p53 and deltaNp63 RNA were seen in OLP compared to normal oral mucosa. When comparing microRNA expression to levels of p53 and p63 RNA, a significant negative correlation was seen between deltaNp63 and miR-203 and between miR-21 and p53, respectively." +tissue_expression_down hsa-mir-10b Breast Neoplasms 21953071 The miRNA was down-regulated during lobular neoplasia progression compared to normal epithelium. +tissue_expression_down hsa-mir-139 Breast Neoplasms 21953071 The miRNA was down-regulated during lobular neoplasia progression compared to normal epithelium. +tissue_expression_down hsa-mir-140 Breast Neoplasms 21953071 The miRNA was down-regulated during lobular neoplasia progression compared to normal epithelium. +tissue_expression_down hsa-mir-224 Breast Neoplasms 21953071 The miRNA was down-regulated during lobular neoplasia progression compared to normal epithelium. +tissue_expression_down hsa-mir-365a Breast Neoplasms 21953071 The miRNA was down-regulated during lobular neoplasia progression compared to normal epithelium. +tissue_expression_down hsa-mir-365b Breast Neoplasms 21953071 The miRNA was down-regulated during lobular neoplasia progression compared to normal epithelium. +tissue_expression_down hsa-mir-450a-1 Breast Neoplasms 21953071 The miRNA was down-regulated during lobular neoplasia progression compared to normal epithelium. +tissue_expression_down hsa-mir-450a-2 Breast Neoplasms 21953071 The miRNA was down-regulated during lobular neoplasia progression compared to normal epithelium. +tissue_expression_down hsa-mir-450b Breast Neoplasms 21953071 The miRNA was down-regulated during lobular neoplasia progression compared to normal epithelium. +tissue_expression_down hsa-mir-100 Pancreatic Neoplasms 21953293 Highly down-regulated in PDAC compared with normal ductal +tissue_expression_down hsa-mir-145 Pancreatic Neoplasms 21953293 Highly down-regulated in PDAC compared with normal ductal +tissue_expression_down hsa-mir-148a Pancreatic Neoplasms 21953293 Highly down-regulated in PDAC compared with normal ductal +tissue_expression_down hsa-mir-199b Pancreatic Neoplasms 21953293 miR-199b-5p: Highly down-regulated in PDAC compared with normal ductal +tissue_expression_down hsa-mir-451a Pancreatic Neoplasms 21953293 Highly down-regulated in PDAC compared with normal ductal +tissue_expression_down hsa-mir-101-1 Lymphoma 21960592 "The down-regulation of miR-16, miR-26a, miR-101, miR-29c and miR138 in the t(14;18)-negative FL( follicular lymphoma ) subset was associated with profound mRNA expression changes of potential target genes involving cell cycle control, apoptosis and B-cell differentiation. miR-16 target CHEK1 showed increased expression on the protein level in t(14;18)-negative FL, while TCL1A expression was reduced, in line with a partial loss of the germinal center B-cell phenotype in this FL subset." +tissue_expression_down hsa-mir-101-2 Lymphoma 21960592 "The down-regulation of miR-16, miR-26a, miR-101, miR-29c and miR138 in the t(14;18)-negative FL( follicular lymphoma ) subset was associated with profound mRNA expression changes of potential target genes involving cell cycle control, apoptosis and B-cell differentiation. miR-16 target CHEK1 showed increased expression on the protein level in t(14;18)-negative FL, while TCL1A expression was reduced, in line with a partial loss of the germinal center B-cell phenotype in this FL subset." +tissue_expression_down hsa-mir-138-1 Lymphoma 21960592 "The down-regulation of miR-16, miR-26a, miR-101, miR-29c and miR138 in the t(14;18)-negative FL( follicular lymphoma ) subset was associated with profound mRNA expression changes of potential target genes involving cell cycle control, apoptosis and B-cell differentiation. miR-16 target CHEK1 showed increased expression on the protein level in t(14;18)-negative FL, while TCL1A expression was reduced, in line with a partial loss of the germinal center B-cell phenotype in this FL subset." +tissue_expression_down hsa-mir-138-2 Lymphoma 21960592 "The down-regulation of miR-16, miR-26a, miR-101, miR-29c and miR138 in the t(14;18)-negative FL( follicular lymphoma ) subset was associated with profound mRNA expression changes of potential target genes involving cell cycle control, apoptosis and B-cell differentiation. miR-16 target CHEK1 showed increased expression on the protein level in t(14;18)-negative FL, while TCL1A expression was reduced, in line with a partial loss of the germinal center B-cell phenotype in this FL subset." +tissue_expression_down hsa-mir-16-1 Lymphoma 21960592 "The down-regulation of miR-16, miR-26a, miR-101, miR-29c and miR138 in the t(14;18)-negative FL( follicular lymphoma ) subset was associated with profound mRNA expression changes of potential target genes involving cell cycle control, apoptosis and B-cell differentiation. miR-16 target CHEK1 showed increased expression on the protein level in t(14;18)-negative FL, while TCL1A expression was reduced, in line with a partial loss of the germinal center B-cell phenotype in this FL subset." +tissue_expression_down hsa-mir-16-2 Lymphoma 21960592 "The down-regulation of miR-16, miR-26a, miR-101, miR-29c and miR138 in the t(14;18)-negative FL( follicular lymphoma ) subset was associated with profound mRNA expression changes of potential target genes involving cell cycle control, apoptosis and B-cell differentiation. miR-16 target CHEK1 showed increased expression on the protein level in t(14;18)-negative FL, while TCL1A expression was reduced, in line with a partial loss of the germinal center B-cell phenotype in this FL subset." +tissue_expression_down hsa-mir-29c Lymphoma 21960592 "The down-regulation of miR-16, miR-26a, miR-101, miR-29c and miR138 in the t(14;18)-negative FL( follicular lymphoma ) subset was associated with profound mRNA expression changes of potential target genes involving cell cycle control, apoptosis and B-cell differentiation. miR-16 target CHEK1 showed increased expression on the protein level in t(14;18)-negative FL, while TCL1A expression was reduced, in line with a partial loss of the germinal center B-cell phenotype in this FL subset." +tissue_expression_down hsa-let-7a-1 Mycosis Fungoides 21966986 "MiR-155 was only found to be slightly overexpressed in MF compared to healthy controls. Furthermore, metastatic MF demonstrated lower concentrations of let-7a, let-7d and let-7f when compared to MF limited to the skin." +tissue_expression_down hsa-let-7a-2 Mycosis Fungoides 21966986 "MiR-155 was only found to be slightly overexpressed in MF compared to healthy controls. Furthermore, metastatic MF demonstrated lower concentrations of let-7a, let-7d and let-7f when compared to MF limited to the skin." +tissue_expression_down hsa-let-7a-3 Mycosis Fungoides 21966986 "MiR-155 was only found to be slightly overexpressed in MF compared to healthy controls. Furthermore, metastatic MF demonstrated lower concentrations of let-7a, let-7d and let-7f when compared to MF limited to the skin." +tissue_expression_down hsa-let-7d Mycosis Fungoides 21966986 "MiR-155 was only found to be slightly overexpressed in MF compared to healthy controls. Furthermore, metastatic MF demonstrated lower concentrations of let-7a, let-7d and let-7f when compared to MF limited to the skin." +tissue_expression_down hsa-let-7f-1 Mycosis Fungoides 21966986 "MiR-155 was only found to be slightly overexpressed in MF compared to healthy controls. Furthermore, metastatic MF demonstrated lower concentrations of let-7a, let-7d and let-7f when compared to MF limited to the skin." +tissue_expression_down hsa-let-7f-2 Mycosis Fungoides 21966986 "MiR-155 was only found to be slightly overexpressed in MF compared to healthy controls. Furthermore, metastatic MF demonstrated lower concentrations of let-7a, let-7d and let-7f when compared to MF limited to the skin." +tissue_expression_down hsa-mir-21 Ovarian Neoplasms 21968270 miR-21 down-regulation promotes apoptosis and inhibits invasion and migration abilities of OVCAR3 (ovarian papillary adenocarcinoma cell lines) cells. +tissue_expression_down hsa-mir-138-1 "Squamous Cell Carcinoma, Head and Neck" 21969367 "In this study, the authors first confirm the microRNA-138-mediated down-regulation of FOSL1 in squamous cell carcinoma (SCC) cell lines." +tissue_expression_down hsa-mir-138-2 "Squamous Cell Carcinoma, Head and Neck" 21969367 "In this study, the authors first confirm the microRNA-138-mediated down-regulation of FOSL1 in squamous cell carcinoma (SCC) cell lines." +tissue_expression_down hsa-mir-410 Neuroblastoma 21970883 "Two, miR-487b and miR-410, were significantly downregulated in the high-risk group. Multivariable analyses showed miR-487b expression as associated with overall survival and disease-free survival in the whole cohort, independently of clinical covariates. Moreover, miR-487b and miR-410 expression was significantly associated with disease-free survival of the non-MYCN-amplified favourable neuroblastoma: localised (stage 1, 2 and 3) and stage 4 of infant <18 months.Conclusion:Expression of miR-487b and miR-410 shows predictive value beyond the classical high-/low-risk stratification and is a biomarker of relapse in favourable neuroblastoma." +tissue_expression_down hsa-mir-487b Neuroblastoma 21970883 "Two, miR-487b and miR-410, were significantly downregulated in the high-risk group. Multivariable analyses showed miR-487b expression as associated with overall survival and disease-free survival in the whole cohort, independently of clinical covariates. Moreover, miR-487b and miR-410 expression was significantly associated with disease-free survival of the non-MYCN-amplified favourable neuroblastoma: localised (stage 1, 2 and 3) and stage 4 of infant <18 months.Conclusion:Expression of miR-487b and miR-410 shows predictive value beyond the classical high-/low-risk stratification and is a biomarker of relapse in favourable neuroblastoma." +tissue_expression_down hsa-mir-107 Astrocytoma 21978395 "miR-107, miR-124, miR-138, and miR-149 were downregulated significantly in grade I-IV astrocytomas, and overexpression of miR-124 and miR-149 inhibited glioblastoma cell proliferation and migration." +tissue_expression_down hsa-mir-124-1 Astrocytoma 21978395 "miR-107, miR-124, miR-138, and miR-149 were downregulated significantly in grade I-IV astrocytomas, and overexpression of miR-124 and miR-149 inhibited glioblastoma cell proliferation and migration." +tissue_expression_down hsa-mir-124-2 Astrocytoma 21978395 "miR-107, miR-124, miR-138, and miR-149 were downregulated significantly in grade I-IV astrocytomas, and overexpression of miR-124 and miR-149 inhibited glioblastoma cell proliferation and migration." +tissue_expression_down hsa-mir-124-3 Astrocytoma 21978395 "miR-107, miR-124, miR-138, and miR-149 were downregulated significantly in grade I-IV astrocytomas, and overexpression of miR-124 and miR-149 inhibited glioblastoma cell proliferation and migration." +tissue_expression_down hsa-mir-138-1 Astrocytoma 21978395 "miR-107, miR-124, miR-138, and miR-149 were downregulated significantly in grade I-IV astrocytomas, and overexpression of miR-124 and miR-149 inhibited glioblastoma cell proliferation and migration." +tissue_expression_down hsa-mir-138-2 Astrocytoma 21978395 "miR-107, miR-124, miR-138, and miR-149 were downregulated significantly in grade I-IV astrocytomas, and overexpression of miR-124 and miR-149 inhibited glioblastoma cell proliferation and migration." +tissue_expression_down hsa-mir-149 Astrocytoma 21978395 "miR-107, miR-124, miR-138, and miR-149 were downregulated significantly in grade I-IV astrocytomas, and overexpression of miR-124 and miR-149 inhibited glioblastoma cell proliferation and migration." +tissue_expression_down hsa-mir-1290 "Carcinoma, Hepatocellular" 21998738 hsa-mir-1290 was down-regulated in HepG2 cells after 5 hours of culture with grape seed proanthocyanidin extract. +tissue_expression_down hsa-mir-187 "Carcinoma, Hepatocellular" 21998738 hsa-mir-187* was down-regulated in HepG2 cells after 5 hours of culture with cocoa proanthocyanidin extract. +tissue_expression_down hsa-mir-2110 "Carcinoma, Hepatocellular" 21998738 hsa-mir-2110 was down-regulated in HepG2 cells after 5 hours of culture with grape seed proanthocyanidin extract. +tissue_expression_down hsa-mir-30b "Carcinoma, Hepatocellular" 21998738 hsa-mir-30b* was down-regulated in HepG2 cells after 5 hours of culture with grape seed proanthocyanidin extract. +tissue_expression_down hsa-mir-320c-1 "Carcinoma, Hepatocellular" 21998738 hsa-mir-320c was down-regulated in HepG2 cells after 5 hours of culture with grape seed proanthocyanidin extract. +tissue_expression_down hsa-mir-320c-2 "Carcinoma, Hepatocellular" 21998738 hsa-mir-320c was down-regulated in HepG2 cells after 5 hours of culture with grape seed proanthocyanidin extract. +tissue_expression_down hsa-mir-323b "Carcinoma, Hepatocellular" 21998738 hsa-mir-453 (note: this miRNA was replaced by hsa-mir-323b) was down-regulated in HepG2 cells after 5 hours of culture with grape seed proanthocyanidin extract. +tissue_expression_down hsa-mir-483 "Carcinoma, Hepatocellular" 21998738 hsa-mir-483-5p was down-regulated in HepG2 cells after 5 hours of culture with grape seed proanthocyanidin extract. +tissue_expression_down hsa-mir-520e "Carcinoma, Hepatocellular" 21998738 hsa-mir-520e was down-regulated in HepG2 cells after 5 hours of culture with epigallocatechin gallate. +tissue_expression_down hsa-mir-608 "Carcinoma, Hepatocellular" 21998738 hsa-mir-608 was down-regulated in HepG2 cells after 5 hours of culture with epigallocatechin gallate. +tissue_expression_down hsa-mir-629 "Carcinoma, Hepatocellular" 21998738 hsa-mir-629 was down-regulated in HepG2 cells after 5 hours of culture with epigallocatechin gallate. +tissue_expression_down hsa-mir-765 "Carcinoma, Hepatocellular" 21998738 hsa-mir-765 was down-regulated in HepG2 cells after 5 hours of culture with cocoa proanthocyanidin extract. +tissue_expression_down hsa-mir-1-1 "Aortic Aneurysm, Thoracic" 22010139 "miRs -1, -21, -29a, -133a, and -486 showed decreased expression in Thoracic Aortic Aneurysm compared to normal aortic specimens.A significant relationship between miR expression levels (miRs -1, -21, -29a, and -133a) and aortic diameter was identified;" +tissue_expression_down hsa-mir-1-2 "Aortic Aneurysm, Thoracic" 22010139 "miRs -1, -21, -29a, -133a, and -486 showed decreased expression in Thoracic Aortic Aneurysm compared to normal aortic specimens.A significant relationship between miR expression levels (miRs -1, -21, -29a, and -133a) and aortic diameter was identified;" +tissue_expression_down hsa-mir-133a-1 "Aortic Aneurysm, Thoracic" 22010139 "miRs -1, -21, -29a, -133a, and -486 showed decreased expression in Thoracic Aortic Aneurysm compared to normal aortic specimens.A significant relationship between miR expression levels (miRs -1, -21, -29a, and -133a) and aortic diameter was identified;" +tissue_expression_down hsa-mir-133a-2 "Aortic Aneurysm, Thoracic" 22010139 "miRs -1, -21, -29a, -133a, and -486 showed decreased expression in Thoracic Aortic Aneurysm compared to normal aortic specimens.A significant relationship between miR expression levels (miRs -1, -21, -29a, and -133a) and aortic diameter was identified;" +tissue_expression_down hsa-mir-21 "Aortic Aneurysm, Thoracic" 22010139 "miRs -1, -21, -29a, -133a, and -486 showed decreased expression in Thoracic Aortic Aneurysm compared to normal aortic specimens.A significant relationship between miR expression levels (miRs -1, -21, -29a, and -133a) and aortic diameter was identified;" +tissue_expression_down hsa-mir-29a "Aortic Aneurysm, Thoracic" 22010139 "miRs -1, -21, -29a, -133a, and -486 showed decreased expression in Thoracic Aortic Aneurysm compared to normal aortic specimens.A significant relationship between miR expression levels (miRs -1, -21, -29a, and -133a) and aortic diameter was identified;" +tissue_expression_down hsa-mir-26b Lichen Planus 22017396 Levels of COX-2 mRNA were significantly higher while levels of miR-26b were significantly lower in OLP lesions compared to controls. Increased expression of COX-2 and decreased expression of miR-26b in OLP suggests both to play a role in OLP. +tissue_expression_down hsa-mir-107 "Carcinoma, Hepatocellular" 22027761 This miRNA was down-regulated in HepG2 cells treated with BJA32515. +tissue_expression_down hsa-mir-125a "Carcinoma, Hepatocellular" 22027761 This miRNA was down-regulated in HepG2 cells treated with BJA32515. +tissue_expression_down hsa-mir-125b-1 "Carcinoma, Hepatocellular" 22027761 This miRNA was down-regulated in HepG2 cells treated with BJA32515. +tissue_expression_down hsa-mir-125b-2 "Carcinoma, Hepatocellular" 22027761 This miRNA was down-regulated in HepG2 cells treated with BJA32515. +tissue_expression_down hsa-mir-133b "Carcinoma, Hepatocellular" 22027761 This miRNA was down-regulated in HepG2 cells treated with BJA32515. +tissue_expression_down hsa-mir-134 "Carcinoma, Hepatocellular" 22027761 This miRNA was down-regulated in HepG2 cells treated with BJA32515. +tissue_expression_down hsa-mir-139 "Carcinoma, Hepatocellular" 22027761 This miRNA was down-regulated in HepG2 cells treated with BJA32515. +tissue_expression_down hsa-mir-144 "Carcinoma, Hepatocellular" 22027761 This miRNA was down-regulated in HepG2 cells treated with BJA32515. +tissue_expression_down hsa-mir-150 "Carcinoma, Hepatocellular" 22027761 This miRNA was down-regulated in HepG2 cells treated with BJA32515. +tissue_expression_down hsa-mir-151a "Carcinoma, Hepatocellular" 22027761 This miRNA was down-regulated in HepG2 cells treated with BJA32515. +tissue_expression_down hsa-mir-181c "Carcinoma, Hepatocellular" 22027761 This miRNA was down-regulated in HepG2 cells treated with BJA32515. +tissue_expression_down hsa-mir-18a "Carcinoma, Hepatocellular" 22027761 This miRNA was down-regulated in HepG2 cells treated with BJA32515. +tissue_expression_down hsa-mir-195 "Carcinoma, Hepatocellular" 22027761 This miRNA was down-regulated in HepG2 cells treated with BJA32515. +tissue_expression_down hsa-mir-197 "Carcinoma, Hepatocellular" 22027761 This miRNA was down-regulated in HepG2 cells treated with BJA32515. +tissue_expression_down hsa-mir-200a "Carcinoma, Hepatocellular" 22027761 This miRNA was down-regulated in HepG2 cells treated with BJA32515. +tissue_expression_down hsa-mir-202 "Carcinoma, Hepatocellular" 22027761 This miRNA was down-regulated in HepG2 cells treated with BJA32515. +tissue_expression_down hsa-mir-208a "Carcinoma, Hepatocellular" 22027761 This miRNA was down-regulated in HepG2 cells treated with BJA32515. +tissue_expression_down hsa-mir-208b "Carcinoma, Hepatocellular" 22027761 This miRNA was down-regulated in HepG2 cells treated with BJA32515. +tissue_expression_down hsa-mir-212 "Carcinoma, Hepatocellular" 22027761 This miRNA was down-regulated in HepG2 cells treated with BJA32515. +tissue_expression_down hsa-mir-214 "Carcinoma, Hepatocellular" 22027761 This miRNA was down-regulated in HepG2 cells treated with BJA32515. +tissue_expression_down hsa-mir-223 "Carcinoma, Hepatocellular" 22027761 This miRNA was down-regulated in HepG2 cells treated with BJA32515. +tissue_expression_down hsa-mir-24-1 "Carcinoma, Hepatocellular" 22027761 This miRNA was down-regulated in HepG2 cells treated with BJA32515. +tissue_expression_down hsa-mir-24-2 "Carcinoma, Hepatocellular" 22027761 This miRNA was down-regulated in HepG2 cells treated with BJA32515. +tissue_expression_down hsa-mir-296 "Carcinoma, Hepatocellular" 22027761 This miRNA was down-regulated in HepG2 cells treated with BJA32515. +tissue_expression_down hsa-mir-30d "Carcinoma, Hepatocellular" 22027761 This miRNA was down-regulated in HepG2 cells treated with BJA32515. +tissue_expression_down hsa-mir-320a "Carcinoma, Hepatocellular" 22027761 This miRNA was down-regulated in HepG2 cells treated with BJA32515. +tissue_expression_down hsa-mir-320b-1 "Carcinoma, Hepatocellular" 22027761 This miRNA was down-regulated in HepG2 cells treated with BJA32515. +tissue_expression_down hsa-mir-320b-2 "Carcinoma, Hepatocellular" 22027761 This miRNA was down-regulated in HepG2 cells treated with BJA32515. +tissue_expression_down hsa-mir-320c-1 "Carcinoma, Hepatocellular" 22027761 This miRNA was down-regulated in HepG2 cells treated with BJA32515. +tissue_expression_down hsa-mir-320d-1 "Carcinoma, Hepatocellular" 22027761 This miRNA was down-regulated in HepG2 cells treated with BJA32515. +tissue_expression_down hsa-mir-320e "Carcinoma, Hepatocellular" 22027761 This miRNA was down-regulated in HepG2 cells treated with BJA32515. +tissue_expression_down hsa-mir-324 "Carcinoma, Hepatocellular" 22027761 This miRNA was down-regulated in HepG2 cells treated with BJA32515. +tissue_expression_down hsa-mir-326 "Carcinoma, Hepatocellular" 22027761 This miRNA was down-regulated in HepG2 cells treated with BJA32515. +tissue_expression_down hsa-mir-330 "Carcinoma, Hepatocellular" 22027761 This miRNA was down-regulated in HepG2 cells treated with BJA32515. +tissue_expression_down hsa-mir-345 "Carcinoma, Hepatocellular" 22027761 This miRNA was down-regulated in HepG2 cells treated with BJA32515. +tissue_expression_down hsa-mir-346 "Carcinoma, Hepatocellular" 22027761 This miRNA was down-regulated in HepG2 cells treated with BJA32515. +tissue_expression_down hsa-mir-361 "Carcinoma, Hepatocellular" 22027761 This miRNA was down-regulated in HepG2 cells treated with BJA32515. +tissue_expression_down hsa-mir-365a "Carcinoma, Hepatocellular" 22027761 This miRNA was down-regulated in HepG2 cells treated with BJA32515. +tissue_expression_down hsa-mir-365b "Carcinoma, Hepatocellular" 22027761 This miRNA was down-regulated in HepG2 cells treated with BJA32515. +tissue_expression_down hsa-mir-370 "Carcinoma, Hepatocellular" 22027761 This miRNA was down-regulated in HepG2 cells treated with BJA32515. +tissue_expression_down hsa-mir-373 "Carcinoma, Hepatocellular" 22027761 This miRNA was down-regulated in HepG2 cells treated with BJA32515. +tissue_expression_down hsa-mir-378a "Carcinoma, Hepatocellular" 22027761 This miRNA was down-regulated in HepG2 cells treated with BJA32515. +tissue_expression_down hsa-mir-381 "Carcinoma, Hepatocellular" 22027761 This miRNA was down-regulated in HepG2 cells treated with BJA32515. +tissue_expression_down hsa-mir-409 "Carcinoma, Hepatocellular" 22027761 This miRNA was down-regulated in HepG2 cells treated with BJA32515. +tissue_expression_down hsa-mir-423 "Carcinoma, Hepatocellular" 22027761 This miRNA was down-regulated in HepG2 cells treated with BJA32515. +tissue_expression_down hsa-mir-483 "Carcinoma, Hepatocellular" 22027761 This miRNA was down-regulated in HepG2 cells treated with BJA32515. +tissue_expression_down hsa-mir-484 "Carcinoma, Hepatocellular" 22027761 This miRNA was down-regulated in HepG2 cells treated with BJA32515. +tissue_expression_down hsa-mir-485 "Carcinoma, Hepatocellular" 22027761 This miRNA was down-regulated in HepG2 cells treated with BJA32515. +tissue_expression_down hsa-mir-486 "Carcinoma, Hepatocellular" 22027761 This miRNA was down-regulated in HepG2 cells treated with BJA32515. +tissue_expression_down hsa-mir-489 "Carcinoma, Hepatocellular" 22027761 This miRNA was down-regulated in HepG2 cells treated with BJA32515. +tissue_expression_down hsa-mir-490 "Carcinoma, Hepatocellular" 22027761 This miRNA was down-regulated in HepG2 cells treated with BJA32515. +tissue_expression_down hsa-mir-492 "Carcinoma, Hepatocellular" 22027761 This miRNA was down-regulated in HepG2 cells treated with BJA32515. +tissue_expression_down hsa-mir-498 "Carcinoma, Hepatocellular" 22027761 This miRNA was down-regulated in HepG2 cells treated with BJA32515. +tissue_expression_down hsa-mir-500a "Carcinoma, Hepatocellular" 22027761 This miRNA was down-regulated in HepG2 cells treated with BJA32515. +tissue_expression_down hsa-mir-500b "Carcinoma, Hepatocellular" 22027761 This miRNA was down-regulated in HepG2 cells treated with BJA32515. +tissue_expression_down hsa-mir-503 "Carcinoma, Hepatocellular" 22027761 This miRNA was down-regulated in HepG2 cells treated with BJA32515. +tissue_expression_down hsa-mir-518b "Carcinoma, Hepatocellular" 22027761 This miRNA was down-regulated in HepG2 cells treated with BJA32515. +tissue_expression_down hsa-mir-520d "Carcinoma, Hepatocellular" 22027761 This miRNA was down-regulated in HepG2 cells treated with BJA32515. +tissue_expression_down hsa-mir-526a-1 "Carcinoma, Hepatocellular" 22027761 This miRNA was down-regulated in HepG2 cells treated with BJA32515. +tissue_expression_down hsa-mir-526a-2 "Carcinoma, Hepatocellular" 22027761 This miRNA was down-regulated in HepG2 cells treated with BJA32515. +tissue_expression_down hsa-mir-526b "Carcinoma, Hepatocellular" 22027761 This miRNA was down-regulated in HepG2 cells treated with BJA32515. +tissue_expression_down hsa-mir-527 "Carcinoma, Hepatocellular" 22027761 This miRNA was down-regulated in HepG2 cells treated with BJA32515. +tissue_expression_down hsa-mir-542 "Carcinoma, Hepatocellular" 22027761 This miRNA was down-regulated in HepG2 cells treated with BJA32515. +tissue_expression_down hsa-mir-92a-1 "Carcinoma, Hepatocellular" 22027761 This miRNA was down-regulated in HepG2 cells treated with BJA32515. +tissue_expression_down hsa-mir-92a-2 "Carcinoma, Hepatocellular" 22027761 This miRNA was down-regulated in HepG2 cells treated with BJA32515. +tissue_expression_down hsa-mir-92b "Carcinoma, Hepatocellular" 22027761 This miRNA was down-regulated in HepG2 cells treated with BJA32515. +tissue_expression_down hsa-mir-99b "Carcinoma, Hepatocellular" 22027761 This miRNA was down-regulated in HepG2 cells treated with BJA32515. +tissue_expression_down hsa-mir-15a "Carcinoma, Hepatocellular" 22033921 The microRNA 15/16 cluster downregulates protein repair isoaspartyl methyltransferase in hepatoma cells. The authors conclude that PCMT is effectively regulated by the miR15a-16-1 cluster and is involved in apoptosis by preserving the structural stability and biological function of BclxL from deamidation. Control of PCMT expression by snRNAs may thus represent a late check point in apoptosis regulation. +tissue_expression_down hsa-mir-16-1 "Carcinoma, Hepatocellular" 22033921 The microRNA 15/16 cluster downregulates protein repair isoaspartyl methyltransferase in hepatoma cells. The authors conclude that PCMT is effectively regulated by the miR15a-16-1 cluster and is involved in apoptosis by preserving the structural stability and biological function of BclxL from deamidation. Control of PCMT expression by snRNAs may thus represent a late check point in apoptosis regulation. +tissue_expression_down hsa-let-7i "Cardiomyopathy, Dilated" 22041329 "Levels of let-7i, miR-126, and miR-155 were lower in the DCM group than in the controls, whereas levels of miR-21 and TLR4 (both mRNA and protein) were higher in the DCM group than in the control group. Levels of let-7i were negatively correlated with TLR4 protein levels in all subjects. After a mean follow-up period of 509 days, 6 DCM patients (5.8%) had died due to a cardiac cause and 15 (14.6%) had developed heart failure. When patients with DCM were divided into tertiles according to let-7i levels, log-rank analysis showed that the DCM subgroup with low let-7i levels was associated with poor clinical outcomes (P = .02)." +tissue_expression_down hsa-mir-126 "Cardiomyopathy, Dilated" 22041329 "Levels of let-7i, miR-126, and miR-155 were lower in the DCM group than in the controls, whereas levels of miR-21 and TLR4 (both mRNA and protein) were higher in the DCM group than in the control group. Levels of let-7i were negatively correlated with TLR4 protein levels in all subjects. After a mean follow-up period of 509 days, 6 DCM patients (5.8%) had died due to a cardiac cause and 15 (14.6%) had developed heart failure. When patients with DCM were divided into tertiles according to let-7i levels, log-rank analysis showed that the DCM subgroup with low let-7i levels was associated with poor clinical outcomes (P = .02)." +tissue_expression_down hsa-mir-155 "Cardiomyopathy, Dilated" 22041329 "Levels of let-7i, miR-126, and miR-155 were lower in the DCM group than in the controls, whereas levels of miR-21 and TLR4 (both mRNA and protein) were higher in the DCM group than in the control group. Levels of let-7i were negatively correlated with TLR4 protein levels in all subjects. After a mean follow-up period of 509 days, 6 DCM patients (5.8%) had died due to a cardiac cause and 15 (14.6%) had developed heart failure. When patients with DCM were divided into tertiles according to let-7i levels, log-rank analysis showed that the DCM subgroup with low let-7i levels was associated with poor clinical outcomes (P = .02)." +tissue_expression_down hsa-mir-150 Myocardial Infarction 22048267 "Comparing MI patients with VR and those without VR, we found miR-146a up-regulation, and miR-150 and miR-155 down-regulation in patients with VR. In conclusion, our study demonstrated an altered expression of miR-146a, miR-150, and miR-155 in MI compared to the normal hearts." +tissue_expression_down hsa-mir-155 Myocardial Infarction 22048267 "Comparing MI patients with VR and those without VR, we found miR-146a up-regulation, and miR-150 and miR-155 down-regulation in patients with VR. In conclusion, our study demonstrated an altered expression of miR-146a, miR-150, and miR-155 in MI compared to the normal hearts." +tissue_expression_down hsa-mir-383 Ependymoma 22053178 underexpression +tissue_expression_down hsa-mir-485 Ependymoma 22053178 miR-485-5p: underexpression +tissue_expression_down hsa-mir-365a Colon Neoplasms 22072615 "microRNA-365, down-regulated in colon cancer, inhibits cell cycle progression and promotes apoptosis of colon cancer cells by probably targeting Cyclin D1 and Bcl-2." +tissue_expression_down hsa-let-7a-1 Glioblastoma 22074483 "Significantly deregulated miRNAs were miR-3163 (fold change 2.0, p = 0.05), miR-539 (fold change 0.5, p = 0.001), miR-1305 (fold change 0.5, p = 0.05), miR-1260 (fold change 0.5, p = 0.03) and let-7a (fold change 0.3, p = 0.02) after temozolomide treatment." +tissue_expression_down hsa-let-7a-2 Glioblastoma 22074483 "Significantly deregulated miRNAs were miR-3163 (fold change 2.0, p = 0.05), miR-539 (fold change 0.5, p = 0.001), miR-1305 (fold change 0.5, p = 0.05), miR-1260 (fold change 0.5, p = 0.03) and let-7a (fold change 0.3, p = 0.02) after temozolomide treatment." +tissue_expression_down hsa-let-7a-3 Glioblastoma 22074483 "Significantly deregulated miRNAs were miR-3163 (fold change 2.0, p = 0.05), miR-539 (fold change 0.5, p = 0.001), miR-1305 (fold change 0.5, p = 0.05), miR-1260 (fold change 0.5, p = 0.03) and let-7a (fold change 0.3, p = 0.02) after temozolomide treatment." +tissue_expression_down hsa-mir-1260a Glioblastoma 22074483 "Significantly deregulated miRNAs were miR-3163 (fold change 2.0, p = 0.05), miR-539 (fold change 0.5, p = 0.001), miR-1305 (fold change 0.5, p = 0.05), miR-1260 (fold change 0.5, p = 0.03) and let-7a (fold change 0.3, p = 0.02) after temozolomide treatment." +tissue_expression_down hsa-mir-1305 Glioblastoma 22074483 "Significantly deregulated miRNAs were miR-3163 (fold change 2.0, p = 0.05), miR-539 (fold change 0.5, p = 0.001), miR-1305 (fold change 0.5, p = 0.05), miR-1260 (fold change 0.5, p = 0.03) and let-7a (fold change 0.3, p = 0.02) after temozolomide treatment." +tissue_expression_down hsa-mir-539 Glioblastoma 22074483 "Significantly deregulated miRNAs were miR-3163 (fold change 2.0, p = 0.05), miR-539 (fold change 0.5, p = 0.001), miR-1305 (fold change 0.5, p = 0.05), miR-1260 (fold change 0.5, p = 0.03) and let-7a (fold change 0.3, p = 0.02) after temozolomide treatment." +tissue_expression_down hsa-mir-27b Lichen Planus 22077423 "miR-27b was significantly down-regulated in OLP tissue, and miR-27b expression was even more suppressed in atrophic-erosive OLP than in reticular OLP. In addition, miR-27b was found to be expressed in the epithelial keratinocyte layer of both normal and OLP tissues." +tissue_expression_down hsa-mir-449a "Carcinoma, Lung, Non-Small-Cell" 22078727 "miR-449a/b was significantly down-regulated in lung cancer tissues compared with normal lung tissues, while HDAC1 was up-regulated in lung cancer tissues.Combined treatment with miR-449a and HDAC inhibitors (apicidin and TSA) in HCC95 cells showed a significant growth reduction compared to mono-treatment with HDAC inhibitors. Interestingly, combination treatment with TSA and miR-449a was had significant growth reduction than a combination with apicidin." +tissue_expression_down hsa-mir-449b "Carcinoma, Lung, Non-Small-Cell" 22078727 "miR-449a/b was significantly down-regulated in lung cancer tissues compared with normal lung tissues, while HDAC1 was up-regulated in lung cancer tissues.Combined treatment with miR-449a and HDAC inhibitors (apicidin and TSA) in HCC95 cells showed a significant growth reduction compared to mono-treatment with HDAC inhibitors. Interestingly, combination treatment with TSA and miR-449a was had significant growth reduction than a combination with apicidin." +tissue_expression_down hsa-mir-218-1 Glioma 22088371 "The expression level of miR-218 is an important reference indicator for the assessment of the grade of gliomas. An aberrant decrease of its expression may lead to an increase of the CDK6 expression and proliferative activity of giloma cells. Introducing exogenous miR-218 may effectively down-regulate the CDK6 expression, inhibit cell proliferation and induce apoptosis of malignant giloma cells." +tissue_expression_down hsa-mir-218-2 Glioma 22088371 "The expression level of miR-218 is an important reference indicator for the assessment of the grade of gliomas. An aberrant decrease of its expression may lead to an increase of the CDK6 expression and proliferative activity of giloma cells. Introducing exogenous miR-218 may effectively down-regulate the CDK6 expression, inhibit cell proliferation and induce apoptosis of malignant giloma cells." +tissue_expression_down hsa-mir-203 Barrett Esophagus 22094011 "We demonstrated unequivocal statistically significant upregulation of two microRNAs (miR-192, 196a) and downregulation of miR-203 and positive miR-196a correlation with progression from intestinal metaplasia to adenocarcinoma compared to normal individuals." +tissue_expression_down hsa-mir-200c Breast Neoplasms 22101791 "Down-regulation of microRNA-200c is associated with drug resistance in human breast cancer.Down-regulated miR-200c was observed in non-responders as compared to responders. In addition, miR-200c expression was observed to be down-regulated over 800-fold in human breast cancer cells resistant to doxorubicin MCF-7/ADR as compared to the parental MCF-7 cells. Up-regulation of miR-200c with transfection of miR-200c mimics in breast cancer cells could enhance the chemosensitivity to epirubicin and reduce expression of multidrug resistance 1 mRNA and P-glycoprotein. Moreover, our study demonstrated that restoration of miR-200c in MCF-7/ADR cells could increase intracellular doxorubicin accumulation determined by flow cytometry." +tissue_expression_down hsa-mir-34a Pancreatic Neoplasms 22114136 "In the initial cohort of 48 PDAC (pancreatic ductal adenocarcinoma) patients, high expression of miR-21 (Hazard ratio (HR): 3.22, 95% Confidence Interval (CI):1.21-8.58) and reduced expression of miR-34a (HR 0.15, 95%CI: 0.06-0.37) and miR-30d (HR:0.30, 95%CI:0.12-0.79) were associated with poor overall survival following resection independent of clinical covariates. In a further validation set of 24 patients miR-21 and miR-34a expression again significantly correlated with overall survival (P = 0.031 and P = 0.001)." +tissue_expression_down hsa-mir-206 Colorectal Carcinoma 22120473 "Increased expression of miR-21, mir-135a and miR-335 was associated with clinical progression of CRC (colorectal cancer), while miR-206 demonstrated an opposite trend. The levels of mir-21 did not associate with the expression of PTEN, an important tumour suppressor in CRC and one of many putative targets of miR-21, but interestingly was associated with stage of disease in the PTEN expressing tumours. Surprisingly, let7a, a KRAS-targeting miR, showed elevated expression in metastatic disease compared to normal mucosa or non-metastatic disease, and only in KRAS mutation positive tumors. Finally, a prognostic signature of miR 21,135a, 335, 206 and let-7a for detecting the presence of metastases had a specificity of 87% and sensitivity of 76% for the presence of metastases." +tissue_expression_down hsa-mir-221 Prostate Neoplasms 22127852 The altered expression of MiR-221/-222 (increased miR-221/-222 expression ) and MiR-23b/-27b (down-regulated ) is associated with the development of human castration resistant prostate cancer. +tissue_expression_down hsa-mir-222 Prostate Neoplasms 22127852 The altered expression of MiR-221/-222 (increased miR-221/-222 expression ) and MiR-23b/-27b (down-regulated ) is associated with the development of human castration resistant prostate cancer. +tissue_expression_down hsa-mir-23b Prostate Neoplasms 22127852 The altered expression of MiR-221/-222 (increased miR-221/-222 expression ) and MiR-23b/-27b (down-regulated ) is associated with the development of human castration resistant prostate cancer. +tissue_expression_down hsa-mir-27b Prostate Neoplasms 22127852 The altered expression of MiR-221/-222 (increased miR-221/-222 expression ) and MiR-23b/-27b (down-regulated ) is associated with the development of human castration resistant prostate cancer. +tissue_expression_down hsa-mir-107 Head And Neck Neoplasms 22158047 microRNA-107 functions as a candidate tumor-suppressor gene in head and neck squamous cell carcinoma by downregulation of protein kinase C +tissue_expression_down hsa-mir-720 Rectal Neoplasms 22172905 "Microarray analysis selected 14 miRNAs as being differentially expressed in TRG1 patients, and 13 were confirmed by qRT-PCR: 11 miRNAs (miR-1183, miR-483-5p, miR-622, miR-125a-3p, miR-1224-5p, miR-188-5p, miR-1471, miR-671-5p, miR-1909, miR-630, miR-765) were significantly upregulated in TRG1 patients, 2 (miR-1274b, miR-720) were downexpressed. MiR-622 and miR-630 had a 100% sensitivity and specificity in selecting TRG1 cases." +tissue_expression_down hsa-mir-122 "Carcinoma, Hepatocellular" 22174818 "Although miR-222, miR-223 or miR-21 were significantly up- or down-regulated between HCC patients and healthy controls, no significant difference was observed in the levels of these miRNAs between HBV patients without and with HCC. MiR-122 in serum was significantly higher in HCC patients than healthy controls (p<0.001). More importantly, it was found that the levels of miR-122 were significantly reduced in the post-operative serum samples when compared to the pre-operative samples. Although serum miR-122 was also elevated in HBV patients with HCC comparing with those without HCC, the difference was at the border line (p=0.043)." +tissue_expression_down hsa-mir-21 "Carcinoma, Hepatocellular" 22174818 "Although miR-222, miR-223 or miR-21 were significantly up- or down-regulated between HCC patients and healthy controls, no significant difference was observed in the levels of these miRNAs between HBV patients without and with HCC. MiR-122 in serum was significantly higher in HCC patients than healthy controls (p<0.001). More importantly, it was found that the levels of miR-122 were significantly reduced in the post-operative serum samples when compared to the pre-operative samples. Although serum miR-122 was also elevated in HBV patients with HCC comparing with those without HCC, the difference was at the border line (p=0.043)." +tissue_expression_down hsa-mir-222 "Carcinoma, Hepatocellular" 22174818 "Although miR-222, miR-223 or miR-21 were significantly up- or down-regulated between HCC patients and healthy controls, no significant difference was observed in the levels of these miRNAs between HBV patients without and with HCC. MiR-122 in serum was significantly higher in HCC patients than healthy controls (p<0.001). More importantly, it was found that the levels of miR-122 were significantly reduced in the post-operative serum samples when compared to the pre-operative samples. Although serum miR-122 was also elevated in HBV patients with HCC comparing with those without HCC, the difference was at the border line (p=0.043)." +tissue_expression_down hsa-mir-223 "Carcinoma, Hepatocellular" 22174818 "Although miR-222, miR-223 or miR-21 were significantly up- or down-regulated between HCC patients and healthy controls, no significant difference was observed in the levels of these miRNAs between HBV patients without and with HCC. MiR-122 in serum was significantly higher in HCC patients than healthy controls (p<0.001). More importantly, it was found that the levels of miR-122 were significantly reduced in the post-operative serum samples when compared to the pre-operative samples. Although serum miR-122 was also elevated in HBV patients with HCC comparing with those without HCC, the difference was at the border line (p=0.043)." +tissue_expression_down hsa-mir-1231 Colon Neoplasms 22180714 "Compared with expression in SW1116 cells, 35 miRNAs (including hsa-miR-192, hsa-miR-29b, hsa-miR-215, hsa-miR-194, hsa-miR-33a and hsa-miR-32) were upregulated more than 1.5-fold, and 11 miRNAs (including hsa-miR-93, hsa-miR-1231, hsa-miRPlus-F1080, hsa-miR-524-3p, hsa-miR-886-3p and hsa-miR-561) were downregulated in SW1116csc." +tissue_expression_down hsa-mir-524 Colon Neoplasms 22180714 "Compared with expression in SW1116 cells, 35 miRNAs (including hsa-miR-192, hsa-miR-29b, hsa-miR-215, hsa-miR-194, hsa-miR-33a and hsa-miR-32) were upregulated more than 1.5-fold, and 11 miRNAs (including hsa-miR-93, hsa-miR-1231, hsa-miRPlus-F1080, hsa-miR-524-3p, hsa-miR-886-3p and hsa-miR-561) were downregulated in SW1116csc." +tissue_expression_down hsa-mir-561 Colon Neoplasms 22180714 "Compared with expression in SW1116 cells, 35 miRNAs (including hsa-miR-192, hsa-miR-29b, hsa-miR-215, hsa-miR-194, hsa-miR-33a and hsa-miR-32) were upregulated more than 1.5-fold, and 11 miRNAs (including hsa-miR-93, hsa-miR-1231, hsa-miRPlus-F1080, hsa-miR-524-3p, hsa-miR-886-3p and hsa-miR-561) were downregulated in SW1116csc." +tissue_expression_down hsa-mir-886 Colon Neoplasms 22180714 "Compared with expression in SW1116 cells, 35 miRNAs (including hsa-miR-192, hsa-miR-29b, hsa-miR-215, hsa-miR-194, hsa-miR-33a and hsa-miR-32) were upregulated more than 1.5-fold, and 11 miRNAs (including hsa-miR-93, hsa-miR-1231, hsa-miRPlus-F1080, hsa-miR-524-3p, hsa-miR-886-3p and hsa-miR-561) were downregulated in SW1116csc." +tissue_expression_down hsa-mir-93 Colon Neoplasms 22180714 "Compared with expression in SW1116 cells, 35 miRNAs (including hsa-miR-192, hsa-miR-29b, hsa-miR-215, hsa-miR-194, hsa-miR-33a and hsa-miR-32) were upregulated more than 1.5-fold, and 11 miRNAs (including hsa-miR-93, hsa-miR-1231, hsa-miRPlus-F1080, hsa-miR-524-3p, hsa-miR-886-3p and hsa-miR-561) were downregulated in SW1116csc." +tissue_expression_down hsa-mir-143 "Allergic Rhinitis,Perennial" 22185732 down-regulated +tissue_expression_down hsa-mir-187 "Allergic Rhinitis,Perennial" 22185732 down-regulated +tissue_expression_down hsa-mir-224 "Allergic Rhinitis,Perennial" 22185732 down-regulated +tissue_expression_down hsa-mir-498 "Allergic Rhinitis,Perennial" 22185732 down-regulated +tissue_expression_down hsa-mir-767 "Allergic Rhinitis,Perennial" 22185732 miR-767-5p: down-regulated +tissue_expression_down hsa-mir-874 "Allergic Rhinitis,Perennial" 22185732 down-regulated +tissue_expression_down hsa-mir-143 Urinary Bladder Cancer 22194833 mir-21 expression increased with worsening clinical diagnosis but that mir-143 was not correlated with histology. These observations were in stark contrast to previous reports involving cervical cancer cell lines in which mir-143 was consistently down-regulated but mir-21 largely unaffected. +tissue_expression_down hsa-mir-192 Gastric Neoplasms 22205577 The down-regulation of miR-192 and -215 was demonstrated to be associated with increased tumor sizes and advanced Borrmann type tumors. +tissue_expression_down hsa-mir-150 Acquired Immunodeficiency Syndrome 22205749 "we used microarray expression analysis to identify miRNAs miR-27b, miR-29b, miR-150, and miR-223 as being significantly downregulated upon CD4(+) T cell activation" +tissue_expression_down hsa-mir-223 Acquired Immunodeficiency Syndrome 22205749 "we used microarray expression analysis to identify miRNAs miR-27b, miR-29b, miR-150, and miR-223 as being significantly downregulated upon CD4(+) T cell activation" +tissue_expression_down hsa-mir-27b Acquired Immunodeficiency Syndrome 22205749 "we used microarray expression analysis to identify miRNAs miR-27b, miR-29b, miR-150, and miR-223 as being significantly downregulated upon CD4(+) T cell activation" +tissue_expression_down hsa-mir-29b Acquired Immunodeficiency Syndrome 22205749 "we used microarray expression analysis to identify miRNAs miR-27b, miR-29b, miR-150, and miR-223 as being significantly downregulated upon CD4(+) T cell activation" +tissue_expression_down hsa-mir-200a Diabetic Nephropathy 22211842 "TGF-beta1 activates Smad3 to regulate microRNAs that mediate renal fibrosis. Of them, miR-21 and miR-192 are upregulated but miR-29 and miR-200 families are downregulated." +tissue_expression_down hsa-mir-200b Diabetic Nephropathy 22211842 "TGF-beta1 activates Smad3 to regulate microRNAs that mediate renal fibrosis. Of them, miR-21 and miR-192 are upregulated but miR-29 and miR-200 families are downregulated." +tissue_expression_down hsa-mir-200c Diabetic Nephropathy 22211842 "TGF-beta1 activates Smad3 to regulate microRNAs that mediate renal fibrosis. Of them, miR-21 and miR-192 are upregulated but miR-29 and miR-200 families are downregulated." +tissue_expression_down hsa-mir-29a Diabetic Nephropathy 22211842 "TGF-beta1 activates Smad3 to regulate microRNAs that mediate renal fibrosis. Of them, miR-21 and miR-192 are upregulated but miR-29 and miR-200 families are downregulated." +tissue_expression_down hsa-mir-29b-1 Diabetic Nephropathy 22211842 "TGF-beta1 activates Smad3 to regulate microRNAs that mediate renal fibrosis. Of them, miR-21 and miR-192 are upregulated but miR-29 and miR-200 families are downregulated." +tissue_expression_down hsa-mir-29b-2 Diabetic Nephropathy 22211842 "TGF-beta1 activates Smad3 to regulate microRNAs that mediate renal fibrosis. Of them, miR-21 and miR-192 are upregulated but miR-29 and miR-200 families are downregulated." +tissue_expression_down hsa-mir-29c Diabetic Nephropathy 22211842 "TGF-beta1 activates Smad3 to regulate microRNAs that mediate renal fibrosis. Of them, miR-21 and miR-192 are upregulated but miR-29 and miR-200 families are downregulated." +tissue_expression_down hsa-mir-145 "Carcinoma, Hepatocellular" 22213236 down-regulated in HCC tissues. +tissue_expression_down hsa-mir-146a "Carcinoma, Hepatocellular" 22213236 down-regulated in HCC tissues. +tissue_expression_down hsa-mir-200c "Carcinoma, Hepatocellular" 22213236 down-regulated in HCC tissues. +tissue_expression_down hsa-mir-223 "Carcinoma, Hepatocellular" 22213236 down-regulated in HCC tissues. +tissue_expression_down hsa-mir-146a Pancreatic Neoplasms 22213426 "We found over-expression of miR-21, miR-221, miR-27a, miR-27b, and miR-155, and down-regulation of miR-216a,miR-216b, miR-217, and miR-146a expression in tumors derived from KC and KCI mouse model" +tissue_expression_down hsa-mir-216a Pancreatic Neoplasms 22213426 "We found over-expression of miR-21, miR-221, miR-27a, miR-27b, and miR-155, and down-regulation of miR-216a,miR-216b, miR-217, and miR-146a expression in tumors derived from KC and KCI mouse model" +tissue_expression_down hsa-mir-216b Pancreatic Neoplasms 22213426 "We found over-expression of miR-21, miR-221, miR-27a, miR-27b, and miR-155, and down-regulation of miR-216a,miR-216b, miR-217, and miR-146a expression in tumors derived from KC and KCI mouse model" +tissue_expression_down hsa-mir-217 Pancreatic Neoplasms 22213426 "We found over-expression of miR-21, miR-221, miR-27a, miR-27b, and miR-155, and down-regulation of miR-216a,miR-216b, miR-217, and miR-146a expression in tumors derived from KC and KCI mouse model" +tissue_expression_down hsa-mir-200c Melanoma 22223089 "miR-200c, miR-205 and miR-211 are downregulated in melanoma and act as tumour suppressors." +tissue_expression_down hsa-mir-205 Melanoma 22223089 "miR-200c, miR-205 and miR-211 are downregulated in melanoma and act as tumour suppressors." +tissue_expression_down hsa-mir-211 Melanoma 22223089 "miR-200c, miR-205 and miR-211 are downregulated in melanoma and act as tumour suppressors." +tissue_expression_down hsa-mir-375 Head And Neck Neoplasms 22234174 Low-Level Expression of miR-375 Correlates with Poor Outcome and Metastasis While Altering the Invasive Properties of Head and Neck Squamous Cell Carcinomas. +tissue_expression_down hsa-mir-203 Melanoma 22235882 "A decreased expression of miR-203 was significantly associated with a shorter survival time. Also, miR-203 and -205 were markedly down-regulated in canine and human MM cell lines tested." +tissue_expression_down hsa-mir-205 Melanoma 22235882 "A decreased expression of miR-203 was significantly associated with a shorter survival time. Also, miR-203 and -205 were markedly down-regulated in canine and human MM cell lines tested." +tissue_expression_down hsa-let-7e Colorectal Carcinoma 22241525 "Six miRNAs were up-regulated from non-neoplastic tissue to dysplasia, but down-regulated from dysplasia to cancer (miR-122, miR-181a, miR-146b-5p, let-7e, miR-17, miR-143)" +tissue_expression_down hsa-mir-122 Colorectal Carcinoma 22241525 "Six miRNAs were up-regulated from non-neoplastic tissue to dysplasia, but down-regulated from dysplasia to cancer (miR-122, miR-181a, miR-146b-5p, let-7e, miR-17, miR-143)" +tissue_expression_down hsa-mir-143 Colorectal Carcinoma 22241525 "Six miRNAs were up-regulated from non-neoplastic tissue to dysplasia, but down-regulated from dysplasia to cancer (miR-122, miR-181a, miR-146b-5p, let-7e, miR-17, miR-143)" +tissue_expression_down hsa-mir-146b Colorectal Carcinoma 22241525 "Six miRNAs were up-regulated from non-neoplastic tissue to dysplasia, but down-regulated from dysplasia to cancer (miR-122, miR-181a, miR-146b-5p, let-7e, miR-17, miR-143)" +tissue_expression_down hsa-mir-17 Colorectal Carcinoma 22241525 "Six miRNAs were up-regulated from non-neoplastic tissue to dysplasia, but down-regulated from dysplasia to cancer (miR-122, miR-181a, miR-146b-5p, let-7e, miR-17, miR-143)" +tissue_expression_down hsa-mir-181a-2 Colorectal Carcinoma 22241525 "Six miRNAs were up-regulated from non-neoplastic tissue to dysplasia, but down-regulated from dysplasia to cancer (miR-122, miR-181a, miR-146b-5p, let-7e, miR-17, miR-143)" +tissue_expression_down hsa-mir-146b Neuroblastoma 22244746 under-expressed in mature neuron. +tissue_expression_down hsa-mir-152 Neuroblastoma 22244746 under-expressed in mature neuron. +tissue_expression_down hsa-mir-339 Neuroblastoma 22244746 miR-339-5p: under-expressed in mature neuron. +tissue_expression_down hsa-mir-370 Neuroblastoma 22244746 under-expressed in neuroblastoma. +tissue_expression_down hsa-mir-9-1 Neuroblastoma 22244746 under-expressed in neuroblastoma. +tissue_expression_down hsa-mir-9-2 Neuroblastoma 22244746 under-expressed in neuroblastoma. +tissue_expression_down hsa-mir-9-3 Neuroblastoma 22244746 under-expressed in neuroblastoma. +tissue_expression_down hsa-mir-34b Parkinson Disease 22245218 "miR-133b is deficient in the PD midbrain as well as in mouse models, and miR-34b/34c are decreased in several affected brain regions in PD and incidental Lewy body disease." +tissue_expression_down hsa-mir-34c Parkinson Disease 22245218 "miR-133b is deficient in the PD midbrain as well as in mouse models, and miR-34b/34c are decreased in several affected brain regions in PD and incidental Lewy body disease." +tissue_expression_down hsa-mir-100 Ovarian Neoplasms 22246341 "The level of miR-100 was significantly lower in EOC (epithelial ovarian cancer) tissues compared to adjacent normal tissues. Low miR-100 expression was found to be closely correlated with advanced FIGO stage, higher serum CA125 expression level and lymph node involvement." +tissue_expression_down hsa-mir-143 Colorectal Carcinoma 22273643 Down-regulation of fecal miR-143 and miR-145 are potential markers for colorectal cancer. +tissue_expression_down hsa-mir-145 Colorectal Carcinoma 22273643 Down-regulation of fecal miR-143 and miR-145 are potential markers for colorectal cancer. +tissue_expression_down hsa-let-7c "Carcinoma, Hepatocellular" 22289550 Levels of let-7c miRNA were significantly lower in HCC tissues than in corresponding normal adjacent tumour tissues and there was a correlation between the downregulation of let-7c and poor tissue differentiation in HCC. +tissue_expression_down hsa-mir-134 Lung Neoplasms 22306127 miR-27b and miR-134 levels were significantly lower in the tumors than normal tissue. +tissue_expression_down hsa-mir-27b Lung Neoplasms 22306127 miR-27b and miR-134 levels were significantly lower in the tumors than normal tissue. +tissue_expression_down hsa-mir-125a Lymphoma 22307176 significantly underexpressed in SMZL (splenic marginal zone lymphoma). +tissue_expression_down hsa-mir-126 Lymphoma 22307176 significantly underexpressed in SMZL (splenic marginal zone lymphoma). +tissue_expression_down hsa-mir-139 Lymphoma 22307176 significantly underexpressed in SMZL (splenic marginal zone lymphoma). +tissue_expression_down hsa-mir-146a Lymphoma 22307176 significantly overexpressed in SMZL (splenic marginal zone lymphoma). +tissue_expression_down hsa-mir-155 Lymphoma 22307176 significantly overexpressed in SMZL (splenic marginal zone lymphoma). +tissue_expression_down hsa-mir-21 Lymphoma 22307176 significantly overexpressed in SMZL (splenic marginal zone lymphoma). +tissue_expression_down hsa-mir-345 Lymphoma 22307176 significantly underexpressed in SMZL (splenic marginal zone lymphoma). +tissue_expression_down hsa-mir-122 "Carcinoma, Hepatocellular" 22312705 MiR-122 increases sensitivity of drug-resistant BEL-7402/5-FU cells to 5-fluorouracil via down-regulation of bcl-2 family proteins. +tissue_expression_down hsa-mir-1322 Esophageal Neoplasms 22315007 "miR-1322 could significantly down-regulate the ECRG2 with TCA3 allele (P<0.01), but it could not down-regulate the ECRG2 with TCA4 allele significantly (P>0.05). MicroRNA-1322 regulates ECRG2 allele specifically and acts as a potential biomarker in patients with esophageal squamous cell carcinoma." +tissue_expression_down hsa-mir-132 Schizophrenia 22315408 MicroRNA-132 downregulation in schizophrenia has implications for both neurodevelopment and adult brain function. +tissue_expression_down hsa-let-7d Breast Neoplasms 22315424 "let-7d, miR-210, and -221 were down-regulated in the in situ and up-regulated in the invasive transition, thus featuring an expression reversal along the cancer progression path." +tissue_expression_down hsa-mir-210 Breast Neoplasms 22315424 "let-7d, miR-210, and -221 were down-regulated in the in situ and up-regulated in the invasive transition, thus featuring an expression reversal along the cancer progression path." +tissue_expression_down hsa-mir-221 Breast Neoplasms 22315424 "let-7d, miR-210, and -221 were down-regulated in the in situ and up-regulated in the invasive transition, thus featuring an expression reversal along the cancer progression path." +tissue_expression_down hsa-mir-223 "Leukemia, Lymphocytic, Chronic, B-Cell" 22321781 The down-regulation of microRNA-223 was associated with disease aggressiveness in CLL. +tissue_expression_down hsa-mir-193a Lung Neoplasms 22325218 mir-33a was down-regulated by 92.8% and mir-193a-3p by 86.5% in epithelial-mesenchymal transition (EMT) on the expression of microRNAs (miRNAs) in lung cancer A549 cells. +tissue_expression_down hsa-mir-33a Lung Neoplasms 22325218 mir-33a was down-regulated by 92.8% and mir-193a-3p by 86.5% in epithelial-mesenchymal transition (EMT) on the expression of microRNAs (miRNAs) in lung cancer A549 cells. +tissue_expression_down hsa-mir-155 Inflammation 22326887 Glucocorticoids inhibit lipopolysaccharide-mediated inflammatory response by downregulating microRNA-155 +tissue_expression_down hsa-mir-17 Urinary Bladder Cancer 22334592 The anticancer activity of CSL in 253JB-V cells is due to induction of ROS and ROS-mediated induction of Sp repressors (ZBTB4/ZBTB10) through downregulation of miR-27a and miR-20a/17-5p. +tissue_expression_down hsa-mir-20a Urinary Bladder Cancer 22334592 The anticancer activity of CSL in 253JB-V cells is due to induction of ROS and ROS-mediated induction of Sp repressors (ZBTB4/ZBTB10) through downregulation of miR-27a and miR-20a/17-5p. +tissue_expression_down hsa-mir-27a Urinary Bladder Cancer 22334592 The anticancer activity of CSL in 253JB-V cells is due to induction of ROS and ROS-mediated induction of Sp repressors (ZBTB4/ZBTB10) through downregulation of miR-27a and miR-20a/17-5p. +tissue_expression_down hsa-mir-142 Osteosarcoma 22350417 reduced expression +tissue_expression_down hsa-mir-16-1 Osteosarcoma 22350417 reduced expression +tissue_expression_down hsa-mir-16-2 Osteosarcoma 22350417 reduced expression +tissue_expression_down hsa-mir-29b-1 Osteosarcoma 22350417 reduced expression +tissue_expression_down hsa-mir-29b-2 Osteosarcoma 22350417 reduced expression +tissue_expression_down hsa-mir-203 Burns 22360957 miR-203 was down-regulated in denatured dermis compared with those in normal skin. +tissue_expression_down hsa-mir-21 Esophageal Neoplasms 22363450 "Curcumin treatment down-regulate the expressions of Notch-1 specific microRNAs miR-21 and miR-34a, and upregulated tumor suppressor let-7a miRNA." +tissue_expression_down hsa-mir-34a Esophageal Neoplasms 22363450 "Curcumin treatment down-regulate the expressions of Notch-1 specific microRNAs miR-21 and miR-34a, and upregulated tumor suppressor let-7a miRNA." +tissue_expression_down hsa-mir-145 Gastric Neoplasms 22370644 "The authors demonstrate a stepwise downregulation of miR-145 level in nontumorous gastric mucosa, primary gastric cancers and their secondary metastases.N-cadherin (CDH2) was proved to be a direct target of miR-145" +tissue_expression_down hsa-mir-155 Myelodysplastic Syndromes 22371183 "Real-time PCR approach confirmed that mir-155, miR-181a and miR-222 were down-expressed in mesenchymal stromal cells from myelodysplastic syndrome patients." +tissue_expression_down hsa-mir-181a-1 Myelodysplastic Syndromes 22371183 "Real-time PCR approach confirmed that mir-155, miR-181a and miR-222 were down-expressed in mesenchymal stromal cells from myelodysplastic syndrome patients." +tissue_expression_down hsa-mir-181a-2 Myelodysplastic Syndromes 22371183 "Real-time PCR approach confirmed that mir-155, miR-181a and miR-222 were down-expressed in mesenchymal stromal cells from myelodysplastic syndrome patients." +tissue_expression_down hsa-mir-222 Myelodysplastic Syndromes 22371183 "Real-time PCR approach confirmed that mir-155, miR-181a and miR-222 were down-expressed in mesenchymal stromal cells from myelodysplastic syndrome patients." +tissue_expression_down hsa-let-7a-1 Gastric Neoplasms 22374783 "Real-time RT-PCR analysis demonstrated an increase in mir-21 and mir-302 expression level in CSCs(cancer stem cells), relative to cancer cells, whereas let-7a expression level was decreased in CSC in comparison with cancer cells. mir-372, mir-373 and mir-520c-5p were markedly increased in cancer cells in comparison with CSCs." +tissue_expression_down hsa-let-7a-2 Gastric Neoplasms 22374783 "Real-time RT-PCR analysis demonstrated an increase in mir-21 and mir-302 expression level in CSCs(cancer stem cells), relative to cancer cells, whereas let-7a expression level was decreased in CSC in comparison with cancer cells. mir-372, mir-373 and mir-520c-5p were markedly increased in cancer cells in comparison with CSCs." +tissue_expression_down hsa-let-7a-3 Gastric Neoplasms 22374783 "Real-time RT-PCR analysis demonstrated an increase in mir-21 and mir-302 expression level in CSCs(cancer stem cells), relative to cancer cells, whereas let-7a expression level was decreased in CSC in comparison with cancer cells. mir-372, mir-373 and mir-520c-5p were markedly increased in cancer cells in comparison with CSCs." +tissue_expression_down hsa-mir-375 Colorectal Carcinoma 22377847 miR-375 expression was frequently downregulated in the colorectal cancer tissues compared to the non-tumor counterparts +tissue_expression_down hsa-mir-183 "Carcinoma, Basal Cell" 22384406 The expression level of miR-183 was consistently lower in infiltrative than nodular tumors and could be one element underlying the difference in invasiveness. +tissue_expression_down hsa-mir-192 Urinary Bladder Cancer 22386240 "Compared with controls, the patients with bladder cancer had a lower expression of the miR-200 family, miR-192, and miR-155 in the urinary sediment; lower expression of miR-192; and higher expression of miR-155 in the urinary supernatant." +tissue_expression_down hsa-mir-200a Urinary Bladder Cancer 22386240 "Compared with controls, the patients with bladder cancer had a lower expression of the miR-200 family, miR-192, and miR-155 in the urinary sediment; lower expression of miR-192; and higher expression of miR-155 in the urinary supernatant." +tissue_expression_down hsa-mir-200b Urinary Bladder Cancer 22386240 "Compared with controls, the patients with bladder cancer had a lower expression of the miR-200 family, miR-192, and miR-155 in the urinary sediment; lower expression of miR-192; and higher expression of miR-155 in the urinary supernatant." +tissue_expression_down hsa-mir-200c Urinary Bladder Cancer 22386240 "Compared with controls, the patients with bladder cancer had a lower expression of the miR-200 family, miR-192, and miR-155 in the urinary sediment; lower expression of miR-192; and higher expression of miR-155 in the urinary supernatant." +tissue_expression_down hsa-mir-130a Prostate Neoplasms 22391564 "MiR-130a, miR-203 and miR-205 jointly repress key oncogenic pathways and are downregulated in prostate carcinoma." +tissue_expression_down hsa-mir-203 Prostate Neoplasms 22391564 "MiR-130a, miR-203 and miR-205 jointly repress key oncogenic pathways and are downregulated in prostate carcinoma." +tissue_expression_down hsa-mir-205 Prostate Neoplasms 22391564 "MiR-130a, miR-203 and miR-205 jointly repress key oncogenic pathways and are downregulated in prostate carcinoma." +tissue_expression_down hsa-mir-100 Bladder Neoplasms 22393979 Differential miRNA expression profiles in bladder urothelial carcinomas identified miR-100 down-regulation and miR-708 up-regulation among the most common alterations +tissue_expression_down hsa-mir-129-1 "Scleroderma, Systemic" 22403442 "IL-17A signaling, not IL-17F, has an antifibrogenic effect via the upregulation of miR-129-5p and the downregulation of connective tissue growth factor and §Ø©ã(I) collagen." +tissue_expression_down hsa-mir-129-2 "Scleroderma, Systemic" 22403442 "IL-17A signaling, not IL-17F, has an antifibrogenic effect via the upregulation of miR-129-5p and the downregulation of connective tissue growth factor and §Ø©ã(I) collagen." +tissue_expression_down hsa-let-7a-1 Breast Neoplasms 22403704 "Treatment with E2, BPA and DDT decreased (p<0.05) miR-21 expression. Several members of the let-7 family (let-7a, let-7b, let-7c, let-7d, let-7e and let-7f), were downregulated (p<0.05) by all three treatments.and miR-15b (p<0.005) and miR-27b (p<0.01) were also downregulated by the three treatments.upregulation of miR-638 (P<0.005), miR-663 (P<0.005), and miR-1915 (P<0.005) was observed after treatment of MCF7 cells with E2, BPA or DDT" +tissue_expression_down hsa-let-7a-2 Breast Neoplasms 22403704 "Treatment with E2, BPA and DDT decreased (p<0.05) miR-21 expression. Several members of the let-7 family (let-7a, let-7b, let-7c, let-7d, let-7e and let-7f), were downregulated (p<0.05) by all three treatments.and miR-15b (p<0.005) and miR-27b (p<0.01) were also downregulated by the three treatments.upregulation of miR-638 (P<0.005), miR-663 (P<0.005), and miR-1915 (P<0.005) was observed after treatment of MCF7 cells with E2, BPA or DDT" +tissue_expression_down hsa-let-7a-3 Breast Neoplasms 22403704 "Treatment with E2, BPA and DDT decreased (p<0.05) miR-21 expression. Several members of the let-7 family (let-7a, let-7b, let-7c, let-7d, let-7e and let-7f), were downregulated (p<0.05) by all three treatments.and miR-15b (p<0.005) and miR-27b (p<0.01) were also downregulated by the three treatments.upregulation of miR-638 (P<0.005), miR-663 (P<0.005), and miR-1915 (P<0.005) was observed after treatment of MCF7 cells with E2, BPA or DDT" +tissue_expression_down hsa-let-7b Breast Neoplasms 22403704 "Treatment with E2, BPA and DDT decreased (p<0.05) miR-21 expression. Several members of the let-7 family (let-7a, let-7b, let-7c, let-7d, let-7e and let-7f), were downregulated (p<0.05) by all three treatments.and miR-15b (p<0.005) and miR-27b (p<0.01) were also downregulated by the three treatments.upregulation of miR-638 (P<0.005), miR-663 (P<0.005), and miR-1915 (P<0.005) was observed after treatment of MCF7 cells with E2, BPA or DDT" +tissue_expression_down hsa-let-7c Breast Neoplasms 22403704 "Treatment with E2, BPA and DDT decreased (p<0.05) miR-21 expression. Several members of the let-7 family (let-7a, let-7b, let-7c, let-7d, let-7e and let-7f), were downregulated (p<0.05) by all three treatments.and miR-15b (p<0.005) and miR-27b (p<0.01) were also downregulated by the three treatments.upregulation of miR-638 (P<0.005), miR-663 (P<0.005), and miR-1915 (P<0.005) was observed after treatment of MCF7 cells with E2, BPA or DDT" +tissue_expression_down hsa-let-7d Breast Neoplasms 22403704 "Treatment with E2, BPA and DDT decreased (p<0.05) miR-21 expression. Several members of the let-7 family (let-7a, let-7b, let-7c, let-7d, let-7e and let-7f), were downregulated (p<0.05) by all three treatments.and miR-15b (p<0.005) and miR-27b (p<0.01) were also downregulated by the three treatments.upregulation of miR-638 (P<0.005), miR-663 (P<0.005), and miR-1915 (P<0.005) was observed after treatment of MCF7 cells with E2, BPA or DDT" +tissue_expression_down hsa-let-7e Breast Neoplasms 22403704 "Treatment with E2, BPA and DDT decreased (p<0.05) miR-21 expression. Several members of the let-7 family (let-7a, let-7b, let-7c, let-7d, let-7e and let-7f), were downregulated (p<0.05) by all three treatments.and miR-15b (p<0.005) and miR-27b (p<0.01) were also downregulated by the three treatments.upregulation of miR-638 (P<0.005), miR-663 (P<0.005), and miR-1915 (P<0.005) was observed after treatment of MCF7 cells with E2, BPA or DDT" +tissue_expression_down hsa-let-7f-1 Breast Neoplasms 22403704 "Treatment with E2, BPA and DDT decreased (p<0.05) miR-21 expression. Several members of the let-7 family (let-7a, let-7b, let-7c, let-7d, let-7e and let-7f), were downregulated (p<0.05) by all three treatments.and miR-15b (p<0.005) and miR-27b (p<0.01) were also downregulated by the three treatments.upregulation of miR-638 (P<0.005), miR-663 (P<0.005), and miR-1915 (P<0.005) was observed after treatment of MCF7 cells with E2, BPA or DDT" +tissue_expression_down hsa-let-7f-2 Breast Neoplasms 22403704 "Treatment with E2, BPA and DDT decreased (p<0.05) miR-21 expression. Several members of the let-7 family (let-7a, let-7b, let-7c, let-7d, let-7e and let-7f), were downregulated (p<0.05) by all three treatments.and miR-15b (p<0.005) and miR-27b (p<0.01) were also downregulated by the three treatments.upregulation of miR-638 (P<0.005), miR-663 (P<0.005), and miR-1915 (P<0.005) was observed after treatment of MCF7 cells with E2, BPA or DDT" +tissue_expression_down hsa-mir-1915 Breast Neoplasms 22403704 "Treatment with E2, BPA and DDT decreased (p<0.05) miR-21 expression. Several members of the let-7 family (let-7a, let-7b, let-7c, let-7d, let-7e and let-7f), were downregulated (p<0.05) by all three treatments.and miR-15b (p<0.005) and miR-27b (p<0.01) were also downregulated by the three treatments.upregulation of miR-638 (P<0.005), miR-663 (P<0.005), and miR-1915 (P<0.005) was observed after treatment of MCF7 cells with E2, BPA or DDT" +tissue_expression_down hsa-mir-27b Breast Neoplasms 22403704 "Treatment with E2, BPA and DDT decreased (p<0.05) miR-21 expression. Several members of the let-7 family (let-7a, let-7b, let-7c, let-7d, let-7e and let-7f), were downregulated (p<0.05) by all three treatments.and miR-15b (p<0.005) and miR-27b (p<0.01) were also downregulated by the three treatments.upregulation of miR-638 (P<0.005), miR-663 (P<0.005), and miR-1915 (P<0.005) was observed after treatment of MCF7 cells with E2, BPA or DDT" +tissue_expression_down hsa-mir-137 Glioblastoma 22406049 miR-137 is frequently down-regulated in glioblastoma and is a negative regulator of Cox-2. +tissue_expression_down hsa-mir-217 Human Immunodeficiency Virus Infection 22406815 MiR-217 is involved in Tat-induced HIV-1 long terminal repeat (LTR) transactivation by down-regulation of SIRT1. +tissue_expression_down hsa-let-7f-2 Breast Neoplasms 22407818 "Aromatase inhibitor treatment of breast cancer cells increases the expression of let-7f, a microRNA targeting CYP19A1." +tissue_expression_down hsa-mir-92a-1 Prostate Neoplasms 22412975 "Isoflavone and BR-DIM down-regulated the expression of miR-92a, which is known to be associated with RANKL signaling, EMT and cancer progression." +tissue_expression_down hsa-mir-92a-2 Prostate Neoplasms 22412975 "Isoflavone and BR-DIM down-regulated the expression of miR-92a, which is known to be associated with RANKL signaling, EMT and cancer progression." +tissue_expression_down hsa-mir-100 Head And Neck Neoplasms 22425712 down-regulation +tissue_expression_down hsa-mir-375 Head And Neck Neoplasms 22425712 down-regulation +tissue_expression_down hsa-mir-99a Head And Neck Neoplasms 22425712 down-regulation +tissue_expression_down hsa-mir-155 Gastric Neoplasms 22426647 microRNA-155 is downregulated in gastric cancer cells and involved in cell metastasis. +tissue_expression_down hsa-let-7c "Carcinoma, Lung, Small-Cell" 22438992 "Downregulation of Six MicroRNAs (has-let-7c, has-miR-100, has-miR-125b, has-miR-143, has-miR-145 and has-miR-199a-5p) Is Associated with Advanced Stage, Lymph Node Metastasis and Poor Prognosis in Small Cell Carcinoma of the Cervix." +tissue_expression_down hsa-mir-100 "Carcinoma, Lung, Small-Cell" 22438992 "Downregulation of Six MicroRNAs (has-let-7c, has-miR-100, has-miR-125b, has-miR-143, has-miR-145 and has-miR-199a-5p) Is Associated with Advanced Stage, Lymph Node Metastasis and Poor Prognosis in Small Cell Carcinoma of the Cervix." +tissue_expression_down hsa-mir-125b-1 "Carcinoma, Lung, Small-Cell" 22438992 "Downregulation of Six MicroRNAs (has-let-7c, has-miR-100, has-miR-125b, has-miR-143, has-miR-145 and has-miR-199a-5p) Is Associated with Advanced Stage, Lymph Node Metastasis and Poor Prognosis in Small Cell Carcinoma of the Cervix." +tissue_expression_down hsa-mir-125b-2 "Carcinoma, Lung, Small-Cell" 22438992 "Downregulation of Six MicroRNAs (has-let-7c, has-miR-100, has-miR-125b, has-miR-143, has-miR-145 and has-miR-199a-5p) Is Associated with Advanced Stage, Lymph Node Metastasis and Poor Prognosis in Small Cell Carcinoma of the Cervix." +tissue_expression_down hsa-mir-143 "Carcinoma, Lung, Small-Cell" 22438992 "Downregulation of Six MicroRNAs (has-let-7c, has-miR-100, has-miR-125b, has-miR-143, has-miR-145 and has-miR-199a-5p) Is Associated with Advanced Stage, Lymph Node Metastasis and Poor Prognosis in Small Cell Carcinoma of the Cervix." +tissue_expression_down hsa-mir-145 "Carcinoma, Lung, Small-Cell" 22438992 "Downregulation of Six MicroRNAs (has-let-7c, has-miR-100, has-miR-125b, has-miR-143, has-miR-145 and has-miR-199a-5p) Is Associated with Advanced Stage, Lymph Node Metastasis and Poor Prognosis in Small Cell Carcinoma of the Cervix." +tissue_expression_down hsa-mir-199a-1 "Carcinoma, Lung, Small-Cell" 22438992 "Downregulation of Six MicroRNAs (has-let-7c, has-miR-100, has-miR-125b, has-miR-143, has-miR-145 and has-miR-199a-5p) Is Associated with Advanced Stage, Lymph Node Metastasis and Poor Prognosis in Small Cell Carcinoma of the Cervix." +tissue_expression_down hsa-mir-199a-2 "Carcinoma, Lung, Small-Cell" 22438992 "Downregulation of Six MicroRNAs (has-let-7c, has-miR-100, has-miR-125b, has-miR-143, has-miR-145 and has-miR-199a-5p) Is Associated with Advanced Stage, Lymph Node Metastasis and Poor Prognosis in Small Cell Carcinoma of the Cervix." +tissue_expression_down hsa-mir-140 Ovarian Neoplasms 22452920 "The expression level of RAD51AP1 was found to be strongly anti-correlated with the expression of hsa-miR-140-3p, which was significantly down-regulated in the tumour samples." +tissue_expression_down hsa-mir-15a Multiple Sclerosis 22463747 miR-15a and 16-1 are downregulated in CD4(+) T cells of multiple sclerosis relapsing patients. +tissue_expression_down hsa-mir-16-1 Multiple Sclerosis 22463747 miR-15a and 16-1 are downregulated in CD4(+) T cells of multiple sclerosis relapsing patients. +tissue_expression_down hsa-mir-215 Colorectal Carcinoma 22469014 "MiR-215, miR-375, miR-378 and miR-422a were significantly decreased, whereas miR-135b was increased in CRC tumor tissues. Levels of miR-215 and miR-422a correlated with clinical stage." +tissue_expression_down hsa-mir-378a Colorectal Carcinoma 22469014 "MiR-215, miR-375, miR-378 and miR-422a were significantly decreased, whereas miR-135b was increased in CRC tumor tissues. Levels of miR-215 and miR-422a correlated with clinical stage." +tissue_expression_down hsa-mir-422a Colorectal Carcinoma 22469014 "MiR-215, miR-375, miR-378 and miR-422a were significantly decreased, whereas miR-135b was increased in CRC tumor tissues. Levels of miR-215 and miR-422a correlated with clinical stage." +tissue_expression_down hsa-mir-125b-1 Prolactinoma 22490835 down-regulated +tissue_expression_down hsa-mir-125b-2 Prolactinoma 22490835 down-regulated +tissue_expression_down hsa-mir-130a Prolactinoma 22490835 down-regulated +tissue_expression_down hsa-mir-199b Prolactinoma 22490835 miR-199b-3p: down-regulated +tissue_expression_down hsa-mir-200b Prolactinoma 22490835 down-regulated +tissue_expression_down hsa-mir-22 Colorectal Carcinoma 22492279 "The relative expression levels of miR-22 were significantly lower in colorectal cancer tissues than those in the normal adjacent mucosa, and low expression of miR-22 correlated with liver metastasis. Kaplan-Meier analysis indicated that patients with reduced miR-22 had a poor overall survival." +tissue_expression_down hsa-mir-10b "Carcinoma, Renal Cell" 22492545 "Expression levels of miR-143, miR-26a, miR-145, miR-10b, miR-195, and miR-126 are lower in the tumors of RCC patients who developed tumor relapse." +tissue_expression_down hsa-mir-126 "Carcinoma, Renal Cell" 22492545 "Expression levels of miR-143, miR-26a, miR-145, miR-10b, miR-195, and miR-126 are lower in the tumors of RCC patients who developed tumor relapse." +tissue_expression_down hsa-mir-143 "Carcinoma, Renal Cell" 22492545 "Expression levels of miR-143, miR-26a, miR-145, miR-10b, miR-195, and miR-126 are lower in the tumors of RCC patients who developed tumor relapse." +tissue_expression_down hsa-mir-145 "Carcinoma, Renal Cell" 22492545 "Expression levels of miR-143, miR-26a, miR-145, miR-10b, miR-195, and miR-126 are lower in the tumors of RCC patients who developed tumor relapse." +tissue_expression_down hsa-mir-195 "Carcinoma, Renal Cell" 22492545 "Expression levels of miR-143, miR-26a, miR-145, miR-10b, miR-195, and miR-126 are lower in the tumors of RCC patients who developed tumor relapse." +tissue_expression_down hsa-mir-26a-1 "Carcinoma, Renal Cell" 22492545 "Expression levels of miR-143, miR-26a, miR-145, miR-10b, miR-195, and miR-126 are lower in the tumors of RCC patients who developed tumor relapse." +tissue_expression_down hsa-mir-26a-2 "Carcinoma, Renal Cell" 22492545 "Expression levels of miR-143, miR-26a, miR-145, miR-10b, miR-195, and miR-126 are lower in the tumors of RCC patients who developed tumor relapse." +tissue_expression_down hsa-mir-106b Neuroblastoma 22498172 "Combination of 4-HPR (N-(4-hydroxyphenyl) retinamide) and EGCG ((-)-epigallocatechin-3-gallate) most significantly decreased expression of OGmiRs (miR-92, miR-93, and miR-106b) and increased expression of TSmiRs (miR-7-1, miR-34a, and miR-99a) in both cell lines(SK-N-BE2 and IMR-32 cells)" +tissue_expression_down hsa-mir-92a-1 Neuroblastoma 22498172 "Combination of 4-HPR (N-(4-hydroxyphenyl) retinamide) and EGCG ((-)-epigallocatechin-3-gallate) most significantly decreased expression of OGmiRs (miR-92, miR-93, and miR-106b) and increased expression of TSmiRs (miR-7-1, miR-34a, and miR-99a) in both cell lines(SK-N-BE2 and IMR-32 cells)" +tissue_expression_down hsa-mir-92a-2 Neuroblastoma 22498172 "Combination of 4-HPR (N-(4-hydroxyphenyl) retinamide) and EGCG ((-)-epigallocatechin-3-gallate) most significantly decreased expression of OGmiRs (miR-92, miR-93, and miR-106b) and increased expression of TSmiRs (miR-7-1, miR-34a, and miR-99a) in both cell lines(SK-N-BE2 and IMR-32 cells)" +tissue_expression_down hsa-mir-92b Neuroblastoma 22498172 "Combination of 4-HPR (N-(4-hydroxyphenyl) retinamide) and EGCG ((-)-epigallocatechin-3-gallate) most significantly decreased expression of OGmiRs (miR-92, miR-93, and miR-106b) and increased expression of TSmiRs (miR-7-1, miR-34a, and miR-99a) in both cell lines(SK-N-BE2 and IMR-32 cells)" +tissue_expression_down hsa-mir-93 Neuroblastoma 22498172 "Combination of 4-HPR (N-(4-hydroxyphenyl) retinamide) and EGCG ((-)-epigallocatechin-3-gallate) most significantly decreased expression of OGmiRs (miR-92, miR-93, and miR-106b) and increased expression of TSmiRs (miR-7-1, miR-34a, and miR-99a) in both cell lines(SK-N-BE2 and IMR-32 cells)" +tissue_expression_down hsa-mir-155 "Leukemia, Myeloid, Chronic" 22511990 "Downregulation of mir-31, mir-155, and mir-564 in chronic myeloid leukemia cells." +tissue_expression_down hsa-mir-31 "Leukemia, Myeloid, Chronic" 22511990 "Downregulation of mir-31, mir-155, and mir-564 in chronic myeloid leukemia cells." +tissue_expression_down hsa-mir-564 "Leukemia, Myeloid, Chronic" 22511990 "Downregulation of mir-31, mir-155, and mir-564 in chronic myeloid leukemia cells." +tissue_expression_down hsa-mir-126 Breast Neoplasms 22524830 "down regulation in mir-17p, mir-126, mir-335, mir-30b" +tissue_expression_down hsa-mir-17 Breast Neoplasms 22524830 "down regulation in mir-17p, mir-126, mir-335, mir-30b" +tissue_expression_down hsa-mir-30b Breast Neoplasms 22524830 "down regulation in mir-17p, mir-126, mir-335, mir-30b" +tissue_expression_down hsa-mir-335 Breast Neoplasms 22524830 "down regulation in mir-17p, mir-126, mir-335, mir-30b" +tissue_expression_down hsa-mir-675 Osteoarthritis 22527881 "Proinflammatory cytokines IL-1beta and TNF-alpha downregulated COL2A1, H19, and miR-675 significantly without close statistical correlation." +tissue_expression_down hsa-mir-133b Prostate Neoplasms 22532850 "Expression of miR-133b in tumor specimens of prostate cancer patients was significantly downregulated in 75% of the cases, when compared with matched healthy tissue." +tissue_expression_down hsa-mir-181a-2 Coronary Artery Disease 22535975 Decreased miR-181a Expression in Monocytes of Obese Patients Is Associated with the Occurrence of Metabolic Syndrome and Coronary Artery Disease. +tissue_expression_down hsa-mir-129-1 "Carcinoma, Hepatocellular" 22536440 "VCP/p97, down-regulated by microRNA-129-5p, could regulate the progression of hepatocellular carcinoma." +tissue_expression_down hsa-mir-129-2 "Carcinoma, Hepatocellular" 22536440 "VCP/p97, down-regulated by microRNA-129-5p, could regulate the progression of hepatocellular carcinoma." +tissue_expression_down hsa-mir-139 "Carcinoma, Basal Cell" 22540308 miR-139-5p is downregulated in the tumor center +tissue_expression_down hsa-mir-140 "Carcinoma, Basal Cell" 22540308 miR-140-3p is downregulated in the tumor center +tissue_expression_down hsa-mir-145 "Carcinoma, Basal Cell" 22540308 downregulated in the tumor center +tissue_expression_down hsa-mir-2861 "Carcinoma, Basal Cell" 22540308 downregulated in the tumor center +tissue_expression_down hsa-mir-29c "Carcinoma, Basal Cell" 22540308 miR-29c and miR-29c* are downregulated in the tumor center +tissue_expression_down hsa-mir-3196 "Carcinoma, Basal Cell" 22540308 downregulated in the tumor center +tissue_expression_down hsa-mir-378a "Carcinoma, Basal Cell" 22540308 downregulated in the tumor center +tissue_expression_down hsa-mir-378b "Carcinoma, Basal Cell" 22540308 downregulated in the tumor center +tissue_expression_down hsa-mir-378c "Carcinoma, Basal Cell" 22540308 downregulated in the tumor center +tissue_expression_down hsa-mir-378d-1 "Carcinoma, Basal Cell" 22540308 downregulated in the tumor center +tissue_expression_down hsa-mir-378d-2 "Carcinoma, Basal Cell" 22540308 downregulated in the tumor center +tissue_expression_down hsa-mir-378e "Carcinoma, Basal Cell" 22540308 downregulated in the tumor center +tissue_expression_down hsa-mir-378f "Carcinoma, Basal Cell" 22540308 downregulated in the tumor center +tissue_expression_down hsa-mir-378g "Carcinoma, Basal Cell" 22540308 downregulated in the tumor center +tissue_expression_down hsa-mir-378h "Carcinoma, Basal Cell" 22540308 downregulated in the tumor center +tissue_expression_down hsa-mir-378i "Carcinoma, Basal Cell" 22540308 downregulated in the tumor center +tissue_expression_down hsa-mir-572 "Carcinoma, Basal Cell" 22540308 downregulated in the tumor center +tissue_expression_down hsa-mir-638 "Carcinoma, Basal Cell" 22540308 downregulated in the tumor center +tissue_expression_down hsa-mir-193b Endometrial Neoplasms 22543862 Decreased expression after Progesterone Treatment. +tissue_expression_down hsa-mir-29c Endometrial Neoplasms 22543862 Decreased expression after Progesterone Treatment. +tissue_expression_down hsa-mir-633 Endometrial Neoplasms 22543862 Decreased expression after Progesterone Treatment. +tissue_expression_down hsa-mir-138-1 Melanoma 22551973 The downregulation of this miRNA was associated with selective genomic loss in SSM cell lines and primary tumors. +tissue_expression_down hsa-mir-138-2 Melanoma 22551973 The downregulation of this miRNA was associated with selective genomic loss in SSM cell lines and primary tumors. +tissue_expression_down hsa-mir-15a Melanoma 22551973 The downregulation of this miRNA was associated with selective genomic loss in SSM cell lines and primary tumors. +tissue_expression_down hsa-mir-16-1 Melanoma 22551973 The downregulation of this miRNA was associated with selective genomic loss in SSM cell lines and primary tumors. +tissue_expression_down hsa-mir-16-2 Melanoma 22551973 The downregulation of this miRNA was associated with selective genomic loss in SSM cell lines and primary tumors. +tissue_expression_down hsa-mir-181a-1 Melanoma 22551973 The downregulation of this miRNA was associated with selective genomic loss in SSM cell lines and primary tumors. +tissue_expression_down hsa-mir-181a-2 Melanoma 22551973 The downregulation of this miRNA was associated with selective genomic loss in SSM cell lines and primary tumors. +tissue_expression_down hsa-mir-191 Melanoma 22551973 The downregulation of this miRNA was associated with selective genomic loss in SSM cell lines and primary tumors. +tissue_expression_down hsa-mir-933 Melanoma 22551973 The downregulation of this miRNA was associated with selective genomic loss in SSM cell lines and primary tumors. +tissue_expression_down hsa-mir-155 Asthma 22558995 The decreased expression level of miR-155 is correlated to asthma disease severity. +tissue_expression_down hsa-mir-16-1 Breast Neoplasms 22583478 Downregulation of the tumor-suppressor miR-16 via progestin-mediated oncogenic signaling contributes to breast cancer development. +tissue_expression_down hsa-mir-125b-1 Laryngeal Neoplasms 22605671 Downregulation +tissue_expression_down hsa-mir-125b-2 Laryngeal Neoplasms 22605671 Downregulation +tissue_expression_down hsa-mir-145 Laryngeal Neoplasms 22605671 Downregulation +tissue_expression_down hsa-mir-214 "Carcinoma, Hepatocellular" 22613005 MicroRNA-214 downregulation contributes to tumor angiogenesis by inducing secretion of the hepatoma-derived growth factor in human hepatoma. +tissue_expression_down hsa-let-7e "Carcinoma, Lung, Non-Small-Cell" 22618509 "We showed that, compared to adjacent non-neoplastic lung tissues, the expressions of miR-125a-5p and let-7e were decreased in AD and SCC samples" +tissue_expression_down hsa-mir-125a "Carcinoma, Lung, Non-Small-Cell" 22618509 "We showed that, compared to adjacent non-neoplastic lung tissues, the expressions of miR-125a-5p and let-7e were decreased in AD and SCC samples" +tissue_expression_down hsa-mir-34a Breast Neoplasms 22623155 MiR-34a inhibits proliferation and migration of breast cancer through down-regulation of Bcl-2 and SIRT1. +tissue_expression_down hsa-mir-34a "Squamous Cell Carcinoma, Sinonasal" 22624980 miR-34a is downregulated in cis-diamminedichloroplatinum treated sinonasal squamous cell carcinoma patients with poor prognosis. +tissue_expression_down hsa-mir-1202 Ovarian Neoplasms 22643117 "We found 37 differentially expressed miRNAs in the CD133(+) spheroid-forming subpopulation of OVCAR3 cells, 34 of which were significantly up-regulated, including miR-205, miR-146a, miR-200a, miR-200b, and miR-3, and 3 of which were significantly down-regulated, including miR-1202 and miR-1181." +tissue_expression_down hsa-mir-1281 Ovarian Neoplasms 22643117 "We found 37 differentially expressed miRNAs in the CD133(+) spheroid-forming subpopulation of OVCAR3 cells, 34 of which were significantly up-regulated, including miR-205, miR-146a, miR-200a, miR-200b, and miR-3, and 3 of which were significantly down-regulated, including miR-1202 and miR-1181." +tissue_expression_down hsa-mir-126 Lung Neoplasms 22672859 "Four up-regulated microRNAs (miR-210, miR-21, miR-31 and miR-182) and two down-regulated mcroiRNAs (miR-126 and miR-145) were consistently reported both in squamous carcinoma and adenocarcinoma-based subgroup analysis" +tissue_expression_down hsa-mir-145 Lung Neoplasms 22672859 "Four up-regulated microRNAs (miR-210, miR-21, miR-31 and miR-182) and two down-regulated mcroiRNAs (miR-126 and miR-145) were consistently reported both in squamous carcinoma and adenocarcinoma-based subgroup analysis" +tissue_expression_down hsa-mir-133a-1 Astrocytoma 22674182 Significantly decreased in grades II-IV patients. +tissue_expression_down hsa-mir-133a-2 Astrocytoma 22674182 Significantly decreased in grades II-IV patients. +tissue_expression_down hsa-mir-150 Astrocytoma 22674182 miR-150*:Significantly decreased in grades II-IV patients. +tissue_expression_down hsa-mir-15b Astrocytoma 22674182 miR-15b*: Significantly decreased in grades II-IV patients. +tissue_expression_down hsa-mir-197 Astrocytoma 22674182 Significantly decreased in grades II-IV patients. +tissue_expression_down hsa-mir-23a Astrocytoma 22674182 Significantly decreased in grades II-IV patients. +tissue_expression_down hsa-mir-497 Astrocytoma 22674182 Significantly decreased in grades II-IV patients. +tissue_expression_down hsa-mir-548b Astrocytoma 22674182 miR-548b-5p: Significantly decreased in grades II-IV patients. +tissue_expression_down hsa-mir-219 Meningioma 22674195 Downregulation of miR-29c-3p and miR-219-5p were found to be associated with advanced clinical stages of meningioma. Kaplan-Meier analysis showed that high expression of miR-190a and low expression of miR-29c-3p and miR-219-5p correlated significantly with higher recurrence rates in meningioma patients. +tissue_expression_down hsa-mir-29c Meningioma 22674195 Downregulation of miR-29c-3p and miR-219-5p were found to be associated with advanced clinical stages of meningioma. Kaplan-Meier analysis showed that high expression of miR-190a and low expression of miR-29c-3p and miR-219-5p correlated significantly with higher recurrence rates in meningioma patients. +tissue_expression_down hsa-mir-182 "Carcinoma, Hepatocellular" 22681717 MicroRNA-182 downregulates metastasis suppressor 1 and contributes to metastasis of hepatocellular carcinoma. +tissue_expression_down hsa-mir-100 Chronic Obstructive Pulmonary Disease 22686440 "There was down-regulation of miR-20a, miR-28-3p, miR-34c-5p, and miR-100, and up-regulation of miR-7, compared with the controls." +tissue_expression_down hsa-mir-20a Chronic Obstructive Pulmonary Disease 22686440 "There was down-regulation of miR-20a, miR-28-3p, miR-34c-5p, and miR-100, and up-regulation of miR-7, compared with the controls." +tissue_expression_down hsa-mir-28 Chronic Obstructive Pulmonary Disease 22686440 "There was down-regulation of miR-20a, miR-28-3p, miR-34c-5p, and miR-100, and up-regulation of miR-7, compared with the controls." +tissue_expression_down hsa-mir-34c Chronic Obstructive Pulmonary Disease 22686440 "There was down-regulation of miR-20a, miR-28-3p, miR-34c-5p, and miR-100, and up-regulation of miR-7, compared with the controls." +tissue_expression_down hsa-mir-7-1 Chronic Obstructive Pulmonary Disease 22686440 "There was down-regulation of miR-20a, miR-28-3p, miR-34c-5p, and miR-100, and up-regulation of miR-7, compared with the controls." +tissue_expression_down hsa-mir-7-2 Chronic Obstructive Pulmonary Disease 22686440 "There was down-regulation of miR-20a, miR-28-3p, miR-34c-5p, and miR-100, and up-regulation of miR-7, compared with the controls." +tissue_expression_down hsa-mir-7-3 Chronic Obstructive Pulmonary Disease 22686440 "There was down-regulation of miR-20a, miR-28-3p, miR-34c-5p, and miR-100, and up-regulation of miR-7, compared with the controls." +tissue_expression_down hsa-mir-10b Urinary Bladder Cancer 22704449 "miR-10b, 19a, 126, 145, 221, 296-5p and 378 were significantly down-regulated in bladder cancer compared to adjacent normal urothelium." +tissue_expression_down hsa-mir-126 Urinary Bladder Cancer 22704449 "miR-10b, 19a, 126, 145, 221, 296-5p and 378 were significantly down-regulated in bladder cancer compared to adjacent normal urothelium." +tissue_expression_down hsa-mir-145 Urinary Bladder Cancer 22704449 "miR-10b, 19a, 126, 145, 221, 296-5p and 378 were significantly down-regulated in bladder cancer compared to adjacent normal urothelium." +tissue_expression_down hsa-mir-19a Urinary Bladder Cancer 22704449 "miR-10b, 19a, 126, 145, 221, 296-5p and 378 were significantly down-regulated in bladder cancer compared to adjacent normal urothelium." +tissue_expression_down hsa-mir-221 Urinary Bladder Cancer 22704449 "miR-10b, 19a, 126, 145, 221, 296-5p and 378 were significantly down-regulated in bladder cancer compared to adjacent normal urothelium." +tissue_expression_down hsa-mir-296 Urinary Bladder Cancer 22704449 "miR-10b, 19a, 126, 145, 221, 296-5p and 378 were significantly down-regulated in bladder cancer compared to adjacent normal urothelium." +tissue_expression_down hsa-mir-378a Urinary Bladder Cancer 22704449 "miR-10b, 19a, 126, 145, 221, 296-5p and 378 were significantly down-regulated in bladder cancer compared to adjacent normal urothelium." +tissue_expression_down hsa-mir-378b Urinary Bladder Cancer 22704449 "miR-10b, 19a, 126, 145, 221, 296-5p and 378 were significantly down-regulated in bladder cancer compared to adjacent normal urothelium." +tissue_expression_down hsa-mir-378c Urinary Bladder Cancer 22704449 "miR-10b, 19a, 126, 145, 221, 296-5p and 378 were significantly down-regulated in bladder cancer compared to adjacent normal urothelium." +tissue_expression_down hsa-mir-378d-1 Urinary Bladder Cancer 22704449 "miR-10b, 19a, 126, 145, 221, 296-5p and 378 were significantly down-regulated in bladder cancer compared to adjacent normal urothelium." +tissue_expression_down hsa-mir-378d-2 Urinary Bladder Cancer 22704449 "miR-10b, 19a, 126, 145, 221, 296-5p and 378 were significantly down-regulated in bladder cancer compared to adjacent normal urothelium." +tissue_expression_down hsa-mir-378e Urinary Bladder Cancer 22704449 "miR-10b, 19a, 126, 145, 221, 296-5p and 378 were significantly down-regulated in bladder cancer compared to adjacent normal urothelium." +tissue_expression_down hsa-mir-378f Urinary Bladder Cancer 22704449 "miR-10b, 19a, 126, 145, 221, 296-5p and 378 were significantly down-regulated in bladder cancer compared to adjacent normal urothelium." +tissue_expression_down hsa-mir-378g Urinary Bladder Cancer 22704449 "miR-10b, 19a, 126, 145, 221, 296-5p and 378 were significantly down-regulated in bladder cancer compared to adjacent normal urothelium." +tissue_expression_down hsa-mir-378h Urinary Bladder Cancer 22704449 "miR-10b, 19a, 126, 145, 221, 296-5p and 378 were significantly down-regulated in bladder cancer compared to adjacent normal urothelium." +tissue_expression_down hsa-mir-378i Urinary Bladder Cancer 22704449 "miR-10b, 19a, 126, 145, 221, 296-5p and 378 were significantly down-regulated in bladder cancer compared to adjacent normal urothelium." +tissue_expression_down hsa-mir-325 Preeclampsia 22710575 The expression of hsa-miR-325 was downregulated in the case of PE. Changes in hsa-miR-325 expression in the case of pregnancy-related hypertensive disorders might affect the oxidative stress pathways and heat-shock protein production. +tissue_expression_down hsa-mir-199a-1 "Carcinoma, Hepatocellular" 22713463 Cisplatin-induced downregulation of miR-199a-5p increases drug resistance by activating autophagy in HCC cell. +tissue_expression_down hsa-mir-199a-2 "Carcinoma, Hepatocellular" 22713463 Cisplatin-induced downregulation of miR-199a-5p increases drug resistance by activating autophagy in HCC cell. +tissue_expression_down hsa-mir-106a Prostate Neoplasms 22719071 downregulated in prostate cancer stem/progenitor cell. +tissue_expression_down hsa-mir-141 Prostate Neoplasms 22719071 downregulated in prostate cancer stem/progenitor cell. +tissue_expression_down hsa-mir-34a Prostate Neoplasms 22719071 downregulated in prostate cancer stem/progenitor cell. +tissue_expression_down hsa-mir-125b-1 "Leukemia, Lymphocytic, Chronic, B-Cell" 22723551 The downregulation of miR-125b in chronic lymphocytic leukemias leads to metabolic adaptation of cells to a transformed state. +tissue_expression_down hsa-mir-125b-2 "Leukemia, Lymphocytic, Chronic, B-Cell" 22723551 The downregulation of miR-125b in chronic lymphocytic leukemias leads to metabolic adaptation of cells to a transformed state. +tissue_expression_down hsa-mir-31 Colorectal Carcinoma 22740910 "Overexpression of miR-145, miR-1, miR-146a, miR-576-5p, miR-126*, HS287, miR-28-5p, miR-143, miR-199b-5p, miR-199a-5p, miR-10b, miR-22, miR-133b, miR-145*, miR-199a, miR-133a, miR-125b and downregulation of miR-31 and HS170 were observed in brain-metastatic carcinomas." +tissue_expression_down hsa-mir-99a "Carcinoma, Oral" 22751686 Downregulation of microRNA 99a in oral squamous cell carcinomas contributes to the growth and survival of oral cancer cells. +tissue_expression_down hsa-mir-650 "Carcinoma, Hepatocellular" 22767438 Upregulation of miR-650 is correlated with down-regulation of ING4 and progression of hepatocellular carcinoma. +tissue_expression_down hsa-mir-125b-1 Myotonic Muscular Dystrophy 22768114 miR-125b-5p: decreased levels compared to controls +tissue_expression_down hsa-mir-193a Myotonic Muscular Dystrophy 22768114 miR-193a-3p: decreased levels compared to controls +tissue_expression_down hsa-mir-193b Myotonic Muscular Dystrophy 22768114 miR-193b-3p: decreased levels compared to controls +tissue_expression_down hsa-mir-378a Myotonic Muscular Dystrophy 22768114 miR-378a-3p: decreased levels compared to controls +tissue_expression_down hsa-let-7e Interstitial Lung Disease 22782705 downregulated +tissue_expression_down hsa-mir-142 Interstitial Lung Disease 22782705 miR-142-5p: downregulated +tissue_expression_down hsa-mir-19a Interstitial Lung Disease 22782705 downregulated +tissue_expression_down hsa-mir-195 Breast Neoplasms 22800791 "The levels of miR-195 in the breast cancer with histological high grade, tumor size of T3-4, lymph nodal involvement or vessel invasion were significantly down-regulated, compared with those of patients with histological low grade (Z = -2.271, P = 0.023), tumor size of T1-2 (Z = -2.687, P = 0.007), no lymph node metastasis (Z = -1.967, P = 0.049) and vessel invasion (Z = -2.432, P = 0.015)." +tissue_expression_down hsa-mir-26b Head And Neck Neoplasms 22811001 "In addition, the expression levels of miR-21 and miR-26b were both reduced in post-operative HNSCC patients with good prognosis." +tissue_expression_down hsa-mir-22 Prostate Neoplasms 22815235 "We previously detected several miRNAs, for example, miR-24 and miR-22, as significantly downregulated in Pca" +tissue_expression_down hsa-mir-24 Prostate Neoplasms 22815235 "We previously detected several miRNAs, for example, miR-24 and miR-22, as significantly downregulated in Pca" +tissue_expression_down hsa-mir-155 Behcet Disease 22815348 Decreased microRNA-155 Expression in Ocular Behcet's Disease but Not in Vogt Koyanagi Harada Syndrome. +tissue_expression_down hsa-let-7i Pancreatic Neoplasms 22820191 "Knockdown of Dicer 1 expression in BxPC-3 and Panc-1 cells resulted in significant increases in KRAS, p53, PTEN, and Dnmts protein levels and significant decreases in miR-22, miR-143, let-7i, and miR-29b expression." +tissue_expression_down hsa-mir-143 Pancreatic Neoplasms 22820191 "Knockdown of Dicer 1 expression in BxPC-3 and Panc-1 cells resulted in significant increases in KRAS, p53, PTEN, and Dnmts protein levels and significant decreases in miR-22, miR-143, let-7i, and miR-29b expression." +tissue_expression_down hsa-mir-22 Pancreatic Neoplasms 22820191 "Knockdown of Dicer 1 expression in BxPC-3 and Panc-1 cells resulted in significant increases in KRAS, p53, PTEN, and Dnmts protein levels and significant decreases in miR-22, miR-143, let-7i, and miR-29b expression." +tissue_expression_down hsa-mir-29b Pancreatic Neoplasms 22820191 "Knockdown of Dicer 1 expression in BxPC-3 and Panc-1 cells resulted in significant increases in KRAS, p53, PTEN, and Dnmts protein levels and significant decreases in miR-22, miR-143, let-7i, and miR-29b expression." +tissue_expression_down hsa-mir-200b Pancreatic Neoplasms 22821831 "Furthermore, MIF-overexpression significantly increased ZEB1/2 and decreased miR-200b expression, while shRNA-mediated inhibition of MIF increased E-cadherin and miR-200b expression, and reduced the expression of ZEB1/2 in Panc1 cells." +tissue_expression_down hsa-mir-145 "Carcinoma, Lung, Non-Small-Cell" 22835608 Low miR-145 and high miR-367 are associated with unfavorable prognosis in resected NSCLC. +tissue_expression_down hsa-mir-124-1 Sepsis 22846781 Corticosteroid resistance in sepsis is influenced by microRNA-124-induced downregulation of glucocorticoid receptor-alpha +tissue_expression_down hsa-mir-124-2 Sepsis 22846781 Corticosteroid resistance in sepsis is influenced by microRNA-124-induced downregulation of glucocorticoid receptor-alpha +tissue_expression_down hsa-mir-195 Melanoma 22847610 miR-195-mediated downregulation of WEE1 in metastatic lesions may help to overcome cell cycle arrest under stress conditions in the local tissue microenvironment to allow unrestricted growth of tumour cells. +tissue_expression_down hsa-let-7b Esophageal Neoplasms 22847808 "Low expression of let-7b and let-7c in before-treatment biopsies from 74 patients of the training set correlated significantly with poor response to chemotherapy, both clinically and histopathologically." +tissue_expression_down hsa-let-7c Esophageal Neoplasms 22847808 "Low expression of let-7b and let-7c in before-treatment biopsies from 74 patients of the training set correlated significantly with poor response to chemotherapy, both clinically and histopathologically." +tissue_expression_down hsa-mir-122 Pancreatic Neoplasms 22850622 "miR-21, miR-155, miR-210, miR-221, and miR-222, were overexpressed in diseased tissues than in the control samples, whereas miR-31, miR-122, miR-145, and miR-146a were underexpressed." +tissue_expression_down hsa-mir-145 Pancreatic Neoplasms 22850622 "miR-21, miR-155, miR-210, miR-221, and miR-222, were overexpressed in diseased tissues than in the control samples, whereas miR-31, miR-122, miR-145, and miR-146a were underexpressed." +tissue_expression_down hsa-mir-146a Pancreatic Neoplasms 22850622 "miR-21, miR-155, miR-210, miR-221, and miR-222, were overexpressed in diseased tissues than in the control samples, whereas miR-31, miR-122, miR-145, and miR-146a were underexpressed." +tissue_expression_down hsa-mir-31 Pancreatic Neoplasms 22850622 "miR-21, miR-155, miR-210, miR-221, and miR-222, were overexpressed in diseased tissues than in the control samples, whereas miR-31, miR-122, miR-145, and miR-146a were underexpressed." +tissue_expression_down hsa-mir-513a-1 Retinoblastoma 22886978 miR-513a-5p expression was decreased in Rb cells after etoposide treatment. +tissue_expression_down hsa-mir-513a-2 Retinoblastoma 22886978 miR-513a-5p expression was decreased in Rb cells after etoposide treatment. +tissue_expression_down hsa-mir-513b Retinoblastoma 22886978 miR-513a-5p expression was decreased in Rb cells after etoposide treatment. +tissue_expression_down hsa-mir-513c Retinoblastoma 22886978 miR-513a-5p expression was decreased in Rb cells after etoposide treatment. +tissue_expression_down hsa-mir-125b-1 Breast Neoplasms 22898264 "Upregulation of miR-21 and miR-191 and downregulation of miR-125b, was found in breast cancer tissue." +tissue_expression_down hsa-mir-125b-2 Breast Neoplasms 22898264 "Upregulation of miR-21 and miR-191 and downregulation of miR-125b, was found in breast cancer tissue." +tissue_expression_down hsa-mir-191 Breast Neoplasms 22898264 "Upregulation of miR-21 and miR-191 and downregulation of miR-125b, was found in breast cancer tissue." +tissue_expression_down hsa-mir-21 Breast Neoplasms 22898264 "Upregulation of miR-21 and miR-191 and downregulation of miR-125b, was found in breast cancer tissue." +tissue_expression_down hsa-mir-1308 Melanoma 22898827 "we assayed the MITF-KD miRNA profiles using a miRNA microarray and found that hsa-miR-1225-3p, hsa-miR-634, hsa-miR-197, hsa-miR-766, hsa-miR-574-5p and hsa-miR-328 were upregulated, and hsa-miR-720 and hsa-miR-1308 were downregulated in MITF knocked down melanocytes." +tissue_expression_down hsa-mir-720 Melanoma 22898827 "we assayed the MITF-KD miRNA profiles using a miRNA microarray and found that hsa-miR-1225-3p, hsa-miR-634, hsa-miR-197, hsa-miR-766, hsa-miR-574-5p and hsa-miR-328 were upregulated, and hsa-miR-720 and hsa-miR-1308 were downregulated in MITF knocked down melanocytes." +tissue_expression_down hsa-mir-19b-2 "Tuberculosis, Pulmonary" 22900099 miR-19b-2*: Underexpression +tissue_expression_down hsa-mir-199a-1 Colorectal Carcinoma 22903020 "miR-199a-5p was expressed at a low level in human primary colonic epithelial cells treated with deoxycholic acid compared with control, and miR-199a-5p was significantly down-regulated in colorectal cancer tissues.CAC1 was a direct miR-199a-5p target.The high miR-199a-5p expression and low CAC1 protein expression reverse the tumor cell drug resistance." +tissue_expression_down hsa-mir-199a-2 Colorectal Carcinoma 22903020 "miR-199a-5p was expressed at a low level in human primary colonic epithelial cells treated with deoxycholic acid compared with control, and miR-199a-5p was significantly down-regulated in colorectal cancer tissues.CAC1 was a direct miR-199a-5p target.The high miR-199a-5p expression and low CAC1 protein expression reverse the tumor cell drug resistance." +tissue_expression_down hsa-mir-143 Pancreatic Neoplasms 22905187 "miR-216a, -196a, -143 und -155) were detected at lower concentrations in feces of PCA patients when compared to controls (p<0.05)." +tissue_expression_down hsa-mir-155 Pancreatic Neoplasms 22905187 "miR-216a, -196a, -143 und -155) were detected at lower concentrations in feces of PCA patients when compared to controls (p<0.05)." +tissue_expression_down hsa-mir-196a-1 Pancreatic Neoplasms 22905187 "miR-216a, -196a, -143 und -155) were detected at lower concentrations in feces of PCA patients when compared to controls (p<0.05)." +tissue_expression_down hsa-mir-196a-2 Pancreatic Neoplasms 22905187 "miR-216a, -196a, -143 und -155) were detected at lower concentrations in feces of PCA patients when compared to controls (p<0.05)." +tissue_expression_down hsa-mir-216a Pancreatic Neoplasms 22905187 "miR-216a, -196a, -143 und -155) were detected at lower concentrations in feces of PCA patients when compared to controls (p<0.05)." +tissue_expression_down hsa-mir-129-1 Breast Neoplasms 22907300 "miR-129 is found to significantly inhibit the migration of MDA-MB-231 both in Transwell migration assay and wound healing assay. Furthermore, miR-129 also shows great suppressive ability to cell mobility and migration in another two breast cancer cell lines BT549 and MDA-MB-435s. Most importantly, miR-129 is down-regulated both in breast cancer tissues compared with the paired adjacent normal breast tissues, and in breast cancer cell lines compared with normal breast epithelial cell MCF10A (P < 0.05)." +tissue_expression_down hsa-mir-129-2 Breast Neoplasms 22907300 "miR-129 is found to significantly inhibit the migration of MDA-MB-231 both in Transwell migration assay and wound healing assay. Furthermore, miR-129 also shows great suppressive ability to cell mobility and migration in another two breast cancer cell lines BT549 and MDA-MB-435s. Most importantly, miR-129 is down-regulated both in breast cancer tissues compared with the paired adjacent normal breast tissues, and in breast cancer cell lines compared with normal breast epithelial cell MCF10A (P < 0.05)." +tissue_expression_down hsa-mir-100 Endometrial Neoplasms 22920721 "Deregulation of miR-100, miR-99a and miR-199b in tissues and plasma coexists with increased expression of mTOR kinase in endometrioid endometrial carcinoma." +tissue_expression_down hsa-mir-128-1 Glioblastoma 22922228 "Platelet-derived growth factor-B (PDGF-B), a potent angiogenic growth factor involved in GBM development and progression, promotes downregulation of pro-oncogenic (miR-21) and anti-oncogenic (miR-128) miRNAs in GBM pathology." +tissue_expression_down hsa-mir-128-2 Glioblastoma 22922228 "Platelet-derived growth factor-B (PDGF-B), a potent angiogenic growth factor involved in GBM development and progression, promotes downregulation of pro-oncogenic (miR-21) and anti-oncogenic (miR-128) miRNAs in GBM pathology." +tissue_expression_down hsa-mir-21 Glioblastoma 22922228 "Platelet-derived growth factor-B (PDGF-B), a potent angiogenic growth factor involved in GBM development and progression, promotes downregulation of pro-oncogenic (miR-21) and anti-oncogenic (miR-128) miRNAs in GBM pathology." +tissue_expression_down hsa-mir-124 Glioblastoma 22929615 "We tested two predicted proneural drivers, miR-124 and miR-132, both underexpressed in proneural tumors, by overexpression in neurospheres and observed a partial reversal of corresponding tumor expression changes." +tissue_expression_down hsa-mir-132 Glioblastoma 22929615 "We tested two predicted proneural drivers, miR-124 and miR-132, both underexpressed in proneural tumors, by overexpression in neurospheres and observed a partial reversal of corresponding tumor expression changes." +tissue_expression_down hsa-let-7c Pancreatic Neoplasms 22929886 "The expression of let-7c, let-7f, and miR-200c were significantly reduced in most patients whereas the expression of miR-486-5p and miR-451 were significantly elevated in all pancreas cancer patients." +tissue_expression_down hsa-let-7f-1 Pancreatic Neoplasms 22929886 "The expression of let-7c, let-7f, and miR-200c were significantly reduced in most patients whereas the expression of miR-486-5p and miR-451 were significantly elevated in all pancreas cancer patients." +tissue_expression_down hsa-let-7f-2 Pancreatic Neoplasms 22929886 "The expression of let-7c, let-7f, and miR-200c were significantly reduced in most patients whereas the expression of miR-486-5p and miR-451 were significantly elevated in all pancreas cancer patients." +tissue_expression_down hsa-mir-200c Pancreatic Neoplasms 22929886 "The expression of let-7c, let-7f, and miR-200c were significantly reduced in most patients whereas the expression of miR-486-5p and miR-451 were significantly elevated in all pancreas cancer patients." +tissue_expression_down hsa-mir-223 Inflammation 22937006 Here we reported that the expression of microRNA-223 (miR-223) was significantly decreased in murine macrophages during activation by lipopolysaccharide (LPS) or poly (I¡ÃC) stimulation. +tissue_expression_down hsa-mir-134 "Carcinoma, Lung, Non-Small-Cell" 22937028 "High expression of miR-100 and low expression of miRNA-93, miRNA-134, miRNA-151 and miRNA-345 were associated with poor survival in both the training and validation cohort." +tissue_expression_down hsa-mir-151a "Carcinoma, Lung, Non-Small-Cell" 22937028 "High expression of miR-100 and low expression of miRNA-93, miRNA-134, miRNA-151 and miRNA-345 were associated with poor survival in both the training and validation cohort." +tissue_expression_down hsa-mir-151b "Carcinoma, Lung, Non-Small-Cell" 22937028 "High expression of miR-100 and low expression of miRNA-93, miRNA-134, miRNA-151 and miRNA-345 were associated with poor survival in both the training and validation cohort." +tissue_expression_down hsa-mir-345 "Carcinoma, Lung, Non-Small-Cell" 22937028 "High expression of miR-100 and low expression of miRNA-93, miRNA-134, miRNA-151 and miRNA-345 were associated with poor survival in both the training and validation cohort." +tissue_expression_down hsa-mir-93 "Carcinoma, Lung, Non-Small-Cell" 22937028 "High expression of miR-100 and low expression of miRNA-93, miRNA-134, miRNA-151 and miRNA-345 were associated with poor survival in both the training and validation cohort." +tissue_expression_down hsa-mir-193a Atrial Fibrillation 22944230 "MiR-155, miR-142-3p, miR-19b, miR-223, miR-146b-5p, miR-486-5p, miR-301b, miR-193b, miR-519b were found to be up-regulated by > 2 folds whereas miR-193a-5p was down-regulated in left atrial appendage (LAA) in patients with atrial fibrillation." +tissue_expression_down hsa-let-7g Breast Neoplasms 22964023 "We identified 11 dysregulated miRNAs in CAFs: three were up-regulated (miR-221-5p, miR-31-3p, miR-221-3p), while eight were down-regulated (miR-205, miR-200b, miR-200c, miR-141, miR-101,miR-342-3p, let-7g, miR-26b)" +tissue_expression_down hsa-mir-101 Breast Neoplasms 22964023 "We identified 11 dysregulated miRNAs in CAFs: three were up-regulated (miR-221-5p, miR-31-3p, miR-221-3p), while eight were down-regulated (miR-205, miR-200b, miR-200c, miR-141, miR-101,miR-342-3p, let-7g, miR-26b)" +tissue_expression_down hsa-mir-141 Breast Neoplasms 22964023 "We identified 11 dysregulated miRNAs in CAFs: three were up-regulated (miR-221-5p, miR-31-3p, miR-221-3p), while eight were down-regulated (miR-205, miR-200b, miR-200c, miR-141, miR-101,miR-342-3p, let-7g, miR-26b)" +tissue_expression_down hsa-mir-200b Breast Neoplasms 22964023 "We identified 11 dysregulated miRNAs in CAFs: three were up-regulated (miR-221-5p, miR-31-3p, miR-221-3p), while eight were down-regulated (miR-205, miR-200b, miR-200c, miR-141, miR-101,miR-342-3p, let-7g, miR-26b)" +tissue_expression_down hsa-mir-200c Breast Neoplasms 22964023 "We identified 11 dysregulated miRNAs in CAFs: three were up-regulated (miR-221-5p, miR-31-3p, miR-221-3p), while eight were down-regulated (miR-205, miR-200b, miR-200c, miR-141, miR-101,miR-342-3p, let-7g, miR-26b)" +tissue_expression_down hsa-mir-205 Breast Neoplasms 22964023 "We identified 11 dysregulated miRNAs in CAFs: three were up-regulated (miR-221-5p, miR-31-3p, miR-221-3p), while eight were down-regulated (miR-205, miR-200b, miR-200c, miR-141, miR-101,miR-342-3p, let-7g, miR-26b)" +tissue_expression_down hsa-mir-26b Breast Neoplasms 22964023 "We identified 11 dysregulated miRNAs in CAFs: three were up-regulated (miR-221-5p, miR-31-3p, miR-221-3p), while eight were down-regulated (miR-205, miR-200b, miR-200c, miR-141, miR-101,miR-342-3p, let-7g, miR-26b)" +tissue_expression_down hsa-mir-342 Breast Neoplasms 22964023 "We identified 11 dysregulated miRNAs in CAFs: three were up-regulated (miR-221-5p, miR-31-3p, miR-221-3p), while eight were down-regulated (miR-205, miR-200b, miR-200c, miR-141, miR-101,miR-342-3p, let-7g, miR-26b)" +tissue_expression_down hsa-mir-146a Tuberculosis 22964481 "we observed that miR-146a expression is also down-regulated in tuberculosis patients, both in PBMCs and PFMCs while miR-424 levels are elevated only in the peripheral compartments." +tissue_expression_down hsa-mir-146 Prion Diseases 22965126 "we show that exosomes released by prion-infected neuronal cells have increased let-7b, let-7i, miR-128a, miR-21, miR-222, miR-29b,miR-342-3p and miR-424 levels with decreased miR-146 a levels compared to non-infected exosomes." +tissue_expression_down hsa-mir-10a "Squamous Cell Carcinoma, Esophageal" 22966337 Down-regulation of microRNA 10a expression in esophageal squamous cell carcinoma cells. +tissue_expression_down hsa-mir-181a "Leukemia, Promyelocytic, Acute" 22967415 "The expression level of miR-15b, miR-16, miR-107, miR-223 and miR-342 in APL CR group were significantly upregulated compared with that of newly diagnosed APL groups (P < 0.05), while the expression level of miR-181a was significantly downregulated (P < 0.05)." +tissue_expression_down hsa-mir-10a "Carcinoma, Hepatocellular" 22976466 "Significant downregulation of miR-10a was observed in tumor compared with non-tumor tissues (0.50 vs. 1.73, p = 0.031)." +tissue_expression_down hsa-mir-143 Cervical Neoplasms 22997891 "The high expression of miR-21 in cervical cancer and Hela cell indicate that it may play a possible role of oncogenes, while miR-143 and miR-373 with low expression may play the role of tumor suppressor genes." +tissue_expression_down hsa-mir-373 Cervical Neoplasms 22997891 "The high expression of miR-21 in cervical cancer and Hela cell indicate that it may play a possible role of oncogenes, while miR-143 and miR-373 with low expression may play the role of tumor suppressor genes." +tissue_expression_down hsa-mir-100 Prostate Neoplasms 22999546 "miR-100 and miR-10a showed under expression and over expression, respectively, in low grade pTa tumors." +tissue_expression_down hsa-mir-140 "Squamous Cell Carcinoma, Skin or Unspecific" 23026055 "Non-stringent filtering with a non-adjusted p ¡Ü 0.01 revealed three up-regulated (hsa-miR-135b, hsa-miR-424 and hsa-miR-766) and six down-regulated (hsa-miR-30a*, hsa-miR-378, hsa-miR-145, hsa-miR-140-3p, hsa-miR-30a and hsa-miR-26a) miRNAs in cSCC" +tissue_expression_down hsa-mir-145 "Squamous Cell Carcinoma, Skin or Unspecific" 23026055 "Non-stringent filtering with a non-adjusted p ¡Ü 0.01 revealed three up-regulated (hsa-miR-135b, hsa-miR-424 and hsa-miR-766) and six down-regulated (hsa-miR-30a*, hsa-miR-378, hsa-miR-145, hsa-miR-140-3p, hsa-miR-30a and hsa-miR-26a) miRNAs in cSCC" +tissue_expression_down hsa-mir-26a "Squamous Cell Carcinoma, Skin or Unspecific" 23026055 "Non-stringent filtering with a non-adjusted p ¡Ü 0.01 revealed three up-regulated (hsa-miR-135b, hsa-miR-424 and hsa-miR-766) and six down-regulated (hsa-miR-30a*, hsa-miR-378, hsa-miR-145, hsa-miR-140-3p, hsa-miR-30a and hsa-miR-26a) miRNAs in cSCC" +tissue_expression_down hsa-mir-30a "Squamous Cell Carcinoma, Skin or Unspecific" 23026055 "Non-stringent filtering with a non-adjusted p ¡Ü 0.01 revealed three up-regulated (hsa-miR-135b, hsa-miR-424 and hsa-miR-766) and six down-regulated (hsa-miR-30a*, hsa-miR-378, hsa-miR-145, hsa-miR-140-3p, hsa-miR-30a and hsa-miR-26a) miRNAs in cSCC" +tissue_expression_down hsa-mir-378 "Squamous Cell Carcinoma, Skin or Unspecific" 23026055 "Non-stringent filtering with a non-adjusted p ¡Ü 0.01 revealed three up-regulated (hsa-miR-135b, hsa-miR-424 and hsa-miR-766) and six down-regulated (hsa-miR-30a*, hsa-miR-378, hsa-miR-145, hsa-miR-140-3p, hsa-miR-30a and hsa-miR-26a) miRNAs in cSCC" +tissue_expression_down hsa-mir-199a-1 Neoplasms [unspecific] 23060436 The microRNA miR-199a-5p down-regulation switches on wound angiogenesis by derepressing the v-ets erythroblastosis virus E26 oncogene homolog 1-matrix metalloproteinase-1 pathway +tissue_expression_down hsa-mir-199a-2 Neoplasms [unspecific] 23060436 The microRNA miR-199a-5p down-regulation switches on wound angiogenesis by derepressing the v-ets erythroblastosis virus E26 oncogene homolog 1-matrix metalloproteinase-1 pathway +tissue_expression_down hsa-mir-328 Glioblastoma 23077581 MiR-328 expression is decreased in high-grade gliomas and is associated with worse survival in primary glioblastoma +tissue_expression_down hsa-mir-1275 "Carcinoma, Hepatocellular" 23082062 "Ten up-regulated miRNAs (miR-217, miR-518b, miR-517c, miR-520g, miR-519a, miR-522, miR-518e, miR-525-3p, miR-512-3p, and miR-518a-3p) and 11 down-regulated miRNAs (miR-138, miR-214, miR-214#, miR-199a-5p, miR-433, miR-511, miR-592, miR-483-3p, miR-483-5p, miR-708 and miR-1275) were identified by Taqman miRNAs array and confirmed quantitatively by reverse transcription polymerase chain reaction in HCC and adjacent non-tumor tissues. " +tissue_expression_down hsa-mir-138 "Carcinoma, Hepatocellular" 23082062 "Ten up-regulated miRNAs (miR-217, miR-518b, miR-517c, miR-520g, miR-519a, miR-522, miR-518e, miR-525-3p, miR-512-3p, and miR-518a-3p) and 11 down-regulated miRNAs (miR-138, miR-214, miR-214#, miR-199a-5p, miR-433, miR-511, miR-592, miR-483-3p, miR-483-5p, miR-708 and miR-1275) were identified by Taqman miRNAs array and confirmed quantitatively by reverse transcription polymerase chain reaction in HCC and adjacent non-tumor tissues. " +tissue_expression_down hsa-mir-199a "Carcinoma, Hepatocellular" 23082062 "Ten up-regulated miRNAs (miR-217, miR-518b, miR-517c, miR-520g, miR-519a, miR-522, miR-518e, miR-525-3p, miR-512-3p, and miR-518a-3p) and 11 down-regulated miRNAs (miR-138, miR-214, miR-214#, miR-199a-5p, miR-433, miR-511, miR-592, miR-483-3p, miR-483-5p, miR-708 and miR-1275) were identified by Taqman miRNAs array and confirmed quantitatively by reverse transcription polymerase chain reaction in HCC and adjacent non-tumor tissues. " +tissue_expression_down hsa-mir-214 "Carcinoma, Hepatocellular" 23082062 "Ten up-regulated miRNAs (miR-217, miR-518b, miR-517c, miR-520g, miR-519a, miR-522, miR-518e, miR-525-3p, miR-512-3p, and miR-518a-3p) and 11 down-regulated miRNAs (miR-138, miR-214, miR-214#, miR-199a-5p, miR-433, miR-511, miR-592, miR-483-3p, miR-483-5p, miR-708 and miR-1275) were identified by Taqman miRNAs array and confirmed quantitatively by reverse transcription polymerase chain reaction in HCC and adjacent non-tumor tissues. " +tissue_expression_down hsa-mir-433 "Carcinoma, Hepatocellular" 23082062 "Ten up-regulated miRNAs (miR-217, miR-518b, miR-517c, miR-520g, miR-519a, miR-522, miR-518e, miR-525-3p, miR-512-3p, and miR-518a-3p) and 11 down-regulated miRNAs (miR-138, miR-214, miR-214#, miR-199a-5p, miR-433, miR-511, miR-592, miR-483-3p, miR-483-5p, miR-708 and miR-1275) were identified by Taqman miRNAs array and confirmed quantitatively by reverse transcription polymerase chain reaction in HCC and adjacent non-tumor tissues. " +tissue_expression_down hsa-mir-483 "Carcinoma, Hepatocellular" 23082062 "Ten up-regulated miRNAs (miR-217, miR-518b, miR-517c, miR-520g, miR-519a, miR-522, miR-518e, miR-525-3p, miR-512-3p, and miR-518a-3p) and 11 down-regulated miRNAs (miR-138, miR-214, miR-214#, miR-199a-5p, miR-433, miR-511, miR-592, miR-483-3p, miR-483-5p, miR-708 and miR-1275) were identified by Taqman miRNAs array and confirmed quantitatively by reverse transcription polymerase chain reaction in HCC and adjacent non-tumor tissues. " +tissue_expression_down hsa-mir-511 "Carcinoma, Hepatocellular" 23082062 "Ten up-regulated miRNAs (miR-217, miR-518b, miR-517c, miR-520g, miR-519a, miR-522, miR-518e, miR-525-3p, miR-512-3p, and miR-518a-3p) and 11 down-regulated miRNAs (miR-138, miR-214, miR-214#, miR-199a-5p, miR-433, miR-511, miR-592, miR-483-3p, miR-483-5p, miR-708 and miR-1275) were identified by Taqman miRNAs array and confirmed quantitatively by reverse transcription polymerase chain reaction in HCC and adjacent non-tumor tissues. " +tissue_expression_down hsa-mir-592 "Carcinoma, Hepatocellular" 23082062 "Ten up-regulated miRNAs (miR-217, miR-518b, miR-517c, miR-520g, miR-519a, miR-522, miR-518e, miR-525-3p, miR-512-3p, and miR-518a-3p) and 11 down-regulated miRNAs (miR-138, miR-214, miR-214#, miR-199a-5p, miR-433, miR-511, miR-592, miR-483-3p, miR-483-5p, miR-708 and miR-1275) were identified by Taqman miRNAs array and confirmed quantitatively by reverse transcription polymerase chain reaction in HCC and adjacent non-tumor tissues. " +tissue_expression_down hsa-mir-708 "Carcinoma, Hepatocellular" 23082062 "Ten up-regulated miRNAs (miR-217, miR-518b, miR-517c, miR-520g, miR-519a, miR-522, miR-518e, miR-525-3p, miR-512-3p, and miR-518a-3p) and 11 down-regulated miRNAs (miR-138, miR-214, miR-214#, miR-199a-5p, miR-433, miR-511, miR-592, miR-483-3p, miR-483-5p, miR-708 and miR-1275) were identified by Taqman miRNAs array and confirmed quantitatively by reverse transcription polymerase chain reaction in HCC and adjacent non-tumor tissues. " +tissue_expression_down hsa-mir-106b "Carcinoma, Hepatocellular" 23087084 miR-106b downregulates adenomatous polyposis coli and promotes cell proliferation in human hepatocellular carcinoma +tissue_expression_down hsa-let-7c Esophageal Neoplasms 23092349 "A number of consistently dysregulated miRNAs have been identified in EAC and/or ESCC, including upregulation of miR-21, miR-192, miR-194, miR-106-25 polycistron (miR-25, miR-93, and miR-106b), miR-10b, miR-151, and miR-93, and downregulation of miR-375, miR-203, miR-205, miR-145, miR- 27b,miR-100, miR-125b, let-7c, etc. " +tissue_expression_down hsa-mir-100 Esophageal Neoplasms 23092349 "A number of consistently dysregulated miRNAs have been identified in EAC and/or ESCC, including upregulation of miR-21, miR-192, miR-194, miR-106-25 polycistron (miR-25, miR-93, and miR-106b), miR-10b, miR-151, and miR-93, and downregulation of miR-375, miR-203, miR-205, miR-145, miR- 27b,miR-100, miR-125b, let-7c, etc. " +tissue_expression_down hsa-mir-125b Esophageal Neoplasms 23092349 "A number of consistently dysregulated miRNAs have been identified in EAC and/or ESCC, including upregulation of miR-21, miR-192, miR-194, miR-106-25 polycistron (miR-25, miR-93, and miR-106b), miR-10b, miR-151, and miR-93, and downregulation of miR-375, miR-203, miR-205, miR-145, miR- 27b,miR-100, miR-125b, let-7c, etc. " +tissue_expression_down hsa-mir-145 Esophageal Neoplasms 23092349 "A number of consistently dysregulated miRNAs have been identified in EAC and/or ESCC, including upregulation of miR-21, miR-192, miR-194, miR-106-25 polycistron (miR-25, miR-93, and miR-106b), miR-10b, miR-151, and miR-93, and downregulation of miR-375, miR-203, miR-205, miR-145, miR- 27b,miR-100, miR-125b, let-7c, etc. " +tissue_expression_down hsa-mir-203 Esophageal Neoplasms 23092349 "A number of consistently dysregulated miRNAs have been identified in EAC and/or ESCC, including upregulation of miR-21, miR-192, miR-194, miR-106-25 polycistron (miR-25, miR-93, and miR-106b), miR-10b, miR-151, and miR-93, and downregulation of miR-375, miR-203, miR-205, miR-145, miR- 27b,miR-100, miR-125b, let-7c, etc. " +tissue_expression_down hsa-mir-205 Esophageal Neoplasms 23092349 "A number of consistently dysregulated miRNAs have been identified in EAC and/or ESCC, including upregulation of miR-21, miR-192, miR-194, miR-106-25 polycistron (miR-25, miR-93, and miR-106b), miR-10b, miR-151, and miR-93, and downregulation of miR-375, miR-203, miR-205, miR-145, miR- 27b,miR-100, miR-125b, let-7c, etc. " +tissue_expression_down hsa-mir-27b Esophageal Neoplasms 23092349 "A number of consistently dysregulated miRNAs have been identified in EAC and/or ESCC, including upregulation of miR-21, miR-192, miR-194, miR-106-25 polycistron (miR-25, miR-93, and miR-106b), miR-10b, miR-151, and miR-93, and downregulation of miR-375, miR-203, miR-205, miR-145, miR- 27b,miR-100, miR-125b, let-7c, etc. " +tissue_expression_down hsa-mir-375 Esophageal Neoplasms 23092349 "A number of consistently dysregulated miRNAs have been identified in EAC and/or ESCC, including upregulation of miR-21, miR-192, miR-194, miR-106-25 polycistron (miR-25, miR-93, and miR-106b), miR-10b, miR-151, and miR-93, and downregulation of miR-375, miR-203, miR-205, miR-145, miR- 27b,miR-100, miR-125b, let-7c, etc. " +tissue_expression_down hsa-mir-375 Glioma 23103713 Correlation of microRNA-375 downregulation with unfavorable clinical outcome of patients with glioma +tissue_expression_down hsa-mir-145 Meningioma 23108408 miRNA-145 is downregulated in atypical and anaplastic meningiomas and negatively regulates motility and proliferation of meningioma cells +tissue_expression_down hsa-mir-24-1 Melanoma 23111773 "In addition to several miRNAs previously known to be associated with CMM, 19 unidentified miRNA candidates were found to be dysregulated in CMM patient samples. Among the 19 novel miRNA candidates, the genes hsa-miR-22, hsa-miR-130b, hsa-miR-146b-5p,hsa-miR-223, hsa-miR-301a, hsa-miR-484, hsa-miR-663, hsa-miR-720, hsa-miR-1260,hsa-miR-1274a, hsa-miR-1274b, hsa-miR-3663-3p, hsa-miR-4281, and hsa-miR-4286 were upregulated, and the genes hsa-miR-24-1*, hsa-miR-26a, hsa-miR-4291, hsa-miR-4317, and hsa-miR-4324 were downregulated." +tissue_expression_down hsa-mir-26a Melanoma 23111773 "In addition to several miRNAs previously known to be associated with CMM, 19 unidentified miRNA candidates were found to be dysregulated in CMM patient samples. Among the 19 novel miRNA candidates, the genes hsa-miR-22, hsa-miR-130b, hsa-miR-146b-5p,hsa-miR-223, hsa-miR-301a, hsa-miR-484, hsa-miR-663, hsa-miR-720, hsa-miR-1260,hsa-miR-1274a, hsa-miR-1274b, hsa-miR-3663-3p, hsa-miR-4281, and hsa-miR-4286 were upregulated, and the genes hsa-miR-24-1*, hsa-miR-26a, hsa-miR-4291, hsa-miR-4317, and hsa-miR-4324 were downregulated." +tissue_expression_down hsa-mir-4291 Melanoma 23111773 "In addition to several miRNAs previously known to be associated with CMM, 19 unidentified miRNA candidates were found to be dysregulated in CMM patient samples. Among the 19 novel miRNA candidates, the genes hsa-miR-22, hsa-miR-130b, hsa-miR-146b-5p,hsa-miR-223, hsa-miR-301a, hsa-miR-484, hsa-miR-663, hsa-miR-720, hsa-miR-1260,hsa-miR-1274a, hsa-miR-1274b, hsa-miR-3663-3p, hsa-miR-4281, and hsa-miR-4286 were upregulated, and the genes hsa-miR-24-1*, hsa-miR-26a, hsa-miR-4291, hsa-miR-4317, and hsa-miR-4324 were downregulated." +tissue_expression_down hsa-mir-4317 Melanoma 23111773 "In addition to several miRNAs previously known to be associated with CMM, 19 unidentified miRNA candidates were found to be dysregulated in CMM patient samples. Among the 19 novel miRNA candidates, the genes hsa-miR-22, hsa-miR-130b, hsa-miR-146b-5p,hsa-miR-223, hsa-miR-301a, hsa-miR-484, hsa-miR-663, hsa-miR-720, hsa-miR-1260,hsa-miR-1274a, hsa-miR-1274b, hsa-miR-3663-3p, hsa-miR-4281, and hsa-miR-4286 were upregulated, and the genes hsa-miR-24-1*, hsa-miR-26a, hsa-miR-4291, hsa-miR-4317, and hsa-miR-4324 were downregulated." +tissue_expression_down hsa-mir-4324 Melanoma 23111773 "In addition to several miRNAs previously known to be associated with CMM, 19 unidentified miRNA candidates were found to be dysregulated in CMM patient samples. Among the 19 novel miRNA candidates, the genes hsa-miR-22, hsa-miR-130b, hsa-miR-146b-5p,hsa-miR-223, hsa-miR-301a, hsa-miR-484, hsa-miR-663, hsa-miR-720, hsa-miR-1260,hsa-miR-1274a, hsa-miR-1274b, hsa-miR-3663-3p, hsa-miR-4281, and hsa-miR-4286 were upregulated, and the genes hsa-miR-24-1*, hsa-miR-26a, hsa-miR-4291, hsa-miR-4317, and hsa-miR-4324 were downregulated." +tissue_expression_down hsa-mir-204 Pulmonary Hypertension 23114789 "MEX suppressed the hypoxic activation of signal transducer and activator of transcription 3 (STAT3) and the upregulation of the miR-17 superfamily of microRNA clusters, whereas it increased lung levels of miR-204, a key microRNA, the expression of which is decreased in human pulmonary hypertension." +tissue_expression_down hsa-mir-10b Breast Neoplasms 23125021 "miR-10b*, a master inhibitor of the cell cycle, is down-regulated in human breast tumours" +tissue_expression_down hsa-mir-495 Leukemia 23132946 MiR-495 is a tumor-suppressor microRNA down-regulated in MLL-rearranged leukemia +tissue_expression_down hsa-mir-224 Prostate Neoplasms 23136246 Downregulation and Prognostic Performance of MicroRNA 224 Expression in Prostate Cancer +tissue_expression_down hsa-mir-383 Medulloblastoma 23157748 "Compared with normal brain tissue, decreased expression of miR-383 but elevated expression of PRDX3 are medulloblastoma tumour and Daoy cell lines" +tissue_expression_down hsa-mir-1 Bladder Neoplasms 23169479 "three miRNAs were upregulated (miR-200b, miR-182 and miR-138) and the other 10 miRNAs were downregulated (miR-1, miR-133a, miR-133b, miR-145, miR-143, miR-204, miR-921, miR-1281, miR-199a and miR-199b)" +tissue_expression_down hsa-mir-1281 Bladder Neoplasms 23169479 "three miRNAs were upregulated (miR-200b, miR-182 and miR-138) and the other 10 miRNAs were downregulated (miR-1, miR-133a, miR-133b, miR-145, miR-143, miR-204, miR-921, miR-1281, miR-199a and miR-199b)" +tissue_expression_down hsa-mir-133a Bladder Neoplasms 23169479 "three miRNAs were upregulated (miR-200b, miR-182 and miR-138) and the other 10 miRNAs were downregulated (miR-1, miR-133a, miR-133b, miR-145, miR-143, miR-204, miR-921, miR-1281, miR-199a and miR-199b)" +tissue_expression_down hsa-mir-133b Bladder Neoplasms 23169479 "three miRNAs were upregulated (miR-200b, miR-182 and miR-138) and the other 10 miRNAs were downregulated (miR-1, miR-133a, miR-133b, miR-145, miR-143, miR-204, miR-921, miR-1281, miR-199a and miR-199b)" +tissue_expression_down hsa-mir-143 Bladder Neoplasms 23169479 "three miRNAs were upregulated (miR-200b, miR-182 and miR-138) and the other 10 miRNAs were downregulated (miR-1, miR-133a, miR-133b, miR-145, miR-143, miR-204, miR-921, miR-1281, miR-199a and miR-199b)" +tissue_expression_down hsa-mir-145 Bladder Neoplasms 23169479 "three miRNAs were upregulated (miR-200b, miR-182 and miR-138) and the other 10 miRNAs were downregulated (miR-1, miR-133a, miR-133b, miR-145, miR-143, miR-204, miR-921, miR-1281, miR-199a and miR-199b)" +tissue_expression_down hsa-mir-199a Bladder Neoplasms 23169479 "three miRNAs were upregulated (miR-200b, miR-182 and miR-138) and the other 10 miRNAs were downregulated (miR-1, miR-133a, miR-133b, miR-145, miR-143, miR-204, miR-921, miR-1281, miR-199a and miR-199b)" +tissue_expression_down hsa-mir-199b Bladder Neoplasms 23169479 "three miRNAs were upregulated (miR-200b, miR-182 and miR-138) and the other 10 miRNAs were downregulated (miR-1, miR-133a, miR-133b, miR-145, miR-143, miR-204, miR-921, miR-1281, miR-199a and miR-199b)" +tissue_expression_down hsa-mir-204 Bladder Neoplasms 23169479 "three miRNAs were upregulated (miR-200b, miR-182 and miR-138) and the other 10 miRNAs were downregulated (miR-1, miR-133a, miR-133b, miR-145, miR-143, miR-204, miR-921, miR-1281, miR-199a and miR-199b)" +tissue_expression_down hsa-mir-921 Bladder Neoplasms 23169479 "three miRNAs were upregulated (miR-200b, miR-182 and miR-138) and the other 10 miRNAs were downregulated (miR-1, miR-133a, miR-133b, miR-145, miR-143, miR-204, miR-921, miR-1281, miR-199a and miR-199b)" +tissue_expression_down hsa-mir-192 Asthma 23170939 MiR-192 was technically validated using real-time reverse transcription-quantitative polymerase chain reaction (RT-qPCR) showing that the level in asthmatics (pre-challenge) was significantly lower than HCs and that post-challenge was significantly lower than pre-challenge. +tissue_expression_down hsa-mir-214 Ovarian Neoplasms 23171795 "We found that in ovarian CAFs, miR-31 and miR-214 were downregulated, whereas miR-155 was upregulated when compared with normal or tumor-adjacent fibroblasts." +tissue_expression_down hsa-mir-31 Ovarian Neoplasms 23171795 "We found that in ovarian CAFs, miR-31 and miR-214 were downregulated, whereas miR-155 was upregulated when compared with normal or tumor-adjacent fibroblasts." +tissue_expression_down hsa-mir-199a-1 "Carcinoma, Renal Cell" 23174576 "A decreased expression of miR-199a is significantly correlated with a higher tumor stage, a greater likeliness of tumor recurrence, and a poorer prognosis in RCC patients" +tissue_expression_down hsa-mir-199a-2 "Carcinoma, Renal Cell" 23174576 "A decreased expression of miR-199a is significantly correlated with a higher tumor stage, a greater likeliness of tumor recurrence, and a poorer prognosis in RCC patients" +tissue_expression_down hsa-mir-216a Pancreatic Neoplasms 23174591 The down-regulated expression of miR-216a in pancreatic cancer suggests the involvement of miR-216a in the tumorigenesis and development of pancreatic cancer +tissue_expression_down hsa-mir-106a Colorectal Carcinoma 23178825 miR-106a overexpression and pRB downregulation in sporadic colorectal cancer +tissue_expression_down hsa-mir-153-1 Neoplasms [unspecific] 23188671 Downregulation of miR-153 contributes to epithelial-mesenchymal transition and tumor metastasis in human epithelial cancer +tissue_expression_down hsa-mir-153-2 Neoplasms [unspecific] 23188671 Downregulation of miR-153 contributes to epithelial-mesenchymal transition and tumor metastasis in human epithelial cancer +tissue_expression_down hsa-mir-26a-1 Melanoma 23190898 MicroRNA-26a Is Strongly Downregulated in Melanoma and Induces Cell Death through Repression of Silencer of Death Domains +tissue_expression_down hsa-mir-26a-2 Melanoma 23190898 MicroRNA-26a Is Strongly Downregulated in Melanoma and Induces Cell Death through Repression of Silencer of Death Domains +tissue_expression_down hsa-mir-421 "Squamous Cell Carcinoma, Skin or Unspecific" 23199656 Aberrant overexpression of miR-421 downregulates ATM and leads to a pronounced DSB repair defect and clinical hypersensitivity in SKX squamous cell carcinoma +tissue_expression_down hsa-mir-186 Lung Neoplasms 23204228 "miR-186 Downregulation Correlates with Poor Survival in Lung Adenocarcinoma,Where It Interferes with Cell-Cycle Regulation" +tissue_expression_down hsa-mir-1228 "Carcinoma, Hepatocellular" 23205106 "The following miRNAs were downregulated in the tumor and non-tumor tissues, and thus could serve as novel biomarkers for chronic liver diseases: miR-18b*, miR-296-5p, miR-557, miR-581, miR-625*, miR-1228, miR-1249 and miR-2116*. Similarly, miR-129*, miR-146b-3p and miR-448 are novel candidates for HCC biomarkers regardless of virus infection." +tissue_expression_down hsa-mir-1249 "Carcinoma, Hepatocellular" 23205106 "The following miRNAs were downregulated in the tumor and non-tumor tissues, and thus could serve as novel biomarkers for chronic liver diseases: miR-18b*, miR-296-5p, miR-557, miR-581, miR-625*, miR-1228, miR-1249 and miR-2116*. Similarly, miR-129*, miR-146b-3p and miR-448 are novel candidates for HCC biomarkers regardless of virus infection." +tissue_expression_down hsa-mir-129 "Carcinoma, Hepatocellular" 23205106 "The following miRNAs were downregulated in the tumor and non-tumor tissues, and thus could serve as novel biomarkers for chronic liver diseases: miR-18b*, miR-296-5p, miR-557, miR-581, miR-625*, miR-1228, miR-1249 and miR-2116*. Similarly, miR-129*, miR-146b-3p and miR-448 are novel candidates for HCC biomarkers regardless of virus infection." +tissue_expression_down hsa-mir-146 "Carcinoma, Hepatocellular" 23205106 "The following miRNAs were downregulated in the tumor and non-tumor tissues, and thus could serve as novel biomarkers for chronic liver diseases: miR-18b*, miR-296-5p, miR-557, miR-581, miR-625*, miR-1228, miR-1249 and miR-2116*. Similarly, miR-129*, miR-146b-3p and miR-448 are novel candidates for HCC biomarkers regardless of virus infection." +tissue_expression_down hsa-mir-18b "Carcinoma, Hepatocellular" 23205106 "The following miRNAs were downregulated in the tumor and non-tumor tissues, and thus could serve as novel biomarkers for chronic liver diseases: miR-18b*, miR-296-5p, miR-557, miR-581, miR-625*, miR-1228, miR-1249 and miR-2116*. Similarly, miR-129*, miR-146b-3p and miR-448 are novel candidates for HCC biomarkers regardless of virus infection." +tissue_expression_down hsa-mir-2116 "Carcinoma, Hepatocellular" 23205106 "The following miRNAs were downregulated in the tumor and non-tumor tissues, and thus could serve as novel biomarkers for chronic liver diseases: miR-18b*, miR-296-5p, miR-557, miR-581, miR-625*, miR-1228, miR-1249 and miR-2116*. Similarly, miR-129*, miR-146b-3p and miR-448 are novel candidates for HCC biomarkers regardless of virus infection." +tissue_expression_down hsa-mir-296 "Carcinoma, Hepatocellular" 23205106 "The following miRNAs were downregulated in the tumor and non-tumor tissues, and thus could serve as novel biomarkers for chronic liver diseases: miR-18b*, miR-296-5p, miR-557, miR-581, miR-625*, miR-1228, miR-1249 and miR-2116*. Similarly, miR-129*, miR-146b-3p and miR-448 are novel candidates for HCC biomarkers regardless of virus infection." +tissue_expression_down hsa-mir-448 "Carcinoma, Hepatocellular" 23205106 "The following miRNAs were downregulated in the tumor and non-tumor tissues, and thus could serve as novel biomarkers for chronic liver diseases: miR-18b*, miR-296-5p, miR-557, miR-581, miR-625*, miR-1228, miR-1249 and miR-2116*. Similarly, miR-129*, miR-146b-3p and miR-448 are novel candidates for HCC biomarkers regardless of virus infection." +tissue_expression_down hsa-mir-557 "Carcinoma, Hepatocellular" 23205106 "The following miRNAs were downregulated in the tumor and non-tumor tissues, and thus could serve as novel biomarkers for chronic liver diseases: miR-18b*, miR-296-5p, miR-557, miR-581, miR-625*, miR-1228, miR-1249 and miR-2116*. Similarly, miR-129*, miR-146b-3p and miR-448 are novel candidates for HCC biomarkers regardless of virus infection." +tissue_expression_down hsa-mir-581 "Carcinoma, Hepatocellular" 23205106 "The following miRNAs were downregulated in the tumor and non-tumor tissues, and thus could serve as novel biomarkers for chronic liver diseases: miR-18b*, miR-296-5p, miR-557, miR-581, miR-625*, miR-1228, miR-1249 and miR-2116*. Similarly, miR-129*, miR-146b-3p and miR-448 are novel candidates for HCC biomarkers regardless of virus infection." +tissue_expression_down hsa-mir-625 "Carcinoma, Hepatocellular" 23205106 "The following miRNAs were downregulated in the tumor and non-tumor tissues, and thus could serve as novel biomarkers for chronic liver diseases: miR-18b*, miR-296-5p, miR-557, miR-581, miR-625*, miR-1228, miR-1249 and miR-2116*. Similarly, miR-129*, miR-146b-3p and miR-448 are novel candidates for HCC biomarkers regardless of virus infection." +tissue_expression_down hsa-mir-544a Glioma 23205130 "Downregulation of miR-544 in tissue, but not in serum, is a novel biomarker of malignant transformation in glioma" +tissue_expression_down hsa-mir-544b Glioma 23205130 "Downregulation of miR-544 in tissue, but not in serum, is a novel biomarker of malignant transformation in glioma" +tissue_expression_down hsa-mir-141 "Carcinoma, Renal Cell" 23206420 A possible role for micro-RNA 141 down-regulation in sunitinib resistant metastatic clear cell renal cell carcinoma through induction of epithelial-to-mesenchymal transition and hypoxia resistance +tissue_expression_down hsa-mir-26b "Carcinoma, Lung, Non-Small-Cell" 23207443 SQCC was distinguished from normal tissue and ADC by high-level miR-205 expression and decreased miR-26b. +tissue_expression_down hsa-mir-107 Glioma 23220650 P53-induced microRNA-107 inhibits proliferation of glioma cells and down-regulates the expression of CDK6 and Notch-2 +tissue_expression_down hsa-mir-150 "Carcinoma, Lung, Non-Small-Cell" 23228962 Expression of miR-150 and miR-3940-5p is reduced in non-small cell lung carcinoma and correlates with clinicopathological features +tissue_expression_down hsa-mir-3940 "Carcinoma, Lung, Non-Small-Cell" 23228962 Expression of miR-150 and miR-3940-5p is reduced in non-small cell lung carcinoma and correlates with clinicopathological features +tissue_expression_down hsa-mir-214 Ovarian Neoplasms 23230184 They found that decreased miR-31 and miR-214 and increased miR-155 expression can reprogram normal fibroblasts into tumor-promoting cancer-associated fibroblasts. +tissue_expression_down hsa-mir-31 Ovarian Neoplasms 23230184 They found that decreased miR-31 and miR-214 and increased miR-155 expression can reprogram normal fibroblasts into tumor-promoting cancer-associated fibroblasts. +tissue_expression_down hsa-mir-326 Glioma 23292865 "Down-regulation of miR-326 may have potential value for predicting clinical outcomes in glioma patients with high pathological grades, suggesting that miR-326 is an important candidate tumor suppressor, and its down-regulated expression may contribute to glioma progression" +tissue_expression_down hsa-mir-9 Waldenstrom Macroglobulinemia 23301642 The most important changes of microRNA are increased expression of miR-155 and decreased expression of miR-9*. +tissue_expression_down hsa-mir-125b-1 Systemic Lupus Erythematosus 23305626 "Further analysis showed that the down-regulation of miR-125b, mainly in T cells, was negatively correlated with lupus nephritis" +tissue_expression_down hsa-mir-125b-2 Systemic Lupus Erythematosus 23305626 "Further analysis showed that the down-regulation of miR-125b, mainly in T cells, was negatively correlated with lupus nephritis" +tissue_expression_down hsa-mir-30c-1 Neoplasms [unspecific] 23318178 Sulfuretin-induced miR-30C selectively downregulates cyclin D1 and D2 and triggers cell death in human cancer cell lines +tissue_expression_down hsa-mir-30c-2 Neoplasms [unspecific] 23318178 Sulfuretin-induced miR-30C selectively downregulates cyclin D1 and D2 and triggers cell death in human cancer cell lines +tissue_expression_down hsa-mir-150 Myocardial Infarction 23326587 "Adenosine increases the migration of EPC. The mechanism involves A(2B) receptor activation, decreased expression of miR-150 and increased expression of CXCR4." +tissue_expression_down hsa-mir-214 Urinary Bladder Cancer 23337879 MiR-214 reduces cell survival and enhances cisplatin-induced cytotoxicity via down-regulation of Bcl2l2 in cervical cancer cells +tissue_expression_down hsa-let-7 Pancreatic Neoplasms 23338123 "The BxPC-3-LN cells expressed lower levels of let-7, miR-34, miR-107, miR-125, miR-128, miR-130, miR-132 and miR-141 than the parental BxPC-3 cells detected by microRNA PCR array, which were reported to have close relation to stem cell factors." +tissue_expression_down hsa-mir-107 Pancreatic Neoplasms 23338123 "The BxPC-3-LN cells expressed lower levels of let-7, miR-34, miR-107, miR-125, miR-128, miR-130, miR-132 and miR-141 than the parental BxPC-3 cells detected by microRNA PCR array, which were reported to have close relation to stem cell factors." +tissue_expression_down hsa-mir-125 Pancreatic Neoplasms 23338123 "The BxPC-3-LN cells expressed lower levels of let-7, miR-34, miR-107, miR-125, miR-128, miR-130, miR-132 and miR-141 than the parental BxPC-3 cells detected by microRNA PCR array, which were reported to have close relation to stem cell factors." +tissue_expression_down hsa-mir-128 Pancreatic Neoplasms 23338123 "The BxPC-3-LN cells expressed lower levels of let-7, miR-34, miR-107, miR-125, miR-128, miR-130, miR-132 and miR-141 than the parental BxPC-3 cells detected by microRNA PCR array, which were reported to have close relation to stem cell factors." +tissue_expression_down hsa-mir-130 Pancreatic Neoplasms 23338123 "The BxPC-3-LN cells expressed lower levels of let-7, miR-34, miR-107, miR-125, miR-128, miR-130, miR-132 and miR-141 than the parental BxPC-3 cells detected by microRNA PCR array, which were reported to have close relation to stem cell factors." +tissue_expression_down hsa-mir-132 Pancreatic Neoplasms 23338123 "The BxPC-3-LN cells expressed lower levels of let-7, miR-34, miR-107, miR-125, miR-128, miR-130, miR-132 and miR-141 than the parental BxPC-3 cells detected by microRNA PCR array, which were reported to have close relation to stem cell factors." +tissue_expression_down hsa-mir-141 Pancreatic Neoplasms 23338123 "The BxPC-3-LN cells expressed lower levels of let-7, miR-34, miR-107, miR-125, miR-128, miR-130, miR-132 and miR-141 than the parental BxPC-3 cells detected by microRNA PCR array, which were reported to have close relation to stem cell factors." +tissue_expression_down hsa-mir-34 Pancreatic Neoplasms 23338123 "The BxPC-3-LN cells expressed lower levels of let-7, miR-34, miR-107, miR-125, miR-128, miR-130, miR-132 and miR-141 than the parental BxPC-3 cells detected by microRNA PCR array, which were reported to have close relation to stem cell factors." +tissue_expression_down hsa-mir-93 Colorectal Carcinoma 23354160 "the downregulation of miR-93 was significantly correlated with unfavorable clinicopathologic features and short overall survival in patients with colon cancer, suggesting that decreased expression of miR-93 be used as a novel prognostic factor for this disease" +tissue_expression_down hsa-mir-34a Colorectal Carcinoma 23355243 The down-regulated expression of miR-34a in colorectal cancer patients is associated with recurrence after radical operation +tissue_expression_down hsa-mir-132 Breast Neoplasms 23399321 MicroRNA-132 is frequently down-regulated in ductal carcinoma in situ (DCIS) of breast and acts as a tumor suppressor by inhibiting cell proliferation +tissue_expression_down hsa-mir-31 Urinary Bladder Cancer 23408039 Decreased expression of microRNA-31 associates with aggressive tumor progression and poor prognosis in patients with bladder cancer +tissue_expression_down hsa-mir-130a Chronic Hepatitis C 23418453 "Seven miRNAs (miR-30b, miR-30c, miR-130a, miR-192, miR-301, miR-324-5p, and miR-565) were down-regulated in HCV-infected Huh7.5 cells (p<0.05) and subsequently up-regulated following interferon-¦Á treatment (p<0.01)" +tissue_expression_down hsa-mir-192 Chronic Hepatitis C 23418453 "Seven miRNAs (miR-30b, miR-30c, miR-130a, miR-192, miR-301, miR-324-5p, and miR-565) were down-regulated in HCV-infected Huh7.5 cells (p<0.05) and subsequently up-regulated following interferon-¦Á treatment (p<0.01)" +tissue_expression_down hsa-mir-301 Chronic Hepatitis C 23418453 "Seven miRNAs (miR-30b, miR-30c, miR-130a, miR-192, miR-301, miR-324-5p, and miR-565) were down-regulated in HCV-infected Huh7.5 cells (p<0.05) and subsequently up-regulated following interferon-¦Á treatment (p<0.01)" +tissue_expression_down hsa-mir-30b Chronic Hepatitis C 23418453 "Seven miRNAs (miR-30b, miR-30c, miR-130a, miR-192, miR-301, miR-324-5p, and miR-565) were down-regulated in HCV-infected Huh7.5 cells (p<0.05) and subsequently up-regulated following interferon-¦Á treatment (p<0.01)" +tissue_expression_down hsa-mir-30c Chronic Hepatitis C 23418453 "Seven miRNAs (miR-30b, miR-30c, miR-130a, miR-192, miR-301, miR-324-5p, and miR-565) were down-regulated in HCV-infected Huh7.5 cells (p<0.05) and subsequently up-regulated following interferon-¦Á treatment (p<0.01)" +tissue_expression_down hsa-mir-324 Chronic Hepatitis C 23418453 "Seven miRNAs (miR-30b, miR-30c, miR-130a, miR-192, miR-301, miR-324-5p, and miR-565) were down-regulated in HCV-infected Huh7.5 cells (p<0.05) and subsequently up-regulated following interferon-¦Á treatment (p<0.01)" +tissue_expression_down hsa-mir-565 Chronic Hepatitis C 23418453 "Seven miRNAs (miR-30b, miR-30c, miR-130a, miR-192, miR-301, miR-324-5p, and miR-565) were down-regulated in HCV-infected Huh7.5 cells (p<0.05) and subsequently up-regulated following interferon-¦Á treatment (p<0.01)" +tissue_expression_down hsa-mir-17 Colon Neoplasms 23436804 "We detect and confirm 27 miRNAs to be significantly changed following ER¦Â expression in SW480 colon cancer cells. Among these, the oncogenic miR-17-92 cluster and miR-200a/b are strongly downregulated. Using target prediction and anticorrelation to gene expression data followed by focused mechanistic studies, we demonstrate that repression of miR-17 is a secondary event following ER¦Â's downregulatory effect on MYC. " +tissue_expression_down hsa-mir-18 Colon Neoplasms 23436804 "We detect and confirm 27 miRNAs to be significantly changed following ER¦Â expression in SW480 colon cancer cells. Among these, the oncogenic miR-17-92 cluster and miR-200a/b are strongly downregulated. Using target prediction and anticorrelation to gene expression data followed by focused mechanistic studies, we demonstrate that repression of miR-17 is a secondary event following ER¦Â's downregulatory effect on MYC. " +tissue_expression_down hsa-mir-19a Colon Neoplasms 23436804 "We detect and confirm 27 miRNAs to be significantly changed following ER¦Â expression in SW480 colon cancer cells. Among these, the oncogenic miR-17-92 cluster and miR-200a/b are strongly downregulated. Using target prediction and anticorrelation to gene expression data followed by focused mechanistic studies, we demonstrate that repression of miR-17 is a secondary event following ER¦Â's downregulatory effect on MYC. " +tissue_expression_down hsa-mir-19b-1 Colon Neoplasms 23436804 "We detect and confirm 27 miRNAs to be significantly changed following ER¦Â expression in SW480 colon cancer cells. Among these, the oncogenic miR-17-92 cluster and miR-200a/b are strongly downregulated. Using target prediction and anticorrelation to gene expression data followed by focused mechanistic studies, we demonstrate that repression of miR-17 is a secondary event following ER¦Â's downregulatory effect on MYC. " +tissue_expression_down hsa-mir-200a Colon Neoplasms 23436804 "We detect and confirm 27 miRNAs to be significantly changed following ER¦Â expression in SW480 colon cancer cells. Among these, the oncogenic miR-17-92 cluster and miR-200a/b are strongly downregulated. Using target prediction and anticorrelation to gene expression data followed by focused mechanistic studies, we demonstrate that repression of miR-17 is a secondary event following ER¦Â's downregulatory effect on MYC. " +tissue_expression_down hsa-mir-200b Colon Neoplasms 23436804 "We detect and confirm 27 miRNAs to be significantly changed following ER¦Â expression in SW480 colon cancer cells. Among these, the oncogenic miR-17-92 cluster and miR-200a/b are strongly downregulated. Using target prediction and anticorrelation to gene expression data followed by focused mechanistic studies, we demonstrate that repression of miR-17 is a secondary event following ER¦Â's downregulatory effect on MYC. " +tissue_expression_down hsa-mir-20a Colon Neoplasms 23436804 "We detect and confirm 27 miRNAs to be significantly changed following ER¦Â expression in SW480 colon cancer cells. Among these, the oncogenic miR-17-92 cluster and miR-200a/b are strongly downregulated. Using target prediction and anticorrelation to gene expression data followed by focused mechanistic studies, we demonstrate that repression of miR-17 is a secondary event following ER¦Â's downregulatory effect on MYC. " +tissue_expression_down hsa-mir-92-1 Colon Neoplasms 23436804 "We detect and confirm 27 miRNAs to be significantly changed following ER¦Â expression in SW480 colon cancer cells. Among these, the oncogenic miR-17-92 cluster and miR-200a/b are strongly downregulated. Using target prediction and anticorrelation to gene expression data followed by focused mechanistic studies, we demonstrate that repression of miR-17 is a secondary event following ER¦Â's downregulatory effect on MYC. " +tissue_expression_down hsa-mir-200a Gastrointestinal Neoplasms 23456798 It was noteworthy that miR-200a was significantly down-regulated in gastric adenocarcinoma samples (P = .04) but was up-regulated in esophageal adenocarcinoma samples (P = .001). +tissue_expression_down hsa-mir-375 "Adenocarcinoma, Gastric" 23461060 "In our study, the expression of a subset of microRNAs was altered in distal gastric adenocarcinoma compared to normal tissue, miR-375 was significantly downregulated in distal gastric adenocarcinoma tissues, to a level that was significantly lower than cardia adenocarcinoma (p < 0.05)." +tissue_expression_down hsa-mir-206 Breast Neoplasms 23466356 miR-206 is down-regulated in breast cancer and inhibits cell proliferation through the up-regulation of cyclinD2 +tissue_expression_down hsa-mir-371 "Carcinoma, Hepatocellular" 23466643 miR-371-5p down-regulates pre mRNA processing factor 4 homolog B (PRPF4B) and facilitates the G1/S transition in human hepatocellular carcinoma cells +tissue_expression_down hsa-mir-135b Esophageal Neoplasms 23477513 patients with either decreased miR-135b or increased miR-145 expression in cancer tissue had improved disease-free survival +tissue_expression_down hsa-mir-146a Ischemia-Reperfusion Injury 23498784 Down-regulation of microRNA-146a in the early stage of liver ischemia-reperfusion injury. +tissue_expression_down hsa-mir-302b "Adenocarcinoma, Gastric" 23508453 "Down-regulation of miR-302b, an ESC-specific microRNA, in Gastric Adenocarcinoma." +tissue_expression_down hsa-let-7i Inflammation 23509825 This let-7i downregulation in dendritic cells constitutes a novel feature of the modulatory activity that helminth-derived antigens exert on their host. +tissue_expression_down hsa-mir-145 "Squamous Cell Carcinoma, Oral" 23548968 Downregulation of miR-145 Expression in Oral Squamous Cell Carcinomas and Its Clinical Significance +tissue_expression_down hsa-mir-27b Colorectal Carcinoma 23593282 "we demonstrated that miR-27b expression is decreased in most CRC tissues and determined that overexpression of miR-27b represses CRC cell proliferation, colony formation and tumor growth in vitro and in vivo." +tissue_expression_down hsa-mir-223 Osteosarcoma 23601845 we found that miRNA-223 was downregulated in both osteosarcoma patients' tumor tissues and osteosarcoma cell lines. +tissue_expression_down hsa-mir-15a "Leukemia, Lymphocytic, Chronic, B-Cell" 23615967 "Significant upregulation of miR-150, miR-29c, miR-143 and miR-223 and downregulation of miR-15a was found in mutated versus unmutated CLL, with miR-15a showing the highest fold difference." +tissue_expression_down hsa-mir-200a Breast Neoplasms 23626803 Reduced expression of miR-200 family members contributes to antiestrogen resistance in LY2 human breast cancer cells. +tissue_expression_down hsa-mir-200b Breast Neoplasms 23626803 Reduced expression of miR-200 family members contributes to antiestrogen resistance in LY2 human breast cancer cells. +tissue_expression_down hsa-mir-200c Breast Neoplasms 23626803 Reduced expression of miR-200 family members contributes to antiestrogen resistance in LY2 human breast cancer cells. +tissue_expression_down hsa-mir-205 Melanoma 23629002 microRNA (miR)-205 is downregulated and acts as a tumor suppressor in human melanoma cells. +tissue_expression_down hsa-let-7e Allergic Rhinitis 23704072 "Subjects with current allergic rhinitis symptoms had increased levels of miR-155, miR-205, and miR-498, but reduced levels of let-7e." +tissue_expression_down hsa-mir-125b Bladder Neoplasms 23712207 "miRNAs downregulated in bladder cancer, such as miR-145, miR-143 and miR125b, are known to be tumour suppressors" +tissue_expression_down hsa-mir-143 Bladder Neoplasms 23712207 "miRNAs downregulated in bladder cancer, such as miR-145, miR-143 and miR125b, are known to be tumour suppressors" +tissue_expression_down hsa-mir-145 Bladder Neoplasms 23712207 "miRNAs downregulated in bladder cancer, such as miR-145, miR-143 and miR125b, are known to be tumour suppressors" +tissue_expression_down hsa-mir-1246 Pulmonary Hypertension 23717609 "We identified several novel downregulated miRNAs (miR-451, miR-1246) and upregulated miRNAs (miR-23b, miR-130a and miR-191) in the circulation of PH subjects." +tissue_expression_down hsa-mir-451 Pulmonary Hypertension 23717609 "We identified several novel downregulated miRNAs (miR-451, miR-1246) and upregulated miRNAs (miR-23b, miR-130a and miR-191) in the circulation of PH subjects." +tissue_expression_down hsa-mir-122 "Carcinoma, Hepatocellular" 23727126 "miR-122, a liver-specific tumor suppressor microRNA, is frequently down-regulated in hepatocellular carcinoma (HCC)" +tissue_expression_down hsa-mir-146a Osteoarthritis 23744481 The downregulation of miR-146a and/or the miR-183 cluster in the central compartments (DRG and spinal cord) are closely associated with the upregulation of inflammatory pain mediators. +tissue_expression_down hsa-mir-183 Osteoarthritis 23744481 The downregulation of miR-146a and/or the miR-183 cluster in the central compartments (DRG and spinal cord) are closely associated with the upregulation of inflammatory pain mediators. +tissue_expression_down hsa-mir-206 Gastric Neoplasms 23751352 Downregulation of microRNA-206 is a potent prognostic marker for patients with gastric cancer. +tissue_expression_down hsa-mir-1-1 Lung Neoplasms 23761296 Sustainable downregulation in the lung tissues in lung carcinogenesis induced by urethane. +tissue_expression_down hsa-mir-1-2 Lung Neoplasms 23761296 Sustainable downregulation in the lung tissues in lung carcinogenesis induced by urethane. +tissue_expression_down hsa-mir-126 Esophageal Neoplasms 23761828 downregulated +tissue_expression_down hsa-mir-223 Esophageal Neoplasms 23761828 downregulated +tissue_expression_down hsa-mir-30b Esophageal Neoplasms 23761828 downregulated +tissue_expression_down hsa-mir-454 Esophageal Neoplasms 23761828 downregulated +tissue_expression_down hsa-mir-486 Esophageal Neoplasms 23761828 downregulated +tissue_expression_down hsa-mir-574 Esophageal Neoplasms 23761828 miR-574-3p:downregulated +tissue_expression_down hsa-mir-22 "Carcinoma, Hepatocellular" 23766411 "miR-22 is downregulated in HCC and its expression is associated with the differentiation, metastasis and prognosis of the carcinoma. Ezrin is a potential regulatory protein of miR-22." +tissue_expression_down hsa-mir-21 Colorectal Carcinoma 23773491 "In Taiwan, downregulation of the APC gene in CRC correlated with gene mutation and mir-21 upregulation. APC mutation and mir-21 expression could be used to predict the clinical outcome of CRC, especially in patients with advanced disease." +tissue_expression_down hsa-mir-17 "Squamous Cell Carcinoma, Oral" 23780339 "miR-17-5p is induced in irradiated OC3 cells and it downregulates p21 protein expression, contributing to the radioresistance of OC3 cells." +tissue_expression_down hsa-mir-205 Hereditary Hemorrhagic Telangiectasia 23800974 MiR-205 is downregulated in hereditary hemorrhagic telangiectasia and impairs TGF-beta signaling pathways in endothelial cells. +tissue_expression_down hsa-mir-27a Pancreatic Neoplasms 23803693 "in Panc1 cells metformin decreased microRNA-27a and induced the Sp repressor, ZBTB10, and disruption of miR-27a:ZBTB10 by metformin was phosphatase dependent." +tissue_expression_down hsa-mir-34c Lung Neoplasms 23805317 MiR-34a and miR-34c were downregulated in lung tumors compared to normal tissues. +tissue_expression_down hsa-mir-124 Glioblastoma 23817964 MiR-124 inhibits the growth of glioblastoma through the downregulation of SOS1. +tissue_expression_down hsa-mir-181b "Carcinoma, Lung, Non-Small-Cell" 23827213 Down-regulation of microRNA-181b is a potential prognostic marker of non-small cell lung cancer. +tissue_expression_down hsa-mir-19a Breast Neoplasms 23831570 MicroRNA-19a-3p inhibits breast cancer progression and metastasis by inducing macrophage polarization through downregulated expression of Fra-1 proto-oncogene. +tissue_expression_down hsa-mir-223 Pancreatic Neoplasms 23834147 Genistein down-regulates miR-223 expression in pancreatic cancer cells. +tissue_expression_down hsa-mir-451 Colorectal Carcinoma 23886157 MicroRNA-451 inhibits growth of human colorectal carcinoma cells via downregulation of Pi3k/Akt pathway. +tissue_expression_down hsa-mir-21 "Carcinoma, Colon" 23894315 Difluorinated-curcumin (CDF) restores PTEN expression in colon cancer cells by down-regulating miR-21. +tissue_expression_down hsa-mir-187 "Carcinoma, Renal Cell, Clear-Cell" 23916610 "MicroRNA-187, down-regulated in clear cell renal cell carcinoma and associated with lower survival, inhibits cell growth and migration though targeting B7-H3." +tissue_expression_down hsa-mir-223 "Carcinoma, Hepatocellular" 23925649 MiR-223 modulates multidrug resistance via downregulation of ABCB1 in hepatocellular carcinoma cells. +tissue_expression_down hsa-mir-34a Prostate Neoplasms 23936419 Our results indicated that genistein inhibited PCa cell growth through down-regulation of oncogenic HOTAIR that is also targeted by tumor suppressor miR-34a. These findings enhance understanding of how genistein regulates lncRNA HOTAIR and miR-34a in PCa. +tissue_expression_down hsa-mir-26b Breast Neoplasms 23939832 MiR-26b is down-regulated in carcinoma-associated fibroblasts from ER-positive breast cancers leading to enhanced cell migration and invasion. +tissue_expression_down hsa-let-7i "Carcinoma, Bladder" 23946872 "Within this group, let-7b and let-7i exhibited decreased expression, while miR-1290 and miR-138 displayed increased expression levels in gemcitabine-resistant cells." +tissue_expression_down hsa-mir-218 Medulloblastoma 23970061 miR-218 is downregulated and directly targets SH3GL1 in childhood medulloblastoma. +tissue_expression_down hsa-mir-205 Prostate Neoplasms 23974361 miR-205 is frequently downregulated in prostate cancer and acts as a tumor suppressor by inhibiting tumor growth. +tissue_expression_down hsa-mir-15 "Leukemia, Lymphocytic, Chronic, B-Cell" 23974981 Defective DROSHA processing contributes to downregulation of MiR-15/-16 in chronic lymphocytic leukemia. +tissue_expression_down hsa-mir-16 "Leukemia, Lymphocytic, Chronic, B-Cell" 23974981 Defective DROSHA processing contributes to downregulation of MiR-15/-16 in chronic lymphocytic leukemia. +tissue_expression_down hsa-mir-145 Inflammation 23980205 "We demonstrate that miR-145, downregulated by IFN-I,targets histone deacetylase 11 to promote innate IL-10 expression in macrophages.Our findings suggest a new IFN-I-mediated negative feedback loop in the fine-tuning of innate IL-10 production that creates precise coordination of innate immune responses." +tissue_expression_down hsa-mir-203 "Carcinoma, Esophageal" 24001611 MiR-203 suppresses tumor growth and invasion and down-regulates MiR-21 expression through repressing Ran in esophageal cancer. +tissue_expression_down hsa-mir-21 "Carcinoma, Esophageal" 24001611 MiR-203 suppresses tumor growth and invasion and down-regulates MiR-21 expression through repressing Ran in esophageal cancer. +tissue_expression_down hsa-mir-137 Melanoma 24001901 "miR-34a, miR-137 and miR-182 all had lower expression levels in uveal melanoma cell lines, compared with normal cells" +tissue_expression_down hsa-mir-182 Melanoma 24001901 "miR-34a, miR-137 and miR-182 all had lower expression levels in uveal melanoma cell lines, compared with normal cells" +tissue_expression_down hsa-mir-155 Choriocarcinoma 24007214 There were low expressions of exosomal miR-155 and miR-196a in serum samples of PC patients when U-6 was used as a control. Serum exosomal miR-17-5p was higher in PC patients than in non-PC patients and healthy participants. +tissue_expression_down hsa-mir-196a Choriocarcinoma 24007214 There were low expressions of exosomal miR-155 and miR-196a in serum samples of PC patients when U-6 was used as a control. Serum exosomal miR-17-5p was higher in PC patients than in non-PC patients and healthy participants. +tissue_expression_down hsa-mir-33a "Carcinoma, Hepatocellular" 24015284 miR-33a down-regulated ¦Â-catenin by directly binding to the 3'-UTR of ¦Â-catenin. These results suggested that AFB1 might down-regulate ¦Â-catenin by up-regulating miR-33a. This understanding opens new lines of thought in the potential role of miR-33a in the clinical therapy of cancer. +tissue_expression_down hsa-mir-199a Lung Neoplasms 24022342 downregulation of miR-199a is essential for hypoxia-induced proliferation through derepressing the expression of HIF1a expression and affecting HIF1a mediated glycolytic pathway in NSCLC progression. +tissue_expression_down hsa-mir-16 Colorectal Carcinoma 24045965 Down-regulation of miR-16 plays critical roles in CRC progression.Low miR-16 expression is an independent factor predicting a poor prognosis for CRC patients. +tissue_expression_down hsa-mir-370 "Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal" 24055400 "In conclusion, our results suggest that miR-370 may function as a tumor suppressor in LSCC through downregulation of FoxM1,suggesting that miR-370 could serve as a novel potential maker for LSCC therapy." +tissue_expression_down hsa-mir-138 Neoplasms [unspecific] 24057215 MiR-138 downregulates miRNA processing in HeLa cells by targeting RMND5A and decreasing Exportin-5 stability. +tissue_expression_down hsa-mir-199a "Carcinoma, Gastric" 24065659 MicroRNA-199a-3p is downregulated in gastric carcinomas and modulates cell proliferation. +tissue_expression_down hsa-let-7f "Leukemia, Myeloid, Acute" 24067109 MicroRNA let-7f is down-regulated in patients with refractory acute myeloid leukemia and is involved in chemotherapy resistance of adriamycin-resistant leukemic cells. +tissue_expression_down hsa-let-7b Primary Biliary Cirrhosis 24074714 "Decreased expression of miR-let-7b may be associated with development and progression of PBC, and this miRNA may represent a novel target of improved diagnostic and preventive strategies for PBC." +tissue_expression_down hsa-mir-27a Intervertebral Disc Degeneration 24086481 This present study revealed that downregulated miR-27a might develop a novel intervention for IDD treatment through the prevention of apoptosis in Nucleus pulposus Cells. +tissue_expression_down hsa-mir-487b Cardiovascular Diseases [unspecific] 24096771 "Angiotensin II-induced hypertension leads to upregulation of miR-487b, which targets IRS1. Via downregulation of IRS1, miR-487b can contribute to cell death and loss of adventitial and medial integrity during hypertension-induced vascular pathology." +tissue_expression_down hsa-mir-760 Gastric Neoplasms 24097871 "Histone mRNA was upregulated, whereas miR-760 was downregulated in the bone marrow and primary tumor of advanced gastric cancer patients, suggesting that the histone mRNA/miR-760 axis had a crucial role in the development of gastric cancer." +tissue_expression_down hsa-mir-30c "Carcinoma, Renal Cell" 24112779 "hypoxia induces EMT in RCC cells through downregulation of miR-30c, which leads to subsequent increase of Slug expression and repression of E-cadherin production, and suggest a potential application of miR-30c in RCC treatment." +tissue_expression_down hsa-mir-34a Ischemic Heart Disease 24123326 "miR-34a was downregulated in heat shocked Sca-11 stem cells (HSSca-11 cells),heat shock induces exosomal transfer of HSF1 from Sca-1(+) cells, which directs ischemic cardiomyocytes toward a prosurvival phenotype by epigenetic repression of miR-34a." +tissue_expression_down hsa-mir-214 "Carcinoma, Hepatocellular" 24129885 "the upregulation of miR-130b and downregulation of miR-199a-5p, miR-199b-5p, and miR-214 were more significant in HCC cell lines" +tissue_expression_down hsa-mir-149 "Carcinoma, Renal Cell" 24137408 "miR-141, miR-149 and miR-429 were downregulated in the ccRCC tissues" +tissue_expression_down hsa-mir-29c "Leukemia, Lymphocytic, Chronic, B-Cell" 24138306 down-regulation of miR-29c is associated with higher tumor burden and significantly predicts short survival in Chinese patients with CLL +tissue_expression_down hsa-mir-661 Breast Neoplasms 24141721 miR-661 downregulates both Mdm2 and Mdm4 to activate p53. +tissue_expression_down hsa-mir-497 Breast Neoplasms 24143964 "downregulation of miR-497 was correlated with BC progression, and miR-497 might be a potential molecular biomarker for predicting the prognosis of patients." +tissue_expression_down hsa-mir-25 "Muscular Dystrophy, Facioscapulohumeral" 24145033 "eight were down-regulated (miR-15b, miR-20b, miR-21, miR-25, miR-100, miR-155, miR-345, and miR-594)" +tissue_expression_down hsa-mir-370 "Leukemia, Myeloid, Chronic" 24148180 MiR-370 sensitized K562 cells to HHT by inducing apoptosis in part by downregulation of FoxM1 expression. These findings may provide further information for CML treatment with HHT. +tissue_expression_down hsa-mir-16 Pleural Mesothelioma 24148817 The miR-15/16 family is downregulated and has tumour suppressor function in MPM. Restoring miR-16 expression represents a novel therapeutic approach for MPM. +tissue_expression_down hsa-mir-141 Esophageal Neoplasms 24155113 "The statistical significance of downregulation in hsa-miR-301a, hsa-miR-141 and hsa-miR-18b expression (P??90% of the 991 lung cancer samples" +tissue_expression_down hsa-mir-490 Lung Neoplasms 28334118 "we found that hsa-mir-210 was upregulated, while hsa-mir-490 and hsa-mir-486 were downregulated in?>?90% of the 991 lung cancer samples" +tissue_expression_down hsa-let-7f Ischemia 28345812 Reduced expression of let-7f activates TGF-¦Â/ALK5 pathway and leads to impaired ischaemia-induced neovascularization after cigarette smoke exposure. +tissue_expression_down hsa-mir-197 "Fibromatosis, Aggressive" 28418912 "The correlation between sporadic DTs and miRNA expression showed that miR-21-3p increased in mutated versus wild-type DTs, while miR-197-3p was decreased" +tissue_expression_down hsa-mir-29b Breast Neoplasms 28465475 Down-regulation of miR-29b in carcinoma associated fibroblasts promotes cell growth and metastasis of breast cancer. +tissue_expression_down hsa-mir-148a "Carcinoma, Gastric" 28475823 Down-regulated miRs specifically correlate with non-cardial gastric cancers and Lauren's classification system. +tissue_expression_down hsa-mir-204 "Carcinoma, Gastric" 28475823 Down-regulated miRs specifically correlate with non-cardial gastric cancers and Lauren's classification system. +tissue_expression_down hsa-mir-31 "Carcinoma, Gastric" 28475823 Down-regulated miRs specifically correlate with non-cardial gastric cancers and Lauren's classification system. +tissue_expression_down hsa-mir-375 "Carcinoma, Gastric" 28475823 Down-regulated miRs specifically correlate with non-cardial gastric cancers and Lauren's classification system. +tissue_expression_down hsa-mir-155 Behcet Disease 28482290 "up regulation of miR-182 and miR-3591-3p; down regulation of miR-155, miR-638 and miR-4488 in the pathogenesis of the disease" +tissue_expression_down hsa-mir-4488 Behcet Disease 28482290 "up regulation of miR-182 and miR-3591-3p; down regulation of miR-155, miR-638 and miR-4488 in the pathogenesis of the disease" +tissue_expression_down hsa-mir-638 Behcet Disease 28482290 "up regulation of miR-182 and miR-3591-3p; down regulation of miR-155, miR-638 and miR-4488 in the pathogenesis of the disease" +tissue_expression_down hsa-mir-200b Colon Neoplasms 28552992 MicroRNA-200b is downregulated in colon cancer budding cells. +tissue_expression_down hsa-mir-1 Pituitary Neoplasms 28577032 "Studies have shown that the levels of miR-1, miR-195, and miR-206 are downregulated in Pas" +tissue_expression_down hsa-mir-195 Pituitary Neoplasms 28577032 "Studies have shown that the levels of miR-1, miR-195, and miR-206 are downregulated in Pas" +tissue_expression_down hsa-mir-206 Pituitary Neoplasms 28577032 "Studies have shown that the levels of miR-1, miR-195, and miR-206 are downregulated in Pas" +tissue_expression_down hsa-mir-200b Liver Cirrhosis 28634212 Prolonged darkness reduces liver fibrosis in a mouse model of primary sclerosing cholangitis by miR-200b down-regulation. +tissue_expression_down hsa-mir-146a Obesity 28652200 Down-regulation of miRNAs in the brain and development of diet-induced obesity +tissue_expression_down hsa-mir-155 Obesity 28652200 Down-regulation of miRNAs in the brain and development of diet-induced obesity. +tissue_expression_down hsa-mir-451 "Carcinoma, Lung, Non-Small-Cell" 28704499 The low expression of miR-451 predicts a worse prognosis in non-small cell lung cancer cases. +tissue_expression_down hsa-mir-122 Stroke 28751928 A Decrease of Brain MicroRNA-122 Level Is an Early Marker of Cerebrovascular Disease in the Stroke-Prone Spontaneously Hypertensive Rat. +tissue_expression_down hsa-mir-138 "Squamous Cell Carcinoma, Esophageal" 28759955 Downregulation of miR-138 predicts poor prognosis in patients with esophageal squamous cell carcinoma +tissue_expression_down hsa-mir-15 Chronic Kidney Disease 28771472 MicroRNAs in the miR-17 and miR-15 families are downregulated in chronic kidney disease with hypertension. +tissue_expression_down hsa-mir-17 Chronic Kidney Disease 28771472 MicroRNAs in the miR-17 and miR-15 families are downregulated in chronic kidney disease with hypertension. +tissue_expression_down hsa-mir-190b Vasomotor Rhinitis 28787742 "there was significant overexpression of miR-543, miR-129-5p, and miR-126-3p, and under-expression of miR-2110, miR-449c-5p, miR-449b-5p, miR-190b, and miR-92b-5p." +tissue_expression_down hsa-mir-2110 Vasomotor Rhinitis 28787742 "there was significant overexpression of miR-543, miR-129-5p, and miR-126-3p, and under-expression of miR-2110, miR-449c-5p, miR-449b-5p, miR-190b, and miR-92b-5p." +tissue_expression_down hsa-mir-449b Vasomotor Rhinitis 28787742 "there was significant overexpression of miR-543, miR-129-5p, and miR-126-3p, and under-expression of miR-2110, miR-449c-5p, miR-449b-5p, miR-190b, and miR-92b-5p." +tissue_expression_down hsa-mir-449c Vasomotor Rhinitis 28787742 "there was significant overexpression of miR-543, miR-129-5p, and miR-126-3p, and under-expression of miR-2110, miR-449c-5p, miR-449b-5p, miR-190b, and miR-92b-5p." +tissue_expression_down hsa-mir-92b Vasomotor Rhinitis 28787742 "there was significant overexpression of miR-543, miR-129-5p, and miR-126-3p, and under-expression of miR-2110, miR-449c-5p, miR-449b-5p, miR-190b, and miR-92b-5p." +tissue_expression_down hsa-mir-17 "Lymphoma, Large B-Cell, Diffuse" 28817403 "PB-DLBCL and DLBCL-GCB-CC also had much higher levels of miR-125a-3p, miR-34-3p, and miR-155-5p, and significantly lower levels of miR-17-5p and miR-17-3p" +tissue_expression_down hsa-mir-200b Colon Neoplasms 28821160 "downregulation of AKT, NF-¦ÊB, Bcl-XL expressions and some key oncomicroRNAs such as miRNA-21 and miRNA-200b significantly" +tissue_expression_down hsa-mir-21 Colon Neoplasms 28821160 "downregulation of AKT, NF-¦ÊB, Bcl-XL expressions and some key oncomicroRNAs such as miRNA-21 and miRNA-200b significantly" +tissue_expression_down hsa-let-7a Lung Neoplasms 28846189 "Let-7a, miR-16 and miR-34a, were found to be significantly downregulated by chronic PM2.5 exposure" +tissue_expression_down hsa-mir-16 Lung Neoplasms 28846189 "Let-7a, miR-16 and miR-34a, were found to be significantly downregulated by chronic PM2.5 exposure" +tissue_expression_down hsa-mir-34a Lung Neoplasms 28846189 "Let-7a, miR-16 and miR-34a, were found to be significantly downregulated by chronic PM2.5 exposure" +tissue_expression_down hsa-mir-148a Colorectal Carcinoma 28863773 Down-regulation of miRNA-148a and miRNA-625-3p in colorectal cancer is associated with tumor budding. +tissue_expression_down hsa-mir-625 Colorectal Carcinoma 28863773 Down-regulation of miRNA-148a and miRNA-625-3p in colorectal cancer is associated with tumor budding. +tissue_expression_down hsa-mir-221 Prostate Neoplasms 28886115 Androgen receptor-mediated downregulation of microRNA-221 and -222 in castration-resistant prostate cancer. +tissue_expression_down hsa-mir-222 Prostate Neoplasms 28886115 Androgen receptor-mediated downregulation of microRNA-221 and -222 in castration-resistant prostate cancer. +tissue_expression_down hsa-mir-21 Alcoholic Cardiomyopathy 29039471 "The present study confirmed that H2S relieves myocardial fibrosis in mice with ACM, and the underlying mechanism may involve the downregulation of autophagy and miR-21 and miR-211 expression levels." +tissue_expression_down hsa-mir-221 Alcoholic Cardiomyopathy 29039471 "The present study confirmed that H2S relieves myocardial fibrosis in mice with ACM, and the underlying mechanism may involve the downregulation of autophagy and miR-21 and miR-211 expression levels." +tissue_expression_down hsa-mir-199a Ovarian Germ Cell Cancer 29138809 "Higher expression of miR-373-3p, miR-372-3p and miR-302c-3p and lower expression of miR-199a-5p, miR-214-5p and miR-202-3p were reproducibly observed in malignant OGCTs as compared to benign OGCTs or SCSTs" +tissue_expression_down hsa-mir-202 Ovarian Germ Cell Cancer 29138809 "Higher expression of miR-373-3p, miR-372-3p and miR-302c-3p and lower expression of miR-199a-5p, miR-214-5p and miR-202-3p were reproducibly observed in malignant OGCTs as compared to benign OGCTs or SCSTs" +tissue_expression_down hsa-mir-214 Ovarian Germ Cell Cancer 29138809 "Higher expression of miR-373-3p, miR-372-3p and miR-302c-3p and lower expression of miR-199a-5p, miR-214-5p and miR-202-3p were reproducibly observed in malignant OGCTs as compared to benign OGCTs or SCSTs" +tissue_expression_down hsa-mir-1 Myocardial Infarction 29162889 "The expression level of miR-143 in monocytes from STEMI patients compared to healthy controls was increased, whereas the expression of miR-1, -92a, -99a, and -223 was reduced significantly" +tissue_expression_down hsa-mir-223 Myocardial Infarction 29162889 "The expression level of miR-143 in monocytes from STEMI patients compared to healthy controls was increased, whereas the expression of miR-1, -92a, -99a, and -223 was reduced significantly" +tissue_expression_down hsa-mir-92a Myocardial Infarction 29162889 "The expression level of miR-143 in monocytes from STEMI patients compared to healthy controls was increased, whereas the expression of miR-1, -92a, -99a, and -223 was reduced significantly" +tissue_expression_down hsa-mir-99a Myocardial Infarction 29162889 "The expression level of miR-143 in monocytes from STEMI patients compared to healthy controls was increased, whereas the expression of miR-1, -92a, -99a, and -223 was reduced significantly" +tissue_expression_down hsa-mir-125b Ovarian Neoplasms 29307001 "miR-26a, miR-125b-5p, miR-17-5p and miR-221 downregulation could be related to poor EOC prognosis" +tissue_expression_down hsa-mir-17 Ovarian Neoplasms 29307001 "miR-26a, miR-125b-5p, miR-17-5p and miR-221 downregulation could be related to poor EOC prognosis" +tissue_expression_down hsa-mir-221 Ovarian Neoplasms 29307001 "miR-26a, miR-125b-5p, miR-17-5p and miR-221 downregulation could be related to poor EOC prognosis" +tissue_expression_down hsa-mir-26a Ovarian Neoplasms 29307001 "miR-26a, miR-125b-5p, miR-17-5p and miR-221 downregulation could be related to poor EOC prognosis" +tissue_expression_down hsa-let-7a "Carcinoma, Hepatocellular" 29314614 "miR-1, miR-122, let-7a, and let-7g were downregulated, whereas miR-10b and miR-21 were upregulated in canine HCC" +tissue_expression_down hsa-let-7g "Carcinoma, Hepatocellular" 29314614 "miR-1, miR-122, let-7a, and let-7g were downregulated, whereas miR-10b and miR-21 were upregulated in canine HCC" +tissue_expression_down hsa-mir-1 "Carcinoma, Hepatocellular" 29314614 "miR-1, miR-122, let-7a, and let-7g were downregulated, whereas miR-10b and miR-21 were upregulated in canine HCC" +tissue_expression_down hsa-mir-122 "Carcinoma, Hepatocellular" 29314614 "miR-1, miR-122, let-7a, and let-7g were downregulated, whereas miR-10b and miR-21 were upregulated in canine HCC" +tissue_expression_down hsa-mir-145 NUT Midline Carcinoma 29322795 "All NMCs showed upregulation of miR-9 and downregulation of miR-99a and miR-145 and two cases featured also upregulation of miR-21, miR-143, and miR-484" +tissue_expression_down hsa-mir-99a NUT Midline Carcinoma 29322795 "All NMCs showed upregulation of miR-9 and downregulation of miR-99a and miR-145 and two cases featured also upregulation of miR-21, miR-143, and miR-484" +tissue_expression_down hsa-mir-125 Infection [unspecific] 29391047 "upregulated miR-21, miR-155, miR-150, and miR-221, as well as downregulated miR-143 and miR-125, all of them previously linked to other bacterial infections" +tissue_expression_down hsa-mir-143 Infection [unspecific] 29391047 "upregulated miR-21, miR-155, miR-150, and miR-221, as well as downregulated miR-143 and miR-125, all of them previously linked to other bacterial infections" +tissue_expression_down hsa-let-7i Hepatoblastoma 29404451 "Let-7i-3p, miR-449b-3p, miR-624-5p, and miR-885-5p were decreased in tumors compared to normal livers" +tissue_expression_down hsa-mir-449b Hepatoblastoma 29404451 "Let-7i-3p, miR-449b-3p, miR-624-5p, and miR-885-5p were decreased in tumors compared to normal livers" +tissue_expression_down hsa-mir-624 Hepatoblastoma 29404451 "Let-7i-3p, miR-449b-3p, miR-624-5p, and miR-885-5p were decreased in tumors compared to normal livers" +tissue_expression_down hsa-mir-885 Hepatoblastoma 29404451 "Let-7i-3p, miR-449b-3p, miR-624-5p, and miR-885-5p were decreased in tumors compared to normal livers" +tissue_expression_down hsa-mir-129 Infection [unspecific] 29425228 "Seven of the 26 miRNAs, miR-99b-5p, miR-129-3p, miR-188-5p, miR-363-3p, miR-1295a, miR-4443 and miR-6721-5p, showed significantly decreased expression in individuals with detectable oral shedding" +tissue_expression_down hsa-mir-1295a Infection [unspecific] 29425228 "Seven of the 26 miRNAs, miR-99b-5p, miR-129-3p, miR-188-5p, miR-363-3p, miR-1295a, miR-4443 and miR-6721-5p, showed significantly decreased expression in individuals with detectable oral shedding" +tissue_expression_down hsa-mir-188 Infection [unspecific] 29425228 "Seven of the 26 miRNAs, miR-99b-5p, miR-129-3p, miR-188-5p, miR-363-3p, miR-1295a, miR-4443 and miR-6721-5p, showed significantly decreased expression in individuals with detectable oral shedding" +tissue_expression_down hsa-mir-363 Infection [unspecific] 29425228 "Seven of the 26 miRNAs, miR-99b-5p, miR-129-3p, miR-188-5p, miR-363-3p, miR-1295a, miR-4443 and miR-6721-5p, showed significantly decreased expression in individuals with detectable oral shedding" +tissue_expression_down hsa-mir-4443 Infection [unspecific] 29425228 "Seven of the 26 miRNAs, miR-99b-5p, miR-129-3p, miR-188-5p, miR-363-3p, miR-1295a, miR-4443 and miR-6721-5p, showed significantly decreased expression in individuals with detectable oral shedding" +tissue_expression_down hsa-mir-6721 Infection [unspecific] 29425228 "Seven of the 26 miRNAs, miR-99b-5p, miR-129-3p, miR-188-5p, miR-363-3p, miR-1295a, miR-4443 and miR-6721-5p, showed significantly decreased expression in individuals with detectable oral shedding" +tissue_expression_down hsa-mir-99b Infection [unspecific] 29425228 "Seven of the 26 miRNAs, miR-99b-5p, miR-129-3p, miR-188-5p, miR-363-3p, miR-1295a, miR-4443 and miR-6721-5p, showed significantly decreased expression in individuals with detectable oral shedding" +tissue_expression_down hsa-mir-192 "Carcinoma, Renal Cell" 29440068 miR-192 and miR-194 as downregulated +tissue_expression_down hsa-mir-194 "Carcinoma, Renal Cell" 29440068 miR-192 and miR-194 as downregulated +tissue_expression_down hsa-mir-125a "Squamous Cell Carcinoma, Oral" 29480379 increased miR-21 levels in conjunction with decreased miR-125a levels in saliva of OLP patients may be indicative for a poor prognosis +tissue_expression_down hsa-mir-34a Cervical Neoplasms 29487007 "MiR-21-5p upregulation, miR-34a downregulation, and hTERC amplification were associated with the aggressive progression of CC, which suggests that miR-21-5p, miR-34a and hTERC might serve as surrogate markers for CC progression and potential molecular targets for blockage of the development of CC" +tissue_expression_down hsa-mir-126 Lung Neoplasms 29516903 "the authors identified a statistically significant miRNA meta-signature of seven upregulated (miR-21, miR-210, miR-182, miR-31, miR-200b, miR-205, and miR-183) and eight downregulated (miR-126-3p, miR-30a, miR-30d, miR-486-5p, miR-451a, miR-126-5p, miR-143, and miR-145) miRNAs" +tissue_expression_down hsa-mir-143 Lung Neoplasms 29516903 "the authors identified a statistically significant miRNA meta-signature of seven upregulated (miR-21, miR-210, miR-182, miR-31, miR-200b, miR-205, and miR-183) and eight downregulated (miR-126-3p, miR-30a, miR-30d, miR-486-5p, miR-451a, miR-126-5p, miR-143, and miR-145) miRNAs" +tissue_expression_down hsa-mir-145 Lung Neoplasms 29516903 "the authors identified a statistically significant miRNA meta-signature of seven upregulated (miR-21, miR-210, miR-182, miR-31, miR-200b, miR-205, and miR-183) and eight downregulated (miR-126-3p, miR-30a, miR-30d, miR-486-5p, miR-451a, miR-126-5p, miR-143, and miR-145) miRNAs" +tissue_expression_down hsa-mir-30a Lung Neoplasms 29516903 "the authors identified a statistically significant miRNA meta-signature of seven upregulated (miR-21, miR-210, miR-182, miR-31, miR-200b, miR-205, and miR-183) and eight downregulated (miR-126-3p, miR-30a, miR-30d, miR-486-5p, miR-451a, miR-126-5p, miR-143, and miR-145) miRNAs" +tissue_expression_down hsa-mir-30d Lung Neoplasms 29516903 "the authors identified a statistically significant miRNA meta-signature of seven upregulated (miR-21, miR-210, miR-182, miR-31, miR-200b, miR-205, and miR-183) and eight downregulated (miR-126-3p, miR-30a, miR-30d, miR-486-5p, miR-451a, miR-126-5p, miR-143, and miR-145) miRNAs" +tissue_expression_down hsa-mir-451a Lung Neoplasms 29516903 "the authors identified a statistically significant miRNA meta-signature of seven upregulated (miR-21, miR-210, miR-182, miR-31, miR-200b, miR-205, and miR-183) and eight downregulated (miR-126-3p, miR-30a, miR-30d, miR-486-5p, miR-451a, miR-126-5p, miR-143, and miR-145) miRNAs" +tissue_expression_down hsa-mir-486 Lung Neoplasms 29516903 "the authors identified a statistically significant miRNA meta-signature of seven upregulated (miR-21, miR-210, miR-182, miR-31, miR-200b, miR-205, and miR-183) and eight downregulated (miR-126-3p, miR-30a, miR-30d, miR-486-5p, miR-451a, miR-126-5p, miR-143, and miR-145) miRNAs" +tissue_expression_down hsa-mir-196b Ovarian Neoplasms 29518404 "Specifically, miR-196b, miR-532, miR-886-3b, and miR-99b exhibited lower levels in HGOSC compared with USC, whereas miR-29c, miR-155, miR-454, miR-146b-5p, miR-486-5p, miR-27a, miR-192, and miR-141 exhibited significantly higher expression in HGOSC samples" +tissue_expression_down hsa-mir-532 Ovarian Neoplasms 29518404 "Specifically, miR-196b, miR-532, miR-886-3b, and miR-99b exhibited lower levels in HGOSC compared with USC, whereas miR-29c, miR-155, miR-454, miR-146b-5p, miR-486-5p, miR-27a, miR-192, and miR-141 exhibited significantly higher expression in HGOSC samples" +tissue_expression_down hsa-mir-886 Ovarian Neoplasms 29518404 "Specifically, miR-196b, miR-532, miR-886-3b, and miR-99b exhibited lower levels in HGOSC compared with USC, whereas miR-29c, miR-155, miR-454, miR-146b-5p, miR-486-5p, miR-27a, miR-192, and miR-141 exhibited significantly higher expression in HGOSC samples" +tissue_expression_down hsa-mir-99b Ovarian Neoplasms 29518404 "Specifically, miR-196b, miR-532, miR-886-3b, and miR-99b exhibited lower levels in HGOSC compared with USC, whereas miR-29c, miR-155, miR-454, miR-146b-5p, miR-486-5p, miR-27a, miR-192, and miR-141 exhibited significantly higher expression in HGOSC samples" +tissue_expression_down hsa-mir-101 "Squamous Cell Carcinoma, Oral" 29533734 "Poor prognosis correlated with upregulation of 9 miRNAs (miR-21, miR-455-5p, miiR-155-5p, miR-372, miR-373, miR-29b, miR-1246, miR-196a, and miR-181) and downregulation of 7 miRNAs (miR-204, miR-101, miR-32, miR-20a, miR-16, miR-17, and miR-125b)" +tissue_expression_down hsa-mir-125b "Squamous Cell Carcinoma, Oral" 29533734 "Poor prognosis correlated with upregulation of 9 miRNAs (miR-21, miR-455-5p, miiR-155-5p, miR-372, miR-373, miR-29b, miR-1246, miR-196a, and miR-181) and downregulation of 7 miRNAs (miR-204, miR-101, miR-32, miR-20a, miR-16, miR-17, and miR-125b)" +tissue_expression_down hsa-mir-16 "Squamous Cell Carcinoma, Oral" 29533734 "Poor prognosis correlated with upregulation of 9 miRNAs (miR-21, miR-455-5p, miiR-155-5p, miR-372, miR-373, miR-29b, miR-1246, miR-196a, and miR-181) and downregulation of 7 miRNAs (miR-204, miR-101, miR-32, miR-20a, miR-16, miR-17, and miR-125b)" +tissue_expression_down hsa-mir-17 "Squamous Cell Carcinoma, Oral" 29533734 "Poor prognosis correlated with upregulation of 9 miRNAs (miR-21, miR-455-5p, miiR-155-5p, miR-372, miR-373, miR-29b, miR-1246, miR-196a, and miR-181) and downregulation of 7 miRNAs (miR-204, miR-101, miR-32, miR-20a, miR-16, miR-17, and miR-125b)" +tissue_expression_down hsa-mir-204 "Squamous Cell Carcinoma, Oral" 29533734 "Poor prognosis correlated with upregulation of 9 miRNAs (miR-21, miR-455-5p, miiR-155-5p, miR-372, miR-373, miR-29b, miR-1246, miR-196a, and miR-181) and downregulation of 7 miRNAs (miR-204, miR-101, miR-32, miR-20a, miR-16, miR-17, and miR-125b)" +tissue_expression_down hsa-mir-20a "Squamous Cell Carcinoma, Oral" 29533734 "Poor prognosis correlated with upregulation of 9 miRNAs (miR-21, miR-455-5p, miiR-155-5p, miR-372, miR-373, miR-29b, miR-1246, miR-196a, and miR-181) and downregulation of 7 miRNAs (miR-204, miR-101, miR-32, miR-20a, miR-16, miR-17, and miR-125b)" +tissue_expression_down hsa-mir-32 "Squamous Cell Carcinoma, Oral" 29533734 "Poor prognosis correlated with upregulation of 9 miRNAs (miR-21, miR-455-5p, miiR-155-5p, miR-372, miR-373, miR-29b, miR-1246, miR-196a, and miR-181) and downregulation of 7 miRNAs (miR-204, miR-101, miR-32, miR-20a, miR-16, miR-17, and miR-125b)" +tissue_expression_down hsa-mir-124 Glioblastoma 29559295 "In our microarray data, lower expression of miR-219-5p, miR-124, and miR-128 and higher expression of miR-21 was observed in GBM compared with the peripheral region, similar to the results of previous reports" +tissue_expression_down hsa-mir-128 Glioblastoma 29559295 "In our microarray data, lower expression of miR-219-5p, miR-124, and miR-128 and higher expression of miR-21 was observed in GBM compared with the peripheral region, similar to the results of previous reports" +tissue_expression_down hsa-mir-219 Glioblastoma 29559295 "In our microarray data, lower expression of miR-219-5p, miR-124, and miR-128 and higher expression of miR-21 was observed in GBM compared with the peripheral region, similar to the results of previous reports" +tissue_expression_down hsa-mir-3127 "Carcinoma, Lung, Non-Small-Cell" 29566281 Downregulation of miR-3127-5p promotes epithelial-mesenchymal transition via FZD4 regulation of Wnt/¦Â-catenin signaling in non-small-cell lung cancer. +tissue_expression_down hsa-mir-135b Prostate Neoplasms 29568403 "top nine miRNA with significantly lower expression level in ExoHypoxic compared to ExoNormoxic were miR-521, miR-27a, miR-324, miR-579, miR-502, miR-222, miR-135b, miR-146a and miR-491." +tissue_expression_down hsa-mir-146a Prostate Neoplasms 29568403 "top nine miRNA with significantly lower expression level in ExoHypoxic compared to ExoNormoxic were miR-521, miR-27a, miR-324, miR-579, miR-502, miR-222, miR-135b, miR-146a and miR-492." +tissue_expression_down hsa-mir-222 Prostate Neoplasms 29568403 "top nine miRNA with significantly lower expression level in ExoHypoxic compared to ExoNormoxic were miR-521, miR-27a, miR-324, miR-579, miR-502, miR-222, miR-135b, miR-146a and miR-491." +tissue_expression_down hsa-mir-27a Prostate Neoplasms 29568403 "top nine miRNA with significantly lower expression level in ExoHypoxic compared to ExoNormoxic were miR-521, miR-27a, miR-324, miR-579, miR-502, miR-222, miR-135b, miR-146a and miR-491." +tissue_expression_down hsa-mir-324 Prostate Neoplasms 29568403 "top nine miRNA with significantly lower expression level in ExoHypoxic compared to ExoNormoxic were miR-521, miR-27a, miR-324, miR-579, miR-502, miR-222, miR-135b, miR-146a and miR-491." +tissue_expression_down hsa-mir-491 Prostate Neoplasms 29568403 "top nine miRNA with significantly lower expression level in ExoHypoxic compared to ExoNormoxic were miR-521, miR-27a, miR-324, miR-579, miR-502, miR-222, miR-135b, miR-146a and miR-492." +tissue_expression_down hsa-mir-502 Prostate Neoplasms 29568403 "top nine miRNA with significantly lower expression level in ExoHypoxic compared to ExoNormoxic were miR-521, miR-27a, miR-324, miR-579, miR-502, miR-222, miR-135b, miR-146a and miR-491." +tissue_expression_down hsa-mir-521 Prostate Neoplasms 29568403 "top nine miRNA with significantly lower expression level in ExoHypoxic compared to ExoNormoxic were miR-521, miR-27a, miR-324, miR-579, miR-502, miR-222, miR-135b, miR-146a and miR-491." +tissue_expression_down hsa-mir-579 Prostate Neoplasms 29568403 "top nine miRNA with significantly lower expression level in ExoHypoxic compared to ExoNormoxic were miR-521, miR-27a, miR-324, miR-579, miR-502, miR-222, miR-135b, miR-146a and miR-491." +tissue_expression_down hsa-mir-145 "Carcinoma, Endometrioid Endometrial" 29569698 miRNA-145 expression was lower in DPEEOC endometrial tissues and higher in DPEEOC ovarian tissues compared to the corresponding normal tissues +tissue_expression_down hsa-mir-143 "Carcinoma, Hepatocellular, HBV-Related" 29616093 "These results indicated that the decreased expression of the miR-143/145 cluster and their host gene MIR143HG in HBV-associated HCC tissue was associated with prognosis, and each of these miRNAs may serve as a valuable diagnostic biomarker for predicting HBV-associated HCC tumorigenesis" +tissue_expression_down hsa-mir-145 "Carcinoma, Hepatocellular, HBV-Related" 29616093 "These results indicated that the decreased expression of the miR-143/145 cluster and their host gene MIR143HG in HBV-associated HCC tissue was associated with prognosis, and each of these miRNAs may serve as a valuable diagnostic biomarker for predicting HBV-associated HCC tumorigenesis" +tissue_expression_down hsa-mir-145 Urinary System Cancer 29623292 the decline of miR-145 expression level have been proved to be able to distinguish bladder cancer patients from non-cancer controls in cell-free urine samples; the elevation of miR-10a and miR-30d was also observed in urine samples from patients with focal segmental glomerulosclerosis +tissue_expression_down hsa-mir-126 Atherosclerosis 29642385 "Moreover, the expression level of miR-126 tended to be downregulated and that of miR-21 tended to be upregulated in ApoE KO mice exposed to the high dose of CS, albeit statistically insignificant" +tissue_expression_down hsa-mir-126 Myocardial Infarction 29642385 "Moreover, the expression level of miR-126 tended to be downregulated and that of miR-21 tended to be upregulated in ApoE KO mice exposed to the high dose of CS, albeit statistically insignificant" +tissue_expression_down hsa-mir-126 Stroke 29642385 "Moreover, the expression level of miR-126 tended to be downregulated and that of miR-21 tended to be upregulated in ApoE KO mice exposed to the high dose of CS, albeit statistically insignificant" +tissue_expression_down hsa-mir-7 Myasthenia Gravis 29655674 miR-7 was the most down-regulated thymic miRNA in MG +tissue_expression_down hsa-mir-10a Ependymoma 29658967 low expression of miR-10a and over-expression of miR-10b and miR-29a in ependymoma +tissue_expression_down hsa-mir-181c Medulloblastoma 29658967 "Low-expression of miR-221, miR-9, and miR-181c/d and over-expression of miR-101, miR-222, miR-139, miR-1827, and miR-34c was found in medulloblastoma" +tissue_expression_down hsa-mir-181d Medulloblastoma 29658967 "Low-expression of miR-221, miR-9, and miR-181c/d and over-expression of miR-101, miR-222, miR-139, miR-1827, and miR-34c was found in medulloblastoma" +tissue_expression_down hsa-mir-221 Medulloblastoma 29658967 "Low-expression of miR-221, miR-9, and miR-181c/d and over-expression of miR-101, miR-222, miR-139, miR-1827, and miR-34c was found in medulloblastoma" +tissue_expression_down hsa-mir-26a Glioma 29658967 "low expression of miR-26a and overexpression of miR-19a/b, miR-24, miR-27a, miR- 584, and miR-527 in low-grade glioma" +tissue_expression_down hsa-mir-9 Medulloblastoma 29658967 "Low-expression of miR-221, miR-9, and miR-181c/d and over-expression of miR-101, miR-222, miR-139, miR-1827, and miR-34c was found in medulloblastoma" +tissue_expression_down hsa-mir-203 "Squamous Cell Carcinoma, Head and Neck" 29667275 "miR-26 and miR-125b may be associated with the progression and metastasis of HNSCC, and that miR-203 is associated with a more favourable prognosis." +tissue_expression_down hsa-mir-26b "Carcinoma, Breast" 29689244 Decreased expression of microRNA-26b in locally advanced and inflammatory breast cancer. +tissue_expression_down hsa-mir-3098 Alcoholic Cardiomyopathy 29734191 The results demonstrated that miR-467d-3p and miR-491-5p were up-regulated and miR-3098-3p was down-regulated in the alcohol-exposed myocardial samples compared with the control samples (P < 0.05). +tissue_expression_down hsa-mir-188 "Carcinoma, Cervical" 29737570 the low expression of miR-188 and high expression of miR-223 correlated with the short survival of CC patients +tissue_expression_down hsa-mir-197 Chronic Obstructive Pulmonary Disease 29757677 "expression levels of miR-98, miR-139-5p, miR-146b-5p, and miR-451 were upregulated, as compared with NS. In contrast, miR-197, miR-204, miR-485-3p, and miR-627 were downregulated." +tissue_expression_down hsa-mir-204 Chronic Obstructive Pulmonary Disease 29757677 "expression levels of miR-98, miR-139-5p, miR-146b-5p, and miR-451 were upregulated, as compared with NS. In contrast, miR-197, miR-204, miR-485-3p, and miR-627 were downregulated." +tissue_expression_down hsa-mir-485 Chronic Obstructive Pulmonary Disease 29757677 "expression levels of miR-98, miR-139-5p, miR-146b-5p, and miR-451 were upregulated, as compared with NS. In contrast, miR-197, miR-204, miR-485-3p, and miR-627 were downregulated." +tissue_expression_down hsa-mir-627 Chronic Obstructive Pulmonary Disease 29757677 "expression levels of miR-98, miR-139-5p, miR-146b-5p, and miR-451 were upregulated, as compared with NS. In contrast, miR-197, miR-204, miR-485-3p, and miR-627 were downregulated." +tissue_expression_down hsa-let-7c "Squamous Cell Carcinoma, Oral" 29764807 "Upregulation of miR-31 and miR-21 and downregulation of miR-99a, let-7c, miR-125b, and miR-100 were found between OSCC and controls" +tissue_expression_down hsa-mir-100 "Squamous Cell Carcinoma, Oral" 29764807 "Upregulation of miR-31 and miR-21 and downregulation of miR-99a, let-7c, miR-125b, and miR-100 were found between OSCC and controls" +tissue_expression_down hsa-mir-125b "Squamous Cell Carcinoma, Oral" 29764807 "Upregulation of miR-31 and miR-21 and downregulation of miR-99a, let-7c, miR-125b, and miR-100 were found between OSCC and controls" +tissue_expression_down hsa-mir-99a "Squamous Cell Carcinoma, Oral" 29764807 "Upregulation of miR-31 and miR-21 and downregulation of miR-99a, let-7c, miR-125b, and miR-100 were found between OSCC and controls" +tissue_expression_down hsa-let-7 Gastric Neoplasms 29797599 "Our data showed that miR-146, miR-375, and Let-7 were down-regulated and miR-19 and miR-21 were up-regulated in GC patients with H. pylori infection" +tissue_expression_down hsa-mir-146 Gastric Neoplasms 29797599 "Our data showed that miR-146, miR-375, and Let-7 were down-regulated and miR-19 and miR-21 were up-regulated in GC patients with H. pylori infection" +tissue_expression_down hsa-mir-375 Gastric Neoplasms 29797599 "Our data showed that miR-146, miR-375, and Let-7 were down-regulated and miR-19 and miR-21 were up-regulated in GC patients with H. pylori infection" +tissue_expression_down hsa-mir-200a Chronic Kidney Disease 29909697 "We recognized in both meta-analysis approaches a significant miRNA meta-signature of five up-regulated (miR-142-3p, miR-223-3p, miR-21-5p, miR-142-5p and miR-214-3p) and two down-regulated (miR-29c-3p and miR-200a-3p) miRNAs" +tissue_expression_down hsa-mir-29c Chronic Kidney Disease 29909697 "We recognized in both meta-analysis approaches a significant miRNA meta-signature of five up-regulated (miR-142-3p, miR-223-3p, miR-21-5p, miR-142-5p and miR-214-3p) and two down-regulated (miR-29c-3p and miR-200a-3p) miRNAs" +tissue_expression_down hsa-mir-141 "Carcinoma, Breast, Triple Negative" 29923083 "(1) upregulated: miR-10b, miR-21, miR-29, miR-9, miR-221/222, miR-373 or (2) downregulated: miR-145, miR-199a-5p, miR-200 family, miR-203, miR-205 in TNBC" +tissue_expression_down hsa-mir-145 "Carcinoma, Breast, Triple Negative" 29923083 "(1) upregulated: miR-10b, miR-21, miR-29, miR-9, miR-221/222, miR-373 or (2) downregulated: miR-145, miR-199a-5p, miR-200 family, miR-203, miR-205 in TNBC" +tissue_expression_down hsa-mir-199a "Carcinoma, Breast, Triple Negative" 29923083 "(1) upregulated: miR-10b, miR-21, miR-29, miR-9, miR-221/222, miR-373 or (2) downregulated: miR-145, miR-199a-5p, miR-200 family, miR-203, miR-205 in TNBC" +tissue_expression_down hsa-mir-200a "Carcinoma, Breast, Triple Negative" 29923083 "(1) upregulated: miR-10b, miR-21, miR-29, miR-9, miR-221/222, miR-373 or (2) downregulated: miR-145, miR-199a-5p, miR-200 family, miR-203, miR-205 in TNBC" +tissue_expression_down hsa-mir-200b "Carcinoma, Breast, Triple Negative" 29923083 "(1) upregulated: miR-10b, miR-21, miR-29, miR-9, miR-221/222, miR-373 or (2) downregulated: miR-145, miR-199a-5p, miR-200 family, miR-203, miR-205 in TNBC" +tissue_expression_down hsa-mir-200c "Carcinoma, Breast, Triple Negative" 29923083 "(1) upregulated: miR-10b, miR-21, miR-29, miR-9, miR-221/222, miR-373 or (2) downregulated: miR-145, miR-199a-5p, miR-200 family, miR-203, miR-205 in TNBC" +tissue_expression_down hsa-mir-429 "Carcinoma, Breast, Triple Negative" 29923083 "(1) upregulated: miR-10b, miR-21, miR-29, miR-9, miR-221/222, miR-373 or (2) downregulated: miR-145, miR-199a-5p, miR-200 family, miR-203, miR-205 in TNBC" +tissue_expression_down hsa-mir-379 Oligodendroglioma 29931616 Identification of miR-379/miR-656 (C14MC) cluster downregulation and associated epigenetic and transcription regulatory mechanism in oligodendrogliomas. +tissue_expression_down hsa-mir-656 Oligodendroglioma 29931616 Identification of miR-379/miR-656 (C14MC) cluster downregulation and associated epigenetic and transcription regulatory mechanism in oligodendrogliomas. +tissue_expression_down hsa-mir-183 "Adenocarcinoma, Pancreatic Ductal" 29952976 the downregulated miR-183 level might be associated with poor prognosis in patients with melanoma and pancreatic ductal adenocarcinoma +tissue_expression_down hsa-mir-183 Melanoma 29952976 the downregulated miR-183 level might be associated with poor prognosis in patients with melanoma and pancreatic ductal adenocarcinoma +tissue_expression_down hsa-mir-490 "Carcinoma, Hepatocellular" 30007991 We found that miR-490-3p is down-regulated in HCC and is related to genes that have potential tumoral functions +tissue_expression_down hsa-mir-486 "Carcinoma, Thyroid, Papillary" 30015845 Downregulation of miR?486?5p in papillary thyroid carcinoma tissue: A study based on microarray and miRNA sequencing. +tissue_expression_down hsa-mir-29a Glioma 30016785 MicroRNA-29a-3p Downregulation Causes Gab1 Upregulation to Promote Glioma Cell Proliferation. +tissue_expression_down hsa-mir-187 Ovarian Neoplasms 30035102 low miR-187 and miR-489 expression was associated with poor prognosis +tissue_expression_down hsa-mir-489 Ovarian Neoplasms 30035102 low miR-187 and miR-489 expression was associated with poor prognosis +tissue_expression_down hsa-mir-204 Hepatitis B Virus Infection 30042818 "miR-204, strongly decreased both HBV DNA and HBsAg in culture supernatant of HepG2-hNTCP-C4 cells" +tissue_expression_down hsa-mir-128 Cholangiocarcinoma 30042823 "High miR-126, low miR-128 and TEMs were independent prognostic factors for recurrence-free and overall survival" +tissue_expression_down hsa-mir-126 Ovarian Neoplasms 30107086 "We report that miR-21 (P?=?0.0001), miR-100 (P?=?0.034), miR-200b (P?=?0.008), and miR-320 (P?=?0.034) are significantly enriched, whereas miR-16 (P?=?0.009), miR-93 (P?=?0.014), miR-126 (P?=?0.012), and miR-223 (P?=?0.029) are underrepresented in exosomes from plasma of EOC patients as compared to those of healthy women. The levels of exosomal miR-23a (P?=?0.009, 0.008) and miR-92a (P?=?009, 0.034) were lower in ovarian cystadenoma patients than in EOC patients and healthy women, respectively" +tissue_expression_down hsa-mir-16 Ovarian Neoplasms 30107086 "We report that miR-21 (P?=?0.0001), miR-100 (P?=?0.034), miR-200b (P?=?0.008), and miR-320 (P?=?0.034) are significantly enriched, whereas miR-16 (P?=?0.009), miR-93 (P?=?0.014), miR-126 (P?=?0.012), and miR-223 (P?=?0.029) are underrepresented in exosomes from plasma of EOC patients as compared to those of healthy women. The levels of exosomal miR-23a (P?=?0.009, 0.008) and miR-92a (P?=?009, 0.034) were lower in ovarian cystadenoma patients than in EOC patients and healthy women, respectively" +tissue_expression_down hsa-mir-223 Ovarian Neoplasms 30107086 "We report that miR-21 (P?=?0.0001), miR-100 (P?=?0.034), miR-200b (P?=?0.008), and miR-320 (P?=?0.034) are significantly enriched, whereas miR-16 (P?=?0.009), miR-93 (P?=?0.014), miR-126 (P?=?0.012), and miR-223 (P?=?0.029) are underrepresented in exosomes from plasma of EOC patients as compared to those of healthy women. The levels of exosomal miR-23a (P?=?0.009, 0.008) and miR-92a (P?=?009, 0.034) were lower in ovarian cystadenoma patients than in EOC patients and healthy women, respectively" +tissue_expression_down hsa-mir-23a Ovarian Neoplasms 30107086 "We report that miR-21 (P?=?0.0001), miR-100 (P?=?0.034), miR-200b (P?=?0.008), and miR-320 (P?=?0.034) are significantly enriched, whereas miR-16 (P?=?0.009), miR-93 (P?=?0.014), miR-126 (P?=?0.012), and miR-223 (P?=?0.029) are underrepresented in exosomes from plasma of EOC patients as compared to those of healthy women. The levels of exosomal miR-23a (P?=?0.009, 0.008) and miR-92a (P?=?009, 0.034) were lower in ovarian cystadenoma patients than in EOC patients and healthy women, respectively" +tissue_expression_down hsa-mir-92a Ovarian Neoplasms 30107086 "We report that miR-21 (P?=?0.0001), miR-100 (P?=?0.034), miR-200b (P?=?0.008), and miR-320 (P?=?0.034) are significantly enriched, whereas miR-16 (P?=?0.009), miR-93 (P?=?0.014), miR-126 (P?=?0.012), and miR-223 (P?=?0.029) are underrepresented in exosomes from plasma of EOC patients as compared to those of healthy women. The levels of exosomal miR-23a (P?=?0.009, 0.008) and miR-92a (P?=?009, 0.034) were lower in ovarian cystadenoma patients than in EOC patients and healthy women, respectively" +tissue_expression_down hsa-mir-93 Ovarian Neoplasms 30107086 "We report that miR-21 (P?=?0.0001), miR-100 (P?=?0.034), miR-200b (P?=?0.008), and miR-320 (P?=?0.034) are significantly enriched, whereas miR-16 (P?=?0.009), miR-93 (P?=?0.014), miR-126 (P?=?0.012), and miR-223 (P?=?0.029) are underrepresented in exosomes from plasma of EOC patients as compared to those of healthy women. The levels of exosomal miR-23a (P?=?0.009, 0.008) and miR-92a (P?=?009, 0.034) were lower in ovarian cystadenoma patients than in EOC patients and healthy women, respectively" +tissue_expression_down hsa-mir-1297 Colon Neoplasms 30127618 "seven miRNAs (hsa-miR-920, hsa-miR-636, hsa-miR-766-3p, hsa-miR-545-5p, hsa-miR-195-3p, hsa-miR-125a-3p, and hsa-miR-196b-3p) were found to be upregulated and six miRNAs (hsa-miR-3613-3p, hsa-miR-29b-3p, hsa-miR-1297, hsa-miR-141-5p, hsa-miR-200c-3p, and hsa-miR-141-3p) were found to be downregulated" +tissue_expression_down hsa-mir-141 Colon Neoplasms 30127618 "seven miRNAs (hsa-miR-920, hsa-miR-636, hsa-miR-766-3p, hsa-miR-545-5p, hsa-miR-195-3p, hsa-miR-125a-3p, and hsa-miR-196b-3p) were found to be upregulated and six miRNAs (hsa-miR-3613-3p, hsa-miR-29b-3p, hsa-miR-1297, hsa-miR-141-5p, hsa-miR-200c-3p, and hsa-miR-141-3p) were found to be downregulated" +tissue_expression_down hsa-mir-200c Colon Neoplasms 30127618 "seven miRNAs (hsa-miR-920, hsa-miR-636, hsa-miR-766-3p, hsa-miR-545-5p, hsa-miR-195-3p, hsa-miR-125a-3p, and hsa-miR-196b-3p) were found to be upregulated and six miRNAs (hsa-miR-3613-3p, hsa-miR-29b-3p, hsa-miR-1297, hsa-miR-141-5p, hsa-miR-200c-3p, and hsa-miR-141-3p) were found to be downregulated" +tissue_expression_down hsa-mir-29b Colon Neoplasms 30127618 "seven miRNAs (hsa-miR-920, hsa-miR-636, hsa-miR-766-3p, hsa-miR-545-5p, hsa-miR-195-3p, hsa-miR-125a-3p, and hsa-miR-196b-3p) were found to be upregulated and six miRNAs (hsa-miR-3613-3p, hsa-miR-29b-3p, hsa-miR-1297, hsa-miR-141-5p, hsa-miR-200c-3p, and hsa-miR-141-3p) were found to be downregulated" +tissue_expression_down hsa-mir-3613 Colon Neoplasms 30127618 "seven miRNAs (hsa-miR-920, hsa-miR-636, hsa-miR-766-3p, hsa-miR-545-5p, hsa-miR-195-3p, hsa-miR-125a-3p, and hsa-miR-196b-3p) were found to be upregulated and six miRNAs (hsa-miR-3613-3p, hsa-miR-29b-3p, hsa-miR-1297, hsa-miR-141-5p, hsa-miR-200c-3p, and hsa-miR-141-3p) were found to be downregulated" +tissue_expression_down hsa-mir-197 Uterine Leiomyoma 30149651 "The relative expression level of miR-15b was upregulated, and the relative expression levels of miR-29a, -29b, -29c, -197, and -200c were downregulated in UL cells compared to those in UM cells" +tissue_expression_down hsa-mir-200c Uterine Leiomyoma 30149651 "The relative expression level of miR-15b was upregulated, and the relative expression levels of miR-29a, -29b, -29c, -197, and -200c were downregulated in UL cells compared to those in UM cells" +tissue_expression_down hsa-mir-29a Uterine Leiomyoma 30149651 "The relative expression level of miR-15b was upregulated, and the relative expression levels of miR-29a, -29b, -29c, -197, and -200c were downregulated in UL cells compared to those in UM cells" +tissue_expression_down hsa-mir-29b Uterine Leiomyoma 30149651 "The relative expression level of miR-15b was upregulated, and the relative expression levels of miR-29a, -29b, -29c, -197, and -200c were downregulated in UL cells compared to those in UM cells" +tissue_expression_down hsa-mir-29c Uterine Leiomyoma 30149651 "The relative expression level of miR-15b was upregulated, and the relative expression levels of miR-29a, -29b, -29c, -197, and -200c were downregulated in UL cells compared to those in UM cells" +tissue_expression_down hsa-mir-199a Cholangiocarcinoma 30165035 "the hsa-miR-205-5p and miR-200 family members were markedly up-regulated for 600-1500 folds, whereas the miR-199 family members and their clustered miRNA, hsa-miR-214-3p, were down-regulated for 1000-2000 folds" +tissue_expression_down hsa-mir-199b Cholangiocarcinoma 30165035 "the hsa-miR-205-5p and miR-200 family members were markedly up-regulated for 600-1500 folds, whereas the miR-199 family members and their clustered miRNA, hsa-miR-214-3p, were down-regulated for 1000-2000 folds" +tissue_expression_down hsa-mir-214 Cholangiocarcinoma 30165035 "the hsa-miR-205-5p and miR-200 family members were markedly up-regulated for 600-1500 folds, whereas the miR-199 family members and their clustered miRNA, hsa-miR-214-3p, were down-regulated for 1000-2000 folds" +tissue_expression_down hsa-mir-124 Gastric Neoplasms 30171475 "The clinical significance of miR-335, miR-124, miR-218 and miR-484 downregulation in gastric cancer." +tissue_expression_down hsa-mir-218 Gastric Neoplasms 30171475 "The clinical significance of miR-335, miR-124, miR-218 and miR-484 downregulation in gastric cancer." +tissue_expression_down hsa-mir-335 Gastric Neoplasms 30171475 "The clinical significance of miR-335, miR-124, miR-218 and miR-484 downregulation in gastric cancer." +tissue_expression_down hsa-mir-484 Gastric Neoplasms 30171475 "The clinical significance of miR-335, miR-124, miR-218 and miR-484 downregulation in gastric cancer." +tissue_expression_down hsa-mir-548c Colorectal Carcinoma 30171732 Downregulation of exosome-encapsulated miR-548c-5p is associated with poor prognosis in colorectal cancer. +tissue_expression_down hsa-mir-192 Irritable Bowel Syndrome 30187701 MiRNAs play a pivotal role in visceral hypersensitivity and might be targets in the treatment of IBS by Tongxieyaofang +tissue_expression_down hsa-mir-221 Irritable Bowel Syndrome 30187701 MiRNAs play a pivotal role in visceral hypersensitivity and might be targets in the treatment of IBS by Tongxieyaofang +tissue_expression_down hsa-mir-223 Irritable Bowel Syndrome 30187701 MiRNAs play a pivotal role in visceral hypersensitivity and might be targets in the treatment of IBS by Tongxieyaofang +tissue_expression_down hsa-mir-24 Irritable Bowel Syndrome 30187701 MiRNAs play a pivotal role in visceral hypersensitivity and might be targets in the treatment of IBS by Tongxieyaofang +tissue_expression_down hsa-mir-31a Irritable Bowel Syndrome 30187701 MiRNAs play a pivotal role in visceral hypersensitivity and might be targets in the treatment of IBS by Tongxieyaofang +tissue_expression_down hsa-let-7b Carcinosarcoma 30200635 "In carcinosarcoma (CS), lower CSS was associated with the upregulation of miR-184, and the downregulation of let-7b-5p and miR-124" +tissue_expression_down hsa-let-7f Endometrial Stromal Sarcoma 30200635 "In endometrial stromal sarcomas (ESS), the upregulation of miR-373-3p, miR-372-3p, and let-7b-5p, and the down-expression of let-7f-5p, miR-23-3p, and let-7b-5p were associated with lower CSS" +tissue_expression_down hsa-mir-10a Leiomyosarcoma 30200635 "In leiomyosarcoma (LMS), there was an association of lower cancer-specific survival (CSS) with the downregulation of miR-125a-5p and miR-10a-5p, and the upregulation of miR-196a-5p and miR-34c-5p" +tissue_expression_down hsa-mir-124 Carcinosarcoma 30200635 "In carcinosarcoma (CS), lower CSS was associated with the upregulation of miR-184, and the downregulation of let-7b-5p and miR-124" +tissue_expression_down hsa-mir-125a Leiomyosarcoma 30200635 "In leiomyosarcoma (LMS), there was an association of lower cancer-specific survival (CSS) with the downregulation of miR-125a-5p and miR-10a-5p, and the upregulation of miR-196a-5p and miR-34c-5p" +tissue_expression_down hsa-mir-23 Endometrial Stromal Sarcoma 30200635 "In endometrial stromal sarcomas (ESS), the upregulation of miR-373-3p, miR-372-3p, and let-7b-5p, and the down-expression of let-7f-5p, miR-23-3p, and let-7b-5p were associated with lower CSS" +tissue_expression_down hsa-let-7a Amyotrophic Lateral Sclerosis 30210287 Results showed that 38 miRNAs were significantly downregulated in sALS +tissue_expression_down hsa-let-7d Amyotrophic Lateral Sclerosis 30210287 Results showed that 38 miRNAs were significantly downregulated in sALS +tissue_expression_down hsa-let-7f Amyotrophic Lateral Sclerosis 30210287 Results showed that 38 miRNAs were significantly downregulated in sALS +tissue_expression_down hsa-let-7g Amyotrophic Lateral Sclerosis 30210287 Results showed that 38 miRNAs were significantly downregulated in sALS +tissue_expression_down hsa-let-7i Amyotrophic Lateral Sclerosis 30210287 Results showed that 38 miRNAs were significantly downregulated in sALS +tissue_expression_down hsa-mir-103a Amyotrophic Lateral Sclerosis 30210287 Results showed that 38 miRNAs were significantly downregulated in sALS +tissue_expression_down hsa-mir-106b Amyotrophic Lateral Sclerosis 30210287 Results showed that 38 miRNAs were significantly downregulated in sALS +tissue_expression_down hsa-mir-128 Amyotrophic Lateral Sclerosis 30210287 Results showed that 38 miRNAs were significantly downregulated in sALS +tissue_expression_down hsa-mir-130a Amyotrophic Lateral Sclerosis 30210287 Results showed that 38 miRNAs were significantly downregulated in sALS +tissue_expression_down hsa-mir-130b Amyotrophic Lateral Sclerosis 30210287 Results showed that 38 miRNAs were significantly downregulated in sALS +tissue_expression_down hsa-mir-144 Amyotrophic Lateral Sclerosis 30210287 Results showed that 38 miRNAs were significantly downregulated in sALS +tissue_expression_down hsa-mir-148a Amyotrophic Lateral Sclerosis 30210287 Results showed that 38 miRNAs were significantly downregulated in sALS +tissue_expression_down hsa-mir-148b Amyotrophic Lateral Sclerosis 30210287 Results showed that 38 miRNAs were significantly downregulated in sALS +tissue_expression_down hsa-mir-151a Amyotrophic Lateral Sclerosis 30210287 Results showed that 38 miRNAs were significantly downregulated in sALS +tissue_expression_down hsa-mir-151b Amyotrophic Lateral Sclerosis 30210287 Results showed that 38 miRNAs were significantly downregulated in sALS +tissue_expression_down hsa-mir-15a Amyotrophic Lateral Sclerosis 30210287 Results showed that 38 miRNAs were significantly downregulated in sALS +tissue_expression_down hsa-mir-15b Amyotrophic Lateral Sclerosis 30210287 Results showed that 38 miRNAs were significantly downregulated in sALS +tissue_expression_down hsa-mir-16 Amyotrophic Lateral Sclerosis 30210287 Results showed that 38 miRNAs were significantly downregulated in sALS +tissue_expression_down hsa-mir-182 Amyotrophic Lateral Sclerosis 30210287 Results showed that 38 miRNAs were significantly downregulated in sALS +tissue_expression_down hsa-mir-183 Amyotrophic Lateral Sclerosis 30210287 Results showed that 38 miRNAs were significantly downregulated in sALS +tissue_expression_down hsa-mir-186 Amyotrophic Lateral Sclerosis 30210287 Results showed that 38 miRNAs were significantly downregulated in sALS +tissue_expression_down hsa-mir-22 Amyotrophic Lateral Sclerosis 30210287 Results showed that 38 miRNAs were significantly downregulated in sALS +tissue_expression_down hsa-mir-221 Amyotrophic Lateral Sclerosis 30210287 Results showed that 38 miRNAs were significantly downregulated in sALS +tissue_expression_down hsa-mir-223 Amyotrophic Lateral Sclerosis 30210287 Results showed that 38 miRNAs were significantly downregulated in sALS +tissue_expression_down hsa-mir-23a Amyotrophic Lateral Sclerosis 30210287 Results showed that 38 miRNAs were significantly downregulated in sALS +tissue_expression_down hsa-mir-26a Amyotrophic Lateral Sclerosis 30210287 Results showed that 38 miRNAs were significantly downregulated in sALS +tissue_expression_down hsa-mir-26b Amyotrophic Lateral Sclerosis 30210287 Results showed that 38 miRNAs were significantly downregulated in sALS +tissue_expression_down hsa-mir-27b Amyotrophic Lateral Sclerosis 30210287 Results showed that 38 miRNAs were significantly downregulated in sALS +tissue_expression_down hsa-mir-28 Amyotrophic Lateral Sclerosis 30210287 Results showed that 38 miRNAs were significantly downregulated in sALS +tissue_expression_down hsa-mir-30b Amyotrophic Lateral Sclerosis 30210287 Results showed that 38 miRNAs were significantly downregulated in sALS +tissue_expression_down hsa-mir-30c Amyotrophic Lateral Sclerosis 30210287 Results showed that 38 miRNAs were significantly downregulated in sALS +tissue_expression_down hsa-mir-342 Amyotrophic Lateral Sclerosis 30210287 Results showed that 38 miRNAs were significantly downregulated in sALS +tissue_expression_down hsa-mir-425 Amyotrophic Lateral Sclerosis 30210287 Results showed that 38 miRNAs were significantly downregulated in sALS +tissue_expression_down hsa-mir-451a Amyotrophic Lateral Sclerosis 30210287 Results showed that 38 miRNAs were significantly downregulated in sALS +tissue_expression_down hsa-mir-532 Amyotrophic Lateral Sclerosis 30210287 Results showed that 38 miRNAs were significantly downregulated in sALS +tissue_expression_down hsa-mir-550a Amyotrophic Lateral Sclerosis 30210287 Results showed that 38 miRNAs were significantly downregulated in sALS +tissue_expression_down hsa-mir-584 Amyotrophic Lateral Sclerosis 30210287 Results showed that 38 miRNAs were significantly downregulated in sALS +tissue_expression_down hsa-mir-93 Amyotrophic Lateral Sclerosis 30210287 Results showed that 38 miRNAs were significantly downregulated in sALS +tissue_expression_down hsa-mir-138 Thyroid Neoplasms 30210669 "We ultimately included five datasets, and further analyzed the four miRNAs that were down-regulated in at least four datasets (miR-7-2-3p, miR-138-5p, miR-144-5p, miR-486-5p)" +tissue_expression_down hsa-mir-144 Thyroid Neoplasms 30210669 "We ultimately included five datasets, and further analyzed the four miRNAs that were down-regulated in at least four datasets (miR-7-2-3p, miR-138-5p, miR-144-5p, miR-486-5p)" +tissue_expression_down hsa-mir-486 Thyroid Neoplasms 30210669 "We ultimately included five datasets, and further analyzed the four miRNAs that were down-regulated in at least four datasets (miR-7-2-3p, miR-138-5p, miR-144-5p, miR-486-5p)" +tissue_expression_down hsa-mir-7-2 Thyroid Neoplasms 30210669 "We ultimately included five datasets, and further analyzed the four miRNAs that were down-regulated in at least four datasets (miR-7-2-3p, miR-138-5p, miR-144-5p, miR-486-5p)" +tissue_expression_down hsa-mir-129 "Squamous Cell Carcinoma, Oral" 30210912 "The expression levels of miR-129-5p and miR-296-5p were significantly downregulated in OLK-OSCC tissues compared to OLK tissues, while miR-450b-5p levels were higher in OLK-OSCC tissues" +tissue_expression_down hsa-mir-296 "Squamous Cell Carcinoma, Oral" 30210912 "The expression levels of miR-129-5p and miR-296-5p were significantly downregulated in OLK-OSCC tissues compared to OLK tissues, while miR-450b-5p levels were higher in OLK-OSCC tissues" +tissue_expression_down hsa-mir-652 Neoplasms [unspecific] 30225717 "Bioinformatic analysis has detected microRNA potentially regulated by xenosensor receptors AhR (miR-28, miR-30c, miR-30e, miR-139, and miR-153) and CAR (miR-29c, miR-31, miR-185, miR-625, and miR-652)" +tissue_expression_down hsa-mir-1294 Gastric Neoplasms 30229824 Expression of miR-1294 is downregulated and predicts a poor prognosis in gastric cancer. +tissue_expression_down hsa-mir-543 Infertility 30231774 Endometrial miR-543 Is Downregulated During the Implantation Window in Women With Endometriosis-Related Infertility. +tissue_expression_down hsa-mir-10b "Carcinoma, Breast" 30250531 3 miRNAs were upregulated: Hsa-miR-21b; hsa-miR-29b; and hsa-miR-155; and 3 miRNAs were downregulated: Hsa-miR-10b; hsa-miR-125; and hsa-miR-145 +tissue_expression_down hsa-mir-125 "Carcinoma, Breast" 30250531 3 miRNAs were upregulated: Hsa-miR-21b; hsa-miR-29b; and hsa-miR-155; and 3 miRNAs were downregulated: Hsa-miR-10b; hsa-miR-125; and hsa-miR-145 +tissue_expression_down hsa-mir-145 "Carcinoma, Breast" 30250531 3 miRNAs were upregulated: Hsa-miR-21b; hsa-miR-29b; and hsa-miR-155; and 3 miRNAs were downregulated: Hsa-miR-10b; hsa-miR-125; and hsa-miR-145 +tissue_expression_down hsa-mir-10a "Carcinoma, Hepatocellular" 30254459 the expression of miR-10a-5p is downregulated and miR-484 is the most abundant miRNA in hepatic precancerous lesions +tissue_expression_down hsa-mir-145 "Carcinoma, Hepatocellular" 30272372 "The high?level expression of IGF2 mRNA and cyclin E1 mRNA was due to the low?level expression of hsa?miR?145?5p, hsa?miR?181a?5p, hsa?miR?199a?5p and hsa?miR?223a?3p, and hsa?miR?26a?5p and hsa?miR?26b?5p, respectively" +tissue_expression_down hsa-mir-181a "Carcinoma, Hepatocellular" 30272372 "The high?level expression of IGF2 mRNA and cyclin E1 mRNA was due to the low?level expression of hsa?miR?145?5p, hsa?miR?181a?5p, hsa?miR?199a?5p and hsa?miR?223a?3p, and hsa?miR?26a?5p and hsa?miR?26b?5p, respectively" +tissue_expression_down hsa-mir-199a "Carcinoma, Hepatocellular" 30272372 "The high?level expression of IGF2 mRNA and cyclin E1 mRNA was due to the low?level expression of hsa?miR?145?5p, hsa?miR?181a?5p, hsa?miR?199a?5p and hsa?miR?223a?3p, and hsa?miR?26a?5p and hsa?miR?26b?5p, respectively" +tissue_expression_down hsa-mir-223a "Carcinoma, Hepatocellular" 30272372 "The high?level expression of IGF2 mRNA and cyclin E1 mRNA was due to the low?level expression of hsa?miR?145?5p, hsa?miR?181a?5p, hsa?miR?199a?5p and hsa?miR?223a?3p, and hsa?miR?26a?5p and hsa?miR?26b?5p, respectively" +tissue_expression_down hsa-mir-26a "Carcinoma, Hepatocellular" 30272372 "The high?level expression of IGF2 mRNA and cyclin E1 mRNA was due to the low?level expression of hsa?miR?145?5p, hsa?miR?181a?5p, hsa?miR?199a?5p and hsa?miR?223a?3p, and hsa?miR?26a?5p and hsa?miR?26b?5p, respectively" +tissue_expression_down hsa-mir-26b "Carcinoma, Hepatocellular" 30272372 "The high?level expression of IGF2 mRNA and cyclin E1 mRNA was due to the low?level expression of hsa?miR?145?5p, hsa?miR?181a?5p, hsa?miR?199a?5p and hsa?miR?223a?3p, and hsa?miR?26a?5p and hsa?miR?26b?5p, respectively" +tissue_expression_down hsa-mir-221 "Carcinoma, Pancreatic" 30333874 "The results revealed that 2 upregulated miRNAs (miR-34a and -193a-3p) and 4 downregulated miRNAs (miR-221, -222, -484, and -502-3p) exhibited a consistent expression pattern between the PC-1.0/PC-1 and AsPC-1/CAPAN-2 pancreatic cancer cells" +tissue_expression_down hsa-mir-222 "Carcinoma, Pancreatic" 30333874 "The results revealed that 2 upregulated miRNAs (miR-34a and -193a-3p) and 4 downregulated miRNAs (miR-221, -222, -484, and -502-3p) exhibited a consistent expression pattern between the PC-1.0/PC-1 and AsPC-1/CAPAN-2 pancreatic cancer cells" +tissue_expression_down hsa-mir-484 "Carcinoma, Pancreatic" 30333874 "The results revealed that 2 upregulated miRNAs (miR-34a and -193a-3p) and 4 downregulated miRNAs (miR-221, -222, -484, and -502-3p) exhibited a consistent expression pattern between the PC-1.0/PC-1 and AsPC-1/CAPAN-2 pancreatic cancer cells" +tissue_expression_down hsa-mir-502 "Carcinoma, Pancreatic" 30333874 "The results revealed that 2 upregulated miRNAs (miR-34a and -193a-3p) and 4 downregulated miRNAs (miR-221, -222, -484, and -502-3p) exhibited a consistent expression pattern between the PC-1.0/PC-1 and AsPC-1/CAPAN-2 pancreatic cancer cells" +tissue_expression_down hsa-mir-138 "Carcinoma, Renal Cell" 30344735 "2 upregulated (hsa-miR-155-5p and hsa-miR-210-5p) and 6 downregulated (hsa-miR-138-5p, hsa-miR-141-5p, hsa-miR-200c-5p, hsa-miR-362-5p, hsa-miR-363-5p and hsa-miR-429) meta-signature miRNAs in renal carcinoma were identified" +tissue_expression_down hsa-mir-141 "Carcinoma, Renal Cell" 30344735 "2 upregulated (hsa-miR-155-5p and hsa-miR-210-5p) and 6 downregulated (hsa-miR-138-5p, hsa-miR-141-5p, hsa-miR-200c-5p, hsa-miR-362-5p, hsa-miR-363-5p and hsa-miR-429) meta-signature miRNAs in renal carcinoma were identified" +tissue_expression_down hsa-mir-200c "Carcinoma, Renal Cell" 30344735 "2 upregulated (hsa-miR-155-5p and hsa-miR-210-5p) and 6 downregulated (hsa-miR-138-5p, hsa-miR-141-5p, hsa-miR-200c-5p, hsa-miR-362-5p, hsa-miR-363-5p and hsa-miR-429) meta-signature miRNAs in renal carcinoma were identified" +tissue_expression_down hsa-mir-362 "Carcinoma, Renal Cell" 30344735 "2 upregulated (hsa-miR-155-5p and hsa-miR-210-5p) and 6 downregulated (hsa-miR-138-5p, hsa-miR-141-5p, hsa-miR-200c-5p, hsa-miR-362-5p, hsa-miR-363-5p and hsa-miR-429) meta-signature miRNAs in renal carcinoma were identified" +tissue_expression_down hsa-mir-363 "Carcinoma, Renal Cell" 30344735 "2 upregulated (hsa-miR-155-5p and hsa-miR-210-5p) and 6 downregulated (hsa-miR-138-5p, hsa-miR-141-5p, hsa-miR-200c-5p, hsa-miR-362-5p, hsa-miR-363-5p and hsa-miR-429) meta-signature miRNAs in renal carcinoma were identified" +tissue_expression_down hsa-mir-429 "Carcinoma, Renal Cell" 30344735 "2 upregulated (hsa-miR-155-5p and hsa-miR-210-5p) and 6 downregulated (hsa-miR-138-5p, hsa-miR-141-5p, hsa-miR-200c-5p, hsa-miR-362-5p, hsa-miR-363-5p and hsa-miR-429) meta-signature miRNAs in renal carcinoma were identified" +tissue_expression_down hsa-mir-30a Idiopathic Pulmonary Fibrosis 30365083 Downregulation of microRNA?30a in bronchoalveolar lavage fluid from idiopathic pulmonary fibrosis patients. +tissue_expression_down hsa-mir-200b Human Cytomegalovirus Infection 30366960 Low tissue levels of 200b-3p and 200c-3p in humans are associated with cytopathic inflammation due to HCMV infection +tissue_expression_down hsa-mir-200c Human Cytomegalovirus Infection 30366960 Low tissue levels of 200b-3p and 200c-3p in humans are associated with cytopathic inflammation due to HCMV infection +tissue_expression_down hsa-mir-1299 Rhinosinusitis 30378273 "Five upregulated miRNAs, including miR-210-5p, miR-3178, miR-585-3p, miR-3146, and miR-320e, and 19 downregulated miRNAs, including miR-32-3p, miR-1299, miR-3196, miR-3924, and miR-548e-3p, were differentially expressed (p < 0.05, fold change >2) in tissues of CRSwNP vs controls" +tissue_expression_down hsa-mir-3196 Rhinosinusitis 30378273 "Five upregulated miRNAs, including miR-210-5p, miR-3178, miR-585-3p, miR-3146, and miR-320e, and 19 downregulated miRNAs, including miR-32-3p, miR-1299, miR-3196, miR-3924, and miR-548e-3p, were differentially expressed (p < 0.05, fold change >2) in tissues of CRSwNP vs controls" +tissue_expression_down hsa-mir-32 Rhinosinusitis 30378273 "Five upregulated miRNAs, including miR-210-5p, miR-3178, miR-585-3p, miR-3146, and miR-320e, and 19 downregulated miRNAs, including miR-32-3p, miR-1299, miR-3196, miR-3924, and miR-548e-3p, were differentially expressed (p < 0.05, fold change >2) in tissues of CRSwNP vs controls" +tissue_expression_down hsa-mir-3924 Rhinosinusitis 30378273 "Five upregulated miRNAs, including miR-210-5p, miR-3178, miR-585-3p, miR-3146, and miR-320e, and 19 downregulated miRNAs, including miR-32-3p, miR-1299, miR-3196, miR-3924, and miR-548e-3p, were differentially expressed (p < 0.05, fold change >2) in tissues of CRSwNP vs controls" +tissue_expression_down hsa-mir-548e Rhinosinusitis 30378273 "Five upregulated miRNAs, including miR-210-5p, miR-3178, miR-585-3p, miR-3146, and miR-320e, and 19 downregulated miRNAs, including miR-32-3p, miR-1299, miR-3196, miR-3924, and miR-548e-3p, were differentially expressed (p < 0.05, fold change >2) in tissues of CRSwNP vs controls" +tissue_expression_down hsa-let-7c Neoplasms [unspecific] 30384176 Identification of key differentially expressed MicroRNAs in cancer patients through pan-cancer analysis(down). +tissue_expression_down hsa-mir-1-2 Neoplasms [unspecific] 30384176 Identification of key differentially expressed MicroRNAs in cancer patients through pan-cancer analysis(down). +tissue_expression_down hsa-mir-1247 Neoplasms [unspecific] 30384176 Identification of key differentially expressed MicroRNAs in cancer patients through pan-cancer analysis(down). +tissue_expression_down hsa-mir-133a-1 Neoplasms [unspecific] 30384176 Identification of key differentially expressed MicroRNAs in cancer patients through pan-cancer analysis(down). +tissue_expression_down hsa-mir-133a-2 Neoplasms [unspecific] 30384176 Identification of key differentially expressed MicroRNAs in cancer patients through pan-cancer analysis(down). +tissue_expression_down hsa-mir-133b Neoplasms [unspecific] 30384176 Identification of key differentially expressed MicroRNAs in cancer patients through pan-cancer analysis(down). +tissue_expression_down hsa-mir-139 Neoplasms [unspecific] 30384176 Identification of key differentially expressed MicroRNAs in cancer patients through pan-cancer analysis(down). +tissue_expression_down hsa-mir-145 Neoplasms [unspecific] 30384176 Identification of key differentially expressed MicroRNAs in cancer patients through pan-cancer analysis(down). +tissue_expression_down hsa-mir-195 Neoplasms [unspecific] 30384176 Identification of key differentially expressed MicroRNAs in cancer patients through pan-cancer analysis(down). +tissue_expression_down hsa-mir-204 Neoplasms [unspecific] 30384176 Identification of key differentially expressed MicroRNAs in cancer patients through pan-cancer analysis(down). +tissue_expression_down hsa-mir-206 Neoplasms [unspecific] 30384176 Identification of key differentially expressed MicroRNAs in cancer patients through pan-cancer analysis(down). +tissue_expression_down hsa-mir-99a Neoplasms [unspecific] 30384176 Identification of key differentially expressed MicroRNAs in cancer patients through pan-cancer analysis(down). +tissue_expression_ns hsa-mir-155 "Lymphoma, Burkitt" 16235244 Expression of BIC and miR-155 in 3 latency type III EBV-positive BL cell lines and in all primary PTLD cases suggests a possible role for EBV latency type III specific proteins in the induction of BIC expression. +tissue_expression_ns hsa-mir-133b "Carcinoma, Rectal" 16854228 "The analysis by several bioinformatics algorithms of colorectal tumours and adjacent non-neoplastic tissues from patients and colorectal cancer cell lines allowed identifying a group of 13 miRNA whose expression is significantly altered in this tumor. The most significantly deregulated miRNA being miR-31, miR-96, miR-133b, miR-135b, miR-145, and miR-183." +tissue_expression_ns hsa-mir-135b "Carcinoma, Rectal" 16854228 "The analysis by several bioinformatics algorithms of colorectal tumours and adjacent non-neoplastic tissues from patients and colorectal cancer cell lines allowed identifying a group of 13 miRNA whose expression is significantly altered in this tumor. The most significantly deregulated miRNA being miR-31, miR-96, miR-133b, miR-135b, miR-145, and miR-183." +tissue_expression_ns hsa-mir-145 "Carcinoma, Rectal" 16854228 "The analysis by several bioinformatics algorithms of colorectal tumours and adjacent non-neoplastic tissues from patients and colorectal cancer cell lines allowed identifying a group of 13 miRNA whose expression is significantly altered in this tumor. The most significantly deregulated miRNA being miR-31, miR-96, miR-133b, miR-135b, miR-145, and miR-183." +tissue_expression_ns hsa-mir-183 "Carcinoma, Rectal" 16854228 "The analysis by several bioinformatics algorithms of colorectal tumours and adjacent non-neoplastic tissues from patients and colorectal cancer cell lines allowed identifying a group of 13 miRNA whose expression is significantly altered in this tumor. The most significantly deregulated miRNA being miR-31, miR-96, miR-133b, miR-135b, miR-145, and miR-183." +tissue_expression_ns hsa-mir-31 "Carcinoma, Rectal" 16854228 "The analysis by several bioinformatics algorithms of colorectal tumours and adjacent non-neoplastic tissues from patients and colorectal cancer cell lines allowed identifying a group of 13 miRNA whose expression is significantly altered in this tumor. The most significantly deregulated miRNA being miR-31, miR-96, miR-133b, miR-135b, miR-145, and miR-183." +tissue_expression_ns hsa-mir-96 "Carcinoma, Rectal" 16854228 "The analysis by several bioinformatics algorithms of colorectal tumours and adjacent non-neoplastic tissues from patients and colorectal cancer cell lines allowed identifying a group of 13 miRNA whose expression is significantly altered in this tumor. The most significantly deregulated miRNA being miR-31, miR-96, miR-133b, miR-135b, miR-145, and miR-183." +tissue_expression_ns hsa-mir-146a Inflammation 16885212 Analysis of miR-146a and miR-146b gene expression unveiled a pattern of induction in response to a variety of microbial components and proinflammatory cytokines. +tissue_expression_ns hsa-mir-146b Inflammation 16885212 Analysis of miR-146a and miR-146b gene expression unveiled a pattern of induction in response to a variety of microbial components and proinflammatory cytokines. +tissue_expression_ns hsa-mir-103 Pancreatic Neoplasms 16966691 "the expression of miR-103 and miR-107, associated with lack of expression of miR-155, discriminates tumors from normal" +tissue_expression_ns hsa-mir-107 Pancreatic Neoplasms 16966691 "the expression of miR-103 and miR-107, associated with lack of expression of miR-155, discriminates tumors from normal" +tissue_expression_ns hsa-mir-155 Pancreatic Neoplasms 16966691 "the expression of miR-103 and miR-107, associated with lack of expression of miR-155, discriminates tumors from normal" +tissue_expression_ns hsa-mir-372 "Carcinoma, Embryonal" 17011485 "Expression of miR-372 and miR-373 seems to be specifically associated with germ cell tumors, as most somatic tumors do not express these miRNAs." +tissue_expression_ns hsa-mir-373 "Carcinoma, Embryonal" 17011485 "Expression of miR-372 and miR-373 seems to be specifically associated with germ cell tumors, as most somatic tumors do not express these miRNAs." +tissue_expression_ns hsa-mir-155 Pancreatic Neoplasms 17149698 "One hundred microRNA precursors were aberrantly expressed in pancreatic cancer or desmoplasia (p < 0.01), including microRNAs previously reported as differentially expressed in other human cancers (miR-155, miR-21, miR-221 and miR-222) as well as those not previously reported in cancer (miR-376a and miR-301)." +tissue_expression_ns hsa-mir-21 Pancreatic Neoplasms 17149698 "One hundred microRNA precursors were aberrantly expressed in pancreatic cancer or desmoplasia (p < 0.01), including microRNAs previously reported as differentially expressed in other human cancers (miR-155, miR-21, miR-221 and miR-222) as well as those not previously reported in cancer (miR-376a and miR-301)." +tissue_expression_ns hsa-mir-221 Pancreatic Neoplasms 17149698 "One hundred microRNA precursors were aberrantly expressed in pancreatic cancer or desmoplasia (p < 0.01), including microRNAs previously reported as differentially expressed in other human cancers (miR-155, miR-21, miR-221 and miR-222) as well as those not previously reported in cancer (miR-376a and miR-301)." +tissue_expression_ns hsa-mir-222 Pancreatic Neoplasms 17149698 "One hundred microRNA precursors were aberrantly expressed in pancreatic cancer or desmoplasia (p < 0.01), including microRNAs previously reported as differentially expressed in other human cancers (miR-155, miR-21, miR-221 and miR-222) as well as those not previously reported in cancer (miR-376a and miR-301)." +tissue_expression_ns hsa-mir-301 Pancreatic Neoplasms 17149698 "One hundred microRNA precursors were aberrantly expressed in pancreatic cancer or desmoplasia (p < 0.01), including microRNAs previously reported as differentially expressed in other human cancers (miR-155, miR-21, miR-221 and miR-222) as well as those not previously reported in cancer (miR-376a and miR-301)." +tissue_expression_ns hsa-mir-376a Pancreatic Neoplasms 17149698 "One hundred microRNA precursors were aberrantly expressed in pancreatic cancer or desmoplasia (p < 0.01), including microRNAs previously reported as differentially expressed in other human cancers (miR-155, miR-21, miR-221 and miR-222) as well as those not previously reported in cancer (miR-376a and miR-301)." +tissue_expression_ns hsa-mir-216 "Adenocarcinoma, Pancreatic Ductal" 17237814 The expression of miR-216 and -217 and lack of expression of miR-133a were identified as characteristic of pancreas tissue. +tissue_expression_ns hsa-mir-217 "Adenocarcinoma, Pancreatic Ductal" 17237814 The expression of miR-216 and -217 and lack of expression of miR-133a were identified as characteristic of pancreas tissue. +tissue_expression_ns hsa-mir-182 Preeclampsia 17346547 "Differential expression between preeclampsia and the control group (miR-210, miR-182) and between preeclampsia + SGA and the control group (miR-210, miR-182*, and others) was found." +tissue_expression_ns hsa-mir-210 Preeclampsia 17346547 "Differential expression between preeclampsia and the control group (miR-210, miR-182) and between preeclampsia + SGA and the control group (miR-210, miR-182*, and others) was found." +tissue_expression_ns hsa-let-7c Prostate Neoplasms 17891175 "We have analysed expression of 328 known and 152 novel human miRNAs in 10 benign peripheral zone tissues and 16 prostate cancer tissues using microarrays and found widespread, but not universal, downregulation of miRNAs in clinically localized prostate cancer relative to benign peripheral zone tissue.These findings have been verified by real-time RT-PCR assays on select miRNAs, including miR-125b, miR-145 and let-7c." +tissue_expression_ns hsa-mir-125b Prostate Neoplasms 17891175 "We have analysed expression of 328 known and 152 novel human miRNAs in 10 benign peripheral zone tissues and 16 prostate cancer tissues using microarrays and found widespread, but not universal, downregulation of miRNAs in clinically localized prostate cancer relative to benign peripheral zone tissue.These findings have been verified by real-time RT-PCR assays on select miRNAs, including miR-125b, miR-145 and let-7c." +tissue_expression_ns hsa-mir-145 Prostate Neoplasms 17891175 "We have analysed expression of 328 known and 152 novel human miRNAs in 10 benign peripheral zone tissues and 16 prostate cancer tissues using microarrays and found widespread, but not universal, downregulation of miRNAs in clinically localized prostate cancer relative to benign peripheral zone tissue.These findings have been verified by real-time RT-PCR assays on select miRNAs, including miR-125b, miR-145 and let-7c." +tissue_expression_ns hsa-mir-15a "Leukemia, Lymphocytic, Chronic, B-Cell" 17941951 altered expression +tissue_expression_ns hsa-mir-16-1 "Leukemia, Lymphocytic, Chronic, B-Cell" 17941951 altered expression +tissue_expression_ns hsa-mir-142 Ovarian Neoplasms 18182067 "We selected and validated the expression of miR-20a, miR-21, miR-26a, miR-18a, miR-206, miR-181a and miR-142-5p and found their differential expression in tissue and cell-specific manners (P<0.05)." +tissue_expression_ns hsa-mir-181a Ovarian Neoplasms 18182067 "We selected and validated the expression of miR-20a, miR-21, miR-26a, miR-18a, miR-206, miR-181a and miR-142-5p and found their differential expression in tissue and cell-specific manners (P<0.05)." +tissue_expression_ns hsa-mir-18a Ovarian Neoplasms 18182067 "We selected and validated the expression of miR-20a, miR-21, miR-26a, miR-18a, miR-206, miR-181a and miR-142-5p and found their differential expression in tissue and cell-specific manners (P<0.05)." +tissue_expression_ns hsa-mir-206 Ovarian Neoplasms 18182067 "We selected and validated the expression of miR-20a, miR-21, miR-26a, miR-18a, miR-206, miR-181a and miR-142-5p and found their differential expression in tissue and cell-specific manners (P<0.05)." +tissue_expression_ns hsa-mir-20a Ovarian Neoplasms 18182067 "We selected and validated the expression of miR-20a, miR-21, miR-26a, miR-18a, miR-206, miR-181a and miR-142-5p and found their differential expression in tissue and cell-specific manners (P<0.05)." +tissue_expression_ns hsa-mir-21 Ovarian Neoplasms 18182067 "We selected and validated the expression of miR-20a, miR-21, miR-26a, miR-18a, miR-206, miR-181a and miR-142-5p and found their differential expression in tissue and cell-specific manners (P<0.05)." +tissue_expression_ns hsa-mir-26a Ovarian Neoplasms 18182067 "We selected and validated the expression of miR-20a, miR-21, miR-26a, miR-18a, miR-206, miR-181a and miR-142-5p and found their differential expression in tissue and cell-specific manners (P<0.05)." +tissue_expression_ns hsa-let-7 Ovarian Neoplasms 18199536 "Here, we show that several miRNAs are altered in human ovarian cancer, with the most significantly deregulated miRNAs being miR-214, miR-199a*, miR-200a, miR-100, miR-125b, and let-7 cluster." +tissue_expression_ns hsa-mir-100 Ovarian Neoplasms 18199536 "Here, we show that several miRNAs are altered in human ovarian cancer, with the most significantly deregulated miRNAs being miR-214, miR-199a*, miR-200a, miR-100, miR-125b, and let-7 cluster." +tissue_expression_ns hsa-mir-125b Ovarian Neoplasms 18199536 "Here, we show that several miRNAs are altered in human ovarian cancer, with the most significantly deregulated miRNAs being miR-214, miR-199a*, miR-200a, miR-100, miR-125b, and let-7 cluster." +tissue_expression_ns hsa-mir-199a Ovarian Neoplasms 18199536 "Here, we show that several miRNAs are altered in human ovarian cancer, with the most significantly deregulated miRNAs being miR-214, miR-199a*, miR-200a, miR-100, miR-125b, and let-7 cluster." +tissue_expression_ns hsa-mir-200a Ovarian Neoplasms 18199536 "Here, we show that several miRNAs are altered in human ovarian cancer, with the most significantly deregulated miRNAs being miR-214, miR-199a*, miR-200a, miR-100, miR-125b, and let-7 cluster." +tissue_expression_ns hsa-mir-146 Inflammation 18291670 Recent evidence showing altered miRNA expression in chronic inflammatory diseases (e.g. miR-203 and miR-146) suggests their involvement in immune-mediated diseases. +tissue_expression_ns hsa-let-7b Melanoma 18477892 "The most significant discriminators were let-7b and miR-199a, and the expression of these miRNAs was validated by quantitative PCR." +tissue_expression_ns hsa-mir-199a Melanoma 18477892 "The most significant discriminators were let-7b and miR-199a, and the expression of these miRNAs was validated by quantitative PCR." +tissue_expression_ns hsa-mir-106a Autistic Disorder 18563458 miR-106a: deregulation +tissue_expression_ns hsa-mir-106b Autistic Disorder 18563458 miR-106b: deregulation +tissue_expression_ns hsa-mir-129-1 Autistic Disorder 18563458 miR-129: deregulation +tissue_expression_ns hsa-mir-129-2 Autistic Disorder 18563458 miR-129: deregulation +tissue_expression_ns hsa-mir-132 Autistic Disorder 18563458 miR-132: deregulation +tissue_expression_ns hsa-mir-140 Autistic Disorder 18563458 miR-140: deregulation +tissue_expression_ns hsa-mir-146b Autistic Disorder 18563458 miR-146b: deregulation +tissue_expression_ns hsa-mir-148b Autistic Disorder 18563458 miR-148b: deregulation +tissue_expression_ns hsa-mir-15a Autistic Disorder 18563458 miR-15a: deregulation +tissue_expression_ns hsa-mir-15b Autistic Disorder 18563458 miR-15b: deregulation +tissue_expression_ns hsa-mir-181d Autistic Disorder 18563458 miR-181d: deregulation +tissue_expression_ns hsa-mir-193b Autistic Disorder 18563458 miR-193b: deregulation +tissue_expression_ns hsa-mir-21 Autistic Disorder 18563458 miR-21: deregulation +tissue_expression_ns hsa-mir-212 Autistic Disorder 18563458 miR-212: deregulation +tissue_expression_ns hsa-mir-23a Autistic Disorder 18563458 miR-23a: deregulation +tissue_expression_ns hsa-mir-27a Autistic Disorder 18563458 miR-27a: deregulation +tissue_expression_ns hsa-mir-381 Autistic Disorder 18563458 miR-381: deregulation +tissue_expression_ns hsa-mir-431 Autistic Disorder 18563458 miR-431: deregulation +tissue_expression_ns hsa-mir-432 Autistic Disorder 18563458 miR-432: deregulation +tissue_expression_ns hsa-mir-484 Autistic Disorder 18563458 miR-484: deregulation +tissue_expression_ns hsa-mir-539 Autistic Disorder 18563458 miR-539: deregulation +tissue_expression_ns hsa-mir-550a-1 Autistic Disorder 18563458 miR-550: deregulation +tissue_expression_ns hsa-mir-550a-2 Autistic Disorder 18563458 miR-550: deregulation +tissue_expression_ns hsa-mir-598 Autistic Disorder 18563458 miR-598: deregulation +tissue_expression_ns hsa-mir-652 Autistic Disorder 18563458 miR-652: deregulation +tissue_expression_ns hsa-mir-7-1 Autistic Disorder 18563458 miR-7: deregulation +tissue_expression_ns hsa-mir-7-2 Autistic Disorder 18563458 miR-7: deregulation +tissue_expression_ns hsa-mir-7-3 Autistic Disorder 18563458 miR-7: deregulation +tissue_expression_ns hsa-mir-93 Autistic Disorder 18563458 miR-93: deregulation +tissue_expression_ns hsa-mir-95 Autistic Disorder 18563458 miR-95: deregulation +tissue_expression_ns hsa-mir-9-1 Brain Neoplasms 18624795 miR-9: Specifically Expressed in Brain Primary Tumors and Can Be Used to Differentiate Primary from Metastatic Brain Tumors +tissue_expression_ns hsa-mir-9-2 Brain Neoplasms 18624795 miR-9: Specifically Expressed in Brain Primary Tumors and Can Be Used to Differentiate Primary from Metastatic Brain Tumors +tissue_expression_ns hsa-mir-92b Brain Neoplasms 18624795 miR-92b: Specifically Expressed in Brain Primary Tumors and Can Be Used to Differentiate Primary from Metastatic Brain Tumors +tissue_expression_ns hsa-mir-9-3 Brain Neoplasms 18624795 miR-9: Specifically Expressed in Brain Primary Tumors and Can Be Used to Differentiate Primary from Metastatic Brain Tumors +tissue_expression_ns hsa-mir-196a-1 Pancreatic Neoplasms 18719196 "miR-196a: biomarkers improved the ability to distinguish between healthy tissue, PDAC, and chronic pancreatitis" +tissue_expression_ns hsa-mir-196a-2 Pancreatic Neoplasms 18719196 "miR-196a: biomarkers improved the ability to distinguish between healthy tissue, PDAC, and chronic pancreatitis" +tissue_expression_ns hsa-mir-217 Pancreatic Neoplasms 18719196 "miR-217: biomarkers improved the ability to distinguish between healthy tissue, PDAC, and chronic pancreatitis" +tissue_expression_ns hsa-mir-135a Prostate Neoplasms 18831788 "In addition, microRNA microarray data from other studies confirm that several predicted microRNAs, including miR-21, miR-135a, and miR-135b, demonstrate differential expression in prostate cancer cells, comparing with normal tissues." +tissue_expression_ns hsa-mir-135b Prostate Neoplasms 18831788 "In addition, microRNA microarray data from other studies confirm that several predicted microRNAs, including miR-21, miR-135a, and miR-135b, demonstrate differential expression in prostate cancer cells, comparing with normal tissues." +tissue_expression_ns hsa-mir-21 Prostate Neoplasms 18831788 "In addition, microRNA microarray data from other studies confirm that several predicted microRNAs, including miR-21, miR-135a, and miR-135b, demonstrate differential expression in prostate cancer cells, comparing with normal tissues." +tissue_expression_ns hsa-let-7a-1 Pituitary Adenoma 18840638 let-7a: deregulation +tissue_expression_ns hsa-let-7a-2 Pituitary Adenoma 18840638 let-7a: deregulation +tissue_expression_ns hsa-let-7a-3 Pituitary Adenoma 18840638 let-7a: deregulation +tissue_expression_ns hsa-mir-141 Pituitary Adenoma 18840638 miR-141: deregulation +tissue_expression_ns hsa-mir-143 Pituitary Adenoma 18840638 miR-143: deregulation +tissue_expression_ns hsa-mir-145 Pituitary Adenoma 18840638 miR-145: deregulation +tissue_expression_ns hsa-mir-150 Pituitary Adenoma 18840638 miR-150: deregulation +tissue_expression_ns hsa-mir-15a Pituitary Adenoma 18840638 miR-15a: deregulation +tissue_expression_ns hsa-mir-16-1 Pituitary Adenoma 18840638 miR-16: deregulation +tissue_expression_ns hsa-mir-16-2 Pituitary Adenoma 18840638 miR-16: deregulation +tissue_expression_ns hsa-mir-21 Pituitary Adenoma 18840638 miR-21: deregulation +tissue_expression_ns hsa-mir-10b Medulloblastoma 18973228 miR-10b: different expression in tumors overexpression or not ErbB2 +tissue_expression_ns hsa-mir-125b-1 Medulloblastoma 18973228 miR-125b: different expression in tumors overexpression or not ErbB2 +tissue_expression_ns hsa-mir-125b-2 Medulloblastoma 18973228 miR-125b: different expression in tumors overexpression or not ErbB2 +tissue_expression_ns hsa-mir-135a-1 Medulloblastoma 18973228 miR-135a: different expression in tumors overexpression or not ErbB2 +tissue_expression_ns hsa-mir-135a-2 Medulloblastoma 18973228 miR-135a: different expression in tumors overexpression or not ErbB2 +tissue_expression_ns hsa-mir-135b Medulloblastoma 18973228 miR-135b: different expression in tumors overexpression or not ErbB2 +tissue_expression_ns hsa-mir-153-1 Medulloblastoma 18973228 miR-153: different expression in tumors overexpression or not ErbB2 +tissue_expression_ns hsa-mir-153-2 Medulloblastoma 18973228 miR-153: different expression in tumors overexpression or not ErbB2 +tissue_expression_ns hsa-mir-181b-1 Medulloblastoma 18973228 miR-181b: different expression in tumors overexpression or not c-Myc +tissue_expression_ns hsa-mir-181b-2 Medulloblastoma 18973228 miR-181b: different expression in tumors overexpression or not c-Myc +tissue_expression_ns hsa-mir-199b Medulloblastoma 18973228 miR-199b: different expression in tumors overexpression or not ErbB2 +tissue_expression_ns hsa-mir-21 "Carcinoma, Hepatocellular" 19120703 "In some cases, aberrantly expressed miRNAs could be linked to cancer-associated pathways, indicating a direct role in liver tumourigenesis. For example, up-regulation of mir-221 and mir-21 could promote cell cycle progression, reduce cell death and favour angiogenesis and invasion." +tissue_expression_ns hsa-mir-221 "Carcinoma, Hepatocellular" 19120703 "In some cases, aberrantly expressed miRNAs could be linked to cancer-associated pathways, indicating a direct role in liver tumourigenesis. For example, up-regulation of mir-221 and mir-21 could promote cell cycle progression, reduce cell death and favour angiogenesis and invasion." +tissue_expression_ns hsa-mir-17 Azoospermia 19210773 miR-17: deregulation +tissue_expression_ns hsa-mir-18a Azoospermia 19210773 miR-18a: deregulation +tissue_expression_ns hsa-mir-19a Azoospermia 19210773 miR-19a: deregulation +tissue_expression_ns hsa-mir-19b-1 Azoospermia 19210773 miR-19b: deregulation +tissue_expression_ns hsa-mir-19b-2 Azoospermia 19210773 miR-19b: deregulation +tissue_expression_ns hsa-mir-20a Azoospermia 19210773 miR-20a: deregulation +tissue_expression_ns hsa-mir-302a Azoospermia 19210773 miR-302a: deregulation +tissue_expression_ns hsa-mir-371a Azoospermia 19210773 mir-371: deregulation +tissue_expression_ns hsa-mir-372 Azoospermia 19210773 mir-372: deregulation +tissue_expression_ns hsa-mir-373 Azoospermia 19210773 mir-373: deregulation +tissue_expression_ns hsa-mir-383 Azoospermia 19210773 miR-383: deregulation +tissue_expression_ns hsa-mir-491 Azoospermia 19210773 miR-491-3p: deregulation +tissue_expression_ns hsa-mir-520d Azoospermia 19210773 miR-520d-3p: deregulation +tissue_expression_ns hsa-mir-92a-1 Azoospermia 19210773 miR-92a: deregulation +tissue_expression_ns hsa-mir-92a-2 Azoospermia 19210773 miR-92a: deregulation +tissue_expression_ns hsa-mir-142 Leukemia 19246560 "Here, we report aberrant expression of hematopoietic-specific miR-223, miR-181a, miR-150, miR-142.3p, and miR-155 in HTLV-I-infected cells in vitro and uncultured ex vivo ATL cells." +tissue_expression_ns hsa-mir-150 Leukemia 19246560 "Here, we report aberrant expression of hematopoietic-specific miR-223, miR-181a, miR-150, miR-142.3p, and miR-155 in HTLV-I-infected cells in vitro and uncultured ex vivo ATL cells." +tissue_expression_ns hsa-mir-155 Leukemia 19246560 "Here, we report aberrant expression of hematopoietic-specific miR-223, miR-181a, miR-150, miR-142.3p, and miR-155 in HTLV-I-infected cells in vitro and uncultured ex vivo ATL cells." +tissue_expression_ns hsa-mir-181a Leukemia 19246560 "Here, we report aberrant expression of hematopoietic-specific miR-223, miR-181a, miR-150, miR-142.3p, and miR-155 in HTLV-I-infected cells in vitro and uncultured ex vivo ATL cells." +tissue_expression_ns hsa-mir-223 Leukemia 19246560 "Here, we report aberrant expression of hematopoietic-specific miR-223, miR-181a, miR-150, miR-142.3p, and miR-155 in HTLV-I-infected cells in vitro and uncultured ex vivo ATL cells." +tissue_expression_ns hsa-mir-152 Preeclampsia 19285651 miR-152: expressed differentially in preeclamptic placentas vs normal controls +tissue_expression_ns hsa-mir-210 Preeclampsia 19285651 miR-210: expressed differentially in preeclamptic placentas vs normal controls +tissue_expression_ns hsa-mir-411 Preeclampsia 19285651 miR-411: expressed differentially in preeclamptic placentas vs normal controls +tissue_expression_ns hsa-mir-127 "Lymphoma, Large B-Cell, Diffuse" 19287466 Specific expression of miR-17-5p and miR-127 in testicular and central nervous system diffuse large B-cell lymphoma. +tissue_expression_ns hsa-mir-17 "Lymphoma, Large B-Cell, Diffuse" 19287466 Specific expression of miR-17-5p and miR-127 in testicular and central nervous system diffuse large B-cell lymphoma. +tissue_expression_ns hsa-mir-196a-1 Barrett Esophagus 19342367 miR-196a: Marker of Progression +tissue_expression_ns hsa-mir-196a-2 Barrett Esophagus 19342367 miR-196a: Marker of Progression +tissue_expression_ns hsa-mir-106a "Carcinoma, Hepatocellular" 19360909 miR-106a: involve +tissue_expression_ns hsa-mir-17 "Carcinoma, Hepatocellular" 19360909 miR-17-5p: involve +tissue_expression_ns hsa-mir-20a "Carcinoma, Hepatocellular" 19360909 miR-20: involve +tissue_expression_ns hsa-mir-20b "Carcinoma, Hepatocellular" 19360909 miR-20: involve +tissue_expression_ns hsa-mir-92a-1 "Carcinoma, Hepatocellular" 19360909 miR-92: involve +tissue_expression_ns hsa-mir-92a-2 "Carcinoma, Hepatocellular" 19360909 miR-92: involve +tissue_expression_ns hsa-mir-92b "Carcinoma, Hepatocellular" 19360909 miR-92: involve +tissue_expression_ns hsa-mir-24 Kaposi Sarcoma 19381257 Mir-140 and Kaposi sarcoma-associated herpesvirus viral miRNAs increased linearly with the degree of transformation. Mir-24 emerged as a biomarker specific for KS. +tissue_expression_ns hsa-mir-126 Lung Neoplasms 19493678 "Comparing paired lung cancer tissue with adjacent normal lung parenchyma, hsa-miR-126*, hsa-miR-145, hsa-miR-21, hsa-miR-182, hsa-miR-183 and hsa-miR-210 were found to be the most differentially expressed miRNAs." +tissue_expression_ns hsa-mir-145 Lung Neoplasms 19493678 "Comparing paired lung cancer tissue with adjacent normal lung parenchyma, hsa-miR-126*, hsa-miR-145, hsa-miR-21, hsa-miR-182, hsa-miR-183 and hsa-miR-210 were found to be the most differentially expressed miRNAs." +tissue_expression_ns hsa-mir-182 Lung Neoplasms 19493678 "Comparing paired lung cancer tissue with adjacent normal lung parenchyma, hsa-miR-126*, hsa-miR-145, hsa-miR-21, hsa-miR-182, hsa-miR-183 and hsa-miR-210 were found to be the most differentially expressed miRNAs." +tissue_expression_ns hsa-mir-183 Lung Neoplasms 19493678 "Comparing paired lung cancer tissue with adjacent normal lung parenchyma, hsa-miR-126*, hsa-miR-145, hsa-miR-21, hsa-miR-182, hsa-miR-183 and hsa-miR-210 were found to be the most differentially expressed miRNAs." +tissue_expression_ns hsa-mir-21 Lung Neoplasms 19493678 "Comparing paired lung cancer tissue with adjacent normal lung parenchyma, hsa-miR-126*, hsa-miR-145, hsa-miR-21, hsa-miR-182, hsa-miR-183 and hsa-miR-210 were found to be the most differentially expressed miRNAs." +tissue_expression_ns hsa-mir-210 Lung Neoplasms 19493678 "Comparing paired lung cancer tissue with adjacent normal lung parenchyma, hsa-miR-126*, hsa-miR-145, hsa-miR-21, hsa-miR-182, hsa-miR-183 and hsa-miR-210 were found to be the most differentially expressed miRNAs." +tissue_expression_ns hsa-mir-21 "Adenocarcinoma, Colon" 19547998 "differential expression, with highest expression levels in SSAs; Levels of miR-181b but not miR-21 differed in HPs and normal mucosa; SSAs exhibited both significantly higher miR-181b levels and miR-21 levels; discriminating potential diagnostic value HP from SSA" +tissue_expression_ns hsa-mir-21 Myocardial Infarction 19706597 "hsa-mir-21:a remarkable example of MicroRNA expression signature; downregulated in infarcted areas, upregulated in border areas" +tissue_expression_ns hsa-mir-17 Glioblastoma 19775293 "Taken together, our results support an important role of altered miRNA expression in gliomas, and suggest miR-17 and miR-184 as interesting candidates contributing to glioma progression." +tissue_expression_ns hsa-mir-184 Glioblastoma 19775293 "Taken together, our results support an important role of altered miRNA expression in gliomas, and suggest miR-17 and miR-184 as interesting candidates contributing to glioma progression." +tissue_expression_ns hsa-mir-34c Ovarian Neoplasms 19798417 High grade serous carcinomas as a group exhibit significant miRNA dysregulation in comparison to tubal epithelium and the levels of miR-34c and miR-422b appear to be prognostically important. +tissue_expression_ns hsa-mir-422b Ovarian Neoplasms 19798417 High grade serous carcinomas as a group exhibit significant miRNA dysregulation in comparison to tubal epithelium and the levels of miR-34c and miR-422b appear to be prognostically important. +tissue_expression_ns hsa-mir-141 Bladder Neoplasms 19945312 "The diagnostic test, based on the three most discriminatory miRNAs in our panel (miR-200c, miR-141, and miR-30b), showed a sensitivity of 100% and a specificity of 96.2%. Such a panel of miRNAs has the potential to identify invasive bladder tumors misclassified in pathologic assessment of bladder biopsy specimens." +tissue_expression_ns hsa-mir-200c Bladder Neoplasms 19945312 "The diagnostic test, based on the three most discriminatory miRNAs in our panel (miR-200c, miR-141, and miR-30b), showed a sensitivity of 100% and a specificity of 96.2%. Such a panel of miRNAs has the potential to identify invasive bladder tumors misclassified in pathologic assessment of bladder biopsy specimens." +tissue_expression_ns hsa-mir-30b Bladder Neoplasms 19945312 "The diagnostic test, based on the three most discriminatory miRNAs in our panel (miR-200c, miR-141, and miR-30b), showed a sensitivity of 100% and a specificity of 96.2%. Such a panel of miRNAs has the potential to identify invasive bladder tumors misclassified in pathologic assessment of bladder biopsy specimens." +tissue_expression_ns hsa-mir-141 Prostate Neoplasms 20014922 "Promising molecular markers identified from gene expression profiling studies include AMACR, EZH2, TMPRSS2-ERG, miR-221 and miR-141, which are described in more detail." +tissue_expression_ns hsa-mir-221 Prostate Neoplasms 20014922 "Promising molecular markers identified from gene expression profiling studies include AMACR, EZH2, TMPRSS2-ERG, miR-221 and miR-141, which are described in more detail." +tissue_expression_ns hsa-mir-1 Cardiomegaly 20015039 "Lately, some highlight articles revealed that the altered expression of miRNAs such as miR-1, miR-133, miR-21, miR-208 etc in hearts also contributed to cardiovascular diseases, such as heart ischemia, cardiac hypertrophy, and arrhythmias." +tissue_expression_ns hsa-mir-133 Vascular Hypertrophy 20015039 "Lately, some highlight articles revealed that the altered expression of miRNAs such as miR-1, miR-133, miR-21, miR-208 etc in hearts also contributed to cardiovascular diseases, such as heart ischemia, cardiac hypertrophy, and arrhythmias." +tissue_expression_ns hsa-mir-208 Vascular Hypertrophy 20015039 "Lately, some highlight articles revealed that the altered expression of miRNAs such as miR-1, miR-133, miR-21, miR-208 etc in hearts also contributed to cardiovascular diseases, such as heart ischemia, cardiac hypertrophy, and arrhythmias." +tissue_expression_ns hsa-mir-21 Cardiomegaly 20015039 "Lately, some highlight articles revealed that the altered expression of miRNAs such as miR-1, miR-133, miR-21, miR-208 etc in hearts also contributed to cardiovascular diseases, such as heart ischemia, cardiac hypertrophy, and arrhythmias." +tissue_expression_ns hsa-mir-143 Neoplasms [unspecific] 20064147 "Overall, the current study suggests that miR-143 is ubiquitously expressed among tissues and is likely to be involved in the regulation of cell proliferation and apoptosis." +tissue_expression_ns hsa-mir-133b Myocardial Infarction 20075508 dysregulation +tissue_expression_ns hsa-mir-150 Myocardial Infarction 20075508 dysregulation +tissue_expression_ns hsa-mir-186 Myocardial Infarction 20075508 dysregulation +tissue_expression_ns hsa-mir-210 Myocardial Infarction 20075508 dysregulation +tissue_expression_ns hsa-mir-451a Myocardial Infarction 20075508 dysregulation +tissue_expression_ns hsa-mir-10a Breast Neoplasms 20099276 "miR-10a:dysregulated miRNAs were miR-146a, miR-10a, miR-221/222, miR-345, miR-200b and miR-200c" +tissue_expression_ns hsa-mir-146a Breast Neoplasms 20099276 "miR-146a:dysregulated miRNAs were miR-146a, miR-10a, miR-221/222, miR-345, miR-200b and miR-200c" +tissue_expression_ns hsa-mir-200b Breast Neoplasms 20099276 "miR-200b:dysregulated miRNAs were miR-146a, miR-10a, miR-221/222, miR-345, miR-200b and miR-200c" +tissue_expression_ns hsa-mir-200c Breast Neoplasms 20099276 "miR-200c:dysregulated miRNAs were miR-146a, miR-10a, miR-221/222, miR-345, miR-200b and miR-200c" +tissue_expression_ns hsa-mir-221 Breast Neoplasms 20099276 "miR-221:dysregulated miRNAs were miR-146a, miR-10a, miR-221/222, miR-345, miR-200b and miR-200c" +tissue_expression_ns hsa-mir-222 Breast Neoplasms 20099276 "miR-222:dysregulated miRNAs were miR-146a, miR-10a, miR-221/222, miR-345, miR-200b and miR-200c" +tissue_expression_ns hsa-mir-345 Breast Neoplasms 20099276 "miR-345:dysregulated miRNAs were miR-146a, miR-10a, miR-221/222, miR-345, miR-200b and miR-200c" +tissue_expression_ns hsa-mir-221 "Leukemia, Myelogenous, Chronic, BCR-ABL Positive" 20299489 "Among them, the expression of miR-34a, miR-221, and miR-222 was induced in the early stages and maintained throughout the late stages of differentiation." +tissue_expression_ns hsa-mir-222 "Leukemia, Myelogenous, Chronic, BCR-ABL Positive" 20299489 "Among them, the expression of miR-34a, miR-221, and miR-222 was induced in the early stages and maintained throughout the late stages of differentiation." +tissue_expression_ns hsa-mir-34a "Leukemia, Myelogenous, Chronic, BCR-ABL Positive" 20299489 "Among them, the expression of miR-34a, miR-221, and miR-222 was induced in the early stages and maintained throughout the late stages of differentiation." +tissue_expression_ns hsa-mir-204 Melanoma 20302635 "Although the number of cases is small, positive lymph node status in the two age groups was characterized by the statistically significant expression of hsa-miR-30a* and hsa-miR-204 (F-test, p-value < 0.001)." +tissue_expression_ns hsa-mir-30a Melanoma 20302635 "Although the number of cases is small, positive lymph node status in the two age groups was characterized by the statistically significant expression of hsa-miR-30a* and hsa-miR-204 (F-test, p-value < 0.001)." +tissue_expression_ns hsa-mir-16 Breast Adenocarcinoma 20433153 "Using isolated total RNA from human breast adenocarcinoma MCF-7 cells, the assay detected specifically miR-21 and miR-16 in parallel, and higher expression of oncogene miR-21 compared to miR-16 was demonstrated." +tissue_expression_ns hsa-mir-21 Breast Adenocarcinoma 20433153 "Using isolated total RNA from human breast adenocarcinoma MCF-7 cells, the assay detected specifically miR-21 and miR-16 in parallel, and higher expression of oncogene miR-21 compared to miR-16 was demonstrated." +tissue_expression_ns hsa-mir-146b "Carcinoma, Thyroid, Papillary" 20459574 Hyalinizing trabecular tumour of the thyroid-differential expression of distinct miRNAs compared with papillary thyroid carcinoma. +tissue_expression_ns hsa-mir-182 Glioma 20472885 miR-182 as a prognostic marker for glioma progression and patient survival. +tissue_expression_ns hsa-mir-200a Neoplasms [unspecific] 20498632 miR-200a:altered microRNA signatures as potent markers for ATCs +tissue_expression_ns hsa-mir-200b Neoplasms [unspecific] 20498632 miR-200b:altered microRNA signatures as potent markers for ATCs +tissue_expression_ns hsa-mir-200c Neoplasms [unspecific] 20498632 miR-200c:altered microRNA signatures as potent markers for ATCs +tissue_expression_ns hsa-mir-21 Neoplasms [unspecific] 20498632 miR-21:altered microRNA signatures as potent markers for ATCs +tissue_expression_ns hsa-mir-30a Neoplasms [unspecific] 20498632 miR-30:altered microRNA signatures as potent markers for ATCs +tissue_expression_ns hsa-mir-92a-1 "Carcinoma, Hepatocellular" 20518884 miR-92a:Deregulation of miR-92a expression is implicated in hepatocellular carcinoma development +tissue_expression_ns hsa-mir-92a-2 "Carcinoma, Hepatocellular" 20518884 miR-92a:Deregulation of miR-92a expression is implicated in hepatocellular carcinoma development +tissue_expression_ns hsa-mir-101 Prostate Neoplasms 20539944 "The aim of this review is to describe the mechanisms of several known miRNAs, summarize recent studies on the relevance of altered expression of oncogenic miRNAs (e.g. miR-221/-222, miR-21, and miR-125b) and tumor suppressor miRNAs (e.g. miR-101, miR-126*, miR-146a, miR-330, miR-34 cluster, and miR-200 family) for PCa." +tissue_expression_ns hsa-mir-125b Prostate Neoplasms 20539944 "The aim of this review is to describe the mechanisms of several known miRNAs, summarize recent studies on the relevance of altered expression of oncogenic miRNAs (e.g. miR-221/-222, miR-21, and miR-125b) and tumor suppressor miRNAs (e.g. miR-101, miR-126*, miR-146a, miR-330, miR-34 cluster, and miR-200 family) for PCa." +tissue_expression_ns hsa-mir-126 Prostate Neoplasms 20539944 "The aim of this review is to describe the mechanisms of several known miRNAs, summarize recent studies on the relevance of altered expression of oncogenic miRNAs (e.g. miR-221/-222, miR-21, and miR-125b) and tumor suppressor miRNAs (e.g. miR-101, miR-126*, miR-146a, miR-330, miR-34 cluster, and miR-200 family) for PCa." +tissue_expression_ns hsa-mir-141 Prostate Neoplasms 20539944 "The aim of this review is to describe the mechanisms of several known miRNAs, summarize recent studies on the relevance of altered expression of oncogenic miRNAs (e.g. miR-221/-222, miR-21, and miR-125b) and tumor suppressor miRNAs (e.g. miR-101, miR-126*, miR-146a, miR-330, miR-34 cluster, and miR-200 family) for PCa." +tissue_expression_ns hsa-mir-146a Prostate Neoplasms 20539944 "The aim of this review is to describe the mechanisms of several known miRNAs, summarize recent studies on the relevance of altered expression of oncogenic miRNAs (e.g. miR-221/-222, miR-21, and miR-125b) and tumor suppressor miRNAs (e.g. miR-101, miR-126*, miR-146a, miR-330, miR-34 cluster, and miR-200 family) for PCa." +tissue_expression_ns hsa-mir-200a Prostate Neoplasms 20539944 "The aim of this review is to describe the mechanisms of several known miRNAs, summarize recent studies on the relevance of altered expression of oncogenic miRNAs (e.g. miR-221/-222, miR-21, and miR-125b) and tumor suppressor miRNAs (e.g. miR-101, miR-126*, miR-146a, miR-330, miR-34 cluster, and miR-200 family) for PCa." +tissue_expression_ns hsa-mir-200b Prostate Neoplasms 20539944 "The aim of this review is to describe the mechanisms of several known miRNAs, summarize recent studies on the relevance of altered expression of oncogenic miRNAs (e.g. miR-221/-222, miR-21, and miR-125b) and tumor suppressor miRNAs (e.g. miR-101, miR-126*, miR-146a, miR-330, miR-34 cluster, and miR-200 family) for PCa." +tissue_expression_ns hsa-mir-200c Prostate Neoplasms 20539944 "The aim of this review is to describe the mechanisms of several known miRNAs, summarize recent studies on the relevance of altered expression of oncogenic miRNAs (e.g. miR-221/-222, miR-21, and miR-125b) and tumor suppressor miRNAs (e.g. miR-101, miR-126*, miR-146a, miR-330, miR-34 cluster, and miR-200 family) for PCa." +tissue_expression_ns hsa-mir-21 Prostate Neoplasms 20539944 "The aim of this review is to describe the mechanisms of several known miRNAs, summarize recent studies on the relevance of altered expression of oncogenic miRNAs (e.g. miR-221/-222, miR-21, and miR-125b) and tumor suppressor miRNAs (e.g. miR-101, miR-126*, miR-146a, miR-330, miR-34 cluster, and miR-200 family) for PCa." +tissue_expression_ns hsa-mir-221 Prostate Neoplasms 20539944 "The aim of this review is to describe the mechanisms of several known miRNAs, summarize recent studies on the relevance of altered expression of oncogenic miRNAs (e.g. miR-221/-222, miR-21, and miR-125b) and tumor suppressor miRNAs (e.g. miR-101, miR-126*, miR-146a, miR-330, miR-34 cluster, and miR-200 family) for PCa." +tissue_expression_ns hsa-mir-222 Prostate Neoplasms 20539944 "The aim of this review is to describe the mechanisms of several known miRNAs, summarize recent studies on the relevance of altered expression of oncogenic miRNAs (e.g. miR-221/-222, miR-21, and miR-125b) and tumor suppressor miRNAs (e.g. miR-101, miR-126*, miR-146a, miR-330, miR-34 cluster, and miR-200 family) for PCa." +tissue_expression_ns hsa-mir-330 Prostate Neoplasms 20539944 "The aim of this review is to describe the mechanisms of several known miRNAs, summarize recent studies on the relevance of altered expression of oncogenic miRNAs (e.g. miR-221/-222, miR-21, and miR-125b) and tumor suppressor miRNAs (e.g. miR-101, miR-126*, miR-146a, miR-330, miR-34 cluster, and miR-200 family) for PCa." +tissue_expression_ns hsa-mir-34 Prostate Neoplasms 20539944 "The aim of this review is to describe the mechanisms of several known miRNAs, summarize recent studies on the relevance of altered expression of oncogenic miRNAs (e.g. miR-221/-222, miR-21, and miR-125b) and tumor suppressor miRNAs (e.g. miR-101, miR-126*, miR-146a, miR-330, miR-34 cluster, and miR-200 family) for PCa." +tissue_expression_ns hsa-mir-429 Prostate Neoplasms 20539944 "The aim of this review is to describe the mechanisms of several known miRNAs, summarize recent studies on the relevance of altered expression of oncogenic miRNAs (e.g. miR-221/-222, miR-21, and miR-125b) and tumor suppressor miRNAs (e.g. miR-101, miR-126*, miR-146a, miR-330, miR-34 cluster, and miR-200 family) for PCa." +tissue_expression_ns hsa-mir-15b Inflammation 20564181 "Of note, differentially expressed miRNAs (hsa-miR-15b and 181b) may have a potential role in regulating these processes." +tissue_expression_ns hsa-mir-181b Inflammation 20564181 "Of note, differentially expressed miRNAs (hsa-miR-15b and 181b) may have a potential role in regulating these processes." +tissue_expression_ns hsa-mir-10a "Squamous Cell Carcinoma, Esophageal" 20588024 "We found that miR-205 and miR-10a were significantly altered in cellular expression, and might be specific for ESCC with potential roles in the pathogenesis. " +tissue_expression_ns hsa-mir-205 "Squamous Cell Carcinoma, Esophageal" 20588024 "We found that miR-205 and miR-10a were significantly altered in cellular expression, and might be specific for ESCC with potential roles in the pathogenesis. " +tissue_expression_ns hsa-mir-130a "Carcinoma, Lung, Non-Small-Cell" 20625274 Multivariate Cox regression analysis showed that miRNA-130a was an independent prognostic factor for patients with NSCLC. +tissue_expression_ns hsa-mir-106a "Carcinoma, Esophageal" 20628822 "Furthermore, miR-106a and miR-148a expression correlates with disease recurrence and tumor-related mortality." +tissue_expression_ns hsa-mir-148a "Carcinoma, Esophageal" 20628822 "Furthermore, miR-106a and miR-148a expression correlates with disease recurrence and tumor-related mortality." +tissue_expression_ns hsa-mir-205 "Carcinoma, Esophageal" 20628822 "The expression of miR-21, miR-106a, miR-148a, miR-205 in formalin-fixed paraffin-embedded specimens was evaluated by TaqMan qPCR assays. Expression was compared with clinicopathological features of the cancers and outcome." +tissue_expression_ns hsa-mir-21 "Carcinoma, Esophageal" 20628822 "The expression of miR-21, miR-106a, miR-148a, miR-205 in formalin-fixed paraffin-embedded specimens was evaluated by TaqMan qPCR assays. Expression was compared with clinicopathological features of the cancers and outcome." +tissue_expression_ns hsa-mir-146a Ischemia-Reperfusion Injury 20651252 "miR-146a:nine miRNAs (miR-21, miR-20a,miR-146a, miR-199a-3p, miR-214, miR-192, miR-187, miR-805, and miR-194) that are differentially expressed following IRI" +tissue_expression_ns hsa-mir-187 Ischemia-Reperfusion Injury 20651252 "miR-187:nine miRNAs (miR-21, miR-20a,miR-146a, miR-199a-3p, miR-214, miR-192, miR-187, miR-805, and miR-194) that are differentially expressed following IRI" +tissue_expression_ns hsa-mir-192 Ischemia-Reperfusion Injury 20651252 "miR-192:nine miRNAs (miR-21, miR-20a,miR-146a, miR-199a-3p, miR-214, miR-192, miR-187, miR-805, and miR-194) that are differentially expressed following IRI" +tissue_expression_ns hsa-mir-194-1 Ischemia-Reperfusion Injury 20651252 "miR-194:nine miRNAs (miR-21, miR-20a,miR-146a, miR-199a-3p, miR-214, miR-192, miR-187, miR-805, and miR-194) that are differentially expressed following IRI" +tissue_expression_ns hsa-mir-194-2 Ischemia-Reperfusion Injury 20651252 "miR-194:nine miRNAs (miR-21, miR-20a,miR-146a, miR-199a-3p, miR-214, miR-192, miR-187, miR-805, and miR-194) that are differentially expressed following IRI" +tissue_expression_ns hsa-mir-199a-1 Ischemia-Reperfusion Injury 20651252 "miR-199a-3p:nine miRNAs (miR-21, miR-20a,miR-146a, miR-199a-3p, miR-214, miR-192, miR-187, miR-805, and miR-194) that are differentially expressed following IRI" +tissue_expression_ns hsa-mir-199a-2 Ischemia-Reperfusion Injury 20651252 "miR-199a-3p:nine miRNAs (miR-21, miR-20a,miR-146a, miR-199a-3p, miR-214, miR-192, miR-187, miR-805, and miR-194) that are differentially expressed following IRI" +tissue_expression_ns hsa-mir-20a Ischemia-Reperfusion Injury 20651252 "miR-20a:nine miRNAs (miR-21, miR-20a,miR-146a, miR-199a-3p, miR-214, miR-192, miR-187, miR-805, and miR-194) that are differentially expressed following IRI" +tissue_expression_ns hsa-mir-21 Ischemia-Reperfusion Injury 20651252 "miR-21:nine miRNAs (miR-21, miR-20a,miR-146a, miR-199a-3p, miR-214, miR-192, miR-187, miR-805, and miR-194) that are differentially expressed following IRI" +tissue_expression_ns hsa-mir-214 Ischemia-Reperfusion Injury 20651252 "miR-214:nine miRNAs (miR-21, miR-20a,miR-146a, miR-199a-3p, miR-214, miR-192, miR-187, miR-805, and miR-194) that are differentially expressed following IRI" +tissue_expression_ns hsa-mir-203 Choriocarcinoma 20652642 miR-203 expression is a new prognostic marker in pancreatic adenocarcinoma patients. +tissue_expression_ns hsa-mir-125b Ovarian Neoplasms 20658525 Our results suggest that aberrantly expressed miR-125b may contribute to OC development. +tissue_expression_ns hsa-mir-155 Breast Neoplasms 20664596 "miR-155:miR-155, is differentially expressed in ER- versus ER+ tumors" +tissue_expression_ns hsa-mir-29a Breast Neoplasms 20664596 "miR-29a:We identified a set of 13 miRNAs of which expression differed between IBC and non-IBC, making these miRNAs candidate markers for the IBC subtype" +tissue_expression_ns hsa-mir-30b Breast Neoplasms 20664596 "miR-30b:We identified a set of 13 miRNAs of which expression differed between IBC and non-IBC, making these miRNAs candidate markers for the IBC subtype" +tissue_expression_ns hsa-mir-342 Breast Neoplasms 20664596 "miR-342-3p:We identified a set of 13 miRNAs of which expression differed between IBC and non-IBC, making these miRNAs candidate markers for the IBC subtype" +tissue_expression_ns hsa-mir-520a Breast Neoplasms 20664596 "miR-520a-5p:We identified a set of 13 miRNAs of which expression differed between IBC and non-IBC, making these miRNAs candidate markers for the IBC subtype" +tissue_expression_ns hsa-mir-126 Immune System Disease [unspecific] 20682703 "Although altered expressions of miR-21 and miR-34a were manifested within cancer cells, those of miR-126 and miR-155 were predominantly confined to endothelial cells and immune cells, respectively." +tissue_expression_ns hsa-mir-155 Immune System Disease [unspecific] 20682703 "Although altered expressions of miR-21 and miR-34a were manifested within cancer cells, those of miR-126 and miR-155 were predominantly confined to endothelial cells and immune cells, respectively." +tissue_expression_ns hsa-mir-21 "Carcinoma, Rectal" 20682703 "Although altered expressions of miR-21 and miR-34a were manifested within cancer cells, those of miR-126 and miR-155 were predominantly confined to endothelial cells and immune cells, respectively." +tissue_expression_ns hsa-mir-34a "Carcinoma, Rectal" 20682703 "Although altered expressions of miR-21 and miR-34a were manifested within cancer cells, those of miR-126 and miR-155 were predominantly confined to endothelial cells and immune cells, respectively." +tissue_expression_ns hsa-mir-103a-1 Gastric Neoplasms 20726036 "miR-103, miR-21, miR-145, miR-106b, miR-146a, and miR-148a separated node-positive from node-negative gastric cancers" +tissue_expression_ns hsa-mir-103a-2 Gastric Neoplasms 20726036 "miR-103, miR-21, miR-145, miR-106b, miR-146a, and miR-148a separated node-positive from node-negative gastric cancers" +tissue_expression_ns hsa-mir-106b Gastric Neoplasms 20726036 "miR-103, miR-21, miR-145, miR-106b, miR-146a, and miR-148a separated node-positive from node-negative gastric cancers" +tissue_expression_ns hsa-mir-145 Gastric Neoplasms 20726036 "miR-103, miR-21, miR-145, miR-106b, miR-146a, and miR-148a separated node-positive from node-negative gastric cancers" +tissue_expression_ns hsa-mir-146a Gastric Neoplasms 20726036 "miR-103, miR-21, miR-145, miR-106b, miR-146a, and miR-148a separated node-positive from node-negative gastric cancers" +tissue_expression_ns hsa-mir-148a Gastric Neoplasms 20726036 "miR-103, miR-21, miR-145, miR-106b, miR-146a, and miR-148a separated node-positive from node-negative gastric cancers" +tissue_expression_ns hsa-mir-21 Gastric Neoplasms 20726036 "miR-103, miR-21, miR-145, miR-106b, miR-146a, and miR-148a separated node-positive from node-negative gastric cancers" +tissue_expression_ns hsa-let-7g Lung Neoplasms 20818338 "Four miRNAs (miR-155, miR-25, miR-495 and miR-7g) were expressed differently among these tumors. miR-155 was upregulated only in EGFR/KRAS-negative group, miR-25 was upregulated only in EGFR-positive group and miR-495 was upregulated only in KRAS-positive adenocarcinomas. " +tissue_expression_ns hsa-mir-155 Lung Neoplasms 20818338 "Four miRNAs (miR-155, miR-25, miR-495 and miR-7g) were expressed differently among these tumors. miR-155 was upregulated only in EGFR/KRAS-negative group, miR-25 was upregulated only in EGFR-positive group and miR-495 was upregulated only in KRAS-positive adenocarcinomas. " +tissue_expression_ns hsa-mir-25 Lung Neoplasms 20818338 "Four miRNAs (miR-155, miR-25, miR-495 and miR-7g) were expressed differently among these tumors. miR-155 was upregulated only in EGFR/KRAS-negative group, miR-25 was upregulated only in EGFR-positive group and miR-495 was upregulated only in KRAS-positive adenocarcinomas. " +tissue_expression_ns hsa-mir-495 Lung Neoplasms 20818338 "Four miRNAs (miR-155, miR-25, miR-495 and miR-7g) were expressed differently among these tumors. miR-155 was upregulated only in EGFR/KRAS-negative group, miR-25 was upregulated only in EGFR-positive group and miR-495 was upregulated only in KRAS-positive adenocarcinomas. " +tissue_expression_ns hsa-mir-31 Inflammatory Bowel Diseases 20848542 Dynamic changes in the expression of MicroRNA-31 during inflammatory bowel disease-associated neoplastic transformation. +tissue_expression_ns hsa-let-7d Prostate Neoplasms 20873592 "The expression profiles of the microRNAs let-7d, let-7g, miR-98, miR-96, miR-182 and miR-183 reflect the biological behavior of PCa to some extent, and might be important biomarkers for the early detection and prognostic assessment of prostate cancer." +tissue_expression_ns hsa-let-7g Prostate Neoplasms 20873592 "The expression profiles of the microRNAs let-7d, let-7g, miR-98, miR-96, miR-182 and miR-183 reflect the biological behavior of PCa to some extent, and might be important biomarkers for the early detection and prognostic assessment of prostate cancer." +tissue_expression_ns hsa-mir-182 Prostate Neoplasms 20873592 "The expression profiles of the microRNAs let-7d, let-7g, miR-98, miR-96, miR-182 and miR-183 reflect the biological behavior of PCa to some extent, and might be important biomarkers for the early detection and prognostic assessment of prostate cancer." +tissue_expression_ns hsa-mir-183 Prostate Neoplasms 20873592 "The expression profiles of the microRNAs let-7d, let-7g, miR-98, miR-96, miR-182 and miR-183 reflect the biological behavior of PCa to some extent, and might be important biomarkers for the early detection and prognostic assessment of prostate cancer." +tissue_expression_ns hsa-mir-96 Prostate Neoplasms 20873592 "The expression profiles of the microRNAs let-7d, let-7g, miR-98, miR-96, miR-182 and miR-183 reflect the biological behavior of PCa to some extent, and might be important biomarkers for the early detection and prognostic assessment of prostate cancer." +tissue_expression_ns hsa-mir-98 Prostate Neoplasms 20873592 "The expression profiles of the microRNAs let-7d, let-7g, miR-98, miR-96, miR-182 and miR-183 reflect the biological behavior of PCa to some extent, and might be important biomarkers for the early detection and prognostic assessment of prostate cancer." +tissue_expression_ns hsa-mir-210 Lung Neoplasms 20885442 These observations help explain contradictory data regarding miR-210 expression and its putative function in solid tumors. +tissue_expression_ns hsa-mir-125b Prostate Neoplasms 20890088 "Normalization of the four miRNAs hsa-miR-96, hsa- miR-125b, hsa-miR-205, and hsa-miR-375, which were previously shown to be regulated, shows that normalization to hsa-mir-16 can lead to biased results." +tissue_expression_ns hsa-mir-16 Prostate Neoplasms 20890088 "Normalization of the four miRNAs hsa-miR-96, hsa- miR-125b, hsa-miR-205, and hsa-miR-375, which were previously shown to be regulated, shows that normalization to hsa-mir-16 can lead to biased results." +tissue_expression_ns hsa-mir-205 Prostate Neoplasms 20890088 "Normalization of the four miRNAs hsa-miR-96, hsa- miR-125b, hsa-miR-205, and hsa-miR-375, which were previously shown to be regulated, shows that normalization to hsa-mir-16 can lead to biased results." +tissue_expression_ns hsa-mir-375 Prostate Neoplasms 20890088 "Normalization of the four miRNAs hsa-miR-96, hsa- miR-125b, hsa-miR-205, and hsa-miR-375, which were previously shown to be regulated, shows that normalization to hsa-mir-16 can lead to biased results." +tissue_expression_ns hsa-mir-96 Prostate Neoplasms 20890088 "Normalization of the four miRNAs hsa-miR-96, hsa- miR-125b, hsa-miR-205, and hsa-miR-375, which were previously shown to be regulated, shows that normalization to hsa-mir-16 can lead to biased results." +tissue_expression_ns hsa-let-7a Prostate Neoplasms 20944140 "The aim of our study was to assess the expression of mir-20a, let-7a, miR-15a and miR-16 in prostate cancer (PCa) and benign prostatic hyperplasia (BPH) tissue and to investigate the relation between the expression of miRNAs and the clinicopathological features of PCa." +tissue_expression_ns hsa-mir-15a Prostate Neoplasms 20944140 "The aim of our study was to assess the expression of mir-20a, let-7a, miR-15a and miR-16 in prostate cancer (PCa) and benign prostatic hyperplasia (BPH) tissue and to investigate the relation between the expression of miRNAs and the clinicopathological features of PCa." +tissue_expression_ns hsa-mir-16 Prostate Neoplasms 20944140 "The aim of our study was to assess the expression of mir-20a, let-7a, miR-15a and miR-16 in prostate cancer (PCa) and benign prostatic hyperplasia (BPH) tissue and to investigate the relation between the expression of miRNAs and the clinicopathological features of PCa." +tissue_expression_ns hsa-mir-20a Prostate Neoplasms 20944140 "The aim of our study was to assess the expression of mir-20a, let-7a, miR-15a and miR-16 in prostate cancer (PCa) and benign prostatic hyperplasia (BPH) tissue and to investigate the relation between the expression of miRNAs and the clinicopathological features of PCa." +tissue_expression_ns hsa-let-7a "Carcinoma, Lung, Non-Small-Cell" 20975375 "In an exploratory study, we determined whether expression of six miRNAs (let-7a, miR-7, miR-21, miR-155, miR-210, and miR-221) previously reported to correlate with invasiveness or outcome in various human malignancies were associated with tumor recurrence in patients with resected stage I NSCLC." +tissue_expression_ns hsa-mir-155 "Carcinoma, Lung, Non-Small-Cell" 20975375 "In an exploratory study, we determined whether expression of six miRNAs (let-7a, miR-7, miR-21, miR-155, miR-210, and miR-221) previously reported to correlate with invasiveness or outcome in various human malignancies were associated with tumor recurrence in patients with resected stage I NSCLC." +tissue_expression_ns hsa-mir-21 "Carcinoma, Lung, Non-Small-Cell" 20975375 "In an exploratory study, we determined whether expression of six miRNAs (let-7a, miR-7, miR-21, miR-155, miR-210, and miR-221) previously reported to correlate with invasiveness or outcome in various human malignancies were associated with tumor recurrence in patients with resected stage I NSCLC." +tissue_expression_ns hsa-mir-210 "Carcinoma, Lung, Non-Small-Cell" 20975375 "In an exploratory study, we determined whether expression of six miRNAs (let-7a, miR-7, miR-21, miR-155, miR-210, and miR-221) previously reported to correlate with invasiveness or outcome in various human malignancies were associated with tumor recurrence in patients with resected stage I NSCLC." +tissue_expression_ns hsa-mir-221 "Carcinoma, Lung, Non-Small-Cell" 20975375 "In an exploratory study, we determined whether expression of six miRNAs (let-7a, miR-7, miR-21, miR-155, miR-210, and miR-221) previously reported to correlate with invasiveness or outcome in various human malignancies were associated with tumor recurrence in patients with resected stage I NSCLC." +tissue_expression_ns hsa-mir-7 "Carcinoma, Lung, Non-Small-Cell" 20975375 "In an exploratory study, we determined whether expression of six miRNAs (let-7a, miR-7, miR-21, miR-155, miR-210, and miR-221) previously reported to correlate with invasiveness or outcome in various human malignancies were associated with tumor recurrence in patients with resected stage I NSCLC." +tissue_expression_ns hsa-let-7a "Carcinoma, Lung, Non-Small-Cell" 20978195 "We also analyzed the association of TP53 mutation status and miR-34a/b/c expression, epidermal growth factor receptor and KRAS mutation status, and miR-21 and Let-7a expression." +tissue_expression_ns hsa-mir-21 "Carcinoma, Lung, Non-Small-Cell" 20978195 "We also analyzed the association of TP53 mutation status and miR-34a/b/c expression, epidermal growth factor receptor and KRAS mutation status, and miR-21 and Let-7a expression." +tissue_expression_ns hsa-mir-34a "Carcinoma, Lung, Non-Small-Cell" 20978195 "We also analyzed the association of TP53 mutation status and miR-34a/b/c expression, epidermal growth factor receptor and KRAS mutation status, and miR-21 and Let-7a expression." +tissue_expression_ns hsa-mir-34b "Carcinoma, Lung, Non-Small-Cell" 20978195 "We also analyzed the association of TP53 mutation status and miR-34a/b/c expression, epidermal growth factor receptor and KRAS mutation status, and miR-21 and Let-7a expression." +tissue_expression_ns hsa-mir-34c "Carcinoma, Lung, Non-Small-Cell" 20978195 "We also analyzed the association of TP53 mutation status and miR-34a/b/c expression, epidermal growth factor receptor and KRAS mutation status, and miR-21 and Let-7a expression." +tissue_expression_ns hsa-mir-155 "Adenocarcinoma, Pancreatic Ductal" 21068491 MicroRNA-21 and microRNA-155 in pancreatic juice have the potential of becoming biomarkers for diagnosing pancreatic ductal adenocarcinoma. +tissue_expression_ns hsa-mir-21 "Adenocarcinoma, Pancreatic Ductal" 21068491 MicroRNA-21 and microRNA-155 in pancreatic juice have the potential of becoming biomarkers for diagnosing pancreatic ductal adenocarcinoma. +tissue_expression_ns hsa-mir-153 Ovarian Neoplasms 21083603 "Deregulation of miR-519a, 153, and 485-5p and its clinicopathological relevance in ovarian epithelial tumours." +tissue_expression_ns hsa-mir-485 Ovarian Neoplasms 21083603 "Deregulation of miR-519a, 153, and 485-5p and its clinicopathological relevance in ovarian epithelial tumours." +tissue_expression_ns hsa-mir-519a Ovarian Neoplasms 21083603 "Deregulation of miR-519a, 153, and 485-5p and its clinicopathological relevance in ovarian epithelial tumours." +tissue_expression_ns hsa-let-7a Lung Neoplasms 21102586 "In AD cases,a SNP within the same haplotype was associated with reduced RNASEN mRNA expression (P=0.013) and with miR expression changes (global P=0.007) of miRs known to be associated with cancer(e.g.,let-7 family, miR-21, miR-25, miR-126 and miR15a)." +tissue_expression_ns hsa-let-7b Lung Neoplasms 21102586 "In AD cases,a SNP within the same haplotype was associated with reduced RNASEN mRNA expression (P=0.013) and with miR expression changes (global P=0.007) of miRs known to be associated with cancer(e.g.,let-7 family, miR-21, miR-25, miR-126 and miR15a)." +tissue_expression_ns hsa-let-7c Lung Neoplasms 21102586 "In AD cases,a SNP within the same haplotype was associated with reduced RNASEN mRNA expression (P=0.013) and with miR expression changes (global P=0.007) of miRs known to be associated with cancer(e.g.,let-7 family, miR-21, miR-25, miR-126 and miR15a)." +tissue_expression_ns hsa-let-7d Lung Neoplasms 21102586 "In AD cases,a SNP within the same haplotype was associated with reduced RNASEN mRNA expression (P=0.013) and with miR expression changes (global P=0.007) of miRs known to be associated with cancer(e.g.,let-7 family, miR-21, miR-25, miR-126 and miR15a)." +tissue_expression_ns hsa-let-7e Lung Neoplasms 21102586 "In AD cases,a SNP within the same haplotype was associated with reduced RNASEN mRNA expression (P=0.013) and with miR expression changes (global P=0.007) of miRs known to be associated with cancer(e.g.,let-7 family, miR-21, miR-25, miR-126 and miR15a)." +tissue_expression_ns hsa-let-7f Lung Neoplasms 21102586 "In AD cases,a SNP within the same haplotype was associated with reduced RNASEN mRNA expression (P=0.013) and with miR expression changes (global P=0.007) of miRs known to be associated with cancer(e.g.,let-7 family, miR-21, miR-25, miR-126 and miR15a)." +tissue_expression_ns hsa-let-7g Lung Neoplasms 21102586 "In AD cases,a SNP within the same haplotype was associated with reduced RNASEN mRNA expression (P=0.013) and with miR expression changes (global P=0.007) of miRs known to be associated with cancer(e.g.,let-7 family, miR-21, miR-25, miR-126 and miR15a)." +tissue_expression_ns hsa-let-7i Lung Neoplasms 21102586 "In AD cases,a SNP within the same haplotype was associated with reduced RNASEN mRNA expression (P=0.013) and with miR expression changes (global P=0.007) of miRs known to be associated with cancer(e.g.,let-7 family, miR-21, miR-25, miR-126 and miR15a)." +tissue_expression_ns hsa-mir-126 Lung Neoplasms 21102586 "In AD cases,a SNP within the same haplotype was associated with reduced RNASEN mRNA expression (P=0.013) and with miR expression changes (global P=0.007) of miRs known to be associated with cancer(e.g.,let-7 family, miR-21, miR-25, miR-126 and miR15a)." +tissue_expression_ns hsa-mir-15a Lung Neoplasms 21102586 "In AD cases,a SNP within the same haplotype was associated with reduced RNASEN mRNA expression (P=0.013) and with miR expression changes (global P=0.007) of miRs known to be associated with cancer(e.g.,let-7 family, miR-21, miR-25, miR-126 and miR15a)." +tissue_expression_ns hsa-mir-202 Lung Neoplasms 21102586 "In AD cases,a SNP within the same haplotype was associated with reduced RNASEN mRNA expression (P=0.013) and with miR expression changes (global P=0.007) of miRs known to be associated with cancer(e.g.,let-7 family, miR-21, miR-25, miR-126 and miR15a)." +tissue_expression_ns hsa-mir-21 Lung Neoplasms 21102586 "In AD cases,a SNP within the same haplotype was associated with reduced RNASEN mRNA expression (P=0.013) and with miR expression changes (global P=0.007) of miRs known to be associated with cancer(e.g.,let-7 family, miR-21, miR-25, miR-126 and miR15a)." +tissue_expression_ns hsa-mir-25 Lung Neoplasms 21102586 "In AD cases,a SNP within the same haplotype was associated with reduced RNASEN mRNA expression (P=0.013) and with miR expression changes (global P=0.007) of miRs known to be associated with cancer(e.g.,let-7 family, miR-21, miR-25, miR-126 and miR15a)." +tissue_expression_ns hsa-mir-98 Lung Neoplasms 21102586 "In AD cases,a SNP within the same haplotype was associated with reduced RNASEN mRNA expression (P=0.013) and with miR expression changes (global P=0.007) of miRs known to be associated with cancer(e.g.,let-7 family, miR-21, miR-25, miR-126 and miR15a)." +tissue_expression_ns hsa-mir-15a Pancreatic Neoplasms 21106054 Dysregulation of miR-15a and miR-214 in human pancreatic cancer. +tissue_expression_ns hsa-mir-214 Pancreatic Neoplasms 21106054 Dysregulation of miR-15a and miR-214 in human pancreatic cancer. +tissue_expression_ns hsa-mir-133a Bone Disease [unspecific] 21108928 "The expression of miRNAs, including miR-18a, miR-133a, miR-141 and miR-19a, was significantly altered in the PDLSCs cultured with ibandronate." +tissue_expression_ns hsa-mir-141 Bone Disease [unspecific] 21108928 "The expression of miRNAs, including miR-18a, miR-133a, miR-141 and miR-19a, was significantly altered in the PDLSCs cultured with ibandronate." +tissue_expression_ns hsa-mir-18a Bone Disease [unspecific] 21108928 "The expression of miRNAs, including miR-18a, miR-133a, miR-141 and miR-19a, was significantly altered in the PDLSCs cultured with ibandronate." +tissue_expression_ns hsa-mir-19a Bone Disease [unspecific] 21108928 "The expression of miRNAs, including miR-18a, miR-133a, miR-141 and miR-19a, was significantly altered in the PDLSCs cultured with ibandronate." +tissue_expression_ns hsa-mir-1-1 Urinary Bladder Cancer 21133599 dysregulated +tissue_expression_ns hsa-mir-1-2 Urinary Bladder Cancer 21133599 dysregulated +tissue_expression_ns hsa-mir-125b-1 Urinary Bladder Cancer 21133599 dysregulated +tissue_expression_ns hsa-mir-125b-2 Urinary Bladder Cancer 21133599 dysregulated +tissue_expression_ns hsa-mir-133a-1 Urinary Bladder Cancer 21133599 dysregulated +tissue_expression_ns hsa-mir-133a-2 Urinary Bladder Cancer 21133599 dysregulated +tissue_expression_ns hsa-mir-133b Urinary Bladder Cancer 21133599 dysregulated +tissue_expression_ns hsa-mir-143 Urinary Bladder Cancer 21133599 dysregulated +tissue_expression_ns hsa-mir-145 Urinary Bladder Cancer 21133599 dysregulated +tissue_expression_ns hsa-mir-200b Urinary Bladder Cancer 21133599 dysregulated +tissue_expression_ns hsa-mir-708 Urinary Bladder Cancer 21133599 dysregulated +tissue_expression_ns hsa-mir-99a Urinary Bladder Cancer 21133599 dysregulated +tissue_expression_ns hsa-mir-99b Urinary Bladder Cancer 21133599 dysregulated +tissue_expression_ns hsa-mir-129-1 Brain Neoplasms 21157891 "MicroRNA-129, miR-142-5p, and miR-25 were differ entially expressed in every pediatric brain tumor type compared to normal tissue controls as measured by microarray." +tissue_expression_ns hsa-mir-129-2 Brain Neoplasms 21157891 "MicroRNA-129, miR-142-5p, and miR-25 were differ entially expressed in every pediatric brain tumor type compared to normal tissue controls as measured by microarray." +tissue_expression_ns hsa-let-7c Nevus 21166724 The microRNA molecular signature of atypic and common acquired melanocytic nevi: differential expression of miR-125b and let-7c. +tissue_expression_ns hsa-mir-125b-1 Nevus 21166724 The microRNA molecular signature of atypic and common acquired melanocytic nevi: differential expression of miR-125b and let-7c. +tissue_expression_ns hsa-mir-125b-2 Nevus 21166724 The microRNA molecular signature of atypic and common acquired melanocytic nevi: differential expression of miR-125b and let-7c. +tissue_expression_ns hsa-mir-29a "Aortic Aneurysm, Thoracic" 21334170 dysregulated +tissue_expression_ns hsa-mir-29b-1 "Aortic Aneurysm, Thoracic" 21334170 dysregulated +tissue_expression_ns hsa-mir-29b-2 "Aortic Aneurysm, Thoracic" 21334170 dysregulated +tissue_expression_ns hsa-mir-29c "Aortic Aneurysm, Thoracic" 21334170 dysregulated +tissue_expression_ns hsa-mir-30a "Aortic Aneurysm, Thoracic" 21334170 dysregulated +tissue_expression_ns hsa-mir-30b "Aortic Aneurysm, Thoracic" 21334170 dysregulated +tissue_expression_ns hsa-mir-30c-1 "Aortic Aneurysm, Thoracic" 21334170 dysregulated +tissue_expression_ns hsa-mir-30c-2 "Aortic Aneurysm, Thoracic" 21334170 dysregulated +tissue_expression_ns hsa-mir-30d "Aortic Aneurysm, Thoracic" 21334170 dysregulated +tissue_expression_ns hsa-mir-30e "Aortic Aneurysm, Thoracic" 21334170 dysregulated +tissue_expression_ns hsa-mir-125a Endometriosis 21335415 "TaqMan real-time PCR was used to assess the expression of the miRNAs (miR-15b, -16, -17-5p, -20a, -21, -125a, -221 and -222), while VEGF-A and TSP-1 mRNA were assessed by real-time PCR, with SYBR Green I and VEGF-A and TSP-1 protein levels were quantified by ELISA." +tissue_expression_ns hsa-mir-15b Endometriosis 21335415 "TaqMan real-time PCR was used to assess the expression of the miRNAs (miR-15b, -16, -17-5p, -20a, -21, -125a, -221 and -222), while VEGF-A and TSP-1 mRNA were assessed by real-time PCR, with SYBR Green I and VEGF-A and TSP-1 protein levels were quantified by ELISA." +tissue_expression_ns hsa-mir-16 Endometriosis 21335415 "TaqMan real-time PCR was used to assess the expression of the miRNAs (miR-15b, -16, -17-5p, -20a, -21, -125a, -221 and -222), while VEGF-A and TSP-1 mRNA were assessed by real-time PCR, with SYBR Green I and VEGF-A and TSP-1 protein levels were quantified by ELISA." +tissue_expression_ns hsa-mir-17 Endometriosis 21335415 "TaqMan real-time PCR was used to assess the expression of the miRNAs (miR-15b, -16, -17-5p, -20a, -21, -125a, -221 and -222), while VEGF-A and TSP-1 mRNA were assessed by real-time PCR, with SYBR Green I and VEGF-A and TSP-1 protein levels were quantified by ELISA." +tissue_expression_ns hsa-mir-20a Endometriosis 21335415 "TaqMan real-time PCR was used to assess the expression of the miRNAs (miR-15b, -16, -17-5p, -20a, -21, -125a, -221 and -222), while VEGF-A and TSP-1 mRNA were assessed by real-time PCR, with SYBR Green I and VEGF-A and TSP-1 protein levels were quantified by ELISA." +tissue_expression_ns hsa-mir-21 Endometriosis 21335415 "TaqMan real-time PCR was used to assess the expression of the miRNAs (miR-15b, -16, -17-5p, -20a, -21, -125a, -221 and -222), while VEGF-A and TSP-1 mRNA were assessed by real-time PCR, with SYBR Green I and VEGF-A and TSP-1 protein levels were quantified by ELISA." +tissue_expression_ns hsa-mir-221 Endometriosis 21335415 "TaqMan real-time PCR was used to assess the expression of the miRNAs (miR-15b, -16, -17-5p, -20a, -21, -125a, -221 and -222), while VEGF-A and TSP-1 mRNA were assessed by real-time PCR, with SYBR Green I and VEGF-A and TSP-1 protein levels were quantified by ELISA." +tissue_expression_ns hsa-mir-222 Endometriosis 21335415 "TaqMan real-time PCR was used to assess the expression of the miRNAs (miR-15b, -16, -17-5p, -20a, -21, -125a, -221 and -222), while VEGF-A and TSP-1 mRNA were assessed by real-time PCR, with SYBR Green I and VEGF-A and TSP-1 protein levels were quantified by ELISA." +tissue_expression_ns hsa-mir-182 Mesothelioma 21358347 dysregulated +tissue_expression_ns hsa-mir-214 Mesothelioma 21358347 dysregulated +tissue_expression_ns hsa-mir-497 Mesothelioma 21358347 dysregulated +tissue_expression_ns hsa-mir-7-1 Mesothelioma 21358347 dysregulated +tissue_expression_ns hsa-mir-7-2 Mesothelioma 21358347 dysregulated +tissue_expression_ns hsa-mir-7-3 Mesothelioma 21358347 dysregulated +tissue_expression_ns hsa-mir-21 Ischemia 21373187 deregulated +tissue_expression_ns hsa-mir-29b-1 Ischemia 21373187 deregulated +tissue_expression_ns hsa-mir-29b-2 Ischemia 21373187 deregulated +tissue_expression_ns hsa-mir-30b Ischemia 21373187 deregulated +tissue_expression_ns hsa-mir-125b-1 Breast Neoplasms 21375733 dysregulated +tissue_expression_ns hsa-mir-125b-2 Breast Neoplasms 21375733 dysregulated +tissue_expression_ns hsa-mir-182 Breast Neoplasms 21375733 dysregulated +tissue_expression_ns hsa-mir-183 Breast Neoplasms 21375733 dysregulated +tissue_expression_ns hsa-mir-195 Breast Neoplasms 21375733 dysregulated +tissue_expression_ns hsa-mir-1-1 Myocardial Infarction 21386882 "miR-1, miR-29b and miR-98 dysregulated." +tissue_expression_ns hsa-mir-1-2 Myocardial Infarction 21386882 "miR-1, miR-29b and miR-98 dysregulated." +tissue_expression_ns hsa-mir-29b-1 Myocardial Infarction 21386882 "miR-1, miR-29b and miR-98 dysregulated." +tissue_expression_ns hsa-mir-29b-2 Myocardial Infarction 21386882 "miR-1, miR-29b and miR-98 dysregulated." +tissue_expression_ns hsa-mir-98 Myocardial Infarction 21386882 "miR-1, miR-29b and miR-98 dysregulated." +tissue_expression_ns hsa-mir-143 Prostate Neoplasms 21400514 "The differential expression of miRNAs miR-375, miR-143 and miR-145 was validated by quantitative PCR. MiRNA in situ hybridization revealed that the differential expression is cancer-cell associated." +tissue_expression_ns hsa-mir-145 Prostate Neoplasms 21400514 "The differential expression of miRNAs miR-375, miR-143 and miR-145 was validated by quantitative PCR. MiRNA in situ hybridization revealed that the differential expression is cancer-cell associated." +tissue_expression_ns hsa-mir-375 Prostate Neoplasms 21400514 "The differential expression of miRNAs miR-375, miR-143 and miR-145 was validated by quantitative PCR. MiRNA in situ hybridization revealed that the differential expression is cancer-cell associated." +tissue_expression_ns hsa-let-7a-1 Barrett Esophagus 21407181 differential expression between Barrett Esophagus patients with and without dysplasia. +tissue_expression_ns hsa-let-7a-2 Barrett Esophagus 21407181 differential expression between Barrett Esophagus patients with and without dysplasia. +tissue_expression_ns hsa-let-7a-3 Barrett Esophagus 21407181 differential expression between Barrett Esophagus patients with and without dysplasia. +tissue_expression_ns hsa-mir-145 Barrett Esophagus 21407181 differential expression between Barrett Esophagus patients with and without dysplasia. +tissue_expression_ns hsa-mir-15b Barrett Esophagus 21407181 differential expression between Barrett Esophagus patients with and without dysplasia. +tissue_expression_ns hsa-mir-203 Barrett Esophagus 21407181 differential expression between Barrett Esophagus patients with and without dysplasia. +tissue_expression_ns hsa-mir-21 Barrett Esophagus 21407181 differential expression between Barrett Esophagus patients with and without dysplasia. +tissue_expression_ns hsa-mir-486 Barrett Esophagus 21407181 differential expression between Barrett Esophagus patients with and without dysplasia. +tissue_expression_ns hsa-let-7i Cerebral Malaria 21422175 "We identified three miRNAs that were differentially expressed in the brain of PbA-infected CBA mice: let7i, miR-27a, and miR-150." +tissue_expression_ns hsa-mir-150 Cerebral Malaria 21422175 "We identified three miRNAs that were differentially expressed in the brain of PbA-infected CBA mice: let7i, miR-27a, and miR-150." +tissue_expression_ns hsa-mir-27a Cerebral Malaria 21422175 "We identified three miRNAs that were differentially expressed in the brain of PbA-infected CBA mice: let7i, miR-27a, and miR-150." +tissue_expression_ns hsa-mir-196a-1 Pancreatic Neoplasms 21463235 altered expression +tissue_expression_ns hsa-mir-196a-2 Pancreatic Neoplasms 21463235 altered expression +tissue_expression_ns hsa-mir-217 Pancreatic Neoplasms 21463235 altered expression +tissue_expression_ns hsa-mir-133a-1 Colorectal Carcinoma 21532750 "miR-215, miR-137, miR-708, miR-31,and miR-135b were differentially expressed in APC tumors and miR-215, miR-133a,miR-467d, miR-218, miR-708, miR-31, and miR-135b in colitis-associated tumors." +tissue_expression_ns hsa-mir-133a-2 Colorectal Carcinoma 21532750 "miR-215, miR-137, miR-708, miR-31,and miR-135b were differentially expressed in APC tumors and miR-215, miR-133a,miR-467d, miR-218, miR-708, miR-31, and miR-135b in colitis-associated tumors." +tissue_expression_ns hsa-mir-135b Colorectal Carcinoma 21532750 "miR-215, miR-137, miR-708, miR-31,and miR-135b were differentially expressed in APC tumors and miR-215, miR-133a,miR-467d, miR-218, miR-708, miR-31, and miR-135b in colitis-associated tumors." +tissue_expression_ns hsa-mir-137 Colorectal Carcinoma 21532750 "miR-215, miR-137, miR-708, miR-31,and miR-135b were differentially expressed in APC tumors and miR-215, miR-133a,miR-467d, miR-218, miR-708, miR-31, and miR-135b in colitis-associated tumors." +tissue_expression_ns hsa-mir-215 Colorectal Carcinoma 21532750 "miR-215, miR-137, miR-708, miR-31,and miR-135b were differentially expressed in APC tumors and miR-215, miR-133a,miR-467d, miR-218, miR-708, miR-31, and miR-135b in colitis-associated tumors." +tissue_expression_ns hsa-mir-218-1 Colorectal Carcinoma 21532750 "miR-215, miR-137, miR-708, miR-31,and miR-135b were differentially expressed in APC tumors and miR-215, miR-133a,miR-467d, miR-218, miR-708, miR-31, and miR-135b in colitis-associated tumors." +tissue_expression_ns hsa-mir-218-2 Colorectal Carcinoma 21532750 "miR-215, miR-137, miR-708, miR-31,and miR-135b were differentially expressed in APC tumors and miR-215, miR-133a,miR-467d, miR-218, miR-708, miR-31, and miR-135b in colitis-associated tumors." +tissue_expression_ns hsa-mir-31 Colorectal Carcinoma 21532750 "miR-215, miR-137, miR-708, miR-31,and miR-135b were differentially expressed in APC tumors and miR-215, miR-133a,miR-467d, miR-218, miR-708, miR-31, and miR-135b in colitis-associated tumors." +tissue_expression_ns hsa-mir-708 Colorectal Carcinoma 21532750 "miR-215, miR-137, miR-708, miR-31,and miR-135b were differentially expressed in APC tumors and miR-215, miR-133a,miR-467d, miR-218, miR-708, miR-31, and miR-135b in colitis-associated tumors." +tissue_expression_ns hsa-mir-150 Psoriasis 21687694 differentially expressed +tissue_expression_ns hsa-mir-197 Psoriasis 21687694 differentially expressed +tissue_expression_ns hsa-mir-423 Psoriasis 21687694 differentially expressed +tissue_expression_ns hsa-mir-1-1 Colorectal Carcinoma 21694772 deregulated +tissue_expression_ns hsa-mir-1-2 Colorectal Carcinoma 21694772 deregulated +tissue_expression_ns hsa-mir-135a-1 Colorectal Carcinoma 21694772 deregulated +tissue_expression_ns hsa-mir-135a-2 Colorectal Carcinoma 21694772 deregulated +tissue_expression_ns hsa-mir-135b Colorectal Carcinoma 21694772 deregulated +tissue_expression_ns hsa-mir-137 Colorectal Carcinoma 21694772 deregulated +tissue_expression_ns hsa-mir-31 Colorectal Carcinoma 21694772 deregulated +tissue_expression_ns hsa-mir-9-1 Colorectal Carcinoma 21694772 deregulated +tissue_expression_ns hsa-mir-9-2 Colorectal Carcinoma 21694772 deregulated +tissue_expression_ns hsa-mir-9-3 Colorectal Carcinoma 21694772 deregulated +tissue_expression_ns hsa-mir-99a Colorectal Carcinoma 21694772 deregulated +tissue_expression_ns hsa-mir-1 Heart Failure 21737570 "In particular, miRNA-1, miRNA-21, miRNA-24, miRNA-29, miRNA-92a, miRNA-126, miRNA-133, miRNA-320, miRNA-199a, miRNA-208, and miRNA-195 have been shown to be regulated after I/R injury." +tissue_expression_ns hsa-mir-126 Heart Failure 21737570 "In particular, miRNA-1, miRNA-21, miRNA-24, miRNA-29, miRNA-92a, miRNA-126, miRNA-133, miRNA-320, miRNA-199a, miRNA-208, and miRNA-195 have been shown to be regulated after I/R injury." +tissue_expression_ns hsa-mir-133 Heart Failure 21737570 "In particular, miRNA-1, miRNA-21, miRNA-24, miRNA-29, miRNA-92a, miRNA-126, miRNA-133, miRNA-320, miRNA-199a, miRNA-208, and miRNA-195 have been shown to be regulated after I/R injury." +tissue_expression_ns hsa-mir-195 Heart Failure 21737570 "In particular, miRNA-1, miRNA-21, miRNA-24, miRNA-29, miRNA-92a, miRNA-126, miRNA-133, miRNA-320, miRNA-199a, miRNA-208, and miRNA-195 have been shown to be regulated after I/R injury." +tissue_expression_ns hsa-mir-199a Heart Failure 21737570 "In particular, miRNA-1, miRNA-21, miRNA-24, miRNA-29, miRNA-92a, miRNA-126, miRNA-133, miRNA-320, miRNA-199a, miRNA-208, and miRNA-195 have been shown to be regulated after I/R injury." +tissue_expression_ns hsa-mir-208 Heart Failure 21737570 "In particular, miRNA-1, miRNA-21, miRNA-24, miRNA-29, miRNA-92a, miRNA-126, miRNA-133, miRNA-320, miRNA-199a, miRNA-208, and miRNA-195 have been shown to be regulated after I/R injury." +tissue_expression_ns hsa-mir-24 Heart Failure 21737570 "In particular, miRNA-1, miRNA-21, miRNA-24, miRNA-29, miRNA-92a, miRNA-126, miRNA-133, miRNA-320, miRNA-199a, miRNA-208, and miRNA-195 have been shown to be regulated after I/R injury." +tissue_expression_ns hsa-mir-29 Heart Failure 21737570 "In particular, miRNA-1, miRNA-21, miRNA-24, miRNA-29, miRNA-92a, miRNA-126, miRNA-133, miRNA-320, miRNA-199a, miRNA-208, and miRNA-195 have been shown to be regulated after I/R injury." +tissue_expression_ns hsa-mir-320 Heart Failure 21737570 "In particular, miRNA-1, miRNA-21, miRNA-24, miRNA-29, miRNA-92a, miRNA-126, miRNA-133, miRNA-320, miRNA-199a, miRNA-208, and miRNA-195 have been shown to be regulated after I/R injury." +tissue_expression_ns hsa-mir-92a Heart Failure 21737570 "In particular, miRNA-1, miRNA-21, miRNA-24, miRNA-29, miRNA-92a, miRNA-126, miRNA-133, miRNA-320, miRNA-199a, miRNA-208, and miRNA-195 have been shown to be regulated after I/R injury." +tissue_expression_ns hsa-mir-216a Fatty Liver [unspecific] 21764575 altered expression +tissue_expression_ns hsa-mir-216b Fatty Liver [unspecific] 21764575 altered expression +tissue_expression_ns hsa-mir-302a Fatty Liver [unspecific] 21764575 altered expression +tissue_expression_ns hsa-mir-146b Thyroid Neoplasms 21778212 "In this context, a small set of miRNAs (i.e. miR-7, miR-146a, miR-146b, miR-200b, miR-221, and miR-222) appears to be useful, though not sufficient per se, in distinguishing TT-UMP from other WDT of the thyroid gland." +tissue_expression_ns hsa-mir-200b Thyroid Neoplasms 21778212 "In this context, a small set of miRNAs (i.e. miR-7, miR-146a, miR-146b, miR-200b, miR-221, and miR-222) appears to be useful, though not sufficient per se, in distinguishing TT-UMP from other WDT of the thyroid gland." +tissue_expression_ns hsa-mir-221 Thyroid Neoplasms 21778212 "In this context, a small set of miRNAs (i.e. miR-7, miR-146a, miR-146b, miR-200b, miR-221, and miR-222) appears to be useful, though not sufficient per se, in distinguishing TT-UMP from other WDT of the thyroid gland." +tissue_expression_ns hsa-mir-222 Thyroid Neoplasms 21778212 "In this context, a small set of miRNAs (i.e. miR-7, miR-146a, miR-146b, miR-200b, miR-221, and miR-222) appears to be useful, though not sufficient per se, in distinguishing TT-UMP from other WDT of the thyroid gland." +tissue_expression_ns hsa-mir-7 Thyroid Neoplasms 21778212 "In this context, a small set of miRNAs (i.e. miR-7, miR-146a, miR-146b, miR-200b, miR-221, and miR-222) appears to be useful, though not sufficient per se, in distinguishing TT-UMP from other WDT of the thyroid gland." +tissue_expression_ns hsa-mir-100 Pancreatic Neoplasms 21785383 "Differentially expressed miRNAs including miR-99a, miR-100, miR-125b, miR-192, and miR-429 were detected in pancreatic cancer stem cells." +tissue_expression_ns hsa-mir-125b-1 Pancreatic Neoplasms 21785383 "Differentially expressed miRNAs including miR-99a, miR-100, miR-125b, miR-192, and miR-429 were detected in pancreatic cancer stem cells." +tissue_expression_ns hsa-mir-125b-2 Pancreatic Neoplasms 21785383 "Differentially expressed miRNAs including miR-99a, miR-100, miR-125b, miR-192, and miR-429 were detected in pancreatic cancer stem cells." +tissue_expression_ns hsa-mir-192 Pancreatic Neoplasms 21785383 "Differentially expressed miRNAs including miR-99a, miR-100, miR-125b, miR-192, and miR-429 were detected in pancreatic cancer stem cells." +tissue_expression_ns hsa-mir-429 Pancreatic Neoplasms 21785383 "Differentially expressed miRNAs including miR-99a, miR-100, miR-125b, miR-192, and miR-429 were detected in pancreatic cancer stem cells." +tissue_expression_ns hsa-mir-99a Pancreatic Neoplasms 21785383 "Differentially expressed miRNAs including miR-99a, miR-100, miR-125b, miR-192, and miR-429 were detected in pancreatic cancer stem cells." +tissue_expression_ns hsa-mir-135b Osteosarcoma 21789031 deregulated +tissue_expression_ns hsa-mir-150 Osteosarcoma 21789031 deregulated +tissue_expression_ns hsa-mir-542 Osteosarcoma 21789031 miR-542-5p: deregulated +tissue_expression_ns hsa-mir-652 Osteosarcoma 21789031 deregulated +tissue_expression_ns hsa-mir-146a Periodontal Diseases 21789961 "hsa-mirNA-146a, hsa-miRNA-146b, and hsa-miRNA-155, showed significant differences between inflamed and healthy gingiva." +tissue_expression_ns hsa-mir-146b Periodontal Diseases 21789961 "hsa-mirNA-146a, hsa-miRNA-146b, and hsa-miRNA-155, showed significant differences between inflamed and healthy gingiva." +tissue_expression_ns hsa-mir-155 Periodontal Diseases 21789961 "hsa-mirNA-146a, hsa-miRNA-146b, and hsa-miRNA-155, showed significant differences between inflamed and healthy gingiva." +tissue_expression_ns hsa-mir-107 Chronic Kidney Disease 21794090 "Differential expression was detected for miR-142-3p, miR-204, miR-107 and miR-211 (p < 0.001) and miR-32 (p < 0.05)." +tissue_expression_ns hsa-mir-142 Chronic Kidney Disease 21794090 "Differential expression was detected for miR-142-3p, miR-204, miR-107 and miR-211 (p < 0.001) and miR-32 (p < 0.05). Furthermore, differential expression of miR-142-3p (p < 0.01), miR-204 (p < 0.01) and miR-211 (p < 0.05) was also observed between patient groups in urine samples." +tissue_expression_ns hsa-mir-204 Chronic Kidney Disease 21794090 "Differential expression was detected for miR-142-3p, miR-204, miR-107 and miR-211 (p < 0.001) and miR-32 (p < 0.05). Furthermore, differential expression of miR-142-3p (p < 0.01), miR-204 (p < 0.01) and miR-211 (p < 0.05) was also observed between patient groups in urine samples." +tissue_expression_ns hsa-mir-211 Chronic Kidney Disease 21794090 "Differential expression was detected for miR-142-3p, miR-204, miR-107 and miR-211 (p < 0.001) and miR-32 (p < 0.05). Furthermore, differential expression of miR-142-3p (p < 0.01), miR-204 (p < 0.01) and miR-211 (p < 0.05) was also observed between patient groups in urine samples." +tissue_expression_ns hsa-mir-32 Chronic Kidney Disease 21794090 "Differential expression was detected for miR-142-3p, miR-204, miR-107 and miR-211 (p < 0.001) and miR-32 (p < 0.05)." +tissue_expression_ns hsa-mir-100 Psoriasis 21807764 deregulated +tissue_expression_ns hsa-mir-142 Psoriasis 21807764 miR-142-3p: deregulated +tissue_expression_ns hsa-mir-21 Psoriasis 21807764 deregulated +tissue_expression_ns hsa-mir-223 Psoriasis 21807764 miR-223 and miR-223*: deregulated +tissue_expression_ns hsa-mir-378a Psoriasis 21807764 deregulated +tissue_expression_ns hsa-mir-146b "Carcinoma, Thyroid, Papillary" 21842215 miRNA profiling of hyalinizing trabecular tumours compared with benign thyroid lesions and papillary thyroid carcinoma failed to demonstrate the characteristic up-regulation found in papillary thyroid carcinoma +tissue_expression_ns hsa-mir-181b "Carcinoma, Thyroid, Papillary" 21842215 miRNA profiling of hyalinizing trabecular tumours compared with benign thyroid lesions and papillary thyroid carcinoma failed to demonstrate the characteristic up-regulation found in papillary thyroid carcinoma +tissue_expression_ns hsa-mir-21 "Carcinoma, Thyroid, Papillary" 21842215 miRNA profiling of hyalinizing trabecular tumours compared with benign thyroid lesions and papillary thyroid carcinoma failed to demonstrate the characteristic up-regulation found in papillary thyroid carcinoma +tissue_expression_ns hsa-mir-221 "Carcinoma, Thyroid, Papillary" 21842215 miRNA profiling of hyalinizing trabecular tumours compared with benign thyroid lesions and papillary thyroid carcinoma failed to demonstrate the characteristic up-regulation found in papillary thyroid carcinoma +tissue_expression_ns hsa-mir-222 "Carcinoma, Thyroid, Papillary" 21842215 miRNA profiling of hyalinizing trabecular tumours compared with benign thyroid lesions and papillary thyroid carcinoma failed to demonstrate the characteristic up-regulation found in papillary thyroid carcinoma +tissue_expression_ns hsa-mir-143 Gastric Neoplasms 21874264 "miR-32,miR-182 and miR-143 dysregulated expression levels are related with different pathological stages of intestinal-type gastric cancers." +tissue_expression_ns hsa-mir-145 Gastric Neoplasms 21874264 "miR-145, miR-27a, miR-494 are differently expressed between intestinal-type and diffuse-type gastric cancers." +tissue_expression_ns hsa-mir-182 Gastric Neoplasms 21874264 "miR-32,miR-182 and miR-143 dysregulated expression levels are related with different pathological stages of intestinal-type gastric cancers." +tissue_expression_ns hsa-mir-27a Gastric Neoplasms 21874264 "miR-145, miR-27a, miR-494 are differently expressed between intestinal-type and diffuse-type gastric cancers." +tissue_expression_ns hsa-mir-32 Gastric Neoplasms 21874264 "miR-32,miR-182 and miR-143 dysregulated expression levels are related with different pathological stages of intestinal-type gastric cancers." +tissue_expression_ns hsa-mir-494 Gastric Neoplasms 21874264 "miR-145, miR-27a, miR-494 are differently expressed between intestinal-type and diffuse-type gastric cancers." +tissue_expression_ns hsa-mir-125b "Carcinoma, Hepatocellular" 21882851 "Many aberrantly expressed miRNAs were related to various cancers (e.g., miR-125b, hepatocellular carcinoma; miR-21, leukemia; miR-16, chronic lymphocytic leukemia;miR-192, pituitary adenomas; miR-199a-3p, ovarian cancer; miR-34a, pancreatic cancer)." +tissue_expression_ns hsa-mir-16 "Leukemia, Lymphocytic, Chronic, B-Cell" 21882851 "Many aberrantly expressed miRNAs were related to various cancers (e.g., miR-125b, hepatocellular carcinoma; miR-21, leukemia; miR-16, chronic lymphocytic leukemia;miR-192, pituitary adenomas; miR-199a-3p, ovarian cancer; miR-34a, pancreatic cancer)." +tissue_expression_ns hsa-mir-192 Pituitary Adenoma 21882851 "Many aberrantly expressed miRNAs were related to various cancers (e.g., miR-125b, hepatocellular carcinoma; miR-21, leukemia; miR-16, chronic lymphocytic leukemia;miR-192, pituitary adenomas; miR-199a-3p, ovarian cancer; miR-34a, pancreatic cancer)." +tissue_expression_ns hsa-mir-199a Ovarian Neoplasms 21882851 "Many aberrantly expressed miRNAs were related to various cancers (e.g., miR-125b, hepatocellular carcinoma; miR-21, leukemia; miR-16, chronic lymphocytic leukemia;miR-192, pituitary adenomas; miR-199a-3p, ovarian cancer; miR-34a, pancreatic cancer)." +tissue_expression_ns hsa-mir-21 Leukemia 21882851 "Many aberrantly expressed miRNAs were related to various cancers (e.g., miR-125b, hepatocellular carcinoma; miR-21, leukemia; miR-16, chronic lymphocytic leukemia;miR-192, pituitary adenomas; miR-199a-3p, ovarian cancer; miR-34a, pancreatic cancer)." +tissue_expression_ns hsa-mir-34a Pancreatic Neoplasms 21882851 "Many aberrantly expressed miRNAs were related to various cancers (e.g., miR-125b, hepatocellular carcinoma; miR-21, leukemia; miR-16, chronic lymphocytic leukemia;miR-192, pituitary adenomas; miR-199a-3p, ovarian cancer; miR-34a, pancreatic cancer)." +tissue_expression_ns hsa-mir-140 "Squamous Cell Carcinoma, Lung" 21890451 "The authors identified a five-microRNA classifier (hsa-miR-210, hsa-miR-182, hsa-miR-486-5p, hsa-miR-30a and hsa-miR-140-3p) that could distinguish SCC (Squamous cell carcinoma) from normal lung tissues." +tissue_expression_ns hsa-mir-182 "Squamous Cell Carcinoma, Lung" 21890451 "The authors identified a five-microRNA classifier (hsa-miR-210, hsa-miR-182, hsa-miR-486-5p, hsa-miR-30a and hsa-miR-140-3p) that could distinguish SCC (Squamous cell carcinoma) from normal lung tissues." +tissue_expression_ns hsa-mir-210 "Squamous Cell Carcinoma, Lung" 21890451 "The authors identified a five-microRNA classifier (hsa-miR-210, hsa-miR-182, hsa-miR-486-5p, hsa-miR-30a and hsa-miR-140-3p) that could distinguish SCC (Squamous cell carcinoma) from normal lung tissues." +tissue_expression_ns hsa-mir-30a "Squamous Cell Carcinoma, Lung" 21890451 "The authors identified a five-microRNA classifier (hsa-miR-210, hsa-miR-182, hsa-miR-486-5p, hsa-miR-30a and hsa-miR-140-3p) that could distinguish SCC (Squamous cell carcinoma) from normal lung tissues." +tissue_expression_ns hsa-mir-486 "Squamous Cell Carcinoma, Lung" 21890451 "The authors identified a five-microRNA classifier (hsa-miR-210, hsa-miR-182, hsa-miR-486-5p, hsa-miR-30a and hsa-miR-140-3p) that could distinguish SCC (Squamous cell carcinoma) from normal lung tissues." +tissue_expression_ns hsa-mir-10a Breast Neoplasms 21955614 Differential expression in tamoxifen-sensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells. +tissue_expression_ns hsa-mir-125b-1 Breast Neoplasms 21955614 Differential expression in tamoxifen-sensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells. +tissue_expression_ns hsa-mir-125b-2 Breast Neoplasms 21955614 Differential expression in tamoxifen-sensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells. +tissue_expression_ns hsa-mir-181a-2 Breast Neoplasms 21955614 Differential expression in tamoxifen-sensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells. +tissue_expression_ns hsa-mir-181b-1 Breast Neoplasms 21955614 Differential expression in tamoxifen-sensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells. +tissue_expression_ns hsa-mir-181b-2 Breast Neoplasms 21955614 Differential expression in tamoxifen-sensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells. +tissue_expression_ns hsa-mir-200a Breast Neoplasms 21955614 Differential expression in tamoxifen-sensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells. +tissue_expression_ns hsa-mir-200b Breast Neoplasms 21955614 Differential expression in tamoxifen-sensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells. +tissue_expression_ns hsa-mir-200c Breast Neoplasms 21955614 Differential expression in tamoxifen-sensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells. +tissue_expression_ns hsa-mir-205 Breast Neoplasms 21955614 Differential expression in tamoxifen-sensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells. +tissue_expression_ns hsa-mir-21 Breast Neoplasms 21955614 Differential expression in tamoxifen-sensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells. +tissue_expression_ns hsa-mir-22 Breast Neoplasms 21955614 Differential expression in tamoxifen-sensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells. +tissue_expression_ns hsa-mir-222 Breast Neoplasms 21955614 Differential expression in tamoxifen-sensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells +tissue_expression_ns hsa-mir-29a Breast Neoplasms 21955614 Differential expression in tamoxifen-sensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells. +tissue_expression_ns hsa-mir-93 Breast Neoplasms 21955614 Differential expression in tamoxifen-sensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells. +tissue_expression_ns hsa-mir-21 Myocardial Infarction 21956146 deregulated +tissue_expression_ns hsa-mir-29a Myocardial Infarction 21956146 deregulated +tissue_expression_ns hsa-mir-196a Breast Neoplasms 21962133 miR-196a has been reported to be aberrantly expressed in breast cancer tissue. +tissue_expression_ns hsa-mir-125a Gastric Neoplasms 21987613 "Five microRNAs (miR-125a-3p, miR-133b, miR-143, miR-195 and miR-212) were differently expressed between different metastatic groups in 30 gastric cancer biopsies (P < 0.05). Partial correlation analysis showed that hsa-mir-212 and hsa-mir-195 were correlated with the status of metastasis to LN in spite of age, gender, tumor location, tumor size, depth of invasion and cell differentiation. ROC analysis indicated that miR-212 and miR-195 have better sensitivities (84.6% and 69.2%, respectively) and specificities (both 100%) in distinguishing biopsies with metastasis to LN from biopsies without metastasis to LN." +tissue_expression_ns hsa-mir-133b Gastric Neoplasms 21987613 "Five microRNAs (miR-125a-3p, miR-133b, miR-143, miR-195 and miR-212) were differently expressed between different metastatic groups in 30 gastric cancer biopsies (P < 0.05). Partial correlation analysis showed that hsa-mir-212 and hsa-mir-195 were correlated with the status of metastasis to LN in spite of age, gender, tumor location, tumor size, depth of invasion and cell differentiation. ROC analysis indicated that miR-212 and miR-195 have better sensitivities (84.6% and 69.2%, respectively) and specificities (both 100%) in distinguishing biopsies with metastasis to LN from biopsies without metastasis to LN." +tissue_expression_ns hsa-mir-143 Gastric Neoplasms 21987613 "Five microRNAs (miR-125a-3p, miR-133b, miR-143, miR-195 and miR-212) were differently expressed between different metastatic groups in 30 gastric cancer biopsies (P < 0.05). Partial correlation analysis showed that hsa-mir-212 and hsa-mir-195 were correlated with the status of metastasis to LN in spite of age, gender, tumor location, tumor size, depth of invasion and cell differentiation. ROC analysis indicated that miR-212 and miR-195 have better sensitivities (84.6% and 69.2%, respectively) and specificities (both 100%) in distinguishing biopsies with metastasis to LN from biopsies without metastasis to LN." +tissue_expression_ns hsa-mir-195 Gastric Neoplasms 21987613 "Five microRNAs (miR-125a-3p, miR-133b, miR-143, miR-195 and miR-212) were differently expressed between different metastatic groups in 30 gastric cancer biopsies (P < 0.05). Partial correlation analysis showed that hsa-mir-212 and hsa-mir-195 were correlated with the status of metastasis to LN in spite of age, gender, tumor location, tumor size, depth of invasion and cell differentiation. ROC analysis indicated that miR-212 and miR-195 have better sensitivities (84.6% and 69.2%, respectively) and specificities (both 100%) in distinguishing biopsies with metastasis to LN from biopsies without metastasis to LN." +tissue_expression_ns hsa-mir-212 Gastric Neoplasms 21987613 "Five microRNAs (miR-125a-3p, miR-133b, miR-143, miR-195 and miR-212) were differently expressed between different metastatic groups in 30 gastric cancer biopsies (P < 0.05). Partial correlation analysis showed that hsa-mir-212 and hsa-mir-195 were correlated with the status of metastasis to LN in spite of age, gender, tumor location, tumor size, depth of invasion and cell differentiation. ROC analysis indicated that miR-212 and miR-195 have better sensitivities (84.6% and 69.2%, respectively) and specificities (both 100%) in distinguishing biopsies with metastasis to LN from biopsies without metastasis to LN." +tissue_expression_ns hsa-mir-130b "Tuberculosis, Pulmonary" 22003408 hsa-mir-130b*: differently expressed in the samples from study participants with active tuberculosis (TB) versus latent tuberculosis infection (LTBI). +tissue_expression_ns hsa-mir-144 "Tuberculosis, Pulmonary" 22003408 hsa-mir-144: differently expressed in the samples from study participants with active tuberculosis (TB) versus latent tuberculosis infection (LTBI). +tissue_expression_ns hsa-mir-155 "Tuberculosis, Pulmonary" 22003408 hsa-mir-155: differently expressed in the samples from study participants with active tuberculosis (TB) versus latent tuberculosis infection (LTBI). +tissue_expression_ns hsa-mir-181b-1 "Tuberculosis, Pulmonary" 22003408 hsa-mir-181b: differently expressed in the samples from study participants with active tuberculosis (TB) versus latent tuberculosis infection (LTBI). +tissue_expression_ns hsa-mir-181b-2 "Tuberculosis, Pulmonary" 22003408 hsa-mir-181b: differently expressed in the samples from study participants with active tuberculosis (TB) versus latent tuberculosis infection (LTBI). +tissue_expression_ns hsa-mir-21 "Tuberculosis, Pulmonary" 22003408 hsa-mir-21*: differently expressed in the samples from study participants with active tuberculosis (TB) versus latent tuberculosis infection (LTBI). +tissue_expression_ns hsa-mir-223 "Tuberculosis, Pulmonary" 22003408 hsa-mir-223: differently expressed in the samples from study participants with active tuberculosis (TB) versus latent tuberculosis infection (LTBI). +tissue_expression_ns hsa-mir-302a "Tuberculosis, Pulmonary" 22003408 hsa-mir-302a: differently expressed in the samples from study participants with active tuberculosis (TB) versus latent tuberculosis infection (LTBI). +tissue_expression_ns hsa-mir-329-1 "Tuberculosis, Pulmonary" 22003408 hsa-mir-329: differently expressed in the samples from study participants with active tuberculosis (TB) versus latent tuberculosis infection (LTBI). +tissue_expression_ns hsa-mir-329-2 "Tuberculosis, Pulmonary" 22003408 hsa-mir-329: differently expressed in the samples from study participants with active tuberculosis (TB) versus latent tuberculosis infection (LTBI). +tissue_expression_ns hsa-mir-342 "Tuberculosis, Pulmonary" 22003408 hsa-mir-342-5p: differently expressed in the samples from study participants with active tuberculosis (TB) versus latent tuberculosis infection (LTBI). +tissue_expression_ns hsa-mir-421 "Tuberculosis, Pulmonary" 22003408 hsa-mir-421: differently expressed in the samples from study participants with active tuberculosis (TB) versus latent tuberculosis infection (LTBI). +tissue_expression_ns hsa-mir-424 "Tuberculosis, Pulmonary" 22003408 hsa-mir-424: differently expressed in the samples from study participants with active tuberculosis (TB) versus latent tuberculosis infection (LTBI). +tissue_expression_ns hsa-mir-451a "Tuberculosis, Pulmonary" 22003408 hsa-mir-451: differently expressed in the samples from study participants with active tuberculosis (TB) versus latent tuberculosis infection (LTBI). +tissue_expression_ns hsa-mir-486 "Tuberculosis, Pulmonary" 22003408 hsa-mir-486-5p: differently expressed in the samples from study participants with active tuberculosis (TB) versus latent tuberculosis infection (LTBI). +tissue_expression_ns hsa-mir-520d "Tuberculosis, Pulmonary" 22003408 hsa-mir-520d-3p: differently expressed in the samples from study participants with active tuberculosis (TB) versus latent tuberculosis infection (LTBI). +tissue_expression_ns hsa-mir-548b "Tuberculosis, Pulmonary" 22003408 hsa-mir-548b-3p: differently expressed in the samples from study participants with active tuberculosis (TB) versus latent tuberculosis infection (LTBI). +tissue_expression_ns hsa-mir-550a-1 "Tuberculosis, Pulmonary" 22003408 hsa-mir-550*: differently expressed in the samples from study participants with active tuberculosis (TB) versus latent tuberculosis infection (LTBI). +tissue_expression_ns hsa-mir-550a-2 "Tuberculosis, Pulmonary" 22003408 hsa-mir-550*: differently expressed in the samples from study participants with active tuberculosis (TB) versus latent tuberculosis infection (LTBI). +tissue_expression_ns hsa-mir-550a-3 "Tuberculosis, Pulmonary" 22003408 hsa-mir-550*: differently expressed in the samples from study participants with active tuberculosis (TB) versus latent tuberculosis infection (LTBI). +tissue_expression_ns hsa-mir-550b-1 "Tuberculosis, Pulmonary" 22003408 hsa-mir-550*: differently expressed in the samples from study participants with active tuberculosis (TB) versus latent tuberculosis infection (LTBI). +tissue_expression_ns hsa-mir-550b-2 "Tuberculosis, Pulmonary" 22003408 hsa-mir-550*: differently expressed in the samples from study participants with active tuberculosis (TB) versus latent tuberculosis infection (LTBI). +tissue_expression_ns hsa-mir-640 "Tuberculosis, Pulmonary" 22003408 hsa-mir-640: differently expressed in the samples from study participants with active tuberculosis (TB) versus latent tuberculosis infection (LTBI). +tissue_expression_ns hsa-mir-516a-1 Frontotemporal Lobar Degeneration 22032330 miR-516a-3p was significantly dysregulated in frontal cortex and cerebellar tissue samples of PGRN mutation carriers. +tissue_expression_ns hsa-mir-516a-2 Frontotemporal Lobar Degeneration 22032330 miR-516a-3p was significantly dysregulated in frontal cortex and cerebellar tissue samples of PGRN mutation carriers. +tissue_expression_ns hsa-mir-548b Frontotemporal Lobar Degeneration 22032330 miR-548b-5p was significantly dysregulated in frontal cortex and cerebellar tissue samples of PGRN mutation carriers. +tissue_expression_ns hsa-mir-548c Frontotemporal Lobar Degeneration 22032330 miR-548c-5p was significantly dysregulated in frontal cortex and cerebellar tissue samples of PGRN mutation carriers. +tissue_expression_ns hsa-mir-571 Frontotemporal Lobar Degeneration 22032330 miR-571 was significantly dysregulated in frontal cortex and cerebellar tissue samples of PGRN mutation carriers. +tissue_expression_ns hsa-mir-922 Frontotemporal Lobar Degeneration 22032330 miR-922 was significantly dysregulated in frontal cortex and cerebellar tissue samples of PGRN mutation carriers. +tissue_expression_ns hsa-mir-126 "Carcinoma, Renal Cell" 22033272 The expression level of this miRNA was significantly altered in two independent cohorts of patients. +tissue_expression_ns hsa-mir-196a-1 "Carcinoma, Renal Cell" 22033272 The expression level of this miRNA was significantly altered in two independent cohorts of patients. +tissue_expression_ns hsa-mir-204 "Carcinoma, Renal Cell" 22033272 The expression level of this miRNA was significantly altered in two independent cohorts of patients. +tissue_expression_ns hsa-mir-215 "Carcinoma, Renal Cell" 22033272 "The expression level of this miRNA was significantly altered in two independent cohorts of patients. Overexpression of miR-215 decreased cellular migration and invasion in an RCC cell line model. In addition, through gene expression profiling, the authors identified direct and indirect targets of miR-215 that can contribute to tumour metastasis." +tissue_expression_ns hsa-mir-124-1 Rheumatoid Arthritis 22100329 deregulated +tissue_expression_ns hsa-mir-124-2 Rheumatoid Arthritis 22100329 deregulated +tissue_expression_ns hsa-mir-124-3 Rheumatoid Arthritis 22100329 deregulated +tissue_expression_ns hsa-mir-132 Rheumatoid Arthritis 22100329 deregulated +tissue_expression_ns hsa-mir-146a Rheumatoid Arthritis 22100329 deregulated +tissue_expression_ns hsa-mir-155 Rheumatoid Arthritis 22100329 deregulated +tissue_expression_ns hsa-mir-15a Rheumatoid Arthritis 22100329 deregulated +tissue_expression_ns hsa-mir-16-1 Rheumatoid Arthritis 22100329 deregulated +tissue_expression_ns hsa-mir-16-2 Rheumatoid Arthritis 22100329 deregulated +tissue_expression_ns hsa-mir-203 Rheumatoid Arthritis 22100329 deregulated +tissue_expression_ns hsa-mir-223 Rheumatoid Arthritis 22100329 deregulated +tissue_expression_ns hsa-mir-346 Rheumatoid Arthritis 22100329 deregulated +tissue_expression_ns hsa-mir-363 Rheumatoid Arthritis 22100329 deregulated +tissue_expression_ns hsa-mir-498 Rheumatoid Arthritis 22100329 deregulated +tissue_expression_ns hsa-let-7f-1 Gastric Neoplasms 22112324 A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemosensitivity +tissue_expression_ns hsa-let-7f-2 Gastric Neoplasms 22112324 A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemosensitivity +tissue_expression_ns hsa-let-7g Gastric Neoplasms 22112324 A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemosensitivity +tissue_expression_ns hsa-mir-1-1 Gastric Neoplasms 22112324 A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemosensitivity +tissue_expression_ns hsa-mir-1-2 Gastric Neoplasms 22112324 A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemosensitivity +tissue_expression_ns hsa-mir-122 Gastric Neoplasms 22112324 A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance +tissue_expression_ns hsa-mir-127 Gastric Neoplasms 22112324 A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemosensitivity +tissue_expression_ns hsa-mir-128-1 Gastric Neoplasms 22112324 A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemosensitivity +tissue_expression_ns hsa-mir-128-2 Gastric Neoplasms 22112324 A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemosensitivity +tissue_expression_ns hsa-mir-130a Gastric Neoplasms 22112324 A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemosensitivity +tissue_expression_ns hsa-mir-132 Gastric Neoplasms 22112324 A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemosensitivity +tissue_expression_ns hsa-mir-140 Gastric Neoplasms 22112324 A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemosensitivity +tissue_expression_ns hsa-mir-146a Gastric Neoplasms 22112324 A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemosensitivity +tissue_expression_ns hsa-mir-146b Gastric Neoplasms 22112324 A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemosensitivity +tissue_expression_ns hsa-mir-155 Gastric Neoplasms 22112324 A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemosensitivity +tissue_expression_ns hsa-mir-16-1 Gastric Neoplasms 22112324 A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemosensitivity +tissue_expression_ns hsa-mir-16-2 Gastric Neoplasms 22112324 A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemosensitivity +tissue_expression_ns hsa-mir-181b-1 Gastric Neoplasms 22112324 A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemosensitivity +tissue_expression_ns hsa-mir-181b-2 Gastric Neoplasms 22112324 A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemosensitivity +tissue_expression_ns hsa-mir-182 Gastric Neoplasms 22112324 A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance +tissue_expression_ns hsa-mir-183 Gastric Neoplasms 22112324 A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance +tissue_expression_ns hsa-mir-185 Gastric Neoplasms 22112324 A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance +tissue_expression_ns hsa-mir-186 Gastric Neoplasms 22112324 A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemosensitivity +tissue_expression_ns hsa-mir-193b Gastric Neoplasms 22112324 A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance +tissue_expression_ns hsa-mir-195 Gastric Neoplasms 22112324 A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemosensitivity +tissue_expression_ns hsa-mir-199b Gastric Neoplasms 22112324 A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemosensitivity +tissue_expression_ns hsa-mir-206 Gastric Neoplasms 22112324 A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance +tissue_expression_ns hsa-mir-223 Gastric Neoplasms 22112324 A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemosensitivity +tissue_expression_ns hsa-mir-224 Gastric Neoplasms 22112324 A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemosensitivity +tissue_expression_ns hsa-mir-26b Gastric Neoplasms 22112324 A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemosensitivity +tissue_expression_ns hsa-mir-320a Gastric Neoplasms 22112324 A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance +tissue_expression_ns hsa-mir-328 Gastric Neoplasms 22112324 A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance +tissue_expression_ns hsa-mir-340 Gastric Neoplasms 22112324 A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemosensitivity +tissue_expression_ns hsa-mir-342 Gastric Neoplasms 22112324 A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemosensitivity +tissue_expression_ns hsa-mir-34c Gastric Neoplasms 22112324 A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemosensitivity +tissue_expression_ns hsa-mir-363 Gastric Neoplasms 22112324 A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance +tissue_expression_ns hsa-mir-374a Gastric Neoplasms 22112324 A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemosensitivity +tissue_expression_ns hsa-mir-374b Gastric Neoplasms 22112324 A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemosensitivity +tissue_expression_ns hsa-mir-421 Gastric Neoplasms 22112324 A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemosensitivity +tissue_expression_ns hsa-mir-487b Gastric Neoplasms 22112324 A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemosensitivity +tissue_expression_ns hsa-mir-497 Gastric Neoplasms 22112324 A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemosensitivity +tissue_expression_ns hsa-mir-503 Gastric Neoplasms 22112324 A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemosensitivity +tissue_expression_ns hsa-mir-513a-1 Gastric Neoplasms 22112324 A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance +tissue_expression_ns hsa-mir-513a-2 Gastric Neoplasms 22112324 A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance +tissue_expression_ns hsa-mir-513b Gastric Neoplasms 22112324 A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance +tissue_expression_ns hsa-mir-513c Gastric Neoplasms 22112324 A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance +tissue_expression_ns hsa-mir-515-1 Gastric Neoplasms 22112324 A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance +tissue_expression_ns hsa-mir-515-2 Gastric Neoplasms 22112324 A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance +tissue_expression_ns hsa-mir-516a-1 Gastric Neoplasms 22112324 A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance +tissue_expression_ns hsa-mir-516a-2 Gastric Neoplasms 22112324 A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance +tissue_expression_ns hsa-mir-516b-1 Gastric Neoplasms 22112324 A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance +tissue_expression_ns hsa-mir-516b-2 Gastric Neoplasms 22112324 A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance +tissue_expression_ns hsa-mir-517a Gastric Neoplasms 22112324 A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance +tissue_expression_ns hsa-mir-518f Gastric Neoplasms 22112324 A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance +tissue_expression_ns hsa-mir-519a-1 Gastric Neoplasms 22112324 A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance +tissue_expression_ns hsa-mir-519a-2 Gastric Neoplasms 22112324 A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance +tissue_expression_ns hsa-mir-519c Gastric Neoplasms 22112324 A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance +tissue_expression_ns hsa-mir-519e Gastric Neoplasms 22112324 A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance +tissue_expression_ns hsa-mir-520a Gastric Neoplasms 22112324 A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance +tissue_expression_ns hsa-mir-520d Gastric Neoplasms 22112324 A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance +tissue_expression_ns hsa-mir-524 Gastric Neoplasms 22112324 A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance +tissue_expression_ns hsa-mir-526a-1 Gastric Neoplasms 22112324 A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance +tissue_expression_ns hsa-mir-526a-2 Gastric Neoplasms 22112324 A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance +tissue_expression_ns hsa-mir-577 Gastric Neoplasms 22112324 A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemosensitivity +tissue_expression_ns hsa-mir-591 Gastric Neoplasms 22112324 A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance +tissue_expression_ns hsa-mir-595 Gastric Neoplasms 22112324 A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance +tissue_expression_ns hsa-mir-601 Gastric Neoplasms 22112324 A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance +tissue_expression_ns hsa-mir-629 Gastric Neoplasms 22112324 A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance +tissue_expression_ns hsa-mir-640 Gastric Neoplasms 22112324 A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance +tissue_expression_ns hsa-mir-658 Gastric Neoplasms 22112324 A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance +tissue_expression_ns hsa-mir-661 Gastric Neoplasms 22112324 A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance +tissue_expression_ns hsa-mir-95 Gastric Neoplasms 22112324 A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemosensitivity +tissue_expression_ns hsa-mir-125b-1 Pancreatic Neoplasms 22114139 altered expression +tissue_expression_ns hsa-mir-125b-2 Pancreatic Neoplasms 22114139 altered expression +tissue_expression_ns hsa-mir-146a Pancreatic Neoplasms 22114139 altered expression +tissue_expression_ns hsa-mir-155 Pancreatic Neoplasms 22114139 altered expression +tissue_expression_ns hsa-mir-182 Pancreatic Neoplasms 22114139 altered expression +tissue_expression_ns hsa-mir-183 Pancreatic Neoplasms 22114139 miR-183*:altered expression +tissue_expression_ns hsa-mir-196b Pancreatic Neoplasms 22114139 altered expression +tissue_expression_ns hsa-mir-200a Pancreatic Neoplasms 22114139 altered expression +tissue_expression_ns hsa-mir-200b Pancreatic Neoplasms 22114139 altered expression +tissue_expression_ns hsa-mir-200c Pancreatic Neoplasms 22114139 altered expression +tissue_expression_ns hsa-mir-203 Pancreatic Neoplasms 22114139 altered expression +tissue_expression_ns hsa-mir-21 Pancreatic Neoplasms 22114139 altered expression +tissue_expression_ns hsa-mir-216a Pancreatic Neoplasms 22114139 altered expression +tissue_expression_ns hsa-mir-216b Pancreatic Neoplasms 22114139 altered expression +tissue_expression_ns hsa-mir-217 Pancreatic Neoplasms 22114139 altered expression +tissue_expression_ns hsa-mir-222 Pancreatic Neoplasms 22114139 altered expression +tissue_expression_ns hsa-mir-296 Pancreatic Neoplasms 22114139 miR-296-5p:altered expression +tissue_expression_ns hsa-mir-338 Pancreatic Neoplasms 22114139 miR-338-3p;altered expression +tissue_expression_ns hsa-mir-486 Pancreatic Neoplasms 22114139 miR-486-3p:altered expression +tissue_expression_ns hsa-mir-603 Pancreatic Neoplasms 22114139 altered expression +tissue_expression_ns hsa-mir-625 Pancreatic Neoplasms 22114139 miR-625*:altered expression +tissue_expression_ns hsa-mir-708 Pancreatic Neoplasms 22114139 altered expression +tissue_expression_ns hsa-mir-10a Urinary Bladder Cancer 22140553 deregulated +tissue_expression_ns hsa-mir-1-1 Urinary Bladder Cancer 22140553 deregulated +tissue_expression_ns hsa-mir-1-2 Urinary Bladder Cancer 22140553 deregulated +tissue_expression_ns hsa-mir-125b-1 Urinary Bladder Cancer 22140553 deregulated +tissue_expression_ns hsa-mir-125b-2 Urinary Bladder Cancer 22140553 deregulated +tissue_expression_ns hsa-mir-133a-1 Urinary Bladder Cancer 22140553 deregulated +tissue_expression_ns hsa-mir-133a-2 Urinary Bladder Cancer 22140553 deregulated +tissue_expression_ns hsa-mir-133b Urinary Bladder Cancer 22140553 deregulated +tissue_expression_ns hsa-mir-143 Urinary Bladder Cancer 22140553 deregulated +tissue_expression_ns hsa-mir-145 Urinary Bladder Cancer 22140553 deregulated +tissue_expression_ns hsa-mir-182 Urinary Bladder Cancer 22140553 deregulated +tissue_expression_ns hsa-mir-183 Urinary Bladder Cancer 22140553 deregulated +tissue_expression_ns hsa-mir-203 Urinary Bladder Cancer 22140553 deregulated +tissue_expression_ns hsa-mir-224 Urinary Bladder Cancer 22140553 deregulated +tissue_expression_ns hsa-mir-1-1 Prostate Neoplasms 22210864 MicroRNA-1 is a candidate tumor suppressor and prognostic marker in human prostate cancer. +tissue_expression_ns hsa-mir-1-2 Prostate Neoplasms 22210864 MicroRNA-1 is a candidate tumor suppressor and prognostic marker in human prostate cancer. +tissue_expression_ns hsa-let-7b Breast Neoplasms 22294324 "let-7b expression was shown to be associated with luminal tumours, and to have an independent significant positive prognostic value in this group. miR-205 is associated with tumours of ductal morphology, and is of significant positive prognostic value within these tumours." +tissue_expression_ns hsa-mir-205 Breast Neoplasms 22294324 "let-7b expression was shown to be associated with luminal tumours, and to have an independent significant positive prognostic value in this group. miR-205 is associated with tumours of ductal morphology, and is of significant positive prognostic value within these tumours." +tissue_expression_ns hsa-mir-146a Lupus Nephritis 22295894 "Intra-renal expression of miR-638, miR-198 and miR-146a are differentially expressed between LN patients and normal controls. Furthermore, the degree of change in glomerular miR-146a and tubulointerstitial miR-638 expression correlated with clinical disease severity." +tissue_expression_ns hsa-mir-198 Lupus Nephritis 22295894 "Intra-renal expression of miR-638, miR-198 and miR-146a are differentially expressed between LN patients and normal controls. Furthermore, the degree of change in glomerular miR-146a and tubulointerstitial miR-638 expression correlated with clinical disease severity." +tissue_expression_ns hsa-mir-638 Lupus Nephritis 22295894 "Intra-renal expression of miR-638, miR-198 and miR-146a are differentially expressed between LN patients and normal controls. Furthermore, the degree of change in glomerular miR-146a and tubulointerstitial miR-638 expression correlated with clinical disease severity." +tissue_expression_ns hsa-mir-145 "Scleroderma, Systemic" 22307526 The expression of the miRNA was correlated with Systemic Scleroderma fibrosis +tissue_expression_ns hsa-mir-146a "Scleroderma, Systemic" 22307526 The expression of the miRNA was correlated with Systemic Scleroderma fibrosis +tissue_expression_ns hsa-mir-146b "Scleroderma, Systemic" 22307526 The expression of the miRNA was correlated with Systemic Scleroderma fibrosis +tissue_expression_ns hsa-mir-21 "Scleroderma, Systemic" 22307526 The expression of the miRNA was correlated with Systemic Scleroderma fibrosis +tissue_expression_ns hsa-mir-29b-1 "Scleroderma, Systemic" 22307526 The expression of the miRNA was correlated with Systemic Scleroderma fibrosis +tissue_expression_ns hsa-mir-29b-2 "Scleroderma, Systemic" 22307526 The expression of the miRNA was correlated with Systemic Scleroderma fibrosis +tissue_expression_ns hsa-mir-31 "Scleroderma, Systemic" 22307526 The expression of the miRNA was correlated with Systemic Scleroderma fibrosis +tissue_expression_ns hsa-mir-503 "Scleroderma, Systemic" 22307526 The expression of the miRNA was correlated with Systemic Scleroderma fibrosis +tissue_expression_ns hsa-let-7i Breast Neoplasms 22315424 "Five noncoding genes were associated with both prognostic signatures-miR-210, -21, -106b*, -197, and let-7i, with miR-210 the only one also involved in the invasive transition." +tissue_expression_ns hsa-mir-106b Breast Neoplasms 22315424 "Five noncoding genes were associated with both prognostic signatures-miR-210, -21, -106b*, -197, and let-7i, with miR-210 the only one also involved in the invasive transition." +tissue_expression_ns hsa-mir-197 Breast Neoplasms 22315424 "Five noncoding genes were associated with both prognostic signatures-miR-210, -21, -106b*, -197, and let-7i, with miR-210 the only one also involved in the invasive transition." +tissue_expression_ns hsa-mir-21 Breast Neoplasms 22315424 "Five noncoding genes were associated with both prognostic signatures-miR-210, -21, -106b*, -197, and let-7i, with miR-210 the only one also involved in the invasive transition." +tissue_expression_ns hsa-mir-10b "Carcinoma, Oral" 22318752 hsa-mir-10b has the potential for Oncogenic Function and Early Detection in Oral Cancer as Identified by microRNA Profiling. +tissue_expression_ns hsa-mir-100 Urinary Bladder Cancer 22330141 "Altered expression of five significantly differentially expressed miRNAs, hsa-miR-9 (1q23.2), hsa-miR-15b (3q25.32), hsa-miR-28-5p (3q27.3), hsa-miR-100 and hsa-miR-125b (both 11q24.1), was directly linked to frequent chromosomal alterations." +tissue_expression_ns hsa-mir-125b-1 Urinary Bladder Cancer 22330141 "Altered expression of five significantly differentially expressed miRNAs, hsa-miR-9 (1q23.2), hsa-miR-15b (3q25.32), hsa-miR-28-5p (3q27.3), hsa-miR-100 and hsa-miR-125b (both 11q24.1), was directly linked to frequent chromosomal alterations." +tissue_expression_ns hsa-mir-15b Urinary Bladder Cancer 22330141 "Altered expression of five significantly differentially expressed miRNAs, hsa-miR-9 (1q23.2), hsa-miR-15b (3q25.32), hsa-miR-28-5p (3q27.3), hsa-miR-100 and hsa-miR-125b (both 11q24.1), was directly linked to frequent chromosomal alterations." +tissue_expression_ns hsa-mir-28 Urinary Bladder Cancer 22330141 "Altered expression of five significantly differentially expressed miRNAs, hsa-miR-9 (1q23.2), hsa-miR-15b (3q25.32), hsa-miR-28-5p (3q27.3), hsa-miR-100 and hsa-miR-125b (both 11q24.1), was directly linked to frequent chromosomal alterations." +tissue_expression_ns hsa-mir-9-1 Urinary Bladder Cancer 22330141 "Altered expression of five significantly differentially expressed miRNAs, hsa-miR-9 (1q23.2), hsa-miR-15b (3q25.32), hsa-miR-28-5p (3q27.3), hsa-miR-100 and hsa-miR-125b (both 11q24.1), was directly linked to frequent chromosomal alterations." +tissue_expression_ns hsa-mir-15b "Carcinoma, Lung, Non-Small-Cell" 22389695 "A combination of two differentially expressed miRNAs miR-15b and miR-27b, was able to discriminate NSCLC from healthy controls with sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of 100% in the training set." +tissue_expression_ns hsa-mir-27b "Carcinoma, Lung, Non-Small-Cell" 22389695 "A combination of two differentially expressed miRNAs miR-15b and miR-27b, was able to discriminate NSCLC from healthy controls with sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of 100% in the training set." +tissue_expression_ns hsa-mir-124-1 Lymphoma 22395483 "A distinct set of five microRNAs (miR-150, miR-550, miR-124a, miR-518b and miR-539) was shown to be differentially expressed in gastritis as opposed to MALT lymphoma." +tissue_expression_ns hsa-mir-150 Lymphoma 22395483 "A distinct set of five microRNAs (miR-150, miR-550, miR-124a, miR-518b and miR-539) was shown to be differentially expressed in gastritis as opposed to MALT lymphoma." +tissue_expression_ns hsa-mir-518b Lymphoma 22395483 "A distinct set of five microRNAs (miR-150, miR-550, miR-124a, miR-518b and miR-539) was shown to be differentially expressed in gastritis as opposed to MALT lymphoma." +tissue_expression_ns hsa-mir-539 Lymphoma 22395483 "A distinct set of five microRNAs (miR-150, miR-550, miR-124a, miR-518b and miR-539) was shown to be differentially expressed in gastritis as opposed to MALT lymphoma." +tissue_expression_ns hsa-mir-550a-1 Lymphoma 22395483 "A distinct set of five microRNAs (miR-150, miR-550, miR-124a, miR-518b and miR-539) was shown to be differentially expressed in gastritis as opposed to MALT lymphoma." +tissue_expression_ns hsa-mir-550a-2 Lymphoma 22395483 "A distinct set of five microRNAs (miR-150, miR-550, miR-124a, miR-518b and miR-539) was shown to be differentially expressed in gastritis as opposed to MALT lymphoma." +tissue_expression_ns hsa-mir-143 Urinary Bladder Cancer 22426337 "miR-143, miR-222, and miR-452 Are Useful as Tumor Stratification and Noninvasive Diagnostic Biomarkers for Bladder Cancer." +tissue_expression_ns hsa-mir-222 Urinary Bladder Cancer 22426337 "miR-143, miR-222, and miR-452 Are Useful as Tumor Stratification and Noninvasive Diagnostic Biomarkers for Bladder Cancer." +tissue_expression_ns hsa-mir-452 Urinary Bladder Cancer 22426337 "miR-143, miR-222, and miR-452 Are Useful as Tumor Stratification and Noninvasive Diagnostic Biomarkers for Bladder Cancer." +tissue_expression_ns hsa-mir-199b Heart Failure 22427379 "Six miRNAs were differently expressed when comparing D-HF (diabetic HF) and ND-HF (nondiabetic HF) patients: miR-34b, miR-34c, miR-199b, miR-210, miR-650, and miR-223." +tissue_expression_ns hsa-mir-210 Heart Failure 22427379 "Six miRNAs were differently expressed when comparing D-HF (diabetic HF) and ND-HF (nondiabetic HF) patients: miR-34b, miR-34c, miR-199b, miR-210, miR-650, and miR-223." +tissue_expression_ns hsa-mir-223 Heart Failure 22427379 "Six miRNAs were differently expressed when comparing D-HF (diabetic HF) and ND-HF (nondiabetic HF) patients: miR-34b, miR-34c, miR-199b, miR-210, miR-650, and miR-223." +tissue_expression_ns hsa-mir-34b Heart Failure 22427379 "Six miRNAs were differently expressed when comparing D-HF (diabetic HF) and ND-HF (nondiabetic HF) patients: miR-34b, miR-34c, miR-199b, miR-210, miR-650, and miR-223." +tissue_expression_ns hsa-mir-34c Heart Failure 22427379 "Six miRNAs were differently expressed when comparing D-HF (diabetic HF) and ND-HF (nondiabetic HF) patients: miR-34b, miR-34c, miR-199b, miR-210, miR-650, and miR-223." +tissue_expression_ns hsa-mir-650 Heart Failure 22427379 "Six miRNAs were differently expressed when comparing D-HF (diabetic HF) and ND-HF (nondiabetic HF) patients: miR-34b, miR-34c, miR-199b, miR-210, miR-650, and miR-223." +tissue_expression_ns hsa-mir-106b Ewing Sarcoma 22429812 "MiR-21, miR-31, miR-31*, miR-106b, miR-145, miR-150*, miR-371-5p, miR-557 and miR-598 showed recurrently altered expression." +tissue_expression_ns hsa-mir-145 Ewing Sarcoma 22429812 "MiR-21, miR-31, miR-31*, miR-106b, miR-145, miR-150*, miR-371-5p, miR-557 and miR-598 showed recurrently altered expression." +tissue_expression_ns hsa-mir-150 Ewing Sarcoma 22429812 "MiR-21, miR-31, miR-31*, miR-106b, miR-145, miR-150*, miR-371-5p, miR-557 and miR-598 showed recurrently altered expression." +tissue_expression_ns hsa-mir-21 Ewing Sarcoma 22429812 "MiR-21, miR-31, miR-31*, miR-106b, miR-145, miR-150*, miR-371-5p, miR-557 and miR-598 showed recurrently altered expression." +tissue_expression_ns hsa-mir-31 Ewing Sarcoma 22429812 "MiR-21, miR-31, miR-31*, miR-106b, miR-145, miR-150*, miR-371-5p, miR-557 and miR-598 showed recurrently altered expression." +tissue_expression_ns hsa-mir-371a Ewing Sarcoma 22429812 "MiR-21, miR-31, miR-31*, miR-106b, miR-145, miR-150*, miR-371-5p, miR-557 and miR-598 showed recurrently altered expression." +tissue_expression_ns hsa-mir-557 Ewing Sarcoma 22429812 "MiR-21, miR-31, miR-31*, miR-106b, miR-145, miR-150*, miR-371-5p, miR-557 and miR-598 showed recurrently altered expression." +tissue_expression_ns hsa-mir-598 Ewing Sarcoma 22429812 "MiR-21, miR-31, miR-31*, miR-106b, miR-145, miR-150*, miR-371-5p, miR-557 and miR-598 showed recurrently altered expression." +tissue_expression_ns hsa-mir-137 Leiomyoma 22446413 deregulated +tissue_expression_ns hsa-mir-217 Leiomyoma 22446413 deregulated +tissue_expression_ns hsa-mir-363 Leiomyoma 22446413 deregulated +tissue_expression_ns hsa-mir-4792 Leiomyoma 22446413 deregulated +tissue_expression_ns hsa-mir-490 Leiomyoma 22446413 deregulated +tissue_expression_ns hsa-mir-135a-1 Lymphoma 22490335 different expression between small lymphocytic leukemia and lymphoma +tissue_expression_ns hsa-mir-135a-2 Lymphoma 22490335 different expression between small lymphocytic leukemia and lymphoma +tissue_expression_ns hsa-mir-150 Lymphoma 22490335 different expression between small lymphocytic leukemia and lymphoma +tissue_expression_ns hsa-mir-184 Lymphoma 22490335 different expression between small lymphocytic leukemia and lymphoma +tissue_expression_ns hsa-mir-342 Lymphoma 22490335 different expression between small lymphocytic leukemia and lymphoma +tissue_expression_ns hsa-mir-363 Lymphoma 22490335 different expression between small lymphocytic leukemia and lymphoma +tissue_expression_ns hsa-mir-708 Lymphoma 22490335 different expression between small lymphocytic leukemia and lymphoma +tissue_expression_ns hsa-mir-103 Lung Neoplasms 22576802 "Among them, some have a well-characterized association with cancer progression, e.g. miR-125b, miR-210, miR-103, miR-194 and miR-500. In summary, it is evident from our results that MTA1 functions in regulating the invasive phenotype of lung cancer cells and this regulation may be through altered miRNA expression." +tissue_expression_ns hsa-mir-125b Lung Neoplasms 22576802 "Among them, some have a well-characterized association with cancer progression, e.g. miR-125b, miR-210, miR-103, miR-194 and miR-500. In summary, it is evident from our results that MTA1 functions in regulating the invasive phenotype of lung cancer cells and this regulation may be through altered miRNA expression." +tissue_expression_ns hsa-mir-194 Lung Neoplasms 22576802 "Among them, some have a well-characterized association with cancer progression, e.g. miR-125b, miR-210, miR-103, miR-194 and miR-500. In summary, it is evident from our results that MTA1 functions in regulating the invasive phenotype of lung cancer cells and this regulation may be through altered miRNA expression." +tissue_expression_ns hsa-mir-210 Lung Neoplasms 22576802 "Among them, some have a well-characterized association with cancer progression, e.g. miR-125b, miR-210, miR-103, miR-194 and miR-500. In summary, it is evident from our results that MTA1 functions in regulating the invasive phenotype of lung cancer cells and this regulation may be through altered miRNA expression." +tissue_expression_ns hsa-mir-500 Lung Neoplasms 22576802 "Among them, some have a well-characterized association with cancer progression, e.g. miR-125b, miR-210, miR-103, miR-194 and miR-500. In summary, it is evident from our results that MTA1 functions in regulating the invasive phenotype of lung cancer cells and this regulation may be through altered miRNA expression." +tissue_expression_ns hsa-mir-182 "Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic" 22582938 Aberrant microRNA-182 expression is associated with glucocorticoid resistance in lymphoblastic malignancies. +tissue_expression_ns hsa-mir-10b "Carcinoma, Renal Cell" 22623952 "The expression levels of miR-10b, miR-139-5p, miR-130b and miR-199b-5p could determine the status of ccRCC metastasis." +tissue_expression_ns hsa-mir-130b "Carcinoma, Renal Cell" 22623952 "The expression levels of miR-10b, miR-139-5p, miR-130b and miR-199b-5p could determine the status of ccRCC metastasis." +tissue_expression_ns hsa-mir-139 "Carcinoma, Renal Cell" 22623952 "The expression levels of miR-10b, miR-139-5p, miR-130b and miR-199b-5p could determine the status of ccRCC metastasis." +tissue_expression_ns hsa-mir-195 "Carcinoma, Renal Cell" 22623952 "The expression levels of miR-10b, miR-139-5p, miR-130b and miR-199b-5p could determine the status of ccRCC metastasis." +tissue_expression_ns hsa-mir-199b "Carcinoma, Renal Cell" 22623952 "The expression levels of miR-10b, miR-139-5p, miR-130b and miR-199b-5p could determine the status of ccRCC metastasis." +tissue_expression_ns hsa-mir-205 Breast Neoplasms 22631664 miR-205 and miR-342 may be used as potential biomarkers for diagnosis of triple negative breast cancer. +tissue_expression_ns hsa-mir-342 Breast Neoplasms 22631664 miR-205 and miR-342 may be used as potential biomarkers for diagnosis of triple negative breast cancer. +tissue_expression_ns hsa-mir-100 Urinary Bladder Cancer 22644299 differential expression in urinary samples +tissue_expression_ns hsa-mir-1224 Urinary Bladder Cancer 22644299 differential expression in urinary samples +tissue_expression_ns hsa-mir-135b Urinary Bladder Cancer 22644299 differential expression in urinary samples +tissue_expression_ns hsa-mir-15a Urinary Bladder Cancer 22644299 differential expression in urinary samples +tissue_expression_ns hsa-mir-15b Urinary Bladder Cancer 22644299 differential expression in urinary samples +tissue_expression_ns hsa-mir-203 Urinary Bladder Cancer 22644299 differential expression in urinary samples +tissue_expression_ns hsa-mir-212 Urinary Bladder Cancer 22644299 differential expression in urinary samples +tissue_expression_ns hsa-mir-24-1 Urinary Bladder Cancer 22644299 differential expression in urinary samples +tissue_expression_ns hsa-mir-27b Urinary Bladder Cancer 22644299 differential expression in urinary samples +tissue_expression_ns hsa-mir-328 Urinary Bladder Cancer 22644299 differential expression in urinary samples +tissue_expression_ns hsa-mir-574 Gastric Neoplasms 22683180 miR-574-3p: Aberrant expression +tissue_expression_ns hsa-mir-125a Head And Neck Neoplasms 22690848 Differential expression +tissue_expression_ns hsa-mir-125b-1 Head And Neck Neoplasms 22690848 Differential expression +tissue_expression_ns hsa-mir-125b-2 Head And Neck Neoplasms 22690848 Differential expression +tissue_expression_ns hsa-mir-203 Head And Neck Neoplasms 22690848 Differential expression +tissue_expression_ns hsa-mir-21 Head And Neck Neoplasms 22690848 Differential expression +tissue_expression_ns hsa-mir-31 Head And Neck Neoplasms 22690848 Differential expression +tissue_expression_ns hsa-mir-199a "Carcinoma, Hepatocellular" 22714032 "the expression of miR-21, miR-221, miR-222 and miR-199a showing characteristic alterations in hepatocellular carcinoma also displayed deregulated expressions in these two early stages." +tissue_expression_ns hsa-mir-21 "Carcinoma, Hepatocellular" 22714032 "the expression of miR-21, miR-221, miR-222 and miR-199a showing characteristic alterations in hepatocellular carcinoma also displayed deregulated expressions in these two early stages." +tissue_expression_ns hsa-mir-221 "Carcinoma, Hepatocellular" 22714032 "the expression of miR-21, miR-221, miR-222 and miR-199a showing characteristic alterations in hepatocellular carcinoma also displayed deregulated expressions in these two early stages." +tissue_expression_ns hsa-mir-222 "Carcinoma, Hepatocellular" 22714032 "the expression of miR-21, miR-221, miR-222 and miR-199a showing characteristic alterations in hepatocellular carcinoma also displayed deregulated expressions in these two early stages." +tissue_expression_ns hsa-mir-155 Lymphoma 22776000 "Although miRNA microarray analysis did not identify statistically significant differentially expressed miRNAs, miRNA-Q-PCR demonstrated statistically significantly differential expression of miR-155, miR-27b, miR-93, miR-29b and miR-92a between tumor-stage MF and C-ALCL." +tissue_expression_ns hsa-mir-27b Lymphoma 22776000 "Although miRNA microarray analysis did not identify statistically significant differentially expressed miRNAs, miRNA-Q-PCR demonstrated statistically significantly differential expression of miR-155, miR-27b, miR-93, miR-29b and miR-92a between tumor-stage MF and C-ALCL." +tissue_expression_ns hsa-mir-29b Lymphoma 22776000 "Although miRNA microarray analysis did not identify statistically significant differentially expressed miRNAs, miRNA-Q-PCR demonstrated statistically significantly differential expression of miR-155, miR-27b, miR-93, miR-29b and miR-92a between tumor-stage MF and C-ALCL." +tissue_expression_ns hsa-mir-92a Lymphoma 22776000 "Although miRNA microarray analysis did not identify statistically significant differentially expressed miRNAs, miRNA-Q-PCR demonstrated statistically significantly differential expression of miR-155, miR-27b, miR-93, miR-29b and miR-92a between tumor-stage MF and C-ALCL." +tissue_expression_ns hsa-mir-93 Lymphoma 22776000 "Although miRNA microarray analysis did not identify statistically significant differentially expressed miRNAs, miRNA-Q-PCR demonstrated statistically significantly differential expression of miR-155, miR-27b, miR-93, miR-29b and miR-92a between tumor-stage MF and C-ALCL." +tissue_expression_ns hsa-mir-10a Urinary Bladder Cancer 22801550 differentially expressed +tissue_expression_ns hsa-mir-193b Urinary Bladder Cancer 22801550 differentially expressed +tissue_expression_ns hsa-mir-203 Urinary Bladder Cancer 22801550 differentially expressed +tissue_expression_ns hsa-mir-20b Urinary Bladder Cancer 22801550 differentially expressed +tissue_expression_ns hsa-mir-338 Urinary Bladder Cancer 22801550 differentially expressed +tissue_expression_ns hsa-mir-345 Urinary Bladder Cancer 22801550 differentially expressed +tissue_expression_ns hsa-mir-34b Urinary Bladder Cancer 22801550 differentially expressed +tissue_expression_ns hsa-mir-34c Urinary Bladder Cancer 22801550 differentially expressed +tissue_expression_ns hsa-mir-424 Urinary Bladder Cancer 22801550 differentially expressed +tissue_expression_ns hsa-mir-512-1 Urinary Bladder Cancer 22801550 differentially expressed +tissue_expression_ns hsa-mir-512-2 Urinary Bladder Cancer 22801550 differentially expressed +tissue_expression_ns hsa-mir-518a-1 Urinary Bladder Cancer 22801550 differentially expressed +tissue_expression_ns hsa-mir-518a-2 Urinary Bladder Cancer 22801550 differentially expressed +tissue_expression_ns hsa-mir-9-1 Urinary Bladder Cancer 22801550 differentially expressed +tissue_expression_ns hsa-mir-9-2 Urinary Bladder Cancer 22801550 differentially expressed +tissue_expression_ns hsa-mir-9-3 Urinary Bladder Cancer 22801550 differentially expressed +tissue_expression_ns hsa-mir-143 Pancreatic Neoplasms 22836856 Changes in miR-143 and miR-21 Expression are correlated with Clinicopathology in Pancreatic Cancers. +tissue_expression_ns hsa-mir-21 Pancreatic Neoplasms 22836856 Changes in miR-143 and miR-21 Expression are correlated with Clinicopathology in Pancreatic Cancers. +tissue_expression_ns hsa-mir-128-1 Glioblastoma 22844109 "Expression of miR-128a, -504, -124a, and -184 each negatively correlated with the expression of mesenchymal markers in GBM." +tissue_expression_ns hsa-mir-128-2 Glioblastoma 22844109 "Expression of miR-128a, -504, -124a, and -184 each negatively correlated with the expression of mesenchymal markers in GBM." +tissue_expression_ns hsa-mir-184 Glioblastoma 22844109 "Expression of miR-128a, -504, -124a, and -184 each negatively correlated with the expression of mesenchymal markers in GBM." +tissue_expression_ns hsa-mir-504 Glioblastoma 22844109 "Expression of miR-128a, -504, -124a, and -184 each negatively correlated with the expression of mesenchymal markers in GBM." +tissue_expression_ns hsa-mir-135b Colorectal Carcinoma 22844381 "Expression of miR-21, miR-31, miR-96 and miR-135b is correlated with the clinical parameters of colorectal cancer." +tissue_expression_ns hsa-mir-21 Colorectal Carcinoma 22844381 "Expression of miR-21, miR-31, miR-96 and miR-135b is correlated with the clinical parameters of colorectal cancer." +tissue_expression_ns hsa-mir-31 Colorectal Carcinoma 22844381 "Expression of miR-21, miR-31, miR-96 and miR-135b is correlated with the clinical parameters of colorectal cancer." +tissue_expression_ns hsa-mir-96 Colorectal Carcinoma 22844381 "Expression of miR-21, miR-31, miR-96 and miR-135b is correlated with the clinical parameters of colorectal cancer." +tissue_expression_ns hsa-mir-144 Colorectal Carcinoma 22850566 differentially expressed +tissue_expression_ns hsa-mir-147b Colorectal Carcinoma 22850566 differentially expressed +tissue_expression_ns hsa-mir-148a Colorectal Carcinoma 22850566 differentially expressed +tissue_expression_ns hsa-mir-190a Colorectal Carcinoma 22850566 differentially expressed +tissue_expression_ns hsa-mir-2110 Colorectal Carcinoma 22850566 differentially expressed +tissue_expression_ns hsa-mir-26a-1 Colorectal Carcinoma 22850566 differentially expressed +tissue_expression_ns hsa-mir-26a-2 Colorectal Carcinoma 22850566 differentially expressed +tissue_expression_ns hsa-mir-26b Colorectal Carcinoma 22850566 differentially expressed +tissue_expression_ns hsa-mir-338 Colorectal Carcinoma 22850566 miR-338-3p: differentially expressed +tissue_expression_ns hsa-mir-375 Colorectal Carcinoma 22850566 differentially expressed +tissue_expression_ns hsa-mir-483 Colorectal Carcinoma 22850566 miR-483-5p: differentially expressed +tissue_expression_ns hsa-mir-492 Colorectal Carcinoma 22850566 differentially expressed +tissue_expression_ns hsa-mir-542 Colorectal Carcinoma 22850566 miR-542-5p: differentially expressed +tissue_expression_ns hsa-mir-584 Colorectal Carcinoma 22850566 differentially expressed +tissue_expression_ns hsa-mir-652 Colorectal Carcinoma 22850566 differentially expressed +tissue_expression_ns hsa-mir-183 Esophageal Neoplasms 22891887 "The relative expressions of miR-155, miR-183, and miR-20a in esophageal tissue were found to be significantly associated with increased risk for esophageal cancer." +tissue_expression_ns hsa-mir-20a Esophageal Neoplasms 22891887 "The relative expressions of miR-155, miR-183, and miR-20a in esophageal tissue were found to be significantly associated with increased risk for esophageal cancer." +tissue_expression_ns hsa-mir-106a Inflammatory Bowel Diseases 22899284 "A significant difference in expressions of miR-19b, miR-106a, and miR-629 was detected between ulcerative colitis and Crohns disease groups (P<0.05)." +tissue_expression_ns hsa-mir-19b-1 Inflammatory Bowel Diseases 22899284 "A significant difference in expressions of miR-19b, miR-106a, and miR-629 was detected between ulcerative colitis and Crohns disease groups (P<0.05)." +tissue_expression_ns hsa-mir-19b-2 Inflammatory Bowel Diseases 22899284 "A significant difference in expressions of miR-19b, miR-106a, and miR-629 was detected between ulcerative colitis and Crohns disease groups (P<0.05)." +tissue_expression_ns hsa-mir-629 Inflammatory Bowel Diseases 22899284 "A significant difference in expressions of miR-19b, miR-106a, and miR-629 was detected between ulcerative colitis and Crohns disease groups (P<0.05)." +tissue_expression_ns hsa-mir-181d Ovarian Neoplasms 22925189 "Expression of four miRNAs (miR-30c, miR-30d, miR-30e-3p, miR-370) was significantly different between carcinomas and benign ovarian tissues as well as between carcinoma and borderline tissues. An additional three miRNAs (miR-181d, miR-30a-3p, miR-532-5p) were significantly different between borderline and carcinoma tissues." +tissue_expression_ns hsa-mir-30a Ovarian Neoplasms 22925189 "Expression of four miRNAs (miR-30c, miR-30d, miR-30e-3p, miR-370) was significantly different between carcinomas and benign ovarian tissues as well as between carcinoma and borderline tissues. An additional three miRNAs (miR-181d, miR-30a-3p, miR-532-5p) were significantly different between borderline and carcinoma tissues." +tissue_expression_ns hsa-mir-30c-1 Ovarian Neoplasms 22925189 "Expression of four miRNAs (miR-30c, miR-30d, miR-30e-3p, miR-370) was significantly different between carcinomas and benign ovarian tissues as well as between carcinoma and borderline tissues. An additional three miRNAs (miR-181d, miR-30a-3p, miR-532-5p) were significantly different between borderline and carcinoma tissues." +tissue_expression_ns hsa-mir-30c-2 Ovarian Neoplasms 22925189 "Expression of four miRNAs (miR-30c, miR-30d, miR-30e-3p, miR-370) was significantly different between carcinomas and benign ovarian tissues as well as between carcinoma and borderline tissues. An additional three miRNAs (miR-181d, miR-30a-3p, miR-532-5p) were significantly different between borderline and carcinoma tissues." +tissue_expression_ns hsa-mir-30d Ovarian Neoplasms 22925189 "Expression of four miRNAs (miR-30c, miR-30d, miR-30e-3p, miR-370) was significantly different between carcinomas and benign ovarian tissues as well as between carcinoma and borderline tissues. An additional three miRNAs (miR-181d, miR-30a-3p, miR-532-5p) were significantly different between borderline and carcinoma tissues." +tissue_expression_ns hsa-mir-30e Ovarian Neoplasms 22925189 "Expression of four miRNAs (miR-30c, miR-30d, miR-30e-3p, miR-370) was significantly different between carcinomas and benign ovarian tissues as well as between carcinoma and borderline tissues. An additional three miRNAs (miR-181d, miR-30a-3p, miR-532-5p) were significantly different between borderline and carcinoma tissues." +tissue_expression_ns hsa-mir-370 Ovarian Neoplasms 22925189 "Expression of four miRNAs (miR-30c, miR-30d, miR-30e-3p, miR-370) was significantly different between carcinomas and benign ovarian tissues as well as between carcinoma and borderline tissues. An additional three miRNAs (miR-181d, miR-30a-3p, miR-532-5p) were significantly different between borderline and carcinoma tissues." +tissue_expression_ns hsa-mir-532 Ovarian Neoplasms 22925189 "Expression of four miRNAs (miR-30c, miR-30d, miR-30e-3p, miR-370) was significantly different between carcinomas and benign ovarian tissues as well as between carcinoma and borderline tissues. An additional three miRNAs (miR-181d, miR-30a-3p, miR-532-5p) were significantly different between borderline and carcinoma tissues." +tissue_expression_ns hsa-mir-126 Coronary Artery Disease 22925274 "MiR-126 was not significantly down-regulated or up-regulated in CAD patients. Interestingly, the level of miR-126 was significantly decreased in patients with CAD and high low-density lipoprotein (LDL) cholesterol level. In contrast, the level of miR-126 was significantly increased when LDL cholesterol was high in patients who had risk factors for CAD but did not have angiographically significant CAD." +tissue_expression_ns hsa-mir-182 "Shock, Septic" 22940033 "We confirmed expression of select miRNAs (miR-182, -199a-5p, -203, -211, -222, and -29b) using quantitative reverse transcriptase-polymerase chain reaction." +tissue_expression_ns hsa-mir-199a "Shock, Septic" 22940033 "We confirmed expression of select miRNAs (miR-182, -199a-5p, -203, -211, -222, and -29b) using quantitative reverse transcriptase-polymerase chain reaction." +tissue_expression_ns hsa-mir-203 "Shock, Septic" 22940033 "We confirmed expression of select miRNAs (miR-182, -199a-5p, -203, -211, -222, and -29b) using quantitative reverse transcriptase-polymerase chain reaction." +tissue_expression_ns hsa-mir-211 "Shock, Septic" 22940033 "We confirmed expression of select miRNAs (miR-182, -199a-5p, -203, -211, -222, and -29b) using quantitative reverse transcriptase-polymerase chain reaction." +tissue_expression_ns hsa-mir-222 "Shock, Septic" 22940033 "We confirmed expression of select miRNAs (miR-182, -199a-5p, -203, -211, -222, and -29b) using quantitative reverse transcriptase-polymerase chain reaction." +tissue_expression_ns hsa-mir-29b "Shock, Septic" 22940033 "We confirmed expression of select miRNAs (miR-182, -199a-5p, -203, -211, -222, and -29b) using quantitative reverse transcriptase-polymerase chain reaction." +tissue_expression_ns hsa-mir-145 Bladder Neoplasms 22961325 Assessment of miR-145 levels was able to distinguish bladder cancer patients from non-cancer controls +tissue_expression_ns hsa-let-7b Breast Neoplasms 22976804 "By means of RT-qPCR, we further investigated miRNA expression in more IMPC (n?=?22) and IDC-NSTs (n?=?24) FFPE samples and found let-7b, miR-30c, miR-148a, miR-181a, miR-181a*, and miR-181b were significantly differently expressed between the two groups. " +tissue_expression_ns hsa-mir-148a Breast Neoplasms 22976804 "By means of RT-qPCR, we further investigated miRNA expression in more IMPC (n?=?22) and IDC-NSTs (n?=?24) FFPE samples and found let-7b, miR-30c, miR-148a, miR-181a, miR-181a*, and miR-181b were significantly differently expressed between the two groups. " +tissue_expression_ns hsa-mir-181a Breast Neoplasms 22976804 "By means of RT-qPCR, we further investigated miRNA expression in more IMPC (n?=?22) and IDC-NSTs (n?=?24) FFPE samples and found let-7b, miR-30c, miR-148a, miR-181a, miR-181a*, and miR-181b were significantly differently expressed between the two groups. " +tissue_expression_ns hsa-mir-181b Breast Neoplasms 22976804 "By means of RT-qPCR, we further investigated miRNA expression in more IMPC (n?=?22) and IDC-NSTs (n?=?24) FFPE samples and found let-7b, miR-30c, miR-148a, miR-181a, miR-181a*, and miR-181b were significantly differently expressed between the two groups. " +tissue_expression_ns hsa-mir-30c Breast Neoplasms 22976804 "By means of RT-qPCR, we further investigated miRNA expression in more IMPC (n?=?22) and IDC-NSTs (n?=?24) FFPE samples and found let-7b, miR-30c, miR-148a, miR-181a, miR-181a*, and miR-181b were significantly differently expressed between the two groups. " +tissue_expression_ns hsa-let-7a "Carcinoma, Lung, Non-Small-Cell" 23043708 "The relative expressions of 11 miRNAs in sputum (miR-21, miR-145,miR-155, miR-205, miR-210, miR-92, miR-17-5p, miR-143, miR-182, miR-372, and let-7a) in addition to U6 were retrospectively assessed in four NSCLC-positive and four negative controls." +tissue_expression_ns hsa-mir-143 "Carcinoma, Lung, Non-Small-Cell" 23043708 "The relative expressions of 11 miRNAs in sputum (miR-21, miR-145,miR-155, miR-205, miR-210, miR-92, miR-17-5p, miR-143, miR-182, miR-372, and let-7a) in addition to U6 were retrospectively assessed in four NSCLC-positive and four negative controls." +tissue_expression_ns hsa-mir-145 "Carcinoma, Lung, Non-Small-Cell" 23043708 "The relative expressions of 11 miRNAs in sputum (miR-21, miR-145,miR-155, miR-205, miR-210, miR-92, miR-17-5p, miR-143, miR-182, miR-372, and let-7a) in addition to U6 were retrospectively assessed in four NSCLC-positive and four negative controls." +tissue_expression_ns hsa-mir-155 "Carcinoma, Lung, Non-Small-Cell" 23043708 "The relative expressions of 11 miRNAs in sputum (miR-21, miR-145,miR-155, miR-205, miR-210, miR-92, miR-17-5p, miR-143, miR-182, miR-372, and let-7a) in addition to U6 were retrospectively assessed in four NSCLC-positive and four negative controls." +tissue_expression_ns hsa-mir-17 "Carcinoma, Lung, Non-Small-Cell" 23043708 "The relative expressions of 11 miRNAs in sputum (miR-21, miR-145,miR-155, miR-205, miR-210, miR-92, miR-17-5p, miR-143, miR-182, miR-372, and let-7a) in addition to U6 were retrospectively assessed in four NSCLC-positive and four negative controls." +tissue_expression_ns hsa-mir-182 "Carcinoma, Lung, Non-Small-Cell" 23043708 "The relative expressions of 11 miRNAs in sputum (miR-21, miR-145,miR-155, miR-205, miR-210, miR-92, miR-17-5p, miR-143, miR-182, miR-372, and let-7a) in addition to U6 were retrospectively assessed in four NSCLC-positive and four negative controls." +tissue_expression_ns hsa-mir-205 "Carcinoma, Lung, Non-Small-Cell" 23043708 "The relative expressions of 11 miRNAs in sputum (miR-21, miR-145,miR-155, miR-205, miR-210, miR-92, miR-17-5p, miR-143, miR-182, miR-372, and let-7a) in addition to U6 were retrospectively assessed in four NSCLC-positive and four negative controls." +tissue_expression_ns hsa-mir-21 "Carcinoma, Lung, Non-Small-Cell" 23043708 "The relative expressions of 11 miRNAs in sputum (miR-21, miR-145,miR-155, miR-205, miR-210, miR-92, miR-17-5p, miR-143, miR-182, miR-372, and let-7a) in addition to U6 were retrospectively assessed in four NSCLC-positive and four negative controls." +tissue_expression_ns hsa-mir-210 "Carcinoma, Lung, Non-Small-Cell" 23043708 "The relative expressions of 11 miRNAs in sputum (miR-21, miR-145,miR-155, miR-205, miR-210, miR-92, miR-17-5p, miR-143, miR-182, miR-372, and let-7a) in addition to U6 were retrospectively assessed in four NSCLC-positive and four negative controls." +tissue_expression_ns hsa-mir-372 "Carcinoma, Lung, Non-Small-Cell" 23043708 "The relative expressions of 11 miRNAs in sputum (miR-21, miR-145,miR-155, miR-205, miR-210, miR-92, miR-17-5p, miR-143, miR-182, miR-372, and let-7a) in addition to U6 were retrospectively assessed in four NSCLC-positive and four negative controls." +tissue_expression_ns hsa-mir-92 "Carcinoma, Lung, Non-Small-Cell" 23043708 "The relative expressions of 11 miRNAs in sputum (miR-21, miR-145,miR-155, miR-205, miR-210, miR-92, miR-17-5p, miR-143, miR-182, miR-372, and let-7a) in addition to U6 were retrospectively assessed in four NSCLC-positive and four negative controls." +tissue_expression_ns hsa-mir-183 "Carcinoma, Thyroid, Medullary" 23072640 "This further validates previously reported miRNA profile analyses and reiterates the potential significance of miR-9*, -183 and -375 in the pathophysiology of MTC." +tissue_expression_ns hsa-mir-375 "Carcinoma, Thyroid, Medullary" 23072640 "This further validates previously reported miRNA profile analyses and reiterates the potential significance of miR-9*, -183 and -375 in the pathophysiology of MTC." +tissue_expression_ns hsa-mir-9 "Carcinoma, Thyroid, Medullary" 23072640 "This further validates previously reported miRNA profile analyses and reiterates the potential significance of miR-9*, -183 and -375 in the pathophysiology of MTC." +tissue_expression_ns hsa-mir-200a "Carcinoma, Renal Cell" 23074016 The entire miR-200 seed family is strongly deregulated in clear cell renal cell cancer compared to the proximal tubular epithelial cells of the kidney +tissue_expression_ns hsa-mir-200b "Carcinoma, Renal Cell" 23074016 The entire miR-200 seed family is strongly deregulated in clear cell renal cell cancer compared to the proximal tubular epithelial cells of the kidney +tissue_expression_ns hsa-mir-200c "Carcinoma, Renal Cell" 23074016 The entire miR-200 seed family is strongly deregulated in clear cell renal cell cancer compared to the proximal tubular epithelial cells of the kidney +tissue_expression_ns hsa-mir-196a "Squamous Cell Carcinoma, Lung" 23074073 "Validation of selected microRNAs by in situ hybridization demonstrated strong expression of hsa-miR-196a in the inner tumor; moderate expression of hsa-miR-224 in the inner tumor and tumor front, and strong expression of hsa-miR-650 in the adjacent lung tissue." +tissue_expression_ns hsa-mir-224 "Squamous Cell Carcinoma, Lung" 23074073 "Validation of selected microRNAs by in situ hybridization demonstrated strong expression of hsa-miR-196a in the inner tumor; moderate expression of hsa-miR-224 in the inner tumor and tumor front, and strong expression of hsa-miR-650 in the adjacent lung tissue." +tissue_expression_ns hsa-mir-650 "Squamous Cell Carcinoma, Lung" 23074073 "Validation of selected microRNAs by in situ hybridization demonstrated strong expression of hsa-miR-196a in the inner tumor; moderate expression of hsa-miR-224 in the inner tumor and tumor front, and strong expression of hsa-miR-650 in the adjacent lung tissue." +tissue_expression_ns hsa-mir-16 Preeclampsia 23083510 "Together, these data suggest that the alteration of miR-16 expression in decidua-derived mesenchymal stem cells may be involved in the development of pre-eclampsia." +tissue_expression_ns hsa-mir-143 Esophageal Neoplasms 23092342 "There are several microRNAs that have been consistently reported to be differentially expressed in esophageal squamous cell carcinoma vs. normal squamous tissue, with prognostic associations for miR-21 (invasion, positive nodes, decreased survival), miR-143 (disease recurrence, invasion depth), and miR-375 (inversely correlated with advanced stage, distant metastasis, poor overall survival, and disease-free survival)." +tissue_expression_ns hsa-mir-21 Esophageal Neoplasms 23092342 "There are several microRNAs that have been consistently reported to be differentially expressed in esophageal squamous cell carcinoma vs. normal squamous tissue, with prognostic associations for miR-21 (invasion, positive nodes, decreased survival), miR-143 (disease recurrence, invasion depth), and miR-375 (inversely correlated with advanced stage, distant metastasis, poor overall survival, and disease-free survival)." +tissue_expression_ns hsa-mir-375 Esophageal Neoplasms 23092342 "There are several microRNAs that have been consistently reported to be differentially expressed in esophageal squamous cell carcinoma vs. normal squamous tissue, with prognostic associations for miR-21 (invasion, positive nodes, decreased survival), miR-143 (disease recurrence, invasion depth), and miR-375 (inversely correlated with advanced stage, distant metastasis, poor overall survival, and disease-free survival)." +tissue_expression_ns hsa-mir-210 "Carcinoma, Renal Cell" 23150176 MiR-210 expression in tumor tissue and in vitro effects of its silencing in renal cell carcinoma +tissue_expression_ns hsa-mir-155 Breast Neoplasms 23162645 miR-155 and miR-31 are differentially expressed in breast cancer patients and are correlated with the estrogen receptor and progesterone receptor status +tissue_expression_ns hsa-mir-31 Breast Neoplasms 23162645 miR-155 and miR-31 are differentially expressed in breast cancer patients and are correlated with the estrogen receptor and progesterone receptor status +tissue_expression_ns hsa-mir-146b "Squamous Cell Carcinoma, Esophageal" 23175214 "The expression levels of miR-21 (p = 0.027), miR-181b (p = 0.002) and miR-146b (p = 0.021) in tumor tissue and miR-21 (p = 0.003) in noncancerous tissue were associated with overall survival of patients. " +tissue_expression_ns hsa-mir-181b "Squamous Cell Carcinoma, Esophageal" 23175214 "The expression levels of miR-21 (p = 0.027), miR-181b (p = 0.002) and miR-146b (p = 0.021) in tumor tissue and miR-21 (p = 0.003) in noncancerous tissue were associated with overall survival of patients. " +tissue_expression_ns hsa-mir-21 "Squamous Cell Carcinoma, Esophageal" 23175214 "The expression levels of miR-21 (p = 0.027), miR-181b (p = 0.002) and miR-146b (p = 0.021) in tumor tissue and miR-21 (p = 0.003) in noncancerous tissue were associated with overall survival of patients. " +tissue_expression_ns hsa-mir-182 Prostate Neoplasms 23184537 Expression of MicroRNAs associated with Gleason grading system in prostate cancer: miR-182-5p is a useful marker for high grade prostate cancer +tissue_expression_ns hsa-mir-24-1 "Carcinoma, Hepatocellular" 23229173 Human hepatocellular carcinoma cell-specific miRNAs reveal the differential expression of miR-24 and miR-27a in cirrhotic/non-cirrhotic HCC +tissue_expression_ns hsa-mir-24-2 "Carcinoma, Hepatocellular" 23229173 Human hepatocellular carcinoma cell-specific miRNAs reveal the differential expression of miR-24 and miR-27a in cirrhotic/non-cirrhotic HCC +tissue_expression_ns hsa-mir-27a "Carcinoma, Hepatocellular" 23229173 Human hepatocellular carcinoma cell-specific miRNAs reveal the differential expression of miR-24 and miR-27a in cirrhotic/non-cirrhotic HCC +tissue_expression_ns hsa-mir-21 Laryngeal Neoplasms 23259291 Expression of mir-21 and mir-375 in laryngeal squamous cell carcinoma +tissue_expression_ns hsa-mir-375 Laryngeal Neoplasms 23259291 Expression of mir-21 and mir-375 in laryngeal squamous cell carcinoma +tissue_expression_ns hsa-mir-124 Mesial Temporal Lobe Epilepsy 23315173 "Expression patterns of miR-124, miR-134, miR-132, and miR-21 in an immature rat model and children with mesial temporal lobe epilepsy." +tissue_expression_ns hsa-mir-132 Mesial Temporal Lobe Epilepsy 23315173 "Expression patterns of miR-124, miR-134, miR-132, and miR-21 in an immature rat model and children with mesial temporal lobe epilepsy." +tissue_expression_ns hsa-mir-134 Mesial Temporal Lobe Epilepsy 23315173 "Expression patterns of miR-124, miR-134, miR-132, and miR-21 in an immature rat model and children with mesial temporal lobe epilepsy." +tissue_expression_ns hsa-mir-21 Mesial Temporal Lobe Epilepsy 23315173 "Expression patterns of miR-124, miR-134, miR-132, and miR-21 in an immature rat model and children with mesial temporal lobe epilepsy." +tissue_expression_ns hsa-mir-150 Myeloproliferative Neoplasms 23343777 "An aberrant expression of miRNAs 10a and 150 could be demonstrated for essential thrombocythemia and PMF as well as for polycythemia vera and PMF, respectively. The expression of miR-150 could further be shown to correlate with both JAK2 allele burden and peripheral blood counts." +tissue_expression_ns hsa-mir-31 Immune System Disease [unspecific] 23352895 "Bantam, miR-276*, miR-10, miR-31 and miR-184 were detected as five most abundant miRNAs in both libraries and 96 miRNAs were identified that were differentially expressed after parasitization." +tissue_expression_ns hsa-let-7a Lung Neoplasms 23365639 "Specifically, let-7 and miR-9 are deregulated in both lung cancers and other solid malignancies." +tissue_expression_ns hsa-mir-9 Lung Neoplasms 23365639 "Specifically, let-7 and miR-9 are deregulated in both lung cancers and other solid malignancies." +tissue_expression_ns hsa-let-7a Melanoma 23377970 "Detailed studies of different groups thereafter identified miRNAs with differential expression in benign melanocytes compared with melanoma cell lines or in benign melanocytic lesions compared with melanomas. Among these were let-7a and b, miR-23a and b, miR-148, miR-155, miR-182, miR-200c, miR-211, miR214, and miR-221 and 222." +tissue_expression_ns hsa-let-7b Melanoma 23377970 "Detailed studies of different groups thereafter identified miRNAs with differential expression in benign melanocytes compared with melanoma cell lines or in benign melanocytic lesions compared with melanomas. Among these were let-7a and b, miR-23a and b, miR-148, miR-155, miR-182, miR-200c, miR-211, miR214, and miR-221 and 222." +tissue_expression_ns hsa-mir-148 Melanoma 23377970 "Detailed studies of different groups thereafter identified miRNAs with differential expression in benign melanocytes compared with melanoma cell lines or in benign melanocytic lesions compared with melanomas. Among these were let-7a and b, miR-23a and b, miR-148, miR-155, miR-182, miR-200c, miR-211, miR214, and miR-221 and 222." +tissue_expression_ns hsa-mir-155 Melanoma 23377970 "Detailed studies of different groups thereafter identified miRNAs with differential expression in benign melanocytes compared with melanoma cell lines or in benign melanocytic lesions compared with melanomas. Among these were let-7a and b, miR-23a and b, miR-148, miR-155, miR-182, miR-200c, miR-211, miR214, and miR-221 and 222." +tissue_expression_ns hsa-mir-182 Melanoma 23377970 "Detailed studies of different groups thereafter identified miRNAs with differential expression in benign melanocytes compared with melanoma cell lines or in benign melanocytic lesions compared with melanomas. Among these were let-7a and b, miR-23a and b, miR-148, miR-155, miR-182, miR-200c, miR-211, miR214, and miR-221 and 222." +tissue_expression_ns hsa-mir-200c Melanoma 23377970 "Detailed studies of different groups thereafter identified miRNAs with differential expression in benign melanocytes compared with melanoma cell lines or in benign melanocytic lesions compared with melanomas. Among these were let-7a and b, miR-23a and b, miR-148, miR-155, miR-182, miR-200c, miR-211, miR214, and miR-221 and 222." +tissue_expression_ns hsa-mir-211 Melanoma 23377970 "Detailed studies of different groups thereafter identified miRNAs with differential expression in benign melanocytes compared with melanoma cell lines or in benign melanocytic lesions compared with melanomas. Among these were let-7a and b, miR-23a and b, miR-148, miR-155, miR-182, miR-200c, miR-211, miR214, and miR-221 and 222." +tissue_expression_ns hsa-mir-214 Melanoma 23377970 "Detailed studies of different groups thereafter identified miRNAs with differential expression in benign melanocytes compared with melanoma cell lines or in benign melanocytic lesions compared with melanomas. Among these were let-7a and b, miR-23a and b, miR-148, miR-155, miR-182, miR-200c, miR-211, miR214, and miR-221 and 222." +tissue_expression_ns hsa-mir-221 Melanoma 23377970 "Detailed studies of different groups thereafter identified miRNAs with differential expression in benign melanocytes compared with melanoma cell lines or in benign melanocytic lesions compared with melanomas. Among these were let-7a and b, miR-23a and b, miR-148, miR-155, miR-182, miR-200c, miR-211, miR214, and miR-221 and 222." +tissue_expression_ns hsa-mir-222 Melanoma 23377970 "Detailed studies of different groups thereafter identified miRNAs with differential expression in benign melanocytes compared with melanoma cell lines or in benign melanocytic lesions compared with melanomas. Among these were let-7a and b, miR-23a and b, miR-148, miR-155, miR-182, miR-200c, miR-211, miR214, and miR-221 and 222." +tissue_expression_ns hsa-mir-23a Melanoma 23377970 "Detailed studies of different groups thereafter identified miRNAs with differential expression in benign melanocytes compared with melanoma cell lines or in benign melanocytic lesions compared with melanomas. Among these were let-7a and b, miR-23a and b, miR-148, miR-155, miR-182, miR-200c, miR-211, miR214, and miR-221 and 222." +tissue_expression_ns hsa-mir-23b Melanoma 23377970 "Detailed studies of different groups thereafter identified miRNAs with differential expression in benign melanocytes compared with melanoma cell lines or in benign melanocytic lesions compared with melanomas. Among these were let-7a and b, miR-23a and b, miR-148, miR-155, miR-182, miR-200c, miR-211, miR214, and miR-221 and 222." +tissue_expression_ns hsa-mir-103 "Diabetes Mellitus, Type 2" 23389544 "The deregulation of miRNAs miR-143 (ref. 4), miR-181 (ref. 5), and miR-103 and miR-107 (ref. 6) alters hepatic insulin sensitivity." +tissue_expression_ns hsa-mir-107 "Diabetes Mellitus, Type 2" 23389544 "The deregulation of miRNAs miR-143 (ref. 4), miR-181 (ref. 5), and miR-103 and miR-107 (ref. 6) alters hepatic insulin sensitivity." +tissue_expression_ns hsa-mir-143 "Diabetes Mellitus, Type 2" 23389544 "The deregulation of miRNAs miR-143 (ref. 4), miR-181 (ref. 5), and miR-103 and miR-107 (ref. 6) alters hepatic insulin sensitivity." +tissue_expression_ns hsa-mir-181 "Diabetes Mellitus, Type 2" 23389544 "The deregulation of miRNAs miR-143 (ref. 4), miR-181 (ref. 5), and miR-103 and miR-107 (ref. 6) alters hepatic insulin sensitivity." +tissue_expression_ns hsa-mir-181-2 "Carcinoma, Thyroid, Papillary" 23427895 "Fourteen miRNAs were deregulated in FVPTC with a fold change of more than five (up/down), including miRNAs known to be upregulated in PTC (miR-146b-3p, -146-5p, -221, -222 and miR-222-5p) and novel miRNAs (miR-375, -551b, 181-2-3p, 99b-3p)." +tissue_expression_ns hsa-mir-375 "Carcinoma, Thyroid, Papillary" 23427895 "Fourteen miRNAs were deregulated in FVPTC with a fold change of more than five (up/down), including miRNAs known to be upregulated in PTC (miR-146b-3p, -146-5p, -221, -222 and miR-222-5p) and novel miRNAs (miR-375, -551b, 181-2-3p, 99b-3p)." +tissue_expression_ns hsa-mir-551b "Carcinoma, Thyroid, Papillary" 23427895 "Fourteen miRNAs were deregulated in FVPTC with a fold change of more than five (up/down), including miRNAs known to be upregulated in PTC (miR-146b-3p, -146-5p, -221, -222 and miR-222-5p) and novel miRNAs (miR-375, -551b, 181-2-3p, 99b-3p)." +tissue_expression_ns hsa-mir-99b "Carcinoma, Thyroid, Papillary" 23427895 "Fourteen miRNAs were deregulated in FVPTC with a fold change of more than five (up/down), including miRNAs known to be upregulated in PTC (miR-146b-3p, -146-5p, -221, -222 and miR-222-5p) and novel miRNAs (miR-375, -551b, 181-2-3p, 99b-3p)." +tissue_expression_ns hsa-mir-146b Gastrointestinal Neoplasms 23456798 "The deregulation of miR-146b-5p, miR-375, miR-148a, miR-31, and miR-451 was associated significantly with gastric adenocarcinomas." +tissue_expression_ns hsa-mir-148a Gastrointestinal Neoplasms 23456798 "The deregulation of miR-146b-5p, miR-375, miR-148a, miR-31, and miR-451 was associated significantly with gastric adenocarcinomas." +tissue_expression_ns hsa-mir-31 Gastrointestinal Neoplasms 23456798 "The deregulation of miR-146b-5p, miR-375, miR-148a, miR-31, and miR-451 was associated significantly with gastric adenocarcinomas." +tissue_expression_ns hsa-mir-375 Gastrointestinal Neoplasms 23456798 "The deregulation of miR-146b-5p, miR-375, miR-148a, miR-31, and miR-451 was associated significantly with gastric adenocarcinomas." +tissue_expression_ns hsa-mir-451 Gastrointestinal Neoplasms 23456798 "The deregulation of miR-146b-5p, miR-375, miR-148a, miR-31, and miR-451 was associated significantly with gastric adenocarcinomas." +tissue_expression_ns hsa-mir-126 Cholangiocarcinoma 23458262 Concomitant dysregulation of microRNAs miR-151-3p and miR-126 correlates with improved survival in resected cholangiocarcinoma +tissue_expression_ns hsa-mir-151 Cholangiocarcinoma 23458262 Concomitant dysregulation of microRNAs miR-151-3p and miR-126 correlates with improved survival in resected cholangiocarcinoma +tissue_expression_ns hsa-mir-302b Ovarian Neoplasms 23484053 hsa-miR-302b expression was significantly associated with time to relapse or overall survival in two data sets of platinum-treated ovarian cancer patients. +tissue_expression_ns hsa-mir-1303 "Carcinoma, Breast" 23526361 "Among these, a 5-miRNA signature comprising miR-421, miR-486, miR-503, miR-720 and miR-1303 was shown to be predictive for IBC phenotype with an overall accuracy of 89%. " +tissue_expression_ns hsa-mir-421 "Carcinoma, Breast" 23526361 "Among these, a 5-miRNA signature comprising miR-421, miR-486, miR-503, miR-720 and miR-1303 was shown to be predictive for IBC phenotype with an overall accuracy of 89%. " +tissue_expression_ns hsa-mir-486 "Carcinoma, Breast" 23526361 "Among these, a 5-miRNA signature comprising miR-421, miR-486, miR-503, miR-720 and miR-1303 was shown to be predictive for IBC phenotype with an overall accuracy of 89%. " +tissue_expression_ns hsa-mir-503 "Carcinoma, Breast" 23526361 "Among these, a 5-miRNA signature comprising miR-421, miR-486, miR-503, miR-720 and miR-1303 was shown to be predictive for IBC phenotype with an overall accuracy of 89%. " +tissue_expression_ns hsa-mir-720 "Carcinoma, Breast" 23526361 "Among these, a 5-miRNA signature comprising miR-421, miR-486, miR-503, miR-720 and miR-1303 was shown to be predictive for IBC phenotype with an overall accuracy of 89%. " +tissue_expression_ns hsa-mir-21 Viral Myocarditis 23544605 Myocardial miR-21 expression was negatively related to viral myocarditis severity. +tissue_expression_ns hsa-mir-135b Colorectal Carcinoma 23568010 "our results are contradictory to previous studies performed on the CRC patients from Chinese population, providing an evidence against usage of serum miR-17-3p, miR-29a, miR-92a and miR-135b as new biomarkers for early detection of CRC" +tissue_expression_ns hsa-mir-17 Colorectal Carcinoma 23568010 "our results are contradictory to previous studies performed on the CRC patients from Chinese population, providing an evidence against usage of serum miR-17-3p, miR-29a, miR-92a and miR-135b as new biomarkers for early detection of CRC" +tissue_expression_ns hsa-mir-29a Colorectal Carcinoma 23568010 "our results are contradictory to previous studies performed on the CRC patients from Chinese population, providing an evidence against usage of serum miR-17-3p, miR-29a, miR-92a and miR-135b as new biomarkers for early detection of CRC" +tissue_expression_ns hsa-mir-92a Colorectal Carcinoma 23568010 "our results are contradictory to previous studies performed on the CRC patients from Chinese population, providing an evidence against usage of serum miR-17-3p, miR-29a, miR-92a and miR-135b as new biomarkers for early detection of CRC" +tissue_expression_ns hsa-mir-221 Ovarian Neoplasms 23569131 Prognostic significance of serum microRNA-221 expression in human epithelial ovarian cancer +tissue_expression_ns hsa-mir-192 "Adenocarcinoma, Pancreatic Ductal" 23612862 miRNA expression profiling of human PDACs and adjacent normal pancreatic tissues identified 16 upregulated miRNAs including miR-192 and 8 downregulated miRNAs. +tissue_expression_ns hsa-mir-100 Prostate Neoplasms 23621234 "In conclusion, expression changes in miRNAs of miR-146a, miR-100, miR-425, miR-193a-3p and, miR-106b in metformin-treated cells may be important." +tissue_expression_ns hsa-mir-106b Prostate Neoplasms 23621234 "In conclusion, expression changes in miRNAs of miR-146a, miR-100, miR-425, miR-193a-3p and, miR-106b in metformin-treated cells may be important." +tissue_expression_ns hsa-mir-146a Prostate Neoplasms 23621234 "In conclusion, expression changes in miRNAs of miR-146a, miR-100, miR-425, miR-193a-3p and, miR-106b in metformin-treated cells may be important." +tissue_expression_ns hsa-mir-193a Prostate Neoplasms 23621234 "In conclusion, expression changes in miRNAs of miR-146a, miR-100, miR-425, miR-193a-3p and, miR-106b in metformin-treated cells may be important." +tissue_expression_ns hsa-mir-425 Prostate Neoplasms 23621234 "In conclusion, expression changes in miRNAs of miR-146a, miR-100, miR-425, miR-193a-3p and, miR-106b in metformin-treated cells may be important." +tissue_expression_ns hsa-mir-141 "Carcinoma, Renal Cell" 23635949 "Our recent studies of microRNA (miRNA) expression signatures demonstrated that the epithelial-mesenchymal transition (EMT)-related microRNA-200 family (miR-200s: miR-200a/b/c, miR-141 and miR-429) were significantly downregulated in renal cell carcinoma (RCC) and putative tumor-suppressive miRNAs in RCC." +tissue_expression_ns hsa-mir-200a "Carcinoma, Renal Cell" 23635949 "Our recent studies of microRNA (miRNA) expression signatures demonstrated that the epithelial-mesenchymal transition (EMT)-related microRNA-200 family (miR-200s: miR-200a/b/c, miR-141 and miR-429) were significantly downregulated in renal cell carcinoma (RCC) and putative tumor-suppressive miRNAs in RCC." +tissue_expression_ns hsa-mir-200b "Carcinoma, Renal Cell" 23635949 "Our recent studies of microRNA (miRNA) expression signatures demonstrated that the epithelial-mesenchymal transition (EMT)-related microRNA-200 family (miR-200s: miR-200a/b/c, miR-141 and miR-429) were significantly downregulated in renal cell carcinoma (RCC) and putative tumor-suppressive miRNAs in RCC." +tissue_expression_ns hsa-mir-200c "Carcinoma, Renal Cell" 23635949 "Our recent studies of microRNA (miRNA) expression signatures demonstrated that the epithelial-mesenchymal transition (EMT)-related microRNA-200 family (miR-200s: miR-200a/b/c, miR-141 and miR-429) were significantly downregulated in renal cell carcinoma (RCC) and putative tumor-suppressive miRNAs in RCC." +tissue_expression_ns hsa-mir-429 "Carcinoma, Renal Cell" 23635949 "Our recent studies of microRNA (miRNA) expression signatures demonstrated that the epithelial-mesenchymal transition (EMT)-related microRNA-200 family (miR-200s: miR-200a/b/c, miR-141 and miR-429) were significantly downregulated in renal cell carcinoma (RCC) and putative tumor-suppressive miRNAs in RCC." +tissue_expression_ns hsa-mir-1 "Carcinoma, Skin" 23646287 "Differential expression of miR-1, a putative tumor suppressing microRNA, in cancer resistant and cancer susceptible mice." +tissue_expression_ns hsa-mir-106b Colorectal Carcinoma 23690963 "Nine of the twelve miRNAs (miR-18a, -20a, -21, -29a, -92a, -106b, -133a, -143, -145) were found to be differentially expressed in CRC patients and controls in the validation samples." +tissue_expression_ns hsa-mir-133a Colorectal Carcinoma 23690963 "Nine of the twelve miRNAs (miR-18a, -20a, -21, -29a, -92a, -106b, -133a, -143, -145) were found to be differentially expressed in CRC patients and controls in the validation samples." +tissue_expression_ns hsa-mir-143 Colorectal Carcinoma 23690963 "Nine of the twelve miRNAs (miR-18a, -20a, -21, -29a, -92a, -106b, -133a, -143, -145) were found to be differentially expressed in CRC patients and controls in the validation samples." +tissue_expression_ns hsa-mir-145 Colorectal Carcinoma 23690963 "Nine of the twelve miRNAs (miR-18a, -20a, -21, -29a, -92a, -106b, -133a, -143, -145) were found to be differentially expressed in CRC patients and controls in the validation samples." +tissue_expression_ns hsa-mir-18a Colorectal Carcinoma 23690963 "Nine of the twelve miRNAs (miR-18a, -20a, -21, -29a, -92a, -106b, -133a, -143, -145) were found to be differentially expressed in CRC patients and controls in the validation samples." +tissue_expression_ns hsa-mir-20a Colorectal Carcinoma 23690963 "Nine of the twelve miRNAs (miR-18a, -20a, -21, -29a, -92a, -106b, -133a, -143, -145) were found to be differentially expressed in CRC patients and controls in the validation samples." +tissue_expression_ns hsa-mir-21 Colorectal Carcinoma 23690963 "Nine of the twelve miRNAs (miR-18a, -20a, -21, -29a, -92a, -106b, -133a, -143, -145) were found to be differentially expressed in CRC patients and controls in the validation samples." +tissue_expression_ns hsa-mir-29a Colorectal Carcinoma 23690963 "Nine of the twelve miRNAs (miR-18a, -20a, -21, -29a, -92a, -106b, -133a, -143, -145) were found to be differentially expressed in CRC patients and controls in the validation samples." +tissue_expression_ns hsa-mir-92a Colorectal Carcinoma 23690963 "Nine of the twelve miRNAs (miR-18a, -20a, -21, -29a, -92a, -106b, -133a, -143, -145) were found to be differentially expressed in CRC patients and controls in the validation samples." +tissue_expression_ns hsa-mir-147b Neuroblastoma 23724168 "Numerous miRNAs were detected by microarrays to be regulated by the combined lithium and valproic acid treatment, and the following candidates were confirmed using real-time PCR: miR-34a, miR-147b, miR-182,miR-222, miR-495, and miR-690. " +tissue_expression_ns hsa-mir-182 Neuroblastoma 23724168 "Numerous miRNAs were detected by microarrays to be regulated by the combined lithium and valproic acid treatment, and the following candidates were confirmed using real-time PCR: miR-34a, miR-147b, miR-182,miR-222, miR-495, and miR-690. " +tissue_expression_ns hsa-mir-222 Neuroblastoma 23724168 "Numerous miRNAs were detected by microarrays to be regulated by the combined lithium and valproic acid treatment, and the following candidates were confirmed using real-time PCR: miR-34a, miR-147b, miR-182,miR-222, miR-495, and miR-690. " +tissue_expression_ns hsa-mir-34a Neuroblastoma 23724168 "Numerous miRNAs were detected by microarrays to be regulated by the combined lithium and valproic acid treatment, and the following candidates were confirmed using real-time PCR: miR-34a, miR-147b, miR-182,miR-222, miR-495, and miR-690. " +tissue_expression_ns hsa-mir-496 Neuroblastoma 23724168 "Numerous miRNAs were detected by microarrays to be regulated by the combined lithium and valproic acid treatment, and the following candidates were confirmed using real-time PCR: miR-34a, miR-147b, miR-182,miR-222, miR-495, and miR-690. " +tissue_expression_ns hsa-mir-690 Neuroblastoma 23724168 "Numerous miRNAs were detected by microarrays to be regulated by the combined lithium and valproic acid treatment, and the following candidates were confirmed using real-time PCR: miR-34a, miR-147b, miR-182,miR-222, miR-495, and miR-690. " +tissue_expression_ns hsa-mir-146a Urinary Bladder Cancer 23749909 altered expression +tissue_expression_ns hsa-mir-155 Urinary Bladder Cancer 23749909 altered expression +tissue_expression_ns hsa-mir-196a-1 Urinary Bladder Cancer 23749909 altered expression +tissue_expression_ns hsa-mir-196a-2 Urinary Bladder Cancer 23749909 altered expression +tissue_expression_ns hsa-mir-203 Urinary Bladder Cancer 23749909 altered expression +tissue_expression_ns hsa-mir-21 Urinary Bladder Cancer 23749909 altered expression +tissue_expression_ns hsa-mir-221 Urinary Bladder Cancer 23749909 altered expression +tissue_expression_ns hsa-mir-27a Urinary Bladder Cancer 23749909 altered expression +tissue_expression_ns hsa-mir-34a Urinary Bladder Cancer 23749909 altered expression +tissue_expression_ns hsa-mir-205 "Carcinoma, Lung, Non-Small-Cell" 23759980 Identification of microRNAs differentially expressed between lung squamous cell carcinoma and lung adenocarcinoma. +tissue_expression_ns hsa-mir-182 Neoplasms [unspecific] 23791657 Meta-analysis of microRNA-183 family expression in human cancer studies comparing cancer tissues with noncancerous tissues. +tissue_expression_ns hsa-mir-183 Neoplasms [unspecific] 23791657 Meta-analysis of microRNA-183 family expression in human cancer studies comparing cancer tissues with noncancerous tissues. +tissue_expression_ns hsa-mir-96 Neoplasms [unspecific] 23791657 Meta-analysis of microRNA-183 family expression in human cancer studies comparing cancer tissues with noncancerous tissues. +tissue_expression_ns hsa-mir-1 Breast Neoplasms 23797906 "The clinical use of miRNA signatures as a noninvasive diagnostic strategy is promising, but should be further validated for different subtypes of breast cancers." +tissue_expression_ns hsa-mir-133a Breast Neoplasms 23797906 "The clinical use of miRNA signatures as a noninvasive diagnostic strategy is promising, but should be further validated for different subtypes of breast cancers." +tissue_expression_ns hsa-mir-133b Breast Neoplasms 23797906 "The clinical use of miRNA signatures as a noninvasive diagnostic strategy is promising, but should be further validated for different subtypes of breast cancers." +tissue_expression_ns hsa-mir-92a Breast Neoplasms 23797906 "The clinical use of miRNA signatures as a noninvasive diagnostic strategy is promising, but should be further validated for different subtypes of breast cancers." +tissue_expression_ns hsa-let-7c "Carcinoma, Renal Cell" 23799849 "MicroRNAs are able to accurately classify RCC samples. Deregulated miRNAs might contribute to the high chemotherapy resistance of RCC. Furthermore, our results indicate that pRCC type 2 tumours could be dependent on oncogenic MYC signalling." +tissue_expression_ns hsa-mir-145 "Carcinoma, Renal Cell" 23799849 "MicroRNAs are able to accurately classify RCC samples. Deregulated miRNAs might contribute to the high chemotherapy resistance of RCC. Furthermore, our results indicate that pRCC type 2 tumours could be dependent on oncogenic MYC signalling." +tissue_expression_ns hsa-mir-200c "Carcinoma, Renal Cell" 23799849 "MicroRNAs are able to accurately classify RCC samples. Deregulated miRNAs might contribute to the high chemotherapy resistance of RCC. Furthermore, our results indicate that pRCC type 2 tumours could be dependent on oncogenic MYC signalling." +tissue_expression_ns hsa-mir-210 "Carcinoma, Renal Cell" 23799849 "MicroRNAs are able to accurately classify RCC samples. Deregulated miRNAs might contribute to the high chemotherapy resistance of RCC. Furthermore, our results indicate that pRCC type 2 tumours could be dependent on oncogenic MYC signalling." +tissue_expression_ns hsa-mir-502 "Carcinoma, Renal Cell" 23799849 "MicroRNAs are able to accurately classify RCC samples. Deregulated miRNAs might contribute to the high chemotherapy resistance of RCC. Furthermore, our results indicate that pRCC type 2 tumours could be dependent on oncogenic MYC signalling." +tissue_expression_ns hsa-mir-135b "Lymphoma, Large B-Cell" 23801630 MicroRNA expression profiling identifies molecular signatures associated with anaplastic large cell lymphoma. +tissue_expression_ns hsa-mir-146a "Lymphoma, Large B-Cell" 23801630 MicroRNA expression profiling identifies molecular signatures associated with anaplastic large cell lymphoma. +tissue_expression_ns hsa-mir-155 "Lymphoma, Large B-Cell" 23801630 MicroRNA expression profiling identifies molecular signatures associated with anaplastic large cell lymphoma. +tissue_expression_ns hsa-mir-512 "Lymphoma, Large B-Cell" 23801630 MicroRNA expression profiling identifies molecular signatures associated with anaplastic large cell lymphoma. +tissue_expression_ns hsa-mir-708 "Lymphoma, Large B-Cell" 23801630 MicroRNA expression profiling identifies molecular signatures associated with anaplastic large cell lymphoma. +tissue_expression_ns hsa-mir-886 "Lymphoma, Large B-Cell" 23801630 MicroRNA expression profiling identifies molecular signatures associated with anaplastic large cell lymphoma. +tissue_expression_ns hsa-mir-219 Obesity 23817051 "the miRNA profile is altered in amnion during obesity and hypothesize that this could affect pathways important for placental growth and function, thereby contributing to an increase in the newborn's risk of future metabolic diseases." +tissue_expression_ns hsa-mir-422b Obesity 23817051 "the miRNA profile is altered in amnion during obesity and hypothesize that this could affect pathways important for placental growth and function, thereby contributing to an increase in the newborn's risk of future metabolic diseases." +tissue_expression_ns hsa-mir-523 Obesity 23817051 "the miRNA profile is altered in amnion during obesity and hypothesize that this could affect pathways important for placental growth and function, thereby contributing to an increase in the newborn's risk of future metabolic diseases." +tissue_expression_ns hsa-mir-575 Obesity 23817051 "the miRNA profile is altered in amnion during obesity and hypothesize that this could affect pathways important for placental growth and function, thereby contributing to an increase in the newborn's risk of future metabolic diseases." +tissue_expression_ns hsa-mir-579 Obesity 23817051 "the miRNA profile is altered in amnion during obesity and hypothesize that this could affect pathways important for placental growth and function, thereby contributing to an increase in the newborn's risk of future metabolic diseases." +tissue_expression_ns hsa-mir-618 Obesity 23817051 "the miRNA profile is altered in amnion during obesity and hypothesize that this could affect pathways important for placental growth and function, thereby contributing to an increase in the newborn's risk of future metabolic diseases." +tissue_expression_ns hsa-mir-659 Obesity 23817051 "the miRNA profile is altered in amnion during obesity and hypothesize that this could affect pathways important for placental growth and function, thereby contributing to an increase in the newborn's risk of future metabolic diseases." +tissue_expression_ns hsa-mir-378 Liver Diseases [unspecific] 23818290 Dietary fisetin protects against hepatosteatosis in association with modulation of lipid metabolism genes and miR-378 in mice +tissue_expression_ns hsa-mir-149 Chordoma 23826111 "This study provides an integrated dataset of the miRNA and mRNA profiles in chordomas, and the results demonstrate that not only the MAPK pathway and its related miRNAs but also the Notch pathway may be involved in chordoma development. The occurrence of chordoma may be associated with dysfunctional calcification or ossification of the notochord." +tissue_expression_ns hsa-mir-1908 Chordoma 23826111 "This study provides an integrated dataset of the miRNA and mRNA profiles in chordomas, and the results demonstrate that not only the MAPK pathway and its related miRNAs but also the Notch pathway may be involved in chordoma development. The occurrence of chordoma may be associated with dysfunctional calcification or ossification of the notochord." +tissue_expression_ns hsa-mir-2861 Chordoma 23826111 "This study provides an integrated dataset of the miRNA and mRNA profiles in chordomas, and the results demonstrate that not only the MAPK pathway and its related miRNAs but also the Notch pathway may be involved in chordoma development. The occurrence of chordoma may be associated with dysfunctional calcification or ossification of the notochord." +tissue_expression_ns hsa-mir-3185 Chordoma 23826111 "This study provides an integrated dataset of the miRNA and mRNA profiles in chordomas, and the results demonstrate that not only the MAPK pathway and its related miRNAs but also the Notch pathway may be involved in chordoma development. The occurrence of chordoma may be associated with dysfunctional calcification or ossification of the notochord." +tissue_expression_ns hsa-mir-663a Chordoma 23826111 "This study provides an integrated dataset of the miRNA and mRNA profiles in chordomas, and the results demonstrate that not only the MAPK pathway and its related miRNAs but also the Notch pathway may be involved in chordoma development. The occurrence of chordoma may be associated with dysfunctional calcification or ossification of the notochord." +tissue_expression_ns hsa-mir-1264 Laryngeal Neoplasms 23826416 Gene and microRNA expression reveals sensitivity to paclitaxel in laryngeal cancer cell line. +tissue_expression_ns hsa-mir-1265 Laryngeal Neoplasms 23826416 Gene and microRNA expression reveals sensitivity to paclitaxel in laryngeal cancer cell line. +tissue_expression_ns hsa-mir-1277 Laryngeal Neoplasms 23826416 Gene and microRNA expression reveals sensitivity to paclitaxel in laryngeal cancer cell line. +tissue_expression_ns hsa-mir-1291 Laryngeal Neoplasms 23826416 Gene and microRNA expression reveals sensitivity to paclitaxel in laryngeal cancer cell line. +tissue_expression_ns hsa-mir-130a Laryngeal Neoplasms 23826416 Gene and microRNA expression reveals sensitivity to paclitaxel in laryngeal cancer cell line. +tissue_expression_ns hsa-mir-195 Laryngeal Neoplasms 23826416 Gene and microRNA expression reveals sensitivity to paclitaxel in laryngeal cancer cell line. +tissue_expression_ns hsa-mir-214 Laryngeal Neoplasms 23826416 Gene and microRNA expression reveals sensitivity to paclitaxel in laryngeal cancer cell line. +tissue_expression_ns hsa-mir-27b Laryngeal Neoplasms 23826416 Gene and microRNA expression reveals sensitivity to paclitaxel in laryngeal cancer cell line. +tissue_expression_ns hsa-mir-191 Preeclampsia 23830491 Several miRNAs are found to be dysregulated in placentas of PE patients and they seem to be closely associated with the early pathogenesis of PE. Further study is necessary to develop tools for early detection and management. +tissue_expression_ns hsa-mir-197 Preeclampsia 23830491 Several miRNAs are found to be dysregulated in placentas of PE patients and they seem to be closely associated with the early pathogenesis of PE. Further study is necessary to develop tools for early detection and management. +tissue_expression_ns hsa-mir-198 Preeclampsia 23830491 Several miRNAs are found to be dysregulated in placentas of PE patients and they seem to be closely associated with the early pathogenesis of PE. Further study is necessary to develop tools for early detection and management. +tissue_expression_ns hsa-mir-202 Preeclampsia 23830491 Several miRNAs are found to be dysregulated in placentas of PE patients and they seem to be closely associated with the early pathogenesis of PE. Further study is necessary to develop tools for early detection and management. +tissue_expression_ns hsa-mir-204 Preeclampsia 23830491 Several miRNAs are found to be dysregulated in placentas of PE patients and they seem to be closely associated with the early pathogenesis of PE. Further study is necessary to develop tools for early detection and management. +tissue_expression_ns hsa-mir-25 Preeclampsia 23830491 Several miRNAs are found to be dysregulated in placentas of PE patients and they seem to be closely associated with the early pathogenesis of PE. Further study is necessary to develop tools for early detection and management. +tissue_expression_ns hsa-mir-26a Preeclampsia 23830491 Several miRNAs are found to be dysregulated in placentas of PE patients and they seem to be closely associated with the early pathogenesis of PE. Further study is necessary to develop tools for early detection and management. +tissue_expression_ns hsa-mir-26b Preeclampsia 23830491 Several miRNAs are found to be dysregulated in placentas of PE patients and they seem to be closely associated with the early pathogenesis of PE. Further study is necessary to develop tools for early detection and management. +tissue_expression_ns hsa-mir-296 Preeclampsia 23830491 Several miRNAs are found to be dysregulated in placentas of PE patients and they seem to be closely associated with the early pathogenesis of PE. Further study is necessary to develop tools for early detection and management. +tissue_expression_ns hsa-mir-342 Preeclampsia 23830491 Several miRNAs are found to be dysregulated in placentas of PE patients and they seem to be closely associated with the early pathogenesis of PE. Further study is necessary to develop tools for early detection and management. +tissue_expression_ns hsa-mir-92b Preeclampsia 23830491 Several miRNAs are found to be dysregulated in placentas of PE patients and they seem to be closely associated with the early pathogenesis of PE. Further study is necessary to develop tools for early detection and management. +tissue_expression_ns hsa-mir-95 Preeclampsia 23830491 Several miRNAs are found to be dysregulated in placentas of PE patients and they seem to be closely associated with the early pathogenesis of PE. Further study is necessary to develop tools for early detection and management. +tissue_expression_ns hsa-mir-483 "Carcinoma, Ovarian, Serous" 23836287 MiRNA expression signature for potentially predicting the prognosis of ovarian serous carcinoma. +tissue_expression_ns hsa-mir-508 "Carcinoma, Ovarian, Serous" 23836287 MiRNA expression signature for potentially predicting the prognosis of ovarian serous carcinoma. +tissue_expression_ns hsa-mir-509 "Carcinoma, Ovarian, Serous" 23836287 MiRNA expression signature for potentially predicting the prognosis of ovarian serous carcinoma. +tissue_expression_ns hsa-mir-510 "Carcinoma, Ovarian, Serous" 23836287 MiRNA expression signature for potentially predicting the prognosis of ovarian serous carcinoma. +tissue_expression_ns hsa-mir-206 Vascular Hypertrophy 23842077 miR-206 was depressed in the hypertrophied RV of Hx rats but was increased in growth-retarded SM. +tissue_expression_ns hsa-mir-205 Wounds and Injuries [unspecific] 23861701 "we predicted that topical treatment of shikonin in vivo affects epithelial-mesenchymal transition (EMT) and the expression of related microRNAs, including 200a, 200b, 200c, 141, 205, and 429 microRNAs, in mouse skin tissues." +tissue_expression_ns hsa-mir-29b "Carcinoma, Hepatocellular" 23863670 The combined detection of miRNA-29b and AFP aids the diagnosis of PHC and the prediction of its prognosis. +tissue_expression_ns hsa-mir-155 Lymphoma 23871213 The expression ratio of miR-17-5p and miR-155 correlates with grading in canine splenic lymphoma. +tissue_expression_ns hsa-mir-1246 Pterygium 23872359 miRNA and mRNA expression profiling identifies members of the miR-200 family as potential regulators of epithelial-mesenchymal transition in pterygium. +tissue_expression_ns hsa-mir-1308 Pterygium 23872359 miRNA and mRNA expression profiling identifies members of the miR-200 family as potential regulators of epithelial-mesenchymal transition in pterygium. +tissue_expression_ns hsa-mir-141 Pterygium 23872359 miRNA and mRNA expression profiling identifies members of the miR-200 family as potential regulators of epithelial-mesenchymal transition in pterygium. +tissue_expression_ns hsa-mir-143 Pterygium 23872359 miRNA and mRNA expression profiling identifies members of the miR-200 family as potential regulators of epithelial-mesenchymal transition in pterygium. +tissue_expression_ns hsa-mir-18a Pterygium 23872359 miRNA and mRNA expression profiling identifies members of the miR-200 family as potential regulators of epithelial-mesenchymal transition in pterygium. +tissue_expression_ns hsa-mir-1972 Pterygium 23872359 miRNA and mRNA expression profiling identifies members of the miR-200 family as potential regulators of epithelial-mesenchymal transition in pterygium. +tissue_expression_ns hsa-mir-1973 Pterygium 23872359 miRNA and mRNA expression profiling identifies members of the miR-200 family as potential regulators of epithelial-mesenchymal transition in pterygium. +tissue_expression_ns hsa-mir-200a Pterygium 23872359 miRNA and mRNA expression profiling identifies members of the miR-200 family as potential regulators of epithelial-mesenchymal transition in pterygium. +tissue_expression_ns hsa-mir-200b Pterygium 23872359 miRNA and mRNA expression profiling identifies members of the miR-200 family as potential regulators of epithelial-mesenchymal transition in pterygium. +tissue_expression_ns hsa-mir-210 Pterygium 23872359 miRNA and mRNA expression profiling identifies members of the miR-200 family as potential regulators of epithelial-mesenchymal transition in pterygium. +tissue_expression_ns hsa-mir-211 Pterygium 23872359 miRNA and mRNA expression profiling identifies members of the miR-200 family as potential regulators of epithelial-mesenchymal transition in pterygium. +tissue_expression_ns hsa-mir-29b Pterygium 23872359 miRNA and mRNA expression profiling identifies members of the miR-200 family as potential regulators of epithelial-mesenchymal transition in pterygium. +tissue_expression_ns hsa-mir-31 Pterygium 23872359 miRNA and mRNA expression profiling identifies members of the miR-200 family as potential regulators of epithelial-mesenchymal transition in pterygium. +tissue_expression_ns hsa-mir-3172 Pterygium 23872359 miRNA and mRNA expression profiling identifies members of the miR-200 family as potential regulators of epithelial-mesenchymal transition in pterygium. +tissue_expression_ns hsa-mir-3175 Pterygium 23872359 miRNA and mRNA expression profiling identifies members of the miR-200 family as potential regulators of epithelial-mesenchymal transition in pterygium. +tissue_expression_ns hsa-mir-375 Pterygium 23872359 miRNA and mRNA expression profiling identifies members of the miR-200 family as potential regulators of epithelial-mesenchymal transition in pterygium. +tissue_expression_ns hsa-mir-451 Pterygium 23872359 miRNA and mRNA expression profiling identifies members of the miR-200 family as potential regulators of epithelial-mesenchymal transition in pterygium. +tissue_expression_ns hsa-mir-486 Pterygium 23872359 miRNA and mRNA expression profiling identifies members of the miR-200 family as potential regulators of epithelial-mesenchymal transition in pterygium. +tissue_expression_ns hsa-mir-663b Pterygium 23872359 miRNA and mRNA expression profiling identifies members of the miR-200 family as potential regulators of epithelial-mesenchymal transition in pterygium. +tissue_expression_ns hsa-mir-665 Pterygium 23872359 miRNA and mRNA expression profiling identifies members of the miR-200 family as potential regulators of epithelial-mesenchymal transition in pterygium. +tissue_expression_ns hsa-mir-675 Pterygium 23872359 miRNA and mRNA expression profiling identifies members of the miR-200 family as potential regulators of epithelial-mesenchymal transition in pterygium. +tissue_expression_ns hsa-mir-934 Pterygium 23872359 miRNA and mRNA expression profiling identifies members of the miR-200 family as potential regulators of epithelial-mesenchymal transition in pterygium. +tissue_expression_ns hsa-let-7e "Colitis, Ulcerative" 23885139 "The present study provides the first evidence that miR-20b, miR-98, miR-125b-1*, and let-7e* are deregulated in patients with UC." +tissue_expression_ns hsa-let-7d Asthma 23885321 "Differential expression of miR-1248, miR-26a, Let-7a, and Let-7d were observed in asthmatic patients compared to controls." +tissue_expression_ns hsa-mir-15b Gastric Neoplasms 23907579 The modulation of miR-15b and miR-16 mediated the apoptosis effects of DHA in gastric cancer cells. +tissue_expression_ns hsa-mir-524 Glioblastoma 23924460 The miRNA gene expression profiles correlate with several selected MRI features of patients with GBM. Further analysis of key imaging features of MRI with correlation with miRNA gene expression patterns may help to guide treatment decisions based on these unique correlative profiles of GBM. +tissue_expression_ns hsa-mir-612 Glioblastoma 23924460 The miRNA gene expression profiles correlate with several selected MRI features of patients with GBM. Further analysis of key imaging features of MRI with correlation with miRNA gene expression patterns may help to guide treatment decisions based on these unique correlative profiles of GBM. +tissue_expression_ns hsa-mir-210 Ischemia 23931770 "The physiopathological significance of miR-210 is context dependent. In the ischemic skeletal muscle it seems to be cytoprotective, regulating oxidative metabolism and oxidative stress." +tissue_expression_ns hsa-let-7g Colorectal Carcinoma 23932154 "Identification of a microRNA expression signature for chemoradiosensitivity of colorectal cancer cells, involving miRNAs-320a, -224, -132 and let7g." +tissue_expression_ns hsa-mir-132 Colorectal Carcinoma 23932154 "Identification of a microRNA expression signature for chemoradiosensitivity of colorectal cancer cells, involving miRNAs-320a, -224, -132 and let7g." +tissue_expression_ns hsa-mir-224 Colorectal Carcinoma 23932154 "Identification of a microRNA expression signature for chemoradiosensitivity of colorectal cancer cells, involving miRNAs-320a, -224, -132 and let7g." +tissue_expression_ns hsa-mir-320a Colorectal Carcinoma 23932154 "Identification of a microRNA expression signature for chemoradiosensitivity of colorectal cancer cells, involving miRNAs-320a, -224, -132 and let7g." +tissue_expression_ns hsa-mir-1280 Neoplasms [unspecific] 23936320 Characterization of microRNA expression profiles and the discovery of novel microRNAs involved in cancer during human embryonic development. +tissue_expression_ns hsa-mir-638 Neoplasms [unspecific] 23936320 Characterization of microRNA expression profiles and the discovery of novel microRNAs involved in cancer during human embryonic development. +tissue_expression_ns hsa-mir-720 Neoplasms [unspecific] 23936320 Characterization of microRNA expression profiles and the discovery of novel microRNAs involved in cancer during human embryonic development. +tissue_expression_ns hsa-mir-106b Bladder Neoplasms 23945108 miRNA profiling identifies candidate mirnas for bladder cancer diagnosis and clinical outcome. +tissue_expression_ns hsa-mir-125b Bladder Neoplasms 23945108 miRNA profiling identifies candidate mirnas for bladder cancer diagnosis and clinical outcome. +tissue_expression_ns hsa-mir-130a Bladder Neoplasms 23945108 miRNA profiling identifies candidate mirnas for bladder cancer diagnosis and clinical outcome. +tissue_expression_ns hsa-mir-130b Bladder Neoplasms 23945108 miRNA profiling identifies candidate mirnas for bladder cancer diagnosis and clinical outcome. +tissue_expression_ns hsa-mir-139 Bladder Neoplasms 23945108 miRNA profiling identifies candidate mirnas for bladder cancer diagnosis and clinical outcome. +tissue_expression_ns hsa-mir-141 Bladder Neoplasms 23945108 miRNA profiling identifies candidate mirnas for bladder cancer diagnosis and clinical outcome. +tissue_expression_ns hsa-mir-145 Bladder Neoplasms 23945108 miRNA profiling identifies candidate mirnas for bladder cancer diagnosis and clinical outcome. +tissue_expression_ns hsa-mir-199a Bladder Neoplasms 23945108 miRNA profiling identifies candidate mirnas for bladder cancer diagnosis and clinical outcome. +tissue_expression_ns hsa-mir-200a Bladder Neoplasms 23945108 miRNA profiling identifies candidate mirnas for bladder cancer diagnosis and clinical outcome. +tissue_expression_ns hsa-mir-205 Bladder Neoplasms 23945108 miRNA profiling identifies candidate mirnas for bladder cancer diagnosis and clinical outcome. +tissue_expression_ns hsa-mir-20a Bladder Neoplasms 23945108 miRNA profiling identifies candidate mirnas for bladder cancer diagnosis and clinical outcome. +tissue_expression_ns hsa-mir-214 Bladder Neoplasms 23945108 miRNA profiling identifies candidate mirnas for bladder cancer diagnosis and clinical outcome. +tissue_expression_ns hsa-mir-222 Bladder Neoplasms 23945108 miRNA profiling identifies candidate mirnas for bladder cancer diagnosis and clinical outcome. +tissue_expression_ns hsa-mir-650 "Adenocarcinoma, Lung" 23991130 miR-650 is a novel prognostic marker in LAD and its expression is a potential indicator of chemosensitivity to docetaxel-based chemotherapy regimen. +tissue_expression_ns hsa-mir-181b Oral Leukoplakia 24020903 some cytological and histopathological parameters used to grade dysplasia are associated with altered miRNA expression. +tissue_expression_ns hsa-mir-21 Oral Leukoplakia 24020903 some cytological and histopathological parameters used to grade dysplasia are associated with altered miRNA expression. +tissue_expression_ns hsa-mir-345 Oral Leukoplakia 24020903 some cytological and histopathological parameters used to grade dysplasia are associated with altered miRNA expression. +tissue_expression_ns hsa-mir-203 Melanoma 24023765 we found extensive sequence variations (isomiRs) and other non-coding small RNAs revealing a complex melanoma transcriptome. Deep-sequencing small RNAs directly from clinically defined specimens provides a robust strategy to improve melanoma diagnostics. +tissue_expression_ns hsa-mir-204 Melanoma 24023765 we found extensive sequence variations (isomiRs) and other non-coding small RNAs revealing a complex melanoma transcriptome. Deep-sequencing small RNAs directly from clinically defined specimens provides a robust strategy to improve melanoma diagnostics. +tissue_expression_ns hsa-mir-205 Melanoma 24023765 we found extensive sequence variations (isomiRs) and other non-coding small RNAs revealing a complex melanoma transcriptome. Deep-sequencing small RNAs directly from clinically defined specimens provides a robust strategy to improve melanoma diagnostics. +tissue_expression_ns hsa-mir-211 Melanoma 24023765 we found extensive sequence variations (isomiRs) and other non-coding small RNAs revealing a complex melanoma transcriptome. Deep-sequencing small RNAs directly from clinically defined specimens provides a robust strategy to improve melanoma diagnostics. +tissue_expression_ns hsa-mir-23b Melanoma 24023765 we found extensive sequence variations (isomiRs) and other non-coding small RNAs revealing a complex melanoma transcriptome. Deep-sequencing small RNAs directly from clinically defined specimens provides a robust strategy to improve melanoma diagnostics. +tissue_expression_ns hsa-mir-26a Melanoma 24023765 we found extensive sequence variations (isomiRs) and other non-coding small RNAs revealing a complex melanoma transcriptome. Deep-sequencing small RNAs directly from clinically defined specimens provides a robust strategy to improve melanoma diagnostics. +tissue_expression_ns hsa-mir-26b Melanoma 24023765 we found extensive sequence variations (isomiRs) and other non-coding small RNAs revealing a complex melanoma transcriptome. Deep-sequencing small RNAs directly from clinically defined specimens provides a robust strategy to improve melanoma diagnostics. +tissue_expression_ns hsa-mir-21 Gastric Neoplasms 24023850 miR-21 has potential diagnostic value with a moderate sensitivity and specificity for GC. More prospective studies on the diagnostic value of miR-21 for GC are needed in the future. +tissue_expression_ns hsa-mir-106b "Carcinoma, Gastric" 24040025 Candidate microRNA biomarkers in human gastric cancer: a systematic review and validation study. +tissue_expression_ns hsa-mir-17 "Carcinoma, Gastric" 24040025 Candidate microRNA biomarkers in human gastric cancer: a systematic review and validation study. +tissue_expression_ns hsa-mir-18a "Carcinoma, Gastric" 24040025 Candidate microRNA biomarkers in human gastric cancer: a systematic review and validation study. +tissue_expression_ns hsa-mir-20a "Carcinoma, Gastric" 24040025 Candidate microRNA biomarkers in human gastric cancer: a systematic review and validation study. +tissue_expression_ns hsa-mir-21 "Carcinoma, Gastric" 24040025 Candidate microRNA biomarkers in human gastric cancer: a systematic review and validation study. +tissue_expression_ns hsa-mir-378 "Carcinoma, Gastric" 24040025 Candidate microRNA biomarkers in human gastric cancer: a systematic review and validation study. +tissue_expression_ns hsa-mir-638 "Carcinoma, Gastric" 24040025 Candidate microRNA biomarkers in human gastric cancer: a systematic review and validation study. +tissue_expression_ns hsa-mir-196a Pancreatic Neoplasms 24048456 "Our results provide experimental evidence to support aberrant expression of miR-196a is associated with abnormal apoptosis, invasion, and proliferation of pancreatic cancer cells." +tissue_expression_ns hsa-mir-146a Inflammatory Bowel Diseases 24051693 "In summary,we demonstrate that miR-31, miR-206, miR-424, and miR-146a are novel specific biomarkers of inflammatory bowel disease." +tissue_expression_ns hsa-mir-206 Inflammatory Bowel Diseases 24051693 "In summary,we demonstrate that miR-31, miR-206, miR-424, and miR-146a are novel specific biomarkers of inflammatory bowel disease." +tissue_expression_ns hsa-mir-31 Inflammatory Bowel Diseases 24051693 "In summary,we demonstrate that miR-31, miR-206, miR-424, and miR-146a are novel specific biomarkers of inflammatory bowel disease." +tissue_expression_ns hsa-mir-424 Inflammatory Bowel Diseases 24051693 "In summary,we demonstrate that miR-31, miR-206, miR-424, and miR-146a are novel specific biomarkers of inflammatory bowel disease." +tissue_expression_ns hsa-mir-650 Glioma 24062138 MicroRNA-650 expression in glioma is associated with prognosis of patients. +tissue_expression_ns hsa-mir-21 Atrial Fibrillation 24069193 "The expression of miRNA-21 in human atrial tissue was found to be related to atrial fibrosis and might affect AF occurrence, indicating its usefulness as a biomarker for cardiac surgery management." +tissue_expression_ns hsa-let-7c Down Syndrome 24071828 Differentially expressed microRNAs may be involved in hemopoietic abnormalities and the immune defects of DS fetuses and newborns. +tissue_expression_ns hsa-mir-125b-2 Down Syndrome 24071828 Differentially expressed microRNAs may be involved in hemopoietic abnormalities and the immune defects of DS fetuses and newborns. +tissue_expression_ns hsa-mir-155 Down Syndrome 24071828 Differentially expressed microRNAs may be involved in hemopoietic abnormalities and the immune defects of DS fetuses and newborns. +tissue_expression_ns hsa-mir-802 Down Syndrome 24071828 Differentially expressed microRNAs may be involved in hemopoietic abnormalities and the immune defects of DS fetuses and newborns. +tissue_expression_ns hsa-mir-99a Down Syndrome 24071828 Differentially expressed microRNAs may be involved in hemopoietic abnormalities and the immune defects of DS fetuses and newborns. +tissue_expression_ns hsa-mir-106 Colorectal Carcinoma 24078989 MiRNAs might soon represent novel prognostic and diagnostic tools in patients at high risk of CRC or being diagnosed with CRC. +tissue_expression_ns hsa-mir-126 Colorectal Carcinoma 24078989 MiRNAs might soon represent novel prognostic and diagnostic tools in patients at high risk of CRC or being diagnosed with CRC. +tissue_expression_ns hsa-mir-21 Colorectal Carcinoma 24078989 MiRNAs might soon represent novel prognostic and diagnostic tools in patients at high risk of CRC or being diagnosed with CRC. +tissue_expression_ns hsa-mir-26b Colorectal Carcinoma 24078989 MiRNAs might soon represent novel prognostic and diagnostic tools in patients at high risk of CRC or being diagnosed with CRC. +tissue_expression_ns hsa-mir-328 Colorectal Carcinoma 24078989 MiRNAs might soon represent novel prognostic and diagnostic tools in patients at high risk of CRC or being diagnosed with CRC. +tissue_expression_ns hsa-mir-345 Colorectal Carcinoma 24078989 MiRNAs might soon represent novel prognostic and diagnostic tools in patients at high risk of CRC or being diagnosed with CRC. +tissue_expression_ns hsa-mir-92a Colorectal Carcinoma 24078989 MiRNAs might soon represent novel prognostic and diagnostic tools in patients at high risk of CRC or being diagnosed with CRC. +tissue_expression_ns hsa-mir-302b "Carcinoma, Hepatocellular" 24083596 miR-302b suppresses HCC growth may due to targeting the EGFR/AKT2/CCND1 pathway. +tissue_expression_ns hsa-mir-10a "Cardiomyopathy, Hypertrophic" 24083979 In silico identification of mRNA targets of differentially expressed miRNAs showed a large proportion of genes involved in cardiac hypertrophy and cardiac beta-adrenergic receptor signaling and we showed reduced phosphorylation of cardiac troponin I in the HCM myocardium when compared with donor. HCM patients with MYBPC3 mutations have a specific miRNA expression profile. Downstream mRNA targets reveal possible involvement in cardiac signaling pathways. +tissue_expression_ns hsa-mir-10b "Cardiomyopathy, Hypertrophic" 24083979 In silico identification of mRNA targets of differentially expressed miRNAs showed a large proportion of genes involved in cardiac hypertrophy and cardiac beta-adrenergic receptor signaling and we showed reduced phosphorylation of cardiac troponin I in the HCM myocardium when compared with donor. HCM patients with MYBPC3 mutations have a specific miRNA expression profile. Downstream mRNA targets reveal possible involvement in cardiac signaling pathways. +tissue_expression_ns hsa-mir-181a-2 "Cardiomyopathy, Hypertrophic" 24083979 In silico identification of mRNA targets of differentially expressed miRNAs showed a large proportion of genes involved in cardiac hypertrophy and cardiac beta-adrenergic receptor signaling and we showed reduced phosphorylation of cardiac troponin I in the HCM myocardium when compared with donor. HCM patients with MYBPC3 mutations have a specific miRNA expression profile. Downstream mRNA targets reveal possible involvement in cardiac signaling pathways. +tissue_expression_ns hsa-mir-184 "Cardiomyopathy, Hypertrophic" 24083979 In silico identification of mRNA targets of differentially expressed miRNAs showed a large proportion of genes involved in cardiac hypertrophy and cardiac beta-adrenergic receptor signaling and we showed reduced phosphorylation of cardiac troponin I in the HCM myocardium when compared with donor. HCM patients with MYBPC3 mutations have a specific miRNA expression profile. Downstream mRNA targets reveal possible involvement in cardiac signaling pathways. +tissue_expression_ns hsa-mir-204 "Cardiomyopathy, Hypertrophic" 24083979 In silico identification of mRNA targets of differentially expressed miRNAs showed a large proportion of genes involved in cardiac hypertrophy and cardiac beta-adrenergic receptor signaling and we showed reduced phosphorylation of cardiac troponin I in the HCM myocardium when compared with donor. HCM patients with MYBPC3 mutations have a specific miRNA expression profile. Downstream mRNA targets reveal possible involvement in cardiac signaling pathways. +tissue_expression_ns hsa-mir-222 "Cardiomyopathy, Hypertrophic" 24083979 In silico identification of mRNA targets of differentially expressed miRNAs showed a large proportion of genes involved in cardiac hypertrophy and cardiac beta-adrenergic receptor signaling and we showed reduced phosphorylation of cardiac troponin I in the HCM myocardium when compared with donor. HCM patients with MYBPC3 mutations have a specific miRNA expression profile. Downstream mRNA targets reveal possible involvement in cardiac signaling pathways. +tissue_expression_ns hsa-mir-34b "Cardiomyopathy, Hypertrophic" 24083979 In silico identification of mRNA targets of differentially expressed miRNAs showed a large proportion of genes involved in cardiac hypertrophy and cardiac beta-adrenergic receptor signaling and we showed reduced phosphorylation of cardiac troponin I in the HCM myocardium when compared with donor. HCM patients with MYBPC3 mutations have a specific miRNA expression profile. Downstream mRNA targets reveal possible involvement in cardiac signaling pathways. +tissue_expression_ns hsa-mir-371 "Cardiomyopathy, Hypertrophic" 24083979 In silico identification of mRNA targets of differentially expressed miRNAs showed a large proportion of genes involved in cardiac hypertrophy and cardiac beta-adrenergic receptor signaling and we showed reduced phosphorylation of cardiac troponin I in the HCM myocardium when compared with donor. HCM patients with MYBPC3 mutations have a specific miRNA expression profile. Downstream mRNA targets reveal possible involvement in cardiac signaling pathways. +tissue_expression_ns hsa-mir-383 "Cardiomyopathy, Hypertrophic" 24083979 In silico identification of mRNA targets of differentially expressed miRNAs showed a large proportion of genes involved in cardiac hypertrophy and cardiac beta-adrenergic receptor signaling and we showed reduced phosphorylation of cardiac troponin I in the HCM myocardium when compared with donor. HCM patients with MYBPC3 mutations have a specific miRNA expression profile. Downstream mRNA targets reveal possible involvement in cardiac signaling pathways. +tissue_expression_ns hsa-mir-497 "Cardiomyopathy, Hypertrophic" 24083979 In silico identification of mRNA targets of differentially expressed miRNAs showed a large proportion of genes involved in cardiac hypertrophy and cardiac beta-adrenergic receptor signaling and we showed reduced phosphorylation of cardiac troponin I in the HCM myocardium when compared with donor. HCM patients with MYBPC3 mutations have a specific miRNA expression profile. Downstream mRNA targets reveal possible involvement in cardiac signaling pathways. +tissue_expression_ns hsa-mir-708 "Cardiomyopathy, Hypertrophic" 24083979 In silico identification of mRNA targets of differentially expressed miRNAs showed a large proportion of genes involved in cardiac hypertrophy and cardiac beta-adrenergic receptor signaling and we showed reduced phosphorylation of cardiac troponin I in the HCM myocardium when compared with donor. HCM patients with MYBPC3 mutations have a specific miRNA expression profile. Downstream mRNA targets reveal possible involvement in cardiac signaling pathways. +tissue_expression_ns hsa-mir-96 "Cardiomyopathy, Hypertrophic" 24083979 In silico identification of mRNA targets of differentially expressed miRNAs showed a large proportion of genes involved in cardiac hypertrophy and cardiac beta-adrenergic receptor signaling and we showed reduced phosphorylation of cardiac troponin I in the HCM myocardium when compared with donor. HCM patients with MYBPC3 mutations have a specific miRNA expression profile. Downstream mRNA targets reveal possible involvement in cardiac signaling pathways. +tissue_expression_ns hsa-mir-150 Traumatic Brain Injury 24108763 neutrophils associated with traumatic injury were found to have a unique miRNA signature. Changes in signaling pathways due to deregulated miRNAs may be involved in the pathological processes of traumatic injury. +tissue_expression_ns hsa-mir-155 Traumatic Brain Injury 24108763 neutrophils associated with traumatic injury were found to have a unique miRNA signature. Changes in signaling pathways due to deregulated miRNAs may be involved in the pathological processes of traumatic injury. +tissue_expression_ns hsa-mir-223 Traumatic Brain Injury 24108763 neutrophils associated with traumatic injury were found to have a unique miRNA signature. Changes in signaling pathways due to deregulated miRNAs may be involved in the pathological processes of traumatic injury. +tissue_expression_ns hsa-mir-23a Traumatic Brain Injury 24108763 neutrophils associated with traumatic injury were found to have a unique miRNA signature. Changes in signaling pathways due to deregulated miRNAs may be involved in the pathological processes of traumatic injury. +tissue_expression_ns hsa-mir-30e Traumatic Brain Injury 24108763 neutrophils associated with traumatic injury were found to have a unique miRNA signature. Changes in signaling pathways due to deregulated miRNAs may be involved in the pathological processes of traumatic injury. +tissue_expression_ns hsa-mir-3945 Traumatic Brain Injury 24108763 neutrophils associated with traumatic injury were found to have a unique miRNA signature. Changes in signaling pathways due to deregulated miRNAs may be involved in the pathological processes of traumatic injury. +tissue_expression_ns hsa-mir-124a "Carcinoma, Lung, Non-Small-Cell" 24113142 The developed prediction algorithm is a valuable potential biomarker for assisting lung cancer diagnosis in minimal biopsy material. A prospective validation is required to measure the enhancement of diagnostic accuracy of our current clinical practice. +tissue_expression_ns hsa-mir-126 "Carcinoma, Lung, Non-Small-Cell" 24113142 The developed prediction algorithm is a valuable potential biomarker for assisting lung cancer diagnosis in minimal biopsy material. A prospective validation is required to measure the enhancement of diagnostic accuracy of our current clinical practice. +tissue_expression_ns hsa-mir-200c "Carcinoma, Lung, Non-Small-Cell" 24113142 The developed prediction algorithm is a valuable potential biomarker for assisting lung cancer diagnosis in minimal biopsy material. A prospective validation is required to measure the enhancement of diagnostic accuracy of our current clinical practice. +tissue_expression_ns hsa-mir-34 "Carcinoma, Lung, Non-Small-Cell" 24113142 The developed prediction algorithm is a valuable potential biomarker for assisting lung cancer diagnosis in minimal biopsy material. A prospective validation is required to measure the enhancement of diagnostic accuracy of our current clinical practice. +tissue_expression_ns hsa-mir-9 "Carcinoma, Lung, Non-Small-Cell" 24113142 The developed prediction algorithm is a valuable potential biomarker for assisting lung cancer diagnosis in minimal biopsy material. A prospective validation is required to measure the enhancement of diagnostic accuracy of our current clinical practice. +tissue_expression_ns hsa-mir-141 "Carcinoma, Renal Cell" 24129247 "Expression analysis of miR-141 or miR-200b accurately distinguished RCTs from normal renal tissues, oncocytoma from RCC and chRCC from oncocytoma. The diagnostic performance was confirmed in the validation set. Interestingly,miR-21, miR-141 and miR-155 expression levels showed prognostic significance in a univariate analysis." +tissue_expression_ns hsa-mir-155 "Carcinoma, Renal Cell" 24129247 "Expression analysis of miR-141 or miR-200b accurately distinguished RCTs from normal renal tissues, oncocytoma from RCC and chRCC from oncocytoma. The diagnostic performance was confirmed in the validation set. Interestingly,miR-21, miR-141 and miR-155 expression levels showed prognostic significance in a univariate analysis." +tissue_expression_ns hsa-mir-21 "Carcinoma, Renal Cell" 24129247 "Expression analysis of miR-141 or miR-200b accurately distinguished RCTs from normal renal tissues, oncocytoma from RCC and chRCC from oncocytoma. The diagnostic performance was confirmed in the validation set. Interestingly,miR-21, miR-141 and miR-155 expression levels showed prognostic significance in a univariate analysis." +tissue_expression_ns hsa-mir-143 Vascular Disease [unspecific] 24166492 The flank sequences of miR-145 and miR-143 play a critical role in their aberrant expression in VSMCs and vascular walls. The genetically engineered smart miRNAs based on their flank sequences may have broadly therapeutic applications for many vascular diseases. +tissue_expression_ns hsa-mir-145 Vascular Disease [unspecific] 24166492 The flank sequences of miR-145 and miR-143 play a critical role in their aberrant expression in VSMCs and vascular walls. The genetically engineered smart miRNAs based on their flank sequences may have broadly therapeutic applications for many vascular diseases. +tissue_expression_ns hsa-mir-205 Prostate Neoplasms 24167554 MicroRNA profiling in prostate cancer--the diagnostic potential of urinary miR-205 and miR-214. +tissue_expression_ns hsa-mir-214 Prostate Neoplasms 24167554 MicroRNA profiling in prostate cancer--the diagnostic potential of urinary miR-205 and miR-214. +tissue_expression_ns hsa-mir-204 Breast Neoplasms 24191129 "The expression and the functional role of several miRNAs (miR-206, miR-31, miR-27a/b, miR-21, miR-92a, miR-205, miR-125a/b, miR-10b, miR-155, miR-146a/b, miR-335, miR-204, miR-211, miR-7, miR-22, miR-126, and miR-17) in breast cancer has been identified." +tissue_expression_ns hsa-mir-10b Breast Neoplasms 24196612 microRNA expression in breast development and breast cancer] +tissue_expression_ns hsa-mir-210 Breast Neoplasms 24196612 microRNA expression in breast development and breast cancer] +tissue_expression_ns hsa-mir-31 Breast Neoplasms 24196612 microRNA expression in breast development and breast cancer] +tissue_expression_ns hsa-mir-335 Breast Neoplasms 24196612 microRNA expression in breast development and breast cancer] +tissue_expression_ns hsa-mir-1287 Laryngeal Neoplasms 24238754 Identification of predictive biomarkers for early diagnosis of larynx carcinoma based on microRNA expression data. +tissue_expression_ns hsa-mir-657 Laryngeal Neoplasms 24238754 Identification of predictive biomarkers for early diagnosis of larynx carcinoma based on microRNA expression data. +tissue_expression_ns hsa-mir-129 Psychiatric Disorders 24246224 Metabolic stress-induced microRNA and mRNA expression profiles of human fibroblasts. +tissue_expression_ns hsa-mir-146b Psychiatric Disorders 24246224 Metabolic stress-induced microRNA and mRNA expression profiles of human fibroblasts. +tissue_expression_ns hsa-mir-543 Psychiatric Disorders 24246224 Metabolic stress-induced microRNA and mRNA expression profiles of human fibroblasts. +tissue_expression_ns hsa-mir-550a Psychiatric Disorders 24246224 Metabolic stress-induced microRNA and mRNA expression profiles of human fibroblasts. +tissue_expression_ns hsa-let-7a "Carcinoma, Hepatocellular, HBV-Related" 24273923 Analysis of microRNA expression profiles in human hepatitis B virus-related hepatocellular carcinoma. +tissue_expression_ns hsa-let-7c "Carcinoma, Hepatocellular, HBV-Related" 24273923 Analysis of microRNA expression profiles in human hepatitis B virus-related hepatocellular carcinoma. +tissue_expression_ns hsa-mir-138 "Carcinoma, Hepatocellular, HBV-Related" 24273923 Analysis of microRNA expression profiles in human hepatitis B virus-related hepatocellular carcinoma. +tissue_expression_ns hsa-mir-183 "Carcinoma, Hepatocellular, HBV-Related" 24273923 Analysis of microRNA expression profiles in human hepatitis B virus-related hepatocellular carcinoma. +tissue_expression_ns hsa-mir-196a "Carcinoma, Hepatocellular, HBV-Related" 24273923 Analysis of microRNA expression profiles in human hepatitis B virus-related hepatocellular carcinoma. +tissue_expression_ns hsa-mir-96 "Carcinoma, Hepatocellular, HBV-Related" 24273923 Analysis of microRNA expression profiles in human hepatitis B virus-related hepatocellular carcinoma. +tissue_expression_ns hsa-mir-330 Neoplasms [unspecific] 24278004 MicroRNA-gene association as a prognostic biomarker in cancer exposes disease mechanisms. +tissue_expression_ns hsa-mir-143 "Carcinoma, Lung, Non-Small-Cell" 24286416 "It is indicated that there is a potential for using miR-143 as a novel diagnostic biomarker for NSCLC. Moreover, miR-150 can be a highly accurate marker for differentiating adenocarcinoma from squamous cell carcinoma." +tissue_expression_ns hsa-mir-150 "Carcinoma, Lung, Non-Small-Cell" 24286416 "It is indicated that there is a potential for using miR-143 as a novel diagnostic biomarker for NSCLC. Moreover, miR-150 can be a highly accurate marker for differentiating adenocarcinoma from squamous cell carcinoma." +tissue_expression_ns hsa-let-7f Bronchopulmonary Dysplasia 24301780 MicroRNA expression profiling studies on bronchopulmonary dysplasia: a systematic review and meta-analysis. +tissue_expression_ns hsa-mir-130b Bronchopulmonary Dysplasia 24301780 MicroRNA expression profiling studies on bronchopulmonary dysplasia: a systematic review and meta-analysis. +tissue_expression_ns hsa-mir-141 Bronchopulmonary Dysplasia 24301780 MicroRNA expression profiling studies on bronchopulmonary dysplasia: a systematic review and meta-analysis. +tissue_expression_ns hsa-mir-146b Bronchopulmonary Dysplasia 24301780 MicroRNA expression profiling studies on bronchopulmonary dysplasia: a systematic review and meta-analysis. +tissue_expression_ns hsa-mir-21 Bronchopulmonary Dysplasia 24301780 MicroRNA expression profiling studies on bronchopulmonary dysplasia: a systematic review and meta-analysis. +tissue_expression_ns hsa-mir-214 Bronchopulmonary Dysplasia 24301780 MicroRNA expression profiling studies on bronchopulmonary dysplasia: a systematic review and meta-analysis. +tissue_expression_ns hsa-mir-29a Bronchopulmonary Dysplasia 24301780 MicroRNA expression profiling studies on bronchopulmonary dysplasia: a systematic review and meta-analysis. +tissue_expression_ns hsa-mir-34a Bronchopulmonary Dysplasia 24301780 MicroRNA expression profiling studies on bronchopulmonary dysplasia: a systematic review and meta-analysis. +tissue_expression_ns hsa-mir-382 Bronchopulmonary Dysplasia 24301780 MicroRNA expression profiling studies on bronchopulmonary dysplasia: a systematic review and meta-analysis. +tissue_expression_ns hsa-mir-411 Bronchopulmonary Dysplasia 24301780 MicroRNA expression profiling studies on bronchopulmonary dysplasia: a systematic review and meta-analysis. +tissue_expression_ns hsa-mir-431 Bronchopulmonary Dysplasia 24301780 MicroRNA expression profiling studies on bronchopulmonary dysplasia: a systematic review and meta-analysis. +tissue_expression_ns hsa-mir-503 Bronchopulmonary Dysplasia 24301780 MicroRNA expression profiling studies on bronchopulmonary dysplasia: a systematic review and meta-analysis. +tissue_expression_ns hsa-mir-10b Pituitary Adenoma 24310454 "We established miRNA expression maps of non-functioning and gonadotropin-secreting pituitary adenomas. The most strongly differentially expressed genes were miR-124a and miR-31 in non-functioning pituitary adenomas, and miR-10b and miR-503 in gonadotropin-secreting pituitary adenomas." +tissue_expression_ns hsa-mir-422a Pituitary Adenoma 24310454 "We established miRNA expression maps of non-functioning and gonadotropin-secreting pituitary adenomas. The most strongly differentially expressed genes were miR-124a and miR-31 in non-functioning pituitary adenomas, and miR-10b and miR-503 in gonadotropin-secreting pituitary adenomas." +tissue_expression_ns hsa-mir-422b Pituitary Adenoma 24310454 "We established miRNA expression maps of non-functioning and gonadotropin-secreting pituitary adenomas. The most strongly differentially expressed genes were miR-124a and miR-31 in non-functioning pituitary adenomas, and miR-10b and miR-503 in gonadotropin-secreting pituitary adenomas." +tissue_expression_ns hsa-mir-520b Pituitary Adenoma 24310454 "We established miRNA expression maps of non-functioning and gonadotropin-secreting pituitary adenomas. The most strongly differentially expressed genes were miR-124a and miR-31 in non-functioning pituitary adenomas, and miR-10b and miR-503 in gonadotropin-secreting pituitary adenomas." +tissue_expression_ns hsa-mir-523 Pituitary Adenoma 24310454 "We established miRNA expression maps of non-functioning and gonadotropin-secreting pituitary adenomas. The most strongly differentially expressed genes were miR-124a and miR-31 in non-functioning pituitary adenomas, and miR-10b and miR-503 in gonadotropin-secreting pituitary adenomas." +tissue_expression_ns hsa-mir-146b Thyroid Lymphoma 24327568 "Histotype-specific miRNA signatures can provide new insight into the molecular mechanisms of thyroid carcinogenesis. The tested 4-miRNA signature is a promising diagnostic tool for differentiating ATC from PTL and non-neoplastic MNG, even in the presence of scant material obtained from minimally invasive procedures." +tissue_expression_ns hsa-mir-221 Thyroid Lymphoma 24327568 "Histotype-specific miRNA signatures can provide new insight into the molecular mechanisms of thyroid carcinogenesis. The tested 4-miRNA signature is a promising diagnostic tool for differentiating ATC from PTL and non-neoplastic MNG, even in the presence of scant material obtained from minimally invasive procedures." +tissue_expression_ns hsa-mir-222 Thyroid Lymphoma 24327568 "Histotype-specific miRNA signatures can provide new insight into the molecular mechanisms of thyroid carcinogenesis. The tested 4-miRNA signature is a promising diagnostic tool for differentiating ATC from PTL and non-neoplastic MNG, even in the presence of scant material obtained from minimally invasive procedures." +tissue_expression_ns hsa-mir-26a Thyroid Lymphoma 24327568 "Histotype-specific miRNA signatures can provide new insight into the molecular mechanisms of thyroid carcinogenesis. The tested 4-miRNA signature is a promising diagnostic tool for differentiating ATC from PTL and non-neoplastic MNG, even in the presence of scant material obtained from minimally invasive procedures." +tissue_expression_ns hsa-let-7g "Carcinoma, Renal Cell, Clear-Cell" 24351440 "MicroRNA expression signatures of stage, grade, and progression in clear cell RCC." +tissue_expression_ns hsa-mir-142 "Carcinoma, Renal Cell, Clear-Cell" 24351440 "MicroRNA expression signatures of stage, grade, and progression in clear cell RCC." +tissue_expression_ns hsa-mir-204 "Carcinoma, Renal Cell, Clear-Cell" 24351440 "MicroRNA expression signatures of stage, grade, and progression in clear cell RCC." +tissue_expression_ns hsa-mir-21 "Carcinoma, Renal Cell, Clear-Cell" 24351440 "MicroRNA expression signatures of stage, grade, and progression in clear cell RCC." +tissue_expression_ns hsa-mir-424 "Carcinoma, Renal Cell, Clear-Cell" 24351440 "MicroRNA expression signatures of stage, grade, and progression in clear cell RCC." +tissue_expression_ns hsa-mir-129-2 "Lymphoma, Large B-Cell" 24358187 MicroRNA profiling of primary cutaneous large B-cell lymphomas. +tissue_expression_ns hsa-mir-214 "Lymphoma, Large B-Cell" 24358187 MicroRNA profiling of primary cutaneous large B-cell lymphomas. +tissue_expression_ns hsa-mir-31 "Lymphoma, Large B-Cell" 24358187 MicroRNA profiling of primary cutaneous large B-cell lymphomas. +tissue_expression_ns hsa-mir-9 "Lymphoma, Large B-Cell" 24358187 MicroRNA profiling of primary cutaneous large B-cell lymphomas. +tissue_expression_ns hsa-mir-17 "Squamous Cell Carcinoma, Esophageal" 24360091 "miR-17, miR-18a, and miR-19a can serve as potential unfavorable prognostic biomarkers in ESCC which are associated with some clinicopathologic factors" +tissue_expression_ns hsa-mir-18a "Squamous Cell Carcinoma, Esophageal" 24360091 "miR-17, miR-18a, and miR-19a can serve as potential unfavorable prognostic biomarkers in ESCC which are associated with some clinicopathologic factors" +tissue_expression_ns hsa-mir-19a "Squamous Cell Carcinoma, Esophageal" 24360091 "miR-17, miR-18a, and miR-19a can serve as potential unfavorable prognostic biomarkers in ESCC which are associated with some clinicopathologic factors" +tissue_expression_ns hsa-mir-141 "Carcinoma, Endometrial" 24363810 Aberrant microRNA expression in endometrial carcinoma using formalin-fixed paraffin-embedded (FFPE) tissues. +tissue_expression_ns hsa-mir-182 "Carcinoma, Endometrial" 24363810 Aberrant microRNA expression in endometrial carcinoma using formalin-fixed paraffin-embedded (FFPE) tissues. +tissue_expression_ns hsa-mir-200a "Carcinoma, Endometrial" 24363810 Aberrant microRNA expression in endometrial carcinoma using formalin-fixed paraffin-embedded (FFPE) tissues. +tissue_expression_ns hsa-mir-200b "Carcinoma, Endometrial" 24363810 Aberrant microRNA expression in endometrial carcinoma using formalin-fixed paraffin-embedded (FFPE) tissues. +tissue_expression_ns hsa-mir-205 "Carcinoma, Endometrial" 24363810 Aberrant microRNA expression in endometrial carcinoma using formalin-fixed paraffin-embedded (FFPE) tissues. +tissue_expression_ns hsa-mir-1323 "Carcinoma, Nasopharyngeal" 24367666 Genome-wide analyses of radioresistance-associated miRNA expression profile in nasopharyngeal carcinoma using next generation deep sequencing. +tissue_expression_ns hsa-mir-324 "Carcinoma, Nasopharyngeal" 24367666 Genome-wide analyses of radioresistance-associated miRNA expression profile in nasopharyngeal carcinoma using next generation deep sequencing. +tissue_expression_ns hsa-mir-34c "Carcinoma, Nasopharyngeal" 24367666 Genome-wide analyses of radioresistance-associated miRNA expression profile in nasopharyngeal carcinoma using next generation deep sequencing. +tissue_expression_ns hsa-mir-371a "Carcinoma, Nasopharyngeal" 24367666 Genome-wide analyses of radioresistance-associated miRNA expression profile in nasopharyngeal carcinoma using next generation deep sequencing. +tissue_expression_ns hsa-mir-4501 "Carcinoma, Nasopharyngeal" 24367666 Genome-wide analyses of radioresistance-associated miRNA expression profile in nasopharyngeal carcinoma using next generation deep sequencing. +tissue_expression_ns hsa-mir-93 "Carcinoma, Nasopharyngeal" 24367666 Genome-wide analyses of radioresistance-associated miRNA expression profile in nasopharyngeal carcinoma using next generation deep sequencing. +tissue_expression_ns hsa-mir-145 Liposarcoma 24375455 MicroRNA expression profiles distinguish liposarcoma subtypes and implicate miR-145 and miR-451 as tumor suppressors. +tissue_expression_ns hsa-mir-451 Liposarcoma 24375455 MicroRNA expression profiles distinguish liposarcoma subtypes and implicate miR-145 and miR-451 as tumor suppressors. +tissue_expression_ns hsa-mir-135a Polycystic Ovarian Syndrome 24390626 Altered microRNA and gene expression in the follicular fluid of women with polycystic ovary syndrome. +tissue_expression_ns hsa-mir-18b Polycystic Ovarian Syndrome 24390626 Altered microRNA and gene expression in the follicular fluid of women with polycystic ovary syndrome. +tissue_expression_ns hsa-mir-32 Polycystic Ovarian Syndrome 24390626 Altered microRNA and gene expression in the follicular fluid of women with polycystic ovary syndrome. +tissue_expression_ns hsa-mir-34c Polycystic Ovarian Syndrome 24390626 Altered microRNA and gene expression in the follicular fluid of women with polycystic ovary syndrome. +tissue_expression_ns hsa-mir-9 Polycystic Ovarian Syndrome 24390626 Altered microRNA and gene expression in the follicular fluid of women with polycystic ovary syndrome. +tissue_expression_ns hsa-mir-34a Glioblastoma 24412053 "Comparing miRNA expression between glioblastoma group and gliomas of grades I-III, 3 miRNAs (miR-10b, mir-34a and miR-101) showed different regulation statuses between high-grade and low-grade tumors." +tissue_expression_ns hsa-mir-23b Myotonic Muscular Dystrophy 24412363 "The Mef2 transcription network is disrupted in myotonic dystrophy heart tissue,dramatically altering miRNA and mRNA expression." +tissue_expression_ns hsa-mir-16 Parkinson Disease 24427314 "We identified a total of 761 genes and 24 miRNAs that were misregulated in the absence of LRRK2 when a false discovery rate of 0.2 was applied. Notably, most changes in gene expression were modest (i.e., <2 fold). By real-time quantitative RT-PCR, we confirmed the variations of selected genes (e.g., adra2, syt2, opalin) and miRNAs (e.g., miR-16, miR-25)." +tissue_expression_ns hsa-mir-126 "Carcinoma, Renal Cell" 24428907 A combined expression level of miR-21 and miR-126 accurately predicted CSS in two independent RCC cohorts and seems feasible for clinical application in assessing prognosis. +tissue_expression_ns hsa-mir-21 "Carcinoma, Renal Cell" 24428907 A combined expression level of miR-21 and miR-126 accurately predicted CSS in two independent RCC cohorts and seems feasible for clinical application in assessing prognosis. +tissue_expression_ns hsa-mir-146a Liver Neoplasms 24431000 Aberrant miRNA expression response to UV irradiation in human liver cancer cells. +tissue_expression_ns hsa-mir-21 Liver Neoplasms 24431000 Aberrant miRNA expression response to UV irradiation in human liver cancer cells. +tissue_expression_ns hsa-mir-26a Liver Neoplasms 24431000 Aberrant miRNA expression response to UV irradiation in human liver cancer cells. +tissue_expression_ns hsa-mir-34a Liver Neoplasms 24431000 Aberrant miRNA expression response to UV irradiation in human liver cancer cells. +tissue_expression_ns hsa-let-7 Prostate Neoplasms 24431212 Aberrant microRNA expression likely controls RAS oncogene activation during malignant transformation of human prostate epithelial and stem cells by arsenic. +tissue_expression_ns hsa-mir-134 Prostate Neoplasms 24431212 Aberrant microRNA expression likely controls RAS oncogene activation during malignant transformation of human prostate epithelial and stem cells by arsenic. +tissue_expression_ns hsa-mir-138 Prostate Neoplasms 24431212 Aberrant microRNA expression likely controls RAS oncogene activation during malignant transformation of human prostate epithelial and stem cells by arsenic. +tissue_expression_ns hsa-mir-143 Prostate Neoplasms 24431212 Aberrant microRNA expression likely controls RAS oncogene activation during malignant transformation of human prostate epithelial and stem cells by arsenic. +tissue_expression_ns hsa-mir-155 Prostate Neoplasms 24431212 Aberrant microRNA expression likely controls RAS oncogene activation during malignant transformation of human prostate epithelial and stem cells by arsenic. +tissue_expression_ns hsa-mir-181c Prostate Neoplasms 24431212 Aberrant microRNA expression likely controls RAS oncogene activation during malignant transformation of human prostate epithelial and stem cells by arsenic. +tissue_expression_ns hsa-mir-181d Prostate Neoplasms 24431212 Aberrant microRNA expression likely controls RAS oncogene activation during malignant transformation of human prostate epithelial and stem cells by arsenic. +tissue_expression_ns hsa-mir-205 Prostate Neoplasms 24431212 Aberrant microRNA expression likely controls RAS oncogene activation during malignant transformation of human prostate epithelial and stem cells by arsenic. +tissue_expression_ns hsa-mir-34c Prostate Neoplasms 24431212 Aberrant microRNA expression likely controls RAS oncogene activation during malignant transformation of human prostate epithelial and stem cells by arsenic. +tissue_expression_ns hsa-mir-373 Prostate Neoplasms 24431212 Aberrant microRNA expression likely controls RAS oncogene activation during malignant transformation of human prostate epithelial and stem cells by arsenic. +tissue_expression_ns hsa-mir-10a Urinary Bladder Cancer 24439061 The role of microRNA profiling in prognosticating progression in Ta and T1 urinary bladder cancer. +tissue_expression_ns hsa-mir-31 Urinary Bladder Cancer 24439061 The role of microRNA profiling in prognosticating progression in Ta and T1 urinary bladder cancer. +tissue_expression_ns hsa-mir-10b Breast Neoplasms 24440078 Detection of miRNA expression in intact cells using activatable sensor oligonucleotides. +tissue_expression_ns hsa-mir-10b Breast Neoplasms 24440980 "MiR-21, -155, -222 and -10b are reliable candidate biomarkers for detection of breast cancer." +tissue_expression_ns hsa-mir-155 Breast Neoplasms 24440980 "MiR-21, -155, -222 and -10b are reliable candidate biomarkers for detection of breast cancer." +tissue_expression_ns hsa-mir-21 Breast Neoplasms 24440980 "MiR-21, -155, -222 and -10b are reliable candidate biomarkers for detection of breast cancer." +tissue_expression_ns hsa-mir-222 Breast Neoplasms 24440980 "MiR-21, -155, -222 and -10b are reliable candidate biomarkers for detection of breast cancer." +tissue_expression_ns hsa-mir-150 "Carcinoma, Thyroid" 24443580 MicroRNA profile of poorly differentiated thyroid carcinomas: new diagnostic and prognostic insights. +tissue_expression_ns hsa-mir-23b "Carcinoma, Thyroid" 24443580 MicroRNA profile of poorly differentiated thyroid carcinomas: new diagnostic and prognostic insights. +tissue_expression_ns hsa-mir-10b "Carcinoma, Lung, Non-Small-Cell" 24448358 "Expression of miR-128, -10b, -502-3p and -192 differed between SCC and AC, and miR-128 and -192 - between NLP and NSCLC." +tissue_expression_ns hsa-mir-128 "Carcinoma, Lung, Non-Small-Cell" 24448358 "Expression of miR-128, -10b, -502-3p and -192 differed between SCC and AC, and miR-128 and -192 - between NLP and NSCLC." +tissue_expression_ns hsa-mir-192 "Carcinoma, Lung, Non-Small-Cell" 24448358 "Expression of miR-128, -10b, -502-3p and -192 differed between SCC and AC, and miR-128 and -192 - between NLP and NSCLC." +tissue_expression_ns hsa-mir-502 "Carcinoma, Lung, Non-Small-Cell" 24448358 "Expression of miR-128, -10b, -502-3p and -192 differed between SCC and AC, and miR-128 and -192 - between NLP and NSCLC." +tissue_expression_ns hsa-mir-662 "Carcinoma, Lung, Non-Small-Cell" 24448358 "Of these six miRNAs, miR-662, -192 and -192* were confirmed as prognostic in the independent SCC cohort." +tissue_expression_ns hsa-let-7 Prostate Neoplasms 24452514 Comprehensive microRNA profiling of prostate cancer cells after ionizing radiation treatment. +tissue_expression_ns hsa-mir-1 Prostate Neoplasms 24452514 Comprehensive microRNA profiling of prostate cancer cells after ionizing radiation treatment. +tissue_expression_ns hsa-mir-106b Prostate Neoplasms 24452514 Comprehensive microRNA profiling of prostate cancer cells after ionizing radiation treatment. +tissue_expression_ns hsa-mir-125b Prostate Neoplasms 24452514 Comprehensive microRNA profiling of prostate cancer cells after ionizing radiation treatment. +tissue_expression_ns hsa-mir-205 Prostate Neoplasms 24452514 Comprehensive microRNA profiling of prostate cancer cells after ionizing radiation treatment. +tissue_expression_ns hsa-mir-20a Prostate Neoplasms 24452514 Comprehensive microRNA profiling of prostate cancer cells after ionizing radiation treatment. +tissue_expression_ns hsa-mir-21 Prostate Neoplasms 24452514 Comprehensive microRNA profiling of prostate cancer cells after ionizing radiation treatment. +tissue_expression_ns hsa-mir-34a Prostate Neoplasms 24452514 Comprehensive microRNA profiling of prostate cancer cells after ionizing radiation treatment. +tissue_expression_ns hsa-mir-521 Prostate Neoplasms 24452514 Comprehensive microRNA profiling of prostate cancer cells after ionizing radiation treatment. +tissue_expression_ns hsa-mir-155 "Carcinoma, Lung, Non-Small-Cell" 24460255 "the miR-155 expression level plays a prognostic role in patients with cancer, especially NSCLCs and digestive system carcinomas." +tissue_expression_ns hsa-mir-1 Atrial Fibrillation 24461008 AF alters the miRNA expression profiles of the left atria of MS patients. These findings may be useful for the biological understanding of AF in MS patients. +tissue_expression_ns hsa-mir-26a Atrial Fibrillation 24461008 AF alters the miRNA expression profiles of the left atria of MS patients. These findings may be useful for the biological understanding of AF in MS patients. +tissue_expression_ns hsa-mir-3613 Atrial Fibrillation 24461008 AF alters the miRNA expression profiles of the left atria of MS patients. These findings may be useful for the biological understanding of AF in MS patients. +tissue_expression_ns hsa-mir-466 Atrial Fibrillation 24461008 AF alters the miRNA expression profiles of the left atria of MS patients. These findings may be useful for the biological understanding of AF in MS patients. +tissue_expression_ns hsa-mir-574 Atrial Fibrillation 24461008 AF alters the miRNA expression profiles of the left atria of MS patients. These findings may be useful for the biological understanding of AF in MS patients. +tissue_expression_ns hsa-mir-146a Mycobacterium Avium Complex Disease 24462562 Analysis of miRNA expression profiling in human macrophages responding to Mycobacterium infection: induction of the immune regulator miR-146a. +tissue_expression_ns hsa-mir-17 Leukemia 24479800 "Aberrant expression of oncogenic miRNAs, including miR-155, miR-17-92, miR-21, miR-125b, miR-93, miR-143-p3, miR-196b, and miR-223 promotes leukemogenesis through increasing the leukemic stem/progenitor cell population, promoting cell proliferation, blocking cell differentiation, and diminishing cell apoptosis." +tissue_expression_ns hsa-mir-133 Polycystic Kidney Disease 24489795 "We found that in ADPKD urine specimens, miRNA previously implicated as kidney tumor suppressors (miR-1 and miR-133), as well as miRNA of presumed inflammatory and fibroblast cell origin (miR-223/miR-199), are dysregulated when compared to other CKD patients. Concordant with findings in the primary tubule epithelial cell model, this suggests roles for dysregulated miRNA in ADPKD pathogenesis and potential use as biomarkers. We intend to assess prognostic potential of miRNA in a followup analysis." +tissue_expression_ns hsa-mir-143 Polycystic Kidney Disease 24489795 "We found that in ADPKD urine specimens, miRNA previously implicated as kidney tumor suppressors (miR-1 and miR-133), as well as miRNA of presumed inflammatory and fibroblast cell origin (miR-223/miR-199), are dysregulated when compared to other CKD patients. Concordant with findings in the primary tubule epithelial cell model, this suggests roles for dysregulated miRNA in ADPKD pathogenesis and potential use as biomarkers. We intend to assess prognostic potential of miRNA in a followup analysis." +tissue_expression_ns hsa-mir-199 Polycystic Kidney Disease 24489795 "We found that in ADPKD urine specimens, miRNA previously implicated as kidney tumor suppressors (miR-1 and miR-133), as well as miRNA of presumed inflammatory and fibroblast cell origin (miR-223/miR-199), are dysregulated when compared to other CKD patients. Concordant with findings in the primary tubule epithelial cell model, this suggests roles for dysregulated miRNA in ADPKD pathogenesis and potential use as biomarkers. We intend to assess prognostic potential of miRNA in a followup analysis." +tissue_expression_ns hsa-mir-205 Polycystic Kidney Disease 24489795 "We found that in ADPKD urine specimens, miRNA previously implicated as kidney tumor suppressors (miR-1 and miR-133), as well as miRNA of presumed inflammatory and fibroblast cell origin (miR-223/miR-199), are dysregulated when compared to other CKD patients. Concordant with findings in the primary tubule epithelial cell model, this suggests roles for dysregulated miRNA in ADPKD pathogenesis and potential use as biomarkers. We intend to assess prognostic potential of miRNA in a followup analysis." +tissue_expression_ns hsa-mir-223 Polycystic Kidney Disease 24489795 "We found that in ADPKD urine specimens, miRNA previously implicated as kidney tumor suppressors (miR-1 and miR-133), as well as miRNA of presumed inflammatory and fibroblast cell origin (miR-223/miR-199), are dysregulated when compared to other CKD patients. Concordant with findings in the primary tubule epithelial cell model, this suggests roles for dysregulated miRNA in ADPKD pathogenesis and potential use as biomarkers. We intend to assess prognostic potential of miRNA in a followup analysis." +tissue_expression_ns hsa-mir-141 Colorectal Carcinoma 24510588 "miR-200a, miR-200c, miR-141, and miR-429 expression levels may identify CRC patients, including those with stage II disease, who are most likely to benefit from adjuvant chemotherapy." +tissue_expression_ns hsa-mir-200a Colorectal Carcinoma 24510588 "miR-200a, miR-200c, miR-141, and miR-429 expression levels may identify CRC patients, including those with stage II disease, who are most likely to benefit from adjuvant chemotherapy." +tissue_expression_ns hsa-mir-200c Colorectal Carcinoma 24510588 "miR-200a, miR-200c, miR-141, and miR-429 expression levels may identify CRC patients, including those with stage II disease, who are most likely to benefit from adjuvant chemotherapy." +tissue_expression_ns hsa-mir-128 Neoplasms [unspecific] 24515752 Microvesicle-associated microRNA expression is altered upon particulate matter exposure in healthy workers and in A549 cells. +tissue_expression_ns hsa-mir-302c Neoplasms [unspecific] 24515752 Microvesicle-associated microRNA expression is altered upon particulate matter exposure in healthy workers and in A549 cells. +tissue_expression_ns hsa-mir-143 "Carcinoma, Cervical" 24517947 "It seemed that miR-143 play an important role in the processes of generation and progression of cervical cancer. However, there was no significant difference found between the different ethnic groups. The expression level of miR-143 might serve as a valuable adjuvant parameter for diagnosing and predicting the state of cervical cancer." +tissue_expression_ns hsa-mir-182 Prostate Neoplasms 24518785 Results show that miR-182 and 187 are promising biomarkers for prostate cancer prognosis to identify patients at risk for progression and for diagnosis to improve the predictive capability of existing biomarkers. +tissue_expression_ns hsa-mir-187 Prostate Neoplasms 24518785 Results show that miR-182 and 187 are promising biomarkers for prostate cancer prognosis to identify patients at risk for progression and for diagnosis to improve the predictive capability of existing biomarkers. +tissue_expression_ns hsa-mir-363 Colorectal Carcinoma 24519049 The expression pattern in female is different from that in male.miR-363 and miR-490-5p possess the potential in screening colorectal cancer patients from healthy people. +tissue_expression_ns hsa-mir-490 Colorectal Carcinoma 24519049 The expression pattern in female is different from that in male.miR-363 and miR-490-5p possess the potential in screening colorectal cancer patients from healthy people. +tissue_expression_ns hsa-mir-195 Bladder Neoplasms 24520312 The microRNA expression signature of bladder cancer by deep sequencing: the functional significance of the miR-195/497 cluster. +tissue_expression_ns hsa-mir-497 Bladder Neoplasms 24520312 The microRNA expression signature of bladder cancer by deep sequencing: the functional significance of the miR-195/497 cluster. +tissue_expression_ns hsa-mir-133a Neuroendocrine Tumors 24535468 Establishment of robust controls for the normalization of miRNA expression in neuroendocrine tumors of the ileum and pancreas. +tissue_expression_ns hsa-mir-191 Neuroendocrine Tumors 24535468 Establishment of robust controls for the normalization of miRNA expression in neuroendocrine tumors of the ileum and pancreas. +tissue_expression_ns hsa-mir-93 Neuroendocrine Tumors 24535468 Establishment of robust controls for the normalization of miRNA expression in neuroendocrine tumors of the ileum and pancreas. +tissue_expression_ns hsa-mir-92a Colorectal Carcinoma 24551148 "MicroRNA-92a might be a novel potential biomarker in the diagnosis of colorectal cancer, and more studies are needed to highlight the theoretical strengths." +tissue_expression_ns hsa-mir-155 Autoimmune Thyroiditis 24554510 microRNA expressions in CD4+ and CD8+ T-cell subsets in autoimmune thyroid diseases. +tissue_expression_ns hsa-mir-200a Autoimmune Thyroiditis 24554510 microRNA expressions in CD4+ and CD8+ T-cell subsets in autoimmune thyroid diseases. +tissue_expression_ns hsa-mir-196a "Carcinoma, Periampullary" 24555977 "Differentially expressed common miRNA signatures identified in PAC subgroups may have a role in pathogenesis of PAC and miR-375, miR-31 and miR-196a expression patterns may differentiate PAC subtypes." +tissue_expression_ns hsa-mir-31 "Carcinoma, Periampullary" 24555977 "Differentially expressed common miRNA signatures identified in PAC subgroups may have a role in pathogenesis of PAC and miR-375, miR-31 and miR-196a expression patterns may differentiate PAC subtypes." +tissue_expression_ns hsa-mir-375 "Carcinoma, Periampullary" 24555977 "Differentially expressed common miRNA signatures identified in PAC subgroups may have a role in pathogenesis of PAC and miR-375, miR-31 and miR-196a expression patterns may differentiate PAC subtypes." +tissue_expression_ns hsa-mir-122 Hepatoblastoma 24570391 MicroRNA expression might predict prognosis of epithelial hepatoblastoma. +tissue_expression_ns hsa-mir-140 Hepatoblastoma 24570391 MicroRNA expression might predict prognosis of epithelial hepatoblastoma. +tissue_expression_ns hsa-mir-17 Hepatoblastoma 24570391 MicroRNA expression might predict prognosis of epithelial hepatoblastoma. +tissue_expression_ns hsa-mir-18a Hepatoblastoma 24570391 MicroRNA expression might predict prognosis of epithelial hepatoblastoma. +tissue_expression_ns hsa-mir-195 Hepatoblastoma 24570391 MicroRNA expression might predict prognosis of epithelial hepatoblastoma. +tissue_expression_ns hsa-mir-210 Hepatoblastoma 24570391 MicroRNA expression might predict prognosis of epithelial hepatoblastoma. +tissue_expression_ns hsa-mir-214 Hepatoblastoma 24570391 MicroRNA expression might predict prognosis of epithelial hepatoblastoma. +tissue_expression_ns hsa-mir-221 Hepatoblastoma 24570391 MicroRNA expression might predict prognosis of epithelial hepatoblastoma. +tissue_expression_ns hsa-mir-222 Hepatoblastoma 24570391 MicroRNA expression might predict prognosis of epithelial hepatoblastoma. +tissue_expression_ns hsa-mir-223 Hepatoblastoma 24570391 MicroRNA expression might predict prognosis of epithelial hepatoblastoma. +tissue_expression_ns hsa-mir-224 Hepatoblastoma 24570391 MicroRNA expression might predict prognosis of epithelial hepatoblastoma. +tissue_expression_ns hsa-mir-34a Hepatoblastoma 24570391 MicroRNA expression might predict prognosis of epithelial hepatoblastoma. +tissue_expression_ns hsa-mir-96 Hepatoblastoma 24570391 MicroRNA expression might predict prognosis of epithelial hepatoblastoma. +tissue_expression_ns hsa-mir-155 Lung Neoplasms 24574164 "Under clinical conditions, mRNA detection is likely unsuitable for improving sensitivity of EBUS-TBNA-facilitated cancer staging. In contrast,detection of miRNA combined with EBUS-TBNA cytology may improve staging sensitivity." +tissue_expression_ns hsa-mir-200c Lung Neoplasms 24574164 "Under clinical conditions, mRNA detection is likely unsuitable for improving sensitivity of EBUS-TBNA-facilitated cancer staging. In contrast,detection of miRNA combined with EBUS-TBNA cytology may improve staging sensitivity." +tissue_expression_ns hsa-mir-21 Lung Neoplasms 24574164 "Under clinical conditions, mRNA detection is likely unsuitable for improving sensitivity of EBUS-TBNA-facilitated cancer staging. In contrast,detection of miRNA combined with EBUS-TBNA cytology may improve staging sensitivity." +tissue_expression_ns hsa-mir-34a Lung Neoplasms 24574164 "Under clinical conditions, mRNA detection is likely unsuitable for improving sensitivity of EBUS-TBNA-facilitated cancer staging. In contrast,detection of miRNA combined with EBUS-TBNA cytology may improve staging sensitivity." +tissue_expression_ns hsa-mir-100 "Adenocarcinoma, Pancreatic Ductal" 24575833 A microRNA meta-signature for pancreatic ductal adenocarcinoma. +tissue_expression_ns hsa-mir-143 "Adenocarcinoma, Pancreatic Ductal" 24575833 A microRNA meta-signature for pancreatic ductal adenocarcinoma. +tissue_expression_ns hsa-mir-148a "Adenocarcinoma, Pancreatic Ductal" 24575833 A microRNA meta-signature for pancreatic ductal adenocarcinoma. +tissue_expression_ns hsa-mir-155 "Adenocarcinoma, Pancreatic Ductal" 24575833 A microRNA meta-signature for pancreatic ductal adenocarcinoma. +tissue_expression_ns hsa-mir-21 "Adenocarcinoma, Pancreatic Ductal" 24575833 A microRNA meta-signature for pancreatic ductal adenocarcinoma. +tissue_expression_ns hsa-mir-217 "Adenocarcinoma, Pancreatic Ductal" 24575833 A microRNA meta-signature for pancreatic ductal adenocarcinoma. +tissue_expression_ns hsa-mir-221 "Adenocarcinoma, Pancreatic Ductal" 24575833 A microRNA meta-signature for pancreatic ductal adenocarcinoma. +tissue_expression_ns hsa-mir-23a "Adenocarcinoma, Pancreatic Ductal" 24575833 A microRNA meta-signature for pancreatic ductal adenocarcinoma. +tissue_expression_ns hsa-mir-31 "Adenocarcinoma, Pancreatic Ductal" 24575833 A microRNA meta-signature for pancreatic ductal adenocarcinoma. +tissue_expression_ns hsa-mir-375 "Adenocarcinoma, Pancreatic Ductal" 24575833 A microRNA meta-signature for pancreatic ductal adenocarcinoma. +tissue_expression_ns hsa-mir-103 Early-Stage Gastric Carcinoma 24577775 Abnormal mirna expression level in early gastric cancer tissues may be associated to the development of gastric cancer. +tissue_expression_ns hsa-mir-141 Early-Stage Gastric Carcinoma 24577775 Abnormal mirna expression level in early gastric cancer tissues may be associated to the development of gastric cancer. +tissue_expression_ns hsa-mir-142 Early-Stage Gastric Carcinoma 24577775 Abnormal mirna expression level in early gastric cancer tissues may be associated to the development of gastric cancer. +tissue_expression_ns hsa-mir-196a Early-Stage Gastric Carcinoma 24577775 Abnormal mirna expression level in early gastric cancer tissues may be associated to the development of gastric cancer. +tissue_expression_ns hsa-mir-25 Early-Stage Gastric Carcinoma 24577775 Abnormal mirna expression level in early gastric cancer tissues may be associated to the development of gastric cancer. +tissue_expression_ns hsa-mir-9-1 Early-Stage Gastric Carcinoma 24577775 Abnormal mirna expression level in early gastric cancer tissues may be associated to the development of gastric cancer. +tissue_expression_ns hsa-mir-196b Tuberculosis 24586438 "The microRNA differential-expression profiles generated in this study provide a good foundation for the development of markers for TB diagnosis, and for investigations on the role of microRNAs in BCG-inoculated and latent-infected individuals." +tissue_expression_ns hsa-mir-376c Tuberculosis 24586438 "The microRNA differential-expression profiles generated in this study provide a good foundation for the development of markers for TB diagnosis, and for investigations on the role of microRNAs in BCG-inoculated and latent-infected individuals." +tissue_expression_ns hsa-mir-106a Ovarian Neoplasms 24591819 Differential microRNA expression signatures and cell type-specific association with Taxol resistance in ovarian cancer cells. +tissue_expression_ns hsa-mir-107 Ovarian Neoplasms 24591819 Differential microRNA expression signatures and cell type-specific association with Taxol resistance in ovarian cancer cells. +tissue_expression_ns hsa-mir-141 Ovarian Neoplasms 24591819 Differential microRNA expression signatures and cell type-specific association with Taxol resistance in ovarian cancer cells. +tissue_expression_ns hsa-mir-187 Ovarian Neoplasms 24591819 Differential microRNA expression signatures and cell type-specific association with Taxol resistance in ovarian cancer cells. +tissue_expression_ns hsa-mir-195 Ovarian Neoplasms 24591819 Differential microRNA expression signatures and cell type-specific association with Taxol resistance in ovarian cancer cells. +tissue_expression_ns hsa-mir-200c Ovarian Neoplasms 24591819 Differential microRNA expression signatures and cell type-specific association with Taxol resistance in ovarian cancer cells. +tissue_expression_ns hsa-mir-378 Ovarian Neoplasms 24591819 Differential microRNA expression signatures and cell type-specific association with Taxol resistance in ovarian cancer cells. +tissue_expression_ns hsa-mir-409 Ovarian Neoplasms 24591819 Differential microRNA expression signatures and cell type-specific association with Taxol resistance in ovarian cancer cells. +tissue_expression_ns hsa-mir-411 Ovarian Neoplasms 24591819 Differential microRNA expression signatures and cell type-specific association with Taxol resistance in ovarian cancer cells. +tissue_expression_ns hsa-mir-432 Ovarian Neoplasms 24591819 Differential microRNA expression signatures and cell type-specific association with Taxol resistance in ovarian cancer cells. +tissue_expression_ns hsa-mir-494 Ovarian Neoplasms 24591819 Differential microRNA expression signatures and cell type-specific association with Taxol resistance in ovarian cancer cells. +tissue_expression_ns hsa-mir-497 Ovarian Neoplasms 24591819 Differential microRNA expression signatures and cell type-specific association with Taxol resistance in ovarian cancer cells. +tissue_expression_ns hsa-mir-622 Ovarian Neoplasms 24591819 Differential microRNA expression signatures and cell type-specific association with Taxol resistance in ovarian cancer cells. +tissue_expression_ns hsa-mir-647 Ovarian Neoplasms 24591819 Differential microRNA expression signatures and cell type-specific association with Taxol resistance in ovarian cancer cells. +tissue_expression_ns hsa-mir-663 Ovarian Neoplasms 24591819 Differential microRNA expression signatures and cell type-specific association with Taxol resistance in ovarian cancer cells. +tissue_expression_ns hsa-mir-96 Ovarian Neoplasms 24591819 Differential microRNA expression signatures and cell type-specific association with Taxol resistance in ovarian cancer cells. +tissue_expression_ns hsa-mir-432 "Carcinoma, Hepatocellular" 24592541 Our study firstly demonstrated that miRNAs were differentially expressed in HCC-MVs compared with CHB and normal controls. Aberrant HCC-MVs miRNAs may play important roles in the development of HCC. +tissue_expression_ns hsa-mir-671 "Carcinoma, Hepatocellular" 24592541 Our study firstly demonstrated that miRNAs were differentially expressed in HCC-MVs compared with CHB and normal controls. Aberrant HCC-MVs miRNAs may play important roles in the development of HCC. +tissue_expression_ns hsa-mir-182 "Squamous Cell Carcinoma, Lung" 24600991 We provide first time evidence through tissue microarray and quantitative PCR validation of mir-182 in the expression of lung squamous cell carcinoma. Our data provide a possible mechanism for lung cancer cell proliferation in lung squamous cell cancer and may be helpful in discovering a new strategy to reveal lung squamous cell carcinoma progress. +tissue_expression_ns hsa-mir-222 "Diabetes Mellitus, Gestational" 24601884 Differential expression of microRNAs in omental adipose tissue from gestational diabetes mellitus subjects reveals miR-222 as a regulator of ER¦Á expression in estrogen-induced insulin resistance. +tissue_expression_ns hsa-mir-25 "Adenocarcinoma, Lung" 24606441 Tissue miR-25 expression may be associated with tumor progression and have prognostic implications in female lung ADC patients. +tissue_expression_ns hsa-mir-202 Endometriosis 24608518 "Differences in miRNA levels could modulate the expression of VEGF-A and TSP-1, which may play an important role in the pathogenesis of endometriosis. The higher angiogenic and proteolytic activities observed in eutopic endometrium from patients might facilitate the implantation of endometrial cells at ectopic sites." +tissue_expression_ns hsa-mir-424 Endometriosis 24608518 "Differences in miRNA levels could modulate the expression of VEGF-A and TSP-1, which may play an important role in the pathogenesis of endometriosis. The higher angiogenic and proteolytic activities observed in eutopic endometrium from patients might facilitate the implantation of endometrial cells at ectopic sites." +tissue_expression_ns hsa-mir-449b Endometriosis 24608518 "Differences in miRNA levels could modulate the expression of VEGF-A and TSP-1, which may play an important role in the pathogenesis of endometriosis. The higher angiogenic and proteolytic activities observed in eutopic endometrium from patients might facilitate the implantation of endometrial cells at ectopic sites." +tissue_expression_ns hsa-mir-556 Endometriosis 24608518 "Differences in miRNA levels could modulate the expression of VEGF-A and TSP-1, which may play an important role in the pathogenesis of endometriosis. The higher angiogenic and proteolytic activities observed in eutopic endometrium from patients might facilitate the implantation of endometrial cells at ectopic sites." +tissue_expression_ns hsa-mir-145 Neoplasms [unspecific] 24609385 "Together, our probabilistic approach of integrating expression and sequence scores establishes a functional link between the aberrant miRNA and mRNA expression, which was previously under-appreciated due to the methodological differences." +tissue_expression_ns hsa-mir-155 Neoplasms [unspecific] 24609385 "Together, our probabilistic approach of integrating expression and sequence scores establishes a functional link between the aberrant miRNA and mRNA expression, which was previously under-appreciated due to the methodological differences." +tissue_expression_ns hsa-mir-183 Neoplasms [unspecific] 24609385 "Together, our probabilistic approach of integrating expression and sequence scores establishes a functional link between the aberrant miRNA and mRNA expression, which was previously under-appreciated due to the methodological differences." +tissue_expression_ns hsa-mir-21 Neoplasms [unspecific] 24609385 "Together, our probabilistic approach of integrating expression and sequence scores establishes a functional link between the aberrant miRNA and mRNA expression, which was previously under-appreciated due to the methodological differences." +tissue_expression_ns hsa-mir-221 Neoplasms [unspecific] 24609385 "Together, our probabilistic approach of integrating expression and sequence scores establishes a functional link between the aberrant miRNA and mRNA expression, which was previously under-appreciated due to the methodological differences." +tissue_expression_ns hsa-mir-222 Neoplasms [unspecific] 24609385 "Together, our probabilistic approach of integrating expression and sequence scores establishes a functional link between the aberrant miRNA and mRNA expression, which was previously under-appreciated due to the methodological differences." +tissue_expression_ns hsa-mir-122 Hepatitis C Virus Infection 24612050 "However, a significant difference was observed in miR-122 expression between patients who showed a sustained virological response (SVR) and those who did not (Pâ€?â€?.05)." +tissue_expression_ns hsa-mir-132 Gastric Neoplasms 24621117 miR-132 could serve as an efficient prognostic factor for gastric cancer patients. +tissue_expression_ns hsa-mir-489 "Carcinoma, Renal Cell" 24621579 New miRNA profiles accurately distinguish renal cell carcinomas and upper tract urothelial carcinomas from the normal kidney. +tissue_expression_ns hsa-mir-17 Breast Neoplasms 24626680 MicroRNA expression profiles in human breast cancer cells after multifraction and single-dose radiation treatment. +tissue_expression_ns hsa-mir-18a Breast Neoplasms 24626680 MicroRNA expression profiles in human breast cancer cells after multifraction and single-dose radiation treatment. +tissue_expression_ns hsa-mir-19a Breast Neoplasms 24626680 MicroRNA expression profiles in human breast cancer cells after multifraction and single-dose radiation treatment. +tissue_expression_ns hsa-mir-19b Breast Neoplasms 24626680 MicroRNA expression profiles in human breast cancer cells after multifraction and single-dose radiation treatment. +tissue_expression_ns hsa-mir-20a Breast Neoplasms 24626680 MicroRNA expression profiles in human breast cancer cells after multifraction and single-dose radiation treatment. +tissue_expression_ns hsa-mir-92a Breast Neoplasms 24626680 MicroRNA expression profiles in human breast cancer cells after multifraction and single-dose radiation treatment. +tissue_expression_ns hsa-mir-146b "Carcinoma, Thyroid, Follicular" 24631480 Differential miRNA expression defines migration and reduced apoptosis in follicular thyroid carcinomas. +tissue_expression_ns hsa-mir-183 "Carcinoma, Thyroid, Follicular" 24631480 Differential miRNA expression defines migration and reduced apoptosis in follicular thyroid carcinomas. +tissue_expression_ns hsa-mir-199b "Carcinoma, Thyroid, Follicular" 24631480 Differential miRNA expression defines migration and reduced apoptosis in follicular thyroid carcinomas. +tissue_expression_ns hsa-mir-221 "Carcinoma, Thyroid, Follicular" 24631480 Differential miRNA expression defines migration and reduced apoptosis in follicular thyroid carcinomas. +tissue_expression_ns hsa-mir-155 "Carcinoma, Breast, Triple Negative" 24632568 microRNA expression profiling identifies a four microRNA signature as a novel diagnostic and prognostic biomarker in triple negative breast cancers. +tissue_expression_ns hsa-mir-27a "Carcinoma, Breast, Triple Negative" 24632568 microRNA expression profiling identifies a four microRNA signature as a novel diagnostic and prognostic biomarker in triple negative breast cancers. +tissue_expression_ns hsa-mir-30e "Carcinoma, Breast, Triple Negative" 24632568 microRNA expression profiling identifies a four microRNA signature as a novel diagnostic and prognostic biomarker in triple negative breast cancers. +tissue_expression_ns hsa-mir-493 "Carcinoma, Breast, Triple Negative" 24632568 microRNA expression profiling identifies a four microRNA signature as a novel diagnostic and prognostic biomarker in triple negative breast cancers. +tissue_expression_ns hsa-mir-10a Breast Neoplasms 24632820 "In summary, we have identified a set of recurrence-related microRNAs with potential prognostic value to identify patients who will likely develop metastasis early after primary breast surgery." +tissue_expression_ns hsa-mir-149 Breast Neoplasms 24632820 "In summary, we have identified a set of recurrence-related microRNAs with potential prognostic value to identify patients who will likely develop metastasis early after primary breast surgery." +tissue_expression_ns hsa-mir-20b Breast Neoplasms 24632820 "In summary, we have identified a set of recurrence-related microRNAs with potential prognostic value to identify patients who will likely develop metastasis early after primary breast surgery." +tissue_expression_ns hsa-mir-30a Breast Neoplasms 24632820 "In summary, we have identified a set of recurrence-related microRNAs with potential prognostic value to identify patients who will likely develop metastasis early after primary breast surgery." +tissue_expression_ns hsa-mir-342 Breast Neoplasms 24632820 "In summary, we have identified a set of recurrence-related microRNAs with potential prognostic value to identify patients who will likely develop metastasis early after primary breast surgery." +tissue_expression_ns hsa-mir-125b Hepatitis C Virus Infection 24637254 "PBMC-miR-125b expression levels were inversely related to the achievement of an SVR in HCV-1 patients, independent of interleukin-28B genotype,and was the single predictor of SVR in non-RVR patients." +tissue_expression_ns hsa-mir-124 "Stroke, Hemorrhagic" 24650689 Both miR-124-3p and miR-16 are diagnostic markers to discriminate HS and IS. +tissue_expression_ns hsa-mir-16 "Stroke, Hemorrhagic" 24650689 Both miR-124-3p and miR-16 are diagnostic markers to discriminate HS and IS. +tissue_expression_ns hsa-mir-23a "Lymphoma, Large B-Cell, Diffuse" 24659264 MicroRNA-23a expression in paraffin-embedded specimen correlates with overall survival of diffuse large B-cell lymphoma. +tissue_expression_ns hsa-mir-130b Pancreatic Neoplasms 24662333 "We developed and validated a 5-miRNA classifier that can accurately predict which preoperative pancreatic EUS-FNA specimens contain PDAC. This test might aid in the diagnosis of pancreatic cancer by reducing the number of FNAs without a definitive adenocarcinoma diagnosis, thereby reducing the number of repeat EUS-FNA procedures." +tissue_expression_ns hsa-mir-135b Pancreatic Neoplasms 24662333 "We developed and validated a 5-miRNA classifier that can accurately predict which preoperative pancreatic EUS-FNA specimens contain PDAC. This test might aid in the diagnosis of pancreatic cancer by reducing the number of FNAs without a definitive adenocarcinoma diagnosis, thereby reducing the number of repeat EUS-FNA procedures." +tissue_expression_ns hsa-mir-148a Pancreatic Neoplasms 24662333 "We developed and validated a 5-miRNA classifier that can accurately predict which preoperative pancreatic EUS-FNA specimens contain PDAC. This test might aid in the diagnosis of pancreatic cancer by reducing the number of FNAs without a definitive adenocarcinoma diagnosis, thereby reducing the number of repeat EUS-FNA procedures." +tissue_expression_ns hsa-mir-196 Pancreatic Neoplasms 24662333 "We developed and validated a 5-miRNA classifier that can accurately predict which preoperative pancreatic EUS-FNA specimens contain PDAC. This test might aid in the diagnosis of pancreatic cancer by reducing the number of FNAs without a definitive adenocarcinoma diagnosis, thereby reducing the number of repeat EUS-FNA procedures." +tissue_expression_ns hsa-mir-24 Pancreatic Neoplasms 24662333 "We developed and validated a 5-miRNA classifier that can accurately predict which preoperative pancreatic EUS-FNA specimens contain PDAC. This test might aid in the diagnosis of pancreatic cancer by reducing the number of FNAs without a definitive adenocarcinoma diagnosis, thereby reducing the number of repeat EUS-FNA procedures." +tissue_expression_ns hsa-mir-125a Obesity 24675842 Adaptive expression of microRNA-125a in adipose tissue in response to obesity in mice and men. +tissue_expression_ns hsa-mir-19a "Carcinoma, Supraglottic" 24676647 MicroRNA expression profiles in supraglottic carcinoma. +tissue_expression_ns hsa-mir-206 "Carcinoma, Supraglottic" 24676647 MicroRNA expression profiles in supraglottic carcinoma. +tissue_expression_ns hsa-mir-21 "Carcinoma, Supraglottic" 24676647 MicroRNA expression profiles in supraglottic carcinoma. +tissue_expression_ns hsa-mir-33a "Carcinoma, Supraglottic" 24676647 MicroRNA expression profiles in supraglottic carcinoma. +tissue_expression_ns hsa-mir-375 "Carcinoma, Supraglottic" 24676647 MicroRNA expression profiles in supraglottic carcinoma. +tissue_expression_ns hsa-mir-30a "Carcinoma, Ovarian, Serous" 24676806 The expression of miR-30a* and miR-30e* is associated with a dualistic model for grading ovarian papillary serious carcinoma. +tissue_expression_ns hsa-mir-30e "Carcinoma, Ovarian, Serous" 24676806 The expression of miR-30a* and miR-30e* is associated with a dualistic model for grading ovarian papillary serious carcinoma. +tissue_expression_ns hsa-mir-21 "Carcinoma, Esophageal" 24680681 The expression of miR-21 and miR-375 predict prognosis of esophageal cancer. +tissue_expression_ns hsa-mir-375 "Carcinoma, Esophageal" 24680681 The expression of miR-21 and miR-375 predict prognosis of esophageal cancer. +tissue_expression_ns hsa-mir-125b-2 Recurrent Spontaneous Abortion 24686457 Genome-wide miRNA profiling of villus and decidua of recurrent spontaneous abortion patients. +tissue_expression_ns hsa-mir-184 Recurrent Spontaneous Abortion 24686457 Genome-wide miRNA profiling of villus and decidua of recurrent spontaneous abortion patients. +tissue_expression_ns hsa-mir-187 Recurrent Spontaneous Abortion 24686457 Genome-wide miRNA profiling of villus and decidua of recurrent spontaneous abortion patients. +tissue_expression_ns hsa-mir-3175 Recurrent Spontaneous Abortion 24686457 Genome-wide miRNA profiling of villus and decidua of recurrent spontaneous abortion patients. +tissue_expression_ns hsa-mir-4672 Recurrent Spontaneous Abortion 24686457 Genome-wide miRNA profiling of villus and decidua of recurrent spontaneous abortion patients. +tissue_expression_ns hsa-mir-517c Recurrent Spontaneous Abortion 24686457 Genome-wide miRNA profiling of villus and decidua of recurrent spontaneous abortion patients. +tissue_expression_ns hsa-mir-519a-1 Recurrent Spontaneous Abortion 24686457 Genome-wide miRNA profiling of villus and decidua of recurrent spontaneous abortion patients. +tissue_expression_ns hsa-mir-520f Recurrent Spontaneous Abortion 24686457 Genome-wide miRNA profiling of villus and decidua of recurrent spontaneous abortion patients. +tissue_expression_ns hsa-mir-520h Recurrent Spontaneous Abortion 24686457 Genome-wide miRNA profiling of villus and decidua of recurrent spontaneous abortion patients. +tissue_expression_ns hsa-mir-522 Recurrent Spontaneous Abortion 24686457 Genome-wide miRNA profiling of villus and decidua of recurrent spontaneous abortion patients. +tissue_expression_ns hsa-let-7d Glioblastoma 24691539 microRNA expression pattern modulates temozolomide response in GBM tumors with cancer stem cells. +tissue_expression_ns hsa-mir-10a Glioblastoma 24691539 microRNA expression pattern modulates temozolomide response in GBM tumors with cancer stem cells. +tissue_expression_ns hsa-mir-10b Glioblastoma 24691539 microRNA expression pattern modulates temozolomide response in GBM tumors with cancer stem cells. +tissue_expression_ns hsa-mir-137 Glioblastoma 24691539 microRNA expression pattern modulates temozolomide response in GBM tumors with cancer stem cells. +tissue_expression_ns hsa-mir-145 Glioblastoma 24691539 microRNA expression pattern modulates temozolomide response in GBM tumors with cancer stem cells. +tissue_expression_ns hsa-mir-153 Glioblastoma 24691539 microRNA expression pattern modulates temozolomide response in GBM tumors with cancer stem cells. +tissue_expression_ns hsa-mir-181b Glioblastoma 24691539 microRNA expression pattern modulates temozolomide response in GBM tumors with cancer stem cells. +tissue_expression_ns hsa-mir-455 Glioblastoma 24691539 microRNA expression pattern modulates temozolomide response in GBM tumors with cancer stem cells. +tissue_expression_ns hsa-mir-9 Glioblastoma 24691539 microRNA expression pattern modulates temozolomide response in GBM tumors with cancer stem cells. +tissue_expression_ns hsa-mir-122 Hepatitis C Virus Infection 24696531 The study thus unveiled the role of miR-122 as a plausible diagnostic biomarker during HCV genotype-3 infection in India. +tissue_expression_ns hsa-mir-215 "Carcinoma, Cervical" 24710934 "It was concluded that the expression level of miR-215 is associated with cervical tumor progression and worse survival rate, suggesting that it may serve as a potential prognostic marker to identify patients at higher risk of recurrence." +tissue_expression_ns hsa-mir-210 Astrocytoma 24729345 "MiR-210 levels can be potentially established as a biomarker for pathological diagnosis of malignant astrocytic tumour progression. In addition,the expression of miR-210 can be utilized as an additional identification measure of glioma tumour origin." +tissue_expression_ns hsa-mir-138 Colon Neoplasms 24732966 "miRs including mir-425, mir-196, mir-155, mir-150, mir-351, mir-16, let-7, mir34, and mir-138 were differentially expressed between the dietary groups." +tissue_expression_ns hsa-mir-21 Uterine Corpus Serous Adenocarcinoma 24748979 microRNA expression patterns across seven cancers are highly correlated and dominated by evolutionarily ancient families. +tissue_expression_ns hsa-mir-21 "Squamous Cell Carcinoma, Oral" 24755828 MiR-21 expression in the tumor stroma of oral squamous cell carcinoma: an independent biomarker of disease free survival. +tissue_expression_ns hsa-mir-200a Obesity 24758184 "Taken together, our data indicate that the dysregulated expression of miRNAs occurs in distinct cell types and is likely to affect cell-specific function(s) of obese WAT." +tissue_expression_ns hsa-mir-200b Obesity 24758184 "Taken together, our data indicate that the dysregulated expression of miRNAs occurs in distinct cell types and is likely to affect cell-specific function(s) of obese WAT." +tissue_expression_ns hsa-mir-335 Obesity 24758184 "Taken together, our data indicate that the dysregulated expression of miRNAs occurs in distinct cell types and is likely to affect cell-specific function(s) of obese WAT." +tissue_expression_ns hsa-mir-342 Obesity 24758184 "Taken together, our data indicate that the dysregulated expression of miRNAs occurs in distinct cell types and is likely to affect cell-specific function(s) of obese WAT." +tissue_expression_ns hsa-mir-122 Varicella 24759212 Dysregulated microRNA expression in serum of non-vaccinated children with varicella. +tissue_expression_ns hsa-mir-132 Varicella 24759212 Dysregulated microRNA expression in serum of non-vaccinated children with varicella. +tissue_expression_ns hsa-mir-197 Varicella 24759212 Dysregulated microRNA expression in serum of non-vaccinated children with varicella. +tissue_expression_ns hsa-mir-363 Varicella 24759212 Dysregulated microRNA expression in serum of non-vaccinated children with varicella. +tissue_expression_ns hsa-mir-629 Varicella 24759212 Dysregulated microRNA expression in serum of non-vaccinated children with varicella. +tissue_expression_ns hsa-mir-125a Post-Traumatic Stress Disorder 24759737 Dysregulation in microRNA expression is associated with alterations in immune functions in combat veterans with post-traumatic stress disorder. +tissue_expression_ns hsa-mir-199a Keloid 24782087 Keloid microRNA expression analysis and the influence of miR-199a-5p on the proliferation of keloid fibroblasts. +tissue_expression_ns hsa-mir-21 Perlman Syndrome 24786382 Our study is the first to investigate the association between placental miRNA expression and macrosomia. Our results indicate that the expression level of miR-21 in placental tissue may be involved in the development of macrosomia. +tissue_expression_ns hsa-mir-145 "Adenocarcinoma, Colon" 24791633 "Differential expression of microRNA-320a, -145, and-192 along the continuum of normal mucosa to high-grade dysplastic adenomas of the colorectum." +tissue_expression_ns hsa-mir-192 "Adenocarcinoma, Colon" 24791633 "Differential expression of microRNA-320a, -145, and-193 along the continuum of normal mucosa to high-grade dysplastic adenomas of the colorectum." +tissue_expression_ns hsa-mir-320a "Adenocarcinoma, Colon" 24791633 "Differential expression of microRNA-320a, -145, and-194 along the continuum of normal mucosa to high-grade dysplastic adenomas of the colorectum." +tissue_expression_ns hsa-mir-26a Multiple Sclerosis 24792898 "miR-326 and miR-26a, two potential markers for diagnosis of relapse and remission phases in patient with relapsing-remitting multiple sclerosis." +tissue_expression_ns hsa-mir-326 Multiple Sclerosis 24792898 "miR-326 and miR-26a, two potential markers for diagnosis of relapse and remission phases in patient with relapsing-remitting multiple sclerosis." +tissue_expression_ns hsa-mir-148a "Carcinoma, Hepatocellular" 24798342 microRNA-148a dysregulation discriminates poor prognosis of hepatocellular carcinoma in association with USP4 overexpression. +tissue_expression_ns hsa-let-7a "Carcinoma, Lung, Non-Small-Cell" 24802132 "Before PRFA, tumor suppressor let-7a and miR-34a were downregulated whereas oncomiR miR-21 was upregulated in primary tumors, and let-7a and miR-126 levels were downregulated whereas oncomiRs miR-21, miR-155 and miR-17-5p/miR-20b levels were upregulated in secondary tumors." +tissue_expression_ns hsa-mir-214 "Carcinoma, Hepatocellular" 24804874 "Among the analysed miRNAs, high miR-214 expression was associated with smaller tumor size (p=0.019), whereas high miR-17-5p expression correlated with better Eastern Cooperative Oncology Group performance status (p=0.003)." +tissue_expression_ns hsa-mir-106b Ovarian Neoplasms 24805828 "The results obtained by miRNA microarrays of differential expression with hsa-miR-106b-3p, hsa-miR-152, hsa-miR-200a-3p, hsa-miR-381, and hsa-miR-429 were confirmed by real-time PCR." +tissue_expression_ns hsa-mir-17 "Carcinoma, Breast, Triple Negative" 24810926 "Triple-negative and luminal A breast tumors: differential expression of miR-18a-5p, miR-17-5p, and miR-20a-5p." +tissue_expression_ns hsa-mir-18a "Carcinoma, Breast, Triple Negative" 24810926 "Triple-negative and luminal A breast tumors: differential expression of miR-18a-5p, miR-17-5p, and miR-20a-5p." +tissue_expression_ns hsa-mir-20a "Carcinoma, Breast, Triple Negative" 24810926 "Triple-negative and luminal A breast tumors: differential expression of miR-18a-5p, miR-17-5p, and miR-20a-5p." +tissue_expression_ns hsa-mir-1271 "Carcinoma, Ovarian" 24816756 A ten-microRNA signature identified from a genome-wide microRNA expression profiling in human epithelial ovarian cancer. +tissue_expression_ns hsa-mir-130b "Carcinoma, Ovarian" 24816756 A ten-microRNA signature identified from a genome-wide microRNA expression profiling in human epithelial ovarian cancer. +tissue_expression_ns hsa-mir-135b "Carcinoma, Ovarian" 24816756 A ten-microRNA signature identified from a genome-wide microRNA expression profiling in human epithelial ovarian cancer. +tissue_expression_ns hsa-mir-141 "Carcinoma, Ovarian" 24816756 A ten-microRNA signature identified from a genome-wide microRNA expression profiling in human epithelial ovarian cancer. +tissue_expression_ns hsa-mir-15b "Carcinoma, Ovarian" 24816756 A ten-microRNA signature identified from a genome-wide microRNA expression profiling in human epithelial ovarian cancer. +tissue_expression_ns hsa-mir-182 "Carcinoma, Ovarian" 24816756 A ten-microRNA signature identified from a genome-wide microRNA expression profiling in human epithelial ovarian cancer. +tissue_expression_ns hsa-mir-183 "Carcinoma, Ovarian" 24816756 A ten-microRNA signature identified from a genome-wide microRNA expression profiling in human epithelial ovarian cancer. +tissue_expression_ns hsa-mir-574 "Carcinoma, Ovarian" 24816756 A ten-microRNA signature identified from a genome-wide microRNA expression profiling in human epithelial ovarian cancer. +tissue_expression_ns hsa-mir-96 "Carcinoma, Ovarian" 24816756 A ten-microRNA signature identified from a genome-wide microRNA expression profiling in human epithelial ovarian cancer. +tissue_expression_ns hsa-mir-106a Atrial Fibrillation 24824214 Mitochondrial respiration and microRNA expression in right and left atrium of patients with atrial fibrillation. +tissue_expression_ns hsa-mir-106b Atrial Fibrillation 24824214 Mitochondrial respiration and microRNA expression in right and left atrium of patients with atrial fibrillation. +tissue_expression_ns hsa-mir-144 Atrial Fibrillation 24824214 Mitochondrial respiration and microRNA expression in right and left atrium of patients with atrial fibrillation. +tissue_expression_ns hsa-mir-15b Atrial Fibrillation 24824214 Mitochondrial respiration and microRNA expression in right and left atrium of patients with atrial fibrillation. +tissue_expression_ns hsa-mir-19 Atrial Fibrillation 24824214 Mitochondrial respiration and microRNA expression in right and left atrium of patients with atrial fibrillation. +tissue_expression_ns hsa-mir-208a Atrial Fibrillation 24824214 Mitochondrial respiration and microRNA expression in right and left atrium of patients with atrial fibrillation. +tissue_expression_ns hsa-mir-23a Atrial Fibrillation 24824214 Mitochondrial respiration and microRNA expression in right and left atrium of patients with atrial fibrillation. +tissue_expression_ns hsa-mir-25 Atrial Fibrillation 24824214 Mitochondrial respiration and microRNA expression in right and left atrium of patients with atrial fibrillation. +tissue_expression_ns hsa-mir-30a Atrial Fibrillation 24824214 Mitochondrial respiration and microRNA expression in right and left atrium of patients with atrial fibrillation. +tissue_expression_ns hsa-mir-363 Atrial Fibrillation 24824214 Mitochondrial respiration and microRNA expression in right and left atrium of patients with atrial fibrillation. +tissue_expression_ns hsa-mir-451 Atrial Fibrillation 24824214 Mitochondrial respiration and microRNA expression in right and left atrium of patients with atrial fibrillation. +tissue_expression_ns hsa-mir-486 Atrial Fibrillation 24824214 Mitochondrial respiration and microRNA expression in right and left atrium of patients with atrial fibrillation. +tissue_expression_ns hsa-mir-590 Atrial Fibrillation 24824214 Mitochondrial respiration and microRNA expression in right and left atrium of patients with atrial fibrillation. +tissue_expression_ns hsa-mir-93 Atrial Fibrillation 24824214 Mitochondrial respiration and microRNA expression in right and left atrium of patients with atrial fibrillation. +tissue_expression_ns hsa-mir-338 Colorectal Carcinoma 24824250 Relationship between miRNA-338-3p expression and progression and prognosis of human colorectal carcinoma. +tissue_expression_ns hsa-mir-155 Neoplasms [unspecific] 24824925 miR-155 as a diagnostic and prognostic marker in hematological and solid malignancies +tissue_expression_ns hsa-mir-370 "Adenocarcinoma, Lung" 24833665 "Different morphologic subtypes of lung AC have distinct miRNA expression profiles, and 3 miRNAs encoded at 14q32 (miR-411, miR-370, and miR-376a) were associated with poor survival after lung AC resection." +tissue_expression_ns hsa-mir-376a "Adenocarcinoma, Lung" 24833665 "Different morphologic subtypes of lung AC have distinct miRNA expression profiles, and 3 miRNAs encoded at 14q32 (miR-411, miR-370, and miR-376a) were associated with poor survival after lung AC resection." +tissue_expression_ns hsa-mir-411 "Adenocarcinoma, Lung" 24833665 "Different morphologic subtypes of lung AC have distinct miRNA expression profiles, and 3 miRNAs encoded at 14q32 (miR-411, miR-370, and miR-376a) were associated with poor survival after lung AC resection." +tissue_expression_ns hsa-mir-146a Pancreatic Neoplasms 24839931 Deregulation of miR-146a expression in a mouse model of pancreatic cancer affecting EGFR signaling. +tissue_expression_ns hsa-mir-142 Breast Neoplasms 24846313 miRNA expression in breast cancer varies with lymph node metastasis and other clinicopathologic features. +tissue_expression_ns hsa-mir-185 Breast Neoplasms 24846313 miRNA expression in breast cancer varies with lymph node metastasis and other clinicopathologic features. +tissue_expression_ns hsa-mir-191 Breast Neoplasms 24846313 miRNA expression in breast cancer varies with lymph node metastasis and other clinicopathologic features. +tissue_expression_ns hsa-mir-200a Breast Neoplasms 24846313 miRNA expression in breast cancer varies with lymph node metastasis and other clinicopathologic features. +tissue_expression_ns hsa-mir-200b Breast Neoplasms 24846313 miRNA expression in breast cancer varies with lymph node metastasis and other clinicopathologic features. +tissue_expression_ns hsa-mir-206 Breast Neoplasms 24846313 miRNA expression in breast cancer varies with lymph node metastasis and other clinicopathologic features. +tissue_expression_ns hsa-mir-29b Breast Neoplasms 24846313 miRNA expression in breast cancer varies with lymph node metastasis and other clinicopathologic features. +tissue_expression_ns hsa-mir-30c Breast Neoplasms 24846313 miRNA expression in breast cancer varies with lymph node metastasis and other clinicopathologic features. +tissue_expression_ns hsa-mir-3196 Breast Neoplasms 24846313 miRNA expression in breast cancer varies with lymph node metastasis and other clinicopathologic features. +tissue_expression_ns hsa-mir-339 Breast Neoplasms 24846313 miRNA expression in breast cancer varies with lymph node metastasis and other clinicopathologic features. +tissue_expression_ns hsa-mir-3923 Breast Neoplasms 24846313 miRNA expression in breast cancer varies with lymph node metastasis and other clinicopathologic features. +tissue_expression_ns hsa-mir-421 Breast Neoplasms 24846313 miRNA expression in breast cancer varies with lymph node metastasis and other clinicopathologic features. +tissue_expression_ns hsa-mir-451 Breast Neoplasms 24846313 miRNA expression in breast cancer varies with lymph node metastasis and other clinicopathologic features. +tissue_expression_ns hsa-mir-542 Breast Neoplasms 24846313 miRNA expression in breast cancer varies with lymph node metastasis and other clinicopathologic features. +tissue_expression_ns hsa-mir-564 Breast Neoplasms 24846313 miRNA expression in breast cancer varies with lymph node metastasis and other clinicopathologic features. +tissue_expression_ns hsa-mir-92a Breast Neoplasms 24846313 miRNA expression in breast cancer varies with lymph node metastasis and other clinicopathologic features. +tissue_expression_ns hsa-mir-21 Lung Neoplasms 24880588 Diagnostic value of microRNA-21 in the diagnosis of lung cancer: evidence from a meta-analysis involving 11 studies. +tissue_expression_ns hsa-mir-324 "Carcinoma, Colon" 24882011 Dysregulation of the miR-324-5p-CUEDC2 axis leads to macrophage dysfunction and is associated with colon cancer. +tissue_expression_ns hsa-mir-195 "Carcinoma, Adrenocortical" 24890943 "In conclusion, (a) miR-483-3p, miR-483-5p, and miR-210 are differentially expressed in ACC variants, and (b) high miR-210 is associated with clinicopathologic parameters of aggressiveness and a poor prognosis." +tissue_expression_ns hsa-mir-1974 "Carcinoma, Adrenocortical" 24890943 "In conclusion, (a) miR-483-3p, miR-483-5p, and miR-210 are differentially expressed in ACC variants, and (b) high miR-210 is associated with clinicopathologic parameters of aggressiveness and a poor prognosis." +tissue_expression_ns hsa-mir-210 "Carcinoma, Adrenocortical" 24890943 "In conclusion, (a) miR-483-3p, miR-483-5p, and miR-210 are differentially expressed in ACC variants, and (b) high miR-210 is associated with clinicopathologic parameters of aggressiveness and a poor prognosis." +tissue_expression_ns hsa-mir-483 "Carcinoma, Adrenocortical" 24890943 "In conclusion, (a) miR-483-3p, miR-483-5p, and miR-210 are differentially expressed in ACC variants, and (b) high miR-210 is associated with clinicopathologic parameters of aggressiveness and a poor prognosis." +tissue_expression_ns hsa-mir-21 Muscle Atrophy 24891504 "Among the different miRNAs, microRNA-206 and -21 were the most induced in denervated muscles." +tissue_expression_ns hsa-mir-101-1 "Adenocarcinoma, Lung" 24893932 "We identified an eight-miRNA signature that is prognostic of LUAD.The miRNA signature, if validated in other prospective studies, may have important implications in clinical practice, in particular identifying a subgroup of patients with LUAD who are at high risk of mortality." +tissue_expression_ns hsa-mir-187 "Adenocarcinoma, Lung" 24893932 "We identified an eight-miRNA signature that is prognostic of LUAD.The miRNA signature, if validated in other prospective studies, may have important implications in clinical practice, in particular identifying a subgroup of patients with LUAD who are at high risk of mortality." +tissue_expression_ns hsa-mir-196b "Adenocarcinoma, Lung" 24893932 "We identified an eight-miRNA signature that is prognostic of LUAD.The miRNA signature, if validated in other prospective studies, may have important implications in clinical practice, in particular identifying a subgroup of patients with LUAD who are at high risk of mortality." +tissue_expression_ns hsa-mir-31 "Adenocarcinoma, Lung" 24893932 "We identified an eight-miRNA signature that is prognostic of LUAD.The miRNA signature, if validated in other prospective studies, may have important implications in clinical practice, in particular identifying a subgroup of patients with LUAD who are at high risk of mortality." +tissue_expression_ns hsa-mir-331 "Adenocarcinoma, Lung" 24893932 "We identified an eight-miRNA signature that is prognostic of LUAD.The miRNA signature, if validated in other prospective studies, may have important implications in clinical practice, in particular identifying a subgroup of patients with LUAD who are at high risk of mortality." +tissue_expression_ns hsa-mir-375 "Adenocarcinoma, Lung" 24893932 "We identified an eight-miRNA signature that is prognostic of LUAD.The miRNA signature, if validated in other prospective studies, may have important implications in clinical practice, in particular identifying a subgroup of patients with LUAD who are at high risk of mortality." +tissue_expression_ns hsa-mir-519a-1 "Adenocarcinoma, Lung" 24893932 "We identified an eight-miRNA signature that is prognostic of LUAD.The miRNA signature, if validated in other prospective studies, may have important implications in clinical practice, in particular identifying a subgroup of patients with LUAD who are at high risk of mortality." +tissue_expression_ns hsa-mir-766 "Adenocarcinoma, Lung" 24893932 "We identified an eight-miRNA signature that is prognostic of LUAD.The miRNA signature, if validated in other prospective studies, may have important implications in clinical practice, in particular identifying a subgroup of patients with LUAD who are at high risk of mortality." +tissue_expression_ns hsa-mir-5000 "Carcinoma, Colon" 24898979 "MiR-5000-3p, miR-5009-3P and miR-552: potential microRNA biomarkers of side population cells in colon cancer." +tissue_expression_ns hsa-mir-5009 "Carcinoma, Colon" 24898979 "MiR-5000-3p, miR-5009-3P and miR-552: potential microRNA biomarkers of side population cells in colon cancer." +tissue_expression_ns hsa-mir-552 "Carcinoma, Colon" 24898979 "MiR-5000-3p, miR-5009-3P and miR-552: potential microRNA biomarkers of side population cells in colon cancer." +tissue_expression_ns hsa-mir-103 Gastric Neoplasms 24902858 This systematic review study of human GC microRNA expression profiling studies would provide information on microRNAs with potential role as the biomarkers in gastric cancer. +tissue_expression_ns hsa-mir-107 Gastric Neoplasms 24902858 This systematic review study of human GC microRNA expression profiling studies would provide information on microRNAs with potential role as the biomarkers in gastric cancer. +tissue_expression_ns hsa-mir-148a Gastric Neoplasms 24902858 This systematic review study of human GC microRNA expression profiling studies would provide information on microRNAs with potential role as the biomarkers in gastric cancer. +tissue_expression_ns hsa-mir-21 Gastric Neoplasms 24902858 This systematic review study of human GC microRNA expression profiling studies would provide information on microRNAs with potential role as the biomarkers in gastric cancer. +tissue_expression_ns hsa-mir-223 Gastric Neoplasms 24902858 This systematic review study of human GC microRNA expression profiling studies would provide information on microRNAs with potential role as the biomarkers in gastric cancer. +tissue_expression_ns hsa-mir-25 Gastric Neoplasms 24902858 This systematic review study of human GC microRNA expression profiling studies would provide information on microRNAs with potential role as the biomarkers in gastric cancer. +tissue_expression_ns hsa-mir-375 Gastric Neoplasms 24902858 This systematic review study of human GC microRNA expression profiling studies would provide information on microRNAs with potential role as the biomarkers in gastric cancer. +tissue_expression_ns hsa-mir-638 Gastric Neoplasms 24902858 This systematic review study of human GC microRNA expression profiling studies would provide information on microRNAs with potential role as the biomarkers in gastric cancer. +tissue_expression_ns hsa-mir-92 Gastric Neoplasms 24902858 This systematic review study of human GC microRNA expression profiling studies would provide information on microRNAs with potential role as the biomarkers in gastric cancer. +tissue_expression_ns hsa-mir-195 "Adenocarcinoma, Lung" 24903339 Lung adenocarcinoma subtypes definable by lung development-related miRNA expression profiles in association with clinicopathologic features. +tissue_expression_ns hsa-mir-30d "Adenocarcinoma, Lung" 24903339 Lung adenocarcinoma subtypes definable by lung development-related miRNA expression profiles in association with clinicopathologic features. +tissue_expression_ns hsa-mir-124 Crohn Disease 24910152 Both inflamed and non-inflamed terminal ileal mucosa in adult patients with active CD have their distinct miRNA expression patterns compared with healthy controls. Dysregulated miRNAs may be responsible for pathogenesis of CD. +tissue_expression_ns hsa-mir-192 Crohn Disease 24910152 Both inflamed and non-inflamed terminal ileal mucosa in adult patients with active CD have their distinct miRNA expression patterns compared with healthy controls. Dysregulated miRNAs may be responsible for pathogenesis of CD. +tissue_expression_ns hsa-mir-361 Crohn Disease 24910152 Both inflamed and non-inflamed terminal ileal mucosa in adult patients with active CD have their distinct miRNA expression patterns compared with healthy controls. Dysregulated miRNAs may be responsible for pathogenesis of CD. +tissue_expression_ns hsa-mir-495 Crohn Disease 24910152 Both inflamed and non-inflamed terminal ileal mucosa in adult patients with active CD have their distinct miRNA expression patterns compared with healthy controls. Dysregulated miRNAs may be responsible for pathogenesis of CD. +tissue_expression_ns hsa-mir-126 Pleural Mesothelioma 24912849 "Diagnostic potential of miR-126, miR-143, miR-145, and miR-652 in malignant pleural mesothelioma." +tissue_expression_ns hsa-mir-221 Acute Liver Failure 24913549 "In liver biopsies, miR-21 and miR-221 displayed a reciprocal expression pattern and were found at lower levels in the spontaneous survivors, whereas miR-122 was elevated in both serum and liver tissue of those patients." +tissue_expression_ns hsa-mir-1248 Breast Neoplasms 24917463 "we identified miRNA expression signatures predictive of BRCA1/2 mutation status in routinely available FFPE breast tumor samples, which may be useful to complement current patient selection criteria for gene testing by identifying individuals with high likelihood of being BRCA1/2 mutation carriers." +tissue_expression_ns hsa-mir-142 Breast Neoplasms 24917463 "we identified miRNA expression signatures predictive of BRCA1/2 mutation status in routinely available FFPE breast tumor samples, which may be useful to complement current patient selection criteria for gene testing by identifying individuals with high likelihood of being BRCA1/2 mutation carriers." +tissue_expression_ns hsa-mir-181a-2 Breast Neoplasms 24917463 "we identified miRNA expression signatures predictive of BRCA1/2 mutation status in routinely available FFPE breast tumor samples, which may be useful to complement current patient selection criteria for gene testing by identifying individuals with high likelihood of being BRCA1/2 mutation carriers." +tissue_expression_ns hsa-mir-25 Breast Neoplasms 24917463 "we identified miRNA expression signatures predictive of BRCA1/2 mutation status in routinely available FFPE breast tumor samples, which may be useful to complement current patient selection criteria for gene testing by identifying individuals with high likelihood of being BRCA1/2 mutation carriers." +tissue_expression_ns hsa-mir-340 Breast Neoplasms 24917463 "we identified miRNA expression signatures predictive of BRCA1/2 mutation status in routinely available FFPE breast tumor samples, which may be useful to complement current patient selection criteria for gene testing by identifying individuals with high likelihood of being BRCA1/2 mutation carriers." +tissue_expression_ns hsa-mir-505 Breast Neoplasms 24917463 "we identified miRNA expression signatures predictive of BRCA1/2 mutation status in routinely available FFPE breast tumor samples, which may be useful to complement current patient selection criteria for gene testing by identifying individuals with high likelihood of being BRCA1/2 mutation carriers." +tissue_expression_ns hsa-mir-205 Colorectal Carcinoma 24935592 Diagnostic and prognostic value of miR-205 in colorectal cancer. +tissue_expression_ns hsa-mir-138 Colon Neoplasms 24941171 This is the first to reveal the importance of aberrant expression of miRNAs in dynamically transformation from chronic colitis to colitis-associated cancer. These findings shed light on revealing the mechanisms of chronic colitis malignant transformation. +tissue_expression_ns hsa-mir-145 Colon Neoplasms 24941171 This is the first to reveal the importance of aberrant expression of miRNAs in dynamically transformation from chronic colitis to colitis-associated cancer. These findings shed light on revealing the mechanisms of chronic colitis malignant transformation. +tissue_expression_ns hsa-mir-146a Colon Neoplasms 24941171 This is the first to reveal the importance of aberrant expression of miRNAs in dynamically transformation from chronic colitis to colitis-associated cancer. These findings shed light on revealing the mechanisms of chronic colitis malignant transformation. +tissue_expression_ns hsa-mir-150 Colon Neoplasms 24941171 This is the first to reveal the importance of aberrant expression of miRNAs in dynamically transformation from chronic colitis to colitis-associated cancer. These findings shed light on revealing the mechanisms of chronic colitis malignant transformation. +tissue_expression_ns hsa-let-7e "Carcinoma, Lung, Non-Small-Cell" 24945821 Differential expression of miR-125a-5p and let-7e predicts the progression and prognosis of non-small cell lung cancer. +tissue_expression_ns hsa-mir-125a "Carcinoma, Lung, Non-Small-Cell" 24945821 Differential expression of miR-125a-5p and let-7e predicts the progression and prognosis of non-small cell lung cancer. +tissue_expression_ns hsa-mir-1 Prostate Neoplasms 24967583 miR-1 and miR-133b are differentially expressed in patients with recurrent prostate cancer. +tissue_expression_ns hsa-mir-133b Prostate Neoplasms 24967583 miR-1 and miR-133b are differentially expressed in patients with recurrent prostate cancer. +tissue_expression_ns hsa-mir-101 Hepatitis B Virus Infection 24971953 "Expression profiling of serum microRNA-101 in HBV-associated chronic hepatitis,liver cirrhosis, and hepatocellular carcinoma." +tissue_expression_ns hsa-mir-143 Neoplasms [unspecific] 24974841 Using microRNA expression profiles the authors were able to distinguish peritumoural tissues according to distance from the primary tumour site. Future application of the method may prove to be useful in early detection of the altered epigenetic regulation in tissue fields representing normal phenotype. This may be helpful in cancer risk assessment and prevention. +tissue_expression_ns hsa-mir-155 Neoplasms [unspecific] 24974841 Using microRNA expression profiles the authors were able to distinguish peritumoural tissues according to distance from the primary tumour site. Future application of the method may prove to be useful in early detection of the altered epigenetic regulation in tissue fields representing normal phenotype. This may be helpful in cancer risk assessment and prevention. +tissue_expression_ns hsa-mir-21 Neoplasms [unspecific] 24974841 Using microRNA expression profiles the authors were able to distinguish peritumoural tissues according to distance from the primary tumour site. Future application of the method may prove to be useful in early detection of the altered epigenetic regulation in tissue fields representing normal phenotype. This may be helpful in cancer risk assessment and prevention. +tissue_expression_ns hsa-mir-221 Neoplasms [unspecific] 24974841 Using microRNA expression profiles the authors were able to distinguish peritumoural tissues according to distance from the primary tumour site. Future application of the method may prove to be useful in early detection of the altered epigenetic regulation in tissue fields representing normal phenotype. This may be helpful in cancer risk assessment and prevention. +tissue_expression_ns hsa-mir-106a "Carcinoma, Renal Cell" 24977165 Exploring the miRNA-mRNA regulatory network in clear cell renal cell carcinomas by next-generation sequencing expression profiles. +tissue_expression_ns hsa-mir-135a "Carcinoma, Renal Cell" 24977165 Exploring the miRNA-mRNA regulatory network in clear cell renal cell carcinomas by next-generation sequencing expression profiles. +tissue_expression_ns hsa-mir-142 "Carcinoma, Renal Cell" 24977165 Exploring the miRNA-mRNA regulatory network in clear cell renal cell carcinomas by next-generation sequencing expression profiles. +tissue_expression_ns hsa-mir-206 "Carcinoma, Renal Cell" 24977165 Exploring the miRNA-mRNA regulatory network in clear cell renal cell carcinomas by next-generation sequencing expression profiles. +tissue_expression_ns hsa-mir-21 "Carcinoma, Renal Cell" 24977165 Exploring the miRNA-mRNA regulatory network in clear cell renal cell carcinomas by next-generation sequencing expression profiles. +tissue_expression_ns hsa-mir-216b "Carcinoma, Renal Cell" 24977165 Exploring the miRNA-mRNA regulatory network in clear cell renal cell carcinomas by next-generation sequencing expression profiles. +tissue_expression_ns hsa-mir-3065 "Carcinoma, Renal Cell" 24977165 Exploring the miRNA-mRNA regulatory network in clear cell renal cell carcinomas by next-generation sequencing expression profiles. +tissue_expression_ns hsa-mir-363 "Carcinoma, Renal Cell" 24977165 Exploring the miRNA-mRNA regulatory network in clear cell renal cell carcinomas by next-generation sequencing expression profiles. +tissue_expression_ns hsa-mir-1244 Pallister-Killian Syndrome 24981202 12p microRNA expression in fibroblast cell lines from probands with Pallister-Killian syndrome. +tissue_expression_ns hsa-mir-202 Multiple System Atrophy 24981430 Altered expression of miR-202 in cerebellum of multiple-system atrophy. +tissue_expression_ns hsa-mir-125b Bladder Neoplasms 25014919 "The results revealed a unique microRNA expression signature in the urine supernatants of UCB patients for the development of molecular diagnostic tests. An effective cell-free urinary microRNA-based model was developed using a combined index of the levels of microRNA-99a and microRNA-125b to detect UCB with good discriminating power, high sensitivity and high specificity." +tissue_expression_ns hsa-mir-99a Bladder Neoplasms 25014919 "The results revealed a unique microRNA expression signature in the urine supernatants of UCB patients for the development of molecular diagnostic tests. An effective cell-free urinary microRNA-based model was developed using a combined index of the levels of microRNA-99a and microRNA-125b to detect UCB with good discriminating power, high sensitivity and high specificity." +tissue_expression_ns hsa-mir-195 Colorectal Carcinoma 25027346 "The 15 differentially expressed miRNAs, especially hsa-miR-195 and hsa-miR-20a may be used as potential biomarkers for early detection and screening of colorectal cancer." +tissue_expression_ns hsa-mir-20a Colorectal Carcinoma 25027346 "The 15 differentially expressed miRNAs, especially hsa-miR-195 and hsa-miR-20a may be used as potential biomarkers for early detection and screening of colorectal cancer." +tissue_expression_ns hsa-let-7b "Adenocarcinoma, Lung" 25028925 "The most significant differences in mRNA expression for recurrent tumors compared to non-recurrent tumors were decreases in miR-106b*, -187, -205, -449b, -774* and increases in miR-151-3p, let-7b, miR-215, -520b, and -512-3p." +tissue_expression_ns hsa-mir-106b "Adenocarcinoma, Lung" 25028925 "The most significant differences in mRNA expression for recurrent tumors compared to non-recurrent tumors were decreases in miR-106b*, -187, -205, -449b, -774* and increases in miR-151-3p, let-7b, miR-215, -520b, and -512-3p." +tissue_expression_ns hsa-mir-151a "Adenocarcinoma, Lung" 25028925 "The most significant differences in mRNA expression for recurrent tumors compared to non-recurrent tumors were decreases in miR-106b*, -187, -205, -449b, -774* and increases in miR-151-3p, let-7b, miR-215, -520b, and -512-3p." +tissue_expression_ns hsa-mir-187 "Adenocarcinoma, Lung" 25028925 "The most significant differences in mRNA expression for recurrent tumors compared to non-recurrent tumors were decreases in miR-106b*, -187, -205, -449b, -774* and increases in miR-151-3p, let-7b, miR-215, -520b, and -512-3p." +tissue_expression_ns hsa-mir-205 "Adenocarcinoma, Lung" 25028925 "The most significant differences in mRNA expression for recurrent tumors compared to non-recurrent tumors were decreases in miR-106b*, -187, -205, -449b, -774* and increases in miR-151-3p, let-7b, miR-215, -520b, and -512-3p." +tissue_expression_ns hsa-mir-215 "Adenocarcinoma, Lung" 25028925 "The most significant differences in mRNA expression for recurrent tumors compared to non-recurrent tumors were decreases in miR-106b*, -187, -205, -449b, -774* and increases in miR-151-3p, let-7b, miR-215, -520b, and -512-3p." +tissue_expression_ns hsa-mir-449b "Adenocarcinoma, Lung" 25028925 "The most significant differences in mRNA expression for recurrent tumors compared to non-recurrent tumors were decreases in miR-106b*, -187, -205, -449b, -774* and increases in miR-151-3p, let-7b, miR-215, -520b, and -512-3p." +tissue_expression_ns hsa-mir-512 "Adenocarcinoma, Lung" 25028925 "The most significant differences in mRNA expression for recurrent tumors compared to non-recurrent tumors were decreases in miR-106b*, -187, -205, -449b, -774* and increases in miR-151-3p, let-7b, miR-215, -520b, and -512-3p." +tissue_expression_ns hsa-mir-520b "Adenocarcinoma, Lung" 25028925 "The most significant differences in mRNA expression for recurrent tumors compared to non-recurrent tumors were decreases in miR-106b*, -187, -205, -449b, -774* and increases in miR-151-3p, let-7b, miR-215, -520b, and -512-3p." +tissue_expression_ns hsa-mir-774 "Adenocarcinoma, Lung" 25028925 "The most significant differences in mRNA expression for recurrent tumors compared to non-recurrent tumors were decreases in miR-106b*, -187, -205, -449b, -774* and increases in miR-151-3p, let-7b, miR-215, -520b, and -512-3p." +tissue_expression_ns hsa-mir-204 Breast Neoplasms 25031750 the miR-204 may be a potential diagnostic and prognostic biomarker of breast cancer. +tissue_expression_ns hsa-let-7g "Squamous Cell Carcinoma, Oral" 25050621 "MicroRNAs MiR-218, MiR-125b, and Let-7g predict prognosis in patients with oral cavity squamous cell carcinoma." +tissue_expression_ns hsa-mir-125b "Squamous Cell Carcinoma, Oral" 25050621 "MicroRNAs MiR-218, MiR-125b, and Let-7g predict prognosis in patients with oral cavity squamous cell carcinoma." +tissue_expression_ns hsa-mir-218 "Squamous Cell Carcinoma, Oral" 25050621 "MicroRNAs MiR-218, MiR-125b, and Let-7g predict prognosis in patients with oral cavity squamous cell carcinoma." +tissue_expression_ns hsa-mir-126 Prolactinoma 25064468 Our study is the first to identify a miRNA expression profile associated with bromocriptine-resistant prolactinoma. +tissue_expression_ns hsa-mir-136 Prolactinoma 25064468 Our study is the first to identify a miRNA expression profile associated with bromocriptine-resistant prolactinoma. +tissue_expression_ns hsa-mir-142 Prolactinoma 25064468 Our study is the first to identify a miRNA expression profile associated with bromocriptine-resistant prolactinoma. +tissue_expression_ns hsa-mir-144 Prolactinoma 25064468 Our study is the first to identify a miRNA expression profile associated with bromocriptine-resistant prolactinoma. +tissue_expression_ns hsa-mir-17 Prolactinoma 25064468 Our study is the first to identify a miRNA expression profile associated with bromocriptine-resistant prolactinoma. +tissue_expression_ns hsa-mir-22 Prolactinoma 25064468 Our study is the first to identify a miRNA expression profile associated with bromocriptine-resistant prolactinoma. +tissue_expression_ns hsa-mir-30a Prolactinoma 25064468 Our study is the first to identify a miRNA expression profile associated with bromocriptine-resistant prolactinoma. +tissue_expression_ns hsa-mir-382 Prolactinoma 25064468 Our study is the first to identify a miRNA expression profile associated with bromocriptine-resistant prolactinoma. +tissue_expression_ns hsa-mir-451 Prolactinoma 25064468 Our study is the first to identify a miRNA expression profile associated with bromocriptine-resistant prolactinoma. +tissue_expression_ns hsa-mir-486 Prolactinoma 25064468 Our study is the first to identify a miRNA expression profile associated with bromocriptine-resistant prolactinoma. +tissue_expression_ns hsa-mir-92a Prolactinoma 25064468 Our study is the first to identify a miRNA expression profile associated with bromocriptine-resistant prolactinoma. +tissue_expression_ns Hsa-mir-93 Prolactinoma 25064468 Our study is the first to identify a miRNA expression profile associated with bromocriptine-resistant prolactinoma. +tissue_expression_ns hsa-mir-18a Acute Respiratory Distress Syndrome 25070658 "miR-26a, miR-346, miR-135b, miR-30a/b, miR-344, and miR-18a targeted multiple altered mRNAs." +tissue_expression_ns hsa-mir-133b Neoplasms [unspecific] 25075017 Prognostic microRNA expression signature from examination of colorectal primary and metastatic tumors. +tissue_expression_ns hsa-mir-210 Neoplasms [unspecific] 25075017 Prognostic microRNA expression signature from examination of colorectal primary and metastatic tumors. +tissue_expression_ns hsa-mir-221 Colon Neoplasms 25075256 "Five miRNAs (miR-203-3p, miR-221-3p, miR-342-3p, miR-491-5p and miR-503-5p) were dysregulated in colon cancer tissue (P < 0.05)." +tissue_expression_ns hsa-mir-150 Digeorge Syndrome 25084529 Decreased DGCR8 expression and miRNA dysregulation in individuals with 22q11.2 deletion syndrome. +tissue_expression_ns hsa-mir-185 Digeorge Syndrome 25084529 Decreased DGCR8 expression and miRNA dysregulation in individuals with 22q11.2 deletion syndrome. +tissue_expression_ns hsa-mir-194 Digeorge Syndrome 25084529 Decreased DGCR8 expression and miRNA dysregulation in individuals with 22q11.2 deletion syndrome. +tissue_expression_ns hsa-mir-155 Hypertension 25087597 "In addition, exercise training in SHR increased levels of microRNA-27a (targeting ACE) and microRNA-155 (targeting AT1R) and decreased levels of microRNA-143 (targeting ACE2) in the aortas." +tissue_expression_ns hsa-mir-1246 Pancreatic Neoplasms 25117811 "miR-1246 expression was associated with chemoresistance and CSC-like properties via CCNG2, and could predict worse prognosis in pancreatic cancer patients." +tissue_expression_ns hsa-mir-378 "Carcinoma, Renal Cell, Clear-Cell" 25119741 "The tumors of patients with ccRCC had lower expression of miR-126 and miR-378 during the early stages of disease (T1), but higher expression of these miRNAs during the later stages of disease (T2/T3)." +tissue_expression_ns hsa-mir-126 Lung Neoplasms 25124149 Expression of microRNA miR-126 and miR-200c is associated with prognosis in patients with non-small cell lung cancer. +tissue_expression_ns hsa-mir-200c Lung Neoplasms 25124150 Expression of microRNA miR-126 and miR-201c is associated with prognosis in patients with non-small cell lung cancer. +tissue_expression_ns hsa-mir-17 Lymphoproliferative Disorders 25130212 "Unsupervised nonhierarchical clustering of the viral and cellular microRNAome distinguished non-EBV-associated from EBV-associated samples and identified a separate group of EBV-associated pCNS PTLD that displayed reduced levels of B cell lymphoma associated oncomiRs such as hsa-miR-155, -21, -221 and the hsa-miR-17-92 cluster." +tissue_expression_ns hsa-mir-181b Male Infertility 25141839 "The expression of three out of five selected miRNAs, including miR-34a, miR-181b and miR-122a, showed some degrees of changes following exposure to oxidative stress." +tissue_expression_ns hsa-mir-133a Hypertrophy 25147795 "Fifty-seven miRNAs were expressed differentially between transgenic and littermate controls, of which most abundant miRNAs, miR-133a and 378a, were significantly differentially expressed." +tissue_expression_ns hsa-mir-21 "Carcinoma, Hepatocellular" 25150373 The results of the present study suggested miR-21 expression level could be a novel potential biomarker for HCC prognosis. +tissue_expression_ns hsa-mir-155 Breast Neoplasms 25157366 MiR-155 detection might have a diagnostic value in breast cancer patients. It might be used as an auxiliary biomarker for different clinicopathological breast cancer. +tissue_expression_ns hsa-mir-31 Heart Transplant Rejection 25176944 "We identified seven miRNAs that were differentially expressed between normal and rejecting heart allografts: miR-10a, miR-21, miR-31, miR-92a, miR-142-3p miR-155, and miR-451" +tissue_expression_ns hsa-mir-106b "Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal" 25189575 "Guo investigated regulation and expression of three miRNAs; miR-21, miR-106b and miR-375. The paper reported these miRNAs as potential biomarkers for laryngeal squamous cell carcinoma diagnosis." +tissue_expression_ns hsa-mir-204 Colorectal Carcinoma 25209181 miR-204-5p expression in colorectal cancer: an autophagy-associated gene. +tissue_expression_ns hsa-mir-146a Asthma 25217662 MicroRNA-146a and microRNA-146b expression and anti-inflammatory function in human airway smooth muscle. +tissue_expression_ns hsa-mir-146b Asthma 25217662 MicroRNA-146a and microRNA-146b expression and anti-inflammatory function in human airway smooth muscle. +tissue_expression_ns hsa-mir-21 Inflammatory Bowel Diseases 25222661 "MiRNAs are differentially expressed in both human IBD and murine colitis, with overlap of several IBD-associated miRNAs. The demonstration that miR-21-/- deletion exacerbated CD4+ T-cell-mediated models of colitis provide further evidence that miRNAs play significant roles in the pathogenesis of IBD." +tissue_expression_ns hsa-mir-135b "Adenocarcinoma, Cervical" 25230213 "MiR-135b, miR-192, and miR-194 are altered in uterine cervical ACA, and miR-363-3p is an independent favorable prognostic factor in ACA. These miRNAs could be of value as biomarkers for the diagnosis and prognosis of ACA." +tissue_expression_ns hsa-mir-192 "Adenocarcinoma, Cervical" 25230213 "MiR-135b, miR-192, and miR-194 are altered in uterine cervical ACA, and miR-363-3p is an independent favorable prognostic factor in ACA. These miRNAs could be of value as biomarkers for the diagnosis and prognosis of ACA." +tissue_expression_ns hsa-mir-194 "Adenocarcinoma, Cervical" 25230213 "MiR-135b, miR-192, and miR-194 are altered in uterine cervical ACA, and miR-363-3p is an independent favorable prognostic factor in ACA. These miRNAs could be of value as biomarkers for the diagnosis and prognosis of ACA." +tissue_expression_ns hsa-mir-31 Colorectal Carcinoma 25232271 MicroRNA-31 expression in colorectal serrated pathway progression. +tissue_expression_ns hsa-mir-23b "Carcinoma, Adenoid Cystic" 25240490 "9 microRNAs were downexpressed in sACC cases and overexpressed in bACC tissues (let-7e, miR-23b, miR-27b, miR-193b, miR-320a, miR-320c, miR-768-5p, miR-1280 and miR-1826) relative to their controls." +tissue_expression_ns hsa-mir-155 Lymphoma 25265435 Differential expression of miR-155 and miR-21 in tumor and stroma cells in diffuse large B-cell lymphoma. +tissue_expression_ns hsa-mir-21 Lymphoma 25265435 Differential expression of miR-155 and miR-21 in tumor and stroma cells in diffuse large B-cell lymphoma. +tissue_expression_ns hsa-mir-10a "Carcinoma, Laryngeal" 25266939 MicroRNA-10a-5p and microRNA-34c-5p in laryngeal epithelial premalignant lesions:differential expression and clinicopathological correlation. +tissue_expression_ns hsa-mir-34c "Carcinoma, Laryngeal" 25266939 MicroRNA-10a-5p and microRNA-34c-5p in laryngeal epithelial premalignant lesions:differential expression and clinicopathological correlation. +tissue_expression_ns hsa-mir-215 Breast Neoplasms 25270284 Aberrant miR-215 expression is associated with clinical outcome in breast cancer patients. +tissue_expression_ns hsa-mir-208 Heart Failure 25287062 "miR-208, which was progressively downregulated as RV failure progressed" +tissue_expression_ns hsa-mir-21 Colorectal Carcinoma 25292032 "Our findings suggest that miR-21 has a potential diagnostic value for CRC with a moderate level of overall diagnostic accuracy. Hence, it could be used as auxiliary means for the initial screening of CRC and avoid unnecessary colonoscopy, which is an invasive and expensive procedure." +tissue_expression_ns hsa-mir-34a Neuroblastoma 25292042 "Hsa-miR-34a, for example, targets gene MYC, which regulates hsa-miR-34a in turn." +tissue_expression_ns hsa-mir-143 Intracranial Aneurysm 25300531 "As compared to normal arteries, we identified 157 microRNAs that were differentially expressed in the aneurysmal tissue (Pâ€?â€?.05 and fold change ≥â€?), including 72 upregulated and 85 downregulated." +tissue_expression_ns hsa-mir-23a Osteosarcoma 25322765 We identified miR-23a as a tumor suppressor in osteosarcoma. Our data clarify the mechanism of osteosarcoma progression and demonstrated the potential for exploiting miR-23a as a diagnostic marker for osteosarcoma. +tissue_expression_ns hsa-mir-335 "Squamous Cell Carcinoma, Esophageal" 25337272 "miR-335 expression isan independent prognostic factor for patients with esophageal cancer, which might be a potential valuable biomarker for ESCC." +tissue_expression_ns hsa-mir-151 Breast Neoplasms 25339470 "Specific differentially expressed miRNAs of the three subtypes were identified, including hsa-miR-99a and hsa-miR-151-3p for DCIS breast cancer, hsa-miR-145 and hsa-miR-210 for invasive breast cancer, and has-miR-205 and has-miR-361-5p metastatic breast cancer." +tissue_expression_ns hsa-mir-224 Hepatitis C Virus Infection 25386083 "Differences in miRNA expression were observed between CHC and steatotic CHC, CHC and steatotic liver, but not between steatotic CHC and steatotic liver of metabolic origin." +tissue_expression_ns hsa-mir-33a Hepatitis C Virus Infection 25386083 "Differences in miRNA expression were observed between CHC and steatotic CHC, CHC and steatotic liver, but not between steatotic CHC and steatotic liver of metabolic origin." +tissue_expression_ns hsa-mir-1246 Pancreatic Neoplasms 25388097 "the concomitant evaluation of PaCIC and PaCa-related miRNA marker panels awaits retrospective analyses of larger cohorts, as it should allow for a highly sensitive, minimally-invasive PaCa diagnostics." +tissue_expression_ns hsa-mir-3976 Pancreatic Neoplasms 25388097 "the concomitant evaluation of PaCIC and PaCa-related miRNA marker panels awaits retrospective analyses of larger cohorts, as it should allow for a highly sensitive, minimally-invasive PaCa diagnostics." +tissue_expression_ns hsa-mir-4306 Pancreatic Neoplasms 25388097 "the concomitant evaluation of PaCIC and PaCa-related miRNA marker panels awaits retrospective analyses of larger cohorts, as it should allow for a highly sensitive, minimally-invasive PaCa diagnostics." +tissue_expression_ns hsa-mir-4644 Pancreatic Neoplasms 25388097 "the concomitant evaluation of PaCIC and PaCa-related miRNA marker panels awaits retrospective analyses of larger cohorts, as it should allow for a highly sensitive, minimally-invasive PaCa diagnostics." +tissue_expression_ns hsa-mir-152 Breast Neoplasms 25393370 "For the first time, a different microRNA expression pattern in male and female fBC has been shown. Moreover, the importance of RASSF1A pathway in male fBC carcinogenesis has been confirmed, highlighting a possible role for miR-152 and miR-497 in controlling MAPK and Hippo signalling pathways, regulated by RASSF1A." +tissue_expression_ns hsa-mir-497 Breast Neoplasms 25393370 "For the first time, a different microRNA expression pattern in male and female fBC has been shown. Moreover, the importance of RASSF1A pathway in male fBC carcinogenesis has been confirmed, highlighting a possible role for miR-152 and miR-497 in controlling MAPK and Hippo signalling pathways, regulated by RASSF1A." +tissue_expression_ns hsa-mir-105 Glioma 25415048 "miRNA expression patterns in the malignant progression of gliomas and a novel prognostic classifier, the five-miRNA signature, serve as a prognostic marker for patient risk stratification in anaplastic gliomas, Secondary and Proneural glioblastomas." +tissue_expression_ns hsa-mir-196a Glioma 25415048 "miRNA expression patterns in the malignant progression of gliomas and a novel prognostic classifier, the five-miRNA signature, serve as a prognostic marker for patient risk stratification in anaplastic gliomas, Secondary and Proneural glioblastomas." +tissue_expression_ns hsa-mir-296 Glioma 25415048 "miRNA expression patterns in the malignant progression of gliomas and a novel prognostic classifier, the five-miRNA signature, serve as a prognostic marker for patient risk stratification in anaplastic gliomas, Secondary and Proneural glioblastomas." +tissue_expression_ns hsa-mir-584 Glioma 25415048 "miRNA expression patterns in the malignant progression of gliomas and a novel prognostic classifier, the five-miRNA signature, serve as a prognostic marker for patient risk stratification in anaplastic gliomas, Secondary and Proneural glioblastomas." +tissue_expression_ns hsa-mir-767 Glioma 25415048 "miRNA expression patterns in the malignant progression of gliomas and a novel prognostic classifier, the five-miRNA signature, serve as a prognostic marker for patient risk stratification in anaplastic gliomas, Secondary and Proneural glioblastomas." +tissue_expression_ns hsa-mir-21 Colorectal Carcinoma 25421755 "miR-21 expression may be a valuable biomarker for prediction of poor prognosis in CRC patients with Dukes' stage B, C and D." +tissue_expression_ns hsa-mir-125b "Carcinoma, Colon" 25421775 "miR-145 and other 16 miRNAs may be used as diagnostic molecular markers of colon cancer, and miR100, miR125a-5p, miR125b, miR145 and miR145* may become the molecular markers of colon cancer lymph node metastasis." +tissue_expression_ns hsa-mir-145 "Carcinoma, Colon" 25421775 "miR-145 and other 16 miRNAs may be used as diagnostic molecular markers of colon cancer, and miR100, miR125a-5p, miR125b, miR145 and miR146* may become the molecular markers of colon cancer lymph node metastasis." +tissue_expression_ns hsa-mir-192 "Adenocarcinoma, Gastric-Esophageal Junction" 25429911 "Comprehensive miRNA profiling showed a differential microRNA expression pattern depending on the histomorphologic regression in the multimodality therapy of locally advanced adenocarcinomas of the gastroesophageal junction. Moreover, using single RT-PCR analyses a prognostic impact of miR-222 and miR-302c was detected." +tissue_expression_ns hsa-mir-21 "Adenocarcinoma, Gastric-Esophageal Junction" 25429911 "Comprehensive miRNA profiling showed a differential microRNA expression pattern depending on the histomorphologic regression in the multimodality therapy of locally advanced adenocarcinomas of the gastroesophageal junction. Moreover, using single RT-PCR analyses a prognostic impact of miR-222 and miR-302c was detected." +tissue_expression_ns hsa-mir-222 "Adenocarcinoma, Gastric-Esophageal Junction" 25429911 "Comprehensive miRNA profiling showed a differential microRNA expression pattern depending on the histomorphologic regression in the multimodality therapy of locally advanced adenocarcinomas of the gastroesophageal junction. Moreover, using single RT-PCR analyses a prognostic impact of miR-222 and miR-302c was detected." +tissue_expression_ns hsa-mir-302c "Adenocarcinoma, Gastric-Esophageal Junction" 25429911 "Comprehensive miRNA profiling showed a differential microRNA expression pattern depending on the histomorphologic regression in the multimodality therapy of locally advanced adenocarcinomas of the gastroesophageal junction. Moreover, using single RT-PCR analyses a prognostic impact of miR-222 and miR-302c was detected." +tissue_expression_ns hsa-mir-381 "Adenocarcinoma, Gastric-Esophageal Junction" 25429911 "Comprehensive miRNA profiling showed a differential microRNA expression pattern depending on the histomorphologic regression in the multimodality therapy of locally advanced adenocarcinomas of the gastroesophageal junction. Moreover, using single RT-PCR analyses a prognostic impact of miR-222 and miR-302c was detected." +tissue_expression_ns hsa-mir-549 "Adenocarcinoma, Gastric-Esophageal Junction" 25429911 "Comprehensive miRNA profiling showed a differential microRNA expression pattern depending on the histomorphologic regression in the multimodality therapy of locally advanced adenocarcinomas of the gastroesophageal junction. Moreover, using single RT-PCR analyses a prognostic impact of miR-222 and miR-302c was detected." +tissue_expression_ns hsa-let-7i Ovarian Disease 25451316 "let-7i-5p, miR-122,miR-152-5p and miR-25-3p could act as diagnostic biomarkers in ovarian cancer." +tissue_expression_ns hsa-mir-122 Ovarian Disease 25451316 "let-7i-5p, miR-122,miR-152-5p and miR-25-3p could act as diagnostic biomarkers in ovarian cancer." +tissue_expression_ns hsa-mir-152 Ovarian Disease 25451316 "let-7i-5p, miR-122,miR-152-5p and miR-25-3p could act as diagnostic biomarkers in ovarian cancer." +tissue_expression_ns hsa-mir-25 Ovarian Disease 25451316 "let-7i-5p, miR-122,miR-152-5p and miR-25-3p could act as diagnostic biomarkers in ovarian cancer." +tissue_expression_ns hsa-mir-34 Neoplasms [unspecific] 25452192 miR-34 family members could be expected to become potential diagnostic and prognostic biomarkers in some types of human cancers. Further well-designed and larger sample studies are surely warranted to identify the role of the miR-34 family in the occurrence and development of tumors. +tissue_expression_ns hsa-mir-21 Glioma 25452796 "Among the six identified differentially expressed miRNAs, hsa-miR-21 and hsa-miR-612 have been previously reported to be associated with glioma." +tissue_expression_ns hsa-mir-103a Mesothelioma 25469901 the use of biomarkers of different molecular classes might be a reasonable approach to assemble a biomarker panel. +tissue_expression_ns hsa-mir-184 "Squamous Cell Carcinoma, Oral" 25482863 "Our results corroborate the previous findings on the overexpression of mir-21 and downregulation of miR-138 in OSCC. As the expression of miR-184 is controversial in tongue/oral cancer, the downregulation may be specific to tumor anatomical localization. On the other hand, to the best of our knowledge, this is the first report to show the association of miR-155 with tobacco chewing and the downregulation of miR-125b-2* in OSCC. Computational predictions suggest that miR-125b-2* may have a role in alternative splicing." +tissue_expression_ns hsa-let-7a Multiple Sclerosis 25487315 some miRNA subsets may be potential biomarkers for MS activity. +tissue_expression_ns hsa-mir-648a Multiple Sclerosis 25487315 some miRNA subsets may be potential biomarkers for MS activity. +tissue_expression_ns hsa-mir-92a Multiple Sclerosis 25487315 some miRNA subsets may be potential biomarkers for MS activity. +tissue_expression_ns hsa-mir-106a Preeclampsia 25499681 facilitate further investigation of aberrant expression of miRNAs in the pathology of preeclampsia. +tissue_expression_ns hsa-mir-363 Preeclampsia 25499681 facilitate further investigation of aberrant expression of miRNAs in the pathology of preeclampsia. +tissue_expression_ns hsa-mir-126 Osteosarcoma 25510179 expression of miR-126 increased the sensitivity of osteosarcoma cells to EGCG through induction of apoptosis. +tissue_expression_ns hsa-mir-96 Bladder Neoplasms 25511320 Urinary miRNA-96 is a good noninvasive diagnostic biomarker for bladder cancer. +tissue_expression_ns hsa-mir-101 "Squamous Cell Carcinoma, Esophageal" 25538231 A significant negative correlation exists between miR-101 or miR-217 and MALAT1 in 42 pairs of ESCC tissue samples and adjacent normal tissues. Mice xenograft data also support the tumor suppressor role of both miRNAs in ESCCs. +tissue_expression_ns hsa-mir-217 "Squamous Cell Carcinoma, Esophageal" 25538231 A significant negative correlation exists between miR-101 or miR-217 and MALAT1 in 42 pairs of ESCC tissue samples and adjacent normal tissues. Mice xenograft data also support the tumor suppressor role of both miRNAs in ESCCs. +tissue_expression_ns hsa-mir-15a Breast Neoplasms 25550542 MiR-15a expression levels could be a promising biological and prognostic marker for overall survival especially in triple-negative BC cases. +tissue_expression_ns hsa-mir-155 Human Papilloma Virus Infection 25550598 Evaluation of miRNA expression might be helpful to distinguish different cervical lesions and might be able to help in the prediction of HPV infection outcome. epithelial cell adhesion molecule +tissue_expression_ns hsa-mir-196a Human Papilloma Virus Infection 25550598 Evaluation of miRNA expression might be helpful to distinguish different cervical lesions and might be able to help in the prediction of HPV infection outcome. epithelial cell adhesion molecule +tissue_expression_ns hsa-mir-203 Human Papilloma Virus Infection 25550598 Evaluation of miRNA expression might be helpful to distinguish different cervical lesions and might be able to help in the prediction of HPV infection outcome. epithelial cell adhesion molecule +tissue_expression_ns hsa-mir-27a Human Papilloma Virus Infection 25550598 Evaluation of miRNA expression might be helpful to distinguish different cervical lesions and might be able to help in the prediction of HPV infection outcome. epithelial cell adhesion molecule +tissue_expression_ns hsa-mir-34a Human Papilloma Virus Infection 25550598 Evaluation of miRNA expression might be helpful to distinguish different cervical lesions and might be able to help in the prediction of HPV infection outcome. epithelial cell adhesion molecule +tissue_expression_ns hsa-mir-132 Inflammation 25564423 We assessed miRNA and mRNA expression in lung infiltrating mononuclear cells following exposure to SEB and found 89 miRNA that were dysregulated (>2-fold) compared with vehicle controls. +tissue_expression_ns hsa-mir-125a Colorectal Adenoma 25586944 "several miRNAs were abnormally expressed in colorectal lesions, identified new deregulated miRs, and showed that several miRNAs could mark the transition from NOR to CRA, thereby marking progression from the early steps of cancer." +tissue_expression_ns hsa-mir-145 Colorectal Adenoma 25586944 "several miRNAs were abnormally expressed in colorectal lesions, identified new deregulated miRs, and showed that several miRNAs could mark the transition from NOR to CRA, thereby marking progression from the early steps of cancer." +tissue_expression_ns hsa-mir-15b Colorectal Adenoma 25586944 "several miRNAs were abnormally expressed in colorectal lesions, identified new deregulated miRs, and showed that several miRNAs could mark the transition from NOR to CRA, thereby marking progression from the early steps of cancer." +tissue_expression_ns hsa-mir-16 Colorectal Adenoma 25586944 "several miRNAs were abnormally expressed in colorectal lesions, identified new deregulated miRs, and showed that several miRNAs could mark the transition from NOR to CRA, thereby marking progression from the early steps of cancer." +tissue_expression_ns hsa-mir-21 Colorectal Adenoma 25586944 "several miRNAs were abnormally expressed in colorectal lesions, identified new deregulated miRs, and showed that several miRNAs could mark the transition from NOR to CRA, thereby marking progression from the early steps of cancer." +tissue_expression_ns hsa-mir-24 Colorectal Adenoma 25586944 "several miRNAs were abnormally expressed in colorectal lesions, identified new deregulated miRs, and showed that several miRNAs could mark the transition from NOR to CRA, thereby marking progression from the early steps of cancer." +tissue_expression_ns hsa-mir-320 Colorectal Adenoma 25586944 "several miRNAs were abnormally expressed in colorectal lesions, identified new deregulated miRs, and showed that several miRNAs could mark the transition from NOR to CRA, thereby marking progression from the early steps of cancer." +tissue_expression_ns hsa-mir-320b Colorectal Adenoma 25586944 "several miRNAs were abnormally expressed in colorectal lesions, identified new deregulated miRs, and showed that several miRNAs could mark the transition from NOR to CRA, thereby marking progression from the early steps of cancer." +tissue_expression_ns hsa-mir-378 Colorectal Adenoma 25586944 "several miRNAs were abnormally expressed in colorectal lesions, identified new deregulated miRs, and showed that several miRNAs could mark the transition from NOR to CRA, thereby marking progression from the early steps of cancer." +tissue_expression_ns hsa-mir-126 Colorectal Carcinoma 25592646 "The intra-tumoural expression of EGFL7 in early stages of CRC may influence the risk of post-surgical recurrence. Differential expression of miRNA-126 seems more pronounced in disseminated disease, which supports its role as a regulator in the metastatic process." +tissue_expression_ns hsa-mir-107 Glioma 25596705 expression level of miR-107 may be a novel and valuable prognostic factor in glioma. +tissue_expression_ns hsa-mir-26a Colorectal Carcinoma 25611389 Genome-wide mRNA and miRNA expression profiling reveal multiple regulatory networks in colorectal cancer. +tissue_expression_ns hsa-mir-375 "Squamous Cell Carcinoma, Tongue" 25633534 "miR-375 inhibits the cell growth, and its expression is correlated with clinical outcomes in TSCC." +tissue_expression_ns hsa-mir-93 "Carcinoma, Hepatocellular" 25633810 "miR-93 stimulated cell proliferation,migration, and invasion through the oncogenic c-Met/PI3K/Akt pathway and also inhibited apoptosis by directly inhibiting PTEN and CDKN1A expression in human HCC." +tissue_expression_ns hsa-mir-146a Psoriasis 25662483 "In the mouse model of Aldara-induced skin inflammation, the level of miR-146a increased" +tissue_expression_ns hsa-mir-1203 "Small Cell Carcinoma, Esophageal" 25667451 The expression profiles of microRNAs in tumors may represent a novel predictor for postoperative outcomes in patients with SCCE. +tissue_expression_ns hsa-mir-1249 "Small Cell Carcinoma, Esophageal" 25667451 The expression profiles of microRNAs in tumors may represent a novel predictor for postoperative outcomes in patients with SCCE. +tissue_expression_ns hsa-mir-3619 "Small Cell Carcinoma, Esophageal" 25667451 The expression profiles of microRNAs in tumors may represent a novel predictor for postoperative outcomes in patients with SCCE. +tissue_expression_ns hsa-mir-4419b "Small Cell Carcinoma, Esophageal" 25667451 The expression profiles of microRNAs in tumors may represent a novel predictor for postoperative outcomes in patients with SCCE. +tissue_expression_ns hsa-mir-4648 "Small Cell Carcinoma, Esophageal" 25667451 The expression profiles of microRNAs in tumors may represent a novel predictor for postoperative outcomes in patients with SCCE. +tissue_expression_ns hsa-mir-4664 "Small Cell Carcinoma, Esophageal" 25667451 The expression profiles of microRNAs in tumors may represent a novel predictor for postoperative outcomes in patients with SCCE. +tissue_expression_ns hsa-mir-143 "Carcinoma, Esophageal" 25667498 Alterations of miRNA expression in ESCC can be correlated with the presence of common risk factors. The altered expression of certain miRNAs could be used as novel molecular markers of esophageal carcinoma. +tissue_expression_ns hsa-mir-203 "Carcinoma, Esophageal" 25667498 Alterations of miRNA expression in ESCC can be correlated with the presence of common risk factors. The altered expression of certain miRNAs could be used as novel molecular markers of esophageal carcinoma. +tissue_expression_ns hsa-mir-205 "Carcinoma, Esophageal" 25667498 Alterations of miRNA expression in ESCC can be correlated with the presence of common risk factors. The altered expression of certain miRNAs could be used as novel molecular markers of esophageal carcinoma. +tissue_expression_ns hsa-mir-21 "Carcinoma, Esophageal" 25667498 Alterations of miRNA expression in ESCC can be correlated with the presence of common risk factors. The altered expression of certain miRNAs could be used as novel molecular markers of esophageal carcinoma. +tissue_expression_ns hsa-mir-221 "Carcinoma, Esophageal" 25667498 Alterations of miRNA expression in ESCC can be correlated with the presence of common risk factors. The altered expression of certain miRNAs could be used as novel molecular markers of esophageal carcinoma. +tissue_expression_ns hsa-mir-23a Gastric Neoplasms 25674252 These results suggest that the dysregulation of miR-23a and miR-23b may be implicated in the progression of human GC. Combined expression of miR-23a and miR-23b appears to be a valuable marker for prognosis of this disease. +tissue_expression_ns hsa-mir-23b Gastric Neoplasms 25674252 These results suggest that the dysregulation of miR-23a and miR-23b may be implicated in the progression of human GC. Combined expression of miR-23a and miR-23b appears to be a valuable marker for prognosis of this disease. +tissue_expression_ns hsa-mir-19b Parkinson Disease 25675938 Our findings indicate that dysregulation of the microRNA miR-19b occurs in the prodromal stage of synucleinopathies. +tissue_expression_ns hsa-mir-29a Parkinson Disease 25675938 Our findings indicate that dysregulation of the microRNA miR-19b occurs in the prodromal stage of synucleinopathies. +tissue_expression_ns hsa-mir-29c Parkinson Disease 25675938 Our findings indicate that dysregulation of the microRNA miR-19b occurs in the prodromal stage of synucleinopathies. +tissue_expression_ns hsa-mir-1207 Gastric Neoplasms 25688358 "Multivariate analysis showed that stromal reaction type, lymphovascular invasion, pathological T category and TNM stage, and expression of miR-1207-5p were independent risk factors of LNM. MiR-1207-5p could serve as a useful biomarker in the prediction of LNM in gastric cancer." +tissue_expression_ns hsa-mir-330 "Muscular Dystrophy, Facioscapulohumeral" 25692472 "This work provides new candidate mechanisms potentially involved in the onset of FSHD pathology. Whether these FSHD specific miRNAs cause deregulations during fetal development, or protect against the appearance of the FSHD phenotype until the second decade of life still needs to be investigated." +tissue_expression_ns hsa-mir-331 "Muscular Dystrophy, Facioscapulohumeral" 25692472 "This work provides new candidate mechanisms potentially involved in the onset of FSHD pathology. Whether these FSHD specific miRNAs cause deregulations during fetal development, or protect against the appearance of the FSHD phenotype until the second decade of life still needs to be investigated." +tissue_expression_ns hsa-mir-34a "Muscular Dystrophy, Facioscapulohumeral" 25692472 "This work provides new candidate mechanisms potentially involved in the onset of FSHD pathology. Whether these FSHD specific miRNAs cause deregulations during fetal development, or protect against the appearance of the FSHD phenotype until the second decade of life still needs to be investigated." +tissue_expression_ns hsa-mir-380 "Muscular Dystrophy, Facioscapulohumeral" 25692472 "This work provides new candidate mechanisms potentially involved in the onset of FSHD pathology. Whether these FSHD specific miRNAs cause deregulations during fetal development, or protect against the appearance of the FSHD phenotype until the second decade of life still needs to be investigated." +tissue_expression_ns hsa-mir-516b "Muscular Dystrophy, Facioscapulohumeral" 25692472 "This work provides new candidate mechanisms potentially involved in the onset of FSHD pathology. Whether these FSHD specific miRNAs cause deregulations during fetal development, or protect against the appearance of the FSHD phenotype until the second decade of life still needs to be investigated." +tissue_expression_ns hsa-mir-517 "Muscular Dystrophy, Facioscapulohumeral" 25692472 "This work provides new candidate mechanisms potentially involved in the onset of FSHD pathology. Whether these FSHD specific miRNAs cause deregulations during fetal development, or protect against the appearance of the FSHD phenotype until the second decade of life still needs to be investigated." +tissue_expression_ns hsa-mir-582 "Muscular Dystrophy, Facioscapulohumeral" 25692472 "This work provides new candidate mechanisms potentially involved in the onset of FSHD pathology. Whether these FSHD specific miRNAs cause deregulations during fetal development, or protect against the appearance of the FSHD phenotype until the second decade of life still needs to be investigated." +tissue_expression_ns hsa-mir-625 "Muscular Dystrophy, Facioscapulohumeral" 25692472 "This work provides new candidate mechanisms potentially involved in the onset of FSHD pathology. Whether these FSHD specific miRNAs cause deregulations during fetal development, or protect against the appearance of the FSHD phenotype until the second decade of life still needs to be investigated." +tissue_expression_ns hsa-mir-155 Mycosis Fungoides 25698383 These results by identifying a number of differentially expressed microRNAs add further insight into the molecular pathogenesis of folliculotropic MF and large cell transformation of MF. +tissue_expression_ns hsa-mir-181b Mycosis Fungoides 25698383 These results by identifying a number of differentially expressed microRNAs add further insight into the molecular pathogenesis of folliculotropic MF and large cell transformation of MF. +tissue_expression_ns hsa-mir-223 Mycosis Fungoides 25698383 These results by identifying a number of differentially expressed microRNAs add further insight into the molecular pathogenesis of folliculotropic MF and large cell transformation of MF. +tissue_expression_ns hsa-mir-326 Mycosis Fungoides 25698383 These results by identifying a number of differentially expressed microRNAs add further insight into the molecular pathogenesis of folliculotropic MF and large cell transformation of MF. +tissue_expression_ns hsa-mir-206 Muscle Diseases [unspecific] 25703017 "Thirty-six miRNAs were differentially expressed between prenatal and postnatal stages of muscle development including several myomiRs (miR-1, miR-206 and let-7 families)." +tissue_expression_ns hsa-mir-183 Prostate Neoplasms 25720086 Urinary miR-183 and miR-205 do not surpass PCA3 in urine as predictive markers for prostate biopsy outcome despite their highly dysregulated expression in prostate cancer tissue. +tissue_expression_ns hsa-mir-205 Prostate Neoplasms 25720086 Urinary miR-183 and miR-205 do not surpass PCA3 in urine as predictive markers for prostate biopsy outcome despite their highly dysregulated expression in prostate cancer tissue. +tissue_expression_ns hsa-let-7a "Carcinoma, Thyroid, Papillary" 25720323 This comprehensive study complements the existing knowledge about deregulated microRNAs in the development of well-differentiated thyroid cancer and identifies novel markers associated with recurrence-free survival. +tissue_expression_ns hsa-mir-1179 "Carcinoma, Thyroid, Papillary" 25720323 This comprehensive study complements the existing knowledge about deregulated microRNAs in the development of well-differentiated thyroid cancer and identifies novel markers associated with recurrence-free survival. +tissue_expression_ns hsa-mir-146b "Carcinoma, Thyroid, Papillary" 25720323 This comprehensive study complements the existing knowledge about deregulated microRNAs in the development of well-differentiated thyroid cancer and identifies novel markers associated with recurrence-free survival. +tissue_expression_ns hsa-mir-192 "Carcinoma, Thyroid, Papillary" 25720323 This comprehensive study complements the existing knowledge about deregulated microRNAs in the development of well-differentiated thyroid cancer and identifies novel markers associated with recurrence-free survival. +tissue_expression_ns hsa-mir-204 "Carcinoma, Thyroid, Papillary" 25720323 This comprehensive study complements the existing knowledge about deregulated microRNAs in the development of well-differentiated thyroid cancer and identifies novel markers associated with recurrence-free survival. +tissue_expression_ns hsa-mir-221 "Carcinoma, Thyroid, Papillary" 25720323 This comprehensive study complements the existing knowledge about deregulated microRNAs in the development of well-differentiated thyroid cancer and identifies novel markers associated with recurrence-free survival. +tissue_expression_ns hsa-mir-222 "Carcinoma, Thyroid, Papillary" 25720323 This comprehensive study complements the existing knowledge about deregulated microRNAs in the development of well-differentiated thyroid cancer and identifies novel markers associated with recurrence-free survival. +tissue_expression_ns hsa-mir-7 "Carcinoma, Thyroid, Papillary" 25720323 This comprehensive study complements the existing knowledge about deregulated microRNAs in the development of well-differentiated thyroid cancer and identifies novel markers associated with recurrence-free survival. +tissue_expression_ns hsa-mir-1914 "Carcinoma, Gastric" 25730011 The miRNA expression patterns in different gastric adenocarcinoma subtypes may help discriminate between signet-ring cell and tubular gland cancer or other gastric cancer subtypes that would otherwise be difficult to identify using routine histological and immunohistochemical analyses. These preliminary data should be verified in further prospective studies. +tissue_expression_ns hsa-mir-499 "Carcinoma, Gastric" 25730011 The miRNA expression patterns in different gastric adenocarcinoma subtypes may help discriminate between signet-ring cell and tubular gland cancer or other gastric cancer subtypes that would otherwise be difficult to identify using routine histological and immunohistochemical analyses. These preliminary data should be verified in further prospective studies. +tissue_expression_ns hsa-mir-524 "Carcinoma, Gastric" 25730011 The miRNA expression patterns in different gastric adenocarcinoma subtypes may help discriminate between signet-ring cell and tubular gland cancer or other gastric cancer subtypes that would otherwise be difficult to identify using routine histological and immunohistochemical analyses. These preliminary data should be verified in further prospective studies. +tissue_expression_ns hsa-mir-628 "Carcinoma, Gastric" 25730011 The miRNA expression patterns in different gastric adenocarcinoma subtypes may help discriminate between signet-ring cell and tubular gland cancer or other gastric cancer subtypes that would otherwise be difficult to identify using routine histological and immunohistochemical analyses. These preliminary data should be verified in further prospective studies. +tissue_expression_ns hsa-mir-125a Head And Neck Adenoid Cystic Carcinoma 25750274 Our data showed significantly different expression patterns of mircoRNA in HNACC and HNSCC supporting the theory of tumor-specific expression and giving hints for different clinical behavior. review +tissue_expression_ns hsa-mir-199a Head And Neck Adenoid Cystic Carcinoma 25750274 Our data showed significantly different expression patterns of mircoRNA in HNACC and HNSCC supporting the theory of tumor-specific expression and giving hints for different clinical behavior. review +tissue_expression_ns hsa-mir-199b Head And Neck Adenoid Cystic Carcinoma 25750274 Our data showed significantly different expression patterns of mircoRNA in HNACC and HNSCC supporting the theory of tumor-specific expression and giving hints for different clinical behavior. review +tissue_expression_ns hsa-mir-214 Head And Neck Adenoid Cystic Carcinoma 25750274 Our data showed significantly different expression patterns of mircoRNA in HNACC and HNSCC supporting the theory of tumor-specific expression and giving hints for different clinical behavior. review +tissue_expression_ns hsa-mir-574 Head And Neck Adenoid Cystic Carcinoma 25750274 Our data showed significantly different expression patterns of mircoRNA in HNACC and HNSCC supporting the theory of tumor-specific expression and giving hints for different clinical behavior. review +tissue_expression_ns hsa-mir-106b "Carcinoma, Colon" 25755775 In situ hybridization analysis of the expression of miR-106b in colonic cancer. +tissue_expression_ns hsa-mir-122 Obesity 25769350 "Deregulation of miR-33 and miR-122, as major regulators of lipid metabolism in liver, has been related to obesity and metabolic syndrome." +tissue_expression_ns hsa-mir-146b "Carcinoma, Thyroid, Papillary" 25771986 "Since miR-146b-5p was mainly expressed in PTC including FVPTC and was not expressed in most FTC, PDTC, or ATC, it may serve as a useful diagnostic marker for PTC. ISH is a useful method to analyze microRNA expression in formalin-fixed paraffin-embedded thyroid tissues." +tissue_expression_ns hsa-mir-21 "Carcinoma, Thyroid, Papillary" 25771986 "Since miR-146b-5p was mainly expressed in PTC including FVPTC and was not expressed in most FTC, PDTC, or ATC, it may serve as a useful diagnostic marker for PTC. ISH is a useful method to analyze microRNA expression in formalin-fixed paraffin-embedded thyroid tissues." +tissue_expression_ns hsa-mir-106a Colorectal Carcinoma 25773836 "Our study revealed dysregulation of expression of ten miRNAs in Turkish colon cancer patients. These miRNAs may be used as potential biomarkers for early detection, screening and surveillance of colorectal cancer, with functional effects on tumor cell behavior." +tissue_expression_ns hsa-mir-127 Colorectal Carcinoma 25773836 "Our study revealed dysregulation of expression of ten miRNAs in Turkish colon cancer patients. These miRNAs may be used as potential biomarkers for early detection, screening and surveillance of colorectal cancer, with functional effects on tumor cell behavior." +tissue_expression_ns hsa-mir-133a Colorectal Carcinoma 25773836 "Our study revealed dysregulation of expression of ten miRNAs in Turkish colon cancer patients. These miRNAs may be used as potential biomarkers for early detection, screening and surveillance of colorectal cancer, with functional effects on tumor cell behavior." +tissue_expression_ns hsa-mir-133b Colorectal Carcinoma 25773836 "Our study revealed dysregulation of expression of ten miRNAs in Turkish colon cancer patients. These miRNAs may be used as potential biomarkers for early detection, screening and surveillance of colorectal cancer, with functional effects on tumor cell behavior." +tissue_expression_ns hsa-mir-135b Colorectal Carcinoma 25773836 "Our study revealed dysregulation of expression of ten miRNAs in Turkish colon cancer patients. These miRNAs may be used as potential biomarkers for early detection, screening and surveillance of colorectal cancer, with functional effects on tumor cell behavior." +tissue_expression_ns hsa-mir-143 Colorectal Carcinoma 25773836 "Our study revealed dysregulation of expression of ten miRNAs in Turkish colon cancer patients. These miRNAs may be used as potential biomarkers for early detection, screening and surveillance of colorectal cancer, with functional effects on tumor cell behavior." +tissue_expression_ns hsa-mir-145 Colorectal Carcinoma 25773836 "Our study revealed dysregulation of expression of ten miRNAs in Turkish colon cancer patients. These miRNAs may be used as potential biomarkers for early detection, screening and surveillance of colorectal cancer, with functional effects on tumor cell behavior." +tissue_expression_ns hsa-mir-155 Colorectal Carcinoma 25773836 "Our study revealed dysregulation of expression of ten miRNAs in Turkish colon cancer patients. These miRNAs may be used as potential biomarkers for early detection, screening and surveillance of colorectal cancer, with functional effects on tumor cell behavior." +tissue_expression_ns hsa-mir-182 Colorectal Carcinoma 25773836 "Our study revealed dysregulation of expression of ten miRNAs in Turkish colon cancer patients. These miRNAs may be used as potential biomarkers for early detection, screening and surveillance of colorectal cancer, with functional effects on tumor cell behavior." +tissue_expression_ns hsa-mir-200a Colorectal Carcinoma 25773836 "Our study revealed dysregulation of expression of ten miRNAs in Turkish colon cancer patients. These miRNAs may be used as potential biomarkers for early detection, screening and surveillance of colorectal cancer, with functional effects on tumor cell behavior." +tissue_expression_ns hsa-mir-200c Colorectal Carcinoma 25773836 "Our study revealed dysregulation of expression of ten miRNAs in Turkish colon cancer patients. These miRNAs may be used as potential biomarkers for early detection, screening and surveillance of colorectal cancer, with functional effects on tumor cell behavior." +tissue_expression_ns hsa-mir-362 Colorectal Carcinoma 25773836 "Our study revealed dysregulation of expression of ten miRNAs in Turkish colon cancer patients. These miRNAs may be used as potential biomarkers for early detection, screening and surveillance of colorectal cancer, with functional effects on tumor cell behavior." +tissue_expression_ns hsa-mir-203 "Adenocarcinoma, Esophageal" 25784377 We suggest that miRNA expression profiling expands current knowledge in molecular pathology of Barrett's-based carcinogenesis and enables identification of molecular biomarkers for early detection of BE dysplasia and progression to EAC. +tissue_expression_ns hsa-mir-205 "Adenocarcinoma, Esophageal" 25784377 We suggest that miRNA expression profiling expands current knowledge in molecular pathology of Barrett's-based carcinogenesis and enables identification of molecular biomarkers for early detection of BE dysplasia and progression to EAC. +tissue_expression_ns hsa-mir-210 "Adenocarcinoma, Esophageal" 25784377 We suggest that miRNA expression profiling expands current knowledge in molecular pathology of Barrett's-based carcinogenesis and enables identification of molecular biomarkers for early detection of BE dysplasia and progression to EAC. +tissue_expression_ns hsa-mir-378 "Adenocarcinoma, Esophageal" 25784377 We suggest that miRNA expression profiling expands current knowledge in molecular pathology of Barrett's-based carcinogenesis and enables identification of molecular biomarkers for early detection of BE dysplasia and progression to EAC. +tissue_expression_ns hsa-mir-140 Osteoarthritis 25785087 We verified that miR-140 and miR-455 were associated with cartilage development +tissue_expression_ns hsa-mir-9 Osteoarthritis 25785087 "miR-9 and miR-98 were involved in the endochondral ossification, suggesting they may be also the key regulators in the process of endochondral ossification." +tissue_expression_ns hsa-mir-98 Osteoarthritis 25785087 "miR-9 and miR-98 were involved in the endochondral ossification, suggesting they may be also the key regulators in the process of endochondral ossification." +tissue_expression_ns hsa-mir-141 Neoplasms [unspecific] 25789530 miR-141 as a prognostic and diagnostic biomarker in different types of cancer +tissue_expression_ns hsa-mir-145 Neoplasms [unspecific] 25792469 "In conclusion, our findings suggest that miR-145 expression is associated with overall survival (OS) in cancer patients and can serve as a promising biomarker for monitoring prognosis." +tissue_expression_ns hsa-mir-517a Preeclampsia 25799546 Placental expression of miR-517a/b and miR-517c contributes to trophoblast dysfunction and preeclampsia. +tissue_expression_ns hsa-mir-517b Preeclampsia 25799546 Placental expression of miR-517a/b and miR-517c contributes to trophoblast dysfunction and preeclampsia. +tissue_expression_ns hsa-mir-517c Preeclampsia 25799546 Placental expression of miR-517a/b and miR-517c contributes to trophoblast dysfunction and preeclampsia. +tissue_expression_ns hsa-mir-1 Colorectal Adenocarcinoma 25803870 Identification and validation of potential biomarkers for the detection of dysregulated microRNA by qPCR in patients with colorectal adenocarcinoma. +tissue_expression_ns hsa-mir-135b Colorectal Adenocarcinoma 25803870 Identification and validation of potential biomarkers for the detection of dysregulated microRNA by qPCR in patients with colorectal adenocarcinoma. +tissue_expression_ns hsa-mir-145 Colorectal Adenocarcinoma 25803870 Identification and validation of potential biomarkers for the detection of dysregulated microRNA by qPCR in patients with colorectal adenocarcinoma. +tissue_expression_ns hsa-mir-3195 Colorectal Adenocarcinoma 25803870 Identification and validation of potential biomarkers for the detection of dysregulated microRNA by qPCR in patients with colorectal adenocarcinoma. +tissue_expression_ns hsa-mir-429 Colorectal Adenocarcinoma 25803870 Identification and validation of potential biomarkers for the detection of dysregulated microRNA by qPCR in patients with colorectal adenocarcinoma. +tissue_expression_ns hsa-mir-4469 Colorectal Adenocarcinoma 25803870 Identification and validation of potential biomarkers for the detection of dysregulated microRNA by qPCR in patients with colorectal adenocarcinoma. +tissue_expression_ns hsa-mir-4510 Colorectal Adenocarcinoma 25803870 Identification and validation of potential biomarkers for the detection of dysregulated microRNA by qPCR in patients with colorectal adenocarcinoma. +tissue_expression_ns hsa-mir-4770 Colorectal Adenocarcinoma 25803870 Identification and validation of potential biomarkers for the detection of dysregulated microRNA by qPCR in patients with colorectal adenocarcinoma. +tissue_expression_ns hsa-mir-549 Colorectal Adenocarcinoma 25803870 Identification and validation of potential biomarkers for the detection of dysregulated microRNA by qPCR in patients with colorectal adenocarcinoma. +tissue_expression_ns hsa-mir-552 Colorectal Adenocarcinoma 25803870 Identification and validation of potential biomarkers for the detection of dysregulated microRNA by qPCR in patients with colorectal adenocarcinoma. +tissue_expression_ns hsa-mir-96 Colorectal Adenocarcinoma 25803870 Identification and validation of potential biomarkers for the detection of dysregulated microRNA by qPCR in patients with colorectal adenocarcinoma. +tissue_expression_ns hsa-mir-99b Colorectal Adenocarcinoma 25803870 Identification and validation of potential biomarkers for the detection of dysregulated microRNA by qPCR in patients with colorectal adenocarcinoma. +tissue_expression_ns hsa-mir-211 Medulloepithelioma 25807141 "We report significantly dysregulated miRNAs in intraocular ME tumors, which exhibited abnormal profiles in other cancers as well such as retinoblastoma and glioblastoma. Pathway analysis of all dysregulated miRNAs shared commonalities with other cancer pathways." +tissue_expression_ns hsa-mir-509 Medulloepithelioma 25807141 "We report significantly dysregulated miRNAs in intraocular ME tumors, which exhibited abnormal profiles in other cancers as well such as retinoblastoma and glioblastoma. Pathway analysis of all dysregulated miRNAs shared commonalities with other cancer pathways." +tissue_expression_ns hsa-mir-1237 Spinal Chordoma 25850393 The data from the current study identified a total of 29 differentially expressed miRNAs in chordoma tissues and reduced miR-1237-3p expression was associated with chordoma invasion and worse recurrence-free survival of the patients. +tissue_expression_ns hsa-mir-143 "Carcinoma, Lung, Non-Small-Cell" 25862841 miRNA expression profiling of sputum and BAL fluids represent a potential means to detect early-stage NSCLC. +tissue_expression_ns hsa-mir-155 "Carcinoma, Lung, Non-Small-Cell" 25862841 miRNA expression profiling of sputum and BAL fluids represent a potential means to detect early-stage NSCLC. +tissue_expression_ns hsa-mir-21 "Carcinoma, Lung, Non-Small-Cell" 25862841 miRNA expression profiling of sputum and BAL fluids represent a potential means to detect early-stage NSCLC. +tissue_expression_ns hsa-mir-210 "Carcinoma, Lung, Non-Small-Cell" 25862841 miRNA expression profiling of sputum and BAL fluids represent a potential means to detect early-stage NSCLC. +tissue_expression_ns hsa-mir-372 "Carcinoma, Lung, Non-Small-Cell" 25862841 miRNA expression profiling of sputum and BAL fluids represent a potential means to detect early-stage NSCLC. +tissue_expression_ns hsa-let-7c Non-Traumatic Osteonecrosis 25863178 Our data also manifests that the signaling pathways regulated by these differentially expressed miRNAs might be important in the pathogenesis of non-traumatic ONFH. +tissue_expression_ns hsa-let-7i Non-Traumatic Osteonecrosis 25863178 Our data also manifests that the signaling pathways regulated by these differentially expressed miRNAs might be important in the pathogenesis of non-traumatic ONFH. +tissue_expression_ns hsa-mir-146b Non-Traumatic Osteonecrosis 25863178 Our data also manifests that the signaling pathways regulated by these differentially expressed miRNAs might be important in the pathogenesis of non-traumatic ONFH. +tissue_expression_ns hsa-mir-320e Non-Traumatic Osteonecrosis 25863178 Our data also manifests that the signaling pathways regulated by these differentially expressed miRNAs might be important in the pathogenesis of non-traumatic ONFH. +tissue_expression_ns hsa-mir-335 Non-Traumatic Osteonecrosis 25863178 Our data also manifests that the signaling pathways regulated by these differentially expressed miRNAs might be important in the pathogenesis of non-traumatic ONFH. +tissue_expression_ns hsa-mir-197 "Carcinoma, Lung, Non-Small-Cell" 25867273 The cost-effective expression analysis of miR-197 could constitute a novel molecular tool for NSCLC management. +tissue_expression_ns hsa-let-7d "Carcinoma, Lung, Non-Small-Cell" 25873351 mRNA and microRNA expression profiles of radioresistant NCI-H520 non-small cell lung cancer cells. +tissue_expression_ns hsa-mir-127 "Carcinoma, Lung, Non-Small-Cell" 25873351 mRNA and microRNA expression profiles of radioresistant NCI-H520 non-small cell lung cancer cells. +tissue_expression_ns hsa-mir-155 "Carcinoma, Lung, Non-Small-Cell" 25873351 mRNA and microRNA expression profiles of radioresistant NCI-H520 non-small cell lung cancer cells. +tissue_expression_ns hsa-mir-103 Intrahepatic Cholangiocarcinoma 25880914 "In this study, a 30-miRNA signature for distinguishing ICC from NIBD, and a 3-miRNA signature for evaluating prognosis of ICC were established, which might be able to serve as biomarkers for prognosis of ICC. Further studies focusing on these miRNAs may shed light on the mechanisms associated with ICC pathogenesis and progression." +tissue_expression_ns hsa-mir-146a Intrahepatic Cholangiocarcinoma 25880914 "In this study, a 30-miRNA signature for distinguishing ICC from NIBD, and a 3-miRNA signature for evaluating prognosis of ICC were established, which might be able to serve as biomarkers for prognosis of ICC. Further studies focusing on these miRNAs may shed light on the mechanisms associated with ICC pathogenesis and progression." +tissue_expression_ns hsa-mir-216a Intrahepatic Cholangiocarcinoma 25880914 "In this study, a 30-miRNA signature for distinguishing ICC from NIBD, and a 3-miRNA signature for evaluating prognosis of ICC were established, which might be able to serve as biomarkers for prognosis of ICC. Further studies focusing on these miRNAs may shed light on the mechanisms associated with ICC pathogenesis and progression." +tissue_expression_ns hsa-mir-216b Intrahepatic Cholangiocarcinoma 25880914 "In this study, a 30-miRNA signature for distinguishing ICC from NIBD, and a 3-miRNA signature for evaluating prognosis of ICC were established, which might be able to serve as biomarkers for prognosis of ICC. Further studies focusing on these miRNAs may shed light on the mechanisms associated with ICC pathogenesis and progression." +tissue_expression_ns hsa-mir-217 Intrahepatic Cholangiocarcinoma 25880914 "In this study, a 30-miRNA signature for distinguishing ICC from NIBD, and a 3-miRNA signature for evaluating prognosis of ICC were established, which might be able to serve as biomarkers for prognosis of ICC. Further studies focusing on these miRNAs may shed light on the mechanisms associated with ICC pathogenesis and progression." +tissue_expression_ns hsa-mir-338 Intrahepatic Cholangiocarcinoma 25880914 "In this study, a 30-miRNA signature for distinguishing ICC from NIBD, and a 3-miRNA signature for evaluating prognosis of ICC were established, which might be able to serve as biomarkers for prognosis of ICC. Further studies focusing on these miRNAs may shed light on the mechanisms associated with ICC pathogenesis and progression." +tissue_expression_ns hsa-mir-513 Intrahepatic Cholangiocarcinoma 25880914 "In this study, a 30-miRNA signature for distinguishing ICC from NIBD, and a 3-miRNA signature for evaluating prognosis of ICC were established, which might be able to serve as biomarkers for prognosis of ICC. Further studies focusing on these miRNAs may shed light on the mechanisms associated with ICC pathogenesis and progression." +tissue_expression_ns hsa-mir-652 Intrahepatic Cholangiocarcinoma 25880914 "In this study, a 30-miRNA signature for distinguishing ICC from NIBD, and a 3-miRNA signature for evaluating prognosis of ICC were established, which might be able to serve as biomarkers for prognosis of ICC. Further studies focusing on these miRNAs may shed light on the mechanisms associated with ICC pathogenesis and progression." +tissue_expression_ns hsa-mir-675 Intrahepatic Cholangiocarcinoma 25880914 "In this study, a 30-miRNA signature for distinguishing ICC from NIBD, and a 3-miRNA signature for evaluating prognosis of ICC were established, which might be able to serve as biomarkers for prognosis of ICC. Further studies focusing on these miRNAs may shed light on the mechanisms associated with ICC pathogenesis and progression." +tissue_expression_ns hsa-mir-155 Respiratory Syncytial Virus Pneumonia 25884957 microRNA expression in nasal epithelium cytology brushings of RSV-positive infants shows a distinct profile of immune-associated miRNA.miR-125a has important functions within NF-¦ÊB signaling and macrophage function. The lack of downregulation of miR-125a and miR-429 in severe disease may help explain differences in disease manifestations on infection with RSV. +tissue_expression_ns hsa-mir-16 Respiratory Syncytial Virus Pneumonia 25884957 microRNA expression in nasal epithelium cytology brushings of RSV-positive infants shows a distinct profile of immune-associated miRNA.miR-125a has important functions within NF-¦ÊB signaling and macrophage function. The lack of downregulation of miR-125a and miR-429 in severe disease may help explain differences in disease manifestations on infection with RSV. +tissue_expression_ns hsa-mir-203a Respiratory Syncytial Virus Pneumonia 25884957 microRNA expression in nasal epithelium cytology brushings of RSV-positive infants shows a distinct profile of immune-associated miRNA.miR-125a has important functions within NF-¦ÊB signaling and macrophage function. The lack of downregulation of miR-125a and miR-429 in severe disease may help explain differences in disease manifestations on infection with RSV. +tissue_expression_ns hsa-mir-27b Respiratory Syncytial Virus Pneumonia 25884957 microRNA expression in nasal epithelium cytology brushings of RSV-positive infants shows a distinct profile of immune-associated miRNA.miR-125a has important functions within NF-¦ÊB signaling and macrophage function. The lack of downregulation of miR-125a and miR-429 in severe disease may help explain differences in disease manifestations on infection with RSV. +tissue_expression_ns hsa-mir-29c Respiratory Syncytial Virus Pneumonia 25884957 microRNA expression in nasal epithelium cytology brushings of RSV-positive infants shows a distinct profile of immune-associated miRNA.miR-125a has important functions within NF-¦ÊB signaling and macrophage function. The lack of downregulation of miR-125a and miR-429 in severe disease may help explain differences in disease manifestations on infection with RSV. +tissue_expression_ns hsa-mir-31 Respiratory Syncytial Virus Pneumonia 25884957 microRNA expression in nasal epithelium cytology brushings of RSV-positive infants shows a distinct profile of immune-associated miRNA.miR-125a has important functions within NF-¦ÊB signaling and macrophage function. The lack of downregulation of miR-125a and miR-429 in severe disease may help explain differences in disease manifestations on infection with RSV. +tissue_expression_ns hsa-mir-34b Respiratory Syncytial Virus Pneumonia 25884957 microRNA expression in nasal epithelium cytology brushings of RSV-positive infants shows a distinct profile of immune-associated miRNA.miR-125a has important functions within NF-¦ÊB signaling and macrophage function. The lack of downregulation of miR-125a and miR-429 in severe disease may help explain differences in disease manifestations on infection with RSV. +tissue_expression_ns hsa-mir-34c Respiratory Syncytial Virus Pneumonia 25884957 microRNA expression in nasal epithelium cytology brushings of RSV-positive infants shows a distinct profile of immune-associated miRNA.miR-125a has important functions within NF-¦ÊB signaling and macrophage function. The lack of downregulation of miR-125a and miR-429 in severe disease may help explain differences in disease manifestations on infection with RSV. +tissue_expression_ns hsa-mir-125b Breast Neoplasms 25886191 We were able to demonstrate for the first time the feasibility to detect distinct BC-dependent urinary miRNA profiles. The expression levels of four urinary miRNAs were specifically altered in our cohort of BC patients compared to healthy controls. This distinct pattern offers the possibility for a specific discrimination between healthy women and primary BC patients. This sustains the potential role of urinary miRNAs as non-invasive innovative urine-based biomarkers for BC detection. +tissue_expression_ns hsa-mir-155 Breast Neoplasms 25886191 We were able to demonstrate for the first time the feasibility to detect distinct BC-dependent urinary miRNA profiles. The expression levels of four urinary miRNAs were specifically altered in our cohort of BC patients compared to healthy controls. This distinct pattern offers the possibility for a specific discrimination between healthy women and primary BC patients. This sustains the potential role of urinary miRNAs as non-invasive innovative urine-based biomarkers for BC detection. +tissue_expression_ns hsa-mir-195 Breast Neoplasms 25886191 We were able to demonstrate for the first time the feasibility to detect distinct BC-dependent urinary miRNA profiles. The expression levels of four urinary miRNAs were specifically altered in our cohort of BC patients compared to healthy controls. This distinct pattern offers the possibility for a specific discrimination between healthy women and primary BC patients. This sustains the potential role of urinary miRNAs as non-invasive innovative urine-based biomarkers for BC detection. +tissue_expression_ns hsa-mir-200b Breast Neoplasms 25886191 We were able to demonstrate for the first time the feasibility to detect distinct BC-dependent urinary miRNA profiles. The expression levels of four urinary miRNAs were specifically altered in our cohort of BC patients compared to healthy controls. This distinct pattern offers the possibility for a specific discrimination between healthy women and primary BC patients. This sustains the potential role of urinary miRNAs as non-invasive innovative urine-based biomarkers for BC detection. +tissue_expression_ns hsa-mir-200c Breast Neoplasms 25886191 We were able to demonstrate for the first time the feasibility to detect distinct BC-dependent urinary miRNA profiles. The expression levels of four urinary miRNAs were specifically altered in our cohort of BC patients compared to healthy controls. This distinct pattern offers the possibility for a specific discrimination between healthy women and primary BC patients. This sustains the potential role of urinary miRNAs as non-invasive innovative urine-based biomarkers for BC detection. +tissue_expression_ns hsa-mir-21 Breast Neoplasms 25886191 We were able to demonstrate for the first time the feasibility to detect distinct BC-dependent urinary miRNA profiles. The expression levels of four urinary miRNAs were specifically altered in our cohort of BC patients compared to healthy controls. This distinct pattern offers the possibility for a specific discrimination between healthy women and primary BC patients. This sustains the potential role of urinary miRNAs as non-invasive innovative urine-based biomarkers for BC detection. +tissue_expression_ns hsa-mir-34a Breast Neoplasms 25886191 We were able to demonstrate for the first time the feasibility to detect distinct BC-dependent urinary miRNA profiles. The expression levels of four urinary miRNAs were specifically altered in our cohort of BC patients compared to healthy controls. This distinct pattern offers the possibility for a specific discrimination between healthy women and primary BC patients. This sustains the potential role of urinary miRNAs as non-invasive innovative urine-based biomarkers for BC detection. +tissue_expression_ns hsa-mir-375 Breast Neoplasms 25886191 We were able to demonstrate for the first time the feasibility to detect distinct BC-dependent urinary miRNA profiles. The expression levels of four urinary miRNAs were specifically altered in our cohort of BC patients compared to healthy controls. This distinct pattern offers the possibility for a specific discrimination between healthy women and primary BC patients. This sustains the potential role of urinary miRNAs as non-invasive innovative urine-based biomarkers for BC detection. +tissue_expression_ns hsa-mir-451 Breast Neoplasms 25886191 We were able to demonstrate for the first time the feasibility to detect distinct BC-dependent urinary miRNA profiles. The expression levels of four urinary miRNAs were specifically altered in our cohort of BC patients compared to healthy controls. This distinct pattern offers the possibility for a specific discrimination between healthy women and primary BC patients. This sustains the potential role of urinary miRNAs as non-invasive innovative urine-based biomarkers for BC detection. +tissue_expression_ns hsa-mir-155 Liposarcoma 25888631 Deregulation of dicer and mir-155 expression in liposarcoma. +tissue_expression_ns hsa-mir-29a Gastric Neoplasms 25889078 Our preliminary results suggest that altered expression of miR-29a-3p is involved in gastric cancer process. The present study provides the first insight into the specific role of miR-29a-3p in gastric carcinogenesis. +tissue_expression_ns hsa-mir-145 Colorectal Carcinoma 25896668 "MiRNA-145 and miRNA-378* are potential biomarkers for early detection of CRC, which may help in diagnosing CRC in early period." +tissue_expression_ns hsa-mir-378 Colorectal Carcinoma 25896668 "MiRNA-145 and miRNA-378* are potential biomarkers for early detection of CRC, which may help in diagnosing CRC in early period." +tissue_expression_ns hsa-mir-198 "Adenocarcinoma, Pancreatic Ductal" 25908274 Our data suggest that altered expression of examined microRNAs is related to neoplastic transformation and progression of the disease and these microRNAs could serve as diagnostic and prognostic biomarkers for pancreatic ductal adenocarcinoma. +tissue_expression_ns hsa-mir-198 Chronic Pancreatitis 25908274 Our data suggest that altered expression of examined microRNAs is related to neoplastic transformation and progression of the disease and these microRNAs could serve as diagnostic and prognostic biomarkers for pancreatic ductal adenocarcinoma. +tissue_expression_ns hsa-mir-21 "Adenocarcinoma, Pancreatic Ductal" 25908274 Our data suggest that altered expression of examined microRNAs is related to neoplastic transformation and progression of the disease and these microRNAs could serve as diagnostic and prognostic biomarkers for pancreatic ductal adenocarcinoma. +tissue_expression_ns hsa-mir-21 Chronic Pancreatitis 25908274 Our data suggest that altered expression of examined microRNAs is related to neoplastic transformation and progression of the disease and these microRNAs could serve as diagnostic and prognostic biomarkers for pancreatic ductal adenocarcinoma. +tissue_expression_ns hsa-mir-217 "Adenocarcinoma, Pancreatic Ductal" 25908274 Our data suggest that altered expression of examined microRNAs is related to neoplastic transformation and progression of the disease and these microRNAs could serve as diagnostic and prognostic biomarkers for pancreatic ductal adenocarcinoma. +tissue_expression_ns hsa-mir-217 Chronic Pancreatitis 25908274 Our data suggest that altered expression of examined microRNAs is related to neoplastic transformation and progression of the disease and these microRNAs could serve as diagnostic and prognostic biomarkers for pancreatic ductal adenocarcinoma. +tissue_expression_ns hsa-mir-34a "Adenocarcinoma, Pancreatic Ductal" 25908274 Our data suggest that altered expression of examined microRNAs is related to neoplastic transformation and progression of the disease and these microRNAs could serve as diagnostic and prognostic biomarkers for pancreatic ductal adenocarcinoma. +tissue_expression_ns hsa-mir-34a Chronic Pancreatitis 25908274 Our data suggest that altered expression of examined microRNAs is related to neoplastic transformation and progression of the disease and these microRNAs could serve as diagnostic and prognostic biomarkers for pancreatic ductal adenocarcinoma. +tissue_expression_ns hsa-mir-106b "Carcinoma, Hepatocellular" 25916067 "A total of 54 differentially expressed miRNAs were identified, in which there were 13 miRNAs published to be related to HCC." +tissue_expression_ns hsa-mir-205 Lung Neoplasms 25917317 MiR-205 and miR-218 expression is associated with carboplatin chemoresistance and regulation of apoptosis via Mcl-1 and Survivin in lung cancer cells. +tissue_expression_ns hsa-mir-218 Lung Neoplasms 25917317 MiR-205 and miR-218 expression is associated with carboplatin chemoresistance and regulation of apoptosis via Mcl-1 and Survivin in lung cancer cells. +tissue_expression_ns hsa-mir-10a "Carcinoma, Cervical" 25920605 This meta-analysis has identified several miRNAs whose expression correlates reliably with cervical cancer. These should be probed in further studies to explore their potential as diagnostic biomarkers. +tissue_expression_ns hsa-mir-141 "Carcinoma, Cervical" 25920605 This meta-analysis has identified several miRNAs whose expression correlates reliably with cervical cancer. These should be probed in further studies to explore their potential as diagnostic biomarkers. +tissue_expression_ns hsa-mir-143 "Carcinoma, Cervical" 25920605 This meta-analysis has identified several miRNAs whose expression correlates reliably with cervical cancer. These should be probed in further studies to explore their potential as diagnostic biomarkers. +tissue_expression_ns hsa-mir-145 "Carcinoma, Cervical" 25920605 This meta-analysis has identified several miRNAs whose expression correlates reliably with cervical cancer. These should be probed in further studies to explore their potential as diagnostic biomarkers. +tissue_expression_ns hsa-mir-15b "Carcinoma, Cervical" 25920605 This meta-analysis has identified several miRNAs whose expression correlates reliably with cervical cancer. These should be probed in further studies to explore their potential as diagnostic biomarkers. +tissue_expression_ns hsa-mir-200a "Carcinoma, Cervical" 25920605 This meta-analysis has identified several miRNAs whose expression correlates reliably with cervical cancer. These should be probed in further studies to explore their potential as diagnostic biomarkers. +tissue_expression_ns hsa-mir-203 "Carcinoma, Cervical" 25920605 This meta-analysis has identified several miRNAs whose expression correlates reliably with cervical cancer. These should be probed in further studies to explore their potential as diagnostic biomarkers. +tissue_expression_ns hsa-mir-20a "Carcinoma, Cervical" 25920605 This meta-analysis has identified several miRNAs whose expression correlates reliably with cervical cancer. These should be probed in further studies to explore their potential as diagnostic biomarkers. +tissue_expression_ns hsa-mir-20b "Carcinoma, Cervical" 25920605 This meta-analysis has identified several miRNAs whose expression correlates reliably with cervical cancer. These should be probed in further studies to explore their potential as diagnostic biomarkers. +tissue_expression_ns hsa-mir-224 "Carcinoma, Cervical" 25920605 This meta-analysis has identified several miRNAs whose expression correlates reliably with cervical cancer. These should be probed in further studies to explore their potential as diagnostic biomarkers. +tissue_expression_ns hsa-mir-148 "Adenocarcinoma, Esophageal" 25928282 "Our data suggest that altered expression of miR-21, miR-29c, miR-148 and miR-203 are related to neoplastic transformation and progression of the disease and these microRNAs could serve as a potential diagnostic and prognostic biomarkers in esophageal cancer." +tissue_expression_ns hsa-mir-148 "Squamous Cell Carcinoma, Esophageal" 25928282 "Our data suggest that altered expression of miR-21, miR-29c, miR-148 and miR-203 are related to neoplastic transformation and progression of the disease and these microRNAs could serve as a potential diagnostic and prognostic biomarkers in esophageal cancer." +tissue_expression_ns hsa-mir-203 "Adenocarcinoma, Esophageal" 25928282 "Our data suggest that altered expression of miR-21, miR-29c, miR-148 and miR-203 are related to neoplastic transformation and progression of the disease and these microRNAs could serve as a potential diagnostic and prognostic biomarkers in esophageal cancer." +tissue_expression_ns hsa-mir-203 "Squamous Cell Carcinoma, Esophageal" 25928282 "Our data suggest that altered expression of miR-21, miR-29c, miR-148 and miR-203 are related to neoplastic transformation and progression of the disease and these microRNAs could serve as a potential diagnostic and prognostic biomarkers in esophageal cancer." +tissue_expression_ns hsa-mir-21 "Adenocarcinoma, Esophageal" 25928282 "Our data suggest that altered expression of miR-21, miR-29c, miR-148 and miR-203 are related to neoplastic transformation and progression of the disease and these microRNAs could serve as a potential diagnostic and prognostic biomarkers in esophageal cancer." +tissue_expression_ns hsa-mir-21 "Squamous Cell Carcinoma, Esophageal" 25928282 "Our data suggest that altered expression of miR-21, miR-29c, miR-148 and miR-203 are related to neoplastic transformation and progression of the disease and these microRNAs could serve as a potential diagnostic and prognostic biomarkers in esophageal cancer." +tissue_expression_ns hsa-mir-29c "Adenocarcinoma, Esophageal" 25928282 "Our data suggest that altered expression of miR-21, miR-29c, miR-148 and miR-203 are related to neoplastic transformation and progression of the disease and these microRNAs could serve as a potential diagnostic and prognostic biomarkers in esophageal cancer." +tissue_expression_ns hsa-mir-29c "Squamous Cell Carcinoma, Esophageal" 25928282 "Our data suggest that altered expression of miR-21, miR-29c, miR-148 and miR-203 are related to neoplastic transformation and progression of the disease and these microRNAs could serve as a potential diagnostic and prognostic biomarkers in esophageal cancer." +tissue_expression_ns hsa-mir-29a "Carcinoma, Renal Cell, Clear-Cell" 25938468 "This study identified 11 commonly dysregulated miRNAs in ccRCC,three of which (miR-199a-5p, miR-22 and miR-429) may represent key miRNAs involved in the pathogenesis of ccRCC. Further studies suggested that miR-199a-5p plays an important role in inhibition of cell invasion of ccRCC cells by suppressing expression of TGFBR1 and JunB." +tissue_expression_ns hsa-mir-429 "Carcinoma, Renal Cell, Clear-Cell" 25938468 "This study identified 11 commonly dysregulated miRNAs in ccRCC,three of which (miR-199a-5p, miR-22 and miR-429) may represent key miRNAs involved in the pathogenesis of ccRCC. Further studies suggested that miR-199a-5p plays an important role in inhibition of cell invasion of ccRCC cells by suppressing expression of TGFBR1 and JunB." +tissue_expression_ns hsa-mir-452 "Carcinoma, Renal Cell, Clear-Cell" 25938468 "This study identified 11 commonly dysregulated miRNAs in ccRCC,three of which (miR-199a-5p, miR-22 and miR-429) may represent key miRNAs involved in the pathogenesis of ccRCC. Further studies suggested that miR-199a-5p plays an important role in inhibition of cell invasion of ccRCC cells by suppressing expression of TGFBR1 and JunB." +tissue_expression_ns hsa-mir-487a "Carcinoma, Renal Cell, Clear-Cell" 25938468 "This study identified 11 commonly dysregulated miRNAs in ccRCC,three of which (miR-199a-5p, miR-22 and miR-429) may represent key miRNAs involved in the pathogenesis of ccRCC. Further studies suggested that miR-199a-5p plays an important role in inhibition of cell invasion of ccRCC cells by suppressing expression of TGFBR1 and JunB." +tissue_expression_ns hsa-mir-491 "Carcinoma, Renal Cell, Clear-Cell" 25938468 "This study identified 11 commonly dysregulated miRNAs in ccRCC,three of which (miR-199a-5p, miR-22 and miR-429) may represent key miRNAs involved in the pathogenesis of ccRCC. Further studies suggested that miR-199a-5p plays an important role in inhibition of cell invasion of ccRCC cells by suppressing expression of TGFBR1 and JunB." +tissue_expression_ns hsa-mir-532 "Carcinoma, Renal Cell, Clear-Cell" 25938468 "This study identified 11 commonly dysregulated miRNAs in ccRCC,three of which (miR-199a-5p, miR-22 and miR-429) may represent key miRNAs involved in the pathogenesis of ccRCC. Further studies suggested that miR-199a-5p plays an important role in inhibition of cell invasion of ccRCC cells by suppressing expression of TGFBR1 and JunB." +tissue_expression_ns hsa-mir-21 Rectal Neoplasms 25953218 MicroRNA-21 expression efficiently predicts preoperative chemoradiotherapy pathological response in locally advanced rectal cancer. +tissue_expression_ns hsa-mir-34a Glioma 25953448 "The top 20 potential miRNAs including MIR-124A, MIR-34A and MIR-34C were screened for a constructing gene-miRNA interaction network." +tissue_expression_ns hsa-mir-4489 Glioma 25954994 The dysregulated miRNAs identified in the present study contribute to the tumorigenesis and malignant progression of gliomas and may serve as useful markers for advanced glioma pathological grading and prognosis. +tissue_expression_ns hsa-mir-196b "Carcinoma, Ovarian" 25964536 "Based on our data, dysregulation of microRNA expression was associated with the recurrence of EOC. Moreover, significantly over- and down-regulated microRNAs can be useful biomarkers for the prediction of recurrence in EOC." +tissue_expression_ns hsa-mir-19b "Carcinoma, Ovarian" 25964536 "Based on our data, dysregulation of microRNA expression was associated with the recurrence of EOC. Moreover, significantly over- and down-regulated microRNAs can be useful biomarkers for the prediction of recurrence in EOC." +tissue_expression_ns hsa-mir-3198 "Carcinoma, Ovarian" 25964536 "Based on our data, dysregulation of microRNA expression was associated with the recurrence of EOC. Moreover, significantly over- and down-regulated microRNAs can be useful biomarkers for the prediction of recurrence in EOC." +tissue_expression_ns hsa-mir-3201 "Carcinoma, Ovarian" 25964536 "Based on our data, dysregulation of microRNA expression was associated with the recurrence of EOC. Moreover, significantly over- and down-regulated microRNAs can be useful biomarkers for the prediction of recurrence in EOC." +tissue_expression_ns hsa-mir-3613 "Carcinoma, Ovarian" 25964536 "Based on our data, dysregulation of microRNA expression was associated with the recurrence of EOC. Moreover, significantly over- and down-regulated microRNAs can be useful biomarkers for the prediction of recurrence in EOC." +tissue_expression_ns hsa-mir-551b "Carcinoma, Ovarian" 25964536 "Based on our data, dysregulation of microRNA expression was associated with the recurrence of EOC. Moreover, significantly over- and down-regulated microRNAs can be useful biomarkers for the prediction of recurrence in EOC." +tissue_expression_ns hsa-mir-7515 "Carcinoma, Ovarian" 25964536 "Based on our data, dysregulation of microRNA expression was associated with the recurrence of EOC. Moreover, significantly over- and down-regulated microRNAs can be useful biomarkers for the prediction of recurrence in EOC." +tissue_expression_ns hsa-mir-8084 "Carcinoma, Ovarian" 25964536 "Based on our data, dysregulation of microRNA expression was associated with the recurrence of EOC. Moreover, significantly over- and down-regulated microRNAs can be useful biomarkers for the prediction of recurrence in EOC." +tissue_expression_ns hsa-mir-155 Cardiovascular Diseases [unspecific] 25978529 microRNA expression patterns have a low diagnostic potential clinically in discriminating DCD liver quality and outcome. +tissue_expression_ns hsa-mir-22 Cardiovascular Diseases [unspecific] 25978529 microRNA expression patterns have a low diagnostic potential clinically in discriminating DCD liver quality and outcome. +tissue_expression_ns hsa-mir-940 Cardiovascular Diseases [unspecific] 25978529 microRNA expression patterns have a low diagnostic potential clinically in discriminating DCD liver quality and outcome. +tissue_expression_ns hsa-mir-191 "Carcinoma, Renal Cell, Chromophobe" 25981392 "mir-191, mir-19a, mir-210, and mir-425 miRNAs are expressed differentially in chRCC, and unique expression of miRNAs is associated with the progression and prognosis of chRCC." +tissue_expression_ns hsa-mir-19a "Carcinoma, Renal Cell, Chromophobe" 25981392 "mir-191, mir-19a, mir-210, and mir-425 miRNAs are expressed differentially in chRCC, and unique expression of miRNAs is associated with the progression and prognosis of chRCC." +tissue_expression_ns hsa-mir-210 "Carcinoma, Renal Cell, Chromophobe" 25981392 "mir-191, mir-19a, mir-210, and mir-425 miRNAs are expressed differentially in chRCC, and unique expression of miRNAs is associated with the progression and prognosis of chRCC." +tissue_expression_ns hsa-mir-425 "Carcinoma, Renal Cell, Chromophobe" 25981392 "mir-191, mir-19a, mir-210, and mir-425 miRNAs are expressed differentially in chRCC, and unique expression of miRNAs is associated with the progression and prognosis of chRCC." +tissue_expression_ns hsa-let-7c "Carcinoma, Bladder" 25990459 this study identified the specific miRNAs associated with the progression and aggressiveness of MIBC and a four-miRNA signature as a promising prognostic parameter of MIBC. +tissue_expression_ns hsa-mir-125b-1 "Carcinoma, Bladder" 25990459 this study identified the specific miRNAs associated with the progression and aggressiveness of MIBC and a four-miRNA signature as a promising prognostic parameter of MIBC. +tissue_expression_ns hsa-mir-193a "Carcinoma, Bladder" 25990459 this study identified the specific miRNAs associated with the progression and aggressiveness of MIBC and a four-miRNA signature as a promising prognostic parameter of MIBC. +tissue_expression_ns hsa-mir-99a "Carcinoma, Bladder" 25990459 this study identified the specific miRNAs associated with the progression and aggressiveness of MIBC and a four-miRNA signature as a promising prognostic parameter of MIBC. +tissue_expression_ns hsa-mir-373 Neoplasms [unspecific] 25990556 "Deregulation of miR-373 has been demonstrated in a number of cancers, whether it acts as an oncogene or a tumor suppressor, however, seems to be context dependent. In this review, we focus on the diverse functions of miR-373 and its implication in cancers." +tissue_expression_ns hsa-let-7 Neoplasms [unspecific] 25998712 "together with the recent identification of novel miRNA regulatory factors and pathways, highlights the importance of miRNA dysregulation in cancer." +tissue_expression_ns hsa-mir-15 Neoplasms [unspecific] 25998712 "together with the recent identification of novel miRNA regulatory factors and pathways, highlights the importance of miRNA dysregulation in cancer." +tissue_expression_ns hsa-mir-16 Neoplasms [unspecific] 25998712 "together with the recent identification of novel miRNA regulatory factors and pathways, highlights the importance of miRNA dysregulation in cancer." +tissue_expression_ns hsa-mir-222 "Adenocarcinoma, Pancreatic Ductal" 26002251 "we found significant adjusted HRs for poor OS for high miR-155, high miR-203, and low miR-34a; and unadjusted HRs for high miR-222 and high miR-10b." +tissue_expression_ns hsa-mir-1 Colorectal Carcinoma 26045793 The potential value of miR-1 and miR-374b as biomarkers for colorectal cancer. +tissue_expression_ns hsa-mir-191 Acute Myocardial Infarction 26046358 "This study highlights the stability of miRNAs after death and long-term fixation, validating their use as reliable biomarkers for AMI during postmortem examination." +tissue_expression_ns hsa-mir-26b Acute Myocardial Infarction 26046358 "This study highlights the stability of miRNAs after death and long-term fixation, validating their use as reliable biomarkers for AMI during postmortem examination." +tissue_expression_ns hsa-mir-30a "Carcinoma, Thyroid, Papillary" 26047355 The results of this study suggest that miR-30a-5p might be a novel diagnostic marker candidate in PTC. Further studies are required to investigate this possibility. +tissue_expression_ns hsa-mir-126 "Carcinoma, Breast, Triple Negative" 26062749 "This study provides strong evidence that the expression levels of miR-374b-5p, miR-27b-3p, miR-126-3p, and miR-218-5p in tumor tissues predict TNBC outcomes." +tissue_expression_ns hsa-mir-218 "Carcinoma, Breast, Triple Negative" 26062749 "This study provides strong evidence that the expression levels of miR-374b-5p, miR-27b-3p, miR-126-3p, and miR-218-5p in tumor tissues predict TNBC outcomes." +tissue_expression_ns hsa-mir-27b "Carcinoma, Breast, Triple Negative" 26062749 "This study provides strong evidence that the expression levels of miR-374b-5p, miR-27b-3p, miR-126-3p, and miR-218-5p in tumor tissues predict TNBC outcomes." +tissue_expression_ns hsa-mir-374b "Carcinoma, Breast, Triple Negative" 26062749 "This study provides strong evidence that the expression levels of miR-374b-5p, miR-27b-3p, miR-126-3p, and miR-218-5p in tumor tissues predict TNBC outcomes." +tissue_expression_ns hsa-mir-31 "Squamous Cell Carcinoma, Oral" 26104160 "MiR-31 and miR-130b, known to inhibit several steps in the metastatic process, were over-expressed in non-metastatic samples and the expression of miR-130b was confirmed in plasma of patients showing no metastasis." +tissue_expression_ns hsa-mir-34a "Adenocarcinoma, Lung" 26104764 The expression of microRNA-34a is inversely correlated with c-MET and CDK6 and has a prognostic significance in lung adenocarcinoma patients. +tissue_expression_ns hsa-let-7a Breast Neoplasms 26130254 "Relative levels of let-7a, miR-17, miR-27b, miR-125a, miR-125b and miR-206 as potential molecular markers to evaluate grade, receptor status and molecular type in breast cancer." +tissue_expression_ns hsa-mir-130b Breast Neoplasms 26152113 Comparative microRNA profiling of sporadic and BRCA1 associated basal-like breast cancers +tissue_expression_ns hsa-mir-149 Breast Neoplasms 26152113 Comparative microRNA profiling of sporadic and BRCA2 associated basal-like breast cancers +tissue_expression_ns hsa-mir-190b Breast Neoplasms 26152113 Comparative microRNA profiling of sporadic and BRCA3 associated basal-like breast cancers +tissue_expression_ns hsa-mir-198 Breast Neoplasms 26152113 Comparative microRNA profiling of sporadic and BRCA4 associated basal-like breast cancers +tissue_expression_ns hsa-mir-218 Breast Neoplasms 26152113 Comparative microRNA profiling of sporadic and BRCA5 associated basal-like breast cancers +tissue_expression_ns hsa-mir-374b Breast Neoplasms 26152113 Comparative microRNA profiling of sporadic and BRCA7 associated basal-like breast cancers +tissue_expression_ns hsa-mir-590 Breast Neoplasms 26152113 Comparative microRNA profiling of sporadic and BRCA6 associated basal-like breast cancers +tissue_expression_ns hsa-mir-892a Breast Neoplasms 26152113 Comparative microRNA profiling of sporadic and BRCA8 associated basal-like breast cancers +tissue_expression_ns hsa-mir-196b Crohn Disease 26164662 "We found a suite of miRNAs, including miR-31-5p, miR-215, miR-223-3p, miR-196b-5p, and miR-203 that stratify patients with CD according to disease behavior independent of the effect of inflammation." +tissue_expression_ns hsa-mir-203 Crohn Disease 26164662 "We found a suite of miRNAs, including miR-31-5p, miR-215, miR-223-3p, miR-196b-5p, and miR-203 that stratify patients with CD according to disease behavior independent of the effect of inflammation." +tissue_expression_ns hsa-mir-1-2 Gastric Neoplasms 26168960 "mir-17, mir-133b, mir-133a-2, and mir-1-2 appear to be a potential novel predictor of tumor stage and preoperative and intraoperative diagnosis." +tissue_expression_ns hsa-mir-133a-2 Gastric Neoplasms 26168960 "mir-17, mir-133b, mir-133a-2, and mir-1-2 appear to be a potential novel predictor of tumor stage and preoperative and intraoperative diagnosis." +tissue_expression_ns hsa-mir-133b Gastric Neoplasms 26168960 "mir-17, mir-133b, mir-133a-2, and mir-1-2 appear to be a potential novel predictor of tumor stage and preoperative and intraoperative diagnosis." +tissue_expression_ns hsa-mir-17 Gastric Neoplasms 26168960 "mir-17, mir-133b, mir-133a-2, and mir-1-2 appear to be a potential novel predictor of tumor stage and preoperative and intraoperative diagnosis." +tissue_expression_ns hsa-mir-23a "Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal" 26175945 MiR-21/miR-375 ratio is an independent prognostic factor in patients with laryngeal squamous cell carcinoma. +tissue_expression_ns hsa-mir-126 Osteosarcoma 26194657 Tissue microRNA-126 expression level predicts outcome in human osteosarcoma. +tissue_expression_ns hsa-mir-148a Breast Neoplasms 26199650 "Based on the results obtained in the last decade, some miRNAs are emerging as biomarkers of BC for diagnosis (i.e., miR-9, miR-10b, and miR-17-5p), prognosis (i.e., miR-148a and miR-335)" +tissue_expression_ns hsa-mir-122 "Carcinoma, Hepatocellular" 26229398 "In summary, all the reported results suggest that differences in miRNA expression exist between HCV-related and HCV-negative NHLs, and further studies will be useful to ascertain if miRNAs are involved in the pathogenesis of HCV-related lymphomas and whether they can be used as biomarkers." +tissue_expression_ns hsa-mir-125a "Carcinoma, Hepatocellular" 26229398 "In summary, all the reported results suggest that differences in miRNA expression exist between HCV-related and HCV-negative NHLs, and further studies will be useful to ascertain if miRNAs are involved in the pathogenesis of HCV-related lymphomas and whether they can be used as biomarkers." +tissue_expression_ns hsa-mir-129 "Carcinoma, Hepatocellular" 26229398 "In summary, all the reported results suggest that differences in miRNA expression exist between HCV-related and HCV-negative NHLs, and further studies will be useful to ascertain if miRNAs are involved in the pathogenesis of HCV-related lymphomas and whether they can be used as biomarkers." +tissue_expression_ns hsa-mir-133b "Carcinoma, Hepatocellular" 26229398 "In summary, all the reported results suggest that differences in miRNA expression exist between HCV-related and HCV-negative NHLs, and further studies will be useful to ascertain if miRNAs are involved in the pathogenesis of HCV-related lymphomas and whether they can be used as biomarkers." +tissue_expression_ns hsa-mir-142 "Carcinoma, Hepatocellular" 26229398 "In summary, all the reported results suggest that differences in miRNA expression exist between HCV-related and HCV-negative NHLs, and further studies will be useful to ascertain if miRNAs are involved in the pathogenesis of HCV-related lymphomas and whether they can be used as biomarkers." +tissue_expression_ns hsa-mir-192 "Carcinoma, Hepatocellular" 26229398 "In summary, all the reported results suggest that differences in miRNA expression exist between HCV-related and HCV-negative NHLs, and further studies will be useful to ascertain if miRNAs are involved in the pathogenesis of HCV-related lymphomas and whether they can be used as biomarkers." +tissue_expression_ns hsa-mir-194 "Carcinoma, Hepatocellular" 26229398 "In summary, all the reported results suggest that differences in miRNA expression exist between HCV-related and HCV-negative NHLs, and further studies will be useful to ascertain if miRNAs are involved in the pathogenesis of HCV-related lymphomas and whether they can be used as biomarkers." +tissue_expression_ns hsa-mir-195 "Carcinoma, Hepatocellular" 26229398 "In summary, all the reported results suggest that differences in miRNA expression exist between HCV-related and HCV-negative NHLs, and further studies will be useful to ascertain if miRNAs are involved in the pathogenesis of HCV-related lymphomas and whether they can be used as biomarkers." +tissue_expression_ns hsa-mir-198 "Carcinoma, Hepatocellular" 26229398 "In summary, all the reported results suggest that differences in miRNA expression exist between HCV-related and HCV-negative NHLs, and further studies will be useful to ascertain if miRNAs are involved in the pathogenesis of HCV-related lymphomas and whether they can be used as biomarkers." +tissue_expression_ns hsa-mir-199a "Carcinoma, Hepatocellular" 26229398 "In summary, all the reported results suggest that differences in miRNA expression exist between HCV-related and HCV-negative NHLs, and further studies will be useful to ascertain if miRNAs are involved in the pathogenesis of HCV-related lymphomas and whether they can be used as biomarkers." +tissue_expression_ns hsa-mir-20 "Carcinoma, Hepatocellular" 26229398 "In summary, all the reported results suggest that differences in miRNA expression exist between HCV-related and HCV-negative NHLs, and further studies will be useful to ascertain if miRNAs are involved in the pathogenesis of HCV-related lymphomas and whether they can be used as biomarkers." +tissue_expression_ns hsa-mir-200a "Carcinoma, Hepatocellular" 26229398 "In summary, all the reported results suggest that differences in miRNA expression exist between HCV-related and HCV-negative NHLs, and further studies will be useful to ascertain if miRNAs are involved in the pathogenesis of HCV-related lymphomas and whether they can be used as biomarkers." +tissue_expression_ns hsa-mir-215 "Carcinoma, Hepatocellular" 26229398 "In summary, all the reported results suggest that differences in miRNA expression exist between HCV-related and HCV-negative NHLs, and further studies will be useful to ascertain if miRNAs are involved in the pathogenesis of HCV-related lymphomas and whether they can be used as biomarkers." +tissue_expression_ns hsa-mir-223 "Carcinoma, Hepatocellular" 26229398 "In summary, all the reported results suggest that differences in miRNA expression exist between HCV-related and HCV-negative NHLs, and further studies will be useful to ascertain if miRNAs are involved in the pathogenesis of HCV-related lymphomas and whether they can be used as biomarkers." +tissue_expression_ns hsa-mir-224 "Carcinoma, Hepatocellular" 26229398 "In summary, all the reported results suggest that differences in miRNA expression exist between HCV-related and HCV-negative NHLs, and further studies will be useful to ascertain if miRNAs are involved in the pathogenesis of HCV-related lymphomas and whether they can be used as biomarkers." +tissue_expression_ns hsa-mir-24 "Carcinoma, Hepatocellular" 26229398 "In summary, all the reported results suggest that differences in miRNA expression exist between HCV-related and HCV-negative NHLs, and further studies will be useful to ascertain if miRNAs are involved in the pathogenesis of HCV-related lymphomas and whether they can be used as biomarkers." +tissue_expression_ns hsa-mir-25 "Carcinoma, Hepatocellular" 26229398 "In summary, all the reported results suggest that differences in miRNA expression exist between HCV-related and HCV-negative NHLs, and further studies will be useful to ascertain if miRNAs are involved in the pathogenesis of HCV-related lymphomas and whether they can be used as biomarkers." +tissue_expression_ns hsa-mir-26b "Carcinoma, Hepatocellular" 26229398 "In summary, all the reported results suggest that differences in miRNA expression exist between HCV-related and HCV-negative NHLs, and further studies will be useful to ascertain if miRNAs are involved in the pathogenesis of HCV-related lymphomas and whether they can be used as biomarkers." +tissue_expression_ns hsa-mir-27a "Carcinoma, Hepatocellular" 26229398 "In summary, all the reported results suggest that differences in miRNA expression exist between HCV-related and HCV-negative NHLs, and further studies will be useful to ascertain if miRNAs are involved in the pathogenesis of HCV-related lymphomas and whether they can be used as biomarkers." +tissue_expression_ns hsa-mir-29a "Carcinoma, Hepatocellular" 26229398 "In summary, all the reported results suggest that differences in miRNA expression exist between HCV-related and HCV-negative NHLs, and further studies will be useful to ascertain if miRNAs are involved in the pathogenesis of HCV-related lymphomas and whether they can be used as biomarkers." +tissue_expression_ns hsa-mir-29b "Carcinoma, Hepatocellular" 26229398 "In summary, all the reported results suggest that differences in miRNA expression exist between HCV-related and HCV-negative NHLs, and further studies will be useful to ascertain if miRNAs are involved in the pathogenesis of HCV-related lymphomas and whether they can be used as biomarkers." +tissue_expression_ns hsa-mir-320 "Carcinoma, Hepatocellular" 26229398 "In summary, all the reported results suggest that differences in miRNA expression exist between HCV-related and HCV-negative NHLs, and further studies will be useful to ascertain if miRNAs are involved in the pathogenesis of HCV-related lymphomas and whether they can be used as biomarkers." +tissue_expression_ns hsa-mir-369 "Carcinoma, Hepatocellular" 26229398 "In summary, all the reported results suggest that differences in miRNA expression exist between HCV-related and HCV-negative NHLs, and further studies will be useful to ascertain if miRNAs are involved in the pathogenesis of HCV-related lymphomas and whether they can be used as biomarkers." +tissue_expression_ns hsa-mir-491 "Carcinoma, Hepatocellular" 26229398 "In summary, all the reported results suggest that differences in miRNA expression exist between HCV-related and HCV-negative NHLs, and further studies will be useful to ascertain if miRNAs are involved in the pathogenesis of HCV-related lymphomas and whether they can be used as biomarkers." +tissue_expression_ns hsa-mir-512 "Carcinoma, Hepatocellular" 26229398 "In summary, all the reported results suggest that differences in miRNA expression exist between HCV-related and HCV-negative NHLs, and further studies will be useful to ascertain if miRNAs are involved in the pathogenesis of HCV-related lymphomas and whether they can be used as biomarkers." +tissue_expression_ns hsa-mir-522 "Carcinoma, Hepatocellular" 26229398 "In summary, all the reported results suggest that differences in miRNA expression exist between HCV-related and HCV-negative NHLs, and further studies will be useful to ascertain if miRNAs are involved in the pathogenesis of HCV-related lymphomas and whether they can be used as biomarkers." +tissue_expression_ns hsa-mir-542 "Carcinoma, Hepatocellular" 26229398 "In summary, all the reported results suggest that differences in miRNA expression exist between HCV-related and HCV-negative NHLs, and further studies will be useful to ascertain if miRNAs are involved in the pathogenesis of HCV-related lymphomas and whether they can be used as biomarkers." +tissue_expression_ns hsa-mir-576 "Carcinoma, Hepatocellular" 26229398 "In summary, all the reported results suggest that differences in miRNA expression exist between HCV-related and HCV-negative NHLs, and further studies will be useful to ascertain if miRNAs are involved in the pathogenesis of HCV-related lymphomas and whether they can be used as biomarkers." +tissue_expression_ns hsa-mir-651 "Carcinoma, Hepatocellular" 26229398 "In summary, all the reported results suggest that differences in miRNA expression exist between HCV-related and HCV-negative NHLs, and further studies will be useful to ascertain if miRNAs are involved in the pathogenesis of HCV-related lymphomas and whether they can be used as biomarkers." +tissue_expression_ns hsa-mir-92 "Carcinoma, Hepatocellular" 26229398 "In summary, all the reported results suggest that differences in miRNA expression exist between HCV-related and HCV-negative NHLs, and further studies will be useful to ascertain if miRNAs are involved in the pathogenesis of HCV-related lymphomas and whether they can be used as biomarkers." +tissue_expression_ns hsa-mir-130a "Carcinoma, Hepatocellular" 26231037 Systematic and integrative analysis of published datesets that compared the miRNA expression profiles between hepatocellular carcinoma (HCC) tissue and paired adjacent noncancerous liver tissue was performed to determine candidate HCC associated miRNAs. +tissue_expression_ns hsa-mir-21 "Carcinoma, Hepatocellular" 26231037 Systematic and integrative analysis of published datesets that compared the miRNA expression profiles between hepatocellular carcinoma (HCC) tissue and paired adjacent noncancerous liver tissue was performed to determine candidate HCC associated miRNAs. +tissue_expression_ns hsa-mir-214 "Carcinoma, Hepatocellular" 26231037 Systematic and integrative analysis of published datesets that compared the miRNA expression profiles between hepatocellular carcinoma (HCC) tissue and paired adjacent noncancerous liver tissue was performed to determine candidate HCC associated miRNAs. +tissue_expression_ns hsa-mir-221 "Carcinoma, Hepatocellular" 26231037 Systematic and integrative analysis of published datesets that compared the miRNA expression profiles between hepatocellular carcinoma (HCC) tissue and paired adjacent noncancerous liver tissue was performed to determine candidate HCC associated miRNAs. +tissue_expression_ns hsa-mir-186 Glioma 26231038 CRNDE affects the malignant biological characteristics of human glioma stem cells by negatively regulating miR-186. +tissue_expression_ns hsa-mir-15a "Carcinoma, Thyroid, Papillary" 26252081 "We found that the area under the curve (AUC) values of 8 miRNAs (miR-106a, miR-15a, miR-30a, miR-30b, miR-20a, miR-20b, miR-30d and miR-30e)" +tissue_expression_ns hsa-mir-20a "Carcinoma, Thyroid, Papillary" 26252081 "We found that the area under the curve (AUC) values of 8 miRNAs (miR-106a, miR-15a, miR-30a, miR-30b, miR-20a, miR-20b, miR-30d and miR-30e)" +tissue_expression_ns hsa-mir-30e "Carcinoma, Thyroid, Papillary" 26252081 "We found that the area under the curve (AUC) values of 8 miRNAs (miR-106a, miR-15a, miR-30a, miR-30b, miR-20a, miR-20b, miR-30d and miR-30e)" +tissue_expression_ns hsa-mir-320 Melanoma 26264058 "hsa-miR-519, ""hsa-miR-431"" and ""hsa-miR-320c"" are possible novel predictions for renal cancer, lung cancer and melanoma, respectively." +tissue_expression_ns hsa-mir-182 Melanoma 26273328 Clinical analyses demonstrated the link of miR-182 expression to poor prognosis in cancer patients. +tissue_expression_ns hsa-mir-4793 Necrotizing Enterocolitis 26274503 "The robust response of miRNA dysregulation in NEC and SIP, and concerted involvement of specific miRNAs in the molecular networks indicated their crucial roles in mucosa integrity and disease pathophysiology." +tissue_expression_ns hsa-mir-1290 Necrotizing Enterocolitis 26274503 "The robust response of miRNA dysregulation in NEC and SIP, and concerted involvement of specific miRNAs in the molecular networks indicated their crucial roles in mucosa integrity and disease pathophysiology." +tissue_expression_ns hsa-mir-194 Necrotizing Enterocolitis 26274503 "The robust response of miRNA dysregulation in NEC and SIP, and concerted involvement of specific miRNAs in the molecular networks indicated their crucial roles in mucosa integrity and disease pathophysiology." +tissue_expression_ns hsa-mir-203 Necrotizing Enterocolitis 26274503 "The robust response of miRNA dysregulation in NEC and SIP, and concerted involvement of specific miRNAs in the molecular networks indicated their crucial roles in mucosa integrity and disease pathophysiology." +tissue_expression_ns hsa-mir-21 Necrotizing Enterocolitis 26274503 "The robust response of miRNA dysregulation in NEC and SIP, and concerted involvement of specific miRNAs in the molecular networks indicated their crucial roles in mucosa integrity and disease pathophysiology." +tissue_expression_ns hsa-mir-31 Necrotizing Enterocolitis 26274503 "The robust response of miRNA dysregulation in NEC and SIP, and concerted involvement of specific miRNAs in the molecular networks indicated their crucial roles in mucosa integrity and disease pathophysiology." +tissue_expression_ns hsa-mir-431 Necrotizing Enterocolitis 26274503 "The robust response of miRNA dysregulation in NEC and SIP, and concerted involvement of specific miRNAs in the molecular networks indicated their crucial roles in mucosa integrity and disease pathophysiology." +tissue_expression_ns hsa-mir-451 Necrotizing Enterocolitis 26274503 "The robust response of miRNA dysregulation in NEC and SIP, and concerted involvement of specific miRNAs in the molecular networks indicated their crucial roles in mucosa integrity and disease pathophysiology." +tissue_expression_ns hsa-mir-23b "Carcinoma, Adenoid Cystic" 26293217 Expression of miR-23b and miR-27b differed between normal breast and normal salivary gland tissue +tissue_expression_ns hsa-mir-22 Neoplasms [unspecific] 26295583 Genome Wide Expression Profiling of Cancer Cell Lines Cultured in Microgravity Reveals Significant Dysregulation of Cell Cycle and MicroRNA Gene Networks. +tissue_expression_ns hsa-mir-16 Neoplasms [unspecific] 26299954 Genome-wide analysis of microRNA and mRNA expression signatures in cancer. +tissue_expression_ns hsa-mir-191 Neoplasms [unspecific] 26299954 Genome-wide analysis of microRNA and mRNA expression signatures in cancer. +tissue_expression_ns hsa-mir-93 Neoplasms [unspecific] 26299954 Genome-wide analysis of microRNA and mRNA expression signatures in cancer. +tissue_expression_ns hsa-mir-31 Inflammation 26303911 "We identified three miRNAs, miR-497, miR-351 and miR-31, that are candidate master regulators of genes associated with neutrophil recruitment." +tissue_expression_ns hsa-mir-16 Endometriosis 26307093 Peritoneal fluid modifies the microRNA expression profile in endometrial and endometriotic cells from women with endometriosis. +tissue_expression_ns hsa-mir-29c Endometriosis 26307093 Peritoneal fluid modifies the microRNA expression profile in endometrial and endometriotic cells from women with endometriosis. +tissue_expression_ns hsa-mir-424 Endometriosis 26307093 Peritoneal fluid modifies the microRNA expression profile in endometrial and endometriotic cells from women with endometriosis. +tissue_expression_ns hsa-mir-200c Uterine Corpus Myxoid Leiomyosarcoma 26307392 Malignant tumors of the uterine corpus: molecular background of their origin. +tissue_expression_ns hsa-mir-146b "Carcinoma, Thyroid, Papillary" 26321247 miRNA-222 and miRNA-146b deregulation are commonly associated with cancer recurrence in patients with papillary thyroid carcinoma. +tissue_expression_ns hsa-mir-222 "Carcinoma, Thyroid, Papillary" 26321247 miRNA-222 and miRNA-146b deregulation are commonly associated with cancer recurrence in patients with papillary thyroid carcinoma. +tissue_expression_ns hsa-mir-34b "Carcinoma, Nasopharyngeal" 26330189 Integrated analysis of the differential cellular and EBV miRNA expression profiles in microdissected nasopharyngeal carcinoma and non-cancerous nasopharyngeal tissues. +tissue_expression_ns hsa-mir-1 "Carcinoma, Breast" 26331797 These findings suggest that abnormal miR-1 expression is associated with an aggressive phenotype of breast carcinoma and that miR-1 status is a potent prognostic factor in human breast cancer patients. +tissue_expression_ns hsa-mir-145 Colorectal Carcinoma 26335822 The analysis of microRNAs miR-200C and miR-145 expression in colorectal cancer of different molecular subtypes. +tissue_expression_ns hsa-mir-200C Colorectal Carcinoma 26335822 The analysis of microRNAs miR-200C and miR-145 expression in colorectal cancer of different molecular subtypes. +tissue_expression_ns hsa-mir-21 Choriocarcinoma 26338526 Statistical analysis of a Bayesian classifier based on the expression of miRNAs. +tissue_expression_ns hsa-mir-451 Endometriosis 26370665 Altered expression of microRNA-451 in eutopic endometrium of baboons (Papioanubis) with endometriosis. +tissue_expression_ns hsa-mir-181c "Carcinoma, Urothelial, Upper Tract" 26397152 Differential microRNA expression in aristolochic acid-induced upper urothelial tract cancers ex vivo. +tissue_expression_ns hsa-mir-330 "Carcinoma, Urothelial, Upper Tract" 26397152 Differential microRNA expression in aristolochic acid-induced upper urothelial tract cancers ex vivo. +tissue_expression_ns hsa-mir-3916 "Carcinoma, Urothelial, Upper Tract" 26397152 Differential microRNA expression in aristolochic acid-induced upper urothelial tract cancers ex vivo. +tissue_expression_ns hsa-mir-4274 "Carcinoma, Urothelial, Upper Tract" 26397152 Differential microRNA expression in aristolochic acid-induced upper urothelial tract cancers ex vivo. +tissue_expression_ns hsa-mir-4784 "Carcinoma, Urothelial, Upper Tract" 26397152 Differential microRNA expression in aristolochic acid-induced upper urothelial tract cancers ex vivo. +tissue_expression_ns hsa-mir-4795 "Carcinoma, Urothelial, Upper Tract" 26397152 Differential microRNA expression in aristolochic acid-induced upper urothelial tract cancers ex vivo. +tissue_expression_ns hsa-mir-488 "Carcinoma, Urothelial, Upper Tract" 26397152 Differential microRNA expression in aristolochic acid-induced upper urothelial tract cancers ex vivo. +tissue_expression_ns hsa-mir-203 "Carcinoma, Lung" 26397233 "Cumulatively,our data purport that p53 not only increased Puma expression directly, but that it may also do so through miR-203. Additionally, functional studies revealed that miR-203 overexpression induced apoptosis and inhibited cell invasiveness." +tissue_expression_ns hsa-mir-203 Colon Neoplasms 26397233 "Cumulatively,our data purport that p53 not only increased Puma expression directly, but that it may also do so through miR-203. Additionally, functional studies revealed that miR-203 overexpression induced apoptosis and inhibited cell invasiveness." +tissue_expression_ns hsa-mir-1 Muscular Dystrophy 26398013 "whereas down-regulation of myogenic miRNAs, including miR-1 and miR-206, is associated with inhibition of muscle regeneration." +tissue_expression_ns hsa-mir-125b Neoplasms [unspecific] 26407906 The aberrant expression of miR-125 familyis tightly related to tumorigenesis and tumor development. +tissue_expression_ns hsa-mir-1271 "Carcinoma, Thyroid, Papillary" 26414548 Further studies are needed to investigate whether miRs are independent predictors of aggressive clinicopathologic features before it can be recommended that miR expression levels should be incorporated into the management algorithm for patients with PTC. A well-designed prospective study is needed to assess these potential associations. +tissue_expression_ns hsa-mir-130b "Carcinoma, Thyroid, Papillary" 26414548 Further studies are needed to investigate whether miRs are independent predictors of aggressive clinicopathologic features before it can be recommended that miR expression levels should be incorporated into the management algorithm for patients with PTC. A well-designed prospective study is needed to assess these potential associations. +tissue_expression_ns hsa-mir-135b "Carcinoma, Thyroid, Papillary" 26414548 Further studies are needed to investigate whether miRs are independent predictors of aggressive clinicopathologic features before it can be recommended that miR expression levels should be incorporated into the management algorithm for patients with PTC. A well-designed prospective study is needed to assess these potential associations. +tissue_expression_ns hsa-mir-146b "Carcinoma, Thyroid, Papillary" 26414548 Further studies are needed to investigate whether miRs are independent predictors of aggressive clinicopathologic features before it can be recommended that miR expression levels should be incorporated into the management algorithm for patients with PTC. A well-designed prospective study is needed to assess these potential associations. +tissue_expression_ns hsa-mir-151 "Carcinoma, Thyroid, Papillary" 26414548 Further studies are needed to investigate whether miRs are independent predictors of aggressive clinicopathologic features before it can be recommended that miR expression levels should be incorporated into the management algorithm for patients with PTC. A well-designed prospective study is needed to assess these potential associations. +tissue_expression_ns hsa-mir-181b "Carcinoma, Thyroid, Papillary" 26414548 Further studies are needed to investigate whether miRs are independent predictors of aggressive clinicopathologic features before it can be recommended that miR expression levels should be incorporated into the management algorithm for patients with PTC. A well-designed prospective study is needed to assess these potential associations. +tissue_expression_ns hsa-mir-199b "Carcinoma, Thyroid, Papillary" 26414548 Further studies are needed to investigate whether miRs are independent predictors of aggressive clinicopathologic features before it can be recommended that miR expression levels should be incorporated into the management algorithm for patients with PTC. A well-designed prospective study is needed to assess these potential associations. +tissue_expression_ns hsa-mir-21 "Carcinoma, Thyroid, Papillary" 26414548 Further studies are needed to investigate whether miRs are independent predictors of aggressive clinicopathologic features before it can be recommended that miR expression levels should be incorporated into the management algorithm for patients with PTC. A well-designed prospective study is needed to assess these potential associations. +tissue_expression_ns hsa-mir-221 "Carcinoma, Thyroid, Papillary" 26414548 Further studies are needed to investigate whether miRs are independent predictors of aggressive clinicopathologic features before it can be recommended that miR expression levels should be incorporated into the management algorithm for patients with PTC. A well-designed prospective study is needed to assess these potential associations. +tissue_expression_ns hsa-mir-222 "Carcinoma, Thyroid, Papillary" 26414548 Further studies are needed to investigate whether miRs are independent predictors of aggressive clinicopathologic features before it can be recommended that miR expression levels should be incorporated into the management algorithm for patients with PTC. A well-designed prospective study is needed to assess these potential associations. +tissue_expression_ns hsa-mir-2861 "Carcinoma, Thyroid, Papillary" 26414548 Further studies are needed to investigate whether miRs are independent predictors of aggressive clinicopathologic features before it can be recommended that miR expression levels should be incorporated into the management algorithm for patients with PTC. A well-designed prospective study is needed to assess these potential associations. +tissue_expression_ns hsa-mir-34b "Carcinoma, Thyroid, Papillary" 26414548 Further studies are needed to investigate whether miRs are independent predictors of aggressive clinicopathologic features before it can be recommended that miR expression levels should be incorporated into the management algorithm for patients with PTC. A well-designed prospective study is needed to assess these potential associations. +tissue_expression_ns hsa-mir-451 "Carcinoma, Thyroid, Papillary" 26414548 Further studies are needed to investigate whether miRs are independent predictors of aggressive clinicopathologic features before it can be recommended that miR expression levels should be incorporated into the management algorithm for patients with PTC. A well-designed prospective study is needed to assess these potential associations. +tissue_expression_ns hsa-mir-623 "Carcinoma, Thyroid, Papillary" 26414548 Further studies are needed to investigate whether miRs are independent predictors of aggressive clinicopathologic features before it can be recommended that miR expression levels should be incorporated into the management algorithm for patients with PTC. A well-designed prospective study is needed to assess these potential associations. +tissue_expression_ns hsa-mir-126 Colorectal Carcinoma 26455548 "To conclude, deregulation of miR-126 in colorectal cancer at the tissue and cellular levels as well as its correlation with various clinicopathological parameters confirm the cancer suppressive role of miR-126 in colorectal cancer." +tissue_expression_ns hsa-mir-139 Colorectal Carcinoma 26462034 Clinical value of integrated-signature miRNAs in colorectal cancer: miRNA expression profiling analysis and experimental validation. +tissue_expression_ns hsa-mir-143 Colorectal Carcinoma 26462034 Clinical value of integrated-signature miRNAs in colorectal cancer: miRNA expression profiling analysis and experimental validation. +tissue_expression_ns hsa-mir-145 Colorectal Carcinoma 26462034 Clinical value of integrated-signature miRNAs in colorectal cancer: miRNA expression profiling analysis and experimental validation. +tissue_expression_ns hsa-mir-17 Colorectal Carcinoma 26462034 Clinical value of integrated-signature miRNAs in colorectal cancer: miRNA expression profiling analysis and experimental validation. +tissue_expression_ns hsa-mir-183 Colorectal Carcinoma 26462034 Clinical value of integrated-signature miRNAs in colorectal cancer: miRNA expression profiling analysis and experimental validation. +tissue_expression_ns hsa-mir-195 Colorectal Carcinoma 26462034 Clinical value of integrated-signature miRNAs in colorectal cancer: miRNA expression profiling analysis and experimental validation. +tissue_expression_ns hsa-mir-20a Colorectal Carcinoma 26462034 Clinical value of integrated-signature miRNAs in colorectal cancer: miRNA expression profiling analysis and experimental validation. +tissue_expression_ns hsa-mir-21 Colorectal Carcinoma 26462034 Clinical value of integrated-signature miRNAs in colorectal cancer: miRNA expression profiling analysis and experimental validation. +tissue_expression_ns hsa-mir-378a Colorectal Carcinoma 26462034 Clinical value of integrated-signature miRNAs in colorectal cancer: miRNA expression profiling analysis and experimental validation. +tissue_expression_ns hsa-mir-17 "Carcinoma, Colon" 26465597 "It is concluded that the expression of miR-17, miR-21, and miR-145 changes at early stages of the normal-adenoma-adenocarcinoma sequence. Thus, these microRNAs may play a role in the development of colon cancer." +tissue_expression_ns hsa-mir-18 "Carcinoma, Colon" 26465597 "It is concluded that the expression of miR-17, miR-21, and miR-145 changes at early stages of the normal-adenoma-adenocarcinoma sequence. Thus, these microRNAs may play a role in the development of colon cancer." +tissue_expression_ns hsa-mir-19a "Carcinoma, Colon" 26465597 "It is concluded that the expression of miR-17, miR-21, and miR-145 changes at early stages of the normal-adenoma-adenocarcinoma sequence. Thus, these microRNAs may play a role in the development of colon cancer." +tissue_expression_ns hsa-mir-19b-1 "Carcinoma, Colon" 26465597 "It is concluded that the expression of miR-17, miR-21, and miR-145 changes at early stages of the normal-adenoma-adenocarcinoma sequence. Thus, these microRNAs may play a role in the development of colon cancer." +tissue_expression_ns hsa-mir-20a "Carcinoma, Colon" 26465597 "It is concluded that the expression of miR-17, miR-21, and miR-145 changes at early stages of the normal-adenoma-adenocarcinoma sequence. Thus, these microRNAs may play a role in the development of colon cancer." +tissue_expression_ns hsa-mir-92-1 "Carcinoma, Colon" 26465597 "It is concluded that the expression of miR-17, miR-21, and miR-145 changes at early stages of the normal-adenoma-adenocarcinoma sequence. Thus, these microRNAs may play a role in the development of colon cancer." +tissue_expression_ns hsa-mir-99b Inflammatory Bowel Diseases 26466382 "These results suggest that the proposed miRNA signature is of relevance for the etiology of IBD. Its diagnostic value, however, should be further evaluated in large, independent, clinically well characterized cohorts." +tissue_expression_ns hsa-mir-182 Prostate Neoplasms 26484677 "Integrated Analysis Reveals together miR-182, miR-200c and miR-221 Can Help in the Diagnosis of Prostate Cancer." +tissue_expression_ns hsa-mir-200c Prostate Neoplasms 26484677 "Integrated Analysis Reveals together miR-182, miR-200c and miR-221 Can Help in the Diagnosis of Prostate Cancer." +tissue_expression_ns hsa-mir-221 Prostate Neoplasms 26484677 "Integrated Analysis Reveals together miR-182, miR-200c and miR-221 Can Help in the Diagnosis of Prostate Cancer." +tissue_expression_ns hsa-mir-100 Bladder Neoplasms 26489968 MiRNAs detected in urine and serum/plasma will demonstrate their potentiality to describe the variegated scenario of BC and to become relevant clinical markers. +tissue_expression_ns hsa-let-7g Alzheimer Disease 26497684 Altered microRNA profiles in cerebrospinal fluid exosome in Parkinson disease and Alzheimer disease. +tissue_expression_ns hsa-let-7g Parkinson Disease 26497684 Altered microRNA profiles in cerebrospinal fluid exosome in Parkinson disease and Alzheimer disease. +tissue_expression_ns hsa-mir-10a Alzheimer Disease 26497684 Altered microRNA profiles in cerebrospinal fluid exosome in Parkinson disease and Alzheimer disease. +tissue_expression_ns hsa-mir-10a Parkinson Disease 26497684 Altered microRNA profiles in cerebrospinal fluid exosome in Parkinson disease and Alzheimer disease. +tissue_expression_ns hsa-mir-153 Alzheimer Disease 26497684 Altered microRNA profiles in cerebrospinal fluid exosome in Parkinson disease and Alzheimer disease. +tissue_expression_ns hsa-mir-153 Parkinson Disease 26497684 Altered microRNA profiles in cerebrospinal fluid exosome in Parkinson disease and Alzheimer disease. +tissue_expression_ns hsa-mir-409 Alzheimer Disease 26497684 Altered microRNA profiles in cerebrospinal fluid exosome in Parkinson disease and Alzheimer disease. +tissue_expression_ns hsa-mir-409 Parkinson Disease 26497684 Altered microRNA profiles in cerebrospinal fluid exosome in Parkinson disease and Alzheimer disease. +tissue_expression_ns hsa-mir-510 "Carcinoma, Ovarian" 26497752 "Profile of differentially expressed miRNAs in high-grade serous carcinoma and clear cell ovarian carcinoma, and the expression of miR-510 in ovarian carcinoma." +tissue_expression_ns hsa-mir-30c "Carcinoma, Prostate" 26499781 The average relative expressions of hsa-miR-203 and hsa-miR-30c in tumor tissues were significantly different from those in adjacent normal tissues +tissue_expression_ns hsa-mir-155 Pancreatic Neoplasms 26499892 "We found miR-21, miR-155 or miR-217 expression values in tumors may differ up to several times" +tissue_expression_ns hsa-mir-196a Pancreatic Neoplasms 26499892 "Moreover, different internal controls can produce controversial results for miR-96, miR-148a or miR-196a quantification." +tissue_expression_ns hsa-mir-200b Hypertrophic Scar 26500110 Aberrant miR-21 and miR-200b expression and its pro-fibrotic potential in hypertrophic scars. +tissue_expression_ns hsa-mir-21 Hypertrophic Scar 26500110 Aberrant miR-21 and miR-200b expression and its pro-fibrotic potential in hypertrophic scars. +tissue_expression_ns hsa-mir-199a Diabetic Cardiomyopathies 26553540 A dysregulation of 316 out of 1008 total miRNAs was observed in the diabetic hearts when compared with controls. +tissue_expression_ns hsa-mir-203 Psoriasis 26559308 "Key roles of several unique miRNAs, such as miR-203 and miR-125b, in inflammatory responses and immune dysfunction, as well as hyperproliferative disorders of psoriatic lesions have been revealed." +tissue_expression_ns hsa-mir-192 Barrett Esophagus 26572780 "MicroRNAs miR-192, -194, -203, -205, and -215 are promising tissue biomarkers for diagnosing BE. Cross-sectional data suggest that microRNAs may have a limited role in separating BE from HGD/EAC epithelia but need further testing in longitudinal follow-up studies." +tissue_expression_ns hsa-mir-194 Barrett Esophagus 26572780 "MicroRNAs miR-192, -194, -203, -205, and -215 are promising tissue biomarkers for diagnosing BE. Cross-sectional data suggest that microRNAs may have a limited role in separating BE from HGD/EAC epithelia but need further testing in longitudinal follow-up studies." +tissue_expression_ns hsa-mir-203 Barrett Esophagus 26572780 "MicroRNAs miR-192, -194, -203, -205, and -215 are promising tissue biomarkers for diagnosing BE. Cross-sectional data suggest that microRNAs may have a limited role in separating BE from HGD/EAC epithelia but need further testing in longitudinal follow-up studies." +tissue_expression_ns hsa-mir-205 Barrett Esophagus 26572780 "MicroRNAs miR-192, -194, -203, -205, and -215 are promising tissue biomarkers for diagnosing BE. Cross-sectional data suggest that microRNAs may have a limited role in separating BE from HGD/EAC epithelia but need further testing in longitudinal follow-up studies." +tissue_expression_ns hsa-mir-215 Barrett Esophagus 26572780 "MicroRNAs miR-192, -194, -203, -205, and -215 are promising tissue biomarkers for diagnosing BE. Cross-sectional data suggest that microRNAs may have a limited role in separating BE from HGD/EAC epithelia but need further testing in longitudinal follow-up studies." +tissue_expression_ns hsa-mir-7 Schizophrenia 26572867 "Here we show post-transcriptional regulation of SHANK3 expression by three microRNAs (miRNAs), miR-7, miR-34a, and miR-504." +tissue_expression_ns hsa-mir-126 Bladder Neoplasms 26576778 "MicroRNA profiling from matched samples in patients shows a significant number of microRNAs up regulated in bladder tumors are identifiable in urine exosomes and WBCs of the same patient, but not in blood plasma. This study demonstrated varying relationships between miRNA detected in biological media from the same patient, and serves to inform the potential of urine-based microRNAs as biomarkers for bladder cancer and potentially other malignancies." +tissue_expression_ns hsa-mir-150 Bladder Neoplasms 26576778 "MicroRNA profiling from matched samples in patients shows a significant number of microRNAs up regulated in bladder tumors are identifiable in urine exosomes and WBCs of the same patient, but not in blood plasma. This study demonstrated varying relationships between miRNA detected in biological media from the same patient, and serves to inform the potential of urine-based microRNAs as biomarkers for bladder cancer and potentially other malignancies." +tissue_expression_ns hsa-mir-15b Bladder Neoplasms 26576778 "MicroRNA profiling from matched samples in patients shows a significant number of microRNAs up regulated in bladder tumors are identifiable in urine exosomes and WBCs of the same patient, but not in blood plasma. This study demonstrated varying relationships between miRNA detected in biological media from the same patient, and serves to inform the potential of urine-based microRNAs as biomarkers for bladder cancer and potentially other malignancies." +tissue_expression_ns hsa-mir-200c Bladder Neoplasms 26576778 "MicroRNA profiling from matched samples in patients shows a significant number of microRNAs up regulated in bladder tumors are identifiable in urine exosomes and WBCs of the same patient, but not in blood plasma. This study demonstrated varying relationships between miRNA detected in biological media from the same patient, and serves to inform the potential of urine-based microRNAs as biomarkers for bladder cancer and potentially other malignancies." +tissue_expression_ns hsa-mir-205 Bladder Neoplasms 26576778 "MicroRNA profiling from matched samples in patients shows a significant number of microRNAs up regulated in bladder tumors are identifiable in urine exosomes and WBCs of the same patient, but not in blood plasma. This study demonstrated varying relationships between miRNA detected in biological media from the same patient, and serves to inform the potential of urine-based microRNAs as biomarkers for bladder cancer and potentially other malignancies." +tissue_expression_ns hsa-mir-21 Bladder Neoplasms 26576778 "MicroRNA profiling from matched samples in patients shows a significant number of microRNAs up regulated in bladder tumors are identifiable in urine exosomes and WBCs of the same patient, but not in blood plasma. This study demonstrated varying relationships between miRNA detected in biological media from the same patient, and serves to inform the potential of urine-based microRNAs as biomarkers for bladder cancer and potentially other malignancies." +tissue_expression_ns hsa-mir-29b Bladder Neoplasms 26576778 "MicroRNA profiling from matched samples in patients shows a significant number of microRNAs up regulated in bladder tumors are identifiable in urine exosomes and WBCs of the same patient, but not in blood plasma. This study demonstrated varying relationships between miRNA detected in biological media from the same patient, and serves to inform the potential of urine-based microRNAs as biomarkers for bladder cancer and potentially other malignancies." +tissue_expression_ns hsa-mir-3007a Bladder Neoplasms 26576778 "MicroRNA profiling from matched samples in patients shows a significant number of microRNAs up regulated in bladder tumors are identifiable in urine exosomes and WBCs of the same patient, but not in blood plasma. This study demonstrated varying relationships between miRNA detected in biological media from the same patient, and serves to inform the potential of urine-based microRNAs as biomarkers for bladder cancer and potentially other malignancies." +tissue_expression_ns hsa-mir-4454 Bladder Neoplasms 26576778 "MicroRNA profiling from matched samples in patients shows a significant number of microRNAs up regulated in bladder tumors are identifiable in urine exosomes and WBCs of the same patient, but not in blood plasma. This study demonstrated varying relationships between miRNA detected in biological media from the same patient, and serves to inform the potential of urine-based microRNAs as biomarkers for bladder cancer and potentially other malignancies." +tissue_expression_ns hsa-mir-720 Bladder Neoplasms 26576778 "MicroRNA profiling from matched samples in patients shows a significant number of microRNAs up regulated in bladder tumors are identifiable in urine exosomes and WBCs of the same patient, but not in blood plasma. This study demonstrated varying relationships between miRNA detected in biological media from the same patient, and serves to inform the potential of urine-based microRNAs as biomarkers for bladder cancer and potentially other malignancies." +tissue_expression_ns hsa-mir-93 Bladder Neoplasms 26576778 "MicroRNA profiling from matched samples in patients shows a significant number of microRNAs up regulated in bladder tumors are identifiable in urine exosomes and WBCs of the same patient, but not in blood plasma. This study demonstrated varying relationships between miRNA detected in biological media from the same patient, and serves to inform the potential of urine-based microRNAs as biomarkers for bladder cancer and potentially other malignancies." +tissue_expression_ns hsa-mir-194 Choriocarcinoma 26578390 "we found hsa-miR-194 and hsa-miR-7 along with 7 transcription factors (TFs) such as SOX11, SMAD3 and SOX4 etc. could correctly differentiate SPN from PanNET" +tissue_expression_ns hsa-mir-204 Choriocarcinoma 26578390 "while hsa-miR-204 and 4 TFs such as SOX9, TCF7 and PPARD etc. were demonstrated as the potential markers for SPN versus PDAC." +tissue_expression_ns hsa-mir-7 Neoplasms [unspecific] 26578390 "we found hsa-miR-194 and hsa-miR-7 along with 7 transcription factors (TFs) such as SOX11, SMAD3 and SOX4 etc. could correctly differentiate SPN from PanNET" +tissue_expression_ns hsa-mir-106b Hepatoblastoma 26613016 These datasets provide a global landscape of miRNA expression for a rare childhood cancer that has not previously been well characterised. These data could serve as a resource for future studies aiming to make comparisons of HB miRNA profiles and to document aberrant miRNA expression in this type of cancer. +tissue_expression_ns hsa-mir-17 Hepatoblastoma 26613016 These datasets provide a global landscape of miRNA expression for a rare childhood cancer that has not previously been well characterised. These data could serve as a resource for future studies aiming to make comparisons of HB miRNA profiles and to document aberrant miRNA expression in this type of cancer. +tissue_expression_ns hsa-mir-191 Hepatoblastoma 26613016 These datasets provide a global landscape of miRNA expression for a rare childhood cancer that has not previously been well characterised. These data could serve as a resource for future studies aiming to make comparisons of HB miRNA profiles and to document aberrant miRNA expression in this type of cancer. +tissue_expression_ns hsa-mir-95 Hepatoblastoma 26613016 These datasets provide a global landscape of miRNA expression for a rare childhood cancer that has not previously been well characterised. These data could serve as a resource for future studies aiming to make comparisons of HB miRNA profiles and to document aberrant miRNA expression in this type of cancer. +tissue_expression_ns hsa-mir-149 Glioma 26617839 "Our study thus demonstrates that miR-149 expression in glioma tissues is critically associated with the prognosis of patients,suggesting its potential clinical significance." +tissue_expression_ns hsa-mir-155 Stroke 26663183 "we will provide insight into recent knowledge from animal and human studies concerning miRNA profiling in acute stroke and their expression dynamics in brain tissue and extracellular fluids (roles of, e.g. let-7 family, miR-21, miR-29 family, miR-124, miR-145, miR-181 family, miR-210 and miR-223)" +tissue_expression_ns hsa-mir-126 Ischemia 26672806 ghrelin treatment activated proangiogenic (miR-126 and miR-132) and antifibrotic (miR-30a) microRNAs (miRs) +tissue_expression_ns hsa-mir-206 Ischemia 26672806 ghrelin treatment activated proangiogenic (miR-126 and miR-132) and antifibrotic (miR-30a) microRNAs (miRs) +tissue_expression_ns hsa-mir-92a Ischemia 26672806 "Further, ghrelin treatment activated proangiogenic (miR-126 and miR-132) and antifibrotic (miR-30a) microRNAs (miRs) while inhibiting antiangiogenic (miR-92a and miR-206) miRs." +tissue_expression_ns hsa-mir-375 Colorectal Carcinoma 26681654 "While the intra-tumor variance of miR-92a, miR-375 and miR-424 is substantial, it only constitutes approximately 30% of the total variation. Functional deregulation between tumor zones might contribute to variations in measured expression levels, and thus knowledge of specific intra-tumor expression patterns is crucial in tissue sampling for research as well as in future diagnostics." +tissue_expression_ns hsa-mir-424 Colorectal Carcinoma 26681654 "While the intra-tumor variance of miR-92a, miR-375 and miR-424 is substantial, it only constitutes approximately 30% of the total variation. Functional deregulation between tumor zones might contribute to variations in measured expression levels, and thus knowledge of specific intra-tumor expression patterns is crucial in tissue sampling for research as well as in future diagnostics." +tissue_expression_ns hsa-mir-92a Colorectal Carcinoma 26681654 "While the intra-tumor variance of miR-92a, miR-375 and miR-424 is substantial, it only constitutes approximately 30% of the total variation. Functional deregulation between tumor zones might contribute to variations in measured expression levels, and thus knowledge of specific intra-tumor expression patterns is crucial in tissue sampling for research as well as in future diagnostics." +tissue_expression_ns hsa-mir-106b Breast Neoplasms 26684238 "Taken together, we have for the first time characterized the BMP4-induced miRNA expression profiles in breast cancer cell lines, showing that induced miRNAs contribute to the fine-tuning of proliferation and migration phenotypes." +tissue_expression_ns hsa-mir-16 Breast Neoplasms 26684238 "Taken together, we have for the first time characterized the BMP4-induced miRNA expression profiles in breast cancer cell lines, showing that induced miRNAs contribute to the fine-tuning of proliferation and migration phenotypes." +tissue_expression_ns hsa-mir-23a Breast Neoplasms 26684238 "Taken together, we have for the first time characterized the BMP4-induced miRNA expression profiles in breast cancer cell lines, showing that induced miRNAs contribute to the fine-tuning of proliferation and migration phenotypes." +tissue_expression_ns hsa-mir-23b Breast Neoplasms 26684238 "Taken together, we have for the first time characterized the BMP4-induced miRNA expression profiles in breast cancer cell lines, showing that induced miRNAs contribute to the fine-tuning of proliferation and migration phenotypes." +tissue_expression_ns hsa-mir-222 Pulmonary Sarcoidosis 26696750 "miRNAs in sarcoid BAL cells detected deregulation of miR-146a, miR-150, miR-202, miR-204, and miR-222 expression comparing to controls" +tissue_expression_ns hsa-mir-1909 Neuroepithelial Tumors 26698155 "Our findings indicated that miR-3138 might act as a tumor suppressor gene when down-regulated and miR-1909* as a putative oncogenic molecule when up-regulated in pediatric DNETs compared to the control cohort. Subsequently, both miRNA signatures might serve as putative diagnostic biomarkers for pediatric DNETs." +tissue_expression_ns hsa-mir-3138 Neuroepithelial Tumors 26698155 "Our findings indicated that miR-3138 might act as a tumor suppressor gene when down-regulated and miR-1909* as a putative oncogenic molecule when up-regulated in pediatric DNETs compared to the control cohort. Subsequently, both miRNA signatures might serve as putative diagnostic biomarkers for pediatric DNETs." +tissue_expression_ns hsa-mir-100 Colorectal Carcinoma 26714601 "The expression of miR-100 is correlated with lymph node metastasis, TNM stage and differentiation grade, and may be a potential biomarker indicating the development of CRC." +tissue_expression_ns hsa-mir-145 Lupus Nephritis 26722454 Association of miRNA-145 expression in vascular smooth muscle cells with vascular damages in patients with lupus nephritis. +tissue_expression_ns hsa-mir-203 Diabetic Foot 26722550 "Our results demonstrated that expression profile of miR-203 in diabetic foot had a positive correlation with the severity of diabetic foot ulcers, which indicated that miR-203 can be served as a new, accurate and validated bio-marker for evaluating the severity of diabetic foot ulcers in clinic. The significant finding of the study: Quantification of miR-203 in different degrees of diabetic foot. This study adds a new bio-marker for evaluation and management of diabetic foot." +tissue_expression_ns hsa-mir-182 "Carcinoma, Hepatocellular" 26728044 "In this study, fifteen microRNAs which were modulated in hepatic tissues and in tumors during the transition NAFLD-NASH-HCC are reported. Besides some already described, new and early dysregulated miRNAs were identified.Functional analyses are needed to validate the results here obtained, and to better define the role of these molecules in the progression of the hepatic disease." +tissue_expression_ns hsa-mir-340 "Carcinoma, Hepatocellular" 26728044 "In this study, fifteen microRNAs which were modulated in hepatic tissues and in tumors during the transition NAFLD-NASH-HCC are reported. Besides some already described, new and early dysregulated miRNAs were identified.Functional analyses are needed to validate the results here obtained, and to better define the role of these molecules in the progression of the hepatic disease." +tissue_expression_ns hsa-mir-484 "Carcinoma, Hepatocellular" 26728044 "In this study, fifteen microRNAs which were modulated in hepatic tissues and in tumors during the transition NAFLD-NASH-HCC are reported. Besides some already described, new and early dysregulated miRNAs were identified.Functional analyses are needed to validate the results here obtained, and to better define the role of these molecules in the progression of the hepatic disease." +tissue_expression_ns hsa-mir-574 "Carcinoma, Hepatocellular" 26728044 "In this study, fifteen microRNAs which were modulated in hepatic tissues and in tumors during the transition NAFLD-NASH-HCC are reported. Besides some already described, new and early dysregulated miRNAs were identified.Functional analyses are needed to validate the results here obtained, and to better define the role of these molecules in the progression of the hepatic disease." +tissue_expression_ns hsa-mir-720 "Carcinoma, Hepatocellular" 26728044 "In this study, fifteen microRNAs which were modulated in hepatic tissues and in tumors during the transition NAFLD-NASH-HCC are reported. Besides some already described, new and early dysregulated miRNAs were identified.Functional analyses are needed to validate the results here obtained, and to better define the role of these molecules in the progression of the hepatic disease." +tissue_expression_ns hsa-mir-21 "Carcinoma, Renal Cell" 26729387 Diagnostic and prognostic accuracy of miR-21 in renal cell carcinoma: a systematic review protocol. +tissue_expression_ns hsa-mir-1 Myocardial Ischemic-Reperfusion Injury 26738985 "Of the 17 miRs, 9 miRs, including miR-1, miR-21, miR-24, and miR-195, which are related to apoptosis, exhibited different expression patterns in the RIPerc group compared with the control." +tissue_expression_ns hsa-mir-195 Myocardial Ischemic-Reperfusion Injury 26738985 "Of the 17 miRs, 9 miRs, including miR-1, miR-21, miR-24, and miR-195, which are related to apoptosis, exhibited different expression patterns in the RIPerc group compared with the control." +tissue_expression_ns hsa-mir-200b Melanoma 26743475 "miR-10b and miR-200b showed independent prognostic value (P=0.002 and 0.047, respectively) in multivariable analysis alongside known clinico-pathological prognostic features" +tissue_expression_ns hsa-mir-141 Prostate Neoplasms 26751899 miRNAs as novel biomarkers in the management of prostate cancer. +tissue_expression_ns hsa-mir-21 Prostate Neoplasms 26751899 miRNAs as novel biomarkers in the management of prostate cancer. +tissue_expression_ns hsa-mir-375 Prostate Neoplasms 26751899 miRNAs as novel biomarkers in the management of prostate cancer. +tissue_expression_ns hsa-mir-146a Autism Spectrum Disorder 26753090 "We identified a signature of four miRNAs (miR-146a, miR-221, miR-654-5p, and miR-656) commonly deregulated in ASD." +tissue_expression_ns hsa-mir-221 Autism Spectrum Disorder 26753090 "We identified a signature of four miRNAs (miR-146a, miR-221, miR-654-5p, and miR-656) commonly deregulated in ASD." +tissue_expression_ns hsa-mir-125a Lupus Nephritis 26762103 "Levels of cell-free miR-125a, miR-150, and miR-155 in the urine supernatant are associated with the expression of LN-Panel biomarkers and some LN measures. These miRNA's may complement, but are unlikely superior to the LN-Panel for estimating concurrent LN activity." +tissue_expression_ns hsa-mir-127 Lupus Nephritis 26762103 "Levels of cell-free miR-125a, miR-150, and miR-155 in the urine supernatant are associated with the expression of LN-Panel biomarkers and some LN measures. These miRNA's may complement, but are unlikely superior to the LN-Panel for estimating concurrent LN activity." +tissue_expression_ns hsa-mir-146a Lupus Nephritis 26762103 "Levels of cell-free miR-125a, miR-150, and miR-155 in the urine supernatant are associated with the expression of LN-Panel biomarkers and some LN measures. These miRNA's may complement, but are unlikely superior to the LN-Panel for estimating concurrent LN activity." +tissue_expression_ns hsa-mir-150 Lupus Nephritis 26762103 "Levels of cell-free miR-125a, miR-150, and miR-155 in the urine supernatant are associated with the expression of LN-Panel biomarkers and some LN measures. These miRNA's may complement, but are unlikely superior to the LN-Panel for estimating concurrent LN activity." +tissue_expression_ns hsa-mir-155 Lupus Nephritis 26762103 "Levels of cell-free miR-125a, miR-150, and miR-155 in the urine supernatant are associated with the expression of LN-Panel biomarkers and some LN measures. These miRNA's may complement, but are unlikely superior to the LN-Panel for estimating concurrent LN activity." +tissue_expression_ns hsa-mir-126 Mesothelioma 26765063 "Subject to validation of the current results in further larger studies, miR-21 and miR-126 profiling could be an effective and reliable tool for the diagnosis of MM in pleural effusions complementary to cytology evaluation." +tissue_expression_ns hsa-mir-21 Mesothelioma 26765063 "Subject to validation of the current results in further larger studies, miR-21 and miR-126 profiling could be an effective and reliable tool for the diagnosis of MM in pleural effusions complementary to cytology evaluation." +tissue_expression_ns hsa-let-7f Pulmonary Sarcoidosis 26768132 "The obtained results suggest that the studied miRNAs play a role in the pathogenesis of sarcoidosis, and that some of them might have negative prognostic value." +tissue_expression_ns hsa-mir-128a Pulmonary Sarcoidosis 26768132 "The obtained results suggest that the studied miRNAs play a role in the pathogenesis of sarcoidosis, and that some of them might have negative prognostic value." +tissue_expression_ns hsa-mir-130a Pulmonary Sarcoidosis 26768132 "The obtained results suggest that the studied miRNAs play a role in the pathogenesis of sarcoidosis, and that some of them might have negative prognostic value." +tissue_expression_ns hsa-mir-15b Pulmonary Sarcoidosis 26768132 "The obtained results suggest that the studied miRNAs play a role in the pathogenesis of sarcoidosis, and that some of them might have negative prognostic value." +tissue_expression_ns hsa-mir-16 Pulmonary Sarcoidosis 26768132 "The obtained results suggest that the studied miRNAs play a role in the pathogenesis of sarcoidosis, and that some of them might have negative prognostic value." +tissue_expression_ns hsa-mir-192 Pulmonary Sarcoidosis 26768132 "The obtained results suggest that the studied miRNAs play a role in the pathogenesis of sarcoidosis, and that some of them might have negative prognostic value." +tissue_expression_ns hsa-mir-20a Pulmonary Sarcoidosis 26768132 "The obtained results suggest that the studied miRNAs play a role in the pathogenesis of sarcoidosis, and that some of them might have negative prognostic value." +tissue_expression_ns hsa-mir-221 Pulmonary Sarcoidosis 26768132 "The obtained results suggest that the studied miRNAs play a role in the pathogenesis of sarcoidosis, and that some of them might have negative prognostic value." +tissue_expression_ns hsa-mir-222 Pulmonary Sarcoidosis 26768132 "The obtained results suggest that the studied miRNAs play a role in the pathogenesis of sarcoidosis, and that some of them might have negative prognostic value." +tissue_expression_ns hsa-mir-1244 Gastric Cardia Adenocarcinoma 26781873 "Four miRNAs (miR-1244, miR-135b-5p, miR-3196, and miR-628-3p) were found to be associated with GCA differentiation." +tissue_expression_ns hsa-mir-135b Gastric Cardia Adenocarcinoma 26781873 "Four miRNAs (miR-1244, miR-135b-5p, miR-3196, and miR-628-3p) were found to be associated with GCA differentiation." +tissue_expression_ns hsa-mir-196a Gastric Cardia Adenocarcinoma 26781873 "miR-196a-5p, was found to be associated with age of GCA onset." +tissue_expression_ns hsa-mir-3196 Gastric Cardia Adenocarcinoma 26781873 "Four miRNAs (miR-1244, miR-135b-5p, miR-3196, and miR-628-3p) were found to be associated with GCA differentiation." +tissue_expression_ns hsa-mir-628 Gastric Cardia Adenocarcinoma 26781873 "Four miRNAs (miR-1244, miR-135b-5p, miR-3196, and miR-628-3p) were found to be associated with GCA differentiation." +tissue_expression_ns hsa-mir-494 Pancreatic Neoplasms 26782462 Correlation of miR-494 expression with tumor progression and patient survival in pancreatic cancer. +tissue_expression_ns hsa-mir-21 Glioma 26799295 "4 hypoxia-mediated microRNAs (miRNA)-miR-210, miR-21, miR-10b, and miR-196b-are upregulated in glioma" +tissue_expression_ns hsa-mir-199a Melanoma 26812476 "Five miRNAs (miR-214, miR146b, miR-143, miR-199a and miR-134) were found to be differentially expressed in M3/ D3 UM tumors." +tissue_expression_ns hsa-mir-146a Vogt-Koyanagi-Harada Disease 26818976 "CNVs of miR-146a, miR-23a and miR-301a confer susceptibility to VKH syndrome, but not to BD." +tissue_expression_ns hsa-mir-1 Endometriosis 26819681 "The expression of miR-1, miR-133a, and miR-451 were reduced significantly (p<0.0001) in the OC patients compared to its associated endometriosis." +tissue_expression_ns hsa-mir-141 Neoplasms [unspecific] 26828359 microRNA (miR)-141 is aberrantly expressed in many human malignant tumors +tissue_expression_ns hsa-mir-223 Autoimmune Diseases [unspecific] 26879236 using co-expression analysis of miRNA expression levels we showed that multiple miRNA contribute to multiple pathways that might be involved in pathogenesis of autoimmune skin blistering disease. +tissue_expression_ns hsa-mir-181c "Squamous Cell Carcinoma, Esophageal" 26888510 "There are significant correlation between miR-181c-3p/miR-5692b expression, clinicopathologic parameters and prognosis. They represent potential prognostic biomarkers in esophageal squamous cell carcinoma." +tissue_expression_ns hsa-mir-5692b "Squamous Cell Carcinoma, Esophageal" 26888510 "There are significant correlation between miR-181c-3p/miR-5692b expression, clinicopathologic parameters and prognosis. They represent potential prognostic biomarkers in esophageal squamous cell carcinoma." +tissue_expression_ns hsa-mir-21 Breast Neoplasms 26891730 Analysis has shown that changes in miR-21 levels might be important for the later and/or late phases of breast cancerogenesis rather than for the initial early phases. +tissue_expression_ns hsa-mir-124a Breast Neoplasms 26897751 MiR-124a and miR-30d were correlated with insulin resistance and development of BC with T2DM. +tissue_expression_ns hsa-mir-124a "Diabetes Mellitus, Type 2" 26897751 MiR-124a and miR-30d were correlated with insulin resistance and development of BC with T2DM. +tissue_expression_ns hsa-mir-30d Breast Neoplasms 26897751 MiR-124a and miR-30d were correlated with insulin resistance and development of BC with T2DM. +tissue_expression_ns hsa-mir-30d "Diabetes Mellitus, Type 2" 26897751 MiR-124a and miR-30d were correlated with insulin resistance and development of BC with T2DM. +tissue_expression_ns hsa-mir-181c Silicosis 26903263 The differential expression of two selected miRNAs hsa-miR-181c-5p and hsa-miR-29a-3p were confirmed by RT-qPCR. +tissue_expression_ns hsa-mir-29a Silicosis 26903263 The differential expression of two selected miRNAs hsa-miR-181c-5p and hsa-miR-29a-3p were confirmed by RT-qPCR. +tissue_expression_ns hsa-mir-27a Colorectal Carcinoma 26913599 Low miR-27a-expressing cells displayed more ecto-calreticulin on the cell surface and increased ATP and HMGB1 secretion than high miR-27a-expressing ones in time-course experiments upon drug exposure. +tissue_expression_ns hsa-mir-130b "Carcinoma, Hepatocellular" 26927562 The expression and clinopathological significance of miR-130b in human hepatocellular carcinoma +tissue_expression_ns hsa-let-7g Rectal Neoplasms 26937645 "We recommend the mean expression of miR-27a, miR-193a-5p and let-7g as normalisation factor, when performing miRNA expression analyses by RT-qPCR on rectal cancer tissue." +tissue_expression_ns hsa-mir-193a Rectal Neoplasms 26937645 "We recommend the mean expression of miR-27a, miR-193a-5p and let-7g as normalisation factor, when performing miRNA expression analyses by RT-qPCR on rectal cancer tissue." +tissue_expression_ns hsa-mir-27a Rectal Neoplasms 26937645 "We recommend the mean expression of miR-27a, miR-193a-5p and let-7g as normalisation factor, when performing miRNA expression analyses by RT-qPCR on rectal cancer tissue." +tissue_expression_ns hsa-mir-645 Rectal Neoplasms 26937645 "We recommend the mean expression of miR-27a, miR-193a-5p and let-7g as normalisation factor, when performing miRNA expression analyses by RT-qPCR on rectal cancer tissue." +tissue_expression_ns hsa-let-7c Breast Neoplasms 26982264 "we identified seven miRNAs (miR-9-5p, miR-9-3p, let-7c, miR-127-3p, miR-99a-5p, miR-129-5p, and miR-146a-5p) that were deregulated as a consequence of claudin 1 overexpression in the MDA-MB231 human breast cancer (HBC) cell line." +tissue_expression_ns hsa-mir-127 Breast Neoplasms 26982264 "we identified seven miRNAs (miR-9-5p, miR-9-3p, let-7c, miR-127-3p, miR-99a-5p, miR-129-5p, and miR-146a-5p) that were deregulated as a consequence of claudin 1 overexpression in the MDA-MB231 human breast cancer (HBC) cell line." +tissue_expression_ns hsa-mir-129 Breast Neoplasms 26982264 "we identified seven miRNAs (miR-9-5p, miR-9-3p, let-7c, miR-127-3p, miR-99a-5p, miR-129-5p, and miR-146a-5p) that were deregulated as a consequence of claudin 1 overexpression in the MDA-MB231 human breast cancer (HBC) cell line." +tissue_expression_ns hsa-mir-146a Breast Neoplasms 26982264 "we identified seven miRNAs (miR-9-5p, miR-9-3p, let-7c, miR-127-3p, miR-99a-5p, miR-129-5p, and miR-146a-5p) that were deregulated as a consequence of claudin 1 overexpression in the MDA-MB231 human breast cancer (HBC) cell line." +tissue_expression_ns hsa-mir-9 Breast Neoplasms 26982264 "we identified seven miRNAs (miR-9-5p, miR-9-3p, let-7c, miR-127-3p, miR-99a-5p, miR-129-5p, and miR-146a-5p) that were deregulated as a consequence of claudin 1 overexpression in the MDA-MB231 human breast cancer (HBC) cell line." +tissue_expression_ns hsa-mir-99a Breast Neoplasms 26982264 "we identified seven miRNAs (miR-9-5p, miR-9-3p, let-7c, miR-127-3p, miR-99a-5p, miR-129-5p, and miR-146a-5p) that were deregulated as a consequence of claudin 1 overexpression in the MDA-MB231 human breast cancer (HBC) cell line." +tissue_expression_ns hsa-mir-199a "Carcinoma, Hepatocellular" 26998997 miTALOS v2: Analyzing Tissue Specific microRNA Function. +tissue_expression_ns hsa-mir-199b "Carcinoma, Hepatocellular" 26998997 miTALOS v3: Analyzing Tissue Specific microRNA Function. +tissue_expression_ns hsa-mir-200 "Carcinoma, Hepatocellular" 26998997 miTALOS v4: Analyzing Tissue Specific microRNA Function. +tissue_expression_ns hsa-mir-571 "Carcinoma, Hepatocellular" 26998997 miTALOS v5: Analyzing Tissue Specific microRNA Function. +tissue_expression_ns hsa-mir-223 Multiple Myeloma 27023728 miR-223 expression in MM-BMMSCs was reduced by the presence of MM cells +tissue_expression_ns hsa-mir-126 Traumatic Brain Injury 27027233 Our results indicated that altered expression of miR-126-3p and miR-3610 may play an important role in the development of TBI-induced hypopituitarism. +tissue_expression_ns hsa-mir-3610 Traumatic Brain Injury 27027233 Our results indicated that altered expression of miR-126-3p and miR-3610 may play an important role in the development of TBI-induced hypopituitarism. +tissue_expression_ns hsa-mir-130a Cardiotoxicity 27033315 "We report on several microRNAs, including miR-34a, miR-34b, miR-187, miR-199a, miR-199b, miR-146a, miR-15b, miR-130a, miR-214, and miR-424, that are differentially expressed upon, and after, treatment with doxorubicin." +tissue_expression_ns hsa-mir-146a Cardiotoxicity 27033315 "We report on several microRNAs, including miR-34a, miR-34b, miR-187, miR-199a, miR-199b, miR-146a, miR-15b, miR-130a, miR-214, and miR-424, that are differentially expressed upon, and after, treatment with doxorubicin." +tissue_expression_ns hsa-mir-15b Cardiotoxicity 27033315 "We report on several microRNAs, including miR-34a, miR-34b, miR-187, miR-199a, miR-199b, miR-146a, miR-15b, miR-130a, miR-214, and miR-424, that are differentially expressed upon, and after, treatment with doxorubicin." +tissue_expression_ns hsa-mir-187 Cardiotoxicity 27033315 "We report on several microRNAs, including miR-34a, miR-34b, miR-187, miR-199a, miR-199b, miR-146a, miR-15b, miR-130a, miR-214, and miR-424, that are differentially expressed upon, and after, treatment with doxorubicin." +tissue_expression_ns hsa-mir-199a Cardiotoxicity 27033315 "We report on several microRNAs, including miR-34a, miR-34b, miR-187, miR-199a, miR-199b, miR-146a, miR-15b, miR-130a, miR-214, and miR-424, that are differentially expressed upon, and after, treatment with doxorubicin." +tissue_expression_ns hsa-mir-199b Cardiotoxicity 27033315 "We report on several microRNAs, including miR-34a, miR-34b, miR-187, miR-199a, miR-199b, miR-146a, miR-15b, miR-130a, miR-214, and miR-424, that are differentially expressed upon, and after, treatment with doxorubicin." +tissue_expression_ns hsa-mir-214 Cardiotoxicity 27033315 "We report on several microRNAs, including miR-34a, miR-34b, miR-187, miR-199a, miR-199b, miR-146a, miR-15b, miR-130a, miR-214, and miR-424, that are differentially expressed upon, and after, treatment with doxorubicin." +tissue_expression_ns hsa-mir-34a Cardiotoxicity 27033315 "We report on several microRNAs, including miR-34a, miR-34b, miR-187, miR-199a, miR-199b, miR-146a, miR-15b, miR-130a, miR-214, and miR-424, that are differentially expressed upon, and after, treatment with doxorubicin." +tissue_expression_ns hsa-mir-34b Cardiotoxicity 27033315 "We report on several microRNAs, including miR-34a, miR-34b, miR-187, miR-199a, miR-199b, miR-146a, miR-15b, miR-130a, miR-214, and miR-424, that are differentially expressed upon, and after, treatment with doxorubicin." +tissue_expression_ns hsa-mir-424 Cardiotoxicity 27033315 "We report on several microRNAs, including miR-34a, miR-34b, miR-187, miR-199a, miR-199b, miR-146a, miR-15b, miR-130a, miR-214, and miR-424, that are differentially expressed upon, and after, treatment with doxorubicin." +tissue_expression_ns hsa-mir-148a Osteosarcoma 27041566 we show that miR-148a-3p and miR-155-5p are species-conserved deregulated miRNA in OS +tissue_expression_ns hsa-mir-155 Osteosarcoma 27041566 we show that miR-148a-3p and miR-155-5p are species-conserved deregulated miRNA in OS +tissue_expression_ns hsa-let-7f Obesity 27049726 "Our study shows that the first evidence of hsa-let-7 family, hsa-miR-15a-5p, hsa-miR-27a-3p, hsa-miR-106b-5p, hsa-miR-148a-3p and hsa-miR-26b-5p got a great weight in adipogenesis" +tissue_expression_ns hsa-mir-1275 "Squamous Cell Carcinoma, Oral" 27056547 "the expression of miR-1275 was variable in tumours, with high levels associated to regional lymph node invasion;" +tissue_expression_ns hsa-mir-29a "Carcinoma, Ovarian, Serous" 27063471 "miR-29a and its target DNMT3A are novel candidate biomarkers of longer and shorter survival, respectively, in metastatic high-grade serous carcinoma." +tissue_expression_ns hsa-mir-21 "Adenocarcinoma, Lung" 27081085 "We identified a regulatory network including miR-15b and miR-155, and transcription factors with prognostic value in lung cancer." +tissue_expression_ns hsa-mir-139 Breast Neoplasms 27082076 miRNAs included in the invasive signatures include downregulation of miR-139-5p in aggressive subtypes and upregulation of miR-29c-5p expression in the luminal subtypes. +tissue_expression_ns hsa-mir-29c Breast Neoplasms 27082076 include downregulation of miR-139-5p in aggressive subtypes and upregulation of miR-29c-5p expression in the luminal subtypes. +tissue_expression_ns hsa-mir-21 "Adenocarcinoma, Pancreatic Ductal" 27086919 We provide further evidence for using miRNAs as diagnostic biomarkers for pancreatic malignancy. +tissue_expression_ns hsa-mir-196 Tuberculosis 27102525 9 miRNAs were differentially expressed after MAP infection. +tissue_expression_ns hsa-mir-24 Cardiovascular Diseases [unspecific] 27108908 "The dysregulation of miR-24 is associated with dysfunction or even damage of VECs, and contributes to the development of cardiovascular disease." +tissue_expression_ns hsa-mir-21 "Carcinoma, Breast, Triple Negative" 27113307 The function of MiR-21 expression differences and pathogenesis on familial and triple negative breast Cancer serum. +tissue_expression_ns hsa-mir-223 Inflammation 27129807 "miR-223 that has been reported to be abnormally expressed in several diseases like diabetes-type2, sepsis, rheumatoid arthritis, viral infections likes' human immunodeficiency virus-1 (HIV-1) and inflammatory disorders." +tissue_expression_ns hsa-mir-223 Sepsis 27129807 "miR-223 that has been reported to be abnormally expressed in several diseases like diabetes-type2, sepsis, rheumatoid arthritis, viral infections likes' human immunodeficiency virus-1 (HIV-1) and inflammatory disorders." +tissue_expression_ns hsa-mir-200 Colorectal Carcinoma 27157610 "The miR-200 family presented as the most powerful determinant of CMS4-specific gene expression, tuning the majority of genes differentially expressed in the poor prognosis subtype," +tissue_expression_ns hsa-mir-125b Oral Neoplasms 27208839 "Differential expression of miR-21, miR-100, miR-125b and miR-375 was validated in oral cytology training sample set." +tissue_expression_ns hsa-mir-150 Bronchopulmonary Dysplasia 27216745 expression of miR-150 was altered in experimental BPD +tissue_expression_ns hsa-mir-127 Balkan Nephropathy 27218105 " Only three microRNAs (hsa-miR-127-3p, hsa-miR-154-5p, and hsa-miR-30a-5p) were downregulated among BEN-UTUC, and one microRNA (hsa-miR-663b) was downregulated among non-BEN-UTUC samples" +tissue_expression_ns hsa-mir-154 Balkan Nephropathy 27218105 " Only three microRNAs (hsa-miR-127-3p, hsa-miR-154-5p, and hsa-miR-30a-5p) were downregulated among BEN-UTUC, and one microRNA (hsa-miR-663b) was downregulated among non-BEN-UTUC samples" +tissue_expression_ns hsa-mir-30a Balkan Nephropathy 27218105 " Only three microRNAs (hsa-miR-127-3p, hsa-miR-154-5p, and hsa-miR-30a-5p) were downregulated among BEN-UTUC, and one microRNA (hsa-miR-663b) was downregulated among non-BEN-UTUC samples" +tissue_expression_ns hsa-mir-663b Balkan Nephropathy 27218105 " Only three microRNAs (hsa-miR-127-3p, hsa-miR-154-5p, and hsa-miR-30a-5p) were downregulated among BEN-UTUC, and one microRNA (hsa-miR-663b) was downregulated among non-BEN-UTUC samples" +tissue_expression_ns hsa-mir-765 Soft Tissue Sarcoma 27223121 miR-765 could possibly be a diagnostic tool for ES because of its 97% specificity and 80% sensitivity. +tissue_expression_ns hsa-mir-630 Rectum Adenocarcinoma 27225591 The miR-630 appeared only with the NR patients and was anti-correlated with a single transcript: RAB5B. +tissue_expression_ns hsa-mir-138 Down Syndrome 27266699 The function of hsa-miR-138-5p and its target EZH2 was involved in hippocampus in DS patients. +tissue_expression_ns hsa-mir-138 Chondrosarcoma 27267924 "increased expression of two microRNAs, miRs-181a and -138, in low-grade chondrosarcomas compared with enchondromas" +tissue_expression_ns hsa-mir-126 "Adenocarcinoma, Lung" 27277197 "Low levels of miR-126-3p and miR-451a were associated with poor pathological stage, large tumor diameter and lymph node metastasis" +tissue_expression_ns hsa-mir-451a "Adenocarcinoma, Lung" 27277197 "Low levels of miR-126-3p and miR-451a were associated with poor pathological stage, large tumor diameter and lymph node metastasis" +tissue_expression_ns hsa-mir-155 Laryngeal Neoplasms 27292022 "miR-21, miR-155, miR-192, and miR-375 Deregulations Related to NF-kappaB Activation in Gastroduodenal Fluid-Induced Early Preneoplastic Lesions of Laryngeal Mucosa In Vivo." +tissue_expression_ns hsa-mir-192 Laryngeal Neoplasms 27292022 "miR-21, miR-155, miR-192, and miR-375 Deregulations Related to NF-kappaB Activation in Gastroduodenal Fluid-Induced Early Preneoplastic Lesions of Laryngeal Mucosa In Vivo." +tissue_expression_ns hsa-mir-21 Laryngeal Neoplasms 27292022 "miR-21, miR-155, miR-192, and miR-375 Deregulations Related to NF-kappaB Activation in Gastroduodenal Fluid-Induced Early Preneoplastic Lesions of Laryngeal Mucosa In Vivo." +tissue_expression_ns hsa-mir-375 Laryngeal Neoplasms 27292022 "miR-21, miR-155, miR-192, and miR-375 Deregulations Related to NF-kappaB Activation in Gastroduodenal Fluid-Induced Early Preneoplastic Lesions of Laryngeal Mucosa In Vivo." +tissue_expression_ns hsa-mir-26a Multiple Sclerosis 27310932 down-regulation of miR-155 and miR-26a was seen in MS patients during and after natalizumab therapy. +tissue_expression_ns hsa-mir-146a Melanoma 27311960 "miR-146a controls melanoma progression in a dual way, promoting growth and inhibiting dissemination" +tissue_expression_ns hsa-mir-130a "Carcinoma, Nasopharyngeal" 27350400 "hsa-miR-205, hsa-miR-18b, hsa-miR-632, hsa-miR-130a, and hsa-miR-34b may be related to the development of nasopharyngeal carcinoma" +tissue_expression_ns hsa-mir-18b "Carcinoma, Nasopharyngeal" 27350400 "hsa-miR-205, hsa-miR-18b, hsa-miR-632, hsa-miR-130a, and hsa-miR-34b may be related to the development of nasopharyngeal carcinoma" +tissue_expression_ns hsa-mir-205 "Carcinoma, Nasopharyngeal" 27350400 "hsa-miR-205, hsa-miR-18b, hsa-miR-632, hsa-miR-130a, and hsa-miR-34b may be related to the development of nasopharyngeal carcinoma" +tissue_expression_ns hsa-mir-34b "Carcinoma, Nasopharyngeal" 27350400 "hsa-miR-205, hsa-miR-18b, hsa-miR-632, hsa-miR-130a, and hsa-miR-34b may be related to the development of nasopharyngeal carcinoma" +tissue_expression_ns hsa-mir-632 "Carcinoma, Nasopharyngeal" 27350400 "hsa-miR-205, hsa-miR-18b, hsa-miR-632, hsa-miR-130a, and hsa-miR-34b may be related to the development of nasopharyngeal carcinoma" +tissue_expression_ns hsa-mir-141 Bladder Neoplasms 27357429 two types of cancer showed opposite expression patterns for miR-200 family miRNAs +tissue_expression_ns hsa-mir-141 "Carcinoma, Renal Cell" 27357429 two types of cancer showed opposite expression patterns for miR-200 family miRNAs +tissue_expression_ns hsa-mir-200 Bladder Neoplasms 27357429 two types of cancer showed opposite expression patterns for miR-200 family miRNAs +tissue_expression_ns hsa-mir-200 "Carcinoma, Renal Cell" 27357429 two types of cancer showed opposite expression patterns for miR-200 family miRNAs +tissue_expression_ns hsa-mir-200a Bladder Neoplasms 27357429 two types of cancer showed opposite expression patterns for miR-200 family miRNAs +tissue_expression_ns hsa-mir-200a "Carcinoma, Renal Cell" 27357429 two types of cancer showed opposite expression patterns for miR-200 family miRNAs +tissue_expression_ns hsa-mir-200b Bladder Neoplasms 27357429 two types of cancer showed opposite expression patterns for miR-200 family miRNAs +tissue_expression_ns hsa-mir-200b "Carcinoma, Renal Cell" 27357429 two types of cancer showed opposite expression patterns for miR-200 family miRNAs +tissue_expression_ns hsa-mir-200c Bladder Neoplasms 27357429 two types of cancer showed opposite expression patterns for miR-200 family miRNAs +tissue_expression_ns hsa-mir-200c "Carcinoma, Renal Cell" 27357429 two types of cancer showed opposite expression patterns for miR-200 family miRNAs +tissue_expression_ns hsa-mir-148a Neoplasms [unspecific] 27390598 Mir-148a is aberrantly expressed in various cancers and has been identified as an oncogenic or tumor suppressor with crucial roles in the molecular mechanisms of oncogenesis. +tissue_expression_ns hsa-let-7 "Adenocarcinoma, Gastric" 27422560 The integrated analysis of miRNA and gene expression profiles showed the let-7 miRNA family playing a central role in the regulatory relationships. +tissue_expression_ns hsa-let-7c "Adenocarcinoma, Gastric" 27422560 "The miRNAs 100, let-7c, 125b and 99a stood out for their association with the diffuse histological subtype." +tissue_expression_ns hsa-mir-10a Breast Neoplasms 27433802 "We identified eight microRNAs (miR-10a, miR-10b, miR-21, miR-124, miR-125b, miR-126, miR-145 and miR-200a) to be associated with DMBA-induced mammary tumor progression." +tissue_expression_ns hsa-mir-10b Breast Neoplasms 27433802 "We identified eight microRNAs (miR-10a, miR-10b, miR-21, miR-124, miR-125b, miR-126, miR-145 and miR-200a) to be associated with DMBA-induced mammary tumor progression." +tissue_expression_ns hsa-mir-124 Breast Neoplasms 27433802 "We identified eight microRNAs (miR-10a, miR-10b, miR-21, miR-124, miR-125b, miR-126, miR-145 and miR-200a) to be associated with DMBA-induced mammary tumor progression." +tissue_expression_ns hsa-mir-125b Breast Neoplasms 27433802 "We identified eight microRNAs (miR-10a, miR-10b, miR-21, miR-124, miR-125b, miR-126, miR-145 and miR-200a) to be associated with DMBA-induced mammary tumor progression." +tissue_expression_ns hsa-mir-126 Breast Neoplasms 27433802 "We identified eight microRNAs (miR-10a, miR-10b, miR-21, miR-124, miR-125b, miR-126, miR-145 and miR-200a) to be associated with DMBA-induced mammary tumor progression." +tissue_expression_ns hsa-mir-145 Breast Neoplasms 27433802 "We identified eight microRNAs (miR-10a, miR-10b, miR-21, miR-124, miR-125b, miR-126, miR-145 and miR-200a) to be associated with DMBA-induced mammary tumor progression." +tissue_expression_ns hsa-mir-21 Breast Neoplasms 27433802 "We identified eight microRNAs (miR-10a, miR-10b, miR-21, miR-124, miR-125b, miR-126, miR-145 and miR-200a) to be associated with DMBA-induced mammary tumor progression." +tissue_expression_ns hsa-mir-375 "Squamous Cell Carcinoma, Head and Neck" 27440205 Primary HNSCC carcinoma tissues can be distinguished from histologically normal-matched noncancerous tumour-adjacent tissues based on hsa-miR-375-3p expression. +tissue_expression_ns hsa-mir-210 Bladder Neoplasms 27441495 "High miR-210 may reflect hypoxia in bladder cancer. However, its ability to predict benefit from hypoxia modification does not improve upon other hypoxia markers. Investigation as part of a miRNA hypoxia signature may reveal the full potential of miR-210." +tissue_expression_ns hsa-mir-212 Schizophrenia 27468165 "miR-132, miR-133a and miR-212 were initially identified as differentially expressed in BP, miR-184 in MDD and miR-34a in both MDD and BP (although none survived multiple correction testing and must be considered preliminary)." +tissue_expression_ns hsa-mir-200c Melanoma 27469124 miR expression profiles can be measured in indeterminate Spitz tumors and correlate with markers of malignant potential. +tissue_expression_ns hsa-mir-221 Breast Neoplasms 27488105 "An increase in miR-221/222 might be an important event for in situ carcinoma formation, and miR-221/222 may be important molecules that highlight potential differences between invasive breast carcinomas associated with non-invasive and pure invasive BCs." +tissue_expression_ns hsa-mir-222 Breast Neoplasms 27488105 "An increase in miR-221/222 might be an important event for in situ carcinoma formation, and miR-221/222 may be important molecules that highlight potential differences between invasive breast carcinomas associated with non-invasive and pure invasive BCs." +tissue_expression_ns hsa-mir-138 "Carcinoma, Thyroid, Follicular" 27547222 Expression of miRNA and Occurrence of Distant Metastases in Patients with H¨¹rthle Cell Carcinoma. +tissue_expression_ns hsa-mir-1285 "Carcinoma, Hepatocellular" 27554417 Diagnosis of HCC for patients with cirrhosis using miRNA profiles of the tumor-surrounding tissue - A statistical model based on stepwise penalized logistic regression. +tissue_expression_ns hsa-mir-943 "Carcinoma, Hepatocellular" 27554417 Diagnosis of HCC for patients with cirrhosis using miRNA profiles of the tumor-surrounding tissue - A statistical model based on stepwise penalized logistic regression. +tissue_expression_ns hsa-let-7b Crohn Disease 27556489 Mucosal MicroRNAs Expression Profiles before and after Exclusive Enteral Nutrition Therapy in Adult Patients with Crohn's Disease. +tissue_expression_ns hsa-mir-124 Crohn Disease 27556489 Mucosal MicroRNAs Expression Profiles before and after Exclusive Enteral Nutrition Therapy in Adult Patients with Crohn's Disease. +tissue_expression_ns hsa-mir-192 Crohn Disease 27556489 Mucosal MicroRNAs Expression Profiles before and after Exclusive Enteral Nutrition Therapy in Adult Patients with Crohn's Disease. +tissue_expression_ns hsa-mir-301a Crohn Disease 27556489 Mucosal MicroRNAs Expression Profiles before and after Exclusive Enteral Nutrition Therapy in Adult Patients with Crohn's Disease. +tissue_expression_ns hsa-mir-423 Crohn Disease 27556489 Mucosal MicroRNAs Expression Profiles before and after Exclusive Enteral Nutrition Therapy in Adult Patients with Crohn's Disease. +tissue_expression_ns hsa-mir-495 Crohn Disease 27556489 Mucosal MicroRNAs Expression Profiles before and after Exclusive Enteral Nutrition Therapy in Adult Patients with Crohn's Disease. +tissue_expression_ns hsa-mir-99a Crohn Disease 27556489 Mucosal MicroRNAs Expression Profiles before and after Exclusive Enteral Nutrition Therapy in Adult Patients with Crohn's Disease. +tissue_expression_ns hsa-mir-146a Psoriasis 27562321 MicroRNA-146a and miR-99a are potential biomarkers for disease activity and clinical efficacy assessment in psoriasis patients treated with traditional Chinese medicine. +tissue_expression_ns hsa-mir-99a Psoriasis 27562321 MicroRNA-146a and miR-99a are potential biomarkers for disease activity and clinical efficacy assessment in psoriasis patients treated with traditional Chinese medicine. +tissue_expression_ns hsa-mir-146a Uveal Melanoma 27565163 Expression of natural killer cell regulatory microRNA by uveal melanoma cancer stem cells. +tissue_expression_ns hsa-mir-155 Melanoma 27565163 Expression of natural killer cell regulatory microRNA by uveal melanoma cancer stem cells. +tissue_expression_ns hsa-mir-200c Colorectal Carcinoma 27565378 "Investigating intra-tumor heterogeneity and expression gradients of miR-21, miR-92a and miR-200c and their potential of predicting lymph node metastases in early colorectal cancer." +tissue_expression_ns hsa-mir-21 Colorectal Carcinoma 27565378 "Investigating intra-tumor heterogeneity and expression gradients of miR-21, miR-92a and miR-200c and their potential of predicting lymph node metastases in early colorectal cancer." +tissue_expression_ns hsa-mir-92a Colorectal Carcinoma 27565378 "Investigating intra-tumor heterogeneity and expression gradients of miR-21, miR-92a and miR-200c and their potential of predicting lymph node metastases in early colorectal cancer." +tissue_expression_ns hsa-mir-574 "Squamous Cell Carcinoma, Esophageal" 27565418 The expression of microRNA 574-3p as a predictor of postoperative outcome in patients with esophageal squamous cell carcinoma. +tissue_expression_ns hsa-mir-125b Melanoma 27566021 MicroRNA dysregulation in melanoma. +tissue_expression_ns hsa-mir-150 Melanoma 27566021 MicroRNA dysregulation in melanoma. +tissue_expression_ns hsa-mir-155 Melanoma 27566021 MicroRNA dysregulation in melanoma. +tissue_expression_ns hsa-mir-205 Melanoma 27566021 MicroRNA dysregulation in melanoma. +tissue_expression_ns hsa-mir-21 Melanoma 27566021 MicroRNA dysregulation in melanoma. +tissue_expression_ns hsa-mir-211 Melanoma 27566021 MicroRNA dysregulation in melanoma. +tissue_expression_ns hsa-mir-1247 Glioblastoma 27572852 "Several crucial genes, TFs, miRNAs and small molecules in the different GBM subgroups were identified, which may be used as potential markers" +tissue_expression_ns hsa-mir-147b Glioblastoma 27572852 "Several crucial genes, TFs, miRNAs and small molecules in the different GBM subgroups were identified, which may be used as potential markers" +tissue_expression_ns hsa-mir-220a Glioblastoma 27572852 "miR-147b, miR-770-5p, miR-220a and miR-1247 were the particular miRNAs in subgroups?1-4" +tissue_expression_ns hsa-mir-770 Glioblastoma 27572852 "Several crucial genes, TFs, miRNAs and small molecules in the different GBM subgroups were identified, which may be used as potential markers" +tissue_expression_ns hsa-mir-146b Aortic Stenosis 27579316 MicroRNA Expression Signature in Degenerative Aortic Stenosis. +tissue_expression_ns hsa-mir-193a Aortic Stenosis 27579316 MicroRNA Expression Signature in Degenerative Aortic Stenosis. +tissue_expression_ns hsa-mir-194 Aortic Stenosis 27579316 MicroRNA Expression Signature in Degenerative Aortic Stenosis. +tissue_expression_ns hsa-mir-1972 Aortic Stenosis 27579316 MicroRNA Expression Signature in Degenerative Aortic Stenosis. +tissue_expression_ns hsa-mir-200b Aortic Stenosis 27579316 MicroRNA Expression Signature in Degenerative Aortic Stenosis. +tissue_expression_ns hsa-mir-21 Aortic Stenosis 27579316 MicroRNA Expression Signature in Degenerative Aortic Stenosis. +tissue_expression_ns hsa-mir-29b Aortic Stenosis 27579316 MicroRNA Expression Signature in Degenerative Aortic Stenosis. +tissue_expression_ns hsa-mir-301a Aortic Stenosis 27579316 MicroRNA Expression Signature in Degenerative Aortic Stenosis. +tissue_expression_ns hsa-mir-3138 Aortic Stenosis 27579316 MicroRNA Expression Signature in Degenerative Aortic Stenosis. +tissue_expression_ns hsa-mir-34a Aortic Stenosis 27579316 MicroRNA Expression Signature in Degenerative Aortic Stenosis. +tissue_expression_ns hsa-mir-3663 Aortic Stenosis 27579316 MicroRNA Expression Signature in Degenerative Aortic Stenosis. +tissue_expression_ns hsa-mir-505 Aortic Stenosis 27579316 MicroRNA Expression Signature in Degenerative Aortic Stenosis. +tissue_expression_ns hsa-mir-513a Aortic Stenosis 27579316 MicroRNA Expression Signature in Degenerative Aortic Stenosis. +tissue_expression_ns hsa-mir-516a Aortic Stenosis 27579316 MicroRNA Expression Signature in Degenerative Aortic Stenosis. +tissue_expression_ns hsa-mir-575 Aortic Stenosis 27579316 MicroRNA Expression Signature in Degenerative Aortic Stenosis. +tissue_expression_ns hsa-mir-630 Aortic Stenosis 27579316 MicroRNA Expression Signature in Degenerative Aortic Stenosis. +tissue_expression_ns hsa-mir-636 Aortic Stenosis 27579316 MicroRNA Expression Signature in Degenerative Aortic Stenosis. +tissue_expression_ns hsa-mir-718 Aortic Stenosis 27579316 MicroRNA Expression Signature in Degenerative Aortic Stenosis. +tissue_expression_ns hsa-mir-99b Aortic Stenosis 27579316 MicroRNA Expression Signature in Degenerative Aortic Stenosis. +tissue_expression_ns hsa-mir-100 "Carcinoma, Bladder" 27586262 microRNA expression profiles as decision-making biomarkers in the management of bladder cancer. +tissue_expression_ns hsa-mir-146b "Carcinoma, Bladder" 27586262 microRNA expression profiles as decision-making biomarkers in the management of bladder cancer. +tissue_expression_ns hsa-mir-193a "Carcinoma, Bladder" 27586262 microRNA expression profiles as decision-making biomarkers in the management of bladder cancer. +tissue_expression_ns hsa-mir-34 "Carcinoma, Bladder" 27586262 microRNA expression profiles as decision-making biomarkers in the management of bladder cancer. +tissue_expression_ns hsa-mir-9 "Carcinoma, Bladder" 27586262 microRNA expression profiles as decision-making biomarkers in the management of bladder cancer. +tissue_expression_ns hsa-mir-92b "Carcinoma, Rectal" 27601590 Genome-Wide miRNA Analysis Identifies miR-188-3p as a Novel Prognostic Marker and Molecular Factor Involved in Colorectal Carcinogenesis. +tissue_expression_ns hsa-mir-33b "Squamous Cell Carcinoma, Esophageal" 27609581 The expression and significance of miR-33b and HMGA2 in esophageal squamous cell carcinoma. +tissue_expression_ns hsa-let-7a Neoplasms [unspecific] 27623940 Aberrant microRNA expression in tumor mycosis fungoides. +tissue_expression_ns hsa-mir-1267 Neoplasms [unspecific] 27623940 Aberrant microRNA expression in tumor mycosis fungoides. +tissue_expression_ns hsa-mir-1282 Neoplasms [unspecific] 27623940 Aberrant microRNA expression in tumor mycosis fungoides. +tissue_expression_ns hsa-mir-200c Neoplasms [unspecific] 27623940 Aberrant microRNA expression in tumor mycosis fungoides. +tissue_expression_ns hsa-mir-210 Neoplasms [unspecific] 27623940 Aberrant microRNA expression in tumor mycosis fungoides. +tissue_expression_ns hsa-mir-29a Neoplasms [unspecific] 27623940 Aberrant microRNA expression in tumor mycosis fungoides. +tissue_expression_ns hsa-mir-3177 Neoplasms [unspecific] 27623940 Aberrant microRNA expression in tumor mycosis fungoides. +tissue_expression_ns hsa-mir-34a Neoplasms [unspecific] 27623940 Aberrant microRNA expression in tumor mycosis fungoides. +tissue_expression_ns hsa-mir-514b Neoplasms [unspecific] 27623940 Aberrant microRNA expression in tumor mycosis fungoides. +tissue_expression_ns hsa-mir-221 "Carcinoma, Prostate" 27630329 "to evaluate miR-23b, miR-26a and miR-221 expression levels in combination with preoperative serum PSA level to the risk of PCa recurrence after radical prostatectomy" +tissue_expression_ns hsa-mir-23b "Carcinoma, Prostate" 27630329 "to evaluate miR-23b, miR-26a and miR-221 expression levels in combination with preoperative serum PSA level to the risk of PCa recurrence after radical prostatectomy" +tissue_expression_ns hsa-mir-26a "Carcinoma, Prostate" 27630329 "to evaluate miR-23b, miR-26a and miR-221 expression levels in combination with preoperative serum PSA level to the risk of PCa recurrence after radical prostatectomy" +tissue_expression_ns hsa-mir-100 "Carcinoma, Bladder" 27631180 Evaluation of miR-182/miR-100 Ratio for Diagnosis and Survival Prediction in Bladder Cancer. +tissue_expression_ns hsa-mir-182 "Carcinoma, Bladder" 27631180 Evaluation of miR-182/miR-100 Ratio for Diagnosis and Survival Prediction in Bladder Cancer. +tissue_expression_ns hsa-mir-143 Atherosclerosis 27631489 Differential Expression of MicroRNAs in Endarterectomy Specimens Taken from Patients with Asymptomatic and Symptomatic Carotid Plaques. +tissue_expression_ns hsa-mir-21 Atherosclerosis 27631489 Differential Expression of MicroRNAs in Endarterectomy Specimens Taken from Patients with Asymptomatic and Symptomatic Carotid Plaques. +tissue_expression_ns hsa-mir-195 Muscular Dystrophy 27651778 "At the epigenetic level, miRNAs are thought to be highly involved in the pathophysiological progress of denervated muscles" +tissue_expression_ns hsa-mir-214 Muscular Dystrophy 27651778 "At the epigenetic level, miRNAs are thought to be highly involved in the pathophysiological progress of denervated muscles" +tissue_expression_ns hsa-mir-221 Muscular Dystrophy 27651778 "At the epigenetic level, miRNAs are thought to be highly involved in the pathophysiological progress of denervated muscles" +tissue_expression_ns hsa-mir-222 Muscular Dystrophy 27651778 "At the epigenetic level, miRNAs are thought to be highly involved in the pathophysiological progress of denervated muscles" +tissue_expression_ns hsa-mir-320 Muscular Dystrophy 27651778 "At the epigenetic level, miRNAs are thought to be highly involved in the pathophysiological progress of denervated muscles" +tissue_expression_ns hsa-mir-222 Breast Neoplasms 27659519 Profiles of miRNAs matched to biology in aromatase inhibitor resistant breast cancer. +tissue_expression_ns hsa-mir-31 Breast Neoplasms 27659519 Profiles of miRNAs matched to biology in aromatase inhibitor resistant breast cancer. +tissue_expression_ns hsa-mir-126 "Carcinoma, Lung, Non-Small-Cell" 27665734 Matrine induces cell cycle arrest and apoptosis with recovery of the expression of miR-126 in the A549 non-small cell lung cancer cell line. +tissue_expression_ns hsa-mir-151a "Carcinoma, Thyroid, Medullary" 27666315 Selection and validation of miRNAs as normalizers for profiling expression of microRNAs isolated from thyroid fine needle aspiration smears. +tissue_expression_ns hsa-mir-197 "Carcinoma, Thyroid, Medullary" 27666315 Selection and validation of miRNAs as normalizers for profiling expression of microRNAs isolated from thyroid fine needle aspiration smears. +tissue_expression_ns hsa-mir-214 "Carcinoma, Thyroid, Medullary" 27666315 Selection and validation of miRNAs as normalizers for profiling expression of microRNAs isolated from thyroid fine needle aspiration smears. +tissue_expression_ns hsa-mir-99a "Carcinoma, Thyroid, Medullary" 27666315 Selection and validation of miRNAs as normalizers for profiling expression of microRNAs isolated from thyroid fine needle aspiration smears. +tissue_expression_ns hsa-mir-27a Down Syndrome 27666924 Integrated microRNA and protein expression analysis reveals novel microRNA regulation of targets in fetal down syndrome. +tissue_expression_ns hsa-mir-27b Down Syndrome 27666924 Integrated microRNA and protein expression analysis reveals novel microRNA regulation of targets in fetal down syndrome. +tissue_expression_ns hsa-mir-329 Down Syndrome 27666924 Integrated microRNA and protein expression analysis reveals novel microRNA regulation of targets in fetal down syndrome. +tissue_expression_ns hsa-mir-135b Colorectal Carcinoma 27672263 "MicroRNA biomarkers predicting risk, initiation and progression of colorectal cancer." +tissue_expression_ns hsa-mir-18a Colorectal Carcinoma 27672263 "MicroRNA biomarkers predicting risk, initiation and progression of colorectal cancer." +tissue_expression_ns hsa-mir-21 Colorectal Carcinoma 27672263 "MicroRNA biomarkers predicting risk, initiation and progression of colorectal cancer." +tissue_expression_ns hsa-mir-601 Colorectal Carcinoma 27672263 "MicroRNA biomarkers predicting risk, initiation and progression of colorectal cancer." +tissue_expression_ns hsa-mir-760 Colorectal Carcinoma 27672263 "MicroRNA biomarkers predicting risk, initiation and progression of colorectal cancer." +tissue_expression_ns hsa-mir-92a Colorectal Carcinoma 27672263 "MicroRNA biomarkers predicting risk, initiation and progression of colorectal cancer." +tissue_expression_ns hsa-mir-155 Liver Injury 27673475 Fine-tuning the expression of microRNA-155 controls acetaminophen-induced liver inflammation. +tissue_expression_ns hsa-mir-122 "Diabetes Mellitus, Type 2" 27681254 Differentially expressed microRNAs in the corpus cavernosum from a murine model with type 2 diabetes mellitus-associated erectile dysfunction. +tissue_expression_ns hsa-mir-133 "Diabetes Mellitus, Type 2" 27681254 Differentially expressed microRNAs in the corpus cavernosum from a murine model with type 2 diabetes mellitus-associated erectile dysfunction. +tissue_expression_ns hsa-mir-18a "Diabetes Mellitus, Type 2" 27681254 Differentially expressed microRNAs in the corpus cavernosum from a murine model with type 2 diabetes mellitus-associated erectile dysfunction. +tissue_expression_ns hsa-mir-206 "Diabetes Mellitus, Type 2" 27681254 Differentially expressed microRNAs in the corpus cavernosum from a murine model with type 2 diabetes mellitus-associated erectile dysfunction. +tissue_expression_ns hsa-mir-10b Obesity 27682205 Impact of endurance exercise training on adipocyte microRNA expression in overweight men. +tissue_expression_ns hsa-mir-204 Obesity 27682205 Impact of endurance exercise training on adipocyte microRNA expression in overweight men. +tissue_expression_ns hsa-mir-3613 Obesity 27682205 Impact of endurance exercise training on adipocyte microRNA expression in overweight men. +tissue_expression_ns hsa-mir-4532 Obesity 27682205 Impact of endurance exercise training on adipocyte microRNA expression in overweight men. +tissue_expression_ns hsa-mir-155 "Carcinoma, Lung, Small-Cell" 27682492 Changes of microRNAs profiling in mesothelial cells exposed to multi-walled carbon nanotubes. +tissue_expression_ns hsa-mir-28 "Carcinoma, Lung, Small-Cell" 27682492 Changes of microRNAs profiling in mesothelial cells exposed to multi-walled carbon nanotubes. +tissue_expression_ns hsa-mir-30 "Carcinoma, Lung, Small-Cell" 27682492 Changes of microRNAs profiling in mesothelial cells exposed to multi-walled carbon nanotubes. +tissue_expression_ns hsa-mir-324 "Carcinoma, Lung, Small-Cell" 27682492 Changes of microRNAs profiling in mesothelial cells exposed to multi-walled carbon nanotubes. +tissue_expression_ns hsa-mir-34c "Carcinoma, Lung, Small-Cell" 27682492 Changes of microRNAs profiling in mesothelial cells exposed to multi-walled carbon nanotubes. +tissue_expression_ns hsa-mir-18a Lung Fibrosis 27689473 Altered microRNA expression profiles in lung damage induced by nanosized SiO2. +tissue_expression_ns hsa-mir-212 Lung Fibrosis 27689473 Altered microRNA expression profiles in lung damage induced by nanosized SiO2. +tissue_expression_ns hsa-mir-128a Mesial Temporal Lobe Epilepsy 27695061 Identification of microRNAs with Dysregulated Expression in Status Epilepticus Induced Epileptogenesis. +tissue_expression_ns hsa-mir-196b Mesial Temporal Lobe Epilepsy 27695061 Identification of microRNAs with Dysregulated Expression in Status Epilepticus Induced Epileptogenesis. +tissue_expression_ns hsa-mir-352 Mesial Temporal Lobe Epilepsy 27695061 Identification of microRNAs with Dysregulated Expression in Status Epilepticus Induced Epileptogenesis. +tissue_expression_ns hsa-mir-31 "Adenocarcinoma, Lung" 27695346 MicroRNA expression profiles predict progression and clinical outcome in lung adenocarcinoma. +tissue_expression_ns hsa-mir-1238 Chronic Brucellosis 27722176 "Altered Expressions of miR-1238-3p, miR-494, miR-6069, and miR-139-3p in the Formation of Chronic Brucellosis." +tissue_expression_ns hsa-mir-139 Chronic Brucellosis 27722176 "Altered Expressions of miR-1238-3p, miR-494, miR-6069, and miR-139-3p in the Formation of Chronic Brucellosis." +tissue_expression_ns hsa-mir-494 Chronic Brucellosis 27722176 "Altered Expressions of miR-1238-3p, miR-494, miR-6069, and miR-139-3p in the Formation of Chronic Brucellosis." +tissue_expression_ns hsa-mir-6069 Chronic Brucellosis 27722176 "Altered Expressions of miR-1238-3p, miR-494, miR-6069, and miR-139-3p in the Formation of Chronic Brucellosis." +tissue_expression_ns hsa-mir-200 Cardiomyopathy 27737314 Analyzing gene expression profiles in dilated cardiomyopathy via bioinformatics methods. +tissue_expression_ns hsa-mir-30 Cardiomyopathy 27737314 Analyzing gene expression profiles in dilated cardiomyopathy via bioinformatics methods. +tissue_expression_ns hsa-mir-9 Cardiomyopathy 27737314 Analyzing gene expression profiles in dilated cardiomyopathy via bioinformatics methods. +tissue_expression_ns hsa-mir-146a Diabetes Mellitus 27743454 "we present an overview of the roles of miRNAs in the islet ¦Â-cell development, focusing on the application of different miRNAs in the experimental protocols" +tissue_expression_ns hsa-mir-200 Diabetes Mellitus 27743454 The role of microRNAs in islet ¦Â-cell development. +tissue_expression_ns hsa-mir-30 Diabetes Mellitus 27743454 The role of microRNAs in islet ¦Â-cell development. +tissue_expression_ns hsa-mir-342 Diabetes Mellitus 27743454 The role of microRNAs in islet ¦Â-cell development. +tissue_expression_ns hsa-mir-34a Diabetes Mellitus 27743454 The role of microRNAs in islet ¦Â-cell development. +tissue_expression_ns hsa-mir-375 Diabetes Mellitus 27743454 The role of microRNAs in islet ¦Â-cell development. +tissue_expression_ns hsa-mir-7 Diabetes Mellitus 27743454 The role of microRNAs in islet ¦Â-cell development. +tissue_expression_ns hsa-mir-1246 "Carcinoma, Breast" 27746365 This study highlights the role of numerous miRNAs in prediction of therapeutic responses and suggests that specific miRNAs could serve as valuable sources for biomarker detections and optimal chemotherapeutic choices for breast cancer patients +tissue_expression_ns hsa-mir-1268a "Carcinoma, Breast" 27746365 This study highlights the role of numerous miRNAs in prediction of therapeutic responses and suggests that specific miRNAs could serve as valuable sources for biomarker detections and optimal chemotherapeutic choices for breast cancer patients +tissue_expression_ns hsa-mir-130a "Carcinoma, Breast" 27746365 This study highlights the role of numerous miRNAs in prediction of therapeutic responses and suggests that specific miRNAs could serve as valuable sources for biomarker detections and optimal chemotherapeutic choices for breast cancer patients +tissue_expression_ns hsa-mir-138 "Carcinoma, Breast" 27746365 This study highlights the role of numerous miRNAs in prediction of therapeutic responses and suggests that specific miRNAs could serve as valuable sources for biomarker detections and optimal chemotherapeutic choices for breast cancer patients +tissue_expression_ns hsa-mir-139 "Carcinoma, Breast" 27746365 This study highlights the role of numerous miRNAs in prediction of therapeutic responses and suggests that specific miRNAs could serve as valuable sources for biomarker detections and optimal chemotherapeutic choices for breast cancer patients +tissue_expression_ns hsa-mir-197 "Carcinoma, Breast" 27746365 This study highlights the role of numerous miRNAs in prediction of therapeutic responses and suggests that specific miRNAs could serve as valuable sources for biomarker detections and optimal chemotherapeutic choices for breast cancer patients +tissue_expression_ns hsa-mir-200b "Carcinoma, Breast" 27746365 This study highlights the role of numerous miRNAs in prediction of therapeutic responses and suggests that specific miRNAs could serve as valuable sources for biomarker detections and optimal chemotherapeutic choices for breast cancer patients +tissue_expression_ns hsa-mir-210 "Carcinoma, Breast" 27746365 This study highlights the role of numerous miRNAs in prediction of therapeutic responses and suggests that specific miRNAs could serve as valuable sources for biomarker detections and optimal chemotherapeutic choices for breast cancer patients +tissue_expression_ns hsa-mir-3613 "Carcinoma, Breast" 27746365 This study highlights the role of numerous miRNAs in prediction of therapeutic responses and suggests that specific miRNAs could serve as valuable sources for biomarker detections and optimal chemotherapeutic choices for breast cancer patients +tissue_expression_ns hsa-mir-4258 "Carcinoma, Breast" 27746365 This study highlights the role of numerous miRNAs in prediction of therapeutic responses and suggests that specific miRNAs could serve as valuable sources for biomarker detections and optimal chemotherapeutic choices for breast cancer patients +tissue_expression_ns hsa-mir-4298 "Carcinoma, Breast" 27746365 This study highlights the role of numerous miRNAs in prediction of therapeutic responses and suggests that specific miRNAs could serve as valuable sources for biomarker detections and optimal chemotherapeutic choices for breast cancer patients +tissue_expression_ns hsa-mir-452 "Carcinoma, Breast" 27746365 This study highlights the role of numerous miRNAs in prediction of therapeutic responses and suggests that specific miRNAs could serve as valuable sources for biomarker detections and optimal chemotherapeutic choices for breast cancer patients +tissue_expression_ns hsa-mir-4644 "Carcinoma, Breast" 27746365 This study highlights the role of numerous miRNAs in prediction of therapeutic responses and suggests that specific miRNAs could serve as valuable sources for biomarker detections and optimal chemotherapeutic choices for breast cancer patients +tissue_expression_ns hsa-mir-671 "Carcinoma, Breast" 27746365 This study highlights the role of numerous miRNAs in prediction of therapeutic responses and suggests that specific miRNAs could serve as valuable sources for biomarker detections and optimal chemotherapeutic choices for breast cancer patients +tissue_expression_ns hsa-mir-7107 "Carcinoma, Breast" 27746365 This study highlights the role of numerous miRNAs in prediction of therapeutic responses and suggests that specific miRNAs could serve as valuable sources for biomarker detections and optimal chemotherapeutic choices for breast cancer patients +tissue_expression_ns hsa-mir-7847 "Carcinoma, Breast" 27746365 This study highlights the role of numerous miRNAs in prediction of therapeutic responses and suggests that specific miRNAs could serve as valuable sources for biomarker detections and optimal chemotherapeutic choices for breast cancer patients +tissue_expression_ns hsa-mir-90b "Carcinoma, Breast" 27746365 This study highlights the role of numerous miRNAs in prediction of therapeutic responses and suggests that specific miRNAs could serve as valuable sources for biomarker detections and optimal chemotherapeutic choices for breast cancer patients +tissue_expression_ns hsa-mir-192 Colorectal Carcinoma 27747302 "high miR-192 and miR-194 correlate with better overall survival in Stage II patients, but worse survival in more advanced Stage III/IV patients" +tissue_expression_ns hsa-mir-194 Colorectal Carcinoma 27747302 "high miR-192 and miR-194 correlate with better overall survival in Stage II patients, but worse survival in more advanced Stage III/IV patients" +tissue_expression_ns hsa-mir-1244 Borna Disease 27748825 Identification and bioinformatic analysis of dysregulated microRNAs in human oligodendroglial cells infected with borna disease virus. +tissue_expression_ns hsa-mir-1290 Borna Disease 27748825 Identification and bioinformatic analysis of dysregulated microRNAs in human oligodendroglial cells infected with borna disease virus. +tissue_expression_ns hsa-mir-146a Borna Disease 27748825 Identification and bioinformatic analysis of dysregulated microRNAs in human oligodendroglial cells infected with borna disease virus. +tissue_expression_ns hsa-mir-1908 Borna Disease 27748825 Identification and bioinformatic analysis of dysregulated microRNAs in human oligodendroglial cells infected with borna disease virus. +tissue_expression_ns hsa-mir-296 Borna Disease 27748825 Identification and bioinformatic analysis of dysregulated microRNAs in human oligodendroglial cells infected with borna disease virus. +tissue_expression_ns hsa-mir-3676 Borna Disease 27748825 Identification and bioinformatic analysis of dysregulated microRNAs in human oligodendroglial cells infected with borna disease virus. +tissue_expression_ns hsa-mir-424 Borna Disease 27748825 Identification and bioinformatic analysis of dysregulated microRNAs in human oligodendroglial cells infected with borna disease virus. +tissue_expression_ns hsa-mir-4521 Borna Disease 27748825 Identification and bioinformatic analysis of dysregulated microRNAs in human oligodendroglial cells infected with borna disease virus. +tissue_expression_ns hsa-mir-7 Borna Disease 27748825 Identification and bioinformatic analysis of dysregulated microRNAs in human oligodendroglial cells infected with borna disease virus. +tissue_expression_ns hsa-mir-449a "Carcinoma, Breast" 27748845 MicroRNA profiling in human breast cancer cell lines exposed to the anti-neoplastic drug cediranib. +tissue_expression_ns hsa-mir-449b "Carcinoma, Breast" 27748845 MicroRNA profiling in human breast cancer cell lines exposed to the anti-neoplastic drug cediranib. +tissue_expression_ns hsa-mir-494 "Carcinoma, Breast" 27748845 MicroRNA profiling in human breast cancer cell lines exposed to the anti-neoplastic drug cediranib. +tissue_expression_ns hsa-mir-886 "Carcinoma, Breast" 27748845 MicroRNA profiling in human breast cancer cell lines exposed to the anti-neoplastic drug cediranib. +tissue_expression_ns hsa-mir-923 "Carcinoma, Breast" 27748845 MicroRNA profiling in human breast cancer cell lines exposed to the anti-neoplastic drug cediranib. +tissue_expression_ns hsa-mir-125a "Carcinoma, Lung" 27748875 MicroRNA expression profiles of granulocytic myeloid?derived suppressor cells from mice bearing Lewis lung carcinoma. +tissue_expression_ns hsa-mir-125b "Carcinoma, Lung" 27748875 MicroRNA expression profiles of granulocytic myeloid?derived suppressor cells from mice bearing Lewis lung carcinoma. +tissue_expression_ns hsa-mir-128 "Carcinoma, Lung" 27748875 MicroRNA expression profiles of granulocytic myeloid?derived suppressor cells from mice bearing Lewis lung carcinoma. +tissue_expression_ns hsa-mir-149 "Carcinoma, Lung" 27748875 MicroRNA expression profiles of granulocytic myeloid?derived suppressor cells from mice bearing Lewis lung carcinoma. +tissue_expression_ns hsa-mir-192 "Carcinoma, Lung" 27748875 MicroRNA expression profiles of granulocytic myeloid?derived suppressor cells from mice bearing Lewis lung carcinoma. +tissue_expression_ns hsa-mir-27a "Carcinoma, Lung" 27748875 MicroRNA expression profiles of granulocytic myeloid?derived suppressor cells from mice bearing Lewis lung carcinoma. +tissue_expression_ns hsa-mir-328 "Carcinoma, Lung" 27748875 MicroRNA expression profiles of granulocytic myeloid?derived suppressor cells from mice bearing Lewis lung carcinoma. +tissue_expression_ns hsa-mir-350 "Carcinoma, Lung" 27748875 MicroRNA expression profiles of granulocytic myeloid?derived suppressor cells from mice bearing Lewis lung carcinoma. +tissue_expression_ns hsa-mir-486 "Carcinoma, Lung" 27748875 MicroRNA expression profiles of granulocytic myeloid?derived suppressor cells from mice bearing Lewis lung carcinoma. +tissue_expression_ns hsa-mir-143 "Carcinoma, Ovarian" 27748916 Dysregulation of micro-143-3p and BALBP1 contributes to the pathogenesis of the development of ovarian carcinoma. +tissue_expression_ns hsa-let-7 Schizophrenia 27748930 "the possible role of let-7, miR-98 and miR-183 as biomarkers for Ca and SZ was investigated in our previous research studies" +tissue_expression_ns hsa-mir-183 Schizophrenia 27748930 "the possible role of let-7, miR-98 and miR-183 as biomarkers for Ca and SZ was investigated in our previous research studies" +tissue_expression_ns hsa-mir-98 Schizophrenia 27748930 "the possible role of let-7, miR-98 and miR-183 as biomarkers for Ca and SZ was investigated in our previous research studies" +tissue_expression_ns hsa-mir-210 Human Immunodeficiency Virus Infection 27749601 "MicroRNA-210, MicroRNA-331, and MicroRNA-7 Are Differentially Regulated in Treated HIV-1-Infected Individuals and Are Associated With Markers of Systemic Inflammation." +tissue_expression_ns hsa-mir-331 Human Immunodeficiency Virus Infection 27749601 "MicroRNA-210, MicroRNA-331, and MicroRNA-7 Are Differentially Regulated in Treated HIV-1-Infected Individuals and Are Associated With Markers of Systemic Inflammation." +tissue_expression_ns hsa-mir-7 Human Immunodeficiency Virus Infection 27749601 "MicroRNA-210, MicroRNA-331, and MicroRNA-7 Are Differentially Regulated in Treated HIV-1-Infected Individuals and Are Associated With Markers of Systemic Inflammation." +tissue_expression_ns hsa-mir-210 Ischemic Diseases [unspecific] 27750254 Temporal Profile of Circulating microRNAs after Global Hypoxia-Ischemia in Newborn Piglets. +tissue_expression_ns hsa-mir-146a "Carcinoma, Bladder" 27751843 Real-time PCR analysis pointed to miR-375 as a biomarker for high-grade bladder cancer while miR-146a could identify low-grade patients +tissue_expression_ns hsa-mir-375 "Carcinoma, Bladder" 27751843 Real-time PCR analysis pointed to miR-375 as a biomarker for high-grade bladder cancer while miR-146a could identify low-grade patients +tissue_expression_ns hsa-mir-630 "Carcinoma, Urothelial" 27752905 Expression of miRNA-630 in bladder urothelial carcinoma and its clinical significance. +tissue_expression_ns hsa-mir-941 Polyangiitis 27755585 MicroRNA-941 Expression in Polymorphonuclear Granulocytes Is Not Related to Granulomatosis with Polyangiitis. +tissue_expression_ns hsa-mir-381 "Carcinoma, Ovarian" 27757782 Identification of candidate biomarkers and analysis of prognostic values in ovarian cancer by integrated bioinformatics analysis. +tissue_expression_ns hsa-mir-424 "Carcinoma, Ovarian" 27757782 Identification of candidate biomarkers and analysis of prognostic values in ovarian cancer by integrated bioinformatics analysis. +tissue_expression_ns hsa-mir-106b "Carcinoma, Cervical" 27764149 miRNA Expression Profiles of HPV-Infected Patients with Cervical Cancer in the Uyghur Population in China. +tissue_expression_ns hsa-mir-15a "Carcinoma, Cervical" 27764149 miRNA Expression Profiles of HPV-Infected Patients with Cervical Cancer in the Uyghur Population in China. +tissue_expression_ns hsa-mir-17 "Carcinoma, Cervical" 27764149 miRNA Expression Profiles of HPV-Infected Patients with Cervical Cancer in the Uyghur Population in China. +tissue_expression_ns hsa-mir-20a "Carcinoma, Cervical" 27764149 miRNA Expression Profiles of HPV-Infected Patients with Cervical Cancer in the Uyghur Population in China. +tissue_expression_ns hsa-mir-21 "Carcinoma, Cervical" 27764149 miRNA Expression Profiles of HPV-Infected Patients with Cervical Cancer in the Uyghur Population in China. +tissue_expression_ns hsa-mir-3653 "Carcinoma, Cervical" 27764149 miRNA Expression Profiles of HPV-Infected Patients with Cervical Cancer in the Uyghur Population in China. +tissue_expression_ns hsa-mir-497 "Carcinoma, Cervical" 27764149 miRNA Expression Profiles of HPV-Infected Patients with Cervical Cancer in the Uyghur Population in China. +tissue_expression_ns hsa-mir-96 "Carcinoma, Cervical" 27764149 miRNA Expression Profiles of HPV-Infected Patients with Cervical Cancer in the Uyghur Population in China. +tissue_expression_ns hsa-mir-133a Cardiovascular Diseases [unspecific] 27765794 Inhibition of Aberrant MicroRNA-133a Expression in Endothelial Cells by Statin Prevents Endothelial Dysfunction by Targeting GTP Cyclohydrolase 1 in Vivo. +tissue_expression_ns hsa-mir-498 "Squamous Cell Carcinoma, Tongue" 27773646 MicroRNA and protein profiles in invasive versus non-invasive oral tongue squamous cell carcinoma cells in vitro. +tissue_expression_ns hsa-mir-940 "Squamous Cell Carcinoma, Tongue" 27773646 MicroRNA and protein profiles in invasive versus non-invasive oral tongue squamous cell carcinoma cells in vitro. +tissue_expression_ns hsa-mir-129 Amyotrophic Lateral Sclerosis 27773796 MicroRNA expression profiles of multiple system atrophy from formalin-fixed paraffin-embedded samples. +tissue_expression_ns hsa-mir-132 Amyotrophic Lateral Sclerosis 27773796 MicroRNA expression profiles of multiple system atrophy from formalin-fixed paraffin-embedded samples. +tissue_expression_ns hsa-mir-125 Colorectal Carcinoma 27775664 A Comprehensive MicroRNA Expression Profile of Liver and Lung Metastases of Colorectal Cancer with Their Corresponding Host Tissue and Its Prognostic Impact on Survival. +tissue_expression_ns hsa-mir-127 Colorectal Carcinoma 27775664 A Comprehensive MicroRNA Expression Profile of Liver and Lung Metastases of Colorectal Cancer with Their Corresponding Host Tissue and Its Prognostic Impact on Survival. +tissue_expression_ns hsa-mir-145 Colorectal Carcinoma 27775664 A Comprehensive MicroRNA Expression Profile of Liver and Lung Metastases of Colorectal Cancer with Their Corresponding Host Tissue and Its Prognostic Impact on Survival. +tissue_expression_ns hsa-mir-19 Colorectal Carcinoma 27775664 A Comprehensive MicroRNA Expression Profile of Liver and Lung Metastases of Colorectal Cancer with Their Corresponding Host Tissue and Its Prognostic Impact on Survival. +tissue_expression_ns hsa-mir-192 Colorectal Carcinoma 27775664 A Comprehensive MicroRNA Expression Profile of Liver and Lung Metastases of Colorectal Cancer with Their Corresponding Host Tissue and Its Prognostic Impact on Survival. +tissue_expression_ns hsa-mir-194 Colorectal Carcinoma 27775664 A Comprehensive MicroRNA Expression Profile of Liver and Lung Metastases of Colorectal Cancer with Their Corresponding Host Tissue and Its Prognostic Impact on Survival. +tissue_expression_ns hsa-mir-199 Colorectal Carcinoma 27775664 A Comprehensive MicroRNA Expression Profile of Liver and Lung Metastases of Colorectal Cancer with Their Corresponding Host Tissue and Its Prognostic Impact on Survival. +tissue_expression_ns hsa-mir-21 Colorectal Carcinoma 27775664 A Comprehensive MicroRNA Expression Profile of Liver and Lung Metastases of Colorectal Cancer with Their Corresponding Host Tissue and Its Prognostic Impact on Survival. +tissue_expression_ns hsa-mir-215 Colorectal Carcinoma 27775664 A Comprehensive MicroRNA Expression Profile of Liver and Lung Metastases of Colorectal Cancer with Their Corresponding Host Tissue and Its Prognostic Impact on Survival. +tissue_expression_ns hsa-mir-429 Colorectal Carcinoma 27775664 A Comprehensive MicroRNA Expression Profile of Liver and Lung Metastases of Colorectal Cancer with Their Corresponding Host Tissue and Its Prognostic Impact on Survival. +tissue_expression_ns hsa-mir-143 Inflammation 27776879 Expression Profiles of Inflammation-associated microRNAs in Periapical Lesions and Human Periodontal Ligament Fibroblasts Inflammation. +tissue_expression_ns hsa-mir-223 Polycystic Ovarian Syndrome 27777110 Altered expression of miRNAs in the uterus from a letrozole-induced rat PCOS model. +tissue_expression_ns hsa-mir-324 Polycystic Ovarian Syndrome 27777110 Altered expression of miRNAs in the uterus from a letrozole-induced rat PCOS model. +tissue_expression_ns hsa-mir-375 Polycystic Ovarian Syndrome 27777110 Altered expression of miRNAs in the uterus from a letrozole-induced rat PCOS model. +tissue_expression_ns hsa-mir-484 Polycystic Ovarian Syndrome 27777110 Altered expression of miRNAs in the uterus from a letrozole-induced rat PCOS model. +tissue_expression_ns hsa-mir-152 Colorectal Carcinoma 27784461 Expression of microRNA-152 in colorectal cancer and its relationship with prognosis. +tissue_expression_ns hsa-let-7d Reproductive System Disease 27789200 "A number of these differentially expressed miRNAs have previously been associated with adipogenesis(e.g. let-7d*, miR-103-2*, -130b, -146b-5-p, -29c, and -26b)" +tissue_expression_ns hsa-mir-103-2 Reproductive System Disease 27789200 "A number of these differentially expressed miRNAs have previously been associated with adipogenesis(e.g. let-7d*, miR-103-2*, -130b, -146b-5-p, -29c, and -26b)" +tissue_expression_ns hsa-mir-130b Reproductive System Disease 27789200 "A number of these differentially expressed miRNAs have previously been associated with adipogenesis(e.g. let-7d*, miR-103-2*, -130b, -146b-5-p, -29c, and -26b)" +tissue_expression_ns hsa-mir-146b Reproductive System Disease 27789200 "A number of these differentially expressed miRNAs have previously been associated with adipogenesis(e.g. let-7d*, miR-103-2*, -130b, -146b-5-p, -29c, and -26b)" +tissue_expression_ns hsa-mir-26b Reproductive System Disease 27789200 "A number of these differentially expressed miRNAs have previously been associated with adipogenesis(e.g. let-7d*, miR-103-2*, -130b, -146b-5-p, -29c, and -26b)" +tissue_expression_ns hsa-mir-29c Reproductive System Disease 27789200 "A number of these differentially expressed miRNAs have previously been associated with adipogenesis(e.g. let-7d*, miR-103-2*, -130b, -146b-5-p, -29c, and -26b)" +tissue_expression_ns hsa-mir-323a Epilepsy 27824513 Aberrant Expression of miR-323a-5p in Patients with Refractory Epilepsy Caused by Focal Cortical Dysplasia. +tissue_expression_ns hsa-mir-9 Cerebral Aneurysm 27824808 Aberrant Expression of microRNA-9 Contributes to Development of Intracranial Aneurysm by Suppressing Proliferation and Reducing Contractility of Smooth Muscle Cells. +tissue_expression_ns hsa-mir-1 Vascular Hypertrophy 27831640 Influence and significance of intervening diabetes microRNA expression profile of NOD mice with exendin-4. +tissue_expression_ns hsa-let-7a Squamous Cell Carcinoma 27835588 Expressions of miR-30c and let-7a are inversely correlated with HMGA2 expression in squamous cell carcinoma of the vulva. +tissue_expression_ns hsa-mir-4717 Guillain-Barre Syndrome 27836180 MicroRNA expression profiling in Guillain-Barr¨¦ syndrome. +tissue_expression_ns hsa-mir-642b Guillain-Barre Syndrome 27836180 MicroRNA expression profiling in Guillain-Barr¨¦ syndrome. +tissue_expression_ns hsa-mir-155 "Carcinoma, Pancreatic" 27840954 Identfication of key miRNAs in pancreatitis using bioinformatics analysis of microarray data. +tissue_expression_ns hsa-mir-15a "Carcinoma, Pancreatic" 27840954 Identfication of key miRNAs in pancreatitis using bioinformatics analysis of microarray data. +tissue_expression_ns hsa-mir-16 "Carcinoma, Pancreatic" 27840954 Identfication of key miRNAs in pancreatitis using bioinformatics analysis of microarray data. +tissue_expression_ns hsa-mir-375 "Carcinoma, Pancreatic" 27840954 Identfication of key miRNAs in pancreatitis using bioinformatics analysis of microarray data. +tissue_expression_ns hsa-mir-429 "Carcinoma, Pancreatic" 27840954 Identfication of key miRNAs in pancreatitis using bioinformatics analysis of microarray data. +tissue_expression_ns hsa-mir-301a Melanoma 27855389 Expression of MicroRNA-301a and its Functional Roles in Malignant Melanoma. +tissue_expression_ns hsa-mir-21 Peritoneal Dialysis Failure 27867039 Peritoneal dialysis effluent miR-21 and miR-589 levels correlate with longitudinal change in peritoneal transport characteristics. +tissue_expression_ns hsa-mir-589 Peritoneal Dialysis Failure 27867039 Peritoneal dialysis effluent miR-21 and miR-589 levels correlate with longitudinal change in peritoneal transport characteristics. +tissue_expression_ns hsa-mir-199a Autoimmune Diseases [unspecific] 27871116 "Excess glucocorticoids have been shown to modulate the expression of miRNAs, including miR-29a, miR-34a-5p, and miR-199a-5p, which regulate the proliferation and differentiation of osteoblast lineage cells" +tissue_expression_ns hsa-mir-29a Autoimmune Diseases [unspecific] 27871116 "Excess glucocorticoids have been shown to modulate the expression of miRNAs, including miR-29a, miR-34a-5p, and miR-199a-5p, which regulate the proliferation and differentiation of osteoblast lineage cells" +tissue_expression_ns hsa-mir-34a Autoimmune Diseases [unspecific] 27871116 "Excess glucocorticoids have been shown to modulate the expression of miRNAs, including miR-29a, miR-34a-5p, and miR-199a-5p, which regulate the proliferation and differentiation of osteoblast lineage cells" +tissue_expression_ns hsa-mir-122 "Carcinoma, Hepatocellular" 27874954 The anti-cancer effects of cisplatin on hepatic cancer are associated with modulation of miRNA-21 and miRNA-122 expression. +tissue_expression_ns hsa-mir-21 "Carcinoma, Hepatocellular" 27874954 The anti-cancer effects of cisplatin on hepatic cancer are associated with modulation of miRNA-21 and miRNA-122 expression. +tissue_expression_ns hsa-mir-200b "Carcinoma, Lung, Non-Small-Cell" 27876017 miR-27b and miR-200b levels were determined in resected adenocarcinoma and squamous cell carcinoma samples by qRT-PCR +tissue_expression_ns hsa-mir-27b "Carcinoma, Lung, Non-Small-Cell" 27876017 miR-27b and miR-200b levels were determined in resected adenocarcinoma and squamous cell carcinoma samples by qRT-PCR +tissue_expression_ns hsa-mir-122 Liver Cirrhosis 27879410 We also detected expression of hsa-miR-122 in primitive ductular reactions expected for hepatocytic differentiation and hsa-miR-23b cluster expression that drives liver cell fate decisions in cells undergoing lineage commitment +tissue_expression_ns hsa-mir-23b Liver Cirrhosis 27879410 We also detected expression of hsa-miR-122 in primitive ductular reactions expected for hepatocytic differentiation and hsa-miR-23b cluster expression that drives liver cell fate decisions in cells undergoing lineage commitment +tissue_expression_ns hsa-mir-146a Chronic Hepatitis C 27888401 The impact of chronic hepatitis C infection on cholesterol metabolism in PBMCs is associated with microRNA-146a expression. +tissue_expression_ns hsa-mir-186 "Squamous Cell Carcinoma, Esophageal" 27889881 Identification of reference genes and miRNAs for qRT-PCR in human esophageal squamous cell carcinoma. +tissue_expression_ns hsa-mir-28 "Squamous Cell Carcinoma, Esophageal" 27889881 Identification of reference genes and miRNAs for qRT-PCR in human esophageal squamous cell carcinoma. +tissue_expression_ns hsa-mir-34a "Squamous Cell Carcinoma, Esophageal" 27889881 Identification of reference genes and miRNAs for qRT-PCR in human esophageal squamous cell carcinoma. +tissue_expression_ns hsa-let-7b "Carcinoma, Prostate" 27903835 "the outcome of the study has important clinical implications for the management of prostate cancer, including the use of miRNA(s) as biomarkers for early detection of prostate cancer" +tissue_expression_ns hsa-mir-1179 "Carcinoma, Prostate" 27903835 "the outcome of the study has important clinical implications for the management of prostate cancer, including the use of miRNA(s) as biomarkers for early detection of prostate cancer" +tissue_expression_ns hsa-mir-1299 "Carcinoma, Prostate" 27903835 "the outcome of the study has important clinical implications for the management of prostate cancer, including the use of miRNA(s) as biomarkers for early detection of prostate cancer" +tissue_expression_ns hsa-mir-155 "Carcinoma, Prostate" 27903835 "the outcome of the study has important clinical implications for the management of prostate cancer, including the use of miRNA(s) as biomarkers for early detection of prostate cancer" +tissue_expression_ns hsa-mir-18a "Carcinoma, Prostate" 27903835 "the outcome of the study has important clinical implications for the management of prostate cancer, including the use of miRNA(s) as biomarkers for early detection of prostate cancer" +tissue_expression_ns hsa-mir-19a "Carcinoma, Prostate" 27903835 "the outcome of the study has important clinical implications for the management of prostate cancer, including the use of miRNA(s) as biomarkers for early detection of prostate cancer" +tissue_expression_ns hsa-mir-200a "Carcinoma, Prostate" 27903835 "the outcome of the study has important clinical implications for the management of prostate cancer, including the use of miRNA(s) as biomarkers for early detection of prostate cancer" +tissue_expression_ns hsa-mir-21 "Carcinoma, Prostate" 27903835 "the outcome of the study has important clinical implications for the management of prostate cancer, including the use of miRNA(s) as biomarkers for early detection of prostate cancer" +tissue_expression_ns hsa-mir-3120 "Carcinoma, Prostate" 27903835 "the outcome of the study has important clinical implications for the management of prostate cancer, including the use of miRNA(s) as biomarkers for early detection of prostate cancer" +tissue_expression_ns hsa-mir-3149 "Carcinoma, Prostate" 27903835 "the outcome of the study has important clinical implications for the management of prostate cancer, including the use of miRNA(s) as biomarkers for early detection of prostate cancer" +tissue_expression_ns hsa-mir-3189 "Carcinoma, Prostate" 27903835 "the outcome of the study has important clinical implications for the management of prostate cancer, including the use of miRNA(s) as biomarkers for early detection of prostate cancer" +tissue_expression_ns hsa-mir-3622b "Carcinoma, Prostate" 27903835 "the outcome of the study has important clinical implications for the management of prostate cancer, including the use of miRNA(s) as biomarkers for early detection of prostate cancer" +tissue_expression_ns hsa-mir-3677 "Carcinoma, Prostate" 27903835 "the outcome of the study has important clinical implications for the management of prostate cancer, including the use of miRNA(s) as biomarkers for early detection of prostate cancer" +tissue_expression_ns hsa-mir-3682 "Carcinoma, Prostate" 27903835 "the outcome of the study has important clinical implications for the management of prostate cancer, including the use of miRNA(s) as biomarkers for early detection of prostate cancer" +tissue_expression_ns hsa-mir-3689d "Carcinoma, Prostate" 27903835 "the outcome of the study has important clinical implications for the management of prostate cancer, including the use of miRNA(s) as biomarkers for early detection of prostate cancer" +tissue_expression_ns hsa-mir-410 "Carcinoma, Prostate" 27903835 "the outcome of the study has important clinical implications for the management of prostate cancer, including the use of miRNA(s) as biomarkers for early detection of prostate cancer" +tissue_expression_ns hsa-mir-4469 "Carcinoma, Prostate" 27903835 "the outcome of the study has important clinical implications for the management of prostate cancer, including the use of miRNA(s) as biomarkers for early detection of prostate cancer" +tissue_expression_ns hsa-mir-4518 "Carcinoma, Prostate" 27903835 "the outcome of the study has important clinical implications for the management of prostate cancer, including the use of miRNA(s) as biomarkers for early detection of prostate cancer" +tissue_expression_ns hsa-mir-5189 "Carcinoma, Prostate" 27903835 "the outcome of the study has important clinical implications for the management of prostate cancer, including the use of miRNA(s) as biomarkers for early detection of prostate cancer" +tissue_expression_ns hsa-mir-639 "Carcinoma, Prostate" 27903835 "the outcome of the study has important clinical implications for the management of prostate cancer, including the use of miRNA(s) as biomarkers for early detection of prostate cancer" +tissue_expression_ns hsa-mir-92b "Carcinoma, Prostate" 27903835 "the outcome of the study has important clinical implications for the management of prostate cancer, including the use of miRNA(s) as biomarkers for early detection of prostate cancer" +tissue_expression_ns hsa-mir-210 "Stroke, Ischemic" 27906445 The expression research of miR-210 in the elderly patients with COPD combined with ischemic stroke. +tissue_expression_ns hsa-mir-130a "Carcinoma, Prostate" 27915273 Altered miRNA expression in high-fat diet-induced prostate cancer progression. +tissue_expression_ns hsa-mir-1276 "Carcinoma, Laryngeal" 27916417 "CCR6 was positively associated with miR-20a-5p, miR-489 and negatively related to miR-29-3p, miR-632 and miR-1276 in laryngeal cancer tissues" +tissue_expression_ns hsa-mir-20a "Carcinoma, Laryngeal" 27916417 "CCR6 was positively associated with miR-20a-5p, miR-489 and negatively related to miR-29-3p, miR-632 and miR-1277 in laryngeal cancer tissues" +tissue_expression_ns hsa-mir-29 "Carcinoma, Laryngeal" 27916417 "CCR6 was positively associated with miR-20a-5p, miR-489 and negatively related to miR-29-3p, miR-632 and miR-1278 in laryngeal cancer tissues" +tissue_expression_ns hsa-mir-489 "Carcinoma, Laryngeal" 27916417 "CCR6 was positively associated with miR-20a-5p, miR-489 and negatively related to miR-29-3p, miR-632 and miR-1279 in laryngeal cancer tissues" +tissue_expression_ns hsa-mir-632 "Carcinoma, Laryngeal" 27916417 "CCR6 was positively associated with miR-20a-5p, miR-489 and negatively related to miR-29-3p, miR-632 and miR-1280 in laryngeal cancer tissues" +tissue_expression_ns hsa-mir-1246 Colorectal Carcinoma 27916938 Comprehensive Analysis of miRNome Alterations in Response to Sorafenib Treatment in Colorectal Cancer Cells. +tissue_expression_ns hsa-mir-1290 Colorectal Carcinoma 27916938 Comprehensive Analysis of miRNome Alterations in Response to Sorafenib Treatment in Colorectal Cancer Cells. +tissue_expression_ns hsa-mir-20a Colorectal Carcinoma 27916938 Comprehensive Analysis of miRNome Alterations in Response to Sorafenib Treatment in Colorectal Cancer Cells. +tissue_expression_ns hsa-mir-3142 Colorectal Carcinoma 27916938 Comprehensive Analysis of miRNome Alterations in Response to Sorafenib Treatment in Colorectal Cancer Cells. +tissue_expression_ns hsa-mir-3182 Colorectal Carcinoma 27916938 Comprehensive Analysis of miRNome Alterations in Response to Sorafenib Treatment in Colorectal Cancer Cells. +tissue_expression_ns hsa-mir-4286 Colorectal Carcinoma 27916938 Comprehensive Analysis of miRNome Alterations in Response to Sorafenib Treatment in Colorectal Cancer Cells. +tissue_expression_ns hsa-mir-4301 Colorectal Carcinoma 27916938 Comprehensive Analysis of miRNome Alterations in Response to Sorafenib Treatment in Colorectal Cancer Cells. +tissue_expression_ns hsa-mir-597 Colorectal Carcinoma 27916938 Comprehensive Analysis of miRNome Alterations in Response to Sorafenib Treatment in Colorectal Cancer Cells. +tissue_expression_ns hsa-mir-720 Colorectal Carcinoma 27916938 Comprehensive Analysis of miRNome Alterations in Response to Sorafenib Treatment in Colorectal Cancer Cells. +tissue_expression_ns hsa-mir-125b "Squamous Cell Carcinoma, Oral" 27935034 Integrated Analysis and MicroRNA Expression Profiling Identified Seven miRNAs Associated With Progression of Oral Squamous Cell Carcinoma. +tissue_expression_ns hsa-mir-133a "Squamous Cell Carcinoma, Oral" 27935034 Integrated Analysis and MicroRNA Expression Profiling Identified Seven miRNAs Associated With Progression of Oral Squamous Cell Carcinoma. +tissue_expression_ns hsa-mir-133b "Squamous Cell Carcinoma, Oral" 27935034 Integrated Analysis and MicroRNA Expression Profiling Identified Seven miRNAs Associated With Progression of Oral Squamous Cell Carcinoma. +tissue_expression_ns hsa-mir-139 "Squamous Cell Carcinoma, Oral" 27935034 Integrated Analysis and MicroRNA Expression Profiling Identified Seven miRNAs Associated With Progression of Oral Squamous Cell Carcinoma. +tissue_expression_ns hsa-mir-21 "Squamous Cell Carcinoma, Oral" 27935034 Integrated Analysis and MicroRNA Expression Profiling Identified Seven miRNAs Associated With Progression of Oral Squamous Cell Carcinoma. +tissue_expression_ns hsa-mir-31 "Squamous Cell Carcinoma, Oral" 27935034 Integrated Analysis and MicroRNA Expression Profiling Identified Seven miRNAs Associated With Progression of Oral Squamous Cell Carcinoma. +tissue_expression_ns hsa-mir-338 "Squamous Cell Carcinoma, Oral" 27935034 Integrated Analysis and MicroRNA Expression Profiling Identified Seven miRNAs Associated With Progression of Oral Squamous Cell Carcinoma. +tissue_expression_ns hsa-mir-1 Aortic Aneurysm 27939432 Regulation of microRNA expression in vascular smooth muscle by MRTF-A and actin polymerization. +tissue_expression_ns hsa-mir-143 Aortic Aneurysm 27939432 Regulation of microRNA expression in vascular smooth muscle by MRTF-A and actin polymerization. +tissue_expression_ns hsa-mir-145 Aortic Aneurysm 27939432 Regulation of microRNA expression in vascular smooth muscle by MRTF-A and actin polymerization. +tissue_expression_ns hsa-mir-22 Aortic Aneurysm 27939432 Regulation of microRNA expression in vascular smooth muscle by MRTF-A and actin polymerization. +tissue_expression_ns hsa-mir-378a Aortic Aneurysm 27939432 Regulation of microRNA expression in vascular smooth muscle by MRTF-A and actin polymerization. +tissue_expression_ns hsa-mir-203 "Squamous Cell Carcinoma, Skin or Unspecific" 27943259 MicroRNA (miR)-203 and miR-205 expression patterns identify subgroups of prognosis in cutaneous squamous cell carcinoma. +tissue_expression_ns hsa-mir-205 "Squamous Cell Carcinoma, Skin or Unspecific" 27943259 MicroRNA (miR)-203 and miR-205 expression patterns identify subgroups of prognosis in cutaneous squamous cell carcinoma. +tissue_expression_ns hsa-mir-15a Salivary Gland Neoplasms 27981346 Altered expression of apoptosis-regulating miRNAs in salivary gland tumors suggests their involvement in salivary gland tumorigenesis. +tissue_expression_ns hsa-mir-16 Salivary Gland Neoplasms 27981346 Altered expression of apoptosis-regulating miRNAs in salivary gland tumors suggests their involvement in salivary gland tumorigenesis. +tissue_expression_ns hsa-mir-17 Salivary Gland Neoplasms 27981346 Altered expression of apoptosis-regulating miRNAs in salivary gland tumors suggests their involvement in salivary gland tumorigenesis. +tissue_expression_ns hsa-mir-20a Salivary Gland Neoplasms 27981346 Altered expression of apoptosis-regulating miRNAs in salivary gland tumors suggests their involvement in salivary gland tumorigenesis. +tissue_expression_ns hsa-mir-21 Salivary Gland Neoplasms 27981346 Altered expression of apoptosis-regulating miRNAs in salivary gland tumors suggests their involvement in salivary gland tumorigenesis. +tissue_expression_ns hsa-mir-29 Salivary Gland Neoplasms 27981346 Altered expression of apoptosis-regulating miRNAs in salivary gland tumors suggests their involvement in salivary gland tumorigenesis. +tissue_expression_ns hsa-mir-34 Salivary Gland Neoplasms 27981346 Altered expression of apoptosis-regulating miRNAs in salivary gland tumors suggests their involvement in salivary gland tumorigenesis. +tissue_expression_ns hsa-mir-34a Salivary Gland Neoplasms 27981346 Altered expression of apoptosis-regulating miRNAs in salivary gland tumors suggests their involvement in salivary gland tumorigenesis. +tissue_expression_ns hsa-mir-106b "Squamous Cell Carcinoma, Esophageal" 27998862 Expression of mir-106b in esophageal squamous cell carcinoma. +tissue_expression_ns hsa-mir-107 Glioma 27999452 "Deregulation of miRNAs is caused by viral infections, tumorigenesis, and so forth" +tissue_expression_ns hsa-mir-126 Glioma 27999452 "Deregulation of miRNAs is caused by viral infections, tumorigenesis, and so forth" +tissue_expression_ns hsa-mir-135 Glioma 27999452 "Deregulation of miRNAs is caused by viral infections, tumorigenesis, and so forth" +tissue_expression_ns hsa-mir-137 Glioma 27999452 "Deregulation of miRNAs is caused by viral infections, tumorigenesis, and so forth" +tissue_expression_ns hsa-mir-138 Glioma 27999452 "Deregulation of miRNAs is caused by viral infections, tumorigenesis, and so forth" +tissue_expression_ns hsa-mir-145 Glioma 27999452 "Deregulation of miRNAs is caused by viral infections, tumorigenesis, and so forth" +tissue_expression_ns hsa-mir-150 Glioma 27999452 "Deregulation of miRNAs is caused by viral infections, tumorigenesis, and so forth" +tissue_expression_ns hsa-mir-155 Glioma 27999452 "Deregulation of miRNAs is caused by viral infections, tumorigenesis, and so forth" +tissue_expression_ns hsa-mir-181a Glioma 27999452 "Deregulation of miRNAs is caused by viral infections, tumorigenesis, and so forth" +tissue_expression_ns hsa-mir-184 Glioma 27999452 "Deregulation of miRNAs is caused by viral infections, tumorigenesis, and so forth" +tissue_expression_ns hsa-mir-205 Glioma 27999452 "Deregulation of miRNAs is caused by viral infections, tumorigenesis, and so forth" +tissue_expression_ns hsa-mir-21 Glioma 27999452 "Deregulation of miRNAs is caused by viral infections, tumorigenesis, and so forth" +tissue_expression_ns hsa-mir-218 Glioma 27999452 "Deregulation of miRNAs is caused by viral infections, tumorigenesis, and so forth" +tissue_expression_ns hsa-mir-7 Glioma 27999452 "Deregulation of miRNAs is caused by viral infections, tumorigenesis, and so forth" +tissue_expression_ns hsa-mir-9 Glioma 27999452 "Deregulation of miRNAs is caused by viral infections, tumorigenesis, and so forth" +tissue_expression_ns hsa-mir-98 Glioma 27999452 "Deregulation of miRNAs is caused by viral infections, tumorigenesis, and so forth" +tissue_expression_ns hsa-mir-99b Glioma 27999452 "Deregulation of miRNAs is caused by viral infections, tumorigenesis, and so forth" +tissue_expression_ns hsa-mir-29a Diabetes Mellitus 28003969 Expression and regulation of microRNA-29a and microRNA-29c in early diabetic rat cataract formation. +tissue_expression_ns hsa-mir-29c Diabetes Mellitus 28003969 Expression and regulation of microRNA-29a and microRNA-29c in early diabetic rat cataract formation. +tissue_expression_ns hsa-mir-26a Pituitary Adenoma 28012286 Expression and Clinical Significance of miR-26a and Pleomorphic Adenoma Gene 1 (PLAG1) in Invasive Pituitary Adenoma. +tissue_expression_ns hsa-mir-142 Lymphoma 28031239 "MicroRNAs 142-3p, miR-155 and miR-203 Are Deregulated in Gastric MALT Lymphomas Compared to Chronic Gastritis." +tissue_expression_ns hsa-mir-155 Lymphoma 28031239 "MicroRNAs 142-3p, miR-155 and miR-203 Are Deregulated in Gastric MALT Lymphomas Compared to Chronic Gastritis." +tissue_expression_ns hsa-mir-203 Lymphoma 28031239 "MicroRNAs 142-3p, miR-155 and miR-203 Are Deregulated in Gastric MALT Lymphomas Compared to Chronic Gastritis." +tissue_expression_ns hsa-mir-34b Prostate Neoplasms 28039468 Differential expression of miR-34b and androgen receptor pathway regulate prostate cancer aggressiveness between African-Americans and Caucasians. +tissue_expression_ns hsa-mir-29 Malignant Neoplasms [unspecific] 28063172 Prognostic value of the MicroRNA-29 family in multiple human cancers: A meta-analysis and systematic review. +tissue_expression_ns hsa-mir-140 Osteoarthritis 28065216 Expression of miRNA-140 in Chondrocytes and Synovial Fluid of Knee Joints in Patients with Osteoarthritis. +tissue_expression_ns hsa-mir-155 Porphyromonas Gingivalis 28069815 Identification and Characterization of MicroRNA Differentially Expressed in Macrophages Exposed to Porphyromonas gingivalis Infection. +tissue_expression_ns hsa-mir-1184 "Carcinoma, Prostate" 28072703 Screening the key microRNAs and transcription factors in prostate cancer based on microRNA functional synergistic relationships. +tissue_expression_ns hsa-mir-1207 "Carcinoma, Prostate" 28072703 Screening the key microRNAs and transcription factors in prostate cancer based on microRNA functional synergistic relationships. +tissue_expression_ns hsa-mir-182 "Carcinoma, Prostate" 28072703 Screening the key microRNAs and transcription factors in prostate cancer based on microRNA functional synergistic relationships. +tissue_expression_ns hsa-mir-183 "Carcinoma, Prostate" 28072703 Screening the key microRNAs and transcription factors in prostate cancer based on microRNA functional synergistic relationships. +tissue_expression_ns hsa-mir-24 "Carcinoma, Prostate" 28072703 Screening the key microRNAs and transcription factors in prostate cancer based on microRNA functional synergistic relationships. +tissue_expression_ns hsa-mir-223 Lyme Disease 28076897 MicroRNA Expression Shows Inflammatory Dysregulation and Tumor-Like Proliferative Responses in Joints of Patients With Postinfectious Lyme Arthritis. +tissue_expression_ns hsa-mir-106a Psoriasis 28077577 Extracellular MicroRNA Signature of Human Helper T Cell Subsets in Health and Autoimmunity. +tissue_expression_ns hsa-mir-146a Psoriasis 28077577 Extracellular MicroRNA Signature of Human Helper T Cell Subsets in Health and Autoimmunity. +tissue_expression_ns hsa-mir-150 Psoriasis 28077577 Extracellular MicroRNA Signature of Human Helper T Cell Subsets in Health and Autoimmunity. +tissue_expression_ns hsa-mir-155 Psoriasis 28077577 Extracellular MicroRNA Signature of Human Helper T Cell Subsets in Health and Autoimmunity. +tissue_expression_ns hsa-mir-19a Psoriasis 28077577 Extracellular MicroRNA Signature of Human Helper T Cell Subsets in Health and Autoimmunity. +tissue_expression_ns hsa-mir-21 Psoriasis 28077577 Extracellular MicroRNA Signature of Human Helper T Cell Subsets in Health and Autoimmunity. +tissue_expression_ns hsa-mir-1 Myotonic Muscular Dystrophy 28078570 Micro-RNA expression in muscle and fiber morphometry in myotonic dystrophy type 1. +tissue_expression_ns hsa-mir-133a Myotonic Muscular Dystrophy 28078570 Micro-RNA expression in muscle and fiber morphometry in myotonic dystrophy type 1. +tissue_expression_ns hsa-mir-133b Myotonic Muscular Dystrophy 28078570 Micro-RNA expression in muscle and fiber morphometry in myotonic dystrophy type 1. +tissue_expression_ns hsa-mir-206 Myotonic Muscular Dystrophy 28078570 Micro-RNA expression in muscle and fiber morphometry in myotonic dystrophy type 1. +tissue_expression_ns hsa-mir-126 Vascular Disease [unspecific] 28082910 "Acute Effects of Different Exercise Protocols on the Circulating Vascular microRNAs -16, -21, and -126 in Trained Subjects." +tissue_expression_ns hsa-mir-16 Vascular Disease [unspecific] 28082910 "Acute Effects of Different Exercise Protocols on the Circulating Vascular microRNAs -16, -21, and -126 in Trained Subjects." +tissue_expression_ns hsa-mir-21 Vascular Disease [unspecific] 28082910 "Acute Effects of Different Exercise Protocols on the Circulating Vascular microRNAs -16, -21, and -126 in Trained Subjects." +tissue_expression_ns hsa-mir-140 Osteoarthritis 28085114 Hydrostatic Pressure Regulates MicroRNA Expression Levels in Osteoarthritic Chondrocyte Cultures via the Wnt/¦Â-Catenin Pathway. +tissue_expression_ns hsa-mir-146a Osteoarthritis 28085114 Hydrostatic Pressure Regulates MicroRNA Expression Levels in Osteoarthritic Chondrocyte Cultures via the Wnt/¦Â-Catenin Pathway. +tissue_expression_ns hsa-mir-146b Osteoarthritis 28085114 Hydrostatic Pressure Regulates MicroRNA Expression Levels in Osteoarthritic Chondrocyte Cultures via the Wnt/¦Â-Catenin Pathway. +tissue_expression_ns hsa-mir-27a Osteoarthritis 28085114 Hydrostatic Pressure Regulates MicroRNA Expression Levels in Osteoarthritic Chondrocyte Cultures via the Wnt/¦Â-Catenin Pathway. +tissue_expression_ns hsa-mir-27b Osteoarthritis 28085114 Hydrostatic Pressure Regulates MicroRNA Expression Levels in Osteoarthritic Chondrocyte Cultures via the Wnt/¦Â-Catenin Pathway. +tissue_expression_ns hsa-mir-365 Osteoarthritis 28085114 Hydrostatic Pressure Regulates MicroRNA Expression Levels in Osteoarthritic Chondrocyte Cultures via the Wnt/¦Â-Catenin Pathway. +tissue_expression_ns hsa-mir-2278 "Carcinoma, Renal Cell" 28099931 A new semisynthetic cardenolide analog 3¦Â-2-(1-amantadine)- 1-on-ethylamine-digitoxigenin (AMANTADIG) affects G2/M cell cycle arrest and miRNA expression profiles and enhances proapoptotic survivin-2B expression in renal cell carcinoma cell lines. +tissue_expression_ns hsa-mir-670 "Carcinoma, Renal Cell" 28099931 A new semisynthetic cardenolide analog 3¦Â-2-(1-amantadine)- 1-on-ethylamine-digitoxigenin (AMANTADIG) affects G2/M cell cycle arrest and miRNA expression profiles and enhances proapoptotic survivin-2B expression in renal cell carcinoma cell lines. +tissue_expression_ns hsa-mir-10b Breast Neoplasms 28101798 "miR-10b, miR-26a, miR-146a And miR-153 Expression in Triple Negative Vs Non Triple Negative Breast Cancer: Potential Biomarkers." +tissue_expression_ns hsa-mir-146a Breast Neoplasms 28101798 "miR-10b, miR-26a, miR-146a And miR-153 Expression in Triple Negative Vs Non Triple Negative Breast Cancer: Potential Biomarkers." +tissue_expression_ns hsa-mir-153 Breast Neoplasms 28101798 "miR-10b, miR-26a, miR-146a And miR-153 Expression in Triple Negative Vs Non Triple Negative Breast Cancer: Potential Biomarkers." +tissue_expression_ns hsa-mir-26a Breast Neoplasms 28101798 "miR-10b, miR-26a, miR-146a And miR-153 Expression in Triple Negative Vs Non Triple Negative Breast Cancer: Potential Biomarkers." +tissue_expression_ns hsa-mir-17 Leukemia 28105201 "Comparison of microRNA expression profiles in K562-cells-derived microvesicles and parental cells, and analysis of their roles in leukemia." +tissue_expression_ns hsa-mir-638 "Squamous Cell Carcinoma, Esophageal" 28108314 MiRNA-638 promotes autophagy and malignant phenotypes of cancer cells via directly suppressing DACT3. +tissue_expression_ns hsa-mir-141 "Adenocarcinoma, Sebaceous" 28119291 miRNA-200c and miRNA-141 as potential prognostic biomarkers and regulators of epithelial-mesenchymal transition in eyelid sebaceous gland carcinoma. +tissue_expression_ns hsa-mir-200c "Adenocarcinoma, Sebaceous" 28119291 miRNA-200c and miRNA-141 as potential prognostic biomarkers and regulators of epithelial-mesenchymal transition in eyelid sebaceous gland carcinoma. +tissue_expression_ns hsa-mir-223 Penis Carcinoma 28122331 Integrative miRNA and mRNA analysis in penile carcinomas reveals markers and pathways with potential clinical impact. +tissue_expression_ns hsa-mir-224 Penis Carcinoma 28122331 Integrative miRNA and mRNA analysis in penile carcinomas reveals markers and pathways with potential clinical impact. +tissue_expression_ns hsa-mir-31 Penis Carcinoma 28122331 Integrative miRNA and mRNA analysis in penile carcinomas reveals markers and pathways with potential clinical impact. +tissue_expression_ns hsa-mir-16 Endometrial Neoplasms 28129244 Aberrant MicroRNA Expression in Patients With Endometrial Cancer. +tissue_expression_ns hsa-mir-106b Chronic Kidney Disease 28148896 "Investigated the safety of intra-renal arterial transfusion of autologous CD34+ cells and time courses of creatinine levels, endothelial dysfunction biomarkers and micro-RNAs in chronic kidney disease patients-phase I clinical trial." +tissue_expression_ns hsa-mir-19a Chronic Kidney Disease 28148896 "Investigated the safety of intra-renal arterial transfusion of autologous CD34+ cells and time courses of creatinine levels, endothelial dysfunction biomarkers and micro-RNAs in chronic kidney disease patients-phase I clinical trial." +tissue_expression_ns hsa-mir-20a Chronic Kidney Disease 28148896 "Investigated the safety of intra-renal arterial transfusion of autologous CD34+ cells and time courses of creatinine levels, endothelial dysfunction biomarkers and micro-RNAs in chronic kidney disease patients-phase I clinical trial." +tissue_expression_ns hsa-mir-26b Chronic Kidney Disease 28148896 "Investigated the safety of intra-renal arterial transfusion of autologous CD34+ cells and time courses of creatinine levels, endothelial dysfunction biomarkers and micro-RNAs in chronic kidney disease patients-phase I clinical trial." +tissue_expression_ns hsa-mir-374a Chronic Kidney Disease 28148896 "Investigated the safety of intra-renal arterial transfusion of autologous CD34+ cells and time courses of creatinine levels, endothelial dysfunction biomarkers and micro-RNAs in chronic kidney disease patients-phase I clinical trial." +tissue_expression_ns hsa-mir-122 "Carcinoma, Renal Cell, Clear-Cell" 28184927 "miR-122 and miR-34a, respectively, may regulate their expression in this cancer" +tissue_expression_ns hsa-mir-34a "Carcinoma, Renal Cell, Clear-Cell" 28184927 Downregulation of OCLN and GAS1 in clear cell renal cell carcinoma. +tissue_expression_ns hsa-mir-21 Pancreatic Neoplasms 28186267 "We also examined miRNA expression [microRNA-21 (miR-21) and microRNA-31 (miR-31)] and epigenetic alterations, including CpG island methylator phenotype (CIMP), potentially associated with the identified miRNAs" +tissue_expression_ns hsa-mir-31 Pancreatic Neoplasms 28186267 "We also examined miRNA expression [microRNA-21 (miR-21) and microRNA-31 (miR-31)] and epigenetic alterations, including CpG island methylator phenotype (CIMP), potentially associated with the identified miRNAs" +tissue_expression_ns hsa-mir-155 Asthma 28199728 Altered miR-155 Expression in Allergic Asthmatic Airways. +tissue_expression_ns hsa-mir-21 Colorectal Carcinoma 28207045 Remodelling of microRNAs in colorectal cancer by hypoxia alters metabolism profiles and 5-fluorouracil resistance. +tissue_expression_ns hsa-mir-210 Colorectal Carcinoma 28207045 Remodelling of microRNAs in colorectal cancer by hypoxia alters metabolism profiles and 5-fluorouracil resistance. +tissue_expression_ns hsa-mir-30d Colorectal Carcinoma 28207045 Remodelling of microRNAs in colorectal cancer by hypoxia alters metabolism profiles and 5-fluorouracil resistance. +tissue_expression_ns hsa-mir-19a Osteosarcoma 28214202 Elevated expression of microRNA-19a predicts a poor prognosis in patients with osteosarcoma. +tissue_expression_ns hsa-let-7a Cutaneous Melanoma 28218741 Identification of microRNAs associated with invasive and aggressive phenotype in cutaneous melanoma by next-generation sequencing. +tissue_expression_ns hsa-let-7b Cutaneous Melanoma 28218741 Identification of microRNAs associated with invasive and aggressive phenotype in cutaneous melanoma by next-generation sequencing. +tissue_expression_ns hsa-mir-182 Cutaneous Melanoma 28218741 Identification of microRNAs associated with invasive and aggressive phenotype in cutaneous melanoma by next-generation sequencing. +tissue_expression_ns hsa-mir-199b Cutaneous Melanoma 28218741 Identification of microRNAs associated with invasive and aggressive phenotype in cutaneous melanoma by next-generation sequencing. +tissue_expression_ns hsa-mir-205 Cutaneous Melanoma 28218741 Identification of microRNAs associated with invasive and aggressive phenotype in cutaneous melanoma by next-generation sequencing. +tissue_expression_ns hsa-mir-21 Cutaneous Melanoma 28218741 Identification of microRNAs associated with invasive and aggressive phenotype in cutaneous melanoma by next-generation sequencing. +tissue_expression_ns hsa-mir-423 Cutaneous Melanoma 28218741 Identification of microRNAs associated with invasive and aggressive phenotype in cutaneous melanoma by next-generation sequencing. +tissue_expression_ns hsa-mir-424 Cutaneous Melanoma 28218741 Identification of microRNAs associated with invasive and aggressive phenotype in cutaneous melanoma by next-generation sequencing. +tissue_expression_ns hsa-mir-26a "Carcinoma, Hepatocellular" 28218742 "MiRNA expression profiles reveal the involvement of miR-26a, miR-548l and miR-34a in hepatocellular carcinoma progression through regulation of ST3GAL5." +tissue_expression_ns hsa-mir-34a "Carcinoma, Hepatocellular" 28218742 "MiRNA expression profiles reveal the involvement of miR-26a, miR-548l and miR-34a in hepatocellular carcinoma progression through regulation of ST3GAL5." +tissue_expression_ns hsa-mir-548l "Carcinoma, Hepatocellular" 28218742 "MiRNA expression profiles reveal the involvement of miR-26a, miR-548l and miR-34a in hepatocellular carcinoma progression through regulation of ST3GAL5." +tissue_expression_ns hsa-mir-17 Neoplasms [unspecific] 28222938 The role of miR-17-92 cluster in the expression of tumor suppressor genes in unrestricted somatic stem cells. +tissue_expression_ns hsa-mir-18a Neoplasms [unspecific] 28222938 The role of miR-17-92 cluster in the expression of tumor suppressor genes in unrestricted somatic stem cells. +tissue_expression_ns hsa-mir-19a Neoplasms [unspecific] 28222938 The role of miR-17-92 cluster in the expression of tumor suppressor genes in unrestricted somatic stem cells. +tissue_expression_ns hsa-mir-19b Neoplasms [unspecific] 28222938 The role of miR-17-92 cluster in the expression of tumor suppressor genes in unrestricted somatic stem cells. +tissue_expression_ns hsa-mir-20a Neoplasms [unspecific] 28222938 The role of miR-17-92 cluster in the expression of tumor suppressor genes in unrestricted somatic stem cells. +tissue_expression_ns hsa-mir-92a Neoplasms [unspecific] 28222938 The role of miR-17-92 cluster in the expression of tumor suppressor genes in unrestricted somatic stem cells. +tissue_expression_ns hsa-mir-155 Atherosclerosis 28234622 "CagA-positive and CagA-negative Helicobacter pylori strains differentially affect the expression of micro RNAs 21, 92a, 155 and 663 in human umbilical vein endothelial cells." +tissue_expression_ns hsa-mir-21 Atherosclerosis 28234622 "CagA-positive and CagA-negative Helicobacter pylori strains differentially affect the expression of micro RNAs 21, 92a, 155 and 663 in human umbilical vein endothelial cells." +tissue_expression_ns hsa-mir-663 Atherosclerosis 28234622 "CagA-positive and CagA-negative Helicobacter pylori strains differentially affect the expression of micro RNAs 21, 92a, 155 and 663 in human umbilical vein endothelial cells." +tissue_expression_ns hsa-mir-92a Atherosclerosis 28234622 "CagA-positive and CagA-negative Helicobacter pylori strains differentially affect the expression of micro RNAs 21, 92a, 155 and 663 in human umbilical vein endothelial cells." +tissue_expression_ns hsa-mir-127 Prostate Neoplasms 28239051 MicroRNA expression profiling in canine prostate cancer. +tissue_expression_ns hsa-mir-203 Endomyocardial Fibrosis 28272698 Effect of miR-203 expression on myocardial fibrosis. +tissue_expression_ns hsa-mir-122 "Carcinoma, Hepatocellular" 28272709 Expression of microRNA-122 and microRNA-22 in HBV-related liver cancer and the correlation with clinical features. +tissue_expression_ns hsa-mir-22 "Carcinoma, Hepatocellular" 28272709 Expression of microRNA-122 and microRNA-22 in HBV-related liver cancer and the correlation with clinical features. +tissue_expression_ns hsa-mir-106b Osteosarcoma 28272712 The expression and function of miRNA-106 in pediatric osteosarcoma. +tissue_expression_ns hsa-mir-542 "Squamous Cell Carcinoma, Oral" 28275798 Expression and correlation of survivin and hsa-miR-542-3p in patients with oral squamous cell carcinoma. +tissue_expression_ns hsa-mir-10b Colorectal Carcinoma 28289479 Colorectal adenoma and carcinoma specific miRNA profiles in biopsy and their expression in plasma specimens. +tissue_expression_ns hsa-mir-183 Colorectal Carcinoma 28289479 Colorectal adenoma and carcinoma specific miRNA profiles in biopsy and their expression in plasma specimens. +tissue_expression_ns hsa-let-7a Pituitary Neoplasms 28300776 Evolution of Fish Let-7 MicroRNAs and Their Expression Correlated to Growth Development in Blunt Snout Bream. +tissue_expression_ns hsa-let-7b Pituitary Neoplasms 28300776 Evolution of Fish Let-7 MicroRNAs and Their Expression Correlated to Growth Development in Blunt Snout Bream. +tissue_expression_ns hsa-let-7c Pituitary Neoplasms 28300776 Evolution of Fish Let-7 MicroRNAs and Their Expression Correlated to Growth Development in Blunt Snout Bream. +tissue_expression_ns hsa-let-7d Pituitary Neoplasms 28300776 Evolution of Fish Let-7 MicroRNAs and Their Expression Correlated to Growth Development in Blunt Snout Bream. +tissue_expression_ns hsa-let-7e Pituitary Neoplasms 28300776 Evolution of Fish Let-7 MicroRNAs and Their Expression Correlated to Growth Development in Blunt Snout Bream. +tissue_expression_ns hsa-let-7f Pituitary Neoplasms 28300776 Evolution of Fish Let-7 MicroRNAs and Their Expression Correlated to Growth Development in Blunt Snout Bream. +tissue_expression_ns hsa-let-7g Pituitary Neoplasms 28300776 Evolution of Fish Let-7 MicroRNAs and Their Expression Correlated to Growth Development in Blunt Snout Bream. +tissue_expression_ns hsa-let-7i Pituitary Neoplasms 28300776 Evolution of Fish Let-7 MicroRNAs and Their Expression Correlated to Growth Development in Blunt Snout Bream. +tissue_expression_ns hsa-mir-150 Human Papilloma Virus Infection 28302562 Dysregulated expression of microRNA-150 in human papillomavirus-induced lesions of K14-HPV16 transgenic mice. +tissue_expression_ns hsa-mir-181a Pituitary Adenoma 28315020 Novel Biomarkers for Non-functioning Invasive Pituitary Adenomas were Identified by Using Analysis of microRNAs Expression Profile. +tissue_expression_ns hsa-mir-181b Pituitary Adenoma 28315020 Novel Biomarkers for Non-functioning Invasive Pituitary Adenomas were Identified by Using Analysis of microRNAs Expression Profile. +tissue_expression_ns hsa-mir-181d Pituitary Adenoma 28315020 Novel Biomarkers for Non-functioning Invasive Pituitary Adenomas were Identified by Using Analysis of microRNAs Expression Profile. +tissue_expression_ns hsa-mir-191 Pituitary Adenoma 28315020 Novel Biomarkers for Non-functioning Invasive Pituitary Adenomas were Identified by Using Analysis of microRNAs Expression Profile. +tissue_expression_ns hsa-mir-3676 Pituitary Adenoma 28315020 Novel Biomarkers for Non-functioning Invasive Pituitary Adenomas were Identified by Using Analysis of microRNAs Expression Profile. +tissue_expression_ns hsa-mir-383 Pituitary Adenoma 28315020 Novel Biomarkers for Non-functioning Invasive Pituitary Adenomas were Identified by Using Analysis of microRNAs Expression Profile. +tissue_expression_ns hsa-mir-598 Pituitary Adenoma 28315020 Novel Biomarkers for Non-functioning Invasive Pituitary Adenomas were Identified by Using Analysis of microRNAs Expression Profile. +tissue_expression_ns hsa-mir-146a Sjogren Syndrome 28339495 MicroRNA expression profiles identify disease-specific alterations in systemic lupus erythematosus and primary Sj?gren's syndrome. +tissue_expression_ns hsa-mir-146a Systemic Lupus Erythematosus 28339495 MicroRNA expression profiles identify disease-specific alterations in systemic lupus erythematosus and primary Sj?gren's syndrome. +tissue_expression_ns hsa-mir-148a Sjogren Syndrome 28339495 MicroRNA expression profiles identify disease-specific alterations in systemic lupus erythematosus and primary Sj?gren's syndrome. +tissue_expression_ns hsa-mir-148a Systemic Lupus Erythematosus 28339495 MicroRNA expression profiles identify disease-specific alterations in systemic lupus erythematosus and primary Sj?gren's syndrome. +tissue_expression_ns hsa-mir-150 Sjogren Syndrome 28339495 MicroRNA expression profiles identify disease-specific alterations in systemic lupus erythematosus and primary Sj?gren's syndrome. +tissue_expression_ns hsa-mir-150 Systemic Lupus Erythematosus 28339495 MicroRNA expression profiles identify disease-specific alterations in systemic lupus erythematosus and primary Sj?gren's syndrome. +tissue_expression_ns hsa-mir-152 Sjogren Syndrome 28339495 MicroRNA expression profiles identify disease-specific alterations in systemic lupus erythematosus and primary Sj?gren's syndrome. +tissue_expression_ns hsa-mir-152 Systemic Lupus Erythematosus 28339495 MicroRNA expression profiles identify disease-specific alterations in systemic lupus erythematosus and primary Sj?gren's syndrome. +tissue_expression_ns hsa-mir-155 Sjogren Syndrome 28339495 MicroRNA expression profiles identify disease-specific alterations in systemic lupus erythematosus and primary Sj?gren's syndrome. +tissue_expression_ns hsa-mir-155 Systemic Lupus Erythematosus 28339495 MicroRNA expression profiles identify disease-specific alterations in systemic lupus erythematosus and primary Sj?gren's syndrome. +tissue_expression_ns hsa-mir-16 Sjogren Syndrome 28339495 MicroRNA expression profiles identify disease-specific alterations in systemic lupus erythematosus and primary Sj?gren's syndrome. +tissue_expression_ns hsa-mir-16 Systemic Lupus Erythematosus 28339495 MicroRNA expression profiles identify disease-specific alterations in systemic lupus erythematosus and primary Sj?gren's syndrome. +tissue_expression_ns hsa-mir-21 Sjogren Syndrome 28339495 MicroRNA expression profiles identify disease-specific alterations in systemic lupus erythematosus and primary Sj?gren's syndrome. +tissue_expression_ns hsa-mir-21 Systemic Lupus Erythematosus 28339495 MicroRNA expression profiles identify disease-specific alterations in systemic lupus erythematosus and primary Sj?gren's syndrome. +tissue_expression_ns hsa-mir-223 Sjogren Syndrome 28339495 MicroRNA expression profiles identify disease-specific alterations in systemic lupus erythematosus and primary Sj?gren's syndrome. +tissue_expression_ns hsa-mir-223 Systemic Lupus Erythematosus 28339495 MicroRNA expression profiles identify disease-specific alterations in systemic lupus erythematosus and primary Sj?gren's syndrome. +tissue_expression_ns hsa-mir-224 Sjogren Syndrome 28339495 MicroRNA expression profiles identify disease-specific alterations in systemic lupus erythematosus and primary Sj?gren's syndrome. +tissue_expression_ns hsa-mir-224 Systemic Lupus Erythematosus 28339495 MicroRNA expression profiles identify disease-specific alterations in systemic lupus erythematosus and primary Sj?gren's syndrome. +tissue_expression_ns hsa-mir-326 Sjogren Syndrome 28339495 MicroRNA expression profiles identify disease-specific alterations in systemic lupus erythematosus and primary Sj?gren's syndrome. +tissue_expression_ns hsa-mir-326 Systemic Lupus Erythematosus 28339495 MicroRNA expression profiles identify disease-specific alterations in systemic lupus erythematosus and primary Sj?gren's syndrome. +tissue_expression_ns hsa-mir-342 Sjogren Syndrome 28339495 MicroRNA expression profiles identify disease-specific alterations in systemic lupus erythematosus and primary Sj?gren's syndrome. +tissue_expression_ns hsa-mir-342 Systemic Lupus Erythematosus 28339495 MicroRNA expression profiles identify disease-specific alterations in systemic lupus erythematosus and primary Sj?gren's syndrome. +tissue_expression_ns hsa-mir-149 "Adenocarcinoma, Lung" 28345454 Genome-wide profiling of micro-RNA expression in gefitinib-resistant human lung adenocarcinoma using microarray for the identification of miR-149-5p modulation. +tissue_expression_ns hsa-mir-155 "Squamous Cell Carcinoma, Head and Neck" 28347920 MiR-200b and miR-155 as predictive biomarkers for the efficacy of chemoradiation in locally advanced head and neck squamous cell carcinoma. +tissue_expression_ns hsa-mir-200b "Squamous Cell Carcinoma, Head and Neck" 28347920 MiR-200b and miR-155 as predictive biomarkers for the efficacy of chemoradiation in locally advanced head and neck squamous cell carcinoma. +tissue_expression_ns hsa-mir-107 Meningioma 28349893 "Expression of miRNA-21, miRNA-107, miRNA-137 and miRNA-29b in meningioma." +tissue_expression_ns hsa-mir-137 Meningioma 28349893 "Expression of miRNA-21, miRNA-107, miRNA-137 and miRNA-29b in meningioma." +tissue_expression_ns hsa-mir-21 Meningioma 28349893 "Expression of miRNA-21, miRNA-107, miRNA-137 and miRNA-29b in meningioma." +tissue_expression_ns hsa-mir-29b Meningioma 28349893 "Expression of miRNA-21, miRNA-107, miRNA-137 and miRNA-29b in meningioma." +tissue_expression_ns hsa-let-7a Salivary Gland Neoplasms 28377929 "Expression, Mutation, and Amplification Status of EGFR and Its Correlation with Five miRNAs in Salivary Gland Tumours." +tissue_expression_ns hsa-mir-133b Salivary Gland Neoplasms 28377929 "Expression, Mutation, and Amplification Status of EGFR and Its Correlation with Five miRNAs in Salivary Gland Tumours." +tissue_expression_ns hsa-mir-140 Salivary Gland Neoplasms 28377929 "Expression, Mutation, and Amplification Status of EGFR and Its Correlation with Five miRNAs in Salivary Gland Tumours." +tissue_expression_ns hsa-mir-99b Salivary Gland Neoplasms 28377929 "Expression, Mutation, and Amplification Status of EGFR and Its Correlation with Five miRNAs in Salivary Gland Tumours." +tissue_expression_ns hsa-mir-516 Gestational Trophoblastic Disease 28381180 "Follow-up of gestational trophoblastic disease/neoplasia via quantification of circulating nucleic acids of placental origin using C19MC microRNAs, hypermethylated RASSF1A, and SRY sequences." +tissue_expression_ns hsa-mir-517 Gestational Trophoblastic Disease 28381180 "Follow-up of gestational trophoblastic disease/neoplasia via quantification of circulating nucleic acids of placental origin using C19MC microRNAs, hypermethylated RASSF1A, and SRY sequences." +tissue_expression_ns hsa-mir-518b Gestational Trophoblastic Disease 28381180 "Follow-up of gestational trophoblastic disease/neoplasia via quantification of circulating nucleic acids of placental origin using C19MC microRNAs, hypermethylated RASSF1A, and SRY sequences." +tissue_expression_ns hsa-mir-520a Gestational Trophoblastic Disease 28381180 "Follow-up of gestational trophoblastic disease/neoplasia via quantification of circulating nucleic acids of placental origin using C19MC microRNAs, hypermethylated RASSF1A, and SRY sequences." +tissue_expression_ns hsa-mir-520h Gestational Trophoblastic Disease 28381180 "Follow-up of gestational trophoblastic disease/neoplasia via quantification of circulating nucleic acids of placental origin using C19MC microRNAs, hypermethylated RASSF1A, and SRY sequences." +tissue_expression_ns hsa-mir-525 Gestational Trophoblastic Disease 28381180 "Follow-up of gestational trophoblastic disease/neoplasia via quantification of circulating nucleic acids of placental origin using C19MC microRNAs, hypermethylated RASSF1A, and SRY sequences." +tissue_expression_ns hsa-mir-526a Gestational Trophoblastic Disease 28381180 "Follow-up of gestational trophoblastic disease/neoplasia via quantification of circulating nucleic acids of placental origin using C19MC microRNAs, hypermethylated RASSF1A, and SRY sequences." +tissue_expression_ns hsa-mir-370 Obesity 28386478 Changes in the MicroRNA Profile Observed in the Subcutaneous Adipose Tissue of Obese Patients after Laparoscopic Adjustable Gastric Banding. +tissue_expression_ns hsa-mir-1179 "Carcinoma, Thyroid, Papillary" 28393181 different miRNA expression profiles are associated with different histological types of PTC and different risks of recurrence +tissue_expression_ns hsa-mir-140 "Carcinoma, Thyroid, Papillary" 28393181 different miRNA expression profiles are associated with different histological types of PTC and different risks of recurrence +tissue_expression_ns hsa-mir-144 "Carcinoma, Thyroid, Papillary" 28393181 different miRNA expression profiles are associated with different histological types of PTC and different risks of recurrence +tissue_expression_ns hsa-mir-146b "Carcinoma, Thyroid, Papillary" 28393181 different miRNA expression profiles are associated with different histological types of PTC and different risks of recurrence +tissue_expression_ns hsa-mir-204 "Carcinoma, Thyroid, Papillary" 28393181 different miRNA expression profiles are associated with different histological types of PTC and different risks of recurrence +tissue_expression_ns hsa-mir-21 "Carcinoma, Thyroid, Papillary" 28393181 different miRNA expression profiles are associated with different histological types of PTC and different risks of recurrence +tissue_expression_ns hsa-mir-221 "Carcinoma, Thyroid, Papillary" 28393181 different miRNA expression profiles are associated with different histological types of PTC and different risks of recurrence +tissue_expression_ns hsa-mir-222 "Carcinoma, Thyroid, Papillary" 28393181 different miRNA expression profiles are associated with different histological types of PTC and different risks of recurrence +tissue_expression_ns hsa-mir-486 "Carcinoma, Thyroid, Papillary" 28393181 different miRNA expression profiles are associated with different histological types of PTC and different risks of recurrence +tissue_expression_ns hsa-mir-7 "Carcinoma, Thyroid, Papillary" 28393181 different miRNA expression profiles are associated with different histological types of PTC and different risks of recurrence +tissue_expression_ns hsa-mir-200b Gastrointestinal Neoplasms 28402940 Prognostic role of microRNAs in human gastrointestinal cancer: A systematic review and meta-analysis. +tissue_expression_ns hsa-mir-200c Gastrointestinal Neoplasms 28402940 Prognostic role of microRNAs in human gastrointestinal cancer: A systematic review and meta-analysis. +tissue_expression_ns hsa-mir-203 "Carcinoma, Rectal" 28403349 "Analysis of gene expression EGFR and KRAS, microRNA-21 and microRNA-203 in patients with colon and rectal cancer and correlation with clinical outcome and prognostic factors." +tissue_expression_ns hsa-mir-21 "Carcinoma, Rectal" 28403349 "Analysis of gene expression EGFR and KRAS, microRNA-21 and microRNA-203 in patients with colon and rectal cancer and correlation with clinical outcome and prognostic factors." +tissue_expression_ns hsa-mir-10a Atherosclerosis 28403739 "Hydrogen Peroxide and Lipopolysaccharide Differentially Affect the Expression of MicroRNAs 10a, 33a, 21, 221 in Endothelial Cells Before and After Coculture With Monocytes." +tissue_expression_ns hsa-mir-21 Atherosclerosis 28403739 "Hydrogen Peroxide and Lipopolysaccharide Differentially Affect the Expression of MicroRNAs 10a, 33a, 21, 221 in Endothelial Cells Before and After Coculture With Monocytes." +tissue_expression_ns hsa-mir-221 Atherosclerosis 28403739 "Hydrogen Peroxide and Lipopolysaccharide Differentially Affect the Expression of MicroRNAs 10a, 33a, 21, 221 in Endothelial Cells Before and After Coculture With Monocytes." +tissue_expression_ns hsa-mir-33a Atherosclerosis 28403739 "Hydrogen Peroxide and Lipopolysaccharide Differentially Affect the Expression of MicroRNAs 10a, 33a, 21, 221 in Endothelial Cells Before and After Coculture With Monocytes." +tissue_expression_ns hsa-mir-150 Burns 28404517 Dysregulation of microRNA biogenesis in the small intestine after ethanol and burn injury. +tissue_expression_ns hsa-let-7d Kidney Diseases [unspecific] 28414804 Cyclosporine A alters expression of renal microRNAs: New insights into calcineurin inhibitor nephrotoxicity. +tissue_expression_ns hsa-mir-130 Kidney Diseases [unspecific] 28414804 Cyclosporine A alters expression of renal microRNAs: New insights into calcineurin inhibitor nephrotoxicity. +tissue_expression_ns hsa-mir-186 Kidney Diseases [unspecific] 28414804 Cyclosporine A alters expression of renal microRNAs: New insights into calcineurin inhibitor nephrotoxicity. +tissue_expression_ns hsa-mir-192 Kidney Diseases [unspecific] 28414804 Cyclosporine A alters expression of renal microRNAs: New insights into calcineurin inhibitor nephrotoxicity. +tissue_expression_ns hsa-mir-200 Kidney Diseases [unspecific] 28414804 Cyclosporine A alters expression of renal microRNAs: New insights into calcineurin inhibitor nephrotoxicity. +tissue_expression_ns hsa-mir-21 Kidney Diseases [unspecific] 28414804 Cyclosporine A alters expression of renal microRNAs: New insights into calcineurin inhibitor nephrotoxicity. +tissue_expression_ns hsa-mir-29 Kidney Diseases [unspecific] 28414804 Cyclosporine A alters expression of renal microRNAs: New insights into calcineurin inhibitor nephrotoxicity. +tissue_expression_ns hsa-mir-30 Kidney Diseases [unspecific] 28414804 Cyclosporine A alters expression of renal microRNAs: New insights into calcineurin inhibitor nephrotoxicity. +tissue_expression_ns hsa-mir-709 Kidney Diseases [unspecific] 28414804 Cyclosporine A alters expression of renal microRNAs: New insights into calcineurin inhibitor nephrotoxicity. +tissue_expression_ns hsa-let-7a Ovarian Neoplasms 28423547 Genomic imbalances are involved in miR-30c and let-7a deregulation in ovarian tumors: implications for HMGA2 expression. +tissue_expression_ns hsa-mir-30c Ovarian Neoplasms 28423547 Genomic imbalances are involved in miR-30c and let-7a deregulation in ovarian tumors: implications for HMGA2 expression. +tissue_expression_ns hsa-mir-20a Toxoplasma gondii Infection 28424428 Global miRNA expression profiling of domestic cat livers following acute Toxoplasma gondii infection. +tissue_expression_ns hsa-mir-132 "Carcinoma, Hepatocellular" 28430373 A five-miRNA expression signature predicts survival in hepatocellular carcinoma. +tissue_expression_ns hsa-mir-1468 "Carcinoma, Hepatocellular" 28430373 A five-miRNA expression signature predicts survival in hepatocellular carcinoma. +tissue_expression_ns hsa-mir-212 "Carcinoma, Hepatocellular" 28430373 A five-miRNA expression signature predicts survival in hepatocellular carcinoma. +tissue_expression_ns hsa-mir-301a "Carcinoma, Hepatocellular" 28430373 A five-miRNA expression signature predicts survival in hepatocellular carcinoma. +tissue_expression_ns hsa-mir-489 "Carcinoma, Hepatocellular" 28430373 A five-miRNA expression signature predicts survival in hepatocellular carcinoma. +tissue_expression_ns hsa-let-7a "Carcinoma, Hepatocellular" 28440732 Expression of microRNA let-7a positively correlates with hepatitis B virus replication in hepatocellular carcinoma tissues. +tissue_expression_ns hsa-mir-150 Myeloma 28458781 MicroRNA expression patterns and target prediction in multiple myeloma development and malignancy. +tissue_expression_ns hsa-mir-21 Infection [unspecific] 28472924 Identification of differentially expressed Atlantic salmon miRNAs responding to salmonid alphavirus (SAV) infection. +tissue_expression_ns hsa-mir-452 "Adenocarcinoma, Lung" 28488527 Clinical value of miR-452-5p expression in lung adenocarcinoma: A retrospective quantitative real-time polymerase chain reaction study and verification based on The Cancer Genome Atlas and Gene Expression Omnibus databases. +tissue_expression_ns hsa-mir-10a "Squamous Cell Carcinoma, Head and Neck" 28495058 miRNA profiling of primary lung and head and neck squamous cell carcinomas: Addressing a diagnostic dilemma. +tissue_expression_ns hsa-mir-10b "Squamous Cell Carcinoma, Head and Neck" 28495058 miRNA profiling of primary lung and head and neck squamous cell carcinomas: Addressing a diagnostic dilemma. +tissue_expression_ns hsa-mir-34a "Squamous Cell Carcinoma, Head and Neck" 28495058 miRNA profiling of primary lung and head and neck squamous cell carcinomas: Addressing a diagnostic dilemma. +tissue_expression_ns hsa-mir-140 Thymoma 28517980 "Among the seven significant miRNAs, six (mir-140, mir-450b, mir-542, mir-639, mir-3613 and mir-3913¨C1) were positively associated with OS, while the remaining one (mir-1976) was negatively correlated" +tissue_expression_ns hsa-mir-1976 Thymoma 28517980 "Among the seven significant miRNAs, six (mir-140, mir-450b, mir-542, mir-639, mir-3613 and mir-3913¨C1) were positively associated with OS, while the remaining one (mir-1976) was negatively correlated" +tissue_expression_ns hsa-mir-3613 Thymoma 28517980 "Among the seven significant miRNAs, six (mir-140, mir-450b, mir-542, mir-639, mir-3613 and mir-3913¨C1) were positively associated with OS, while the remaining one (mir-1976) was negatively correlated" +tissue_expression_ns hsa-mir-3913 Thymoma 28517980 "Among the seven significant miRNAs, six (mir-140, mir-450b, mir-542, mir-639, mir-3613 and mir-3913¨C1) were positively associated with OS, while the remaining one (mir-1976) was negatively correlated" +tissue_expression_ns hsa-mir-450b Thymoma 28517980 "Among the seven significant miRNAs, six (mir-140, mir-450b, mir-542, mir-639, mir-3613 and mir-3913¨C1) were positively associated with OS, while the remaining one (mir-1976) was negatively correlated" +tissue_expression_ns hsa-mir-542 Thymoma 28517980 "Among the seven significant miRNAs, six (mir-140, mir-450b, mir-542, mir-639, mir-3613 and mir-3913¨C1) were positively associated with OS, while the remaining one (mir-1976) was negatively correlated" +tissue_expression_ns hsa-mir-639 Thymoma 28517980 "Among the seven significant miRNAs, six (mir-140, mir-450b, mir-542, mir-639, mir-3613 and mir-3913¨C1) were positively associated with OS, while the remaining one (mir-1976) was negatively correlated" +tissue_expression_ns hsa-let-7b "Carcinoma, Lung, Non-Small-Cell" 28534369 "The relationship between miR-17-5p, miR-92a, and let-7b expression with non-small cell lung cancer targeted drug resistance." +tissue_expression_ns hsa-mir-17 "Carcinoma, Lung, Non-Small-Cell" 28534369 "The relationship between miR-17-5p, miR-92a, and let-7b expression with non-small cell lung cancer targeted drug resistance." +tissue_expression_ns hsa-mir-92a "Carcinoma, Lung, Non-Small-Cell" 28534369 "The relationship between miR-17-5p, miR-92a, and let-7b expression with non-small cell lung cancer targeted drug resistance." +tissue_expression_ns hsa-mir-126 Neoplasms [unspecific] 28536479 Circulating microRNA-214 and -126 as potential biomarkers for canine neoplastic disease. +tissue_expression_ns hsa-mir-214 Neoplasms [unspecific] 28536479 Circulating microRNA-214 and -126 as potential biomarkers for canine neoplastic disease. +tissue_expression_ns hsa-mir-15a "Carcinoma, Lung, Non-Small-Cell" 28537679 MiR-15a expression analysis in non-small cell lung cancer A549 cells under local hypoxia microenvironment. +tissue_expression_ns hsa-mir-217 "Adenocarcinoma, Pancreatic Ductal" 28539816 hsa-miR-96 and hsa-miR-217 Expression Down-Regulates with Increasing Dysplasia in Pancreatic Intraepithelial Neoplasias and Intraductal Papillary Mucinous Neoplasms. +tissue_expression_ns hsa-mir-96 "Adenocarcinoma, Pancreatic Ductal" 28539816 hsa-miR-96 and hsa-miR-217 Expression Down-Regulates with Increasing Dysplasia in Pancreatic Intraepithelial Neoplasias and Intraductal Papillary Mucinous Neoplasms. +tissue_expression_ns hsa-mir-29b Parkinson Disease 28540642 Plasma and White Blood Cells Show Different miRNA Expression Profiles in Parkinson's Disease. +tissue_expression_ns hsa-mir-30a Parkinson Disease 28540642 Plasma and White Blood Cells Show Different miRNA Expression Profiles in Parkinson's Disease. +tissue_expression_ns hsa-mir-21 Glioma 28547591 MicroRNA-21 expression in the prognosis of low-grade gliomas: data from the cancer genome atlas (TCGA) project. +tissue_expression_ns hsa-mir-200b Pancreatic Neoplasms 28548126 MicroRNA dysregulation in the tumor microenvironment influences the phenotype of pancreatic cancer. +tissue_expression_ns hsa-mir-200c Pancreatic Neoplasms 28548126 MicroRNA dysregulation in the tumor microenvironment influences the phenotype of pancreatic cancer. +tissue_expression_ns hsa-mir-21 Pancreatic Neoplasms 28548126 MicroRNA dysregulation in the tumor microenvironment influences the phenotype of pancreatic cancer. +tissue_expression_ns hsa-mir-210 Pancreatic Neoplasms 28548126 MicroRNA dysregulation in the tumor microenvironment influences the phenotype of pancreatic cancer. +tissue_expression_ns hsa-mir-106a "Carcinoma, Colon" 28571588 Expression profiling indicating low selenium-sensitive microRNA levels linked to cell cycle and cell stress response pathways in the CaCo-2 cell line. +tissue_expression_ns hsa-mir-200c "Carcinoma, Colon" 28571588 Expression profiling indicating low selenium-sensitive microRNA levels linked to cell cycle and cell stress response pathways in the CaCo-2 cell line. +tissue_expression_ns hsa-mir-205 "Carcinoma, Colon" 28571588 Expression profiling indicating low selenium-sensitive microRNA levels linked to cell cycle and cell stress response pathways in the CaCo-2 cell line. +tissue_expression_ns hsa-mir-302d "Carcinoma, Colon" 28571588 Expression profiling indicating low selenium-sensitive microRNA levels linked to cell cycle and cell stress response pathways in the CaCo-2 cell line. +tissue_expression_ns hsa-mir-373 "Carcinoma, Colon" 28571588 Expression profiling indicating low selenium-sensitive microRNA levels linked to cell cycle and cell stress response pathways in the CaCo-2 cell line. +tissue_expression_ns hsa-mir-4454 "Carcinoma, Colon" 28571588 Expression profiling indicating low selenium-sensitive microRNA levels linked to cell cycle and cell stress response pathways in the CaCo-2 cell line. +tissue_expression_ns hsa-mir-483 "Carcinoma, Colon" 28571588 Expression profiling indicating low selenium-sensitive microRNA levels linked to cell cycle and cell stress response pathways in the CaCo-2 cell line. +tissue_expression_ns hsa-mir-512 "Carcinoma, Colon" 28571588 Expression profiling indicating low selenium-sensitive microRNA levels linked to cell cycle and cell stress response pathways in the CaCo-2 cell line. +tissue_expression_ns hsa-mir-93 "Carcinoma, Colon" 28571588 Expression profiling indicating low selenium-sensitive microRNA levels linked to cell cycle and cell stress response pathways in the CaCo-2 cell line. +tissue_expression_ns hsa-mir-99b "Carcinoma, Colon" 28571588 Expression profiling indicating low selenium-sensitive microRNA levels linked to cell cycle and cell stress response pathways in the CaCo-2 cell line. +tissue_expression_ns hsa-mir-1178 "Carcinoma, Pancreatic" 28592083 Correlation between miR-1178 expression and clinicopathological significance in human pancreatic cancer. +tissue_expression_ns hsa-mir-146b "Carcinoma, Thyroid, Papillary" 28599426 Dynamic monitoring of circulating microRNAs as a predictive biomarker for the diagnosis and recurrence of papillary thyroid carcinoma. +tissue_expression_ns hsa-mir-221 "Carcinoma, Thyroid, Papillary" 28599426 Dynamic monitoring of circulating microRNAs as a predictive biomarker for the diagnosis and recurrence of papillary thyroid carcinoma. +tissue_expression_ns hsa-mir-183 "Carcinoma, Tounge" 28616749 miR-183 and miR-21 expression as biomarkers of progression and survival in tongue carcinoma patients. +tissue_expression_ns hsa-mir-21 "Carcinoma, Tounge" 28616749 miR-183 and miR-21 expression as biomarkers of progression and survival in tongue carcinoma patients. +tissue_expression_ns hsa-mir-145 "Carcinoma, Prostate" 28617988 MiR-145 detection in urinary extracellular vesicles increase diagnostic efficiency of prostate cancer based on hydrostatic filtration dialysis method. +tissue_expression_ns hsa-mir-7 "Adenocarcinoma, Lung" 28618418 Prognostic Significance of microRNA-7 and its Roles in the Regulation of Cisplatin Resistance in Lung Adenocarcinoma. +tissue_expression_ns hsa-mir-375 Colorectal Carcinoma 28618945 "The expression profiling of serum miR-92a, miR-375, and miR-760 in colorectal cancer: An Egyptian study." +tissue_expression_ns hsa-mir-760 Colorectal Carcinoma 28618945 "The expression profiling of serum miR-92a, miR-375, and miR-760 in colorectal cancer: An Egyptian study." +tissue_expression_ns hsa-mir-92a Colorectal Carcinoma 28618945 "The expression profiling of serum miR-92a, miR-375, and miR-760 in colorectal cancer: An Egyptian study." +tissue_expression_ns hsa-mir-127 Prostate Neoplasms 28621736 A Panel of MicroRNAs as Diagnostic Biomarkers for the Identification of Prostate Cancer. +tissue_expression_ns hsa-mir-21 Gastric Neoplasms 28628924 Chrysin Alters microRNAs Expression Levels in Gastric Cancer Cells: Possible Molecular Mechanism. +tissue_expression_ns hsa-mir-221 Gastric Neoplasms 28628924 Chrysin Alters microRNAs Expression Levels in Gastric Cancer Cells: Possible Molecular Mechanism. +tissue_expression_ns hsa-mir-34a Gastric Neoplasms 28628924 Chrysin Alters microRNAs Expression Levels in Gastric Cancer Cells: Possible Molecular Mechanism. +tissue_expression_ns hsa-let-7a "Carcinoma, Thyroid" 28655518 Effects of long non-coding RNA H19 and microRNA let7a expression on thyroid cancer prognosis. +tissue_expression_ns hsa-mir-133b Glioma 28675056 MicroRNA-133b expression associates with clinicopathological features and prognosis in glioma. +tissue_expression_ns hsa-mir-29a Acquired Immunodeficiency Syndrome 28692540 Unique microRNA expression in the colonic mucosa during chronic HIV-1 infection. +tissue_expression_ns hsa-let-7a "Carcinoma, Renal Cell, Clear-Cell" 28694731 Detection of let-7 miRNAs in urine supernatant as potential diagnostic approach in non-metastatic clear-cell renal cell carcinoma. +tissue_expression_ns hsa-let-7b "Carcinoma, Renal Cell, Clear-Cell" 28694731 Detection of let-7 miRNAs in urine supernatant as potential diagnostic approach in non-metastatic clear-cell renal cell carcinoma. +tissue_expression_ns hsa-let-7d "Carcinoma, Renal Cell, Clear-Cell" 28694731 Detection of let-7 miRNAs in urine supernatant as potential diagnostic approach in non-metastatic clear-cell renal cell carcinoma. +tissue_expression_ns hsa-let-7e "Carcinoma, Renal Cell, Clear-Cell" 28694731 Detection of let-7 miRNAs in urine supernatant as potential diagnostic approach in non-metastatic clear-cell renal cell carcinoma. +tissue_expression_ns hsa-let-7g "Carcinoma, Renal Cell, Clear-Cell" 28694731 Detection of let-7 miRNAs in urine supernatant as potential diagnostic approach in non-metastatic clear-cell renal cell carcinoma. +tissue_expression_ns hsa-mir-126 "Carcinoma, Colon" 28714375 "The association of miR-126-3p, miR-126-5p and miR-664-3p expression profiles with outcomes of patients with metastatic colorectal cancer treated with bevacizumab." +tissue_expression_ns hsa-mir-664 "Carcinoma, Colon" 28714375 "The association of miR-126-3p, miR-126-5p and miR-664-3p expression profiles with outcomes of patients with metastatic colorectal cancer treated with bevacizumab." +tissue_expression_ns hsa-mir-146a Down Syndrome 28720071 Developmental Expression and Dysregulation of miR-146a and miR-155 in Down's Syndrome and Mouse Models of Down's Syndrome and Alzheimer's Disease. +tissue_expression_ns hsa-mir-155 Down Syndrome 28720071 Developmental Expression and Dysregulation of miR-146a and miR-155 in Down's Syndrome and Mouse Models of Down's Syndrome and Alzheimer's Disease. +tissue_expression_ns hsa-mir-204 "Carcinoma, Hepatocellular" 28746200 Promising significance of the association of miR-204-5p expression with clinicopathological features of hepatocellular carcinoma +tissue_expression_ns hsa-mir-130b Penis Carcinoma 28751665 "hsa-miR-31, hsa-miR-34a and hsa-miR-130b, were significantly associated with over-represented pathways in cancer" +tissue_expression_ns hsa-mir-31 Penis Carcinoma 28751665 "hsa-miR-31, hsa-miR-34a and hsa-miR-130b, were significantly associated with over-represented pathways in cancer" +tissue_expression_ns hsa-mir-34a Penis Carcinoma 28751665 "hsa-miR-31, hsa-miR-34a and hsa-miR-130b, were significantly associated with over-represented pathways in cancer" +tissue_expression_ns hsa-mir-29b Heart Failure 28765595 Integration of miRNA and mRNA expression profiles reveals microRNA-regulated networks during muscle wasting in cardiac cachexia. +tissue_expression_ns hsa-mir-145 Irritable Bowel Syndrome 28774781 "In all studied IBS samples disturbances in expression of cytokines IL-6, IL-10 and TNF-¦Á as well as miR-145, miR-148-5p and miR-592 were observed" +tissue_expression_ns hsa-mir-148 Irritable Bowel Syndrome 28774781 "In all studied IBS samples disturbances in expression of cytokines IL-6, IL-10 and TNF-¦Á as well as miR-145, miR-148-5p and miR-592 were observed" +tissue_expression_ns hsa-mir-592 Irritable Bowel Syndrome 28774781 "In all studied IBS samples disturbances in expression of cytokines IL-6, IL-10 and TNF-¦Á as well as miR-145, miR-148-5p and miR-592 were observed" +tissue_expression_ns hsa-mir-129 Sertoli Cell-Only Syndrome 28779347 "Among the highest differentially expressed miRNAs only seven, hsa-miR-34b, hsa-miR-34b*, hsa-miR-34c-5p, hsa-miR-449a, hsa-miR-449b*, hsa-miR-517b, and hsa-miR-129-3p, were shared by the three histopathological conditions and were strongly downregulated compared to the normal group " +tissue_expression_ns hsa-mir-34b Sertoli Cell-Only Syndrome 28779347 "Among the highest differentially expressed miRNAs only seven, hsa-miR-34b, hsa-miR-34b*, hsa-miR-34c-5p, hsa-miR-449a, hsa-miR-449b*, hsa-miR-517b, and hsa-miR-129-3p, were shared by the three histopathological conditions and were strongly downregulated compared to the normal group " +tissue_expression_ns hsa-mir-34c Sertoli Cell-Only Syndrome 28779347 "Among the highest differentially expressed miRNAs only seven, hsa-miR-34b, hsa-miR-34b*, hsa-miR-34c-5p, hsa-miR-449a, hsa-miR-449b*, hsa-miR-517b, and hsa-miR-129-3p, were shared by the three histopathological conditions and were strongly downregulated compared to the normal group " +tissue_expression_ns hsa-mir-449a Sertoli Cell-Only Syndrome 28779347 "Among the highest differentially expressed miRNAs only seven, hsa-miR-34b, hsa-miR-34b*, hsa-miR-34c-5p, hsa-miR-449a, hsa-miR-449b*, hsa-miR-517b, and hsa-miR-129-3p, were shared by the three histopathological conditions and were strongly downregulated compared to the normal group " +tissue_expression_ns hsa-mir-449b Sertoli Cell-Only Syndrome 28779347 "Among the highest differentially expressed miRNAs only seven, hsa-miR-34b, hsa-miR-34b*, hsa-miR-34c-5p, hsa-miR-449a, hsa-miR-449b*, hsa-miR-517b, and hsa-miR-129-3p, were shared by the three histopathological conditions and were strongly downregulated compared to the normal group " +tissue_expression_ns hsa-mir-517b Sertoli Cell-Only Syndrome 28779347 "Among the highest differentially expressed miRNAs only seven, hsa-miR-34b, hsa-miR-34b*, hsa-miR-34c-5p, hsa-miR-449a, hsa-miR-449b*, hsa-miR-517b, and hsa-miR-129-3p, were shared by the three histopathological conditions and were strongly downregulated compared to the normal group " +tissue_expression_ns hsa-mir-21 "Carcinoma, Lung, Non-Small-Cell" 28799568 Association of long non-coding RNA H19 and microRNA-21 expression with the biological features and prognosis of non-small cell lung cancer. +tissue_expression_ns hsa-mir-21 Cardiovascular Diseases [unspecific] 28802862 MicroRNA-21: Expression in oligodendrocytes and correlation with low myelin mRNAs in depression and alcoholism. +tissue_expression_ns hsa-mir-223 Mastitis 28831974 Expression profiles of miRNAs from bovine mammary glands in response to Streptococcus agalactiae-induced mastitis. +tissue_expression_ns hsa-mir-375 "Carcinoma, Thyroid, Medullary" 28861609 MiR-375 and YAP1 expression profiling in medullary thyroid carcinoma and their correlation with clinical-pathological features and outcome. +tissue_expression_ns hsa-mir-10b Neoplasms [unspecific] 28864233 MicroRNA-10b and the clinical outcomes of various cancers: A systematic review and meta-analysis. +tissue_expression_ns hsa-mir-125a "Carcinoma, Hepatocellular" 28878257 Molecular mechanisms governing microRNA-125a expression in human hepatocellular carcinoma cells. +tissue_expression_ns hsa-mir-155 Breast Neoplasms 28882698 Prognostic value of microRNA-9 and microRNA-155 expression in triple-negative breast cancer +tissue_expression_ns hsa-mir-9 Breast Neoplasms 28882698 Prognostic value of microRNA-9 and microRNA-155 expression in triple-negative breast cancer +tissue_expression_ns hsa-mir-34c Infertility 28886318 New insights into the expression profile of MicroRNA-34c and P53 in infertile men spermatozoa and testicular tissue. +tissue_expression_ns hsa-mir-145 Pancreatic Adenocarcinoma 28903323 The pancreatic tumor microenvironment drives changes in miRNA expression that promote cytokine production and inhibit migration by the tumor associated stroma. +tissue_expression_ns hsa-mir-205 Pancreatic Adenocarcinoma 28903323 The pancreatic tumor microenvironment drives changes in miRNA expression that promote cytokine production and inhibit migration by the tumor associated stroma. +tissue_expression_ns hsa-mir-424 Skin Hemangioma 28928430 The expression and function of miR-424 in infantile skin hemangioma and its mechanism. +tissue_expression_ns hsa-mir-205 "Carcinoma, Nasopharyngeal" 28931826 MicroRNA profiling study reveals miR-150 in association with metastasis in nasopharyngeal carcinoma +tissue_expression_ns hsa-mir-34a "Carcinoma, Hepatocellular" 28950684 Deregulation of miR-34a and Its Chaperon Hsp70 in Hepatitis C virus-Induced Liver Cirrhosis and Hepatocellular Carcinoma Patients +tissue_expression_ns hsa-mir-200c "Squamous Cell Carcinoma, Sinonasal" 28960576 Deregulation of selected microRNAs in sinonasal carcinoma: Value of miR-21 as prognostic biomarker in sinonasal squamous cell carcinoma. +tissue_expression_ns hsa-mir-21 "Squamous Cell Carcinoma, Sinonasal" 28960576 Deregulation of selected microRNAs in sinonasal carcinoma: Value of miR-21 as prognostic biomarker in sinonasal squamous cell carcinoma. +tissue_expression_ns hsa-mir-125b "Carcinoma, Hepatocellular" 28984009 MicroRNA-125b expression and intrahepatic metastasis are predictors for early recurrence after hepatocellular carcinoma resection. +tissue_expression_ns hsa-mir-181a African Swine Fever 29041944 Differential expression of porcine microRNAs in African swine fever virus infected pigs: a proof-of-concept study. +tissue_expression_ns hsa-mir-21 Pancreatic Adenocarcinoma 29069873 These molecules are often aberrantly expressed and exhibit oncogenic and/or tumor suppressor functions in PDAC +tissue_expression_ns hsa-mir-143 Breast Neoplasms 29073169 Expression and function of the miR-143/145 cluster in vitro and in vivo in human breast cancer. +tissue_expression_ns hsa-mir-145 Breast Neoplasms 29073169 Expression and function of the miR-143/145 cluster in vitro and in vivo in human breast cancer. +tissue_expression_ns hsa-let-7a "Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal" 29082244 "Expression Levels and Clinical Significance of miR-21-5p, miR-let-7a, and miR-34c-5p in Laryngeal Squamous Cell Carcinoma." +tissue_expression_ns hsa-mir-21 "Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal" 29082244 "Expression Levels and Clinical Significance of miR-21-5p, miR-let-7a, and miR-34c-5p in Laryngeal Squamous Cell Carcinoma." +tissue_expression_ns hsa-mir-34c "Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal" 29082244 "Expression Levels and Clinical Significance of miR-21-5p, miR-let-7a, and miR-34c-5p in Laryngeal Squamous Cell Carcinoma." +tissue_expression_ns hsa-mir-1 "Adenocarcinoma, Pancreatic Ductal" 29085459 Abnormal alterations of miR-1 and miR-214 are associated with clinicopathological features and prognosis of patients with PDAC. +tissue_expression_ns hsa-mir-214 "Adenocarcinoma, Pancreatic Ductal" 29085459 Abnormal alterations of miR-1 and miR-214 are associated with clinicopathological features and prognosis of patients with PDAC. +tissue_expression_ns hsa-mir-203 "Carcinoma, Lung, Non-Small-Cell" 29088807 Identification of microRNA differentially expressed in three subtypes of non-small cell lung cancer and in silico functional analysis. +tissue_expression_ns hsa-mir-205 "Carcinoma, Lung, Non-Small-Cell" 29088807 Identification of microRNA differentially expressed in three subtypes of non-small cell lung cancer and in silico functional analysis. +tissue_expression_ns hsa-mir-375 "Carcinoma, Lung, Non-Small-Cell" 29088807 Identification of microRNA differentially expressed in three subtypes of non-small cell lung cancer and in silico functional analysis. +tissue_expression_ns hsa-mir-302a "Carcinoma, Mucoepidermoid" 29095552 miRNA expression profile of mucoepidermoid carcinoma. +tissue_expression_ns hsa-mir-10b Breast Neoplasms 29113216 miR-10b is a useful marker for predicting metastasis and angiogenesis in ANN breast cancer +tissue_expression_ns hsa-mir-372 "Adenocarcinoma, Gastric" 29135097 Analysis of expression profile of miRNA in stomach adenocarcinoma. +tissue_expression_ns hsa-mir-143 Colon Neoplasms 29152124 "The LASSO regression analysis identified a 16-miRNA signature including miR-143-5p, miR-27a-3p, miR-31-5p, miR-181a-5p, miR-30b-5p, miR-30d-5p, miR-146a-5p, miR-23a-3p, miR-150-5p, miR-210-3p, miR-25-3p, miR-196a-5p, miR-148a-3p, miR-222-3p, miR-30c-5p and miR-223-3p" +tissue_expression_ns hsa-mir-146a Colon Neoplasms 29152124 "The LASSO regression analysis identified a 16-miRNA signature including miR-143-5p, miR-27a-3p, miR-31-5p, miR-181a-5p, miR-30b-5p, miR-30d-5p, miR-146a-5p, miR-23a-3p, miR-150-5p, miR-210-3p, miR-25-3p, miR-196a-5p, miR-148a-3p, miR-222-3p, miR-30c-5p and miR-223-3p" +tissue_expression_ns hsa-mir-148a Colon Neoplasms 29152124 "The LASSO regression analysis identified a 16-miRNA signature including miR-143-5p, miR-27a-3p, miR-31-5p, miR-181a-5p, miR-30b-5p, miR-30d-5p, miR-146a-5p, miR-23a-3p, miR-150-5p, miR-210-3p, miR-25-3p, miR-196a-5p, miR-148a-3p, miR-222-3p, miR-30c-5p and miR-223-3p" +tissue_expression_ns hsa-mir-150 Colon Neoplasms 29152124 "The LASSO regression analysis identified a 16-miRNA signature including miR-143-5p, miR-27a-3p, miR-31-5p, miR-181a-5p, miR-30b-5p, miR-30d-5p, miR-146a-5p, miR-23a-3p, miR-150-5p, miR-210-3p, miR-25-3p, miR-196a-5p, miR-148a-3p, miR-222-3p, miR-30c-5p and miR-223-3p" +tissue_expression_ns hsa-mir-181a Colon Neoplasms 29152124 "The LASSO regression analysis identified a 16-miRNA signature including miR-143-5p, miR-27a-3p, miR-31-5p, miR-181a-5p, miR-30b-5p, miR-30d-5p, miR-146a-5p, miR-23a-3p, miR-150-5p, miR-210-3p, miR-25-3p, miR-196a-5p, miR-148a-3p, miR-222-3p, miR-30c-5p and miR-223-3p" +tissue_expression_ns hsa-mir-196a Colon Neoplasms 29152124 "The LASSO regression analysis identified a 16-miRNA signature including miR-143-5p, miR-27a-3p, miR-31-5p, miR-181a-5p, miR-30b-5p, miR-30d-5p, miR-146a-5p, miR-23a-3p, miR-150-5p, miR-210-3p, miR-25-3p, miR-196a-5p, miR-148a-3p, miR-222-3p, miR-30c-5p and miR-223-3p" +tissue_expression_ns hsa-mir-210 Colon Neoplasms 29152124 "The LASSO regression analysis identified a 16-miRNA signature including miR-143-5p, miR-27a-3p, miR-31-5p, miR-181a-5p, miR-30b-5p, miR-30d-5p, miR-146a-5p, miR-23a-3p, miR-150-5p, miR-210-3p, miR-25-3p, miR-196a-5p, miR-148a-3p, miR-222-3p, miR-30c-5p and miR-223-3p" +tissue_expression_ns hsa-mir-222 Colon Neoplasms 29152124 "The LASSO regression analysis identified a 16-miRNA signature including miR-143-5p, miR-27a-3p, miR-31-5p, miR-181a-5p, miR-30b-5p, miR-30d-5p, miR-146a-5p, miR-23a-3p, miR-150-5p, miR-210-3p, miR-25-3p, miR-196a-5p, miR-148a-3p, miR-222-3p, miR-30c-5p and miR-223-3p" +tissue_expression_ns hsa-mir-223 Colon Neoplasms 29152124 "The LASSO regression analysis identified a 16-miRNA signature including miR-143-5p, miR-27a-3p, miR-31-5p, miR-181a-5p, miR-30b-5p, miR-30d-5p, miR-146a-5p, miR-23a-3p, miR-150-5p, miR-210-3p, miR-25-3p, miR-196a-5p, miR-148a-3p, miR-222-3p, miR-30c-5p and miR-223-3p" +tissue_expression_ns hsa-mir-23a Colon Neoplasms 29152124 "The LASSO regression analysis identified a 16-miRNA signature including miR-143-5p, miR-27a-3p, miR-31-5p, miR-181a-5p, miR-30b-5p, miR-30d-5p, miR-146a-5p, miR-23a-3p, miR-150-5p, miR-210-3p, miR-25-3p, miR-196a-5p, miR-148a-3p, miR-222-3p, miR-30c-5p and miR-223-3p" +tissue_expression_ns hsa-mir-25 Colon Neoplasms 29152124 "The LASSO regression analysis identified a 16-miRNA signature including miR-143-5p, miR-27a-3p, miR-31-5p, miR-181a-5p, miR-30b-5p, miR-30d-5p, miR-146a-5p, miR-23a-3p, miR-150-5p, miR-210-3p, miR-25-3p, miR-196a-5p, miR-148a-3p, miR-222-3p, miR-30c-5p and miR-223-3p" +tissue_expression_ns hsa-mir-27a Colon Neoplasms 29152124 "The LASSO regression analysis identified a 16-miRNA signature including miR-143-5p, miR-27a-3p, miR-31-5p, miR-181a-5p, miR-30b-5p, miR-30d-5p, miR-146a-5p, miR-23a-3p, miR-150-5p, miR-210-3p, miR-25-3p, miR-196a-5p, miR-148a-3p, miR-222-3p, miR-30c-5p and miR-223-3p" +tissue_expression_ns hsa-mir-30b Colon Neoplasms 29152124 "The LASSO regression analysis identified a 16-miRNA signature including miR-143-5p, miR-27a-3p, miR-31-5p, miR-181a-5p, miR-30b-5p, miR-30d-5p, miR-146a-5p, miR-23a-3p, miR-150-5p, miR-210-3p, miR-25-3p, miR-196a-5p, miR-148a-3p, miR-222-3p, miR-30c-5p and miR-223-3p" +tissue_expression_ns hsa-mir-30c Colon Neoplasms 29152124 "The LASSO regression analysis identified a 16-miRNA signature including miR-143-5p, miR-27a-3p, miR-31-5p, miR-181a-5p, miR-30b-5p, miR-30d-5p, miR-146a-5p, miR-23a-3p, miR-150-5p, miR-210-3p, miR-25-3p, miR-196a-5p, miR-148a-3p, miR-222-3p, miR-30c-5p and miR-223-3p" +tissue_expression_ns hsa-mir-30d Colon Neoplasms 29152124 "The LASSO regression analysis identified a 16-miRNA signature including miR-143-5p, miR-27a-3p, miR-31-5p, miR-181a-5p, miR-30b-5p, miR-30d-5p, miR-146a-5p, miR-23a-3p, miR-150-5p, miR-210-3p, miR-25-3p, miR-196a-5p, miR-148a-3p, miR-222-3p, miR-30c-5p and miR-223-3p" +tissue_expression_ns hsa-mir-31 Colon Neoplasms 29152124 "The LASSO regression analysis identified a 16-miRNA signature including miR-143-5p, miR-27a-3p, miR-31-5p, miR-181a-5p, miR-30b-5p, miR-30d-5p, miR-146a-5p, miR-23a-3p, miR-150-5p, miR-210-3p, miR-25-3p, miR-196a-5p, miR-148a-3p, miR-222-3p, miR-30c-5p and miR-223-3p" +tissue_expression_ns hsa-mir-503 Breast Neoplasms 29164842 "miR-503 is expressed in numerous types of tumors such as breast cancer, prostate cancer, lung cancer, colorectal cancer, hepatocellular carcinoma, glioblastoma andseveral others" +tissue_expression_ns hsa-mir-503 "Carcinoma, Hepatocellular" 29164842 "miR-503 is expressed in numerous types of tumors such as breast cancer, prostate cancer, lung cancer, colorectal cancer, hepatocellular carcinoma, glioblastoma andseveral others" +tissue_expression_ns hsa-mir-503 Colorectal Carcinoma 29164842 "miR-503 is expressed in numerous types of tumors such as breast cancer, prostate cancer, lung cancer, colorectal cancer, hepatocellular carcinoma, glioblastoma andseveral others" +tissue_expression_ns hsa-mir-503 Glioblastoma 29164842 "miR-503 is expressed in numerous types of tumors such as breast cancer, prostate cancer, lung cancer, colorectal cancer, hepatocellular carcinoma, glioblastoma andseveral others" +tissue_expression_ns hsa-mir-503 Lung Neoplasms 29164842 "miR-503 is expressed in numerous types of tumors such as breast cancer, prostate cancer, lung cancer, colorectal cancer, hepatocellular carcinoma, glioblastoma andseveral others" +tissue_expression_ns hsa-mir-503 Prostate Neoplasms 29164842 "miR-503 is expressed in numerous types of tumors such as breast cancer, prostate cancer, lung cancer, colorectal cancer, hepatocellular carcinoma, glioblastoma andseveral others" +tissue_expression_ns hsa-mir-106b "Carcinoma, Hepatocellular" 29179453 MicroRNA deregulation in nonalcoholic steatohepatitis-associated liver carcinogenesis +tissue_expression_ns hsa-mir-126 "Carcinoma, Renal Cell, Clear-Cell" 29202733 Expression of micro-RNAs and genes related to angiogenesis in ccRCC and associations with tumor characteristics +tissue_expression_ns hsa-mir-200b "Carcinoma, Renal Cell, Clear-Cell" 29202733 Expression of micro-RNAs and genes related to angiogenesis in ccRCC and associations with tumor characteristics +tissue_expression_ns hsa-let-7a Periodontitis 29226952 "Differential expression of microRNAs let-7a, miR-125b, miR-100, and miR-21 and interaction with NF-kB pathway genes in periodontitis pathogenesis" +tissue_expression_ns hsa-mir-100 Periodontitis 29226952 "Differential expression of microRNAs let-7a, miR-125b, miR-100, and miR-21 and interaction with NF-kB pathway genes in periodontitis pathogenesis" +tissue_expression_ns hsa-mir-125b Periodontitis 29226952 "Differential expression of microRNAs let-7a, miR-125b, miR-100, and miR-21 and interaction with NF-kB pathway genes in periodontitis pathogenesis" +tissue_expression_ns hsa-mir-21 Periodontitis 29226952 "Differential expression of microRNAs let-7a, miR-125b, miR-100, and miR-21 and interaction with NF-kB pathway genes in periodontitis pathogenesis" +tissue_expression_ns hsa-mir-155 "Carcinoma, Hepatocellular" 29291025 "tissue miR-9, miR-21, miR-22, miR-29c, miR-34a, miR-34c, miR-155, miR-199a, miR-200a, miR-203, miR-221 and blood miR-21, miR-148a, miR-192, miR-224 demonstrate significantly prognostic value" +tissue_expression_ns hsa-mir-199a "Carcinoma, Hepatocellular" 29291025 "tissue miR-9, miR-21, miR-22, miR-29c, miR-34a, miR-34c, miR-155, miR-199a, miR-200a, miR-203, miR-221 and blood miR-21, miR-148a, miR-192, miR-224 demonstrate significantly prognostic value" +tissue_expression_ns hsa-mir-200a "Carcinoma, Hepatocellular" 29291025 "tissue miR-9, miR-21, miR-22, miR-29c, miR-34a, miR-34c, miR-155, miR-199a, miR-200a, miR-203, miR-221 and blood miR-21, miR-148a, miR-192, miR-224 demonstrate significantly prognostic value" +tissue_expression_ns hsa-mir-203 "Carcinoma, Hepatocellular" 29291025 "tissue miR-9, miR-21, miR-22, miR-29c, miR-34a, miR-34c, miR-155, miR-199a, miR-200a, miR-203, miR-221 and blood miR-21, miR-148a, miR-192, miR-224 demonstrate significantly prognostic value" +tissue_expression_ns hsa-mir-22 "Carcinoma, Hepatocellular" 29291025 "tissue miR-9, miR-21, miR-22, miR-29c, miR-34a, miR-34c, miR-155, miR-199a, miR-200a, miR-203, miR-221 and blood miR-21, miR-148a, miR-192, miR-224 demonstrate significantly prognostic value" +tissue_expression_ns hsa-mir-221 "Carcinoma, Hepatocellular" 29291025 "tissue miR-9, miR-21, miR-22, miR-29c, miR-34a, miR-34c, miR-155, miR-199a, miR-200a, miR-203, miR-221 and blood miR-21, miR-148a, miR-192, miR-224 demonstrate significantly prognostic value" +tissue_expression_ns hsa-mir-29c "Carcinoma, Hepatocellular" 29291025 "tissue miR-9, miR-21, miR-22, miR-29c, miR-34a, miR-34c, miR-155, miR-199a, miR-200a, miR-203, miR-221 and blood miR-21, miR-148a, miR-192, miR-224 demonstrate significantly prognostic value" +tissue_expression_ns hsa-mir-34a "Carcinoma, Hepatocellular" 29291025 "tissue miR-9, miR-21, miR-22, miR-29c, miR-34a, miR-34c, miR-155, miR-199a, miR-200a, miR-203, miR-221 and blood miR-21, miR-148a, miR-192, miR-224 demonstrate significantly prognostic value" +tissue_expression_ns hsa-mir-34c "Carcinoma, Hepatocellular" 29291025 "tissue miR-9, miR-21, miR-22, miR-29c, miR-34a, miR-34c, miR-155, miR-199a, miR-200a, miR-203, miR-221 and blood miR-21, miR-148a, miR-192, miR-224 demonstrate significantly prognostic value" +tissue_expression_ns hsa-mir-9 "Carcinoma, Hepatocellular" 29291025 "tissue miR-9, miR-21, miR-22, miR-29c, miR-34a, miR-34c, miR-155, miR-199a, miR-200a, miR-203, miR-221 and blood miR-21, miR-148a, miR-192, miR-224 demonstrate significantly prognostic value" +tissue_expression_ns hsa-mir-103a Vulvar Squamous Tumor 29299981 "Expression levels of six microRNAs-hsa-miR-425-5p, hsa-miR-191-5p, hsa-miR-93-5p, hsa-miR-423-5p, hsa-miR-103a-3p, and hsa-miR-16-5p-were analyzed by quantitative reverse transcription polymerase chain reaction in plasma samples" +tissue_expression_ns hsa-mir-16 Vulvar Squamous Tumor 29299981 "Expression levels of six microRNAs-hsa-miR-425-5p, hsa-miR-191-5p, hsa-miR-93-5p, hsa-miR-423-5p, hsa-miR-103a-3p, and hsa-miR-16-5p-were analyzed by quantitative reverse transcription polymerase chain reaction in plasma samples" +tissue_expression_ns hsa-mir-191 Vulvar Squamous Tumor 29299981 "Expression levels of six microRNAs-hsa-miR-425-5p, hsa-miR-191-5p, hsa-miR-93-5p, hsa-miR-423-5p, hsa-miR-103a-3p, and hsa-miR-16-5p-were analyzed by quantitative reverse transcription polymerase chain reaction in plasma samples" +tissue_expression_ns hsa-mir-423 Vulvar Squamous Tumor 29299981 "Expression levels of six microRNAs-hsa-miR-425-5p, hsa-miR-191-5p, hsa-miR-93-5p, hsa-miR-423-5p, hsa-miR-103a-3p, and hsa-miR-16-5p-were analyzed by quantitative reverse transcription polymerase chain reaction in plasma samples" +tissue_expression_ns hsa-mir-425 Vulvar Squamous Tumor 29299981 "Expression levels of six microRNAs-hsa-miR-425-5p, hsa-miR-191-5p, hsa-miR-93-5p, hsa-miR-423-5p, hsa-miR-103a-3p, and hsa-miR-16-5p-were analyzed by quantitative reverse transcription polymerase chain reaction in plasma samples" +tissue_expression_ns hsa-mir-93 Vulvar Squamous Tumor 29299981 "Expression levels of six microRNAs-hsa-miR-425-5p, hsa-miR-191-5p, hsa-miR-93-5p, hsa-miR-423-5p, hsa-miR-103a-3p, and hsa-miR-16-5p-were analyzed by quantitative reverse transcription polymerase chain reaction in plasma samples" +tissue_expression_ns hsa-let-7c Mitral Valve Disease 29315310 "Dysregulation of valvular interstitial cell let-7c, miR-17, miR-20a, and miR-30d in naturally occurring canine myxomatous mitral valve disease" +tissue_expression_ns hsa-mir-17 Mitral Valve Disease 29315310 "Dysregulation of valvular interstitial cell let-7c, miR-17, miR-20a, and miR-30d in naturally occurring canine myxomatous mitral valve disease" +tissue_expression_ns hsa-mir-20a Mitral Valve Disease 29315310 "Dysregulation of valvular interstitial cell let-7c, miR-17, miR-20a, and miR-30d in naturally occurring canine myxomatous mitral valve disease" +tissue_expression_ns hsa-mir-30d Mitral Valve Disease 29315310 "Dysregulation of valvular interstitial cell let-7c, miR-17, miR-20a, and miR-30d in naturally occurring canine myxomatous mitral valve disease" +tissue_expression_ns hsa-mir-186 Acute Peritonitis 29360196 "The data from the current study provide novel evidence of the differential expression of miRNAs in ascites from patients with PCA and SBP, which may offer an additional miRNA-based molecular approach for the differential diagnosis of PCA" +tissue_expression_ns hsa-mir-186 Peritoneal Neoplasms 29360196 "The data from the current study provide novel evidence of the differential expression of miRNAs in ascites from patients with PCA and SBP, which may offer an additional miRNA-based molecular approach for the differential diagnosis of PCA" +tissue_expression_ns hsa-mir-21 Acute Peritonitis 29360196 "The data from the current study provide novel evidence of the differential expression of miRNAs in ascites from patients with PCA and SBP, which may offer an additional miRNA-based molecular approach for the differential diagnosis of PCA" +tissue_expression_ns hsa-mir-21 Peritoneal Neoplasms 29360196 "The data from the current study provide novel evidence of the differential expression of miRNAs in ascites from patients with PCA and SBP, which may offer an additional miRNA-based molecular approach for the differential diagnosis of PCA" +tissue_expression_ns hsa-mir-222 Acute Peritonitis 29360196 "The data from the current study provide novel evidence of the differential expression of miRNAs in ascites from patients with PCA and SBP, which may offer an additional miRNA-based molecular approach for the differential diagnosis of PCA" +tissue_expression_ns hsa-mir-222 Peritoneal Neoplasms 29360196 "The data from the current study provide novel evidence of the differential expression of miRNAs in ascites from patients with PCA and SBP, which may offer an additional miRNA-based molecular approach for the differential diagnosis of PCA" +tissue_expression_ns hsa-mir-223 Acute Peritonitis 29360196 "The data from the current study provide novel evidence of the differential expression of miRNAs in ascites from patients with PCA and SBP, which may offer an additional miRNA-based molecular approach for the differential diagnosis of PCA" +tissue_expression_ns hsa-mir-223 Peritoneal Neoplasms 29360196 "The data from the current study provide novel evidence of the differential expression of miRNAs in ascites from patients with PCA and SBP, which may offer an additional miRNA-based molecular approach for the differential diagnosis of PCA" +tissue_expression_ns hsa-mir-483 Acute Peritonitis 29360196 "The data from the current study provide novel evidence of the differential expression of miRNAs in ascites from patients with PCA and SBP, which may offer an additional miRNA-based molecular approach for the differential diagnosis of PCA" +tissue_expression_ns hsa-mir-483 Peritoneal Neoplasms 29360196 "The data from the current study provide novel evidence of the differential expression of miRNAs in ascites from patients with PCA and SBP, which may offer an additional miRNA-based molecular approach for the differential diagnosis of PCA" +tissue_expression_ns hsa-let-7a Chronic Obstructive Pulmonary Disease 29371906 Profile of epigenetic mechanisms in lung tumors of patients with underlying chronic respiratory conditions +tissue_expression_ns hsa-let-7a Lung Neoplasms 29371906 Profile of epigenetic mechanisms in lung tumors of patients with underlying chronic respiratory conditions +tissue_expression_ns hsa-let-7c Chronic Obstructive Pulmonary Disease 29371906 Profile of epigenetic mechanisms in lung tumors of patients with underlying chronic respiratory conditions +tissue_expression_ns hsa-let-7c Lung Neoplasms 29371906 Profile of epigenetic mechanisms in lung tumors of patients with underlying chronic respiratory conditions +tissue_expression_ns hsa-mir-126 Chronic Obstructive Pulmonary Disease 29371906 Profile of epigenetic mechanisms in lung tumors of patients with underlying chronic respiratory conditions +tissue_expression_ns hsa-mir-126 Lung Neoplasms 29371906 Profile of epigenetic mechanisms in lung tumors of patients with underlying chronic respiratory conditions +tissue_expression_ns hsa-mir-155 Chronic Obstructive Pulmonary Disease 29371906 Profile of epigenetic mechanisms in lung tumors of patients with underlying chronic respiratory conditions +tissue_expression_ns hsa-mir-155 Lung Neoplasms 29371906 Profile of epigenetic mechanisms in lung tumors of patients with underlying chronic respiratory conditions +tissue_expression_ns hsa-mir-200b Chronic Obstructive Pulmonary Disease 29371906 Profile of epigenetic mechanisms in lung tumors of patients with underlying chronic respiratory conditions +tissue_expression_ns hsa-mir-200b Lung Neoplasms 29371906 Profile of epigenetic mechanisms in lung tumors of patients with underlying chronic respiratory conditions +tissue_expression_ns hsa-mir-21 Chronic Obstructive Pulmonary Disease 29371906 Profile of epigenetic mechanisms in lung tumors of patients with underlying chronic respiratory conditions +tissue_expression_ns hsa-mir-21 Lung Neoplasms 29371906 Profile of epigenetic mechanisms in lung tumors of patients with underlying chronic respiratory conditions +tissue_expression_ns hsa-mir-210 Chronic Obstructive Pulmonary Disease 29371906 Profile of epigenetic mechanisms in lung tumors of patients with underlying chronic respiratory conditions +tissue_expression_ns hsa-mir-210 Lung Neoplasms 29371906 Profile of epigenetic mechanisms in lung tumors of patients with underlying chronic respiratory conditions +tissue_expression_ns hsa-mir-30a Chronic Obstructive Pulmonary Disease 29371906 Profile of epigenetic mechanisms in lung tumors of patients with underlying chronic respiratory conditions +tissue_expression_ns hsa-mir-30a Lung Neoplasms 29371906 Profile of epigenetic mechanisms in lung tumors of patients with underlying chronic respiratory conditions +tissue_expression_ns hsa-mir-451 Chronic Obstructive Pulmonary Disease 29371906 Profile of epigenetic mechanisms in lung tumors of patients with underlying chronic respiratory conditions +tissue_expression_ns hsa-mir-451 Lung Neoplasms 29371906 Profile of epigenetic mechanisms in lung tumors of patients with underlying chronic respiratory conditions +tissue_expression_ns hsa-mir-135a Pituitary Adenoma 29374071 "elevant compensatory mechanisms were found through the changes in miR involved in osteoblastogenesis (miR-210-5p, miR-135a-5p, miR-211, miR-23a-3p, miR-204-5p)" +tissue_expression_ns hsa-mir-204 Pituitary Adenoma 29374071 "elevant compensatory mechanisms were found through the changes in miR involved in osteoblastogenesis (miR-210-5p, miR-135a-5p, miR-211, miR-23a-3p, miR-204-5p)" +tissue_expression_ns hsa-mir-210 Pituitary Adenoma 29374071 "elevant compensatory mechanisms were found through the changes in miR involved in osteoblastogenesis (miR-210-5p, miR-135a-5p, miR-211, miR-23a-3p, miR-204-5p)" +tissue_expression_ns hsa-mir-2110 Pituitary Adenoma 29374071 "elevant compensatory mechanisms were found through the changes in miR involved in osteoblastogenesis (miR-210-5p, miR-135a-5p, miR-211, miR-23a-3p, miR-204-5p)" +tissue_expression_ns hsa-mir-23a Pituitary Adenoma 29374071 "elevant compensatory mechanisms were found through the changes in miR involved in osteoblastogenesis (miR-210-5p, miR-135a-5p, miR-211, miR-23a-3p, miR-204-5p)" +tissue_expression_ns hsa-mir-200 "Squamous Cell Carcinoma, Oral" 29375721 Dysregulation of miR-200 family microRNAs and epithelial-mesenchymal transition markers in oral squamous cell carcinoma +tissue_expression_ns hsa-mir-15b Ovarian Disease 29377183 "miR-379, miR-15b, miR-691, miR-872 and miR-1897-5p are potentially useful markers of ovarian toxicity and dysfunction" +tissue_expression_ns hsa-mir-1897 Ovarian Disease 29377183 "miR-379, miR-15b, miR-691, miR-872 and miR-1897-5p are potentially useful markers of ovarian toxicity and dysfunction" +tissue_expression_ns hsa-mir-379 Ovarian Disease 29377183 "miR-379, miR-15b, miR-691, miR-872 and miR-1897-5p are potentially useful markers of ovarian toxicity and dysfunction" +tissue_expression_ns hsa-mir-691 Ovarian Disease 29377183 "miR-379, miR-15b, miR-691, miR-872 and miR-1897-5p are potentially useful markers of ovarian toxicity and dysfunction" +tissue_expression_ns hsa-mir-872 Ovarian Disease 29377183 "miR-379, miR-15b, miR-691, miR-872 and miR-1897-5p are potentially useful markers of ovarian toxicity and dysfunction" +tissue_expression_ns hsa-let-7b Ovarian Neoplasms 29385306 "RT-PCR revealed a significantly increased expression of ovarian miRNAs (let-7b, miR-17-5p miR-181a, and miR-151), which inhibit follicular granulosa cell proliferation" +tissue_expression_ns hsa-mir-151 Ovarian Neoplasms 29385306 "RT-PCR revealed a significantly increased expression of ovarian miRNAs (let-7b, miR-17-5p miR-181a, and miR-151), which inhibit follicular granulosa cell proliferation" +tissue_expression_ns hsa-mir-17 Ovarian Neoplasms 29385306 "RT-PCR revealed a significantly increased expression of ovarian miRNAs (let-7b, miR-17-5p miR-181a, and miR-151), which inhibit follicular granulosa cell proliferation" +tissue_expression_ns hsa-mir-181a Ovarian Neoplasms 29385306 "RT-PCR revealed a significantly increased expression of ovarian miRNAs (let-7b, miR-17-5p miR-181a, and miR-151), which inhibit follicular granulosa cell proliferation" +tissue_expression_ns hsa-mir-10b "Carcinoma, Thyroid, Anaplastic" 29397781 "These results demonstrate that IR deregulates microRNA expression, affecting the double-strand DNA breaks repair efficiency of irradiated thyroid cells, and suggest that miR-10b-5p overexpression may be an innovative approach for anaplastic thyroid cancer therapy by increasing cancer cell radiosensitivity." +tissue_expression_ns hsa-mir-146a Diabetic Peripheral Neuropathy 29398906 "miR-146a is involved in the pathogenesis of DPN, and its expression level is closely related to the inflammatory responses that aggravate sciatic nerve injuries" +tissue_expression_ns hsa-mir-200b "Carcinoma, Renal Cell" 29416756 "miR-126, miR-222 and miR-200b were significantly differentially expressed between the subtypes by in situ hybridization" +tissue_expression_ns hsa-mir-221 "Carcinoma, Renal Cell" 29416756 "miR-126, miR-222 and miR-201b were significantly differentially expressed between the subtypes by in situ hybridization" +tissue_expression_ns hsa-mir-222 "Carcinoma, Renal Cell" 29416756 "miR-126, miR-222 and miR-202b were significantly differentially expressed between the subtypes by in situ hybridization" +tissue_expression_ns hsa-mir-29b "Carcinoma, Breast" 29422258 miR-29b levels constitute a promising biomarker of favorable prognosis for patients with invasive ductal breast carcinoma +tissue_expression_ns hsa-mir-195 Adrenal Cortex Neoplasms 29429354 "Several tissue microRNAs, such as miR-483-5p, miR-503, miR-210, miR-335 and miR-195 were found to be differentially expressed among benign and malignant adrenocortical tumours" +tissue_expression_ns hsa-mir-210 Adrenal Cortex Neoplasms 29429354 "Several tissue microRNAs, such as miR-483-5p, miR-503, miR-210, miR-335 and miR-195 were found to be differentially expressed among benign and malignant adrenocortical tumours" +tissue_expression_ns hsa-mir-335 Adrenal Cortex Neoplasms 29429354 "Several tissue microRNAs, such as miR-483-5p, miR-503, miR-210, miR-335 and miR-195 were found to be differentially expressed among benign and malignant adrenocortical tumours" +tissue_expression_ns hsa-mir-483 Adrenal Cortex Neoplasms 29429354 "Several tissue microRNAs, such as miR-483-5p, miR-503, miR-210, miR-335 and miR-195 were found to be differentially expressed among benign and malignant adrenocortical tumours" +tissue_expression_ns hsa-mir-503 Adrenal Cortex Neoplasms 29429354 "Several tissue microRNAs, such as miR-483-5p, miR-503, miR-210, miR-335 and miR-195 were found to be differentially expressed among benign and malignant adrenocortical tumours" +tissue_expression_ns hsa-mir-222 "Carcinoma, Thyroid, Papillary" 29435194 miRNA dysregulation and the risk of metastasis and invasion in papillary thyroid cancer: a systematic review and meta-analysis +tissue_expression_ns hsa-mir-155 Lung Neoplasms 29437031 Underexpression of miR-486-5p but not Overexpression of miR-156 is Associated with Lung Cancer Stages +tissue_expression_ns hsa-mir-486 Lung Neoplasms 29437031 Underexpression of miR-486-5p but not Overexpression of miR-155 is Associated with Lung Cancer Stages +tissue_expression_ns hsa-mir-126 Parathyroid Carcinoma 29453660 "miR-139, miR-222, miR-30b, miR-517c, and miR-126* were differentially expressed between PCa and PAd." +tissue_expression_ns hsa-mir-139 Parathyroid Carcinoma 29453660 The combined analysis of miR-139 and miR-30b may be used as a potential diagnostic strategy for distinguishing Pca from PAd +tissue_expression_ns hsa-mir-222 Parathyroid Carcinoma 29453660 "miR-139, miR-222, miR-30b, miR-517c, and miR-126* were differentially expressed between PCa and PAd." +tissue_expression_ns hsa-mir-30b Parathyroid Carcinoma 29453660 The combined analysis of miR-139 and miR-31b may be used as a potential diagnostic strategy for distinguishing Pca from PAd +tissue_expression_ns hsa-mir-517c Parathyroid Carcinoma 29453660 "miR-139, miR-222, miR-30b, miR-517c, and miR-126* were differentially expressed between PCa and PAd." +tissue_expression_ns hsa-let-7i "Carcinoma, Nasopharyngeal" 29455649 "miR-142, miR-26a, miR-141 and let-7i have significant prognostic power" +tissue_expression_ns hsa-mir-141 "Carcinoma, Nasopharyngeal" 29455649 "miR-142, miR-26a, miR-141 and let-7i have significant prognostic power" +tissue_expression_ns hsa-mir-142 "Carcinoma, Nasopharyngeal" 29455649 "miR-142, miR-26a, miR-141 and let-7i have significant prognostic power" +tissue_expression_ns hsa-mir-26a "Carcinoma, Nasopharyngeal" 29455649 "miR-142, miR-26a, miR-141 and let-7i have significant prognostic power" +tissue_expression_ns hsa-mir-125b Breast Neoplasms 29483949 Differentially expressed miRNAs provide insights of this uncommon but highly aggressive pathology +tissue_expression_ns hsa-mir-101-1 Multiple Myeloma 29546453 "All these miRNAs were significantly over-expressed in patients vs controls (MIR-16-1, MIR-21, MIR-23A, MIR-28, MIR-101-1, MIR-124-1, MIR-129, MIR-139, MIR-145, MIR-149, MIR-202, MIR-221, MIR-424, MIR-520)" +tissue_expression_ns hsa-mir-124-1 Multiple Myeloma 29546453 "All these miRNAs were significantly over-expressed in patients vs controls (MIR-16-1, MIR-21, MIR-23A, MIR-28, MIR-101-1, MIR-124-1, MIR-129, MIR-139, MIR-145, MIR-149, MIR-202, MIR-221, MIR-424, MIR-520)" +tissue_expression_ns hsa-mir-129 Multiple Myeloma 29546453 "All these miRNAs were significantly over-expressed in patients vs controls (MIR-16-1, MIR-21, MIR-23A, MIR-28, MIR-101-1, MIR-124-1, MIR-129, MIR-139, MIR-145, MIR-149, MIR-202, MIR-221, MIR-424, MIR-520)" +tissue_expression_ns hsa-mir-139 Multiple Myeloma 29546453 "All these miRNAs were significantly over-expressed in patients vs controls (MIR-16-1, MIR-21, MIR-23A, MIR-28, MIR-101-1, MIR-124-1, MIR-129, MIR-139, MIR-145, MIR-149, MIR-202, MIR-221, MIR-424, MIR-520)" +tissue_expression_ns hsa-mir-145 Multiple Myeloma 29546453 "All these miRNAs were significantly over-expressed in patients vs controls (MIR-16-1, MIR-21, MIR-23A, MIR-28, MIR-101-1, MIR-124-1, MIR-129, MIR-139, MIR-145, MIR-149, MIR-202, MIR-221, MIR-424, MIR-520)" +tissue_expression_ns hsa-mir-149 Multiple Myeloma 29546453 "All these miRNAs were significantly over-expressed in patients vs controls (MIR-16-1, MIR-21, MIR-23A, MIR-28, MIR-101-1, MIR-124-1, MIR-129, MIR-139, MIR-145, MIR-149, MIR-202, MIR-221, MIR-424, MIR-520)" +tissue_expression_ns hsa-mir-16 Multiple Myeloma 29546453 "All these miRNAs were significantly over-expressed in patients vs controls (MIR-16-1, MIR-21, MIR-23A, MIR-28, MIR-101-1, MIR-124-1, MIR-129, MIR-139, MIR-145, MIR-149, MIR-202, MIR-221, MIR-424, MIR-520)" +tissue_expression_ns hsa-mir-202 Multiple Myeloma 29546453 "All these miRNAs were significantly over-expressed in patients vs controls (MIR-16-1, MIR-21, MIR-23A, MIR-28, MIR-101-1, MIR-124-1, MIR-129, MIR-139, MIR-145, MIR-149, MIR-202, MIR-221, MIR-424, MIR-520)" +tissue_expression_ns hsa-mir-21 Multiple Myeloma 29546453 "All these miRNAs were significantly over-expressed in patients vs controls (MIR-16-1, MIR-21, MIR-23A, MIR-28, MIR-101-1, MIR-124-1, MIR-129, MIR-139, MIR-145, MIR-149, MIR-202, MIR-221, MIR-424, MIR-520)" +tissue_expression_ns hsa-mir-221 Multiple Myeloma 29546453 "All these miRNAs were significantly over-expressed in patients vs controls (MIR-16-1, MIR-21, MIR-23A, MIR-28, MIR-101-1, MIR-124-1, MIR-129, MIR-139, MIR-145, MIR-149, MIR-202, MIR-221, MIR-424, MIR-520)" +tissue_expression_ns hsa-mir-23a Multiple Myeloma 29546453 "All these miRNAs were significantly over-expressed in patients vs controls (MIR-16-1, MIR-21, MIR-23A, MIR-28, MIR-101-1, MIR-124-1, MIR-129, MIR-139, MIR-145, MIR-149, MIR-202, MIR-221, MIR-424, MIR-520)" +tissue_expression_ns hsa-mir-28 Multiple Myeloma 29546453 "All these miRNAs were significantly over-expressed in patients vs controls (MIR-16-1, MIR-21, MIR-23A, MIR-28, MIR-101-1, MIR-124-1, MIR-129, MIR-139, MIR-145, MIR-149, MIR-202, MIR-221, MIR-424, MIR-520)" +tissue_expression_ns hsa-mir-424 Multiple Myeloma 29546453 "All these miRNAs were significantly over-expressed in patients vs controls (MIR-16-1, MIR-21, MIR-23A, MIR-28, MIR-101-1, MIR-124-1, MIR-129, MIR-139, MIR-145, MIR-149, MIR-202, MIR-221, MIR-424, MIR-520)" +tissue_expression_ns hsa-mir-520 Multiple Myeloma 29546453 "All these miRNAs were significantly over-expressed in patients vs controls (MIR-16-1, MIR-21, MIR-23A, MIR-28, MIR-101-1, MIR-124-1, MIR-129, MIR-139, MIR-145, MIR-149, MIR-202, MIR-221, MIR-424, MIR-520)" +tissue_expression_ns hsa-mir-15a "Carcinoma, Renal Cell" 29549624 MicroRNA-15a expression measured in urine samples as a potential biomarker of renal cell carcinoma. +tissue_expression_ns hsa-mir-191 "Carcinoma, Breast" 29555574 "4 miRNAs (miR-191-5p, miR-214-3p, miR-451a, and miR-489) were validated in a total of 159 patients including a training set" +tissue_expression_ns hsa-mir-214 "Carcinoma, Breast" 29555574 "4 miRNAs (miR-191-5p, miR-214-3p, miR-451a, and miR-489) were validated in a total of 159 patients including a training set" +tissue_expression_ns hsa-mir-451a "Carcinoma, Breast" 29555574 "4 miRNAs (miR-191-5p, miR-214-3p, miR-451a, and miR-489) were validated in a total of 159 patients including a training set" +tissue_expression_ns hsa-mir-489 "Carcinoma, Breast" 29555574 "4 miRNAs (miR-191-5p, miR-214-3p, miR-451a, and miR-489) were validated in a total of 159 patients including a training set" +tissue_expression_ns hsa-mir-1226 "Carcinoma, Breast" 29557813 whereas miR-342 and miR-1226 may be associated with tamoxifen resistance in breast cancer cells +tissue_expression_ns hsa-mir-342 "Carcinoma, Breast" 29557813 whereas miR-342 and miR-1226 may be associated with tamoxifen resistance in breast cancer cells +tissue_expression_ns hsa-mir-21 Colorectal Carcinoma 29564561 "The expression levels of miR-7 and -21 were up-regulated in non-granular type of laterally spreading tumor, UCAT, and SSA/P compared with those in polypoid and FAP tumors" +tissue_expression_ns hsa-mir-7 Colorectal Carcinoma 29564561 "The expression levels of miR-7 and -21 were up-regulated in non-granular type of laterally spreading tumor, UCAT, and SSA/P compared with those in polypoid and FAP tumors" +tissue_expression_ns hsa-mir-142 Uterine Corpus Endometrial Carcinoma 29567372 A six-microRNA signature predicts survival of patients with uterine corpus endometrial carcinoma. +tissue_expression_ns hsa-mir-146a Uterine Corpus Endometrial Carcinoma 29567372 A six-microRNA signature predicts survival of patients with uterine corpus endometrial carcinoma. +tissue_expression_ns hsa-mir-15a Uterine Corpus Endometrial Carcinoma 29567372 A six-microRNA signature predicts survival of patients with uterine corpus endometrial carcinoma. +tissue_expression_ns hsa-mir-1976 Uterine Corpus Endometrial Carcinoma 29567372 A six-microRNA signature predicts survival of patients with uterine corpus endometrial carcinoma. +tissue_expression_ns hsa-mir-3170 Uterine Corpus Endometrial Carcinoma 29567372 A six-microRNA signature predicts survival of patients with uterine corpus endometrial carcinoma. +tissue_expression_ns hsa-mir-135b Colorectal Carcinoma 29633600 "detection on miR-21, miR-135b, miR-31 and miR-20a levels in the tissue might be helpful to illuminate the molecular mechanisms underlying CRC carcinogenesis and serve as tumor-associated biomarkers for diagnosis" +tissue_expression_ns hsa-mir-20a Colorectal Carcinoma 29633600 "detection on miR-21, miR-135b, miR-31 and miR-20a levels in the tissue might be helpful to illuminate the molecular mechanisms underlying CRC carcinogenesis and serve as tumor-associated biomarkers for diagnosis" +tissue_expression_ns hsa-mir-21 Colorectal Carcinoma 29633600 "detection on miR-21, miR-135b, miR-31 and miR-20a levels in the tissue might be helpful to illuminate the molecular mechanisms underlying CRC carcinogenesis and serve as tumor-associated biomarkers for diagnosis" +tissue_expression_ns hsa-mir-31 Colorectal Carcinoma 29633600 "detection on miR-21, miR-135b, miR-31 and miR-20a levels in the tissue might be helpful to illuminate the molecular mechanisms underlying CRC carcinogenesis and serve as tumor-associated biomarkers for diagnosis" +tissue_expression_ns hsa-mir-1 Ischemia-Reperfusion Injury 29642230 "Most commonly reported miRNAs with differential expression between preconditioned and control groups include miR-1, miR-21 and miR-144" +tissue_expression_ns hsa-mir-144 Ischemia-Reperfusion Injury 29642230 "Most commonly reported miRNAs with differential expression between preconditioned and control groups include miR-1, miR-21 and miR-144" +tissue_expression_ns hsa-mir-21 Ischemia-Reperfusion Injury 29642230 "Most commonly reported miRNAs with differential expression between preconditioned and control groups include miR-1, miR-21 and miR-144" +tissue_expression_ns hsa-mir-371a Germ Cell Tumor 29685967 Germ cell tumour subtypes display differential expression of microRNA371a-3p. +tissue_expression_ns hsa-mir-128 Pediatric Ependymoma 29704232 "miR-543, miR-495-3p, miR-299-3p, miR-139-5p and miR-128-3p were identified to have CD44 positively co-regulated potential target oncogenes" +tissue_expression_ns hsa-mir-139 Pediatric Ependymoma 29704232 "miR-543, miR-495-3p, miR-299-3p, miR-139-5p and miR-128-3p were identified to have CD44 positively co-regulated potential target oncogenes" +tissue_expression_ns hsa-mir-299 Pediatric Ependymoma 29704232 "miR-543, miR-495-3p, miR-299-3p, miR-139-5p and miR-128-3p were identified to have CD44 positively co-regulated potential target oncogenes" +tissue_expression_ns hsa-mir-495 Pediatric Ependymoma 29704232 "miR-543, miR-495-3p, miR-299-3p, miR-139-5p and miR-128-3p were identified to have CD44 positively co-regulated potential target oncogenes" +tissue_expression_ns hsa-mir-543 Pediatric Ependymoma 29704232 "miR-543, miR-495-3p, miR-299-3p, miR-139-5p and miR-128-3p were identified to have CD44 positively co-regulated potential target oncogenes" +tissue_expression_ns hsa-mir-327 Parathyroid Carcinoma 29724878 The aberrantly expressed miR-372 partly impairs sensitivity to apoptosis in parathyroid tumor cells. +tissue_expression_ns hsa-mir-429 "Carcinoma, Bladder" 29747777 miR-429 expression in bladder cancer and its correlation with tumor behavior and clinical outcome. +tissue_expression_ns hsa-let-7b Thyroid Neoplasms 29762469 "The expression of miRNAs hsa-let-7f-5p, has-let-7b-5p hsa-miR-146b-5p and hsa-miR-146b-3p was modulated heterogeneously" +tissue_expression_ns hsa-let-7f Thyroid Neoplasms 29762469 "The expression of miRNAs hsa-let-7f-5p, has-let-7b-5p hsa-miR-146b-5p and hsa-miR-146b-3p was modulated heterogeneously" +tissue_expression_ns hsa-mir-146b Thyroid Neoplasms 29762469 "The expression of miRNAs hsa-let-7f-5p, has-let-7b-5p hsa-miR-146b-5p and hsa-miR-146b-3p was modulated heterogeneously" +tissue_expression_ns hsa-mir-493 "Carcinoma, Breast, Triple Negative" 29777630 MicroRNA-493 is a prognostic factor in triple-negative breast cancer. +tissue_expression_ns hsa-mir-34a Leukemia 29780367 Expression of miR-34a in T-Cells Infected by Human T-Lymphotropic Virus 1. +tissue_expression_ns hsa-mir-355 Hearing Disorders 29781875 "Most fluids showed expression of miR-355, miR-509p, miR-515p, miR-3p, miR-873, and miR-616, but also showed significant differences between the fluid types, suggesting that miRNA profiling may be used as a diagnostic tool" +tissue_expression_ns hsa-mir-509 Hearing Disorders 29781875 "Most fluids showed expression of miR-355, miR-509p, miR-515p, miR-3p, miR-873, and miR-616, but also showed significant differences between the fluid types, suggesting that miRNA profiling may be used as a diagnostic tool" +tissue_expression_ns hsa-mir-515 Hearing Disorders 29781875 "Most fluids showed expression of miR-355, miR-509p, miR-515p, miR-3p, miR-873, and miR-616, but also showed significant differences between the fluid types, suggesting that miRNA profiling may be used as a diagnostic tool" +tissue_expression_ns hsa-mir-616 Hearing Disorders 29781875 "Most fluids showed expression of miR-355, miR-509p, miR-515p, miR-3p, miR-873, and miR-616, but also showed significant differences between the fluid types, suggesting that miRNA profiling may be used as a diagnostic tool" +tissue_expression_ns hsa-mir-873 Hearing Disorders 29781875 "Most fluids showed expression of miR-355, miR-509p, miR-515p, miR-3p, miR-873, and miR-616, but also showed significant differences between the fluid types, suggesting that miRNA profiling may be used as a diagnostic tool" +tissue_expression_ns hsa-mir-153 "Carcinoma, Cervical" 29805649 Aberrant expression of miR-153 is associated with the poor prognosis of cervical cancer. +tissue_expression_ns hsa-mir-223 "Carcinoma, Breast" 29805680 Exosome-encapsulated microRNA-223-3p as a minimally invasive biomarker for the early detection of invasive breast cancer. +tissue_expression_ns hsa-let-7c Colon Neoplasms 29844680 "five hub miRNAs were identified to be related to prognosis (hsa-miR-125b-5p, hsa-miR-145-5p, hsa-let-7c-5p, hsa-miR-218-5p and hsa-miR-125b-2-3p)" +tissue_expression_ns hsa-mir-125b Colon Neoplasms 29844680 "five hub miRNAs were identified to be related to prognosis (hsa-miR-125b-5p, hsa-miR-145-5p, hsa-let-7c-5p, hsa-miR-218-5p and hsa-miR-125b-2-3p)" +tissue_expression_ns hsa-mir-145 Colon Neoplasms 29844680 "five hub miRNAs were identified to be related to prognosis (hsa-miR-125b-5p, hsa-miR-145-5p, hsa-let-7c-5p, hsa-miR-218-5p and hsa-miR-125b-2-3p)" +tissue_expression_ns hsa-mir-218 Colon Neoplasms 29844680 "five hub miRNAs were identified to be related to prognosis (hsa-miR-125b-5p, hsa-miR-145-5p, hsa-let-7c-5p, hsa-miR-218-5p and hsa-miR-125b-2-3p)" +tissue_expression_ns hsa-mir-10b Gastric Neoplasms 29848733 "Tumor Expression of miR-10b, miR-21, miR-143 and miR-145 Is Related to Clinicopathological Features of Gastric Cancer in a Central European Population." +tissue_expression_ns hsa-mir-143 Gastric Neoplasms 29848733 "Tumor Expression of miR-10b, miR-21, miR-143 and miR-145 Is Related to Clinicopathological Features of Gastric Cancer in a Central European Population." +tissue_expression_ns hsa-mir-145 Gastric Neoplasms 29848733 "Tumor Expression of miR-10b, miR-21, miR-143 and miR-145 Is Related to Clinicopathological Features of Gastric Cancer in a Central European Population." +tissue_expression_ns hsa-mir-21 Gastric Neoplasms 29848733 "Tumor Expression of miR-10b, miR-21, miR-143 and miR-145 Is Related to Clinicopathological Features of Gastric Cancer in a Central European Population." +tissue_expression_ns hsa-let-7a "Carcinoma, Lung, Non-Small-Cell" 29862540 We found that miR-21 and let-7a were significantly dysregulated in NSCLC patients +tissue_expression_ns hsa-mir-21 "Carcinoma, Lung, Non-Small-Cell" 29862540 We found that miR-21 and let-7a were significantly dysregulated in NSCLC patients +tissue_expression_ns hsa-mir-185 Gastric Neoplasms 29879180 "The Zsummary algorithm identified an activated module (miR-486, miR-451, miR-185, and miR-600) which might serve as diagnostic biomarker of GC" +tissue_expression_ns hsa-mir-451 Gastric Neoplasms 29879180 "The Zsummary algorithm identified an activated module (miR-486, miR-451, miR-185, and miR-600) which might serve as diagnostic biomarker of GC" +tissue_expression_ns hsa-mir-486 Gastric Neoplasms 29879180 "The Zsummary algorithm identified an activated module (miR-486, miR-451, miR-185, and miR-600) which might serve as diagnostic biomarker of GC" +tissue_expression_ns hsa-mir-600 Gastric Neoplasms 29879180 "The Zsummary algorithm identified an activated module (miR-486, miR-451, miR-185, and miR-600) which might serve as diagnostic biomarker of GC" +tissue_expression_ns hsa-mir-146a Hepatoblastoma 29889802 "MicroRNA-17, MicroRNA-19b, MicroRNA-146a, MicroRNA-302d Expressions in Hepatoblastoma and Clinical Importance." +tissue_expression_ns hsa-mir-17 Hepatoblastoma 29889802 "MicroRNA-17, MicroRNA-19b, MicroRNA-146a, MicroRNA-302d Expressions in Hepatoblastoma and Clinical Importance." +tissue_expression_ns hsa-mir-19b Hepatoblastoma 29889802 "MicroRNA-17, MicroRNA-19b, MicroRNA-146a, MicroRNA-302d Expressions in Hepatoblastoma and Clinical Importance." +tissue_expression_ns hsa-mir-302d Hepatoblastoma 29889802 "MicroRNA-17, MicroRNA-19b, MicroRNA-146a, MicroRNA-302d Expressions in Hepatoblastoma and Clinical Importance." +tissue_expression_ns hsa-mir-106b "Carcinoma, Hepatocellular" 29899182 "In further analysis, eight miRNAs, including miR-4270, miR-125b-5p, miR-199a-3p, miR-10a-5p, miR-424-5p, miR-195-5p, miR-106b-5p and miR-3651, were retained" +tissue_expression_ns hsa-mir-10a "Carcinoma, Hepatocellular" 29899182 "In further analysis, eight miRNAs, including miR-4270, miR-125b-5p, miR-199a-3p, miR-10a-5p, miR-424-5p, miR-195-5p, miR-106b-5p and miR-3651, were retained" +tissue_expression_ns hsa-mir-125b "Carcinoma, Hepatocellular" 29899182 "In further analysis, eight miRNAs, including miR-4270, miR-125b-5p, miR-199a-3p, miR-10a-5p, miR-424-5p, miR-195-5p, miR-106b-5p and miR-3651, were retained" +tissue_expression_ns hsa-mir-195 "Carcinoma, Hepatocellular" 29899182 "In further analysis, eight miRNAs, including miR-4270, miR-125b-5p, miR-199a-3p, miR-10a-5p, miR-424-5p, miR-195-5p, miR-106b-5p and miR-3651, were retained" +tissue_expression_ns hsa-mir-199a "Carcinoma, Hepatocellular" 29899182 "In further analysis, eight miRNAs, including miR-4270, miR-125b-5p, miR-199a-3p, miR-10a-5p, miR-424-5p, miR-195-5p, miR-106b-5p and miR-3651, were retained" +tissue_expression_ns hsa-mir-3651 "Carcinoma, Hepatocellular" 29899182 "In further analysis, eight miRNAs, including miR-4270, miR-125b-5p, miR-199a-3p, miR-10a-5p, miR-424-5p, miR-195-5p, miR-106b-5p and miR-3651, were retained" +tissue_expression_ns hsa-mir-424 "Carcinoma, Hepatocellular" 29899182 "In further analysis, eight miRNAs, including miR-4270, miR-125b-5p, miR-199a-3p, miR-10a-5p, miR-424-5p, miR-195-5p, miR-106b-5p and miR-3651, were retained" +tissue_expression_ns hsa-mir-4270 "Carcinoma, Hepatocellular" 29899182 "In further analysis, eight miRNAs, including miR-4270, miR-125b-5p, miR-199a-3p, miR-10a-5p, miR-424-5p, miR-195-5p, miR-106b-5p and miR-3651, were retained" +tissue_expression_ns hsa-mir-155 "Squamous Cell Carcinoma, Tongue" 29909906 "MicroRNA-155, -185 and -193b as biomarkers in human papillomavirus positive and negative tonsillar and base of tongue squamous cell carcinoma." +tissue_expression_ns hsa-mir-185 "Squamous Cell Carcinoma, Tongue" 29909906 "MicroRNA-155, -185 and -193b as biomarkers in human papillomavirus positive and negative tonsillar and base of tongue squamous cell carcinoma." +tissue_expression_ns hsa-mir-193b "Squamous Cell Carcinoma, Tongue" 29909906 "MicroRNA-155, -185 and -193b as biomarkers in human papillomavirus positive and negative tonsillar and base of tongue squamous cell carcinoma." +tissue_expression_ns hsa-mir-146 "Squamous Cell Carcinoma, Oral" 29914173 altered expression of miR-146a and miR-191 was also observed in regenerative areas after OSCC resection +tissue_expression_ns hsa-mir-191 "Squamous Cell Carcinoma, Oral" 29914173 altered expression of miR-146a and miR-191 was also observed in regenerative areas after OSCC resection +tissue_expression_ns hsa-mir-1252 "Squamous Cell Carcinoma, Head and Neck" 29927717 "The differential expression profiles of these reporter biomolecules were cross-validated by independent RNA-Seq and miRNA-Seq datasets, and risk discrimination performance of the reporter biomolecules, BLNK, CCL2, E4F1, FOSL1, ISG15, MMP9, MYCN, MYH11, miR-1252, miR-29b, miR-29c, miR-3610, miR-431, and miR-523, was also evaluated" +tissue_expression_ns hsa-mir-29b "Squamous Cell Carcinoma, Head and Neck" 29927717 "The differential expression profiles of these reporter biomolecules were cross-validated by independent RNA-Seq and miRNA-Seq datasets, and risk discrimination performance of the reporter biomolecules, BLNK, CCL2, E4F1, FOSL1, ISG15, MMP9, MYCN, MYH11, miR-1252, miR-29b, miR-29c, miR-3610, miR-431, and miR-523, was also evaluated" +tissue_expression_ns hsa-mir-29c "Squamous Cell Carcinoma, Head and Neck" 29927717 "The differential expression profiles of these reporter biomolecules were cross-validated by independent RNA-Seq and miRNA-Seq datasets, and risk discrimination performance of the reporter biomolecules, BLNK, CCL2, E4F1, FOSL1, ISG15, MMP9, MYCN, MYH11, miR-1252, miR-29b, miR-29c, miR-3610, miR-431, and miR-523, was also evaluated" +tissue_expression_ns hsa-mir-3610 "Squamous Cell Carcinoma, Head and Neck" 29927717 "The differential expression profiles of these reporter biomolecules were cross-validated by independent RNA-Seq and miRNA-Seq datasets, and risk discrimination performance of the reporter biomolecules, BLNK, CCL2, E4F1, FOSL1, ISG15, MMP9, MYCN, MYH11, miR-1252, miR-29b, miR-29c, miR-3610, miR-431, and miR-523, was also evaluated" +tissue_expression_ns hsa-mir-431 "Squamous Cell Carcinoma, Head and Neck" 29927717 "The differential expression profiles of these reporter biomolecules were cross-validated by independent RNA-Seq and miRNA-Seq datasets, and risk discrimination performance of the reporter biomolecules, BLNK, CCL2, E4F1, FOSL1, ISG15, MMP9, MYCN, MYH11, miR-1252, miR-29b, miR-29c, miR-3610, miR-431, and miR-523, was also evaluated" +tissue_expression_ns hsa-mir-523 "Squamous Cell Carcinoma, Head and Neck" 29927717 "The differential expression profiles of these reporter biomolecules were cross-validated by independent RNA-Seq and miRNA-Seq datasets, and risk discrimination performance of the reporter biomolecules, BLNK, CCL2, E4F1, FOSL1, ISG15, MMP9, MYCN, MYH11, miR-1252, miR-29b, miR-29c, miR-3610, miR-431, and miR-523, was also evaluated" +tissue_expression_ns hsa-mir-133a Colon Neoplasms 29930763 Extensive screening of microRNA populations identifies hsa-miR-375 and hsa-miR-133a-3p as selective markers for human rectal and colon cancer. +tissue_expression_ns hsa-mir-133a Rectal Neoplasms 29930763 Extensive screening of microRNA populations identifies hsa-miR-375 and hsa-miR-133a-3p as selective markers for human rectal and colon cancer. +tissue_expression_ns hsa-mir-375 Colon Neoplasms 29930763 Extensive screening of microRNA populations identifies hsa-miR-375 and hsa-miR-133a-3p as selective markers for human rectal and colon cancer. +tissue_expression_ns hsa-mir-375 Rectal Neoplasms 29930763 Extensive screening of microRNA populations identifies hsa-miR-375 and hsa-miR-133a-3p as selective markers for human rectal and colon cancer. +tissue_expression_ns hsa-mir-221 Liver Fibrosis 29932949 miRNA-221 and miRNA-222 are promising biomarkers for progression of liver fibrosis in HCV Egyptian patients. +tissue_expression_ns hsa-mir-222 Liver Fibrosis 29932949 miRNA-221 and miRNA-222 are promising biomarkers for progression of liver fibrosis in HCV Egyptian patients. +tissue_expression_ns hsa-mir-21 Glioma 29949235 MicroRNAs as potential biomarkers for the diagnosis of c: A systematic review and meta-analysis. +tissue_expression_ns hsa-mir-548c Rectal Neoplasms 29956755 "Among these differentially expressed miRNAs, miR?548c?5p, miR?548d?5p and miR?663a were significantly associated with a CR to nCRT" +tissue_expression_ns hsa-mir-548d Rectal Neoplasms 29956755 "Among these differentially expressed miRNAs, miR?548c?5p, miR?548d?5p and miR?663a were significantly associated with a CR to nCRT" +tissue_expression_ns hsa-mir-663a Rectal Neoplasms 29956755 "Among these differentially expressed miRNAs, miR?548c?5p, miR?548d?5p and miR?663a were significantly associated with a CR to nCRT" +tissue_expression_ns hsa-mir-299 "Carcinoma, Hepatocellular" 29963149 Prognostic value of hsa-mir-299 and hsa-mir-7706 in hepatocellular carcinoma. +tissue_expression_ns hsa-mir-7706 "Carcinoma, Hepatocellular" 29963149 Prognostic value of hsa-mir-299 and hsa-mir-7706 in hepatocellular carcinoma. +tissue_expression_ns hsa-mir-145 "Squamous Cell Carcinoma, Esophageal" 29963194 "3 types of miRNA (miR-21, miR-25 and miR-145) in serum could serve as potential biomarkers for ESCC" +tissue_expression_ns hsa-mir-21 "Squamous Cell Carcinoma, Esophageal" 29963194 "3 types of miRNA (miR-21, miR-25 and miR-145) in serum could serve as potential biomarkers for ESCC" +tissue_expression_ns hsa-mir-25 "Squamous Cell Carcinoma, Esophageal" 29963194 "3 types of miRNA (miR-21, miR-25 and miR-145) in serum could serve as potential biomarkers for ESCC" +tissue_expression_ns hsa-mir-4758 Ganglioglioma 29963264 MicroRNA519d and microRNA4758 can identify gangliogliomas from dysembryoplastic neuroepithelial tumours and astrocytomas. +tissue_expression_ns hsa-mir-519d Ganglioglioma 29963264 MicroRNA519d and microRNA4758 can identify gangliogliomas from dysembryoplastic neuroepithelial tumours and astrocytomas. +tissue_expression_ns hsa-mir-122 Liver Injury 29963269 Mining of potential microRNAs with clinical correlation - regulation of syndecan-1 expression by miR-122-5p altered mobility of breast cancer cells and possible correlation with liver injury. +tissue_expression_ns hsa-mir-34a Amyotrophic Lateral Sclerosis 29973608 "miR-34a and miR504 appeared particularly relevant due to their involvement in the p53 pathway, synaptic vesicle regulation and general involvement in neurodegenerative diseases" +tissue_expression_ns hsa-mir-504 Amyotrophic Lateral Sclerosis 29973608 "miR-34a and miR504 appeared particularly relevant due to their involvement in the p53 pathway, synaptic vesicle regulation and general involvement in neurodegenerative diseases" +tissue_expression_ns hsa-mir-135b Oral Neoplasms 29976158 "Differential expression of hsa-miR-221, hsa-miR-21, hsa-miR-135b, and hsa-miR-29c suggests a field effect in oral cancer." +tissue_expression_ns hsa-mir-21 Oral Neoplasms 29976158 "Differential expression of hsa-miR-221, hsa-miR-21, hsa-miR-135b, and hsa-miR-29c suggests a field effect in oral cancer." +tissue_expression_ns hsa-mir-221 Oral Neoplasms 29976158 "Differential expression of hsa-miR-221, hsa-miR-21, hsa-miR-135b, and hsa-miR-29c suggests a field effect in oral cancer." +tissue_expression_ns hsa-mir-29c Oral Neoplasms 29976158 "Differential expression of hsa-miR-221, hsa-miR-21, hsa-miR-135b, and hsa-miR-29c suggests a field effect in oral cancer." +tissue_expression_ns hsa-mir-15a Lung Neoplasms 29980036 "Hsa-miR-197-3p, hsa-miR-29a-3p, hsa-miR-15a-5p, hsa-miR-16-5p and hsa-miR-92a-3p are found significantly expressed in association with exposures" +tissue_expression_ns hsa-mir-16 Lung Neoplasms 29980036 "Hsa-miR-197-3p, hsa-miR-29a-3p, hsa-miR-15a-5p, hsa-miR-16-5p and hsa-miR-92a-3p are found significantly expressed in association with exposures" +tissue_expression_ns hsa-mir-197 Lung Neoplasms 29980036 "Hsa-miR-197-3p, hsa-miR-29a-3p, hsa-miR-15a-5p, hsa-miR-16-5p and hsa-miR-92a-3p are found significantly expressed in association with exposures" +tissue_expression_ns hsa-mir-29a Lung Neoplasms 29980036 "Hsa-miR-197-3p, hsa-miR-29a-3p, hsa-miR-15a-5p, hsa-miR-16-5p and hsa-miR-92a-3p are found significantly expressed in association with exposures" +tissue_expression_ns hsa-mir-92a Lung Neoplasms 29980036 "Hsa-miR-197-3p, hsa-miR-29a-3p, hsa-miR-15a-5p, hsa-miR-16-5p and hsa-miR-92a-3p are found significantly expressed in association with exposures" +tissue_expression_ns hsa-mir-320 Chronic Obstructive Pulmonary Disease 29981854 Genome-wide MicroRNA Expression Profiles in COPD: Early Predictors for Cancer Development. +tissue_expression_ns hsa-mir-483 Adrenal Cortex Neoplasms 29982598 The lack of significantly different expression of hsa-miR-483-3p and hsa-miR-483-5p between AML and ACC might limit their applicability as diagnostic miRNA markers for ACC +tissue_expression_ns hsa-let-7a "Carcinoma, Breast" 29995098 Expression of tumor suppressors miR-195 and let-7a as potential biomarkers of invasive breast cancer. +tissue_expression_ns hsa-mir-195 "Carcinoma, Breast" 29995098 Expression of tumor suppressors miR-195 and let-7a as potential biomarkers of invasive breast cancer. +tissue_expression_ns hsa-mir-99a Prostate Neoplasms 29997385 Expression of microRNA-99a-3p in Prostate Cancer Based on Bioinformatics Data and Meta-Analysis of a Literature Review of 965 Cases. +tissue_expression_ns hsa-mir-141 "Carcinoma, Renal Cell" 30008851 miR-224/miR-141 ratio as a novel diagnostic biomarker in renal cell carcinoma. +tissue_expression_ns hsa-mir-224 "Carcinoma, Renal Cell" 30008851 miR-224/miR-141 ratio as a novel diagnostic biomarker in renal cell carcinoma. +tissue_expression_ns hsa-mir-141 Prostate Neoplasms 30014459 "Combination of three miRNA (miR-141, miR-21, and miR-375) as potential diagnostic tool for prostate cancer recognition." +tissue_expression_ns hsa-mir-21 Prostate Neoplasms 30014459 "Combination of three miRNA (miR-141, miR-21, and miR-375) as potential diagnostic tool for prostate cancer recognition." +tissue_expression_ns hsa-mir-375 Prostate Neoplasms 30014459 "Combination of three miRNA (miR-141, miR-21, and miR-375) as potential diagnostic tool for prostate cancer recognition." +tissue_expression_ns hsa-mir-18a Colorectal Carcinoma 30018727 miR-18a-5p functioned as an oncogene and prognostic biomarker in RCC +tissue_expression_ns hsa-let-7a "Carcinoma, Breast" 30019863 Differential altered expression of let-7a and miR-205 tumor-suppressor miRNAs in different subtypes of breast cancer under treatment with Taxol. +tissue_expression_ns hsa-mir-205 "Carcinoma, Breast" 30019863 Differential altered expression of let-7a and miR-205 tumor-suppressor miRNAs in different subtypes of breast cancer under treatment with Taxol. +tissue_expression_ns hsa-mir-200b "Adenocarcinoma, Lung" 30022565 Altered editing level of microRNAs is a potential biomarker in lung adenocarcinoma. +tissue_expression_ns hsa-mir-99a "Adenocarcinoma, Lung" 30022565 Altered editing level of microRNAs is a potential biomarker in lung adenocarcinoma. +tissue_expression_ns hsa-mir-33 Coronary Artery Disease 30022694 Circulating miRNA-33: a potential biomarker in patients with Coronary Artery Disease (CAD). +tissue_expression_ns hsa-mir-221 Osteosarcoma 30024497 MiRNA-221 from tissue may predict the prognosis of patients with osteosarcoma. +tissue_expression_ns hsa-mir-184 Glaucoma 30025119 "Relative expression patterns of hsa-miR-184, hsa-miR-486-5p, and hsa-miR-93-5p were confirmed by quantitative PCR" +tissue_expression_ns hsa-mir-486 Glaucoma 30025119 "Relative expression patterns of hsa-miR-184, hsa-miR-486-5p, and hsa-miR-93-5p were confirmed by quantitative PCR" +tissue_expression_ns hsa-mir-93 Glaucoma 30025119 "Relative expression patterns of hsa-miR-184, hsa-miR-486-5p, and hsa-miR-93-5p were confirmed by quantitative PCR" +tissue_expression_ns hsa-let-7g "Carcinoma, Hepatocellular" 30026054 "A number of miRNAs implicated in HCC, including miR-101, miR-140, miR-152, miR-199a-3p, and let-7g, were downregulated in CHB" +tissue_expression_ns hsa-mir-101 "Carcinoma, Hepatocellular" 30026054 "A number of miRNAs implicated in HCC, including miR-101, miR-140, miR-152, miR-199a-3p, and let-7g, were downregulated in CHB" +tissue_expression_ns hsa-mir-140 "Carcinoma, Hepatocellular" 30026054 "A number of miRNAs implicated in HCC, including miR-101, miR-140, miR-152, miR-199a-3p, and let-7g, were downregulated in CHB" +tissue_expression_ns hsa-mir-152 "Carcinoma, Hepatocellular" 30026054 "A number of miRNAs implicated in HCC, including miR-101, miR-140, miR-152, miR-199a-3p, and let-7g, were downregulated in CHB" +tissue_expression_ns hsa-mir-199a "Carcinoma, Hepatocellular" 30026054 "A number of miRNAs implicated in HCC, including miR-101, miR-140, miR-152, miR-199a-3p, and let-7g, were downregulated in CHB" +tissue_expression_ns hsa-mir-100 "Carcinoma, Urothelial" 30026881 "six were associated with high risk (hsa-miR-99a-5p, hsa-miR-100-5p, hsa-miR-125b-5p, hsa-miR-4324, hsa-miR-34b-5p, and hsa-miR-135a-3p) and three were shown to be protective (hsa-miR-145-5p, hsa-miR-29c-3p, and hsa-miR-33b-3p)" +tissue_expression_ns hsa-mir-125b "Carcinoma, Urothelial" 30026881 "six were associated with high risk (hsa-miR-99a-5p, hsa-miR-100-5p, hsa-miR-125b-5p, hsa-miR-4324, hsa-miR-34b-5p, and hsa-miR-135a-3p) and three were shown to be protective (hsa-miR-145-5p, hsa-miR-29c-3p, and hsa-miR-33b-3p)" +tissue_expression_ns hsa-mir-135a "Carcinoma, Urothelial" 30026881 "six were associated with high risk (hsa-miR-99a-5p, hsa-miR-100-5p, hsa-miR-125b-5p, hsa-miR-4324, hsa-miR-34b-5p, and hsa-miR-135a-3p) and three were shown to be protective (hsa-miR-145-5p, hsa-miR-29c-3p, and hsa-miR-33b-3p)" +tissue_expression_ns hsa-mir-145 "Carcinoma, Urothelial" 30026881 "six were associated with high risk (hsa-miR-99a-5p, hsa-miR-100-5p, hsa-miR-125b-5p, hsa-miR-4324, hsa-miR-34b-5p, and hsa-miR-135a-3p) and three were shown to be protective (hsa-miR-145-5p, hsa-miR-29c-3p, and hsa-miR-33b-3p)" +tissue_expression_ns hsa-mir-29c "Carcinoma, Urothelial" 30026881 "six were associated with high risk (hsa-miR-99a-5p, hsa-miR-100-5p, hsa-miR-125b-5p, hsa-miR-4324, hsa-miR-34b-5p, and hsa-miR-135a-3p) and three were shown to be protective (hsa-miR-145-5p, hsa-miR-29c-3p, and hsa-miR-33b-3p)" +tissue_expression_ns hsa-mir-33b "Carcinoma, Urothelial" 30026881 "six were associated with high risk (hsa-miR-99a-5p, hsa-miR-100-5p, hsa-miR-125b-5p, hsa-miR-4324, hsa-miR-34b-5p, and hsa-miR-135a-3p) and three were shown to be protective (hsa-miR-145-5p, hsa-miR-29c-3p, and hsa-miR-33b-3p)" +tissue_expression_ns hsa-mir-34b "Carcinoma, Urothelial" 30026881 "six were associated with high risk (hsa-miR-99a-5p, hsa-miR-100-5p, hsa-miR-125b-5p, hsa-miR-4324, hsa-miR-34b-5p, and hsa-miR-135a-3p) and three were shown to be protective (hsa-miR-145-5p, hsa-miR-29c-3p, and hsa-miR-33b-3p)" +tissue_expression_ns hsa-mir-4324 "Carcinoma, Urothelial" 30026881 "six were associated with high risk (hsa-miR-99a-5p, hsa-miR-100-5p, hsa-miR-125b-5p, hsa-miR-4324, hsa-miR-34b-5p, and hsa-miR-135a-3p) and three were shown to be protective (hsa-miR-145-5p, hsa-miR-29c-3p, and hsa-miR-33b-3p)" +tissue_expression_ns hsa-mir-99a "Carcinoma, Urothelial" 30026881 "six were associated with high risk (hsa-miR-99a-5p, hsa-miR-100-5p, hsa-miR-125b-5p, hsa-miR-4324, hsa-miR-34b-5p, and hsa-miR-135a-3p) and three were shown to be protective (hsa-miR-145-5p, hsa-miR-29c-3p, and hsa-miR-33b-3p)" +tissue_expression_ns hsa-mir-143 Prostate Neoplasms 30027097 "MicroRNAs like miR-23b, miR-95, miR-143, and miR-183 can be utilized in assisting the diagnosis and prognosis of prostate cancer as biomarkers" +tissue_expression_ns hsa-mir-183 Prostate Neoplasms 30027097 "MicroRNAs like miR-23b, miR-95, miR-143, and miR-183 can be utilized in assisting the diagnosis and prognosis of prostate cancer as biomarkers" +tissue_expression_ns hsa-mir-23b Prostate Neoplasms 30027097 "MicroRNAs like miR-23b, miR-95, miR-143, and miR-183 can be utilized in assisting the diagnosis and prognosis of prostate cancer as biomarkers" +tissue_expression_ns hsa-mir-95 Prostate Neoplasms 30027097 "MicroRNAs like miR-23b, miR-95, miR-143, and miR-183 can be utilized in assisting the diagnosis and prognosis of prostate cancer as biomarkers" +tissue_expression_ns hsa-mir-141 Prostate Neoplasms 30037718 "The refined miRNA panel (KCa-6: miR-27b, -942, -497, -144, -141 and -27a) was more capable of predicting the overall survival than was any single miRNAs included in it" +tissue_expression_ns hsa-mir-144 Prostate Neoplasms 30037718 "The refined miRNA panel (KCa-6: miR-27b, -942, -497, -144, -141 and -27a) was more capable of predicting the overall survival than was any single miRNAs included in it" +tissue_expression_ns hsa-mir-27a Prostate Neoplasms 30037718 "The refined miRNA panel (KCa-6: miR-27b, -942, -497, -144, -141 and -27a) was more capable of predicting the overall survival than was any single miRNAs included in it" +tissue_expression_ns hsa-mir-27b Prostate Neoplasms 30037718 "The refined miRNA panel (KCa-6: miR-27b, -942, -497, -144, -141 and -27a) was more capable of predicting the overall survival than was any single miRNAs included in it" +tissue_expression_ns hsa-mir-497 Prostate Neoplasms 30037718 "The refined miRNA panel (KCa-6: miR-27b, -942, -497, -144, -141 and -27a) was more capable of predicting the overall survival than was any single miRNAs included in it" +tissue_expression_ns hsa-mir-942 Prostate Neoplasms 30037718 "The refined miRNA panel (KCa-6: miR-27b, -942, -497, -144, -141 and -27a) was more capable of predicting the overall survival than was any single miRNAs included in it" +tissue_expression_ns hsa-mir-185 Asthma 30040124 Asthma diagnosis using integrated analysis of eosinophil microRNAs. +tissue_expression_ns hsa-mir-21 Cholangiocarcinoma 30050323 miR-21 may be a promising biomarker for diagnosis and prognosis of CCA +tissue_expression_ns hsa-mir-21 "Carcinoma, Lung, Non-Small-Cell" 30050938 Multiple miRNAs such as miR-21 and miR-210 could be used as diagnostic tools for NSCLC +tissue_expression_ns hsa-mir-210 "Carcinoma, Lung, Non-Small-Cell" 30050938 Multiple miRNAs such as miR-21 and miR-210 could be used as diagnostic tools for NSCLC +tissue_expression_ns hsa-mir-139 "Carcinoma, Breast" 30055304 "Tree-based machine learning modelstrained in my analysis used hsa-miR-139 with hsa-miR-183 to classify breast tumors from normal samples, and hsa-miR4728 with hsa-miR190b to further classify these tumors into three major subtypes of breast cancer" +tissue_expression_ns hsa-mir-183 "Carcinoma, Breast" 30055304 "Tree-based machine learning modelstrained in my analysis used hsa-miR-139 with hsa-miR-183 to classify breast tumors from normal samples, and hsa-miR4728 with hsa-miR190b to further classify these tumors into three major subtypes of breast cancer" +tissue_expression_ns hsa-mir-1296 "Carcinoma, Hepatocellular" 30064138 "four miRNAs (mir-1296, mir-23c, mir-149, and mir-95) were finally selected for further validation and analysis" +tissue_expression_ns hsa-mir-149 "Carcinoma, Hepatocellular" 30064138 "four miRNAs (mir-1296, mir-23c, mir-149, and mir-95) were finally selected for further validation and analysis" +tissue_expression_ns hsa-mir-23c "Carcinoma, Hepatocellular" 30064138 "four miRNAs (mir-1296, mir-23c, mir-149, and mir-95) were finally selected for further validation and analysis" +tissue_expression_ns hsa-mir-95 "Carcinoma, Hepatocellular" 30064138 "four miRNAs (mir-1296, mir-23c, mir-149, and mir-95) were finally selected for further validation and analysis" +tissue_expression_ns hsa-mir-99a "Squamous Cell Carcinoma, Head and Neck" 30087832 our study may provide insights into the expression and mechanism of miR-99a-5p in HNSCC +tissue_expression_ns hsa-mir-155 "Carcinoma, Breast" 30088260 "metformin may modulate the pro-apoptotic Bax, anti-apoptotic Bcl-2, MMP-2, MMP-9, miR-21 and miR-155 expression levels. These findings may be instrumental for the clinical management and/or (targeted) treatment of breast cancer" +tissue_expression_ns hsa-mir-21 "Carcinoma, Breast" 30088260 "metformin may modulate the pro-apoptotic Bax, anti-apoptotic Bcl-2, MMP-2, MMP-9, miR-21 and miR-155 expression levels. These findings may be instrumental for the clinical management and/or (targeted) treatment of breast cancer" +tissue_expression_ns hsa-mir-17 Lung Neoplasms 30089594 "six microRNAs (miR-17, miR-190b, miR-19a, miR-19b, miR-26b, and miR-375) provided high diagnostic accuracy in discriminating lung cancer patients from healthy individuals" +tissue_expression_ns hsa-mir-190b Lung Neoplasms 30089594 "six microRNAs (miR-17, miR-190b, miR-19a, miR-19b, miR-26b, and miR-375) provided high diagnostic accuracy in discriminating lung cancer patients from healthy individuals" +tissue_expression_ns hsa-mir-19a Lung Neoplasms 30089594 "six microRNAs (miR-17, miR-190b, miR-19a, miR-19b, miR-26b, and miR-375) provided high diagnostic accuracy in discriminating lung cancer patients from healthy individuals" +tissue_expression_ns hsa-mir-19b Lung Neoplasms 30089594 "six microRNAs (miR-17, miR-190b, miR-19a, miR-19b, miR-26b, and miR-375) provided high diagnostic accuracy in discriminating lung cancer patients from healthy individuals" +tissue_expression_ns hsa-mir-26b Lung Neoplasms 30089594 "six microRNAs (miR-17, miR-190b, miR-19a, miR-19b, miR-26b, and miR-375) provided high diagnostic accuracy in discriminating lung cancer patients from healthy individuals" +tissue_expression_ns hsa-mir-375 Lung Neoplasms 30089594 "six microRNAs (miR-17, miR-190b, miR-19a, miR-19b, miR-26b, and miR-375) provided high diagnostic accuracy in discriminating lung cancer patients from healthy individuals" +tissue_expression_ns hsa-mir-141 Ovarian Neoplasms 30095616 MicroRNA-200 and microRNA-30 family as prognostic molecular signatures in ovarian cancer: A meta-analysis. +tissue_expression_ns hsa-mir-200a Ovarian Neoplasms 30095616 MicroRNA-200 and microRNA-30 family as prognostic molecular signatures in ovarian cancer: A meta-analysis. +tissue_expression_ns hsa-mir-200b Ovarian Neoplasms 30095616 MicroRNA-200 and microRNA-30 family as prognostic molecular signatures in ovarian cancer: A meta-analysis. +tissue_expression_ns hsa-mir-200c Ovarian Neoplasms 30095616 MicroRNA-200 and microRNA-30 family as prognostic molecular signatures in ovarian cancer: A meta-analysis. +tissue_expression_ns hsa-mir-30d Ovarian Neoplasms 30095616 MicroRNA-200 and microRNA-30 family as prognostic molecular signatures in ovarian cancer: A meta-analysis. +tissue_expression_ns hsa-mir-326 Gastric Neoplasms 30096452 Purified sulforaphane from broccoli (Brassica oleracea var. italica) leads to alterations of CDX1 and CDX2 expression and changes in miR-9 and miR-326 levels in human gastric cancer cells. +tissue_expression_ns hsa-mir-9 Gastric Neoplasms 30096452 Purified sulforaphane from broccoli (Brassica oleracea var. italica) leads to alterations of CDX1 and CDX2 expression and changes in miR-9 and miR-326 levels in human gastric cancer cells. +tissue_expression_ns hsa-mir-199b Parathyroid Carcinoma 30104706 Differential expression of miRNA199b-5p as a novel biomarker for sporadic and hereditary parathyroid tumors. +tissue_expression_ns hsa-mir-183 Renal Oncocytoma 30116406 "miR-498 (formation of the oncocytoma-specific slice-form of vimentin, Vim3), miR-183 (associated with increased CO2 levels), miR-205, and miR-31 (signaling through downregulation of PKC epsilon, shown previously)" +tissue_expression_ns hsa-mir-205 Renal Oncocytoma 30116406 "miR-498 (formation of the oncocytoma-specific slice-form of vimentin, Vim3), miR-183 (associated with increased CO2 levels), miR-205, and miR-31 (signaling through downregulation of PKC epsilon, shown previously)" +tissue_expression_ns hsa-mir-31 Renal Oncocytoma 30116406 "miR-498 (formation of the oncocytoma-specific slice-form of vimentin, Vim3), miR-183 (associated with increased CO2 levels), miR-205, and miR-31 (signaling through downregulation of PKC epsilon, shown previously)" +tissue_expression_ns hsa-mir-498 Renal Oncocytoma 30116406 "miR-498 (formation of the oncocytoma-specific slice-form of vimentin, Vim3), miR-183 (associated with increased CO2 levels), miR-205, and miR-31 (signaling through downregulation of PKC epsilon, shown previously)" +tissue_expression_ns hsa-let-7a-3 "Adenocarcinoma, Pancreatic Ductal" 30127641 "Eleven miRNAs (hsa-mir-501, hsa-mir-4521, hsa-mir-5091, hsa-mir-24-1, hsa-mir-126, hsa-mir-30e, hsa-mir-3157, hsa-let-7a-3, hsa-mir-133a-1, hsa-mir-4709, and hsa-mir-421) were used to construct a prognostic signature using the step function" +tissue_expression_ns hsa-mir-126 "Adenocarcinoma, Pancreatic Ductal" 30127641 "Eleven miRNAs (hsa-mir-501, hsa-mir-4521, hsa-mir-5091, hsa-mir-24-1, hsa-mir-126, hsa-mir-30e, hsa-mir-3157, hsa-let-7a-3, hsa-mir-133a-1, hsa-mir-4709, and hsa-mir-421) were used to construct a prognostic signature using the step function" +tissue_expression_ns hsa-mir-133a-1 "Adenocarcinoma, Pancreatic Ductal" 30127641 "Eleven miRNAs (hsa-mir-501, hsa-mir-4521, hsa-mir-5091, hsa-mir-24-1, hsa-mir-126, hsa-mir-30e, hsa-mir-3157, hsa-let-7a-3, hsa-mir-133a-1, hsa-mir-4709, and hsa-mir-421) were used to construct a prognostic signature using the step function" +tissue_expression_ns hsa-mir-24-1 "Adenocarcinoma, Pancreatic Ductal" 30127641 "Eleven miRNAs (hsa-mir-501, hsa-mir-4521, hsa-mir-5091, hsa-mir-24-1, hsa-mir-126, hsa-mir-30e, hsa-mir-3157, hsa-let-7a-3, hsa-mir-133a-1, hsa-mir-4709, and hsa-mir-421) were used to construct a prognostic signature using the step function" +tissue_expression_ns hsa-mir-30e "Adenocarcinoma, Pancreatic Ductal" 30127641 "Eleven miRNAs (hsa-mir-501, hsa-mir-4521, hsa-mir-5091, hsa-mir-24-1, hsa-mir-126, hsa-mir-30e, hsa-mir-3157, hsa-let-7a-3, hsa-mir-133a-1, hsa-mir-4709, and hsa-mir-421) were used to construct a prognostic signature using the step function" +tissue_expression_ns hsa-mir-3157 "Adenocarcinoma, Pancreatic Ductal" 30127641 "Eleven miRNAs (hsa-mir-501, hsa-mir-4521, hsa-mir-5091, hsa-mir-24-1, hsa-mir-126, hsa-mir-30e, hsa-mir-3157, hsa-let-7a-3, hsa-mir-133a-1, hsa-mir-4709, and hsa-mir-421) were used to construct a prognostic signature using the step function" +tissue_expression_ns hsa-mir-421 "Adenocarcinoma, Pancreatic Ductal" 30127641 "Eleven miRNAs (hsa-mir-501, hsa-mir-4521, hsa-mir-5091, hsa-mir-24-1, hsa-mir-126, hsa-mir-30e, hsa-mir-3157, hsa-let-7a-3, hsa-mir-133a-1, hsa-mir-4709, and hsa-mir-421) were used to construct a prognostic signature using the step function" +tissue_expression_ns hsa-mir-4521 "Adenocarcinoma, Pancreatic Ductal" 30127641 "Eleven miRNAs (hsa-mir-501, hsa-mir-4521, hsa-mir-5091, hsa-mir-24-1, hsa-mir-126, hsa-mir-30e, hsa-mir-3157, hsa-let-7a-3, hsa-mir-133a-1, hsa-mir-4709, and hsa-mir-421) were used to construct a prognostic signature using the step function" +tissue_expression_ns hsa-mir-4709 "Adenocarcinoma, Pancreatic Ductal" 30127641 "Eleven miRNAs (hsa-mir-501, hsa-mir-4521, hsa-mir-5091, hsa-mir-24-1, hsa-mir-126, hsa-mir-30e, hsa-mir-3157, hsa-let-7a-3, hsa-mir-133a-1, hsa-mir-4709, and hsa-mir-421) were used to construct a prognostic signature using the step function" +tissue_expression_ns hsa-mir-501 "Adenocarcinoma, Pancreatic Ductal" 30127641 "Eleven miRNAs (hsa-mir-501, hsa-mir-4521, hsa-mir-5091, hsa-mir-24-1, hsa-mir-126, hsa-mir-30e, hsa-mir-3157, hsa-let-7a-3, hsa-mir-133a-1, hsa-mir-4709, and hsa-mir-421) were used to construct a prognostic signature using the step function" +tissue_expression_ns hsa-mir-5091 "Adenocarcinoma, Pancreatic Ductal" 30127641 "Eleven miRNAs (hsa-mir-501, hsa-mir-4521, hsa-mir-5091, hsa-mir-24-1, hsa-mir-126, hsa-mir-30e, hsa-mir-3157, hsa-let-7a-3, hsa-mir-133a-1, hsa-mir-4709, and hsa-mir-421) were used to construct a prognostic signature using the step function" +tissue_expression_ns hsa-mir-203 Esophageal Neoplasms 30127973 Identification and verification of differentially expressed microRNAs and their target genes for the diagnosis of esophageal cancer. +tissue_expression_ns hsa-let-7b Smoke Inhalation Injury 30139538 Expression profile of microRNAs in bronchoalveolar lavage fluid of rats as predictors for smoke inhalation injury. +tissue_expression_ns hsa-let-7c Smoke Inhalation Injury 30139538 Expression profile of microRNAs in bronchoalveolar lavage fluid of rats as predictors for smoke inhalation injury. +tissue_expression_ns hsa-mir-205 Smoke Inhalation Injury 30139538 Expression profile of microRNAs in bronchoalveolar lavage fluid of rats as predictors for smoke inhalation injury. +tissue_expression_ns hsa-mir-34b Smoke Inhalation Injury 30139538 Expression profile of microRNAs in bronchoalveolar lavage fluid of rats as predictors for smoke inhalation injury. +tissue_expression_ns hsa-mir-34c Smoke Inhalation Injury 30139538 Expression profile of microRNAs in bronchoalveolar lavage fluid of rats as predictors for smoke inhalation injury. +tissue_expression_ns hsa-mir-92a Smoke Inhalation Injury 30139538 Expression profile of microRNAs in bronchoalveolar lavage fluid of rats as predictors for smoke inhalation injury. +tissue_expression_ns hsa-mir-92b Smoke Inhalation Injury 30139538 Expression profile of microRNAs in bronchoalveolar lavage fluid of rats as predictors for smoke inhalation injury. +tissue_expression_ns hsa-mir-1 Tetralogy Of Fallot 30150777 "miR-1/miR-133, which have been identified as essential for cardiac development, account for the most variance of sRNA expression between sexes in TOF hearts" +tissue_expression_ns hsa-mir-133b Tetralogy Of Fallot 30150777 "miR-1/miR-133, which have been identified as essential for cardiac development, account for the most variance of sRNA expression between sexes in TOF hearts" +tissue_expression_ns hsa-mir-125a "Carcinoma, Pancreatic" 30165365 "We identified that miR-23a, miR-30a, miR-125a, miR-129-1, miR-181b-1, miR-203, miR-221, miR-222, and miR-1301 had moderate diagnostic value for PaCa and predicted overall survival in PaCa patients" +tissue_expression_ns hsa-mir-129-1 "Carcinoma, Pancreatic" 30165365 "We identified that miR-23a, miR-30a, miR-125a, miR-129-1, miR-181b-1, miR-203, miR-221, miR-222, and miR-1301 had moderate diagnostic value for PaCa and predicted overall survival in PaCa patients" +tissue_expression_ns hsa-mir-1301 "Carcinoma, Pancreatic" 30165365 "We identified that miR-23a, miR-30a, miR-125a, miR-129-1, miR-181b-1, miR-203, miR-221, miR-222, and miR-1301 had moderate diagnostic value for PaCa and predicted overall survival in PaCa patients" +tissue_expression_ns hsa-mir-181b-1 "Carcinoma, Pancreatic" 30165365 "We identified that miR-23a, miR-30a, miR-125a, miR-129-1, miR-181b-1, miR-203, miR-221, miR-222, and miR-1301 had moderate diagnostic value for PaCa and predicted overall survival in PaCa patients" +tissue_expression_ns hsa-mir-203 "Carcinoma, Pancreatic" 30165365 "We identified that miR-23a, miR-30a, miR-125a, miR-129-1, miR-181b-1, miR-203, miR-221, miR-222, and miR-1301 had moderate diagnostic value for PaCa and predicted overall survival in PaCa patients" +tissue_expression_ns hsa-mir-221 "Carcinoma, Pancreatic" 30165365 "We identified that miR-23a, miR-30a, miR-125a, miR-129-1, miR-181b-1, miR-203, miR-221, miR-222, and miR-1301 had moderate diagnostic value for PaCa and predicted overall survival in PaCa patients" +tissue_expression_ns hsa-mir-222 "Carcinoma, Pancreatic" 30165365 "We identified that miR-23a, miR-30a, miR-125a, miR-129-1, miR-181b-1, miR-203, miR-221, miR-222, and miR-1301 had moderate diagnostic value for PaCa and predicted overall survival in PaCa patients" +tissue_expression_ns hsa-mir-23a "Carcinoma, Pancreatic" 30165365 "We identified that miR-23a, miR-30a, miR-125a, miR-129-1, miR-181b-1, miR-203, miR-221, miR-222, and miR-1301 had moderate diagnostic value for PaCa and predicted overall survival in PaCa patients" +tissue_expression_ns hsa-mir-30a "Carcinoma, Pancreatic" 30165365 "We identified that miR-23a, miR-30a, miR-125a, miR-129-1, miR-181b-1, miR-203, miR-221, miR-222, and miR-1301 had moderate diagnostic value for PaCa and predicted overall survival in PaCa patients" +tissue_expression_ns hsa-mir-181a Myeloma 30170425 The expression and role of miR-181a in multiple myeloma. +tissue_expression_ns hsa-let-7g "Carcinoma, Head And Neck" 30171046 "A five-miRNA-signature (hsa-let-7g-3p, hsa-miR-6508-5p, hsa-miR-210-5p, hsa-miR-4306 and hsa-miR-7161-3p) predicted freedom from recurrence in DKTK-ROG, which was confirmed in LMU-KKG" +tissue_expression_ns hsa-mir-210 "Carcinoma, Head And Neck" 30171046 "A five-miRNA-signature (hsa-let-7g-3p, hsa-miR-6508-5p, hsa-miR-210-5p, hsa-miR-4306 and hsa-miR-7161-3p) predicted freedom from recurrence in DKTK-ROG, which was confirmed in LMU-KKG" +tissue_expression_ns hsa-mir-4306 "Carcinoma, Head And Neck" 30171046 "A five-miRNA-signature (hsa-let-7g-3p, hsa-miR-6508-5p, hsa-miR-210-5p, hsa-miR-4306 and hsa-miR-7161-3p) predicted freedom from recurrence in DKTK-ROG, which was confirmed in LMU-KKG" +tissue_expression_ns hsa-mir-6508 "Carcinoma, Head And Neck" 30171046 "A five-miRNA-signature (hsa-let-7g-3p, hsa-miR-6508-5p, hsa-miR-210-5p, hsa-miR-4306 and hsa-miR-7161-3p) predicted freedom from recurrence in DKTK-ROG, which was confirmed in LMU-KKG" +tissue_expression_ns hsa-mir-7161 "Carcinoma, Head And Neck" 30171046 "A five-miRNA-signature (hsa-let-7g-3p, hsa-miR-6508-5p, hsa-miR-210-5p, hsa-miR-4306 and hsa-miR-7161-3p) predicted freedom from recurrence in DKTK-ROG, which was confirmed in LMU-KKG" +tissue_expression_ns hsa-mir-140 Multiple Sclerosis 30175165 "5 miRNAs (hsa-miR-484, hsa-miR-140-5p, hsa-miR-320a, hsa-miR-486-5p, and hsa-miR-320c) showed a significant difference between patients with MS and healthy individuals" +tissue_expression_ns hsa-mir-320a Multiple Sclerosis 30175165 "5 miRNAs (hsa-miR-484, hsa-miR-140-5p, hsa-miR-320a, hsa-miR-486-5p, and hsa-miR-320c) showed a significant difference between patients with MS and healthy individuals" +tissue_expression_ns hsa-mir-320c Multiple Sclerosis 30175165 "5 miRNAs (hsa-miR-484, hsa-miR-140-5p, hsa-miR-320a, hsa-miR-486-5p, and hsa-miR-320c) showed a significant difference between patients with MS and healthy individuals" +tissue_expression_ns hsa-mir-484 Multiple Sclerosis 30175165 "5 miRNAs (hsa-miR-484, hsa-miR-140-5p, hsa-miR-320a, hsa-miR-486-5p, and hsa-miR-320c) showed a significant difference between patients with MS and healthy individuals" +tissue_expression_ns hsa-mir-486 Multiple Sclerosis 30175165 "5 miRNAs (hsa-miR-484, hsa-miR-140-5p, hsa-miR-320a, hsa-miR-486-5p, and hsa-miR-320c) showed a significant difference between patients with MS and healthy individuals" +tissue_expression_ns hsa-mir-4511 "Carcinoma, Bladder" 30183088 "the proposed non-invasive diagnostic tool based on the expression ratio of urinary cell-free miR-6124 to miR-4511 can reduce unnecessary cystoscopies in patients with hematuria undergoing evaluation for BC, with a minimal loss in sensitivity for detecting cancer" +tissue_expression_ns hsa-mir-6124 "Carcinoma, Bladder" 30183088 "the proposed non-invasive diagnostic tool based on the expression ratio of urinary cell-free miR-6124 to miR-4511 can reduce unnecessary cystoscopies in patients with hematuria undergoing evaluation for BC, with a minimal loss in sensitivity for detecting cancer" +tissue_expression_ns hsa-mir-18a Neoplasms [unspecific] 30189225 Ribonucleic-acid-biomarker candidates for early-phase group detection of common cancers. +tissue_expression_ns hsa-mir-21 Neoplasms [unspecific] 30189225 Ribonucleic-acid-biomarker candidates for early-phase group detection of common cancers. +tissue_expression_ns hsa-mir-221 Neoplasms [unspecific] 30189225 Ribonucleic-acid-biomarker candidates for early-phase group detection of common cancers. +tissue_expression_ns hsa-mir-375 Neoplasms [unspecific] 30189225 Ribonucleic-acid-biomarker candidates for early-phase group detection of common cancers. +tissue_expression_ns hsa-mir-1290 "Carcinoma, Lung, Non-Small-Cell" 30190521 "combination of miR-1290, miR-196b and miR-135a in tumor tissue, and miR-21, miR-25, miR27b, and miR-326 in plasma were predictive for response to platinum-based chemotherapy in advanced NSCLC" +tissue_expression_ns hsa-mir-135a "Carcinoma, Lung, Non-Small-Cell" 30190521 "combination of miR-1290, miR-196b and miR-135a in tumor tissue, and miR-21, miR-25, miR27b, and miR-326 in plasma were predictive for response to platinum-based chemotherapy in advanced NSCLC" +tissue_expression_ns hsa-mir-196b "Carcinoma, Lung, Non-Small-Cell" 30190521 "combination of miR-1290, miR-196b and miR-135a in tumor tissue, and miR-21, miR-25, miR27b, and miR-326 in plasma were predictive for response to platinum-based chemotherapy in advanced NSCLC" +tissue_expression_ns hsa-mir-10a "Carcinoma, Cervical" 30191988 "The upregulation of some circulating miRNAs, for example, miRNA-20a, miRNA-203, miRNA-21, miRNA-205, miRNA-218, and miR-485-5, as well as tissue-specific miRNAs, for example, miR-7, miR-10a, miR-17-5p, miR-135b, miR-149, and miR-203 have been found in patients with CC" +tissue_expression_ns hsa-mir-135b "Carcinoma, Cervical" 30191988 "The upregulation of some circulating miRNAs, for example, miRNA-20a, miRNA-203, miRNA-21, miRNA-205, miRNA-218, and miR-485-5, as well as tissue-specific miRNAs, for example, miR-7, miR-10a, miR-17-5p, miR-135b, miR-149, and miR-203 have been found in patients with CC" +tissue_expression_ns hsa-mir-149 "Carcinoma, Cervical" 30191988 "The upregulation of some circulating miRNAs, for example, miRNA-20a, miRNA-203, miRNA-21, miRNA-205, miRNA-218, and miR-485-5, as well as tissue-specific miRNAs, for example, miR-7, miR-10a, miR-17-5p, miR-135b, miR-149, and miR-203 have been found in patients with CC" +tissue_expression_ns hsa-mir-17 "Carcinoma, Cervical" 30191988 "The upregulation of some circulating miRNAs, for example, miRNA-20a, miRNA-203, miRNA-21, miRNA-205, miRNA-218, and miR-485-5, as well as tissue-specific miRNAs, for example, miR-7, miR-10a, miR-17-5p, miR-135b, miR-149, and miR-203 have been found in patients with CC" +tissue_expression_ns hsa-mir-203 "Carcinoma, Cervical" 30191988 "The upregulation of some circulating miRNAs, for example, miRNA-20a, miRNA-203, miRNA-21, miRNA-205, miRNA-218, and miR-485-5, as well as tissue-specific miRNAs, for example, miR-7, miR-10a, miR-17-5p, miR-135b, miR-149, and miR-203 have been found in patients with CC" +tissue_expression_ns hsa-mir-7 "Carcinoma, Cervical" 30191988 "The upregulation of some circulating miRNAs, for example, miRNA-20a, miRNA-203, miRNA-21, miRNA-205, miRNA-218, and miR-485-5, as well as tissue-specific miRNAs, for example, miR-7, miR-10a, miR-17-5p, miR-135b, miR-149, and miR-203 have been found in patients with CC" +tissue_expression_ns hsa-mir-141 "Carcinoma, Bladder" 30194772 "miR-21-5p, miR-141-3p, and miR-205-5p levels in urine-promising biomarkers for the identification of prostate and bladder cancer." +tissue_expression_ns hsa-mir-141 Prostate Neoplasms 30194772 "miR-21-5p, miR-141-3p, and miR-205-5p levels in urine-promising biomarkers for the identification of prostate and bladder cancer." +tissue_expression_ns hsa-mir-205 "Carcinoma, Bladder" 30194772 "miR-21-5p, miR-141-3p, and miR-205-5p levels in urine-promising biomarkers for the identification of prostate and bladder cancer." +tissue_expression_ns hsa-mir-205 Prostate Neoplasms 30194772 "miR-21-5p, miR-141-3p, and miR-205-5p levels in urine-promising biomarkers for the identification of prostate and bladder cancer." +tissue_expression_ns hsa-mir-21 "Carcinoma, Bladder" 30194772 "miR-21-5p, miR-141-3p, and miR-205-5p levels in urine-promising biomarkers for the identification of prostate and bladder cancer." +tissue_expression_ns hsa-mir-21 Prostate Neoplasms 30194772 "miR-21-5p, miR-141-3p, and miR-205-5p levels in urine-promising biomarkers for the identification of prostate and bladder cancer." +tissue_expression_ns hsa-mir-301a Prostate Neoplasms 30195463 miR-301a expression: Diagnostic and prognostic marker for prostate cancer. +tissue_expression_ns hsa-mir-200b Glioma 30197535 MicroRNA-200b expression level is negatively associated with pathological grading in human gliomas. +tissue_expression_ns hsa-mir-206 "Colitis, Ulcerative" 30204869 miR-206 as a Biomarker for Response to Mesalamine Treatment in Ulcerative Colitis. +tissue_expression_ns hsa-mir-1246 Gastrointestinal Neoplasms 30235938 Exosomal miR-1246 in body fluids is a potential biomarker for gastrointestinal cancer. +tissue_expression_ns hsa-mir-320a Cardiac Myxoma 30250535 Specific miRNA expression profile in the blood serum of cardiac myxoma patients. +tissue_expression_ns hsa-mir-634 Cardiac Myxoma 30250535 Specific miRNA expression profile in the blood serum of cardiac myxoma patients. +tissue_expression_ns hsa-mir-1260a Prostate Neoplasms 30250996 Expression patterns and bioinformatic analysis of miR-1260a and miR-1274a in Prostate Cancer Tunisian patients. +tissue_expression_ns hsa-mir-1274a Prostate Neoplasms 30250996 Expression patterns and bioinformatic analysis of miR-1260a and miR-1274a in Prostate Cancer Tunisian patients. +tissue_expression_ns hsa-mir-125b "Carcinoma, Lung, Non-Small-Cell" 30254489 Establishment and validation of a 7-microRNA prognostic signature for non-small cell lung cancer. +tissue_expression_ns hsa-mir-148b "Carcinoma, Lung, Non-Small-Cell" 30254489 Establishment and validation of a 7-microRNA prognostic signature for non-small cell lung cancer. +tissue_expression_ns hsa-mir-155 "Carcinoma, Lung, Non-Small-Cell" 30254489 Establishment and validation of a 7-microRNA prognostic signature for non-small cell lung cancer. +tissue_expression_ns hsa-mir-21 "Carcinoma, Lung, Non-Small-Cell" 30254489 Establishment and validation of a 7-microRNA prognostic signature for non-small cell lung cancer. +tissue_expression_ns hsa-mir-32 "Carcinoma, Lung, Non-Small-Cell" 30254489 Establishment and validation of a 7-microRNA prognostic signature for non-small cell lung cancer. +tissue_expression_ns hsa-mir-365 "Carcinoma, Lung, Non-Small-Cell" 30254489 Establishment and validation of a 7-microRNA prognostic signature for non-small cell lung cancer. +tissue_expression_ns hsa-mir-375 "Carcinoma, Lung, Non-Small-Cell" 30254489 Establishment and validation of a 7-microRNA prognostic signature for non-small cell lung cancer. +tissue_expression_ns hsa-mir-196a Pancreatic Adenocarcinoma 30258849 Evaluation of Plasma MicroRNAs as Diagnostic and Prognostic Biomarkers in Pancreatic Adenocarcinoma: miR-196a and miR-210 Could Be Negative and Positive Prognostic Markers +tissue_expression_ns hsa-mir-210 Pancreatic Adenocarcinoma 30258849 Evaluation of Plasma MicroRNAs as Diagnostic and Prognostic Biomarkers in Pancreatic Adenocarcinoma: miR-196a and miR-210 Could Be Negative and Positive Prognostic Markers +tissue_expression_ns hsa-mir-21 Stroke 30267810 MiR-21 was found to be normally up and down regulated in all types of strokes +tissue_expression_ns hsa-mir-138 "Adenocarcinoma, Lung" 30271594 Expression profiling and microRNA regulation of the LKB1 pathway in young and aged lung adenocarcinoma patients. +tissue_expression_ns hsa-mir-145 "Adenocarcinoma, Lung" 30271594 Expression profiling and microRNA regulation of the LKB1 pathway in young and aged lung adenocarcinoma patients. +tissue_expression_ns hsa-mir-153 "Adenocarcinoma, Lung" 30271594 Expression profiling and microRNA regulation of the LKB1 pathway in young and aged lung adenocarcinoma patients. +tissue_expression_ns hsa-mir-182 "Adenocarcinoma, Lung" 30271594 Expression profiling and microRNA regulation of the LKB1 pathway in young and aged lung adenocarcinoma patients. +tissue_expression_ns hsa-mir-183 "Adenocarcinoma, Lung" 30271594 Expression profiling and microRNA regulation of the LKB1 pathway in young and aged lung adenocarcinoma patients. +tissue_expression_ns hsa-mir-214 "Adenocarcinoma, Lung" 30271594 Expression profiling and microRNA regulation of the LKB1 pathway in young and aged lung adenocarcinoma patients. +tissue_expression_ns hsa-mir-214 "Adenocarcinoma, Lung" 30271594 Expression profiling and microRNA regulation of the LKB1 pathway in young and aged lung adenocarcinoma patients. +tissue_expression_ns hsa-mir-29b "Adenocarcinoma, Lung" 30271594 Expression profiling and microRNA regulation of the LKB1 pathway in young and aged lung adenocarcinoma patients. +tissue_expression_ns hsa-mir-29c "Adenocarcinoma, Lung" 30271594 Expression profiling and microRNA regulation of the LKB1 pathway in young and aged lung adenocarcinoma patients. +tissue_expression_ns hsa-mir-30b "Adenocarcinoma, Lung" 30271594 Expression profiling and microRNA regulation of the LKB1 pathway in young and aged lung adenocarcinoma patients. +tissue_expression_ns hsa-mir-30c "Adenocarcinoma, Lung" 30271594 Expression profiling and microRNA regulation of the LKB1 pathway in young and aged lung adenocarcinoma patients. +tissue_expression_ns hsa-mir-33a "Adenocarcinoma, Lung" 30271594 Expression profiling and microRNA regulation of the LKB1 pathway in young and aged lung adenocarcinoma patients. +tissue_expression_ns hsa-mir-34a "Adenocarcinoma, Lung" 30271594 Expression profiling and microRNA regulation of the LKB1 pathway in young and aged lung adenocarcinoma patients. +tissue_expression_ns hsa-mir-34a "Adenocarcinoma, Lung" 30271594 Expression profiling and microRNA regulation of the LKB1 pathway in young and aged lung adenocarcinoma patients. +tissue_expression_ns hsa-mir-34c "Adenocarcinoma, Lung" 30271594 Expression profiling and microRNA regulation of the LKB1 pathway in young and aged lung adenocarcinoma patients. +tissue_expression_ns hsa-mir-34c "Adenocarcinoma, Lung" 30271594 Expression profiling and microRNA regulation of the LKB1 pathway in young and aged lung adenocarcinoma patients. +tissue_expression_ns hsa-mir-93 "Adenocarcinoma, Lung" 30271594 Expression profiling and microRNA regulation of the LKB1 pathway in young and aged lung adenocarcinoma patients. +tissue_expression_ns hsa-mir-96 "Adenocarcinoma, Lung" 30271594 Expression profiling and microRNA regulation of the LKB1 pathway in young and aged lung adenocarcinoma patients. +tissue_expression_ns hsa-mir-17 Gastrointestinal Neoplasms 30275704 Prognostic value of miR-17-5p in gastrointestinal cancers: a systematic review and meta-analysis. +tissue_expression_ns hsa-mir-139 "Carcinoma, Hepatocellular" 30290990 Low microRNA-139 expression associates with poor prognosis in patients with tumors: A meta-analysis. +tissue_expression_ns hsa-mir-106b Pancreatic Endocrine Carcinoma 30299890 "The expression of hsa-miR-106b, hsa-miR-10a and especially hsa-miR-21 has prognostic relevance regarding progression-free and overall survival in patients with PanNENs" +tissue_expression_ns hsa-mir-10a Pancreatic Endocrine Carcinoma 30299890 "The expression of hsa-miR-106b, hsa-miR-10a and especially hsa-miR-21 has prognostic relevance regarding progression-free and overall survival in patients with PanNENs" +tissue_expression_ns hsa-mir-21 Pancreatic Endocrine Carcinoma 30299890 "The expression of hsa-miR-106b, hsa-miR-10a and especially hsa-miR-21 has prognostic relevance regarding progression-free and overall survival in patients with PanNENs" +tissue_expression_ns hsa-mir-182 "Carcinoma, Bladder" 30304549 Comprehensive analysis of microRNA-messenger RNA regulatory network in gemcitabine-resistant bladder cancer cells. +tissue_expression_ns hsa-mir-320a "Carcinoma, Bladder" 30304549 Comprehensive analysis of microRNA-messenger RNA regulatory network in gemcitabine-resistant bladder cancer cells. +tissue_expression_ns hsa-mir-550a "Carcinoma, Bladder" 30304549 Comprehensive analysis of microRNA-messenger RNA regulatory network in gemcitabine-resistant bladder cancer cells. +tissue_expression_ns hsa-mir-10a "Carcinoma, Urothelial, Upper Tract" 30315887 "OS was best predicted by miR-10a-5p, miR-199a-5p, miR-30c-5p, and miR-10b-5p" +tissue_expression_ns hsa-mir-10b "Carcinoma, Urothelial, Upper Tract" 30315887 "OS was best predicted by miR-10a-5p, miR-199a-5p, miR-30c-5p, and miR-10b-5p" +tissue_expression_ns hsa-mir-199a "Carcinoma, Urothelial, Upper Tract" 30315887 "OS was best predicted by miR-10a-5p, miR-199a-5p, miR-30c-5p, and miR-10b-5p" +tissue_expression_ns hsa-mir-30c "Carcinoma, Urothelial, Upper Tract" 30315887 "OS was best predicted by miR-10a-5p, miR-199a-5p, miR-30c-5p, and miR-10b-5p" +tissue_expression_ns hsa-let-7c "Carcinoma, Bladder" 30322728 " we identified a subset of 6 miRs (let-7c, miR-135a, miR-135b, miR-148a, miR-204, miR-345) that distinguished BC from controls with an area under the curve of 88.3%" +tissue_expression_ns hsa-mir-135a "Carcinoma, Bladder" 30322728 " we identified a subset of 6 miRs (let-7c, miR-135a, miR-135b, miR-148a, miR-204, miR-345) that distinguished BC from controls with an area under the curve of 88.3%" +tissue_expression_ns hsa-mir-135b "Carcinoma, Bladder" 30322728 " we identified a subset of 6 miRs (let-7c, miR-135a, miR-135b, miR-148a, miR-204, miR-345) that distinguished BC from controls with an area under the curve of 88.3%" +tissue_expression_ns hsa-mir-148a "Carcinoma, Bladder" 30322728 " we identified a subset of 6 miRs (let-7c, miR-135a, miR-135b, miR-148a, miR-204, miR-345) that distinguished BC from controls with an area under the curve of 88.3%" +tissue_expression_ns hsa-mir-204 "Carcinoma, Bladder" 30322728 " we identified a subset of 6 miRs (let-7c, miR-135a, miR-135b, miR-148a, miR-204, miR-345) that distinguished BC from controls with an area under the curve of 88.3%" +tissue_expression_ns hsa-mir-345 "Carcinoma, Bladder" 30322728 " we identified a subset of 6 miRs (let-7c, miR-135a, miR-135b, miR-148a, miR-204, miR-345) that distinguished BC from controls with an area under the curve of 88.3%" +tissue_expression_ns hsa-mir-141 Prostate Neoplasms 30334974 "PCA3, hK2, and miRNA-141 were biomarkers of Pca with potential clinical application value, especially in patients with PSA gray area" +tissue_expression_ns hsa-mir-296 "Squamous Cell Carcinoma, Lung" 30337605 "miR-296-5p, miR-324-3p, and miR-3928-3p expression was significantly associated with poor prognosis" +tissue_expression_ns hsa-mir-324 "Squamous Cell Carcinoma, Lung" 30337605 "miR-296-5p, miR-324-3p, and miR-3928-3p expression was significantly associated with poor prognosis" +tissue_expression_ns hsa-mir-3928 "Squamous Cell Carcinoma, Lung" 30337605 "miR-296-5p, miR-324-3p, and miR-3928-3p expression was significantly associated with poor prognosis" +tissue_expression_ns hsa-mir-424 Prostate Neoplasms 30345533 differential expression of miR-424 and miR-572 in recurrent PCa specimens can serve as novel biomarkers for prediction of Pca progression +tissue_expression_ns hsa-mir-572 Prostate Neoplasms 30345533 differential expression of miR-424 and miR-572 in recurrent PCa specimens can serve as novel biomarkers for prediction of Pca progression +tissue_expression_ns hsa-mir-106a "Cardiomyopathy, Dilated" 30346833 miR-15b-5p and miR-106a-5p expression levels could potentially serve as useful biomarkers for distinguishing between IsDC and IdDC +tissue_expression_ns hsa-mir-15b "Cardiomyopathy, Dilated" 30346833 miR-15b-5p and miR-106a-5p expression levels could potentially serve as useful biomarkers for distinguishing between IsDC and IdDC +tissue_expression_ns hsa-mir-155 Colorectal Carcinoma 30348685 "Expression of Circulating miR-155, miR-21, miR-221, miR-30a, miR-34a and miR-29a: Comparison of Colonic and Rectal Cancer." +tissue_expression_ns hsa-mir-21 Colorectal Carcinoma 30348685 "Expression of Circulating miR-155, miR-21, miR-221, miR-30a, miR-34a and miR-29a: Comparison of Colonic and Rectal Cancer." +tissue_expression_ns hsa-mir-221 Colorectal Carcinoma 30348685 "Expression of Circulating miR-155, miR-21, miR-221, miR-30a, miR-34a and miR-29a: Comparison of Colonic and Rectal Cancer." +tissue_expression_ns hsa-mir-29a Colorectal Carcinoma 30348685 "Expression of Circulating miR-155, miR-21, miR-221, miR-30a, miR-34a and miR-29a: Comparison of Colonic and Rectal Cancer." +tissue_expression_ns hsa-mir-30a Colorectal Carcinoma 30348685 "Expression of Circulating miR-155, miR-21, miR-221, miR-30a, miR-34a and miR-29a: Comparison of Colonic and Rectal Cancer." +tissue_expression_ns hsa-mir-34a Colorectal Carcinoma 30348685 "Expression of Circulating miR-155, miR-21, miR-221, miR-30a, miR-34a and miR-29a: Comparison of Colonic and Rectal Cancer." +tissue_expression_ns hsa-mir-1246 "Carcinoma, Breast" 30350935 In Situ Detection of Plasma Exosomal MicroRNA-1246 for Breast Cancer Diagnostics by a Au Nanoflare Probe. +tissue_expression_ns hsa-mir-4507 Prader-Willi Syndrome 30352401 "A different signature of miRNAs significantly distinguished PWS with steatosis from PWS without steatosis, involving miR-619-5p, miR-4507, miR-4656, miR-7847-3p and miR-6782-5p" +tissue_expression_ns hsa-mir-4656 Prader-Willi Syndrome 30352401 "A different signature of miRNAs significantly distinguished PWS with steatosis from PWS without steatosis, involving miR-619-5p, miR-4507, miR-4656, miR-7847-3p and miR-6782-5p" +tissue_expression_ns hsa-mir-619 Prader-Willi Syndrome 30352401 "A different signature of miRNAs significantly distinguished PWS with steatosis from PWS without steatosis, involving miR-619-5p, miR-4507, miR-4656, miR-7847-3p and miR-6782-5p" +tissue_expression_ns hsa-mir-6782 Prader-Willi Syndrome 30352401 "A different signature of miRNAs significantly distinguished PWS with steatosis from PWS without steatosis, involving miR-619-5p, miR-4507, miR-4656, miR-7847-3p and miR-6782-5p" +tissue_expression_ns hsa-mir-7847 Prader-Willi Syndrome 30352401 "A different signature of miRNAs significantly distinguished PWS with steatosis from PWS without steatosis, involving miR-619-5p, miR-4507, miR-4656, miR-7847-3p and miR-6782-5p" +tissue_expression_ns hsa-mir-1283 Endometriosis 30359864 "the treatment of quercetin induced miR-503-5p, miR-1283, miR-3714 and miR-6867-5p related to CCND1 in both cell lines and also stimulated miR-503-5p and miR-546 expression in the mouse model" +tissue_expression_ns hsa-mir-3714 Endometriosis 30359864 "the treatment of quercetin induced miR-503-5p, miR-1283, miR-3714 and miR-6867-5p related to CCND1 in both cell lines and also stimulated miR-503-5p and miR-546 expression in the mouse model" +tissue_expression_ns hsa-mir-503 Endometriosis 30359864 "the treatment of quercetin induced miR-503-5p, miR-1283, miR-3714 and miR-6867-5p related to CCND1 in both cell lines and also stimulated miR-503-5p and miR-546 expression in the mouse model" +tissue_expression_ns hsa-mir-503 Endometriosis 30359864 "the treatment of quercetin induced miR-503-5p, miR-1283, miR-3714 and miR-6867-5p related to CCND1 in both cell lines and also stimulated miR-503-5p and miR-546 expression in the mouse model" +tissue_expression_ns hsa-mir-6867 Endometriosis 30359864 "the treatment of quercetin induced miR-503-5p, miR-1283, miR-3714 and miR-6867-5p related to CCND1 in both cell lines and also stimulated miR-503-5p and miR-546 expression in the mouse model" +tissue_expression_ns hsa-mir-21 X-linked Alport Syndrome 30370838 Abnormal Expression of miR-21 in Kidney Tissue of Dogs With X-Linked Hereditary Nephropathy: A Canine Model of Chronic Kidney Disease. +tissue_expression_ns hsa-mir-1307 "Carcinoma, Breast" 30382159 "four miRNAs, hsa-miR-503, hsa-miR-1307, hsa-miR-212 and hsa-miR-592, were significantly associated with the prognosis of patients with breast cancer" +tissue_expression_ns hsa-mir-212 "Carcinoma, Breast" 30382159 "four miRNAs, hsa-miR-503, hsa-miR-1307, hsa-miR-212 and hsa-miR-592, were significantly associated with the prognosis of patients with breast cancer" +tissue_expression_ns hsa-mir-503 "Carcinoma, Breast" 30382159 "four miRNAs, hsa-miR-503, hsa-miR-1307, hsa-miR-212 and hsa-miR-592, were significantly associated with the prognosis of patients with breast cancer" +tissue_expression_ns hsa-mir-592 "Carcinoma, Breast" 30382159 "four miRNAs, hsa-miR-503, hsa-miR-1307, hsa-miR-212 and hsa-miR-592, were significantly associated with the prognosis of patients with breast cancer" +tissue_expression_up hsa-mir-155 "Lymphoma, Hodgkin" 12661002 upregulated +tissue_expression_up hsa-mir-17 "Leukemia, B-Cell" 15944707 overexpression +tissue_expression_up hsa-mir-17 "Lymphoma, B-Cell" 15944707 overexpressed +tissue_expression_up hsa-mir-18a "Leukemia, B-Cell" 15944707 overexpression +tissue_expression_up hsa-mir-18a "Lymphoma, B-Cell" 15944707 overexpressed +tissue_expression_up hsa-mir-19a "Leukemia, B-Cell" 15944707 overexpression +tissue_expression_up hsa-mir-19a "Lymphoma, B-Cell" 15944707 overexpressed +tissue_expression_up hsa-mir-19b-1 "Leukemia, B-Cell" 15944707 overexpression +tissue_expression_up hsa-mir-19b-1 "Lymphoma, B-Cell" 15944707 overexpressed +tissue_expression_up hsa-mir-19b-2 "Lymphoma, B-Cell" 15944707 overexpressed +tissue_expression_up hsa-mir-20a "Leukemia, B-Cell" 15944707 overexpression +tissue_expression_up hsa-mir-92a-1 "Leukemia, B-Cell" 15944707 overexpression +tissue_expression_up hsa-mir-21 Glioblastoma 16024602 upregulated +tissue_expression_up hsa-mir-21 Glioblastoma 16039986 upregulated +tissue_expression_up hsa-mir-155 "Lymphoma, Large B-Cell, Diffuse" 16041695 upregulated +tissue_expression_up hsa-mir-155 Breast Neoplasms 16103053 upregulated +tissue_expression_up hsa-mir-21 Breast Neoplasms 16103053 upregulation +tissue_expression_up hsa-mir-15b Hepatitis C Virus Infection 16331254 overexpression +tissue_expression_up hsa-mir-182 Hepatitis C Virus Infection 16331254 overexpression +tissue_expression_up hsa-mir-18a "Carcinoma, Hepatocellular" 16331254 upregulated +tissue_expression_up hsa-mir-18b "Carcinoma, Hepatocellular" 16331254 upregulated +tissue_expression_up hsa-mir-199b Hepatitis C Virus Infection 16331254 overexpression +tissue_expression_up hsa-mir-20a "Carcinoma, Hepatocellular" 16331254 overexpression +tissue_expression_up hsa-mir-20b "Carcinoma, Hepatocellular" 16331254 overexpression +tissue_expression_up hsa-mir-224 "Carcinoma, Hepatocellular" 16331254 upregulated +tissue_expression_up hsa-mir-224 Hepatitis C Virus Infection 16331254 overexpression +tissue_expression_up hsa-mir-92a-1 "Carcinoma, Hepatocellular" 16331254 overexpression +tissue_expression_up hsa-mir-92a-2 "Carcinoma, Hepatocellular" 16331254 overexpression +tissue_expression_up hsa-mir-92b "Carcinoma, Hepatocellular" 16331254 overexpression +tissue_expression_up hsa-mir-221 "Carcinoma, Thyroid, Papillary" 16365291 upregulation +tissue_expression_up hsa-mir-106a Colon Neoplasms 16461460 overexpressed +tissue_expression_up hsa-mir-106a Pancreatic Neoplasms 16461460 overexpressed +tissue_expression_up hsa-mir-106a Prostate Neoplasms 16461460 overexpressed +tissue_expression_up hsa-mir-107 Colon Neoplasms 16461460 overexpressed +tissue_expression_up hsa-mir-107 Gastric Neoplasms 16461460 overexpressed +tissue_expression_up hsa-mir-107 Pancreatic Neoplasms 16461460 overexpressed +tissue_expression_up hsa-mir-128-2 Colon Neoplasms 16461460 overexpressed +tissue_expression_up hsa-mir-128-2 Lung Neoplasms 16461460 overexpressed +tissue_expression_up hsa-mir-128-2 Pancreatic Neoplasms 16461460 overexpressed +tissue_expression_up hsa-mir-146a Breast Neoplasms 16461460 overexpressed +tissue_expression_up hsa-mir-146a Pancreatic Neoplasms 16461460 overexpressed +tissue_expression_up hsa-mir-146a Prostate Neoplasms 16461460 overexpressed +tissue_expression_up hsa-mir-146b Breast Neoplasms 16461460 overexpressed +tissue_expression_up hsa-mir-146b Pancreatic Neoplasms 16461460 overexpressed +tissue_expression_up hsa-mir-146b Prostate Neoplasms 16461460 overexpressed +tissue_expression_up hsa-mir-155 Breast Neoplasms 16461460 overexpressed +tissue_expression_up hsa-mir-155 Colon Neoplasms 16461460 overexpressed +tissue_expression_up hsa-mir-155 Lung Neoplasms 16461460 overexpressed +tissue_expression_up hsa-mir-17 Breast Neoplasms 16461460 overexpressed +tissue_expression_up hsa-mir-17 Colon Neoplasms 16461460 overexpressed +tissue_expression_up hsa-mir-17 Lung Neoplasms 16461460 overexpressed +tissue_expression_up hsa-mir-17 Pancreatic Neoplasms 16461460 overexpressed +tissue_expression_up hsa-mir-17 Prostate Neoplasms 16461460 overexpressed +tissue_expression_up hsa-mir-181b-1 Breast Neoplasms 16461460 overexpressed +tissue_expression_up hsa-mir-181b-1 Pancreatic Neoplasms 16461460 overexpressed +tissue_expression_up hsa-mir-181b-1 Prostate Neoplasms 16461460 overexpressed +tissue_expression_up hsa-mir-191 Colon Neoplasms 16461460 overexpressed +tissue_expression_up hsa-mir-191 Gastric Neoplasms 16461460 overexpressed +tissue_expression_up hsa-mir-191 Lung Neoplasms 16461460 overexpressed +tissue_expression_up hsa-mir-191 Pancreatic Neoplasms 16461460 overexpressed +tissue_expression_up hsa-mir-191 Prostate Neoplasms 16461460 overexpressed +tissue_expression_up hsa-mir-199a-1 Lung Neoplasms 16461460 overexpressed +tissue_expression_up hsa-mir-199a-1 Pancreatic Neoplasms 16461460 overexpressed +tissue_expression_up hsa-mir-199a-1 Prostate Neoplasms 16461460 overexpressed +tissue_expression_up hsa-mir-20a Colon Neoplasms 16461460 overexpressed +tissue_expression_up hsa-mir-20a Pancreatic Neoplasms 16461460 overexpressed +tissue_expression_up hsa-mir-20a Prostate Neoplasms 16461460 overexpressed +tissue_expression_up hsa-mir-21 Breast Neoplasms 16461460 overexpressed +tissue_expression_up hsa-mir-21 Colon Neoplasms 16461460 overexpressed +tissue_expression_up hsa-mir-21 Gastric Neoplasms 16461460 overexpressed +tissue_expression_up hsa-mir-21 Lung Neoplasms 16461460 overexpressed +tissue_expression_up hsa-mir-21 Pancreatic Neoplasms 16461460 overexpressed +tissue_expression_up hsa-mir-21 Prostate Neoplasms 16461460 overexpressed +tissue_expression_up hsa-mir-214 Gastric Neoplasms 16461460 overexpressed +tissue_expression_up hsa-mir-214 Pancreatic Neoplasms 16461460 overexpressed +tissue_expression_up hsa-mir-214 Prostate Neoplasms 16461460 overexpressed +tissue_expression_up hsa-mir-221 Colon Neoplasms 16461460 overexpressed +tissue_expression_up hsa-mir-221 Gastric Neoplasms 16461460 overexpressed +tissue_expression_up hsa-mir-221 Pancreatic Neoplasms 16461460 overexpressed +tissue_expression_up hsa-mir-223 Colon Neoplasms 16461460 overexpressed +tissue_expression_up hsa-mir-223 Gastric Neoplasms 16461460 overexpressed +tissue_expression_up hsa-mir-223 Pancreatic Neoplasms 16461460 overexpressed +tissue_expression_up hsa-mir-223 Prostate Neoplasms 16461460 overexpressed +tissue_expression_up hsa-mir-24-1 Colon Neoplasms 16461460 overexpressed +tissue_expression_up hsa-mir-24-1 Gastric Neoplasms 16461460 overexpressed +tissue_expression_up hsa-mir-24-1 Pancreatic Neoplasms 16461460 overexpressed +tissue_expression_up hsa-mir-24-2 Colon Neoplasms 16461460 overexpressed +tissue_expression_up hsa-mir-24-2 Gastric Neoplasms 16461460 overexpressed +tissue_expression_up hsa-mir-24-2 Pancreatic Neoplasms 16461460 overexpressed +tissue_expression_up hsa-mir-25 Gastric Neoplasms 16461460 overexpressed +tissue_expression_up hsa-mir-25 Pancreatic Neoplasms 16461460 overexpressed +tissue_expression_up hsa-mir-25 Prostate Neoplasms 16461460 overexpressed +tissue_expression_up hsa-mir-29b-1 Breast Neoplasms 16461460 overexpressed +tissue_expression_up hsa-mir-29b-1 Colon Neoplasms 16461460 overexpressed +tissue_expression_up hsa-mir-29b-1 Pancreatic Neoplasms 16461460 overexpressed +tissue_expression_up hsa-mir-29b-1 Prostate Neoplasms 16461460 overexpressed +tissue_expression_up hsa-mir-30c-1 Colon Neoplasms 16461460 overexpressed +tissue_expression_up hsa-mir-30c-1 Pancreatic Neoplasms 16461460 overexpressed +tissue_expression_up hsa-mir-30c-1 Prostate Neoplasms 16461460 overexpressed +tissue_expression_up hsa-mir-30c-2 Colon Neoplasms 16461460 overexpressed +tissue_expression_up hsa-mir-30c-2 Pancreatic Neoplasms 16461460 overexpressed +tissue_expression_up hsa-mir-30c-2 Prostate Neoplasms 16461460 overexpressed +tissue_expression_up hsa-mir-32 Colon Neoplasms 16461460 overexpressed +tissue_expression_up hsa-mir-32 Pancreatic Neoplasms 16461460 overexpressed +tissue_expression_up hsa-mir-32 Prostate Neoplasms 16461460 overexpressed +tissue_expression_up hsa-mir-106a Lung Neoplasms 16530703 upregulation +tissue_expression_up hsa-mir-146a Lung Neoplasms 16530703 upregulation +tissue_expression_up hsa-mir-146b Lung Neoplasms 16530703 upregulation +tissue_expression_up hsa-mir-150 Lung Neoplasms 16530703 upregulation +tissue_expression_up hsa-mir-155 Lung Neoplasms 16530703 upregulation +tissue_expression_up hsa-mir-17 Lung Neoplasms 16530703 upregulation +tissue_expression_up hsa-mir-191 Lung Neoplasms 16530703 upregulation +tissue_expression_up hsa-mir-197 Lung Neoplasms 16530703 upregulation +tissue_expression_up hsa-mir-203 Lung Neoplasms 16530703 upregulation +tissue_expression_up hsa-mir-205 Lung Neoplasms 16530703 upregulation +tissue_expression_up hsa-mir-21 Lung Neoplasms 16530703 upregulation +tissue_expression_up hsa-mir-210 Lung Neoplasms 16530703 upregulation +tissue_expression_up hsa-mir-212 Lung Neoplasms 16530703 upregulation +tissue_expression_up hsa-mir-214 Lung Neoplasms 16530703 upregulation +tissue_expression_up hsa-mir-24-2 Lung Neoplasms 16530703 upregulation +tissue_expression_up hsa-mir-221 "Carcinoma, Thyroid, Papillary" 16728577 upregulation +tissue_expression_up hsa-mir-222 "Carcinoma, Thyroid, Papillary" 16728577 upregulation +tissue_expression_up hsa-mir-141 Cholangiocarcinoma 16762633 "MiR-21, miR-141, and miR-200b were highly over-expressed in malignant cholangiocytes." +tissue_expression_up hsa-mir-200b Cholangiocarcinoma 16762633 "MiR-21, miR-141, and miR-200b were highly over-expressed in malignant cholangiocytes." +tissue_expression_up hsa-mir-21 Cholangiocarcinoma 16762633 "MiR-21, miR-141, and miR-200b were highly over-expressed in malignant cholangiocytes." +tissue_expression_up hsa-mir-183 Lung Neoplasms 17028596 "mir-124, mir-183, mir-223, mir-29 mir-124a-3 downregulated in lung cancer (Yanaihara et al., 2006);" +tissue_expression_up hsa-mir-206 Breast Neoplasms 17028596 "mir-206 upregulated in breast cancer (Iorio et al., 2005)." +tissue_expression_up hsa-mir-21 Neoplasms [unspecific] 17028596 "mir-21 upregulated in glioblastoma and associated with antiapoptosis upregulated in breast cancer (Iorio et al., 2005), and in a signature for solid cancers (Volinia et al., 2006)." +tissue_expression_up hsa-mir-221 Thyroid Neoplasms 17028596 Upregulated mir-221/222 in papillary thyroid cancer +tissue_expression_up hsa-mir-222 Thyroid Neoplasms 17028596 Upregulated mir-221/222 in papillary thyroid cancer +tissue_expression_up hsa-mir-9-1 Breast Neoplasms 17028596 "mir-9 increased in breast cancers (Iorio et al., 2005), but downregulated in lung cancers (Yanaihara et al., 2006)" +tissue_expression_up hsa-mir-9-2 Breast Neoplasms 17028596 "mir-9 increased in breast cancers (Iorio et al., 2005), but downregulated in lung cancers (Yanaihara et al., 2006)" +tissue_expression_up hsa-mir-9-3 Breast Neoplasms 17028596 "mir-9 increased in breast cancers (Iorio et al., 2005), but downregulated in lung cancers (Yanaihara et al., 2006)" +tissue_expression_up hsa-mir-195 "Cardiomyopathy, Hypertrophic" 17108080 "miR-23a, miR-23b, miR-24, miR-195, and miR-214, all of which were up-regulated during cardiac hypertrophy, appeared to be capable of inducing hypertrophic growth in vitro." +tissue_expression_up hsa-mir-195 Heart Failure 17108080 overexpressed +tissue_expression_up hsa-mir-199a-1 "Cardiomyopathy, Hypertrophic" 17108080 overexpressed +tissue_expression_up hsa-mir-199a-2 "Cardiomyopathy, Hypertrophic" 17108080 overexpressed +tissue_expression_up hsa-mir-214 "Cardiomyopathy, Hypertrophic" 17108080 overexpressed +tissue_expression_up hsa-mir-23a "Cardiomyopathy, Hypertrophic" 17108080 "miR-23a, miR-23b, miR-24, miR-195, and miR-214, all of which were up-regulated during cardiac hypertrophy, appeared to be capable of inducing hypertrophic growth in vitro." +tissue_expression_up hsa-mir-23b "Cardiomyopathy, Hypertrophic" 17108080 "miR-23a, miR-23b, miR-24, miR-195, and miR-214, all of which were up-regulated during cardiac hypertrophy, appeared to be capable of inducing hypertrophic growth in vitro." +tissue_expression_up hsa-mir-24-1 "Cardiomyopathy, Hypertrophic" 17108080 "miR-23a, miR-23b, miR-24, miR-195, and miR-214, all of which were up-regulated during cardiac hypertrophy, appeared to be capable of inducing hypertrophic growth in vitro." +tissue_expression_up hsa-mir-24-2 "Cardiomyopathy, Hypertrophic" 17108080 "miR-23a, miR-23b, miR-24, miR-195, and miR-214, all of which were up-regulated during cardiac hypertrophy, appeared to be capable of inducing hypertrophic growth in vitro." +tissue_expression_up hsa-mir-106b Schizophrenia 17326821 upregulation +tissue_expression_up hsa-mir-1-1 Coronary Artery Disease 17401374 overexpressed +tissue_expression_up hsa-mir-1-2 Coronary Artery Disease 17401374 overexpressed +tissue_expression_up hsa-mir-196a-2 Pancreatic Neoplasms 17473300 "Finally, high expression of miR-196a-2 was found to predict poor survival (median, 14.3 months [95% confidence interval, 12.4-16.2] vs 26.5 months [95% confidence interval, 23.4-29.6]; P = .009)." +tissue_expression_up hsa-mir-21 Breast Neoplasms 17531469 "MiR-21 is found to be highly expressed in numerous cancers like breast cancer, and glioblastoma and pancreatic cancer." +tissue_expression_up hsa-mir-21 Cholangiocarcinoma 17531469 "Recently Meng et al. showed that miR-21 is also overexpressed in malignant cholangiocarcinomas, a highly chemoresistant cancer type, knockdown of miR-21 sensitised cholangiocarcinoma cell lines for treatment with gemcitabin, whereas transfection of non-malignant cholangiocytes with precursor miR-21 made cells more resistant to gemcitabin." +tissue_expression_up hsa-mir-21 Glioblastoma 17531469 "MiR-21 is found to be highly expressed in numerous cancers like breast cancer, and glioblastoma and pancreatic cancer." +tissue_expression_up hsa-mir-21 Pancreatic Neoplasms 17531469 "MiR-21 is found to be highly expressed in numerous cancers like breast cancer, and glioblastoma and pancreatic cancer." +tissue_expression_up hsa-mir-143 "Carcinoma, Rectal" 17553685 Characterized mechanism of alpha-mangostin-induced cell death: caspase-independent apoptosis with release of endonuclease-G from mitochondria and increased miR-143 expression in human colorectal cancer DLD-1 cells. +tissue_expression_up hsa-mir-126 "Leukemia-Lymphoma, Precursor B-Cell Lymphoblastic" 17604727 strongly expressed +tissue_expression_up hsa-let-7a-1 Heart Failure 17606841 upregulated +tissue_expression_up hsa-let-7a-2 Heart Failure 17606841 upregulated +tissue_expression_up hsa-let-7b Heart Failure 17606841 upregulated +tissue_expression_up hsa-let-7c Heart Failure 17606841 upregulated +tissue_expression_up hsa-let-7d Heart Failure 17606841 upregulated +tissue_expression_up hsa-let-7e Heart Failure 17606841 upregulated +tissue_expression_up hsa-let-7f-1 Heart Failure 17606841 upregulated +tissue_expression_up hsa-let-7f-2 Heart Failure 17606841 upregulated +tissue_expression_up hsa-mir-106b Heart Failure 17606841 upregulated +tissue_expression_up hsa-mir-10b Heart Failure 17606841 upregulated +tissue_expression_up hsa-mir-1-1 Heart Failure 17606841 upregulated +tissue_expression_up hsa-mir-1-2 Heart Failure 17606841 upregulated +tissue_expression_up hsa-mir-125a Heart Failure 17606841 upregulated +tissue_expression_up hsa-mir-126 Heart Failure 17606841 upregulated +tissue_expression_up hsa-mir-129-2 Heart Failure 17606841 upregulated +tissue_expression_up hsa-mir-130a Heart Failure 17606841 upregulated +tissue_expression_up hsa-mir-132 Heart Failure 17606841 upregulated +tissue_expression_up hsa-mir-196a-1 Heart Failure 17606841 upregulated +tissue_expression_up hsa-mir-196a-2 Heart Failure 17606841 upregulated +tissue_expression_up hsa-mir-199b Heart Failure 17606841 upregulated +tissue_expression_up hsa-mir-200c Heart Failure 17606841 upregulated +tissue_expression_up hsa-mir-204 Heart Failure 17606841 upregulated +tissue_expression_up hsa-mir-205 Heart Failure 17606841 upregulated +tissue_expression_up hsa-mir-208a Heart Failure 17606841 upregulated +tissue_expression_up hsa-mir-21 Heart Failure 17606841 upregulated +tissue_expression_up hsa-mir-210 Heart Failure 17606841 upregulated +tissue_expression_up hsa-mir-211 Heart Failure 17606841 upregulated +tissue_expression_up hsa-mir-212 Heart Failure 17606841 upregulated +tissue_expression_up hsa-mir-215 Heart Failure 17606841 upregulated +tissue_expression_up hsa-mir-26a-1 Heart Failure 17606841 upregulated +tissue_expression_up hsa-mir-26a-2 Heart Failure 17606841 upregulated +tissue_expression_up hsa-mir-28 Heart Failure 17606841 upregulated +tissue_expression_up hsa-mir-296 Heart Failure 17606841 upregulated +tissue_expression_up hsa-mir-297 Heart Failure 17606841 upregulated +tissue_expression_up hsa-mir-29a Heart Failure 17606841 upregulated +tissue_expression_up hsa-mir-29b-1 Heart Failure 17606841 upregulated +tissue_expression_up hsa-mir-300 Heart Failure 17606841 upregulated +tissue_expression_up hsa-mir-302a Heart Failure 17606841 upregulated +tissue_expression_up hsa-mir-32 Heart Failure 17606841 upregulated +tissue_expression_up hsa-mir-320a Heart Failure 17606841 upregulated +tissue_expression_up hsa-mir-330 Heart Failure 17606841 upregulated +tissue_expression_up hsa-mir-340 Heart Failure 17606841 upregulated +tissue_expression_up hsa-mir-34b Heart Failure 17606841 upregulated +tissue_expression_up hsa-mir-365a Heart Failure 17606841 upregulated +tissue_expression_up hsa-mir-365b Heart Failure 17606841 upregulated +tissue_expression_up hsa-mir-367 Heart Failure 17606841 upregulated +tissue_expression_up hsa-mir-372 Heart Failure 17606841 upregulated +tissue_expression_up hsa-mir-373 Heart Failure 17606841 upregulated +tissue_expression_up hsa-mir-377 Heart Failure 17606841 upregulated +tissue_expression_up hsa-mir-381 Heart Failure 17606841 upregulated +tissue_expression_up hsa-mir-382 Heart Failure 17606841 upregulated +tissue_expression_up hsa-mir-423 Heart Failure 17606841 upregulated +tissue_expression_up hsa-mir-424 Heart Failure 17606841 upregulated +tissue_expression_up hsa-mir-429 Heart Failure 17606841 upregulated +tissue_expression_up hsa-mir-432 Heart Failure 17606841 upregulated +tissue_expression_up hsa-mir-500a Heart Failure 17606841 upregulated +tissue_expression_up hsa-mir-520c Heart Failure 17606841 upregulated +tissue_expression_up hsa-mir-525 Heart Failure 17606841 upregulated +tissue_expression_up hsa-mir-98 Heart Failure 17606841 upregulated +tissue_expression_up hsa-mir-146a Psoriasis 17622355 miR-146a was significantly over-expressed in psoriatic lesional skin p<0.001) but not in atopic eczema lesions when compared with healthy skin. +tissue_expression_up hsa-mir-203 Psoriasis 17622355 upregulation (lead to downregulation of its target SOCS3) +tissue_expression_up hsa-mir-21 Atopic Dermatitis 17622355 miR-21 was significantly up-regulated both psoriasis (p<0.001) and atopic eczema (p<0.001) as compared with healthy skin. +tissue_expression_up hsa-mir-21 Psoriasis 17622355 miR-21 was significantly up-regulated both psoriasis (p<0.001) and atopic eczema (p<0.001) as compared with healthy skin. +tissue_expression_up hsa-mir-221 Glioblastoma 17627278 "Interestingly, high levels of miR-221&222 appear in glioblastomas and correlate with low levels of p27(Kip1) protein. Thus, deregulated expression of miR-221&222 promotes cancerous growth by inhibiting the expression of p27(Kip1)." +tissue_expression_up hsa-mir-222 Glioblastoma 17627278 "Interestingly, high levels of miR-221&222 appear in glioblastomas and correlate with low levels of p27(Kip1) protein. Thus, deregulated expression of miR-221&222 promotes cancerous growth by inhibiting the expression of p27(Kip1)." +tissue_expression_up hsa-mir-103-1 Bladder Neoplasms 17826655 "Human micro-RNAs miR-223, miR-26b, miR-221, miR-103-1, miR-185, miR-23b, miR-203, miR-17-5p, miR-23a, and miR-205 were significantly up-regulated in bladder cancers (P < 0.05) compared to normal bladder mucosa." +tissue_expression_up hsa-mir-17 Bladder Neoplasms 17826655 "Human micro-RNAs miR-223, miR-26b, miR-221, miR-103-1, miR-185, miR-23b, miR-203, miR-17-5p, miR-23a, and miR-205 were significantly up-regulated in bladder cancers (P < 0.05) compared to normal bladder mucosa." +tissue_expression_up hsa-mir-185 Bladder Neoplasms 17826655 "Human micro-RNAs miR-223, miR-26b, miR-221, miR-103-1, miR-185, miR-23b, miR-203, miR-17-5p, miR-23a, and miR-205 were significantly up-regulated in bladder cancers (P < 0.05) compared to normal bladder mucosa." +tissue_expression_up hsa-mir-203 Bladder Neoplasms 17826655 "Human micro-RNAs miR-223, miR-26b, miR-221, miR-103-1, miR-185, miR-23b, miR-203, miR-17-5p, miR-23a, and miR-205 were significantly up-regulated in bladder cancers (P < 0.05) compared to normal bladder mucosa." +tissue_expression_up hsa-mir-205 Bladder Neoplasms 17826655 "Human micro-RNAs miR-223, miR-26b, miR-221, miR-103-1, miR-185, miR-23b, miR-203, miR-17-5p, miR-23a, and miR-205 were significantly up-regulated in bladder cancers (P < 0.05) compared to normal bladder mucosa." +tissue_expression_up hsa-mir-221 Bladder Neoplasms 17826655 "Human micro-RNAs miR-223, miR-26b, miR-221, miR-103-1, miR-185, miR-23b, miR-203, miR-17-5p, miR-23a, and miR-205 were significantly up-regulated in bladder cancers (P < 0.05) compared to normal bladder mucosa." +tissue_expression_up hsa-mir-223 Bladder Neoplasms 17826655 "Human micro-RNAs miR-223, miR-26b, miR-221, miR-103-1, miR-185, miR-23b, miR-203, miR-17-5p, miR-23a, and miR-205 were significantly up-regulated in bladder cancers (P < 0.05) compared to normal bladder mucosa." +tissue_expression_up hsa-mir-23a Bladder Neoplasms 17826655 "Human micro-RNAs miR-223, miR-26b, miR-221, miR-103-1, miR-185, miR-23b, miR-203, miR-17-5p, miR-23a, and miR-205 were significantly up-regulated in bladder cancers (P < 0.05) compared to normal bladder mucosa." +tissue_expression_up hsa-mir-23b Bladder Neoplasms 17826655 "Human micro-RNAs miR-223, miR-26b, miR-221, miR-103-1, miR-185, miR-23b, miR-203, miR-17-5p, miR-23a, and miR-205 were significantly up-regulated in bladder cancers (P < 0.05) compared to normal bladder mucosa." +tissue_expression_up hsa-mir-26b Bladder Neoplasms 17826655 "Human micro-RNAs miR-223, miR-26b, miR-221, miR-103-1, miR-185, miR-23b, miR-203, miR-17-5p, miR-23a, and miR-205 were significantly up-regulated in bladder cancers (P < 0.05) compared to normal bladder mucosa." +tissue_expression_up hsa-mir-140 Ovarian Neoplasms 17875710 "The most significantly overexpressed miRNAs were miR-200a, miR-141, miR-200c, and miR-200b, whereas miR-199a, miR-140, miR-145, and miR-125b1 were among the most down-modulated miRNAs." +tissue_expression_up hsa-mir-141 Ovarian Neoplasms 17875710 "The most significantly overexpressed miRNAs were miR-200a, miR-141, miR-200c, and miR-200b, whereas miR-199a, miR-140, miR-145, and miR-125b1 were among the most down-modulated miRNAs." +tissue_expression_up hsa-mir-145 Ovarian Neoplasms 17875710 "The most significantly overexpressed miRNAs were miR-200a, miR-141, miR-200c, and miR-200b, whereas miR-199a, miR-140, miR-145, and miR-125b1 were among the most down-modulated miRNAs." +tissue_expression_up hsa-mir-199a Ovarian Neoplasms 17875710 "The most significantly overexpressed miRNAs were miR-200a, miR-141, miR-200c, and miR-200b, whereas miR-199a, miR-140, miR-145, and miR-125b1 were among the most down-modulated miRNAs." +tissue_expression_up hsa-mir-200a Ovarian Neoplasms 17875710 "The most significantly overexpressed miRNAs were miR-200a, miR-141, miR-200c, and miR-200b, whereas miR-199a, miR-140, miR-145, and miR-125b1 were among the most down-modulated miRNAs." +tissue_expression_up hsa-mir-200b Ovarian Neoplasms 17875710 "The most significantly overexpressed miRNAs were miR-200a, miR-141, miR-200c, and miR-200b, whereas miR-199a, miR-140, miR-145, and miR-125b1 were among the most down-modulated miRNAs." +tissue_expression_up hsa-mir-200c Ovarian Neoplasms 17875710 "The most significantly overexpressed miRNAs were miR-200a, miR-141, miR-200c, and miR-200b, whereas miR-199a, miR-140, miR-145, and miR-125b1 were among the most down-modulated miRNAs." +tissue_expression_up hsa-mir-34a Colon Neoplasms 17875987 highly upregulated +tissue_expression_up hsa-mir-34a Neuroblastoma 17888029 All of the Fe-NTA-induced rat renal carcinomas and an array of human cancers (151 positive cases of 177) showed high expression of miRNA-34a. +tissue_expression_up hsa-mir-183 Retinitis Pigmentosa 18034880 "Expression of miR-1 and miR-133 decreased by more than 2.5-fold (P < 0.001), whereas expression of miR-96 and miR-183 increased by more than 3-fold (P < 0.001) in Pro347Ser retinas, as validated by qPCR." +tissue_expression_up hsa-mir-96 Retinitis Pigmentosa 18034880 "Expression of miR-1 and miR-133 decreased by more than 2.5-fold (P < 0.001), whereas expression of miR-96 and miR-183 increased by more than 3-fold (P < 0.001) in Pro347Ser retinas, as validated by qPCR." +tissue_expression_up hsa-let-7g Schizophrenia 18184693 upregulated +tissue_expression_up hsa-let-7i Neoplasms [unspecific] 18187804 "Changing the cellular levels of let-7i, mir-16, and mir-21 affected the potencies of a number of the anticancer agents by up to 4-fold." +tissue_expression_up hsa-mir-16 Neoplasms [unspecific] 18187804 "Changing the cellular levels of let-7i, mir-16, and mir-21 affected the potencies of a number of the anticancer agents by up to 4-fold." +tissue_expression_up hsa-mir-21 Neoplasms [unspecific] 18187804 "Changing the cellular levels of let-7i, mir-16, and mir-21 affected the potencies of a number of the anticancer agents by up to 4-fold." +tissue_expression_up hsa-mir-21 "Carcinoma, Rectal" 18196926 "Expression levels of analyzed miRNAs significantly differed among tumors and adjacent non-tumor tissues: miR-21 (p = 0.0001) and miR-31 (p = 0.0006) were upregulated, and miR-143 (p = 0.011) and miR-145 (p = 0.003) were downregulated in tumors." +tissue_expression_up hsa-mir-31 "Carcinoma, Rectal" 18196926 "Expression levels of analyzed miRNAs significantly differed among tumors and adjacent non-tumor tissues: miR-21 (p = 0.0001) and miR-31 (p = 0.0006) were upregulated, and miR-143 (p = 0.011) and miR-145 (p = 0.003) were downregulated in tumors." +tissue_expression_up hsa-mir-203 Esophageal Neoplasms 18242245 Both mir_203 and mir_205 were expressed 2- to 10-fold lower in squamous cell carcinoma and adenocarcinomas than in normal epithelium. +tissue_expression_up hsa-mir-205 Esophageal Neoplasms 18242245 Both mir_203 and mir_205 were expressed 2- to 10-fold lower in squamous cell carcinoma and adenocarcinomas than in normal epithelium. +tissue_expression_up hsa-mir-100 "Carcinoma, Hepatocellular" 18307259 "miR-122, miR-100, and miR-10a were overexpressed whereas miR-198 and miR-145 were up to 5-fold down-regulated in hepatic tumors compared to normal liver parenchyma." +tissue_expression_up hsa-mir-10a "Carcinoma, Hepatocellular" 18307259 "miR-122, miR-100, and miR-10a were overexpressed whereas miR-198 and miR-145 were up to 5-fold down-regulated in hepatic tumors compared to normal liver parenchyma." +tissue_expression_up hsa-mir-122 "Carcinoma, Hepatocellular" 18307259 "miR-122, miR-100, and miR-10a were overexpressed whereas miR-198 and miR-145 were up to 5-fold down-regulated in hepatic tumors compared to normal liver parenchyma." +tissue_expression_up hsa-mir-191 Neoplasms [unspecific] 18375788 increased +tissue_expression_up hsa-mir-146a Rheumatoid Arthritis 18383392 This study provides the first description of increased expression of miRNA miR-155 and miR-146a in RA. +tissue_expression_up hsa-mir-155 Rheumatoid Arthritis 18383392 This study provides the first description of increased expression of miRNA miR-155 and miR-146a in RA. +tissue_expression_up hsa-mir-221 Neoplasms [unspecific] 18413744 "Thus, the physiologic up-regulation of miR-221 and miR-222 is tightly linked to a cell cycle checkpoint that ensures cell survival by coordinating competency for initiation of S phase with growth factor signaling pathways that stimulate cell proliferation." +tissue_expression_up hsa-mir-222 Neoplasms [unspecific] 18413744 "Thus, the physiologic up-regulation of miR-221 and miR-222 is tightly linked to a cell cycle checkpoint that ensures cell survival by coordinating competency for initiation of S phase with growth factor signaling pathways that stimulate cell proliferation." +tissue_expression_up hsa-mir-126 "Carcinoma, Hepatocellular" 18433021 "miR-96 was overexpressed in HBV tumors, and miR-126* was down-regulated in alcohol-related hepatocellular carcinoma." +tissue_expression_up hsa-mir-141 Ovarian Neoplasms 18451233 Higher +tissue_expression_up hsa-mir-18a Ovarian Neoplasms 18451233 Higher +tissue_expression_up hsa-mir-429 Ovarian Neoplasms 18451233 Higher +tissue_expression_up hsa-mir-93 Ovarian Neoplasms 18451233 Higher +tissue_expression_up hsa-mir-150 Retinal Neovascularization 18500251 increased +tissue_expression_up hsa-mir-184 Retinal Neovascularization 18500251 increased +tissue_expression_up hsa-mir-31 Retinal Neovascularization 18500251 increased +tissue_expression_up hsa-mir-451a Retinal Neovascularization 18500251 increased +tissue_expression_up hsa-mir-21 Ovarian Neoplasms 18560586 "we identify several miRNAs aberrantly expressed in human ovarian cancer tissues and cell lines. miR-221 stands out as a highly elevated miRNA in ovarian cancer, while miR-21 and several members of the let-7 family are found downregulated." +tissue_expression_up hsa-mir-146b Thyroid Neoplasms 18587330 miR-146b: overexpressed +tissue_expression_up hsa-mir-221 Thyroid Neoplasms 18587330 miR-221: overexpressed +tissue_expression_up hsa-mir-222 Thyroid Neoplasms 18587330 miR-222: overexpressed +tissue_expression_up hsa-mir-146a Urinary Bladder Cancer 18596939 miR-146a: upregulated +tissue_expression_up hsa-mir-155 Urinary Bladder Cancer 18596939 miR-155: upregulated +tissue_expression_up hsa-mir-15b Urinary Bladder Cancer 18596939 miR-15b: upregulated +tissue_expression_up hsa-mir-16-1 Urinary Bladder Cancer 18596939 miR-16: upregulated +tissue_expression_up hsa-mir-16-2 Urinary Bladder Cancer 18596939 miR-16: upregulated +tissue_expression_up hsa-mir-21 Pancreatic Neoplasms 18642050 miR-21: MicroRNA-21 is overexpressed in pancreatic cancer and a potential predictor of survival +tissue_expression_up hsa-let-7f "Carcinoma, Pancreatic" 18665421 "In addition, when analyzed according to specific cancer phenotypes, miR-15a and miR-16 show a significant downregulation in canine ductal carcinomas while miRsR-181b, -21, -29b, and let-7f show a significant upregulation in canine tubular papillary carcinomas." +tissue_expression_up hsa-mir-181b "Carcinoma, Pancreatic" 18665421 "In addition, when analyzed according to specific cancer phenotypes, miR-15a and miR-16 show a significant downregulation in canine ductal carcinomas while miRsR-181b, -21, -29b, and let-7f show a significant upregulation in canine tubular papillary carcinomas." +tissue_expression_up hsa-mir-21 "Carcinoma, Pancreatic" 18665421 "In addition, when analyzed according to specific cancer phenotypes, miR-15a and miR-16 show a significant downregulation in canine ductal carcinomas while miRsR-181b, -21, -29b, and let-7f show a significant upregulation in canine tubular papillary carcinomas." +tissue_expression_up hsa-mir-29b "Carcinoma, Pancreatic" 18665421 "In addition, when analyzed according to specific cancer phenotypes, miR-15a and miR-16 show a significant downregulation in canine ductal carcinomas while miRsR-181b, -21, -29b, and let-7f show a significant upregulation in canine tubular papillary carcinomas." +tissue_expression_up hsa-mir-106b Prostate Neoplasms 18676839 miR-106b: significantly higher expression +tissue_expression_up hsa-mir-25 Prostate Neoplasms 18676839 miR-25: significantly higher expression +tissue_expression_up hsa-mir-32 Prostate Neoplasms 18676839 miR-32: significantly higher expression +tissue_expression_up hsa-mir-93 Prostate Neoplasms 18676839 miR-93: significantly higher expression +tissue_expression_up hsa-mir-205 "Carcinoma, Lung, Non-Small-Cell" 18719201 miR-205: overexpression +tissue_expression_up hsa-mir-21 "Carcinoma, Lung, Non-Small-Cell" 18719201 miR-21: overexpression +tissue_expression_up hsa-mir-146a Rheumatoid Arthritis 18759964 miR-146a: Upregulated miR-146a expression in peripheral blood mononuclear cells +tissue_expression_up hsa-let-7a-1 Head And Neck Neoplasms 18798260 let-7a: overexpressed +tissue_expression_up hsa-let-7a-2 Head And Neck Neoplasms 18798260 let-7a: overexpressed +tissue_expression_up hsa-let-7a-3 Head And Neck Neoplasms 18798260 let-7a: overexpressed +tissue_expression_up hsa-let-7b Head And Neck Neoplasms 18798260 let-7b: overexpressed +tissue_expression_up hsa-let-7c Head And Neck Neoplasms 18798260 let-7c: overexpressed +tissue_expression_up hsa-let-7d Head And Neck Neoplasms 18798260 let-7d: overexpressed +tissue_expression_up hsa-let-7e Head And Neck Neoplasms 18798260 let-7e: overexpressed +tissue_expression_up hsa-let-7f-1 Head And Neck Neoplasms 18798260 let-7f: overexpressed +tissue_expression_up hsa-let-7f-2 Head And Neck Neoplasms 18798260 let-7f: overexpressed +tissue_expression_up hsa-let-7g Head And Neck Neoplasms 18798260 let-7g: overexpressed +tissue_expression_up hsa-let-7i Head And Neck Neoplasms 18798260 let-7i: overexpressed +tissue_expression_up hsa-mir-142 Head And Neck Neoplasms 18798260 miR-142-3p: overexpressed +tissue_expression_up hsa-mir-146b Head And Neck Neoplasms 18798260 miR-146b: overexpressed +tissue_expression_up hsa-mir-155 Head And Neck Neoplasms 18798260 miR-155: overexpressed +tissue_expression_up hsa-mir-18a Head And Neck Neoplasms 18798260 miR-18: overexpressed +tissue_expression_up hsa-mir-18b Head And Neck Neoplasms 18798260 miR-18: overexpressed +tissue_expression_up hsa-mir-21 Head And Neck Neoplasms 18798260 miR-21: overexpressed +tissue_expression_up hsa-mir-29c Head And Neck Neoplasms 18798260 miR-29c: overexpressed +tissue_expression_up hsa-mir-143 Obesity 18809385 miR-143: Up-regulated expression of microRNA-143 in association with obesity in adipose +tissue_expression_up hsa-mir-204 Breast Neoplasms 18922924 miR-204: upregulated +tissue_expression_up hsa-mir-510 Breast Neoplasms 18922924 miR-510: upregulated +tissue_expression_up hsa-mir-135b Prostate Neoplasms 18949015 miR-135b: up-regulated +tissue_expression_up hsa-mir-194-1 Prostate Neoplasms 18949015 miR-194: up-regulated +tissue_expression_up hsa-mir-194-2 Prostate Neoplasms 18949015 miR-194: up-regulated +tissue_expression_up hsa-mir-126 Ovarian Neoplasms 18954897 miR-126: over-expressed +tissue_expression_up hsa-mir-21 Ovarian Neoplasms 18954897 miR-21: over-expressed +tissue_expression_up hsa-mir-29a Ovarian Neoplasms 18954897 miR-29a: over-expressed +tissue_expression_up hsa-mir-92b Ovarian Neoplasms 18954897 miR-92: over-expressed +tissue_expression_up hsa-mir-93 Ovarian Neoplasms 18954897 miR-93: over-expressed +tissue_expression_up hsa-mir-106a Gastric Neoplasms 18996365 "The level of miR-106a in cancer tissues was significantly higher than that in non-tumor tissues, with an average 1.625-fold increase. miR-106a level was significantly associated with tumor stage, size and differentiation; lymphatic and distant metastasis; and invasion (P<0.01)." +tissue_expression_up hsa-mir-15b Pancreatic Neoplasms 19030927 miR-15b: upregulated +tissue_expression_up hsa-mir-186 Pancreatic Neoplasms 19030927 miR-186: upregulated +tissue_expression_up hsa-mir-190a Pancreatic Neoplasms 19030927 miR-190: upregulated +tissue_expression_up hsa-mir-196a-1 Pancreatic Neoplasms 19030927 miR-196a: upregulated +tissue_expression_up hsa-mir-196a-2 Pancreatic Neoplasms 19030927 miR-196a: upregulated +tissue_expression_up hsa-mir-200b Pancreatic Neoplasms 19030927 miR-200b: upregulated +tissue_expression_up hsa-mir-221 Pancreatic Neoplasms 19030927 miR-221: upregulated +tissue_expression_up hsa-mir-222 Pancreatic Neoplasms 19030927 miR-222: upregulated +tissue_expression_up hsa-mir-95 Pancreatic Neoplasms 19030927 miR-95: upregulated +tissue_expression_up hsa-mir-221 "Carcinoma, Thyroid, Papillary" 19030936 Primary or mature miR-221 were overexpressed in PTC as compared with HT-ori3. +tissue_expression_up hsa-mir-103a-1 "Adenocarcinoma, Endometrial" 19065659 miR-103: upregulated +tissue_expression_up hsa-mir-103a-2 "Adenocarcinoma, Endometrial" 19065659 miR-103: upregulated +tissue_expression_up hsa-mir-106a "Adenocarcinoma, Endometrial" 19065659 miR-106a: upregulated +tissue_expression_up hsa-mir-151a "Adenocarcinoma, Endometrial" 19065659 miR-151: upregulated +tissue_expression_up hsa-mir-155 "Adenocarcinoma, Endometrial" 19065659 miR-155: upregulated +tissue_expression_up hsa-mir-182 "Adenocarcinoma, Endometrial" 19065659 miR-182: upregulated +tissue_expression_up hsa-mir-183 "Adenocarcinoma, Endometrial" 19065659 miR-183: upregulated +tissue_expression_up hsa-mir-194-1 "Adenocarcinoma, Endometrial" 19065659 miR-194: upregulated +tissue_expression_up hsa-mir-194-2 "Adenocarcinoma, Endometrial" 19065659 miR-194: upregulated +tissue_expression_up hsa-mir-200a "Adenocarcinoma, Endometrial" 19065659 miR-200a: upregulated +tissue_expression_up hsa-mir-200c "Adenocarcinoma, Endometrial" 19065659 miR-200c: upregulated +tissue_expression_up hsa-mir-203 "Adenocarcinoma, Endometrial" 19065659 miR-203: upregulated +tissue_expression_up hsa-mir-205 "Adenocarcinoma, Endometrial" 19065659 miR-205: upregulated +tissue_expression_up hsa-mir-210 "Adenocarcinoma, Endometrial" 19065659 miR-210: upregulated +tissue_expression_up hsa-mir-223 "Adenocarcinoma, Endometrial" 19065659 miR-223: upregulated +tissue_expression_up hsa-mir-95 "Adenocarcinoma, Endometrial" 19065659 miR-95: upregulated +tissue_expression_up hsa-mir-100 Endometriosis 19074548 miR-100: upregulated +tissue_expression_up hsa-mir-1-1 Endometriosis 19074548 miR-1: upregulated +tissue_expression_up hsa-mir-1-2 Endometriosis 19074548 miR-1: upregulated +tissue_expression_up hsa-mir-125a Endometriosis 19074548 miR-125a: upregulated +tissue_expression_up hsa-mir-125b-1 Endometriosis 19074548 miR-125b: upregulated +tissue_expression_up hsa-mir-125b-2 Endometriosis 19074548 miR-125b: upregulated +tissue_expression_up hsa-mir-126 Endometriosis 19074548 miR-126: upregulated +tissue_expression_up hsa-mir-143 Endometriosis 19074548 miR-143: upregulated +tissue_expression_up hsa-mir-145 Endometriosis 19074548 miR-145: upregulated +tissue_expression_up hsa-mir-150 Endometriosis 19074548 miR-150: upregulated +tissue_expression_up hsa-mir-194-1 Endometriosis 19074548 miR-194: upregulated +tissue_expression_up hsa-mir-194-2 Endometriosis 19074548 miR-194: upregulated +tissue_expression_up hsa-mir-223 Endometriosis 19074548 miR-223: upregulated +tissue_expression_up hsa-mir-29c Endometriosis 19074548 miR-29c: upregulated +tissue_expression_up hsa-mir-365a Endometriosis 19074548 miR-365: upregulated +tissue_expression_up hsa-mir-365b Endometriosis 19074548 miR-365: upregulated +tissue_expression_up hsa-mir-99a Endometriosis 19074548 miR-99a: upregulated +tissue_expression_up hsa-mir-99b Endometriosis 19074548 miR-99b: upregulated +tissue_expression_up hsa-mir-205 "Adenocarcinoma, Endometrial" 19077565 miR-205: upregulated +tissue_expression_up hsa-mir-429 "Adenocarcinoma, Endometrial" 19077565 miR-429: upregulated +tissue_expression_up hsa-mir-449a "Adenocarcinoma, Endometrial" 19077565 miR-449: upregulated +tissue_expression_up hsa-mir-449b "Adenocarcinoma, Endometrial" 19077565 miR-449: upregulated +tissue_expression_up hsa-mir-21 Breast Ductal Carcinoma 19080492 miR-21: expression is significantly higher than the normal controls +tissue_expression_up hsa-mir-223 Ischemia-Reperfusion Injury 19104939 miR-223: miR-223 expression levels were greatly up-regulated in the livers after 75 min ischemia followed by 120 min reperfusion when compared to sham controls +tissue_expression_up hsa-mir-210 Neoplasms [unspecific] 19141645 "two miRs, miR-210 and miR-373, are up-regulated in a hypoxia-inducible factor-1alpha-dependent manner in hypoxic cells" +tissue_expression_up hsa-mir-373 Neoplasms [unspecific] 19141645 "two miRs, miR-210 and miR-373, are up-regulated in a hypoxia-inducible factor-1alpha-dependent manner in hypoxic cells" +tissue_expression_up hsa-mir-150 Gastric Neoplasms 19148490 miR-150: patients with high expression levels have lower survival time +tissue_expression_up hsa-mir-20b Gastric Neoplasms 19148490 miR-20b: patients with high expression levels have lower survival time +tissue_expression_up hsa-mir-34b Gastric Neoplasms 19148490 miR-34b: upregulated in undifferentiated gastric cancer +tissue_expression_up hsa-mir-34c Gastric Neoplasms 19148490 miR-34c: upregulated in undifferentiated gastric cancer +tissue_expression_up hsa-mir-21 Astrocytoma 19159078 miR-21: upregulation +tissue_expression_up hsa-mir-221 Astrocytoma 19159078 miR-221: upregulation +tissue_expression_up hsa-mir-155 Neoplasms [unspecific] 19175697 "The expression of a subset of miRs (e.g. miR-21 and miR-155) was found to be consistently up-regulated, whereas another subset of miRs (e.g.miR-143 and miR-145) was consistently down-regulated across different cancer types suggesting their involvement in regulating common cellular processes whose deregulation may lead to tumourigenesis." +tissue_expression_up hsa-mir-21 Neoplasms [unspecific] 19175697 "The expression of a subset of miRs (e.g. miR-21 and miR-155) was found to be consistently up-regulated, whereas another subset of miRs (e.g.miR-143 and miR-145) was consistently down-regulated across different cancer types suggesting their involvement in regulating common cellular processes whose deregulation may lead to tumourigenesis." +tissue_expression_up hsa-mir-106b Gastric Neoplasms 19175831 miR-106b: overexpressed +tissue_expression_up hsa-mir-17 Gastric Neoplasms 19175831 miR-17: overexpressed +tissue_expression_up hsa-mir-18a Gastric Neoplasms 19175831 miR-18a: overexpressed +tissue_expression_up hsa-mir-18b Gastric Neoplasms 19175831 miR-18b: overexpressed +tissue_expression_up hsa-mir-19a Gastric Neoplasms 19175831 miR-19a: overexpressed +tissue_expression_up hsa-mir-20a Gastric Neoplasms 19175831 miR-20a: overexpressed +tissue_expression_up hsa-mir-20b Gastric Neoplasms 19175831 miR-20b: overexpressed +tissue_expression_up hsa-mir-21 Gastric Neoplasms 19175831 miR-21: overexpressed +tissue_expression_up hsa-mir-340 Gastric Neoplasms 19175831 miR-340*: overexpressed +tissue_expression_up hsa-mir-421 Gastric Neoplasms 19175831 miR-421: overexpressed +tissue_expression_up hsa-mir-658 Gastric Neoplasms 19175831 miR-658: overexpressed +tissue_expression_up hsa-mir-21 Head And Neck Neoplasms 19179615 miR-21: is frequently overexpressed in human HNSCC +tissue_expression_up hsa-mir-146a Hepatitis B Virus Infection 19187610 miR-146a: up-regulated +tissue_expression_up hsa-mir-181a-2 Hepatitis B Virus Infection 19187610 miR-181a: up-regulated +tissue_expression_up hsa-mir-181b-1 Hepatitis B Virus Infection 19187610 miR-181b: up-regulated +tissue_expression_up hsa-mir-181b-2 Hepatitis B Virus Infection 19187610 miR-181b: up-regulated +tissue_expression_up hsa-mir-200a Hepatitis B Virus Infection 19187610 miR-200: up-regulated +tissue_expression_up hsa-mir-200b Hepatitis B Virus Infection 19187610 miR-200: up-regulated +tissue_expression_up hsa-mir-200c Hepatitis B Virus Infection 19187610 miR-200: up-regulated +tissue_expression_up hsa-mir-17 Colorectal Carcinoma 19201770 miR-17-3p: up-regulated both in plasma and tissue samples +tissue_expression_up hsa-mir-21 Breast Neoplasms 19212625 "miR-21: upregulated, The expression levels of miR-21 were correlated with PTEN and commonly used clinicopathologic features of breast cancer" +tissue_expression_up hsa-mir-155 "Carcinoma, Renal Cell" 19228262 miR-155: overexpressed in malignant cancer than non-malignant one +tissue_expression_up hsa-mir-16-1 "Carcinoma, Renal Cell" 19228262 miR-16: overexpressed in malignant cancer than non-malignant one +tissue_expression_up hsa-mir-16-2 "Carcinoma, Renal Cell" 19228262 miR-16: overexpressed in malignant cancer than non-malignant one +tissue_expression_up hsa-mir-210 "Carcinoma, Renal Cell" 19228262 miR-210: overexpressed in malignant cancer than non-malignant one +tissue_expression_up hsa-mir-224 "Carcinoma, Renal Cell" 19228262 miR-224: overexpressed in malignant cancer than non-malignant one +tissue_expression_up hsa-mir-452 "Carcinoma, Renal Cell" 19228262 miR-452*: overexpressed in malignant cancer than non-malignant one +tissue_expression_up hsa-mir-21 Esophageal Neoplasms 19276261 "miR-21: overexpressed compared with with matched normal epitheliums, regulates the proliferation and invasion" +tissue_expression_up hsa-mir-143 Endotoxemia 19284987 "Data analysis revealed that five miRNAs consistently responded to LPS-infusion, four of which were down-regulated (miR-146b, miR-150, miR-342, and let-7g) and one was up-regulated (miR-143). The miR-150 and mir-342 response was confirmed by real-time PCR." +tissue_expression_up hsa-mir-17 Colorectal Carcinoma 19287964 miR-17-5p: up-regulated +tissue_expression_up hsa-mir-183 Colorectal Carcinoma 19287964 miR-183: up-regulated +tissue_expression_up hsa-mir-18a Colorectal Carcinoma 19287964 miR-18a: up-regulated +tissue_expression_up hsa-mir-20a Colorectal Carcinoma 19287964 miR-20a: up-regulated +tissue_expression_up hsa-mir-31 Colorectal Carcinoma 19287964 miR-31: up-regulated +tissue_expression_up hsa-mir-92b Colorectal Carcinoma 19287964 miR-92: up-regulated +tissue_expression_up hsa-mir-155 Breast Neoplasms 19290006 "Compared with normal breast samples, a panel of miRs was consistently dysregulated in breast cancer, including earlier-reported breast cancer-related miRs, such as upregulated miR-21, miR-155, miR-191, and miR-196a, and downregulated miR-125b and miR-221." +tissue_expression_up hsa-mir-191 Breast Neoplasms 19290006 "Compared with normal breast samples, a panel of miRs was consistently dysregulated in breast cancer, including earlier-reported breast cancer-related miRs, such as upregulated miR-21, miR-155, miR-191, and miR-196a, and downregulated miR-125b and miR-221." +tissue_expression_up hsa-mir-196a Breast Neoplasms 19290006 "Compared with normal breast samples, a panel of miRs was consistently dysregulated in breast cancer, including earlier-reported breast cancer-related miRs, such as upregulated miR-21, miR-155, miR-191, and miR-196a, and downregulated miR-125b and miR-221." +tissue_expression_up hsa-mir-21 Breast Neoplasms 19290006 "Compared with normal breast samples, a panel of miRs was consistently dysregulated in breast cancer, including earlier-reported breast cancer-related miRs, such as upregulated miR-21, miR-155, miR-191, and miR-196a, and downregulated miR-125b and miR-221." +tissue_expression_up hsa-mir-21 Cholangiocarcinoma 19296468 miR-21: overexpressed +tissue_expression_up hsa-mir-299 Primary Biliary Cirrhosis 19345069 A total of 35 independent miRNAs were found to be differentially expressed in PBC (p < 0.001).Quantitative PCR was employed to validate down-regulation of microRNA-122a (miR-122a) and miR-26a and the increased expression of miR-328 and miR-299-5p. +tissue_expression_up hsa-mir-328 Primary Biliary Cirrhosis 19345069 A total of 35 independent miRNAs were found to be differentially expressed in PBC (p < 0.001).Quantitative PCR was employed to validate down-regulation of microRNA-122a (miR-122a) and miR-26a and the increased expression of miR-328 and miR-299-5p. +tissue_expression_up hsa-mir-140 Salivary Gland Neoplasms 19347935 miR-140: up-regulated +tissue_expression_up hsa-mir-154 Salivary Gland Neoplasms 19347935 miR-154: up-regulated +tissue_expression_up hsa-mir-188 Salivary Gland Neoplasms 19347935 miR-188: up-regulated +tissue_expression_up hsa-mir-21 Salivary Gland Neoplasms 19347935 miR-21: up-regulated +tissue_expression_up hsa-mir-23b Salivary Gland Neoplasms 19347935 miR-23b: up-regulated +tissue_expression_up hsa-mir-299 Salivary Gland Neoplasms 19347935 miR-299-3p: up-regulated +tissue_expression_up hsa-mir-29c Salivary Gland Neoplasms 19347935 miR-29c: up-regulated +tissue_expression_up hsa-mir-301a Salivary Gland Neoplasms 19347935 miR-301: up-regulated +tissue_expression_up hsa-mir-301b Salivary Gland Neoplasms 19347935 miR-301: up-regulated +tissue_expression_up hsa-mir-302c Salivary Gland Neoplasms 19347935 miR-302c: up-regulated +tissue_expression_up hsa-mir-337 Salivary Gland Neoplasms 19347935 miR-337: up-regulated +tissue_expression_up hsa-mir-376a-1 Salivary Gland Neoplasms 19347935 miR-376a: up-regulated +tissue_expression_up hsa-mir-376a-2 Salivary Gland Neoplasms 19347935 miR-376a: up-regulated +tissue_expression_up hsa-mir-409 Salivary Gland Neoplasms 19347935 miR-409-3p: up-regulated +tissue_expression_up hsa-mir-449a Salivary Gland Neoplasms 19347935 miR-449: up-regulated +tissue_expression_up hsa-mir-449b Salivary Gland Neoplasms 19347935 miR-449: up-regulated +tissue_expression_up hsa-mir-495 Salivary Gland Neoplasms 19347935 miR-495: up-regulated +tissue_expression_up hsa-mir-99b Salivary Gland Neoplasms 19347935 miR-99b: up-regulated +tissue_expression_up hsa-mir-130b Head And Neck Neoplasms 19351747 miR-130b: up-regulated +tissue_expression_up hsa-mir-181a-2 Head And Neck Neoplasms 19351747 miR-181a: up-regulated +tissue_expression_up hsa-mir-181b-1 Head And Neck Neoplasms 19351747 miR-181b: up-regulated +tissue_expression_up hsa-mir-181b-2 Head And Neck Neoplasms 19351747 miR-181b: up-regulated +tissue_expression_up hsa-mir-181d Head And Neck Neoplasms 19351747 miR-181d: up-regulated +tissue_expression_up hsa-mir-18a Head And Neck Neoplasms 19351747 miR-18a: up-regulated +tissue_expression_up hsa-mir-193b Head And Neck Neoplasms 19351747 miR-193b: up-regulated +tissue_expression_up hsa-mir-21 Head And Neck Neoplasms 19351747 miR-21: up-regulated +tissue_expression_up hsa-mir-221 Head And Neck Neoplasms 19351747 miR-221: up-regulated +tissue_expression_up hsa-mir-455 Head And Neck Neoplasms 19351747 miR-455: up-regulated +tissue_expression_up hsa-mir-491 Head And Neck Neoplasms 19351747 miR-491: up-regulated +tissue_expression_up hsa-let-7a-1 "Carcinoma, Adrenocortical" 19351815 let-7a: upregulated +tissue_expression_up hsa-let-7a-2 "Carcinoma, Adrenocortical" 19351815 let-7a: upregulated +tissue_expression_up hsa-let-7a-3 "Carcinoma, Adrenocortical" 19351815 let-7a: upregulated +tissue_expression_up hsa-let-7b "Carcinoma, Adrenocortical" 19351815 let-7b: upregulated +tissue_expression_up hsa-let-7c "Carcinoma, Adrenocortical" 19351815 let-7c: upregulated +tissue_expression_up hsa-let-7d "Carcinoma, Adrenocortical" 19351815 let-7d: upregulated +tissue_expression_up hsa-mir-100 "Carcinoma, Adrenocortical" 19351815 miR-100: upregulated +tissue_expression_up hsa-mir-1-1 "Carcinoma, Adrenocortical" 19351815 miR-1: upregulated +tissue_expression_up hsa-mir-1-2 "Carcinoma, Adrenocortical" 19351815 miR-1: upregulated +tissue_expression_up hsa-mir-125b-1 "Carcinoma, Adrenocortical" 19351815 miR-125b: upregulated +tissue_expression_up hsa-mir-125b-2 "Carcinoma, Adrenocortical" 19351815 miR-125b: upregulated +tissue_expression_up hsa-mir-126 "Carcinoma, Adrenocortical" 19351815 miR-126: upregulated +tissue_expression_up hsa-mir-130a "Carcinoma, Adrenocortical" 19351815 miR-130a: upregulated +tissue_expression_up hsa-mir-132 "Carcinoma, Adrenocortical" 19351815 miR-132: upregulated +tissue_expression_up hsa-mir-133a-1 "Carcinoma, Adrenocortical" 19351815 miR-133a: upregulated +tissue_expression_up hsa-mir-133a-2 "Carcinoma, Adrenocortical" 19351815 miR-133a: upregulated +tissue_expression_up hsa-mir-135a-1 "Carcinoma, Adrenocortical" 19351815 miR-135a: upregulated +tissue_expression_up hsa-mir-135a-2 "Carcinoma, Adrenocortical" 19351815 miR-135a: upregulated +tissue_expression_up hsa-mir-137 "Carcinoma, Adrenocortical" 19351815 miR-137: upregulated +tissue_expression_up hsa-mir-143 "Carcinoma, Adrenocortical" 19351815 miR-143: upregulated +tissue_expression_up hsa-mir-145 "Carcinoma, Adrenocortical" 19351815 miR-145: upregulated +tissue_expression_up hsa-mir-146a "Carcinoma, Adrenocortical" 19351815 miR-146a: upregulated +tissue_expression_up hsa-mir-155 "Carcinoma, Adrenocortical" 19351815 miR-155: upregulated +tissue_expression_up hsa-mir-15b "Carcinoma, Adrenocortical" 19351815 miR-15b: upregulated +tissue_expression_up hsa-mir-16-1 "Carcinoma, Adrenocortical" 19351815 miR-16: upregulated +tissue_expression_up hsa-mir-16-2 "Carcinoma, Adrenocortical" 19351815 miR-16: upregulated +tissue_expression_up hsa-mir-17 "Carcinoma, Adrenocortical" 19351815 miR-17-5p: upregulated +tissue_expression_up hsa-mir-192 "Carcinoma, Adrenocortical" 19351815 miR-192: upregulated +tissue_expression_up hsa-mir-194-1 "Carcinoma, Adrenocortical" 19351815 miR-194: upregulated +tissue_expression_up hsa-mir-194-2 "Carcinoma, Adrenocortical" 19351815 miR-194: upregulated +tissue_expression_up hsa-mir-200b "Carcinoma, Adrenocortical" 19351815 miR-200b: upregulated +tissue_expression_up hsa-mir-200c "Carcinoma, Adrenocortical" 19351815 miR-200c: upregulated +tissue_expression_up hsa-mir-203 "Carcinoma, Adrenocortical" 19351815 miR-203: upregulated +tissue_expression_up hsa-mir-222 "Carcinoma, Adrenocortical" 19351815 miR-222: upregulated +tissue_expression_up hsa-mir-23b "Carcinoma, Adrenocortical" 19351815 miR-23b: upregulated +tissue_expression_up hsa-mir-28 "Carcinoma, Adrenocortical" 19351815 miR-28: upregulated +tissue_expression_up hsa-mir-30a "Carcinoma, Adrenocortical" 19351815 miR-30a-3p: upregulated +tissue_expression_up hsa-mir-335 "Carcinoma, Adrenocortical" 19351815 miR-335: upregulated +tissue_expression_up hsa-mir-375 "Carcinoma, Adrenocortical" 19351815 miR-375: upregulated +tissue_expression_up hsa-mir-449a "Carcinoma, Adrenocortical" 19351815 miR-449: upregulated +tissue_expression_up hsa-mir-449b "Carcinoma, Adrenocortical" 19351815 miR-449: upregulated +tissue_expression_up hsa-mir-7-1 "Carcinoma, Adrenocortical" 19351815 miR-7: upregulated +tissue_expression_up hsa-mir-7-2 "Carcinoma, Adrenocortical" 19351815 miR-7: upregulated +tissue_expression_up hsa-mir-7-3 "Carcinoma, Adrenocortical" 19351815 miR-7: upregulated +tissue_expression_up hsa-mir-221 Prostate Neoplasms 19351832 miR-221: Overexpression +tissue_expression_up hsa-mir-222 Prostate Neoplasms 19351832 miR-222: Overexpression +tissue_expression_up hsa-mir-100 "Carcinoma, Hepatocellular" 19360909 miR-100: overexpressed In HCC patients with hepatitis C and liver cirrhosis +tissue_expression_up hsa-mir-10a "Carcinoma, Hepatocellular" 19360909 miR-10a: overexpressed In HCC patients with hepatitis C and liver cirrhosis +tissue_expression_up hsa-mir-203 "Carcinoma, Hepatocellular" 19360909 miR-203: up-regulated in HCC compared to benign hepatocellular tumors +tissue_expression_up hsa-mir-21 "Carcinoma, Hepatocellular" 19360909 miR-21: up-regulated in HCC compared to benign hepatocellular tumors +tissue_expression_up hsa-mir-221 "Carcinoma, Hepatocellular" 19360909 miR-221: up-regulated in HCC compared to benign hepatocellular tumors +tissue_expression_up hsa-mir-222 "Carcinoma, Hepatocellular" 19360909 miR-222: up-regulated in HCC compared to benign hepatocellular tumors +tissue_expression_up hsa-mir-224 "Carcinoma, Hepatocellular" 19360909 miR-224: up-regulated in HCC compared to benign hepatocellular tumors +tissue_expression_up hsa-mir-34a "Carcinoma, Hepatocellular" 19360909 miR-34a: up-regulated in HCC compared to benign hepatocellular tumors +tissue_expression_up hsa-mir-342 Breast Neoplasms 19432961 MiR-342 expression was highest in ER and HER2/neu-positive luminal B tumours and lowest in triple-negative tumours. MiR-520g expression was elevated in ER and PR-negative tumours. +tissue_expression_up hsa-mir-520g Breast Neoplasms 19432961 MiR-342 expression was highest in ER and HER2/neu-positive luminal B tumours and lowest in triple-negative tumours. MiR-520g expression was elevated in ER and PR-negative tumours. +tissue_expression_up hsa-mir-27a Ovarian Neoplasms 19446316 High expression of hsa-mir-27a identified a sub-group of patients with very poor prognosis. +tissue_expression_up hsa-mir-21 "Carcinoma, Lung, Non-Small-Cell" 19446359 Mir-21 expression in the sputum specimens was significantly higher in cancer patients (76.32+/-9.79) than cancer-free individuals (62.24+/-3.82) (P<0.0001). +tissue_expression_up hsa-mir-335 Obesity 19460359 These findings provide the first evidence that the up-regulated expressions of miR-335 in liver and WAT of obese mice might contribute to the pathophysiology of obesity. +tissue_expression_up hsa-mir-150 Inflammation 19525145 "Specifically, recent studies indicate that those miRNAs that are selectively and/or highly expressed in immune cells including the miR-17-92 cluster, miR-150, miR-155, miR-181 and miR-223 have a 'permissive' function in the maturation, proliferation and differentiation of myeloid and lymphoid cells." +tissue_expression_up hsa-mir-155 Inflammation 19525145 "Specifically, recent studies indicate that those miRNAs that are selectively and/or highly expressed in immune cells including the miR-17-92 cluster, miR-150, miR-155, miR-181 and miR-223 have a 'permissive' function in the maturation, proliferation and differentiation of myeloid and lymphoid cells." +tissue_expression_up hsa-mir-17 Inflammation 19525145 "Specifically, recent studies indicate that those miRNAs that are selectively and/or highly expressed in immune cells including the miR-17-92 cluster, miR-150, miR-155, miR-181 and miR-223 have a 'permissive' function in the maturation, proliferation and differentiation of myeloid and lymphoid cells." +tissue_expression_up hsa-mir-18 Inflammation 19525145 "Specifically, recent studies indicate that those miRNAs that are selectively and/or highly expressed in immune cells including the miR-17-92 cluster, miR-150, miR-155, miR-181 and miR-223 have a 'permissive' function in the maturation, proliferation and differentiation of myeloid and lymphoid cells." +tissue_expression_up hsa-mir-181 Inflammation 19525145 "Specifically, recent studies indicate that those miRNAs that are selectively and/or highly expressed in immune cells including the miR-17-92 cluster, miR-150, miR-155, miR-181 and miR-223 have a 'permissive' function in the maturation, proliferation and differentiation of myeloid and lymphoid cells." +tissue_expression_up hsa-mir-19a Inflammation 19525145 "Specifically, recent studies indicate that those miRNAs that are selectively and/or highly expressed in immune cells including the miR-17-92 cluster, miR-150, miR-155, miR-181 and miR-223 have a 'permissive' function in the maturation, proliferation and differentiation of myeloid and lymphoid cells." +tissue_expression_up hsa-mir-19b-1 Inflammation 19525145 "Specifically, recent studies indicate that those miRNAs that are selectively and/or highly expressed in immune cells including the miR-17-92 cluster, miR-150, miR-155, miR-181 and miR-223 have a 'permissive' function in the maturation, proliferation and differentiation of myeloid and lymphoid cells." +tissue_expression_up hsa-mir-20a Inflammation 19525145 "Specifically, recent studies indicate that those miRNAs that are selectively and/or highly expressed in immune cells including the miR-17-92 cluster, miR-150, miR-155, miR-181 and miR-223 have a 'permissive' function in the maturation, proliferation and differentiation of myeloid and lymphoid cells." +tissue_expression_up hsa-mir-223 Inflammation 19525145 "Specifically, recent studies indicate that those miRNAs that are selectively and/or highly expressed in immune cells including the miR-17-92 cluster, miR-150, miR-155, miR-181 and miR-223 have a 'permissive' function in the maturation, proliferation and differentiation of myeloid and lymphoid cells." +tissue_expression_up hsa-mir-92-1 Inflammation 19525145 "Specifically, recent studies indicate that those miRNAs that are selectively and/or highly expressed in immune cells including the miR-17-92 cluster, miR-150, miR-155, miR-181 and miR-223 have a 'permissive' function in the maturation, proliferation and differentiation of myeloid and lymphoid cells." +tissue_expression_up hsa-mir-30a "Squamous Cell Carcinoma, Esophageal" 19536617 high expression levels; might play a important role in the development of the cancer +tissue_expression_up hsa-mir-210 Adrenal Cortex Neoplasms 19546168 significantly higher expressed +tissue_expression_up hsa-mir-503 Adrenal Cortex Neoplasms 19546168 significantly higher expressed +tissue_expression_up hsa-mir-15a Pancreatic Neoplasms 19551852 differentially expressed; associates with poorer survival +tissue_expression_up hsa-mir-203 Pancreatic Neoplasms 19551852 differentially expressed; associates with poorer survival +tissue_expression_up hsa-mir-210 Pancreatic Neoplasms 19551852 differentially expressed; associates with poorer survival +tissue_expression_up hsa-mir-222 Pancreatic Neoplasms 19551852 differentially expressed; associates with poorer survival +tissue_expression_up hsa-mir-1224 Fatty Liver [unspecific] 19572984 expression increased after Lieber-DeCarli or MCD; +tissue_expression_up hsa-mir-182 Fatty Liver [unspecific] 19572984 expression increased after Lieber-DeCarli or MCD; +tissue_expression_up hsa-mir-146a Melanoma 19578755 overexpressed +tissue_expression_up hsa-mir-17 Melanoma 19578755 miR-17-5p; overexpressed +tissue_expression_up hsa-mir-18a Melanoma 19578755 overexpressed +tissue_expression_up hsa-mir-20a Melanoma 19578755 overexpressed +tissue_expression_up hsa-mir-155 Myocardial Infarction 19581315 "Overexpressed; arrhythmogenic miR-1, contributing to ischaemic arrhythmogenesis stimulated by beta-adrenergic pathway; downregulatied by propranolol together with SRF" +tissue_expression_up hsa-mir-221 "Carcinoma, Hepatocellular" 19585654 critical player; up-regulated; could directly target hepatic transcriptional regulators of differentiation and an inhibitor of Wnt/beta-catenin signaling +tissue_expression_up hsa-mir-17 Lung Neoplasms 19597473 miR-17-5p ; frequent overexpression +tissue_expression_up hsa-mir-20a Lung Neoplasms 19597473 miR-17-92 overexpression may serve as a fine-tuning influence to counterbalance the generation of DNA damage +tissue_expression_up hsa-mir-18a Breast Neoplasms 19624877 Differential expression profiles of microRNAs between breast cancer cells and mammary epithelial cells: mir-18a and mir-195 were highly expressed in MCF-7 cells; target genes of mir-200b were predicted by informatics analysis. +tissue_expression_up hsa-mir-200b Breast Neoplasms 19624877 Differential expression profiles of microRNAs between breast cancer cells and mammary epithelial cells: mir-18a and mir-195 were highly expressed in MCF-7 cells; target genes of mir-200b were predicted by informatics analysis. +tissue_expression_up hsa-mir-223 Breast Neoplasms 19624877 Differential expression profiles of microRNAs between breast cancer cells and mammary epithelial cells: mir-18a and mir-195 were highly expressed in MCF-7 cells; target genes of mir-200b were predicted by informatics analysis. +tissue_expression_up hsa-mir-195 Eclampsia 19642860 increased in placenta +tissue_expression_up hsa-mir-21 Eclampsia 19642860 increased in placenta +tissue_expression_up hsa-mir-222 Eclampsia 19642860 increased in placenta +tissue_expression_up hsa-mir-26b Eclampsia 19642860 increased in placenta +tissue_expression_up hsa-mir-335 Eclampsia 19642860 increased in placenta +tissue_expression_up hsa-mir-155 Neoplasms [unspecific] 19652553 "overexpression, target MYC antagonist MNT" +tissue_expression_up hsa-mir-137 Colon Neoplasms 19659786 "expressed differently, miR-137 upregulated in non-cancerous colonic tissues from colon cancer patients with lymph node metastasis" +tissue_expression_up hsa-mir-221 Cholesteatoma 19672202 up-regulated concurrent with down-regulation of PTEN +tissue_expression_up hsa-mir-21 "Adenocarcinoma, Colon" 19672269 expression Increased +tissue_expression_up hsa-mir-183 Neoplasms [unspecific] 19676045 up-regulated +tissue_expression_up hsa-mir-96 Neoplasms [unspecific] 19676045 up-regulated +tissue_expression_up hsa-mir-21 Alzheimer Disease 19683563 "up-regulated, inhibits bcl2 translation" +tissue_expression_up hsa-mir-18a Breast Neoplasms 19684618 higher levels of expression in ERalpha-negative tumors +tissue_expression_up hsa-mir-34a Breast Neoplasms 19684618 higher levels of expression in ERalpha-negative tumors +tissue_expression_up hsa-mir-107 "Diabetes Mellitus, Type 2" 19689793 over-expressed in insulin target tissues +tissue_expression_up hsa-mir-125a Hepatoblastoma 19701500 upregulated +tissue_expression_up hsa-mir-150 Hepatoblastoma 19701500 upregulated +tissue_expression_up hsa-mir-214 Hepatoblastoma 19701500 upregulated +tissue_expression_up hsa-mir-208a Cardiomegaly 19726871 overexpression +tissue_expression_up hsa-mir-155 "Leukemia, Myeloid, Acute" 19744129 "Their aberrant expression has been associated with solid tumors and hematopoietic malignancies as suggested by the frequent deletion of mir-15a and mir-16-1 in chronic lymphocytic leukemia, the increased levels of mir-155 in diffuse large B-cell lymphomas and the increased levels of mir-181 in acute myeloid leukemia M1 and M2. " +tissue_expression_up hsa-mir-155 "Lymphoma, Large B-Cell, Diffuse" 19744129 "Their aberrant expression has been associated with solid tumors and hematopoietic malignancies as suggested by the frequent deletion of mir-15a and mir-16-1 in chronic lymphocytic leukemia, the increased levels of mir-155 in diffuse large B-cell lymphomas and the increased levels of mir-181 in acute myeloid leukemia M1 and M2. " +tissue_expression_up hsa-mir-130a Lung Neoplasms 19748927 "miR-21, mir-31, miR-130a, miR-146b and miR-377 were consistently upregulated, whereas miR-1 and miR-143 were downregulated in lung tumors relative to normal lungs." +tissue_expression_up hsa-mir-146b Lung Neoplasms 19748927 "miR-21, mir-31, miR-130a, miR-146b and miR-377 were consistently upregulated, whereas miR-1 and miR-143 were downregulated in lung tumors relative to normal lungs." +tissue_expression_up hsa-mir-21 Lung Neoplasms 19748927 "miR-21, mir-31, miR-130a, miR-146b and miR-377 were consistently upregulated, whereas miR-1 and miR-143 were downregulated in lung tumors relative to normal lungs." +tissue_expression_up hsa-mir-31 Lung Neoplasms 19748927 "miR-21, mir-31, miR-130a, miR-146b and miR-377 were consistently upregulated, whereas miR-1 and miR-143 were downregulated in lung tumors relative to normal lungs." +tissue_expression_up hsa-mir-377 Lung Neoplasms 19748927 "miR-21, mir-31, miR-130a, miR-146b and miR-377 were consistently upregulated, whereas miR-1 and miR-143 were downregulated in lung tumors relative to normal lungs." +tissue_expression_up hsa-mir-192 Squamous Cell Carcinoma 19789312 "In adenocarcinoma patients, miR-21, miR-223, miR-192, and miR-194 expression was elevated, whereas miR-203 expression was reduced in cancerous compared with noncancerous tissue." +tissue_expression_up hsa-mir-194 Squamous Cell Carcinoma 19789312 "In adenocarcinoma patients, miR-21, miR-223, miR-192, and miR-194 expression was elevated, whereas miR-203 expression was reduced in cancerous compared with noncancerous tissue." +tissue_expression_up hsa-mir-21 Squamous Cell Carcinoma 19789312 "In adenocarcinoma patients, miR-21, miR-223, miR-192, and miR-194 expression was elevated, whereas miR-203 expression was reduced in cancerous compared with noncancerous tissue." +tissue_expression_up hsa-mir-223 Squamous Cell Carcinoma 19789312 "In adenocarcinoma patients, miR-21, miR-223, miR-192, and miR-194 expression was elevated, whereas miR-203 expression was reduced in cancerous compared with noncancerous tissue." +tissue_expression_up hsa-mir-29a Lung Neoplasms 19818597 "MiRNA expression profiling of human NSCLC cell lines indicated that miR-29a levels were reduced in more invasive cell lines. Exogenous overexpression of miR-29a in both lung and pancreatic cancer cell lines resulted in a significant reduction in the invasion phenotype, as well as in proliferation." +tissue_expression_up hsa-mir-15b Melanoma 19830692 "MiR-15b:MiR-15b and miR-210 were significantly upregulated, miR-34a was significantly downregulated in melanomas" +tissue_expression_up hsa-mir-210 Melanoma 19830692 "miR-210:MiR-15b and miR-210 were significantly upregulated, miR-34a was significantly downregulated in melanomas" +tissue_expression_up hsa-mir-210 Adrenal Cortex Neoplasms 19849700 up-regulated +tissue_expression_up hsa-mir-484 Adrenal Cortex Neoplasms 19849700 up-regulated +tissue_expression_up hsa-mir-193b Hematologic Neoplasms 19883314 miR-193b-365 significantly up-regulated in MM +tissue_expression_up hsa-mir-200a "Adenocarcinoma, Endometrial" 19891660 up-regulated +tissue_expression_up hsa-mir-200b "Adenocarcinoma, Endometrial" 19891660 up-regulated +tissue_expression_up hsa-mir-205 "Adenocarcinoma, Endometrial" 19891660 up-regulated +tissue_expression_up hsa-mir-141 Nephrosclerosis 19910931 significantly higher in patients with hypertensive nephrosclerosis than controls +tissue_expression_up hsa-mir-192 Nephrosclerosis 19910931 significantly higher in patients with hypertensive nephrosclerosis than controls +tissue_expression_up hsa-mir-200a Nephrosclerosis 19910931 significantly higher in patients with hypertensive nephrosclerosis than controls +tissue_expression_up hsa-mir-200b Nephrosclerosis 19910931 significantly higher in patients with hypertensive nephrosclerosis than controls +tissue_expression_up hsa-mir-205 Nephrosclerosis 19910931 significantly higher in patients with hypertensive nephrosclerosis than controls +tissue_expression_up hsa-mir-429 Nephrosclerosis 19910931 significantly higher in patients with hypertensive nephrosclerosis than controls +tissue_expression_up hsa-mir-223 Rheumatoid Arthritis 19931339 miR-223 is overexpressed in T-lymphocytes of patients affected by rheumatoid arthritis. +tissue_expression_up hsa-mir-17 "Lymphoma, B-Cell" 19945163 miR-17-5p:the detection of upregulation of miR-17-5p and miR-181a in B- and T-cell lymphomas respectively +tissue_expression_up hsa-mir-17 "Lymphoma, T-Cell" 19945163 miR-17-5p:the detection of upregulation of miR-17-5p and miR-181a in B- and T-cell lymphomas respectively +tissue_expression_up hsa-mir-181a-1 "Lymphoma, B-Cell" 19945163 miR-181a:the detection of upregulation of miR-17-5p and miR-181a in B- and T-cell lymphomas respectively +tissue_expression_up hsa-mir-181a-1 "Lymphoma, T-Cell" 19945163 miR-181a:the detection of upregulation of miR-17-5p and miR-181a in B- and T-cell lymphomas respectively +tissue_expression_up hsa-mir-181a-2 "Lymphoma, B-Cell" 19945163 miR-181a:the detection of upregulation of miR-17-5p and miR-181a in B- and T-cell lymphomas respectively +tissue_expression_up hsa-mir-181a-2 "Lymphoma, T-Cell" 19945163 miR-181a:the detection of upregulation of miR-17-5p and miR-181a in B- and T-cell lymphomas respectively +tissue_expression_up hsa-mir-629 Breast Neoplasms 19946373 upregulated +tissue_expression_up hsa-mir-629 Colon Neoplasms 19946373 upregulated +tissue_expression_up hsa-mir-629 Liver Neoplasms 19946373 upregulated +tissue_expression_up hsa-mir-629 Lung Neoplasms 19946373 upregulated +tissue_expression_up hsa-mir-629 Lymphoma 19946373 upregulated +tissue_expression_up hsa-mir-629 Ovarian Neoplasms 19946373 upregulated +tissue_expression_up hsa-mir-629 Prostate Neoplasms 19946373 upregulated +tissue_expression_up hsa-mir-629 Testicular Neoplasms 19946373 upregulated +tissue_expression_up hsa-mir-214 Gastric Neoplasms 20022810 high expression +tissue_expression_up hsa-mir-125a Retinal Degeneration 20053268 Over-expression +tissue_expression_up hsa-mir-204 Retinal Degeneration 20053268 Over-expression +tissue_expression_up hsa-mir-205 "Carcinoma, Lung, Non-Small-Cell" 20068099 hsa-miR-205 is a miRNA that is highly expressed in lung squamous cell carcinomas (SqCC) but not in lung adenocarcinomas. +tissue_expression_up hsa-mir-222 "Carcinoma, Hepatocellular" 20103675 overexpression +tissue_expression_up hsa-mir-106b Colon Neoplasms 20132431 "A total of 14 miRNAs were found to be associated with colonic cancer, in which the expression of miR-106b, miR-135b, miR-18a, miR-18b, miR-196b, miR-19a, miR-224, miR-335, miR-424, miR-20a*, miR-301b and miR-374a were up-regulated and the expression of miR-378 and miR-378* were downregulated in colonic cancer tissues, compared with the para-cancerous control." +tissue_expression_up hsa-mir-135b Colon Neoplasms 20132431 "A total of 14 miRNAs were found to be associated with colonic cancer, in which the expression of miR-106b, miR-135b, miR-18a, miR-18b, miR-196b, miR-19a, miR-224, miR-335, miR-424, miR-20a*, miR-301b and miR-374a were up-regulated and the expression of miR-378 and miR-378* were downregulated in colonic cancer tissues, compared with the para-cancerous control." +tissue_expression_up hsa-mir-18a Colon Neoplasms 20132431 "A total of 14 miRNAs were found to be associated with colonic cancer, in which the expression of miR-106b, miR-135b, miR-18a, miR-18b, miR-196b, miR-19a, miR-224, miR-335, miR-424, miR-20a*, miR-301b and miR-374a were up-regulated and the expression of miR-378 and miR-378* were downregulated in colonic cancer tissues, compared with the para-cancerous control." +tissue_expression_up hsa-mir-18b Colon Neoplasms 20132431 "A total of 14 miRNAs were found to be associated with colonic cancer, in which the expression of miR-106b, miR-135b, miR-18a, miR-18b, miR-196b, miR-19a, miR-224, miR-335, miR-424, miR-20a*, miR-301b and miR-374a were up-regulated and the expression of miR-378 and miR-378* were downregulated in colonic cancer tissues, compared with the para-cancerous control." +tissue_expression_up hsa-mir-196b Colon Neoplasms 20132431 "A total of 14 miRNAs were found to be associated with colonic cancer, in which the expression of miR-106b, miR-135b, miR-18a, miR-18b, miR-196b, miR-19a, miR-224, miR-335, miR-424, miR-20a*, miR-301b and miR-374a were up-regulated and the expression of miR-378 and miR-378* were downregulated in colonic cancer tissues, compared with the para-cancerous control." +tissue_expression_up hsa-mir-19a Colon Neoplasms 20132431 "A total of 14 miRNAs were found to be associated with colonic cancer, in which the expression of miR-106b, miR-135b, miR-18a, miR-18b, miR-196b, miR-19a, miR-224, miR-335, miR-424, miR-20a*, miR-301b and miR-374a were up-regulated and the expression of miR-378 and miR-378* were downregulated in colonic cancer tissues, compared with the para-cancerous control." +tissue_expression_up hsa-mir-20a Colon Neoplasms 20132431 "A total of 14 miRNAs were found to be associated with colonic cancer, in which the expression of miR-106b, miR-135b, miR-18a, miR-18b, miR-196b, miR-19a, miR-224, miR-335, miR-424, miR-20a*, miR-301b and miR-374a were up-regulated and the expression of miR-378 and miR-378* were downregulated in colonic cancer tissues, compared with the para-cancerous control." +tissue_expression_up hsa-mir-224 Colon Neoplasms 20132431 "A total of 14 miRNAs were found to be associated with colonic cancer, in which the expression of miR-106b, miR-135b, miR-18a, miR-18b, miR-196b, miR-19a, miR-224, miR-335, miR-424, miR-20a*, miR-301b and miR-374a were up-regulated and the expression of miR-378 and miR-378* were downregulated in colonic cancer tissues, compared with the para-cancerous control." +tissue_expression_up hsa-mir-301b Colon Neoplasms 20132431 "A total of 14 miRNAs were found to be associated with colonic cancer, in which the expression of miR-106b, miR-135b, miR-18a, miR-18b, miR-196b, miR-19a, miR-224, miR-335, miR-424, miR-20a*, miR-301b and miR-374a were up-regulated and the expression of miR-378 and miR-378* were downregulated in colonic cancer tissues, compared with the para-cancerous control." +tissue_expression_up hsa-mir-335 Colon Neoplasms 20132431 "A total of 14 miRNAs were found to be associated with colonic cancer, in which the expression of miR-106b, miR-135b, miR-18a, miR-18b, miR-196b, miR-19a, miR-224, miR-335, miR-424, miR-20a*, miR-301b and miR-374a were up-regulated and the expression of miR-378 and miR-378* were downregulated in colonic cancer tissues, compared with the para-cancerous control." +tissue_expression_up hsa-mir-374a Colon Neoplasms 20132431 "A total of 14 miRNAs were found to be associated with colonic cancer, in which the expression of miR-106b, miR-135b, miR-18a, miR-18b, miR-196b, miR-19a, miR-224, miR-335, miR-424, miR-20a*, miR-301b and miR-374a were up-regulated and the expression of miR-378 and miR-378* were downregulated in colonic cancer tissues, compared with the para-cancerous control." +tissue_expression_up hsa-mir-424 Colon Neoplasms 20132431 "A total of 14 miRNAs were found to be associated with colonic cancer, in which the expression of miR-106b, miR-135b, miR-18a, miR-18b, miR-196b, miR-19a, miR-224, miR-335, miR-424, miR-20a*, miR-301b and miR-374a were up-regulated and the expression of miR-378 and miR-378* were downregulated in colonic cancer tissues, compared with the para-cancerous control." +tissue_expression_up hsa-let-7i Neoplasms [unspecific] 20145181 overexpression +tissue_expression_up hsa-let-7i "Squamous Cell Carcinoma, Head and Neck" 20145181 overexpression +tissue_expression_up hsa-mir-106b Neoplasms [unspecific] 20145181 Upregulation +tissue_expression_up hsa-mir-106b "Squamous Cell Carcinoma, Head and Neck" 20145181 Upregulation +tissue_expression_up hsa-mir-142 Neoplasms [unspecific] 20145181 overexpression +tissue_expression_up hsa-mir-142 "Squamous Cell Carcinoma, Head and Neck" 20145181 miR-142-3p; overexpression +tissue_expression_up hsa-mir-155 Neoplasms [unspecific] 20145181 overexpression +tissue_expression_up hsa-mir-155 "Squamous Cell Carcinoma, Head and Neck" 20145181 overexpression +tissue_expression_up hsa-mir-16-1 Neoplasms [unspecific] 20145181 Upregulation +tissue_expression_up hsa-mir-16-2 Neoplasms [unspecific] 20145181 Upregulation +tissue_expression_up hsa-mir-20a Neoplasms [unspecific] 20145181 Upregulation +tissue_expression_up hsa-mir-20a "Squamous Cell Carcinoma, Head and Neck" 20145181 Upregulation +tissue_expression_up hsa-mir-21 Neoplasms [unspecific] 20145181 overexpression +tissue_expression_up hsa-mir-21 "Squamous Cell Carcinoma, Head and Neck" 20145181 overexpression +tissue_expression_up hsa-mir-423 Neoplasms [unspecific] 20145181 Upregulation +tissue_expression_up hsa-mir-423 "Squamous Cell Carcinoma, Head and Neck" 20145181 Upregulation +tissue_expression_up hsa-mir-142 Neoplasms [unspecific] 20178649 "Most of the differentially expressed miRNAs were downregulated in germinomas, but miR-142-5p and miR-146a were upregulated." +tissue_expression_up hsa-mir-146a Neoplasms [unspecific] 20178649 "Most of the differentially expressed miRNAs were downregulated in germinomas, but miR-142-5p and miR-146a were upregulated." +tissue_expression_up hsa-mir-451 Polycythemia Vera 20218812 We observed that miR-451 up-regulation and miR-150 down-regulation are associated with progression of erythroid maturation in K562 cells. +tissue_expression_up hsa-mir-21 Astrocytoma 20219352 "miR-21:hsa-miR-21, hsa-miR-181b and hsa-miR-106a as prognostic indicators of astrocytoma" +tissue_expression_up hsa-mir-182 "Leukemia, Biphenotypic, Acute" 20227111 miR-182:miR-584 and miR-182 upregulation in the CD34(+)CD38(-) fraction +tissue_expression_up hsa-mir-584 "Leukemia, Biphenotypic, Acute" 20227111 miR-584:miR-584 and miR-182 upregulation in the CD34(+)CD38(-) fraction +tissue_expression_up hsa-mir-136 Lung Neoplasms 20237410 "We found that miR-136, miR-376a, and miR-31 were each prominently overexpressed in murine lung cancers." +tissue_expression_up hsa-mir-31 Lung Neoplasms 20237410 "We found that miR-136, miR-376a, and miR-31 were each prominently overexpressed in murine lung cancers." +tissue_expression_up hsa-mir-376a-1 Lung Neoplasms 20237410 "We found that miR-136, miR-376a, and miR-31 were each prominently overexpressed in murine lung cancers." +tissue_expression_up hsa-mir-376a-2 Lung Neoplasms 20237410 "We found that miR-136, miR-376a, and miR-31 were each prominently overexpressed in murine lung cancers." +tissue_expression_up hsa-mir-17 Neoplasms [unspecific] 20299512 "The miR-17-92 cluster (encoding miR-17, -18a, -19a/b, -20a, and miR-92a) is highly expressed in tumor cells and is up-regulated by ischemia." +tissue_expression_up hsa-mir-18a Neoplasms [unspecific] 20299512 "The miR-17-92 cluster (encoding miR-17, -18a, -19a/b, -20a, and miR-92a) is highly expressed in tumor cells and is up-regulated by ischemia." +tissue_expression_up hsa-mir-19a Neoplasms [unspecific] 20299512 "The miR-17-92 cluster (encoding miR-17, -18a, -19a/b, -20a, and miR-92a) is highly expressed in tumor cells and is up-regulated by ischemia." +tissue_expression_up hsa-mir-19b-1 Neoplasms [unspecific] 20299512 "The miR-17-92 cluster (encoding miR-17, -18a, -19a/b, -20a, and miR-92a) is highly expressed in tumor cells and is up-regulated by ischemia." +tissue_expression_up hsa-mir-20a Neoplasms [unspecific] 20299512 "The miR-17-92 cluster (encoding miR-17, -18a, -19a/b, -20a, and miR-92a) is highly expressed in tumor cells and is up-regulated by ischemia." +tissue_expression_up hsa-mir-92a-1 Neoplasms [unspecific] 20299512 "The miR-17-92 cluster (encoding miR-17, -18a, -19a/b, -20a, and miR-92a) is highly expressed in tumor cells and is up-regulated by ischemia." +tissue_expression_up hsa-mir-143 "Adenocarcinoma, Esophageal" 20301167 upregulated +tissue_expression_up hsa-mir-145 "Adenocarcinoma, Esophageal" 20301167 upregulated +tissue_expression_up hsa-mir-203 "Adenocarcinoma, Esophageal" 20301167 miR-203:Levels of miR-203 and miR-205 were high in normal squamous epithelium and low in columnar epithelia +tissue_expression_up hsa-mir-205 "Adenocarcinoma, Esophageal" 20301167 miR-205:Levels of miR-203 and miR-205 were high in normal squamous epithelium and low in columnar epithelia +tissue_expression_up hsa-mir-21 "Adenocarcinoma, Esophageal" 20301167 upregulated +tissue_expression_up hsa-mir-215 "Adenocarcinoma, Esophageal" 20301167 upregulated +tissue_expression_up hsa-mir-183 Breast Neoplasms 20331864 up-regulated in male breast cancer +tissue_expression_up hsa-mir-197 Breast Neoplasms 20331864 up-regulated in male breast cancer +tissue_expression_up hsa-mir-21 Breast Neoplasms 20331864 up-regulated in male breast cancer +tissue_expression_up hsa-mir-493 Breast Neoplasms 20331864 up-regulated in male breast cancer +tissue_expression_up hsa-mir-519d Breast Neoplasms 20331864 up-regulated in male breast cancer +tissue_expression_up hsa-mir-302a Neoplasms [unspecific] 20332240 overexpressed +tissue_expression_up hsa-mir-302b Neoplasms [unspecific] 20332240 overexpressed +tissue_expression_up hsa-mir-302c Neoplasms [unspecific] 20332240 overexpressed +tissue_expression_up hsa-mir-302d Neoplasms [unspecific] 20332240 overexpressed +tissue_expression_up hsa-mir-302e Neoplasms [unspecific] 20332240 overexpressed +tissue_expression_up hsa-mir-302f Neoplasms [unspecific] 20332240 overexpressed +tissue_expression_up hsa-mir-371a Neoplasms [unspecific] 20332240 overexpressed +tissue_expression_up hsa-mir-372 Neoplasms [unspecific] 20332240 overexpressed +tissue_expression_up hsa-mir-373 Neoplasms [unspecific] 20332240 overexpressed +tissue_expression_up hsa-mir-193b Melanoma 20357817 "Furthermore, low expression of miR-191 and high expression of miR-193b were associated with poor melanoma-specific survive" +tissue_expression_up hsa-mir-21 Lung Neoplasms 20363096 "upregulated; Deregulated expression of miR-21, miR-143 and miR-181a in non small cell lung cancer is related to clinicopathologic characteristics or patient prognosis" +tissue_expression_up hsa-let-7a-1 Neoplasms [unspecific] 20370992 over-expressed +tissue_expression_up hsa-let-7a-2 Neoplasms [unspecific] 20370992 over-expressed +tissue_expression_up hsa-let-7a-3 Neoplasms [unspecific] 20370992 over-expressed +tissue_expression_up hsa-mir-182 Neoplasms [unspecific] 20370992 over-expressed +tissue_expression_up hsa-mir-21 Neoplasms [unspecific] 20370992 over-expressed +tissue_expression_up hsa-mir-21 Gastric Neoplasms 20372781 Expression of miR-21 in cancer tissues was significantly higher than in non-cancer tissues +tissue_expression_up hsa-mir-142 Glioblastoma 20380575 "miR-142-3p:The miR-17-3p, miR-17-5p, miR-19a, miR-19b, miR-142-3p, and miR-142-5p were upregulated in both M059K and M059J cells." +tissue_expression_up hsa-mir-143 Glioblastoma 20380575 "miR-143:The miR-15a, miR-16, miR-143, miR-155, and miR-21 were upregulated in M059K" +tissue_expression_up hsa-mir-155 Glioblastoma 20380575 "miR-155:The miR-15a, miR-16, miR-143, miR-155, and miR-21 were upregulated in M059K" +tissue_expression_up hsa-mir-15a Glioblastoma 20380575 "miR-15a:The miR-15a, miR-16, miR-143, miR-155, and miR-21 were upregulated in M059K" +tissue_expression_up hsa-mir-16-1 Glioblastoma 20380575 "miR-16:The miR-15a, miR-16, miR-143, miR-155, and miR-21 were upregulated in M059K" +tissue_expression_up hsa-mir-16-2 Glioblastoma 20380575 "miR-16:The miR-15a, miR-16, miR-143, miR-155, and miR-21 were upregulated in M059K" +tissue_expression_up hsa-mir-17 Glioblastoma 20380575 "miR-17-3p:The miR-17-3p, miR-17-5p, miR-19a, miR-19b, miR-142-3p, and miR-142-5p were upregulated in both M059K and M059J cells." +tissue_expression_up hsa-mir-19a Glioblastoma 20380575 "miR-19a:The miR-17-3p, miR-17-5p, miR-19a, miR-19b, miR-142-3p, and miR-142-5p were upregulated in both M059K and M059J cells." +tissue_expression_up hsa-mir-19b-1 Glioblastoma 20380575 "miR-19b:The miR-17-3p, miR-17-5p, miR-19a, miR-19b, miR-142-3p, and miR-142-5p were upregulated in both M059K and M059J cells." +tissue_expression_up hsa-mir-19b-2 Glioblastoma 20380575 "miR-19b:The miR-17-3p, miR-17-5p, miR-19a, miR-19b, miR-142-3p, and miR-142-5p were upregulated in both M059K and M059J cells." +tissue_expression_up hsa-mir-21 Glioblastoma 20380575 "miR-21:The miR-15a, miR-16, miR-143, miR-155, and miR-21 were upregulated in M059K" +tissue_expression_up hsa-mir-155 Breast Neoplasms 20388420 "The expression of miR-155 is up-regulated in primary breast cancer, especially in patients with positive estrogen and progesterone receptor." +tissue_expression_up hsa-mir-106a Glioma 20406893 "miR17 family, mir183-182, and the SC-specific clusters mir367-302 and mir371-373,which are upregulated in gliomas," +tissue_expression_up hsa-mir-106b Glioma 20406893 "miR17 family, mir183-182, and the SC-specific clusters mir367-302 and mir371-373,which are upregulated in gliomas," +tissue_expression_up hsa-mir-17 Glioma 20406893 "miR17 family, mir183-182, and the SC-specific clusters mir367-302 and mir371-373,which are upregulated in gliomas," +tissue_expression_up hsa-mir-182 Glioma 20406893 "miR17 family, mir183-182, and the SC-specific clusters mir367-302 and mir371-373,which are upregulated in gliomas," +tissue_expression_up hsa-mir-183 Glioma 20406893 "miR17 family, mir183-182, and the SC-specific clusters mir367-302 and mir371-373,which are upregulated in gliomas," +tissue_expression_up hsa-mir-18a Glioma 20406893 "miR17 family, mir183-182, and the SC-specific clusters mir367-302 and mir371-373,which are upregulated in gliomas," +tissue_expression_up hsa-mir-18b Glioma 20406893 "miR17 family, mir183-182, and the SC-specific clusters mir367-302 and mir371-373,which are upregulated in gliomas," +tissue_expression_up hsa-mir-20a Glioma 20406893 "miR17 family, mir183-182, and the SC-specific clusters mir367-302 and mir371-373,which are upregulated in gliomas," +tissue_expression_up hsa-mir-20b Glioma 20406893 "miR17 family, mir183-182, and the SC-specific clusters mir367-302 and mir371-373,which are upregulated in gliomas," +tissue_expression_up hsa-mir-302a Glioma 20406893 "miR17 family, mir183-182, and the SC-specific clusters mir367-302 and mir371-373,which are upregulated in gliomas," +tissue_expression_up hsa-mir-302b Glioma 20406893 "miR17 family, mir183-182, and the SC-specific clusters mir367-302 and mir371-373,which are upregulated in gliomas," +tissue_expression_up hsa-mir-302c Glioma 20406893 "miR17 family, mir183-182, and the SC-specific clusters mir367-302 and mir371-373,which are upregulated in gliomas," +tissue_expression_up hsa-mir-302d Glioma 20406893 "miR17 family, mir183-182, and the SC-specific clusters mir367-302 and mir371-373,which are upregulated in gliomas," +tissue_expression_up hsa-mir-367 Glioma 20406893 "miR17 family, mir183-182, and the SC-specific clusters mir367-302 and mir371-373,which are upregulated in gliomas," +tissue_expression_up hsa-mir-371a Glioma 20406893 "miR17 family, mir183-182, and the SC-specific clusters mir367-302 and mir371-373,which are upregulated in gliomas," +tissue_expression_up hsa-mir-373 Glioma 20406893 "miR17 family, mir183-182, and the SC-specific clusters mir367-302 and mir371-373,which are upregulated in gliomas," +tissue_expression_up hsa-mir-93 Glioma 20406893 "miR17 family, mir183-182, and the SC-specific clusters mir367-302 and mir371-373,which are upregulated in gliomas," +tissue_expression_up hsa-mir-133a-2 Colorectal Adenocarcinoma 20413677 "miR-133b:eleven miRNAs (miR-183, -31, -20, -25, -92, -93, -17, -135a, -203,-133b, and -223) were over-expressed in CRC relative to mucosa," +tissue_expression_up hsa-mir-135a-1 Colorectal Adenocarcinoma 20413677 "miR-135a:eleven miRNAs (miR-183, -31, -20, -25, -92, -93, -17, -135a, -203,-133b, and -223) were over-expressed in CRC relative to mucosa," +tissue_expression_up hsa-mir-135a-2 Colorectal Adenocarcinoma 20413677 "miR-135a:eleven miRNAs (miR-183, -31, -20, -25, -92, -93, -17, -135a, -203,-133b, and -223) were over-expressed in CRC relative to mucosa," +tissue_expression_up hsa-mir-17 Colorectal Adenocarcinoma 20413677 "miR-17:eleven miRNAs (miR-183, -31, -20, -25, -92, -93, -17, -135a, -203,-133b, and -223) were over-expressed in CRC relative to mucosa," +tissue_expression_up hsa-mir-183 Colorectal Adenocarcinoma 20413677 "miR-183:eleven miRNAs (miR-183, -31, -20, -25, -92, -93, -17, -135a, -203,-133b, and -223) were over-expressed in CRC relative to mucosa," +tissue_expression_up hsa-mir-203 Colorectal Adenocarcinoma 20413677 "miR-203:eleven miRNAs (miR-183, -31, -20, -25, -92, -93, -17, -135a, -203,-133b, and -223) were over-expressed in CRC relative to mucosa," +tissue_expression_up hsa-mir-20a Colorectal Adenocarcinoma 20413677 "miR-20:eleven miRNAs (miR-183, -31, -20, -25, -92, -93, -17, -135a, -203,-133b, and -223) were over-expressed in CRC relative to mucosa," +tissue_expression_up hsa-mir-223 Colorectal Adenocarcinoma 20413677 "miR-223:eleven miRNAs (miR-183, -31, -20, -25, -92, -93, -17, -135a, -203,-133b, and -223) were over-expressed in CRC relative to mucosa," +tissue_expression_up hsa-mir-25 Colorectal Adenocarcinoma 20413677 "miR-25:eleven miRNAs (miR-183, -31, -20, -25, -92, -93, -17, -135a, -203,-133b, and -223) were over-expressed in CRC relative to mucosa," +tissue_expression_up hsa-mir-31 Colorectal Adenocarcinoma 20413677 "miR-31:eleven miRNAs (miR-183, -31, -20, -25, -92, -93, -17, -135a, -203,-133b, and -223) were over-expressed in CRC relative to mucosa," +tissue_expression_up hsa-mir-92a-1 Colorectal Adenocarcinoma 20413677 "miR-92:eleven miRNAs (miR-183, -31, -20, -25, -92, -93, -17, -135a, -203,-133b, and -223) were over-expressed in CRC relative to mucosa," +tissue_expression_up hsa-mir-92a-2 Colorectal Adenocarcinoma 20413677 "miR-92:eleven miRNAs (miR-183, -31, -20, -25, -92, -93, -17, -135a, -203,-133b, and -223) were over-expressed in CRC relative to mucosa," +tissue_expression_up hsa-mir-93 Colorectal Adenocarcinoma 20413677 "miR-93:eleven miRNAs (miR-183, -31, -20, -25, -92, -93, -17, -135a, -203,-133b, and -223) were over-expressed in CRC relative to mucosa," +tissue_expression_up hsa-mir-126 Lung Neoplasms 20418022 "This set includes hsa-miR-182, which was most strongly over-expressed in the lung primary tumors, and hsa-miR-126, which was over-expressed in the metastatic tumors." +tissue_expression_up hsa-mir-182 Lung Neoplasms 20418022 "This set includes hsa-miR-182, which was most strongly over-expressed in the lung primary tumors, and hsa-miR-126, which was over-expressed in the metastatic tumors." +tissue_expression_up hsa-mir-372 Liver Neoplasms 20423907 "microRNA-372:CREB up-regulates long non-coding RNA, HULC expression through interaction with microRNA-372 in liver cancer" +tissue_expression_up hsa-mir-106a Toxoplasma gondii Infection 20423977 hsa-mir-106a:human miR-17 family members that are increased by infection with the intracellular parasite Toxoplasma gondii +tissue_expression_up hsa-mir-106b Toxoplasma gondii Infection 20423977 hsa-mir-106b:human miR-17 family members that are increased by infection with the intracellular parasite Toxoplasma gondii +tissue_expression_up hsa-mir-17 Toxoplasma gondii Infection 20423977 hsa-mir-17:human miR-17 family members that are increased by infection with the intracellular parasite Toxoplasma gondii +tissue_expression_up hsa-mir-18a Toxoplasma gondii Infection 20423977 hsa-mir-18a:human miR-17 family members that are increased by infection with the intracellular parasite Toxoplasma gondii +tissue_expression_up hsa-mir-18b Toxoplasma gondii Infection 20423977 hsa-mir-18b:human miR-17 family members that are increased by infection with the intracellular parasite Toxoplasma gondii +tissue_expression_up hsa-mir-20a Toxoplasma gondii Infection 20423977 hsa-mir-20a:human miR-17 family members that are increased by infection with the intracellular parasite Toxoplasma gondii +tissue_expression_up hsa-mir-20b Toxoplasma gondii Infection 20423977 hsa-mir-20b:human miR-17 family members that are increased by infection with the intracellular parasite Toxoplasma gondii +tissue_expression_up hsa-mir-93 Toxoplasma gondii Infection 20423977 hsa-mir-93:human miR-17 family members that are increased by infection with the intracellular parasite Toxoplasma gondii +tissue_expression_up hsa-mir-221 Glioblastoma 20428775 miR-221:STAT1/2 upregulation under the transcriptional control of INF-alpha signaling after knockdown of miR-221/222 cluster in U251 glioma cells +tissue_expression_up hsa-mir-222 Glioblastoma 20428775 miR-222:STAT1/2 upregulation under the transcriptional control of INF-alpha signaling after knockdown of miR-221/222 cluster in U251 glioma cells +tissue_expression_up hsa-mir-205 "Squamous Cell Carcinoma, Esophageal" 20428818 miR-205:miR-205 and miR-21 are specific markers for HNSCC and ESCC +tissue_expression_up hsa-mir-205 "Squamous Cell Carcinoma, Head and Neck" 20428818 miR-205:miR-205 and miR-21 are specific markers for HNSCC and ESCC +tissue_expression_up hsa-mir-21 "Squamous Cell Carcinoma, Esophageal" 20428818 miR-21:miR-205 and miR-21 are specific markers for HNSCC and ESCC +tissue_expression_up hsa-mir-21 "Squamous Cell Carcinoma, Head and Neck" 20428818 miR-21:miR-205 and miR-21 are specific markers for HNSCC and ESCC +tissue_expression_up hsa-mir-146a Melanoma 20442294 miR-146a:miR-146a and miR-155 were upregulated in all analyzed patients but none of the cell lines +tissue_expression_up hsa-mir-155 Melanoma 20442294 miR-155:miR-146a and miR-155 were upregulated in all analyzed patients but none of the cell lines +tissue_expression_up hsa-mir-208 "Cardiomyopathy, Dilated" 20447577 "Levels of miR-208, miR-208b, and miR-499 were higher in DCM patients than in controls." +tissue_expression_up hsa-mir-208b "Cardiomyopathy, Dilated" 20447577 "Levels of miR-208, miR-208b, and miR-499 were higher in DCM patients than in controls." +tissue_expression_up hsa-mir-499 "Cardiomyopathy, Dilated" 20447577 "Levels of miR-208, miR-208b, and miR-499 were higher in DCM patients than in controls." +tissue_expression_up hsa-mir-1-1 Rhabdomyosarcoma 20466878 miR-1:mRNA targets of miR-1 and miR-133a are up-regulated in rhabdomyosarcomas +tissue_expression_up hsa-mir-1-2 Rhabdomyosarcoma 20466878 miR-1:mRNA targets of miR-1 and miR-133a are up-regulated in rhabdomyosarcomas +tissue_expression_up hsa-mir-133a-1 Rhabdomyosarcoma 20466878 miR-133a:mRNA targets of miR-1 and miR-133a are up-regulated in rhabdomyosarcomas +tissue_expression_up hsa-mir-296 "Squamous Cell Carcinoma, Esophageal" 20485139 miR-296:MiR-296 might play important roles in the pathogenesis of esophageal cancer and considered as a potential target for this malignancy intervention +tissue_expression_up hsa-mir-206 Myotonic Muscular Dystrophy 20487562 microRNA-206:Overexpression of microRNA-206 in the skeletal muscle from myotonic dystrophy type 1 patients +tissue_expression_up hsa-mir-18a Lung Neoplasms 20508945 "Seven miRNAs of hsa-miR-21, hsa-miR-31, hsa-miR-34a, hsa-miR-22*, hsa-miR-504, hsa-miR-18a, and hsa-miR-412 were observed to be upregulated greater than twofold in the squamous cell lung carcinoma tissues compared with normal tissues, whereas 23 miRNAs of hsa-miR-30a, hsa-miR-30d, hsa-miR-126, hsa-miR-652, hsa-miR-100, hsa-miR-143, hsa-miR-130a, hsa-miR-145, hsa-miR-30e, hsa-miR-126*, hsa-miR-181a, hsa-miR-125b, hsa-miR-886-3p, hsa-miR-451, hsa-miR-29c, hsa-miR-26b, hsa-miR-101, hsa-miR-320, hsa-miR-30b, hsa-miR-886-5p, hsa-miR-29a, hsa-miR-26a, and hsa-miR-99a were found to be downregulated greater than twofold." +tissue_expression_up hsa-mir-21 Lung Neoplasms 20508945 "Seven miRNAs of hsa-miR-21, hsa-miR-31, hsa-miR-34a, hsa-miR-22*, hsa-miR-504, hsa-miR-18a, and hsa-miR-412 were observed to be upregulated greater than twofold in the squamous cell lung carcinoma tissues compared with normal tissues, whereas 23 miRNAs of hsa-miR-30a, hsa-miR-30d, hsa-miR-126, hsa-miR-652, hsa-miR-100, hsa-miR-143, hsa-miR-130a, hsa-miR-145, hsa-miR-30e, hsa-miR-126*, hsa-miR-181a, hsa-miR-125b, hsa-miR-886-3p, hsa-miR-451, hsa-miR-29c, hsa-miR-26b, hsa-miR-101, hsa-miR-320, hsa-miR-30b, hsa-miR-886-5p, hsa-miR-29a, hsa-miR-26a, and hsa-miR-99a were found to be downregulated greater than twofold." +tissue_expression_up hsa-mir-22 Lung Neoplasms 20508945 "Seven miRNAs of hsa-miR-21, hsa-miR-31, hsa-miR-34a, hsa-miR-22*, hsa-miR-504, hsa-miR-18a, and hsa-miR-412 were observed to be upregulated greater than twofold in the squamous cell lung carcinoma tissues compared with normal tissues, whereas 23 miRNAs of hsa-miR-30a, hsa-miR-30d, hsa-miR-126, hsa-miR-652, hsa-miR-100, hsa-miR-143, hsa-miR-130a, hsa-miR-145, hsa-miR-30e, hsa-miR-126*, hsa-miR-181a, hsa-miR-125b, hsa-miR-886-3p, hsa-miR-451, hsa-miR-29c, hsa-miR-26b, hsa-miR-101, hsa-miR-320, hsa-miR-30b, hsa-miR-886-5p, hsa-miR-29a, hsa-miR-26a, and hsa-miR-99a were found to be downregulated greater than twofold." +tissue_expression_up hsa-mir-31 Lung Neoplasms 20508945 "Seven miRNAs of hsa-miR-21, hsa-miR-31, hsa-miR-34a, hsa-miR-22*, hsa-miR-504, hsa-miR-18a, and hsa-miR-412 were observed to be upregulated greater than twofold in the squamous cell lung carcinoma tissues compared with normal tissues, whereas 23 miRNAs of hsa-miR-30a, hsa-miR-30d, hsa-miR-126, hsa-miR-652, hsa-miR-100, hsa-miR-143, hsa-miR-130a, hsa-miR-145, hsa-miR-30e, hsa-miR-126*, hsa-miR-181a, hsa-miR-125b, hsa-miR-886-3p, hsa-miR-451, hsa-miR-29c, hsa-miR-26b, hsa-miR-101, hsa-miR-320, hsa-miR-30b, hsa-miR-886-5p, hsa-miR-29a, hsa-miR-26a, and hsa-miR-99a were found to be downregulated greater than twofold." +tissue_expression_up hsa-mir-34a Lung Neoplasms 20508945 "Seven miRNAs of hsa-miR-21, hsa-miR-31, hsa-miR-34a, hsa-miR-22*, hsa-miR-504, hsa-miR-18a, and hsa-miR-412 were observed to be upregulated greater than twofold in the squamous cell lung carcinoma tissues compared with normal tissues, whereas 23 miRNAs of hsa-miR-30a, hsa-miR-30d, hsa-miR-126, hsa-miR-652, hsa-miR-100, hsa-miR-143, hsa-miR-130a, hsa-miR-145, hsa-miR-30e, hsa-miR-126*, hsa-miR-181a, hsa-miR-125b, hsa-miR-886-3p, hsa-miR-451, hsa-miR-29c, hsa-miR-26b, hsa-miR-101, hsa-miR-320, hsa-miR-30b, hsa-miR-886-5p, hsa-miR-29a, hsa-miR-26a, and hsa-miR-99a were found to be downregulated greater than twofold." +tissue_expression_up hsa-mir-412 Lung Neoplasms 20508945 "Seven miRNAs of hsa-miR-21, hsa-miR-31, hsa-miR-34a, hsa-miR-22*, hsa-miR-504, hsa-miR-18a, and hsa-miR-412 were observed to be upregulated greater than twofold in the squamous cell lung carcinoma tissues compared with normal tissues, whereas 23 miRNAs of hsa-miR-30a, hsa-miR-30d, hsa-miR-126, hsa-miR-652, hsa-miR-100, hsa-miR-143, hsa-miR-130a, hsa-miR-145, hsa-miR-30e, hsa-miR-126*, hsa-miR-181a, hsa-miR-125b, hsa-miR-886-3p, hsa-miR-451, hsa-miR-29c, hsa-miR-26b, hsa-miR-101, hsa-miR-320, hsa-miR-30b, hsa-miR-886-5p, hsa-miR-29a, hsa-miR-26a, and hsa-miR-99a were found to be downregulated greater than twofold." +tissue_expression_up hsa-mir-504 Lung Neoplasms 20508945 "Seven miRNAs of hsa-miR-21, hsa-miR-31, hsa-miR-34a, hsa-miR-22*, hsa-miR-504, hsa-miR-18a, and hsa-miR-412 were observed to be upregulated greater than twofold in the squamous cell lung carcinoma tissues compared with normal tissues, whereas 23 miRNAs of hsa-miR-30a, hsa-miR-30d, hsa-miR-126, hsa-miR-652, hsa-miR-100, hsa-miR-143, hsa-miR-130a, hsa-miR-145, hsa-miR-30e, hsa-miR-126*, hsa-miR-181a, hsa-miR-125b, hsa-miR-886-3p, hsa-miR-451, hsa-miR-29c, hsa-miR-26b, hsa-miR-101, hsa-miR-320, hsa-miR-30b, hsa-miR-886-5p, hsa-miR-29a, hsa-miR-26a, and hsa-miR-99a were found to be downregulated greater than twofold." +tissue_expression_up hsa-mir-106a Colon Neoplasms 20551304 miRNA expression profiles from 29 patients showed higher expression of miR-21 and miR-106a in patients with adenomas and CRCs compared with individuals free of colorectal neoplasia. +tissue_expression_up hsa-mir-21 "Carcinoma, Rectal" 20551304 miRNA expression profiles from 29 patients showed higher expression of miR-21 and miR-106a in patients with adenomas and CRCs compared with individuals free of colorectal neoplasia. +tissue_expression_up hsa-mir-155 "Colitis, Ulcerative" 20586854 miR-155:Upregulated miRNA may be responsible for the development of intestinal inflammation in UC +tissue_expression_up hsa-mir-21 "Colitis, Ulcerative" 20586854 miR-21:Upregulated miRNA may be responsible for the development of intestinal inflammation in UC +tissue_expression_up hsa-mir-183 "Carcinoma, Hepatocellular" 20602797 "Among the 25 HCC samples analyzed, microRNA-183 was significantly up-regulated (twofold to 367-fold) in 17 samples compared with the matching nontumoral liver tissues." +tissue_expression_up hsa-mir-103a-1 Breast Neoplasms 20603000 "miR-103:In human breast cancer, high levels of miR-103/107 are associated with metastasis and poor outcome" +tissue_expression_up hsa-mir-103a-2 Breast Neoplasms 20603000 "miR-103:In human breast cancer, high levels of miR-103/107 are associated with metastasis and poor outcome" +tissue_expression_up hsa-mir-107 Breast Neoplasms 20603000 "miR-107:In human breast cancer, high levels of miR-103/107 are associated with metastasis and poor outcome" +tissue_expression_up hsa-mir-126 "Carcinoma, Hepatocellular" 20619223 miR-126:hsa-miR-126 showed higher expression levels in hepatocellular carcinomas +tissue_expression_up hsa-mir-125a "Squamous Cell Carcinoma, Lung" 20620595 miR-125a-5p:The miRNAs miR-185 * and miR-125a-5p were significantly upregulated in lung SCC +tissue_expression_up hsa-mir-185 "Squamous Cell Carcinoma, Lung" 20620595 miR-185:The miRNAs miR-185 * and miR-125a-5p were significantly upregulated in lung SCC +tissue_expression_up hsa-mir-103a-1 Lung Neoplasms 20624269 "miR-103:we found significant overexpression of miR-103, miR-107, miR-301 and miR-338 in lung cancer cells as compared to HBECs" +tissue_expression_up hsa-mir-103a-2 Lung Neoplasms 20624269 "miR-103:we found significant overexpression of miR-103, miR-107, miR-301 and miR-338 in lung cancer cells as compared to HBECs" +tissue_expression_up hsa-mir-107 Lung Neoplasms 20624269 "miR-107:we found significant overexpression of miR-103, miR-107, miR-301 and miR-338 in lung cancer cells as compared to HBECs" +tissue_expression_up hsa-mir-301a Lung Neoplasms 20624269 "miR-301:we found significant overexpression of miR-103, miR-107, miR-301 and miR-338 in lung cancer cells as compared to HBECs" +tissue_expression_up hsa-mir-338 Lung Neoplasms 20624269 "miR-338:we found significant overexpression of miR-103, miR-107, miR-301 and miR-338 in lung cancer cells as compared to HBECs" +tissue_expression_up hsa-mir-1-1 Myelodysplastic Syndromes 20627384 miR-1:Evaluation in a larger cohort could confirm the up-regulation of the miR-1 in MDS +tissue_expression_up hsa-mir-1-2 Myelodysplastic Syndromes 20627384 miR-1:Evaluation in a larger cohort could confirm the up-regulation of the miR-1 in MDS +tissue_expression_up hsa-mir-1246 Adenovirus Infection 20634878 miR-1246:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control +tissue_expression_up hsa-mir-1247 Adenovirus Infection 20634878 miR-1247:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control +tissue_expression_up hsa-mir-1273a Adenovirus Infection 20634878 miR-1273:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control +tissue_expression_up hsa-mir-1302-1 Adenovirus Infection 20634878 miR-1302-1:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control +tissue_expression_up hsa-mir-1302-2 Adenovirus Infection 20634878 miR-1302-2:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control +tissue_expression_up hsa-mir-1302-3 Adenovirus Infection 20634878 miR-1302-3:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control +tissue_expression_up hsa-mir-1302-4 Adenovirus Infection 20634878 miR-1302-4:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control +tissue_expression_up hsa-mir-1302-5 Adenovirus Infection 20634878 miR-1302-5:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control +tissue_expression_up hsa-mir-1302-6 Adenovirus Infection 20634878 miR-1302-6:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control +tissue_expression_up hsa-mir-1302-7 Adenovirus Infection 20634878 miR-1302-7:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control +tissue_expression_up hsa-mir-1302-8 Adenovirus Infection 20634878 miR-1302-8:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control +tissue_expression_up hsa-mir-146b Adenovirus Infection 20634878 miR-146b:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control +tissue_expression_up hsa-mir-150 Adenovirus Infection 20634878 miR-150:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control +tissue_expression_up hsa-mir-17 Adenovirus Infection 20634878 miR-17:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control +tissue_expression_up hsa-mir-18a Adenovirus Infection 20634878 miR-18a:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control +tissue_expression_up hsa-mir-191 Adenovirus Infection 20634878 miR-191:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control +tissue_expression_up hsa-mir-1972-1 Adenovirus Infection 20634878 miR-1972:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control +tissue_expression_up hsa-mir-320c-2 Adenovirus Infection 20634878 miR-320c-2:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control +tissue_expression_up hsa-mir-324 Adenovirus Infection 20634878 miR-324:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control +tissue_expression_up hsa-mir-342 Adenovirus Infection 20634878 miR-342:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control +tissue_expression_up hsa-mir-345 Adenovirus Infection 20634878 miR-345:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control +tissue_expression_up hsa-mir-378a Adenovirus Infection 20634878 miR-378:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control +tissue_expression_up hsa-mir-454 Adenovirus Infection 20634878 miR-454:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control +tissue_expression_up hsa-mir-505 Adenovirus Infection 20634878 miR-505:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control +tissue_expression_up hsa-mir-566 Adenovirus Infection 20634878 miR-566:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control +tissue_expression_up hsa-mir-589 Adenovirus Infection 20634878 miR-589:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control +tissue_expression_up hsa-mir-627 Adenovirus Infection 20634878 miR-627:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control +tissue_expression_up hsa-mir-635 Adenovirus Infection 20634878 miR-635:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control +tissue_expression_up hsa-mir-7-1 Adenovirus Infection 20634878 miR-7-1:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control +tissue_expression_up hsa-mir-7-2 Adenovirus Infection 20634878 miR-7-2:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control +tissue_expression_up hsa-mir-7-3 Adenovirus Infection 20634878 miR-7-3:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control +tissue_expression_up hsa-mir-744 Adenovirus Infection 20634878 miR-744:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control +tissue_expression_up hsa-mir-92a-1 Adenovirus Infection 20634878 miR-92a-1:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control +tissue_expression_up hsa-mir-942 Adenovirus Infection 20634878 miR-942:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control +tissue_expression_up hsa-mir-33 Squamous Cell Carcinoma 20652977 "The miRNAs miR-363, miR-33, and miR-497 were upregulated, whereas miR-155, miR-181a, miR-181b, miR-29a, miR-218, miR-222, miR-221, and miR-142-5p were downregulated in HPV-positive cells compared to both HPV-negative SCCHN and normal oral keratinocytes." +tissue_expression_up hsa-mir-363 Squamous Cell Carcinoma 20652977 "The miRNAs miR-363, miR-33, and miR-497 were upregulated, whereas miR-155, miR-181a, miR-181b, miR-29a, miR-218, miR-222, miR-221, and miR-142-5p were downregulated in HPV-positive cells compared to both HPV-negative SCCHN and normal oral keratinocytes." +tissue_expression_up hsa-mir-497 Squamous Cell Carcinoma 20652977 "The miRNAs miR-363, miR-33, and miR-497 were upregulated, whereas miR-155, miR-181a, miR-181b, miR-29a, miR-218, miR-222, miR-221, and miR-142-5p were downregulated in HPV-positive cells compared to both HPV-negative SCCHN and normal oral keratinocytes." +tissue_expression_up hsa-mir-17 Pancreatic Neoplasms 20703102 "MicroRNA miR-17-5p is overexpressed in pancreatic cancer, associated with a poor prognosis, and involved in cancer cell proliferation and invasion" +tissue_expression_up hsa-mir-21 Astrocytoma 20711171 Inhibition of two glioblastoma-upregulated miRNAs (miR-21 and miR-23a) and exogenous overexpression of two glioblastoma-downregulated miRNAs (miR-218 and miR-219-5p) resulted in reduced soft agar colony formation but showed varying effects on cell proliferation and chemosensitivity. +tissue_expression_up hsa-mir-23a Astrocytoma 20711171 Inhibition of two glioblastoma-upregulated miRNAs (miR-21 and miR-23a) and exogenous overexpression of two glioblastoma-downregulated miRNAs (miR-218 and miR-219-5p) resulted in reduced soft agar colony formation but showed varying effects on cell proliferation and chemosensitivity. +tissue_expression_up hsa-let-7f Ovarian Neoplasms 20716115 "Reduced miR-145 and miR-214 and elevated let-7f, miR-182, miR-210, miR-200c, miR-222 and miR-23a levels were found in effusions in both sets." +tissue_expression_up hsa-mir-182 Ovarian Neoplasms 20716115 "Reduced miR-145 and miR-214 and elevated let-7f, miR-182, miR-210, miR-200c, miR-222 and miR-23a levels were found in effusions in both sets." +tissue_expression_up hsa-mir-200c Ovarian Neoplasms 20716115 "Reduced miR-145 and miR-214 and elevated let-7f, miR-182, miR-210, miR-200c, miR-222 and miR-23a levels were found in effusions in both sets." +tissue_expression_up hsa-mir-210 Ovarian Neoplasms 20716115 "Reduced miR-145 and miR-214 and elevated let-7f, miR-182, miR-210, miR-200c, miR-222 and miR-23a levels were found in effusions in both sets." +tissue_expression_up hsa-mir-222 Ovarian Neoplasms 20716115 "Reduced miR-145 and miR-214 and elevated let-7f, miR-182, miR-210, miR-200c, miR-222 and miR-23a levels were found in effusions in both sets." +tissue_expression_up hsa-mir-23a Ovarian Neoplasms 20716115 "Reduced miR-145 and miR-214 and elevated let-7f, miR-182, miR-210, miR-200c, miR-222 and miR-23a levels were found in effusions in both sets." +tissue_expression_up hsa-mir-106a Breast Neoplasms 20801493 "A high correlation of miRNA expression level was found between breast tumor tissues and sera. MiR-21, miR-106a and miR-155 were significantly over-expressed in the tumor specimens compared with those in normal controls (P < 0.05), whereas miR-126, miR-199a and miR-335 were significantly under-expressed (P < 0.05)." +tissue_expression_up hsa-mir-155 Breast Neoplasms 20801493 "A high correlation of miRNA expression level was found between breast tumor tissues and sera. MiR-21, miR-106a and miR-155 were significantly over-expressed in the tumor specimens compared with those in normal controls (P < 0.05), whereas miR-126, miR-199a and miR-335 were significantly under-expressed (P < 0.05)." +tissue_expression_up hsa-mir-21 Breast Neoplasms 20801493 "A high correlation of miRNA expression level was found between breast tumor tissues and sera. MiR-21, miR-106a and miR-155 were significantly over-expressed in the tumor specimens compared with those in normal controls (P < 0.05), whereas miR-126, miR-199a and miR-335 were significantly under-expressed (P < 0.05)." +tissue_expression_up hsa-mir-223 Gastrointestinal Neoplasms 20802470 "Taken together, aberrant E2A expression is a diagnostic feature of a subtype of gastric MALT lymphoma with weaker plasmacytoid infiltrates and stronger miR-223 expression." +tissue_expression_up hsa-mir-20b Laryngeal Neoplasms 20806854 upregulated by 3 multiple +tissue_expression_up hsa-mir-31 Laryngeal Neoplasms 20806854 upregulated by 3 multiple +tissue_expression_up hsa-mir-93 Laryngeal Neoplasms 20806854 upregulated by 3 multiple +tissue_expression_up hsa-let-7a-1 Spinal Cord Injuries 20816819 Let-7a:SCI results in increased expression of miR Let-7a and miR16 +tissue_expression_up hsa-let-7a-2 Spinal Cord Injuries 20816819 Let-7a:SCI results in increased expression of miR Let-7a and miR16 +tissue_expression_up hsa-let-7a-3 Spinal Cord Injuries 20816819 Let-7a:SCI results in increased expression of miR Let-7a and miR16 +tissue_expression_up hsa-mir-15b Spinal Cord Injuries 20816819 "spinal cord injury (SCI)results in increased expression of miR Let-7a and miR16 while exercise leads to elevated levels of miR21 and decreased levels of miR15b. These changes in miR expression are correlated with changes in expression of their target genes: pro-apoptotic (decreased PTEN, PDCD4, and RAS mRNA) and anti-apoptotic (increased Bcl-2 mRNA) target genes. This is accompanied by a down-regulation of mRNA for caspase-7 and caspase-9 and reduced levels of caspase-7 protein." +tissue_expression_up hsa-mir-16-1 Spinal Cord Injuries 20816819 miR16:SCI results in increased expression of miR Let-7a and miR16 +tissue_expression_up hsa-mir-16-2 Spinal Cord Injuries 20816819 miR16:SCI results in increased expression of miR Let-7a and miR16 +tissue_expression_up hsa-mir-192 Neoplasms [unspecific] 20864637 "miR-192:Hsa-miR-193-3p was overexpressed in MPM, while hsa-miR-200c and hsa-miR-192 were overexpressed in peripheral lung adenocarcinoma and carcinomas" +tissue_expression_up hsa-mir-193a Mesothelioma 20864637 "miR-193-3p:Hsa-miR-193-3p was overexpressed in MPM, while hsa-miR-200c and hsa-miR-192 were overexpressed in peripheral lung adenocarcinoma and carcinomas" +tissue_expression_up hsa-mir-200c "Adenocarcinoma, Lung" 20864637 "miR-200c:Hsa-miR-193-3p was overexpressed in MPM, while hsa-miR-200c and hsa-miR-192 were overexpressed in peripheral lung adenocarcinoma and carcinomas" +tissue_expression_up hsa-mir-200a "Fatty Liver, Non-Alcoholic" 20956972 "The miRNAs analysis showed the significant downregulation of three miRNAs (miR-122, miR-451 and miR-27) and the upregulation of miR-200a, miR-200b and miR-429 in HFD, SD-HF and HFD-HF rats" +tissue_expression_up hsa-mir-200b "Fatty Liver, Non-Alcoholic" 20956972 "The miRNAs analysis showed the significant downregulation of three miRNAs (miR-122, miR-451 and miR-27) and the upregulation of miR-200a, miR-200b and miR-429 in HFD, SD-HF and HFD-HF rats" +tissue_expression_up hsa-mir-429 "Fatty Liver, Non-Alcoholic" 20956972 "The miRNAs analysis showed the significant downregulation of three miRNAs (miR-122, miR-451 and miR-27) and the upregulation of miR-200a, miR-200b and miR-429 in HFD, SD-HF and HFD-HF rats" +tissue_expression_up hsa-mir-195 Astrocytoma 20976148 The observation that miR-34a and miR-195 levels were increased in the RISC of U-87 astrocytoma cells suggests an oncogenic role for these miRNAs. +tissue_expression_up hsa-mir-34a Astrocytoma 20976148 The observation that miR-34a and miR-195 levels were increased in the RISC of U-87 astrocytoma cells suggests an oncogenic role for these miRNAs. +tissue_expression_up hsa-mir-141 "Carcinoma, Endometrioid Endometrial" 21035172 "A miRNA microarray showed that the miR-200 family, including hsa-miR-141, hsa-miR-200a, hsa-miR-200b, hsa-miR-200c, and hsa-miR-429, was up-regulated in EECs as compared with that in normal endometrial tissues." +tissue_expression_up hsa-mir-200a "Carcinoma, Endometrioid Endometrial" 21035172 "A miRNA microarray showed that the miR-200 family, including hsa-miR-141, hsa-miR-200a, hsa-miR-200b, hsa-miR-200c, and hsa-miR-429, was up-regulated in EECs as compared with that in normal endometrial tissues." +tissue_expression_up hsa-mir-200b "Carcinoma, Endometrioid Endometrial" 21035172 "A miRNA microarray showed that the miR-200 family, including hsa-miR-141, hsa-miR-200a, hsa-miR-200b, hsa-miR-200c, and hsa-miR-429, was up-regulated in EECs as compared with that in normal endometrial tissues." +tissue_expression_up hsa-mir-200c "Carcinoma, Endometrioid Endometrial" 21035172 "A miRNA microarray showed that the miR-200 family, including hsa-miR-141, hsa-miR-200a, hsa-miR-200b, hsa-miR-200c, and hsa-miR-429, was up-regulated in EECs as compared with that in normal endometrial tissues." +tissue_expression_up hsa-mir-429 "Carcinoma, Endometrioid Endometrial" 21035172 "These results indicate that the miR-200 family is highly expressed in EECs compared with that of normal endometrial tissues and could play an important role in cancer growth. Specifically, anti-miR-429 could enhance the cytotoxic activity with cisplatin in EECs." +tissue_expression_up hsa-mir-196a "Niemann-Pick Disease, Type C" 21075073 "We found that three miRNAs, miR-196a, miR-196b and miR-296 were up-regulated (>3.5-fold increase, p<0.05) whereas 38 miRNAs were significantly down-regulated in NPC cells (>3.5-fold decrease, p<0.05)." +tissue_expression_up hsa-mir-196b "Niemann-Pick Disease, Type C" 21075073 "We found that three miRNAs, miR-196a, miR-196b and miR-296 were up-regulated (>3.5-fold increase, p<0.05) whereas 38 miRNAs were significantly down-regulated in NPC cells (>3.5-fold decrease, p<0.05)." +tissue_expression_up hsa-mir-296 "Niemann-Pick Disease, Type C" 21075073 "We found that three miRNAs, miR-196a, miR-196b and miR-296 were up-regulated (>3.5-fold increase, p<0.05) whereas 38 miRNAs were significantly down-regulated in NPC cells (>3.5-fold decrease, p<0.05)." +tissue_expression_up hsa-mir-192 Gastric Neoplasms 21119604 MicroRNA-192 and -215 are upregulated in human gastric cancer in vivo and suppress ALCAM expression in vitro. +tissue_expression_up hsa-mir-215 Gastric Neoplasms 21119604 MicroRNA-192 and -215 are upregulated in human gastric cancer in vivo and suppress ALCAM expression in vitro. +tissue_expression_up hsa-mir-155 "Carcinoma, Endometrial" 21125666 "Up-regulated miRNAs included miR-155, miR-369-5p, miR-370, miR-450a and miR-542-5p. These data suggest that in human ECS, the interplay between transcriptional repressors of E-cadherin and miRNAs provides a link between EMT-activation and the maintenance of stemness." +tissue_expression_up hsa-mir-369 "Carcinoma, Endometrial" 21125666 "Up-regulated miRNAs included miR-155, miR-369-5p, miR-370, miR-450a and miR-542-5p. These data suggest that in human ECS, the interplay between transcriptional repressors of E-cadherin and miRNAs provides a link between EMT-activation and the maintenance of stemness." +tissue_expression_up hsa-mir-450a "Carcinoma, Endometrial" 21125666 "Up-regulated miRNAs included miR-155, miR-369-5p, miR-370, miR-450a and miR-542-5p. These data suggest that in human ECS, the interplay between transcriptional repressors of E-cadherin and miRNAs provides a link between EMT-activation and the maintenance of stemness." +tissue_expression_up hsa-mir-542 "Carcinoma, Endometrial" 21125666 "Up-regulated miRNAs included miR-155, miR-369-5p, miR-370, miR-450a and miR-542-5p. These data suggest that in human ECS, the interplay between transcriptional repressors of E-cadherin and miRNAs provides a link between EMT-activation and the maintenance of stemness." +tissue_expression_up hsa-mir-34a Myelodysplastic Syndromes 21150891 "In early MDS, we monitored upregulation of proapoptotic miR-34a" +tissue_expression_up hsa-mir-7-1 Neurilemmoma 21156648 miRNA-7 attenuation in schwannoma tumors stimulates growth by upregulating three oncogenic signaling pathways. +tissue_expression_up hsa-mir-7-2 Neurilemmoma 21156648 miRNA-7 attenuation in schwannoma tumors stimulates growth by upregulating three oncogenic signaling pathways. +tissue_expression_up hsa-mir-7-3 Neurilemmoma 21156648 miRNA-7 attenuation in schwannoma tumors stimulates growth by upregulating three oncogenic signaling pathways. +tissue_expression_up hsa-mir-1-1 Myotonic Muscular Dystrophy 21169019 "We found that miR-1 and miR-335 were up-regulated, whereas miR-29b and c, and miR-33 were down-regulated in DM1 biopsies compared to controls." +tissue_expression_up hsa-mir-335 Myotonic Muscular Dystrophy 21169019 "We found that miR-1 and miR-335 were up-regulated, whereas miR-29b and c, and miR-33 were down-regulated in DM1 biopsies compared to controls." +tissue_expression_up hsa-mir-1179 Colorectal Carcinoma 21174058 "miR-150*, miR-125b-2*, miR-1179 and miR-139-3p were up-regulated in colorectal cancers with liver metastasis" +tissue_expression_up hsa-mir-125b-2 Colorectal Carcinoma 21174058 "miR-150*, miR-125b-2*, miR-1179 and miR-139-3p were up-regulated in colorectal cancers with liver metastasis" +tissue_expression_up hsa-mir-139 Colorectal Carcinoma 21174058 "miR-150*, miR-125b-2*, miR-1179 and miR-139-3p were up-regulated in colorectal cancers with liver metastasis" +tissue_expression_up hsa-mir-150 Colorectal Carcinoma 21174058 "miR-150*, miR-125b-2*, miR-1179 and miR-139-3p were up-regulated in colorectal cancers with liver metastasis" +tissue_expression_up hsa-mir-210 Liver Neoplasms 21175813 upregulated after arsenic trioxide treatment in HepG-2 cells +tissue_expression_up hsa-mir-24-1 Liver Neoplasms 21175813 upregulated after arsenic trioxide treatment in HepG-2 cells +tissue_expression_up hsa-mir-24-2 Liver Neoplasms 21175813 upregulated after arsenic trioxide treatment in HepG-2 cells +tissue_expression_up hsa-mir-29a Liver Neoplasms 21175813 "upregulated after arsenic trioxide treatment in HepG-2 cells miR-29a showed a positive therapeutic effect in liver cancer cells by inhibiting cell growth and inducing cell apoptosis, and PPM1D was confirmed to be the target gene of miR-29a." +tissue_expression_up hsa-mir-30a Liver Neoplasms 21175813 upregulated after arsenic trioxide treatment in HepG-2 cells +tissue_expression_up hsa-mir-10b Liver Neoplasms 21176238 overexpressed in side population of HCC cells compared to fetal liver cells +tissue_expression_up hsa-mir-21 Liver Neoplasms 21176238 overexpressed in side population of HCC cells compared to fetal liver cells +tissue_expression_up hsa-mir-34c Liver Neoplasms 21176238 miR-34c-3p is overexpressed in side population of HCC cells compared to fetal liver cells +tissue_expression_up hsa-mir-183 Ovarian Neoplasms 21176563 "Increased expression of miR-183 and miR-22 may both repress the protein level of ezrin, indicating that miR-183 and miR-22 may bear a potential role in inhibiting ovarian cancer metastasis in a ezrin-mediated way" +tissue_expression_up hsa-mir-22 Ovarian Neoplasms 21176563 "Increased expression of miR-183 and miR-22 may both repress the protein level of ezrin, indicating that miR-183 and miR-22 may bear a potential role in inhibiting ovarian cancer metastasis in a ezrin-mediated way" +tissue_expression_up hsa-mir-330 Prostate Neoplasms 21177307 "We also observed a significant down-regulation of androgen-regulated miRNA-21 and up-regulation of a tumor suppressor, miRNA-330, in tumors of mice treated with EGCG" +tissue_expression_up hsa-let-7e Synovial Sarcoma 21213367 upregulated +tissue_expression_up hsa-mir-125a Synovial Sarcoma 21213367 hsa-mir-125a-3p upregulated +tissue_expression_up hsa-mir-99b Synovial Sarcoma 21213367 upregulated +tissue_expression_up hsa-mir-29b-1 Urinary Bladder Cancer 21223810 "In grade I, grade II, grade III, grade I + II + III, infiltrating and non-infiltrating groups, hsa-miR-29b-1* was up-regulated while hsa-miR-923 and hsa-miR-300 were down-regulated" +tissue_expression_up hsa-mir-129-1 "Squamous Cell Carcinoma, Oral" 21244772 "Thirteen miRNA were significantly overexpressed (miR-489, miR-129, miR-23a, miR-214, miR-23b, miR-92, miR-25, miR-210, miR-212, miR-515, miR-146b, miR-21, miR-338) and 6 miRNA were underexpressed (miR-520h, miR-197, miR-378, miR-135b, miR-224, miR-34a) in oral tumours. Underexpression of mir-155, let-7i, mir-146a was found to characterize progression to metastastatic tumours." +tissue_expression_up hsa-mir-129-2 "Squamous Cell Carcinoma, Oral" 21244772 "Thirteen miRNA were significantly overexpressed (miR-489, miR-129, miR-23a, miR-214, miR-23b, miR-92, miR-25, miR-210, miR-212, miR-515, miR-146b, miR-21, miR-338) and 6 miRNA were underexpressed (miR-520h, miR-197, miR-378, miR-135b, miR-224, miR-34a) in oral tumours. Underexpression of mir-155, let-7i, mir-146a was found to characterize progression to metastastatic tumours." +tissue_expression_up hsa-mir-146b "Squamous Cell Carcinoma, Oral" 21244772 "Thirteen miRNA were significantly overexpressed (miR-489, miR-129, miR-23a, miR-214, miR-23b, miR-92, miR-25, miR-210, miR-212, miR-515, miR-146b, miR-21, miR-338) and 6 miRNA were underexpressed (miR-520h, miR-197, miR-378, miR-135b, miR-224, miR-34a) in oral tumours. Underexpression of mir-155, let-7i, mir-146a was found to characterize progression to metastastatic tumours." +tissue_expression_up hsa-mir-21 "Squamous Cell Carcinoma, Oral" 21244772 "Thirteen miRNA were significantly overexpressed (miR-489, miR-129, miR-23a, miR-214, miR-23b, miR-92, miR-25, miR-210, miR-212, miR-515, miR-146b, miR-21, miR-338) and 6 miRNA were underexpressed (miR-520h, miR-197, miR-378, miR-135b, miR-224, miR-34a) in oral tumours. Underexpression of mir-155, let-7i, mir-146a was found to characterize progression to metastastatic tumours." +tissue_expression_up hsa-mir-210 "Squamous Cell Carcinoma, Oral" 21244772 "Thirteen miRNA were significantly overexpressed (miR-489, miR-129, miR-23a, miR-214, miR-23b, miR-92, miR-25, miR-210, miR-212, miR-515, miR-146b, miR-21, miR-338) and 6 miRNA were underexpressed (miR-520h, miR-197, miR-378, miR-135b, miR-224, miR-34a) in oral tumours. Underexpression of mir-155, let-7i, mir-146a was found to characterize progression to metastastatic tumours." +tissue_expression_up hsa-mir-212 "Squamous Cell Carcinoma, Oral" 21244772 "Thirteen miRNA were significantly overexpressed (miR-489, miR-129, miR-23a, miR-214, miR-23b, miR-92, miR-25, miR-210, miR-212, miR-515, miR-146b, miR-21, miR-338) and 6 miRNA were underexpressed (miR-520h, miR-197, miR-378, miR-135b, miR-224, miR-34a) in oral tumours. Underexpression of mir-155, let-7i, mir-146a was found to characterize progression to metastastatic tumours." +tissue_expression_up hsa-mir-214 "Squamous Cell Carcinoma, Oral" 21244772 "Thirteen miRNA were significantly overexpressed (miR-489, miR-129, miR-23a, miR-214, miR-23b, miR-92, miR-25, miR-210, miR-212, miR-515, miR-146b, miR-21, miR-338) and 6 miRNA were underexpressed (miR-520h, miR-197, miR-378, miR-135b, miR-224, miR-34a) in oral tumours. Underexpression of mir-155, let-7i, mir-146a was found to characterize progression to metastastatic tumours." +tissue_expression_up hsa-mir-23a "Squamous Cell Carcinoma, Oral" 21244772 "Thirteen miRNA were significantly overexpressed (miR-489, miR-129, miR-23a, miR-214, miR-23b, miR-92, miR-25, miR-210, miR-212, miR-515, miR-146b, miR-21, miR-338) and 6 miRNA were underexpressed (miR-520h, miR-197, miR-378, miR-135b, miR-224, miR-34a) in oral tumours. Underexpression of mir-155, let-7i, mir-146a was found to characterize progression to metastastatic tumours." +tissue_expression_up hsa-mir-23b "Squamous Cell Carcinoma, Oral" 21244772 "Thirteen miRNA were significantly overexpressed (miR-489, miR-129, miR-23a, miR-214, miR-23b, miR-92, miR-25, miR-210, miR-212, miR-515, miR-146b, miR-21, miR-338) and 6 miRNA were underexpressed (miR-520h, miR-197, miR-378, miR-135b, miR-224, miR-34a) in oral tumours. Underexpression of mir-155, let-7i, mir-146a was found to characterize progression to metastastatic tumours." +tissue_expression_up hsa-mir-25 "Squamous Cell Carcinoma, Oral" 21244772 "Thirteen miRNA were significantly overexpressed (miR-489, miR-129, miR-23a, miR-214, miR-23b, miR-92, miR-25, miR-210, miR-212, miR-515, miR-146b, miR-21, miR-338) and 6 miRNA were underexpressed (miR-520h, miR-197, miR-378, miR-135b, miR-224, miR-34a) in oral tumours. Underexpression of mir-155, let-7i, mir-146a was found to characterize progression to metastastatic tumours." +tissue_expression_up hsa-mir-338 "Squamous Cell Carcinoma, Oral" 21244772 "Thirteen miRNA were significantly overexpressed (miR-489, miR-129, miR-23a, miR-214, miR-23b, miR-92, miR-25, miR-210, miR-212, miR-515, miR-146b, miR-21, miR-338) and 6 miRNA were underexpressed (miR-520h, miR-197, miR-378, miR-135b, miR-224, miR-34a) in oral tumours. Underexpression of mir-155, let-7i, mir-146a was found to characterize progression to metastastatic tumours." +tissue_expression_up hsa-mir-489 "Squamous Cell Carcinoma, Oral" 21244772 "Thirteen miRNA were significantly overexpressed (miR-489, miR-129, miR-23a, miR-214, miR-23b, miR-92, miR-25, miR-210, miR-212, miR-515, miR-146b, miR-21, miR-338) and 6 miRNA were underexpressed (miR-520h, miR-197, miR-378, miR-135b, miR-224, miR-34a) in oral tumours. Underexpression of mir-155, let-7i, mir-146a was found to characterize progression to metastastatic tumours." +tissue_expression_up hsa-mir-515-1 "Squamous Cell Carcinoma, Oral" 21244772 "Thirteen miRNA were significantly overexpressed (miR-489, miR-129, miR-23a, miR-214, miR-23b, miR-92, miR-25, miR-210, miR-212, miR-515, miR-146b, miR-21, miR-338) and 6 miRNA were underexpressed (miR-520h, miR-197, miR-378, miR-135b, miR-224, miR-34a) in oral tumours. Underexpression of mir-155, let-7i, mir-146a was found to characterize progression to metastastatic tumours." +tissue_expression_up hsa-mir-515-2 "Squamous Cell Carcinoma, Oral" 21244772 "Thirteen miRNA were significantly overexpressed (miR-489, miR-129, miR-23a, miR-214, miR-23b, miR-92, miR-25, miR-210, miR-212, miR-515, miR-146b, miR-21, miR-338) and 6 miRNA were underexpressed (miR-520h, miR-197, miR-378, miR-135b, miR-224, miR-34a) in oral tumours. Underexpression of mir-155, let-7i, mir-146a was found to characterize progression to metastastatic tumours." +tissue_expression_up hsa-mir-92a-1 "Squamous Cell Carcinoma, Oral" 21244772 "Thirteen miRNA were significantly overexpressed (miR-489, miR-129, miR-23a, miR-214, miR-23b, miR-92, miR-25, miR-210, miR-212, miR-515, miR-146b, miR-21, miR-338) and 6 miRNA were underexpressed (miR-520h, miR-197, miR-378, miR-135b, miR-224, miR-34a) in oral tumours. Underexpression of mir-155, let-7i, mir-146a was found to characterize progression to metastastatic tumours." +tissue_expression_up hsa-mir-92a-2 "Squamous Cell Carcinoma, Oral" 21244772 "Thirteen miRNA were significantly overexpressed (miR-489, miR-129, miR-23a, miR-214, miR-23b, miR-92, miR-25, miR-210, miR-212, miR-515, miR-146b, miR-21, miR-338) and 6 miRNA were underexpressed (miR-520h, miR-197, miR-378, miR-135b, miR-224, miR-34a) in oral tumours. Underexpression of mir-155, let-7i, mir-146a was found to characterize progression to metastastatic tumours." +tissue_expression_up hsa-mir-92b "Squamous Cell Carcinoma, Oral" 21244772 "Thirteen miRNA were significantly overexpressed (miR-489, miR-129, miR-23a, miR-214, miR-23b, miR-92, miR-25, miR-210, miR-212, miR-515, miR-146b, miR-21, miR-338) and 6 miRNA were underexpressed (miR-520h, miR-197, miR-378, miR-135b, miR-224, miR-34a) in oral tumours. Underexpression of mir-155, let-7i, mir-146a was found to characterize progression to metastastatic tumours." +tissue_expression_up hsa-let-7c Prostate Neoplasms 21255804 "Using the Cox regression test the risk of recurrence was 3.0, 3.3, 2.7 and 3.4 for high levels of miR-100, miR-145, miR-191 and miR-let7c, respectively." +tissue_expression_up hsa-mir-100 Prostate Neoplasms 21255804 "Using the Cox regression test the risk of recurrence was 3.0, 3.3, 2.7 and 3.4 for high levels of miR-100, miR-145, miR-191 and miR-let7c, respectively." +tissue_expression_up hsa-mir-145 Prostate Neoplasms 21255804 "Using the Cox regression test the risk of recurrence was 3.0, 3.3, 2.7 and 3.4 for high levels of miR-100, miR-145, miR-191 and miR-let7c, respectively." +tissue_expression_up hsa-mir-191 Prostate Neoplasms 21255804 "Using the Cox regression test the risk of recurrence was 3.0, 3.3, 2.7 and 3.4 for high levels of miR-100, miR-145, miR-191 and miR-let7c, respectively." +tissue_expression_up hsa-mir-495 Breast Neoplasms 21258409 "miR-495 is upregulated by E12/E47 in breast cancer stem cells, and promotes oncogenesis and hypoxia resistance via downregulation of E-cadherin and REDD1." +tissue_expression_up hsa-mir-126 "Carcinoma, Lung, Non-Small-Cell" 21264844 Independent and tissue-specific prognostic impact of miR-126 in nonsmall cell lung cancer: Coexpression with vascular endothelial growth factor-A predicts poor survival. +tissue_expression_up hsa-mir-126 Esophageal Neoplasms 21269950 hsa-mir-126 is upregulated and hsa-miR-518b is downregulated in esophageal squamous carcinoma +tissue_expression_up hsa-mir-21 Breast Neoplasms 21270527 "miR-21, miR-210 and miR-221 were significantly overexpressed, whereas miR-10b, miR-145, miR-205, miR-122a were significantly underexpressed in the triple-negative primary breast cancers." +tissue_expression_up hsa-mir-210 Breast Neoplasms 21270527 "miR-21, miR-210 and miR-221 were significantly overexpressed, whereas miR-10b, miR-145, miR-205, miR-122a were significantly underexpressed in the triple-negative primary breast cancers." +tissue_expression_up hsa-mir-221 Breast Neoplasms 21270527 "miR-21, miR-210 and miR-221 were significantly overexpressed, whereas miR-10b, miR-145, miR-205, miR-122a were significantly underexpressed in the triple-negative primary breast cancers." +tissue_expression_up hsa-mir-181a-2 Breast Neoplasms 21271219 Increased miR-21 and miR-181a levels were significantly associated with shortened +tissue_expression_up hsa-mir-21 Breast Neoplasms 21271219 "Increased miR-21 and miR-181a levels were significantly associated with shortened disease-free survival(DFS; p=0.0003, 0.0007) and overall survival (OS; p=0.0351, 0.0443), respectively. Accumulation of miR-21 and miR-181a in bone marrow appears to be associated with prognosis in breast cancer patients. The much higher significant correlation with microRNA levels and prognosis suggests epistatic effects on multiple target genes in the bone marrow of breast cancer patients." +tissue_expression_up hsa-mir-373 Breast Neoplasms 21271679 miR-373 was found to be capable of promoting breast cancer invasion and metastasis +tissue_expression_up hsa-mir-221 Thyroid Neoplasms 21275764 mir-221 was overexpressed in 19 patients (p<0.0001) with a sensitive yield of 95%. +tissue_expression_up hsa-mir-638 Lung Neoplasms 21303527 We found the upregulation of microRNA-638 and microRNA-923 in bostrycin-treated lung adenocarcinoma cells +tissue_expression_up hsa-let-7b Preeclampsia 21309633 "Six miRNAs were more than 2-fold over-expressed in severe preeclampsia: let-7b, miRNA-302*, miRNA-104, miRNA-128a, miRNA-182* and miRNA-133b." +tissue_expression_up hsa-mir-128-1 Preeclampsia 21309633 "Six miRNAs were more than 2-fold over-expressed in severe preeclampsia: let-7b, miRNA-302*, miRNA-104, miRNA-128a, miRNA-182* and miRNA-133b." +tissue_expression_up hsa-mir-128-2 Preeclampsia 21309633 "Six miRNAs were more than 2-fold over-expressed in severe preeclampsia: let-7b, miRNA-302*, miRNA-104, miRNA-128a, miRNA-182* and miRNA-133b." +tissue_expression_up hsa-mir-133b Preeclampsia 21309633 "Six miRNAs were more than 2-fold over-expressed in severe preeclampsia: let-7b, miRNA-302*, miRNA-104, miRNA-128a, miRNA-182* and miRNA-133b." +tissue_expression_up hsa-mir-182 Preeclampsia 21309633 "Six miRNAs were more than 2-fold over-expressed in severe preeclampsia: let-7b, miRNA-302*, miRNA-104, miRNA-128a, miRNA-182* and miRNA-133b." +tissue_expression_up hsa-mir-21 Preeclampsia 21309633 "Six miRNAs were more than 2-fold over-expressed in severe preeclampsia: let-7b, miRNA-302*, miRNA-104, miRNA-128a, miRNA-182* and miRNA-133b." +tissue_expression_up hsa-mir-302a Preeclampsia 21309633 "Six miRNAs were more than 2-fold over-expressed in severe preeclampsia: let-7b, miRNA-302*, miRNA-104, miRNA-128a, miRNA-182* and miRNA-133b." +tissue_expression_up hsa-mir-302b Preeclampsia 21309633 "Six miRNAs were more than 2-fold over-expressed in severe preeclampsia: let-7b, miRNA-302*, miRNA-104, miRNA-128a, miRNA-182* and miRNA-133b." +tissue_expression_up hsa-mir-302c Preeclampsia 21309633 "Six miRNAs were more than 2-fold over-expressed in severe preeclampsia: let-7b, miRNA-302*, miRNA-104, miRNA-128a, miRNA-182* and miRNA-133b." +tissue_expression_up hsa-mir-302d Preeclampsia 21309633 "Six miRNAs were more than 2-fold over-expressed in severe preeclampsia: let-7b, miRNA-302*, miRNA-104, miRNA-128a, miRNA-182* and miRNA-133b." +tissue_expression_up hsa-mir-302e Preeclampsia 21309633 "Six miRNAs were more than 2-fold over-expressed in severe preeclampsia: let-7b, miRNA-302*, miRNA-104, miRNA-128a, miRNA-182* and miRNA-133b." +tissue_expression_up hsa-mir-302f Preeclampsia 21309633 "Six miRNAs were more than 2-fold over-expressed in severe preeclampsia: let-7b, miRNA-302*, miRNA-104, miRNA-128a, miRNA-182* and miRNA-133b." +tissue_expression_up hsa-mir-17 Mesothelioma 21317924 Hsa-miR-17* was significantly upregulated and hsa-miR-30c was significantly downregulated by Onconase treatment in all cell lines +tissue_expression_up hsa-mir-492 Hepatoblastoma 21319197 MicroRNA-492 is processed from the keratin 19 gene and up-regulated in metastatic hepatoblastoma. +tissue_expression_up hsa-mir-151a "Carcinoma, Hepatocellular" 21319996 miR-30d and miR-151 were amplified in ~50% of Hepatitis B Virus-Associated HCC tumor tissues +tissue_expression_up hsa-mir-30d "Carcinoma, Hepatocellular" 21319996 miR-30d and miR-151 were amplified in ~50% of Hepatitis B Virus-Associated HCC tumor tissues +tissue_expression_up hsa-mir-21 Breast Neoplasms 21326627 miR-21 Expression in Pregnancy-Associated Breast Cancer: A Possible Marker of Poor Prognosis. +tissue_expression_up hsa-mir-21 Endometrial Neoplasms 21330826 Highly increased maspin expression corresponds with up-regulation of miR-21 in endometrial cancer +tissue_expression_up hsa-mir-142 Gastric Neoplasms 21343377 A high frequency recurrence and poor survival were observed in gastric cancer cases with high level of hsa-miR-375 and low level of hsa-miR-142-5p (P < 0.001). The results indicate that the combination of hsa-miR-375 and hsa-miR-142-5p as a predictor of disease progression has the potential to predict recurrence risk for GC patients. +tissue_expression_up hsa-mir-142 Gastrointestinal Neoplasms 21343377 "A high frequency recurrence and poor survival were observed in GC cases with high level of hsa-miR-375 and low level of hsa-miR-142-5p (P < 0.001),indicating that the combination of hsa-miR-375 and hsa-miR-142-5p as a predictor of disease progression has the potential to predict recurrence risk for GC patients" +tissue_expression_up hsa-mir-375 Gastric Neoplasms 21343377 A high frequency recurrence and poor survival were observed in gastric cancer cases with high level of hsa-miR-375 and low level of hsa-miR-142-5p (P < 0.001). The results indicate that the combination of hsa-miR-375 and hsa-miR-142-5p as a predictor of disease progression has the potential to predict recurrence risk for GC patients. +tissue_expression_up hsa-mir-375 Gastrointestinal Neoplasms 21343377 "A high frequency recurrence and poor survival were observed in GC cases with high level of hsa-miR-375 and low level of hsa-miR-142-5p (P < 0.001),indicating that the combination of hsa-miR-375 and hsa-miR-142-5p as a predictor of disease progression has the potential to predict recurrence risk for GC patients" +tissue_expression_up hsa-mir-142 Pancreatic Neoplasms 21347785 patients with high miR-142-5p and miR-204 expression had significantly longer survival times than those with low miR-142-5p (P = 0.0077) and miR-204 (P = 0.0054) expression in the gemcitabine-treated group. +tissue_expression_up hsa-mir-204 Pancreatic Neoplasms 21347785 patients with high miR-142-5p and miR-204 expression had significantly longer survival times than those with low miR-142-5p (P = 0.0077) and miR-204 (P = 0.0054) expression in the gemcitabine-treated group. +tissue_expression_up hsa-mir-106a Mesothelioma 21358347 "miR 17-5p, 18a, 19b, 20a, 20b, 25, 92, 106a, 106b, were markedly upregulated" +tissue_expression_up hsa-mir-106b Mesothelioma 21358347 "miR 17-5p, 18a, 19b, 20a, 20b, 25, 92, 106a, 106b, were markedly upregulated" +tissue_expression_up hsa-mir-17 Mesothelioma 21358347 "miR 17-5p, 18a, 19b, 20a, 20b, 25, 92, 106a, 106b, were markedly upregulated" +tissue_expression_up hsa-mir-18a Mesothelioma 21358347 "miR 17-5p, 18a, 19b, 20a, 20b, 25, 92, 106a, 106b, were markedly upregulated" +tissue_expression_up hsa-mir-19b-1 Mesothelioma 21358347 "miR 17-5p, 18a, 19b, 20a, 20b, 25, 92, 106a, 106b, were markedly upregulated" +tissue_expression_up hsa-mir-19b-2 Mesothelioma 21358347 "miR 17-5p, 18a, 19b, 20a, 20b, 25, 92, 106a, 106b, were markedly upregulated" +tissue_expression_up hsa-mir-20a Mesothelioma 21358347 "miR 17-5p, 18a, 19b, 20a, 20b, 25, 92, 106a, 106b, were markedly upregulated" +tissue_expression_up hsa-mir-20b Mesothelioma 21358347 "miR 17-5p, 18a, 19b, 20a, 20b, 25, 92, 106a, 106b, were markedly upregulated" +tissue_expression_up hsa-mir-25 Mesothelioma 21358347 "miR 17-5p, 18a, 19b, 20a, 20b, 25, 92, 106a, 106b, were markedly upregulated" +tissue_expression_up hsa-mir-92a-1 Mesothelioma 21358347 "miR 17-5p, 18a, 19b, 20a, 20b, 25, 92, 106a, 106b, were markedly upregulated" +tissue_expression_up hsa-mir-92a-2 Mesothelioma 21358347 "miR 17-5p, 18a, 19b, 20a, 20b, 25, 92, 106a, 106b, were markedly upregulated" +tissue_expression_up hsa-mir-125b Psoriasis 21373745 "Real-time PCR and immunohistochemistry showed that p63 expression was not significantly affected, whereas NB-UVB phototherapy significantly decreased expression ofmiR-21 (p = 0.003) and increased miR-125b levels (p = 0.003). The results indicate that the unresolved p63 abnormality in treated epidermis may play a role in maintenance of this disease." +tissue_expression_up hsa-mir-125a Retinoblastoma 21373755 "We identified a cluster of miRNAs that includes miR-181b, miR-125a-3p, miR-30c-2, miR-497 and miR-491-3p as hypoxia-regulated miRNAs (HRMs) in retinoblastoma cells, of which miR-181b was the most typically differentially expressed miRNA under hypoxic conditions." +tissue_expression_up hsa-mir-181b-1 Retinoblastoma 21373755 "We identified a cluster of miRNAs that includes miR-181b, miR-125a-3p, miR-30c-2, miR-497 and miR-491-3p as hypoxia-regulated miRNAs (HRMs) in retinoblastoma cells, of which miR-181b was the most typically differentially expressed miRNA under hypoxic conditions." +tissue_expression_up hsa-mir-181b-2 Retinoblastoma 21373755 "We identified a cluster of miRNAs that includes miR-181b, miR-125a-3p, miR-30c-2, miR-497 and miR-491-3p as hypoxia-regulated miRNAs (HRMs) in retinoblastoma cells, of which miR-181b was the most typically differentially expressed miRNA under hypoxic conditions." +tissue_expression_up hsa-mir-30c-2 Retinoblastoma 21373755 "We identified a cluster of miRNAs that includes miR-181b, miR-125a-3p, miR-30c-2, miR-497 and miR-491-3p as hypoxia-regulated miRNAs (HRMs) in retinoblastoma cells, of which miR-181b was the most typically differentially expressed miRNA under hypoxic conditions." +tissue_expression_up hsa-mir-491 Retinoblastoma 21373755 "We identified a cluster of miRNAs that includes miR-181b, miR-125a-3p, miR-30c-2, miR-497 and miR-491-3p as hypoxia-regulated miRNAs (HRMs) in retinoblastoma cells, of which miR-181b was the most typically differentially expressed miRNA under hypoxic conditions." +tissue_expression_up hsa-mir-497 Retinoblastoma 21373755 "We identified a cluster of miRNAs that includes miR-181b, miR-125a-3p, miR-30c-2, miR-497 and miR-491-3p as hypoxia-regulated miRNAs (HRMs) in retinoblastoma cells, of which miR-181b was the most typically differentially expressed miRNA under hypoxic conditions." +tissue_expression_up hsa-mir-18a Nasopharyngeal Neoplasms 21373758 overexpressed +tissue_expression_up hsa-mir-210 Preeclampsia 21388517 Elevated levels of hypoxia-inducible microRNA-210 in pre-eclampsia: new insights into molecular mechanisms for the disease. +tissue_expression_up hsa-mir-16-1 "Carcinoma, Lung, Non-Small-Cell" 21400525 miR-16 levels in tumor samples may be a prognostic marker in NSCLC. +tissue_expression_up hsa-mir-16-2 "Carcinoma, Lung, Non-Small-Cell" 21400525 miR-16 levels in tumor samples may be a prognostic marker in NSCLC. +tissue_expression_up hsa-mir-155 Mycosis Fungoides 21406335 upregulated in tumor stage MF compared to benign inflammatory dermatoses. +tissue_expression_up hsa-mir-92a-1 Mycosis Fungoides 21406335 upregulated in tumor stage MF compared to benign inflammatory dermatoses. +tissue_expression_up hsa-mir-92a-2 Mycosis Fungoides 21406335 upregulated in tumor stage MF compared to benign inflammatory dermatoses. +tissue_expression_up hsa-mir-93 Mycosis Fungoides 21406335 upregulated in tumor stage MF compared to benign inflammatory dermatoses. +tissue_expression_up hsa-mir-125b-1 Breast Neoplasms 21409395 "let7c, miR-125b, miR-126, miR-127-3p, miR-143, miR-145, miR-146b-5p, and miR-199a-3p), preferentially expressed in normal basal cells" +tissue_expression_up hsa-mir-125b-2 Breast Neoplasms 21409395 "let7c, miR-125b, miR-126, miR-127-3p, miR-143, miR-145, miR-146b-5p, and miR-199a-3p), preferentially expressed in normal basal cells" +tissue_expression_up hsa-mir-126 Breast Neoplasms 21409395 "let7c, miR-125b, miR-126, miR-127-3p, miR-143, miR-145, miR-146b-5p, and miR-199a-3p), preferentially expressed in normal basal cells" +tissue_expression_up hsa-mir-127 Breast Neoplasms 21409395 "let7c, miR-125b, miR-126, miR-127-3p, miR-143, miR-145, miR-146b-5p, and miR-199a-3p), preferentially expressed in normal basal cells" +tissue_expression_up hsa-mir-143 Breast Neoplasms 21409395 "let7c, miR-125b, miR-126, miR-127-3p, miR-143, miR-145, miR-146b-5p, and miR-199a-3p), preferentially expressed in normal basal cells" +tissue_expression_up hsa-mir-145 Breast Neoplasms 21409395 "let7c, miR-125b, miR-126, miR-127-3p, miR-143, miR-145, miR-146b-5p, and miR-199a-3p), preferentially expressed in normal basal cells" +tissue_expression_up hsa-mir-146b Breast Neoplasms 21409395 "let7c, miR-125b, miR-126, miR-127-3p, miR-143, miR-145, miR-146b-5p, and miR-199a-3p), preferentially expressed in normal basal cells" +tissue_expression_up hsa-mir-199a-1 Breast Neoplasms 21409395 "let7c, miR-125b, miR-126, miR-127-3p, miR-143, miR-145, miR-146b-5p, and miR-199a-3p), preferentially expressed in normal basal cells" +tissue_expression_up hsa-mir-199a-2 Breast Neoplasms 21409395 "let7c, miR-125b, miR-126, miR-127-3p, miR-143, miR-145, miR-146b-5p, and miR-199a-3p), preferentially expressed in normal basal cells" +tissue_expression_up hsa-mir-200c Breast Neoplasms 21409395 "Both miR-200c and miR-429, two members of the miR-200 family were expressed in the luminal and basal type of breast cancer in contrast to malignant myoepithelioma." +tissue_expression_up hsa-mir-429 Breast Neoplasms 21409395 "Both miR-200c and miR-429, two members of the miR-200 family were expressed in the luminal and basal type of breast cancer in contrast to malignant myoepithelioma." +tissue_expression_up hsa-mir-155 Colorectal Carcinoma 21412018 High miR-155 expression was significantly correlated with lymph node metastases. The overall (OS) and disease-free survival (DFS) rates of patients with high miR-155 expression were also significantly worse than those in patients with low miR-155 expression. +tissue_expression_up hsa-mir-21 Colorectal Carcinoma 21412018 "High miR-21 expression was significantly associated with venous invasion, liver metastasis and tumor stage.The overall (OS) and disease-free survival (DFS) rates of patients with high miR-21 expression were significantly worse than those of patients with low miR-21 expression." +tissue_expression_up hsa-mir-21 Obesity 21426570 mir-21 is up-regulated in subcutaneous adipose tissue in human obesity +tissue_expression_up hsa-mir-100 Endometriosis 21436257 up-regulated in endometriomas compared with endometrium. +tissue_expression_up hsa-mir-193a Endometriosis 21436257 miR-193a-3p and miR-193a-5p up-regulated in endometriomas compared with endometrium. +tissue_expression_up hsa-mir-202 Endometriosis 21436257 up-regulated in endometriomas compared with endometrium. +tissue_expression_up hsa-mir-29c Endometriosis 21436257 up-regulated in endometriomas compared with endometrium. +tissue_expression_up hsa-mir-485 Endometriosis 21436257 miR-485-3p up-regulated in endometriomas compared with endometrium. +tissue_expression_up hsa-mir-509-3 Endometriosis 21436257 miR-509-3-5p up-regulated in endometriomas compared with endometrium. +tissue_expression_up hsa-mir-574 Endometriosis 21436257 miR-574-3p up-regulated in endometriomas compared with endometrium. +tissue_expression_up hsa-mir-708 Endometriosis 21436257 up-regulated in endometriomas compared with endometrium. +tissue_expression_up hsa-mir-720 Endometriosis 21436257 up-regulated in endometriomas compared with endometrium. +tissue_expression_up hsa-mir-143 "Diabetes Mellitus, Type 2" 21441927 Obesity-induced overexpression of miRNA-143 inhibits insulin-stimulated AKT activation and impairs glucose metabolism. +tissue_expression_up hsa-mir-143 Esophageal Neoplasms 21453382 The high levels of expression of mature MIR143 and mature MIR145 were associated with recurrence of metastasis in ESCC patients.The high expression of mature MIR21 and mature MIR205 was associated with lymph node positivity in ESCC patients (P < 0.05). +tissue_expression_up hsa-mir-145 Esophageal Neoplasms 21453382 The high levels of expression of mature MIR143 and mature MIR145 were associated with recurrence of metastasis in ESCC patients.The high expression of mature MIR21 and mature MIR205 was associated with lymph node positivity in ESCC patients (P < 0.05). +tissue_expression_up hsa-mir-205 Esophageal Neoplasms 21453382 The high levels of expression of mature MIR143 and mature MIR145 were associated with recurrence of metastasis in ESCC patients.The high expression of mature MIR21 and mature MIR205 was associated with lymph node positivity in ESCC patients (P < 0.05). +tissue_expression_up hsa-mir-21 Esophageal Neoplasms 21453382 The high levels of expression of mature MIR143 and mature MIR145 were associated with recurrence of metastasis in ESCC patients.The high expression of mature MIR21 and mature MIR205 was associated with lymph node positivity in ESCC patients (P < 0.05). +tissue_expression_up hsa-mir-223 Esophageal Neoplasms 21453483 miR-223 regulates migration and invasion by targeting Artemin in human esophageal carcinoma. +tissue_expression_up hsa-mir-155 Multiple Sclerosis 21453702 Several miRNAs such as miR-155 or miR-326 are considerably overexpressed in active MS lesions versus controls +tissue_expression_up hsa-mir-326 Multiple Sclerosis 21453702 Several miRNAs such as miR-155 or miR-326 are considerably overexpressed in active MS lesions versus controls +tissue_expression_up hsa-mir-210 Sarcoma [unspecific] 21455991 Expression of microRNA 210 associates with poor survival and age of tumor onset of soft-tissue sarcoma patients. +tissue_expression_up hsa-mir-221 "Carcinoma, Hepatocellular" 21458843 Deregulated expression of microRNA-221 with the potential for prognostic biomarkers in surgically resected hepatocellular carcinoma. +tissue_expression_up hsa-mir-21 Pancreatic Neoplasms 21463919 "over-expression of Notch-1 leads to increased expression of miR-21, and decreased expression of miR-200b, miR-200c, let-7a, let-7b, and let-7c. over-expression of Notch-1 led to the induction of EMT phenotype" +tissue_expression_up hsa-mir-141 Urinary Bladder Cancer 21464941 "Compared to matched histologically normal urothelium, upregulated." +tissue_expression_up hsa-mir-17 Urinary Bladder Cancer 21464941 "Compared to matched histologically normal urothelium, upregulated." +tissue_expression_up hsa-mir-183 Urinary Bladder Cancer 21464941 "Compared to matched histologically normal urothelium, upregulated." +tissue_expression_up hsa-mir-18a Urinary Bladder Cancer 21464941 "Compared to matched histologically normal urothelium, upregulated." +tissue_expression_up hsa-mir-19a Urinary Bladder Cancer 21464941 "Compared to matched histologically normal urothelium, upregulated." +tissue_expression_up hsa-mir-19b-1 Urinary Bladder Cancer 21464941 "Compared to matched histologically normal urothelium, upregulated." +tissue_expression_up hsa-mir-19b-2 Urinary Bladder Cancer 21464941 "Compared to matched histologically normal urothelium, upregulated." +tissue_expression_up hsa-mir-200a Urinary Bladder Cancer 21464941 "Compared to matched histologically normal urothelium, upregulated." +tissue_expression_up hsa-mir-200b Urinary Bladder Cancer 21464941 "Compared to matched histologically normal urothelium, upregulated." +tissue_expression_up hsa-mir-200c Urinary Bladder Cancer 21464941 "Compared to matched histologically normal urothelium, upregulated." +tissue_expression_up hsa-mir-20a Urinary Bladder Cancer 21464941 "Compared to matched histologically normal urothelium, upregulated." +tissue_expression_up hsa-mir-429 Urinary Bladder Cancer 21464941 "Compared to matched histologically normal urothelium, upregulated." +tissue_expression_up hsa-mir-92a-1 Urinary Bladder Cancer 21464941 "Compared to matched histologically normal urothelium, upregulated." +tissue_expression_up hsa-mir-92a-2 Urinary Bladder Cancer 21464941 "Compared to matched histologically normal urothelium, upregulated." +tissue_expression_up hsa-mir-96 Urinary Bladder Cancer 21464941 "Compared to matched histologically normal urothelium, upregulated." +tissue_expression_up hsa-mir-210 "Carcinoma, Renal Cell" 21465485 "Overexpression of miR-210, a downstream target of HIF1, causes centrosome amplification in renal carcinoma cells." +tissue_expression_up hsa-mir-146a Sjogren Syndrome 21469088 Altered miR-146a expression in Sjogren's syndrome +tissue_expression_up hsa-mir-139 "Carcinoma, Adrenocortical" 21471143 "ACCs (adrenocortical carcinomas) exhibited significantly lower levels of miR-139-3p (up to 8.49-fold, p<0.001), miR-675 (up to 23.25-fold, p<0.001) and miR-335 (up to 5.25-fold, p<0.001)." +tissue_expression_up hsa-mir-375 "Carcinoma, Adrenocortical" 21471143 "ACCs (adrenocortical carcinomas) exhibited significantly lower levels of miR-139-3p (up to 8.49-fold, p<0.001), miR-675 (up to 23.25-fold, p<0.001) and miR-335 (up to 5.25-fold, p<0.001)." +tissue_expression_up hsa-mir-675 "Carcinoma, Adrenocortical" 21471143 "ACCs (adrenocortical carcinomas) exhibited significantly lower levels of miR-139-3p (up to 8.49-fold, p<0.001), miR-675 (up to 23.25-fold, p<0.001) and miR-335 (up to 5.25-fold, p<0.001)." +tissue_expression_up hsa-mir-483 "Carcinoma, Adrenocortical" 21472710 "miRs -100, -125b, and -195 were significantly down-regulated, whereas miR-483-5p was significantly up-regulated in malignant as compared with benign tumors." +tissue_expression_up hsa-mir-106a Glioblastoma 21483847 "miR-106aa upregulated in Glioblastoma vs Normal. Ten miRNAs (miR-20a, miR-106a, miR-17-5p, miR-31, miR-222, miR-148a, miR-221, miR-146b, miR-200b, and miR-193a) could be a signature predicding survival in Glioblastoma." +tissue_expression_up hsa-mir-146b Glioblastoma 21483847 "miR-146b upregulated in Glioblastoma vs Normal. Ten miRNAs (miR-20a, miR-106a, miR-17-5p, miR-31, miR-222, miR-148a, miR-221, miR-146b, miR-200b, and miR-193a) could be a signature predicding survival in Glioblastoma." +tissue_expression_up hsa-mir-148a Glioblastoma 21483847 "miR-148a upregulated in Glioblastoma vs Normal. Ten miRNAs (miR-20a, miR-106a, miR-17-5p, miR-31, miR-222, miR-148a, miR-221, miR-146b, miR-200b, and miR-193a) could be a signature predicding survival in Glioblastoma." +tissue_expression_up hsa-mir-17 Glioblastoma 21483847 "miR-17-5p upregulated in Glioblastoma vs Normal. Ten miRNAs (miR-20a, miR-106a, miR-17-5p, miR-31, miR-222, miR-148a, miR-221, miR-146b, miR-200b, and miR-193a) could be a signature predicding survival in Glioblastoma." +tissue_expression_up hsa-mir-193a Glioblastoma 21483847 "miR-193a upregulated in Glioblastoma vs Normal. Ten miRNAs (miR-20a, miR-106a, miR-17-5p, miR-31, miR-222, miR-148a, miR-221, miR-146b, miR-200b, and miR-193a) could be a signature predicding survival in Glioblastoma." +tissue_expression_up hsa-mir-200b Glioblastoma 21483847 "miR-200b upregulated in Glioblastoma vs Normal. Ten miRNAs (miR-20a, miR-106a, miR-17-5p, miR-31, miR-222, miR-148a, miR-221, miR-146b, miR-200b, and miR-193a) could be a signature predicding survival in Glioblastoma." +tissue_expression_up hsa-mir-106a Melanoma 21509659 significantly up-regulated in uveal melanomas compared with normal uveal tissues +tissue_expression_up hsa-mir-17 Melanoma 21509659 significantly up-regulated in uveal melanomas compared with normal uveal tissues +tissue_expression_up hsa-mir-20a Melanoma 21509659 significantly up-regulated in uveal melanomas compared with normal uveal tissues +tissue_expression_up hsa-mir-21 Melanoma 21509659 significantly up-regulated in uveal melanomas compared with normal uveal tissues +tissue_expression_up hsa-mir-34a Melanoma 21509659 significantly up-regulated in uveal melanomas compared with normal uveal tissues +tissue_expression_up hsa-mir-21 Sezary Disease 21525938 "MicroRNA profiling reveals that miR-21, miR-486 and miR-214 are upregulated and involved in cell survival in Sezary Syndrome." +tissue_expression_up hsa-mir-214 Sezary Disease 21525938 "MicroRNA profiling reveals that miR-21, miR-486 and miR-214 are upregulated and involved in cell survival in Sezary Syndrome." +tissue_expression_up hsa-mir-486 Sezary Disease 21525938 "MicroRNA profiling reveals that miR-21, miR-486 and miR-214 are upregulated and involved in cell survival in Sezary Syndrome." +tissue_expression_up hsa-mir-146b Thyroid Neoplasms 21537871 "miR-146b, miR-221, miR-222, miR-155, miR-31 upregulation and miR-1, miR-34b, miR-130b, miR-138 downregulation in aggressive compared with nonaggressive PTC." +tissue_expression_up hsa-mir-155 Thyroid Neoplasms 21537871 "miR-146b, miR-221, miR-222, miR-155, miR-31 upregulation and miR-1, miR-34b, miR-130b, miR-138 downregulation in aggressive compared with nonaggressive PTC." +tissue_expression_up hsa-mir-221 Thyroid Neoplasms 21537871 "miR-146b, miR-221, miR-222, miR-155, miR-31 upregulation and miR-1, miR-34b, miR-130b, miR-138 downregulation in aggressive compared with nonaggressive PTC." +tissue_expression_up hsa-mir-222 Thyroid Neoplasms 21537871 "miR-146b, miR-221, miR-222, miR-155, miR-31 upregulation and miR-1, miR-34b, miR-130b, miR-138 downregulation in aggressive compared with nonaggressive PTC." +tissue_expression_up hsa-mir-31 Thyroid Neoplasms 21537871 "miR-146b, miR-221, miR-222, miR-155, miR-31 upregulation and miR-1, miR-34b, miR-130b, miR-138 downregulation in aggressive compared with nonaggressive PTC." +tissue_expression_up hsa-mir-20a Colorectal Carcinoma 21551242 "MiR-20a and miR-31 were found to be significantly upregulated in more than one study, and miR-143 and miR-145 were found to be significantly downregulated in CRC tissue in six or more studies." +tissue_expression_up hsa-mir-31 Colorectal Carcinoma 21551242 "MiR-20a and miR-31 were found to be significantly upregulated in more than one study, and miR-143 and miR-145 were found to be significantly downregulated in CRC tissue in six or more studies." +tissue_expression_up hsa-mir-126 Thyroid Neoplasms 21553140 miR-7 and miR-126 could be candidate diagnostic microRNAs for thyroid histologic subtypes. +tissue_expression_up hsa-mir-7-1 Thyroid Neoplasms 21553140 miR-7 and miR-126 could be candidate diagnostic microRNAs for thyroid histologic subtypes. +tissue_expression_up hsa-mir-7-2 Thyroid Neoplasms 21553140 miR-7 and miR-126 could be candidate diagnostic microRNAs for thyroid histologic subtypes. +tissue_expression_up hsa-mir-7-3 Thyroid Neoplasms 21553140 miR-7 and miR-126 could be candidate diagnostic microRNAs for thyroid histologic subtypes. +tissue_expression_up hsa-mir-101-1 Head And Neck Neoplasms 21560177 "Docetaxel resistant cells showed significant downregulation of miR-100, miR-130a, and miR-197 and upregulation in miR-101, miR-181b, miR-181d, and miR-195 expression when compared with their parent cells (p < .01)." +tissue_expression_up hsa-mir-101-1 "Squamous Cell Carcinoma, Head and Neck" 21560177 "Docetaxel resistant cells showed significant downregulation of miR-100, miR-130a, and miR-197 and upregulation in miR-101, miR-181b, miR-181d, and miR-195 expression when compared with their parent cells (p < .01)." +tissue_expression_up hsa-mir-101-2 Head And Neck Neoplasms 21560177 "Docetaxel resistant cells showed significant downregulation of miR-100, miR-130a, and miR-197 and upregulation in miR-101, miR-181b, miR-181d, and miR-195 expression when compared with their parent cells (p < .01)." +tissue_expression_up hsa-mir-101-2 "Squamous Cell Carcinoma, Head and Neck" 21560177 "Docetaxel resistant cells showed significant downregulation of miR-100, miR-130a, and miR-197 and upregulation in miR-101, miR-181b, miR-181d, and miR-195 expression when compared with their parent cells (p < .01)." +tissue_expression_up hsa-mir-181b-1 Head And Neck Neoplasms 21560177 "Docetaxel resistant cells showed significant downregulation of miR-100, miR-130a, and miR-197 and upregulation in miR-101, miR-181b, miR-181d, and miR-195 expression when compared with their parent cells (p < .01)." +tissue_expression_up hsa-mir-181b-1 "Squamous Cell Carcinoma, Head and Neck" 21560177 "Docetaxel resistant cells showed significant downregulation of miR-100, miR-130a, and miR-197 and upregulation in miR-101, miR-181b, miR-181d, and miR-195 expression when compared with their parent cells (p < .01)." +tissue_expression_up hsa-mir-181b-2 Head And Neck Neoplasms 21560177 "Docetaxel resistant cells showed significant downregulation of miR-100, miR-130a, and miR-197 and upregulation in miR-101, miR-181b, miR-181d, and miR-195 expression when compared with their parent cells (p < .01)." +tissue_expression_up hsa-mir-181b-2 "Squamous Cell Carcinoma, Head and Neck" 21560177 "Docetaxel resistant cells showed significant downregulation of miR-100, miR-130a, and miR-197 and upregulation in miR-101, miR-181b, miR-181d, and miR-195 expression when compared with their parent cells (p < .01)." +tissue_expression_up hsa-mir-181d Head And Neck Neoplasms 21560177 "Docetaxel resistant cells showed significant downregulation of miR-100, miR-130a, and miR-197 and upregulation in miR-101, miR-181b, miR-181d, and miR-195 expression when compared with their parent cells (p < .01)." +tissue_expression_up hsa-mir-181d "Squamous Cell Carcinoma, Head and Neck" 21560177 "Docetaxel resistant cells showed significant downregulation of miR-100, miR-130a, and miR-197 and upregulation in miR-101, miR-181b, miR-181d, and miR-195 expression when compared with their parent cells (p < .01)." +tissue_expression_up hsa-mir-195 Head And Neck Neoplasms 21560177 "Docetaxel resistant cells showed significant downregulation of miR-100, miR-130a, and miR-197 and upregulation in miR-101, miR-181b, miR-181d, and miR-195 expression when compared with their parent cells (p < .01)." +tissue_expression_up hsa-mir-195 "Squamous Cell Carcinoma, Head and Neck" 21560177 "Docetaxel resistant cells showed significant downregulation of miR-100, miR-130a, and miR-197 and upregulation in miR-101, miR-181b, miR-181d, and miR-195 expression when compared with their parent cells (p < .01)." +tissue_expression_up hsa-mir-9-1 Colorectal Carcinoma 21562850 MicroRNA-9 up-regulation is involved in colorectal cancer metastasis via promoting cell motility. +tissue_expression_up hsa-mir-9-2 Colorectal Carcinoma 21562850 MicroRNA-9 up-regulation is involved in colorectal cancer metastasis via promoting cell motility. +tissue_expression_up hsa-mir-9-3 Colorectal Carcinoma 21562850 MicroRNA-9 up-regulation is involved in colorectal cancer metastasis via promoting cell motility. +tissue_expression_up hsa-let-7d Lung Neoplasms 21563230 "Specifically, thirteen novel asbestos-related miRNAs (over-expressed: miR-148b, miR-374a, miR-24-1*, Let-7d, Let-7e, miR-199b-5p, miR-331-3p, and miR-96 and under-expressed: miR-939, miR-671-5p, miR-605, miR-1224-5p and miR-202) and inversely correlated target genes (e.g., GADD45A, LTBP1, FOSB, NCALD, CACNA2D2, MTSS1, EPB41L3) were identified. " +tissue_expression_up hsa-let-7e Lung Neoplasms 21563230 "Specifically, thirteen novel asbestos-related miRNAs (over-expressed: miR-148b, miR-374a, miR-24-1*, Let-7d, Let-7e, miR-199b-5p, miR-331-3p, and miR-96 and under-expressed: miR-939, miR-671-5p, miR-605, miR-1224-5p and miR-202) and inversely correlated target genes (e.g., GADD45A, LTBP1, FOSB, NCALD, CACNA2D2, MTSS1, EPB41L3) were identified. " +tissue_expression_up hsa-mir-148b Lung Neoplasms 21563230 "Specifically, thirteen novel asbestos-related miRNAs (over-expressed: miR-148b, miR-374a, miR-24-1*, Let-7d, Let-7e, miR-199b-5p, miR-331-3p, and miR-96 and under-expressed: miR-939, miR-671-5p, miR-605, miR-1224-5p and miR-202) and inversely correlated target genes (e.g., GADD45A, LTBP1, FOSB, NCALD, CACNA2D2, MTSS1, EPB41L3) were identified. " +tissue_expression_up hsa-mir-199b Lung Neoplasms 21563230 "Specifically, thirteen novel asbestos-related miRNAs (over-expressed: miR-148b, miR-374a, miR-24-1*, Let-7d, Let-7e, miR-199b-5p, miR-331-3p, and miR-96 and under-expressed: miR-939, miR-671-5p, miR-605, miR-1224-5p and miR-202) and inversely correlated target genes (e.g., GADD45A, LTBP1, FOSB, NCALD, CACNA2D2, MTSS1, EPB41L3) were identified. " +tissue_expression_up hsa-mir-24-1 Lung Neoplasms 21563230 "Specifically, thirteen novel asbestos-related miRNAs (over-expressed: miR-148b, miR-374a, miR-24-1*, Let-7d, Let-7e, miR-199b-5p, miR-331-3p, and miR-96 and under-expressed: miR-939, miR-671-5p, miR-605, miR-1224-5p and miR-202) and inversely correlated target genes (e.g., GADD45A, LTBP1, FOSB, NCALD, CACNA2D2, MTSS1, EPB41L3) were identified. " +tissue_expression_up hsa-mir-331 Lung Neoplasms 21563230 "Specifically, thirteen novel asbestos-related miRNAs (over-expressed: miR-148b, miR-374a, miR-24-1*, Let-7d, Let-7e, miR-199b-5p, miR-331-3p, and miR-96 and under-expressed: miR-939, miR-671-5p, miR-605, miR-1224-5p and miR-202) and inversely correlated target genes (e.g., GADD45A, LTBP1, FOSB, NCALD, CACNA2D2, MTSS1, EPB41L3) were identified. " +tissue_expression_up hsa-mir-374a Lung Neoplasms 21563230 "Specifically, thirteen novel asbestos-related miRNAs (over-expressed: miR-148b, miR-374a, miR-24-1*, Let-7d, Let-7e, miR-199b-5p, miR-331-3p, and miR-96 and under-expressed: miR-939, miR-671-5p, miR-605, miR-1224-5p and miR-202) and inversely correlated target genes (e.g., GADD45A, LTBP1, FOSB, NCALD, CACNA2D2, MTSS1, EPB41L3) were identified. " +tissue_expression_up hsa-mir-96 Lung Neoplasms 21563230 "Specifically, thirteen novel asbestos-related miRNAs (over-expressed: miR-148b, miR-374a, miR-24-1*, Let-7d, Let-7e, miR-199b-5p, miR-331-3p, and miR-96 and under-expressed: miR-939, miR-671-5p, miR-605, miR-1224-5p and miR-202) and inversely correlated target genes (e.g., GADD45A, LTBP1, FOSB, NCALD, CACNA2D2, MTSS1, EPB41L3) were identified. " +tissue_expression_up hsa-mir-34a Colorectal Carcinoma 21566225 The gene encoding the miR-34a microRNA is a transcriptional target of the p53 tumor suppressor protein and subject to epigenetic inactivation in colorectal cancer and numerous other tumor types +tissue_expression_up hsa-mir-185 Colorectal Carcinoma 21573504 "High expression of miR-185 and low expression of miR-133b were correlated with poor survival (p=0.001 and 0.028, respectively) and metastasis (p=0.007 and 0.036, respectively) in colorectal cancer." +tissue_expression_up hsa-mir-31 "Squamous Cell Carcinoma, Cerevial" 21590768 "miR-31 up-regulation in Drosha-overexpressing samples/cell lines was the highest-ranked change (by adjusted p value) in both analyses, an observation validated by northern blotting." +tissue_expression_up hsa-mir-1207 Prostate Neoplasms 21592394 "Among these miR-22, miR-29ab, miR-134, miR-1207-5p and miR-371-5p are up regulated, while miR-17 and miR-20a, members of the miR-17/92 cluster are down regulated." +tissue_expression_up hsa-mir-134 Prostate Neoplasms 21592394 "Among these miR-22, miR-29ab, miR-134, miR-1207-5p and miR-371-5p are up regulated, while miR-17 and miR-20a, members of the miR-17/92 cluster are down regulated." +tissue_expression_up hsa-mir-22 Prostate Neoplasms 21592394 "Among these miR-22, miR-29ab, miR-134, miR-1207-5p and miR-371-5p are up regulated, while miR-17 and miR-20a, members of the miR-17/92 cluster are down regulated." +tissue_expression_up hsa-mir-29a Prostate Neoplasms 21592394 "Among these miR-22, miR-29ab, miR-134, miR-1207-5p and miR-371-5p are up regulated, while miR-17 and miR-20a, members of the miR-17/92 cluster are down regulated." +tissue_expression_up hsa-mir-29b Prostate Neoplasms 21592394 "Among these miR-22, miR-29ab, miR-134, miR-1207-5p and miR-371-5p are up regulated, while miR-17 and miR-20a, members of the miR-17/92 cluster are down regulated." +tissue_expression_up hsa-mir-371 Prostate Neoplasms 21592394 "Among these miR-22, miR-29ab, miR-134, miR-1207-5p and miR-371-5p are up regulated, while miR-17 and miR-20a, members of the miR-17/92 cluster are down regulated." +tissue_expression_up hsa-mir-126 Prostate Neoplasms 21594291 "In addition, anti-invasive microRNAs such as miR-335, miR-205, miR-200, and miR-126, were up-regulated, whereas pro-invasive microRNA such as miR-21 and miR-373, were down-regulated." +tissue_expression_up hsa-mir-200 Prostate Neoplasms 21594291 "In addition, anti-invasive microRNAs such as miR-335, miR-205, miR-200, and miR-126, were up-regulated, whereas pro-invasive microRNA such as miR-21 and miR-373, were down-regulated." +tissue_expression_up hsa-mir-205 Prostate Neoplasms 21594291 "In addition, anti-invasive microRNAs such as miR-335, miR-205, miR-200, and miR-126, were up-regulated, whereas pro-invasive microRNA such as miR-21 and miR-373, were down-regulated." +tissue_expression_up hsa-mir-335 Prostate Neoplasms 21594291 "In addition, anti-invasive microRNAs such as miR-335, miR-205, miR-200, and miR-126, were up-regulated, whereas pro-invasive microRNA such as miR-21 and miR-373, were down-regulated." +tissue_expression_up hsa-mir-126 Asthma 21605405 upregulated compared with normal control +tissue_expression_up hsa-let-7b "Carcinoma, Lung, Non-Small-Cell" 21622546 "Eighteen cases were classified as AD and 13 as SCC by light microscopy and immunocytochemistry. miRNA expression profiles demonstrated considerable, statistically significant differences between AD and SCC, showing an upregulation of hsa-let-7a, hsa-let-7b, hsa-let-7c,hsa-let-7f, hsa-let-7g, hsa-let-7i, and hsa-miR-98 and a downregulation of hsa-miR-205 in AD specimens" +tissue_expression_up hsa-let-7c "Carcinoma, Lung, Non-Small-Cell" 21622546 "Eighteen cases were classified as AD and 13 as SCC by light microscopy and immunocytochemistry. miRNA expression profiles demonstrated considerable, statistically significant differences between AD and SCC, showing an upregulation of hsa-let-7a, hsa-let-7b, hsa-let-7c,hsa-let-7f, hsa-let-7g, hsa-let-7i, and hsa-miR-98 and a downregulation of hsa-miR-205 in AD specimens" +tissue_expression_up hsa-let-7f "Carcinoma, Lung, Non-Small-Cell" 21622546 "Eighteen cases were classified as AD and 13 as SCC by light microscopy and immunocytochemistry. miRNA expression profiles demonstrated considerable, statistically significant differences between AD and SCC, showing an upregulation of hsa-let-7a, hsa-let-7b, hsa-let-7c,hsa-let-7f, hsa-let-7g, hsa-let-7i, and hsa-miR-98 and a downregulation of hsa-miR-205 in AD specimens" +tissue_expression_up hsa-let-7g "Carcinoma, Lung, Non-Small-Cell" 21622546 "Eighteen cases were classified as AD and 13 as SCC by light microscopy and immunocytochemistry. miRNA expression profiles demonstrated considerable, statistically significant differences between AD and SCC, showing an upregulation of hsa-let-7a, hsa-let-7b, hsa-let-7c,hsa-let-7f, hsa-let-7g, hsa-let-7i, and hsa-miR-98 and a downregulation of hsa-miR-205 in AD specimens" +tissue_expression_up hsa-let-7i "Carcinoma, Lung, Non-Small-Cell" 21622546 "Eighteen cases were classified as AD and 13 as SCC by light microscopy and immunocytochemistry. miRNA expression profiles demonstrated considerable, statistically significant differences between AD and SCC, showing an upregulation of hsa-let-7a, hsa-let-7b, hsa-let-7c,hsa-let-7f, hsa-let-7g, hsa-let-7i, and hsa-miR-98 and a downregulation of hsa-miR-205 in AD specimens" +tissue_expression_up hsa-mir-98 "Carcinoma, Lung, Non-Small-Cell" 21622546 "Eighteen cases were classified as AD and 13 as SCC by light microscopy and immunocytochemistry. miRNA expression profiles demonstrated considerable, statistically significant differences between AD and SCC, showing an upregulation of hsa-let-7a, hsa-let-7b, hsa-let-7c,hsa-let-7f, hsa-let-7g, hsa-let-7i, and hsa-miR-98 and a downregulation of hsa-miR-205 in AD specimens" +tissue_expression_up hsa-mir-1271 Head And Neck Neoplasms 21637912 hsa-mir-1271 was upregulated compared with normal tissue. +tissue_expression_up hsa-mir-181a-2 Head And Neck Neoplasms 21637912 hsa-mir-181a-2* was upregulated compared with normal tissue. +tissue_expression_up hsa-mir-181b-1 Head And Neck Neoplasms 21637912 hsa-mir-181b was upregulated compared with normal tissue. +tissue_expression_up hsa-mir-181b-2 Head And Neck Neoplasms 21637912 hsa-mir-181b was upregulated compared with normal tissue. +tissue_expression_up hsa-mir-221 Head And Neck Neoplasms 21637912 hsa-mir-221* was upregulated compared with normal tissue. +tissue_expression_up hsa-mir-744 Head And Neck Neoplasms 21637912 hsa-mir-744 was upregulated compared with normal tissue. +tissue_expression_up hsa-mir-133b Lung Neoplasms 21648427 Mice treated with pre-miR-133b containing lipoplexes had mature miR-133b expression in lung ~52-fold higher than untreated mice. +tissue_expression_up hsa-mir-31 "Squamous Cell Carcinoma, Esophageal" 21658006 miR-31 was up-regulated in 77.8% of the ESCC tissues. Serum miR-31 levels in ESCC patients were significantly higher than in normal controls (P<0.001). +tissue_expression_up hsa-mir-106a "Carcinoma, Rectal" 21671476 "One of the most up-regulated miRNAs, miRNA-106a, was consistently reported to be differentially expressed in six studies and the five most down-regulated miRNAs, miR-30a-3p, miR-139, miR-145, miR-125a and miR-133a, were consistently reported to be differentially expressed in four studies." +tissue_expression_up hsa-mir-155 Rheumatoid Arthritis 21690378 "miR-155 is up-regulated in synovial membrane and synovial fluid (SF) macrophages from patients with rheumatoid arthritis (RA). The increased expression of miR-155 in SF CD14(+) cells was associated with lower expression of the miR-155 target, Src homology 2-containing inositol phosphatase-1 (SHIP-1), an inhibitor of inflammation." +tissue_expression_up hsa-let-7e Heart Failure 21690488 "The absolute expression levels of hcmv-miR-UL112, miR-296-5p, and let-7e were further determined in 127 patients and 67 control subjects (fold changes are 2.5, 0.5, and 1.7 respectively; all P<0.0001)." +tissue_expression_up hsa-mir-122 Hepatitis B Virus Infection 21692939 Expression of the liver-specific miR-122 was significantly up-regulated in HBV-infected patients. +tissue_expression_up hsa-mir-122 Liver Failure 21692939 The expression levels of miR-122 and miR-194 correlated negatively with the age of patients with CHB (chronic hepatitis B) or ACLF (acute-on-chronic liver failure). +tissue_expression_up hsa-mir-194-1 Liver Failure 21692939 The expression levels of miR-122 and miR-194 correlated negatively with the age of patients with CHB (chronic hepatitis B) or ACLF (acute-on-chronic liver failure). +tissue_expression_up hsa-mir-194-2 Liver Failure 21692939 The expression levels of miR-122 and miR-194 correlated negatively with the age of patients with CHB (chronic hepatitis B) or ACLF (acute-on-chronic liver failure). +tissue_expression_up hsa-mir-148a Gastric Neoplasms 21703006 "miR-148a could reduce the invasiveness, migratory and adhesive activities of gastric tumor cells. Most importantly, elevated miR-148a level in gastric cancer tissues was strongly correlated with distant metastasis, organ and peritoneal invasion and reduced survival rate." +tissue_expression_up hsa-mir-31 Kaposi Sarcoma 21715310 "In the present study, we show that Kaposi sarcoma-associated herpesvirus (KSHV), the etiological agent of KS, induces global miRNA changes in lymphatic endothelial cells (LECs). Specifically, the miR-221/miR-222 cluster is down-regulated, whereas miR-31 is up-regulated." +tissue_expression_up hsa-mir-17 Gastrointestinal Neoplasms 21743960 Our study suggests that the presence of BM-DTCs and the upregulation of the miR-17-92 cluster in tumors are both significant but independent prognostic markers in gastrointestinal cancer patients. +tissue_expression_up hsa-mir-18 Gastrointestinal Neoplasms 21743960 Our study suggests that the presence of BM-DTCs and the upregulation of the miR-17-92 cluster in tumors are both significant but independent prognostic markers in gastrointestinal cancer patients. +tissue_expression_up hsa-mir-19a Gastrointestinal Neoplasms 21743960 Our study suggests that the presence of BM-DTCs and the upregulation of the miR-17-92 cluster in tumors are both significant but independent prognostic markers in gastrointestinal cancer patients. +tissue_expression_up hsa-mir-19b-1 Gastrointestinal Neoplasms 21743960 Our study suggests that the presence of BM-DTCs and the upregulation of the miR-17-92 cluster in tumors are both significant but independent prognostic markers in gastrointestinal cancer patients. +tissue_expression_up hsa-mir-20a Gastrointestinal Neoplasms 21743960 Our study suggests that the presence of BM-DTCs and the upregulation of the miR-17-92 cluster in tumors are both significant but independent prognostic markers in gastrointestinal cancer patients. +tissue_expression_up hsa-mir-92-1 Gastrointestinal Neoplasms 21743960 Our study suggests that the presence of BM-DTCs and the upregulation of the miR-17-92 cluster in tumors are both significant but independent prognostic markers in gastrointestinal cancer patients. +tissue_expression_up hsa-mir-215 Colorectal Carcinoma 21752725 miR-215 has a unique potential as a prognostic biomarker in stage II and III colon cancer. +tissue_expression_up hsa-mir-21 "Adenocarcinoma, Pancreatic Ductal" 21757972 Elevated microRNA miR-21 Levels in Pancreatic Cyst Fluid Are Predictive of Mucinous Precursor Lesions of Ductal Adenocarcinoma. +tissue_expression_up hsa-mir-155 "Carcinoma, Hepatocellular" 21762537 ectopic expression of miR-155 upregulated the expression of several IFN-inducible antivirus genes in human hepatoma cells. +tissue_expression_up hsa-mir-106a Melanoma 21763111 "Early steps in skin tumor formation in HPV8-CER mice were associated with an upregulation of the oncogenic miRNA-17-5p, -21 and -106a and a downregulation of the tumor-suppressive miRNA-155 and -206, which could be demonstrated by qPCR and in situ hybridization." +tissue_expression_up hsa-mir-17 Melanoma 21763111 "Early steps in skin tumor formation in HPV8-CER mice were associated with an upregulation of the oncogenic miRNA-17-5p, -21 and -106a and a downregulation of the tumor-suppressive miRNA-155 and -206, which could be demonstrated by qPCR and in situ hybridization." +tissue_expression_up hsa-mir-21 Melanoma 21763111 "Early steps in skin tumor formation in HPV8-CER mice were associated with an upregulation of the oncogenic miRNA-17-5p, -21 and -106a and a downregulation of the tumor-suppressive miRNA-155 and -206, which could be demonstrated by qPCR and in situ hybridization." +tissue_expression_up hsa-mir-21 Renal Fibrosis 21775484 miR-21 expression was upregulated in response to treatment with TGF-beta1 or TNF-alpha in human renal tubular epithelial cells in vitro. +tissue_expression_up hsa-mir-181b "Carcinoma, Breast" 21779448 "we focused on miR-181b, which was overexpressed in several malignant neoplasias including breast carcinomas. " +tissue_expression_up hsa-mir-122 Thyroid Neoplasms 21779480 The miRNA increased 8.9-fold (P < 0.05) in all Thyroid Neoplasms versus normal. +tissue_expression_up hsa-mir-122 "Carcinoma, Renal Cell" 21784468 Overexpression +tissue_expression_up hsa-mir-155 "Carcinoma, Renal Cell" 21784468 Overexpression +tissue_expression_up hsa-mir-210 "Carcinoma, Renal Cell" 21784468 Overexpression +tissue_expression_up hsa-mir-145 "Lymphoma, B-Cell" 21803762 miR-9 is upregulated. +tissue_expression_up hsa-mir-17 "Lymphoma, B-Cell" 21803762 miR-17-5p is upregulated. +tissue_expression_up hsa-mir-193b "Lymphoma, B-Cell" 21803762 miR-9 is upregulated. +tissue_expression_up hsa-mir-199a-1 "Lymphoma, B-Cell" 21803762 miR-9 is upregulated. +tissue_expression_up hsa-mir-199a-2 "Lymphoma, B-Cell" 21803762 miR-9 is upregulated. +tissue_expression_up hsa-mir-20a "Lymphoma, B-Cell" 21803762 miR-20a is upregulated. +tissue_expression_up hsa-mir-214 "Lymphoma, B-Cell" 21803762 miR-9 is upregulated. +tissue_expression_up hsa-mir-9-1 "Lymphoma, B-Cell" 21803762 miR-9 is upregulated. +tissue_expression_up hsa-mir-9-2 "Lymphoma, B-Cell" 21803762 miR-9 is upregulated. +tissue_expression_up hsa-mir-9-3 "Lymphoma, B-Cell" 21803762 miR-9 is upregulated. +tissue_expression_up hsa-mir-146a Rheumatoid Arthritis 21810022 "miRNA 146a expression was significantly higher in patients with RA than in those with OA and in controls.In patients with RA, miRNA 146a positively correlated with TNF-a (p=0.0003), erythrocyte sedimentation rate (ESR)(p=0.022), and DAS 28 (p=0.009)." +tissue_expression_up hsa-mir-32 "Leukemia, Myeloid" 21816906 "MicroRNA-32 upregulation by 1,25-dihydroxyvitamin D3 in human myeloid leukemia cells leads to Bim targeting and inhibition of AraC-induced apoptosis." +tissue_expression_up hsa-let-7a-1 Colorectal Carcinoma 21826996 upregulated in colon cancer compared to normal colonic mucosa +tissue_expression_up hsa-let-7a-2 Colorectal Carcinoma 21826996 upregulated in colon cancer compared to normal colonic mucosa +tissue_expression_up hsa-let-7a-3 Colorectal Carcinoma 21826996 upregulated in colon cancer compared to normal colonic mucosa +tissue_expression_up hsa-mir-106a Colorectal Carcinoma 21826996 upregulated in colon cancer compared to normal colonic mucosa +tissue_expression_up hsa-mir-17 Colorectal Carcinoma 21826996 upregulated in colon cancer compared to normal colonic mucosa +tissue_expression_up hsa-mir-182 Colorectal Carcinoma 21826996 upregulated in colon cancer compared to normal colonic mucosa +tissue_expression_up hsa-mir-200c Colorectal Carcinoma 21826996 upregulated in colon cancer compared to normal colonic mucosa +tissue_expression_up hsa-mir-20a Colorectal Carcinoma 21826996 upregulated in colon cancer compared to normal colonic mucosa +tissue_expression_up hsa-mir-92a-1 Colorectal Carcinoma 21826996 upregulated in colon cancer compared to normal colonic mucosa +tissue_expression_up hsa-mir-92a-2 Colorectal Carcinoma 21826996 upregulated in colon cancer compared to normal colonic mucosa +tissue_expression_up hsa-mir-93 Colorectal Carcinoma 21826996 upregulated in colon cancer compared to normal colonic mucosa +tissue_expression_up hsa-mir-491 Glioblastoma 21831363 "miR-491-5p has high positive correlation with MMP-9 expression and its upregulation was demonstrated to reduce the levels of MMP-9 expression and inhibit cellular invasion in U251 and U87 glioma cells. Furthermore, miR-491-5p suppressed glioma cell invasion via targeting MMP-9 directly." +tissue_expression_up hsa-mir-885 Glioblastoma 21831363 miR-885-5p has high positive correlation with MMP-9 expression and its upregulation was demonstrated to reduce the levels of MMP-9 expression and inhibit cellular invasion in U251 and U87 glioma cells. +tissue_expression_up hsa-mir-148a Alzheimer Disease 21834602 upregulated in bone marrow plasma cells from patients with immunoglobulin light chain (AL) amyloidosis compared with controls. +tissue_expression_up hsa-mir-16-2 Alzheimer Disease 21834602 upregulated in bone marrow plasma cells from patients with immunoglobulin light chain (AL) amyloidosis compared with controls. +tissue_expression_up hsa-mir-26a-1 Alzheimer Disease 21834602 upregulated in bone marrow plasma cells from patients with immunoglobulin light chain (AL) amyloidosis compared with controls. +tissue_expression_up hsa-mir-26a-2 Alzheimer Disease 21834602 upregulated in bone marrow plasma cells from patients with immunoglobulin light chain (AL) amyloidosis compared with controls. +tissue_expression_up hsa-mir-100 Muscular Dystrophy 21840938 highly expressed in fetal muscle. +tissue_expression_up hsa-mir-127 Muscular Dystrophy 21840938 miR-127-3p: highly expressed in fetal muscle. +tissue_expression_up hsa-mir-136 Muscular Dystrophy 21840938 miR-136*: highly expressed in fetal muscle. +tissue_expression_up hsa-mir-148a Muscular Dystrophy 21840938 highly expressed in fetal muscle. +tissue_expression_up hsa-mir-192 Muscular Dystrophy 21840938 highly expressed in fetal muscle. +tissue_expression_up hsa-mir-335 Muscular Dystrophy 21840938 highly expressed in fetal muscle. +tissue_expression_up hsa-mir-376c Muscular Dystrophy 21840938 highly expressed in fetal muscle. +tissue_expression_up hsa-mir-489 Muscular Dystrophy 21840938 highly expressed in fetal muscle. +tissue_expression_up hsa-mir-502 Muscular Dystrophy 21840938 miR-502-3p: highly expressed in fetal muscle. +tissue_expression_up hsa-let-7f-2 Biliary Tract Neoplasms 21858175 The miRNA let-7f-2* was significantly more highly expressed in the malignant group than in the benign group. +tissue_expression_up hsa-let-7i Biliary Tract Neoplasms 21858175 The miRNA let-7i* was significantly more highly expressed in the malignant group than in the benign group. +tissue_expression_up hsa-mir-105-1 Biliary Tract Neoplasms 21858175 The miRNA was significantly more highly expressed in the malignant group than in the benign group. +tissue_expression_up hsa-mir-105-2 Biliary Tract Neoplasms 21858175 The miRNA was significantly more highly expressed in the malignant group than in the benign group. +tissue_expression_up hsa-mir-145 Biliary Tract Neoplasms 21858175 The miRNA miR-145* was significantly more highly expressed in the malignant group than in the benign group. +tissue_expression_up hsa-mir-147b Biliary Tract Neoplasms 21858175 The miRNA was significantly more highly expressed in the malignant group than in the benign group. +tissue_expression_up hsa-mir-199a-1 Biliary Tract Neoplasms 21858175 The miRNA miR-199a-3p was significantly more highly expressed in the malignant group than in the benign group. +tissue_expression_up hsa-mir-199a-2 Biliary Tract Neoplasms 21858175 The miRNA miR-199a-3p was significantly more highly expressed in the malignant group than in the benign group. +tissue_expression_up hsa-mir-222 Biliary Tract Neoplasms 21858175 The miRNA miR-222* was significantly more highly expressed in the malignant group than in the benign group. +tissue_expression_up hsa-mir-302c Biliary Tract Neoplasms 21858175 The miRNA miR-302c* was significantly more highly expressed in the malignant group than in the benign group. +tissue_expression_up hsa-mir-9-1 Biliary Tract Neoplasms 21858175 The miRNA was significantly more highly expressed in the malignant group than in the benign group. +tissue_expression_up hsa-mir-9-2 Biliary Tract Neoplasms 21858175 The miRNA was significantly more highly expressed in the malignant group than in the benign group. +tissue_expression_up hsa-mir-9-3 Biliary Tract Neoplasms 21858175 The miRNA was significantly more highly expressed in the malignant group than in the benign group. +tissue_expression_up hsa-mir-942 Biliary Tract Neoplasms 21858175 The miRNA was significantly more highly expressed in the malignant group than in the benign group. +tissue_expression_up hsa-mir-21 "Carcinoma, Adrenocortical" 21859927 "Among others, miR-483-3p, miR-483-5p, miR-210, and miR-21 were found overexpressed,while miR-195, miR-497, and miR-1974 were underexpressed in ACC. " +tissue_expression_up hsa-mir-210 "Carcinoma, Adrenocortical" 21859927 "Among others, miR-483-3p, miR-483-5p, miR-210, and miR-21 were found overexpressed,while miR-195, miR-497, and miR-1974 were underexpressed in ACC. " +tissue_expression_up hsa-mir-483 "Carcinoma, Adrenocortical" 21859927 "Among others, miR-483-3p, miR-483-5p, miR-210, and miR-21 were found overexpressed,while miR-195, miR-497, and miR-1974 were underexpressed in ACC. " +tissue_expression_up hsa-mir-506 Melanoma 21860416 "miR-506-514 cluster was consistently overexpressed in nearly all melanomas tested (30-60 fold, P<0.001), regardless of mutations in N-ras or B-raf." +tissue_expression_up hsa-mir-507 Melanoma 21860416 "miR-506-514 cluster was consistently overexpressed in nearly all melanomas tested (30-60 fold, P<0.001), regardless of mutations in N-ras or B-raf." +tissue_expression_up hsa-mir-508 Melanoma 21860416 "miR-506-514 cluster was consistently overexpressed in nearly all melanomas tested (30-60 fold, P<0.001), regardless of mutations in N-ras or B-raf." +tissue_expression_up hsa-mir-509-1 Melanoma 21860416 "miR-506-514 cluster was consistently overexpressed in nearly all melanomas tested (30-60 fold, P<0.001), regardless of mutations in N-ras or B-raf." +tissue_expression_up hsa-mir-509-2 Melanoma 21860416 "miR-506-514 cluster was consistently overexpressed in nearly all melanomas tested (30-60 fold, P<0.001), regardless of mutations in N-ras or B-raf." +tissue_expression_up hsa-mir-509-3 Melanoma 21860416 "miR-506-514 cluster was consistently overexpressed in nearly all melanomas tested (30-60 fold, P<0.001), regardless of mutations in N-ras or B-raf." +tissue_expression_up hsa-mir-510 Melanoma 21860416 "miR-506-514 cluster was consistently overexpressed in nearly all melanomas tested (30-60 fold, P<0.001), regardless of mutations in N-ras or B-raf." +tissue_expression_up hsa-mir-513a-1 Melanoma 21860416 "miR-506-514 cluster was consistently overexpressed in nearly all melanomas tested (30-60 fold, P<0.001), regardless of mutations in N-ras or B-raf." +tissue_expression_up hsa-mir-513a-2 Melanoma 21860416 "miR-506-514 cluster was consistently overexpressed in nearly all melanomas tested (30-60 fold, P<0.001), regardless of mutations in N-ras or B-raf." +tissue_expression_up hsa-mir-513b Melanoma 21860416 "miR-506-514 cluster was consistently overexpressed in nearly all melanomas tested (30-60 fold, P<0.001), regardless of mutations in N-ras or B-raf." +tissue_expression_up hsa-mir-513c Melanoma 21860416 "miR-506-514 cluster was consistently overexpressed in nearly all melanomas tested (30-60 fold, P<0.001), regardless of mutations in N-ras or B-raf." +tissue_expression_up hsa-mir-514a-1 Melanoma 21860416 "miR-506-514 cluster was consistently overexpressed in nearly all melanomas tested (30-60 fold, P<0.001), regardless of mutations in N-ras or B-raf." +tissue_expression_up hsa-mir-514a-2 Melanoma 21860416 "miR-506-514 cluster was consistently overexpressed in nearly all melanomas tested (30-60 fold, P<0.001), regardless of mutations in N-ras or B-raf." +tissue_expression_up hsa-mir-514a-3 Melanoma 21860416 "miR-506-514 cluster was consistently overexpressed in nearly all melanomas tested (30-60 fold, P<0.001), regardless of mutations in N-ras or B-raf." +tissue_expression_up hsa-mir-155 Melanoma 21863027 PCR analysis revealed primary cutaneous melanomas had an 8.6-fold overexpression of miR-21 and a 7.5-fold overexpression of miR-155 compared with benign naevi (P<0.0001). +tissue_expression_up hsa-mir-21 Melanoma 21863027 PCR analysis revealed primary cutaneous melanomas had an 8.6-fold overexpression of miR-21 and a 7.5-fold overexpression of miR-155 compared with benign naevi (P<0.0001). +tissue_expression_up hsa-mir-144 Colorectal Carcinoma 21863218 Differential expression of miR-144* as a novel fecal-based diagnostic marker for colorectal cancer. +tissue_expression_up hsa-mir-181b-1 Gastric Neoplasms 21876743 Doxifluridine/Oxaliplatin treated advanced stage gastric cancer patients. The expression of miR-181b and miR-21 was significantly overexpressed in gastric tumors compared to normal gastric tissues. +tissue_expression_up hsa-mir-181b-2 Gastric Neoplasms 21876743 Doxifluridine/Oxaliplatin treated advanced stage gastric cancer patients. The expression of miR-181b and miR-21 was significantly overexpressed in gastric tumors compared to normal gastric tissues. +tissue_expression_up hsa-mir-21 Gastric Neoplasms 21876743 Doxifluridine/Oxaliplatin treated advanced stage gastric cancer patients. The expression of miR-181b and miR-21 was significantly overexpressed in gastric tumors compared to normal gastric tissues. +tissue_expression_up hsa-mir-142 "Squamous Cell Carcinoma, Esophageal" 21882196 "MiR-31 and miR-142-3p expression were correlated to histological differentiation in ESCC (P<0.05, Student's t-test); high miR-142-3p expression was associated with a poor prognosis in all 91 ESCC patients (P=0.014, log-rank) and identified as an independent prognostic factor in ESCC (P=0.017, univariate Cox; P=0.022, multivariate Cox). More importantly, stratified analysis indicated that high miR-142-3p expression was correlated to a poor prognosis within good-prognosis groups comprised of ESCC patients with small tumor size, negative lymph node metastasis, or early stage (all P<0.05)." +tissue_expression_up hsa-mir-31 "Squamous Cell Carcinoma, Esophageal" 21882196 "MiR-31 and miR-142-3p expression were correlated to histological differentiation in ESCC (P<0.05, Student's t-test); high miR-142-3p expression was associated with a poor prognosis in all 91 ESCC patients (P=0.014, log-rank) and identified as an independent prognostic factor in ESCC (P=0.017, univariate Cox; P=0.022, multivariate Cox). More importantly, stratified analysis indicated that high miR-142-3p expression was correlated to a poor prognosis within good-prognosis groups comprised of ESCC patients with small tumor size, negative lymph node metastasis, or early stage (all P<0.05)." +tissue_expression_up hsa-mir-21 "Squamous Cell Carcinoma, Esophageal" 21883657 miR-21 expression was significantly up-regulated in the whole spectrum of preneoplastic/neoplastic lesions considered. +tissue_expression_up hsa-mir-133a-1 "Cardiomyopathy, Hypertrophic" 21893044 Hydrogen sulphide inhibits cardiomyocyte hypertrophy by up-regulating miR-133a. +tissue_expression_up hsa-mir-133a-1 Hypertrophy 21893044 Hydrogen sulphide inhibits cardiomyocyte hypertrophy by up-regulating miR-133a +tissue_expression_up hsa-mir-133a-2 "Cardiomyopathy, Hypertrophic" 21893044 Hydrogen sulphide inhibits cardiomyocyte hypertrophy by up-regulating miR-133a. +tissue_expression_up hsa-mir-133a-2 Hypertrophy 21893044 Hydrogen sulphide inhibits cardiomyocyte hypertrophy by up-regulating miR-133a +tissue_expression_up hsa-mir-141 Endometrial Neoplasms 21897839 "The entire miR-200 family (miR-200a/b/c, miR-141, and miR-429) was up-regulated in cases of EEC (endometrioid endometrial adenocarcinoma)." +tissue_expression_up hsa-mir-200a Endometrial Neoplasms 21897839 "The entire miR-200 family (miR-200a/b/c, miR-141, and miR-429) was up-regulated in cases of EEC (endometrioid endometrial adenocarcinoma)." +tissue_expression_up hsa-mir-200b Endometrial Neoplasms 21897839 "The entire miR-200 family (miR-200a/b/c, miR-141, and miR-429) was up-regulated in cases of EEC (endometrioid endometrial adenocarcinoma)." +tissue_expression_up hsa-mir-200c Endometrial Neoplasms 21897839 "The entire miR-200 family (miR-200a/b/c, miR-141, and miR-429) was up-regulated in cases of EEC (endometrioid endometrial adenocarcinoma)." +tissue_expression_up hsa-mir-429 Endometrial Neoplasms 21897839 "The entire miR-200 family (miR-200a/b/c, miR-141, and miR-429) was up-regulated in cases of EEC (endometrioid endometrial adenocarcinoma)." +tissue_expression_up hsa-mir-141 "Carcinoma, Ehrlich Tumor" 21899346 "Two clusters miR-183~miR-96~miR-182 and miR-200b~miR-200a~miR-429 as well as miR-141 to be consistently up-regulated in the MDR (Multidrug resistance) cell lines, while miR-125b-5p and the two clusters miR-30d~miR-30b and miR-23b~miR-27b~miR-24-1 were down-regulated in most of the resistant EAT (Ehrlich ascites tumor) cells." +tissue_expression_up hsa-mir-182 "Carcinoma, Ehrlich Tumor" 21899346 "Two clusters miR-183~miR-96~miR-182 and miR-200b~miR-200a~miR-429 as well as miR-141 to be consistently up-regulated in the MDR (Multidrug resistance) cell lines, while miR-125b-5p and the two clusters miR-30d~miR-30b and miR-23b~miR-27b~miR-24-1 were down-regulated in most of the resistant EAT (Ehrlich ascites tumor) cells." +tissue_expression_up hsa-mir-183 "Carcinoma, Ehrlich Tumor" 21899346 "Two clusters miR-183~miR-96~miR-182 and miR-200b~miR-200a~miR-429 as well as miR-141 to be consistently up-regulated in the MDR (Multidrug resistance) cell lines, while miR-125b-5p and the two clusters miR-30d~miR-30b and miR-23b~miR-27b~miR-24-1 were down-regulated in most of the resistant EAT (Ehrlich ascites tumor) cells." +tissue_expression_up hsa-mir-200a "Carcinoma, Ehrlich Tumor" 21899346 "Two clusters miR-183~miR-96~miR-182 and miR-200b~miR-200a~miR-429 as well as miR-141 to be consistently up-regulated in the MDR (Multidrug resistance) cell lines, while miR-125b-5p and the two clusters miR-30d~miR-30b and miR-23b~miR-27b~miR-24-1 were down-regulated in most of the resistant EAT (Ehrlich ascites tumor) cells." +tissue_expression_up hsa-mir-200b "Carcinoma, Ehrlich Tumor" 21899346 "Two clusters miR-183~miR-96~miR-182 and miR-200b~miR-200a~miR-429 as well as miR-141 to be consistently up-regulated in the MDR (Multidrug resistance) cell lines, while miR-125b-5p and the two clusters miR-30d~miR-30b and miR-23b~miR-27b~miR-24-1 were down-regulated in most of the resistant EAT (Ehrlich ascites tumor) cells." +tissue_expression_up hsa-mir-429 "Carcinoma, Ehrlich Tumor" 21899346 "Two clusters miR-183~miR-96~miR-182 and miR-200b~miR-200a~miR-429 as well as miR-141 to be consistently up-regulated in the MDR (Multidrug resistance) cell lines, while miR-125b-5p and the two clusters miR-30d~miR-30b and miR-23b~miR-27b~miR-24-1 were down-regulated in most of the resistant EAT (Ehrlich ascites tumor) cells." +tissue_expression_up hsa-mir-96 "Carcinoma, Ehrlich Tumor" 21899346 "Two clusters miR-183~miR-96~miR-182 and miR-200b~miR-200a~miR-429 as well as miR-141 to be consistently up-regulated in the MDR (Multidrug resistance) cell lines, while miR-125b-5p and the two clusters miR-30d~miR-30b and miR-23b~miR-27b~miR-24-1 were down-regulated in most of the resistant EAT (Ehrlich ascites tumor) cells." +tissue_expression_up hsa-mir-27b Glioblastoma 21922148 "Real-time PCR showed that miR-27b was up-regulated in glioma samples and glioma cells. Down-regulation of miR-27b triggered growth inhibition, induced apoptosis and inhibited invasion in glioma cells. In addition, Western blot assay showed that STAT3, c-myc and cyclin D1 were knocked down after treatment with miR-27b inhibitor." +tissue_expression_up hsa-mir-27b Glioma 21922148 Real-time PCR showed that miR-27b was up-regulated in glioma samples and glioma cells. +tissue_expression_up hsa-mir-21 Colorectal Carcinoma 21930727 "The expression of miR-21 and miR-92a was significantly higher in CRC tissues compared with their adjacent normal tissues (p<0.0001). Patients with CRC had a significantly higher stool miR-21 level (p<0.01) and miR-92a level (p<0.0001) compared with normal controls. Stool miR-92a, but not miR-21, was significantly higher in patients with polyps than in controls (p<0.0001). At a cut-off value of 435 copies/ng of stool RNA, miR-92a had a sensitivity of 71.6% and 56.1% for CRC and polyp, respectively, and a specificity of 73.3%. In addition, the stool miR-92a level demonstrated a higher sensitivity for distal CRC than proximal CRC (p<0.05), and a higher sensitivity for advanced adenoma than minor polyps (p<0.05). Removal of tumour resulted in reduced stool miR-21 and miR-92a levels (p<0.01), and the removal of advanced adenoma resulted in a reduction of the stool miR-92a level (p<0.05)." +tissue_expression_up hsa-mir-92a-1 Colorectal Carcinoma 21930727 "The expression of miR-21 and miR-92a was significantly higher in CRC tissues compared with their adjacent normal tissues (p<0.0001). Patients with CRC had a significantly higher stool miR-21 level (p<0.01) and miR-92a level (p<0.0001) compared with normal controls. Stool miR-92a, but not miR-21, was significantly higher in patients with polyps than in controls (p<0.0001). At a cut-off value of 435 copies/ng of stool RNA, miR-92a had a sensitivity of 71.6% and 56.1% for CRC and polyp, respectively, and a specificity of 73.3%. In addition, the stool miR-92a level demonstrated a higher sensitivity for distal CRC than proximal CRC (p<0.05), and a higher sensitivity for advanced adenoma than minor polyps (p<0.05). Removal of tumour resulted in reduced stool miR-21 and miR-92a levels (p<0.01), and the removal of advanced adenoma resulted in a reduction of the stool miR-92a level (p<0.05)." +tissue_expression_up hsa-mir-92a-2 Colorectal Carcinoma 21930727 "The expression of miR-21 and miR-92a was significantly higher in CRC tissues compared with their adjacent normal tissues (p<0.0001). Patients with CRC had a significantly higher stool miR-21 level (p<0.01) and miR-92a level (p<0.0001) compared with normal controls. Stool miR-92a, but not miR-21, was significantly higher in patients with polyps than in controls (p<0.0001). At a cut-off value of 435 copies/ng of stool RNA, miR-92a had a sensitivity of 71.6% and 56.1% for CRC and polyp, respectively, and a specificity of 73.3%. In addition, the stool miR-92a level demonstrated a higher sensitivity for distal CRC than proximal CRC (p<0.05), and a higher sensitivity for advanced adenoma than minor polyps (p<0.05). Removal of tumour resulted in reduced stool miR-21 and miR-92a levels (p<0.01), and the removal of advanced adenoma resulted in a reduction of the stool miR-92a level (p<0.05)." +tissue_expression_up hsa-mir-126 Medulloblastoma 21931624 hsa-mir-126 was significantly up-regulated in primary Medulloblastoma specimens relative to CD133+ NSCs (Neural Stem Cells). +tissue_expression_up hsa-mir-127 Medulloblastoma 21931624 hsa-mir-127-3p was significantly up-regulated in primary Medulloblastoma specimens relative to CD133+ NSCs (Neural Stem Cells). +tissue_expression_up hsa-mir-143 Medulloblastoma 21931624 hsa-mir-143 was significantly up-regulated in primary Medulloblastoma specimens relative to CD133+ NSCs (Neural Stem Cells). +tissue_expression_up hsa-mir-144 Medulloblastoma 21931624 hsa-mir-144* was significantly up-regulated in primary Medulloblastoma specimens relative to CD133+ NSCs (Neural Stem Cells). +tissue_expression_up hsa-mir-145 Medulloblastoma 21931624 hsa-mir-145 was significantly up-regulated in primary Medulloblastoma specimens relative to CD133+ NSCs (Neural Stem Cells). +tissue_expression_up hsa-mir-146a Medulloblastoma 21931624 hsa-mir-146a was significantly up-regulated in primary Medulloblastoma specimens relative to CD133+ NSCs (Neural Stem Cells). +tissue_expression_up hsa-mir-193a Medulloblastoma 21931624 hsa-mir-193a-5p was significantly up-regulated in primary Medulloblastoma specimens relative to CD133+ NSCs (Neural Stem Cells). +tissue_expression_up hsa-mir-203 Medulloblastoma 21931624 hsa-mir-203 was significantly up-regulated in primary Medulloblastoma specimens relative to CD133+ NSCs (Neural Stem Cells). +tissue_expression_up hsa-mir-21 Medulloblastoma 21931624 hsa-mir-21* was significantly up-regulated in primary Medulloblastoma specimens relative to CD133+ NSCs (Neural Stem Cells). +tissue_expression_up hsa-mir-223 Medulloblastoma 21931624 hsa-mir-223 was significantly up-regulated in primary Medulloblastoma specimens relative to CD133+ NSCs (Neural Stem Cells). +tissue_expression_up hsa-mir-323a Medulloblastoma 21931624 hsa-mir-323-3p was significantly up-regulated in primary Medulloblastoma specimens relative to CD133+ NSCs (Neural Stem Cells). +tissue_expression_up hsa-mir-338 Medulloblastoma 21931624 hsa-mir-338-3p was significantly up-regulated in primary Medulloblastoma specimens relative to CD133+ NSCs (Neural Stem Cells). +tissue_expression_up hsa-mir-361 Medulloblastoma 21931624 hsa-mir-361-3p was significantly up-regulated in primary Medulloblastoma specimens relative to CD133+ NSCs (Neural Stem Cells). +tissue_expression_up hsa-mir-376a-1 Medulloblastoma 21931624 hsa-mir-376 was significantly up-regulated in primary Medulloblastoma specimens relative to CD133+ NSCs (Neural Stem Cells). +tissue_expression_up hsa-mir-376a-2 Medulloblastoma 21931624 hsa-mir-376 was significantly up-regulated in primary Medulloblastoma specimens relative to CD133+ NSCs (Neural Stem Cells). +tissue_expression_up hsa-mir-376c Medulloblastoma 21931624 hsa-mir-376c was significantly up-regulated in primary Medulloblastoma specimens relative to CD133+ NSCs (Neural Stem Cells). +tissue_expression_up hsa-mir-379 Medulloblastoma 21931624 hsa-mir-379 was significantly up-regulated in primary Medulloblastoma specimens relative to CD133+ NSCs (Neural Stem Cells). +tissue_expression_up hsa-mir-409 Medulloblastoma 21931624 hsa-mir-409-3p was significantly up-regulated in primary Medulloblastoma specimens relative to CD133+ NSCs (Neural Stem Cells). +tissue_expression_up hsa-mir-494 Medulloblastoma 21931624 hsa-mir-494 was significantly up-regulated in primary Medulloblastoma specimens relative to CD133+ NSCs (Neural Stem Cells). +tissue_expression_up hsa-mir-495 Medulloblastoma 21931624 hsa-mir-495 was significantly up-regulated in primary Medulloblastoma specimens relative to CD133+ NSCs (Neural Stem Cells). +tissue_expression_up hsa-mir-539 Medulloblastoma 21931624 hsa-mir-539 was significantly up-regulated in primary Medulloblastoma specimens relative to CD133+ NSCs (Neural Stem Cells). +tissue_expression_up hsa-mir-1-1 Breast Neoplasms 21931769 "ATF-126 and Maspin cDNA induction led to the re-activation of tumor suppressive miRNAs also expressed in neural cells, such as miR-1 and miR-34, and to the down-regulation of potential oncogenic miRNAs, such as miR-10b, miR-124, and miR-363." +tissue_expression_up hsa-mir-1-2 Breast Neoplasms 21931769 "ATF-126 and Maspin cDNA induction led to the re-activation of tumor suppressive miRNAs also expressed in neural cells, such as miR-1 and miR-34, and to the down-regulation of potential oncogenic miRNAs, such as miR-10b, miR-124, and miR-363." +tissue_expression_up hsa-mir-34a Breast Neoplasms 21931769 "ATF-126 and Maspin cDNA induction led to the re-activation of tumor suppressive miRNAs also expressed in neural cells, such as miR-1 and miR-34, and to the down-regulation of potential oncogenic miRNAs, such as miR-10b, miR-124, and miR-363." +tissue_expression_up hsa-mir-223 Breast Neoplasms 21939504 "miR-223, a miRNA specific for IL-4-activated macrophages, was detected within the exosomes released by macrophages and was significantly elevated in the co-cultivated SKBR3 and MDA-MB-231 cells." +tissue_expression_up hsa-mir-1299 Ovarian Neoplasms 21939554 The miRNA was upregulated in cis-platin resistant (A2780/CP70) vs. cis-platin sensitive (A2780) ovarian cancer cell lines. +tissue_expression_up hsa-mir-193b Ovarian Neoplasms 21939554 The miRNA was upregulated in cis-platin resistant (A2780/CP70) vs. cis-platin sensitive (A2780) ovarian cancer cell lines. +tissue_expression_up hsa-mir-300 Ovarian Neoplasms 21939554 The miRNA was upregulated in cis-platin resistant (A2780/CP70) vs. cis-platin sensitive (A2780) ovarian cancer cell lines. +tissue_expression_up hsa-mir-642a Ovarian Neoplasms 21939554 The miRNA was upregulated in cis-platin resistant (A2780/CP70) vs. cis-platin sensitive (A2780) ovarian cancer cell lines. +tissue_expression_up hsa-let-7c Retinoblastoma 21941147 differential expression between RB cell lines of different growth patterns: SNUOT-Rb1 with adherent and more rapid growth and Y79 with nonadherent and slower growth. +tissue_expression_up hsa-let-7i Retinoblastoma 21941147 differential expression between RB cell lines of different growth patterns: SNUOT-Rb1 with adherent and more rapid growth and Y79 with nonadherent and slower growth. +tissue_expression_up hsa-mir-10b Retinoblastoma 21941147 differential expression between RB cell lines of different growth patterns: SNUOT-Rb1 with adherent and more rapid growth and Y79 with nonadherent and slower growth. +tissue_expression_up hsa-mir-124-1 Retinoblastoma 21941147 differential expression between RB cell lines of different growth patterns: SNUOT-Rb1 with adherent and more rapid growth and Y79 with nonadherent and slower growth. +tissue_expression_up hsa-mir-124-2 Retinoblastoma 21941147 differential expression between RB cell lines of different growth patterns: SNUOT-Rb1 with adherent and more rapid growth and Y79 with nonadherent and slower growth. +tissue_expression_up hsa-mir-124-3 Retinoblastoma 21941147 differential expression between RB cell lines of different growth patterns: SNUOT-Rb1 with adherent and more rapid growth and Y79 with nonadherent and slower growth. +tissue_expression_up hsa-mir-135b Retinoblastoma 21941147 differential expression between RB cell lines of different growth patterns: SNUOT-Rb1 with adherent and more rapid growth and Y79 with nonadherent and slower growth. +tissue_expression_up hsa-mir-142 Retinoblastoma 21941147 hsa-mir-142-5p: differential expression between RB cell lines of different growth patterns: SNUOT-Rb1 with adherent and more rapid growth and Y79 with nonadherent and slower growth. +tissue_expression_up hsa-mir-29a Retinoblastoma 21941147 differential expression between RB cell lines of different growth patterns: SNUOT-Rb1 with adherent and more rapid growth and Y79 with nonadherent and slower growth. +tissue_expression_up hsa-mir-29b-1 Retinoblastoma 21941147 differential expression between RB cell lines of different growth patterns: SNUOT-Rb1 with adherent and more rapid growth and Y79 with nonadherent and slower growth. +tissue_expression_up hsa-mir-29b-2 Retinoblastoma 21941147 differential expression between RB cell lines of different growth patterns: SNUOT-Rb1 with adherent and more rapid growth and Y79 with nonadherent and slower growth. +tissue_expression_up hsa-mir-29c Retinoblastoma 21941147 differential expression between RB cell lines of different growth patterns: SNUOT-Rb1 with adherent and more rapid growth and Y79 with nonadherent and slower growth. +tissue_expression_up hsa-mir-34a Retinoblastoma 21941147 differential expression between RB cell lines of different growth patterns: SNUOT-Rb1 with adherent and more rapid growth and Y79 with nonadherent and slower growth. +tissue_expression_up hsa-mir-34c Retinoblastoma 21941147 hsa-mir-34c-5p: differential expression between RB cell lines of different growth patterns: SNUOT-Rb1 with adherent and more rapid growth and Y79 with nonadherent and slower growth. +tissue_expression_up hsa-mir-203 Lichen Planus 21943223 "Increased expression of miR-21 and miR-203, decreased expression of miR-125, and down-regulation of p53 and deltaNp63 RNA were seen in OLP compared to normal oral mucosa. When comparing microRNA expression to levels of p53 and p63 RNA, a significant negative correlation was seen between deltaNp63 and miR-203 and between miR-21 and p53, respectively." +tissue_expression_up hsa-mir-21 Lichen Planus 21943223 "Increased expression of miR-21 and miR-203, decreased expression of miR-125, and down-regulation of p53 and deltaNp63 RNA were seen in OLP compared to normal oral mucosa. When comparing microRNA expression to levels of p53 and p63 RNA, a significant negative correlation was seen between deltaNp63 and miR-203 and between miR-21 and p53, respectively." +tissue_expression_up hsa-mir-34c Alzheimer Disease 21946562 The authors identify miR-34c as a negative constraint of memory consolidation and show that miR-34c levels are elevated in the hippocampus of AD patients and corresponding mouse models. +tissue_expression_up hsa-mir-182 Breast Neoplasms 21953071 The miRNA was up-regulated during lobular neoplasia progression compared to normal epithelium. +tissue_expression_up hsa-mir-183 Breast Neoplasms 21953071 The miRNA was up-regulated during lobular neoplasia progression compared to normal epithelium. +tissue_expression_up hsa-mir-203 Breast Neoplasms 21953071 The miRNA was up-regulated during lobular neoplasia progression compared to normal epithelium. +tissue_expression_up hsa-mir-375 Breast Neoplasms 21953071 The miRNA was up-regulated during lobular neoplasia progression compared to normal epithelium. Hsa-miR-375 is differentially expressed during breast lobular neoplasia and promotes loss of mammary acinar polarity. +tissue_expression_up hsa-mir-425 Breast Neoplasms 21953071 miR-425-5p was up-regulated during lobular neoplasia progression compared to normal epithelium. +tissue_expression_up hsa-mir-194-1 Pancreatic Neoplasms 21953293 Highly up-regulated in PDAC compared with normal ductal +tissue_expression_up hsa-mir-194-2 Pancreatic Neoplasms 21953293 Highly up-regulated in PDAC compared with normal ductal +tissue_expression_up hsa-mir-210 Pancreatic Neoplasms 21953293 Highly up-regulated in PDAC compared with normal ductal +tissue_expression_up hsa-mir-425 Pancreatic Neoplasms 21953293 Highly up-regulated in PDAC compared with normal ductal +tissue_expression_up hsa-mir-429 Pancreatic Neoplasms 21953293 Highly up-regulated in PDAC compared with normal ductal +tissue_expression_up hsa-mir-210 Lung Neoplasms 21965273 Green tea polyphenol EGCG suppresses lung cancer cell growth through upregulating miR-210 expression caused by stabilizing HIF-1{alpha} +tissue_expression_up hsa-mir-155 Mycosis Fungoides 21966986 "MiR-155 was only found to be slightly overexpressed in MF compared to healthy controls. Furthermore, metastatic MF demonstrated lower concentrations of let-7a, let-7d and let-7f when compared to MF limited to the skin." +tissue_expression_up hsa-mir-106a Alopecia 21967250 "We detected the significant upregulation of miR-221, miR-125b, miR-106a and miR-410 in balding papilla cells." +tissue_expression_up hsa-mir-125b Alopecia 21967250 "We detected the significant upregulation of miR-221, miR-125b, miR-106a and miR-410 in balding papilla cells." +tissue_expression_up hsa-mir-221 Alopecia 21967250 "We detected the significant upregulation of miR-221, miR-125b, miR-106a and miR-410 in balding papilla cells." +tissue_expression_up hsa-mir-410 Alopecia 21967250 "We detected the significant upregulation of miR-221, miR-125b, miR-106a and miR-410 in balding papilla cells." +tissue_expression_up hsa-mir-21 Pancreatic Neoplasms 21983937 "miRNA-21 was the most significantly overexpressed miRNA in the pancreatic ductal adenocarcinomas analyzed, and was also highly expressed in 75% of the 65 pancreatic ductal adenocarcinomas examined by real-time RT-PCR. High miRNA-21 expression was correlated with a worse prognosis in the pancreatic ductal adenocarcinoma patients (P=0.045). The immunohistochemical expression patterns of PDCD4 (reduced nuclear staining pattern) and TIMP3 (downregulated expression) were significantly associated with both the upregulated miR-21 expression (P<0.05) and the poor survival of the patients (P<0.001 and P=0.001, respectively). Our data suggest that an overexpression of miRNA-21 is, therefore, associated with the biological behavior of pancreatic ductal adenocarcinoma via the downregulation of the expression of tumor suppressors, PDCD4 and TIMP3, thus resulting in tumor progression and the adverse clinical course of pancreatic ductal adenocarcinoma." +tissue_expression_up hsa-mir-155 "Lymphoma, B-Cell" 21987025 "Four of miRNAs (miR-15a, miR-16-1, miR-29c, and miR-155) were significantly elevated in DLBCL (diffuse large B cell lymphoma) serum when compared with normal controls (P<0.05), while miR-34a was downregulated in DLBCL serum when compared with controls (P<0.05). Receiver operating characteristic analyses reflects strong discriminating DLBCL from controls, with area under the curves of 0.7722, 0.7002, 0.6672, 0.8538, and 0.7157 for miR-15a, miR-16-1, miR-29c, miR-34a, and miR-155, respectively. At the cut-off value of 0.0006 for miR-15a, the sensitivity was 80% and the specificity was 76%; at the cut-off value of 0.0886 for miR-16-1, the sensitivity was 94% and the specificity was 51%; at the cut-off value of 1.395 for miR-34a, the sensitivity was 100% and the specificity was 70%; at the cut-off value of 0.0022 for miR-155, the sensitivity was 83% and the specificity was 65%." +tissue_expression_up hsa-mir-15a "Lymphoma, B-Cell" 21987025 "Four of miRNAs (miR-15a, miR-16-1, miR-29c, and miR-155) were significantly elevated in DLBCL (diffuse large B cell lymphoma) serum when compared with normal controls (P<0.05), while miR-34a was downregulated in DLBCL serum when compared with controls (P<0.05). Receiver operating characteristic analyses reflects strong discriminating DLBCL from controls, with area under the curves of 0.7722, 0.7002, 0.6672, 0.8538, and 0.7157 for miR-15a, miR-16-1, miR-29c, miR-34a, and miR-155, respectively. At the cut-off value of 0.0006 for miR-15a, the sensitivity was 80% and the specificity was 76%; at the cut-off value of 0.0886 for miR-16-1, the sensitivity was 94% and the specificity was 51%; at the cut-off value of 1.395 for miR-34a, the sensitivity was 100% and the specificity was 70%; at the cut-off value of 0.0022 for miR-155, the sensitivity was 83% and the specificity was 65%." +tissue_expression_up hsa-mir-16-1 "Lymphoma, B-Cell" 21987025 "Four of miRNAs (miR-15a, miR-16-1, miR-29c, and miR-155) were significantly elevated in DLBCL (diffuse large B cell lymphoma) serum when compared with normal controls (P<0.05), while miR-34a was downregulated in DLBCL serum when compared with controls (P<0.05). Receiver operating characteristic analyses reflects strong discriminating DLBCL from controls, with area under the curves of 0.7722, 0.7002, 0.6672, 0.8538, and 0.7157 for miR-15a, miR-16-1, miR-29c, miR-34a, and miR-155, respectively. At the cut-off value of 0.0006 for miR-15a, the sensitivity was 80% and the specificity was 76%; at the cut-off value of 0.0886 for miR-16-1, the sensitivity was 94% and the specificity was 51%; at the cut-off value of 1.395 for miR-34a, the sensitivity was 100% and the specificity was 70%; at the cut-off value of 0.0022 for miR-155, the sensitivity was 83% and the specificity was 65%." +tissue_expression_up hsa-mir-29c "Lymphoma, B-Cell" 21987025 "Four of miRNAs (miR-15a, miR-16-1, miR-29c, and miR-155) were significantly elevated in DLBCL (diffuse large B cell lymphoma) serum when compared with normal controls (P<0.05), while miR-34a was downregulated in DLBCL serum when compared with controls (P<0.05). Receiver operating characteristic analyses reflects strong discriminating DLBCL from controls, with area under the curves of 0.7722, 0.7002, 0.6672, 0.8538, and 0.7157 for miR-15a, miR-16-1, miR-29c, miR-34a, and miR-155, respectively. At the cut-off value of 0.0006 for miR-15a, the sensitivity was 80% and the specificity was 76%; at the cut-off value of 0.0886 for miR-16-1, the sensitivity was 94% and the specificity was 51%; at the cut-off value of 1.395 for miR-34a, the sensitivity was 100% and the specificity was 70%; at the cut-off value of 0.0022 for miR-155, the sensitivity was 83% and the specificity was 65%." +tissue_expression_up hsa-mir-146a Systemic Lupus Erythematosus 21987229 "The levels of urinary miR-146a and miR-155 in patients with SLE were significantly higher than that in healthy controls. Calcitriol treatment reduced the levels of urinary miR-155 in patients with SLE. The level of urinary miR-146a significantly correlated with estimated glomerular filtration rate. The level of urinary miR-155 significantly correlated with proteinuria and systemic lupus erythematosus disease activity index (r=0.278, P=0.002). The level of urinary miR-146a reversely correlated with the urinary expression of TNF-a. Our results suggested that miR-146a and miR-155 might play important roles in the pathophysiology of SLE and the levels of urinary miR-146a and miR-155 could be used as potential markers for diagnosis, disease activity, and therapeutic response." +tissue_expression_up hsa-mir-155 Systemic Lupus Erythematosus 21987229 "The levels of urinary miR-146a and miR-155 in patients with SLE were significantly higher than that in healthy controls. Calcitriol treatment reduced the levels of urinary miR-155 in patients with SLE. The level of urinary miR-146a significantly correlated with estimated glomerular filtration rate. The level of urinary miR-155 significantly correlated with proteinuria and systemic lupus erythematosus disease activity index (r=0.278, P=0.002). The level of urinary miR-146a reversely correlated with the urinary expression of TNF-a. Our results suggested that miR-146a and miR-155 might play important roles in the pathophysiology of SLE and the levels of urinary miR-146a and miR-155 could be used as potential markers for diagnosis, disease activity, and therapeutic response." +tissue_expression_up hsa-mir-96 Urinary Bladder Cancer 21993544 hsa-mir-96 up-regulates MAP4K1 and IRS1 and may function as a promising diagnostic marker in human bladder urothelial carcinomas. +tissue_expression_up hsa-mir-1224 "Carcinoma, Hepatocellular" 21998738 hsa-mir-1224-3p was up-regulated in HepG2 cells after 5 hours of culture with grape seed proanthocyanidin extract. +tissue_expression_up hsa-mir-1234 "Carcinoma, Hepatocellular" 21998738 hsa-mir-1234 was up-regulated in HepG2 cells after 5 hours of culture with grape seed proanthocyanidin extract. +tissue_expression_up hsa-mir-1249 "Carcinoma, Hepatocellular" 21998738 hsa-mir-1249 was up-regulated in HepG2 cells after 5 hours of culture with grape seed proanthocyanidin extract. +tissue_expression_up hsa-mir-15b "Carcinoma, Hepatocellular" 21998738 hsa-mir-15b* was up-regulated in HepG2 cells after 5 hours of culture with grape seed proanthocyanidin extract. +tissue_expression_up hsa-mir-197 "Carcinoma, Hepatocellular" 21998738 hsa-mir-197 was up-regulated in HepG2 cells after 5 hours of culture with grape seed proanthocyanidin extract. +tissue_expression_up hsa-mir-449b "Carcinoma, Hepatocellular" 21998738 hsa-mir-449b* was up-regulated in HepG2 cells after 5 hours of culture with grape seed proanthocyanidin extract. +tissue_expression_up hsa-mir-522 "Carcinoma, Hepatocellular" 21998738 hsa-mir-522 was up-regulated in HepG2 cells after 5 hours of culture with grape seed proanthocyanidin extract. +tissue_expression_up hsa-mir-532 "Carcinoma, Hepatocellular" 21998738 hsa-mir-532-3p was up-regulated in HepG2 cells after 5 hours of culture with grape seed proanthocyanidin extract. +tissue_expression_up hsa-mir-744 "Carcinoma, Hepatocellular" 21998738 hsa-mir-744* was up-regulated in HepG2 cells after 5 hours of culture with grape seed proanthocyanidin extract. +tissue_expression_up hsa-mir-146a Osteoarthritis 22006119 "The relative expression levels of miR-146a, 155, 181a, and 223 in the OA patients were significantly higher than those found in healthy controls. In the early stages of OA, miR-146a and 223 expressions were significantly higher than they were at later stages. There was a significant correlation between the expression of miR-223 and KS. This study demonstrated that high expression levels of miR-146a, 155, 181a, and 223 in the PBMCs of OA patients might be related to the pathogenesis of OA." +tissue_expression_up hsa-mir-155 Osteoarthritis 22006119 "The relative expression levels of miR-146a, 155, 181a, and 223 in the OA patients were significantly higher than those found in healthy controls. In the early stages of OA, miR-146a and 223 expressions were significantly higher than they were at later stages. There was a significant correlation between the expression of miR-223 and KS. This study demonstrated that high expression levels of miR-146a, 155, 181a, and 223 in the PBMCs of OA patients might be related to the pathogenesis of OA." +tissue_expression_up hsa-mir-181a-1 Osteoarthritis 22006119 "The relative expression levels of miR-146a, 155, 181a, and 223 in the OA patients were significantly higher than those found in healthy controls. In the early stages of OA, miR-146a and 223 expressions were significantly higher than they were at later stages. There was a significant correlation between the expression of miR-223 and KS. This study demonstrated that high expression levels of miR-146a, 155, 181a, and 223 in the PBMCs of OA patients might be related to the pathogenesis of OA." +tissue_expression_up hsa-mir-181a-2 Osteoarthritis 22006119 "The relative expression levels of miR-146a, 155, 181a, and 223 in the OA patients were significantly higher than those found in healthy controls. In the early stages of OA, miR-146a and 223 expressions were significantly higher than they were at later stages. There was a significant correlation between the expression of miR-223 and KS. This study demonstrated that high expression levels of miR-146a, 155, 181a, and 223 in the PBMCs of OA patients might be related to the pathogenesis of OA." +tissue_expression_up hsa-mir-223 Osteoarthritis 22006119 "The relative expression levels of miR-146a, 155, 181a, and 223 in the OA patients were significantly higher than those found in healthy controls. In the early stages of OA, miR-146a and 223 expressions were significantly higher than they were at later stages. There was a significant correlation between the expression of miR-223 and KS. This study demonstrated that high expression levels of miR-146a, 155, 181a, and 223 in the PBMCs of OA patients might be related to the pathogenesis of OA." +tissue_expression_up hsa-mir-100 Thyroid Neoplasms 22006248 "miR-100, miR-125b, miR-138, and miR-768-3p were overexpressed in malignant samples of follicular origin (P <0.001), and in Hurthle cell carcinoma samples alone (P < 0.01). Only miR-125b was significantly overexpressed in follicular carcinoma samples (P < .05)." +tissue_expression_up hsa-mir-125b-1 Thyroid Neoplasms 22006248 "miR-100, miR-125b, miR-138, and miR-768-3p were overexpressed in malignant samples of follicular origin (P < .001), and in Hurthle cell carcinoma samples alone (P < .01). Only miR-125b was significantly overexpressed in follicular carcinoma samples (P < .05)." +tissue_expression_up hsa-mir-125b-2 Thyroid Neoplasms 22006248 "miR-100, miR-125b, miR-138, and miR-768-3p were overexpressed in malignant samples of follicular origin (P < .001), and in Hurthle cell carcinoma samples alone (P < .01). Only miR-125b was significantly overexpressed in follicular carcinoma samples (P < .05)." +tissue_expression_up hsa-mir-138-1 Thyroid Neoplasms 22006248 "miR-100, miR-125b, miR-138, and miR-768-3p were overexpressed in malignant samples of follicular origin (P < .001), and in Hurthle cell carcinoma samples alone (P < .01). Only miR-125b was significantly overexpressed in follicular carcinoma samples (P < .05)." +tissue_expression_up hsa-mir-138-2 Thyroid Neoplasms 22006248 "miR-100, miR-125b, miR-138, and miR-768-3p were overexpressed in malignant samples of follicular origin (P < .001), and in Hurthle cell carcinoma samples alone (P < .01). Only miR-125b was significantly overexpressed in follicular carcinoma samples (P < .05)." +tissue_expression_up hsa-let-7a-1 "Carcinoma, Hepatocellular" 22027761 This miRNA was up-regulated in HepG2 cells treated with BJA32515. +tissue_expression_up hsa-let-7a-2 "Carcinoma, Hepatocellular" 22027761 This miRNA was up-regulated in HepG2 cells treated with BJA32515. +tissue_expression_up hsa-let-7a-3 "Carcinoma, Hepatocellular" 22027761 This miRNA was up-regulated in HepG2 cells treated with BJA32515. +tissue_expression_up hsa-mir-105-1 "Carcinoma, Hepatocellular" 22027761 This miRNA was up-regulated in HepG2 cells treated with BJA32515. +tissue_expression_up hsa-mir-105-2 "Carcinoma, Hepatocellular" 22027761 This miRNA was up-regulated in HepG2 cells treated with BJA32515. +tissue_expression_up hsa-mir-106a "Carcinoma, Hepatocellular" 22027761 This miRNA was up-regulated in HepG2 cells treated with BJA32515. +tissue_expression_up hsa-mir-10b "Carcinoma, Hepatocellular" 22027761 This miRNA was up-regulated in HepG2 cells treated with BJA32515. +tissue_expression_up hsa-mir-146a "Carcinoma, Hepatocellular" 22027761 This miRNA was up-regulated in HepG2 cells treated with BJA32515. +tissue_expression_up hsa-mir-148b "Carcinoma, Hepatocellular" 22027761 This miRNA was up-regulated in HepG2 cells treated with BJA32515. +tissue_expression_up hsa-mir-17 "Carcinoma, Hepatocellular" 22027761 This miRNA was up-regulated in HepG2 cells treated with BJA32515. +tissue_expression_up hsa-mir-182 "Carcinoma, Hepatocellular" 22027761 This miRNA was up-regulated in HepG2 cells treated with BJA32515. +tissue_expression_up hsa-mir-193a "Carcinoma, Hepatocellular" 22027761 This miRNA was up-regulated in HepG2 cells treated with BJA32515. +tissue_expression_up hsa-mir-196a-1 "Carcinoma, Hepatocellular" 22027761 This miRNA was up-regulated in HepG2 cells treated with BJA32515. +tissue_expression_up hsa-mir-196a-2 "Carcinoma, Hepatocellular" 22027761 This miRNA was up-regulated in HepG2 cells treated with BJA32515. +tissue_expression_up hsa-mir-205 "Carcinoma, Hepatocellular" 22027761 This miRNA was up-regulated in HepG2 cells treated with BJA32515. +tissue_expression_up hsa-mir-21 "Carcinoma, Hepatocellular" 22027761 This miRNA was up-regulated in HepG2 cells treated with BJA32515. +tissue_expression_up hsa-mir-210 "Carcinoma, Hepatocellular" 22027761 This miRNA was up-regulated in HepG2 cells treated with BJA32515. +tissue_expression_up hsa-mir-217 "Carcinoma, Hepatocellular" 22027761 This miRNA was up-regulated in HepG2 cells treated with BJA32515. +tissue_expression_up hsa-mir-222 "Carcinoma, Hepatocellular" 22027761 This miRNA was up-regulated in HepG2 cells treated with BJA32515. +tissue_expression_up hsa-mir-25 "Carcinoma, Hepatocellular" 22027761 This miRNA was up-regulated in HepG2 cells treated with BJA32515. +tissue_expression_up hsa-mir-29a "Carcinoma, Hepatocellular" 22027761 This miRNA was up-regulated in HepG2 cells treated with BJA32515. +tissue_expression_up hsa-mir-302b "Carcinoma, Hepatocellular" 22027761 This miRNA was up-regulated in HepG2 cells treated with BJA32515. +tissue_expression_up hsa-mir-302c "Carcinoma, Hepatocellular" 22027761 This miRNA was up-regulated in HepG2 cells treated with BJA32515. +tissue_expression_up hsa-mir-30a "Carcinoma, Hepatocellular" 22027761 This miRNA was up-regulated in HepG2 cells treated with BJA32515. +tissue_expression_up hsa-mir-34c "Carcinoma, Hepatocellular" 22027761 This miRNA was up-regulated in HepG2 cells treated with BJA32515. +tissue_expression_up hsa-mir-372 "Carcinoma, Hepatocellular" 22027761 This miRNA was up-regulated in HepG2 cells treated with BJA32515. +tissue_expression_up hsa-mir-376a-1 "Carcinoma, Hepatocellular" 22027761 This miRNA was up-regulated in HepG2 cells treated with BJA32515. +tissue_expression_up hsa-mir-376a-2 "Carcinoma, Hepatocellular" 22027761 This miRNA was up-regulated in HepG2 cells treated with BJA32515. +tissue_expression_up hsa-mir-379 "Carcinoma, Hepatocellular" 22027761 This miRNA was up-regulated in HepG2 cells treated with BJA32515. +tissue_expression_up hsa-mir-432 "Carcinoma, Hepatocellular" 22027761 This miRNA was up-regulated in HepG2 cells treated with BJA32515. +tissue_expression_up hsa-mir-450a-1 "Carcinoma, Hepatocellular" 22027761 This miRNA was up-regulated in HepG2 cells treated with BJA32515. +tissue_expression_up hsa-mir-450a-2 "Carcinoma, Hepatocellular" 22027761 This miRNA was up-regulated in HepG2 cells treated with BJA32515. +tissue_expression_up hsa-mir-450b "Carcinoma, Hepatocellular" 22027761 This miRNA was up-regulated in HepG2 cells treated with BJA32515. +tissue_expression_up hsa-mir-493 "Carcinoma, Hepatocellular" 22027761 This miRNA was up-regulated in HepG2 cells treated with BJA32515. +tissue_expression_up hsa-mir-508 "Carcinoma, Hepatocellular" 22027761 This miRNA was up-regulated in HepG2 cells treated with BJA32515. +tissue_expression_up hsa-mir-517c "Carcinoma, Hepatocellular" 22027761 This miRNA was up-regulated in HepG2 cells treated with BJA32515. +tissue_expression_up hsa-mir-519e "Carcinoma, Hepatocellular" 22027761 This miRNA was up-regulated in HepG2 cells treated with BJA32515. +tissue_expression_up hsa-mir-96 "Carcinoma, Hepatocellular" 22027761 This miRNA was up-regulated in HepG2 cells treated with BJA32515. +tissue_expression_up hsa-mir-98 "Carcinoma, Hepatocellular" 22027761 This miRNA was up-regulated in HepG2 cells treated with BJA32515. +tissue_expression_up hsa-mir-223 Rheumatoid Arthritis 22032299 miR-223 is overexpressed in T-lymphocytes of early rheumatoid arthritis patients. +tissue_expression_up hsa-mir-146a Sjogren Syndrome 22033216 "We found that both miR-146a and miR-146b, furthermore, the gene of TRAF6 were significantly overexpressed in the Sjogren's patients, whereas the expression of IRAK1 gene was significantly decreased." +tissue_expression_up hsa-mir-146b Sjogren Syndrome 22033216 "We found that both miR-146a and miR-146b, furthermore, the gene of TRAF6 were significantly overexpressed in the Sjogren's patients, whereas the expression of IRAK1 gene was significantly decreased." +tissue_expression_up hsa-mir-21 "Cardiomyopathy, Dilated" 22041329 "Levels of let-7i, miR-126, and miR-155 were lower in the DCM group than in the controls, whereas levels of miR-21 and TLR4 (both mRNA and protein) were higher in the DCM group than in the control group. Levels of let-7i were negatively correlated with TLR4 protein levels in all subjects. After a mean follow-up period of 509 days, 6 DCM patients (5.8%) had died due to a cardiac cause and 15 (14.6%) had developed heart failure. When patients with DCM were divided into tertiles according to let-7i levels, log-rank analysis showed that the DCM subgroup with low let-7i levels was associated with poor clinical outcomes (P = .02)." +tissue_expression_up hsa-mir-1300 Pancreatic Neoplasms 22042419 "Among aberrantly expressed 122 microRNAs in IPMN, miR-552, miR-25*, miR-183, miR-1300, miR-196a, miR-182*, and miR-30c-1* were consistently increased more than 3-fold." +tissue_expression_up hsa-mir-182 Pancreatic Neoplasms 22042419 "Among aberrantly expressed 122 microRNAs in IPMN, miR-552, miR-25*, miR-183, miR-1300, miR-196a, miR-182*, and miR-30c-1* were consistently increased more than 3-fold." +tissue_expression_up hsa-mir-183 Pancreatic Neoplasms 22042419 "Among aberrantly expressed 122 microRNAs in IPMN, miR-552, miR-25*, miR-183, miR-1300, miR-196a, miR-182*, and miR-30c-1* were consistently increased more than 3-fold." +tissue_expression_up hsa-mir-196a Pancreatic Neoplasms 22042419 "Among aberrantly expressed 122 microRNAs in IPMN, miR-552, miR-25*, miR-183, miR-1300, miR-196a, miR-182*, and miR-30c-1* were consistently increased more than 3-fold." +tissue_expression_up hsa-mir-25 Pancreatic Neoplasms 22042419 "Among aberrantly expressed 122 microRNAs in IPMN, miR-552, miR-25*, miR-183, miR-1300, miR-196a, miR-182*, and miR-30c-1* were consistently increased more than 3-fold." +tissue_expression_up hsa-mir-30c Pancreatic Neoplasms 22042419 "Among aberrantly expressed 122 microRNAs in IPMN, miR-552, miR-25*, miR-183, miR-1300, miR-196a, miR-182*, and miR-30c-1* were consistently increased more than 3-fold." +tissue_expression_up hsa-mir-552 Pancreatic Neoplasms 22042419 "Among aberrantly expressed 122 microRNAs in IPMN, miR-552, miR-25*, miR-183, miR-1300, miR-196a, miR-182*, and miR-30c-1* were consistently increased more than 3-fold." +tissue_expression_up hsa-mir-106b Periodontal Diseases 22043006 "Two microRNA species (miR-30e, miR-106b) were up-regulated in non-obese individuals with periodontal disease." +tissue_expression_up hsa-mir-18a Obesity 22043006 "Two microRNA species (miR-18a, miR-30e) were up-regulated among obese individuals with a healthy periodontium." +tissue_expression_up hsa-mir-30e Obesity 22043006 "Two microRNA species (miR-18a, miR-30e) were up-regulated among obese individuals with a healthy periodontium." +tissue_expression_up hsa-mir-30e Periodontal Diseases 22043006 "Two microRNA species (miR-30e, miR-106b) were up-regulated in non-obese individuals with periodontal disease." +tissue_expression_up hsa-mir-101 Colon Neoplasms 22043014 "The development of colonic inflammation in IL-10(-/-) mice was accompanied by upregulation in the expression of 10 miRNAs (miR-19a, miR-21, miR-31, miR-101, miR-223, miR-326, miR-142-3p, miR-142-5p, miR-146a, and miR-155)" +tissue_expression_up hsa-mir-142 Colon Neoplasms 22043014 "The development of colonic inflammation in IL-10(-/-) mice was accompanied by upregulation in the expression of 10 miRNAs (miR-19a, miR-21, miR-31, miR-101, miR-223, miR-326, miR-142-3p, miR-142-5p, miR-146a, and miR-155)" +tissue_expression_up hsa-mir-146a Colon Neoplasms 22043014 "The development of colonic inflammation in IL-10(-/-) mice was accompanied by upregulation in the expression of 10 miRNAs (miR-19a, miR-21, miR-31, miR-101, miR-223, miR-326, miR-142-3p, miR-142-5p, miR-146a, and miR-155)" +tissue_expression_up hsa-mir-155 Colon Neoplasms 22043014 "The development of colonic inflammation in IL-10(-/-) mice was accompanied by upregulation in the expression of 10 miRNAs (miR-19a, miR-21, miR-31, miR-101, miR-223, miR-326, miR-142-3p, miR-142-5p, miR-146a, and miR-155)" +tissue_expression_up hsa-mir-19a Colon Neoplasms 22043014 "The development of colonic inflammation in IL-10(-/-) mice was accompanied by upregulation in the expression of 10 miRNAs (miR-19a, miR-21, miR-31, miR-101, miR-223, miR-326, miR-142-3p, miR-142-5p, miR-146a, and miR-155)" +tissue_expression_up hsa-mir-21 Colon Neoplasms 22043014 "The development of colonic inflammation in IL-10(-/-) mice was accompanied by upregulation in the expression of 10 miRNAs (miR-19a, miR-21, miR-31, miR-101, miR-223, miR-326, miR-142-3p, miR-142-5p, miR-146a, and miR-155)" +tissue_expression_up hsa-mir-223 Colon Neoplasms 22043014 "The development of colonic inflammation in IL-10(-/-) mice was accompanied by upregulation in the expression of 10 miRNAs (miR-19a, miR-21, miR-31, miR-101, miR-223, miR-326, miR-142-3p, miR-142-5p, miR-146a, and miR-155)" +tissue_expression_up hsa-mir-31 Colon Neoplasms 22043014 "The development of colonic inflammation in IL-10(-/-) mice was accompanied by upregulation in the expression of 10 miRNAs (miR-19a, miR-21, miR-31, miR-101, miR-223, miR-326, miR-142-3p, miR-142-5p, miR-146a, and miR-155)" +tissue_expression_up hsa-mir-326 Colon Neoplasms 22043014 "The development of colonic inflammation in IL-10(-/-) mice was accompanied by upregulation in the expression of 10 miRNAs (miR-19a, miR-21, miR-31, miR-101, miR-223, miR-326, miR-142-3p, miR-142-5p, miR-146a, and miR-155)" +tissue_expression_up hsa-mir-210 "Carcinoma, Renal Cell" 22043236 "For miR-92a, and a striking inverse correlation with VHL mRNA levels was found. For the hypoxia-regulated miR-210, clear cell tumors showed significantly higher expression levels when compared to tumor of non-clear cell histology (9.90-fold vs. 1.36, p<0.001)." +tissue_expression_up hsa-mir-92a-1 "Carcinoma, Renal Cell" 22043236 "For miR-92a, and a striking inverse correlation with VHL mRNA levels was found. For the hypoxia-regulated miR-210, clear cell tumors showed significantly higher expression levels when compared to tumor of non-clear cell histology (9.90-fold vs. 1.36, p<0.001)." +tissue_expression_up hsa-mir-92a-2 "Carcinoma, Renal Cell" 22043236 "For miR-92a, and a striking inverse correlation with VHL mRNA levels was found. For the hypoxia-regulated miR-210, clear cell tumors showed significantly higher expression levels when compared to tumor of non-clear cell histology (9.90-fold vs. 1.36, p<0.001)." +tissue_expression_up hsa-mir-146a Creutzfeldt-Jakob Disease 22043907 "Upregulation of micro RNA-146a (miRNA-146a), a marker for inflammatory neurodegeneration, in sporadic Creutzfeldt-Jakob disease (sCJD) and Gerstmann-Straussler-Scheinker (GSS) syndrome." +tissue_expression_up hsa-mir-146a Gerstmann-Straussler-Scheinker Syndrome 22043907 "Upregulation of micro RNA-146a (miRNA-146a), a marker for inflammatory neurodegeneration, in sporadic Creutzfeldt-Jakob disease (sCJD) and Gerstmann-Straussler-Scheinker (GSS) syndrome." +tissue_expression_up hsa-mir-182 Prostate Neoplasms 22045813 The miR-183-96-182 cluster is overexpressed in prostate tissue and regulates zinc homeostasis in prostate cells. +tissue_expression_up hsa-mir-183 Prostate Neoplasms 22045813 The miR-183-96-182 cluster is overexpressed in prostate tissue and regulates zinc homeostasis in prostate cells. +tissue_expression_up hsa-mir-96 Prostate Neoplasms 22045813 The miR-183-96-182 cluster is overexpressed in prostate tissue and regulates zinc homeostasis in prostate cells. +tissue_expression_up hsa-mir-195 Gastric Neoplasms 22046085 "Three miRs, miR-451, miR-199a-3p and miR-195 were found to be differentially expressed in tumors from patients with good prognosis vs patients with bad prognosis (P < 0.0002, 0.0027 and 0.0046 respectively). High expression of each miR was associated with poorer prognosis for both recurrence and survival. Using miR-451, the positive predictive value for non-recurrence was 100% (13/13)." +tissue_expression_up hsa-mir-199a-1 Gastric Neoplasms 22046085 "Three miRs, miR-451, miR-199a-3p and miR-195 were found to be differentially expressed in tumors from patients with good prognosis vs patients with bad prognosis (P < 0.0002, 0.0027 and 0.0046 respectively). High expression of each miR was associated with poorer prognosis for both recurrence and survival. Using miR-451, the positive predictive value for non-recurrence was 100% (13/13)." +tissue_expression_up hsa-mir-199a-2 Gastric Neoplasms 22046085 "Three miRs, miR-451, miR-199a-3p and miR-195 were found to be differentially expressed in tumors from patients with good prognosis vs patients with bad prognosis (P < 0.0002, 0.0027 and 0.0046 respectively). High expression of each miR was associated with poorer prognosis for both recurrence and survival. Using miR-451, the positive predictive value for non-recurrence was 100% (13/13)." +tissue_expression_up hsa-mir-451a Gastric Neoplasms 22046085 "Three miRs, miR-451, miR-199a-3p and miR-195 were found to be differentially expressed in tumors from patients with good prognosis vs patients with bad prognosis (P < 0.0002, 0.0027 and 0.0046 respectively). High expression of each miR was associated with poorer prognosis for both recurrence and survival. Using miR-451, the positive predictive value for non-recurrence was 100% (13/13)." +tissue_expression_up hsa-mir-96 "Carcinoma, Lung, Non-Small-Cell" 22046296 hsa-mir-96 is significantly and consistently up-regulated in all 6 NSCLCs. +tissue_expression_up hsa-mir-135a-1 Ependymoma 22053178 overexpression +tissue_expression_up hsa-mir-135a-2 Ependymoma 22053178 overexpression +tissue_expression_up hsa-mir-17 Ependymoma 22053178 miR-17-5p: overexpression +tissue_expression_up hsa-mir-10b Breast Neoplasms 22057972 "High level of miR-21, miR-10b, and miR-31 expression in bilateral vs. unilateral breast carcinomas." +tissue_expression_up hsa-mir-21 Breast Neoplasms 22057972 "High level of miR-21, miR-10b, and miR-31 expression in bilateral vs. unilateral breast carcinomas." +tissue_expression_up hsa-mir-31 Breast Neoplasms 22057972 "High level of miR-21, miR-10b, and miR-31 expression in bilateral vs. unilateral breast carcinomas." +tissue_expression_up hsa-mir-3163 Glioblastoma 22074483 "Significantly deregulated miRNAs were miR-3163 (fold change 2.0, p = 0.05), miR-539 (fold change 0.5, p = 0.001), miR-1305 (fold change 0.5, p = 0.05), miR-1260 (fold change 0.5, p = 0.03) and let-7a (fold change 0.3, p = 0.02) after temozolomide treatment." +tissue_expression_up hsa-mir-31 "Carcinoma, Oral" 22083872 "Salivary miR-31 was significantly increased in patients with oral carcinoma at all clinical stages, including very small tumors. However, our preliminary analysis showed no increase of salivary miR-31in patients with oral verrucous leukoplakia relative to controls. The miR-31 was more abundant in saliva than in plasma, suggesting salivary miR-31 was a more sensitive marker for oral malignancy. After excision of oral carcinoma, salivary miR-31 was remarkably reduced, indicating that most of the upregulated salivary miR-31 came from tumor tissues." +tissue_expression_up hsa-mir-128-1 Multiple Sclerosis 22088562 "miR-128 and miR-27b were increased in naive and miR-340 in memory CD4(+) T cells from patients with multiple sclerosis, inhibiting Th2 cell development and favouring pro-inflammatory Th1 responses." +tissue_expression_up hsa-mir-128-2 Multiple Sclerosis 22088562 "miR-128 and miR-27b were increased in naive and miR-340 in memory CD4(+) T cells from patients with multiple sclerosis, inhibiting Th2 cell development and favouring pro-inflammatory Th1 responses." +tissue_expression_up hsa-mir-27b Multiple Sclerosis 22088562 "miR-128 and miR-27b were increased in naive and miR-340 in memory CD4(+) T cells from patients with multiple sclerosis, inhibiting Th2 cell development and favouring pro-inflammatory Th1 responses." +tissue_expression_up hsa-mir-192 Barrett Esophagus 22094011 "We demonstrated unequivocal statistically significant upregulation of two microRNAs (miR-192, 196a) and downregulation of miR-203 and positive miR-196a correlation with progression from intestinal metaplasia to adenocarcinoma compared to normal individuals." +tissue_expression_up hsa-mir-196a-1 Barrett Esophagus 22094011 "We demonstrated unequivocal statistically significant upregulation of two microRNAs (miR-192, 196a) and downregulation of miR-203 and positive miR-196a correlation with progression from intestinal metaplasia to adenocarcinoma compared to normal individuals." +tissue_expression_up hsa-mir-196a-2 Barrett Esophagus 22094011 "We demonstrated unequivocal statistically significant upregulation of two microRNAs (miR-192, 196a) and downregulation of miR-203 and positive miR-196a correlation with progression from intestinal metaplasia to adenocarcinoma compared to normal individuals." +tissue_expression_up hsa-mir-155 Breast Neoplasms 22105810 "The relative expression of miR-155 was significantly higher in breast cancer tissues than in corresponding nontumor tissues. High miR-155 expression was correlated with higher tumor grade, advanced tumor stage and lymph node metastasis (P=0.012, 0.001, and 0.003, respectively). Kaplan-Meier survival analysis indicated that the disease-free and overall survival rates of high miR-155 group were significantly lower than those of low miR-155 group (P=0.038 and 0.029, respectively). Multivariate analysis showed that high miR-155 expression was a poor prognostic factor (P=0.009). Furthermore, antisense targeting miR-155 could inhibit growth, induce cell arrest in G(0) /G(1) phase, enhance apoptosis, and increase radiosensitivity in breast cancer cells." +tissue_expression_up hsa-let-7a Pancreatic Neoplasms 22108826 "These effects were associated with decreased expression of EZH2 and increased expression of a panel of tumor-suppressive microRNAs (miRNA), including let-7a, b, c, d, miR-26a, miR-101, miR-146a, andmiR-200b, c that are typically lost in pancreatic cancer." +tissue_expression_up hsa-let-7b Pancreatic Neoplasms 22108826 "These effects were associated with decreased expression of EZH2 and increased expression of a panel of tumor-suppressive microRNAs (miRNA), including let-7a, b, c, d, miR-26a, miR-101, miR-146a, andmiR-200b, c that are typically lost in pancreatic cancer." +tissue_expression_up hsa-let-7c Pancreatic Neoplasms 22108826 "These effects were associated with decreased expression of EZH2 and increased expression of a panel of tumor-suppressive microRNAs (miRNA), including let-7a, b, c, d, miR-26a, miR-101, miR-146a, andmiR-200b, c that are typically lost in pancreatic cancer." +tissue_expression_up hsa-let-7d Pancreatic Neoplasms 22108826 "These effects were associated with decreased expression of EZH2 and increased expression of a panel of tumor-suppressive microRNAs (miRNA), including let-7a, b, c, d, miR-26a, miR-101, miR-146a, andmiR-200b, c that are typically lost in pancreatic cancer." +tissue_expression_up hsa-mir-101 Pancreatic Neoplasms 22108826 "These effects were associated with decreased expression of EZH2 and increased expression of a panel of tumor-suppressive microRNAs (miRNA), including let-7a, b, c, d, miR-26a, miR-101, miR-146a, andmiR-200b, c that are typically lost in pancreatic cancer." +tissue_expression_up hsa-mir-146a Pancreatic Neoplasms 22108826 "These effects were associated with decreased expression of EZH2 and increased expression of a panel of tumor-suppressive microRNAs (miRNA), including let-7a, b, c, d, miR-26a, miR-101, miR-146a, andmiR-200b, c that are typically lost in pancreatic cancer." +tissue_expression_up hsa-mir-200b Pancreatic Neoplasms 22108826 "These effects were associated with decreased expression of EZH2 and increased expression of a panel of tumor-suppressive microRNAs (miRNA), including let-7a, b, c, d, miR-26a, miR-101, miR-146a, andmiR-200b, c that are typically lost in pancreatic cancer." +tissue_expression_up hsa-mir-200c Pancreatic Neoplasms 22108826 "These effects were associated with decreased expression of EZH2 and increased expression of a panel of tumor-suppressive microRNAs (miRNA), including let-7a, b, c, d, miR-26a, miR-101, miR-146a, andmiR-200b, c that are typically lost in pancreatic cancer." +tissue_expression_up hsa-mir-26a Pancreatic Neoplasms 22108826 "These effects were associated with decreased expression of EZH2 and increased expression of a panel of tumor-suppressive microRNAs (miRNA), including let-7a, b, c, d, miR-26a, miR-101, miR-146a, andmiR-200b, c that are typically lost in pancreatic cancer." +tissue_expression_up hsa-mir-21 Pancreatic Neoplasms 22114136 "In the initial cohort of 48 PDAC (pancreatic ductal adenocarcinoma) patients, high expression of miR-21 (Hazard ratio (HR): 3.22, 95% Confidence Interval (CI):1.21-8.58) and reduced expression of miR-34a (HR 0.15, 95%CI: 0.06-0.37) and miR-30d (HR:0.30, 95%CI:0.12-0.79) were associated with poor overall survival following resection independent of clinical covariates. In a further validation set of 24 patients miR-21 and miR-34a expression again significantly correlated with overall survival (P = 0.031 and P = 0.001)." +tissue_expression_up hsa-mir-122 Hepatitis C Virus Infection 22114337 "A high level of miR122 was expressed by lentiviral vector into human liver cell lines at a level comparable to the endogenous level in Huh7 cells. Among the cell lines we examined, Hep3B cells stably expressing miR122 (Hep3B/miR122) exhibited a significant enhancement of HCVcc propagation. Surprisingly, the productions of infectious particles in Hep3B/miR122 cells upon infection with HCVcc were comparable to those in Huh7 cells. Furthermore, a line of cured cells established by elimination of HCV RNA from the Hep3B/miR122 replicon cells exhibited an enhanced expression of miR122 and a continuous increase of infectious titers of HCVcc in every passage." +tissue_expression_up hsa-mir-10b Pancreatic Neoplasms 22117151 "miR-10b is upregulated in pancreatic ductal adenocarcinoma and can be used as a diagnostic marker in endoscopic ultrasound-guided fine-needle aspiration biopsies of suspicious pancreatic lesions. In addition, miR-10b may be able to guide neoadjuvant gemcitabine-based chemoradiotherapy and predict metastatic-free survival and overall survival." +tissue_expression_up hsa-mir-221 Prostate Neoplasms 22117988 "The level of ARHI mRNA was significantly lower in aggressive compared with non-aggressive prostate cancer tissue samples. In contrast, microRNA 221 and 222 levels were significantly higher in aggressive compared with non-aggressive prostate cancer tissue samples." +tissue_expression_up hsa-mir-222 Prostate Neoplasms 22117988 "The level of ARHI mRNA was significantly lower in aggressive compared with non-aggressive prostate cancer tissue samples. In contrast, microRNA 221 and 222 levels were significantly higher in aggressive compared with non-aggressive prostate cancer tissue samples." +tissue_expression_up hsa-let-7a-1 Colorectal Carcinoma 22120473 "Increased expression of miR-21, mir-135a and miR-335 was associated with clinical progression of CRC (colorectal cancer), while miR-206 demonstrated an opposite trend. The levels of mir-21 did not associate with the expression of PTEN, an important tumour suppressor in CRC and one of many putative targets of miR-21, but interestingly was associated with stage of disease in the PTEN expressing tumours. Surprisingly, let7a, a KRAS-targeting miR, showed elevated expression in metastatic disease compared to normal mucosa or non-metastatic disease, and only in KRAS mutation positive tumors. Finally, a prognostic signature of miR 21,135a, 335, 206 and let-7a for detecting the presence of metastases had a specificity of 87% and sensitivity of 76% for the presence of metastases." +tissue_expression_up hsa-let-7a-2 Colorectal Carcinoma 22120473 "Increased expression of miR-21, mir-135a and miR-335 was associated with clinical progression of CRC (colorectal cancer), while miR-206 demonstrated an opposite trend. The levels of mir-21 did not associate with the expression of PTEN, an important tumour suppressor in CRC and one of many putative targets of miR-21, but interestingly was associated with stage of disease in the PTEN expressing tumours. Surprisingly, let7a, a KRAS-targeting miR, showed elevated expression in metastatic disease compared to normal mucosa or non-metastatic disease, and only in KRAS mutation positive tumors. Finally, a prognostic signature of miR 21,135a, 335, 206 and let-7a for detecting the presence of metastases had a specificity of 87% and sensitivity of 76% for the presence of metastases." +tissue_expression_up hsa-let-7a-3 Colorectal Carcinoma 22120473 "Increased expression of miR-21, mir-135a and miR-335 was associated with clinical progression of CRC (colorectal cancer), while miR-206 demonstrated an opposite trend. The levels of mir-21 did not associate with the expression of PTEN, an important tumour suppressor in CRC and one of many putative targets of miR-21, but interestingly was associated with stage of disease in the PTEN expressing tumours. Surprisingly, let7a, a KRAS-targeting miR, showed elevated expression in metastatic disease compared to normal mucosa or non-metastatic disease, and only in KRAS mutation positive tumors. Finally, a prognostic signature of miR 21,135a, 335, 206 and let-7a for detecting the presence of metastases had a specificity of 87% and sensitivity of 76% for the presence of metastases." +tissue_expression_up hsa-mir-135a-1 Colorectal Carcinoma 22120473 "Increased expression of miR-21, mir-135a and miR-335 was associated with clinical progression of CRC (colorectal cancer), while miR-206 demonstrated an opposite trend. The levels of mir-21 did not associate with the expression of PTEN, an important tumour suppressor in CRC and one of many putative targets of miR-21, but interestingly was associated with stage of disease in the PTEN expressing tumours. Surprisingly, let7a, a KRAS-targeting miR, showed elevated expression in metastatic disease compared to normal mucosa or non-metastatic disease, and only in KRAS mutation positive tumors. Finally, a prognostic signature of miR 21,135a, 335, 206 and let-7a for detecting the presence of metastases had a specificity of 87% and sensitivity of 76% for the presence of metastases." +tissue_expression_up hsa-mir-135a-2 Colorectal Carcinoma 22120473 "Increased expression of miR-21, mir-135a and miR-335 was associated with clinical progression of CRC (colorectal cancer), while miR-206 demonstrated an opposite trend. The levels of mir-21 did not associate with the expression of PTEN, an important tumour suppressor in CRC and one of many putative targets of miR-21, but interestingly was associated with stage of disease in the PTEN expressing tumours. Surprisingly, let7a, a KRAS-targeting miR, showed elevated expression in metastatic disease compared to normal mucosa or non-metastatic disease, and only in KRAS mutation positive tumors. Finally, a prognostic signature of miR 21,135a, 335, 206 and let-7a for detecting the presence of metastases had a specificity of 87% and sensitivity of 76% for the presence of metastases." +tissue_expression_up hsa-mir-21 Colorectal Carcinoma 22120473 "Increased expression of miR-21, mir-135a and miR-335 was associated with clinical progression of CRC (colorectal cancer), while miR-206 demonstrated an opposite trend. The levels of mir-21 did not associate with the expression of PTEN, an important tumour suppressor in CRC and one of many putative targets of miR-21, but interestingly was associated with stage of disease in the PTEN expressing tumours. Surprisingly, let7a, a KRAS-targeting miR, showed elevated expression in metastatic disease compared to normal mucosa or non-metastatic disease, and only in KRAS mutation positive tumors. Finally, a prognostic signature of miR 21,135a, 335, 206 and let-7a for detecting the presence of metastases had a specificity of 87% and sensitivity of 76% for the presence of metastases." +tissue_expression_up hsa-mir-335 Colorectal Carcinoma 22120473 "Increased expression of miR-21, mir-135a and miR-335 was associated with clinical progression of CRC (colorectal cancer), while miR-206 demonstrated an opposite trend. The levels of mir-21 did not associate with the expression of PTEN, an important tumour suppressor in CRC and one of many putative targets of miR-21, but interestingly was associated with stage of disease in the PTEN expressing tumours. Surprisingly, let7a, a KRAS-targeting miR, showed elevated expression in metastatic disease compared to normal mucosa or non-metastatic disease, and only in KRAS mutation positive tumors. Finally, a prognostic signature of miR 21,135a, 335, 206 and let-7a for detecting the presence of metastases had a specificity of 87% and sensitivity of 76% for the presence of metastases." +tissue_expression_up hsa-let-7a-1 Periodontitis 22128589 "Six miRNA genes, let-7a, let-7c, miR-130a, miR301a, miR-520d, and miR-548a, were up-regulated more than 8 fold compared to the healthy gingiva. miR-181b, miR-19b, miR-23a, miR-30a, miR-let7a, and miR-301a, were amplified successfully and increased much more in periodontitis gingivae than in healthy ones." +tissue_expression_up hsa-let-7a-2 Periodontitis 22128589 "Six miRNA genes, let-7a, let-7c, miR-130a, miR301a, miR-520d, and miR-548a, were up-regulated more than 8 fold compared to the healthy gingiva. miR-181b, miR-19b, miR-23a, miR-30a, miR-let7a, and miR-301a, were amplified successfully and increased much more in periodontitis gingivae than in healthy ones." +tissue_expression_up hsa-let-7a-3 Periodontitis 22128589 "Six miRNA genes, let-7a, let-7c, miR-130a, miR301a, miR-520d, and miR-548a, were up-regulated more than 8 fold compared to the healthy gingiva. miR-181b, miR-19b, miR-23a, miR-30a, miR-let7a, and miR-301a, were amplified successfully and increased much more in periodontitis gingivae than in healthy ones." +tissue_expression_up hsa-let-7c Periodontitis 22128589 "Six miRNA genes, let-7a, let-7c, miR-130a, miR301a, miR-520d, and miR-548a, were up-regulated more than 8 fold compared to the healthy gingiva. miR-181b, miR-19b, miR-23a, miR-30a, miR-let7a, and miR-301a, were amplified successfully and increased much more in periodontitis gingivae than in healthy ones." +tissue_expression_up hsa-mir-130a Periodontitis 22128589 "Six miRNA genes, let-7a, let-7c, miR-130a, miR301a, miR-520d, and miR-548a, were up-regulated more than 8 fold compared to the healthy gingiva. miR-181b, miR-19b, miR-23a, miR-30a, miR-let7a, and miR-301a, were amplified successfully and increased much more in periodontitis gingivae than in healthy ones." +tissue_expression_up hsa-mir-181b-1 Periodontitis 22128589 "Six miRNA genes, let-7a, let-7c, miR-130a, miR301a, miR-520d, and miR-548a, were up-regulated more than 8 fold compared to the healthy gingiva. miR-181b, miR-19b, miR-23a, miR-30a, miR-let7a, and miR-301a, were amplified successfully and increased much more in periodontitis gingivae than in healthy ones." +tissue_expression_up hsa-mir-181b-2 Periodontitis 22128589 "Six miRNA genes, let-7a, let-7c, miR-130a, miR301a, miR-520d, and miR-548a, were up-regulated more than 8 fold compared to the healthy gingiva. miR-181b, miR-19b, miR-23a, miR-30a, miR-let7a, and miR-301a, were amplified successfully and increased much more in periodontitis gingivae than in healthy ones." +tissue_expression_up hsa-mir-19b-1 Periodontitis 22128589 "Six miRNA genes, let-7a, let-7c, miR-130a, miR301a, miR-520d, and miR-548a, were up-regulated more than 8 fold compared to the healthy gingiva. miR-181b, miR-19b, miR-23a, miR-30a, miR-let7a, and miR-301a, were amplified successfully and increased much more in periodontitis gingivae than in healthy ones." +tissue_expression_up hsa-mir-19b-2 Periodontitis 22128589 "Six miRNA genes, let-7a, let-7c, miR-130a, miR301a, miR-520d, and miR-548a, were up-regulated more than 8 fold compared to the healthy gingiva. miR-181b, miR-19b, miR-23a, miR-30a, miR-let7a, and miR-301a, were amplified successfully and increased much more in periodontitis gingivae than in healthy ones." +tissue_expression_up hsa-mir-23a Periodontitis 22128589 "Six miRNA genes, let-7a, let-7c, miR-130a, miR301a, miR-520d, and miR-548a, were up-regulated more than 8 fold compared to the healthy gingiva. miR-181b, miR-19b, miR-23a, miR-30a, miR-let7a, and miR-301a, were amplified successfully and increased much more in periodontitis gingivae than in healthy ones." +tissue_expression_up hsa-mir-301a Periodontitis 22128589 "Six miRNA genes, let-7a, let-7c, miR-130a, miR301a, miR-520d, and miR-548a, were up-regulated more than 8 fold compared to the healthy gingiva. miR-181b, miR-19b, miR-23a, miR-30a, miR-let7a, and miR-301a, were amplified successfully and increased much more in periodontitis gingivae than in healthy ones." +tissue_expression_up hsa-mir-30a Periodontitis 22128589 "Six miRNA genes, let-7a, let-7c, miR-130a, miR301a, miR-520d, and miR-548a, were up-regulated more than 8 fold compared to the healthy gingiva. miR-181b, miR-19b, miR-23a, miR-30a, miR-let7a, and miR-301a, were amplified successfully and increased much more in periodontitis gingivae than in healthy ones." +tissue_expression_up hsa-mir-520d Periodontitis 22128589 "Six miRNA genes, let-7a, let-7c, miR-130a, miR301a, miR-520d, and miR-548a, were up-regulated more than 8 fold compared to the healthy gingiva. miR-181b, miR-19b, miR-23a, miR-30a, miR-let7a, and miR-301a, were amplified successfully and increased much more in periodontitis gingivae than in healthy ones." +tissue_expression_up hsa-mir-548a-1 Periodontitis 22128589 "Six miRNA genes, let-7a, let-7c, miR-130a, miR301a, miR-520d, and miR-548a, were up-regulated more than 8 fold compared to the healthy gingiva. miR-181b, miR-19b, miR-23a, miR-30a, miR-let7a, and miR-301a, were amplified successfully and increased much more in periodontitis gingivae than in healthy ones." +tissue_expression_up hsa-mir-548a-2 Periodontitis 22128589 "Six miRNA genes, let-7a, let-7c, miR-130a, miR301a, miR-520d, and miR-548a, were up-regulated more than 8 fold compared to the healthy gingiva. miR-181b, miR-19b, miR-23a, miR-30a, miR-let7a, and miR-301a, were amplified successfully and increased much more in periodontitis gingivae than in healthy ones." +tissue_expression_up hsa-mir-548a-3 Periodontitis 22128589 "Six miRNA genes, let-7a, let-7c, miR-130a, miR301a, miR-520d, and miR-548a, were up-regulated more than 8 fold compared to the healthy gingiva. miR-181b, miR-19b, miR-23a, miR-30a, miR-let7a, and miR-301a, were amplified successfully and increased much more in periodontitis gingivae than in healthy ones." +tissue_expression_up hsa-mir-206 Muscular Dystrophy 22129894 The expression of miR-206 is increased in muscular dystrophy. +tissue_expression_up hsa-mir-9-1 Melanoma 22131135 MicroRNA-9 up-regulates E-cadherin through inhibition of NF-kB1-Snail1 pathway in melanoma. +tissue_expression_up hsa-mir-21 Urinary Bladder Cancer 22133680 Nuclear and cytoplasmatic PDCD4 immunostaining decreased significantly with histopathological progression of the tumor (p<0001). Controls showed strong nuclear and cytoplasmatic immunohistochemical staining. MiR-21 up regulation in tissue corresponded to PDCD4 suppression. +tissue_expression_up hsa-mir-146a Lichen Planus 22139425 Increased miRNA-146a and miRNA-155 expressions in oral lichen planus. +tissue_expression_up hsa-mir-155 Lichen Planus 22139425 Increased miRNA-146a and miRNA-155 expressions in oral lichen planus. +tissue_expression_up hsa-mir-187 Gastric Neoplasms 22169097 "Genome-wide miRNA expression profiles followed with Real-Time quantitative RT-PCR (qRT-PCR) assays revealed that miR-187(*), miR-371-5p and miR-378 were significantly elevated in GC patients. Further validation indicated that miR-378 alone could yields a ROC curve area of 0.861 with 87.5% sensitivity and 70.73% specificity in discriminating GC patients from healthy controls." +tissue_expression_up hsa-mir-371a Gastric Neoplasms 22169097 "Genome-wide miRNA expression profiles followed with Real-Time quantitative RT-PCR (qRT-PCR) assays revealed that miR-187(*), miR-371-5p and miR-378 were significantly elevated in GC patients. Further validation indicated that miR-378 alone could yields a ROC curve area of 0.861 with 87.5% sensitivity and 70.73% specificity in discriminating GC patients from healthy controls." +tissue_expression_up hsa-mir-378a Gastric Neoplasms 22169097 "Genome-wide miRNA expression profiles followed with Real-Time quantitative RT-PCR (qRT-PCR) assays revealed that miR-187(*), miR-371-5p and miR-378 were significantly elevated in GC patients. Further validation indicated that miR-378 alone could yields a ROC curve area of 0.861 with 87.5% sensitivity and 70.73% specificity in discriminating GC patients from healthy controls." +tissue_expression_up hsa-mir-375 "Carcinoma, Lung, Small-Cell" 22172490 miR-375 is highly expressed and possibly transactivated by achaete-scute complex homolog 1 in small-cell lung cancer cells. +tissue_expression_up hsa-mir-1183 Rectal Neoplasms 22172905 "Microarray analysis selected 14 miRNAs as being differentially expressed in TRG1 patients, and 13 were confirmed by qRT-PCR: 11 miRNAs (miR-1183, miR-483-5p, miR-622, miR-125a-3p, miR-1224-5p, miR-188-5p, miR-1471, miR-671-5p, miR-1909, miR-630, miR-765) were significantly upregulated in TRG1 patients, 2 (miR-1274b, miR-720) were downexpressed. MiR-622 and miR-630 had a 100% sensitivity and specificity in selecting TRG1 cases." +tissue_expression_up hsa-mir-1224 Rectal Neoplasms 22172905 "Microarray analysis selected 14 miRNAs as being differentially expressed in TRG1 patients, and 13 were confirmed by qRT-PCR: 11 miRNAs (miR-1183, miR-483-5p, miR-622, miR-125a-3p, miR-1224-5p, miR-188-5p, miR-1471, miR-671-5p, miR-1909, miR-630, miR-765) were significantly upregulated in TRG1 patients, 2 (miR-1274b, miR-720) were downexpressed. MiR-622 and miR-630 had a 100% sensitivity and specificity in selecting TRG1 cases." +tissue_expression_up hsa-mir-125a Rectal Neoplasms 22172905 "Microarray analysis selected 14 miRNAs as being differentially expressed in TRG1 patients, and 13 were confirmed by qRT-PCR: 11 miRNAs (miR-1183, miR-483-5p, miR-622, miR-125a-3p, miR-1224-5p, miR-188-5p, miR-1471, miR-671-5p, miR-1909, miR-630, miR-765) were significantly upregulated in TRG1 patients, 2 (miR-1274b, miR-720) were downexpressed. MiR-622 and miR-630 had a 100% sensitivity and specificity in selecting TRG1 cases." +tissue_expression_up hsa-mir-1471 Rectal Neoplasms 22172905 "Microarray analysis selected 14 miRNAs as being differentially expressed in TRG1 patients, and 13 were confirmed by qRT-PCR: 11 miRNAs (miR-1183, miR-483-5p, miR-622, miR-125a-3p, miR-1224-5p, miR-188-5p, miR-1471, miR-671-5p, miR-1909, miR-630, miR-765) were significantly upregulated in TRG1 patients, 2 (miR-1274b, miR-720) were downexpressed. MiR-622 and miR-630 had a 100% sensitivity and specificity in selecting TRG1 cases." +tissue_expression_up hsa-mir-188 Rectal Neoplasms 22172905 "Microarray analysis selected 14 miRNAs as being differentially expressed in TRG1 patients, and 13 were confirmed by qRT-PCR: 11 miRNAs (miR-1183, miR-483-5p, miR-622, miR-125a-3p, miR-1224-5p, miR-188-5p, miR-1471, miR-671-5p, miR-1909, miR-630, miR-765) were significantly upregulated in TRG1 patients, 2 (miR-1274b, miR-720) were downexpressed. MiR-622 and miR-630 had a 100% sensitivity and specificity in selecting TRG1 cases." +tissue_expression_up hsa-mir-1909 Rectal Neoplasms 22172905 "Microarray analysis selected 14 miRNAs as being differentially expressed in TRG1 patients, and 13 were confirmed by qRT-PCR: 11 miRNAs (miR-1183, miR-483-5p, miR-622, miR-125a-3p, miR-1224-5p, miR-188-5p, miR-1471, miR-671-5p, miR-1909, miR-630, miR-765) were significantly upregulated in TRG1 patients, 2 (miR-1274b, miR-720) were downexpressed. MiR-622 and miR-630 had a 100% sensitivity and specificity in selecting TRG1 cases." +tissue_expression_up hsa-mir-483 Rectal Neoplasms 22172905 "Microarray analysis selected 14 miRNAs as being differentially expressed in TRG1 patients, and 13 were confirmed by qRT-PCR: 11 miRNAs (miR-1183, miR-483-5p, miR-622, miR-125a-3p, miR-1224-5p, miR-188-5p, miR-1471, miR-671-5p, miR-1909, miR-630, miR-765) were significantly upregulated in TRG1 patients, 2 (miR-1274b, miR-720) were downexpressed. MiR-622 and miR-630 had a 100% sensitivity and specificity in selecting TRG1 cases." +tissue_expression_up hsa-mir-622 Rectal Neoplasms 22172905 "Microarray analysis selected 14 miRNAs as being differentially expressed in TRG1 patients, and 13 were confirmed by qRT-PCR: 11 miRNAs (miR-1183, miR-483-5p, miR-622, miR-125a-3p, miR-1224-5p, miR-188-5p, miR-1471, miR-671-5p, miR-1909, miR-630, miR-765) were significantly upregulated in TRG1 patients, 2 (miR-1274b, miR-720) were downexpressed. MiR-622 and miR-630 had a 100% sensitivity and specificity in selecting TRG1 cases." +tissue_expression_up hsa-mir-630 Rectal Neoplasms 22172905 "Microarray analysis selected 14 miRNAs as being differentially expressed in TRG1 patients, and 13 were confirmed by qRT-PCR: 11 miRNAs (miR-1183, miR-483-5p, miR-622, miR-125a-3p, miR-1224-5p, miR-188-5p, miR-1471, miR-671-5p, miR-1909, miR-630, miR-765) were significantly upregulated in TRG1 patients, 2 (miR-1274b, miR-720) were downexpressed. MiR-622 and miR-630 had a 100% sensitivity and specificity in selecting TRG1 cases." +tissue_expression_up hsa-mir-671 Rectal Neoplasms 22172905 "Microarray analysis selected 14 miRNAs as being differentially expressed in TRG1 patients, and 13 were confirmed by qRT-PCR: 11 miRNAs (miR-1183, miR-483-5p, miR-622, miR-125a-3p, miR-1224-5p, miR-188-5p, miR-1471, miR-671-5p, miR-1909, miR-630, miR-765) were significantly upregulated in TRG1 patients, 2 (miR-1274b, miR-720) were downexpressed. MiR-622 and miR-630 had a 100% sensitivity and specificity in selecting TRG1 cases." +tissue_expression_up hsa-mir-765 Rectal Neoplasms 22172905 "Microarray analysis selected 14 miRNAs as being differentially expressed in TRG1 patients, and 13 were confirmed by qRT-PCR: 11 miRNAs (miR-1183, miR-483-5p, miR-622, miR-125a-3p, miR-1224-5p, miR-188-5p, miR-1471, miR-671-5p, miR-1909, miR-630, miR-765) were significantly upregulated in TRG1 patients, 2 (miR-1274b, miR-720) were downexpressed. MiR-622 and miR-630 had a 100% sensitivity and specificity in selecting TRG1 cases." +tissue_expression_up hsa-mir-192 Colon Neoplasms 22180714 "Compared with expression in SW1116 cells, 35 miRNAs (including hsa-miR-192, hsa-miR-29b, hsa-miR-215, hsa-miR-194, hsa-miR-33a and hsa-miR-32) were upregulated more than 1.5-fold, and 11 miRNAs (including hsa-miR-93, hsa-miR-1231, hsa-miRPlus-F1080, hsa-miR-524-3p, hsa-miR-886-3p and hsa-miR-561) were downregulated in SW1116csc." +tissue_expression_up hsa-mir-194 Colon Neoplasms 22180714 "Compared with expression in SW1116 cells, 35 miRNAs (including hsa-miR-192, hsa-miR-29b, hsa-miR-215, hsa-miR-194, hsa-miR-33a and hsa-miR-32) were upregulated more than 1.5-fold, and 11 miRNAs (including hsa-miR-93, hsa-miR-1231, hsa-miRPlus-F1080, hsa-miR-524-3p, hsa-miR-886-3p and hsa-miR-561) were downregulated in SW1116csc." +tissue_expression_up hsa-mir-215 Colon Neoplasms 22180714 "Compared with expression in SW1116 cells, 35 miRNAs (including hsa-miR-192, hsa-miR-29b, hsa-miR-215, hsa-miR-194, hsa-miR-33a and hsa-miR-32) were upregulated more than 1.5-fold, and 11 miRNAs (including hsa-miR-93, hsa-miR-1231, hsa-miRPlus-F1080, hsa-miR-524-3p, hsa-miR-886-3p and hsa-miR-561) were downregulated in SW1116csc." +tissue_expression_up hsa-mir-29b Colon Neoplasms 22180714 "Compared with expression in SW1116 cells, 35 miRNAs (including hsa-miR-192, hsa-miR-29b, hsa-miR-215, hsa-miR-194, hsa-miR-33a and hsa-miR-32) were upregulated more than 1.5-fold, and 11 miRNAs (including hsa-miR-93, hsa-miR-1231, hsa-miRPlus-F1080, hsa-miR-524-3p, hsa-miR-886-3p and hsa-miR-561) were downregulated in SW1116csc." +tissue_expression_up hsa-mir-32 Colon Neoplasms 22180714 "Compared with expression in SW1116 cells, 35 miRNAs (including hsa-miR-192, hsa-miR-29b, hsa-miR-215, hsa-miR-194, hsa-miR-33a and hsa-miR-32) were upregulated more than 1.5-fold, and 11 miRNAs (including hsa-miR-93, hsa-miR-1231, hsa-miRPlus-F1080, hsa-miR-524-3p, hsa-miR-886-3p and hsa-miR-561) were downregulated in SW1116csc." +tissue_expression_up hsa-mir-33a Colon Neoplasms 22180714 "Compared with expression in SW1116 cells, 35 miRNAs (including hsa-miR-192, hsa-miR-29b, hsa-miR-215, hsa-miR-194, hsa-miR-33a and hsa-miR-32) were upregulated more than 1.5-fold, and 11 miRNAs (including hsa-miR-93, hsa-miR-1231, hsa-miRPlus-F1080, hsa-miR-524-3p, hsa-miR-886-3p and hsa-miR-561) were downregulated in SW1116csc." +tissue_expression_up hsa-mir-155 Down Syndrome 22182977 "a screening of micro-RNA (miRNA) from Down's syndrome brain and peripheral tissues indicated an upregulation of a chromosome 21-encoded miRNA-155 and a decrease in the abundance of the miRNA-155 mRNA target complement factor H (CFH), an important repressor of the innate immune response." +tissue_expression_up hsa-mir-7-1 "Allergic Rhinitis,Perennial" 22185732 up-regulated +tissue_expression_up hsa-mir-7-2 "Allergic Rhinitis,Perennial" 22185732 up-regulated +tissue_expression_up hsa-mir-7-3 "Allergic Rhinitis,Perennial" 22185732 up-regulated +tissue_expression_up hsa-mir-21 Urinary Bladder Cancer 22194833 mir-21 expression increased with worsening clinical diagnosis but that mir-143 was not correlated with histology. These observations were in stark contrast to previous reports involving cervical cancer cell lines in which mir-143 was consistently down-regulated but mir-21 largely unaffected. +tissue_expression_up hsa-mir-192 Diabetic Nephropathy 22211842 "TGF-beta1 activates Smad3 to regulate microRNAs that mediate renal fibrosis. Of them, miR-21 and miR-192 are upregulated but miR-29 and miR-200 families are downregulated." +tissue_expression_up hsa-mir-21 Diabetic Nephropathy 22211842 "TGF-beta1 activates Smad3 to regulate microRNAs that mediate renal fibrosis. Of them, miR-21 and miR-192 are upregulated but miR-29 and miR-200 families are downregulated." +tissue_expression_up hsa-mir-122 "Carcinoma, Hepatocellular" 22213236 up-regulated in HCC tissues.correlated with cirrhosis +tissue_expression_up hsa-mir-21 "Carcinoma, Hepatocellular" 22213236 up-regulated in HCC tissues.correlated with cirrhosis;associated with tumor stage and poor prognosis. +tissue_expression_up hsa-mir-221 "Carcinoma, Hepatocellular" 22213236 up-regulated in HCC tissues.correlated with cirrhosis;associated with tumor stage and poor prognosis. +tissue_expression_up hsa-mir-222 "Carcinoma, Hepatocellular" 22213236 up-regulated in HCC tissues. +tissue_expression_up hsa-mir-31 "Carcinoma, Hepatocellular" 22213236 up-regulated in HCC tissues.correlated with cirrhosis +tissue_expression_up hsa-mir-155 Pancreatic Neoplasms 22213426 "We found over-expression of miR-21, miR-221, miR-27a, miR-27b, and miR-155, and down-regulation of miR-216a,miR-216b, miR-217, and miR-146a expression in tumors derived from KC and KCI mouse model" +tissue_expression_up hsa-mir-21 Pancreatic Neoplasms 22213426 "We found over-expression of miR-21, miR-221, miR-27a, miR-27b, and miR-155, and down-regulation of miR-216a,miR-216b, miR-217, and miR-146a expression in tumors derived from KC and KCI mouse model" +tissue_expression_up hsa-mir-221 Pancreatic Neoplasms 22213426 "We found over-expression of miR-21, miR-221, miR-27a, miR-27b, and miR-155, and down-regulation of miR-216a,miR-216b, miR-217, and miR-146a expression in tumors derived from KC and KCI mouse model" +tissue_expression_up hsa-mir-27a Pancreatic Neoplasms 22213426 "We found over-expression of miR-21, miR-221, miR-27a, miR-27b, and miR-155, and down-regulation of miR-216a,miR-216b, miR-217, and miR-146a expression in tumors derived from KC and KCI mouse model" +tissue_expression_up hsa-mir-27b Pancreatic Neoplasms 22213426 "We found over-expression of miR-21, miR-221, miR-27a, miR-27b, and miR-155, and down-regulation of miR-216a,miR-216b, miR-217, and miR-146a expression in tumors derived from KC and KCI mouse model" +tissue_expression_up hsa-mir-483 "Diabetes Mellitus, Type 2" 22223106 "Increased miR-483-3p expression in vivo, programmed by early-life nutrition, limits storage of lipids in adipose tissue, causing lipotoxicity and insulin resistance and thus increasing susceptibility to metabolic disease." +tissue_expression_up hsa-mir-155 "Leukemia, Lymphocytic, Chronic, B-Cell" 22238073 SOCS1 is significantly up-regulated in Nutlin-3-treated p53(wild-type) B chronic lymphocytic leukemia (B-CLL) samples and shows an inverse correlation with miR-155. +tissue_expression_up hsa-mir-107 Prostate Neoplasms 22240788 miR-107 and miR-574-3p were quantified at significantly higher concentrations in the urine of men with prostate cancer compared with controls. +tissue_expression_up hsa-mir-574 Prostate Neoplasms 22240788 miR-107 and miR-574-3p were quantified at significantly higher concentrations in the urine of men with prostate cancer compared with controls. +tissue_expression_up hsa-mir-101-1 Pheochromocytoma 22241719 "miR-483-5p, miR-183, and miR-101 had significantly higher expression in malignant tumors as compared to their benign counterparts." +tissue_expression_up hsa-mir-101-2 Pheochromocytoma 22241719 "miR-483-5p, miR-183, and miR-101 had significantly higher expression in malignant tumors as compared to their benign counterparts." +tissue_expression_up hsa-mir-183 Pheochromocytoma 22241719 "miR-483-5p, miR-183, and miR-101 had significantly higher expression in malignant tumors as compared to their benign counterparts." +tissue_expression_up hsa-mir-483 Pheochromocytoma 22241719 "miR-483-5p, miR-183, and miR-101 had significantly higher expression in malignant tumors as compared to their benign counterparts." +tissue_expression_up hsa-mir-221 Liver Cirrhosis 22267590 MicroRNA-221/222 upregulation indicates the activation of stellate cells and the progression of liver fibrosis. +tissue_expression_up hsa-mir-222 Liver Cirrhosis 22267590 MicroRNA-221/222 upregulation indicates the activation of stellate cells and the progression of liver fibrosis. +tissue_expression_up hsa-let-7a-1 Cholesteatoma 22289526 "Levels of miR-21 and let-7a microRNA were significantly higher in cholesteatoma tissue compared with normal skin, especially in paediatric patients." +tissue_expression_up hsa-let-7a-2 Cholesteatoma 22289526 "Levels of miR-21 and let-7a microRNA were significantly higher in cholesteatoma tissue compared with normal skin, especially in paediatric patients." +tissue_expression_up hsa-let-7a-3 Cholesteatoma 22289526 "Levels of miR-21 and let-7a microRNA were significantly higher in cholesteatoma tissue compared with normal skin, especially in paediatric patients." +tissue_expression_up hsa-mir-21 Cholesteatoma 22289526 "Levels of miR-21 and let-7a microRNA were significantly higher in cholesteatoma tissue compared with normal skin, especially in paediatric patients." +tissue_expression_up hsa-mir-21 Colorectal Carcinoma 22289545 There was a significantly higher level of miR-21 in CRC tumour tissue than in NAT and high expression of miR-21 was significantly correlated with advanced clinical stage and poor cell differentiation. +tissue_expression_up hsa-mir-200a Breast Neoplasms 22294488 The miRNA-200 family and miRNA-9 exhibit differential expression in primary versus corresponding metastatic tissue in breast cancer. +tissue_expression_up hsa-mir-200b Breast Neoplasms 22294488 The miRNA-200 family and miRNA-9 exhibit differential expression in primary versus corresponding metastatic tissue in breast cancer. +tissue_expression_up hsa-mir-200c Breast Neoplasms 22294488 The miRNA-200 family and miRNA-9 exhibit differential expression in primary versus corresponding metastatic tissue in breast cancer. +tissue_expression_up hsa-mir-9-1 Breast Neoplasms 22294488 The miRNA-200 family and miRNA-9 exhibit differential expression in primary versus corresponding metastatic tissue in breast cancer. +tissue_expression_up hsa-mir-9-2 Breast Neoplasms 22294488 The miRNA-200 family and miRNA-9 exhibit differential expression in primary versus corresponding metastatic tissue in breast cancer. +tissue_expression_up hsa-mir-9-3 Breast Neoplasms 22294488 The miRNA-200 family and miRNA-9 exhibit differential expression in primary versus corresponding metastatic tissue in breast cancer. +tissue_expression_up hsa-mir-145 Prostate Neoplasms 22298119 Significantly increased miR-145 expression were observed for patients with intermediate or high risk D'Amico scores compared to patients with low risk scores +tissue_expression_up hsa-mir-20a Prostate Neoplasms 22298119 miR-20a was significantly overexpressed in plasma from patients with stage 3 tumors compared to stage 2 or below (P=0.03). +tissue_expression_up hsa-mir-21 Prostate Neoplasms 22298119 The expression levels for miR-20a and miR-21 were significantly increased in patients with high risk CAPRA scores +tissue_expression_up hsa-mir-21 Laryngeal Neoplasms 22320969 "Mir-21 was up-regulated in LSCCs and HSCCs compared to adjacent non-tumor tissues (P < 0.05), and the up-regulated expression of mir-21 was associated with clinical stage (P = 0.001), T classification (P = 0.007), pathologic differentiation (P = 0.025), and lymph node positivity (P = 0.002)." +tissue_expression_up hsa-mir-21 "Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal" 22320969 "Mir-21 was up-regulated in LSCCs (laryngeal squamous cell carcinomas) and HSCCs(hypopharyngeal squamous cell carcinomas) compared to adjacent non-tumor tissues (P < 0.05), and the up-regulated expression of mir-21 was associated with clinical stage (P = 0.001), T classification (P = 0.007), pathologic differentiation (P = 0.025), and lymph node positivity (P = 0.002)." +tissue_expression_up hsa-mir-210 Breast Neoplasms 22323552 High Expression of MicroRNA-210 is an Independent Factor Indicating a Poor Prognosis in Japanese Triple-negative Breast Cancer Patients. +tissue_expression_up hsa-mir-21 Breast Neoplasms 22323912 "High miR-21 expression was associated with mastectomy, larger tumor size, higher stage, higher grade, estrogen receptor (ER) negative, human epidermal growth factor receptor 2 (HER2) positive, HER2 positive breast cancer subtype, high Ki-67 expression, and death." +tissue_expression_up hsa-mir-1-1 Myocardial Infarction 22330002 "MiR-1, -21 -133a and -423-5p showed a 3- to 10-fold increase and miR-499-5p exhibited >80-fold increase in acute NSTEMI patient vs. CTR." +tissue_expression_up hsa-mir-1-2 Myocardial Infarction 22330002 "MiR-1, -21 -133a and -423-5p showed a 3- to 10-fold increase and miR-499-5p exhibited >80-fold increase in acute NSTEMI patient vs. CTR." +tissue_expression_up hsa-mir-133a-1 Myocardial Infarction 22330002 "MiR-1, -21 -133a and -423-5p showed a 3- to 10-fold increase and miR-499-5p exhibited >80-fold increase in acute NSTEMI patient vs. CTR." +tissue_expression_up hsa-mir-133a-2 Myocardial Infarction 22330002 "MiR-1, -21 -133a and -423-5p showed a 3- to 10-fold increase and miR-499-5p exhibited >80-fold increase in acute NSTEMI patient vs. CTR." +tissue_expression_up hsa-mir-21 Myocardial Infarction 22330002 "MiR-1, -21 -133a and -423-5p showed a 3- to 10-fold increase and miR-499-5p exhibited >80-fold increase in acute NSTEMI patient vs. CTR." +tissue_expression_up hsa-mir-423 Myocardial Infarction 22330002 "MiR-1, -21 -133a and -423-5p showed a 3- to 10-fold increase and miR-499-5p exhibited >80-fold increase in acute NSTEMI patient vs. CTR." +tissue_expression_up hsa-mir-21 Glioma 22335906 miR-21 was up-regulated 1.49-fold in SHG-44(R) cells (Radioresistant cell line) relative to the SHG-44 cells. +tissue_expression_up hsa-mir-34b Ovarian Neoplasms 22340095 "The expressions of miR-449a/b, miR-34b and miR-34c were 19-fold to 21-fold elevated after p53 activation by genotoxic agent adriamycin." +tissue_expression_up hsa-mir-34c Ovarian Neoplasms 22340095 "The expressions of miR-449a/b, miR-34b and miR-34c were 19-fold to 21-fold elevated after p53 activation by genotoxic agent adriamycin." +tissue_expression_up hsa-mir-449a Ovarian Neoplasms 22340095 "The expressions of miR-449a/b, miR-34b and miR-34c were 19-fold to 21-fold elevated after p53 activation by genotoxic agent adriamycin." +tissue_expression_up hsa-mir-449b Ovarian Neoplasms 22340095 "The expressions of miR-449a/b, miR-34b and miR-34c were 19-fold to 21-fold elevated after p53 activation by genotoxic agent adriamycin." +tissue_expression_up hsa-mir-182 "Lymphoma, Hodgkin" 22343918 "In cHL cell lines FOXO1 is inactivated by multiple mechanisms, including constitutive activation of AKT/PKB and MAPK/ERK kinases and up-regulation of microRNAs miR-96, miR-182, and miR-183." +tissue_expression_up hsa-mir-183 "Lymphoma, Hodgkin" 22343918 "In cHL cell lines FOXO1 is inactivated by multiple mechanisms, including constitutive activation of AKT/PKB and MAPK/ERK kinases and up-regulation of microRNAs miR-96, miR-182, and miR-183." +tissue_expression_up hsa-mir-96 "Lymphoma, Hodgkin" 22343918 "In cHL cell lines FOXO1 is inactivated by multiple mechanisms, including constitutive activation of AKT/PKB and MAPK/ERK kinases and up-regulation of microRNAs miR-96, miR-182, and miR-183." +tissue_expression_up hsa-mir-148b Ovarian Neoplasms 22344713 "miR-148b was overexpressed in 92.21% (71/77) of the ovarian cancer samples examined, and overexpression of miR-148b in ovarian cancer tissues was not associated with any of the clinicopathological features of patients with ovarian cancer." +tissue_expression_up hsa-mir-181a-1 Osteosarcoma 22350417 high expression +tissue_expression_up hsa-mir-181a-2 Osteosarcoma 22350417 high expression +tissue_expression_up hsa-mir-181b-1 Osteosarcoma 22350417 high expression +tissue_expression_up hsa-mir-181b-2 Osteosarcoma 22350417 high expression +tissue_expression_up hsa-mir-181c Osteosarcoma 22350417 high expression +tissue_expression_up hsa-mir-125b-1 Glioma 22360855 "The levels of miRNA-125b and MMP9 were significantly higher in SU3 and SU2, also a highly invasive GSCPs we established before, than in U251s." +tissue_expression_up hsa-mir-663a Burns 22360957 miR-663 was up-regulated in denatured dermis compared with those in normal skin. +tissue_expression_up hsa-mir-206 Prolactinoma 22366961 miR-206 was significantly up-regulated in prolactinomas following bromocriptine treatment. +tissue_expression_up hsa-mir-516b-1 Prolactinoma 22366961 miR-516b was significantly up-regulated in prolactinomas following bromocriptine treatment. +tissue_expression_up hsa-mir-516b-2 Prolactinoma 22366961 miR-516b was significantly up-regulated in prolactinomas following bromocriptine treatment. +tissue_expression_up hsa-mir-550a-1 Prolactinoma 22366961 miR-516b was significantly up-regulated in prolactinomas following bromocriptine treatment. +tissue_expression_up hsa-mir-550a-2 Prolactinoma 22366961 miR-550 was significantly up-regulated in prolactinomas following bromocriptine treatment. +tissue_expression_up hsa-mir-671 Prolactinoma 22366961 miR-671-5p was significantly up-regulated in prolactinomas following bromocriptine treatment. +tissue_expression_up hsa-mir-21 Gastric Neoplasms 22374783 "Real-time RT-PCR analysis demonstrated an increase in mir-21 and mir-302 expression level in CSCs(cancer stem cells), relative to cancer cells, whereas let-7a expression level was decreased in CSC in comparison with cancer cells. mir-372, mir-373 and mir-520c-5p were markedly increased in cancer cells in comparison with CSCs." +tissue_expression_up hsa-mir-302a Gastric Neoplasms 22374783 "Real-time RT-PCR analysis demonstrated an increase in mir-21 and mir-302 expression level in CSCs(cancer stem cells), relative to cancer cells, whereas let-7a expression level was decreased in CSC in comparison with cancer cells. mir-372, mir-373 and mir-520c-5p were markedly increased in cancer cells in comparison with CSCs." +tissue_expression_up hsa-mir-302b Gastric Neoplasms 22374783 "Real-time RT-PCR analysis demonstrated an increase in mir-21 and mir-302 expression level in CSCs(cancer stem cells), relative to cancer cells, whereas let-7a expression level was decreased in CSC in comparison with cancer cells. mir-372, mir-373 and mir-520c-5p were markedly increased in cancer cells in comparison with CSCs." +tissue_expression_up hsa-mir-302c Gastric Neoplasms 22374783 "Real-time RT-PCR analysis demonstrated an increase in mir-21 and mir-302 expression level in CSCs(cancer stem cells), relative to cancer cells, whereas let-7a expression level was decreased in CSC in comparison with cancer cells. mir-372, mir-373 and mir-520c-5p were markedly increased in cancer cells in comparison with CSCs." +tissue_expression_up hsa-mir-302d Gastric Neoplasms 22374783 "Real-time RT-PCR analysis demonstrated an increase in mir-21 and mir-302 expression level in CSCs(cancer stem cells), relative to cancer cells, whereas let-7a expression level was decreased in CSC in comparison with cancer cells. mir-372, mir-373 and mir-520c-5p were markedly increased in cancer cells in comparison with CSCs." +tissue_expression_up hsa-mir-302e Gastric Neoplasms 22374783 "Real-time RT-PCR analysis demonstrated an increase in mir-21 and mir-302 expression level in CSCs(cancer stem cells), relative to cancer cells, whereas let-7a expression level was decreased in CSC in comparison with cancer cells. mir-372, mir-373 and mir-520c-5p were markedly increased in cancer cells in comparison with CSCs." +tissue_expression_up hsa-mir-302f Gastric Neoplasms 22374783 "Real-time RT-PCR analysis demonstrated an increase in mir-21 and mir-302 expression level in CSCs(cancer stem cells), relative to cancer cells, whereas let-7a expression level was decreased in CSC in comparison with cancer cells. mir-372, mir-373 and mir-520c-5p were markedly increased in cancer cells in comparison with CSCs." +tissue_expression_up hsa-mir-372 Gastric Neoplasms 22374783 "Real-time RT-PCR analysis demonstrated an increase in mir-21 and mir-302 expression level in CSCs(cancer stem cells), relative to cancer cells, whereas let-7a expression level was decreased in CSC in comparison with cancer cells. mir-372, mir-373 and mir-520c-5p were markedly increased in cancer cells in comparison with CSCs." +tissue_expression_up hsa-mir-373 Gastric Neoplasms 22374783 "Real-time RT-PCR analysis demonstrated an increase in mir-21 and mir-302 expression level in CSCs(cancer stem cells), relative to cancer cells, whereas let-7a expression level was decreased in CSC in comparison with cancer cells. mir-372, mir-373 and mir-520c-5p were markedly increased in cancer cells in comparison with CSCs." +tissue_expression_up hsa-mir-520c Gastric Neoplasms 22374783 "Real-time RT-PCR analysis demonstrated an increase in mir-21 and mir-302 expression level in CSCs(cancer stem cells), relative to cancer cells, whereas let-7a expression level was decreased in CSC in comparison with cancer cells. mir-372, mir-373 and mir-520c-5p were markedly increased in cancer cells in comparison with CSCs." +tissue_expression_up hsa-mir-20a Glioma 22381757 The glioma tissues showed significantly up-regulated expression of miR-20a compared with normal brain tissues (P=0.035). The expression level of miR-20a was higher in high-grade than in low-grade gliomas. miR-20a mimics significantly enhanced the proliferation of U251 cells and the percentage of S-phase cells. +tissue_expression_up hsa-mir-19b-1 Colon Neoplasms 22382630 "In response to 5-FU, miR-19b and miR-21 were over-expressed in 5-FU-resistant cells." +tissue_expression_up hsa-mir-19b-2 Colon Neoplasms 22382630 "In response to 5-FU, miR-19b and miR-21 were over-expressed in 5-FU-resistant cells." +tissue_expression_up hsa-mir-21 Colorectal Carcinoma 22382630 "In response to 5-FU, miR-19b and miR-21 were over-expressed in 5-FU-resistant cells." +tissue_expression_up hsa-mir-199a-1 Chronic Obstructive Pulmonary Disease 22383663 "miR-34a and miR-199a-5p expression was increased and the phosphorylation of AKT was decreased in COPD lungs. The miR-199a-5p expression was correlated with HIF-1§Ø©ãprotein expression in COPD patient's lungs. Transfection of HPMVEC with the miR-199a-5p precursor gene decreased HIF-1§Ø©ãprotein expression, and transfection with the miR-34a precursor gene increased miR-199a-5p expression." +tissue_expression_up hsa-mir-34a Chronic Obstructive Pulmonary Disease 22383663 "miR-34a and miR-199a-5p expression was increased and the phosphorylation of AKT was decreased in COPD lungs. The miR-199a-5p expression was correlated with HIF-1§Ø©ãprotein expression in COPD patient's lungs. Transfection of HPMVEC with the miR-199a-5p precursor gene decreased HIF-1§Ø©ãprotein expression, and transfection with the miR-34a precursor gene increased miR-199a-5p expression." +tissue_expression_up hsa-mir-155 Urinary Bladder Cancer 22386240 "Compared with controls, the patients with bladder cancer had a lower expression of the miR-200 family, miR-192, and miR-155 in the urinary sediment; lower expression of miR-192; and higher expression of miR-155 in the urinary supernatant." +tissue_expression_up hsa-mir-708 Bladder Neoplasms 22393979 Differential miRNA expression profiles in bladder urothelial carcinomas identified miR-100 down-regulation and miR-708 up-regulation among the most common alterations +tissue_expression_up hsa-mir-126 Colorectal Carcinoma 22397399 The median miRNA-126 expression level was significantly higher in patients responding to XELOX (capecitabine and oxaliplatin). +tissue_expression_up hsa-mir-638 Breast Neoplasms 22403704 "Treatment with E2, BPA and DDT decreased (p<0.05) miR-21 expression. Several members of the let-7 family (let-7a, let-7b, let-7c, let-7d, let-7e and let-7f), were downregulated (p<0.05) by all three treatments.and miR-15b (p<0.005) and miR-27b (p<0.01) were also downregulated by the three treatments.upregulation of miR-638 (P<0.005), miR-663 (P<0.005), and miR-1915 (P<0.005) was observed after treatment of MCF7 cells with E2, BPA or DDT" +tissue_expression_up hsa-mir-663a Breast Neoplasms 22403704 "Treatment with E2, BPA and DDT decreased (p<0.05) miR-21 expression. Several members of the let-7 family (let-7a, let-7b, let-7c, let-7d, let-7e and let-7f), were downregulated (p<0.05) by all three treatments.and miR-15b (p<0.005) and miR-27b (p<0.01) were also downregulated by the three treatments.upregulation of miR-638 (P<0.005), miR-663 (P<0.005), and miR-1915 (P<0.005) was observed after treatment of MCF7 cells with E2, BPA or DDT" +tissue_expression_up hsa-mir-107 Gastric Neoplasms 22407237 "In the analysis by real-time PCR-based miRNA arrays using pooled RNA samples from five gastric cancer patients, expression of miR-107, miR-21, miR-196a, miR-26b, miR-9, miR-142-3p, miR-30b, miR-150, miR-191 and miR-17 was found to be upregulation.miR-107 expression showed significant association with depth of tumor invasion, lymph node metastasis and stage. In Kaplan-Meier survival curve analysis, overall survival rates (OS) and disease-free survival rates (DFS) of patients with high miR-107 expression were significantly worse than those of patients with low miR-107 expression. In the Cox multivariate analysis, it was shown that miR-107 expression in gastric cancer tissues was an independent prognostic factor for OS and DFS. Significant inverse correlations were demonstrated between miR-107 and DICER1 mRNA. Our results indicate that miR-107 may be useful as an effective biomarker for prediction of a poor prognosis in gastric cancer patients." +tissue_expression_up hsa-mir-142 Gastric Neoplasms 22407237 "In the analysis by real-time PCR-based miRNA arrays using pooled RNA samples from five gastric cancer patients, expression of miR-107, miR-21, miR-196a, miR-26b, miR-9, miR-142-3p, miR-30b, miR-150, miR-191 and miR-17 was found to be upregulation.miR-107 expression showed significant association with depth of tumor invasion, lymph node metastasis and stage. In Kaplan-Meier survival curve analysis, overall survival rates (OS) and disease-free survival rates (DFS) of patients with high miR-107 expression were significantly worse than those of patients with low miR-107 expression. In the Cox multivariate analysis, it was shown that miR-107 expression in gastric cancer tissues was an independent prognostic factor for OS and DFS. Significant inverse correlations were demonstrated between miR-107 and DICER1 mRNA. Our results indicate that miR-107 may be useful as an effective biomarker for prediction of a poor prognosis in gastric cancer patients." +tissue_expression_up hsa-mir-150 Gastric Neoplasms 22407237 "In the analysis by real-time PCR-based miRNA arrays using pooled RNA samples from five gastric cancer patients, expression of miR-107, miR-21, miR-196a, miR-26b, miR-9, miR-142-3p, miR-30b, miR-150, miR-191 and miR-17 was found to be upregulation.miR-107 expression showed significant association with depth of tumor invasion, lymph node metastasis and stage. In Kaplan-Meier survival curve analysis, overall survival rates (OS) and disease-free survival rates (DFS) of patients with high miR-107 expression were significantly worse than those of patients with low miR-107 expression. In the Cox multivariate analysis, it was shown that miR-107 expression in gastric cancer tissues was an independent prognostic factor for OS and DFS. Significant inverse correlations were demonstrated between miR-107 and DICER1 mRNA. Our results indicate that miR-107 may be useful as an effective biomarker for prediction of a poor prognosis in gastric cancer patients." +tissue_expression_up hsa-mir-17 Gastric Neoplasms 22407237 "In the analysis by real-time PCR-based miRNA arrays using pooled RNA samples from five gastric cancer patients, expression of miR-107, miR-21, miR-196a, miR-26b, miR-9, miR-142-3p, miR-30b, miR-150, miR-191 and miR-17 was found to be upregulation.miR-107 expression showed significant association with depth of tumor invasion, lymph node metastasis and stage. In Kaplan-Meier survival curve analysis, overall survival rates (OS) and disease-free survival rates (DFS) of patients with high miR-107 expression were significantly worse than those of patients with low miR-107 expression. In the Cox multivariate analysis, it was shown that miR-107 expression in gastric cancer tissues was an independent prognostic factor for OS and DFS. Significant inverse correlations were demonstrated between miR-107 and DICER1 mRNA. Our results indicate that miR-107 may be useful as an effective biomarker for prediction of a poor prognosis in gastric cancer patients." +tissue_expression_up hsa-mir-191 Gastric Neoplasms 22407237 "In the analysis by real-time PCR-based miRNA arrays using pooled RNA samples from five gastric cancer patients, expression of miR-107, miR-21, miR-196a, miR-26b, miR-9, miR-142-3p, miR-30b, miR-150, miR-191 and miR-17 was found to be upregulation.miR-107 expression showed significant association with depth of tumor invasion, lymph node metastasis and stage. In Kaplan-Meier survival curve analysis, overall survival rates (OS) and disease-free survival rates (DFS) of patients with high miR-107 expression were significantly worse than those of patients with low miR-107 expression. In the Cox multivariate analysis, it was shown that miR-107 expression in gastric cancer tissues was an independent prognostic factor for OS and DFS. Significant inverse correlations were demonstrated between miR-107 and DICER1 mRNA. Our results indicate that miR-107 may be useful as an effective biomarker for prediction of a poor prognosis in gastric cancer patients." +tissue_expression_up hsa-mir-196a-1 Gastric Neoplasms 22407237 "In the analysis by real-time PCR-based miRNA arrays using pooled RNA samples from five gastric cancer patients, expression of miR-107, miR-21, miR-196a, miR-26b, miR-9, miR-142-3p, miR-30b, miR-150, miR-191 and miR-17 was found to be upregulation.miR-107 expression showed significant association with depth of tumor invasion, lymph node metastasis and stage. In Kaplan-Meier survival curve analysis, overall survival rates (OS) and disease-free survival rates (DFS) of patients with high miR-107 expression were significantly worse than those of patients with low miR-107 expression. In the Cox multivariate analysis, it was shown that miR-107 expression in gastric cancer tissues was an independent prognostic factor for OS and DFS. Significant inverse correlations were demonstrated between miR-107 and DICER1 mRNA. Our results indicate that miR-107 may be useful as an effective biomarker for prediction of a poor prognosis in gastric cancer patients." +tissue_expression_up hsa-mir-196a-2 Gastric Neoplasms 22407237 "In the analysis by real-time PCR-based miRNA arrays using pooled RNA samples from five gastric cancer patients, expression of miR-107, miR-21, miR-196a, miR-26b, miR-9, miR-142-3p, miR-30b, miR-150, miR-191 and miR-17 was found to be upregulation.miR-107 expression showed significant association with depth of tumor invasion, lymph node metastasis and stage. In Kaplan-Meier survival curve analysis, overall survival rates (OS) and disease-free survival rates (DFS) of patients with high miR-107 expression were significantly worse than those of patients with low miR-107 expression. In the Cox multivariate analysis, it was shown that miR-107 expression in gastric cancer tissues was an independent prognostic factor for OS and DFS. Significant inverse correlations were demonstrated between miR-107 and DICER1 mRNA. Our results indicate that miR-107 may be useful as an effective biomarker for prediction of a poor prognosis in gastric cancer patients." +tissue_expression_up hsa-mir-21 Gastric Neoplasms 22407237 "In the analysis by real-time PCR-based miRNA arrays using pooled RNA samples from five gastric cancer patients, expression of miR-107, miR-21, miR-196a, miR-26b, miR-9, miR-142-3p, miR-30b, miR-150, miR-191 and miR-17 was found to be upregulation.miR-107 expression showed significant association with depth of tumor invasion, lymph node metastasis and stage. In Kaplan-Meier survival curve analysis, overall survival rates (OS) and disease-free survival rates (DFS) of patients with high miR-107 expression were significantly worse than those of patients with low miR-107 expression. In the Cox multivariate analysis, it was shown that miR-107 expression in gastric cancer tissues was an independent prognostic factor for OS and DFS. Significant inverse correlations were demonstrated between miR-107 and DICER1 mRNA. Our results indicate that miR-107 may be useful as an effective biomarker for prediction of a poor prognosis in gastric cancer patients." +tissue_expression_up hsa-mir-26b Gastric Neoplasms 22407237 "In the analysis by real-time PCR-based miRNA arrays using pooled RNA samples from five gastric cancer patients, expression of miR-107, miR-21, miR-196a, miR-26b, miR-9, miR-142-3p, miR-30b, miR-150, miR-191 and miR-17 was found to be upregulation.miR-107 expression showed significant association with depth of tumor invasion, lymph node metastasis and stage. In Kaplan-Meier survival curve analysis, overall survival rates (OS) and disease-free survival rates (DFS) of patients with high miR-107 expression were significantly worse than those of patients with low miR-107 expression. In the Cox multivariate analysis, it was shown that miR-107 expression in gastric cancer tissues was an independent prognostic factor for OS and DFS. Significant inverse correlations were demonstrated between miR-107 and DICER1 mRNA. Our results indicate that miR-107 may be useful as an effective biomarker for prediction of a poor prognosis in gastric cancer patients." +tissue_expression_up hsa-mir-30b Gastric Neoplasms 22407237 "In the analysis by real-time PCR-based miRNA arrays using pooled RNA samples from five gastric cancer patients, expression of miR-107, miR-21, miR-196a, miR-26b, miR-9, miR-142-3p, miR-30b, miR-150, miR-191 and miR-17 was found to be upregulation.miR-107 expression showed significant association with depth of tumor invasion, lymph node metastasis and stage. In Kaplan-Meier survival curve analysis, overall survival rates (OS) and disease-free survival rates (DFS) of patients with high miR-107 expression were significantly worse than those of patients with low miR-107 expression. In the Cox multivariate analysis, it was shown that miR-107 expression in gastric cancer tissues was an independent prognostic factor for OS and DFS. Significant inverse correlations were demonstrated between miR-107 and DICER1 mRNA. Our results indicate that miR-107 may be useful as an effective biomarker for prediction of a poor prognosis in gastric cancer patients." +tissue_expression_up hsa-mir-9-1 Gastric Neoplasms 22407237 "In the analysis by real-time PCR-based miRNA arrays using pooled RNA samples from five gastric cancer patients, expression of miR-107, miR-21, miR-196a, miR-26b, miR-9, miR-142-3p, miR-30b, miR-150, miR-191 and miR-17 was found to be upregulation.miR-107 expression showed significant association with depth of tumor invasion, lymph node metastasis and stage. In Kaplan-Meier survival curve analysis, overall survival rates (OS) and disease-free survival rates (DFS) of patients with high miR-107 expression were significantly worse than those of patients with low miR-107 expression. In the Cox multivariate analysis, it was shown that miR-107 expression in gastric cancer tissues was an independent prognostic factor for OS and DFS. Significant inverse correlations were demonstrated between miR-107 and DICER1 mRNA. Our results indicate that miR-107 may be useful as an effective biomarker for prediction of a poor prognosis in gastric cancer patients." +tissue_expression_up hsa-mir-9-2 Gastric Neoplasms 22407237 "In the analysis by real-time PCR-based miRNA arrays using pooled RNA samples from five gastric cancer patients, expression of miR-107, miR-21, miR-196a, miR-26b, miR-9, miR-142-3p, miR-30b, miR-150, miR-191 and miR-17 was found to be upregulation.miR-107 expression showed significant association with depth of tumor invasion, lymph node metastasis and stage. In Kaplan-Meier survival curve analysis, overall survival rates (OS) and disease-free survival rates (DFS) of patients with high miR-107 expression were significantly worse than those of patients with low miR-107 expression. In the Cox multivariate analysis, it was shown that miR-107 expression in gastric cancer tissues was an independent prognostic factor for OS and DFS. Significant inverse correlations were demonstrated between miR-107 and DICER1 mRNA. Our results indicate that miR-107 may be useful as an effective biomarker for prediction of a poor prognosis in gastric cancer patients." +tissue_expression_up hsa-mir-9-3 Gastric Neoplasms 22407237 "In the analysis by real-time PCR-based miRNA arrays using pooled RNA samples from five gastric cancer patients, expression of miR-107, miR-21, miR-196a, miR-26b, miR-9, miR-142-3p, miR-30b, miR-150, miR-191 and miR-17 was found to be upregulation.miR-107 expression showed significant association with depth of tumor invasion, lymph node metastasis and stage. In Kaplan-Meier survival curve analysis, overall survival rates (OS) and disease-free survival rates (DFS) of patients with high miR-107 expression were significantly worse than those of patients with low miR-107 expression. In the Cox multivariate analysis, it was shown that miR-107 expression in gastric cancer tissues was an independent prognostic factor for OS and DFS. Significant inverse correlations were demonstrated between miR-107 and DICER1 mRNA. Our results indicate that miR-107 may be useful as an effective biomarker for prediction of a poor prognosis in gastric cancer patients." +tissue_expression_up hsa-mir-155 Graft-Versus-Host Disease 22408260 miR-155 up-regulation was shown in specimens from patients with pathological evidence of intestinal aGVHD (Acute graft-versus-host disease). +tissue_expression_up hsa-mir-26a-1 Multiple Endocrine Neoplasia Type 1 22409234 "The authors found that in hADSCs the siRNA-induced silencing of MEN1 mRNA resulted in a down regulation of miR-26a, with a consequent up-regulation of SMAD1 protein." +tissue_expression_up hsa-mir-26a-2 Multiple Endocrine Neoplasia Type 1 22409234 "The authors found that in hADSCs the siRNA-induced silencing of MEN1 mRNA resulted in a down regulation of miR-26a, with a consequent up-regulation of SMAD1 protein." +tissue_expression_up hsa-mir-21 Psoriasis 22417311 MiR-21 is up-regulated in psoriasis and suppresses T cell apoptosis. +tissue_expression_up hsa-mir-196a-1 Gastric Neoplasms 22420029 "The expression level of miR-196a microRNA significantly increased in primary gastric cancer tissues versus adjacent normal tissues. In addition, extracellular miR-196a detected in conditioned medium was strongly correlated with its cellular expression status and increased circulating miR-196a in patient serum was associated with gastric cancer disease status and relapse." +tissue_expression_up hsa-mir-196a-2 Gastric Neoplasms 22420029 "The expression level of miR-196a microRNA significantly increased in primary gastric cancer tissues versus adjacent normal tissues. In addition, extracellular miR-196a detected in conditioned medium was strongly correlated with its cellular expression status and increased circulating miR-196a in patient serum was associated with gastric cancer disease status and relapse." +tissue_expression_up hsa-mir-130b Head And Neck Neoplasms 22425712 up-regulation +tissue_expression_up hsa-mir-155 Head And Neck Neoplasms 22425712 up-regulation +tissue_expression_up hsa-mir-21 Head And Neck Neoplasms 22425712 up-regulation +tissue_expression_up hsa-mir-223 Head And Neck Neoplasms 22425712 up-regulation +tissue_expression_up hsa-mir-31 Head And Neck Neoplasms 22425712 up-regulation +tissue_expression_up hsa-mir-29a Colon Neoplasms 22426940 "High expression of miR-29a was associated with a longer disease-free survival (DFS) for patients with stage 2 colon cancer, on both univariate and multivariate analyses." +tissue_expression_up hsa-mir-216a Heart Failure 22427379 "miR-216a was strongly increased in both D-HF (diabetic HF) and ND-HF (nondiabetic HF) patients, negatively correlated with left ventricular ejection fraction." +tissue_expression_up hsa-mir-106a Gastric Neoplasms 22431000 miR-106a Is frequently upregulated in gastric cancer and inhibits the extrinsic apoptotic pathway by targeting FAS. +tissue_expression_up hsa-mir-34a "Carcinoma, Lung, Non-Small-Cell" 22438124 Delta-tocotrienol suppresses Notch-1 pathway by up-regulating miR-34a in non-small cell lung cancer cells. +tissue_expression_up hsa-mir-15a Leukemia 22449094 Pure curcumin decreases the expression of WT1 by upregulation of miR-15a and miR-16-1 in leukemic cells. +tissue_expression_up hsa-mir-16-1 Leukemia 22449094 Pure curcumin decreases the expression of WT1 by upregulation of miR-15a and miR-16-1 in leukemic cells. +tissue_expression_up hsa-mir-16-2 Leukemia 22449094 Pure curcumin decreases the expression of WT1 by upregulation of miR-15a and miR-16-1 in leukemic cells. +tissue_expression_up hsa-mir-101-2 Gastric Neoplasms 22450781 Lack of microRNA-101 causes E-cadherin functional deregulation through EZH2 upregulation in intestinal gastric cancer. +tissue_expression_up hsa-mir-100 Pancreatic Neoplasms 22466166 "Carcinomas showed higher expression of miR-21, miR-221, miR-155, miR-100, and miR-181b than benign lesions. Cellblocks containing carcinoma showed higher expression of miR-21, miR-221, and miR-196a than those from benign lesions." +tissue_expression_up hsa-mir-155 Pancreatic Neoplasms 22466166 "Carcinomas showed higher expression of miR-21, miR-221, miR-155, miR-100, and miR-181b than benign lesions. Cellblocks containing carcinoma showed higher expression of miR-21, miR-221, and miR-196a than those from benign lesions." +tissue_expression_up hsa-mir-181b-1 Pancreatic Neoplasms 22466166 "Carcinomas showed higher expression of miR-21, miR-221, miR-155, miR-100, and miR-181b than benign lesions. Cellblocks containing carcinoma showed higher expression of miR-21, miR-221, and miR-196a than those from benign lesions." +tissue_expression_up hsa-mir-181b-2 Pancreatic Neoplasms 22466166 "Carcinomas showed higher expression of miR-21, miR-221, miR-155, miR-100, and miR-181b than benign lesions. Cellblocks containing carcinoma showed higher expression of miR-21, miR-221, and miR-196a than those from benign lesions." +tissue_expression_up hsa-mir-196a-1 Pancreatic Neoplasms 22466166 "Carcinomas showed higher expression of miR-21, miR-221, miR-155, miR-100, and miR-181b than benign lesions. Cellblocks containing carcinoma showed higher expression of miR-21, miR-221, and miR-196a than those from benign lesions." +tissue_expression_up hsa-mir-196a-2 Pancreatic Neoplasms 22466166 "Carcinomas showed higher expression of miR-21, miR-221, miR-155, miR-100, and miR-181b than benign lesions. Cellblocks containing carcinoma showed higher expression of miR-21, miR-221, and miR-196a than those from benign lesions." +tissue_expression_up hsa-mir-21 Pancreatic Neoplasms 22466166 "Carcinomas showed higher expression of miR-21, miR-221, miR-155, miR-100, and miR-181b than benign lesions. Cellblocks containing carcinoma showed higher expression of miR-21, miR-221, and miR-196a than those from benign lesions." +tissue_expression_up hsa-mir-221 Pancreatic Neoplasms 22466166 "Carcinomas showed higher expression of miR-21, miR-221, miR-155, miR-100, and miR-181b than benign lesions. Cellblocks containing carcinoma showed higher expression of miR-21, miR-221, and miR-196a than those from benign lesions." +tissue_expression_up hsa-mir-424 Urinary Bladder Cancer 22469983 Suppressed miR-424 expression via upregulation of target gene Chk1 contributes to the progression of cervical cancer. +tissue_expression_up hsa-mir-21 Colorectal Carcinoma 22476768 Kaplan-Meier analysis proved that the miR-21 expression levels are correlated to shorter overall survival of CRC patients. +tissue_expression_up hsa-mir-151a Breast Neoplasms 22489664 miR-151-5p upregulation may suppress metastasis in primary breast tumors. +tissue_expression_up hsa-mir-151b Breast Neoplasms 22489664 miR-151-5p upregulation may suppress metastasis in primary breast tumors. +tissue_expression_up hsa-mir-23b Prolactinoma 22490835 up-regulated +tissue_expression_up hsa-mir-342 Prolactinoma 22490835 miR-342-3p: up-regulated +tissue_expression_up hsa-mir-432 Prolactinoma 22490835 up-regulated +tissue_expression_up hsa-mir-493 Prolactinoma 22490835 up-regulated +tissue_expression_up hsa-mir-664 Prolactinoma 22490835 miR-664*: up-regulated +tissue_expression_up hsa-mir-10b Breast Neoplasms 22492962 "The levels of miR-10b and miR-21 are found significantly increased in the CSF (cerebrospinal fluid) of patients with glioblastoma and brain metastasis of breast and lung cancer, compared with tumors in remission and a variety of nonneoplastic conditions." +tissue_expression_up hsa-mir-10b Glioblastoma 22492962 "The levels of miR-10b and miR-21 are found significantly increased in the CSF (cerebrospinal fluid) of patients with glioblastoma and brain metastasis of breast and lung cancer, compared with tumors in remission and a variety of nonneoplastic conditions." +tissue_expression_up hsa-mir-10b Lung Neoplasms 22492962 "The levels of miR-10b and miR-21 are found significantly increased in the CSF (cerebrospinal fluid) of patients with glioblastoma and brain metastasis of breast and lung cancer, compared with tumors in remission and a variety of nonneoplastic conditions." +tissue_expression_up hsa-mir-21 Breast Neoplasms 22492962 "The levels of miR-10b and miR-21 are found significantly increased in the CSF (cerebrospinal fluid) of patients with glioblastoma and brain metastasis of breast and lung cancer, compared with tumors in remission and a variety of nonneoplastic conditions." +tissue_expression_up hsa-mir-21 Glioblastoma 22492962 "The levels of miR-10b and miR-21 are found significantly increased in the CSF (cerebrospinal fluid) of patients with glioblastoma and brain metastasis of breast and lung cancer, compared with tumors in remission and a variety of nonneoplastic conditions." +tissue_expression_up hsa-mir-21 Lung Neoplasms 22492962 "The levels of miR-10b and miR-21 are found significantly increased in the CSF (cerebrospinal fluid) of patients with glioblastoma and brain metastasis of breast and lung cancer, compared with tumors in remission and a variety of nonneoplastic conditions." +tissue_expression_up hsa-mir-34a Neuroblastoma 22498172 "Combination of 4-HPR (N-(4-hydroxyphenyl) retinamide) and EGCG ((-)-epigallocatechin-3-gallate) most significantly decreased expression of OGmiRs (miR-92, miR-93, and miR-106b) and increased expression of TSmiRs (miR-7-1, miR-34a, and miR-99a) in both cell lines(SK-N-BE2 and IMR-32 cells)" +tissue_expression_up hsa-mir-7-1 Neuroblastoma 22498172 "Combination of 4-HPR (N-(4-hydroxyphenyl) retinamide) and EGCG ((-)-epigallocatechin-3-gallate) most significantly decreased expression of OGmiRs (miR-92, miR-93, and miR-106b) and increased expression of TSmiRs (miR-7-1, miR-34a, and miR-99a) in both cell lines(SK-N-BE2 and IMR-32 cells)" +tissue_expression_up hsa-mir-99a Neuroblastoma 22498172 "Combination of 4-HPR (N-(4-hydroxyphenyl) retinamide) and EGCG ((-)-epigallocatechin-3-gallate) most significantly decreased expression of OGmiRs (miR-92, miR-93, and miR-106b) and increased expression of TSmiRs (miR-7-1, miR-34a, and miR-99a) in both cell lines(SK-N-BE2 and IMR-32 cells)" +tissue_expression_up hsa-mir-146a Osteoarthritis 22507670 "IL-1¦Â responsive miR-146a is overexpressed in an experimentally induced OA model, accompanied by upregulation of VEGF and downregulation of Smad4 in vivo." +tissue_expression_up hsa-mir-200c Endometrial Neoplasms 22514717 The expression levels of miR-200c (P<0.0001) and miR-205 (P<0.0001) were significantly increased in endometrial tumors compared to normal tissues. Kaplan-Meier survival analysis revealed that high levels of miR-205 expression were associated with poor patient overall survival. +tissue_expression_up hsa-mir-205 Endometrial Neoplasms 22514717 The expression levels of miR-200c (P<0.0001) and miR-205 (P<0.0001) were significantly increased in endometrial tumors compared to normal tissues. Kaplan-Meier survival analysis revealed that high levels of miR-205 expression were associated with poor patient overall survival. +tissue_expression_up hsa-mir-155 Demyelinating Diseases 22517757 "Both in vivo and in vitro, myelin antigen stimulation resulted in significant up-regulation of miR-301a, miR-21, and miR-155." +tissue_expression_up hsa-mir-21 Demyelinating Diseases 22517757 "Both in vivo and in vitro, myelin antigen stimulation resulted in significant up-regulation of miR-301a, miR-21, and miR-155." +tissue_expression_up hsa-mir-132 "Liver Diseases, Alcoholic" 22518321 "In this paper, we summarize the current knowledge of miRNAs in ALD and also report increased expression of miR-155 and miR-132 in the total liver as well as in isolated hepatocytes and KCs of alcohol-fed mice." +tissue_expression_up hsa-mir-155 "Liver Diseases, Alcoholic" 22518321 "In this paper, we summarize the current knowledge of miRNAs in ALD and also report increased expression of miR-155 and miR-132 in the total liver as well as in isolated hepatocytes and KCs of alcohol-fed mice." +tissue_expression_up hsa-mir-125b-1 Breast Neoplasms 22523546 "miR-125b was significantly associated with therapeutic response, exhibiting higher expression level in non-responsive patients." +tissue_expression_up hsa-mir-125b-2 Breast Neoplasms 22523546 "miR-125b was significantly associated with therapeutic response, exhibiting higher expression level in non-responsive patients." +tissue_expression_up hsa-mir-10a Breast Neoplasms 22524830 "The BC patients showed an up-regulation in miRNAs (mir-155, mir-10,mir-21 and mir-373)" +tissue_expression_up hsa-mir-10b Breast Neoplasms 22524830 "The BC patients showed an up-regulation in miRNAs (mir-155, mir-10,mir-21 and mir-373)" +tissue_expression_up hsa-mir-155 Breast Neoplasms 22524830 "The BC patients showed an up-regulation in miRNAs (mir-155, mir-10,mir-21 and mir-373)" +tissue_expression_up hsa-mir-21 Breast Neoplasms 22524830 "The BC patients showed an up-regulation in miRNAs (mir-155, mir-10,mir-21 and mir-373)" +tissue_expression_up hsa-mir-373 Breast Neoplasms 22524830 "The BC patients showed an up-regulation in miRNAs (mir-155, mir-10,mir-21 and mir-373)" +tissue_expression_up hsa-mir-155 Endometrial Neoplasms 22525818 miR-155 was over-expressed and AGTR1 was underexpressed in endometrial carcinoma tissues. +tissue_expression_up hsa-mir-106b "Carcinoma, Basal Cell" 22540308 upregulated in the tumor center +tissue_expression_up hsa-mir-125a "Carcinoma, Basal Cell" 22540308 miR-125a-5p is upregulated in the tumor center +tissue_expression_up hsa-mir-17 "Carcinoma, Basal Cell" 22540308 upregulated in the tumor center +tissue_expression_up hsa-mir-181c "Carcinoma, Basal Cell" 22540308 miR-181c and miR-181c* are upregulated in the tumor center +tissue_expression_up hsa-mir-181d "Carcinoma, Basal Cell" 22540308 upregulated in the tumor center +tissue_expression_up hsa-mir-182 "Carcinoma, Basal Cell" 22540308 upregulated in the tumor center +tissue_expression_up hsa-mir-18a "Carcinoma, Basal Cell" 22540308 upregulated in the tumor center +tissue_expression_up hsa-mir-18b "Carcinoma, Basal Cell" 22540308 upregulated in the tumor center +tissue_expression_up hsa-mir-19b-1 "Carcinoma, Basal Cell" 22540308 miR-19b is upregulated in the tumor center +tissue_expression_up hsa-mir-19b-2 "Carcinoma, Basal Cell" 22540308 miR-19b is upregulated in the tumor center +tissue_expression_up hsa-mir-455 "Carcinoma, Basal Cell" 22540308 miR-455-5p and miR-455-3p are upregulated in the tumor center +tissue_expression_up hsa-mir-542 "Carcinoma, Basal Cell" 22540308 miR-542 is upregulated in the tumor center +tissue_expression_up hsa-mir-93 "Carcinoma, Basal Cell" 22540308 upregulated in the tumor center +tissue_expression_up hsa-mir-30b "Squamous Cell Carcinoma, Oral" 22542163 Amplification and up-regulation of microRNA-30b in oral squamous cell cancers. +tissue_expression_up hsa-mir-142 Endometrial Neoplasms 22543862 miR-142-5p: Increased expression after Progesterone Treatment. +tissue_expression_up hsa-mir-146b Endometrial Neoplasms 22543862 miR-146b-5p: Increased expression after Progesterone Treatment. +tissue_expression_up hsa-mir-21 Endometrial Neoplasms 22543862 Increased expression after Progesterone Treatment. +tissue_expression_up hsa-mir-625 Endometrial Neoplasms 22543862 miR-625*: Increased expression after Progesterone Treatment. +tissue_expression_up hsa-mir-34a Colorectal Carcinoma 22562822 "microRNA-34a, microRNA-155 and microRNA-200c overexpression in human colorectal cancer." +tissue_expression_up hsa-mir-93 Gastric Neoplasms 22567743 "miR-93 is highly elevated in gastric cancer, especially in advanced and metastasized gastric cancer, suggesting miR-93 may play critical roles in carcinogenesis of gastric cancer. Overexpression of miR-93 can serve as a novel prognostic marker for gastric cancer." +tissue_expression_up hsa-mir-708 "Carcinoma, Lung, Non-Small-Cell" 22573352 Increased miR-708 expression in NSCLC and its association with poor survival in lung adenocarcinoma from never smokers. +tissue_expression_up hsa-mir-17 "Carcinoma, Hepatocellular" 22583011 miR-17-5p was significantly upregulated in HCCs. HCC with metastasis had higher miR-17-5p levels than that without metastasis. +tissue_expression_up hsa-mir-142 Atopic Dermatitis 22594804 "In humans sensitized with DPCP, we found significant upregulation of miR-21, miR-142-3p, miR-142-5p and miR-223 in challenged skin." +tissue_expression_up hsa-mir-21 Atopic Dermatitis 22594804 "In humans sensitized with DPCP, we found significant upregulation of miR-21, miR-142-3p, miR-142-5p and miR-223 in challenged skin." +tissue_expression_up hsa-mir-223 Atopic Dermatitis 22594804 "In humans sensitized with DPCP, we found significant upregulation of miR-21, miR-142-3p, miR-142-5p and miR-223 in challenged skin." +tissue_expression_up hsa-mir-150 Inflammation 22595106 "Of the 335 human miRNAs identified in the pulp tissues, 3 miRNAs, miR-150, miR-584, and miR-766, were significantly up-regulated in inflamed pulps as compared with normal pulps" +tissue_expression_up hsa-mir-584 Inflammation 22595106 "Of the 335 human miRNAs identified in the pulp tissues, 3 miRNAs, miR-150, miR-584, and miR-766, were significantly up-regulated in inflamed pulps as compared with normal pulps" +tissue_expression_up hsa-mir-766 Inflammation 22595106 "Of the 335 human miRNAs identified in the pulp tissues, 3 miRNAs, miR-150, miR-584, and miR-766, were significantly up-regulated in inflamed pulps as compared with normal pulps" +tissue_expression_up hsa-mir-205 Laryngeal Neoplasms 22605671 Upregulation +tissue_expression_up hsa-mir-21 Laryngeal Neoplasms 22605671 Upregulation +tissue_expression_up hsa-mir-708 Laryngeal Neoplasms 22605671 Upregulation +tissue_expression_up hsa-mir-93 Laryngeal Neoplasms 22605671 Upregulation +tissue_expression_up hsa-mir-221 Gastric Neoplasms 22613407 "MiR-221 was up-regulated in 88% (81/92) of gastric cancer tissue samples compared with their paired adjacent nontumour tissue samples. High expression of miR-221 showed a significant correlation with advanced tumour-node-metastasis stage, local invasion and lymphatic metastasis." +tissue_expression_up hsa-mir-130a Ovarian Neoplasms 22614869 Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance. +tissue_expression_up hsa-mir-155 "Carcinoma, Hepatocellular" 22629365 "High expression levels of miR-155, miR-15a, miR-432, miR-486-3p, miR-15b and miR-30b were significantly associated with recurrence-free." +tissue_expression_up hsa-mir-15a "Carcinoma, Hepatocellular" 22629365 "High expression levels of miR-155, miR-15a, miR-432, miR-486-3p, miR-15b and miR-30b were significantly associated with recurrence-free." +tissue_expression_up hsa-mir-15b "Carcinoma, Hepatocellular" 22629365 "High expression levels of miR-155, miR-15a, miR-432, miR-486-3p, miR-15b and miR-30b were significantly associated with recurrence-free." +tissue_expression_up hsa-mir-30b "Carcinoma, Hepatocellular" 22629365 "High expression levels of miR-155, miR-15a, miR-432, miR-486-3p, miR-15b and miR-30b were significantly associated with recurrence-free." +tissue_expression_up hsa-mir-432 "Carcinoma, Hepatocellular" 22629365 "High expression levels of miR-155, miR-15a, miR-432, miR-486-3p, miR-15b and miR-30b were significantly associated with recurrence-free." +tissue_expression_up hsa-mir-486 "Carcinoma, Hepatocellular" 22629365 "High expression levels of miR-155, miR-15a, miR-432, miR-486-3p, miR-15b and miR-30b were significantly associated with recurrence-free." +tissue_expression_up hsa-mir-34a Head And Neck Neoplasms 22629428 Dysregulation of microRNA-34a expression in head and neck squamous cell carcinoma promotes tumor growth and tumor angiogenesis. +tissue_expression_up hsa-mir-21 Breast Neoplasms 22638884 "miR-21 was significantly overexpressed in human solid cancerous serum relative to normal control (P < 0.001), and its sensitivity and specificity were significantly higher than the currently used tumor markers." +tissue_expression_up hsa-mir-21 Colorectal Carcinoma 22638884 "miR-21 was significantly overexpressed in human solid cancerous serum relative to normal control (P < 0.001), and its sensitivity and specificity were significantly higher than the currently used tumor markers." +tissue_expression_up hsa-mir-21 Esophageal Neoplasms 22638884 "miR-21 was significantly overexpressed in human solid cancerous serum relative to normal control (P < 0.001), and its sensitivity and specificity were significantly higher than the currently used tumor markers." +tissue_expression_up hsa-mir-21 Gastric Neoplasms 22638884 "miR-21 was significantly overexpressed in human solid cancerous serum relative to normal control (P < 0.001), and its sensitivity and specificity were significantly higher than the currently used tumor markers." +tissue_expression_up hsa-mir-21 Lung Neoplasms 22638884 "miR-21 was significantly overexpressed in human solid cancerous serum relative to normal control (P < 0.001), and its sensitivity and specificity were significantly higher than the currently used tumor markers." +tissue_expression_up hsa-mir-181a-2 Colorectal Carcinoma 22641662 "KRAS up-regulates the expression of miR-181a, miR-200c and miR-210 in a three-dimensional-specific manner in DLD-1 colorectal cancer cells." +tissue_expression_up hsa-mir-200c Colorectal Carcinoma 22641662 "KRAS up-regulates the expression of miR-181a, miR-200c and miR-210 in a three-dimensional-specific manner in DLD-1 colorectal cancer cells." +tissue_expression_up hsa-mir-210 Colorectal Carcinoma 22641662 "KRAS up-regulates the expression of miR-181a, miR-200c and miR-210 in a three-dimensional-specific manner in DLD-1 colorectal cancer cells." +tissue_expression_up hsa-mir-146a Ovarian Neoplasms 22643117 "We found 37 differentially expressed miRNAs in the CD133(+) spheroid-forming subpopulation of OVCAR3 cells, 34 of which were significantly up-regulated, including miR-205, miR-146a, miR-200a, miR-200b, and miR-3, and 3 of which were significantly down-regulated, including miR-1202 and miR-1181." +tissue_expression_up hsa-mir-200a Ovarian Neoplasms 22643117 "We found 37 differentially expressed miRNAs in the CD133(+) spheroid-forming subpopulation of OVCAR3 cells, 34 of which were significantly up-regulated, including miR-205, miR-146a, miR-200a, miR-200b, and miR-3, and 3 of which were significantly down-regulated, including miR-1202 and miR-1181." +tissue_expression_up hsa-mir-200b Ovarian Neoplasms 22643117 "We found 37 differentially expressed miRNAs in the CD133(+) spheroid-forming subpopulation of OVCAR3 cells, 34 of which were significantly up-regulated, including miR-205, miR-146a, miR-200a, miR-200b, and miR-3, and 3 of which were significantly down-regulated, including miR-1202 and miR-1181." +tissue_expression_up hsa-mir-205 Ovarian Neoplasms 22643117 "We found 37 differentially expressed miRNAs in the CD133(+) spheroid-forming subpopulation of OVCAR3 cells, 34 of which were significantly up-regulated, including miR-205, miR-146a, miR-200a, miR-200b, and miR-3, and 3 of which were significantly down-regulated, including miR-1202 and miR-1181." +tissue_expression_up hsa-mir-3 Ovarian Neoplasms 22643117 "We found 37 differentially expressed miRNAs in the CD133(+) spheroid-forming subpopulation of OVCAR3 cells, 34 of which were significantly up-regulated, including miR-205, miR-146a, miR-200a, miR-200b, and miR-3, and 3 of which were significantly down-regulated, including miR-1202 and miR-1181." +tissue_expression_up hsa-mir-335 Glioma 22644918 Tumor microRNA-335 expression is associated with poor prognosis in human glioma. +tissue_expression_up hsa-mir-92a-1 "Scleroderma, Systemic" 22661558 microRNA-92a expression in the sera and dermal fibroblasts increases in patients with scleroderma. +tissue_expression_up hsa-mir-92a-2 "Scleroderma, Systemic" 22661558 microRNA-92a expression in the sera and dermal fibroblasts increases in patients with scleroderma. +tissue_expression_up hsa-mir-182 Lung Neoplasms 22672859 "Four up-regulated microRNAs (miR-210, miR-21, miR-31 and miR-182) and two down-regulated mcroiRNAs (miR-126 and miR-145) were consistently reported both in squamous carcinoma and adenocarcinoma-based subgroup analysis" +tissue_expression_up hsa-mir-21 Lung Neoplasms 22672859 "Four up-regulated microRNAs (miR-210, miR-21, miR-31 and miR-182) and two down-regulated mcroiRNAs (miR-126 and miR-145) were consistently reported both in squamous carcinoma and adenocarcinoma-based subgroup analysis" +tissue_expression_up hsa-mir-210 Lung Neoplasms 22672859 "Four up-regulated microRNAs (miR-210, miR-21, miR-31 and miR-182) and two down-regulated mcroiRNAs (miR-126 and miR-145) were consistently reported both in squamous carcinoma and adenocarcinoma-based subgroup analysis" +tissue_expression_up hsa-mir-31 Lung Neoplasms 22672859 "Four up-regulated microRNAs (miR-210, miR-21, miR-31 and miR-182) and two down-regulated mcroiRNAs (miR-126 and miR-145) were consistently reported both in squamous carcinoma and adenocarcinoma-based subgroup analysis" +tissue_expression_up hsa-mir-190a Meningioma 22674195 Downregulation of miR-29c-3p and miR-219-5p were found to be associated with advanced clinical stages of meningioma. Kaplan-Meier analysis showed that high expression of miR-190a and low expression of miR-29c-3p and miR-219-5p correlated significantly with higher recurrence rates in meningioma patients. +tissue_expression_up hsa-mir-221 Glioma 22681957 High level of miR-221/222 confers increased cell invasion and poor prognosis in glioma. +tissue_expression_up hsa-mir-222 Glioma 22681957 High level of miR-221/222 confers increased cell invasion and poor prognosis in glioma. +tissue_expression_up hsa-mir-17 Osteosarcoma 22682620 up-regulated in osteosarcoma. +tissue_expression_up hsa-mir-18a Osteosarcoma 22682620 up-regulated in osteosarcoma. +tissue_expression_up hsa-mir-19a Osteosarcoma 22682620 up-regulated in osteosarcoma. +tissue_expression_up hsa-mir-19b-1 Osteosarcoma 22682620 up-regulated in osteosarcoma. +tissue_expression_up hsa-mir-20a Osteosarcoma 22682620 up-regulated in osteosarcoma. +tissue_expression_up hsa-mir-92a-1 Osteosarcoma 22682620 up-regulated in osteosarcoma. +tissue_expression_up hsa-mir-134 Pancreatic Neoplasms 22690071 "miR-95, miR-134 and miR-34c-3p are the top three miRNAs regulated by glargine (3.65-fold, 2.67-fold and 2.60-fold changes respectively, P < 0.01) in Sw1990 cells." +tissue_expression_up hsa-mir-34c Pancreatic Neoplasms 22690071 "miR-95, miR-134 and miR-34c-3p are the top three miRNAs regulated by glargine (3.65-fold, 2.67-fold and 2.60-fold changes respectively, P < 0.01) in Sw1990 cells." +tissue_expression_up hsa-mir-95 Pancreatic Neoplasms 22690071 "miR-95, miR-134 and miR-34c-3p are the top three miRNAs regulated by glargine (3.65-fold, 2.67-fold and 2.60-fold changes respectively, P < 0.01) in Sw1990 cells." +tissue_expression_up hsa-mir-21 Urinary Bladder Cancer 22704449 High miR-21 expression correlated with worse overall patient survival (p = 0.0099). +tissue_expression_up hsa-mir-21 Melanoma 22716245 microRNA-21 is upregulated in malignant melanoma and influences apoptosis of melanocytic cells. +tissue_expression_up hsa-mir-301a Prostate Neoplasms 22719071 upregulated in prostate cancer stem/progenitor cell. +tissue_expression_up hsa-mir-301b Prostate Neoplasms 22719071 upregulated in prostate cancer stem/progenitor cell. +tissue_expression_up hsa-mir-452 Prostate Neoplasms 22719071 upregulated in prostate cancer stem/progenitor cell. +tissue_expression_up hsa-mir-137 Glioblastoma 22722712 "miR-181b, miR-153, miR-145, miR-137, and let-7d were significantly upregulated after treatment with both TMZ (temozolomide ) and OLE (Olea europaea leaf extract)." +tissue_expression_up hsa-mir-145 Glioblastoma 22722712 "miR-181b, miR-153, miR-145, miR-137, and let-7d were significantly upregulated after treatment with both TMZ (temozolomide ) and OLE (Olea europaea leaf extract)." +tissue_expression_up hsa-mir-153-1 Glioblastoma 22722712 "miR-181b, miR-153, miR-145, miR-137, and let-7d were significantly upregulated after treatment with both TMZ (temozolomide ) and OLE (Olea europaea leaf extract)." +tissue_expression_up hsa-mir-153-2 Glioblastoma 22722712 "miR-181b, miR-153, miR-145, miR-137, and let-7d were significantly upregulated after treatment with both TMZ (temozolomide ) and OLE (Olea europaea leaf extract)." +tissue_expression_up hsa-mir-181b-1 Glioblastoma 22722712 "miR-181b, miR-153, miR-145, miR-137, and let-7d were significantly upregulated after treatment with both TMZ (temozolomide ) and OLE (Olea europaea leaf extract)." +tissue_expression_up hsa-mir-181b-2 Glioblastoma 22722712 "miR-181b, miR-153, miR-145, miR-137, and let-7d were significantly upregulated after treatment with both TMZ (temozolomide ) and OLE (Olea europaea leaf extract)." +tissue_expression_up hsa-mir-1 Heart Failure 22735911 "Some miRNAs highly expressed in the heart, such as miR-1,miR-133 and miR-208, are strongly associated with the development of cardiac hypertrophy, while the exact role of miR-21 in the cardiovascular system remains controversial." +tissue_expression_up hsa-mir-133 Heart Failure 22735911 "Some miRNAs highly expressed in the heart, such as miR-1,miR-133 and miR-208, are strongly associated with the development of cardiac hypertrophy, while the exact role of miR-21 in the cardiovascular system remains controversial." +tissue_expression_up hsa-mir-208 Heart Failure 22735911 "Some miRNAs highly expressed in the heart, such as miR-1,miR-133 and miR-208, are strongly associated with the development of cardiac hypertrophy, while the exact role of miR-21 in the cardiovascular system remains controversial." +tissue_expression_up hsa-mir-21 Heart Failure 22735911 "Some miRNAs highly expressed in the heart, such as miR-1,miR-133 and miR-208, are strongly associated with the development of cardiac hypertrophy, while the exact role of miR-21 in the cardiovascular system remains controversial." +tissue_expression_up hsa-mir-21 Multiple Myeloma 22739167 "It is concluded that the expression levels of miR-21 in BMMNC of MM patients are significantly higher than in normal bone marrow, these data indicated that miR-21 may play an important role in the development of MM." +tissue_expression_up hsa-mir-10b Colorectal Carcinoma 22740910 "Overexpression of miR-145, miR-1, miR-146a, miR-576-5p, miR-126*, HS287, miR-28-5p, miR-143, miR-199b-5p, miR-199a-5p, miR-10b, miR-22, miR-133b, miR-145*, miR-199a, miR-133a, miR-125b and downregulation of miR-31 and HS170 were observed in brain-metastatic carcinomas." +tissue_expression_up hsa-mir-125b Colorectal Carcinoma 22740910 "Overexpression of miR-145, miR-1, miR-146a, miR-576-5p, miR-126*, HS287, miR-28-5p, miR-143, miR-199b-5p, miR-199a-5p, miR-10b, miR-22, miR-133b, miR-145*, miR-199a, miR-133a, miR-125b and downregulation of miR-31 and HS170 were observed in brain-metastatic carcinomas." +tissue_expression_up hsa-mir-126 Colorectal Carcinoma 22740910 "Overexpression of miR-145, miR-1, miR-146a, miR-576-5p, miR-126*, HS287, miR-28-5p, miR-143, miR-199b-5p, miR-199a-5p, miR-10b, miR-22, miR-133b, miR-145*, miR-199a, miR-133a, miR-125b and downregulation of miR-31 and HS170 were observed in brain-metastatic carcinomas." +tissue_expression_up hsa-mir-133a Colorectal Carcinoma 22740910 "Overexpression of miR-145, miR-1, miR-146a, miR-576-5p, miR-126*, HS287, miR-28-5p, miR-143, miR-199b-5p, miR-199a-5p, miR-10b, miR-22, miR-133b, miR-145*, miR-199a, miR-133a, miR-125b and downregulation of miR-31 and HS170 were observed in brain-metastatic carcinomas." +tissue_expression_up hsa-mir-133b Colorectal Carcinoma 22740910 "Overexpression of miR-145, miR-1, miR-146a, miR-576-5p, miR-126*, HS287, miR-28-5p, miR-143, miR-199b-5p, miR-199a-5p, miR-10b, miR-22, miR-133b, miR-145*, miR-199a, miR-133a, miR-125b and downregulation of miR-31 and HS170 were observed in brain-metastatic carcinomas." +tissue_expression_up hsa-mir-143 Colorectal Carcinoma 22740910 "Overexpression of miR-145, miR-1, miR-146a, miR-576-5p, miR-126*, HS287, miR-28-5p, miR-143, miR-199b-5p, miR-199a-5p, miR-10b, miR-22, miR-133b, miR-145*, miR-199a, miR-133a, miR-125b and downregulation of miR-31 and HS170 were observed in brain-metastatic carcinomas." +tissue_expression_up hsa-mir-145 Colorectal Carcinoma 22740910 "Overexpression of miR-145, miR-1, miR-146a, miR-576-5p, miR-126*, HS287, miR-28-5p, miR-143, miR-199b-5p, miR-199a-5p, miR-10b, miR-22, miR-133b, miR-145*, miR-199a, miR-133a, miR-125b and downregulation of miR-31 and HS170 were observed in brain-metastatic carcinomas." +tissue_expression_up hsa-mir-146a Colorectal Carcinoma 22740910 "Overexpression of miR-145, miR-1, miR-146a, miR-576-5p, miR-126*, HS287, miR-28-5p, miR-143, miR-199b-5p, miR-199a-5p, miR-10b, miR-22, miR-133b, miR-145*, miR-199a, miR-133a, miR-125b and downregulation of miR-31 and HS170 were observed in brain-metastatic carcinomas." +tissue_expression_up hsa-mir-199a Colorectal Carcinoma 22740910 "Overexpression of miR-145, miR-1, miR-146a, miR-576-5p, miR-126*, HS287, miR-28-5p, miR-143, miR-199b-5p, miR-199a-5p, miR-10b, miR-22, miR-133b, miR-145*, miR-199a, miR-133a, miR-125b and downregulation of miR-31 and HS170 were observed in brain-metastatic carcinomas." +tissue_expression_up hsa-mir-199b Colorectal Carcinoma 22740910 "Overexpression of miR-145, miR-1, miR-146a, miR-576-5p, miR-126*, HS287, miR-28-5p, miR-143, miR-199b-5p, miR-199a-5p, miR-10b, miR-22, miR-133b, miR-145*, miR-199a, miR-133a, miR-125b and downregulation of miR-31 and HS170 were observed in brain-metastatic carcinomas." +tissue_expression_up hsa-mir-22 Colorectal Carcinoma 22740910 "Overexpression of miR-145, miR-1, miR-146a, miR-576-5p, miR-126*, HS287, miR-28-5p, miR-143, miR-199b-5p, miR-199a-5p, miR-10b, miR-22, miR-133b, miR-145*, miR-199a, miR-133a, miR-125b and downregulation of miR-31 and HS170 were observed in brain-metastatic carcinomas." +tissue_expression_up hsa-mir-28 Colorectal Carcinoma 22740910 "Overexpression of miR-145, miR-1, miR-146a, miR-576-5p, miR-126*, HS287, miR-28-5p, miR-143, miR-199b-5p, miR-199a-5p, miR-10b, miR-22, miR-133b, miR-145*, miR-199a, miR-133a, miR-125b and downregulation of miR-31 and HS170 were observed in brain-metastatic carcinomas." +tissue_expression_up hsa-mir-576 Colorectal Carcinoma 22740910 "Overexpression of miR-145, miR-1, miR-146a, miR-576-5p, miR-126*, HS287, miR-28-5p, miR-143, miR-199b-5p, miR-199a-5p, miR-10b, miR-22, miR-133b, miR-145*, miR-199a, miR-133a, miR-125b and downregulation of miR-31 and HS170 were observed in brain-metastatic carcinomas." +tissue_expression_up hsa-mir-127 Thyroid Neoplasms 22747440 "MTC and CCH were both characterized by a significant overexpression of the whole set of miRNAs (the increase being 4.2-fold for miR-21, 6.7-fold for miR-127, 8.8-fold for miR-154, 6.6-fold for miR-224, 5.8-fold for miR-323, 6.1-fold for miR-370, 13-fold for miR-9*, 6.7-fold for miR-183, and 10.1 for miR-375, p<0.0001)." +tissue_expression_up hsa-mir-154 Thyroid Neoplasms 22747440 "MTC and CCH were both characterized by a significant overexpression of the whole set of miRNAs (the increase being 4.2-fold for miR-21, 6.7-fold for miR-127, 8.8-fold for miR-154, 6.6-fold for miR-224, 5.8-fold for miR-323, 6.1-fold for miR-370, 13-fold for miR-9*, 6.7-fold for miR-183, and 10.1 for miR-375, p<0.0001)." +tissue_expression_up hsa-mir-183 Thyroid Neoplasms 22747440 "MTC and CCH were both characterized by a significant overexpression of the whole set of miRNAs (the increase being 4.2-fold for miR-21, 6.7-fold for miR-127, 8.8-fold for miR-154, 6.6-fold for miR-224, 5.8-fold for miR-323, 6.1-fold for miR-370, 13-fold for miR-9*, 6.7-fold for miR-183, and 10.1 for miR-375, p<0.0001)." +tissue_expression_up hsa-mir-21 Thyroid Neoplasms 22747440 "MTC and CCH were both characterized by a significant overexpression of the whole set of miRNAs (the increase being 4.2-fold for miR-21, 6.7-fold for miR-127, 8.8-fold for miR-154, 6.6-fold for miR-224, 5.8-fold for miR-323, 6.1-fold for miR-370, 13-fold for miR-9*, 6.7-fold for miR-183, and 10.1 for miR-375, p<0.0001)." +tissue_expression_up hsa-mir-224 Thyroid Neoplasms 22747440 "MTC and CCH were both characterized by a significant overexpression of the whole set of miRNAs (the increase being 4.2-fold for miR-21, 6.7-fold for miR-127, 8.8-fold for miR-154, 6.6-fold for miR-224, 5.8-fold for miR-323, 6.1-fold for miR-370, 13-fold for miR-9*, 6.7-fold for miR-183, and 10.1 for miR-375, p<0.0001)." +tissue_expression_up hsa-mir-323 Thyroid Neoplasms 22747440 "MTC and CCH were both characterized by a significant overexpression of the whole set of miRNAs (the increase being 4.2-fold for miR-21, 6.7-fold for miR-127, 8.8-fold for miR-154, 6.6-fold for miR-224, 5.8-fold for miR-323, 6.1-fold for miR-370, 13-fold for miR-9*, 6.7-fold for miR-183, and 10.1 for miR-375, p<0.0001)." +tissue_expression_up hsa-mir-370 Thyroid Neoplasms 22747440 "MTC and CCH were both characterized by a significant overexpression of the whole set of miRNAs (the increase being 4.2-fold for miR-21, 6.7-fold for miR-127, 8.8-fold for miR-154, 6.6-fold for miR-224, 5.8-fold for miR-323, 6.1-fold for miR-370, 13-fold for miR-9*, 6.7-fold for miR-183, and 10.1 for miR-375, p<0.0001)." +tissue_expression_up hsa-mir-375 Thyroid Neoplasms 22747440 "MTC and CCH were both characterized by a significant overexpression of the whole set of miRNAs (the increase being 4.2-fold for miR-21, 6.7-fold for miR-127, 8.8-fold for miR-154, 6.6-fold for miR-224, 5.8-fold for miR-323, 6.1-fold for miR-370, 13-fold for miR-9*, 6.7-fold for miR-183, and 10.1 for miR-375, p<0.0001)." +tissue_expression_up hsa-mir-9 Thyroid Neoplasms 22747440 "MTC and CCH were both characterized by a significant overexpression of the whole set of miRNAs (the increase being 4.2-fold for miR-21, 6.7-fold for miR-127, 8.8-fold for miR-154, 6.6-fold for miR-224, 5.8-fold for miR-323, 6.1-fold for miR-370, 13-fold for miR-9*, 6.7-fold for miR-183, and 10.1 for miR-375, p<0.0001)." +tissue_expression_up hsa-mir-125b-2 Myotonic Muscular Dystrophy 22768114 miR-125b-5p: decreased levels compared to controls +tissue_expression_up hsa-mir-146b Myotonic Muscular Dystrophy 22768114 higher levels compared to controls +tissue_expression_up hsa-mir-208a Myotonic Muscular Dystrophy 22768114 miR-146b-5p: higher levels compared to controls +tissue_expression_up hsa-mir-221 Myotonic Muscular Dystrophy 22768114 higher levels compared to controls +tissue_expression_up hsa-mir-34a Myotonic Muscular Dystrophy 22768114 miR-34a-5p: higher levels compared to controls +tissue_expression_up hsa-mir-34b Myotonic Muscular Dystrophy 22768114 miR-34b-3p: higher levels compared to controls +tissue_expression_up hsa-mir-34c Myotonic Muscular Dystrophy 22768114 miR-34c-5p: higher levels compared to controls +tissue_expression_up hsa-mir-381 Myotonic Muscular Dystrophy 22768114 higher levels compared to controls +tissue_expression_up hsa-mir-92a-1 Colorectal Carcinoma 22772712 Overexpression of miR-92a correlates with tumor metastasis and poor prognosis in patients with colorectal cancer. +tissue_expression_up hsa-mir-668 Interstitial Lung Disease 22782705 upregulated +tissue_expression_up hsa-mir-92b Interstitial Lung Disease 22782705 upregulated +tissue_expression_up hsa-mir-15a Ischemia-Reperfusion Injury 22783320 MicroRNA-15a/b are up-regulated in response to myocardial ischemia/reperfusion injury. +tissue_expression_up hsa-mir-15a Myocardial Ischemic-Reperfusion Injury 22783320 MicroRNA-15a/b are up-regulated in response to myocardial ischemia/reperfusion injury. +tissue_expression_up hsa-mir-15b Ischemia-Reperfusion Injury 22783320 MicroRNA-15a/b are up-regulated in response to myocardial ischemia/reperfusion injury. +tissue_expression_up hsa-mir-15b Myocardial Ischemic-Reperfusion Injury 22783320 MicroRNA-15a/b are up-regulated in response to myocardial ischemia/reperfusion injury. +tissue_expression_up hsa-mir-182 Glioma 22788545 "The concentration of miRNA-182 in glioma patients was found to be 3.1 times as high as that in healthy persons, a conclusion in excellent agreement with a separate qPCR measurement of the expression level." +tissue_expression_up hsa-mir-21 Head And Neck Neoplasms 22811001 "The expression level of miR-21 was significantly up-regulated in plasma samples obtained from HNSCC patients (p<0.01) than those from healthy subjects, which were in consistent with our finding in HNSCC tissues." +tissue_expression_up hsa-mir-142 Eosinophilic Esophagitis 22815788 "Compared to the post-glucocorticoid treated esophageal mucosa,MiR-214, miR-146b-5b, 146a, 145, 142-3p and 21 were upregulated." +tissue_expression_up hsa-mir-145 Eosinophilic Esophagitis 22815788 "Compared to the post-glucocorticoid treated esophageal mucosa,MiR-214, miR-146b-5b, 146a, 145, 142-3p and 21 were upregulated." +tissue_expression_up hsa-mir-146a Eosinophilic Esophagitis 22815788 "Compared to the post-glucocorticoid treated esophageal mucosa,MiR-214, miR-146b-5b, 146a, 145, 142-3p and 21 were upregulated." +tissue_expression_up hsa-mir-146b Eosinophilic Esophagitis 22815788 "Compared to the post-glucocorticoid treated esophageal mucosa,MiR-214, miR-146b-5b, 146a, 145, 142-3p and 21 were upregulated." +tissue_expression_up hsa-mir-21 Eosinophilic Esophagitis 22815788 "Compared to the post-glucocorticoid treated esophageal mucosa,MiR-214, miR-146b-5b, 146a, 145, 142-3p and 21 were upregulated." +tissue_expression_up hsa-mir-106b Glioma 22825541 Upregulation of miR-20a and miR-106b is involved in the acquisition of malignancy of pediatric brainstem gliomas. +tissue_expression_up hsa-mir-20a Glioma 22825541 Upregulation of miR-20a and miR-106b is involved in the acquisition of malignancy of pediatric brainstem gliomas. +tissue_expression_up hsa-mir-146a Nasopharyngeal Neoplasms 22843060 Expression of miRNA-146a in nasopharyngeal carcinoma is upregulated by Epstein-Barr virus latent membrane protein 1. +tissue_expression_up hsa-mir-214 Liver Cirrhosis 22849305 miR-214-5p was upregulated in human and mouse livers in a fibrosis progression-dependent manner. +tissue_expression_up hsa-mir-155 Pancreatic Neoplasms 22850622 "miR-21, miR-155, miR-210, miR-221, and miR-222, were overexpressed in diseased tissues than in the control samples, whereas miR-31, miR-122, miR-145, and miR-146a were underexpressed." +tissue_expression_up hsa-mir-21 Pancreatic Neoplasms 22850622 "miR-21, miR-155, miR-210, miR-221, and miR-222, were overexpressed in diseased tissues than in the control samples, whereas miR-31, miR-122, miR-145, and miR-146a were underexpressed." +tissue_expression_up hsa-mir-210 Pancreatic Neoplasms 22850622 "miR-21, miR-155, miR-210, miR-221, and miR-222, were overexpressed in diseased tissues than in the control samples, whereas miR-31, miR-122, miR-145, and miR-146a were underexpressed." +tissue_expression_up hsa-mir-222 Pancreatic Neoplasms 22850622 "miR-21, miR-155, miR-210, miR-221, and miR-222, were overexpressed in diseased tissues than in the control samples, whereas miR-31, miR-122, miR-145, and miR-146a were underexpressed." +tissue_expression_up hsa-mir-208b Heart Failure 22859947 "Increasing doses of doxorubicin, but not etoposide (a Topoisomerase II inhibitor devoid of cardiovascular toxicity), specifically induced the up-regulation of miR-208b, miR-216b, miR-215, miR-34c and miR-367 in rat hearts. " +tissue_expression_up hsa-mir-215 Heart Failure 22859947 "Increasing doses of doxorubicin, but not etoposide (a Topoisomerase II inhibitor devoid of cardiovascular toxicity), specifically induced the up-regulation of miR-208b, miR-216b, miR-215, miR-34c and miR-367 in rat hearts. " +tissue_expression_up hsa-mir-216b Heart Failure 22859947 "Increasing doses of doxorubicin, but not etoposide (a Topoisomerase II inhibitor devoid of cardiovascular toxicity), specifically induced the up-regulation of miR-208b, miR-216b, miR-215, miR-34c and miR-367 in rat hearts. " +tissue_expression_up hsa-mir-34c Heart Failure 22859947 "Increasing doses of doxorubicin, but not etoposide (a Topoisomerase II inhibitor devoid of cardiovascular toxicity), specifically induced the up-regulation of miR-208b, miR-216b, miR-215, miR-34c and miR-367 in rat hearts. " +tissue_expression_up hsa-mir-367 Heart Failure 22859947 "Increasing doses of doxorubicin, but not etoposide (a Topoisomerase II inhibitor devoid of cardiovascular toxicity), specifically induced the up-regulation of miR-208b, miR-216b, miR-215, miR-34c and miR-367 in rat hearts. " +tissue_expression_up hsa-mir-141 Urinary Bladder Cancer 22886973 "hsa-mir-29c, hsa-miR-200a, hsa-miR-378, hsa-miR-429, hsa-miR-200c and hsa-miR-141 were up-regulated, while hsa-miR-451 was down-regulated." +tissue_expression_up hsa-mir-200a Urinary Bladder Cancer 22886973 "hsa-mir-29c, hsa-miR-200a, hsa-miR-378, hsa-miR-429, hsa-miR-200c and hsa-miR-141 were up-regulated, while hsa-miR-451 was down-regulated." +tissue_expression_up hsa-mir-200c Urinary Bladder Cancer 22886973 "hsa-mir-29c, hsa-miR-200a, hsa-miR-378, hsa-miR-429, hsa-miR-200c and hsa-miR-141 were up-regulated, while hsa-miR-451 was down-regulated." +tissue_expression_up hsa-mir-29c Urinary Bladder Cancer 22886973 "hsa-mir-29c, hsa-miR-200a, hsa-miR-378, hsa-miR-429, hsa-miR-200c and hsa-miR-141 were up-regulated, while hsa-miR-451 was down-regulated." +tissue_expression_up hsa-mir-378a Urinary Bladder Cancer 22886973 "hsa-mir-29c, hsa-miR-200a, hsa-miR-378, hsa-miR-429, hsa-miR-200c and hsa-miR-141 were up-regulated, while hsa-miR-451 was down-regulated." +tissue_expression_up hsa-mir-378b Urinary Bladder Cancer 22886973 "hsa-mir-29c, hsa-miR-200a, hsa-miR-378, hsa-miR-429, hsa-miR-200c and hsa-miR-141 were up-regulated, while hsa-miR-451 was down-regulated." +tissue_expression_up hsa-mir-378c Urinary Bladder Cancer 22886973 "hsa-mir-29c, hsa-miR-200a, hsa-miR-378, hsa-miR-429, hsa-miR-200c and hsa-miR-141 were up-regulated, while hsa-miR-451 was down-regulated." +tissue_expression_up hsa-mir-378d-1 Urinary Bladder Cancer 22886973 "hsa-mir-29c, hsa-miR-200a, hsa-miR-378, hsa-miR-429, hsa-miR-200c and hsa-miR-141 were up-regulated, while hsa-miR-451 was down-regulated." +tissue_expression_up hsa-mir-378d-2 Urinary Bladder Cancer 22886973 "hsa-mir-29c, hsa-miR-200a, hsa-miR-378, hsa-miR-429, hsa-miR-200c and hsa-miR-141 were up-regulated, while hsa-miR-451 was down-regulated." +tissue_expression_up hsa-mir-378e Urinary Bladder Cancer 22886973 "hsa-mir-29c, hsa-miR-200a, hsa-miR-378, hsa-miR-429, hsa-miR-200c and hsa-miR-141 were up-regulated, while hsa-miR-451 was down-regulated." +tissue_expression_up hsa-mir-378f Urinary Bladder Cancer 22886973 "hsa-mir-29c, hsa-miR-200a, hsa-miR-378, hsa-miR-429, hsa-miR-200c and hsa-miR-141 were up-regulated, while hsa-miR-451 was down-regulated." +tissue_expression_up hsa-mir-378g Urinary Bladder Cancer 22886973 "hsa-mir-29c, hsa-miR-200a, hsa-miR-378, hsa-miR-429, hsa-miR-200c and hsa-miR-141 were up-regulated, while hsa-miR-451 was down-regulated." +tissue_expression_up hsa-mir-378h Urinary Bladder Cancer 22886973 "hsa-mir-29c, hsa-miR-200a, hsa-miR-378, hsa-miR-429, hsa-miR-200c and hsa-miR-141 were up-regulated, while hsa-miR-451 was down-regulated." +tissue_expression_up hsa-mir-378i Urinary Bladder Cancer 22886973 "hsa-mir-29c, hsa-miR-200a, hsa-miR-378, hsa-miR-429, hsa-miR-200c and hsa-miR-141 were up-regulated, while hsa-miR-451 was down-regulated." +tissue_expression_up hsa-mir-429 Urinary Bladder Cancer 22886973 "hsa-mir-29c, hsa-miR-200a, hsa-miR-378, hsa-miR-429, hsa-miR-200c and hsa-miR-141 were up-regulated, while hsa-miR-451 was down-regulated." +tissue_expression_up hsa-mir-221 Asthma 22895815 Upregulation of miRNA-221 and miRNA-485-3p in pediatric asthma. +tissue_expression_up hsa-mir-485 Asthma 22895815 Upregulation of miRNA-221 and miRNA-485-3p in pediatric asthma. +tissue_expression_up hsa-mir-1225 Melanoma 22898827 "we assayed the MITF-KD miRNA profiles using a miRNA microarray and found that hsa-miR-1225-3p, hsa-miR-634, hsa-miR-197, hsa-miR-766, hsa-miR-574-5p and hsa-miR-328 were upregulated, and hsa-miR-720 and hsa-miR-1308 were downregulated in MITF knocked down melanocytes." +tissue_expression_up hsa-mir-197 Melanoma 22898827 "we assayed the MITF-KD miRNA profiles using a miRNA microarray and found that hsa-miR-1225-3p, hsa-miR-634, hsa-miR-197, hsa-miR-766, hsa-miR-574-5p and hsa-miR-328 were upregulated, and hsa-miR-720 and hsa-miR-1308 were downregulated in MITF knocked down melanocytes." +tissue_expression_up hsa-mir-328 Melanoma 22898827 "we assayed the MITF-KD miRNA profiles using a miRNA microarray and found that hsa-miR-1225-3p, hsa-miR-634, hsa-miR-197, hsa-miR-766, hsa-miR-574-5p and hsa-miR-328 were upregulated, and hsa-miR-720 and hsa-miR-1308 were downregulated in MITF knocked down melanocytes." +tissue_expression_up hsa-mir-574 Melanoma 22898827 "we assayed the MITF-KD miRNA profiles using a miRNA microarray and found that hsa-miR-1225-3p, hsa-miR-634, hsa-miR-197, hsa-miR-766, hsa-miR-574-5p and hsa-miR-328 were upregulated, and hsa-miR-720 and hsa-miR-1308 were downregulated in MITF knocked down melanocytes." +tissue_expression_up hsa-mir-634 Melanoma 22898827 "we assayed the MITF-KD miRNA profiles using a miRNA microarray and found that hsa-miR-1225-3p, hsa-miR-634, hsa-miR-197, hsa-miR-766, hsa-miR-574-5p and hsa-miR-328 were upregulated, and hsa-miR-720 and hsa-miR-1308 were downregulated in MITF knocked down melanocytes." +tissue_expression_up hsa-mir-766 Melanoma 22898827 "we assayed the MITF-KD miRNA profiles using a miRNA microarray and found that hsa-miR-1225-3p, hsa-miR-634, hsa-miR-197, hsa-miR-766, hsa-miR-574-5p and hsa-miR-328 were upregulated, and hsa-miR-720 and hsa-miR-1308 were downregulated in MITF knocked down melanocytes." +tissue_expression_up hsa-mir-128a Colon Neoplasms 22898888 "in colonic fibroblasts p38 was only moderately activated, p53 as well as p16 expressions were upregulated in the presence of increased expression of miR-34a, miR-128a and miR-449a." +tissue_expression_up hsa-mir-34a Colon Neoplasms 22898888 "in colonic fibroblasts p38 was only moderately activated, p53 as well as p16 expressions were upregulated in the presence of increased expression of miR-34a, miR-128a and miR-449a." +tissue_expression_up hsa-mir-449a Colon Neoplasms 22898888 "in colonic fibroblasts p38 was only moderately activated, p53 as well as p16 expressions were upregulated in the presence of increased expression of miR-34a, miR-128a and miR-449a." +tissue_expression_up hsa-mir-147a "Tuberculosis, Pulmonary" 22900099 Overexpression +tissue_expression_up hsa-mir-147b "Tuberculosis, Pulmonary" 22900099 Overexpression +tissue_expression_up hsa-mir-3179-1 "Tuberculosis, Pulmonary" 22900099 Overexpression +tissue_expression_up hsa-mir-3179-2 "Tuberculosis, Pulmonary" 22900099 Overexpression +tissue_expression_up hsa-mir-3179-3 "Tuberculosis, Pulmonary" 22900099 Overexpression +tissue_expression_up hsa-mir-181b-1 Gastric Neoplasms 22901205 The upregulation of miR-181b may play an important role in the progress of gastric cancer and miR-181b maybe a potential molecular target for anticancer therapeutics of gastric cancer. +tissue_expression_up hsa-mir-181b-2 Gastric Neoplasms 22901205 The upregulation of miR-181b may play an important role in the progress of gastric cancer and miR-181b maybe a potential molecular target for anticancer therapeutics of gastric cancer. +tissue_expression_up hsa-mir-200b Endometrial Neoplasms 22904162 miR-200b and -210 were significantly up-regulated in the cancerous endometrium. +tissue_expression_up hsa-mir-210 Endometrial Neoplasms 22904162 miR-200b and -210 were significantly up-regulated in the cancerous endometrium. +tissue_expression_up hsa-mir-10b Pancreatic Neoplasms 22910491 MicroRNA-10b is overexpressed in pancreatic cancer. +tissue_expression_up hsa-mir-155 "Carcinoma, Neuroendocrine" 22924844 The expression levels of miR-21 and miR-155 were significantly higher in high-grade NE carcinomas (LCNECs and SCLCs) than in carcinoid tumors (TCs and ACs) (each P < 0.001). The expression level of miR-21 in carcinoid tumors with lymph node metastasis was significantly higher than in carcinoid tumors without lymph node metastasis (P= 0.010). +tissue_expression_up hsa-mir-21 "Carcinoma, Neuroendocrine" 22924844 The expression levels of miR-21 and miR-155 were significantly higher in high-grade NE carcinomas (LCNECs and SCLCs) than in carcinoid tumors (TCs and ACs) (each P < 0.001). The expression level of miR-21 in carcinoid tumors with lymph node metastasis was significantly higher than in carcinoid tumors without lymph node metastasis (P= 0.010). +tissue_expression_up hsa-mir-451a Pancreatic Neoplasms 22929886 "The expression of let-7c, let-7f, and miR-200c were significantly reduced in most patients whereas the expression of miR-486-5p and miR-451 were significantly elevated in all pancreas cancer patients." +tissue_expression_up hsa-mir-451b Pancreatic Neoplasms 22929886 "The expression of let-7c, let-7f, and miR-200c were significantly reduced in most patients whereas the expression of miR-486-5p and miR-451 were significantly elevated in all pancreas cancer patients." +tissue_expression_up hsa-mir-486 Pancreatic Neoplasms 22929886 "The expression of let-7c, let-7f, and miR-200c were significantly reduced in most patients whereas the expression of miR-486-5p and miR-451 were significantly elevated in all pancreas cancer patients." +tissue_expression_up hsa-mir-135b Esophageal Neoplasms 22939244 Patients with high levels of miR-135b or miR-145 in the posttreatment biopsy specimens had significantly shorter median disease-free survival (DFS) than did those with low levels. +tissue_expression_up hsa-mir-16-1 Acute Lung Injury 22940131 "miR-16 upregulates ENaC, a major sodium channel involved in resolution of pulmonary edema in acute lung injury." +tissue_expression_up hsa-mir-16-2 Acute Lung Injury 22940131 "miR-16 upregulates ENaC, a major sodium channel involved in resolution of pulmonary edema in acute lung injury." +tissue_expression_up hsa-mir-142 Atrial Fibrillation 22944230 "MiR-155, miR-142-3p, miR-19b, miR-223, miR-146b-5p, miR-486-5p, miR-301b, miR-193b, miR-519b were found to be up-regulated by > 2 folds whereas miR-193a-5p was down-regulated in left atrial appendage (LAA) in patients with atrial fibrillation." +tissue_expression_up hsa-mir-146b Atrial Fibrillation 22944230 "MiR-155, miR-142-3p, miR-19b, miR-223, miR-146b-5p, miR-486-5p, miR-301b, miR-193b, miR-519b were found to be up-regulated by > 2 folds whereas miR-193a-5p was down-regulated in left atrial appendage (LAA) in patients with atrial fibrillation." +tissue_expression_up hsa-mir-155 Atrial Fibrillation 22944230 "MiR-155, miR-142-3p, miR-19b, miR-223, miR-146b-5p, miR-486-5p, miR-301b, miR-193b, miR-519b were found to be up-regulated by > 2 folds whereas miR-193a-5p was down-regulated in left atrial appendage (LAA) in patients with atrial fibrillation." +tissue_expression_up hsa-mir-193b Atrial Fibrillation 22944230 "MiR-155, miR-142-3p, miR-19b, miR-223, miR-146b-5p, miR-486-5p, miR-301b, miR-193b, miR-519b were found to be up-regulated by > 2 folds whereas miR-193a-5p was down-regulated in left atrial appendage (LAA) in patients with atrial fibrillation." +tissue_expression_up hsa-mir-19a Atrial Fibrillation 22944230 "MiR-155, miR-142-3p, miR-19b, miR-223, miR-146b-5p, miR-486-5p, miR-301b, miR-193b, miR-519b were found to be up-regulated by > 2 folds whereas miR-193a-5p was down-regulated in left atrial appendage (LAA) in patients with atrial fibrillation." +tissue_expression_up hsa-mir-19b-1 Atrial Fibrillation 22944230 "MiR-155, miR-142-3p, miR-19b, miR-223, miR-146b-5p, miR-486-5p, miR-301b, miR-193b, miR-519b were found to be up-regulated by > 2 folds whereas miR-193a-5p was down-regulated in left atrial appendage (LAA) in patients with atrial fibrillation." +tissue_expression_up hsa-mir-19b-2 Atrial Fibrillation 22944230 "MiR-155, miR-142-3p, miR-19b, miR-223, miR-146b-5p, miR-486-5p, miR-301b, miR-193b, miR-519b were found to be up-regulated by > 2 folds whereas miR-193a-5p was down-regulated in left atrial appendage (LAA) in patients with atrial fibrillation." +tissue_expression_up hsa-mir-223 Atrial Fibrillation 22944230 "MiR-155, miR-142-3p, miR-19b, miR-223, miR-146b-5p, miR-486-5p, miR-301b, miR-193b, miR-519b were found to be up-regulated by > 2 folds whereas miR-193a-5p was down-regulated in left atrial appendage (LAA) in patients with atrial fibrillation." +tissue_expression_up hsa-mir-486 Atrial Fibrillation 22944230 "MiR-155, miR-142-3p, miR-19b, miR-223, miR-146b-5p, miR-486-5p, miR-301b, miR-193b, miR-519b were found to be up-regulated by > 2 folds whereas miR-193a-5p was down-regulated in left atrial appendage (LAA) in patients with atrial fibrillation." +tissue_expression_up hsa-mir-519b Atrial Fibrillation 22944230 "MiR-155, miR-142-3p, miR-19b, miR-223, miR-146b-5p, miR-486-5p, miR-301b, miR-193b, miR-519b were found to be up-regulated by > 2 folds whereas miR-193a-5p was down-regulated in left atrial appendage (LAA) in patients with atrial fibrillation." +tissue_expression_up hsa-mir-221 Breast Neoplasms 22964023 "We identified 11 dysregulated miRNAs in CAFs: three were up-regulated (miR-221-5p, miR-31-3p, miR-221-3p), while eight were down-regulated (miR-205, miR-200b, miR-200c, miR-141, miR-101,miR-342-3p, let-7g, miR-26b)" +tissue_expression_up hsa-mir-31 Breast Neoplasms 22964023 "We identified 11 dysregulated miRNAs in CAFs: three were up-regulated (miR-221-5p, miR-31-3p, miR-221-3p), while eight were down-regulated (miR-205, miR-200b, miR-200c, miR-141, miR-101,miR-342-3p, let-7g, miR-26b)" +tissue_expression_up hsa-mir-424 Tuberculosis 22964481 "we observed that miR-146a expression is also down-regulated in tuberculosis patients, both in PBMCs and PFMCs while miR-424 levels are elevated only in the peripheral compartments." +tissue_expression_up hsa-let-7b Prion Diseases 22965126 "we show that exosomes released by prion-infected neuronal cells have increased let-7b, let-7i, miR-128a, miR-21, miR-222, miR-29b,miR-342-3p and miR-424 levels with decreased miR-146 a levels compared to non-infected exosomes." +tissue_expression_up hsa-let-7i Prion Diseases 22965126 "we show that exosomes released by prion-infected neuronal cells have increased let-7b, let-7i, miR-128a, miR-21, miR-222, miR-29b,miR-342-3p and miR-424 levels with decreased miR-146 a levels compared to non-infected exosomes." +tissue_expression_up hsa-mir-128a Prion Diseases 22965126 "we show that exosomes released by prion-infected neuronal cells have increased let-7b, let-7i, miR-128a, miR-21, miR-222, miR-29b,miR-342-3p and miR-424 levels with decreased miR-146 a levels compared to non-infected exosomes." +tissue_expression_up hsa-mir-21 Prion Diseases 22965126 "we show that exosomes released by prion-infected neuronal cells have increased let-7b, let-7i, miR-128a, miR-21, miR-222, miR-29b,miR-342-3p and miR-424 levels with decreased miR-146 a levels compared to non-infected exosomes." +tissue_expression_up hsa-mir-222 Prion Diseases 22965126 "we show that exosomes released by prion-infected neuronal cells have increased let-7b, let-7i, miR-128a, miR-21, miR-222, miR-29b,miR-342-3p and miR-424 levels with decreased miR-146 a levels compared to non-infected exosomes." +tissue_expression_up hsa-mir-29b Prion Diseases 22965126 "we show that exosomes released by prion-infected neuronal cells have increased let-7b, let-7i, miR-128a, miR-21, miR-222, miR-29b,miR-342-3p and miR-424 levels with decreased miR-146 a levels compared to non-infected exosomes." +tissue_expression_up hsa-mir-342 Prion Diseases 22965126 "we show that exosomes released by prion-infected neuronal cells have increased let-7b, let-7i, miR-128a, miR-21, miR-222, miR-29b,miR-342-3p and miR-424 levels with decreased miR-146 a levels compared to non-infected exosomes." +tissue_expression_up hsa-mir-424 Prion Diseases 22965126 "we show that exosomes released by prion-infected neuronal cells have increased let-7b, let-7i, miR-128a, miR-21, miR-222, miR-29b,miR-342-3p and miR-424 levels with decreased miR-146 a levels compared to non-infected exosomes." +tissue_expression_up hsa-mir-107 "Leukemia, Promyelocytic, Acute" 22967415 "The expression level of miR-15b, miR-16, miR-107, miR-223 and miR-342 in APL CR group were significantly upregulated compared with that of newly diagnosed APL groups (P < 0.05), while the expression level of miR-181a was significantly downregulated (P < 0.05)." +tissue_expression_up hsa-mir-15b "Leukemia, Promyelocytic, Acute" 22967415 "The expression level of miR-15b, miR-16, miR-107, miR-223 and miR-342 in APL CR group were significantly upregulated compared with that of newly diagnosed APL groups (P < 0.05), while the expression level of miR-181a was significantly downregulated (P < 0.05)." +tissue_expression_up hsa-mir-16 "Leukemia, Promyelocytic, Acute" 22967415 "The expression level of miR-15b, miR-16, miR-107, miR-223 and miR-342 in APL CR group were significantly upregulated compared with that of newly diagnosed APL groups (P < 0.05), while the expression level of miR-181a was significantly downregulated (P < 0.05)." +tissue_expression_up hsa-mir-223 "Leukemia, Promyelocytic, Acute" 22967415 "The expression level of miR-15b, miR-16, miR-107, miR-223 and miR-342 in APL CR group were significantly upregulated compared with that of newly diagnosed APL groups (P < 0.05), while the expression level of miR-181a was significantly downregulated (P < 0.05)." +tissue_expression_up hsa-mir-342 "Leukemia, Promyelocytic, Acute" 22967415 "The expression level of miR-15b, miR-16, miR-107, miR-223 and miR-342 in APL CR group were significantly upregulated compared with that of newly diagnosed APL groups (P < 0.05), while the expression level of miR-181a was significantly downregulated (P < 0.05)." +tissue_expression_up hsa-mir-103 Gastrointestinal Neoplasms 22996433 "The high expression of miR-20a, miR-25, miR-93, miR-103, miR-106a, miR-106b, miR-130 was associated with lymph node metastasis" +tissue_expression_up hsa-mir-106a Gastrointestinal Neoplasms 22996433 "The high expression of miR-20a, miR-25, miR-93, miR-103, miR-106a, miR-106b, miR-130 was associated with lymph node metastasis" +tissue_expression_up hsa-mir-106b Gastrointestinal Neoplasms 22996433 "The high expression of miR-20a, miR-25, miR-93, miR-103, miR-106a, miR-106b, miR-130 was associated with lymph node metastasis" +tissue_expression_up hsa-mir-130 Gastrointestinal Neoplasms 22996433 "The high expression of miR-20a, miR-25, miR-93, miR-103, miR-106a, miR-106b, miR-130 was associated with lymph node metastasis" +tissue_expression_up hsa-mir-20a Gastrointestinal Neoplasms 22996433 "The high expression of miR-20a, miR-25, miR-93, miR-103, miR-106a, miR-106b, miR-130 was associated with lymph node metastasis" +tissue_expression_up hsa-mir-221 Gastrointestinal Neoplasms 22996433 "The high expression of miR-222 and miR-221 showed correlation with shorter metastasis-free survival (P?=?0.039 and 0.033,respectively), and miR-222 high expression was related to reduced overall survival (P?=?0.012)." +tissue_expression_up hsa-mir-222 Gastrointestinal Neoplasms 22996433 "The high expression of miR-222 and miR-221 showed correlation with shorter metastasis-free survival (P?=?0.039 and 0.033,respectively), and miR-222 high expression was related to reduced overall survival (P?=?0.012)." +tissue_expression_up hsa-mir-25 Gastrointestinal Neoplasms 22996433 "The high expression of miR-20a, miR-25, miR-93, miR-103, miR-106a, miR-106b, miR-130 was associated with lymph node metastasis" +tissue_expression_up hsa-mir-93 Gastrointestinal Neoplasms 22996433 "The high expression of miR-20a, miR-25, miR-93, miR-103, miR-106a, miR-106b, miR-130 was associated with lymph node metastasis" +tissue_expression_up hsa-mir-21 Cervical Neoplasms 22997891 "The high expression of miR-21 in cervical cancer and Hela cell indicate that it may play a possible role of oncogenes, while miR-143 and miR-373 with low expression may play the role of tumor suppressor genes." +tissue_expression_up hsa-mir-10a Prostate Neoplasms 22999546 "miR-100 and miR-10a showed under expression and over expression, respectively, in low grade pTa tumors." +tissue_expression_up hsa-mir-135b "Squamous Cell Carcinoma, Skin or Unspecific" 23026055 "Non-stringent filtering with a non-adjusted p ¡Ü 0.01 revealed three up-regulated (hsa-miR-135b, hsa-miR-424 and hsa-miR-766) and six down-regulated (hsa-miR-30a*, hsa-miR-378, hsa-miR-145, hsa-miR-140-3p, hsa-miR-30a and hsa-miR-26a) miRNAs in cSCC" +tissue_expression_up hsa-mir-424 "Squamous Cell Carcinoma, Skin or Unspecific" 23026055 "Non-stringent filtering with a non-adjusted p ¡Ü 0.01 revealed three up-regulated (hsa-miR-135b, hsa-miR-424 and hsa-miR-766) and six down-regulated (hsa-miR-30a*, hsa-miR-378, hsa-miR-145, hsa-miR-140-3p, hsa-miR-30a and hsa-miR-26a) miRNAs in cSCC" +tissue_expression_up hsa-mir-766 "Squamous Cell Carcinoma, Skin or Unspecific" 23026055 "Non-stringent filtering with a non-adjusted p ¡Ü 0.01 revealed three up-regulated (hsa-miR-135b, hsa-miR-424 and hsa-miR-766) and six down-regulated (hsa-miR-30a*, hsa-miR-378, hsa-miR-145, hsa-miR-140-3p, hsa-miR-30a and hsa-miR-26a) miRNAs in cSCC" +tissue_expression_up hsa-mir-372 Seminoma 23064661 "Hsa-mir-372 was upregulated around 1,270-fold (95?% confidence interval (CI) 525.2-3,064.8; sp?=?8.1e-5 by Mann-Whitney U test)" +tissue_expression_up hsa-mir-217 "Carcinoma, Hepatocellular" 23082062 "Ten up-regulated miRNAs (miR-217, miR-518b, miR-517c, miR-520g, miR-519a, miR-522, miR-518e, miR-525-3p, miR-512-3p, and miR-518a-3p) and 11 down-regulated miRNAs (miR-138, miR-214, miR-214#, miR-199a-5p, miR-433, miR-511, miR-592, miR-483-3p, miR-483-5p, miR-708 and miR-1275) were identified by Taqman miRNAs array and confirmed quantitatively by reverse transcription polymerase chain reaction in HCC and adjacent non-tumor tissues. " +tissue_expression_up hsa-mir-512 "Carcinoma, Hepatocellular" 23082062 "Ten up-regulated miRNAs (miR-217, miR-518b, miR-517c, miR-520g, miR-519a, miR-522, miR-518e, miR-525-3p, miR-512-3p, and miR-518a-3p) and 11 down-regulated miRNAs (miR-138, miR-214, miR-214#, miR-199a-5p, miR-433, miR-511, miR-592, miR-483-3p, miR-483-5p, miR-708 and miR-1275) were identified by Taqman miRNAs array and confirmed quantitatively by reverse transcription polymerase chain reaction in HCC and adjacent non-tumor tissues. " +tissue_expression_up hsa-mir-517c "Carcinoma, Hepatocellular" 23082062 "Ten up-regulated miRNAs (miR-217, miR-518b, miR-517c, miR-520g, miR-519a, miR-522, miR-518e, miR-525-3p, miR-512-3p, and miR-518a-3p) and 11 down-regulated miRNAs (miR-138, miR-214, miR-214#, miR-199a-5p, miR-433, miR-511, miR-592, miR-483-3p, miR-483-5p, miR-708 and miR-1275) were identified by Taqman miRNAs array and confirmed quantitatively by reverse transcription polymerase chain reaction in HCC and adjacent non-tumor tissues. " +tissue_expression_up hsa-mir-518a "Carcinoma, Hepatocellular" 23082062 "Ten up-regulated miRNAs (miR-217, miR-518b, miR-517c, miR-520g, miR-519a, miR-522, miR-518e, miR-525-3p, miR-512-3p, and miR-518a-3p) and 11 down-regulated miRNAs (miR-138, miR-214, miR-214#, miR-199a-5p, miR-433, miR-511, miR-592, miR-483-3p, miR-483-5p, miR-708 and miR-1275) were identified by Taqman miRNAs array and confirmed quantitatively by reverse transcription polymerase chain reaction in HCC and adjacent non-tumor tissues. " +tissue_expression_up hsa-mir-518b "Carcinoma, Hepatocellular" 23082062 "Ten up-regulated miRNAs (miR-217, miR-518b, miR-517c, miR-520g, miR-519a, miR-522, miR-518e, miR-525-3p, miR-512-3p, and miR-518a-3p) and 11 down-regulated miRNAs (miR-138, miR-214, miR-214#, miR-199a-5p, miR-433, miR-511, miR-592, miR-483-3p, miR-483-5p, miR-708 and miR-1275) were identified by Taqman miRNAs array and confirmed quantitatively by reverse transcription polymerase chain reaction in HCC and adjacent non-tumor tissues. " +tissue_expression_up hsa-mir-518e "Carcinoma, Hepatocellular" 23082062 "Ten up-regulated miRNAs (miR-217, miR-518b, miR-517c, miR-520g, miR-519a, miR-522, miR-518e, miR-525-3p, miR-512-3p, and miR-518a-3p) and 11 down-regulated miRNAs (miR-138, miR-214, miR-214#, miR-199a-5p, miR-433, miR-511, miR-592, miR-483-3p, miR-483-5p, miR-708 and miR-1275) were identified by Taqman miRNAs array and confirmed quantitatively by reverse transcription polymerase chain reaction in HCC and adjacent non-tumor tissues. " +tissue_expression_up hsa-mir-519a "Carcinoma, Hepatocellular" 23082062 "Ten up-regulated miRNAs (miR-217, miR-518b, miR-517c, miR-520g, miR-519a, miR-522, miR-518e, miR-525-3p, miR-512-3p, and miR-518a-3p) and 11 down-regulated miRNAs (miR-138, miR-214, miR-214#, miR-199a-5p, miR-433, miR-511, miR-592, miR-483-3p, miR-483-5p, miR-708 and miR-1275) were identified by Taqman miRNAs array and confirmed quantitatively by reverse transcription polymerase chain reaction in HCC and adjacent non-tumor tissues. " +tissue_expression_up hsa-mir-520g "Carcinoma, Hepatocellular" 23082062 "Ten up-regulated miRNAs (miR-217, miR-518b, miR-517c, miR-520g, miR-519a, miR-522, miR-518e, miR-525-3p, miR-512-3p, and miR-518a-3p) and 11 down-regulated miRNAs (miR-138, miR-214, miR-214#, miR-199a-5p, miR-433, miR-511, miR-592, miR-483-3p, miR-483-5p, miR-708 and miR-1275) were identified by Taqman miRNAs array and confirmed quantitatively by reverse transcription polymerase chain reaction in HCC and adjacent non-tumor tissues. " +tissue_expression_up hsa-mir-522 "Carcinoma, Hepatocellular" 23082062 "Ten up-regulated miRNAs (miR-217, miR-518b, miR-517c, miR-520g, miR-519a, miR-522, miR-518e, miR-525-3p, miR-512-3p, and miR-518a-3p) and 11 down-regulated miRNAs (miR-138, miR-214, miR-214#, miR-199a-5p, miR-433, miR-511, miR-592, miR-483-3p, miR-483-5p, miR-708 and miR-1275) were identified by Taqman miRNAs array and confirmed quantitatively by reverse transcription polymerase chain reaction in HCC and adjacent non-tumor tissues. " +tissue_expression_up hsa-mir-525 "Carcinoma, Hepatocellular" 23082062 "Ten up-regulated miRNAs (miR-217, miR-518b, miR-517c, miR-520g, miR-519a, miR-522, miR-518e, miR-525-3p, miR-512-3p, and miR-518a-3p) and 11 down-regulated miRNAs (miR-138, miR-214, miR-214#, miR-199a-5p, miR-433, miR-511, miR-592, miR-483-3p, miR-483-5p, miR-708 and miR-1275) were identified by Taqman miRNAs array and confirmed quantitatively by reverse transcription polymerase chain reaction in HCC and adjacent non-tumor tissues. " +tissue_expression_up hsa-mir-106 Esophageal Neoplasms 23092349 "A number of consistently dysregulated miRNAs have been identified in EAC and/or ESCC, including upregulation of miR-21, miR-192, miR-194, miR-106-25 polycistron (miR-25, miR-93, and miR-106b), miR-10b, miR-151, and miR-93, and downregulation of miR-375, miR-203, miR-205, miR-145, miR- 27b,miR-100, miR-125b, let-7c, etc. " +tissue_expression_up hsa-mir-106b Esophageal Neoplasms 23092349 "A number of consistently dysregulated miRNAs have been identified in EAC and/or ESCC, including upregulation of miR-21, miR-192, miR-194, miR-106-25 polycistron (miR-25, miR-93, and miR-106b), miR-10b, miR-151, and miR-93, and downregulation of miR-375, miR-203, miR-205, miR-145, miR- 27b,miR-100, miR-125b, let-7c, etc. " +tissue_expression_up hsa-mir-10b Esophageal Neoplasms 23092349 "A number of consistently dysregulated miRNAs have been identified in EAC and/or ESCC, including upregulation of miR-21, miR-192, miR-194, miR-106-25 polycistron (miR-25, miR-93, and miR-106b), miR-10b, miR-151, and miR-93, and downregulation of miR-375, miR-203, miR-205, miR-145, miR- 27b,miR-100, miR-125b, let-7c, etc. " +tissue_expression_up hsa-mir-151 Esophageal Neoplasms 23092349 "A number of consistently dysregulated miRNAs have been identified in EAC and/or ESCC, including upregulation of miR-21, miR-192, miR-194, miR-106-25 polycistron (miR-25, miR-93, and miR-106b), miR-10b, miR-151, and miR-93, and downregulation of miR-375, miR-203, miR-205, miR-145, miR- 27b,miR-100, miR-125b, let-7c, etc. " +tissue_expression_up hsa-mir-192 Esophageal Neoplasms 23092349 "A number of consistently dysregulated miRNAs have been identified in EAC and/or ESCC, including upregulation of miR-21, miR-192, miR-194, miR-106-25 polycistron (miR-25, miR-93, and miR-106b), miR-10b, miR-151, and miR-93, and downregulation of miR-375, miR-203, miR-205, miR-145, miR- 27b,miR-100, miR-125b, let-7c, etc. " +tissue_expression_up hsa-mir-194 Esophageal Neoplasms 23092349 "A number of consistently dysregulated miRNAs have been identified in EAC and/or ESCC, including upregulation of miR-21, miR-192, miR-194, miR-106-25 polycistron (miR-25, miR-93, and miR-106b), miR-10b, miR-151, and miR-93, and downregulation of miR-375, miR-203, miR-205, miR-145, miR- 27b,miR-100, miR-125b, let-7c, etc. " +tissue_expression_up hsa-mir-21 Esophageal Neoplasms 23092349 "A number of consistently dysregulated miRNAs have been identified in EAC and/or ESCC, including upregulation of miR-21, miR-192, miR-194, miR-106-25 polycistron (miR-25, miR-93, and miR-106b), miR-10b, miR-151, and miR-93, and downregulation of miR-375, miR-203, miR-205, miR-145, miR- 27b,miR-100, miR-125b, let-7c, etc. " +tissue_expression_up hsa-mir-25 Esophageal Neoplasms 23092349 "A number of consistently dysregulated miRNAs have been identified in EAC and/or ESCC, including upregulation of miR-21, miR-192, miR-194, miR-106-25 polycistron (miR-25, miR-93, and miR-106b), miR-10b, miR-151, and miR-93, and downregulation of miR-375, miR-203, miR-205, miR-145, miR- 27b,miR-100, miR-125b, let-7c, etc. " +tissue_expression_up hsa-mir-93 Esophageal Neoplasms 23092349 "A number of consistently dysregulated miRNAs have been identified in EAC and/or ESCC, including upregulation of miR-21, miR-192, miR-194, miR-106-25 polycistron (miR-25, miR-93, and miR-106b), miR-10b, miR-151, and miR-93, and downregulation of miR-375, miR-203, miR-205, miR-145, miR- 27b,miR-100, miR-125b, let-7c, etc. " +tissue_expression_up hsa-mir-155 "Carcinoma, Lung, Non-Small-Cell" 23099007 High expression of miR-21 and miR-155 predicts recurrence and unfavourable survival in non-small cell lung cancer. +tissue_expression_up hsa-mir-21 "Carcinoma, Lung, Non-Small-Cell" 23099007 High expression of miR-21 and miR-155 predicts recurrence and unfavourable survival in non-small cell lung cancer. +tissue_expression_up hsa-mir-1260 Melanoma 23111773 "In addition to several miRNAs previously known to be associated with CMM, 19 unidentified miRNA candidates were found to be dysregulated in CMM patient samples. Among the 19 novel miRNA candidates, the genes hsa-miR-22, hsa-miR-130b, hsa-miR-146b-5p,hsa-miR-223, hsa-miR-301a, hsa-miR-484, hsa-miR-663, hsa-miR-720, hsa-miR-1260,hsa-miR-1274a, hsa-miR-1274b, hsa-miR-3663-3p, hsa-miR-4281, and hsa-miR-4286 were upregulated, and the genes hsa-miR-24-1*, hsa-miR-26a, hsa-miR-4291, hsa-miR-4317, and hsa-miR-4324 were downregulated." +tissue_expression_up hsa-mir-1274a Melanoma 23111773 "In addition to several miRNAs previously known to be associated with CMM, 19 unidentified miRNA candidates were found to be dysregulated in CMM patient samples. Among the 19 novel miRNA candidates, the genes hsa-miR-22, hsa-miR-130b, hsa-miR-146b-5p,hsa-miR-223, hsa-miR-301a, hsa-miR-484, hsa-miR-663, hsa-miR-720, hsa-miR-1260,hsa-miR-1274a, hsa-miR-1274b, hsa-miR-3663-3p, hsa-miR-4281, and hsa-miR-4286 were upregulated, and the genes hsa-miR-24-1*, hsa-miR-26a, hsa-miR-4291, hsa-miR-4317, and hsa-miR-4324 were downregulated." +tissue_expression_up hsa-mir-1274b Melanoma 23111773 "In addition to several miRNAs previously known to be associated with CMM, 19 unidentified miRNA candidates were found to be dysregulated in CMM patient samples. Among the 19 novel miRNA candidates, the genes hsa-miR-22, hsa-miR-130b, hsa-miR-146b-5p,hsa-miR-223, hsa-miR-301a, hsa-miR-484, hsa-miR-663, hsa-miR-720, hsa-miR-1260,hsa-miR-1274a, hsa-miR-1274b, hsa-miR-3663-3p, hsa-miR-4281, and hsa-miR-4286 were upregulated, and the genes hsa-miR-24-1*, hsa-miR-26a, hsa-miR-4291, hsa-miR-4317, and hsa-miR-4324 were downregulated." +tissue_expression_up hsa-mir-130b Melanoma 23111773 "In addition to several miRNAs previously known to be associated with CMM, 19 unidentified miRNA candidates were found to be dysregulated in CMM patient samples. Among the 19 novel miRNA candidates, the genes hsa-miR-22, hsa-miR-130b, hsa-miR-146b-5p,hsa-miR-223, hsa-miR-301a, hsa-miR-484, hsa-miR-663, hsa-miR-720, hsa-miR-1260,hsa-miR-1274a, hsa-miR-1274b, hsa-miR-3663-3p, hsa-miR-4281, and hsa-miR-4286 were upregulated, and the genes hsa-miR-24-1*, hsa-miR-26a, hsa-miR-4291, hsa-miR-4317, and hsa-miR-4324 were downregulated." +tissue_expression_up hsa-mir-146b Melanoma 23111773 "In addition to several miRNAs previously known to be associated with CMM, 19 unidentified miRNA candidates were found to be dysregulated in CMM patient samples. Among the 19 novel miRNA candidates, the genes hsa-miR-22, hsa-miR-130b, hsa-miR-146b-5p,hsa-miR-223, hsa-miR-301a, hsa-miR-484, hsa-miR-663, hsa-miR-720, hsa-miR-1260,hsa-miR-1274a, hsa-miR-1274b, hsa-miR-3663-3p, hsa-miR-4281, and hsa-miR-4286 were upregulated, and the genes hsa-miR-24-1*, hsa-miR-26a, hsa-miR-4291, hsa-miR-4317, and hsa-miR-4324 were downregulated." +tissue_expression_up hsa-mir-22 Melanoma 23111773 "In addition to several miRNAs previously known to be associated with CMM, 19 unidentified miRNA candidates were found to be dysregulated in CMM patient samples. Among the 19 novel miRNA candidates, the genes hsa-miR-22, hsa-miR-130b, hsa-miR-146b-5p,hsa-miR-223, hsa-miR-301a, hsa-miR-484, hsa-miR-663, hsa-miR-720, hsa-miR-1260,hsa-miR-1274a, hsa-miR-1274b, hsa-miR-3663-3p, hsa-miR-4281, and hsa-miR-4286 were upregulated, and the genes hsa-miR-24-1*, hsa-miR-26a, hsa-miR-4291, hsa-miR-4317, and hsa-miR-4324 were downregulated." +tissue_expression_up hsa-mir-223 Melanoma 23111773 "In addition to several miRNAs previously known to be associated with CMM, 19 unidentified miRNA candidates were found to be dysregulated in CMM patient samples. Among the 19 novel miRNA candidates, the genes hsa-miR-22, hsa-miR-130b, hsa-miR-146b-5p,hsa-miR-223, hsa-miR-301a, hsa-miR-484, hsa-miR-663, hsa-miR-720, hsa-miR-1260,hsa-miR-1274a, hsa-miR-1274b, hsa-miR-3663-3p, hsa-miR-4281, and hsa-miR-4286 were upregulated, and the genes hsa-miR-24-1*, hsa-miR-26a, hsa-miR-4291, hsa-miR-4317, and hsa-miR-4324 were downregulated." +tissue_expression_up hsa-mir-301a Melanoma 23111773 "In addition to several miRNAs previously known to be associated with CMM, 19 unidentified miRNA candidates were found to be dysregulated in CMM patient samples. Among the 19 novel miRNA candidates, the genes hsa-miR-22, hsa-miR-130b, hsa-miR-146b-5p,hsa-miR-223, hsa-miR-301a, hsa-miR-484, hsa-miR-663, hsa-miR-720, hsa-miR-1260,hsa-miR-1274a, hsa-miR-1274b, hsa-miR-3663-3p, hsa-miR-4281, and hsa-miR-4286 were upregulated, and the genes hsa-miR-24-1*, hsa-miR-26a, hsa-miR-4291, hsa-miR-4317, and hsa-miR-4324 were downregulated." +tissue_expression_up hsa-mir-3663 Melanoma 23111773 "In addition to several miRNAs previously known to be associated with CMM, 19 unidentified miRNA candidates were found to be dysregulated in CMM patient samples. Among the 19 novel miRNA candidates, the genes hsa-miR-22, hsa-miR-130b, hsa-miR-146b-5p,hsa-miR-223, hsa-miR-301a, hsa-miR-484, hsa-miR-663, hsa-miR-720, hsa-miR-1260,hsa-miR-1274a, hsa-miR-1274b, hsa-miR-3663-3p, hsa-miR-4281, and hsa-miR-4286 were upregulated, and the genes hsa-miR-24-1*, hsa-miR-26a, hsa-miR-4291, hsa-miR-4317, and hsa-miR-4324 were downregulated." +tissue_expression_up hsa-mir-4281 Melanoma 23111773 "In addition to several miRNAs previously known to be associated with CMM, 19 unidentified miRNA candidates were found to be dysregulated in CMM patient samples. Among the 19 novel miRNA candidates, the genes hsa-miR-22, hsa-miR-130b, hsa-miR-146b-5p,hsa-miR-223, hsa-miR-301a, hsa-miR-484, hsa-miR-663, hsa-miR-720, hsa-miR-1260,hsa-miR-1274a, hsa-miR-1274b, hsa-miR-3663-3p, hsa-miR-4281, and hsa-miR-4286 were upregulated, and the genes hsa-miR-24-1*, hsa-miR-26a, hsa-miR-4291, hsa-miR-4317, and hsa-miR-4324 were downregulated." +tissue_expression_up hsa-mir-4286 Melanoma 23111773 "In addition to several miRNAs previously known to be associated with CMM, 19 unidentified miRNA candidates were found to be dysregulated in CMM patient samples. Among the 19 novel miRNA candidates, the genes hsa-miR-22, hsa-miR-130b, hsa-miR-146b-5p,hsa-miR-223, hsa-miR-301a, hsa-miR-484, hsa-miR-663, hsa-miR-720, hsa-miR-1260,hsa-miR-1274a, hsa-miR-1274b, hsa-miR-3663-3p, hsa-miR-4281, and hsa-miR-4286 were upregulated, and the genes hsa-miR-24-1*, hsa-miR-26a, hsa-miR-4291, hsa-miR-4317, and hsa-miR-4324 were downregulated." +tissue_expression_up hsa-mir-484 Melanoma 23111773 "In addition to several miRNAs previously known to be associated with CMM, 19 unidentified miRNA candidates were found to be dysregulated in CMM patient samples. Among the 19 novel miRNA candidates, the genes hsa-miR-22, hsa-miR-130b, hsa-miR-146b-5p,hsa-miR-223, hsa-miR-301a, hsa-miR-484, hsa-miR-663, hsa-miR-720, hsa-miR-1260,hsa-miR-1274a, hsa-miR-1274b, hsa-miR-3663-3p, hsa-miR-4281, and hsa-miR-4286 were upregulated, and the genes hsa-miR-24-1*, hsa-miR-26a, hsa-miR-4291, hsa-miR-4317, and hsa-miR-4324 were downregulated." +tissue_expression_up hsa-mir-663 Melanoma 23111773 "In addition to several miRNAs previously known to be associated with CMM, 19 unidentified miRNA candidates were found to be dysregulated in CMM patient samples. Among the 19 novel miRNA candidates, the genes hsa-miR-22, hsa-miR-130b, hsa-miR-146b-5p,hsa-miR-223, hsa-miR-301a, hsa-miR-484, hsa-miR-663, hsa-miR-720, hsa-miR-1260,hsa-miR-1274a, hsa-miR-1274b, hsa-miR-3663-3p, hsa-miR-4281, and hsa-miR-4286 were upregulated, and the genes hsa-miR-24-1*, hsa-miR-26a, hsa-miR-4291, hsa-miR-4317, and hsa-miR-4324 were downregulated." +tissue_expression_up hsa-mir-720 Melanoma 23111773 "In addition to several miRNAs previously known to be associated with CMM, 19 unidentified miRNA candidates were found to be dysregulated in CMM patient samples. Among the 19 novel miRNA candidates, the genes hsa-miR-22, hsa-miR-130b, hsa-miR-146b-5p,hsa-miR-223, hsa-miR-301a, hsa-miR-484, hsa-miR-663, hsa-miR-720, hsa-miR-1260,hsa-miR-1274a, hsa-miR-1274b, hsa-miR-3663-3p, hsa-miR-4281, and hsa-miR-4286 were upregulated, and the genes hsa-miR-24-1*, hsa-miR-26a, hsa-miR-4291, hsa-miR-4317, and hsa-miR-4324 were downregulated." +tissue_expression_up hsa-mir-125b-1 Myocardial Ischemic-Reperfusion Injury 23123599 SR-A deficiency reduces myocardial ischemia/reperfusion injury; involvement of increased microRNA-125b expression in macrophages +tissue_expression_up hsa-mir-125b-2 Myocardial Ischemic-Reperfusion Injury 23123599 SR-A deficiency reduces myocardial ischemia/reperfusion injury; involvement of increased microRNA-125b expression in macrophages +tissue_expression_up hsa-mir-138 Bladder Neoplasms 23169479 "three miRNAs were upregulated (miR-200b, miR-182 and miR-138) and the other 10 miRNAs were downregulated (miR-1, miR-133a, miR-133b, miR-145, miR-143, miR-204, miR-921, miR-1281, miR-199a and miR-199b)" +tissue_expression_up hsa-mir-146b Bladder Neoplasms 23169479 "Except for two miRNAs, miR-146b and miR-9, which were specifically upregulated in MIBC, the majority of miRNAs (n = 13) were deregulated in the same way in the two types of bladder tumors" +tissue_expression_up hsa-mir-182 Bladder Neoplasms 23169479 "three miRNAs were upregulated (miR-200b, miR-182 and miR-138) and the other 10 miRNAs were downregulated (miR-1, miR-133a, miR-133b, miR-145, miR-143, miR-204, miR-921, miR-1281, miR-199a and miR-199b)" +tissue_expression_up hsa-mir-200b Bladder Neoplasms 23169479 "three miRNAs were upregulated (miR-200b, miR-182 and miR-138) and the other 10 miRNAs were downregulated (miR-1, miR-133a, miR-133b, miR-145, miR-143, miR-204, miR-921, miR-1281, miR-199a and miR-199b)" +tissue_expression_up hsa-mir-9 Bladder Neoplasms 23169479 "Except for two miRNAs, miR-146b and miR-9, which were specifically upregulated in MIBC, the majority of miRNAs (n = 13) were deregulated in the same way in the two types of bladder tumors" +tissue_expression_up hsa-mir-155 Ovarian Neoplasms 23171795 "We found that in ovarian CAFs, miR-31 and miR-214 were downregulated, whereas miR-155 was upregulated when compared with normal or tumor-adjacent fibroblasts." +tissue_expression_up hsa-mir-200c Breast Neoplasms 23185507 miR-200c targets a NF-kB up-regulated TrkB/NTF3 autocrine signaling loop to enhance anoikis sensitivity in triple negative breast cancer +tissue_expression_up hsa-mir-205 "Carcinoma, Lung, Non-Small-Cell" 23207443 SQCC was distinguished from normal tissue and ADC by high-level miR-205 expression and decreased miR-26b. +tissue_expression_up hsa-mir-122 Hepatitis B Virus Infection 23221562 HBV mRNAs-mediated miR-122 inhibition up-regulates PTTG1-binding protein which promotes HCC tumor growth and cell invasion +tissue_expression_up hsa-mir-17 Glioma 23226946 Increased Expression of microRNA-17 Predicts Poor Prognosis in Human Glioma +tissue_expression_up hsa-mir-18a Colon Neoplasms 23229340 MicroRNA-18a upregulates autophagy and ataxia telangiectasia mutated gene expression in HCT116 colon cancer cells +tissue_expression_up hsa-mir-155 Ovarian Neoplasms 23230184 They found that decreased miR-31 and miR-214 and increased miR-155 expression can reprogram normal fibroblasts into tumor-promoting cancer-associated fibroblasts. +tissue_expression_up hsa-mir-181a-2 Breast Neoplasms 23241956 TGF-beta upregulates miR-181a expression to promote breast cancer metastasis +tissue_expression_up hsa-mir-182 Ovarian Neoplasms 23262295 The upregulation of signal transducer and activator of transcription 5-dependent microRNA-182 and microRNA-96 promotes ovarian cancer cell proliferation by targeting forkhead box O3 upon leptin stimulation +tissue_expression_up hsa-mir-96 Ovarian Neoplasms 23262295 The upregulation of signal transducer and activator of transcription 5-dependent microRNA-182 and microRNA-96 promotes ovarian cancer cell proliferation by targeting forkhead box O3 upon leptin stimulation +tissue_expression_up hsa-mir-183 Glioma 23263745 MicroRNA-183 upregulates HIF-1a by targeting isocitrate dehydrogenase 2 (IDH2) in glioma cells +tissue_expression_up hsa-mir-224 Glioma 23263909 Upregulation of microRNA-224 confers a poor prognosis in glioma patients +tissue_expression_up hsa-mir-103 Bladder Neoplasms 23266581 "Quantitative real-time PCR was applied to measure the levels of 22 microRNAs upregulated in BCA tissue (miR-15a, miR-18a, miR-21, miR-93, miR-96, miR-103, miR-130b, miR-135b, miR-141, miR-182, miR-183, miR-190, miR-191, miR-200b, miR-422b, miR-425, miR-449b, miR-601, miR-639, miR-644, miR-649 and miR-1233) in the marker identification cohort" +tissue_expression_up hsa-mir-1233 Bladder Neoplasms 23266581 "Quantitative real-time PCR was applied to measure the levels of 22 microRNAs upregulated in BCA tissue (miR-15a, miR-18a, miR-21, miR-93, miR-96, miR-103, miR-130b, miR-135b, miR-141, miR-182, miR-183, miR-190, miR-191, miR-200b, miR-422b, miR-425, miR-449b, miR-601, miR-639, miR-644, miR-649 and miR-1233) in the marker identification cohort" +tissue_expression_up hsa-mir-130b Bladder Neoplasms 23266581 "Quantitative real-time PCR was applied to measure the levels of 22 microRNAs upregulated in BCA tissue (miR-15a, miR-18a, miR-21, miR-93, miR-96, miR-103, miR-130b, miR-135b, miR-141, miR-182, miR-183, miR-190, miR-191, miR-200b, miR-422b, miR-425, miR-449b, miR-601, miR-639, miR-644, miR-649 and miR-1233) in the marker identification cohort" +tissue_expression_up hsa-mir-135b Bladder Neoplasms 23266581 "Quantitative real-time PCR was applied to measure the levels of 22 microRNAs upregulated in BCA tissue (miR-15a, miR-18a, miR-21, miR-93, miR-96, miR-103, miR-130b, miR-135b, miR-141, miR-182, miR-183, miR-190, miR-191, miR-200b, miR-422b, miR-425, miR-449b, miR-601, miR-639, miR-644, miR-649 and miR-1233) in the marker identification cohort" +tissue_expression_up hsa-mir-141 Bladder Neoplasms 23266581 "Quantitative real-time PCR was applied to measure the levels of 22 microRNAs upregulated in BCA tissue (miR-15a, miR-18a, miR-21, miR-93, miR-96, miR-103, miR-130b, miR-135b, miR-141, miR-182, miR-183, miR-190, miR-191, miR-200b, miR-422b, miR-425, miR-449b, miR-601, miR-639, miR-644, miR-649 and miR-1233) in the marker identification cohort" +tissue_expression_up hsa-mir-15a Bladder Neoplasms 23266581 "Quantitative real-time PCR was applied to measure the levels of 22 microRNAs upregulated in BCA tissue (miR-15a, miR-18a, miR-21, miR-93, miR-96, miR-103, miR-130b, miR-135b, miR-141, miR-182, miR-183, miR-190, miR-191, miR-200b, miR-422b, miR-425, miR-449b, miR-601, miR-639, miR-644, miR-649 and miR-1233) in the marker identification cohort" +tissue_expression_up hsa-mir-182 Bladder Neoplasms 23266581 "Quantitative real-time PCR was applied to measure the levels of 22 microRNAs upregulated in BCA tissue (miR-15a, miR-18a, miR-21, miR-93, miR-96, miR-103, miR-130b, miR-135b, miR-141, miR-182, miR-183, miR-190, miR-191, miR-200b, miR-422b, miR-425, miR-449b, miR-601, miR-639, miR-644, miR-649 and miR-1233) in the marker identification cohort" +tissue_expression_up hsa-mir-183 Bladder Neoplasms 23266581 "Quantitative real-time PCR was applied to measure the levels of 22 microRNAs upregulated in BCA tissue (miR-15a, miR-18a, miR-21, miR-93, miR-96, miR-103, miR-130b, miR-135b, miR-141, miR-182, miR-183, miR-190, miR-191, miR-200b, miR-422b, miR-425, miR-449b, miR-601, miR-639, miR-644, miR-649 and miR-1233) in the marker identification cohort" +tissue_expression_up hsa-mir-18a Bladder Neoplasms 23266581 "Quantitative real-time PCR was applied to measure the levels of 22 microRNAs upregulated in BCA tissue (miR-15a, miR-18a, miR-21, miR-93, miR-96, miR-103, miR-130b, miR-135b, miR-141, miR-182, miR-183, miR-190, miR-191, miR-200b, miR-422b, miR-425, miR-449b, miR-601, miR-639, miR-644, miR-649 and miR-1233) in the marker identification cohort" +tissue_expression_up hsa-mir-190 Bladder Neoplasms 23266581 "Quantitative real-time PCR was applied to measure the levels of 22 microRNAs upregulated in BCA tissue (miR-15a, miR-18a, miR-21, miR-93, miR-96, miR-103, miR-130b, miR-135b, miR-141, miR-182, miR-183, miR-190, miR-191, miR-200b, miR-422b, miR-425, miR-449b, miR-601, miR-639, miR-644, miR-649 and miR-1233) in the marker identification cohort" +tissue_expression_up hsa-mir-191 Bladder Neoplasms 23266581 "Quantitative real-time PCR was applied to measure the levels of 22 microRNAs upregulated in BCA tissue (miR-15a, miR-18a, miR-21, miR-93, miR-96, miR-103, miR-130b, miR-135b, miR-141, miR-182, miR-183, miR-190, miR-191, miR-200b, miR-422b, miR-425, miR-449b, miR-601, miR-639, miR-644, miR-649 and miR-1233) in the marker identification cohort" +tissue_expression_up hsa-mir-200b Bladder Neoplasms 23266581 "Quantitative real-time PCR was applied to measure the levels of 22 microRNAs upregulated in BCA tissue (miR-15a, miR-18a, miR-21, miR-93, miR-96, miR-103, miR-130b, miR-135b, miR-141, miR-182, miR-183, miR-190, miR-191, miR-200b, miR-422b, miR-425, miR-449b, miR-601, miR-639, miR-644, miR-649 and miR-1233) in the marker identification cohort" +tissue_expression_up hsa-mir-21 Bladder Neoplasms 23266581 "Quantitative real-time PCR was applied to measure the levels of 22 microRNAs upregulated in BCA tissue (miR-15a, miR-18a, miR-21, miR-93, miR-96, miR-103, miR-130b, miR-135b, miR-141, miR-182, miR-183, miR-190, miR-191, miR-200b, miR-422b, miR-425, miR-449b, miR-601, miR-639, miR-644, miR-649 and miR-1233) in the marker identification cohort" +tissue_expression_up hsa-mir-422b Bladder Neoplasms 23266581 "Quantitative real-time PCR was applied to measure the levels of 22 microRNAs upregulated in BCA tissue (miR-15a, miR-18a, miR-21, miR-93, miR-96, miR-103, miR-130b, miR-135b, miR-141, miR-182, miR-183, miR-190, miR-191, miR-200b, miR-422b, miR-425, miR-449b, miR-601, miR-639, miR-644, miR-649 and miR-1233) in the marker identification cohort" +tissue_expression_up hsa-mir-425 Bladder Neoplasms 23266581 "Quantitative real-time PCR was applied to measure the levels of 22 microRNAs upregulated in BCA tissue (miR-15a, miR-18a, miR-21, miR-93, miR-96, miR-103, miR-130b, miR-135b, miR-141, miR-182, miR-183, miR-190, miR-191, miR-200b, miR-422b, miR-425, miR-449b, miR-601, miR-639, miR-644, miR-649 and miR-1233) in the marker identification cohort" +tissue_expression_up hsa-mir-449b Bladder Neoplasms 23266581 "Quantitative real-time PCR was applied to measure the levels of 22 microRNAs upregulated in BCA tissue (miR-15a, miR-18a, miR-21, miR-93, miR-96, miR-103, miR-130b, miR-135b, miR-141, miR-182, miR-183, miR-190, miR-191, miR-200b, miR-422b, miR-425, miR-449b, miR-601, miR-639, miR-644, miR-649 and miR-1233) in the marker identification cohort" +tissue_expression_up hsa-mir-601 Bladder Neoplasms 23266581 "Quantitative real-time PCR was applied to measure the levels of 22 microRNAs upregulated in BCA tissue (miR-15a, miR-18a, miR-21, miR-93, miR-96, miR-103, miR-130b, miR-135b, miR-141, miR-182, miR-183, miR-190, miR-191, miR-200b, miR-422b, miR-425, miR-449b, miR-601, miR-639, miR-644, miR-649 and miR-1233) in the marker identification cohort" +tissue_expression_up hsa-mir-639 Bladder Neoplasms 23266581 "Quantitative real-time PCR was applied to measure the levels of 22 microRNAs upregulated in BCA tissue (miR-15a, miR-18a, miR-21, miR-93, miR-96, miR-103, miR-130b, miR-135b, miR-141, miR-182, miR-183, miR-190, miR-191, miR-200b, miR-422b, miR-425, miR-449b, miR-601, miR-639, miR-644, miR-649 and miR-1233) in the marker identification cohort" +tissue_expression_up hsa-mir-644 Bladder Neoplasms 23266581 "Quantitative real-time PCR was applied to measure the levels of 22 microRNAs upregulated in BCA tissue (miR-15a, miR-18a, miR-21, miR-93, miR-96, miR-103, miR-130b, miR-135b, miR-141, miR-182, miR-183, miR-190, miR-191, miR-200b, miR-422b, miR-425, miR-449b, miR-601, miR-639, miR-644, miR-649 and miR-1233) in the marker identification cohort" +tissue_expression_up hsa-mir-649 Bladder Neoplasms 23266581 "Quantitative real-time PCR was applied to measure the levels of 22 microRNAs upregulated in BCA tissue (miR-15a, miR-18a, miR-21, miR-93, miR-96, miR-103, miR-130b, miR-135b, miR-141, miR-182, miR-183, miR-190, miR-191, miR-200b, miR-422b, miR-425, miR-449b, miR-601, miR-639, miR-644, miR-649 and miR-1233) in the marker identification cohort" +tissue_expression_up hsa-mir-93 Bladder Neoplasms 23266581 "Quantitative real-time PCR was applied to measure the levels of 22 microRNAs upregulated in BCA tissue (miR-15a, miR-18a, miR-21, miR-93, miR-96, miR-103, miR-130b, miR-135b, miR-141, miR-182, miR-183, miR-190, miR-191, miR-200b, miR-422b, miR-425, miR-449b, miR-601, miR-639, miR-644, miR-649 and miR-1233) in the marker identification cohort" +tissue_expression_up hsa-mir-96 Bladder Neoplasms 23266581 "Quantitative real-time PCR was applied to measure the levels of 22 microRNAs upregulated in BCA tissue (miR-15a, miR-18a, miR-21, miR-93, miR-96, miR-103, miR-130b, miR-135b, miR-141, miR-182, miR-183, miR-190, miR-191, miR-200b, miR-422b, miR-425, miR-449b, miR-601, miR-639, miR-644, miR-649 and miR-1233) in the marker identification cohort" +tissue_expression_up hsa-mir-21 Pancreatic Neoplasms 23272057 "Here, we show, for the first time, that hypoxia leads to increased expression of VEGF, IL-6, and CSC signature genes Nanog, Oct4 and EZH2 consistent with increased cell migration/invasion and angiogenesis, and the formation of pancreatospheres,concomitant with increased expression of miR-21 and miR-210 in human pancreatic cancer (PC) cells" +tissue_expression_up hsa-mir-210 Pancreatic Neoplasms 23272057 "Here, we show, for the first time, that hypoxia leads to increased expression of VEGF, IL-6, and CSC signature genes Nanog, Oct4 and EZH2 consistent with increased cell migration/invasion and angiogenesis, and the formation of pancreatospheres,concomitant with increased expression of miR-21 and miR-210 in human pancreatic cancer (PC) cells" +tissue_expression_up hsa-mir-372 "Carcinoma, Hepatocellular" 23291979 Upregulation of microRNA-372 associates with tumor progression and prognosis in hepatocellular carcinoma +tissue_expression_up hsa-mir-199a-1 Colorectal Carcinoma 23292866 miR-199a-3p may serve as an efficient biomarker for diagnosis and novel prognostic indicator in colorectal cancer +tissue_expression_up hsa-mir-199a-2 Colorectal Carcinoma 23292866 miR-199a-3p may serve as an efficient biomarker for diagnosis and novel prognostic indicator in colorectal cancer +tissue_expression_up hsa-mir-143 Esophagitis 23297865 "Elevated miR-143, miR-145 and miR-205 expression was observed in oesophageal squamous mucosa of individuals with ulcerative oesophagitis." +tissue_expression_up hsa-mir-145 Esophagitis 23297865 "Elevated miR-143, miR-145 and miR-205 expression was observed in oesophageal squamous mucosa of individuals with ulcerative oesophagitis." +tissue_expression_up hsa-mir-205 Esophagitis 23297865 "Elevated miR-143, miR-145 and miR-205 expression was observed in oesophageal squamous mucosa of individuals with ulcerative oesophagitis." +tissue_expression_up hsa-mir-372 Glioma 23298385 Correlation of microRNA-372 upregulation with poor prognosis in human glioma. +tissue_expression_up hsa-mir-155 Waldenstrom Macroglobulinemia 23301642 The most important changes of microRNA are increased expression of miR-155 and decreased expression of miR-9*. +tissue_expression_up hsa-mir-124 Heart Failure 23307820 "The significant upregulation of miR-124 and miR-134 in the seizure-related stages and children suggested that both can be potential targets for anticonvulsant drugs in the epileptic developing brains, while the different expression patterns of miR-132 and miR-21 may suggest different functions in MTLE pathogenesis." +tissue_expression_up hsa-mir-134 Heart Failure 23307820 "The significant upregulation of miR-124 and miR-134 in the seizure-related stages and children suggested that both can be potential targets for anticonvulsant drugs in the epileptic developing brains, while the different expression patterns of miR-132 and miR-21 may suggest different functions in MTLE pathogenesis." +tissue_expression_up hsa-mir-124a "Aortic Aneurysm, Abdominal" 23316282 "MicroRNAs related to fibrosis (miR-29b),inflammation (miR-124a, miR-146a, miR-155, and miR-223), and endothelium(miR-126, let-7 family members, and miR-21) were significantly upregulated in AAA tissue. " +tissue_expression_up hsa-mir-126 "Aortic Aneurysm, Abdominal" 23316282 "MicroRNAs related to fibrosis (miR-29b),inflammation (miR-124a, miR-146a, miR-155, and miR-223), and endothelium(miR-126, let-7 family members, and miR-21) were significantly upregulated in AAA tissue. " +tissue_expression_up hsa-mir-146a "Aortic Aneurysm, Abdominal" 23316282 "MicroRNAs related to fibrosis (miR-29b),inflammation (miR-124a, miR-146a, miR-155, and miR-223), and endothelium(miR-126, let-7 family members, and miR-21) were significantly upregulated in AAA tissue. " +tissue_expression_up hsa-mir-155 "Aortic Aneurysm, Abdominal" 23316282 "MicroRNAs related to fibrosis (miR-29b),inflammation (miR-124a, miR-146a, miR-155, and miR-223), and endothelium(miR-126, let-7 family members, and miR-21) were significantly upregulated in AAA tissue. " +tissue_expression_up hsa-mir-223 "Aortic Aneurysm, Abdominal" 23316282 "MicroRNAs related to fibrosis (miR-29b),inflammation (miR-124a, miR-146a, miR-155, and miR-223), and endothelium(miR-126, let-7 family members, and miR-21) were significantly upregulated in AAA tissue. " +tissue_expression_up hsa-mir-29b "Aortic Aneurysm, Abdominal" 23316282 "MicroRNAs related to fibrosis (miR-29b),inflammation (miR-124a, miR-146a, miR-155, and miR-223), and endothelium(miR-126, let-7 family members, and miR-21) were significantly upregulated in AAA tissue. " +tissue_expression_up hsa-mir-199a-1 "Carcinoma, Hepatocellular" 23319430 Propofol induces apoptosis of hepatocellular carcinoma cells by upregulation of microRNA-199a expression +tissue_expression_up hsa-mir-199a-2 "Carcinoma, Hepatocellular" 23319430 Propofol induces apoptosis of hepatocellular carcinoma cells by upregulation of microRNA-199a expression +tissue_expression_up hsa-mir-221 "Carcinoma, Hepatocellular" 23320393 Increased MiR-221 expression in hepatocellular carcinoma tissues and its role in enhancing cell growth and inhibiting apoptosis in vitro +tissue_expression_up hsa-mir-192 "Diabetes Mellitus, Type 2" 23372846 "Several highly-expressed islet miRNAs, such as miR-375, have established roles in the regulation of islet function, but others (e.g. miR-27b-3p, miR-192-5p) have not previously been described in the context of islet biology." +tissue_expression_up hsa-mir-27b "Diabetes Mellitus, Type 2" 23372846 "Several highly-expressed islet miRNAs, such as miR-375, have established roles in the regulation of islet function, but others (e.g. miR-27b-3p, miR-192-5p) have not previously been described in the context of islet biology." +tissue_expression_up hsa-mir-375 "Diabetes Mellitus, Type 2" 23372846 "Several highly-expressed islet miRNAs, such as miR-375, have established roles in the regulation of islet function, but others (e.g. miR-27b-3p, miR-192-5p) have not previously been described in the context of islet biology." +tissue_expression_up hsa-mir-29c Schizophrenia 23382797 "RT-PCR validation confirmed that two miRNAs, miR-497 in SZ samples and miR-29c in BD samples, have significantly increased expression when compared to control samples. These results warrant future studies to evaluate the potential of exosome-derived miRNAs to serve as biomarkers of SZ and BD." +tissue_expression_up hsa-mir-497 Schizophrenia 23382797 "RT-PCR validation confirmed that two miRNAs, miR-497 in SZ samples and miR-29c in BD samples, have significantly increased expression when compared to control samples. These results warrant future studies to evaluate the potential of exosome-derived miRNAs to serve as biomarkers of SZ and BD." +tissue_expression_up hsa-mir-21 Thyroid Neoplasms 23416953 "there were significant associations (P<0.05) between BRAF(V600E) and a higher tumor-node-metastasis staging (III/IV), and between miR-21* over-expression and lymph node metastasis." +tissue_expression_up hsa-mir-146b "Carcinoma, Thyroid, Papillary" 23427895 "Fourteen miRNAs were deregulated in FVPTC with a fold change of more than five (up/down), including miRNAs known to be upregulated in PTC (miR-146b-3p, -146-5p, -221, -222 and miR-222-5p) and novel miRNAs (miR-375, -551b, 181-2-3p, 99b-3p)." +tissue_expression_up hsa-mir-221 "Carcinoma, Thyroid, Papillary" 23427895 "Fourteen miRNAs were deregulated in FVPTC with a fold change of more than five (up/down), including miRNAs known to be upregulated in PTC (miR-146b-3p, -146-5p, -221, -222 and miR-222-5p) and novel miRNAs (miR-375, -551b, 181-2-3p, 99b-3p)." +tissue_expression_up hsa-mir-222 "Carcinoma, Thyroid, Papillary" 23427895 "Fourteen miRNAs were deregulated in FVPTC with a fold change of more than five (up/down), including miRNAs known to be upregulated in PTC (miR-146b-3p, -146-5p, -221, -222 and miR-222-5p) and novel miRNAs (miR-375, -551b, 181-2-3p, 99b-3p)." +tissue_expression_up hsa-mir-210 Osteosarcoma 23430441 miR-210 upregulation showed a strong correlation with tumor aggressive progression of pediatric osteosarcoma and could help prognostic screening of patients with this malignancy +tissue_expression_up hsa-mir-146a Melanoma 23441115 "MiR-146a and miR-26a were overexpressed more than threefold in VH from patients with uveal melanomas compared to the other pathological groups (Wilcoxon signed-rank test, p value <0.05)." +tissue_expression_up hsa-mir-26a Melanoma 23441115 "MiR-146a and miR-26a were overexpressed more than threefold in VH from patients with uveal melanomas compared to the other pathological groups (Wilcoxon signed-rank test, p value <0.05)." +tissue_expression_up hsa-mir-182 Colorectal Carcinoma 23474644 Up-regulation of miR-182 expression in colorectal cancer tissues and its prognostic value +tissue_expression_up hsa-mir-200c Head And Neck Neoplasms 23474763 "expression of p21, miR-34a and miR-200c are increased, demonstrating functional p53 reactivation." +tissue_expression_up hsa-mir-34a Head And Neck Neoplasms 23474763 "expression of p21, miR-34a and miR-200c are increased, demonstrating functional p53 reactivation." +tissue_expression_up hsa-mir-145 Esophageal Neoplasms 23477513 patients with either decreased miR-135b or increased miR-145 expression in cancer tissue had improved disease-free survival +tissue_expression_up hsa-mir-17 Glioblastoma 23497354 In glioblastoma a high ratio of miR-17 to miR-221/222 was predictive of better overall survival suggesting that high miR-221/222 expression is more adverse for patients than high miR-17 expression. +tissue_expression_up hsa-mir-221 Glioblastoma 23497354 In glioblastoma a high ratio of miR-17 to miR-221/222 was predictive of better overall survival suggesting that high miR-221/222 expression is more adverse for patients than high miR-17 expression. +tissue_expression_up hsa-mir-625 Colorectal Carcinoma 23506979 High expression of microRNA-625-3p is associated with poor response to first-line oxaliplatin based treatment of metastatic colorectal cancer +tissue_expression_up hsa-mir-17 Stroke 23511639 These data indicate that the miR17-92 cluster plays an important role in mediating neural progenitor cell function and that the Shh signaling pathway is involved in up-regulating miR17-92 cluster expression. +tissue_expression_up hsa-mir-18 Stroke 23511639 These data indicate that the miR17-92 cluster plays an important role in mediating neural progenitor cell function and that the Shh signaling pathway is involved in up-regulating miR17-92 cluster expression. +tissue_expression_up hsa-mir-19a Stroke 23511639 These data indicate that the miR17-92 cluster plays an important role in mediating neural progenitor cell function and that the Shh signaling pathway is involved in up-regulating miR17-92 cluster expression. +tissue_expression_up hsa-mir-19b-1 Stroke 23511639 These data indicate that the miR17-92 cluster plays an important role in mediating neural progenitor cell function and that the Shh signaling pathway is involved in up-regulating miR17-92 cluster expression. +tissue_expression_up hsa-mir-20a Stroke 23511639 These data indicate that the miR17-92 cluster plays an important role in mediating neural progenitor cell function and that the Shh signaling pathway is involved in up-regulating miR17-92 cluster expression. +tissue_expression_up hsa-mir-92-1 Stroke 23511639 These data indicate that the miR17-92 cluster plays an important role in mediating neural progenitor cell function and that the Shh signaling pathway is involved in up-regulating miR17-92 cluster expression. +tissue_expression_up hsa-mir-125b Leukemia 23550646 "miRNAs such as miR-21, miR-125b, miR-155, miR-196, and miR-210 that are critical for the immune response or hypoxia are often overexpressed in cancers and leukemias" +tissue_expression_up hsa-mir-155 Leukemia 23550646 "miRNAs such as miR-21, miR-125b, miR-155, miR-196, and miR-210 that are critical for the immune response or hypoxia are often overexpressed in cancers and leukemias" +tissue_expression_up hsa-mir-196 Leukemia 23550646 "miRNAs such as miR-21, miR-125b, miR-155, miR-196, and miR-210 that are critical for the immune response or hypoxia are often overexpressed in cancers and leukemias" +tissue_expression_up hsa-mir-21 Leukemia 23550646 "miRNAs such as miR-21, miR-125b, miR-155, miR-196, and miR-210 that are critical for the immune response or hypoxia are often overexpressed in cancers and leukemias" +tissue_expression_up hsa-mir-210 Leukemia 23550646 "miRNAs such as miR-21, miR-125b, miR-155, miR-196, and miR-210 that are critical for the immune response or hypoxia are often overexpressed in cancers and leukemias" +tissue_expression_up hsa-mir-146a Ovarian Neoplasms 23554878 "These observations suggest that at least two of the miRNAs, miR-146a and miR-150, up-regulated in omental lesions, stimulate survival and increase drug tolerance." +tissue_expression_up hsa-mir-150 Ovarian Neoplasms 23554878 "These observations suggest that at least two of the miRNAs, miR-146a and miR-150, up-regulated in omental lesions, stimulate survival and increase drug tolerance." +tissue_expression_up hsa-mir-141 Azoospermia 23559187 "Genome-wide microRNA expression profiling in idiopathic non-obstructive azoospermia: significant up-regulation of miR-141, miR-429 and miR-7-1-3p" +tissue_expression_up hsa-mir-429 Azoospermia 23559187 "Genome-wide microRNA expression profiling in idiopathic non-obstructive azoospermia: significant up-regulation of miR-141, miR-429 and miR-7-1-3p" +tissue_expression_up hsa-mir-7-1 Azoospermia 23559187 "Genome-wide microRNA expression profiling in idiopathic non-obstructive azoospermia: significant up-regulation of miR-141, miR-429 and miR-7-1-3p" +tissue_expression_up hsa-mir-7-2 Azoospermia 23559187 "Genome-wide microRNA expression profiling in idiopathic non-obstructive azoospermia: significant up-regulation of miR-141, miR-429 and miR-7-1-3p" +tissue_expression_up hsa-mir-7-3 Azoospermia 23559187 "Genome-wide microRNA expression profiling in idiopathic non-obstructive azoospermia: significant up-regulation of miR-141, miR-429 and miR-7-1-3p" +tissue_expression_up hsa-mir-10b Thyroid Neoplasms 23563786 "The miR-221/222 cluster, miR-10b and miR-92a are highly upregulated in metastatic minimally invasive follicular thyroid carcinoma" +tissue_expression_up hsa-mir-221 Thyroid Neoplasms 23563786 "The miR-221/222 cluster, miR-10b and miR-92a are highly upregulated in metastatic minimally invasive follicular thyroid carcinoma" +tissue_expression_up hsa-mir-222 Thyroid Neoplasms 23563786 "The miR-221/222 cluster, miR-10b and miR-92a are highly upregulated in metastatic minimally invasive follicular thyroid carcinoma" +tissue_expression_up hsa-mir-92a-1 Thyroid Neoplasms 23563786 "The miR-221/222 cluster, miR-10b and miR-92a are highly upregulated in metastatic minimally invasive follicular thyroid carcinoma" +tissue_expression_up hsa-mir-92a-2 Thyroid Neoplasms 23563786 "The miR-221/222 cluster, miR-10b and miR-92a are highly upregulated in metastatic minimally invasive follicular thyroid carcinoma" +tissue_expression_up hsa-mir-155 Breast Neoplasms 23568502 17¦Â-Estradiol up-regulates miR-155 expression and reduces TP53INP1 expression in MCF-7 breast cancer cells +tissue_expression_up hsa-mir-146b "Carcinoma, Thyroid, Papillary" 23569392 "In addition, the miR-146b expression level was significantly higher in the massive extrathyroidal invasion group than in the minimal extrathyroidal invasion group" +tissue_expression_up hsa-mir-145 Glioblastoma 23577178 "Most importantly, higher hsa-miR-145 expression in GBM tumors yielded significantly better survival (p<0.005) in a subset of patients thus validating it as a genuine tumor suppressor miRNA." +tissue_expression_up hsa-mir-146a Sepsis 23596477 We observed a significant increase in miR-146a expression in the initial cohort of 6 non-sepsis-SIRS patients compared to the 4 sepsis patients(P=0.01) +tissue_expression_up hsa-mir-132 Inflammatory Bowel Diseases 23598815 MiR-132 levels are higher in inflamed compared with apparently quiescent intestinal biopsies from patients with IBD. +tissue_expression_up hsa-let-7i Ankylosing Spondylitis 23607629 "In the functional studies, the increased let-7i expression facilitated the T helper type 1 (IFN-¦Ã) immune response in T cells." +tissue_expression_up hsa-mir-203 Psoriasis 23608026 "MiR-203 is a miRNA preferentially expressed in the skin, and an important regulator of keratinocyte differentiation. MiR-203 has been implicated in skin diseases, in particular in psoriasis in which it is overexpressed, and in basal cell carcinoma where it acts as a tumor suppressor miRNA." +tissue_expression_up hsa-mir-143 "Leukemia, Lymphocytic, Chronic, B-Cell" 23615967 "Significant upregulation of miR-150, miR-29c, miR-143 and miR-223 and downregulation of miR-15a was found in mutated versus unmutated CLL, with miR-15a showing the highest fold difference." +tissue_expression_up hsa-mir-150 "Leukemia, Lymphocytic, Chronic, B-Cell" 23615967 "Significant upregulation of miR-150, miR-29c, miR-143 and miR-223 and downregulation of miR-15a was found in mutated versus unmutated CLL, with miR-15a showing the highest fold difference." +tissue_expression_up hsa-mir-223 "Leukemia, Lymphocytic, Chronic, B-Cell" 23615967 "Significant upregulation of miR-150, miR-29c, miR-143 and miR-223 and downregulation of miR-15a was found in mutated versus unmutated CLL, with miR-15a showing the highest fold difference." +tissue_expression_up hsa-mir-29c "Leukemia, Lymphocytic, Chronic, B-Cell" 23615967 "Significant upregulation of miR-150, miR-29c, miR-143 and miR-223 and downregulation of miR-15a was found in mutated versus unmutated CLL, with miR-15a showing the highest fold difference." +tissue_expression_up hsa-mir-181a Breast Neoplasms 23656790 "We report that miR-181a and miR-181b were overexpressed in more aggressive breast cancers, and their expression correlates inversely with ATM levels." +tissue_expression_up hsa-mir-181b Breast Neoplasms 23656790 "We report that miR-181a and miR-181b were overexpressed in more aggressive breast cancers, and their expression correlates inversely with ATM levels." +tissue_expression_up hsa-mir-210 Heart Failure 23660476 miR-210 and miR-30a were elevated in the HF and fetus groups. +tissue_expression_up hsa-mir-30a Heart Failure 23660476 miR-210 and miR-30a were elevated in the HF and fetus groups. +tissue_expression_up hsa-mir-10b Ovarian Neoplasms 23670532 Loss of HOXD10 expression induced by upregulation of miR-10b accelerates the migration and invasion activities of ovarian cancer cells. +tissue_expression_up hsa-mir-155 Allergic Rhinitis 23704072 "Subjects with current allergic rhinitis symptoms had increased levels of miR-155, miR-205, and miR-498, but reduced levels of let-7e." +tissue_expression_up hsa-mir-205 Allergic Rhinitis 23704072 "Subjects with current allergic rhinitis symptoms had increased levels of miR-155, miR-205, and miR-498, but reduced levels of let-7e." +tissue_expression_up hsa-mir-498 Allergic Rhinitis 23704072 "Subjects with current allergic rhinitis symptoms had increased levels of miR-155, miR-205, and miR-498, but reduced levels of let-7e." +tissue_expression_up hsa-mir-328 Atrial Fibrillation 23710743 miR-328 expression is significantly increased in patients with AF +tissue_expression_up hsa-mir-130a Pulmonary Hypertension 23717609 "We identified several novel downregulated miRNAs (miR-451, miR-1246) and upregulated miRNAs (miR-23b, miR-130a and miR-191) in the circulation of PH subjects." +tissue_expression_up hsa-mir-191 Pulmonary Hypertension 23717609 "We identified several novel downregulated miRNAs (miR-451, miR-1246) and upregulated miRNAs (miR-23b, miR-130a and miR-191) in the circulation of PH subjects." +tissue_expression_up hsa-mir-23b Pulmonary Hypertension 23717609 "We identified several novel downregulated miRNAs (miR-451, miR-1246) and upregulated miRNAs (miR-23b, miR-130a and miR-191) in the circulation of PH subjects." +tissue_expression_up hsa-mir-192 "Adenocarcinoma, Esophageal" 23724052 "6 miRNAs (up-regulated: miR-194, miR-31, miR-192, and miR-200a; down-regulated: miR-203 and miR-205) in EAC" +tissue_expression_up hsa-mir-194 "Adenocarcinoma, Esophageal" 23724052 "6 miRNAs (up-regulated: miR-194, miR-31, miR-192, and miR-200a; down-regulated: miR-203 and miR-205) in EAC" +tissue_expression_up hsa-mir-200a "Adenocarcinoma, Esophageal" 23724052 "6 miRNAs (up-regulated: miR-194, miR-31, miR-192, and miR-200a; down-regulated: miR-203 and miR-205) in EAC" +tissue_expression_up hsa-mir-203 "Adenocarcinoma, Esophageal" 23724052 "6 miRNAs (up-regulated: miR-194, miR-31, miR-192, and miR-200a; down-regulated: miR-203 and miR-205) in EAC" +tissue_expression_up hsa-mir-205 "Adenocarcinoma, Esophageal" 23724052 "6 miRNAs (up-regulated: miR-194, miR-31, miR-192, and miR-200a; down-regulated: miR-203 and miR-205) in EAC" +tissue_expression_up hsa-mir-31 "Adenocarcinoma, Esophageal" 23724052 "6 miRNAs (up-regulated: miR-194, miR-31, miR-192, and miR-200a; down-regulated: miR-203 and miR-205) in EAC" +tissue_expression_up hsa-mir-130b Inflammation 23733276 "Statistical analysis considering liver donor meta-data including correction for multiple testing revealed strongly elevated levels of miR-21, miR-34a, miR-130b, and miR-132 in cholestatic liver and of miR-21 and miR-130b during inflammation, as indicated by elevated C-reactive protein levels in serum." +tissue_expression_up hsa-mir-132 Inflammation 23733276 "Statistical analysis considering liver donor meta-data including correction for multiple testing revealed strongly elevated levels of miR-21, miR-34a, miR-130b, and miR-132 in cholestatic liver and of miR-21 and miR-130b during inflammation, as indicated by elevated C-reactive protein levels in serum." +tissue_expression_up hsa-mir-21 Inflammation 23733276 "Statistical analysis considering liver donor meta-data including correction for multiple testing revealed strongly elevated levels of miR-21, miR-34a, miR-130b, and miR-132 in cholestatic liver and of miR-21 and miR-130b during inflammation, as indicated by elevated C-reactive protein levels in serum." +tissue_expression_up hsa-mir-34a Inflammation 23733276 "Statistical analysis considering liver donor meta-data including correction for multiple testing revealed strongly elevated levels of miR-21, miR-34a, miR-130b, and miR-132 in cholestatic liver and of miR-21 and miR-130b during inflammation, as indicated by elevated C-reactive protein levels in serum." +tissue_expression_up hsa-mir-221 Obesity 23756832 Human adipose microRNA-221 is upregulated in obesity and affects fat metabolism downstream of leptin and TNF-alpha +tissue_expression_up hsa-mir-101-1 Esophageal Neoplasms 23761828 upregulated +tissue_expression_up hsa-mir-101-2 Esophageal Neoplasms 23761828 upregulated +tissue_expression_up hsa-mir-130a Esophageal Neoplasms 23761828 upregulated +tissue_expression_up hsa-mir-130b Esophageal Neoplasms 23761828 upregulated +tissue_expression_up hsa-mir-143 Esophageal Neoplasms 23761828 upregulated +tissue_expression_up hsa-mir-15a Esophageal Neoplasms 23761828 upregulated +tissue_expression_up hsa-mir-196b Esophageal Neoplasms 23761828 upregulated +tissue_expression_up hsa-mir-200a Esophageal Neoplasms 23761828 upregulated +tissue_expression_up hsa-mir-210 Esophageal Neoplasms 23761828 upregulated +tissue_expression_up hsa-mir-27a Esophageal Neoplasms 23761828 upregulated +tissue_expression_up hsa-mir-28 Esophageal Neoplasms 23761828 miR-28-3p: upregulated +tissue_expression_up hsa-mir-31 Esophageal Neoplasms 23761828 upregulated +tissue_expression_up hsa-mir-452 Esophageal Neoplasms 23761828 upregulated +tissue_expression_up hsa-mir-99b Esophageal Neoplasms 23761828 upregulated +tissue_expression_up hsa-mir-192 Ovarian Neoplasms 23766361 "The clear cell histotype is characterized by a five-fold (log scale) higher expression of miR-30a and miR-30a*, while mucinous histotype has five-fold (log scale) higher levels of miR-192/194. Furthermore a mucinous-specific regulatory loop involving miR-192/194 cluster and a differential regulation of E2F3 in clear cell histotype were identified." +tissue_expression_up hsa-mir-194-1 Ovarian Neoplasms 23766361 "The clear cell histotype is characterized by a five-fold (log scale) higher expression of miR-30a and miR-30a*, while mucinous histotype has five-fold (log scale) higher levels of miR-192/194. Furthermore a mucinous-specific regulatory loop involving miR-192/194 cluster and a differential regulation of E2F3 in clear cell histotype were identified." +tissue_expression_up hsa-mir-194-2 Ovarian Neoplasms 23766361 "The clear cell histotype is characterized by a five-fold (log scale) higher expression of miR-30a and miR-30a*, while mucinous histotype has five-fold (log scale) higher levels of miR-192/194. Furthermore a mucinous-specific regulatory loop involving miR-192/194 cluster and a differential regulation of E2F3 in clear cell histotype were identified." +tissue_expression_up hsa-mir-30a Ovarian Neoplasms 23766361 "The clear cell histotype is characterized by a five-fold (log scale) higher expression of miR-30a and miR-30a*, while mucinous histotype has five-fold (log scale) higher levels of miR-192/194. Furthermore a mucinous-specific regulatory loop involving miR-192/194 cluster and a differential regulation of E2F3 in clear cell histotype were identified." +tissue_expression_up hsa-mir-34a Breast Neoplasms 23771315 Synergistic effects of curcumin with emodin against the proliferation and invasion of breast cancer cells through upregulation of mir-34a. +tissue_expression_up hsa-mir-874 Gastric Neoplasms 23800944 "These results provide a mechanism by which AQP3 is upregulated, as well as highlight the importance of miR-874 in gastric cancer development and progression." +tissue_expression_up hsa-mir-181c Gastric Neoplasms 23803080 "The expression of miR-181c is upregulated in GC tissues and plasma, and the miR-181c expression level in GC plasma is positively correlated to that in the corresponding cancer tissues. Plasma miR-181c is possibly a new serological marker for GC diagnosis." +tissue_expression_up hsa-mir-107 Glioma 23811124 Low-expression of microRNA-107 inhibits cell apoptosis in glioma by upregulation of SALL4. +tissue_expression_up hsa-mir-19a Glioma 23824915 miR-19a and miR-19b overexpression in gliomas. +tissue_expression_up hsa-mir-19b Glioma 23824915 miR-19a and miR-19b overexpression in gliomas. +tissue_expression_up hsa-mir-146b Intestinal Schistosomiasis 23825609 "miRNAs exhibiting a peak expression in the late phase of infection (dpi 45), such as mmu-miR-223, mmu-miR-146a/b, mmu-miR-155, mmu-miR-34c, mmu-miR-199, and mmu-miR-134, may represent a molecular ignature of the development of schistosomal hepatopathy." +tissue_expression_up hsa-mir-124 Stroke 23826665 The level of miR-124 is significantly increased in ischemic penumbra as compared with that in nonischemic area of MACO mice. +tissue_expression_up hsa-mir-301a Gastric Neoplasms 23832550 "miR-301a overexpression correlated with TNM stage and prognosis,suggesting that miR-301a is involved in cellular clone formation, migration, and invasion in vitro and may play an important role in the clinical progression and prognosis of gastric cancer." +tissue_expression_up hsa-mir-200b Gastric Neoplasms 23851184 Diallyl disulfide suppresses proliferation and induces apoptosis in human gastric cancer through Wnt-1 signaling pathway by up-regulation of miR-200b and miR-22. +tissue_expression_up hsa-mir-22 Gastric Neoplasms 23851184 Diallyl disulfide suppresses proliferation and induces apoptosis in human gastric cancer through Wnt-1 signaling pathway by up-regulation of miR-200b and miR-22. +tissue_expression_up hsa-mir-155 "Carcinoma, Hepatocellular" 23863669 MicroRNA-155 is over-expressed in primary HCC with tumor recurrence and may serve as a novel biomarker for tumor recurrence and survival of HCC patients after LT. The detection of microRNA-155 is of clinical significance in HCC. +tissue_expression_up hsa-mir-675 "Carcinoma, Hepatocellular" 23864307 Expression of the miR-675 in hepatocellular carcinoma links a dramatic upregulation of proliferative and growth capacity with inhibition of motility in HCC cells. +tissue_expression_up hsa-mir-21 Gastric Neoplasms 23888942 Oxidative stress upregulates PDCD4 expression in patients with gastric cancer via miR-21. +tissue_expression_up hsa-mir-27 Hepatitis C Virus Infection 23897856 Hepatitis C virus induced up-regulation of microRNA-27: a novel mechanism for hepatic steatosis. +tissue_expression_up hsa-mir-143 Lung Neoplasms 23904792 "The up-regulated miR-143 in lung cancer could significantly inhibit cell migration and invasion, and this might work through targeting CD44v3, which was newly identified by us." +tissue_expression_up hsa-mir-203 Ovarian Neoplasms 23918241 Upregulation of microRNA-203 is associated with advanced tumor progression and poor prognosis in epithelial ovarian cancer. +tissue_expression_up hsa-mir-182 Prostate Neoplasms 23936432 Inhibition of proliferation and induction of autophagy by atorvastatin in PC3 prostate cancer cells correlate with downregulation of Bcl2 and upregulation of miR-182 and p21. +tissue_expression_up hsa-mir-31 Choriocarcinoma 23946296 MicroRNA-31 predicts the presence of lymph node metastases and survival in patients with lung adenocarcinoma. +tissue_expression_up hsa-mir-138 "Carcinoma, Bladder" 23946872 "Within this group, let-7b and let-7i exhibited decreased expression, while miR-1290 and miR-138 displayed increased expression levels in gemcitabine-resistant cells." +tissue_expression_up hsa-mir-132 Inflammation 23951048 Chronic ethanol feeding up-regulated miR-155 and miR-132 expression in mouse cerebellum. +tissue_expression_up hsa-mir-10a Breast Neoplasms 23968733 Increased expression of miR-126 and miR-10a predict prolonged relapse-free time of primary oestrogen receptor-positive breast cancer following tamoxifen treatment. +tissue_expression_up hsa-mir-126 Breast Neoplasms 23968733 Increased expression of miR-126 and miR-10a predict prolonged relapse-free time of primary oestrogen receptor-positive breast cancer following tamoxifen treatment. +tissue_expression_up hsa-mir-18b Breast Neoplasms 23970382 MicroRNA-18b is upregulated in breast cancer and modulates genes involved in cell migration. +tissue_expression_up hsa-mir-215 Gastric Neoplasms 23981575 Frequently up-regulated miR-215 in gastric cancer may influence cell proliferation by targeting RB1. +tissue_expression_up hsa-mir-9 Lung Neoplasms 24019037 "MiR-9 was up-regulated in non-small cell lung cancer tissues and correlated with adverse clinical features and unfavorable survival, indicating that miR-9 might be involved in non-small lung cancer progression and could serve as a promising biomarker for further risk stratification in the treatment of this cancer." +tissue_expression_up hsa-mir-26b Alzheimer Disease 24027266 "MiR-26b, upregulated in Alzheimer's disease, activates cell cycle entry,tau-phosphorylation, and apoptosis in postmitotic neurons." +tissue_expression_up hsa-mir-126 "Carcinoma, Cervical" 24037526 Repression of miR-126 and upregulation of adrenomedullin in the stromal endothelium by cancer-stromal cross talks confers angiogenesis of cervical cancer. +tissue_expression_up hsa-mir-214 Pediatric Osteosarcoma 24038809 Our data offer evidence that upregulated expression of miR-214 may be linked to tumor progression and adverse prognosis in pediatric osteosarcoma.Further investigation in prospective studies would appear warranted. +tissue_expression_up hsa-mir-1 Myocardial Infarction 24046434 "Consistent with previous publications, cardiac specific miR-1 and miR-133a were up-regulated in STEMI patients compared with healthy controls (both, P < 0.0001)" +tissue_expression_up hsa-mir-182 "Carcinoma, Colon" 24053448 "Our data suggest that miR-182 targets the anti-angiogenic factor TSP-1 and that anti-miR-182 determines an upregulation of TSP-1 expression in colon cancer cells. Moreover, anti-miR-182 exerts a transcriptional regulatory mechanism of tsp-1 modulating Egr-1 and Sp-1 function. Anti-miR-182 could be used to restore TSP-1 expression in order to contrast angiogenic and invasive events in CRC." +tissue_expression_up hsa-mir-9 Glioma 24122417 Increased expression of microRNA-9 predicts an unfavorable prognosis in human glioma. +tissue_expression_up hsa-mir-21 "Carcinoma, Colon" 24122631 High miR-21 expression from FFPE tissues is associated with poor survival and response to adjuvant chemotherapy in colon cancer. +tissue_expression_up hsa-mir-222 "Carcinoma, Hepatocellular" 24124720 "Serum miR-222, upregulated in HCC, maybe helpful in prognosis of HCC patients." +tissue_expression_up hsa-mir-222 Ovarian Neoplasms 24137356 miR-222 is upregulated in epithelial ovarian cancer and promotes cell proliferation by downregulating P27kip1. +tissue_expression_up hsa-mir-32 "Muscular Dystrophy, Facioscapulohumeral" 24145033 "Twenty-one microRNAs (miR-1, miR-7, miR-15a, miR-22, miR-30e, miR-32, miR-107, miR-133a, miR-133b, miR-139, miR-152, miR-206, miR-223, miR-302b, miR-331, miR-362, miR-365, miR-382, miR-496, miR-532, miR-654, and miR-660) were up-regulated" +tissue_expression_up hsa-mir-525 Neoplasms [unspecific] 24147004 "The transient up-regulation of miR-525-3p, and the resultant repression of its direct targets ARRB1, TXN1 and HSPA9, is required for cell survival following irradiation. The conserved function of miR-525-3p across several cell types makes this microRNA pathway a promising target for modifying the efficacy of radiotherapy." +tissue_expression_up hsa-mir-183 Colorectal Carcinoma 24150523 "The increased expression of miR-183 is closely related to advanced clinical stage, lymph node and distant metastases, and poor prognosis of CRC,indicating that miR-183 may serve as a predictive biomarker for the prognosis or the aggressiveness of CRC." +tissue_expression_up hsa-mir-155 Rheumatoid Arthritis 24151514 "An inflammatory milieu may alter miRNA expression profiles in rheumatoid arthritis. miR-155 is upregulated in RA-FLS, and it may be a protective factor against the inflammatory effect in part by attenuating expression of IKBKE." +tissue_expression_up hsa-mir-221 Glioblastoma 24155920 "A number of changes in the levels of microRNAs were detected in differentiating GICs, including over-expression of hsa-miR-21, hsa-miR-29a, hsa-miR-29b, hsa-miR-221 and hsa-miR-222, and down-regulation of hsa-miR-93 and hsa-miR-106a." +tissue_expression_up hsa-mir-222 Glioblastoma 24155920 "A number of changes in the levels of microRNAs were detected in differentiating GICs, including over-expression of hsa-miR-21, hsa-miR-29a, hsa-miR-29b, hsa-miR-221 and hsa-miR-222, and down-regulation of hsa-miR-93 and hsa-miR-106a." +tissue_expression_up hsa-mir-125b Glioblastoma 24169356 High-level expression of miR-125b is associated with poor outcomes of GMB. MiR-125b may have an oncogenic role in GMB cells by promoting cell proliferation and inhibiting apoptosis. +tissue_expression_up hsa-mir-518b Chondrosarcoma 24173143 Gallic acid induces apoptosis and inhibits cell migration by upregulating miR-518b in SW1353 human chondrosarcoma cells. +tissue_expression_up hsa-mir-122 "Carcinoma, Renal Cell" 24175769 The up-regulation of miR-122 may play an important role in the progress of renal cancer through activating PI3K/Akt signal pathway and could be a potential molecular target for anti-cancer therapeutics. +tissue_expression_up hsa-mir-198 "Carcinoma, Esophageal" 24175778 miR-198 overexpression is involved in the poor prognosis of esophageal cancer and can be used as a biomarker for selection of cases requiring especial attention. +tissue_expression_up hsa-mir-29a Neoplasms [unspecific] 24210072 MicroRNA-29a upregulates MMP2 in oral squamous cell carcinoma to promote cancer invasion and anti-apoptosis. +tissue_expression_up hsa-mir-31 "Squamous Cell Carcinoma, Oral" 24238414 The up-regulated level of microRNA-31 expression may be related to the pathogenesis of OSCC. +tissue_expression_up hsa-mir-150 Chronic Heart Failure 24239242 MicroRNA-150 counteracts ADIPOR2 up-regulation in CHF and thus may contribute to adiponectin resistance. Targeting microRNA-150 may be a future strategy to restore cardioprotective adiponectin effects. +tissue_expression_up hsa-mir-424 Prostate Neoplasms 24244675 MiR-424/503-mediated Rictor upregulation promotes tumor progression. +tissue_expression_up hsa-mir-503 Prostate Neoplasms 24244675 MiR-424/503-mediated Rictor upregulation promotes tumor progression. +tissue_expression_up hsa-mir-21 Colorectal Carcinoma 24265822 The present findings suggest that high expression of miR-21 might predict poor prognosis in patients with colorectal cancer. +tissue_expression_up hsa-mir-25 Colorectal Carcinoma 24293092 The expression of miR-25 is increased in colorectal cancer and is associated with patient prognosis. +tissue_expression_up hsa-mir-21 "Carcinoma, Lung, Non-Small-Cell" 24293118 Our data suggest a novel molecular mechanism in which inhibition of microRNA-21 and upregulation of PTEN mediate the anticancer activities of curcumin in NSCLC cells. Suppression of microRNA-21 may thus have therapeutic benefits against this malignancy. +tissue_expression_up hsa-mir-655 "Squamous Cell Carcinoma, Esophageal" 24314023 Mir-655 up-regulation suppresses cell invasion by targeting pituitary tumor-transforming gene-1 in esophageal squamous cell carcinoma. +tissue_expression_up hsa-mir-143 "Diabetes Mellitus, Type 2" 24333576 Adipocyte-derived factors impair insulin signaling in differentiated human vascular smooth muscle cells via the upregulation of miR-143. +tissue_expression_up hsa-mir-125b Amyotrophic Lateral Sclerosis 24336079 "We identified upregulation of selected immune-enriched miRNAs, recognizing miR-22, miR-155, miR-125b and miR-146b among the most highly modulated." +tissue_expression_up hsa-mir-146b Amyotrophic Lateral Sclerosis 24336079 "We identified upregulation of selected immune-enriched miRNAs, recognizing miR-22, miR-155, miR-125b and miR-146b among the most highly modulated." +tissue_expression_up hsa-mir-23b Lymphoma 24356489 We found that miR-23a & miR-23b were up-regulated in radiation induced thymic lymphoma tissue samples. +tissue_expression_up hsa-mir-210 Glioma 24382515 MicroRNA-210 overexpression predicts poorer prognosis in glioma patients. +tissue_expression_up hsa-mir-98 Glioma 24392454 Overexpression of RKIP inhibits cell invasion in glioma cell lines through upregulation of miR-98. +tissue_expression_up hsa-mir-128 Salmonellosis 24415783 "Salmonella can upregulate intestinal epithelial miR-128 expression,which, in turn, decreases levels of epithelial cell-secreted M-CSF and M-CSF-induced macrophage recruitment. mir-9-5p" +tissue_expression_up hsa-mir-155 "Squamous Cell Carcinoma, Oral" 24439918 "In OSSC, upregulation of miR-155 correlated with the histologic grade and can be used as a potential prognostic biomarker." +tissue_expression_up hsa-mir-146 "Carcinoma, Lung, Non-Small-Cell" 24448024 microRNA-146 up-regulation predicts the prognosis of non-small cell lung cancer by miRNA in situ hybridization. +tissue_expression_up hsa-mir-17 Melanoma 24462553 "We show that miRNAs of the miR-17-92 cluster (miR-20a2, miR-92a1, miR-17 and miR-18a), miR-126, miR-182, miR-210 and miR-214 are upregulated and their respective target genes (RUNX1, HIF1A, TGFBR2, THBS1 and JAK2) are down-regulated in melanoma." +tissue_expression_up hsa-mir-214 Melanoma 24462553 "We show that miRNAs of the miR-17-92 cluster (miR-20a2, miR-92a1, miR-17 and miR-18a), miR-126, miR-182, miR-210 and miR-214 are upregulated and their respective target genes (RUNX1, HIF1A, TGFBR2, THBS1 and JAK2) are down-regulated in melanoma." +tissue_expression_up hsa-mir-214 Ovarian Neoplasms 24479883 "Members of the miR-200 family, miR-182, miR-214 and miR-221 are frequently up-regulated, whereas miR-100, let-7i, miR-199a, miR-125b, mir-145 and miR-335 are often down-regulated in ovarian cancer compared with normal ovarian tissue." +tissue_expression_up hsa-mir-30a Ovarian Neoplasms 24479883 "Clear cell carcinoma has a significantly higher expression of miR-30a and miR-30a*, whereas mucinous histotype has elevated levels of miR-192/194." +tissue_expression_up hsa-mir-888 Breast Neoplasms 24480745 "As a potential role in intercellular adhesiveness and maintenance of malignant tissue architecture, the results indicate that miR-888 is a repressor of the AJ pathway in MCF-7 cells and that up-regulation of miR-888 contributes to aggressiveness in MCF-7 SP cells." +tissue_expression_up hsa-mir-31 Oral Neoplasms 24480806 miR-31 is upregulated in oral premalignant epithelium and contributes to the immortalization of normal oral keratinocytes. +tissue_expression_up hsa-mir-135b "Carcinoma, Endometrioid Endometrial" 24491411 "Quantitative reverse-transcriptase PCR identified 8 EEC-associated miRNAs in tissue (upregulated: miR-499, miR-135b, miR-205, downregulated: miR-10b, miR-195, miR-30a-5p, miR-30a-3p and miR-21)." +tissue_expression_up hsa-mir-145 Endometriosis 24495683 "Up-regulation of mir-29c, mir-200a, mir-145 in the endometrial tissue might play a role in endometriosis associated infertility." +tissue_expression_up hsa-mir-200a Endometriosis 24495683 "Up-regulation of mir-29c, mir-200a, mir-145 in the endometrial tissue might play a role in endometriosis associated infertility." +tissue_expression_up hsa-mir-29c Endometriosis 24495683 "Up-regulation of mir-29c, mir-200a, mir-145 in the endometrial tissue might play a role in endometriosis associated infertility." +tissue_expression_up hsa-mir-143 Allergic Rhinitis 24513959 "Downregulation of miR-18a, miR-126, let-7e, miR-155, and miR-224 and upregulation of miR-498, miR-187, miR-874, miR-143, and miR-886-3p were observed in asthmatic patients in comparison to controls. The differences in miRNA expression were mainly similar in asthmatics with and without AR." +tissue_expression_up hsa-mir-143 Asthma 24513959 "Downregulation of miR-18a, miR-126, let-7e, miR-155, and miR-224 and upregulation of miR-498, miR-187, miR-874, miR-143, and miR-886-3p were observed in asthmatic patients in comparison to controls. The differences in miRNA expression were mainly similar in asthmatics with and without AR." +tissue_expression_up hsa-mir-187 Allergic Rhinitis 24513959 "Downregulation of miR-18a, miR-126, let-7e, miR-155, and miR-224 and upregulation of miR-498, miR-187, miR-874, miR-143, and miR-886-3p were observed in asthmatic patients in comparison to controls. The differences in miRNA expression were mainly similar in asthmatics with and without AR." +tissue_expression_up hsa-mir-187 Asthma 24513959 "Downregulation of miR-18a, miR-126, let-7e, miR-155, and miR-224 and upregulation of miR-498, miR-187, miR-874, miR-143, and miR-886-3p were observed in asthmatic patients in comparison to controls. The differences in miRNA expression were mainly similar in asthmatics with and without AR." +tissue_expression_up hsa-mir-498 Allergic Rhinitis 24513959 "Downregulation of miR-18a, miR-126, let-7e, miR-155, and miR-224 and upregulation of miR-498, miR-187, miR-874, miR-143, and miR-886-3p were observed in asthmatic patients in comparison to controls. The differences in miRNA expression were mainly similar in asthmatics with and without AR." +tissue_expression_up hsa-mir-498 Asthma 24513959 "Downregulation of miR-18a, miR-126, let-7e, miR-155, and miR-224 and upregulation of miR-498, miR-187, miR-874, miR-143, and miR-886-3p were observed in asthmatic patients in comparison to controls. The differences in miRNA expression were mainly similar in asthmatics with and without AR." +tissue_expression_up hsa-mir-874 Allergic Rhinitis 24513959 "Downregulation of miR-18a, miR-126, let-7e, miR-155, and miR-224 and upregulation of miR-498, miR-187, miR-874, miR-143, and miR-886-3p were observed in asthmatic patients in comparison to controls. The differences in miRNA expression were mainly similar in asthmatics with and without AR." +tissue_expression_up hsa-mir-874 Asthma 24513959 "Downregulation of miR-18a, miR-126, let-7e, miR-155, and miR-224 and upregulation of miR-498, miR-187, miR-874, miR-143, and miR-886-3p were observed in asthmatic patients in comparison to controls. The differences in miRNA expression were mainly similar in asthmatics with and without AR." +tissue_expression_up hsa-mir-886 Allergic Rhinitis 24513959 "Downregulation of miR-18a, miR-126, let-7e, miR-155, and miR-224 and upregulation of miR-498, miR-187, miR-874, miR-143, and miR-886-3p were observed in asthmatic patients in comparison to controls. The differences in miRNA expression were mainly similar in asthmatics with and without AR." +tissue_expression_up hsa-mir-886 Asthma 24513959 "Downregulation of miR-18a, miR-126, let-7e, miR-155, and miR-224 and upregulation of miR-498, miR-187, miR-874, miR-143, and miR-886-3p were observed in asthmatic patients in comparison to controls. The differences in miRNA expression were mainly similar in asthmatics with and without AR." +tissue_expression_up hsa-mir-182 "Carcinoma, Lung, Non-Small-Cell" 24575749 "In patients with SCC and in stage II patients, high tumor cell miR-182 expression is an independent positive prognostic factor." +tissue_expression_up hsa-mir-25 "Carcinoma, Hepatocellular" 24593846 Our data suggests that the overexpression of miR-25 in HCC tissues is of predictive value on poor prognosis. +tissue_expression_up hsa-mir-206 Alzheimer Disease 24604632 "We now report that miR-206 is upregulated in the hippocampal tissue, cerebrospinal fluid, and plasma of embryonic APP/PS1 transgenic mice." +tissue_expression_up hsa-mir-93 Breast Neoplasms 24606013 These results suggest that overexpression of miR-93 in FFPE tissues may serve as an indispensable source for biomarker discovery and validation in breast cancer patients. +tissue_expression_up hsa-mir-126 Asthma 24615202 In mice models of asthma it has been found that increased levels of miR-21 and miR-126 +tissue_expression_up hsa-mir-630 Gastric Neoplasms 24621930 Increased microRNA-630 expression in gastric cancer is associated with poor overall survival. +tissue_expression_up hsa-mir-196a Pancreatic Intraductal Papillary Mucinous Neoplasms 24622064 Elevated expression of miR-196a in pancreatic juice samples is predictive of intestinal-type IPMNs. +tissue_expression_up hsa-mir-125b Melanoma 24635082 "MLK3 is upregulated in metastatic melanoma, and regulates cell proliferation and invasion in melanoma cells. MLK3 is a direct target of miR-125b." +tissue_expression_up hsa-mir-149 Lung Fibrosis 24641842 Down-regulation of miR-149 and up-regulation of IL-6 might be involved in the progression of silica-induced pulmonary fibrosis; miR-149 could negatively regulate IL-6 expression. +tissue_expression_up hsa-mir-17 Osteosarcoma 24645838 Upregulation of microRNA-17-92 cluster associates with tumor progression and prognosis in osteosarcoma. +tissue_expression_up hsa-mir-106a Colorectal Carcinoma 24670448 "plasma miR-106a is up-regulated in CRC patients, suggesting its potential value for the diagnosis of CRC." +tissue_expression_up hsa-mir-155 "Squamous Cell Carcinoma, Oral" 24692283 "MiRNA-155 was overexpressed in OSCC and it was located in the cancer nest, inflammatory area, and vascular endothelium of OSCC. High miRNA-155 expression level in ACF may predict poor prognosis in patients with OSCC." +tissue_expression_up hsa-mir-1224 Acute Kidney Failure 24695114 "Ischemia-reperfusion caused highly reproducible, progressive, concordant elevation of miR-714, miR-1188, miR-1897-3p, miR-877*, and miR-1224 in plasma and kidneys at 3, 6 and 24 hours after acute kidney injury compared to the sham-operated mice (nâ€?â€?)." +tissue_expression_up hsa-mir-25 "Carcinoma, Ovarian" 24696291 "The increased expression of miR-25 is closely related to poor prognosis of EOC, indicating that miR-25 may serve as a predictive biomarker for the prognosis of EOC." +tissue_expression_up hsa-mir-98 Breast Neoplasms 24696733 Over-expression of miR-98 in FFPE tissues might serve as a valuable source for biomarker discovery in breast cancer patients. +tissue_expression_up hsa-mir-218 "Adenocarcinoma, Lung" 24705471 ADAM9 up-regulates N-cadherin via miR-218 suppression in lung adenocarcinoma cells. +tissue_expression_up hsa-mir-199a Colorectal Carcinoma 24711074 MiR-199a-5p loss up-regulated DDR1 aggravated colorectal cancer by activating epithelial-to-mesenchymal transition related signaling. +tissue_expression_up hsa-let-7b Infertility 24711889 "Mir-100, let-7b levels were significantly higher than those in control group (P=0.008 and P=0.009, respectively)." +tissue_expression_up hsa-mir-223 Knee Osteoarthritis 24727161 Peroxisomal dysfunction is associated with up-regulation of apoptotic cell death via miR-223 induction in knee osteoarthritis patients with type 2 diabetes mellitus. +tissue_expression_up hsa-mir-4284 Glioblastoma 24732116 "A novel berbamine derivative inhibits cell viability and induces apoptosis in cancer stem-like cells of human glioblastoma, via up-regulation of miRNA-4284 and JNK/AP-1 signaling." +tissue_expression_up hsa-mir-21 Acute Lung Injury 24736893 miR-21 was upregulated in the OA group throughout the 24 h following OA challenge. +tissue_expression_up hsa-mir-1246 Neuroblastoma 24739954 Parallel mRNA and microRNA profiling of HEV71-infected human neuroblastoma cells reveal the up-regulation of miR-1246 in association with DLG3 repression. +tissue_expression_up hsa-mir-196a Osteosarcoma 24747591 "Our present data indicate the involvement of miR-196a and miR-196b upregulation in the pathogenesis of osteosarcoma. More importantly, the altered levels of circulating miR-196a and miR-196b might have great potential to serve as novel and non-invasive prognostic factors for this malignancy." +tissue_expression_up hsa-mir-196b Osteosarcoma 24747591 "Our present data indicate the involvement of miR-196a and miR-196b upregulation in the pathogenesis of osteosarcoma. More importantly, the altered levels of circulating miR-196a and miR-196b might have great potential to serve as novel and non-invasive prognostic factors for this malignancy." +tissue_expression_up hsa-mir-21 "Carcinoma, Esophageal" 24756761 Nicotine upregulates microRNA-21 and promotes TGF-¦Â-dependent epithelial-mesenchymal transition of esophageal cancer cells. +tissue_expression_up hsa-mir-378 Obesity 24771406 "TNF-¦Á, IL-6, and leptin upregulated miR-378 expression indicating that miR-378 probably is a novel mediator in the development of insulin resistance related to obesity." +tissue_expression_up hsa-mir-21 "Carcinoma, Breast" 24781337 Higher miR-21 expression in invasive breast carcinomas is associated with positive estrogen and progesterone receptor status in patients from Serbia. +tissue_expression_up hsa-mir-183 "Adenocarcinoma, Lung" 24805982 Up-regulation of microRNA-183-3p is a potent prognostic marker for lung adenocarcinoma of female non-smokers. +tissue_expression_up hsa-mir-26b "Adenocarcinoma, Lung" 24815696 Huaier suppresses proliferation and induces apoptosis in human pulmonary cancer cells via upregulation of miR-26b-5p. +tissue_expression_up hsa-mir-196a "Carcinoma, Cervical" 24817935 Heterogeneity of microRNAs expression in cervical cancer cells: over-expression of miR-196a. +tissue_expression_up hsa-mir-23b "Leukemia, Myeloid, Acute" 24828865 MicroRNA-26a-5p and microRNA-23b-3p up-regulate peroxiredoxin III in acute myeloid leukemia. +tissue_expression_up hsa-mir-26a "Leukemia, Myeloid, Acute" 24828865 MicroRNA-26a-5p and microRNA-23b-3p up-regulate peroxiredoxin III in acute myeloid leukemia. +tissue_expression_up hsa-mir-155 "Carcinoma, Lung, Non-Small-Cell" 24854560 High expression of miR-155 represents a valuable marker of poor clinical outcomes in patients with stage III NSCLC. +tissue_expression_up hsa-mir-9 Ovarian Neoplasms 24870723 The present study provided evidence that curcumin exerts its cytotoxic effects against SKOV3 ovarian cancer cells largely through upregulation of miR-9 and subsequent modulation of Akt/FOXO1 axis. Further studies are needed to identify direct targets of miR-9 that mediate the anticancer effects of curcumin in ovarian cancer cells. +tissue_expression_up hsa-mir-155 "Carcinoma, Colon" 24888652 "The expression of miR-155 is up-regulated in colon cancer tissue. A combination of miR-155 level assay in colon cancer tissue and the serum CEA level both pre- and postoperatively can afford more accurate information for diagnosis and prognosis, especially for predicting recurrence and metastasis postoperatively." +tissue_expression_up hsa-mir-155 Rheumatoid Arthritis 24909288 "TPT suppressed the expression of miR-155 and up-regulated the release of SHIP-1, thus inhibiting the inflammatory response in the LPS-stimulated monocytes of RA patients." +tissue_expression_up hsa-mir-224 "Carcinoma, Hepatocellular" 24923856 These results indicate for the first time that miR-224 upregulation and AKT activation may synergistically associate with tumor progression of HCC.The combined high expression of miR-224 and pAKT may be a potential indicator for predicting unfavorable prognosis in HCC patients. +tissue_expression_up hsa-mir-21 "Carcinoma, Breast, Triple Negative" 24930006 High expression of miR-21 in triple-negative breast cancers was correlated with a poor prognosis and promoted tumor cell in vitro proliferation. +tissue_expression_up hsa-mir-326 Multiple Sclerosis 24936144 "For instance, miR-21, miR-142-3p, miR-146a, miR-146b, miR-155 and miR-326 were up-regulated in both peripheral blood mononuclear cells (PBMCs) and brain white matter lesions from MS patients and mouse model as well." +tissue_expression_up hsa-mir-155 Early-Stage Breast Carcinoma 24938880 OncomiRs are significantly more abundant in the sera of EBC patients compared to controls at diagnosis. Differences in oncomiR levels reflecting EBC risk were also observed. Testing the oncomiRs may be useful for diagnostic purpose and possibly also for relapse detection in follow-up studies of EBC. +tissue_expression_up hsa-mir-181b Early-Stage Breast Carcinoma 24938880 OncomiRs are significantly more abundant in the sera of EBC patients compared to controls at diagnosis. Differences in oncomiR levels reflecting EBC risk were also observed. Testing the oncomiRs may be useful for diagnostic purpose and possibly also for relapse detection in follow-up studies of EBC. +tissue_expression_up hsa-mir-19a Early-Stage Breast Carcinoma 24938880 OncomiRs are significantly more abundant in the sera of EBC patients compared to controls at diagnosis. Differences in oncomiR levels reflecting EBC risk were also observed. Testing the oncomiRs may be useful for diagnostic purpose and possibly also for relapse detection in follow-up studies of EBC. +tissue_expression_up hsa-mir-24 Early-Stage Breast Carcinoma 24938880 OncomiRs are significantly more abundant in the sera of EBC patients compared to controls at diagnosis. Differences in oncomiR levels reflecting EBC risk were also observed. Testing the oncomiRs may be useful for diagnostic purpose and possibly also for relapse detection in follow-up studies of EBC. +tissue_expression_up hsa-mir-129 Gastric Neoplasms 24969565 lncRNA-AC130710 targeting by miR-129-5p is upregulated in gastric cancer and associates with poor prognosis. +tissue_expression_up hsa-mir-15a Macular Degeneration 24970617 The expression of several miRNAs related to angiogenesis and fibrosis was expressed significantly higher in the vitreous of eyes with PDR.Further studies are needed to understand the role played by the miRNAs in the biological function of the eye. +tissue_expression_up hsa-mir-29a Macular Degeneration 24970617 The expression of several miRNAs related to angiogenesis and fibrosis was expressed significantly higher in the vitreous of eyes with PDR.Further studies are needed to understand the role played by the miRNAs in the biological function of the eye. +tissue_expression_up hsa-mir-320a Macular Degeneration 24970617 The expression of several miRNAs related to angiogenesis and fibrosis was expressed significantly higher in the vitreous of eyes with PDR.Further studies are needed to understand the role played by the miRNAs in the biological function of the eye. +tissue_expression_up hsa-mir-320b Macular Degeneration 24970617 The expression of several miRNAs related to angiogenesis and fibrosis was expressed significantly higher in the vitreous of eyes with PDR.Further studies are needed to understand the role played by the miRNAs in the biological function of the eye. +tissue_expression_up hsa-mir-423 Macular Degeneration 24970617 The expression of several miRNAs related to angiogenesis and fibrosis was expressed significantly higher in the vitreous of eyes with PDR.Further studies are needed to understand the role played by the miRNAs in the biological function of the eye. +tissue_expression_up hsa-mir-93 Macular Degeneration 24970617 The expression of several miRNAs related to angiogenesis and fibrosis was expressed significantly higher in the vitreous of eyes with PDR.Further studies are needed to understand the role played by the miRNAs in the biological function of the eye. +tissue_expression_up hsa-mir-192 Gastric Neoplasms 24981590 These data suggest that frequently up-regulated miR-215/192 in gastric cancer may participate in gastric cancer progression. +tissue_expression_up hsa-mir-215 Gastric Neoplasms 24981590 These data suggest that frequently up-regulated miR-215/192 in gastric cancer may participate in gastric cancer progression. +tissue_expression_up hsa-mir-302f Breast Neoplasms 24982406 MiR-337 and miR-302f were commonly overexpressed in HER2-postive breast and gastric cancer. MiR-139 and miR-129 were commonly underexpressed in HER2-positive breast and gastric cancer. +tissue_expression_up hsa-mir-155 Colon Neoplasms 24989910 The level of miR-155 was gradually elevated with the formation of colitis-associated colon cancer. +tissue_expression_up hsa-mir-141 Chondrosarcoma 24992595 Paeonol suppresses chondrosarcoma metastasis through up-regulation of miR-141 by modulating PKC¦Ä and c-Src signaling pathway. +tissue_expression_up hsa-mir-143 Chronic Hepatitis 24993656 "In conclusion, the expression of miR-143 and miR-215 in serum were significantly up-regulated in patients with chronic hepatitis and HCC. Due to its reasonable sensitivity and specificity for both diseases, miR-143 and miR-215 could be as potential circulating biomarkers." +tissue_expression_up hsa-mir-215 Chronic Hepatitis 24993656 "In conclusion, the expression of miR-143 and miR-215 in serum were significantly up-regulated in patients with chronic hepatitis and HCC. Due to its reasonable sensitivity and specificity for both diseases, miR-143 and miR-215 could be as potential circulating biomarkers." +tissue_expression_up hsa-mir-126 Asthma 24995087 "Compared to the normal group, miR-21 and miR-126 expression was significantly upregulated in asthma patients regardless of treatment." +tissue_expression_up hsa-mir-141 "Carcinoma, Lung, Non-Small-Cell" 25003366 High miR-141 and miR-200c expression are associated with shorter OS in NSCLC patients with adenocarcinoma through MET and angiogenesis. +tissue_expression_up hsa-mir-200c "Carcinoma, Lung, Non-Small-Cell" 25003366 High miR-141 and miR-200c expression are associated with shorter OS in NSCLC patients with adenocarcinoma through MET and angiogenesis. +tissue_expression_up hsa-mir-758 Hepatitis C Virus Infection 25008898 Hepatitis C virus infection decreases the expression of Toll-like receptors 3 and 7 via upregulation of miR-758. +tissue_expression_up hsa-mir-1288 Ectopic Pregnancy 25013942 "Microarray studies showed that four miRNAs were differentially downregulated (hsa-mir-196b, hsa-mir-30a, hsa-mir-873, and hsa-mir-337-3p) and three upregulated (hsa-mir-1288, hsa-mir-451, and hsa-mir-223) in EP compared to control tissue samples." +tissue_expression_up hsa-mir-223 Ectopic Pregnancy 25013942 "Microarray studies showed that four miRNAs were differentially downregulated (hsa-mir-196b, hsa-mir-30a, hsa-mir-873, and hsa-mir-337-3p) and three upregulated (hsa-mir-1288, hsa-mir-451, and hsa-mir-223) in EP compared to control tissue samples." +tissue_expression_up hsa-mir-451 Ectopic Pregnancy 25013942 "Microarray studies showed that four miRNAs were differentially downregulated (hsa-mir-196b, hsa-mir-30a, hsa-mir-873, and hsa-mir-337-3p) and three upregulated (hsa-mir-1288, hsa-mir-451, and hsa-mir-223) in EP compared to control tissue samples." +tissue_expression_up hsa-mir-210 Preeclampsia 25015807 "This increases the expression of miR-210 in the placenta causing repression of mitochondria-associated target genes, potentially leading to mitochondrial and placental dysfunction." +tissue_expression_up hsa-mir-145 Colorectal Carcinoma 25019299 Up-regulation of microRNA-145 associates with lymph node metastasis in colorectal cancer. +tissue_expression_up hsa-mir-139 Breast Neoplasms 25027758 "Down-regulation of miR-486-5p and miR-139-5p, in conjunction with up-regulation of miR-21, may represent a useful signature for the identification of high-risk breast cancer patients." +tissue_expression_up hsa-mir-21 Breast Neoplasms 25027758 "Down-regulation of miR-486-5p and miR-139-5p, in conjunction with up-regulation of miR-21, may represent a useful signature for the identification of high-risk breast cancer patients." +tissue_expression_up hsa-mir-486 Breast Neoplasms 25027758 "Down-regulation of miR-486-5p and miR-139-5p, in conjunction with up-regulation of miR-21, may represent a useful signature for the identification of high-risk breast cancer patients." +tissue_expression_up hsa-mir-630 Kidney Neoplasms 25031755 "The study proves for the first time that miR-630 is upregulated in a majority of ccRCC patients. It also shows that miR-630 expression is an independent prognostic factor for patients with renal cancer, which might be a potential valuable biomarker for ccRCC." +tissue_expression_up hsa-mir-182 Colorectal Carcinoma 25031782 Increased expression of miRNA-182 in colorectal carcinoma: an independent and tissue-specific prognostic factor. +tissue_expression_up hsa-mir-31 Kawasaki Syndrome 25039241 "These results suggest that the decrease in FoxP3(+) Treg might be associated with decreased expression of miR-155, leading to aberrant SOCS1/STAT-5 signalling and overexpression of miR-31 in patients with acute KD." +tissue_expression_up hsa-mir-106b Medulloblastoma 25041637 These data suggested the upregulation of miR-106b in MB and the involvement of miR-106b in MB biology. +tissue_expression_up hsa-mir-143 Sepsis 25043848 "Through microRNA microarray and qRT-PCR we found that the levels of miR-27a, miR-153 and miR-143 are up regulated, while let-7a, miR-218 and miR-129-5p are down regulated in lungs of septic mice." +tissue_expression_up hsa-mir-34c Alzheimer Disease 25052764 "We have used an in vivo neonatal mouse model to induce ketamine-related neurotoxicity in the hippocampus, and found that miR-34c, a microRNA associated with pathogenesis of Alzheimer's disease, was significantly upregulated during ketamine-induced hippocampal neurodegeneration." +tissue_expression_up hsa-let-7d HIV-Associated Lipodystrophy 25063777 "Eleven other miRNAs (i.e. miR-let-7d, miR-24, miR-30c, miR-125a-3p, miR-149, miR-191, miR-196-b, miR-218, miR-342-3p, miR-452 and miR-454*) were 2- to 2.5-fold more expressed in HIV+ samples than in controls." +tissue_expression_up hsa-mir-125 HIV-Associated Lipodystrophy 25063777 "Eleven other miRNAs (i.e. miR-let-7d, miR-24, miR-30c, miR-125a-3p, miR-149, miR-191, miR-196-b, miR-218, miR-342-3p, miR-452 and miR-454*) were 2- to 2.5-fold more expressed in HIV+ samples than in controls." +tissue_expression_up hsa-mir-125a HIV-Associated Lipodystrophy 25063777 "Eleven other miRNAs (i.e. miR-let-7d, miR-24, miR-30c, miR-125a-3p, miR-149, miR-191, miR-196-b, miR-218, miR-342-3p, miR-452 and miR-454*) were 2- to 2.5-fold more expressed in HIV+ samples than in controls." +tissue_expression_up hsa-mir-149 HIV-Associated Lipodystrophy 25063777 "Eleven other miRNAs (i.e. miR-let-7d, miR-24, miR-30c, miR-125a-3p, miR-149, miR-191, miR-196-b, miR-218, miR-342-3p, miR-452 and miR-454*) were 2- to 2.5-fold more expressed in HIV+ samples than in controls." +tissue_expression_up hsa-mir-186 HIV-Associated Lipodystrophy 25063777 "Ten of these (i.e. miR-186, miR-199a-3p, miR-214, miR-374a, miR-487b, miR-532-5p, miR-628-5p, miR-874, miR-125-b-1* and miR-374b*) were up-regulated to a significant degree" +tissue_expression_up hsa-mir-191 HIV-Associated Lipodystrophy 25063777 "Eleven other miRNAs (i.e. miR-let-7d, miR-24, miR-30c, miR-125a-3p, miR-149, miR-191, miR-196-b, miR-218, miR-342-3p, miR-452 and miR-454*) were 2- to 2.5-fold more expressed in HIV+ samples than in controls." +tissue_expression_up hsa-mir-196b HIV-Associated Lipodystrophy 25063777 "Eleven other miRNAs (i.e. miR-let-7d, miR-24, miR-30c, miR-125a-3p, miR-149, miR-191, miR-196-b, miR-218, miR-342-3p, miR-452 and miR-454*) were 2- to 2.5-fold more expressed in HIV+ samples than in controls." +tissue_expression_up hsa-mir-199a HIV-Associated Lipodystrophy 25063777 "Ten of these (i.e. miR-186, miR-199a-3p, miR-214, miR-374a, miR-487b, miR-532-5p, miR-628-5p, miR-874, miR-125-b-1* and miR-374b*) were up-regulated to a significant degree" +tissue_expression_up hsa-mir-214 HIV-Associated Lipodystrophy 25063777 "Ten of these (i.e. miR-186, miR-199a-3p, miR-214, miR-374a, miR-487b, miR-532-5p, miR-628-5p, miR-874, miR-125-b-1* and miR-374b*) were up-regulated to a significant degree" +tissue_expression_up hsa-mir-218 HIV-Associated Lipodystrophy 25063777 "Eleven other miRNAs (i.e. miR-let-7d, miR-24, miR-30c, miR-125a-3p, miR-149, miR-191, miR-196-b, miR-218, miR-342-3p, miR-452 and miR-454*) were 2- to 2.5-fold more expressed in HIV+ samples than in controls." +tissue_expression_up hsa-mir-24 HIV-Associated Lipodystrophy 25063777 "Eleven other miRNAs (i.e. miR-let-7d, miR-24, miR-30c, miR-125a-3p, miR-149, miR-191, miR-196-b, miR-218, miR-342-3p, miR-452 and miR-454*) were 2- to 2.5-fold more expressed in HIV+ samples than in controls." +tissue_expression_up hsa-mir-30c HIV-Associated Lipodystrophy 25063777 "Eleven other miRNAs (i.e. miR-let-7d, miR-24, miR-30c, miR-125a-3p, miR-149, miR-191, miR-196-b, miR-218, miR-342-3p, miR-452 and miR-454*) were 2- to 2.5-fold more expressed in HIV+ samples than in controls." +tissue_expression_up hsa-mir-342 HIV-Associated Lipodystrophy 25063777 "Eleven other miRNAs (i.e. miR-let-7d, miR-24, miR-30c, miR-125a-3p, miR-149, miR-191, miR-196-b, miR-218, miR-342-3p, miR-452 and miR-454*) were 2- to 2.5-fold more expressed in HIV+ samples than in controls." +tissue_expression_up hsa-mir-374a HIV-Associated Lipodystrophy 25063777 "Ten of these (i.e. miR-186, miR-199a-3p, miR-214, miR-374a, miR-487b, miR-532-5p, miR-628-5p, miR-874, miR-125-b-1* and miR-374b*) were up-regulated to a significant degree" +tissue_expression_up hsa-mir-374b HIV-Associated Lipodystrophy 25063777 "Ten of these (i.e. miR-186, miR-199a-3p, miR-214, miR-374a, miR-487b, miR-532-5p, miR-628-5p, miR-874, miR-125-b-1* and miR-374b*) were up-regulated to a significant degree" +tissue_expression_up hsa-mir-452 HIV-Associated Lipodystrophy 25063777 "Eleven other miRNAs (i.e. miR-let-7d, miR-24, miR-30c, miR-125a-3p, miR-149, miR-191, miR-196-b, miR-218, miR-342-3p, miR-452 and miR-454*) were 2- to 2.5-fold more expressed in HIV+ samples than in controls." +tissue_expression_up hsa-mir-454 HIV-Associated Lipodystrophy 25063777 "Eleven other miRNAs (i.e. miR-let-7d, miR-24, miR-30c, miR-125a-3p, miR-149, miR-191, miR-196-b, miR-218, miR-342-3p, miR-452 and miR-454*) were 2- to 2.5-fold more expressed in HIV+ samples than in controls." +tissue_expression_up hsa-mir-487b HIV-Associated Lipodystrophy 25063777 "Ten of these (i.e. miR-186, miR-199a-3p, miR-214, miR-374a, miR-487b, miR-532-5p, miR-628-5p, miR-874, miR-125-b-1* and miR-374b*) were up-regulated to a significant degree" +tissue_expression_up hsa-mir-532 HIV-Associated Lipodystrophy 25063777 "Ten of these (i.e. miR-186, miR-199a-3p, miR-214, miR-374a, miR-487b, miR-532-5p, miR-628-5p, miR-874, miR-125-b-1* and miR-374b*) were up-regulated to a significant degree" +tissue_expression_up hsa-mir-628 HIV-Associated Lipodystrophy 25063777 "Ten of these (i.e. miR-186, miR-199a-3p, miR-214, miR-374a, miR-487b, miR-532-5p, miR-628-5p, miR-874, miR-125-b-1* and miR-374b*) were up-regulated to a significant degree" +tissue_expression_up hsa-mir-874 HIV-Associated Lipodystrophy 25063777 "Ten of these (i.e. miR-186, miR-199a-3p, miR-214, miR-374a, miR-487b, miR-532-5p, miR-628-5p, miR-874, miR-125-b-1* and miR-374b*) were up-regulated to a significant degree" +tissue_expression_up hsa-mir-92a Myocardial Infarction 25064220 miR-92a expression in ischemia-reperfusion group was significantly higher than in sham operation group +tissue_expression_up hsa-mir-222 Bladder Neoplasms 25078265 Increased expression of miR-222 is associated with poor prognosis in bladder cancer. +tissue_expression_up hsa-mir-190 Epstein-Barr Virus Infection 25086243 mir-190 is upregulated in Epstein-Barr Virus type I latency and modulates cellular mRNAs involved in cell survival and viral reactivation. +tissue_expression_up hsa-mir-145 Malignant Neoplasms [unspecific] 25106061 "Our findings indicate that high miR-145 expression is better at predicting patient survival rather than disease progression for malignant tumors, especially for SCC and glioblastoma in Asians. Considering the insufficient evidence, further investigations and more studies are needed." +tissue_expression_up hsa-mir-19a Bladder Neoplasms 25107371 Our data indicated that miR-19a might act as an oncogenic microRNA in bladder cancer and was significantly up-regulated in bladder cancer carcinogenesis. The oncogenic role of miR19a in bladder cancer was dependent on targeting PTEN. +tissue_expression_up hsa-mir-106a Gastric Neoplasms 25115709 Similarly up-regulated microRNA-106a in matched formalin-fixed paraffin-embedded and fresh frozen samples and the dynamic changes during gastric carcinogenesis and development. +tissue_expression_up hsa-mir-24 Breast Neoplasms 25120807 Over-expression of miR-24 and miR-378 in FFPE tissue of breast cancer patients might conduct as an ideal source for biomarker discovery and validation in breast cancer patients. +tissue_expression_up hsa-mir-378a Breast Neoplasms 25120807 Over-expression of miR-24 and miR-378 in FFPE tissue of breast cancer patients might conduct as an ideal source for biomarker discovery and validation in breast cancer patients. +tissue_expression_up hsa-mir-31 "Carcinoma, Gingival" 25126847 "Expression of hsa-miR-31 was significantly up-regulated in both cancer and leukoplakia tissues and, thus, may be one of the molecular markers of leukoplakia which may progress to gingivo-buccal cancer." +tissue_expression_up hsa-mir-582 Prostate Neoplasms 25176332 Our results suggest that up-regulation of miR-582-5p contributes to an increase in the proliferation of prostate cancer cells under androgen deprived conditions. +tissue_expression_up hsa-mir-146a Diabetic Nephropathy 25182190 "Taken together, these findings indicate that the increased expression of miR-155 and miR-146a in the DN patients and in the experimental DN animal models was found to contribute to inflammation-mediated glomerular endothelial injury." +tissue_expression_up hsa-mir-155 Diabetic Nephropathy 25182190 "Taken together, these findings indicate that the increased expression of miR-155 and miR-146a in the DN patients and in the experimental DN animal models was found to contribute to inflammation-mediated glomerular endothelial injury." +tissue_expression_up hsa-mir-140 Spinal Chordoma 25197358 "Over-expression of miR-140-3p is correlated with recurrence and tumor invasion, suggesting that miR-140-3p could be a new predictor for recurrence and prognosis in patients with spinal chordoma." +tissue_expression_up hsa-mir-185 "Carcinoma, Renal Cell" 25217984 Elevated microRNA-185 is associated with high vascular endothelial growth factor receptor 2 expression levels and high microvessel density in clear cell renal cell carcinoma. +tissue_expression_up hsa-mir-129 Colorectal Carcinoma 25218158 Piceatannol promotes apoptosis via up-regulation of microRNA-129 expression in colorectal cancer cell lines. +tissue_expression_up hsa-mir-132 Glioma 25234714 Upregulation of miR-132 expression in glioma and its clinical significance. +tissue_expression_up hsa-mir-7 Pancreatic Neoplasms 25256401 Curcumin inhibits cell growth and invasion through up-regulation of miR-7 in pancreatic cancer cells. +tissue_expression_up hsa-mir-155 Rectal Neoplasms 25261908 Increase in the expression of miR-155 might represent a potential valuable marker for rectal carcinoma N and combined tumor-node-metastasis staging. +tissue_expression_up hsa-mir-10a Breast Neoplasms 25266482 These findings indicate that higher expression of RUNX2 and miR-10a/b was associated with adverse outcome of breast cancer. Expression levels of RUNX2 and miR-10a/b individually or jointly are potential prognostic factors for predicting breast cancer recurrence. Data from in vitro studies support the notion that RUNX2 promoted cell motility by upregulating miR-10a/b. +tissue_expression_up hsa-mir-10b Breast Neoplasms 25266482 These findings indicate that higher expression of RUNX2 and miR-10a/b was associated with adverse outcome of breast cancer. Expression levels of RUNX2 and miR-10a/b individually or jointly are potential prognostic factors for predicting breast cancer recurrence. Data from in vitro studies support the notion that RUNX2 promoted cell motility by upregulating miR-10a/b. +tissue_expression_up hsa-mir-184 Glioma 25277131 miR-184 upregulation enhanced the malignant phenotype of human glioma cancer cells by reducing FIH-1 protein expression. +tissue_expression_up hsa-mir-141 Bladder Neoplasms 25304156 Increased miR-141 expression is associated with diagnosis and favorable prognosis of patients with bladder cancer. +tissue_expression_up hsa-mir-214 Pancreatic Neoplasms 25304377 "Thirteen miRNAs (miR-138, miR-195, miR-204, miR-216a, miR-217, miR-218, miR-802, miR-155, miR-214, miR-26a, miR-30b, miR-31, and miR-125) were enriched and two miRNAs (miR-451a and miR-4284) were depleted in the cyst fluids derived from invasive carcinomas." +tissue_expression_up hsa-mir-218 Pancreatic Neoplasms 25304377 "Thirteen miRNAs (miR-138, miR-195, miR-204, miR-216a, miR-217, miR-218, miR-802, miR-155, miR-214, miR-26a, miR-30b, miR-31, and miR-125) were enriched and two miRNAs (miR-451a and miR-4284) were depleted in the cyst fluids derived from invasive carcinomas." +tissue_expression_up hsa-mir-30b Pancreatic Neoplasms 25304377 "Thirteen miRNAs (miR-138, miR-195, miR-204, miR-216a, miR-217, miR-218, miR-802, miR-155, miR-214, miR-26a, miR-30b, miR-31, and miR-125) were enriched and two miRNAs (miR-451a and miR-4284) were depleted in the cyst fluids derived from invasive carcinomas." +tissue_expression_up hsa-mir-301a Breast Neoplasms 25311065 Upregulation of miR-301a correlates with poor prognosis in triple-negative breast cancer. +tissue_expression_up hsa-mir-137 Bladder Neoplasms 25330156 MicroRNA-137 upregulation increases bladder cancer cell proliferation and invasion by targeting PAQR3. +tissue_expression_up hsa-mir-21 Breast Neoplasms 25337203 Prognostic and clinicopathological significance of microRNA-21 overexpression in breast cancer: a meta-analysis. +tissue_expression_up hsa-mir-195 Cardiovascular Diseases [unspecific] 25339460 "The cardiac dysfunction of the rat with selenium deficiency was mainly associated with five upregulated miRNAs, which were miR-374, miR-16, miR-199a-5p, miR-195 and miR-30e*, and three downregulated miRNAs, which were miR-3571, miR-675 and miR-450a*." +tissue_expression_up hsa-mir-30d Diabetic Cardiomyopathies 25341033 Our study revealed that mir-30d expression was substantially increased in streptozotocin (STZ)-induced diabetic rats and in high-glucose-treated cardiomyocytes as well. +tissue_expression_up hsa-mir-128a "Carcinoma, Hepatocellular" 25345933 miR-128a is up-regulated in HCC and promotes HCC cell proliferation by targeting RND3. +tissue_expression_up hsa-mir-31 Pleural Mesothelioma 25358615 Upregulation of microRNA-31 associates with a poor prognosis of malignant pleural mesothelioma with sarcomatoid component. +tissue_expression_up hsa-mir-200a Ovarian Neoplasms 25374174 miR-200a overexpression in advanced ovarian carcinomas as a prognostic indicator. +tissue_expression_up hsa-mir-196a Gastric Neoplasms 25374225 Association of miR-193b down-regulation and miR-196a up-regulation with clinicopathological features andprognosis in gastric cancer. +tissue_expression_up hsa-mir-210 "Carcinoma, Lung, Non-Small-Cell" 25384507 "At the same time, miR-21 and miR-210 were upregulated by 53.3 and 66.6% in cancer tissue versus matched adjacent normal tissues, respectively." +tissue_expression_up hsa-mir-141 Endometriosis 25386850 "We found five miRNAs specific to epithelial cells--miR-34c, miR-449a, miR-200a, miR-200b and miR-141 showing significantly higher expression in peritoneal endometriotic lesions compared to healthy peritoneal tissues." +tissue_expression_up hsa-mir-200b Endometriosis 25386850 "We found five miRNAs specific to epithelial cells--miR-34c, miR-449a, miR-200a, miR-200b and miR-141 showing significantly higher expression in peritoneal endometriotic lesions compared to healthy peritoneal tissues." +tissue_expression_up hsa-mir-143 Endometriosis 25408705 miR-143 was up-regulated in EC (p=0.000) compared to EN. +tissue_expression_up hsa-mir-145 Endometriosis 25408705 The miR-145 was up-regulated in both EU (p=0.004) and EC (p=0.000) in compared to EN group. +tissue_expression_up hsa-mir-194 Gastric Neoplasms 25412959 "miR-194 overexpression or RBX1 lowexpression was associated with prolonged survival of GC patients. In conclusion, upregulation of miR-194 can inhibit proliferation, migration, and invasion of GC cells, possibly by targeting RBX1. Aberrant expression of miR-194 and RBX1 is correlated to GC patient survival time." +tissue_expression_up hsa-mir-18a Gastric Neoplasms 25416437 "miR-18a may be a promising biomarker for the detection of gastric cancer and its upregulation may be potentially associated with unfavorable prognosis of bladder cancer, suggesting that miR-18a might serve as a potential biological marker for further risk stratification in the management of gastric cancer." +tissue_expression_up hsa-mir-224 Colorectal Adenocarcinoma 25420464 "miR-224 is significantly upregulated in malignant colorectal tumors compared to adjacent non-cancer mucosae, and its enhanced expression constitutes an independent predictor of short-term relapse and poor overall survival in colorectal adenocarcinoma patients." +tissue_expression_up hsa-mir-221 Glioma 25428536 "There are a series of abnormal miRNA expressions in glioma. Among them, miR-221 and miR -222 are clustered miR s with elevated expressions. The over-expressions of miR-221 and miR-222 can be considered as new molecular tags for human glioma (Tab. 5, Fig. 4, Ref. 30)." +tissue_expression_up hsa-mir-222 Glioma 25428536 "There are a series of abnormal miRNA expressions in glioma. Among them, miR-221 and miR -222 are clustered miR s with elevated expressions. The over-expressions of miR-221 and miR-222 can be considered as new molecular tags for human glioma (Tab. 5, Fig. 4, Ref. 30)." +tissue_expression_up hsa-mir-21 Breast Neoplasms 25440114 "the context of altered miR-21 expression provides clinically relevant information. Importantly, miR-21 expression was predominantly up-regulated and potentially prognostic in the tumor stroma of TNBC." +tissue_expression_up hsa-mir-145 Aortic Aneurysm 25465469 The increased expression of microRNA-145 promotes media remodeling through TGF-b1 in the aortic aneurysm wall. +tissue_expression_up hsa-mir-106b "Carcinoma, Hepatocellular" 25466449 miR-106b expression was significantly upregulated in HCC and could serve as a potential unfavorable prognostic biomarker. +tissue_expression_up hsa-mir-21 "Squamous Cell Carcinoma, Oral" 25482863 "Our results corroborate the previous findings on the overexpression of mir-21 and downregulation of miR-138 in OSCC. As the expression of miR-184 is controversial in tongue/oral cancer, the downregulation may be specific to tumor anatomical localization. On the other hand, to the best of our knowledge, this is the first report to show the association of miR-155 with tobacco chewing and the downregulation of miR-125b-2* in OSCC. Computational predictions suggest that miR-125b-2* may have a role in alternative splicing." +tissue_expression_up hsa-mir-146a Diabetes Mellitus 25490205 abnormal miR-146a upregulation may be an important mechanism of delayed wound healing in the diabetic cornea. +tissue_expression_up hsa-mir-125b Glioma 25502291 "Higher expressions of miR-125b and miR-222 have also been proved to be associated with glioma. Furthermore, glioma patients with higher miR-125b, miR-221, and miR-222 expression were manifested to have poorer prognostic status, which might be attributed to their attenuated sensitivity to chemotherapy and radiotherapy." +tissue_expression_up hsa-mir-221 Glioma 25502291 "Higher expressions of miR-125b and miR-222 have also been proved to be associated with glioma. Furthermore, glioma patients with higher miR-125b, miR-221, and miR-222 expression were manifested to have poorer prognostic status, which might be attributed to their attenuated sensitivity to chemotherapy and radiotherapy." +tissue_expression_up hsa-mir-222 Glioma 25502291 "Higher expressions of miR-125b and miR-222 have also been proved to be associated with glioma. Furthermore, glioma patients with higher miR-125b, miR-221, and miR-222 expression were manifested to have poorer prognostic status, which might be attributed to their attenuated sensitivity to chemotherapy and radiotherapy." +tissue_expression_up hsa-mir-10b Neoplasms [unspecific] 25510966 high-expression of microRNA-10b can predict worse outcomes in some types of cancer and the regular monitoring of miR-10b expression might be useful in the clinical practice. +tissue_expression_up hsa-mir-374b Gastric Neoplasms 25516656 upregulation of miR-374b-5p contributes to gastric cancer cell metastasis and invasion through inhibition of RECK expression. +tissue_expression_up hsa-mir-146a "Carcinoma, Thyroid" 25524940 Up-regulation of miR-146a and miR-146b expression in tissues was related to carcinogenesis and deterioration of PTC. MicroRNA-146a and miR-146b expressed in thyroid tissue may act as potential biomarkers for PTC patients. +tissue_expression_up hsa-mir-146b "Carcinoma, Thyroid" 25524940 Up-regulation of miR-146a and miR-146b expression in tissues was related to carcinogenesis and deterioration of PTC. MicroRNA-146a and miR-146b expressed in thyroid tissue may act as potential biomarkers for PTC patients. +tissue_expression_up hsa-mir-143 Osteosarcoma 25562163 "TGF-¦Â1 up-regulates versican expression bysuppressing miR-143, and this pathway is important for osteosarcoma cell migration and invasion." +tissue_expression_up hsa-mir-21 "Carcinoma, Colon" 25569638 the primary tumor in colon cancer releases high concentrations of miR-21 in the MV but that these concentrations are later diluted in the circulatory system. MV expression of miR-21 may be a stronger prognostic marker than PV expression. +tissue_expression_up hsa-mir-210 Glioblastoma 25586423 Acute hypoxia induces upregulation of microRNA-210 expression in glioblastoma spheroids. +tissue_expression_up hsa-mir-142 Atherosclerosis 25586666 the upregulation of miR-142-5p expression may regulate apoptosis in human macrophages by targeting TGF-¦Â2. This effect may have an important role in the progression of atherosclerosis. +tissue_expression_up hsa-mir-196a Osteosarcoma 25599934 the effects of miR-196a over-expression on tumour cell response may be strictly related to species and cell type. Further studies are needed to define the impact of miRNA deregulation on OS development. +tissue_expression_up hsa-mir-155 Lung Neoplasms 25603615 The current paper on Meta-analysis demonstrated a correlation between the high expression of miRNA-155 and the outcome of patients with non-small cell lung cancer. +tissue_expression_up hsa-mir-125b Breast Neoplasms 25605244 up-regulation of miR-125b or targeting Sema4C could serve as novel approaches to reverse chemotherapy resistance in breast cancers. +tissue_expression_up hsa-mir-34a Osteonecrosis 25612520 The expression of miR-34a and miR-146a and genes in the predict pathways were significantly up-regulated. +tissue_expression_up hsa-mir-132 "Leukemia, Lymphocytic, Chronic, B-Cell" 25645730 Increased chronic lymphocytic leukemia proliferation upon IgM stimulation is sustained by the upregulation of miR-132 and miR-212. +tissue_expression_up hsa-mir-212 "Leukemia, Lymphocytic, Chronic, B-Cell" 25645730 Increased chronic lymphocytic leukemia proliferation upon IgM stimulation is sustained by the upregulation of miR-132 and miR-212. +tissue_expression_up hsa-mir-92a Colorectal Adenocarcinoma 25663865 A statistically significant difference was observed between the expression levels of miR-92a in CA and the paralesional normal controls. +tissue_expression_up hsa-mir-199 Irritable Bowel Syndrome 25681400 Decreased miR-199 augments visceral pain in patients with IBS through translational upregulation of TRPV1. +tissue_expression_up hsa-mir-21 Ischemia-Reperfusion Injury 25691473 miR-21 has been shown to be enriched in kidney tissue in mice and humans with acute kidney injury +tissue_expression_up hsa-mir-218 Gastric Neoplasms 25694126 Thermo-chemotherapy Induced miR-218 upregulation inhibits the invasion of gastric cancer via targeting Gli2 and E-cadherin. +tissue_expression_up hsa-mir-1280 "Carcinoma, Lung, Non-Small-Cell" 25698202 The miR-1280 expression was significantly higher in the NSCLC tissues than distal normal tissues +tissue_expression_up hsa-mir-141 Bladder Neoplasms 25703910 "There was a more expression rate of miR-200c, miR-141 and miR-30b in bladder cancer tissues than healthy adjacent control tissues. Further studies are needed to draw final conclusion." +tissue_expression_up hsa-mir-200c Bladder Neoplasms 25703910 "There was a more expression rate of miR-200c, miR-141 and miR-30b in bladder cancer tissues than healthy adjacent control tissues. Further studies are needed to draw final conclusion." +tissue_expression_up hsa-mir-30b Bladder Neoplasms 25703910 "There was a more expression rate of miR-200c, miR-141 and miR-30b in bladder cancer tissues than healthy adjacent control tissues. Further studies are needed to draw final conclusion." +tissue_expression_up hsa-mir-21 Multiple Myeloma 25704079 EBV could further exacerbate the disease by inducing miR-21 +tissue_expression_up hsa-mir-146b Atherosclerosis 25743474 Aa challenge significantly increased the expression of miR-146b and miR-155 in the aorta. +tissue_expression_up hsa-mir-181b Adenovirus Infection 25744056 The expression patterns of these miRNAs changed dramatically during the course of the infection +tissue_expression_up hsa-mir-191 Adenovirus Infection 25744056 The expression patterns of these miRNAs changed dramatically during the course of the infection +tissue_expression_up hsa-mir-21 "Adenocarcinoma, Esophageal" 25746664 "miRs such as miR-192, miR-196 and miR-21 were frequently noted to up-regulated whereas miR-203, miR-205 and miR-let-7 were commonly down-regulated during the development of Barrett's oesophagus to oesophageal adenocarcinoma." +tissue_expression_up hsa-mir-503 "Carcinoma, Esophageal" 25750296 High miR-503 expression was identified as an independent prognostic predictor in patients with EC according to multivariate analysis +tissue_expression_up hsa-mir-146b Gastroduodenal Ulcer 25753878 "This study indicated that the up-regulation of miR-155 and miR-146b decreases H. pylori (cagA+)-introduced IL6 overexpression, which might weaken the cleanup of H. pylori (cagA+) and contributes to ulcer." +tissue_expression_up hsa-mir-155 Gastroduodenal Ulcer 25753878 "This study indicated that the up-regulation of miR-155 and miR-146b decreases H. pylori (cagA+)-introduced IL6 overexpression, which might weaken the cleanup of H. pylori (cagA+) and contributes to ulcer." +tissue_expression_up hsa-mir-150 "Carcinoma, Lung, Non-Small-Cell" 25755784 Our data indicated that overexpression of miR-150 in NSCLC tissues has prognostic value. +tissue_expression_up hsa-mir-10b Glioma 25773393 Correlation of microRNA-10b upregulation and poor prognosis in human gliomas. +tissue_expression_up hsa-mir-1246 "Squamous Cell Carcinoma, Oral" 25791131 High miR-1246 expression is associated with poor prognosis in OSCC and may serve as a novel prognostic marker in OSCC. +tissue_expression_up hsa-mir-125b Mesial Temporal Lobe Epilepsy 25801837 "In TLE patients, miR-183, miR- 135a, miR-125b, miR-30c and miR-27a were upregulated, whereas miR-128 was downregulated." +tissue_expression_up hsa-mir-183 Mesial Temporal Lobe Epilepsy 25801837 "In TLE patients, miR-183, miR- 135a, miR-125b, miR-30c and miR-27a were upregulated, whereas miR-128 was downregulated." +tissue_expression_up hsa-mir-24 Hyperglycemia 25814526 Hyperglycemia repression of miR-24 coordinately upregulates endothelial cell expression and secretion of von Willebrand factor. +tissue_expression_up hsa-let-7g Follicular Atresia 25824548 let-7g was highly expressed during follicle atresia +tissue_expression_up hsa-mir-200c "Carcinoma, Renal Cell" 25860934 Loss of miR-200c up-regulates CYP1B1 and confers docetaxel resistance in renal cell carcinoma. +tissue_expression_up hsa-let-7a "Squamous Cell Carcinoma, Head and Neck" 25862914 The microRNA profile seems to play a potential role in the pathobiology of oropharyngeal and laryngeal HNSCC. Up-regulation of miR34a in p16-positive oropharyngeal cancer has not been so far described and additional studies are warranted. +tissue_expression_up hsa-mir-200c "Squamous Cell Carcinoma, Head and Neck" 25862914 The microRNA profile seems to play a potential role in the pathobiology of oropharyngeal and laryngeal HNSCC. Up-regulation of miR34a in p16-positive oropharyngeal cancer has not been so far described and additional studies are warranted. +tissue_expression_up hsa-mir-21 "Squamous Cell Carcinoma, Head and Neck" 25862914 The microRNA profile seems to play a potential role in the pathobiology of oropharyngeal and laryngeal HNSCC. Up-regulation of miR34a in p16-positive oropharyngeal cancer has not been so far described and additional studies are warranted. +tissue_expression_up hsa-mir-34a "Squamous Cell Carcinoma, Head and Neck" 25862914 The microRNA profile seems to play a potential role in the pathobiology of oropharyngeal and laryngeal HNSCC. Up-regulation of miR34a in p16-positive oropharyngeal cancer has not been so far described and additional studies are warranted. +tissue_expression_up hsa-mir-375 "Squamous Cell Carcinoma, Head and Neck" 25862914 The microRNA profile seems to play a potential role in the pathobiology of oropharyngeal and laryngeal HNSCC. Up-regulation of miR34a in p16-positive oropharyngeal cancer has not been so far described and additional studies are warranted. +tissue_expression_up hsa-mir-125a Autoimmune Thyroiditis 25863684 Decreased expression of microRNA-125a-3p upregulates interleukin-23 receptor in patients with Hashimoto's thyroiditis. +tissue_expression_up hsa-mir-155 Atherosclerosis 25872580 "our data demonstrate that miR-155 is significantly upregulated in atherosclerotic plaque, functioning to accelerate the proliferation and migration of VSMCs by targeting eNOS." +tissue_expression_up hsa-mir-375 Diabetes Mellitus 25875172 "These findings support an important role of miR-375 in regulation of human ¦Â-cell phenotype, and suggest that miR-375 upregulation may facilitate the generation of functional insulin-producing cells following ex-vivo expansion of human islet cells." +tissue_expression_up hsa-mir-155 Waldenstrom Macroglobulinemia 25893290 "In two cell lines, miR-155 upregulation, which is common in WM, was responsible for the inhibition of FOXO3a and Bim expression." +tissue_expression_up hsa-mir-20b "Carcinoma, Breast" 25893380 miR-20b is up-regulated in brain metastases from primary breast cancers. +tissue_expression_up hsa-mir-10b Endometriosis 25896413 miR-10b directly targets ZEB1 and PIK3CA to curb adenomyotic epithelial cell invasiveness via upregulation of E-Cadherin and inhibition of Akt phosphorylation. +tissue_expression_up hsa-mir-21 Myocardial Infarction 25896982 "Compared to sham group, we found a twofold increase in the cardiac expression of microRNA-21 and 0.5-fold decrease in microRNA-29b in heart tissue from vehicle-treated MI." +tissue_expression_up hsa-mir-9 Osteoarthritis 25917063 These findings implicate miR-9-mediated suppression of MCPIP-1 in the pathogenesis of OA via up-regulation of IL-6 expression in IL-1¦Â-stimulated human OA chondrocytes. +tissue_expression_up hsa-mir-122 Human Immunodeficiency Virus Infection 25920531 "our results revealed that the Vpr-upregulated expression of miR-122 is closely related to the stimulation of HCV 5' UTR activity and HCV replication by Vpr, providing new evidence for how HIV interacts with HCV during HIV/HCV co-infection." +tissue_expression_up hsa-mir-221 Inflammation 25926893 "Interestingly, miR-221 (2-fold, Pâ€?â€?.002), miR-222 (2.5-fold, Pâ€?â€?.04), and miR-155 (5-fold, Pâ€?â€?.015) were increased in inflamed adipocytes" +tissue_expression_up hsa-mir-222 Inflammation 25926893 "Interestingly, miR-221 (2-fold, Pâ€?â€?.002), miR-222 (2.5-fold, Pâ€?â€?.04), and miR-155 (5-fold, Pâ€?â€?.015) were increased in inflamed adipocytes" +tissue_expression_up hsa-mir-15a Cataract 25932180 "hsa-miR-15a-5p, hsa-miR-15a-3p, and hsa-miR-16-1-5p were expressed at low levels in normal lens epithelial cells but at significantly higher levels in corresponding cells of patients" +tissue_expression_up hsa-mir-221 Colon Neoplasms 25932237 "high expression of miR-211 (HR=2.394, 95% CI: 1.210-4.910, P=0.006) were identified as risk factors for colon cancer prognosis" +tissue_expression_up hsa-mir-155 Prostate Neoplasms 25938433 "hsa-miR-155, hsa-miR-141 and hsa-miR-21 gene expressions were significantly elevated (66-85%, P<0.05) in tumor specimens" +tissue_expression_up hsa-mir-328 "Leukemia, Myeloid, Chronic" 25948184 "miR-328 has been successfully constructed and transfected into K562 cells, miR-328 inhibits the proliferation of K562 cells by up-regulation of C/EBP¦Á." +tissue_expression_up hsa-mir-21 "Adenocarcinoma, Esophageal" 25950983 microRNA-21 expression is elevated in esophageal adenocarcinoma after neoadjuvant chemotherapy. +tissue_expression_up hsa-mir-182 Prostate Neoplasms 25977730 MicroRNA expression profiling in primary PCa and morphological normal prostate (MNPT) tissues identified 17 miRNAs significantly overexpressed in PCa. +tissue_expression_up hsa-mir-15a Asthma 25979194 miRNA regulation network demonstrated that miR-16 and miR-15a had higher degree. +tissue_expression_up hsa-mir-16 Asthma 25979194 miRNA regulation network demonstrated that miR-16 and miR-15a had higher degree. +tissue_expression_up hsa-mir-34a Melanoma 25982144 Real-time PCR analysis showed 14-fold increase of miR-34a expression in the SDT group compared to the control group +tissue_expression_up hsa-mir-141 Colorectal Carcinoma 25989926 "A set of three specific fecal miRNAs is overexpressed before surgery, and return within the normal range after cancer removal could be considered as an appealing opportunity for a new reliable tool for CRC secondary prevention. However, their role needs to be explored in large prospective trials and compared with the existing screening tools." +tissue_expression_up hsa-mir-16 Colorectal Carcinoma 25989926 "A set of three specific fecal miRNAs is overexpressed before surgery, and return within the normal range after cancer removal could be considered as an appealing opportunity for a new reliable tool for CRC secondary prevention. However, their role needs to be explored in large prospective trials and compared with the existing screening tools." +tissue_expression_up hsa-mir-19b Colorectal Carcinoma 25989926 "A set of three specific fecal miRNAs is overexpressed before surgery, and return within the normal range after cancer removal could be considered as an appealing opportunity for a new reliable tool for CRC secondary prevention. However, their role needs to be explored in large prospective trials and compared with the existing screening tools." +tissue_expression_up hsa-mir-20a Colorectal Carcinoma 25989926 "A set of three specific fecal miRNAs is overexpressed before surgery, and return within the normal range after cancer removal could be considered as an appealing opportunity for a new reliable tool for CRC secondary prevention. However, their role needs to be explored in large prospective trials and compared with the existing screening tools." +tissue_expression_up hsa-mir-21 Colorectal Carcinoma 25989926 "A set of three specific fecal miRNAs is overexpressed before surgery, and return within the normal range after cancer removal could be considered as an appealing opportunity for a new reliable tool for CRC secondary prevention. However, their role needs to be explored in large prospective trials and compared with the existing screening tools." +tissue_expression_up hsa-mir-92a Colorectal Carcinoma 25989926 "A set of three specific fecal miRNAs is overexpressed before surgery, and return within the normal range after cancer removal could be considered as an appealing opportunity for a new reliable tool for CRC secondary prevention. However, their role needs to be explored in large prospective trials and compared with the existing screening tools." +tissue_expression_up hsa-mir-141 Bladder Neoplasms 25991007 The present meta-analysis identified eight highly significant and consistently dysregulated miRNAs from 19 datasets. We also constructed an eight-miRNA signature which provided predictive and prognostic value that complements traditional clinicopathological risk factors. +tissue_expression_up hsa-mir-200c Bladder Neoplasms 25991007 The present meta-analysis identified eight highly significant and consistently dysregulated miRNAs from 19 datasets. We also constructed an eight-miRNA signature which provided predictive and prognostic value that complements traditional clinicopathological risk factors. +tissue_expression_up hsa-mir-21 Bladder Neoplasms 25991007 The present meta-analysis identified eight highly significant and consistently dysregulated miRNAs from 19 datasets. We also constructed an eight-miRNA signature which provided predictive and prognostic value that complements traditional clinicopathological risk factors. +tissue_expression_up hsa-mir-146a "Carcinoma, Thyroid, Papillary" 26003825 "Our results demonstrate that down-regulation of THR¦Â is a common feature of PTCs. While it is not associated with a more aggressive phenotype of PTC, it correlates with the reduction of all the markers of differentiation and is associated with overexpression of some miRNAs supposed to play a role in thyroid tumorigenesis." +tissue_expression_up hsa-mir-21 "Carcinoma, Thyroid, Papillary" 26003825 "Our results demonstrate that down-regulation of THR¦Â is a common feature of PTCs. While it is not associated with a more aggressive phenotype of PTC, it correlates with the reduction of all the markers of differentiation and is associated with overexpression of some miRNAs supposed to play a role in thyroid tumorigenesis." +tissue_expression_up hsa-mir-221 "Carcinoma, Thyroid, Papillary" 26003825 "Our results demonstrate that down-regulation of THR¦Â is a common feature of PTCs. While it is not associated with a more aggressive phenotype of PTC, it correlates with the reduction of all the markers of differentiation and is associated with overexpression of some miRNAs supposed to play a role in thyroid tumorigenesis." +tissue_expression_up hsa-mir-21 Neoplasms [unspecific] 26032086 "miR-21, miR-148a, miR-505, and miR-1207-5p were found to be upregulated in growth factors-induced EMT process" +tissue_expression_up hsa-mir-132 "Leukemia, Lymphocytic, Chronic, B-Cell" 26036258 The SIRT1/TP53 axis is activated upon B-cell receptor triggering via miR-132 up-regulation in chronic lymphocytic leukemia cells. +tissue_expression_up hsa-mir-32 Lung Neoplasms 26036635 Tanshinones suppress AURKA through up-regulation of miR-32 expression in non-small cell lung cancer. +tissue_expression_up hsa-mir-141 "Carcinoma, Endometrial" 26045795 miR-200a/miR-141 and miR-205 upregulation might be associated with hormone receptor status and prognosis in endometrial carcinomas. +tissue_expression_up hsa-mir-200a "Carcinoma, Endometrial" 26045795 miR-200a/miR-141 and miR-205 upregulation might be associated with hormone receptor status and prognosis in endometrial carcinomas. +tissue_expression_up hsa-mir-205 "Carcinoma, Endometrial" 26045795 miR-200a/miR-141 and miR-205 upregulation might be associated with hormone receptor status and prognosis in endometrial carcinomas. +tissue_expression_up hsa-mir-1 Acute Myocardial Infarction 26046358 "This study highlights the stability of miRNAs after death and long-term fixation, validating their use as reliable biomarkers for AMI during postmortem examination." +tissue_expression_up hsa-mir-208b Acute Myocardial Infarction 26046358 "This study highlights the stability of miRNAs after death and long-term fixation, validating their use as reliable biomarkers for AMI during postmortem examination." +tissue_expression_up hsa-mir-196a Breast Neoplasms 26062455 MicroRNA-196a post-transcriptionally upregulates the UBE2C proto-oncogene and promotes cell proliferation in breast cancer. +tissue_expression_up hsa-mir-182 Neoplasms [unspecific] 26063957 "High miR-182 expression is associated with poor OS and DFS/RFS/RFI in some types of cancers, and miR-182 may be a useful prognostic biomarker for predicting cancer prognosis. However, given the current insufficient relevant data, further clinical studies are needed." +tissue_expression_up hsa-mir-197 Glioblastoma 26081814 FUS1 acts as a tumor-suppressor gene by upregulating miR-197 in human glioblastoma. +tissue_expression_up hsa-mir-21 Myocardial Ischemic-Reperfusion Injury 26097555 "this study revealed the mechanism that TMZ up-regulated miR-21 expression, then miR-21 targeted PTEN increasing the PI3K pathway and finally the activation of this pathway counteracted the apoptotic effect of hypoxia/reperfusion." +tissue_expression_up hsa-mir-124 "Carcinoma, Gastric" 26109806 Paeoniflorin inhibits human gastric carcinoma cell proliferation through up-regulation of microRNA-124 and suppression of PI3K/Akt and STAT3 signaling. +tissue_expression_up hsa-mir-146b Myeloproliferative Neoplasms 26116595 Up-regulation of MicroRNA 146b is Associated with Myelofibrosis in Myeloproliferative Neoplasms. +tissue_expression_up hsa-mir-218 Glioma 26133092 Propofol suppresses proliferation and invasion of glioma cells by upregulating microRNA-218 expression. +tissue_expression_up hsa-mir-190b Breast Neoplasms 26141719 "This study reveals miR-190b as the highest up-regulated miRNA in hormone-dependent breast cancers. Due to its specificity and high expression level, miR-190b could therefore represent a new biomarker in hormone-dependent breast cancers but its exact role carcinogenesis remains to elucidate." +tissue_expression_up hsa-mir-211 Colorectal Carcinoma 26152286 MicroRNA 211 expression is upregulated and associated with poor prognosis in colorectal cancer: a case-control study. +tissue_expression_up hsa-mir-372 "Carcinoma, Oral" 26152520 Upregulation of miR-372 and -373 associates with lymph node metastasis and poor prognosis of oral carcinomas. +tissue_expression_up hsa-mir-373 "Carcinoma, Oral" 26152520 Upregulation of miR-372 and -373 associates with lymph node metastasis and poor prognosis of oral carcinomas. +tissue_expression_up hsa-mir-126 Heart Failure 26162916 "RV failure in PAH is associated with a specific molecular signature within the RV, contributing to a decrease in RV vascular density and promoting the progression to RV failure. More importantly, miR-126 upregulation in the RV improves microvessel density and RV function in experimental PAH." +tissue_expression_up hsa-mir-183 "Adenocarcinoma, Lung" 26170125 down-regulation of miR-34c and up-regulation of miR-183 and miR-210 were identified in caner groups +tissue_expression_up hsa-mir-210 "Adenocarcinoma, Lung" 26170125 down-regulation of miR-34c and up-regulation of miR-183 and miR-210 were identified in caner groups +tissue_expression_up hsa-mir-34 Neoplasms [unspecific] 26177460 miR-34a overexpression leads to variable effects on p53 levels in p53-sufficient human cancer cell lines. +tissue_expression_up hsa-mir-34a Neoplasms [unspecific] 26177460 miR-34a overexpression leads to variable effects on p53 levels in p53-sufficient human cancer cell lines. +tissue_expression_up hsa-mir-21 Ischemia-Reperfusion Injury 26178499 Renal expressions of miR-21 and miR-106a were significantly elevated in ischemia 20 min and 30 min groups at 12 h and 24 h post-reperfusion +tissue_expression_up hsa-mir-21 Coronary Artery Disease 26183619 miR-21 expression was increased in human tissue samples from patients with ISR compared with coronary artery disease specimen +tissue_expression_up hsa-mir-15b Glioma 26191187 Up-regulation of microRNA-15b correlates with unfavorable prognosis and malignant progression of human glioma. +tissue_expression_up hsa-mir-184 Lung Neoplasms 26199015 miRNA-197 and miRNA-184 are overexpressed in EGFR-mutant patients with BM and they might be a new biomarker for stratifying the risk of BM in this subpopulation. +tissue_expression_up hsa-mir-1298 Vascular Disease [unspecific] 26199195 Keep calm and carry on: miR-1298 prevents up-regulation of Cx43 and secures a quiescent vascular smooth muscle cell. +tissue_expression_up hsa-mir-184 Sebaceous Carcinoma 26203913 "Serial testing and validation confirmed overexpression of 2 miRNAs previously reported to be oncogenic, miR-486-5p (4.4-fold; Pâ€?â€?.4 ×â€?0-8) and miR-184 (3.5-fold; Pâ€?â€?.7 ×â€?0-6)" +tissue_expression_up hsa-mir-21 Gastric Neoplasms 26209976 "It seems that miR-21 and miR-221 expression pattern in Iranian patients with gastric cancer are similar to any other population. Considering the increased expression level of two miRNAs in cancerous tissue compared to normal tissue as well as the area under ROC curve, miR-21 and miR-221 can be used for early detection of gastric cancer." +tissue_expression_up hsa-mir-221 Gastric Neoplasms 26209976 "It seems that miR-21 and miR-221 expression pattern in Iranian patients with gastric cancer are similar to any other population. Considering the increased expression level of two miRNAs in cancerous tissue compared to normal tissue as well as the area under ROC curve, miR-21 and miR-221 can be used for early detection of gastric cancer." +tissue_expression_up hsa-mir-206 Preeclampsia 26213997 Our pilot study has identified miRNA-206 as a novel factor upregulated in preeclampsia within the maternal circulation and in placental tissue. +tissue_expression_up hsa-mir-133a Pancreatic Neoplasms 26214431 Propofol suppresses proliferation and invasion of pancreatic cancer cells by upregulating microRNA-133a expression. +tissue_expression_up hsa-mir-17 "Leukemia-Lymphoma, Adult T-Cell" 26231295 Upregulation of miRNA-17 and miRNA-19 is associated with unfavorable prognosis in patients with T-cell lymphoblastic lymphoma. +tissue_expression_up hsa-mir-19 "Leukemia-Lymphoma, Adult T-Cell" 26231295 Upregulation of miRNA-17 and miRNA-19 is associated with unfavorable prognosis in patients with T-cell lymphoblastic lymphoma. +tissue_expression_up hsa-mir-210 Neoplasms [unspecific] 26239498 MicroRNA-210 is upregulated by hypoxia-inducible factor-1¦Á in the stromal cells of giant cell tumors of bone. +tissue_expression_up hsa-mir-130b Glioblastoma 26241672 Upregulation of miR-130b enhances stem cell-like phenotype in glioblastoma by inactivating the Hippo signaling pathway. +tissue_expression_up hsa-mir-21 Myocardial Infarction 26253453 "Compared with the CON group, miR-1 was downregulated, whereas miR-21 was upregulated, and BCL2 messenger RNA (mRNA) was upregulated, whereas BAX mRNA and programmed cell death 4 mRNA remained unchanged in the IPO group." +tissue_expression_up hsa-let-7b Obesity 26258540 "Specifically, miR-28, miR-26, and let-7b previously shown to inhibit sex steroid production in human granulosa cells, were up-regulated." +tissue_expression_up hsa-mir-221 "Carcinoma, Hepatocellular" 26258795 MiR-221 and miR-222 (miR-221/222) are well-studied oncogenic microRNAs that are frequently upregulated in several types of human tumors +tissue_expression_up hsa-mir-221 Choriocarcinoma 26258795 MiR-221 and miR-222 (miR-221/222) are well-studied oncogenic microRNAs that are frequently upregulated in several types of human tumors +tissue_expression_up hsa-mir-196a Glioma 26261539 Our results suggested that both high-miR-196a and low-miR-367 expression may be associated with aggressive progression and unfavorable clinical outcome in glioma patients. And combination of high-miR-196a and low-miR-367 expression may be a novel biomarker in identifying a poor prognosis group of high-grade glioma. +tissue_expression_up hsa-mir-155 Colorectal Carcinoma 26261588 "miR-155-5p expression is up-regulated in most CRC and promotes proliferation, invasion and metastasis of CRC cells. It may play an essential role in tumorigenesis and tumor progression of CRC." +tissue_expression_up hsa-mir-21 "Carcinoma, Cervical" 26261606 "MiR-21 upregulation is associated with aggressive progression and poor prognosis in cervical cancer, which suggests that miR-21 might be identified as an independent marker for predicting the clinical outcome of cervical cancer patients." +tissue_expression_up hsa-mir-21 "Carcinoma, Hepatocellular" 26261620 Our results suggested that increased expression of miR-21 was significantly correlated with tumor progression and could be a novel potential biomarker for HCC prognosis. +tissue_expression_up hsa-mir-122 Hepatitis C Virus Infection 26272127 The levels of miR-122 were higher in liver than those in blood from individuals infected with HCV genotypes 1 and 3 +tissue_expression_up hsa-mir-125b "Fatty Liver, Non-Alcoholic" 26272872 Our findings identify a novel mechanism by which estrogen protects against hepatic steatosis in female mice via upregulating miR-125b expression. +tissue_expression_up hsa-mir-20a "Carcinoma, Adenoid Cystic" 26293217 Increased expression of miR-17 and miR-20a was found in bACCs compared with bNs +tissue_expression_up hsa-mir-146a Systemic Lupus Erythematosus 26315540 "Type I IFN inhibits the maturation of miR-146a through the up-regulation of MCPIP-1, and thus contributes to the uncontrolled inflammation and excessive inflammatory gene expression in SLE." +tissue_expression_up hsa-mir-146b Atrial Fibrillation 26319023 "Expression of inflammation-associated miRNAs is significantly up-regulated in the left atrial appendage of patients with non-valvular paroxysmal atrial fibrillation, which may play a significant role in electrical and structural remodeling." +tissue_expression_up hsa-mir-155 Atrial Fibrillation 26319023 "Expression of inflammation-associated miRNAs is significantly up-regulated in the left atrial appendage of patients with non-valvular paroxysmal atrial fibrillation, which may play a significant role in electrical and structural remodeling." +tissue_expression_up hsa-mir-19b Atrial Fibrillation 26319023 "Expression of inflammation-associated miRNAs is significantly up-regulated in the left atrial appendage of patients with non-valvular paroxysmal atrial fibrillation, which may play a significant role in electrical and structural remodeling." +tissue_expression_up hsa-mir-21 Spinal Cord Injuries 26323253 "miRâ€?46a, miRâ€?1 and miRâ€?50 expression was upregulated during H2O2 treatment." +tissue_expression_up hsa-mir-195 Prostate Neoplasms 26338045 "Collectively,this is the first report unveils that loss of miR-195 expression and thus uncontrolled BCOX1 upregulation might drive PCa metastasis." +tissue_expression_up hsa-mir-21 Cardiovascular Diseases [unspecific] 26342092 "MiR-146b-5p, -146a, -21, -150, -155, -299-5p are overexpressed in the presence of inflammation in TABs from patients with GCA." +tissue_expression_up hsa-mir-21 "Carcinoma, Breast" 26342497 Chromosome 17 aneusomy and miR-21 expression are positively correlated and can potentially serve as prognostic markers in BC. +tissue_expression_up hsa-mir-21 Glioblastoma 26344589 "The results indicate that compound 1j can enhance apoptosis, retard proliferation, and up-regulate PDCD4, a target protein of miR-21. In addition,the compound 1j does not influence the expression of multiple miRNAs and the genes that participate in miRNA universal biosynthesis pathway. These results strongly support the assumption that title compounds can serve as a small molecule inhibitor of miR-21." +tissue_expression_up hsa-mir-192 Lung Neoplasms 26351877 "Collectively, our findings suggested that curcumin inhibited cell proliferation and induced apoptosis of human non-small cell lung cancer cells through the upregulation of miR-192-5p and suppression of the PI3K/Akt signaling pathway." +tissue_expression_up hsa-mir-134 Ovarian Neoplasms 26363097 "In conclusion, our findings indicate that repression of miR-134 and consequent up-regulation of Pak2 might contribute to paclitaxel resistance." +tissue_expression_up hsa-mir-155 Gaucher Disease 26376862 sustained up-regulation of miR-155 +tissue_expression_up hsa-mir-31 "Carcinoma, Thyroid, Papillary" 26380656 "miR-21, miR-146b, miR-221, miR-222, miR-31, and miR-3613 were up-regulated" +tissue_expression_up hsa-mir-10b Medulloblastoma 26394044 microRNA-10b Is Overexpressed and Critical for Cell Survival and Proliferation in Medulloblastoma. +tissue_expression_up hsa-mir-27b "Carcinoma, Cervical" 26397063 "In summary, the present study revealed that miR-27b is upregulated by HPV16 E7 to inhibit PPAR¦Ã expression and promotes proliferation and invasion in cervical carcinoma cells." +tissue_expression_up hsa-mir-155 Muscular Dystrophy 26398013 "Up-regulation of immune-related miRNAs in muscle, for example, miR-155 and miR-146, is associated with autoimmunity" +tissue_expression_up hsa-mir-155 "Carcinoma, Breast, Triple Negative" 26398931 "These results indicate that miR-155-5p antagonizes bufalin sensitivity in TNBC cells, and that downregulation of DNMT1 and DNMT3a may be responsible for the bufalin-induced upregulation of miR-155-5p." +tissue_expression_up hsa-mir-429 Heart Failure 26408546 "17 miRNAs exhibited particularly high increases in expression, including miR-598, miR-429, miR-224, miR-425, and miR-221." +tissue_expression_up hsa-mir-21 "Carcinoma, Hepatocellular" 26436398 "We concluded that miR-21 might be complementary to alpha fetal protein in HCC diagnosis, and might serve as an attractive estimator of HCC. We also demonstrated that miR-21 overexpression was associated with HCC TNM stage and with poor survival." +tissue_expression_up hsa-mir-106a Glioma 26439036 "Elevated expression of miRNA-106a plays a crucial role in the development and progression of glioma, probably by promoting the proliferation and suppressing the apoptosis of glioma cells through the JNK/MAPK signaling pathway." +tissue_expression_up hsa-mir-34a Cardiovascular Diseases [unspecific] 26446137 "overexpression of miR-34a was significantly associated with increased apoptosis, impaired cell vitality and aggravated senescence." +tissue_expression_up hsa-mir-15a Leukemia 26456833 miR-223 and miR-15a were upregulated in 11/19 JMML bone marrow mononuclear cells harboring PTPN11 mutations +tissue_expression_up hsa-mir-223 Atherosclerosis 26492242 an obvious increase of miR-223 was observed in aortic atherosclerotic lesions. +tissue_expression_up hsa-mir-15a "Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal" 26497405 "We detected miR-363 and miR-15a, and their expression levels were significantly increased in the HPV-16-positive patients and in FaDu cells expressing HPV-16 E6-E7." +tissue_expression_up hsa-mir-590 Vulvar Squamous Cell Carcinoma 26498065 "In conclusion, we present the miRNA expression profile in VSCC, and our findings suggest that the upregulation of miR-590-5p promotes cellular malignant behaviours via the target gene TGF¦ÂRII." +tissue_expression_up hsa-mir-92a Esophageal Neoplasms 26498375 "13 miRNAs were up-regulated including hsa-mir-153-2, hsa-mir-92a-1 and hsa-mir-182; while 27 miRNAs were down-regulated including hsa-mir comprising 29a, hsa-mir-100 and hsa-mir-139 and so on." +tissue_expression_up hsa-mir-214 "Scleroderma, Localized" 26498408 The levels of miR-214 in hair shafts of patients with dermatomyositis were significantly higher than those of normal subjects and patients with scleroderma. +tissue_expression_up hsa-mir-92b "Squamous Cell Carcinoma, Oral" 26503628 "Taken together, our results indicate that miR-92b upregulation accelerates tumor growth and present a novel mechanism of miRNA-mediated NF-¦ÊB activation in OSCC." +tissue_expression_up hsa-mir-146a Osteoarthritis 26505891 miR-146a significantly up-regulated and miR-27b significantly down-regulated at all time points +tissue_expression_up hsa-mir-145 Urinary Bladder Cancer 26514209 "Results indicate that miR-145 suppresses syndecan-1 and, by this mechanism, up-regulates stem cell factors and induces cell senescence and differentiation. We propose that miR-145 may confer stem cell-like properties on urothelial carcinoma cells and thus facilitate differentiation into multiple cell types." +tissue_expression_up hsa-let-7f Colon Neoplasms 26556872 "highly up-regulated miRNAs, let-7f-5p, miR-455-3p, miR-98, miR-155-5p and the down-regulated miRNAs, miR-1, miR-127-5p, miR-142-5p, miR-202-5p were associated with colon cancer pathways" +tissue_expression_up hsa-mir-155 Colon Neoplasms 26556872 "highly up-regulated miRNAs, let-7f-5p, miR-455-3p, miR-98, miR-155-5p and the down-regulated miRNAs, miR-1, miR-127-5p, miR-142-5p, miR-202-5p were associated with colon cancer pathways" +tissue_expression_up hsa-mir-20a Lung Neoplasms 26560875 increased expression of miR-20 in lung cancer +tissue_expression_up hsa-mir-21 "Carcinoma, Lung, Non-Small-Cell" 26563758 "Higher expression levels of miR-21, AmiR-27a, and miR-218 detected in this study suggest potential roles of these miRNAs in primary resistance to EGFR-TKI in advanced NSCLC patients with EGFR exon 19 deletion mutations. These findings need to be further confirmed in a study with a larger sample size." +tissue_expression_up hsa-mir-21 Acute Kidney Failure 26577279 "A set of microRNAs was differentially expressed after renal damage, among them miR-21, which was up-regulated." +tissue_expression_up hsa-mir-183 "Carcinoma, Hepatocellular" 26640336 "miRNA-183 was the most up-regulated, followed by miRNA-373. miRNA-129 and miRNA-188 were both strongly down-regulated and miRNA-378 was down-regulated a small amount." +tissue_expression_up hsa-mir-22 Toxic Encephalopathy 26649298 "Our results demonstrated that PFOS exposure decreased miR-16 expression and increased miR-22 expression, which may represent a possible mechanism by which PFOS decreases BDNF protein levels. PFOS may inhibit BDNF-ERK-CREB signalling by increasing miR-22 levels, which may, in part, explain the mechanism of PFOS neurotoxicity." +tissue_expression_up hsa-mir-106b Cutaneous Melanoma 26662433 This study showed that miR-106b may contribute to the progression of cutaneous melanoma and its up-regulation may be independently associated with poor prognosis of cutaneous melanoma. This suggests that miR-106b might serve as a promising biological marker for further risk stratification in the management of cutaneous melanoma. +tissue_expression_up hsa-mir-210 "Carcinoma, Renal Cell, Clear-Cell" 26670229 miR-21-5p and miR-210-3p resulted the most significantly up-regulated miRNAs in this patient cohort +tissue_expression_up hsa-mir-132 Aneurysmal Subarachnoid Hemorrhage 26675167 "Our study demonstrated that as compared to healthy control, miR-132 and miR-324 showed a upregulation in both SAH DCI and Non-DCI groups. However,the differences between the SAH DCI and non-DCI groups were not statistically significant." +tissue_expression_up hsa-mir-324 Aneurysmal Subarachnoid Hemorrhage 26675167 "Our study demonstrated that as compared to healthy control, miR-132 and miR-324 showed a upregulation in both SAH DCI and Non-DCI groups. However,the differences between the SAH DCI and non-DCI groups were not statistically significant." +tissue_expression_up hsa-mir-15b "Lymphoma, Mantle-Cell" 26676972 Our present findings suggest that the upregulated expression of miR-15b is likely to play an important role in the trans-formation of cMCL to aMCL. +tissue_expression_up hsa-mir-130a Chronic Alcohol-Induced Alveolar Macrophage Dysfunction 26677910 "Alcohol increased levels of microRNA-130a/-301a, these findings demonstrate that targeting PPAR¦Ã provides a novel therapeutic approach for mitigating alcohol-induced AM derangements and susceptibility to lung infection" +tissue_expression_up hsa-mir-301a Chronic Alcohol-Induced Alveolar Macrophage Dysfunction 26677910 "Alcohol increased levels of microRNA-130a/-301a, these findings demonstrate that targeting PPAR¦Ã provides a novel therapeutic approach for mitigating alcohol-induced AM derangements and susceptibility to lung infection" +tissue_expression_up hsa-mir-205 Neoplasms [unspecific] 26681200 "miR-9, mi-R-19a, miR-22 and miR-205 that promote EMT, fibrosis and tumorigenesis were up-regulated." +tissue_expression_up hsa-mir-126 "Lymphoma, Large B-Cell, Diffuse" 26683099 "We observed increased expression of proangiomiRs Let-7f, miR-17, miR-18a, miR-19b, miR-126, miR-130a, miR-210, miR-296 and miR-378" +tissue_expression_up hsa-mir-130a "Lymphoma, Large B-Cell, Diffuse" 26683099 "We observed increased expression of proangiomiRs Let-7f, miR-17, miR-18a, miR-19b, miR-126, miR-130a, miR-210, miR-296 and miR-378" +tissue_expression_up hsa-mir-296 "Lymphoma, Large B-Cell, Diffuse" 26683099 "We observed increased expression of proangiomiRs Let-7f, miR-17, miR-18a, miR-19b, miR-126, miR-130a, miR-210, miR-296 and miR-378" +tissue_expression_up hsa-mir-378 "Lymphoma, Large B-Cell, Diffuse" 26683099 "We observed increased expression of proangiomiRs Let-7f, miR-17, miR-18a, miR-19b, miR-126, miR-130a, miR-210, miR-296 and miR-378" +tissue_expression_up hsa-mir-125b Melanoma 26684239 "miR-34a, miR-100 and miR-125b showed high expression in both resistant cells and in tumor biopsies" +tissue_expression_up hsa-mir-381 Neoplasms [unspecific] 26688820 Further study revealed that I¦ÊB¦Á was a target gene of miR-381. The upregulation of miR-381 under LPS stimulation contributes to respiratory infections mainly by targeting I¦ÊB¦Á. +tissue_expression_up hsa-mir-205 Barrett Esophagus 26711784 we observed significantly higher levels of miR-205 in tumor tissue of esophageal squamous cell carcinoma +tissue_expression_up hsa-mir-205 Choriocarcinoma 26711784 we observed significantly higher levels of miR-205 in tumor tissue of esophageal squamous cell carcinoma +tissue_expression_up hsa-mir-103a Pancreatic Neoplasms 26714641 "We identified suitable reference miRNAs for future miRNA expression experiments using CRC- and PC FFPE tissue samples. Formalin fixation decreased miRNA expression considerably, while the effect of increasing sample age was estimated to be negligible in a clinical setting." +tissue_expression_up hsa-mir-9 "Stroke, Ischemic" 26718002 The expression of miR-9 in the peri-infarct cortex was increased in the EA group compared with the MCAO group +tissue_expression_up hsa-mir-27a Glaucoma 26720444 miR-27a was significantly upregulated. +tissue_expression_up hsa-mir-146a Stroke 26738853 stroke considerably increased miR-146a density in the corpus callosum and subventricular zone (SVZ) of the lateral ventricle of the ischemic hemisphere. +tissue_expression_up hsa-mir-222 Thyroid Neoplasms 26745212 miR-221 and miR-222 are consistently upregulated in different types of thyroid carcinomas +tissue_expression_up hsa-mir-146a Inflammatory Bowel Diseases 26752469 Expression of miR-146a and -155 was higher in the inflamed mucosa of children with CD and UC than in the intact mucosa. Expression of miR-122 elevated in the macroscopically intact colonic regions of CD compared with controls and patients with UC. +tissue_expression_up hsa-mir-622 Ovarian Neoplasms 26774475 Platinum and PARP Inhibitor Resistance Due to Overexpression of MicroRNA-622 in BRCA1-Mutant Ovarian Cancer. +tissue_expression_up hsa-mir-200a Colorectal Carcinoma 26790446 "The expression of MMP-2 and -9 was elevated, on the other hand, in cell lines derived from primary tumor cancer cells as well as the expression of miR-21, miR-29a, and miR-200a." +tissue_expression_up hsa-mir-21 Colorectal Carcinoma 26790446 "The expression of MMP-2 and -9 was elevated, on the other hand, in cell lines derived from primary tumor cancer cells as well as the expression of miR-21, miR-29a, and miR-200a." +tissue_expression_up hsa-mir-29a Colorectal Carcinoma 26790446 "The expression of MMP-2 and -9 was elevated, on the other hand, in cell lines derived from primary tumor cancer cells as well as the expression of miR-21, miR-29a, and miR-200a." +tissue_expression_up hsa-mir-21 Choriocarcinoma 26807210 "the expression of miR-200b, miR-200c, miR-451, miR-223 and miR-21 were significantly upregulated in mucinous cystadenocarcinoma" +tissue_expression_up hsa-mir-223 Choriocarcinoma 26807210 "the expression of miR-200b, miR-200c, miR-451, miR-223 and miR-21 were significantly upregulated in mucinous cystadenocarcinoma" +tissue_expression_up hsa-mir-15a Astrocytoma 26813564 miR-15a and miR-24-1 were found upregulated in EP relapsed and EP deceased cases +tissue_expression_up hsa-mir-15a Ependymoma 26813564 miR-15a and miR-24-1 were found upregulated in EP relapsed and EP deceased cases +tissue_expression_up hsa-mir-24 Astrocytoma 26813564 miR-15a and miR-24-1 were found upregulated in EP relapsed and EP deceased cases +tissue_expression_up hsa-mir-24 Ependymoma 26813564 miR-15a and miR-24-1 were found upregulated in EP relapsed and EP deceased cases +tissue_expression_up hsa-mir-375 "Carcinoma, Thyroid, Follicular" 26818914 Only miR-375 was over-expressed in the FNs diagnosed as carcinomas and in the PMs. +tissue_expression_up hsa-mir-21 Gastric Neoplasms 26824898 hsa-miR-21-5p was more highly expressed in the recurrence group than in the nonrecurrence group +tissue_expression_up hsa-mir-221 "Carcinoma, Lung, Non-Small-Cell" 26831656 The relative expression levels of microRNA-221 in the pathological tissues were remarkably higher than that in the corresponding normal tissues +tissue_expression_up hsa-mir-138 "Squamous Cell Carcinoma, Oral" 26841253 Upregulation of miR-138 and miR-183 was observed in 50.0% of the samples +tissue_expression_up hsa-mir-183 "Squamous Cell Carcinoma, Oral" 26841253 Upregulation of miR-138 and miR-183 was observed in 50.0% of the samples +tissue_expression_up hsa-mir-205 "Squamous Cell Carcinoma, Oral" 26841253 "Upregulation of miR-138, miRNA-145, and miR-205 was associated with advanced tumor stages, vascular invasion, and lymph node metastasis, respectively." +tissue_expression_up hsa-mir-4423 Cardiotoxicity 26842497 "early deregulation of miR-187-3p, miR-182-5p, miR-486-3p, miR-486-5p, miR-34a-3p, miR-4423-3p, miR-34c-3p, miR-34c-5p and miR-1303, and also the prolonged up-regulation of miR-182-5p, miR-4423-3p and miR-34c-5p." +tissue_expression_up hsa-mir-761 "Carcinoma, Hepatocellular" 26845057 MicroRNA-761 is upregulated in hepatocellular carcinoma and regulates tumorigenesis by targeting Mitofusin-2. +tissue_expression_up hsa-mir-21 Colorectal Carcinoma 26845148 "In the context of previous studies demonstrating increased miRNA-21 expression in metastatic primary tumors, our findings raise the question whether miRNA-21 might be involved in the initiation but not in the perpetuation and growth of metastases." +tissue_expression_up hsa-mir-155 "Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal" 26847279 "The expression of tissue and plasma miR-155 were significantly up-regulated in patients with LSCC. Our work will serve as a basis for further investigation, preferably large-scale validation in clinical trials." +tissue_expression_up hsa-mir-155 Neoplasms [unspecific] 26850462 miR-155 is an oncogenic miRNA that is often overexpressed in cancer and is associated with poor prognosis. +tissue_expression_up hsa-mir-210 "Squamous Cell Carcinoma, Esophageal" 26851030 "squamous cell carcinoma (9.26-fold, p<0.001) and adenocarcinoma cell lines (4.95-fold, p<0.001) and miR-27a-star was significantly up-regulated in adenocarcinoma cell lines (4.79-fold, p=0.04)." +tissue_expression_up hsa-mir-21 Preeclampsia 26859593 "we could observe a significant increase in gene expression of miR-155 (p<0.001), miR-21 (p<0.0001) and miR-122 (p<0.01) in preeclamptic placentas." +tissue_expression_up hsa-mir-130a Hepatitis B Virus Infection 26871786 Upregulation of miRNA-130a Represents Good Prognosis in Patients With HBV-Related Acute-on-Chronic Liver Failure: A Prospective Study. +tissue_expression_up hsa-mir-132 Inflammatory Bowel Diseases 26878986 significant upregulation of miR-132 and miR-223 was confirmed +tissue_expression_up hsa-mir-223 Inflammatory Bowel Diseases 26878986 significant upregulation of miR-132 and miR-223 was confirmed +tissue_expression_up hsa-mir-181a "Diabetes Mellitus, Type 1" 26892629 miRNA-181a expression was significantly higher in diabetic children and adolescents +tissue_expression_up hsa-mir-155 Breast Neoplasms 26901459 MiRNA-155 was selected for being overexpressed in breast cancer +tissue_expression_up hsa-mir-31 Esophageal Neoplasms 26918602 "miR-223, miR-21, and miR-31 as the top-up-regulated species" +tissue_expression_up hsa-mir-155 Vitiligo 26941046 "miR-99b, miR-125b, miR-155 and miR-199a-3p were found to be increased and miR-145 was found to be decreased in the skin of patients with vitiligo." +tissue_expression_up hsa-mir-103a Helicobacter pylori Infection 26945693 "miRNAs miR-103a-3p, miR-181c-5p, miR-370-3p, miR-375 and miR-223-3p were evaluated in tissue samples" +tissue_expression_up hsa-mir-181c Helicobacter pylori Infection 26945693 "miRNAs miR-103a-3p, miR-181c-5p, miR-370-3p, miR-375 and miR-223-3p were evaluated in tissue samples" +tissue_expression_up hsa-mir-223 Helicobacter pylori Infection 26945693 "miRNAs miR-103a-3p, miR-181c-5p, miR-370-3p, miR-375 and miR-223-3p were evaluated in tissue samples" +tissue_expression_up hsa-mir-370 Helicobacter pylori Infection 26945693 "miRNAs miR-103a-3p, miR-181c-5p, miR-370-3p, miR-375 and miR-223-3p were evaluated in tissue samples" +tissue_expression_up hsa-mir-375 Helicobacter pylori Infection 26945693 "miRNAs miR-103a-3p, miR-181c-5p, miR-370-3p, miR-375 and miR-223-3p were evaluated in tissue samples" +tissue_expression_up hsa-mir-20a "Lymphoma, Hodgkin" 26951445 miR-20a-5p were found to be increased in cHL +tissue_expression_up hsa-mir-150 Lupus Nephritis 26961386 Overexpression of miR-150 is observed in renal biopsies from patients with lupus nephritis +tissue_expression_up hsa-mir-182 Hypoxic-Ischemic Encephalopathy 26975828 miRNA-182 was highly expressed in the pineal gland. +tissue_expression_up hsa-mir-27a "Carcinoma, Cervical" 26987623 B4GALT3 up-regulation by miR-27a contributes to the oncogenic activity in human cervical cancer cells. +tissue_expression_up hsa-mir-21 Periodontitis 26987780 "Seven randomly selected up-regulated (miR-21-5p, 498, 548a-5p) and down-regulated (miR-495-3p, 539-5p, 34c-3p and 7a-2-3p) miRNAs were examined by qRT-PCR, and the results proved the accuracy of the miRNA" +tissue_expression_up hsa-mir-10b Glioma 26988656 Expression levels of miR-10b in glioma tissue were significantly higher than in normal brain tissue +tissue_expression_up hsa-mir-301a Prostate Neoplasms 26990571 High levels of miR-301a (above the median) were associated with an increased risk of biochemical recurrence +tissue_expression_up hsa-mir-210 Melanoma 27009863 Hypoxia-induced gene signatures and overexpression of the hypoxia-regulated miRNA hsa-miR-210 characterized CDXs. +tissue_expression_up hsa-mir-595 "Carcinoma, Thyroid, Papillary" 27022736 "Interestingly, in PTC cell lines and PTC tissues, expression of IL-22 and miR-595 was upregulated and Sox17 downregulated compared with normal thyroid" +tissue_expression_up hsa-mir-21 Prostate Neoplasms 27040772 the expression level of miR-21 was significantly increased in PCa tissues +tissue_expression_up hsa-mir-9 Osteosarcoma 27051003 miR-9 was significantly upregulated in OS tissues and cell lines compared to the corresponding non-cancerous bone tissues +tissue_expression_up hsa-mir-200a Melanoma 27054085 "Among the up-regulated miRNAs, miR-21, miR-200a and miR-141, are well known to be involved in carcinogenesis." +tissue_expression_up hsa-mir-142 "Squamous Cell Carcinoma, Oral" 27056547 "let-7a, let-7d, let-7f and miR-16 were downregulated while miR-29b, miR-142-3p, miR-144, miR-203, and miR-223 were upregulated in OSCC" +tissue_expression_up hsa-mir-144 "Squamous Cell Carcinoma, Oral" 27056547 "let-7a, let-7d, let-7f and miR-16 were downregulated while miR-29b, miR-142-3p, miR-144, miR-203, and miR-223 were upregulated in OSCC" +tissue_expression_up hsa-mir-203 "Squamous Cell Carcinoma, Oral" 27056547 "let-7a, let-7d, let-7f and miR-16 were downregulated while miR-29b, miR-142-3p, miR-144, miR-203, and miR-223 were upregulated in OSCC" +tissue_expression_up hsa-mir-223 "Squamous Cell Carcinoma, Oral" 27056547 "let-7a, let-7d, let-7f and miR-16 were downregulated while miR-29b, miR-142-3p, miR-144, miR-203, and miR-223 were upregulated in OSCC" +tissue_expression_up hsa-mir-29b "Squamous Cell Carcinoma, Oral" 27056547 "let-7a, let-7d, let-7f and miR-16 were downregulated while miR-29b, miR-142-3p, miR-144, miR-203, and miR-223 were upregulated in OSCC" +tissue_expression_up hsa-mir-149 "Fatty Liver, Non-Alcoholic" 27061435 miR-149 was increased in HepG2 cells treated with long-chain fatty acid (FFA) +tissue_expression_up hsa-mir-128 Glioblastoma 27063952 "The three most over-expressed miRs in the non-differentiated GSCs compared to xenografts were miR-126, -137 and -128." +tissue_expression_up hsa-mir-181a Heart Failure 27072074 "In coronary sinus samples, the microRNAs miR-16-5p, miR-27a-3p, miR-27b-3p, miR-29b-3p, miR-29c-3p, miR-30e-5p, miR-92a-3p, miR-125b-5p, miR-140-5p, miR-195-5p, miR-424-5p, and miR-451a were significantly down-regulated, and let-7a-5p, let-7c-5p, let-7e-5p, miR-23b-3p, miR-107, miR-155-5p, miR-181a-5p, miR-181b-5p and miR-320a were up-regulated in heart failure." +tissue_expression_up hsa-mir-21 "Carcinoma, Lung, Non-Small-Cell" 27072269 "miR-15a/16, miR-34a, miR-126 and miR-128 were down-regulated significantly. (>2-fold change), while miR-21 and miR.210 were up-regulated in A549." +tissue_expression_up hsa-mir-210 "Carcinoma, Lung, Non-Small-Cell" 27072269 "miR-15a/16, miR-34a, miR-126 and miR-128 were down-regulated significantly. (>2-fold change), while miR-21 and miR.210 were up-regulated in A549." +tissue_expression_up hsa-mir-146a Rheumatoid Arthritis 27079198 "miR-146a, miR-155, and miR-223 were significantly elevated in RA compared to OA synovial tissues" +tissue_expression_up hsa-mir-155 Rheumatoid Arthritis 27079198 "miR-146a, miR-155, and miR-223 were significantly elevated in RA compared to OA synovial tissues" +tissue_expression_up hsa-mir-223 Rheumatoid Arthritis 27079198 "miR-146a, miR-155, and miR-223 were significantly elevated in RA compared to OA synovial tissues" +tissue_expression_up hsa-mir-21 Breast Neoplasms 27082076 included upregulation of miR-21-5p and the miR-200 family and downregulation of let-7 family members in DCIS samples. +tissue_expression_up hsa-mir-23a Coronary Artery Disease 27085964 MiR-23a was enriched in not only diseased endothelial progenitor cells (EPCs) but also in the plasma of patients with coronary artery disease (CAD). +tissue_expression_up hsa-mir-155 "Leukemia, Lymphocytic, Chronic, B-Cell" 27111859 miR-143 was downregulated and miR-155 was overexpressed in 13q-H. +tissue_expression_up hsa-mir-146a Hepatitis C Virus Infection 27147737 miR-146a-5p level was consistently increased in HCV-infected hepatocyte-like cells +tissue_expression_up hsa-mir-155 Behcet Disease 27156371 The expression of miR-155 and IL-17 was significantly increased in CD4+ T cells of patients with active BD. +tissue_expression_up hsa-let-7b Prostate Neoplasms 27157642 up-regulation of let-7b is characteristic of prostatic TAMs +tissue_expression_up hsa-mir-125b Hepatitis C Virus Infection 27158204 "In response to HCV core protein stimulation, cytokine production was up-regulated and miR-125b expression was down-regulated in THP-1 cells." +tissue_expression_up hsa-mir-155 Renal Fibrosis 27158339 MiR-155 levels were higher in UUO mouse kidneys +tissue_expression_up hsa-mir-199a Pulmonary Hypertension 27162619 All 4 miRNAs were upregulated in the lung and right ventricle +tissue_expression_up hsa-mir-425 Cervical Neoplasms 27166306 miR-425-5p is up-regulated in cervical cancer and serum miR-425-5p may serve as a potential prognostic biomarker for cervical cancer. +tissue_expression_up hsa-mir-141 Biliary Tract Neoplasms 27172928 Overexpression of miRNA 141 is an indicator of a poor prognosis in patients with biliary tract cancer +tissue_expression_up hsa-mir-4532 Hypertension 27176897 "4 were upregulated (miRâ€?18a, miRâ€?27, miRâ€?18e and miRâ€?532) and 2 downregulated (miRâ€?8 and miRâ€?35b) in SPE placentas compared with controls." +tissue_expression_up hsa-mir-518a Hypertension 27176897 "4 were upregulated (miRâ€?18a, miRâ€?27, miRâ€?18e and miRâ€?532) and 2 downregulated (miRâ€?8 and miRâ€?35b) in SPE placentas compared with controls." +tissue_expression_up hsa-mir-518e Hypertension 27176897 "4 were upregulated (miRâ€?18a, miRâ€?27, miRâ€?18e and miRâ€?532) and 2 downregulated (miRâ€?8 and miRâ€?35b) in SPE placentas compared with controls." +tissue_expression_up hsa-mir-527 Hypertension 27176897 "4 were upregulated (miRâ€?18a, miRâ€?27, miRâ€?18e and miRâ€?532) and 2 downregulated (miRâ€?8 and miRâ€?35b) in SPE placentas compared with controls." +tissue_expression_up hsa-mir-21 Gastric Neoplasms 27179559 miR-21 is overexpressed in tumour tissue +tissue_expression_up hsa-mir-21 Salivary Gland Neoplasms 27184509 "tissue samples were studied miR-21, miR-31, miR-199a-5p, miR-146b, miR-345 were up-regulated" +tissue_expression_up hsa-mir-93 Glioma 27185265 the upregulated miR-93 level was significantly associated with the advanced malignancy. +tissue_expression_up hsa-mir-10b "Carcinoma, Nasopharyngeal" 27186392 we show that microRNA-10b (miR-10b) is up-regulated in HNE1/DDP cells +tissue_expression_up hsa-mir-182 Alcoholic Hepatitis 27196584 miR-182 was the most highly expressed miRNA in AH +tissue_expression_up hsa-mir-301b Pancreatic Neoplasms 27197190 PDAC tumors expressing high levels of MIF displayed elevated levels of miR-301b and reduced levels of NR3C2. +tissue_expression_up hsa-mir-183 Glioma 27215622 "In conclusion, our study indicated that miR-183 was upregulated in glioma, and that it may be used as a potential biomarker of poor prognosis in patients with glioma." +tissue_expression_up hsa-mir-206 Soft Tissue Sarcoma 27223121 "At least threefold overexpression of one of miR-206,-381, and 671-5p was detected in all MPNSTs, EMCSs, SSs and 7 MCs." +tissue_expression_up hsa-mir-381 Soft Tissue Sarcoma 27223121 "At least threefold overexpression of one of miR-206,-381, and 671-5p was detected in all MPNSTs, EMCSs, SSs and 7 MCs." +tissue_expression_up hsa-mir-671 Soft Tissue Sarcoma 27223121 "At least threefold overexpression of one of miR-206,-381, and 671-5p was detected in all MPNSTs, EMCSs, SSs and 7 MCs." +tissue_expression_up hsa-mir-29a Acute Pancreatitis 27239114 The expression of miR-29a was much higher in the AEP group compared with the control group +tissue_expression_up hsa-mir-126 Asthma 27247924 "Elevated levels of miRNA-126, IL-13 mRNA and pathological changes were observed in the sensitized group compared to the control group" +tissue_expression_up hsa-mir-1287 Colorectal Carcinoma 27251300 MiR-1287 was significantly upregulated in the group of CRC samples compared with matched noncancerous tissue samples. +tissue_expression_up hsa-mir-128a Preeclampsia 27261578 miR-128a is an up-regulated miRNA in patient with PE. +tissue_expression_up hsa-mir-181a Colorectal Carcinoma 27264420 IL-1β induced the expression of miR-181a. +tissue_expression_up hsa-mir-196 "Adenocarcinoma, Pancreatic Ductal" 27267055 The expressions of all microRNAs were 1.4-3.7 times higher (significantly) in the PAC group compared to non-cancer patients. +tissue_expression_up hsa-mir-200 "Adenocarcinoma, Pancreatic Ductal" 27267055 The expressions of all microRNAs were 1.4-3.7 times higher (significantly) in the PAC group compared to non-cancer patients. +tissue_expression_up hsa-mir-21 Cervical Neoplasms 27278606 the expression of miR-21 was upregulated and the expression of miR-143 was downregulated by the HPV16 E7 oncoprotein in vivo +tissue_expression_up hsa-mir-199a Obesity 27279151 miRâ€?99aâ€?p may represent a factor in the modulation of obesity‑associated IR +tissue_expression_up hsa-mir-9 Neoplasms [unspecific] 27284255 higher expression level of miR-9 significantly predicted worse OS in various carcinomas +tissue_expression_up hsa-mir-126 Atherosclerosis 27288564 "Aroclor 1260 increased miR-21, miR-31, miR-126, miR-221 and miR-222 expression levels." +tissue_expression_up hsa-mir-21 Atherosclerosis 27288564 "Aroclor 1260 increased miR-21, miR-31, miR-126, miR-221 and miR-222 expression levels." +tissue_expression_up hsa-mir-221 Atherosclerosis 27288564 "Aroclor 1260 increased miR-21, miR-31, miR-126, miR-221 and miR-222 expression levels." +tissue_expression_up hsa-mir-222 Atherosclerosis 27288564 "Aroclor 1260 increased miR-21, miR-31, miR-126, miR-221 and miR-222 expression levels." +tissue_expression_up hsa-mir-31 Atherosclerosis 27288564 "Aroclor 1260 increased miR-21, miR-31, miR-126, miR-221 and miR-222 expression levels." +tissue_expression_up hsa-mir-181b "Carcinoma, Lung, Non-Small-Cell" 27291819 miR-181b-5p was up-regulated in squamous cell carcinoma +tissue_expression_up hsa-mir-133a "Cardiomyopathy, Dilated" 27292200 "Endomyocardial expression of miR-155 and miR-133a, as quantified by reverse transcription-PCR (RT-PCR), was up-regulated in patients with iCMP as compared with patients with DCM." +tissue_expression_up hsa-mir-182 Ovarian Neoplasms 27295517 miR-182 expression is significantly increased in EOC +tissue_expression_up hsa-mir-106b "Carcinoma, Hepatocellular" 27298561 The value of miR-106b expression in HBV-associated HCC patients was significantly higher +tissue_expression_up hsa-mir-200c Interstitial Lung Disease 27309544 "The miR-200c level in the SSc group was significantly higher than in the DM/PM, pSS, and RA groups" +tissue_expression_up hsa-mir-155 Multiple Sclerosis 27310932 up-regulation of miR-155 (p value = 0.009) and miR-132 (p value = 0.04) in MS patients +tissue_expression_up hsa-mir-208a Myocardial Infarction 27314868 over-expression of miR-208a in myocardial infarction tissue +tissue_expression_up hsa-mir-486 Kideny Transplant Rejection 27323802 iR-486-5p and its target PTEN/foxO3 mRNA were significantly overexpressed (pâ€?â€?.01) and underexpressed (pâ€?â€?.01) +tissue_expression_up hsa-mir-301a Prostate Neoplasms 27327120 MiR-301a and miR-301b are 2 hypoxia responsive miRNAs that are significantly upregulated in hypoxia in prostate cancer cells. +tissue_expression_up hsa-mir-301b Prostate Neoplasms 27327120 MiR-301a and miR-301b are 2 hypoxia responsive miRNAs that are significantly upregulated in hypoxia in prostate cancer cells. +tissue_expression_up hsa-mir-9 Cervical Neoplasms 27345415 MiR-9 up-regulated in cervical cancer +tissue_expression_up hsa-mir-126 "Shock, Hemorrhagic" 27345902 miR-29a and miR-126 were upregulated +tissue_expression_up hsa-mir-29a "Shock, Hemorrhagic" 27345902 miR-29a and miR-126 were upregulated +tissue_expression_up hsa-mir-29b Colorectal Carcinoma 27346400 The expression level of miR-29b is reduced in colorectal cancer tissues compared with that in the adjacent colorectal tissues. +tissue_expression_up hsa-mir-146b "Carcinoma, Thyroid" 27347103 "the expression levels of miR146b, miR221 and miR222 were significantly higher" +tissue_expression_up hsa-mir-221 "Carcinoma, Thyroid" 27347103 "the expression levels of miR146b, miR221 and miR222 were significantly higher" +tissue_expression_up hsa-mir-100 Bladder Neoplasms 27350368 "six up-regulated candidate miRNAs (miR-182-5p, miR-935, miR-518e-3p, miR-573, miR-100-3p, and miR-3171)" +tissue_expression_up hsa-mir-182 Bladder Neoplasms 27350368 "six up-regulated candidate miRNAs (miR-182-5p, miR-935, miR-518e-3p, miR-573, miR-100-3p, and miR-3171)" +tissue_expression_up hsa-mir-3171 Bladder Neoplasms 27350368 "six up-regulated candidate miRNAs (miR-182-5p, miR-935, miR-518e-3p, miR-573, miR-100-3p, and miR-3171)" +tissue_expression_up hsa-mir-518e Bladder Neoplasms 27350368 "six up-regulated candidate miRNAs (miR-182-5p, miR-935, miR-518e-3p, miR-573, miR-100-3p, and miR-3171)" +tissue_expression_up hsa-mir-573 Bladder Neoplasms 27350368 "six up-regulated candidate miRNAs (miR-182-5p, miR-935, miR-518e-3p, miR-573, miR-100-3p, and miR-3171)" +tissue_expression_up hsa-mir-935 Bladder Neoplasms 27350368 "six up-regulated candidate miRNAs (miR-182-5p, miR-935, miR-518e-3p, miR-573, miR-100-3p, and miR-3171)" +tissue_expression_up hsa-mir-192 Hepatitis C Virus Infection 27350618 miR-192 expression was induced by HCV infection +tissue_expression_up hsa-mir-21 Proliferative Vitreoretinal Disease 27351379 miR-21 expression positively correlates with disease progression +tissue_expression_up hsa-mir-372 "Carcinoma, Urothelial" 27351382 "high primary tumour levels of E2F1, miR-21 and miR-372 are associated with poor PFS independent of clinical prognostic factors." +tissue_expression_up hsa-mir-222 Thyroid Neoplasms 27353001 miR-25 and miR-222 expression was upregulated in 8505C +tissue_expression_up hsa-mir-25 Thyroid Neoplasms 27353001 miR-25 and miR-222 expression was upregulated in 8505C +tissue_expression_up hsa-mir-34 Idiopathic Pulmonary Fibrosis 27362652 "miR-34a, miR-34b, and miR-34c, but not miR-20a, miR-29c, or miR-let-7f were significantly higher in type II AECs from IPF patients." +tissue_expression_up hsa-mir-506 "Adenocarcinoma, Pancreatic Ductal" 27371108 miR-506 expression was higher in PDAC +tissue_expression_up hsa-mir-143 Barrett Esophagus 27374102 "miR-143, miR-145, miR-194 and miR-215 levels were significantly higher" +tissue_expression_up hsa-mir-143 Choriocarcinoma 27374102 "miR-143, miR-145, miR-194 and miR-215 levels were significantly higher" +tissue_expression_up hsa-mir-194 Barrett Esophagus 27374102 "miR-143, miR-145, miR-194 and miR-215 levels were significantly higher" +tissue_expression_up hsa-mir-215 Barrett Esophagus 27374102 "miR-143, miR-145, miR-194 and miR-215 levels were significantly higher" +tissue_expression_up hsa-mir-210 Cerebral Ischemia 27386874 "miR-210 expression in the hippocampus of the I/R group at 6, 24 and 96 h after reperfusion was significantly increased at each time point, while its expression in the group treated with HRS was significantly decreased." +tissue_expression_up hsa-mir-34 Liver Fibrosis 27387128 Further studies showed that the miR-34a/SIRT1/p53 signaling pathway was activated in hepatocytes but not in HSCs. +tissue_expression_up hsa-mir-34a Liver Fibrosis 27387128 "In the present study, using a CCl4-induced rat liver fibrosis model, we found that the miR-34a/SIRT1/p53 signaling pathway was activated and could be inhibited by SIRT1 activator SRT1720." +tissue_expression_up hsa-mir-141 Sarcoma [unspecific] 27402864 combined expression of miR-200s and GRHL2 further upregulates epithelial genes to induce MET. +tissue_expression_up hsa-mir-200a Sarcoma [unspecific] 27402864 combined expression of miR-200s and GRHL2 further upregulates epithelial genes to induce MET. +tissue_expression_up hsa-mir-200b Sarcoma [unspecific] 27402864 combined expression of miR-200s and GRHL2 further upregulates epithelial genes to induce MET. +tissue_expression_up hsa-mir-200c Sarcoma [unspecific] 27402864 combined expression of miR-200s and GRHL2 further upregulates epithelial genes to induce MET. +tissue_expression_up hsa-mir-429 Sarcoma [unspecific] 27402864 combined expression of miR-200s and GRHL2 further upregulates epithelial genes to induce MET. +tissue_expression_up hsa-let-7a "Carcinoma, Breast, Triple Negative" 27404381 "Interestingly, despite being a known tumor suppressor, Let-7a showed a significant overexpression in TNBCs." +tissue_expression_up hsa-mir-21 "Carcinoma, Breast, Triple Negative" 27404381 "While miR-21, miR-221 and miR-210 showed significant over-expression, miR-195 and miR-145 were downregulated and well correlated with various clinicopathological and demographic risk factors, tumor grade, clinical stage and hormone receptor status." +tissue_expression_up hsa-mir-210 "Carcinoma, Breast, Triple Negative" 27404381 "While miR-21, miR-221 and miR-210 showed significant over-expression, miR-195 and miR-145 were downregulated and well correlated with various clinicopathological and demographic risk factors, tumor grade, clinical stage and hormone receptor status." +tissue_expression_up hsa-mir-221 "Carcinoma, Breast, Triple Negative" 27404381 "While miR-21, miR-221 and miR-210 showed significant over-expression, miR-195 and miR-145 were downregulated and well correlated with various clinicopathological and demographic risk factors, tumor grade, clinical stage and hormone receptor status." +tissue_expression_up hsa-mir-483 Atrial Fibrillation 27422887 Sixteen microRNAs were differentially expressed in the atrial myocardium of POAF patients when compared with those maintaining sinus rhythm. miR-208a was the most underexpressed [fold change (FC) = 2.458] and miR-483-5p the most overexpressed (FC = 1.804). +tissue_expression_up hsa-mir-221 "Carcinoma, Renal Cell, Clear-Cell" 27427222 miRNA-21 and miRNA-221 expressions were significantly up-regulated in tumor specimens compared to normal tissue (P<0.05). +tissue_expression_up hsa-mir-375 "Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal" 27446362 "The results of the present study suggested that miR-148a and miR-375 were significantly upregulated in LSCC tissues, and increased expression of miR-375 was associated with a more aggressive phenotype of LSCC." +tissue_expression_up hsa-mir-146a Crohn Disease 27468194 The elevated expression of miR-146a and -155 in the inflamed duodenal mucosa of CD patients suggests the role of these miRs in the pathomechanism of inflammatory bowel disease. +tissue_expression_up hsa-mir-155 Crohn Disease 27468194 The elevated expression of miR-146a and -155 in the inflamed duodenal mucosa of CD patients suggests the role of these miRs in the pathomechanism of inflammatory bowel disease. +tissue_expression_up hsa-mir-155 Melanoma 27469124 "A comparison of Spitzoid melanomas to benign nevi revealed overexpression of miR-21, miR-150, and miR-155 in the malignant primaries (p < 0.05)." +tissue_expression_up hsa-mir-155 Lymphoma 27473081 "T-MF showed higher miR17 and miR-18a expression compared to F-MF and TR-MF (p â‰?0.0387) while miR19b, miR92a, and miR-155 showed increased levels in F-MF and TR-MF with respect to T-MF (p â‰?0.0360)." +tissue_expression_up hsa-mir-17 Lymphoma 27473081 "Furthermore, MF patients showed higher miRNA expression compared to controls (p â‰?0.0223). T-MF showed higher miR17 and miR-18a expression compared to F-MF and TR-MF (p â‰?0.0387) while miR19b, miR92a, and miR-155 showed increased levels in F-MF and TR-MF with respect to T-MF (p â‰?0.0360)." +tissue_expression_up hsa-mir-18a Lymphoma 27473081 "Furthermore, MF patients showed higher miRNA expression compared to controls (p â‰?0.0223). T-MF showed higher miR17 and miR-18a expression compared to F-MF and TR-MF (p â‰?0.0387) while miR19b, miR92a, and miR-155 showed increased levels in F-MF and TR-MF with respect to T-MF (p â‰?0.0360)." +tissue_expression_up hsa-mir-19b Lymphoma 27473081 "Furthermore, MF patients showed higher miRNA expression compared to controls (p â‰?0.0223). T-MF showed higher miR17 and miR-18a expression compared to F-MF and TR-MF (p â‰?0.0387) while miR19b, miR92a, and miR-155 showed increased levels in F-MF and TR-MF with respect to T-MF (p â‰?0.0360)." +tissue_expression_up hsa-mir-92a Lymphoma 27473081 "Furthermore, MF patients showed higher miRNA expression compared to controls (p â‰?0.0223). T-MF showed higher miR17 and miR-18a expression compared to F-MF and TR-MF (p â‰?0.0387) while miR19b, miR92a, and miR-155 showed increased levels in F-MF and TR-MF with respect to T-MF (p â‰?0.0360)." +tissue_expression_up hsa-mir-146b Otitis Media 27497395 Middle ear miR-146a and miR-146b expression was elevated in otitis media patients relative to control subjects and correlated with middle ear epithelial thickness. +tissue_expression_up hsa-mir-221 "Adenocarcinoma, Esophageal" 27501171 MiR-221 was overexpressed in 5-FU resistant EC cell lines as well as in human EAC tissue. +tissue_expression_up hsa-mir-181b "Squamous Cell Carcinoma, Oral" 27509922 he expression levels of miRâ€?81b and Bclâ€? in OVC were significantly higher compared with normal mucosal tissue (NM); +tissue_expression_up hsa-mir-34b Seizures 27514646 "We discovered that miR-34b-5p, a member of the miR-34 family, increased significantly in flurothyl-treated rat hippocampus tissue." +tissue_expression_up hsa-mir-210 Male Infertility 27535712 " Compared with obstructive azoospermia (OA) as normal control, our results suggest that miR-210 was significantly up-regulated in testis of patients with NOA (P<0.05)" +tissue_expression_up hsa-let-7b Chronic Inflammation 27539004 "PM2.5 exposure increased miR-3560 and let-7b-5p in the hippocampus, two proteins that regulate genes Oxct1 and Lin28b that control ketogenesis and glycosylation, and neural cell differentiation, respectively" +tissue_expression_up hsa-mir-3560 Chronic Inflammation 27539004 "PM2.5 exposure increased miR-3560 and let-7b-5p in the hippocampus, two proteins that regulate genes Oxct1 and Lin28b that control ketogenesis and glycosylation, and neural cell differentiation, respectively" +tissue_expression_up hsa-mir-3588 Chronic Inflammation 27539004 "Expression levels of cortical miR-6315, miR-3588, and miR-466b-5p were upregulated" +tissue_expression_up hsa-mir-466b Chronic Inflammation 27539004 "Expression levels of cortical miR-6315, miR-3588, and miR-466b-5p were upregulated" +tissue_expression_up hsa-mir-6315 Chronic Inflammation 27539004 "Expression levels of cortical miR-6315, miR-3588, and miR-466b-5p were upregulated" +tissue_expression_up hsa-mir-34a "Stroke, Ischemic" 27545688 Increased Expression of mir-34a-5p and Clinical Association in Acute Ischemic Stroke Patients and in a Rat Model. +tissue_expression_up hsa-mir-16 "Carcinoma, Gastric" 27605261 High expression of miR-16 and miR-451 predicating better prognosis in patients with gastric cancer. +tissue_expression_up hsa-mir-451 "Carcinoma, Gastric" 27605261 High expression of miR-16 and miR-451 predicating better prognosis in patients with gastric cancer. +tissue_expression_up hsa-mir-126 "Carcinoma, Ovarian, Clear Cell" 27612152 MicroRNA Gene Expression Signature Driven by miR-9 Overexpression in Ovarian Clear Cell Carcinoma. +tissue_expression_up hsa-mir-9 "Carcinoma, Ovarian, Clear Cell" 27612152 MicroRNA Gene Expression Signature Driven by miR-9 Overexpression in Ovarian Clear Cell Carcinoma. +tissue_expression_up hsa-mir-107 "Adenocarcinoma, Colon" 27658891 "the top most upregulated and downregulated miRNAs in HPNM included miR-145, -143, -107, -194, and -26a (upregulated), and miR-663, -1268, -320b, -1275, and -322b (downregulated)" +tissue_expression_up hsa-mir-143 "Adenocarcinoma, Colon" 27658891 "the top most upregulated and downregulated miRNAs in HPNM included miR-145, -143, -107, -194, and -26a (upregulated), and miR-663, -1268, -320b, -1275, and -321b (downregulated)" +tissue_expression_up hsa-mir-145 "Adenocarcinoma, Colon" 27658891 "the top most upregulated and downregulated miRNAs in HPNM included miR-145, -143, -107, -194, and -26a (upregulated), and miR-663, -1268, -320b, -1275, and -320b (downregulated)" +tissue_expression_up hsa-mir-194 "Adenocarcinoma, Colon" 27658891 "the top most upregulated and downregulated miRNAs in HPNM included miR-145, -143, -107, -194, and -26a (upregulated), and miR-663, -1268, -320b, -1275, and -323b (downregulated)" +tissue_expression_up hsa-mir-26a "Adenocarcinoma, Colon" 27658891 "the top most upregulated and downregulated miRNAs in HPNM included miR-145, -143, -107, -194, and -26a (upregulated), and miR-663, -1268, -320b, -1275, and -324b (downregulated)" +tissue_expression_up hsa-mir-98 Osteoarthritis 27676099 Upregulation of miR-98 Inhibits Apoptosis in Cartilage Cells in Osteoarthritis. +tissue_expression_up hsa-mir-155 Psoriasis 27706699 Increased miR-155-5p expression in dermal mesenchymal stem cells of psoriatic patients: comparing the microRNA expression profile by microarray. +tissue_expression_up hsa-mir-203 Psoriasis 27729619 upregulation of miR-31/miR-203 and downregulation of hsa-miR-99a/miR-125b work together in concert to facilitate the development of psoriasis pathogenesis +tissue_expression_up hsa-mir-31 Psoriasis 27729619 upregulation of miR-31/miR-203 and downregulation of hsa-miR-99a/miR-125b work together in concert to facilitate the development of psoriasis pathogenesis +tissue_expression_up hsa-mir-140 "Carcinoma, Breast" 27746365 "MiR-222, miR-29a, miR-34a, miR-423, miR-140, miR-3178, miR-574, miR-6780b and miR-744 exhibited significantly higher expression levels in surgically-resected specimens compared with pre-neoadjuvant chemotherapy biopsies" +tissue_expression_up hsa-mir-222 "Carcinoma, Breast" 27746365 "MiR-222, miR-29a, miR-34a, miR-423, miR-140, miR-3178, miR-574, miR-6780b and miR-744 exhibited significantly higher expression levels in surgically-resected specimens compared with pre-neoadjuvant chemotherapy biopsies" +tissue_expression_up hsa-mir-29a "Carcinoma, Breast" 27746365 "MiR-222, miR-29a, miR-34a, miR-423, miR-140, miR-3178, miR-574, miR-6780b and miR-744 exhibited significantly higher expression levels in surgically-resected specimens compared with pre-neoadjuvant chemotherapy biopsies" +tissue_expression_up hsa-mir-3178 "Carcinoma, Breast" 27746365 "MiR-222, miR-29a, miR-34a, miR-423, miR-140, miR-3178, miR-574, miR-6780b and miR-744 exhibited significantly higher expression levels in surgically-resected specimens compared with pre-neoadjuvant chemotherapy biopsies" +tissue_expression_up hsa-mir-34a "Carcinoma, Breast" 27746365 "MiR-222, miR-29a, miR-34a, miR-423, miR-140, miR-3178, miR-574, miR-6780b and miR-744 exhibited significantly higher expression levels in surgically-resected specimens compared with pre-neoadjuvant chemotherapy biopsies" +tissue_expression_up hsa-mir-423 "Carcinoma, Breast" 27746365 "MiR-222, miR-29a, miR-34a, miR-423, miR-140, miR-3178, miR-574, miR-6780b and miR-744 exhibited significantly higher expression levels in surgically-resected specimens compared with pre-neoadjuvant chemotherapy biopsies" +tissue_expression_up hsa-mir-574 "Carcinoma, Breast" 27746365 "MiR-222, miR-29a, miR-34a, miR-423, miR-140, miR-3178, miR-574, miR-6780b and miR-744 exhibited significantly higher expression levels in surgically-resected specimens compared with pre-neoadjuvant chemotherapy biopsies" +tissue_expression_up hsa-mir-6780b "Carcinoma, Breast" 27746365 "MiR-222, miR-29a, miR-34a, miR-423, miR-140, miR-3178, miR-574, miR-6780b and miR-744 exhibited significantly higher expression levels in surgically-resected specimens compared with pre-neoadjuvant chemotherapy biopsies" +tissue_expression_up hsa-mir-744 "Carcinoma, Breast" 27746365 "MiR-222, miR-29a, miR-34a, miR-423, miR-140, miR-3178, miR-574, miR-6780b and miR-744 exhibited significantly higher expression levels in surgically-resected specimens compared with pre-neoadjuvant chemotherapy biopsies" +tissue_expression_up hsa-mir-222 "Carcinoma, Breast" 27746366 MiR-222 promotes drug-resistance of breast cancer cells to adriamycin via modulation of PTEN/Akt/FOXO1 pathway. +tissue_expression_up hsa-mir-543 "Carcinoma, Lung, Non-Small-Cell" 27769862 miR-543 is up-regulated in gefitinib-resistant non-small cell lung cancer and promotes cell proliferation and invasion via phosphatase and tensin homolog. +tissue_expression_up hsa-mir-223 Obesity 27812198 Visceral Adipose MicroRNA 223 Is Upregulated in Human and Murine Obesity and Modulates the Inflammatory Phenotype of Macrophages. +tissue_expression_up hsa-mir-124 "Squamous Cell Carcinoma, Skin or Unspecific" 27818465 The expression of miR-124 increases in aged skin to cause cell senescence and it decreases in squamous cell carcinoma. +tissue_expression_up hsa-mir-16 Rheumatoid Arthritis 27875659 Upregulated Expression of microRNA-16 Correlates with Th17/Treg Cell Imbalance in Patients with Rheumatoid Arthritis. +tissue_expression_up hsa-mir-16 "Adenocarcinoma, Colon" 27930363 Upregulated miR-16 expression is an independent indicator of relapse and poor overall survival of colorectal adenocarcinoma patients. +tissue_expression_up hsa-mir-24 "Adenocarcinoma, Colon" 27939727 Elevated expression of miR-24-3p is a potentially adverse prognostic factor in colorectal adenocarcinoma. +tissue_expression_up hsa-mir-222 "Carcinoma, Gastric" 27994199 Upregulation of miR-222 in both Helicobacter pylori- infected and noninfected gastric cancer patients. +tissue_expression_up hsa-mir-23a Muscle Atrophy 28000445 Delphinidin Prevents Muscle Atrophy and Upregulates miR-23a Expression. +tissue_expression_up hsa-mir-15a Glioma 28060761 "Sensitivity and specificity analysis indicated miR-15a, miR-16, miR-21, miR-23a, and miR-9 were up-regulated, while miR-124 was down-regulated in glioma" +tissue_expression_up hsa-mir-16 Glioma 28060761 "Sensitivity and specificity analysis indicated miR-15a, miR-16, miR-21, miR-23a, and miR-9 were up-regulated, while miR-124 was down-regulated in glioma" +tissue_expression_up hsa-mir-21 Glioma 28060761 "Sensitivity and specificity analysis indicated miR-15a, miR-16, miR-21, miR-23a, and miR-9 were up-regulated, while miR-124 was down-regulated in glioma" +tissue_expression_up hsa-mir-23a Glioma 28060761 "Sensitivity and specificity analysis indicated miR-15a, miR-16, miR-21, miR-23a, and miR-9 were up-regulated, while miR-124 was down-regulated in glioma" +tissue_expression_up hsa-mir-9 Glioma 28060761 "Sensitivity and specificity analysis indicated miR-15a, miR-16, miR-21, miR-23a, and miR-9 were up-regulated, while miR-124 was down-regulated in glioma" +tissue_expression_up hsa-mir-21 "Carcinoma, Skin" 28069514 "Increased microRNA 21 expression contributes to arsenic induced skin lesions, skin cancers and respiratory distress in chronically exposed individuals." +tissue_expression_up hsa-mir-125b Acute Peritonitis 28074870 MicroRNA-155 is upregulated in ascites in patients with spontaneous bacterial peritonitis. +tissue_expression_up hsa-mir-143 "Carcinoma, Nasopharyngeal" 28105209 Upregulated microRNA-143 inhibits cell proliferation in human nasopharyngeal carcinoma. +tissue_expression_up hsa-mir-21 "Carcinoma, Renal Cell" 28184919 Upregulation of miR-21 expression is a valuable predicator of advanced clinicopathological features and poor prognosis in patients with renal cell carcinoma through the p53/p21?cyclin?E2?Bax/caspase-3 signaling pathway. +tissue_expression_up hsa-mir-605 "Carcinoma, Renal Cell" 28222071 miR-605 is elevated at baseline in the Responders and is downregulated with treatment in Responders as compared with Progressors +tissue_expression_up hsa-mir-193a Nephrotic Syndrome 28299339 The miR-193a expression levels only slightly increased in NS patients +tissue_expression_up hsa-let-7b Endocrine Gland Neoplasms 28322989 "Several miRNAs show lowered expression in endocrine cancers (i.e. miR-200s, miR-126, miR-7, miR-29a, miR-30a, miR-137, miR-206, miR-101, miR-613, miR-539, miR-205, miR-9, miR-195), while others are commonly overexpressed (i.e. miR-21, miR-183, miR-31, miR-let7b, miR-584, miR-146b, miR-221, miR-222, miR-25, miR-595)" +tissue_expression_up hsa-mir-146b Endocrine Gland Neoplasms 28322989 "Several miRNAs show lowered expression in endocrine cancers (i.e. miR-200s, miR-126, miR-7, miR-29a, miR-30a, miR-137, miR-206, miR-101, miR-613, miR-539, miR-205, miR-9, miR-195), while others are commonly overexpressed (i.e. miR-21, miR-183, miR-31, miR-let7b, miR-584, miR-146b, miR-221, miR-222, miR-25, miR-595)" +tissue_expression_up hsa-mir-183 Endocrine Gland Neoplasms 28322989 "Several miRNAs show lowered expression in endocrine cancers (i.e. miR-200s, miR-126, miR-7, miR-29a, miR-30a, miR-137, miR-206, miR-101, miR-613, miR-539, miR-205, miR-9, miR-195), while others are commonly overexpressed (i.e. miR-21, miR-183, miR-31, miR-let7b, miR-584, miR-146b, miR-221, miR-222, miR-25, miR-595)" +tissue_expression_up hsa-mir-21 Endocrine Gland Neoplasms 28322989 "Several miRNAs show lowered expression in endocrine cancers (i.e. miR-200s, miR-126, miR-7, miR-29a, miR-30a, miR-137, miR-206, miR-101, miR-613, miR-539, miR-205, miR-9, miR-195), while others are commonly overexpressed (i.e. miR-21, miR-183, miR-31, miR-let7b, miR-584, miR-146b, miR-221, miR-222, miR-25, miR-595)" +tissue_expression_up hsa-mir-221 Endocrine Gland Neoplasms 28322989 "Several miRNAs show lowered expression in endocrine cancers (i.e. miR-200s, miR-126, miR-7, miR-29a, miR-30a, miR-137, miR-206, miR-101, miR-613, miR-539, miR-205, miR-9, miR-195), while others are commonly overexpressed (i.e. miR-21, miR-183, miR-31, miR-let7b, miR-584, miR-146b, miR-221, miR-222, miR-25, miR-595)" +tissue_expression_up hsa-mir-222 Endocrine Gland Neoplasms 28322989 "Several miRNAs show lowered expression in endocrine cancers (i.e. miR-200s, miR-126, miR-7, miR-29a, miR-30a, miR-137, miR-206, miR-101, miR-613, miR-539, miR-205, miR-9, miR-195), while others are commonly overexpressed (i.e. miR-21, miR-183, miR-31, miR-let7b, miR-584, miR-146b, miR-221, miR-222, miR-25, miR-595)" +tissue_expression_up hsa-mir-25 Endocrine Gland Neoplasms 28322989 "Several miRNAs show lowered expression in endocrine cancers (i.e. miR-200s, miR-126, miR-7, miR-29a, miR-30a, miR-137, miR-206, miR-101, miR-613, miR-539, miR-205, miR-9, miR-195), while others are commonly overexpressed (i.e. miR-21, miR-183, miR-31, miR-let7b, miR-584, miR-146b, miR-221, miR-222, miR-25, miR-595)" +tissue_expression_up hsa-mir-31 Endocrine Gland Neoplasms 28322989 "Several miRNAs show lowered expression in endocrine cancers (i.e. miR-200s, miR-126, miR-7, miR-29a, miR-30a, miR-137, miR-206, miR-101, miR-613, miR-539, miR-205, miR-9, miR-195), while others are commonly overexpressed (i.e. miR-21, miR-183, miR-31, miR-let7b, miR-584, miR-146b, miR-221, miR-222, miR-25, miR-595)" +tissue_expression_up hsa-mir-584 Endocrine Gland Neoplasms 28322989 "Several miRNAs show lowered expression in endocrine cancers (i.e. miR-200s, miR-126, miR-7, miR-29a, miR-30a, miR-137, miR-206, miR-101, miR-613, miR-539, miR-205, miR-9, miR-195), while others are commonly overexpressed (i.e. miR-21, miR-183, miR-31, miR-let7b, miR-584, miR-146b, miR-221, miR-222, miR-25, miR-595)" +tissue_expression_up hsa-mir-595 Endocrine Gland Neoplasms 28322989 "Several miRNAs show lowered expression in endocrine cancers (i.e. miR-200s, miR-126, miR-7, miR-29a, miR-30a, miR-137, miR-206, miR-101, miR-613, miR-539, miR-205, miR-9, miR-195), while others are commonly overexpressed (i.e. miR-21, miR-183, miR-31, miR-let7b, miR-584, miR-146b, miR-221, miR-222, miR-25, miR-595)" +tissue_expression_up hsa-mir-210 Lung Neoplasms 28334118 "we found that hsa-mir-210 was upregulated, while hsa-mir-490 and hsa-mir-486 were downregulated in?>?90% of the 991 lung cancer samples" +tissue_expression_up hsa-mir-888 "Carcinoma, Hepatocellular" 28337887 Up-regulation of miR-888-5p in hepatocellular carcinoma cell lines and its effect on malignant characteristics of cells. +tissue_expression_up hsa-mir-137 "Carcinoma, Hepatocellular" 28350139 Upregulation of miR-137 reverses sorafenib resistance and cancer-initiating cell phenotypes by degrading ANT2 in hepatocellular carcinoma. +tissue_expression_up hsa-mir-223 "Carcinoma, Gastrooesophageal" 28395057 Early miR-223 Upregulation in Gastroesophageal Carcinogenesis. +tissue_expression_up hsa-let-7a "Carcinoma, Gastric" 28399984 Up-regulation of Let-7a Expression Induces Gastric Carcinoma Cell Apoptosis In Vitro. +tissue_expression_up hsa-mir-21 "Fibromatosis, Aggressive" 28418912 "The correlation between sporadic DTs and miRNA expression showed that miR-21-3p increased in mutated versus wild-type DTs, while miR-197-3p was decreased" +tissue_expression_up hsa-mir-93 Glioma 28440610 Evaluation Expression of Microrna-93 and Integrin ¦¢8 in Different Types of Glioma Tumors +tissue_expression_up hsa-mir-182 Behcet Disease 28482290 "up regulation of miR-182 and miR-3591-3p; down regulation of miR-155, miR-638 and miR-4488 in the pathogenesis of the disease" +tissue_expression_up hsa-mir-3591 Behcet Disease 28482290 "up regulation of miR-182 and miR-3591-3p; down regulation of miR-155, miR-638 and miR-4488 in the pathogenesis of the disease" +tissue_expression_up hsa-mir-101 Colon Neoplasms 28560419 Upregulation of miR-101 enhances the cytotoxic effect of anticancer drugs through inhibition of colon cancer cell proliferation. +tissue_expression_up hsa-mir-143 Breast Neoplasms 28588724 Upregulation of microRNA-143 reverses drug resistance in human breast cancer cells via inhibition of cytokine-induced apoptosis inhibitor 1. +tissue_expression_up hsa-mir-199a Colorectal Carcinoma 28639895 Upregulation of miR-199a/b contributes to cisplatin resistance via Wnt/¦Â-catenin-ABCG2 signaling pathway in ALDHA1+ colorectal cancer stem cells. +tissue_expression_up hsa-mir-199b Colorectal Carcinoma 28639895 Upregulation of miR-199a/b contributes to cisplatin resistance via Wnt/¦Â-catenin-ABCG2 signaling pathway in ALDHA1+ colorectal cancer stem cells. +tissue_expression_up hsa-mir-9 "Carcinoma, Hepatocellular" 28774651 "inhibition of hsa_circ_0071410 increased the expression of miR-9-5p, resulting in the attenuation of irradiation induced HSC activation" +tissue_expression_up hsa-mir-155 Systemic Lupus Erythematosus 28779021 "IFN-¦Á impairs insulin-mediated NO production, and altered gene expression resulted from eNOS instability, possibly due to enhanced miR-155 expression" +tissue_expression_up hsa-mir-126 Vasomotor Rhinitis 28787742 "there was significant overexpression of miR-543, miR-129-5p, and miR-126-3p, and under-expression of miR-2110, miR-449c-5p, miR-449b-5p, miR-190b, and miR-92b-5p." +tissue_expression_up hsa-mir-129 Vasomotor Rhinitis 28787742 "there was significant overexpression of miR-543, miR-129-5p, and miR-126-3p, and under-expression of miR-2110, miR-449c-5p, miR-449b-5p, miR-190b, and miR-92b-5p." +tissue_expression_up hsa-mir-543 Vasomotor Rhinitis 28787742 "there was significant overexpression of miR-543, miR-129-5p, and miR-126-3p, and under-expression of miR-2110, miR-449c-5p, miR-449b-5p, miR-190b, and miR-92b-5p." +tissue_expression_up hsa-mir-125a "Lymphoma, Large B-Cell, Diffuse" 28817403 "PB-DLBCL and DLBCL-GCB-CC also had much higher levels of miR-125a-3p, miR-34-3p, and miR-155-5p, and significantly lower levels of miR-17-5p and miR-17-3p" +tissue_expression_up hsa-mir-155 "Lymphoma, Large B-Cell, Diffuse" 28817403 "PB-DLBCL and DLBCL-GCB-CC also had much higher levels of miR-125a-3p, miR-34-3p, and miR-155-5p, and significantly lower levels of miR-17-5p and miR-17-3p" +tissue_expression_up hsa-mir-34 "Lymphoma, Large B-Cell, Diffuse" 28817403 "PB-DLBCL and DLBCL-GCB-CC also had much higher levels of miR-125a-3p, miR-34-3p, and miR-155-5p, and significantly lower levels of miR-17-5p and miR-17-3p" +tissue_expression_up hsa-mir-125b Colorectal Carcinoma 28881590 Upregulation of microRNA-125b by G-CSF promotes metastasis in colorectal cancer +tissue_expression_up hsa-mir-210 "Adenocarcinoma, Esophageal" 28968550 "Expression levels of miR-25 and miR-210 were significantly higher, and those of PTEN and AIFM3 significantly lower" +tissue_expression_up hsa-mir-25 "Adenocarcinoma, Esophageal" 28968550 "Expression levels of miR-25 and miR-210 were significantly higher, and those of PTEN and AIFM3 significantly lower" +tissue_expression_up hsa-mir-223 Chorioamnionitis 29083107 Increased miR-223 expression in foetal organs is a signature of acute chorioamnionitis with systemic consequences. +tissue_expression_up hsa-mir-214 "Carcinoma, Hepatocellular" 29088870 high miR-214 could be a promising biomarker for prognosis prediction of cancer +tissue_expression_up hsa-mir-21 "Carcinoma, Thyroid, Medullary" 29107050 MicroRNA-21 and long non-coding RNA MALAT1 are overexpressed markers in medullary thyroid carcinoma. +tissue_expression_up hsa-mir-16 Glioblastoma 29110584 "Our data demonstrated a significant upregulation of five microRNAs (hsa-miR-16, hsa-miR-17, hsa-miR-21, hsa-miR-221, and hsa-miR-375)" +tissue_expression_up hsa-mir-17 Glioblastoma 29110584 "Our data demonstrated a significant upregulation of five microRNAs (hsa-miR-16, hsa-miR-17, hsa-miR-21, hsa-miR-221, and hsa-miR-375)" +tissue_expression_up hsa-mir-21 Glioblastoma 29110584 "Our data demonstrated a significant upregulation of five microRNAs (hsa-miR-16, hsa-miR-17, hsa-miR-21, hsa-miR-221, and hsa-miR-375)" +tissue_expression_up hsa-mir-221 Glioblastoma 29110584 "Our data demonstrated a significant upregulation of five microRNAs (hsa-miR-16, hsa-miR-17, hsa-miR-21, hsa-miR-221, and hsa-miR-375)" +tissue_expression_up hsa-mir-375 Glioblastoma 29110584 "Our data demonstrated a significant upregulation of five microRNAs (hsa-miR-16, hsa-miR-17, hsa-miR-21, hsa-miR-221, and hsa-miR-375)" +tissue_expression_up hsa-mir-302c Ovarian Germ Cell Cancer 29138809 "Higher expression of miR-373-3p, miR-372-3p and miR-302c-3p and lower expression of miR-199a-5p, miR-214-5p and miR-202-3p were reproducibly observed in malignant OGCTs as compared to benign OGCTs or SCSTs" +tissue_expression_up hsa-mir-372 Ovarian Germ Cell Cancer 29138809 "Higher expression of miR-373-3p, miR-372-3p and miR-302c-3p and lower expression of miR-199a-5p, miR-214-5p and miR-202-3p were reproducibly observed in malignant OGCTs as compared to benign OGCTs or SCSTs" +tissue_expression_up hsa-mir-373 Ovarian Germ Cell Cancer 29138809 "Higher expression of miR-373-3p, miR-372-3p and miR-302c-3p and lower expression of miR-199a-5p, miR-214-5p and miR-202-3p were reproducibly observed in malignant OGCTs as compared to benign OGCTs or SCSTs" +tissue_expression_up hsa-mir-21 Gastric Neoplasms 29142602 there was a higher expression of VEGF and miR-21 in GC tissues compared with that in morphologically adjacent normal tissues whereas PPAR¦Á expression was decreased +tissue_expression_up hsa-mir-143 Myocardial Infarction 29162889 "The expression level of miR-143 in monocytes from STEMI patients compared to healthy controls was increased, whereas the expression of miR-1, -92a, -99a, and -223 was reduced significantly" +tissue_expression_up hsa-mir-10a Pancreatic Neoplasms 29169171 "miR-27a, miR-27b, miR-9, miR10a and miR-10b were up-regulated in PDAC cells compared to HPDE cells" +tissue_expression_up hsa-mir-10b Pancreatic Neoplasms 29169171 "miR-27a, miR-27b, miR-9, miR10a and miR-10b were up-regulated in PDAC cells compared to HPDE cells" +tissue_expression_up hsa-mir-27a Pancreatic Neoplasms 29169171 "miR-27a, miR-27b, miR-9, miR10a and miR-10b were up-regulated in PDAC cells compared to HPDE cells" +tissue_expression_up hsa-mir-27b Pancreatic Neoplasms 29169171 "miR-27a, miR-27b, miR-9, miR10a and miR-10b were up-regulated in PDAC cells compared to HPDE cells" +tissue_expression_up hsa-mir-9 Pancreatic Neoplasms 29169171 "miR-27a, miR-27b, miR-9, miR10a and miR-10b were up-regulated in PDAC cells compared to HPDE cells" +tissue_expression_up hsa-mir-181a Adenosquamous Pancreas Carcinoma 29221165 "Furthermore, lower Ang-1 and Tie-2 transcript levels and higher increases of miR-21-5p, miR27a-3p and miR-181a-5p levels were found in the rarest form of pancreatic carcinoma." +tissue_expression_up hsa-mir-21 Adenosquamous Pancreas Carcinoma 29221165 "Furthermore, lower Ang-1 and Tie-2 transcript levels and higher increases of miR-21-5p, miR27a-3p and miR-181a-5p levels were found in the rarest form of pancreatic carcinoma." +tissue_expression_up hsa-mir-27a Adenosquamous Pancreas Carcinoma 29221165 "Furthermore, lower Ang-1 and Tie-2 transcript levels and higher increases of miR-21-5p, miR27a-3p and miR-181a-5p levels were found in the rarest form of pancreatic carcinoma." +tissue_expression_up hsa-mir-155 Congenital Heart Diseases 29281614 "Mir-486-3p, mir-486-5p, and mir-155-5p increased in patients with cyanotic heart disease compared with those without heart disease" +tissue_expression_up hsa-mir-486 Congenital Heart Diseases 29281614 "Mir-486-3p, mir-486-5p, and mir-155-5p increased in patients with cyanotic heart disease compared with those without heart disease" +tissue_expression_up hsa-mir-10b "Carcinoma, Hepatocellular" 29314614 "miR-1, miR-122, let-7a, and let-7g were downregulated, whereas miR-10b and miR-21 were upregulated in canine HCC" +tissue_expression_up hsa-mir-21 "Carcinoma, Hepatocellular" 29314614 "miR-1, miR-122, let-7a, and let-7g were downregulated, whereas miR-10b and miR-21 were upregulated in canine HCC" +tissue_expression_up hsa-mir-143 NUT Midline Carcinoma 29322795 "All NMCs showed upregulation of miR-9 and downregulation of miR-99a and miR-145 and two cases featured also upregulation of miR-21, miR-143, and miR-484" +tissue_expression_up hsa-mir-21 NUT Midline Carcinoma 29322795 "All NMCs showed upregulation of miR-9 and downregulation of miR-99a and miR-145 and two cases featured also upregulation of miR-21, miR-143, and miR-484" +tissue_expression_up hsa-mir-484 NUT Midline Carcinoma 29322795 "All NMCs showed upregulation of miR-9 and downregulation of miR-99a and miR-145 and two cases featured also upregulation of miR-21, miR-143, and miR-484" +tissue_expression_up hsa-mir-9 NUT Midline Carcinoma 29322795 "All NMCs showed upregulation of miR-9 and downregulation of miR-99a and miR-145 and two cases featured also upregulation of miR-21, miR-143, and miR-485" +tissue_expression_up hsa-mir-122 Hepatitis C Virus Infection 29359389 "MicroRNAs associated with HCV-related immunopathogenesis which were found to be enriched in exosomes of HCV viremic patients (in particular, miR-122-5p, miR-222-3p, miR-146a, miR-150-5p, miR-30c, miR-378a-3p and miR-20a-5p) were markedly reduced by DAA therapy" +tissue_expression_up hsa-mir-146a Hepatitis C Virus Infection 29359389 "MicroRNAs associated with HCV-related immunopathogenesis which were found to be enriched in exosomes of HCV viremic patients (in particular, miR-122-5p, miR-222-3p, miR-146a, miR-150-5p, miR-30c, miR-378a-3p and miR-20a-5p) were markedly reduced by DAA therapy" +tissue_expression_up hsa-mir-150 Hepatitis C Virus Infection 29359389 "MicroRNAs associated with HCV-related immunopathogenesis which were found to be enriched in exosomes of HCV viremic patients (in particular, miR-122-5p, miR-222-3p, miR-146a, miR-150-5p, miR-30c, miR-378a-3p and miR-20a-5p) were markedly reduced by DAA therapy" +tissue_expression_up hsa-mir-20a Hepatitis C Virus Infection 29359389 "MicroRNAs associated with HCV-related immunopathogenesis which were found to be enriched in exosomes of HCV viremic patients (in particular, miR-122-5p, miR-222-3p, miR-146a, miR-150-5p, miR-30c, miR-378a-3p and miR-20a-5p) were markedly reduced by DAA therapy" +tissue_expression_up hsa-mir-222 Hepatitis C Virus Infection 29359389 "MicroRNAs associated with HCV-related immunopathogenesis which were found to be enriched in exosomes of HCV viremic patients (in particular, miR-122-5p, miR-222-3p, miR-146a, miR-150-5p, miR-30c, miR-378a-3p and miR-20a-5p) were markedly reduced by DAA therapy" +tissue_expression_up hsa-mir-30c Hepatitis C Virus Infection 29359389 "MicroRNAs associated with HCV-related immunopathogenesis which were found to be enriched in exosomes of HCV viremic patients (in particular, miR-122-5p, miR-222-3p, miR-146a, miR-150-5p, miR-30c, miR-378a-3p and miR-20a-5p) were markedly reduced by DAA therapy" +tissue_expression_up hsa-mir-378a Hepatitis C Virus Infection 29359389 "MicroRNAs associated with HCV-related immunopathogenesis which were found to be enriched in exosomes of HCV viremic patients (in particular, miR-122-5p, miR-222-3p, miR-146a, miR-150-5p, miR-30c, miR-378a-3p and miR-20a-5p) were markedly reduced by DAA therapy" +tissue_expression_up hsa-mir-183 "Carcinoma, Thyroid, Medullary" 29388012 Tumour expression levels of miR-21 (p=0.0008) and miR-183 (p=0.0096) were higher in the LNI group +tissue_expression_up hsa-mir-21 "Carcinoma, Thyroid, Medullary" 29388012 Tumour expression levels of miR-21 (p=0.0008) and miR-183 (p=0.0097) were higher in the LNI group +tissue_expression_up hsa-mir-150 Infection [unspecific] 29391047 "upregulated miR-21, miR-155, miR-150, and miR-221, as well as downregulated miR-143 and miR-125, all of them previously linked to other bacterial infections" +tissue_expression_up hsa-mir-155 Infection [unspecific] 29391047 "upregulated miR-21, miR-155, miR-150, and miR-221, as well as downregulated miR-143 and miR-125, all of them previously linked to other bacterial infections" +tissue_expression_up hsa-mir-21 Infection [unspecific] 29391047 "upregulated miR-21, miR-155, miR-150, and miR-221, as well as downregulated miR-143 and miR-125, all of them previously linked to other bacterial infections" +tissue_expression_up hsa-mir-221 Infection [unspecific] 29391047 "upregulated miR-21, miR-155, miR-150, and miR-221, as well as downregulated miR-143 and miR-125, all of them previously linked to other bacterial infections" +tissue_expression_up hsa-mir-142 "Carcinoma, Renal Cell" 29440068 "miR-21, miR-142-3p, miR-142-5p, miR-150, and miR-155 as significantly upregulated" +tissue_expression_up hsa-mir-150 "Carcinoma, Renal Cell" 29440068 "miR-21, miR-142-3p, miR-142-5p, miR-150, and miR-155 as significantly upregulated" +tissue_expression_up hsa-mir-155 "Carcinoma, Renal Cell" 29440068 "miR-21, miR-142-3p, miR-142-5p, miR-150, and miR-155 as significantly upregulated" +tissue_expression_up hsa-mir-21 "Carcinoma, Renal Cell" 29440068 "miR-21, miR-142-3p, miR-142-5p, miR-150, and miR-155 as significantly upregulated" +tissue_expression_up hsa-mir-129-2 "Squamous Cell Carcinoma, Head and Neck" 29455435 two namely Hsa-miR-129-2-3p and Hsa-miR-449a were found to be up-regulated as compared to HPV -ve cells +tissue_expression_up hsa-mir-449a "Squamous Cell Carcinoma, Head and Neck" 29455435 two namely Hsa-miR-129-2-3p and Hsa-miR-449a were found to be up-regulated as compared to HPV -ve cells +tissue_expression_up hsa-let-7b Pleural Mesothelioma 29462963 "They reported 12 over-expressed miRNAs (let-7b*, miR-1228*, miR-195*, miR-30b*, miR-32*, miR-345, miR-483-3p, miR-584, miR-595, miR-615-3p, and miR-885-3p) and nine sub-expressed (let-7e*, miR-144*, miR-203, miR-340*, miR-34a*, miR-423, miR-582, miR-7-1* and miR-9) in MPM tissue compared to the single control" +tissue_expression_up hsa-let-7e Pleural Mesothelioma 29462963 "They reported 12 over-expressed miRNAs (let-7b*, miR-1228*, miR-195*, miR-30b*, miR-32*, miR-345, miR-483-3p, miR-584, miR-595, miR-615-3p, and miR-885-3p) and nine sub-expressed (let-7e*, miR-144*, miR-203, miR-340*, miR-34a*, miR-423, miR-582, miR-7-1* and miR-9) in MPM tissue compared to the single control" +tissue_expression_up hsa-mir-1228 Pleural Mesothelioma 29462963 "They reported 12 over-expressed miRNAs (let-7b*, miR-1228*, miR-195*, miR-30b*, miR-32*, miR-345, miR-483-3p, miR-584, miR-595, miR-615-3p, and miR-885-3p) and nine sub-expressed (let-7e*, miR-144*, miR-203, miR-340*, miR-34a*, miR-423, miR-582, miR-7-1* and miR-9) in MPM tissue compared to the single control" +tissue_expression_up hsa-mir-144 Pleural Mesothelioma 29462963 "They reported 12 over-expressed miRNAs (let-7b*, miR-1228*, miR-195*, miR-30b*, miR-32*, miR-345, miR-483-3p, miR-584, miR-595, miR-615-3p, and miR-885-3p) and nine sub-expressed (let-7e*, miR-144*, miR-203, miR-340*, miR-34a*, miR-423, miR-582, miR-7-1* and miR-9) in MPM tissue compared to the single control" +tissue_expression_up hsa-mir-195 Pleural Mesothelioma 29462963 "They reported 12 over-expressed miRNAs (let-7b*, miR-1228*, miR-195*, miR-30b*, miR-32*, miR-345, miR-483-3p, miR-584, miR-595, miR-615-3p, and miR-885-3p) and nine sub-expressed (let-7e*, miR-144*, miR-203, miR-340*, miR-34a*, miR-423, miR-582, miR-7-1* and miR-9) in MPM tissue compared to the single control" +tissue_expression_up hsa-mir-203 Pleural Mesothelioma 29462963 "They reported 12 over-expressed miRNAs (let-7b*, miR-1228*, miR-195*, miR-30b*, miR-32*, miR-345, miR-483-3p, miR-584, miR-595, miR-615-3p, and miR-885-3p) and nine sub-expressed (let-7e*, miR-144*, miR-203, miR-340*, miR-34a*, miR-423, miR-582, miR-7-1* and miR-9) in MPM tissue compared to the single control" +tissue_expression_up hsa-mir-30b Pleural Mesothelioma 29462963 "They reported 12 over-expressed miRNAs (let-7b*, miR-1228*, miR-195*, miR-30b*, miR-32*, miR-345, miR-483-3p, miR-584, miR-595, miR-615-3p, and miR-885-3p) and nine sub-expressed (let-7e*, miR-144*, miR-203, miR-340*, miR-34a*, miR-423, miR-582, miR-7-1* and miR-9) in MPM tissue compared to the single control" +tissue_expression_up hsa-mir-32 Pleural Mesothelioma 29462963 "They reported 12 over-expressed miRNAs (let-7b*, miR-1228*, miR-195*, miR-30b*, miR-32*, miR-345, miR-483-3p, miR-584, miR-595, miR-615-3p, and miR-885-3p) and nine sub-expressed (let-7e*, miR-144*, miR-203, miR-340*, miR-34a*, miR-423, miR-582, miR-7-1* and miR-9) in MPM tissue compared to the single control" +tissue_expression_up hsa-mir-340 Pleural Mesothelioma 29462963 "They reported 12 over-expressed miRNAs (let-7b*, miR-1228*, miR-195*, miR-30b*, miR-32*, miR-345, miR-483-3p, miR-584, miR-595, miR-615-3p, and miR-885-3p) and nine sub-expressed (let-7e*, miR-144*, miR-203, miR-340*, miR-34a*, miR-423, miR-582, miR-7-1* and miR-9) in MPM tissue compared to the single control" +tissue_expression_up hsa-mir-345 Pleural Mesothelioma 29462963 "They reported 12 over-expressed miRNAs (let-7b*, miR-1228*, miR-195*, miR-30b*, miR-32*, miR-345, miR-483-3p, miR-584, miR-595, miR-615-3p, and miR-885-3p) and nine sub-expressed (let-7e*, miR-144*, miR-203, miR-340*, miR-34a*, miR-423, miR-582, miR-7-1* and miR-9) in MPM tissue compared to the single control" +tissue_expression_up hsa-mir-34a Pleural Mesothelioma 29462963 "They reported 12 over-expressed miRNAs (let-7b*, miR-1228*, miR-195*, miR-30b*, miR-32*, miR-345, miR-483-3p, miR-584, miR-595, miR-615-3p, and miR-885-3p) and nine sub-expressed (let-7e*, miR-144*, miR-203, miR-340*, miR-34a*, miR-423, miR-582, miR-7-1* and miR-9) in MPM tissue compared to the single control" +tissue_expression_up hsa-mir-423 Pleural Mesothelioma 29462963 "They reported 12 over-expressed miRNAs (let-7b*, miR-1228*, miR-195*, miR-30b*, miR-32*, miR-345, miR-483-3p, miR-584, miR-595, miR-615-3p, and miR-885-3p) and nine sub-expressed (let-7e*, miR-144*, miR-203, miR-340*, miR-34a*, miR-423, miR-582, miR-7-1* and miR-9) in MPM tissue compared to the single control" +tissue_expression_up hsa-mir-483 Pleural Mesothelioma 29462963 "They reported 12 over-expressed miRNAs (let-7b*, miR-1228*, miR-195*, miR-30b*, miR-32*, miR-345, miR-483-3p, miR-584, miR-595, miR-615-3p, and miR-885-3p) and nine sub-expressed (let-7e*, miR-144*, miR-203, miR-340*, miR-34a*, miR-423, miR-582, miR-7-1* and miR-9) in MPM tissue compared to the single control" +tissue_expression_up hsa-mir-582 Pleural Mesothelioma 29462963 "They reported 12 over-expressed miRNAs (let-7b*, miR-1228*, miR-195*, miR-30b*, miR-32*, miR-345, miR-483-3p, miR-584, miR-595, miR-615-3p, and miR-885-3p) and nine sub-expressed (let-7e*, miR-144*, miR-203, miR-340*, miR-34a*, miR-423, miR-582, miR-7-1* and miR-9) in MPM tissue compared to the single control" +tissue_expression_up hsa-mir-584 Pleural Mesothelioma 29462963 "They reported 12 over-expressed miRNAs (let-7b*, miR-1228*, miR-195*, miR-30b*, miR-32*, miR-345, miR-483-3p, miR-584, miR-595, miR-615-3p, and miR-885-3p) and nine sub-expressed (let-7e*, miR-144*, miR-203, miR-340*, miR-34a*, miR-423, miR-582, miR-7-1* and miR-9) in MPM tissue compared to the single control" +tissue_expression_up hsa-mir-595 Pleural Mesothelioma 29462963 "They reported 12 over-expressed miRNAs (let-7b*, miR-1228*, miR-195*, miR-30b*, miR-32*, miR-345, miR-483-3p, miR-584, miR-595, miR-615-3p, and miR-885-3p) and nine sub-expressed (let-7e*, miR-144*, miR-203, miR-340*, miR-34a*, miR-423, miR-582, miR-7-1* and miR-9) in MPM tissue compared to the single control" +tissue_expression_up hsa-mir-615 Pleural Mesothelioma 29462963 "They reported 12 over-expressed miRNAs (let-7b*, miR-1228*, miR-195*, miR-30b*, miR-32*, miR-345, miR-483-3p, miR-584, miR-595, miR-615-3p, and miR-885-3p) and nine sub-expressed (let-7e*, miR-144*, miR-203, miR-340*, miR-34a*, miR-423, miR-582, miR-7-1* and miR-9) in MPM tissue compared to the single control" +tissue_expression_up hsa-mir-7-1 Pleural Mesothelioma 29462963 "They reported 12 over-expressed miRNAs (let-7b*, miR-1228*, miR-195*, miR-30b*, miR-32*, miR-345, miR-483-3p, miR-584, miR-595, miR-615-3p, and miR-885-3p) and nine sub-expressed (let-7e*, miR-144*, miR-203, miR-340*, miR-34a*, miR-423, miR-582, miR-7-1* and miR-9) in MPM tissue compared to the single control" +tissue_expression_up hsa-mir-885 Pleural Mesothelioma 29462963 "They reported 12 over-expressed miRNAs (let-7b*, miR-1228*, miR-195*, miR-30b*, miR-32*, miR-345, miR-483-3p, miR-584, miR-595, miR-615-3p, and miR-885-3p) and nine sub-expressed (let-7e*, miR-144*, miR-203, miR-340*, miR-34a*, miR-423, miR-582, miR-7-1* and miR-9) in MPM tissue compared to the single control" +tissue_expression_up hsa-mir-9 Pleural Mesothelioma 29462963 "They reported 12 over-expressed miRNAs (let-7b*, miR-1228*, miR-195*, miR-30b*, miR-32*, miR-345, miR-483-3p, miR-584, miR-595, miR-615-3p, and miR-885-3p) and nine sub-expressed (let-7e*, miR-144*, miR-203, miR-340*, miR-34a*, miR-423, miR-582, miR-7-1* and miR-9) in MPM tissue compared to the single control" +tissue_expression_up hsa-mir-181d "Carcinoma, Adenoid Cystic" 29467480 hsa-miR-455-5p and hsa-miR-181d-5p were upregulated in carcinomas of both salivary and lacrimal gland +tissue_expression_up hsa-mir-455 "Carcinoma, Adenoid Cystic" 29467480 hsa-miR-455-5p and hsa-miR-181d-5p were upregulated in carcinomas of both salivary and lacrimal gland +tissue_expression_up hsa-mir-21 "Squamous Cell Carcinoma, Oral" 29480379 increased miR-21 levels in conjunction with decreased miR-125a levels in saliva of OLP patients may be indicative for a poor prognosis +tissue_expression_up hsa-mir-21 Cervical Neoplasms 29487007 "MiR-21-5p upregulation, miR-34a downregulation, and hTERC amplification were associated with the aggressive progression of CC, which suggests that miR-21-5p, miR-34a and hTERC might serve as surrogate markers for CC progression and potential molecular targets for blockage of the development of CC" +tissue_expression_up hsa-mir-182 Lung Neoplasms 29516903 "the authors identified a statistically significant miRNA meta-signature of seven upregulated (miR-21, miR-210, miR-182, miR-31, miR-200b, miR-205, and miR-183) and eight downregulated (miR-126-3p, miR-30a, miR-30d, miR-486-5p, miR-451a, miR-126-5p, miR-143, and miR-145) miRNAs" +tissue_expression_up hsa-mir-183 Lung Neoplasms 29516903 "the authors identified a statistically significant miRNA meta-signature of seven upregulated (miR-21, miR-210, miR-182, miR-31, miR-200b, miR-205, and miR-183) and eight downregulated (miR-126-3p, miR-30a, miR-30d, miR-486-5p, miR-451a, miR-126-5p, miR-143, and miR-145) miRNAs" +tissue_expression_up hsa-mir-200b Lung Neoplasms 29516903 "the authors identified a statistically significant miRNA meta-signature of seven upregulated (miR-21, miR-210, miR-182, miR-31, miR-200b, miR-205, and miR-183) and eight downregulated (miR-126-3p, miR-30a, miR-30d, miR-486-5p, miR-451a, miR-126-5p, miR-143, and miR-145) miRNAs" +tissue_expression_up hsa-mir-205 Lung Neoplasms 29516903 "the authors identified a statistically significant miRNA meta-signature of seven upregulated (miR-21, miR-210, miR-182, miR-31, miR-200b, miR-205, and miR-183) and eight downregulated (miR-126-3p, miR-30a, miR-30d, miR-486-5p, miR-451a, miR-126-5p, miR-143, and miR-145) miRNAs" +tissue_expression_up hsa-mir-21 Lung Neoplasms 29516903 "the authors identified a statistically significant miRNA meta-signature of seven upregulated (miR-21, miR-210, miR-182, miR-31, miR-200b, miR-205, and miR-183) and eight downregulated (miR-126-3p, miR-30a, miR-30d, miR-486-5p, miR-451a, miR-126-5p, miR-143, and miR-145) miRNAs" +tissue_expression_up hsa-mir-210 Lung Neoplasms 29516903 "the authors identified a statistically significant miRNA meta-signature of seven upregulated (miR-21, miR-210, miR-182, miR-31, miR-200b, miR-205, and miR-183) and eight downregulated (miR-126-3p, miR-30a, miR-30d, miR-486-5p, miR-451a, miR-126-5p, miR-143, and miR-145) miRNAs" +tissue_expression_up hsa-mir-31 Lung Neoplasms 29516903 "the authors identified a statistically significant miRNA meta-signature of seven upregulated (miR-21, miR-210, miR-182, miR-31, miR-200b, miR-205, and miR-183) and eight downregulated (miR-126-3p, miR-30a, miR-30d, miR-486-5p, miR-451a, miR-126-5p, miR-143, and miR-145) miRNAs" +tissue_expression_up hsa-mir-141 Ovarian Neoplasms 29518404 "Specifically, miR-196b, miR-532, miR-886-3b, and miR-99b exhibited lower levels in HGOSC compared with USC, whereas miR-29c, miR-155, miR-454, miR-146b-5p, miR-486-5p, miR-27a, miR-192, and miR-141 exhibited significantly higher expression in HGOSC samples" +tissue_expression_up hsa-mir-146b Ovarian Neoplasms 29518404 "Specifically, miR-196b, miR-532, miR-886-3b, and miR-99b exhibited lower levels in HGOSC compared with USC, whereas miR-29c, miR-155, miR-454, miR-146b-5p, miR-486-5p, miR-27a, miR-192, and miR-141 exhibited significantly higher expression in HGOSC samples" +tissue_expression_up hsa-mir-155 Ovarian Neoplasms 29518404 "Specifically, miR-196b, miR-532, miR-886-3b, and miR-99b exhibited lower levels in HGOSC compared with USC, whereas miR-29c, miR-155, miR-454, miR-146b-5p, miR-486-5p, miR-27a, miR-192, and miR-141 exhibited significantly higher expression in HGOSC samples" +tissue_expression_up hsa-mir-192 Ovarian Neoplasms 29518404 "Specifically, miR-196b, miR-532, miR-886-3b, and miR-99b exhibited lower levels in HGOSC compared with USC, whereas miR-29c, miR-155, miR-454, miR-146b-5p, miR-486-5p, miR-27a, miR-192, and miR-141 exhibited significantly higher expression in HGOSC samples" +tissue_expression_up hsa-mir-27a Ovarian Neoplasms 29518404 "Specifically, miR-196b, miR-532, miR-886-3b, and miR-99b exhibited lower levels in HGOSC compared with USC, whereas miR-29c, miR-155, miR-454, miR-146b-5p, miR-486-5p, miR-27a, miR-192, and miR-141 exhibited significantly higher expression in HGOSC samples" +tissue_expression_up hsa-mir-29c Ovarian Neoplasms 29518404 "Specifically, miR-196b, miR-532, miR-886-3b, and miR-99b exhibited lower levels in HGOSC compared with USC, whereas miR-29c, miR-155, miR-454, miR-146b-5p, miR-486-5p, miR-27a, miR-192, and miR-141 exhibited significantly higher expression in HGOSC samples" +tissue_expression_up hsa-mir-454 Ovarian Neoplasms 29518404 "Specifically, miR-196b, miR-532, miR-886-3b, and miR-99b exhibited lower levels in HGOSC compared with USC, whereas miR-29c, miR-155, miR-454, miR-146b-5p, miR-486-5p, miR-27a, miR-192, and miR-141 exhibited significantly higher expression in HGOSC samples" +tissue_expression_up hsa-mir-486 Ovarian Neoplasms 29518404 "Specifically, miR-196b, miR-532, miR-886-3b, and miR-99b exhibited lower levels in HGOSC compared with USC, whereas miR-29c, miR-155, miR-454, miR-146b-5p, miR-486-5p, miR-27a, miR-192, and miR-141 exhibited significantly higher expression in HGOSC samples" +tissue_expression_up hsa-mir-1246 "Squamous Cell Carcinoma, Oral" 29533734 "Poor prognosis correlated with upregulation of 9 miRNAs (miR-21, miR-455-5p, miiR-155-5p, miR-372, miR-373, miR-29b, miR-1246, miR-196a, and miR-181) and downregulation of 7 miRNAs (miR-204, miR-101, miR-32, miR-20a, miR-16, miR-17, and miR-125b)" +tissue_expression_up hsa-mir-155 "Squamous Cell Carcinoma, Oral" 29533734 "Poor prognosis correlated with upregulation of 9 miRNAs (miR-21, miR-455-5p, miiR-155-5p, miR-372, miR-373, miR-29b, miR-1246, miR-196a, and miR-181) and downregulation of 7 miRNAs (miR-204, miR-101, miR-32, miR-20a, miR-16, miR-17, and miR-125b)" +tissue_expression_up hsa-mir-181 "Squamous Cell Carcinoma, Oral" 29533734 "Poor prognosis correlated with upregulation of 9 miRNAs (miR-21, miR-455-5p, miiR-155-5p, miR-372, miR-373, miR-29b, miR-1246, miR-196a, and miR-181) and downregulation of 7 miRNAs (miR-204, miR-101, miR-32, miR-20a, miR-16, miR-17, and miR-125b)" +tissue_expression_up hsa-mir-196a "Squamous Cell Carcinoma, Oral" 29533734 "Poor prognosis correlated with upregulation of 9 miRNAs (miR-21, miR-455-5p, miiR-155-5p, miR-372, miR-373, miR-29b, miR-1246, miR-196a, and miR-181) and downregulation of 7 miRNAs (miR-204, miR-101, miR-32, miR-20a, miR-16, miR-17, and miR-125b)" +tissue_expression_up hsa-mir-21 "Squamous Cell Carcinoma, Oral" 29533734 "Poor prognosis correlated with upregulation of 9 miRNAs (miR-21, miR-455-5p, miiR-155-5p, miR-372, miR-373, miR-29b, miR-1246, miR-196a, and miR-181) and downregulation of 7 miRNAs (miR-204, miR-101, miR-32, miR-20a, miR-16, miR-17, and miR-125b)" +tissue_expression_up hsa-mir-29b "Squamous Cell Carcinoma, Oral" 29533734 "Poor prognosis correlated with upregulation of 9 miRNAs (miR-21, miR-455-5p, miiR-155-5p, miR-372, miR-373, miR-29b, miR-1246, miR-196a, and miR-181) and downregulation of 7 miRNAs (miR-204, miR-101, miR-32, miR-20a, miR-16, miR-17, and miR-125b)" +tissue_expression_up hsa-mir-372 "Squamous Cell Carcinoma, Oral" 29533734 "Poor prognosis correlated with upregulation of 9 miRNAs (miR-21, miR-455-5p, miiR-155-5p, miR-372, miR-373, miR-29b, miR-1246, miR-196a, and miR-181) and downregulation of 7 miRNAs (miR-204, miR-101, miR-32, miR-20a, miR-16, miR-17, and miR-125b)" +tissue_expression_up hsa-mir-373 "Squamous Cell Carcinoma, Oral" 29533734 "Poor prognosis correlated with upregulation of 9 miRNAs (miR-21, miR-455-5p, miiR-155-5p, miR-372, miR-373, miR-29b, miR-1246, miR-196a, and miR-181) and downregulation of 7 miRNAs (miR-204, miR-101, miR-32, miR-20a, miR-16, miR-17, and miR-125b)" +tissue_expression_up hsa-mir-455 "Squamous Cell Carcinoma, Oral" 29533734 "Poor prognosis correlated with upregulation of 9 miRNAs (miR-21, miR-455-5p, miiR-155-5p, miR-372, miR-373, miR-29b, miR-1246, miR-196a, and miR-181) and downregulation of 7 miRNAs (miR-204, miR-101, miR-32, miR-20a, miR-16, miR-17, and miR-125b)" +tissue_expression_up hsa-mir-125b Glioblastoma 29538610 "Upregulation of miR-125b, miR-181d, and miR-221 Predicts Poor Prognosis in MGMT Promoter-Unmethylated Glioblastoma Patients" +tissue_expression_up hsa-mir-181d Glioblastoma 29538610 "Upregulation of miR-125b, miR-181d, and miR-221 Predicts Poor Prognosis in MGMT Promoter-Unmethylated Glioblastoma Patients" +tissue_expression_up hsa-mir-221 Glioblastoma 29538610 "Upregulation of miR-125b, miR-181d, and miR-221 Predicts Poor Prognosis in MGMT Promoter-Unmethylated Glioblastoma Patients" +tissue_expression_up hsa-mir-320 Osteonecrosis 29551500 Upregulation of microRNA-320 decreases the risk of developing steroid-induced avascular necrosis of femoral head by inhibiting CYP1A2 both in vivo and in vitro. +tissue_expression_up hsa-mir-21 Glioblastoma 29559295 "In our microarray data, lower expression of miR-219-5p, miR-124, and miR-128 and higher expression of miR-21 was observed in GBM compared with the peripheral region, similar to the results of previous reports" +tissue_expression_up hsa-mir-155 "Scleroderma, Systemic" 29559981 "miR-21-5p, miR-92a-3p, miR-155-5p, and miR-16-5p expression was significantly higher in SSc sera compared to healthy controls" +tissue_expression_up hsa-mir-16 "Scleroderma, Systemic" 29559981 "miR-21-5p, miR-92a-3p, miR-155-5p, and miR-16-5p expression was significantly higher in SSc sera compared to healthy controls" +tissue_expression_up hsa-mir-21 "Scleroderma, Systemic" 29559981 "miR-21-5p, miR-92a-3p, miR-155-5p, and miR-16-5p expression was significantly higher in SSc sera compared to healthy controls" +tissue_expression_up hsa-mir-92a "Scleroderma, Systemic" 29559981 "miR-21-5p, miR-92a-3p, miR-155-5p, and miR-16-5p expression was significantly higher in SSc sera compared to healthy controls" +tissue_expression_up hsa-mir-127 Prostate Neoplasms 29568403 "The top 11 miRNAs with significantly higher level in ExoHypoxic compared to ExoNormoxic were miR-517a, miR-204, miR-885, miR-143, miR-335, miR-127, miR-542, miR-433, miR-451, miR-92a and miR-186a" +tissue_expression_up hsa-mir-143 Prostate Neoplasms 29568403 "The top 11 miRNAs with significantly higher level in ExoHypoxic compared to ExoNormoxic were miR-517a, miR-204, miR-885, miR-143, miR-335, miR-127, miR-542, miR-433, miR-451, miR-92a and miR-184a" +tissue_expression_up hsa-mir-181a Prostate Neoplasms 29568403 "The top 11 miRNAs with significantly higher level in ExoHypoxic compared to ExoNormoxic were miR-517a, miR-204, miR-885, miR-143, miR-335, miR-127, miR-542, miR-433, miR-451, miR-92a and miR-191a" +tissue_expression_up hsa-mir-204 Prostate Neoplasms 29568403 "The top 11 miRNAs with significantly higher level in ExoHypoxic compared to ExoNormoxic were miR-517a, miR-204, miR-885, miR-143, miR-335, miR-127, miR-542, miR-433, miR-451, miR-92a and miR-182a" +tissue_expression_up hsa-mir-335 Prostate Neoplasms 29568403 "The top 11 miRNAs with significantly higher level in ExoHypoxic compared to ExoNormoxic were miR-517a, miR-204, miR-885, miR-143, miR-335, miR-127, miR-542, miR-433, miR-451, miR-92a and miR-185a" +tissue_expression_up hsa-mir-433 Prostate Neoplasms 29568403 "The top 11 miRNAs with significantly higher level in ExoHypoxic compared to ExoNormoxic were miR-517a, miR-204, miR-885, miR-143, miR-335, miR-127, miR-542, miR-433, miR-451, miR-92a and miR-188a" +tissue_expression_up hsa-mir-451 Prostate Neoplasms 29568403 "The top 11 miRNAs with significantly higher level in ExoHypoxic compared to ExoNormoxic were miR-517a, miR-204, miR-885, miR-143, miR-335, miR-127, miR-542, miR-433, miR-451, miR-92a and miR-189a" +tissue_expression_up hsa-mir-517a Prostate Neoplasms 29568403 "The top 11 miRNAs with significantly higher level in ExoHypoxic compared to ExoNormoxic were miR-517a, miR-204, miR-885, miR-143, miR-335, miR-127, miR-542, miR-433, miR-451, miR-92a and miR-181a" +tissue_expression_up hsa-mir-542 Prostate Neoplasms 29568403 "The top 11 miRNAs with significantly higher level in ExoHypoxic compared to ExoNormoxic were miR-517a, miR-204, miR-885, miR-143, miR-335, miR-127, miR-542, miR-433, miR-451, miR-92a and miR-187a" +tissue_expression_up hsa-mir-885 Prostate Neoplasms 29568403 "The top 11 miRNAs with significantly higher level in ExoHypoxic compared to ExoNormoxic were miR-517a, miR-204, miR-885, miR-143, miR-335, miR-127, miR-542, miR-433, miR-451, miR-92a and miR-183a" +tissue_expression_up hsa-mir-92a Prostate Neoplasms 29568403 "The top 11 miRNAs with significantly higher level in ExoHypoxic compared to ExoNormoxic were miR-517a, miR-204, miR-885, miR-143, miR-335, miR-127, miR-542, miR-433, miR-451, miR-92a and miR-190a" +tissue_expression_up hsa-mir-145 "Carcinoma, Ovarian" 29569698 miRNA-145 expression was lower in DPEEOC endometrial tissues and higher in DPEEOC ovarian tissues compared to the corresponding normal tissues +tissue_expression_up hsa-mir-373 "Squamous Cell Carcinoma, Esophageal" 29578163 "Upregulation of miR-371-373 cluster, a human embryonic stem cell specific microRNA cluster, in esophageal squamous cell carcinoma" +tissue_expression_up hsa-let-7a Pancreatic Neoplasms 29596326 These effects were associated with increases in the expression of let-7a microRNA; suppression of K-Ras and survivin; and the elimination of drug-resistant cancer stem/tumor-initiating cells +tissue_expression_up hsa-mir-20a Breast Neoplasms 29617404 "Our results suggest a role for miR-20a in the regulation of breast cancer angiogenesis, and raise the possibility of its use as an angiogenic biomarker" +tissue_expression_up hsa-mir-10a Urinary System Cancer 29623292 the decline of miR-145 expression level have been proved to be able to distinguish bladder cancer patients from non-cancer controls in cell-free urine samples5; the elevation of miR-10a and miR-30d was also observed in urine samples from patients with focal segmental glomerulosclerosis +tissue_expression_up hsa-mir-30d Urinary System Cancer 29623292 the decline of miR-145 expression level have been proved to be able to distinguish bladder cancer patients from non-cancer controls in cell-free urine samples5; the elevation of miR-10a and miR-30d was also observed in urine samples from patients with focal segmental glomerulosclerosis +tissue_expression_up hsa-mir-155 Atherosclerosis 29642385 Exposure to the high dose of CS also significantly upregulated the miRNA-155 level in the aortic tissues of ApoE KO mice +tissue_expression_up hsa-mir-155 Myocardial Infarction 29642385 Exposure to the high dose of CS also significantly upregulated the miRNA-155 level in the aortic tissues of ApoE KO mice +tissue_expression_up hsa-mir-155 Stroke 29642385 Exposure to the high dose of CS also significantly upregulated the miRNA-155 level in the aortic tissues of ApoE KO mice +tissue_expression_up hsa-mir-21 Atherosclerosis 29642385 "Moreover, the expression level of miR-126 tended to be downregulated and that of miR-21 tended to be upregulated in ApoE KO mice exposed to the high dose of CS, albeit statistically insignificant" +tissue_expression_up hsa-mir-21 Myocardial Infarction 29642385 "Moreover, the expression level of miR-126 tended to be downregulated and that of miR-21 tended to be upregulated in ApoE KO mice exposed to the high dose of CS, albeit statistically insignificant" +tissue_expression_up hsa-mir-21 Stroke 29642385 "Moreover, the expression level of miR-126 tended to be downregulated and that of miR-21 tended to be upregulated in ApoE KO mice exposed to the high dose of CS, albeit statistically insignificant" +tissue_expression_up hsa-mir-101 Medulloblastoma 29658967 "Low-expression of miR-221, miR-9, and miR-181c/d and over-expression of miR-101, miR-222, miR-139, miR-1827, and miR-34c was found in medulloblastoma" +tissue_expression_up hsa-mir-10b Ependymoma 29658967 low expression of miR-10a and over-expression of miR-10b and miR-29a in ependymoma +tissue_expression_up hsa-mir-139 Medulloblastoma 29658967 "Low-expression of miR-221, miR-9, and miR-181c/d and over-expression of miR-101, miR-222, miR-139, miR-1827, and miR-34c was found in medulloblastoma" +tissue_expression_up hsa-mir-1827 Medulloblastoma 29658967 "Low-expression of miR-221, miR-9, and miR-181c/d and over-expression of miR-101, miR-222, miR-139, miR-1827, and miR-34c was found in medulloblastoma" +tissue_expression_up hsa-mir-19a Glioma 29658967 "low expression of miR-26a and overexpression of miR-19a/b, miR-24, miR-27a, miR- 584, and miR-528 in low-grade glioma" +tissue_expression_up hsa-mir-19b Glioma 29658967 "low expression of miR-26a and overexpression of miR-19a/b, miR-24, miR-27a, miR- 584, and miR-529 in low-grade glioma" +tissue_expression_up hsa-mir-222 Medulloblastoma 29658967 "Low-expression of miR-221, miR-9, and miR-181c/d and over-expression of miR-101, miR-222, miR-139, miR-1827, and miR-34c was found in medulloblastoma" +tissue_expression_up hsa-mir-24 Glioma 29658967 "low expression of miR-26a and overexpression of miR-19a/b, miR-24, miR-27a, miR- 584, and miR-530 in low-grade glioma" +tissue_expression_up hsa-mir-27a Glioma 29658967 "low expression of miR-26a and overexpression of miR-19a/b, miR-24, miR-27a, miR- 584, and miR-531 in low-grade glioma" +tissue_expression_up hsa-mir-29a Ependymoma 29658967 low expression of miR-10a and over-expression of miR-10b and miR-29a in ependymoma +tissue_expression_up hsa-mir-34c Medulloblastoma 29658967 "Low-expression of miR-221, miR-9, and miR-181c/d and over-expression of miR-101, miR-222, miR-139, miR-1827, and miR-34c was found in medulloblastoma" +tissue_expression_up hsa-mir-527 Glioma 29658967 "low expression of miR-26a and overexpression of miR-19a/b, miR-24, miR-27a, miR- 584, and miR-533 in low-grade glioma" +tissue_expression_up hsa-mir-584 Glioma 29658967 "low expression of miR-26a and overexpression of miR-19a/b, miR-24, miR-27a, miR- 584, and miR-532 in low-grade glioma" +tissue_expression_up hsa-mir-155 Down Syndrome 29661714 microRNA 155 up regulation in the CNS is strongly correlated to Down's syndrome dementia. +tissue_expression_up hsa-mir-124 Non Specific Chronic Endometritis 29663566 "MiR-27a-3p and miR-124-3p, upregulated in endometrium and serum from women affected by Chronic Endometritis, are new potential molecular markers of endometrial receptivity." +tissue_expression_up hsa-mir-27a Non Specific Chronic Endometritis 29663566 "MiR-27a-3p and miR-124-3p, upregulated in endometrium and serum from women affected by Chronic Endometritis, are new potential molecular markers of endometrial receptivity." +tissue_expression_up hsa-mir-125b "Squamous Cell Carcinoma, Head and Neck" 29667275 "miR-26 and miR-125b may be associated with the progression and metastasis of HNSCC, and that miR-203 is associated with a more favourable prognosis." +tissue_expression_up hsa-mir-26 "Squamous Cell Carcinoma, Head and Neck" 29667275 "miR-26 and miR-125b may be associated with the progression and metastasis of HNSCC, and that miR-203 is associated with a more favourable prognosis." +tissue_expression_up hsa-mir-375 "Carcinoma, Thyroid, Follicular" 29683529 High expression values of MirR-375 provided 100% ROM +tissue_expression_up hsa-mir-133a "Carcinoma, Breast" 29698983 high responders exhibited increased miR-133a-3p and a borderline statistically significant increase in miR-370-3p +tissue_expression_up hsa-mir-370a "Carcinoma, Breast" 29698983 high responders exhibited increased miR-133a-3p and a borderline statistically significant increase in miR-370-3p +tissue_expression_up hsa-mir-18a Osteonecrosis 29700584 Bioinformatics genetic network analysis focusing on the six miRNAs found the upregulated miR-18a and miR-19a are associated with angiogenesis after induction of ischemia +tissue_expression_up hsa-mir-19a Osteonecrosis 29700584 Bioinformatics genetic network analysis focusing on the six miRNAs found the upregulated miR-18a and miR-19a are associated with angiogenesis after induction of ischemia +tissue_expression_up hsa-mir-21 "Adenocarcinoma, Ampullary" 29731265 MiR-21 up-regulation in ampullary adenocarcinoma and its pre-invasive lesions. +tissue_expression_up hsa-mir-467d Alcoholic Cardiomyopathy 29734191 The results demonstrated that miR-467d-3p and miR-491-5p were up-regulated and miR-3098-3p was down-regulated in the alcohol-exposed myocardial samples compared with the control samples (P < 0.05). +tissue_expression_up hsa-mir-491 Alcoholic Cardiomyopathy 29734191 The results demonstrated that miR-467d-3p and miR-491-5p were up-regulated and miR-3098-3p was down-regulated in the alcohol-exposed myocardial samples compared with the control samples (P < 0.05). +tissue_expression_up hsa-mir-223 "Carcinoma, Cervical" 29737570 the low expression of miR-188 and high expression of miR-223 correlated with the short survival of CC patients +tissue_expression_up hsa-mir-92b Cholangiocarcinoma 29749758 The high level of miR-92b was associated with adverse outcomes in cholangiocarcinoma patients +tissue_expression_up hsa-mir-203 "Carcinoma, Breast" 29750301 Sevoflurane suppresses proliferation by upregulating microRNA-203 in breast cancer cells. +tissue_expression_up hsa-mir-140 Fatty Liver [unspecific] 29751019 "the expression of Rev-erb¦Á-targeting miRNAs, miR-140-5p, 185-5p, 326-5p and 328-5p were increased in this group." +tissue_expression_up hsa-mir-185 Fatty Liver [unspecific] 29751019 "the expression of Rev-erb¦Á-targeting miRNAs, miR-140-5p, 185-5p, 326-5p and 328-5p were increased in this group." +tissue_expression_up hsa-mir-326 Fatty Liver [unspecific] 29751019 "the expression of Rev-erb¦Á-targeting miRNAs, miR-140-5p, 185-5p, 326-5p and 328-5p were increased in this group." +tissue_expression_up hsa-mir-328 Fatty Liver [unspecific] 29751019 "the expression of Rev-erb¦Á-targeting miRNAs, miR-140-5p, 185-5p, 326-5p and 328-5p were increased in this group." +tissue_expression_up hsa-mir-139 Chronic Obstructive Pulmonary Disease 29757677 "expression levels of miR-98, miR-139-5p, miR-146b-5p, and miR-451 were upregulated, as compared with NS. In contrast, miR-197, miR-204, miR-485-3p, and miR-627 were downregulated." +tissue_expression_up hsa-mir-146b Chronic Obstructive Pulmonary Disease 29757677 "expression levels of miR-98, miR-139-5p, miR-146b-5p, and miR-451 were upregulated, as compared with NS. In contrast, miR-197, miR-204, miR-485-3p, and miR-627 were downregulated." +tissue_expression_up hsa-mir-451 Chronic Obstructive Pulmonary Disease 29757677 "expression levels of miR-98, miR-139-5p, miR-146b-5p, and miR-451 were upregulated, as compared with NS. In contrast, miR-197, miR-204, miR-485-3p, and miR-627 were downregulated." +tissue_expression_up hsa-mir-98 Chronic Obstructive Pulmonary Disease 29757677 "expression levels of miR-98, miR-139-5p, miR-146b-5p, and miR-451 were upregulated, as compared with NS. In contrast, miR-197, miR-204, miR-485-3p, and miR-627 were downregulated." +tissue_expression_up hsa-mir-21 "Squamous Cell Carcinoma, Oral" 29764807 "Upregulation of miR-31 and miR-21 and downregulation of miR-99a, let-7c, miR-125b, and miR-100 were found between OSCC and controls" +tissue_expression_up hsa-mir-31 "Squamous Cell Carcinoma, Oral" 29764807 "Upregulation of miR-31 and miR-21 and downregulation of miR-99a, let-7c, miR-125b, and miR-100 were found between OSCC and controls" +tissue_expression_up hsa-mir-3666 Colorectal Carcinoma 29772445 The protective role of all-transretinoic acid (ATRA) against colorectal cancer development is achieved via increasing miR-3666 expression and decreasing E2F7 expression. +tissue_expression_up hsa-mir-19 Gastric Neoplasms 29797599 "Our data showed that miR-146, miR-375, and Let-7 were down-regulated and miR-19 and miR-21 were up-regulated in GC patients with H. pylori infection" +tissue_expression_up hsa-mir-21 Gastric Neoplasms 29797599 "Our data showed that miR-146, miR-375, and Let-7 were down-regulated and miR-19 and miR-21 were up-regulated in GC patients with H. pylori infection" +tissue_expression_up hsa-mir-451 Placenta Cancer 29805755 "The results showed that miR-451 and miR-720, highly expressed placental miRNAs, presented very low or undetectable expression in cancer cell lines compared to the normal placenta and healthy tissues" +tissue_expression_up hsa-mir-720 Placenta Cancer 29805755 "The results showed that miR-451 and miR-720, highly expressed placental miRNAs, presented very low or undetectable expression in cancer cell lines compared to the normal placenta and healthy tissues" +tissue_expression_up hsa-let-7a "Adenocarcinoma, Lung" 29806739 miR-126 (P < 0.001) and Let-7a (P = 0.015) levels were significantly higher in the BAL fluid of lung adenocarcinoma patients than in control subjects +tissue_expression_up hsa-mir-126 "Adenocarcinoma, Lung" 29806739 miR-126 (P < 0.001) and Let-7a (P = 0.015) levels were significantly higher in the BAL fluid of lung adenocarcinoma patients than in control subjects +tissue_expression_up hsa-mir-324 Lung Neoplasms 29844840 The data revealed that miR-324-5p and -3p were significantly overexpressed in lung cancer cells +tissue_expression_up hsa-mir-106b Gastric Neoplasms 29859516 "Up-Regulation of miR-21, miR-25, miR-93, and miR-106b in Gastric Cancer" +tissue_expression_up hsa-mir-21 Gastric Neoplasms 29859516 "Up-Regulation of miR-21, miR-25, miR-93, and miR-106b in Gastric Cancer" +tissue_expression_up hsa-mir-25 Gastric Neoplasms 29859516 "Up-Regulation of miR-21, miR-25, miR-93, and miR-106b in Gastric Cancer" +tissue_expression_up hsa-mir-93 Gastric Neoplasms 29859516 "Up-Regulation of miR-21, miR-25, miR-93, and miR-106b in Gastric Cancer" +tissue_expression_up hsa-mir-17 Colorectal Carcinoma 29902577 Early metastatic colorectal cancers show increased tissue expression of miR-17/92 cluster members in the invasive tumor front. +tissue_expression_up hsa-mir-18 Colorectal Carcinoma 29902577 Early metastatic colorectal cancers show increased tissue expression of miR-17/92 cluster members in the invasive tumor front. +tissue_expression_up hsa-mir-19a Colorectal Carcinoma 29902577 Early metastatic colorectal cancers show increased tissue expression of miR-17/92 cluster members in the invasive tumor front. +tissue_expression_up hsa-mir-19b-1 Colorectal Carcinoma 29902577 Early metastatic colorectal cancers show increased tissue expression of miR-17/92 cluster members in the invasive tumor front. +tissue_expression_up hsa-mir-20a Colorectal Carcinoma 29902577 Early metastatic colorectal cancers show increased tissue expression of miR-17/92 cluster members in the invasive tumor front. +tissue_expression_up hsa-mir-92-1 Colorectal Carcinoma 29902577 Early metastatic colorectal cancers show increased tissue expression of miR-17/92 cluster members in the invasive tumor front. +tissue_expression_up hsa-mir-192 Barrett Esophagus 29906417 "The miRNAs with the greatest increases in BE tissues (7.9-fold increase in expression or more, P < .0001: MIR196a, MIR192, MIR194, and MIR215) each identified BE vs control tissues" +tissue_expression_up hsa-mir-194 Barrett Esophagus 29906417 "The miRNAs with the greatest increases in BE tissues (7.9-fold increase in expression or more, P < .0001: MIR196a, MIR192, MIR194, and MIR215) each identified BE vs control tissues" +tissue_expression_up hsa-mir-196a Barrett Esophagus 29906417 "The miRNAs with the greatest increases in BE tissues (7.9-fold increase in expression or more, P < .0001: MIR196a, MIR192, MIR194, and MIR215) each identified BE vs control tissues" +tissue_expression_up hsa-mir-215 Barrett Esophagus 29906417 "The miRNAs with the greatest increases in BE tissues (7.9-fold increase in expression or more, P < .0001: MIR196a, MIR192, MIR194, and MIR215) each identified BE vs control tissues" +tissue_expression_up hsa-mir-142 Chronic Kidney Disease 29909697 "We recognized in both meta-analysis approaches a significant miRNA meta-signature of five up-regulated (miR-142-3p, miR-223-3p, miR-21-5p, miR-142-5p and miR-214-3p) and two down-regulated (miR-29c-3p and miR-200a-3p) miRNAs" +tissue_expression_up hsa-mir-21 Chronic Kidney Disease 29909697 "We recognized in both meta-analysis approaches a significant miRNA meta-signature of five up-regulated (miR-142-3p, miR-223-3p, miR-21-5p, miR-142-5p and miR-214-3p) and two down-regulated (miR-29c-3p and miR-200a-3p) miRNAs" +tissue_expression_up hsa-mir-214 Chronic Kidney Disease 29909697 "We recognized in both meta-analysis approaches a significant miRNA meta-signature of five up-regulated (miR-142-3p, miR-223-3p, miR-21-5p, miR-142-5p and miR-214-3p) and two down-regulated (miR-29c-3p and miR-200a-3p) miRNAs" +tissue_expression_up hsa-mir-223 Chronic Kidney Disease 29909697 "We recognized in both meta-analysis approaches a significant miRNA meta-signature of five up-regulated (miR-142-3p, miR-223-3p, miR-21-5p, miR-142-5p and miR-214-3p) and two down-regulated (miR-29c-3p and miR-200a-3p) miRNAs" +tissue_expression_up hsa-mir-10b "Carcinoma, Breast, Triple Negative" 29923083 "(1) upregulated: miR-10b, miR-21, miR-29, miR-9, miR-221/222, miR-373 or (2) downregulated: miR-145, miR-199a-5p, miR-200 family, miR-203, miR-205 in TNBC" +tissue_expression_up hsa-mir-21 "Carcinoma, Breast, Triple Negative" 29923083 "(1) upregulated: miR-10b, miR-21, miR-29, miR-9, miR-221/222, miR-373 or (2) downregulated: miR-145, miR-199a-5p, miR-200 family, miR-203, miR-205 in TNBC" +tissue_expression_up hsa-mir-221 "Carcinoma, Breast, Triple Negative" 29923083 "(1) upregulated: miR-10b, miR-21, miR-29, miR-9, miR-221/222, miR-373 or (2) downregulated: miR-145, miR-199a-5p, miR-200 family, miR-203, miR-205 in TNBC" +tissue_expression_up hsa-mir-222 "Carcinoma, Breast, Triple Negative" 29923083 "(1) upregulated: miR-10b, miR-21, miR-29, miR-9, miR-221/222, miR-373 or (2) downregulated: miR-145, miR-199a-5p, miR-200 family, miR-203, miR-205 in TNBC" +tissue_expression_up hsa-mir-29 "Carcinoma, Breast, Triple Negative" 29923083 "(1) upregulated: miR-10b, miR-21, miR-29, miR-9, miR-221/222, miR-373 or (2) downregulated: miR-145, miR-199a-5p, miR-200 family, miR-203, miR-205 in TNBC" +tissue_expression_up hsa-mir-373 "Carcinoma, Breast, Triple Negative" 29923083 "(1) upregulated: miR-10b, miR-21, miR-29, miR-9, miR-221/222, miR-373 or (2) downregulated: miR-145, miR-199a-5p, miR-200 family, miR-203, miR-205 in TNBC" +tissue_expression_up hsa-mir-9 "Carcinoma, Breast, Triple Negative" 29923083 "(1) upregulated: miR-10b, miR-21, miR-29, miR-9, miR-221/222, miR-373 or (2) downregulated: miR-145, miR-199a-5p, miR-200 family, miR-203, miR-205 in TNBC" +tissue_expression_up hsa-mir-210 Neuroendocrine Tumors 29983867 "NEN metastases were associated with elevated levels of miR-30a-5p, miR-210, miR-339-3p, miR-345 and miR-660" +tissue_expression_up hsa-mir-30a Neuroendocrine Tumors 29983867 "NEN metastases were associated with elevated levels of miR-30a-5p, miR-210, miR-339-3p, miR-345 and miR-660" +tissue_expression_up hsa-mir-339 Neuroendocrine Tumors 29983867 "NEN metastases were associated with elevated levels of miR-30a-5p, miR-210, miR-339-3p, miR-345 and miR-660" +tissue_expression_up hsa-mir-345 Neuroendocrine Tumors 29983867 "NEN metastases were associated with elevated levels of miR-30a-5p, miR-210, miR-339-3p, miR-345 and miR-660" +tissue_expression_up hsa-mir-660 Neuroendocrine Tumors 29983867 "NEN metastases were associated with elevated levels of miR-30a-5p, miR-210, miR-339-3p, miR-345 and miR-660" +tissue_expression_up hsa-mir-146b Glioblastoma 30018734 The immune-related microRNA miR-146b is upregulated in glioblastoma recurrence. +tissue_expression_up hsa-mir-21 Lung Neoplasms 30030592 Overview upon miR-21 in lung cancer: focus on NSCLC. +tissue_expression_up hsa-mir-192 "Carcinoma, Ovarian" 30038317 The microRNA miR-192/215 family is upregulated in mucinous ovarian carcinomas. +tissue_expression_up hsa-mir-215 "Carcinoma, Ovarian" 30038317 The microRNA miR-192/215 family is upregulated in mucinous ovarian carcinomas. +tissue_expression_up hsa-mir-126 Cholangiocarcinoma 30042823 "High miR-126, low miR-128 and TEMs were independent prognostic factors for recurrence-free and overall survival" +tissue_expression_up hsa-mir-515 "Carcinoma, Hepatocellular" 30052636 "HCC had significantly higher expression of members of the chromosome 19 miRNA cluster (C19MC), including miR-515-5p, miR-517a, miR-518b, and miR-520c-3p" +tissue_expression_up hsa-mir-517a "Carcinoma, Hepatocellular" 30052636 "HCC had significantly higher expression of members of the chromosome 19 miRNA cluster (C19MC), including miR-515-5p, miR-517a, miR-518b, and miR-520c-3p" +tissue_expression_up hsa-mir-518b "Carcinoma, Hepatocellular" 30052636 "HCC had significantly higher expression of members of the chromosome 19 miRNA cluster (C19MC), including miR-515-5p, miR-517a, miR-518b, and miR-520c-3p" +tissue_expression_up hsa-mir-520c "Carcinoma, Hepatocellular" 30052636 "HCC had significantly higher expression of members of the chromosome 19 miRNA cluster (C19MC), including miR-515-5p, miR-517a, miR-518b, and miR-520c-3p" +tissue_expression_up hsa-mir-372 "Adenocarcinoma, Lung" 30066858 "the predicted miRNA, miR-372-3p, exhibited a high expression in both the NSCLC and LUAD tissues" +tissue_expression_up hsa-mir-372 "Carcinoma, Lung, Non-Small-Cell" 30066858 "the predicted miRNA, miR-372-3p, exhibited a high expression in both the NSCLC and LUAD tissues" +tissue_expression_up hsa-mir-141 Neoplasms [unspecific] 30069274 Correlation between miR-200 Family Overexpression and Cancer Prognosis. +tissue_expression_up hsa-mir-200a Neoplasms [unspecific] 30069274 Correlation between miR-200 Family Overexpression and Cancer Prognosis. +tissue_expression_up hsa-mir-200b Neoplasms [unspecific] 30069274 Correlation between miR-200 Family Overexpression and Cancer Prognosis. +tissue_expression_up hsa-mir-200c Neoplasms [unspecific] 30069274 Correlation between miR-200 Family Overexpression and Cancer Prognosis. +tissue_expression_up hsa-mir-429 Neoplasms [unspecific] 30069274 Correlation between miR-200 Family Overexpression and Cancer Prognosis. +tissue_expression_up hsa-mir-152 "Carcinoma, Adenoid Cystic" 30069755 "qPCR identified high expression of hsa-mir-21, hsa-mir-181a-2, and hsa-mir-152 to be associated with reduced OS and high expression of hsa-miR-374c to be associated with improved RFS" +tissue_expression_up hsa-mir-181a "Carcinoma, Adenoid Cystic" 30069755 "qPCR identified high expression of hsa-mir-21, hsa-mir-181a-2, and hsa-mir-152 to be associated with reduced OS and high expression of hsa-miR-374c to be associated with improved RFS" +tissue_expression_up hsa-mir-21 "Carcinoma, Adenoid Cystic" 30069755 "qPCR identified high expression of hsa-mir-21, hsa-mir-181a-2, and hsa-mir-152 to be associated with reduced OS and high expression of hsa-miR-374c to be associated with improved RFS" +tissue_expression_up hsa-mir-374c "Carcinoma, Adenoid Cystic" 30069755 "qPCR identified high expression of hsa-mir-21, hsa-mir-181a-2, and hsa-mir-152 to be associated with reduced OS and high expression of hsa-miR-374c to be associated with improved RFS" +tissue_expression_up hsa-mir-122 Liver Injury 30087537 "In liver injury, the levels of miR-122-5p, miR-192-5p, miR-223-3p, and miR-1224-5p were reported to be elevated in the sera" +tissue_expression_up hsa-mir-1224 Liver Injury 30087537 "In liver injury, the levels of miR-122-5p, miR-192-5p, miR-223-3p, and miR-1224-5p were reported to be elevated in the sera" +tissue_expression_up hsa-mir-192 Liver Injury 30087537 "In liver injury, the levels of miR-122-5p, miR-192-5p, miR-223-3p, and miR-1224-5p were reported to be elevated in the sera" +tissue_expression_up hsa-mir-223 Liver Injury 30087537 "In liver injury, the levels of miR-122-5p, miR-192-5p, miR-223-3p, and miR-1224-5p were reported to be elevated in the sera" +tissue_expression_up hsa-mir-112 Astrocytoma 30090984 "we found the upregulation of miR-210-3p, miR-155-5p, miR-UL-112-3p, miR-183-5p, and miR-223-5p in high-grade astrocytic tumors as compared with low-grade tumor tissues" +tissue_expression_up hsa-mir-155 Astrocytoma 30090984 "we found the upregulation of miR-210-3p, miR-155-5p, miR-UL-112-3p, miR-183-5p, and miR-223-5p in high-grade astrocytic tumors as compared with low-grade tumor tissues" +tissue_expression_up hsa-mir-183 Astrocytoma 30090984 "we found the upregulation of miR-210-3p, miR-155-5p, miR-UL-112-3p, miR-183-5p, and miR-223-5p in high-grade astrocytic tumors as compared with low-grade tumor tissues" +tissue_expression_up hsa-mir-210 Astrocytoma 30090984 "we found the upregulation of miR-210-3p, miR-155-5p, miR-UL-112-3p, miR-183-5p, and miR-223-5p in high-grade astrocytic tumors as compared with low-grade tumor tissues" +tissue_expression_up hsa-mir-223 Astrocytoma 30090984 "we found the upregulation of miR-210-3p, miR-155-5p, miR-UL-112-3p, miR-183-5p, and miR-223-5p in high-grade astrocytic tumors as compared with low-grade tumor tissues" +tissue_expression_up hsa-mir-100 Ovarian Neoplasms 30107086 "We report that miR-21 (P?=?0.0001), miR-100 (P?=?0.034), miR-200b (P?=?0.008), and miR-320 (P?=?0.034) are significantly enriched, whereas miR-16 (P?=?0.009), miR-93 (P?=?0.014), miR-126 (P?=?0.012), and miR-223 (P?=?0.029) are underrepresented in exosomes from plasma of EOC patients as compared to those of healthy women. The levels of exosomal miR-23a (P?=?0.009, 0.008) and miR-92a (P?=?009, 0.034) were lower in ovarian cystadenoma patients than in EOC patients and healthy women, respectively" +tissue_expression_up hsa-mir-200b Ovarian Neoplasms 30107086 "We report that miR-21 (P?=?0.0001), miR-100 (P?=?0.034), miR-200b (P?=?0.008), and miR-320 (P?=?0.034) are significantly enriched, whereas miR-16 (P?=?0.009), miR-93 (P?=?0.014), miR-126 (P?=?0.012), and miR-223 (P?=?0.029) are underrepresented in exosomes from plasma of EOC patients as compared to those of healthy women. The levels of exosomal miR-23a (P?=?0.009, 0.008) and miR-92a (P?=?009, 0.034) were lower in ovarian cystadenoma patients than in EOC patients and healthy women, respectively" +tissue_expression_up hsa-mir-21 Ovarian Neoplasms 30107086 "We report that miR-21 (P?=?0.0001), miR-100 (P?=?0.034), miR-200b (P?=?0.008), and miR-320 (P?=?0.034) are significantly enriched, whereas miR-16 (P?=?0.009), miR-93 (P?=?0.014), miR-126 (P?=?0.012), and miR-223 (P?=?0.029) are underrepresented in exosomes from plasma of EOC patients as compared to those of healthy women. The levels of exosomal miR-23a (P?=?0.009, 0.008) and miR-92a (P?=?009, 0.034) were lower in ovarian cystadenoma patients than in EOC patients and healthy women, respectively" +tissue_expression_up hsa-mir-320 Ovarian Neoplasms 30107086 "We report that miR-21 (P?=?0.0001), miR-100 (P?=?0.034), miR-200b (P?=?0.008), and miR-320 (P?=?0.034) are significantly enriched, whereas miR-16 (P?=?0.009), miR-93 (P?=?0.014), miR-126 (P?=?0.012), and miR-223 (P?=?0.029) are underrepresented in exosomes from plasma of EOC patients as compared to those of healthy women. The levels of exosomal miR-23a (P?=?0.009, 0.008) and miR-92a (P?=?009, 0.034) were lower in ovarian cystadenoma patients than in EOC patients and healthy women, respectively" +tissue_expression_up hsa-mir-210 Prostate Neoplasms 30109809 The upregulation of hypoxia-related miRNA 210 in primary tumor of lymphogenic metastatic prostate cancer. +tissue_expression_up hsa-mir-1 "Carcinoma, Lung, Non-Small-Cell" 30114862 "MiR-1, miR-124, and miR-196a are overexpressed in EGFR T790M mutated NSCLC" +tissue_expression_up hsa-mir-124 "Carcinoma, Lung, Non-Small-Cell" 30114862 "MiR-1, miR-124, and miR-196a are overexpressed in EGFR T790M mutated NSCLC" +tissue_expression_up hsa-mir-196a "Carcinoma, Lung, Non-Small-Cell" 30114862 "MiR-1, miR-124, and miR-196a are overexpressed in EGFR T790M mutated NSCLC" +tissue_expression_up hsa-mir-195 Chronic Obstructive Pulmonary Disease 30115538 "FGFR1 was also a predicted target for some up-regulated miRNAs in COPD bronchial epithelial cells, including hsa-miR-195-5p, hsa-miR-424-5p, and hsa-miR-6724-5p" +tissue_expression_up hsa-mir-424 Chronic Obstructive Pulmonary Disease 30115538 "FGFR1 was also a predicted target for some up-regulated miRNAs in COPD bronchial epithelial cells, including hsa-miR-195-5p, hsa-miR-424-5p, and hsa-miR-6724-5p" +tissue_expression_up hsa-mir-6724 Chronic Obstructive Pulmonary Disease 30115538 "FGFR1 was also a predicted target for some up-regulated miRNAs in COPD bronchial epithelial cells, including hsa-miR-195-5p, hsa-miR-424-5p, and hsa-miR-6724-5p" +tissue_expression_up hsa-mir-125a Colon Neoplasms 30127618 "seven miRNAs (hsa-miR-920, hsa-miR-636, hsa-miR-766-3p, hsa-miR-545-5p, hsa-miR-195-3p, hsa-miR-125a-3p, and hsa-miR-196b-3p) were found to be upregulated and six miRNAs (hsa-miR-3613-3p, hsa-miR-29b-3p, hsa-miR-1297, hsa-miR-141-5p, hsa-miR-200c-3p, and hsa-miR-141-3p) were found to be downregulated" +tissue_expression_up hsa-mir-195 Colon Neoplasms 30127618 "seven miRNAs (hsa-miR-920, hsa-miR-636, hsa-miR-766-3p, hsa-miR-545-5p, hsa-miR-195-3p, hsa-miR-125a-3p, and hsa-miR-196b-3p) were found to be upregulated and six miRNAs (hsa-miR-3613-3p, hsa-miR-29b-3p, hsa-miR-1297, hsa-miR-141-5p, hsa-miR-200c-3p, and hsa-miR-141-3p) were found to be downregulated" +tissue_expression_up hsa-mir-196b Colon Neoplasms 30127618 "seven miRNAs (hsa-miR-920, hsa-miR-636, hsa-miR-766-3p, hsa-miR-545-5p, hsa-miR-195-3p, hsa-miR-125a-3p, and hsa-miR-196b-3p) were found to be upregulated and six miRNAs (hsa-miR-3613-3p, hsa-miR-29b-3p, hsa-miR-1297, hsa-miR-141-5p, hsa-miR-200c-3p, and hsa-miR-141-3p) were found to be downregulated" +tissue_expression_up hsa-mir-545 Colon Neoplasms 30127618 "seven miRNAs (hsa-miR-920, hsa-miR-636, hsa-miR-766-3p, hsa-miR-545-5p, hsa-miR-195-3p, hsa-miR-125a-3p, and hsa-miR-196b-3p) were found to be upregulated and six miRNAs (hsa-miR-3613-3p, hsa-miR-29b-3p, hsa-miR-1297, hsa-miR-141-5p, hsa-miR-200c-3p, and hsa-miR-141-3p) were found to be downregulated" +tissue_expression_up hsa-mir-636 Colon Neoplasms 30127618 "seven miRNAs (hsa-miR-920, hsa-miR-636, hsa-miR-766-3p, hsa-miR-545-5p, hsa-miR-195-3p, hsa-miR-125a-3p, and hsa-miR-196b-3p) were found to be upregulated and six miRNAs (hsa-miR-3613-3p, hsa-miR-29b-3p, hsa-miR-1297, hsa-miR-141-5p, hsa-miR-200c-3p, and hsa-miR-141-3p) were found to be downregulated" +tissue_expression_up hsa-mir-766 Colon Neoplasms 30127618 "seven miRNAs (hsa-miR-920, hsa-miR-636, hsa-miR-766-3p, hsa-miR-545-5p, hsa-miR-195-3p, hsa-miR-125a-3p, and hsa-miR-196b-3p) were found to be upregulated and six miRNAs (hsa-miR-3613-3p, hsa-miR-29b-3p, hsa-miR-1297, hsa-miR-141-5p, hsa-miR-200c-3p, and hsa-miR-141-3p) were found to be downregulated" +tissue_expression_up hsa-mir-920 Colon Neoplasms 30127618 "seven miRNAs (hsa-miR-920, hsa-miR-636, hsa-miR-766-3p, hsa-miR-545-5p, hsa-miR-195-3p, hsa-miR-125a-3p, and hsa-miR-196b-3p) were found to be upregulated and six miRNAs (hsa-miR-3613-3p, hsa-miR-29b-3p, hsa-miR-1297, hsa-miR-141-5p, hsa-miR-200c-3p, and hsa-miR-141-3p) were found to be downregulated" +tissue_expression_up hsa-mir-1225 Laryngeal Neoplasms 30138106 MicroRNA-1225-5p acts as a tumor-suppressor in laryngeal cancer via targeting CDC14B. +tissue_expression_up hsa-mir-421 "Carcinoma, Lung, Non-Small-Cell" 30147363 Upregulated expression of miR-421 is associated with poor prognosis in non-small-cell lung cancer. +tissue_expression_up hsa-mir-15b Uterine Leiomyoma 30149651 "The relative expression level of miR-15b was upregulated, and the relative expression levels of miR-29a, -29b, -29c, -197, and -200c were downregulated in UL cells compared to those in UM cells" +tissue_expression_up hsa-mir-223 Amyotrophic Lateral Sclerosis 30154826 Wide-Ranging Analysis of MicroRNA Profiles in Sporadic Amyotrophic Lateral Sclerosis Using Next-Generation Sequencing. +tissue_expression_up hsa-mir-336 Amyotrophic Lateral Sclerosis 30154826 Wide-Ranging Analysis of MicroRNA Profiles in Sporadic Amyotrophic Lateral Sclerosis Using Next-Generation Sequencing. +tissue_expression_up hsa-mir-510 Fragile X Syndrome 30160796 High expression of miR-510 was associated with CGG expansion located at upstream of FMR1 into full mutation. +tissue_expression_up hsa-mir-141 Cholangiocarcinoma 30165035 "the hsa-miR-205-5p and miR-200 family members were markedly up-regulated for 600-1500 folds, whereas the miR-199 family members and their clustered miRNA, hsa-miR-214-3p, were down-regulated for 1000-2000 folds" +tissue_expression_up hsa-mir-200a Cholangiocarcinoma 30165035 "the hsa-miR-205-5p and miR-200 family members were markedly up-regulated for 600-1500 folds, whereas the miR-199 family members and their clustered miRNA, hsa-miR-214-3p, were down-regulated for 1000-2000 folds" +tissue_expression_up hsa-mir-200b Cholangiocarcinoma 30165035 "the hsa-miR-205-5p and miR-200 family members were markedly up-regulated for 600-1500 folds, whereas the miR-199 family members and their clustered miRNA, hsa-miR-214-3p, were down-regulated for 1000-2000 folds" +tissue_expression_up hsa-mir-200c Cholangiocarcinoma 30165035 "the hsa-miR-205-5p and miR-200 family members were markedly up-regulated for 600-1500 folds, whereas the miR-199 family members and their clustered miRNA, hsa-miR-214-3p, were down-regulated for 1000-2000 folds" +tissue_expression_up hsa-mir-205 Cholangiocarcinoma 30165035 "the hsa-miR-205-5p and miR-200 family members were markedly up-regulated for 600-1500 folds, whereas the miR-199 family members and their clustered miRNA, hsa-miR-214-3p, were down-regulated for 1000-2000 folds" +tissue_expression_up hsa-mir-429 Cholangiocarcinoma 30165035 "the hsa-miR-205-5p and miR-200 family members were markedly up-regulated for 600-1500 folds, whereas the miR-199 family members and their clustered miRNA, hsa-miR-214-3p, were down-regulated for 1000-2000 folds" +tissue_expression_up hsa-let-7i Traumatic Brain Injury 30177873 "no significant variations of the 65 inflammatory proteins detected in saliva between groups but 5 microRNAs, miR-27b-3p (p = 0.016), let-7i-5p (p = 0.001), miR-142-3p(p = 0.008), miR-107 (p = 0.028), miR-135b-5p (p = 0.017) significantly upregulated in concussed athletes" +tissue_expression_up hsa-mir-107 Traumatic Brain Injury 30177873 "no significant variations of the 65 inflammatory proteins detected in saliva between groups but 5 microRNAs, miR-27b-3p (p = 0.016), let-7i-5p (p = 0.001), miR-142-3p(p = 0.008), miR-107 (p = 0.028), miR-135b-5p (p = 0.017) significantly upregulated in concussed athletes" +tissue_expression_up hsa-mir-135b Traumatic Brain Injury 30177873 "no significant variations of the 65 inflammatory proteins detected in saliva between groups but 5 microRNAs, miR-27b-3p (p = 0.016), let-7i-5p (p = 0.001), miR-142-3p(p = 0.008), miR-107 (p = 0.028), miR-135b-5p (p = 0.017) significantly upregulated in concussed athletes" +tissue_expression_up hsa-mir-142 Traumatic Brain Injury 30177873 "no significant variations of the 65 inflammatory proteins detected in saliva between groups but 5 microRNAs, miR-27b-3p (p = 0.016), let-7i-5p (p = 0.001), miR-142-3p(p = 0.008), miR-107 (p = 0.028), miR-135b-5p (p = 0.017) significantly upregulated in concussed athletes" +tissue_expression_up hsa-mir-27b Traumatic Brain Injury 30177873 "no significant variations of the 65 inflammatory proteins detected in saliva between groups but 5 microRNAs, miR-27b-3p (p = 0.016), let-7i-5p (p = 0.001), miR-142-3p(p = 0.008), miR-107 (p = 0.028), miR-135b-5p (p = 0.017) significantly upregulated in concussed athletes" +tissue_expression_up hsa-let-7f Irritable Bowel Syndrome 30187701 MiRNAs play a pivotal role in visceral hypersensitivity and might be targets in the treatment of IBS by Tongxieyaofang +tissue_expression_up hsa-let-7i Irritable Bowel Syndrome 30187701 MiRNAs play a pivotal role in visceral hypersensitivity and might be targets in the treatment of IBS by Tongxieyaofang +tissue_expression_up hsa-mir-130b Irritable Bowel Syndrome 30187701 MiRNAs play a pivotal role in visceral hypersensitivity and might be targets in the treatment of IBS by Tongxieyaofang +tissue_expression_up hsa-mir-132 Irritable Bowel Syndrome 30187701 MiRNAs play a pivotal role in visceral hypersensitivity and might be targets in the treatment of IBS by Tongxieyaofang +tissue_expression_up hsa-mir-21 Irritable Bowel Syndrome 30187701 MiRNAs play a pivotal role in visceral hypersensitivity and might be targets in the treatment of IBS by Tongxieyaofang +tissue_expression_up hsa-mir-29a Irritable Bowel Syndrome 30187701 MiRNAs play a pivotal role in visceral hypersensitivity and might be targets in the treatment of IBS by Tongxieyaofang +tissue_expression_up hsa-mir-375 Irritable Bowel Syndrome 30187701 MiRNAs play a pivotal role in visceral hypersensitivity and might be targets in the treatment of IBS by Tongxieyaofang +tissue_expression_up hsa-let-7b Endometrial Stromal Sarcoma 30200635 "In endometrial stromal sarcomas (ESS), the upregulation of miR-373-3p, miR-372-3p, and let-7b-5p, and the down-expression of let-7f-5p, miR-23-3p, and let-7b-5p were associated with lower CSS" +tissue_expression_up hsa-mir-184 Carcinosarcoma 30200635 "In carcinosarcoma (CS), lower CSS was associated with the upregulation of miR-184, and the downregulation of let-7b-5p and miR-124" +tissue_expression_up hsa-mir-196a Leiomyosarcoma 30200635 "In leiomyosarcoma (LMS), there was an association of lower cancer-specific survival (CSS) with the downregulation of miR-125a-5p and miR-10a-5p, and the upregulation of miR-196a-5p and miR-34c-5p" +tissue_expression_up hsa-mir-34c Leiomyosarcoma 30200635 "In leiomyosarcoma (LMS), there was an association of lower cancer-specific survival (CSS) with the downregulation of miR-125a-5p and miR-10a-5p, and the upregulation of miR-196a-5p and miR-34c-5p" +tissue_expression_up hsa-mir-372 Endometrial Stromal Sarcoma 30200635 "In endometrial stromal sarcomas (ESS), the upregulation of miR-373-3p, miR-372-3p, and let-7b-5p, and the down-expression of let-7f-5p, miR-23-3p, and let-7b-5p were associated with lower CSS" +tissue_expression_up hsa-mir-373 Endometrial Stromal Sarcoma 30200635 "In endometrial stromal sarcomas (ESS), the upregulation of miR-373-3p, miR-372-3p, and let-7b-5p, and the down-expression of let-7f-5p, miR-23-3p, and let-7b-5p were associated with lower CSS" +tissue_expression_up hsa-mir-450b "Squamous Cell Carcinoma, Oral" 30210912 "The expression levels of miR-129-5p and miR-296-5p were significantly downregulated in OLK-OSCC tissues compared to OLK tissues, while miR-450b-5p levels were higher in OLK-OSCC tissues" +tissue_expression_up hsa-mir-141 "Carcinoma, Cervical" 30221475 "The expression levels of six miRNAs (miR-20a, miR-92a, miR-141, miR-183*, miR-210 and miR-944) were found to be significantly up-regulated in cervical cancer" +tissue_expression_up hsa-mir-183 "Carcinoma, Cervical" 30221475 "The expression levels of six miRNAs (miR-20a, miR-92a, miR-141, miR-183*, miR-210 and miR-944) were found to be significantly up-regulated in cervical cancer" +tissue_expression_up hsa-mir-20a "Carcinoma, Cervical" 30221475 "The expression levels of six miRNAs (miR-20a, miR-92a, miR-141, miR-183*, miR-210 and miR-944) were found to be significantly up-regulated in cervical cancer" +tissue_expression_up hsa-mir-210 "Carcinoma, Cervical" 30221475 "The expression levels of six miRNAs (miR-20a, miR-92a, miR-141, miR-183*, miR-210 and miR-944) were found to be significantly up-regulated in cervical cancer" +tissue_expression_up hsa-mir-92a "Carcinoma, Cervical" 30221475 "The expression levels of six miRNAs (miR-20a, miR-92a, miR-141, miR-183*, miR-210 and miR-944) were found to be significantly up-regulated in cervical cancer" +tissue_expression_up hsa-mir-944 "Carcinoma, Cervical" 30221475 "The expression levels of six miRNAs (miR-20a, miR-92a, miR-141, miR-183*, miR-210 and miR-944) were found to be significantly up-regulated in cervical cancer" +tissue_expression_up hsa-mir-139 Neoplasms [unspecific] 30225717 "Bioinformatic analysis has detected microRNA potentially regulated by xenosensor receptors AhR (miR-28, miR-30c, miR-30e, miR-139, and miR-153) and CAR (miR-29c, miR-31, miR-185, miR-625, and miR-652)" +tissue_expression_up hsa-mir-153 Neoplasms [unspecific] 30225717 "Bioinformatic analysis has detected microRNA potentially regulated by xenosensor receptors AhR (miR-28, miR-30c, miR-30e, miR-139, and miR-153) and CAR (miR-29c, miR-31, miR-185, miR-625, and miR-652)" +tissue_expression_up hsa-mir-185 Neoplasms [unspecific] 30225717 "Bioinformatic analysis has detected microRNA potentially regulated by xenosensor receptors AhR (miR-28, miR-30c, miR-30e, miR-139, and miR-153) and CAR (miR-29c, miR-31, miR-185, miR-625, and miR-652)" +tissue_expression_up hsa-mir-28 Neoplasms [unspecific] 30225717 "Bioinformatic analysis has detected microRNA potentially regulated by xenosensor receptors AhR (miR-28, miR-30c, miR-30e, miR-139, and miR-153) and CAR (miR-29c, miR-31, miR-185, miR-625, and miR-652)" +tissue_expression_up hsa-mir-29c Neoplasms [unspecific] 30225717 "Bioinformatic analysis has detected microRNA potentially regulated by xenosensor receptors AhR (miR-28, miR-30c, miR-30e, miR-139, and miR-153) and CAR (miR-29c, miR-31, miR-185, miR-625, and miR-652)" +tissue_expression_up hsa-mir-30c Neoplasms [unspecific] 30225717 "Bioinformatic analysis has detected microRNA potentially regulated by xenosensor receptors AhR (miR-28, miR-30c, miR-30e, miR-139, and miR-153) and CAR (miR-29c, miR-31, miR-185, miR-625, and miR-652)" +tissue_expression_up hsa-mir-30e Neoplasms [unspecific] 30225717 "Bioinformatic analysis has detected microRNA potentially regulated by xenosensor receptors AhR (miR-28, miR-30c, miR-30e, miR-139, and miR-153) and CAR (miR-29c, miR-31, miR-185, miR-625, and miR-652)" +tissue_expression_up hsa-mir-31 Neoplasms [unspecific] 30225717 "Bioinformatic analysis has detected microRNA potentially regulated by xenosensor receptors AhR (miR-28, miR-30c, miR-30e, miR-139, and miR-153) and CAR (miR-29c, miR-31, miR-185, miR-625, and miR-652)" +tissue_expression_up hsa-mir-625 Neoplasms [unspecific] 30225717 "Bioinformatic analysis has detected microRNA potentially regulated by xenosensor receptors AhR (miR-28, miR-30c, miR-30e, miR-139, and miR-153) and CAR (miR-29c, miR-31, miR-185, miR-625, and miR-652)" +tissue_expression_up hsa-mir-183 Endometrial Neoplasms 30226564 "Upregulation of miR-183-5p is responsible for the promotion of apoptosis and inhibition of the epithelial-mesenchymal transition, proliferation, invasion and migration of human endometrial cancer cells by downregulating Ezrin." +tissue_expression_up hsa-mir-3195 Traumatic Brain Injury 30226895 The expression levels of miR-3195 and miR-328-5p were higher in the severe TBI group than in the mild and moderate TBI groups +tissue_expression_up hsa-mir-328 Traumatic Brain Injury 30226895 The expression levels of miR-3195 and miR-328-5p were higher in the severe TBI group than in the mild and moderate TBI groups +tissue_expression_up hsa-mir-486 Colorectal Carcinoma 30239392 MiR-486-5p Downregulation Marks an Early Event in Colorectal Carcinogenesis. +tissue_expression_up hsa-mir-211 Medulloblastoma 30244244 "Ligustrazine Inhibits Growth, Migration and Invasion of Medulloblastoma Daoy Cells by Up-Regulation of miR-211." +tissue_expression_up hsa-mir-155 "Carcinoma, Breast" 30250531 3 miRNAs were upregulated: Hsa-miR-21b; hsa-miR-29b; and hsa-miR-155; and 3 miRNAs were downregulated: Hsa-miR-10b; hsa-miR-125; and hsa-miR-145 +tissue_expression_up hsa-mir-21b "Carcinoma, Breast" 30250531 3 miRNAs were upregulated: Hsa-miR-21b; hsa-miR-29b; and hsa-miR-155; and 3 miRNAs were downregulated: Hsa-miR-10b; hsa-miR-125; and hsa-miR-145 +tissue_expression_up hsa-mir-29b "Carcinoma, Breast" 30250531 3 miRNAs were upregulated: Hsa-miR-21b; hsa-miR-29b; and hsa-miR-155; and 3 miRNAs were downregulated: Hsa-miR-10b; hsa-miR-125; and hsa-miR-145 +tissue_expression_up hsa-mir-484 "Carcinoma, Hepatocellular" 30254459 the expression of miR-10a-5p is downregulated and miR-484 is the most abundant miRNA in hepatic precancerous lesions +tissue_expression_up hsa-mir-107 Gastric Neoplasms 30258124 "Six miRNA (miR-601, miR-107, miR-18a, miR-370, miR-300, and miR-96) showed increased expression in gastric cancer compared to normal or adenoma samples" +tissue_expression_up hsa-mir-18a Gastric Neoplasms 30258124 "Six miRNA (miR-601, miR-107, miR-18a, miR-370, miR-300, and miR-96) showed increased expression in gastric cancer compared to normal or adenoma samples" +tissue_expression_up hsa-mir-300 Gastric Neoplasms 30258124 "Six miRNA (miR-601, miR-107, miR-18a, miR-370, miR-300, and miR-96) showed increased expression in gastric cancer compared to normal or adenoma samples" +tissue_expression_up hsa-mir-370 Gastric Neoplasms 30258124 "Six miRNA (miR-601, miR-107, miR-18a, miR-370, miR-300, and miR-96) showed increased expression in gastric cancer compared to normal or adenoma samples" +tissue_expression_up hsa-mir-601 Gastric Neoplasms 30258124 "Six miRNA (miR-601, miR-107, miR-18a, miR-370, miR-300, and miR-96) showed increased expression in gastric cancer compared to normal or adenoma samples" +tissue_expression_up hsa-mir-96 Gastric Neoplasms 30258124 "Six miRNA (miR-601, miR-107, miR-18a, miR-370, miR-300, and miR-96) showed increased expression in gastric cancer compared to normal or adenoma samples" +tissue_expression_up hsa-mir-29c Acute Liver Failure 30264499 Comparison of microRNA expressions for the identification of chemical hazards in in vivo and in vitro hepatic injury models. +tissue_expression_up hsa-mir-26b "Carcinoma, Hepatocellular" 30309482 Lentiviral-mediated microRNA-26b up-regulation inhibits proliferation and migration of hepatocellular carcinoma cells. +tissue_expression_up hsa-mir-21 Ischemia-Reperfusion Injury 30309483 MicroRNA-21 is upregulated during intestinal barrier dysfunction induced by ischemia reperfusion. +tissue_expression_up hsa-mir-193a "Carcinoma, Pancreatic" 30333874 "The results revealed that 2 upregulated miRNAs (miR-34a and -193a-3p) and 4 downregulated miRNAs (miR-221, -222, -484, and -502-3p) exhibited a consistent expression pattern between the PC-1.0/PC-1 and AsPC-1/CAPAN-2 pancreatic cancer cells" +tissue_expression_up hsa-mir-34a "Carcinoma, Pancreatic" 30333874 "The results revealed that 2 upregulated miRNAs (miR-34a and -193a-3p) and 4 downregulated miRNAs (miR-221, -222, -484, and -502-3p) exhibited a consistent expression pattern between the PC-1.0/PC-1 and AsPC-1/CAPAN-2 pancreatic cancer cells" +tissue_expression_up hsa-mir-155 "Carcinoma, Renal Cell" 30344735 "2 upregulated (hsa-miR-155-5p and hsa-miR-210-5p) and 6 downregulated (hsa-miR-138-5p, hsa-miR-141-5p, hsa-miR-200c-5p, hsa-miR-362-5p, hsa-miR-363-5p and hsa-miR-429) meta-signature miRNAs in renal carcinoma were identified" +tissue_expression_up hsa-mir-210 "Carcinoma, Renal Cell" 30344735 "2 upregulated (hsa-miR-155-5p and hsa-miR-210-5p) and 6 downregulated (hsa-miR-138-5p, hsa-miR-141-5p, hsa-miR-200c-5p, hsa-miR-362-5p, hsa-miR-363-5p and hsa-miR-429) meta-signature miRNAs in renal carcinoma were identified" +tissue_expression_up hsa-let-7b Periodontitis 30350903 "the most expressed miRNAs in both groups were hsa-miR-1274b, hsa-let-7b-5p, hsa-miR-24-3p, hsa-miR-19b-3p, hsa-miR-720, hsa-miR-126-3p, hsa-miR-17-3p and hsa-miR-21-3p." +tissue_expression_up hsa-mir-126 Periodontitis 30350903 "the most expressed miRNAs in both groups were hsa-miR-1274b, hsa-let-7b-5p, hsa-miR-24-3p, hsa-miR-19b-3p, hsa-miR-720, hsa-miR-126-3p, hsa-miR-17-3p and hsa-miR-21-3p." +tissue_expression_up hsa-mir-1274b Periodontitis 30350903 "the most expressed miRNAs in both groups were hsa-miR-1274b, hsa-let-7b-5p, hsa-miR-24-3p, hsa-miR-19b-3p, hsa-miR-720, hsa-miR-126-3p, hsa-miR-17-3p and hsa-miR-21-3p." +tissue_expression_up hsa-mir-17 Periodontitis 30350903 "the most expressed miRNAs in both groups were hsa-miR-1274b, hsa-let-7b-5p, hsa-miR-24-3p, hsa-miR-19b-3p, hsa-miR-720, hsa-miR-126-3p, hsa-miR-17-3p and hsa-miR-21-3p." +tissue_expression_up hsa-mir-19b Periodontitis 30350903 "the most expressed miRNAs in both groups were hsa-miR-1274b, hsa-let-7b-5p, hsa-miR-24-3p, hsa-miR-19b-3p, hsa-miR-720, hsa-miR-126-3p, hsa-miR-17-3p and hsa-miR-21-3p." +tissue_expression_up hsa-mir-21 Periodontitis 30350903 "the most expressed miRNAs in both groups were hsa-miR-1274b, hsa-let-7b-5p, hsa-miR-24-3p, hsa-miR-19b-3p, hsa-miR-720, hsa-miR-126-3p, hsa-miR-17-3p and hsa-miR-21-3p." +tissue_expression_up hsa-mir-24 Periodontitis 30350903 "the most expressed miRNAs in both groups were hsa-miR-1274b, hsa-let-7b-5p, hsa-miR-24-3p, hsa-miR-19b-3p, hsa-miR-720, hsa-miR-126-3p, hsa-miR-17-3p and hsa-miR-21-3p." +tissue_expression_up hsa-mir-720 Periodontitis 30350903 "the most expressed miRNAs in both groups were hsa-miR-1274b, hsa-let-7b-5p, hsa-miR-24-3p, hsa-miR-19b-3p, hsa-miR-720, hsa-miR-126-3p, hsa-miR-17-3p and hsa-miR-21-3p." +tissue_expression_up hsa-mir-1283 Parkinson Disease 30359694 "all three FTY720s increased miR376b-3p, while FTY720-C2 also increased miR-128-3p, miR-146b-5p, miR-7a-5p, and miR-9-5p, and FTY720-Mitoxy also increased miR-30d-5p" +tissue_expression_up hsa-mir-146b Parkinson Disease 30359694 "all three FTY720s increased miR376b-3p, while FTY720-C2 also increased miR-128-3p, miR-146b-5p, miR-7a-5p, and miR-9-5p, and FTY720-Mitoxy also increased miR-30d-5p" +tissue_expression_up hsa-mir-30d Parkinson Disease 30359694 "all three FTY720s increased miR376b-3p, while FTY720-C2 also increased miR-128-3p, miR-146b-5p, miR-7a-5p, and miR-9-5p, and FTY720-Mitoxy also increased miR-30d-5p" +tissue_expression_up hsa-mir-376b Parkinson Disease 30359694 "all three FTY720s increased miR376b-3p, while FTY720-C2 also increased miR-128-3p, miR-146b-5p, miR-7a-5p, and miR-9-5p, and FTY720-Mitoxy also increased miR-30d-5p" +tissue_expression_up hsa-mir-7a Parkinson Disease 30359694 "all three FTY720s increased miR376b-3p, while FTY720-C2 also increased miR-128-3p, miR-146b-5p, miR-7a-5p, and miR-9-5p, and FTY720-Mitoxy also increased miR-30d-5p" +tissue_expression_up hsa-mir-9 Parkinson Disease 30359694 "all three FTY720s increased miR376b-3p, while FTY720-C2 also increased miR-128-3p, miR-146b-5p, miR-7a-5p, and miR-9-5p, and FTY720-Mitoxy also increased miR-30d-5p" +tissue_expression_up hsa-mir-210 Rhinosinusitis 30378273 "Five upregulated miRNAs, including miR-210-5p, miR-3178, miR-585-3p, miR-3146, and miR-320e, and 19 downregulated miRNAs, including miR-32-3p, miR-1299, miR-3196, miR-3924, and miR-548e-3p, were differentially expressed (p < 0.05, fold change >2) in tissues of CRSwNP vs controls" +tissue_expression_up hsa-mir-3146 Rhinosinusitis 30378273 "Five upregulated miRNAs, including miR-210-5p, miR-3178, miR-585-3p, miR-3146, and miR-320e, and 19 downregulated miRNAs, including miR-32-3p, miR-1299, miR-3196, miR-3924, and miR-548e-3p, were differentially expressed (p < 0.05, fold change >2) in tissues of CRSwNP vs controls" +tissue_expression_up hsa-mir-3178 Rhinosinusitis 30378273 "Five upregulated miRNAs, including miR-210-5p, miR-3178, miR-585-3p, miR-3146, and miR-320e, and 19 downregulated miRNAs, including miR-32-3p, miR-1299, miR-3196, miR-3924, and miR-548e-3p, were differentially expressed (p < 0.05, fold change >2) in tissues of CRSwNP vs controls" +tissue_expression_up hsa-mir-320e Rhinosinusitis 30378273 "Five upregulated miRNAs, including miR-210-5p, miR-3178, miR-585-3p, miR-3146, and miR-320e, and 19 downregulated miRNAs, including miR-32-3p, miR-1299, miR-3196, miR-3924, and miR-548e-3p, were differentially expressed (p < 0.05, fold change >2) in tissues of CRSwNP vs controls" +tissue_expression_up hsa-mir-585 Rhinosinusitis 30378273 "Five upregulated miRNAs, including miR-210-5p, miR-3178, miR-585-3p, miR-3146, and miR-320e, and 19 downregulated miRNAs, including miR-32-3p, miR-1299, miR-3196, miR-3924, and miR-548e-3p, were differentially expressed (p < 0.05, fold change >2) in tissues of CRSwNP vs controls" +tissue_expression_up hsa-mir-1269a Neoplasms [unspecific] 30384176 Identification of key differentially expressed MicroRNAs in cancer patients through pan-cancer analysis.(up) +tissue_expression_up hsa-mir-183 Neoplasms [unspecific] 30384176 Identification of key differentially expressed MicroRNAs in cancer patients through pan-cancer analysis.(up) +tissue_expression_up hsa-mir-210 Neoplasms [unspecific] 30384176 Identification of key differentially expressed MicroRNAs in cancer patients through pan-cancer analysis.(up) +tissue_expression_up hsa-mir-301b Neoplasms [unspecific] 30384176 Identification of key differentially expressed MicroRNAs in cancer patients through pan-cancer analysis.(up) +tissue_expression_up hsa-mir-3648 Neoplasms [unspecific] 30384176 Identification of key differentially expressed MicroRNAs in cancer patients through pan-cancer analysis.(up) +tissue_expression_up hsa-mir-3687 Neoplasms [unspecific] 30384176 Identification of key differentially expressed MicroRNAs in cancer patients through pan-cancer analysis.(up) +tissue_expression_up hsa-mir-4746 Neoplasms [unspecific] 30384176 Identification of key differentially expressed MicroRNAs in cancer patients through pan-cancer analysis.(up) +tissue_expression_up hsa-mir-760 Neoplasms [unspecific] 30384176 Identification of key differentially expressed MicroRNAs in cancer patients through pan-cancer analysis.(up) +tissue_expression_up hsa-mir-96 Neoplasms [unspecific] 30384176 Identification of key differentially expressed MicroRNAs in cancer patients through pan-cancer analysis.(up) diff --git a/modulector/files/drugs.xls b/modulector/files/drugs.xls new file mode 100644 index 0000000000000000000000000000000000000000..4d183f7bea5efbf6f178a3d4097762eaa9086379 GIT binary patch literal 1330176 zcmeFa2Vi7ZdG-u?<)&?Rpolc4e(x!N5owNrOi-@{F{* zGR^eRd+!7Yy(grQ00~J5DWs4_2mum8dT0qGB>4Y(-gC|^BWW@D_$T@JFg&Z7JNKS@ z>f6tIe)ltHeeq2nxc8TGeg9pSJ2CgY+fU7%oVtDwK0oj@f8oqrF5>e5U%z+z?YD>9 zZsWs~!BfCf!PCIg!85=!!B2o^foFr~faikef#-u4fER)nffs|90E+(cfB!%Bz<>I( zPo%F;0(Sx$^E-o6z^On(emb}dI0M`j+zl`Va%X|NgR{XoKy&0=a8GbAa2~ifxDU85 zxF0wlTmT|)fA9eCK=2@NA$Tyj2n>QDa51<941+u79!@w0_0_+BpU<&L3d%=}pAJ`8b4z2DoqDDY_T7*GfEU;!+G23P{iU_pbaqko$-|^Etaxf^L0{-*11?3we(?)d>U7dBovECFs_tQrDr40~4%| zCTq3@-T6QH^_<-2DfyIK{~O))Q+K$2)(+Rt+2;B%Z5hjbR1HtH=$zb1J6u9ITpc9+RV2FDD)znA%goHX66;r^Of-G2Cb^Gh@JY)Oog}ZEj{Wa%oe|^^u?|t{(w!i;% z=Wc)fIrrNB`cC!Psr(O}ta47?(m$_1ZTsu4K3ng1_1Sv;oV#ydPRaUb>-`@-Pxs$> zOMP7bpR(n;8?Rir?uQqaZtMET*MGSEuywp1df)BG_q6l3zy5PO%&Q-Cp49HG@=p!p z{#nzNE(qg(TK4+s;ri*x^@yp0j_LX*zTQWl#a6bX+h>I9FI`&t*aaWEAa~M7Y+c_q zT>mVbFZa;6KJh$!=~-u;d-}Pj=T3U{Nvi)&^y+S*oWA;;xx@9d!gb1j#p$o0{FfU& zx%-yuj{cmTy6)=l?ms77kLlzkM)&R!u75W77%Gjv?fUIpt{a`-$5s2!UB74l^^?vx zOYPly-OZCN*LN!4mvb-5f71zPIt@7WUe%|5V&pXI)OFqei5>2@`b(2e-S679wS1K` zAhX1__eV~H-%`%~x7>f99m>%>vHDzLh47E-Prdg`JJf$-hxQJfxP3kEzwP~R%}oq2 ztl!DLHy+e)B$7wph3cRkuNF6WwT#`Ob9`7b#ERq(dl?fQG>Z715_vu-=t z{@(qzlkD%=x82$Po^#us_W$ZN$uq)+ zqZ`jX{*C4M#(N(B#!7tSy^eolHNNq@3Cau2k_%|l4 ze(>>c46QyrcM*n(fhXMH=JDxRF8TUTH@UB8V8lErH!$|7Pd>|CI17vB$;kzG@gA5s zPsv^kKMZgEp~iAKkEMiBB$TVWBkZ5y9fj;WDm-xy%%+)lguXkA@ygVwYIm2icZUu< zgEz$u8sW~fFu%r+hfX;Idu)8ysNGdd?i%&=JOgWOeAk%WHJaQt=I=TW+XPMBo@|_l zk$20FVfvhh^>@pUq1oqQ7T)q>Xytj>i?{q3y7xQ`$ycm^hM%6rpuUh%l_f`{wEOJ2~pI$XHQUHJF-!U0`4;f48w;eFG3 z-}hen)`g_*j~O@tF7tHkdar#oCJNqsc%{);FX_s&Uw3wLrK~GocvtF5MOTWSPF<<$ z$~mVT#|aH~PJ(`VI9 ze_@06H{4Uno&L4EbM0d+np1L59yk>P-^T~8;NL59=YJh$FW<>2cLDfDPWd*bp8v>2 z(Kr7Dp8}6j%4&1=-~?6@{_d{#8hBZHtMyhZT5YsC3mdHlFWx&fK{cj!^Ko+j)LDFN ztTz_co1Hdyt*>+zBc4CJ)>vpZdc1$K(_U=qSL!-5y?=^7H#F*9ewl47HM))VLPPg& ztgUsr>-WL=acr&I==D_GT77-J(QQYarO4_<{aTIn{3!LG-akDtSJZzaWjb%7x!8=F z?Z^6h@Q#Dm95`?q_ca%~oqD%h-=yLDI;)+iS6^#3+P&yJd>b39^>#GhZPa_~(L$Y? zbfbkvtJS-HONsRsHR(m`D~+g;s$jRX)ND0+u7kdPJ3BJtqw=k znrm7wI!a$e8?=3Sqg7vTEJpSAVpPliyx2L~&L?;Dn#=9xQj?mmw>G1}nahiXVr^(R zl-PIoe51*0S3A6BeT8;!tfh)t>U5)tsr}J9ow2^!Xs;LOG#<=-;KU&_=;@a(pBC&FnGFYdY8nDE0VhI=yn2ILH`nXy%_EJ7 zm$vfj&DBOUGdZi#-RMQD8$Bl6M(`bK+s*Uinvc4Ko_i~GB~dTXslqm4gnYI^qs z9lp4+z$h%zh1PqTJYmwL$BSz=fvk)2<&yO=Q!8Jpj?^`7le;H&O-|5(3ys3NGIO!j zIMQhOfu7}2SA;#MfwE%jZVveH~$VO~+VCeIO?+=@Eggbx@7L}{fN@s&9 zR$pSKMb<86TBo$89 zwYk_h1^3?CTDNngvB)x;+FdMG$BNvOSqr%F8r|j^^`vt1tqyB=a;j9lgxS*WENref zdbkTQoOV_l`J)u-W>`eAOn=QPTDQ6hiCElZWLQnjg{ZgLUhMKfbhNp?!qBt^Yqt!! z`9(wQVk=coNYEkcj$UJUB+TF~YhqA?RjJl5cHPe>_n}&2K=vJebh%n8grON9nIDb^ zczkTgK9{O)jI=hAg*4b$_T^N^eTk*fMDVeO)(V6w$$r-coL0 zlI6644PG|$Cd)0de;2u?Mb_iH{l?o0t?%Bj#;eR8^;%2Spkr@pQLlC0G|D?d`3IqN+t)Xt ztl}zKme)^DjpfJ77qSlFLL$LT18ACPMSYQVmz@%`@e|CsmF9et372|seFGvN9pka( zF4QDi?skr{1dlZ9Q9YWPJaAPhzt~u7v?+KUmc0NoX!cfd10HQey_L>U(V3O{dgN=B zyknv_Gnp@?Ii*NIs|g#Y#?V}?hwa~9h)XjLqgSYwqS??G=Do4J6y=OkE7X&7tGd0T z2Qe0@f`F>+x|Jdt_0?#--d%2RX|UN|Xl*QtHZA0*ZPIdILD!_lG1xhkIzUC$2(Ck`Is(p3lca_PYSgXOW|=-NG3?w#dP zHPt?shpcB~&h0Dfx}k?yBWZ^5FbSsT8HJ-Jr7Go$ew2&FdVV2APpXw&rD_eDux}G0 zdaMqMi0TW?#c1Eu#AGu%Fmd%*xq3gMHfVHKb}@1h9lmOJx3U)z3tjn+B^bX6UO!%d$;gkmrUlRyZN?9`4XqQSYt6GMYR znoZGxltk-h#qMLQ-^yc=YnGOflud|8msO8g!;p!2nELvrZ;78Qso~?TPQLyA?<$lB za{H0RHo6kSkTE1$4o4e3^|LjJe}jb13+t`TUb8n0AzJEeh?s~DjYKQSWKyL~Mt33v zZD&eK{96pOCRJ0L?UKnajmqO;8pV{sRvt?^Um7dTyFZKkDNDG^m&zmjTN$l+c8^$~ zku}!8V6!wutdPFb^MOH)XF;*Zy3UsnASAcwBci4&OCRTh+@Hweh3FoHl#R|e*6aC( zDC1(Y(~1W7l!v?kH#$~9d6}Nvn;+dyd6{8+!(&OQuAfam@q$T|6wYj0g9>ZWZ&zaB z!hzgehaZpdNOKud&A>F_IUV#gH(7>h2jl}fvx>MPsmRTnd}=hjI%f)!)qc&o$v#e8 zHJ2V%b)Q7U&c=GQr<@vnEeIs#LUbK6@O-b)MXrqym;#*79N`Ub)nTG z6hBEZR@|Tw>he$lJ$|Os+7xYQH&`6y@ygub-UAa?MiW;ag8$ku;(pjKiN+LSlSWwm z-gwbzHDtVy{ti6}OgWws(b7iS889^Ox~eT}!8mwxnQ#$EQsHHUQ_}klN|JKkYaX-L zqN@ki?s>Y%Mro9PjEq!@w&usfnm794*MGftGbJH#MKcEusPpD#_NJ!#(ar`luI@-R zo!m4Us?mqvxW1_lNll;YZm!jrTJ!@xgq5+XCgDCacSxCz8fzN1 zR#OvR1`p<8tvWum&iq}oCQATylU?h@=&J^)P9@fvj0-)nrua1??oLzPVP1Mwkr9ZQ zht@+Ve6$_>E z*!Zr-%31+pUmht{hi)pM-|cB5zM;+q<$Gilbuc4%MDXr?lXLk}X~YQ4>{W-TWD8c@ z&%k@pbFq}s>n)bJo6-?dzLg(Ak5L%Sh?Td6hG8g({$5L9in%4f0Oiq=YeUYc+j2BF zF&n`f^7D+fz9ZJJV=juyc_b8Q5uF(5r+&lOA`V`7U4K&?siBuydm0W~L;0}ac)t^4 z#70N+iL6vA*Qk3&B64-JUN=cmc1gWjT9M=}Di@lb4=RP9%0@O0LpP$outgj532S_R zSMN~D5`rxgL7Y6oc!IXk;+@IVQ|nUIp}kmeR_&S4$S_8%E=S2GoDHI$5f;4gsPYy% zUB`+27(leTvFZ>Hc__|W2*;UjtZOaCQ>;=cT@=IvC#S8}S6A!Z%_vMLTl100gnyhH zm_|)rK#lESqLXSogwnjT@*0`)E3LnYJ};HrSpeouDR;I7St8O_g$BG?X@)W(np7MlF^G#Rk&pXgEgrT7GY9qtiv$hv2p31(3P1R;}K!<+sJ| z#&VEhH1lKPlA`FWE@xb4sqZN4N;h?lup*rD6bn48N-A}YW2#g+-A{;UCM;-)L+ec& zs>ZtJ(G_$oC-J11kL3K#USc;yMn8%jI{OmI5TS1ZTS-Jjd@vJ87j1|$#y-h)UQ&eo zkE8I{5kQTym^~HSD>t?p8#gyroAr0{Y@*83Ew1GfQPKkz+$P*`ywV&MNHh1odRE-^~2x{CKttfH$n^Un6dJ4K)iZ$=VvytHbj1Lr(xVQC1=VQeh$t8T-& zJUn;U5YrZghljw{^g6FPM#dq#ebb?u>rb#AgLT(@E9Hd0HH5`7Ilp%^xLG4HKd5_0(+ZI?3j0lOBzsWks> z0S|ygaGV*@`sSK6F4j~FV}?d=Yn$~bx+%UyyD@c7rzdws1JB1@f7~NxGLCx$@7mkeL@&G@X&aGE$w> z_7OoDu=KRoL`%`8!uL>D%%0USy~eve>sUw`VsRCd%7cv0;3v*jCZCn2R|F>3e**-o z-foy-I4gQe4-QNQ0m^1Ep3>MBy`8xoj_Kn+y)9GqoK#C}=c2!i(Mj)5X`q4gU7m{& zbIi#cG=ImmC6lK{Xv=$?XrQj-#_bq%iV3GY;l_Kt@)zpB>r=c}LUUlgs*2S-7Kb!L zcHqGK(F){s^Gg8w-{^JLR_e=mpo4g9wZ1XAiGGs;jOr-rkBuB>3SGIwgUkj*pyd_h z^+kE|wOWkOnih*+7QN}!;*Bi6)+VzptVWZoq-AE*1DV>=RNYi7Pq>}AMtWW{wQXJ| zj%~9!sy|}?1Z&JK>(u&nQlA^A!VnW-xI8?P$IhHTlxL2%I-9M$*(0a&%dL%t&e~=d zj)4v?4@G0`$})Zcq>er}Rj=?g_MA>c?Z(llEzO87Uc-(9;cjEm-2L#0O1V}k(U(C| zRZ}zE)#yngZ@Gz-nsE$+Q*n+{i<=5p4CE#mIpCnOtqn|C$R_KK+^RqUc8VZpW$CNy1{0}eg1eT` z1vp4FRq>KN0xO>E84Q`Lb*yjhgT_x{yHnb|^T3H;nsDBZV&amKdWA>Onx11*3XgE_ zkR>N7A&=ulU+H~hU|>J$Qlbt@{p^|}TMDUE(GE(SBHbzk^QDz1sh3Al@}yu&Rcvry z1GQ2AO6{5_f+a%bokO*}g)IV;e0D0MQ_1v{Qw*Jg=)TM89hAo&irFf)kXqQoqZ|~% z61C~CNe_inUT*hpsgJ=u-ZYikDb8w%)Z8Wh=W6a;^r2o-bM=<({mT)XujOpt;4ZaK zE!G?5lGk@B=}r-E^EXjo72BiwN)c7t)N_OM$mIlP7C_Csr zTEC9@Ku^u_mU-(DMcWPWd_>G%dIVJmdF!1|K0AgQ#r~c<-WW=i{;!Re>a~ZSR)~XI z;QGj!G~D>Ap8a+C-#m(S=8Rg>rPkknM7NGs#YXEc2pS>8u2wGPMdy#zF)4RDC=8Y1 z8qBuYZW4Tye68cWXhegvQ`ZmSflbG7MHIK%L7%|p1TBj8;F+GfKHBg3>co752tBCL zo{Y3N?R`kjV`Go+?wZ;OT|A(ImR&h9O-~66s1?q1?rD08X~-%NhZsT7(lzsnI?9n# zUVBkxxVqb15W6=PVfpPuVK0}AVu#smVae^F_Y!x7e2!FT(hOd=ZUc1^k4EQa^V6kkty^T|E_@Cri1er~W&^Q1 zl&_TI-dU{oTZzp!Q5&*vE)k>^UE654BMiN0va3#rKhkMoOzz~@@SpR59J7$|RbQBw6>*9Xov1!fXoVa_$wTfLrsU1g%}_z#X=a17;M^ssL!%JgnP>o$ z7UMu|s)h}91An|3_u{%lDg6#Yv}1=2cA+#*=pByq*~HhHw;hEG`Uk-Q1Qc-iaq+^wdQ1vD43!H+Eb*Kn---x*RTO0Gl=QVpPQDb$!yV+5Y?X(}p z^jr>pSU(=gV~Yyl>a3a07zPclg0Xb_Iuu@k0XYPpTOfdZ*^Y7#N0o7#DPtvi27TSr z@*T&F<%!2jbE`yH)XLhD)CVkeic+Avy~}IZyGajY5tKvqu#5B8V%*<07qV1=p#my} zS9;h$;ey^a7gkzyMv?&Uj6c?<})T(N6v z{_O0sPU<%6XMB37nVS11uZ|5FR>j!=0x1ze2$l`|QQa(mb$J5AMmo?~hMGk-HP0li zaD7-Dsnl@R^z~uf|B4?El3%qtRzkzu1Ep=Y(EzWijg+18yBMy@X5tA(l>BTyg6^g) zA%q{Mrch!gUxhkjlT(9IG7*Gixz)i79a-GPC(K$Ht;&3)fsF^$8}QPPdcBjrr#qH5 zEd0+c)LU7`db+AG7n|AoR*7Q=oyjpp%+tjND^ue4(!&I;(k1aYrCM&BAt8GOt^2q? zM_4H|snK1}&uMA|4)0vIK!87GXVo-~r^sujgGVokdW87oz7Q>GVMr;@D`Wh_o=qBx$?xNlG(j=ome{W!;MPjOgL zK{oR$zOL}P49WBnCC)_Y$YH+38osizx`1JXWf7vvs_b)MUfr6XT$vyu+u6Vf3T=rl z_Lw zkJE=rnF(nhMt#I}DPJDeh0=)pU+(UzKGN-@OZ-T9gu;34SM^4C+$)Hc%pg^;>QA)T z!lcQ}Ld59X!76JJ+k+ExvlDUXX06srG5LPat>^HW0%CcwpN!IQH-N`;@)llXAuukQ zHnsuFeD3-!U#bPCoy4uAOZ@b!`0&>S|2H^B%KTs*ipyNxV-FUY;78?^g9F+H;%bc@ z%32xAU&&sj`4nwrBVPqxGu>ER>vSKO%i$7ixFE@VtBJ;IB*&(5G&p@_exyR&Ww@QG z>Nd?`x{M#YNOkbCeBtZX3kg|{h_y=0u5P-p00x@{N5C zVyR}$=gLTYg(+iwX1&;DH-~$^R3m~|1y##7^}0m;j`@2kBWx(pZ>4ahRxVl(cbU8X zCc?_Y|RI=Us$G;~ofo{JVdt5^tEZcH@$3buJ&xSuiMxeA*Z9dE__jlRiC z?Ryf?m%PVT-)JCk#j;f_p*QrNQK83dOxwKq)wM44sUy z6K#4JJdi(xpyUPGT6qNe8{+!551m}w5`v`H6FM1}DT!{0IhkcNu~cc~GMEP9!QApP z(=YI1bUOv7CQBiJA}YjMZ>)q4%F0B8YYH?k4fXYbu}3v*j4&6xKZ?2yyKKY`ohM7u zwhKYh8zSo)1;@Zn(a@q5cv)J`;H%xImLk!mLk`;;tC(Vu6=-cgu?ZD-&524i|B88L zlkxF*0IZ^(PwwB3$MwHI=Ae=i7Jk%X4zyS02a7pKvsv~U5J7)1Z>Hw_!MxeC)y~(yj zqbOc+a;9}HysdBNQd2vJ5umo3&7D!fnbrFUy537^Y{bFo8a6VB4IxKK#AYn?LIs#$ zQkAVh3bNwx+>c)ANY9bc(HdV5utlJ`0qZ-^^pv(#sf}PdkYyG_=o)&)>e@zc16#lm ziB_0XM0DI93C9Zp!4$!9UF70^wDXe@L+ivGg;BD-oTqxp_Dz+eTDw?6=iSz>bav`! zztOD_slroX+rgN{NUb5Nm?>6GRmJm0=B}NY$ZUd=m@*vUPw;d(h>pf^jF$Pw!_(?O znR8Z~w$-EFCVgmXa|^=5we=Qk0+Gh^qe@90awiN*xR^Y+$5HR6Y+*u_O&_4xnQ_W3 zkAKO&cRS(Jb9fb}8YK^6P7r;CjUlXeW7Llf2y6 zCAICuG$sp>J$^m1yed^I*=l%AY8{3;*}^xGkfP%bz#Fii3Tkr!cJoflby%r5QYEzq zTS>d?my!ux8{g`Sx?!P#jlLU;R3@n$?6+swbkwtjKcuh2?v6fVndyp{?gJMyo*e5# ztOUdjc6C)u^Yps@n6bdj1i8FYyfF0l%t(!oo@%&zw5)N%%Fb=|QG=AJ1L3R8-oa>N z+DT!x0+uU%F;+ws9Hk&OnLs?-5oNO22y&dSub02#ooFWK1$!q1a$}LVd+96MKa>c2 zikMEV)IdIb2Z|uj95u-{t6)*?w_VBC#U=|K<7N^PX0ryj*dBVFs5WKNpw$Zv1)?j6EQvvfyd>;FJ(Mcs zJ9>Gyp-npoO15Fs3by`B_khuWcyo~R$|mJld}}IP$q|LLjx)Hrx?!HG@_1=JU&Aw) zTo}oGuM`*ZCGv%Y->V~|^A{UA2v;hjRWgWJjZ#($SftC^;}|6Z2wIA_#kz@Zj4y=L z$saYTmEdhpeBImVZnXSYSkcuRjV?R2_=>RMb>l!;ENaKAPsDRxQE zhNqIatby-_sH~R7ifxylWV>1@MoN)5Nvv6&?-42Klyzhbgh;V6*CHa2bR~)2nIiSs z4BLfNr?5Rrkzb0t>ThEbxmM?1wR6*26W-ujPq)0UQ20W6oI84Tc*^Pp7_!e zC$0P>hD^N@%F))UmW|B<_0`p7D@Td`oXE4ltP2hgjC$1v}aAp71RqvO-TcaF`;Y^Ax!qY!9_Xun}Tgwx`PGDV`Dw0qGxQW5wpIe`G8r z*8mnf5(79Rswy}cdO1UZ>Ov4ZXwO}2betn&Ge_5kxotJaq>v_*WP zOA#2hT2~8mW`#0;zwr?tfY2YkO}4j{cJmf?$4l$7T_Q+Znd|_vgG+{m7I^tdA0YwS zO}Wjx(=8H-wr#r<>f2C=4ys*gvs0KAcmicx^@h)CY<3;Tmam`66|--56XR`l+#6!c zrC^aAuP`pU8%Ke&wO0GhAASqzb43l9a1VaRo(w}proB2=a;(FBoal@}nIT`3cG z?o9W~t!Bvc)Qheu*Gkh{?xolK=A+cjn&-(LBncdD^OfX{KzvDIF;@5n?nalLfCZpk zpy*Ccqi{YLQ?01c79Gjvuv6I9C94FS|b+R45+@t zupdj&6t}jDS-=GjHASqLe&8kXR0Xtp6#1L_z0WSjL{fpOcUZ~lydXRM_uHGQDY@cD z&E8aIZTw*NCLGu^XcqG6L6i)IwA1Dpqh3n8(q8P~%7#+G ztGXL$-8E(c-g=g*6RnHWIHeQ6^$LGFkPE3ZR&g81GD`#0B%?La60!0yv#=M>U1hW! zCGvmq3)pvQLEhlLgu%*|U5bUVMx7BFPYvV*p2&;jEQoDnm`zY(G8+fhHs&!Tt?;bH zg~sC)w{>Ss`&Bj`@6LR<5MKj*gC;7Xt1UI^@A{;VkU8 zUD+gZ1f_C~{ZfHiT9w6|6kIFw|&l+Qs3nzGm%24FcC&oBE-A>FS zjJ}GG4Hz~Ix)K{o2y))`-S$d!BqvXV;Zo>g+MBEzn3*>{8p~rn!!w$D6m0dT}+jM#9EX5)o9;JI5wPn+N2)~`coEJqR-eGPB@>-k||Tl zZX~b}z)s&CoKP#>&h`F%jpC$oDbBm%(OMO81Jf?tXW-NmQA;|A-rBk$MMFx0wz4SU zVBW;_{=|e*IufPFWp9|}-U{kO-JW-MZSF|!QAX`WTA?(KKUkf$<)hM9>l*E-Se>*PrA~>V4!XP8cXye53~Euh zr)>39FNP~6%2WDU)jX+l__boaG;i%mHk(M{*)SC;s9aKfx?FXqVz~`AN`5QFtUiQRk4Ji zx0V!O;a(QMgUoLApn)iI(%uqB)JQBrLLs=iFvKQuUz%UO5~XEZ^X8aMCt91x8u*DU zsM#W+aB-PPv@U8+Q9g3W9Kj?Ht4vwbL)E-=fSVx%P}_SpNXi!807GMA94au~!0p57 zZSmP2rp4-FQC{n=bnt-nQbD^8F&r7OLK(1>nWPCI7o)2xs+_{a%y;A)X#CVAc8LD_ z#p_y1hWk+yucdnaVB+^H9W!sT zJSj8Brdz5`YnV^n!qRhj2Q0mg`L`Er8<70CY&anLVs*92ra%I-E#@X<9w57)2)UH+ z9$T?piZ`$NmdFU8?U$h*iGBw&QdF+_O3%zuZAtZgX2@a!iq6*F68V)adX5iBP|HWJF^>z(lkn1vEyQafkj(h4cC7x z24#{!#qTeC6YCg*9U5+iWUEP7c8k&MTwcPz(JANCGjp0GgN&g;I}-9^N*AjSWm$Li zp<1pvPmlzZ@p%g+4FXW5GRAkO{q}XVl{PY>--AqJA5~MQKnLoa3eD1w>0ChH5Gyx;o40^jbg*fZs< zihwGaK zF|5?v)!9Bdg(~9~N^b)Xu-PTCN4rHXx0M!t_ANnlbAlXHqQ7z|l~bK#o$kgwawNXf zko9bQd=%xea|DAcukgky7WZ^4vZ`Xd5U*?y!0=8qh}-BY8du>l*_=3iWie-6%3dm! z_D&Q&?RpD-%*+v?u=ojXx5%u(NrG6bq!4xQX{J|kkGt989mtqr%p1N9o9?gQp=&2y z@T!)RszwA56rAZmj4mr*Bc!uOQk89Nh(tlj9d_ImqC?I$hy~t_;V}J>eXNyqkLa+Eq&b-M4i+M2Q!txXBLl0 zu(Vo0gF720y{V~KD_4&>I-2UIB=UMJ>7uQ&o(&08kiJMchrQUR6af_Jf?UId98UJ- zM^!exrD@pc=qNIZ(-SS!@8yyT=s9Lstn{UR_Tf>s$PoqjKSGm)Xm)7I%0>rS1--|E zN=_Y|5M^SQzSqJ+=6s7DX5M+<2qRWcY(iUXzM5E+W>dormJUjZ8LJD!(7aI+Ya1JC zBL$dXjS$*Fy6I@b(%QMSv9gY7H=?9YQf7ya!_|@vdg|jenp|ve>JKkT^R~;p6>iu` z<7ASI{HydXy)2$SVamBi#pb#`=T5dlDS4m0#a?zI^LB2ahOH(91jwc$OU)uzZZ(@o zgI}va&iO8upH3V;Ajf;2G%?C2Toe?r-y14u0LKbR`ocCz<5mS+o8y zi4vC4!zDMdT>xxqwg-VfwF!4(|K!AMGOttRy(mOJxEwD%GYB1_BEcNwVh~)cfT9JI zMJ5=rlz>$J_{cK4=m~w^IaWbtE}4|lrMu{eq{(?RGs*a*`(%)ku}vl_m*91fZrjf5 zuhgm!#b_o2;8vqnlEPKyvm}DSy}@OE3FfWr80-uUQ;rkmI!d{h(tLdC(DkSxku$XGpdu}2m1*pEeT4)G zI{1P3V3-YLnHV+rpQYlCBj>ivO3BZ4S|LshMIne)A_mmwNb?A%p;^3G+ygG4QKUaU zJ*DFaki}5bFRG(y;ZrxxTHTUo?eZQ}BV#*ZXEHnGg21_yCf3D~QMMFg$navO)7q=$ za`oa|u1Q>Qm!v92hLIvW=H^H#N=`nADien?ew3K($tFUM2xJe_3e!2#`e{0Yw15Pn za9L?l1(=yhX+a0@vG0lfPO1}kJ0`1FkWwpa!bq{T^!UmVlynzEAl93bcB1?pZ~4AC z)Qtxyptyc(Jzu_vDTSV;e6egyCiBL!zF}|wB5!R5VGNe+O#fck{ag*rE zgqtRPQ~11@8myZ;ZB&vi$LMU69dKi9SDLq}HjZI&WKL4F?IzYjNOlW^dUKI52lkMz zu4(cig(0`n1EyL?B)4U#LoO^viSe^|aU^U>RkTf70>KYIGJTE z+3e#^0}7k4y|$LgyJW_TCFIU{=u*)olQ+zi#wSYJ-4s`LhuN=Q-a?Mlp`7620+0O? zGGau-5okg{f5brxM{F|sdyPWf5J(Ki^@~=8t$q_XpTyzb~mjjhuPQ4QQoH95ZAdcRi(xHkR zg78!)uXD`ETIXhwiM=7>;QJcqlpi;qdf$yI1_%-UPL(MmxX z1@;JFVno#;y;qB_zzDWU@a_Q}q#AK@qnLeSd`ZhiL7Lt2cmccJB;5?x)MB;?NKwhY z+w3HX<4PE0bca>W@?3U;hUSBbA!?utIe{?ui)Laaw$q;`p4NcN_5gJScxB9vP*JcLa#)ndB3S*De!Rl)c2W zjg*#S(*iq(V<+io2FZ0Xf3ZR}oUX3MMzboYlh&PFS}2|Bx!Wh^lJmU&jf&UU)kS#07- z;;54rT{JnJFU8a>?ifckSSS5=?3>GTh?!&G-UwhvfIM*L-cCL8-W&<=dLAUeQ=4y6E{p8?}lW^gS1KiC8@G}hOJLJ z#^;v7R{q3VnO|2Rg0=+7U7u!mejO(H`XykBBgR|loH*#K%mkHMfkaIe(<{vuEg2+y z-i^_+S0yV-{os1TQGZLLLsj#m6~c=H4;ZbC6xc1N>!tK+#1n@Ad1W1KhP-xOfFz?` z=_K`WThW)vh7HTQixnK>aIn;ErHO^;FxsIkfkui*1nr8Zi`C6q@I*ED3Lis~;nYyu zZ^MLl=T@N;k?aAc4399silbx(jzZ*#E}+!=4{08|6aQGKw!M90U#~ ztmX|Qq>qm~wLOGAB|0YhfE0oWHY9Vxiygk|)v)5|2yVd1Fi~v=J|jgUkRej!MifPk zg;Y7JbKN^Ya3r|%D{Q9J7ubXwqI@^E?t>HomFSb)#2O)ufX>C_GRN=?ll$I0H#FFZ zsZIiMdwY_eGAbvY;s^uz&ctB|l(%j&Zo_mm0;@!yGLN{lr>Um#ijc^}Ih#ugG+&X1 zBRaJ8WwF*2!j1z|EPMBPD*m`=xsqghbwMwxQgxi|)LD|RzMNn|?%yAKeBw2yk?Ey7 zbW3$J@=3Kc!U$X1*w&g@!vffR1k7i~dF^kb2&IU|!AbJCu=i4YeGxZixAdI`5^=?X5M#o2p60`jZ zI$3oa3lL;}kNnLV#R%tW8yTACS%`ZkIHxX`>$d=)=xuT)FUDkcpyG&n<4y&HipQiw z!=$}#GM?LP(xxo?ke)jVgmKHt%{aKG9QOVkKyqtH_#lJd>T$jt z%|IwMZhz0yX{W_gd6{0>QD^X{x^%r5ea85A*dNgOyrFUUo}fR=5|km_lyg56T1U^GfPC)uD^{ z$#!Ou zV{B3UF6Lc&I!^8kztNT%S(CR}g||6=!{=Y#h{8mqm7 zH7GoMiv#^;IFf&^j&bh>@qq@vSDYjA0{(UvHtp5Hqcz>buZtGCvuyT7NBgS5 z2Td}T*her5EQTi(s-umq5TYiwX-0;q6B6XaE*?jsQc4*X-?Ra^!a1ktXjhZb*t|53 zSQG9(M!0*%%C>~wY;}w3A^`rkH6-1nC*36&0K22P=h9lfBgKmP0U{ zcgVID7cyn4pX#5rl_{ySb5vz1oXvwy%TgIH+gY6fa% zscN!a7os!Q*n2iTF>{qoP{xBqCM!pYW2H*p|Ahr;bKe_DtdAO^flm(5#qH@`X1+VL z;+%$POfJj;@d?o<@2uK+4imVhP(8IoWV^Z}iUFD&1**SfIpH5bKhbxM`CeP16xXA5l&bgu=<@)3bZc zX3MK=Tvu#1z!zmM;OK=qYLiY+L%)wx)<@gdukcYdDx)w2D^(JhVX}d7pY3}Xg4bV_ z!MS}ya_5raAnCBwRPa?*=qYjqCq-yw7zHDHP|u=K(Z5&zk#0% z(O|j4-=Y6|t3R&l!^9m84IeHJABrj7R^;q9nAzbCG6+J<=N&V{Cpm`sKehdv#Vs#D z9o8f-6f0euQtF9*jN%)o3W6Ib%e7Zkd!cMGU>!Td+!1jg3$+U!#Y%w{VR_Reu`Qd! zzk)DAN^FUbWJ}m(E`q?`v>2A%4!I5?6EZ+tvMWzc;p#48UJ1eM^ft|QmdZd`P2AL$h(B$k>1#HsuOl%D$^cq1?@tP2*#3&1W z(!tcufh5NnbI#JrsC@5Tf*sMTJ^3JQl@v3JqBuUrq98yX8gi`B3X7sD3C}61wo|5W zH5lhZ!kd=3W%e=@B^g7Ntb?2auCSCU@qLQISUWSBpHTF6Cwbm>&f7K#^~6l;=F*D^ zp7O_JIEEGiC!F<1RgoO!G~_Iq?X#LOMYgM_tH!RWx$8Z5&x(7_Kfqjb_qltZF>}nz z^^IH6R_8-NeQ~r*=-=+S>S)#7wwS%mi4k;Hnm$NUm-7W)5G%2M7Gz9Y6%JUW1=}cS zg@1GgSF;o_e?`q$uJw4q`k-Bv8amGl5mW>#PmqWi2#z_BnC6nqC2P@UqcJk9lVVSO zU2BRjwcEF6www<(a@Pli2;Q%Cv^CsCb2Dwdt0*mzr0}?BopxnuL*vR=$~Ox}@-JXA z$HDbpT`88Tm^-tlF(Faxfm;$1hP4knHRyof}295bYcQhT?z5b(!799uv*+02AiM-uZY}I_1LKp8eNFA=w;N@ zO4D5ygO)CIu!J#0mW`Cvs5(N%Im~Hplbh|YELF<{i&zy%{op55QU}%mRL?oi*b<=f z*fQX(E!u{r#^V=o@ujjW`!kTFG4rgCDH)C|1D=b9RsJL@;Bw!Enxrb>b9f|riMj`4 zJg1#munvu7d0-sIOSmZ0mD}XEb&ubV$LfD*tjar#Ray=lsbyl`#>xs3nPF=(3L;S; ztw6zRqiKINJM$|)65jY)A_=71S1gW?BbZHYE}$c?DM@QIF*wXbw(A^y3!Q&08#3qlq|?J(%EX+nDlwC^B$@~Q4}`xLY_V>WkYB zxWpCOZ?Isy8{EmW+F@{%Cv|GC_Ai8Im6D{CNpa%QAd9?F@RebXZ4 z^}osOcGyR9m5AR|Cs!-Cr$OfiYo~%s(=kc=Cb%!ztq}4p7IL}Vy>jR0?wz}UznAm( zA^hFL-@W{uUbyVCg|Y1H@Y{oOV=Mhi0)(E{}${e*o9@x+urI6 zvycxDk}L}(0dPkVycu|39LJlu(+nw)k@R%l1iSr}t9DJ?ye^h0!;<5MaXfs?Sz@!S z<`iK7k{FDUXad=nVySRb#vG7n;r{pVl#e3tMQq0<6K|K=a3IJoGTV*j2VWF-MVkjjr&GZmYN^6ToRH9 zez05;@*m1uWReqe(aU(1@ezL6tzcl8Je9`l+W1ZeFcB*la>)%Q#QGcw5{Z)%3E6X5 zyqz$vDV&kB3y`_Jv6pTn;xGw_Rw#qJ6CF~?li7Q=dU@`CB;%2==4M((g+m`tRgdRU z8Nz<^*o&7*ZCo7VIMQ6MnjdtV5!{golKnbEMCc7x@|<_yT-3$uxFRe*t?SaXZq(&AKlE*2u%y|PYJD&Wv=3GGXBCJAdlN%)tx)cd?$=(W- zpSMX!voun+o6{uVU@+1B>!f5SAXtWK*;?cX{J~mQcoQlQEu=7PCp}!Y{@9?jLr8;8 zV6{6gNlI&oSt*Yw&#_2JoH~q8E+wiiSE|fWiMnauuSv-CXDl6CGwmdVtitFm2))A3 z%HH5kKC}QlKLagysYa2r0ur%P-4ep1`iI3;G#aEv!4(44Wdz(dFbh}-%`tM~zswWb z;MzrxWBHA^S?UJWx2mga5m5NLAbBZZr7$xNfPeta&%T3q+%%( zAz7`JDk5s+UL%a7NnBglW-~TYu09Zc+<;?ZY-zQy7Lhh9HdYSqo5W+UA6@`EjI&;6 zN{VpKvkaMZk0q>9aVD%^nW@BfVqdIS^{mfE$n`ZP$eEejbI_&`PNC>3jA&R5prCG- zl-sPWGTgkYVLDCNbG}^o1DRlxGlQAL<-93(yx(o+hzW^I@39oA&at9ucj)$UUYv3D zhEf+)U8s|@nQ7GwPE_eE+~P!w5RM2BNivjVmozq!G*(5*npDP$?n-@LX&=$uTa9Hret0t`ea=0i2kj}bf48OFS$O45hG*On zue$dS@c4Q@eTqK4cJ6>n1E}G!kwuyWEynab8IxU|r3%r(7 z@^IyYJ2iR;aQWaQ5^F1NTCjBlz!8=3wDS6uSzKF7(DF$Zo06g{i=V{o{&yAqw%@@_ zDs^o|PDZYtRuXX+orKG7a&8|tSl%Eq!Lb^HyUv_?B=ON5Nmy%OVjazc?DjB?Cfr%T>JMsJqASxhL zv`NSq8{yw-3SQ1QOVIET`W(VS?4pdw{@D>Pw=>S=6^Uk)5lDn)HJRq2eP)qDD{zTC zXsNA`Y7u^$-nr(CNR^B7T3Rdt=Z8mN^PRZ3$q`5NK*@Glk=(z%N-BZ3<6fskW_G;& zae**c);!4waNVpomy{}mxEu==mdM9ji8D{1DdB@;z3m!Ozygn#UAiZt{xpJS7}^qw z39*bH5AmTxh11x)#DPH#r8+-$AvE1)F%vuy2L1?J6b6W zie2)_YIItuGYy7`O_%bn{j=g5E?;dN2dsTfm6RNj7P#=V(RV5pA2xMgZA zFjbMf*AJv!t~X(lek9l{B$}O1Wt1^Z&yrZl1xpuAtSt;qH`}`|Q97fA#;@dZ$zD-X zq-Y~`7z10c^28Cj(W;a4oKfeL5lk#(3c$>4a+`uSi#}7oJ(#cRpib-AvVu{MfJ9y-yC*~<*jpvn{L?Wbhl^n2ab#i5^+$bZyS8}^D-$!{mmbEN;f)Prsjuihy z+Db1eKh7z+cGL$qBa_c0p5{rnXB>Y?eP&{EBJUU_>>rstNqBcSo$zit#7Me#j0V{o zRw~0Rn-!>I&{IfNY;lcqm;<^q+%MN zLS42Zk!yk&)h-mv#EPl{Monr-o+lE)i^6OqwImLUleXmtMI3n=!8#llr{E!kk2;&y zkp}cCGZiZ7SI?4foAR1m6M0KBbIiwa>#?%=9Yc7cj39cA+9+arxFEI8!_K=yHc6kT zHm;c}qocyHMuoixkkX8V&tdm*Is~H4w|4W)#KB2a6sHeFV|OIeMRW-hE*&d7$WE!D z=^w^;{dlewn`D^d2%Y&x4j3RM6SON2C6o)wt9$?hXX z?bvLO21DREk>GA8lTA;z6ucud9Vr44^I|`%pA8-)>v79H5ybQoTa|9djoZYY>~u

rcpFm8i8z_NpagXO4xrv$m8neY-^RDpfutm)A;uCA~#z@f|BSsNdU_ z9Z~;HN>WR@_OD~R$G4m{X|ZZC1p_?{Gjw+cMlXiFHG%tOTy+*K$vqMh67_qxmxh$y z{dKwXav~T~l`O?oM z@>7aCGXvb9AGcuVZ|qCM>Xwh@x;I*db-{Ztl`@H}D^?gw>rDz^Kulhms-55IC!3lc;CACx&1&rBN1rJ&zKk3)a+MKaVJh06Zo>N!=MWi?x!r-(5wDey3I1{a6B% zXoeKqL?lw`K~xU7wu$n}u#^rnaX$sAC7jxh+0i0bPz!vd3MD1)RMs=h2X?Mmdi#*C zd5UZLw9S3d!0~qaByqT_$KdR4=g^yxQ&Gy4WItuo@Y+kl=&72|au6z=h=PU05;>Cf z;1sppV=_E(&X(-vGBorar9O441O`^J2YBZUeHf1hMh^>aKccM^*!YtuH1;%1S#+Bd zM*C8p+Y4T)+`MVYu0JM;cW$v+_%WKCnwm)k(f1Xv1m?4qU6cC{Cw7#?eqrL0WUM%5 z-QAzu`~Th<=Bw#5%=r@Zb+@`mm=SbuDc{lm&>7|!B&IlNoRr=8D_Zjs*yAKq@0 zJ6b$Gw*KM^A12d0TQ%57-d&a96h}Fe&9`tF&6>B~wz6Rw^qoc$6 z3;9g!#jE-{8 zcCc2cdD#otTrqkoFreQAI2?@^N*6|hV;tYG6p`>tr^`0kp_jD5`?}IvUE1(6OqYg4 z#iWhQQaE&+YAvI)&|`Xop4z6$dB)9Z&26r^e$(Z|Wzk`F({4=wFjTl`Ah$ndMcp=J zo^2OBMPV`sOHDHto2tgtA*{m`Lc;M;L>D`&w9R>+sX`b=^!aqVF69Semc~N7l{?H> zaaH7x6r0k|l~I=yKFd4&qY4t#O(E~txDI%=r^-dI$HkjEb(xuK`@0ik_159uvF~!fbYX+31JwK44RLt;E~isrTAU_t&3$-Mn@&(X}|G5UlOqqk_;@0U|s`O3I^l2M?b3WK8*fQ+bFfa9d z&3eHMpm960k#ydwq1w3Q6?pu+;ZRX`=ue#Zj(%}%+>SmNXJzIFzX20Anbth%cZn1t zi8vxEIz~a$JwZU3a(|sT_h5JA@Ap1~Z4~l)z z$=~)tVh119SofU+G4vrdZ1kHq{!*E(eWpjTq;VVv;l(t7CW>j;NU|ZEaBSbs^rE)> zAK6}H8fINWh1l3JlJTim#xiE~k+C8!_Dqy)v~PF$e3yaqnOm^u~SojS#bQH*Dj zTUF}m3}vb#e3_R+1&ZzY?her;5m`jG#_MpYPC;4MY{*cc+S|y*6-<-_P9d3zu$d~u zk@vIE2IY8_=!~ZQ7{UD!)!S4cNkN~80lf_zy^NQ7(@d_htyQP2 z`aX6aYHS6pxvhY@K2r2)qq8F&0z^fj;ib0S#2pc&%_5qyqTC8qA=`~73a$Soa?OE(V(eW>_=Gj{=g{jE>D#zlH|*DYHT8{X>G@G9e#D|TFC0D zvJWEZT5LxgiQ?s|R1}JcgknA53G5ACCV5yi^pXF1#q%>Rw&#DS=4l=^QXOSaa?17o zIJx|u;0*%oT-)yhV;5rbXu-#v?~_;*trvY3nVpJqxu%gcA|x#N=PW3JgC0%7=dhFw z9c`B=`ixfLafm27u~`Bvqn3)%b#F|o#^M2-jvc&oI-646tIK+aH2MIIg`qDw?Qe0^wb_+0G-i^rQ>8&{yhc7hSErEw3!R)9eOI zE}3*HIlOO(5^A!}U9C_v$+;S|3BAnbnE%xWPiXjF

EM&!JMP!3Gu|Gp=k& z`lT{bxi}_u<#OdR`{FE|eJ@PuzsmUGN6UX8nOY#2Bc(DX057>~=a9RFmZay6^s0mh zph>9#h3NiRt=#S}g{04UPBJ(*$W_1Tf5^hUuOuu;rxzx!TE!MCq)I0jD&|+eEbvKj z$GW;mu#$@e4l%z9TGD3t4l%t7x{7kT;-Zm@JRL%)beBA9>s;$v)UOL<+RgPAwHUE? z=?x*INjsRj+^zR2h*#>bJH}Ca`4y?v;dL%rt80~7_RlBb+$u+R&Vh6m0Bv9z zw0A9A&~x&eLZJ0dHCsXA%lzv?LU!8S7`oy6b$l|YNvpC$qdsskZRw#^O{cIvxA?)g8? zuJb>WU8izKGPYF5@QN)V%(n2)l1UA>6#G(o_*VBQViZ$nEZ77JpCao#6yoZQWhE!C zr%9mw6eJt$1&(7u-tCk%__IRMLed6Dupayl~?<6PRof&meQ1}~lQfO4_u#pdd`KcK4| zK2(a0_@u7NNMJb?|K>~xT}`KX$~u@j@`xt*O>Nii-#=7f^W)Z2&VAcr?o)D!%CLZH zl=3!8>WX9#Lt+hbdv|*}Fx1|QhqP5k6`q&Eb*~H+|p>;ya^`pMJ3l`L{V-{w+*VT zQ%+1EPb%yrh@hf)b#;f{ag*64?&OU)Q!Qs9{)W0{yzjhZiu=xR*6vJ()najUEPdn^ z*)2z7@wA??bk=IM(_(3rX~97qmWZ7*IqR!y7-v@+Iv}2{CbvoD zvcx$U&bW!YZ{OTrf_I;m*q})dHZs3!cSAc?*tc0fh71{`3#7@7b&LFUXHdpQM%k0I zFIlLsF(~Mlsh62{uVY?xcxbw!fdIVD#MyMDidsP7&heeHD5fhSDGoOYb1trr+oXqk zbBUm3obdA3;S?qW77qgP`)=6#7KnyDC5|(>H0J6KHBTMIa7+*qKhG8beN==n?l>Rt zQy#0Hoy)ls7@#cXi8DLMT=En>>6{o$Lb6796<5~pVEGK2?~C<}Q5A`gI%Eoeqm%vJ z#&_9N9jPgWlo(cmBTVI@Crl;h=dwF7+{bbz#c!cadZD^RE#Bw$6Np@eBLv9@96w*G z)V4ixFjlED4k*rMNLxP0ER0iiEJGJPy^SpOTO9J6G(&{fPOl2mGaI}^W2$AHX_zk$ z{W}W8TwdhElMIO0`pSRae*5h|OuUR_O)m$p0PwWjtH7%PyFqfV12tX^fH#6S zfj5Jn1mtDPy%oF-{1kXQcn3hO%e@P{8@va+7rYO=AAA6O5PS#_k)6XWk;8VE!wi=D zS@3h<=fN+4kAhzWzXU!8J`O$sP~CIC0zL_T75p0bb?_;Gi6ZxD@SEVbz;A=!0iOZC z3w{s$KKKLhS@4J8kH8;;KLLLVJ_r5`d>-K1&V2#=1^6QP68JLsOYm3VE8wreSHa%^ zRJ7dRfxid;0R9pD6ZmKFHSl%t4e(9yE$}bkU%|J*cfh{^Mn3ml@E_nm!S}%JAUDAO z!3p3*a1yu^I2qg-oB~b-aH!nr;4a_{a940Qa3(kl+#Q?^&H?uT=Yo5Jdx7)7y}^CJ zeZl>}`QQQ&f%}68fCqvHfeXQd!9`#Y41tTmC14ojK>_RnMNk4|Pytm?10!G*jDc}* zDYy(=4juv?3LXZo025$0m;_T`57-N?1pB~#@NjSyH~_HC=MI8HU z1H2Qw3%nb=2fP=&54<0I0DKU92z(g)H24|t5%9C%=fKZ{UjQEkzX*N_d<=XXd;0RIWT2W|(s6IlP?1aKla3ET;s4DJk00jGk~!0F&F;0$nA za5r!!I1AhzoDI$a_W;gql0%cGERZs&XU=)mjad0WP3|tN#0v-w;2Ce`TU^kcqQ(zC+3$6tF zz<%&>a1}TJrolmQ2+V-1!7Mlo=D;=JT5uh>9^3$K1djlZ1UG?4fk%VKfI6553t$m6 zz!F#nE1(G;3vLE2unO9s1J=MTpbL6n9c+Lj;3zl-Ho>jnap3Xb3E+v~N#Hi{WbhR5 zRPZ$Lbnp!DOz;!nS>V~=IpDeAdEoir1>l9?Mc~EYCE%stW#HxD72uWNRp8a&HQ=@2 zb>Q{j4d9L7P2kPoC&635Tfy7FPl30CcYt?-cY$|<_kj0;_ks6=4}cGX4}lMZp9Vhz zJ_3Fg{2cgs@C)Fh;1|I!fscWYgHM282EPJ634Rs)8u)eaDexQM)8IG3Z-L(izXLu4 zei!^6_Uj=^y z{ucZl_H178Q<0N(`P0{;U36?_|f2mBlOcko^CAK*X1_rUEScOvT_ zoB&P)CxJVGlfj+ADS-W^xzoVu;4a_{a940Qa3(kl+#Q?^&H?uT=Yo5Jdx7)7y}^CJ zeZl>}`QQQ&f%}68fCqvHfeXQd!9`#Y41tTmC14ojK>_RnMNk4|Pytm?10!G*jDc}* zDYy(=4juv?3LXZo025$0m;_T`57-N?1pB~#@NjSyH~^->L2wAnfUChQI1J{%HQ-us z9k?Fc0B!`20FMMWfk%NygU5h6m1}(4(+Mom0z%8H)dSD%F zfFs~2I0iPst>AIs@!$#IiQq}#Ht=Nd6!28=H1Krr4Dd|w6X03k+2A?gx!`%=`QQcM zh2TZt#o#62rQl`Y<=_?ImEcw2)!;SYwcvH&_23QQjo?k-&EO}&Tfkev+rUqOw}W?p zcY=3;cZ2tU_k#C<_k$0B4}uSY4}+fuKLb7jeir;3_<8UP;G^Id!7qW2fscbvfL{i` z0zL_T75p0bb?_mQr|P6Q``JAsqIoxv&KRB#$N9oz++0qzR! z2F?U$fxCmV!8za_;9PJ|a4&EkxHq^DxG%ULI3HX9B5;530PsNYAaEggFt`W|f+27* zxC9J?JSc!&pa@E!43y%m3Tj{kjDj&R4lV_kfy==|z(c{qz!hKu>;{uy3hV)U!IfYi z*bg2Kt^x z3Z4d@4xRy?34Q`R3p^V<2Rs)%4?G{d0K5>q2)r1)1iTcy47?n?0=yEu3cMP;2D}!$ z4!j<`0lX2s3A`EnBzOyWD|j3DDe!ji4)9L!F7R&f9`Ii9KJb3<0q{ZaA@JeLDptz6YhvZp7)^vp2RyUVgJQr%rM-E1eix@V_Xf0iFq-1)dF_1HKV_6ZmHET<|>bE#O8m`@IByr!S{iegI9p>2d@OL0zUv=4So>( z5O@uEEqERHVelj1N5PMQ9|u1HUJu>?-UxmYya~J+yal`!ybZh^yaT)wybJskcsKZI z@E-79@H60j;Qiod!Owx82Oj_*1Rnw)2EPD40)7$v68L5CE8thbN5QXwUk4up9|yky zeiQr__-*hz;1l3?!S8|J2Y&$m5PTB+5%?7NWAG>7)8J3RpMgIIe*yjy{1x~N_$>Hq z@HgOZ!QX+u2mb*65&RSQ9QZu=XYeoJ3*cYD*iG60;6~sQaAR;2a8qzIaC7ig;1=MP z;8x();5Oj4;CA5l;11x9;7;Jq;4a{<;BMgV;2z+f;9lU~;6C8KAOrUU_XiIE4+NKj z2Z0BJaiF{&s)62M+}g0}ls}0FMM;1E#@# zFar*NgWwQ2432=K;8Ebw;24+%$H57353v7dP;CgT#?0_4<*Mld6 zr+}w|r-5$(PY2Hc&jil`&j!x{-w3`5d^311cpmr`@U7ta;054?;M>5rgBO7pgYN(@ z0WSsL30?-i3w$^D9`L>3`@qY=E5P@ISAti89{{fgKL~yZyav1$ybk;@_!01<;K#s^ zgP#De2X6px1V0Jh1l|nZ0^SPV2Hp;HW_!sa6@ULL(X6%1(BX9}0F}Ml1DYzN9Iru7Y3vf$tD{yOY8*p22J8*k&2XIGl zCvazQ7jRc_H*j}w4{%R#FK};gA8=ogf%}2`g9m^If=j`Jz=Od!m;hf59s(vo1*q!F zWuOM?KyfZj&;rUtpwjVO&;wK8a_~^_Fz|5j2=GYoHDDU-2Q%ORI0z1b!{7)w3LXU> z4UU0Xa2%WfC&6RDDR3Ihfh)k3;41J~a5Z=wxCVSJxE4Gfd>wcKP~x3=umEH_9e^|7 zELZ}|;ECWmumVI;QPTV!K=UzfLDVb1V02`16~VW2Ywj*2>4O(W8lZZPk`5hH-I;Sp9F6L zZw7AxZv}4yZwK!H?*#7xKLy?mej2<7ychfocprE__*w9C;OD^yzz4yHz=y#vfRBJ* z1iu7+8T<pYv9+x$H2$IZ-CzfzXg69{0{g8_+9XO;P=5FfIkGE1b+lR1^yWP z3HUVlQ}Act&%s}SzXX2;J_9}r{u=xZ_*?LI;P1gdfPV!41U?5o5B?ea3-|)~SD=L9 z`@oIBCE&*3Cg7&vX5i-FtH3S5Ey1n8t-)=;ZNcrp?ZF+u9l@QzoxxqeUBTVJ-N8M; zJ;A-ey}^CJeSy+l+z;FzJODfpTnZip9t_5T%6xn^cnFvT6`)Yg%Rmh%DXsEYH9-p~ zd|BE2%a9=rj(5&R^06L>Rt3wSGd8+bc- z2Y4rV7x*dgZt&CKJ>b3IXTbZw`@zqGp94P+J^(%lJ_J4tegS+0{37@z@XO#=z^{Uj zf?or_4n77x4t@jtCipGz+u(P=C&2H5-vhr7{s8h-(#%=*_32p^$4Q>N&3vLH)5AFc&2<`;#4DJH%3hoB(4(ZgFc=3D;H$wyz$B=ED!2^PKpixI66CaivJ-Sb7pNTU6u2Bb z6g&((96SO%5_}Dq2K&JbH~4W0wO5quN)X7F6_Jn${xTfy_e z3&0D(w}Ed5F9I(H-vM3%UJAYwybOF7_-^n$;CsRMftQ0YReiFP1ycxU&ycN6+ydAs)yc4_&{1kXM_-XJS z@LupU;CHCC*afIPr;voKL>vS{u2BZ_zd_g_-pVt z;BUd-fxid;0R9pD6ZjnXJosnuFW?K{U%?n&ll#Dpz$M_u;3nXv;AY_F;H$tbz%9Y8 zz^%b;z-__p!0o{uz#YMzz@5Qez+J)Jz}>+;z&*jez`enJz6u?9j}^EA?u# zh@))Q9%^59tF8P?;uQP-ZN1vazioyPA#b9ce=oo5YleeCnh0nmnZm*mnW;5diq#9055&CzB z*w4(>sgLU^a=hB%g0iY*k00B2nwS?a$+I}7h>dJaaT$tCnFk)Sqqvw=i}uL4LIF1` z;X2g|E2?pM6p8A3Zty=vlML-wuY!4eOu6Ob zbHv>8GbBZm;4eXVY ze!QHrDNax+={DZoX?Y2}yL-%sdE(Z}c`Vw^)IXL|Ass{)zi{zZ9LPs!r{`+5TD{w? z#}-&%$uI3*qXT7`9xkkJ&MS{F_iN&L=6$%IP>c{ZvWBENfNQMzh(uSu^T z7o(aM>HRi+&iGfWb{QyeO?k%$d5h~@v&ko4+uAi+lZqVkC@_z<@}RgOcd9KF;LtT{ zTh}STZHM#eZqy{X3B@k%hTHGHIR-F3Mla#9ZfCi)*aT`!ziCM0mWjb@F+}WQbw%n{ z^mcTBV?bDuEPdbSHEl{T?!&9+c}jMFs;5U^<8{)4f5j{6#T6JfZ@t%BX=|(BTej`J zj)(`3WtPBw$%bZ&|MtM@*ew55@mvoi+v{$%m9boE{Lil+E!o#$p;Wo%-muXY-820n0brOF#L~iv`c z4MuxF$b_!poHibn7D!-s&3Q)WtItNI!U#5vj5A+oUFP38L4_(>@)47 zm^gf5tXKnS5~y~s+0B2Ms+CU5R`N?4fz|G{YsEcNrF%Lx)~6lHmBuZ@UyYi=Yf6`O z>+!NusjXV0)xjQVx%8gQiJO=CeA4z{b3yU?r78vr;AS(H!jrhf;?1lL#p;|}KDVA# zJgWzrl}MxY^TgLJP?3!N;`@Ni9E}(#qpD<$&O9+1hdh4(8HdRtsF0t?J1q`KsivX> zP(RzXPciq(f~p{v`&=cB&Jqw-=^PSQ>(F9=-W z^4YVhT9S~iNVxL&KTq_SiU+Zz0uNKq{6YLfFqYR+wJ^xxfNnuaM`n-!of9sAbZWg2 zRmr&02db~|j)XRK`Ci``8yXYYX`1v5qVuW}8dgZ`u(qgT)y1_juUc`f#15{cryh!{ zzFJj}p`tIhDmDx;4o^|3s^LIA4VICTbDbLyNxKrJV|`^1Pz11SoG%yn`Ct(qZlPT&T`tY z#9|$b{?_)edKMKGxn<5$W;f;))9NLt%!VyV#gI?5uWbdfdi4rkuE=`HTjp<5dX4IB zP^>BG%y@r-Y;yGHF7V)sM5dDEh@soxnQ0!XGf4}BuVXE4uduhY8*Ev4@Y?Pb<`Zd& zTWz<;AY7)z65Qm^QVbylCs(qw{d1&~{3ae9vp2CXc;n;K3V-w(Je~uHnZ3ZgV`ljU#6;Al>| zNi21Yf?ZTq(EWrH4{lgrU7m-)n{d_Z-IYBtm_Bbe&h8xR6VF}qv>VIuglIrpZ7K5J zB>uZ>`noNnIVAV6+RZ#tlte{F6~(JuSNUqoqg%C$Vauqtq>?pr6_?(2RyUTA<*KhQ zo>hdJYqGSU*U0OoWbMmmpyJB?bolg93ZFq=?Pt#vuj*1E15o-*55i@gCB37>CB2Dh zkvVbJH@D}PMGiE2EVwO#+m##FvcZVLj?d>KH<`^It~cTQGR{K#lM$R%xc|bA>U~y@ zogx+X4F61IoT^uyA}vfWn~{=&0i9O*qOd-A9@}GceMEi3m|o}f%YMyU&4)BE{YjTO zL1@M$TRo~<^G8*m&7+kl%PLHZwrhrzuD=pij_66Fh=y(O_oAh)-{Iluib|r3UDcqL zjI^XB$_nz6Y|p`BHDN4jy+)Uljf0zG;9)55p*HEkq`^4tWiYkbZ&Z=A~#Je`dMhtl%%K0|Mav%wv5Sp8m50Kx2pG)(qS`C>!ZIV%xkRT zv!kw0x(?Tu_%rqWx;;r(Dx1!ZebTt;IcmfEaT&i#v+{vU)WZxJ_6oFx({_c_3EN!l z4zb-pX)Ystph*wZ9Dp6|mho5*sX9G zQqFBysx0kn+d?lZHqR&*&C-YRmiM6K0ZX5J@m6&h?%Fe<>IGY;563{p!8|25oXr}1 zmk~}9cED8HR!S%pn#o+x$@YulRHKn3w5WG$wRZ7KE4iJTkF{L9LRnK5uiD)PitM1k zQ69ahI~YH3WX_WPaWXfiYW23*A@WYZYsCXNXJ0rrDoXC6mtfdZT~C!j`=e`0=*>l* zN`%P_dDrpY09?lN&(aJ;f2>5odY6@wMMY@MVX$uM*UYS&2yxz=uXJGaA@J9CueYSw6l z^KtNUJ3Tm}E7!|Lkk>EE&r`+(u2I|xFDw#E3t8Gi5Lj%PJG-^ap3&8Z7O$8+c}=}` zt*e!&Hb-hk4xoi)%ot}@*3WNmTFPZl$3bS1b?yw+tLw-mYG+t|F9%)TP+HE#&MY=) zNor$#TP_*I7qTG-rr(mXB&RQZYfOb1%f>geN7Sl~HbXa!t%M@paOL4$m5Gvdm1n5& zd(yTgBy1*cO1czhh&U}-QJw<7Q)N=}m*9*%RJ=T802i;Ac-UAL)%49q0|xUb3OKkY zl#YSH>~YWLtUo@tJ*YG+BaAJf{lWQ1WWFwuLZT#r&y zk@|&`UUkmTx$@t*i3>j_PD99yldv@5vHKTRTqlupO8M60$fjP0NZv-HUfr^Ft(}_Y zhq9c6&QhC(aeD5A#$6pUCWGl&Sy{i{xa+jj1w|h>$=G=$@zv6Hk}+g^aJe*|69r*P z%`$BiN(Eu+jS{9_W0AR{4Exsh4J6;0*Bm(gWe36454NR7k?KOK5(cz*c{ZB1Z=+K% zF3q~7peZNmx3{Yny({Ub+PzlsOF#d!WLavrr=;n2T9FdnTD@8N*edI;dW{|{c!uio zOWWD$rR}pYl&AY^jKV;rnSHj0=kNeIZHkOQIdZ8ZCoIfTa)Wjp=L)K)q2?d0 z@xY59*!(ZA!R((yi=y8=yO(a*)ro7XAA!`zLI9M$)_RNDBK3r~by_c(g)PeG#uW7( zY!sULQQmBaOkB-INc`BYg+J=Crb)X=8ZIqPA3@!rPa=^8&us6q`up8*$SAG95ks~*-y?iNKUV4thbU#LFaj_;DB94KxOUa`5^CB({IQ3Q^ zCCOY&!l}7lnmrw>0?n+?Kr>dDK91Cai7FF#pA{t{?t2FPwUUr^d|C-f+ZFM6kV13$I!B((gwjfHdwkxxP6O{wAa}!vN{H@CQ`1cs>lLyN3|UfiOa^ zOtV4f+4kp=W9FCFMGO`3`^JvgRF!*h`bg#U)$OZo)#Sag*@F?W zeH7~277R(q7@G}9*San-RU;{mR|ODEjtaGO&uH|vSJASCBe5V}to8o9C2RApGl#nK z0VKH(%;m>b!+aKVF}!3`iR(0{%2;aUBS>H5{XV>#=307atc9vG(a}qByIOuLz^+BA{nZ5Vw znYwH$rZj^p6r`~sIxIq&GY}LbR2DeP1{azeQmUFBTir?!(sA5?X ziMV7LZBW8Jx8}1ujE(K8Af=OSmi*!<&{Bo+sCJ)Z&0Yyvr=0EC-7O`o37f_oiqtcN zgM?Amz+jo)T(1r}*<4#{EEn6LD#H#^6-(cq9~N*>RY^t6Yf=6XYQDC`8bhB>}}<``$>!3Mf>UCJLE#O(jkl9TC4&#u34(aHQYY?qv7rfSXN zmy#K9s?}m+`gziB_tV35s@5rPDjmC1wJsYT3FgcSsV>)~kxv|J^2$Bp4;Xhf-k2(_ z?yk;<;(pC!u!PyB)Mg3E#6ue+!mCeWC=05QTV8`>=h`ai+m4E#La>1)Qda5fOZrVH zKBg1x8!QRRfL-)rl5VK7H_9`kNNyQKYz&{&7343|3fq3BQ)sd|J=_Wg8QJ@7Sv)EP zBNirIfm8 zR@NwHHr}#Mbh0IQD5F62XpG|&sMwE5nB1WUbYb7U0N<;|J@$u)dzwX&@@wUVsi(-E3qv7P0VO=&eSmw6g8rb7htjJcY6bJ#6Tubr`^3D zfBfXkzolVKBz*Svd~jyaJPp=xLZFX(^=S@Xj6t+D!44H0P!Q-+HrRTz^W^_Z5196U zmIq9GUc}%l&jW@NZHDS_tS!|YMkZN|;zPSx$BhFs^g}Lt2&8HNWx|mHQZ;xn%({%L zQkYlbnPg(?Zi6eX6xy>+-;mrH2a&eon|3?dpqDd9qk7rZ`OO_FtWf3+2A(Ibo0o_h zSy^61b%xYqUscI9JIC^0UxSxjXDM1S)Tj-T377+@Qs;Tz0sEx>B=kW>@E{wgake7H z5+8w37)V!Rvz3jTP+002PhwIfY9#(-0T|{y*gNa&ZvtnJee!-jbXa-r_ zxV&njKuJx*gxu6fUmWB;^k@`jPKC&JR~lX&XYu?&%V+{)acSJ|!|ce>D>3ckqeG&5 z7gc!i^kxwNgfsJuVHY#`%N4)LdYlX!iH)80Pm{9emXO??#5|v756&G)6kxn*G5j{% zA_@&@Or6wg#e~1)cM_(qLIo8~RICYI>USKv*7QV`U+WSxMz1yoo(>ZA_66vTeGjyllXm*hys_l@Gms z%W$REzc=vBHT-@pmfjt%(s#0Tj*so<+mq%QzuO92wv_JeKkU|8*-2&V)e|@HZEj*M zR=;BL7WGM9?5PD+PxsFi^M}?b#Lsd#_i`}BHyyJh$InyTQ@%q!)$=3YwQv&GRihSb zcmMA5-aht&bt`>(fGG=o2Dc1&*Xh2QoAWEWaTkx4`k>>L^IA(GQ8;x@Kd z^KW5!o%@%XP^^T7^`P-NDn(Az(3TbQDmH5A){jq5xQ7s}Lmy6^I9-7xo2Lyl0y&Qc z^T#I})SqbO5d4AF?{#Xu+UKgE*)tkwRKh9aNb9E7+(Mwi!?gS$Gxa5U17xAR|CEon zedzi>Ydu)tysQTLbdj9oWYULT_12J5EHQZg^yj7ajGDSyonI(~r8jk-|MNl0b2~AO zrES$I1~0F7>gt-GCudVGx*Gds$_hvcg2p-xCQmd+s!gQc=jLCfL6>r54cHWu+E% zixgx-&ZCvVuzCqSI(j8qu%jjGVLUy&Z(2>o6E0`ERtFM_mxrrnFJ0eQru+xWclsjc z*Lg{l3NRpy0S}<7XPASa+rXmZ-m2AiCiWec)wx0Dh3%5(^KeAo;_+$`!FMyPZw?#p%PxX0I_3Y8GQYL~_#DF%qF4D9j}_(sj3O^ULPOl9o~KacJ_!HcA`6 z&UYcHx#w`FMcXSqu8WI>cY*49Pi8UvOugJRy}A7x&Pl#$n5s=b)!j|eexIVqg9-W6 zy)%4&@2L%&Ge5RobE%JdC={zX-{pkm>S z(^@t?K6iTB49Owj?g@B`=86DT=amOe#SUo164$-RpGgNMAAvD!(=krTwz%vDXMJDq z3g)YRDo!YE)M9&Sic4mHvE>oaV+Nkh9sB<+&W(D5U)tmJb4 zMjF@UU%ny6ooA#wUunZ72_`B2gIWM5tyX8Mmch3?y4`V$-;u$wz|Qx}*R#|$%dkEh z>qH-@Rw{Gh=XBt7R0T3J`8MsvIkUP`GP&u;xYyW`pgkXp|au>PM0Zh7hA5Cm6D!-4~o4jM3*<4 z#}^A%WwjJEJMqV2KH3a3V%qM&R``j^xL z8xLm+n&%U|2Ev+7-oQkBiIQ(h+eJcW1C6NOZJ!CdQbeFDb+0%b4#}G`0>KNA)hOYR zIZ%5+WgD25_>v>6iLoJ(3CWKw2viKaK=du-VB_?sXkGuhk`&4NLjp;yN7L1cl z#cfTQpQY9gn{F9C&bmOcDXo!20&vF1S>m$8dOEQT6k|s)1(v1Ueqlt$*)eGns#%Mo zbR0Wj0VDx^?fDU9aHo^nk6PVkjnIXeqX+9X?0eCf-JF%6G_tzxt^j8{7j|irUcm>_ zKkZRCHtIyM--1rq*5FPei38A;$9mt??0iP4C7u}(Ngz{>M!3OH< z7XMTGYo?g-JM>m+!&OL9-TZr2qbrUS3O}Un!d9bDv=2gt5V|qaEpM)7nS?-ub%md$ z+l#$uA`H&kqS?rK&?_hquG#{8ERAv?lXnP0-epxnlRuE)%kQP0dY5e5==?Q{A z=H%*crs(+<7%KD+DU16YYpF11T|k{ z)Dxue{wak`u!~C0(7k5iXxm9SAUtrz0i7la_Y7`&F)p+@)w>(}PJ#0jA6;27zkuAh z`#iB7#f-VPYLNM%3XmaImA4ld1^6B|%uqbWS)5CJsY_Xkg-_v@Oam)a}wEIIuuqD(ji3@Z z=&TKXs7_OS9Tgx{%mIY(M(X}uk0tzl7I4q+no zPOE)qjJoAOCV!9TCReB83UpnBK;f*2BRs`ksZf(KREJKTboaZ{tNq26)q)#>%~6Etm#C#LK^q@Z-Z_L@ZqNVm@VOitx?cdC;=tJ@qDKh=A+?o|FBUEUFL zf0jrQodJQkP9HvPQ%^sXmo)8QwLxf+5V7I^rQ?(P!ys+d18rB7+{W+6}O(|%>HIOo+ z)|@bfrok-WxUlw-;)|hb^^2jZwWk{0a?vr*@6OdeXPPqE<)c9$kaKpK=)ZPD5@r?M zxX@SEo6Y&`LHdJS9?Y8v?H-T8(cjw9V{Wr=-!ZuO>y2+N(y6%&=E?askOIVEOV$}T zIc#lg)?@$=#MM>e%w6(`Y5e>*1^O!Z*yXIq&8sz~Y*S#fe)lURHMrzB+M1-oC|kM2 zvW>J5B^S?ewzu3M!>yz}$$(L^bZ)a-BlJ)8J!`?iYWXVw~bzD$QLX5i8_bQkG;xy{9Bt z{S_0*Nmf;gM7_17(X51h_L7eD{%`Voze?nv`3VD~a9gj5r7d}gND z)6fO=DT!HL9lV+qu4%n=r?;nC1qts}5@+#7r`0X!Qm>MnV9k1Ms)%JSrF`T_D5AG| z=}FS=b-T?doMl5gsYEwfI0ABJvDo+7qpv=Fu!V4QTw13+a)p$RV3@YZWR4sS19LeH z{)YIjZB`$Kxn*gY+$PASK4s3T)u*Q9#pldbv(`8h{%X_$!__2LOmy3AHA204l2;aA z_B#3B?fR7Qb9zJt=58@>x>N6Z%iVVH2kv%4U;$*Y69nhneV*BNvvs3oPNFijbQ_hW z~O3Tx8S^uP9SE@+PefLqt--yGBKLu#YdHc(br=!XwUB@a0<7pjz}s zHCajhoIB}B6wr&pdZs(FQ%hGHJ2E}QIH-zcG?K5ZSA_gdC9AU5?)4O8w10U;5q|jj zJt(dz#hwJeg8m|U?P5vISdi8GU<%I2J-DwBbH=dMTgu-`ZVO`Y&n+)*qaiSHa8lbc zT};N{TO3v#Q{%DG>btjFiPQW2&Oq>M$8B$8*4caA47Mw8FHR)bDY$6%zC5 z^Xf!8KO9PDrM)n(gl;7ppP4?^!KH)6+^D-BIWpGCnF`XNHClKUM3;`jcf%;}(2WHR z6bku1Z`M-fK)W~9h}*td%h}UrE#+z9C(}&}KiPh(^5sqihUI#W^NO(+Mb;K)QBp;x zm^uGkfwA%YEmHf+M_^z4p^ZjeE^is!&JaGOQo5zaH~KAJ-M}?YZg$1zMz}kEQ#TEL z1%2=a_eEYP{;E{HHCm9)J56TeiCV+~Ip-+-ySq6m8F1mq7+n{|#fW>67CiDcXYCF- zGVY~M7ssP_lonkndz2EgtVI|9D7`&A;r$Eiz=WmTef`)y#@;~6-INyent5CoLE-5y z&0a}D?35@lTvqxkG(Ar(31e_6oK^q4_941fbh46)EN&`$BHpWHgToO?u*(*iE9(sJkxyuqeqD@t)}p zVy7kDkV4`-Ov!?JCbQi{^^$#KvyV!)Y>CDf@we(qLO7+cbejl3Eb5|bUu8A$| z4C=oXr5TgPsNQy7px$xjpx$w%Z@ueLM9nGxz16Gv884}-UW;4<7TQF5jlMq+ZukAM zXOk$g^u&(Gl5k0LDmJveQ8bfl<(u_XYMdhQ48nhSWk-JZ%&e;&TkYl)9xf*~ckmM8 zYb50i`g{m0|Mo&3-dbTHYsBvKv!|C6vp~~>%1tLvs*v03=I}%UgiJ~i9-=jwqoU#JK}N$=H9_Vw z1-kF@mC%#?iP~$0bQSy%SPbgHwJ>=zqrUmOH>WKfnjTkSnb}G);NW!Pm|pZA3rJ!+@~r4zo13@ti*{WeRyvY#=wqmjsnK2_*BKHjJk9 zocl24h%DcQ=L;jJHwqEzB9I6*_PA~NCVJY5(R1t^I=| z;^NpN7vlrdGcijF4B6@qi7m-H3yTILy^`&pKGdn>w2IS|JQ~hBk8a&sgkxOr==?~67BS%D~^AwzC@%pw74d3KFVpZq)iQ<-$ z_cN{!?q;j_Ts$dwhF*(ad;0~&^WLoX?ariJCk|M@^-8rFALe4iKp#sj*(i*M z;g|@LaMia1TPktWA@}pdBUqHNe!{MewNTr^L5iKEVJv(qk4S$&;%;V1G`+7 zYy~xa#p&-hZh0f!q>JP$AqR8pXWt(X`lin5kU^6z7N+{+V`Im|9h!LO>65(yxhgBP z%dEoO;X@US!+p0t#80P=9+h*m=Bgy?_54mslm3qhAW<6lKiMOC@O&w<2Q2^5d1jAeFy|F(-Fj^t76UibbrQmeV6QBnB`GB| zxX90xjh{SljLb+APboE_eWAn)tX8fKgfZdPVqgUc1TNY-I@7p4C2g=T%KI}Cv|*KF zMB8TcXYI2|Hek#VY+FvLfWqF3f8pU5S8rVh;cg3UJaNNj_ScSHZ}Ic|?(Lz+n zVTrDkFO0?#*K9n)B83`^K)o8Gz``Kzf4vBx?EGm$tu)5SAw? z`l%YlgS|IRphv^%xaMMKh)|ti#q%f^qrT*+kF1tfB?}a%`LhGG{B`6oWi*S-)5aN# z@*kp zZHbA|mj|XmsR0mMly4f5JJeVp|L^WGHkEKj>N(!Ryr4*ZZ_I`IW?6FN)a=nnY%JW* zht=#uEchgpN1d?U;QnQ~fh2~%ScFZ;(8JNbDbI3Pe&UL;uX8*kNqwgC-7)WHmhFak znwf4CefQGF89ZARI}K}G_*0dp2yQ9g^g76s)5em5XnyM1+H7Hgl@XGq8XFc%ep*Y_ z!-N@lC_?l_W{l%tGSCaE1^`PJ*=$=*wn{aMHw=gkJhMDRuk3yP_-I<~*yCkb%20X80%I{` zeQGV>Yy*RXla}@#Z=5eYQ78pBn&As`34K5TuH-kl4zRgU-u1boUdb4TV3b;ea5Io` z>G0qTiA)nmqI#E1G%MTM>t!9jiA_H+wr>`7nX)-cAK0RbRBNnfD!t2aL~WZB=K|`n zZB%RSis|{IQ!S&8s=2YlR+H@wmsCvsmS(RWpn&rdOfr1Bn{Wk%p@+?lEhjBP=aFr_?^}f+O zDx<6-s2AwpCjZqHa;5EabrEA*9s8lNea^*rc_m%E$wl%wj-8j~SGq=p5v$;rtm{wW zQTkoqsB`*P)@vVT_gdC4r2``yak;GBN&I+Eam_gGonkU7Xf5@Pw5ocl+R>8>`?;Q! zPFtN%8uGLBMfQ0wxu$*nsjntO68VcnI#_zpZ=yLcqtxTI@de( z`W#vk$n(6Mw44%grmU>5FUHalA{o)=lD%k;!;cMHMC4yO-MXC{!L8L&V!vXP+Sz^W zdQ6C9EjZb4)PnW2uJmc)C_r_RH;+ov+=mmn)y@PRs_OfZ3_a2|cY2WlJ*l0tSFOgp zH&C{#C#0&@sh6~37-OHN*dC;}NCri8%$Jcfb1;PP;wH$*q$MDbMw66o#-9}uj+@k) zU4Ji=C1cY?reR2G5v;+?M8%M}+n^2216lTJn)?r&cx*1I#;$H9t>y{tnk5?CYZaE9 zl0PVmE*%;e#@ubFr2B`cm#llO#uRBIPY_3yN!zv2=MO$`gr7%WfeK|p+T!KHr^xb3 z$gG8)cAG=p)no1ucHKo=qH5#j`njOX$Q7@w=AicF5IekoHkBcmxS)>|E6IX6KAkY~ zUxspyO)N+Mlgl|0_-ZNlltPY0DPQNK$KZ`7IMNd*jNJ9Zj&vltS@y2>2wN%fIGw#+dle^3Ua)CjFqYyDLr`jd?u1MM`G-ucfs;IQ5F-y7F=l8^BZ1JDlwQca+#3O5>o4dR9g*~aWe^&O6oT)T^ltzJ&! zbH@`am~oNi$r52Mi(DEt+*xxm)ZL51x0OcOGl7FGF9BP2NNtqIrPCgvVa0hkHQHpm z@%(*byrHzj>R+=P>flD}BJ?Br-cORP*Qr8~UlRQt+;2*Gwbsnvt2_b>ogRX!FOR|_ zc4A|Q#8%C;$Qzgd#Zc=iOE-}=I?nvl>dK-s@it7Y&U{4y|M1Re3otF{KN>ijM%=@~ z5m~HQo!g|r!%J*S`4H6};iDe1junSir4m%seu&8lSsKLmb8nF2C|sa;RP$e_)7Alc z!f6|Ol5`@*`Q)w+8lJkc>=9++ntak~K;X%JS1RyB-H_Z-r71^;n+C?FwMTNJ_P;T? zk>wHik7PKCo3!j0ON!(2CM|tzcbhkM@nvIdpF6E8vyMAxDz}hoxJafD>wF$&bj27- zvDW%l?v`S7C28nt)x44GYEfrbjP5*FMd!yTC+x2B>+(P$=hTsvPMaLCh~(sbkrRQ+ z;EL&2UM9&1k*$>*M2*k8^D4QEY<27lZD&M%Pz;S#XS%THGh=iNdef@qO5s*5Wuz&P zlJYdQcDIGsL5whx)3<3~l5&t*yKJUt3!qc(pCg(fJ8^s|->NmZ+=X?*qZA{=AXxXb z)8qY>{`OgsTz)IxFBJ|OG89j|>Z+5aeE7|JJNNW%)kZ1YloIfU4zPprMO#{yt!CrY zKGpZ)*iwvO*p*RRWR-N#Xd#HBNkza9aqA4J(=#-yR;sKZGl7mkF%-t<2{)x-aPOh| ze!PcxoDw4W7^)pqCaBWz22rAQyxVBr+80s697qKjw1QCDKz5`b4L{Ah_nTk00DZ(X zRw#;Wpvmu<&7Pc2R-={>`~(utXeA#f#&{^9x(nUO&1>ok1?{{mlVVBsIO=$9o@KgM zuVUj1^OpM%sU^5-H%io8WdC?ptc*_zKGnBg8D6`(?C!1lPor7EE|dYRj?N?Qed#)) z3sG5|Rv_)cJ)c{+X~#aCggQ)feJqQuR{ah1J`#IJ-Hk}oVic=*$GrldrP+w$xvF5P zPYPm}l29-v23=U{U22MCJxyh=M zVyo96f~g#};;X2N+%u=`B6)}`WE)0m?ACQaz*H+cBc=Q!C!3Sq z$sWGVl1x=5gb-LOH(J@CMusuX<0=?S+TcDyY%!(Ju^z%M@Xv3cr=f zWp!t;BG~CYZeNVYHzkFo-H8~S(A4&Jk37n1h-0?P~pmR48&MY%H$+LsB%$z`@$wpF&`*>D2bNz zJ)=^e!We3bj)Lds3GK$Ec|v>Zl1`;La{*RZ5RPG^NsIA2pCwS8qkNd*Ct6%vB-PR= zAeLHn#i&CYNqrm|;9OcPRZmS5vJI=xq5YG`OrM$f9F7b!lg#ilpjjm=Oe-oOVP*~d z1eW?ROY@3TbL+WIL-!YSON}Q;(kU8E)7kjpQ)!Gye!7>uR2!|-g&&e2<>EoPDB@j+ zul8P5_?{@%Ys5Gr8$}Z6tN9{4@f;rC6ls^uL`o&rpXGmDVI+*19bLnFJng$gp$?8c zBm1|R`Q}Z(qKwRv86ja8Y4|{w4%vU0zdLkPW8N{95Hp zZ+!d$OQoa$i9aWV3HCf}BjdL5S|R1GoGLEx(3~`hx1*gw_2CNA#GR46w5Uc*kY~Tl z9GiwPE?QDd&u62uXTew3Zj}zGnUJ!{Y#zd>9Sl2!6`!@gFz z_B`91Hf=1Cs%{wXrhc&Yoi{A|9+`tr(ImsSh(K}{)fRi9Q6u*Ya>J6<2DBvq$|kVH zELa{@^ep(m%G)CMtj6X@*VS1gqso#;-8%CyQZH=exZTX5M39^eeGe-rl2U)z87JlPoBCKMlQD<}(9wC}X4XcU0ay*{wYzZ?MUjxTjZ3 zMouYDVyLBVVNw#c9nLlJ@MB_%11nZ8#%T%J8$l2@eLzb~{gpF8PsCR6c7v&4Bh=$% zf+UStH_WcCPVas)mN9>FHcnb@Vgp!jxvk=?W4S1a{vOa)uaE{jZUWaDYz&P4UivEY*4qdt|*ES7I~ z_Q6&%FGV4lJ@f;q5&xk!Af8&P9{CRseCm)*%uYmdmBc^h!yg^$oa(Ubbe7{EgZPKL z3G>rg|E60HcXf4=>aK3xeQ65<4{#@_4pM4SQ6=J`-p7ATj zdL`Z6vu{Z}m&Y=ZQYV)Onh5#D@=7%-?WtZDvHL$i{3+);N|Fa-oUCBDj?NdvQ!p4& zof9^YMyEItMD~Z%IJi;5Vx5Jnj8N04Wl;U3o8P9am2UDh_jkcNy2A)bS82wgi4(Gr z-cj(gT<97!3*m6@g=}2a*NvIBi*n0kAJdF$d?edSV8>sSO)aJu65a-y7?=xmi@t zAPPYGlRT9o&rKehl6a&C&iGvMNS#n$>`BTHc7Y<1PZdWYJzVs+!5fgNNAjvXKbKP;Fx?@*4FF^bBiBG5$s4)jL>-t6vs#=g*Aq^(DU|la6N8=l-GGX|9vr8Ae^9 zEyL$AZH$s<5wNbP|6zVDd4&vQAPWf>ssr99%LsLwmdvg4>&P1 zryyC2e>IE5rshu(v{Ri+wKz+iH0m513Xa8UMJfwMPQJ_5Ix8yAxSc$uuzUDZYF}c? z$ph=>*EhH42|izYt;8Ikcw_o)q>6zt9|4=QbabE?Ug}|a6TyR#FZQ^-zi(pelX0SE zXG|*mig2im+*!ApiUEXS9=$aVBg3J90ON)IY2*2G7PFRCWRAX;d7n3wARDS-cr6u|OB`y#G2 z@Dl$iPQEAzSvxUz?N^+WZN=X){l*)+#Zsom#zt z3i0GR`II5?sHQp6@Yvqy=Z=phvo4_^Qz#+)EbmOEw$LuIYWd?k{Zx2Bb#V=*^x6H> zIRPvMq;eS1;_>N7<-+-6VWlQQrPDHZ!%P=WDXKKhBrLRcBL{#^PtLr3J* z8O`_y80rObx|a6 zobM)3XQ$;CN8c>to-~(b*&SxTwX1xZasWC$c4F*Gb2w7ABN#E1+p1CP$p4kg!!K28R zj*2);n`Ptw*8d1%?-CY{&emi)Yac6&h0oI{W+%PBI%OU4v9D)<_ltv1)MM?;N} zJwzB%%8;|>@|kK^JQ~1tD18-p*_PmWHaqyZBfaD}t)je}Gi7J2_-(A%Xf#xzcqsIPD z*R3MD>MQ8HNPnZ&(d9uxlJRJ;&LsuWODd{W0pi`XZiK z4!oB4TVvYBeZR9ocD_jiQz(A+N)?Zd3)>g99ySo)IfID`ULyiI=spn+U8}P(=wByQ z577s5$#t6$5_zG{wJ7WZ%l#X$ti&qa^?H2@cgWNw++v!=V{O9a#j7*C`=n*%?8ogc zaUjpHF3iu;2_8RGxsFs{{rzdbP3gp$o~$;uLs2^UP=8om-ZgMlhHWxC@Hq5e_*Ig? zOy26+6|4PC-ngU+j5C%#!i{zejp-n8eyp6FnI)w~5tJ@IgB5jhvwy>~rSQ$mIFR&| z)HiN&E7;D*m&~wmQi`y{yeSi+*(l>45%(gN)*n4&)8i(pDDJ-eB*o`!B+o2n>JzRT z4B9X;)Mb7;JOmwHI|g&=9lXJHmg||7{wl_^bs2u)o?*_Iw(&V;rN2Uz_DPG;QsNuC zhu|wx-v&;ra}|H7HYy|LeMdz-vP4Z?x2YW~?o6KEaXS!D$R4!&)SK{iy*bh-Za1@g ztOjj{7@x198w{0ZQ>>=Bj@SeqnR!exP}Y5}+&C~3{1Npt3bK=@4jw2jt7areJV|QZ zdD2bQ8GMM06`+-2eub=-3u2;=V^N8ZIBT=Ii9@Xl#yO%H+Cr`^3*=KdI z>(35gTYR+0g5A#-q^}MLQd}ICU2$$5$7?H@lsh;<-(u9~WTK$N`~`i19LL9qfD{A> zt*+&RG}o+=L(yqFluD;#=$aWNQoFVCwG(Iwq34fAezx&)yW&s-#pIZPZ`y`}ncG%K z?i(`hEfx87Tit%XmU|^7N2Apw=gtu?k%ZC~J|w7qJ!`ZPBa40T!2+c1XS?cX>D(cL^LnfEja<(@trbAQEMpb%l^fCm_RY{~V=a zL`|6@jGED4$lI}F$uNlJOGjd2YaChr)&B0xaW>jK#2OAmk1ECnKeKwAjCYabhbT<^ zN9b~C$a7;0MK+S%U2E6#{I;!LN+UQ=OQE*i_Ef%udn45l8NR993|k6zCoU^}8cMKy z7N<(|qEnlSk&P+2sdam;2fFi(CA`xyMSeL{7F*eM%ZqE2>B0=kqz|$uu!+{Mub30m zMqcD8BdU^Mdd8h&)e;cuJZCm^0*tiePk_v)jtR!T=m4B*RG-ZnAT`V+ykjgPRk~KI zShkxHBZJ)>^=Z_IXMM1NGNPr~+(l}Jx*PdQ`)SXP=5(c`QmoZWRj6vMcKyFV&(`{P ztFC_d%dZp+<--0QdbU&niya~L8^tFf-%>O07Kt(0j& z0P(t;iJUE3StOXq%eu8=@>R)IfuvR%g!{9!jQKM@J2rL-KNR;7h|Va?M)0OA zhen=!%!q6{9tM#IIp4R}@o6uIJA^D`P!Se`Uc-n9B5k5bi#jyzc)gu13R&c%-;Q|F zyhl3a6Mux($1)9urE`i^)yv2D;hAGI*5vWWoTyj73?|bCg&_VXXTo{p*w}>&pPCbp z9Fi_pI`ysu2d9aW3c9s`()S_-Otq|?tUzR&DM^Du#S=C=x;d;gw3;sPkm|c3i-hoq z(Z@AJ0@oJGSh?&JWW*M#n8FJeRNZqFMA6(OYu5-wUlynJ7w`ULwtr!Tw@`Dl{FPR& zA=hP@dbMw(BNr9RDlSw?PN6eIf!NJ@=LH&3733+jW)_2*Y!XIF8eLbx*$A*-*=MG; z$(uyugF1H}5v7PKM#ou+LY4S!I0MsD8LMKCkw92htf}JcNpku~ec`EGlrxE=1`$qG z4tSu1gq#+IKG$#nAcZs|aQf$G)o8C7RsxV!5JXCnMe4_0bL7Tf7)VYWu zyh&9x9cK1;-JB~dQTcAGmM5Aeb@xtwTu zv~+tUJ!ZS$jmy5#ozllvJ5Qro4#ci^Btxon8buHg;4`-le0z1y2_WFHr+7y`z)87gU<-=n_7V+d}k@e@*I+8H`ZaP z@Mh#smYcQ~E^wawCFCEPpl0`G5e!*g$jS0$;p6AF7WB`XYviAc3=<#V(0AK4iu0Hy zuE;dwDijwX_TP0Fd9R2 z=gNbk%V6zYC92N%ZSHY%cO2Nd4Xjrk)m!+ldxssSNk}dAZuMCUKuJi3W*Cm6 z78B0I1SLwu;uTFbbs9HKmJ*xH^Oo{FQB|q($ZAn#n573c{b#sVbD$+zOr}Okqv$i_ z%St2elV2p6a>KU#VtjG=0-EE_4Ktamcg3+L?XG@v zn~7{_uT)4l8ffBLk}Oo&wwYIA!&ox+>>Ake4qhTmKopu^sh z01jKTq=6ky45gn@#U_PoGj_pcK}XS^ntL@CM*+!))c@ID?dr($%pef>;J=(JI@|3X z5#5vI9G2UNlAFan64MnPC9T<3q@swkD*M0RLFdslQxG-{Qg>Z z>0}cx^lBWJ-#u^ND@?CHwhS$AhLtlNyPrpIRbfn-E)cSksGS zHpELbx43jVJ>)lqTFEkEF*ir%$Z%$)goLNX4N`P^1q&1K_%sqtAK4Y(xF8qtnhmL8Dw?^9!K9aHXy(@1tidH6KUFpvjqDOqxXK{L!Y9GgA(;qGWTcXD_?%?1=s-DsWtF~LP9{-Q?_GpZFd$2^VK-1<)4qW>0^;)e*jg4Jn zwI@-o7L_A1tjXchA_gY)zsNOjd8Lwe``YSTT&x{kR<`rBHqsW18U!*rvPhueuA4BSOD;62gEM<2T(rJfRZ;;cisi9-MZ-=4w`H8px35ne}aOPN}uyi2&Eg(Y)n##ms>6KraZVN$fv z&Qg0}9yF7OCgNXCO0&drG!paB>EIiTA(;L~Kbz|>uO2LZMJ2LKfFRie@l@(FU_k*H7x9RiMz1apK70S_ zr)URG*iuUjIb6smu}2h?jgsm$+HdJg7bD4$qFr}~9ac~p#6YKrtdQP-!MkX+Oc zFI6Z7tJ%>w9ifr*P4i|#Ch4#NF4Rj;4ZEwKRjSA`hDGm+fxj*p_&P<#i(gjCztjn- z+>h6sy=PtpM=yP94j0T*TFw^knWhpz6{@%9Ds)su$;-V**(*uK$Z@pnB!iGn7mca8 zKoH$2+FaP~oT94>iDpe2+hQ?xlONHuSnW!{-Zo2JjC37 zg3AuBI~eIqG|YK>n)K>cYTF-%Xt7=Ra1F`sqKb<2N#bu*uX_h&8^c?PhtM&cM^DSu zyPv6;C+(TYvL3vUS@0O=6srXZKThNp+!tBRS41*gi1smu)^x>q&ksoPvXwDWEb?&h z+A=9tITT6v1m|Y03B7^t*OVqlTfuY566`lI<8lNbq4A;RvvMuVx=B^_cG=ad-tFv2 zC|jRLtj^V}JW#H}3*;tcyANZzQ{yv}Y0}81WVtA{oh$J*CX0i?1~mRj+t6vXSJc(6 z-f|z7>dmd4iumWuGo6M_JMLLa><03tw(?vfOay*CYlG{3RxuMm`SXvGe8|*f&PnAa z$PFLMPvaxXJu=-6Em$vp?<*lWkspQgbxemqEwA`YdQiUCkDo^4Vy{qozAd>TFBzls zsOe%KmZA~coo4%q@bx~K)b>f(r*y_jqqo-~iZ3ko_zRt#MJ}0~s7;l;0_)x4Y?>;a zS`=t4?ny{UjhKfvtQ0c}16FFR*6BSM?=S6>MJUA3qOrxE7`h==kP(?gU98_$2%MTYh7xkP%+58ItOd#mN}OdosV1SDNijB7}kw; z_urWG|38xNA5xk)RbB&MxxERMvYjOvPt4Y+z~~0ZdGirSN;qtme!czot)<;YZ2LFGp*y(@Z8_|h>d_Y8;& z@zPNu%|{5zpgOVwAC{01b&4&-eGvt_y>`Y`b9J3Kd4ZFX4C)NK?+R0)#~jc>+g|+% z^OsECexvl@yj9VZU7IrOyvynx+SWTH%E>)%P+!@bArE!vgWb7-tzBsg`xdq}ny{Ke z6tl-d4yfw=@Kw6t>KWg!P@f6Xvt3grar9Ni=iB|uAgPIH6!lY9mXnh`D*fOGN-OZ% zDkaP2jFa5EAvgS%7VR!JJFq?)$%0+blLiv*5J_z;iiMJmi$6Y@Jxuzh_5>jlv++t- ztJEoPmvG^=wgpT?`IO_Uk)Kk1c@bFovys)tX~28IenZW6Wbf??m-_{z4df;gqv9p1qV(?y^A0?<|xq|)C`7I4UK@xDwu7q0LLHN18zX1!Xc&g)Caj`lwWANR zlrzkdZB2`qF!wogI2=yel%+bUMg#E`ZrW~J9Ei+XQbg|r{3c?Qp5^;GKDQHdzXdgw zsB6)*JPItfH8FrW6CYnr?IKRtlj;NxD3nSXb!G4x;uopT=k56}f_b8^N`XwskH3A# z-#tbuAjw!6C254bC`u4A?Q({ZR)a`_Jae{?43uy*dkC4>CO008lTWNiAV(!hap4QA zs7`{$0|!VwmuxV0R9;?;uH~Dn9JWNR&wTBsykWE3X~p=2)a|xb>r5elpFUDKeRZhu zEMJouQnSGx8eil~YnY|ijQVOP)Hm#}{RfU8DhfPzsvAzi3dK;+L5U=~Rx>CfO`OJk z$`)3kx`b3&le#vZNfwo&>lR{nb0wSf^Ly}`l!CBOx%8N}^u;oUEs%Op`e3mHG74KD z&4M{UQ3(3zs_!4(&vvQxk0nk(_Kv;FNDApHTD+P5%7UDQWloS}JwDSvJwfEy?BP!H zpw}}ur)6i8?Es$MeHVT++Bh~Mc9!UI7ipsUxP4>$IhNg|Y$8{ogD@S%7DjFjK@(=d zWMqx0b`iwE*d32X@`nXka)7%XM(afD$?8yuk^5aIuYh$C4r_e&aHT`uHKH07auxjN z8Gvm3^fsQjtS`kUO=dIvf%BoMMJKaU3_dZVgjerOAjaY%#4huWTyNo@$qItzCtDw_ z9|15p6b(q(G{>q4w;_yR9m0AiS39W&Lko1tcC3wSh@cGltgZMEhZ1QhMK8rTpxaXt z*X-zhu#J1dSa$#R{I-GtVwRZf$fGNbE2N+~yOdX1EkzorkO&lJs;^TiD&L_iFLNsU;XD9zfX{KP^$aya23B6$^Y(S0f=J<0bUB|TDx5>SSg}ID(Oo7A74DSdt}ti0 z#ziF;FAj3I1eDZXEH|51k20y6K1fzPtM)3-XJZr#f~7%h960iki{_f(1CG5sG|JGM z`P`NWwe|As(24};qeJ#g-nQIWCWRHbnq8dh?8Y^3#MvpyS3cL-nMjU5_{&m4)NU`= zb#(Gjku-p;(d^W_nChleHE*s{N)=ZN>)Y6k=5x899j}8=RtRjmlwEfgEm#_&o{!o) zscs08%!vRi%jAhKlcrfNnofFh#T{alJhb;VsGt-wEehl^=S@4cv{+KT*37lwNIs)% zbx11u|4E25U-Gg5RsApJ;2YH#$<0_KK`JC0>*eM2^i%dAXlKRAw1o=E>{qbq1pyzv zbZp<8kr#IwksE}ZLY%Y|ZYk2=M16>p6l~F66Tun3Ct+o^yNYl%#d} zY6v7!{Gn}}kfAIb)VYSV?9Hnx8HLp8`z^X6CFePN$SI+wOcd6Ss+4AyE?HrxYCDza zWWgL33Ys86N?AcyBJ13#_kN6}8laSefgW3@eQ&_{Q)GZe`Q1YsE= zk3^?LTU{j|x1+%1v-)DJHWyWqCVOlMrp%JtWoM zl5P{X4;^JimPV3!uef3^H7v2s%)y{~##u}cFNr#t)MlzsA=!ia^O!djo@xE=kfO_ro^aj|&Myo$w#>FG2`^pv#n7{#qz6XXAm@YPtZpq7 z9804%)s>`u7{OBV&}#pDBF^irlJ`B6+{f8fobhElPQ90#emWywBfY8rRU0l;Z>8#X zAYvD??sYmT|5WQV^DtB@Nfe`w@vKl-QhuWROCA>6>6CpEn#p{umhS0wqaLQyCB)UZ z$v0{hpO1US2{RcKj6f69Vtd+?EH$V6bF0?N2{u(X!n?Z8Jo2cfPdhkte~_mp<`OkybKl$tk8^ za?NaK>c1Z)khq(#hq9{z?#;=l_S;~PqPrW)NErwQ%Gqd{ z6PiUSS1uBg<22&7Mg!C&GkktqYAHy-*S?rPRmZHUk)eiD!tQWibSWM zohD)jeV@E7c|1Ln~-fo}=#tF^N`(+x?o zwxuiA>Ss8fI)zGDHmv1&f`d(?r2BG1mX7xQ%d55l6xBc`&Cq-<5vw-n5zc*6>ARlW zh3&H=0YjmC(rt|lp}sM*0$X%<2hEBDa}k9IrX{aoqrNfuRt_YYO$O?Yw(l!1l-nbY zcWdpw{Gr?^ITZU6D-{Rlsw1vcNOw9X^E&S5Dh?pJ=A~^@^+wu^5g8@X7*-#Gr*f42 z&0K%*^o)_Y!v|-a)*rQMci^#z6)Rr zyGjflY{*tNdvdzOT_{^641xzz(l`EptACbQGM=}f8~TgV))7(S3ALSU(+TJuEsANO z$w^&lOpZ>l^=;(=Ny~+9g}ceL>z=C0R;hcN4>g}1x$IOiG@r$>XVKHjZfFdOtg@NR z&;#-f``qf$wV^Jm0SDnBuLrGu$aFY(chcAkc>S5Nt}PP>9tk??q_!w8QPUURkhNl}ax|?TM59z_rG%hKQWT8)a z+7*1X{Q<9GG3A+rj7w2-$(DB)4|kkorN@k1rn^V^2+vK+(GxGU%EpuW8C?bca#M_V z*E;9%@r_a1aWAZcrAx`PY(}=#?3@V~hs##T(lMZhwH%t2cSkpy8EA_)$pf41CH^0K zZyIA+n&x-iblZXvV7onxJy>22V~UQb&U^FTbMD&h8HkKrr!z8RGNZcP({9X-B{QQd zG9o&bs*18?Y`kD$n?%pxSd02UYt`3neP_`nB)1bn~<@%ul| zyWWVb?soU|beE=5m3i+y=e+NG-sM^U&-27o0HPAB@wrG^pVSy$#xsn6!jfX{Pbd|= zOva&XKmXF^y^o1umC~^XB`BsXimJsx6h>4B30F-s6_o$;7b|`6@(oxy;v@q?sFb(` z(U6UP_wuEd;Wq>S-0XJ}&&v9LjzA#tq~0l6{@nG)Q`~9pgz>z+#cAr;FhBtdDqw_m z$_;cmZY>NQ#8)3K-^jMw;EEw}DiJ6I7(iHWs5DN9@D9tD;yF=05VV84Nt3H-)3nAS zjq<`Uugly?wPub9=b>-aF<=mNT$evMXXIppFC7@2!B>&8K}~UI)#e>fL&RGcv}5%aJITY8yHj)O6s2$I8#W^+`|zX) zH-p-}?dY79>rzh9>rPd7uAcEu&n?@I9GY|f7l__5Arh%Bd0Ot@H#lqMggvqMmm{`x z(k^j?{*~2`dm+>XDN%9*Wv)>Oz88LR-?1jd8@g$N^^}I9ko-%4FZvdXn5bruruU`w zP!3Mv{VJWJ>Gu2+d)#-)XIQjCny)az}13FL8qWpM{*HnKw&t6V6JShI1&^TnpG)W3FCvDIk_ z5*ZGO4v$t-PD_6TH;pF~FLe2>OoNG;uR3&-@wmg8m!51<9Li@Wr%`<*(NuYM+sTaX zcgSc!^bGD}UP5vg@w{fhRp!1Ji0}_5^1F+@iX5RAc!7*pRQ23;t_{ey7f(%!|+DCmJK{|CYeYir_!QPHaJPdAIlPSUcTUTR%Hd9SNXI@ ztjz?O9t!z03e!yRfpd%nRuz{4_B_fp$2H~Sa0>RJl zN=6UbX#I;k@s4B-c4N{hIZ06!O${%b(I6Dg^FVP;e3k`on=KRQA=^sB%X=;y$97un zDE(?t%Ta93ZgY^DrFV#QA`9??zFk|B#LCk^Px*XvdNy{RX=KW@ZKs_QOz5W+t<|qy z6T^O&Tl~@Hrrktpt@nynVpkCW%Vbl*Tw6QFz|d3@mlLQvwkEUZAWy=}C2?*9|`4C4W8kUK3)LVDdgZ4gneYx9h;_oRQ1QW7$YD zPS;>jW*sP(hJX*xU61MDm8>KXN`s=3DJE64=Do>O0EQx^kCFBeVwi2&nl+Ei!1Y@k zGAMO<$R^z|VHD;$RrI_qSuJ|%>_g${+-4?uNHU3J8ZUn*zF!J;l4&HCxj-g4BWL{6 z?@Hk`K}b_H;CAmvnxEusX|COweK>LTfySf67d{RyxM}w&}FH}adv%L zz24W57Ig0#`Nce^o}{KxDA$%q56IwR{+Ns8fu*#}|L1B!$b?CL?u%t)3lW}O9DQ4U zL#eQ9zeT134vrC}yt{6U{L$4FV%t}AroZS2j<*l((ssF> z+=ZEQ9&PUQN6;hRHN+aB3rUfOWSw9+;3R@@Q@b)zL2|mg0dK!qxDqkdm9sRPN*oI0 zf$*d1+AL*NomVnNJE}?hR6^V~0U*rk@$tzKbO@Ph4yK~PLK$PTn)eo6NR;*$dbeI6 zWS42;Y5?a3aLfy|l?QCBkGQY9QUCF+>*8t0mbh6z*|qJd8i3m1FKA7bg|BN<8@+p^ zdfVda?5%A@A>I?!NsGGPPR_iQO~j=x=7RPq$4gq9uBcTdp!1+)9a8=3$Ei%uxT*s+ zz4u7@-Pw3Eb^3@CS?M?NE3|x~es&Hu~HuBzgWgi)UTAiKn>0qrGun ziA3#4Z9gD<1rzX5u*=Rz-LK=En8gco&jHyRj+QuI-(2>eogTV9T}PR-9gNQziyp#Y zB2PC~n8l1_6!Y1a^ z1ajuqG`K1TkX>4D?!23)^==-Q{GA#w?eB=z)T2vCe>QhIQ`ne{7kBR6+s3+?5-ng_ zR5C>Ox@0>c{Ky49%3DS`@FM6PpV+pR+6fG|HrvlD`1PBx z2x(Z!kj<_&^d22a*JY%fgSTfa8|0-g8SbzhRZHI%yQOlXvqeT}^OWXBTBsTvR~j60 z;wUlnIYyCUpK+2(k&@li6}L`KQ+KIu*L*Q!gBMNU^3R@-MLDe5e3pFq^F>+1i)T`; zueqEjJBkIq{FvOeyZ8nk-GAOvHbvHzYo_GCDHESq$r)_qwVAG>sY_fk+Bjv9ilXQ~ zygg^r*6(XUNR_Z#UvbN&Sew^e&SLP7HWE$MuFP(VoXhRs+)5nRO|3b{--6*iFkT&{ zh%Icf8;o}g$wL{!J7f>Ft~Zl`O+s&NUDaF5NT?R|zYKTRdvsG~PMN#YV@2t`q`~vA~FVc6MoV#K1l)-w{h=%Up2T zKY5z~X6DqG8V2zy3tfZ%8r$ymC!>g_pyA><0mrdKvS}Ey5C#q}D9ayP+2$`cQH;qZ znkXqz6Dnlvbh~P364?TXq}u&1Cp5)GEGlp)8#37q7Q=EKXY+XyjTghxM$TR;ciNZ? zH<2||Ta|rM?p$o>)h?P(lRJGeN}GRC#SK!st{f8_DhW@E$~n(y6XRJ_2Z1XIAFvpe zGT>~!NY+fQB%|$O1XD|IRK6;2RDGS)tad)FPIsF*-l8pEW6>@0$tsl&+ONLObJoj+ z)#&nFQEN1_F3)4PEDkUSbMf3va3Ww>t+Nr%_wS0u{a37T-<}n&i6*5*w`_j9+f<3Z z%HU@S)7jj!S!KfxE9l0XbIOQ963Ai2+`m2`8{~C^YF3Pd$khVt~ZM$>l z%MTwl(GDB%wW*ItQdDca#P&MTjfsYn%wO6~C22=wmz!Wyt9m+*Jj8sy^t{_E9fg=u zXm)hIF=vG$7 z9vO)O{n5CkV}D_4a#K(G)V0oN0XOj-;w<|$Bz-&_z9R`A6$FL%le_7#(UDPN&;F)I z%@^#Ui@Znq9SWLEXsaG0!niS&eaS#U5u;F zrn6Dn*5iKpxs6J|V$3W>x9Oq`2^^yJW*$(|SSVWcmGw<6OqTz2JQ^}`+$GaHwt~au z$HIcRparA<#-)-hm~&@u=_ypwhLwu-JcMB)D4b51`R$$iPi@M#Hny8DQL_sl54&IB zW~2>EOE06S?`E87S{?f`9QAVsszn{m*H*c-sBt_`lSNL(^hR|M#jujVM#Dm!n*DlA zp!lqOEYVcSjZSGcvsc$^tq<<#X$6809kkn$o4n~SPcaz{;))Wu39 zNn2`a!?qidudX9qDY>zjR0Jy(fc5yl8I*m~VQKZ8;NA9c-30{W`%l6=zq%3tWdI0`I9r~8dq75^~B}ENSaKTEF1X0p6Qch)GR=b|nQWoWJGD;z4q&UYXuPen;Y8U*`yG>|Ot+%he3}VKptsi>#y1J?7Jb?5!;{vlTonJmE;IH2*Vp-e?Hv^nU6_z%rQw@*7%iu zQ{A9Mw^|a!vi)%WWZzFpiETmzNimcwCZu%SPjF=E479M^R@3lg>VFPE__H!(=>;>c}*mklvuSz=iT|vEfu| z$OIGw6*Ki^?{r`tLJ!ihysLvIy>+n^oa&Qcb)*qSoyDaa#>I69UBt-@?&C~3OC4$0 zR>gP6(}I^TR*KzY%Ioq$lqmA&zyFoXN5jAEI_rP#`#;*n-}YdWURP;K!&&zZ#{_SR zvWf146i^~}i4G~-dGmPZLEBAcpOsTbR1!`Vvx5FX+?z)ShbQ8S;)g1^6tATUz?`el z#1~?#;kX%-ksB0K`;;9S97Q?=4#gJBspHaogBH@uVt4S$bUoYEhOAId_Cgq@f9G!j z$z`NQ{vvbBAfQ&QaZY0ONQhXKj66Nzfo~oP2aLk!$1yM2CB)rKqk6Uuz3>NRD{!Af z4mefvqi1aixSU*C5DLLQ0!?7(S(CsLa{NjZ#}eaFMjlHYVss3=XeOHofmTf0+~(G+ zy&ZjhY3s$v?R@&=iQN1g8$Gqh$ditjE8+HY&fNJ4!Y&~C4oW+o>^xz{4d2rW=TSqHj z-gHtKj4;q7>bh+HXIRNg^Z$X^%Nd5!(A@Ip2`bt7)-_^Vd?R}ywxQ)XVCrzFqM&)`t<0%FB38*Lbr8qqrY{xkFF7rEbk*@F;yhBl1s4v;OK(P z(dR7W*&A)?8=?!i%!*{G8%c#qI7Gjy{X*Pfn{eq29RBf1&|?PZD$mOwpgcGpy?VzX z7$WOFZ+CePOm zH~1doMU9?TuNnbP9P}vUi5`o*=MhG6Py-CEl%YH(db#jEdm(@yuZhynJ+Ja2oldCb z_I*q7TI}cHd=_D+8heASVTU&>(Fh@mTg2kv4MnQXZ-+PHP2+#0+a&y_gPqEMg z`Bp3)L%z-n6c2jYkoe42v!*zH(l@;Q{(nxH*wO$ilshk=43BZ{*mu|8&W9i21VN-I zR1_vH@58bXy;dS+D~FjMD!Vqa)XA$$P^R}D3|bQM+7#Vx;``k9JsrPp1>#fb7(9xJ zIAr3tkkDd!Y$zO_L&4!Qz*EA+tZj%HrR-Edn#bd|DxZbz=ee=s>2hC@ol3J_IppRN zYG&q1%rM6%&_;GKlgJ1YI@hPq!G6=bHoQ%^_xU9yuvDnrDp~PWm1R$;4r^JHX3#LnmlG(ZtqjZgNl14Uw()xDbB z(VEBZzHOP78a-Y)Nz@v9KMqm|h3FYX^k4;_s&EqR99>#1Awvp5T_B*ChXZ6N`J|~A z6D(9?m1ToM_#T+)c1dJJ9m^n13L_Jrp)KIwZ#p{gYY>*C$6uTlvZ#m*r&U3Q7*toI z7I~X}+z%Jaj}DG*M*J+1ga|Z^5tP2aSg=gr@3#-S!Jm|EGddU2mM-R4GLezagylghJTGQPo$Ryx1g2#{akx)Gq}4W(5YP*Sv-X^OC#1+kNFrNA>Jf$atn zlDW>6%3K*`xl&y~!4b$Z%dl;&;sLe;TS{x6@AXEvyZ-Ls`5G$7>mxGRkYxVqXuUsj z)9N|Ig1nY%cQ>EDw@$|6)KV5FI2xKpq5M;MOY&Mli%}yKspI7AgqmMxf=$_c^AO9B zz`&4TDI7-kLv})sbJUqq0KgZTw~f;*z|}AZ|D9}vm)PrMHxq924K_Ok`UyUx0=A6- zW@JV42sR;09TuZ|{EiH65isWw0M;)PlDKJ5myA7kAg|Et4uW+IsqA#BMe~^yvn2kM^CZ`bfCgJD^(ko^I`s#P9Q<(U(O%&NU0M*j)c9 zG!M9&m!87Ljudlra-sauD)nobH-u2dM*Mxsq8V7B^1__~uH)zIf;jcj9$CXDh{6O7zd0e}xf=$OQNV0-@Oz{4UPxz& zXUuMmEoobN2Vj#65s1pvZUReqSY-L@Xjo(6Rb0_P%G|rIf)D(;lpemQ*j0y z0>a+%N_>x%ia0*EJ6*~=d##9Yutr5+D_xW?#JGpS4bGKoZna5qt%fs9Qj)=TSWYCq zxT$RZ7BFy*;kUtQx#c+eO2g^w4Wz(?eRzTzA^9oiPS9)}zQJs*GR`j4?+Z0{a;gG< znoM$LuA3IfMt54Nd8 zRLUN*(C1jw5<4!1%yv4)XyZ zS0_3iTWUKs#D1QzTh2a^93PJ5+g@%=$z#)yy~o&IqJ_!2Ps@a{X zC8LrrzXCzyNe;p4+xzy>s%x#-%gjM;o@aSVCcuI}+%y}UOyh1EUEPIiwGgN`pf6|- zYXmL6I@tfU$YPbByYvVn1SZNGvP*xGFvKn(k(e&cQpy5#>jAr?YI z^EQ$q*JokKG-%tWaXRV!0NLmbhwENfj@cN5o=BtLFKpKp?3m!oh(2Q-ORF~0<0MIp zHQ2Em4`Y7zc32@8+pYvvgR3YlH;AX@Rl1HILt4qQTn%+3Pe|T&quFp6@l!kl_#*ha z2=U8zaZgt|%NWM=MXxtw9~F+hQbzrrgbL2)J1{jYZoA~cVwa0KlX*@0cB*EEQc|FB zM5snXfog4S^>s=$TGsOiH`(7T0%NN{yJGUu6NbqmSH&JI7PGu<>cF{ffyYO}UAaJ4 z6byc@AVIS1Ok30gCB78j3~4@eD)tY-VK_&RNy-p6R2uRG`>UxaCJpqL`(*b) z_Qfe9k(Lhx`5JrLzY<9xkamwKlyj<8p8vZ(B9_Cf;G$uXQOWC!HHD0JCvPa}CRsYD zL7+@R`x%nKlZ@t#mD@Zx14ps-)o1r?#q~u<_tk4u_c>@H5%3j4z>2lXb`lj zkpRq^1O3_#=j*qNwIFMHi}U%ezb#h2E*_hLh1WJ5(lg)iR6Fs^Myy4SK;(UHxjR&X2)_UhKv)dXwQN|0j^Gw zGVO4>WE1VwB3MSrAlpDF7^;jEX2YuAE68Q?vY-iCo>zD*pa#lA?mSwTCIfE^*5{q~ zh=NOOD`=MpQ-B}{4<{m%)nE;p(X81&rL3!oq{i%!Ld}6=QFLQ8&(qf_-nAW;6nof? zV-g8=TDi~KDj1b&bD0E`)elgzW-(%b7D{$ACeEg4alDx3u4-p{jdGq=CJVp}Q`oel zJS96ur-je*?dAtH7k*5&zn)0vQXx+FasLnt0!0c=qRC?TxoC-CdtNh_Ijm{xYOlY! z-2P+8*yKZ(PXUT4^6Hdg=h^d3)$>ktExPCIlp9@yf5i+4&=v{iA03ipC4<~n+;bN2 zZGxVWfg1?P0ORZPqR@&wTmEV^d;AItlee$@GF+}iMbC90hJd>sEvulH!rPsndW8aM zxshYUbIfQC?96U2k5BNvGi`vSSQ}#}Ivy}EP^Y zulMCBG{Td}c4z4%q}Rb!$a>~ zlP`8QcDlUx3wB$=7|i^H#3#25$y85{WJwV-fePK<+VR;0Aqq^C!{}ZdsChC{`Sia1 z1qT1Jvl8D%37wF=A|qpUsxekDW>*uYjiagH4>*#sq!3-WeBW$vfF1BxyOYHYlI&gW z1@>Q7psne`IwCnX&Zc7)TF~pSkeD`qMto`e`Tcvvd5)Oy>+Lc@Zw}6d5oOKHz)e!H z_~G>4COX{q-7Wp2-Ke>g-Shw?)h41B4t9RTp2P3)&;w1lBv$NtSJy3R8B-9}$-0sx z$7>{HhEAHMsw26Z%$5Cr^MJKxyy$;^@r> z&EM$t_FiMKmeK6w=#D%z)Uys+7~&Dh2`*v#Cl>&l@qc{&P9FtudID+1zC{mtVnkDm-RL66*@-DD{+fZvrfeOpz?4A~ z#qZ5@Y~S152y_A*fr3Tl&XNmD_sLI&=jreRcp!x!|Gr-D$>rXmLmObhrwR#V!14`F zu_Z#hj{3nhRfKvtpj}gTcD#%W5Ul`%|EqUvg99k5uj4OtxJ7Q1Y$e)IMPL*KClXX9 zPf?Va@E^jds0AknA_#g?Mc8%7MVj=B+K}B=X|MI~Io8(e85J8aBC<5AJ&_f~zgx-W$Q4F10Q12o)%37`TEIzK6>6+WKon$##64FNBZ`(b} z>Lvp0sd3!m?eFh1p(wo*!?YapNi*lax1k5`QFdv)jYzEG3*D+7$EQR+2mI#09$G6R z!1|+g$kB$HQUBcut3F5TwUc}Oa#LDBVPy1&9ds8F2LtY=0$C|9viYDNvJ{@9Okv@{ z0ECUY)c9TUt)(5?ox%N|uKUq2Q%5NovCX}k8}Quna@=3TQxr?&_z|rMyr};1Ua%T* zvQox2@P(4IRCtXO0*!}CtSD!xb7RJXt4a(BOg(~RzfIh*pW*n>w*wq@K>+deF+9lX zvq+jwv4hJ}K42y!9l79Ra$7wafq?Q}-fC3gjGu)a9`VSs$x5oXv-o=oe_!V2*ZHL%y?{IRq7)3y*b2rh>>aXX*`lv>Fu>Hd z5q2M(0y8UykG)HIM^@!iYuy;ys+z;iF%Obt2BE+uH7LZ~l(`QMKR8kEVvd^|EVP)D z*7^DSgb%>e>d0Pq#83#xuGu$Im@~b>SaEd4w*0JT*elLKL|ri1>PQl|IfL0!;Vv!U zG3AFCTr?y2`^c2&up1@L5Jx7t1@L74-o4$&06?&W#@Y18i}5a!I^E3Sj zuxWPaKYopBB0XtXCZ>2+8q2Fy)PA;QrSFhsj}o9*km(eeqnHdVTUzib^rEs!$6HfdEfiN2*c2~|x zS({>f75`b4=6dTuqv}%i8Cn)oshW?cN5oE>x;TY-(`a3@xzTPl{CkEqoevJ7J_59u zJ?CvUP-#i;>-Z?X7FMu_{7xA0ljlieNtz0RJ24*YPM@u>JjYlyH=OPH;OACYt)E7t zWyPV4h9W!S8C6GLA1I@}cYOdrS&wkjG z{*2xk{5I|KLx(P@qKLt!71D_8@bE5z1D3C?ptZ?xR+!d(mv}_? z8}3N0$%w@YraGe67fVS_x0KNT_yDJ2B7KsieGOd|8ZD(tDzND`Mkbpa90$?sb4t5G=a{V`wC=pE7MFW6D zaT|`1grYoOz5VbFln<4*xqg4tOvPw}uy*s&QKJwfEnyUbpMM!kXpCCHW>C^qy@82p z5wv_0B^&(OUQhLX?`#0zwf(ejLx(n#JX63=PcH3hN(@m9!DjV?qG7q>mfj{(>bzEY z2>;S*zws?TK{*H;)Rx9lN|KNsf2qC`uYh|6kPqenFx}WTKoLI3zNJQ zo%9_XT;d6o%6eaa<2Nho5JsU6IDu9pS$+Y|tM_{U`Llc0{kDCOY7L60GVU3Qz&r2FT%)xtNUfybp_x6TVJODr_XGg`55~)1f!_R^n z4UiYuWG@fJMwGDD8x*OqPj@~DFJ$URLNc(y>}6K6*{+3(81{Z%ley_O)(5{C8gWIj zS{J>oMe{T@J74Ng|G_MD8}%V846F{hM3RjOXV^=Tk_LZwtYKgiXG~AP87+l}X4fiB zEMAbsmq_Sw=5S2#{RF>?4L4>4;&vCs%>&H>p*UYF`OyT`%2c-HEAWSx$X(1jKah(c z!)OA^#jQ_T1qBZik|WHrg#fgDy=sUsiwPn0)AeCjuJQB15I6n7=|i@h?~T`=l*`tq zdt1aM*e;9qi{ZLh73Tu+_=fCAp;uRA*mO-y5flwx%U#HmrJqvVT#x`5ea!Zwz=@FU zX>}9c#v%4b;dw>`L$MMwed&j8xb&lA4tOY;s}Z(0<@eJ;48Sy3`em)d`!cWc```)B6-le0{TFJEDKi(&Hne3wm5 z&M@H@++|lH7~}%$KrA%Do%IxZobF!h9sEQ~fOtQ+3HQw=_Xd}q9Ah~k3CnSH$=L7#l zRaX`QqqyPcG-N4y?<$Z-IeC!}5*G+OMcC>+1(LBk7t8k*KkByI&FA;;nyHYnu*zk3 z-Ef=&KUfxwYrM|WN}o1|!owH$TM9LdsKNb!C^b0-va??guydq!i0>QQ4?M0lRU()CM|pCmMcb5N9aDS zd^!gSjhV_=dG_zBDCBTD9buk%N)>yV00?uS;U5FoXx#bDvcF4Ixtogi4*n5#U%rbG zADl68emU&Fm7AOBrIRp@b{=bO30qexSQ2j|-JBhMY*Od@h=jqJrqlLxbLXC>*xs#q zzVQ{1+=H3?uR9xC%vc1NZBhQCXeI52q*|tvJ1(ZV+#GB^1!&(R@b>7EzFBF~Qo zE_|8;FqRBNlw0)r2l1tv-d3--!kEnz0&bfuX1>f%H~Qq#-8BW0&+NSTaWV|%13UTs zcD5|{03k%NhMIP3V(Q~I9jQ9pt4g&#TvRb>-Ds4xvO+3AgiCb?spGXwz0`T(>oOtT ztcpGuFD8p5SP-}pamxg;q@0Yjy_@oU`wN=wqNM-OOs5UISt{o0<(sEq6a^M^F)3W;n@DS9+8n)6r?mE#disRM=ZC zMTcOJ7bhPsNokX9j=EoCDMm;uiq=XhZICkHNm%`2S+}+-T*Jngz}`2^!A?eMjIt=Z z@1U=^zO)3|Eh1N9%vGk&oBp@2Jt?|uRfbe>zQ$zA;RyTRyGRZ|2|3F*ig;%k6L-_v zu4aD{`}=kVR1o1fwRSvRo#Rx_!A2o_V8E_SHuG{_V0$4K8Pkr9IVnuxkyl5T2unmG zAqfOCA;ZhFBFhplAv|TA&|-7L`>K2!^LZ@U!07rZ;!~ds;T`MAI7JgtJgjJtD6ACL zI;!G~xDtzBAY2rWu<8|cm`=y!{J3}cF=^G2Wh^Uoya8fO&!QOP>C_#hA?4 zadG}*w}_yB46Bm(@6qdGWnxoxSv&DR2Ww}QK&(tGZE48E=YSIW)QjB&jNocYL@~M= zCAKH!MrcQeUdO_70&F{LEV-;A)&+@hFoaaAoPA8{&fB8>#fZHsf~!`J%zX3{6A+*8 z(8?NpHN1=Z6k=4&`6cgs!svY5`dht9;_&M+M?hrc>cg{)9nqJvs_9)XLtC!Exd@;) zm3pc1`;4}|GOL;1a!LQ13n3+S{{g>TFdB!oD<4`^4<&Fk%<%(eIkx93qu)nVO>lM8 z6~)}Dp8p2V3YA&|-S_z}Jg6|9N2rOqQ*Es=TPiT9_Fhp|@O}PX?%h~^kd0t_AkLc<$;{f7x)P5$x4$P&SpRJE0wao=k@Bz&Gp=JDJR6iS7(8z zJ%)dKI#Z}iO51_fY*eO!x5KH<#R?!RkI2_TF+iSOX>Jp6)Cq6U zoCRnB~Qd?r5|9%BUgX!_6 z&M1bl;?^&L~l6RMT@0(i2Bt;{yxNmuiW{VU~*EakYWzUL}QdOutVmLNpJ#ETI zMhUkarczVw)h zMF##}k7n@KWoHJ8Yn5UUGg297JTL+cJbAL?uTu>*+5yg+``eq%F$xOlZB3?+LVSSR zx1&3Hi7ZOibF{f}4-gL!z{6dRfo*+N7?nXoRtk;-fhH!nF#9pDFz4-Uqv8?Xg_*Wo zXr(TSXj(~$^TqHx!3eaXh#Jp#0m>*&Gg@GhYgy@ZGDl7GuiOfB^;+DfJV#zjjSa_e zAlD8Xu|zW(TtpWu#z{nX^NAVPxUp^4_ySUxEi5by=J!%9pgBitxCo3C%BXA?OLeiF z93*TY#g>|M6*bbS;3bPmeg=2!Kjjq#Z+7g4F11(gWMdg-BPD{7g-*Q}3ZM0^m$H`; z?Ix|AF($n?EgW5t9O%_+FHWHwXOnkwOX)qCD8}3>)%B%kktoc;Y`Vf{$Oim`Sk#cg zN0N24F;wnh5zmy9u$6$6Z!63k+%}%(1+Tpr)R6mMd$*n;v$>(kWxJUBR?$9^*(J$J zhLnUUSx|Mq#$=a$m+x!Hia*l)B>zjA8{)2*A;sy*cxP)tm(v^X?r5jJdu(~6R$Eoo zuKK>tWZc#JhS%C_kuW7=UcXa0tjckYXtAZA-5c)iuD#WayFaE4d2&X7RsgQ@Y2cXs!!_1-*5FxP4b<9(|sS=U(I# z>ZQ;zkzV6;D;8I+oSf>>cjoqah_usSr@W0EKFtwO$vaPs)sEtqTo-ojr&>!@yPio| zprhglE4`Q#Aa`&3Gs8W0+hxlHHEGBOabX)@r}rIS5n6cT}%BC%;cL|P)Wm5!@7 zj>17#&L1~j!y8%}!!bm`Jll>HNEL`E~qp+e!Rw0)_N^ey<@Ls)HD> z=x)_Oj5P5%*F?>C`6b>XT3%-ZRHpKlJ11!NZrc!viucQXJ){L$7&2j#Gb0AHxZOb< z#=R;Yz@mKUW$dVGQYwr^wjDj8DBM@}govbUEwZhgGJ4rIGy>1*F0LlKiTIn}r7-?% zFA*(fc7LK_l;U0!M%wHBc<&c_zq$8|{994Wm85iwthsbqJ1T))Loy2gXPAEq;(u4saCkC}O(Y%C9A76uAqLO?6#rnTH2SIkqEJpL|f2rqp49J8OPwIA|xF zpAE8GVgg3?hc<{>MENYWYR{ByOG7;?253QYDrCV%=72c7YMKhzkXNvplFAc_$7BJv z3N00>&;1EFOTpV?C&Z>n_#gv1J;mMm=JYVSJlb(>*;$Mh^Ws{nMNC=K!h}1Tj7HrT zbv`z2Pq;1ZoYfZmq29sT)sj>`WG6_1(f-NN!=(i;+M_)BTDxdfYH&GZV0&cP`>mX? zA5W~dD}*kbM2jJ2V50@yWKzB3XttQ7Bvn;b#o=%^Z>Ssbx&8(rKNm{T=dQdnNR*^kR09TBIQGF$apqh>cNSckbPxr!!8ZqS+N)(0t zd?RP;mc~NDo1T|DZ_<@^hv95deg%`8v>n=rEVipk>SC*yMteh*z>hbyjyS%nj&ufzw(iQ-ggFKHk-E$h^3 z?IPBZ=ENoF5+93GHDv!KC&##)QMPlM(Q!XkDW;`1`6S2Xv~Yj2!B&$=eQc)XE7&WR zBy3=xZTwbIjNM%-X=QW;@eK0$n7IunlhDC6`HOIpK9wPNuZ%#(_O#n9gXW%U1Y|#C zsSj#fePXABKW-8Lal~Le$cEy3mnaD3h>n8SM9t`UedWPM_RVBIA6#75#<8~f?05AE z?k`^HTaAZOOSO}gD(K(Giff<6KD-Cs*rFU5oWTSGOg5(7=yh}InV*Xk$-{|g|bobs7@woq)Q zp4}&yRf>x;()9Sn6Ie13sv_3zW7!l)_YH!K;Bb?yKL8L7*<$Avp;OuoPd2;$Zek_k{Z; zN6AN~t5ND&BG*asifN4$O1y?IN%wiKlBV}}HT5s!-d&`wK`m=lW@V^SNkpK72^lph z$rmI&QK`wKlvKt5DE`K;7&_c^^Zhh*{8HICBIlkYc2`3YyHTuKO5wGF5f6v+_MZa# zLOiCQx9QU48`8~Ex^6RBjuWYJ;X7KH_f>_i;v_nvCZE4tet<82SN!4f0>d8v!X1#8 zJ|Z=d*%1{NYPP_=ItF%troW}c8J43Msm%&ID_@0tI!0;ixQC(IFd;*b9)jbMvq|f9 zVE%hVe=0X{WhKPp#sNWBR5ks!_+Kz;e(*piNe&Uxeh7!p{bX`J*=bJ0A(L=2cK zhk`Y#0+mYC$_8WSq%_7cfQByForJYy32Cr)fAa;Jvaq(hhZOX%!9Qh4XEwU^cmArJ zgws|oxOQAx%4;44ZJaNnFAM(%dTwj4pGac9^c16rc*=Z0Hc)JFg}}u|^&(lLbr*jb+o<;AgIhV$?Nu&MZfejG0rHlh-1z<%C9hAiCv zHKIUyk^|a+GCilN>6M2&FlVM+s4IZ^XTx!!8b|cKKum?%ptH7cj~oAVGJRilBxS-Xiz~w8LoKMsAT12DZFGb zF(|iS|L71%z@x;|71i z;*2kl?Cv zc~9yp9lvJnL&W>Rf$D3VpTG8y;;Fh zCRMtD#uL*bDA>TrCXk^uH6GELL+Kky- zh1nc{X20#c*ia$}2a3qxkrz7&0qta0BuQ6Cx7*3uvq$S>$h^1Ktt(ZLg1MxmX#b?t zMHiV~8w)e=z8@xU=;@;^)R}sGD~;>+I~+;!!b3vAIqq4}WJKEVB8**mI`i0V!_LbM z>*KbXmkzY{aOB8K^4OA}Ww!gSDh(8ebUdkC`52Uw<~!Rf?qmLw4P;i;>!kWprmg$+ zBgyJJD=~nh`7p_CMU6`f)!-st(hEpLx1&v3I$=%{6uja!Qph#kF*%#IV`@I zQ^^R-VkAubZn{?DzZRoPJD4vNkrJL-R<6k5u$#`yi&yEqVm!!`6P+LXY-F7?KfG}X-Tt{%yFCdAG1fFyGwe_EAfO}UT> z7MXrN_&*T9KSaa3LK`GCi2WKCNp{=qr}rAix)L)PzR#RS)Qb{LRwl-5KX~>czwFv} z^E(Yg71LsBZ9T4)8e<_F8e0Inf@c+x)fA!LlFMl17UfkIc`o19RDd@`VWBu*VkT~s<(H=ZX(Udedu@@msBYHJUn_vx^g z8sKnRMW%APlBBp;lqZ+=Q*_T_!RAambtTlN1y!B8s%YMDKK(y?w;UWIB~S=SDR**X zeaLqQ1VuNO++f#3&!oo105i29SDI8n{U-O9GF`~A76Z~eTuaV22Ouf@OZ}C-IH+pD zm4^FnD)gEI(iAi%K+6&LI_7f>l;ua89A+l)5^^HH3cNH5Fe`zcq?mdDy9b74@Repl zBUiD3>@9wdnJ_#q&wBrboUBWBE(GSJa_HjKLU-Dx@*?>$bny) zmOwg^)1v@=;XsQK9E&Gl#JFhgZ5ca2`%qqWUAwOJSRx|V|Dli~c9*9XGsP2In|d4l zXh8@8*drTQinxVG7@c^j8fTC(qf#0+@UdX3!lP4hh+&JZaQpBCTOCyJMO`WU3N~_h4o{F30xl>vav37WzHxbWH2^P6DRL5Q99<@~Mlqj} zo3N(FO^h{Y&eOXDah;bXKWP`QM=8E~$X zX_h*!m=S%>-LSV8qf?@JMl@P`3+EwHgUPnDK6MteeCZ3v(2x{?S5X~PHQo9tVF|-a z6&@eFcqD)r9+~4yl3fRr4GB#?@v$185SOspkxFq-I1+|O;*7}pVd!GpR&4D6^y5|7 z8!LSeUV_00N!uOCjL?n)$KI6T=Jzyny4*o#&|3I>>2o*4k*LH}HTSKB>_J1OkNXOf zvtk`88FRv3Xx8rEUH|pH-jW=(j7>>)Oym9w>~leoOhnPE;lpCxUrA*1d+lA){cgze zQI`_UM;IiT6${lm|3U!~D#!#!;U%VdGrHPQFGsGENuT%FUY^c1oY^x7gImP5_Kv9B z`Uf!aUp2lP#pp?2tLHqVF9}scsA|>mh$-gbZQCA!$z@1&&h-pCl5^ zoQLX8BZ=QM6d<`QL?GY{%8RXe8Tlfs)XLl5=A5$=*-*^AnoJsBc)gM+=(9~xrdhul z7y0JV_#13fiL-7ljR3T`;rhw=YK{~3S#CfhhIa1q1{VkHslC^fzQA&xpD|3XCsRE< z78yOdwK|ca;Hpg+XkggWMJGAb&LO_uT+9y;(>g72B7buWsg&v4J?QTm&jU`1%T7V8 zSnj-ZggRUL`Y8p$83)p6D^z85x>T7WNY0>S6}bmJ4&|R9$IQ7E>tcP6j!08P*ln|> zOfsXX1oCf1OyY8f_`7&upp0N1V)m?%8`*z!$}pyB*$8+*tCwk;)%_b_yKJaJ!{&Vm zVEbR}-MWuR)0*HWA3KYFO&@b|K{1aD(OWB3YMJW9gc2ukjuj;cctA4S z69{09acvibNOCCU>SY4yFEhVzct zT}E?esu;ixkT3H8eb3a6?uSzC=v3V=DgnjW1O-3(Arr^iY))B$zO>nTOE#~XB3U9o zXJlN%n3gOX$Y^KXjg1vIyD1G@o+fw5n&MlRyrmSeP)A{Jr;7*ymQ$Z}| z!|sRdpmc+@$M^ahFM_$Qt9fo$mGT}hhB1#H_Z7!th|MrYhjE4TQyhlzY#fd9-LOg^ z(yfF&r|2N=tE`5TNsQ_1hHZ7Fn^%VP>3kdn5Z$;k!WhQPrAp42jTEkr&UALUOPQu< zni`KMm|W0w4$#)mU?M?fNAS=0=J=9A^p;R68x;LGz#>-Zvd}+qbJ@vX+;(0S3s%J|lk5ZnJC2OOc8`5W)#d zMVKeN)j{)=tn!#c9ABpwjG{h35|b0I8X(&RxC>pU>?*2tyV5CL+CW^87M5SI*gGA5 zo4lYEK_AXW(S4?Iu!WJ2!n9Ykcs827OSzgQ*yzJPV!rC$+*akHnTa=Ka_ev1?YCV7 zEB%?9jc2x=ZtPPplXeJP{3>A{+IwBrDTEQ|#Vo2ypdx?Dxd~MPtH&0R?1YQM=N?fg zs>1Id9v#U)&6?!hMab0&A%Rv!Z1A7UlNHk_nIf&#XO-BYNQb0;m1-$vS$n~4W9IyH zlTEufXdcH%!uv0L1h?NDc=8sF%pN_{25#6AvMdF~tN`(aJxZ_4!an7x_Hg2`romG4 zZ12LMg1lM0)f&#*yd;dP}%a@g*&#cwy za!(fKj}DIhYVTGqC47@dB*N+TQ6NuEL0wHT7nNWSV2{D*9$FsNTX_xX=RA&tb3&zJFqa{J!EWg{A+~T4=@hQ?1``Qgl51qs4Gk>dQCiA zyWV#7+D-55J{_e<)J#Yf*T1f=yMe$9GW#_Ts4h3%d>Da8-LPVBqpo6+<93(`Wkpay zGL3^sKnv{0qV@5tjY@hq+$$~&+i`_LpVTR_=T+)na7)ppNh>iZmyavr__WOS4@$kt zqdT6B@)_Ezq;tfON%^ki6ODnn7^>@0%Nez?6Ealnt$Lku1S7=FnFVbqt_?t=E&Ln=)(3HxcY-vZK4b^M=aAMmB5l zV)uYkdMu;WvU&diQ{d%=CH>~Z-rn~gMkqYdP~bM_Br`ee>&+gXEa;MFVcG=ah` zN%+RV@oNt&rHpmC&(>EgQL)F_pPq>(N+#^uYDmE#BOxLfY9v6=9ssmpqM`0^JD4=h z zVx6kdrd?|jsC~%m=#{8(ME~u^pjrDe#(bdgn9rLvP3by=zua2?mDLiS_XmHq*j=nv zame9)5%0$FL=+1lQ(dLY0<DeMa3Yv5(99$QJFWLXS&1~MpkkzMDB5AoGc=vQas|y zWRwOmuT3$!m>Vov5?5w<5GAHkSCZjmR3?d~+TEx;0wdBY#iLQ+IGM=B5CFh(Pl<1? z#iIPlB5tf}oA*G`MB7JHulx57Utf`SP2E8t+BjQo_8$jZ#73-Z{?}2d|CD^+kxy_*<;2&L^xLpP%IFs2Od%B*i%^^%s6 zPqjE5TI*yYY==pfX@|?Gne(wBg6S0!GqN)10AT~**>Z$mEVUc3wCE;Tpo-0af$5qK z8;eRIv62Q(YOyBuTGQ%D;rQ;YisXa5#`zR-FcxhHVCqbxlfHNyG|?Pf=DMBhg}Lrm z)DwRtvD*e&mp6vNDBC^b$NO4Y3VkfB8upWn?(TWWjL*);F*iZYRxvDgBXj!TrT zO$n5`I<;Y~VGbvgk^~NClSJg(8uUKxB6OApVGU`h-EJh;B&w<{=Wv4vqwU&C&7MtT z5^ye5jE3_$NoqXTDpNeyO2uP5T})Hwx;4onb*8OZl}>Iv9VdCHtuv@8qI^M%?~x%0 zpdDwiB?~=Z67XDz+^1B>go2X?&nVy@mbd!t<;^>5TugwPP_a2v%2d<~jL`{oTg)d- zKOAweFbP4kqVzs_gwjq=5fvu@SsKjXf9&0QgwaMu7MXuMD^HmVQKl-vU7Ox}m~xIW z{dl&zRkKbsX?;7m5M^MTKwdgbXX;hR4`E7j?G24bzlgXv2s-DI%&=fD@3(LF#Oy&b zL46a{h>$BXnq}DVF89eS6|)g}HpVBtN8IxZpXpiiy8k`ufjl=Hiktf0*mc#y5Kvh&En}X5&MJGTHiW8C`|8up zeY#8S>R#2R(4G2Q7#L+Q%Emy=UbI`WWmY$QlC;~3PfhB)G?Qt?)Mk^IgRUz@Neh%8zF$BDL$1kGRg)IhmCliz%NhFr!MM6Lc_^U;<10e7zrSr_J3RoX&MJ zCuceT3`Sqjl+7dQ69I$yJd|;2HeM0%bPjKEZJ^nTsUNy-Qr1K%bcp7OP*7W*KuVdR z5dZJT!KH?u9+0U}SjxK!D!6Di-GO6@%77DpR|)lZHt*dt?zUw`+=D`5$CK`1afPE& zBk*^00-)~}Y@jHE<(>haj#bGU=D8w9Gr$+meit~YrRyo(q=;Qx3n-w2{dF@W4}R)f z&vh}Z8}bFd+v`p7VqzEvDSf-UP59`c;ayQ*3G^#$6^xx5GNiu#aCtTOPld}hW2Np3l|<>7M49+-0k`3@Jx)@| z>TnWNT=K}~v>H*cQ1eojJte0i2CJS^Ssq}(4yCVI`8S97`_N3a>})A~gcnz*gt=fE z*IR6VDGi)WVupXke5@S|UJY(*zI=XfGi?BAuQ(@tJx7Knwil(mg#q-&X{oPr5R{AG zW9kBOtXW$;zdahhxIJoLtoK`1d%@S+qY*z)#`L45Y4QEhupiX<{vvIS{>eutWD?@W zgHsg!{^(JE|ByvFIXd|oO80H*qQCk=_qp5c=Wdf9_x+=$W66$!Sq`YgM)oZl=#bz{oM+AkHWYa+jgzG4HJ@w;_oGhEs zAOsZ#_di=TyIO8rbkS%UTPSyrEiIS61KJ)H1_%c(>tgOw1S)>`nmZ?bq>~H1yjH-5 zxVFkGN)ZYko$L{{ZFOR)YhzBU;Ura4@4A)b2C3eLuE>wGgF66gJ)Gq5_;( zy3Y%wHD2k@N_I)fQQS_bBSih+w~uas9jzKz5xSJB`F^K;lQfa)TAZa6^lzil`xIOS zlJI1E!wM$JYZGauId&q(j5l6c`Pnox{7RUc%*$nm59HmWkkexKAWf7qH_}9`EZKD{ z0jcbY+}-j=1**cfCgR-O9g)2I!QIjNJAgv0HnVuD6_d_x+_guWWU6y!`}N+f4M6y= z2AzOda3$xir7`;U!Sr7-rRt8UU8+4VmCBRo*YN$QstGe71ykwLr2y%(66VJwNJ~^A z#|G%W_*Aq^dBK4}?`M0rc6d;De(8nMy`=L=6BEK;pFMM|2j<3T2iMFth%xZjRI`Fe zNMCzMaS6|LUW-rm|R;wnwZO~0GT1!YP7xk?wH#l;?3?ffXV)3=0QQ^D%F>FO- zfjK%lNpGZ5n4xtWApjjC~oQH9#p+F_m85m#Fa#D8tuFgT8bJlcqcJWE= z)S6AYe^0ZfSXs2h124Hw@|_P)&fYig?b)HlBW=Go0GeR6*r9@uz+lH!4cuU$4rBsx zm3g#j8MiFQ;Tuk#qPjMAo)^ixL*ybTIB4^#7zO!s=K^h-t=(^{b7Kt%cKizF;eF!F z5L@C}&?$nGqTZa*GL(pzQUW_T?s~O=NLCtIvwvx|+c&nKtPUrUyszZ6ld_C-<7=k9RNI1UdzlpC;%evLL)qj9LoB%lLj5F_GaZLYU7VDzEVAg&lGki( zN`-H{Rk?4vVkMnS(=y7wl)9?z9#yi^;bc(@L9-6Q={Zm!OriViw?Lp~-I!!~FZNzj zm-zHGSvn4v6OI^pA5n`gR)mD}gR{#wIxG?dVO_*s=f?(r)l5grea{i>7!H*(32Enq z2@!whh{iDp(R3C-93WI<>-}y#^;l>fimH>+yd)H`4zCoA1GEQ3RN`8N{{Y;JPUnH| zQhWE$E?=1}6I^?!%->FDshoE=Ugo_{36IGHUi}6@EwR=fYpO8ABVJvwNLQ}cwjSTz zT;C&BGs3Tu8V1r>C@GPWTG#X4fDO&7!Kl3VN~3{weUO(cn_8W=*0Ie*<$epJ!IjPSgzO)tP4@E#qE2Pb!re)J1+9%drZG zJ7g}1-T0VuF3p7g%6R1g2-0b#R>oasSv;A4S4Z1nKu(Q@0KW}6g#xN~AI&F;l8hO*zbeFZx6BlHboK ztxPOzsd&OITVY#U05i7zmLazrpL99*bTo z=nQccd#_0w5)4b`^-53(8jBOp`hTmg{tM#+3N0{T8!?zgo(vOjEMlbGZJK1*L!s1# zxzyaR42>vj5wn#kP+W%>#$uvvOWqV!Z|m}{U!hrh`eO6R=K25v!r0Nn&#__ERgQjt zrn%_m#mMQO9w2fUkSuY866Gtx{=`wZaL|Ywd|TUD?_)WNO1`HjYs|D6W`Gg09C+J2be*Tb*FSqrB4TLPrP$oMN;?i`X_sEUq z^MpjOOys>QB~Sb+|Hd>`%m9{Gzt1X*J zv=Js=QjD-1H`~HCLO|cHj8?ta(u(re724;c$*&ig!+tCKw~1GW`!48qU@Nel?e%~9 z^0;|wu1!Pz1dICUj$e5jI}YhBSkXJ@R2jHruVz|l1I_tLvM5j(_4ijsrQI&8yQPu% zI`rH0Qt7Pt0g|skwz_%~ak}npZrJg$I)M%WhOKi9ZFl5I_K?>eG8U~DH1$uy=&s1m zt!>8y`ROxu6sz7l^+dV^-<7g0Y1VHNelT~0Q+k8%g;jJ(@-3uzuyIRPi^Lzvt4Tjd z(3fX>N=a`gJ`5y?6gT+PR8aZDQ1`)waj2AX$QRhHywg18k|vei8+IK#R4W0dKZrDR zU3irwBZaRNRt_?jPwse0vW`j)v48;Q!SMW8f&Kamp}Ig#Im~BHTHg@5X4YDA_GP)t z@&bM0*&bkCVqrwN>U20?y)pg#jkksgWNUe56anBPzt_u4vXhB=uX*%rXXEkn!8bDR z6GO3$n8hHblcw|llr5~HG&7IUB(E=r(x0*j5S7;s{6 zV%ilJV$}_pveN2Ww$E0vpu=g7J)I1zAin7^nc{0S?{rxD7il3T%kJtjh|^K5DcnuQ zwK18h$)gm=Gb#PiluB;%W26l){R2EUn<|Syq|TG&FAX;W*JV`j`^Sx@RWuV-5t3uJ zf>sV|@C9F!A9yN&U11O&Pv}t`)5$u>77k*KpJc0Eta;Ic==)8CXXL0EOk8#!HqWT%V@Z+c&| z%1@&kl0yvWWx?GsImAr~A7XllmQ)W5{>(yhi0g?Y>eLXPPD1GZjwh5H;w6}hGvp#q zzwL6>YUIF8Z`fRWLr(~i=u}lLVLn{sHJufti8akp9#jyh`3!-niTRc5jjuFwC+KTM zaarQgFj1{V88^nIHif24R{%S-St7mJD#@|RttJ1{HcD`>S&49wd&%pPtX*#ZY}2v-TE5rv{AZgM(2?RF;_pJ$+}!siZJk(~t64|=SIPbt zz0Wo?+KT-uz^%FQ+zxtaUW%=zd70uM*(BL_e;QmNGQ$w*Q@E7QDJpXes?0JvN3(gK z(j9V-!9w5yM`Wx58;T=#@AZ|1?kOD7irzh;&{xpW?9mb{8<(4#pd-r}*935wChWbTnc(XOSq+<;Bk zK#FNWMIjTzv8O~g&8V{Oktf`qN;=ao{|uti{D92hESLa4aRz_ccihP5>+i+1e8Xn_ z6RY}XWje95V7~ohtQ&i7(6j6umCR*`|FlJ9^vm8o+i()6vfuy4tj@~W3dpTXhxVq? z22W=2%H?w%Ink^VX(0khZksF zH;G5H@iO0E8nniXi8B6}JTybCFFsesvBe|_VYAZDHJXpd9XYrr{RdVhhp2_ULjVm4 zOp#u)WJgTJoSr!NS9`b&k7=Mb0Fi~RANDg2_!K#k!diBTEXhgW3L0VlI>X(|1Sv9C zx;+ABvF?lgu@?toPvFD{hpB zDsCki?AZ8_tVO?o-RWi?C+Mo9Og%gGAw4R#QQYgoTDw^~a%pgj1YgQ=t+ZWP&J*`j ztftDbC}i7X2_0j)&$m+2ierCFDHXLeVzkaZYv`;;GrDBz)kC-KZuRSVxIbXbs!EzU zZ$!b?+&9|iR;An-v7aBx>>VAq$=B-EE-1hRMG04&5U6IK&n4^8$1sYDF!;iUc%LhA z)cadIUgDR%0?Z5VwIRi-oiMmE-vl+@`X36GV+Melc8DtAph z3uuh9JfcF_B5ns55k6k?trj}VVt`%ty<-7SZ+h}}vvGHm-YscM1YVR*4pT$S_O%2) z`w=1DM-tfpgoZ?}FBRN1C5(GG7$bw5gMswCuPudZ2K)N4SM{jqu3ihx;qV;~MnhT{ z4LZW;)VMb@o;R=8ZzpO}m3kY`%Ajo0p3jG$I#T@|6<>&v>!p;c(DgWd^C}-Urzn|K zYIn`7D~x_R5#?8CadI)tOVUYuH9a1G>T-a!-%$>*Onru^4v8hsOIwt#q*Ma)+D=i2 z5YEOaH^991A3%_1DHTLjv~xt%Ok8{jU>*=AuuNwc!$dO|rSX`X=85etN-vnMB%A%B z8ucP)?^<-tuc6?ZnBrZ$t>?@B*5l{hqWgk?!-O~kAG_+iczE=_zGIY!o{=IY!UZA` z^FZ(a%@tCs#?i-hD!EZOgOXk*?><5wI57<>n`^tIn2%M6_u$FZvc!O9kjCGR!6WAX7mOzUJgu-29#yY{Q ztQcAdQkMgLMLrJk&M(Gng>;@K^>UQm?TrcGbnf1%#J<5n3<=DVQ5~UZ@ zG85EjT9r2#O(zNud_l&9*Gq-goV+BU9UvH=(@?7HdW$Z5s2B5kkU8#nF)!8#9+7>9 zi^UJ$!c5AAS(MYsni zo1`g|6ih(lVfALyF7g&GRI~uzviNSLDyuZ$D!!74Jl*(#2;Bqjy>iN3;{4WHF!{p* z1V*z}yM)@55|wMqINPJrJH(6@9;TK+zQ{_)CHEb6a5)O92$V0bca+#O#0L z@&kn_l`(XG$E{xT7+9l1trD!=>ZoV-FL`8Kvb6p}^+)s){Ee-F{bEZso=uc)U|sx) z49=_q%m|Aq0X6Up`>1-f2IZGHq$=eS8W!DP{*JYfG6`LK#O`Yc<9AE}a}zv>1w$*) z*FMG#zV-?HL*lwT`+)T7M?#vrt&XsaGjYWFis2S48iNRvV8hW{MSjTV-MGkAHo{St zQt^4vU9rq;rjp=ND{c~m62Dbj!sv5|)&ty#mRP}vxvWUj?_d<3f1?cqDpuxl$Z~(R7~N$XsC$1lG-$QYy!@n`l8>DqZaQD9Df7($|cnl#&2* zr64T2l22Eu;OR;_!)=+$f-9rw(jHeC)JO+hjb~EndR)!JE6cs};;AgsxT{cATuIMR zXr$N`BNji-PhBU1D^cjBwY~b8H1NteL~^%$p;!_U0VmMgxJsa>#flp4xUvn=eL=`Y zxs%{fCT1Q^up&kd(XFJnq>Z#H<1!!LXucRn{2+duVvmeVaauv!X_JuvH_rhLBt#E& zp$e@`SE2|$9+z1JxspUet`z%USJL{BwxsH35djEePH-hJU}wv_4jNZH#+5wqS+Se+ zOyV3BL115%OUBnU;bm6q;fMgQxMRS^=1z5GbRLKZSDFwiiso22s)BdQXnk2YLumCF znJv3+4t-DwEb(MKs3??oH=kH4h}z$bR&#lI*A}r$LAAbTP@&C9Dq3Z-xBSJ9t_Xl&mz5 zCuN-|CS{VyR>?`!esQSuHD>p$j{I;u&qCLvSO}om39>n!=afDjp@uzrzJb*F6C$rV-#RM4^eNI$ij5G zzjATWMZ`L2e)tt~_-kQ_ttE$1gHK)_U-=t(-NmQB6Dx!mC znD$?7xgn)*8pLc`jh$sHwry$QlT=OIBw5ldD( zqZn|M=1XCCNRy=`frJ*l&D83euDlo}tK%|&FkQXarHw+s$F+-TB0vYNUNrlW?P=WQ z`F#nbNXdZ-A}L8L1C|B|vnOa#lIQj0?U|e~h1~r%}xMcZ2&&ElQxAl9d z2B%G8c_yp*FBXSro014AY$oqLGXj)PA`N}_D@Rq!Ps7Shf5}!ZovA8Rff_tXdL@Z- zwJf7VB4=f20nX4-KJwT2C4zF=B(qiKzeqK8#(C*kWBmKSK2SkG}7;rfnZ*2 z6S&MQDgN^!4I4T5^JdarWosS9FVg_)N#sqY`AsAc#EmgGgMQIjB$)m#5wJARXILm?oT0)R8_&FdG+)O z*Mxl%D#;N^hZZyJ7$&d4pzD53Eo~7e@Q?zm9iJVmsrNm$UY4MhgdA1OvT8Rda#`Or z+7ib(=>1&pmWMld*nw`=izwG=9K3^3_44XmkkrNsUFf=g(ctv2pi};W`gCUCs&Zlk z3O!^}b+1p)HUO{ZJhMi7&smH^###VsHbw-MtswhzhW$J1Gbisuurb7 zTZ7e9S7_W5bj)X{pEjApSL+~eZM!LV7srCFnh#@T7S4Hi$5pb=7SDCnKq=$3(;Q99 zW3jA5WjDeil{^y_aH1tBv22-O@cfn1$=N`;7{>h4SO{wB!r@J#qFqZCgVF(nA#yk) zAY}s>t@3B!peN@qkXH)3TjrO_yFp5+Yd5AKgP7qtWL!A~u}C6OZ2K6L+#htkLF6K0 z&|keaKRHD)Ew_(l87T^{M(0U?ycos6a6VQZ8)#glVgw5R|Lna5m=?#k?%TuQ?kQ$?%R#`YwP%Bm}$Ka2aQw?MWK~_jCmjz$3>#Q(G`orqLPuUkqetz+` zjTqlI-<|TDGh*CSa|h<=$$bmT%>|os52tPgm6aSanX+`9owzUPX)gwmQ%L=nR41@& zhiDy(Bya;mpG-zfZo*W?JM?4aempk>DGwVFc_ryoKCPaTCdD~9%8R_FQ1c?IcI@be zPV$s}NzNrhXL^dJ=CzL^J(f$>>+7|nW~yxTh{^eKraIh;p*vDnj>wXA<$C*^9)g5Z5iG6}b8>LPh0LGIsYb!qFBF%VlV@mgL~PC!l?Nj= z(U;P|5Xcm5IIof?4lvhRm#ZJhyj(773`>>U3WK2b{Y*beo(s0~$t8}#V^Xqxwgo51P$XY6;+MbH01#bw|UJ4C0SS)lXCD}1aFDNUswx0aY@=eR^Zcs@`n($KF z)8i`zB~!uw#^iiK{(t`Dys^6C%H~h3tyGXk9bZYaE~Dc7!qAS32(9x&QrI~thP<@2 zwKPk5bmS~KrCQgK$yy|TMai_d&YPU!A+@Ic`44mITuX3XEl;=XK56oV{M=7=HfR{ekD=h0MW}yjq`v+)}JhE-b^+WtlKuIVdkTudtkt&KCQjn;QGcJvS5V z+>1Mq&u#zL(*R_qW+|SvkHrVxs&~i!`UFB=ZebA^@(PKeps*)zP06+9K;`ec{PNb& zttz)txH=Fn%~W-^cMr-<=Y82A6xcRelc?Dejj)&hXtk_PANFbpRC8f@p zfke_WQ5WmIlEjd{pvquM@?y!u zGAy(w0Z7V1wss|I&|>41SQZ4PRq+N6J||E-iEH#=zPa;e&6&4mot#f1M=rU&t$M5{ z%1NC0s57^LiJQ09AFik!^tp1o(5khwb#3Q`xCS6N6Fo@Fv3DAwE2b;h>|t!Hb4HIG zHbRb^)SXIV$O7}Dlhnbj0`YTV6=&IV_RO@jV#^_Ja=FaHUHWV?{~ci1#-98xQmbvZ zshCbc5M6b~iWUcndb>uMZV#1LInz-+lou!O{FF4;F~Is8+b|aB zW;NDX>jEq;NSG|Qj9F6VI01w`BC)+e=O@2NW{%{v(Mc;-Ef5XMk#DQr-JJjXR*shX zm7}~OLw>N6xlBS(iy~e)>(`P@Nh?GHc}cg!u;Rk7zb%6)4wkwGEHTk4KERSfvjK+Y zyY(!7`>_)4f)dx_VFkQLXj;zgbD8|(s4d#JrSQcb!XfvFW6 zuP-TzN6^VJvl<;`AFW5Au9ciYH>D^Zf}_-;{Mlw3M6g|Lo*s;=$+EmAs3V1bMV}<_ zM;CF?qq5C}a+bMjn7nO7a@uioapDHXG8!+H7Z>e_YGsQD)1PIMyrn00fq7S*dM|r8 z$JBpcfvsLzbrr^YF?C0(Iwx1jf0x43+e2K7BHd0oQJ(D2%oAswG~`js=*FmZbd&to z=|y1fv$>k1hyUt7!X7#c#yR7()YuPiPIyNL1%*M5YHDrM(hzW+htFO>vm<%)R~hh%adXF21R zK6ZgKf8oh$n!~k?;cTTQSnn0z_$&#II9$@HIb1i)t=*72hY6$5eejYp>xSejhDCJl z{cPqAr{Y(lj=(jr}{h-P*CDDm1Y7YhpV*V3jMsI^00F! zvu4gfmC!Gf7g&EoiFmMr-z@8dZMBgpH%_pWCFJv#92SPpuayM*MM`)xlq?7|EoezN z%O_vmxphl;%0}i}j0VYptIX@%^d(6*n7qz9O*M^bq^u>d(=R1Fl_O(P2ggR;t*k4_ zFSXWGBuqkb>q;fTKND(|>;$t4QbGf3NpPa4fwd%9&5;cdR9v}j5hWq?YKgLyJuKJ7 z%+Hb0x|x>ye>mV&-_R$gZ-MxB`pU)z5tnSHl_5!f5l(Q4M-+Y~x{Q)!>y+%u)$`Dc z^76Xsa74D-iYG$HDS^X+&ry}NxLQj29Q<2K)H3?Ygqa<)xNFO#gyOuecCN34R&9t# zY}G6&;H5D#PIu=fmxN36B*C4ED+!^vXV-UHG4YW`h54@ThbCNRCEcWU3EkT% z2~M!#wtmfFX9G)cIJhg2teFhaZ36B3kewnDk=tKfA)+@3chjiQ{3FDHj-?ui-Q7jBNa!=at4SIbcsIeHL|-qxmP&D%b; zl;=cGUO>5)=Rdd98{iW<3Dy5x^GUwxfN(-DW@q(k$B0F;&WCt1B< zzmD8HefR$T^gCt$w=0<18`((b68LwP zINfzy=H+k!Vk>cMw1iT$&iZWS&;dupei7N5WhQD%lFKZMWP^H;#-CDlQCVPGf+>Z% zpUB=3*;8oF0t$b*OdZ-6i3^B+mK%_lvX?}b#hRk|a+ty*=d3JcCy5;U>~iq;D7Rwg zi(BMXR_t=-VL&Cz4=Lz3n8 zmR`7=Sf%P4Y_!*MmVvpjTT9b)THV_*R87zQM|^WR|u0(pNKTC^{!9B$NP=ypN{i?eOL2|b4M=i+Za4!cdCHoI zh?X8K=Nv7Yx2n5bJRP4uG*=F#U1{$P&;Lm|*m7^2YfWZ_dMwX{`Xz@N=xuRmA;W4W z`O9ql9PBh+LuwttzdBP`56!XDwBk<-_RCaMmOCWCO*n(n9ReYjq z5xNkv0LS$p$_ixFJI1cGS}a}}rup@ZKsn(qWq4~z`K%Zja=9N%<3#DzS#6Q+EB+VB zq@(LZmeEQ9u@Y8|c<+gvEfYF;q?_&EY^%2HHQ^c}o4q)bTZW*IQiTyBI~6YnmLy(N z=7w#uJ0koUvTi#J%7{M*ih;LlNhMpTx?&n_9h9vsiNeZVeUXuU@H!Eu?RrT9y{^n1 z%OZ>a!@4AS><(>Bk)LeFOmYZNvRHS%w5BCwN~` zJNT1RdaOAYs~Y~?a<{xj8X}({ne(l`LJT1N+H!Zon6wv(6x%RLN@yNLkz5UCgC@5k zwvcm^7p_|^J3!>nV3`q`rMLRZeLwEbQ)zO{urVN%6VRyJlvh-g-&Ia??%SiNFM2Tt zty{Tp-tu)zdrI#|DzY5!Dce1J6pfxRv1gujTE;0$b5<@|fcYYS=U7gUVG}2elIhQ$ z@f?%f(`2{r*{-DarkvyU|NWc#OC~#A6^xBAxn=HrDOWdP$}jOhBzKlx(~}de$7OKw zwKsabgw87PMK|$0gWWBxmmQ{GieWFa&`sL9JzX!ti5GarmsIFw((%S~-K?!k8TCqw zctK;l*E-%m9q(5zibl)gM%_mp@6^_f>G9k0WuaqEba(c6zLG+Y)6O^T22B9VR}PJf zd}Xq5GUPVr9F_NyDr4UeHZXZ|hKr34^U86|1#v0$CH8q3x$U9)JV zj476_o3~Wnkn8K4Hjm{!WJkiN(PK(;Wxwv)ReDnU|5uKl;ci;J zavH3Q$HFegC@-J|_j2x(&gpz*R1J6&?x8g)FOA%wIa|08P;Ddtsl#?tSMjl1uMJa7%T|vyP68Sag^pMI_~dd?dSLT3!q3awlJ$C3)5;47wK8(*nQ1*FrEk97@X7X6uksAuE)&3I|KHEE zk%j7M=h@W!zwAKX!vEjSvso30Tn@>!9bsBbCRT;)RWa>`$dkS0!As<9Y1^ff1Ho!9Kz9VEdnCJxuX$s)H>7f*u)zG^j3 zPX7$bm)~fI0yIPs$E&cV&$k z*H;cLmbxe#M`AaDm>`_QEuI3c+Dm1sQ7=l9z%u`8a{eXIG>X}4y|-@ceE>o74HvdeePBDrw@rN<`9b_L4B zAc+q|2Me=S#@pG9<0QBMD``Vz8_I#=Bvms!OLjy_)3Iuam{zgHvaJS_kO$ZU&vS2y zvMQu))-y}uo`bgP$*mpnRaDxxFOtm*@j*3l&qCYx)pCN0w*GnujrJ1s;FtsCNj-%{ zdmh?%7%Bg=r?+T-MUREi9*aLgMUR15Bk{{5b(Q>`yq?yc=HfS;gy*1?M`e+Q^%xs{ zkDeH#M9C9gbVG(-R~Yw|!gE;SV{P)I8?*aJuc}y1ewiz8(*t$pV$;S!^4G4vs)wA& zqG!YOzy-W%fN^l|}wSZ-dKJ0e-K*$HR)lUgHxgQujpG0DJ4ny6uu<<=wd2bBFA)y_IK zI#y1Km--xCKO%}6)Q_TE+0?nXZ4^yEQ+g6vQS{q`QS`VxaDXhg&XVr@-EFg?t|E|Q z$7Ds%$SEve&C81F%5}HRj?Ic1%SkQIU!N6iZy7}|zLFIkBd2Q|`cqa^ubq_9q)N1| zO%%P}txD8Up8tAOm8g-Fw`oO{=m;4~^gXFcR9pW0+O<`pQ-o>5qgA37l77*LRidVX zz2nC!QE$n=Thr|54EgViU9+Qqh3mw!?C8!8QIs<>JL)OBBi3ZHqr)VBkLlS_z3eFZ zVqtdltd#fV{@KxU!gcxK+0g>wfB(4b=pyMY-E&rUv|jShso6~aCxS5l$Sd$q6)8Ka zRa2g<-Y~kW-qT{Db`=^p&u!~Ol; zkeFHkJR+xs!`QwdL19G7FCNj)bio#BDI#Se7HtbBbwgChieMQxYj;g zOX&X&^4AvSonFnS*NN&x-EQ>Zy7C+T4&GNUsu%s*(x=yt>PPnkd<|r$*53httEg2p zJt(iWn1(RDr0_fxN}n1{rSxfH!ovKE#4LsR z7e@zC`Z_UlVfw+*v6OyXbR4B`j?SX=v!k;qeOq)TrEib6Q~FiW4obfxx`Wd1j2@@- zC!!}P{mJNcN`E7IgVNuOKBx3AqAw`@%jh>s|2_Jh(*F>}xAKds)Q4WLm&q0}bMn8M zRisAa?>=JWgj8>`s>GVS7vhyXBfl|zN?VT%YMSQJ_GhBB zk2Wn^(o|F8w5k-UMxp8wQvHdatRW%QoH$fdLaH)cuWh;~)Rr$Jt%ZFuq^~01A%1eb^c1SdcgRGK?rWb^ zdeykN1f^G9i$hAUTBh_>K!57RdkFn1M_)z0KqgYHi*qQw>RTKN=~Xi(MXGn2mM!#? zoP4uEulg6KDSeI$DSbx?DSbBRTNl+cPloi_qD7OWM`7PmQ;t~dEFq=O7W%!TO{;5E z-#a?k(Ps<&_Qy&Xk8 z3H31{t$CG>zM9Cs($QBF`brs)#ProfQkCwzRFjh9kjh?rOO??N?RwYI@~TM<_Ih7U z=%+Z@R}=b5al*#3uO{@B(cqJI3cZ(oHPH8S<<^yF@?5B%gsk3c4bC|F>d<>D`|8k~ ze3P%b(EB=3-N{~gs|#_M7SdN2dS7d+3w=h0X)%3u=zXT=*V&n9nv;EX=zXCpSM|Qg zg;ejY=BQ=!^fidS2GQ3b`Wi%EgXn8O_Qj?=?WKD98bn_M^b-^GHHf~3*v*U_<{4{1 z4Y8Y^UM;bw*WSOkm^DFPYVy@2`kIbjHK!)%f9TQ%^`$0hPEDfM9(G20t+DKDf_~dE zTdHQF`A+sVL0|65tt-9K{w@^KYs=y3YY}}d&<`;AYJon-g|yZVl#tTb0{t&jWBJq~ z`dUO^3-p5|pVnF(9b}^2KD~nIYk_{SD@o~xxKL;@wWag)+Cq8Rs~yioLrp%li{4_Y zMbhJKV|uNrndr{)Dv-U_17B-v6TNst(cDA^JM0^g13>he`Y;>p<@P$4syrnMbeO=P~x}d-6GZ`g{JnIsDU81iG`rYK6D*L*iZ(QdSk^N$)_jN(PyDL{^ zKiY*t*=x_o)7K;VdY~U;^3@~ydX8Rs>w(_(f$9-`J)*Bi^z~Bd>k)lD$llWHIM~}9 z?Vox2`b1wJ^kWTueWI@q`aL8~Yi)hdcM>(!-%_9SzCO{{2mLt7r?RgP`pkW`sh3tC z^y6K*D*KEJh4k7odHM!Kub!BU^h{%>2Bh~5KtDm!l)eGz50FMk=^KE4FPAU0_cA7w zcTSWvrEdWG+9fTCz5(bbx%^5$*@cwewzb;-_4Eyiz9G>!B>IL#-;n4VlIAod*{eUw z(>F||Z%FhFp*edS`i9UPORu`>=^GKf`oA*LM~Nlci0B)EzCzMe_KiTlQ;f38z7f$k zBKk(4uatZ$`$nK|K9FVK2=vl;n766yr@2rldmTe~dL1u#d$0ZPOtg>5r~O%P@3nuJ ziKa`M(l-YEr_vcw`o^U9jfuW7=xuAI?Ujr?F3KUzX$*Q9ESR?`{R|fh>2=KG>6;LJ z6VUHx@--p)CZL}wX-eM&^cQ~~m)C@3--PI!fPR+bQ`t8G{lwf6G&*Sl`q{2rrJv(M zA-#^#JbhE5Z%Ufel<1q1<}@YEX-f1>iM}c5=NkH^pr7AxB+)ko{XE0lRP=tTOp?Ts zX-aypqeoBQjOd#YeKVqOM)b{yz8TRsBl>1U-z=5B8PPXGtzBT~n-RT^c0GM_qHhlR zg(hEf(AyTNIp}>T?B6#h`sPI6oamc_e(~Z_B>U!|U*yVF%~|Y1q2{RV@$@Z-z6I!) zn0zgWz6H^@fb8vWX#sk*2U>?)5Pb{KFO@Xa`xc--`tZ?2-vac@Tz;ir?m|j$MdMdxD<6716f>{c4l1716hH^eW$0B>Pq*`&LBX3iNB_ol4&d^qa2RSLnSz zrxobex^k8N02d1B)z9MTTN8b2&>v{>wFZ5T3#q+7NJ1+6)}UWLVR)AQmewTu)5q1yQ1Dv)~JJ|bU4ShT6->VPM)3+!3_Mkt`0l z{zOSr&FKL8d!<{bwYCG%cL4ns_ZHRrlO&{i-vRXX7yL$=(*g7+yByk6IK_pm-s^l) zj>IPCDmtdbbxMiroD$b1C9Z2qoVGW~a=WL*^+<{9nG)A4C9Zc$T%VMAjpQsN3z;-s6ti(J&Nmz0%y=aO-yDRJsKOFmbg5~u#MMLHirF_T-@M+uD

cBQTNYq zZ_&EHRYF?#JA!^^Fq!Y=$lhFGam`)=5is)R)r}VngqarF9a6ipqbQ1cC z=sZ`h&H|k8LOKg@feESg@${XEzBA}AbWeu#ok4$*q$z!8&|kh!Oy8O4I}?3p&|fV1 zl)iH+eP^QYESlr#J4>7A>D5kFM3)%CE}*~Eg;e&JxlpJ%T}X4ffPSJF7nOY%(wr_t z-v#uS%R8063+Sf}-A=Oa0{SalxjKJzr3>l&k(Iq#^o*nL3ccTMp6m*}zsiL|`mRLZ z6?)%mZcN{m=(|GiZC|e|YVFnXPNnY(y}$g!kEqS-3cbI^m8)&uwJsFaT5Wq|-qoaa z1APM*QoqXeE);4`H_+c8X{tHhK;Qq?Y{0v!&}3&slc|{q3$?rQhK~A-%Te8Ci7`OQr|t?{uM1_C3hn z_aNE#AldgI+4mrNU1{cJ-y>D_JxKOF(ATrF??F9P?Rj|mo#4iL}3>Z|P0+y+N=27NzeEdOLU5oAkan(f0FN6reIL*dHE-!d^nE}-OwyFT59saOT_2*?v&Fn$r4Q(bOFpIV z1N!9LT_4boaOJAzjC3KDy;@5BW!gjb^nHoGFVXiU`o2Wpm+1SF=JX}{zC_OK-)p?;(} z{fNFF=pUDSO5YFkof$|ORT5QC;EKQ?`iVolkD?BZ!Km% z=&i-fC(X$x`h3t&ly@q9KIoHkcln^7n8PRl{XAE$YR-HY3h4_a*2}(-=nILykYry- z^o2xUNc4q7Ur6+Ysq}?JUkIDCz|a?xz1MNPr!OMeR2+?2=q_6a#eGlcA-%A+K=`0#h`!2JXs9-!(1rr-xoW2)tq9`TVHN5 z)!Jgv+x~qq=nt27s@@laKIzLX2K@$CuF`LGp|IAfZ^YA=5Pb>gpEdbPNcJT}Ujq8` z#jI%ySVEdpLi8n|e@@=1^d+Egeq6Tr(fwMD63{>I%2mC8!G%KEmrAUsF9rRJ=E+jf zzvMz;tt|!p%aW$DF9rSPmt?)W(3g_zOF_TIy+!+&uSiJgOF_T>oV8-_{R*p6(7)<( zsO(>Jp-}efZ}RkIL|;bqWmId+h`x;I%SiTRL|+EkTl%t8`ZA&~L#?&+Wz{Tq^|vM&eyqtf)L?8`~^YC^!-Wp{fWLm(f3cK?@#poiM~J4YwtZ1y=mk-0Q7cbH~{oZTv}*z27un$ z$N`}Dp>S+90Q61VTU76tN=Ws70O*tRrUO8~%;iwMU+zMo-s||n(+?#2fuI)`6ZByq z$$lW{r%Re@&Op%HwHgCSa|ROqK*;_r$*1%KLBDO>T$;NZ2>Q2Oxk~?z3xzgEM>(E; z5NXaJ(7$W)4I=tMpnp%&lztHC>&u5!y&puHGl(>25a{2Rd`dqE^s^6HMf8I}|A8x4 z=|6O#Q1&|h%0wTTw85bN*oAat_=yXJ7IQG@Kb1749}N0`r1PcpgGu&-N%n(5|C!`d z`oW<8r3$a=91Qx;UAb!Szi^>Y_CqAr(+>gtm*&YKko{LK6zcsDr}s)f1oX8(s|orc zL_Y-dt=(Hx@4uFi(hmXs))5(!{SeT9<8r9%ce;?J*ZHHN5}Wk%>u5C@rz6p1oQ^z` zaXNxa#*Ipe+btz-_msHNDRE;`;&c>}ELTS#$v7QZB;#}>k&Mfv#OYWe`J9dsl5u;b z#OatI`J9dcl5vw$;&gP7d`^4*$vExtC*vwp;-;p=O-qSWiO0u)DTh8%FfQK)<;p_T>(vx<8EQhY|g-RQh2= zKaA*y5xv%FPd}XKhlBomLqDA8hlBnHNmI);9P~5B#A_yo6a8?aA5QecQ|X5j{cxfm zPV{PhJpBlw9|8Iw4gCnBA3?Go5!>A+vFt~H-j2{l5d8?y|0M5JyE_8(-LBt@?CuEA z|Ln?DyZeg^S-Y#+tadUJ{c6%ig8nxb(l#&Og+jd_>FDFPglptRlI%x<-u9M8g1$iB zsq`a3pWFj867+?xT&34>a9mQ@Vyi{>^rMJ=6l8zB$v2An8>2vfgQThEjDqa#49qCd z7rT6+H*^%}Z?xgp- zJIzu0-9c}6@a#_XyA%EHpf8hmD*f)DPwwE^9rQZ-QeD|yYOUYFvpbCvv_1Fqqltbr z=%xFKw~Qv)j|RQ=(v^NR=BdTVpW5d9d?|8D5Vfd1m;x6;^t4CwzbyklT7|8${{ zUi(O%ek{?C1^t62-&oR|v7|X;L2v!&V~Kt&(T@ea^`nmkebSFU7W5Cha#eF4aUrGe zWX?)}v=YU)AttP-|uBBP5fdevXbhJiYGL&qTJTpu6=m(Gqz=33a!=r{9z4 z_au7Vt?zdY?n(5zTi^Rtbho~&T1~7+*M0gKIef{MtFmA2LZRm9_{h^wAo>ZQ*O83U zPXK+63+b9@9nq-f=vf0Yf)%42KdJQAV(M7~e%^Ef=&Oq)RrV7=|I5SUsh2hZ^fipM zCqVXca-Dg1s5yH{`JR3+qTdVjwzb-e==Xx`ZELj`=xuAY7s-AvqTdVjwG91Up#N}D z1<~&X`r3wfFSJ&5Tqu;ijyXO3M53Pv`no3HMADpzPIFZD6G6XTrb$%x6N!Ez(N84$ ziK+AxiGCu{Po$p0B%+^0^pilpTAom*Nkl)%(Z^|F4|x*NPa^tBpkE{JRLz+L`s7}K zNuXcr%2mBTz=cBD>p0%aelqCm8EH=j{b45GWTKz!=vDTUA$vOmGnwcogMPhxi`Lr1 zC8YF|L7$v~nGE_3E{D=@bfJ)bZ;AEvdlS8$-jtDZePY?~P4s&c{obIrE4ue4`n`#M zZ^-@_d8g9v4f^D2`n^Galq*;1H@i?+Yt^E7`YE8VZ)86O^e>rwQ$U~NLTYnfmXOMR z3h3<&%oL)Z0{Sg3pUVCf2`T*)&?jeLrhxucmqY1abD>c7YV$mO1<_X!eFf21K=zit zg6JziZ!Km8(N{qBmcAmDzJlm0U@RHC0svY$%yQ;B|RD*aTVpGx#o ziC%qpUUQ}q{WQ>@U}Qgy=%<1HL?ioYptn02rjhKY5&bmKpCtKI@27!2xszcU=udX# zY7hAo7Yg-Wy^WrJAEMs}^zWK{`w;y;pnp%&RCD$Ly`96@hh)DG(eDHL_a&dw?*sbe z9L7GN|G<^2wYGt=B>Rx;)i3Jlr-Qzsd2%}FPd9Iw4tm?ioDO;oDgAWN+m+KTguc?z???1{qNAtZPc+A$<+C5r???3e3B8=RW6Il4Wbe=N*-z*z zqc(9{JHcWFwTj)RiV>1Ze!w<0BOWlG%s zDRHY(;Ua;tolPJ2WLud%{T;?bjybw09fE zsW#4(I60BcXzEN@E?f6!qW0v=6Y-Ow<(la%SDY4(5@wR+nhDF*#JxrBuJxnOgyl;5 z(PyIW7rGp3cZ*yov|L(KJpC-9p9OmBN1sJ)-Yn2tKl&`#UF%1m1^QxB-YlY@11TsJ=|`Up`rBQ(D*GKS6w<5p@$_?ueh%pE*nSSt&jGz1+s^^L9ox?# z`Z+{D2lRss{T$FIJ<)SOKiKfj5!w5*q~@T%(ZZyuo%Hl`iGD8V+nYKu7xdc0P)(l; z`VNw&vY!k3f`Reu*IdxsQNmoJp9}gN$)~cP3;Mz5-b9}0xuEap%2oPKE)?p$T69l8 zkLc%t-g-ml5&b;STW{z*&|7clJd*u9qMrwP>kXX;`lL5>9_Ys#In9IKXIv$ zR?^ciAo>NM*PgiQ$^z2+1)$e{uF@|6yMx)PxXEw=#!_? zECjt;!?;|fSL+goLVE3ac=|;|zXzntio6aDg3`sGBw9GYY4my^BMQHQ5rLG&v?-`miyAla{QvRC>Qptr5n3ef8* z=K8Hy5d8|!_mwo2{fby~S{@~`_b1)10DZ2@ud?swLZR$+eB|j@fiWWPV??JU6lkbPs9PiMb$v=qN3oCVk)^vPL({XxIM%1nA6LC73fRM?_34?6HLBUr1z^pf1;$R>{o%_`V&_X{VK?Qi+hXGTYusz&?o(g zt3Yr4iK|5Ky+3gk^xm!)P;2h#R}=ke(7$WST}||>L2vzut3hx5iL0sBt|t1`(46<> zovJyjL7(&|t_J-Fu3VM9^(U?-dTlqRM5RXBYlMDEROUi@zCgJPh2z>aq&aJZz9L%n zs@zf`I<|&nzeeaQo#w0&`YBO=d8g8^5&Fugb)VPigy%IvUl|Q><<^xP16{~^g|sAX z(K3#HEo48)Jh_%+zm{abmSn${WWSbVzm{abmSn#+RrYI1_G@7=KQv!rEy-S6;0i~7 zfY4V&gAM%wLSGRLaiLK52axO!fb55lj%(%tLNDicyL_QP@c^N(h=xj<%KiYMuZTJw zem$M-aDdQPM8jNu^~eo(q3~o1?FV@J1Bw1XqCb#q&VfXKAkiO4vOiE{?@t9ekmwIg zr9Y794;0yZ`U6Gw{#*_1sZ5GSm|u2~&`*j+x{!K9N4Zca`-6!7AZSiOK|HQKi0BU@ z`h%c3yU9CM_6G_5q-fh$?~*U~AZX6+u3W9Pqg^O$t+c-+=MkHl}TY7J8%Bf!^Btb5W8&?v9qGOHg*&hu0#$C6PPvKzDk8|ZJ z{dgA&Wv@L?Pk#u}9|C&o&pCwX4*|XP=Ntlh>(4oa=noCZU?^wytq z2wJNl=1Uv`*;{{(`b9ncp+tWu=!cqohZ6mvpdTh_D*Ho0Z_gJvl;{s7`a?lKT=J>x z4+VYle1StjKf;x(vLER}q3pF6(4n1^wytq7||a_^oN1o z`g0D8^*(XJ^I@R3{v5q+%CBxajPzc6Po91~(XR)+^@yw|*{=t^^@ywoz4eH!C;Ih7 zzn(N_J?NV!JR<8sZ#^RGK|jODem&8vSKQMdPV|R^K4a?3;Y5Ep==YQ~)ttjY-@a>H zzYiz+!-@WI(CamAsyT;)e(=`|sE2$w==XBvs_ZAakkuTWKiVMlp-*4qHm1aFN{Krn zCGNaad~S0}-0>-K+G9@U)t+)PPW!~kIPDoHWrKJA&-)5umr;&?89pM>yH5 zM2-Nx>QNjD*X15TcJ~O-s~=G5j{tqr8+ruj)!P=oO*KcoS8*t$S3BwHk0g4%`!N$) zuh5Z1f25;Vy+0E4)+=-*WN*hfM-u&!ptoM3BSGId;T1X(^wukMBs9l*g^r{)Pc6Eq zKZ^AJD9}$c-{mNxKZ@v&0{zxmuVkxyjw1S_KyST5M}dAHd8f+$D9}GSdlUJzjspF3 zSFXx_Ul$5%t+qX${%F$sqe1_!`DRCx-X9J6_aseae>CW=XX0qk+qt`=N$-ya{ri$n z>5m3|(lc>1=s$4fD!uhg98I#Q8C{ut0-H+(hqH;w`QELX15&vv0u@3lRj6wNVd#|r(VXs!!|+qvK;iZ^xI%3jMC*%VR-r$Ct-K@9p^VSjgUv613;x>5n7&W0@0s9^d}Jg2}FMaY0e2me*)2;kV=07(Vsx{ClI~%kUjm0M1Laa z>l&>(ku>K-r#Y(kCxYJYWH^yzeJ!`PSu^bZi2fAN&yswq_osk9x!U0r(9d?|s@~hx z4yO>kjyb*TPbKx z)>QhfpkL$4RlQ&9LSbvAUK~$`UB+&Wjd4S&jh_)X>um$?Mjm~iT+HYKNIxp z1XA%8bM1L01pOs2~ z7SW%DT5IXgB8z!8(Vq?a1I$-C8}xQudp7C)*`)VpgWis7&j!66m7fiIJFYz&^mbf( zHt3V%+Ot7#$F*mJ-i~X}CcRf5o|pYLqTdF3>r2~4^xKGj8|bYsZ5!zA?AJEXTVL8X z&|6>HHqa-1Y1=@*LC92dwt?RI(zcQ8&msDAi2fX+KZoegA^LNO{v4t|hv?4%z4fJ? zlS+RM(VqkQjpnzUL$W`Y=+6cHfkt!A1-*^{R0ijg-k%G4?O&_SIT!SHt;V@Te=g{) zFYR2=+qD|!fdp>E-`Jg}8 zrG-A^^Fe=zq^a!B2mLRX#U-3i^yh=#*4pzS`>zfC`Jhkko;n}&-x%KWp*cHUC~Rvl z0R5qc@B+{u=0fTb`O4(GfMkCG$^HV++wf4{sN-EAeH_CqQ8LXFL1S1=ZY>A zw&eWBMJaI?r^H>75_f4zoP3g9%D6lw?uwMSD^udOr^H>A5_fe<+%+k2*QUf>mlAh< zO56=8aW|&K-INk{b4uJTDRH-^#NCz>cY8|Qj+D4N5T`9#B&%i`M5+gOraX67O5EKk zardOe-J243Um{K|!G#i+iEQn;kZR9`sQc?pUAmC$?uDp5hfA8){R>fhE*3K!zcZW# zxR7ekg;aYkOszc^Qti2rYR`qP_Gn33Q#}1eM1K+Jzn3TCCqv715$J!AG^M`?^!5a} zi>U5jMD!OC{Y9zt7ZLqMM1K*{Yn{$S8;pD}2EFwsUJQEGc%{FXWPdT}Rr8hpV$j>& zQx}82*yRh)7P%PoT06AWxES=w-BTBXUTaHSuC^LlPvTJ6YN+**m6wM863}mQA+@`< zw{!{F-Al;sUIKdCTe^f~e+gu7drOyq-u9L*iRlyfEnWip4Tkp;$lmsrE+N^go%HmV z68)u+{SoH3TuStpI(n7JrJ&dGS{w@3z6|tsbbJ}f{xZ-vac|N7#vlnP{bis} z`f@J={a}|P^yOYgve&l9(_c>XmxF$&dCTQQe>v!fNt){Y<)F7~g)S%h%ZdJS$bPuw zQ~Jw6pIj?+Ip{~Ya#i*tT`1IhZ6!VZ6-0jp=puO#{_iT+BWzmn*$B>F2sZ+*E} zrqW+Y^j8x7l|-*S4^O|H=(mI3`f|4u{dUk>U+#9$TVL*WqTf#R+d*%Ax!XaX^yO{` z{dl7*+d*%Ax!XZ+*9&ML$N*M6s`zlP|q0loD^UqkfQfPSXrR@q+zdh3b4hUl*$`fETxOY*7B zxd!w}PxLjQx1Q*0KyN+K*O1<8582aSOZ3-*-g=_1CHiYYzf>fm^w)ykdZMo-&AFE7 zuLZsJL|+T~q$m1X&|6RRwV=1Y+-php+L!nA*Ae}7M1LL8Uq|%U5&d;Ue;v_Z2YTy? zzAlyiI-xusQm|mXH_Wyd&+up$Sp!cD0P4x9de?8G(5BjC@PSu?2 zL7!YFb3N#nxpKAEE_b1@wbEXqr@w*dZvegRDcnG^zX9~Nr*H#gZ+i+i5d95Ae*@^P zAN>Z>Ci&hai3+I#KwXQC5K+RdOp(S@{szrvJzGs*sD zlKst~zp2jv)R3Er{$`T>&7j{RB`E#Pp#Snyy~}=82fMoMX3(GHD3tzW7Yg-W$MKoy z6q9xf=udT_aCCAD(ceP!w}9S`PHrL1xdrrgbaD&m?daqd&?kMlw}5_wk=iY=Id*h% z3pA&NNmGx5r@xixZ-wUAvDK|ae=E`7O7yo9{jEfQE9eiGQdRc1rqbU^^tXb3qvH)V zM|~rn{x;B`W@LXG==U`FZX>6CKptrY{-A0;o8)?pMpjYpP(%%O9K$E)>$M7su1zPV~2f-dfDtiT-xbTZ?%+=&i-Pon(JI(ccbw+e^D0^vSW+ z?Vz_~tJ`67h8X(WNpsZSf?*RRyhW-wszXSA-8TvawZ|@qsgXr%d`a3}X zxa3pKxdZgcy9Vz7{S&TSZLOYkp-^+whv(_Fo+Z(FN7L2uiFJ3+4@mHnNdx2@Hk zM1LpI-wAp^!c?ghOa zo!kq0J36_S=F*=@`-uKNN3Zh+_X~Y;{^)^}xCc|>9!iOOI3@0plsL7+$#T{H zCgaq$CgaqWCgaqiCgYw;iF-OF?wORhXH(*yONo0vCGLfkxEE96UP_63IVJ9ul(<(@ z;$BOMdp#xYjg+`IQ{vuAiF-RG?wyplcT?itOT=j%zF*>e?YW<7&;3+;?x)&wKh>W5 zsrKAYwda1SJ@=#b*s=ZnskP^Rsy+8p?YZC89;Mfs;^`kC`Ui;q0iu6^=pP{Z2Z;Uw zqJMzsA4sKtfao6}`Ui+!>$InTkmw(b>E#LioezTEw#pBJ-iJcZ#DhftAkjYvdh3~Z z5cEmU#Dk!>o{0xRZ#@$ag5HjC)cSb(hlu_m(62W14-x%CME?+EZ-2`}ME?-cKLq+U z@=onKKTPxwgTA+U%fm$fu%p+$-ov1``;Q(5 zeIJ)EoV$A%^nE2w=^qAta{tl8pwD&rwYSvIg_PdPUM;$(e+2Z~%#)9R{si-@A0fSe z1oS6Ln$kZ4db`@@5t98QkiGRxJOcWYB%jhh0{Y}?n@2!@vMV=SZSx4}y|z7>=p4iQ zDCn&QJPP`AU0OKn`zYwolQgA&6!d@8j%&!HME@x0&oC^Hf_|%^e-!keR$;%&qo6~f1Kza7uoy!?j9%l$BF)N(A)d&9w++8iT-h-e>|1` zaiV{m=pQG|(VmB=e}d?rfaciM4o{HYKLL8X+TjV%+tm(F5d9NG{{+!LkxKsr(LX`- zPmsmbK9Z+@lIWiVz4gdFNwR;EWd9`Stw-)jqJNU;pCtMxQ|X^1`X`D0Ns_(x<~;pV zME?}%zmq4lwR(!^pCbCFKyU9Fe2VCwBKoI@{;5>@r-=S3qJN6$wcqLKpCkK7YgmYjygR3b433f z=&djJIii1#^!_=}TTk?JB>U$;zutVo=Rj{g(a(WC>4|<0^c!3brMI5w=ScQCKJxU> z6aDj`FEwv@p6H(^`sYD!Z|i%WWdA(TKM(pVjO?EW{g(&w-Nw&@{z@b5=b<^m^O~{zcH= zmerT&Uj+RPF2B;>=t3dAj*cr_Kj$T)e+l$AnS3vSK1ZHcX}<*en{^)7(FMF9Z=VhVy`>bCU`bp6p@=m3HS?DK4B|kn- z=Xkv=^pm1HUAc87be9X&lTbG!L-ja#`d5hl70{0|`CcK-d4=d-i8aTZLiP&Lze4n{ zKy!98^sj(Ec?#Jp(45^}xvDv%T`1HX^^JJ?SBd^r(BEzHy-J$%D(LT#G?o3Upr79$ zmi?bHO7yR$(!Wadufpb7`d6u~RWFXOwXZ?%t>(N2dOLsg8qvQ7dOLsg8tCo( z(QBY@Y`*SmLho;kdkysW%CA<kI_U2=^sj@y|ByRn7GQn{JL~&8=pS(9s^&cCLZRlU zXUx;TLG*8c{vng^4WfU;(W~aX0s7%}W6gPk=-(jvH$eZep??GP)qm+o7V{0zKjO+& z`bS+z>20l5AD*Xwljz?By=`mXB>Fdr{!P%^w)RcZoHvR7P0&AP=-&kW;s%3={!P$7 zZg}5>-ap|&q3qS$=;_}g`nN#8pFE-3@fPX*TcDpQX)61-KyO!Ay+yKri|F41{Vd6+ zdjA&alPj#=0=->f^%m&u3ahuM)~a9B)4xshZ-agxc|z&mCi=HQKi$y34SKsa?`@L( z+eH61=v8J)|2F8ijhid7_p2S=2ECHS<*MeWuQm>ave#Ho{|?c=1Nw~lX73RFJD}fF z(p2{EfZm>=_72g%L-g-}euCsv`gcH|JVWgr(AzWA-hu4x8EWs4?A6!o>E9*#cS&>J zCHi+sbKWJ*d6zWjU7~*%^iLZ4cR_z~leHxKcR~M@k=nbUf7*pY*{fIF)4vD$XUvoD zf&O&!&E5mOwTkb7UPCJT_dsv=e!WMse-HH58}%OOtvBjD&?onPy$AX;UAd|`XStB2 z*ZHIOB{n(l@7t(%qjyxad)4ML8 zmo%+C@1yoS`BiI^7LF3$NA0nm==V{3UXXlhx!yd`VWZygH-wti2eguu2&p|(%b%q z)@d*M4~hOmqW_TSKP37OiT*>P|B&cE1pTYRqO$)G^tH$M z_3`u{5&cJ?*LFp}(nr*4d<1&6+NwDpf!>}%_7Ty4MD!nl{(Z@(^dEsfc?#J_p#Q*? ztD2)yjwwQVwUd=@eEBiae=PKs(FrEs$3*`z==e@gV9lHPwx^q&&_r$qlL(SI6ij-mfFmHtzr{}g)vk)i*TMrhhfW}=Tx+GnIW zpOM~wMw;^(>HTM<_n#5{XQcO^k=}ons`sCf-hT%A297Y4y|(9>=o6FnIp}SV=yTA| zbZMcz{~Yw%#;E3e4tl#L`g79z&p~fzzdk4W&q1F&eeZM7+tc?x2faOg?{kv9_B<-0 zPYvN0LSGSm=0bY1{^u?f(tjcJ710-l{tKb6i29Ehm8Ev!3zGd8LhrpoUkH6g^rhre zz5hb!E22lw|D9^>7eZeVedWrnE1|DlsGfxS2(^}^eWZ+|{}Qsd^j|{u*SjY}`Y$2- z8zfC-|0QH^_nUr6^j|{uP25|w)_!B?zl7|kypT)w{!7Syr{Vn)vj5hFLW`-rxlHt( zN&5=)-@A~`o7&OwS5#}i0=?~Le+7CwI{u0@=PRQB3Yt?UrK;?|0{ymQwop&uE6|sl z-}{x&PmTJ!P^kCX@AULv6aCka{ZNzdYpS(hgMOH#sqDW7ye8_xesQ~K{>*_TWq`tLyhhkLiu|LH;@y^iEO z{r5!wJ<)$p^xqTx_mI79<-RBS?}`3<(EnxVzfYzAp6I`a=2-ggNpp0}>FIwU`X4}V zS6KZ3dQ12N=zS=Z{SQR{1JVBg`ZZFj%Kit?Cs$bg0Q$A^jOzUlpg+Kc!dk1NV^9Ah z(f(ly?Wd9@RtxxMm$lm(2ekA%IiT+2>Tc6gCpila=egwVsY5fR#>(ly?WUu3R zPyZ9q{{;HKjmG^%^gn_AA4$_%`xEGI`=Sb@^%K$mMD#xq{ZFa%KN0;;ME?`ftH;69 z|4j5hgZ^Jb|1)XM&!jm&livRfdOPF(GtvJHdU-K4=V#F0bn;57wLgPCOP*29`5E+8 zTqvxy>KpO&zYzT|ME?uX|3dV?5dANp&o<@#LiE27{V%EXzYzT|ps(uQ7SgL1$J75x z^uL1Mt}OhO=zn$esyV-c-mWbC74&vx;jcvhE9mXY!e2q3Tv_-l=yT0C{}uH8Tqvxy z>TmM&zk$A*`JKOketKpccT9t^hX%_-$8%Vq~Yk_|4#J3 z6aDXy{gIMS>3;|PlP5kSeayuj?CjU?pg+o$tF6^$7Yb#sK0HtV2k5IC+5Z9h8ZH#} z@BaXOO-WPP{{i~3(y`L7^ato|t^EV^)~E0X=--!8mHrRVCp{v6fc^u+`v)|~jtu`G zo1@;wO4q;tlj#2xdhZeWlVtxV=&eWOPtaSB$e$$pKZV|VME(?d?-BV^=y&yq{3-O_ zBl4%vdymMULSN~8Y3djCvi}S8wT!g?g6!>@)W4|K{ssE;L^oCTe}UevN&SoH|AOr8 zEWlroy`2U43$jnHN&O45Ki}y6Uyyxm#}wKe_26crIwtLJp|6bUx{%7go(qMV^S97f zM)f64>Hik`%4o{5vEKhpn)A2NS4N$T9{dg2H;{a)Ie$a;udaWY#Qa<$erbD>c7>J|60{}-BLW&bbe?bzyHqW>54c5L-8=+sPI7GZFX-*q>R)J%9b5hDET+yM3GOcQ6T2jI&&kbQUww zp2p@xS)t{MvUL7vf~osamX2}kUh^m`oIi@P!qqlWmi9L$NGJ5PcP*uR`=yh`tKZS0VZ;L|=vItEAFb zA^Iv=D*FY7zDia|uhz%YXA^xk=ogxN*`T-M;cU?RP&hiyCi-lm&nEh8&@WEhWuFcD z=BAy<27L<`3hC8OdittFUlsH%O}?rm`>LRCC26WTRU!MU_Kh{CD(FS4(etZH^i@IM zTJovpR0aLmpC*##R0Vw-SFXywtqUo=?Pse+_w?0>z8dK57^fP^zM7N0(pLk$9ph93 zy&dCJBl>Efw_}`Ypiho*s)62)ajHS~c8pUEnq%p;?eX;0LEp~&&g!6V??P&Gtgcii z`s$$n^uu^;U!7!M9rU)JT^;ltYzV(kAr2DFx!n1s)Ihqm8-Jv=t80FwUzYr zHHf|j(bpi^*C6^DL|+5+dl}8CLG(3^JZHAwc_o_qS5L|>EWYZ84; zqOVExH9>F3I5mmBCehbSrLRf!H9_Cm(AOk-?RjLPE+(xO=)1a*wpQI-DAb%wy09 zi(ki`Yjq%dYccCU_IBp64rE^<`INp6WWQ-E`_bz__NA^|m3^5Dg|$}uou0lf(bt9E zA7*M_UDEryr1y0}Z+DT@CHlIcw|XGKuBl>!vw-&P==*x}l>w$iG@p_uOs|Wi2M%wjI zYX`VcD0}V8d;0oBUmx@*7~c9sUmx_=Gf^M()-zF`=<5@GebApI?^M~>2Yqt4Y<Eac2B05kesu%VoCZ#F^m{e{y=}=FfZkfn21MTg^n;A-8^oH^ zqdwW32B078%2mx7;zA+4j*mQjL!xg;^bLu=A<;J^`i4Z`kmwtNeyE{um`dM}=o>HzxYVMBkX`8xwtFqHj#HZ=6csnCKf5ePfcnj*jJaRwLggpdaZ% zYVWPZY(n%+oaU(Pn}FV0%qF0>_Pz<|t;K8tdTTM8#Po^tshfa)gQ=%YKyNK(6Qb8~ zyr*wU^i3gqOW%~}n-YCfqHjv{O^LoK=noe%wK+{w>6;RLQ_ycTzojYBtH;69HzWFH zpufuGYew|Vh`t%WXjVo6z=Cv-QHm8LN zsc)pxX-;#ZZ%%sOoamdA-Zv+`Z%%sOT6K28hAwJnIg17y6C|I?z7;g*=slkz&1nVA*~^uy znlsUbLd{VhUdGY4hUQrM*3g_K=9{%9*|!G$Qb|+#)}XiNc(o?_*3ca5iEa(enPli& zLvwyP?n3INwT9+QHoUDx_EV$1T_~)z>TUG&ZHT@N(YGP`Hbmcs=-Uu|8=`Lm`YDFK zO)7mGqHja=ZOCG(U)0mLCHl6YuQ0#5E!En#ptt?9wxIVR^<&!Bsx8sCCE2%4rEg30 zZHc}u(W?j7)3+n~c0}Kf=-Ux}JECt#vTsN9?MU|RQt8_feLK)s8X2}Ddi6DX`u0TM z9`tr)VSA!)@90(U+k@V&ENoBo?TNlU$-aFmeS4yBPqJ@M^y(G&^c{%41JQRN`VK_j zf#^FBeFviNK(g}7xQ{pyi@JH6^ZFN?iAp zxE?8SJyYU(rNpTZGx^)pKbeeEzhp8_{gBBx^+qP+@>1gRQ{oCz;tEsZic;c=Q{qZe z;!0EE%2MLWQ{wuk#0^M^8<-L|C?#%iO5Bh{oc426|9tJqq1uy!+GE$NK0{zeXJ zk6o{lgW6-)tK?Aa$)VblgW5Al+HY;Kb5MJdyR~yrdj^{}J_of&CU?+h%W<_w>9wYK z`i?~35%hNMxFgm5j-a=5#~nd$=Z-rPeMh422zonr+!6H2x#NzYw{yoGh2F2r?Ff47 zN7p*-={tdbsYiFFO-`XQJ;6dOJev4Em%;t~2O27+vWM z*>7~Au%E4V($jYV{WK%{E}*wQtu7?{E}*wQtuCOqKCLc9-v#v6Bi9A=)~D44^huvq z7tmXuRu{rq&H9V_*54fOk&C%ZxRr@JS^S%7Y&Io%+8yJNT;$-Wz8Z`TTSgY4~Ep>B|Ua>sBt$o@=M zuGU(+W4Ig1UR%jbG}G{Q2fZC7bO-$k^Oo+U_uYxUJLv5xWZj9rJLv5wp*!ejNqH*! z?x6qUh5cyut2^jtJ0_){<3iymLECdr--GCTfZmSKdXV1t0KFZd^#J{sW`x#*=z9=- z575sw^gTd7rSoUxndkxfd4{(KYVCX%3Tv(QJUo3*qVEa%B}Vo=N%lRR>{YjWg5K7N zo7t!}3`d&oe z3-s0#-3#>A-uD8%^-S~vebO`03-s1A(F?M-o{3(h_u8BD^u0lEW!M|^3(Pm`P4vBq zzBkeLCi>o>U+CVVD@_(jNM+v}^keU0KYDM_FLpUp_DftS)O)pSmC;g@)<@{QRqP}5 zesyIZ()&K3xAwjd=&il)Lz>e^=)J}4BeM6aEBgrjuB$8i2)$oj*+*pWS6B8C*;hJ` zoc542(K18dm-N0bWWSHmxV}W+7xdF5P3?VO(A(2F`VxI#()+&9oVO&O%DyjTpFEwT zFJ%9=D_3Rzjthmd*S`FuXt|-!75Yih3KvqJ)(&|>Yi2HKPOj4&rOySuJxeN=G$&W+ z{rbdQq4#G=y+2DTS7bjaTIra=v!ry?AvM~h^@Hs9cOj+!(fsOuMBk6- z`+>f8lXwoJAJO-N?Crd1Kgizt(fdL6-LB`;R{KHrx=TT&)(^FIm17EJuj3<6pGWk0 z&>TyjNA!6_pGWk0M4w0Wc|@O=N}oscd7xiy=<{H6tS4GWa-Ke)=<|s_pXl?6KA-6G zi9Vm`^NBt`l|G;7^FhDH(B~7qjyXMj0qED7CksITlKFxKpwDq3U7Po^gjDYfK)?B= z9r)G-ptnA)0?^w&W&!A5k$hTf3qZgAoVDanECBtht|YCsuengzTIuN6(-#tbA?RN> z`3i}?5VC(m(v-ds^pEDnnp#Nog+yOS^o6PPg+yNn*<1QTYOQn}FDn|2w2MG*TdN|_ zAL!CTPjnIJ50W&cF9N+BXa(69k>(T$y|+0TS@OrAp3Fhj9SbRXwG;S3iV#SIG(ip{n4&mr9Z}nLfNZl z%+r?>eL2yW6MZ?+mlJ(C>3uoTmlJ(?Dt$T8my701jgB?+BIUo7ub%^3jtWfdfHrJ%IyZb23Ku z14(n#gX`%B5&a<0XUwl2M4B@Q^m|I0%6<^&?OxwOL_dh=2Z4TqJQ(y}izJnP zFzAyf`VR*EH%8inA^V*!6l#uo#XbEHq8|eK6Ab+jlKl|SpD1Z6`yrs8_S)sBAw!6M z20{Tu{JBh`d(ZTL{90K~2T)8UylU>Nt>s--Lp-;|<3`>a{o)R}A zC2nL&+^Cee-BRLqPl+3y5;rC#Zfr`Nw&=;~BDRDDW;`U3#Xqm*{}b>)?EfladTk+oGMFZSHJQ=uUEhFP}|Q#`aICfcQ0)}5A?|^ zFnOTYD=>MWmn@KI=OMkcX|K;q`n;siOZvQ|&rABe6#KlS&rABeL497*=Ouk!(o64? zie9nbOFrmFxRT6qH1_#OpO5tUNS}{lpO5tUNS`mL&qw-vq|Zls=_kEDKk4%$_C4&` zCO_%(L$7zr=Z9YJl+RE4{G`thz1}IGANu5-^7*0HJLU5my}wgFKlFO#QF?T*FF^VN z(C@YS0?_MNuK@Hq)++%0L^GU}+$=zuQ-JgZpx`}_+)zuz5K z#@Pp4NzZw5BsuqZeL>O}H2UmF<`J3y86R&HBz-}n&yHFgxzPU4_zbO}(fj?01)-PG zz32-XeLA}KzGE~yE@<>=Gm6#YO6+A!no-E?SYt0|$t;)mg^WHc8fo*s5Msa1zON8v zP9f;mo7ZH#Q3$cur@I%T*cUQ-zcNt>dWo6n3mLt+Tl>p*=x*&oh`q?fTL_sWXYNcX z9($?vu`i6+tG+Pw58LmoFlA0*7kl}eg`wB1DolA_7@4DU`@+yaVl$^OGADKSS2

|-xDxxvTuJmAdl`9n{mZ0(8G4-^zf7@z8G4-^znqD^ogKeS`j<)nGW0q- zei{1Y?D%Eqb$0wR`W&4dzf7%G#z7FG~8N(ChrN zDD=tsWl`vLepwWGuk*{I)Zfdv)9Z_oz8Lg6zbr=jV$kdSvKaI_zbr=jVx%tyz0NO- zW%7RG`E(aaG3a%ESqyreUlya-%Lv))i<7=M^pW`=(lU#azBt9cIP`kIX>rmQCw+0~ z&0)~z6oCH)ky(e=mmqx!(w8883DTD!eF@T+Abknw z8=IqwzC=)8g7hVjIjS!~nIrQfuP;gZlB6$5`jVtCN&1qcFG>26&^NRCl0kh*(w8KC zNz%(q&g)B&z7+Ir?RlaU=}ST1&b%g>QwsVfB{TccOF^%*lTxHF1$}$-K8bxP=r6mZ zrfIeQ*@2~?@8FIrnbXmg;+Z3JPOmRb`qI!pY2Q~GdOe?(hF(gdFAcr!%Pmd%(xfj9 z{b-x_rJ=ugcxTd=hW=GMUMY>(k8!2AUS`K$p9TGE_J3wUKh~AvqqHp2XFi&2t zO%`QN7W6}G46>ltb(JjW*OcQvCky&?Cjo$BzC~NfbQv9hPWsTmCG0Pf#b~MHOP0^P%`s}Dpy;Wv} z?C(@AYxLRCRCiptel*RMWQ2U5{U&98Y_5gb*UFK;oXH%27fCs4wdD|d-J?_vvDZCH zYB*~lD?eKzub zx&55kq|b(ag>ALj(0_A#W;HaM^x2d-*~pyg=6w?TY-G*{ZErB^iT>#b*~pxg?zoco zt6V9b_p;L9^=Z7;MKW@M43Z$<9{cICS$(#y7eFf52K%X(pRR;sT|Z-CVgdO z&Rm;0l}Rsa&0b%H^i`nOaZVM|S8;k7=Tw1S$2nCf_Ekt8p~yD(S0|zAEXfQsz_*>Z_8zDrHVprxQ&7pdru127)W}vQC zpsseHu1=t?ZlF%)=1HH-(35pC&rjCLnJQT)XQ*VI%$1ULGP6t8$qXr3Co`2~UGqR) zi$Gn=KwYaqUF$$yn?POLKwY~)UHd>?hd^D&KwYOmUFSeumq1(Tpw4!w@`s*}Dt^g7n74!w@`sza~y%j%@B4*l=OB4_OC&`)WyoOat( zhyD-it&V>8PgjcTrA>Q%4bs1$HITN8R+)2d1OnxwA@y*UhGUlaP| znpREdbxo@#^tz^1ll0P0dVMX@*MeT}WT-{@T23#mrxx@&-l#?TTBNT9eIuJWwV+Sl z$xsXW#x_@KLEprc;+Z2oy4Tl+ex5zI*M?qOZEec?+R$sOtqr}l+S;VA4ZZG}s13bd zH?0kQ^15kl==Hj3ZKL;3xvuTbc@i}__jr9B($|50mH8i;{~2GIsN-TUwfe) zq_0EzI?&Izq4*h z-PI+1UDDTuzN^igy3i-@yQ>R*H=8SUq3`ZWqSsa{=X0;GNBVlu&#~{TNBVlCuLr$8 z8KoZS>yf@5^mEPMlpeDl^vNfq)PsJWJFaBTd{>I=W#r-Y^`T#6zoq)n53=v8PkCP- z`oZQk$(;Jo>s=)ENnam&UDK)$z1}rgANu57gY}`;y9Vnc?}s}@TrXoJzbe##^bL&O z-!<64=>5u11EbHBMBl*Z{au3%jNach*ud!hJunT7-rqIY!07*b*I)yq_je68FnWL2 zU<1=?{au4Hn)9)52>oIk`-X_U-Zj{eGN&PBPD8|A?;31Kv2TdjkFv3Ah}i30gAEb; zxoS$_D!JI zYt~Jm*LxnDK%czlu?h5g&tntl^`6HjlsPi%FspS|*cAFtO`T*wQ|MQ_*WzcZrY`oG z{~2FbX$rlr3Nt=|(UbAjSv2RBDX3*<3>t@g=uUR*PUawg?^~0;HT2bN-nWKce=)8#^xEIICVgw@tJ}P94Sn(#<61*s z!yQ*LM}IM{HDZ62eNEOzyuJIkUL;Cc#l=p3+*LK<#dS8lPyK77Ow$Mjb-xm7h zZ%?&_-W=Q>S7M*TmEw9?Z}R$fq;E(1cBF4d`gWvmhuG(|$7@IWcBF3?)VCvjJH&pg z`)hH%tc-bmd+4{>|Jfe;DK_@)N#7p&spd85@7qIPx=JQm?J0BGL$7x-w1?i9iV^1#7FcUpl?!u=d~T6-)>{r0kPlVN^!lcHhO(W(sv|%N78pBeMi!FgkHxv z9ZBDj^c{oxj->Ah{Z6azNPUj1i+X)0(sv?#C(?H!eJ9d)qRi<;`c9%;>bnN@T}j^+u~&UpmpO9%sGHFzuYYt8)b$9|^$gVY3e@!u)b$C}^$pbZ z3)J-w)C~yK4Gh!`3e*h_)C~#L$~q;K~0d zf{WR{CjfdN!Cpa)J;m%NvoCo^R1^FwVrNhJ$Y=a>qf1o z8(L3Z^P2Qr-OzgU3FFm}w(~a7Gw_xk(My;nCwVrNhJ=*rArFeaJ(sw6)chYw! zeRtA#Cw+I)cc-@BJ*e+a`tGFf?%KY@UfOiFTbbxV`W{B_*Asgfy|ykNJ+X(;|93sHhtd1>#2!ZP*Asgfz4_aAmLR>4k9|+*_t;$N ziP-CUVo!>FPuK5C=JZ7Dbv>~sVy~m6o`}7!C-y|_bv>~sVxL@3?1|XxdSXw+Ue^6Z!hTIawXZHsOu`dpwDeTbuZ|3U8NWFx~|fT^u3_hHLYIIpEQ3(&Uw9{ zPd*W-7xbsxk>s4GPXy{kdg;;A(O&EAZS?6#*R*<@*r%g??zQ+CyEnzYx6!Agd%n#) zoufDDdmFvq;n&;f)6stOH$~qYnNzU-2XqHdZ=+8~2i$RGhu=Y0ijOzs+>>(pK9u); zkU6@uwGU-ZAJX?h>~&{rAJX?h>~*}+2eH?kt$h&t^zWM2B=7q|f3dmDCp|%5=yh)2m-Kz1f6u&6V&50~hW4k->2LJD z$Lx>1KVse|vF~s6>FAp^J1Ot`Bkzy8BT3#LbEWvsRv9CuqT}|p0nndtCFyg1w4Zta z<^2H4`vHi(J_&08#eM){ue0L;h`qVk0sR2PKKUf90f_z2?zoaUt(+-7zm(CO*AFE9 zKxB^2?FW*6AoM!79|*n9?FW*6An6A}uXFo>&?o2i1EJTs{Xk@n&g}j#m3 z5cE2?A4K{=(CgfO5cE2?A4Him2zs5{4}xCj_Jg2L&g}<5uXFoB(CgfO5b0%v?Dd05 zKbZ7`Nk5qMgGoOadY#)3CjDU24-V=FlYTJtI=3H8dKt@m{SeX*A^i~24!(hs4` z8AAFYq#qL04!qxWKD zheDs+FEAAPZno79MeNHMr}Xzjq1UsO%#X5MpEJzp%`*~h`yK{;F8jV=M(@X%!;IdK zF^3s_I@+EybA(~gU*+Bxzms7Y^jDkLq{kd)^jXmzT|c9{Wrsn3jeEbu{#sXx_c=0? zGf#oE-r=MlPWs`bA5Qw=q#thd=E;!uc*9NX%SE@?NDeppbab70P4vT!-mH=seLCuJ zlRjHyxY4Jh>)rdMzdz-K@%~=soIZ12LFQ=eUxD77{_&l?g3QV7O7i?V-R1KNGDmm$ zyh54t3NlB>n6DuA8?62nWKME#-Ybax3+_k~`xjj)K2ng`vDc3v{Rrsw`q2o=`w_@{ zy?!(TdcA%$g7hOuKLUEael!C5qn!YuVHg#6!d!iXcYCBvNq!Nqe(v+`giQ79!>hu(7$V5 z6a8rDw=5}$tG=U2KbrKTp?}Z3PxPaqpHr|TT?H5o{rm2?GS2zHmEw6Xt2kc&D(PQ^ zzNL-9tCTsfLa*zeuR`xj@uwraO8Qr!Z)IcuD)c=T$enBc%Hylhw|2)BeH&Mb_n5NY zydF>c#wPQ#>26~;>j)6WouN?!u&TGeH^4{vlQ0BUyT}P^#5Ir8fWx=HENv69KRYh&SZ{Xjgry3kNtS)KeC^5JYuh_ zQRAuAjz{culr|o**VU-;6#Mary{<-$N9=VqYCK|}T#Xu!*z0Q4c;vmVMvbTbUgj66 z=ws`h0R1Pf6rUMRApHc=Pk>%$h7+LIv(*IXb!IpLdL3gr=Mu_+0my~KM|QT-M03Lq@PIoiO8JN=20cmz9&-bCmOxKTXrHcXNLKklJ^sl zITc=-O?S&qMCQzN$Cb>P~~i85yr zWzM8v=1ii@nM9d0$;Do-AH8n$$+iE-JC$(+(6yDK;8U6-GV^f!a&`kK;7a%-I74v(m>s^K;7~{-HJfn%0S(!K;7y< z-I_q%+Cbg9K;8O4oy;PV-|xmmowQTQzwGD>+g@Hr+yBy)L;V^=e9k_WYSM2{bbYj{W)(k=_iwZa!@~+^pj27PehZP(PLQQ_=6Lek%H1-DM{Iq}NX){WR!*xB6+Mp9a0o3#LKu zOYvF4G}2Ea{j{Kd8tJEzej4eeM^8n6SmAW&|8%AJcw;*BDxB{068q`U>v&^2Vz1+k z>Co$VV|qq!T90JTbm)`gjp-S^ZDG@)|I3-;nIq>Oub)Bs8Hl~Eqt77y4ARda{S4C2 zApH!|&j{*gkbVaAEv1UFDCh2FAekSQ>2K6&Z zKNI>E&J>TmoX@>}7U^eE>}QdF7U^e^eirFxk$x8GX9e}MNI#2WKZ{~7Bac+{ul;1R zp^xmU=4{f>CjD&E&nEqB($6OSY|_sT>SvRFHpPB6>1B+RiVO^6(>c)RaHV+W%pv_8 z($69N9MaDr{T$NI3F_yNeh%s9kX}Y}UO$)ga}j&Jb8Rl^=aPOd^m^yoT!0zMtdIgXSz~6_VY+TkM#2>_VXzA z^CL> zVlT4}uU|;|g^2yV_M2EpnX}O8CH4!U*ZZs&LVuro-#O+88vBLN-)~+M{X*z3ySld- zrTJ$`Erk97_kM}}gRT^hz08kN(YZF-i=aQxl_d7x+wW`<=@&u&gLzH#i=eOaa%POV zi1L0B<^3Y)&o@U9{UYd_l+C8K+(pn|;1r_2(3RqPnaO$mV$v^0?Dej}#iUelhe_O7j!o7DIor^)5!{T;fV`z05hiehKN9K(ALGmymu5>6bvS zS00y8-Y30eypBx6!eZxQ4gGcIHPNqz{+;Pp;agfw`qiXg4gK}z zeWG8T$@^Q1)7fe@^f$QUivC7ditA+!&+FHaehu{1%>R(gSws3Y&=)bUiGB_ARld#i zm}^MChV*Mlzb2?(L;5x7b5y^E`g>Vz^!l}=Ukm+B_EWE=ykARszZUv6PhF4Cxt8>6 zNxzo#YlHf=q+d(=wWODIQLkS|`gPFfw)%CXUq||N(0}n@W@q6#(yt@^I_PgUe^WAN z9rPQ{C_$OC4*FZ%aV2wZb)|TpBP+OGzaIMA?EhR3{q3$4-w(W=^y{H-V+IwHW9v!3 z9(uj;Y$6OEn9qzcIztffCdRc4Ec0J|>(r+;Obaa<}-v-M24Mv|G z-ECfzyx(B-*-@V{XG6b%^c#%cUwPbM^x4rp=6w?T4MuOSJl?#Ft{-hM`t0alcU)P8 zz0Z|om(L{I1Iem*+UYlvek1gQ-2aTPfNw8;#!oGVVsB z|L-s3ZZvxT%eWg&-uqw1-DvVYbMKd2KiXvU$#wqCfx0b$x~+k_ZGpNs0(IL1bvpue zI|FsQ0(EA9_@B?QCs6lhpzf_e-QGamzChjnK;3~r-N8WJp+Mc?K;7Gcx+8(Qqk+0( zfx6>?x)XuAlYzQZfx6Ryx_1I~?=E*_BXlKBYJ5mUcZ_2o2lp8O#02#b8V)cYcuILlYTSw57?e- zGxQtII86H!H$(rR^=^jVm$dDRUfQ(pcejv!i_!ZXA6tyx@A%ka^nS<37U+MtC3Du; zV)Xv%*A~)mLBCtcuB&Xx^t;vnBK;QhyOr&_$`+&dJ3h9U*!$-hN$=y&d0U}>$bRar zMxTmw$H!L0URQp$B6Fl9XN|4M9NqD;mHOSSMxTmw$H!KqPer=pW2@1pqU4T`twwL2 z$6@>Xtw!&kXS9{Z8`4jvqKB<_8}vHP-UfXM`&YJ6=4^w$q}6YOzRe?<*l(lE*#^Ci zv$sKC+PqKBdE1~r{|SD&`!?va+;K%;)|KKTRq4@F(IZy>2K0}*lEl7(`5%&FZ&2*t zpxD0w{pjj%=gj<1Sx?k8tv8_8>ql=uU(x(c(Z2!x?ixMJc*C!0y#akCcU;j|cBS}u zL(V35QTC+T;RekbX7l744UzmxPkq1S77J4r7i z53k=v`d!fLirg;J?;`y!=ygSI7iG>a=ygSI7wLCp^pA|8HLYFHceCI5F6ebdZWr{r zDkNj1bo7MH^xa0Ej-GU-_+E|O(C4;)bGOm^y&AiXK0DIA8oQ0&_xHPv-mgsTHhRBT zW4F=&cdy27qxX9?b{oCl?XcVE&EK{P8O^1feh*@=`aOvKQ}(m$q1f+1?4LHTNvqw1 z*gs%4k4dZDL$Tk3*lUluClh;nw%UW(x2gXRJ&kD(V*iXguJk$2x>CH)k#VQjze)Nx zq1USbZ<78^%A7Yd`oiZx|0eX>W4=lHH=)<70B=H{ybACp^m-NGO=ON<1$dM4UPj2~ zjs*M3-h%#lSCSr6cNM=yne!I(x~upt=yg}|TNL}ZNdFe}FPI}pfBzQrdple}^UJrO zf6*x<_Aj|oyvLNWyw~p~{a(aAkA2@>iv3=S{a)xN?mzQv$(+5U-%I+vq~9CV?i3a;AL;jz zUgk$$zn}E`q0evi`$@ka`T|zJANsK?GFKk=lYT$x_mh5qP`{t_`$@l_^fHt4`U9jt z0DVELKS25e&=<1$1JJivmeC&|{Q=S+ApL=${s8F@kp2MaWzLx$6}G~IMxPzM>`KyV zX<)G1L zM@5}N`uk$86kk`7*>TG04;^0v{N-wbl4_(5n3FRDYE8M@fGanWI^Cl=MeQe-!$^to~?Fe-!#sHik!$ zIjTQOnIr2>=KdJ_KaWA5isG{ycH^w+uLO6;$9rT8dKR>r*kIO&fg_BzfvPWt1}>p15)^g7NtPWt1dKMuX# zJ#`%V35_-+; zlhFH8yw#p0{YlcFgua#S?@vOXyzlNL^sU`-MX&eWokZ+)ZYArY*-=@mKV|gUQ8`zV z9#ijuIYs(YPA{=PWn!Nl={+!~NPo)c{kis((Pu|y8iUxMGWzT&c@NAfqtA}?9+*=m zbNoFpr_f{SH4It7O-0$(dm6D%yOOk8UC%j9`qQL8jm**YoYT_;H{XR`$2spp zuj8C|N&hb8{kzcXIOkpHljEFsq1SQFyGHNFIqy2XTt9lx=#$rv-VfA$5UBewQ1?-w z?&Cn+CxN<819hJT>OK$DeG#bpGEnzbpziBH-8X@{Zv%DT1?s*J)cp{s`!P`WQ=snW zK;18aIvH0aze^bnCF^9QldO}GO|ni#2+2AbXC&+7tdy*ivr)3{-$b39$t3@L>v@k_ z&wFS+H=6&E`JeGC-|wOI++<#pe)m1Jo=2X`T(^G@tw--(Z`f8>p5dHhm>u#I(N&i0S z--o`sd7tRthd#O6=6&dE*k0y+^jtMvDSpP5Hl6Lx8Xp+FIS1LE>jR@V*N!062#!{%>_{sW`Wj&7W|oUYq{VD#pWVRu}aB~)=G znP2L9qVzsK_8%hlRqg-$5V6vtt;(ocH*N2LD}j`YH5!$L6O-|KGX&r_k#i zo1a3j_dI@T^nPwH=X3MRyf)gOA#*hLpCRvchV~ihKSS(whV~gUM`viCQS3jX%=rwN z^Sp_HWX@;EoLrN0(@OMb$Q(0SMdo~l%&Fo^@g7q~9$x=B=|6|Qp?%-ylsTWf%#qyu z9D40BKPUa?r2icHMppkh^vPc>`yBel?zl3?Y2r%pyq7VO*MC9!FQC_zi7zPjUqG+x zDqoQP3(|i<`Y)i@b(JrmPp+$c0lltFe1X{O%ETAcW6EgG>%S!Zm!$ua^k0(xOVWQy z`Y%cUCG@(k@?}u}CG@%~^d;%PB)yC~Q&BCO_g_J;GqkUuUuFJ>WXD&OIbXTVk+aoT z(Ce<^uSowD^g74+3VQv`wXdL0{^r_O&@Zt4{a4U0bftLS%Lv))zb5_HM(>}G{x#{p zCjHk&@1KwUHR-=LdjEX%uc3d&993HF*GB)}=c9jZ^#1wiUqk<#jp5hmG4*UEWBIg; z{WnIRj&z3hjnSv0+V*?-hVb^1hbX3RuP0@b? z{lsHOXrIhC(ARaxmHxh-E5-YJnRWQse~Z|w{##^@?lk$9^8Q=sb*IU<$Q<2i@-6AV zrM&+ZvEOL>oNtjiL-sT`BV_-3>fa)BHrdbnEn>gfmExHr^CPeSj`ZI_|EzuAcclLg z`sd7RlK0<1ug_5Xjxy&v(tij226I%2{ddqOpP}|0^e?#M%J}|8SBm$TGL!TA?@9kX z^!4p`_C00J_mnx`LqFyEO#A+xV*fqqzlXko&7AL{?^Ed!I$M1YeM5I#(Km9XxL)R* zUjGB>e}G=+RzHyb2k3Qf^#k-exB7wfKalwhHu zkEH*R^gojRN7DaD`X5REBlL}J?0*dEe3<^qPo)1TsQ-!dKau_?(#wj2*Z)lVpP_GN^*@vTXXu+-{m;;U z@mNOxGwFXO{m+y+KL_-^ zE9rkFy^IpQ{x{P9M*81K{~PIlBmHlr|Bdv&QS5&U>VG5sZ>0Z?^fFfU`rk?aJM=AW z?0=`s`5pRJHt&Cj{vUHnk@4K`r2n1tzf{qLmzo%Ave_4+?Z{|D*+ApIYt z|AX{@kp2(S|3R_;BdGs_^nZ~457Nu1-|PP*{h!dcwz2<{^nXI%#>W0n=>K>r6Z=0& z|0n7Hq}cx%)c;BPKS}>5>1Cea^?#B6FVg=-`oBp37wP{Z{a>X2i(>y*Q2!U{|04Zg zq?Z+3um79$e?#Ba#{O^Ub?*8%^xEhA4gDQv$y4(FZ_@uw`oAgme+Tt{lm2hg|4n*X zYxeqoNdFJ%{~`T9r2mKX|B(J4(*HxT|0k&bhxGrD{vXoIs<_wx3%#zw{tNwbJ2w57 zGUs3DSJ?jkU+DFh690w%arZvi2e0>j{R@3N^L@$)`CsVosan{K@2lLT&q)3k`u6ra z|JUfvo@!UpF{WHUlHbisuJar8f9mAd@{<2ge$g&jcV?jOEK_$$^sI?fWPYipQY6Pc zJ5VRTe31Nq@{0$_y7K~c=LhO82-IB|sJqD2B|pc-fx1fqb(aR}{uijbEKqlOpzex5 z-Iam5T!Ff)0(G+6Bl+26mq)Trc5o!?WXDFbPWEji>uw0t-5995DN!fAjO1S`>S%K_ z$|28C(G`in`j@&VXL~)-#}QYyO9P&NE1V2K4RB zYcke51NvWX&ioF{8KghM=>1ym8PK;k?~}HF2J}tdd&lS-xVC==^c~!BMc>T{<9cb+ zsi?bsEeG^HTqz#=9Hh@dvCl!V&jG#OIhliEp96Z`ZIc7~Vu0`=p|t)|(UhUal0^=Olej(&r?7PSWQjeNNKn4C-@|J}2pOl3x1B?5MZ(o@w;v z-dR@?z3vS?lk{gouX{t!gkJZCo@w;{D!`ePIcFNZ-y3?S(f@aE=$S_E_lBNn^nP#X znMUvLxs@J074@~=vk?1!t|a>Yt`xuWcoy_J-Z%^TE%nbt3ptDO{w#|9S%|$p`S2{n z{+6Gb(k`>J5c>h{xRN;oT}d-XTGv@QE;jq+rB%vVC>0H||Lbggj=`=ZpQDG(#IxyJ zI2)g%r+H1<@7eeqOR_R^wX-RQ&c^4^Ro%1kIeMA*N&7t;pJVsnx2XM|jnC2B9alcb z09TUFAuBBMInK_ZpF_@^{&So|pW__#L;dYvI0v6Y`>1p1`#1-mWAs^>71DF)bDTq; z;~adBzUFVr=Qt<$InJTaaSqyoevWg{7W8wR<35L+?X%tYaV}cL5c_?cYd(j+qJ1uX zj&t4TkZ<)|d=CAL=bF#qTgAENbNDOT=b}~U7437;Dw0>U&qb@yE86FxRp=G%b6u;D z@8eweIb?+5zmN0qeGIjq<2-yHdTskW`W)xE&mnnr9zKU&+dhxJkMr<-=(X+h@O|jD z?ep+`B(H6shwnqLZJ&qlL$7V0N8iVJ?sLef%72dY@i~Us&v8CJ$HO+S&Zp0DzWW^V zeVk9<$NBU*&d2A_dw$Nx=P@M;RB;=ePi$W25;i z(mpQ0=SZ%>Ux3fC$sI{P$7WZG_g5FV&mp5%|2ZzC&v79>$8h`YTu9%?h3@;1yt)vd zBX7G*e{~^!9~aW+xDcP?74tXcb6kkeG5Xy8roXD=#v2#nbBu7ul@;NUt`z?q7rM_O zBX0jWE~3wI5kAK;8;OhP`?v_7%8vUVky^FNVH|)n82C!o|?*FSA?>{Vf+{^cT~& za53pGhQ65joANDOoM{ys&!?*j7elYV%yKbWcgiW^dYQ#|{UxNogxbO-6#Gl4EnGrv z;S%Ue+2dV8`b(hKJD)FsK6&T!CD3QN_e)zS<4T%C5__3%dHtoNzm)WslKxWCUrPE* zDRV9*{iUS8G^oFn^p_&`Wv%{F*CUBuW`KhpmX`i5qfocW*e+0Or+XrmNq;%?x_jbs=yhyyIq5H_*k2C4?w+_D`sD73 z%c0lZ6PH7;yC*KE%#n2gufKxySCIY+(qBRPD@cC@>8~LD6{No+sK0{rSCIY+ioL90 zq@uAlSFVI!$JtjxuRFxAgkIx&CG=8~%()VJ-64J@>92%d$Jtjx|C7y}E1^&B5Wf=o zZZ=o0gkE=uUrDi-wHB|>MfzN%&qexNq|ZhAT%^xM`drX=wfbB^eJ;}Hg1)=`EV(H5 zvMQ8zvA@db)6qElO1ez;g0$MJj6NMr z>HjV5p18{B)6oQ{keTL0SCW~gUPYGmDU`fH%CW?qxL zzXp2UUwjSpI_|uN^w&UN-Mmj?e+~4>{l(WnU&9?&`um!$6hGI>nxNNTOZsb}*BZR9TNBZlamz8@t zGh9b`f1S(w%xm%cnXZFgR-Q7i#a9-ugI?A%CHB`rzhqc5TBEoQdRaBhykBB3D?yo3 zJod8Anu;dbHgP@auZLcDDqc_e>q&n-#r}GV{q+?4>!H`3iq}J*+^Kjy^tw~=dc?ko z&7A8g?`1_e6}@itH$Xqxm1Lywy?x&eq`v|BAIxi#_cuVVPc6QI^8N_Obyes_#9miZZlt`IRd%nxiS#!?uWLa!QS5JWnIo~k33^=% zx{35Rk^Uy=buH+op#CP(-$eSGoL;UA}{^@W=Qb+-iSZVlAk7O1;DPh2BH-5034KT!8Tpzgsy-9v%8hXZww1nM3Q)IAocdpuD0M4;};K;2V; zx~Btm&jjk84b(jssCzz8_d=lV#YCO-!jgZ!_2j13lN+sPn(Z@kQ`^st)-&C_Caoto zT2GVvGd+85>bY`L>&cDQGsC=3dam4PJ=?F}M=Qd)(RyaO<4Vsp%a!6YG-)Z>uHU`c z=(D5Q_J7`N^!_f`o2l*JOl|*WqxW~g-b`)(W~2Alqi!~Oe;4e{M*rWtU~e{he;4e{ zrtSN?U~e{U-#<}K+H~6KZz26HMxT!6*w1nc#r_tfPe*gjYZCigj6NNeo}G#PEfo7( zjNaeZaf{KXqj~0i68l?>J{^rNe~3n^w-|jon(vM)Bh>}26yN77y^q)5O8Q%oIak>C z-Ab{)m12J@GDn}9eJjQOR-^ah>|3E?O`?5Dn+^tY4#cGBMtz3#!do%FXuztqP5cIbaN>oL=6{T__l zpFXI17YH+N9p-$D92 zpf~>!d4C7=k6hQ<==~1yJD^|fjw|{#t`yhHS<>t8B>kPxzhpD#PSW2AeI7enx)b^} z=2Rfx=be-}car{2=<}NQNvpjR`h)2Ov?hHg^!eOzMW5f5;ytFE&%ORG(%%LBNIOfo zi!$df%AC6>bM7MjU8KJY`cdX@ivBL>$L9Rk=>4w^-v#|>cU;lG>Pm6Fj6A&lZqnZk zeaid~iRj%F`@5kpVP2EWxf}W~-pX7LxSKNPZqnZk{aTwjcSAp;{w1^$eK+*$Y_8mm zR=eJn;(8e)dHp@4zXy7~DsvC%?}1*g%G?9JUX{6r^!Jed9_V!?`X1<$E7A8ruPf2_ zK(A}L_fVfBqdBj?m-P2SAKCBhUdo(%UFJya?}c8UFmx|v&b_3+7kab344HE;^bNZ3 z6GZQY-cazJ-wSX-{W{(jQmPx|{we?Mi;{iMI2^!Eq#_mlp9 z6Z`Vf2AlWyQ|8E6-s>MA{R7bJs?Ypm^be8#A<{oY`iDsW5a}Nx{X@_ljPy9g{&DDapXKAw>psiJN&h(M zABX-etA8B&E(a@;{&DE{TJPhC{XSQU>t$`k>z^R~6VSJ`J?#?|`zN5++0+xz`;zQ& zz0AEYz7qWe^sUTm68k5hPd-`e3Fu$5V}mE4Z{z-2TraCQUjHQNpM*YT|H_jT`zN6< zVP2EWc@p{?Z_j*7Pa^iJf0APVB=jY1kNG6@$)}n<34JMdT*;i$t`u*zvfkwNPm%s9 z=;huC$(*N1{}l9cXM*UTf?l7=_7v%#BK=dOe=4Ydiu6w*_Nsr1`g>U!^ZKVr|1|V> zTm93de;WFGto~`}i1)rFiDZ z8lKlbL;7c+zt_I+8Or--T;5CUpMhRS$j?B3pL<_C@1KGGe)F2>pMgI449;huf55$8 z^bfjHTraDQUjHoVpM_rUzI~ST&qA+v-#!by-hKNl#r|1}{j<>PYSgpPe{t79iv6?D z@3+0ov&ftSt`yhHx~SJb2mL|&Kc9nsxoz#wQRX}cz224b9Q1lu%5%``ipX=&>s=|& zL9chEJO_R9u9WAX*Sk`lgI@1Sd5+FjvV!aN&y)Un=w${Vt@e4+KM%c(uO)MyhyIJU znSJ%oL$7_#^Q3WqN7kCX{srg{+1S4T z{YV@87btUHpuB$pdfol`0_k6Xew6zw@n6Px0s7?b&ljNA-JdTY_PYD?1&Y0_ihKQw zq<<0mCH7OlNctB^|04AIWTO{J|03yMMC_NEzbUbQ5&Gnljb4O)nLDn;ez_}Y-plo) zmrQN)`ca-hUEV-lzCd06KwW`AUBN(Ip+H^XK;6rMx*~zPqJg?%fx6;>I#~xw#zoeD zl655mb)^Dzr2}y3d~EU_4q3=FPXNV9lh;@@hdRWQc_Nz2W?-k0^~v4*IfsBNT0{)B?fuW_I0G1 zhuVG~wEfF%&y@#lUw0kkLEBI6I>>{zue%QNpy$$E2YIOHk~W==j@VC@*XaFkCgnx! zzcT+rgn6OQZ54Tq-aj=vFJiC1uaVd2{oMn3jox4V%4_ugso8mr{=ZMw%4_ugso8mr z-aj=vuhE;oZ57h{q@tr%pAWG==1Q_>;z##CO^1cA{Cro@K_64Ay(WnsV3qXI; z#;^eNr(7wnmvfJ~OU}Ml5PIEhQxN(oR$q|x1)-m6^#!3XZ8ow=L<*9=AZ1QL=%<jc%y6anXi3hJUSEjxg`n5Hp@m3ai1NM=^tv~+5cE3MD+Imn zwkbq;UnrCJiQn`o1bsJ~D}@ky-5Xkn`W!i*dwpTj7lwY0{VRn@UzqfTq1Rt}E=>Bu zq%REpT=O?2_JuQ<^TCH^r0VYgEe!oUcU)PCp6^QW*vrVn>tBXmX9+JuKi2#Y$%mIo z|1#-chJM4<{m;n!&-lv3%g}49eHr>8=5LDrW$4$G<7*f%LqE(Pu{= zxRUJE_|TQ&cQO=%{zvm}=`o8zpQ~u*%40E#eKDi=do_v~eLDKc{7uQ6Vn%PywO1dY z-44Z!J{^7Rjw|QdPh2U!+d)RiDW@-v*sH!cGUrqKzTy=7;x6`*>BXVf^F(oqeR0HI z$2r9j`_HVtIAZ@!nSbfNw&IBW=kB26(0^h+i|9*2uTP6FN&1qcFA2RqExsi5$*0AagkGN(U()FP)8b3g zC{1Q^USEpzrJ&cR`IRDlDd?ZG`clyA)BH-2z7*+8LBGMqz7+Jyr}>qF{ssFjmxBI9 zSBhtj%sIWjH0eu2uX{C0Q{I<$c`vzA8hUNDrAc3!^rfNKy&9!6d7s#;Q5t&Pt5F)6 zqkA<&uY74D`BJqYPzE8R&JdMj7aJuSOZ@bzWPB^ktwgZS`fK zPwv$y1AUhDmVv&kE5%!_tT=dmS<;tu!f^%A9QItC{#nkC_dC@2bZih7K)6nZ~hcxuM+aXPvlO}x{dfn}ihCaF5Aq~Cmc1T07yB*Th z=g7*K*Ow=KdFb^XnDUf4sg-CjMUzzlkNne@t zl}TS2dOcfJCVgenR}ShclfE+avS(cMl_~bJ)@<&OveB*r{SU5$l|WaD&#kIJ|C4!5 z^1cf68y>j`N2o&jDwH`@p#RytPhwvM`n)&ZV%Br~p42MP|Kg4-{r#`56mPY%DxQvh zv#(V(`gHWWD~bLOSBkG=R)zjg^P1?ZLVvb>rcPDLoT^6eXNFacJ{|pK-Y5F1MxTzh zynd8shEFl1()&&2`cXBbPhJzL9;mAksH+*Ms}-oL9jL1lsH+>Os~4!N zAE;{(sB0LgYZRz!9H?s&sB0RiYZj<$9;j;(sFRiDWb9i7>RJct+63y_2I^!lQ1Te< z19cq&bsYnBodR{819e>jbzKv6(i2Gj`PNg7T2D3fT-ti7QO{M4T2D1K+XVuYj{p(87_VsS<>U7Sl4!z#3T|Lw9 zK9=blt5e&rPCZw3^js(HSg$&IuH+Nts-x#RWk+|_(eIvirFhRJZQ9I!&deOQ2K443 zo#;PnAof%2nm`STeGTY!9lZwhx{h9hVqXJ#y#iAMdR<4a0ex~Ey$1BUj$Q+LT}Q7$ z;|=M3yuK#sYeKK<=ru`S6MC5sOTSwadR<4aNwKd9y{@Czg#ITR`1&a`7U^q|z82|gk-ir6U9G-WP+yDmwV>~AKT9o&z4Yi_ zUz_x`q1USbwMk!_^tGYas{pl0Uz_x`q1USbwV|JpxC&4kdc6uz+vxpOfZC*&bC1{8 zA$=XA_rDHOhxBzwU&rYEuY=SfeI29szYbCddi`~fI!6EBUk9mU^#0dD>LB*d+16Lb z=>6|0$yw6t>q7s5?Q`lP_C3x2kiNAp^ttUfSQq+U<~7Otx`=(9YMIs0x}>j**y~zu zUFdt8_sMvpZYFb{olWbBbrJhM?zj^BzOEGSbL4!Ul82c>SPyz#o2m!>6#J>`QS9qM zuYFEE=(W$O2fdC|>p`!5PCe+gD}vd^gpz4kfv5PR)&>QUy%$Rj(-Y4!DuK07+o zm88Gdr&!jf*w=?%pJG`bdVPvzeWUkR-0K^?zv5os=>1bH>l^)lpJG|x=>1bH>l?j) zie-Id&Lo=wGDgad&a&PH(4Xx}@x2-iDE1AY*B-M0@?L*4wgF{M1JXBueug=^WKIL< zlfN0;0Q#9u7{6P#fzkWBWo0y%a{7kI9Mv~O=IFV$A;rES^m?vsh}i3sQ5urIA?1BT zWX|(e-w>ITEAdNQ4UsvOt-c{Lr;01Z^IpcCUf+oHji8qileF4Kq;CYhjN+u#HiBMv zbT^{BZ$$b=(Cd!wM$jjBbT@)tcXT&`UUzgiqP&+8ve!2zePif#XKQ21oW_(njiJ|_ zt&O4Aovn>Y-xzw`+1eQTG^YL?0S@|hOWjPkx2^g2pw27Nhm4v{{m z8T37}_<7gOpwG7FnPx^`K1#civ|7D;N@j9i-yHf2tiCy7uh&hRQ{Fdsc`q%xImNy? z#lAVkzB%-I-LyIM$?K-gq1WrC%@KROZrYq;FLO?>Zvp*eG7_x3yOUU z(zk$qi0$!OQ0!X-W8Z>e--2S_0(y&&nfGDl~IttfM3#UT~_ z&w5)^-nT~P=vCj=q;CzqUiEDayD!RL4fJ~5v`r@ViR-3qpx5iBZ4i6C zZrXP z?MdIB^sqYeMi!Fguap0cZ5E< z7rP_$x)-}6^1g{v#PeR(MYE#oY_vNWeO7e6D@p8E*%3x3(sy!tIa_stUVksO6X`n{ zy`LF&GWx7&wH@blGWx9Oi68f$l@)ckNq-fmlhJ2IYus@!G^J~7>+57PC(Hdtv#j8z zq8qHYGh%)EO^Vy|bb&Xo5u zb4o=wS#KBUbGwr0yVw|XA$=F<^*Oy=px5X0b|HNi=ygq@3-n*v%;^Gs@;SX-p#R$D zN*CzAaiw_X$f~&4cO`vSmR5a5U3j% zs2dch8yu*UJ-SW(^^7G1` z=474hY);lq2-Hms)J;m%$rwoT&$pg#)Oxz1^?YwzT{mhy-Oze|Ft17L>4w&$Pu}cC zt*0Bco^I57x&>QLH)=iIsP%Mntw;3IQoO!9>AOSU+3LHKzB}}~BG(;yy@t`9^xdJ? z*>QL1^%_QZ=#$qlxbJ)qa8G4+66N2)!H-p|l_7`-W(Bgja#hta2_XV&ub>v|Y{I=a;_eAVf-xIOd9ezDY-xGS>;nx#--Qm}h^gR)KT}SVU*y|3zo``*NhhI;` zUU&HQMCRxYzn+vi(ocGQFVgpdUZ2L)i!!GdWlk^Xbw#chWlk^B_kv!Z#?%Y?VAr(zkiHM} zx~|d(`l051lJ|X}zqsyiG|uh={V;c2S<@QsO7U^FoF%=!FX{V2FMYZ6PJJnJ`cmff z&FJktFnvkim-Kz1m-C_M`$C_*2c|Fda=yqMH+~OHUy8k)&%M4M^mo|U_k&*d$n_(A zKhpPuUiZlLBYi*Ub&p&>=yi`=Kj@Qt{Q&57emMYoonH>1*bgB60O)moIRN_P{Bi*FI=>uX^yMR+Uk-p?&sH*; z^ZJ3L9|-++s~<@Efza{UGS|Tsw&LgP_;`eh~D@{(cbjhJsc*2$^%Y6UOH_ zGD1#8_t@74Lw~O;$qY?nKbT@am|{PeVn3K-KbZ7`DfWYdu^&vaA55_yOtF`~%j<`b zehB6L5Yi8!ydOe&KZNu{NIwMn=S{{*k2wVTA4>Y6 z(CfO&P|BR4E_0;M84A7jIYUW5l=MTP*L9Vl&?nbbhC;9FDnp^yb(Nu{m-&&`4uGgI<5dW*GFzt6#&Q*Q;N{px3Kk!$>bPxm0wY&Gg~W z-|tG2_bu%=IGkcXoMJzm^utL%ob0crJD?$A$(6_eUS4jT~#a?E|S6cBP9<=_>olWFDW29fT8)fw6B3+RiWm>J@ zVKs_kKZ;^M%IN(Lt5K9Wqm16~uo{KfKVxG*%IN>Q!)lb#`yE!JOy-n}bcfX_lR5s{ zove+doPIQ7uQS8Z=yMj@Z)r5eel+xp%xjW4qY?XO%uq`D&(YB9C~Y*wel%jg*t}0- zKN_*W<9fbZb~IwY#2r^g$V*)*-fCqP$Ln7u{j1QgweNeCV*jd(y?9@RUis7e+~NT=6#YmuR))@_v}$GGJoYm0^ZK#S>%4X>^oQ*G z#*%(4^oPxB68o{x4>+_6c|Vq7KNfnO*N%n$ZSy|SkA=R=IC(C+|FzAr&>wNf75!0H zis!w|9=(1X>Bo_N9O=iAejMq?QS8T&ejMq?1@+@dKMrRr)sLghk#$k8A5Z%6&>yp( zdOYdJLx0@7Cb1t6z5YVzc#8da(vK(o_@I6~>Bp0PJn3Zx*Xt*cegf$ykbVN`Cy;&u z#eM?mCy;(ZP(Ok66G%US^s?5Rik`A(tBKHSe?Jj=T?w2>`iao%O5jB3btP~j=_f*e zx%~zwLch_JB=09epZvAliO_Fy?~uIT>`L*xmsN4EpG5je&})x5iS(18*B)~c^x9)i zqRg2@`bp4hk2wkYWRE!sdhIbMnb`XtbCQd_Tt9l<=#$q2CI{-K1nQ;+>ZS$irU&X~ z1nOo6>ShJ%W(Vr#1nTAn>gEON<_GE)1nL$B>J|m+76XrrSmIvxq1nO1> z>Q)8nRtM_V1nSlX>edD7)}yY78U2}mXIx@_m;BObL*V~yOw`FZNAfQfJ#E|m>u5dC zxRQ*s&oTca^FQPF9=?v&bFO(!`rX&jdh|J7uT$H9oqDd<(R$u9P-*+GqxB@8>8WR5Fs{}S`*GNpLimzLu7lc9gs>L;V^>uTs^w0#}VO@>}dqMr=Cu7*ygwm%vA zQPwgUdR+~j41IDnbTah18af&MuC9hoM%&jpjba&suWMRUpii!8O@ZD}5bY_@>otriq?g_&J9^%Fr<%89M=!Wid^i16(oZG* zRHOG#KAcMWsYdVTms5@2KlyN~(f{|!hf|H-KlyN~(fi+?nrifZH@)_Fl^M{#}OEyXHe{CQ0!-reg?&UMlkj>DE2cb_A^K?XGyQ0N&1V~DQtW3!zoPS*XlFA?Ka=z`q0ejnru3LIq3=`a5n7p;34KGmw`nF~pU)}c za~wIJd;KiZ&w{?1ZTqt*_OqaubBy$uv!Ji?ZRU3YW|4jt>1UCCR!~2S^s`7mi()S$ z53iq1`q|Lux1V}8>1RV4)nUNG6#BHSD6F7uB*%;{T%3ZU1bjR$#s=E(CfO&9O!jjWe)Uu z{YXZ0W=FWy&oz4gwAHyrpN{mZ?_AQ)g_@3dLPC-#6Ec+#yrGc@57j9^!`4Kd6YRaLiYOkq@Rz> zQT=?<&nNwS($A;7pHKSvq@N$u&nNwS($6QojOD$40qGY&ue*E}K(C{;1<>m#Z2|PU z%Vz<_egWwhK>w5ZCM0tfWb!`o#LorLceCHt0_45!@>xK7nRR&mLeeiZdcT&tkn{^l zztHIYTJA#9FEo0;mb(yoUCUjFyubFoW0dy`k@wHqOkW7SuH`N?dcT${^P?=6_lt}^ zE7Cq^5n`|Vau<<)5$P8p_PQ^35oOLIqxYk&5UfaYHiv1GO zFM(d~WLN@y@=k^&(CeKHOOQEwC&Lob%j`H66|vvTQs|4ilJuC`YL}9JsnbjBmqM?t zb}7YvDfHT7E`?rO?NaEId-Ik;udQ||^xA5dl3wQVSx&zUd0))xmr>p?BmFYcFQdF) zMzLQ;dB2SEepxW@mr>p?L*5s6rg+}Vii3~+a>QQs%b|bL_FT(Jznt{Tq1PvVE+_qR z%ADnheacv*$6SusFX;9xjWL%a_9d)$IbvVZmEvPeSsO`3rR-}fpfBx8k~tNveg*Wo zT}ggVy^<+O=B$8TuidSn%vnMD70{nF?-TtB=##tYS3rNt9ZA*{PP{(yv79Rlkz-D@nhS^eds)T|O(JPww(r3BB&}S!rVLcloSD-s>n$ z)|VHGk*cRQ>i zy{wFR{c6&$hF*6&tfttnhF*6&tS0?x(yu1{YUp*h!)oZ0yB$_TU&_v{Rzt759afWG z*6_?;VVgN?pfBr6lJ|RU#;u{)uW_-Lyk7(TM6-!YzKJ!^>(#F{&})ym2Ks$A@7F+| ztA9?@YW@93YoOonjw_jSz?I^8FRP7Szn1iCP3-+RXD#X1l76kx`*F@%(yujoKh9YT zy^eF%8vTE-S+6yEf6aO=Vz1+zwI=p{oFnU^SuXbLj6N$WXJfw(nUl+omev`)pSi3v z`bk^UawI_R%*?~9Lf)DQBfJ?YmQy?JViJ>Gf~d;cpU>y17gU1#;{5qr_6V|P!jN9?b6 z@0Yn%wvFg|ioL8g`^?#Z%+c6yfWC;$xDAv!8<06g&1(|-4aoajF39Bl2E<-xh8w8W zZb0mdnfFQTHz4nmPrBWJ*cW%lmHs~EO7Ymss<_v0B>hI{^@*Pwq0epq%0}q*iJu#x z*C&2%B>hIxZ-icUh=_h8^vNfFZiHT+__+~z-_(8+8(p6x>-?L{-$`CS+8n6c5~$l6 zsM{8(dm~V{Jy5qJP`5Ksw<}P$J5aYLQ1@n_?yW%G-ay^HK;8a8-GM;e!9d-iK;7X$ z-P?h>BZ0c3fx2UXy5oVm6M?#ufx1(Hy3>KWcLH_qChFw;B>CrC&n9X;o2d0{qSmvC zTF)kGJ)5ZYY@*h)39Uz;m%Az0dNxt(*+i{plWRSqmzLu7n@PVJ`m4?V$o$Xv)vwLa zUt?aAo@+Dob1LiqjQ<|SX3}ql{#x@sY5SX@FY;4qbH;Ar?poap{dMlR(sNz!O7Wgc z+O*eifj(_}=q=EXweQ+2 z3cZe&wwlcGqou9L9KCiY{iN4#gTA8GZ$s>R+E2ZW@_rliz07NpIoqJur;u%<*l(lE z*#^DbHzcv&2K^n0r;u%fUhdA3jNJx(UssA}j`ZkW{|4#bfL_noZ&2*tfL_noZ$N*G zJ!8K?`Zq}b2K0KyegpdC8T$?B^^E-nTCJY3-=J12=N_-$PWtW8>)lh^DfZi;*Sn{- zL$7yFZ72P9(r<@e@1EKYee&+9?a=GpQ`@1}yQj93Ue1zUzk~EUpx0}6J1F)$DDQVb zuUCC{K(E*Cc94Dt^m^@X2lUBncRQfhYj-=K*K2n>DDUNb?)5vNuVnLnC-iz1U?;_X zC-iz1U?=o?6<{aDekb(W=j?=js2Ouf-tUAydGFUw=!e;H*-qsBa94`wy^K7(ei!L? zL9adLE{gpwiv6yP-roDQi}brlzYBWpF?T_q>@jyiuRZ22#9n*MT@-s6BW1fDb2sUC z8+~?E(autLlYY0;OTVxidY#+vHhTXYuiZxPufXg!`s}EZ`I{2^-A11s-8gZ%nI*Jw zXRF;tpB+_p$CX(^6<3lO+9dl;$Y{>Teh>7OZRYGj>~*ik9@6h|dg(FuK(Bi>_E7Bi zAojXfV-I4ldo}hT_Q|~(dk}lwtFZ^M*S#8hsMX52GZj^_-Z!Dw7`_R8Rrgx_Dc5h3 z{!QrbsFC^oqc@>nV8``uLSN1O75R-$<-p`g*1$`nRCJc;x}3 z_bU@`L0{j!Lq-Y>Tq&-XvAoysCH-E+UiEt^bM}&cFX{J^elPS5?a}ulb5y@KsNYNa zy~vzK?){?Ik%G)RQc+|3+CJ!;xRS(PpP{yo^!r@qNUPlky=L4#((i*_uVL(iUZ0`1 z5BlUY)b>HI&rsV3y*@*2AN4shKl1whq~DL&>uTtJ=yTiFz8`vB4c!mDuI28BUPo#B zNxvWZPPWh44}GqV{QSE8(08`I%zo&*xKcd!GL!TA1EfCyeN+2Q93cGx==F;G0qFIL z`vHpm0n#6UzNlSSIRJg~x2Fz3U(B}p1JDyJR+%(l}b(CaAe2zn#BGX^fRU$%bEF~@!$15 zX7qlHdCchjE}vsY|KD9c$Bf?Z@;PQ=pN?8v{V@}J|7>ts88caBUpr2Df1L9EIK}?B zi@kV{L$7&%oHFM)<^6HW`{Tj9KTdgn9GRnee;k>kR{>5y-`46+K;O=lWTc>1eNT}7 zgwspxPe89%eNRy4oPb_eL{30I)1IwPK>tPCnKZ^c0sSm{emVjDY*&i6+LNR|N&1tB zeGl8(Pg3TbgubVFP4p+BUy_x{`;!#=lcYZheJ}Gq$@`Pg?;iXX_4g;C@9mB&c|X9F z;`&oYpA~8BPm%r<^yBTPK1H!V1-`xiJzxs6w`u67A75yor&x*P% zJwexxPC?(nX22=LzN0H$6jgTDk7NZm?ewQfe;RttoYSN~O__6=GUv3>r=w2xc&AB! z+UV1f*}Mwx#pDDFNNNE z$V;KOYwc3XoTboDmA|KE&Qj>@TDz2DzZ98cJ>;c`{TD9pmm+f>sB{Xom`f4+^PG1n zV*i!PfTh&l>#TUt{|){5?t6bj-&+2Kwkv;={%`2p$Y-km8~XL96>e%W+InvDe8~Ta|cx3oD^cVSWXx?A!k1X$X{b-q-KX?6Td8BMbq-FBLhV_G+GAJVWvD&Y?k=O2YZ+>f zwY$rx-Cag?e;I0z%?d3;-M3kxWvD%?3m!vte;I1eJ+8JdL*2i`)t+Tk_qC>^l1trZ z%c?YVMr1kkw(`9kdVBKba_Bcmi>GyeIrO0CmV!r}<{VQq9wF3G}ZYv7?3evA2{R+~ri0W66 zeg)}QQ0%q!3Hp_!UkUvaPQQ}$E4^N$y%KuMxRsPSE1|dE(n{!`l;70YuY~@N?X@Ly z!dvrJLjROMueQ5S`=jjGYde|mGv^=D{{y|fN#!5PoPVIVH>vysy}e20AJYFL`q1C_ zNA&6BGRaic|0DYRq~eI@XfF33(dQ>GJMTXd`*iY(KgyoV)fPR(eii9gi9YNVT1By6 zV>h1lC(p;e+ke6P?d(TBZ4tB^UiS7?=FPS`7?*Pc8d`_-b) zOD=bHcr{{gd!kp9el_V=XYzi0rq-?|{c6#NJ<+R0ANEAA7X9ISqF0MP?1^42`tYpc z)uIp2D%PuH(61r=8t84O(;Cr-ola{+A9gye5q;R{v<79hv=+?`Hq zkoUIJX^rT^PNy}fwKm4l>v`J8el6+Ol721e*OGoM>DP)r>~vZy`mob!E%M%WI;}!82VeQzByr@m`<*CBJRlFu~n*CBI$ zcqQ{>ly!)`&4#WMeJZh@>N>>!YWbel+I6CrcSp@APHoOQ#Qqw8UTt%(^+(p%)3#3g zNI}1z^y{IwS)uim_v?M$XMQDnR%kut{d&@`hu&s|)wJ$DE1qC>{Y)3dRzV4K(XHdz4dc8KyUq= z4bbPVerR=+kN_O|-9fnu*cx&Ma7euY2Ej=lEfgMJg~H<5l5={J#n6X`dR zeiP|8A@-)<6xDAc{U*eIrPFVs*z2exm0a&~Wi#~F=4^)ER$w+$-fxE9R$w+mZ!0jH zNxzx$elzs80<#(V+!dJ3(Ax^kX6S7NW;67*`laKeRC0sUZ-M?sf24C-Pq;R63&nm5 z<^2}uTg=SV+AWm#TcEdI+7{@al;70M*#dp;n-aG`|CB$kUag+?N7!d#6I_a(`|^o-EX=L z`WOALWnZmybeu|VcKYqm-{Oxnb8Kw2o%GwGx3SfB=35QTC+T-a^*c$wlk_`DuX7`L zK67@7J}t$)9Z^t(vEE2DS)`(32pCHm06-zECczuzVL!~6HUL?8P1yF@?9 zzl&s-=qLI80y>M6_WIqTPka4t(TAtX@20%p4ZW?K?uOphO?N|YeazjW4^NffE&6nF zo5V+3%-y0t{HgN0MIW9jzgzU-sq(u;AKDz9Zwi^S2bp8B--FoOT<#vy?}2`*v;>;> zd!V~^(V4NJ-%I+v&|43A zFJ;bNpE=q?-V43;kM>gL>?QqP=&gsm7y8^D@?PkzhrAbh>ml!j-o{oshZpqwNWTyI z(_9SpQSA3Yf4YnPKIj*X%B;ZbquB2w{XXc=aIxP9eZ_J!sF$`6`ZN7`wU>65Kgzz= z>TF}s{|Ei;uGanseMto&G5MYNhj{LBF5$`$@l_^!rJ_pY;1F_WMb{pY;2q`u(KekIcEt>GxCS=nQVq zA0Yh!=xuazfb#x;&wH)42cWmn$pMP}0n#5J{Q>B6M<)lMx6#P~=xuazfb=@ooJ#I? z|7QnDe-Qe*?pk}0^ar7@=dQH}p>NkC^Q7B@6#IjuKM4Ijaz1S_4?=%Or>iON4?=&h zH)-DA=Z~^8M`y)T$^GuLL(o6qkF=j-u|GumLlpZ%6#GLI`$MEZM6o{5PKT2fZRqpyxfk>Iq5Bqn8B4vdmWkn)oMI&X!B4x!RWhEkIB_m~}B4wo`Wo05| zWg}(fB4y89B4yPhW%>@a+`oCvNLj5&S?x$!ok&^T zNLjs{GQAdP{-u%!U42R9QDv#*A%CQ`$DUGd|3c`8($U>{o&)w0-_J&%L35b__BcL!)_a`(`g_3 zf}&3+54+eG6n#2*#2;nfJylTj>Eu!QOk-bA^y%cCD~sXUUJ!cgsTPF3p^Ice(WjHg z?b6(Z!97N_wpI_I?DYTso znNt{%Qg^~BxQ!PxHQy6(~{p`ZX9NSe~75GuQ2=unIwFvaNJ6nrD zZ#!Fyh(7FWEkb&|_5^)V(ieqZ$8Z|oqNFbhy^fGH?~6je%iT3tl=MYOUle+sQP9jO z3Vn-JO{BjORvwE&ujBU2d9}^aad74+yPvIB$)GPr`eM-QC`i9ojP%7QbBa;s6eE2x z(ibCrv8cWn>5CzAOka#*uh;XSFHZX6(Ax;DIOTnD(ibOvanctjeR1e*gjO8-+!0!F z=x=v@%;M172(38uHbT>$M=E*JwMQjLUjllav(wm@pxBpyUT4HKb4oy8by#MER)X{; zNMC|tUm_a&5)}Iq6#Ehsd+j5olBb-$Bq0hbVt|at!-(5-Q?Y_H`q}SeDe)6=_mlAz`@{B*yYwg3XZ7oHaQ_5$K#=ey3 z!}Cf@k-n7ZLwjFJ^x=7>r9^-D^GZvJK0L3ql<33rN=u18Jg-#yoq1kgn)Ia+dz;fL zP5RQLFOAsSbG%AJZ`az=q%SS{FsD^o^oP%Bl@@)N(<&|cyyQ(+3rdSVJjY9W$Z4-H zL;5nJ&zF_0Ox~BF%qb)KaIGza*xR+XjOfF)whZaZh(4XzwYH4t(@E~Nwv6c0iCt^U zh(26v%OLi4t<}D~?Bj5`QWkk{nNt?Azsdbym!;U3^|99)T^6yoYi(J|oU)YnWs&#x zKJ~K5`#W;pr(PC$e~Uk_w)eOCqwGGWjyi(A9O=uEz8vYxk-i-1%aOhu>B~WXn^^Q} zRW7P8NBVN8wWcqJT5Bz)j*o)AJn73rZ*5L_%AE4hTbolJdTVpalfFFZ%R_H%PI>5a z+nn;yTbolJdTVpaLvQ^Y9mxfK1=3f5-qx%ukiG)+wq{)cdRw!u0KL`P3Z$<9y{%bS zfIfH4x&rjJW?cb#TeGe}dL45HeMQn&gx>B{u1J|v(Pxgfm=&S7JC!R!Z+9wJBz;Bb z?M~&2(C6N%ToHP^Q@JAacBgVh((C9rwD*-npPxMI>To5|hr4Afk-n1GYptzBd0$EN zq0Olz`fw*hCDDhwWh;sP@VjLzi9XydTS@fcZrMtr4|mJzI6jp;=e(5>`{(_U_U~=| zs50p*LvQOxm7%xwqso-`l@WVe{i=-E+v-@{<$K))@?%*a(CeHGGIA$^soz6$B9kiH7(b#5f+t3v;Ri+xq- zt(R66dK(#5h2DB;RiU?DT2<0lrM#~Sz4h;_LZ92euL`~O@2f&@J>;sS*IAsPuSWW6 z(A(&w8tJP+Z=;iHnapvclWL@|M*3=`uNKu;BYic}S0la7HwArl(pQJxMkm!tU)^Vp z*4paO+qJej>8q2zI_axN_0>sVo%Gd7uQOxvUMiO>H7M_EK)>DfF>6rX*YJAH`x?-f ztdz<78qiyNUxV_#Mn*5csn^;X&^LXScQe<>=>2)Mr*M+1eKkn0b9kxbC8w_mz4dcy zLVuzAUQLR9P3Y~JCN-hAXPVTc*w>`k*M$CJ`AyZ=%;}!cWowV4Txeucj>1&BTtee&neLB(m zqg7u^^!draxqJ^yEzzeFy$e~hvX*2{I{CpLWzRW}Qst)Fypx(TA&5ZRmfI@2S4F=%v5>2G6C{hW<6LQ2p!v zNc9$boxx3ceH~=Z8}47$LFU*~{|_jQmt z&-6QqR$%HNbEdgIaUIm!>Ha8tMnvbDgT5~5>q39It37oobLvv&)P??*BAI96*Cl;j z=xq+UF7%f=eO>5t?_8@3z1_K17kayMtuE!g&WZ-tfB(dVuuG>DWnjFdHslr@f&HHnlp zjg&QulpPT%YaS_U5h-gKDQgueYaJ3hO zq^wJ%tZSsKTcoUeq^w7ztY@UGSEQ_WPMNmJnt!48)Ti20UusX-;a8t(PkpLA^`-WN z6`1-|_v=gT2`e!5QG09!ras!;+^4(ON4wkIwN>>|_iY8HzSRA&0;4r0-?zIBM4z9$ z>Dt`}(A%6=1JXAjeFNx6x652n8j!w$=);^=1JQ>$tp=h$d`_!@=);^=1JQ>$tp=hG zb6Q%b^Sr(x=^LWuvN^4Wq;E+2hG@BLPOBm58Wza^tLaz5%l$4`_~A1+n3u2dfS)Vh}zvoXm@P|rV%p7_T@Ip zw7WS^Mrnk0*Y@Q$Lgv`M+(x)+*vy2slR@8@^o^mnIjzPN`^G-@T6-EpZ~g4X6#K@c zZw$T7X*GsEcTTG@^fsr}7z6t4@kY2AnLEn`0O`%`xa-}Khn|i(WmYPEULaXlRTQ;T4X-fL0&|f3%iT3rH zLcf0XB~=>oud;HzR#B z=pT`YsJxfkAOb+9j`|~|BL^Ij?jMfN7;Jqc?5lP(l=$~>?Ya#k@FF*^@Yi};- zTSEVV)3-$IwN=s_Yf1W+q;CoRsj?|0^DndS^KVJ9ZwbAwxoO_Fgud)u{b|*=CG^^! zWPVLEN9$+iC_8hs-ue_SWXKB7G~;w}Rf&NiPi#dkruLA7zBTDvBlfn-r#0zYlfE_dPh6CVPixY*rp###z3uX8 z4Snt|pVrWy=Q5`?^tQ{VHR-i4pYLPeM)di~$1e75L?2cj+mOBu>D!1ttUR_MeH+n- zURoQ`hhAD6(I4JRYa{y5OKT(g&`WD0`p`?$QAg0XC4F1cw&HJ{b*YQ!%A4&QnkvX5Zzr>NGKho>(gWle6+79~M_nWqZUN+exSK6W03d|j4x0pIQ4*K?_ zZx8(!?r+wf^zFS~Gp9XePJ7Cn_M~qQ{g*Ct+C%@&spF}a)*kw={CPF@U;CqMy^iC9 zz60qyK!1|^n{^<42hw*SeFutt2hw+d-uB6KfIfGhOb6)gPKFMMz3r3fKrN=uI0Su1 z(szX3##SAnukZd}Izn$_tB%my*s3GxJCeR5^nb{&Xx?{(KKBhm9ijizpGjl?mp{sm zz0QpUeJ9d)g1(8%xK0%NP89o26#Gt;Ih{z~33^-g?F4=9s&6OgZPm9EVsERyoe+B) z8R{%f(03+%XXtIsx--STGxWA*-5GjYv+hj#&ZO^5`p!{(XVP~jeP`0^d{fYOf&Lp; zL%Kk3Ph;vr`YzD7ar5Y1ptq+nb)n4Z0=@O`yFlO7&7*gLeo@CI^bEBw(07x6qb))g z=)3!)?99=bu~hP{^LC}!cZL2H`4{>tT}j^+`d8&MZ85t-KkK#3^98z6?7LFzyFxGj z5P9Df`gXNW5&iUfiJT>KCf&{ax<9Yx{Tu!$Td#9?spLDS?*{$%{z&_n-?;kHjq<*m z&wJH(gWhJMyOF*d^wz)c2EENhcY{86Cb}D9Z!^)|B=%t@x*KJV&Nk+GeRt94B|kWQ zcf{Uiqq>v6JL$VaZ?jR|DRa7uKJ?PMi$2Uobr=2Nvr*keA7-Pvi$2Uobr*e@jnaA1 z5c?j8z3F>EZ`ax$r0+rc9?;vhwg>5ZQ0DYN?Co0H1F_G&*7iW`?ONLdc`q%Nx{BDp5vjT`$V}UZT%WOy5iNvgRkh zsaLCBqR&r;mU)Yw<_`N=Q-yxPb7)gNW=G|^e{RPsOfS#Qdm-iZB$uC3|~eSH^^ z-q72sZ*RojR(*R@?0Zw@^hWG$)wefdpZg|@-iW=e`u0YxwN>BVh`r7P>iSV1(dVuo z^^KJEiMao7-%0@-Xj)|0w zj+Es^%Em;>j*XO!jg;j_%F>atagnm|k+KPqvWbzhNs+S2k+LZ{Wm-=)|K$0#uJ-hi z+9OY@^+(ye4*F2t??ZLJkJO&9>!1(So<350!mfipsQb3-pbzSP?yiGAQhUO#gFaGw z!mfipQhUO>z1Eae@`v;GMcx0?AL$kQSy$WpQr+(hy*(kKFY3NMA)+tz9sT#RpJ&t; zb^m$!Ok1wLnYv&5P@z;Z-uE~9qVC%hBKqR0@uL4V?QhsBfY#}t???K6Xt_qZ@AV^n zKj=rvXWHNB2mPsT^{XGXyZxx;>IeP1PTvpuYrZ^zdQ1JFf6t#+uNv?BqwL<2wmw1M zpY;8q@9e(UpE9REWln$S?PPM6QXy~o4cQo{4o&IR(bKj?a zH1zq-do->ZX@8WRIohJ<`@A0@`ut?6(+?1R*c&>4Vn4vgUhDn<=xtVLfat^C&;gPj#T^Lr-;}=nwCy4itUpsSXr)o=P*A@_sP%Hjh3SdYeZd z41MlA`e5j79(^!st<9qk_Pr&In)W2OL!h^{yCI|>0==!>4T0X)?uL+l z2*rK~^tN_41p3^yyCKlq+T9T7ZS8Id#a{bJK|d6FYjcJ|Z>s=9DRYMU%+b6b3calY z3?=-6<{dz=ee3W6na|)7)pBW%?151(hnp3Fwzer{V>uGBmFSa z4}<<(k!ju!i|U7wei-!UyZ@JAq}P6DI{C+C&T!F(Crb{8UU#f(jtwXMaMBNl{({E# zFSGBn9xnRu+{WRePbbgHZ>oN{=+jA?JJ!*?zQaYIPF8u7_H&;1itK$d+CxqytKGjG zf!MF{N7`a;cmLNTNI!z~BcQi^xg!vJTf-QE*jud~L76im6Z@Qfxg!w!o&LPq=Gea6 z5malnFCX+N=+`=Z3bD7fyA5_((17)kn((AyfuNa$@1VQBdkpE1LF_lkXR1F2 z`gxrTx__CyW_^t4LqF#j(dQ@YB|fS@M)di~H$T5ZGZV*%K0o=_#qb!3eLC6TkFxtY zI_3=e(WDoEzeR$ICXwl~<+Zty6KSxXKLoaPK=|@99QGQePqoLn6 zZ9la+qoJSV&#UXEll@Wlx~YziQ^`j6f0hURCV!-D&Un|)$)mi_qgtDX*xxekXS_)z z51C_kPvs$Vtj)^RDB*Y=ZonVNIxgMtuGImGtr+{+nh=MC_8g>93S*!px^BD zV~{yEk3NPnXAJZ=xsjn zSZZ^0ZX}g#bKbGgZ}&%ezj{c^P#tAJLHo-pY-|A+p`_= zq0fD`Lq7EOY=?Z&hi5zFlV0bWf<8_9H1tzkOPeNr8v3bDpN8I^Uzdj7dJ1XMr=g!F z-_u%~hCcWCb!q6Q`}1n8o#BtN^Im7hf_@z7$3bsnt8viV*ma!Gd%YHngFbww?Y(>% zt^YXEkAvRER^y=09b1iq-o{qrkU1avU(43(9A191(`C+h(dQ?-{89Eknen6_@AZ1M z8ZY{=Pi8!2&Un#>aqW1~hkY{RMSu7{nen0z`((z8KJ1ejFPS6P68D$T*~XxsK>7(1 zzOc(@0_i7^egf$yQ07b^{RGlai0UVheggEiPi6w?bzU^j$9^K|Cn9rfPGKVHCz5_5 zGRNi=CX#+4=_iUl%qdJ1{o!*86Gb296efy3FB#(UVWQ~6oPy5aro4U<^4>CM67*f< zUubSmBK;)jb=6ffXA<;nWVo97m)WC}NtE}KkoR`S<|O3(sdEoX4>>%MWfJmU*F-bF zrnOer7&AxNd9SlPK|h)FlcBe#%1?&AzRS4D(A!hxCqr*fm7h$ppG^A6&|fW))HY`_ z^tn%!pA7vqF4~h(YwfA>lhI<@EUeCo2mKV%Pl3L=tL;-rKLz?4@|nhd3iMA*%EV_1 z)!Hefp8|bN`JU>hKtFWHXqwNN0(~uiUX6Wif26Tjy{;ck6@Bjd(X>d}^hnu^NZHIt z*>RDwS&_2Yk+M0FvbmA6d6BaDk+KDmvW1bdMUk?_k+S0>WhX?+PK=bD6e&A7Qg%wD z?9@ovX_2ziBV}hq%Fc|GorN-;^^*SzltaGg{TI3UqW4?mmMw{totsmpErI4=s6A7u z_DrSPGnH!3RH{8wsrF2zx<8d_&s3^CQ=_$KD%GB;QuoItyIo5#mFm9Ml%StR`f1Ro z+~{H&>8C+IQa;nVKMnf2O)_7<`dv7b)*>Co?S?e6rbemd!=L%-L>emd#3^$GeJq@Mx(KKH#D zq@Mx(fAX2eeg^b+G|$9-2E~2`>1RN{-|1&Szi-`HG`^ex{Q-YoZFdj)qwH&*wv$0W z6Z%8$U(STycGJ&<-g=`mq1PkT&xGD~)6b;X&xGFQRc1n8QqHPZjhWEr?xvp!z3rx- ziP+n2`k9EmjW4xD5BlSvPl{w>cpUUExU0=^q(6@I$3fpzCYZG)IF4d}9P~E6JP!I7 z-8Jtx=$n>4jjnmeLI09Jug1QBH)Y3OuRZb}8TZ*N=!F8sEa>e%j9H|gMfzFL+kF_b zNIwgDn@67oz1@c~3;NvqFlIsjl>A*a7PHXiJnfIN^?H>I`q`BCv!S=q@odWb+0fhQ zcsBGlI-X6LGn?{$HuT!=Yv#;`KKFeXv!U1Pfa+%>bMy+3Im*`S^*re3kbVyIAG#KE z4#j>B#eNR-{Yq!fFo*PWNIwVqkK{L1KL`4vyBbL5gr4dg=s))7)yygE@?j3;z4km( zNfGziT32d7m?nJ{NkMN1uz>>(jV3 z_H#+EeWbjknDfpPeV!j*&Xd@WO$N9a%p?6g($9mwUAxRP7Uq$Dp6J8)a-QhNCIemU z=ZQWqx#QoZ^p4kgq92)p$Ly6)(!f-k(?Xm-wUX7E?zZsid^iFDCtB=sURDzL;Xa82XO#nZ|xG z^!7&b#gsXVp|>_?G4!3}d#Yay{ROuSq}VTpUKT{~mt2g@>Ee&F^IpeCL4Q2ykB9yN z_kVpn#r}BcAC%8je?0V~Cuh!gJjMQa(jO1~L-IY<9}oTS@69Lu@z6i)&#SS2#2;nr zbtD(`Cy@RG=)ZCKcLM28@R_6f6QH*p-6xR#1j?Kfp#Rq8{Rx@OxxA3*L*|?Sz3u2e zL1G_vbe}+ZuVc=%&zuuQpH9lSJUUVI;fX*elKw=}pD6mUH}6EsoD)SK_U4@^`tU@c z6Geac6M;??eb}3KqUgikyc0zq_U7s6IK=)W#NPBLA@*h6|I0~~_a{MLPCnDvpM==A zb5GYkiDG{eVsEPeCn5Ib<$IbrCn5Hie7}rp?MaAz1%F=6oQnP^J9Bg#AM_`a{$$dh zO!|{ae=_M$hF-pmT6Z$(PbU4zQT@rJKN+>QlGC3|?Y+)81pO(bKLvW5M?Zx!=MMmKHPg?@x!ms{9+x%F_}1YW^s@*6Pey zo{#+*qL({NTNI)@kZXOjL*=CZ&$ ztGjFMnb7CH8TU-Y-rkIRCNig{|F!Jc>uh7%$NntRpGEq!NPiaT&m#RV(@Axg4`)g2!_`X1$06^}M&4WIoDIG1 zTGjkJ8<|tz^&8Gc=IEYKt+i((b549IbLZOGl=o*N@9k=JHex@_>CZ;qS8Q^NT&-sL zKIYko{cxv08+kv%A7#g0NA5v?4(ZQ<-qtYAA^kbf+Zx6>(AyfuIix>_^yffdLn5iQ z_8jPc-#vwTY3D#+(?$Cn=xg~S)!WEWXBvWj3F((Wzrb8v7;C%hUk= zN=rz;g!D_GxBUW3pwHbeumpPBFR%o9+b^($T1=f4m(>~fe|9eE&xO8@|1A3rF6TmT zGlAzqKk(MfTjl1ij-X(DZ3<6c4?&SvPjwGk+LfyWmiVZu8Ndh9VxpeQg&^m?7B$V z^^vk0B4sy5%5I93-5e>qB~o^4r0ljx+3k_CJ0fLwM#}Drl-(UEyC+h1Z%&!Erka1L zL@F(6?Rls@4gHb!mTXV-d8qr=8$FL|&v}`aOD20VznQ)AeI9C$^_I>CcDW?twX<>i+qpKOg!> z-Bsg!=+~e2C|xzqhyF2loj4!*$NiDjeT|dW={z6%3q+rnG;*=O0Q!oq-MxVH7m)q} z=!?GJt3c*Avv*fsAo|c-x&Zo0@|)UnT_AdyPptMQ%_m*}ePw@MZMmxWqwLsg>y!5S z3rT;W=+jAS7yAoEA9_m{iazv~E);z_*;c1zDb-&{SB(orANm^?ieC0`%WtawLeZy_ zUe|7-{>Fu(PbY2td9}ZBq(92u(XH)d$efFiITrhi5c@aX_b#H?U*u!2-ir`>s}mQI z{vu?K^*1g;?B8lCmyrGv=ts+MYUW%5eaTMMX^e9T^m+cg8vA4Y zQFh+zRWj%=CHmsr`TWaW3RPVCIsbItkzym`pZdwIrL5B zH&uT*^v^uSeZ9+}Z|cvh`eyzpJMXoR6!ce+{tD<%a{t#?kp2qNUqSjSD08kL{T0xk z>|%cf^tsQ}xdQrA{CQPx&(ygBnPV$3+M5gdE1^Ha{eNBwz3qv$c(%gBkg5LT$S3%#xf0jK; zxXSA_bFQM;UqzX774+86xeEH0@|&7DS3&>9r~7C&^eX6E`SWUv+1ejvXO8xegZ^sD zoU5U4 z`rKVU*FbN(e6B&}*e;)ID06hwkxDu`@3qi(@<*ya&dnxWOL>1S^t0qMjs3OIKhP<2 zRlb(=*Frzr|B62GbB-Ko?5~Bs?5p2X?5~A>uK$L{ex5(d&Kw;d1^soTzYdwx+5Nv< zNBZl0-mCsP=x;eSlR4Ls{yNfMhuC+K-&Fl|nY>?CjjpxVLEqJ%SM$D`Kg!nYNG|BF zC;j!%TkNkV{q+?4>nZlvlm2?>=eyWl552|y`e^L0r`TVQ%vs>SpPlzQ=FCgFyZ^Hr zL?8P1H;6v$7r24+H&E3TCrWRA@MuPqp(%%BTt-#zu`dcXPZ-L%cU~VD(EzsMw_7>=E z1?Cp$b5~$)f!2HPJ z)~s)ZKKChPw?c1g*0)0cy~}`GNw4!wL4O_i9WoK;5Lf=ZK4nF zBe)HEdmq7VqCfnN(6@;`yb<~~WRAU$;5N~R_YvsKSlZXx+eM#F`npn)kPhKAnucER*-QQ|xbtzM=n~&MB0W?`f^Q9r|CE{6upKw?kjv zpI7G;`gv3K8ivl{1^peQzXN)k5xGP3VMgQ*=yg1z`a7Vv8Ie0E_IHRr%!u3}u@5sM zcR-&zBXS4yHY0L}#6HZ3+(EI|*~XALcOr8v_ID!hZCraNWzLxOZCraN>F-3| z+lyn?cEgnyGegH^fofQ8~WUl;oZ>N$nb9HZDe>iVs9fuoof#Idq{r|^wz(>hhl#Z z^wz(>2YTz@-$VL)NPiFX*1x|8`rQ8gJqmi=5B4v+9%ASanJsBx`DpK}zr0khU*|U+d=OSg# zN6KD^l)V@!lcndw{vIz!%3g_-y&5TdEmHP+r0k7I*_)BFw<2Y4N6Oxbl)al%rfrVq zU#LCzQSG^pYR`RCd+wv!b05{7`>5T$k800-sQW)lUC=A`ebL%;AJv}wQ1`9&+(%ap zttml&Kk4s>-rk3CKk4s>{x?zR75jeZ?R^;cQ{BIx^!Jng{;2+b(%(<|`$?~LI_MuD z{R5ZKxT5GjM5Bi5m|1e^2tG*AD{$Yy!!_eE4upTD;!=!&0dRz50EAo_bZQxKAjAa&ouUr zh(4XH{_Kd78j(jx|A^?rzT8JdpH7C#_q5G=xu!YDCr-Cez?;=3jK;UJjQtx`Vmh5 zsKh>HIZuc_mHcq$TAGP|07R<~pCbKJq<@O^+CvWdr%C@b^e?+M=V{8E zr=fpEKGV#38v0F5GIy>$O?m$`>7R!FZFjYL8u}&E_^!dHp?}9+pPm+dDtXr*WoM4| z<%9ki(mw;ey-DR6iv2Sb`)4Tj&rs~2A^kJZ+nZFLfj;+5D$hV~Z&G;%dV7<~Gl;#7 zj&;-#^v{z1S?K4xp2D*f`)8qF;Cc$rLO=TYOzfW}{j;Qh7Wy%gje50u7W#gtOr-sZ z&q9B!%h+e3AM1~@W3S_*pns0^&q1H>zV{sIpQG46N3nm7^v{w0InqBD)jvo2=b%q} zMYdi?azXz*>7R$*o>%%j>7R$*o>%%j^!B{c=SlxO>7OV4^HKftq<8O*{{r+)CF3-6UVuLLJuojo-^^v~3(z0okFsO0 zqvN1|k@PP@-`sugMT-54(6^A!w9R=DdV3Gdi==;%^e>YB#i;&8(!WUh7b*5Sjt}~m zNdFS_b_dT(6#JJb_AgQFUn2cWq<;x|yMyN?=yUJjc?o*EgXbma?GB!oNUt*vLH{!8 zUnc#_q<@+8FO&Xd=;h1kVZ2QGmr4I}RR1#RUxt3X%lnr}uX7`zm-dS2)5!$)FJBQr zc$fVvq7Uz~e?|1+UG}etKAqUR>|cT2?%;Vv^x>(KuZTXK*t_gs5&hxsvVTSN>13i; zXb*XkKg#Z<=`4;s)6sqQs_655FYQ&t-rgAZD#iX)iv6n;`&TJ*UKM@lA-^j6{KVcE z_p0dgliWAPy(;?rOOl7nKR8F>A2Qf%-5i|(aCGj zTZ{P`^wwg&MzMblnPcmwuOV}mNe@HYoY#;!&-6Qqu2!!hbEdi0;x%N>bbplH=IG3r z?5K3!*P)-`kFwXSU#Hl=4!!NwcpZA%tMNMNUx$9C|IO^Z8m~j2yI13N=xwjY>(JYp z_3M=PI)^8_N!)M00sSn0qp+mrex>EDFj_N2ZEz3oYTlVblS>EDFj z_N2ZEeeRyrH=(yZsc(ut>`8qSvA15D&Wom!*)G~|K|jYIY3x(3<$H_tZ$Up&KGUn! zThOonIw@=J9BidIq2UZ{X58?E6UB50SDTBV|8D%6^WN{SqnrHB$D! zNZD_Zvfm?Re?-dujFkNqDO(yT`#YyhuPB;-q4vB-wdXz5p3<(?y+^g@J*qwLq4q49 zovHipQSEt;YR`M9J+ocie-E|iiFQk=-F*+WXO2Iw*8REu$ZC)3wWb99`=o!L^zW1Y zebT>A`u9oyKIz|wexB36AJxB4`uB0gHvRk5-_SZ8^dFG^1JZv$`VUC|0qH-WcJ~9) ze*pagxgu!0`$1Iy0qH*={RgDi)+gvcB>jib+w(0xgucFO|2~A?o^SCX^!9v<4@v(a z=|6oFLYPH4@s}>WYB*^`j1He5$Qi7{YRw#2zvQ4`f4AM z{v*2Z~L@9BmHNj{|x$R@;z;HK7&4YpVnv4Pj~IZXULox{wTY>*Pchve@^<(p`YWv z_c>+G=RR{Zt3HR`vg&ive@^<(GkNdypF=-y-T>;Ueh&RfF4~_%f3iQy)@vUr=)WNS z7to*P^j}cyzkvR9`AlQ~1@wzXWyUyPkp2tOe*yg&PX7h;70b;a{TI-m>Cdaz+Ozyo zwqAR4LH{N6r?~&mFQK=Yi7!e2CG<8k@g?*&Gw~(qzl7fQX?+R(sd5I*oG&w(vvCF0 z+ApD(N`%(pOT_+kf0V7)erM2sMf$IxKf`_RE7E@j{h9Ka#{Mhl+sI;}=FwNA|BCcq zL4THfPxW6xzv4@7bH0N9Y=2&j{W<<9TdzIj{A7vy>}%2ICpNzPTJ-tJx&E{475A@2 zpP!s3pQ-+9(dQ?NhG+C&lm2Vbhh4>Ai#|U&U%sdMuSGBKqAj_X_T_#p`uyYqe_nmE z{)PT1`%Nm^mk;`HptpIIZ=k==W!yIu`){DXUp`a)H_$&Ki}M=$Z$uy71M`jO!;IWF z&_5vGQ~fv4ck2G0=);>-zJdO3e_oxDyU6Lkkrp$Z-0MEmQHR{E;6D2nnPd8IkvSLp z&$91a`xcpFWBYHBIW5jE2K~2)z0HPxi_EcEp>L5nm&k9b{##_ulA-TY-hYeCxzwLm zGv_jYl$|*`J_`EpNdF!5Hjn-tVsEYDcV4g2{to)^S@yN|JJNp#z0IS42Yv25`ghRV zJodJ?XzE{r9BT zF=r~d-2GjCfc^@9q_aXcGw}oIfAD(E`yZgUnTa1LbABNG5767p#1GKt&P@COz0FMg zAbPp?%Vqixq}S1L(EmvK9})WtT?~JuTKgmP_Fm~9p||%+|48~DN&h4C_Fm~9q0fD< z^pDWnd!>Jb-rg(yBlOnK(Q$mx|3vzqptm*apD6Y}`PggT|3sPd6ZE#r=O@zt1pSrr z*VS746ZE-j);~dSYt}y@b8OA}CyKq!I0XIA&|l>;=V$0Ex$*GNr2pCLHFJK3{*v1= z&(!&uV*fMrHlO%2^mg~u&(P=IJ@qs6cK6iJ&~I{?^E1U>=SG757t;R%z3p!Mh4jCW z{uk(NciS(d{{?#6oA(R!JH(=~|0R<-IlJ3_f&M(_{RMh^&*Lu?d!5Az`d>-^tLVcW zJin6uSJM9~`fvx&ucZG~^x<0jEA(~;&#$6C{0^R9MIY|q`4xJ*gXdS#hv#_dd{fZ> z5BjTJ=KK$_zskknf6&+WN7?VY`yXO&@4NdS>Hmk=TQBW@&|fRRqOt!UVxRlIyZ<5f z*ZDJPn{&NC(yNu#TAdjS`rkd&kCX8tHU_Bz`b^nZ~459pV=zu6y@Ie$R^ zw|u5;&L7a*Gm`%x{U4yeIe$W*`;N^&p|^Kz{)t*U!)4B& z)MDxkZYsIf>HmWMI)9`+h3!uN7wP{Z{a?`AbJ_o**#8B+wfBEPZ!P9u&^OI_F8g25 z@AT)@*q`Y1e^Kmpt~r%l@4QPX_Dd0a>tik@{Zg;jItik@{ZfkkQs}LZxfJ@` zKIT&Bt&h1Bv9~_vQqt?Jc+me%`oBs4H|hT-{okbj8+!RNYWv@$|C{uGNA-V`{%`0D z`(Lv*N7s**i9UC|XL+P-MWk$Hr0kza*{Vp{>PXp|NZHy**}6#C`bgQok+KbuvW=0l zO_8$Ak+Ln3vaOM_ZIQC=k+L0;vYnB#U6Hcgk+MCJvb~YAeUY;NB4zs{Wd|Z<2P0*N za>}&UYX0RXH@LdLOlnVlV(soS)SeeyPjwk;Pkq;(EJN*iQ9jeF#xm5N$+Gb%^PAaY z`(;vl!q|S9)Si5K2YBYHu}o@De)7StmuPIiOlnWQyfHgd`<6-VNy{6k?MQn|t(-z@ zO3*JS{c_STC;f8LFDLzSsrzAOVmaxTLw}=0ORss$qx$8fUrzev(sG5F39Zv9ANv*5 za;<>g=5kk%eg*VXB?cP%70}yU?h0ymS5V8f0xj1x`JU=mpykS)%Uyw%Yr2c?3bb4^ z{E@X>`d8N0C+Js_ekJtw%+{5pUkSZEvvno(_RQ9m(A&JqO46@{-k#aI68hX{wyuQU zp4qw*`kP#CucWJnwv$2s59$AbUM8xL&Hs@8AL#8al7FDLyGZ^a{XeAt2l_u;?Eis2 z_nEE#K>w#duU@hL@<-XR*A_i5x!L`ntrC4+a*IFG{)Rm#dKL6`RbBN>N7=F0t7OoxA^jTY zt+%v>V!y`6UeB-wdi%SqfnL6hv#%lj8tARJvP49i4foxxh5inI zUd{VE{ZV%8wdawa+~q!7C;EJ!_v@gytJONnoORIK)oLB|cC}h3`q195qr6`y`f#;c zC;G#$R_jC`u2$}qwHF{o-${>kGqQ@G?RwE4UTfEjKGfRvsI@i3sX4kHwYHjTfwVW5^7?;~Ii~*?u|LZH%k0eg z*X#8+|E0|Nm-PQq-v5itX(zv_ne#6)C)IpIA$f0mJ$sAIzsQ{S{=Aww9sH4Ij^(}f zJA-}$={G=cc`wd>NvEKl_jW0Klego+@KyTyA4bbO~FE>DM|YORisf_@9>w?J?6 ziCdtr?`qE$=&zO|&HF9T+kD~{(r+RC7K;6rsD2CSw~&4d#a>5pLBEysTcOuhN!yjJ zq~8j?)_K)$g?^sAE-Ldcvsb^il71`2err^}mGoOlzm;OIW6q%8M*3~g-|sSK8|k+} z|A2g^`fbpkDG#qw{WgmIHqvh+{kEun8|k-^ejCMJN5?_Go%GwGx6#RV(r<@;s>_`1 z(A(%_JL$KRemnFwI@u0=?&xGY^fo%#4*d+5vD+#3I*t$e9i-m@{ev#{JD|6o*beBs z%C|N4JD|7y?>k7pgY-L~w|C3#fc}|sBWbV34(K29=hds#!~Q6{#nc&xpx;UQozNd} zJ?otm`<>7ql+RSZ6Z%)yW%7O}^wv|@N&218+Y^CyLZACYpq32bIZ^qpPy}cQC7wLDAei!uiX53xS=e`+t7xeaK++EPyn{juM zUT1NFemCiNL*LTHem7;#Zs=`nwHx|2gERXDc0=FFe=qwk@!in3me2HRwHx}1)i0LJ z3A-J3L*K@KUo)qzKg!M=oo@>IJOu-CcdzL$Tijz1>B!2YS1UWDmuD4`Ofq z`#sQ)b^1NfUy#>D`uCH4FKrL>`OdpXVm~fP`=e~V&Wr{9UefP{-c}y>QtbCq?Ds-% zE023gznAoTp+8q5qOso#eeT;7_CkN2i`rgf&iVc*Td#9?LBEgm`$QjB9`})cAL;jr zKCC?MBmF+nhn2^D(A&!6KG7e(^0-g*VdZfj^tST2Px3yjJnC#?DtXl9%74&5=8trA zGT!~o{v-W=r2h}Gzh&Cbh4gCmALadjh`p_0{0IF6`Av=ee~A4T(=VXB{|~XB=+CQp zKgl0y?5%&V^P)k&ANt3gem^qjP4_q3Px}2{uipL8+qGan#eP5Zwtlo9`nTjaRlgtl z-1iaehyHDUUe&+jkFqmIXK;i50O=1vKh%Bi0O=1vKTJN;_Wl6$4NGNu3I|Akfb<8T zA1>ch{Q>Ax@0O(g{Q>Al`17hh<&UysuXD{oe~|PCp|_sGLFntdUpWZO%U_YP6)4^ieE zqRcr&u|GumL(re>^oO9&eRkj>=uh$I)!5s!0}uJDm98HpGRnzaKPnI@D;O!0|AE84 zTR2iyBvMv1QdTTdRy5QdTZfRz6ZzAyQT`QdTKaRyk5u zB~n&3QdTWeRy|TyBT`l~QdTQcRy$HwCsI~7QdTdgOj}INKY1ghYiX0h`b?cC{gGZZ zY{y4ZID1wokwnY9LqhAmzV2MwMz`Z5DXb$j>!~J%wYOyZRg%Jb$FS}ANDAvSb#ixn zB!x>!sqOek3Ty4L9Un>I?7FWtC6zqoyak|t+8?RjdP@bMukUJP0qCu_Q~-MGEfpYr z0qCu_Q~-MGEfs)1x3^RPdh0C}5Pj$^6@cEZd0MA~z996^IDJ7`ZcZi7I&VSJ7li&f z`AlP95c+N}XV&ftLf_GUFT1B&5c=okGi`SZLf^FZA)1jZ2>lEG`x^Tf{ZaN+LtCGq zFGTu6(A!m`5a|m+KUIEH^@X6ft41N{?W$1-v9~LBA?WR@Q3(3nt41N{?W$1-nPXRt zLX5E47MM+0 zt+kW=QFe=|*Ylt+PWs}A{ce|k#YtZr`aS-$>^BG%Cw+0!7l(eod{6bopbtmsel zKGFF9E&HOq3vf3FvKRq6A`ZGZQ69UxM@{GI}|y z>PtYMJ2O!NdYhRj0lm#kl%O_8`$(zed6z3Cp?|?2Y3A5$Xi3tSgx+RDOG0n6p(ROQ z5_-GVmW2LAIfLp;Lci_no|HKyp?}FMG;?0|N7=F0-dxa^B7G^u-t?tNUyAglNM8zi zYwt^uz7*+8MfIgfUkb4|eJP5)_B&I_EAIcSH1x0fBaQt7F5^l=Z*6*M=pU5N^lDWa z`q5IgG*e5HzBKeUIxY?ULoV-2L;w4G^C|C3L;tWpug3lnf0P}2?I8z!8PbB~TG{hTt;e=Fb9%qatX?mHREKrhqUh(#HR{kY_Nf24Zr z=V)I(=*yD6EcAB2X<5>jC4E`wFKC=OUs=lgvZOByeHCd>R9_bQ+;@7Hg}$n5bIKxf zs`;aAy^cD9z8v(gxy&gC{b_E^uN>ulIq2=}z~!K~w*!}>*q0N1*kM%;`ZMG=RbLMJ zMa%dO{c_Ns>CdZ~bCy5K-lL@BqdcGYCEwH7R}g(VxnjyXf-RHV$Qh}hd5`V~oE5wW*B^eZCvc87jN%AAVGd+Q-rMCRBX`W2Bm zxp(MSMCRBX`W2D)ue)rnNG+z0j)T4u=_`@G66q_Ez7pvxK`)asXfrC2z7pvxMfH_P zUkUm*oW2t2bsQh`l}TS2db>lvGU+QrZ+GZdhTiVbuS~J8O!~^uzv(ikGW3tkEl1bd z%Fw^%a-}l#Z~LR{Hb-Y1g1!prt3YpKt16_g0{v8}J=)$^f!@YeRY+fj^i`mrCg0P% zuL6DU*s2Qj(_PK10{skslzp|*xsjl+O8TnM&v)Oe3cX!xt3n@+viq1-p|?4Os-&+9 z{Q{@2n#r7V2h+8-D)bBed9}q{HPTljeKo}1{$Hw*z8dMP zL2o0&YS8D-Csu>r<`b(S_BJxChP=0Ht}x@v`+n0}(BJC6p|$olf0W(k=)7nudE0qwQ{LBx z-rD=xlsUDbxAwj^^w!?jCVg$n``U>8Ou3S2i&-1`+$XZshTfjYQX8?iC$iM0yw@3A znLl;#a$=rQ0(hKZ@V4pK;Pz(%+<9H>Fbcb4)i;mz7F)K&OIorzTwWb zI?#9X=hfJE_ea?+rp`47eO=PmMeJ?Gy)NnNQs&gn=-rBYUFdDay)NnNLT@YXb)nB) zajy%#t+>}k>}|!pF2!DF#Z$?9F52~=f8QTz>}?LY9%W8F=xq+U9`rVcT#sU34|*G0 z)q~#Vkn2I8JBM5kdYeP8hc?Gn-0S&TtLsPgMW4HV)F4vUFjCeiQr0+9)+AEaG*Z?q zQg%e7ta+rYMWn1{q^wn>taYTUO{A=Cr0mE@*-??Qc9F97k+KevvW}6mPLZHp%PWb>vYgJBz;5Z zt*6?M^bMi6zG*|~!%_AcMnlp!gx-3p4KpoQ&KgET=&h&P5PIvWHYB~aK0)7z^o^j` z{W$vn*@*Owpx50l+FNP_ebKzkzT8HXIgLo)2ztBbHG=+ud8g4Rp%L^Sy8LYf{YU;N z`W6_6abT<}#ct&?) z(I5Vd?#7}|C!czS&P;sfkFsYbv_(%PpS#bRQ0$u^_NTdwYl7I<_eZ+wYfr*zg4o-W zu$oZpn^5eVAogd-uV`?P`WsCtbDH|R z*UV`Oz3uR83cd9=nv%XL^w!^Kn$hR%@M{Xa^*5R#bF9D7l=5D$lBwhi7yD+=f9a33 zzhV2dnvuR4>6<}s`?Q*oz8Um36Wt7Y+o#nG`rLh5&7ik^TFs!heOk>(uh;XSKZ5i} zAojMy?+DT#LHZ-0w;g^*P~IN_z4exkfc{*UIY&UByTk7Y=+ASxas>3}`=jhyt38jP zZw~!eF80kS@0(NJH;3NxzB%Q6bISYXlsU~Q@0&;SzB%Q6bLh`<`sRqe%_nLfDV2Qf zye&xI0(!gFwjg~A=06V&HR)SZ>|00mtx4aS^sPy+efd=Kjm!Hs(0}WXw8gy3t(vug-ug0apubx_ z)7ZCx-rhCXhV*Tqw>GB@^dGy-X#;)ky9V1p|B3t??V+?0eJZhc4Yr|LtD}yfZ%g{N zh`qI#ZAsr2di{SiYkDd-?0Cz8&2k3K0h8>`{kzohK-bRKUsKwM7hoJ9B`i{_Bi`kL%9ig`tvm^A@Vs@m= z=}7vH(El!DGR>Th&_A+Z5RI)mLjQ*w({+UYPk)r1IXX8I^qolG33}Vz)`>Ew6ZE#b ztrPUNyR8$&z7y#?L2tX;IzgYiyR8%Sw!5tp^tQXL6J?Ih;skwX=znrGq%-vPeCp1m z?+kq#m-n5aU+@R&d_(2?`iBiL%*ow63Y9|(06n7tuyr9{gKAr){k_) zDd@Y9z6PmW@!%HQM3*k9nTwLM7R1NsZywYCTJFSyyL9u)f?&|4p~ z2lN-o_q5jbfc}fCzn0j~t7lI~=mGu3{=6FdEBsM*>~#h==zEgBr^G(oxz-bU>xuP* z-fC@6(T6+NdXm1U=);|BJ)yTd*LsTn@H^Lfiay-A))RT(!}Zg9O6LvR8M3%`A`(C2YPsaCooStFT zOZ554qyD`5bnVCdQTEfdbyhsYzBgiT`rgQU>mm0heQ&SV9&&GFj{RMFlfE}H$9DPj zM(nMJ+#8vb+e7Y+%&{JFZ^Yhu$i01=qw7a~M4!8U)HhPrFH+V&Qg(EtY(S)JV5DqN zq-=1cY)GVRXryddq-=PkY(%6i6)77TDH|0jJ0?;#I#QMwDH{_hJ2p}_Hd2-!DN9Gn z#zo4;N6IEd$|gq2CPm67N6Mz;lxf~;{)O7phiXqB)Sk|+*7c#<)5q5yz2@~n?XhQc z_o3R;hiXqB)SgeJ9nyBU4{Fc6a=a(H4{Fb6uC3~W+ViLZO$qwGr0)y8y`i=* z>HB)U#-K0N{l3uK__8nQ`$BJTsO<}V?i*_RLT_)V?F+rVp|-ED`+8oj(?Q>l^!=c> zH`MlnzP|fQ^n<>IL_}lX4|;n;Z9mfYBYi*8_lxTLk-i`4`;lH-pP=s#{U7eC(I0vn zfi^oRZuacZ>tlm2Ka zO(%ak@6n=9`)l6OqE9D(`OmWNyF1!vj>i6I(WjHLdoyP^n)3c=(T`0Uy1&`cqE9DF z*bhYJEP1c2WKP&^GZ2~ck3X;W^;Y?#>^4WQ zl0iQR`ql1V4uXD-Khn&xT002(wep!}&LHRy*3D$jAj+IU(A)TO5cD=e8wC9qmky>; z!XW6^`SYrNy+6v<>-9Y72a|p<^#8i=4W`%+_OVy}VCa|1fKBsgFzE-AelY0=NA-hA zKNz*v^n|$opY#CS?fnez-rd-%yJEP>TIf z=xvAJP>TIf#NJxWp@_Y;m_rf!+#P;H5qsO=Hx#kA9ezV8_S%~Z`eCFW2EDcS!$?02 zdTZ~8L2vE-Fwzer{V>uGgFd&t9|pa(_rsvy?BY9&^xE%CC0pEQ!=c~mk2G^E_QOd( zoMJzmVn3Yp!%07!^uwdEA5O6!PO%?OdhH>nl5NgA0{ZR#C|f^*^dm?=g7hOuKZ5il zNIxQ~A3^#Nq#r?g?aQZ<9nPDAey2ZDy=6{{^eM`m6lG3|^eO0VY@dSO){j!q=dK^6 zpttp-6!f-!l!D%7#^dq6)<@6(w_jZ@~Na(H28411JB|Z{*yGwi|^c~&xa3u6L zz8net^YWQqtwuthdzbh~=Be=U1vLdQozKZ^9Dpg+ldZxqFTl+PS(;YUGl zqvKH&`%$DH1-@ zcbynbnKK&thvhTXkA{9x>&&%wH1sw)8BKXV8u~}%dzv|;q5q`zw=}0U8u~~5c~$?I zKg!nY=s4)}NS_CNWA~THquA&9*lXtGQRd`P?DI&U2mN08P1WZ?U-5}8q|bwXpFgk8 zC;sP;vimtYjt}}Vq#r~2F{B?u`Z1&*L$M!2`Z1&*6V;C){TRvnpdUjmrp`E|ecm4n z{eJiVc`Wq$9!rhyv7|p1dVNczX3nwDKX7&d_b;<|79K15aNpgrqE9CWTCIac)P9SeQC9<`t!OR*nI z`mxX_MKhT*7W#r8d`J4R&=-(@qfr|xu}>!j{ZY1FXL0g;?DI*V553*7nNRwBpE(-) zeCX|t&3wxHe9?!oRlexM9h>>0Km3l(e9?zHHuFUv?%2$i%n5gF>U>j(eVX)X(WjF- z?r)YReVX)X=m*}Kd2?2pVxJa$7}ur|dwE^e;|Jg#XgPL%a0)TX~e#WKgy21 z&WwdxJC5|@5PO@;9Y^|cUax=ManReBmF=qx+Td(AW1zx~tRn3yg=}_6v-s*pDau zc<61vzR$HU|9!(ocYXmGe#@{RG5*wS1;|KLPrKqceZ& z2^9MYq@Mu&8u^~K_Y#NOV7K9ORtGq^!NiS(18 zPh5*RiS(05KM8uhL6rz0NfU z{bbTlhQ7S}D@`W-WUtp+I~jVbwUbFdne>yPuk12sGW5?hXiW1tlcBHT&#U^X{wTYj zqqE{cKZW#Dptt`06w3Q4&|Ck03iQ^$p8~!0(x#Ap3iKOY?599K_WL%Zp91|R7wsv? zoX!5o^tygDRrI;*N7Eu@(<5awB4slpWyeLzW<|`2);k+LO` zvU79FwAO0=h1xTfYR^>E9$P<}N_Bs#ulw5WPDSmp^`og&_oq_rnTpzD>qk>FEmzL^ z(NxqPTR)nL+GFcSQ>oq6niBNWNIwnwDXz_!Ms@kkk>7buZ`svWmcWuUW(octefqbU=>Clh9KGV;h zPO+a(`svW$EZ1MvPltZ}e16~Jbm$lP^QwNaKeCofGe=vWpr1kd8Kj><`Wd93LHZe_ zpF#Q=q@NMh&mjE_WRB@)Q0B}e{Y=u&B>ha%&m{d!($6IQOw!MU{&TVpbK`>JpfB!^vNK1oJwZQ<^s}J1U1qZ=_Oqb3U1qZod)s9;i}bTdKMVRlT&m9^*3gdem3;B zW<4AF+%@aj(A%2zZ0K#xdNyT_UeAMm4(aDm=FFkYnM0W~2YSn+IndklE#{DZ4)peX zi#gEeKHp*v^!9vpq(Yz0HQsgZ@I-($1sU z&!gDSqu9?Q{XFPx9(^A47r8cP9`seO-$^ra^Ps=jpI7yl_@nGvtG&6PpHH!$54}Ah zVm`%wKJ@m4i22al6C&nAZ%?I}PqCj5{Y-bYnh$;M6C&nAZ%>GrkIb@AsB32!x6Ao~2IqCc-=O^dM zXR2Qa{UX^Uuh;K|q+dw-h0vcb-&6fU=zl4>mu7_)LVtljukP@x?DPvI_W53~efgkY zM47V)`YP^wizx3GL0?rqQ~e_7Crh%Zei7*xi9XE8ErR}am-maHANcTV6#GTcSM%r9 z*jM*Q8hcyy)lo;#FDCtB=7UUe(ud`o$9akU2U&N+mVjXU9Wt?e_7aPbE5j)`%WYu|J;j{&>;L z9{1^)yTp%2?4NP1#POm}VI1*)w(c^}s-g=6@CKwC6pin(&bz<);g6Z)Is3VbHM1vnB!5L#1Hze9h6`-b$GH@Z@4e=l>+M0At=tPJ#pTuEXt<2d=N z%TVmgKrf>t$(%CK_j*kK&(vLjGSJ`bepB>vh8KMq=<|$QM*V#m=;b_`Jg(@Uvu(Hx z^_Vg{_WH8W-(rtc7O{Waey=R)%Tnf)g}y_D5eOz^OP&4W{%9`y}lguw_1HU(w8HBIntLSeL2dUa?s!Aep6y!*pwvp z<)ELkbPL749P~xpHzfAAyHaZA$cjTEy2E}}9{M|7DK&G-lfFDlsV-Q zd(E8k!OSU7nNuF;TFspDlsU3Cl8ElI-U`s)?MkWo3Z$<<`U<44K>7-#uR!_=L45_% zS0H@_(#tANBD%+VD?)#-D~bL-S4tfzRHV$Q2z{GtU&BbDB4tiR%KM7Y-*0|XGN&T+ z>$|=}d0!Fw2i$Qba~^c1)Xb6fCa+R^_3|0vND#49=3m3W#}JqC5gTEIh9FYne>&R*FL8*Wlm+%SB75uoXXJ0`<%+q zYoAlu=zX748TumjJS=N?iRe-5tpfdHu9T{;Li#GCuR{7Nq_0ByDx|Lx)K?*W71CEB zy{tBReO1y|r5>{?>8p~yD(S0I=2RtpRnk`t>Z_8zDl+GB8_}wymvvF|lsEfXHRzvo zCB)wTD^(+XHPTmuUe__JL9bW&RD=F0_nXq+KW$3VYO6ut;jLaY&Z!3dGwvIbInTOM z>e)(GaLswxepVg&=UqwkI!dcf`s$>w4!w@js#EN%lfF7)ulnlH&wlM~8s}7p{spIy zKIcVOO6_xGtvM0BWIw9`{mZVDn)fwGUxV~DD06C%z6SKSx!+7Z*VceOey*(ny`F1p zAah=E-%r)cs(2!L)qYkJ`l7BRdL5gomR>Ido?1nL?F>KX;=8VBl{ z1nQaw>Y4@Wng{Ay1nOD_>RJWrS_kUd1nSxb>e>bB+6U@71nN2l>N*ALItS{y1nRm5 z>beE${s`1{57hOD)yb$`@-Gp+X4^|Gw4T>pDYf;~qSjN3T2C!%J+-Ly)S}i?i&{^u zVC$(xt)~{Xo?5Q;h+bMsB6`DmYeWC0E2ZjdlfE|TYm>e<>1&g|HtA~z^|eV~8+ute zOnOt#8q%h{z7FZ@;Eb(3R~^#VA$=Xv*CBl!($^tFYo*Yj2{jL$R0MCp~)0 zM!T-joA<`Ml3eMu!_MvNLSM+9zw1JO%&ZH_?6@xU1>Z`pOw@&5*U{@5y}w4TuFyf@5Vz2LHs7JA{2feJo zh`t{5b#6<>ryj+=p3(d3wCX`W-0JH=e_xkg7yI>yuF$kiG%*^=#%efL@=B(tz|0NZ$Z@eKJY| z=!?XjjM4yleKJY|6Z;a8J{hF}^1g`uTjVV1^$khi5PH2Px*=swL&}_n(CanP4Jq#% zlD;AI@0zTT*f)g!u4|^!%0xrx-?N$15UuuoS4xe&oX@?!5$PL2ug`U9MEXY1>vLTi zL9fqsX+*JaMEXY1nyMpx5WRG@{tc$iwR!lfE(Zy7SnWGN&>0 zy7Sl=dfj9D{k@ElyuJzPn~=T<>6?(g z3F(_q<}@LF6Vf*c>YI?h3G|KZ%5W2ky^Q9(zA5ROLVvC8tD2I&DfHKw&!op}3jOB3 zSK*A(l=MwW-xT@}Y~DA8zC!6+XkDc#^u=tZH--K~S4z!$8FzYpGtxJMUa!??M*3#Z z>$Muqpx0|Pno;I7BYiXI^;(T)(8sUUXa>DrtI-U4z1pD}#a>3pUf-Pb%}L*!^vy}% zob=5}-<6?>Y#`0d@g7hs&--7flNZ*3=ElA&j^ev#*Yc*N~ z^({!>g7hs&FS8D>Z%O)=&})C+5_;X8X$ifK6k0;B{e4Ty`HvLxcU+0RK1-?t>17qi>pPOZqtW|kNp&QBN78pRdjBk` zj->Bs^!`edj?n9~q&gb?|36ErqtW|kNp(c*pRt+K(dhlNq-4Fx>pMYT()Kx>5c`q# z%B)VL??n1eh0&eG>}B7G;szP*iPC+J7nt9&{oGba~6RlXBqKiVBvVn4=}QqNYh zGUoN2N#B|Dok`!B^qooH8G60ip)=__lfH9M- z_Iq7O-^J-A+FhXc-%EX4Ul-`VbH5_%=--=?%nZ9g|K_ATG(zqI{SWRN68j%rDK+-8 z+GzGEY_4>LUe^@5La*bTuB7kk^m4B43cZeVx+3maRN8*l&FG6oU%Ha41ezPlkj>qoFXT#c@7K+yB>Ha9U;9XI z`+ug!zMIkeYm~Yfeevj4^F7gbGx}mtow8Z86pN~u1Ld&a&uRXj+uV_InNnd_%56$T zY)Mvd6VX@J`v+qGwJV8UpNanm#r_Y9{U6ZlGx7gG?DdKMe<1ccQuqV0*JtAYf!N2N ziT?*;|EcX|{y^+MbEVYGk+o*8?@s#e$Q(V_b|-yz(szem&$Zp5*O5YZ=yjyf9eO=m zb%#EFuI&zeEgRqN(ARdQRK2Wpx3pu9?KUl(6{zbSsOuA`>l>)+7pUtW zs2dQd8yKh?6sQ{`~+@EMYU%FCi+n1K&^*u@76MDT5qbKQmI=#f8 zC-i#8?n(Ndr0)s+x2AWIw%-%_USnF(RR=wx|IYS6J&nFZ^t~&kp7W$ldwnm`_ac2S z()S{LFVgpdUay(xMfzT(?-kVdB7HB!{s*h?<$5lOn)E(i-<$NkN#C3Fy-DAj^u3|i z@kVdb_a=SspuRWhdy~F5>HCnr59#|ruX`AMpf6<4J$<0BXR=Yo8-1YHJ&Zn-Iekdq z2YTJZ=mULx52FwCx`)vRnWK9ceV{L571E>o*!LxUU()v_eP7b|C4FCteP7b|C4JwZ zzAx$fLf^=?+PkAFe0W6Zxu z{}=R?&2LKP`~`jdJ&%7uU&S3)^1iAorJieL&gu0dNk0;LJ=cyT{YdEbTssnaJ=cz; z*pDRrNa#0M{YdEJ_gRmGexvn{M4z+Cl~VOGJNEif(2unD`iz3Unf=}<(vO0^x%o`; zeiZcjF8fiW9|e62_baj*+R~IH_M@PWzsr6U^sU@Cq}8@|rPNj{^LVcxP5RNKA5Hqv zq#sTC(Udu(Nk1B~SN-Uqel+PvBk$W-{b@{bu{UF{B>@{TB0?#C{C) zc}(XjecTw*k0JdS=(n2hN$kf!U%F};>M_Sazs((2@;K0^_jhcLHG2PU*|A2S7JX`dQ}knvJ}tVj`xv@obF9&) zMW4Cj%C&hVT`BdBOVKe>5JM)4^uWcw|oe8Oh_3IUU_`C3Ex{$>S;SWo0Z8{cODx zpx3qB3DE03?h`2QCqS?FxKDsy?{S|%`U%kM9>xUdzp}BP0Db%(_X*JJJ?<0GW9mKb z6DaRx4bO~$tbQW&zq*p_0_bykCsOPuLa$GFo(R1@;dvtTdbXNK`iao%TgxUwAAf7v zMCkRcWfP&-x0X#Ly{tASqTj4{67;{jlIS&aCXs#;WzHnZoJkb>Nt8L0D03zSGiMTI z&LrqHb0$&d$hxR`8jAJ)4SiWx5`9J6UjC-c`5XF5<}=Crzo9>Qb7u6Ie^c!LHhRB* z^f&aCZRY$9{V!WLn_0Pk|Iy#jS8>Ocysu^ZoWCjdvVv=No2_@U(WgbKpNzb(VSi;Z z=_iwZGU+FielqDN8+}?-&KytroXJLS-be8JMCvgo8+}?--kGGwtl&!0W8Pz1w5&C! zJN*>WPk~;q#hyZ$Gleo|3iNs{_7uvTDMs(F#hzmH>5*QGJ;mtLqxiMhQ;a@6s%X7a zOy>A&v8R~W`)jdfRorLJRLY#G&{wj*GL`gGNk0|(*)@_^J4_}0ROG$(Ia8CFV}4U& zKNXpCUx|lJ=J;!|rzSJU9aqLVRb5HPIkJEBkI~2XkER9crU&X~1nOo6>ShJ%W(Vr# z1nTAn>gEON<_GE)1nL$B>J|m+76XrrSmIvxq1nO1>>Q)8nRtM_V1nSlX z>edD7)(7e~1nM>h>NW-HHV5jq#Oh>JDf#DH&p*_9{z2=}9hiTp_59;nPx4n%$9n%z z>-mRT&p&8Ax&!kMT2Fij<{z{k-GTYXw0*w=^AGjA(o(#B8tJEzej4egk$xK5zK#Q@ zL9aV7(?~y!^wWa+X{4WqbDr+NOe4LtX|JD7`st*fPWtJjpHBMe(Cc_(I_amAetJ+p zo%GX5Kb`c_`*{5f($9ciujrlueIa|cnE}0C(LDoty`p;tWzG!J&w#$TJ!8*+{$%4n zX&rqA^dH)D?F?kjN3N7QJDy4UnWUcyeVYB=Op5(Xiv3KA{Y=u&B>ha%&kX8kl71%i z=}wWVmmb~6eirFxLI1do_AJuRa(Wpp&4OO<)}BTBS)`vu`dLB!EYi;+{Vd8HIrn(| zY|_t$UUy(-Q|8QuUUy(-L$5n9vnlUqlYTbzXG}!oj6FM<_pu$A+0g3_%xvWSIUB>- zq?fa#*UusS9O(5rtvM9?ITZUj(Cd!-9MaDr{T%4^{-Zh2$L~Ly1HImVGzWUU|7Z^B z<$Uh-b4foJdVRY4T++`a{aonv>F#qWbLNtMF7(yxXlX9=#n;TGarRv3tK0F>T6yub)TydC==x?mW`ZBmF$+buD)u>F1Gt9`yQ@>v_<}pK?79dVR|EJm~c) z*Yha$GDhE}Z~Xis*`apqIz%qRVP=!@FCpAUV3oVzIY^Pzvu z9arW!ue(xe>}53P^$SS90QxuV_ZEszrGl71oS7eZgtWU=%)3!y(b zCJS8~x)AzWHq#eEU)z;Z`+FH7d;KEPFM?k8O&3w@7a{h#Z@LJ2-8WrCdB2GCi=cno z#6a|mppWmHE`nb7O&3A0`=*O1_A-|D`o*MQ4E?({+KVani=ltdd?vA941I-%k}GnH zDfWv=zZm)ttbQ@{IUeJuyDx^mm^-fI{YS2p8he>_c>NO6FM(cneV0(|m$!9N{Zi<44`V6x zx`(lp^h-&<6nfn^T?&1C-*hSTx^KD^dfhi&N6ejy8R?giei`YPQRXZo z{W8)o3+k7Vei`(7$L2E9%be5emy>=u^q<>|TTc4r(0^e*lgwETy*^!gIq8>^emV4| z%=e_#E{8t;bnWHPmv+aMy#LabQuAJB$6mjJ^edph&F&_xpuAt<@?QG;70_#czk>8D zNWTL5!sa(czXJMULlU%yu>$%c?zp1A-IY?$Rx*$G`jw<#3B9h!t)$qmgkIMZS3$ebmvlp1?kaq#+8q+bQS-Zi+2^sAuP zy9QT5uXhcuBK<1TuYz9h8e9c^{I0=O(ATl&r&Z9`b){6jtc`g6YSOQUUhf)QP5RZ) z>s^DZq1U?xSCf7<=~t6}bx^;W^s7m~np&-_;&}ZU=(hAm)ehu_`FTfh;` zk$xTN*O7i5>DQ5d9mRef>DQ5dT~NP{^y`e?>{;7c`8v|e8lKm$C;fWptJ|opr_5Oo zz4VdN->-*$P`za4tf$zoC;fWp^`6J|(8uq?SPy+IcUNk*n1L-$FKiK@HjgGKAHUjRBlLQ;!^ULh zI7RB&N>*_F4$LOfZ!-GyNUzn{MEXsn-$eRNq~B!pe#d>2(Wgi2Y@f5q=*@2Wr?Y6! zdXv$ccY@n11U4CcdbGinQtx?`wPy2_VjJzv(ChBkX2f21eK(VSGxWOayBT`j_1#SR z&4|73z-&hBzcOu5GG{YlAK&%ejM(e0?`ESn@71!cb~EL@tcrX67SeBlUa!sDLV3T% z<-PRqTcFo*&KA;dA^jHUe=>O>`Yq7Mug%*6yb3{!b_D8n2I_VN>UIa}_5|wo2I}?&>h=ff4g~5B2I>w4>JA6${teU}3Do@;s5=^{ zI~J%r9;iDJs5=>`I~Axq9jH4Ks5={|I~S-sAE>(!sJj@byA-RFyqEk-L=A1*--_1L z$dzQ@UY|I-m0HhM*LtMi-HO(uPn_L~)}wnEThV%MbHADT?8>cZJ@IE(Zbj=U;=Unm zzp*Q&_Pf$jynY+>+J?8G?d#Kiw~>Au>9;|z&nn(V`fbpEYmOt)+J?5T&nn&qef(L) z+n|5IdbgqN>(hR>QO_l9+T2BN|Ih8vH+3b6z3R732h~PXyWxef&=O-O%fu^1BgxeIn3q(#u)W>-Ug;59#-ieh=yQkbV#8 z_mF-M^vz8>lf2&()bD}5g>8#_pl|6)sd+Ew^R%dy{cNw%r$wz@Nv;j;Yx8d}>GzU; zuhE@|9Soz`BXPmB85yx(i|Y0<|o45TZa_8NU!)ZZOfuC5&5N~u>@ z%E%)TwXxoPh`s9fA@=%q;C-auNBVt;y}liIAL;i|?Drw|ZO!o{_WKa~GGni&U4VUv zeLH88KBv7arJk*1jO6wENxz@;`$@l_^!rJ_pE74Z>GzX7pFYoBuf`uH822cXwJ=K%FN z2S_jD&P3GF>JLKS$(2&aIR`2B2PyUkq1SQFLDCyz~l zLa%T0I7oUKA$$EH(jP+Xb(D69^oK})i1ddja}JUI5a|yE^@m7*2$}P^jp!lL%UC`U zb+(@!hF(W$hoRTE*c_(JISldSK0iPS%=sEOZtDI?_!VpFU9^}iv7RPKU6h&ed52Q{}=kM?pH+L z&FcS!zRsGW)aU#Q{U7cd(&uz{rPTgj=0}OBhyCmb>5oAFx%oe2Ja>fjM@WAJdVR9~ z5$N@aKu4he!u^Wqr6jRG0)71bM@OJ9<-Q>!h0?B+s+XBuBKp(n|AW4#D@m(W{ePtY zkM#eM{y&QSf6(h&4gN#kKW&a6`v0JhzZc*?==Hq-{~>dFIa8`$=A2%Cl=Mdt``-3@ zM@fH_^hcr3_(Ads&qtxxG3HU|Z+5>TvF~H`N1-qHL~Pm-8Uq2`ngi7US`K$ ze~k3Upzm+LcZ~GMoL;i(81&lOkCFZu>5n1ysy`OgA0z!S#9sBssMX3m-s_J;KfrpA zL;tn;KSX$(^v9w9#(XAy&T;7Vtp>+Qe;oS4?l&d&-iD-!Z>?HICXoBXGwpS^k+#gtBr|hw2k&T=*PH{#9q&} z=SY9f>7~y(2fdCI&Oxtz&N=AyTzd|BJ=dOtK7Ot}2fdza&p|)dnNs^4Sr_&C^Q1qI z*lXsTC;fTSpQp?@Pq9Bwu|H3-KOciE?1x~cc3m$pe}EqE?=N7f1s{FpziWO-4%hlD+6@}19evg>aGsdT@$Fg zHc)q6pziuWovfL~bLhrE-A%DN>2oCi644~vULy0f;Y9SeE2XxcD0AxDBBRW*3m|7X zY5S2$F|)R0-;x?-PJPE~lv&=dt8G8ZEMq-w`%z|jzizzkN15gQy4v=m%&BcZ$}DG% zBDU>IOG!kNtv3VoQ(P%kpMmrlNS}f98AzXj^chH>A*jzl`V6GcKzeD@UZ0Wl88eGs z_m47?J|pQfLa)1D8KKuRc1F@?gkE>QGD08U{mKZv?tW!7djF=*jL_@4iu68SpNaID zNS}%HnMj|B^qEMXiS(JE*WIs7L479DXCi$jioNuciD;_LmCK<2$CXku=Q7e?M*7Pr zb1tLIxs3FeQRZA0%$&<8b1tLIxs3GYuqpb?q|c1l>lr&U=`)i)GwCx^>@$--GwCx2 z^_fYZ8L`*(#LT3Zb5A0gW}}@2dL1ukfnL`Wvp`?Sw)QO0&$R1_S(2I4Hn|Frh4fjV zzs?;&`W#(P%#zHU*jur)K(FhGS)kYT#4MEea+dV^tfbEhy{;!_rPybs*k^@a*Augn zJ}dNHtv)MaKi!mMZl4wU_a>mX9y|$Meq|ZV69Hh??)aM|54$|i!y^Q9(J}2~Z>|dP|`mfDMT!cAEpA&jr zk;@6auE^yieNO1-y5CG)70L;Hd_^uN^tvLK6M9{l$Vqw`cP65F_P29EKi`#7`}o_MD^m?w%1^sRAH$`9Alq7RGKEm`AMH2vDf}SKlDZHctz%%iD;$$I}1R+%9T{WjS>8~LD6{Np{Vt)nn zI?lNQdL8Fn0eyU&a|QG|&bb1yU+YY%J*KQUc>R^6zY?+6R(mDsuO$7I&}*x`lJfpa z=yjZPCFT8rGyN zHR-P={nezun)Fwb{%VT-)ug|g^j8Pi&^w*O9 zTGC%j`fEvlE$Oc%{k5dOHmJXr^w&bK`=-}Y>}9pl>#rmIbss3Nq`#i@*F&#s zY1c!qk<10Z8l#|v6mHGufKuxH<11Y(%(S(8%Tcx z>2DzY4bbaa+6_Vd4Wz$;^fyrKWvw|8t+#*KjnHp!B{|oAZCmY)q`wh*ZM8R2-rq=> zb0g_*q`bc|nD;kQ-roqlw%Qv>FRS8Se-r6%qE>qo>2D(aO{Bkx^f!_ICeq&&)Zaw< zo1oWLdy~r?**_{|^zpTS^Z3R8tGgvocWa>Twm@CsK%LwJ9zU+!2_CPzBT#o|pzf|f z-Q9t@djfU$2I}q$)ZHJbdmvEvV4&`yK;6TEx<>+aj|S=<3)D&f8jqj!kMTO`594)m z-D$k;=|J5xfx2e{b+U>Q|Gnp9bu!M8{PV4+5Vf8{bk-2D_e&D8JSO!}Ki ze{)cOGwE+e+t+pUn@KNiIuUKOJ?$;f>xlCf=yi^B3+Znm{VmYz4DA-^b%u5e^g2Vk z1$v#K-2#1lhIR||Izzh!vDa%uZy~+(K3;z->2HNz*U@h!{jH?G6?$Dqzm;NtEA+aK zek=64j(#ij@pbfDq1ScvTM_$BHomu#Ui!&IwAp@k8}wUTDRo`tHqzfl`rDw_8QN`> z_qRc>Gql^F*OlnoppUPs+y;GLr$}8_xsCLNNne=sg%Nw5Ult~PVbT{SePQTzhE|yL zg-KsHs4qz5aI6-%k45Nq;-(Zzuij6#Lsre>>@K59)6x{q3Z`o%C`(_xd}a-)b}N z4(PwOW4${_e+TqB*1H3GouS=9vA+X)ouSkPx>n!0;=;O15JE7NE!ky6T zEa6V*b;n)CNM3&z>F+}9Reu-h?;`zOq`!;wcai=s=yjHGS5SW!>F*-_U8I-MTq4?G zqkT8@J6%a)ug^!noAh^+{%+{?$@+Iw=G+Z^dpjGy8+v`R{@u{WpR9j3^c~$dq{rOl zOtKF){Z?;-s?i2ZJ>zlUNkBjiN1 z$9{G%^m|=NVy{mjyBGRG_OHGddVLDnz0m7Z$nGWmz0m6uBJPF0v3)|sz0k+sT6Qn= z`qr|0jlM)Q-yJtK_A-|D`uj+KA7cNi{oZ{P`}-*N_d&1EZM+Y9ZMFB2{yyl7n%|VY zyZfMzKezEd==Hgc_aXNBWUgk$${{ZP9fL^cFcz`nJ0qFHwjR&CDd%qqa{R5sIWm*;`Ugq>AoOSKGf5sK{eu+y2PyUsQro`L(s>cU-uC7rEPnA2(katl|-*+E14a8{llbx7`Yq-&iTxwcPajz{gS6pCDE5z#{t@W6n(vAJ5$FdMeb4C2+@$YQe+2q% z?zoaU+g&MDFDnjS|0wAng}$u)H+vL%?N=V9ynmGP{!xnkqojWn`f}zsMgJ)Db%uRL zv40f$&NkYQBK8%WB2_PIBVPX)=^ukWVSnW@iv45IziU2|*gppSjfInW{}|~XBmHC0 zzh}ND`p2Mu?%=l+`^TVv-yK(C|A8x|>SYzj>mMim?;wt|YP7K1bGky#7hjKMB1)L+we@ zKS}y0p}*^^WPF|^{gcq^)Ayc)UZ0`%B=qrTs67e2K11zEqxa8Hdy+r}?PWJ_Y?@n*mQD_W!z4 zYTnCgqt`zT{So_rJ`Me5`)~F%>7RyP-?{cQ^!m=Vr%C@b^!fz2r=j0!epB-PY3Sqc zTzeY&ZSJ_}F7RpMTkUfc`{yX{pMzdo?Q_t_TkUhuYpZ>ZTJ3Wb zds!7vM8|EkpNIa0D@o?)zUlL%f1dQuCu48#pm?72&qJ>(BF{swE8x#3W54w(YPHWp zuPflsLodCH{JTEy^s;~Sf~k$K^S>CVdnr)&a-i;&K;5f>x}t%)*8+8~2kPDk)V&#~ zdn-`)cA)N^KwTnG_imu>y+Gajfw~U@b;Sa89|r0^3e*)3)TIUL(gSrR0(Bn;>OKk7 zeHy6yEKpZ6Q1^MPPO?$*&&+>pdwBt^=aeg@ww@QL^}Il>=LKp#FHq}wfm+WC)OubB zww@QL^}Il>=LOe#L@zDH>t7`Oi|Dzu?Y~I+7fJsj>0g9iS0-L0{fnf3F{po$^e-B{ z>49uSUnIS>=|ptee)badXIv>Y_AinCCDOk{`j;s7FOmKw(!UhczeM_%DE2RrUV5KI zbk=%bhF<3}FC+H4`}H#EUnc#_(ChBk%h2oY*UQlB?$^uE>+aXf(8qVbUWQ(Gzg~u3 zcfVdHz4Vh_{|f0}fnL{DUV*-l9R<7sy{@ag0==%Qyh54t3iQ|6_`CwW-UIUr^zmov zyaK)61M>~#r{=_{j1RH-rcLDe-(P&yL%P-Zsu>1 z@y4sr$M^1DgQRpwYlH|RvqZcK8QPLMp#{SyZFt;yC z`l6KgMWNSSfTGFRcYTG<*hQh&U4Wv{>n=c1(#u)W>t7@NYlyw-UnBi%q<@X{uaW*W z(!U11?gG3P)W1gh*GT^w>E(Q$h%VY_zYhH+SCZIkt9_mHuao|D=(W|pPWsoOf6D!) z+zaruDM{wM4t@N(+}EMk>vCU*KFXRLExk^98F?h44ED1(px0T#8;Jdzww=B~`Zu6| z%X}uYgg2nq_rSaXz23?22J|{hcmuJ2+k8*-Z$KY^56m0TzvGT8{e8lfQpedcMoL5( zt^Q5ubr;}G==B}1Z$e+l{>q!s>pL0VgkImt@FvCnO{4eE4tx`OeaGvY(8u5L`X==H zj@LI4dws|2n-qH)&80j2TSlKAss1hK=h}BUyhX8p3;KEXuEDpU?^P}N9Iv-1_HP+| zdUT8ZtKTyE^yq>)s>J>+qfd|K7oAJb=zh!S)1yo_qHh^}dUVNrL&gSg8GX9jKaz2$ zkNw*e`?sMtuNlYp-lo{U4gE9bGs&E{ld&(M|EJt%ts{lEDRbUN?9GDf4CD`I)$8+`_St%Gv6ou z`_R`jYc-NN??bQ8%zU5p@00$0=nhZKK>?^V$kcG zREj~bZ&E2nc`x&Lum6zrACmq<(tk+$4@v(a^xEHlNcs;+|6x%7A?ZIv=IEPLJ|w-Y zIC%X>r2hzdJzIT5`j4R3v(-n?pR{MIk0|yZk^Up-i`(_YkD#wp>g;-oJg)E6gxancv3*vl%8ALpbQ zeR`zp=xIiu9<8vgJI4#7t$#9X-4ngMUrOp>CtNQ zJ?V4Oj6OX&JdwvaX-1zO<*;YTG^0J$ z(tkqwPe}g>=|3U;C#3&`^q-Lalc4?+(tiSd2IG`-?I)y{bq1U%mehPj3EtQ`_uWzaR6ncG2<)@VQvV!aNpFv;1 z>OVv5^<4WI^o4Be`3!nJ*M0`Qo@+lN{b$hYx%M;Y^<4WI^zn1;XVB}p_A}`9T>BZt zUe=nuz9i{OLa%45lB6#Qy`HT~La%45lB6$5`jXJ=*{US;@v~J)==E$>(&$S>dbTP_ zdRZ0s`p-%KxzVRZPujEG=af00Q|5eb^l4F<)wz(HpOgM`qfd`C_Mb!lls(seZuIHV zwfC&0dF|&$pB_E!jw^l6Gp?lbTG>DP!sz4sN2LOFr2}Q_iLc;w?N(Rfx0q*y0U?~a)G+?fw~HTx{86iN`bn{ zfx0Szx~hS?YJs}yfw~%jx|*>%>4hc#64B+hulfS5=L%Pnez&phtG=Mt^98k@FVOZo zm~SV4Gxhm(Ur^is0T>2K9Qq*&mf?nTZQwn;0i%ltN`=y}QvqmZCC)@ExDd=mIx|vp@OF=)y zo}){l-<|48sd{PCX;DGzEp7B^(N(S_vDbHcmnMB_=J$h-QPmiP|u`g}(Y0>t&gXmo(rHwueG<{t*83%8 z&XopT!BKFsr?}`3P#J*tX z*J!NwC1QWQJFaBT4X%_r){}nH>%SuXSJ2;R`|GbL@4rIqZ!({W{wwGodL}tb_=@yj zk^U>ve-+e!Mf$IhIjaAP&Us&x{%g{I4ZWVRzoyLj8hSlre+|8!vA?Fg{~CHd=Y0*m zp0U4%K7Pjj8hSlre@$oXuSqZG9v}N}NdFD=`kv8mDE8k#uXCJlpx5_|ena|iNdFD= zW;%h)`3CyE(Q0%(dF@NdF!5-E7`}NBZxe|HJ0}chH~B zk!-c!QQm)N^nSGT9rTs$)s^2FeX*#2yNc;Qmq1U%!e@}V;J@mQ*^L;Y!Z_bRf)%O(p@1eiN#_oHgPmgZ2ea`nrpB|ko zFq6i5-y3~;bd&96zBl^xsE{kA&h2H4TitO*f14|%>SZ+N^*@sSN9YUN z@BIk9uB-eA{hKy(euTc{zsZrpkCZt-lKw~Ni&*`S&=+`T5$S(~{&sg<(cj@psd^cA z`d0fB@?JCNCuEMkbL}U}`=5|G+UNX)%+YtQ{Y07blhK>8h|QdzkoTqRx%MZcH&-hx z`<(WVenQ@twrAI$koRA@Qfl7I2-)j@CjHOQzhPVL&y@E+L$9&_8G4QV&!qpE^gl!Y zmibLN*ZvHBfx;b({u|e7e}?{TcU(EwzT--%dKt@m{V$~dB^i6$+J7PaFVO3o5`TeS z-<0?Z>3<>pFQoq^sQ-oZzaaLi|Al%?nRR&mucZGKdL1eJN}2O3^g2@b6?z>h{7QNM zE9rlQzL1Umuh2i&Z6wA1SLkoH(f-xwOGLN0QflmFe&qGPk^VR6br0h=(*Fj%?qU1} zz3yTBMzQ~m^uIx`dl#m{1|!vJM=joyPC%Lze8Wl9ar-HBUeg|z05hi zz6|NhK(A|BWhnM#pw~X94D`CDRfb|;hV*5i*EOv&(8t%b%0RDcT4fM>UDGN`@_xf_AF9*HeJynkM<)GKQr^-REcTbh0*q0-HIq2Kl{=OXa@w=zWL9cgD zl|$_H?x}K=_p;*P_2o%lp7iBOU!L^kNnf7y7-#uK>N?xmF>luR!_=q_04FS;g`Cilnay{SD^-kg-=q=%t+| zOQ}!vuL!-qW3wXVeMQn&g#JeJo09hxq0iHw@8GEj{Y~z;lJ|vNN%|b^F=f5U>noAI z67*%Qw-V_qA@=&WRD#}@QrB}Tk-if2dgodt=;L>;Rf4{}JFe*U&b3Muds!Lt`pTrQ z484xhDwDpl(@URI8G0S1Ri@ZiCVge-TiCp>oXniva^IcbKdKCUOM7;$jLd1}N~y7z zH9W7cLi#GuU$Wn;Li#FBFL_jjVqXRNOmfCO~&5p zt3p4qIG<~)Lf_RLSM=RnDfL_{>!My?4f?yRz8dtpZ(5D?)kt3rdfhjzM*3>d>%M6< z=yl(;8uamf(`wM`zG*dNj_#XQqr8_D+(dM@^;U;oS7EC|Z-(9IWvWA8$d#nex!IH? z_SK=k_L1E7|4f}3R)=2K(yBv$k2#+7In|*rdAK%ZPIc(-btZ}ZeXf)mds%Dt`Wlq? zH7M_EQ0!~C*h}8mpuDd^v9CdSUjzDYvn2I3pzk%N6^)QwZjf0Dl~BjoR0DOE44 z;$B~q^fjT^5pqq^*Mwe2$TgwY5pqrFbse)N>1#r-BjlRU$4AIDq1O>|O=Qj{oA)(c z=E(k0Eu)X`AJq=j)d|$q4b;^O)YT8vH3-x-4AeCW)HM#&H3`%;4b(LY)HM&(wFuO; z4Aiv>)U^)OwF%U<4b-&@)U^-PbqLgT4AgZB)O8NjbqUmU4b*iD)cp~t>mI1<5v!Ay zCHd!DPc3Rawa|Kgw0%`AYCW~6?bo8VUyIs)Eowcr(0YC{zbQReEwr8nHD9Nms}@?% z&+fR=bN%8y9fuS36e{y^i&yO?!PE($_)kb+lB6^mRyI2YMYX)uEoN z4(aPaucM_p(C?3pmg+#Sqoq1DTB_rEF3B9}eTuu-*ERa$(StVjb&cNd+t($1UDDSz zdcSX9mttSn=>1A`U864^>ArnkqyPVX`?^N&_wDN%eQ~#MU)SjU_2|-1`q>slF zdWd~9n{oA^FXT#c#%^v(k~#Gdd%f4Z9_i~L_BvXshuF6?-;>O#huG)&_O!_yzi(O( zv2W#$B$?CNl~OaOzR{;g4_j}2qxY-L^^HC~Qhj~W*GKGCU!U~#NnhXS{WWs+jXphE zXGXuGuaDT5{B#zr<<>{+*V_?teG~iiXoD-IuI0+PClNhj^$iev&71~^eHHt?29!As zpf|4|N9-Fwf3k0KgwTNW4G?=BEj2*w58Bu_Kp}_A5)Ln z5c-AgxYA=Ta;4PFk@LCNH-i3gt8awZAG3dTBhoi=ddd4n(C4^3xo_Ht^o=O?jiA@P zyGGC#8U8-$8$o}<9ar>a>}aVG`W&6($jHO%8w^Q_?pjeN&@PkM8<6xp&tTdcF6nsnPrUkD3~NdbHI1rsRE7 zqfd*9e!rdioTf&f9xZdnl|E;=E2Z}LGVUxEJ!$pLjJ}xLd2D9%#iLhkpVN%=%}C!2 zv47~HWZpNU*f%qJfA3c_qc0v6HNPqPW=3Bu>T+N+?VC0;`r^@R?znQcdfkYJ0kIq92|zIjmJob=62=6HQ`lQ~{5 zWBIh`DI5D1MxPcv?MgCIc*d1duQX|4^l8zv<}=Z^F#5EpK#!!p1?gLmzJ<}JMbDY< zN$gu7b5<9=M48jV=+mO--Eni7(hIJX+m!CH{gKQ%5>DUJ=*|6<_Wx{&*pG4lXR5v> zVz1XIwM6Xo8l{$$_brXy?>x3N`b1R9{HEwz8ohbSRmB_3NWtH^*3#(B8;jj>rN=A2&NhV*Tq*InN>&=<15(gu3n^=$*a?)tVNeH+rZfnIlg+dv=R^=$*a z?)tVt>~-I?4aHt&$6nu-^lg)wV@DWmN#7QF-Suq?z3%$9C4F1cw17`8_3cRC4tj01?MUAadTq7spx0L04tgD>wIh8y=+BscL20$^pzrm|7|NV>(4V#c z%I%;(=Sr!WBP$MG-=6gCp-?Lq2IqKIj?O`v2RcM_RxQ2TWx#j zi{HA3W+&~T|Jof_`kZfEDOE3PBVI38mHHmD1N6Eg*8zGR1$Tg6SL8ZCuPbsLNZ*0< z9iV^P#=Zme@fEoa(7$7&-2t&rxKgTKR&l((Bk4Or|E~RBM~Zz%=ylJ!BlNmw-H|e< zBk4OruY1-Vp^xubcZ6Q|tUE&gkyD6XM+&mujvv(wAmsx$PO zRh>!Sne?5Zzry^cwA#+l54-s`GduakT_@8S`YYXWCGQKmQflVN8lKm8A$=FAOI$BZV%|$9LSjKwsK=yCC*ox>9Q9$ZDh4cO`vS z=x5vhzAMGPE5*Jm#l9=)yOO>u^hM0rRAS#1`qJBfpqXJ;=x;awkNmrKh5im#O4ZA{ zsMmKReK+XuwBPGSvF`@`UFI{1eK+Xe{4jaEZlv!<`fjA}7SwkmeK*o~qr8_DT(AFw z^nXBq*2ex1(*FVdIrEw5|A4;Bok{&4l=pv-{txKSo9{{N|A7ANzN#kn{`qx(K!3p< zSMvU%E2YL>)|$P(JM=Hw5ps9v^=jtsr0)*BUd`McdcB&tJL$VauU9j7hhDE{?hbwY zYUb|H>($KNP3-;sN8Ks*vMTQNJxJdJdcB&t2jzVam-iC;9?K zx`BbZL4mr#fx01qx}kx(VS&2gfw~cay1xQ-BLj7#0(GMUbz=f`V*_>L0(Ij9brS-0 z69aXV0(E}}>Lv&3rUdGy#_FU`mi+Ur=TB-qf1>r=X8w=l|0%O$JuCm|T2Jz`%=B66 z^(uc->-iI{=ZyJH>AC(y>nSkk2#r+#MC&>0jw@~doGYcCv8APWeNWQ&Bz;e6`#nkD z6K!ArvYvF-=t=sXr0*Hj_auE!^jxa%>Ds~A_ac2SqxU;7y-457>80oDW%Par zrWf^Gy^P-P!1RJ%cVK!M{r~U4^fG$C1JesVm)<$q%jo?MjPyQU-y8au>{+8XVy|~k z^`^5%Z|L>zsosda-aXZu^t};#-GS*1{gZZ%(;Kn><kBiNiXM~MD(it ztRM8cBG(Uk-LvjT`hHF?t*0OK+G_hz?E68lJ23sA|H;Hv`ka2y$M>xJLI1OjeLrN* zFRqlDIdYavkBVA-f1~$%cm0jt@7?vMyzdXa?%nl=UUwe*lfJ*v`@OsVM(_9T`WtSeT+I{^AOoI>=wog#JTQAQpKryq#SQT;$< zj?Rt;QsxYFnIrmv(Ch4YAjN(lWzIlkj?Rt;B6H%iu9SMV8ceYtOtBwq^!{u$m|{N|nWM9W!A9?|7Z{ApiQnfx z7@4E@`42XFf4#t9&RT`yq(^TUI{=v46&%Cx(!Ih|^1-GX$~MK4%EUeh6Z( zXR9HI{j=sbCH6xQ`yzMbp_Pdti2ZZ!xYFN0?@FoT92p^d{ZP^mh5kkRy`iKZ3jIsw zGs&Ex&^Ng|xsE=R^g~HMl=MS``k|yBip){{P|6$`%X|GW(hq~aux;(bNI%TQUi8DD zuV5x~@-H!r^utI$4Eh|l&lv`No^Jdmm0{2qamSU|-|kAOv6oqg*AFNCaOktz*bj%k zkZnuDq0eSxKOFiu%>t(Ahm(Fd>4!tV)%=QN&T#1C?*$kR{Wf>XcJra67TaAQ%t^F4qNtrVe`gP_r$@`Je&we18IU^}^ zMnbRSoRNrqdz<$op)WXhGtI3=Lf^q=`bZP|5>ZE2N*(9O?AScp&gw@&|E?>^buzm1 zIErFF%EeyvqoCKF$5E6yqewprdc9+F6!h_($5GJh&f_R#j_y2;qP&-Ryw{H={b4CjDsWb?0$3^zog?(a`J8<7mWQcOFMm-ph)E*N-9n80hQT zj2lClGX{EnZsQo}^|_5>NI!=3W1z2Z^L`BU@#i*jwQXU;&}Zy(vO2)cfZC_=8S`0cfZC# zue)F4DE8w>KMs1`{Tc^-eD`Y{^t$^s4tcM;U*jlqWWCAj$CG|M^tuBxp7i5g-b;@; z9(wID$CG|M>BmEVg=tIDV~&SDz5_EJdfkB;554ZdjHlSk%9z(rApHc=PaypS(oZ1$ z1j?KVq@O_g2|@h?(oaCd_R%$ej@Z=*#3SZ^u6r(ej@27 zl71reI=-I>eSCaB5&F`$ubYV2f9Xo8{k^OY^zn7{Nzm7_-bv8wI{GBads!Ft`oBs4H}r$-ul!B=ze)c$ z^!ikgze)c$>Hmg)u=!2N`@f-&KNaL}=!dxD%DHx^E2WMUWCb@7y>FvEnKEZG^m@1K zWXhb$(Cgi@lcCqUWhaw+r zA^jBS)9m-AQ0%9;*h`-?1$ymsrjULL>8Fr>N>D$A^i!ZucZyWKtcrX6RMJm{UPlU3 zNk7%;CGV#~uOo%2q@POqsidD8)K4Y-RMJm%eU9uO{bTg;{iA7ty6J(s8G*W)fx20N zy4iucIf1&lfx3Bty7_^+1%bMSfx1P3y2XLIC4su7fx2aZy5)ho6@j{yfx1-h(*=K=FQ>39D@>!~sQFwJrPLF;+Y9am;(54lom z+n1JN-h*lT-D%Jlb0wMM=+*SosO?Xqwm%Jey_$X+^m>)qH0bqChH232Id2;D@vG^l zL4U%YC#KCoq~* zewfwIfL_NNGoT-CJ`?>6=*MQbmsaFvKtIBLUoz)In-4Q6_R>$Lxy+eq^l8yY_Wzuj zjJ^Gpna~%q|DH3UA7wt1yq^hu$+4NxLS|Ct%rts`J^DnPqs=oH@|%vHyZ|DE4z)?4|9`fnG;TbD-B1xjD#tT@{*xyx(gx zXAbgy^M{u*C8CerHF9&1_xs#&CGYpUQfiMW=X0;0OZvIce`0fNF2#N>^q-o~B=6@! zzx$D7=FFwo&n5j_=&M=%T<8l{*texKJ+@y zo==%GpE74YWzKxk&nNwS($5d-=aYUu^g2tJPkI^6dHn*?FMwXh*$YU&!09D(7C^7# z>;K>7uwUl7zUApHW;FCe{)JH37(=@&x3%jW$;%AAGJ@3wir5PE&T?n2TpB>h6@ z_n7ZV<}6I=WAE2p2)$V-z}aIV^mS~HxsdcSLiYMaq+bNRu4yfz*e`-!*R&QvuWMS1 zNWX~mi=fvvtwqqs*R&QvuWMS1jNZ)O?ccHpdff$(vAowWCjDaQ^_iKANxv9+eP-rj z==GVIi=o$1+G5f#hJL;6a~4D2?x)Gs0Z64EcB*vtIL>z9&#DfD`+#!}KRgnG27NiJ zUj}{rX-vzYFYk^kd0)YmQZq;9oL;{i`j73IVL9~e?Dv+Fe!0_2kGULr-Md>(`sL8; z-raKOb?sOL~CFxg^ekJKwl71z%+LfeV zN&1yR{YuiWgnqN_b5@dGRvi57WEJUG8GTyxiT&Ox(ywxQ8Dp-ZykBMX=B`RRK3`?@ z{u-rKMxPdaYJOABR;!FYExNJ$7@D1|GWxXWGk08>os@K?)Y*xwjrj5XYSOPZ`t;}# zdzM=beIeTlRzv@&`AqVDHT3;@t;O5mS5xd)lYX_)`zx$g8~y)ZVYS-m{S{WLP3+U7 z^7d-_)h71o?hYPV#qqIUL;5wz*jxP?qxaX2tucE4l;Jf-pB5dxC3$XNL$O~&`ZdYe zo8Oe!uR-jOmO4+flQqfMyW`5;vL#(9^=?^NZ%Ra;+IG4YdR-A&i@euefVGr4YhC6@ z?AIdpx(l!tvDewjTI9XX%GV!H^xYS$aRe;>hmqffqpK-%|u zq?fg3uis4i&7|K<`pu-@O#02F-%R?=6#LCV{btf{CjDm8%c{87Zz25_ z=x5s&vW4_ppr2ztlOA&m^kr^;13C8*y*`Yn_>Tby3@kG2|peE(=$ zpl*AhZbzVQXP|CZpl)}dZcm_YZ=h~ppl*Ml?m(dKV4&_$pzd&>?%zP&kwD#lfx4rC zx?_R5JF=(}6m<`zHQxE_d6+>*TJLc-{Fx-GxBi#X#MqSe=}MB>#Nt z*-EWvE47}j)Oxm3>)A@JXDhY+t<-w9QqQ$D*m|~7>)A?ef2(UfqL-H9_1j3ljr7|{ zzm4?UNWYEr+ep8S+WxknejDkxk$xNLrA>SNcG7Q$UY}C1o%GwG*QXS0hhCpju$_9Y z?WErhy*{O2JM{6V6l{n7YkTJ14!u65U_10z+1^xoAFtm*`W?{gSZ@dEcR;UWy&cf& zSZ@dEcaVMu^v{~3%UEv*^aXnsqWz;C(0}HHa?UI1N~tT+(ocH*PSWp$Ue{H2La%El zJE8Zb)cfvsl71)YcS5i0Dm$T%udD2YUe{H2BKEqjvXf%J%jnahuk6`;m(iz1U%Qfw z^+wux;x3B)F6edlYZqd#yI;GE-p?<08NJ{A+GX^9_iLBY|NrjSE~EFmU%QMxJ$l>D zFLxQe-~EzvkJs-e{cglw^}9*GoAkR$znk>CNxvKVw&tjkIlF`U-K5`5`rXj$NL9{~ zY0)<}+Iyh?)|FDn*?UO82YQ_)?15fq344s*&l2_+y`LrQF?#>jvOUnpX9;_t*IB|I z=yjaEhhi`1^F;KW_3lO9fA317KW5v@UdsEuF7IWuv=@5aao>x)*OBU8qc`t2bH5^2 zbnE+EpyR?{|7R z=k14Hd!YTK-w(acj`u_Vkoir?`~A=-?mS34kNcs2*d14T%tu@)b#^SHIj=uJ`UBAG zzUcwdA0Yh!(jOrG0n#6UUiVE8Kp)>XJpjG#n;t;yb>H*=WsZzHz5XES4?@4o{?!Me zFXT${ywcsKBzb=jdfh)dNcw}MKM4IE^F4|ELFiA$_Kyxiulq*_jlM*r`$q>!FC%2H zKScUN(6_Vw{UM6|A&UJWiv1zdA0quB=-Zp$6#XISyJWg#^4>q!kpIuFzFAI{xInelm0O250m~d^qs8!a8Q4k^oNl-sy|GvR%RVu|1atPh5mD! zEB{jF{0sdTHgo=kzL&kK_+RL?$NZP{|3Y8NX3oFR$FC~>7y8ofxR~3!QtCKI=0{$C zg!D(C*S)(V6#FC4>)zcF=ymVz2(CZG&QN&(%V2)CsBeUalH&Qr8`eR1#cL9!3-XDWrcL9z;ue$)pDE7yU-tS=? zGkU)ZaLnlce;44G(feJ1V@B_H0gf5H-vy9)yw@Km{c-4<+4gdr^v9uZZa$OPA5X@< zL~1D+s&Bgu%=}#EF**~%~v=c_}_b^Tvz2Cz) zVf20v4IPeT8@ z&HIzc`*t?=Cn@hwQr@3L>~-JtB<1}{H+P z<-M%pc>O8TpMqX{%u}R41-CZy1DZ04MUUhlI$NBVQn>wVVepx67X&r#-_gI>>8 z=b+ze_2;0E-)DUe`fb*G4tl-M`W!Mx=T@>VniiF}-t$JE7FBSi)LHp?(w~Q3XXWRi z*ID^_qxZA&^G5Gy<>!sw&&tmm{r|s9{JhcocZr`jdjBr*^G5GiL}Udw5mmI_3y6Is zR}y_?S4zE#{{r+?%x7}8x&VDqGkueJ;swf_3y8hWYcC-7Rn7M#?=K+s{nk#RebWnw zeKmJn8Rt}YrPR!kwPvrs2z?Fve_ll9=m_~D#r`7nUzmSg(O-nVmmMKrq|CWUd4Cal z9U)(YK0ZRe2)&MwFCufkw0U%q`W#sm_xekuzeKI}66r5NudVhH^xA4KQS2{~{u1=s zYA-<_Z?%`8*H(LpTJ0sLm;IwC%m42YWC+w{4Af-`)Lj;+Gk?tg?L%Y<)MX9SWee10 z57gxd)a4A+~($S0d8cag;^Y6ZNbSWs&tneYQxHMV{^+f3`@JMV{`i&lZWYNYACu7KyT? z_FU3ZygmczGeE!D_8A$VFXT$1-(pJAb7g=&&(q0%Hv{Q2kUj(STg~^R-^~Dh{G68o zdOhc5fPT9>ZmM3|wAW`OeMac@jGdA684-IuV`qe3&)6ABpON$#NuM#O&q(@=q|b=h z7qNef^gdpn3Hn+#b234%vxH2PIhiPPGC{AigiO%uT5cxjb(W9`dYvU?f<8V=$OOI4 z5;8%rvxH2fmwqx4)wbTtps(XflJ~k2eHrO5BmHI2>q_)xq`wS$J!4-6{c)Q)mq8!D zPU|x0YuWf-2EDFCUq*WA(Y-!1=`$nts?SXN%%smu`pl%yO!~~w*R=Y~L49V@XNJDE z{aZ4V-We)x_Sf ztH}A>XHGWKXMSDP$GdkU4tqS2kph-usn}GAA1{N9UK>5PN+mLpEei{GANh z5c{{SJ{vMe-^q}TGDk)pUZ0)x*`c3pz1c~h9r`)uGwJWML$B8gWhZ@h(r1TWuTRVl zef;{w?9l7=iP??bU!Rzr^fE^B`W&Rs0lnTuk^_3(Bgz52-bIoFdcBJz2kCQ=J_q!A z7fBB2<9CtdfL`w+$${7>Yz%XdUPg0XpA-7}Hpg;8uPbsnDfT&`*A=;((Cc#>bCNzM z^g2?=3BA5CE+_QyH^$|JzLoXnMC@C;lC;_)wj|?Dug^vLT+r)UZZ3*_F6iZ7LNX^; zQg7c5oQw3iNS_OOUCYe{eS9r97xcQ8n+vhmwcK2Yy>o_Mj#XdLm zI?l-ry^eEoL$9N>+@#M9{Z{i=OOKfw`uI2}H}uGMKA!h9x~lNWk@4@_R@A9deLeg9Ej=>IaGi9Rp%MXu-j zP4hxO(tTe>$fH~-HScA95&&db9_Br_|@AFaY^FgnDPCn@4 zeNH~;wa>|i*lVAYk1|JQa$cXG^!cGLYyax}q|Xn%_MiEo_odXkr}C3NKlJ5n?DIn( zzyByd^yS@gCH8v%QGU|PoYU(IkiG!)ciVGb0n!(6ddZvu(CgDy3n2D-7fAuq7l8g= z^P7@61)wi*b$zp*=byj3fO?yQnE5%;s@rh`$ z^=5;9i7QE~J#7Di*(mneDE8T)*XJ2!BYigLb$p)<`Xe@TvOynzo>4aFkGkW^Na2_( zrM6mGaq#-=&@Z+6?1;TSJ1{%xvy(nM^!n_;?4-|5nUfv*W#$NyIoY9q@;ZJhNOtI# zJB8?1xKgTK)<(QO2kCQ=J_qS@kUj_Lb3m_Ws~n`yLHZm)eGby+Fqz}^IVf{v6(G$-8G4-=-VA+wW_UC7Gi|QijJ(&G;my$N zNI}+{(w#o1(WghNtv)AWuTQ4PN&1|m&k4OgnIb3Ya~i$hS(wx4{gWwj8vTEtOp(** z{gWwj8hy7Ymz}reH2QAt-Y;1h^Rdr`*sDGl^m?w%1$_Y*f4H}t=` z&rdNgR+}68_EkF3^`qR-x3kgC4gH_)NU5z>RvSA->#R4A(RYg0 zyHe`&sq;|gO3a) z{%s1fE}C%qyomh$x@`Wllcm^<0||dOg?XBYi&T^<0|| zdOg?XgFb$)%?G`nYx5y<^jw>d`W#tnPDGom_ZH|kyOQMnkM@6k3&s8x7ke4!+ycGs zNxcPn?eA}aUiYNl0=@Q_w?H4?lX?sEKfB|~I7i<~d<*GiRXpA4^BaA7w8iT4Q;(US z^!Z7jAA0RE^OHWm(fb}VztQ_1Gr!UQx5vzH^uEW;Z(^SwHMiHS^BaBgSw3?8sDRPO z?=dMDs4EnxD;%gR5~wR0s7njf6${iA57d-5RJX6{ss6s4EkwD;uaQ7pN;A zsH+gDs~D)O6sW5lsH+mFs~V`Q7O1NpsH+jEs~M=P6{xEnsH+pGs~fA69#itq>`Afh zr2yK#o;3=f^-Q*Bn*!8&3ZV7qyX*^~_589gx$0YhdaeT0_6wlxe`VUW^t%Pn_T%re zFMziHwQc(a&~ts`O49G@Xh~X%*B2yxLFkv**+oIp7o@gd5c(gY&ir7ihW_y7lvL} zCJI9zUzsQjy{=3YhF(`D3PYb}Vp7V-8ujjlX zlsQG9*K=MG=;PpGNvL(x;JL&XS2p z^~FeE40*4krDCKnM*3o;FGl)eq%TJLVnKZ|(iekXM@z*>FX!__wAV(vIP^EVlEi+A z9j6qBzJP5n#i3tnK9jLtap+&P&uuJD`r^=QpHm$AW#)U*-xr5IOP?#u9LL|uP#pT@ z?zl46Tj5Hn{k@DlyuJkKOHiLvf?{6+dhK&cK(BpH3F!5jbqUg!fL{BY641x{oD$G$ zpHl*{*FL8NVxMMXC}SkAFG>26&_877c_k_KC82-Vd?v9k3H|Cd$#ZQkREyiv6vmzZLpy<~K!uEA;Uv>)#4}c6VIKoE)x{s+V!6*OwxFDbklBeJRqHB7G@} zeJRqHB7Lc#z7*+8nb>!Z?zI_EiZVw=$X;KX^rfL6WWQIM^rf9%GN&~3yYnXhN~K9( zn)IciA7*}2VqY5i`CThe=9Gqhh&!(6hq_W~>}4$P^<_w32KwRldu1r^%RoQEd?xxb z&_7!ysV_tNGNdm9{b2Jw(U%G8%aFbdVz2r#)MLu5!|ThEzAW^kt-dV9zAVMQEcEZR zPrfm(Ea}UVzAWj>2K8l0UzYS`DRX3g3o z)mNm8p{x8uVjr-dBS@e#N~S^yA!dC3EzOdo}2FJx5l?yuLc=tCPMu>8q2zI>o*^>8q2z zI_awi_0^%@Wb?i{Vz2t@6nk02^ZFXl-(+*F2K4$qf*Pc+;q=ny)PP>!M^FQLUC*fj zy{@CzfL`B6Py_n-`v_`4ukRzM0lmJDpa#WWRvW#(CiI7_z9#fb?O(7a<$X=)mzmE* zUlV%WA6AoMUlaP}?pI_dx$Y0E34MHjSWW14e^^bU?;Ndi-%ssxWL?zjYe9e5>T5y2 z)_$)R#l9BBz83Vlo4FS0YeB!x{fg+`ki()S;xQXb9 z_131muMNHKu&Pb5uMNHKu&NEc?y#y&`r4HDwUIgc^u5~9$M;3nhF6(h=G1|He1+s$xeoNYmR5)Kb)au=z9+G- z1N~K1a?rRuplsR=NbLv8`J5B0R?CV0W zJ5B0BuRBfZLLc90QWyH8)>{{`KjuoB_j3KHp3%pzAJq@kH3-x-4AeCW)HM#&H3`%; z4b(LY)HM&(wFuO;4Aiv>)U^)OB?5JA0(ETzb?pLm?E`h`fw~TXx{iUmPJz0NKwV~_ zu5+NSOQ7zyKwZ~BUAI78_ds2bSe>lrNdB1}l(xOpL+d%|O49c4vUyvNT2DRKdXm4A zI^L*9t*0Kf{d#CUcbngowqFme=cZ+S%ys+T`E@saJ+z*C+;OGt-|I@LZC_f7*ViX~ zeYAZYE!8J|ebU!Q+t;yEebUz_eSPS4v{WDZ_-Ls<^g3Fqk2AK8H|o<_L)x_0Hz0ij z==J(h1JXBedg*r?K(E)28bGh(jRvG|0KHy6YLJY5Y=2?{==J(h1L*boQ3KLT@8k6i zp+99ary=xu#%@UZhNN!@y`HffQtTT-uV?Ir(CZnyA@uPxc0=g(jNK4=J!3Z{z4Vh_ z-w68CR^JHvA8p1pB7Gy$H-cWTA2otr&v}iY*RftB=zp?#-w68n^`l16|Ll${d9POi z8qpbBdUUUEO!~&q>qxaR=^K;2G4wi8ZA_WdnDmXI*O6*t=;I^R#?b3XwJ~C^Bh|*F zZ({Tr(HR@0~ZMV{YGs^i4?L#OTd)%I$cg31vX`i$s+JFYyPZq7lAI+I(K+jFirAlbCFwCW@0*goDe0S1 z-Zv$EQ_B0Ml=n@8dEb=szA5E>Q_6cepL=~X(l?{bX-4{Hq;E!<(~R`ZNZ$EF4$-{hyHd~lGuM~|4PkC z-<03aryNX+oz6I%9kiJDw--7fl5PQ|PpxDc3&g)x}z9sa!SED8ATavyd z^txB0CFxs|z9s2f2K6mT-;(q#NiXA0uWv>AR?ug)D+H}b--`6Dpr60-GGtCG(zhag zE7G?L>RXY%73o`%UPj1X-RXe(HR)TEUdHlXpCEk#dVM-a0{Q~>|B`@SpU#nhUZ2j9AbkRQouMV5*QawNppQSD zBLTfWog)FgKAj^0y{>7=tRvm^Ic<#I>>jjzP8;ZTM|T^FeH+T0Hp$HClI+#mK(8Z( zHb(EyR&9*l?@w%F^#9$T*v9Dn{=_y$pB}ZgSKQkey?@uB%#VER+amU=ZwtN7?b}l9 z+d{8%`?k>Q+`cX8+amT^?cb~|Vt=10NsrkUv0whwC>r0lMeOf)-;f^j0ar>L-^)zS z>)VmO9rU`c(vI})px1SkcF^m(N;}G&cBF3y{hLDyD@x2L>sPqA+gy{^c$hyE^e1c`ln=xgkLkM=~jhyHG-kl5ej zN~vcnnH`&Xm;Edq`uki-&b2y1PN%$2r@T*xUPs93q)&%lN66{W>j*g=`uGSr9eN!h zrz7@%*>OWUwOX0SdwmDecR=h_-+}ZUNZ*0<9Z27S^c_gwA*k;_`VP?R_`U<_WyK*8 z-EX7a5&8#QNn)?pFgjA^bc9~7A9aLY=d~Rv?>kc7cZB{ga|V>m=?H!NPKJ)q>-D3K z(Camfj-;2hkwo;M^>%{(Ay*RpbbGGtMEXw9&oH0K*{T!tyUoJ1jGa1>z7xg16ZASt z>jZs#l-3D)9i?@GUdK6|NH426=IPwln_=`B(ZjAJdVRWf2I(`P*Jp!gK(EgR&oFxb z?7$48_x*i_(fenEXBho|pADX2^#0l48Ak7)4W422{z+J}-js+QvEEF?{!v#F{caok zOv?LA==a#zXF}h;douQ!l=qnw`%J`sulb&2P9|di#{ENRe4mNf?{mkMK4-rxrS_Pz zGUoN2N#7Z*cByUcohkO6pP7wGlQwJxOZLi#SyYmeCl z`uLq|U7(+7&re;D_j>1A7vz1K{Y+LHz5X`nAG4Wr8}#Mfzf64+(QQsI?esS2wa>YY z^tVB;BZb?bH`8}y&TY`gpRRoy^cCH4CH9qEDK+-8F6#ANN#7OvAvWW>Qs#7peyI6O zV&65H_p6dS$-9!iE9tvJpKkI%^1dtd@i*gkgzi@AkzUrCy}mo?yF*{q{>{3RzPr;) z?7Ks+Z^rFT`tGFfPWtXaeRtA#Cw+I)%c{87_aJ=_=yi3cx0&ot=)ef-*859syUT@UE>+FcLVYUTP-Pos}tKk5~z>m8`;6R7JOsOuM~>mR5a z5U3j%s2dch8yu(`5~v#*s2dij8y=_|5vUs(s2dfi8y%<{6Q~;-s2dlk8y~2f5U86N zsGAh1n;fW{5~!ORsGAn3n;xi}5v!B_Uh>bko}SctdQ$7@Nv)?RwVs~TdU{gp=}E1p zCt8nQ`R*BPJw2)Q^rY6))3qMaOH1+kUZn3u`d*~(MfzT(?*+Zi?R$~F7q$IfL47aM z_cD6_-nm|+mp1M7y-DAj^u0;noAkX&-<$NkN#C1d-#e)9P5R!X?@fB?eZ0O8>H9$c zs6A`+A$=d{A2XlHS)&j1`YfqFlsSD!--lw~C#dg3`aYC7eMm3;q}TT)eP7b|C4FDg z_a%K_ihW)tl3sdrukT0tex&b5`hKMENBVxG???K6lsWx^`hKME zNBVxG?@#*vr0);?Up904L$9OJ{?PkU>NV^BlsWxL-yeFt*StUU@q5ktL;sIEu8j5m zb*0ofj+`ZZ><5s30QCAUk^!V2K>7iQz5ZVYkbVH^2SBgyA{hXE{9Pmipx1Yi3_$ER z*zxiJioKlAy?!9+2STr-rGb<=1EJT^(m?2Sv^0?P14%y+`r0OvGR__deU8{$%LYQ< z%|?45^k(Xc+226ubuCv$9$r6)^n;++dte4p><3Zo2T|+?k$w>A2SK0B>IXp|zXxUz z^x3U<5cD}*DRqt`V4!i+#(r-I#eN9Ieh9^W2*rK~>4!i+*6N2q zAK$An1p0CAxT4p+8bc`WW!&lYLrFgr`U&<|hEnW@LO;=bCb1t1{qVNQD=5_;XEG%}g@u{}y7q1Qc1BcazlN+T(A zWG3hJqo9A<#(os^x)ME#GG`R@x)MDK`rURVdKATe6!dxxV-)nd5aRK>w!gF~>k3 zzjikU`nPN!IR>$R+m%xDUgq(M=sD{h3;px1l&T*~`mv-ROZu^-A4~eNq#qm9k0t$B z(vPLs%Zfv0^n&${Gy2TvMOTs?R$tk^Y8>gu8GT0dwfRi?`*B8}5k33V71zpKd7RPv zYZ&8<-e1EQXY`rTH|BfN=ZrJ@%;=rESuRU`M)EkL&y2ox$CYas-@8)k`;TO8B;oYq z5qs5-N8W4Zj3@ngiv4(s{dkJ~c#8da#9qgk;}QG#7;`*guVc*dh`o+6$5ZTO702r* zkbVO6KiL2E1kz7{{zvnf#C`(wIa(%13KK{_f%Frg|H*t$Vm|@;k{=hP{(b`VKfB|~ z+3FWpO3iy&Z}R$yq@M`=ul9QrNk0+#-^^#Cp9uXgCR~y^6G=aj^b<)xF{qzN`iY3W z>L*g{Wo69kCy{;<^uJsEB+^fUUT0I2p!cQJ=ao(({Up*)3hF13eiG>?kzUsDynZt2 zCqrM;_EnQfKN8AwsQ%FCB^iwGI zvM%cNQ%OG+dYQjSHcut}RMJm{e*V+?FHdg6s9uNIwmF z9i>ep{WQ`~gI-5z(-3-c^;WzKZcPlsN|_tT+|kME~LujBja(D%1}$8_k^Y+IC7 z@$~2=tDj-?>5*PHoniEyqQ*AwXHe{CQ0!+wU!g+s%Hs^^byhyZ=>55NhS7J5nwZ~| z{(gqhr$?K=e23nqFvI9OMNQpt<++W`TgELM<_7BK z1?uJp>J|j*76$4T1?mXroRmImsU1?rXu>Q)5mRtD-;1?pA@>edA6)&}a<1?tuZ z>NW)G%vRO^{CzhC>NW@Jwgl?72I{s2>b3{!cEswWHzRqRudQb$^<2_Y5>7wM=o69ZXQAiP zcY4nv{Vb=K7|eoR&xf<9=bA-5*DUDuo!+z1bH(53Jqvn$r}r%A^_||cNH1;L>t~aG zHuNoQA2*xyv!U0gG0lcvpT;zs^s`An8~Rq}H>KyA4SoD+OtYbH?T#xW)r2d_cq7f0 zr1$aqIi#NheJA%XQ{VYF2l@>2nT$8)K>tnM}d8D5Qz3$VR2fgmonn(J1(Cf;? zJm_^jaUS&XeOmLN*L_;^px1p`^XQB{pY-!dKOg#OHrn$k@8?4=?Nl;nKJ>azYd-1c zlYTz*GtBoS@8?4w-={Sn`kC&ylJ~P*DK&HCEa_vv0Q%Q#>=!`)rG2i;0*d_t=)ba0 zrC9*|;Hp_Lrd>e#1<>nS?gHq~nEP==zX19lp5gVx1<;?h_v|b{?9aJUYO9s=xz{fw z{X)_&B>h6tFC_g!=ykNTkn{^lzc8p@Ncx4OUr3oFBM+}%MEXV0>)ZMkQRXb7%vl7z zzO8Q&=@*fH5%l`DzD3Z--`2MX`ZW7DUj)6rt#1+OWsKzYi%Gv2dVSyBVv7A@==FVf zi=o%|-7O~lV$v^${yme$k~xc^kH5ucG4$`-OkWKB2dCnPx0Wq2djC%EB}VVpw3ZmXf1mmiqxbLhUSjnBeW&*lqxbLhUSjkaQFl8_ zSYl%D?;4bGr;q(o=wG+3b}3@N*8Z=TQsykB%vp-q>)os%@I`4&qN z`}p0mOA-4G?iUjh9)R=)z7qvzTc&=;`(>lM)JxpoEg zdahkTnX`gg?F#7iT)P7L__=lk^m?vc0ll7USCC%jM_#{@^eds)9&;tdekH|zCG^^3 zuB6znB>hV0wZ~iueZ0q934NOFF;_ybJ?2Wvdzs03{VLM0g8m&F?Nt=}RnWg{K9iBc zD(LmSU#m#Jiu9|Xf6shR@_rTc@g8#(^x9*tf?j*fRTO)fb9()1(yu1{YSOPJ{c6&$ zCjDyCuO|KKpnf&!S3`fj9U-qKz08iyJ7R67uYq1$?HcIk*zc{O%vs|yN80`x=yh(j zhV*No*D>ZA=;xZ>l-RFF%jD(9d(nl^%1xE2W;TWFDW0-n06((7*3W(&uR2 zuOnL;9 zL9e^%*FoRj?xtS{y`HVsL7&yOo^{acZu)i5$9L1OgI;&juQU42(MQgd8hcqA@%r_o zUysbu-Sq1z_Um2jC3DtO=By|EdeW~a{raGOJ?Ym&ue<5jQ{Kxej@NG>{RZf(+Nf7_q{RYx+ApHi?%X*X7ZzTOj==FZnjg&bXq1XFOHzxDm z+#Di*iH(%^8%e(r`u4WR+z5UASyCIJPq$Iqh`jIUN~xJ6D`Q^2iS(PGA7j6_iDJLW z#a_IdD04PZ>^G5q6ZE=AX%qDEJxZIP*XP%5f?oG1ZKBxA8eV4fv27EZNxvETAMH7B zGsS*0^gr2|;b!RXt#B=3znNmc+2}Lfn{hWAeP;BDIiB>Gn~gp*s&U0L^k&@6MxPmd z>P&Lg_cK>YeS?s!Hl|0P+t0QbeR`yQ&KBtN+t_a*{TAp8n$INfw?Ln}Qc}N#^jnPH zucL1<`VLWH^F7gTG5U_t>@k;L)-mP1zFUmGLsY~a_Zm|w>PnJ1X|^Qmq6w$pO0nMx zeKi~Vt&}-ip|5UZzZLp2`;&RUl`>~5WzJS)j$ZZMip&{5=pS>o^3P@8ip;6ujw@%Y zny!?Z_p*ZP_1j3l4SKzPw2k!JT;5CUwE=T5UgI=#6Z6p0Q==J*1Ht6HmkG4Ut z*N?U#@Adl8Hac6$T5}@$!e-8P=)ZI&Ia_Iezn%2konBh)cIb7au$?kzJL$JWf0Mc2 zUNUDp^f@}$qATv(q0egX$=?orHdjiGy{w9R{SMOaK<$b{c*B`q8dH-R?l$o zg+Sfyfx0^ab$15p?h4f19jLn}P6L>_qF)b(NiHJvvg|iPod*Dm&47*4x&z6Rjt{uCf!YN7q$$qV4Ot%1-LJq@{TM zF6h6p`dw)Idi`h@>32E3#9$ZoT)RlWi`xD!==J*1F6iUek9I+?*N=8Vuh)-u(Rf4J zwAb$@{ch<0vVF#G((fkyZqn~2{ch6lhW>9G``ysT@59&){Xg!wsrO;*CcX4NUcZO* zd!W~m>K^KM_du^B)jiPblTr3SuPf1eNWTYq9jWd~>SIqm-2=UjRQDkEI#S(3dg&*< zelO|w(ph6K>Gwk4)5J&eelPTT*4Rt>y`8hfGFv<1OONjL z`$)eJdYxbHBmF+;b$+=IdYxbHqs-Yy`hCz3Gc$EL=k0_3iy;l^jJ*%~;pX2+o7xBc z2v^c`o_w~S^!rJ_pY;1lzn}E`Nxz@;`$@ka`jJ+@Kd9eN`u(KePqCM?q>udp(jS06 zr(H!oK>7pF=Q5v3<{W_ju-)Nzfb<7Qe*pSi_WIEQ=->FY2VFNk0DW$I#pnR^-`alg z0Q70LMa%iz>kpFtAoMy?JqW#y=MF-z*X|BNuREO%La!s$gQPzQy^d55LLVQg9)w;; zst2Lhk?KLx%g7@UeP{n?hoJx7mE>&ovHgD@qSzmT{uA434?+Kr=}IIU4^iw7k^T_$ zpPKJU-XDVgmn;X&ETO-dOkHKaf3-R8XYRPtW6ri2aESCWM)LZ@q(6+SFzF9N zU($RgnR6KW79EoM!_aGwd6@Kvp-;1Ue;E4S9}K35-mmj~Kn*r*(uf=Llua5$JWF))CSlF?v70JYw{IpVkqh|L;DnBS!D{X&o_{ z6YV?`W^X4}tbB-E)M$}}`2Q;@oYV>B8xjU}R?O$}I)VaNkkQ32Q)_V+@^Rp{S z-s?4tW0X0^px0{{#}IqHhH;Ga$B;R?mU|4Dqt`HwA#>u_FpeQ}^cu!7v|7D}ag6d_ z#`0c&ob<<$_qt!;IK}=r#r`<-x?kWp>5r5CIP`k;>p1lB{Q}3KpJ`j|ap?8AF2|wQ zt6wtf@cI*^KSBBvq(4FW6Qn;u`V*u-0sRcy=bQ-YPmulu^t0^$u}^n;nREKspGNFee;WEZwzZ#zzJUD;o`!y|`Aquz)6nx$eN=ygTz48{Ho>CZr~D{^O`kFUs`fnHbS&LHn~MeYpsIWmv;`m>}z3%%~m zJ4^br(Cgm3v(W3_ytAY~OZv0W>)yPx(8u@YorPZa=ADIJ_vW1?y{tHR{W;Q~gI=#; zoFn}?%KLNB>otsXq(4XcbI?C#TkSdMbPR~KF_dK4XK1bF@y#74t&qJ?Q z0nU^Dywl4W`#khI{yb0m^Q1oyy7=$zW}}NEW7}Hd}rYW=yhk|1?bQMb?qV+ZJOq1XKaw?iM_FK|2bX?ErO zcIb7#!0i-!SsBZ4{rw%Jzr*PL9;G{s-tSSm!|44Ur8|t??@_wL==~n0JB;4%QM$wE z{T`(|jQ+oSla9|BH?Nokrg|`qh{s+V=qMD(ZC-%a|vq1SWm-K4)8dOg?P4ZWUg?}lF2G4H0> z-wnNoYU&A^knj>oYU& zfnJ}Pc@O3NJx1@xIrkv%TiDFG2YLVCFK6kA{`Vm7TiRT?$LRetGw(5Z@1L0|Yt3GN zFX`_k{k^2Wm-P3N{$A4GOZt1EUt?E9?hWeiCH=jmzZd!)HjiXgJQ4kEV}Bnq=O0%} zT>-xjdOaiE2feO{+y}j`fZs=%b00ECSHSN>=I9FeeaM{n3iy4<99;pw&*=Tm!uwp0 zDc6tgH~RSXqXzi!p~dnr)&a-i;&K;5f>y4M1AuLtVh2-Lk9sCz3=_jaJ}oj~2Y zu{s&0N&Y3Ge{FlYAFU_4BDpqoKia;oOx#ax|9-R{U75Hatw&cT?x)ssKU$B@FYia| z(Upn&(R$)56ZfO_=*q)SjYBKv-cK z=zE#-uZ%Yyg8q*edYIX`~G`>hyAiN1@lV`J<$Nl=P26pUwQ`MgJ)D@u!eI3Vn8)9gjkv!T&{2rrLE9Y~sf1LD> zL$6QPf1L9Eap?8Q`j3`#0(xDUc!FB3jFG(lNzy+F zy{=3=NwI$tdR>`#5_(;kc#`x_lKx5Pb!Fm7=;JFBPeQLN6Hh{~D-%yr>}53P^-q!h zDd_d;*Hff_3VOZz^%V4a_3J6h`=?0%6!d9!P3tM><5$0)f?ltFJq5j9{d$UGFXK+H zf1319L;tT`8GD*C=V{8ErzvxuhW=vPUq4Oyr=gF`XVT|94gKkrBk9`R)6ie!zAv+c z_w63Jrz!R_LiYM+NdFAKu0)E-mD@`)&m9UD9gz4qJBLZ4=1@GQmtS?G(I&qV($ z^lywz>Yt^|d6x9gLSNj*{#oc7d|Qv!Ri1_ZVrLS4NvBBF%d8_2U1I;`bI@PvN;1FH zan5t3f6ir&=%0gL$2reY?4Kk3bI|KJ=ecC;W8<9Xpx1HEbI5xg=R8MwFY_a>f1dQu zBlbGZd7d)odFXYV^E~uA&Uv2n&y)Un=yja)JoIU?anAG5&$rQj-st@}=Xui0OwQ|H zApHx_H@4^K7bx~GQ0!lT{_v+)Vr23HWzGwve*yX?cBJqE^fz7oF^zLxfWE0au4GO# zS4th{$eh#bUnKpD&^Nc=dy(`nI=zf@UW8uT%ZsFck@PQ;{>7mFMbf{B%u)S|6nmK+ zd;R}N|3Bz^SpEMfbN&Z?PxG1N{r{lX9ajG%{r^b+zhvHQ(0Z0uhqy{wIR{VSw@1$uo`;wz+oh4imLuWw3xh4inG{uR={64bv!`d3K* z3h8AP$Ln7u{j1RHn-X6o{i~#Z6?%PB;;W>8mGrNY{?(xVRnoso`d3LW>rGz&8tGqy z{zv;adyVw3k^VL4^-ks2px4>SYovb-dR-BD4f^<<%CABHvpcS|TD?>GHRyFkL{`SU z{&mv7PWsnL|2pYkC;jWBf1UKNlm7Lf{&mv7j@av+%CD1N*6_Uk4br~>eN7vKH=r-z zN|%`L)iNb%wQoTGOXp;3e}gjT4d`_(?G5NV*%9&^(9ce zCdFRXMZNwl(!T}0zW3`b(!T}0zW3`b==Hr{Z;}2j(!T}0zW3`b=;QDGdJB4e@7G(< z@3*mki}bRBn;uqqYg>OKh6eHf_wC{Xutpzf1E-KT-N&jNLy2kO2E)O{JK`zlcPb)fE>K;5^2 zy6*yY-v{b`2-N);sQW2U_j91`mq6XGfx6!Ub-xGd{s`3l8L0a!Q1^GB?w>&2zp*-L zwUU3n^}L7HbCvD6-b3s8&bG7nsP()@t>-mN&i0dI#PX~^zW1Yedu+h`abF3C;j`Re?O>ypY-pO z{(aI*oA&w-NdE!!I#T_B^dFG^1L$?6`T^-bApHlV{~)OUfb<`b{sYoW@8k6!lKw;J zb)@htTUt^+V`&r1~N0KZIUKsvklhAE|x_y^d5rgkHybAG&^5@?QE$um6bj zA3?9SSV<0I&GyzvqA`|Wt+BhpKco`|lt z?et^luW=Sq0IRNdYv7ALi$fg{|V_o3F%SoV7tm{u`332}pxA!_z4n-2K(9UK z7o`6JdhId4fIi-1egVDqm|sAzGqf*AFQYlH{}TFZZJ+Zc^e1fWzl6SkE6MCw_a}Y{ zz3xx^68g&SU#9L){1W<8<};b&e3{h8_9uP`z3xx^68bal*HUN4GVb*HuSowD^dH;r zeMS1O5c^NeXOcNzL9chNeMOn`6=JV*oUfq&)at*2K7QxgSI~dvjw^F}y>sm=#9r4` zWQ6SXUz7f8==I9u*QEa%dcE@aHS~Jr@oUn5P5Q5)f86T7hCcp|*RP@1cf5XWV&6H^ zcf5X0nImI)um6Vh-;n+r(tktxZ%F?Q<^4CL|AzG61ohvL{u^XYAG?d{8`8_H!|T5# z{kNq5mh|6}{#(+2OZsm~|1I?ThR|<=`fo}9E$P1{z08li{yWlt2mPZq|Gp#rchEm( zK9juv4tjk{<#&`h-;w@1iv4#%{dc7Qjxy&v(#uTF>%S-c_oV-x^xu>Id(wYTvHza* z-&5?r59+@s{r436?@2FnPOtxg^gmGM{6P92D06kH-`$l`drX-fd;O23{}K8z_Ip1ju|^gojRN9c7`=tt<| zS73gGURQ;FgkD#Lex%sTJU%13&YqusGWv{2&sIMfy?=wyPZax~jNZRN=qD3<{|2F- zjNaeL@RQN|6}g{`-oHWUC!_!G8-#u`djAHYpN!tWLFgx=H@|HoDk~0|(e+mUv(aZp zH@H&j-LgMZ?0~Z1nza*`J};yJdei`v2Z7`!n=)of2G*}O0oZyV*e|}{#T0quff>=O0oZyV*e|}Ue=p3oc=e`|3MP_IknZ=yPH(N9=W+^SjX}A|2=aPO<;p=>0t~zZ-ob(jN17qfbQf9`kpjPej^d{%-W<`iyO- zzZ-qR-ES&uco|VPtN+93&0oU)%Rdl%Gu^{gfIld6{-DhH1F>&kLI0(^gGa~re^BiI zF#3#WzxhoWA^(BQ=~C|y-9_?;(Pu;l+;QdZsh91}!aorE9riO>ZA?Vjt^QBMK8Gu% z-iPrg>Hj4CpNPHQhw&%H{!heyojYFY6Q2J>?Bn-g{E67>eHect_WC5EKPmRIE}9YD zY`uRW_BmZi^m+%+Uz9n2L9ci4`~|(I^@{jr2m`p z{%_>{L*_RnbN)u```>*J?UVT%v47YdSH|~`xKe7~%UZM7|3mtJ&}wtr|I0t5|A+Md zK;M7!>se%d?jO?sL;8Q9&tra5^#4FVdYe2AXSCbh_7C)V-EpPW=5wXgagMBtd;Pzp z{}*~4=lo0hf1O^u|3a^={a?!ae@Xu@^g7P@7y9@(=U?b`obxa8UdK8ABJb18UqY@Q zMP|+tzkYO4pe{?G?&3h*C4st219j%V^q=Ei9;mw_PaGja zT_32sAy9W?pzfwXUDiNdwm@C>KwXYN-OYizoPoMrfx6s*x;%lpyn(uWfx24)b@^j; zlJ}B-zV$@r)iH_a7TeAu^Ew7ovghyUa(Ro5wvgy@Srw9!j8vn`amM~2`8JQ}^3?av zMJBBhk>2kt8yw8lbn~0i_M^+?j6J#KWYcr`yGWwT<&0gx9aq|ZL03v``_fXp{vy&} zMEZ+Je-Y^~BK<|sx3fLvMWnxo^cMy77m@y=%SB(v>My!HRWEJY>$8wP3+c0vJ`3ry zkUk6add|y2`Yfc+64YlQeHQ2oTYVPNOYh_L7nA;C=-;t1ycqfdt|XcBt|>|8TnxQF zoBm?bUrhRop?}YOPcr9X=;P0(zZm-W-H{~r*V{Ap#n9`Dob;0>4{fGj0(}8jlDyYz z7?)7&FQM390=-_txPn|n! zrHFkSd)!MY_LoB6)_f+hzZ80XcHpHH`%6iGDfIW5?@8=0g?{-{qo~zh3jO`=xDxvZ zTq$+DA?F^`qHVMq_)xq`wS$U5UO7dR>XW40>IOzKryjL4V5XFM~dQr~GBm z>q_)xi2WI>zl>sUe%j~@S^eeE7j`AdoN4xZms93kPMLE#^m@L$4#%%c0k+ z0GB8A6*ijK`)8tMx=Rvg^7Jeq;s4rNPh+CuQ2+I zNar|Lkp2pz_vn4Tw(MXQGAYbh0*&t&J`y18PP%ef4Rcw{SzW&KJaYUo>7{ngNS|Mnv2ucpko zn)Fvgzu(6GYUt}c-iP#8Lw~ou>*Z?b?{TG6y^K4({u=0u*j9TD^qcKj?iz~yHI(<) zK!0z}MHflzuOa<4(Cawo8tC;t>uaFDvr|smBXpguOybk&!Hgm2^=KTjB((L#;=#RSN%Ix@< zE2ZjX){*Y?*BiZgUYY&BTo1k8>w7)vuP6QW(CfXv*Hi4TH+tV=UT^gN8EV%X{ePdK zcD>R2XQ*9oVxJz}Wn16%rq4-t_gTyQ$jAN$#9s9`K(8xuH$Y#&#^46%bw%z5=ygTz z2GZYv*y}jw2E@LSX@k<|+<@3GE?SoI{szRpvTdg~7=7ociYukYUS@J$eBOSzKh zWo1HoH<=xKeOBmoW|$Rv?J=`b?6XqrvqG;uW>)CUyw4sXb!M0qdhIc@LLcujvqG;u zW>)C6$IMFSTA9ateKyi(gI;^gY^2Xd`fSi^kC}~PpAE6s{yrP@+GA#eKHg(ygI;^g zY|t08J!Ur2%Zh{7XD5Aj=yh(DoiZmo^g6f74!zE;vXeeL>9a%sp82~--e-qCKDWva z{rmQBmmPYYTV*G`tc@h1(l)DdKwrj{WQ44?8;D_gj4q=pS&U)K)92I9`7<>2F5tSJ}VW&6GJeQ|8bz`PU!Vqn-h9%wK<`WKTjqn^!hxRoQS zVxNm*p9}g=>}pgl(&wVQ&jr1%M&*J&z8aMadR>jm1--6D<$_*&Oj*Orh|1Y$=QjF` zsJtts&aHBjJ~!!e8@-=ft#TW^pIgal zV|rA0e+kJ0~koRi1s{WvF& z(Wgfv?Fc!K(fe_Ztcxa`J})vy^?9Mc?$YF0CokoFUg)nkpUK=RFZ30bB;O#Em-Km& zIXceCi_E#fd{0_!US!Vv7v7^WW?p2@jqbQIQmAO-o0l?2R&c#OAL;XvJ|F4xkv<>k z^Fe>HjaEL==OcZ-pgtez^C9mmS$#gz%UW|Hs%$^I1^OzkB>jDP+tc1cnRAQF92sxi z0=>5OTPW{uA^k1Tn-c?Ke+%@95?|4i4{w3KqC2j{zLG1Y_L#CN?)CXepC7T;5psTt zeSYY5gq$CG9Uk0>Iw(yiUjJ42I|rRb;Sa8#RGLE0(B(=b+-oUN(Jgl2kOcM>dFS{$_47m2kI&W z>M926Dh28)2kNQ>>Z%6nss-w*2kL4B>S_k+Y6a?Q2kPns>gvYoq}59P`PNf_T2BGA z9$iN-KyAN(Yx~mg7C`IKb@T$%_6tz!DS+0a>*xj0dgANo1<-nQ9lZcrkFKK^pq@)w ziq{t;eL?8;Jun5S?H7bz-vd(+dVLQ}LDCl_eL?8;J);GokH2TMAoLwUnruK(C{vBBU<@eKqr>tZx{Y@3m&@7<{^wr&QC39-HQtCNRdUUTZ zO8TPEKWJlLl=MYOUle-XuTqrsMM+;2`iIPKioPiH@%<`Ap?}yNSM-m#lAiMbxu?v5*?r4_D}s+aS*k9~2{7l*!ujdpR$oZ`^ydjX0=ukQsY4!y1l6(@ah z=v$fJ6n$~%NUyv zL;oeJORP$*rWn6?)yLbu0AoeOk9duTKQJ6?)yLbt{b&WZdcXrAS{2`UzHFieg_1 z`ibT<$(&Nq4{w`X6)HusFGc!N&`&bolgudv{Y}^N)vr>}Pj<(Zyr1GqshJ}qWUns` zeI467m4^OD`@PZ>`_eAsoFZ=vSEUN$kr& zf8BuJXl`Ey`jzgua<*FKN~y7zS%=q`C4E`wbuG6n>B~Z|Yq@2i*R|ZT6#KHIFAM#9 zR$mtS_*!mR=yff(Eb?C0a?8>vSy?#+L_T`K|GwR;;5qj@eIit^v-Z1}0`p9xdpBa_5{dPH{&ve%?WG0u0>e*Z= z552BTlt=7!q)?vp<)QCsVkmiE9(o-ql&8!okJx85|57aF5qljelt=92BZcyay^a*h zBlh*3Fg0^z&Y6fB*v~3J-_Vt0T}4}M1?aU`tN^`~L|*}VZM79B_7$MlR$BpjZM7Ak zkGI+i&}*x$0KGm-ssd$>%#IULBkQe5`ih9X>MN4IBIzrVz9Q)>lD;D8D+cuyNna6q z?Q<$Z-`IL(9`E&)NMDKcl}KNS^p!|oiS(67Uy1aUg8E9NuLQl`>syIpFDnj-sEPf* zREEB(E2XZ;RVIC9rxx`u=ye@k z)<(R(3hApL_WG>YDx|MM`YNQaLi#GCuLAu5J4&kp{qA!sX>L^o`hj*_R>kN$M}u4` zb(|xsI9^|s^i`p+YX1^dNnh3JrPWr2UT20?DRZilzAE%OGpq`Id}de`dYu_ogZGqu`s&b6ACTuk%`275DnO(6_Mqy3nt+ zzfzZCUzcKE7ka(#t}bOxUFg@jUrD|1t}gWP`|j#OzrlS&`W(IQuCCL|^`m-5AHRN7 zKTy{oP}eX}*CM{a#nSr{_fx0e%y4wPET?2L90(IR3bv<0_0W2<+O|*+ZC_X9>Y??-SLEuU_2`ORJ+ysY zk*h~Nm$a0OsFl^%H~NgIsVm8jkGl3uU!U53eQNvljXoo4&@6eDs&DlEDFyY7-tYLR zZ}b^aJ@cE=bJaI`vzLFy3A$^wzR_ny_1$r0cHF>~Qtw)oHtqEdNZ-K3-s>BXz5(eQ zkiG%Mz5(eQkiJ1s-+=TDOzgeBfr-6;Yo7EziKw-Wc0*)N!j)u>qy26}(l;c1L+W=M zQoq{}nWOz~LuAf+lSdN!hQWTfA@#crkvZD$Hgx^2otb{tUIop^DeS`ZyHmpm2;2TgJ^T53G{7UDK&GNkiH4& zn^5eVQ06oteG`g(lVI$dQ0$vf<}{(qX-fL0q;E>GZ%X>6q;E>GZ%VOmO8TZ0`=-Iz zH>KD&g21$qr7iM`eqdSX2IAuqu4j2yl+Oa zmyt&zYH#(;p-*?E)OD5Sq;Kx@lIhK%*I7by%ADrV>)EO~^t!In9QydWN^|Hd+Vfj; z#J-X%rOt6=jO6t#NZ$gn*PTu+pf6y5r3Li5)2RjYy3?rz#l8jUTR^WnomxO2-|5r> zdfn;N0(#x))PiC!qq&TzgN=4eqxVneXbJr}>upK;me8L!pUE7jCG>w3O+M+iCFxrl zy+7BsH2RFFqdA`R_brXyyxaJn)0bwXyo0Bu(Pu=RoJn?9X1G%76MqQK<$Y`Dbysm~=pV8DeQW54H(o|7a;>3% z)b{tSp?}PkQuAKM@?M`HeFA#DV>3be1jRl9z232zAbo=L35tCp8T;5Bn+fP=+Kf#= zuXk)FsK=C9M~2IsHpu%fHgnog-nXH=Z$o+C2KrxY-nXI5X+wG626=y*IfCSUn_%9z zp}cQn^yV$#&Xk(>GC#_6`nIHR3w<_w<)$sgzAeSRE%dXCBu5HuDfVrRzEf1lMzXEZ zXGSN?Z;HOH(Pu_wHh)gnkJ=i2X4K7k+Zuglbjm4YjHz>bnaTOgX@|_w*tdheraf*u zihVoiYnjia)wWB<-d=fZNBVZi9PRJhA#?P3M(vO}O+Gn5dEXA1Q^y@wMrn0jDRq=4 zb55^sPx|)IkFnotPqAhU(;$2{Wy1A8Kvo( zR(r~OnH_t5I_cA)PuQ_yI>kO6`Zne>iG4csw-ilgPCDt+NuLgVTk}29r$b-os{u5| zOozUmJFe*4yHaYOBlCE#??Czv(En|}*MamMp#R5wCi)K0pZ`30=UNBScOZQS(su~z zJCMEu`W)4FpxDcbgV%S2zPoKN9ii8IzdBOpbaa^``i{`+yn z8PGp$epB*31NzI%?S`ql+cKbk#2r`izNZtW_BpcNl!$uS&oZI!?MgDv(Q|Dk=`%^6 z3B8_cGbwX2q1TZ@CiFVa$%H=sM(9lFXWBj|6S3EGZ6@Wttc-bmXVP~@>}T6w=?r}V zSCVI%%rPa&`_9mxPEYRg=}h|0r0)#)e z&+EI8z67QqHlxpobewaW(f@aRf1Au*5eOJa4tnYqfIysHf4# zuOIaa)b$S3^$FDV4b=4u)b$V44G7c?4Acz@)C~^Q4GGi@4b%+_)C~{RjR@3@4AhMZ z)Qt|*jS19^4b+Vb)Qu0+O$gLY4Ae~u)J+c5O$pRZ4b)8w)J+f6&4|^>>_qa_z%sr0)g2&M$jGAD>_L zf?nsBy-eHp^UGe)>+D$CwAc40eQ)Ro+8Fevez&*lcO?eBq1SU>Z|b>vlfF0feNEpe z=e*v~-#Pp(8ZGsPzMt(sdqdyfl~PBl())OQAJX@Met`X6AJX?BeIL^IA$=dx_aS|s zpuP|3`;fj5#a{YJukTCxzR>Ggqc3GnU+DF$(HD9>YxJee=}Y>)lsSE&&k=hzeP8Ii z*}r*ToHe?;QtC)mdUUVvNBVxy>l~*a#lD}5y|mhX(CZwhAH}{O>H9&ibDVzA$LBcx zpw~H0Kj?Li(~n{==N_-`Px}7Qce4NM{uKNE&}W#>MBg9!Z_Lt-w1WPm?@#*v$;>g| zlf3T_eg7L8(aJ>sWahZzN~`VfN~w82fb;`MKY;WDNI!t|14uuB^aDsgfb;```T?XL zfY=YP`T-PsIiLI34C2>Kz`I|%xru9VtpWsKzYgGoOadR>tlO!~pl>x$f9=ygSIFzE-A zelYa9A~zWN_=?x$e^%KM=%?tl z3caq#4TV0wA~zIzU6C6Ky{^a&rB*8=WUn7a`eCFWM*3l-A4d9N(CdoaFwzer{ji{Z z80m*W|BjvU3?sda<-LA5>4!tF>xsijKb-W#q1W}q;iMl<`r**)dg5^ClJp}f_9IC@lJp~k z`jMm`3BBHbG?Mf(lk=G~3i{!;)s8~uthLb|MVT{-GG`R@x;Jzb#eNhrXPx_%)V-mj zkU8(FJXJ<8|Nk5wOqmACb#bz|= zM;pC=i_K`nUf*If+UWoL7MszCy}rd}G-9uBu^COVm)UVfG}7wF7=1=G%9Ug#TGtcD zQ09z*Ue^=HAof4l^~5ohIb)38uP2T%dcU4H2KxAZfiXt!*AvGWy2?r=*{z!%x}s# zXB_fAzE5Tx^1h-wuB@Y1a;4N!nyig@{dm%khrX))-gwfFcX~P3j!$Mzk>pO3@uVM5 z`ti_Lv-QmS57alC#4=_inW0_i7^egf$yK;O{6#GdO`$^F2-BXjG*Ky7y(ocf^ zA@iG(_miNH-#s-6`iI?dMgNE^rDl$-;d%XJ(ocq7*AymG>?cF7YYLO0*ENO76#L1f zpA5aeDRDCN@wZe?hF;%NIT^8k(&{H8_By_o)kd$MLi#Dt547K#Lb0FXVlREp6zH|j znL@FjLi#Dt>uS^#=;NzVQ=r$?s439vYSa|U99b9j`l+O!3jF}vUZ#?MD(R<^ek$pw zl71@brv~*?Nk5hJQ%Nr?xL!Yv^wTJFrcvfhqs*B`nKO+tXBz3JL9eZL8uanisAtDrOhDy4ARelUf0rQkbVZ~XOMnIP(Oq8GoT-5 z^)p=T<@(V~qmN%dniZ&<9jKcVsGA$8n-{2?AE;Xps9PAQTNJ2U9H?6os9PGSTNbEW z9;jOps9PDRTNS8V9jIFqs9PJTTNkKXAE?_9sM{E*+Z3qV9H`q8sM{K-+ZL$X9;n+9 ztCRj-^3S)Pnbdk_qV+>1RW)>*%wg*LC#Sq@PXt z+0gg3`q|LO*U@J~-_Lqy8@*pgpY3`s`I}4clNI!@4b4Wjj^m9l*hxBuT z`Z=VZgV+zS|Cc$WmwwXg=aPOd^aJhp=2G6zrM#aDy^faVl724f=aPOd^zn7{xzJCx znLZc#DXx^7Intwh{XEjogMNtB&m;Xj($6FPJm_^DeIDuOK|j>|rsVxR=;zO9Mppsm zK|jnLS6c0GS4!2(xyS40lYTz*Q|5mihhPGrRo=uegX6|?Y~?A{dBvMw}A3~0rWG>XVT{^fPS}GUX-@9fMUM@dcBij z0rX$l*e`&7eZvIl7eN2DjrIa$&Nr@wZjl^*k$E2YL>#z*z~N=J<7V8F%{FFGcKUTm4dGj;=&6rPwc}*e``%SE84aekn3XSE839 z_Uq06T4KKxnG;`$UW&}omFT5twYn0$l+IQ%LN@zrt#=vpx}LZUdVR|9GSV+2{W9qF zDZ|U4*L9U;(Cd2QGU%7v%vlEg7oT*aK4%&9D{QVTgMOterRKei<-LA6^qM)#q1Wq2 z%SpeS^vj{w>qpB;zZ`nKcDEdQy?(SD`uO#u<{mcP z&y`Z|Tw6i<6{KGQz23RDg7hn(*ZzJ5^x9*tfIfcb+6w4@w!O>>==CXNE2zhm`B5U8 zZ@nv_U*JljKVg4mCG-VcNp^JWy9QT6ukRXM34LYvFH?6{u7v)S`AqVDWm2E_UwStE zO6X6!?@OO^#+6btM`m(fzl!v$kU9D;l2sJ@RTTSG(CfQMRza`hoK=+ftDx6+k*tC~ z{w|VL(CfQMR+-rQcaf~3*vp*L>sOP0HS}Zb|9Um)S3A9o4OT<1W6ag0UrqYe(2upT zUk!cy{-f2DL&&@9)f8BJAiM{Xd*O=J*JJ)0$pNJM&?^=reTFRWY6#KO< z_A<^{OPRA4dhIdSQta1K=By27&RWWxwP>}AoiH`_vf_}4me|kMLBG_Mq}A#bn02II zNBVWp>$AbvQS8@|ejW6W+5UbV^n!FYLnCqd}9&hEP0$2|Sn zdN)A7(v?#68%V!_^czUOf%F?lzk&1{g8B`l-$42e)aS^0QzBYry&Iul?MkB85%NaT zZzTOj=yim=kuql^^g6!Z2)&MwH$opDA#a3UN5~tE-j9$sl3rHEGM#=C={KR(=Cpm) zCem*r{U+!iHA~;pe{Q1KZ!&s6Lf&Nbnb8^(A30lXGWyIYM@_z4c9YR(Mr&;hHyM3q zw9b`M$C$E)m+thNjXphEZ~x_H==GZQX3}pa{buO(n)POi{br;0SKK!ny}xF?+35d! z&3d!Z`)k&ljox3g-fUv;uUX4#qtBczh`s8!K(ALGw?JRO{w20RuU8(oK(ALGw~&4d zGDpXlTaY<=4Py&3Cw}E|3o=KqJZ?ee=)JyMsMX54sMl{L{Z{Db*u5HCNxv2Px#lzJ z@3%tVzi0BA^;XhvCH+?D=b7(G=4^#Nt>z)RX1x{q`R=%q_X}Jpwa1hdT(93o`fbox zy)>E4+bDCkQRZxee*O65oom}D@3)bD8}u7&-fx3G%jM@uzYY40Hh;I7*e9Y*u9T{m zwPvs1PWtW8>ocsjQ|z}xug|dB4!u6ZYCGw-lYTq&o2`C3^k4k%COTVfhklFoZb#;9 zb){6jtcrX64$|*{Ua$J@ApH*L^{Vd<==G}a4$7Pzq~Ae#zXSRlv7O{Qpx0}6I}rQs zw!Q6eJ*Heg+G+Ih>qol+b-M#~djfTP19kfXb^8N#2Lg2m19gW2b%z6WM*?+619is& zb;kpBCjxaR19hhYb*BS$X99I+19j&Db>{(P~ooz(VsQtR1?*0asF{heq%FFsU> z+Wt32cj z%Y0AH8oQv6Uq9LfeQ(>^cR{b$k9N^HPujHC?zxeykU4rM!#;|=oO`@}Kk4^Fug^!{PqE)mvENUz z-%qjMPx}4PM|P~YANtcPM^fzfLw}JS-R*}yiz`X&bzS8E=?{?p0O=2q{s8F@kp2Ml z`mW0Zq(4CV13~=((jS1ni){r5DE4wb_pv_+{Vv-=4nnW**F8v?a}auczwSZk_5HdB zDRT}&uWPvnq1XE`4niM)zwSZk_5HdBq1X589wfbtJiPu8=?_7#caa>T*dKDSm;U|` z^m-S`A<`cr{UOpHfs=&=NH1d~uRl!s!=yh<`op9@O!~u=_lHS; znDmE(`op9@487h(a+vfon)CW2q(1_^UIjQp`Xi)20=-@ZI70d(q(1_^UIjP;ef%oG z5$N?Qz!B(+*{c9YNH62gM6}yx`cde0c6=22J?^uM&A-(1=~1Vbv&K>A{b#Aqw>S#D z&W?{luQRlx(8p(JN1@jl+EM8DI)(H(jcrLr$XkIBv%0@nv&%G zG3fQ}O~)wq$4GyS^v8nwW28R@{XXYS)yr5u5$(619f$saE6JLcUb{O^nRDF5Ui8PI z*K2pjsns5bex3baABSGA-5rNMe(ml!^m^^?IP`k$?l@(R%sLX$LF+vM{UKLM)t?~! z3DTb+{Rz^aApHr_p9tztkp2YePmo^bM_zxD^e2%y`lQ>Fq(4delhEsvZcmc_B{NPmj-r$~Q_ z^rwRQQ=~sd`ctHrIcFj|YQ3kSKjuoJ*S#92Nq?I3r=i!q8mCEr8hTyJJq^9Cqn}Rd zW6y0o4gE~pQcgp!do@l&f3y8eX2)KC2KwVxe+HSOS02wmU%-7Y^~&QJ==I9u8R+%O z;~D6+$2=BWojGf1dQ` zq1XGY&y)T<^m?E5dFb^%>+_^PPx|xF>+Iw_^zqrrdFXX^avpk}ot&q*Ky7T%A5<7ITxVUan1$k^~&P~=yimA0eT(hT!214&ba`+j&m+RU(AkkE|6Z< zo4o#Z=ucYx?a=GF_IA?WPWu0|b=Toi+*}yI2Y08qT-@E=9TvGQ_fnxPb$9AU-QB1g zwXd$YySux)YmqPK-JE3JZT{hTlD)h0+rvpFGBf)R^m?xShhqN^^m?xS2YNl%{sVpL zx%MCE^<4W8^m?xShxD>C=JlgVKN@=N??;n)C2F^!jY@(bQ^X4KES>YNI^{dhPGWK(8wzV@N;7>1B*L26`Q1jv@UR=(WEe1N~{c zrZ5KjqTe5)=gEwL{*0XqjxqWn(Z8+~?=fYy(d);Oek|$7l71}d$C7?5<^5RFk0t%s zpnfdr$C7?5#a`A$&1k^JejN0_yONx1H`u;v9Q0|fBxkFQrX)S)IOz2^c*c=_9Q4|1 z$3efzyid+nzaI~M z?|%B1@!83E(vK(o_@I6~>Bl4Q3)$-h##8KNt=a1*K>vr0{RHSQweOoinKQvLWf z^zUB1Je#zF35b1N_ddBsNv{`}0R3g=HHrNM=;sU@Va`^=D@NwM$@j|>;4XLXm)Kw7 zO7Ymss(5Dfr}a)W`pihjITMXOGt#@nCz5_5=_eY!ze{`~wc3d$_WmyMiAJ9p>0ROz zjsCxPiBB}K&y4gg@rfq(nb8uP0TWH^lh;Mc{?R0(Pu)M79H^TTsGAz7n--{>9;llU zsGAw6n-!>=9jKcVsGA$8n-{2?AE;Xps9PAQTNJ2U9H?6os9PGSTNbEW9;jOps9PDR zTNS8V9jIFqs9PJTTNkKXAE?_9sN0xQC+$q~FA@D^ThAo4{l8sF`rQS#$D2g0XA-rZ zNof0@m>Xl0pBeADCZXrjbKWGh{e`yQorJbu;)QIc?ceO${v`BVi`;SLoVVDO;%#4A zO1jfehW;O`pNyVMulSfu`pKl94830QF`3%_WTW?2d`vcaf5pdSqyO&}ACryVU-2>7 zw0(cY$7Iv?{S_b5roDa&>8C(n!uEJmjNU)lbc)d@OVaO7LC-bAjwYu-U(&rVuAhR~ zmol$OzdHr`>W}ZrksdwdVm}43FYVqhu`lCF@z_i6lj&kVmGo0dKb7=TNk5hJQ;ptS zLuijT)x_RES$`_}-Lh6c)#yzxYV?^g{Z#b3<=p$F-yLo9VJiAvo#RM9>GOUX>8C;8 z$Y$I$%A9E~b0pKJA#-%BH;po98uDIe$I}q|#y0P#A@5V45HSt0Z{m(C=e(w_B(c{$ z4C&Fmemd!=L$7oD>CmUyPnizAUR69DdY#)(hhFFQ(@8%a`d`hbNajq3zIw{seme9z zx1WyjhR*G$(|AM9JzhV9^fRFEZ@n`}KLh#!<~7Ot8PE?mA(j7$8PMwtZ3gLQKtIUp zXF#8~c`4K9_^T^tK%ef8E3v=CmEw6nlk_u5KNI?U?E7X?=FFtbnMs*5lQL%}>1RTJ zuhq|lKJ}{Nnb6 zmfMl)ETcE=u6*)3ty!d>W%T~4;#o$Y8LcqylgycA^qJ9tF|(-E&NBMUXslC6s~zV` z@vDku?Lz%BlbEwo=y7Mh`r8^XCwAHJD!c$r_PRN zBlbEwo{hZM+3{@3dl@4oq6yYJ2l|PwBy=J(NI!=%XAbnb zDl`ZB)K#H5(Cezu9O!jbXbxqLjOG&2Byq^obu7=Jfy^K4(eje%PA#?P)+vg&FNI#GC z^Pt!3a_2#xdR^{3==HkXc}DNA%biD=BO~NY7yJ37pAUTt8-w|zpHKSv(ChW+^Nl_; zdc!m4BY6SEegWnE0>pl&d7tPPAoi)xNM3;0?{deL z*y}Tr7f|NNti$UUl71od)9rUzNcx4)&oHlvej)THwkNL*T}b+cq+baAO!Gd`FNA(Z zol9sfcOmq%+;OG9pY2NVvz5$`ynYes7m z)ad<4VX4uZr_tGw!cwC*@4Nae^*Kw8J|nuq9ao-TH`JBn`E{S#Zzl72ANys{&$Y2% zhS=*!VHsktWB6r=y_BTYE<@~fq_B)KXBlFzBZXy%y^a)?A@->wg=L7njue(5_Bv8n zMzNO_heR~bdY415!sXDfw{x83q+bsG2J@QemnZe->SBbvoHA!Q^c&r$$n)zqnUeH5 z%c1Z6C_krnc`|d{JEYHJ#htMuj`2`pif;-TmikVC$2#3bvo%ynZF=S0eBAF7cJ5UrG9v$a}p@ zd?jVhN~8DZ+Lh3^wy|Gn^#8p}e5KL*yTn&QuXl;BG!+BCF79^%tR68U25M5qg!;`(K1!W%T|xl~+Mu*S1<& z8T0zpq+d`T^lQ*+bymIx`ZW8k z*Fdkc@-@hNot3YFzM1>W_`SYskU2UlUxU0)ot3Xa-s`M<4Khb(-{W`?{H~YSI6#I41|88EB9&;V^L;uQ#9&;V(*HNoo zXY}TNTsuNuhs-J3?-z5n@_QKTkU4+4<4WHDV(zuxHm4$OLFj?S&tCo|{gfi%WkkIXsljw}8BJ@#C?9+{(S3bNMh z^&3dP0eYQVZ6N&y(rBx)dtFY zSrzyCjile0)Z72Fjile`^s@f65qdpGZ=~37B>l#u-h8Hji ze{>~1*UJ9UCZkW?KiV9q+Y+eT8mQYAsM{W>+YzYS8K~P8sM{T=+Y_kU8>rhCsM{Z? zI}oTl7^piGs5=~}I})fn8mK!Ks5>60I}xZm8K^rIs5>2~I}@n;H&AyrPbko=s>y%WOZk39Uz0LpM?D*+i{p6SbaA)b=-_^%S!`!6vkxdre7N&nC2< z)YZ^UXgwd;_Oc1*JY5alL~UPMN+Mcry_=z5;YxDO(|&g|={GyQoHaI6zq^^*{$}WP zq`H~<-Oa&%cQf_7o1xc!cQf_7(x$zB3+cBY_E*^$Y=J(_#&8Stz0GT)-va&6gUOYN zEu`N<`Yq6Jva#O+{ZF0mp|i#o=&yFim7Z&uD{0RqnIpZA*KdV>rH%bo=qK9uZKc?6 zb+J!=O8m)(TS>o_GG{CFlgwvI=4^$&b%!x@&+S&|C%fZ{eu^u__0msfMysrM8}#X} zB$-pezHb}pw?SXgye6^VhS)c5n_NfVM*3|=@2@)8X7rg+lryQ{X7rg+)+vi(!OpsnyE4$Ln{Heh2io*x2u&yx#%+tv2>Mpda)` zGWI)2zk~EUpdV~kCU!u7;)TyBb9O*~u^k`nF!~`;rYprWXD8`*l71)j8TNfUDfT;E z?B#!VC-ger*h%`Gq~A&Uok9Ih((fewPU>^yeC}hvi}bso*Olm9q~GQAk~zDe*Olm9 zq~AsQU8LU?)bAqwF4FHJy^K7(emCiNL$6OM*iD(U8+v_8!EWgFDFwSpznk>Cq1UGr z?1nz|DFwTs*QXThhWuTs8=yf%859#-ieh>8e zeDpogr#>Hj5A^zc^gYm<%RtZr?IFF4=DdC{>GwjP-?rMllsS7TbM`|2*bT`e>?QqP z((i@-X7icS-|vO~`^FpS>dL*)-{_7j{ryd@6mPXM?)3V7q~8a(`u)&X zx96_?6#M-Y`~A>gx;6Q0@cT)>pY;2ouVFq@V!t2yk$3c^k-~oHYr5l#zLqP+V=rTQ zuRlQg1JIYU?d1T){s8o)&1=%<9Dx4&E0URWfHLO*=?_3(#=KAT2cYkLY!K-WKws7! zSM=pvDIR;7b$ILd*wI3q=A?Vwh*Ch6bpx39;93uT8(jS6; zux+)6pdXRm(zM#4?i!^-&}Z0odI)_^rYprWM`m(ff0*=#Nq?C1he>~!^oJ?$50m~d z=?@3>he>~!^oJ?-GUxRABcwk9{i8PaN1)fyz!B)BB(Xn|%=@R4d4Ggre}wc$pnu%F zPxAf<^r<`UN1%Vg9ar-HNmq);US`K$f0Xn`p-l_W z{uuQ7^u1%y>(lp+k^UI;x_5UB`q#{7ivAe%1#dV-`eV?)?v5*C%r{&qu9p=DuRl)u z-6VU74-3jPZ_wG(WuX}eVpkL=q@z~2M zj@O?g{YlcFB>hR!pCtWB(w`*#Nz$JT>Q9pXB=p+ zk^Yp^OUpV1y?+S!`Y3OxUej57THvdkO{xtM`%xlu;oQA$~zGN?Pnqq$%dR>h=joA0Kd4C%E#KgR$ zKMlRPsRMn^X~aI^N^!lc;d%WT(w~9;wEfm+pii@(a)x4mhGKt)^k+za2Kr+*_Gh54 zy}cUg&p?0N9amz1!jeF!kg_b_B#)a%beucNfH&~LC=b(Ug(7W$3mHOZW_(C2LOLKbNS zXQ9{e{aNUBly(;SP3C=~KMVasrR6u3{WYm)q2KI|E3x0=N^!lc;ClTz(w~EVt9{=& ziv2kkd(oeRensz5(4QmyIntja{kfq29O=&?_S>8yo;kACoQSsD*Um$~!t=y+7BUM~|sHiQ|R>qvVRnrze(Lc$`Yu{8mP+_sLLLx%Mqx{8K^T~>_3*= zfx0|_y1aq9e1W?Bfw}^Lx`KhaLV>!%fx04rx}t%)Vu8Bifx3$VbtM9IB?EP(0(GSW zb!7r|Wdn8P0(IpBbrk}26;tY@kCgmNxYiTp&SFa1dLnaUWFi`C`|Buo{JAbsZn^JM zM;KA=_%1+{TgDr@5*_7^Uo#Pzgi1u?>{%nqok#xim21p6dzhPFM!DtQ!}0F8((g`i zrFg$9Eye4zkUk6ax)PlQ`ZW6~S)kXI=q%9dN^};|XCZwS=yfGJ3-qZg(OIC^mFO(F zrRTcDp0Ts!j_ajOdwo{YXN6u@qO(%$vr_D{QtY#mJ}c?7l0IutpOy4kq1ScvtfZIT z$Lq6^J{$D95}l3o*_>Yb-E7e7N^~~TXCr+!(q{|mvyna<>9dhu`bn?PPWtT7>q>NX z%AD-b>q>NX=yfGJJL$8NK0EZf5}h6T)RpM$(CbQccIcn8nUfuQJ?BY}?)5oHp9A{0 z?RrcOihT|jdujVQD06av>UOgZP}fPQ4Q3#Qfj(NYfR-*v~8R{NeS#m5_R z?(zDZq|ZtEoTSf5`kbWCN&1|m&k6neR-ZGd&q?~6CiY&RlVUGtNw3dE`drZK948m) zb3w0joLtcB948m)bCEt5^g74M1%2uqCl~ZO$H@h~&T(>)-h5b0pPTf#q1QQ1Zp!=I z6#Lv1``o0@P5Ru>>l`OH^r>^4+|cVBCpYvu$H`548F~2F=OKL_=&!Urd>+#0f&MD< zn)Eq&p#Nf5az>a3dYvWYA$=a`uQuhntTKtIeKS2E`sSBm%dGDh%F*Hxi>q|ZnCe9-HvP(I3>e9-HvP(J8&RVW|ysjEWypx0HQe9-F^ z-T5eUWZdcX`Jvxy_4%RKU4Zheo=yeaH81%Y_ zQH=D(NM8*4P3BW1?~6g7x`$B=`pxc0lJ{F&DSob%d3++;Xa1GeSDf_4q1QF7;-oJQ zy{>5$hhEpTibJpS+Tx@y4!y2v6^A}`O{+Ncx~5eeea;(JUz{>WRva>-{Z@Yw^aor? z?)|E1-**vZ&PC8mFC%$>k0v9vWDmN zWk_F!^kqn2hV*4fUxs2|hV*4fUnZz8L;5n%YwXLAURE13U7u5y^kt3S|59RE(w8-Q z|4WHwjXn|S-BV>rU)JdTI(k{7&y0?nqe|?{8hvIo>d-P;M=xvinb8UJH`0TZMdqAz zC0$3C*JNGP>&ub89Q5_)Yt26IE0Ded@_v_Ddl6Fw(pNy< z?>4WAz5?>Tb(e0~{i;Cv3Y7O1koSAc`$S&>c|YTm)1TzYIA+@e%pib5o zQva@Ypsr4!u5O^NUZAdipsqonu3@0AQJ}7Ipsq=vu4$mIS)i_Ypsq!ru4SOERiLhQ zpsr1zu5F;MU7)UgpsqtoowR7lKi_)NsP&|w_55t}HjUbT8d}dU<~3>iX=puq)<{F! z*L!Z$sP&|w_55nyCv86stta)K+cdPE-`sJf_5AKi@mYej6tAyD`byB7K?HiPN~Es@ z{pIF0(N}_AujsBsJy#{tSAzZ#yLVg(`VtTG)s>Z?f7I?4S2AafMD&;|#r4vry}mN( zD?@*W)mMgId#B2-=MsHo==Cm=%Fyc^r!wg)L$7y{RE9qFE|SX7>s=(3q1U@eDw}@S zU-2QmkJncreHG}VJjvKsA$=96m;9?j{caWLv$*%g``s$g&$qF!0)6|+!)fQS3iMgs z`z7|-TuJ*~Ij;1RUSE~;RiW42ud1Z4>hu!(s?h81S5=CARf>I8=v$iqPs#hL(2soX zRinS&?VDDG-b^`=u~kj%heWMiDXy0u-RrB7z8dMPk-i$~tC7AM^aJhjs*%1L>8l0x z)kt3rnRB;sO0=sXb97xr&OKgVo%GeA?`6;X)uB(brs~l5w&RWJ(CdA7)hYJXNnaiM zK6boO9r~ix-lf=AhrX{nu4GO>SBmGooF%=!2I*@+udAUoNM8ebT@9@Py{?AVfL`}7 zYLLDL^w~`oOXk#o{)=Vrk-i4>Ic%oaK1&d{Ch2QZ>}!&~ zCiLyh|Dfn=LZA98sWqW*Z~vETBJVr6QatuD^6;^*MfzH#uSNP=q_0K#S`_e<^qtN7 zB=)tTUy}I~WlnAAySU>@-gkAScdH4)Wgop)JMpUdEkXUzhZCp})a?N?p>|C4F7Q zUcXCS($^(@UDDSL>g$reF6rx1k0~Q$udhe?deG~=U-d{|&*>#|>Orsfe$}JQsYm*H z(BEKt%zDtL-uqP#`WtN@Sr2->_p2V|y^Q6(zCP*elfFLb>yy4d>FbleKI!X2f3wxs z59;fazCP*elU`;WUf+Q94WM6T^S%M}X|5#eDyvONV&4Gz84Z)U*?=;q0qGk+|BfB! zG=RRuEWYoq0rcOiO7T`J^CPcsNcx7*ceCDx6#Ir0`-aeezcUY7RzuP^ zBz;5ZyPMCHKBpn{Me}W^R@)Hz9`3l(=k#=?c&n9}oYyxZeIw|5+4nUfeIuurexVWc z+G-n-z7gpgk-kw---z^$kU6SvM6FiloL=9U^o^mk~xi`Ki?pkIgLr* znDmXIFK%Ps82Tkg`1ddxL!Z|jS7M*fmExHrvtzGsLi#4q>+GZn>6?(g3G_NUX+ruY zq;CR!eq)i$X_Acn<0nk!_-mA!KwrRmn;`ZDT`8V9GLQHArlfBQeM{S3nv%XL^sUTm z68omm*B_OPeN*UlZq=0ZO`+H8WST-h{HF7yZwh^DcU*~m8&`_QURE5uz8UG8k-iz} zn~}a5>6=mPn~}a5>6-=h%}C!2eNG`8`)1T*%G!w6Hz$2_=yff(IrM3^4L65g*K(Uf zuWPx@N#C6G&7prhXEJk|Lx1AWoOCZhbLgKielTzbElA%2`ocEvTR{KNlD;MBTL$$lN#Bz6Eh%$kWz6eak-io5dTm}S%KKK(>$Q2U zpx0~jT2bs{~-W zz-CTs==Hhmtts}cN#7d!LFRqZW44Aq^||b=p-*?ml|JVZSBhtjtTuXm8`8IdKC)xI zHWd3d(979X^1co9^?T+*J8MI+Z$tVv&}Xruv^LP+{1`t~z76zQ-El>q&6Px7-F_EY z7xntKq;E_5wxn-M`nIHROR;ZD`nIHR8`QTYeOqKsE%U@X>4Dl(=Ew@J*S8~mJLq*C zvmIqlJLq*CvmNxhj@gc4-;VU{px0S>JLpS%o<@C6JLs>l@ofkFP*;k_Ue=nuzCG#N zlfFIa+mpUM>DyE6+mpUM>DveO?MdGr`sZ!tw5Qn1s<_v8Abkhuf41Mc1L-?JuPfjk zpw|`f4y5lu`VP?Vw|UKyMx}h0N*T^s;}{(dbk6VmbxtItS{y z1nRm5>beE$x(Did1nPPQ>Ust0dI#$I1nT+*>iPxh5`nt@fw}>Kx`BbZL4msTK;6ZG zx=R9eg9CLLfx65<-H<@trGdK30(F-M>aGaX4Gq*?nNlbHnB<>tJsqj_bVTbZX2&TV zso(AB`rYKG#8-tnQtRnRt*0YePjNe1>WJ1eqE0hvJsr_{E^^0}vqlM5iuYX7QoOzs z={rHM*Q0l$w%-Z*t4zNj=e$m6`(Nxzw$Dza??n1e&|hudCui(V(5GIH-U<3)w$JH= zwttN)#n0H%roFy1={rNOcTaUDeP`(P?y1hu>)lhGq1QQ1XVQ0u{x;ilb%uV=EnO(~ zouR+o_Envszr&T{v6tS*>${M?3+cO%z6AM8=T}a=B^j%!PD;X>O zq}O*PeOJ2rD@_Iny6=a)U8*Zrd& zr0)TJCG(lm=k$PnLYDrf)!yxP9(zDv()N)(5c?`l5!d%5eNWQ&gnom)POB$nPEY7J z+UvA>LOt&4O^}R{o z8~U%!z4X#M^`_YOhW?c8g?mGh8FzYpU()x5 z{-ljTU()v_eP7b|rP%i+eP8I$+Wx+8P~R8&fwrCYh5lcsh{s+=$X?%%^!=dMJ?nm? z?+3l^S@(lp_pJMoz8~rPL7&I!`$50urVPrQe$eN&-hM_uB+BPX@w}I@yw@j4pCEmL z^a;`@NS~n0NsvB4`b1ElAbkR{FJ=4B1f8v9*5UR2N#7rO-Mi}#y|&E$&`U}B`~J}D z-d%r+eSgyTCw>2*zCY>vQ|$YbUgk$$KY;WDpufegq7ESa0MZYD{@HoS-e~~o2atXM z=?4V$14uuB^aDsQGdZsxNcw@$KW5Jp11WO`LjQnyO=3SVnK_k`R}~MW%o#}ffzazU zN&}&PY{_Mm_XD9{U|a1#WX?iYinm&sb9((C(hq`OpW8Ty^n;++=Qa+4UZ2}Ih+;p8 z^n;);ZGIhH`ujo9uQ_=o=?6hy#{Po(Am~fmydOk8rp%7LKArUG(ATo9J)QLF(APGv zN$k_1?|pGHbJ8jH>7-AGzKpSmJ{|h*GjAn*I`n0&Hy!$Nt`v{G%;UZOV$xp>{ROMP znDYK&m-liWz8HFK(HE2cV$xp>ePl9D^cO?_+v|6d{$l8}*o?gx`mC-L*UO57*Iz>V zOGtkS=`SJuC8WOu`fT=imyrGv(q9tPUqbpzpr7hKEv}cf5w9Oi`oYkbxBq8@Nk7=> zC36NtU;CY8s~t?SA58ke&{wdTGZ^~wZ{0<)9}Im(cU&3gq`6XDFRM6SpF#Qz=quUx zWsp9D^cm2vFc-o}9%Ya|gY+5DSGM{L=ts7=oAepbS8>M`eN|VA>t(&k>oZB8nT)+{ z` z%Nm~7UkZIq`#mp(zLcF8TuS;&Nq;HyGt9!hWX`1&`%4jf{WXP4p)YGbQ}mZY|K=Bc zDE5~^U&|>(U*0L=nIo%>UVjih{{bkU9XIe;M>^Cf!2%%b@?-9ar?DTq&-Xby2Usob;DN-^jl2a_G}+3@(Shv3X7OmqUN) zz@+|i(qB&c%b{;#-Y5FYp&xwhQ>4Ef`ljxxYtl zDCviiekkdOl71+~ekkdOl747VKa})CNk5eIvMTQNSCalp=wGl=yOQ$$O6YZbek1po5v9&bFPGb&MWij3acxjf5shGGUr8C(!7`bqpOTQb^qwK+NyJsPNcEKv7&N}crZl7GJS zTt%(tDzu&r<}Z?eDR=Ls*(|;at!JZoP5Rxd(0cT_p;uAczlvJVRcJk%%=@I@y$Y=- z^|_%}q4jKb$CcKz#g(-6h)G(C*I!NgtD)a&-*+{&{i~_%Uk$xJH}q=KUrqX}Nq==v ze>Lf^#%O7qQ^e02(x&}=pTkH$40`>|zhTtx4uf8Q^KTgR`kQ~lNI%Tz{V#P6GkX7< zf5VJEBTD_vzhOq75$SLK4KsTGn}5Shzw3YVPkJ98`)i=DZO19sK(AMsT|@e7px3L+ zu7O^!GP{QQ-D?ngeIn2`h`qV&9+`6uVt;$H$4tNL@8G!xv2Sf>HP;~aZCoiHd+8^= z{#w#s3%x#-=32^}YhC6@{#^^b&M&W}*k4QfYoXVt(p(FD>Qia1g!8=?x?D&4>!8=?x?BgnKG)?s(qBjV>qviHP=6iiuOt0+q?dD#*I!Ti z>!IIZdztGgbFPPeqj^pGoa>?2C!<_X`s+!5J@lK*`=rmg9{SWLqg)UDW_MiabM)!% z*OOk(l3srU>2DzY4Wz$;^f!?H2GZX^`Wr}pLr{MM>2E;nReuBNZ!~&;r~HkiztQM3 zqdK+?-$jy>?|&8hMx)P+@|yKEiT#a6pBYtXvz_iW zztQMTzv7N7eNH`Bl0HZ0mooD3`kP396X|av{Y|95iS##-{wC7j1buyD5&ca;{Y}s} zu-=2D_e&7{8>nbXkfZ#MdL#6CTG z$n8AdZ1h8;Mpl0_GN-XC#m}`en)9*0h4i;TU)-*u-a`6YNPi3Reniz|=G;R1TS$Kk zWzH?Z*xy2#a|^}(7K*)$JH7r^(%(w@TS2D?dt)#z|^tV#x+#1y1N||#j>2D>y zjF5fi+(!D_NPipYZzKI}q`!^yw~_ufqrWn0Vl(HqVCLLLnRA=b4~?4I%()GHj<#AE z%lp{hPWs!S*FB8eNq;-(Z--v@Fm5OP?WDh*GUxVS>~E*cxt(HvJH=jR9bSJ2>F*%@ z9i+d5^mjo2qTPYHgYF*@{out1L`jJ+D zC+Y7b{hgFKcLp=(PNPq_KIcxOH&5rVnR6#)j?Coz2>CA3-(~a}(PegYcbC!oCt=-X z^!`a$cNu*~bfj{!&$-L!{j;R*BK=)PpAlVdK2!SpyNuqv@9ML3wz|vcGomZpaplP< zLtROpXH?gYB4p0#M+$dC-^_l`yAgYR;^*BI`@1RjcO&-t#Lv4CdtDW}+vpRKKJoKz zqfbQo#Lv5pJ`trp@$+uPUZ41RH)5~9q;faKUS`K$e-G*JA^kn1zlZeqkp3Rh-$VL) zNPkaIe-G*Jfxfwo=snQu^#U@FPed*3YxhEbz|_fjV68mdy=G+VY;3_+5Rp?&muXD$hyuaR+; zymSxae$wCX^fE%eA9~%xxF34m!?>UH_d~CH823Y;x`%N;^ty*}KlHkXaX;y0y~*nz zfWEEOKY-XDwVCq(=^r5d1JLI!mb|*{0gC+t(CZ$?1JEBcpD8`&1JGChc_6K$KLGu4 zcU;N)yKUY-K&@6*#=QPP(mzQ02TA`R=^rHhgQS0u^beB$!Jz&@(m#mU>+e}VNP1br z^ZJKK{}AaPBKLjs2rWe@Qgro?JOEiOmcjHTsJqGf}gjmfw`B zxl+8pm$l}E(?3S~$DqH`zV9*8KL-6(<~7kj2EAUz{}^S?W5^sm*FJ{K>1t#D7&2#A z$($ikcUOw*WmVkkA1D3e(CfWlkCXm!==I*O$D!AIzaFQ| zd7Si*L$A-UdK~)HXIMQBy*|V0apb)|!|HM5z09p-|L6&$PuYfkOy%4B-F;MqXpzh^B-7A5*R|9pg1?pZ8)V&d?doxh?R-o?fK;1im zx_1M0?*;1K57d1Ss2drm`!G=VQK0VQK;0*Sx=&N;WCSPq=UdMc)Owzvw*LgRo+qg7 zKS6E(32OUKQ0sXDt*3`=`%ffW&jb9s(odlE^t7%03ACPGt|V<=X9?0$y#7hjKS}y0 zN&h72pCtX0)b^hw{gb4BGN^x&^iPuhNjm3AoA&w%RR{(Caw+DaxFuNdFY{dcX5i(5K$- z{1o(hzw=Yj>;2A8xqesjUiwL|f1319LtogQ^PVRC(@vlKl=wX`Pm}&>(mxHoK3n8z z=zpqIm1by9Lw}Jwu8gxwxKjL_Cq25?KSTOwpw~Oso}tWn270}7?HR;g?_7I^^v{s~ z8R*}!^UG(TPrY;P8R&1fSExLL*x%twalM>-y#86zKTG;&N&hVApC$dXq<@z5&qA;F z-8~!BKTG;&N&hTmj+`aE{yEY=NBZYT{~YO`BmHxve~$FeL9chNJr~qJNBZYT{~YO` zC;juJe;#_h2j+RwKM%d$1M@ue+M=H){qv-M9(uh8=6UE-?}2$9dc6ncdFb^XnCD3^ zBM%?@7fAmC>0coI3#5O6^e;fK>nbmh{sq#%5Y)dw`WK-8*4_j20_kOpjsN`xi<7BJ`(C8Pz`RI$8O?e9OQe4ZdcF7S zCFnIfUV>ix`R(Fc{f;YWW#T31U$ec;OVGdWO7T8N#+_dO zGU;E2K4IVYGR6L7==+=3WRCMP^cBoBN_zj7DfTau{$=O~nD73 z3VjWCT#0>6SCZK47*l2)UjG{DUxQxn!+4Ei{~GjqAI59Y>wOrnk^VK(zef7kg8J7; z{~BVi`qvP9)yw?I>tBbyw;fBr4!vIG^E&BYhhDGpc^!Ja%I9^;oY$e(t9)LEUa#_b z9s1O(d|roMukv{vdcDf$b;=x>$$9-7q<;hYk#;TY4a%H1T;@pLzXAP(QpsP%euMOH zkp2zmU$x_$H=rLgn4hWh2J|1g<4WdySLq*CiHz>DgKKRZ&K{vgkGPF z@+S29WRy3dZ)Qh@Z&K#G3H`6;HOc!op-+7__?yuG=H4&*-(4x*=g92X>)#^%TZp}0 z6a5zH--2GRiGB-uy(aoCiv3%pe+&8vw$;7`ed?2L--5oq^}b~?XGqk+mEwAt$9w(T zq<)(MsVc+)-^wsRO8t;()9n!x8{qRSVXRCKe{|@E-JJ9P@KJP$Z@FRXQ#XHbf zcgK~?so_fTyqC3+MAYAU--UjFD@op0us!X&q<xu6{uj`5LQQp5tne!g>YfTnQt9=jpk$tbFv(rIL1V(Wb$ z`b%6XzWen)#r}QDocE#ES^4|W>+aY4q<qcdVvp&-tPi@ zVDy>M0rNhI{Rc*Ge#^c?)|{EKb@UI6J~KM#jw{!PWja%Q7eLnVynZCnLRv*$xLDogR{v*Um7<%1-`Iz({lm27quQu3{U@aV1p30}eWL#a z`Z166qaO1U=r6PR`w8@yyOQYj>NZ&w_xevs|0(G|CH<$Q|CIEflKxZDe+vB-#v=Mp zgZfWN|0(oCt^QM&_p*QVnbD{2AAKIE`yx>HWuWe>K;74Yx>13;Zvu7S2I{^G)O{bQ z`yo*Gzd+rOfx4dpbw3B{ehJk58mRj%Q1^SF?vFs-pMko+0(E}}>i!ATjSkd}3Dk`Z z)Qt<&jStjK2-HnXsgtv-vG5tSp3l&F^cf4Eq4nr97CuAk(W?$V zqt^2oT2C2!#{LYgr}wcz)b>9^>nUr`a-X5~lyjwc+n1K&^`DdebLi*T=Z$_2y{>6} z4!tkMcL6@9w*NWlKZky<`Alj1pF=-k_@$)(9Qt|gxH3|m?@DpKv}v#Z0{Sa$FYyKR zkJ(Yy7Zm$1pnu%FCjIUg$+L#}$yfRR{DNZt1@wBY&==6}vuBMjpntbZg7jZNzu%rG zzCi2`xKdm%y^q&_N%}9L|K7guON#xMF7~4T68hTLCiP#E{!8d}mhdI?KUn>j(2v@( zm9Fsn68itS}*5)%MbG|bA%&1J=Rdi+RS4N*1wQIbS38Iz#)K z^j|}-GqkS}d!3A!(~qt$-{z1}_b4fHxv{f6}4K)=bnPxRkFpL+MyH_&gk z-fz%q3)#&1hGPG%(Py|>!ndUV7I}Y}{XhGbGUr>D_tMLJ3%&NA-x|H2p?z!g{{EwH zjow_*Z9Y@<-x_^JRN<39={l`%jow_*?T#yRoT081zvod#9+^)69qGR_`pl@QJx_c` zvHuSGX67~NbH0Oq)EBF=$#?mVV*efKzcc#GXtjx?=)W_1BfES$wc78DJ~LWlqy3$U zeP(o@?eD)cvCniX(K1Hzne#pL*Vy**Ju*kHNB^E;|GkU7=)Z?vuSfr$^8R~d&O0^_ zzDMTh_2}Otb5gHI{~nq1o_mM1+V@>a@?KY>Wi*!=U2DBRK(F)5AE4Jh=LgdN0KN7( zKR~a2&JU#j!RY<(>;8b)UuXNA9}xTRAD>UL{{gYT-kBu!H@H$f_A>4?*N5BJ{zv-% zL4S|^*8d~@|6J@PSN=zN|3A|I53w)iK1Hrazt@x`bN+|ekN8P;zx);5|3mEWbMKJY z4|k<_pCcn=um6$q{zvGw&-sz^{zvGw&-oF0?Q?#ly#En;?eBj?=4`V1AE8g}bAE(g z`qta5+RXVG`i6FY_-E*Uw*O~8lm2JubzS9W=yhG?XXtfZY)|_u>3^lz|4Om{mGr-o z{#Vlf8r1(v`d<-y)&EL)FLO?>|Bdv&LI0G^``<|a8}v`xy#EdQ>#s_#qyI+w-$?%( z^v{_0NuTpuGIQE|XGUrM4*lPtf7TsW#yQWqQoPTR*>NJe$>#m<(BJGzvYx2dDE&_Q z-=WuQlzxX^uTlD)^uLq-cj(it{&(n4yzm+6e~12J>;2uten_;Hi4o{~-Mz&|l&d@w}H62e1E=^nXI%!uC0T zlKxMpmyyDsh`s(g>z}0mlk|U*{?DNPPtyNM`adc5vNq!Nf06z#=+9dHU!?!b>E&Ge z7xel+@fYd;BK=>`pR+yYU(n~hZ3)dz{(}CzJFaBT1y_p4URH6u{%_L%4ZW`A{!MxR zH}qGT&y?8z4ZW`A{tdm3@Bb$K-_T!e-Y2d0Z|GCka{q>YnDzdRKIa-&itA;)$?N|i z{XfuOus!WR6#IWD_Ww}q{~`T9r2hwceQx7F(5F7P@gL~*xsCroug`7#hcZW2#=L$s z=|_`(H0ei^el+PvL$A+m98LPsq#qsBk0$+S=r`N5&S=uh8lKmWf&LcTV~&CTCEMD^ zkbaEQOXiG${z#PU@5fNykAYs-bH+fg>p5efPhHO$1HG>2jDcR)bH~HGtTJ$ z`z)VvM(>~HGtR``Kg(yF(feol$O>+z(~l?pc%#pZZnb$do?<_qVn5#KGo!{oCZG5@ zp7i5MKOXwq%x6lUGv4UUQ$eO~qq)_1qtA?PcgGd|9j+9gTgh6p&zuR+-)aAH0%EUM z`Ai`F1kz7H?DZ<236%E}kU2U#nSjjEt9&LPb5gJJnSjjEt9&LP@AWF536%G;D(>|Y zNk5VF6G=aj^b<)xkzzlQ^b<)xF{qzN`ianQuqz@HonH2jCK-L|{?X(>-IPGx)Ii;| zK;85}-Hbrp%s}0&K;7&>-JC$(+(6yDK;8U6-GV^f!a&`kK;7a%-I74v(m>s^K;7~{ z-HJfn%0S(!K;7y<-I_q%+Cbg9K;8O4-G)Hj#*{i4rAhwz)-#D(&m^=SU746f{q7{R z9$lH3gw~@g6O*X*Orq8^39V<7>Aj`rnuOMqx-u~dt!K0C;U}T>=xXRB*Lp-REye36 zlYTPkCzF0M=_iwZGU+FielqDN2lbOlKNDWsob z^k&z>ye8v~DMp_W<$N=FRq+(kPceGGmOI7hGopLU`y}>Lj6Ng!zU~-W%bjBM8PUD& zxL6H!B{^$+YQKy0K3+eS^ixScmGo0dKb7=TNk5hJQ%OHHsGmyusV4SjE!XO&n%H~2 z^ppOKJ&p9!jNY$APb2*_WR9*xPebPDO7t|+Pb2*_qxUP((~SPVE78-8-mgSYgMPTx zPlH}ZOVXqJyq^yJ{q`@XBky%3dOGwv3!4tTlq7SeL$52*)1lX~-gM->u0&5q-s?*A zbmV>NO7wK(y{<%0N8am7^mOFC>gC*%h#s)s8PMy>#0=<%o4=6uJ%jW!oId$ld~QF3 zVm||VUCW&T{r%=MCGTfIU*a#m_iG0954hvXNcBNiiqFvGEa~+#q1Rc$Oz3srbSCL% zI=#exCStGqrZXw_GojaU_Dtw?-*hJQsr#lgq1S!WnI`sr-*hJRIkQMVi}HRJ^lj}N zXBO#aIlaVw7WA4`vncknpx3e9Ea>&QjkBOneQx6{==HgcvyeIZ+{RgyIWqF_v7b%) z+0g5A8)uV#HuU=3#@W#8a~o%qem3c6lYVwkKb!QkNk5zPGDb34W%GUx^#9su&!Nnj zL;5)`_L4bsD0Aje=FFkYnM0W~Czv^ND0Aje=FFkYkx$ew($6FPJm_bdxvuEvL4R|hcC>#q5BgblK0FWl*{&4t zb7X|<_47$TA9`KWnh$-Njlq2AuQDacocYk}n$~>E`}w4w5B=5VeWITaed?OleCUU{ zBT0{`Yg+Rub7U;<^$VbX#AeO{==I4c3rN2JdfmfV0KM*EEFk>?=yhFX0rZ=!egX8U zPexe)y*?Rb0b;LDMp;05nRR&mLg*j0`i0Qzy#Na-a~4wOEQDU~1z1S>h0tq{xe$82 z7hoausrLdbgkJ9jSO~q|3$T#%GCwj`>Raz3=pT0_X|;M6$s&sVBIxxll10$#T_lSr z?-x<#EP{T5&HF{rr`|=f2>SLma~2uBzl&rM^xA4=CYOkwu-?U_UyRu6J&%hi_KPX@ zi=o$h9v4&W7n6Q5^m@l(vL2M`p)fzm)V#5&Pfl zxoauumy&)d^wrHWp^O`rl71=amqP!$`Aq3^mO@`W|NV4z+fwNNaL1KCCyTwdc`4~- z9`E(bpnuB7ewoqx>%*3jei`YP8NI(gY#Hg78NFXmTn4>fAGXZs|9gGdGNbp`hb=?w z_4=@7M(?jQkrjtbmpRLgJ~MjS>X#dRX0*`8U^(fRlYY6;o2LvPOs*#`C;f8hE88}> z+~_l-MK<=!jXople$y6OPh1ZDVs~7bTP<-V(QB)fwGpphLHZS>UqSj6q+db$70~Mr z%nH)4ApMGQl?^FAnmB@STb5>HHvl4l)dRcEuM9!BK<1p^<29O`c39jq}8s1KJ{F?3VJ=)u7Y0AwX3Mr%F0+Gde-V!L$5vNYUs7k zSxvEDO|f4Mz4ke)q1QXtRzt5n=4$A*&shz9YM-+jdhK&oL$7_#YKpzA;U%KytbPsj z`Awbld}~O*hV*MlzlQW{NWX^kYe>H)s9!_+HKboddRc8uM9*9OTIh9#x0dv4Nxzo# zYe~PB^lM4Kmh@|b`n9BAOZv5xIkGOAh+eSzb!H^kb3N(TLqFB(*F%5(xbd{(z8?B%?zl2ao9;^S*@>(*d;JE| zZ-8EV%nhX9K>7{PYmd2s^czUO0ebB*H$b1-V{U+6d&~`py^hj0P~OX`xYuul{w13^ z8=>E8cWyRP=4^z1pLtE@RvV$exkYjnb|dt0jU z$Yvw-f4Y*+Yi0jvlhLQ{A8iiQZ3)zE4b*K5)NK#c?FiKE4Akuk)a?$`?FrQF4b<%m z)a?({9SGDN4AdP8)Ey4g9SPJO4b&YA)Ey7hoe0#O4Ah+p)SV90oe9+a8>l-Qs5=*^ zJ0GaKkWwe-HOW8UdNxt(*+i{p6SbaA)Ot2i>)AwYe-pKyP1Jfe1zXQ1YCW5%^=zWH zFD=FEH$(rjZTp*{*BRPo>bW*k&$StPouO@}w!ayA9dB%gUT0{Vp--KmZH8WFXq%ze z8QNw#Ye<_;M6X!y7V3AmK>wxZsuFTNha3$@zBy*(q$%x*xuWdE@jOZ;_k{R09_H472V!xI2Ta7*= z8q_#B%Gye?-)i*!Uh}O+pAn6+=e(^(pAlW!@jKf6+G_L}(Kqh6^2FJ1T}kfN*4;1Z zC%t|f>9?8Kd;K=jZzKIS(r=^KZ!`MAQDuAdZKU58)NdpGHj_CS(Q!nA} zbg|z~`t3%a8NF@)C$<~C|6PFXM(=+YV7t+0Mk_w!< zl+4*~^qJ9~5_4&Ox!ve9qj%kLWrp^iE5&EWa_&hu{SM^4X3h@ey*~MH2gQB|#eN6! zUZ1hBgY-Kn?{^^Y^~r}jkoT!iKHP!4*C!wDK&#a!AMT(&N6wO7zmxPkq1UzCozSP* z4A=?%Ri-54jh)czTJBEDoSmfK3B9i6?u0&dEq5pM!`zYLYq>kA&)G%#U8LUy{XO8e47EMbr#?e%5A*}waV7Tp6tX>} zm(iTp?}h$-+rIZg|AqaOy_7k7q1WHn-3z_`zV2Si`@PWX%EVsi_4jr6LZABkx_hD5 z-`CxX*z51>?j^m9JH37%>GwgeS6A*M{XUoX68nA7>(!O}DE9lH*InOz(3@pbL#sas{YS1OD-*gRcaZc4q1P3; zgV5`W+(FVGq`W@}{U)0^2cb`0kvj;zuE-rk>~%%%AZ3osj}pxqX+f0*=#q1W}q!=yh<`oqxcdg9?^=A`Ul9EM)k6AwfGr(H)sOtF_aXCnICdXGT= zg)52vBimyhA^j2PKeqk-5$Mn4O^%R{K(DJpM=0-)K)=R}80B1h1o~08_Mjb@Bhat4 zqsk-DuXCmNs*uc%z5XclUt0Z9wA!y+DLy+nO0ho*{RXp?BIAam6#JvlYma#p`mfDr zivB3{zy0zSU5|bg`cdw5oJI$(&^DkCXm5>5oId(DpgU zp)c`5Hj_CwSB%X6oBZD$hklVeuILxLQap2HZ6rPV-hQ(aMxP%2;7XGB|Jb}gLHZM< zKLP!-mnQWmD05C2y`LGLF#7apwE0ZQoD)W$9yLF@C`bHv9#0s3dNjrzH-B_RRNChK z2^0G(+~$sj zBw~NuyifEe5&O;+D$}g|Bw~NU9amz1(v{+|m-QyEKSlae(CgDyPm%r<^tElDa|(KW z+UhCNpCbJ!==E8#r=U-LR_rP0^;xl}(C5^&{}ZREzn7JL;5q&Z#1t-=A40Euf;w?u|GrlGth4`?-Tu*Wb7ZloBI1R&~J9f zl^(N@jr|#ly{tASqMvNE|Aqc%SCZH_vY+xV^g8?d7kXccU)A|9#r|K)oPVJ=3qR2R z3w@&2KH7o#7y2gdxT0_BO7Z?))xXUi9an zpJ5(aB>nX{(w`&!Ip`lWpDFrt(AOW*#GGq~x&Hnf^bfh?N}uzvE5&0kYt3GNp7iIT z*ZrgOq(4vk^U&-5(RtFJC;fTouQp>Y(VvI@%;GCae;)c_c3gHIeawVT2px67XFOdEM=`TR9_gPiE?1z=e7*np@&xMg2I}$!>hcHb3Iys32I>k0 z>Iw(yiUjJ42I`6h>WT;IE(+9@2-KAf)RhX5>aaFiSo$r>uT$X@<`96_xVS8;%#4Aiq~f$eHQ5Ts^To9&*Jpb?`DBsuPV+$ z`Yfc+Li#L0eHPMZA$=CoOPluktfbEhy{@Zdg+9%mIkQ5q>nd5H*L9Vwq|ZwFtkCPa zN>=Err>v`Fg3zID8|kw_-_nk7vr+7`LEp-}Cb7>3ef?3%vtu^W zXCr+!=#Sa6MmFe&-*n!bHT)BSvO(Y49aqL1ZCojyInqyheRk4khyG6+?d%l$?9l&Z z#~az9KTs{XcbA>?*-4)r`tequ9s0+vu0*qh?9flJXSwVq_K9esE5-HFqkDZ0(&vEw zw0&O=(&un_FKs^u^xB4VkUj_Lb5QJaKwo=%HPYvR{2s4lH|cYeJ~#Bbrj?uYxk;ZpsLxIM+@#MkKq1WB7{Lt&}SAJxU#$HCq zUSELp1)$fvND5Hw3qY@TkraSl?;fT*J z=%28;T@bO?y}N?cYGu~p^@T`Zi1dX>Ux@UDNMDHbg-Blr`p0eF7YgbNk-iZ0PulNN zi1ac)%5bYfg-Kr+dVQ`-ValAs(Cc$u3PZ2Ybtz1lQ`qSJeHev}J~R5$991%>u+jhb zxh{o`-apr+u+f|6x|nxJTP$q!{w{Hu$@$n9f&Op%mqno0^~55iF9N-;Cl-NTpLAP< zVqXNY*Y(6Ah`p{S7D4P&*At5%_PU-}1bP34jeQYnwKC`Q`l6&S3cao;7A1XA=r@|r zlyOc`=yg4@D8;@g>5D?Y$-GZuUljV(XFC*yezWx!MdoaArFf4ivtzT;Z=+p|^ugY zN$iV5f9c9m$j#!EImJm|9D04GPI2ffzgwAl%;M0$=8h}p+Sgqv-eby&gV$d~`iqiz zZ{K$j=`SMvMWnxoVt*0oFCzU#LH$LfzbKjaP7&A3+KAVeAbknw^=wsw^d+FzvsDS` z^=wswVqb#vC7{={RSD=*&sHU%*Rxd#==E$>f?BPt;&^>Y(wBr@uhl3Cz0RLXLN6uB zoRZM%wHhTU_9aPQ5_-K>qa^gH*J_l6Ua!?CiM-cqHA<3R)|FKuRD*WDfXo)_NAfMoyXFYIi-!>?>v?^dcX5n+UWng z^H|#G{mx@)6Z>?x^H|#G)7{Ratl=e`z6@fo`ZCb}Y-3P{VqXUOUu^8lK(F_}l!3mP zdtZDltqfxSt9eagUk0&HebQ|i#Qrz;e(7_5ccpl%mDR?~XuOSmS)kC$f|^djCY0vL^PK(ONskENf!# z@7R=e(Tr$<)t58+jA)`ONq?`u^H`4b<)E)`vQb)XIq3Cw9?KcMdB&VQUOA)Bj2hUy zEeE}nB=+TuJ|o)l)c15Xb2+2Wh#IvVxl)O|stdl=tN+@5@u( zm#4fhPkCP+vDaC7dCL3pl=tO>d0(FLzC7~&PWxTTBky%~B5TbFr>{VHUjcgk4U`HL z`wGzOZ=h6wUVj6n0%cAGqxWmb6_EG(8z>c!_o=^uQUQ5i)_N7;46~8BE`O<(fjM*D%@sP&`;TTdFbo;0)` zy$>VJwI0z+OY!puo9hiyu9>Keepj!VsBB_CB+_dpDx=>mX-(4m zczqSpSAkx40jf~uRH4kN0=@16R3Uv8(pQ1Lr8&C9z6$gspL>-?s#TzG<%FVd?Mm^p zhV+wOUzPM#pSCwL475Zi7HHm#y=wDp=5B_(nQsz`8eO2fen|n}2Ulsb{jo%}E zRp^)4`&6sqoVV1KM6a=z9^LD!k-i%Ax++wS^wpr(RiSFo>#9&S(pMvWHRz|Aql&&7 z^aU^eg!I**pKks}GQAq~Gh8VidpY-beRa}ThklBUeRay5>XbRvq1U^$tCPMu>8nFO z)qJMtt3#i9w{~^t^=|Fz$ouI|5!cIE((7xGz6SKVZ(4)&HK5mh(;Cq0zG)50`x>OL z0ln^<)<|Yf%D!n0=yl(;24b)KrZs4^BrnmZXLZA^!43wWro(kmExHrVyf@5^sDT*u1ETM z(62VH$=RwN^fMYJGp-)Rz8>l8k-lC~UytiV2ihU!BeIuhc z&+#(dV)8F#HB{GC8X3J`(`sb&nUSvLHZpqiy8vyr)A+uT(Pu`p-En1ANZM!ev*XY4 zk~yc>Hzs{!(l;i3W70P!ePfD!W70Qr_WmhkGCNLp zv2Q~9CZumd`X;1rLi#48Z$kPe$Q;!-G5U1GK7JQT6Qdt${;!kzCdeF#vV4~&lsPhw z_pxtE`liVH;`X|-rlfC5`liVH5ml2%XiEB~q;E=@(=-_Srj$8NDfUe%_OjyOW8aMQ z%}C#j^vy`$jP%V&-;DIljQ&a!!DQw%3&y^g(VKe^Y_yvp_7Y`@eKW*f*Ar!J#K*ol z>6=4;OU~r`nv=dc>6=6U>OB3+c&lwr`sNh-=E2xEr`R{A*f*!x%PNkKeGAgJAbktc zw;+8B=s&Ug78Lsyq;Em7ZxM`r3yOUUihT=;y{tF+{=OyjbL{_8OX%OW{ccOrwaXMXYut5&3M1-X82x{DVA>eH-+^g^R@=wMz71Nf z?!d^pXnM5BdfOU(x?4+YYhph*>SpI;Z7KF`UF;=u+CtyBaq@cLwiNreM(=kX+Zz4g zsJr=0(YH1F^l0SX4Rp_ATcaNw^>D|{Z%RE~sembI=Ew?eMzq-K+adN#Tqz#=b`<+| z6#I4*`*sxjb`<+|6#I6;*tetDx1-p%qu9$@b4Ik(dfP+4%$4H$_M~r5`u3!6Px|(x zZ%_L6L4AADw}*bYGs!qdGe=g%GolstwGPm)bfx$Tcn8Xy4wN|^jNb1bbwK85kJ*7T zr-RY^{i6=hr|uthfL`~HIvBm*Kk8s&@Ar>78fohOQKvv%=RjSTK%J}(r+%KS2B+4^ zns91ek3e0|KwYmuUGG3$pFmyTKwZB;T_RA|KTtOyP&Y78Hz-h-9;mxGPyxm$La$H4>PoTiO8TzQ z&oZAWvF{3f<)Tw)tk)I#+3vWK_vYaf7`1mLy|fLl??(D=r0+)hZlv!<`fjA}M*42h zzhFjgqVE>ecO!i_#9sB?NH6CeukTL!?xgQd`tGFfPWtYYIo(O$onqfTsP9ht?r62w z*lUHllU~k}Uf+ZCJxJe!^gT%5gY-Q}--Gl$DE2*q`W~e3LHZt~m-D&T_auE!=x5lB z>q+{a(9bllNq^rH`nzi+pM2Pp^gT)6lVaa9sP9Soo}}+d`d*~(MfzT(??w7vr0+%g zUZn3u`d$?KUO{~?()S{LFVf2x$;ZAo>3c)}ww+z{hF<58y`lG|_`SZpq1TaWZ_@XM z{vGp~(rSA{KQh||)93g*HhV+=t~;*u_wTtH9*jzboCB^nFR+m-Kz1 z*I#DtOZvXh>+eeUg+BFnrTap!zboArnWMkV+!vXn;~W_wdwoCXSD88)!S#b)@8Ic2 z`hHF?t+pTZdIwKGihV!mb!DO-^v7)M`$3<22TwofpRm#H2fg0G(~t6A#`0dDAbkRQ zT~|qvKH>E8JrflB1oS#eOOQSRy{@Yypif;_NkFgbDhZ?a>naI~z05kizCY>vL$A-0 z>QDOqPA{?V54}E1sz2%blfFOn3vKNCL!bIAss7L}va#h9M-=r_9~NuRUDmEy6N zIj4C(u#NU0(ho9vzxy?aVn2vtKgj6)?$;pF4>Eec`!&eu{qENwqyO*j*C3-eS9Cj5 zeE(>WiM`)HlG$;()2EX@o%HFXPbYmk>C;J{PWp7j{{L*<1(aOHwg%wF0tCHCa0nLM z?cr_#8i>urmAJdRhq$|kxVsB+7vfIb-R0H(yLMIohhp7z*E-ed>2LPzs#A8Vb^R!_ z(f@b-D6`S~^`p$l99=)kOqnC&cpv*Lq|buP(ei&j!7&A7vwbHqvKadcS^@YV>~nDAnlyyMB}keP`Q7rb4glN2#Qj znX#1ER_o0Uz0O8uH+sLDIXmgIlRmrA`?=ig6#MK(?^gk`8@->)&2IGnJrh5>(fc#; zvm3oXRX)4X`%~p*4$tdzkUj_Wx|=x%^yzIxau~he&71>z-OZeX^f^eM1A5)foCEsk zZsr`&>u%;8&~LNx%>lj6qswe#Jht7wmJ|9N?n+hxbS5w->2o6X`ONPk{hXYMyf+V< zNyg=*%*lz&(Y3pr$efSO>0xrO&56tzn&u*nPI4l1J~96$@zdm9`=z@|zSqjUsMqHr zeJT{7k7wL16J{QG47wL16K37nmi}bmW_n%sQF66!T?_~zp>vNMnH}raDW^U5w zhF;Ii%niMsnVFmPxk;ZJdOb5UH}ugnGjl_)XJ+Pxey7cc+*E62t~n*P%f6P!=*>!? zyGmX^%0v1*(Cf-$9_aPiuRKQYS03{iyUZeMI zPG0Eunop3t&kKF4$s_5>wY<>pa|+S#cUPkCZR(pmf0WOZM%Quj2g(Wr$_k=P_NAKt zZny_OuTbFM{ShcD94IRiC@UH$D;6j#9w;jjC@UE#D-|d!9VjakC@UK%D;Fp$A1JF3 zD61GKs}v}!94M<2D61MMs}?A$9w@63D61JLs}(4#9Vn|4DU&u?^3T_vd{le#q2e zD1g{My6MO&UT0vyaV^&`fu@`-6tol=WMt4EP{&DLqh|D=)oRTXA zkvXcDb~5f_U&!d=F}-UPf_{Sin-`+YDTKV&^Xm#B@Adq;LWsTgvkMu$UpFm;*ylGt zQ(|Ap=*_G{l_yMZ$)7k|2(h2!K3956ligKvZ%JBoum6Mee?YIZp?^TH_q;!#_gBd? z(SMNs57PeueUUT?{U6Zxo6yGS{V4^1Kws4S8;SNGCidB5#oSf0UhX|!UzqfTNne=s zg-Kr+vDe?FF!b-)XcZ=XVbT{4>I;*;u+f`6XjWesy(O)+a+mb_BBU=u`XZz+Li!@4 zF9N;Jh87`x5z-e4>Wh%R2SQsBz4VcM?2D7WIP^_lsUyIbBa^u6sOo1Cw+0~mztj`ZBB9M zXI9QZ=hqd7ewq7R$@}H*DmnJjoAde-q%Q%zt{;^keF@T+AbkmneF@T+fL_;+N~;O91Y)1T=8^O}y}l&rOG2+LW=YbQBz;NJmxNx|k4lohB=ov|R1*5= z`cX;fb^WL$^bgpbq9rMFq=)SFrJz4(%A}<&1$_>C&nrdxQcf>Dg;LOW%Ky(ziT6oA zN1wYZ1-(AGRtox@_Fh{G`XvSG({p#FpwHz#S28EJyOPY&*h^pD>r0cqw9)(TvM){g z(xfkK^!~f-OH<~QHhO=CT50I@yX;FF{eQp9zO>Q%@3JqA*z0%Mmo~BYy)+qhczqe@ z582q4LG1suIaUVx^zKSdoz!z(${_Z7u1guxmqF}x1*Q!2dWKpV#6Eh4S{cM%&rmC4 z^x0!=-RCC9UdBgWUzYS`q1P3dvZODI*zYhuQ!=M4^tu957J9u~l_h;y=y#g;Nt;s^ z`sfNwS?G6JZ&}1%pFb)~c`qZmcB~W{ z>!#(PZ)kp|=*vN$uI*WKxAObZ%R%4BeXitvV|SI@V#=5^9y?<7<)J_7u4HCH_b8R8 z*q4W1_b8QzUiT=KCw+P7bw;i{^fm41qyyeANiQ=F@z`THDE5^|UkUo3 zZLO^YeSB70ihU*Me{r8Hv5&i}NnaUyt+kb*uVLONwYDwhcE(-Fe9lUkcAqQr zIcwaN^c1w8BXf8uv9s1&-RM(d+TK@3>~%MDb&7p;=yf-9b;MqGGgmiyKNDTu=>1G| zb)!#-Wwb43b?E1w8&5OQ)r~$S_LFTftDD%T#(s8JqSy5!nQcsoowNEH(4Ti#$*TZ0 zNM8ebT?MF-$Q=9pQ4OQ_s{l0+dpYw>{(?0Sd%2RluK|5@6`%(6x(ZMO`U}pKte1Jw zl-Nc4T21ILxvOM-P14sSeNEEWBz;ZN*Cc(-puQ&QYeKJ2Pt`Pe@6YL#8Qgg6vh~(7 z`grV$yGrgU)FOQ?=(VR%3wrG-)S|qvW%PbFs+Q5mV_R%{U(4vt_mloyh(?CBj6NRQ zYFqePsI~gNzO|^<%3O15?5g$FHu}`qHFqVo_PV=Dp2w_h^#0qpYa4xP?8a{sr-IZb zeQm`48EdJH*qanW=F~R&)Yyu*mQk&(ZS<+J8_d6vT&s=Po2J2DCD&S+6^}c89mHPs zbx>=ymsW>jUx#8}hhkp`dTlZ5Q0(g<_S#FUgV?8w^wR1e_S#FUgV<{?t&WSmtRK}i z`sn&my+B$0Kv{!8S;IhCqd-~XKv|POS<^sSvp`w%Kv|1G*`I;3mVvTXfwI{fwJy_vL1o5o`JGnfwJC_GO1aTf4=tA zrP@;$wWo}&wRKT@bQD$>wMXyRby0it+dS%0-LFfvr!H!be)m~j)Sl>fpVdX}(eFO1 zi`t{#eOA}i9??rp@%nnCuLu3FR$q_mem&@aGp|X1qaO5?-%hkH^{DRGBYi#SXPNiO zJ+B`0t(KNEJypL7P!Iaq?sKK5I>%il_f(}$dwqS<*N6UN`@Z_5uMhnv<~7mRhhEQ# zu21^-r}4*<)$kRq`l7S|6`(K>7xxZ$SD6q;Ej_ z2BdF5`UcS7YV{3*`Ua$LK>7yA9PR5#JL&ZeN#789^QCvV+cYG7L+A|*v2O_dlLho& zCa*j;Bz;4QeZ!!>A?X{Ez9H$QMfdtfq;Ev}Mx<{<`bMO0M6qu~`bHG{MnQce(l;V~ zBdWD>@A3M^q;E`_)0p&)DRUZA<}`+0R{8bSGtxIh?DcnPMzL>3`ex8ywVBfl z`n09i(9A?L=&!lYl@{~5yGqteAIZnQIq922ud_nUN#7iLofT>hz0L|XCw+6$H-}zl zg_=VjofT>hz0L|XH<{ySg_=|5NN>*TTadm5^xDsEL3!T-dL84mfL_NqElA&j^ev#* zTH6BpbbZs)oK_3ybK7XQfIg4AN{+qsJH7r-(*Ftld7E*6lKxNVFSyr|^ZrlL|4I5k zp}%O}Cwc!T^qJnzMkBO8p}*vQw#5FjyGqte583NmlD;MBTavyd>046XwRXb&C1S7omek%$U*79mL4T7S%e8`jtesP6MS0%}dhKJjf{?|<*^;bz8zw(Gtuo3dtG^KhuB9~9@`=Iy7Ji0=>5uLJIWjx z9eaIy(zl0RpImECnbV#!r+q^Ia5J0@-k$XBN#7oNeR8cm^wB5R+C#5TuC+(z=#y*h zDRX2T@AVy^zs1JB1N0qi#&sZl2hw+dUZ2D0K>7~QcXU4``8kXZ&_~bl>HvLb_YSGG z`W!|F(#wp4*LNg+N9cRljO$4Hj?nisugS=;BlMT-Z{3mdz9Z>7BKCR;Sx4yi-S|7T zm>r?-j`jOppTva z*9Ce#0j>-5dIDS*(#yxwdX7XtryJ?J zk-i)0y9M>#NZ*b0-AFI9jb7iK^xdKV#_GG1zB}~aT77ruyG^_ay|nJ6?@s#er0*Wo zcPD*!(sw7l%!_(`57PI5{yVGhLHZuhe{c0Ypf5i@q3=QZ9;EL<`W``j57PG_eGk&h z3~oGjyUp~T(5H1*lK0xj>`8gwlk&bN^xDVlN&249Yag>G^xDVl34OGW*%SJ@wteUc zz4kGCLa#k!nQQj?UZn4Z*sH!5>3fmB7wLPEz8C3xL9czxUO{~?()WVCp8Z{VQS4<_ zJhO{^Z==r~yTiu5H}v|QYrRR|oAkY**Y8~GP5RzO?^k_$8@>O|wcbYm-|t-OZS?*- z*LoYh|IW4EMxXf3HCaFEWAxGWqrQQ%eu1+7fwBRCvVnoJL4mTr0%d~(WkUjGLjz^Q z0%gMkWg`M*BLiil0%fBEWn%(mV*_R50%hY-#?N$32>iQ=fwD<~vdMw6DS@)7fwF0V zvgv`c8G*8yfwEbVG8u!wP4W7^r0)y8u733;eP5@S zJ9b~xeO>+POZvW~?+d-Ie)WYuy86`@dR_hMi-teY=yhJDAL;u+uj@zsppUK}^@Cp5kNO$CUq9+ccMWNMyuLr_`;)#u z>HCwuKk56EzCY>vL$B*c{e$}cr0-Aq{uFy@C%t|E=?6fs>qi4fKLC0ILtk$I^tygD zfb;`MKY;WDg8BiZA3*v6q?Z=m>j#p4AoR8ENNFJH2SQ)fye4@+FcJHw6Z^CVQr-_F z{Xpn{GGj-X4IK#meb0BIRe*ue|7^#X1CjT?xU1yZP`USb{UFj0g1&@(-yqTtg1)4A zP4t7H&(tX23;GoM zzQ3T?b&9{B_gBd+=3k`$i}Zhy{;#0^FVg=7eX3I=>*ap#^@B-282S%vD>In%gPmSt zKNzvsZ!H^4`oW|hO!~n={b14$CjDT_`yr$sLi!=lXSDhuq#pvkuD}d|URPj-kbVg1 zhd{3@Fhih^uD}d|URPj-An$cw?htA*rH|xeKa})Cq1P3dp_KPSq1P3dq0s9J%uvz~ zCH+w7KQ$4NT00c_=nBkG=yThs4TWA;V1`ocr8npG!$?02`n>k13?uz8=<}J^By)yA zuP5COgI@1e!$?02`uyg7q8|o*rq{owS)pOj7jT~|J%xhqDmm|^-|6+kNk1I=xNUQW zlYTh#zuGouIP_0GpBUQ@r`QiC{cz}iGw&1qaOgifQiSxwq5s`|uIMwlt7N_OkiC8c z=|@1XyXi+z-j9G@S71g!ue<3-K(D*$N05F5^tzjV1oY9}^dq3x-Si`nIl7yE1m(T- z<-L9+^mp13+DPbi9(^RmekAldk3JH5okt%@u^$P&&ZCcnUgyzALLZ$+9|^tAqmM+J z)7ECrNYcxw!|O+peiZaNk3NcGKZ;^MDxtUY=%YwKiu9wP*Ln0&&`0OdM?tUi=%WyO zokt%aI>Bkwpe->bz(fels#u@#8p9L6a^!{0Z zaYpZ-1sG@a{#gJS$D6&));k{h``nf2@3Q@)@f7>6 zmGo0dKNb3`=4VQqGZp&i?zXAWUvrk$xKKr$Mh{t7*_j$5zvz*Rj6AIsDRZWi zemd!=L$523)1i;9JWhvRS01NBuPcw!NiQ?FUO$8MGoaU%#~Gxb0lls~&VXK59%qn# z2I*&zenwC~gY+{MU3r{I`kBz{%HvGvb>(p;>1UFDCh2De^)pF7 zlk_u5FSFuaKa2FUpx2ehS)`u@y{1UCCR!~2S^s`7m%jsqPXtvQu z*N^4|%H{^j<^{_B4wTIglr0F9Eew<`3Y0Allr0IAEe(_{3zRJnl&uJqtqhc{3Y4u5 zl&uMrtqqi|3zYp6C|e&W+Yl(*7%1BmDBBz;+Y%_-8YtTqDBB(=+Yu>~yOrdhuRXJ= z_RL1@(OIF{RC{Kl_T)2n6zOlwM(xpAq1jY>W>f8%joS0Q`Bb^*%|`7>SM^Raui{TB zn2p-=gZVcJq1-iobXUpqDpFIteh%s9kbVy7=a7C5>E}SNql7u6pF{dNLH!)k&q3W+ z{T$SN9VJMe_WHS`p9{VAmgbUvF7(=4nhU-5mgZ9I=aPOd^g5q7H=&R0=$;F`&L_@= zUgs0%x|U1+F4FpV{XEjogT8|8Z_I;U`_l8E_gBgD=<`TFkM#4PuV{XzWX?S3qvsjT zgTAYsgPRAvo@X?V^wLgx{okbj8~W$%Px+hlf0O=i#9n`wzbSM6CjH;gXD~lg^nXKN zV0UqvPy8GD7u@Gc-oNOsl6$JsqI>;(($9zfCHubllsWUEf7!eywRS%A8M7qn*?iK^ zC;fcV&kyS7lYTy8ulo5Ed%5>`{Q~Ikw`2PS(CcYT3n=yrTptk~#I&$Bs z`$f<K9YyNFT|^ehKN9K)=!c)=Nmg1o}LUe_>| z8NGiNU>WJ9hwSysNxvL=UBg%oz21?QLoZj7Im;7zyN0ox^vg-V9C}^DSPp%34P!a< zx`weFvDY<><8DpxF+Fv1tSepJ%j=V!sah*UgNww3zD>vA3r&tuuOm z8q+%H->~aH>x|xiC&N0U|L?cKuQPi8ZSd=iJ~bwD3o@Eo2mPzIJ(ALR>@n;8hcf3M zWX>q}FK;scGQGQ!Gc!kw2%xltO{*%c2$FI|_ z&VP_OW8M3u#T@6ZlKYr4H{$i{q1QgrUGe3RF2B>hI{zqG&gM$&JD{wwpEWX?wDo4=CSo41kl8%e*B zV!tt{-$?q6q~8d=u3^Z`nAdM2{U*|HBK;=PZzBCB(r+UDCW`&0pnenSH<5l5#a`y{ z;<3kVt=$a$6YfgdoV~WbY=%C)yOLVF&s<6DH$#6dQ=(ni485MKu^D=8?>9rg-@H$1 z?PloD-N@%^Y=-`T`y}aO*0&k3ne;N-==EDjzap0ElY=!=)jr~^WkGZSlHb-V~Q({lrT-j#y zDY2*ARr1|x8)eQm==E;34SM|sp=~Di{%*C+=>0bcZ8Lg*x7ud(|GisnGkSlw+Gg~r zF+F{6n~A+Y`B3JX%{|C^wwbalq~8v`?ibh&z3vy-PMNcvGG{wtU&{Q= zB=5H)_J>Ny&O$$jydAMGZU5%m5&JUkDmnHtEAI6>NWX*hJ4nBS^gBqugY-K{zXSTR zR=*>t-$D8vq~GE4Ue=Fx8hv#AXjh_qL^Z0vut~J*#nF>32b| z^D4Wb*U|AV=ttVNW*782I^G4nj*fRh9~~Xs@2F(fhl`Zlm{ijon7??;5*}{=avP-A3>48oQ0&-!*pA zT|-)*)Yx;@`>)Zb#-4XqvcoTfyGlOw^k1X*r=I?6^r^9IZ{CZ0`@fVq|3d$az2p81 z{R`%2O6L4)^r^A$8t$d~%CH-E~ z?}c8!9e6M4_mX}u>GuZpd!c{XMtd*m_abw2K2h#HDK2yNk$#`ir^H^dKV={3_Zhu8 z3);LUeZ74~Z{`HfW?EQDV z%KbdHs%QEB&`0;>9)w=^CJilVbULlUial5rq~~Lv6ueFVd(W9eVFuz zNq?C1hlBdVq(2P3?#n$)dg*t1{Sne1f&K%V=|@O^#ObBYIRd@z%RNH+Bcwk<`XfR8 z5z-$a{Snej583OFlKv?4dS>QP%ABLn>zSEHq1Q7rkCOf<>5oFMXJ#ISK6+;6QRwx| z%%jljnVCl^@1-yA^~XqmjP%Dye~k3UNPi4^?PDGz{V~!X3+j)N{uuO4?Yzn{(#xpB z>yMNEIP?o_<{T&eap)JC*Cca}Ltp-dZ*Y#+afZ zrPeNSSIMJe86SE53DTc{KBIl#3CjBu(Ce<^6VU6f;uEAlLHZNW>#pJx&_{O_pMYL> z6`wG%_q&QuQ0!$S=k+H^e-iqb?Wdn4{YmJxe}58seeUig=}(gWB=k4fvHeNti`Rab zW+qNTf1~?c(ck2*l4CDpPOm>j`ctGoMfy{uKSlael=r7de~R>{g8EaWKZV%8WKSVG zMX{IBvDcp_{b}g6r*N9`{xtO3Q#cL1_7qN2>`#;aH1xW=?KJf1BD>p8L$ABrPD8J| z+fI{S#_?W%hV*Bk*KzF`iv1brbzFM}dL7rEq1c}x{Tb+WTzdxk=(zR_^g6CR1HF!G z&yZeb9K8N4>CZx6!q(ceq(AF2NA9&}q1SuuS&IEx(w~LCr1_cB=A4DTah)G%RDKrv zQtopl?@PO@(0V+6nmM)@%r&lc zzO%hQok!+$aaYN)m-!~IzX1K4b|i2C`hK>pxeP0`!|_m!QnK0R2Gsxf1(9?n?AJGL)GyufIt8i_rgRf9s3Tr?-F4i_o_; zuZjL5^f@*Rg8m|9&PC{TZ{9`dTbcKX{v!0xbb7|@Zp-tOo`!P~`qu7qMc>9(UxNM<^P1={L9ge@Tq6A?(qDo;n~nXYMBZoS@4LGMeTt3tC6hVX zW2x>cSueAVUVoYNm!a2vk(ViRE>qrLhF$$6Bz08Yx{T1lnvUz_6`q%8=>B6He0h3Iu$D|5|We~t9lNPms=*GPYj^w*%*{{1!5UnBjsp#B=^ zuR-6=>aS6IFSFuaf1UK#q1W9G*D3F>yS$e+@;dZ-uf0zC>!iO9z3z6np2+*iZinm8 z>u!hZ$a~!{a26Et7M9qh)eJYP3ww z9gUXB>7&syIj1pNCZ{z<%j8-8XqlW_5iOJR6ryGF)PJ;0o~4hL$rJU_GI?q}S|;nE z(K6Zd9xao7GSM>GuNN(oU1iZS*{c;TlQr;Yne2*+mdW0zXqoIkik8XlhG?1Wafp`5 zT6VNdRyRo#ghN1gaVrgZklh%+}TG=z9`&D9T$Sv@)Nl?QSfs%qME?iKUhK#0-(z6H6=eiCTMNX{FuO+7nBg-0n(E@%kH}f7_JF zZ*~Lp9c-I%1L<#oUVay8cW;1RPr1GUdR+y$0eW3Ox&eAUC;A5Hqo-Wo0DWioxuVxo zu5W-|+g+*C@z^`odn5Gkx+{sj&dA+J`Wu~Ie$N}B*T2h+6#E;Y*ZnFtLVuq<-Tg-B z(`EmJM#ncof4?13-iX*g;I5KmFRhQ)-$eSG5PO}=y@~WUIlaXGCg^o8_a@TcMEaYc zZ)JN+H$i`BUvBED-UNMX+dsMq`Zn$=`JN~3WJ>Hk8||BoJ|*_PyGmZWyBYfQ_V0N! z^xEIJ8G7w++-&rI?e1oy_iJ}I8@*qafyLNZ8(fhT#n~gp-_JK1c@A!}wJtg*k z_O)A}ztgObNIu+x*lTa;7Si8B`ddhU3+Znm{Vk-wC8)oJ^tV8-`&Di+dGGhD$i2sW zXS&s=f&L?Rl^pvtq)$WoG^9^M`ZT0ZL;5s9eHzlIA$=O?d)o|$@$**X{X6b+rOkQQ zT_xwe+|RxKHqzflwe~iuwYNFF)Y{vi*IIiU>2D+bZP4oq%x%y|S72^~URPjlL#@>n znA@nul%9vz-%k45q1Soz+bMHyhhFE=Z--vz(QhaH?WDgQdYwnV9s1}z`t8u`Jo@cM zpFO7Y=(m$z`bb`%mh@>!pO*A#NuQSVX-S`!^l3?-HmFZa`n04^3%!o*r8npGcaZ)L z=;L;5bO-70fL?dg-vPburoV&qcaZ)L=yf;!9neR2)87HT?xw#3nWMYu@1WRAztijQ zB>kPxXSDU@PRjc`q1SozJE7Nk^gBs^C+Y8mUgy#8gg!ctekb%gkA5fgai>VGwbDcO z`nyPf7xcf{_uWOYzYF@`%xh9>?}A>x=kYG+b%b^o>FdkWH*_xig@e>e2m?ECH}{oT-~nAb#qH}uCoPu%71CjH%{zdMmR=6#~S z8~VccenUNlyAzq?K38gOVRx0Rmr;k;-$VL)NPiFM?;-s?q`!ys_mKV`(%%!*-$VL) zkU2%H{vN8eGCuP9dr5yU^g1JVFX``vUT5U)gc{||b-pZ*Vef0g`<`~OJ)Khpn?V*fwr zix>ZvGUtELe{Q}1gZ>M5m8_RBr`O*{`uiwz?xWb>N11aUWzK!1zmN3yL7&FD{yyk$wSD6Ipuf#sCF^B$?DhAP{(k5Onp2$RFL*!c?}uK$G46io^)GQh^xDt4 zpY-=bKgj${$(;M4kA7p^{m|<-#@!G7Urv#%mvOw;KS25iNdExoA0Yh$q8e5c=o} z%!APD3e1Dh>k7<+bgz}U5wA}N{g=UNC&;H zVWfjz&lgAsee`^RbkOVh0_mXF^99n8US@H;{vpyo1pQmKzC1*k^APlJo7Y7D5cD~I zPyE&oQRX~E`iG!@$GlJS{vqhI6>31W_95usb)PHu+V|X*8e7agWoFFlA0hoC z(AT%`dxT>D2=ooiYZCiMpdXt#aq8qFq<@6;k3iqhyia2PNFsAuE;p+H#h=pkqeq}` ztznl>mMckqtG|A?|YPD|0u=&(L~~;Ow^V=yk8gQ_z>T z8Ss?T%lc7z<4&H_moj-8BwF@NpiG`si2l3h0%h`4K=j|qvjNdE+1np2lfC@WGTG4| zEt7rc(K6XZ9xapI8bXlNA1z?l}=ABS9;VQ9VMiv+LNAYPkO37=}~+1d!^H(_C!Ys=}~)hl#m{^N57dl zy{kQ(mzf5r%C@b>7OS3)1-eI`YYx>D*cV8gZigQ|1{~JCcV^YuYZR0 z&p=fg6O71O5>*Mv$lKxrJKTG;&N&hVApC$dXq<@z5&j$6+lKxr5UiHsX?4_Ob`sYah z9P}^Q-qLfVe-8SW&1-VUehzv)0q!}{KS%oKpx5*3o`XJme%*7>>-lxhL9ZvkJqNvx z5~M}<`sbn75!&<6Yftrg==Hw#JoIuU`sbnVWP7U5Q{F!hy^a!|hhF>H&qKc?($9V# zdhKUF5B+z>DfRSu(#yRk9{b+DmVsiQ0s2uk<1$d}GeAGu>N7yEr*mY0{yq1;rKh<|dbFc>(&b%=<+D0`zNAN77EG7oh*zeXi)gaaYNDxu1Lei==-M zvA@&i{fm@2FH+{b2z~7$iNEfPq<@k0FG643{7lim2>sBvx6=siMd*vV&lPngxY&_`DRUV>g%0bWAh>ngxY zl=sp{^7@xa|1$Ktqx)sboR^{39o;WOuRFS5CjHB#e;In+(fu;?=^{J2Uxr?HbiWL} z*>;Moe3|spoAdftNdF4-I-mFo>0g0fdkU{WukFz*q<@9(F<5DUqA6lm2zmzn;*W_eq=cI`o$g)-e5?%5GNZb?C3U&y_ak zn!8GFb7a)v^>09*(UeKM{RZ?ppZEsp-+*4{6W@Sd=M&$c%y|QPoeg~hdYw;v1N!KE z;v3NGeBv93z0N1TLA6%KM_&IX>EDE2=M&$AUTfx?&}&cOP3Uz#@lA^To6u`d;Z5kz zm=;80|0eX&`NTJ&uWMVGH=);WW`2`0M@Dj9{}$=rBK=#We~a{Qk^U{xzeW1Dpx4>Z zw}Se&NdFe}_3ZER7R6r1oL>Jn^gr3mc^i726?&U8=WXb9R_JZ$bynzY(!UM8&S||3 zz0L}~4SjT0=xykAR_JY`_p?H8lU_#0UjGj1-+}&l`^4}&6#I85_U}Mn*(90Nmv<=d z-y!`w(3>BH%y}oF@4=_iyaRm(_qkGQUvO8+wN}RQ@z~Ec+V4WIy|j0s*WC{9QtaP_ zUUxgZ3%%}kc$Z@TF7!Gp^e*(e+u>d4qq`m6g}AFw9{a`W--ABx zuB4BtPfxu^v40PGeR}FW=r6hVCGYBdkM!?BuTM|C2YvMEsrR7Qr>EY7UZ0+Nk7}*V zjd=b0(En-`?<4lrZSU@V(!USAo+b4@^m>-m`xN{4q1P7kedv$aHs^ilqi0FI5B*VF zPv3|Bn7c~O9GS&QiT!519~ga#+coHish@|En1%{s>+Sfir=BWNd#QrV&xgS#Ie2CcVz3W57-d`o3LiQo${fEdL-JACzGAFt> z??YtHJMMF(&C$JiA5yKAIXtibi1Z&pU&j8Fk4XQK(@Q_+Bj|N+-ba-8ACdke=yh-2 zN6<(2=6wXc?#=rMd9Qo(KB8JHvyEQ=G3h^sUQb8(nDYK(==F4jkD=Go5k4mU$E5!l z`ph>bGUsFHqo*T$485L?@UhWnj}12OkR1J(^fE8%^`DUb6X_9qnkPh9NfXMRGN z^9kucA^j($|0JmYg!G?4uiv@$3F&19*Xute{io1>U^C}a(tqmok~yD3ug^SwO8QSp z|0(G|4eCE7{ime=l=L#!?De0K{xj(Hxx3FOb3TJ!pS$}EdVTKhGtz%X`p=-(aqVZ& zf47g%ZTt-S&ur8_gZ^`OCGEY=rOB+g*MCm>&!N9$dl;Wn>_3P8vUyEn|2gz&?3(rG z(Cf(XbJBkfeX99X=^=j(eY=r7pYu8N+0DO^to+>QO7*f<^o1!+p3|2ynF)-R zeHAE^_0{OVlXbsnnXIiv%VcIRS|&4k(K4AQiqM8EUz3)G%#?sMg?aot^M?UB!wn&S0elKxBRGurokN%}9L*ZIUR zQTKH|@k`QwN%}9L*ZIURp^wfdehIzKCw_^#uk(ptqTSV&OX{@Oe?|JQpx61tuc+Pq z3VNMS{0e%VPyCAXUy=SRYInbaK02TH74*4n)V_jV=M%poy|g}F|265qCjHl>|C;n) zlm2UJcfTh6*QEbCsQ;SuUqj#2j#a)Uy|j~F{|)KCf&N|_gKsEvzM;JT272wOenYYU zhV%7W$(CfU)cclN0^xr|>+m3O*3+lfk{dc7QjxtB?l3xEk>A#0w zSHHd|{rAx8>eu(s>+09{r2n4u-;@6Pp#FQ(e^2`Fq1V{U{oLz+ApH-}AGUwNA4vZL z^ha!O=?CbGe~?)H`hoO6kp2hCoF9VvA4vZL>3<--^gO)&N7DZYeP8oemOI0br2i56 ze&#jF`yZjNzDoaP^1RBAr2mm(|6@@9Bk6x6{g0G6(ns?8jHJ&9eO_DJGm<_d^!dzd zqR$Aue%D||ihV}XXM{e#d7rd78KKYgy3ELxe@b^(W`w?g`&?;r3c9Q0S}VOdum6ek zKS8hK%b!U96ZAU1{0Vv;U;YHW?nnQL^glu0(T*>Ff7v(*I2QpGp5S>3@b^&*=U+sQ;PtKa>7v(n}B7>wh8rFQos4^uLh) z7t;Si`d>)@3-o$M_b);HFQos4^uLf^`tn{MCw(0H3O3{7(Chs)4!yrh?qkMDA18er z`ieI1+09JsQnW2yFQOXQ`Blo!y`{wQ{xrZ#{c(2a_y^NhD@3SQG z-o7sj>9ZvA-n=IIEYNEoGYjdnK(A|eS)kXoyDZR0*Y2`FuWNT%Ozi#IT^7n5nQ`#? ztfbEhy`HI)l`7$>$k~lPHI^sWd|Lg=ZuF_K&GsIj-RM(emCf_DiJvX2Upk*7 zb9i2#gY-F|*KutQ(&vC)$F(`2*ES~y^x8wtLHZn|&k@w;Abk$#x7gn$hl#z{ORvD| zbCNzM>2s1kC+TyNJ}1RKC+TyNK4(y$lk_>Ef6b0hbCO=#cAxjTpqF`3`77l@-gmIM zl8f>_7xdCbO6KH(UY~) z=FCLv%?-V-o92f8E&Ee)lRmf8%kP;RdTsA>L$5n(b3?DY9dbjj>!!J(&-Bs}`o6o| z(CfNsZq(ZMog(>OD{imPL;5_>S51@nOXMMa9;cVs=Yf7f?Zk6;c_{XINS_D#YUXE3 zt<3}d>)GEidr}Lyacv&xtGmyYdu(Cdl*c@cX((Lb+iF=eeNpV3Fx4e|%d3Ixgu2FeNr%KiwH z6-HS`(~_9~Zny_$=@kk5yP|=zVu7;afwB^TvXX(aQh~D4fwD4zva*4)a)Gk)fwBsL zvWkJSN`bP68z(M|V2qL+#O>PWfEz z5uwzSIQ~CzC3>kTi7V0TX}|eNpC5WX?KeO4dfIP(s{8q&*PTxJq1V%X^Ftp!?KeO4 zdfIP(==HSU{G=DD*B3y`rTPMBxuk~6?^1yD1*qLE0DZ6La^0Btm&vg&K>7mEOA8_G zZUN{&`l%AlOca1#T8zX`lY5@D6^X0lc2{g(Uy$?#q1Ul}LDCl_eL?7TY+sP>8U>-( znTdkX>*%;3^wF_>LFnt6CQZBr5&L@XO7uE9mMEmU%qe8_sWEB)YD`+v z#OF#+)n6s=(~`eWW~cvy^nW1s>1-eI4-6lD|Rd55)dq z^P1@YF#61~40R6Nk~vo0-Ld~b>>qLOmpk^O?kYKRB%gfj3zNPu=?jy-FzE}EzOd1o zeQfsg3Y*yb@181**gt0Vg%NwvrzYtOBleHG_e<>M{w05j!lu^xezs(Z&-)_Cd(E68 z&}(0>2<3edm-q5Biy-f{uUCZfz6kPO`+7wXd+qBLLEcCA$Q42CwXatMdH=4>`yyy_ zGT1B0YOgO!`l8TlZ>cEs>D~L}yi)Bg6@^}VOGPQ~i;})5^x9i03VpP5D_3(Y~)ZWlnMEb+md*WC`q5qsV3P@FPHYJ=C8AbknSoDvlK63}brl%UKhLHZJ;FF~;{k;t6L z(^Dm&*WC^!px50FB}gy*POmRX`jXHWv+ZC>ihW5}YbA3^Lf`N4M7vOu^1dYLOG01V z{7lK5lF&z2+)F~QEAAzcIVGJU`EDgWWUntp`clyAet}Y?FGc!N(CdDIQlu|M`clyA zihHS`z7*+8A@;gopcK_w>C1b4Y0{U5{z=>JmL`2^=$|sLN$g8Q|Mn+|du?gbmnMB_ zihb#zzBK7eQ|wEVUPc{WUxxH$px0TUGSH{Db+`=lIxAELdYu(2L;5nLF9W^q)hH9x zmmz%_ihUW%dl?^jeOc0%g+8B+eOc0%g+8N=eOc)998Zkx%aXn<>B~~)lnv_3lD;hI z%aUG3a$aAK^yQ#0YwJrn(wBq2oOw+$ryTT$%necQyyZw=j`ZaybIJwvlD;D8WyZnlE0Mku^d=pU&6P-B3Hp3Cb1Ffv zJ54H)z7pvxL7(5ePwrNgppWh}sRVri_qj4MEa8p@l=9|2}D(S0|zAEXflD;bGtCGGd>8nDo`(&yH^;Jn< zmGo6fFEe9aUybzDNMDWg)kt5B^wmgTjr7$>UoEJwM*3=`uSR;A!}I#;q_0l;>ZGqu z`s$>wPWtMkuMWNL@~IxwS0{aS(pM+F%r<&`4bs;jeGSsrAbkze*C2fj($^q;ji9~; z>1&X_2I*y9)az@KzGgyi+p3z->&Uw%^!_S&k5Wz2*Cc&S=u6rbvnKS>Q^;yUU&?*1 zw3wycRdS0dGq_$~i}bai*KutvihV8UbzEBuvDa~JEz;K_eJ$wCSN)*9uLb??VktBe zSPObX!F{HdiGB9i9quZ5Tq|?UUSFH^wV~HDO=?r@YrEJ>Kc_bIdZtNj($^+^ZPM2c z>T8p}HtB0q=E$tL*ViF^okZr?b*DO{uS5De&^KO|h*lla*CBl!($@*<>yW+<>FYSX ztRK}i`sn&my+B$0Kv{!8S;IhCqd-~XKv|POS<^sSvp`w%Kv|1G*`I;3mVvTXfwI{fwJy_vL1o5o`JGnfwJC_G8s)t z{`uNdmugR4)SlXQ$46aix$2_!RJA)k>LyyQr*A=9Qx~;IcRJOj+EW*`XSo?SNl&#d zYESJoIjQBUi`uioj;-qAuCdZxCAYg$Q@p+&>FYsX!M4}+sP5Nubzfpo4|=_a)T6pz zkM#ARuW0WY^`MXLY^?`+b!cf5TlR-!-K5@%jeP%PgJz zW(}a%J#r05-@xe;|1$ZG-GDNu0b;K^{2D;7d*m8GAN}U62GHvsxdzA_-6Pk4VlVBa z*Eb}6L((@SeM8bWq|9kZ`i7)$2)*u+YZ%lwBz;5DH-uhSzobR?`bMO01ikK&Yef1+ z(CZ$#M$qdXxkjXKMEXV)`$j>1Bhoh_eIts!+^y%G|tibFrS5j-6K!3OC7D_E>Li#48Zvy>J z^FFDyO`tDOqdc{kO`zZ9K1pirJ+{_1q0Eu{xz{%(eN)mmC4E!GUiD2$-<0%CN#B(8 zO@sQTq;HDYtG+4erRU-G&7haLb%|j!=yjJ_Gs>K1uGUKIn?bL;%$h;3GZW3A*Ij1K zpx0ey&7hC&GHV9C?lNlzz3wt=MwughB(HBy`sUD&wfEZQq;F38=Fn$2llZNhlfF6W zn?pa&{7lK5=83$&vkGNSbLhvr&y~!%!9K&)oMJD%IWzvT(QW~~uA8=i{*?VGEhuwZ zK!4i2Cb4e;eY&3#r>(Z2%xM9=uA8=ie!lG~w17V2(w|7*0{S_&Z_omfCNTuJ7%H2Tc3`W0?Xle}M`CG^j^cSzJq5RESQQo(r%xQ(#KWg45`c{d|Ig^Pprxo;% zxz82-$ z(szblSHC(#pWgm1ouSv&ug=ix>Q`sdcP4#j=ymn0GxX8bug=ix>Q`szb@i(=>1Dpj z>${M?3+cO%z6AOL%&-!+QUZ3^tM*42h zYag>4^!luCH|V3!`gVg}pY`nqy*}&Pjr20x==I%6-<|Z`N#C9H-AUgadTn#MlfFCY zy9f2%N#EV*%@dopm)4#1GB4`&JxJdJ`dYT0_JCez`+7hxSJFf70ln^K?m@BdLHZuh zn?V@*m_4A6?q==*eO>pt(#O;%m3u(1^Eonu>-9aMmsJ_boSuo;+n>^tV&5|nd-Iy; zdqS^!lzNiBC-gd())RVtTDB+j(Whm5La$HD_DsayDU$p5GS?iB$vTX9dqJ=5eJ|+s ztk_;?UxV)vLHvOmkG7xdHZ$gmgkeuleB z*2}DT9P{9!?+v}oD<`g!M~1yAb9z(e^oCwXhP^5Fy(x2gL$4#l-U)qVWY`;e9U1mU z>~&<=+vUBiAN4WP==xFLKv};)S^q%UfI!*6K-r)`*`>4CBtfwGx_ zvRRQbsUebozV`H?+S3PhU-yRgq1w|2wMX}c_Cf8@y`g(f(xp}%B5 zp)a*ueW~T@3%x!))i+W1OMXvd`@YcY(^Gw+*QclY(p^L9bgEfvN&II0j6OA{?QTD# zPmK+=EnYw9)7#d&pV6nrhMCvouF=ov&2z^?^rs|0f7H+D{WCEAj6O9s+`La>-_Ph% zW1X_ErROmE8GUMOg!^214r8RdN`3}LTA#Sn_ebni-ygBp?_}st`u>Q$eji4E#9seq z{i)sUPqFWh*z0#P^hfNY--pp3vH#tA`y=-Hoecdc_R>yz{Q%MrfWC^2_5jikfL_0Q zY5?^5-BSZ7a|V!p0QA+&&y?5?fIj-&Qv;ya@17a}eGR8b&U`Lfpu6Wu9hQ4fJSHo6 zi7R<(P=$k_*ZIUj6#GHY>wMxM=yg7E5M|CF(hq|E5i=_;u^$Be=JR=})((RHQ9E-! z2zptiO9+$u8*-P7$7BsmUi%BNmo=rtmGn2vqL971$y}v(SF(PjdxidjUiS+9Mf$&> z*HOY>&}XwP=3mg)&-{O8COVIqG)`+j=??R=Q*5;VGWzT>St&}Gk~2r{=UzV;dRdi` ze>oVjzt#572UF|^BlfqM*QCuE41Gp398bJ2xy>02z4lZGL%-9+Kw>`_`snJ{V8nix zjniPnez&_yj=l6eynYDunmI$D*RunMkbVgCdUoIt==JQtA&9*`=RbrpX9)CTtbPde z(QnQg0{vL)9RmG0ca^M{K9V_a$3}Z7>4!pp*uHNl)!Ly{YllLgcK>aN{ZPuBq0sBo zvO}RiV)a9zkA5$}Q0R}k&y_LGF?W@mIntZ+`eCFW2E93Y0H$FS`(e=6F|SGH41>O3 zOZ}J0D=@=IKaBLlg8E^kABNbgei*g)((m;8;iMl9{Ym><52x4poX9=ZbARMvz|m@?JlZ^dm_>lJp}+8hWj@qoGf4|DL0v*IGLodabpiDep&q|j^*c7lQs&6$IBwRC6Z&za9|yhOYsXRMjDue9wd0`Id+j*r z^#4@rl?+cKM8lewVFb|y|(ug60wi8_YnnSgNdY{NcxG;>x|q)=yjLRMCi4LJP~@Gk(&s8bg#xl z=ygVJqS5=k8WSn@GK&+B$@-&sCqXakd5J6O-`{U*?IhAqBK;)j8+S=#-lfdufvpd+p~;BE8Hv#my>R!aJGtlPPm1lYTPkCsXE3rp%d4`pJ|z zlY^NvnKEZG^yTf{YBFVx%#3;c6w*&2{S?wqA^jB6Pa*vj(oZ4%l%ReJ>8C)i_u46> zmpQz6Ox7PISEfQQ>v@SQ$sFz9PbK|S(oaq3ZU25M<^5FBPo>P68qA!jlsQu=bEcAB zW*fbJ8tJE**yo5Hx3zW}>8Fu?8uanIU&e1ejr7wBt=I=S+t_z5QLLL$Cdu>CkIGXFBPplYTnsrw8@ZNk5(R(@8HgxL!Yl^fRC@W4$vd z_A@B<`WZp}4ARda{S4B}T(j5DB>hb2Pgwm-($6IQOz4}xpBSCY zB>ha%&m{fKpnfLlXOey<>19^j>t~UE7WDdUeX~eE3;G)7ULf~cbF7E?Df(@Fvq(RS z^s`7mE2y7E`dOr(<@Bqm0}Wpe{%^8#gm2g>FL$`%C576!@|1|pJgO|@q>)t=d|_K03;ir3E}{T%3ZR%j0C=RmKsLUW+kS)nAuOZvIc>nLF^>E}}H=R&Wegt^e`tk7K2&xKw`33H*(5E&)Rg*MwFNIwtyq4usZkM#3MKM#5xCCsDP&x2k^3G<-WQNldvqoag*(Ca8+p3(bJ z!aV48WC6p(*I5RzoFOD z-T#I@db<1H&^L0QBr_Au-Bt2Tw6y46KcDpT5&LHLee)^y^C|Z8q3?7{;#8XXq@Pdv z`J|s8)XyjVd}NO5=Tq$E-V=|>ekY0j0_c0VD~Y}4{Q}Z2ApHW$`vsKu3n=dwP~I;H z=KTW7`vuVJ=y(C;z1$_^X0J~|zmQ_TkZSEh(k~?aLeeiJ{X)_&B>lpmej(`>l71oS z<$fMFdxR4DMbOI*9QjKuBK;!LFCzUS(k~+YBGNA+{i2|L5$P8}uWimE(o4@Hjy(_J zT@1bKAxK;$XU<~MFDCtB(k~|cV$v@r{o=#qsOCQOcsA|1SpqEv6(Jw*l zwWqp-^h==Ep6U|lwWqoSdYxBULi#1p>&(Ow=%X_eOQ6@8i6zkM%)}Ckz4Ye1ektjf zLa*~GOG&?!V!sr6omW{(`lX~_O8TWi{Zi5|CH+#0z4SZ1ei`YPQQj{j{W8)oqs&=G znX`=a%P4b}1v6(EWzI6n`(+e+=^=ala?&q1`jps*c1~+K>6ep!xzVS@%CEl@8MmBb zzuf5kcX}^}{v-1}NoMxSbS zP$cqxh0&+R{Lmokw4Z%(>tG z)+-Tvokw4p$ehSL`buPu&ZDnH=8SXiPwpwm_$VHe{U*}Ntb$(lZzQggTg+9IIjbmh zR#D!sqP$;4dB2MCepN8Ha zdOclx4fN5|wbwwer)#f)UQgFvLwXq<$78Z%L%eIDmmLs^E6E()o41zqYoXV@d26B9 zy?JY)*SpnP=(T^p7W(;Sv?*=QTIfrE+tTclDeU&itc8Ao9g(huexbWc&U+chd;L1n zuS4u7+uFX4^y?^d)?f1r<^tML!? zmE7k_d#~qe{6l(~8%cGUv)<^3c2q~BolDY0BOb2b>gd0+l3bg$iD^eM62?sM-nS9#pk zUFNE{jiJmp#bdH#Lo#3^GDl;-5t-A?zHcLC&PJCxGOpd2i2cLOZb~xGWyK1DW)Zmyx(N>nPcytUPb4!Z!-GKv8lGT*km#% zbL_{P)pVD+(poEXcyY7qAo1E}#9mv>&Cu%_#%9X<&Cu%_#%Abs4P!Iq{bs~o_lIpp z?6rTt8L^M{?>8g%+P~k7Hb?vSo2k8**+#G5Li#Px=ddx@Lb2aMvEKr{?$y`=z2^NE z(rVXR?=^!%-Kq@-wM69 zm|LN*nI@4rTcOXkVG*4#uoe1R=HE#EZiT+KyOO-u=Z|Ct*Xy^DejD_Au z^tvB-8^wMb>9;|z`+>JXA3cd^8}zy#cpLP(A9x#Oj?6Wi=h)5v%kR0J^xL7=o#fjo z@3%v*JIS|0uRZJS6#MO@-wypnn>pK|kM1Pj4*eyYvD=})?5>jA9GMl5$7HvR=yyOb zyH65V($DE&+twWv`yCYf9nkAD?mI}o1A1*ScR;`0?q=Qr{YUo}q`i4NpqE`F35B$n zvMVETrFvOE+G$Fo>qol+WxE4q{|3tT1j_aX%Jv1y_6N!i1j-Hu$_@p}4hPDP1j>#E z%8mufjt9z41j zfwJq7GRa2Czqr|DlgQ1Ts6CV2mDHa4w)X6#y1x^(N9WOZqW0)K`cA4nJ5hUdl&}-E zN9WOZqV`1R(RZTu=sfyP)cxj8k=*V|O^L^*Snn?Ar@E_T{Vvk)BK35NS7qz=mr@ekR>35^u)m4Dq)N<{nmTNckx(cwH^t(yFoAkSb`rV}8P5RxW zm)0j9n`Wc^FZ9#hmBe0m+x$!Ve@Xu@^tzk=U(){zz4n&=gGzOcT6C}9 zOZvUg>yD4T6#Kmt`@PWXj*q>h-%I+vq~9CV?E$lz_4`S`ANtd_t=doe{S^ECiM+Ra zL-#|kW1Rh@-w(a6`tFB5y6U?hdR_J1553N5?I*q5&%OQt=?_4!--mI4^8Nty8Exzj zK(F72ae!iffb<8T-)SNuBeVn1kNm0v^_C7mpWpt?4?thQT_v~o((~~8gV4_~WpXDw z2>pKh1ld8-AB6sZc}+6sAoSOs)b}Nijt@eweZ7Ow>*)9(^h=ujK+k?1g#MuWTJO3r5MrkpIu zF!YD*Z+)2Z{xIeJVd%G;W4$CIhbeOolm0O24+r&!Nq?C1heg`Xi)2Li!`5 zKSKH=6#FBjKSKH=LH!ZZA0hn_(n}9H#ocRj7}%E z{hZcOqxUm%M~&XhX_=oXwf3mdr^KG@HNnhj`R6c>8oim*a-S-y1g=ym<*IP|)Hbe#0Zq1W}J z`DE22@?B%a?f->g>#r_28Pe89T z(I=pf&P1PpUT30DK(8~=Cn)b_B{P-}J7_Y~<*k^Yp?`&Hjlq(5c! ze%1FB^dFf!r_|b0M*rVc-&02KSA9=GudBYNOzh2fNZQ{;M#u5kTpR7v(951NiT!EB zeyIDG@|?A{E2l|+8nM^?VW&xdnqq$%dfgv(8nKV=4?B(64|kuNyg%$TWsZ#FQ_cRa zg!hcmr(&<9=+78^YHX#Q!9GK=KSTO6MxPpc`FP@7_A{hEgV;Y~EoY2AHMYw9Oo{y& zqfd!_S8O+}0-QnYSG&)Z7ITfeN?yZ|8Hc#jpGE9v+u!9ZV!zjZ?pf&5yDM37-)F8Q z@6RIk*D@tyaF+CE5qoVh&m#8w&HF@u7O_8f<6pFPcNVcf;66!WU*GD_Qi~~bBbj5e z$4#Pr&ge6nU1EAAEvB~j=P35)DE8-|*Y^G#>CYLxUj;a4^nMlKoYDVx72urF`&EE* zChs%H9;Vz2u1h`pXydY)o`9(p~m^gQ%>Ug>$#pQqTLN9^^y z(({OY^t{sZh`pXydLFe_&nrDov6uO#cue-VN$f8`FMGxkR}y>GUm*Pj(qAC`1?Y8j za)I<0px5s=y#Rgm`%N!EuitNa0eby@(+i}RnK7@wNcxM2y`CL-k@Od#FKI_77opd) z120nSFOvQu^qFm~y_m@RW_>8{FG8QiX8J{=&mPO_u9Dk(nZxt?OQgR<`b(t0MEXml zzeM^=q`w4xHmkoB)L$a~CDLD_*vo9A*Iy?6W$07vZ+#hhZSOBb@2`^AtS^)PGU+c< z>@NrPmq~w_^p{C5^P*mVh4fcQe}(i{NPh*f*Wcv|>93If3dR0PP=AH=SD;U|F}y;0 znZfn?tE9gQ{Rg()y-ND4PA~2KRp?JWm)OOBmGoChf0bf?HK@Nz`l}TCtE88?X0N|S z`fH@WM*3@{zef6Nq`yY`YZUuyLH#w-U!&MxBfZRud;N9NUx!{>%I zJ^kd&sk)_G7kX{)FOmKd=`TV5tobc+ue}6)#lnx%%Ht*IpL5?NZO-%VO8fV+eiX}d z`MN=-Kw0KMS(ZRq)<9XdKw0)cS&l$i&OlkNK$-amU$*{{Cs39*P?j%HmOoHdAW&8? zP*x~VRya^rBv4i~P*yBZRyWv-%Q`NAl(6ZEogKH*K)OP%)m%%smu`pl%yO!~~E&kVix^)iz_GwCx2^_fYZne>?{ z_R{)zeHPMZfj+OD1I|MFETqo@y}mUs3uR6g(r1BwiX9zif&PYuXQ|!I0{tZSy^=YT z-Bog5PufYZ&r15N&^NcEi>##23VjRnGs*j`(APba`0HjReOA(Eh5i@Y*UJk1g313G zz2B#m75bL$dqv;MT_x+KMfdt_q|ZkBY^2Xd`fQ}nMwye1^w~(CEvU~%`fMh12FD8I zN<=0bGDl}7~oMl2kCPJ^*KnN zgY-El_HsY>`kbWCN&1|m&q?~6q|ZtEoTSf5`kX<1PSWQjeNNI#&%^6;kvpOUIQRd_#eJ;xTT+rA2tO{jLF6e)C-z&BDH+PksInqb+`rM?? z4gH_?bGb>M8+skpGM$L zGMK=$=)aO zLa*`7OR>*OvCj*A7W+5LOZvRf$IQ<}pBMT&cFm%7)4b4Ua-WyX$?UF@_0mK3`h3to zZ~GMapx4vg^N~KE(@WmxgI-T}&qsNm4|<(P&zHy?8~c3FM^AUp2mLA=?R<#6p6;Fx znWHO@(w9$lb6WXHpC5XCk|96o^FyysGUSI|=4j+^ou4u%ztQ`7^!(5-HhY96_W6xI zHMZi;_i0yge(0CjeZ={pU+S*%#fH0G#WLzhclrXPFJScPF?ljiOa&_zi4 ziG2a1PmfjHmN@ya0O<>mzJSrEn`gcf`T|Cu9-DH*pEMI)!06Ls@?2Nqdu2bmJSUa7 zlKtql?cYVlM?P~3LNCuG$^Tgpv6p9j5?9HmtrkS=nv%+VG1 zf{495yCShKh|C#r-^5a|mA^@T`Z2$`e$LX`J1=Jfi)q%RD;JgFi7>cW)wg`w9Ls4(>YN@B15 z`@*Cz481%*A+awE{eg8qQtS&uFHb2XzE@%|yZ#eb$+4HwvDX(NeG%xl*&HiEu`dF> zK1EUldVPwd2(>vyNM8i{o#uCnz6kWucQO=#ewX`R>0|D8SIK%A$9sKI(ieqZpTj6h zu`lXkFL_@yp|{Ur6eWF8(ieqZcbXK1KKdL+QRwwKjH1XKeGa22-D_pW!Rw2Wz8LiH z+rL>c(ibCrG3XB*O1$r`7_~XYNM8(kc>+OVUkv)(jZ^7vRSbIB=P$WZ40_o&pSViC zTglvr*B2*!ap=$5zgcn0oZ`@bYj_bUv{J^v}8PO`cCIL2ZuAH+g+Y(wBt(ciY1#N&1q||6zV6`jXK9Haro7 zlB6$5`jXJ=xV9wp(H?S1=(UGj5}BiY%#xJ%GBf7&rAS{2`l&Vsr6})9xxANbECs!` zn59Txiu9$RpJsliWKJpQH>~VVd0z_p>F#?ab7r`!lD=$EUzYS`5qsIUocN~X*vkyA*Iz;U zE1=i@{S~CY!s#V*u7F*ppW+NuYi7)&GajvU+u1v^)lBS zkI9~9`InU=eL3iFu%9bO`f{W%2fgkzDM$Kpq%Q~kjplbstt|(Abf-x<=yj(_IivR{ z5tXAhM`p#-&2Hp`zP!<=$7GMN{9DQ!eR}K~t1nOb@}w_s^y#qy4fS)$J>>F6?{_Icdi1j-r)${GdA8VAan z1j?EQ%9;hrng_~S1j7IuR!_=(Cg`Y6-Zx!^c6^7A*ioF`U<44KzgauakCpf5$%f5%N})! zeMRV}+BvO?(5KkHL`CRzw@pRpb+=7L(pQ9Dd#V+o*WET1q5mzi+omG)y4$8A+TH7H z3@cK*E3J>$S0a5S(pMsVCDKu#IMlsT1M=Ez^EGW6P0txWpLq_0e|uN>4@CVgenS0=r*=w4ri^i@b-h4fWOUxoBl zNMD8YRVemVg8C|?uL8a9wy8pTx%YT|Rnk|5UU%D6C4E(=m)=rU=ykVERnk`_eN~Em z)u6sA>8n!gtCC*sl3rhp^wmgTjr7$>UybzDNMDWg)hPDWg8FKtuST)2MtZrQdwq4% zSBGBrhE^wib<$UdUiS-BCw+C&SBGBr3si?bx?i9=^txZ5y3zan0@b0{QG)b5yuJqM zYe287zBNc+1A1NctpR;q(}j~dT!ZvANM8eb9Ua$zKDz2#1A1NctpUBR`qrS>OCQPW zYm&Yu>1&d{Ch2REz9#fKpIDRhHA!DHsIN)-n#deo^{q+zTBNT<`dZNUwD+f4q^|{i zFY`00wY8v^JD1#pX+k8$&3ALb)z7@L`^nKj-O6J7fRr2^!`kg-ZwMkza z`o8vawV_XOSF&c^&s>SVHuMYZD4{mRzBcJ=LvOZzLth*E+)ephm)g*$x^EKwAa|8K zLX#e{*ViF^9q41Wr%;DtUx#XKokZqz&w<$2q1e|UeI4jCncpd~uLJ#*6|AoVeP;K) zqR-;4lJ(M;_xie|uM54do7Sb+*L8ZymAcUDy|ymt>yo}M<$Yb~qjOqyq1QRBx~R1} zr&X8oUPc{WUythoA(W%kDiRu0D67LW&^}tPey4# znImIPuWv~DhS2MpbwlViw;NL4Hza*SihV=UH-ui-tQ$ffU9)Zoy{=g|gkIOI8a0i1dv}--z^$pw|`mMx<{<`bI&0Bhoh_eIwG#INs|ULoZLzN=wohdYuhz zO!~%7FYSF}=yf)?^YDW5I(Cax~&7hB-k0Gt$d^lh-#VeRJq_Cb~K4 zo0Gmd^g0vW9QwkxXVM&cor!J^y`GNH9Qx=?baUuexz9`9>rRvAlsPgp=JhQ|-vav0 z_P4YkeGAgJNW|Wr%iet2m^$ouGCjdqB=JcXQ4NUhbq8tstxvKL#{kJ=l3bX}-JpsZt{ ztW%(@bD*qCpsZ`4tXrV0d!VdGpsZ)0tXH6{cc83Kpe!CJ>l-NR7bxo=C>szcOAV9_ z43rHDl%)mA(gS4~fwIAYvLS)8p@FhtfwJL&vJru@k&!aVP02rBd)ia&X^+~YdxhFl z-EWWDqkDzgqxR@tq4rew+f(gnkJ@w2WWTh#?NNK8dxhGg_MEq^OnbCk`kvADuJ(vt zYKqzIZR=SF=;itI#Lr~)Yo`4z9jNYiaCKkqc^#nF_s(^IUVBR&px04C2k3S6s{{1W z)vpfF>*`kr=ymn01N1r@Ds|fHJCeR5Vz1|TbtHX9==B`0j?n8lUL8r_k@Ou&-!Z7~ zNcxVX??|zi)+cVBkWWOr6ZG=@xx~H`^!nUqC(4{o(Cc%bouJp}K0A@V6ZE?J)hW^L z+RW($ee^m1PSERf{+*!z$Yww%(n~v;5z~8ZXQR)EslKz(`|~Y2Q|voa=5#iCf4)U$ z(swrcj95kc?VXL@pKsCG=r2FtqO;Lw#PocN&PMOgx9Dv2zP}+YdORjioJ+L3AolVE zcj8L&UQZ$GLb2}xeNWrh>w?(pDP&zp--R-#3u1rH#=Z+;A3cSv3u3RQkaa=q^%Sx$ z6nnY%q?)I#6W*>ypNg}+MBmlKJ}uV8_Efu4?7LFzyF%ZvVd81+uFz|5sjJcZ9Uond zJ}uVO{7z|ex*C0I?8wElv>&~z(Wk|_x$n(uuDZLceCA4@o|3y{JSNXZWQ}&h`o+4yCL?`@ntu}UdNZ+5PKb8c0=s7&5`@L z*LNp<)dJjeU3M*Q7Q#BeW6a zVH8SH zAEEUz`pZXXeT+UG&#y}z?ql@ncpf})l{`X|zPyip9Qw?rO#aU}GN*y{#wqr37yHEj znS3%zoMInG=4ekLj@X+;KD767WKO)sH(5-}?An|-GN+OIUKyb^c2~)5j*L3IzAx$f zLVwZD$MmJx_l5o&^D}8N`y%hBG|P;Cbzjo=C4FD$dzn0tyH#K43s*T{T1@{Qn7+{W zwz<+5nbXHzCF^B;y`C@7kJ=m=$$5Q$()Wj6SAF|a?E6EntG@lA*Hz#Cl=uBf-yeEi_3aORbk(;% z^t$TXA9`K&?N4ovj5)o20Ok`+=k%2z@ED$6adeKK zz05dx{UFj0f?ii12SKm%R)e7TSII5rAn0}NZV>4QL9Z*1gP@PDJPv|hR~`pJuPcv( zDDP!%#Ou>Yp9cM3cC|Q-VxI>6-{xo1=A#LCn$;vVz+Cbm&{U?-hM3ca^M{`6jQ=Abke(`n+id=`*0$=S?%9 zU(hQN`wY@&kUj%?ecm(!`snkf8PMzVrWwc_ePT0%@?K`fynZn02a|p<=?9a3FzE+F zug{wfCjDU24-V=FlYTJi2a{gr@VtHq>4!ky+WyUkK(F<52=x9cxz-MWUVCXnNIwMn zHa2sHKwq_bep){o0)1Qey^=ZY+*NYs$ZVt64<-Fj(hnv5P|^=Y?DgL=l=MSMKNR}* zRzEbTA4>Y6h`s8EQkx_5qFz6Y^uwU4#J7hX?h;Nk5$Q!zuPM*X;Ep zNIwF4U4a=v`VlU3B=#eq*QaGikbVT|M?kMDFe9LkuE30dKAVxr-E{=?x&kwT^fD{% z^&?3?5_+8h9|?Vm9VLu}UT45ZLa#I6BS}A!^dq4^XMT&c_amW?&VY}E{=EApskJ%- zKGNxB{b-cYN7s)=2g=3-%EkuD#s$j82g)V{$|eTNCI!kS2g;@d%BBX&rUlBT2g+sy z%4P=2W(CS-2g>FI%H{^j<^{^;2g()%$`%I776r-{2g;TN%9aMomIca|2g+6i%2r0o zq-II}`PwrIwMSe3QK&r=ZM!>)>i#HK_Y=P*`JOk5YR@Rto=NVv$oX}X&6U)iQK&sV zAK-i5DAb-Q?h{gbrn)P+=jmLo)Ree6kt)$jjHbFj8hU*n#%QYhqoLRLVT?xI*Y{zJ zhF;f?MpNA%jk>R=6pV&G`aX=&(Chm!Mx*8W+Kw4U(_KUAwAYUz{TS#k+Ru%l*pG3s zmv(my^twlG4C%*^ehlfy1odM`KZf*UNH48VJeI@8ek}Ak-IdIvud(glSc?5v=+~N` ziGD2f`sS>$q#p~t&P0!eew}T1$0qcVy+UK5U+=zGGG~jsO71O5JDKYA0|FYFj zCjDf}`^nIscs>#P$y946Q|u>0|BB6=$ zLb0D}q~`t5);pE-Q;pug6?-b_r$WEoL_{)YD)f4u(Nxk;HG2OJo~cIf--fPC z8NF}sry0FJrC^%TUw%r#G^6*Y6ihREe@ekLqxXB{q=)P?XF6i9`sv6Vor#`Kv7ZjT z&O}c~>~$u3I_ak)bF|h@N9O2E^mJrSbS8Q_GDl~krz3N8CVDz$j`Zcdeg^4hK>x2@ z`TX(sg1 zJxVj7*F8!z5qsUEG!wDc9}MnPy5c??v5&rMa5iH9tNUKboH@3?GMi#AV@|K1L;5+0 zz3S(Xeh%s9kbVy7=a7C5>E{IXb4Wi2nWJw?oI`pU9jBXngeSd{7PGXw zO77>(HTraO#!;fy&Nce4#nO6R)F zHTraOPLC?2y)Wmkq`g0B|1L6)Pj&ivq@PE5KaXNRk77TM@_ru0eje%PQQprB=KVa% z`+3OwK6VXb9`auM_cG%Ucl!Cr9F6^a=;zvh=X}!7cY2BTeCTyFKOcG>*Um@gXnQ{& znKRG)PH8dcBXgo}Et`+bneV<=@?PIsHlH#_=0?1J0qGZzegWwhkbVK_7m$7d=@*cG zK~TSd^b3&ps$T%T#$IM|ynZ3{wL~)=%e#Fi=o%~oW+Q}&gU$qyq7sVuU|s?CD32A^Epc> zbCyu%EP-Cc@K$D3Q_vOf%j`N36?|3<~W{}O+<;a?9#wl&ea>^Q+XZHFPq+bEO z-l{qzh%kNwPz22!-P|mL){R-&yPPGF1=$&c>^oMQKRzR<9{R-%{t(O^bGb?BR zWh;$7EmqxKCGRR+N&1yeFKzuwqxZWCSCW1ua$eh;l}4Wy(_MutjsEgog)5ET?px?j^>C6CTlQSDhpwPzLTzV?(>QOmUobzgf*t5El~ zr?d)nKiX4Tg}SdjrB$f=IyzfLEtk|3uU}32)o8hNE^#&KSCf7<^g5Tgn)Iuo*SfzN zdYwyL4SjSjaW(Whm$=&K{aoT|YPqCNr<+rG60u)n^k!V;u9D}o){uS;>DQp;(o;9r zP|LN(=>0u!jnVu0tTje|`Fz$IqxbV!YmDB{XRR^%bT>Ma)+g@tYY}_ZuSM)1xBbJl zq+d(=wTOM&O!;wNT1&BCi`eTuZ!Kc~g!!Fv&s&SwPk8VlnnPcU*gxsMS7QH^yGowN zm3GqW*Fj&$#(o|2MeMz29qHGRejW514rPaa9mRef<^4M7bw+3%^wAlibPA)!CmMbtdT7lYTwLem(T{ z&F3Wc>!Dxq_;(ch_0TtP-z#IwhVCjk_Hyrun^Sob`VG+6cURKp=u>MONWTGkeQIq3 z^!n7=2Fjcbq~8F21M>}{-vIrVD)mfn$v@-20s1C(B)H*2`ToJ=V~AHyXW} zleY2QXkwopYiBcOBW2D;%AAcxpC0SjJrRSAM(^iTHX6OJwHu8-J=Wg*PSI~Pdh>+$ zN}f~MX!Pl^4(@wpPNk!}O73UN{oLy}k$w~DH<5l5={J#n6UBZL={J#nQ&7K&^qWlV zy?&F)dp}B$o=0k|k&XRkqfa&G%OqmB8F{Zyt!*a#X3}p)=IB#vn@PW!^qY}6`qbKH zqrd#Awav&JeQIqpYOOxCwi&fn=W(Tv6nFY9$a~dqN$71JZ6W;@(rf zvvJ!uG>9>=9dr-ff^xH|lo%GU|_xc^A-$D8vq~AgM9i-nu`W>X-LHZp*{SMOaApH)~ z%c#TacanZ5^!ohEPSWp$UY~#23B5l5vXk^XNxu_%eg0)9^wH;Ec0!+Ob95*4gWOf} z-AcwsUcZaO2qzj3f*gWK|kDjcR@eG zT_x9A8OeG5Zqo0DUS}qDL$B@1Zs`40^3Jy1q~A^Y-O%gI#BS)LGZVX^*O`gk(Cf^^ zZps`Pb9((A((i%3mc2*sA^jewms-0Av9D`SoZJJw?(o?|`aRIsu|0)7&=)Sb-o)NN zgRuwty6$_Wy|3r4l4CEUW3S%}eG^kAt@vK(^#roLq~8m@oLuP2c0MeOwivb_|08OMA5KGN@lUZ3;bNBVsf`+d;sbH4j1bM`^6 zBg1{r>$r9w^wH;h_d&nPX8Jzp^*P^tq?Z{7uisDl{iNSd`u(KePx}3&-%tAe(62Ny z=_%|F>i3g=KlH2Zzhyt^Wo{%MYie`l0QAk=mGtj5_6JCRfb<7Qe}MD{NPmE0e;}wo zK>7m|`vatxS)6#Rx%D0-{XxWDpKm`%`h(Ex^X&(r*XP?0lKvp+4??fcw;zN)`h5FA z==J&bgV5{q?FUIO^G$Jc3R|L{9)iB5yTW{qc^X#g@FD0^>|gK@^uL&&Nt<&B`iC1P z_Cy|nURT=>L9e6oL(uOoYDpGrY2>RdL_sXdJcXyS1x00DLGjD3WhmAhN z_3sZO_80Bv4wL>c^!l9dVd(Wa-@_F9!$$AdFAf`hhB-$pp+9W&8L5o9Kd&7=EuY1Fekp2i_zr+5` zjv)5BH|$6vb0SZz9YO4MZ`cuJj_wURg3Qr*beV08<18Y{j-$|bu==Bjz3xXn3ccQ4 zk3uh3k~v4A*ZrtRq1U_BQRub3KMK9>M?DIC^h}MT(CdEGqtNSq)T5-Ac~P%FM*3q$ z@6Q%EM*3rngx8WKQYY?^5O*L*}%ych_Uk>ngx8qxWYE z$PBL6ABVo9js0=NeyaT~$0>7;L$B*c#}Rv7KRQnOhRJm%Kj-y}n7|BpzO{-*=w6jms6Dz@z>@xq(2S4?#Vq3z3$09P5RTMKMlR^$vq8ybWiSS=ygx- zX`_$FbWiSS==F{*b=vE%B>k1pUt^yixRUf&LjQ-oqg+Yt?vaQaGRfzp{ zR(};`jLf^hF(wAznb({lm2SbUrn*Un)Fvg|EGzo^s}!H>aT`gPu0H~`oHa8 z;%d@Mi|+N;kp3FdUqkw9NPi9KuOa<4q`wCGf2{tRp#B=tUqkw9NH6yuuRlZjGtld- z&>85pPjLo%f0aBdbcXb2NPh-;ofSF*eRNjn4D`CQ@(lDkD|Cixt=uKO{#w#s3w_-F z&90@`UkiO-^E2shT#MM3tCASYT}%3FNq;T$x|9A|=%YL7uT8|>eXrD7-AR8f>E(VN zH)l&GzV|xlJG(0x<6N}u?sXLV>s;(be;xGtuDk02-*`uA5#*dg*z1{q>~392HMo zN2|Y)^fyBPllhrs&W+HI=+P1Hl)jPlHVE<;flKxhwm!9ga(CfYHR?7QZ5qllm z-wJ(0n>n{4_R*8~ZiT*)`(DYM#_lS46+p&EUVj_uZ-ZX@_qS2z+y=e&?{9-%`}enz z{x;Iz2EF$0Z-YMCzrPK7?cd*KV(<5&-$t>Qk(}4xPWs!S*Hz!!Nq;-^qfA7k&AAYrM>9r`gg+P5Qf#=5KIS}S8tufGHO9;Qt4 z;ST6^9{mo=oI70Ri2e@fbq(VViv1nX>zvjd(CaF|9neSDFz$eUmG#~M{c3lWte4TT z*WU?!PpiKZ`Zw(7?xfh?3H_VqXQICo`YmtVhkx~*q`wn-Z87hJ{w?!4iT$0>uQ)p2 z>~`>HHr@&S+wOZM@85A($$2m1c(1>U^mmc|F4Esc`nyPf7iG>}q`!;wcLnu#k^U~k zUiEiTizzb>UVk^~?}q+e`>(#6^mjx5p81)?{%+`>uAj)byD9c}lm2ef-yPK7P5Qe@ ze>dr6Zp7>FA^kn1zlZeqkp3Rh-$Sv#hxGT5{+^)z9@5`K`g=$(vp8OVFX``vURMF` zCH=k7*EP>)NbK*0URMF`rP$v~`g@_*Re*b;k3J!OFZ8+!a4+<_3UDv!WxmPl?<4(v z&>t~EX@Ty8UhhcvK`&RLzYqF{OKwIl?LN}qNBaAq-(h~I)Y|)?zdw!Nl6W8VN8R^I ztv%+hlG_}a8T0!8LEp=iiT8id@3VRTKhpn?^#6nY<*ixm=aNrG_#gE9-EWbTa1NL& z(f<$n?=t=}ZI0hr_&?|mx=)Dykh@B5b7T%L9_wwr_d~Beh5Mn8+kf@_lsWf9-`D(1 zVt;=kb6!gHkngA1-w(a^6z)gt$C=NG{(k7wDt$rw!|sQEy!&3!PjFYsv6tCKuYZ8_ z4?wRoA`g)M0qAu$>H+9As~#Zz1EhZddYut@0Q%@`)C17#jK~AXdz}$^0C}&yG?^Fm z`Uj!cd+meJ>u!e!DRUl#UUxe@2)*uhco2H+-#-Ywj%y!;UUxe@2z_+7!-LT4Zife< z*WC^el3r$Tz5XHS^O_hbi_CL$7Vl!_e!T!o!p~4^!+PhF<3s z9)>ZJI;Ze3^g5^TFtwO6EAI7=kp2-9`ysLKZEb&q^pBAK5$NOjYog70g!GS) z{t?nY64XCJ`bS9rh||mZ(W6EmT|as(Q1*DB?1@0xlYz3Q0%cDJ%AN_7JsT){E>QM- zpzMV}*^7a)mjY!k2g+Uvl)V}#do57*dZ6r$K-rstvbO?dZwJcW36#AXD0?qZ_I{x3 zgFxAbfwGSRWoH9rA4kgMt}OZIYtN%pdmcs0r89DmQp@!yYLCvyJ&M|+Gjfko?Rk`H z&!bd(9u3x>N2&HaO10-vS9?S+HO1>6BmHC0>x|rERQDgFy8jsTIwSWO=^rEgW2Ap9 zsDF&~kCFZ{(o3E8`o~HCIP^c*mg{lSKTi6`q2JOpabD}=q<@_BkCXoKp#E{vKTi6` zNiVIB*FQn}C!pVI`zcS5{t41Q0sT+0g#HQAKSBB@NdH7o{{-ouApH}hmv++YpCtX0 z(ChO@Pm=yg(mx5kK7aHi>7OM1lcaw#sDG05Pm=yg(o2i(^-q!hDd>N+ne!CspMqZJ za-V`;=W?GS{ZpiWiu6wf^-q!hDbhbhdb#&_{nOC*HDywxpN9T3tA85$6n7=h0(@?+ zq@VpX^#7TS+KJC4j}o4SUi;ZkL;r>Oobzeg5h`p{^KLfq? zv*mv7_0K}z&&K{)=ye|bS<*iXz0RXQ3%$;xKMTF~v!8`td#cYuf6m7KS?HrZ)n}pC zp6avEU$B3PXDRm5^N7d#Tkmtw4{%q~Q`Oz{&yoH)=yf;!bI|K<`sXP2&r$53gZ=}n ze-8TS`_`U={zL114*HMWRq_Z;`bb{?JoKqn|2)P1dD1^mv45Uo|2)P1d5Zn>6#M6c zv45Uo|2*_MN_d`P|ALWbn0GWJ>e~y@4{}!$`xUmnyg>RFpkHKuCbjkj=zpt_cqhOM z6#Ey9-tP^4!RRy0n+y`Q_64IiZ-Tq{67BGN!RRy0`vTM?dqXqaRq_r$>35npHrt=Q zNctBMdmSCWNctC{*U|Bd(Cg^p!ZkFEAB6m{w31C1ih}fzXW}B#r-Adb;bQ9=yk>YCCVJ> z%X|IHq<}fOVlSf(uYZN~ zuRyQ+1zsWjE70qHfmfi{{Q|F${uR={0=@1Rcm?|Cet}mKnUg7z_pd;&`vqR1*vt6H z>tBU_uql&!=Bv=_xh}6#=Dg}MM{4b>(CfJ_uaf>%=yeU_Rp@UvwO#JDuR?#v#_hBU z@GA7T*w*4z=x=pb$t|XgvI@ykp2zm^*M|;px5Ux-XQ%O(Cb|88_?@q?iX`xkr@`V@C1eavUfmE`@K(9fyX z8T06GlKxHTwU7BG^v{~lN#4H+eZ|6$(_HSG&_CzCN&1-P0A19@H>uXjjDy#|1^saQ zZ+Q#)w{s^x_ZG$eEtfe`zu$shTmQG9*IwFN&}%R4E$H7dzf<&YL4RP~kEDMK`gh&; z%1rco?n+{>`yyp-#JtE9v!JEVVy^zT5gwf3E${vFc4L$&rD(#w34 z*S|~pca7dZhw(1y-zELKM(>})c$f6=8ohtV@lvYGQ9Vz1Boz6X7Ztv&BSuh06vhuG`0zVA`qzlYdst$h#rN6c@L zynhd|-|@n1llNoF>zi5ML+l@Q-z0hen7c}Db7T(B>)$8+`_Svi@O{$1550~I-%n)D z@I?K7pJM+$>EDN5M~3f19~~LK550~I-$(3qWcWU{IWpVm^&gP_1L(Dn`2l6l2QG7@ z&G`U&ZF4>#{RgD~0DA3XegJ*6kNE-g+Q<9=dhKI=Kzf-MO?Pe1hen?s8*MY^L*)HX z+r#+K=*=12_AmIM(I>8?&G`^{|5L?8>_0Sme=5j_M(tW5dkvl+5|i=*`)F zqyM4N$%jUt9vkkySI+Vo;jWU;rj{98AN!9G`!QDk5n{j3dOxDrf8=5>`i~HMT{r!R zV*e3hulL%I5PQAXeuUUZ*G)e{>~-DrBg9_UO+TVGN9LO2<}DP7sGX(EISajx%Fj~X zpM_pW_4X1e+<1oclR;$`rO^e(CfeeCjH){o8^X>|SQe4y+?pzM=C*{6ZB&jMwi2g<$(lzkZ}`zlcOb)f8G zpzNDK*|&kR?*e7t2g-g3l>Hbe`zcWNbD->(K-sT>vflz_zX!_x2$cO9DEli=_IIG{ zpFr8afwKPsWtSpl(%wt{`Py@iYR@^;eeLU=quO(hYR@^;9vz{bqn7I&YLAXD&!P5c zU+)}hPjrNK4z*{MZ86WG_UH)h9JO3hQ@s8>^b<^({L9WmuQSo-spUEkz0O3RhhAr* z&y)T>(dUhRuz6#Nnv(n3Qm4KC0_iW1{sQSQkp2ScFOdEM z=`WD}LQsE!^cSF?Wc3#)_R{)z{U^{*w*TiR&~LMU!B0s43G~~|&*Yx>3H16dj891a z3G_O~`2_l%=5x~Segb{|iGR=-=M(66x$l+O?{-(ov6ptzyurkJKZRb$IG;kVqvKC0 z?>~iJN5`K+ucPBnN&hM3{io3DDFvTGA3deuQ|R@Sf=`k6dP>2k?ye!ZEiJlvADGpD z2K_X5CHK6k_TKXu#r`ws^?B#dpx5V}KO_BTlsTV4ug^PwmdKpVr%deq-q6pW*XNx- zL+0r7&Yw}{$i2twKPUa?h`m1V{5i$`bLh3__c`?bDtZ0rbJBlK`p<*<&q@C|=|3mE z+$FvK3(|i9eKVVJUy%L_rPzT z{|fqAHt)Zp*ndT_{|b6N5$G%EwXgRT>A!+rPXzi3`sj&3UqP=Y0)1ul{zRa!NH2XP zum2kQ>84C-^w-djvih$n_FqHa)BH>_=WFOke4jXV@@tCy*U)QE^=s(QnMg{D`8D*n zbeu~wa$iF~+I_F+$GEHHe)dJuUnKoS=?@0e0>Awr=za#y3$Q;#wN3~W)9bW%E>A#15 zt*tNLlm2_BmrVa2dc9kHPkH}6>Az3t&F_?2`#toi+~-CAjh%`9fnqNsIj{c_`WdE7BKjlrt!;hzk@P=O?0=-#|46a_5wX`k z=8w?p+sJ=}KKeHDAEDQ`k^hLy(f4`(NO~D_di_tN|B3WJk^U#r|3vzqNdFV*e}Z1$ zM*dS!{}btdBK=R$>rN9H9ee%Hr2iRueH;1Dr2iRueH;1D(CgdCe|8r3P zGwFXO{m&G88OMA5FQos4^uLh)7t;Si`d>)@3+aEM*#8pL|3dm-NdF7PUS=G;{#Vlf z3jJBzV*Uz!io254uaC`@)Y@O6*IhoplKxlH{|fy%^Es)tzd|3~Z-=HsSzx_ApbvE=j=yf*qH|V3Y zp}#?|v!TBs_BtE-8|h^hCmx$+y}v`RW2@hxUz9!ZZ~2|{zmxuV=$|&5Z{=V8JL!Li zUe_>whkmj7of7-sp|3l*k!kP!8piL?FLB>1FEe9a z|0n7HgkIN={v`dM(ChlqpU~_2(VwLMlk|T=Z?+&J_J2YjJuCK4=u>Ux{fW#Op4Yo>}9qwZr)Cp$nC$OpXaVbuRVpoN&h$W+Ee%&dhIFv4ZZdh{)S$A3V%bd zJ%zuakMmDNvRoA1hJLNPO4es4 zeP+^UCVghoXC{4S(q|6pGm}0u=`)jFTAz4qo%Lpce!aU&)@LDo7Sd-SeHPMZA$=Co zX9?=FkUk6PvyfieNi*kSy;-5(=&q9WSxKLj^jS%tmGoIjpOy4kgZiwb&r15Nq?Z;w z9@}KS*`VL-u9EfHNS}@L*+`#_^w~(Cjr7@q`fQ}nM*3`|mwS(yYqZ|%&~J5D$@=W1 z&rbU6q|Z+J?4-|5`s_h{cG71jeRk5zT{0fqX1zI}-|ntNU(5E-b3m_ihB=^@D;c5X zfL=!lIiRoYK9}5L=73&D2|1vTjuLV}ucL$<(Ca862kGU09*^y?-ki|ybXUo-&q=Y* zNwLpKvCm1d&q=Y*NwLovjD1dueNKvfPSQ)y!_2W;Z!YL}yQ}2b=c3r>qS)u6*yp0y z=OTSBihZtN>~m4paq~Wl#3&&*^n2Zv=&!PK0=Y?_oAkM%&paS;zC~_| zeQxM0xZfi8+N;f#%uM8lzIco4%-G(q`sRlI8utmg*Pd}#$@g06&3Szu(&xdw_FDV7 zJfzR#^m32R1HIOXJfzP<`aFoe>hlEkc}SlJu~&T_ioN+!l0Gl=`)usQ|HbD}Q#maZGUoL9!lW+@ zz3x#eOqo*{dflT`7<%2KRG9RINnaTH_e~ayzA*G>rgftg_rlPBU^BfiV*jDLO4iHh z*z1dsz6kVJ*|w?(>5D+GwYCWKZEbvtkiH1%i$MQ}Z83{Le@lVBq%Q*f)$V&G_Sd+p zWW9{zy}l^vi$br@0u-gpDGI$l3s4k#eM-D2^g5qdl=MZR*JlBWLLYq=peXeEEI?7j zUY`Xhin~=+8z-4@@cLq;F9v17tj>r0Tn1oYa!FF|=<0($M=mw;aT_a&gOZDUu0^d+Fz{(TAPqy765&};v`1oYa! zFG2krnQ!v?lF%QqZEH#B^&GE~q%R4*p5s*#dOgRhB*nfY^twl>B=mZYS4rrj=XjNb zUeEC=3B8`_0yuLK)OB=m^_Nz4MOOw8|(fen=N<*)0PHCg}&wiDL zUZ4FcZSB|_sKV`U#(fhY?mofUw-^N|W=>6Nc%NV_X8+RF__iy8tdC_?6xb>Dr z>`%BW=^;0;`m&@i>+~`@DT~a}(Meg-mqq62JZ4$MzM=V@k~w9OInh&w%OZ0cx$l)0 zv$4BM&K#M+_4+GFe+BaXR{OatpigmEG7Ec~xsvw&3g}zjods*wS3uvy{h!Hm3RggX zyZM>uuYkU4*-Kf>vo>yb+ZE8?;XW_=JKa^XUgny;z8vYxK|j^DeC0@A4zZtR?^flY z*WJwJDE8$j_T`}0-OS~nkG{RB9Q3-Ixtz(I!Lh;iO%~;-#gtibuP;yf@}w_M`tqbN zPx|ttFHidN(5KnaN%^3@Jn73ruY0k}JH4zQr5Jtm`J)PfvWkJSN`bP;p|C$HNS_H~k2Fh9m%324?+62nl2Flt+%B01V{PVRZg=$XsP?2#?MZR9NAyxtyuJeIE0Ded=_`=F0_iJ|z5?kh zP~EQ()K?&V1?V&EF3Ad{mpbkB6-i$adVP|iBIzqSz1%e_La$FUR3v>x(pRL|R}AVa zlD;Cvz9Q+R_3`>jq_0H!N~Etu`bwm)MEXjkuSBu06x3HDeI<&0CDKbf>GhRKUm5zf z_HR}h`V>>mCF3eXzs~$jVqY2h38NDGax0U*GU+Qrzuw+8Dnnnj)%7%&TN(Nd?tA5) zx6xh69b3nj(xQ8P71CEBeHGGIA$=9nSAkw#LH!D)j%@Xji4osp>LE{t{K8*S=m=ihWhmSB3sx^E;)tR2BN%(_g2#+^W$3=e}2B zf5}}X_m<=?>Gjn}Uk&UybzDpg&}Or|7FeevA z($_oau97oH?&n@#9r}~DpIsgL<@R4)o%Ge6Uh=*=^!mJMb<$UdUPoxvp3Mj44bsz$&8Y>wJ_}F_`g7)U68l=vNB2b6g8sbwUWxq$ca@wuwT(W*jW27HzP8b4 z#J1Vb)h2yy==EvY+R*FMvb8DpwT<4NZ&BOmGh*+VIw<ll4{Oi$;iWAy%Xjygu~Pv@v(^yZX}iiymrWAy%X zjyj~TWAy%Xjygtv`RN>WjNYHlQOD^0=^S-T-utn=^yTAtSEaPub)na>eO+XZj_vDG z-q&?`pZHwz>3ek%dmSCuMds+(zAiFH$M$uRIRk2ZL!;xm$Q&Kp*EM?c#&??mb*ZNy zqmFp&N}K8RNM8?n-Pu}?GN&H&y0f(&GDml|)}y?yNBVluH@5TW^`PHUr5>%o)Puf> zo&T(7^n+tf-Bog}mGP0+*C%~_=%?C$b$yC`eTsd3==EM(pYpyw>FYy3&HPTu`})vt zSlOLc0qR3P-F>gbeuleBuC+3f%ZOcNW8Z-E4WQ3&R}UIc>>EH|!2C?woCeT0+?oSD zxCW$eVD$dX%mzlEVct%e&^IvpjM#~a{66&tMxPP8#+jtn`m5yAm}Jap_5|4fvmxml zLa+OB8lU z^^Hj1i1dv}--z^$NZ*L`jY!`J`pu@tD4EkJsBc92Mx<{pm~F_BtEUrY83O3^kd>iN~(DKWj$%X3$Ty z-`fnCqpe~yWRAZ|zFRe;%xOlM(+shnW`3u{z8Nwn+F~|C?6t*ghRo3xvl(TM%s0hj zH&}gh=x=mak~!MuG^f084!yQH&8gNlCw+6$H-}zpZFA_OZBBFOwasZxwYE9wWoFFl zTadm5#l8i_z6Hg;1@!utXhHfGq;Em7ZxM`r3yOUUihT>x%N$b> z6#JIYYn#&&dTn!BlD;MBTSBjGPD|*cZB9$*wasZsZB9$l%WPvjcC*#Df?i|T3VL0` zXhr%~(CZpTE9i9%qZRbpOKU~?R?y#W^S%}I(KU=#(CZpTE9i9%qZR38UNj!N#p+u_ zf2+Gn&imG+Z%ujMn)1Fi#lAJ^TSKq++Sb9mZwuIZPpx4t@+mOBu>D!RLO;F#4^leDrhV(Mm?DcI)-{Q_nE17!mOWvPL(fq}9?fwHtfS$d!> zBTzOtP&On`HZ)K+EKoK)P&Oh^HZoEsqjJeVvx03~+V-eDx4SE8cXhu?d#d~GQG0a1 zN_*5E-LKLfwMS=#+N1X9ewFs9J-T0|J!(&Mze;=59^J3f9<@jJtF(8uNAyxtyuJhJ zJD~2bv30Nm)%_08>wIDd=yg7^1J(Tw(Cchy2k1B2y59l%=zL-a=yg7^1N1td*nwIu zsncHHk@Ov**K=JuQtUgrc2`En9ii8AT{@D!Bk4Orzs~AA2K60D-;wkkNiVIB*LQ;c z4x2fhpxjb^d$aNxpC+KxPu@m$=t-cfV(evv%LBGp=uZ(eayQ}0e zjH?%YKx;L~l zVy}BcJ5%0Ei*9y<*l2eleHYSqA$=FpcOiWj(svbsD>3+cO%UhX~VvAe9k ztI?;Mcl{=M-Cd2|%!b-AZ&%WHb$Ks!zbo|mH|uKjem1nL(fhgFu10TWL(T7$5n5NH zPmh&5akm*?E^wpcu10TWL*4hv_;Q51lJVt9n@4h&j5~cd#Qq+u?}pfGo70W*z8myw z&2N!f+YNecbGlL9cSG#8&FO~NYn#&zv5&Sn-4J_ibGlKj?MAg$?&n_Lo%G$I*EXj+ z#lE|Xz396`uWe3u(sw6)cj&dv=^oT~Cw+I)cPG8{JiNXK>3bk^TG$za9;EL<`W{B_ zclh-neGjAeJN$Y;uRHvD82#lt{CXI@-{IE-dfnmI!|44EKj|ZReNX7`wVBfsvDYUV zdXl~;>3bsfy0f(>>3bsf+UE3xUY}&>iP%Syr#Uq1PuFdQz>G-dxuB(j?yCZg8rDh zN^b9aLw~>Z_NL6~jo9njU2oF&CVg+{b?vS<>3dV&_lEvPQ`@D@=?#5!?XEZUH`#Wj zx6%8xyWW)d(nC%+Z%9u3JNr=P^g-UYvw7c#^nFO*2YKJIyZ)Bs7PF7h`@Nxkj6OZq z-pqz6PWm|MG^%3*EXjw>HCttFZ6TX&WlX#OPSNx z=zW{h*XYw?+UE2%`pes#zDDocoW4e%7SlGTFSR)`K1z>0X!ZS!K0Wr3yOLUahy9!N zgFeM(V?XHcG(VH}z8~^_#65|ft^JJN-)s9(?E4}1J?*`=A7cObZ+B7V^h4}>*}H2$ z#J;z?O3oY^$(g6xthYZh=Mi@$`nlHIpJLzN#a`Nl{?Kbrp+CjGztQ{C5&9c_JT}k# zPN}v1jozFOaLaI7yX$ZC@z`M-wf;tL&dqU(HiRuluEf6VF!pv}?K_Xd!D z0O<#iegNhD0O+;F900wZzBd5+=;?a{px4v)20*W;?+u_fM@Gk9pGx{v==J=%RMMwH zujkjLLa*o7rIJ3C^r@sz4eC=#pGx{v(#tsB>jy%w_u7Hb>ul&i=u_-pa3J(L8#)kr zoedobz0QUXq|6xz{p~h$1}5~89o++=*V)j4(CcjIK+?;MgVzrt{h&nbZG9O;u^;3z zM{4aL=ufY zp9XzL`?)lVeH!$g%+Exh2K|yDiMv%A>C;G`M*6g%K8^Hgh`s955PQ|jERNTwlRh2# z&Q_mJ`gG{KSbaM5M{J9kPWp7xr;|QCs81(-I_c9%FY`@apF#Qz=(}2d2I(`P?`HKG z(9gLm(cWi}K7;fbq|XTIGf1C7`V7*`%$U~?CjDUOx7m6+nDm38*Exm3(CeJSVCc1{ zFqrg%q3>vRUPyaC82Syv8dBa5hJLDz+F!(#ve4*AFHAQ0On(7z`!-Q0Tw0nKKmn zDa|sYpEH#7LrFiB^h1OCp`;&5`k|zkc~P$)M*3mUpSC+qhLL_4^jF%QCc~g#@@gXX z!$?1j^uwS(X+9^JGc2edM*3l-A4Yna!Hvfrw|#@*&_Cg>q@Od>=KXN!wJ$RqdbyI! z84kU^$9*{Th27_*pQE#|!=eAi{7m%2p+C?mPP=@DL;tP&ytMb*_c4t*g)C1 zK-u^}*@QsZ#6a1kK-uI#*_1%p)Iiy^K-u&_*^EHh%s|g=K-uy@*@{5f%1D{?DkcAX?HNV2XB2ABRy!XvifYd& zs{5l*dwz-~p2HYLwPzI7o>5eLMg?onD5^c9sP>F)=lpXiH(WDpL07kX~9JuOAEjllGoB7J40_jV1k9 z=yilP7J40_jfGxEXk($*+0e1j>j-Tu^wIq)W1-g(+F0mygf

=F7OXU~nC^M#BePmjIhK;LEP zy9|Aoq3<&EU538Pw0)PM?=tjVl)lT*cS+m7p3--jxW|5cpx4E;W# zUrgti`-EP<%YL6}`+bIfpU{8Hk%4}n&_D8r`%UER6Z&tb^!tSV53*989>+!keYc_S z7W%ogzjO<|#&);Rhf@A(hi=pM-G;tf=;za3+b#6PyD@bOz21$fTj=#}Ox-4Oa1*|nmdZg_?b-(Z5J%+x=(D(SraXz$tkI?`4&(4}7B0WO? zlWe=_wLi^D`L@ULra<3o=zE1;kLUE7w(rf_9`wCJug7zGgv_{YL*HlU`-EQ4oA#Nu?-P1GXWb|C zx_8ni^u_b0eL{aBjo3b+*E`+znaII0yg=V?==%+QzoG9p^!!Xy zO5bnj`-T3o^tJSxw#U)NK)+w;H>PdBU+DF`>3$RU`-NW5o9-8SJ#V_-(C-&|J#V^S z==HqmexWa(H{CDvdfs%u(Cc~A{e~XLMFahSp&t->J#RW-=m&&e&zlYiy`DE6F!Te4 zen9B;yy<|@7tfmx2)&*+9dPvSE@Wxj4;XqJ!EH|})7Cy9^tx|#K1xZGX_v9~AlvS9|({Lf^gb zeI{cb6#Ckf_n<`1rmU3Dm^dmP=nonCLx%p4p+98k4;lJHrtJ?I`a_2P5T!q4=nonC zLs`zj`J+Kce{E9hW)VrE_o_QAnmwmHOl4w&z znXy*$WatY$9J=vW0m_g|k zby*2Vdp?ool0lP^2D6NWdBmXf3cVI$(Ddm+=@oh{#Gv#Fy%u6ndPVVCh(YNUdM(7D z^a{NeVle9!phpjAPwG?N!$Pll@v!u1{Z!Op)29y${eO3_4D^SEUOyFe*!1bcLa$@l zVWIzy^C6!e7W(3+q7DoF|43Wyu+ZzLq7EB+^wsvHA*DYe^joqL+Fs9195M7qgkH~0 z91(gwH*v(!A2Au}h|vFTN`FM?i{~be2>mxw`XfUB&8(Eqr^qUSe#p=dN!#lYhanR= zLqe}d9EOBmk2nmO$Qd&9Lqe}d9EOCxc)jhA(CZP0A)(hJ4nt-nM*a)*!-jrX=-XYc zMT`xbwjUPy4p)cB85VlI=lrmtA2#&ELf`3ph@4@eFWz&0Sm^bh^TR^FC!@%>Ju-Em zA2IYJLa+CnA2IYJLa+Cn9}#-J=lqDFA2IYJhJJ+7j~Mz9LqB5T9%D+NA2sx&La$c~ zkDACC6?*O8qe34_IKr$~3y&K5QK8qXg-3+$hp()N0M{FtFXCT*{y)iI&hYn_it+ZV5OJ|=Ci z*E%0_^x<0PW776I`^PLT&`%ip38B|(J||4uPnfo!5PJRm{)C~QF!U2b|Fr9a$e0sC zU%cjXLg@9H&k1RJz2AO5B^naO^^7$S!-#|ZQ=%=LZ zKa}RGDbw~-rtPPM{s)Qw6zr6tpEC4QhJK3DPZ|0tLqBDDE#~Nfe%jDa3%!%1MW+q@ zw4t9C`lnvFEL}5y@8fAhKW*rzDgCsepEmTBT^g3D{7y9C8bzJB#q>+AH+FnPi^uNkV`Fp@(Uoy1)tf8Nkw*NsI_p^q6R@(lDY0jCIwx7N7 z3fcOsY5Q4ed$*ai4tKcP>3qmJv(olA-2I&Sgu<+}{jO}gINH;emGU_Ud%b~v&d|>Z z{hz021?CL>oX~&Y)uHX@g#MVjWCd+EXXxh){hUOO($7))IYU1uk)!l;CUUTU9_Z%{ z{k+iYl~ePEeqQMH%Bgvw*DI&y4gI{KpBMV?x_1I?KQHvfE2rj#Uay>*mtLz^YR{Wq ziz5kv{-mKlDfIejz>`9+v*43LA4>T%D<=*8Nke~9=qFS9lR{toG~h|0pGsrxq_q8X zRzl?HOaaF{0{w!aUl97a)VE;h7YzM^w7tHT1w+4J=of^3KBZp}`r>(^1)+a2jr0Yf z*YiRPrtNWbCeWWU^rwXWR7!u!M9wLpUvzbd`%^+c-RX~Vo)UUJMtjQ8pA!1hDg7xQ z_ty=XnZhZdKa*`2z4mNY%J*6vM+)?dhJI1#b>C{ywEd!K`$g0Ci$bsaR*QyyQRsEw zYEkHm`&NrWulrVu()PMF_Cjd=sR2; z=+6lK|NNGZoHK_0jA{EbLO<+$$T??(zWdJan$L8d5&DsAyNI08td#GyIEvVww5IfD zg?>j?!VLMtX~dm1^k;?MO^Jp6tZ(~1KO&tq^k+@mpA~vNvvOAGi)U8O3ca3LIqTX! zoLM<*+8)O{-Dh}G-gAz=C)t&iFjJ^c`~Eo-Ip<8|oOATmMA>#RQ)tXe*fV@NZBZPV4fN*?{dpHTf&RRq zKX2&I8~XFo_L_6f8~XEx{ye2WZ|Kjvwh#2@UE6#5@4IWHuS=G{;hHR2m8^VYrCYj} zm?ZA3^>xXLH%i>Y>yk^}xKH#e-dKgY!q4*LO7X$tPJbnJ?q=;@y$p{VWX(DG`--c+ zDY-GZ4bPk4zu!=@V#V0Xo02hXIsI9lEc==JLFr2Od&Nq()yq~TU%Te_-8Cfcq5Hks zrL19)yC=CG=?nD9-+l3~{;=&xXZ<13FE~Yi?q2TT+~;>5b2Z<*APo_xN+k+T;pHg%`HWJ;OuG9$I$QR|nny@6_vZ zS+dX7taRT5d$n6HS@x5a*I}6?%deHicKHi#`PL&W-Sdc;e(DH?qK4OB)X>014Q)`= z@QxKVv~W>F(-$@2EbzG-O)psw?_$w=717Wp#r3Ws8rrJ39@?>}AzF(XW+X+;C7LCg z>(Wa!L`l($s3~fziH6U?71z6&Xz209^>9?8sNF)eTZwiX(cVKew}WK1@%03+0(q^+ zjUE19uge;jyKkmjEnQbtUHTftqAI%dHHb)6bm?mlm)MTq5|&-*b`YIi?w_uY$KHb& zZC#vYu*PyqkqDxM7x`4_Ymz~qTNR{cPZQw<_C!OAkiKo+QUR!N3``sD3(m4Y*X%rLO^ z+0U&(YSDFd={@LIs_4?!yuDAkI(e)6lzuePzuoCRKlUlHXWyNUHr?*AZ)@yRhVcin zqaN&2BC2$L5socjpVA)*!26az8i2mRYp_qrpAGwzyaxM}yaxM}yaxM}OKaqtEL=@- zPJ-EdQCmwi%;1abVeVek?j{=M>njU)Kze(ha+Q1%yx4xf?E92UBNH=JM4@ItztrA| zSmZT`NM3`u%pb+uoAq@>CkWKno7Esjkp+6>7wag&+xwKOlfQqTax`mC->yEd{zLXD z_5H!pKimK7eafW-x=-1kd$pbo`;@#5emVCkF_vt1ueq4JT8P$4v>im-Nwi%=Ya?1a z(K?9MNwnQW+e5T2qU|NxKB9FKt%qp6MC&73KhgFRZGdP8h<1=@hYH&N562PmeKuqc zL@KXAyz&}EEw4fB@)|@iuR$F18bmX%K}_=+L^f)c<{`v4_aMr74Pu?wAmVuq;-1$a z`cbo#4Sj&upeG=EF7=>4a1VL~uR-77HRvHcOQWB_lmF*4J9+9O1Jw4fn>4?1mWWTFO9$omFjk$Vu4yasW} zdo-dGo~3;qG0F)LseC(#S6+jt5kZ{+Q3W=po(ipB|0D-kPsLKjAg# zExZPOh7+LYEUiKQzTj$#`TH@VJx;Xuie^8t{{+#VB;Kcp_CBJ$pJ*Q-+6RgDA)%+T%i02-}J+DFZ z^BVL4UW1;%YtSEf4SEHyLEqpt=pnoY{e;(`x9}SD8D4{)v$Q6EM!6(^M)~Tua7NjA zE_GY+XO!K8qyc}@A339ZofMY2lht_i&-je;sQmn?T&1j!!&S=P%Uz}Xz52IymGXdZ zm*v;W^54tfo7`WFsQ9_5a24<}qAe%d3Zh*?G`v&AZCpmQ%Zav9O(QY8xJBW58(cVe4)kMR4T4cGIXzwE0yNPxS(QYN$ZA5zy z(QYqj$k_NP7_HT~zV=Tk@6VWykt&V8* z1r77hHBRICYt2RD7k`4QJVf8q0}`K(lY?DH@B0PlZyM)}cSxc{ywKl&E; z-yP*gKji*ANiB}OQQV9wcNiU%8$Iv{iRWUm^zr(fWzDpJ)R_J3zF9L_1W_ zFn?@t8js(Gi^ebfh*j?266Hr+bAMx$AANxPo1*;aFWkR1%8$Oq{moH+^h199cw3Yo zeHNc+$us!*=k_Q+`ZxEtMEQ{mxW6^ZkGzp*$79dGBg&5)!~Hv>{K!Y#zbnd*+{OKE zQGVn(?r)FsBPViyN0cA=6X&n<&*9s@Gs=%#%l*5f{K(7PzbDF%9M1h+QGVq6{A1_HOl4w&znXy=Lc2+vXe#9#GACB@PuDSn6lplS7`-h_Z=r7zq9OXyf z;{K5+Kl&l}k4E{?XSshY%8&ld{YRtx$OYU#9_2^g;QnJ#e&iVLpNR4!A94R=lpnc^ z`=_G($aCC39py((T8k;A!vF3OL5&;9dJevA#= ze=^FCafJI9qWlmT~{-C_lzM?mrXd#~8`|XQTWWPr3hGlpkX+ z_n(jQW1QyxN22@~)4BiAi~2GDyx{!B`R8Lqdz@(RCE622dy;5R5$%0Mdq2@WK(r4M z?L$QSFws6jw5N&oQKCIVv}cL-F`|8(XrCb3CyDkP(Vi#T3q*U7XrCh5r-}9w(LO`8 z&l2tBf`<9y1*h@&y>QX^g&(oX{f|ZY5!dWfZ)=msqx|RteEaW>@}s|S{}WMu^eygx zGRlvB$o)@6`O#;&|9w$@^l$Eef0Q4&fcrlX5#?(WWSP8LeC*dk-YM4P%YH3nqP$vs?AJnWD%Rx7el29Hyjpzh*Fyd( z*5u26Eo8L3T72x+LXIoe&7=x>EmC-XS|c;*Gj8wmA}i~U(BiS zv%GM(*JYyFZ==Hc#r0MY?Goa}JA`k^atrqkTqoPTjA(d+itDW;+7(2*l4w^E?P{W3 zLo~Eik>xs~p#_WUT~D+di1rSm-AJ@|5^XinZX(*vM0=NL_U< z5bgGY_I3HzH-AmtGB@sAnSI-oFCpgec@JMgwBge;zJxeKUhySFSSTU3LJ3h7N{FXW zLL`L}VkndlJ)wlS2_-~KC?Qrt2~iSCh!5PQ+H)c@LLFivln@P}gg6K#L_jFvy$>b4 z>!F1AJCyKFISP3OWNhl#cLJ5%(N{ES2LNtUD;vkd|0ilHVK9umThZ5fJ zP{KPMN_dY$3GZ$w;e8DyyrZFn_cE05F8UJkM}sRB^T!sVH4?3JgqFbZW$xWw;ii6gb*ok`ckgzRd_(>w+b~CJ8y}jTnVT7% zU(>ueG%~rSy7J+@hmVX*PL4>JG>(ssB5A(m9~Xaqqi^vUe)=;clci6Axc<(QFaO|2 z9YDiUZgZF;rKVdX^-Tfl2QQzWz5%Zny7xUyn_ltO+bibGlFS=jMgP(A}m;pcI zelhob$^BxBfA*6k!R!#;$&u-qg&AMQbK(beSPvsrgZoWho&9~3gVUZer#v?AAReOURrm{s*gYKUjIWs`pvCQyR@JUIPGTl ziw)v;mHUMkuWisRSGZsNtZ~1nZ*ae;N86!{$C$hC?CR*8of$qkG~ak~d~&#ZWHvkx z+5yj7T2fK^aMijE>q^#@l~-cqef#I1x&`(mGw$EKdw-jgX}6qBPQNLn)o#Sl%!qg> z<`DK|ceu`V0fFOwdfe7$lZoVra7=jdP5iyVMIfFEeGVKkR;>To8{AaI{VYqG+?J=3 z<4K2OI40Vg`Gf7Fk7ygjdRx;Km$~guCL^)7CF@=3wy)cMGq2yjdW`p7$w~M6r`+}F zc<) Date: Thu, 21 Mar 2024 17:12:49 -0300 Subject: [PATCH 19/21] documentation --- README.md | 2 +- 1 file changed, 1 insertion(+), 1 deletion(-) diff --git a/README.md b/README.md index 99ae8e1..c7abefb 100644 --- a/README.md +++ b/README.md @@ -166,7 +166,7 @@ If no gene symbol is entered, all miRNA interactions are returned. If a miRNA is ### MiRNA details -This functionality allows obtaining different information about a miRNA, such as its sequence, its previous identifiers and databases where information about it can be found.. +This functionality allows obtaining different information about a miRNA, such as its sequence, its previous identifiers and databases where information about it can be found. - URL: `/mirna` - Required query params: From f465a0860dbf2e8e9747849b7e7e402cd0470bba Mon Sep 17 00:00:00 2001 From: mauricio Date: Fri, 22 Mar 2024 19:35:11 -0300 Subject: [PATCH 20/21] Documentation --- ModulectorBackend/settings.py | 2 +- README.md | 34 +++--- docker-compose_dist.yml | 2 +- modulector/files/.Rhistory | 100 ------------------ .../files/get_diseases_and_drugs_data.r | 70 ------------ 5 files changed, 19 insertions(+), 189 deletions(-) delete mode 100644 modulector/files/.Rhistory delete mode 100644 modulector/files/get_diseases_and_drugs_data.r diff --git a/ModulectorBackend/settings.py b/ModulectorBackend/settings.py index 1cd60b3..9b683be 100644 --- a/ModulectorBackend/settings.py +++ b/ModulectorBackend/settings.py @@ -13,7 +13,7 @@ import os # Modulector version -VERSION: str = '2.1.3' +VERSION: str = '2.1.4' # Default primary key field type # https://docs.djangoproject.com/en/4.0/ref/settings/#default-auto-field diff --git a/README.md b/README.md index c7abefb..79234ba 100644 --- a/README.md +++ b/README.md @@ -184,7 +184,7 @@ This functionality allows obtaining different information about a miRNA, such as - `mirbase_accession_id`: miRNA accession ID (MIMAT) according to miRBase DB. - `links`: List of JSON containing the following information: - `source`: Name of the database where you can find information related to miRNA. - - `url`: URL to access the `source` database for the miRNA of interest. + - `url`: URL to access the source database for the miRNA of interest. - Example: - URL: - Response: @@ -527,7 +527,7 @@ Returns information on a methylation site. ### Diseases -Returns a paginated response of diseases related to a miRNA. +This service provides information, with evidence supported by experiments, on the relationships between miRNAs and human diseases. - URL: `/diseases` - Method: GET @@ -541,11 +541,11 @@ Returns a paginated response of diseases related to a miRNA. - Success Response: - Code: 200 - Content: - - `id`: internal ID of the record. - - `category`: disease category. - - `disease`: disease name. - - `pubmed`: Pubmed URL. - - `description`: description about why this miRNA is related to this disease. + - `id`: Internal ID of the record in the HMDD database. + - `category`: Category codes assigned by the HMDD database to classify diseases. Possible codes can be found in the [database documentation](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10767894/table/tbl1/?report=objectonly). + - `disease`: Name of the disease associated with the miRNA used as a parameter. + - `pubmed`: URL to the scientific article in the Pubmed database where the evidence that relates miRNA to the disease is found. + - `description`: Short description of why this miRNA is related to this disease. - Example: - URL: - Response: @@ -570,7 +570,7 @@ Returns a paginated response of diseases related to a miRNA. - Error Response: - Code: 200 - Content: empty paginated response (number of elements = 0) -- Additional details: **We capitalize the R present in the miRNA for each record because they are mature, however, the file does not format it correctly and on the website they show up capitalized** +- Additional details: **We capitalize the R present in the miRNA for each record in HMDD database because they are mature, however, the file does not format it correctly and on the website they show up capitalized** ### Drugs @@ -589,15 +589,15 @@ Returns a paginated response of experimentally validated small molecules (or dru - Success Response: - Code: 200 - Content: - - `id`: internal ID of the record. - - `small_molecule`: small molecule (or drug). - - `fda_approved`: approved by FDA or not. - - `detection_method`: experimental detection method. - - `condition`: tissues or conditions for detection. - - `pubmed`: Pubmed URL. - - `reference`: reference title. - - `expression_pattern`: expression pattern of miRNA. - - `support`: support information for this effect. + - `id`: Internal ID of the record in the [SM2miR Database](http://www.jianglab.cn/SM2miR/). + - `small_molecule`: Small molecule (or drug) name. + - `fda_approved`: Indicates with a boolean whether the small molecule or drug is approved by the FDA. + - `detection_method`: Experimental detection method. The different methods can be: `Northern blot`, `Luciferase reporter assay`, `Illumina HiSeq2000`, `TaqMan low-density array`, `Microarray`, `Northern blot`, `MiRNA PCR array`, `Quantitative real-time PCR` or `Microarray`. + - `condition`: Tissues or conditions for detection. + - `pubmed`: URL to the scientific article in the Pubmed database where the evidence that relates miRNA to the small molecule is found. + - `reference`: Title of the scientific article where the evidence that relates miRNA to the small molecule is found. + - `expression_pattern`: Expression pattern of miRNA. The different methods can be: `up-regualted`or `down-regualted`. + - `support`: Brief text with supporting information for this drug-miRNA relationship. - Example: - URL: * - Response: diff --git a/docker-compose_dist.yml b/docker-compose_dist.yml index 91e136f..77881d9 100644 --- a/docker-compose_dist.yml +++ b/docker-compose_dist.yml @@ -31,7 +31,7 @@ services: # Django Backend Server web_modulector: - image: omicsdatascience/modulector:2.1.2 + image: omicsdatascience/modulector:2.1.4 restart: always depends_on: - db_modulector diff --git a/modulector/files/.Rhistory b/modulector/files/.Rhistory deleted file mode 100644 index 099e01a..0000000 --- a/modulector/files/.Rhistory +++ /dev/null @@ -1,100 +0,0 @@ -library(multiMiR) -db.ver = multimir_dbInfoVersions() # versiones de multimir -db.ver -# cambiar version a la ultima -vers_table <- multimir_dbInfoVersions() -curr_vers <- vers_table[1, "VERSION"] # current version -multimir_switchDBVersion(db_version = curr_vers) -db.tables = multimir_dbTables() # tablas de la db de multimir (dbs integradas) -db.tables -db.info = multimir_dbInfo() # informacion d elas dbs integradas -db.info -# Agrupadores de tablas. Nos interesa en principio "disease.drugs" -predicted_tables() -validated_tables() -diseasedrug_tables() -reverse_table_lookup("targetscan") -db.count = multimir_dbCount() # obtiene registros por base de datos intergadas a multimir -db.count -apply(db.count[,-1], 2, sum) -db.tables = multimir_dbTables() # tablas de la db de multimir (dbs integradas) -db.tables -db.info = multimir_dbInfo() # informacion d elas dbs integradas -db.info -diseasedrug_tables() -db.count = multimir_dbCount() # obtiene registros por base de datos intergadas a multimir -db.count -apply(db.count[,-1], 2, sum) -# Otener listado de todos los genes, drogas, enfermedades y mirnas: -miRNAs = list_multimir("mirna") -genes = list_multimir("gene") -head(drugs) -drugs = list_multimir("drug") -diseases = list_multimir("disease") -head(drugs) -head(diseases) -# Ejemplo: obtener informacion para un mirna: -example1 <- get_multimir(mirna = 'hsa-miR-18a-3p', summary = TRUE) -View(example1) -View(example1@data) -# Pruebas Mauri -miRNAs = list_multimir("mirna") # obtengo todos los mirnas -human_miRNAs <- subset(miRNAs, org == "hsa") # filtro los mirnas humanos -all_mirna_drugs <- list() # aca guardo resultados -# Itero por cada mirna humano para obtener informacion de drogas -for (mirna in human_miRNAs$mature_mirna_id) { -print(mirna) -mirna_drugs <- get_multimir(mirna=mirna, table="disease.drug", summary = FALSE) # table="all" tampoco da lo que necesitmos -# Store drugs for this miRNA -all_mirna_drugs[[mirna]] <- mirna_drugs@data$disease_drug -} -View(mirna_drugs) -View(mirna_drugs@data) -mirna_drugs <- get_multimir(mirna='hsa-miR-18a-3p', table="disease.drug", summary = FALSE) # table="all" tampoco da lo que necesitmos -View(mirna_drugs@data) -# Intento de otra forma: -drugs = list_multimir("drug") # Obtengo todas las drogas dispnibles -all_mirna_drugs <- list() # aca guardo resultados -all_mirna_drugs <- list() # aca guardo resultados -# Itero por cada droga para obtener informacion de mirnas -for (d in drugs$drug) { -mirna_drugs <- get_multimir(disease.drug = d, table = 'disease.drug', summary = TRUE) # table="all" tampoco da lo que necesitmos -# Store drugs for this miRNA -all_mirna_drugs[[d]] <- mirna_drugs@data$mature_mirna_id -} -# Itero por cada droga para obtener informacion de mirnas -for (d in drugs$drug) { -mirna_drugs <- get_multimir(disease.drug = d, table = 'disease.drug', summary = FALSE) # table="all" tampoco da lo que necesitmos -# Store drugs for this miRNA -all_mirna_drugs[[d]] <- mirna_drugs@data$mature_mirna_id -} -# Intento de otra forma: -drugs = list_multimir("drug") # Obtengo todas las drogas dispnibles -all_mirna_drugs <- list() # aca guardo resultados -# Itero por cada droga para obtener informacion de mirnas -for (d in drugs$drug) { -mirna_drugs <- get_multimir(disease.drug = d, table = 'disease.drug', summary = FALSE) # table="all" tampoco da lo que necesitmos -# Store drugs for this miRNA -all_mirna_drugs[[d]] <- mirna_drugs@data$mature_mirna_id -} -# Itero por cada droga para obtener informacion de mirnas -for (d in drugs$drug) { -mirna_drugs <- get_multimir(disease.drug = d, table = 'disease.drug', summary = FALSE) # table="all" tampoco da lo que necesitmos -# Store drugs for this miRNA -# all_mirna_drugs[[d]] <- mirna_drugs@data$mature_mirna_id -} -View(mirna_drugs@data) -# Ejemplo: obtener infoamcion acerca de la droga cisplatin -example2 <- get_multimir(disease.drug = 'cisplatin', table = 'disease.drug') -View(example2) -View(example2@data) -# Ejemplo: obtener infoamcion acerca de la droga cisplatin -example2 <- get_multimir(disease.drug = 'cisplatin', table = 'disease.drug', summary = TRUE) -View(example2@summary) -mirna_drugs <- get_multimir(mirna='hsa-miR-18a-3p', table="all", summary = TRUE) # table="all" tampoco da lo que necesitmos -View(mirna_drugs) -View(mirna_drugs@data) -View(mirna_drugs@summary) -mirna_drugs <- get_multimir(mirna='hsa-miR-18a-3p', table="disease.drug", summary = FALSE) # table="all" tampoco da lo que necesitmos -View(mirna_drugs) -View(mirna_drugs@data) diff --git a/modulector/files/get_diseases_and_drugs_data.r b/modulector/files/get_diseases_and_drugs_data.r deleted file mode 100644 index 899b080..0000000 --- a/modulector/files/get_diseases_and_drugs_data.r +++ /dev/null @@ -1,70 +0,0 @@ -library(multiMiR) -db.ver = multimir_dbInfoVersions() # versiones de multimir -db.ver - -# cambiar version a la ultima -vers_table <- multimir_dbInfoVersions() -curr_vers <- vers_table[1, "VERSION"] # current version -multimir_switchDBVersion(db_version = curr_vers) - -db.tables = multimir_dbTables() # tablas de la db de multimir (dbs integradas) -db.tables - -db.info = multimir_dbInfo() # informacion d elas dbs integradas -db.info - -# Agrupadores de tablas. Nos interesa en principio "disease.drugs" -predicted_tables() -validated_tables() -diseasedrug_tables() -reverse_table_lookup("targetscan") - -db.count = multimir_dbCount() # obtiene registros por base de datos intergadas a multimir -db.count -apply(db.count[,-1], 2, sum) - -# Otener listado de todos los genes, drogas, enfermedades y mirnas: -miRNAs = list_multimir("mirna") -genes = list_multimir("gene") -drugs = list_multimir("drug") -diseases = list_multimir("disease") -head(miRNAs) -head(genes) -head(drugs) -head(diseases) - -# Ejemplo: obtener informacion para un mirna: -example1 <- get_multimir(mirna = 'hsa-miR-18a-3p', summary = TRUE) -head(example1@data) - -# Ejemplo: obtener infoamcion acerca de la droga cisplatin -example2 <- get_multimir(disease.drug = 'cisplatin', table = 'disease.drug') -head(example2@data) - -# Pruebas Mauri -miRNAs = list_multimir("mirna") # obtengo todos los mirnas -human_miRNAs <- subset(miRNAs, org == "hsa") # filtro los mirnas humanos - -all_mirna_drugs <- list() # aca guardo resultados - -# Itero por cada mirna humano para obtener informacion de drogas -for (mirna in human_miRNAs$mature_mirna_id) { - print(mirna) - mirna_drugs <- get_multimir(mirna=mirna, table="disease.drug", summary = FALSE) # table="all" tampoco da lo que necesitmos - - # Store drugs for this miRNA - all_mirna_drugs[[mirna]] <- mirna_drugs@data$disease_drug -} - -# Intento de otra forma: -drugs = list_multimir("drug") # Obtengo todas las drogas dispnibles - -all_mirna_drugs <- list() # aca guardo resultados - -# Itero por cada droga para obtener informacion de mirnas -for (d in drugs$drug) { - mirna_drugs <- get_multimir(disease.drug = d, table = 'disease.drug', summary = TRUE) # table="all" tampoco da lo que necesitmos - - # Store drugs for this miRNA - all_mirna_drugs[[d]] <- mirna_drugs@data$mature_mirna_id -} From 1584e4f5874a962b6366ea9a026bc8b00a0c3f7b Mon Sep 17 00:00:00 2001 From: mauricio Date: Mon, 25 Mar 2024 11:14:09 -0300 Subject: [PATCH 21/21] Improved documentation --- README.md | 18 +++++++++++------- 1 file changed, 11 insertions(+), 7 deletions(-) diff --git a/README.md b/README.md index 79234ba..c990ceb 100644 --- a/README.md +++ b/README.md @@ -40,7 +40,11 @@ Modulector obtains information from different bioinformatics databases or resour mirDIP is an integrative database of human microRNA target predictions. Modulector use mirDIP 5.2. 2. miRNA data: [miRBase: the microRNA database](https://mirbase.org/). miRBase is a searchable database of published miRNA sequences and annotations. Each entry in the miRBase Sequence database represents a predicted hairpin portion of a miRNA transcript (termed hairpin in the database), with information on the location and sequence of the mature miRNA sequence (termed mature). Modulector use miRBase 22.1. -3. Methylation data: Illumina [Infinium MethylationEPIC 2.0](https://www.illumina.com/products/by-type/microarray-kits/infinium-methylation-epic.html) array. +3. Relationship data between miRNA and diseases: [HMDD: the Human microRNA Disease Database](https://www.cuilab.cn/hmdd). + Increasing reports have shown that miRNAs play important roles in various critical biological processes. For their importance, the dysfunctions of miRNAs are associated with a broad spectrum of diseases. The Human microRNA Disease Database (HMDD) is a database that curated experiment-supported evidence for human microRNA (miRNA) and disease associations. Modulector use HMDD v3.2 . +4. Relationship data between miRNA and drugs: [SM2miR Database](http://www.jianglab.cn/SM2miR/). + Many studies have demonstrated that bioactive small molecules (or drugs) can regulate the miRNA expression, which indicate that targeting miRNAs with small molecules is a new type of therapy for human diseases. SM2miR is a manual curated database which collects and incorporates the experimentally validated small molecules' effects on miRNA expression in 21 species from the published papers. Modulector uses leaked data from the SM2miR database for Homo Sapiens, in the version released on Apr. 27, 2015. +5. Methylation data: Illumina [Infinium MethylationEPIC 2.0](https://www.illumina.com/products/by-type/microarray-kits/infinium-methylation-epic.html) array. The Infinium MethylationEPIC v2.0 BeadChip Kit is a genome-wide methylation screening tool that targets over 935,000 CpG sites in the most biologically significant regions of the human methylome. At Modulector we use the information provided by Illumina on its [product files](https://support.illumina.com/downloads/infinium-methylationepic-v2-0-product-files.html) website. ## Usage @@ -183,7 +187,7 @@ This functionality allows obtaining different information about a miRNA, such as - `mirna_sequence`: miRNA nucleotide sequence. - `mirbase_accession_id`: miRNA accession ID (MIMAT) according to miRBase DB. - `links`: List of JSON containing the following information: - - `source`: Name of the database where you can find information related to miRNA. + - `source`: Name of the database where you can find information related to miRNA. For this version you will always receive the `mirbase` value. - `url`: URL to access the source database for the miRNA of interest. - Example: - URL: @@ -481,13 +485,13 @@ Returns information on a methylation site. - Success Response: - Code: 200 - Content: - - `name`: name of methylation site. + - `name`: name of methylation site according to the Illumina Infinium MethylationEPIC 2.0 array. - `aliases`: list of other names for the same methylation site on other Illumina arrays (EPIC v2, EPIC v1, Methyl450, and Methyl27). - - `chromosome_position`: information about the chromosome, position, and strand on which the site is located. + - `chromosome_position`: String with information about the chromosome, position, and strand on which the site is located. Format: `chr:position [strand]` - `ucsc_cpg_islands`: List of islands related to the methylation site according to the UCSC database. Each element in the view is a JSON with the following content: - - `cpg_island`: chromosomal coordinates where the island is located. - - `relation`: Relation of the site to the CpG island. The values it can take are *Island*=within boundaries of a CpG Island, *N_Shore*=0-2kb 5' of Island, *N_Shelf*=2kb-4kb 5' of Island, *S_Shore*=0-2kb 3' of Island, *S_Shelf*=2kb-4kb 3' of Island. - - `genes`: The value is a JSON where each key is a gene that is related to the methylation site. Values for each gene is a list that contains the region of the gene where the methylation site is located. These regions, according to the NCBI RefSeq database, can be: *5UTR*=5' untranslated region between the TSS and ATG start site, *3UTR*=3' untranslated region between stop codon and poly A signal, *exon_#*, *TSS200*=1-200 bp 5' the TSS, *TS1500*=200-1500 bp 5' of the TSS. + - `cpg_island`: chromosomal coordinates where the island is located. Format: `chr:start position-end position` + - `relation`: Relation of the site to the CpG island. The values it can take are `Island`=within boundaries of a CpG Island, `N_Shore`=0-2kb 5' of Island, `N_Shelf`=2kb-4kb 5' of Island, `S_Shore`=0-2kb 3' of Island, `S_Shelf`=2kb-4kb 3' of Island. + - `genes`: The value is a JSON where each key is a gene that is related to the methylation site. Values for each gene is a list that contains the region of the gene where the methylation site is located. These regions, according to the NCBI RefSeq database, can be: `5UTR`=5' untranslated region between the TSS and ATG start site, `3UTR`=3' untranslated region between stop codon and poly A signal, `exon_#`, `TSS200`=1-200 bp 5' the TSS, or `TS1500`=200-1500 bp 5' of the TSS. TSS=*Transcription Start Site*. - Example: - URL: - Response:

eFjF_Nv|JA`flZGy%PJS?kYLwyl~( z`bp5o%+EwW3Hm#B%_99I=rg&`i++gh?N6e-m!3yF_LR-o$yv9!pw}nYrcmBX zZ_ewdl71>;ullK^pGx|vq@POqsidC@y*_t0HK?CT`l+O!O8RM}pGNv=iOjM2H;po9 z8ua=U$u#KoDUxZVpGNv=(CaRpNbjLmz#|>vZUcxz9_j)pxv3C%yFL ze78HoK3+v3fD{zdaUCGTfI z-?S-@j%PsslKWoKzwEA(N5?Yih{s;BKbr~ttL{ql`rO@2%AA?de{4(=`!!0Pb7oQO zXF;#)rn4yTXF;!h%vsRiX!Wz8kFJ}}g8n9}pJnuZ-E|_oJ0CK(3{&6^mCxs+0Z!@`#DDM_sPsLdjHJh9HYPdna4Rs@1J>`WAy%+$2mst zcRR@F*vEb@^l#eO&qeIDe?OP>bD`J%{aom^e?J#`?cdKu?6rSC7qQp={anO8+P|NR z*lYiOE@H3!`?(Z*8OMA5JkrmDey;tS&7-`Z=ki{1Wghg}9?hfJ&m;Xj=ym0B9`w>>eCTy#I3N1wH+DBqD*Lzf&4>Og_r0S3+Fd30F=cMV>lcuI0b+mAer^H9eu0a< z=odhL);tm;e~AU8UqJc=q+bx!FChH_WRB_=Q0!$E$LkkD|Bj9QLg;_Cf5C;MUr73e z(C03am=ReBz22=BLa%+yh0yE?t3Nnb8XAF5PF>rmHDQ4 z>|N_!1pRyNN;0R8{oEqToJG*rwJqi%=)Yc=4Y6NDv0p^7Uj%&%^EuHkf__Gm6?DG9 zBIsMX?-hM3ca?mvm6HDOtD`Kz3x$3O!~#7Urd>^82acQrNz+e z9;L;|9NnX|m|`z;cwWB*`uA<@mq4#)J1imn64Eb$Ue9(|Li#1p>%DdfWzLdB=0whR zSOWbjn>kCM*LR68p}d#bMz3E=`lUwiPv2Wg`lX~_YV>|@-cr&pHG02KW-0W#PiCpn zU%pRfsnPp=GE1S?eKJdp-ruccUexQCLH~h`{W8Q}?^eqw@0UTZcdKQHz22>sL9chK zWr)4rt(HNrcdKQI*hlsYEJN(|ZnX@0y<07#*vkyA*Dojia_Dtu;c|-oa*F+O=yhk| za*F+O(l3WzcNQ*(KDx7TIrO@-a5?n4vv4`-Wv}mC);ZzgCidCG`5< zua(g2d%sqaekJKwLO;ct5AFH7?GF_T}8EL71f?qRQFc}YtJgGJ*%khuX43V^ios2el_V=LqEgTy4BF9 z*!$>e=x5qJ6RV+rxo)DTx|;N>Nxz!v{_3E9HR)GV-Cs@ZuGDF-Uqkve(0^#}fNMy< z2KtZ8&!nHdCeiNJPw3Z>ehul@kbX^2zlQW{NWX?+FRhQ)uOUmMh~CH-2`uO+>-lU~1$^y{F1)6U1NBmFwkuYhI{<-}8|wHu)y@qOa`x*MU_y+RvF zzY+Q~rsWd-M(Eo<%j-uQp?}c!(l$c>kh@AAp~?N+ykXh?%QiuO&Rxm)Qb%Z;DDO8> z-fx0lM`)W!zX^Js%iRRM&P;4d#6FGR=CKKS9ieT4UPow~DE89x@cPZ9-;CJnT<&Iy z{buNOE_XBZI+wedGG{aCH$#8U#(p#O(Yf5s(4V(=md(&#a97E(mp+o$Zz25_=yf)9 z3+cB&ud|_Bpx4>ZEu`N<`Yoj264Y-Y{TAqTCVC6SUV3wBE_1dTeOm0i&77@9@5h&0 zDRZ_`=4>^3Kfc^bnX}dC{rGaL(fj8xwi^BA9>)78)Cm9UX6{%-IgTj*hoOucPDb(Cg@U zJ2FQ{$J>!PIy&Bt%!$tBZb#32Y1 z&-_eU%pK65`8v^J?x5K3puFD!eSO>B?|^>ALjrrRuMiP%SWn(TyLcbe=pvG+So zc2ewReB|}JNWTlQ*PSN2DDQVc-^;XP68l}y>rRthq~AsQUC{ToE#@xhqdQG@L2s6G z&}-U-%!#|J^6G80<+ub{R+%(v^ly*NyeOJrr&z^Q0(_m?DtUY_fYKjQ0(_Wuk$K< zDE50O_IrY{-$SwAgV=v$=W_Q@=E&$cE%v3=?=||g*jMf@`n}N0nu}!4UZeNz z{a%XwUZeNz{a&N@?fqWFzI5$(=@hcPh~&U1#__36zYnqh+UoZq z_Fe36*+=?)q~C|wH*A<#1=vTi-)Ho`z2Aq}ceU;PKBG^K9l3ax+WUQoeK+^L(<` zSIIpEnQ@3a{eIH#hkmB*-R-Bm-w(aE_xqvO_I^Lbem`Z-e&~By{eEOl;VK7c6<|N~ zy{&gYGN+HbO0KmsH{$gNNPmFx{s6`P0OkDw%KHPPKS25el=laMd4GWN{s8pa<{Y5B zmsy;6?4r$;gQP!5`h%oDNcw}MKS-H#kn{&he=w*&Ncw|RYY&oM=9}WNZ>;_h^xwKG zxm#%;^AKguA?US_c?f##V;&;?A?US#e+c?>rnXBz=MePK9`YgR&)XLM5cJx|JVbh# z8T0zX&}*A>7_rwCn8OtN!_aG+a~OJEfjLZ>a~OJEfjJDluH7AmzG`Fz<}mcDto|_c zx&m{U^fHI%^+!m51bW@8afI|oNPh%+-K%kg^hZd41o|6o?2kYn-K%i~`kSo&h|&AK z8b?SkvyG{-?`*Cdh5mbYC7Gi=^vUjVaMsH5pwEr@h7d6kvSnn~?A4BYQciS=2A9H${Pdo;_#$!KN{c-4jbXO949oHU*KE(=; zL$Bl7%Y3O^~x_=t_=;-(~^g22|4ZZeMPm^BibUgNdw(c@)ikk}q@Zj$5?(Saq!nTE$ z_oWVXcXwB)d;7J;-L1vlwYa;xJ73PTImtXr{%~E%vO712lT2jfn2mOK>bbf@|C)W{ zTX%|mcj#X?pNYOZ^w%{`p7XkszB~0?-JyTOd{53A-J$QjY8J57PGt>U)sB2V$@K9u#}&C%wKW z>3c%|zU{AjlD;SOAK1+43B5jrtS9MvlD;SOpV-Xl34Q8WqbKxw*60bno;7-sUV8LI zblhf6FVgpdUay(xMS0%~dc9_%7xa3~L@($E+g8_$^u3@TVm_11=>`4h40X&7jDI6} zFX)H5?@Q*KaKd=z$hpVsdqb~%PH*UStk;|Ly`k69U2o`pDL&Tg4ZV)_dPA@GVf2PR zb*$GLdL8TaM(lO0*PCK5XGyQ`L;60X??d`Nr0+xeK9o6qNZ$u~9jW#S>idws59#}m zUe4!U-I=QzJ=GU_UDN7I`o7S=X7j!;^r?4G^@U#Vp6Uy| z-aXY9dR-Ngkw+prX|t*y^ru`&#@R=0tL;az@8@DKJ!U`X_1e&Wr0)m4UK`pEdYxbP zgT89YwW0l>*K0%jL4VHneEmo-W27{v?{D;J(P^vikJ#(8r213r`$MnKlIjn=K1-^< z(femf^*4GyL+fw!X^}ols=v{vMXAq{>TmREkv>bRztN{hZS5XLf1^*2YTJm)Xf6?* zvEBiQy*U78S_7chInDsm4}f0hI0K;9InDrz{Q$&X=Qslp`%N};1|asSbDRN){bnbW zK1b&`11R4UY9!%dfoLMNcw@$>vg#Up-;Uo zcOdk7UG6|+j$W5L5PF>*%Lq9UseTaY2O;)V?El#y=(SfIM0r05`j^cTjEwvSQS1ki zeh~CI&2LJ7KM4A~zh6!L{UGS8y5mahtGSZSapXucmiPL>(4V)l9}KNI44}soPA)-Sl z_CqN4L!f{A5&fI-v(*sN4}t!1d#)V4t)l5RM8I)>W7nlIO&H|k14ZbuOC7B5zuF} z|LPH>A3^#N(6`T&eD~A{(vKkh2#WoPpne4DN05F5>17`8^&?3?lJp}o_D-nll0&Q`MC+pIsdxM5&geLpB~jbn7sGvU&@?+jo!bl?_Z-&j~1KX6#c(OpB7#B*cRGx|JUfv zJ+SV$GQMBxN;1CJyqDF+gwv0MK9|*xL+tfU7UM`i4tjl)#W=)X-()e4Vm}VC*SXa= z#9rTIF%Gd$eUrsF#9rTIF%CVZzR6-7^_a3Q>hs6iO zDfZ(@KOXu`roBk)$3s8(suw78#zWuPX8L&OySP$3?_~wo>nD(Y0`$6`Gl6110eW4} znE<`6=S+ZJ*K;O7udQ|h^tzri0s7SSoC(nDdd>vs%^&DVCQzRvYt4x$kNs>S=_f+3 z&#;MkG-sld;KKR zPl8^bVKs^LlSn@adVPk~B+^eJ{Up*)3hF13eiG>?x!BA8(PX1f-9MTVsGAz7n--{> z9;llUsGAw6n-!>=9jKcVsGA$8n-{2?AE;Xps9PAQTNJ2U9H?6os9PGS`!7(pEKs*R zP`4sbw=z(-Dp0pNP`4&fw>D6>E>O2VP`4paw=tzoT9)KrBFbz2OqMd3l8!efqxI~y zt!^^4p2^gDCZqM_+?n0}N_@OAnOe_eYCV&Kt!FZ|p2^gDCcD-nUTG;_KLu@H^;4jK z#_Fe#ehTTQK(EgYokDGY3hAeieo9b3h4fQMKZW$troDbD>8C=kSKCY_{Z!IVgtzZW9 z`CUm?L-l&}8PJ!vzcK@Qy*_aU^m={b4CwWG^cm3Wirft7hnZiI*w092PRiZdGoaV& z(PtoYM!4g~&)9PA@%ovhpNZJNnlsNwJ>^{Y>+~GKs-V%AA>`p9%eI<~Kz@ z6Z*QH8kspx7Z>}P(7*1EE3tpWmEy6Nv!vJ0BK<7r$Ju}NEYi<%dhyPJUT4R%NI#48 zv!EYuV?PV}f?XdV{VeDwxZ}zkXQC^`^>RM<`q`wP4ZY4UXH(|PhF<5Fv!U1dz$2Od$}vcGe<@qUO$KQbD-Ci=sBdH1HG<9 z&w*Z7qUVr)4(aDWuPf1Wl6jwUFTfn=btQTZ^q<%n+8pY0WQ=5<&Sn0T444ajL06Ji zt8<*Wq@N4D&T-~KuXCKaq@N4D&d}yUzsW>WVm}x9)H%*v=yi@W7p+$3ICDuaqdBji zNBVh)z4rI>DDUUFyqDSWJm|H*pGW$6(CgW19`xGZ&x1a-zn=&FK$|P`5c@%{6wjRb zq@Qo}9V3nXe53bwPt7O&eA3T1dVe+jeA3T1dVe+je53bQ)6X~hOYfeVZ}k4|srg3l zucn`GV(+h!lM%9cON;qaGG_r|U)Yr-bM$Prfbt6zxB*>3;O7E<0XgnozlOfqL7^cUJE zW3Z57zYuyoTP=isr}>`b{X*zZWaK_)A@pWx6%kzs{rk4nE+oCoI?Vg(t#=Xh#au~Z zuRZ1>(l3Hud(1`9Ymd2z^oyX^HLXR^>x$eW=-*FSky`}4uE;HdURUH6QLB~tk=HMV zzPQydM(p3WF<4Cc#n69XW4{=By-sE^=@(PxEQVgMlUWRX>UA=Uq1WqV78`vc((7av zlU`?XVT{^gI=$8SO&fJn9E4N4Ejyxd!kcE>X%dA%i2gHDrNqZv(*aHuYkU^`z*c-u!8b_1@wvglg~6+LHZS>Ujcm? z^P3X;70{o#cefd1`nlB#=*zm}O6<$IQap2H6(=n!Z$DcJeFayNk;3J64R|HB+LfeV zY4mB4zH4x$(fg}>RvNv(%4em~`*#hlH2O>5HMr8~{ksNNn%Mid^{qs!t!=YP)|Q|9|73o)zURK5uF7~TQzZ#kIiv4%4ro3Mb zybBL$9KE`2HS+!qr-)~ctl=f1isnzr z`!awX|8f47;lhGM@4dVQzz8tC<%%4?w4oyRrM>j-%b^fSz;Me=?P^iN;gmF8A! zpr2_+Hfx}tDQBfJ?Ynzem&*=deW~a z{raGOJ?YmY_MhA91=l0?dbX0aX0P8s`VG+Q-Le}fb2d=sY@p29K(XII`VG+QJqR11 zPrV0W1N3ced)olL-h;4#GDlX$6HyiOr?lFQ&{uUOX|+01*hu<~(CbKHBlJ2_*hsP8 z2)&N)H$uP3_Bk7&PaP?2gkDDq8==>8?MA1U{i97rn!10qIZ(GHP`5Quw=Gb&Jy5qJ zP`5Ksw<}P$J5aYLP`5Www=Yn)KTvldPzOK2UcdPGFsYa&o-N=^=vY& zCoM9Ucwn5p$+VudXyLrQZZg%~y{5v9>%63+cB& zukRw+Li#PF-xAbsA^jHUH{0v9wvb+WpF~vM{3$Wq3VjV%l76?f{a0@#{Z`U%CH+>4 z{Z{ICw?eOP2i^*O>f3?0La%QJ-U_|G9eAtjcf~9Hq}OjF{Wip2_1j3ljr7|{zm4?U zNWTsGD@;Tr@3#f@+ep8S^xG)*(xZF*cG7Q$Uf*rJo%GwG*LNFlhhE=pyq)yhNxz+9 zzdfkmPWtVn-%hcYbC1{WApH)~?;!mS((fSs4$|)+{SJ!#j-Y-A>35KR2gP2_l3u?P zdYvWggkINjcanam%N$vm*a^L^RRqj=yff3r_uYJ$DO2? z^SRgWf?j6{yP($@+AiqJ+n#n8^g2V^1-;JDc9DJ;^g2V^1-;JDc0r#yL)!(t&d_!t z_Bun`MS2-|q(wE&pVEeR8+}@&&yw10^l4Eo_gN-$*3dqEx6vm{68qgopBCjc!?WbC z#IMWUZS?+ZwcF^;*~a{)wA$T9pB62h`47Dfez(!5MRnY9UMUqhho3S=+mMa<}=anfnKk4+C#D5WAy$$|2;-;EarQn-(&RY(ZmeP z==#JxMsG~+xT5!^`1Of0noC6Wt$r^ur-3U;f8WrRWK~ErXD>3Rk@-yYdyzR)&1<+N z_IpXcmojHBGN-Zmp6K@?bM~Bgk*@IDi_B@_jw`D|Osn^!w3j@3QT5Kk4^Ff4BKe^!uUT(Kwm+`$@l_^!uS-YrZG3-w*w-DQ|Du5B)lK zT#5a9SBl48#`1}%g^l(B=v%r{e1>*_^ar5V8QKBpb%u6;GUovFIzu}E{U)nF0DbBV z?Ev(q3qT$oKy4zE8*`h$qQuH_yi{Xyt;E%zYwx|Vy8^an|Qkn{(G`h%oD zNcw}woT~QUBJ-n;Q7aqmLq>1*C|xPOZ+ZxN?J*BQFD1#GLq_lSFb+}X95Q;phjGa0 z{l4iTqrY?ypR?Y>h`kCABlfzcb(ms*7{HjY4kPxurga#x*EOxf6nmL-CZaZ0e+2r=TuJg? z-(quw^hcoAx7ZwkUf*JKgkpb$GUo{N`mER^(5Jq|<_Prq7Mml`>w931kX~lTUVoJI zM-h8{i_KBWoTHREN1@lZ*c>JOQPLkJ{n4QQDCv)q{wV2X9`E(XpugP4{upJ>F^c^$ z%A8}AImak-j#1_uqs%!L%$#GCImak-j*(tg9K8NG>5oG{%C_(0q(2V*XxnO!Lw}%3 z^67iWDfY)ne;oSGHt&x^zvY!OW;N7bVRan(G48n1-;Z^rc#kP-BVK=k^e0Gvg7hay ze}eQUDE22ve**f`R(}He&kuY}Yq=+&zrtp~3B>+NSBmRp702sOlKv#=Pm=y5=}(gW zB=oxTc#`xdNq-Xh?oW>*{YmK0*l3@G{;Vs-^|IcSh_15#vQyA&pK}WOFYWhEk^U6) zy6bxidfoLsMVWI7dOg>kf?juhPeGr$>w5}%-Ss_X^nTa(6y?3FjCuWO(w~N2*K$vj z{xtMDQaBC0jucK)>`#;aH1wNHM5Mnz4SniJ;WYF*QaFv+>qy}=>17Si>(5Z;oPl0P zX=g}(26`Q(oq=9QX=f<*XDD;dK;Opd&p==F@A77Z?4Js92KsyK|M?l{?{%ek=E!QJ z*PkW*S?G0ye3tZQq1Pu7orPXU$Y&|`XGwn+`o?B$Nn(E%`p>J>BmG(Eo7nZIv&fvL zt`yhHx~SKmBmFt(btUi|^g4<-2fZ(4F~8zVGBeb*v~#3C2feNYo`XJhCGZ^dx)OK} zv7csU5;F5Shs@C(7+JyX5M6Ell+Vr^eTV28SCWy!SUXENPx|vtFQc^ch`l~L@H}PC zd87C9+Ve*5pB;GK=r4VC;CZ9>&kj6q^c~#Owa*)U2lsSsS!?bXU2DA;jJ{)Zoh!x1 zm={QYf%F%Q-j6Xakp6mc@eSKG3G_+b&PqDGUp;PXP9lZ7m+!sW6X=l935j`MCRxi z^P=l>WdA72bLsw3hCp4$KwYLlUFJYtmOx$BKwY*#UG_j-jzC?`KwYjto%zRKvR{@b zP?tAQmoHG4KTua7P**TeS13?dI8aw4P**fiS1eFhJWy96P**ZgS1M3fI#5?8P**lk zS1zSa`YOr4M0CAv?NJ`N|L6u+lAcRv$5Ed6s!)_i?v&Trag;~;U7a0AdEzT_Q670S zvyL~SJlRcYlWjdwo*br>dd80O|620E{ znE`t37cxL!&h*LB?`D8r@B7REz25hk0eW4_%>cdL_n86u)cZa&K(F_GW`O=?XNv2k zO(&wZ_Op!8w{s=Ye`(J)87cM|q3>!w6MaVL?_Aj%=bntv>zY=#nyP2TZ zmFP^+YrmTb`qX|m6ZG2eW-_1msBmJb;XC{4S==GZD%%sl@y==DB~ zETqpu`Yh1veHdAiu}`@VBMbC;A4V4FKe3sU1$rGV$+^etvywh5^e@;EZdT~E)n zm*Qi+tfbFM`mE6F6C$!gpZbJ|tkA#Yjw^YuPl(7$v6r)?*JmSrHs}*}te1^qpAGt3 zY@d@2u`gRCIbzI4`fQ}n2K}w(dos?>2K{CG9-(#gY|!84jw|~1t`zTc_+de7szh(mtHTB-RS-G0@+RG z`0E9-o7ns71!Uxrh;Fs|9MIq9O48@(u5S*?oE(%nIS_lzqa296&h2v`_IkF;f!OPw zb&h1-SINuLv$qxzhr&q?~6q|ZtEoTSeQz3y4( z4C-@|J}2pOQmd8GoY&_feJ<#A&pH?Bb3w0r*14e9J?mVg&qexN6#HC3eJ;}HB7H83 zy^K4(J~!!elRh`;bCW(d>2s4lH|cXz>~jb8xk;a!^tmbarV!KTA$=a`b(EF|`tr6P z%LBcR((*vBqqIDv&qMk=&~GxoB7IIC=u<~&d7$6yjuaoI<)PTiSl-7zFZAtgtIZ4j zQTr=-DfW3?-pe>AFZBA<$-Jb`3%%ZVmlt}y&pK~1_9;)D%nSW-cU;jwZ_ieFDfTk! z@cMkD&qw-vq|ZnCe5B7u`h29%NBVq0eLm9XL+0rF)bo*E=0}OBgN=56%AEYrYoC*! z^!c4$W(oPB*B&!J>GM2Q;&rf-upYlFGWsc0`yuJYG3y{75=?jp)0O<>m zz5wY9K(9S!fuOzs=?jp)0L5PBoL*m$^aY{U9Ux;Ea^Y}z`yUqK; z(BI)oGE&fYt`&y9yzL1JL$B{#D-6B9bFDD+I=3oJ`ohrbJJ$+BpZdsti+)O&r4 zKtIsNsff}0XFC+3%#pPbuP;jaqDJrU^({*JqNFcs^nN|DDCvtDy~&UNoH9pN#=O1+=}SPb z^V$-mF9E&IYfC_{^V$-WIVDJ60(za-mPqPT=CviD*LiIT26q%TRCQ26(0^*jIVDLitBqb?iu9$RPq(e06zNMr-^qL? zeNHLpue&8VuPsITQlu{h{hj7}k~yWIZ}`bIG_NfM{ax<3GD^GKmEx;WvM%cNrAc2J zdRY74n=zp>E@Y2Y8T~jDcc`qxt>Crv* zUseYCdtFJ+R=RgrhGJg^dfmG#gV^idT^Wjf8Kd`4J}hJO>Ct`W2on1;MsJ>KIAkeZ zSy;yC)1&*HLT2TiT`9f;BWukaoW3mS%OdtgZ4Am9y}xF%tkL_cI?Eb;dNk8s$ygTp zV(xqK96P**QdS3gkK zAW+vZP}e9>*EmquBv98hP}eL_*E~?yB2d>dP}eF@*E&$wCQx@-pziXNI++tO?5OyZYQ_oc%Jy!+unVdDsqvtAVf|vZw`2JCO(|Y`9sXW?#B|F|IkGB8* z3)!-Eh~0lw9&Nv}JFc8H%tEXE?ReXlmXdHiR|V2nfc`%Fy$YnS0R8>uGtpOoUY`?P zfzBEg=&Vrz`fG9|d#(ybZ+5>L7B)LDcbYIIpA%gH`fJVKkyuo~8T&d{itD9KdwoUH zSA_l1h@6`}89M;H}x z&U?U>;(FMN1H66q^JuTR#mMEXjkuLON_^P8ft1pTj{bffFEDnZ}E z9aqj8EnO+DmwwXgE0ex5^#9rKRi@0T4E-|mnZ&*_^q>DX7XR0kq1Tn@%A~Ih{gNz6 zeP!rhZuk@FD?`83{2j@h%831ct`yfxkM8wVNM8kd9cNb|eHG|+oLvQa9cNde*jFKa z73g)GT?P8oH%e52UdP#0koP*yu0o?FIrn&dRnk|5{w5pys+2iZp}*P2zAE(k*0QRk zuS)u=(6=?;lgz0Ked=4wszTq+9as9Cgeytx^@?seOL~1Z(pQ820ehyeM*39)RL+-euf7q4cnIq?Oudhz}>d-%7M=jMU zbE-rCr1?zpzB=^nze!%%TAlRONnaiMN36a&^aU?#LHg>@KWe?zk@t_eQd}=153jF5 z`Wn!0xBq7~NM8eb-Sw>jz3%$fAbkze*C2h3puPs_YmmMM@?PhcGDh~@-8)`I>y`+r^w`sZCK-fCss>Gicq zUmN{`r6PxVe`H=^us^sMEcs$Kk1Gut@bHbipO3? z$X;KE^mU-u*>N4x*KvC3bLv2^eNG+H*CBl!=yi5n2l~|6aUJM&$Gr|>ue0Mi)Zfck z-s|gUNUpOewOt0pwHmGFPW3k zmExHr^CPdXPx|`MKWf`cebUz_eSOl`hhE1y^+{hJ`Zw)8kM*Hn)A0?`*N6T&8}0hZ zR_jV}z0Bmiz5(RRic# zudr$Wy)Tq&OSvf|+NO-SE_^i4?Lg!D~F--I%!3F(`VzDZEug!E02_o{C~nImf> zUf-1TO`-2;|J6+?@0&v3%X}u8(-iur>m+AGO-bLB^i84fZN4YtoTkvvEWOCY-ao&t zDfE5ZaV7RI+Mc8->17qi>zk3j8T1Qn{xzf6H>21$gI=F6(2VrWNZ$^<`sSo>PWtAgZw~!SCX%9W4*g9>Z>9de zIrJ~vXg5dZyy8l6y{wG+)uq021R-+62S{cC0? zPV_B|zC-l(h&8kl-2(d8?QUHQ=-+UqxL(%qeC%67|Em3WwuD~S6k1Z=w}f8T6k0;B zYYHu)*FEc&h`nCj))M;VHgj4c_HY0867@MPpAR-|u5 z`c|ZGMfz40`&OiHMfz4jeJj$pB7H0B?`2)o>syn)HT0|Ozq&Q)TSLFvd?tNPYv^az zPxd*jDfX>N-M>U)ZG%OyERaETcECepsqup?)E_49f7)zfx5InU3#FdQ=sn7K;2z|y1N5) z_XO(h4bzl5myRV{`mXhZ7 zkFF&Bl}4Wy-DUfXD~;aod|wH@_FPvQeOh#+V)CqUrP2GV>8~XHl}4Wy-EDqT#v4}} zz4>0}bF_DSrO_LcJ8o`My4RKBSJO+I_C42C&}-j%6?(2m?Dwvs*k9#(E{VZa=(+s& z;(K>jq33$k{fgZC^_VG%{wnlbH;v<~>90c1^|RZ8hX8E z;%ex1J@IPNU+wggIafok>xoxW=3H&`e&7CTWX@gY39O>O8nM53TYnS#m)+jo)rkGu z&Lpva$Ccu-mwwXguOa<4$ednwym1ZbuOa<4$ei{KlbLf3>8~OEHKe~LsK18v*O;@0 z*I#4K8vZ^E>CwIZTGC&O*q^ayn`=pbE%ay2XA=8s5&NtilB=QDQr=%{^nTa(TIBt^ zCXy2SYoYIUVkE`>TIk=i(Z1H`)1&uYNm^}f8&Ns;c>Q&xzmD|Rk^VZ;Uq|}uDE8Np z{yNfM7t~)z`s+x4or%5I%UROvuP6QW$eh1zd%51|eV=o^(Z@^DV`{6tp7hs~{(9)U z+g5u$^e;a;mSTTB^gY~hCH6gCDXy3EdAe)0H<11Y#9p7Va06mr-u|E6fY|FZ7H&Z7 z^%)B{kp2dv_g6aIfV^*Oc0na`ZZP`vXiHswhT08ApB}ZdJEb=u_6b*t_xCdLNI3nC zq`wjRH|-OeZ=}q*5qgdGjnMm2yvMxJ=*_B*{a4>;^yYZB&$-d)&2`KDo}$_DjYe;- z4|B(r9`hYnijP!fjO6tJJPp{!9BeZ$a$K+8Epd zz5c)40=<+Zb8dlt$Cl(fy>EeDSA}kYURQ-~fxeuL{VmYHe)H=l_WmlLTc9uRjw`XR z;7X#`RUw%ldHt=Vzm@d2lKxiG-%9#hp})=ck++imR?^=Z)Za?_TM_$;R(~rpNA)t3 z^ZMIJe;es_QRdu6`rAl2HI+lGWcvdYN;2eS6Zkhkk>NVSCE^ z_Rw#%nbRJ6eHv4H(zhpld+0Zr?@6E29{SX~2HQiw*&SChN1v?Uo?5NUj?-PM?Lhht zMxP#iX@8{y={rE*)qEy--vN4k5>^Mw`wm9$`}+@gVCo)_uf5&=2jhy zK0R7vuW#sJVxJzZb*1=7LFVykPJcV}U2Utq-RRRI9i`oF^nN6EyV1u>@lo3C6#Lta z-uL&n8+}@&qqN(NJ}pWerQL4yX_1c7Ziik+X}6o$`!S}hIQY!DgYkPx>-$abq`bcqdVRm?ozUz1P46WAout1L`mc>eGUra{FMQI0 zW+!(-|BdzD3H`UO6py{EHYTF)>}PjD|Gg{8C{5RM?xNV=zl-#D zLEp{vAfmqu`aL`DA^ly@e`R}_yP*HtmEy6Nb)h&Y(%%iejxq0sUUz-(PUd~e`>gMVUUz-(HhRD7dpDhHWd+yk?;-s?&=I|C1|8=5)9JXZMo+Ug&$6&m?p1g}(j0N&USP`+K3+dF{Q>_cY%V{k_nynfwH0 z&b`q0a>o^YZ&!+Ej;xA%{e7grk6P`0(3iLU?tRc}tGy3;ZMFB2{yx&*2mL1VE26&- z`qZ})-v_Ru1jy%DH;Gf?+dpziHJ-8(6D(#uHx`POqkwVwOYdOox5<$h}W_fyYxKU$Bzq4s|2 zx$dW)>wdJJ4{htYAFU_#{kr#~^?c-xD{cRCSBm#s(o(#>GwC}+uPYOssqJ@$URNeM zL$50novH12CVgkp8Cr#l8#0 zz67!u*K^(jqqzw>#6EST`VeBTBh`lxdmX7hM6s81 zkJmp;`iG%^!M65?DRUlnnIo;|Vd!;^^Dt%3!=!&0dcB(dVdzt@rhgcEy_)`E==Ey) zhePqn* zQ_kmJ|0wjo*}wTH^tz_?C}qy0(CeDkqtNS`)}y3<6nb3^eH8jlCL%IgdKCK9HLXXX z-)y7yDD+!gDXy21hu1#_{qI))81&!U?>$Dbf6T>RMyiiNzwnF97-v65ne!O*Ke%6! z{i7dEN%W6Fe<1ygSicVCFnQneznnx*GZf^tuu)By}m){Ns9eb zM&BX&+j^gZUe8ufA@=%Aou?>so}$co3VMB}&Qlcor;Og8t)4P^|4f~yjQ-MR>O5ui z{+T*Y8GVOnoSmUPW%T};Ix?0|IQ`S4e;WGxYz&^J*gp;Z{pK@iwNFE@cZoku`ll)O zPb2o7&G)3$K8@J7uPgW6Jzq}m5`P-8@8XUtt@Z&|inm&sb$I5uTD_xpM`$EjrOz9A8;j! zy|!AJ$$9;Aq<;>vztifUBmHv}`{$tlvGejwGH!Sd`r7V$a=n1+pM(A`^O+7fAmC z^!fz27ogWCz`a2F7ogXX!VA#r6X0HeKJ^K3FF>zPfO`RYeFEGIl=m`^H!DWg`y%vx zTuJnG?7#X&(!U6OUGtg5{zd5bypjdcdXe-mlKw^LTbS=j>|ccb=_YT}y#Oyl-_jjd zGN+X*#rqstaq#+=NdFQtr?vgwOO*F7xxAPE-It)(5%NpW>s^B{k^Uv<^{JCDL7)0= z*_WWd%pF(s`kdaE5PQAPTGmFq{$17qi>t7-LE6`tQWAF;;UxEHA^Oy$-$hIj=*nea`F9>n_0S6#Lhq*FNWU=u`Wg*P+)w=XL0{&v_ks zJ=e-=qu0Md`Zo~!FRk|t(!T+HSM!;~{tf8$dVx1c{|4#bfc`7fM9pAr6`ZuB1@%@|7>-hdn(!UA4j_==uUdQ)u zLZ3Rme-nBg-@l32>-hdn${bn2O^XIu?^{Nn77cc#c;>uC`nM=^-lEKT%jnIDksX=5 zW%TCFwzlVb%jlCOiTztfpB8QTfUm`V%jnah`tBRD8g*Z`>s^r^r`zt?*;1K57d1SsQWNb_feqk<3Qaffx1rvb)N<5J`dD= z5vcnzP}en3*DX-@RiN(cK;1Wix^Dw@-v#Qv57e34YA*Rd`Y}-VQ=snWK;18ax?clz zzXj@k57hk;sQX`_?$4Au8DmQRC87~FH{V6uAL&Z*w*M}*{dcMDze{cZU26O9Qrmx* z+Wx!2w*M}*{dcMDze{ajT1p}sWxek~KiZW<|AFoQ-Xr~c(Cc%&-h*DB3!(i*)zlYh<(D9;%98>eZ2ky(tiNG?gD&3`VXMj zf6E8Z`;uJgq@$$|NdE!!x(o0D^r^c5A3(3W03SfFy8s_h?4_Ud`VXNWV>9Q&ue z&WDsaA41>Nd?sg&524q&{f89$524q&{fE%&TJDF?r_Sv^gkGPF@*(v4WRwp{FFm@~ ze?ny}yI!6QfU$7MtIcvEC;}pB7#B z*cQ4j_Y=}^r`Q7{T%uX z?)wt^X|5FS?`1TXh$dM57tl|1C5gSRhJHb@{{s51<~OC!`2u?FF~6YLe*wMrm|sAz zJ?0nCr}mg%K(9UK7t~{ZL9v%{r`LZ;`Y#cCeKN|I6#Fls*C(TV3B5iUP~#J;Q1`!`B- zC4E<;_s@0d3Vlo4YP%Z!rEiqzYV`h%5?!HhZChX`hS=*$bT`s>qu6(YURR>KA@->&(cKVxU5V}ny{<%eL*{6YDYK45G}-FE zf_{oCN#5(;-B%R*uPF9kL9csvUy=SR=(WfE3i>y*CNt+N=sT{QZ8FC{jp-}s-!gwk zdW5f_f7_MfnIrR~v}mgJehvLJSCY&zn?m@NuSx$k>Ayzi=zZ2-lm2U?_dAbY8+}^T z+x({F{ntjH7TtM8Ke}7?Yokw#`ncoD?6|Kh$?RBHCS)e(_1}>G8|1y}zajlMr2mHW z-$1YH=-(K(ti`we?$6jOzhL5<@UPVZ%pQRz05fiF81G&{#)d|j_%|sx5%8-@%^{RoOU+a-y(B#eE%)wz08ii{yWlt2mO8a zSH6S3yer9@aql-J>2tn=UUz-Jqu75(`tP9cY`!O%^Bwf5yT0E+-^CqC&Q`kX`yKSU zhavNLum7I(-$S3Uebx7*{~ocw#e63E@1fVXRDMsf|DN>UL$7bC{2uz$w^V))y}qUL zd&FMfQu#f_URE5u{s-u%+gAGn^sQ_Rejxo1(6_d+{{ecvgXag*{{X$7Ykz>gqxn}$ z?0cE^>> z(QA}`q1ekBULu-py}v>~$CX4s%Kpl)r2iHA(dIMBoL`|oP$l_n@LwtRze2Agg3TAHQuWtJl`iXW_`71JKk}JjYURE0u(Om2OjWXvq>T`Z0{cq4~pYt2^ z+UNX6`rjz_zd^5k&Tr7C_Bp>nuYJyM)aU$0v6pqxL^RLpe}{g)D@p8i|LAwp{|>!r zrilIT(Cf_bchdh(vHu-!`m|_?`AuoH|1F%bQqh<(w&%TufU6S2R?#_3PQ{$5wo9#i&@{xbU1{iDAFb=?DXJpy$-19iOu zb-e?1eFAlT19klZb^QZ%0|Ipe19gJ}b%O(SLjrX}19ig!b;AR7BLa0J19hVUb)y4y zV*+(!19krd>i!MXjSJL`57bQv)J+W3O-iYgk&Wb^Z#{oe>-mdX&tKGf{-W0N7qy-UlJ%0sT&tKGf{zB{d)Q(jDLeEvzwk2sPUjH}g|Azhr_cx{I(th`E*Y8RU z{)XOv79XkpP5Qr~*FB8Cp-81Da`X10PvpsYV==EBm9;EL< z`X12hwL(2e-vfHRR;UN`daY0o=u@v1>H)o8E7Svey;i6P>7}3a`ktik3B9g{_N2V; z34K>H0+ZPHgkD!ed(v5>C-gc)>j}Niae6|Zx*FOOdR-0e3BB$g^@Lt$$I_#FeJ|4Y zg8nsorARN*_k#X)^O@*-L4RH23fmB7xZtK@5wo@7xcYXjiWWKUeLekjw|Er zw_GVcQk8R$*Y_rUZ|DE5%2ueWBN0u`l#GQtb=9_Bnl_*O6*p=yi_M7y3H3&*=+& zYM;{=dhK)iBKA5`?MrztBacM1%6j`jzuJ}J`hKMENBVxG???K6r0+-ienEXd()S~M zKhnz>DG{x)-u}?9b)~qzKk56EzCY>vlfFOc`;)$ZP~V^Q{Yl@S^fH=DMC+_~0QBo! zN%T6-9zc0N0D7IF4S-%}Xagwk2atXM^g2Tu0DbBVZ2&sUdEkf^}%`v zLch_K;`)K4A4vLvq#sE7futWu`hh|HK++E+{Xo(Wf_{_r4uXEOE5-GLNI!`5gGfJ! z^n*x0i1dSk`az^0MEXIbm$7^z+G4$fq2KCC@w^{Qc|Vx)elX?zV9NW!q#sOqKRB58 zgDLL^Q{E3Iz05ii(KhQH0{wPZitC4vehBG@kbVg1hmd{<>4yaMLr6b_^g~E5^P@zx z!+M88ztffCnKP6!XDDUPP|BR4lsQ95Ka?_OXfShzQsxY$%o$30naL%hUDi7c`rWQ1 z`f+xAKa65O%*9^D_rsvqGubfG4V8%KA*@45LpWu!wxj+lZ_z#2&b3WkD%C(pxBQf{RrrPup@;L$;`=g z(dhkZ=m_Y4bjOw0|Kv)#t|G^kdA!$;gnp0BoRQG$9r`0F??*zfcj%9VUhmK!NwFUZ zz0OWXLchtzekAm%Po)_Ny*`y@B=TOLN;8u3URE5^qrKKUief(s`n`6?aun%DLBG#@ zCYdt|`p26kpP4y|Vn530{WVIXj6OYTohzC5qm14>Ww`xJx<+Y~(Wggk%-@mtjxzf6 zXrB|xik!|)WNoB_(~l+(RYZRwX=-TCiebrSy{zNMEmW(Yz*`VTq)jTj-l9(fnLWsW1!b@&KQdQ z7|Q!G$Q&K#j7jEwTYg*L7-Wu)bH*TZbeuDWGDp^%6462H9Si*-SBmS$l71}d$C7?5 z>Bo|OEa}Gv^D~l^%1CE5-YJS#9+CaikxIR;%aQaikwd`f;QmNBVK39|ygjYsW!f zFy&l34thP;jzjGATsw|pFYBU-=(vscc<4{KQap3UQ|64P%o$IaGoJM0Nk5)4XM8Yo z##82ur_32odRf6uL?^9x0`#X`DXyPD`U#|;K>7)!pFsKvq@NJfPaypS(oZ10tTlIt zPFwFp=+C&4=(WF}NSQOyWsdas6QS4sej@278olrDCmOx)?yfrU*|Z*iW$R>W zJ(ErA@mID^Hm#>)q*u01Hm&Egg2M_9gbxrqiPf);ksYi>?&ElVK|9r;>iE(fd0Yrc&&uBK8$+45k{rzms9A(O-He z!&Jmx?_`*2^!`qUsffMq-AV70aQbPapN4){@BNwveR->x2EE?T_iGwrpL*}tG{j!-{hEf@>%Cvo5PO~DNI&WI(@8%a`pC{pr&H{wQ|zZhuj}a3 zNk5(R)1l8`&l=OAfBbEJ=ihYbGrHr-STB<+#b?LTqkH`f($9dtxSbo#pxDoVzJ&Qq zTI~$z``?qC5zZj}4ARelzNGn{j8tbpf77w{=9&rrM4%bamvYAyeQ8&U>*d_z^)sQ5 zOr5lenb5y(|J5@o_A{Z^XX?y^UZ1Hmlk_v8*SY;n==YiY6a7r+Q=h3b6Z-u&M`xPM zNkj)+DL&4Yv!vJ0f1RQ&`$w~&*PX{%(5GHq zISYEdx^foudVS(7>T~3L?)9@tKb!QkNk5zPvq?W2dhIc1lYTboX9xAONk5zPvq>)_ z53ip?`Z>_+wV`t;bLK#=yI*sl*K0%PQ0(WBeh%s91od-BKZo>lNH1d~ub)f$xul;< z`njZ^OZvGK`?;i_OZvG%{an(|CH-8|%V;hUWi)?EJDmr;w%U2nAGPge9_iOMsEBbb> z6z_8ukbVK_7a;a}u3bR-1<>ocb^-Kyu3bR-1*Bg9y`F0qBxB#IpIOU&xST!#ZUOXq zu3ca<$KPkYfHFtM@`)&mjrKz5v$_&uZ~xC0l73+__U1E*{X*!A-kiK%U?J%jl73+_ zbIkXozh4M_&Fxj_3crQP%yGw+*q?Bvc#n9_W zVKMZnBZbA#>qucS^g2>lOqnAyIj>(r`X$icW!wG|(l3Et*K(IYuWPwWNWX;iOQ6@a z+$GSb?pZH^Ue|J$K(A}LODOg-=S+{XnLi~1mKuF}q46_OQF~7Sn4uI@_wn& z`|7P9snK6LzF%te{!ZnkM(@Y>OO4*otz>qb7G<~k{}B5et|T+V z>NfWOk^Vo@|7Y~(*)8{1&muAS4|*Lb{Acw3-mm|RJ}s(Yep6cQf6!0O-iNL#{tx<^ z?znRAS59Y&-}@!=_zq6LjP%QpIl88`jP%P$zYLk9Yg)@lzs%_Un$|L-_iI|qjQ-L! ztz|~<*R+%Qp<6MMgJx`JA*tm1h6O46@{UhlhG zNwHrE{ryHEv0n+j-gmc>^eaif68g?ozY_Y?`|egk-^KhLX+~z z{VM2Ru-{unv0vq4FGpAfz4k||px38@tRnp?==F-)RnVtiQM(Fyy`pv%^m;|@DvG_V zjHN}n%%7rIZS-kTZdZ!mExVfZtDRnAzuM^2BE4I7HR)GVt6gpM{%+aTMt|wuva5~W z-z~e^=>6TYtBu~@Zz^keUcZL)YY_WpHuh^szlQW{5c?yQlOyCcM(>}5wTAR-pf?1x z+BMMcnSPpfeb+#r*T!%S^!Z#Vu9wwDuU||0wWME5`n9BAOZv5>UrYM6(C4@MwL$$_ z=nGiyTIdV9Qd}?VqF%p_^y^5!j`ZtDzmD|lkU4s`T1WbI6#I2S{W|CiS?@ZE{W@e$ zZJQ6Wg6s9`Nxz=->q)Nk>pBk4Diek1fnt$t%rzmfDCNx#wQW&dcC`JL4Lqs@W3ErGhNfx2yh zy6u6w9f7)?fx2CRy4``gJ%PHtfx3Nxy8VH=1A)4Ofx1J1y2F9GBZ0c3fx2UXy5oVm z6M?#ufx1(Hy3>KWGl9CZfx2^ny7Pg$3xT?eDRpv=mi#mCMKgaUOBqb5xGTxrUPr2% zsP$|@>(PV2R5zK{ z<43BSOzZK_N0*k8h)P)RX4Cc)ZoIJ>ZC}?_Hj{oc^t!IH8G2n;*$lmomNt`qGxWNy zvN@?wSy$N%y{@ZlHhRCVvKe|^(~>rAp1p4MTc9uHN)r2LY)`uddL7Sgp|i#o==I6^ zTS&i!^jo0sY*ss@-`xWJnI-p`RUv*cFj2i2Vbu6py|1K3>0-^ji^oeLBZh z(r<-cpU$xrdVM;_R?=@J{Z{DPnuv&gEA**P=hzB;I~%pF&?j6eu9tq&>$gE)+Qxnx z^mXjNdK+cVHt6e`&*Yr94SIc6@ix+LgI;$5wn4AYD&7Wt>a&WsL9fp$-Uhust9Tpb zz4Yi_za9EAR=*wkx9vLQcG7Q${vGp~=(j`Py=$`VZzuhB=yff3JM_8(vmN@>9hmLV z@3+z34!!QcY$v^(d%S)J>32YX$o|R>%A6gP_dB5fylHZry@T{SNWX*hJA(Qhq~AgM z9n@;&Ea~+-Nxu{NFKp)QB>hg(?}YwHl+^De{Z7*FB>m2yekbX7l71)Y<$Uh-yGXwa z`a(8yc9DJ;>32c@@y}Ut*4Rb*U8LVd`dvZ&F4FHJ{VvkW$iwS*lYTe!`lim^q~8s_ zzNvFJ^!ldG-O%eSVK?b_LtoY$Rr;LW(5Jqsb2s$*rq12a>zg`vlU~M1iKv|UQ_i(} zpx6F>5A>^S-tU3Fyer8#d$lP^tK9?r%=-E(@pl{VfnN78_CWuGx#~*vd!R2mdxPok z{gbfvK>wq?GHZ{~cZz;;rTEH(jONU<2dsWC^c7r5&Q^P^cQ3_$FJ;bN=yUGOju`Bv z%-Kt^-%FXZH<&qlDRcHx=Ill6^=bzhcY6Ik((gm;wa45?vEK*1_L%#i*B)~p>GzR- zAL;i6_4`P_kM#RUzn}E`NxvU@9VzUm*zc#O`rAB0}7b~s4- zgV5{M4hNyvs~rxK{vhcOlKx;&e~|PCNq>;^GC%VAL!>_hy`HTOk^T_H{t)zfwmL-m zL!>`M`a?neA<`cr{UOrJOwQ{Mlm0ODdbT=D`op9@485MM4wL>c=?|0sa8Q4k^oL1* znDjE|OhgsUpVHqSfnNLjBhWu#d(0!GKjQSs?`1K+qGSIfq(1_^_V-7if71M>^!G=g z|M;C7Xvh5s^iR3t%G~N{SBm%dGCTJAqoh9yz3x07g}%J~m7~z>&f`(UUUwdklKv>^ zk3z3Ik4K?T-FZ9;z3x07MeKFw@hHV!=J6e(N;dY#ps(yoa<;nGj&qJt?2ozF%enR# z^bH#(M`_2P*O9_8qxbtq$DqH?{HDbIn9+BLe%-qvONZ!nx8r^c`s>|sCH6PCQatvu z;*fCqoYTtBlfA!%sdXgJ~Q(;Vz1B4 zJWjEfwGppBLHZNW>#pw!%A6C>>#pw!=ylik1nEzZ{si=GO#VsiPe5NZ<%vKipf{Jw zp)H<({$5v#&kSW1$Lmj${v_#7lKv#=Pm=y5WzI>`pCtXsp#CK3PeQLxWI0K(m-QyE zKSlae(7$5;)u%{*3i?;gXOj1)pnv+-O~4pN3w0%+r+jr(NDBzZdT@PgCZcCjDvXwZ}XSeQJ++ z8v3WK_cUU!J?3e|Ue|ME4KFRKYV~J~J}s)|O7Y#VGo(M`^b-3sCiZ^!>kR477`^Xv z&KSMl{W@dxm+pR@F?zrIb;juZ?$;Tk_q$)R+L(x{Tkl!KzJ@DFk6F`|;!hzv>+}-) zv&bAhTb(8SS&IEx#9pt}IE&b)UaN5yvDa%g&LZ}Dt;Si3y{wC-N42c*9Q3taNv_qX z<4W--5uI~-iTydFPmeO%Yn0AW-k&pif33zjqfd|On%|VXKWFsmQSYx8(%#)Uqc?9E za>tcxHR`*PT&tn86IsFS;PmH7e;#?S{r!2$ob#kVkJ#(g4(BQM=P7f}8@<2U;k?mb zdbPuOqxV-koHw!eckrAyvG;fI$Xc_H{RPrrF#5D;pIs5TKz+^yqfd+W+qJX{$oqx! zvgeUJx?uEv-}D0MFCg{@%=aYr7ZCdmmuJkH9y`}wKhFiUUz*jQtU5M>@Onry6bz9Vt0na!h1_K(c1>X+1I4Af-`)MXCTWeL<}4b)`|)MXFUL%2`8qV4}S7vqqFx*0gj7Cdw;kY~6v0^2VP47v+ub zA4Pd(|44UWqP*BYO4)&l^2+{^?!ZKO<2x{sxs<}}ciFZiEye3IkUj(HGmt(5=`)Z% z1N1se$UyoGq|Xr4XCQqB=s&eRR|e8&Bz;EGXN11FUCGM`y`GgbLf^uCCg;42(AVvq z9CKx)*k>etM(B^(em5iZFF$s{^j!W45gDOx>5eO7y;iQIJ(pyT^gcfJnMj|B^qEMX ziS(IBpNaIDNS}%HnS%OEq|anx@Aa7|_R>#!eP+^UhF(XinMt1+di|fs481SK^FA}_ zGefT<)y&YRj#M*4|CG(`%+NpWO7YlBkM8wZNS_7zx%RroETqpu`Yfc+LV2Hs^jV<) z!aVm|&Usm&pZM~fG)u?={d{*^iTwgsitFXvi_f0lmJ} zAP4mNR)ZX*&q4Ye(Cb?bawPTp9--LhfL`BfkOO*st3eLR92p~deNN~b+5e@S&>ywA zl9Td2r^|cEoSe|>9XvTH?{h-0yS_Q0*E@J}LZ5mEPfqCd4xXIQpR;GHoTQi0oY&_f zeJ;}HB7H8>=OTSB(&r+5F4E@;>T{7k7xa4nQ7+QUxYO%%lRh`}+G=xC=H!N6TWxOW zwbkaP%*hSC-l?1$`fm1In;ZJn=auG$UY}Q*8+v_SX>RB>?`4GS^?6922l`evbMlZr z5A?0gXOcO2px0++<{^C^(&vF*pP88l`qXD;=7C&H2Hp&#nL zFK4U9wk_r*z05kiJ|FZ=?BC1>{r5KZ`ADCS@;)E*3%|&Wm9cyj`+SJ~5AIiFg#4o^ zi9R3n2hz{bC@mlKKe=y+{%2Q;_n0z2N<>YqH$U{vTuH|FdTnTa%AEYr?=Zh9vCj{^ zUK^U9^!cIJJ&gQ_{Z6aT5B-UZeT?4Uxt1ULUDlf)ne)EwbMjN{WhUqK1xQ~2u}|3l z!2+Z&0KNA21)$gdz5wY9kiG!)+TRy|KJ_g&1)$gdz5rUS_V)!yFLTaB)Z9k9An6N2 z|ALJ{LCTzhE^}m@T@ZR5V-_TRLDCn5Uhf4c2z~0k00p7fdjSeUulE8JB)!az6HyDR zF9dx{SCY(m%jye}zL3*P<`jay|A)!hNg>h~f?iu~A?WpNRS5d3Deu@U1pT}2xRUq! zj?F^Q>nKg;@m^n;^o0@o_wBC~rpze}{RieV(HDk(c!%UVdSTKRCVgS(KQZ5vR$CbQ zxm_2Sy!Y2?6o&pIcU;kb?n?1dnyfgOnTw5f5$IdHlEhxGb|^ynBGBvA4n?5Xs~w7v zz6kU>QYZrbKC3SRed_gLMWEkry+x2Y2V5!M=g8WK*B2#yQ4@RrOp~INIYlXRiWoZM?8vUiuG%0HI{+T94q1R`c6g8RS@4J&#oJ7>dM!OjFm${O} zzKWd>7bAT!(icPQUp7rd+Hf)GbxoldV&Bcit{C(=&2LKP6hrLu{(d!`t%@P`Ro!tV zbE>&gJod8Ql!z|3-r~^fGt`PB?{nK8vpDIClfF3gZ$FaM7pK@4hhF>p;?O^C&$Y#& z@86KGQ7R7oqwct(f6SHQdRZCs`Vyos0e!-LuLR|N3Fx)IF9E&w_a#VQg7hVz*Z#f) z^r`)Q3Fx)IFG2l%3F&ub89Q5OCPhF1mZH|5{`uBZo?1_Nw4QS|Z_88bDNn7ZJhh(k)OyNO z>nV@cbKbU|@@PFdpIS=e?DA+m7u<1WW#XbMY3mWav=pzeK>7;M>kO>|=_`=F0_iJ| zz5?khK(8~j3ecy{&?-Rxiyh}wK+mN!vu9MW^g27PNasB1eZ0OB^jFz)UM1-JTW=+beI*xr znW0sJzUG6;k!mH~7E=ttNcn99%}S@~V@*y3d+T$62_P~O*o{(jRIrO&AWy*^u{2I*^%z6SK2&G$rK1Nziw zi`0O=i*4sMpnt%X;(8e)d3{aN*M$BF+uzqDeNE_}G@psSCiLyUNv@;Uq`a?5`kK)H zVCR=Lq2KcauT0d0{%Lny8L2+wO7Xmx(VW-UB7H5=*CKr_($^w=Ez;K_eJ$vpG8Tz_ zt)RXZ>1!eOs;@<7D;alseQna$CVg$v*Cu^!($^+^ZPM3<{#mQ99n{w*eQna$CcTW1 zy}l0g*V!Jk4)nVFRfqI-px526I?(IxR~^#VfnLwGb)fHNGp7#psk>iwpx526I?(Ix zR~_neWGtWN`un=1uWR&a(e?J7ePUgs_v?vu zjXpinxqV%uPmAVG9z;*Vs%!LV(GBjna(&{Bt|aS;f7&)Ivko8odeGlw|7N{p?A_mt zUtv`*8GEa*huG^I$?H+<>ml~t+^@*~(O0G7xh_YI)`(6-tJ&=>vYIE^tIK>v|D zuJo86yHY&%GUx0NwYB<&M&BW7=SnipF}J2*tk;lQZA0iQn9n5d8$w^wY;MZGr6K7X z8ogf?YH0Kwqe|v`k~s~HzC-l>3)!;9?}2G(^c|zh?zr-7@G7p9$CPx0EVJW;(>Frw z6IR~{vCn2l3XMqL2>R^iGtoDK{-$=xe`h1oH=@jGgxGJg`bLO->bvY4A@-ZCw-GXD ziz~%rFZ1}c=oag3Z1ic7>Khw1@`<%u` zZ=TF&kKWkm)1tf0Z%XVN8@>5n=W}#DdSjzci|%p9m3sm1b*1>d0J7qch;Fs|CW!rQ zt|XarmpyJ1ihUEr{%-S`=$jz+dIwJv#9p7P(FC#A6}cvez1|DZ1hG%O7oZ7Zzs?<3 z@_xN5N$mA%2U#0QMD4A&DfAs&N%Y(8_nMNvDfGH$-4uG=vu;ZIrlfBQz3y2zg+6u9 zx+(O!XWi6fPNzustec|GQN66|%=dp#+`?o2yFnYi9C~J6$=nm^`NwIH<*mrcF#YYM)p-(fP ziM}Ob-~YKAGKjt<^qFig(UM}{60uJ=-;+M4C1PK6OhuYowM6VYx#LQ!z0;NAtyWeW zO}}D4YX$w?t|YBiM+&Vd_N^%Pt)SPDLM!NXq|gfbZno{Wf?h`ot)NfcfoTQ3jucuU zb9AK8iZVymMZLZ?^!HeOYs6l!QEE;4*3j!UO0A*SYm{0;KiFnmYv^@^+#32J<}-i{c@E)3wW-D0<&SlHOD zbjKxD*p=???(URsknRrY?nY9&ZS1aZ&a-o7-sdv@H?!WoKhB=%H&UaQ+$Us)T+o#y z@AVEI*=tTj6|FZ5VqeLXMBmPSE(__iK;OdrO!Qfx|Mk&p&}y?F_BvW+p}fz6*z0JO z1+h;at+F8YI$C9+J|_!hj_iu3M3t>KEA&-dN%VSlmz6RnE9HGw==JO_E9tWuy`QCJ zHF|$`m(}PmKfB9n^#1HFtI?NrZ*R(K^kp&D%K1??qfb6R${wi85va=WT*HiUsP52kKG+bsq%kN(Aak2I^7+ zb!maR4+C|j0(GSWb!7r|Wdn8P0(Iq+>STP9{7bmjlZ{$WHuSsN_Onsj&qi%O8@2sx z)OxZ}+s}r!ukQuOhPHpllS64QHyhf%z84@H+J0f%3umLYFD=FEvy(nM^g2_`PWtT7 z>r6E}^g2_`PWtSm&knuLRI@{$JX6gMz0Op#8@->YW+%P0X|K;g`W(>fOf?7fTsd6N zC4a#j(CfT42kCQ=J_qzVQ_TT=@=P@c^m=__4#Zw(syU$7^`-PaUZ0cnIiXM3zgbR- zeNO20^eZRydis@<^f^hN6M8-U$_ah)=~qtZ_4F$z^m_W0lVUIZq}S(yzN#HHazU@B zU%4puxm@gJ%*zG6o_^&beJ<#AzL5)hJ^jiBee&s7F6j02D;F|nww-O|qS#B1?)AAz zpWEpD6@Ix%pPTf#jox43mz(stjo#0*b3?CJ_~kbG%jem-jo#0*b0hY8g&&f-%&r5lq7kce; z@AzQqgNH@r_7N#lGhg?eF5lu z+TT(DdhOE-KrbcH7l3}~HCJGsU4ZljNMC^T1%mnlq%VNjtG)o~Wj5#a1xa5JdR?Iv zBz-~Xb%jl36;AoeHizdAws1oWrO&qSYq{?>QX|D6eneS-7} zihUv&`vk>4f!J$*pP5ByQMMz(S^hK!E z%K9iJs%LYhDD?GRDZV-`3cdC@MWNR|rzrHgIxb53qDJpm$3>0aua1iv{pG9UqDJpm z$3>0aoU7RD1&SKIe-DhTx+}VIP|)gTb%U8q1RJ@;?V0UKylI+ zCw+0~bzh}8^vU}w#i7@ImEy=8-ODXbdRZNNeG2pq>|Y`Udc9LQh4d-V>z&Fe(CeMb zDWp$)lfyK%ac~)CbUaaNjFErrtgE0b;LfE7@`I`Vyos z0lltHN|3$;=}SPbtCJF>FG2be(Cg}?1oX+PlM>MD>ZAnnezyI$lpwwAjU=LmHdjhQ z-^i7u&(X{&NtsiUGN&YEPD$u>H?$;WPD#p~lEKU=NtsiUGN&ZzWf#Z1MbUawp>N_! zqJPtla;X&iREm8n^h2AakF}{3`&8(w+a50!`nSyQl(9Ay`t7Ihr5SQ6^l!WGl|JVk zSBj6dvft$OX{1j>=BPf6^l79|BYhh5y0%IqeH!W0g8DSlry=%lUYp*g(kS+_Gv@Ul zLa!szhtQX|QTveeACmq<=rdJHU!8mi{T$m%d*mBlZ*R->fw0OOw7d zVt-}v^w^gseQCu0QTJOU_LEFWVqY4uzvt~~6#LSM{bctE=`p9cQatvuFY5JWNM8o} zsrGYaNMFY3rH3yAy=Gh)(w8B98RWg{%LMghNM8ndulh2`dz~rB4sIf9VPjtw`j)OF zeU8o)%0i#f_Pb@F*O@|D=yj%0mh@$z*LhA^=yj%07W(9wLRsi_rcf4oohg(hz3eq7 zqE^;h4*J%v6xWv{eL2#XBYip2mm_^S(w7VB%aOhu>C2H`cEuA>8|y6(eOp%&eO24q z%Twl*hrXKmnXFFALqFk-^!8Go^yQ(~{=Pi)HO%KE@5@7f>nHnYZB-unn(lig?`ye| z_V;prRKe(z&yOkw>M8~5DhKMS1nQ~=>Z%3mst4+71nO!A>S_h*Y6t4-1nTMr>gomR z>Ido?1nL?F>KX;=8VBl{1nQaw>Y4@Wng{Ay1nOD_>RJWrS_kUd1nSxb>e>bB+9%aX zk16@*TTcaQJr&UJYU`;$t)~LDo(j}@Dp2dGK&__&wVn#W)>DC6PX)C7I=1yxptdh9 z#hh;2)?ShH6=~F{NcxJ<>o`#ndS8maQKBO0D?;Die4n)aiqQZ2?q}5YD?;DFnWXJ^ zbR}*35_@UWUSEmym7worKUazLl}KNS^py~Mo$FO1eI?RY3hFD7z7k@u`bvm>COdXX z?_-{BXoZ!b@8U}Fez!8|D^uoFrp&2KnNu11ckH-dnKGwxFmozX=2WK4sZ5z8{iN4d zA$=9f`zoZbLi#GCuR{7N(Ccie3hAo^^;Jk;1$rGds!;5uM>kJ_w9&2#eK%K<*k`s; zt4jK+E^}nes|x+V2lC=dr>c}WRVj0-LjR)qos#!ep+7n*7p-xsLjRKcUdj8HT`8XT zGWK|VHPTl@>{VZl^wmgTjr7$>UybzDpnt{cs|EGdNM8-HSA8|g92q6OzB=^XZS1R4 z=2Rzrb;_LTlsVO**Q;%+L*K*wPMK%xe4~0WbE;G3RHw|TPMIU)x!2bqeGSsrAbkze z*C2fj($^q;4a)l(L46I<*PvEggJLf;kF=<#jZ96WPm6lFQhbG0lk_zyb7~sBU!m0` zeNChHE3}$M?^kFwjsEf#T1}((E3}$M?^kFwjoz=&WR8@GdRuQT#J-O!#pl_zpx0GG zE$DTXPz$lwRYEP&*Fx-dl~4<@*HuC-#6EeIPz$lwRYEPqURMdVDE2a&OGJIGw>I?s zTuJo0Gf|sjUz=iI8+zSWsSUl3R<)sj!uA=pp?}i0+S<^s-g}D1+S<@(a-WbsXQnH~ z*OxNyGyW-qP+y1ibr5^i*P+yo}M>18gThz44HJ<`{Mex&`I)gyg9 z($|Cj74t$NnLE`ZeLd($x!)o^=6X|-(W)Nwoet-r(W)NwW85bsa|StKe6*5PM)`wol+WLsSj#l*%`%HG0 zChH@wZ$SD6h<#=og9fB;K>7xxZ$SD6q;CMdj7xhIkJ-T`i9UCwXtsq zz3yo>Bz;5DH-ujIv>HOMV{Jp|hq>Pw-_vRcee#}GL+Eu+t0DBdE7XwmvgY*qMx<{< z`bMO0MEXXgZv=fY``2wm`bLPo?rAj&>Kl>15$PL|URK9m-Po%V2*%W$>VN>XJAH6B*n>xMB@0&ue`{+%fpJVsYn?kSq=uM&5ee|Z# zC-0*-g}$O)hc`8PzmMJ&dhK&$ZzK_ou=-}uk94K@Slf*B%}C!2dYvgWqs(arz4n;R zpw|^9z3wMAhhFy+o0Gmd z^rPMHjL+|zL!Z2#*c^J@Pi&6N$zsosnv-7kn-b9&`@35}Kh~8b_If>V3+Q!@*#dgK z7oY|7dM`i=(zk$K=a?-Jd!1vpfIfMS*#dfkoTa&&u z^g7nIrp###{T>^G*3j!{)f)Qbv9>kzI@Y#^UdP(jq?dhBuWv*8Hi*6I+mOBu>D!RL z4fHzJwjq5R(zglf+mOBu>D!QAc5uDEE$Q1ruVZan(zkVb8Ee}@uj52pihWzsw1D6k>)VmO9qHSVz8&e?k-i13;(Sf=#fx5AQx^YQ$(&tG2`PS2c zT2BXRJsqg^bfDJLfm%-oYCRpO^>je%(J`+>u=RAH*3*GnPX}uI(o)R0W=FY>&};wM zk@Ou&-;wkkN#Bw59ZBDj^c{oxj->BM`i`#cOYEghdwnO;cYrDdA8IAdYvtGfnH}zT}UrIy4QCleOF|T&X&58zANdwlD;eSI$P>W z`mUt!8q{|seOJ14jr83}-z})`M*41~ z??!qVCB42o>ARD@JL$WVzB}o=Q|!BwzB}o=2ld@a-<|Z`NiXAhBARY9y$AFf!yeH0 zv3pZJpx5G^QR#@1Mrh zgY+`)%K>m z?@h7qP5R!X?;X_lCVg+x_a?o}JH5US>HCnr59#}mz7Og9Q0)7Vz7Og91oeGL--q;l zNG~&FukTCxzR+j3tMb02@9XrE_kE$)HBMjXb&b;(dR^o6g_r0+-ieiVCIb$ES$ z=x5nJr$6*MOY2Yi{-o~@z0T75lfFOnv)%8EpMLd+K6#ebA9|go^@o0r`+WTLOV&q; zXs-R)N6^o6CFwEe+P~6A&}VcddB5pAQN#xUxmNtN6^3S{?GXPO+P~H=bN9& z+1*FbXL{(rtISh#%){Dlw4ayvn=Wvlm$SQtt`yhHO3v#CkbVGSuTNVYK(Qa-VlVkO z0D2we22kt=AojW&Iskfo+Ufx4lb^Oa0I}Dntqwr!^=YdED05`Z>GcCiKM?xH_Fp}a z^aDvhkn{tg*E!}u(hr1QpD!>lJ#*&Bn-cwdzXn3D&lea7y*^)HAhlXq9VepsHdh8g zzrd9wbM$`GL8Ko9z20v+C_V4(TgwJPKgXV741!+o;28wH-fubx`sDjf2SKm*n+}40 zp)<3fc4~G7t`I+SXVCePEwZRno!4&(!(CeLRgP~8p zb8Rs6dgt0;qxW~N4W`VI9f#CtvGoq2%ozgx0vp32q#pwPLi01x4}reilJr(P#OVFg z_l6j~ziV)a(WgcQ>|NqRj6OA5|LY=pp3xAaPmK!N`@)A9eOgq=mEzAclD&}>ryolC zq0s9Sfre7%40U-g`k~P4J&!{v_CrZO)ad;^k3)_A@_QbK8oj^gaj4Pzw|NXTvG;HD zkX@XF(+?y4FzDa4nKO)HKMeZ!Y~~DuUf(r1jP%1ObA};vR-3<>^q9ktIe9Mf8{>u{ zbF#SamCVWNO7R|3_M5zZIO&H&ukW)SPWs`{>-(&SL$B|%9!~n|Fg8q#CYmI_l@6aDbdf69EjXtrtGTP`<-7`r?8@+#C>1d<(&nq2m z^!|CJqmAA_uXME0`yO+&(fj9>jy8J#ywcG|fBExDM;pC=Ug>C~_s=UGZS<+`8OgGP zTQXW|^<#{_WVFnc;?I*ALzy#%GG`3*`rO7blsRLJ-ak)fjM4k&HjXj+%bzDR#_0X? zWX2f1e{SO#qxaWE%3ia1%A56$MdmDbC7CIdwtvB~lsRLe*Xtt3B6IY*$g!j!i_Fnk z+E`?co>`AY<|Ln4k45I_ne|v?j-FYMrOc6C@w8}#^^P<8v}mO($u+6x>?k*m^y8ra z$@CpET8)GLo`UK3-HoHXABWgKW@9kU=+mO}cB~zT*q^*_A3f=I9Adx9DP*j@=oA`z zIY0W?=#$Tn#s}&q1nMRR>Lvy1CI{-K1nQ;+>ZS$irU&X~1nOo6>ShJ%W(Vr#1nTAn z>gEON<_GE)1nL$B>J|m+76c?n3#mlAd7ko^u=VP>eeM-T{X#11w zZ0TdP{iADZn>CJqO2Nly`;*=G%7{J1mEx-eX(?Vmp7i6PZ);oac+!ujes?_dGrFYf z$5YQW9(rBljE7#IQZOF+!UJ`**xffPSz0UYV)xbEWu9ReB#E`-!BVh!I<# zRXmaO6G=bO=>0R)CQ|GtqTkinPlR5dp*9iy?gP&sp?-HF`rUVJu1v(Jq0dm8NMoM# zlZj}J&GbpouXQCE^Yl8cNziAsF_;9sUZ*t)vDfRgCXs#;Vy|P~B=hGDmv!M6}L&Cquv9mEyZXlSw}rdfgS84886OO@>}~g(j1JGW5DDG&w!* zlXitBL$A9+lc8T|qc$0O-A|OU$Lpt%ehTvbJ~Jvy?=*${UOF^wUT`jr7w~&{iCh2EV z>}MkOx-&5ou}|Kan2Ffy&csZUIUh#4Gcl7gN9LVr(JuQhn??Fr7_Gjst$h~hXBmBJ z^sV`s#D131r$)PXTz`v1WR}tU_2n$1_d9a45c^B!a}xVmi2cc|S6-VIwQ~FDvk?35 z-1kcCe{dyPUp{a1NM^{1Xt&kRhCa6|N!}N5|7SdNW+V0m&Cf(X8?k@PK9giN#eO!$ zel}uX$b3%pvl08mnj1~t`<>|7h<#!Ay^{9{SBlRRWG?UZbD%F^^>dIp`u3(d6#F^Q z>)V^=K(B9annU_I(D$?7J_q`KHuiI%PkwvT9O(PoXwN~Pqi=7TLp`RfIug+y>zxbz zURRRX|82i_F7-Kcq1QG%7kXcck5+Rj_H&{C$NWx-{aomi-w-+%`hVT`O5XqHO7T8N z)<<4HkM#2pdp*OLNBViBpGW$66#IFkp9j63Va$U*`5DRcpw}~ud5FE9Va%i0%StX0 z?X%II5B;aEB(c|>iTRW{^P$(BiTTj$&cuAu&nNwS=(pO~&ri>sJJw$vpCQkOew&T< zeDpbH@{Re*eA3IB)9V+IegR^y`URw4K>7uwUqJc=q+bAiPn-7(g8BudUqJc=q?gsP z*Dr*Azm5Gu=yh$ikTPeX%N*%*7D7M6uB{f5ej)Tazh4NwuB{eApS-qO2z>_|?S;r3 zU0W?Ay{zNCei7*xk$w^B7mci)h-I^7mK!1;2Uw&frekb}9qxU<}pBQ~wwAt?YeFFWx?sM^( z!Y4*wGP=+FOfu&aqc_j*Z2!eI@wb+JV)P}W``zbnjw(eDxRSiJOrL}$`%P(1ztrfx za4G4Rl71=amy&*|(VN|3`+ZAI>`O+E*}wc!qfd(-wECq+p9Xz=p0m{G)1rsm=VhLA z$i{c6$$P&OEjwe0=&=3SGGxwtJ6~A_z0MStQRXZ|=IBge88Sy_3d<;SmQmg>L+13e znX?R;lRQ&chRo5K!ZNg4ohd9stJT=c9-h}PC;f7x_fM5y4!zC>mP0Qk=`oiZz26a8 zPWt6W?@s}iL$5m`%MttJ9g*dTz3zxChhBF?mLvAMDwo|xuU`TE5&M@|f!MFGfAbZj zU*YsJCtiWr>%VLT=~qyzT>bsKkD@nf+`uEM}M86XH-tcu+^_Z<|JGx z-ebyMv)8XC{c7m-y}qj{_N$@S_xi4eUf=7xn)ItlzZ&`mw$E7&ee!#KS3_UV_BpGe zukT9n%#mGjuU|v@HPGt}c@4#W4dwkB%KJ5>Uqkve(CZ9&4fM$~NW=IHU;W72kN#2>b3^zwgu|82kLeN>UIX|b_MEo z2kQ0&>h=ce_66!b4b<%q)Ex-a9SqbR3e+7A)Ex=beHN%Y8mK!Ks5>60I}xZm8K^sz zR44tt|?#dUU3`mRiqRw4Rpc zbJFjwMeDgELuJ~LTZ`7y%6+el8m(O^-g8My@%nY7Uk81{_8IF)zYh8$=4YZ`2fe<7 zXC1Zub);Vhy}pBI9rVfX;8_Q~zJq5S+P=PnXB~|i(x$zBJ?Ym&|D4sYr=DxQ>$ya~ z9{SAruEPp;J@opV==G#u5B&?~cS`Knr^o)jt|s=)+=#s%`poWoCH616Qatw3`y`^z z>L*UZx&B=#Gj@Ac%1 zv?I3>`q%9fA~r(*hAYL#Jn7NBeiP|8LI0cmn{6WfCg^{6Ka0QPbrZ#Y6X`cW|A+aU z=r=)M{Ed>-YBxdur~BQKIe)oQJac61@%qiA-%PRJO#00f`^^;l&7|K<`pwWEvwhBH z=#$UxHbZ~h_A;B%YEQUQJoa0lKV~z13-rfbN%DS%{oEGlbuPUHdR--KfnJ|YzlHQ$ zpx1qsEzr-j`Yq5WKbw9F^t0UeO5V?QrFiURJU8z>w%)DKpL8YBYoD`~^jk^46?*M+ zwnDFc&Q^;3R_L|Q*$Vv~Nqx>%=rh|~*^1a}pR?7?mSnV&nMZ1L%6hj^=4>;WlNx2U zzhxWgw~>CE(Wgc^@}=+jZ8Lg*3b4)S{VBjUqfd>pncpdSzs=}VqsQ9MrR#FH8GUM$ z-F>gDj&rz@td8{*K;}qZzn%2kNxz-++eyEj^xF}89c#Cfemm*62ld-Yzum;%>$jWO zd%eu&5-#>TNWTNER@XQ?NWTMmUE}OP=I9z{2j%?^%A6g@99`q=K;|T`adsec3foNI zfy_y`QatZv-kBDiwwbfj=+mMzt`vXr;ZD-;q}cB?djI6ZouuDs^#1H_r_uW-AMQl# z^VB>`XLmb|-aq+pCu0Ap-P78M*z3-O%#ah&S?k?}*q?JHX|32h~XV$xe`rV}8P5Rx?YwTs!k%-RQXzzjkf-A*)%sr&vL;5|?Ymd1HdhIdy zP~Pu>UVF?v&?onpd!Wy3dzn4ZYmd2y^s+umL>H}hFZ7?glITm@_OciHjIJd2AL$9q zUg-4%W-s)5;=Y&kd!g5{b}#hFW9?q(b*$YBy^gheNiQq8MD&IA?t}hISBl4eAH{wj z#eN^fejmktAL;i|?Dqv@zmHQ(Y;( zmn*AdbEUoY?kD|zv|61h?5Ei8r`YeO*zc#<@2A-Br`Ycg#(qD=em}*2KgC|w@hQ7ouKLEYn19Jd+9cvF5y`L!@FnWIv%mJgn{2rJCM(^)|IbifD z(F)s!4;a0F@0aX2B%J;r=?^0I8|>!}lKvp+4?>^g=JXspNcw{m`-6!6M)Nx*a}FZ* z*P3Nb{Ca_di2Ww_y)wVAaJ~NS_zYS0M!fzI=?_7#ea<21wa+;Oz4keWpw~X<5cJyT z93uT8=(W!|1buR!a|n9va}H6TbBHoWc5%G^FzF9NpRh4FO!~vn>z=}4=ygxwFzFAI z{xI~qr*IhhW`5A2=xD&pUJxR2=q(7 zyb^l~M@WB!^hZd4B&a_^`Xi)2LVDR5^ZL)AzhqnOXV8Cb$EVMr*Iw~6%KOitzwz_y zq5q8ZpFyuzGk*sCH|BRr-hT%D(3}Zc*M0{5x9)o-?=QJhJnv->&+Ctp{wVa{+s_>( z{ZY~%g}&Dt4?=&G^hZg5l=Me~`lF;jirB0EDCNEEHhTRr(jSAqt<@hR{V~!XgMNm+ zUf>w%k3p~N+GEh`^#aGBPrhE@81x<7_e$*bdVynic@)Z3-tT_9vn5XY=4B^!@Cq?@8#Fm%NWgtCP@=a^EYNGuoBnv6o$OuRlflQ_w$Y zuL3wl`ctGo1${HqL?n++QS48V{uJ~#+WU`AL4WJ$oTNVmeJ1z4qJPSjR4?a8r;R@O z{OC-e?rfm$T%hiJpzcDT?qZi!PY{S&DBH&FLqQk`VFCZr) z*;r)0aVDrgL;5qO-}U-4rr-5?Y14jikp2tOe-YGw zLHaL9{{>>Nd$}_6NJKwd@0Za3;!2_)Z2#3?Qs#U~ne!#|yL(@a(dtXme+m5%_gf_P zLrqEg`!Autl=i1tCHVU=zJz|5`-H@PxGTkDFLR_s^sDuL1^sWX6xV-6`mad;73ses z{a2*_3b9xHS3&((r2h)BSN&I%_cEJHM88|_*U|4mT;4e7su{(|kd zzoERB8FC`}(?KvhiG3bB)_x0pMw@@%LZ8?COjc;$Lf>dn`tyvwCH=S1YoGHi z^aagslH~oj(BJXoP?Pu7+?6KZLSM-4Mtuu?VONUhz0Bp!T{_l#3HpCrN%R-2_Y&zZ zL4VQwO!Swa*DFmfk^U0tFF~(Ynp}cD`AU;Z(Cd{ZmyF(DX>y5TFRKo(|Bm$EA#?Ql z#P29`zH^x)v!(B#*PV&)NdFz_zk^<{Py7!0l42ty{wPC{(I7Y z552z2{(Fl3_s|!x`-$H}U+%l~cTas!`tM2qJ@iw|-%K*+d+4)l?L!4FnWLL`vd8JFnWLL`-9Q@Q{Nwq z{_^+T{b2O|)b|IY_wT#=!NlHQO)qQCge>nd&ishjU*SrU_pjLs=|H_YcG_CKa)&QN*pmw&dykBI%7?t5jlddrn0_L*#3 zl-04<|3vzqkU6@a_!GtcCyM<~(9f{@i9eD4C+KxQ@h9kYKk+B%llK#Ug1&7T8&n9#HGt_=IdjAYH*>OljS6S~b&|mFJk~!Dezu7O8Iln-Ez4@7B&M(jxD4d>u zzd*06@?Q}9em0W7AoizCNiydb#6J01QokVfXWS0YXnX}u*;5W*g-zal_gI@3b`i)}$8|D3P(CfWlzd@gT@7Hh8>%CvU8NGih$Zr&T z*>5u0VWa&!^w+zR#9q(tey7;~4!y2UeurLHC%;qP{|>#*6n=+ZS0}$ipS(Kx9eQ1z z{Epb`>g0Fmb$%~9V-toIM2FX>Ls|1h!lckui{vHyc&|A*20J9z#e{U1i}@8J2v z=>2oN{xJH>pX2q1(fj9k{bBU}IbMGlz3=a34=)kjX!U<0_BXkb#9rT0`6ucBB>kU= zy}tMBPtyO1*y~k3eHjAE-=zPW^na87@1Xu~(*I5Rzez7UxQXaC>-`7%+g&NH|A+Mdkp3Ui|3mtJNdFJ% z{|V~_^mn^bT>l^G|0Df>r2mif|B?Pb(*GCK|3~`&NdKSH%lT21;qvpND*|;_ z2I{T~)Lk8@yCzU~ZJ_SDK;89$x*Gy@HwNl%3e?>ksJkUlcWa<7L!j=qK;7+ux;p}O zcLwV23e?>lsJkancWSQiv{xbCILL>c7CC>hPKOaEN_`ot)M+{vKxjVMF>=^Rmp_-<&FA-)?L zWeDwtMj7I}p-~2zsp@8v z1oc;t{tD7xL3(M^iRc0Ay%PEdT`8`=lJr-S{z}qcN%|{Eepx0+~Uj@BBqx&kO_xA!^W%Pc9c9qflXLMg>^p`)Q z`zoXN&*;9&=>0RguQGanHNEtc<_Trido^PJKUWgHUUhIa^t$tNHS|)F724I%>s1F= zBlfyNyBe|YXWPrwh`pYhUX9o%Uv+RbVy{;nT#eZ4RR>oi_PRQj9=&Ari1l7$^d+N= zt`whVUqkw9NPmsd`+4>?lsVTJy`N`aWAuKWeT~syKF_|!=>0tV8l(5~>}wEv)yvqE z7Cmac*CO_hxst?Q@BO-#GUr<8_1S^fBKCUk*R`a-7W&6*?5{O?{~WJtp>K7?R=O_t zTIe5l3dx)&Tq(XvkWn(l>8~UGbs0pjI}_JY?60HPUkAPJOk78qa~ah-{MO4PvaFkEM1@2_l?@!adLC;j!%n+;<0@Yhr9uZR9ooA=j4|G;av z*#9$ry}=x;FkMD%a>6xx}%0r~;v|B-R= z2DI9Nt`r}wWR8>)J!!M*M(8uSQap2Rq|CXIGUrChoEu4hBgOtk%A6a6nR6p$&W*^N z{B|$*M#>zS&6&T8_1;AKn<(}-QS5J`*xy94zlroWQS5J`*xwY4{Y@16n<(}-p~uvn z37L1AYq+fbX6T=GrFfrnGwE-JUi+Mzq1Qg=X6W_Q_h!=H4888F+zfs4zRJze>%Pj( z(Ca+sX41j})Qh`o+hvg$B*W!h+Gfc|+`lGy8xTn5UV4AAS2Tn6ZMhMa-) z8AzXjGABbYb23ooWT4E+K$#=!qeS$A_1*@3W><>qZzKI}q`!^yw~_uf(%(k<+k*Pr zNPipYZzH{|^8OCW`#Yf5Ip!VE_p`0; z4(Q)Ezf(r5JD|_>^sQ#J@>e_D0eu$ty)xEjb)|T#mDRD=-%0vAq0eqVcPHuZgg%G) znZ*81=zBevel`7_q`#B&car|jp#DzM--*mo{hbthS;r@$mu}&>uA?^%DELpr2AFFU=J0g8rC2>Aws5e1c@_0A&-OZt0Be{WEK zFX`_k{k^1@{ic%9YgT`s(U*)~ccu8s@IKPtNBaAW-meVrBmI3w?^lNR8NFW_-e>fe zuMF=qdcQKf&*=Ti@IIsWSJcYRSjp%O>%AZPH(e>Nzn}E?lm33v-%tAcNq;}-?+@zl zC;k1Tzn}E7hi6XXt@i0Q%Op&v^iu^XugFdDR1?e}FRQ0m_^Q zf|>IGWzGYXIS)|g$Zlgw^tRPMX!I%3JFX-%1zp!ZNcsmU_76g@>)HoN|De(P{hSAl z-mhyPH2TZewGSG-U)Mfp^!~*CL8JF4?y@hMh~Bl{hY)+s`-c$wpKPD=5a}Nx{X@{- zcxU=(^$_$r);>hBe+aSHs~sLf>@&?RM*aOmi2X0_d!@&0Y{$%p5PMyn$PTX8KTP_E zN&hhEA13|7q<@(750n03(mx#3KTP_EkvXb=m@-H9n$x29Z0!FB{rj#YSNYsx|JDD4 zKBJAu|BOB@GRMN`@Be4?=FaFI>HYoxNdG^h_gDG+&*;-46BdkC|1)~?Jj`|nXg}wF zMxPel=Dt_~%-v5z;?`*gtCiEizg?g4pYh$RnhGg!29o z#9ntq9zotG?}$8t*z1nSBZ$53h&T9t+ex9;kaFQ1@h@E>ocH zsX*P+fx2e`bfQ^~y&tH{5~$0XR41!)$-jhaJsGL>WJK%9Zg-P1QqPrmMWiW6<}pJ?&%E zb3F!qU)ys%2ED$^{xQ-&M*7D{|5#A}80jA){bQt;-pA`7C;j8le{KJQkCXm!=)W;P zlYaMc=xdn^A|)FiC;j83f1LD>2lbDW{&CVjPI~Dlz5WT(KLP!ClcQpKg7i;7Kf(M= z^iM$F%3K(h{(r{z(Vrmw6O{K)1ocml{t41QL3-)Yz5YqkKMB3=$URAU|D?-%@jeN? z?#Mlf*z0cSlcawVdfkzG68hvFxhJ959l0l=*B!YhNiSoM*Jpx0i=A&|g1()dXJ?|= zXM(=Hoo8o)eu8NR@^8sR`b^O4>Npehx;oATee&u!6ZE<|&IJ7>+xjv=uX8;aCB6PB z(mw@#efznmDE3de*h}U-1--8ApCbKJq<@O^PX+Z)k^U*tKSi;Z@!ad5CjHaU>)QTl z(mxHouI-GtkfI zlAbxwkp3Cy^_u8spx0HxGtehr6a5VI9qixy8R+$z=w~SQGDq_IXG#Ao>7OP2v!s8P z^v{z1S<*iXeS0I5(dyZt{#nvL3w=lXZ+VttFS9wXe~$FeK|jNO?m5ywNBZZW*XK4q zNBZYT{~YxC+{WjiPkwIWbI{Ln-z$5$vt21ZQ;>P5*FR7C=b_iH^DUl-UY~FAyotSkLd5eFdzm47{R^ajf%Gqs{sq#%K>8P; z*VXY0q0dN@e@*m@q<@k0FB-kyk$aIc=S8FU zJ8~~VuWvPY(daMVk$chT{f^v=XtnxQgBMNg{Wa0DKJxmPpwDW@+LsV}y-wyO(!WId zmk@isPUah)lX(f5qkFlslJokPq0eUZ zFGD}re(%eqf0^_zL$CLnzD%)y8Tujax5V!^eHr@X`%Pblewh1&>0crJD~SCAx_Od$m`d3N+D(PP({i~#ZmGrNY{#DYyO8QrW`d3N+Dl$j)uaaKY@rfwA&6U@n z&*4h(bJN$L&uIUiuR*V;zOO;Ar@pU|{x#@zUHcmJdcDAF&?jFn@EY`by})bG>-7S! zQRc{wLn6v)y{|)`%aug0*9*K(v40(Uy0gJwkcolxn6E>he7(Ty z&=1jXr2I=3R%y|R)q1U9}^Y{ko-+*3cX>UMp zrgPB00sZ#AyUg9P{=L3$K;PAUujG9%SBm%dvWw&OZ<78^=yjg+Ch6ZK{hQG1Jm*c) zze)Nxq1SoNo6slEbKZnr=Q(eh*!y|To0Rvm-{kdgk^U{C_oLNYq<@R_ZyCKGt==O2 zTSo6ktGA%n(dsRuzkIZM%jo@R^%gQmN2|At-k%@I&X~F5)8@+CMxPqpY@d<%HuRJ2 z-|TJDzfJnLp)dYQdXM=w>EAYbe}?h4(WgdJZ05Xe^r=y)Y}3t7w11-i+eV)nO?BUU zvnfq;C3#EbI9rlEJaZ?w)xU$-=XE7%wY%N_8GlRVJEVUHnWOWZcc9l<+B=jv?;!Sj z%5*B8t%?wh35mUE?epCkLCrdPDy_elR9TI~S4 z8}%M#&U+O5_n^2BW552xy_I>E}-LmhK{(aKF552xy_I>D+-!1z-^!jeu_mMgJ zZrS%Kb7ZgC>$8wP3-mf#Wue$-fnGl`yH^g2t+njZV4 zSz1=;b(WSDdY$KFg;uI+Of zy}6!Z$yapEL@uLGi}KjDeJ-O$&J`wa^D-DEy>v9^?6922m1Q< zb9pHCc_?%8K(8k-c}Sm!^m$01C#cUu`aGo1gUr!AEg2=fJ}>F>Lf_l|&GM2yFX{6_ z|6`PXrBhzg=Ouk!(&r88^O8O<>GP6a#&fUFNBVrw-)Uz(`ADCS^!cFgHvC%bY2_n* zKGNqSeZHVRAL;XvJ|F32=8=es+q};Yy{>WcL!aHw&-0T$Kk4&BKX&ic*UA`@pY-{m z*ELRl=(E^WLVoCXx4MbeIQgN^>b_UjIN4k&zB3_nB(E<(`U24Bu%9aceMZ{~3P7LJ z{7m-I3qaqhRQl?;0O<>mz5wY91oZ_-UjVUJeF5q*Wj5#a1xa5JdcA9~An6N2uXpei zgkJC9DG0reRs~645c-#IO7C+DLZAG`xPs8@8{-NZ{fCjhF|HtGj?6ntMkzLP3K@OL zNXObjM(_7k3Q^`1qRc5|^nPEZ5XHWb(fj_skkR|=atj&#<@+jyjNb376f$~$U2Y+x z_oo0dLpD!pviib^eF;~J&(aE$zA)(vBlbE=D@^*rh`p|H3M2M9ODl}nC(qIfBlbE= zD~!z1Sz2L=z0BnkQAz7fK%eSLaeadH3DPG>pCEmL^a;`@g8BsM6Qoa2-pi^Z5v5sg z5$Hd3rMSKb>5GuQ2grL4Co^rc-Xt}jaZqNFcM z`l6&SO8TOtFB;SrC4EuS7bU%{#(V`eLLn2EERZi$Sk_PBG|p zhFlDKogo*4KKZKRV$kahxft|~?1*2C^s?sk`r@Q7jvlj-=sTOANq=7) z`UNTJds@XQ_Qj#see~kc>ppsM=#%%+i$kyb=*6M$<`nT+nyik!K85rtq)#Dz3h7fw zpF;W+(x;F*-es(#zgRBC2G)C84kEN}|_0HcOJeB=ouyT@rfTi7rX{ zlB6$5`jSC?Nz#`jeM!>GE>0q{CgfO0iF+*r$>{mGr5kPYvo*NuNsk zRMN|Sli91Agu5!JBX523H= zO7Yl#Ncs;c_8(I0KP3H!r2mlg9|rXwlKw-|e@J@S!!u`=)>{ht+O8ye9j!`1uh$`! zf?i6}-u6O9dL6AwL9e4#Dd>|&t5VSGXjKY&-OnjSdf9DEM0KpUH1u^{ zN%VThW@*xwhFGN%k>P8rh64sIf9V7+CbZ|F*K zeOc0%C4E`amnD5!(w8ND*`U5G>C2M7Ea_#h**qiHddorI*p)=Dqg6T5mxEqMt8&om zXjP8%&eF<5ud}rBq%RM> z&eF<5ud}rB&?nE*%0sWSwDQpF)ehyMm)$5iKdNB#$>&EE19g=Gb(I5kRRVQY19jB` zb=3oPH3D@t19i0mb+rR^bpmyD19kNRb@c;v4FYuy19go8b&UgcO#*dI19i;;b}F|PtzkB)g2 z(0cS*p$gP`Dp2dGK&_`ju=P}+)>DC6PX*U{L@zBR5jC@|y(09@T`Au7D^lC9NNv9& zwf%~uuSoieq^}s%S0sH!(pRLOOWL&8SAxEU)mK97``EQnCDK=dzOS8cRDxdbKdMCf zO3?RnzeTRD>~BhP3Q!69TdV(Wu9@)HX;p&$Blii}ksIJj@!e4AeZ0Oh=_^C8&*-j9 z`pVGjGrB87ug~bN486{lDwDo4Vt?A|D?^|BjPA2=Ysu+D*^qJY4m)KV^`n0HAnN4(lRK@7iqN8^I zzKYSOMaNtzew~)|=w4ry^i@e;mGo6fUzPM#DfU%KUzPM#gZiqZuL}JOc0atT$$Nj5 znT$O?bE-kF{Yo`tj;=4Ok-i%Ay1uLiy{<2-QS7TBb98lF4Vj~><7&v9JfH7NEn^YHqbq_2tCYoAk-^fjT^ zKBp%1+UL|HeNEEWBz?`Gz9#8wlD;PNdh#f9q%;@%TBNTj5`nsgA8`Re&eO=PmCB4k$y}lml>p?%m>g$od9_i~ruUB-}BYi#S zb%jr8S_~H-LVR`JJL~0DbZ`(G8&2YoZ&N%<*sYXh5-- zm0Tj~V58j-`i`z7vDeILNcx7PZ%CQbkTRzs=^Ik!Gz?}=L&}_n(9gCpY)E=pbDG@; z>um&mXIB!v?o2d-KBN6DjiA?^iAK=t&O{^9HzIu_=yhkJQF`Vi-G|W#dfl05gjU=ik~xio`o^ShO!~$Y zds)XPqAoVtO`z}UN)r3;?Z3JS>6?(g3H16d`zEAs0=% z{UxV}$6j_EyuK;vn6L48xwHzj>jioNWO zczrX{H-r8M`>$?B`exAUJ?_n**L&QXk-iz}n~}a*P~VL7%}C#j^s2YK0h&XvrvS}KFZ)ei--7flpl@qq z--7flNZ$f_y+gkR#l8jfI@Y#;Uhi>lk*gg$wu&=Pu`DYP`P_xFCaq}a^3H%9@g6$`kt;7 zA8T8azBR?ZHO0O)>049mTT|>?2V>uwV&9r#-urnJ z_jM(Sz3zy#g+8NgJ#C@a9g(((z3zy#C4F1OUUx*=BKEo?(iX8#-Vtew*z1l+TV#&z zh_t2H%U*LL>Sw*}pzrTWaeX_|wE(9qHSVz8&dhS3D7YWWDX7 zAK*%HeS6ZkCw+U;wD!aOz0=G2Q3s<>K0oRhsOuD{>l~=-5~%AM zsOuJ}>mI1<5vc1KsOuG|>m8`;6R7JOsOuM~>mR85C{Q;bP&Y78Hz-gyI8ZkvP&YJC zH!M&$JWw|xP&YDAH!4=w;fl&QZyX({8xyD-8>kx>tCM#k$*z#(Um_Z4+e-(u9_@EK zV8qrnP6ui|9ngAojne_GN7pzVsP%L}>(Ti}2eckt<8(mlNj`n;fYzgHoDOI`y2k0? zT94?Zr6i(3R^Ji&!LD>=R4V$;_OuIA*+X>}rfC(?H!eW#$l z6X`pVz7t}vyP?wicztKmcZR;c{a1IU*mtJbcTUe7`;6|+r0-1n&ZO@g)ORL*XVP~j zz4Vh_--YyDpx3!x7t(iuUgvsUpx3!x7t(hjeHYSq3F^C$z6pd{t zNZ*b0-ALapsP9JlZlv!pxF0-URTFGpx4!L57PI5URTFGpif>M_kdnk$338L za%K9dMGw-;%){$@lD;SOy1wj5`ktik3B9f_ds6IsLa(D$Pv~`h*%SKY^<_`!b$!{> z=>7V#C-k}_Cv&7kG{lZiy`UfJN-|T`v9=fV8EyaB3wj-EdqJ;bZ7wA;FH|cwmzBlQ6lfF0Udk6KsN#C3F zy-6?gPOtAn`aZ}U-3{$SnbU_drw{acolGCn_aS{B=yf-=Pf*{7^nFO*hx9T-PDCSY zwEIFo(v{+CoW2zMzR>IXvM=IXvM=5(+_&>bNWHAv$THDYoF5(`s6;RAN1Pi^n?Cy z+voHny{tOSwYOH^ANnz_6pwv>ihX~IeSeC5e~Nv7ihX~Ieg9zW`%~=uQ|$YbUe-sc z(OB#K$mq@Uc3esHFW7(eN2LD<`po8Ma=pMu(0|qZ8qAPCGJ5kSNxOsnkh0r4-D!Dl71lcx)VK+^s+kk`az^0MEXIbA4K{=q#s23L8Ko<`awbcAkq(l zUS|q}NH6PnuOCeM!A9@zHyup+!K5E-^nO2aF!Xwd{$S+2&J+ei|Bh)BlJ|p+{__3A z!A9@*69+@D&+!_Jyw{n6>^LN%2{zM*KtIuy;(g8#=yj$r1bXf7hamRa-wz@E5X4^l z`ytS4e?J7VPwwxBAokkd4}o6$`ymv2*&9hjldN|r^pjmFt{+PJp`;&5`k|yBO8TLs z9~#sTCH+v+4<)_q;v}Le);kRPsjd|7bB0mo45Q2$MtMJs@_rcQ{V>Y=VZpo~MtMIB zdTq7CNH6QE{C;f2J4=4R_(hn#7aMBMC>W7nlIP}_Thm&4*#=L$6=|@nj z9YOjLq#t4QzSWMP%o$2pRR_Q}`gjYRCvxKGI0 zoq=H-A4##7-Nr;T-FinsKf{&ct#%aYM?tTB&M4@$&lyFr9|gVkIisl6j)Fe9&lv^1 z_Bo@d)s7;)?29I%nbtcR`dO|N*N-OsXwr`+{bm39A99N3#$B=#u>Bo?M4C%*^ehlfy1odM`KZf*UNH2TMiD<6%j)i`nD~Vq3KN?H= zvC!-NM`NMa`;W$wek|$7l74JZKbG`kNk5kKvMZj5=3DPL=oh$BJoe*AKaOHQj$%KK z^y5fBj`ZV#`f;QmNBVJ2FXu-e8-4Qm(fB~!gh1WIK;5K3-Q+;sltA6oK;5)J-Sj}+ zj6mJYK;5iB-RwZ!oIu^&K;67R-TXk^fbR?)q%P-Np*4pBl(wz7TWgmF7(zFKhb=6#EIJpFsKvq@NJfPaypS(oZ10^gdock@OQO_7h1z(di`y z6Djr+Nk5VF6G=ZYsGmssiKL%Mdg&+AqEBqJCqci|mE``TZMURn>?G1pa(apVB%@D@ za^x+4rTkkak$#fV`*;3LGWxV=yZN1x_mhl1EgJgPPP+eSlF_F{%bY^?RhGMw%v5!K zDLs0^=_iwZGGedSt4xMIqn$rahF<4-lM#EJ>rE#8WW-+QdXo`*U0+T{?33qulM#EJ z>rJLHZ!*PR#-2p9!v4#qK)=$J;v@DH(oZ4%6w*&2{S?wqA^nt~ehTTQkbVm3Wt2=r ztE_h_^s8M-^g3IbO8TkL>uhN%^g3IbO8Tj!pGx|vLH$(HPbK|S(#v?B7Ok<~X-1zG zt#ze%-cO^vpGJ88DZNPoun_7R>u;$oq9pA$h;vmEw6XGmk{H!TxMIV!zRq z;+Zp@Vn3ZSXF6rhbka|!*iWa}PY=d^I>mlE#eO=)Ugk)NXp{BMfPS+p#q~2tKZEo$ zNI!%0Ge|#!^fQ9`8Kj><`Wd8`*<2#pV!bn=-|9;7yq`(>nUwc4Deq^JekSQ>l741T zKa=z`Nk5bHGVe@8+pKpM^xIu2uAfEvS)`vu`dOr(MfzE!pB2>4BK<7V&mz6dkQ31k z>zxh#PFIR&&TP`prp%d5nKPU8vq?Xj^s|Hd*`%LM`q`wHxqKqpWxaEt-|b3q{T$NI zA^jZE&msLB($69NoS=RV>F1Ds4(Vmpk%;zK?_B8jx>8&}m-KT*texKI!L^em?2vlYTzw=LhxkNk57uwUqJc=LHz>KFChH_(#z^N5goSPh0q^yrMP|}=@*iIA?X*Aej(`>l73-O zzmW6`NxzWvvW`zgpIPrB=#RQmT)&9)i%7qS^ovNpi1dp{zbL3*MEXUfUqpJ@aY#hR ztamZ=$6YC|UrhSNq+d+>#iUX(py3F()RUUqR3(JAZw1bW>Y_ylXK@>i#?3_pS1|Lkh>Io%QY z1o}*s(sx8YfnMK-@d@-5+;5Q`5h=;a@Du2}%@{{JBA-BC(S1U$QL5xh@oQ3LzsZ~_ zSp8Dy&$v=N_Dd=DODXnCDfUY#_Dd=DODXnCgRx&qv0qBDUrMo;ov}o8)_Rvgf6kRe z-`K8Xmr?AOL9c&_WzhSQyp>o_eV37b8T3ue@08dtgFgAazRRF*>b_TYqx8ML%b?F> ze3dH`ju}JJ!1obOO zzXEy#!|B%wioNWMrn$^nN&1yW@1G~LlJqN~?`ssYpR*EreYV3&%KMc@@1O0k(&+uO z9ab9s<nix`%d<6wu&Gw0(I*H zbsGY88v}Kl0(F}Mbz1^;TLX350(IL1bvpueI|FsQ0(H9sb$bGJdjoa*0(GAT>h=ff z4g~5B2I>w4>JA6$js)sH3)CGA)Ex`d9S_u<2-KYn)SXJIlRa?$O^Q5JuM4wyzI_SS}C7Ew5wVzu@`gNpV2Yt6v>EqHm=yk+iXY~Gk zi|dR&C0b_n>x@1ndgG_P*Q7+P9*ImeC8Fz$J|$Z2zV~KRDs1O^>rC5EiFCdpZ92{A z*OPv|iG5nM$6lkkp7iTUzuxH6qG!KLzczF|^<3-Gb3JCqp7lnb7VR~^Q)0i~=*_z- zYo4W^Ydw0deeQc@%=^@p;$xolJ_)DaK>7{H96iI>0DVTQ*Z{qrVQfI`^$cSJ={Hd3 zY(VC`Z+?sDHz0HFNqXPn24qfI_f3*HhIxZzTOj(r={9*+}}0 zq~93SZzTOjj2b;`9&MyCPkMB(-$eRN(BEhOW}8UA3HtlZ&t$f=3Hli(T#~n&DE6C3 zzX|#W%;zNbo1ic7b8*vZ8@asS1pR~VdnNV{xl%m#GWH~*FKs*B4Eg4k=H zvxW3qoL*wT1$ymswvc`c^g7qu0{v_o`z_Ef=-!vsms_BpW23zV`kD5M?k%L3@!adT zl71`nyKQ^fO8Tv&-wM4x&uA;<{Z`U%g?^81wOiBkzUNgYbNn+iw?ePaGumqO{&_}Q zDeq47QPe8|k+}zxuwOS4bXhqu6hQzMqZ3Ht74=*l&Y=dCB{X zzMjkbZP1T$-z#}P+La{lHFIQ+KM(<||GD9{`T(bIIi2V<) zB(ZF-?IMX}#SvEPN*Z!s3hoLz{0tqku|-tR)}w_5Km#D1GA z#ru1i%X|H9=zp~O-H5$D`EWPscawfM^!nt(-K5_Qz21Mc8+yG!`+nkvg+{qJ*3|Qz1}6h2l|Zmx9ovl?-Jhwz1}6hhxB_$zlZdDg8DtA-$VL6 zq?h%P*Y73$Ug%rdzu8`j{a)zxKI^^E>wVUHNxzr$dr7}HsNYNay`_x=3=6Z@3t{;Sf*+5;x`Den3(*>N!U)>-dC z(jP?Zb!~MJ`iwRP2cg%s)j{ZWZFLZOUDqB&>~*X?h}geoR;d#EgNS|dy9N&;_WG{D zgGTS)HF%IRNA^a%{t)R8k^T_r50U;5=?_ut50U;5^m=vMA?TB@ZaW0MUfp&Gd4Ix2 z?GWi@7bg+@Vq}JdfgE@41MyB$YJPp zN8~W{FWP?lF!Vadl>MgE=vS*hV)UueZ>}VHzrcR(2*v&g^b5_;WS(;b`f^LI!aVSZ z(WkomO^;CCA2IsWsDR00$($obpBkyqfd*b z*}VVE=+mMZqqowI$Y(~M7X9fIqW{a4;yWU;hnM2?M@fGanWHPiqm(&EDRYh@_BzKr zN_l^jVt>@=eV=pG=r8YcjvBr1bB>zWmvw#4QIk1kU7sVnjR~heM*3sWU$B3rV-)*i z&|fq^lh_}F{@>#1z1lI-AEUfKhP?mWd`>dw81nwtE2q-B_89X13-`U!=XA1bt7Ft^ zWna|mkCXm5^abp1IZm-Z4t+tZKMwt4H>K;3lm0mAk3(O`>W@R8SaT!IkdH%O*nO{z zRtZ;%k5;mS>-8r{e*${l&pAP{KLNe&=bV6E_j68={sieyK(G5bC!kN>&p83T?&q99 zpQHOZC#cVny=JdJN&1t}>lL*pNq-W0y`uIc^m;|@Nz$Jr{YmJxzds3ma({mkdhPE| zLa+V(Ny;4A75Dm6(En}Q_o;Nf?J-Z0{uJ~&zdr@N&hJl={uK1OIynWsu1-!tpS(Ib z1--6LPCK;5^2x=Vq&?*et-2kL$Z)cqK!`zcWObD-{*K;5r_y59nIzX$662-N)a>SRAh^3S)P)6{xSqxI)?N3hccTZF6IZdtS zG_{`7!Paw{TF+@}J*Qpk5xuk&uRlZjGtlq0t?mrz&p@vy-)ErL-Ow}8>pc4m^t#45 z1N|QJJ7vr}1AX$--OoU;yP;={-tUH`95p(m*1^@*697++Gi1aJ^4Os^!}O&>3ve7e{4^C4*GvxDZWBGNBVQ5 zKZn@sZ0Q`u{+!YK71}wY_p_yQMt}Ki>73E~+0r?qPl+1X`Nlb;_d9aZPbQrHJn7FP zb2{74orgZ7&7B3l#ec6#EO%XEG1^N&lQ&r={1( zU4VXw{a0UrexcQ0NY~%o+{~8z`OyXF7rF11+0qsEuEPtI_cHc){YB`nu=pa8|k+} z|Bo9jZ6p0Quh(4J2EAPc*hczol=s^Z`^06=He}9YmoB5s*@n!?=Q3v-VxQla(#P34 z@(B9vq~A{Z?WEsM`t79O4t)XldD}_9o%GwI`t79OPWtW0dz;(q7%7z$aJjOB@_q;O zXSmq!ApH)~?;!mSiv14g?QFFJ`ZMKkYM-+M`bw7_kUl3|yW0W%S^jgi)t>E3>9N<* zTy|2>>351gJ1OK#+TYuguy#UkJ?2j6?MYZWp|>Yt?G$}@64p-9hbLj}6n%IS)=tsq zeG=AA(T68t?UdN(BvXsz_GdfMYHejg$DOI9u=DOh?2Gu4>Q}nHZWqOV7sY-T#eNrJ zZ#!FeQReJI?Ct8;F2p|b>envB-mZS_Lgv^t>s^#NIzk@j^}9tsE-C8tyCrkNNMSeW zcYD2_t#*q(j1+d0em7!onX_B;;py(XMW1)1uv_$Dq_A7`;py(X5qrB^R>$%=UcX25 zIY}|6-y{04H*^nW&K~G(Z|EMx-u8y>A^jfFhrOYDkU93Q!9CDtzH4v~^k2J7--FEg z#+TB^IXdgeNs2q~Udo)ki2W|tckCtoUeRYKyX9vZ`@M+$`|lJjrTyn#(T5eey`m4} zoW0QRk>Ar+yBGTJdgU)HZ%*^qtoK5{*MF|&{XSnRrGMLHv(AsQlM+t7DlD?#w zBZGFF|No%O`GYd&59r6VwSSquqx%oi{~`M9B650qCpxlIm@Id4Ti>yk4{B0Q5Gm zIzajZlr;xLALdmDM4xwFbwKoCUUfiXAFg~Ikl2SSU%D=m^7@0MKPW9$GRO5(2dTv# zgx=;=2cfrl)j`r9q}U%s>}_6k5V6mkR~W}oQceC>WB51p z)qP1b$Mk=b{%_L%P5Qq{|2OIXCjH-0{okbjoAiHE=IHvJjFFu8i0E^Y8orc1#yLWH ze*}6P;~atB#yCeve?;_QjB`Zv;r^E+qR)H(%MsCs`(KWTKHUFuMD*dwd%DsXVt*8| zKiTPzB6Ie;j5|uPKk8$zea=zn?Fqw2p|>;DQN-TX(2pYavhaYsKZ@9AK4JJMVt>GY zuJ)MroY5r5CIO&g*{y6E6lm0mAkCXm*RDYcG$Dy|;P97({t}~~Snl4vPKwrz3();@pl=ml~ zxBmVF^w!^>pu9f;y`5`MKyUs1iClfgI@$^7t-n7Z`q1B>Aib`LXD79t_aEr%_>zu} zdlk#=kNzS3Kcdf0ddtr=@Ba~fcCuiy{YxDkTi*X8`Y^WtNA%fAANf7)@Ba~fc2alw z12j7RNA%fAU;nu}I_~F7Haga8M~VD5^V(6qNS*%E%zsxPQdcliS13|fI8s+6Qdcxm zS1eLjJW^L8QdcrkS1M9hI#O3AQdc%oS1wXlK2ld9QdcojcT%LTQlzeOq^?S&u4<&N zTBNReq^?G!?&L^a%}8CXj5<9>YyO4Sla$RTd2g*JDXVSY_NpXh)8{uyS-n%+_NpXh z3rWfLsw8F8XU0j{^wyJ+2(fIX;f3BYMcKA~ISWnw@(B~(8e&`pvxki49eSYW{$GMNB&aF!1hyLJsx6<{C{LqheO}gx+>@7bJZ_uh-ZYgx+>@7bJZ_(ibFs z!Kl6<=?jv+pyYjcud(*%L0^dUg`l@NP9f44@_KFig(&ugNMDHbg`l@NP9f+s=QxF+ zw>eHB=xvTui1d2y3HrjMFARNW*Io*fzA*G%OWUoZ8u*^kG-BHgT4sqi$MRR>n(~vU)z_o$9zgksxJclo(8$C zwg~BqkiH1?FF1V>=r>KTL%W=cK>wo4^db`bRPvH9rR(*49`r>?Ule-lbBdC_C}MAY zPEqKs&nZg!qNFbh{bIMSQWW|f3;U72DD+EQUsn|RrM{G|*O5oi7bAT!(ibCrG13J#ZI?+2=(%wnwW3^m|-;D?xf4cLse)(w7u{xcX9(^d+I!W6@Sy zQuN{KOG(m~6n)sIQ4)IFr%_V$d9S{d6n(h*QWARGr%_V$VV{PMkb}My^z~fqOCk2Z zyQ}o2D050dzfFFo`cjDfiJG}RW+~E_LhLVgu`30=-E&t8v48uV!O~++@#CCQi2Zi| zxftj8lD1k~71FVM(3d8CY3O&l-z!bAFHNy84gGi0479&5P5RQLFHQQ=QGIFBmqzS& zctyHiXC0}ezKeDl=xu~t2Kqy;uPQ^aF9ZEy|FiTlW*O3#f!@ZLWuX7t^*LprAJcIh zU2QJ|{Sp7SHTFk+DP6Dgqg2ws>B~aj(3f<4ZzJTg6#KG1_8RT7h`qJwvZOCd`m)g5 z2)QiunIq(~xv_U=*Rr{>_oejyUT1Qtq>=NMgTApZss2WH)a6KD4*HwqXPWorpg-d7 z#Vtqra?sl~jB?Pw=FYX{pkFe8@AEAO{p;@RS`PX*d?`KlI_JzunmBKH=$rbIt|!)U z*SX7!KF7~M%8Nd?r26ur&q;bdJutt16Xl_|m5K7A4?F40i#{i5CZC|=obsZV=PJMS z0qvwOFM7FJ?-e??YT--ieU8qKQ(j+z^c9fzb`_uk<$VRj-d2SwAojK@RDoh&fikB8 zVsEQL6%hN(s{j=cds`K%Ah8dtLKUdL*Li%8hGGd?EV^&7&ZB3yv^tPr@nPRW&O+jCU z^i_~KHn*xm`YO=d+^P!nHn*xmd0&O}RdO@O^_W$l&zxITf!^j;RnTf>*%asTDx}wy zu~gE=MY}5WZGA~&|C0L#tCGGd#l9-VzAEXflD;bRFU#N5R$CSNuDzb66_KjYzv4ev z^Zr#|N^iBgh8OhJpl|2&)e!q`uJu%dzP2yv%&@zZw7;(g{lW3M@u^0cQw@3>rB#D| zoYPl>err}|8l_c(KHGV#A@(`Glzz6-)y8Ze`|6_4PTD(tb?9v+usZ3hBlfluSRHy> z39L@BuP*v9Lar|Qoa9`0-&b|fXD8)HJVNW})kUA3Jn6jEMW2&AE5WPi?fG0j~Ab zM(erW-RoSNT2F0iJ+-Oz)Q+~E+SGb#Q|qbiTaW6sr38H)($|50pwrhOeI4irIei`I zS3Hq>r*<9E*CBl!($|UV>yW+<>FbbQ+jP*^C4F7!?HWd1>UZl>zgri2yM|Gh^mR#J z7kYalO|dV3;GUFhwJG|PtjkD{K zz8>l8L2o;q>Or5m)2SZx_5`we(A!R@dZgEWQsy!4ELUIj*@>O=>O*g%rTUaP^`W=X zQhn%cv{Ya8VMlR&(TDLyebI+|{OgN8?>+wYMIY|*uP^#=-L$^w!)Qr+^q_A*`Ua$L zK>7xxZ$SD6q;Ej_2GCz2>uWmBZV=TsAbkVUH-O%*`s%qSm2`EnZ-~t4=1V$Svir;% zQsy*--tIGR2)*5B-jFh*1 z=^J~!j+PojZ{zI7(A%0;W6GSyq7UQj#-h(V&TcIFFwSl)`tY>R#-a~*4C=@umGp4> zCZulyy6QGHX=Hzj>j((7n0=$nzg8T2;J zZbq?h2EC25n?Y~m>}I5IM*3!?Zx+=zBYiW{HzU1{JA=MC>6=4uj=3m^p;0$p|?9_+mgO5^mdg-RIjDnN!hSH*HIL zogHT-eO>I^QQo(M-ZG~h>Dzg|#=ae8PCMvrq|lBsryXTZyJ+ULqs(cC%z4hW+IGks zo1N%9KIQf8N#7oNyZ@*?>Dzm~#=bqpzCC45dy0K~#Qs{>=d?%cGw(lYkJ#J&N9_^& zYn;A4VsCm~amY#fx!8ArzP~T&mB$a<70V8!@8If4br zrz6F_BVupY?m8m&nb+<*BKCIet|MY^*X}w}-s>t((03wzC+L^DKBp7uJ5lUALH}6u zZa73UPpcZPm|%bd>8PjJ82 zne?4W-x>O=r+-#JTR~^&?a6zcp|@Q=ouQxT^qrx9d&XALukt%hIzvCnf3BWuC;L*m zURTC~z6u z>2H0ZqT=s7;2x>4SIXFKsVBNBYijMySUhQgMLYeO*BgD27Oo8 z*L8!wn=hqjj;@Q!JsK`ox|6=U=(CfFZY8ig#lE|by=HoM=+gG#z9%xrt{?S8=2(B<6Pc6Q-}gl3 zSbyIWnPdHZPwMY=RXjTx?DV~$AL2`zId{2UrWfgZ`OMMS_Y!?}Vt42FqP*`V`Y=N7 zh0M8I{-$P5FJw;U-TA$cId*q`FVTm)^LvRt_wIbXe$-p^nb(i{MC$rR>iR|M`bX*p zMCt}c>IOyX21n|KMCyh{>V`$?hDYi~MCwwJx{;B(QIWdQk-9OFx~xdu*ht+ek-Bk_ zy6i|@PNZ&pq;5i_ZepZvQlxHjq;5*2ZfZuI_L!P~Dc^c}Q|sxCwr}I?-qd<}`__~D zSJG$4y{Yx|rncW3ZT~7a-sp|CpE=I%jka&&?A~bmHqP!%=R9pGS;+WUw;D;efX z>9gZLr0?VP+V=aP=d#&xAJX@sw%gUWKP&+){pf4NZ$|r?uyS#Vw~NN^!-F1_N(+0eR!Tu zKhfvi(cMquU<7hvbm86`vKVm=9m(nw*Kk56EzCUG7f717-%;`^= z(?6Oy{V8+$i#|N3xWDMbbBeV`m*?m@?*P&dK&!Q#P6ME~arOY{ZKu-!=xwLd0MZXY z=GYl~05YeCJLe5R<_!FepHn;lnbXsqYX^vaeA3I8bgXByV?Fl-{Xo(WB>h0r44}H!c(T6@q&*xdm80Q@feU>k!>j#s5FzE-AelYYlQXNeC z!K5D?)ek29VCa{*@$z8kE%rL{kX^6NI|P|?iZ7|&t~?GQ{SfHw%Ht5|?aJd2iv1AE zoFT{@yYe^$nUi_taR@TUt~?GAeR#t45Xu}KBV{GyoOdYn*}jw>`=O*CO0geGu^&pY zA4;(wO0gdrjr~xH{ZPc-o_aWxVy~mQoFvD2he1EymvoNvvzr?YgWmd_VbJe)bDUw& zR~nZ4PU&H!A13;+rZr6TIms_>hBi#}ImvfbKBC?9!$hBxOz;YwHWQqJ5ydi zob0H(-lw8@pQ5}^A@A)y zBq`**UG>#jN6PC*l71xgb_dT$(vS3d9U+f|-e%P!Nk5V@XCyMm_M?wP=49?iABoJd z{pcf+Ikq2tB>EiF>-;F_N0ELM^tMN76zNBKy^fGaL2rAMMv;CL=|@3tdz3~&pSeeA z6!f-7X%zIfM`;xF*5B()E-RVrGJUk@vyv&kl-^^GCjDsAkEYBSP5RN4Iio3aMn^Me zG-b|c%AC=ZIXdS|B~zVu3}QdcmsH=BV)7X!J{_Y+5FhU+f`Y{yy zF^GL@`8^%qk3sA=y}C#GobasDF^GK||G9d$YU@ksD{?wJP9@WwHw*e1zNC74qd^ww zv!J&(8e~ClZ#2k)-bM;pq|btWrhJ0xv!MU!f}m0I}Z8< zzNC8FFEEbu|wK0B(E90SGBoD$o@>WLZ$~zsVn3erv!gDE1RXA6B9#h(4@FO%Q$F)u;)g z535lVL?7O-IYIPcZ=S9;ro4V4=_ev{o^zQqk@OS2USmIzVn2~$KapZT5wU+>{-*Z# z6La(aqM0;8o`~4L;6GRU`xkvF{cNS{qN!x5i}obSoJr7IpEC*i+U~DRg5LU^NzhxL zGl}$*NIwaB>vJaM>NEBzO@iL~oJrJbCsF3;3T`S{=Jba1MJF%xbPodaP5q)^N z^Ayo%C-!vbDWVV8?xs-QPZ51ivd7J>riflAC)&A;oWh&{XBKE(@&$QJ}MeJ>l(o~B5REqsn#NPHOO-1Z8_b5$8 z>}`+IRMCe$N>dSg?J@QG(KOL#UO$>1shbh0n;EH_6{(vYshbn2n;WT{7pa>csap`K zTNtTZ6scPrsaq1MTN;RV=e%jub4~L-m$sg1Xgzk$n}*h7)oat!$Z~D*GbKYCNlzz_B zHXZacNI!%0Ge|#!^fO35gJM5}^fO35BdVW4`WZNDn0^MGHMI9hC97So%!Gc8FKOo3 zId3Lq&P<;!Ljy`gOjP z9{bs(pH2GNq@PXt*`%LMv7a4{{cMW;Y>NGCioKqDQptMfodf*_UsAn28D$RT{T%4+ z$tZK6w~sGDq~`$tZJ3uV=}uWTW%W6@6B+$(Pc5 z%()c%xjy#V=gfuPdd#_`pDX$>OPDMA&|}UOecm2(uINLLIal=I`q5m`hwDdrK2If^ zop&B$zr~l*V?U2#KaXNRk77TM^z$h8^C6b+HOGv+j^h-#uvyQCf9OqpM{kguRdRrA*3cZbGmO^hUa!aAN z{(dR+HbP!1`q1Am6@BRMmx?}bf4@}pp}$`$`mDsR`YsiH7$NKYDCPCbNWTnuZ|B-& z6#He++qrfb^meXYMzLQ;v0sMR+qrfbVxM`gU541(xpo<1Z|`_qMtQF@xm0qVi}rHp z&-bPD%vnzQ<&-(gDRY*SemUuvQ|2s>X3lcToaK}`%PDho&Y6{5;JhnDpOswbOX-=j zf-+|XWzGu9oE4NgD=2eTQ0A>Plf&#ckS*}=+B`$ZEpGNxANPimiZRDNt z8vE0rKfggM(w_!>2j@KvdEe2O()GGFl9gQHysMD+SNc+V-mjwAucFwmqP$;4`c;(o zt0?bRMe}|Y<^3w;z1_LCit=7pak7%DoOdA3pYEvFQr@qH-u5W1h2HikttI_h(ytYLPI7~Mg692N(Pt;; zfBzueMY2}(*-1lb8~V1mwW7~KZ?IP6;SLgAzspW;bk=nwUx)K-PRZPrsC6V?2l;sU znU0RvK|XM#{mb;XsH`LTI+155AIa~jd>!PQ#y(2&b&!ATKUd|S_)@xFR~l2vO-{dF z^r_@#U(&3xYe(xTYu5X$(RtN+=xzM79&xv~#jO{8cn`#S(Wer-cC=pf^3H{fYe(xv zpOT}?jm3J2d$@MAUSc1f=C5m_LBE0Y8xVUN9dDr6Z-CxL#~Yxx(eVb-Zy@~!=xubo z0s73*@doH^bi6_IVRXEK^tyT*^czXP5qevR+DNhANU`5YvENAgjilcQz0GMiLZ3OO z-3Yy1Gu?>T+njbI^fsr}b>^((7MClVpug3Z()*iDq~GNAn)jQax6$z?YO$Lr?>C7) zjE*;nKJVywljy_fc$4VEHPcO^52IsU5l?yjX3}p)>}`+CX3Ct+(AyrF&AFLVrx5yu z%@q616#LDHy^V1;BlekNoXv>6jd3<3_BO`Z>@!EN9c>YP=Cz~KBXwINb!SBC&WzNZ z6{$NrQg=?I?%YV-d6ByFBXt)<>Mo4bT@r0&v4-DQ!w%OiDHMCz`L)Lj*+ zyE;;LO{DJHNZoajy6Yo#H$>`gjMUu}sk=E+cS}Z{_V=29S;=j#wQoV|x!sr2+x`}6 z`&+2(Z=troh1&iWYWrKL?Qe;;{Vmk?x1jAWb7O`r)b_Qdq`dxg(w|Ok|8#2mr&HTM zo!b8C)b>xOwtqU>zOBZcj<%n<8h1L{zOBZcj<#>Bai{yXud&xQ9rRmCzZH60joV84 zt9o_^jk@B)4XRb<|0llqCoFV#f1>g+QYd@Kj+~G3)Ows2gclwg}@^kEX3Z<*k_UcEYXMctg}QP z&e&&(KJOX(EYXKE_E~7PHbXdzTCJXYvng}VM&=xl-_zKijm+s=vo6hy&qn4P^q;GlbI6y{N2+?34El3Oe-83~ zq8sm?L;7=|pCmui(b754+nUNbl=tV5{v7CSym1cnnd6OfptteHIcT*u-Z+QyUeD)Q z$-i8*&xQU$UrNuMb18GqrOY{(GUr^1{kfDm=ThdJ8_k?^DRa(6=Gc1Hxs*9N@<@68 zd89uNvA1>H^GJUl>CYqmc@+EeDE8+e_8SW4X3lwt{kSjQq}|--A@&>P-)NtH9%8@A zm(nvw$4IH@Os}j*#Uol+Jq*^pE?J>MiycQS2|G*k44kzlih~k^Ulz{YBB(UqrFL zh+=;c>2)lhN}h1ui=ltgmsD>(=EW5Ii=nq3^J3_&$Gn*I7nA;C=&i@R82Zc}^J3_& z$GjMN>oG5e-p;i;>&Qx;a^6cQ_Loqfa|y-%5+8f*?=OMg&b607Z`Y145q&tuFNNOj!MGH9y9eV^ ziv6V&`%4jfy9eV^#6I&Lj7t%Fy9eV^#NO_~xRf$SXL70JX{Wyo`hWY9W{!<9FC+bB z(AyaEGU#oLc^T<1BmHI2+ZgjQ=rhNdmqBl1%*#X{#+a8;=IESLzDei39QtQ{N%eNN zx|}lSa>|^`DRVBT%({YA1c%M z{%YvE_|Mf=+truSM`^l>6ZF@R{u;!-r5oK{L;7n-e+~4PR~wX1^XMArt-rs9^w&V& zO8%yf6t02(>l^x${u=08`_I*N^ftbfuGjUZpud*%*OLBP(qBvZYe|1C>8~aIwa~Y9 z`fH>5Ye|1CGRO4SQr_#zSkPYw{fjPhu7iHI`_8W;{dLgKk)LVaUkCl|9dk$I*HPwN z2mMR_Z|XISdGdQ2`|F@D{q#pPzP}Fo`Tlb?_B~zZTt|7YYj{C_J@nRhTo3*A?mN4l z^w(4DuZOhZ`vNH$Y#(&5mz?ez+SU-vE8)a~*Dg z-k$4l12V^+D1QU#bzL;u>u(f&wttu4jS~Ct?7ACCf1{7Rw$mG-x9{vm(TDqAZWMiZ zcHNDl56`Z2D_e&7{9Ms=t}^HzRXQe=}u{u8OCU z*Icx3p}fBZdK;zPLYZ@m&m4{YEzsNe{uavnTS$Kk^tPsO3-p<53b#OSYYMkOZ)*y- zc)eafx>fX<*N<+C)ZHGbyCYI}XQb|~NZs9$x_csZ_eSdOi`3m8se2$&_peCZgOR$2 zB6SZ(>K=*IJsPQdEK>J)r0$7G-II~Jry_MvN9z6^se2|;_iUu@xk%mfk-8TmbuXe$ z*SY0C`O4rvx0f>ho%WcTf1&l)9oLQ+uvk(Rwo9hvkCGEKyx{|h(pudguw?V(u|H}gM zFYU~58|iO@-tN@Cjr6yX{x;Iz7S-QI`rFX-wyqEPJcV~ zySGFCz5GmjuG^t6Et9$2znQ*Y<#y=p*>$%=|AYLV#{PEbXRKdAXN}vT|IvT0#=eZZ zl5#urwyvVRPbzuSdGCP!Enm`e-d6Wl?jZdg(4QecQ~e#evCqmq=iNcEzXSSB{;%j* z?@TGF{toEhzUVy~>)iqUS^hUvf4(oJpYybz4Ej5vf7|KrMC@&Ld?)Gegx+SycS3Ko z<2y-zC&m6w#D1JaQuTL2pZT84JE6DtT;3^}Gd{_2vA>ftM|bppP z7xWj&&ouUTLI2|T+|0R)^mmc|F6b|j-&6fv(3hTjm|}ky^q2b2RsChYlpcFM_XPdj zq`w>b?(S;w-OyXBy&L*aN`GGF-O$?%?QYWF4Sf&!o2tJX`i6~5(>VKX=zIFl)y(PT zOX+$&O9uTtq`wFHKJNGKA^knj_m!V%?C(MB&u>;8t@a+$-$VL)NPkaMe-G*JL7!v# zdnj}Ce4d@W<1+nT(Pt;``jWQV$6UtUOPO;o^pDHWRDUn@_Rg<+MIXl5_liEOhTbds z@XoJ$MW6SbU-ybWyz}c`(T8__-7ESq&eoAfcJiL{-Ut2rzNC74KKFg3zYltQKKFgl z+w-~a6TQ4u%pLW8qR&ZMxo_}3(dU*lbMAxwr!(%S9e(#g-`f9%>WBG~>YKY(pkt(Q z$p_ARzv#y$ANrEcak@Cg{ggTP`@GlK-!J;`PU-uRIkv;^e(0^oykGR;X`lCtKJU{$ z?-zY|+UNZe`|z~S`w@HV?{zenNN*eori9RP;cXDp4{TJ!~CHgSG{1-CkbNM~h{|m9-^X!|nU*KPe z{ij}`ne&-1Y3A5CM@Pu1iE4aLWi1ZJ6y~h3_ z=+C~kFnY{~NdFM@HpYAidK+Ut1byZh^C9SMjQJ4sHcESl^g8PZ`iG(a+UXxg-rM^a z9)`ZQ%fE-AxA!qT486UN;bGE0484ug9){kYF#Is|Z)d!Z;bG|QeGCsnZ|`Gx7Q0yOp-rmRX2wj zN1?Y-+M^WvN1?Y-+N03hDD6?`ZKUuh<^7}37c7$7Y9EFE^)eU9I43-D@=@pu$-mJy z^{D8_Cxv|}eWajs&Y*vc^pBDLG15Oq`o~EB80jA){bSG#|Qlr zq<@0+Pmulz(mz4^CrJMU>7St3KM~bGLHZ|1{{+QeR~&-=Nzy+F{jaWW zbrok^@~!J-o)-PMIWl&ra^}pR41XJAEmAgsdxLSziAP>7PO7 z*jny06#Hi=_Rk=5Y%TX0(mzA`XG9zhvrObJj^8Q)m{a-Hj&m!-e{@Q@%wa+5& z54dPQi@ZPROX+7TU2RMy-#Ptr(0}hsI!d!QDLhB9e~x1R9Q5`kh382B9P~EMc@BCT z=R5~}=9?6rgWlex@Er8^CWYtFYHft9>!R`mGv|FC`X78r$M^QOxaUd#Jn5eoeRx~k z^Q3=X^kF~n^P&%Li+dhxbi_4)$zmHqFfx7rsF`zrD??eAYe-Z$L5tx#67&R;)z0kN;@ ze_#9iYQB^{x6-xd5c?NN|03yMB>jt|f06Vrie7p(_jxZ$?8hZ_U3+;Ev9Ip*FN$7f zN}`vUnb*IF*w^sCud)Bp<-?1Jy=9KBiif;^iS#c)Z&$xwLgrYjeF>RkSHE6D-rKdi zmk@g!W4=VK_9euAtsINS{w3sn=C!+*5PQ3J_Y(5nu716Qyw~x)UO#$S^qJR>UWwGb z8maqFr0&0wy4NCguSe?Mh}69qse3C@_jaW2ok-ogk-GOHb?-;&K8VzP7^(XxQulGB z?vqH}r;)nPB6Xif>b{87eHp3yDpL1#r0$zY-M5jt|3&J)i`0FeQK$1C&A+VVC)cuG zM(g?6m-MV*XY7}$-+h_--IvjN?2P>~T91uXUzXMr#v3n7>j`Jg}xYU+C?u@n7ietnpvy?X2-%(*Kt-=f8-(oi+Z8*k_(K{)^b# zS>wNS*7z?n$Mo8xXC*tG_ciEu`BHl9U!&N+MzMd5V*eWHU!&N+MzMb_8vEBM_OBuK zcK^|96nj1Qq>|mv`#R}gN2|5_k6x$PzYe|KfAl)^cK^}qq<@`a|2krC_aD8E*k|5< z^g3d1_aD8E*#F?(6!|*EUeA(pJ=^KufPSwpY3yxo{|4#bfc`h>kF?dk0lm%b-+H9sd3N%L^S%lFK3~%L<^b3y+O>EA)@P5%z*-y!`wq<@F>?~wi-=&vZ0tA8h|e~0w%kp3O$Z*j5L zac7o~{kx=p7kV4#yi0liF6I5Z(AzlYUCNwyN&l|s!#L+%(dS*6cvtjcob#^evl6=( z;9b#&l?fdo%aaXVuDnP3_n^0DEWAgte-C9@Ao}d&kT0e8 zm>*E)d_bA=f#^ez`2p!apv?IId4IRle}KHte7Eig$oqSo{sW19=rKPKedsZDeiZZ{ zlKw+#wI5RKKZM@;oDUIu>vKL7edu#OB>jibTc7hG^qGCmhtOM}^C7j`4@DpL3+PNP zJ2~v4{Sowk`;umk?HBln^dCWQ`vpFN-u4T8B>J#l;3Lt8{Q@6}KI|9x2>Q(Z0v|!& z+Knndg5LHEd_;PkbEc9b&igU){-`gh-gb0W9V&1_s5huA5-3cjJzN2 zGUsFDeddntkCFEyT;_Z%`tYW{kCFG*YISxT^q-La6J(A(7yJ{7{U^}dbHP7>-kuBo z3F$u}{U^}dbHP7>KJ&TYpFnTV1^)zkd$RT?&|9n3d3?}+O8QSp|0(G|CH<$Q{}g(g zoqS6APf7o2RR1aIKPCOAq}LUPRC3Ja%4eki4EknnhV~g{&S%iuHH^=oZ#lRKMjxL+ zZ~J6EBmHO4w{SDV&!8_~Y5KNo#=a>AF= z$2p%<>_3Oz`kc?9w?5}{(T6_gbJ2%2h0jGF_9%TW`n-FTJ{Nu1qx3mi?Ql2h`J7s< zuHvMUf1LLV#6FQa9l?Ep*l%^M=L^z*0sR^BGd){<0sUicU*s2*_g^6PHY@)EvA2DZ zUm*6G`y#(U?9cL_tFgCzkzY`&)%B*J|C01yLVuq7D_>IPd`X$}CG=Mp%Do5XOVWQy z`Y)kBNB*XsYrl-@za;&a$a~X&NqSuwOC|YSw7-I07D*BNub{X4O~0bpe+9kWZ~7JV zcE9OYr2mTY{wwJ1e$%g@&%EFCE9mWh)2~Dy?l=94^ty%@^k0+yYtnyB`magZ>cbA@=`6>(PV$w@obM3(DU)8K>qp-q_FubP`A+mX$v3{FvA1!Ku8OCU z!Yap9^xsq7e~;L=cJtcr5&O(HRDO@x+Z!ss zN9^qlmEZe5N3S3KAkxh1M?XgDeu~un9I5*yQuk}5?zc$Y?~%G~k-F`Xx*d_aosqg- zk-FWHx;>G)y^*>?c_DAaeiqsv5)E$h}9g5T)j@11fsXG#>I~u7w7O6WP zsXGy=`zNDLdl}8Y?4+ptZ*EDSdRokv(#Lu~Q0w^tt;fcCKcMy4SnmgEJz=c(gS4J7 z*84$PPZ;a{Agw3wSnmgEJz=c(1KPfg^?pFV+uZd>+EP+p|0CMI>3^g%_K&3h5qcYM z{0O~`H-4nH|0A{iAJO)0yzwL2e&%@NN3?w#Z~Q3wFy8plw|$Maw(0DoxQq5rqR&oB z_)>c8e}^%(XT&~pRp@8L-d2TvM!##TLO&z+Hd@ktGL@8e z-d~_E<4dZy(b6xZ{{?y*E&T$$jh22P{V$~d1^Q9$oc9a#nWLp&ptsS|FVNd)=@-fz z?a@<7S?B!~`f|RM9{XQO|0~7*SBm|wr2m!lzf$afjmG|0iv6z?`(G*cdhU^D9Xs!D z&{yy!)!QuLH`4zGy|vokptn~08|i-|{cq4)tNji7%vSpw^ww&B6Mbm4zmZ3>I`)5-Ntze8`k_DXB+9ak$xLx&bDagY@^KCMwzpX^g8m$N-DZs*)IC5 z34`eykm5S=<~i~ zbcg7}J4SbiKD=Xehv?;RyKL6coV>H!d3Pdnj=EXRPGpX)hVG=;??mivHFPIpZ>ym@ zDfT-lb9N$gY&CQzGADC2bSE;$Rzr6pb5h=$KF85oHk?06US@A}Wx+3|b6l&;qiaw@6nV!s>uYQCg- zZ+*^g((m?qouTc9-uj%~6#Lzz-wnO>IlH0H>~nTQZ+*^g#NPUx-PCGzET2lMJMSLS z??LQshPH?Deh>6EL)!zr&CvFceh=yQK;PQMeh>7SGqgR>+YD_F^fp7=1HH{Jb=HxU z)NuN}(4Xu}>3z;#iv3=S{a)y;&)G|vvsd(?&)F;b(C6$GecnE2ujoUcvsd(CPxM~& zIi}b7QOfK8ApIYReYR`Ee~|tUuh+c)1A5E*KS=)v#r_Y(zPx0yt_uBu*jF0go%SgG zf!J4Ynf?c2U(uJ+SA}#Ymy^_V(cTArEniCCRlJY%`@CNBexK;WuHt=^Ir~H(b`|dv zeb`mJPxRSI=C0y>q7S=@_lZ92D&8lt5352t=gdxOJMW*O&ra(2l4g!wasQL@{!i#_ zZuKW(Z*!|ZMIZY6KPhwm6n%DLSKR-EKJ(h$pP~7ouKM>U)ApHU8&vh$u2PpQs zHWKs)p|9^U=OFZdxT8J@z4a>xp|=t8LFmu#n7c3XAjSS5^mf1LLFjkM-_$r}i z6#GMzIfp3ry51D@he>}Jv9~Lahbi`lDfWklKhe>}Jdb{#?82ZdBkB6bR zE02evw=0i_Nv|toLH{@Oja=;ihJK^_&i*F--=zN=`uoq!UDNuTV*fYvcJ1zO=r_B} z`5XF%ZLgL4P3QRQrhh}f#ec45&gs6CK1$Oyyj0TId5=Kf#FsR4E^}8bkC6Td>5o9) zcTMgSS&oqY2*v&g^q0%u)Vx2EoA*V}BmEKRukfF%J?53Zl&;s+#-Kk+`lHn69HqQJ zN_l^j^8P64kCOf<<^9oU-XEpBKT3Ijlrl%xMT7nr>5q~A80n9Z{ut?xL2o_gG14C+ z{jsS280n8uk9myrx`LaPG7;LvLfu`Y^^kF8VOW zJTCgYW6a~C4`a;Zq7QGNKQ8*PyG_@cvy$e{dqVVCNef>}*PkH$3DTb+{Rz^aApHr_ zpNQ&Dkp2Ypwww6`>2*~+D{1Mx|3Kf$m(unBkp3Ui|3mtJDDVFv{XeAtC#wI4^#4F# z)wSAxpx1GZUO&>CL^H1+<%`tikJJ^2)D?`>6^hgqj?@*2)D?}?6^qmrkJOcj)Rm0X zm5S7rj?|Tj)Rm3Ym5bDskJMF&)K!esofN67Bz0x*)SD#Pk}n6}W#vd+6{?$!e^)h9 zS1nRk9d#$m7%fR&&X@bUH6s7+)0! z_$B4^32?Rj&-BTgw!<$er_YkI9ezo<^c{Xlx%3@=NxAeLen~lbSi1*y!oMT?@Ow; z6}kM-+xLY+Znrn=)*a$fat?HuYlh}b{ke_vzY#hcPIM|J#2QHWw+Nc7>VZz0j=z3N*?^kHS95L&IROcavXhdUYc+!OSLNncp{oUo2wnDm83 zAJ)+ei$1KQ7bbmS(iaweSVu1``n>Dtg+(9M(F;Sr&-FlsMIYAD^(>i6y1Qr>LFV-E zC5?Rp_YD@I%qimYUi;l5h`szN^t44N?~5RF>{(JpkU0%q<`hBZ%=l>mtwa|=<}~u3 ztC`c-mo#&1T}995L0^>gMbY0kalcoTVqX;crt&jwwMC&HIyP5dl=MYOUzGGkqxzzx zFN!|L^hMFAoMMzY#VGHKMf1KG<$W>A z`(l*$I!4M$dOL4%(Pt%nd`a~-ODIm6Q`~2c#=bc8)?*f@*cT^#anXk!v$*K<_L#** zA9~E>Q_nRz3Fv?9Q382 z@9*@b5PKV?m7>^}g5E}HrJ%P_S}BTsDd@MlRs2%WpCKiUeJSY6AHRjhIi;XK)BlF{ zIcND&`q@gy^4ZA%=PeEWKwnC~gQqmbzBJ{1Y0-x}cuG_3OH<~Q7Jazqv9##(-t$;m z^x>Yz(h~b{2Ty5oIkH6!c|DUzYS`Nne)qWl3L_ z^kqq3mh@$#`m&@ii@ZP8>C2K{XL3Pbj`ZcAf8WKR9O=uEz8v&7zn$AVl_PyQ=xvl% z4*CyV?8`x4>AV6G`vrbIu^jXt`p?zz{YSo(ey-IyXDS)&a-}@<*5{Om-qv!!=p z=_`=F0>!=p#l8Z?z5>O*LNxXjDE1XZA7WpD^g551KHYgMLO;xxw7<8j02QIH?Y_Z^ z(A)K+iqPBjql(a5e_xSeUlICmP0!(pMsVB_I2I`3onN%9T!LVH~6D zIpH`e({WTr3$WFN%5)r+aU8a~P#MQzs|%IsI4aX|RK{`G>Oy54N9O86WgLgCE>y;G zoa6e=%Klr>d!n#VT?f zVWwV1jw8&ss>pHVoo`i<;|TMuDsmiQ-%=Ghj@I4=y6o_$DwO|S;-jp4OGK%WciY|4?B)(bR5;_II7WcRHNglM&Cy@IgT(7s3yme zcOFnpjw8$is>yMLU2xUp`^en|r^ivvABV0_rjoHvULD7AiZAJL*ww!3bR5;`II80~ z>}p?iI*#i2KJ4sV9p8tIjH>6hkBqB*)$x67ao>D(d>>=ojJ7(p^XmRMbWJrJM-3du zICmU1kXK9H->X5#QG<@729Cqtf>8s_YMBx=%e)WmU|ke_KguZiP$YI}b40W~SFYSQ;n6W_-u`91wUYU2CI+}m9f-^XbG zx!TTcZ+A_~tD62ebiF;5jCbEaEgZ)LU()Zx_RZCzuzhp2a2&R8t`;3fEjo@` zIF8nC-&`#mN9Mk{S~!k2@^5q%suuFf_RZD8ap+lGzmHlt4!uTITaF`K>&U$hQ72MY zH&RzGQdd7x*C0~YFjChjQr9?A*CbNcRO&LXwKa>>HILM_h}5-=)U}G#wT{%aiPW`? z)U}J$wU5+wh}3nA)OCu~b&k|^iPUwC)OCy0b&u5bh}89r)b+}!(=65ellRxTmQ!2W zk-T}%mvsDM&*ZHw?I=9mv$nLO^iujWd23VuT$}o}+UVEpnY^{puVp@yw>J8YzWcUBGpy zKd3|fK^^o5whOop`h(0}z;)0c*e>8Y=nrfca2@Io>iFZ(cAiS6I(c0j$24Ek9Chh9>f$(TTwE8&kvT4|i{r3yaa}o%aMi6Y_0M(vacJL^ zN~Sw`JsigjUrIlYdUPE1=s4=panz&Zs7J?9kB*~W^f>C#anz&Zs7K#NJ%1e9pQe(T zPF^3!G0T_qIG%KwRG*HcK91ulmsj<19D5q%u29vdLagS@}>0gOMQPFdJae>vz@#Fj$@85rMHg;)IJ(e`)EMzqX8X9 z13Hcd)IJ(S+eZUx9}TE|G@$RJfjv(-e5;`xN0@Ill;a5Vt%hEPi{=d(U|h8G4kpv zH=b;ayt=-?KeBor+DBvL)z$uUbv${EFQvDS#{M{TOcRcy2^~ihI*ulE98Ksrn$U4H zq2p*m$I%4GajiR!Ceh<)LdVer?Zb|v3AK+V{y20TmP!`7OlpebSmaBZSGJrEyqTUq8am@8sO>rEyqOK#x zpl?R{X80CN-;DIlNZ*X~%}C#j^vy`$EUIrt`ex9tboyqb*RgHTHz$2_(l;l4bJ8~_ zeRI+`Cw+6$H;?L@lfF6hc0Hgu>2(yIl`M9-(gOM=zLef0wIF>9(zk%#dZZSlZz1~7 zv$ha@=#g58K5viILiC|WY9acp#C9sS5Pi6Us`G_ZvebE7Lch$HRBvn2EupXN`kI!| z+nRJs=xt59CFxrt_I5p>C1T&+UBzpO*k?XPuq9$|PZ4Y>`tgZ9MX)8sUS~Ez--`6D zkU6GrMfz5xZ$yEW-s zi$3f*X-)dpq7Ucf)}jyR&dIGspZA>HTJ+(Z+*6n5Z;Q;ab&$3c`?k>AI!IgSZ5^a7>D!XNE%dey(iZy6b&$5u zw{hzrZK1bykhaj<)eN11r;^j0z8&ONZwI~2cG^L2vz>ONZ%6ue(A#XM z9rT&Aop#XMY^R;*!)&J=#a`D6h_M~r5nbSU+ zIqfNP+EeDVr`YSNMk-nByd9ul=S%6a??AEdK(X&YvF||o4y5luvF{L#eFutt2a0_M zioLGC$UEbmwBMvDcL%S;2SSPS9`i zCDm7PBaBX@?*x5S`I(N=IzfN`!7WcEx(4X#0s<*jIXUhA|l=q#Xw~<0;(svep7%6lXeHbZp7Jc54 zLTAy3kwRzDhq+5#mn+?%Kf{+ab8MW`jr83}-;MO$NZ*b0-ALaps_#bn zZlv!`|hOgPI=#*^1gdC@4HjpcNhKS#O{Xa zF8axScdD)u=XiY&()XZIS`UhS57CEFS`X2OQCbhthf!J&()SR37^U?Pecn-857CEF zS`X2OQCbhthf$iYXUkm$F4{dw-xGQNs~gexBz;fB{x|uV_Lw~pd)u|qlVabKGN&gp z$98S>MCN4f+USYQv0WQIMIY|C?n#-WEAK(yi}byqx3@y{B7HCD?X3{KptrX|^n%`I z<-JJX3wnDiL@($w-wM$SdV4EGFX-*r{=K|juTk|Dede{DK9Rbt^nIcK+v)p~ zzAyCh%UIFv3w&ST`o5&^OM2~ng1#T=`$3;_>%#p=-w*nc@-sba z^n>1>WY>>k-;ebDpts!){h-g>?a&YU(f)JOcRTch-e$+zPo|P{U8eVk{ybmOyzlJp zd+iUs#kW87UF2t~?+<;;yK}#Z{-p0u`u-IA{?M>IdZN-E-atKyN#A2atXM^tMBH0Q8wVbO%6hJ9Gyib8Lt1 z0LmOa_v9q!yJ!z2{Xo%&cXkdW{Xo(W6n%KQ&OnO&K+%V%>kJfqc)HF&(dT`-&Op(J zr|S$9eR#UgK+%V%>*!fB=m(L0km$pT+#t&PL81?1y+NW6W4%G54`aPSq7O5)LD27! zoAx&4k7&ziv1ALhdVNcAagR`sWL?L;f{Mwv4VdYc^&gWhJx!$?1j^uwUH+3_&wGiS%cptsraFz9V|JPdlf z`laJec@B#64k!I^#NJkghLe6c^tLKA9C}+78czD*q#q8wtqKi?K66!QIP|tEG#vWN zy)eDM*Aa3mxx)Qy1oT(>lE&WjBS=4j^dm?=g7hOuKLYw{uFn|({m{S0(3;i==&QS4 zW(4##d?|fROULp#$yLsqg8ph>O7HJel=msh`;_QIf1e_KO7x+>Pl-PC_bJim?e9~f z5B+^g^r62`N#=z9US}OCuOCVJk<@BOl71xVMBx0Z0YDXgW z)@ny0_SR}gQmfVZkzAp7(H;f;wZ5d8)7$l!qbPGmLElGyrXz(>&_CNHcTegl(vKqj zDCqmj@9EiU6!ahGJVbZkje@?P|6CpC^!KIo%+Z-#(2pklXvE$|X`?CjqoKD^+Gyx) zls205qe(v+dYhe$hCXwYHX3>xrHw}HZIm{eVy|<~pdUl}G0q#p}?MK`h@OZu^-9}E4~`nk~>3%#uhjV1k9 z=>I61oA+a(Fa2U4>M_Scf1PW6W1+v^m(u%tU2zEdQ%HXb^b6f+=@iPGQ=nfYKhsuw z3iM+x%iS4w3dQ~u(w_qTRnmKFt33t!9Si%>&bU*cU*bPkTkTR`O3xf!8wvVxq#sB6 zaikwd`f;QmNBVK39|!$nv8aArR6maN;}Cn(kE6`dRh*#DCVe*Pvq_&#`fSo?lRlgD z+0ZX@`s}DaoAlYF&nCUDHwAqT>2q@RuC?b--skwd*ZE}*^zx_BOXQF~hx9qnFOq+$ zvCo12?9GEI?{lDE?Eji(&Jtfr&m3JD3;OY-9}j&u_j}_h_T!=NEyrUkG<+A zK)-2ju6_dPCy;&u=_f?>6G%US^b;s^bhR<)Cz5_*ZsruuHBBV_MAA=${_J<{U#71{ zO(gw9(oc-)Cz5_5=_it2*F}SV66q&FZ};9zqRg2Dz1@2=33|KtW)j7I66q&FZ}Zwo z&}YtTCqX~jedm+VYHeOSiS)XH8}yS&KNb_>soUvxxt;urjULL^eHzlm_qs~ z(2ta#seTIdJKoEE{^S(WPa*vj=x4dJ)fDK*)%#t>nBi{sDbUaMpR4*gzNC6v3Di~b zpr1DC@E>gEXQnw*ew=q(;DN?sNqfSQ( znt!R}M%VVIq4nJ4OFF-_U1rm$^-M$Sv0Y}<(0Xi_*)(cB)2Q`KL+i0!X4BAmGIyCx zL+i0!X47!iuzSs?q4ikX*On6W(@8%aZQoYprb93P93!IX&}&J1uIbR*+t~XFCh2FAekSQ>l71%XXGZliNk5bH zGbwYlpA7n0q@RV%v3oOSQRd9@nWNv}Ea)|la!cu>rCFq(1-;#yF$?<4doyN1Z}(=* zLgv^#4YNqEJ$fp+-9>vg^mq7DdhBOY>}ON#XH)EFQ|xDxem2E^b~N_0DfY7|_OmH- z^xPBlb4Wi2v9~^F4(aEReh%s9kbVy7=a7C*R6mFGb4Wjj^m>*I`njZ^OMT8<%AC1A zbF|Ny3%&I@b4fp!^mC!NK4&iUnSIV&=&jG0i_Eb;XD(%qp3hUsoi11AK`&Lv-+9na zbK~846#IG550#&(ejfBw_U67PcpmBJk$xWZa)A{i)p^kOd~+tv(B?t^yc?U&gZ>3y zN*}4}$V09XIsJUm%herU(!94P4a_I~eCX{-1M_qBPZhvX&li2Tb~j)2;o9AN(T67u z%oly$Ck@OOeR$Hqe9?y|4a}F=hqv167%7$9h6l z`-RZo{9(bu+G8#x{X)_&gubWzO`YQ`g#P_?B_wmg-E0e?@8v&NX9>N1DLr#^+!^$X zNWTdBzV7!HQRXayzMuR|^L`QZ>n7y3mqnysMEXUfUli3ZBK;!7-t>#8&(RTb&@U$a zV(9xj{bJHDhJJw4FNXelm-mZFznJukNxwL%UrhSNq+d*W9m@y(64Eb$exTDYA^j5Q z2RZ!`=vO?E+iI7PehKN9kbX&2zl8KlNWX;iI_t(!JwtD%=)Mvu7~db>+}HT2eFu7=+3 z5?>9y-6g&{SD*3R)z#43UE-?|d%MqiHD!*jH)SP{IPV(hAN3`Tz4iBNNWX^kYoNFO zehul@h(4UH)`&jz_iIF-x4&N_`q1C65q)?%{u43%%XRu$D4sEoIJH#NO^?Sc}+a-pQ~Qv9~)J)*^H4`IBoYb94LVV&s1NMRktex2yUNMW7m^NtkOi9U=J)`>oh6xNA8JRM(G z8?(HAJ?YmY_Le#8DRb6S=B%g8Sx=d>p7iS}bJj;QXFX-kdSuQrcNJhgWsa_k%IwcY zdjsh=K)=w9Y&MX7gV*bPWCQf_r!WTEK$)|FGG_xa$F7@hK;~p#H{F2DvFoNAL?5o3 zZlKK372KfT2>lc8ST<6hvyt>0ym`jilGL=A7h7=iMawoa8BA(*0p~yV2by%KJ^C&q?l)pQ(P6=yQ@6FDQc8ZzBCB z(TDwEn?#?J+$+DQGs8`y&q?mT@y$Xx$vXcWpiQFBNuKr!&HI1*Qu_WdT@_Cy&$yp$ zM(m&UrS!AaX3}p)?Cor|8L_vs)n>|^&6GKt5qmpZZO)B-#=BfLBldQ-+AOgTXRFPK zy^hlK`q38AXI?)#JyN$dQg=qA?#xKtS&_Q4BX#FQ>duYSofoM)KT>x=r0&8<-9?eQ ziz9WHMCvY$)Lj;-yF5~NMWpV^NZnPDx~n5~*F@^BjnrKisk=T>cSEG^#z@^wk-D2B zb+=^HX^*M-7h2C2YCT)fbJ-kc3-w%EsOQ>()?;&=E!29pQ0v)()?;&=EoeQNbDS+` zJvPVLf}YFfI9q({QN6a5?BqGu+D{jKcJjP0rJu1+r?!7O^mfKR9eO)spDy}v#y(y2 zVYGC*=))QNbkXNMW1lYiaK=7e^x=$sy6D3hTidjZq?~sv>9NycXxNYv%bul$(PO_o@XW`dC%$^-+M>;-Fik}JL+<9ONPW>#;9lXb)v`I z_sTD0Jnl;J%NTk^xAZ=#PG6t&^^M-&MN*&i^+{jf=>1j2^(k}e8@(Sj>Knbks<=L4 zpZpum^^M+NRa_sjUt#AP^$~m3OFx+!O}4RbVDx6}awXC4w0l|&D03P>ulL5Z|))~yqw0o2GCD+3dx*3PLVj~Nsk_jrrH0qq0z^p>8>Ps z-^RYLA;rES#l9i*`ir9tDfSJG-v54CL!*yH`ir9tjXoB2NczRmhDL9$k$2xKW1jxv zXhXDGjlGOLUf+oHjnL=lDxnd@z7h1gN@xVVt`ZuNz7gpgL9eTXM$jj(5*k6TtAs`v zv2~Tui1ac_dVOQkH-=tM0UA^68$+)<6OEzQor%VzZ%q2e(Cf}bW9XB2CK^MpI}?r3 zW9rUCW9VhRAw8yy=U)FO>HmcO2lsy_{%+r&(En&&leylX(0~41{92(uDewOz{h!eP zWZoxv|0nc$bMg7npV0s8zE|eizqnH3wL&uUFg>o#^d`{Hbfv`pz6oVc6X>YI_i8R?smUgn)C(JY%Q&5b@Kn(a!7cMUeD%xP}) z{;t91M(^($Y)+ZeoHD1m(fcPvG&lNd?;31w^!^DE&5=3B?P%59=uKAIe{-23r$%$E zw*_K9*Oe0WElA&j^esr=g7hs&--7flg8CMuZ$bJNq?fsT%;{T_z9llJjU6>wQs%UD znInBpOJt6YRxK%WT2kh;MCRyd)e@PLJX*Cx=IChE(&+tY)e@Pbqm`^WyuKCbTS0%n z{a0#5v2O+a1Lif+w}M{p;AutrR-|tQ{e$Lx(qp!QKKTxwR?t7>zE^t8hg~W0+*H;_ zUf-JZt)YLwW?XBEeQW3+G_Q%iHS|rZ#pjr69!PAEHZAjk+dcA|E4fM%(@U($m z@8D?zz23pohB8OioL>JI>HmUWpRfEE>HmUWpRfEE^!j||zexWV>HmUWpRfEE^vTax z{tJ42zVctt>+_ZWBE77Ry}m8!+d{8Trf5t0w$SSgxh?cMLvBm@wxn+hz25uP7W(8T zQ?!L%pG?sfdVMlQThhxq-s{_uz8&=XWQumAZwI|TnW7!^`ecfBq;E(1cBF3?)VCvj zJJPo!z3e!6eS6ZkhhBF>+e2^ucgzjiL+?xS>&m{AI8$g(`u5Q4ZfJYxlXpYgL$AA` z?V;DZNZONL_C~zE1L-@&V{ccK9Vqr4;<0zHCF(m+>^qRY1N4{dOrZnxwQj9L*C=&> z{(}2#=`k<5QevMYyEtCok@Ov**Lz?(lD;GKdJjy;c;?u9U^^nL9h3~bRvBx(sv?#r=Y$Q z={u3W6X|7V%b9GsZK$GwC~%zBBZC4@_s$cP4#j(svH(JCnXM={u8N_VB#E z3+cN+ug`YqLYdPA`e#iBNbI{nug`YqLi#SG?*hHv1JecixhW^e$+%dJjw& z=yhc%yNzDomGoVq*E@K+lD;eSdIwKe==BbsuB7iu`mUt!8q{|seOJAR7>8}xbyPdDh3@8IbMz23po4SKzUryJ>I2R9Zi zv~!^Dr0)*B&J?cXN#7lMohfvOK6$3l9eSN9bcbGN3f)OB zd(B?ogY-S1*XJnpAbk($&6_cH^?=@&5=W~Zr0)T}&J=n;pFC6O0lm%?dO)u;g&w4r zUGdatk&XS|MxPojb|u*fTxn;>e;a*jw91v_^lP=9A^&ak=KQKee1`ltWzOG5pAxmS zf9KyupBk+(?~@tw-$rlNi4*wr>u;k^jg~lt>;x`#CEW>>^P`?dpL~AwPoS<>psshI zu1}z@Z=kMUpss(Q?%zP&fI!{AK;57~-QYmokU-tgK;5uF-S9x&h(O)QK;5W7-RMBw zm_XgwK;5`N-G70)@qxMtfx3x-x=De$$$`2lfx4+lb+Vr*`4@AorzhI}GMlMA(f0M} zk3FgF_e9&*r$6>Y+t;T*_N1PxC$;^aX#4u~$DU~W$xnamiMFp#f9z@6{!5WQ{jn#t zeQ7CP{}1W^fnJ~E^$+yse@9>SkL$T)#Qq0*{iWT1ps#L6+_5A^yRuYaIVeva2a z(ARYDmznByu9P@al{TFcEw|C`W%Ma-w%^O>Q=HDM4 z`PF*+Q|$Xw?E6Enzkb@EV&9)Kr$6+1tx$jHD<=K=X@BVJy6=_P>#v{oM~|tQBjdT( z{|o&Z8~cBuzuV4_{w4jtPA~t0|3Ys*3YqgS^g2`h7kZs7{R{m)cDD3yTwggS-9_>* z^!K{&75#m#l$iH2^YHosq#r=~0i+*5`T?XLK>7is9{~ORRzD!9A3*v6$Q;!VpwUX^ zNM1jX^aG*Sz1)GM9|*nf^@B)1i1dR< zKZx{$NI!`5gGfJ!Vm~OTA4K{=q#s1Fmw9I_T5B_XF!bwON%|Z;yBkdU!IU|JDRTxx zul@aC==C>v21BoBcY~o%KD!$Xy`J3-hF;I^22<>1hV1o2NIwLzSN#yu4!(hnj1 z5Yi8UUeE4^1ocBmKZNu{NH24FuOCYKq0o1;J?&7^4~4$Fc}-?%L!rNrHQwh8rOX*h z`k~NoFlSQI-w%bp-=~jJe?JuZjrQDXDD<0LDY3toRfpFPBmFSa4uG3+jiFei-S8QQph?C?#5NGkv(xr$n0f!;Rk0F^7|WxXT=g{cxlAbIjpJZ?1x} z|7OFD-p?_I8@-=n4mbL1=a|Ed-p?_I8@->U4L5o}OOutH*N-6m2-1%r{Rq;JApHo6 z{Rq;JApMA-egx@9kbVT|Wz89jHrUvYMCNRCCFyhW*%*!_{YcV}MCLT=lo4a?Na(fC z8Hvo%dCo{=&LJ}@OWuz}=5%-{MtMIHnRD2V+#``WM_eg!td-TV*N-CoD8ydpn4?HP ziu9upd!1vBBK;_%_jAlq(CZv?l+j;1#~fw!evUZ`dYxmALhN;(BkTBBw8=($H1wNY zNn)>ek&Gt&Xwr{H?DdN7(Udu(DfXkG*IC+V#6J0o?$L<7UeP@odcC51G__jUaq#*v zq#uJmNA+V!KZf*UNI!=3V@N-S^kahhF{B>@{kL|OHiq=FH{$hUNk5h{XDsQ*l71{@ z&REKvv6MMuDRagKGiNMi&REKvvB(^~UO;wnV$l|xE90Qw>PnJ1FWXi-j`ZV5KMt|) z@Yd>dGG87Cz4n;nDE8x^f5m*JwAyiq{erjanO5sp<>L_hSKar@4EZ%zN^G^V-{kfG zk^Vnq&OqDR|0Df>r2h~4s_(|f+W#o_|3R-S!~dWkWc!@|pzpV1C#`G$gMP64UfItX z;!25Qt?Z1&qHQ+XSnmYrce;}3f42W-6Dal*p#R0ZCS&ac=+E?x z$9@9oCs5{0fL{Ci3D76^_Yj z;``_mNk5VF6G=ZYsGmssiKL%Mdf6BC`bngp1ig;6lSn^_^pl|1v33&aCy{;<=_dvC zlSn^_^pi+0JGfpyne>yP*ZzJo=_iwZGW0rHO@>}q<&#N28G0S9CdczW>7K{Q(CcV5 z8G0S9CX-(Fn!SDs>8DViGlle1NIwO7?Q^D3?59Alea;lcd_xh>OYo9X}dc8(zD)idtOod*rQJM<9UZXUX^i!eNK4&WQdX3Ul=nE!2 zWq2y|dX3Ul#Qt^L*G+Y?m-C}(MxT6sG(Au^BTzRpP&X@3H#<-_Cr~#xP&Y47H$PCf zAW*k3P`4;hw>VI@Bv7|BP`4~lw>(g{B2c$7P`4^jw>nU_CQ!FFP`55nw?0s}AyBt5 zP`4>iw>eO^B~Z6DsZM4#l7GJSOrzE_4XvlNT~$w`wm*&9{xr0n1J}hzjcL?#O{3N` z4Xvk)UE5DX>zR_~Sz6;vL+dG&B|d^qL+dH$6p8Z=;u^>k@VA{pXa_;=6ds8DRHhRZQAQ+ zkbVZ~XOMmd>1U9B2E~2`>1U9BMo>S4^fM59)z6@QS9+gVw9C$qW}NsW!n`J#GYk4D_A0YklsU7Y*M0O^(6=)06a6gcbAE7+ z=Gn8LZ|%NU^le-zQ7=7us*C+>($6;f)JXNSNk5zPvq?Xj^s|lLUo$b==u@NhW`-;J z*+!olz5eQKIzO6i^r_JXJ42prGAA|K=t_y_M>6)rqP;fSb4Wi2v2SPp>N%7-b0~A> zK)<9}dbIC3q@P2vpM%(M$q?7iLF{kM&G*2}LF~ua-N`w~`?0Q+*lJ~ztR3yM`ng75 zJIZd`_gv`pKL5F-pG*3=(CZT-=2G6zHG01zH`nO>6C&ms{k2bsm}~U@2@!LR-v5^U zT+?d(6Cz|hk2(E3#D2g1TjoKpr(g3(KaceDpx4u{c@+D3h`qMjd5FEvROcb~$){iQ z5c|6J-+Ufoucu%0sLzp^M=UyEz4M_z=t|P(=(CFFQ{K;qUY}JwA9{UO@qE(HC;fcr z^;yO9p-+BR@qFlSFxe&J%zWteS;h0+Tu)w;Igoh1Q&>oPnRmvbBR1NLkU2+P zNis)QXp2a{i1dq)Il4kyMEXU@9No)ZM0vj`p7%*Bv_;4qU7;;P=6r3}=!+Uq=u^tv0mob<~{ zzZ`nqnOF|Jp1>@JUPr6t(Cf~`a_EzHCYD35I}^)|-tSB-hhBFkWX=u;v+ zfmuQN6{KHb^eK^^z^ows3ZwTYFe{+f6POi7f9(m(3ZwTYFe?yyJ%L$a^r`L|C0QNU ziH_Mma;4GNiH^HcqJAamSCW1u=~t3|CFxfheVs`4D}(x#q+esf;L_si_)yc&7G+?5hnC$cwUezDkk z*Fb;Pl@iC=HKbod`Zdt&Si6SwYoOP$b`A78$6Nz_^4Z-Q=yj}JgS^)sa}Bjx*~O_7 zowMGx$ei=8l$bedNxzo#YbkTqQs%6s%vnpBvo@GHYbkTqQs%6s%#r=3SaiX9*CF;7 zT}fj9n_ZKwgTA!=7hDJZ@8&gG*RDhCdzodf%v;xyejUYr9b$jTe2T0L*CF=FXBg`c zdp*NghuG^G#yX0nZl@Dfa83*E5Xuq+d_^^`u`P)UPM~deX0l zUR$l~;l-j$Hrg9Vzk$Zu4W!>d`VEx#8z}ELkbVQ@{f1!PZ=k&20KLvJH;`U-8@+xb z={J&oBk4Diek18Ol71uUHpw=>05hEA%?Y+-mfGmbTUC z{XA!@(O)}D+iLWFmbTUC{XA!@(Z_$CRnCvL8GZ8k(e^;yjzHbcK;5oD-R?l$og+SfKK;5N4-Q_^tl|bFqq&n%HB>(C}Y0Q7)C22irT`95kY@^n*jatt(YCYSi z^=zZovyEEMwqWboMy+QXwVrLR^@vwmN-Roez1z`qnF9Wn?dZAm%GT|q-wwTA*}5G) zmtNVroqDeA=(+UlcsqJ7y|Q&XdamRvTeqX<(kolHqvz5qTenlsC2cwurMLPW&|kFs zM?0X`-OwG-m$rY|4(N3^bO-dh8@hvHzXN(5^L9Y5yP-RvPu>mP0sRejH*^Q|x*NI! zdR-k$@8k75Nxu{N`gW$elVZQqWsdv{?u1_d&301kcanZ5^bO2s%1m`9^ab0TrW2T* z&^L77D`$6&Tq$vlBmHD7%3x!^3;K+%l(@#(MfzP%FZ1kO(CZp!7wLCFuWOuL(CZp! z7xc+%oL$iC8fO<`ud}6HlsVF)d;MWqz28^aO_?KOPb|u0qrC_E%&sJ{uV*uT59R$H=GvXYRKJ&EFXOq_?}Oe{p~u_@z21MckM#STURv!w=>7ZT zUUS`<*ay9yo9=^N??2iX&-Y_aE(pUhm-9M|zogc>R9T?7ouKR~gU*__uOB>h3sA0+)j(jO%KLDC;2{XvTT!Jz&i=?{|rAjMwhov|p3 z`LE>fA?UNZlJq&+V;&;?A(uJQ=Ny7wd(1=BY7arLW9=d6wZ}XJeezE9A?UToJY@8~ z$2>%_ml<*_%4WTXq1TzhVZ>ffeGilVFzF9Nucy9;Nq?C1hoS%7_Lzs`u}`|^@i6pt zZQpSivH!!B631GZ%g3VZR(}Ng9Ihm>*Aw?6q(4IXBhc%K`w`L~A^j2PhnSg^^!G=g zAKAEtnJK*Qo{xS6`k{8Vbp-lBS>xGpgkmqN4zE8-`lA&4qohAd`lA&4qohAd`lHb6 zOyOuS_D3o9N1@jf_oJkj^^w;fBmFVbA0z!S(jO!JG14C+{V~d%V?q5f(jTMDIYzBk zR&ri{ob<<`*Rl3E>5r5CIP^N!9w+^A(jSMufzA8l&?nCnjzizjX8LjHb*w#3dRcRN z{Rz^afL{BY6Qn;u`V-J=pL2rrCrEz+dhK&gK%d;_oPb{YoD)Xx`3E8S+W!^*)S~@z^Kbhj9{my$|Cg zVz2jMoFu)h`w(_e~My%iei6?^s?g+i*nm& zpCU8&5;8E5p;!>&oyn=}(jXH1xVMJPm#F%J4MwH`tZoX~bSvhNq#| zm7(m7nCIqM{Tb-CZr~&lflYy*^*y3}wz4%A7OMZ!OASslm5KX`@P)rl=tV2-tXm}H+sL9d*0}; z-OD|1^nNe*ywUr;-19~s-^-OgQugp-PJaQhH&y6AFQC=xZqxIXJYIxePaZEquYHc}i+cSf(qBUC zwbfpt*k7W|xkPz?iDG|=^p_~_F9q}d66O6R%KJ+cd)dMD`pcxhO!~{DzfAheq`yr1 z%cQ?d`pZH6Wzt`UUQb{ylV0|kz5WX6uRyQ+Iaeriu0XH*Iai?9{hTY5Iai?9wbd2q zb(VGo`s7*K73g)Ab_IH!rCp)SkzH}Gze@V6(CZxYD#iXP#r`VvI>)?9`m3bBO8Too z{Z-OmCH+;Wm-8bt;9YZmlqOJ@Hc*!?P?tVXmmyG>F;JH&P?tGSmnBe_HBgr=P?tSW zmm^S@GfiZn!Jg>1Cu7N{0_`pX67a{)ig$L zu9jK;hS`~T+wDxGF?v(Bv%55TWheR_S4!N8mNxD6X-S_J`e&^^E%c>bN%YT|lIYVy z|NV{ef0wk->r6E*>C-}A%e+tYX`#=0YhiN-kN-vTw9waf-z54MT`6%_NO~WyPe=N6 z(CdAl=}4arvDf=P(?PHIeWs(>rz3qj==HwObkG+}y6-a`^m^ZCI>i2Ut526VG4|3= zdVPA*r-$D3&B%xJlsV~L=17}J54~npdeWySeR}Bgo6nTkr-y!Mner6-^w1Y@-z%{% z=t_yPmmb~gGmt(5^l#YrWuVw+fc{PMnq*D}=zHyp|D72qb25-VLp<-z`$V4s`dT#~ zqWkVL#Pi;LFY?}%67@3nczs6FXN3L}`@W16`-~L(j1>Ef6#I;%&j|geR-Y02T`5s7GY_xNLi#MwU$%Q%St#$bK(Ei}&H}wYqdN=fvyeUu^!kMHEYK%E zVLS`;&%5sxeJxi?%p92`#iA0XyO6#kEA%B@Nk*%I_OH%LvCryaFReB!^tzvzmGoJm z*LikU=yg9aEA+|xiCLl7{lu)M$MpM&S_&g>&O~;j_d65WF^1LY)e(!zS#K`HzPu|*?Dgy}7wL16J{MxI zXLq?spNnFj3$fSz#9WAd@*SJG5c|3|({mwn^!z9n#a`A&v8aOe=7zqaD~VpO=*~_0 z+@#M9ypl$yF$64*Il99&}-~vCFk{dNS_CNj;`(V zkUkIT^FXg_`#hx2L$S{Tz3xopfj)U>A`kSsGm!`SruJVV55->AoL--o^m(Dz{ys11 z^O8O<^xEI&C4FAf=Y?MT`@GO6_xE|B*Zw}Q(fj^BFU4L~$6lY0^!cdA%t!isq|ayc zzQ@c*`g}(3d(3>$Ymb@F=&$WD^BKMGG4mnz+GFN3dcT(|>-bny$!2u8l9u}>bY@+0;-TIEOVm)p$APqCLB2d^(c`T`XD z0;DfM`T`XD0u=iK6#D`c`vSq(7ogY|px76n*vsBXEUIFoT@d=Jt|YP7^P_^$m$oq| z2)&*k6-4ay{HP%Gdh%EhvDZGQAoSbJr^pPsAYz|#*Yl%-(Chh8L5jWX;&^=_ z(ifsWrx3-y5XHU_^xEeXqSzOr%qaxD_Bn;1PwsOHL9cyIA?UTwDFnUlqsx9%Z5R8( z&{wmuFATk2t5KNrg-Kr+dc9VoFy(z=qxVloC~Wlp=?I05{@SM_6gGPQbcDi2@1KrP z*y#P!5oBj9)#;0nz6kREkljfsLYY&<=>4x$7D3)GS(rJ8%(IIay?>&A5z-eidjBhx zMUeMf?n|4|{E~^=&nbeuKkB|$cB78FQsS>v${wE2oT8*JirDLpNKw)kMeKD)q$pyq zJ0e9XbBZE!^4a!M6q&Qp=6z9QPM4?OrIle(WX>k{4q2UScBRA_vg|g-qUttRic#Jd zgI>?9i;=z<^m=Ap40=7YE=Kxdl=sD;*E8#4&?lc+7lZx=v-XvL$zsU+8(k@JWhnci zv8aaC7l*#4D@mVo(*D)ODesF@-WP{nPkoD1-WP{n`<&v?>nyD}^vS2b#i7?z-{R2g z^}xlc&ygKmuP;IR5{SL_m?bFoC7{9g-M`uf= z<843bcVJ4R_2_J=G+K|&mP%9GmzLu7Wk_EJdR9%A9hPIps)Sj`Zay_T_@HFGsO2N3kzQ zdg&*#LByipd;*3Q&dgRY+e2vDYU8RUv&9qxXAS zRiM{BttyCp^6!3CLG16cCq`AE*FCK&M(_8uWR4VzZnx2{3jH0fB(c|dc2&|>C4JR+ z?CllZRiW2aLRHH9s?h5^yJ|f4Nmq1NMeKE+T@`wrXIG`Xm)V@xS0jBj8m+34z8dMP zL9e4#HHv*T%A9J@>u6OC`sC578uU6^RWo`&T2&*x%sailI`nti*jI=C6WccP5&O^GXD61&X_2K496`$S&@`s80EuL1o9_t~;DanY3$^)i?D z`kJJ#3H@(&Kc*(>YeN5{c}>nuYa;e%%49(7Ym&Yu>1#r-qg74llSiwX(CcVb6S3FP zswQQQtU6-RT{c&)qrATkdfivKj`Y_-ulp+3L9hEN*OC4@%KPh}*L{`ipikacxej{W zSGf-Q8|}Wzb)=W|k@+1$tG^!ldt6ES96dj}p7Q>Bm-iC;>!H{4qw7h3J@h)(UJt#F zwbw(RJl0+hy^gilL$71)^`w`TTr9fRdT)UKK35WbJDce@kp2eJ-vGTn>GlTF-vE7k z_bGCHSO-&*yuShZBdHh6^-W#ERz?DSb&9;{t zNq-~sdOiA$(ChW+HKtNupl_oRKE_7iV}zK8o>(Ld-+iF#Qb$D)VqYd1mv zuq!3T{wC7jM6th#Vt*6qZzBCoq`xT``#~~IyX1%vS|F|n9#{L%4-$Jp! zg<^jT>2D$ZEu_CC82ei&_P0>%Z-HKCX|gvGi=MFFTcLl_l@j&0lKxiG-%9#hNq;Np zZzcV$LH(_yzm@d2QtV|HCl)h8znx+) zJ7clv85`|8NPh?E?;!mhq`!mocR;VFzITxR4$|Kd)Zan+JBF*@{out1L`sDupPUyA2zZ0?7KIcw~z3euc ztCFqvF6f_krNq3yi}ZI-$k*%3wrJE?;^eIi+cUtq`w=P zqhsyeq`#YDe>cVcZqnaP`nySgcQE#MQ|#}CzLt&X-K3Wt+*nlGzIG4v`h0dnoqzkp3Rh-$VL)g0a7cVt)_xFF0Z1{9g8&z5ZU(-%I*?Nq;Zt?BX9q*`=GDmN|N__@^~NV?<4(v(Cf+Leb8&4b073N zL%t7sJ$bwj`s9syK;5H( zy2k=_j|b|W2-H0psCz0<_jI7{nLu4EQ1@)0?zuqS^MSfrfx6m(x)%ah+bNX*FQk|2helr8O8(9m$vJ?2cXx} zuLq#l)2|1p=XwBoy`uX8==JpL0qB#j6?y=AJ^gwBdOiJmfb`O)W6?`C+7CkivMVLV z{y~cUgB1G*DfSOi>>s4qKS;5EFc|v>DfSOSuXoBnNP6jg%sGYiJ_P-%t|WRr{d$P> z50U;M=ygBwA&UJ&6#Ivu*ZstYpikaUdUnDh@Lb7tB# z_QRxqnDh@r|6um`Z1Q1>{llbx82Z;td}L?hVd$4Etwi@>JPiHoHii!)_HVdS;)pFh zy19zazV-<8Z@H4hK9e179-+K{1p3T&NA3~mpL`~+e}wdpK;P1~mq(!AW=f)e1p2ps z`I>en9)W(ldxz{y|rM!O>vDZH5QPRsO8H?Vv-p8PS&y^DM{xQ-&M*7Dn?;oSQe~dEcG0OYLf_eWK z<^5xn_m7cY#&h!=C+mG2`VU-5^m?_;7St3KM{=m6BPR=DE3c4 zuUFH{94QukXruik>7RsNccPz!zO;?VlhEr<^pnu*PV|$cf0Fc1La#f~PePx(6a6Ig zx)c2*Vt=FEiGGswGMkG{a*7v>2scf{!H5b^c1qEpf@*A;!NQw#J-;G`JN)Z%sW$~PptQ8=s$HOxzBp3 zec#iRIZspOJZdZf`qXHd`ApG2ZS*P8qaW>{`>dZf`qXH- z`(8QqUExZJ_aDg&Ip*}wkp3BDj{dInGZg!0px57(eg?7E-<5ub^v_W2pF!;Pccq^} z>?qMW~%z4)6{h9T%lsV5* z<~(ck{yvOnDfZ7Ib99dRtkL_sr=B(XYwyE&7MY`G*3TNfzkBLg6MKJVE$gF{=yU6R z&gfI3FI-7lZ4LWx_8i6jIp}Me*QC`xhu9zZA)fco8GUM`XV%X_f1Udj$$KeD?4Lv4 z@2Ee}z zEyVsQ^Z&^Dsg}{FMo+tvWRAvOR>wZ}wMkzadhPFPlfE|e+TYiPUi#NVY~pn`DZ~yUVvUo68jgR z*ZVMDApHxZe*yacWsJxE1?cOnoo7ZX|Ld$TK>w@xeC>PK92dPn`1DUk>t7-LE2Mvg^skWq71F;#`d3K*3dR1Fp#Bxo zze4&~NH6=MvFKZy>90cnohv2I(q1L~t1fe-zkk)}{VeTO=*&eC2rdVja*ARQ1=e!1eX={27dY$LIhS=*o z=QYy5hS=*o=QZecp7R=FpFGcb4YAjG&TG)$Xy-YvA@(}f%3gCU`oZd7hyF)bO59U; zonrqw#r}2Zbx+}S(!Wmn*P+)FnAhW(leDMsI`nmIoL+}s_Y__yz3hs6{Trlz1F_c~ zkvB;H2I=1*{TrlzgY<7e|GSaNSo=m${|4#bfc_8rx4hx>a(?ut(I=lDy%nf?J5cvd zpzhs3-Ftz$_XBkw1nNEv)O{4F`#4bdNuci2K;377y3Yf3Uj*vD4AgxUsQWrl_f4Sg z+d$oSfx7Plbw32^ehk$86sY?-Q1?rq?tg*0Ujuc&1?qlJs*^dUu%;y-BU-O|%}p&;L!dp5*)d-$d)t`~2TDt;au==1sI7 z-I0@);`MKl{w<^TYx}oI{}$=rGI~F1yhUyQEu;6N##_+qsPUH3Ups2NW%Pd3cnfV` zM~%0P-j5p6reo1hwx@lY^l#Is@iz3O?Z3p^(Ceu2He#=%#@nQSn_~Yq^g3$1jo2rT z8gC=^I%>QP{f&0ic$;D`y-zIq+3Mec{ufu0QKO#qzC-$Vpx3jzcc9m^yLU+c4(Z>4 zzJd8n>383OKKbnK9q1dn@0B%gK$){iMLa(P^?;`Jq*uUjn(o2sXi~eV${T}qcx>Dl4%6k<1_b7AT zqs)1a^zV`WJ<6Q-f|>IkWzKt)Iq#8P#-2LSZ`S+1(btK7ccsKu`##0~eTx12M(jibYk&VC=|6;C_i{gkK6x+qL+Euc_e12p?&W?+dYO56 z{YRw#2(9)9+g?5*{YTLMXkL?5!bi}5{#^W*vpypIN2LD<`k&1Eq|f;X`nxxZ zp#Rx@uk<;;xKiTUUgk)#sDX|4$Iv%)C5e4CyC3s0<^9K$_a8%F^YKhr)qD)S?&W?= z`j4TnVfR%&j_V6IG+AI#){6%WTg4nw<510=-@%_X%SEiGANE6#Gx0 z|J1xDvHt}6T5XC!{|V*&C#3%b`u27w`V;66d?L@x^!EaM0{!Ridqw|+D<$e>-s$z9 zlKxZDe@gmKN&hM7KPCOAr2iE9&x}Pf=hLA6Q__EmR;&6?smGKVve$n``p-!J8RXx=BW{~Y=isYB`H@pI@Oa^EYN^RO!=W{#{ny#5R5|FnP0 z7trfo?ibLTmmvHCdS6Ps_v;JNe?j^$px52dFQ8A}%l!g+-OK#~vDe+uFDP?lePr$_ zwcal&_Fq!$zogiINwNQuV*e%Sza;&a6#FlOvHy}{|0VPq`!6YTWF=>2a8~~n^vzsJ zdQ3gT_=@yjLBGfROGxH?1-+hOd`0@NNdFb|dWP{8^vP!!UqP>D7+)FvOOc*od_{U$ zbH<|P*84T|EnG?Tx-;=LWzN?wb433&^t!L|HR->GUU!AQhFDM<#?@zzJ zF?xUc^^MV|M9HUL-xz&Lq^Dos7`;FJ`o`$}>6fhIQ=R@>(tm66-d`{9Eyey@iv71n z@2?m5mSX>{(fjKKzBPJ(y}-B7Ctok{t#6T|M(7cudy2j6;-o}vt^NnZzMU&2#{LJ2{SOrTA1L-eQ0#x8*#AJW{~;Lr zA1L-eQ0#x8*vo!XO4QzZe}uk+D<$fGB>j)1|B>`RlKw~1|48~DgZdvy|0DEzy}*yq z|828FcE(boj@J7V^qpKOQU4R^e5>}3xxCF*Rw zKSSTel@j$olm2JY|4jOyN&hqHeej&Z=i^ihv*84xBk3~IPN%UK6j{T4H|AT(3c}>RJ z|3RPgu6SSdKchFljN{%Xzht53rvEegShUT&CUeaH8NIn8HtCAm{~3KO+V0*jb4Od&(f^9rm+Ucyt~B`-v472duZ*>?yHes~)^=8)Bb4&-o3puj}3+vDbOdZ-~8~e#x$QEb3{! zzeE3zD~Z0j{gmG+bAE@ug?UZ%ze7LerMUNZ(*F*<#{PF?PAl_1iT&@;=ltLtU1{<= z^sU|Z${e$eD@o>vUe1r|8h!Hl(I0`jdV#w7fw~5Px`u(eMuEDe>hDIt1!E2I@Km>N*GNx&-RF2I{&6 z>beK&dIakJPO6iAbjd&8dg`L}^s=p|F17u-)b{IA+pkM)zb>_&y43dTqV;IouN!Rp zb*b&wHKT@a`*o?`m6j5VdRy-w(D!jAY5NCltNVlWe~|tU=(Fz4jK1m*(*FUy-h225 z^oPu6O56Vf`sAl``~kf_o#PMak2r<4eTluaX|JzG`g(}{7xsPiNMDci^`O^ZZ>mT7 zdZe#M`g%cqJ<``BeLd=TrT6jr`lPQ9y*?SGKI!X|zCQH&WR&`(uTT2=q^}>;*C%~_ z($^=w^pjrSfbSy(hj6Nmm?@H2Yb#>f`^oGZwkHkm`zFFl=MwW-!!Oi zO8TaxZ%TTZ&3Sz@(l;}Dzbn*?^vy`$%;^2DP&3juL*DBup&9ggtwuAWzjjxsnbG@G z-)7M3wHnQk_qs}ud8gMmhh9&=nj`jl3ecSN&7EF)lIDoLX*}p@o0GmdVy``BbLjPo z?&gSn@+m-b#9mJUnnPbGmwt9)k0~?cSTxAC+7{3cb|vX^bSJt6>03Cxd@z7=AxbIewVz0NUPA@<30%vOlK&M{jd_BzLGg;uM1FY6<(Z%ujM8hXu~)}(Ju zv2RV8)0*_HDRWv==ClrGPHW1X)|5G|NiQoouWv*8Hq_^|A$=Rtx1r2wL;5z9Ic=cV zKBrAEbJ|emw1HmxoHmp>vgV9M!)@mLMVa##VqY_3ytV&D`oBp37h?Zc(Z|wA5A+xG zx~KIQV*i1?6X7rDuQQ)1tCPPF`wd+mrW5zS5c})h_sZJp23JaKwX!<)`nIHROZv8? zZ%g{Nq;E_5wxn+h{f$=NHmGk)`nHI@>f0i7wAIQwJ{FCzv2REEcBF4d`gWvmNBVZ8 zZ%6ue6#I5TeLK>(BYiu{d)aaD`u3!6Px|(xZ%_L6q;F69_M~r5v2P#Lw7}(??Czvr0+ob4y5lu`VJKP4nchf(sv+z2hz(fj@Nf2eMi!FBz;HH zcO-pB(sv|%M~Z#NpuQvNJCeR5>1Dqu7LBs8??n1er0+!fPNeTd`c90)2P) z4(ad5I#XhQFT0JgXqtyF%aV*7&&A6?*f*_*=R{ zf2Xx{MeIK`?~~E0EA%9sVL9b6C>xRtv+Mc*~Bfae4dVP1&cSqi< zzB}o=lfFCYyOX{<>ARD@dr;q<^xdJ?C$e-Wz3er6eGk(2Abk(g_aJ=_()S>J57PG_ zeUG5N2kCo2|E-OE57Nu7xYz$p`oE#qE6M*R{okbj8+yHx{BO$pzoFN))!)$TmE?az zpL`|x-_YxotOp@F(#fx6*=x)Fi8k%78Vfx6Lwx-o&ev4OgAfx7jnd z69RP;19g)Eb&~^iQv!8Ulj>xAlKk_nrzf?Zo@hNwY`@!+T2D`EJw4HS^!}rs)b@K) z>*6MC(bu|EMQgkKTXO6Rl^tQ^=Sntw;3IQex3WJ5Kxq{UleCQKOgLPyC1U z|3Kf{?kD~OeXZB^GZU{m_=kF~f1vMU-X~+;KhSTO_K6v>zb+LSPuwI|9rShID`Q?i zS4teQrA?P`CIlsUZ-`v&HH68qkWee(TBy^%S3|50y@8hZaxZ`be2zmoKm zUf+lGeQ4C^Lz&Zu^1cuBI%@PGeIL^IfnG5t6O zo#_71>rQlkWKQx*Pnjd*x!3Oq z`i%0o{7d?ON&heO_nOa?R{JmXOMcEqYn*?fzt4TI#QuI)O6)OZ=Hc}NNIwAj2krX? zQ05GP{vq?4=m$Xm^ULwr4z&g%z}eh~DJTKyo>4}$(Ns~-gY z*Q4W4V;V&IL8Ko<`awbcAkq&a{UFlIywhCIZu`i=MxWxYi5_h9DbanluNq8wKbZ1< zu+gVP4?Z5xoWVx#ukage^uEU&Z1gG7{pK?z?*|)wN>ujuVRVJxV53io9&q0)W9@^k zlz3(>Gi0wHLi!=3A42*eq#r{1A&9;1L=PeT5Yi6`>W7eih>5+|4>7U#C+;$ruN}>_ zu^(#mwWC?CBr^pat%j0*DCvhHb9A&CO8TLsA8Pb|v>Iyk*N#?0joyz|Lyf+6^rc;2 z4mEl|TFI&-=Jdmm_p_~j81nvQ`)@Xk^utI$40`=_;9=0~U4z4r_qsDN40->G&75J# z`{Z8-9)`Ss)qSt@nEI<_!zk}%edP7SNk1HVo!<{9{czF`hhFFR!zuQ|q1V;%aOib@ zKOFkx`TcO{b$&nG#NIz&U^w(T$CQ;^ESh7ZJp%fhOzk0kv_(vKwl z$e?~C=|@8UwaxpHlsU3GjztTscNFvsT}kwMwZkaVk0Sjj==ExcQP7(Y#;j))=|@4Y z=cc2ePd+yt1-+h|j)Gp#O-GSl*706Hn)IWQ_qroDn)IVdKbm4cnqohi^rI>Eql2*@ zO|c&hz3#}3CcW%9c>NgCkAYr)PkjvZrENsVK(D{2J_dUIJ@qlrYo9ZQ^kbmkW_=JvCwOuGnQgM7JBV-#zL=s z&RFP^`<$`RYo9aL=zX6vmh`fV84*KNh3ygzapD!>DvDfDdjDuc#OxbVp`v0I`Z1w*^uTM7rkM#dRuTM7r z4|;vF`F|Aq|DbPaGwwgiod2Ltz7OL+=(oFf$Y`baVf;sW*%?c9ea?8&k2iY1BQl=! zve5{dlAIJ0jza-tUNvH~MRLM8+Gv-w_#aV()iE#v8rg5s^K-ShU1O zdjj-JT}gV(-8KdjNIwDkJ?1r8olJoKO09SwIf3*OD03zt_IkJM1jIi1ZrKTlz1}T5 z0eP=?%TA!!%Wk9BPbB?BWRCtyu5Cz z`sC4S67)J+O@dxWt4XAn9bB)UO!~=){m*u;H<|R4p*Kg3&`*xXzHj_5n@sx2q@PUs z$wB>O(oZJ+WYWuCv)4}{{S@f+TI?yLpF**p0=-^~J%#jBNI!-2Q-b;_q@P0iDWsQO zaj&0B`l-+#x4ANv^i!cfVKZkc^she=f2PS)(oZG*RMJlk>Zg)^D(R;>y__FSGy3H7 zqv?UV8G*W)fx20Ny4iucIf1&lfx3Bty7_^+1%bMSfx1P3y2XLIC4su7fx2aZy5)ho z6@j{yfx18F!^I_amAemd!=lYTnsr;~nqP(PjY)1lW@!gSJ0n~p^*>?k(_`jxIE zW1gOT&mjE_($9ci&oE|C&ou*jooCO0Ue7RQK%abuF#~!%`JQ3){^WZG>81CHMXRiL zCiJUaN%WdIGf6*_^fM{;Gb#2nDfTld_A`UApGmQwNtrVfdYxxWKk4l5c?+9JBMOF zhhjem`VJZ5*J;fm{T$NIA^n`7eh%s9kbVy7Wt5CX>uj{=l724qx+6E2^m9o+7kXVC z&!xPdOZvIc>*{ze^vSE^xzOwCcrG$$xsBmm%6l2lYe(y?exA|SjyAZGWRC9T&LjOi z($9ll_j2b^?B^N1-$$Qk^nNdQp3z^smpjks{a)@oqpuwmv1bwUjJ~$J&tGO9wWE#J zJ0JQ@u9T>sPx|?!pHKSvq@Pdv`J|s8)XyjVeA3S+z08qf(PryifXvzAN}|`3#|5Nc z;Pf))Er8y<4eOr;q+fu{(Vd9}$Q*qV)&gWs^2y@@WR9LZE?`1X@i?&+t zLg=@-Qlfq#=@*iIA?X*Aej(`>l73-OzmW6`NxzWvGViP%ZMWV<(C=`i#LQVl`bADJ z>&r!yIg6mzdCnrroJEv5i-MW6h%#ppGUo|q$Qj*eC`LpD#su-?U_UyMFS?>Aix zeQBE=i=o&1O&3G2_nR)J*e|BoFGlS3e$&N>ee(ULixGRh-*hozU(2p?7gOwIE}t6h zwE88aUt;tr(IGp#TSEFJMxPQLHm^zSml%CYv}9rC9MTGw7`;EcTSBp4V)Uue5%WIT z4P9dNsnM4E(q>FexL#n1(Wgd7-S^6_&~aDFA)jqyD65Xz(JrfB3jJkA>4_z;?44E^}=E^c;&U{x&yk0<7a{mgrPv2Vwy*_P5RZOUrqYeq+d<0U&|vFNz{?Df#=UE=GJIjUbz`t_t=Px|$wUr+k= zCiY&xKB!+$`t_t=PkPzIi$y1_egpI;T}fiES2J%Q{RZguYUT~l>($H~pw~I(2I%z+ zV*~VhHS-4Oldopp0KHz#ya9T>nt221Ww+7mHWsI5&G`tHJPPtg#JR- zc&2Zp*l&bhccV5!KikgIHbVdTBQ5AD!yBQWV>5jt^mAP)F>_>JG{wb!6X`cWKho+q zL0{Uo#ZAy_f4>QO?e8~H>^B*`e^GBsGwC-Y_CHzuW}~ki{WfYthQupsHzW2x z+g7_7vH!)DazwAWE6HWA+3UAJf6C_l7U*?PVGHTEKyUs>WX=}obx&anWzH6(_j?Lk zjNb1lY=QpPlgmiI#pwN>!WN_VdkR}j-upcT*%kMBzm@b`KWGl9CZfx2^ny7Pg$3xT?efx1h9y32vOD}lPJNp+Ixl7GJS zY@^n*4Xx)c+X}W(zq<{s=Wg5fx1sf%c`2Un+oFOHXB%42J?4GVdbXkUJi3Q} z6?+?6&%N$@ynZ|Bw?lv0_G8UG4*iuqr|F*C?a-ff-z#nZoGWSDm)J|2_WB*9-vRxT_OISS`W?_eWnL5g z4(Q8fi^qNk#eN6rcR>HNd7tQaKp&f$mDct32f^hJD{o z%AB3hziD0*{Z8n6nG0kjB0DMeJ4wG2`nSycM86aIS~cbOF#Nq=JE4EueXr=>aizrA zOF!xLyGXwa`Ym>zvWxV)pxTye6^V1AWN~as3|B?;-sj z=yf-A5A?~qp?jd$-OxRlE!A?0M7@lXUcZ<0d!g68+`XjV3%%~;?uB0Wa`%#cFX{J^ zes55}m-Kr{zZa_n?J;FM_xgRL-v@ma`&aKH{XXcc+Su=d{>c~OvEN5|zmN3$ps#4& zCz-Pk`nPv{OnJW#`bzG5C37mfQey07=Hd1Gp+9f?*8R|ru^G3Y^!uS7YhIJg*$@4Z z3h~|0{m|=NZ$I>Ub>)8Of3$PG{m@r^<8hkn?T7v+JGAAnwe z+xP(V+A;^2cg&BHa-~CA0+)j(jTPNvCKQY{t)R8L9f4Ue2Daipx56v zJ_Nn~w(%j-A0quBiv6LW{t)R8k^T_HUS`N%f0*=#Nq?C1he>~!^oL1*nDmD!_J@P| z!=yh<`ok1^najtb3$~pef&QW^$-as{L+uFZkGRZ{R(k|`efr)J=*^cIy?o1qk zUawI)64xjFzU~p|>$>+#pQF!5KSHsWRfpFfCH+wod;i?VqohAd`lCkgpWAqp^hb@} z?@SzpUZ0_M)ab8$ZsSp-_s?xSirDKj)Q%dxzb0DNM_zvn`b#$U$B;R@Z48b0DU9iz;Vm7Lcf zC;f5g^#tZP>5n7!dIEDCdOd+TPWt1dKMuW~z#NA@`2^-T^m+nw9I@9EnB%0EHK*5~ zApHsGb)IvA^e3R#dCm#wb)IvA^e0Gv0(zb2oPa)go^t|vo#&i@zLp(pPf*^=>e%Z~ zlKv$0I?p*t`jgP>Jm)0zI?p*t`jezTN&1sP{YlcFB>hR!%R1icPeFg#=KU$?b*6BN z^rxWLnZhaPb*69%dYvhpf?j6|r=ZuF!YSyJX9}mF*O|g8=yj%WiuAJMV4gE=y{9Sm zr=hQJ*9E6Ze;WD*<~3=xr=frU&GN7^~pHF?p=>7Al z<UbKJ^)+zxMgmXN=xIpZbi6y?;LS854Vdx2){qq(*71_bg(c)|GH}XaDN6(3?LK zf7w~+r6jRG3w=d12+2z8EXDq;(btK}y7!5Gn4M#uHTu-3W|#f+RFJbqpBfFfv&ys3 zk8mZ?>-mxFH+lUz(w{@@^V|2GBmFtjpM$<$`MCZZ>Cch=9AdBfb3y$%=+oI4o+JG^ z#9sBXGZu5PKTrDe(BELAcAoU-onE4S9(w(EIZyiYl=tV6_cxl)l)OKWypL5mlr9#% z?DlfcBkyl=-zzhPn_WrrUiGqv=k*sze*yY0?E5Z|{({p>=3IbYe~;h-=`WD}0`za0 zY!v+k=r1gP!?fDBo&Ey!Z`+K$fIjCPS4wQPvfJqO7fF8+`iWM5k@OdxUSfZdVt zf0<%`ne>-Qe;N93ZR{^YpS+)Q8T#*Rv@aubbU)`ZjaIVP?DbcmPjBkPbOrk6Hsh{9 zU)p}=73f=-*Ch5=pnrL7Kl?s8fiWLqONqaKbOrjB=6w?TE6|tiP?lEZSDM>8~R8dg^->vDekfRnlJ#>aUXis)@b%{UfWtir7n^ zBj-nQER}qIlqR9>{xrGp|D{c+i)>xGKwbJkU4}qi#z0-BKwaiQU6w#y)<9jhKwb7g zU5-Fq&OlwRKwa)YU7kQ)-auWxKwbVoU4cMd!9ZQ1KwaTLU6DXt(Li0XKwa@bU5P+l z$v|DHq&jKel7GJSMCL}rSfp(~$|tiWJwJ-_r86aM`%ykwU+Vc$lu!1w^!zBwm)Q2B ze2Hy8$|qNR)Uo|;luxc#saN}UYWq<>xn3p3_OwwxX+5c~l-TyArFeZB(x)MP8q%jB zeHzlIfnM8w8q%jBeVU*?4e8U6K25$vy|ihsPfPl=&^NdJXIj#ygt(}(i zX-S_J`V6MOlzulY^aozeO=DhK=#ONK_uFZW-dw-rN{M5h^ggjDqa7#GL7&N$By$Se z9xol~(?MUvye6YYI_L+!7XQ9Bpvic&HF^34*Dlg)uNr~bkG-b-z)m! zu9O&i=_kEDJ?YaU_PR5Xp7iOV*PV&<(Cf}bdeWySeR}A1XCgiH$vYG2q1T;>^oYIg zOr)pGksdu3Wwz1I0DTr$lGy9|G6U%|K(Fh|4AATPG6U%|kUj(Sy1vW+ee(J;1N6GS z%z(Vt^<@U=^$bJCo>-LCdNV?w&6N`M8A+d!^chK?k@Oi!pON$#gZhl5&q(@=q?b`L zCCYBSnV{Eepw}KV8}!;^W+Qzz(r1Hyp82aKbFx8S zHt!6|oNUm~w9dnQJM>NLXq7#v&rbU6 zq|Z*Vml?9x=OBF!(&r$34$|i!eGba|9Hh@dvCk3I=OBF!vNJm zC+TyNJ}2pOl0GNtbCNzM#Xe_HpOf@CNuQJSvg+{qT%^wh{T!Qdxk#T2`nl#cX|=ha z|GLt{xY8sSWlk>A=c3r>3hHx_J{M(9F4D{T$m?^HJ~!!elRh`;bCW(d#XdLbb5rbd z2lcs0pPOQzoAk1h^ZGob&jWoHJIdvOUPr4u(CcWG2l^}5#d9+c>GP025A-=r4=sI8 z9_XiBNTL2d5A?ZgFP;bb+^&?^=g6AV>+_O6FZ6lr`|^@LFX{6_Kf_$UFYC3uq|ZzG zyrj+?acE5m%y|7!C-AL;XvJ|FaY>YI=9J|FbDuaXb?-_2)A z?DIjN{F`g}ps(w`SLXMBxKd*5WgYMJ`JvBiqn#i6E_PjzpY-`jpC9@ug`1$&<|loA z==J<4KlHk%l^^;Eb$CB9KlEMQ_lmxoD<$e>$HD6hkiG!v3y{75=?jp)0A)@A(ib3o zfuOzs=?frpw%D_X0+czjH<^qO=>}keL zIYpt@%qdEG*=;oEkk(ra`Xa6*t#*Enc+`rKz8L9?8NGRq@ndhKmC>pg>5Cb?zwfRX zTI~Y!nUeR#j6OB$aQh-UH!WuL=IR-zkXBpFl@iZQWna|CzBuWNBXe{|q&W1YZ3YyF zUUx)_Blfx@Qk?X~DRYV=_PQfd9I;Q{5h;$?>yAiq6MKK+UYuetJGfq7g7hUwUxM@{ zNMC~VB`EJpkiG=zO9b^LNM8c_KkaB$g7mW2?DZu{UlMwqA(te5N$7QkToQVnA(y1s zmn3~j=yhdS68hwoVM*w9Wmpn=T^W`nz3hs6eJSXR+Z-zez0MR$QQnuLye|d4&J;?K zz7+I2Qz!+!&J;>PpFC421-;G`N}<*2Orez1%lT1hqfb6RDif$H8>lN6s4E|+s}QKG z7^tfhsH+^Ps}iWI8mOxlsH+~Rs}ZQH8K}E1PTU_t-5RL7 zEl_uRpze-9-JOBDy8?B02kPz#)ZH7XyDzCudU(k{-+D?@>nV-av&HtbrK#%NV`i%Pm9wZW*KZd%0zd-tXm>G5Txwa?2RK z-^(py+P>e*Eo1a4?kNS*rejWDmh@#2`ycHtYFX;J%2Ll&7O|i6Tl_g*WvS;XOZ{$H z#QrDqnG*Z5h<(kMZZb1ff4xds#QtaZy)x$g;!25gJ?VYCz8vYxL9cVYa-=Uu`f||g zT(2DI%aOhu^m?^TIp~wGwkZd_UTsqj{jOeZQ_l6flB3d3dVP7)mxulnn{nkSbIL>i zsd-KEzC84`+QhH$D^L3Jq%RMB9W(w)?8`%crb$l|`}f@{p*-|2*fF|1#=I9@Nn)>g zFFm@~S0H@_=u_WkK>7;Mr#eNVUdA4;uSoie z(BEd;enrw(bb5(>MdrAy0^g2_mMEXjkuLQl$R4YNBJX5U%z0OoCL9b_bl_>9JJooy_q^}IUo&r=ReP!tN z6reKndJ0gP^p#0p8G7AEuMBiaUzPM#Nne%pRY_l!^i@e;m118t zsIN-;s-&+8l0x)kt5BGN&5p zW!~xa)k$BS^wmjUo%Gd7U!7uKo%Gd7Up=U=PWtK;`|6~Z8M4>cAbkz!^~r}dpw~XV z2K2s^c;{LTihT{z*MMGsbFBvS$xlA40lhx?um<${n`<>lFLQaXuSxovq_0W(nxwCZ z*z4a?lk_!7U-SR%oq2R!*LB`6Ne$FY$ucEdl0{MTM1mNIi3C7^AOVsXNRXHak{~e= z#6$uh2u>0uOY$sB9yHjpB|DKU#~E6?b=x>~>_7TfVrMmLB`Y0P>;4lvjgu;Nx*9vN z-Sh2p_dR!Cd=8Hkr%Am861eYt=YH@0-g*1%bMEl&6MDUG<2p*e&d{$j^y>^g_BsOn zdPBcn=y#-XzuwTV7kd4a_NL^y>}%dZE`(iLV#>;-|#d3w>L*UF4khtdyUn zVgD%5ml*mIp`S>7C5FDlw0((b`w~N6V(3eRe$qWB<~b!o|J0)`<_t`U&`)LC1^skZ z%F|;{F3@i<^c#f!XXz|$gQ4GG=rAqE&(CbyjWkSCueFw{gUau-H6MDU> zxXeUOnb7Nz=rW<#<0@rBU%aZgOz8Eh;xeJvtBT7^+hadI(3czfa-nxStMZCjhQ7kkR|vhHyQ>iT;<>vDp}&x}T7|UzV_7LbzsIqWK)=z@Zxs4( zr@oDbexsq^DD--V=Zz-rHyZklLjMQuInir33Vrbo&l`na@9?})+WtRg6nT0a#R>G4 zLcb=B`%0nLPft~v$f*?ib*?WVaw>&hKRs1x+P+fg^>|{X&{wCuwo>S)D;_a>hLu8J zllId}Y5Ur&l&8n>ra)h1=&OWYuSu;k^i@Lt5!WK1uM&E_Cbi1YR~h;$q5o*w_EkcE z?bzQq`fz<%mC!$vwsw`Y{j*sqpL1|zEYMdQ`f8!qW4YBPa;i<_RD1gLtZ%iUuQv46 zLa#ZeTIh?%a;t@2kL6ZN+v~C1YSU|R3@^~v2>l&twaym&=>b>YlU9-YilKP^c+U5p~rF2p5)Gy zev_l`N$$!@ICuBubf&P$&~Fm@ucXIwHVM7nziyMG5BDqGI{9I z(CaaUI-%EN3U!9Q&d}Eh{eMa6>x8~|Eq0yI|JO9u>Ll*G!ZGAm(`Ts{dffx57kZS?_VtdwC)rc#W4qqa*PF2LU=xgNM) zBIgU)c5w{(^{k}Fka7N~!O>rv+~(rf{iL5O+CsEOqBRk1E76*XwvA}piPl22R-)}7 z+D@YFB3c{K+KJXdv`(V!CfXjNbrEeZ(e@Fon`k{m>m^zr(fWzDpJ)R_J3zF9L_1W_ zu*ZY=YftV^`%8oL{RgrVGS`D?-fb|wr@{1|2I>3yxz7gaJ^D?Z4W{omNZ)_hJts0( zgY^9yZhq43<1A#y(Ho@iugkWJJ+$>%DL-36PjQ4P?-rqdC@X=!D!oE#i=p2l^wq8o zeSeFmcU>ASvc>fMErx!J(EoKh*V`iW3*$d^v!!sY&=#Su$+ipn+N_kHEul}hCl9B* zjY7XJD}i3mz%&~AM$`6_$W1DD-+YeWTD9ueNCvdcE4FQSz={ZPRE* z4P>9LWPQrpB=jX&3H16&h9*PbWayiOUO&muWayhr-feR9;jX7mj(+JksWdtIaM#l& zN8gp`H%c@)`tYsT$dfLrQr@kGeyfam9cjMaD)eiz5LX{Xq2FrS zeygZmieygz0Nn9&3vQTjMx}^0{u2azfI^5rLTIMq2DI- zgRTy3zfI`%&WGDf+ix@U+l2nG^P%mx34QU-huehyNVZ+H{ZLlQw>?J5K)+q+H>7d2 zUFgfxJ-h9Oe!I|DxH`~p7y8#e|0gSubGDnd-!Alem+S39zcI}@+lBt|=eC)nLfeJD zGTScbtFlr)=U_Y!^eu+IMd*K+zUmgC*V$5w>9s9FuitmqV%omN(6^9b~KaHFnCUSO|$k|~c zXNPI~9gaR+m%GE!hwE~82>ro<|6s20+adJ-IUQYhIQrh?WO|qD9flsWxvr!v<=rW5 zU!Ika@7(|{Bj`>;zf=OD?S3=I&C2?Q8Gs-TZFUuUDFV9N(UW*xWpl>tuZ9=azg*HRqmeHf_+k{?c z3T=kI&Cs_AyG#@J(k;UBBx#G z^;mAZ(Ce|>c0=E8=-Y*UbK3UpLSMW`a=XyiWrR4ETc4Hkk%PUCK;L2LI}Ck?q3a?~t)p={rou#QssB?=J)lC`_*aM zzSGcm3ca5F>hy76xJPoQ(CgW+PKg{n`_*Y82YYgXez&3DE%Z85*lpT=x6lu|_Y-ly zTj+JBu-ml#ZbQG@$G!8R*X|bj;!I(;kNY%McKf)`O8LmaK4+lcW9at?{i~PzY_Z4C z?-BaHNptcZq1T+V$F%((L%&DpUvtk1`aPb0W4D